We O 
implemented O 
a O 
two O 
- O 
step O 
approach O 
to O 
detect O 
potential O 
predictor O 
gene O 
variants O 
for O 
neuroleptic O 
- O 
induced O 
tardive O 
dyskinesia O 
( O 
TD O 
) O 
in O 
schizophrenic O 
subjects O 
. O 
First O 
, O 
we O 
screened O 
associations O 
by O 
using O 
a O 
genome O 
- O 
wide O 
( O 
Illumina O 
HumanHapCNV370 O 
) O 
SNP O 
array O 
in O 
61 O 
Japanese O 
schizophrenia O 
patients O 
with O 
treatment-resistant O 
TD O 
and O 
61 O 
Japanese O 
schizophrenia O 
patients O 
without O 
TD O 
. O 
Next O 
, O 
we O 
performed O 
a O 
replication O 
analysis O 
in O 
36 O 
treatment-resistant O 
TD O 
and O 
138 O 
non-TD O 
subjects O 
. O 
An O 
association O 
of O 
an O 
SNP O 
in O 
the O 
DPP6 O 
( O 
dipeptidyl O 
peptidase O 
- O 
like O 
protein-6 O 
) O 
gene O 
, O 
rs6977820 O 
, O 
the O 
most O 
promising O 
association O 
identified O 
by O 
the O 
screen O 
, O 
was O 
significant O 
in O 
the O 
replication O 
sample O 
( O 
allelic O 
P=0.008 O 
in O 
the O 
replication O 
sample O 
, O 
allelic O 
P=4.6 O 
× O 
10(-6) O 
, O 
odds O 
ratio O 
2.32 O 
in O 
the O 
combined O 
sample O 
) O 
. O 
The O 
SNP O 
is O 
located O 
in O 
intron-1 O 
of O 
the O 
DPP6 O 
gene O 
and O 
the O 
risk O 
allele O 
was O 
associated O 
with O 
decreased O 
DPP6 O 
gene O 
expression O 
in O 
the O 
human O 
postmortem O 
prefrontal O 
cortex O 
. O 
Chronic O 
administration O 
of O 
haloperidol B-TRIVIAL 
increased O 
Dpp6 O 
expression O 
in O 
mouse O 
brains O 
. O 
DPP6 O 
is O 
an O 
auxiliary O 
subunit O 
of O 
Kv4 O 
and O 
regulates O 
the O 
properties O 
of O 
Kv4 O 
, O 
which O 
regulates O 
the O 
activity O 
of O 
dopaminergic O 
neurons O 
. O 
The O 
findings O 
of O 
this O 
study O 
indicate O 
that O 
an O 
altered O 
response O 
of O 
Kv4 O 
/ O 
DPP6 O 
to O 
long O 
- O 
term O 
neuroleptic O 
administration O 
is O 
involved O 
in O 
neuroleptic O 
- O 
induced O 
TD O 
. O 

is O 
a O 
cause O 
of O 
economic O 
losses O 
in O 
broiler O 
production O 
. O 
In O 
this O 
study O 
, O 
the O 
effect O 
of O 
one O 
commercial O 
nanocompound O 
, O 
Nanocid O 
( O 
Nano O 
Nasb O 
Pars O 
Co O 
. O 
, O 
Iran O 
) O 
was O 
evaluated O 
in O 
reduction O 
of O 
aflatoxin B-FAMILY 
effects O 
on O 
the O 
growth O 
and O 
performance O 
indices O 
in O 
broiler O 
chickens O 
suffering O 
from O 
experimental O 
aflatoxicosis O 
. O 
For O 
this O 
, O 
a O 
total O 
of O 
300 O 
one O 
- O 
day O 
- O 
old O 
broiler O 
chicks O 
( O 
Ross O 
strain O 
) O 
were O 
randomly O 
divided O 
into O 
4 O 
groups O 
with O 
3 O 
replicates O 
of O 
15 O 
chicks O 
in O 
each O 
separated O 
pen O 
during O 
the O 
28-day O 
experiment O 
. O 
Treatment O 
groups O 
including O 
group O 
A O 
: O 
chickens O 
fed O 
basal O 
diet O 
, O 
group O 
B O 
: O 
chickens O 
fed O 
3 O 
ppm O 
productive O 
aflatoxin B-FAMILY 
in O 
basal O 
diet O 
, O 
group O 
C O 
: O 
chickens O 
fed O 
basal O 
diet O 
plus O 
2500 O 
ppm O 
Nanocid O 
, O 
and O 
group O 
D O 
: O 
chickens O 
fed O 
3 O 
ppm O 
productive O 
aflatoxin B-FAMILY 
and O 
2500 O 
ppm O 
Nanocid O 
, O 
in O 
basal O 
diet O 
. O 
Data O 
on O 
body O 
weight O 
, O 
body O 
weight O 
gain O 
( O 
BWG O 
) O 
, O 
feed O 
intake O 
, O 
and O 
feed O 
conversion O 
ratio O 
( O 
FCR O 
) O 
were O 
recorded O 
at O 
weekly O 
intervals O 
. O 
Also O 
cumulative O 
data O 
were O 
assessed O 
. O 
Results O 
showed O 
, O 
although O 
supplement O 
of O 
Nanocid O 
to O 
conventional O 
diet O 
had O 
no O 
effect O 
on O 
performance O 
but O 
addition O 
of O 
Nanocid O 
to O 
diet O 
containing O 
3 O 
ppm O 
aflatoxin B-FAMILY 
increased O 
significantly O 
the O 
cumulative O 
BWG O 
, O 
cumulative O 
feed O 
consumption O 
and O 
decreased O 
FCR O 
in O 
the O 
last O 
2 O 
weeks O 
of O 
experimental O 
period O 
. O 
The O 
improvement O 
in O 
these O 
performance O 
indices O 
by O 
supplement O 
of O 
Nanocid O 
to O 
diet O 
containing O 
aflatoxin B-FAMILY 
showed O 
the O 
ability O 
of O 
Nanocid O 
to O 
diminish O 
the O 
inhibitory O 
effects O 
of O 
aflatoxin B-FAMILY 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
cigarette O 
smoking O 
and O 
occupational O 
exposure O 
to O 
heavy O 
metals O 
on O 
the O 
degree O 
of O 
pro O 
- O 
oxidant O 
/ O 
antioxidant O 
imbalance O 
in O 
smelters O 
. O 
The O 
investigations O 
were O 
performed O 
on O 
the O 
blood O 
and O 
urine O 
of O 
400 O 
subjects O 
: O 
300 O 
male O 
copper B-SYSTEMATIC 
smelters O 
and O 
100 O 
nonexposed O 
male O 
subjects O 
. O 
Biological O 
material O 
was O 
divided O 
into O 
three O 
groups O 
: O 
nonsmokers O 
, O 
those O 
who O 
smoked O 
less O 
than O 
20 O 
cigarettes O 
a O 
day O 
and O 
those O 
who O 
smoked O 
more O 
than O 
20 O 
cigarettes O 
a O 
day O 
. O 
The O 
results O 
showed O 
a O 
significant O 
increase O 
in O 
the O 
concentration O 
of O 
lead O 
, O 
cadmium B-SYSTEMATIC 
and O 
arsenic B-SYSTEMATIC 
in O 
the O 
blood O 
and O 
urine O 
of O 
smelters O 
, O 
while O 
smoking O 
more O 
than O 
20 O 
cigarettes O 
a O 
day O 
caused O 
a O 
further O 
increase O 
in O 
the O 
concentration O 
of O 
these O 
metals O 
. O 
The O 
level O 
of O 
malondialdehyde B-TRIVIAL 
was O 
approximately O 
twofold O 
higher O 
in O 
the O 
plasma O 
of O 
the O 
smelters O 
compared O 
to O 
the O 
control O 
group O 
. O 
We O 
have O 
observed O 
a O 
disturbance O 
in O 
the O 
level O 
of O 
antioxidants O 
in O 
erythrocyte O 
lysate O 
manifested O 
by O 
an O 
increase O 
in O 
metallothionein O 
and O 
glutathione B-TRIVIAL 
concentrations O 
as O 
well O 
as O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
and O 
the O 
decrease O 
in O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
activity O 
. O 
Cigarette O 
smoking O 
, O 
years O 
of O 
work O 
in O 
metallurgy O 
and O 
age O 
of O 
smelters O 
were O 
additional O 
factors O 
significantly O 
affecting O 
the O 
pro O 
- O 
oxidant O 
/ O 
antioxidant O 
balance O 
. O 

induces O 
the O 
expression O 
of O 
cyclooxygenase-2 O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
. O 

factor-κB O 
( O 
NF-κB O 
) O 
is O 
a O 
transcription O 
factor O 
that O 
mediates O 
the O 
inducible O 
expression O 
of O 
a O 
variety O 
of O 
genes O 
involved O 
in O 
immune O 
and O 
inflammatory O 
responses O 
. O 
NF-κB O 
activation O 
induces O 
numerous O 
proinflammatory O 
gene O 
products O 
including O 
cytokines O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
. O 
The O 
divalent O 
heavy O 
metal O 
mercury B-SYSTEMATIC 
has O 
been O 
used O 
for O 
thousands O 
of O 
years O 
. O 
Although O 
mercury B-SYSTEMATIC 
is O 
clearly O 
toxic O 
to O 
most O 
mammalian O 
organ O 
systems O 
, O 
especially O 
the O 
immune O 
system O 
, O 
exposure O 
has O 
still O 
increased O 
in O 
some O 
areas O 
of O 
the O 
world O 
. O 
However O 
, O 
the O 
underlying O 
toxic O 
mechanism O 
is O 
not O 
clearly O 
identified O 
. O 
Here O 
, O 
we O 
report O 
biochemical O 
evidence O 
that O 
mercury B-SYSTEMATIC 
alone O 
induces O 
NF-κB O 
activation O 
, O 
resulting O 
in O 
the O 
induced O 
expression O 
of O 
COX-2 O 
and O 
iNOS O 
. O 
The O 
results O 
suggest O 
that O 
mercury B-SYSTEMATIC 
can O 
induce O 
inflammatory O 
diseases O 
by O 
lowering O 
host O 
defense O 
. O 

effects O 
of O 
chromium B-SYSTEMATIC 
on O 
tannery O 
workers O 
at O 
Sialkot O 
( O 
Pakistan O 
) O 
. O 

is O 
widely O 
used O 
in O 
the O 
leather O 
industry O 
, O 
and O 
tannery O 
workers O 
are O 
under O 
constant O 
threat O 
of O 
adverse O 
health O 
effects O 
due O 
to O 
its O 
excessive O 
exposure O 
. O 
Our O 
objective O 
was O 
to O 
find O 
out O 
the O 
toxic O 
effects O 
of O 
chromium B-SYSTEMATIC 
on O 
tannery O 
workers O 
at O 
Sialkot O 
, O 
Pakistan O 
. O 
A O 
total O 
of O 
240 O 
males O 
consisting O 
of O 
120 O 
workers O 
from O 
tanneries O 
at O 
Sialkot O 
and O 
equal O 
number O 
of O 
controls O 
were O 
included O 
. O 
Blood O 
complete O 
counts O 
, O 
high O 
- O 
sensitive O 
C-reactive O 
protein O 
, O 
malondialdehyde B-TRIVIAL 
and O 
routine O 
biochemical O 
tests O 
were O 
carried O 
out O 
by O 
routine O 
procedures O 
. O 
Chromium B-SYSTEMATIC 
levels O 
in O 
blood O 
( O 
BCr O 
) O 
and O 
urine O 
were O 
analyzed O 
using O 
graphite B-TRIVIAL 
furnace O 
atomic O 
absorption O 
spectrophotometer O 
Perkin O 
Elmer O 
analyst-200 O 
. O 
Results O 
revealed O 
that O 
all O 
the O 
workers O 
were O 
male O 
with O 
average O 
age O 
of O 
33 O 
years O 
and O 
15 O 
( O 
13% O 
) O 
had O 
skin O 
rashes O 
, O 
14 O 
( O 
12% O 
) O 
had O 
chronic O 
bronchitis O 
, O 
10 O 
( O 
8% O 
) O 
had O 
gastritis O 
and O 
4 O 
( O 
3% O 
) O 
conjunctivitis O 
. O 
The O 
tannery O 
workers O 
had O 
significantly O 
raised O 
median O 
( O 
interquartile O 
range O 
) O 
of O 
BCr O 
569 O 
( O 
377-726 O 
) O 
nmol O 
/ O 
L O 
as O 
compared O 
to O 
318 O 
( O 
245-397 O 
) O 
nmol O 
/ O 
L O 
in O 
the O 
control O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Sixty O 
- O 
five O 
( O 
54% O 
) O 
workers O 
had O 
BCr O 
levels O 
above O 
the O 
upper O 
limit O 
set O 
by O 
Agency O 
for O 
Toxic O 
Substance O 
and O 
Drug O 
Registry O 
. O 
The O 
urinary O 
chromium B-SYSTEMATIC 
excretion O 
was O 
significantly O 
high O 
in O 
workers O 
131 O 
( O 
46-312 O 
) O 
nmol O 
/ O 
L O 
as O 
compared O 
to O 
13 O 
( O 
3-26 O 
) O 
nmol O 
/ O 
L O 
in O 
controls O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
workers O 
had O 
hematological O 
, O 
hepatic O 
and O 
renal O 
function O 
impairment O 
because O 
of O 
oxidative O 
stress O 
on O 
body O 
systems O 
. O 
It O 
is O 
concluded O 
that O 
about O 
half O 
of O 
the O 
workers O 
had O 
excessive O 
exposure O 
to O 
chromium B-SYSTEMATIC 
in O 
the O 
tanneries O 
at O 
Sialkot O 
. O 
They O 
had O 
significantly O 
raised O 
chromium B-SYSTEMATIC 
levels O 
in O 
their O 
biological O 
fluids O 
and O 
adverse O 
health O 
effects O 
due O 
to O 
enhanced O 
oxidative O 
stress O 
and O 
inflammatory O 
changes O 
. O 

investigation O 
of O 
a O 
number O 
of O 
plant O 
extracts O 
for O 
allelopathic O 
activity O 
using O 
seed O 
germination O 
inhibition O 
bioassay O 
showed O 
a O 
promising O 
activity O 
of O 
the O 
water O 
extract O 
of O 
the O 
aerial O 
parts O 
of O 
Mikania O 
scandens O 
. O 
Activity O 
- O 
guided O 
fractionation O 
of O 
the O 
M O 
. O 
scandens O 
extract O 
led O 
to O 
the O 
isolation O 
of O 
the O 
highly O 
allelopathic O 
active O 
compound O 
mikanolide B-TRIVIAL 
, O 
with O 
minimum O 
inhibitory O 
concentration O 
of O 
0.083 O 
µM O 
mL(-1) O 
. O 
As O 
M O 
. O 
scandens O 
is O 
a O 
highly O 
abundant O 
invasive O 
plant O 
in O 
Sri O 
Lanka O 
and O 
other O 
South O 
Asian O 
countries O 
, O 
this O 
plant O 
could O 
be O 
developed O 
as O 
an O 
environment O 
friendly O 
natural O 
herbicide O 
, O 
either O 
in O 
crude O 
form O 
as O 
shredded O 
plant O 
material O 
or O 
as O 
pure O 
mikanolide B-TRIVIAL 
, O 
which O 
is O 
the O 
major O 
constituent O 
( O 
∼0.02% O 
) O 
in O 
the O 
plant O 
. O 

of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
in O 
different O 
types O 
of O 
processed O 
foods O 
. O 

aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PCAHs B-ABBREVIATION 
) O 
, O 
particularly O 
those O 
with O 
a O 
high O 
molecular O 
weight O 
, O 
have O 
been O 
classified O 
as O 
probable O 
carcinogens O 
to O 
humans O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
is O 
to O 
determine O 
the O 
levels O 
of O 
PCAHs B-ABBREVIATION 
in O 
samples O 
of O 
meat O 
, O 
fish O 
, O 
chicken O 
, O 
fried O 
potato O 
, O 
and O 
toasted O 
bread O 
, O 
which O 
will O 
be O 
thermally O 
processed O 
using O 
conventional O 
and O 
microwave O 
ovens O 
. O 
Different O 
samples O 
will O 
be O 
collected O 
and O 
analyzed O 
for O 
five O 
PCAHs B-ABBREVIATION 
including O 
pyrene B-SYSTEMATIC 
, O 
benzo(a)anthracene B-SYSTEMATIC 
, O 
benzo(e)pyrene B-SYSTEMATIC 
, O 
benzoflouroanthene B-SYSTEMATIC 
, O 
and O 
benzo(a)pyrene B-SYSTEMATIC 
. O 
The O 
analytical O 
method O 
involves O 
saponification O 
with O 
methanolic B-SYSTEMATIC 
potassium I-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
, O 
extraction O 
with O 
cyclohexane B-SYSTEMATIC 
, O 
and O 
determination O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
there O 
is O 
a O 
variation O 
in O 
the O 
detected O 
PCAHs B-ABBREVIATION 
in O 
different O 
foodstuffs O 
. O 
Fried O 
potato O 
processed O 
by O 
conventional O 
oven O 
or O 
microwave O 
oven O 
showed O 
none O 
of O 
the O 
selected O 
studied O 
PCAHs B-ABBREVIATION 
. O 
It O 
was O 
found O 
that O 
, O 
chicken O 
showed O 
higher O 
content O 
levels O 
of O 
total O 
PCAHs B-ABBREVIATION 
than O 
the O 
meat O 
and O 
fish O 
. O 
Data O 
are O 
the O 
highest O 
mean O 
concentrations O 
of O 
fluoranthene B-SYSTEMATIC 
and O 
benzo(a)pyrene B-SYSTEMATIC 
but O 
within O 
low O 
limit O 
. O 
The O 
obtained O 
results O 
were O 
compared O 
with O 
international O 
permissible O 
levels O 
to O 
avoid O 
pollution O 
, O 
which O 
may O 
cause O 
hazardous O 
effects O 
on O 
individual O 
and O 
society O 
. O 

of O 
Thiovit B-TRIVIAL 
( O 
R O 
) O 
Jet O 
on O 
the O 
structure O 
of O 
thoracic O 
microtrichia O 
/ O 
trichomes O 
in O 
Drosophila O 
melanogaster O 
. O 

used O 
fungicides O 
and O 
pesticides O 
are O 
known O 
to O 
have O 
profound O 
effect O 
on O 
several O 
nontarget O 
organisms O 
, O 
which O 
is O 
a O 
cause O 
of O 
concern O 
. O 
The O 
present O 
study O 
aims O 
to O 
demonstrate O 
the O 
effect O 
of O 
a O 
fungicide O 
, O 
Thiovit B-TRIVIAL 
( O 
® O 
) O 
Jet O 
on O 
the O 
structure O 
of O 
epidermal O 
microtrichia O 
( O 
trichome O 
) O 
of O 
the O 
dorsal O 
thorax O 
in O 
Drosophila O 
melanogaster O 
. O 
External O 
morphology O 
and O 
structural O 
variations O 
of O 
thoracic O 
appendages O 
have O 
been O 
extensively O 
studied O 
using O 
scanning O 
electron O 
microscope O 
from O 
flies O 
treated O 
with O 
different O 
concentrations O 
of O 
Thiovit B-TRIVIAL 
Jet O 
( O 
20 O 
, O 
30 O 
, O 
40 O 
or O 
200 O 
μg O 
/ O 
ml O 
) O 
. O 
Similar O 
to O 
the O 
effect O 
of O 
other O 
fungicides O 
like O 
captan B-TRIVIAL 
and O 
captafol B-TRIVIAL 
which O 
are O 
reported O 
to O 
produce O 
somatic O 
mutations O 
in O 
the O 
same O 
organism O 
, O 
the O 
present O 
study O 
successfully O 
demonstrates O 
variation O 
in O 
the O 
trichome O 
/ O 
microtrichia O 
structure O 
of O 
the O 
dorsal O 
thorax O 
of O 
D O 
. O 
melanogaster O 
. O 
Structural O 
variations O 
were O 
observed O 
to O 
be O 
associated O 
with O 
different O 
concentrations O 
of O 
Thiovit B-TRIVIAL 
Jet O 
( O 
30 O 
, O 
40 O 
and O 
200 O 
μg O 
/ O 
ml O 
) O 
, O 
but O 
the O 
maximum O 
notable O 
change O 
was O 
found O 
with O 
40 O 
μg O 
/ O 
ml O 
treatment O 
. O 
The O 
gross O 
abnormality O 
in O 
the O 
trichome O 
structure O 
may O 
be O 
due O 
to O 
mutation O 
in O 
proteins O 
associated O 
with O 
normal O 
cuticular O 
deposition O 
. O 

and O 
traditional O 
medicines O 
are O 
being O 
widely O 
used O 
in O 
practice O 
in O 
many O 
countries O 
for O 
their O 
benefits O 
of O 
treating O 
different O 
ailments O 
. O 
A O 
large O 
number O 
of O 
plants O 
in O 
Morocco O 
were O 
used O 
in O 
folk O 
medicine O 
to O 
treat O 
immune O 
- O 
related O 
disorders O 
. O 
The O 
objective O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
immunomodulatory O 
activity O 
of O 
protein O 
extracts O 
( O 
PEs O 
) O 
of O 
14 O 
Moroccan O 
medicinal O 
plants O 
. O 
This O 
activity O 
was O 
tested O 
on O 
the O 
proliferation O 
of O 
immune O 
cells O 
. O 
The O 
prepared O 
total O 
and O 
PEs O 
of O 
the O 
plant O 
samples O 
were O 
tested O 
using O 
MTT B-ABBREVIATION 
( O 
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
assay O 
on O 
the O 
splenocytes O 
with O 
or O 
without O 
stimulation O 
by O 
concanavalin-A O 
( O 
Con-A O 
) O 
, O 
a O 
mitogenic O 
agent O 
used O 
as O 
positive O 
control O 
. O 
The O 
results O 
of O 
this O 
study O 
indicated O 
different O 
activity O 
spectra O 
. O 
Three O 
groups O 
of O 
activities O 
were O 
observed O 
. O 
The O 
first O 
group O 
represented O 
by O 
Citrullus O 
colocynthis O 
, O 
Urtica O 
dioica O 
, O 
Elettaria O 
cardamomum O 
, O 
Capparis O 
spinosa O 
and O 
Piper O 
cubeba O 
showed O 
a O 
significant O 
immunosuppressive O 
activity O 
. O 
The O 
second O 
group O 
that O 
showed O 
a O 
significant O 
immunostimulatory O 
activity O 
was O 
represented O 
by O 
Aristolochia O 
longa O 
, O 
Datura O 
stramonium O 
, O 
Marrubium O 
vulgare O 
, O 
Sinapis O 
nigra O 
, O 
Delphynium O 
staphysagria O 
, O 
Lepidium O 
sativum O 
, O 
Ammi O 
visnaga O 
and O 
Tetraclinis O 
articulata O 
. O 
The O 
rest O 
of O 
the O 
plant O 
extracts O 
did O 
not O 
alter O 
the O 
proliferation O 
induced O 
by O 
Con-A O 
. O 
This O 
result O 
was O 
more O 
important O 
for O 
the O 
PE O 
than O 
for O 
the O 
total O 
extract O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
revealed O 
an O 
interesting O 
immunomodulating O 
action O 
of O 
certain O 
PEs O 
, O 
which O 
could O 
explain O 
their O 
traditional O 
use O 
. O 
The O 
results O 
of O 
this O 
study O 
may O 
also O 
have O 
implications O 
in O 
therapeutic O 
treatment O 
of O 
infections O 
, O 
such O 
as O 
prophylactic O 
and O 
adjuvant O 
with O 
cancer O 
chemotherapy O 
. O 

of O 
three O 
steroidal B-FAMILY 
saponins I-FAMILY 
from O 
Ophiopogon O 
japonicus O 
( O 
Liliaceae O 
) O 
via O 
high O 
- O 
performance O 
liquid O 
chromatography O 
with O 
mass O 
spectrometry O 
. O 

simple O 
and O 
accurate O 
analytical O 
method O 
was O 
developed O 
for O 
simultaneous O 
quantification O 
of O 
three O 
steroidal B-FAMILY 
saponins I-FAMILY 
in O 
the O 
roots O 
of O 
Ophiopogon O 
japonicus O 
via O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
with O 
mass O 
spectrometry O 
( O 
MS O 
) O 
in O 
this O 
study O 
. O 
Separation O 
was O 
performed O 
on O 
a O 
Tigerkin O 
C(18) O 
column O 
and O 
detection O 
was O 
performed O 
by O 
mass O 
spectrometry O 
. O 
A O 
mobile O 
phase O 
consisted O 
of O 
0.02% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
water O 
( O 
v O 
/ O 
v O 
) O 
and O 
0.02% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
acetonitrile B-SYSTEMATIC 
( O 
v O 
/ O 
v O 
) O 
was O 
used O 
with O 
a O 
flow O 
rate O 
of O 
0.5 O 
mL O 
min(-1) O 
. O 
The O 
quantitative O 
HPLC-MS O 
method O 
was O 
validated O 
for O 
linearity O 
, O 
precision O 
, O 
repeatability O 
, O 
stability O 
, O 
recovery O 
, O 
limits O 
of O 
detection O 
and O 
quantification O 
. O 
This O 
developed O 
method O 
provides O 
good O 
linearity O 
( O 
r O 
> O 
0.9993 O 
) O 
, O 
intra- O 
and O 
inter O 
- O 
day O 
precisions O 
( O 
RSD O 
< O 
4.18% O 
) O 
, O 
repeatability O 
( O 
RSD O 
< O 
5.05% O 
) O 
, O 
stability O 
( O 
RSD O 
< O 
2.08% O 
) O 
and O 
recovery O 
( O 
93.82-102.84% O 
) O 
for O 
three O 
steroidal B-FAMILY 
saponins I-FAMILY 
. O 
It O 
could O 
be O 
considered O 
as O 
a O 
suitable O 
quality O 
control O 
method O 
for O 
O O 
. O 
japonicus O 
. O 

new O 
steroidal B-FAMILY 
glycosides I-FAMILY 
from O 
roots O 
of O 
Reineckia O 
carnea O 
. O 

new O 
spirostanols B-FAMILY 
and O 
a O 
new O 
furostanol B-TRIVIAL 
, O 
reinocarnoside B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
( I-MULTIPLE 
3 I-MULTIPLE 
) I-MULTIPLE 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Reineckia O 
carnea O 
, O 
together O 
with O 
two O 
known O 
compounds O 
, O 
(25S)-1β,3β,4β-trihydroxyspirostan-5β-yl-O-β-D-glucopyranoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
kitigenin-5β-O-β-D-glucopyranoside B-SYSTEMATIC 
( O 
5 O 
) O 
. O 
The O 
structures O 
of O 
three O 
new O 
compounds O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
including O 
1-D O 
NMR O 
, O 
2-D O 
NMR O 
and O 
MS O 
spectrums O 
, O 
and O 
their O 
anticancer O 
activities O 
were O 
evaluated O 
by O 
MTT B-ABBREVIATION 
method O 
. O 

the O 
Barents O 
Sea O 
, O 
the O 
limited O 
data O 
on O 
biological O 
relevant O 
indicators O 
and O 
their O 
responses O 
to O 
various O 
anthropogenic O 
stressors O 
have O 
hindered O 
the O 
development O 
of O 
a O 
consistent O 
scientific O 
basis O 
for O 
selecting O 
indicator O 
species O 
and O 
developing O 
practical O 
procedures O 
for O 
environmental O 
monitoring O 
. O 
Accordingly O 
, O 
the O 
main O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
develop O 
a O 
common O 
set O 
of O 
baseline O 
values O 
for O 
contaminants O 
and O 
biomarkers O 
in O 
three O 
species O 
, O 
and O 
to O 
identify O 
their O 
strengths O 
and O 
limitations O 
in O 
monitoring O 
of O 
the O 
Barents O 
Sea O 
. O 
Blue O 
mussel O 
( O 
Mytilus O 
edulis O 
) O 
, O 
Icelandic O 
scallop O 
( O 
Chlamys O 
islandica O 
) O 
and O 
Atlantic O 
cod O 
( O 
Gadus O 
morhua O 
) O 
were O 
sampled O 
from O 
a O 
north O 
Norwegian O 
fjord O 
in O 
March O 
, O 
June O 
, O 
September O 
and O 
December O 
2010 O 
. O 
Digestive O 
glands O 
from O 
the O 
bivalve O 
species O 
and O 
liver O 
from O 
Atlantic O 
cod O 
were O 
analysed O 
for O 
biomarkers O 
of O 
oxidative O 
stress O 
( O 
catalase O 
[ O 
CAT O 
] O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
[ O 
GPX O 
] O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
activities O 
[ O 
GST O 
] O 
, O 
lipid O 
peroxidation O 
as O 
thiobarbituric B-SYSTEMATIC 
reactive O 
substances O 
[ O 
TBARS O 
] O 
and O 
total O 
oxyradical O 
scavenging O 
capacity O 
[ O 
TOSC O 
] O 
) O 
, O 
biotransformation O 
( O 
ethoxyresorufine B-SYSTEMATIC 
- O 
O B-FORMULA 
-deethylase O 
activity O 
[ O 
EROD O 
] O 
) O 
and O 
general O 
stress O 
( O 
lysosomal O 
membrane O 
stability O 
[ O 
LMS O 
] O 
) O 
. O 
Concentrations O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
and O 
metals O 
in O 
the O 
bivalves O 
and O 
PAH B-ABBREVIATION 
metabolites O 
in O 
fish O 
bile O 
were O 
quantified O 
. O 
Finally O 
, O 
energy O 
reserves O 
( O 
total O 
lipids O 
, O 
proteins O 
and O 
carbohydrates O 
) O 
and O 
electron O 
transport O 
system O 
( O 
ETS O 
) O 
activity O 
in O 
the O 
digestive O 
gland O 
of O 
the O 
bivalves O 
and O 
liver O 
of O 
Atlantic O 
cod O 
provided O 
background O 
information O 
for O 
reproductive O 
cycle O 
and O 
general O 
physiological O 
status O 
of O 
the O 
organisms O 
. O 
Blue O 
mussel O 
and O 
Icelandic O 
scallop O 
showed O 
very O 
similar O 
trends O 
in O 
biological O 
cycle O 
, O 
biomarker O 
expression O 
and O 
seasonality O 
. O 
Biomarker O 
baselines O 
in O 
Atlantic O 
cod O 
showed O 
weaker O 
seasonal O 
variability O 
. O 
However O 
, O 
important O 
biological O 
events O 
may O 
have O 
been O 
undetected O 
due O 
to O 
the O 
large O 
time O 
intervals O 
between O 
sampling O 
occasions O 
. O 
Physiological O 
biomarkers O 
such O 
as O 
energy O 
reserves O 
and O 
ETS O 
activity O 
were O 
recommended O 
as O 
complementary O 
parameters O 
to O 
the O 
commonly O 
used O 
stress O 
biomarkers O 
, O 
as O 
they O 
provided O 
valuable O 
information O 
on O 
the O 
physiological O 
status O 
of O 
the O 
studied O 
organisms O 
. O 
Interpretation O 
of O 
the O 
seasonality O 
in O 
oxidative O 
stress O 
biomarkers O 
was O 
in O 
general O 
difficult O 
but O 
TOSC O 
and O 
lipid O 
peroxidation O 
were O 
preferred O 
over O 
the O 
antioxidant O 
enzyme O 
activities O 
. O 
This O 
study O 
is O 
the O 
first O 
reporting O 
seasonal O 
baseline O 
in O 
these O 
three O 
species O 
in O 
a O 
sub-Arctic O 
location O 
. O 
Overall O 
, O 
the O 
Icelandic O 
scallop O 
was O 
considered O 
the O 
most O 
adequate O 
organism O 
for O 
environmental O 
monitoring O 
in O 
the O 
Barents O 
Sea O 
due O 
to O 
the O 
interpretability O 
of O 
the O 
biomarker O 
data O 
as O 
well O 
as O 
its O 
abundance O 
, O 
ease O 
to O 
handle O 
and O 
wide O 
distribution O 
from O 
the O 
southern O 
Barents O 
Sea O 
to O 
Svalbard O 
. O 

episode O 
modulates O 
the O 
response O 
of O 
river O 
biofilms O 
to O 
triclosan B-TRIVIAL 
. O 

consequences O 
of O 
global O 
change O 
on O 
rivers O 
include O 
altered O 
flow O 
regime O 
, O 
and O 
entrance O 
of O 
compounds O 
that O 
may O 
be O 
toxic O 
to O 
biota O 
. O 
When O 
water O 
is O 
scarce O 
, O 
a O 
reduced O 
dilution O 
capacity O 
may O 
amplify O 
the O 
effects O 
of O 
chemical O 
pollution O 
. O 
Therefore O 
, O 
studying O 
the O 
response O 
of O 
natural O 
communities O 
to O 
compromised O 
water O 
flow O 
and O 
to O 
toxicants O 
is O 
critical O 
for O 
assessing O 
how O 
global O 
change O 
may O 
affect O 
river O 
ecosystems O 
. O 
This O 
work O 
aims O 
to O 
investigate O 
how O 
an O 
episode O 
of O 
drought O 
might O 
influence O 
the O 
response O 
of O 
river O 
biofilms O 
to O 
pulses O 
of O 
triclosan B-TRIVIAL 
( O 
TCS B-ABBREVIATION 
) O 
. O 
The O 
objectives O 
were O 
to O 
assess O 
the O 
separate O 
and O 
combined O 
effects O 
of O 
simulated O 
drought O 
( O 
achieved O 
through O 
drastic O 
flow O 
alteration O 
) O 
and O 
of O 
TCS B-ABBREVIATION 
exposure O 
on O 
biofilms O 
growing O 
in O 
artificial O 
channels O 
. O 
Thus O 
, O 
three O 
- O 
week O 
- O 
old O 
biofilms O 
were O 
studied O 
under O 
four O 
conditions O 
: O 
Control O 
( O 
normal O 
water O 
flow O 
) O 
; O 
Simulated O 
Drought O 
( O 
1 O 
week O 
reduced O 
flow O 
+ O 
2 O 
days O 
interrupted O 
flow O 
) O 
; O 
TCS B-ABBREVIATION 
only O 
( O 
normal O 
water O 
flow O 
plus O 
a O 
48-h O 
pulse O 
of O 
TCS B-ABBREVIATION 
) O 
; O 
and O 
Simulated O 
Drought+ O 
TCS B-ABBREVIATION 
. O 
All O 
channels O 
were O 
then O 
left O 
for O 
2 O 
weeks O 
under O 
steady O 
flow O 
conditions O 
, O 
and O 
their O 
responses O 
and O 
recovery O 
were O 
studied O 
. O 
Several O 
descriptors O 
of O 
biofilms O 
were O 
analyzed O 
before O 
and O 
after O 
each O 
step O 
. O 
Flow O 
reduction O 
and O 
subsequent O 
interruption O 
were O 
found O 
to O 
provoke O 
an O 
increase O 
in O 
extracellular O 
phosphatase O 
activity O 
, O 
bacterial O 
mortality O 
and O 
green O 
algae O 
biomass O 
. O 
The O 
TCS B-ABBREVIATION 
pulses O 
severely O 
affected O 
biofilms O 
: O 
they O 
drastically O 
reduced O 
photosynthetic O 
efficiency O 
, O 
the O 
viability O 
of O 
bacteria O 
and O 
diatoms O 
, O 
and O 
phosphate B-SYSTEMATIC 
uptake O 
. O 
Latent O 
consequences O 
evidenced O 
significant O 
combined O 
effects O 
caused O 
by O 
the O 
two O 
stressors O 
. O 
The O 
biofilms O 
exposed O 
only O 
to O 
TCS B-ABBREVIATION 
recovered O 
far O 
better O 
than O 
those O 
subjected O 
to O 
both O 
altered O 
flow O 
and O 
subsequent O 
TCS B-ABBREVIATION 
exposure O 
: O 
the O 
latter O 
suffered O 
more O 
persistent O 
consequences O 
, O 
indicating O 
that O 
simulated O 
drought O 
amplified O 
the O 
toxicity O 
of O 
this O 
compound O 
. O 
This O 
finding O 
has O 
implications O 
for O 
river O 
ecosystems O 
, O 
as O 
it O 
suggests O 
that O 
the O 
toxicity O 
of O 
pollutants O 
to O 
biofilms O 
may O 
be O 
exacerbated O 
following O 
a O 
drought O 
. O 

aimed O 
to O 
determine O 
the O 
genotoxic O 
potential O 
of O 
essential O 
oil O 
( O 
EO O 
) O 
obtained O 
from O 
Nepeta O 
nuda O 
. O 
The O 
chemical O 
content O 
of O 
EO O 
was O 
measured O 
via O 
gas O 
chromatography O 
/ O 
mass O 
spectrometry O 
. O 
The O 
most O 
abundant O 
contents O 
were O 
4aα,7β,7aα-nepetalactone B-SYSTEMATIC 
( O 
18.10% O 
) O 
, O 
germacrene B-TRIVIAL 
( O 
15.68% O 
) O 
and O 
elemol B-TRIVIAL 
( O 
14.38% O 
) O 
. O 
For O 
genotoxic O 
effects O 
of O 
EO O 
, O 
Zea O 
mays O 
' O 
seeds O 
were O 
exposed O 
to O 
four O 
different O 
concentrations O 
of O 
this O 
oil O 
. O 
Inhibition O 
of O 
root O 
and O 
stem O 
growth O 
were O 
observed O 
with O 
an O 
increase O 
in O 
EO O 
concentrations O 
. O 
Randomly O 
amplified O 
polymorphic O 
DNA O 
( O 
RAPD O 
) O 
method O 
was O 
used O 
to O 
determine O 
the O 
genotoxic O 
effects O 
of O 
EO O 
. O 
Some O 
changes O 
occurred O 
in O 
RAPD O 
profiles O 
of O 
germinated O 
EO O 
- O 
treated O 
seeds O 
. O 
Even O 
though O 
total O 
soluble O 
protein O 
quantity O 
vary O 
, O 
the O 
data O 
observed O 
from O 
the O 
protein O 
profiles O 
of O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
- O 
polyacrylamide B-SYSTEMATIC 
gel O 
electrophoresis O 
( O 
SDS B-ABBREVIATION 
-PAGE O 
) O 
showed O 
that O 
there O 
was O 
a O 
little O 
differentiation O 
between O 
band O 
profiles O 
of O 
treated O 
samples O 
and O 
control O 
group O 
. O 
We O 
concluded O 
that O 
the O 
basis O 
of O 
interactions O 
between O 
plants O 
, O 
like O 
allelopathy O 
, O 
may O 
be O 
related O 
with O 
genotoxic O 
effects O 
of O 
EO O 
. O 

, O 
accumulation O 
and O 
toxicokinetics O 
of O 
aluminum B-SYSTEMATIC 
in O 
some O 
tissues O 
of O 
male O 
albino O 
rats O 
. O 

the O 
present O 
work O 
, O 
the O 
lethality O 
percentiles O 
including O 
median O 
lethal O 
doses O 
( O 
LD50 O 
) O 
, O 
accumulation O 
, O 
distribution O 
and O 
toxicokinetics O 
of O 
aluminum B-SYSTEMATIC 
in O 
the O 
liver O 
, O 
kidney O 
, O 
intestine O 
, O 
brain O 
and O 
serum O 
of O 
male O 
albino O 
rats O 
, O 
following O 
a O 
single O 
oral O 
administration O 
were O 
studied O 
throughout O 
1 O 
, O 
3 O 
, O 
7 O 
, O 
14 O 
and O 
28 O 
days O 
. O 
The O 
estimated O 
LD50 O 
at O 
24 O 
h O 
was O 
3.45 O 
g O 
Al B-FORMULA 
/ O 
kg O 
body O 
weight O 
( O 
b.wt O 
. O 
) O 
. O 
The O 
utilized O 
dose O 
of O 
Al B-FORMULA 
was O 
1 O 
/ O 
50 O 
LD50 O 
( O 
0.07 O 
g O 
Al B-FORMULA 
/ O 
kg O 
b.wt O 
. O 
) O 
. O 
Aluminum B-SYSTEMATIC 
residues O 
, O 
in O 
Al B-FORMULA 
-treated O 
rats O 
, O 
were O 
significantly O 
decreased O 
in O 
response O 
to O 
the O 
experimental O 
periods O 
and O 
were O 
negatively O 
correlated O 
with O 
time O 
. O 
In O 
addition O 
, O 
the O 
hepatic O 
, O 
renal O 
, O 
intestinal O 
, O 
brain O 
and O 
serum O 
Al B-FORMULA 
contents O 
were O 
significantly O 
higher O 
than O 
the O 
corresponding O 
controls O 
at O 
all O 
experimental O 
periods O 
, O 
except O 
the O 
brain O 
that O 
showed O 
significant O 
depletion O 
when O 
compared O 
with O 
its O 
corresponding O 
control O 
after O 
28 O 
days O 
. O 
Kinetically O 
, O 
the O 
highest O 
average O 
of O 
Al B-FORMULA 
area O 
under O 
concentration O 
- O 
time O 
curves O 
( O 
AUCtotal O 
, O 
μg O 
/ O 
g O 
day O 
) O 
and O 
area O 
under O 
moment O 
concentration O 
- O 
time O 
curves O 
( O 
AUMCtotal O 
, O 
µg O 
/ O 
g O 
day(2) O 
) O 
recorded O 
in O 
the O 
brain O 
followed O 
by O 
kidney O 
, O 
serum O 
, O 
intestine O 
and O 
liver O 
. O 
The O 
longest O 
elimination O 
half O 
- O 
life O 
time O 
( O 
t O 
1 O 
/ O 
2 O 
, O 
day O 
) O 
and O 
the O 
mean O 
residence O 
time O 
( O 
MRT O 
, O 
day O 
) O 
were O 
recorded O 
in O 
the O 
brain O 
followed O 
by O 
the O 
liver O 
, O 
kidney O 
, O 
serum O 
and O 
intestine O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
slowest O 
clearance O 
rates O 
( O 
Cls O 
, O 
L O 
/ O 
day O 
) O 
of O 
Al O 
, O 
in O 
order O 
, O 
were O 
recorded O 
in O 
brain O 
, O 
kidney O 
, O 
serum O 
, O 
intestine O 
and O 
the O 
liver O 
. O 
The O 
elimination O 
rate O 
constant O 
( O 
Lz O 
, O 
day(-) O 
( O 
1 O 
) O 
) O 
of O 
Al B-FORMULA 
from O 
the O 
brain O 
was O 
less O 
than O 
that O 
in O 
the O 
intestine O 
and O 
serum O 
was O 
less O 
than O 
that O 
in O 
the O 
liver O 
and O 
kidney O 
. O 
The O 
computed O 
maximum O 
concentrations O 
( O 
C O 
max O 
) O 
of O 
Al B-FORMULA 
in O 
the O 
intestine O 
> O 
kidney O 
> O 
serum O 
> O 
brain O 
> O 
liver O 
were O 
recorded O 
after O 
3 O 
, O 
3.8 O 
, O 
2.2 O 
, O 
5.4 O 
and O 
3.8 O 
days O 
, O 
respectively O 
. O 
The O 
computed O 
starting O 
concentration O 
( O 
C O 
0 O 
, O 
μg O 
) O 
of O 
Al B-FORMULA 
in O 
serum O 
was O 
higher O 
than O 
its O 
level O 
in O 
the O 
intestine O 
followed O 
by O 
the O 
brain O 
, O 
kidney O 
and O 
liver O 
. O 

tumor O 
- O 
suppressive O 
role O 
of O 
monoglyceride B-SYSTEMATIC 
lipase O 
in O 
human O 
colorectal O 
cancer O 
. O 

monoglyceride B-SYSTEMATIC 
lipase O 
( O 
MGL O 
) O 
is O 
a O 
recently O 
identified O 
lipase O 
and O 
very O 
little O 
is O 
known O 
about O 
its O 
regulation O 
and O 
function O 
in O 
cellular O 
regulatory O 
processes O 
, O 
particularly O 
in O 
context O 
to O 
human O 
malignancy O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
regulation O 
and O 
function O 
of O 
MGL O 
in O 
human O 
cancer(s) O 
and O 
report O 
that O 
MGL O 
expression O 
was O 
either O 
absent O 
or O 
reduced O 
in O 
the O 
majority O 
of O 
primary O 
colorectal O 
cancers O 
. O 
Immunohistochemical O 
studies O 
showed O 
that O 
reduction O 
of O 
MGL O 
expression O 
in O 
the O 
colorectal O 
tumor O 
tissues O 
predominantly O 
occurred O 
in O 
the O 
cancerous O 
epithelial O 
cells O 
. O 
MGL O 
was O 
found O 
to O 
reside O 
in O 
the O 
core O 
surface O 
of O 
a O 
cellular O 
organelle O 
named O 
' O 
lipid O 
body O 
' O 
. O 
Furthermore O 
, O 
it O 
was O 
found O 
to O 
interact O 
selectively O 
with O 
a O 
number O 
of O 
phospholipids O 
, O 
including O 
phosphatidic B-FAMILY 
acid I-FAMILY 
and O 
phosphoinositol(3,4,5)P3 B-SYSTEMATIC 
, O 
phosphoinositol(3,5)P2 B-SYSTEMATIC 
, O 
phosphoinositol(3,4)P2 B-SYSTEMATIC 
and O 
several O 
other O 
phosphoinositides B-FAMILY 
, O 
and O 
among O 
all O 
phosphoinositides B-FAMILY 
analyzed O 
, O 
its O 
interaction O 
with O 
PI(3,4,5)P3 B-SYSTEMATIC 
was O 
found O 
to O 
be O 
the O 
strongest O 
. O 
In O 
addition O 
, O 
overexpression O 
of O 
MGL O 
suppressed O 
colony O 
formation O 
in O 
tumor O 
cell O 
lines O 
and O 
knockdown O 
of O 
MGL O 
resulted O 
in O 
increased O 
Akt O 
phosphorylation O 
. O 
Taken O 
together O 
, O 
our O 
results O 
suggest O 
that O 
MGL O 
plays O 
a O 
negative O 
regulatory O 
role O 
in O 
phosphatidylinositol B-TRIVIAL 
-3 O 
kinase O 
/ O 
Akt O 
signaling O 
and O 
tumor O 
cell O 
growth O 
. O 

brachystachyum O 
is O 
a O 
hemiparasitic O 
plant O 
widely O 
distributed O 
in O 
México O 
that O 
belongs O 
to O 
the O 
Viscaceae O 
family O 
. O 
It O 
has O 
been O 
commonly O 
used O 
in O 
folk O 
medicine O 
as O 
a O 
substitute O 
for O 
the O 
European O 
mistletoe O 
. O 
In O 
this O 
chemical O 
study O 
, O 
morolic B-TRIVIAL 
acid I-TRIVIAL 
was O 
isolated O 
as O 
the O 
major O 
component O 
( O 
47.54% O 
of O 
the O 
total O 
composition O 
of O 
acetone B-SYSTEMATIC 
extract O 
) O 
of O 
this O 
plant O 
. O 
In O 
addition O 
, O 
19 O 
known O 
compounds O 
were O 
identified O 
: O 
β-sitosteryl B-MULTIPLE 
and I-MULTIPLE 
stigmasteryl I-MULTIPLE 
linoleates I-MULTIPLE 
, O 
β-sitosterol B-TRIVIAL 
, O 
stigmasterol B-TRIVIAL 
, O 
triacontanol B-TRIVIAL 
, O 
squalene B-MULTIPLE 
, I-MULTIPLE 
α- I-MULTIPLE 
and I-MULTIPLE 
β-amyrin I-MULTIPLE 
, O 
lupeol B-TRIVIAL 
, O 
lupenone B-TRIVIAL 
, O 
betulin B-TRIVIAL 
aldehyde I-TRIVIAL 
, O 
betulon B-TRIVIAL 
aldehyde I-TRIVIAL 
, O 
oleanolic B-TRIVIAL 
aldehyde I-TRIVIAL 
, O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
betulonic B-TRIVIAL 
acid I-TRIVIAL 
, O 
moronic B-TRIVIAL 
acid I-TRIVIAL 
, O 
morolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
flavonoids B-FAMILY 
acacetin B-TRIVIAL 
and O 
acacetin B-SYSTEMATIC 
7-methyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
. O 
There O 
have O 
been O 
no O 
previous O 
reports O 
in O 
the O 
literature O 
on O 
the O 
chemical O 
composition O 
of O 
this O 
potential O 
natural O 
source O 
of O 
hypoglycaemic O 
and O 
antihypertensive O 
compounds O 
. O 

kinases O 
facilitate O 
c-myc O 
IRES O 
activity O 
in O 
rapamycin B-TRIVIAL 
-treated O 
multiple O 
myeloma O 
cells O 
. O 

mTOR O 
inhibitor O 
rapalogs O 
prevent O 
cap O 
- O 
dependent O 
translation O 
of O 
cell O 
- O 
cycle O 
proteins O 
like O 
c-myc O 
, O 
continuing O 
tumor O 
cell O 
growth O 
depends O 
on O 
cap O 
- O 
independent O 
translation O 
, O 
which O 
is O 
mediated O 
by O 
internal O 
ribosome O 
entry O 
sites O 
( O 
IRESes O 
) O 
located O 
in O 
the O 
5'-UTR O 
( O 
untranslated O 
region O 
) O 
of O 
transcripts O 
. O 
To O 
investigate O 
if O 
rapalog O 
- O 
induced O 
activation O 
of O 
MNK O 
kinases O 
had O 
a O 
role O 
in O 
such O 
IRES O 
activity O 
, O 
we O 
studied O 
multiple O 
myeloma O 
( O 
MM O 
) O 
cells O 
. O 
Rapamycin B-TRIVIAL 
( O 
RAP B-ABBREVIATION 
)-activated O 
MNK1 O 
kinase O 
activity O 
in O 
MM O 
cell O 
lines O 
and O 
primary O 
specimens O 
by O 
a O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
- O 
dependent O 
mechanism O 
. O 
Pharmacological O 
inhibition O 
of O 
MNK O 
activity O 
or O 
genetic O 
silencing O 
of O 
MNK1 O 
prevented O 
a O 
rapalog O 
- O 
induced O 
upregulation O 
of O 
c-myc O 
IRES O 
activity O 
. O 
Although O 
RAP B-ABBREVIATION 
, O 
used O 
alone O 
, O 
had O 
little O 
effect O 
on O 
myc O 
protein O 
expression O 
, O 
when O 
combined O 
with O 
a O 
MNK O 
inhibitor O 
, O 
myc O 
protein O 
expression O 
was O 
abrogated O 
. O 
In O 
contrast O 
, O 
there O 
was O 
no O 
inhibition O 
of O 
myc O 
RNA O 
, O 
consistent O 
with O 
an O 
effect O 
on O 
myc O 
translation O 
. O 
In O 
a O 
RAP B-ABBREVIATION 
-resistant O 
MM O 
cell O 
lines O 
as O 
well O 
as O 
a O 
resistant O 
primary O 
MM O 
specimen O 
, O 
co O 
- O 
exposure O 
to O 
a O 
MNK O 
inhibitor O 
or O 
MNK1 O 
knockdown O 
significantly O 
sensitized O 
cells O 
for O 
RAP B-ABBREVIATION 
-induced O 
cytoreduction O 
. O 
Studies O 
in O 
MNK-null O 
murine O 
embryonic O 
fibroblasts O 
additionally O 
supported O 
a O 
role O 
for O 
MNK O 
kinases O 
in O 
RAP B-ABBREVIATION 
-induced O 
myc O 
IRES O 
stimulation O 
. O 
These O 
results O 
indicate O 
that O 
MNK O 
kinase O 
activity O 
has O 
a O 
critical O 
role O 
in O 
the O 
fail O 
- O 
safe O 
mechanism O 
of O 
IRES-dependent O 
translation O 
when O 
mTOR O 
is O 
inhibited O 
. O 
As O 
kinase O 
activity O 
also O 
regulated O 
sensitivity O 
to O 
RAP B-ABBREVIATION 
, O 
the O 
data O 
also O 
provide O 
a O 
rationale O 
for O 
therapeutically O 
targeting O 
MNK O 
kinases O 
for O 
combined O 
treatment O 
with O 
mTOR O 
inhibitors O 
. O 

hypothesis O 
of O 
cancer O 
stem O 
cells O 
has O 
been O 
proposed O 
to O 
explain O 
the O 
therapeutic O 
failure O 
in O 
a O 
variety O 
of O 
cancers O 
including O 
lung O 
cancers O 
. O 
Previously O 
, O 
we O 
demonstrated O 
acquisition O 
of O 
epithelial O 
- O 
mesenchymal O 
transition O 
, O 
a O 
feature O 
highly O 
reminiscent O 
of O 
cancer O 
stem O 
- O 
like O 
cells O 
, O 
in O 
gefitinib B-TRIVIAL 
-resistant O 
A549 O 
cells O 
( O 
A549 O 
/ O 
GR O 
) O 
. O 
Here O 
, O 
we O 
show O 
that O 
A549 O 
/ O 
GR O 
cells O 
contain O 
a O 
high O 
proportion O 
of O 
CXCR4+ O 
cells O 
that O 
are O 
responsible O 
for O 
having O 
high O 
potential O 
of O 
self O 
- O 
renewal O 
activity O 
in O 
vitro O 
and O 
tumorigenicity O 
in O 
vivo O 
. O 
A549 O 
/ O 
GR O 
cells O 
exhibited O 
strong O 
sphere O 
- O 
forming O 
activity O 
and O 
high O 
CXCR4 O 
expression O 
and O 
SDF-1α O 
secretion O 
compared O 
with O 
parent O 
cells O 
. O 
Pharmacological O 
inhibition O 
( O 
AMD3100 O 
) O 
and O 
/ O 
or O 
siRNA O 
transfection O 
targeting O 
CXCR4 O 
significantly O 
suppressed O 
sphere O 
- O 
forming O 
activity O 
in O 
A549 O 
and O 
A549 O 
/ O 
GR O 
cells O 
, O 
and O 
in O 
various O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
cell O 
lines O 
. O 
A549 O 
/ O 
GR O 
cells O 
showed O 
enhanced O 
Akt O 
, O 
mTOR O 
and O 
STAT3 O 
( O 
Y705 O 
) O 
phosphorylation O 
. O 
Pharmacological O 
inhibition O 
of O 
phosphatidyl B-TRIVIAL 
inositol I-TRIVIAL 
3-kinase O 
or O 
transfection O 
with O 
wild O 
- O 
type O 
PTEN O 
suppressed O 
phosphorylation O 
of O 
Akt O 
, O 
mTOR O 
and O 
STAT3 O 
( O 
Y705 O 
) O 
, O 
sphere O 
formation O 
, O 
and O 
CXCR4 O 
expression O 
in O 
A549 O 
/ O 
GR O 
cells O 
, O 
whereas O 
mutant O 
PTEN O 
enhanced O 
these O 
events O 
. O 
Inhibition O 
of O 
STAT3 O 
by O 
WP1066 B-IDENTIFIER 
or O 
siSTAT3 O 
significantly O 
suppressed O 
the O 
sphere O 
formation O 
, O 
but O 
not O 
CXCR4 O 
expression O 
, O 
indicating O 
that O 
STAT3 O 
is O 
a O 
downstream O 
effector O 
of O 
CXCR4 O 
- O 
mediated O 
signaling O 
. O 
FACS-sorted O 
CXCR4+ O 
A549 O 
/ O 
GR O 
cells O 
formed O 
many O 
large O 
spheres O 
, O 
had O 
self O 
- O 
renewal O 
capacity O 
, O 
demonstrated O 
radiation O 
resistance O 
in O 
vitro O 
and O 
exhibited O 
stronger O 
tumorigenic O 
potential O 
in O 
vivo O 
than O 
CXCR4- O 
cells O 
. O 
Lentiviral O 
- O 
transduction O 
of O 
CXCR4 O 
enhanced O 
sphere O 
formation O 
and O 
tumorigenicity O 
in O 
H460 O 
and O 
A549 O 
cells O 
, O 
whereas O 
introduction O 
of O 
siCXCR4 O 
suppressed O 
these O 
activities O 
in O 
A549 O 
/ O 
GR O 
cells O 
. O 
Our O 
data O 
indicate O 
that O 
CXCR4+ O 
NSCLC O 
cells O 
are O 
strong O 
candidates O 
for O 
tumorigenic O 
stem O 
- O 
like O 
cancer O 
cells O 
that O 
maintain O 
stemness O 
through O 
a O 
CXCR4-medated O 
STAT3 O 
pathway O 
and O 
provide O 
a O 
potential O 
therapeutic O 
target O 
for O 
eliminating O 
these O 
malignant O 
cells O 
in O 
NSCLC O 
. O 

chemical O 
composition O 
of O 
essential O 
oil O 
obtained O 
by O 
hydrodistillation O 
of O 
the O 
fresh O 
aerial O 
parts O 
of O 
Mentha O 
requienii O 
Bentham O 
( O 
Lamiaceae O 
) O 
collected O 
on O 
the O 
Gennargentu O 
Mountains O 
( O 
Sardinia O 
, O 
Italy O 
) O 
has O 
been O 
investigated O 
by O 
gas O 
chromatography O 
and O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
The O 
main O 
constituents O 
that O 
resulted O 
were O 
pulegone B-TRIVIAL 
( O 
78% O 
) O 
, O 
menthone B-TRIVIAL 
( O 
0.5% O 
) O 
, O 
isomenthone B-TRIVIAL 
( O 
18% O 
) O 
, O 
isopulegone B-TRIVIAL 
( O 
1.3% O 
) O 
and O 
limonene B-TRIVIAL 
( O 
1.76% O 
) O 
. O 
In O 
vitro O 
antifungal O 
activity O 
is O 
evaluated O 
in O 
order O 
to O 
identify O 
new O 
means O 
that O 
could O 
be O 
helpful O 
in O 
the O 
prevention O 
of O 
contamination O 
in O 
indoor O 
environments O 
. O 

sources O 
and O 
medium O 
pH O 
affects O 
the O 
growth O 
of O 
Withania O 
somnifera O 
( O 
L O 
. O 
) O 
Dunal O 
adventitious O 
roots O 
and O 
withanolide B-TRIVIAL 
A I-TRIVIAL 
production O 
. O 

work O 
deals O 
with O 
optimisation O 
of O 
adventitious O 
root O 
suspension O 
culture O 
of O 
Withania O 
somnifera O 
( O 
L O 
. O 
) O 
Dunal O 
( O 
Solanaceae O 
) O 
for O 
the O 
production O 
of O 
biomass O 
and O 
withanolide B-TRIVIAL 
A I-TRIVIAL 
and O 
we O 
investigated O 
the O 
effect O 
of O 
carbon B-SYSTEMATIC 
source O 
and O 
the O 
initial O 
medium O 
pH O 
on O 
growth O 
and O 
production O 
of O 
withanolide B-TRIVIAL 
A I-TRIVIAL 
in O 
adventitious O 
root O 
cultures O 
of O 
Withania O 
somnifera O 
. O 
A O 
2% O 
sucrose B-TRIVIAL 
concentration O 
was O 
found O 
to O 
be O 
best O 
for O 
both O 
biomass O 
( O 
113.58 O 
g O 
L(-1) O 
fresh O 
weight O 
( O 
FW O 
) O 
and O 
11.33 O 
g O 
L(-1) O 
dry O 
weight O 
( O 
DW O 
) O 
) O 
and O 
secondary O 
metabolite O 
accumulation O 
( O 
8.93 O 
mg O 
g(-1) O 
DW O 
) O 
in O 
the O 
tested O 
range O 
of O 
concentration O 
( O 
1-8% O 
) O 
. O 
The O 
biomass O 
of O 
adventitious O 
roots O 
was O 
optimal O 
when O 
the O 
initial O 
medium O 
pH O 
was O 
5.8 O 
( O 
113.26 O 
g O 
L(-1) O 
FW O 
and O 
11.33 O 
g O 
L(-1) O 
DW O 
) O 
but O 
the O 
withanolide B-TRIVIAL 
A I-TRIVIAL 
production O 
was O 
highest O 
at O 
the O 
medium O 
pH O 
level O 
of O 
5.5 O 
( O 
9.09 O 
mg O 
g(-1) O 
DW O 
) O 
. O 

of O 
pharmacokinetics O 
in O 
beagle O 
dogs O 
of O 
nimesulide B-TRIVIAL 
bilayer O 
tablets O 
with O 
dispersible O 
tablets O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
compare O 
the O 
in O 
vitro O 
release O 
and O 
the O 
in O 
vivo O 
pharmacokinetics O 
of O 
bilayer O 
tablets O 
with O 
the O 
conventional O 
dispersible O 
tablets O 
of O 
nimesulide B-TRIVIAL 
. O 
The O 
tablets O 
were O 
administered O 
to O 
beagle O 
dogs O 
and O 
the O 
plasma O 
levels O 
of O 
nimesulide B-TRIVIAL 
were O 
determined O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography-MS O 
/ O 
MS O 
. O 
The O 
pharmacokinetic O 
parameters O 
were O 
calculated O 
using O 
a O 
noncompartmental O 
model O 
. O 
The O 
bilayer O 
tablets O 
showed O 
a O 
biphasic O 
in O 
vitro O 
release O 
pattern O 
with O 
initial O 
burst O 
release O 
and O 
sustained O 
release O 
following O 
the O 
quasi-Fickian O 
diffusion O 
- O 
based O 
release O 
mechanism O 
. O 
The O 
C(max) O 
, O 
t(max) O 
, O 
mean O 
residence O 
time O 
( O 
MRT O 
) O 
, O 
and O 
area O 
under O 
the O 
curve O 
from O 
0 O 
to O 
36 O 
h O 
were O 
10.8 O 
± O 
4.2 O 
μg O 
/ O 
mL O 
, O 
2.3 O 
± O 
1 O 
h O 
, O 
6.7 O 
± O 
2.1 O 
h O 
, O 
81.5 O 
± O 
26.7 O 
μg·h O 
/ O 
mL O 
for O 
the O 
bilayer O 
tablets O 
and O 
14.8 O 
± O 
5.8 O 
μg O 
/ O 
mL O 
, O 
2.7 O 
± O 
0.8 O 
h O 
, O 
5.6 O 
± O 
0.9 O 
h O 
, O 
95.4 O 
± O 
44.2 O 
μg·h O 
/ O 
mL O 
for O 
the O 
dispersible O 
tablets O 
. O 
Compared O 
with O 
the O 
dispersible O 
tablets O 
, O 
the O 
bilayer O 
tablets O 
have O 
lower O 
C(max) O 
, O 
similar O 
t(max) O 
, O 
and O 
longer O 
MRT O 
. O 
The O 
aforementioned O 
pharmacokinetic O 
parameters O 
, O 
especially O 
the O 
MRT O 
demonstrated O 
to O 
be O 
valuable O 
for O 
evaluating O 
the O 
biphasic O 
characteristics O 
. O 
This O 
study O 
provides O 
a O 
promising O 
in O 
vivo O 
evaluation O 
method O 
for O 
the O 
bilayer O 
tablets O 
with O 
biphasic O 
release O 
pattern O 
. O 

PLA B-ABBREVIATION 
-based O 
in O 
situ O 
forming O 
implants O 
for O 
controlled O 
release O 
of O 
Ivermectin B-TRIVIAL 
a O 
BCS O 
Class O 
II O 
drug O 
: O 
solvent O 
selection O 
based O 
on O 
physico O 
- O 
chemical O 
characterization O 
. O 

situ O 
forming O 
implants O 
( O 
ISI O 
) O 
prepared O 
from O 
biodegradable O 
polymers O 
such O 
as O 
poly(D,L-lactide) B-SYSTEMATIC 
( O 
PLA B-ABBREVIATION 
) O 
and O 
biocompatible O 
solvents O 
can O 
be O 
used O 
to O 
obtain O 
sustained O 
drug O 
release O 
after O 
parenteral O 
administration O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
study O 
the O 
effect O 
of O 
several O 
biocompatible O 
solvents O 
with O 
different O 
physico O 
- O 
chemical O 
properties O 
on O 
the O 
release O 
of O 
ivermectin B-TRIVIAL 
( O 
IVM B-ABBREVIATION 
) O 
, O 
an O 
antiparasitic O 
BCS O 
II O 
drug O 
, O 
from O 
in O 
situ O 
forming O 
PLA B-ABBREVIATION 
-based O 
implants O 
. O 
The O 
solvents O 
evaluated O 
were O 
N-methyl-2-pyrrolidone B-SYSTEMATIC 
( O 
NMP B-ABBREVIATION 
) O 
, O 
2-pyrrolidone B-SYSTEMATIC 
( O 
2P O 
) O 
, O 
triacetine B-TRIVIAL 
( O 
TA O 
) O 
and O 
benzyl B-SYSTEMATIC 
benzoate I-SYSTEMATIC 
( O 
BB O 
) O 
. O 
Hansen's O 
solubility O 
parameters O 
of O 
solvents O 
were O 
used O 
to O 
explain O 
polymer O 
/ O 
solvent O 
interactions O 
leading O 
to O 
different O 
rheological O 
behaviours O 
. O 
The O 
stability O 
of O 
the O 
polymer O 
and O 
drug O 
in O 
the O 
solvents O 
were O 
also O 
evaluated O 
by O 
size O 
exclusion O 
and O 
high O 
performance O 
liquid O 
chromatography O 
, O 
respectively O 
. O 
The O 
two O 
major O 
factors O 
determining O 
the O 
rate O 
of O 
IVM B-ABBREVIATION 
release O 
from O 
ISI O 
were O 
miscibility O 
of O 
the O 
solvent O 
with O 
water O 
and O 
the O 
viscosity O 
of O 
the O 
polymer O 
solutions O 
. O 
In O 
general O 
, O 
the O 
release O 
rate O 
increased O 
with O 
increasing O 
water O 
miscibility O 
of O 
the O 
solvent O 
and O 
decreasing O 
viscosity O 
in O 
the O 
following O 
order O 
NMP B-ABBREVIATION 
> O 
2P O 
> O 
TA O 
> O 
BB O 
. O 
Scanning O 
electron O 
microscopy O 
revealed O 
a O 
relationship O 
between O 
the O 
rate O 
of O 
IVM B-ABBREVIATION 
release O 
and O 
the O 
surface O 
porosity O 
of O 
the O 
implants O 
, O 
release O 
being O 
higher O 
as O 
implant O 
porosity O 
increased O 
. O 
Finally O 
, O 
drug O 
and O 
polymer O 
stability O 
in O 
the O 
solvents O 
followed O 
the O 
same O 
trends O 
, O 
increasing O 
when O 
polymer O 
- O 
solvent O 
affinities O 
and O 
water O 
content O 
in O 
solvents O 
decreased O 
. O 
IVM B-ABBREVIATION 
degradation O 
was O 
accelerated O 
by O 
the O 
acid O 
environment O 
generated O 
by O 
the O 
degradation O 
of O 
the O 
polymer O 
but O 
the O 
drug O 
did O 
not O 
affect O 
PLA B-ABBREVIATION 
stability O 
. O 

triterpene B-FAMILY 
from O 
Salix O 
caprea O 
L O 
. O 
( O 
goat O 
willow O 
) O 
. O 

investigation O 
of O 
low O 
polar O 
solvent O 
extract O 
of O 
Salix O 
caprea O 
through O 
chromatographic O 
techniques O 
led O 
to O 
the O 
isolation O 
of O 
new O 
triterpene B-FAMILY 
as O 
1α,3β,25-trihydroxy-9(11)-ene-16-one-9,10-seco-9,19-cyclolanostane B-SYSTEMATIC 
( O 
1 O 
) O 
along O 
with O 
fatty B-SYSTEMATIC 
alcohols I-SYSTEMATIC 
. O 
The O 
structure O 
of O 
compound O 
1 O 
was O 
established O 
by O 
IR O 
, O 
HRESI O 
/ O 
MS O 
and O 
NMR O 
including O 
1D O 
and O 
2D O 
experiments O 
. O 
The O 
compound O 
1 O 
showed O 
moderate O 
in O 
vitro O 
antiplasmodial O 
activity O 
. O 

investigation O 
of O 
the O 
aerial O 
part O 
and O 
the O 
roots O 
of O 
Euphorbia O 
hyberna O 
L O 
. O 
subs O 
. O 
hyberna O 
. O 
resulted O 
in O 
the O 
isolation O 
and O 
identification O 
of O 
four O 
triterpenoids B-FAMILY 
( O 
3β-O-octadecanoyllupeol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
glut-5-en-3β-ol B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
24-methylenecicloartan-3β-ol B-SYSTEMATIC 
( O 
3 O 
) O 
and O 
cicloart-23-ene-3β,25-diol B-SYSTEMATIC 
( O 
6 O 
) O 
) O 
along O 
with O 
the O 
phenolic O 
compounds O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
( O 
4 O 
) O 
and O 
3,3'-di-O-methylellagic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
7 O 
) O 
. O 
Although O 
these O 
are O 
all O 
known O 
compounds O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
their O 
isolation O 
from O 
this O 
plant O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectral O 
methods O 
, O 
including O 
2D O 
NMR O 
experiences O 
, O 
and O 
confirmed O 
by O 
comparing O 
with O 
the O 
literature O 
data O 
. O 

elucidation O 
of O 
a O 
new O 
natural O 
diketopiperazine B-FAMILY 
from O 
a O 
Microbispora O 
aerata O 
strain O 
isolated O 
from O 
Livingston O 
Island O 
, O 
Antarctica O 
. O 

new O 
natural O 
diketopiperazine B-FAMILY 
( O 
1 O 
) O 
was O 
obtained O 
from O 
the O 
culture O 
broth O 
of O 
Microbispora O 
aerata O 
strain O 
imbas-11A O 
, O 
isolated O 
from O 
penguin O 
excrements O 
collected O 
on O 
the O 
Antarctic O 
Livingston O 
Island O 
. O 
Compound O 
1 O 
was O 
purified O 
consecutively O 
by O 
solvent O 
extraction O 
, O 
silica O 
gel O 
column O 
chromatography O 
and O 
preparative O 
HPLC O 
. O 
The O 
structure O 
of O 
the O 
compound O 
was O 
elucidated O 
by O 
1D O 
and O 
2D O 
NMR O 
experiments O 
and O 
mass O 
spectrometric O 
investigations O 
. O 
The O 
absolute O 
configuration O 
of O 
compound O 
1 O 
was O 
determined O 
by O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
and O 
NOESY O 
correlations O 
. O 
A O 
low O 
antiproliferative O 
and O 
cytotoxic O 
effect O 
of O 
trans-cyclo-(D-tryptophanyl-L-tyrosyl) B-SYSTEMATIC 
( O 
1 O 
) O 
was O 
determined O 
with O 
L-929 O 
mouse O 
fibroblast O 
cells O 
, O 
K-562 O 
human O 
leukemia O 
cells O 
and O 
HeLa O 
human O 
cervix O 
carcinoma O 
. O 
Trans-cyclo-(D-tryptophanyl-L-tyrosyl) B-SYSTEMATIC 
( O 
1 O 
) O 
did O 
not O 
show O 
antimicrobial O 
activity O 
at O 
a O 
concentration O 
of O 
50 O 
µg O 
per O 
disc O 
against O 
Bacillus O 
subtilis O 
, O 
Staphylococcus O 
aureus O 
, O 
Streptomyces O 
viridochromogenes O 
, O 
Escherichia O 
coli O 
, O 
Candida O 
albicans O 
and O 
Mucor O 
miehei O 
. O 

tamala O 
Nees O 
and O 
Eberm O 
( O 
tejpat O 
) O 
and O 
Pimenta O 
dioica O 
( O 
L O 
. O 
) O 
Merr O 
( O 
pimento O 
) O 
leaves O 
are O 
commonly O 
used O 
for O 
flavouring O 
food O 
and O 
widely O 
used O 
in O 
pharmaceutical O 
preparations O 
because O 
of O 
their O 
hypoglycemic O 
, O 
carminative O 
and O 
stimulant O 
properties O 
. O 
In O 
this O 
study O 
, O 
we O 
compared O 
the O 
chemical O 
composition O 
and O 
antioxidant O 
activities O 
of O 
tejpat O 
and O 
pimento O 
essential O 
oils O 
by O 
employing O 
various O 
in O 
vitro O 
methods O 
. O 
GC O 
and O 
GC-MS O 
analyses O 
were O 
done O 
to O 
find O 
out O 
the O 
chemical O 
composition O 
, O 
and O 
the O 
main O 
constituent O 
identified O 
in O 
tejpat O 
and O 
pimento O 
leaf O 
oils O 
was O 
eugenol B-TRIVIAL 
. O 
Both O 
the O 
oils O 
showed O 
significant O 
radical O 
scavenging O 
activity O 
against O 
DPPH B-ABBREVIATION 
and O 
superoxide B-TRIVIAL 
radicals O 
with O 
a O 
potent O 
metal O 
chelating O 
activity O 
and O 
were O 
compared O 
with O 
that O 
of O 
standard O 
compound O 
, O 
eugenol B-TRIVIAL 
. O 
Among O 
the O 
two O 
oils O 
, O 
tejpat O 
oil O 
showed O 
better O 
activity O 
in O 
terms O 
of O 
antioxidative O 
potential O 
. O 

and O 
lipoxygenase O 
inhibiting O 
new O 
iridoid B-FAMILY 
glucosides I-FAMILY 
from O 
Caryopteris O 
odorata O 
. O 

phytochemical O 
investigation O 
of O 
the O 
ethylacetate B-SYSTEMATIC 
-soluble O 
fraction O 
of O 
Caryopteris O 
odorata O 
( O 
Ham O 
. O 
ex O 
Roxb O 
. O 
) O 
led O 
to O 
the O 
isolation O 
of O 
four O 
new O 
iridoid B-FAMILY 
glucosides I-FAMILY 
( O 
1-4 O 
) O 
: O 
8-O-trans-cinnamoyl B-SYSTEMATIC 
caryoptoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
8-O-trans-cinnamoyl B-SYSTEMATIC 
shanzhiside I-SYSTEMATIC 
methylester I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
8-O-trans-cinnamoyl B-SYSTEMATIC 
mussaenoside I-SYSTEMATIC 
( O 
3 O 
) O 
and O 
8-O-cafeoyl B-SYSTEMATIC 
massenoside I-SYSTEMATIC 
( O 
4 O 
) O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
determined O 
by O 
FAB-MS O 
, O 
IR O 
, O 
1D O 
and O 
2D-NMR O 
spectroscopy O 
and O 
by O 
comparing O 
with O 
the O 
published O 
data O 
of O 
the O 
closely O 
related O 
compounds O 
. O 
The O 
antioxidant O 
potential O 
of O 
the O 
isolated O 
iridoids B-FAMILY 
( O 
1-4 O 
) O 
was O 
evaluated O 
relative O 
to O 
conventionally O 
used O 
standards O 
and O 
these O 
molecules O 
exhibited O 
good O 
antioxidant O 
potential O 
. O 
Moreover O 
, O 
their O 
inhibitory O 
potential O 
was O 
also O 
screened O 
against O 
three O 
enzymes O 
, O 
namely O 
acetyl B-SYSTEMATIC 
cholinesterase O 
, O 
butyrylcholinesterase O 
and O 
lipoxygenase O 
. O 
These O 
iridoid B-FAMILY 
glucosides I-FAMILY 
were O 
found O 
to O 
be O 
inactive O 
against O 
acetyl B-SYSTEMATIC 
and O 
butyrylcholinesterases O 
but O 
active O 
against O 
lipoxygenase O 
. O 

Bcl-2 O 
family O 
members O 
of O 
the O 
Bcl-2 O 
homology O 
(BH)3 O 
- O 
only O 
subgroup O 
are O 
critical O 
for O 
the O 
establishment O 
and O 
maintenance O 
of O 
tissue O 
homeostasis O 
and O 
can O 
mediate O 
apoptotic O 
cell O 
death O 
in O 
response O 
to O 
developmental O 
cues O 
or O 
exogenously O 
induced O 
forms O 
of O 
cell O 
stress O 
. O 
On O 
the O 
basis O 
of O 
the O 
biochemical O 
experiments O 
as O 
well O 
as O 
genetic O 
studies O 
in O 
mice O 
, O 
the O 
BH3 O 
- O 
only O 
proteins O 
Bad O 
and O 
Bmf O 
have O 
been O 
implicated O 
in O 
different O 
proapoptotic O 
events O 
such O 
as O 
those O 
triggered O 
by O 
glucose B-TRIVIAL 
- O 
or O 
trophic O 
factor O 
- O 
deprivation O 
, O 
glucocorticoids O 
, O 
or O 
histone O 
deacetylase O 
inhibition O 
, O 
as O 
well O 
as O 
suppression O 
of O 
B-cell O 
lymphomagenesis O 
upon O 
aberrant O 
expression O 
of O 
c-Myc O 
. O 
To O 
address O 
possible O 
redundancies O 
in O 
cell O 
death O 
regulation O 
and O 
tumor O 
suppression O 
, O 
we O 
generated O 
compound O 
mutant O 
mice O 
lacking O 
both O 
genes O 
. O 
Our O 
studies O 
revealed O 
lack O 
of O 
redundancy O 
in O 
most O 
paradigms O 
of O 
lymphocyte O 
apoptosis O 
tested O 
in O 
tissue O 
culture O 
. O 
Only O 
spontaneous O 
cell O 
death O 
of O 
thymocytes O 
kept O 
in O 
low O 
glucose B-TRIVIAL 
or O 
that O 
of O 
pre-B O 
cells O 
deprived O 
of O 
cytokines O 
was O 
significantly O 
delayed O 
when O 
both O 
genes O 
were O 
lacking O 
. O 
Of O 
note O 
, O 
despite O 
these O 
minor O 
apoptosis O 
defects O 
we O 
observed O 
compromised O 
lymphocyte O 
homeostasis O 
in O 
vivo O 
that O 
affected O 
mainly O 
the O 
B-cell O 
lineage O 
. O 
Long O 
- O 
term O 
follow O 
- O 
up O 
revealed O 
significantly O 
reduced O 
latency O 
to O 
spontaneous O 
tumor O 
formation O 
in O 
aged O 
mice O 
when O 
both O 
genes O 
were O 
lacking O 
. O 
Together O 
our O 
study O 
suggests O 
that O 
Bad O 
and O 
Bmf O 
co O 
- O 
regulate O 
lymphocyte O 
homeostasis O 
and O 
limit O 
spontaneous O 
transformation O 
by O 
mechanisms O 
that O 
may O 
not O 
exclusively O 
be O 
linked O 
to O 
the O 
induction O 
of O 
lymphocyte O 
apoptosis O 
. O 

the O 
roles O 
of O 
mGlu2 O 
and O 
mGlu3 O 
receptors O 
using O 
LY541850 B-IDENTIFIER 
, O 
an O 
mGlu2 O 
agonist O 
/ O 
mGlu3 O 
antagonist O 
. O 

the O 
potential O 
therapeutic O 
relevance O 
of O 
group O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
, O 
there O 
has O 
been O 
a O 
lack O 
of O 
pharmacological O 
tools O 
for O 
separating O 
the O 
roles O 
of O 
mGlu2 O 
and O 
mGlu3 O 
receptor O 
subtypes O 
. O 
LY541850 B-IDENTIFIER 
was O 
claimed O 
from O 
human O 
mGlu O 
receptors O 
expressed O 
in O 
non-neuronal O 
cells O 
to O 
be O 
a O 
selective O 
orthosteric O 
mGlu2 O 
agonist O 
and O 
mGlu3 O 
antagonist O 
. O 
We O 
have O 
verified O 
this O 
pharmacological O 
profile O 
of O 
LY541850 B-IDENTIFIER 
in O 
hippocampal O 
slices O 
. O 
Field O 
excitatory O 
post O 
- O 
synaptic O 
potentials O 
( O 
fEPSPs O 
) O 
evoked O 
by O 
stimulation O 
of O 
the O 
temporo O 
- O 
ammonic O 
path O 
( O 
TAP O 
) O 
input O 
to O 
CA1 O 
stratum O 
lacunosum O 
moleculare O 
( O 
SLM O 
) O 
were O 
inhibited O 
by O 
LY541850 B-IDENTIFIER 
in O 
mGlu3- O 
/ O 
- O 
mice O 
( O 
EC(50) O 
38 O 
nM O 
) O 
and O 
wild O 
- O 
type O 
littermates O 
( O 
EC(50) O 
42 O 
nM O 
) O 
to O 
a O 
similar O 
extent O 
but O 
were O 
not O 
significantly O 
affected O 
in O 
mGlu2- O 
/ O 
- O 
mice O 
. O 
The O 
group O 
II O 
agonist O 
, O 
DCG-IV O 
, O 
inhibited O 
the O 
fEPSP O 
in O 
all O 
three O 
genotypes O 
. O 
Co-application O 
of O 
DCG-IV O 
and O 
LY541850 B-IDENTIFIER 
in O 
mGlu3- O 
/ O 
- O 
and O 
wild O 
- O 
type O 
littermates O 
resulted O 
in O 
an O 
additive O 
effect O 
, O 
whereas O 
in O 
mGlu2- O 
/ O 
- O 
mice O 
, O 
LY541850 B-IDENTIFIER 
reversed O 
the O 
inhibitory O 
action O 
of O 
DCG-IV O 
. O 
These O 
results O 
confirm O 
the O 
selective O 
mGlu2 O 
agonist O 
and O 
mGlu3 O 
antagonist O 
actions O 
of O 
LY541850 B-IDENTIFIER 
. O 
A O 
similar O 
profile O 
of O 
activity O 
was O 
seen O 
in O 
medial O 
perforant O 
path O 
synapse O 
to O 
the O 
dentate O 
gyrus O 
. O 
Systemic O 
administration O 
of O 
LY541850 B-IDENTIFIER 
to O 
wild O 
- O 
type O 
mice O 
, O 
reduced O 
the O 
increase O 
in O 
locomotor O 
activity O 
following O 
both O 
phencyclidine B-TRIVIAL 
and O 
amphetamine B-TRIVIAL 
administration O 
. O 
These O 
data O 
support O 
the O 
hypothesis O 
that O 
mGlu2 O 
receptors O 
mediate O 
the O 
antipsychotic O 
effects O 
of O 
mixed O 
group O 
II O 
agonists O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

study O 
was O 
designed O 
to O 
examine O 
the O 
in O 
vitro O 
antiproliferative O 
effect O 
of O 
the O 
horse O 
chestnut O 
extract O 
( O 
HCE O 
) O 
on O 
cancer O 
cell O 
lines O 
. O 
Furthermore O 
, O 
we O 
have O 
investigated O 
the O 
in O 
vitro O 
effect O 
of O 
HCE O 
on O 
some O 
angiogenic O 
events O 
by O 
using O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
. O 
The O 
cell O 
proliferation O 
was O 
evaluated O 
by O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
assay O 
and O 
anchorage O 
- O 
independent O 
growth O 
by O 
colony O 
- O 
forming O 
assay O 
. O 
To O 
understand O 
the O 
growth O 
inhibitory O 
effects O 
, O 
carcinoma O 
cell O 
lines O 
( O 
Jurkat O 
, O 
CEM O 
, O 
HeLa O 
, O 
and O 
MCF-7 O 
) O 
were O 
treated O 
with O 
various O 
concentrations O 
of O 
HCE O 
. O 
Incubation O 
of O 
Jurkat O 
, O 
CEM O 
, O 
HeLa O 
, O 
and O 
MCF-7 O 
cancer O 
cells O 
with O 
HCE O 
at O 
125 O 
µg O 
/ O 
mL O 
for O 
72 O 
h O 
caused O 
93.7% O 
, O 
32.3% O 
, O 
20.4% O 
and O 
40.4% O 
reduction O 
in O 
cell O 
survival O 
. O 
Colony O 
- O 
forming O 
assay O 
also O 
confirmed O 
growth O 
- O 
inhibitory O 
effects O 
of O 
the O 
compound O 
studied O 
. O 
In O 
HeLa O 
HCE O 
- O 
treated O 
cells O 
, O 
we O 
found O 
a O 
significant O 
increase O 
in O 
cells O 
having O 
sub-G(0) O 
/ O 
G(1) O 
DNA O 
content O 
which O 
is O 
considered O 
to O 
be O 
a O 
marker O 
of O 
apoptotic O 
cell O 
death O 
. O 
Apoptosis O 
was O 
also O 
further O 
confirmed O 
by O 
DNA O 
fragmentation O 
analysis.Furthermore O 
, O 
HCE O 
inhibited O 
migration O 
of O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
as O 
well O 
as O 
decreased O 
secretion O 
of O 
matrix O 
metalloproteinase O 
and O 
vascular O 
endothelial O 
growth O 
factor.In O 
conclusion O 
, O 
the O 
present O 
study O 
has O 
assessed O 
the O 
in O 
vitro O 
antiproliferative O 
/ O 
antiangiogenic O 
potential O 
of O 
HCE O 
. O 
These O 
results O 
generate O 
a O 
rationale O 
for O 
in O 
vivo O 
efficacy O 
studies O 
with O 
horse O 
chestnut O 
in O 
preclinical O 
cancer O 
models O 
. O 

of O 
4-hydroxy-3,4-dialkyl-2,6-diaryl-piperidine B-FAMILY 
derivatives O 
as O 
potent O 
antimicrobial O 
agent O 
. O 

series O 
of O 
4-hydroxy-3,4-dialkyl-2,6-diaryl-piperidine B-FAMILY 
( O 
7-12 O 
) O 
have O 
been O 
synthesised O 
by O 
reduction O 
of O 
3-alkyl-2,6-diarylpiperidin-4-one B-FAMILY 
using O 
the O 
Grignard B-FAMILY 
reagent I-FAMILY 
. O 
Structural O 
assignments O 
and O 
conformational O 
analysis O 
of O 
the O 
compounds O 
were O 
established O 
based O 
on O 
the O 
spectral O 
studies O 
. O 
All O 
the O 
piperdin-4-ol B-SYSTEMATIC 
derivatives O 
( O 
7-12 O 
) O 
were O 
assayed O 
for O 
antibacterial O 
, O 
antifungal O 
and O 
anthelmintic O 
activities O 
and O 
they O 
exhibited O 
significant O 
results O 
. O 

sylvestre O 
( O 
CS O 
149 O 
) O 
, O 
known O 
to O 
be O 
a O 
rich O 
source O 
of O 
saponins B-FAMILY 
and O 
other O 
valuable O 
phytochemicals O 
, O 
has O 
been O 
analysed O 
for O 
antimicrobial O 
activity O 
. O 
The O 
chloroform B-TRIVIAL 
extracts O 
of O 
aerial O 
and O 
root O 
parts O 
of O 
G O 
. O 
sylvestre O 
exhibited O 
higher O 
antimicrobial O 
activity O 
as O 
compared O 
to O 
diethyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
and O 
acetone B-SYSTEMATIC 
. O 
The O 
root O 
extracts O 
of O 
chloroform B-TRIVIAL 
have O 
shown O 
competitive O 
minimum O 
inhibitory O 
concentration O 
and O 
minimum O 
bactericidal O 
concentration O 
values O 
in O 
the O 
range O 
of O 
0.04-1.28 O 
mg O 
mL(-1) O 
and O 
0.08-2.56 O 
mg O 
/ O 
mL O 
, O 
respectively O 
, O 
towards O 
the O 
pathogens O 
. O 
The O 
GC-MS O 
analysis O 
of O 
chloroform B-TRIVIAL 
extracts O 
has O 
shown O 
the O 
presence O 
of O 
compounds O 
like O 
eicosane B-SYSTEMATIC 
, O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
stigmasterol B-TRIVIAL 
and O 
vitamin B-FAMILY 
E I-FAMILY 
. O 

water O 
extraction O 
method O 
has O 
been O 
used O 
to O 
extract O 
plant O 
proteins O 
from O 
the O 
roots O 
of O 
Eurycoma O 
longifolia O 
harvested O 
from O 
Perak O 
and O 
Pahang O 
, O 
Malaysia O 
. O 
On O 
the O 
basis O 
of O 
the O 
spectroscopic O 
Bradford O 
assay O 
, O 
Tongkat O 
Ali O 
Perak O 
and O 
Pahang O 
contained O 
0.3868 O 
and O 
0.9573 O 
mg O 
mL(-1) O 
of O 
crude O 
protein O 
, O 
respectively O 
. O 
The O 
crude O 
proteins O 
were O 
separated O 
by O 
one O 
dimensional O 
15% O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
polyacrylamide I-SYSTEMATIC 
gel O 
electrophoresis O 
into O 
two O 
( O 
49.8 O 
and O 
5.5 O 
kD O 
) O 
and O 
four O 
( O 
49.8 O 
, O 
24.7 O 
, O 
21.1 O 
and O 
5.5 O 
kD O 
) O 
protein O 
spots O 
for O 
Tongkat O 
Ali O 
Perak O 
and O 
Pahang O 
, O 
respectively O 
. O 
Isoleucine B-TRIVIAL 
was O 
present O 
in O 
the O 
highest O 
concentration O 
significantly O 
. O 
Both O 
plant O 
samples O 
showed O 
differences O 
in O 
the O 
mineral O 
and O 
trace O 
element O 
profiles O 
, O 
but O 
the O 
minerals O 
calcium B-SYSTEMATIC 
, O 
magnesium B-SYSTEMATIC 
and O 
potassium B-SYSTEMATIC 
were O 
present O 
in O 
the O 
highest O 
concentration O 
. O 
The O 
highly O 
concerned O 
toxic O 
metals O 
such O 
as O 
arsenic B-SYSTEMATIC 
and O 
lead O 
were O 
not O 
detected O 
. O 

significant O 
progress O 
has O 
been O 
made O 
in O 
understanding O 
the O 
importance O 
of O 
Wnt O 
signaling O 
in O 
the O 
initiation O 
of O 
colorectal O 
cancer O 
, O 
less O 
is O 
known O 
about O 
responses O 
that O 
accompany O 
the O 
reversal O 
of O 
oncogenic O 
Wnt O 
signaling O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
analyze O 
in O 
vivo O 
and O 
in O 
vitro O 
responses O 
to O 
an O 
' O 
ideal O 
' O 
Wnt O 
pathway O 
inhibitor O 
as O 
a O 
model O 
for O 
the O 
therapeutic O 
targeting O 
of O 
the O 
pathway O 
. O 
A O 
tetracycline B-FAMILY 
-inducible O 
transgenic O 
mouse O 
model O 
expressing O 
truncated O 
β-catenin O 
( O 
ΔN89β-catenin O 
) O 
that O 
exhibited O 
a O 
strong O 
intestinal O 
hyperplasia O 
was O 
analyzed O 
during O 
the O 
removal O 
of O 
oncogenic O 
β-catenin O 
expression O 
both O 
in O 
3D O 
' O 
crypt O 
culture O 
' O 
and O 
in O 
vivo O 
. O 
Oncogenic O 
Wnt O 
signaling O 
was O 
rapidly O 
and O 
completely O 
reversed O 
. O 
The O 
strongest O 
inhibition O 
of O 
Wnt O 
target O 
gene O 
expression O 
occurred O 
within O 
24 O 
h O 
of O 
doxycycline O 
removal O 
at O 
which O 
time O 
the O 
target O 
genes O 
Ascl2 O 
, O 
Axin2 O 
and O 
C-myc O 
were O 
downregulated O 
to O 
levels O 
below O 
that O 
in O 
the O 
control O 
intestine O 
. O 
In O 
vitro O 
, O 
the O 
small O 
molecule O 
Wnt O 
inhibitor O 
CCT036477 O 
induced O 
a O 
response O 
within O 
4 O 
h O 
of O 
treatment O 
. O 
By O 
7 O 
days O 
following O 
doxycycline B-TRIVIAL 
withdrawal O 
, O 
gene O 
expression O 
, O 
cell O 
proliferation O 
and O 
tissue O 
morphology O 
were O 
undistinguishable O 
from O 
control O 
animals.In O 
conclusion O 
, O 
these O 
results O 
demonstrate O 
that O 
the O 
reversal O 
of O 
Wnt O 
signaling O 
by O 
inhibitors O 
should O 
ideally O 
be O 
studied O 
within O 
hours O 
of O 
treatment O 
. O 
The O 
reversible O 
system O 
described O 
, O 
involving O 
medium O 
throughput O 
in O 
vitro O 
approaches O 
and O 
rapid O 
in O 
vivo O 
responses O 
, O 
should O 
allow O 
the O 
rapid O 
advance O 
of O 
early O 
stage O 
compounds O 
into O 
efficacy O 
models O 
that O 
are O 
more O 
usually O 
considered O 
later O 
in O 
the O 
drug O 
discovery O 
pipeline O 
. O 

cells O 
activate O 
pathways O 
that O 
facilitate O 
and O 
stimulate O 
glycolysis O 
even O 
in O 
the O 
presence O 
of O 
adequate O 
levels O 
of O 
oxygen B-SYSTEMATIC 
in O 
order O 
to O 
satisfy O 
their O 
continuous O 
need O 
of O 
molecules O 
, O 
such O 
as O 
nucleotides O 
, O 
ATP B-ABBREVIATION 
and O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
necessary O 
to O 
support O 
their O 
rapid O 
proliferation O 
. O 
Accordingly O 
, O 
a O 
variety O 
of O 
human O 
tumors O 
are O 
characterized O 
by O 
elevated O 
expression O 
levels O 
of O 
the O 
hexokinase O 
2 O 
isoform O 
( O 
HK2 O 
) O 
. O 
Although O 
different O 
molecular O 
mechanisms O 
, O 
including O 
genetic O 
and O 
epigenetic O 
mechanisms O 
, O 
have O 
been O 
suggested O 
to O 
account O 
for O 
the O 
altered O 
expression O 
of O 
HK2 O 
in O 
tumors O 
, O 
the O 
potential O 
role O 
of O 
microRNAs O 
( O 
miRNAs O 
) O 
in O 
the O 
regulation O 
of O 
HK2 O 
expression O 
has O 
not O 
been O 
evaluated O 
. O 
Here O 
, O 
we O 
report O 
that O 
miR-143 O 
inhibits O 
HK2 O 
expression O 
via O 
a O 
conserved O 
miR-143 O 
recognition O 
motif O 
located O 
in O 
the O 
3'-untranslated O 
region O 
( O 
3'UTR O 
) O 
of O 
HK2 O 
mRNA O 
. O 
We O 
demonstrate O 
that O 
miR143 O 
inhibits O 
HK2 O 
expression O 
both O 
in O 
primary O 
keratinocytes O 
and O 
in O 
head O 
and O 
neck O 
squamous O 
cell O 
carcinoma O 
( O 
HNSCC O 
) O 
- O 
derived O 
cell O 
lines O 
. O 
Importantly O 
, O 
we O 
found O 
that O 
miR-143 O 
inversely O 
correlates O 
with O 
HK2 O 
expression O 
in O 
HNSCC O 
- O 
derived O 
cell O 
lines O 
and O 
in O 
primary O 
tumors O 
. O 
We O 
also O 
report O 
that O 
the O 
miRNA-dependent O 
regulation O 
of O 
hexokinase O 
expression O 
is O 
not O 
limited O 
to O 
HK2 O 
as O 
miR-138 O 
targets O 
HK1 O 
via O 
a O 
specific O 
recognition O 
motif O 
located O 
in O 
its O 
3'UTR O 
. O 
All O 
these O 
data O 
unveil O 
a O 
new O 
miRNA-dependent O 
mechanism O 
of O 
regulation O 
of O 
hexokinase O 
expression O 
potentially O 
important O 
in O 
the O 
regulation O 
of O 
glucose B-TRIVIAL 
metabolism O 
of O 
cancer O 
cells O 
. O 

E I-TRIVIAL 
, O 
a O 
new O 
C21 B-FORMULA 
steroid B-FAMILY 
from O 
Cynanchum O 
stauntonii O 
. O 

E I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
new O 
C(21) B-FORMULA 
steroid B-FAMILY 
sapogenin O 
, O 
along O 
with O 
three O 
known O 
ones O 
( O 
2-4 O 
) O 
were O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Cynanchum O 
stauntonii O 
( O 
Decne O 
. O 
) O 
Schltr O 
. O 
ex O 
Levl O 
. O 
Their O 
structures O 
were O 
established O 
mainly O 
by O 
the O 
spectroscopic O 
analysis O 
, O 
including O 
2D O 
NMR O 
. O 
All O 
the O 
isolated O 
compounds O 
were O 
evaluated O 
for O 
their O 
cytotoxicity O 
against O 
human O 
cancer O 
cell O 
lines O 
HeLa O 
, O 
Bel-7402 O 
, O 
SGC-7901 O 
and O 
BGC-823 O 
. O 

method O 
for O 
the O 
simultaneous O 
quantitation O 
of O 
boeravinone B-TRIVIAL 
E I-TRIVIAL 
and O 
boeravinone B-TRIVIAL 
B I-TRIVIAL 
in O 
Boerhaavia O 
diffusa O 
extract O 
and O 
its O 
formulation O 
. O 

high O 
- O 
performance O 
liquid O 
chromatography O 
method O 
was O 
developed O 
and O 
validated O 
for O 
the O 
simultaneous O 
quantitation O 
of O 
two O 
major O 
rotenoids B-FAMILY 
, O 
boeravinone B-TRIVIAL 
E I-TRIVIAL 
and O 
boeravinone B-TRIVIAL 
B I-TRIVIAL 
, O 
in O 
Boerhaavia O 
diffusa O 
extract O 
and O 
its O 
formulation O 
. O 
Chromatographic O 
separation O 
was O 
carried O 
out O 
on O 
an O 
Inertsil O 
ODS-3 O 
column O 
by O 
using O 
gradient O 
mobile O 
phase O 
containing O 
0.1% O 
v O 
/ O 
v O 
orthophosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
water O 
and O 
acetonitrile B-SYSTEMATIC 
. O 
The O 
detection O 
was O 
carried O 
out O 
at O 
276 O 
nm O 
. O 
The O 
method O 
was O 
validated O 
for O 
specificity O 
, O 
precision O 
, O 
accuracy O 
and O 
robustness O 
. O 
The O 
linearity O 
( O 
r O 
(2) O 
= O 
0.9989 O 
and O 
0.9991 O 
) O 
was O 
found O 
to O 
be O 
in O 
the O 
range O 
of O 
7.26-35.75 O 
µg O 
mL(-1) O 
and O 
2.20-11.00 O 
µg O 
mL(-1) O 
for O 
boeravinone B-MULTIPLE 
E I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
, O 
respectively O 
. O 
The O 
percent O 
recovery O 
observed O 
from O 
the O 
extract O 
sample O 
was O 
95.22-95.83 O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
influence O 
of O 
both O 
facility O 
location O 
and O 
typology O 
of O 
fish O 
farm O 
on O 
some O 
ecotoxicological O 
, O 
qualitative O 
and O 
reproductive O 
variables O 
in O 
European O 
sea O 
bass O 
Dicentrarchus O 
labrax O 
L O 
. O 
Several O 
variables O 
were O 
investigated O 
: O 
gonado O 
- O 
somatic O 
index O 
( O 
GSI O 
) O 
, O 
liver O 
- O 
somatic O 
index O 
( O 
LSI O 
) O 
; O 
7-ethoxyresorufin B-SYSTEMATIC 
- O 
O B-FORMULA 
-deethylase O 
( O 
EROD O 
) O 
, O 
benzo(a)pyrene B-SYSTEMATIC 
monooxygenase O 
and O 
acetylcholinesterase O 
activities O 
; O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
testosterone B-TRIVIAL 
, O 
17β-estradiol B-SYSTEMATIC 
, O 
total O 
lipid O 
, O 
phospholipid O 
( O 
PL O 
) O 
and O 
triglyceride B-FAMILY 
contents O 
. O 
In O 
addition O 
, O 
the O 
histological O 
sections O 
of O 
gonads O 
were O 
examined O 
. O 
Results O 
suggest O 
that O 
LSI O 
, O 
EROD O 
activity O 
, O 
GSI O 
, O 
GSH B-ABBREVIATION 
, O 
PL O 
, O 
hormone O 
levels O 
and O 
gonad O 
morphology O 
were O 
influenced O 
by O 
different O 
facility O 
locations O 
and O 
typologies O 
of O 
fish O 
farm O 
. O 

of O 
the O 
physicochemical O 
and O 
biopharmaceutical O 
properties O 
of O 
fluoro B-FAMILY 
- I-FAMILY 
indomethacin I-FAMILY 
. O 

nanocarriers O 
have O 
shown O 
great O 
potential O 
in O 
therapy O 
and O 
as O 
diagnostic O 
probes O 
, O 
e.g O 
. O 
in O 
imaging O 
of O 
cancer O 
and O 
inflammation O 
. O 
Imaging O 
can O 
be O 
applied O 
to O 
localize O 
the O 
carrier O 
or O 
the O 
drug O 
itself O 
in O 
the O 
body O 
and O 
/ O 
or O 
tissues O 
. O 
In O 
this O 
particular O 
case O 
it O 
is O 
important O 
that O 
drug O 
molecules O 
have O 
the O 
characteristics O 
for O 
possible O 
detection O 
, O 
e.g O 
. O 
after O 
modification O 
with O 
positron O 
emission O 
tomography O 
compliant O 
radioisotopes O 
, O 
without O 
affecting O 
their O 
pharmacological O 
behavior O 
. O 
In O 
order O 
to O 
easily O 
and O 
efficiently O 
follow O 
the O 
ADME O 
profile O 
of O 
the O 
drug O 
after O 
loaded O 
into O 
nanocarriers O 
, O 
the O 
drug O 
can O 
be O 
radiolabelled O 
with O 
, O 
e.g O 
. O 
18F B-FORMULA 
-label O 
, O 
in O 
order O 
to O 
assess O 
its O 
biodistribution O 
after O 
enteral O 
and O 
parenteral O 
administration O 
in O 
rats O 
. O 
However O 
, O 
this O 
is O 
only O 
possible O 
if O 
the O 
derivative O 
compound O 
behaves O 
similarly O 
to O 
the O 
parent O 
drug O 
compound O 
. O 
In O 
this O 
study O 
, O 
indomethacin B-TRIVIAL 
( O 
a O 
poorly O 
water O 
- O 
soluble O 
drug O 
) O 
was O 
chosen O 
as O 
a O 
model O 
compound O 
and O 
aimed O 
to O 
evaluate O 
the O 
physicochemical O 
and O 
biopharmaceutical O 
properties O 
of O 
an O 
analog O 
of O 
indomethacin B-TRIVIAL 
( O 
IMC B-ABBREVIATION 
) O 
, O 
fluoro B-FAMILY 
- I-FAMILY 
indomethacin I-FAMILY 
( O 
F-IMC B-ABBREVIATION 
) O 
. O 
Although O 
some O 
of O 
the O 
physicochemical O 
and O 
biopharmaceutical O 
properties O 
of O 
IMC B-ABBREVIATION 
are O 
already O 
known O 
, O 
in O 
order O 
to O 
establish O 
a O 
feasible O 
comparison O 
between O 
IMC B-ABBREVIATION 
and O 
F-IMC B-ABBREVIATION 
, O 
the O 
behavior O 
of O 
the O 
former O 
was O 
also O 
investigated O 
in O 
the O 
same O 
conditions O 
as O 
for O 
F-IMC B-ABBREVIATION 
. O 
In O 
this O 
context O 
, O 
both O 
IMC B-ABBREVIATION 
and O 
F-IMC B-ABBREVIATION 
were O 
thermally O 
and O 
morphologically O 
studied O 
. O 
Furthermore O 
, O 
the O 
following O 
properties O 
were O 
also O 
studied O 
for O 
both O 
compounds O 
: O 
pKa O 
and O 
logP O 
, O 
solubility O 
and O 
dissolution O 
profiles O 
at O 
physiological O 
pH O 
values O 
, O 
and O 
toxicity O 
at O 
different O 
concentrations O 
in O 
Caco-2 O 
cells O 
. O 
Finally O 
, O 
the O 
transport O 
across O 
Caco- O 
2 O 
monolayers O 
of O 
the O 
IMC B-ABBREVIATION 
and O 
F-IMC B-ABBREVIATION 
at O 
physiological O 
pH O 
range O 
was O 
also O 
investigated O 
. O 
The O 
results O 
obtained O 
showed O 
similar O 
values O 
in O 
pKalogP O 
, O 
solubility O 
, O 
dissolution O 
, O 
cytotoxicity O 
, O 
and O 
permeability O 
for O 
both O 
compounds O 
. O 
Thus O 
, O 
there O 
might O 
be O 
strong O 
evidence O 
that O 
both O 
IMC B-ABBREVIATION 
and O 
F-IMC B-ABBREVIATION 
should O 
have O 
a O 
similar O 
ADME O 
behavior O 
and O 
profiles O 
in O 
vivo O 
. O 
The O 
results O 
provide O 
fundamental O 
tools O 
and O 
ideas O 
for O 
further O 
research O 
with O 
nanocarriers O 
of O 
18F-IMC B-FORMULA 
. O 

furostanol B-TRIVIAL 
saponins B-FAMILY 
from O 
the O 
rhizomes O 
of O 
Tupistra O 
chinensis O 
. O 

new O 
furostanol B-TRIVIAL 
saponins B-FAMILY 
( O 
1-3 O 
) O 
, O 
including O 
a O 
polyhydroxyl B-SYSTEMATIC 
saponin B-FAMILY 
, O 
were O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Tupistra O 
chinensis O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
identified O 
by O 
NMR O 
, O 
MS O 
spectral O 
data O 
and O 
chemical O 
methods O 
. O 

promotes O 
glutamate B-TRIVIAL 
AMPA B-ABBREVIATION 
receptor O 
phosphorylation O 
via O 
activation O 
of O 
PKA O 
/ O 
DARPP-32 O 
signaling O 
in O 
striatopallidal O 
medium O 
spiny O 
neurons O 
. O 

I O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluRs O 
) O 
, O 
which O 
comprise O 
mGlu1Rs O 
and O 
mGlu5Rs O 
, O 
are O 
enriched O 
in O 
striatal O 
medium O 
spiny O 
neurons O 
( O 
MSNs O 
) O 
, O 
where O 
they O 
modulate O 
glutamatergic O 
transmission O 
. O 
Here O 
, O 
we O 
have O 
examined O 
the O 
effect O 
of O 
group O 
I O 
mGluRs O 
on O 
the O 
regulation O 
of O 
the O 
state O 
of O 
phosphorylation O 
of O 
the O 
GluA1 O 
subunit O 
of O 
the O 
AMPA B-ABBREVIATION 
glutamate B-TRIVIAL 
receptor O 
. O 
We O 
found O 
that O 
incubation O 
of O 
mouse O 
striatal O 
slices O 
with O 
the O 
group O 
I O 
mGluR O 
agonist O 
(R,S)-3,5-dihydroxyphenylglycine B-SYSTEMATIC 
( O 
DHPG B-ABBREVIATION 
) O 
promotes O 
GluA1 O 
phosphorylation O 
at O 
the O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
site O 
, O 
Ser B-FORMULA 
845 O 
. O 
This O 
effect O 
is O 
prevented O 
by O 
2-methyl-6-(phenylethynyl)pyridine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
MPEP B-ABBREVIATION 
) O 
, O 
a O 
selective O 
mGlu5R O 
antagonist O 
. O 
The O 
increase O 
in O 
GluA1 O 
phosphorylation O 
produced O 
by O 
DHPG B-ABBREVIATION 
is O 
also O 
prevented O 
by O 
blockade O 
of O 
adenosine B-TRIVIAL 
A2A O 
receptors O 
( O 
A2ARs O 
) O 
, O 
which O 
are O 
known O 
to O 
promote O 
cAMP B-ABBREVIATION 
signaling O 
specifically O 
in O 
striatopallidal O 
MSNs O 
, O 
as O 
well O 
as O 
by O 
enzymatic O 
degradation O 
of O 
endogenous O 
adenosine B-TRIVIAL 
, O 
achieved O 
with O 
adenosine B-TRIVIAL 
deaminase O 
. O 
The O 
ability O 
of O 
DHPG B-ABBREVIATION 
to O 
increase O 
PKA-dependent O 
phosphorylation O 
of O 
GluA1 O 
depends O 
on O 
concomitant O 
activation O 
of O 
the O 
dopamine B-TRIVIAL 
- O 
and O 
cAMP B-ABBREVIATION 
-regulated O 
phosphoprotein O 
of O 
32kDa O 
( O 
DARPP-32 O 
) O 
. O 
Thus O 
, O 
inactivation O 
of O 
the O 
PKA O 
phosphorylation O 
site O 
of O 
DARPP-32 O 
abolishes O 
the O 
effect O 
of O 
DHPG B-ABBREVIATION 
. O 
Moreover O 
, O 
cell O 
- O 
specific O 
knock O 
out O 
of O 
DARPP-32 O 
in O 
striatopallidal O 
, O 
but O 
not O 
in O 
striatonigral O 
, O 
MSNs O 
prevents O 
the O 
increase O 
in O 
Ser B-FORMULA 
845 O 
phosphorylation O 
induced O 
by O 
DHPG B-ABBREVIATION 
. O 
These O 
results O 
indicate O 
that O 
activation O 
of O 
mGlu5Rs O 
promotes O 
PKA O 
/ O 
DARPP-32-dependent O 
phosphorylation O 
of O 
downstream O 
target O 
proteins O 
in O 
striatopallidal O 
MSNs O 
and O 
that O 
this O 
effect O 
is O 
exerted O 
via O 
potentiation O 
of O 
tonic O 
A2AR O 
transmission O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

, O 
pharmacokinetic O 
and O 
pharmacodynamic O 
evaluations O 
of O 
novel O 
ternary O 
solid O 
dispersion O 
of O 
rebamipide B-TRIVIAL 
with O 
poloxamer B-TRIVIAL 
407 I-TRIVIAL 
. O 

study O 
was O 
conducted O 
primarily O 
to O 
improve O 
the O 
solubility O 
of O 
rebamipide B-TRIVIAL 
, O 
a O 
poorly O 
water O 
- O 
soluble O 
anti-ulcer O 
drug O 
, O 
using O 
novel O 
ternary O 
solid O 
dispersion O 
( O 
SD O 
) O 
systems O 
and O 
secondly O 
to O 
evaluate O 
the O 
effect O 
of O 
solubility O 
enhancement O 
on O 
its O 
pharmacokinetic O 
( O 
PK O 
) O 
and O 
pharmacodynamic O 
( O 
PD O 
) O 
profile O 
. O 
After O 
dissolving O 
the O 
three O 
components O 
in O 
aqueous O 
medium O 
, O 
ternary O 
SD O 
containing O 
the O 
drug O 
, O 
sodium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
( O 
NaOH B-FORMULA 
) O 
and O 
PVP-VA O 
64 O 
was O 
achieved O 
by O 
spray O 
drying O 
method O 
, O 
which O 
was O 
used O 
as O 
primary O 
SD O 
. O 
Poloxamer B-TRIVIAL 
407 I-TRIVIAL 
, O 
a O 
surfactant O 
polymer O 
, O 
was O 
incorporated O 
in O 
this O 
primary O 
SD O 
by O 
four O 
different O 
methods O 
: O 
co O 
- O 
grinding O 
, O 
physical O 
mixing O 
, O 
melting O 
or O 
spray O 
drying O 
. O 
SD O 
was O 
then O 
characterized O 
by O 
dissolution O 
test O 
, O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
powder O 
X-ray O 
diffraction O 
( O 
PXRD O 
) O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
. O 
The O 
spray O 
dried O 
SD O 
of O 
poloxamer B-TRIVIAL 
407 I-TRIVIAL 
together O 
with O 
primary O 
SD O 
displayed O 
highest O 
dissolution O 
rate O 
of O 
the O 
drug O 
of O 
about O 
70% O 
after O 
2 O 
h O 
. O 
DSC O 
, O 
PXRD O 
and O 
FT-IR O 
characterized O 
the O 
amorphous O 
state O 
and O 
molecular O 
dispersion O 
of O 
the O 
drug O 
in O 
the O 
SD O 
. O 
PK O 
and O 
PD O 
studies O 
in O 
Sprague-Dawley O 
rats O 
revealed O 
that O 
the O 
bioavailability O 
of O 
the O 
drug O 
using O 
optimal O 
SD O 
was O 
about O 
twofold O 
higher O 
than O 
that O 
of O 
reference O 
product O 
, O 
and O 
the O 
irritation O 
area O 
of O 
stomach O 
was O 
significantly O 
reduced O 
in O 
the O 
ulcer O 
- O 
induced O 
rat O 
model O 
using O 
optimal O 
SD O 
as O 
compared O 
to O 
the O 
reference O 
product O 
. O 

risk O 
of O 
fungal O 
diseases O 
in O 
immunocompromised O 
patients O 
, O 
emerging O 
fungal O 
pathogens O 
, O 
limited O 
repertoire O 
of O 
antifungal O 
drugs O 
and O 
resistance O 
development O 
against O 
the O 
drugs O 
demands O 
for O 
development O 
of O 
new O 
and O 
effective O 
antifungal O 
agents O 
. O 
With O 
greater O 
knowledge O 
of O 
fungal O 
metabolism O 
efforts O 
are O 
being O 
made O 
to O 
inhibit O 
specific O 
enzymes O 
involved O 
in O 
different O 
biochemical O 
pathways O 
for O 
the O 
development O 
of O 
antifungal O 
drugs O 
. O 
Chitin O 
synthase O 
is O 
one O 
such O 
promising O 
target O 
as O 
it O 
is O 
absent O 
in O 
plants O 
and O 
mammals O 
. O 
Nikkomycin B-TRIVIAL 
Z I-TRIVIAL 
, O 
a O 
chitin O 
synthase O 
inhibitor O 
is O 
under O 
clinical O 
development O 
. O 
Chitin O 
synthesis O 
in O 
fungi O 
, O 
chitin O 
synthase O 
as O 
a O 
target O 
for O 
antifungal O 
agent O 
development O 
, O 
different O 
chitin O 
synthase O 
inhibitors O 
isolated O 
from O 
natural O 
sources O 
, O 
randomly O 
synthesized O 
and O 
modified O 
from O 
nikkomycin B-TRIVIAL 
and O 
polyoxin B-FAMILY 
are O 
discussed O 
in O 
this O 
review O 
. O 

of O 
the O 
effects O 
of O 
venlafaxine B-TRIVIAL 
and O 
pregabalin B-TRIVIAL 
on O 
the O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
inhalation O 
models O 
of O 
Generalised O 
Anxiety O 
Disorder O 
and O 
panic O 
. O 

studies O 
have O 
shown O 
that O 
subjective O 
and O 
objective O 
symptoms O 
of O 
anxiety O 
induced O 
by O 
7.5% O 
CO(2) B-FORMULA 
inhalation O 
can O 
be O 
attenuated O 
by O 
anxiolytics O 
such O 
as O 
lorazepam B-TRIVIAL 
and O 
, O 
to O 
a O 
lesser O 
extent O 
, O 
paroxetine B-TRIVIAL 
. O 
Venlafaxine B-TRIVIAL 
and O 
pregabalin B-TRIVIAL 
, O 
two O 
other O 
licensed O 
treatments O 
for O 
Generalised O 
Anxiety O 
Disorder O 
, O 
were O 
used O 
to O 
further O 
investigate O 
the O 
7.5% O 
and O 
35% O 
CO(2) B-FORMULA 
models O 
of O 
anxiety O 
in O 
healthy O 
volunteers O 
. O 
Fifty O 
- O 
four O 
participants O 
were O 
randomised O 
to O 
receive O 
either O 
placebo O 
, O 
venlafaxine B-TRIVIAL 
or O 
pregabalin B-TRIVIAL 
. O 
Study O 
treatments O 
were O 
dosed O 
incrementally O 
over O 
a O 
three O 
week O 
period O 
, O 
to O 
reach O 
daily O 
doses O 
of O 
150 O 
mg O 
venlafaxine B-TRIVIAL 
and O 
200mg O 
pregabalin B-TRIVIAL 
by O 
the O 
CO(2) B-FORMULA 
challenge O 
test O 
day O 
. O 
Participants O 
inhaled O 
air O 
7.5% O 
CO(2) B-FORMULA 
for O 
20 O 
minutes O 
( O 
single O 
- O 
blind O 
presentation O 
) O 
, O 
and O 
a O 
non-blinded O 
single O 
vital O 
capacity O 
of O 
35% O 
CO(2) B-FORMULA 
. O 
Subjective O 
ratings O 
were O 
recorded O 
before O 
and O 
after O 
each O 
inhalation O 
. O 
Both O 
7.5% O 
and O 
35% O 
CO(2) B-FORMULA 
inhalations O 
produced O 
the O 
expected O 
effects O 
of O 
increased O 
ratings O 
of O 
symptoms O 
of O 
panic O 
and O 
anxiety O 
, O 
with O 
increased O 
blood O 
pressure O 
and O 
heart O 
rate O 
. O 
No O 
significant O 
treatment O 
effects O 
were O 
found O 
, O 
although O 
there O 
were O 
trends O 
towards O 
a O 
reduction O 
in O 
feeling O 
tense O 
and O 
nervous O 
by O 
both O 
drugs O 
compared O 
with O 
placebo O 
during O 
the O 
7.5% O 
CO(2) B-FORMULA 
challenge O 
, O 
and O 
a O 
reduction O 
in O 
alertness O 
generally O 
in O 
the O 
venlafaxine B-TRIVIAL 
group O 
compared O 
with O 
the O 
pregabalin B-TRIVIAL 
group O 
. O 
In O 
contrast O 
with O 
the O 
clear O 
anxiolytic O 
effects O 
of O 
benzodiazepines B-FAMILY 
reported O 
in O 
several O 
previous O 
CO(2) B-FORMULA 
studies O 
, O 
these O 
findings O 
suggest O 
that O 
the O 
anxiogenic O 
effects O 
of O 
CO(2) B-FORMULA 
challenges O 
are O 
not O 
significantly O 
influenced O 
by O 
these O 
serotonergic O 
and O 
GABAergic O 
anxiolytics O 
. O 
This O 
may O 
be O 
due O 
to O 
a O 
lack O 
of O 
sensitivity O 
of O 
the O 
CO(2) B-FORMULA 
challenges O 
in O 
healthy O 
volunteers O 
to O 
these O 
drug O 
types O 
. O 

- O 
assisted O 
synthesis O 
of O 
N-isobutyl-4,5-epoxy-2(E)-decenamide B-SYSTEMATIC 
. O 

new O 
and O 
efficient O 
synthesis O 
of O 
a O 
naturally O 
occurring O 
amide B-FAMILY 
alkaloid O 
, O 
N-isobutyl-4,5-epoxy-2(E)-decenamide B-SYSTEMATIC 
isolated O 
from O 
the O 
roots O 
of O 
Piper O 
nigrum O 
has O 
been O 
described O 
involving O 
a O 
total O 
of O 
nine O 
steps O 
. O 
Octanal B-SYSTEMATIC 
and O 
2-bromoacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
have O 
been O 
used O 
as O 
the O 
starting O 
materials O 
. O 

metabotropic O 
glutamate B-TRIVIAL 
receptor O 
8 O 
agonist O 
(S)-3,4-DCPG B-SYSTEMATIC 
reverses O 
motor O 
deficits O 
in O 
prolonged O 
but O 
not O 
acute O 
models O 
of O 
Parkinson's O 
disease O 
. O 

glutamate B-TRIVIAL 
receptors O 
( O 
mGlus O 
) O 
are O 
7 O 
Transmembrane O 
Spanning O 
Receptors O 
( O 
7TMs O 
) O 
that O 
are O 
differentially O 
expressed O 
throughout O 
the O 
brain O 
and O 
modulate O 
synaptic O 
transmission O 
at O 
both O 
excitatory O 
and O 
inhibitory O 
synapses O 
. O 
Recently O 
, O 
mGlus O 
have O 
been O 
implicated O 
as O 
therapeutic O 
targets O 
for O 
many O 
disorders O 
of O 
the O 
central O 
nervous O 
system O 
, O 
including O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
nonselective O 
agonists O 
of O 
group O 
III O 
mGlus O 
have O 
antiparkinsonian O 
effects O 
in O 
several O 
animal O 
models O 
of O 
PD O 
, O 
suggesting O 
that O 
these O 
receptors O 
represent O 
promising O 
targets O 
for O 
treating O 
the O 
motor O 
symptoms O 
of O 
PD O 
. O 
However O 
, O 
the O 
relative O 
contributions O 
of O 
different O 
group O 
III O 
mGlu O 
subtypes O 
to O 
these O 
effects O 
have O 
not O 
been O 
fully O 
elucidated O 
. O 
Here O 
we O 
report O 
that O 
intracerebroventricular O 
( O 
icv O 
) O 
administration O 
of O 
the O 
mGlu(8)-selective O 
agonist O 
(S)-3,4-dicarboxyphenylglycine B-SYSTEMATIC 
( O 
DCPG B-ABBREVIATION 
[ O 
2.5 O 
, O 
10 O 
, O 
or O 
30 O 
nmol O 
] O 
) O 
does O 
not O 
alleviate O 
motor O 
deficits O 
caused O 
by O 
acute O 
( O 
2 O 
h O 
) O 
treatment O 
with O 
haloperidol B-TRIVIAL 
or O 
reserpine B-TRIVIAL 
. O 
However O 
, O 
following O 
prolonged O 
pretreatment O 
with O 
haloperidol B-TRIVIAL 
( O 
three O 
doses O 
evenly O 
spaced O 
over O 
18-20 O 
h O 
) O 
or O 
reserpine B-TRIVIAL 
( O 
18-20 O 
h O 
) O 
, O 
DCPG B-ABBREVIATION 
robustly O 
reverses O 
haloperidol B-TRIVIAL 
-induced O 
catalepsy O 
and O 
reserpine B-TRIVIAL 
-induced O 
akinesia O 
. O 
Furthermore O 
, O 
DCPG B-ABBREVIATION 
( O 
10 O 
nmol O 
, O 
icv O 
) O 
reverses O 
the O 
long O 
- O 
lasting O 
catalepsy O 
induced O 
by O 
20 O 
h O 
pretreatment O 
with O 
the O 
decanoate B-SYSTEMATIC 
salt I-SYSTEMATIC 
of O 
haloperidol B-TRIVIAL 
. O 
Finally O 
, O 
icv O 
administration O 
of O 
DCPG B-ABBREVIATION 
ameliorates O 
forelimb O 
use O 
asymmetry O 
caused O 
by O 
unilateral O 
6-hydroxydopamine B-SYSTEMATIC 
lesion O 
of O 
substantia O 
nigra O 
dopamine B-TRIVIAL 
neurons O 
. O 
These O 
findings O 
suggest O 
that O 
mGlu(8) O 
may O 
partially O 
mediate O 
the O 
antiparkinsonian O 
effects O 
of O 
group O 
III O 
mGlu O 
agonists O 
in O 
animal O 
models O 
of O 
PD O 
in O 
which O 
dopamine B-TRIVIAL 
depletion O 
or O 
blockade O 
of O 
D(2) O 
- O 
like O 
dopamine B-TRIVIAL 
receptors O 
is O 
prolonged O 
and O 
indicate O 
that O 
selective O 
activation O 
of O 
mGlu(8) O 
may O 
represent O 
a O 
novel O 
therapeutic O 
strategy O 
for O 
alleviating O 
the O 
motor O 
symptoms O 
of O 
PD O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

brain O 
GABA B-ABBREVIATION 
- O 
benzodiazepine B-FAMILY 
receptor O 
alpha-5 O 
subtype O 
in O 
autism O 
spectrum O 
disorder O 
: O 
a O 
pilot O 
[(11)C]Ro15-4513 B-IDENTIFIER 
positron O 
emission O 
tomography O 
study O 
. O 

( O 
gamma-amino-butyric B-SYSTEMATIC 
- I-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
is O 
the O 
primary O 
inhibitory O 
neurotransmitter O 
in O 
the O 
human O 
brain O 
. O 
It O 
has O 
been O 
proposed O 
that O 
the O 
symptoms O 
of O 
autism O 
spectrum O 
disorders O 
( O 
ASDs O 
) O 
are O 
the O 
result O 
of O 
deficient O 
GABA B-ABBREVIATION 
neurotransmission O 
, O 
possibly O 
including O 
reduced O 
expression O 
of O 
GABAA O 
receptors O 
. O 
However O 
, O 
this O 
hypothesis O 
has O 
not O 
been O 
directly O 
tested O 
in O 
living O 
adults O 
with O 
ASD O 
. O 
In O 
this O 
preliminary O 
investigation O 
, O 
we O 
used O 
Positron O 
Emission O 
Tomography O 
( O 
PET O 
) O 
with O 
the O 
benzodiazepine B-FAMILY 
receptor O 
PET O 
ligand O 
[(11)C]Ro15-4513 B-IDENTIFIER 
to O 
measure O 
α1 O 
and O 
α5 O 
subtypes O 
of O 
the O 
GABAA O 
receptor O 
levels O 
in O 
the O 
brain O 
of O 
three O 
adult O 
males O 
with O 
well O 
- O 
characterized O 
high O 
- O 
functioning O 
ASD O 
compared O 
with O 
three O 
healthy O 
matched O 
volunteers O 
. O 
We O 
found O 
significantly O 
lower O 
[(11)C]Ro15-4513 B-IDENTIFIER 
binding O 
throughout O 
the O 
brain O 
of O 
participants O 
with O 
ASD O 
( O 
p O 
< O 
0.0001 O 
) O 
compared O 
with O 
controls O 
. O 
Planned O 
region O 
of O 
interest O 
analyses O 
also O 
revealed O 
significant O 
reductions O 
in O 
two O 
limbic O 
brain O 
regions O 
, O 
namely O 
the O 
amygdala O 
and O 
nucleus O 
accumbens O 
bilaterally O 
. O 
Further O 
analysis O 
suggested O 
that O 
these O 
results O 
were O 
driven O 
by O 
lower O 
levels O 
of O 
the O 
GABAA O 
α5 O 
subtype O 
. O 
These O 
results O 
provide O 
initial O 
evidence O 
of O 
a O 
GABAA O 
α5 O 
deficit O 
in O 
ASD O 
and O 
support O 
further O 
investigations O 
of O 
the O 
GABA B-ABBREVIATION 
system O 
in O 
this O 
disorder O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

and O 
mimulone B-TRIVIAL 
B I-TRIVIAL 
: O 
Two O 
new O 
C-geranylated B-FAMILY 
flavonoids I-FAMILY 
from O 
Paulownia O 
tomentosa O 
fruits O 
. O 

new O 
discovered O 
C-geranylated B-FAMILY 
flavonoids I-FAMILY 
tomentomimulol B-TRIVIAL 
( O 
1 O 
) O 
and O 
mimulone B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Paulownia O 
tomentosa O 
( O 
Thunb O 
) O 
. O 
Steud O 
. O 
( O 
Paulowniaceae O 
) O 
fruits O 
by O 
exhaustive O 
chromatographic O 
separation O 
together O 
with O 
one O 
known O 
compound O 
tanariflavanone B-TRIVIAL 
D I-TRIVIAL 
( O 
3 O 
) O 
. O 
The O 
identification O 
of O 
compounds O 
and O 
structure O 
elucidation O 
was O 
carried O 
out O 
using O 
1D O 
and O 
2D O 
NMR O 
experiments O 
, O 
as O 
well O 
as O 
mass O 
spectroscopy O 
, O 
ultra O 
- O 
violet O 
, O 
infra O 
red O 
and O 
CD O 
experiments O 
. O 

new O 
cyclododeca[d]oxazole B-SYSTEMATIC 
derivative O 
from O 
Streptomyces O 
spp O 
. O 
CIBYL1 O 
. O 

novel O 
secondary O 
metabolite O 
, O 
N-trans-cinnamoyl B-SYSTEMATIC 
2-amino-3a,4,5,6,7,8,9,10,11,12,13,13a-dodecahydrocyclododeca[d]oxazole I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
Streptomyces O 
spp O 
. O 
CIBYL1 O 
, O 
along O 
with O 
five O 
known O 
compounds O 
, O 
pimprinine B-TRIVIAL 
( O 
2 O 
) O 
, O 
(3R,4S,5R,6R)-3,4,5,6-tetrahydro-4-hydroxy-3,5,6-trimethyl-2H-pyran-2-one B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
indolyl-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
2-phenylacetamide B-SYSTEMATIC 
( O 
5 O 
) O 
and O 
di(1H-pyrrol-2-yl)methanone B-SYSTEMATIC 
( O 
6 O 
) O 
. O 
The O 
structures O 
of O 
these O 
metabolites O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
analysis O 
of O 
spectroscopic O 
data O 
, O 
including O 
OR O 
, O 
IR O 
, O 
HRMS O 
, O 
1D O 
and O 
2D O 
NMR O 
data O 
and O 
chemical O 
derivation O 
. O 

allosteric O 
modulation O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
5 O 
results O 
in O 
broad O 
spectrum O 
activity O 
relevant O 
to O 
treatment O 
resistant O 
depression O 
. O 

suggests O 
that O 
30-50% O 
of O 
patients O 
suffering O 
from O 
major O 
depressive O 
disorder O 
( O 
MDD O 
) O 
are O 
classified O 
as O 
suffering O 
from O 
treatment O 
resistant O 
depression O 
( O 
TRD O 
) O 
as O 
they O 
have O 
an O 
inadequate O 
response O 
to O 
standard O 
antidepressants O 
. O 
A O 
key O 
feature O 
of O 
this O 
patient O 
population O 
is O 
the O 
increased O 
incidence O 
of O 
co O 
- O 
morbid O 
symptoms O 
like O 
anxiety O 
and O 
pain O 
. O 
Recognizing O 
that O 
current O 
standards O 
of O 
care O 
are O 
largely O 
focused O 
on O 
monoaminergic O 
mechanisms O 
of O 
action O 
( O 
MOAs O 
) O 
, O 
innovative O 
approaches O 
to O 
drug O 
discovery O 
for O 
TRD O 
are O 
targeting O 
glutamate B-TRIVIAL 
hyperfunction O 
. O 
Here O 
we O 
describe O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
profile O 
of O 
GRN-529 B-IDENTIFIER 
, O 
a O 
novel O 
negative O 
allosteric O 
modulator O 
( O 
NAM O 
) O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
5 O 
( O 
mGluR5 O 
) O 
. O 
In O 
cell O 
based O 
pharmacology O 
assays O 
, O 
GRN-529 B-IDENTIFIER 
is O 
a O 
high O 
affinity O 
( O 
Ki O 
5.4 O 
nM O 
) O 
, O 
potent O 
( O 
IC50 O 
3.1 O 
nM O 
) O 
and O 
selective O 
( O 
> O 
1000-fold O 
selective O 
vs O 
mGluR1 O 
) O 
mGluR5 O 
NAM O 
. O 
Acute O 
administration O 
of O 
GRN-529 B-IDENTIFIER 
( O 
0.1-30 O 
mg O 
/ O 
kg O 
p.o O 
. O 
) O 
had O 
dose O 
- O 
dependent O 
efficacy O 
across O 
a O 
therapeutically O 
relevant O 
battery O 
of O 
animal O 
models O 
, O 
comprising O 
depression O 
( O 
decreased O 
immobility O 
time O 
in O 
tail O 
suspension O 
and O 
forced O 
swim O 
tests O 
) O 
and O 
2 O 
of O 
the O 
co O 
- O 
morbid O 
symptoms O 
overrepresented O 
in O 
TRD O 
, O 
namely O 
anxiety O 
( O 
attenuation O 
of O 
stress O 
- O 
induced O 
hyperthermia O 
, O 
and O 
increased O 
punished O 
crossings O 
in O 
the O 
four O 
plate O 
test O 
) O 
and O 
pain O 
( O 
reversal O 
of O 
hyperalgesia O 
due O 
to O 
sciatic O 
nerve O 
ligation O 
or O 
inflammation O 
) O 
. O 
The O 
potential O 
side O 
effect O 
liability O 
of O 
GRN-529 B-IDENTIFIER 
was O 
also O 
assessed O 
using O 
preclinical O 
models O 
: O 
GRN-529 B-IDENTIFIER 
had O 
no O 
effect O 
on O 
rat O 
sexual O 
behavior O 
or O 
motor O 
co O 
- O 
ordination O 
( O 
rotarod O 
) O 
, O 
however O 
it O 
impaired O 
cognition O 
in O 
mice O 
( O 
social O 
odor O 
recognition O 
) O 
. O 
Efficacy O 
and O 
side O 
effects O 
of O 
GRN-529 B-IDENTIFIER 
were O 
compared O 
to O 
standard O 
of O 
care O 
agents O 
( O 
antidepressant O 
, O 
anxiolytic O 
or O 
analgesics O 
) O 
and O 
the O 
tool O 
mGluR5 O 
NAM O 
, O 
MTEP B-ABBREVIATION 
. O 
To O 
assess O 
the O 
relationship O 
between O 
target O 
occupancy O 
and O 
efficacy O 
, O 
ex O 
vivo O 
receptor O 
occupancy O 
was O 
measured O 
in O 
parallel O 
with O 
efficacy O 
testing O 
. O 
This O 
revealed O 
a O 
strong O 
correlation O 
between O 
target O 
engagement O 
, O 
exposure O 
and O 
efficacy O 
across O 
behavioral O 
endpoints O 
, O 
which O 
supports O 
the O 
potential O 
translational O 
value O 
of O 
PET O 
imaging O 
to O 
dose O 
selection O 
in O 
patients O 
. O 
Collectively O 
this O 
broad O 
spectrum O 
profile O 
of O 
efficacy O 
of O 
GRN-529 B-IDENTIFIER 
supports O 
our O 
hypothesis O 
that O 
negative O 
allosteric O 
modulation O 
of O 
mGluR5 O 
could O 
represent O 
an O 
innovative O 
therapeutic O 
approach O 
to O 
the O 
treatment O 
of O 
TRD O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate O 
Receptors' O 
. O 

work O 
reports O 
variations O 
in O 
the O 
yields O 
and O 
quality O 
of O 
volatiles O 
produced O 
from O 
Eucalyptus O 
citriodora O 
leaves O 
by O 
different O 
hydrodistillation O 
( O 
HD O 
) O 
and O 
supercritical O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
extraction O 
( O 
SCE O 
) O 
techniques O 
. O 
HD O 
techniques O 
( O 
1.5% O 
) O 
produced O 
higher O 
yields O 
compared O 
to O 
SCE O 
( O 
0.7% O 
) O 
. O 
Citronellal B-TRIVIAL 
, O 
the O 
major O 
component O 
, O 
was O 
maximum O 
in O 
the O 
extract O 
produced O 
by O 
SCE O 
( O 
79% O 
) O 
followed O 
by O 
oil O 
produced O 
by O 
water O 
- O 
steam O 
distillation O 
( O 
WSD O 
) O 
( O 
72.6% O 
) O 
and O 
water O 
distillation O 
( O 
WD O 
) O 
( O 
62.4% O 
) O 
techniques O 
. O 
Chemical O 
composition O 
of O 
glycoside O 
- O 
bound O 
volatiles O 
produced O 
by O 
acid O 
hydrolysis O 
during O 
HD O 
was O 
found O 
to O 
be O 
very O 
different O 
from O 
free O 
volatiles O 
, O 
although O 
in O 
a O 
minor O 
quantity O 
. O 
The O 
extent O 
of O 
artefact O 
formation O 
and O 
release O 
of O 
aglycones O 
was O 
more O 
profound O 
in O 
the O 
bound O 
volatile O 
oil O 
produced O 
by O 
WD O 
than O 
WSD O 
. O 
Highest O 
oxygenated B-FAMILY 
monoterpenes I-FAMILY 
were O 
found O 
in O 
SCE O 
and O 
WSD O 
( O 
93% O 
each O 
) O 
followed O 
by O 
WD O 
( O 
91.4% O 
) O 
. O 
Although O 
the O 
SCE O 
produced O 
lower O 
yields O 
than O 
the O 
HD O 
techniques O 
, O 
its O 
extract O 
is O 
superior O 
in O 
quality O 
in O 
terms O 
of O 
higher O 
concentration O 
of O 
citronellal B-TRIVIAL 
. O 

, O 
stroke O 
, O 
and O 
inflammation O 
: O 
the O 
potential O 
for O 
estrogen B-FAMILY 
-mediated O 
immunoprotection O 
in O 
stroke O 
. O 

is O 
the O 
third O 
leading O 
cause O 
of O 
death O 
and O 
the O 
primary O 
cause O 
of O 
disability O 
in O 
the O 
developed O 
world O 
. O 
Experimental O 
and O 
clinical O 
data O 
indicate O 
that O 
stroke O 
is O 
a O 
sexually O 
dimorphic O 
disease O 
, O 
with O 
males O 
demonstrating O 
an O 
enhanced O 
intrinsic O 
sensitivity O 
to O 
ischemic O 
damage O 
throughout O 
most O 
of O 
their O 
lifespan O 
. O 
The O 
neuroprotective O 
role O 
of O 
estrogen B-FAMILY 
in O 
the O 
female O 
brain O 
is O 
well O 
established O 
, O 
however O 
, O 
estrogen B-FAMILY 
exposure O 
can O 
also O 
be O 
deleterious O 
, O 
especially O 
in O 
older O 
women O 
. O 
The O 
mechanisms O 
for O 
this O 
remain O 
unclear O 
. O 
Our O 
current O 
understanding O 
is O 
based O 
on O 
studies O 
examining O 
estrogen B-FAMILY 
as O 
it O 
relates O 
to O 
neuronal O 
injury O 
, O 
yet O 
cerebral O 
ischemia O 
also O 
induces O 
a O 
robust O 
sterile O 
inflammatory O 
response O 
involving O 
local O 
and O 
systemic O 
immune O 
cells O 
. O 
Despite O 
the O 
potent O 
anti-inflammatory O 
effects O 
of O 
estrogen B-FAMILY 
, O 
few O 
studies O 
have O 
investigated O 
the O 
contribution O 
of O 
estrogen B-FAMILY 
to O 
sex O 
differences O 
in O 
the O 
inflammatory O 
response O 
to O 
stroke O 
. O 
This O 
review O 
examines O 
the O 
potential O 
role O 
for O 
estrogen B-FAMILY 
-mediated O 
immunoprotection O 
in O 
ischemic O 
injury O 
. O 

of O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
for O 
oral O 
bioavailability O 
enhancement O 
of O 
berberine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
self O 
- O 
microemulsifying O 
drug O 
delivery O 
system O 
( O 
SMEDDS O 
) O 
to O 
improve O 
the O 
oral O 
bioavailability O 
of O 
Berberine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
BBH B-ABBREVIATION 
) O 
, O 
an O 
important O 
bioactive O 
compound O 
from O 
Chinese O 
Medicines O 
with O 
poor O 
water O 
solubility O 
. O 
Pseudoternary O 
phase O 
diagrams O 
were O 
constructed O 
using O 
oil O 
, O 
surfactant O 
and O 
co O 
- O 
surfactant O 
types O 
to O 
identify O 
the O 
efficient O 
self O 
- O 
microemulsification O 
region O 
. O 
SMEDDS O 
was O 
characterized O 
by O 
morphological O 
observation O 
, O 
droplet O 
size O 
, O 
zeta-potential O 
determination O 
, O 
stability O 
, O 
in O 
vitro O 
release O 
and O 
in O 
vivo O 
bioavailability O 
study O 
. O 
The O 
optimal O 
formulation O 
with O 
the O 
best O 
self O 
- O 
microemulsifying O 
and O 
solubilization O 
ability O 
consisted O 
of O 
40% O 
( O 
w O 
/ O 
w O 
) O 
of O 
ethyl B-SYSTEMATIC 
linoleate I-SYSTEMATIC 
and O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
2 O 
: O 
1 O 
) O 
, O 
35% O 
( O 
w O 
/ O 
w O 
) O 
Tween-80 B-TRIVIAL 
and O 
25% O 
( O 
w O 
/ O 
w O 
) O 
glycerol B-TRIVIAL 
. O 
The O 
SMEDDS O 
of O 
BBH B-ABBREVIATION 
could O 
exhibit O 
good O 
stability O 
. O 
In O 
vitro O 
release O 
test O 
showed O 
a O 
complete O 
release O 
of O 
BBH B-ABBREVIATION 
from O 
SMEDDS O 
was O 
in O 
5 O 
h O 
. O 
In O 
vivo O 
results O 
indicated O 
that O 
the O 
peak O 
plasma O 
concentration O 
(C(max)) O 
and O 
the O 
area O 
under O 
the O 
curve O 
( O 
AUC(0→12 O 
h O 
) O 
) O 
of O 
SMEDDS O 
of O 
BBH B-ABBREVIATION 
were O 
higher O 
than O 
the O 
commercial O 
tablet O 
by O 
163.4% O 
and O 
154.2% O 
, O 
respectively O 
. O 
The O 
relative O 
bioavailability O 
of O 
SMEDDS O 
of O 
BBH B-ABBREVIATION 
was O 
enhanced O 
about O 
2.42-fold O 
compared O 
with O 
the O 
commercial O 
tablet O 
in O 
rats O 
. O 
The O 
study O 
confirmed O 
that O 
the O 
SMEDDS O 
formulation O 
could O 
be O 
used O 
as O 
a O 
possible O 
alternative O 
to O 
traditional O 
oral O 
formulations O 
of O 
BBH B-ABBREVIATION 
to O 
improve O 
its O 
bioavailability O 
. O 

review O 
describes O 
the O 
neuroendocrinological O 
aspects O 
of O 
catamenial O 
epilepsy O 
, O 
a O 
menstrual O 
cycle O 
- O 
related O 
seizure O 
disorder O 
in O 
women O 
with O 
epilepsy O 
. O 
Catamenial O 
epilepsy O 
is O 
a O 
multifaceted O 
neuroendocrine O 
condition O 
in O 
which O 
seizures O 
are O 
clustered O 
around O 
specific O 
points O 
in O 
the O 
menstrual O 
cycle O 
, O 
most O 
often O 
around O 
perimenstrual O 
or O 
periovulatory O 
period O 
. O 
Three O 
types O 
of O 
catamenial O 
seizures O 
( O 
perimenstrual O 
, O 
periovulatory O 
and O 
inadequate O 
luteal O 
) O 
have O 
been O 
identified O 
. O 
The O 
molecular O 
pathophysiology O 
of O 
catamenial O 
epilepsy O 
remains O 
unclear O 
. O 
Cyclical O 
changes O 
in O 
the O 
circulating O 
levels O 
of O 
estrogens B-FAMILY 
and O 
progesterone B-TRIVIAL 
( O 
P O 
) O 
play O 
a O 
central O 
role O 
in O 
the O 
development O 
of O 
catamenial O 
epilepsy O 
. O 
Endogenous O 
neurosteroids O 
such O 
as O 
allopregnanolone B-TRIVIAL 
( O 
AP O 
) O 
and O 
allotetrahydrodeoxycorticosterone B-TRIVIAL 
( O 
THDOC B-ABBREVIATION 
) O 
that O 
modulate O 
seizure O 
susceptibility O 
could O 
play O 
a O 
critical O 
role O 
in O 
catamenial O 
epilepsy O 
. O 
In O 
addition O 
, O 
plasticity O 
in O 
GABA B-ABBREVIATION 
-A O 
receptor O 
subunits O 
could O 
play O 
a O 
role O 
in O 
the O 
enhanced O 
seizure O 
susceptibility O 
in O 
catamenial O 
epilepsy O 
. O 
P O 
- O 
derived O 
neurosteroids O 
such O 
as O 
AP O 
and O 
THDOC B-ABBREVIATION 
potentiate O 
synaptic O 
GABA B-ABBREVIATION 
-A O 
receptor O 
function O 
and O 
also O 
activate O 
extrasynaptic O 
GABA B-ABBREVIATION 
-A O 
receptors O 
in O 
the O 
hippocampus O 
and O 
thus O 
may O 
represent O 
endogenous O 
regulators O 
of O 
catamenial O 
seizure O 
susceptibility O 
. O 
Experimental O 
studies O 
have O 
shown O 
that O 
neurosteroids O 
confer O 
greater O 
seizure O 
protection O 
in O 
animal O 
models O 
of O 
catamenial O 
epilepsy O 
, O 
especially O 
without O 
evident O 
tolerance O 
to O 
their O 
actions O 
during O 
chronic O 
therapy O 
. O 
In O 
the O 
recently O 
completed O 
NIH-sponsored O 
, O 
placebo O 
controlled O 
phase O 
3 O 
clinical O 
trial O 
, O 
P O 
therapy O 
proved O 
to O 
be O 
beneficial O 
only O 
in O 
women O 
with O 
perimenstrual O 
catamenial O 
epilepsy O 
but O 
not O 
in O 
non-catamenial O 
subjects O 
. O 
Neurosteroid O 
analogs O 
with O 
favorable O 
profile O 
may O 
be O 
useful O 
in O 
the O 
treatment O 
of O 
catamenial O 
epilepsy O 
. O 

acid I-FAMILY 
composition O 
of O 
the O 
edible O 
sea O 
cucumber O 
Athyonidium O 
chilensis O 
. O 

edible O 
sea O 
cucumber O 
Athyonidium O 
chilensis O 
is O 
a O 
fishery O 
resource O 
of O 
high O 
commercial O 
value O 
in O 
Chile O 
, O 
but O 
no O 
information O 
on O 
its O 
lipid O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
has O 
been O 
previously O 
reported O 
. O 
Phospholipids O 
were O 
the O 
major O 
lipid O 
contents O 
of O 
the O 
ethanolic O 
extracts O 
of O 
tubules O 
, O 
internal O 
organs O 
and O 
body O 
wall O 
of O 
A O 
. O 
chilensis O 
. O 
Saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
predominated O 
in O 
tubule O 
phospholipids O 
( O 
40.69% O 
) O 
, O 
while O 
in O 
internal O 
organs O 
and O 
body O 
wall O 
phospholipids O 
, O 
the O 
monounsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
were O 
in O 
higher O 
amounts O 
( O 
41.99% O 
and O 
37.94% O 
, O 
respectively O 
) O 
. O 
The O 
main O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
phospholipids O 
were O 
C20 O 
: O 
2ω-6 O 
, O 
arachidonic B-MULTIPLE 
( I-MULTIPLE 
C20 I-MULTIPLE 
: I-MULTIPLE 
4ω-6 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
eicosapentaenoic I-MULTIPLE 
( I-MULTIPLE 
C20 I-MULTIPLE 
: I-MULTIPLE 
5ω-3 I-MULTIPLE 
) I-MULTIPLE 
acids I-MULTIPLE 
. O 
These O 
results O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
A O 
. O 
chilensis O 
is O 
a O 
valuable O 
food O 
for O 
human O 
consumption O 
in O 
terms O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
. O 

antioxidant O 
activity O 
of O 
allylpyrocatechol B-SYSTEMATIC 
is O 
mediated O 
via O 
decreased O 
generation O 
of O 
free O 
radicals O 
along O 
with O 
escalation O 
of O 
antioxidant O 
mechanisms O 
. O 

( O 
APC B-ABBREVIATION 
) O 
is O 
responsible O 
for O 
the O 
antiinflammatory O 
activity O 
exhibited O 
by O 
the O 
methanolic O 
extract O 
of O 
leaves O 
of O 
Piper O 
betle O 
. O 
As O 
antiinflammatory O 
compounds O 
may O 
display O 
antioxidant O 
properties O 
and O 
vice O 
versa O 
, O 
we O 
investigated O 
the O 
antioxidant O 
effect O 
of O 
APC B-ABBREVIATION 
. O 
APC B-ABBREVIATION 
effectively O 
reduced O 
phorbol B-TRIVIAL 
- O 
myristate B-TRIVIAL 
- O 
acetate B-SYSTEMATIC 
-induced O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
superoxide B-TRIVIAL 
in O 
murine O 
peritoneal O 
macrophages O 
as O 
well O 
as O 
inhibited O 
Escherichia O 
- O 
coli O 
- O 
induced O 
phagocytic O 
activity O 
of O 
macrophages O 
. O 
Furthermore O 
, O 
pBluescript O 
SK(+) O 
plasmid O 
DNA O 
damage O 
induced O 
by O 
addition O 
of O 
sodium B-SYSTEMATIC 
ascorbate I-SYSTEMATIC 
was O 
attenuated O 
by O 
APC B-ABBREVIATION 
as O 
it O 
inhibited O 
transformation O 
of O 
the O 
supercoiled O 
form O 
to O 
a O 
relaxed O 
form O 
. O 
In O 
addition O 
, O 
APC B-ABBREVIATION 
increased O 
the O 
enzymatic O 
( O 
catalase O 
) O 
and O 
nonenzymatic O 
( O 
GSH B-ABBREVIATION 
) O 
antioxidant O 
components O 
of O 
murine O 
macrophages O 
. O 
Taken O 
together O 
, O 
APC B-ABBREVIATION 
exhibited O 
an O 
antioxidant O 
activity O 
which O 
was O 
mediated O 
both O 
via O 
decreased O 
generation O 
of O 
free O 
radicals O 
along O 
with O 
increase O 
in O 
cellular O 
antioxidants O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
Crataegus O 
microphylla O 
on O 
vascular O 
dysfunction O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
. O 

dysfunction O 
plays O 
a O 
key O 
role O 
in O 
the O 
pathogenesis O 
of O 
diabetic O 
vascular O 
disease O 
. O 
In O 
this O 
study O 
, O 
we O 
aimed O 
to O 
investigate O 
whether O 
chronic O 
in O 
vivo O 
treatment O 
of O 
Crataegus O 
microphylla O 
( O 
CM O 
) O 
extract O 
in O 
diabetic O 
rats O 
induced O 
with O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
, O 
intraperitoneal O 
, O 
65 O 
mg O 
/ O 
kg O 
) O 
preserves O 
vascular O 
function O 
and O 
to O 
evaluate O 
whether O 
the O 
reduction O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
proinflammatory O 
cytokines O 
, O 
and O 
lipid O 
peroxidation O 
mediates O 
its O 
mechanisms O 
of O 
action O 
. O 
Starting O 
at O 
4 O 
weeks O 
of O 
diabetes O 
, O 
CM O 
extract O 
( O 
100 O 
mg O 
/ O 
kg O 
) O 
was O 
administrated O 
to O 
diabetic O 
rats O 
for O 
4 O 
weeks O 
. O 
In O 
aortic O 
rings O 
, O 
relaxation O 
to O 
acetylcholine B-SYSTEMATIC 
and O 
vasoreactivity O 
to O 
noradrenaline B-TRIVIAL 
were O 
impaired O 
, O 
whereas O 
aortic O 
iNOS O 
expression O 
and O 
plasma O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
total O 
nitrite B-SYSTEMATIC 
- O 
nitrate B-SYSTEMATIC 
, O 
and O 
malondialdehite B-TRIVIAL 
levels O 
were O 
increased O 
in O 
diabetic O 
rats O 
compared O 
with O 
controls O 
. O 
Chronic O 
CM O 
treatment O 
significantly O 
corrected O 
all O 
the O 
above O 
abnormalities O 
in O 
diabetic O 
rats O 
. O 
In O 
comparison O 
, O 
pretreatment O 
of O 
the O 
aorta O 
of O 
diabetic O 
rats O 
with O 
N-[3(aminomethyl) B-SYSTEMATIC 
benzyl]-acetamidine I-SYSTEMATIC 
, O 
dihydrochloride B-SYSTEMATIC 
( O 
10(-5) O 
M O 
) O 
, O 
a O 
selective O 
inhibitor O 
of O 
iNOS O 
, O 
produced O 
a O 
similar O 
recovery O 
in O 
vascular O 
reactivity O 
. O 
These O 
results O 
suggest O 
that O 
chronic O 
in O 
vivo O 
treatment O 
of O 
CM O 
preserves O 
endothelium O 
- O 
dependent O 
relaxation O 
and O 
vascular O 
contraction O 
in O 
STZ B-ABBREVIATION 
-induced O 
diabetes O 
, O 
possibly O 
by O 
reducing O 
iNOS O 
expression O 
in O 
the O 
aorta O 
and O 
by O 
decreasing O 
plasma O 
levels O 
of O 
TNF-α O 
and O 
IL-6 O 
and O 
by O 
preventing O 
lipid O 
peroxidation O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

new O 
pyrimidinedione B-FAMILY 
derivative O 
from O 
the O 
gorgonian O 
coral O 
Verrucella O 
umbraculum O 
. O 

new O 
pyrimidinedione B-FAMILY 
derivative O 
, O 
9-acetyl-1,3,7-trimethyl-pyrimidinedione B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
gorgonian O 
coral O 
Verrucella O 
umbraculum O 
, O 
together O 
with O 
two O 
known O 
compounds O 
, O 
caffeine B-TRIVIAL 
( O 
2 O 
) O 
and O 
1,3-dimethylpyrimidine-2,4(1H,3H)-dione B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
The O 
structure O 
of O 
1 O 
was O 
elucidated O 
by O 
the O 
aid O 
of O 
1D O 
, O 
2D O 
NMR O 
and O 
MS O 
experiments O 
. O 
The O 
structures O 
of O 
the O 
known O 
compounds O 
were O 
identified O 
by O 
comparison O 
of O 
their O 
spectroscopic O 
data O 
with O 
those O 
reported O 
in O 
the O 
literature O 
. O 

of O 
supplementation O 
with O 
curcuminoids B-FAMILY 
on O 
dyslipidemia O 
in O 
obese O 
patients O 
: O 
a O 
randomized O 
crossover O 
trial O 
. O 

is O 
a O 
leading O 
risk O 
factor O 
for O 
cardiovascular O 
disease O 
and O 
is O 
also O 
a O 
common O 
feature O 
of O 
obesity O 
. O 
Curcumin B-TRIVIAL 
is O 
a O 
bioactive O 
phytochemical O 
with O 
well O 
- O 
known O 
antioxidant O 
, O 
anti-inflammatory O 
, O 
and O 
cardioprotective O 
properties O 
. O 
The O 
present O 
study O 
investigated O 
the O 
hypolipidemic O 
activity O 
of O 
curcumin B-TRIVIAL 
in O 
obese O 
individuals O 
. O 
Participants O 
( O 
n O 
= O 
30 O 
) O 
were O 
treated O 
with O 
curcuminoids B-FAMILY 
( O 
1 O 
g O 
/ O 
day O 
) O 
, O 
or O 
placebo O 
in O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
, O 
crossover O 
trial O 
. O 
Serum O 
concentrations O 
of O 
total O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
and O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
together O 
with O 
anthropometric O 
parameters O 
and O 
high O 
- O 
sensitivity O 
C-reactive O 
protein O 
were O 
measured O 
before O 
and O 
after O 
each O 
treatment O 
period O 
. O 
Anthropometric O 
parameters O 
including O 
weight O 
, O 
BMI O 
, O 
waist O 
circumference O 
, O 
hip O 
circumference O 
, O 
arm O 
circumference O 
, O 
and O 
body O 
fat O 
remained O 
statistically O 
unchanged O 
by O 
the O 
end O 
of O 
trial O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
As O 
for O 
the O 
lipid O 
profile O 
parameters O 
, O 
serum O 
triglycerides B-FAMILY 
were O 
significantly O 
reduced O 
following O 
curcumin B-TRIVIAL 
supplementation O 
( O 
p O 
= O 
0.009 O 
) O 
. O 
However O 
, O 
curcuminoids B-FAMILY 
were O 
not O 
found O 
to O 
affect O 
serum O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
and O 
high O 
- O 
sensitivity O 
C-reactive O 
protein O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
In O 
summary O 
, O 
the O 
findings O 
of O 
the O 
present O 
study O 
indicated O 
that O 
curcuminoid O 
supplementation O 
( O 
1 O 
g O 
/ O 
day O 
for O 
30 O 
days O 
) O 
leads O 
to O 
a O 
significant O 
reduction O 
in O 
serum O 
triglycerides B-FAMILY 
concentrations O 
but O 
do O 
not O 
have O 
a O 
significant O 
influence O 
on O 
other O 
lipid O 
profile O 
parameters O 
as O 
well O 
as O 
body O 
mass O 
index O 
and O 
body O 
fat O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

first O 
total O 
synthesis O 
of O 
apigenin B-SYSTEMATIC 
7-O-β-D-cellobiosyl-4'-O-β-D-glucopyranoside I-SYSTEMATIC 
isolated O 
from O 
Salvia O 
uliginosa O 
. O 

first O 
total O 
synthesis O 
of O 
apigenin B-SYSTEMATIC 
7-O-β-D-cellobioside I-SYSTEMATIC 
( O 
5 O 
) O 
and O 
apigenin B-SYSTEMATIC 
7-O-β-D-cellobiosyl-4'-O-β-D-glucopyranoside I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
which O 
were O 
isolated O 
from O 
petals O 
of O 
Salvia O 
patens O 
and O 
Salvia O 
uliginosa O 
, O 
were O 
achieved O 
in O 
four O 
and O 
six O 
steps O 
and O 
76% O 
and O 
57% O 
, O 
respectively O 
, O 
overall O 
yield O 
, O 
from O 
naringenin B-TRIVIAL 
( O 
1 O 
) O 
. O 
The O 
total O 
synthesis O 
contained O 
two O 
- O 
glycosylation O 
, O 
acetylation O 
, O 
oxidation O 
, O 
selective O 
deacetylation O 
and O 
deprotection O 
steps O 
. O 
Although O 
this O 
route O 
contained O 
six O 
steps O 
, O 
the O 
targeted O 
compounds O 
were O 
obtained O 
with O 
higher O 
yields O 
and O 
easier O 
purifications O 
than O 
other O 
synthetic O 
methods O 
. O 

of O 
semisynthetic O 
acetal B-FAMILY 
triterpenes I-FAMILY 
from O 
one O 
- O 
pot O 
vicinal B-FAMILY 
diol I-FAMILY 
cleavage O 
following O 
by O 
lactolization O 
: O 
Reaction O 
promoted O 
by O 
NaIO4 B-FORMULA 
/ O 
SiO2 B-FORMULA 
gel O 
in O 
THF B-ABBREVIATION 
. O 

situ O 
C-C B-FORMULA 
bond O 
cleavage O 
of O 
vicinal B-FAMILY 
diol I-FAMILY 
following O 
by O 
the O 
lactolisation O 
resulted O 
from O 
separated O 
treatment O 
of O 
Arjunolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
, O 
24-hydroxytormentic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
3-O-β-D-glucopyranosylsitosterol B-SYSTEMATIC 
( O 
3 O 
) O 
with O 
sodium B-SYSTEMATIC 
periodate I-SYSTEMATIC 
and O 
silica B-TRIVIAL 
gel I-TRIVIAL 
in O 
dried O 
THF B-ABBREVIATION 
according O 
to O 
the O 
strategic O 
position O 
of O 
hydroxyl B-SYSTEMATIC 
functions O 
in O 
the O 
molecule O 
. O 
The O 
reaction O 
led O 
to O 
a O 
lactol B-FAMILY 
pentacyclic I-FAMILY 
triterpenes I-FAMILY 
1A O 
, O 
2A O 
and O 
a O 
bicyclotriacetal B-TRIVIAL 
of I-TRIVIAL 
β-sitosterol I-TRIVIAL 
3A O 
. O 
These O 
products O 
were O 
further O 
acetylated O 
and O 
the O 
cytotoxicity O 
of O 
all O 
molecules O 
was O 
evaluated O 
against O 
human O 
fibrosarcoma O 
HT1080 O 
cancer O 
cells O 
lines O 
. O 

tree O 
oil O 
( O 
TTO O 
) O 
is O 
a O 
steam O 
distillate O 
of O 
Melaleuca O 
alternifolia O 
that O 
demonstrates O 
broad O 
- O 
spectrum O 
antibacterial O 
activity O 
. O 
This O 
study O 
was O 
designed O 
to O 
document O 
how O 
TTO O 
challenge O 
influences O 
the O 
Staphylococcus O 
aureus O 
transcriptome O 
. O 
Overall O 
, O 
bioinformatic O 
analyses O 
( O 
S O 
. O 
aureus O 
microarray O 
meta-database O 
) O 
revealed O 
that O 
both O 
ethanol O 
and O 
TTO O 
induce O 
related O 
transcriptional O 
alterations O 
. O 
TTO O 
challenge O 
led O 
to O 
the O 
down O 
- O 
regulation O 
of O 
genes O 
involved O 
with O 
energy O 
- O 
intensive O 
transcription O 
and O 
translation O 
, O 
and O 
altered O 
the O 
regulation O 
of O 
genes O 
involved O 
with O 
heat O 
shock O 
( O 
e.g O 
. O 
clpC O 
, O 
clpL O 
, O 
ctsR O 
, O 
dnaK O 
, O 
groES O 
, O 
groEL O 
, O 
grpE O 
and O 
hrcA O 
) O 
and O 
cell O 
wall O 
metabolism O 
( O 
e.g O 
. O 
cwrA O 
, O 
isaA O 
, O 
sle1 O 
, O 
vraSR O 
and O 
vraX O 
) O 
. O 
Inactivation O 
of O 
the O 
heat O 
shock O 
gene O 
dnaK O 
or O 
vraSR O 
which O 
encodes O 
a O 
two O 
- O 
component O 
regulatory O 
system O 
that O 
responds O 
to O 
peptidoglycan O 
biosynthesis O 
inhibition O 
led O 
to O 
an O 
increase O 
in O 
TTO O 
susceptibility O 
which O 
demonstrates O 
a O 
protective O 
role O 
for O 
these O 
genes O 
in O 
the O 
S O 
. O 
aureus O 
TTO O 
response O 
. O 
A O 
gene O 
( O 
mmpL O 
) O 
encoding O 
a O 
putative O 
resistance O 
, O 
nodulation O 
and O 
cell O 
division O 
efflux O 
pump O 
was O 
also O 
highly O 
induced O 
by O 
TTO O 
. O 
The O 
principal O 
antimicrobial O 
TTO O 
terpene B-FAMILY 
, O 
terpinen-4-ol B-SYSTEMATIC 
, O 
altered O 
ten O 
genes O 
in O 
a O 
transcriptional O 
direction O 
analogous O 
to O 
TTO O 
. O 
Collectively O 
, O 
this O 
study O 
provides O 
additional O 
insight O 
into O 
the O 
response O 
of O 
a O 
bacterial O 
pathogen O 
to O 
the O 
antimicrobial O 
terpene O 
mixture O 
TTO O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

effects O 
of O 
methiocarb B-TRIVIAL 
on O 
oxidative O 
damage O 
and O 
the O 
protective O 
effects O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
taurine B-TRIVIAL 
in O 
the O 
liver O 
and O 
kidney O 
of O 
Wistar O 
rats O 
. O 

( O 
MC O 
) O 
is O 
a O 
widely O 
used O 
carbamate B-FAMILY 
pesticide O 
in O 
agriculture O 
and O 
health O 
programs O 
. O 
Although O 
the O 
main O 
molecular O 
mechanism O 
of O 
carbamate B-FAMILY 
toxicity O 
involves O 
acetylcholinesterase O 
inhibition O 
, O 
studies O 
have O 
also O 
implicated O 
the O 
induction O 
of O 
oxidative O 
stress O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
was O 
aimed O 
to O 
evaluate O 
the O 
effect O 
of O 
acute O 
MC O 
exposure O 
on O 
lipid O 
peroxidation O 
, O 
antioxidant O 
defense O 
systems O 
, O 
histological O 
changes O 
in O 
Wistar O 
rats O 
and O 
the O 
protective O 
effect O 
of O 
pretreatment O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
taurine B-TRIVIAL 
. O 
A O 
total O 
of O 
48 O 
rats O 
were O 
randomly O 
divided O 
into O 
six O 
groups O 
. O 
Rats O 
in O 
group O 
I O 
were O 
given O 
corn O 
oil O 
, O 
while O 
those O 
in O 
group O 
III O 
were O 
dosed O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
100 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
) O 
and O 
in O 
group O 
V O 
were O 
dosed O 
with O 
taurine B-TRIVIAL 
( O 
50 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 
Rats O 
in O 
group O 
II O 
were O 
administered O 
with O 
MC O 
only O 
( O 
25 O 
mg O 
/ O 
kg O 
b.w O 
. O 
, O 
1 O 
/ O 
4 O 
of O 
median O 
lethal O 
dose O 
( O 
LD(50) O 
) O 
) O 
, O 
while O 
those O 
in O 
groups O 
IV O 
and O 
VI O 
were O 
pretreated O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
100 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
and O 
taurine B-TRIVIAL 
( O 
50 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
for O 
20 O 
days O 
, O 
respectively O 
, O 
and O 
then O 
exposed O 
to O 
MC O 
( O 
25 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
. O 
The O 
rats O 
administered O 
with O 
MC O 
showed O 
significant O 
increase O 
in O 
the O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
in O 
the O 
liver O 
and O 
kidney O 
as O 
an O 
index O 
of O 
lipid O 
peroxidation O 
. O 
Levels O 
of O 
glutathione B-TRIVIAL 
and O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
were O 
significantly O 
increased O 
, O 
while O 
activity O 
of O 
glutathione B-TRIVIAL 
reductase O 
remained O 
unchanged O 
in O 
both O 
the O 
tissues O 
after O 
MC O 
treatment O 
. O 
Mild O 
degenerative O 
histological O 
changes O 
were O 
observed O 
in O 
liver O 
tissue O 
, O 
while O 
the O 
changes O 
in O 
kidney O 
tissue O 
were O 
more O 
severe O 
then O 
liver O 
after O 
MC O 
treatment O 
. O 
Pretreatment O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
taurine B-TRIVIAL 
resulted O 
in O 
a O 
significant O 
decrease O 
in O 
the O 
lipid O 
peroxidation O 
and O 
alleviating O 
effects O 
on O 
antioxidant O 
defense O 
systems O 
in O 
both O 
the O 
tissues O 
, O 
while O 
protective O 
effects O 
on O 
the O 
histological O 
changes O 
were O 
shown O 
only O 
in O 
kidney O 
when O 
compared O 
with O 
liver O 
. O 
In O 
conclusion O 
, O 
the O 
study O 
has O 
demonstrated O 
that O 
the O 
acute O 
MC O 
exposure O 
in O 
Wistar O 
rats O 
caused O 
oxidative O 
damage O 
on O 
liver O 
and O 
kidney O 
, O 
which O 
were O 
partly O 
ameliorated O 
by O 
the O 
pretreatment O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
taurine B-TRIVIAL 
. O 

advances O 
in O 
medicinal O 
chemistry O 
of O 
sulfonamides B-FAMILY 
. O 
Rational O 
design O 
as O 
anti-tumoral O 
, O 
anti-bacterial O 
and O 
anti-inflammatory O 
agents O 
. O 

, O 
cancer O 
is O 
becoming O 
one O 
of O 
the O 
major O 
problems O 
of O 
public O 
health O 
in O 
the O 
world O 
. O 
Pharmacology O 
treatment O 
is O 
a O 
way O 
to O 
increase O 
quality O 
and O 
long O 
life O 
. O 
Predominantly O 
, O 
in O 
last O 
decade O 
sulfonamide B-SYSTEMATIC 
derivatives O 
have O 
been O 
described O 
as O 
potential O 
carbonic O 
anhydrase O 
inhibitors O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
describe O 
recent O 
advances O 
during O 
the O 
last O 
decade O 
in O 
medicinal O 
chemistry O 
of O 
sulfonamides B-FAMILY 
derivatives O 
with O 
some O 
examples O 
of O 
rational O 
design O 
as O 
anti-tumoral O 
, O 
antibacterial O 
and O 
anti-inflammatory O 
agents O 
. O 
We O 
show O 
strategy O 
design O 
, O 
structure O 
- O 
activity O 
relationship O 
, O 
biological O 
activity O 
and O 
advances O 
of O 
new O 
sulfonamide B-SYSTEMATIC 
compounds O 
that O 
have O 
more O 
health O 
significance O 
than O 
some O 
clinically O 
used O 
sulfonamides B-FAMILY 
. O 

terpenoid B-FAMILY 
pathway O 
as O 
a O 
source O 
of O 
health O 
promoting O 
compounds O 
. O 

is O 
an O 
important O 
crop O 
plant O 
grown O 
mainly O 
for O 
its O 
fiber O 
and O 
seeds O 
, O 
which O 
are O 
also O 
rich O 
in O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
and O 
valuable O 
antioxidants O 
derived O 
from O 
the O 
terpenoid B-FAMILY 
pathways O 
including O 
carotenoids O 
, O 
tocochromanols B-FAMILY 
and O 
sterols B-FAMILY 
. O 
Many O 
of O 
those O 
components O 
found O 
in O 
flax O 
have O 
been O 
recently O 
shown O 
to O 
positively O 
influence O 
human O 
health O 
. O 
Although O 
terpenes B-FAMILY 
vary O 
greatly O 
in O 
their O 
chemical O 
structure O 
, O 
mainly O 
two O 
mechanisms O 
of O 
their O 
biological O 
activity O 
can O 
be O 
considered O 
: O 
direct O 
antioxidation O 
, O 
and O 
a O 
recently O 
explored O 
one O 
, O 
connected O 
to O 
specific O 
receptor O 
and O 
cell O 
signaling O 
pathway O 
activation O 
. O 
Recent O 
studies O 
show O 
that O 
many O 
of O 
the O 
health O 
promoting O 
agents O 
derived O 
from O 
flax O 
act O 
through O 
both O 
of O 
the O 
mentioned O 
mechanisms O 
, O 
resulting O 
in O 
synergistic O 
physiological O 
effects O 
. O 
The O 
work O 
summarizes O 
the O 
two O 
mechanisms O 
, O 
focusing O 
mainly O 
on O 
the O 
one O 
involving O 
cell O 
signaling O 
, O 
as O 
a O 
promising O 
target O 
for O 
medicine O 
and O 
pharmacotherapy O 
. O 

this O 
study O 
, O 
the O 
direct O 
influence O 
of O 
bilberry O 
( O 
Vaccinium O 
myrtillus O 
) O 
fruit O 
extracts O 
( O 
aqueous O 
and O 
ethanolic O 
) O 
rich O 
in O 
anthocyanins B-FAMILY 
on O 
the O 
oxidative O 
phosphorylation O 
of O 
isolated O 
rat O 
heart O 
mitochondria O 
was O 
investigated O 
in O 
vitro O 
. O 
Higher O 
concentrations O 
of O 
bilberry O 
extracts O 
concentration O 
- O 
dependently O 
inhibited O 
mitochondrial O 
state O 
3 O 
respiration O 
( O 
by O 
23%-61% O 
) O 
with O 
pyruvate B-TRIVIAL 
plus O 
malate B-TRIVIAL 
, O 
mildly O 
( O 
by O 
1.2- O 
to O 
1.3-fold O 
) O 
uncoupled O 
the O 
oxidative O 
phosphorylation O 
, O 
and O 
increased O 
( O 
by O 
30%-87% O 
) O 
the O 
state O 
4 O 
respiration O 
rate O 
in O 
the O 
presence O 
of O 
exogenous O 
cytochrome O 
c O 
. O 
Succinate B-TRIVIAL 
oxidation O 
was O 
less O 
affected O 
. O 
Pure O 
anthocyanins B-FAMILY 
, O 
the O 
main O 
components O 
of O 
used O 
extracts O 
, O 
malvidin-3-glucoside B-SYSTEMATIC 
, O 
malvidin-3-galactoside B-SYSTEMATIC 
, O 
and O 
cyanidin-3-galactoside B-SYSTEMATIC 
, O 
had O 
no O 
effect O 
on O 
oxidation O 
of O 
pyruvate B-TRIVIAL 
plus O 
malate B-TRIVIAL 
. O 
A O 
statistically O 
significant O 
decrease O 
in O 
H2 B-FORMULA 
O2 I-FORMULA 
production O 
by O 
mitochondria O 
was O 
found O 
in O 
the O 
presence O 
of O 
bilberry O 
fruit O 
extracts O 
. O 
Our O 
findings O 
show O 
that O 
bilberry O 
fruit O 
anthocyanin B-FAMILY 
-rich O 
extracts O 
possess O 
direct O 
effects O 
on O 
rat O 
heart O 
mitochondrial O 
function O 
in O 
vitro O 
. O 
These O 
findings O 
give O 
the O 
first O 
insights O 
into O 
the O 
mechanism(s) O 
of O 
their O 
action O 
on O 
cellular O 
energy O 
metabolism O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

extract O 
of O 
Magnolia O 
officinalis O 
prevents O 
lipopolysaccharide-induced O 
memory O 
deficiency O 
via O 
its O 
antineuroinflammatory O 
and O 
antiamyloidogenic O 
effects O 
. O 

bark O 
contains O 
several O 
compounds O 
such O 
as O 
magnolol B-TRIVIAL 
, O 
honokiol B-TRIVIAL 
, O 
4-O-methylhonokiol B-SYSTEMATIC 
, O 
obovatol B-TRIVIAL 
, O 
and O 
other O 
neolignan B-FAMILY 
compounds O 
. O 
These O 
compounds O 
have O 
been O 
reported O 
to O 
have O 
various O 
beneficial O 
effects O 
in O 
various O 
diseases O 
. O 
There O 
is O 
sufficient O 
possibility O 
that O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Magnolia O 
officinalis O 
is O 
more O 
effective O 
in O 
amyloidogenesis O 
via O 
synergism O 
of O 
these O 
ingredients O 
. O 
Neuroinflammation O 
has O 
been O 
known O 
to O 
play O 
a O 
critical O 
role O 
in O 
the O 
pathogenesis O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
We O 
investigated O 
whether O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
M. O 
officinalis O 
( O 
10 O 
mg O 
/ O 
kg O 
in O 
0.05% O 
ethanol B-SYSTEMATIC 
) O 
prevents O 
memory O 
dysfunction O 
and O 
amyloidogenesis O 
in O 
AD O 
mouse O 
model O 
by O 
intraperitoneal O 
lipopolysaccharide O 
( O 
LPS O 
, O 
250 O 
µg O 
/ O 
kg O 
/ O 
day O 
for O 
seven O 
times O 
) O 
injection O 
. O 
We O 
found O 
that O 
ethanol B-SYSTEMATIC 
extract O 
of O 
M. O 
officinalis O 
prevented O 
LPS-induced O 
memory O 
deficiency O 
as O 
well O 
as O 
inhibited O 
the O 
LPS-induced O 
elevation O 
of O 
inflammatory O 
proteins O 
, O 
such O 
as O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
and O 
cyclooxygenase O 
2 O 
, O 
and O 
activation O 
of O 
astrocytes O 
and O 
microglia O 
. O 
In O 
particular O 
, O 
administration O 
of O 
M. O 
officinalis O 
ethanol B-SYSTEMATIC 
extract O 
inhibited O 
LPS-induced O 
amyloidogenesis O 
, O 
which O 
resulted O 
in O 
the O 
inhibition O 
of O 
amyloid O 
precursor O 
protein O 
, O 
beta-site O 
amyloid O 
- O 
precursor O 
- O 
protein O 
- O 
cleaving O 
enzyme O 
1 O 
and O 
C99 O 
. O 
Thus O 
, O 
this O 
study O 
shows O 
that O 
ethanol B-SYSTEMATIC 
extract O 
of O 
M. O 
officinalis O 
prevents O 
LPS-induced O 
memory O 
impairment O 
as O 
well O 
as O 
amyloidogenesis O 
via O 
inhibition O 
of O 
neuroinflammation O 
and O 
suggests O 
that O 
ethanol B-SYSTEMATIC 
extract O 
of O 
M. O 
officinalis O 
might O 
be O 
a O 
useful O 
intervention O 
for O 
neuroinflammation O 
- O 
associated O 
diseases O 
such O 
as O 
AD O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

glutamate B-TRIVIAL 
receptor O 
4 O 
in O 
the O 
basal O 
ganglia O 
of O 
parkinsonian O 
monkeys O 
: O 
ultrastructural O 
localization O 
and O 
electrophysiological O 
effects O 
of O 
activation O 
in O 
the O 
striatopallidal O 
complex O 
. O 

III O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluR4,7,8 O 
) O 
are O 
widely O 
distributed O 
in O 
the O 
basal O 
ganglia O 
. O 
Injection O 
of O 
group O 
III O 
mGluR O 
agonists O 
into O 
the O 
striatopallidal O 
complex O 
alleviates O 
parkinsonian O 
symptoms O 
in O 
6-hydroxydopamine B-SYSTEMATIC 
-treated O 
rats O 
. O 
In O 
vitro O 
rodent O 
studies O 
have O 
suggested O 
that O 
this O 
may O 
be O 
partly O 
due O 
to O 
modulation O 
of O 
synaptic O 
transmission O 
at O 
striatopallidal O 
and O 
corticostriatal O 
synapses O 
through O 
mGluR4 O 
activation O 
. O 
However O 
, O 
the O 
in O 
vivo O 
electrophysiological O 
effects O 
of O 
group O 
III O 
mGluRs O 
activation O 
upon O 
basal O 
ganglia O 
neurons O 
activity O 
in O 
nonhuman O 
primates O 
remain O 
unknown O 
. O 
Thus O 
, O 
in O 
order O 
to O 
examine O 
the O 
anatomical O 
substrates O 
and O 
physiological O 
effects O 
of O 
group O 
III O 
mGluRs O 
activation O 
upon O 
striatal O 
and O 
pallidal O 
neurons O 
in O 
monkeys O 
, O 
we O 
used O 
electron O 
microscopy O 
immunohistochemistry O 
to O 
localize O 
mGluR4 O 
, O 
combined O 
with O 
local O 
administration O 
of O 
the O 
group O 
III O 
mGluR O 
agonist O 
L-AP4 B-IDENTIFIER 
, O 
or O 
the O 
mGluR4 O 
positive O 
allosteric O 
modulator O 
VU0155041 B-IDENTIFIER 
, O 
to O 
assess O 
the O 
effects O 
of O 
group O 
III O 
mGluR O 
activation O 
on O 
the O 
firing O 
rate O 
and O 
pattern O 
of O 
striatal O 
and O 
pallidal O 
neurons O 
in O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
) O 
- O 
treated O 
parkinsonian O 
monkeys O 
. O 
At O 
the O 
ultrastructural O 
level O 
, O 
striatal O 
mGluR4 O 
immunoreactivity O 
was O 
localized O 
in O 
pre- O 
( O 
60% O 
) O 
and O 
post O 
- O 
synaptic O 
( O 
30% O 
) O 
elements O 
, O 
while O 
in O 
the O 
GPe O 
, O 
mGluR4 O 
was O 
mainly O 
expressed O 
pre O 
- O 
synaptically O 
( O 
90% O 
) O 
. O 
In O 
the O 
putamen O 
, O 
terminals O 
expressing O 
mGluR4 O 
were O 
evenly O 
split O 
between O 
putative O 
excitatory O 
and O 
inhibitory O 
terminals O 
, O 
while O 
in O 
the O 
GPe O 
, O 
most O 
labeled O 
terminals O 
displayed O 
the O 
ultrastructural O 
features O 
of O 
striatal O 
- O 
like O 
inhibitory O 
terminals O 
, O 
though O 
putative O 
excitatory O 
boutons O 
were O 
also O 
labeled O 
. O 
No O 
significant O 
difference O 
was O 
found O 
between O 
normal O 
and O 
parkinsonian O 
monkeys O 
. O 
Extracellular O 
recordings O 
in O 
awake O 
MPTP B-ABBREVIATION 
-treated O 
monkeys O 
revealed O 
that O 
local O 
microinjections O 
of O 
small O 
volumes O 
of O 
L-AP4 B-IDENTIFIER 
resulted O 
in O 
increased O 
firing O 
rates O 
in O 
one O 
half O 
of O 
striatal O 
cells O 
and O 
one O 
third O 
of O 
pallidal O 
cells O 
, O 
while O 
a O 
significant O 
number O 
of O 
neurons O 
in O 
both O 
structures O 
showed O 
either O 
opposite O 
effects O 
, O 
or O 
did O 
not O 
display O 
any O 
significant O 
rate O 
changes O 
following O 
L-AP4 B-IDENTIFIER 
application O 
. O 
VU0155041 B-IDENTIFIER 
administration O 
had O 
little O 
effect O 
on O 
firing O 
rates O 
. O 
Both O 
compounds O 
also O 
had O 
subtle O 
effects O 
on O 
bursting O 
and O 
oscillatory O 
properties O 
, O 
acting O 
to O 
increase O 
the O 
irregularity O 
of O 
firing O 
. O 
The O 
occurrence O 
of O 
pauses O 
in O 
firing O 
was O 
reduced O 
in O 
the O 
majority O 
( O 
80% O 
) O 
of O 
GPe O 
neurons O 
after O 
L-AP4 B-IDENTIFIER 
injection O 
. O 
Our O 
findings O 
indicate O 
that O 
glutamate B-TRIVIAL 
can O 
mediate O 
multifarious O 
physiological O 
effects O 
upon O 
striatal O 
and O 
pallidal O 
neurons O 
through O 
activation O 
of O 
pre O 
- O 
synaptic O 
group O 
III O 
mGluRs O 
at O 
inhibitory O 
and O 
excitatory O 
synapses O 
in O 
parkinsonian O 
monkeys O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

and O 
antibacterial O 
activity O 
of O 
Schiff B-FAMILY 
bases I-FAMILY 
from O 
16-isopropyl-5 B-SYSTEMATIC 
, I-SYSTEMATIC 
9-dimethyltetracyclo I-SYSTEMATIC 
[ I-SYSTEMATIC 
10.2.2.0(1 I-SYSTEMATIC 
, I-SYSTEMATIC 
10).0(4 I-SYSTEMATIC 
, I-SYSTEMATIC 
9 I-SYSTEMATIC 
) I-SYSTEMATIC 
] I-SYSTEMATIC 
hexadec-15-ene-5 I-SYSTEMATIC 
, I-SYSTEMATIC 
14-dicarboxylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

, I-SYSTEMATIC 
9-dimethyltetracyclo I-SYSTEMATIC 
[ I-SYSTEMATIC 
10.2.2.0(1 I-SYSTEMATIC 
, I-SYSTEMATIC 
10).0(4 I-SYSTEMATIC 
, I-SYSTEMATIC 
9 I-SYSTEMATIC 
) I-SYSTEMATIC 
] I-SYSTEMATIC 
hexadec-15-ene-5 I-SYSTEMATIC 
, I-SYSTEMATIC 
14-dicarboxylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
1b O 
) O 
was O 
prepared O 
from O 
rosin O 
through O 
a O 
Diels-Alder O 
addition O 
reaction O 
. O 
Then O 
, O 
a O 
group O 
of O 
Schiff B-FAMILY 
bases I-FAMILY 
derived O 
from O 
1b O 
was O 
synthesised O 
. O 
Their O 
structures O 
were O 
characterised O 
by O 
IR O 
, O 
(1)H B-FORMULA 
-NMR O 
, O 
MS O 
and O 
elemental O 
analysis O 
. O 
The O 
antibacterial O 
activities O 
of O 
these O 
newly O 
synthesised O 
Schiff B-FAMILY 
bases I-FAMILY 
were O 
also O 
investigated O 
. O 
The O 
results O 
show O 
that O 
these O 
compounds O 
possess O 
antibacterial O 
activities O 
against O 
Staphylococcus O 
aureus O 
and O 
Escherichia O 
coli O 
. O 
Among O 
them O 
, O 
compounds O 
5a O 
, O 
5b O 
and O 
5c O 
, O 
exhibit O 
remarkable O 
antibacterial O 
activity O 
against O 
E O 
. O 
coli O 
. O 

growth O 
factor O 
- O 
beta O 
( O 
TGF-β O 
) O 
has O 
a O 
dual O 
role O 
in O 
epithelial O 
malignancies O 
, O 
including O 
head O 
and O 
neck O 
squamous O 
cell O 
carcinoma O 
( O 
HNSCC O 
) O 
. O 
Attenuation O 
of O 
canonical O 
TGF-β O 
signaling O 
enhances O 
de O 
novo O 
tumor O 
development O 
, O 
whereas O 
TGF-β O 
overexpression O 
and O 
signaling O 
paradoxically O 
promotes O 
malignant O 
progression O 
. O 
We O 
recently O 
observed O 
that O 
TGF-β-induced O 
growth O 
arrest O 
response O 
is O 
attenuated O 
, O 
in O 
association O 
with O 
aberrant O 
activation O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
, O 
a O 
transcription O 
factor O 
, O 
which O 
promotes O 
malignant O 
progression O 
in O 
HNSCC O 
. O 
However O 
, O 
what O 
role O 
cross O 
- O 
talk O 
between O 
components O 
of O 
the O 
TGF-β O 
and O 
NF-κB O 
pathways O 
plays O 
in O 
altered O 
activation O 
of O 
these O 
pathways O 
has O 
not O 
been O 
established O 
. O 
Here O 
, O 
we O 
show O 
TGF-β O 
receptor O 
II O 
and O 
TGF-β-activated O 
kinase O 
1 O 
( O 
TAK1 O 
) O 
are O 
predominantly O 
expressed O 
in O 
a O 
subset O 
of O 
HNSCC O 
tumors O 
with O 
nuclear O 
activation O 
of O 
NF-κB O 
family O 
member O 
RELA O 
( O 
p65 O 
) O 
. O 
Further O 
, O 
TGF-β1 O 
treatment O 
induced O 
sequential O 
phosphorylation O 
of O 
TAK1 O 
, O 
IKK O 
, O 
IκBα O 
and O 
RELA O 
in O 
human O 
HNSCC O 
lines O 
. O 
TAK1 O 
enhances O 
TGF-β-induced O 
NF-κB O 
activation O 
, O 
as O 
TAK1 O 
siRNA O 
knockdown O 
decreased O 
TGF-β1-induced O 
phosphorylation O 
of O 
IKK O 
, O 
IκB O 
and O 
RELA O 
, O 
degradation O 
of O 
IκBα O 
, O 
RELA O 
nuclear O 
translocation O 
and O 
DNA O 
binding O 
, O 
and O 
NF-κB-induced O 
reporter O 
and O 
target O 
gene O 
transcription O 
. O 
Functionally O 
, O 
TAK1 O 
siRNA O 
inhibited O 
cell O 
proliferation O 
, O 
migration O 
and O 
invasion O 
. O 
Celastrol B-TRIVIAL 
, O 
a O 
TAK1 O 
inhibitor O 
and O 
anti-inflammatory O 
compound O 
used O 
in O 
traditional O 
Chinese O 
medicine O 
, O 
also O 
decreased O 
TGF-β1-induced O 
phosphorylation O 
of O 
TAK1 O 
and O 
RELA O 
, O 
and O 
suppressed O 
basal O 
, O 
TGF-β1- O 
and O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
(TNF-α)-induced O 
NF-κB O 
reporter O 
gene O 
activity O 
. O 
Celastrol B-TRIVIAL 
also O 
inhibited O 
cell O 
proliferation O 
, O 
while O 
increasing O 
sub-G0 O 
DNA O 
fragmentation O 
and O 
Annexin O 
V O 
markers O 
of O 
apoptosis O 
. O 
Furthermore O 
, O 
TGF-β O 
and O 
RELA O 
activation O 
promoted O 
SMAD7 O 
expression O 
. O 
In O 
turn O 
, O 
SMAD7 O 
preferentially O 
suppressed O 
TGF-β-induced O 
SMAD O 
and O 
NF-κB O 
reporters O 
when O 
compared O 
with O 
constitutive O 
or O 
TNF-α-induced O 
NF-κB O 
reporter O 
gene O 
activation O 
. O 
Thus O 
, O 
cross O 
- O 
talk O 
by O 
TGF-β O 
via O 
TAK1 O 
and O 
NF-κB O 
promotes O 
the O 
malignant O 
phenotype O 
of O 
HNSCC O 
. O 
Moreover O 
, O 
NF-κB O 
may O 
contribute O 
to O 
the O 
downstream O 
attenuation O 
of O 
canonical O 
TGF-β O 
signaling O 
through O 
increased O 
SMAD7 O 
expression O 
. O 
Celastrol B-TRIVIAL 
highlights O 
the O 
therapeutic O 
potential O 
of O 
agents O 
targeting O 
TAK1 O 
as O 
a O 
key O 
node O 
in O 
this O 
pro O 
- O 
oncogenic O 
TGF-β-NF-κB O 
signal O 
pathway O 
. O 

2 O 
diabetes O 
is O 
frequently O 
associated O 
with O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
. O 
Insulin O 
resistance O 
( O 
IR O 
) O 
is O 
thought O 
to O 
be O 
the O 
underlying O 
pathophysiology O 
of O 
MetS O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
examine O 
the O 
association O 
of O 
MetS O 
with O 
IR O 
and O 
beta O 
cell O 
function O 
. O 
This O 
is O 
a O 
cross O 
- O 
sectional O 
study O 
in O 
NHANES O 
1999-2000 O 
participants O 
who O 
were O 
at O 
least O 
18 O 
years O 
old O 
, O 
including O 
911 O 
non-Hispanic O 
whites O 
( O 
NHW O 
) O 
, O 
398 O 
non-Hispanic O 
blacks O 
( O 
NHB O 
) O 
, O 
and O 
595 O 
Mexican-Americans O 
( O 
MA O 
) O 
. O 
MetS O 
was O 
defined O 
based O 
on O 
the O 
revised O 
ATP O 
III O 
. O 
IR O 
and O 
beta O 
cell O 
function O 
were O 
calculated O 
using O 
homeostasis O 
model O 
assessment O 
( O 
HOMA-IR O 
and O 
HOMA-B O 
) O 
. O 
The O 
high O 
- O 
risk O 
tertile O 
was O 
defined O 
as O 
the O 
highest O 
HOMA-IR O 
and O 
lowest O 
HOMA-B O 
. O 
The O 
odds O 
ratio O 
( O 
OR O 
) O 
was O 
calculated O 
against O 
the O 
other O 
two O 
tertiles O 
. O 
The O 
relationship O 
of O 
HOAM-IR O 
and O 
HOMA-B O 
with O 
the O 
components O 
of O 
MetS O 
was O 
also O 
examined O 
. O 
IR O 
was O 
a O 
risk O 
factor O 
of O 
MetS O 
in O 
all O 
three O 
ethnic O 
groups O 
( O 
OR O 
4.17-12.01 O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
Fasting O 
glucose B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
and O 
HDL O 
cholesterol B-TRIVIAL 
were O 
associated O 
with O 
IR O 
( O 
P O 
< O 
0.001 O 
) O 
and O 
correlated O 
with O 
HOMA-IR O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
while O 
inconsistent O 
results O 
were O 
noted O 
in O 
blood O 
pressure O 
and O 
waist O 
circumference O 
among O 
three O 
racial O 
/ O 
ethnic O 
groups O 
. O 
However O 
, O 
in O 
the O 
MetS O 
subjects O 
, O 
32 O 
% O 
of O 
NHW O 
, O 
28 O 
% O 
of O 
NHB O 
, O 
and O 
44 O 
% O 
of O 
MA O 
were O 
not O 
in O 
the O 
IR O 
tertile O 
and O 
in O 
the O 
IR O 
subjects O 
, O 
25 O 
% O 
of O 
NHW O 
, O 
36 O 
% O 
NHB O 
, O 
and O 
30 O 
% O 
of O 
MA O 
did O 
not O 
have O 
MetS O 
. O 
No O 
relationship O 
was O 
found O 
between O 
beta O 
cell O 
function O 
and O 
MetS O 
. O 
Although O 
IR O 
is O 
a O 
risk O 
factor O 
for O 
MetS O 
, O 
IR O 
is O 
neither O 
necessary O 
nor O 
required O 
for O 
MetS O 
. O 

extract O 
of O 
Glinus O 
lotoides O 
, O 
a O 
medicinal O 
plant O 
used O 
in O 
Africa O 
and O 
Asia O 
for O 
various O 
therapeutic O 
purposes O 
, O 
was O 
recently O 
shown O 
to O 
cause O 
DNA O 
damage O 
in O 
vitro O 
. O 
To O 
further O 
explore O 
the O 
potential O 
genotoxicity O 
of O 
this O 
plant O 
, O 
fractionation O 
of O 
the O 
crude O 
extract O 
was O 
performed O 
using O 
reverse O 
phase O 
solid O 
- O 
phase O 
extraction O 
and O 
a O 
stepwise O 
gradient O 
elution O 
of O 
methanol B-SYSTEMATIC 
in O 
water O 
. O 
Four O 
fractions O 
were O 
collected O 
and O 
subsequently O 
analysed O 
for O 
their O 
DNA O 
damaging O 
effects O 
in O 
mouse O 
lymphoma O 
cells O 
using O 
an O 
alkaline O 
version O 
of O 
the O 
comet O 
assay O 
. O 
To O 
identify O 
potential O 
genotoxic O 
and O 
non-genotoxic O 
principles O 
, O 
each O 
fraction O 
was O 
then O 
subjected O 
to O 
liquid O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
, O 
LC-MS O 
/ O 
MS O 
. O 
1D O 
and O 
2D O 
nuclear O 
magnetic O 
resonance O 
analyses O 
were O 
used O 
to O 
confirm O 
the O 
identity O 
of O 
some O 
saponins B-FAMILY 
. O 
Although O 
fractions O 
containing O 
a O 
mixture O 
of O 
flavonoids B-FAMILY 
and O 
oleanane B-TRIVIAL 
-type O 
saponins B-FAMILY 
or O 
oleanane B-TRIVIAL 
-type O 
saponins B-FAMILY 
alone O 
produced O 
no O 
DNA O 
damage O 
, O 
those O 
containing O 
hopane B-TRIVIAL 
-type O 
saponins B-FAMILY 
exhibited O 
a O 
pronounced O 
DNA O 
damaging O 
effect O 
without O 
affecting O 
the O 
viability O 
of O 
the O 
cells O 
. O 
To O 
conclude O 
, O 
even O 
if O 
this O 
study O 
presents O 
evidence O 
that O 
hopane B-TRIVIAL 
-type O 
of O 
saponins B-FAMILY 
are O 
endowed O 
with O 
a O 
DNA O 
damaging O 
ability O 
, O 
further O 
studies O 
are O 
needed O 
before O 
individual O 
saponins B-FAMILY 
can O 
be O 
cited O 
as O 
a O 
culprit O 
for O 
the O 
previously O 
reported O 
genotoxicity O 
of O 
the O 
crude O 
extract O 
of O 
G O 
. O 
lotoides O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

treatment O 
with O 
myo-inositol B-TRIVIAL 
reduces O 
white O 
adipose O 
tissue O 
accretion O 
and O 
improves O 
insulin O 
sensitivity O 
in O 
female O 
mice O 
. O 

2 O 
diabetes O 
is O 
a O 
complex O 
disease O 
characterized O 
by O 
a O 
state O 
of O 
insulin O 
resistance O 
in O 
peripheral O 
tissues O 
such O 
as O 
skeletal O 
muscle O 
, O 
adipose O 
tissue O 
or O 
liver O 
. O 
Some O 
inositol B-TRIVIAL 
isomers O 
have O 
been O 
reported O 
to O 
possess O 
insulin O 
- O 
mimetic O 
activity O 
and O 
to O 
be O 
efficient O 
in O 
lowering O 
blood O 
glucose O 
level O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
in O 
mice O 
the O 
metabolic O 
effects O 
of O 
a O 
chronic O 
treatment O 
with O 
myo-inositol B-TRIVIAL 
, O 
the O 
most O 
common O 
stereoisomer O 
of O 
inositol B-TRIVIAL 
. O 
Mice O 
given O 
myo-inositol B-TRIVIAL 
treatment O 
( O 
0.9 O 
or O 
1.2 O 
mg O 
g(-1) O 
day(-1) O 
, O 
15 O 
days O 
, O 
orally O 
or O 
intraperitoneally O 
) O 
exhibited O 
an O 
improved O 
glucose B-TRIVIAL 
tolerance O 
due O 
to O 
a O 
greater O 
insulin O 
sensitivity O 
. O 
Mice O 
treated O 
with O 
myo-inositol B-TRIVIAL 
exhibited O 
a O 
decreased O 
white O 
adipose O 
tissue O 
accretion O 
( O 
-33% O 
, O 
P O 
< O 
0.005 O 
) O 
compared O 
with O 
controls O 
. O 
The O 
decrease O 
in O 
white O 
adipose O 
tissue O 
deposition O 
was O 
due O 
to O 
a O 
decrease O 
in O 
adipose O 
cell O 
volume O 
( O 
-33% O 
, O 
P O 
< O 
0.05 O 
) O 
, O 
while O 
no O 
change O 
was O 
noticed O 
in O 
total O 
adipocyte O 
number O 
. O 
In O 
skeletal O 
muscle O 
, O 
in O 
vivo O 
as O 
well O 
as O 
ex O 
vivo O 
myo-inositol B-TRIVIAL 
treatment O 
increased O 
protein O 
kinase O 
B O 
/ O 
Akt O 
phosphorylation O 
under O 
baseline O 
and O 
insulin O 
- O 
stimulated O 
conditions O 
, O 
suggesting O 
a O 
synergistic O 
action O 
of O 
myo-inositol B-TRIVIAL 
treatment O 
and O 
insulin O 
on O 
proteins O 
of O 
the O 
insulin O 
signalling O 
pathway O 
. O 
Myo-inositol B-TRIVIAL 
could O 
therefore O 
constitute O 
a O 
viable O 
nutritional O 
strategy O 
for O 
the O 
prevention O 
and O 
/ O 
or O 
treatment O 
of O 
insulin O 
resistance O 
and O 
type O 
2 O 
diabetes O 
. O 

mechanisms O 
that O 
desensitize O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
signaling O 
: O 
an O 
overview O 
. O 

purpose O 
of O 
the O 
present O 
article O 
is O 
to O 
review O 
our O 
actual O 
knowledge O 
on O 
the O 
desensitization O 
of O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
based O 
on O 
the O 
literature O 
available O 
so O 
far O 
, O 
with O 
the O 
attempt O 
to O 
emphasize O 
all O 
converging O 
data O 
and O 
to O 
give O 
a O 
possible O 
explanation O 
to O 
those O 
evidences O 
that O 
still O 
remain O 
controversial O 
. O 
1 O 
. O 
We O 
review O 
our O 
knowledge O 
on O 
the O 
regulation O 
of O 
mGlu O 
receptors O 
based O 
on O 
the O 
available O 
literature O 
2 O 
. O 
We O 
report O 
converging O 
data O 
and O 
we O 
comment O 
on O 
issues O 
that O 
still O 
remain O 
controversial O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

interactions O 
with O 
multidrug O 
therapy O 
in O 
pediatric O 
oncology O 
. O 

with O 
cancer O 
receive O 
multidrug O 
therapy O 
. O 
Antineoplastic O 
agents O 
and O 
supportive O 
care O 
drugs O 
are O 
often O 
administered O 
together O 
, O 
leading O 
to O 
potential O 
drug O 
- O 
drug O 
interactions O 
. O 
These O 
interactions O 
may O 
have O 
significant O 
clinical O 
implications O 
in O 
terms O 
of O 
toxicity O 
or O 
a O 
decrease O 
in O 
the O 
efficacy O 
of O 
the O 
treatment O 
administered O 
. O 
Here O 
, O 
we O 
focus O 
on O 
the O 
role O 
of O 
azoles B-FAMILY 
and O 
their O 
main O 
pharmacokinetic O 
interactions O 
with O 
the O 
principal O 
classes O 
of O 
drugs O 
used O 
in O 
pediatric O 
oncology O 
. O 
The O 
co O 
- O 
administration O 
of O 
azoles B-FAMILY 
and O 
antineoplastic O 
agents O 
, O 
corticosteroids B-FAMILY 
, O 
immunosuppressants O 
, O 
antacids O 
, O 
antiemetics O 
, O 
antiepileptic O 
drugs O 
and O 
analgesics O 
was O 
investigated O 
, O 
and O 
a O 
practical O 
guide O 
on O 
the O 
management O 
of O 
these O 
drugs O 
when O 
administered O 
together O 
is O 
provided O 
. O 

different O 
species O 
of O 
nonliving O 
red O 
algal O 
biomass O 
Laurancia O 
obtusa O 
, O 
Geldiella O 
acerosa O 
and O 
Hypnea O 
sp O 
. O 
were O 
used O 
to O 
build O 
three O 
types O 
of O 
fixed O 
- O 
bed O 
column O 
for O 
the O 
removal O 
of O 
toxic O 
heavy O 
metal O 
ions O 
such O 
as O 
Cu(2+) B-FORMULA 
, O 
Zn(2+) B-FORMULA 
, O 
Mn(2+) B-FORMULA 
and O 
Ni(2+) B-FORMULA 
from O 
industrial O 
effluent O 
. O 
In O 
general O 
, O 
the O 
highest O 
efficiency O 
of O 
metal O 
ion O 
bioremoval O 
was O 
recorded O 
for O 
algal O 
column O 
of O 
L O 
. O 
obtusa O 
followed O 
by O 
G O 
. O 
acerosa O 
and O 
the O 
lowest O 
one O 
was O 
recorded O 
for O 
Hypnea O 
sp O 
. O 
, O 
with O 
mean O 
removal O 
values O 
of O 
94% O 
, O 
85% O 
and O 
71% O 
, O 
respectively O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
biological O 
treatments O 
of O 
industrial O 
effluents O 
with O 
these O 
algal O 
columns O 
, O 
using O 
standard O 
algal O 
biotest O 
, O 
Pseudokirchneriella O 
subcapitata O 
, O 
were O 
capable O 
of O 
reducing O 
effluent O 
toxicities O 
from O 
75% O 
to O 
15% O 
, O 
respectively O 
. O 
Red O 
algal O 
column O 
may O 
be O 
considered O 
as O 
an O 
inexpensive O 
and O 
efficient O 
alternative O 
treatment O 
for O 
conventional O 
removal O 
technology O 
, O 
for O 
sequestering O 
heavy O 
metal O 
ions O 
from O 
industrial O 
effluents O 
. O 

cardiac O 
valve O 
abnormalities O 
and O 
left O 
ventricular O 
hypertrophy O 
are O 
present O 
in O 
untreated O 
patients O 
with O 
mucopolysaccharidosis O 
type O 
VI O 
( O 
MPS O 
VI O 
) O 
. O 
Cardiac O 
ultrasound O 
was O 
performed O 
to O 
investigate O 
these O 
findings O 
in O 
subjects O 
during O 
long O 
- O 
term O 
enzyme O 
replacement O 
therapy O 
( O 
ERT O 
) O 
with O 
recombinant O 
human O 
arylsulfatase O 
B O 
( O 
rhASB O 
, O 
rh O 
N-acetylgalactosamine B-SYSTEMATIC 
4-sulfatase O 
, O 
galsulfase O 
, O 
Naglazyme O 
® O 
) O 
. O 
Studies O 
were O 
conducted O 
in O 
54 O 
subjects O 
before O 
ERT O 
was O 
begun O 
and O 
at O 
specific O 
intervals O 
for O 
up O 
to O 
96 O 
weeks O 
of O 
weekly O 
infusions O 
of O 
rhASB O 
at O 
1 O 
mg O 
/ O 
kg O 
during O 
phase O 
1 O 
/ O 
2 O 
, O 
phase O 
2 O 
, O 
and O 
phase O 
3 O 
trials O 
of O 
rhASB O 
. O 
At O 
baseline O 
, O 
mitral O 
and O 
aortic O 
valve O 
obstruction O 
was O 
present O 
and O 
was O 
significantly O 
greater O 
in O 
those O 
≥ O 
12 O 
years O 
of O 
age O 
. O 
Mild O 
mitral O 
and O 
trace O 
aortic O 
regurgitation O 
were O 
present O 
, O 
the O 
former O 
being O 
significantly O 
greater O 
in O 
those O 
< O 
12 O 
years O 
. O 
Left O 
ventricular O 
hypertrophy O 
, O 
with O 
averaged O 
z-scores O 
ranging O 
from O 
1.6-1.9 O 
SD O 
greater O 
than O 
normal O 
, O 
was O 
present O 
for O 
ages O 
both O 
< O 
12 O 
and O 
≥ O 
12 O 
years O 
. O 
After O 
96 O 
weeks O 
of O 
ERT O 
, O 
ventricular O 
septal O 
hypertrophy O 
regressed O 
in O 
those O 
< O 
12 O 
years O 
. O 
For O 
those O 
≥ O 
12 O 
years O 
, O 
septal O 
hypertrophy O 
was O 
unchanged O 
, O 
and O 
aortic O 
regurgitation O 
increased O 
statistically O 
but O 
not O 
physiologically O 
. O 
Obstructive O 
gradients O 
across O 
mitral O 
and O 
aortic O 
valves O 
remained O 
unchanged O 
. O 
The O 
results O 
suggest O 
that O 
long O 
- O 
term O 
ERT O 
is O 
effective O 
in O 
reducing O 
intraventricular O 
septal O 
hypertrophy O 
and O 
preventing O 
progression O 
of O 
cardiac O 
valve O 
abnormalities O 
when O 
administered O 
to O 
those O 
< O 
12 O 
years O 
of O 
age O 
. O 

and O 
formulation O 
of O 
newly O 
synthesized O 
QNT3-18 B-IDENTIFIER 
for O 
development O 
of O 
a O 
skin O 
whitening O 
agent O 
. O 

molecules O 
having O 
the O 
structure O 
of O 
(E)-2-(4-tert-butylbenzylidene) B-SYSTEMATIC 
hydrazinecarbothioamide I-SYSTEMATIC 
( O 
QNT3-18 B-IDENTIFIER 
) O 
or O 
4-tert-butylphenylthiourea B-SYSTEMATIC 
( O 
QNT3-20 B-IDENTIFIER 
) O 
was O 
synthesized O 
and O 
presupposed O 
to O 
inhibit O 
melanogenesis O 
through O 
the O 
inhibition O 
of O 
tyrosinase O 
, O 
which O 
is O 
involved O 
in O 
melanin O 
formation O 
. O 
Therefore O 
, O 
we O 
seek O 
to O 
develop O 
these O 
new O 
molecules O 
as O 
skin O 
whitening O 
agents O 
in O 
topical O 
formulations O 
based O 
on O 
preformulation O 
studies O 
. O 
QNT3-18 B-IDENTIFIER 
or O 
QNT3-20 B-IDENTIFIER 
showed O 
a O 
strong O 
single O 
endothermic O 
peak O 
at O 
159.34°C O 
with O 
10.79 O 
μm-sized O 
or O 
at O 
150.69°C O 
with O 
9 O 
μm-sized O 
aggregated O 
particles O 
, O 
respectively O 
. O 
Both O 
QNT3-18 B-IDENTIFIER 
and O 
QNT3-20 B-IDENTIFIER 
did O 
not O 
show O 
cytotoxicity O 
at O 
effective O 
concentration O 
range O 
( O 
0.4 O 
µM O 
) O 
against O 
keratinocyte O 
cells O 
and O 
QNT3-18 B-IDENTIFIER 
was O 
more O 
retained O 
than O 
QNT3-20 B-IDENTIFIER 
in O 
the O 
skin O 
instead O 
of O 
permeating O 
through O 
the O 
skin O 
. O 
QNT3-18 B-IDENTIFIER 
or O 
QNT3-20 B-IDENTIFIER 
was O 
practically O 
insoluble O 
in O 
water O 
; O 
the O 
aqueous O 
solubility O 
was O 
3.8 O 
± O 
0.37 O 
or O 
130.6 O 
± O 
2.52 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 
Also O 
, O 
the O 
partition O 
coefficient O 
value O 
( O 
log O 
P O 
) O 
corresponding O 
to O 
the O 
quotient O 
between O 
aqueous O 
and O 
octanol B-SYSTEMATIC 
concentration O 
of O 
the O 
molecule O 
was O 
3.9 O 
or O 
2.6 O 
, O 
respectively O 
. O 
The O 
skin O 
retention O 
amount O 
of O 
QNT3-18 B-IDENTIFIER 
was O 
1.7-fold O 
higher O 
than O 
that O 
of O 
QNT3-20 B-IDENTIFIER 
. O 
When O 
the O 
optimal O 
SLN O 
cream O 
( O 
J3 O 
formulation O 
) O 
containing O 
4 O 
μM O 
QNT3-18 B-IDENTIFIER 
was O 
applied O 
on O 
the O 
backs O 
of O 
hairless O 
rats O 
for O 
4 O 
days O 
after O 
UV O 
irradiation O 
for O 
7 O 
days O 
and O 
the O 
skin O 
color O 
was O 
checked O 
by O 
reflectance O 
spectrophotometer O 
, O 
the O 
rat O 
skin O 
treated O 
with O 
SLN O 
cream O 
with O 
QNT3-18 B-IDENTIFIER 
quickly O 
recovered O 
to O 
normal O 
compared O 
to O 
skin O 
treated O 
with O 
SLN O 
cream O 
without O 
QNT3-18 B-IDENTIFIER 
. O 
Taken O 
together O 
, O 
this O 
study O 
suggests O 
that O 
topical O 
formulations O 
such O 
as O 
creams O 
including O 
SLNs O 
with O 
QNT3-18 B-IDENTIFIER 
might O 
be O 
appropriate O 
carriers O 
for O 
skin O 
whitening O 
agents O 
. O 

of O 
tetrabrombisphenol B-SYSTEMATIC 
A I-SYSTEMATIC 
on O 
induction O 
of O 
apoptosis O 
in O 
the O 
testes O 
and O 
changes O 
in O 
expression O 
of O 
selected O 
testicular O 
genes O 
in O 
CD1 O 
mice O 
. O 

A I-SYSTEMATIC 
( O 
TBBPA B-ABBREVIATION 
) O 
is O 
a O 
substance O 
widely O 
used O 
in O 
industry O 
as O 
a O 
flame O 
retardant O 
. O 
TBBPA B-ABBREVIATION 
was O 
found O 
in O 
the O 
environment O 
and O 
was O 
detected O 
even O 
in O 
the O 
human O 
body O 
. O 
The O 
effect O 
of O 
this O 
chemical O 
was O 
observed O 
in O 
different O 
cell O 
lines O 
in O 
vitro O 
and O 
it O 
is O 
supposed O 
that O 
TBBPA B-ABBREVIATION 
may O 
affect O 
various O 
hormonal O 
systems O 
in O 
vivo O 
. O 
In O 
this O 
study O 
we O 
examined O 
the O 
effect O 
of O 
TBBPA B-ABBREVIATION 
on O 
the O 
reproductive O 
parameters O 
of O 
two O 
generations O 
of O 
outbred O 
mice O 
in O 
vivo O 
. O 
Experimental O 
and O 
control O 
animals O 
of O 
F1 O 
generation O 
were O 
bred O 
in O 
various O 
conditions O 
to O 
enable O 
evaluation O 
of O 
the O 
possible O 
trans-generational O 
effect O 
. O 
An O 
increased O 
incidence O 
of O 
apoptosis O 
in O 
the O 
testes O 
and O 
changes O 
in O 
the O 
morphometry O 
of O 
seminiferous O 
tubules O 
was O 
detected O 
in O 
the O 
experimental O 
animals O 
. O 
In O 
addition O 
, O 
changes O 
in O 
the O 
expression O 
pattern O 
of O 
selected O 
genes O 
encoding O 
proteins O 
that O 
play O 
an O 
important O 
role O 
during O 
spermatogenesis O 
were O 
observed O 
. O 
In O 
contrast O 
, O 
sperm O 
quality O 
and O 
reproduction O 
were O 
not O 
affected O 
by O 
TBBPA B-ABBREVIATION 
. O 

membrane O 
potential O 
( O 
∆Ψm O 
) O 
contributes O 
to O 
determining O 
a O 
driving O 
force O 
for O 
calcium B-SYSTEMATIC 
to O 
enter O 
the O 
mitochondria O 
. O 
It O 
has O 
been O 
demonstrated O 
that O 
even O 
a O 
small O 
mitochondrial O 
depolarization O 
is O 
sufficient O 
to O 
prevent O 
mitochondrial O 
calcium O 
overload O 
and O 
the O 
subsequent O 
apoptosis O 
. O 
Therefore O 
, O 
mild O 
mitochondrial O 
depolarization O 
has O 
been O 
recently O 
evaluated O 
as O 
a O 
novel O 
mechanism O 
of O 
neuroprotection O 
via O 
inhibiting O 
neurotoxic O 
mitochondrial O 
calcium B-SYSTEMATIC 
overload O 
during O 
neuronal O 
insults O 
. O 
In O 
the O 
present O 
study O 
, O 
using O 
both O 
real O 
- O 
time O 
recording O 
and O 
flow O 
cytometric O 
analyses O 
of O 
∆Ψm O 
, O 
we O 
demonstrated O 
that O 
ethanolic O 
peel O 
extract O 
of O 
Citrus O 
sunki O 
Hort O 
. O 
ex O 
Tanaka O 
( O 
CPE O 
) O 
and O 
its O 
active O 
compounds O 
are O 
capable O 
of O 
inducing O 
a O 
mild O 
mitochondrial O 
depolarization O 
. O 
Polymethoxylated B-FAMILY 
flavones I-FAMILY 
such O 
as O 
nobiletin B-TRIVIAL 
and O 
tangeretin B-TRIVIAL 
were O 
found O 
as O 
the O 
active O 
compounds O 
responsible O 
for O 
CPE O 
effects O 
on O 
∆Ψm O 
. O 
Neuronal O 
viability O 
was O 
significantly O 
increased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
by O 
CPE O 
treatment O 
in O 
H2 B-FORMULA 
O2 I-FORMULA 
-stimulated O 
HT-22 O 
cells O 
as O 
an O 
in O 
vitro O 
neuronal O 
insult O 
model O 
. O 
CPE O 
treatment O 
significantly O 
inhibited O 
H2 B-FORMULA 
O2 I-FORMULA 
-induced O 
apoptotic O 
processes O 
such O 
as O 
chromatin O 
condensation O 
, O 
caspase O 
3 O 
activation O 
and O 
anti- O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
cleavage O 
. O 
CPE O 
treatment O 
significantly O 
blocked O 
mitochondrial O 
calcium O 
overload O 
in O 
H2 B-FORMULA 
O2 I-FORMULA 
-stimulated O 
HT-22 O 
neurons O 
as O 
indicated O 
by O 
rhod-2 O 
acetoxymethyl B-SYSTEMATIC 
ester I-SYSTEMATIC 
. O 
Taken O 
together O 
, O 
our O 
findings O 
suggest O 
that O 
CPE O 
and O 
its O 
active O 
compounds O 
may O 
be O 
considered O 
as O 
promising O 
neuroprotective O 
agents O 
via O 
inducing O 
a O 
mild O 
mitochondrial O 
depolarization O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

manuscript O 
describes O 
methodology O 
and O 
a O 
prediction O 
model O 
for O 
the O 
MUTZ-LC O 
migration O 
assay O 
. O 
The O 
assay O 
represents O 
the O 
physiological O 
change O 
in O 
Langerhans O 
cell O 
( O 
LC O 
) O 
behavior O 
after O 
exposure O 
to O 
a O 
sensitizing O 
chemical O 
, O 
resulting O 
in O 
LC O 
migration O 
from O 
the O 
epidermis O 
to O 
the O 
dermis O 
. O 
MUTZ-LC O 
are O 
derived O 
from O 
the O 
commercially O 
available O 
MUTZ-3 O 
cell O 
line O 
. O 
Upon O 
exposure O 
to O 
a O 
sensitizer O 
MUTZ-LC O 
migrate O 
preferentially O 
towards O 
CXCL12 O 
whereas O 
upon O 
exposure O 
to O 
a O 
non-sensitizer O 
MUTZ-LC O 
migrate O 
towards O 
CCL5 O 
. O 
A O 
CXCL12 O 
/ O 
CCL5 O 
ratio O 
> O 
1.1 O 
in O 
2 O 
/ O 
3 O 
independent O 
experiments O 
is O 
indicative O 
of O 
a O 
sensitizer O 
, O 
whereas O 
a O 
CXCL12 O 
/ O 
CCL5 O 
ratio O 
≤ O 
1.1 O 
is O 
indicative O 
of O 
a O 
non-sensitizer O 
. O 
At O 
non O 
cytotoxic O 
chemical O 
concentrations O 
9 O 
sensitizers O 
( O 
2,4-dinitrochlorobenzene B-SYSTEMATIC 
, O 
paraphenylendiamine B-SYSTEMATIC 
, O 
cinnamaldehyde B-TRIVIAL 
, O 
isoeugenol B-TRIVIAL 
, O 
nickel B-SYSTEMATIC 
- I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
tetramethylthiuram B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
, O 
eugenol B-TRIVIAL 
, O 
cinnamic B-SYSTEMATIC 
- I-SYSTEMATIC 
alcohol I-SYSTEMATIC 
, O 
ammonium B-SYSTEMATIC 
- I-SYSTEMATIC 
hexachloroplatinate I-SYSTEMATIC 
) O 
were O 
distinguished O 
from O 
4 O 
non O 
sensitizers O 
( O 
sodium B-SYSTEMATIC 
lauryl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
, O 
phenol B-SYSTEMATIC 
, O 
octanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
. O 
Critical O 
points O 
in O 
assay O 
performance O 
are O 
(i) O 
MUTZ-3 O 
passage O 
number O 
after O 
thawing O 
( O 
p6-p40 O 
) O 
; O 
(ii) O 
cell O 
viability O 
( O 
> O 
80% O 
) O 
; O 
(iii) O 
standard O 
curve O 
to O 
optimize O 
correlation O 
of O 
fluorescence O 
with O 
cell O 
number O 
; O 
and O 
(iv) O 
optimization O 
of O 
the O 
concentration O 
of O 
rhCXCL12 O 
and O 
rhCCL5 O 
in O 
transwell O 
. O 
The O 
protocol O 
has O 
been O 
tested O 
in O 
three O 
European O 
laboratories O 
and O 
results O 
suggest O 
that O 
it O 
may O 
provide O 
working O 
conditions O 
for O 
performing O 
the O 
DC O 
migration O 
assay O 
which O 
is O 
aimed O 
at O 
distinguishing O 
sensitizers O 
from O 
non O 
sensitizers O 
. O 

article O 
reports O 
phytochemical O 
and O 
biological O 
studies O 
on O 
Nepeta O 
binaludensis O 
and O 
Nepeta O 
crassifolia O 
. O 
Both O 
species O 
were O 
investigated O 
for O 
their O 
angiotensin O 
- O 
converting O 
enzyme O 
( O 
ACE O 
) O 
inhibitory O 
activity O 
and O 
antioxidant O 
properties O 
through O 
three O 
in O 
vitro O 
models O 
[ O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
, O 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
ABTS B-ABBREVIATION 
) O 
and O 
ferric O 
reducing O 
antioxidant O 
power O 
( O 
FRAP O 
) O 
assay O 
] O 
. O 
Aerial O 
parts O 
were O 
extracted O 
with O 
methanol B-SYSTEMATIC 
and O 
partitioned O 
between O 
water O 
and O 
subsequently O 
n-hexane B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
n-butanol B-SYSTEMATIC 
. O 
N O 
. O 
binaludensis O 
methanol B-SYSTEMATIC 
extract O 
exerted O 
significantly O 
higher O 
reducing O 
power O 
( O 
1.9 O 
μM O 
Fe B-FORMULA 
(II) I-FORMULA 
/g O 
) O 
than O 
did O 
the O 
positive O 
control O 
butylhydroxytoluene B-SYSTEMATIC 
( O 
63.2 O 
μM O 
Fe B-FORMULA 
(II) I-FORMULA 
/g O 
) O 
in O 
FRAP O 
assay O 
. O 
The O 
highest O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
activity O 
was O 
found O 
for O 
N O 
. O 
crassifolia O 
, O 
with O 
IC50 O 
values O 
of O 
9.6 O 
and O 
12.1 O 
µg O 
/ O 
mL O 
for O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
n-butanol B-SYSTEMATIC 
fractions O 
, O 
respectively O 
. O 
n-Butanol B-SYSTEMATIC 
fraction O 
of O 
both O 
species O 
showed O 
the O 
highest O 
ACE O 
inhibitory O 
activity O 
, O 
with O 
IC50 O 
values O 
of O 
59.3 O 
and O 
81.7 O 
µg O 
/ O 
mL O 
for O 
N O 
. O 
binaludensis O 
and O 
N O 
. O 
crassifolia O 
, O 
respectively O 
. O 
Phytochemical O 
investigations O 
resulted O 
in O 
the O 
isolation O 
of O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
, O 
apigenin B-TRIVIAL 
, O 
luteolin B-TRIVIAL 
and O 
ixoroside B-TRIVIAL 
. O 
Apigenin-7-O-glucoside B-SYSTEMATIC 
, O 
8-hydroxycirsimaritin B-SYSTEMATIC 
and O 
cirsimaritin B-TRIVIAL 
were O 
furthermore O 
identified O 
in O 
N O 
. O 
crassifolia O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
-soluble O 
fraction O 
. O 
Nepetanudoside B-TRIVIAL 
B I-TRIVIAL 
was O 
isolated O 
from O 
the O 
n-butanol B-SYSTEMATIC 
fraction O 
of O 
N O 
. O 
binaludensis O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

in O 
the O 
structure O 
of O 
anthocyanins B-FAMILY 
from O 
the O 
two O 
amphibious O 
plants O 
, O 
Lobelia O 
cardinalis O 
and O 
Nesaea O 
crassicaulis O 
. O 

foliar O 
anthocyanin B-FAMILY 
profiles O 
of O 
two O 
amphibious O 
plants O 
, O 
Nesaea O 
crassicaulis O 
and O 
Lobelia O 
cardinalis O 
were O 
analysed O 
for O 
the O 
first O 
time O 
. O 
N O 
. O 
crassicaulis O 
produced O 
very O 
simple O 
anthocyanins B-FAMILY 
, O 
achieving O 
the O 
highest O 
concentrations O 
when O 
grown O 
submerged O 
. O 
In O 
contrast O 
, O 
L O 
. O 
cardinalis O 
produced O 
leaves O 
with O 
a O 
high O 
content O 
of O 
very O 
complex O 
, O 
acylated B-FAMILY 
anthocyanins I-FAMILY 
, O 
especially O 
when O 
growing O 
emergent O 
. O 
Anthocyanins B-FAMILY 
were O 
separated O 
by O 
high O 
performance O 
liquid O 
chromatography O 
. O 
Nesaea O 
crassicaulis O 
anthocyanins B-FAMILY 
were O 
identified O 
according O 
to O 
their O 
fragment O 
mass O 
spectra O 
and O 
ultra O 
- O 
visible O 
- O 
violet O 
spectral O 
characteristics O 
and O 
1D O 
and O 
2D O 
NMR O 
spectra O 
as O 
-3,5-di-O-β-glucosides B-SYSTEMATIC 
of I-SYSTEMATIC 
delphinidin I-SYSTEMATIC 
, O 
cyanidin B-TRIVIAL 
, O 
petunidin B-TRIVIAL 
, O 
malvidin B-TRIVIAL 
and O 
peonidin B-TRIVIAL 
as O 
well O 
as O 
cyanidine B-TRIVIAL 
and O 
peonidin-3-O-β-glucoside B-SYSTEMATIC 
. O 
In O 
L O 
. O 
cardinalis O 
cyanidin-3-O-[6-O-(4-O-E-p-coumaroyl-O-α-rhamnopyranosyl)-β-glucopyrano]-5-O-β-glucopyranoside B-SYSTEMATIC 
was O 
the O 
major O 
anthocyanin B-FAMILY 
and O 
contributed O 
more O 
than O 
98% O 
of O 
total O 
anthocyanin B-FAMILY 
content O 
. O 
The O 
remaining O 
2% O 
was O 
made O 
up O 
by O 
cyanidin-3-O-[6-O-(4-O-E-caffeoyl-O-α-rhamnopyranosyl)-β-glucopyrano]-5-O-β-glucopyranoside B-SYSTEMATIC 
and O 
pelargonidin-3-O-[6-O-(4-O-E-p-coumaroyl-O-α-rhamnopyranosyl)-β-glucopyrano]-5-O-β-glucopyranoside B-SYSTEMATIC 
. O 

of O 
mGlu5 O 
receptors O 
with O 
the O 
novel O 
enhancer O 
, O 
VU0360172 B-IDENTIFIER 
, O 
reduces O 
spontaneous O 
absence O 
seizures O 
in O 
WAG O 
/ O 
Rij O 
rats O 
. O 

epilepsy O 
is O 
generated O 
by O 
the O 
cortico O 
- O 
thalamo O 
- O 
cortical O 
network O 
, O 
which O 
undergoes O 
a O 
finely O 
tuned O 
regulation O 
by O 
metabotropic O 
glutamate O 
( O 
mGlu O 
) O 
receptors O 
. O 
We O 
have O 
shown O 
previously O 
that O 
potentiation O 
of O 
mGlu1 O 
receptors O 
reduces O 
spontaneous O 
occurring O 
spike O 
and O 
wave O 
discharges O 
( O 
SWDs O 
) O 
in O 
the O 
WAG O 
/ O 
Rij O 
rat O 
model O 
of O 
absence O 
epilepsy O 
, O 
whereas O 
activation O 
of O 
mGlu2 O 
/ O 
3 O 
and O 
mGlu4 O 
receptors O 
produces O 
the O 
opposite O 
effect O 
. O 
Here O 
, O 
we O 
have O 
extended O 
the O 
study O 
to O 
mGlu5 O 
receptors O 
, O 
which O 
are O 
known O 
to O 
be O 
highly O 
expressed O 
within O 
the O 
cortico O 
- O 
thalamo O 
- O 
cortical O 
network O 
. O 
We O 
used O 
presymptomatic O 
and O 
symptomatic O 
WAG O 
/ O 
Rij O 
rats O 
and O 
aged O 
- O 
matched O 
ACI O 
rats O 
. O 
WAG O 
/ O 
Rij O 
rats O 
showed O 
a O 
reduction O 
in O 
the O 
mGlu5 O 
receptor O 
protein O 
levels O 
and O 
in O 
the O 
mGlu5-receptor O 
mediated O 
stimulation O 
of O 
polyphosphoinositide B-SYSTEMATIC 
hydrolysis O 
in O 
the O 
ventrobasal O 
thalamus O 
, O 
whereas O 
the O 
expression O 
of O 
mGlu5 O 
receptors O 
was O 
increased O 
in O 
the O 
somatosensory O 
cortex O 
. O 
Interestingly O 
, O 
these O 
changes O 
preceded O 
the O 
onset O 
of O 
the O 
epileptic O 
phenotype O 
, O 
being O 
already O 
visible O 
in O 
pre O 
- O 
symptomatic O 
WAG O 
/ O 
Rij O 
rats O 
. O 
SWDs O 
in O 
symptomatic O 
WAG O 
/ O 
Rij O 
rats O 
were O 
not O 
influenced O 
by O 
pharmacological O 
blockade O 
of O 
mGlu5 O 
receptors O 
with O 
MTEP B-ABBREVIATION 
( O 
10 O 
or O 
30 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
, O 
but O 
were O 
significantly O 
decreased O 
by O 
mGlu5 O 
receptor O 
potentiation O 
with O 
the O 
novel O 
enhancer O 
, O 
VU036017 B-IDENTIFIER 
2 O 
( O 
3 O 
or O 
10 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
, O 
without O 
affecting O 
motor O 
behaviour O 
. O 
The O 
effect O 
of O 
VU036017 B-IDENTIFIER 
2 O 
was O 
prevented O 
by O 
co O 
- O 
treatment O 
with O 
MTE B-ABBREVIATION 
P O 
. O 
These O 
findings O 
suggest O 
that O 
changes O 
in O 
mGlu5 O 
receptors O 
might O 
lie O 
at O 
the O 
core O 
of O 
the O 
absence O 
- O 
seizure O 
prone O 
phenotype O 
of O 
WAG O 
/ O 
Rij O 
rats O 
, O 
and O 
that O 
mGlu5 O 
receptor O 
enhancers O 
are O 
potential O 
candidates O 
to O 
the O 
treatment O 
of O 
absence O 
epilepsy O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamat B-TRIVIAL 
e O 
Receptors' O 
. O 

exposure O 
to O 
low O 
dose O 
corticosterone B-TRIVIAL 
persistently O 
modulates O 
hippocampal O 
mineralocorticoid O 
receptor O 
expression O 
and O 
improves O 
locomotor O 
/ O 
exploratory O 
behaviour O 
in O 
a O 
mouse O 
model O 
of O 
Rett O 
syndrome O 
. O 

syndrome O 
( O 
RTT O 
) O 
is O 
a O 
pervasive O 
neurodevelopmental O 
disorder O 
, O 
primarily O 
affecting O 
girls O 
. O 
RTT O 
causes O 
a O 
wide O 
variety O 
of O 
debilitating O 
symptoms O 
and O 
no O 
cure O 
currently O 
exists O 
. O 
Mouse O 
models O 
bearing O 
mutations O 
in O 
the O 
Mecp2 O 
gene O 
recapitulate O 
most O 
physiological O 
and O 
behavioural O 
RTT O 
- O 
related O 
abnormalities O 
. O 
Stimulating O 
neonatal O 
environments O 
( O 
e.g O 
. O 
brief O 
maternal O 
separations O 
or O 
maternal O 
low O 
- O 
dose O 
corticosterone B-TRIVIAL 
supplementation O 
) O 
reduce O 
stress O 
and O 
fear O 
responses O 
at O 
adulthood O 
. O 
The O 
present O 
study O 
investigated O 
whether O 
impacting O 
early O 
in O 
development O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
axis O 
, O 
by O 
exposing O 
Mecp2-308 O 
mutant O 
pups O 
to O 
a O 
low O 
dose O 
of O 
corticosterone B-TRIVIAL 
( O 
50 O 
µg O 
/ O 
ml O 
, O 
during O 
the O 
1st O 
week O 
of O 
life O 
) O 
may O 
contrast O 
RTT O 
- O 
related O 
abnormalities O 
in O 
neuroendocrine O 
regulation O 
and O 
behavioural O 
adaptation O 
at O 
adulthood O 
. O 
In O 
line O 
with O 
previous O 
reports O 
, O 
when O 
fully O 
symptomatic O 
, O 
MeCP2-308 O 
mice O 
showed O 
a O 
reduction O 
in O 
the O 
regular O 
nocturnal O 
hyperactivity O 
in O 
the O 
home O 
- O 
cage O 
and O 
increased O 
anxiety O 
- O 
like O 
behaviours O 
and O 
plasma O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
levels O 
in O 
response O 
to O 
restraint O 
stress O 
. O 
An O 
abnormal O 
elevation O 
in O 
mRNA O 
levels O 
of O 
mineralocorticoid O 
receptors O 
( O 
MR O 
) O 
and O 
BDNF O 
gene O 
was O 
also O 
evident O 
in O 
the O 
hippocampus O 
of O 
fully O 
symptomatic O 
mutant O 
mice O 
. O 
Neonatal O 
CORT B-ABBREVIATION 
modulated O 
MR O 
gene O 
expression O 
and O 
behavioural O 
reactivity O 
towards O 
a O 
novel O 
object O 
, O 
also O 
restoring O 
wt O 
- O 
like O 
levels O 
of O 
locomotor O 
/ O 
exploratory O 
behaviour O 
in O 
mutant O 
mice O 
. O 
Enhanced O 
sensitivity O 
to O 
the O 
neonatal O 
treatment O 
( O 
in O 
terms O 
of O 
increase O 
in O 
GR O 
and O 
MR O 
mRNA O 
levels O 
) O 
, O 
was O 
also O 
evident O 
in O 
the O 
hippocampus O 
of O 
MeCP2-308 O 
mice O 
compared O 
to O 
wt O 
littermates O 
. O 
Present O 
results O 
corroborate O 
the O 
hypothesis O 
that O 
targeting O 
the O 
glucocorticoid O 
system O 
may O 
prove O 
valid O 
in O 
contrasting O 
at O 
least O 
some O 
of O 
the O 
RTT O 
- O 
related O 
symptoms O 
and O 
provide O 
evidence O 
that O 
pharmacological O 
interventions O 
during O 
critical O 
early O 
time O 
windows O 
can O 
persistently O 
improve O 
the O 
behavioural O 
phenotype O 
of O 
RTT O 
mice O 
. O 
Current O 
data O 
also O 
support O 
the O 
emerging O 
role O 
played O 
by O 
Mecp2 O 
in O 
mediating O 
the O 
epigenetic O 
programming O 
induced O 
by O 
early O 
life O 
events O 
and O 
indicate O 
that O 
, O 
in O 
the O 
absence O 
of O 
functional O 
MeCP2 O 
, O 
programming O 
of O 
the O 
central O 
nervous O 
system O 
in O 
response O 
to O 
early O 
environmental O 
stimuli O 
is O 
abnormally O 
regulated O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
Neurodevelopmental O 
Disorders' O 
. O 

, O 
characterisation O 
and O 
biological O 
evaluation O 
of O 
a O 
phenoxazine B-SYSTEMATIC 
, O 
a O 
natural O 
dyestuff O 
isolated O 
from O 
leaves O 
of O 
Peristrophe O 
bivalvis O 
. O 

bivalvis O 
( O 
L O 
. O 
) O 
Merr O 
. O 
( O 
Acanthaceae O 
) O 
is O 
a O 
wild O 
growing O 
and O 
cultivated O 
plant O 
used O 
for O 
dyeing O 
of O 
foods O 
by O 
the O 
ethnic O 
minorities O 
of O 
Vietnam O 
. O 
The O 
major O 
component O 
of O 
the O 
colour O 
aqueous O 
extract O 
( O 
CAE O 
) O 
of O 
its O 
leaves O 
was O 
identified O 
as O 
peristrophine B-TRIVIAL 
by O 
spectral O 
analysis O 
, O 
especially O 
the O 
2D O 
NMR O 
spectra O 
( O 
HSQC O 
, O 
HMBC O 
and O 
NOESY O 
) O 
. O 
Considering O 
the O 
widespread O 
utilisation O 
of O 
the O 
decoction O 
of O 
this O 
plant O 
for O 
food O 
dyeing O 
, O 
we O 
evaluated O 
the O 
acute O 
oral O 
toxicity O 
of O 
the O 
CAE O 
. O 
Based O 
on O 
the O 
results O 
in O 
an O 
acute O 
toxicity O 
study O 
in O 
mice O 
, O 
the O 
LD50 O 
value O 
of O 
the O 
CAE O 
was O 
determined O 
as O 
9100 O 
± O 
290 O 
mg O 
kg(-1) O 
body O 
weight O 
. O 
Additionally O 
, O 
in O 
vitro O 
cytotoxic O 
assay O 
showed O 
an O 
inhibition O 
of O 
peristrophine O 
against O 
Hepatocellular O 
carcinoma O 
( O 
HepG2 O 
, O 
IC503.90 O 
µg O 
mL(-1) O 
) O 
. O 
CAE O 
and O 
peristrophine B-TRIVIAL 
( O 
1 O 
) O 
have O 
also O 
been O 
tested O 
for O 
their O 
ability O 
to O 
affect O 
the O 
cell O 
number O 
of O 
the O 
OCI O 
acute O 
myeloid O 
leukaemia O 
cell O 
line O 
. O 
CAE O 
and O 
peristrophine B-TRIVIAL 
significantly O 
decreased O 
the O 
OCI O 
cell O 
number O 
at O 
different O 
concentrations O 
and O 
times O 
of O 
treatment O 
. O 

species O 
different O 
from O 
the O 
official O 
bearberry O 
, O 
Arctostaphylos O 
uva O 
- O 
ursi O 
, O 
are O 
sold O 
through O 
conventional O 
markets O 
and O 
also O 
through O 
non-controlled O 
Internet O 
websites O 
, O 
putting O 
consumer O 
safety O 
at O 
risk O 
owing O 
to O 
the O 
lack O 
of O 
quality O 
control O 
. O 
Recently O 
, O 
Arctostaphylos O 
pungens O 
has O 
become O 
one O 
of O 
the O 
most O 
used O 
species O 
as O 
a O 
raw O 
material O 
for O 
herbal O 
medicines O 
and O 
dietary O 
supplements O 
in O 
the O 
place O 
of O 
official O 
bearberry O 
, O 
a O 
plant O 
used O 
for O 
the O 
treatment O 
of O 
various O 
urinary O 
disorders O 
. O 
A O 
fingerprint O 
identification O 
based O 
on O 
an O 
integrated O 
application O 
of O 
different O 
analytical O 
techniques O 
( O 
HPTLC O 
, O 
NMR O 
, O 
HPLC-DAD O 
and O 
LC-ESI-MS O 
) O 
is O 
here O 
described O 
to O 
distinguish O 
A O 
. O 
uva O 
- O 
ursi O 
from O 
A O 
. O 
pungens O 
. O 
The O 
HPTLC O 
and O 
HPLC-DAD O 
fingerprints O 
resulted O 
the O 
simplest O 
methods O 
to O 
differentiate O 
the O 
two O 
species O 
, O 
whereas O 
LC-ESI-MS O 
was O 
more O 
useful O 
to O 
quantify O 
arbutin B-TRIVIAL 
, O 
the O 
main O 
component O 
of O 
bearberry O 
, O 
and O 
to O 
evaluate O 
its O 
different O 
content O 
in O 
the O 
two O 
species O 
. O 
This O 
multidisciplinary O 
study O 
showed O 
for O 
the O 
first O 
time O 
a O 
specific O 
phytochemical O 
fingerprint O 
of O 
the O 
new O 
species O 
A O 
. O 
pungens O 
. O 

( O 
7-DHC B-SYSTEMATIC 
) O 
accumulates O 
in O 
tissues O 
and O 
fluids O 
of O 
patients O 
with O 
Smith-Lemli-Opitz O 
syndrome O 
( O 
SLOS O 
) O 
, O 
which O 
is O 
caused O 
by O 
mutations O 
in O 
the O 
gene O 
encoding O 
3β-hydroxysterol B-FAMILY 
-Δ(7)-reductase O 
( O 
DHCR7 O 
) O 
. O 
We O 
recently O 
reported O 
that O 
7-DHC B-SYSTEMATIC 
is O 
the O 
most O 
reactive O 
lipid O 
molecule O 
toward O 
free O 
radical O 
oxidation O 
( O 
lipid O 
peroxidation O 
) O 
and O 
14 O 
oxysterols B-FAMILY 
have O 
been O 
identified O 
as O 
products O 
of O 
oxidation O 
of O 
7-DHC B-SYSTEMATIC 
in O 
solution O 
. O 
As O 
the O 
high O 
oxidizability O 
of O 
7-DHC B-SYSTEMATIC 
may O 
lead O 
to O 
systemic O 
oxidative O 
stress O 
in O 
SLOS O 
patients O 
, O 
we O 
report O 
here O 
lipid O 
biomarkers O 
of O 
oxidative O 
stress O 
in O 
a O 
Dhcr7-KO O 
mouse O 
model O 
of O 
SLOS O 
, O 
including O 
oxysterols B-FAMILY 
, O 
isoprostanes B-FAMILY 
( O 
IsoPs B-ABBREVIATION 
) O 
, O 
and O 
neuroprostanes B-FAMILY 
( O 
NeuroPs B-ABBREVIATION 
) O 
that O 
are O 
formed O 
from O 
the O 
oxidation O 
of O 
7-DHC B-SYSTEMATIC 
, O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
respectively O 
. O 
In O 
addition O 
to O 
a O 
previously O 
described O 
oxysterol B-FAMILY 
, O 
3β,5α-dihydroxycholest-7-en-6-one B-SYSTEMATIC 
( O 
DHCEO B-ABBREVIATION 
) O 
, O 
we O 
provide O 
evidence O 
for O 
the O 
chemical O 
structures O 
of O 
three O 
new O 
oxysterols B-FAMILY 
in O 
the O 
brain O 
and O 
/ O 
or O 
liver O 
tissue O 
of O 
Dhcr7-KO O 
mice O 
, O 
two O 
of O 
which O 
were O 
quantified O 
. O 
We O 
find O 
that O 
levels O 
of O 
IsoPs B-ABBREVIATION 
and O 
NeuroPs B-ABBREVIATION 
are O 
also O 
elevated O 
in O 
brain O 
and O 
/ O 
or O 
liver O 
tissues O 
of O 
Dhcr7-KO O 
mice O 
relative O 
to O 
matching O 
WT O 
mice O 
. O 
While O 
IsoPs B-ABBREVIATION 
and O 
NeuroPs B-ABBREVIATION 
have O 
been O 
established O 
as O 
a O 
reliable O 
measurement O 
of O 
lipid O 
peroxidation O 
and O 
oxidative O 
stress O 
in O 
vivo O 
, O 
we O 
show O 
that O 
in O 
this O 
genetic O 
SLOS O 
mouse O 
model O 
, O 
7-DHC B-SYSTEMATIC 
-derived O 
oxysterols B-FAMILY 
are O 
present O 
at O 
much O 
higher O 
levels O 
than O 
IsoPs B-ABBREVIATION 
and O 
NeuroPs B-ABBREVIATION 
and O 
thus O 
are O 
better O 
markers O 
of O 
lipid O 
oxidation O 
and O 
related O 
oxidative O 
stress O 
. O 

study O 
on O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
the O 
fruit O 
bodies O 
of O 
Vietnamese O 
fungus O 
Daldinia O 
concentrica O 
has O 
led O 
to O 
the O 
isolation O 
and O 
structural O 
elucidation O 
of O 
three O 
cytotoxic O 
constituents O 
, O 
6,8-dihydroxy-3-methyl-3,4-dihydroisocoumarin B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(22R)-hydroxylanosta-7,9(11),24-trien-3-one B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
ergosterol B-TRIVIAL 
( O 
3 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
2D-NMR O 
and O 
FT-ICR-MS O 
. O 
All O 
the O 
three O 
compounds O 
showed O 
moderate O 
cytotoxicity O 
against O 
four O 
cancer O 
cells O 
, O 
KB O 
( O 
a O 
human O 
epidermal O 
carcinoma O 
) O 
, O 
MCF7 O 
( O 
human O 
breast O 
carcinoma O 
) O 
, O 
SK-LU-1 O 
( O 
human O 
lung O 
carcinoma O 
) O 
and O 
HepG2 O 
( O 
hepatocellular O 
carcinoma O 
) O 
. O 
In O 
addition O 
, O 
the O 
isocoumarin B-TRIVIAL 
( O 
1 O 
) O 
inhibited O 
the O 
growth O 
of O 
Staphylococcus O 
aureus O 
with O 
the O 
IC50 O 
value O 
of O 
87.81 O 
µg O 
mL(-1) O 
. O 

present O 
, O 
the O 
identification O 
of O 
potentially O 
sensitizing O 
chemicals O 
is O 
carried O 
out O 
using O 
animal O 
models O 
. O 
However O 
, O 
it O 
is O 
very O 
important O 
from O 
ethical O 
, O 
safety O 
and O 
economic O 
point O 
of O 
view O 
to O 
have O 
biological O 
markers O 
to O 
discriminate O 
allergy O 
and O 
irritation O 
events O 
, O 
and O 
to O 
be O 
able O 
to O 
classify O 
sensitizers O 
according O 
to O 
their O 
potency O 
, O 
without O 
the O 
use O 
of O 
animals O 
. O 
Within O 
the O 
Sens O 
- O 
it O 
- O 
iv O 
EU O 
Frame O 
Programme O 
6 O 
funded O 
Integrated O 
Project O 
( O 
LSHB-CT-2005-018681 O 
) O 
, O 
a O 
number O 
of O 
in O 
vitro O 
, O 
human O 
cell O 
based O 
assays O 
were O 
developed O 
which O 
, O 
when O 
optimized O 
and O 
used O 
in O 
an O 
integrated O 
testing O 
strategy O 
, O 
may O 
be O 
able O 
to O 
distinguish O 
sensitizers O 
from O 
non-sensitizers O 
. O 
This O 
study O 
describes O 
two O 
of O 
these O 
assays O 
, O 
which O 
when O 
used O 
in O 
a O 
tiered O 
strategy O 
, O 
may O 
be O 
able O 
to O 
identify O 
contact O 
sensitizers O 
and O 
also O 
to O 
quantify O 
sensitizer O 
potency O 
. O 
Tier O 
1 O 
is O 
the O 
human O 
keratinocyte O 
NCTC2544 O 
IL-18 O 
assay O 
and O 
tier O 
2 O 
is O 
the O 
Epidermal O 
Equivalent O 
potency O 
assay O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
show O 
the O 
transferability O 
of O 
the O 
two O 
- O 
tiered O 
approach O 
with O 
training O 
chemicals O 
: O 
3 O 
sensitizers O 
( O 
DNCB B-ABBREVIATION 
, O 
resorcinol B-TRIVIAL 
, O 
pPD B-ABBREVIATION 
) O 
and O 
1 O 
non O 
sensitizer O 
( O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
) O 
in O 
tier O 
1 O 
and O 
2 O 
sensitizers O 
with O 
different O 
potency O 
in O 
tier O 
2 O 
( O 
DNCB B-ABBREVIATION 
; O 
extreme O 
and O 
resorcinol B-TRIVIAL 
; O 
moderate O 
) O 
. O 
The O 
chemicals O 
were O 
tested O 
in O 
a O 
non-coded O 
fashion O 
. O 
Here O 
we O 
describe O 
the O 
transferability O 
to O 
naïve O 
laboratories O 
, O 
the O 
establishment O 
of O 
the O 
standard O 
operating O 
procedure O 
, O 
critical O 
points O 
, O 
acceptance O 
criteria O 
and O 
project O 
management O 
. O 
Both O 
assays O 
were O 
successfully O 
transferred O 
to O 
laboratories O 
that O 
had O 
not O 
performed O 
the O 
assays O 
previously O 
. O 
The O 
two O 
tiered O 
approach O 
may O 
offer O 
an O 
unique O 
opportunity O 
to O 
provide O 
an O 
alternative O 
method O 
to O 
the O 
Local O 
Lymph O 
Node O 
Assay O 
( O 
LLNA O 
) O 
. O 
These O 
assays O 
are O 
both O 
based O 
on O 
the O 
use O 
of O 
human O 
keratinocytes O 
, O 
which O 
have O 
been O 
shown O 
over O 
the O 
last O 
two O 
decades O 
, O 
to O 
play O 
a O 
key O 
role O 
in O 
all O 
phases O 
of O 
skin O 
sensitization O 
. O 

facilitates O 
the O 
effectiveness O 
of O 
extinction O 
to O 
reduce O 
drug O 
- O 
primed O 
reinstatement O 
of O 
cocaine B-TRIVIAL 
-induced O 
conditioned O 
place O 
preference O 
. O 

is O 
a O 
disease O 
that O 
is O 
characterized O 
by O 
compulsive O 
drug O 
- O 
seeking O 
and O 
use O 
despite O 
negative O 
health O 
and O 
social O 
consequences O 
. O 
One O 
obstacle O 
in O 
treating O 
addiction O 
is O 
a O 
high O 
susceptibility O 
for O 
relapse O 
which O 
persists O 
despite O 
prolonged O 
periods O 
of O 
abstinence O 
. O 
Relapse O 
can O 
be O 
triggered O 
by O 
drug O 
predictive O 
stimuli O 
such O 
as O 
environmental O 
context O 
and O 
drug O 
associated O 
cues O 
, O 
as O 
well O 
as O 
the O 
addictive O 
drug O 
itself O 
. O 
The O 
conditioned O 
place O 
preference O 
( O 
CPP O 
) O 
behavioral O 
model O 
is O 
a O 
useful O 
paradigm O 
for O 
studying O 
the O 
ability O 
of O 
these O 
drug O 
predictive O 
stimuli O 
to O 
reinstate O 
drug O 
- O 
seeking O 
behavior O 
. O 
The O 
present O 
study O 
investigated O 
the O 
dose O 
- O 
dependent O 
effects O 
of O 
D-serine B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
30 O 
mg O 
/ O 
kg O 
and O 
100 O 
mg O 
/ O 
kg O 
) O 
on O 
extinction O 
training O 
and O 
drug O 
- O 
primed O 
reinstatement O 
in O 
cocaine B-TRIVIAL 
-conditioned O 
rats O 
. O 
In O 
the O 
first O 
experiment O 
, O 
D-serine B-TRIVIAL 
had O 
no O 
effect O 
on O 
the O 
acquisition O 
or O 
development O 
of O 
cocaine B-TRIVIAL 
-induced O 
locomotor O 
sensitization O 
or O 
CPP O 
. O 
In O 
the O 
second O 
experiment O 
, O 
D-serine B-TRIVIAL 
treatment O 
resulted O 
in O 
significantly O 
decreased O 
time O 
spent O 
in O 
the O 
drug O 
- O 
paired O 
compartment O 
following O 
completion O 
of O 
an O 
extinction O 
protocol O 
. O 
A O 
cocaine B-TRIVIAL 
-primed O 
reinstatement O 
test O 
indicated O 
that O 
the O 
combination O 
of O 
extinction O 
training O 
along O 
with O 
D-serine B-TRIVIAL 
treatment O 
resulted O 
in O 
a O 
significant O 
reduction O 
of O 
drug O 
- O 
seeking O 
behavior O 
. O 
The O 
third O 
experiment O 
assessed O 
D-serine B-TRIVIAL 
' O 
s O 
long O 
- O 
term O 
effects O 
to O 
diminish O 
drug O 
- O 
primed O 
reinstatement O 
. O 
D-serine B-TRIVIAL 
treatment O 
given O 
during O 
extinction O 
was O 
effective O 
in O 
reducing O 
drug O 
- O 
seeking O 
for O 
more O 
than O 
four O 
weeks O 
of O 
abstinence O 
after O 
the O 
last O 
cocaine B-TRIVIAL 
exposure O 
. O 
These O 
findings O 
demonstrate O 
that O 
D-serine B-TRIVIAL 
may O 
be O 
an O 
effective O 
adjunct O 
therapeutic O 
agent O 
along O 
with O 
cognitive O 
behavioral O 
therapy O 
for O 
the O 
treatment O 
of O 
cocaine B-TRIVIAL 
addiction O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

plasticity O 
at O 
hippocampal O 
excitatory O 
synapses O 
has O 
been O 
proposed O 
as O 
the O 
cellular O 
mechanism O 
underlying O 
spatial O 
learning O 
and O 
memory O 
. O 
However O 
, O 
most O 
previous O 
studies O 
have O 
focused O 
on O 
the O 
role O 
of O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
in O 
learning O 
and O 
memory O 
, O 
and O 
much O 
less O 
is O 
known O 
about O 
the O 
role O 
of O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
. O 
Here O 
, O 
we O 
report O 
that O 
hippocampal O 
- O 
dependent O 
spatial O 
learning O 
in O 
the O 
Morris O 
water O 
maze O 
facilitated O 
hippocampal O 
CA1 O 
LTD O 
induction O 
in O 
vivo O 
. O 
The O 
LTD O 
can O 
be O 
blocked O 
by O 
systemic O 
application O 
of O 
the O 
selective O 
GluN2B O 
antagonist O 
Ro25-6981 B-IDENTIFIER 
( O 
6 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
or O 
a O 
synthetic O 
peptide O 
Tat-GluA2(3Y) O 
( O 
3 O 
μmol O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
that O 
interferes O 
with O 
the O 
endocytosis O 
of O 
AMPA B-ABBREVIATION 
receptors O 
. O 
In O 
addition O 
, O 
systemic O 
or O 
intrahippocampal O 
administration O 
of O 
these O 
two O 
mechanistically O 
and O 
structurally O 
distinct O 
inhibitors O 
impaired O 
spatial O 
reversal O 
learning O 
of O 
a O 
novel O 
target O 
location O 
, O 
when O 
the O 
hidden O 
platform O 
was O 
moved O 
to O 
the O 
quadrant O 
opposite O 
the O 
initial O 
target O 
location O 
. O 
Notably O 
, O 
acute O 
elevated O 
- O 
platform O 
stress O 
, O 
which O 
facilitates O 
hippocampal O 
LTD O 
induction O 
, O 
enhanced O 
both O 
acquisition O 
and O 
retrieval O 
of O 
spatial O 
reversal O 
memory O 
. O 
The O 
present O 
study O 
demonstrates O 
that O 
reversal O 
learning O 
is O 
impaired O 
by O 
blocking O 
hippocampal O 
LTD O 
, O 
and O 
enhanced O 
by O 
facilitating O 
hippocampal O 
LTD O 
, O 
suggesting O 
that O 
hippocampal O 
LTD O 
may O 
be O 
necessary O 
and O 
sufficient O 
to O 
mediate O 
new O 
information O 
processing O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

Inhibitory O 
Effect O 
of O 
20(S)-Protopanaxatriol B-SYSTEMATIC 
( O 
ppt B-ABBREVIATION 
) O 
Towards O 
UGT1A1 O 
and O 
UGT2B7 O 
. O 

, O 
a O 
commonly O 
used O 
natural O 
product O 
, O 
has O 
been O 
frequently O 
reported O 
to O 
induce O 
herb O 
- O 
drug O 
interaction O 
with O 
many O 
clinical O 
drugs O 
. O 
The O 
intestinal O 
bacterial O 
metabolites O 
of O 
ginsenosides B-FAMILY 
have O 
been O 
widely O 
regarded O 
as O 
the O 
substance O 
basis O 
for O 
ginseng O 
- O 
drug O 
interactions O 
. O 
To O 
date O 
, O 
little O 
is O 
known O 
about O 
the O 
inhibitory O 
effect O 
of O 
intestinal O 
bacterial O 
metabolites O 
of O 
ginsenosides B-FAMILY 
towards O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGTs O 
) O 
. O 
In O 
vitro O 
investigation O 
of O 
the O 
inhibition O 
of O 
20(S)-protopanaxatriol B-SYSTEMATIC 
( O 
ppt B-ABBREVIATION 
) O 
towards O 
UGT1A1 O 
and O 
UGT2B7 O 
was O 
carried O 
out O 
. O 
The O 
results O 
showed O 
that O 
ppt O 
exhibited O 
strong O 
noncompetitive O 
inhibition O 
towards O 
UGT1A1 O 
and O 
competitive O 
inhibition O 
towards O 
UGT2B7 O 
. O 
The O 
inhibition O 
kinetic O 
parameters O 
( O 
Ki O 
) O 
were O 
calculated O 
to O 
be O 
8.8 O 
and O 
2.2 O 
μM O 
for O 
UGT1A1 O 
and O 
UGT2B7 O 
, O 
respectively O 
. O 
Using O 
the O 
maximum O 
plasma O 
concentration O 
of O 
ppt O 
, O 
the O 
alteration O 
of O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
was O 
calculated O 
to O 
be O 
20% O 
and O 
70% O 
respectively O 
for O 
UGT1A1 O 
- O 
mediated O 
and O 
UGT2B7 O 
- O 
mediated O 
metabolism O 
. O 
However O 
, O 
given O 
that O 
the O 
varied O 
contribution O 
of O 
these O 
two O 
UGT O 
isoforms O 
towards O 
drug O 
metabolism O 
and O 
the O 
influence O 
of O 
herb O 
complexity O 
and O 
individual O 
difference O 
, O 
the O 
explanation O 
of O 
these O 
results O 
should O 
be O 
paid O 
more O 
caution O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
in O 
persistent O 
forms O 
of O 
hippocampal O 
plasticity O 
and O 
learning O 
. O 

and O 
processing O 
of O 
information O 
at O 
the O 
synaptic O 
level O 
is O 
enabled O 
by O 
the O 
ability O 
of O 
synapses O 
to O 
persistently O 
alter O 
their O 
efficacy O 
. O 
This O 
phenomenon O 
, O 
known O 
as O 
synaptic O 
plasticity O 
, O 
is O 
believed O 
to O 
underlie O 
multiple O 
forms O 
of O 
long O 
- O 
term O 
memory O 
in O 
the O 
mammalian O 
brain O 
. O 
It O 
has O 
become O 
apparent O 
that O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptor O 
is O 
critically O 
required O 
for O 
both O 
persistent O 
forms O 
of O 
memory O 
and O 
persistent O 
synaptic O 
plasticity O 
. O 
Persistent O 
forms O 
of O 
synaptic O 
plasticity O 
comprise O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
and O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
that O 
last O 
at O 
least O 
for O 
4 O 
h O 
but O 
can O 
be O 
followed O 
in O 
vivo O 
for O 
days O 
and O 
weeks O 
. O 
These O 
types O 
of O 
plasticity O 
are O 
believed O 
to O 
be O 
analogous O 
to O 
forms O 
of O 
memory O 
that O 
persist O 
for O 
similar O 
time O 
- O 
spans O 
. O 
The O 
mGlu O 
receptors O 
are O 
delineated O 
into O 
three O 
distinct O 
groups O 
based O 
on O 
their O 
G O 
- O 
protein O 
coupling O 
and O 
agonist O 
affinity O 
and O 
also O 
exercise O 
distinct O 
roles O 
in O 
the O 
way O 
they O 
regulate O 
both O 
long O 
- O 
term O 
plasticity O 
and O 
long O 
- O 
term O 
hippocampus O 
- O 
dependent O 
memory O 
. O 
Here O 
, O 
the O 
mGlu O 
receptors O 
will O 
be O 
reviewed O 
both O 
in O 
general O 
, O 
and O 
in O 
the O 
particular O 
context O 
of O 
their O 
role O 
in O 
persistent O 
( O 
> O 
4 O 
h O 
) O 
forms O 
of O 
hippocampus O 
- O 
dependent O 
synaptic O 
plasticity O 
and O 
memory O 
, O 
as O 
well O 
as O 
forms O 
of O 
synaptic O 
plasticity O 
that O 
have O 
been O 
shown O 
to O 
be O 
directly O 
regulated O 
by O 
memory O 
events O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

response O 
to O 
sulpiride B-TRIVIAL 
in O 
social O 
anxiety O 
disorder O 
: O 
D2 O 
receptor O 
function O 
. O 

previous O 
studies O 
have O 
suggested O 
that O 
patients O 
with O 
social O 
anxiety O 
disorder O 
( O 
SAD O 
) O 
have O 
a O 
hypoactive O 
central O 
dopaminergic O 
system O 
. O 
Supporting O 
this O 
there O 
have O 
been O 
reports O 
from O 
neuroimaging O 
studies O 
of O 
reduced O 
striatal O 
D2 O 
receptor O 
binding O 
in O 
subjects O 
with O 
SAD O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
D2 O 
receptor O 
sensitivity O 
in O 
patients O 
with O 
SAD O 
compared O 
with O 
a O 
group O 
of O 
matched O 
, O 
healthy O 
controls O 
using O 
a O 
neuroendocrine O 
challenge O 
with O 
the O 
selective O 
D2 O 
antagonist O 
, O 
sulpiride B-TRIVIAL 
. O 
D2 O 
receptor O 
function O 
was O 
assessed O 
in O 
23 O 
subjects O 
with O 
generalized O 
SAD O 
and O 
23 O 
matched O 
, O 
healthy O 
controls O 
using O 
a O 
challenge O 
with O 
400 O 
mg O 
of O 
a O 
selective O 
D2 O 
antagonist O 
, O 
sulpiride B-TRIVIAL 
in O 
a O 
randomized O 
, O 
placebo O 
- O 
controlled O 
, O 
crossover O 
design O 
. O 
Response O 
to O 
sulpiride B-TRIVIAL 
was O 
measured O 
by O 
the O 
change O 
in O 
prolactin O 
level O 
and O 
changes O 
in O 
self O 
- O 
rated O 
measures O 
of O 
social O 
anxiety O 
, O 
mood O 
and O 
the O 
ability O 
to O 
experience O 
pleasure O 
. O 
There O 
was O 
no O 
significant O 
difference O 
in O 
prolactin O 
response O 
to O 
sulpiride B-TRIVIAL 
between O 
the O 
two O 
groups O 
. O 
Sulpiride B-TRIVIAL 
resulted O 
in O 
no O 
effect O 
in O 
either O 
the O 
SAD O 
or O 
healthy O 
control O 
group O 
on O 
measures O 
of O 
social O 
anxiety O 
, O 
mood O 
or O 
the O 
ability O 
to O 
experience O 
pleasure O 
. O 
Contrary O 
to O 
our O 
hypothesis O 
, O 
in O 
this O 
study O 
we O 
found O 
no O 
evidence O 
of O 
reduced O 
D2 O 
receptor O 
function O 
in O 
subjects O 
with O 
SAD O 
compared O 
with O 
healthy O 
controls O 
. O 

mammalian O 
cells O 
rely O 
on O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
to O 
maintain O 
function O 
and O 
for O 
survival O 
. O 
The O 
heart O 
has O 
the O 
highest O 
basal O 
ATP B-ABBREVIATION 
demand O 
of O 
any O 
organ O 
due O 
to O 
the O 
necessity O 
for O 
continuous O 
contraction O 
. O 
As O 
such O 
, O 
the O 
ability O 
of O 
the O 
cardiomyocyte O 
to O 
monitor O 
cellular O 
energy O 
status O 
and O 
adapt O 
the O 
supply O 
of O 
substrates O 
to O 
match O 
the O 
energy O 
demand O 
is O 
crucial O 
. O 
One O 
important O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
protein O 
kinase O 
that O 
monitors O 
cellular O 
energy O 
status O 
in O 
the O 
heart O 
is O 
adenosine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
. O 
AMPK O 
is O 
also O 
a O 
key O 
enzyme O 
that O 
controls O 
multiple O 
catabolic O 
and O 
anabolic O 
biochemical O 
pathways O 
in O 
the O 
heart O 
and O 
indirectly O 
plays O 
a O 
crucial O 
role O 
in O 
regulating O 
cardiac O 
function O 
in O 
both O 
physiological O 
and O 
pathophysiological O 
conditions O 
. O 
Herein O 
, O 
we O 
review O 
the O 
involvement O 
of O 
AMPK O 
in O 
myocardial O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
glucose B-TRIVIAL 
transport O 
and O 
utilization O 
, O 
as O 
it O 
relates O 
to O 
basal O 
cardiac O 
function O 
. O 
We O 
also O 
assess O 
the O 
literature O 
amassed O 
on O 
cardiac O 
AMPK O 
and O 
discuss O 
the O 
controversies O 
surrounding O 
the O 
role O 
of O 
AMPK O 
in O 
physiological O 
and O 
pathophysiological O 
processes O 
in O 
the O 
heart O 
. O 
The O 
work O 
reviewed O 
herein O 
also O 
emphasizes O 
areas O 
that O 
require O 
further O 
investigation O 
for O 
the O 
purpose O 
of O 
eventually O 
translating O 
this O 
information O 
into O 
improved O 
patient O 
care O 
. O 

and O 
mediators O 
of O 
add O 
- O 
on O 
mirtazapine B-TRIVIAL 
-induced O 
cognitive O 
enhancement O 
in O 
schizophrenia O 
-- O 
a O 
path O 
model O 
investigation O 
. O 

aimed O 
to O 
evaluate O 
predictors O 
and O 
mediators O 
of O 
enhancing O 
effect O 
of O 
adjunctive O 
mirtazapine B-TRIVIAL 
on O 
cognition O 
in O 
schizophrenia O 
. O 
Patients O 
with O 
difficult O 
- O 
to O 
- O 
treat O 
schizophrenia O 
received O 
either O 
mirtazapine B-TRIVIAL 
( O 
n O 
= O 
19 O 
) O 
or O 
placebo O 
( O 
n O 
= O 
18 O 
) O 
in O 
a O 
double O 
- O 
blind O 
fashion O 
for O 
six O 
weeks O 
. O 
Mirtazapine B-TRIVIAL 
outperformed O 
placebo O 
on O 
the O 
Block O 
Design O 
and O 
Stroop O 
Dots O 
. O 
In O 
the O 
present O 
subsidiary O 
study O 
, O 
factors O 
underlying O 
this O 
difference O 
were O 
explored O 
with O 
Path O 
Analysis O 
. O 
Add O 
- O 
on O 
mirtazapine B-TRIVIAL 
had O 
an O 
independent O 
enhancing O 
effect O 
on O 
the O 
Block O 
Design O 
- O 
measured O 
visuo O 
- O 
spatial O 
functioning O 
. O 
Further O 
, O 
this O 
effect O 
was O 
mediated O 
via O 
changes O 
in O 
positive O 
, O 
depressive O 
and O 
parkinsonism O 
symptoms O 
, O 
but O 
not O 
in O 
negative O 
symptoms O 
. O 
This O 
effect O 
was O 
predicted O 
by O 
higher O 
doses O 
of O 
FGAs O 
, O 
longer O 
duration O 
of O 
illness O 
and O 
lower O 
initial O 
Block O 
Design O 
scores O 
. O 
Path O 
Analysis O 
model O 
fit O 
was O 
good O 
. O 
Mirtazapine B-TRIVIAL 
may O 
have O 
direct O 
and O 
indirect O 
favorable O 
effects O 
on O 
visuo O 
- O 
spatial O 
functioning O 
, O 
but O 
further O 
research O 
is O 
needed O 
. O 
Path O 
analysis O 
may O 
be O 
a O 
feasible O 
statistical O 
method O 
for O 
further O 
research O 
of O 
neurocognition O 
in O 
psychopharmacological O 
interventions O 
in O 
schizophrenia O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

flaxseed O 
oil O 
supplementation O 
ameliorates O 
the O 
effect O 
of O 
cisplatin B-TRIVIAL 
on O 
brush O 
border O 
membrane O 
enzymes O 
and O 
antioxidant O 
system O 
in O 
rat O 
intestine O 
. O 

( O 
CP O 
; O 
cis-diamminedichloroplatinum B-SYSTEMATIC 
II I-SYSTEMATIC 
) O 
is O 
a O 
drug O 
widely O 
used O 
against O 
different O 
types O 
of O 
solid O 
tumors O 
. O 
Patients O 
receiving O 
CP O 
, O 
however O 
, O 
experience O 
very O 
profound O 
and O 
long O 
lasting O 
gastrointestinal O 
symptoms O 
. O 
Recently O 
, O 
ω-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
-enriched O 
flaxseed O 
/ O 
flaxseed O 
oil O 
( O 
FXO O 
) O 
has O 
shown O 
numerous O 
health O 
benefits O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
investigate O 
whether O 
FXO O 
can O 
prevent O 
CP-induced O 
adverse O 
biochemical O 
changes O 
in O 
the O 
small O 
intestine O 
of O 
rats O 
. O 
A O 
single O 
intraperitoneal O 
dose O 
of O 
CP O 
( O 
6 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
was O 
administered O 
to O 
male O 
Wistar O 
rats O 
fed O 
with O 
control O 
diet O 
( O 
CP O 
group O 
) O 
and O 
FXO O 
diet O 
( O 
CPFXO O 
group O 
) O 
. O 
Administration O 
of O 
CP O 
led O 
to O 
a O 
significant O 
decline O 
in O 
the O 
specific O 
activities O 
of O 
brush O 
border O 
membrane O 
enzymes O 
both O 
in O 
the O 
mucosal O 
homogenates O 
and O 
in O 
the O 
isolated O 
membrane O 
vesicles O 
. O 
Lipid O 
peroxidation O 
and O 
total O 
sulfhydryl B-FAMILY 
groups O 
were O 
altered O 
upon O 
CP O 
treatment O 
, O 
indicating O 
the O 
generation O 
of O 
oxidative O 
stress O 
. O 
The O 
activities O 
of O 
SOD O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
also O 
decreased O 
in O 
CP O 
- O 
treated O 
rats O 
. O 
In O 
contrast O 
, O 
dietary O 
supplementation O 
of O 
FXO O 
prior O 
to O 
and O 
following O 
CP O 
treatment O 
significantly O 
attenuated O 
the O 
CP-induced O 
changes O 
in O 
all O 
these O 
parameters O 
. O 
FXO O 
feeding O 
markedly O 
enhanced O 
resistance O 
to O 
CP-elicited O 
adverse O 
gastrointestinal O 
effects O 
. O 
The O 
results O 
suggest O 
that O 
FXO O 
owing O 
to O 
its O 
intrinsic O 
biochemical O 
/ O 
antioxidant O 
properties O 
is O 
an O 
effective O 
agent O 
in O 
reducing O 
the O 
adverse O 
effects O 
of O 
CP O 
on O 
intestine O 
. O 

binding O 
in O 
water O 
at O 
lanthanide B-FAMILY 
centres O 
: O 
from O 
structure O 
and O 
selectivity O 
to O 
signalling O 
and O 
sensing O 
. O 

anion O 
binding O 
at O 
lanthanide B-FAMILY 
centres O 
in O 
aqueous O 
media O 
has O 
emerged O 
as O 
an O 
effective O 
means O 
of O 
signalling O 
and O 
sensing O 
the O 
presence O 
of O 
selected O 
anions O 
. O 
The O 
constitution O 
and O 
configuration O 
of O 
a O 
wide O 
range O 
of O 
anion O 
adducts O 
has O 
been O 
defined O 
by O 
X-ray O 
analyses O 
and O 
NMR O 
methods O 
, O 
and O 
both O 
chelating O 
and O 
monodentate O 
binding O 
modes O 
characterised O 
. O 
Variation O 
of O 
the O 
lanthanide B-FAMILY 
ion O 
modulates O 
charge O 
density O 
, O 
and O 
ligand O 
modification O 
allows O 
alteration O 
of O 
both O 
the O 
peripheral O 
electrostatic O 
gradient O 
and O 
the O 
local O 
steric O 
demand O 
at O 
the O 
metal O 
centre O 
. O 
Thus O 
, O 
selectivity O 
for O 
a O 
target O 
anion O 
can O 
be O 
engineered O 
, O 
and O 
the O 
affinity O 
constant O 
modulated O 
to O 
target O 
the O 
desired O 
concentration O 
range O 
. O 
Changes O 
in O 
anion O 
concentration O 
can O 
be O 
monitored O 
rapidly O 
, O 
accurately O 
and O 
with O 
high O 
spatial O 
resolution O 
using O 
optical O 
emission O 
spectroscopy O 
and O 
microscopy O 
, O 
facilitating O 
the O 
measurement O 
of O 
anions O 
such O 
as O 
bicarbonate B-SYSTEMATIC 
, O 
lactate B-FAMILY 
, O 
citrate B-FAMILY 
and O 
urate B-SYSTEMATIC 
in O 
a O 
variety O 
of O 
bio O 
- O 
fluids O 
. O 

constituents O 
and O 
biological O 
screening O 
of O 
Astragalus O 
bombycinus O 
Boiss O 
. O 

new O 
flavonoid B-FAMILY 
compounds O 
were O 
isolated O 
from O 
Astragalus O 
bombycinus O 
Boiss O 
. O 
and O 
identified O 
as O 
quercetin-3,7-di-O-β-glucopyranoside B-SYSTEMATIC 
4'-O-α-rhamnopyranoside I-SYSTEMATIC 
and O 
5,2',4'-trihydroxy-flavone-8-C-α-arabinopyranoside-7-O-β-glucopyranoside B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
apigenin B-TRIVIAL 
, O 
apigenin-7-O-β-glucopyranoside B-SYSTEMATIC 
, O 
apigenin B-SYSTEMATIC 
7-O-gentobioside I-SYSTEMATIC 
, O 
luteolin B-TRIVIAL 
, O 
luteolin-7-O-β-glucopyranoside B-SYSTEMATIC 
, O 
quercetin-3,7-di-O-β-glucopyranoside B-SYSTEMATIC 
, O 
quercetin-3-O-β-glucopyranoside-7-O-α-rhamnopyranoside B-SYSTEMATIC 
and O 
daidzein B-TRIVIAL 
were O 
also O 
isolated O 
and O 
identified O 
. O 
The O 
structure O 
elucidation O 
of O 
the O 
isolated O 
compounds O 
was O 
performed O 
by O 
chromatographic O 
, O 
chemical O 
and O 
spectroscopic O 
methods O 
. O 
Antioxidant O 
and O 
cytotoxic O 
activities O 
were O 
also O 
determined O 
for O 
the O 
four O 
consecutive O 
extracts O 
of O 
the O 
plant O 
. O 

compounds O 
were O 
isolated O 
from O 
the O 
culture O 
of O 
an O 
endophytic O 
bacterium O 
Pseudomonas O 
brassicacearum O 
subsp O 
. O 
Neoaurantiaca O 
in O 
Salvia O 
miltiorrhiza O 
Bunge O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
as O 
cyclo-(Gly-L-Ala) B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
cyclo-(L-Ala-L-Ala) B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
cyclo-(L-Pro-Gly) B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
cyclo-(L-Pro-L-Ser) B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
cyclo-(L-Ala-trans-4-hydroxy-L-Pro) B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
c O 
yclo-(L-Val-L-Pro) B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
cyclo-(Gly-L-Tyr) B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
cyclo-(L-Ala-L-Tyr) B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
cyclo-(L-Tyr-trans-4-hydroxy-L-Pro) B-SYSTEMATIC 
( O 
9 O 
) O 
, O 
3-methylhydantoin B-SYSTEMATIC 
( O 
10 O 
) O 
and O 
2-piperidinone B-SYSTEMATIC 
( O 
11 O 
) O 
. O 
All O 
these O 
compounds O 
were O 
isolated O 
from O 
this O 
bacterium O 
for O 
the O 
first O 
time O 
. O 
The O 
brine O 
shrimp O 
lethality O 
, O 
antifungal O 
and O 
antibacterial O 
activities O 
of O 
these O 
compounds O 
were O 
evaluated O 
. O 
The O 
results O 
indicated O 
that O 
some O 
cyclodipeptides B-FAMILY 
may O 
play O 
an O 
important O 
role O 
in O 
plant O 
- O 
bacteria O 
interactions O 
. O 

between O 
iodide B-SYSTEMATIC 
dosimetry O 
and O 
terephthalic B-TRIVIAL 
acid I-TRIVIAL 
dosimetry O 
to O 
evaluate O 
the O 
reactive O 
radical O 
production O 
due O 
to O 
the O 
acoustic O 
cavitation O 
activity O 
. O 

cavitation O 
plays O 
an O 
important O 
role O 
in O 
sonochemical O 
processes O 
and O 
the O 
rate O 
of O 
sonochemical O 
reaction O 
is O 
influenced O 
by O 
sonication O 
parameters O 
. O 
There O 
are O 
several O 
methods O 
to O 
evaluate O 
cavitation O 
activity O 
such O 
as O 
chemical O 
dosimetry O 
. O 
In O 
this O 
study O 
, O 
to O 
comparison O 
between O 
iodide B-SYSTEMATIC 
dosimetry O 
and O 
terephthalic B-TRIVIAL 
acid I-TRIVIAL 
dosimetry O 
, O 
efficacy O 
of O 
sonication O 
parameters O 
in O 
reactive O 
radical O 
production O 
has O 
been O 
considered O 
by O 
iodide B-SYSTEMATIC 
and O 
terephthalic B-TRIVIAL 
acid I-TRIVIAL 
dosimetries O 
. O 
For O 
this O 
purpose O 
, O 
efficacy O 
of O 
different O 
exposure O 
parameters O 
on O 
cavitations O 
production O 
by O 
1 O 
MHz O 
ultrasound O 
has O 
been O 
studied O 
. O 
The O 
absorbance O 
of O 
KI B-FORMULA 
dosimeter O 
was O 
measured O 
by O 
spectrophotometer O 
and O 
the O 
fluorescence O 
of O 
terephthalic B-TRIVIAL 
acid I-TRIVIAL 
dosimeter O 
was O 
measured O 
using O 
spectrofluorometer O 
after O 
sonication O 
. O 
The O 
result O 
of O 
experiments O 
related O 
to O 
sonication O 
time O 
and O 
intensity O 
showed O 
that O 
with O 
increasing O 
time O 
of O 
sonication O 
or O 
intensity O 
, O 
the O 
absorbance O 
is O 
increased O 
. O 
It O 
has O 
been O 
shown O 
that O 
the O 
absorbance O 
for O 
continuous O 
mode O 
is O 
remarkably O 
higher O 
than O 
for O 
pulsing O 
mode O 
( O 
p-value O 
< O 
0.05 O 
) O 
. O 
Also O 
results O 
show O 
that O 
with O 
increasing O 
the O 
duty O 
cycles O 
of O 
pulsed O 
field O 
, O 
the O 
inertial O 
cavitation O 
activity O 
is O 
increased O 
. O 
With O 
compensation O 
of O 
sonication O 
time O 
or O 
intensity O 
in O 
different O 
duty O 
cycles O 
, O 
no O 
significant O 
absorbance O 
difference O 
were O 
observed O 
unless O 
20% O 
duty O 
cycle O 
. O 
A O 
significant O 
correlation O 
between O 
the O 
absorbance O 
and O 
fluorescence O 
intensities O 
( O 
count O 
) O 
at O 
different O 
intensity O 
( O 
R O 
= O 
0.971 O 
) O 
, O 
different O 
sonication O 
time O 
( O 
R O 
= O 
0.999 O 
) O 
and O 
different O 
duty O 
cycle O 
( O 
R O 
= O 
0.967 O 
) O 
were O 
observed O 
( O 
p-value O 
< O 
0.05 O 
) O 
. O 
It O 
is O 
concluded O 
that O 
the O 
sonication O 
parameters O 
having O 
important O 
influences O 
on O 
reactive O 
radical O 
production O 
. O 
These O 
results O 
suggest O 
that O 
there O 
is O 
a O 
correlation O 
between O 
iodide B-SYSTEMATIC 
dosimetry O 
and O 
terephthalic B-TRIVIAL 
acid I-TRIVIAL 
dosimetry O 
to O 
examine O 
the O 
acoustic O 
cavitation O 
activity O 
in O 
ultrasound O 
field O 
. O 

of O 
a O 
deficit O 
of O 
arousal O 
with O 
fatigue O 
in O 
multiple O 
sclerosis O 
: O 
effect O 
of O 
modafinil B-TRIVIAL 
. O 

sclerosis O 
( O 
MS O 
) O 
is O 
a O 
multifocal O 
demyelinating O 
disease O 
of O 
the O 
central O 
nervous O 
system O 
, O 
leading O 
to O 
chronic O 
disability O 
. O 
Fatigue O 
is O 
a O 
common O 
and O 
distressing O 
symptom O 
of O 
MS O 
which O 
is O 
unrelated O 
to O 
its O 
clinical O 
form O 
, O 
stage O 
of O 
development O 
, O 
the O 
degree O 
of O 
disability O 
, O 
or O 
the O 
lesion O 
load O 
on O 
magnetic O 
resonance O 
imaging O 
. O 
Fatigue O 
in O 
MS O 
is O 
associated O 
with O 
excessive O 
daytime O 
sleepiness O 
and O 
autonomic O 
dysfunction O 
. O 
Recently O 
it O 
has O 
been O 
reported O 
that O 
the O 
wakefulness O 
- O 
promoting O 
drug O 
modafinil B-TRIVIAL 
may O 
relieve O 
fatigue O 
in O 
MS O 
patients O 
and O 
ameliorate O 
the O 
associated O 
cognitive O 
difficulties O 
. O 
However O 
, O 
it O 
is O 
not O 
clear O 
to O 
what O 
extent O 
the O 
anti-fatigue O 
effect O 
of O 
modafinil B-TRIVIAL 
may O 
be O 
related O 
to O 
its O 
alerting O 
and O 
sympathetic O 
activating O 
effects O 
. O 
We O 
addressed O 
this O 
question O 
by O 
comparing O 
three O 
groups O 
of O 
subjects O 
, O 
MS O 
patients O 
with O 
fatigue O 
, O 
MS O 
patients O 
without O 
fatigue O 
and O 
healthy O 
controls O 
, O 
matched O 
for O 
age O 
and O 
sex O 
, O 
on O 
measures O 
of O 
alertness O 
( O 
self O 
- O 
ratings O 
on O 
the O 
Epworth O 
and O 
Stanford O 
Sleepiness O 
Scales O 
and O 
on O 
a O 
battery O 
of O 
visual O 
analogue O 
scales O 
; O 
critical O 
flicker O 
fusion O 
frequency O 
; O 
Pupillographic O 
Sleepiness O 
Test O 
; O 
choice O 
reaction O 
time O 
) O 
and O 
autonomic O 
function O 
( O 
systolic O 
and O 
diastolic O 
blood O 
pressure O 
, O 
heart O 
rate O 
, O 
pupil O 
diameter O 
) O 
, O 
and O 
by O 
examining O 
the O 
effect O 
of O 
a O 
single O 
dose O 
( O 
200 O 
mg O 
) O 
of O 
modafinil B-TRIVIAL 
on O 
these O 
measures O 
. O 
MS O 
patients O 
with O 
fatigue O 
, O 
compared O 
with O 
healthy O 
controls O 
, O 
had O 
reduced O 
level O 
of O 
alertness O 
on O 
all O 
the O 
tests O 
used O 
; O 
MS O 
patients O 
without O 
fatigue O 
did O 
not O 
differ O 
from O 
healthy O 
controls O 
. O 
MS O 
patients O 
with O 
fatigue O 
had O 
a O 
reduced O 
level O 
of O 
cardiovascular O 
sympathetic O 
activation O 
compared O 
to O 
the O 
other O 
two O 
groups O 
. O 
Modafinil B-TRIVIAL 
displayed O 
alerting O 
and O 
sympathomimetic O 
effects O 
in O 
all O 
three O 
groups O 
of O 
subjects O 
. O 
As O 
fatigue O 
in O 
MS O 
is O 
associated O 
with O 
reduced O 
levels O 
of O 
alertness O 
and O 
sympathetic O 
activity O 
, O 
modafinil B-TRIVIAL 
may O 
exert O 
its O 
anti-fatigue O 
effect O 
in O 
MS O 
by O 
correcting O 
these O 
deficiencies O 
. O 
The O 
anti-fatigue O 
effect O 
of O 
modafinil B-TRIVIAL 
may O 
reflect O 
the O 
activation O 
of O 
the O 
noradrenergic O 
locus O 
coeruleus O 
( O 
LC O 
) O 
, O 
since O 
there O 
is O 
evidence O 
that O 
this O 
wakefulness O 
- O 
promoting O 
nucleus O 
is O 
damaged O 
in O 
MS O 
, O 
and O 
that O 
modafinil B-TRIVIAL 
, O 
probably O 
via O 
the O 
dopaminergic O 
system O 
, O 
can O 
stimulate O 
the O 
LC O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

glutamate B-TRIVIAL 
( O 
mGlu O 
) O 
receptors O 
modulate O 
pain O 
from O 
within O 
the O 
midbrain O 
periaqueductal O 
grey O 
( O 
PAG O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
postsynaptic O 
mGlu O 
receptor O 
mediated O 
effects O 
on O 
rat O 
PAG O 
neurons O 
were O 
examined O 
using O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
recordings O 
in O 
brain O 
slices O 
. O 
The O 
selective O 
group O 
I O 
agonist O 
DHPG B-ABBREVIATION 
( O 
10 O 
μM O 
) O 
produced O 
an O 
inward O 
current O 
in O 
all O 
PAG O 
neurons O 
tested O 
which O 
was O 
associated O 
with O 
a O 
near O 
parallel O 
shift O 
in O 
the O 
current-voltage O 
relationship O 
. O 
By O 
contrast O 
, O 
the O 
group O 
II O 
and O 
III O 
mGlu O 
receptor O 
agonists O 
DCG-IV O 
( O 
1 O 
μM O 
) O 
and O 
l-AP4 O 
( O 
3 O 
μM O 
) O 
produced O 
an O 
outward O 
current O 
in O 
only O 
10-20% O 
of O 
PAG O 
neurons O 
tested O 
. O 
The O 
DHPG B-ABBREVIATION 
induced O 
current O 
was O 
concentration O 
dependent O 
( O 
EC(50) O 
= O 
1.4 O 
μM O 
) O 
, O 
was O 
reduced O 
by O 
the O 
mGlu1 O 
antagonist O 
CPCCOEt B-FORMULA 
( O 
100 O 
μM O 
) O 
, O 
and O 
was O 
further O 
reduced O 
by O 
CPCCOEt B-FORMULA 
in O 
combination O 
with O 
the O 
mGlu5 O 
antagonist B-ABBREVIATION 
MPEP I-ABBREVIATION 
( O 
10 O 
μM O 
) O 
. O 
The O 
glutamate B-TRIVIAL 
transport O 
blocker O 
TBOA B-ABBREVIATION 
( O 
30 O 
μM O 
) O 
also O 
produced O 
an O 
inward O 
current O 
, O 
however O 
, O 
this O 
was O 
largely O 
abolished O 
by O 
CNQX B-ABBREVIATION 
( O 
10 O 
μM O 
) O 
plus O 
AP5 B-ABBREVIATION 
( O 
25 O 
μM O 
) O 
. O 
Slow O 
EPSCs O 
were O 
evoked O 
following O 
train O 
, O 
but O 
not O 
single O 
shock O 
stimulation O 
, O 
which O 
were O 
enhanced O 
by O 
TBOA B-ABBREVIATION 
( O 
30 O 
μM O 
) O 
. O 
The O 
TBOA B-ABBREVIATION 
enhancement O 
of O 
slow O 
EPSCs O 
was O 
abolished O 
by O 
MPEP B-ABBREVIATION 
plus O 
CPCCOEt B-FORMULA 
. O 
These O 
findings O 
indicate O 
that O 
endogenously O 
released O 
glutamate B-TRIVIAL 
, O 
under O 
conditions O 
in O 
which O 
neurotransmitter O 
spill O 
- O 
over O 
is O 
enhanced O 
, O 
activates O 
group O 
I O 
mGlu O 
receptors O 
to O 
produce O 
excitatory O 
currents O 
within O 
PAG O 
. O 
Thus O 
, O 
postsynaptic O 
group O 
I O 
mGlu O 
receptors O 
have O 
the O 
potential O 
to O 
directly O 
modulate O 
the O 
analgesic O 
, O 
behavioural O 
and O 
autonomic O 
functions O 
of O 
the O 
PAG O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate B-TRIVIAL 
Receptors' O 
. O 

receptor O 
activated O 
insulin O 
secretion O 
from O 
pancreatic O 
β-cells O 
: O 
mechanism O 
and O 
glucose B-TRIVIAL 
dependence O 
. O 

major O 
goal O 
in O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
is O 
to O 
control O 
the O 
hyperglycaemia O 
characteristic O 
of O 
the O 
disease O 
. O 
However O 
, O 
treatment O 
with O 
common O 
therapies O 
such O 
as O 
insulin O 
or O 
insulinotrophic O 
sulphonylureas O 
( O 
SU O 
) O 
, O 
while O 
effective O 
in O 
reducing O 
hyperglycaemia O 
, O 
may O 
impose O 
a O 
greater O 
risk O 
of O 
hypoglycaemia O 
, O 
as O 
neither O 
therapy O 
is O 
self O 
- O 
regulated O 
by O 
ambient O 
blood O 
glucose B-TRIVIAL 
concentrations O 
. O 
Hypoglycaemia O 
has O 
been O 
associated O 
with O 
adverse O 
physical O 
and O 
psychological O 
outcomes O 
and O 
may O 
contribute O 
to O 
negative O 
cardiovascular O 
events O 
; O 
hence O 
minimization O 
of O 
hypoglycaemia O 
risk O 
is O 
clinically O 
advantageous O 
. O 
Stimulation O 
of O 
insulin O 
secretion O 
from O 
pancreatic O 
β-cells O 
by O 
glucagon O 
- O 
like O 
peptide O 
1 O 
receptor O 
( O 
GLP-1R O 
) O 
agonists O 
is O 
known O 
to O 
be O 
glucose B-TRIVIAL 
-dependent O 
. O 
GLP-1R O 
agonists O 
potentiate O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
and O 
have O 
little O 
or O 
no O 
activity O 
on O 
insulin O 
secretion O 
in O 
the O 
absence O 
of O 
elevated O 
blood O 
glucose B-TRIVIAL 
concentrations O 
. O 
This O 
' O 
glucose B-TRIVIAL 
-regulated O 
' O 
activity O 
of O 
GLP-1R O 
agonists O 
makes O 
them O 
useful O 
and O 
potentially O 
safer O 
therapeutics O 
for O 
overall O 
glucose B-TRIVIAL 
control O 
compared O 
to O 
non-regulated O 
therapies O 
; O 
hyperglycaemia O 
can O 
be O 
reduced O 
with O 
minimal O 
hypoglycaemia O 
. O 
While O 
the O 
inherent O 
mechanism O 
of O 
action O 
of O 
GLP-1R O 
agonists O 
mediates O 
their O 
glucose B-TRIVIAL 
dependence O 
, O 
studies O 
in O 
rats O 
suggest O 
that O 
SUs O 
may O 
uncouple O 
this O 
dependence O 
. O 
This O 
hypothesis O 
is O 
supported O 
by O 
clinical O 
studies O 
showing O 
that O 
the O 
majority O 
of O 
events O 
of O 
hypoglycaemia O 
in O 
patients O 
treated O 
with O 
GLP-1R O 
agonists O 
occur O 
in O 
patients O 
treated O 
with O 
a O 
concomitant O 
SU O 
. O 
This O 
review O 
aims O 
to O 
discuss O 
the O 
current O 
understanding O 
of O 
the O 
mechanisms O 
by O 
which O 
GLP-1R O 
signalling O 
promotes O 
insulin O 
secretion O 
from O 
pancreatic O 
β-cells O 
via O 
a O 
glucose B-TRIVIAL 
-dependent O 
process O 
. O 

long O 
- O 
chain O 
aliphatic O 
compounds O 
, O 
including O 
one O 
new O 
polyketide B-FAMILY 
derivative O 
, O 
dindygulerione B-TRIVIAL 
C I-TRIVIAL 
( O 
1 O 
) O 
, O 
one O 
new O 
octaketide B-SYSTEMATIC 
derivative O 
, O 
dindygulerione B-TRIVIAL 
D I-TRIVIAL 
( O 
2 O 
) O 
and O 
one O 
new O 
acylresorcinol B-SYSTEMATIC 
derivative O 
dindyguleranone B-TRIVIAL 
( O 
3 O 
) O 
were O 
isolated O 
from O 
the O 
whole O 
plant O 
of O 
the O 
Chinese O 
anticancer O 
folk O 
medicine O 
Peperomia O 
dindygulensis O 
Miq O 
. O 
( O 
Piperaceae O 
) O 
. O 
Dindygulerione B-TRIVIAL 
C I-TRIVIAL 
is O 
an O 
unprecedented O 
example O 
of O 
a O 
N- O 
containing O 
polyketide B-FAMILY 
. O 
The O 
chemical O 
structures O 
and O 
configurations O 
of O 
1-3 O 
were O 
elucidated O 
as O 
(-)-(4S)-2-[(Z)-1'-(6″,7″-dihydroxyphenethyl-amino)octadec-11'-enylidene]-4-hydroxycyclohexane-1,3-dione B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(+)-2-heptadecyl-4-hydroxy-3,4,7,8-tetrahydro-2H-chromen-5(6H)-one B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
2-(1,3-dihydroxyphenyl)-octacosan-1'-one B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
respectively O 
, O 
by O 
comparing O 
with O 
the O 
literature O 
data O 
and O 
extensive O 
spectroscopic O 
methods O 
, O 
including O 
2-D O 
NMR O 
and O 
circular O 
dichroism O 
spectroscopic O 
analysis O 
. O 
The O 
cytotoxicity O 
of O 
1-3 O 
was O 
evaluated O 
against O 
Hep3B O 
and O 
HepG2 O 
liver O 
cancer O 
cell O 
lines O 
. O 

mixed O 
hydroxyapatite B-TRIVIAL 
-multiwall O 
carbon B-SYSTEMATIC 
nanotubes O 
composite O 
coatings O 
on O 
biomedical O 
alloys O 
by O 
electrophoretic O 
deposition O 
. O 

( O 
HA O 
) O 
coatings O 
have O 
been O 
used O 
to O 
improve O 
biological O 
and O 
mechanical O 
fixation O 
of O 
metallic O 
prosthesis O 
. O 
Because O 
of O 
extraordinary O 
features O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
, O 
they O 
have O 
a O 
lot O 
of O 
facilities O 
, O 
such O 
as O 
extremely O 
strong O 
nanoreinforcement O 
materials O 
for O 
composites O 
. O 
HA O 
powders O 
were O 
synthesized O 
and O 
mixed O 
with O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNTs O 
) O 
by O 
a O 
hydrothermal O 
process O 
. O 
Calcium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
Ca B-FORMULA 
(CH(3)COO)(2) I-FORMULA 
) O 
and O 
phosphoric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
H(3)PO(4) B-FORMULA 
) O 
were O 
used O 
as O 
starting O 
materials O 
for O 
synthesizing O 
nano-HA O 
powders O 
. O 
HA-MWCNTs O 
were O 
treated O 
together O 
hydrothermally O 
at O 
200 O 
°C O 
for O 
2 O 
h O 
to O 
synthesize O 
nano-HA O 
powders O 
mixed O 
homogeneously O 
with O 
MWCNTs O 
. O 
Cathodic O 
deposits O 
were O 
obtained O 
on O 
Ti B-FORMULA 
-based O 
alloys O 
using O 
suspensions O 
containing O 
nano-HA O 
and O 
MWCNTs O 
dispersed O 
in O 
n-butanol B-SYSTEMATIC 
solvent O 
. O 
It O 
was O 
shown O 
that O 
MWCNTs O 
interacted O 
with O 
HA O 
powders O 
during O 
hydrothermal O 
processing O 
, O 
and O 
therefore O 
, O 
they O 
can O 
easily O 
be O 
dispersed O 
within O 
aqueous O 
- O 
based O 
suspensions O 
. O 
It O 
was O 
also O 
shown O 
that O 
hydrothermal O 
surface O 
modification O 
of O 
MWCNTs O 
with O 
functional O 
groups O 
was O 
achievable O 
, O 
which O 
was O 
a O 
significant O 
step O 
toward O 
eliminating O 
nonwetting O 
surface O 
behavior O 
of O 
MWCNTs O 
, O 
resulting O 
in O 
obtaining O 
homogeneous O 
dispersion O 
of O 
them O 
in O 
liquids O 
. O 

leaves O 
and O 
flowers O 
of O 
Siamese O 
neem O 
tree O 
( O 
Azadirachta O 
indica O 
A O 
. O 
Juss O 
. O 
var O 
. O 
siamensis O 
Valeton O 
) O 
are O 
commonly O 
consumed O 
as O 
a O 
bitter O 
tonic O 
vegetable O 
. O 
Active O 
antioxidant O 
components O 
in O 
the O 
flowers O 
are O 
rutin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
flavonoids B-FAMILY 
. O 
The O 
aqueous O 
extracts O 
of O 
young O 
flowers O 
collected O 
from O 
14 O 
different O 
locations O 
in O 
Thailand O 
were O 
quantitatively O 
analysed O 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
for O 
the O 
contents O 
of O 
rutin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
, O 
and O 
were O 
determined O 
for O 
the O 
loss O 
on O 
drying O 
, O 
heavy O 
metals O 
and O 
pesticide O 
residues O 
, O 
microbial O 
contamination O 
, O 
solubility O 
, O 
chromatographic O 
fingerprints O 
and O 
acute O 
toxicity O 
. O 
The O 
extracts O 
contained O 
rutin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
in O 
the O 
ranges O 
from O 
388 O 
to O 
1178 O 
mg% O 
dry O 
weight O 
( O 
average O 
772 O 
mg% O 
) O 
, O 
and O 
1 O 
to O 
10 O 
mg% O 
dry O 
weight O 
( O 
average O 
5 O 
mg% O 
) O 
, O 
respectively O 
. O 
EC50 O 
of O 
the O 
scavenging O 
activity O 
of O 
all O 
extracts O 
was O 
found O 
in O 
the O 
range O 
of O 
27-133 O 
µg O 
mL(-1) O 
. O 
Loss O 
on O 
drying O 
of O 
the O 
extracts O 
was O 
less O 
than O 
7% O 
w O 
/ O 
w O 
and O 
no O 
sign O 
of O 
toxicity O 
( O 
LD50 O 
> O 
5 O 
g O 
kg(-1) O 
) O 
was O 
found O 
. O 

distribution O 
in O 
plant O 
organs O 
of O 
tomato O 
introgression O 
lines O 
. O 

content O 
of O 
total O 
polyphenols B-FAMILY 
, O 
chlorogenic B-FAMILY 
, O 
caffeic B-FAMILY 
( O 
CaA B-ABBREVIATION 
) O 
and O 
ferulic B-FAMILY 
acids I-FAMILY 
, O 
and O 
rutin B-TRIVIAL 
, O 
was O 
investigated O 
in O 
plant O 
organs O 
of O 
three O 
introgression O 
lines O 
( O 
IL7-3 O 
, O 
IL10-1 O 
and O 
IL12-4 O 
) O 
of O 
Solanum O 
pennellii O 
in O 
Solanum O 
lycopersicum O 
cv O 
M82 O 
and O 
compared O 
with O 
that O 
of O 
cropped O 
parental O 
. O 
Such O 
study O 
aims O 
to O 
evidence O 
factors O 
associated O 
to O 
the O 
introgressions O 
that O 
can O 
affect O 
polyphenol B-FAMILY 
distribution O 
in O 
plant O 
. O 
Among O 
genotypes O 
few O 
differences O 
in O 
polyphenols B-FAMILY 
were O 
recorded O 
on O 
fresh O 
weight O 
basis O 
. O 
IL7-3 O 
showed O 
higher O 
total O 
polyphenols B-FAMILY 
in O 
fruits O 
and O 
lower O 
rutin B-TRIVIAL 
in O 
leaves O 
than O 
the O 
other O 
genotypes O 
. O 
IL12-4 O 
showed O 
an O 
increasing O 
trend O 
of O 
total O 
polyphenol B-FAMILY 
concentration O 
in O 
fresh O 
vegetative O 
organs O 
; O 
however O 
, O 
this O 
seems O 
to O 
depend O 
on O 
the O 
lower O 
water O 
content O 
rather O 
than O 
on O 
a O 
higher O 
polyphenol B-FAMILY 
biosynthesis O 
in O 
the O 
genotype O 
. O 
IL10-1 O 
sowed O 
higher O 
CaA B-ABBREVIATION 
and O 
lignin O 
contents O 
in O 
leaves O 
. O 
Such O 
differences O 
agree O 
with O 
the O 
morphological O 
and O 
physiological O 
traits O 
of O 
the O 
genotypes O 
. O 

strawberry O 
( O 
Fragaria O 
X O 
ananassa O 
, O 
Duch O 
. O 
) O 
represents O 
a O 
relevant O 
source O 
of O 
micronutrients O 
, O 
such O 
as O 
minerals O 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
folate B-TRIVIAL 
and O 
phenolic B-FAMILY 
substances O 
, O 
most O 
of O 
which O 
are O 
natural O 
antioxidants O 
and O 
contribute O 
to O 
the O 
high O 
nutritional O 
quality O 
of O 
the O 
fruit O 
. O 
All O 
these O 
compounds O 
are O 
essential O 
for O 
health O 
and O 
, O 
in O 
particular O 
, O 
strawberry O 
phenolics O 
are O 
best O 
known O 
for O 
their O 
antioxidant O 
and O 
anti-inflammatory O 
action O 
, O 
and O 
possess O 
directly O 
and O 
indirectly O 
antimicrobial O 
, O 
anti-allergy O 
and O 
anti-hypertensive O 
properties O 
, O 
as O 
well O 
as O 
the O 
capacity O 
to O 
inhibit O 
the O 
activities O 
of O 
some O 
physiological O 
enzymes O 
and O 
receptor O 
properties O 
. O 
The O 
main O 
objective O 
of O 
this O 
article O 
is O 
to O 
review O 
and O 
update O 
the O 
current O 
knowledge O 
on O 
the O 
potential O 
impact O 
of O 
the O 
strawberry O 
on O 
human O 
health O 
, O 
with O 
particular O 
attention O 
on O 
compounds O 
and O 
their O 
possible O 
mechanisms O 
of O 
action O 
. O 

excretion O 
of O 
parabens B-FAMILY 
in O 
pregnant O 
Japanese O 
women O 
. O 

excretion O 
of O 
free O 
and O 
total O 
( O 
free O 
plus O 
conjugated O 
) O 
forms O 
of O 
methyl B-MULTIPLE 
, I-MULTIPLE 
ethyl I-MULTIPLE 
, I-MULTIPLE 
n-propyl I-MULTIPLE 
and I-MULTIPLE 
n-butyl I-MULTIPLE 
parabens I-MULTIPLE 
( O 
MP O 
, O 
EP O 
, O 
PP O 
and O 
BP O 
, O 
respectively O 
) O 
and O 
their O 
metabolite O 
p-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
were O 
measured O 
for O 
111 O 
pregnant O 
Japanese O 
women O 
. O 
Frequent O 
detection O 
of O 
parabens B-FAMILY 
and O 
their O 
metabolite O 
indicated O 
that O 
exposure O 
takes O 
place O 
daily O 
for O 
pregnant O 
Japanese O 
women O 
. O 
The O 
estrogenic O 
potency O 
of O 
PP O 
was O 
20 O 
times O 
higher O 
than O 
those O 
of O 
the O 
other O 
3 O 
parabens O 
for O 
the O 
present O 
subjects O 
when O 
both O 
abundance O 
in O 
the O 
urine O 
and O 
the O 
relative O 
estrogenic O 
activity O 
of O 
each O 
compound O 
was O 
considered O 
. O 
Detection O 
of O 
free O 
parabens O 
suggested O 
dermal O 
exposure O 
, O 
probably O 
from O 
their O 
inclusion O 
in O 
personal O 
care O 
products O 
. O 
No O 
statistical O 
association O 
was O 
found O 
between O 
the O 
anogenital O 
index O 
( O 
birth O 
weight O 
- O 
adjusted O 
AGD O 
) O 
of O 
male O 
offspring O 
and O 
the O 
concentrations O 
of O 
any O 
parabens B-FAMILY 
in O 
the O 
urine O 
of O 
the O 
mothers O 
suggesting O 
that O 
the O 
parabens B-FAMILY 
were O 
not O 
apparently O 
estrogenically O 
active O 
at O 
the O 
exposure O 
level O 
of O 
the O 
present O 
subjects O 
. O 

and O 
antioxidant O 
activity O 
of O 
flowers O 
of O 
Mexican O 
Crataegus O 
spp O 
. O 

and O 
antioxidant O 
activity O 
of O 
extracts O 
of O 
flowers O 
from O 
some O 
Mexican O 
accessions O 
of O 
Crataegus O 
were O 
studied O 
using O 
six O 
accessions O 
with O 
the O 
purpose O 
of O 
contributing O 
to O 
the O 
knowledge O 
of O 
the O 
nutraceutical O 
properties O 
of O 
the O 
accessions O 
of O 
the O 
Germplasm O 
Bank O 
of O 
the O 
Universidad O 
Autonoma O 
Chapingo O 
. O 
Flavonoids B-FAMILY 
were O 
identified O 
by O 
HPLC-MS O 
. O 
Among O 
the O 
flavonoids B-FAMILY 
, O 
the O 
quercetin B-SYSTEMATIC 
3-O-glucoside I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
quercetin B-SYSTEMATIC 
3-O-rhamnoside I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
quercetin B-SYSTEMATIC 
3-O-rhamnosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
6)-glucoside I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
quercetin B-SYSTEMATIC 
3-O-rhamnosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-[rhamnosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
6)]-glucoside I-SYSTEMATIC 
( O 
1 O 
) O 
were O 
assigned O 
. O 
Flavonoid B-FAMILY 
content O 
and O 
radical O 
scavenging O 
activity O 
explain O 
some O 
of O 
the O 
medicinal O 
properties O 
attributed O 
to O 
flowers O 
of O 
Mexican O 
hawthorns O 
. O 

purpureocaerulea O 
is O 
a O 
little O 
- O 
known O 
plant O 
used O 
in O 
the O 
folk O 
tradition O 
for O 
the O 
preparation O 
of O 
a O 
decoction O 
in O 
Sud O 
, O 
Italy O 
, O 
where O 
it O 
is O 
appreciated O 
for O 
its O 
beneficial O 
effects O 
on O 
liver O 
diseases O 
. O 
These O 
properties O 
may O 
be O 
due O 
to O 
the O 
presence O 
of O 
antioxidant O 
compounds O 
. O 
This O 
study O 
presents O 
the O 
phenolic O 
characterisation O 
and O 
the O 
antioxidant O 
activity O 
( O 
AA O 
) O 
of O 
B O 
. O 
purpureocaerulea O 
extracts O 
obtained O 
by O 
decoction O 
, O 
ethanol B-SYSTEMATIC 
infusion O 
and O 
ethanol B-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
macerations O 
. O 
Total O 
phenols O 
ranged O 
between O 
69 O 
and O 
100 O 
mg O 
g(-1 O 
) O 
dry O 
weight O 
( O 
DW O 
) O 
. O 
The O 
main O 
compounds O 
were O 
: O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
lithospermic B-TRIVIAL 
acid I-TRIVIAL 
and O 
salvianolic B-TRIVIAL 
acid I-TRIVIAL 
C I-TRIVIAL 
. O 
The O 
extracts O 
showed O 
a O 
good O 
AA O 
, O 
particularly O 
high O 
for O 
the O 
decoction O 
( O 
142-283 O 
µmol O 
TE O 
g(-1) O 
DW O 
; O 
TE O 
, O 
Trolox B-TRIVIAL 
equivalent O 
) O 
and O 
ethanol B-SYSTEMATIC 
maceration O 
extract O 
( O 
214-364 O 
µmol O 
TE O 
g(-1) O 
DW O 
) O 
when O 
determined O 
by O 
DPPH B-ABBREVIATION 
and O 
ferric B-SYSTEMATIC 
reducing O 
antioxidant O 
power O 
test O 
, O 
respectively O 
. O 

- O 
birth O 
rates O 
after O 
HP-hMG O 
stimulation O 
in O 
the O 
long O 
GnRH O 
agonist O 
protocol O 
: O 
association O 
with O 
mid O 
- O 
follicular O 
hCG O 
and O 
progesterone B-TRIVIAL 
concentrations O 
, O 
but O 
not O 
with O 
LH O 
concentrations O 
. O 

aim O 
of O 
this O 
retrospective O 
study O 
was O 
to O 
investigate O 
the O 
impact O 
of O 
endogenous O 
and O 
exogenous O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
activity O 
on O 
treatment O 
outcome O 
, O 
when O 
taking O 
into O 
consideration O 
potential O 
confounding O 
variables O 
. O 
Data O 
were O 
derived O 
from O 
IVF O 
patients O 
( O 
n O 
= O 
358 O 
) O 
stimulated O 
with O 
highly O 
purified O 
menotrophin O 
( O 
HP-hMG O 
) O 
in O 
a O 
long O 
gonadotrophin O 
- O 
releasing O 
hormone O 
( O 
GnRH O 
) O 
agonist O 
protocol O 
. O 
Simple O 
retrospective O 
logistic O 
regression O 
analysis O 
showed O 
that O 
the O 
mid O 
- O 
follicular O 
exogenous O 
concentrations O 
of O 
human O 
chorionic O 
gonadotrophin O 
( O 
hCG O 
) O 
( O 
p O 
= O 
0.027 O 
) O 
, O 
provided O 
by O 
the O 
HP-hMG O 
preparation O 
, O 
and O 
female O 
age O 
( O 
p O 
= O 
0.009 O 
) O 
were O 
significantly O 
associated O 
with O 
live O 
- O 
birth O 
rate O 
, O 
while O 
the O 
mid O 
- O 
follicular O 
progesterone B-TRIVIAL 
concentration O 
( O 
p O 
= O 
0.075 O 
) O 
, O 
the O 
estradiol B-TRIVIAL 
concentration O 
on O 
last O 
stimulation O 
day O 
( O 
p O 
= O 
0.075 O 
) O 
and O 
number O 
of O 
embryos O 
transferred O 
( O 
p O 
= O 
0.071 O 
) O 
were O 
borderline O 
significant O 
. O 
Endogenous O 
LH O 
was O 
not O 
associated O 
with O 
live O 
- O 
birth O 
rate O 
; O 
neither O 
at O 
start O 
of O 
stimulation O 
( O 
p O 
= O 
0.123 O 
) O 
, O 
nor O 
in O 
the O 
mid O 
- O 
follicular O 
phase O 
( O 
p O 
= O 
0.933 O 
) O 
or O 
on O 
the O 
last O 
day O 
of O 
stimulation O 
( O 
p O 
= O 
0.589 O 
) O 
. O 
In O 
the O 
multiple O 
regression O 
analysis O 
of O 
life O 
birth O 
, O 
mid O 
- O 
follicular O 
hCG O 
( O 
p O 
= O 
0.016 O 
) O 
was O 
identified O 
as O 
a O 
positive O 
predictor O 
, O 
and O 
age O 
( O 
p O 
= O 
0.004 O 
) O 
and O 
mid O 
- O 
follicular O 
progesterone B-TRIVIAL 
( O 
p O 
= O 
0.029 O 
) O 
as O 
negative O 
predictors O 
. O 
In O 
conclusion O 
, O 
mid O 
- O 
follicular O 
concentrations O 
of O 
exogenous O 
hCG O 
and O 
progesterone B-TRIVIAL 
, O 
but O 
not O 
endogenous O 
LH O 
, O 
are O 
associated O 
with O 
live O 
- O 
birth O 
rate O 
in O 
IVF O 
patients O 
treated O 
with O 
HP-hMG O 
in O 
a O 
long O 
GnRH O 
agonist O 
cycle O 
. O 

and O 
characterization O 
of O 
composite O 
YSZ- O 
PEI B-ABBREVIATION 
electrophoretically O 
deposited O 
membrane O 
for O 
Li B-FORMULA 
-ion O 
battery O 
. O 

this O 
work O 
, O 
the O 
electrophoretic O 
- O 
deposition O 
( O 
EPD O 
) O 
method O 
was O 
used O 
to O 
fabricate O 
pristine O 
and O 
composite O 
ceramic O 
- O 
polymer O 
membranes O 
for O 
application O 
in O 
planar O 
and O 
3D O 
microbattery O 
configurations O 
. O 
The O 
major O 
focus O 
was O 
on O 
the O 
effect O 
of O 
polyethyleneimine B-SYSTEMATIC 
additive O 
on O 
the O 
morphology O 
, O 
composition O 
, O 
and O 
electrochemical O 
properties O 
of O 
the O 
membrane O 
. O 
The O 
ionic O 
conductivity O 
, O 
cycleability O 
, O 
and O 
charge O 
/ O 
discharge O 
behavior O 
of O 
planar O 
LiFePO(4) B-FORMULA 
/ O 
Li B-FORMULA 
cells O 
comprising O 
composite O 
porous O 
YSZ O 
- O 
based O 
membrane O 
with O 
impregnated O 
LiPF(6) B-FORMULA 
EC O 
: O 
DEC O 
electrolyte O 
were O 
found O 
to O 
be O 
similar O 
to O 
the O 
cells O 
with O 
commercial O 
Celgard O 
membrane O 
. O 
Conformal O 
EPD O 
coating O 
of O 
the O 
electrode O 
materials O 
by O 
a O 
thin O 
- O 
film O 
ceramic O 
separator O 
is O 
advantageous O 
for O 
high O 
- O 
power O 
operation O 
and O 
safety O 
of O 
batteries O 
. O 

response O 
analysis O 
of O 
monophthalates B-FAMILY 
in O 
the O 
murine O 
embryonic O 
stem O 
cell O 
test O 
assessed O 
by O 
cardiomyocyte O 
differentiation O 
and O 
gene O 
expression O 
. O 

embryonic O 
stem O 
cell O 
test O 
( O 
EST O 
) O 
is O 
based O 
on O 
compound O 
- O 
induced O 
inhibition O 
of O 
cardiomyocyte O 
differentiation O 
of O 
pluripotent O 
stem O 
cells O 
. O 
We O 
examined O 
the O 
use O 
of O 
transcriptomics O 
to O 
assess O 
concentration O 
- O 
effect O 
relationships O 
and O 
performed O 
potency O 
ranking O 
within O 
a O 
chemical O 
class O 
. O 
Three O 
embryotoxic O 
phthalate B-FAMILY 
monoesters I-FAMILY 
, O 
monobutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MBuP B-FORMULA 
) O 
, O 
monobenzyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MBzP B-FORMULA 
) O 
and O 
mono-(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MEHP B-ABBREVIATION 
) O 
and O 
the O 
non-embryotoxic O 
monomethyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
MMP B-ABBREVIATION 
) O 
were O 
studied O 
for O 
their O 
effects O 
on O 
gene O 
expression O 
. O 
Effects O 
on O 
gene O 
expression O 
were O 
observed O 
at O 
concentrations O 
that O 
did O 
not O 
inhibit O 
cardiomyocyte O 
differentiation O 
or O 
induce O 
cytotoxicity O 
. O 
The O 
embryotoxic O 
phthalate B-FAMILY 
monoesters I-FAMILY 
altered O 
the O 
expression O 
of O 
668 O 
commonly O 
expressed O 
genes O 
in O 
a O 
concentration O 
- O 
dependent O 
fashion O 
. O 
The O 
same O 
potency O 
ranking O 
was O 
observed O 
for O 
morphology O 
and O 
gene O 
expression O 
( O 
MEHP B-ABBREVIATION 
> O 
MBzP B-FORMULA 
> O 
MBuP B-FORMULA 
> O 
MMP B-ABBREVIATION 
) O 
. O 
These O 
results O 
indicate O 
that O 
integrating O 
transcriptomics O 
provides O 
a O 
sensitive O 
method O 
to O 
measure O 
the O 
dose O 
- O 
dependent O 
effects O 
of O 
phthalate B-SYSTEMATIC 
monoester I-SYSTEMATIC 
exposure O 
and O 
enables O 
potency O 
ranking O 
based O 
on O 
a O 
common O 
mode O 
of O 
action O 
within O 
a O 
class O 
of O 
compounds O 
. O 
Transcriptomic O 
approaches O 
may O 
improve O 
the O 
applicability O 
of O 
the O 
EST O 
, O 
in O 
terms O 
of O 
sensitivity O 
and O 
specificity O 
. O 

carota O 
L O 
. O 
ssp O 
. O 
carota O 
( O 
Apiacea O 
) O 
is O 
used O 
in O 
traditional O 
medicine O 
in O 
Lebanon O 
and O 
in O 
different O 
regions O 
throughout O 
the O 
world O 
. O 
The O 
present O 
study O 
investigates O 
the O 
in O 
vitro O 
anticancer O 
activities O 
of O 
Daucus O 
carota O 
oil O 
extract O 
( O 
DCOE O 
) O 
on O 
four O 
human O 
cancer O 
cell O 
lines O 
as O 
well O 
as O 
its O 
in O 
vitro O 
antioxidant O 
activity O 
. O 
DCOE O 
was O 
extracted O 
from O 
the O 
dried O 
umbels O 
with O 
50 O 
: O 
50 O 
acetone B-SYSTEMATIC 
- O 
methanol B-SYSTEMATIC 
. O 
The O 
oil O 
extract O 
was O 
analyzed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
and O 
screened O 
for O 
its O 
antioxidant O 
properties O 
in O 
vitro O 
using O 
1,1-diphenyl-2-picryl B-SYSTEMATIC 
hydrazyl I-SYSTEMATIC 
free O 
radical O 
scavenging O 
assay O 
( O 
DPPH B-ABBREVIATION 
) O 
, O 
ferrous B-SYSTEMATIC 
ion O 
chelating O 
assay O 
( O 
FIC O 
) O 
and O 
the O 
ferric B-SYSTEMATIC 
reducing O 
antioxidant O 
power O 
assay O 
( O 
FRAP O 
) O 
. O 
The O 
anticancer O 
activity O 
of O 
the O 
oil O 
extract O 
against O 
human O 
colon O 
( O 
HT-29 O 
, O 
Caco-2 O 
) O 
and O 
breast O 
( O 
MCF-7 O 
, O 
MDA-MB-231 O 
) O 
cancer O 
cell O 
lines O 
was O 
evaluated O 
using O 
the O 
trypan B-TRIVIAL 
blue I-TRIVIAL 
exclusion O 
method O 
and O 
the O 
WST-1 O 
cell O 
proliferation O 
assay O 
. O 
DCOE O 
exhibited O 
antioxidant O 
activity O 
in O 
all O 
assays O 
used O 
. O 
The O 
FRAP O 
value O 
was O 
164 O 
± O 
5.5 O 
µmol O 
FeSO4 B-FORMULA 
/g O 
, O 
and O 
the O 
IC50 O 
values O 
for O 
DPPH B-ABBREVIATION 
and O 
FIC O 
assays O 
were O 
2.1 O 
± O 
0.03 O 
mg O 
/ O 
ml O 
and O 
0.43 O 
± O 
0.02 O 
mg O 
/ O 
ml O 
, O 
respectively O 
. O 
Also O 
, O 
DCOE O 
demonstrated O 
a O 
significant O 
increase O 
in O 
cell O 
death O 
and O 
decrease O 
in O 
cell O 
proliferation O 
. O 
The O 
effect O 
of O 
DCOE O 
on O 
the O 
cell O 
lines O 
exhibited O 
time O 
and O 
dose O 
- O 
dependent O 
responses O 
. O 
The O 
present O 
study O 
established O 
that O 
DCOE O 
possesses O 
both O 
antioxidant O 
and O 
promising O 
anticancer O 
activities O 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Effects O 
of O 
a O 
Purified O 
Saponin B-FAMILY 
Mixture O 
from O 
Astragalus O 
corniculatus O 
Bieb O 
. O 
, O 
in O 
vivo O 
Hepatotoxicity O 
Models O 
. O 

this O 
study O 
, O 
the O 
in O 
vivo O 
effects O 
of O 
a O 
purified O 
saponin B-FAMILY 
mixture O 
( O 
PSM O 
) O 
, O 
obtained O 
from O 
Astragalus O 
corniculatus O 
Bieb O 
. O 
, O 
were O 
investigated O 
using O 
two O 
in O 
vivo O 
hepatotoxicity O 
models O 
based O 
on O 
liver O 
damage O 
caused O 
by O 
paracetamol B-TRIVIAL 
( O 
PC O 
) O 
and O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl4 B-FORMULA 
) O 
. O 
The O 
effects O 
of O 
PSM O 
were O 
compared O 
with O 
silymarin B-FAMILY 
. O 
Male O 
Wistar O 
rats O 
were O 
challenged O 
orally O 
with O 
20% O 
CCl4 B-FORMULA 
or O 
PC O 
( O 
2 O 
g O 
/ O 
kg O 
) O 
four O 
days O 
after O 
being O 
pre O 
- O 
treated O 
with O 
PSM O 
( O 
100 O 
mg O 
/ O 
kg O 
) O 
or O 
silymarin B-FAMILY 
( O 
200 O 
mg O 
/ O 
kg O 
) O 
. O 
A O 
significant O 
decrease O 
of O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
activities O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
and O 
an O 
increase O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
quantity O 
was O 
observed O 
after O 
CCl4 B-FORMULA 
and O 
PC O 
administration O 
alone O 
. O 
PSM O 
pre O 
- O 
treatment O 
decreased O 
serum O 
transaminases O 
and O 
LDH O 
activities O 
and O 
MDA B-ABBREVIATION 
levels O 
and O 
increased O 
the O 
levels O 
of O 
cell O 
protector O 
GSH B-ABBREVIATION 
. O 
Biotransformation O 
phase O 
I O 
enzymes O 
were O 
also O 
assessed O 
in O 
both O 
models O 
. O 
In O 
the O 
CCl4 B-FORMULA 
hepatotoxicity O 
model O 
, O 
pre O 
- O 
treatment O 
with O 
PSM O 
or O 
silymarin B-FAMILY 
resulted O 
in O 
significantly O 
increased O 
activities O 
of O 
ethylmorphine B-SYSTEMATIC 
- O 
N B-FORMULA 
-demethylase O 
and O 
aniline B-SYSTEMATIC 
4-hydroxylase O 
activity O 
and O 
cytochrome O 
P450 O 
, O 
compared O 
to O 
the O 
CCl4 B-FORMULA 
only O 
group O 
. O 
Neither O 
silymarin B-FAMILY 
nor O 
PSM O 
influenced O 
PC O 
biotransformation O 
. O 
Our O 
results O 
suggest O 
that O 
PSM O 
, O 
obtained O 
from O 
A O 
. O 
corniculatus O 
, O 
Bieb O 
. O 
showed O 
in O 
vivo O 
hepatoprotective O 
and O 
antioxidant O 
activities O 
against O 
CCl4 B-FORMULA 
and O 
PC-induced O 
liver O 
damage O 
comparable O 
to O 
that O 
of O 
silymarin B-FAMILY 
. O 
Copyright O 
© O 
2012 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

our O 
current O 
research O 
work O 
, O 
the O 
effect O 
of O 
ultrasound O 
irradiation O 
on O 
the O 
enzymatic O 
activity O 
and O 
enzymatic O 
hydrolysis O 
kinetic O 
parameters O 
of O 
dextran O 
catalysis O 
by O 
dextranase O 
were O 
investigated O 
. O 
Furthermore O 
, O 
the O 
effects O 
of O 
ultrasound O 
irradiation O 
on O 
the O 
structure O 
of O 
dextranase O 
were O 
investigated O 
with O 
the O 
aid O 
of O 
fluorescence O 
spectroscopy O 
and O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectroscopy O 
. O 
The O 
maximum O 
activity O 
of O 
dextranase O 
was O 
observed O 
when O 
the O 
sample O 
was O 
treated O 
with O 
ultrasound O 
at O 
25 O 
kHz O 
, O 
40 O 
W O 
for O 
15 O 
min O 
, O 
under O 
which O 
the O 
enzyme O 
activity O 
increased O 
by O 
13.43% O 
compared O 
the O 
routine O 
thermal O 
incubation O 
at O 
50 O 
°C O 
. O 
Experimental O 
Kinetics O 
results O 
, O 
demonstrated O 
that O 
, O 
both O 
the O 
V(max) O 
and O 
K(M) O 
values O 
of O 
dextranase O 
increased O 
with O 
ultrasound O 
- O 
treated O 
compared O 
with O 
the O 
incubation O 
at O 
50 O 
°C O 
. O 
Likewise O 
, O 
both O 
the O 
catalytic O 
and O 
specificity O 
constants O 
were O 
higher O 
under O 
the O 
effects O 
of O 
an O 
ultrasonic O 
field O 
, O 
indicating O 
that O 
, O 
the O 
substrate O 
is O 
converted O 
into O 
the O 
product O 
at O 
an O 
increased O 
rate O 
when O 
compared O 
with O 
the O 
incubation O 
at O 
50 O 
°C O 
. O 
On O 
the O 
other O 
hand O 
, O 
fluorescence O 
and O 
CD O 
spectra O 
reflected O 
that O 
the O 
ultrasound O 
irradiation O 
had O 
increased O 
the O 
number O 
of O 
tryptophan B-TRIVIAL 
on O 
dextranase O 
surface O 
with O 
increased O 
α-helix O 
by O 
15.74% O 
and O 
reduced O 
random O 
coil O 
by O 
5.41% O 
upon O 
ultrasound O 
- O 
treated O 
dextranase O 
protein O 
compared O 
to O 
the O 
control O 
, O 
which O 
were O 
helpful O 
for O 
the O 
improvement O 
of O 
its O 
activity O 
. O 

modulates O 
spontaneous O 
and O 
sensory O 
- O 
evoked O 
discharge O 
of O 
locus O 
coeruleus O 
noradrenergic O 
neurons O 
. O 

( O 
ATM B-ABBREVIATION 
) O 
is O 
a O 
potent O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
uptake O 
inhibitor O 
and O 
increases O 
both O 
NE O 
and O 
dopamine O 
synaptic O 
levels O 
in O 
prefrontal O 
cortex O 
, O 
where O 
it O 
is O 
thought O 
to O 
exert O 
its O 
beneficial O 
effects O 
on O 
attention O 
and O 
impulsivity O 
. O 
At O 
the O 
behavioral O 
level O 
, O 
ATM B-ABBREVIATION 
has O 
been O 
shown O 
to O 
cause O 
improvements O 
on O 
the O 
measures O 
of O 
executive O 
functions O 
, O 
such O 
as O 
response O 
inhibition O 
, O 
working O 
memory O 
and O 
attentional O 
set O 
shifting O 
across O 
different O 
species O 
. O 
However O 
, O 
the O 
exact O 
mechanism O 
of O 
action O 
for O 
ATM B-ABBREVIATION 
' O 
s O 
effects O 
on O 
cognition O 
is O 
still O 
not O 
clear O 
. O 
One O 
possible O 
target O 
for O 
the O 
cognitive O 
enhancing O 
effects O 
of O 
ATM B-ABBREVIATION 
is O 
the O 
noradrenergic O 
locus O 
coeruleus O 
( O 
LC O 
) O 
, O 
the O 
only O 
source O 
of O 
NE O 
to O 
key O 
forebrain O 
areas O 
such O 
as O 
cerebral O 
cortex O 
and O 
hippocampus O 
. O 
Although O 
it O 
is O 
known O 
that O 
ATM B-ABBREVIATION 
increases O 
NE O 
availability O 
overall O 
by O 
blocking O 
reuptake O 
of O 
NE O 
, O 
the O 
effects O 
of O 
this O 
agent O 
on O 
impulse O 
activity O 
of O 
LC O 
neurons O 
have O 
not O 
been O 
reported O 
. O 
Here O 
, O 
the O 
effect O 
of O 
ATM B-ABBREVIATION 
( O 
0.1-1 O 
mg O 
/ O 
kg O 
, O 
ip O 
) O 
on O 
NE-LC O 
neurons O 
was O 
investigated O 
by O 
recording O 
extracellular O 
activity O 
of O 
LC O 
neurons O 
in O 
isoflurane B-TRIVIAL 
-anesthetized O 
rats O 
. O 
ATM B-ABBREVIATION 
caused O 
a O 
significant O 
decrease O 
of O 
the O 
tonic O 
activity O 
of O 
LC O 
single O 
- O 
units O 
, O 
although O 
leaving O 
intact O 
the O 
sensory O 
- O 
evoked O 
excitatory O 
component O 
of O 
LC O 
phasic O 
response O 
. O 
Moreover O 
, O 
the O 
magnitude O 
of O 
the O 
inhibitory O 
component O 
of O 
LC O 
response O 
to O 
paw O 
stimulation O 
was O 
increased O 
after O 
1 O 
mg O 
/ O 
kg O 
of O 
ATM B-ABBREVIATION 
and O 
its O 
duration O 
was O 
prolonged O 
at O 
0.3 O 
mg O 
/ O 
kg O 
. O 
Together O 
, O 
these O 
effects O 
of O 
ATM B-ABBREVIATION 
produced O 
an O 
increase O 
in O 
the O 
phasic O 
- O 
to O 
- O 
tonic O 
ratio O 
of O 
LC O 
phasic O 
response O 
to O 
sensory O 
stimulation O 
. O 
ATM B-ABBREVIATION 
also O 
modulated O 
the O 
average O 
sensory O 
- O 
evoked O 
local O 
field O 
potential O 
( O 
LFP O 
) O 
and O 
spike O 
- O 
field O 
coherence O 
in O 
LC O 
depending O 
on O 
the O 
dose O 
tested O 
. O 
The O 
lower O 
dose O 
( O 
0.1 O 
mg O 
/ O 
kg O 
) O 
significantly O 
decreased O 
early O 
positive O 
and O 
negative O 
components O 
of O 
the O 
sensory O 
- O 
evoked O 
LFP O 
response O 
. O 
Higher O 
doses O 
( O 
0.3-1 O 
mg O 
/ O 
kg O 
) O 
initially O 
increased O 
and O 
then O 
decreased O 
the O 
amplitude O 
of O 
components O 
of O 
the O 
evoked O 
fields O 
, O 
whereas O 
the O 
spike O 
- O 
field O 
coherence O 
was O 
enhanced O 
by O 
1 O 
mg O 
/ O 
kg O 
ATM B-ABBREVIATION 
across O 
frequency O 
bands O 
. O 
Finally O 
, O 
coherence O 
between O 
LC O 
fields O 
and O 
EEG O 
signals O 
was O 
generally O 
increased O 
by O 
1 O 
mg O 
/ O 
kg O 
ATM B-ABBREVIATION 
, O 
whereas O 
0.1 O 
and O 
0.3 O 
mg O 
/ O 
kg O 
respectively O 
decreased O 
and O 
increased O 
coherence O 
values O 
in O 
specific O 
frequency O 
bands O 
. O 
Taken O 
together O 
these O 
results O 
suggest O 
that O 
ATM B-ABBREVIATION 
effects O 
on O 
LC O 
neuronal O 
activity O 
are O 
dose O 
- O 
dependent O 
, O 
with O 
different O 
doses O 
affecting O 
different O 
aspects O 
of O 
LC O 
firing O 
. O 
This O 
modulation O 
of O 
activity O 
of O 
LC-NE O 
neurons O 
may O 
play O 
a O 
role O 
in O 
the O 
cognitive O 
effects O 
of O 
ATM B-ABBREVIATION 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

maternal O 
exposure O 
to O 
the O 
antidepressants O 
fluoxetine B-TRIVIAL 
and O 
St O 
. O 
John's O 
Wort O 
induce O 
long O 
- O 
term O 
reproductive O 
effects O 
on O 
male O 
rats O 
? O 

on O 
the O 
limited O 
number O 
of O 
studies O 
that O 
have O 
investigated O 
the O 
adverse O 
effects O 
of O 
maternal O 
treatment O 
with O 
antidepressants O 
on O 
the O 
development O 
of O 
male O 
descendents O 
, O 
this O 
study O 
was O 
carried O 
out O 
in O 
rat O 
in O 
order O 
to O 
evaluate O 
if O 
maternal O 
exposure O 
to O 
fluoxetine B-TRIVIAL 
( O 
FLX B-ABBREVIATION 
) O 
or O 
St O 
. O 
John's O 
Wort O 
( O 
SJW O 
) O 
could O 
disrupt O 
the O 
development O 
of O 
male O 
offspring O 
. O 
The O 
dams O 
were O 
treated O 
daily O 
, O 
by O 
gavage O 
, O 
with O 
7.5 O 
mg O 
/ O 
kg O 
of O 
FLX B-ABBREVIATION 
or O 
100 O 
mg O 
/ O 
kg O 
SJW O 
during O 
pregnancy O 
and O 
lactation O 
. O 
The O 
reproductive O 
and O 
behavior O 
parameters O 
were O 
analyzed O 
in O 
male O 
pups O 
. O 
Results O 
showed O 
decreases O 
in O 
the O 
weight O 
of O 
the O 
full O 
seminal O 
vesicle O 
and O 
in O 
the O 
number O 
of O 
spermatozoa O 
. O 
Moreover O 
, O 
FLX B-ABBREVIATION 
-exposed O 
pups O 
presented O 
reduced O 
seminiferous O 
epithelium O 
height O 
and O 
diameter O 
of O 
seminiferous O 
tubules O 
. O 
The O 
present O 
study O 
shows O 
that O 
maternal O 
exposure O 
to O 
FLX B-ABBREVIATION 
, O 
but O 
not O 
SJW O 
could O 
interfere O 
on O 
reproductive O 
parameters O 
in O 
adult O 
male O 
rats O 
. O 

stem O 
cells O 
( O 
ESCs O 
) O 
provide O 
a O 
valuable O 
in O 
vitro O 
model O 
for O 
testing O 
toxicity O 
of O 
chemicals O 
and O 
environmental O 
contaminants O 
including O 
cigarette O 
smoke O 
. O 
Mouse O 
ESCs O 
were O 
acutely O 
or O 
chronically O 
exposed O 
to O 
smoke O 
components O 
, O 
cigarette O 
smoke O 
condensate O 
( O 
CSC O 
) O 
, O 
or O 
cadmium B-SYSTEMATIC 
, O 
an O 
abundant O 
component O 
of O 
CSC O 
, O 
and O 
then O 
evaluated O 
for O 
their O 
self O 
- O 
renewal O 
, O 
apoptosis O 
, O 
DNA O 
damage O 
and O 
telomere O 
function O 
. O 
Acute O 
exposure O 
of O 
ESCs O 
to O 
high O 
dose O 
of O 
CSC O 
or O 
cadmium B-SYSTEMATIC 
increased O 
DNA O 
damage O 
and O 
apoptosis O 
. O 
Yet O 
, O 
ESCs O 
exhibited O 
a O 
remarkable O 
capacity O 
to O 
recover O 
following O 
absence O 
of O 
exposure O 
. O 
Chronic O 
exposure O 
of O 
ESCs O 
to O 
low O 
dose O 
of O 
CSC O 
or O 
cadmium B-SYSTEMATIC 
resulted O 
in O 
shorter O 
telomeres O 
and O 
DNA O 
damage O 
. O 
Together O 
, O 
acute O 
exposure O 
of O 
ESCs O 
to O 
CSC O 
or O 
cadmium B-SYSTEMATIC 
causes O 
immediate O 
cell O 
death O 
and O 
reduces O 
pluripotency O 
, O 
while O 
chronic O 
exposure O 
of O 
ESCs O 
to O 
CSC O 
or O 
cadmium B-SYSTEMATIC 
leads O 
to O 
DNA O 
damage O 
and O 
telomere O 
shortening O 
. O 
Notably O 
, O 
a O 
sub O 
- O 
proportion O 
of O 
ESCs O 
during O 
passages O 
is O 
selected O 
to O 
resist O 
to O 
smoke O 
- O 
induced O 
oxidative O 
damage O 
to O 
telomeres O 
. O 

deposition O 
of O 
the O 
thiophene B-SYSTEMATIC 
-based O 
copolymer O 
and O 
its O 
composites O 
with O 
C60 B-TRIVIAL 
. O 

deposition O 
is O 
a O 
useful O 
and O 
efficient O 
technique O 
to O 
deposit O 
conjugated O 
polymers O 
, O 
if O 
suitable O 
suspension O 
of O 
the O 
target O 
polymer O 
is O 
obtained O 
. O 
Unfortunately O 
, O 
neither O 
general O 
theory O 
nor O 
universal O 
procedure O 
for O 
the O 
preparation O 
of O 
a O 
suspension O 
suitable O 
for O 
electrophoretic O 
deposition O 
has O 
seemed O 
to O 
be O 
established O 
yet O 
. O 
Thus O 
, O 
accumulation O 
of O 
individual O 
knowledge O 
is O 
still O 
important O 
in O 
this O 
area O 
. O 
Here O 
, O 
the O 
preparation O 
of O 
suspensions O 
of O 
a O 
thiophene B-SYSTEMATIC 
-based O 
polymer O 
poly(3-octylthiophene-2,5-diyl-co-3-decyloxythiophene-2,5-diyl) B-SYSTEMATIC 
( O 
POT-co-DOT B-ABBREVIATION 
) O 
and O 
their O 
application O 
to O 
the O 
electrophoretic O 
deposition O 
have O 
been O 
reported O 
. O 
The O 
suspensions O 
of O 
POT-co-DOT B-ABBREVIATION 
with O 
various O 
good O 
/ O 
poor O 
solvents O 
ratios O 
were O 
easily O 
obtained O 
by O 
mixing O 
a O 
toluene B-TRIVIAL 
solution O 
of O 
the O 
polymer O 
and O 
acetonitrile B-SYSTEMATIC 
. O 
The O 
composition O 
of O 
the O 
dispersion O 
medium O 
significantly O 
affects O 
the O 
surface O 
morphology O 
of O 
the O 
film O 
prepared O 
by O 
the O 
electrophoretic O 
deposition O 
in O 
the O 
suspension O 
. O 
Composite O 
films O 
consisting O 
of O 
POT-co-DOT B-ABBREVIATION 
and O 
C(60) B-TRIVIAL 
have O 
also O 
been O 
successfully O 
prepared O 
by O 
electrophoretic O 
deposition O 
. O 
Because O 
the O 
optical O 
absorption O 
peak O 
at O 
333 O 
nm O 
in O 
C(60) B-TRIVIAL 
showed O 
neither O 
significant O 
broadening O 
nor O 
a O 
red O 
shift O 
, O 
C(60) B-TRIVIAL 
molecules O 
were O 
expected O 
to O 
be O 
well O 
- O 
dispersed O 
in O 
the O 
composite O 
films O 
. O 
A O 
photovoltaic O 
device O 
with O 
a O 
composite O 
film O 
prepared O 
from O 
a O 
POT-co-DOT B-ABBREVIATION 
/ O 
C(60) B-TRIVIAL 
= O 
2 O 
: O 
1 O 
suspension O 
showed O 
10 O 
times O 
larger O 
short O 
- O 
circuit O 
current O 
density O 
and O 
5 O 
times O 
larger O 
power O 
conversion O 
efficiency O 
than O 
a O 
device O 
with O 
pure O 
POT-co-DOT B-ABBREVIATION 
, O 
although O 
further O 
work O 
is O 
required O 
to O 
improve O 
the O 
device O 
performance O 
. O 

requirements O 
for O 
effective O 
oximes B-FAMILY 
- O 
Evaluation O 
of O 
kinetic O 
in O 
vitro O 
data O 
with O 
phosphylated O 
human O 
AChE O 
and O 
structurally O 
different O 
oximes B-FAMILY 
. O 

of O 
poisoning O 
by O 
various O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
nerve O 
agents O 
with O 
established O 
acetylcholinesterase O 
( O 
AChE O 
) O 
reactivators O 
( O 
oximes B-FAMILY 
) O 
is O 
insufficient O 
. O 
In O 
consequence O 
, O 
extensive O 
research O 
programs O 
have O 
been O 
undertaken O 
in O 
various O 
countries O 
in O 
the O 
past O 
decades O 
to O 
identify O 
more O 
effective O 
oximes B-FAMILY 
. O 
The O 
efficacy O 
of O 
new O 
compounds O 
has O 
been O 
investigated O 
with O 
different O 
in O 
vitro O 
and O 
in O 
vivo O 
models O 
which O 
hamper O 
the O 
comparison O 
of O 
results O 
from O 
different O 
laboratories O 
. O 
The O 
crucial O 
mechanism O 
of O 
action O 
of O 
oximes B-FAMILY 
is O 
the O 
reactivation O 
of O 
phosphylated O 
AChE O 
. O 
The O 
kinetic O 
properties O 
of O 
these O 
compounds O 
can O 
be O 
quantified O 
in O 
vitro O 
with O 
isolated O 
AChE O 
from O 
different O 
origin O 
. O 
It O 
was O 
tempting O 
to O 
evaluate O 
the O 
reactivation O 
kinetics O 
of O 
a O 
series O 
of O 
oximes B-FAMILY 
with O 
various O 
OP O 
inhibitors O 
performed O 
under O 
identical O 
experimental O 
conditions O 
in O 
order O 
to O 
get O 
insight O 
into O 
structural O 
requirements O 
for O 
adequate O 
affinity O 
and O 
reactivity O 
towards O 
inhibited O 
AChE O 
. O 
The O 
determination O 
of O 
reactivation O 
rate O 
constants O 
with O 
bispyridinium B-FAMILY 
oximes I-FAMILY 
having O 
different O 
linkers O 
, O 
bearing O 
oxime B-SYSTEMATIC 
group(s) O 
at O 
different O 
positions O 
and O 
having O 
in O 
part O 
additional O 
substituents O 
revealed O 
that O 
( O 
a O 
) O 
the O 
reactivating O 
potency O 
was O 
dependent O 
on O 
the O 
position O 
of O 
the O 
oxime B-SYSTEMATIC 
groups O 
and O 
of O 
additional O 
substituents O 
, O 
( O 
b O 
) O 
small O 
modifications O 
of O 
the O 
oxime B-SYSTEMATIC 
structure O 
had O 
an O 
in O 
part O 
marked O 
effect O 
on O 
the O 
kinetic O 
properties O 
and O 
( O 
c O 
) O 
no O 
single O 
oxime B-SYSTEMATIC 
had O 
an O 
adequate O 
reactivating O 
potency O 
with O 
AChE O 
inhibited O 
by O 
structurally O 
different O 
OP O 
. O 
These O 
and O 
previous O 
studies O 
underline O 
the O 
necessity O 
to O 
investigate O 
in O 
detail O 
the O 
kinetic O 
properties O 
of O 
novel O 
oximes B-FAMILY 
and O 
that O 
the O 
identification O 
of O 
a O 
single O 
oxime B-SYSTEMATIC 
being O 
effective O 
against O 
a O 
broad O 
range O 
of O 
structurally O 
different O 
OP O 
will O 
remain O 
a O 
major O 
challenge O 
. O 

present O 
characterization O 
of O 
the O 
metabolic O 
performance O 
of O 
human O 
cryopreserved O 
hepatocytes O 
cultivated O 
in O 
a O 
platform O 
of O 
parallelized O 
microfluidic O 
biochips O 
. O 
The O 
RTqPCR O 
analysis O 
revealed O 
that O 
the O 
mRNA O 
levels O 
of O 
the O 
cytochromes O 
P450 O 
( O 
CYP O 
1A2 O 
, O 
2B6 O 
, O 
2C8 O 
, O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
20 O 
, O 
3A4 O 
) O 
were O 
reduced O 
after O 
the O 
adhesion O 
period O 
( O 
when O 
compared O 
to O 
the O 
post O 
- O 
thawing O 
step O 
) O 
. O 
The O 
microfluidic O 
perfusion O 
played O 
a O 
part O 
in O 
stabilizing O 
and O 
partially O 
recovering O 
the O 
levels O 
of O 
the O 
HNF4α O 
, O 
PXR O 
, O 
OAPT2 O 
, O 
CYP O 
1A2 O 
, O 
2B6 O 
, O 
2C19 O 
and O 
3A4 O 
mRNA O 
on O 
contrary O 
to O 
non-perfused O 
cultures O 
. O 
Fluorescein B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
staining O 
and O 
P-gp O 
mRNA O 
level O 
illustrated O 
the O 
hepatocytes O 
' O 
polarity O 
in O 
the O 
biochips O 
. O 
Drug O 
metabolism O 
was O 
assessed O 
using O 
midazolam B-TRIVIAL 
, O 
tolbutamide B-TRIVIAL 
, O 
caffeine B-TRIVIAL 
, O 
omeprazole B-TRIVIAL 
, O 
dextromethorphan B-TRIVIAL 
, O 
acetaminophen B-TRIVIAL 
and O 
repaglinide B-TRIVIAL 
as O 
probes O 
. O 
Metabolite O 
detection O 
and O 
quantification O 
revealed O 
that O 
CYP1A2 O 
( O 
via O 
the O 
detection O 
of O 
paraxanthine B-TRIVIAL 
) O 
, O 
CYP3A4 O 
( O 
via O 
1-OH-midazolam B-TRIVIAL 
, O 
and O 
omeprazole B-TRIVIAL 
sulfone I-TRIVIAL 
detection O 
) O 
, O 
CYP2C8 O 
( O 
via O 
hydroxyl-repaglinide B-SYSTEMATIC 
detection O 
) O 
, O 
CYP2C19 O 
( O 
via O 
hydroxy-omeprazole B-SYSTEMATIC 
detection O 
) O 
and O 
CYP2D6 O 
( O 
via O 
dextrorphan B-TRIVIAL 
detection O 
) O 
were O 
functional O 
in O 
our O 
microfluidic O 
configurations O 
. O 
Furthermore O 
, O 
the O 
RTqPCR O 
analysis O 
showed O 
that O 
the O 
drugs O 
acted O 
as O 
inductors O 
leading O 
to O 
overexpression O 
of O 
mRNA O 
levels O 
when O 
compared O 
to O 
post O 
- O 
thawing O 
values O 
( O 
such O 
as O 
for O 
HNF4α O 
, O 
PXR O 
and O 
CYP3A4 O 
by O 
dextromethorpahn B-TRIVIAL 
and O 
omeprazole B-TRIVIAL 
) O 
. O 
Finally O 
, O 
intrinsic O 
in O 
vitro O 
biochip O 
clearances O 
were O 
extracted O 
using O 
a O 
PBPK O 
model O 
for O 
predictions O 
. O 
The O 
biochip O 
predictions O 
were O 
compared O 
to O 
literature O 
in O 
vitro O 
data O 
and O 
in O 
vivo O 
situations O 
. O 

A I-FAMILY 
deficiency O 
disturbs O 
collagen O 
IV O 
and O 
laminin O 
composition O 
and O 
decreases O 
matrix O 
metalloproteinase O 
concentrations O 
in O 
rat O 
lung O 
. O 
Partial O 
reversibility O 
by O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
. O 

A I-FAMILY 
is O 
essential O 
for O 
lung O 
development O 
and O 
pulmonary O 
cell O 
differentiation O 
. O 
Its O 
deficiency O 
leads O 
to O 
altered O 
lung O 
structure O 
and O 
function O 
and O 
to O 
basement O 
membrane O 
architecture O 
and O 
composition O 
disturbances O 
. O 
Previously O 
, O 
we O 
showed O 
that O 
lack O 
of O 
retinoids B-FAMILY 
thickens O 
the O 
alveolar O 
basement O 
membrane O 
and O 
increases O 
collagen O 
IV O 
, O 
which O 
are O 
reversed O 
by O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
the O 
main O 
biologically O 
active O 
vitamin B-FAMILY 
A I-FAMILY 
form O 
. O 
This O 
study O 
analyzed O 
how O 
vitamin B-FAMILY 
A I-FAMILY 
deficiency O 
affects O 
the O 
subunit O 
composition O 
of O 
collagen O 
IV O 
and O 
laminin O 
of O 
lung O 
basement O 
membranes O 
and O 
pulmonary O 
matrix O 
metalloproteinase O 
content O 
, O 
plus O 
the O 
recovering O 
effect O 
of O 
all-trans-retinoic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Male O 
weanling O 
pups O 
were O 
fed O 
a O 
retinol B-TRIVIAL 
-adequate O 
/ O 
-deficient O 
diet O 
until O 
60 O 
days O 
old O 
. O 
A O 
subgroup O 
of O 
vitamin-A B-FAMILY 
-deficient O 
pups O 
received O 
daily O 
intraperitoneal O 
all-trans-retinoic B-TRIVIAL 
acid I-TRIVIAL 
injections O 
for O 
10 O 
days O 
. O 
Collagen O 
IV O 
and O 
laminin O 
chain O 
composition O 
were O 
modified O 
in O 
vitamin-A B-FAMILY 
-deficient O 
rats O 
. O 
The O 
protein O 
and O 
mRNA O 
contents O 
of O 
chains O 
α1 O 
(IV) O 
, O 
α3 O 
(IV) O 
and O 
α4 O 
(IV) O 
increased O 
; O 
those O 
of O 
chains O 
α2 O 
(IV) O 
and O 
α5 O 
(IV) O 
remained O 
unchanged O 
; O 
and O 
the O 
protein O 
and O 
mRNA O 
contents O 
of O 
laminin O 
chains O 
α5 O 
, O 
β1 O 
and O 
γ1 O 
decreased O 
. O 
The O 
mRNA O 
of O 
laminin O 
chains O 
α2 O 
and O 
α4 O 
also O 
decreased O 
. O 
Matrix O 
metalloproteinases O 
2 O 
and O 
9 O 
decreased O 
, O 
but O 
the O 
tissue O 
inhibitors O 
of O 
metalloproteinases O 
1 O 
and O 
2 O 
did O 
not O 
change O 
. O 
Treating O 
vitamin-A B-FAMILY 
-deficient O 
rats O 
with O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
reversed O 
all O 
alterations O 
, O 
but O 
laminin O 
chains O 
α2 O 
, O 
α4 O 
and O 
α5 O 
and O 
matrix O 
metalloproteinase O 
2 O 
remained O 
low O 
. O 
In O 
conclusion O 
, O 
vitamin B-FAMILY 
A I-FAMILY 
deficiency O 
alters O 
the O 
subunit O 
composition O 
of O 
collagen O 
IV O 
and O 
laminin O 
and O 
the O 
lung's O 
proteolytic O 
potential O 
, O 
which O 
are O 
partly O 
reverted O 
by O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
. O 
These O 
alterations O 
could O 
contribute O 
to O 
impaired O 
lung O 
function O 
and O 
predispose O 
to O 
pulmonary O 
disease O 
. O 

alignment O 
of O 
barium B-SYSTEMATIC 
ferrite I-SYSTEMATIC 
nanoparticles O 
from O 
their O 
suspensions O 
in O 
electric O 
and O 
magnetic O 
fields O 
. O 

alignment O 
of O 
plate O 
- O 
like O 
barium B-SYSTEMATIC 
ferrite I-SYSTEMATIC 
nanoparticles O 
, O 
with O 
diameters O 
of O 
10-350 O 
nm O 
and O 
thicknesses O 
of O 
3-10 O 
nm O 
, O 
in O 
electric O 
and O 
/ O 
or O 
magnetic O 
fields O 
was O 
studied O 
. O 
Stable O 
suspensions O 
were O 
prepared O 
in O 
1-butanol B-SYSTEMATIC 
with O 
dodecylbenzenesulphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
surfactant O 
. O 
The O 
deposits O 
were O 
produced O 
from O 
the O 
suspensions O 
with O 
classic O 
electrophoretic O 
deposition O 
, O 
electrophoretic O 
deposition O 
in O 
a O 
magnetic O 
field O 
, O 
and O 
with O 
drying O 
in O 
a O 
magnetic O 
field O 
. O 
The O 
experiments O 
, O 
supported O 
by O 
theoretical O 
calculations O 
, O 
show O 
that O 
the O 
alignment O 
of O 
the O 
nanoplates O 
in O 
the O 
deposits O 
was O 
determined O 
by O 
the O 
interplay O 
between O 
the O 
hydrodynamic O 
, O 
electric O 
, O 
and O 
magnetic O 
forces O 
. O 
The O 
preferential O 
alignment O 
of O 
the O 
nanoplates O 
in O 
plane O 
with O 
the O 
substrate O 
coincided O 
with O 
their O 
magnetic O 
orientation O 
, O 
and O 
it O 
increased O 
with O 
the O 
shape O 
anisotropy O 
of O 
the O 
particles O 
. O 
The O 
deposits O 
were O 
sintered O 
at O 
1150 O 
°C O 
for O 
5 O 
h O 
to O 
obtain O 
ceramic O 
films O 
, O 
which O 
showed O 
a O 
magnetic O 
orientation O 
up O 
to O 
90% O 
. O 

imperfecta O 
( O 
OI O 
) O 
is O 
a O 
genetic O 
bone O 
dysplasia O 
characterized O 
by O 
osteopenia O 
and O 
easy O 
susceptibility O 
to O 
fracture O 
. O 
Symptoms O 
are O 
most O 
prominent O 
during O 
childhood O 
. O 
Although O 
antiresorptive O 
bisphosphonates O 
have O 
been O 
widely O 
used O 
to O 
treat O 
pediatric O 
OI O 
, O 
controlled O 
trials O 
show O 
improved O 
vertebral O 
parameters O 
but O 
equivocal O 
effects O 
on O 
long O 
- O 
bone O 
fracture O 
rates O 
. O 
New O 
treatments O 
for O 
OI O 
are O 
needed O 
to O 
increase O 
bone O 
mass O 
throughout O 
the O 
skeleton O 
. O 
Sclerostin O 
antibody O 
( O 
Scl-Ab O 
) O 
therapy O 
is O 
potently O 
anabolic O 
in O 
the O 
skeleton O 
by O 
stimulating O 
osteoblasts O 
via O 
the O 
canonical O 
wnt O 
signaling O 
pathway O 
, O 
and O 
may O 
be O 
beneficial O 
for O 
treating O 
OI O 
. O 
In O 
this O 
study O 
, O 
Scl-Ab O 
therapy O 
was O 
investigated O 
in O 
mice O 
heterozygous O 
for O 
a O 
typical O 
OI-causing O 
Gly B-FORMULA 
→ O 
Cys B-FORMULA 
substitution O 
in O 
col1a1 O 
. O 
Two O 
weeks O 
of O 
Scl-Ab O 
successfully O 
stimulated O 
osteoblast O 
bone O 
formation O 
in O 
a O 
knock O 
- O 
in O 
model O 
for O 
moderately O 
severe O 
OI O 
( O 
Brtl O 
/ O 
+ O 
) O 
and O 
in O 
WT O 
mice O 
, O 
leading O 
to O 
improved O 
bone O 
mass O 
and O 
reduced O 
long O 
- O 
bone O 
fragility O 
. O 
Image O 
- O 
guided O 
nanoindentation O 
revealed O 
no O 
alteration O 
in O 
local O 
tissue O 
mineralization O 
dynamics O 
with O 
Scl-Ab O 
. O 
These O 
results O 
contrast O 
with O 
previous O 
findings O 
of O 
antiresorptive O 
efficacy O 
in O 
OI O 
both O 
in O 
mechanism O 
and O 
potency O 
of O 
effects O 
on O 
fragility O 
. O 
In O 
conclusion O 
, O 
short O 
- O 
term O 
Scl-Ab O 
was O 
successfully O 
anabolic O 
in O 
osteoblasts O 
harboring O 
a O 
typical O 
OI-causing O 
collagen O 
mutation O 
and O 
represents O 
a O 
potential O 
new O 
therapy O 
to O 
improve O 
bone O 
mass O 
and O 
reduce O 
fractures O 
in O 
pediatric O 
OI O 
. O 

association O 
between O 
osteoporosis O 
and O 
cardiovascular O 
diseases O 
has O 
been O 
demonstrated O 
. O 
Higher O 
cardiovascular O 
risk O 
has O 
also O 
been O 
correlated O 
with O 
vertebral O 
fractures O 
. O 
However O 
, O 
the O 
association O 
between O 
osteoporotic O 
vertebral O 
fracture O 
and O 
the O 
possibly O 
higher O 
risk O 
of O 
stroke O 
remains O 
uncertain O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
the O 
incidence O 
, O 
risk O 
, O 
and O 
type O 
of O 
stroke O 
in O 
patients O 
with O 
osteoporotic O 
vertebral O 
fracture O 
. O 
Patients O 
with O 
osteoporotic O 
vertebral O 
fracture O 
were O 
identified O 
( O 
n O 
= O 
380 O 
) O 
and O 
10 O 
age- O 
and O 
sex O 
- O 
matched O 
controls O 
per O 
case O 
( O 
comparison O 
group O 
, O 
n O 
= O 
3795 O 
) O 
were O 
chosen O 
from O 
a O 
nationwide O 
representative O 
cohort O 
of O 
999997 O 
people O 
from O 
1998 O 
to O 
2005 O 
. O 
Both O 
groups O 
were O 
followed O 
- O 
up O 
for O 
stroke O 
events O 
for O 
3 O 
years O 
, O 
matched O 
by O 
propensity O 
scores O 
with O 
adjustments O 
for O 
covariates O 
such O 
as O 
comorbidities O 
( O 
ie O 
, O 
hypertension O 
, O 
diabetes O 
, O 
arrhythmia O 
, O 
or O 
coronary O 
heart O 
diseases O 
) O 
and O 
exposure O 
to O 
medications O 
( O 
ie O 
, O 
aspirin B-TRIVIAL 
, O 
lipid O 
lowering O 
drug O 
, O 
or O 
nitrates B-FAMILY 
) O 
, O 
and O 
assessed O 
by O 
Kaplan-Meier O 
and O 
Cox O 
regression O 
analyses O 
. O 
The O 
incidence O 
rate O 
of O 
stroke O 
in O 
the O 
osteoporotic O 
vertebral O 
fracture O 
group O 
( O 
37.5 O 
per O 
1000 O 
person O 
- O 
years O 
; O 
95% O 
confidence O 
interval O 
[ O 
CI O 
] O 
, O 
27.5-51.2 O 
) O 
was O 
significantly O 
higher O 
than O 
in O 
the O 
comparison O 
group O 
( O 
14 O 
per O 
1000 O 
person O 
- O 
years O 
; O 
95% O 
CI O 
, O 
12.0-16.4 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Stroke O 
was O 
more O 
likely O 
to O 
occur O 
in O 
the O 
osteoporotic O 
vertebral O 
fracture O 
patients O 
than O 
in O 
the O 
normal O 
controls O 
( O 
crude O 
hazard O 
ratio O 
[ O 
HR O 
] O 
2.68 O 
, O 
95% O 
CI O 
1.89-3.79 O 
, O 
p O 
< O 
0.001 O 
; O 
adjusted O 
HR O 
2.71 O 
, O 
95% O 
CI O 
1.90-3.86 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
In O 
conclusion O 
, O 
patients O 
with O 
osteoporotic O 
vertebral O 
fracture O 
have O 
a O 
higher O 
risk O 
of O 
stroke O 
( O 
ie O 
, O 
both O 
ischemic O 
and O 
hemorrhagic O 
) O 
and O 
require O 
stroke O 
prevention O 
strategies O 
. O 

new O 
diarylbutane B-FAMILY 
lignans I-FAMILY 
from O 
the O 
resin O 
of O 
Bursera O 
fagaroides O 
. O 

new O 
diarylbutane B-FAMILY 
lignans I-FAMILY 
, O 
named O 
9-acetyl-9'-pentadecanoil- B-SYSTEMATIC 
dihydroclusin I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
2,3-demethoxy-secoisolintetralin B-SYSTEMATIC 
monoacetate I-SYSTEMATIC 
( O 
4 O 
) O 
and O 
dihydroclusin B-SYSTEMATIC 
monoacetate I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
have O 
been O 
isolated O 
from O 
the O 
resin O 
of O 
Bursera O 
fagaroides O 
, O 
together O 
with O 
two O 
known O 
ones O 
, O 
2,3-demethoxy-secoisolintetralin B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
dihydroclusin B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
3 O 
) O 
. O 
The O 
complete O 
structure O 
assignments O 
were O 
obtained O 
by O 
means O 
of O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectra O 
. O 

chemical O 
composition O 
of O 
the O 
Pelargonium O 
graveolens O 
essential O 
oil O 
allowed O 
the O 
identification O 
of O 
15 O 
compounds O 
( O 
93.86% O 
of O 
the O 
total O 
essential O 
oil O 
) O 
. O 
The O 
major O 
fractions O 
were O 
citronellol B-TRIVIAL 
( O 
35% O 
) O 
and O 
geraniol B-TRIVIAL 
( O 
28.8% O 
) O 
. O 
The O 
chemical O 
composition O 
of O 
the O 
Artemisia O 
arborescens O 
essential O 
oil O 
revealed O 
twenty O 
- O 
one O 
compounds O 
representing O 
93.57% O 
of O 
the O 
total O 
essential O 
oil O 
. O 
The O 
main O 
compounds O 
were O 
chamazulene B-TRIVIAL 
( O 
31.9% O 
) O 
and O 
camphor B-TRIVIAL 
( O 
25.8% O 
) O 
. O 
The O 
insecticidal O 
effects O 
were O 
tested O 
towards O 
the O 
insect O 
Rhysopertha O 
dominica O 
. O 
Results O 
revealed O 
that O 
these O 
two O 
essential O 
oils O 
were O 
highly O 
effective O 
against O 
R O 
. O 
dominica O 
at O 
the O 
dose O 
of O 
50 O 
µL O 
on O 
Petri O 
dish O 
of O 
8.5 O 
cm O 
of O 
diameter O 
. O 
The O 
antifungal O 
activity O 
was O 
evaluated O 
against O 
Rhizoctonia O 
solani O 
and O 
results O 
showed O 
that O 
both O 
of O 
the O 
essential O 
oils O 
were O 
highly O 
active O 
at O 
a O 
dose O 
of O 
12.5 O 
µL O 
/ O 
20 O 
mL O 
of O 
PDA O 
. O 
Moreover O 
, O 
the O 
inhibitory O 
effect O 
of O 
P O 
. O 
graveolens O 
essential O 
oil O 
was O 
evidenced O 
as O 
stronger O 
than O 
that O 
of O 
the O 
A O 
. O 
arborescens O 
oil O 
for O 
all O 
the O 
tested O 
doses O 
. O 

new O 
cyclonerol B-TRIVIAL 
derivative O 
from O 
a O 
marine O 
- O 
derived O 
fungus O 
Ascotricha O 
sp O 
. O 
ZJ-M-5 O 
. O 

new O 
sesquiterpene B-FAMILY 
, O 
ascotrichic O 
acid O 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
a O 
marine O 
- O 
derived O 
fungus O 
Ascotricha O 
sp O 
. O 
, O 
together O 
with O 
the O 
other O 
two O 
known O 
analogues O 
, O 
cyclonerodiol B-TRIVIAL 
( O 
2 O 
) O 
and O 
10(Z)-cyclonerotriol B-TRIVIAL 
( O 
3 O 
) O 
. O 
Its O 
structure O 
was O 
established O 
by O 
spectroscopic O 
methods O 
( O 
1D O 
and O 
2D O 
NMR O 
, O 
HR-ESI-MS O 
) O 
. O 

, O 
a O 
selenium B-SYSTEMATIC 
metabolite O 
, O 
modulates O 
p53 O 
pathway O 
and O 
inhibits O 
the O 
growth O 
of O 
colon O 
cancer O 
xenografts O 
in O 
Balb O 
/ O 
c O 
mice O 
. O 

is O 
has O 
been O 
hypothesized O 
that O 
methylselenol B-SYSTEMATIC 
is O 
a O 
critical O 
selenium B-SYSTEMATIC 
metabolite O 
for O 
anticancer O 
activity O 
in O 
vivo O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
protein O 
array O 
which O 
contained O 
112 O 
different O 
antibodies O 
known O 
to O 
be O 
involved O 
in O 
the O 
p53 O 
pathway O 
to O 
investigate O 
the O 
molecular O 
targets O 
of O 
methylselenol B-SYSTEMATIC 
in O 
human O 
HCT116 O 
colon O 
cancer O 
cells O 
. O 
The O 
array O 
analysis O 
indicated O 
that O 
methylselenol B-SYSTEMATIC 
exposure O 
changed O 
the O 
expression O 
of O 
11 O 
protein O 
targets O 
related O 
to O 
the O 
regulation O 
of O 
cell O 
cycle O 
and O 
apoptosis O 
. O 
Subsequently O 
, O 
we O 
confirmed O 
these O 
proteins O 
with O 
the O 
Western O 
blotting O 
approach O 
, O 
and O 
found O 
that O 
methylselenol B-SYSTEMATIC 
increased O 
the O 
expression O 
of O 
GADD O 
153 O 
and O 
p21 O 
but O 
reduced O 
the O 
level O 
of O 
c-Myc O 
, O 
E2F1 O 
and O 
Phos O 
p38 O 
MAP O 
kinase O 
. O 
Similar O 
to O 
our O 
previous O 
report O 
on O 
human O 
HCT116 O 
colon O 
cancer O 
cells O 
, O 
methylselenol B-SYSTEMATIC 
also O 
inhibited O 
cell O 
growth O 
and O 
led O 
to O 
an O 
increase O 
in O 
G1 O 
and O 
G2 O 
fractions O 
with O 
a O 
concomitant O 
drop O 
in O 
S-phase O 
in O 
mouse O 
colon O 
cancer O 
MC26 O 
cells O 
. O 
When O 
the O 
MC26 O 
cells O 
were O 
transplanted O 
to O 
their O 
immune O 
- O 
competent O 
Balb O 
/ O 
c O 
mice O 
, O 
methylselenol B-SYSTEMATIC 
-treated O 
MC26 O 
cells O 
had O 
significantly O 
less O 
tumor O 
growth O 
potential O 
than O 
that O 
of O 
untreated O 
MC26 O 
cells O 
. O 
Taken O 
together O 
, O 
our O 
data O 
suggest O 
that O 
methylselenol B-SYSTEMATIC 
modulates O 
the O 
expression O 
of O 
key O 
genes O 
related O 
to O 
cell O 
cycle O 
and O 
apoptosis O 
and O 
inhibits O 
colon O 
cancer O 
cell O 
proliferation O 
and O 
tumor O 
growth O 
. O 

of O 
biotin B-TRIVIAL 
supplementation O 
in O 
the O 
diet O 
on O 
insulin O 
secretion O 
, O 
islet O 
gene O 
expression O 
, O 
glucose B-TRIVIAL 
homeostasis O 
and O 
beta-cell O 
proportion O 
. O 

its O 
role O 
as O 
a O 
carboxylase O 
cofactor O 
, O 
biotin B-TRIVIAL 
has O 
a O 
wide O 
repertoire O 
of O 
effects O 
on O 
gene O 
expression O 
, O 
development O 
and O 
metabolism O 
. O 
Pharmacological O 
concentrations O 
of O 
biotin B-TRIVIAL 
enhance O 
insulin O 
secretion O 
and O 
the O 
expression O 
of O 
genes O 
and O 
signaling O 
pathways O 
that O 
favor O 
islet O 
function O 
in O 
vitro O 
. O 
However O 
, O 
the O 
in O 
vivo O 
effects O 
of O 
biotin B-TRIVIAL 
supplementation O 
on O 
pancreatic O 
islet O 
function O 
are O 
largely O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
whether O 
in O 
vivo O 
biotin B-TRIVIAL 
supplementation O 
in O 
the O 
diet O 
has O 
positive O 
effects O 
in O 
rodent O 
pancreatic O 
islets O 
. O 
Male O 
BALB O 
/ O 
cAnN O 
Hsd O 
mice O 
were O 
fed O 
a O 
control O 
or O 
a O 
biotin B-TRIVIAL 
-supplemented O 
diet O 
over O 
8 O 
weeks O 
postweaning O 
and O 
tested O 
for O 
glucose B-TRIVIAL 
homeostasis O 
, O 
insulin O 
secretion O 
, O 
islet O 
gene O 
expression O 
and O 
pancreatic O 
morphometry O 
. O 
Insulin O 
secretion O 
increased O 
from O 
the O 
islets O 
of O 
biotin B-TRIVIAL 
-supplemented O 
mice O 
, O 
together O 
with O 
the O 
messenger O 
RNA O 
( O 
mRNA O 
) O 
expression O 
of O 
several O 
transcription O 
factors O 
regulating O 
insulin O 
expression O 
and O 
secretion O 
, O 
including O 
forkhead O 
box O 
A2 O 
, O 
pancreatic O 
and O 
duodenal O 
homeobox O 
1 O 
and O 
hepatocyte O 
nuclear O 
factor O 
4α O 
. O 
The O 
mRNA O 
abundance O 
of O 
glucokinase O 
, O 
Cacna1d O 
, O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
, O 
and O 
insulin O 
also O 
increased O 
. O 
Consistent O 
with O 
these O 
effects O 
, O 
glucose B-TRIVIAL 
tolerance O 
improved O 
, O 
and O 
glucose B-TRIVIAL 
-stimulated O 
serum O 
insulin O 
levels O 
increased O 
in O 
biotin B-TRIVIAL 
-supplemented O 
mice O 
, O 
without O 
changes O 
in O 
fasting O 
glucose B-TRIVIAL 
levels O 
or O 
insulin O 
tolerance O 
. O 
Biotin B-TRIVIAL 
supplementation O 
augmented O 
the O 
proportion O 
of O 
beta O 
cells O 
by O 
enlarging O 
islet O 
size O 
and O 
, O 
unexpectedly O 
, O 
also O 
increased O 
the O 
percentage O 
of O 
islets O 
with O 
alpha O 
cells O 
at O 
the O 
islet O 
core O 
. O 
mRNA O 
expression O 
of O 
neural O 
cell O 
adhesion O 
molecule O 
1 O 
, O 
an O 
adhesion O 
protein O 
participating O 
in O 
the O 
maintenance O 
of O 
islet O 
architecture O 
, O 
decreased O 
in O 
biotin B-TRIVIAL 
-supplemented O 
islets O 
. O 
These O 
findings O 
provide O 
, O 
for O 
the O 
first O 
time O 
, O 
insight O 
into O 
how O 
biotin B-TRIVIAL 
supplementation O 
exerts O 
its O 
effects O 
on O 
function O 
and O 
proportion O 
of O 
beta O 
cells O 
, O 
suggesting O 
a O 
role O 
for O 
biotin B-TRIVIAL 
in O 
the O 
prevention O 
and O 
treatment O 
of O 
diabetes O 
. O 

caffeine B-TRIVIAL 
prevents O 
changes O 
in O 
inhibitory O 
avoidance O 
memory O 
and O 
hippocampal O 
BDNF O 
immunocontent O 
in O 
middle O 
- O 
aged O 
rats O 
. O 

effects O 
of O 
caffeine B-TRIVIAL 
on O 
memory O 
processes O 
have O 
been O 
observed O 
in O 
animal O 
models O 
relevant O 
to O 
neurodegenerative O 
diseases O 
and O 
aging O 
, O 
although O 
the O 
underlying O 
mechanisms O 
remain O 
unknown O 
. O 
Because O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
is O 
associated O 
with O 
memory O 
formation O 
and O 
BDNF's O 
actions O 
are O 
modulated O 
by O 
adenosine B-TRIVIAL 
receptors O 
, O 
the O 
molecular O 
targets O 
for O 
the O 
psychostimulant O 
actions O 
of O 
caffeine B-TRIVIAL 
, O 
we O 
here O 
compare O 
the O 
effects O 
of O 
chronic O 
caffeine B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
mL O 
drinking O 
solution O 
for O 
30 O 
days O 
) O 
on O 
short- O 
and O 
long O 
term O 
memory O 
and O 
on O 
levels O 
of O 
hippocampal O 
proBDNF O 
, O 
mature O 
BDNF O 
, O 
TrkB O 
and O 
CREB O 
in O 
young O 
( O 
3 O 
month O 
old O 
) O 
and O 
middle O 
- O 
aged O 
( O 
12 O 
month O 
old O 
) O 
rats O 
. O 
Caffeine B-TRIVIAL 
treatment O 
substantially O 
reduced O 
i O 
) O 
age O 
- O 
related O 
impairments O 
in O 
the O 
two O 
types O 
of O 
memory O 
in O 
an O 
inhibitory O 
avoidance O 
paradigm O 
, O 
and O 
ii O 
) O 
parallel O 
increases O 
in O 
hippocampal O 
BDNF O 
levels O 
. O 
In O 
addition O 
, O 
chronic O 
caffeine B-TRIVIAL 
increased O 
proBDNF O 
and O 
CREB O 
concentrations O 
, O 
and O 
decreased O 
TrkB O 
levels O 
, O 
in O 
hippocampus O 
regardless O 
of O 
age O 
. O 
These O 
data O 
provide O 
new O 
evidence O 
in O 
favor O 
of O 
the O 
hypothesis O 
that O 
modifications O 
in O 
BDNF O 
and O 
related O 
proteins O 
in O 
the O 
hippocampus O 
contribute O 
to O 
the O 
pro O 
- O 
cognitive O 
effects O 
of O 
caffeine B-TRIVIAL 
on O 
age O 
- O 
associated O 
losses O 
in O 
memory O 
encoding O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

enhancement O 
by O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
from O 
child O 
- O 
hood O 
to O 
old O 
age O 
: O 
findings O 
from O 
animal O 
and O 
clinical O 
studies O 
. O 

polyunsaturated I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFAs B-ABBREVIATION 
) O 
, O 
including O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
and O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
are O 
major O 
components O 
of O 
neuronal O 
membranes O 
and O 
have O 
a O 
wide O 
range O 
of O 
functions O 
, O 
from O 
modulating O 
synaptic O 
plasticity O 
and O 
neurochemistry O 
, O 
to O 
neuroimmune O 
- O 
modulation O 
and O 
neuroprotection O 
. O 
Thus O 
, O 
it O 
is O 
not O 
surprising O 
that O 
n-3 O 
PUFA B-ABBREVIATION 
are O 
widely O 
acknowledged O 
to O 
have O 
cognitive O 
- O 
enhancing O 
effects O 
. O 
Although O 
clinical O 
evidence O 
is O 
somewhat O 
conflicting O 
, O 
probably O 
in O 
large O 
part O 
due O 
to O 
methodological O 
issues O 
, O 
animal O 
studies O 
have O 
consistently O 
demonstrated O 
that O 
n-3 O 
PUFA B-ABBREVIATION 
are O 
indispensable O 
for O 
proper O 
brain O 
development O 
, O 
may O 
enhance O 
cognitive O 
function O 
in O 
healthy O 
, O 
adult O 
individuals O 
and O 
attenuate O 
cognitive O 
impairment O 
in O 
aging O 
and O 
age O 
- O 
related O 
disorders O 
, O 
such O 
as O 
dementia O 
. O 
This O 
review O 
discusses O 
and O 
integrates O 
up O 
to O 
date O 
evidence O 
from O 
clinical O 
and O 
animal O 
studies O 
investigating O 
the O 
cognitive O 
- O 
enhancing O 
effects O 
of O 
n-3 O 
PUFA B-ABBREVIATION 
during O 
development O 
, O 
child- O 
and O 
adult O 
- O 
hood O 
, O 
as O 
well O 
as O 
old O 
- O 
age O 
with O 
associated O 
neurodegenerative O 
diseases O 
, O 
such O 
as O 
Alzheimer's O 
disease O 
. O 
Furthermore O 
, O 
we O 
cover O 
the O 
major O 
underlying O 
biochemical O 
and O 
neurophysiological O 
mechanisms O 
by O 
which O 
n-3 O 
PUFA B-ABBREVIATION 
mediate O 
these O 
effects O 
on O 
cognition O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

biochemical O 
and O 
functional O 
efficacies O 
confirm O 
ZIP B-ABBREVIATION 
as O 
a O 
potent O 
competitive O 
inhibitor O 
of O 
PKMζ O 
in O 
neurons O 
. O 

is O 
an O 
autonomously O 
active O 
, O 
atypical O 
protein O 
kinase O 
C O 
( O 
aPKC O 
) O 
isoform O 
that O 
is O 
both O 
necessary O 
and O 
sufficient O 
for O 
maintaining O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
and O 
long O 
- O 
term O 
memory O 
. O 
The O 
myristoylated B-TRIVIAL 
ζ-pseudosubstrate I-TRIVIAL 
peptide I-TRIVIAL 
, O 
ZIP B-ABBREVIATION 
, O 
potently O 
inhibits O 
PKMζ O 
biochemically O 
in O 
vitro O 
, O 
within O 
cultured O 
cells O 
, O 
and O 
within O 
neurons O 
in O 
hippocampal O 
slices O 
, O 
and O 
reverses O 
LTP O 
maintenance O 
and O 
erases O 
long O 
- O 
term O 
memory O 
storage O 
. O 
A O 
recent O 
study O 
( O 
Wu-Zhang O 
et O 
al O 
. O 
, O 
2012 O 
) O 
, O 
however O 
, O 
suggested O 
ZIP B-ABBREVIATION 
was O 
not O 
effective O 
on O 
a O 
PKMζ O 
fusion O 
protein O 
overexpressed O 
in O 
cultured O 
cells O 
. O 
Chelerythrine B-TRIVIAL 
, O 
a O 
redox O 
- O 
sensitive O 
PKC O 
inhibitor O 
that O 
inhibits O 
PKMζ O 
and O 
disrupts O 
LTP O 
maintenance O 
and O 
memory O 
storage O 
, O 
was O 
also O 
reported O 
by O 
Wu-Zhang O 
et O 
al O 
. O 
( O 
2012 O 
) O 
not O 
to O 
inhibit O 
the O 
expressed O 
PKMζ O 
fusion O 
protein O 
. O 
However O 
, O 
the O 
efficacy O 
of O 
inhibitors O 
on O 
endogenous O 
enzymes O 
in O 
cells O 
may O 
not O 
be O 
adequately O 
assessed O 
in O 
expression O 
systems O 
in O 
which O 
levels O 
of O 
expression O 
of O 
exogenous O 
enzymes O 
greatly O 
exceed O 
those O 
of O 
endogenous O 
enzymes O 
. O 
Thus O 
, O 
we O 
show O 
, O 
biochemically O 
, O 
that O 
when O 
PKMζ O 
reaches O 
a O 
level O 
beyond O 
that O 
necessary O 
for O 
substrate O 
phosphorylation O 
such O 
that O 
much O 
of O 
the O 
enzyme O 
is O 
excess O 
or O 
' O 
spare O 
' O 
kinase O 
, O 
ZIP B-ABBREVIATION 
and O 
chelerythrine B-TRIVIAL 
do O 
not O 
effectively O 
block O 
substrate O 
phosphorylation O 
. O 
We O 
also O 
show O 
that O 
the O 
cellular O 
overexpression O 
techniques O 
used O 
by O 
Wu-Zhang O 
et O 
al O 
. O 
( O 
2012 O 
) O 
increase O 
kinase O 
levels O 
~30-40 O 
fold O 
above O 
normal O 
levels O 
in O 
transfected O 
cells O 
. O 
Using O 
a O 
mathematical O 
model O 
we O 
show O 
that O 
at O 
such O 
level O 
of O 
overexpression O 
, O 
standard O 
concentrations O 
of O 
inhibitor O 
should O 
have O 
no O 
noticeable O 
effect O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
the O 
standard O 
concentrations O 
of O 
ZIP B-ABBREVIATION 
, O 
but O 
not O 
scrambled O 
ZIP B-ABBREVIATION 
, O 
inhibit O 
the O 
ability O 
of O 
PKMζ O 
to O 
potentiate O 
AMPAR O 
responses O 
at O 
postsynaptic O 
sites O 
, O 
the O 
physiological O 
function O 
of O 
the O 
kinase O 
. O 
Wu-Zhang O 
et O 
al O 
. O 
( O 
2012 O 
) O 
had O 
also O 
claimed O 
that O 
staurosporine B-TRIVIAL 
, O 
a O 
general O 
kinase O 
inhibitor O 
that O 
does O 
not O 
effectively O 
inhibit O 
PKMζ O 
biochemically O 
in O 
vitro O 
, O 
nonetheless O 
indirectly O 
blocked O 
the O 
PKMζ O 
fusion O 
protein O 
overexpressed O 
in O 
cultured O 
cells O 
by O 
inhibiting O 
phosphoinositide-dependent O 
protein O 
kinase-1 O 
( O 
PDK1 O 
) O 
. O 
However O 
, O 
here O 
we O 
show O 
that O 
staurosporine B-TRIVIAL 
does O 
not O 
affect O 
PDK1 O 
phosphorylation O 
of O 
the O 
endogenous O 
PKMζ O 
in O 
hippocampal O 
slices O 
. O 
Thus O 
, O 
the O 
biochemical O 
in O 
vitro O 
effects O 
of O 
PKMζ O 
inhibitors O 
correspond O 
with O 
their O 
intracellular O 
effects O 
, O 
and O 
ZIP B-ABBREVIATION 
and O 
chelerythrine B-TRIVIAL 
, O 
together O 
with O 
scrambled O 
ZIP B-ABBREVIATION 
and O 
staurosporine B-TRIVIAL 
as O 
controls O 
, O 
are O 
effective O 
tools O 
to O 
examine O 
the O 
function O 
of O 
PKMζ O 
in O 
neurons O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

uterine O 
myoma O 
pseudocapsule O 
is O 
a O 
neurovascular O 
bundle O 
surrounding O 
fibroid O 
, O 
containing O 
neuropeptides O 
, O 
probably O 
involved O 
in O 
uterine O 
scar O 
healing O 
. O 
We O 
studied O 
neurotensin B-TRIVIAL 
( O 
NT O 
) O 
, O 
neuropeptide O 
tyrosine B-TRIVIAL 
( O 
NPY O 
) O 
, O 
and O 
protein O 
gene O 
product O 
9.5 O 
( O 
PGP O 
9.5 O 
) O 
nerve O 
fibres O 
in O 
the O 
pseudocapsule O 
neurovascular O 
bundle O 
of O 
intramural O 
uterine O 
fibroids O 
on O 
67 O 
no O 
pregnant O 
women O 
by O 
intracapsular O 
myomectomy O 
sparing O 
the O 
neurovascular O 
bundle O 
, O 
sampling O 
full O 
thickness O 
specimens O 
of O 
the O 
pseudocapsule O 
of O 
uterine O 
fibroids O 
( O 
PUF O 
) O 
and O 
normal O 
myometrium O 
( O 
NM O 
) O 
obtained O 
from O 
the O 
fundus O 
uteri O 
( O 
FU O 
) O 
and O 
the O 
uterine O 
body O 
( O 
UB O 
) O 
. O 
The O 
samples O 
were O 
sent O 
for O 
histological O 
and O 
immunofluorescent O 
analyses O 
and O 
compared O 
by O 
morphometrical O 
quantification O 
. O 
The O 
Conventional O 
Unit O 
( O 
C.U O 
. O 
) O 
difference O 
of O 
NT O 
, O 
NPY O 
, O 
and O 
PGP O 
9.5 O 
nerve O 
fibres O 
was O 
statistically O 
analyzed O 
. O 
Our O 
results O 
showed O 
that O 
NT O 
, O 
NPY O 
, O 
and O 
PGP O 
9.5 O 
neurofibers O 
are O 
almost O 
equally O 
present O 
in O 
PUF O 
as O 
in O 
NM O 
of O 
a O 
no O 
pregnant O 
uterus O 
. O 
As O 
all O 
of O 
these O 
neuropeptides O 
are O 
present O 
in O 
the O 
uterine O 
muscle O 
and O 
can O 
affect O 
muscle O 
contractility O 
, O 
uterine O 
peristalsis O 
and O 
muscular O 
healing O 
. O 
A O 
myomectomy O 
respecting O 
the O 
pseudocapsule O 
neurofibers O 
should O 
facilitate O 
smooth O 
muscle O 
scarring O 
and O 
promote O 
restoration O 
of O 
normal O 
uterine O 
peristalsis O 
with O 
a O 
possible O 
positive O 
influence O 
on O 
fertility O 
. O 

hormone O 
leptin O 
is O 
a O 
critical O 
regulator O 
of O 
adipogenesis O 
and O 
energy O 
metabolism O 
. O 
Similarly O 
, O 
leptin O 
- O 
deficient O 
ob O 
/ O 
ob O 
mice O 
display O 
various O 
metabolic O 
abnormalities O 
, O 
including O 
not O 
only O 
obesity O 
and O 
insulin O 
resistance O 
, O 
but O 
also O 
hypogonadism O 
and O 
high O 
bone O 
mass O 
. O 
By O 
genome O 
- O 
wide O 
expression O 
analysis O 
using O 
hypothalamus O 
RNA O 
from O 
wild O 
- O 
type O 
and O 
ob O 
/ O 
ob O 
mice O 
, O 
we O 
observed O 
the O 
increased O 
expression O 
of O 
the O 
gene O 
for O 
transthyretin O 
( O 
Ttr O 
) O 
in O 
the O 
latter O 
, O 
as O 
confirmed O 
by O 
quantitative O 
real O 
- O 
time O 
- O 
polymerase O 
chain O 
reaction O 
. O 
Because O 
Ttr O 
encodes O 
a O 
carrier O 
protein O 
for O 
retinol O 
transport O 
, O 
and O 
because O 
we O 
further O 
found O 
increased O 
retinol O 
levels O 
in O 
the O 
serum O 
of O 
ob O 
/ O 
ob O 
mice O 
, O 
we O 
investigated O 
whether O 
the O 
additional O 
absence O 
of O 
Ttr O 
would O 
influence O 
the O 
ob O 
/ O 
ob O 
phenotype O 
. O 
It O 
was O 
found O 
that O 
Ttr O 
- O 
deficient O 
ob O 
/ O 
ob O 
mice O 
were O 
indistinguishable O 
from O 
ob O 
/ O 
ob O 
littermates O 
in O 
terms O 
of O 
body O 
weight O 
, O 
as O 
well O 
as O 
serum O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
cholesterol B-TRIVIAL 
levels O 
. O 
Although O 
all O 
of O 
these O 
parameters O 
were O 
identical O 
to O 
wild O 
- O 
type O 
controls O 
in O 
Ttr O 
- O 
deficient O 
mice O 
, O 
we O 
found O 
that O 
the O 
sole O 
deletion O 
of O 
Ttr O 
caused O 
a O 
significant O 
increase O 
of O 
trabecular O 
bone O 
mass O 
, O 
bone O 
marrow O 
adiposity O 
and O 
mean O 
adipocyte O 
area O 
in O 
white O 
adipose O 
tissue O 
. O 
Interestingly O 
, O 
all O 
these O 
latter O 
parameters O 
were O 
highest O 
in O 
Ttr O 
- O 
deficient O 
ob O 
/ O 
ob O 
mice O 
, O 
and O 
only O 
in O 
these O 
mice O 
did O 
we O 
observe O 
a O 
full O 
penetrance O 
of O 
liver O 
steatosis O 
at O 
24 O 
weeks O 
of O 
age O 
. O 
Taken O 
together O 
, O 
our O 
data O 
demonstrate O 
that O 
the O 
increased O 
expression O 
of O 
Ttr O 
in O 
ob O 
/ O 
ob O 
mice O 
does O 
not O 
cause O 
( O 
but O 
rather O 
attenuates O 
) O 
their O 
phenotypic O 
abnormalities O 
. O 

of O 
fenofibrate B-TRIVIAL 
, O 
a O 
PPAR-α O 
ligand O 
, O 
on O 
the O 
haemodynamics O 
of O 
glycerol B-TRIVIAL 
-induced O 
renal O 
failure O 
in O 
rats O 
. O 

modulating O 
effect O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
ligand O 
on O 
haemodynamic O 
effects O 
of O 
phenylepherine B-TRIVIAL 
( O 
PE O 
) O 
, O 
angiotensin O 
II O 
( O 
AII O 
) O 
, O 
endothelin O 
1 O 
( O 
ET1 O 
) O 
, O 
acetylcholine B-SYSTEMATIC 
( O 
Ach B-ABBREVIATION 
) O 
, O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
( O 
SNP B-ABBREVIATION 
) O 
and O 
isoproterenol B-TRIVIAL 
( O 
ISO B-ABBREVIATION 
) O 
were O 
evaluated O 
in O 
glycerol B-TRIVIAL 
-induced O 
acute O 
kidney O 
injury O 
in O 
rats O 
. O 
The O 
effect O 
of O 
PE O 
on O 
fenofibrate B-TRIVIAL 
-treated O 
animals O 
was O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
mean O 
arterial O 
blood O 
pressure O 
( O 
MAP O 
) O 
. O 
For O 
AII O 
and O 
ET1 O 
, O 
MAP O 
was O 
also O 
increased O 
for O 
the O 
fenofibrate B-TRIVIAL 
group O 
but O 
not O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
. O 
On O 
the O 
medullary O 
blood O 
flow O 
( O 
MBF O 
) O 
, O 
while O 
the O 
lower O 
doses O 
of O 
PE O 
and O 
AII O 
increased O 
the O 
perfusion O 
unit O 
on O 
the O 
fenofibrate B-TRIVIAL 
-treated O 
group O 
, O 
the O 
higher O 
doses O 
decreased O 
the O 
perfusion O 
unit O 
. O 
The O 
ET1 O 
increased O 
the O 
perfusion O 
unit O 
on O 
this O 
group O 
but O 
not O 
in O 
dose O 
- O 
dependent O 
fashion O 
. O 
The O 
effects O 
of O 
PE O 
and O 
AII O 
on O 
the O 
cortical O 
blood O 
flow O 
( O 
CBF O 
) O 
of O 
fenofibrate B-TRIVIAL 
-treated O 
group O 
is O 
similar O 
to O 
that O 
of O 
MBF O 
for O 
the O 
same O 
group O 
but O 
not O 
for O 
ET1 O 
. O 
The O 
effect O 
of O 
Ach B-ABBREVIATION 
, O 
SNP B-ABBREVIATION 
and O 
ISO B-ABBREVIATION 
in O 
all O 
the O 
groups O 
was O 
the O 
decrease O 
in O 
MAP O 
. O 
ISO B-ABBREVIATION 
caused O 
dose O 
- O 
dependent O 
increase O 
in O 
MBF O 
of O 
fenofibrate B-TRIVIAL 
-treated O 
group O 
. O 
The O 
effect O 
of O 
Ach B-ABBREVIATION 
, O 
SNP B-ABBREVIATION 
and O 
ISO B-ABBREVIATION 
on O 
the O 
CBF O 
perfusion O 
unit O 
was O 
that O 
of O 
the O 
increase O 
for O 
the O 
fenofibrate B-TRIVIAL 
-treated O 
group O 
. O 
The O 
study O 
showed O 
that O 
fenofibrate B-TRIVIAL 
did O 
not O 
attenuate O 
increased O 
blood O 
pressure O 
induced O 
by O 
PE O 
, O 
AII O 
and O 
ET1 O 
but O 
caused O 
enhanced O 
vasodilation O 
by O 
Ach B-ABBREVIATION 
, O 
SNP B-ABBREVIATION 
and O 
ISO B-ABBREVIATION 
. O 

characterised O 
62 O 
non-diabetic O 
, O 
middle O 
- O 
aged O 
, O 
Caucasians O 
with O 
and O 
without O 
the O 
T O 
risk O 
allele O 
of O 
rs7903146 O 
in O 
transcription O 
factor O 
7- O 
like O 
2 O 
( O 
TCF7L2 O 
) O 
with O 
regard O 
to O 
secretion O 
of O 
insulin O 
, O 
glucagon O 
, O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
polypeptide O 
( O 
GIP O 
) O 
, O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
as O 
well O 
as O 
insulin O 
sensitivity O 
and O 
endogenous O 
glucose B-TRIVIAL 
production O 
. O 
All O 
participants O 
had O 
a O 
3-h O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
, O 
an O 
intravenous O 
glucose B-TRIVIAL 
tolerance O 
test O 
and O 
a O 
euglycaemic O 
, O 
hyperinsulinaemic O 
clamp O 
. O 
After O 
adjustment O 
for O 
age O 
and O 
sex O 
, O 
risk O 
T O 
allele O 
carriers O 
had O 
higher O 
haemoglobin O 
A1c O 
levels O 
( O 
p O 
= O 
0.03 O 
) O 
, O 
reduced O 
first O 
- O 
phase O 
insulin O 
response O 
( O 
p O 
= O 
0.048 O 
) O 
, O 
higher O 
peripheral O 
insulin O 
sensitivity O 
( O 
p O 
= O 
0.05 O 
) O 
and O 
lower O 
fasting O 
GIP O 
concentrations O 
( O 
p O 
= O 
0.003 O 
) O 
than O 
CC O 
allele O 
carriers O 
. O 
The O 
latter O 
was O 
also O 
reflected O 
by O 
lower O 
total O 
GIP O 
secretion O 
during O 
the O 
OGTT O 
( O 
p O 
= O 
0.018 O 
) O 
. O 
We O 
found O 
no O 
significant O 
differences O 
in O 
endogenous O 
glucose B-TRIVIAL 
production O 
, O 
hepatic O 
insulin O 
sensitivity O 
or O 
fasting O 
concentrations O 
of O 
glucose B-TRIVIAL 
, O 
insulin O 
, O 
glucagon O 
and O 
GLP-1 O 
between O 
the O 
groups O 
. O 
The O 
findings O 
suggest O 
that O 
the O 
effect O 
of O 
TCF7L2 O 
on O 
diabetes O 
risk O 
may O 
include O 
reduced O 
secretion O 
of O 
GIP O 
. O 

H(+) B-FORMULA 
-ATPase O 
( O 
V-ATPase O 
) O 
, O 
a O 
multisubunit O 
enzyme O 
located O 
at O 
the O 
ruffled O 
border O 
and O 
in O 
lysosomes O 
of O 
osteoclasts O 
, O 
is O 
necessary O 
for O 
bone O 
resorption O 
. O 
We O 
previously O 
showed O 
that O 
heterozygous O 
mice O 
with O 
an O 
R740S O 
mutation O 
in O 
the O 
a3 O 
subunit O 
of O 
V-ATPase O 
( O 
+ O 
/ O 
R740S O 
) O 
have O 
mild O 
osteopetrosis O 
resulting O 
from O 
an O 
∼90% O 
reduction O 
in O 
proton O 
translocation O 
across O 
osteoclast O 
membranes O 
. O 
Here O 
we O 
show O 
that O 
lysosomal O 
pH O 
is O 
also O 
higher O 
in O 
+ O 
/ O 
R740S O 
compared O 
with O 
wild O 
- O 
type O 
( O 
+ O 
/ O 
+ O 
) O 
osteoclasts O 
. O 
Both O 
osteoclast O 
number O 
and O 
size O 
were O 
decreased O 
in O 
cultures O 
of O 
+ O 
/ O 
R740S O 
compared O 
with O 
+ O 
/ O 
+ O 
bone O 
marrow O 
cells O 
, O 
with O 
concomitant O 
decreased O 
expression O 
of O 
key O 
osteoclast O 
markers O 
( O 
TRAP O 
, O 
cathepsin O 
K O 
, O 
OSCAR O 
, O 
DC-STAMP O 
, O 
and O 
NFATc1 O 
) O 
, O 
suggesting O 
that O 
low O 
lysosomal O 
pH O 
plays O 
an O 
important O 
role O 
in O 
osteoclastogenesis O 
. O 
To O 
elucidate O 
the O 
molecular O 
mechanism O 
of O 
this O 
inhibition O 
, O 
NFATc1 O 
activation O 
was O 
assessed O 
. O 
NFATc1 O 
nuclear O 
translocation O 
was O 
significantly O 
reduced O 
in O 
+ O 
/ O 
R740S O 
compared O 
with O 
+ O 
/ O 
+ O 
cells O 
; O 
however O 
, O 
this O 
was O 
not O 
because O 
of O 
impaired O 
enzymatic O 
activity O 
of O 
calcineurin O 
, O 
the O 
phosphatase O 
responsible O 
for O 
NFATc1 O 
dephosphorylation O 
. O 
Protein O 
and O 
RNA O 
expression O 
levels O 
of O 
regulator O 
of O 
calcineurin O 
1 O 
( O 
RCAN1 O 
) O 
, O 
an O 
endogenous O 
inhibitor O 
of O 
NFATc1 O 
activation O 
and O 
a O 
protein O 
degraded O 
in O 
lysosomes O 
, O 
were O 
not O 
significantly O 
different O 
between O 
+ O 
/ O 
R740S O 
and O 
+ O 
/ O 
+ O 
osteoclasts O 
, O 
but O 
the O 
RCAN1 O 
/ O 
NFATc1 O 
ratio O 
was O 
significantly O 
higher O 
in O 
+ O 
/ O 
R740S O 
versus O 
+ O 
/ O 
+ O 
cells O 
. O 
The O 
lysosomal O 
inhibitor O 
chloroquine B-TRIVIAL 
significantly O 
increased O 
RCAN1 O 
accumulation O 
in O 
+ O 
/ O 
+ O 
cells O 
, O 
consistent O 
with O 
the O 
hypothesis O 
that O 
higher O 
lysosomal O 
pH O 
impairs O 
RCAN1 O 
degradation O 
, O 
leading O 
to O 
a O 
higher O 
RCAN1 O 
/ O 
NFATc1 O 
ratio O 
and O 
consequently O 
NFATc1 O 
inhibition O 
. O 
Our O 
data O 
indicate O 
that O 
increased O 
lysosomal O 
pH O 
in O 
osteoclasts O 
leads O 
to O 
decreased O 
NFATc1 O 
signaling O 
and O 
nuclear O 
translocation O 
, O 
resulting O 
in O 
a O 
cell O 
autonomous O 
impairment O 
of O 
osteoclastogenesis O 
in O 
vitro O 
. O 

profiling O 
of O 
TRPV1 O 
antagonists O 
of O 
the O 
benzothiazole B-SYSTEMATIC 
amide I-SYSTEMATIC 
series O 
: O 
implications O 
for O 
in O 
vitro O 
genotoxicity O 
assessment O 
. O 

vitro O 
metabolic O 
profiling O 
and O 
in O 
vitro O 
genotoxicity O 
assessment O 
are O 
important O 
aspects O 
of O 
the O 
drug O 
discovery O 
program O 
as O 
they O 
eliminate O 
harmful O 
compounds O 
from O 
further O 
development O 
. O 
In O 
standard O 
in O 
vitro O 
genotoxicity O 
testing O 
, O 
induced O 
rat O 
liver O 
S9 O 
is O 
used O 
as O 
an O 
exogenous O 
bio O 
- O 
activation O 
system O 
for O 
detecting O 
promutagens O 
. O 
In O 
this O 
study O 
we O 
show O 
that O 
rat O 
liver O 
S9 O 
is O 
an O 
insufficient O 
system O 
regarding O 
the O 
conversion O 
of O 
TRPV1 O 
antagonists O 
of O 
the O 
benzothiazole B-SYSTEMATIC 
amide I-SYSTEMATIC 
series O 
into O 
relevant O 
in O 
vivo O 
metabolites O 
. O 
Human O 
and O 
rat O 
hepatocyte O 
experiments O 
demonstrated O 
generation O 
of O 
an O 
aryl B-FAMILY 
amine I-FAMILY 
metabolite O 
that O 
was O 
subsequently O 
N B-FORMULA 
-acetylated O 
. O 
The O 
hydrolyzed O 
metabolites O 
as O 
well O 
as O 
the O 
parent O 
compound O 
were O 
also O 
metabolized O 
into O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
conjugates O 
. O 
Rat O 
liver O 
S9 O 
exhibited O 
a O 
very O 
low O 
amide B-FAMILY 
hydrolysis O 
capacity O 
and O 
no O 
formation O 
of O 
GSH B-ABBREVIATION 
conjugates O 
when O 
supplemented O 
with O 
NADPH B-ABBREVIATION 
and O 
GSH B-ABBREVIATION 
. O 
The O 
discrepancy O 
in O 
metabolic O 
capability O 
between O 
hepatocytes O 
and O 
rat O 
liver O 
S9 O 
led O 
to O 
confounding O 
results O 
in O 
in O 
vitro O 
genotoxicity O 
assessment O 
for O 
this O 
chemical O 
class O 
as O 
judged O 
by O 
the O 
results O 
of O 
Ames O 
test O 
, O 
mouse O 
lymphoma O 
assay O 
, O 
SOS O 
/ O 
umu O 
test O 
and O 
Comet O 
assay O 
in O 
rat O 
hepatocytes O 
. O 
This O 
study O 
highlights O 
the O 
pivotal O 
role O 
that O 
understanding O 
the O 
mechanism O 
of O 
metabolite O 
formation O 
has O 
in O 
interpreting O 
as O 
well O 
as O 
designing O 
reliable O 
and O 
relevant O 
in O 
vitro O 
genotoxicity O 
experiments O 
. O 

impact O 
of O 
FANCD2 O 
deficiency O 
on O 
formaldehyde B-SYSTEMATIC 
-induced O 
toxicity O 
in O 
human O 
lymphoblastoid O 
cell O 
lines O 
. O 

( O 
FA O 
) O 
, O 
a O 
major O 
industrial O 
chemical O 
and O 
ubiquitous O 
environmental O 
pollutant O 
, O 
has O 
recently O 
been O 
classified O 
by O 
the O 
International O 
Agency O 
for O 
Research O 
on O 
Cancer O 
as O 
a O 
human O 
leukemogen O 
. O 
The O 
major O 
mode O 
of O 
action O 
of O 
FA O 
is O 
thought O 
to O 
be O 
the O 
formation O 
of O 
DNA O 
- O 
protein O 
cross O 
- O 
links O 
( O 
DPCs O 
) O 
. O 
Repair O 
of O 
DPCs O 
may O 
be O 
mediated O 
by O 
the O 
Fanconi O 
anemia O 
pathway O 
; O 
however O 
, O 
data O 
supporting O 
the O 
involvement O 
of O 
this O 
pathway O 
are O 
limited O 
, O 
particularly O 
in O 
human O 
hematopoietic O 
cells O 
. O 
Therefore O 
, O 
we O 
assessed O 
the O 
role O 
of O 
FANCD2 O 
, O 
a O 
critical O 
component O 
of O 
the O 
Fanconi O 
anemia O 
pathway O 
, O 
in O 
FA-induced O 
toxicity O 
in O 
human O 
lymphoblast O 
cell O 
models O 
of O 
FANCD2 O 
deficiency O 
( O 
PD20 O 
cells O 
) O 
and O 
FANCD2 O 
sufficiency O 
( O 
PD20-D2 O 
cells O 
) O 
. O 
After O 
treatment O 
of O 
the O 
cells O 
with O 
0-150 O 
μM O 
FA O 
for O 
24 O 
h O 
, O 
DPCs O 
were O 
increased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
both O 
cell O 
lines O 
, O 
with O 
greater O 
increases O 
in O 
FANCD2-deficient O 
PD20 O 
cells O 
. O 
FA O 
also O 
induced O 
cytotoxicity O 
, O 
micronuclei O 
, O 
chromosome O 
aberrations O 
, O 
and O 
apoptosis O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
both O 
cell O 
lines O 
, O 
with O 
greater O 
increases O 
in O 
cytotoxicity O 
and O 
apoptosis O 
in O 
PD20 O 
cells O 
. O 
Increased O 
levels O 
of O 
γ-ATR O 
and O 
γ-H2AX O 
in O 
both O 
cell O 
lines O 
suggested O 
the O 
recognition O 
of O 
FA-induced O 
DNA O 
damage O 
; O 
however O 
, O 
the O 
induction O 
of O 
BRCA2 O 
was O 
compromised O 
in O 
FANCD2-deficient O 
PD20 O 
cells O 
, O 
potentially O 
reducing O 
the O 
capacity O 
to O 
repair O 
DPCs O 
. O 
Together O 
, O 
these O 
findings O 
suggest O 
that O 
FANCD2 O 
protein O 
and O 
the O 
Fanconi O 
anemia O 
pathway O 
are O 
essential O 
to O 
protect O 
human O 
lymphoblastoid O 
cells O 
against O 
FA O 
toxicity O 
. O 
Future O 
studies O 
are O 
needed O 
to O 
delineate O 
the O 
role O 
of O 
this O 
pathway O 
in O 
mitigating O 
FA-induced O 
toxicity O 
, O 
particularly O 
in O 
hematopoietic O 
stem O 
cells O 
, O 
the O 
target O 
cells O 
in O 
leukemia O 
. O 

- I-SYSTEMATIC 
keto I-SYSTEMATIC 
reductases O 
( O 
AKRs O 
) O 
metabolize O 
a O 
wide O 
range O 
of O 
substrates O 
, O 
including O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
, O 
generating O 
metabolites O 
( O 
o-quinones B-FAMILY 
) O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
which O 
are O 
capable O 
of O 
initiating O 
and O 
promoting O 
carcinogenesis O 
. O 
Exposure O 
to O 
PAHs B-ABBREVIATION 
, O 
their O 
metabolites O 
, O 
and O 
ROS O 
further O 
increase O 
AKRs O 
isoform O 
expression O 
that O 
may O 
amplify O 
oxidative O 
damage O 
. O 
Human O 
AKR O 
enzymes O 
are O 
highly O 
polymorphic O 
, O 
and O 
allelic O 
variants O 
may O 
contribute O 
to O 
different O 
AKRs O 
expression O 
in O 
individuals O 
. O 
Despite O 
the O 
importance O 
of O 
AKRs O 
in O 
PAHs B-ABBREVIATION 
metabolism O 
, O 
there O 
are O 
no O 
studies O 
that O 
evaluate O 
, O 
in O 
general O 
human O 
populations O 
, O 
the O 
effect O 
of O 
PAHs B-ABBREVIATION 
on O 
AKRs O 
expression O 
in O 
peripheral O 
blood O 
lymphocytes O 
( O 
PBLs O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
effect O 
of O 
tobacco O 
smoke O 
exposure O 
, O 
and O 
AKR1A1*2 O 
and O 
AKR1C3*2 O 
polymorphisms O 
, O 
on O 
AKR1A1 O 
and O 
AKR1C1-AKR1C3 O 
messenger O 
RNA O 
( O 
mRNA O 
) O 
levels O 
in O 
PBLs O 
from O 
smokers O 
. O 
In O 
the O 
smoker O 
group O 
, O 
there O 
is O 
a O 
statistically O 
significant O 
positive O 
association O 
between O 
AKR1A1 O 
, O 
AKR1C1 O 
, O 
and O 
AKR1C3 O 
mRNA O 
induction O 
and O 
urine O 
cotinine B-TRIVIAL 
levels O 
in O 
individuals O 
with O 
a O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
less O 
than O 
25 O 
. O 
However O 
, O 
AKR1A1*2 O 
and O 
AKR1C3*2 O 
alleles O 
did O 
not O 
influence O 
AKR1A1 O 
and O 
AKR1C1-AKR1C3 O 
mRNA O 
levels O 
. O 
These O 
results O 
suggest O 
that O 
AKRs O 
induction O 
by O 
PAHs B-ABBREVIATION 
in O 
smokers O 
' O 
PBLs O 
is O 
associated O 
with O 
BMI O 
; O 
therefore O 
, O 
the O 
role O 
of O 
adipose O 
tissue O 
accumulation O 
in O 
PAHs B-ABBREVIATION 
' O 
effects O 
needs O 
further O 
investigation O 
. O 

airway O 
smooth O 
muscle O 
( O 
ASM O 
) O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathophysiology O 
of O 
asthma O 
and O 
chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
. O 
ASM O 
cells O 
express O 
a O 
wide O 
range O 
of O 
receptors O 
involved O 
in O 
contraction O 
, O 
growth O 
, O 
matrix O 
protein O 
production O 
and O 
the O 
secretion O 
of O 
cytokines O 
and O 
chemokines O 
. O 
Transforming O 
growth O 
factor O 
beta O 
( O 
TGF-β O 
) O 
is O 
one O 
of O 
the O 
major O 
players O 
in O 
determining O 
the O 
structural O 
and O 
functional O 
abnormalities O 
of O 
the O 
ASM O 
in O 
asthma O 
and O 
COPD O 
. O 
It O 
is O 
increasingly O 
evident O 
that O 
TGF-β O 
functions O 
as O 
a O 
master O 
switch O 
, O 
controlling O 
a O 
network O 
of O 
intracellular O 
and O 
autocrine O 
signaling O 
loops O 
that O 
effect O 
ASM O 
phenotype O 
and O 
function O 
. O 
In O 
this O 
review O 
, O 
the O 
various O 
elements O 
that O 
participate O 
in O 
non-canonical O 
TGF-β O 
signaling O 
, O 
including O 
MAPK O 
, O 
PI3K O 
, O 
WNT O 
/ O 
β-catenin O 
, O 
and O 
Ca(2+) B-FORMULA 
, O 
are O 
discussed O 
, O 
focusing O 
on O 
their O 
effect O 
on O 
ASM O 
phenotype O 
and O 
function O 
. O 
In O 
addition O 
, O 
new O 
aspects O 
of O 
ASM O 
biology O 
and O 
their O 
possible O 
association O 
with O 
non-canonical O 
TGF-β O 
signaling O 
will O 
be O 
discussed O 
. O 

, O 
oxygen B-SYSTEMATIC 
or O 
sulfur B-SYSTEMATIC 
containing O 
heterocyclic O 
compounds O 
as O 
analgesic O 
drugs O 
used O 
as O 
modulators O 
of O 
the O 
nitroxidative O 
stress O 
. O 

lines O 
of O 
evidence O 
suggest O 
that O 
heterocyclic O 
compounds O 
used O 
as O 
analgesic O 
, O 
anti-inflammatory O 
and O 
anti-migraine O 
agents O 
can O 
be O 
potent O 
regulators O 
of O 
the O 
nitroxidative O 
stress O 
and O 
targeting O 
free O 
nitrogen B-SYSTEMATIC 
and O 
oxygen B-SYSTEMATIC 
radicals O 
is O 
a O 
very O 
promising O 
strategy O 
for O 
future O 
pain O 
management O 
. O 
Both O 
classical O 
analgesics O 
( O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
, O 
opioid O 
drugs O 
) O 
and O 
many O 
analgesic O 
adjuvants O 
, O 
including O 
desipramine B-TRIVIAL 
, O 
duloxetine B-TRIVIAL 
, O 
fluoxetine B-TRIVIAL 
, O 
paroxetine B-TRIVIAL 
, O 
escitalopram B-TRIVIAL 
, O 
phenytoin B-TRIVIAL 
or O 
carbamazepine B-TRIVIAL 
and O 
α-lipoic B-TRIVIAL 
acid I-TRIVIAL 
can O 
modulate O 
the O 
balance O 
between O 
pro O 
- O 
oxidant O 
and O 
antioxidant O 
processes O 
in O 
the O 
mammalian O 
tissues O 
and O 
these O 
properties O 
of O 
drugs O 
such O 
as O 
indomethacin B-TRIVIAL 
, O 
meloxicam B-TRIVIAL 
, O 
tenoxicam B-TRIVIAL 
, O 
valdecoxib B-TRIVIAL 
or O 
some O 
metabolites O 
of O 
analgesic O 
drugs O 
formed O 
by O 
the O 
activity O 
of O 
tissue O 
peroxidases O 
may O 
contribute O 
to O 
their O 
clinical O 
efficacy O 
and O 
drug O 
- O 
related O 
toxic O 
effects O 
, O 
including O 
gastrointestinal O 
ulcers O 
, O 
hepatic O 
failure O 
, O 
agranulocytosis O 
, O 
aplastic O 
anemia O 
, O 
neutropenia O 
, O 
opiate O 
- O 
induced O 
hyperalgesia O 
and O 
tolerance O 
. O 
The O 
antioxidant O 
capacities O 
of O 
novel O 
heterocyclic O 
compounds O 
, O 
including O 
the O 
compounds O 
acting O 
either O 
by O 
prevention O 
of O 
formation O 
or O 
catalyzed O 
decomposition O 
of O 
peroxynitrite B-SYSTEMATIC 
anion O 
( O 
ONOO- B-FORMULA 
) O 
, O 
namely O 
the O 
peroxynitrite B-SYSTEMATIC 
decomposition O 
catalysts O 
or O 
as O 
superoxide B-TRIVIAL 
( O 
O2 B-FORMULA 
•- I-FORMULA 
)-scavengers O 
which O 
are O 
the O 
functional O 
mimetics O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
enzymes O 
( O 
SODm O 
) O 
, O 
as O 
well O 
as O 
the O 
derivatives O 
of O 
6-nitro-3,4-methylenedioxyphenyl-Nacylhydrazone B-SYSTEMATIC 
( O 
LASSBio-881 B-IDENTIFIER 
) O 
or O 
γ-butyrolactone B-SYSTEMATIC 
( O 
LPP1 O 
, O 
BM113 O 
, O 
BM113A O 
, O 
BM138 O 
and O 
BM138A O 
) O 
are O 
also O 
discussed O 
as O 
potent O 
and O 
promising O 
future O 
heterocyclic O 
analgesics O 
. O 

human O 
Aurora O 
kinase O 
inhibitor O 
danusertib B-TRIVIAL 
is O 
a O 
lead O 
compound O 
for O 
anti-trypanosomal O 
drug O 
discovery O 
via O 
target O 
repurposing O 
. O 

drugs O 
for O 
neglected O 
tropical O 
diseases O 
such O 
as O 
human O 
African O 
trypanosomiasis O 
( O 
HAT O 
) O 
are O 
needed O 
, O 
yet O 
drug O 
discovery O 
efforts O 
are O 
not O 
often O 
focused O 
on O 
this O 
area O 
due O 
to O 
cost O 
. O 
Target O 
repurposing O 
, O 
achieved O 
by O 
the O 
matching O 
of O 
essential O 
parasite O 
enzymes O 
to O 
those O 
human O 
enzymes O 
that O 
have O 
been O 
successfully O 
inhibited O 
by O 
small O 
molecule O 
drugs O 
, O 
provides O 
an O 
attractive O 
means O 
by O 
which O 
new O 
drug O 
optimization O 
programs O 
can O 
be O 
pragmatically O 
initiated O 
. O 
In O 
this O 
report O 
we O 
describe O 
our O 
results O 
in O 
repurposing O 
an O 
established O 
class O 
of O 
human O 
Aurora O 
kinase O 
inhibitors O 
, O 
typified O 
by O 
danusertib B-TRIVIAL 
( O 
1 O 
) O 
, O 
which O 
we O 
have O 
observed O 
to O 
be O 
an O 
inhibitor O 
of O 
trypanosomal O 
Aurora O 
kinase O 
1 O 
( O 
TbAUK1 O 
) O 
and O 
effective O 
in O 
parasite O 
killing O 
in O 
vitro O 
. O 
Informed O 
by O 
homology O 
modeling O 
and O 
docking O 
, O 
a O 
series O 
of O 
analogs O 
of O 
1 O 
were O 
prepared O 
that O 
explored O 
the O 
scope O 
of O 
the O 
chemotype O 
and O 
provided O 
a O 
nearly O 
25-fold O 
improvement O 
in O 
cellular O 
selectivity O 
for O 
parasite O 
cells O 
over O 
human O 
cells O 
. O 

of O 
benzo(a)pyrene B-SYSTEMATIC 
-induced O 
colon O 
polyps O 
in O 
ApcMin O 
mice O 
by O 
resveratrol B-TRIVIAL 
. O 

dietary O 
exposure O 
to O 
benzo(a)pyrene B-SYSTEMATIC 
( O 
BaP B-ABBREVIATION 
) O 
has O 
generated O 
interest O 
with O 
regard O 
to O 
the O 
association O 
of O 
BaP B-ABBREVIATION 
with O 
gastrointestinal O 
carcinogenesis O 
. O 
Since O 
colon O 
cancer O 
ranks O 
third O 
among O 
cancer O 
- O 
related O 
mortalities O 
, O 
it O 
is O 
necessary O 
to O 
evaluate O 
the O 
effect O 
of O 
phytochemicals O 
on O 
colon O 
cancer O 
initiation O 
and O 
progression O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
preventive O 
effects O 
of O 
resveratrol B-TRIVIAL 
( O 
RVT B-ABBREVIATION 
) O 
on O 
BaP B-ABBREVIATION 
-induced O 
colon O 
carcinogenesis O 
in O 
Apc(Min) O 
mouse O 
model O 
. O 
For O 
the O 
first O 
group O 
of O 
mice O 
, O 
100 O 
μg O 
BaP B-ABBREVIATION 
/ O 
kg O 
body O 
weight O 
was O 
administered O 
to O 
mice O 
in O 
peanut O 
oil O 
via O 
oral O 
gavage O 
over O 
a O 
60-day O 
period O 
. O 
For O 
the O 
second O 
group O 
, O 
RVT B-ABBREVIATION 
was O 
coadministered O 
with O 
BaP B-ABBREVIATION 
at O 
a O 
dose O 
of O 
45 O 
μg O 
/ O 
kg O 
. O 
For O 
the O 
third O 
group O 
, O 
RVT B-ABBREVIATION 
was O 
administered O 
for O 
1 O 
week O 
prior O 
to O 
BaP B-ABBREVIATION 
exposure O 
for O 
60 O 
days O 
. O 
Jejunum O 
, O 
colon O 
and O 
liver O 
were O 
collected O 
at O 
60 O 
days O 
post O 
BaP B-ABBREVIATION 
and O 
RVT B-ABBREVIATION 
exposure O 
; O 
adenomas O 
in O 
jejunum O 
and O 
colon O 
were O 
counted O 
and O 
subjected O 
to O 
histopathology O 
. O 
RVT B-ABBREVIATION 
reduced O 
the O 
number O 
of O 
colon O 
adenomas O 
in O 
BaP B-ABBREVIATION 
+ O 
RVT B-ABBREVIATION 
-treated O 
mice O 
significantly O 
compared O 
to O 
that O 
in O 
mice O 
that O 
received O 
BaP B-ABBREVIATION 
alone O 
. O 
While O 
dysplasia O 
of O 
varying O 
degrees O 
was O 
noted O 
in O 
colon O 
of O 
BaP B-ABBREVIATION 
-treated O 
mice O 
, O 
the O 
dysplasias O 
were O 
of O 
limited O 
occurrence O 
in O 
RVT B-ABBREVIATION 
-treated O 
mice O 
. O 
To O 
ascertain O 
whether O 
the O 
tumor O 
inhibition O 
is O 
a O 
result O 
of O 
altered O 
BaP B-ABBREVIATION 
-induced O 
toxicity O 
of O 
tumor O 
cells O 
, O 
growth O 
, O 
apoptosis O 
and O 
proliferation O 
of O 
adenocarcinoma O 
cells O 
were O 
assessed O 
posttreatment O 
with O 
RVT B-ABBREVIATION 
and O 
BaP B-ABBREVIATION 
. O 
Cotreatment O 
with O 
RVT B-ABBREVIATION 
increased O 
apoptosis O 
and O 
decreased O 
cell O 
proliferation O 
to O 
a O 
greater O 
extent O 
than O 
with O 
BaP B-ABBREVIATION 
alone O 
. O 
Overall O 
, O 
our O 
observations O 
reveal O 
that O 
RVT B-ABBREVIATION 
inhibits O 
colon O 
tumorigenesis O 
when O 
given O 
together O 
with O 
BaP B-ABBREVIATION 
and O 
holds O 
promise O 
as O 
a O 
therapeutic O 
agent O 
. O 

of O 
a O 
subchondral O 
fracture O 
is O 
one O 
of O 
the O 
earliest O 
signs O 
of O 
structural O 
failure O 
of O 
the O 
immature O 
femoral O 
head O 
following O 
ischemic O 
osteonecrosis O 
, O 
and O 
this O 
eventually O 
leads O 
to O 
a O 
flattening O 
deformity O 
of O 
the O 
femoral O 
head O 
. O 
The O 
mechanical O 
and O 
mineralization O 
changes O 
in O 
the O 
femoral O 
head O 
preceding O 
subchondral O 
fracture O 
have O 
not O 
been O 
elucidated O 
. O 
We O 
hypothesized O 
that O 
ischemic O 
osteonecrosis O 
leads O 
to O 
early O 
material O 
and O 
mechanical O 
alterations O 
in O 
the O 
bone O 
of O 
the O 
subchondral O 
region O 
. O 
The O 
purpose O 
of O 
this O 
investigation O 
was O 
to O 
assess O 
the O 
bone O 
of O 
the O 
subchondral O 
region O 
for O 
changes O 
in O 
the O 
histology O 
of O 
bone O 
cells O 
, O 
microcrack O 
density O 
, O 
mineral O 
content O 
, O 
and O 
nanoindentation O 
properties O 
at O 
an O 
early O 
stage O 
of O 
ischemic O 
osteonecrosis O 
in O 
a O 
piglet O 
model O 
. O 
This O 
large O 
animal O 
model O 
has O 
been O 
shown O 
to O 
develop O 
a O 
subchondral O 
fracture O 
and O 
femoral O 
head O 
deformity O 
resembling O 
juvenile O 
femoral O 
head O 
osteonecrosis O 
. O 
The O 
unoperated O 
, O 
left O 
femoral O 
head O 
of O 
each O 
piglet O 
( O 
n=8 O 
) O 
was O 
used O 
as O 
a O 
normal O 
control O 
, O 
while O 
the O 
right O 
side O 
had O 
a O 
surgical O 
ischemia O 
induced O 
by O 
disrupting O 
the O 
femoral O 
neck O 
vessels O 
with O 
a O 
ligature O 
. O 
Hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
( O 
H&E O 
) O 
staining O 
and O 
TUNEL O 
assay O 
were O 
performed O 
on O 
femoral O 
heads O 
from O 
3 O 
piglets O 
. O 
Quantitative O 
backscattered O 
electron O 
imaging O 
, O 
nanoindentation O 
, O 
and O 
microcrack O 
assessments O 
were O 
performed O 
on O 
the O 
subchondral O 
region O 
of O 
both O 
control O 
and O 
ischemic O 
femoral O 
heads O 
from O 
5 O 
piglets O 
. O 
H&E O 
staining O 
and O 
TUNEL O 
assay O 
showed O 
extensive O 
cell O 
death O 
and O 
an O 
absence O 
of O 
osteoblasts O 
in O 
the O 
ischemic O 
side O 
compared O 
to O 
the O 
normal O 
control O 
. O 
Microcrack O 
density O 
in O 
the O 
ischemic O 
side O 
( O 
3.2±0.79 O 
cracks O 
/ O 
mm(2) O 
) O 
was O 
significantly O 
higher O 
compared O 
to O 
the O 
normal O 
side O 
( O 
0.27±0.27 O 
cracks O 
/ O 
mm(2) O 
) O 
in O 
the O 
subchondral O 
region O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
weighted O 
mean O 
of O 
the O 
weight O 
percent O 
distribution O 
of O 
calcium B-SYSTEMATIC 
( O 
CaMean O 
) O 
also O 
was O 
significantly O 
higher O 
in O 
the O 
ischemic O 
subchondral O 
region O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Furthermore O 
, O 
the O 
nanoindentation O 
modulus O 
within O 
localized O 
areas O 
of O 
subchondral O 
bone O 
was O 
significantly O 
increased O 
in O 
the O 
ischemic O 
side O 
( O 
16.8±2.7GPa O 
) O 
compared O 
to O 
the O 
normal O 
control O 
( O 
13.3±3.2GPa O 
) O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Taken O 
together O 
, O 
these O 
results O 
support O 
the O 
hypothesis O 
that O 
the O 
nanoindentation O 
modulus O 
of O 
the O 
subchondral O 
trabecular O 
bone O 
is O 
increased O 
in O 
the O 
early O 
stage O 
of O 
ischemic O 
osteonecrosis O 
of O 
the O 
immature O 
femoral O 
head O 
and O 
makes O 
it O 
more O 
susceptible O 
to O 
microcrack O 
formation O 
. O 
We O 
postulate O 
that O 
continued O 
loading O 
of O 
the O 
hip O 
joint O 
when O 
there O 
is O 
a O 
lack O 
of O 
bone O 
cells O 
to O 
repair O 
the O 
microcracks O 
due O 
to O 
ischemic O 
osteonecrosis O 
leads O 
to O 
microcrack O 
accumulation O 
and O 
subsequent O 
subchondral O 
fracture O 
. O 

major O 
indole B-FAMILY 
alkaloid I-FAMILY 
N,β-D-glucopyranosyl B-TRIVIAL 
vincosamide I-TRIVIAL 
from O 
leaves O 
of O 
Psychotria O 
leiocarpa O 
Cham O 
. O 
& O 
Schltdl O 
. O 
is O 
not O 
an O 
antifeedant O 
but O 
shows O 
broad O 
antioxidant O 
activity O 
. O 

vincosamide I-TRIVIAL 
( O 
GPV B-ABBREVIATION 
) O 
, O 
a O 
major O 
alkaloid O 
of O 
Psychotria O 
leiocarpa O 
, O 
constitutes O 
up O 
to O 
2.5% O 
of O 
the O 
dry O 
weight O 
in O 
leaves O 
. O 
Alkaloid O 
content O 
was O 
not O 
elicited O 
by O 
mechanical O 
wounding O 
or O 
jasmonate O 
. O 
At O 
concentrations O 
found O 
in O 
natural O 
conditions O 
or O 
2.5 O 
fold O 
higher O 
, O 
GPV B-ABBREVIATION 
did O 
not O 
inhibit O 
herbivory O 
in O 
two O 
unrelated O 
generalist O 
models O 
( O 
Helix O 
aspersa O 
and O 
Spodoptera O 
frugiperda O 
) O 
or O 
in O 
a O 
specific O 
interaction O 
model O 
( O 
Heliconius O 
erato O 
fed O 
with O 
Passiflora O 
suberosa O 
) O 
. O 
In O 
situ O 
staining O 
assay O 
showed O 
quenching O 
activity O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
by O 
GPV B-ABBREVIATION 
. O 
Exposure O 
of O 
P O 
. O 
leiocarpa O 
to O 
acute O 
UV-B O 
stress O 
did O 
not O 
change O 
GPV B-ABBREVIATION 
or O 
chlorophyll B-FAMILY 
content O 
, O 
indicating O 
high O 
tolerance O 
to O 
this O 
stress O 
by O 
the O 
species O 
. O 
In O 
vitro O 
antioxidant O 
tests O 
against O 
singlet O 
oxygen B-SYSTEMATIC 
, O 
superoxide B-TRIVIAL 
anions O 
and O 
hydroxyl B-SYSTEMATIC 
radicals O 
showed O 
efficient O 
quenching O 
activity O 
of O 
the O 
alkaloid O 
. O 
GPV B-ABBREVIATION 
was O 
not O 
effective O 
as O 
antifeedant O 
, O 
but O 
it O 
may O 
act O 
indirectly O 
in O 
P O 
. O 
leiocarpa O 
protection O 
against O 
oxidative O 
stress O 
generated O 
upon O 
wounding O 
, O 
UV O 
exposure O 
and O 
perhaps O 
other O 
environmental O 
stresses O 
. O 

this O 
study O 
we O 
analyzed O 
some O 
aspects O 
of O 
the O 
assessment O 
of O 
developmental O 
delay O 
in O 
the O 
zebrafish O 
embryotoxicity O 
/ O 
teratogenicity O 
test O 
and O 
explored O 
the O 
suitability O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
as O 
a O 
biochemical O 
marker O 
and O 
as O 
a O 
higher O 
throughput O 
alternative O 
to O 
morphological O 
endpoints O 
such O 
as O 
head O 
- O 
trunk O 
angle O 
, O 
tail O 
length O 
and O 
morphological O 
score O 
. O 
Embryos O 
were O 
exposed O 
from O 
4 O 
to O 
52 O 
h O 
post O 
- O 
fertilization O 
( O 
hpf O 
) O 
to O 
a O 
selection O 
of O 
known O 
embryotoxic O 
/ O 
teratogen O 
compounds O 
( O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
caffeine B-TRIVIAL 
, O 
sodium B-SYSTEMATIC 
salicylate I-SYSTEMATIC 
, O 
glucose B-TRIVIAL 
, O 
hydroxyurea B-SYSTEMATIC 
, O 
methoxyacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
boric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
paraoxon B-SYSTEMATIC 
- I-SYSTEMATIC 
methyl I-SYSTEMATIC 
) O 
over O 
a O 
concentration O 
range O 
. O 
They O 
were O 
evaluated O 
for O 
AChE O 
activity O 
, O 
head O 
- O 
trunk O 
angle O 
, O 
tail O 
length O 
and O 
several O 
qualitative O 
parameters O 
integrated O 
in O 
a O 
morphological O 
score O 
. O 
In O 
general O 
, O 
the O 
different O 
patterns O 
of O 
the O 
concentration O 
- O 
response O 
curves O 
allowed O 
distinguishing O 
between O 
chemicals O 
that O 
produced O 
growth O 
retardation O 
( O 
valproic B-MULTIPLE 
and I-MULTIPLE 
methoxyacetic I-MULTIPLE 
acid I-MULTIPLE 
) O 
and O 
chemicals O 
that O 
produced O 
non-growth O 
- O 
delay O 
related O 
malformations O 
. O 
An O 
acceptable O 
correlation O 
between O 
the O 
morphological O 
score O 
, O 
AChE O 
activity O 
and O 
head O 
- O 
trunk O 
angle O 
as O 
markers O 
of O 
developmental O 
delay O 
was O 
observed O 
, O 
being O 
AChE O 
activity O 
particularly O 
sensitive O 
to O 
detect O 
delay O 
in O 
the O 
absence O 
of O 
malformations O 
. O 

: O 
Effects O 
of O 
nanometer O 
- O 
sized O 
silver B-SYSTEMATIC 
materials O 
on O 
survival O 
response O 
of O 
Caspian O 
roach O 
( O 
Rutilus O 
rutilus O 
caspicus O 
) O 
. O 

vitro O 
anti-genotoxic O 
properties O 
of O 
bile O 
pigments O 
have O 
been O 
explored O 
and O 
confirmed O 
recently O 
. O 
Despite O 
these O 
reports O 
mechanisms O 
to O 
explain O 
DNA O 
protection O 
by O 
endogenous O 
bile O 
pigments O 
remain O 
unclear O 
. O 
Surprisingly O 
, O 
the O 
quantification O 
of O 
cellular O 
pigment O 
absorption O 
which O 
could O 
represent O 
a O 
fundamental O 
prerequisite O 
for O 
intracellular O 
( O 
e.g O 
. O 
, O 
anti-mutagenic O 
) O 
effects O 
, O 
has O 
not O 
been O 
explored O 
. O 
Therefore O 
, O 
we O 
aimed O 
to O 
measure O 
the O 
amounts O 
of O 
un- O 
/ O 
conjugated O 
bilirubin B-TRIVIAL 
as O 
well O 
as O 
biliverdin B-TRIVIAL 
absorbed O 
into O 
colonies O 
of O 
Salmonella O 
typhimurium O 
, O 
utilising O 
HPLC O 
analyses O 
, O 
and O 
to O 
observe O 
whether O 
intracellular O 
compound O 
concentrations O 
could O 
predict O 
anti-genotoxic O 
effects O 
. O 
HPLC O 
analyses O 
confirmed O 
that O 
bacterial O 
bile O 
pigment O 
absorption O 
was O 
concentration O 
- O 
dependent O 
. O 
Plate O 
bile O 
pigment O 
concentrations O 
were O 
inversely O 
associated O 
with O 
genotoxicity O 
of O 
all O 
tested O 
mutagens O 
, O 
irrespective O 
of O 
strain O 
and O 
test O 
conditions O 
. O 
However O 
, O 
protection O 
against O 
frame O 
- O 
shift O 
mutation O 
in O 
strain O 
TA98 O 
most O 
strongly O 
depended O 
on O 
the O 
bacterial O 
absorption O 
of O 
bilirubin B-TRIVIAL 
and O 
biliverdin B-TRIVIAL 
, O 
which O 
indicates O 
that O 
bile O 
pigments O 
can O 
protect O 
by O 
intercepting O 
mutations O 
extracellularly O 
and O 
specifically O 
inhibit O 
frame O 
- O 
shift O 
mutations O 
intracellularly O 
. O 

inducing O 
acute O 
irritant O 
contact O 
dermatitis O 
mobilize O 
intracellular O 
calcium B-SYSTEMATIC 
in O 
human O 
keratinocytes O 
. O 

Ca(2+) B-FORMULA 
increase O 
is O 
a O 
common O 
feature O 
of O 
multiple O 
cellular O 
pathways O 
associated O 
with O 
receptor O 
and O 
channel O 
activation O 
, O 
mediator O 
secretion O 
and O 
gene O 
regulation O 
. O 
We O 
investigated O 
the O 
possibility O 
of O 
using O 
this O 
Ca(2+) B-FORMULA 
signal O 
as O 
a O 
biomarker O 
for O 
a O 
reaction O 
to O 
chemical O 
irritants O 
of O 
normal O 
human O 
keratinocytes O 
( O 
NHK O 
) O 
in O 
submerged O 
primary O 
cell O 
culture O 
. O 
We O 
tested O 
14 O 
referenced O 
chemical O 
compounds O 
classified O 
as O 
strong O 
( O 
seven O 
) O 
, O 
weak O 
( O 
four O 
) O 
or O 
non- O 
( O 
three O 
) O 
irritants O 
in O 
acute O 
irritant O 
contact O 
dermatitis O 
. O 
We O 
found O 
that O 
the O 
strong O 
irritant O 
compounds O 
tested O 
at O 
20-40 O 
mM O 
induced O 
an O 
intracellular O 
Ca(2+) B-FORMULA 
increase O 
measurable O 
by O 
spectrofluorimetry O 
in O 
an O 
automated O 
test O 
. O 
Weak O 
and O 
non-irritant O 
compounds O 
however O 
did O 
not O 
increase O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
. O 
We O 
further O 
investigated O 
the O 
mechanisms O 
by O 
which O 
the O 
amine B-SYSTEMATIC 
heptylamine B-SYSTEMATIC 
, O 
classified O 
as O 
a O 
R34 O 
corrosive O 
compound O 
, O 
increases O 
intracellular O 
Ca(2+) B-FORMULA 
. O 
Heptylamine B-SYSTEMATIC 
( O 
20mM O 
) O 
induced O 
an O 
ATP B-ABBREVIATION 
release O 
that O 
persisted O 
in O 
the O 
absence O 
of O 
intra- O 
and O 
extra O 
- O 
cellular O 
Ca(2+) B-FORMULA 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
this O 
ATP B-ABBREVIATION 
activates O 
NHK O 
purinergic O 
receptors O 
that O 
subsequently O 
cause O 
the O 
increase O 
in O 
intracellular O 
Ca(2+) B-FORMULA 
from O 
sarcoplasmic O 
reticular O 
stores O 
. O 
We O 
conclude O 
that O 
measuring O 
the O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
in O 
NHK O 
is O 
a O 
suitable O 
and O 
easy O 
way O 
of O 
determining O 
any O 
potential O 
reaction O 
to O 
soluble O 
chemical O 
compounds O 
. O 

treatment O 
with O 
nanoparticle O 
containing O 
aerosols O 
appears O 
a O 
promising O 
new O 
therapeutic O 
option O 
but O 
new O 
formulations O 
have O 
to O 
be O 
assessed O 
for O 
efficacy O 
and O 
toxicity O 
. O 
We O 
evaluated O 
the O 
utility O 
of O 
a O 
VITROCELL®6 O 
PT-CF O 
+ O 
PARI O 
LC O 
SPRINT O 
® O 
Baby O 
Nebulizer O 
( O 
PARI O 
BOY O 
) O 
system O 
compared O 
with O 
a O 
conventional O 
MicroSprayer O 
. O 
A549 O 
cells O 
were O 
cultured O 
in O 
the O 
air O 
- O 
liquid O 
interface O 
, O 
exposed O 
to O 
nanoparticle O 
aerosols O 
and O 
characterized O 
by O 
measurement O 
of O 
transepithelial O 
electrical O 
resistance O 
and O 
staining O 
for O 
tight O 
junction O 
proteins O 
. O 
Deposition O 
and O 
distribution O 
rates O 
of O 
polystyrene B-SYSTEMATIC 
particles O 
and O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
on O 
the O 
cells O 
were O 
assessed O 
. O 
In O 
addition O 
, O 
cytotoxicity O 
of O 
aerosols O 
containing O 
polystyrene B-SYSTEMATIC 
particles O 
was O 
compared O 
with O 
cytotoxicity O 
of O 
polystyrene B-SYSTEMATIC 
particles O 
in O 
suspension O 
tested O 
in O 
submersed O 
cultures O 
. O 
Exposure O 
by O 
itself O 
in O 
both O 
exposure O 
systems O 
did O 
not O 
damage O 
the O 
cells O 
. O 
Deposition O 
rates O 
of O 
aerosolized O 
polystyrene B-SYSTEMATIC 
particles O 
were O 
about O 
700 O 
times O 
and O 
that O 
of O 
carbon B-SYSTEMATIC 
nanotubes O 
about O 
4 O 
times O 
higher O 
in O 
the O 
MicroSprayer O 
than O 
in O 
the O 
VITROCELL®6 O 
PT-CF O 
system O 
. O 
Cytotoxicity O 
of O 
amine B-SYSTEMATIC 
-functionalized O 
polystyrene B-SYSTEMATIC 
nanoparticles O 
was O 
significantly O 
higher O 
when O 
applied O 
as O 
an O 
aerosol O 
on O 
cell O 
cultured O 
in O 
air O 
- O 
liquid O 
interface O 
culture O 
compared O 
with O 
nanoparticle O 
suspensions O 
tested O 
in O 
submersed O 
culture O 
. O 
The O 
higher O 
cytotoxicity O 
of O 
aerosolized O 
nanoparticles O 
underscores O 
the O 
importance O 
of O 
relevant O 
exposure O 
systems O 
. O 

graphene B-TRIVIAL 
foams O 
. O 

static O 
and O 
dynamic O 
wetting O 
properties O 
of O 
a O 
3D O 
graphene B-TRIVIAL 
foam O 
network O 
are O 
reported O 
. O 
The O 
foam O 
is O 
synthesized O 
using O 
template O 
- O 
directed O 
chemical O 
vapor O 
deposition O 
and O 
contains O 
pores O 
several O 
hundred O 
micrometers O 
in O 
dimension O 
while O 
the O 
walls O 
of O 
the O 
foam O 
comprise O 
few O 
- O 
layer O 
graphene B-TRIVIAL 
sheets O 
that O 
are O 
coated O 
with O 
Teflon B-TRIVIAL 
. O 
Water O 
contact O 
angle O 
measurements O 
reveal O 
that O 
the O 
foam O 
is O 
superhydrophobic O 
with O 
an O 
advancing O 
contact O 
angle O 
of O 
∼163 O 
degrees O 
while O 
the O 
receding O 
contact O 
angle O 
is O 
∼143 O 
degrees O 
. O 
The O 
extremely O 
water O 
repellent O 
nature O 
of O 
the O 
foam O 
is O 
also O 
confirmed O 
when O 
impacting O 
water O 
droplets O 
are O 
able O 
to O 
completely O 
rebound O 
from O 
the O 
surface O 
. O 
Such O 
superhydrophobic O 
graphene B-TRIVIAL 
foams O 
show O 
potential O 
in O 
a O 
variety O 
of O 
applications O 
ranging O 
from O 
anti-sticking O 
and O 
self O 
- O 
cleaning O 
to O 
anti-corrosion O 
and O 
low O 
- O 
friction O 
coatings O 
. O 

of O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
alone O 
and O 
in O 
combination O 
with O 
its O 
metabolite O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
glucuronide I-TRIVIAL 
on O 
rat O 
embryos O 
in O 
vitro O 
. O 

acid I-TRIVIAL 
( O 
MPA B-ABBREVIATION 
) O 
is O 
an O 
immunosuppressive O 
agent O 
that O 
acts O 
as O 
a O 
selective O 
, O 
non-reversible O 
inhibitor O 
of O 
the O 
enzyme O 
inosine-5'-monophosphate B-SYSTEMATIC 
dehydrogenase O 
( O 
IMPDH O 
) O 
. O 
Malformations O 
have O 
been O 
described O 
in O 
children O 
after O 
maternal O 
exposure O 
to O 
mycophenolate B-TRIVIAL 
. O 
However O 
, O 
the O 
causal O 
link O 
is O 
unclear O 
in O 
most O 
cases O 
because O 
women O 
had O 
been O 
treated O 
with O 
a O 
combination O 
of O 
drugs O 
and O 
birth O 
defects O 
may O 
have O 
other O 
causes O 
. O 
Therefore O 
, O 
it O 
is O 
important O 
to O 
study O 
the O 
action O 
of O 
this O 
drug O 
and O 
its O 
main O 
metabolite O 
on O 
embryonic O 
tissue O 
. O 
We O 
studied O 
the O 
teratogenic O 
potential O 
of O 
MPA B-ABBREVIATION 
and O 
its O 
major O 
metabolite O 
, O 
the O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
glucuronide I-TRIVIAL 
( O 
MPAG B-ABBREVIATION 
) O 
in O 
the O 
rat O 
whole O 
- O 
embryo O 
culture O 
. O 
A O 
total O 
of O 
147 O 
day O 
9.5 O 
embryos O 
were O 
cultivated O 
for O 
48 O 
h O 
in O 
the O 
standard O 
medium O 
containing O 
85 O 
% O 
serum O 
. O 
We O 
tested O 
MPA B-ABBREVIATION 
at O 
concentrations O 
of O 
0.1 O 
; O 
0.25 O 
; O 
0.5 O 
; O 
0.75 O 
mg O 
/ O 
l O 
( O 
0.31 O 
; O 
0.78 O 
; O 
1.56 O 
; O 
2.34 O 
μM O 
) O 
and O 
MPA B-TRIVIAL 
glucuronide I-TRIVIAL 
at O 
concentrations O 
of O 
3 O 
; O 
10 O 
; O 
30 O 
; O 
100 O 
mg O 
/ O 
l O 
( O 
6.04 O 
; O 
20.14 O 
; O 
60.43 O 
; O 
201.43 O 
μM O 
) O 
. O 
Both O 
substances O 
are O 
highly O 
protein O 
bound O 
, O 
and O 
MPA B-TRIVIAL 
glucuronide I-TRIVIAL 
might O 
displace O 
MPA B-ABBREVIATION 
from O 
protein O 
binding O 
. O 
Therefore O 
, O 
we O 
examined O 
whether O 
the O 
effects O 
of O 
MPA B-ABBREVIATION 
can O 
be O 
enhanced O 
when O 
studied O 
in O 
combination O 
with O 
the O 
glucuronide O 
. O 
Furthermore O 
, O 
the O 
focus O 
was O 
on O 
additional O 
endpoints O 
to O 
the O 
standard O 
evaluation O 
of O 
cultivated O 
embryos O 
, O 
such O 
as O 
development O 
of O 
cranial O 
nerves O 
[ O 
trigeminal O 
nerve O 
(V) O 
, O 
facial O 
nerve O 
(VII) O 
, O 
glossopharyngeal O 
nerve O 
(IX) O 
, O 
vagus O 
nerve O 
(X) O 
] O 
after O 
staining O 
with O 
an O 
antibody O 
against O 
2H3 O 
neurofilament O 
. O 
Ultrastructural O 
changes O 
were O 
evaluated O 
by O 
electron O 
microscopy O 
. O 
At O 
a O 
concentration O 
of O 
0.75 O 
mg O 
MPA B-ABBREVIATION 
/l O 
medium O 
, O 
all O 
embryos O 
showed O 
dysmorphic O 
changes O 
. O 
Embryos O 
exposed O 
to O 
0.25 O 
mg O 
MPA B-ABBREVIATION 
/l O 
medium O 
showed O 
impaired O 
development O 
of O 
nerves O 
, O 
and O 
at O 
0.1 O 
mg O 
/ O 
l O 
, O 
no O 
effects O 
were O 
detectable O 
. O 
Concentration O 
- O 
dependent O 
ultrastructural O 
changes O 
, O 
such O 
as O 
signs O 
of O 
apoptosis O 
, O 
were O 
found O 
by O 
electron O 
microscopy O 
. O 
The O 
examination O 
of O 
the O 
metabolite O 
in O 
this O 
assay O 
showed O 
that O 
at O 
a O 
concentration O 
of O 
100 O 
mg O 
MPAG B-ABBREVIATION 
/l O 
, O 
the O 
embryos O 
exhibited O 
distinct O 
malformations O 
. O 
This O 
is O 
probably O 
caused O 
by O 
MPA B-ABBREVIATION 
, O 
which O 
was O 
detectable O 
at O 
0.6 O 
% O 
in O 
the O 
material O 
used O 
for O 
our O 
experiments O 
. O 
The O 
combination O 
of O 
the O 
parent O 
compound O 
( O 
0.03 O 
; O 
0.1 O 
; O 
0.25 O 
mg O 
/ O 
l O 
) O 
with O 
its O 
metabolite O 
MPAG B-ABBREVIATION 
( O 
3 O 
mg O 
/ O 
l O 
) O 
did O 
not O 
cause O 
enhanced O 
toxicity O 
under O 
our O 
experimental O 
conditions O 
. O 
IMPDH O 
, O 
the O 
target O 
enzyme O 
of O 
MPA B-ABBREVIATION 
, O 
could O 
be O 
detected O 
in O 
rat O 
embryos O 
on O 
day O 
9.5 O 
of O 
embryonic O 
development O 
as O 
well O 
as O 
at O 
the O 
end O 
of O 
the O 
culture O 
period O 
48 O 
h O 
later O 
. O 
In O 
summary O 
, O 
MPA B-ABBREVIATION 
impairs O 
embryonic O 
development O 
at O 
low O 
, O 
therapeutically O 
relevant O 
concentrations O 
, O 
but O 
the O 
glucuronide O 
does O 
not O 
exhibit O 
such O 
a O 
potential O 
. O 
Activity O 
of O 
MPA B-ABBREVIATION 
is O 
not O 
enhanced O 
by O 
MPAG B-ABBREVIATION 
. O 

activities O 
of O 
a O 
cocaine B-TRIVIAL 
hydrolase O 
engineered O 
from O 
human O 
butyrylcholinesterase O 
against O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-cocaine I-MULTIPLE 
. O 

can O 
be O 
argued O 
that O 
an O 
ideal O 
anti- O 
cocaine B-TRIVIAL 
medication O 
would O 
be O 
one O 
that O 
accelerates O 
cocaine B-TRIVIAL 
metabolism O 
producing O 
biologically O 
inactive O 
metabolites O 
via O 
a O 
route O 
similar O 
to O 
the O 
primary O 
cocaine B-TRIVIAL 
-metabolizing O 
pathway O 
, O 
i.e O 
. O 
, O 
hydrolysis O 
catalyzed O 
by O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
in O 
plasma O 
. O 
However O 
, O 
wild O 
- O 
type O 
BChE O 
has O 
a O 
low O 
catalytic O 
efficiency O 
against O 
naturally O 
occurring O 
(-)-cocaine B-TRIVIAL 
. O 
Interestingly O 
, O 
wild O 
- O 
type O 
BChE O 
has O 
a O 
much O 
higher O 
catalytic O 
activity O 
against O 
unnatural O 
(+)-cocaine B-TRIVIAL 
. O 
According O 
to O 
available O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
imaging O 
analysis O 
using O 
[(11)C](-)-cocaine B-SYSTEMATIC 
and O 
[(11)C](+)-cocaine B-SYSTEMATIC 
tracers O 
in O 
human O 
subjects O 
, O 
only O 
[(11)C](-)-cocaine B-SYSTEMATIC 
was O 
observed O 
in O 
the O 
brain O 
, O 
whereas O 
no O 
significant O 
[(11)C](+)-cocaine B-SYSTEMATIC 
signal O 
was O 
observed O 
in O 
the O 
brain O 
. O 
The O 
available O 
PET O 
data O 
imply O 
that O 
an O 
effective O 
therapeutic O 
enzyme O 
for O 
treatment O 
of O 
cocaine B-TRIVIAL 
abuse O 
could O 
be O 
an O 
exogenous O 
cocaine B-TRIVIAL 
-metabolizing O 
enzyme O 
with O 
a O 
catalytic O 
activity O 
against O 
(-)-cocaine B-TRIVIAL 
comparable O 
to O 
that O 
of O 
wild O 
- O 
type O 
BChE O 
against O 
(+)-cocaine B-TRIVIAL 
. O 
Our O 
recently O 
designed O 
A199S O 
/ O 
F227A O 
/ O 
S287G O 
/ O 
A328 O 
W O 
/ O 
Y332G O 
mutant O 
of O 
human O 
BChE O 
has O 
a O 
considerably O 
improved O 
catalytic O 
efficiency O 
against O 
(-)-cocaine B-TRIVIAL 
and O 
has O 
been O 
proven O 
active O 
in O 
vivo O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
have O 
characterized O 
the O 
catalytic O 
activities O 
of O 
wild O 
- O 
type O 
BChE O 
and O 
the O 
A199S O 
/ O 
F227A O 
/ O 
S287G O 
/ O 
A328 O 
W O 
/ O 
Y332G O 
mutant O 
against O 
both O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-cocaine I-MULTIPLE 
at O 
the O 
same O 
time O 
under O 
the O 
same O 
experimental O 
conditions O 
. O 
Based O 
on O 
the O 
obtained O 
kinetic O 
data O 
, O 
the O 
A199S O 
/ O 
F227A O 
/ O 
S287G O 
/ O 
A328 O 
W O 
/ O 
Y332G O 
mutant O 
has O 
a O 
similarly O 
high O 
catalytic O 
efficiency O 
( O 
kcat O 
/ O 
KM O 
) O 
against O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-cocaine I-MULTIPLE 
, O 
and O 
indeed O 
has O 
a O 
catalytic O 
efficiency O 
( O 
kcat O 
/ O 
KM=1.84×10(9)M(-1)min(-1) O 
) O 
against O 
(-)-cocaine B-TRIVIAL 
comparable O 
to O 
that O 
( O 
kcat O 
/ O 
KM=1.37×10(9)M(-1)min(-1) O 
) O 
of O 
wild O 
- O 
type O 
BChE O 
against O 
(+)-cocaine B-TRIVIAL 
. O 
Thus O 
, O 
the O 
mutant O 
may O 
be O 
used O 
to O 
effectively O 
prevent O 
(-)-cocaine B-TRIVIAL 
from O 
entering O 
brain O 
and O 
producing O 
physiological O 
effects O 
in O 
the O 
enzyme O 
- O 
based O 
treatment O 
of O 
cocaine O 
abuse O 
. O 

is O 
an O 
acquired O 
depigmentation O 
disorder O 
affecting O 
0.1% O 
to O 
> O 
8.8% O 
in O 
Indian O 
population O 
. O 
Psoralen B-TRIVIAL 
and O 
ultraviolet O 
A O 
radiation O 
( O 
PUVA O 
) O 
is O 
a O 
gold O 
standard O 
treatment O 
for O 
vitiligo O 
, O 
however O 
, O 
response O 
is O 
still O 
empirical O 
. O 
In O 
order O 
to O 
investigate O 
whether O 
drug O 
response O 
variation O 
is O 
influenced O 
by O 
the O 
repair O 
ability O 
of O 
PUVA O 
treated O 
vitiligo O 
subjects O 
, O 
single O 
cell O 
gel O 
electrophoresis O 
( O 
SCGE O 
) O 
for O 
genotoxicity O 
and O 
serum O 
malonaldehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
for O 
cytotoxicity O 
were O 
performed O 
on O 
107 O 
subjects O 
( O 
77 O 
cases O 
and O 
30 O 
healthy O 
controls O 
) O 
in O 
South O 
Indian O 
population O 
. O 
In O 
vitro O 
repair O 
ability O 
was O 
assessed O 
by O 
considering O 
the O 
residual O 
damage O 
. O 
A O 
significant O 
difference O 
was O 
observed O 
between O 
the O 
patients O 
and O 
controls O 
with O 
regard O 
to O 
their O 
mean O 
values O 
of O 
DNA O 
damage O 
and O 
MDA B-ABBREVIATION 
levels O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
On O 
categorization O 
to O 
fast O 
and O 
slow O 
responders O 
based O 
on O 
the O 
time O 
of O 
response O 
, O 
patients O 
exhibited O 
a O 
significant O 
deviation O 
in O 
residual O 
DNA O 
damage O 
, O 
suggestive O 
of O 
variation O 
with O 
respect O 
to O 
DNA O 
repair O 
efficiency O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
our O 
knowledge O 
with O 
respect O 
to O 
PUVA O 
drug O 
response O 
variation O 
in O 
vitiligo O 
in O 
relation O 
to O 
DNA O 
repair O 
. O 
Large O 
systematic O 
studies O 
on O 
DNA O 
repair O 
may O 
help O 
in O 
a O 
better O 
understanding O 
of O 
the O 
mechanisms O 
involved O 
in O 
the O 
PUVA O 
drug O 
response O 
variation O 
. O 

glycogen O 
loading O 
dampens O 
glycogen O 
synthesis O 
seen O 
in O 
response O 
to O 
either O 
hyperinsulinemia O 
or O 
intraportal O 
glucose B-TRIVIAL 
infusion O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
effect O 
of O 
liver O 
glycogen O 
loading O 
on O 
net O 
hepatic O 
glycogen O 
synthesis O 
during O 
hyperinsulinemia O 
or O 
hepatic O 
portal O 
vein O 
glucose B-TRIVIAL 
infusion O 
in O 
vivo O 
. O 
Liver O 
glycogen O 
levels O 
were O 
supercompensated O 
( O 
SCGly O 
) O 
in O 
two O 
groups O 
( O 
using O 
intraportal O 
fructose B-TRIVIAL 
infusion O 
) O 
but O 
not O 
in O 
two O 
others O 
( O 
Gly O 
) O 
during O 
hyperglycemic O 
- O 
normoinsulinemia O 
. O 
Following O 
a O 
2-h O 
control O 
period O 
during O 
which O 
fructose B-TRIVIAL 
infusion O 
was O 
stopped O 
, O 
there O 
was O 
a O 
2-h O 
experimental O 
period O 
in O 
which O 
the O 
response O 
to O 
hyperglycemia O 
plus O 
either O 
4× O 
basal O 
insulin O 
( O 
INS O 
) O 
or O 
portal O 
vein O 
glucose B-TRIVIAL 
infusion O 
( O 
PoG O 
) O 
was O 
measured O 
. O 
Increased O 
hepatic O 
glycogen O 
reduced O 
the O 
percent O 
of O 
glucose B-TRIVIAL 
taken O 
up O 
by O 
the O 
liver O 
that O 
was O 
deposited O 
in O 
glycogen O 
( O 
74 O 
± O 
3 O 
vs O 
. O 
53 O 
± O 
5% O 
in O 
Gly O 
+ O 
INS O 
and O 
SCGly O 
+ O 
INS O 
, O 
respectively O 
, O 
and O 
72 O 
± O 
3 O 
vs O 
. O 
50 O 
± O 
6% O 
in O 
Gly O 
+ O 
PoG O 
and O 
SCGly O 
+ O 
PoG O 
, O 
respectively O 
) O 
. O 
The O 
reduction O 
in O 
liver O 
glycogen O 
synthesis O 
in O 
SCGly O 
+ O 
INS O 
was O 
accompanied O 
by O 
a O 
decrease O 
in O 
both O 
insulin O 
signaling O 
and O 
an O 
increase O 
in O 
AMPK O 
activation O 
, O 
whereas O 
only O 
the O 
latter O 
was O 
observed O 
in O 
SCGly O 
+ O 
PoG O 
. O 
These O 
data O 
indicate O 
that O 
liver O 
glycogen O 
loading O 
impairs O 
glycogen O 
synthesis O 
regardless O 
of O 
the O 
signal O 
used O 
to O 
stimulate O 
it O 
. O 

bioactive O 
probe O 
of O 
the O 
oxidative O 
pentose B-FAMILY 
phosphate I-FAMILY 
cycle O 
: O 
novel O 
strategy O 
to O 
reverse O 
radioresistance O 
in O 
glucose B-TRIVIAL 
deprived O 
human O 
colon O 
cancer O 
cells O 
. O 

specific O 
effects O 
of O 
glucose B-TRIVIAL 
deprivation O 
on O 
oxidative O 
pentose B-FAMILY 
phosphate I-FAMILY 
cycle O 
( O 
OPPC O 
) O 
function O 
, O 
thiol B-FAMILY 
homeostasis O 
, O 
protein O 
function O 
and O 
cell O 
survival O 
remain O 
unclear O 
due O 
to O 
lack O 
of O 
a O 
glucose B-TRIVIAL 
-sensitive O 
chemical O 
probe O 
. O 
Using O 
p53 O 
wild O 
type O 
and O 
mutant O 
human O 
colon O 
cells O 
, O 
we O 
determined O 
the O 
effects O 
of O 
hydroxyethyl B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
HEDS B-ABBREVIATION 
) O 
on O 
NADPH B-ABBREVIATION 
, O 
GSH B-ABBREVIATION 
, O 
GSSG B-ABBREVIATION 
, O 
total O 
glutathione B-TRIVIAL 
, O 
total O 
non O 
- O 
protein O 
and O 
protein O 
thiol O 
levels O 
, O 
the O 
function O 
of O 
the O 
DNA O 
repair O 
protein O 
Ku O 
, O 
and O 
the O 
susceptibility O 
to O 
radiation O 
- O 
induced O 
free O 
radicals O 
under O 
normal O 
glucose B-TRIVIAL 
or O 
glucose B-TRIVIAL 
-deprived O 
conditions O 
. O 
HEDS B-ABBREVIATION 
is O 
rapidly O 
detoxified O 
in O 
normal O 
glucose B-TRIVIAL 
but O 
triggered O 
a O 
p53 O 
- O 
independent O 
metabolic O 
stress O 
in O 
glucose B-TRIVIAL 
depleted O 
state O 
that O 
caused O 
loss O 
of O 
NADPH B-ABBREVIATION 
, O 
protein O 
and O 
non O 
- O 
protein O 
thiol B-FAMILY 
homeostasis O 
and O 
Ku O 
function O 
, O 
and O 
enhanced O 
sensitivity O 
of O 
both O 
p53 O 
wild O 
type O 
and O 
mutant O 
cells O 
to O 
radiation O 
induced O 
oxidative O 
stress O 
. O 
Additionally O 
, O 
high O 
concentration O 
of O 
HEDS B-ABBREVIATION 
alone O 
induced O 
cell O 
death O 
in O 
p53 O 
wild O 
type O 
cells O 
without O 
significant O 
effect O 
on O 
p53 O 
mutant O 
cells O 
. O 
HEDS B-ABBREVIATION 
offers O 
a O 
useful O 
tool O 
to O 
gain O 
insights O 
into O 
how O 
glucose B-TRIVIAL 
metabolism O 
affects O 
OPPC O 
dependent O 
stress O 
- O 
induced O 
cellular O 
functions O 
and O 
injury O 
, O 
including O 
in O 
tumor O 
cells O 
, O 
where O 
our O 
findings O 
imply O 
a O 
novel O 
therapeutic O 
approach O 
to O 
target O 
glucose B-TRIVIAL 
deprived O 
tumor O 
. O 
Our O 
work O 
introduces O 
a O 
novel O 
probe O 
to O 
address O 
cancer O 
metabolism O 
and O 
ischemic O 
pathology O 
. O 

pharmacology O 
of O 
etoposide B-TRIVIAL 
in O 
children O 
undergoing O 
autologous O 
stem O 
cell O 
transplantation O 
for O 
various O 
solid O 
tumours O 
. O 

. O 
The O 
population O 
pharmacokinetics O 
of O 
high O 
- O 
dose O 
etoposide O 
was O 
studied O 
in O 
a O 
group O 
of O 
young O 
children O 
and O 
adolescents O 
. O 
2 O 
. O 
Twenty O 
- O 
six O 
children O 
and O 
adolescent O 
were O 
administered O 
high O 
- O 
dose O 
etoposide B-TRIVIAL 
as O 
a O 
continuous O 
infusion O 
over O 
24 O 
h O 
. O 
Etoposide B-TRIVIAL 
plasma O 
concentration O 
- O 
time O 
data O 
was O 
modelled O 
using O 
NONMEM O 
® O 
7 O 
. O 
The O 
effect O 
of O 
age O 
, O 
weight O 
, O 
serum O 
creatinine B-TRIVIAL 
( O 
SCr O 
) O 
, O 
and O 
gender O 
on O 
pharmacokinetic O 
parameters O 
( O 
CL O 
and O 
V(d) O 
) O 
were O 
determined O 
by O 
a O 
nonlinear O 
mixed O 
effect O 
model O 
. O 
3 O 
. O 
The O 
pharmacokinetics O 
of O 
etoposide B-TRIVIAL 
based O 
on O 
BSA O 
dosing O 
was O 
best O 
described O 
with O 
a O 
1-compartment O 
structural O 
model O 
which O 
was O 
parameterised O 
in O 
terms O 
of O 
clearance O 
( O 
CL O 
) O 
and O 
volume O 
of O 
distribution O 
(V(d)) O 
. O 
An O 
exponential O 
error O 
model O 
was O 
used O 
to O 
explain O 
intersubject O 
variability O 
and O 
a O 
proportional O 
error O 
model O 
was O 
used O 
to O 
describe O 
residual O 
or O 
intrapatient O 
variability O 
. O 
The O 
final O 
model O 
parameter O 
estimates O 
for O 
the O 
typical O 
( O 
normalised O 
to O 
70 O 
kg O 
) O 
values O 
of O 
CL O 
and O 
V(d) O 
were O 
2.31 O 
L O 
/ O 
hr O 
and O 
17.5 O 
L O 
, O 
respectively O 
. O 
The O 
CL O 
and O 
V(d) O 
allometrically O 
increased O 
with O 
weight O 
with O 
the O 
power O 
of O 
3 O 
/ O 
4 O 
and O 
1 O 
, O 
respectively O 
. O 
After O 
accounting O 
for O 
weight O 
dependence O 
using O 
the O 
allometric O 
scaling O 
, O 
age O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
and O 
gender O 
did O 
not O 
have O 
any O 
influence O 
on O 
model O 
parameters O 
. O 
4 O 
. O 
The O 
results O 
of O 
this O 
children O 
and O 
adolescent O 
population O 
pharmacokinetic O 
study O 
indicates O 
that O 
etoposide B-TRIVIAL 
pharmacokinetics O 
were O 
influenced O 
by O 
body O 
weight O 
on O 
an O 
allometric O 
basis O 
. O 
The O 
pharmacokinetic O 
parameters O 
CL O 
and O 
V(d) O 
increased O 
with O 
increasing O 
weight O 
similar O 
to O 
BSA O 
. O 

of O 
the O 
mechanism O 
of O 
ribose B-TRIVIAL 
conjugation O 
in O 
a O 
pyrazole B-SYSTEMATIC 
-containing O 
compound O 
in O 
rodent O 
liver O 
. O 

. O 
Here O 
we O 
report O 
on O 
the O 
mechanism O 
of O 
ribose B-TRIVIAL 
conjugation O 
, O 
through O 
NADH B-ABBREVIATION 
as O 
a O 
cofactor O 
, O 
of O 
a O 
pyrazole B-SYSTEMATIC 
-containing O 
compound O 
( O 
PT O 
) O 
. O 
Incubation O 
of O 
PT O 
in O 
rat O 
liver O 
microsomes O 
supplemented O 
with O 
NADP B-ABBREVIATION 
⁺/ O 
H B-FORMULA 
, O 
NAD B-ABBREVIATION 
⁺/ O 
H B-FORMULA 
, O 
and O 
β-nicotinamide B-FAMILY 
mononucleotide I-FAMILY 
( O 
NMN B-ABBREVIATION 
) O 
resulted O 
in O 
complete O 
conjugation O 
to O 
the O 
adenine B-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
conjugate O 
( O 
ADP B-ABBREVIATION 
-C O 
) O 
, O 
adenine B-TRIVIAL 
dinucleotide O 
conjugate O 
( O 
AD-C O 
) O 
, O 
and O 
5-phosphoribose B-SYSTEMATIC 
conjugate O 
( O 
Rib B-ABBREVIATION 
-C1 O 
) O 
, O 
respectively O 
. O 
In O 
hepatocytes O 
, O 
PT O 
predominantly O 
formed O 
three O 
ribose B-TRIVIAL 
conjugates O 
: O 
Rib B-ABBREVIATION 
-C1 O 
, O 
the O 
ribose B-TRIVIAL 
conjugate O 
( O 
Rib B-ABBREVIATION 
-C2 O 
) O 
, O 
and O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
of O 
Rib B-ABBREVIATION 
-C2 O 
( O 
Rib B-ABBREVIATION 
-C3 O 
) O 
. O 
2 O 
. O 
Phosphatase O 
inhibitors O 
were O 
added O 
to O 
hepatocyte O 
incubations O 
. O 
AD-C O 
was O 
detected O 
in O 
this O 
reaction O 
, O 
which O 
suggests O 
that O 
one O 
of O 
the O 
major O 
pathways O 
for O 
the O 
formation O 
of O 
the O 
ribose B-TRIVIAL 
conjugates O 
is O 
through O 
NAD B-ABBREVIATION 
⁺/ O 
H B-FORMULA 
. O 
When O 
AD-C O 
was O 
incubated O 
with O 
phosphatase O 
, O 
Rib B-ABBREVIATION 
-C1 O 
and O 
Rib B-ABBREVIATION 
-C2 O 
formed O 
. O 
3 O 
. O 
To O 
understand O 
the O 
in O 
vivo O 
relevance O 
of O 
this O 
metabolic O 
pathway O 
, O 
rats O 
were O 
dosed O 
with O 
PT O 
and O 
Rib B-ABBREVIATION 
-C2 O 
was O 
found O 
in O 
the O 
urine O 
. O 
4 O 
. O 
Structure O 
- O 
activity O 
relationship O 
shows O 
that O 
replacement O 
of O 
the O 
distal O 
thiazole B-SYSTEMATIC 
group O 
in O 
the O 
PT O 
to O 
a O 
phenyl B-SYSTEMATIC 
group O 
abolishes O 
this O 
conjugation O 
. O 
Three O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
in O 
the O 
active O 
site O 
preferentially O 
interact O 
with O 
the O 
sulfur B-SYSTEMATIC 
atom O 
in O 
the O 
thiazole B-SYSTEMATIC 
of O 
PT O 
. O 
5 O 
. O 
In O 
summary O 
, O 
PT O 
forms O 
direct O 
AD-C O 
in O 
hepatocytes O 
, O 
which O 
is O 
further O 
hydrolyzed O 
by O 
phosphatase O 
to O 
give O 
ribose B-TRIVIAL 
conjugates O 
. O 

repositioning O 
, O 
exemplified O 
by O 
sildenafil B-TRIVIAL 
and O 
thalidomide B-TRIVIAL 
, O 
is O 
a O 
promising O 
way O 
to O 
explore O 
alternative O 
indications O 
for O 
existing O 
drugs O 
. O 
Recent O 
research O 
has O 
shown O 
that O 
bioinformatics O 
- O 
based O 
approaches O 
have O 
the O 
potential O 
to O 
offer O 
systematic O 
insights O 
into O 
the O 
complex O 
relationships O 
among O 
drugs O 
, O 
targets O 
and O 
diseases O 
necessary O 
for O 
successful O 
repositioning O 
. O 
In O 
this O 
article O 
, O 
we O 
propose O 
the O 
key O 
bioinformatics O 
steps O 
essential O 
for O 
discovering O 
valuable O 
repositioning O 
methods O 
. O 
The O 
proposed O 
steps O 
( O 
repurposing O 
with O 
a O 
purpose O 
, O 
repurposing O 
with O 
a O 
strategy O 
and O 
repurposing O 
with O 
confidence O 
) O 
are O 
aimed O 
at O 
providing O 
a O 
repurposing O 
pipeline O 
, O 
with O 
particular O 
focus O 
on O 
the O 
proposed O 
Drugs O 
of O 
New O 
Indications O 
( O 
DNI O 
) O 
database O 
, O 
which O 
can O 
be O 
used O 
alongside O 
currently O 
available O 
resources O 
to O 
improve O 
in O 
silico O 
drug O 
repositioning O 
. O 

neutron O 
scattering O 
is O 
one O 
of O 
the O 
most O 
powerful O 
tools O 
for O 
studying O 
dynamics O 
in O 
biological O 
matter O 
. O 
Using O 
the O 
cold O 
neutron O 
backscattering O 
spectrometer O 
IN16 O 
at O 
the O 
Institut O 
Laue O 
Langevin O 
( O 
ILL O 
, O 
Grenoble O 
, O 
France O 
) O 
, O 
temperature O 
dependence O 
of O 
cholinesterases O 
' O 
dynamics O 
( O 
human O 
butyrylcholinesterase O 
from O 
plasma O 
: O 
hBChE O 
; O 
recombinant O 
human O 
acetylcholinesterase O 
: O 
hAChE O 
and O 
recombinant O 
mouse O 
acetylcholinesterase O 
: O 
mAChE O 
) O 
was O 
examined O 
using O 
elastic O 
incoherent O 
neutron O 
scattering O 
( O 
EINS O 
) O 
. O 
The O 
dynamics O 
was O 
characterized O 
by O 
the O 
averaged O 
atomic O 
mean O 
square O 
displacement O 
( O 
MSD O 
) O 
, O 
associated O 
with O 
the O 
sample O 
flexibility O 
at O 
a O 
given O 
temperature O 
. O 
We O 
found O 
MSD O 
values O 
of O 
hAChE O 
above O 
the O 
dynamical O 
transition O 
temperature O 
( O 
around O 
200K O 
) O 
larger O 
than O 
for O 
mAChE O 
and O 
hBChE O 
, O 
implying O 
that O 
hAChE O 
is O 
more O 
flexible O 
than O 
the O 
other O 
ChEs O 
. O 
Activation O 
energies O 
for O 
thermodynamical O 
transition O 
were O 
extracted O 
through O 
the O 
frequency O 
window O 
model O 
( O 
FWM O 
) O 
( O 
Becker O 
et O 
al O 
. O 
2004 O 
) O 
[ O 
1 O 
] O 
and O 
turned O 
out O 
to O 
increase O 
from O 
hBChE O 
to O 
mAChE O 
and O 
finally O 
to O 
hAChE O 
, O 
inversely O 
to O 
the O 
MSDs O 
relations O 
. O 
Between O 
280 O 
and O 
316K O 
, O 
catalytic O 
studies O 
of O 
these O 
enzymes O 
were O 
carried O 
out O 
using O 
thiocholine B-FAMILY 
esters I-FAMILY 
: O 
at O 
the O 
same O 
temperature O 
, O 
the O 
hAChE O 
activity O 
was O 
systematically O 
higher O 
than O 
the O 
mAChE O 
or O 
hBChE O 
ones O 
. O 
Our O 
results O 
thus O 
suggest O 
a O 
strong O 
correlation O 
between O 
dynamics O 
and O 
activity O 
within O 
the O 
ChE O 
family O 
. O 
We O 
also O 
studied O 
and O 
compared O 
the O 
ChEs O 
thermal O 
inactivation O 
kinetics O 
. O 
Here O 
, O 
no O 
direct O 
correlation O 
with O 
the O 
dynamics O 
was O 
observed O 
, O 
thus O 
suggesting O 
that O 
relations O 
between O 
enzyme O 
dynamics O 
and O 
catalytic O 
stability O 
are O 
more O 
complex O 
. O 
Finally O 
, O 
the O 
possible O 
relation O 
between O 
flexibility O 
and O 
protein O 
ability O 
to O 
grow O 
in O 
crystals O 
is O 
discussed O 
. O 

chemical O 
investigation O 
of O 
the O 
intra- O 
and O 
intermolecular O 
proton O 
transfer O 
reactions O 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
in O 
4-amino-5-(2-hydroxyphenyl)-2H-1,2,4-triazole-3(4H)-thione B-SYSTEMATIC 
. O 

intramolecular O 
thione B-FAMILY 
- I-FAMILY 
thiol I-FAMILY 
tautomerism O 
and O 
intermolecular O 
double O 
proton O 
transfer O 
reaction O 
of O 
the O 
hydrogen B-SYSTEMATIC 
-bonded O 
thione B-MULTIPLE 
and I-MULTIPLE 
thiol I-MULTIPLE 
dimers I-MULTIPLE 
in O 
the O 
title O 
triazole B-FAMILY 
compound O 
were O 
studied O 
at O 
the O 
B3LYP O 
level O 
of O 
theory O 
using O 
6-311 O 
+ O 
+ O 
G(d,p) O 
basis O 
function O 
. O 
The O 
influence O 
of O 
the O 
solvent O 
on O 
the O 
single O 
and O 
double O 
proton O 
transfer O 
reactions O 
was O 
examined O 
in O 
three O 
solvents O 
( O 
chloroform B-TRIVIAL 
, O 
methanol B-SYSTEMATIC 
and O 
water O 
) O 
using O 
the O 
polarizable O 
continuum O 
model O 
( O 
PCM O 
) O 
approximation O 
. O 
The O 
computational O 
results O 
show O 
that O 
the O 
thione B-FAMILY 
tautomer O 
is O 
the O 
most O 
stable O 
isomer O 
with O 
a O 
very O 
high O 
tautomeric O 
energy O 
barrier O 
both O 
in O 
the O 
gas O 
phase O 
and O 
in O 
solution O 
phase O 
, O 
indicating O 
a O 
quite O 
disfavored O 
process O 
. O 
The O 
solvent O 
effect O 
is O 
found O 
to O 
be O 
sizable O 
with O 
increasing O 
polarity O 
. O 
In O 
the O 
double O 
proton O 
transfer O 
reaction O 
, O 
the O 
thione B-FAMILY 
dimer I-FAMILY 
is O 
found O 
to O 
be O 
more O 
stable O 
than O 
thiol B-FAMILY 
dimer I-FAMILY 
both O 
in O 
the O 
gas O 
phase O 
and O 
in O 
solution O 
phase O 
. O 
The O 
energetic O 
and O 
thermodynamic O 
parameters O 
of O 
the O 
double O 
proton O 
transfer O 
process O 
show O 
that O 
the O 
double O 
proton O 
exchange O 
from O 
thione B-FAMILY 
dimer I-FAMILY 
to O 
thiol B-FAMILY 
dimer I-FAMILY 
is O 
thermodynamically O 
unfavored O 
. O 
However O 
, O 
the O 
exchange O 
from O 
thiol B-FAMILY 
dimer I-FAMILY 
to O 
thione B-FAMILY 
dimer I-FAMILY 
for O 
the O 
gas O 
phase O 
and O 
water O 
phase O 
seems O 
to O 
be O 
feasible O 
with O 
a O 
low O 
barrier O 
height O 
and O 
with O 
a O 
negative O 
value O 
in O 
enthalpy O 
and O 
free O 
energy O 
changes O 
. O 
In O 
addition O 
, O 
the O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
were O 
analyzed O 
in O 
the O 
gas O 
phase O 
regarding O 
their O 
geometries O 
and O 
energies O 
. O 
It O 
is O 
found O 
that O 
all O 
complex O 
formations O 
are O 
enthalpically O 
favored O 
, O 
and O 
the O 
stability O 
of O 
the O 
H B-FORMULA 
-bonds O 
comes O 
in O 
the O 
order O 
of O 
S1 B-FORMULA 
- O 
H2 B-FORMULA 
··· O 
N2 B-FORMULA 
> O 
N2 B-FORMULA 
- O 
H2 B-FORMULA 
··· O 
S1 B-FORMULA 
> O 
N3 B-FORMULA 
- O 
H3B B-FORMULA 
··· O 
O1 B-FORMULA 
. O 
Finally O 
, O 
non-linear O 
optical O 
properties O 
were O 
carried O 
out O 
at O 
the O 
same O 
calculation O 
level O 
in O 
the O 
gas O 
phase O 
. O 

levels O 
of O 
sodium B-SYSTEMATIC 
- I-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
NIS O 
) O 
promoter O 
in O 
benign O 
and O 
malignant O 
thyroid O 
tumors O 
with O 
reduced O 
NIS O 
expression O 
. O 

methylation O 
regulates O 
gene O 
expression O 
. O 
Aberrant O 
methylation O 
plays O 
an O 
important O 
role O 
in O 
human O 
tumorigenesis O 
. O 
We O 
have O 
previously O 
detected O 
reduced O 
NIS O 
mRNA O 
expression O 
in O 
thyroid O 
tumors O 
as O 
compared O 
to O 
non-tumor O 
tissues O 
. O 
Thus O 
, O 
in O 
this O 
study O 
we O 
investigated O 
whether O 
the O 
methylation O 
of O 
the O 
CpG-island O 
located O 
in O 
the O 
NIS O 
gene O 
promoter O 
was O 
associated O 
with O 
reduced O 
mRNA O 
expression O 
in O 
thyroid O 
tumors O 
. O 
Methylation O 
levels O 
of O 
30 O 
pairs O 
of O 
samples O 
from O 
10 O 
benign O 
and O 
20 O 
malignant O 
thyroid O 
tumors O 
( O 
T O 
) O 
along O 
with O 
matched O 
non-tumor O 
( O 
NT O 
) O 
areas O 
were O 
determined O 
by O 
semiquantitative O 
methylation O 
specific-PCR O 
. O 
NIS O 
methylation O 
was O 
detected O 
in O 
all O 
samples O 
. O 
Methylation O 
levels O 
and O 
frequencies O 
did O 
not O 
differ O 
between O 
the O 
groups O 
and O 
were O 
not O 
associated O 
with O 
BRAF O 
mutational O 
status O 
. O 
Highest O 
methylation O 
levels O 
and O 
frequencies O 
were O 
detected O 
in O 
the O 
5 O 
' O 
region O 
of O 
the O 
CpG B-ABBREVIATION 
-island O 
decreasing O 
toward O 
the O 
3 O 
' O 
end O 
. O 
Intraindividual O 
analysis O 
( O 
T O 
versus O 
NT O 
) O 
showed O 
high O 
tumor O 
methylation O 
levels O 
in O 
40 O 
% O 
of O 
the O 
samples O 
in O 
the O 
benign O 
group O 
and O 
30 O 
% O 
in O 
the O 
malignant O 
group O 
, O 
associated O 
with O 
low O 
NIS O 
mRNA O 
expression O 
. O 
No O 
quantitative O 
correlation O 
was O 
detected O 
between O 
methylation O 
levels O 
and O 
mRNA O 
expression O 
in O 
any O 
the O 
groups O 
. O 
The O 
results O 
of O 
this O 
study O 
showed O 
that O 
methylation O 
of O 
NIS O 
promoter O 
is O 
a O 
very O 
frequent O 
event O 
in O 
both O 
benign O 
and O 
malignant O 
tumors O 
as O 
well O 
as O 
in O 
their O 
surrounding O 
tissues O 
, O 
and O 
characterized O 
a O 
non-homogeneous O 
methylation O 
pattern O 
along O 
the O 
CpG B-ABBREVIATION 
island O 
. O 
Therefore O 
, O 
further O 
investigations O 
involving O 
other O 
sites O 
that O 
may O 
be O 
implicated O 
in O 
methylation O 
regulation O 
of O 
NIS O 
expression O 
are O 
warranted O 
. O 

in O 
FKBP10 O 
, O 
which O 
result O 
in O 
Bruck O 
syndrome O 
and O 
recessive O 
forms O 
of O 
osteogenesis O 
imperfecta O 
, O 
inhibit O 
the O 
hydroxylation O 
of O 
telopeptide O 
lysines B-FAMILY 
in O 
bone O 
collagen O 
. O 

biallelic O 
mutations O 
in O 
non-collagen O 
genes O 
account O 
for O 
< O 
10% O 
of O 
individuals O 
with O 
osteogenesis O 
imperfecta O 
, O 
the O 
characterization O 
of O 
these O 
genes O 
has O 
identified O 
new O 
pathways O 
and O 
potential O 
interventions O 
that O 
could O 
benefit O 
even O 
those O 
with O 
mutations O 
in O 
type O 
I O 
collagen O 
genes O 
. O 
We O 
identified O 
mutations O 
in O 
FKBP10 O 
, O 
which O 
encodes O 
the O 
65 O 
kDa O 
prolyl B-TRIVIAL 
cis-trans O 
isomerase O 
, O 
FKBP65 O 
, O 
in O 
38 O 
members O 
of O 
21 O 
families O 
with O 
OI O 
. O 
These O 
include O 
10 O 
families O 
from O 
the O 
Samoan O 
Islands O 
who O 
share O 
a O 
founder O 
mutation O 
. O 
Of O 
the O 
mutations O 
, O 
three O 
are O 
missense O 
; O 
the O 
remainder O 
either O 
introduce O 
premature O 
termination O 
codons O 
or O 
create O 
frameshifts O 
both O 
of O 
which O 
result O 
in O 
mRNA O 
instability O 
. O 
In O 
four O 
families O 
missense O 
mutations O 
result O 
in O 
loss O 
of O 
most O 
of O 
the O 
protein O 
. O 
The O 
clinical O 
effects O 
of O 
these O 
mutations O 
are O 
short O 
stature O 
, O 
a O 
high O 
incidence O 
of O 
joint O 
contractures O 
at O 
birth O 
and O 
progressive O 
scoliosis O 
and O 
fractures O 
, O 
but O 
there O 
is O 
remarkable O 
variability O 
in O 
phenotype O 
even O 
within O 
families O 
. O 
The O 
loss O 
of O 
the O 
activity O 
of O 
FKBP65 O 
has O 
several O 
effects O 
: O 
type O 
I O 
procollagen O 
secretion O 
is O 
slightly O 
delayed O 
, O 
the O 
stabilization O 
of O 
the O 
intact O 
trimer O 
is O 
incomplete O 
and O 
there O 
is O 
diminished O 
hydroxylation O 
of O 
the O 
telopeptide O 
lysyl B-TRIVIAL 
residues O 
involved O 
in O 
intermolecular O 
cross O 
- O 
link O 
formation O 
in O 
bone O 
. O 
The O 
phenotype O 
overlaps O 
with O 
that O 
seen O 
with O 
mutations O 
in O 
PLOD2 O 
( O 
Bruck O 
syndrome O 
II O 
) O 
, O 
which O 
encodes O 
LH2 O 
, O 
the O 
enzyme O 
that O 
hydroxylates B-FAMILY 
the O 
telopeptide O 
lysyl B-TRIVIAL 
residues O 
. O 
These O 
findings O 
define O 
a O 
set O 
of O 
genes O 
, O 
FKBP10 O 
, O 
PLOD2 O 
and O 
SERPINH1 O 
, O 
that O 
act O 
during O 
procollagen O 
maturation O 
to O 
contribute O 
to O 
molecular O 
stability O 
and O 
post O 
- O 
translational O 
modification O 
of O 
type O 
I O 
procollagen O 
, O 
without O 
which O 
bone O 
mass O 
and O 
quality O 
are O 
abnormal O 
and O 
fractures O 
and O 
contractures O 
result O 
. O 

effect O 
of O 
tungsten B-SYSTEMATIC 
carbide I-SYSTEMATIC 
nanoparticles O 
on O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
current O 
of O 
hippocampal O 
CA1 O 
pyramidal O 
neurons O 
. O 

and O 
relevant O 
products O 
are O 
now O 
being O 
widely O 
used O 
in O 
the O 
world O 
, O 
and O 
their O 
safety O 
becomes O 
a O 
great O 
concern O 
for O 
the O 
general O 
public O 
. O 
Tungsten B-SYSTEMATIC 
carbide I-SYSTEMATIC 
nanoparticles O 
( O 
nano- O 
WC B-FORMULA 
) O 
are O 
widely O 
used O 
in O 
metallurgy O 
, O 
aeronautics O 
and O 
astronautics O 
, O 
however O 
our O 
knowledge O 
regarding O 
the O 
influence O 
of O 
nano- O 
WC B-FORMULA 
on O 
neurons O 
is O 
still O 
lacking O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
impact O 
of O 
nano- O 
WC B-FORMULA 
on O 
tetrodotoxin B-TRIVIAL 
( O 
TTX B-ABBREVIATION 
)-sensitive O 
voltage O 
- O 
activated O 
sodium B-SYSTEMATIC 
current O 
( O 
I( O 
Na B-FORMULA 
) O 
) O 
of O 
hippocampal O 
CA1 O 
pyramidal O 
neurons O 
. O 
Results O 
showed O 
that O 
acute O 
exposure O 
of O 
nano- O 
WC B-FORMULA 
attenuated O 
the O 
peak O 
amplitudes O 
of O 
I( O 
Na B-FORMULA 
) O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
The O 
minimal O 
effective O 
concentration O 
was O 
10(-5)g O 
/ O 
ml O 
. O 
The O 
exposure O 
of O 
nano- O 
WC B-FORMULA 
significantly O 
decreased O 
current O 
amplitudes O 
of O 
the O 
current-voltage O 
curves O 
of O 
I( O 
Na B-FORMULA 
) O 
from O 
-50 O 
to O 
+ O 
50 O 
mV O 
, O 
shifted O 
the O 
steady O 
- O 
state O 
activation O 
and O 
inactivation O 
curves O 
of O 
I( O 
Na B-FORMULA 
) O 
negatively O 
and O 
delayed O 
the O 
recovery O 
of O 
I( O 
Na B-FORMULA 
) O 
from O 
inactivation O 
state O 
. O 
After O 
exposure O 
to O 
nano- O 
WC B-FORMULA 
, O 
the O 
peak O 
amplitudes O 
, O 
overshoots O 
and O 
the O 
V-thresholds O 
of O 
action O 
potentials O 
( O 
APs O 
) O 
were O 
markedly O 
reduced O 
. O 
These O 
results O 
suggested O 
that O 
exposure O 
of O 
nano- O 
WC B-FORMULA 
could O 
influence O 
some O 
characteristics O 
of O 
APs O 
evoked O 
from O 
the O 
hippocampal O 
CA1 O 
neurons O 
by O 
modifying O 
the O 
kinetics O 
of O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
channels O 
( O 
VGSCs O 
) O 
. O 

mediates O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
induced O 
cell O 
death O 
through O 
p85 O 
S6K1 O 
. O 

IκB O 
kinase O 
( O 
IKK O 
) O 
/ O 
NF-κB O 
pathway O 
has O 
been O 
shown O 
to O 
be O 
a O 
major O 
regulator O 
in O 
cell O 
survival O 
. O 
However O 
, O 
the O 
mechanisms O 
through O 
which O 
IKK O 
mediates O 
cell O 
death O 
are O 
not O 
clear O 
. O 
In O 
this O 
study O 
, O 
we O 
showed O 
that O 
IKK-β O 
contributed O 
to O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H(2)O(2) B-FORMULA 
)-induced O 
cell O 
death O 
independent O 
of O 
the O 
NF-κB O 
pathway O 
. O 
Our O 
results O 
demonstrated O 
that O 
the O 
pro O 
- O 
death O 
function O 
of O 
IKK-β O 
under O 
oxidative O 
stress O 
was O 
mediated O 
by O 
p85 O 
S6K1 O 
( O 
S6 O 
kinase O 
1 O 
) O 
, O 
but O 
not O 
p70 O 
S6K1 O 
through O 
a O 
rapamycin B-TRIVIAL 
-insensitive O 
and O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
kinase O 
- O 
independent O 
mechanism O 
. O 
We O 
found O 
that O 
IKK-β O 
associated O 
with O 
p85 O 
, O 
but O 
not O 
p70 O 
S6K1 O 
, O 
which O 
was O 
required O 
for O 
H(2)O(2) B-FORMULA 
-induced O 
activation O 
of O 
p85 O 
S6K1 O 
. O 
IKK-β O 
and O 
p85 O 
S6K1 O 
contributed O 
to O 
H(2)O(2) B-FORMULA 
-induced O 
phosphorylation O 
of O 
Mdm2 O 
( O 
S166 O 
) O 
and O 
p53 O 
accumulation O 
. O 
p85 O 
S6K1 O 
is O 
critical O 
for O 
IKK-β O 
- O 
mediated O 
cell O 
death O 
. O 
Thus O 
, O 
these O 
findings O 
established O 
a O 
novel O 
oxidative O 
stress O 
- O 
responsive O 
pathway O 
that O 
involves O 
IKK-β O 
, O 
p85 O 
S6K1 O 
and O 
Mdm2 O 
, O 
which O 
is O 
response O 
for O 
H(2)O(2) B-FORMULA 
-induced O 
cell O 
death O 
. O 
Our O 
results O 
have O 
important O 
implications O 
for O 
IKK-β O 
and O 
p85 O 
S6K1 O 
as O 
potential O 
targets O 
for O 
the O 
prevention O 
of O 
diseases O 
involved O 
in O 
oxidative O 
stress O 
- O 
induced O 
aberrant O 
cell O 
death O 
. O 

mouse O 
pulmonary O 
dose O 
and O 
time O 
course O 
responses O 
to O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanospheres O 
and O 
nanobelts O 
. O 

anatase O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO(2) B-FORMULA 
) O 
nanoparticles O 
( O 
NPs O 
) O 
were O 
prepared O 
; O 
nanospheres O 
( O 
NSs O 
) O 
, O 
short O 
nanobelts O 
( O 
NB1 O 
) O 
, O 
and O 
long O 
nanobelts O 
( O 
NB2 O 
) O 
. O 
These O 
NPs O 
were O 
used O 
to O 
investigate O 
the O 
effect O 
of O 
NP O 
shape O 
and O 
length O 
on O 
lung O 
toxicity O 
. O 
Mice O 
were O 
exposed O 
( O 
0-30 O 
µg O 
per O 
mouse O 
) O 
by O 
pharyngeal O 
aspiration O 
and O 
pulmonary O 
toxicity O 
was O 
assessed O 
over O 
a O 
112-day O 
time O 
course O 
. O 
Whole O 
lung O 
lavage O 
data O 
indicated O 
that O 
NB1- O 
and O 
NB2-exposed O 
mice O 
, O 
but O 
not O 
NS-exposed O 
mice O 
, O 
had O 
significant O 
dose- O 
and O 
time O 
- O 
dependent O 
pulmonary O 
inflammation O 
and O 
damage O 
. O 
Histopathological O 
analyses O 
at O 
112 O 
days O 
postexposure O 
determined O 
no O 
interstitial O 
fibrosis O 
in O 
any O 
NS-exposed O 
mice O 
, O 
an O 
increased O 
incidence O 
in O 
30 O 
µg O 
NB1-exposed O 
mice O 
, O 
and O 
significant O 
interstitial O 
fibrosis O 
in O 
30 O 
µg O 
NB2-exposed O 
mice O 
. O 
At O 
112 O 
days O 
postexposure O 
, O 
lung O 
burden O 
of O 
NS O 
was O 
decreased O 
by O 
96.4% O 
and O 
NB2 O 
by O 
80.5% O 
from O 
initial O 
deposition O 
levels O 
. O 
At O 
112 O 
days O 
postexposure O 
, O 
enhanced O 
dark O 
field O 
microscopy O 
determined O 
that O 
alveolar O 
macro- O 
phages O 
were O 
the O 
dominant O 
deposition O 
site O 
, O 
but O 
a O 
fraction O 
of O 
NB1 O 
and O 
NB2 O 
was O 
observed O 
in O 
the O 
alveolar O 
interstitial O 
spaces O 
. O 
For O 
the O 
30 O 
µg O 
exposure O 
groups O 
at O 
112 O 
days O 
postexposure O 
, O 
confocal O 
micro- O 
scopy O 
and O 
immunofluorescent O 
staining O 
demonstrated O 
that O 
retained O 
NB2 O 
but O 
not O 
NS O 
were O 
present O 
in O 
the O 
interstitium O 
subjacent O 
to O 
the O 
terminal O 
bronchiole O 
near O 
the O 
normal O 
location O 
of O 
the O 
smallest O 
lymphatic O 
capillaries O 
in O 
the O 
lung O 
. O 
These O 
lymphatic O 
capillaries O 
play O 
a O 
critical O 
role O 
in O 
particle O 
clearance O 
, O 
and O 
the O 
accumulation O 
of O 
NB2 O 
, O 
but O 
not O 
NS O 
, O 
suggests O 
possible O 
impaired O 
lymphatic O 
clearance O 
by O 
the O 
high O 
aspect O 
ratio O 
particles O 
. O 
In O 
summary O 
, O 
our O 
data O 
indicate O 
that O 
TiO(2) B-FORMULA 
NP O 
shape O 
alters O 
pulmonary O 
responses O 
, O 
with O 
severity O 
of O 
responses O 
being O 
ranked O 
as O 
NS O 
< O 
NB1 O 
< O 
NB2 O 
. O 

of O 
parabens B-FAMILY 
on O 
adipocyte O 
differentiation O 
. O 

are O 
a O 
group O 
of O 
alkyl B-FAMILY 
esters I-FAMILY 
of O 
p-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
that O 
include O 
methylparaben B-SYSTEMATIC 
, O 
ethylparaben B-SYSTEMATIC 
, O 
propylparaben B-SYSTEMATIC 
, O 
butylparaben B-SYSTEMATIC 
, O 
and O 
benzylparaben B-SYSTEMATIC 
. O 
Paraben B-MULTIPLE 
esters I-MULTIPLE 
and I-MULTIPLE 
their I-MULTIPLE 
salts I-MULTIPLE 
are O 
widely O 
used O 
as O 
preservatives O 
in O 
cosmetics O 
, O 
toiletries O 
, O 
food O 
, O 
and O 
pharmaceuticals O 
. O 
Humans O 
are O 
exposed O 
to O 
parabens B-FAMILY 
through O 
the O 
use O 
of O 
such O 
products O 
from O 
dermal O 
contact O 
, O 
ingestion O 
, O 
and O 
inhalation O 
. O 
However O 
, O 
research O 
on O 
the O 
effects O 
of O 
parabens B-FAMILY 
on O 
health O 
is O 
limited O 
, O 
and O 
the O 
effects O 
of O 
parabens B-FAMILY 
on O 
adipogenesis O 
have O 
not O 
been O 
systematically O 
studied O 
. O 
Here O 
, O 
we O 
report O 
that O 
( O 
1 O 
) O 
parabens B-FAMILY 
promote O 
adipogenesis O 
( O 
or O 
adipocyte O 
differentiation O 
) O 
in O 
murine O 
3T3-L1 O 
cells O 
, O 
as O 
revealed O 
by O 
adipocyte O 
morphology O 
, O 
lipid O 
accumulation O 
, O 
and O 
mRNA O 
expression O 
of O 
adipocyte O 
- O 
specific O 
markers O 
; O 
( O 
2 O 
) O 
the O 
adipogenic O 
potency O 
of O 
parabens B-FAMILY 
is O 
increased O 
with O 
increasing O 
length O 
of O 
the O 
linear O 
alkyl O 
chain O 
in O 
the O 
following O 
potency O 
ranking O 
order O 
: O 
methyl B-SYSTEMATIC 
- O 
< O 
ethyl B-SYSTEMATIC 
- O 
< O 
propyl B-SYSTEMATIC 
- O 
< O 
butylparaben B-SYSTEMATIC 
. O 
The O 
extension O 
of O 
the O 
linear O 
alkyl O 
chain O 
with O 
an O 
aromatic O 
ring O 
in O 
benzylparaben B-SYSTEMATIC 
further O 
augments O 
the O 
adipogenic O 
ability O 
, O 
whereas O 
4-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
the O 
common O 
metabolite O 
of O 
all O 
parabens B-FAMILY 
, O 
and O 
the O 
structurally O 
related O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
without O 
the O 
OH B-FORMULA 
group O 
) O 
are O 
inactive O 
in O 
promoting O 
3T3-L1 O 
adipocyte O 
differentiation O 
; O 
( O 
3 O 
) O 
parabens B-FAMILY 
activate O 
glucocorticoid O 
receptor O 
and O 
/ O 
or O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
in O 
3T3-L1 O 
preadipocytes O 
; O 
however O 
, O 
no O 
direct O 
binding O 
to O 
, O 
or O 
modulation O 
of O 
, O 
the O 
ligand O 
binding O 
domain O 
of O 
the O 
glucocorticoid O 
receptor O 
by O 
parabens B-FAMILY 
was O 
detected O 
by O 
glucocorticoid O 
receptor O 
competitor O 
assays O 
; O 
and O 
lastly O 
, O 
( O 
4 O 
) O 
parabens B-FAMILY 
, O 
butyl- B-MULTIPLE 
and I-MULTIPLE 
benzylparaben I-MULTIPLE 
in O 
particular O 
, O 
also O 
promote O 
adipose O 
conversion O 
of O 
human O 
adipose O 
- O 
derived O 
multipotent O 
stromal O 
cells O 
. O 
Our O 
results O 
suggest O 
that O 
parabens B-FAMILY 
may O 
contribute O 
to O 
obesity O 
epidemic O 
, O 
and O 
the O 
role O 
of O 
parabens B-FAMILY 
in O 
adipogenesis O 
in O 
vivo O 
needs O 
to O 
be O 
examined O 
further O 
. O 

present O 
study O 
aimed O 
to O 
investigate O 
the O 
actions O 
of O 
fibroblast O 
growth O 
factor O 
21 O 
( O 
FGF21 O 
) O 
on O 
energy O 
balance O 
in O 
a O 
natural O 
model O 
of O 
relative O 
fatness O 
, O 
the O 
Siberian O 
hamster O 
. O 
Hamsters O 
were O 
studied O 
under O 
long O 
days O 
( O 
LD O 
) O 
to O 
promote O 
weight O 
gain O 
, O 
or O 
short O 
days O 
to O 
induce O 
weight O 
loss O 
, O 
and O 
treated O 
with O 
rhFGF21 O 
( O 
3 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
via O 
s.c O 
. O 
minipumps O 
for O 
14 O 
days O 
. O 
On O 
days O 
7-9 O 
, O 
detailed O 
assessments O 
of O 
ingestive O 
behaviour O 
, O 
metabolic O 
gas O 
exchange O 
and O 
locomotor O 
activity O 
were O 
made O 
. O 
FGF21 O 
caused O 
substantial O 
( O 
P O 
< O 
0.0001 O 
) O 
weight O 
loss O 
in O 
the O 
fat O 
LD O 
state O 
but O 
not O 
in O 
the O 
lean O 
SD O 
state O 
: O 
at O 
the O 
end O 
of O 
the O 
study O 
, O 
FGF21 O 
- O 
treated O 
hamsters O 
in O 
LD O 
lost O 
18% O 
of O 
body O 
weight O 
compared O 
to O 
vehicle O 
controls O 
, O 
which O 
is O 
comparable O 
to O 
the O 
natural O 
body O 
weight O 
loss O 
observed O 
in O 
SD O 
. O 
Epididymal O 
fat O 
pads O 
, O 
a O 
correlate O 
of O 
total O 
carcass O 
fat O 
content O 
, O 
were O 
reduced O 
by O 
19% O 
in O 
FGF21 O 
treated O 
hamsters O 
in O 
LD O 
, O 
whereas O 
no O 
difference O 
was O 
found O 
in O 
SD O 
. O 
Body O 
weight O 
loss O 
in O 
LD O 
was O 
associated O 
with O 
a O 
reduction O 
in O 
food O 
intake O 
( O 
P O 
< O 
0.001 O 
) O 
and O 
a O 
decreased O 
respiratory O 
exchange O 
ratio O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
indicating O 
increased O 
fat O 
oxidation O 
. O 
Treatment O 
with O 
FGF21 O 
maintained O 
the O 
normal O 
nocturnal O 
increase O 
in O 
oxygen B-SYSTEMATIC 
consumption O 
and O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
production O 
into O 
the O 
early O 
light O 
phase O 
in O 
hamsters O 
in O 
LD O 
, O 
indicating O 
increased O 
energy O 
expenditure O 
, O 
although O 
locomotor O 
activity O 
was O 
unaffected O 
. O 
These O 
data O 
suggest O 
a O 
greater O 
efficacy O 
of O 
FGF21 O 
in O 
hamsters O 
in O 
LD O 
compared O 
to O 
those O 
in O 
SD O 
, O 
which O 
is O 
consistent O 
with O 
both O 
the O 
peripheral O 
and O 
possibly O 
central O 
actions O 
of O 
FGF21 O 
with O 
respect O 
to O 
promoting O 
a O 
lean O 
phenotype O 
. O 
The O 
observed O 
differences O 
in O 
FGF21 O 
sensitivity O 
may O 
relate O 
to O 
day O 
length O 
- O 
induced O 
changes O 
in O 
adipose O 
tissue O 
mass O 
. O 

examine O 
the O 
effects O 
of O 
standardized O 
( O 
reference O 
) O 
tobacco O 
preparations O 
on O 
human O 
oral O 
cavity O 
cells O 
, O 
two O 
oral O 
squamous O 
cell O 
carcinoma O 
cell O 
lines O 
( O 
101A O 
, O 
101B O 
) O 
and O 
normal O 
human O 
gingival O 
epithelial O 
cells O 
( O 
HGEC O 
) O 
were O 
treated O 
with O 
cigarette O 
smoke O 
total O 
particulate O 
matter O 
( O 
TPM O 
) O 
, O 
smokeless O 
tobacco O 
extracted O 
with O 
complete O 
artificial O 
saliva O 
( O 
ST O 
/ O 
CAS O 
) O 
, O 
or O 
whole O 
- O 
smoke O 
conditioned O 
media O 
( O 
WS-CM O 
) O 
. O 
EC-50 O 
values O 
, O 
as O 
determined O 
by O 
sulforhodamine B-TRIVIAL 
B I-TRIVIAL 
assays O 
, O 
varied O 
among O 
the O 
cell O 
types O 
and O 
agents O 
. O 
When O 
normalized O 
to O 
nicotine B-TRIVIAL 
content O 
, O 
cytotoxicity O 
for O 
WS-CM O 
and O 
TPM O 
was O 
higher O 
compared O 
to O 
that O 
observed O 
with O 
ST O 
/ O 
CAS O 
. O 
Nicotine B-TRIVIAL 
alone O 
had O 
no O 
or O 
only O 
minimal O 
cytotoxicity O 
for O 
all O 
cell O 
types O 
in O 
the O 
applied O 
range O 
. O 
Activation O 
of O 
pro O 
- O 
apoptotic O 
caspase-3 O 
was O 
examined O 
in O 
all O 
cell O 
types O 
at O 
their O 
respective O 
EC-50 O 
doses O 
for O 
the O 
three O 
agents O 
. O 
TPM O 
, O 
but O 
not O 
ST O 
/ O 
CAS O 
or O 
WS-CM O 
significantly O 
activated O 
caspase-3 O 
in O 
all O 
three O 
cell O 
types O 
. O 
Fluorescence O 
- O 
activated O 
cell O 
sorting O 
( O 
FACS O 
) O 
for O 
expression O 
of O 
the O 
early O 
apoptosis O 
marker O 
Annexin O 
V O 
and O 
for O 
nuclear O 
staining O 
by O 
7-aminoactinomycin B-SYSTEMATIC 
( O 
7-AAD B-SYSTEMATIC 
) O 
revealed O 
different O 
extents O 
of O 
apoptosis O 
versus O 
non-apoptotic O 
cell O 
death O 
for O 
the O 
three O 
agents O 
. O 
These O 
data O 
characterize O 
differential O 
responses O 
of O 
normal O 
and O 
malignant O 
oral O 
cells O 
after O 
exposure O 
to O 
TPM O 
, O 
ST O 
/ O 
CAS O 
, O 
or O 
WS-CM O 
. O 
They O 
assist O 
in O 
understanding O 
differential O 
effects O 
of O 
combustible O 
versus O 
non-combustible O 
tobacco O 
products O 
, O 
and O 
in O 
identifying O 
novel O 
biomarkers O 
for O 
tobacco O 
smoke O 
exposure O 
and O 
effect O 
in O 
the O 
oral O 
cavity O 
. O 

of O 
energy O 
metabolism O 
is O 
critical O 
for O 
the O 
prevention O 
of O 
obesity O 
, O 
diabetes O 
, O 
and O 
hepatic O 
steatosis O 
. O 
Here O 
, O 
we O 
report O 
an O 
important O 
role O 
for O 
the O 
pleckstrin O 
homology O 
- O 
related O 
domain O 
family O 
member O 
, O 
T-cell O 
death O 
- O 
associated O 
gene O 
51 O 
( O 
TDAG51 O 
) O 
, O 
in O 
the O 
regulation O 
of O 
energy O 
metabolism O 
. O 
TDAG51 O 
expression O 
was O 
examined O 
during O 
adipocyte O 
differentiation O 
. O 
Adipogenic O 
potential O 
of O 
preadipocytes O 
with O 
knockdown O 
or O 
absence O 
of O 
TDAG51 O 
was O 
assessed O 
. O 
Weight O 
gain O 
, O 
insulin O 
sensitivity O 
, O 
metabolic O 
rate O 
, O 
and O 
liver O 
lipid O 
content O 
were O 
also O 
compared O 
between O 
TDAG51-deficient O 
( O 
TDAG51(- O 
/ O 
- O 
) O 
) O 
and O 
wild O 
- O 
type O 
mice O 
. O 
In O 
addition O 
to O 
its O 
relatively O 
high O 
expression O 
in O 
liver O 
, O 
TDAG51 O 
was O 
also O 
present O 
in O 
white O 
adipose O 
tissue O 
( O 
WAT O 
) O 
. O 
TDAG51 O 
was O 
downregulated O 
during O 
adipogenesis O 
, O 
and O 
TDAG51(- O 
/ O 
- O 
) O 
preadipocytes O 
exhibited O 
greater O 
lipogenic O 
potential O 
. O 
TDAG51(- O 
/ O 
- O 
) O 
mice O 
fed O 
a O 
chow O 
diet O 
exhibited O 
greater O 
body O 
and O 
WAT O 
mass O 
, O 
had O 
reduced O 
energy O 
expenditure O 
, O 
displayed O 
mature O 
- O 
onset O 
insulin O 
resistance O 
( O 
IR O 
) O 
, O 
and O 
were O 
predisposed O 
to O 
hepatic O 
steatosis O 
. O 
TDAG51(- O 
/ O 
- O 
) O 
mice O 
had O 
increased O 
hepatic O 
triglycerides B-FAMILY 
and O 
SREBP-1 O 
target O 
gene O 
expression O 
. O 
Furthermore O 
, O 
TDAG51 O 
expression O 
was O 
inversely O 
correlated O 
with O 
fatty O 
liver O 
in O 
multiple O 
mouse O 
models O 
of O 
hepatic O 
steatosis O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
suggest O 
that O 
TDAG51 O 
is O 
involved O 
in O 
energy O 
homeostasis O 
at O 
least O 
in O 
part O 
by O 
regulating O 
lipogenesis O 
in O 
liver O 
and O 
WAT O 
, O 
and O 
hence O 
, O 
may O 
constitute O 
a O 
novel O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
obesity O 
and O 
IR O 
. O 

- O 
exchange O 
is O 
a O 
powerful O 
simulation O 
method O 
for O 
sampling O 
the O 
basins O 
of O 
a O 
rugged O 
energy O 
landscape O 
. O 
The O 
replica O 
- O 
exchange O 
method's O 
sampling O 
is O 
efficient O 
because O 
it O 
allows O 
replicas O 
to O 
perform O 
round O 
trips O 
in O 
temperature O 
space O 
, O 
thereby O 
visiting O 
both O 
low O 
and O 
high O 
temperatures O 
in O 
the O 
same O 
simulation O 
. O 
However O 
, O 
replicas O 
have O 
a O 
diffusive O 
walk O 
in O 
temperature O 
space O 
, O 
and O 
the O 
round O 
trip O 
rate O 
decreases O 
significantly O 
with O 
the O 
system O 
size O 
. O 
These O 
drawbacks O 
make O 
convergence O 
of O 
the O 
simulation O 
even O 
more O 
difficult O 
than O 
it O 
already O 
is O 
when O 
bigger O 
systems O 
are O 
tackled O 
. O 
Here O 
, O 
we O 
present O 
a O 
simple O 
modification O 
of O 
the O 
exchange O 
method O 
. O 
In O 
this O 
method O 
, O 
one O 
of O 
the O 
replicas O 
steadily O 
raises O 
or O 
lowers O 
its O 
temperature O 
. O 
We O 
tested O 
the O 
convective O 
replica O 
- O 
exchange O 
method O 
on O 
three O 
systems O 
of O 
varying O 
complexity O 
: O 
the O 
alanine B-FAMILY 
dipeptide I-FAMILY 
in O 
implicit O 
solvent O 
, O 
the O 
GB1 O 
β-hairpin O 
in O 
explicit O 
solvent O 
and O 
the O 
Aβ(25-35) O 
homotrimer O 
in O 
a O 
coarse O 
grained O 
representation O 
. O 
For O 
the O 
highly O 
frustrated O 
Aβ(25-35) O 
homotrimer O 
, O 
the O 
proposed O 
" O 
convective O 
" O 
replica O 
- O 
exchange O 
method O 
is O 
twice O 
as O 
fast O 
as O 
the O 
standard O 
method O 
. O 
It O 
discovered O 
24 O 
out O 
of O 
27 O 
free O 
- O 
energy O 
basins O 
in O 
less O 
than O 
500 O 
ns O 
. O 
It O 
also O 
prevented O 
the O 
formation O 
of O 
groups O 
of O 
replicas O 
that O 
usually O 
form O 
on O 
either O 
side O 
of O 
an O 
exchange O 
bottleneck O 
, O 
leading O 
to O 
a O 
more O 
efficient O 
sampling O 
of O 
new O 
energy O 
basins O 
than O 
in O 
the O 
standard O 
method O 
. O 

electrophoretic O 
deposition O 
of O 
GdOCl B-FORMULA 
nanoplatelets O 
. O 

deposition O 
has O 
emerged O 
as O 
a O 
versatile O 
and O 
precisely O 
tunable O 
approach O 
for O 
the O 
rapid O 
deposition O 
of O 
conformal O 
thin O 
films O 
of O 
colloidal O 
nanocrystals O 
. O 
The O 
electrophoretic O 
deposition O 
of O 
phosphor O 
particles O 
has O 
assumed O 
special O 
significance O 
in O 
recent O 
years O 
as O 
a O 
commercially O 
viable O 
means O 
toward O 
the O 
fabrication O 
of O 
large O 
- O 
area O 
, O 
ultrathin O 
high O 
- O 
resolution O 
emissive O 
display O 
screens O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
the O 
anisotropic O 
shape O 
of O 
colloidal O 
ligand O 
- O 
passivated O 
GdOCl B-FORMULA 
nanoplatelets O 
enables O 
their O 
assembly O 
with O 
remarkable O 
substrate O 
alignment O 
and O 
a O 
high O 
packing O 
density O 
upon O 
electrophoretic O 
deposition O 
. O 
GdOCl B-FORMULA 
nanocrystals O 
are O 
promising O 
candidates O 
for O 
phosphor O 
applications O 
given O 
their O 
low O 
maximum O 
phonon O 
cutoff O 
energy O 
, O 
robust O 
chemical O 
stability O 
over O 
prolonged O 
periods O 
of O 
operation O 
, O 
and O 
ability O 
to O 
promote O 
efficacious O 
phonon O 
energy O 
transfer O 
to O 
dopant O 
ions O 
. O 
Potentiostatic O 
deposition O 
of O 
GdOCl B-FORMULA 
nanoplatelets O 
from O 
cyclohexane B-SYSTEMATIC 
dispersions O 
allows O 
the O 
deposition O 
of O 
individual O 
nanoplatelets O 
with O 
their O 
basal O 
planes O 
parallel O 
to O 
the O 
electrode O 
surface O 
. O 
Tuning O 
the O 
applied O 
voltage O 
and O 
solution O 
concentration O 
allows O 
control O 
of O 
film O 
thickness O 
, O 
ranging O 
up O 
to O 
several O 
tens O 
of O 
micrometers O 
. O 
The O 
high O 
degree O 
of O 
particle O 
alignment O 
is O 
attributed O 
to O 
anisotropic O 
charge O 
distribution O 
and O 
entrainment O 
within O 
electroosmotic O 
flows O 
established O 
in O 
the O 
vicinity O 
of O 
the O 
electrode O 
surface O 
. O 
The O 
oriented O 
high O 
- O 
particle O 
- O 
density O 
GdOCl B-FORMULA 
nanoplatelet O 
thin O 
films O 
are O 
possible O 
candidates O 
for O 
phosphor O 
applications O 
, O 
which O 
is O 
illustrated O 
by O 
the O 
green O 
emission O 
from O 
a O 
Tb-doped B-FORMULA 
GdOCl I-FORMULA 
thin O 
film O 
on O 
indium B-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ITO B-ABBREVIATION 
) O 
- O 
coated O 
glass O 
. O 

, O 
generally O 
administered O 
via O 
metered O 
dose O 
or O 
dry O 
powder O 
inhalers O 
, O 
are O 
the O 
mainstays O 
of O 
pharmacological O 
treatment O 
of O 
stable O 
COPD O 
. O 
Inhaled O 
long O 
- O 
acting O 
beta-agonists O 
( O 
LABA O 
) O 
and O 
anticholinergics O 
are O 
the O 
bronchodilators O 
primarily O 
used O 
in O 
the O 
chronic O 
treatment O 
of O 
COPD O 
. O 
Anticholinergics O 
act O 
as O 
muscarinic O 
acetylcholine O 
receptor O 
antagonists O 
and O 
are O 
frequently O 
preferred O 
over O 
beta-agonists O 
for O 
their O 
minimal O 
cardiac O 
stimulatory O 
effects O 
and O 
greater O 
efficacy O 
in O 
most O 
studies O 
. O 
Their O 
therapeutic O 
efficacy O 
is O 
based O 
on O 
the O 
fact O 
that O 
vagally O 
mediated O 
bronchoconstriction O 
is O 
the O 
major O 
reversible O 
component O 
of O 
airflow O 
obstruction O 
in O 
patients O 
with O 
COPD O 
. O 
However O 
, O 
bronchodilators O 
are O 
effective O 
only O 
on O 
the O 
reversible O 
component O 
of O 
airflow O 
obstruction O 
, O 
which O 
by O 
definition O 
is O 
limited O 
, O 
as O 
COPD O 
is O 
characterized O 
by O 
a O 
fixed O 
or O 
poorly O 
reversible O 
airflow O 
obstruction O 
. O 
Inhaled O 
anticholinergic O 
antimuscarinic O 
drugs O 
approved O 
for O 
the O 
treatment O 
of O 
COPD O 
include O 
ipratropium B-TRIVIAL 
bromide I-TRIVIAL 
, O 
oxitropium B-TRIVIAL 
bromide I-TRIVIAL 
and O 
tiotropium B-TRIVIAL 
bromide I-TRIVIAL 
. O 
Ipratropium B-TRIVIAL 
bromide I-TRIVIAL 
, O 
the O 
prototype O 
of O 
anticholinergic O 
bronchodilators O 
, O 
is O 
a O 
short O 
- O 
acting O 
agent O 
. O 
Oxitropium B-TRIVIAL 
bromide I-TRIVIAL 
is O 
administered O 
twice O 
a O 
day O 
. O 
Tiotropium B-TRIVIAL 
bromide I-TRIVIAL 
, O 
the O 
only O 
long O 
- O 
acting O 
antimuscarinic O 
agent O 
( O 
LAMA O 
) O 
currently O 
approved O 
, O 
is O 
administered O 
once O 
a O 
day O 
. O 
Newer O 
LAMAs O 
including O 
aclidinium B-TRIVIAL 
bromide I-TRIVIAL 
and O 
glycopyrrolate B-TRIVIAL 
bromide I-TRIVIAL 
are O 
currently O 
in O 
phase O 
III O 
development O 
for O 
treatment O 
of O 
COPD O 
. O 
Some O 
new O 
LAMAs O 
, O 
including O 
glycocpyrrolate O 
, O 
are O 
suitable O 
for O 
once O 
daily O 
administration O 
and O 
, O 
unlike O 
tiotropium B-TRIVIAL 
, O 
have O 
a O 
rapid O 
onset O 
of O 
action O 
. O 
New O 
LAMAs O 
and O 
their O 
combination O 
with O 
ultra-LABA O 
and O 
, O 
possibly O 
, O 
inhaled O 
corticosteroids O 
, O 
seem O 
to O 
open O 
new O 
perspectives O 
in O 
the O 
management O 
of O 
COPD O 
. O 
Dual O 
- O 
pharmacology O 
muscarinic O 
antagonist-beta2 O 
agonist O 
( O 
MABA O 
) O 
molecules O 
present O 
a O 
novel O 
approach O 
to O 
the O 
treatment O 
of O 
COPD O 
by O 
combining O 
muscarinic O 
antagonism O 
and O 
beta2 O 
agonism O 
in O 
a O 
single O 
molecule O 
. O 

obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
is O 
an O 
increasing O 
global O 
health O 
problem O 
and O 
cause O 
of O 
death O 
. O 
COPD O 
is O 
a O 
chronic O 
inflammatory O 
disease O 
predominantly O 
affecting O 
small O 
airways O 
and O 
lung O 
parenchyma O 
that O 
leads O 
to O 
progressive O 
airway O 
obstruction O 
. O 
However O 
, O 
current O 
therapies O 
fail O 
to O 
prevent O 
either O 
disease O 
progression O 
or O 
mortality O 
. O 
The O 
mainstay O 
of O 
current O 
drug O 
therapy O 
is O 
long O 
- O 
acting O 
bronchodilators O 
. O 
Several O 
once O 
daily O 
inhaled O 
β2-agonists O 
and O 
muscarinic O 
antagonists O 
( O 
and O 
combinations O 
) O 
are O 
now O 
in O 
development O 
. O 
No O 
treatments O 
effectively O 
suppress O 
chronic O 
inflammation O 
in O 
COPD O 
lungs O 
. O 
With O 
better O 
understanding O 
of O 
the O 
inflammatory O 
and O 
destructive O 
process O 
in O 
the O 
pathophysiology O 
of O 
COPD O 
, O 
several O 
new O 
therapeutic O 
targets O 
have O 
been O 
identified O 
. O 
Several O 
mediator O 
antagonists O 
or O 
inhibitors O 
tested O 
in O 
COPD O 
have O 
so O 
far O 
been O 
disappointing O 
, O 
but O 
CXCR2 O 
antagonists O 
that O 
block O 
pulmonary O 
neutrophil O 
and O 
monocyte O 
recruitment O 
are O 
more O 
promising O 
. O 
Broad O 
spectrum O 
anti-inflammatory O 
drugs O 
may O 
be O 
more O 
effective O 
, O 
and O 
include O 
inhibitors O 
of O 
the O 
proinflammatory O 
enzymes O 
phosphodiesterase-4 O 
, O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
, O 
Janus O 
kinases O 
, O 
NF-κB O 
kinase O 
and O 
PI3 O 
kinase-γ O 
and O 
-δ O 
, O 
but O 
side O 
effects O 
after O 
oral O 
administration O 
are O 
a O 
major O 
limitation O 
so O 
that O 
in O 
future O 
inhaled O 
delivery O 
may O 
be O 
necessary O 
. O 
A O 
new O 
promising O 
approach O 
is O 
reversal O 
of O 
corticosteroid B-TRIVIAL 
resistance O 
through O 
increasing O 
histone O 
deacetylase-2 O 
( O 
HDAC2 O 
) O 
activity O 
. O 
This O 
might O 
be O 
achieved O 
by O 
existing O 
treatments O 
such O 
as O 
theophylline B-TRIVIAL 
, O 
nortriptyline B-TRIVIAL 
and O 
macrolides B-FAMILY 
, O 
or O 
more O 
selectively O 
by O 
PI3 O 
kinase-δ O 
inhibitors O 
. O 
Thus O 
although O 
there O 
have O 
been O 
major O 
advances O 
in O 
the O 
development O 
of O 
long O 
- O 
acting O 
bronchodilators O 
for O 
COPD O 
, O 
it O 
has O 
proved O 
difficult O 
to O 
find O 
anti-inflammatory O 
treatments O 
that O 
are O 
safe O 
and O 
effective O 
. O 

comparative O 
study O 
of O 
two O 
novel O 
nanosized O 
radiolabeled O 
analogues O 
of O 
methionine B-TRIVIAL 
for O 
SPECT O 
tumor O 
imaging O 
. O 

has O 
been O 
reported O 
that O 
most O 
tumor O 
cells O 
show O 
an O 
increased O 
uptake O 
of O 
variety O 
of O 
amino B-FAMILY 
acids I-FAMILY 
specially O 
methionine B-TRIVIAL 
when O 
compared O 
with O 
normal O 
cells O 
and O 
amino B-FAMILY 
acid I-FAMILY 
transport O 
is O 
generally O 
increased O 
in O 
malignant O 
transformation O 
. O 
Based O 
on O 
the O 
evidences O 
, O 
two O 
novel O 
nanosized O 
analogues O 
of O 
methionine B-TRIVIAL 
( O 
Anionic O 
Linear O 
Globular O 
Dendrimer O 
G(2) O 
, O 
a O 
biodigredabale O 
anionic O 
linear O 
globular- O 
Methionin B-TRIVIAL 
, O 
and O 
DTPA B-ABBREVIATION 
- O 
Methionine B-TRIVIAL 
( O 
1 O 
) O 
conjugates O 
) O 
were O 
synthesized O 
and O 
labeled O 
with O 
(99m)Tc B-FORMULA 
and O 
used O 
in O 
tumor O 
imaging/ O 
therapy O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
results O 
showed O 
marked O 
tumor O 
SPECT O 
molecular O 
imaging O 
liabilities O 
for O 
both O 
compounds O 
but O 
with O 
a O 
better O 
performance O 
by O 
administration O 
of O 
(99m)Tc B-FORMULA 
-Dendrimer O 
G(2)- O 
Methionin B-TRIVIAL 
. O 
The O 
results O 
also O 
showed O 
a O 
good O 
anticancer O 
activity O 
for O 
99mTc B-FORMULA 
- O 
DTPA B-ABBREVIATION 
- O 
Methionine B-TRIVIAL 
. O 
Based O 
on O 
the O 
present O 
study O 
(99m)Tc B-FORMULA 
-Dendrimer O 
G(2)- O 
Methionin B-TRIVIAL 
or O 
99mTc B-FORMULA 
- O 
DTPA B-ABBREVIATION 
-( O 
Methionine B-TRIVIAL 
)(1 O 
) O 
have O 
potentials O 
to O 
be O 
used O 
in O 
tumor O 
molecular O 
imaging O 
as O 
well O 
as O 
cancer O 
therapy O 
in O 
future O 
. O 

of O 
tub O 
gene O 
in O 
mice O 
induces O 
obesity O 
, O 
suggesting O 
that O 
tub O 
could O 
be O 
an O 
important O 
regulator O 
of O 
energy O 
balance O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
investigated O 
whether O 
insulin O 
, O 
leptin O 
, O 
and O 
obesity O 
can O 
modulate O 
Tub O 
in O 
vivo O 
in O 
hypothalamic O 
nuclei O 
, O 
and O 
we O 
investigated O 
possible O 
consequences O 
on O 
energy O 
balance O 
, O 
neuropeptide O 
expression O 
, O 
and O 
hepatic O 
glucose B-TRIVIAL 
metabolism O 
. O 
Food O 
intake O 
, O 
metabolic O 
characteristics O 
, O 
signaling O 
proteins O 
, O 
and O 
neuropeptide O 
expression O 
were O 
measured O 
in O 
response O 
to O 
fasting O 
and O 
refeeding O 
, O 
intracerebroventricular O 
insulin O 
and O 
leptin O 
, O 
and O 
Tub O 
antisense O 
oligonucleotide O 
( O 
ASO O 
) O 
. O 
Tub O 
tyrosine B-TRIVIAL 
phosphorylation O 
( O 
Tub-p- O 
tyr B-FORMULA 
) O 
is O 
modulated O 
by O 
nutritional O 
status O 
. O 
Tub O 
is O 
a O 
substrate O 
of O 
insulin O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
( O 
IRTK O 
) O 
and O 
leptin O 
receptor O 
(LEPR)-Janus O 
kinase O 
2 O 
( O 
JAK2 O 
) O 
in O 
hypothalamic O 
nuclei O 
. O 
After O 
leptin O 
or O 
insulin O 
stimulation O 
, O 
Tub O 
translocates O 
to O 
the O 
nucleus O 
. O 
Inhibition O 
of O 
Tub O 
expression O 
in O 
hypothalamus O 
by O 
ASO O 
increased O 
food O 
intake O 
, O 
fasting O 
blood O 
glucose B-TRIVIAL 
, O 
and O 
hepatic O 
glucose B-TRIVIAL 
output O 
, O 
decreased O 
O(2) B-FORMULA 
consumption O 
, O 
and O 
blunted O 
the O 
effect O 
of O 
insulin O 
or O 
leptin O 
on O 
proopiomelanocortin O 
, O 
thyroid O 
- O 
releasing O 
hormone O 
, O 
melanin O 
- O 
concentrating O 
hormone O 
, O 
and O 
orexin O 
expression O 
. O 
In O 
hypothalamus O 
of O 
mice O 
administered O 
a O 
high O 
- O 
fat O 
diet O 
, O 
there O 
is O 
a O 
reduction O 
in O 
leptin O 
and O 
insulin O 
- O 
induced O 
Tub-p- O 
tyr B-FORMULA 
and O 
nuclear O 
translocation O 
, O 
which O 
is O 
reversed O 
by O 
reducing O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
expression O 
. O 
These O 
results O 
indicate O 
that O 
Tub O 
has O 
a O 
key O 
role O 
in O 
the O 
control O 
of O 
insulin O 
and O 
leptin O 
effects O 
on O 
food O 
intake O 
, O 
and O 
the O 
modulation O 
of O 
Tub O 
may O 
contribute O 
to O 
insulin O 
and O 
leptin O 
resistance O 
in O 
DIO O 
mice O 
. O 

effects O 
of O 
glabridin B-TRIVIAL 
-rich O 
supercritical O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
extract O 
of O 
licorice O 
in O 
high O 
- O 
fat O 
- O 
fed O 
obese O 
mice O 
. O 

( O 
Glycyrrhiza O 
glabra O 
Linne O 
) O 
is O 
a O 
well O 
- O 
known O 
medicinal O 
plant O 
and O 
glabridin B-TRIVIAL 
is O 
an O 
isoflavan B-FAMILY 
isolated O 
from O 
licorice O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
anti-obesity O 
effect O 
of O 
glabridin B-TRIVIAL 
and O 
glabridin B-TRIVIAL 
-rich O 
supercritical O 
fluid O 
extract O 
of O 
licorice O 
( O 
LSC O 
) O 
. O 
Glabridin B-TRIVIAL 
effectively O 
inhibited O 
adipogenesis O 
in O 
3T3-L1 O 
cells O 
. O 
Moreover O 
, O 
LSC O 
showed O 
inhibitory O 
effect O 
on O 
adipogenesis O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
inhibitory O 
effect O 
of O 
LSC O 
resulted O 
from O 
inhibiting O 
the O 
induction O 
of O 
the O 
transcriptional O 
factors O 
CCAAT O 
enhancer O 
binding O 
protein O 
alpha O 
and O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
gamma O 
. O 
Then O 
we O 
fed O 
mice O 
with O 
high O 
- O 
fat O 
diet O 
containing O 
none O 
, O 
0.1% O 
and O 
0.25% O 
LSC O 
for O 
8weeks O 
to O 
explore O 
the O 
anti-obesity O 
effect O 
of O 
LSC O 
in O 
vivo O 
. O 
LSC O 
significantly O 
reduced O 
weight O 
gain O 
by O 
high O 
- O 
fat O 
diet O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
reductions O 
of O 
the O 
hypertrophy O 
of O 
white O 
adipose O 
tissue O 
and O 
of O 
fat O 
cell O 
size O 
were O 
also O 
observed O 
. O 
In O 
the O 
liver O 
, O 
LSC O 
supplementation O 
effectively O 
inhibited O 
high O 
- O 
fat O 
diet O 
- O 
induced O 
hepatic O 
steatosis O 
through O 
downregulation O 
of O 
gluconeogenesis O 
related O 
phosphoenolpyruvate B-SYSTEMATIC 
carboxykinase O 
and O 
glucose B-TRIVIAL 
6-phosphatase O 
and O 
upregulation O 
of O 
the O 
β-oxidation O 
related O 
carnitine B-TRIVIAL 
palmitoyltransferase O 
1 O 
. O 
Taken O 
together O 
, O 
our O 
results O 
suggest O 
that O 
glabridin B-TRIVIAL 
and O 
glabridin B-TRIVIAL 
-rich O 
licorice O 
extract O 
would O 
be O 
effective O 
anti-obesity O 
agents O 
. O 

of O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
ligands O 
on O 
male O 
sexual O 
behavior O 
in O 
rats O 
. O 

glutamate B-TRIVIAL 
receptors O 
( O 
mGluRs O 
) O 
, O 
particularly O 
mGluR2 O 
/ O 
3 O 
, O 
mGluR5 O 
and O 
mGluR7 O 
, O 
have O 
received O 
much O 
attention O 
in O 
medication O 
development O 
for O 
the O 
treatment O 
of O 
drug O 
addiction O 
and O 
other O 
neuropsychiatric O 
diseases O 
. O 
However O 
, O 
little O 
is O 
known O 
as O 
to O 
whether O 
mGluR O 
ligands O 
also O 
alter O 
natural O 
sexual O 
behavior O 
, O 
a O 
possible O 
unwanted O 
effect O 
when O 
used O 
in O 
humans O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
used O 
classical O 
copulatory O 
behaviors O 
to O 
evaluate O 
the O 
effects O 
of O 
LY379268 B-IDENTIFIER 
( O 
a O 
selective O 
mGluR2 O 
/ O 
3 O 
agonist O 
) O 
, O 
MPEP B-ABBREVIATION 
( O 
a O 
selective O 
mGluR5 O 
antagonist O 
) O 
and O 
AMN082 B-IDENTIFIER 
( O 
a O 
selective O 
mGluR7 O 
agonist O 
) O 
, O 
on O 
male O 
sexual O 
performance O 
in O 
rats O 
. O 
We O 
found O 
that O 
systemic O 
administration O 
of O 
LY379268 B-IDENTIFIER 
( O 
1 O 
, O 
3 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
had O 
no O 
effect O 
, O 
while O 
MPEP B-ABBREVIATION 
( O 
20 O 
mg O 
/ O 
kg O 
, O 
but O 
not O 
10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
and O 
AMN082 B-IDENTIFIER 
( O 
10 O 
, O 
20 O 
mg O 
/ O 
kg O 
, O 
but O 
not O 
3 O 
mg O 
/ O 
kg O 
) O 
produced O 
a O 
significant O 
and O 
dose O 
- O 
dependent O 
reduction O 
in O 
both O 
sex O 
- O 
seeking O 
and O 
sex O 
- O 
performance O 
behaviors O 
, O 
manifested O 
as O 
an O 
increase O 
in O 
mount O 
or O 
intromission O 
latency O 
and O 
time O 
required O 
for O 
ejaculation O 
, O 
and O 
a O 
reduction O 
in O 
mount O 
or O 
intromission O 
frequency O 
. O 
This O 
inhibition O 
lasted O 
for O 
about O 
30-60 O 
min O 
. O 
These O 
findings O 
suggest O 
that O 
compounds O 
that O 
target O 
mGluR5 O 
or O 
mGluR7 O 
, O 
but O 
not O 
mGluR2 O 
/ O 
3 O 
, O 
may O 
have O 
short O 
- O 
term O 
inhibitory O 
effects O 
on O 
male O 
sexual O 
performance O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Metabotropic O 
Glutamate O 
Receptors' O 
. O 

and O 
cortisol B-TRIVIAL 
responses O 
following O 
an O 
acute O 
session O 
of O 
respiratory O 
muscle O 
endurance O 
training O 
in O 
severely O 
obese O 
patients O 
. O 

is O 
well O 
established O 
that O 
obese O 
patients O 
are O 
hypo O 
- O 
responsive O 
to O 
classical O 
GH-releasing O 
stimuli O 
, O 
including O 
aerobic O 
exercise O 
. O 
Recently O 
, O 
we O 
have O 
demonstrated O 
that O 
whole O 
body O 
vibration O 
was O 
able O 
to O 
markedly O 
stimulate O 
GH O 
secretion O 
in O 
obese O 
patients O 
, O 
thus O 
suggesting O 
that O 
this O 
refractoriness O 
is O 
not O 
absolute O 
but O 
dependent O 
on O 
the O 
GH-releasing O 
stimulus O 
. O 
Furthermore O 
, O 
we O 
have O 
shown O 
the O 
ability O 
of O 
a O 
respiratory O 
muscle O 
endurance O 
training O 
( O 
RMET O 
) O 
to O 
stimulate O 
GH O 
and O 
cortisol B-TRIVIAL 
secretion O 
in O 
healthy O 
subjects O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
RMET O 
on O 
GH O 
and O 
cortisol B-TRIVIAL 
responses O 
in O 
severely O 
obese O 
patients O 
. O 
Eight O 
severely O 
obese O 
patients O 
( O 
4 O 
M O 
/ O 
4 O 
F O 
, O 
mean O 
age±SEM O 
: O 
22.8±1.6 O 
years O 
, O 
body O 
mass O 
index O 
, O 
BMI O 
: O 
39.9±1.1 O 
kg O 
/ O 
m2 O 
) O 
underwent O 
an O 
incremental O 
progressive O 
RMET O 
protocol O 
of O 
11 O 
daily O 
sessions O 
, O 
obtained O 
through O 
the O 
use O 
of O 
a O 
specifically O 
designed O 
respiratory O 
device O 
( O 
Spiro O 
Tiger O 
® O 
) O 
. O 
The O 
12th O 
session O 
of O 
RMET O 
( O 
15 O 
min O 
duration O 
: O 
1 O 
min O 
at O 
a O 
respiration O 
rate O 
of O 
28 O 
acts O 
/ O 
min O 
, O 
5 O 
min O 
at O 
32 O 
acts O 
/ O 
min O 
, O 
5 O 
min O 
at O 
34 O 
acts O 
/ O 
min O 
, O 
4 O 
min O 
at O 
36 O 
acts O 
/ O 
min O 
) O 
was O 
associated O 
with O 
blood O 
samplings O 
for O 
determination O 
of O 
GH O 
, O 
cortisol B-TRIVIAL 
, O 
and O 
lactate B-FAMILY 
( O 
LA O 
) O 
levels O 
. O 
An O 
age- O 
and O 
sex O 
- O 
matched O 
normal O 
- O 
weighted O 
control O 
group O 
( O 
n=7 O 
, O 
4 O 
M O 
/ O 
3 O 
F O 
, O 
age O 
: O 
26.1±3.1 O 
years O 
, O 
BMI O 
: O 
22.4±0.6 O 
kg O 
/ O 
m2 O 
) O 
was O 
also O 
recruited O 
. O 
In O 
both O 
normal O 
- O 
weighted O 
subjects O 
and O 
obese O 
patients O 
, O 
GH O 
secretion O 
significantly O 
increased O 
after O 
a O 
15-min O 
RMET O 
session O 
. O 
Although O 
serum O 
GH O 
levels O 
at O 
30 O 
min O 
were O 
higher O 
in O 
normal O 
- O 
weighted O 
subjects O 
than O 
in O 
obese O 
patients O 
, O 
there O 
was O 
no O 
statistically O 
significant O 
difference O 
in O 
either O 
GH O 
peaks O 
or O 
net O 
GH O 
areas O 
under O 
the O 
curve O 
between O 
the O 
2 O 
groups O 
. O 
RMET O 
significantly O 
increased O 
serum O 
cortisol B-TRIVIAL 
levels O 
in O 
normal O 
- O 
weighted O 
subjects O 
, O 
but O 
was O 
associated O 
to O 
a O 
progressive O 
cortisol B-TRIVIAL 
decline O 
in O 
obese O 
patients O 
. O 
RMET O 
stimulated O 
LA O 
production O 
, O 
with O 
no O 
significant O 
differences O 
in O 
normal O 
- O 
weighted O 
subjects O 
and O 
in O 
obese O 
patients O 
. O 
A O 
15-min O 
RMET O 
session O 
was O 
capable O 
to O 
induce O 
a O 
GH O 
response O 
in O 
severely O 
obese O 
patients O 
, O 
which O 
was O 
comparable O 
to O 
that O 
recorded O 
in O 
normal O 
- O 
weighted O 
subjects O 
. O 
A O 
progressive O 
decline O 
in O 
serum O 
cortisol B-TRIVIAL 
levels O 
occurred O 
in O 
obese O 
patients O 
after O 
RMET O 
, O 
while O 
an O 
opposite O 
pattern O 
( O 
i O 
. O 
e O 
. O 
, O 
a O 
significant O 
cortisol B-TRIVIAL 
increase O 
) O 
was O 
found O 
in O 
normal O 
- O 
weighted O 
subjects O 
. O 
Optimization O 
of O 
long O 
- O 
term O 
RMET O 
protocols O 
could O 
represent O 
a O 
valid O 
strategy O 
to O 
( O 
physiologically O 
) O 
stimulate O 
GH O 
/ O 
IGF-I O 
system O 
in O 
those O 
GH O 
hyposecretory O 
states O 
such O 
as O 
obesity O 
. O 

molecular O 
mechanisms O 
by O 
which O 
cellular O 
energy O 
status O 
regulates O 
global O 
protein O 
synthesis O 
in O 
mammary O 
epithelial O 
cells O 
have O 
not O 
been O 
characterized O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effect O 
of O 
AMP-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
activation O 
by O 
2-deoxyglucose B-SYSTEMATIC 
on O 
protein O 
synthesis O 
and O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
( O 
mTORC1 O 
) O 
signaling O 
pathway O 
in O 
bovine O 
mammary O 
epithelial O 
cells O 
. O 
Phosphorylation O 
of O 
AMPK O 
at O 
Thr B-FORMULA 
172 O 
increased O 
by O 
1.4-fold O 
within O 
5 O 
min O 
, O 
and O 
remained O 
elevated O 
throughout O 
a O 
30-min O 
time O 
course O 
, O 
in O 
response O 
to O 
2-deoxyglucose B-SYSTEMATIC 
. O 
Global O 
rates O 
of O 
protein O 
synthesis O 
declined O 
by O 
78% O 
of O 
control O 
values O 
. O 
The O 
decline O 
in O 
protein O 
synthesis O 
was O 
associated O 
with O 
repression O 
of O 
mTORC1 O 
signaling O 
, O 
as O 
indicated O 
by O 
reduced O 
phosphorylation O 
of O 
ribosomal O 
protein O 
S6 O 
kinase O 
1 O 
and O 
eIF4E O 
binding O 
protein-1 O 
( O 
4E-BP1 O 
) O 
. O 
Phosphorylation O 
of O 
ER-stress O 
marker O 
eIF2α O 
was O 
also O 
increased O 
but O 
only O 
at O 
30 O 
min O 
of O 
2-deoxyglucose B-SYSTEMATIC 
exposure O 
. O 
2-Deoxyglucose B-SYSTEMATIC 
increased O 
phosphorylation O 
of O 
tuberous O 
sclerosis O 
complex O 
2 O 
( O 
TSC2 O 
) O 
on O 
AMPK O 
consensus O 
sites O 
but O 
did O 
not O 
change O 
the O 
amount O 
of O 
TSC1 O 
bound O 
to O 
TSC2 O 
. O 
Activation O 
of O 
AMPK O 
did O 
not O 
result O 
in O 
changes O 
in O 
the O 
amount O 
of O 
raptor O 
bound O 
to O 
mTOR O 
. O 
The O 
inhibitory O 
effects O 
of O 
AMPK O 
activation O 
on O 
mTORC1 O 
signaling O 
were O 
associated O 
with O 
a O 
marked O 
increase O 
in O 
Ser B-FORMULA 
792 O 
phosphorylation O 
on O 
raptor O 
. O 
Collectively O 
, O 
the O 
results O 
suggest O 
that O 
activation O 
of O 
AMPK O 
represses O 
global O 
protein O 
synthesis O 
in O 
mammary O 
epithelial O 
cells O 
through O 
inhibition O 
of O 
mTORC1 O 
signaling O 
. O 

associated O 
with O 
the O 
glucose B-TRIVIAL 
-lowering O 
effect O 
of O 
vildagliptin B-TRIVIAL 
identified O 
from O 
the O 
results O 
of O 
the O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
in O 
Japanese O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 

order O 
to O 
investigate O 
the O 
factors O 
contributing O 
to O 
the O 
glucose B-TRIVIAL 
-lowering O 
effect O 
of O 
vildagliptin B-TRIVIAL 
, O 
we O 
analyzed O 
the O 
results O 
of O 
the O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
together O 
with O 
several O 
clinical O 
parameters O 
in O 
Japanese O 
patients O 
with O 
type O 
2 O 
diabetes O 
before O 
and O 
after O 
24 O 
weeks O 
of O 
treatment O 
with O 
vildagliptin B-TRIVIAL 
. O 
The O 
data O 
of O 
the O 
13 O 
patients O 
who O 
satisfactorily O 
completed O 
the O 
follow O 
- O 
up O 
examinations O 
were O 
included O 
. O 
After O 
24 O 
weeks O 
treatment O 
with O 
vildagliptin B-TRIVIAL 
, O 
the O 
patients O 
were O 
classified O 
into O 
a O 
responder O 
group O 
( O 
69.2% O 
) O 
and O 
a O 
non-responder O 
group O 
( O 
30.8% O 
) O 
; O 
the O 
responders O 
consisting O 
of O 
subjects O 
whose O 
HbA1c O 
decreased O 
following O 
24 O 
weeks O 
treatment O 
with O 
vildagliptin B-TRIVIAL 
, O 
and O 
the O 
non-responders O 
consisting O 
of O 
subjects O 
who O 
did O 
not O 
show O 
any O 
significant O 
decrease O 
of O 
HbA1c O 
. O 
There O 
were O 
no O 
differences O 
in O 
baseline O 
characteristics O 
between O 
the O 
two O 
groups O 
before O 
administration O 
of O 
vildagliptin B-TRIVIAL 
. O 
After O 
24 O 
weeks O 
of O 
treatment O 
, O 
HbA1c O 
was O 
significantly O 
reduced O 
from O 
7.3 O 
± O 
0.5% O 
to O 
6.7 O 
± O 
0.5% O 
in O 
the O 
responder O 
group O 
( O 
P O 
= O 
0.0077 O 
) O 
, O 
while O 
it O 
tended O 
to O 
rather O 
increased O 
from O 
7.1 O 
± O 
0.6% O 
to O 
7.5 O 
± O 
0.7% O 
in O 
the O 
non-responder O 
group O 
( O 
P O 
= O 
0.0679 O 
) O 
. O 
Also O 
, O 
parameters O 
reflecting O 
the O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
, O 
such O 
as O 
the O 
insulinogenic O 
index O 
and O 
oral O 
disposition O 
index O 
, O 
were O 
significantly O 
higher O 
in O 
the O 
responder O 
group O 
than O 
in O 
the O 
non-responder O 
group O 
, O 
whereas O 
insulin O 
sensitivity O 
was O 
similar O 
between O 
the O 
two O 
groups O 
. O 
These O 
results O 
suggest O 
that O 
the O 
difference O 
in O 
the O 
degree O 
of O 
improvement O 
of O 
the O 
glucose B-TRIVIAL 
tolerance O 
between O 
the O 
responder O 
group O 
and O 
non-responder O 
group O 
in O 
this O 
study O 
could O 
be O 
associated O 
with O 
the O 
effect O 
of O 
vildagliptin B-TRIVIAL 
on O 
the O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
secretion O 
, O 
but O 
not O 
on O 
the O 
insulin O 
sensitivity O 
. O 

neutral O 
platinum B-SYSTEMATIC 
complexes O 
bearing O 
an O 
asymmetric O 
N(^) O 
N(^) O 
N O 
ligand O 
for O 
high O 
- O 
performance O 
solution O 
- O 
processed O 
OLEDs O 
. O 

synthesis O 
and O 
full O 
characterization O 
of O 
new O 
platinum B-SYSTEMATIC 
complexes O 
bearing O 
a O 
bulky O 
asymmetric O 
dianionic O 
tridentate O 
ligand O 
is O 
reported O 
. O 
The O 
hindrance O 
of O 
the O 
ligand O 
prevents O 
detrimental O 
intermolecular O 
interactions O 
yielding O 
to O 
highly O 
emitting O 
species O 
in O 
both O 
crystalline O 
state O 
and O 
thin O 
- O 
film O 
. O 
Such O 
properties O 
prompted O 
their O 
successful O 
use O 
in O 
solution O 
- O 
processed O 
OLEDs O 
, O 
showing O 
remarkable O 
external O 
quantum O 
efficiency O 
up O 
to O 
5.6% O 
. O 

from O 
Acorus O 
gramineus O 
alleviates O 
epilepsy O 
by O 
modulating O 
A O 
- O 
type O 
GABA B-ABBREVIATION 
receptors O 
. O 

(α)-asarone B-TRIVIAL 
is O 
a O 
major O 
effective O 
compound O 
isolated O 
from O 
the O 
Chinese O 
medicinal O 
herb O 
Acorus O 
gramineus O 
, O 
which O 
is O 
widely O 
used O 
in O 
clinical O 
practice O 
as O 
an O 
antiepileptic O 
drug O 
; O 
however O 
, O 
its O 
mechanism O 
of O 
action O 
remains O 
unclear O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
characterized O 
the O 
action O 
of O 
α-asarone B-TRIVIAL 
on O 
the O 
excitability O 
of O 
rat O 
hippocampal O 
neurons O 
in O 
culture O 
and O 
on O 
the O 
epileptic O 
activity O 
induced O 
by O 
pentylenetetrazole B-SYSTEMATIC 
or O 
kainate B-TRIVIAL 
injection O 
in O 
vivo O 
. O 
Under O 
cell O 
- O 
attached O 
configuration O 
, O 
the O 
firing O 
rate O 
of O 
spontaneous O 
spiking O 
was O 
inhibited O 
by O 
application O 
of O 
α-asarone B-TRIVIAL 
, O 
which O 
was O 
maintained O 
in O 
the O 
Mg(2+) B-FORMULA 
-free O 
solution O 
. O 
Under O 
whole O 
- O 
cell O 
configuration O 
, O 
α-asarone O 
induced O 
inward O 
currents O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
with O 
an O 
EC(50) O 
of O 
248 O 
± O 
33 O 
μM O 
, O 
which O 
was O 
inhibited O 
by O 
a O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
blocker O 
picotoxin B-TRIVIAL 
and O 
a O 
competitive O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptor O 
antagonist O 
bicuculline B-TRIVIAL 
but O 
not O 
a O 
specific O 
glycine B-TRIVIAL 
receptor O 
inhibitor O 
strychnine B-TRIVIAL 
. O 
Measurement O 
of O 
tonic O 
GABA B-ABBREVIATION 
currents O 
and O 
miniature O 
spontaneous O 
inhibitory O 
postsynaptic O 
currents O 
indicated O 
that O 
α-asarone B-TRIVIAL 
enhanced O 
tonic O 
GABAergic O 
inhibition O 
while O 
left O 
phasic O 
GABAergic O 
inhibition O 
unaffected O 
. O 
In O 
both O 
pentylenetetrazole B-SYSTEMATIC 
and O 
kainate B-TRIVIAL 
seizure O 
models O 
, O 
α-asarone B-TRIVIAL 
suppressed O 
epileptic O 
activity O 
of O 
mice O 
by O 
prolonging O 
the O 
latency O 
to O 
clonic O 
and O 
tonic O 
seizures O 
and O 
reducing O 
the O 
mortality O 
as O 
well O 
as O 
the O 
susceptibility O 
to O 
seizure O 
in O 
vivo O 
presumably O 
dependent O 
on O 
the O 
activation O 
of O 
GABA B-ABBREVIATION 
( O 
A O 
) O 
receptors O 
. O 
In O 
summary O 
, O 
our O 
results O 
suggest O 
that O 
α-asarone B-TRIVIAL 
inhibits O 
the O 
activity O 
of O 
hippocampal O 
neurons O 
and O 
produces O 
antiepileptic O 
effect O 
in O 
central O 
nervous O 
system O 
through O 
enhancing O 
tonic O 
GABAergic O 
inhibition O 
. O 

library O 
of O 
more O 
than O 
200 O 
novel O 
uncharged O 
oxime B-SYSTEMATIC 
reactivators O 
was O 
used O 
to O 
select O 
and O 
refine O 
lead O 
reactivators O 
of O 
human O 
acetylcholinesterase O 
( O 
hAChE O 
) O 
covalently O 
conjugated O 
with O 
sarin B-TRIVIAL 
, O 
cyclosarin B-TRIVIAL 
, O 
VX O 
, O 
paraoxon B-TRIVIAL 
and O 
tabun B-TRIVIAL 
. O 
N- B-FAMILY 
substituted I-FAMILY 
2-hydroxyiminoacetamido I-FAMILY 
alkylamines I-FAMILY 
were O 
identified O 
as O 
best O 
reactivators O 
and O 
reactivation O 
kinetics O 
of O 
the O 
lead O 
oximes B-FAMILY 
, O 
RS41A B-NO_CLASS 
and O 
RS194B B-NO_CLASS 
, O 
were O 
analyzed O 
in O 
detail O 
. O 
Compared O 
to O 
reference O 
pyridinium B-SYSTEMATIC 
reactivators O 
, O 
2PAM B-ABBREVIATION 
and O 
MMB4 B-IDENTIFIER 
, O 
molecular O 
recognition O 
of O 
RS41A B-NO_CLASS 
reflected O 
in O 
its O 
Kox O 
constant O 
was O 
compromised O 
by O 
an O 
order O 
of O 
magnitude O 
on O 
average O 
for O 
different O 
OP-hAChE O 
conjugates O 
, O 
without O 
significant O 
differences O 
in O 
the O 
first O 
order O 
maximal O 
phosphorylation O 
rate O 
constant O 
k2 O 
. O 
Systematic O 
structural O 
modifications O 
of O 
the O 
RS41A B-NO_CLASS 
lead O 
resulted O 
in O 
several O 
- O 
fold O 
improvement O 
with O 
reactivator O 
, O 
RS194B B-NO_CLASS 
. O 
Kinetic O 
analysis O 
indicated O 
Kox O 
reduction O 
for O 
RS194B B-NO_CLASS 
as O 
the O 
main O 
kinetic O 
constant O 
leading O 
to O 
efficient O 
reactivation O 
. O 
Subtle O 
structural O 
modifications O 
of O 
RS194B B-NO_CLASS 
were O 
used O 
to O 
identify O 
essential O 
determinants O 
for O 
efficient O 
reactivation O 
. O 
Computational O 
molecular O 
modeling O 
of O 
RS41A B-NO_CLASS 
and O 
RS194B B-NO_CLASS 
interactions O 
with O 
VX O 
inhibited O 
hAChE O 
, O 
bound O 
reversibly O 
in O 
Michaelis O 
type O 
complex O 
and O 
covalently O 
in O 
the O 
pentacoordinate O 
reaction O 
intermediate O 
suggests O 
that O 
the O 
faster O 
reactivation O 
reaction O 
is O 
a O 
consequence O 
of O 
a O 
tighter O 
RS194B B-NO_CLASS 
interactions O 
with O 
hAChE O 
peripheral O 
site O 
( O 
PAS O 
) O 
residues O 
, O 
in O 
particular O 
with O 
D74 O 
, O 
resulting O 
in O 
lower O 
interaction O 
energies O 
for O 
formation O 
of O 
both O 
the O 
binding O 
and O 
reactivation O 
states O 
. O 
Desirable O 
in O 
vitro O 
reactivation O 
properties O 
of O 
RS194B B-NO_CLASS 
, O 
when O 
coupled O 
with O 
its O 
in O 
vivo O 
pharmacokinetics O 
and O 
disposition O 
in O 
the O 
body O 
, O 
reveal O 
the O 
potential O 
of O 
this O 
oxime B-SYSTEMATIC 
design O 
as O 
promising O 
centrally O 
and O 
peripherally O 
active O 
antidotes O 
for O 
OP O 
toxicity O 
. O 

( O 
α-catenin O 
) O 
gene O 
variants O 
are O 
associated O 
with O 
diisocyanate B-SYSTEMATIC 
asthma O 
: O 
a O 
replication O 
study O 
in O 
a O 
caucasian O 
worker O 
population O 
. O 

, O 
a O 
genome O 
- O 
wide O 
association O 
study O 
( O 
GWAS O 
) O 
conducted O 
in O 
Korean O 
subjects O 
identified O 
four O 
CTNNA3 O 
( O 
alpha-T O 
catenin O 
) O 
single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
( O 
rs10762058 O 
, O 
rs7088181 O 
, O 
rs1786929 O 
, O 
and O 
rs4378283 O 
) O 
associated O 
with O 
diisocyanate B-SYSTEMATIC 
-induced O 
occupational O 
asthma O 
( O 
DA O 
) O 
. O 
The O 
CTNNA3 O 
gene O 
codes O 
for O 
a O 
cadherin O 
involved O 
in O 
formation O 
of O 
stretch O 
- O 
resistant O 
cell O 
- O 
cell O 
adhesions O 
. O 
We O 
conducted O 
a O 
candidate O 
gene O 
association O 
study O 
to O 
replicate O 
these O 
findings O 
in O 
Caucasian O 
workers O 
. O 
Genotyping O 
was O 
performed O 
on O 
DNA O 
using O 
a O 
5 O 
' O 
nuclease O 
PCR O 
assay O 
collected O 
from O 
410 O 
diisocyanate B-SYSTEMATIC 
-exposed O 
and O 
predominantly O 
Canadian O 
workers O 
including O 
132 O 
workers O 
with O 
DA O 
confirmed O 
by O 
a O 
specific O 
inhalation O 
challenge O 
( O 
DA+ O 
) O 
; O 
131 O 
symptomatic O 
workers O 
in O 
whom O 
DA O 
was O 
excluded O 
by O 
a O 
negative O 
challenge O 
( O 
DA- O 
) O 
; O 
and O 
147 O 
hexamethylene B-SYSTEMATIC 
diisocyanate I-SYSTEMATIC 
-exposed O 
asymptomatic O 
workers O 
( O 
AWs O 
) O 
. O 
As O 
in O 
the O 
Korean O 
study O 
, O 
highly O 
linked O 
CTNNA3 O 
rs7088181 O 
and O 
rs10762058 O 
SNPs O 
( O 
but O 
not O 
rs4378283 O 
and O 
rs1786929 O 
) O 
were O 
significantly O 
associated O 
with O 
DA+ O 
when O 
compared O 
with O 
AWs O 
but O 
not O 
in O 
comparison O 
with O 
DA- O 
workers O 
( O 
p O 
≤ O 
0.05 O 
) O 
. O 
After O 
adjusting O 
for O 
potentially O 
confounding O 
variables O 
of O 
age O 
, O 
smoking O 
status O 
, O 
and O 
duration O 
of O 
exposure O 
, O 
minor O 
allele O 
homozygotes O 
of O 
rs7088181 O 
and O 
rs10762058 O 
SNPs O 
were O 
at O 
increased O 
risk O 
for O 
DA O 
compared O 
with O 
AWs O 
( O 
OR O 
= O 
9.05 O 
[ O 
95% O 
CI O 
: O 
1.69 O 
, O 
48.54 O 
] O 
and O 
OR O 
= O 
6.82 O 
[ O 
95% O 
CI O 
: O 
1.65 O 
, O 
28.24 O 
] O 
, O 
respectively O 
) O 
. O 
In O 
conclusion O 
, O 
we O 
replicated O 
results O 
from O 
the O 
only O 
reported O 
GWAS O 
study O 
of O 
DA O 
demonstrating O 
an O 
association O 
between O 
two O 
closely O 
linked O 
CTNNA3 O 
gene O 
SNPs O 
and O 
DA O 
. O 
These O 
findings O 
lend O 
further O 
support O 
to O 
the O 
clinical O 
relevance O 
of O 
these O 
genotypes O 
in O 
predicting O 
susceptibility O 
to O 
DA O 
and O 
the O 
potential O 
importance O 
of O 
catenins O 
in O 
the O 
disease O 
process O 
. O 

( O 
AChE O 
) O 
at O 
the O 
neuromuscular O 
junction O 
( O 
NMJ O 
) O 
is O 
anchored O 
to O 
the O 
synaptic O 
basal O 
lamina O 
via O 
a O 
triple O 
helical O 
collagen O 
Q O 
( O 
ColQ O 
) O 
in O 
the O 
form O 
of O 
asymmetric O 
AChE O 
( O 
AChE O 
/ O 
ColQ O 
) O 
. O 
The O 
C B-FORMULA 
-terminal O 
domain O 
of O 
ColQ O 
binds O 
to O 
MuSK O 
, O 
the O 
muscle O 
- O 
specific O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
, O 
that O 
mediates O 
a O 
signal O 
for O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
AChR O 
) O 
clustering O 
at O 
the O 
NMJ O 
. O 
ColQ O 
also O 
binds O 
to O 
heparan O 
sulfate O 
proteoglycans O 
including O 
perlecan O 
. O 
Congenital O 
defects O 
of O 
ColQ O 
cause O 
endplate O 
AChE O 
deficiency O 
. O 
A O 
single O 
intravenous O 
administration O 
of O 
adeno O 
- O 
associated O 
virus O 
serotype O 
8 O 
(AAV8)-COLQ O 
to O 
Colq- O 
/ O 
- O 
mice O 
rescued O 
motor O 
functions O 
, O 
synaptic O 
transmission O 
, O 
and O 
the O 
ultrastructure O 
of O 
NMJ O 
. O 
We O 
also O 
injected O 
AAV1-COLQ-IRES-EGFP O 
to O 
the O 
left O 
tibialis O 
anterior O 
and O 
observed O 
colocalization O 
of O 
AChE O 
/ O 
ColQ O 
at O 
all O 
the O 
examined O 
NMJs O 
of O 
the O 
non-injected O 
limbs O 
. O 
Additionally O 
, O 
injection O 
of O 
purified O 
recombinant O 
AChE O 
/ O 
ColQ O 
protein O 
complex O 
into O 
gluteus O 
maximus O 
accumulated O 
AChE O 
in O 
non-injected O 
forelimbs O 
. O 
These O 
observations O 
suggest O 
that O 
the O 
tissue O 
- O 
targeting O 
signal O 
of O 
ColQ O 
can O 
be O 
exploited O 
to O 
specifically O 
deliver O 
the O 
transgene O 
product O 
to O 
the O 
target O 
tissue O 
. O 
MuSK O 
antibody O 
- O 
positive O 
myasthenia O 
gravis O 
( O 
MG O 
) O 
accounts O 
for O 
5-15% O 
of O 
autoimmune O 
MG O 
. O 
As O 
AChR O 
deficiency O 
is O 
typically O 
mild O 
and O 
as O 
cholinesterase O 
inhibitors O 
are O 
generally O 
ineffective O 
or O 
worsen O 
myasthenic O 
symptoms O 
, O 
we O 
asked O 
if O 
the O 
patient's O 
MuSK-IgG O 
interferes O 
with O 
binding O 
of O 
ColQ O 
to O 
MuSK O 
. O 
In O 
vitro O 
overlay O 
of O 
AChE O 
/ O 
ColQ O 
to O 
muscle O 
sections O 
of O 
Colq- O 
/ O 
- O 
mice O 
revealed O 
that O 
MuSK-IgG O 
blocks O 
binding O 
of O 
ColQ O 
to O 
the O 
NMJ O 
. O 
In O 
vitro O 
plate O 
- O 
binding O 
of O 
MuSK O 
to O 
ColQ O 
disclosed O 
that O 
MuSK-IgG O 
exerts O 
a O 
dose O 
- O 
dependent O 
block O 
of O 
MuSK-ColQ O 
interaction O 
. O 
In O 
addition O 
, O 
passive O 
transfer O 
of O 
MuSK-IgG O 
to O 
mice O 
reduced O 
the O 
size O 
and O 
density O 
of O 
ColQ O 
to O 
∼10% O 
of O 
controls O 
and O 
had O 
a O 
lesser O 
effect O 
on O 
the O 
sizes O 
and O 
densities O 
of O 
AChR O 
and O 
MuSK O 
. O 
Elucidation O 
of O 
molecular O 
mechanisms O 
of O 
specific O 
binding O 
of O 
ColQ O 
to O 
the O 
NMJ O 
enabled O 
us O 
to O 
ameliorate O 
devastating O 
myasthenic O 
symptoms O 
of O 
Colq- O 
/ O 
- O 
mice O 
and O 
to O 
reveal O 
bases O 
of O 
anti-MuSK O 
MG O 
. O 

A I-TRIVIAL 
sensitizes O 
TRAIL-induced O 
apoptosis O 
via O 
the O 
upregulation O 
of O 
DR5 O 
in O 
an O 
eIF2α O 
/ O 
CHOP-dependent O 
manner O 
. O 

necrosis O 
factor O 
- O 
related O 
apoptosis O 
- O 
inducing O 
ligand O 
( O 
TRAIL O 
) O 
is O 
one O 
of O 
the O 
most O 
promising O 
candidates O 
for O 
new O 
cancer O 
therapeutics O 
. O 
However O 
, O 
resistance O 
to O 
TRAIL O 
in O 
some O 
cancers O 
remains O 
a O 
current O 
problem O 
in O 
recent O 
. O 
The O 
protein O 
- O 
folding O 
compartment O 
of O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
is O 
particularly O 
sensitive O 
to O 
disturbances O 
, O 
which O 
, O 
if O 
severe O 
, O 
may O 
trigger O 
apoptosis O 
. O 
Therefore O 
, O 
we O 
examined O 
whether O 
verrucarin B-TRIVIAL 
A I-TRIVIAL 
( O 
VA O 
) O 
sensitize O 
TRAIL-induced O 
apoptosis O 
in O 
cancer O 
cells O 
by O 
induction O 
of O 
ER O 
stress O 
. O 
We O 
first O 
found O 
that O 
VA O 
induces O 
a O 
major O 
molecule O 
of O 
ER O 
stress O 
, O 
CCAAT O 
/ O 
enhancer O 
binding O 
protein O 
homologous O 
protein O 
(CHOP)-dependent O 
DR5 O 
induction O 
and O 
subsequently O 
increases O 
TRAIL-induced O 
cleavage O 
of O 
caspases O 
and O 
PARP O 
in O 
TRAIL-resistant O 
Hep3B O 
cells O 
. O 
Importantly O 
, O 
the O 
transient O 
knockdown O 
using O 
siRNA O 
for O 
CHOP O 
abrogated O 
VA-induced O 
DR5 O 
expression O 
and O 
attenuated O 
TRAIL-induced O 
apoptosis O 
. O 
Treatment O 
with O 
VA O 
also O 
increased O 
the O 
levels O 
of O 
phosphorylation O 
of O 
eukaryotic O 
translation O 
initiation O 
factor-2α O 
( O 
eIF2α O 
) O 
, O 
which O 
is O 
a O 
common O 
cellular O 
response O 
of O 
ER O 
stress O 
. O 
Furthermore O 
, O 
salubrinal B-TRIVIAL 
, O 
a O 
specific O 
eIF2α O 
phosphorylation O 
- O 
inducing O 
agent O 
, O 
increased O 
CHOP O 
and O 
DR5 O 
expression O 
in O 
the O 
presence O 
of O 
VA O 
. O 
In O 
contrast O 
, O 
transfection O 
of O 
mutant-eIF2α O 
significantly O 
reversed O 
VA-induced O 
apoptosis O 
with O 
downregulation O 
of O 
CHOP-dependent O 
DR5 O 
expression O 
. O 
Therefore O 
, O 
VA-induced O 
eIF2α O 
phosphorylation O 
seemed O 
to O 
be O 
important O 
for O 
CHOP O 
and O 
DR5 O 
upregulation O 
and O 
TRAIL-induced O 
apoptosis O 
. O 
In O 
addition O 
, O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
is O 
an O 
effector O 
molecular O 
in O 
sensitization O 
of O 
VA-induced O 
ER O 
stress O 
. O 
We O 
concluded O 
that O 
VA O 
triggers O 
TRAIL-induced O 
apoptosis O 
by O 
eIF2α O 
/ O 
CHOP-dependent O 
DR5 O 
induction O 
via O 
ROS O 
generation O 
. O 

common O 
mechanism O 
for O 
resistance O 
to O 
oxime B-SYSTEMATIC 
reactivation O 
of O 
acetylcholinesterase O 
inhibited O 
by O 
organophosphorus B-FAMILY 
compounds O 
. O 

of O 
oxime B-SYSTEMATIC 
therapy O 
is O 
currently O 
the O 
standard O 
approach O 
used O 
to O 
reverse O 
the O 
acute O 
toxicity O 
of O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
compounds O 
, O 
which O 
is O 
usually O 
attributed O 
to O 
OP O 
inhibition O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
. O 
Rate O 
constants O 
for O 
reactivation O 
of O 
OP-inhibited O 
AChE O 
by O 
even O 
the O 
best O 
oximes O 
, O 
such O 
as O 
HI-6 B-IDENTIFIER 
and O 
obidoxime B-TRIVIAL 
, O 
can O 
vary O 
> O 
100-fold O 
between O 
OP-AChE O 
conjugates O 
that O 
are O 
easily O 
reactivated O 
and O 
those O 
that O 
are O 
difficult O 
to O 
reactivate O 
. O 
To O 
gain O 
a O 
better O 
understanding O 
of O 
this O 
oxime B-SYSTEMATIC 
specificity O 
problem O 
for O 
future O 
design O 
of O 
improved O 
reactivators O 
, O 
we O 
conducted O 
a O 
QSAR O 
analysis O 
for O 
oxime B-SYSTEMATIC 
reactivation O 
of O 
AChE O 
inhibited O 
by O 
OP O 
agents O 
and O 
their O 
analogues O 
. O 
Our O 
objective O 
was O 
to O 
identify O 
common O 
mechanism(s) O 
among O 
OP-AChE O 
conjugates O 
of O 
phosphates B-FAMILY 
, O 
phosphonates B-FAMILY 
and O 
phosphoramidates B-FAMILY 
that O 
result O 
in O 
resistance O 
to O 
oxime B-SYSTEMATIC 
reactivation O 
. O 
Our O 
evaluation O 
of O 
oxime B-SYSTEMATIC 
reactivation O 
of O 
AChE O 
inhibited O 
by O 
a O 
sarin O 
analogue O 
, O 
O-methyl B-SYSTEMATIC 
isopropylphosphonofluoridate I-SYSTEMATIC 
, O 
or O 
a O 
cyclosarin B-TRIVIAL 
analogue O 
, O 
O-methyl B-SYSTEMATIC 
cyclohexylphosphonofluoridate I-SYSTEMATIC 
, O 
indicated O 
that O 
AChE O 
inhibited O 
by O 
these O 
analogues O 
was O 
at O 
least O 
70-fold O 
more O 
difficult O 
to O 
reactivate O 
than O 
AChE O 
inhibited O 
by O 
sarin B-TRIVIAL 
or O 
cyclosarin B-TRIVIAL 
. O 
In O 
addition O 
, O 
AChE O 
inhibited O 
by O 
an O 
analogue O 
of O 
tabun B-TRIVIAL 
( O 
i.e O 
. O 
, O 
O-ethyl B-SYSTEMATIC 
isopropylphosphonofluoridate I-SYSTEMATIC 
) O 
was O 
nearly O 
as O 
resistant O 
to O 
reactivation O 
as O 
tabun B-TRIVIAL 
-inhibited O 
AChE O 
. O 
QSAR O 
analysis O 
of O 
oxime O 
reactivation O 
of O 
AChE O 
inhibited O 
by O 
these O 
OP O 
compounds O 
and O 
others O 
suggested O 
that O 
the O 
presence O 
of O 
both O 
a O 
large O 
substituent O 
( O 
i.e O 
. O 
, O 
⩾the O 
size O 
of O 
dimethylamine B-SYSTEMATIC 
) O 
and O 
an O 
alkoxy B-FAMILY 
substituent O 
in O 
the O 
structure O 
of O 
OP O 
compounds O 
is O 
the O 
common O 
feature O 
that O 
results O 
in O 
resistance O 
to O 
oxime B-SYSTEMATIC 
reactivation O 
of O 
OP-AChE O 
conjugates O 
whether O 
the O 
OP O 
is O 
a O 
phosphate B-SYSTEMATIC 
, O 
phosphonate B-SYSTEMATIC 
or O 
phosphoramidate B-SYSTEMATIC 
. O 

neurotoxicity O 
of O 
hallucinogenic O 
amphetamines B-FAMILY 
in O 
primary O 
cultures O 
of O 
hippocampal O 
neurons O 
. O 

( O 
MDMA B-ABBREVIATION 
or O 
" O 
Ecstasy B-TRIVIAL 
" O 
) O 
and O 
2,5-dimethoxy-4-iodoamphetamine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
DOI B-ABBREVIATION 
) O 
are O 
hallucinogenic O 
amphetamines B-FAMILY 
with O 
addictive O 
properties O 
. O 
The O 
hippocampus O 
is O 
involved O 
in O 
learning O 
and O 
memory O 
and O 
seems O 
particularly O 
vulnerable O 
to O 
amphetamine B-TRIVIAL 
' O 
s O 
neurotoxicity O 
. O 
We O 
evaluated O 
the O 
neurotoxicity O 
of O 
DOI B-ABBREVIATION 
and O 
MDMA B-ABBREVIATION 
in O 
primary O 
neuronal O 
cultures O 
of O 
hippocampus O 
obtained O 
from O 
Wistar O 
rat O 
embryos O 
( O 
E-17 O 
to O 
E-19 O 
) O 
. O 
Mature O 
neurons O 
after O 
10 O 
days O 
in O 
culture O 
were O 
exposed O 
for O 
24 O 
or O 
48 O 
h O 
either O 
to O 
MDMA B-ABBREVIATION 
( O 
100-800 O 
μM O 
) O 
or O 
DOI B-ABBREVIATION 
( O 
10-100 O 
μM O 
) O 
. O 
Both O 
the O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
release O 
and O 
the O 
tetrazolium B-SYSTEMATIC 
-based O 
( O 
MTT B-ABBREVIATION 
) O 
assays O 
revealed O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
neuronal O 
death O 
and O 
mitochondrial O 
dysfunction O 
after O 
exposure O 
to O 
both O 
drugs O 
. O 
Both O 
drugs O 
promoted O 
a O 
significant O 
increase O 
in O 
caspase-8 O 
and O 
caspase-3 O 
activities O 
. O 
At O 
concentrations O 
that O 
produced O 
similar O 
levels O 
of O 
neuronal O 
death O 
, O 
DOI B-ABBREVIATION 
promoted O 
a O 
higher O 
increase O 
in O 
the O 
activity O 
of O 
both O 
caspases O 
than O 
MDMA B-ABBREVIATION 
. O 
In O 
the O 
mitochondrial O 
fraction O 
of O 
neurons O 
exposed O 
24h O 
to O 
DOI B-ABBREVIATION 
or O 
MDMA B-ABBREVIATION 
, O 
we O 
found O 
a O 
significant O 
increase O 
in O 
the O 
67 O 
kDa O 
band O 
of O 
apoptosis O 
inducing O 
factor O 
( O 
AIF O 
) O 
by O 
Western O 
blot O 
. O 
Moreover O 
, O 
24h O 
exposure O 
to O 
DOI B-ABBREVIATION 
promoted O 
an O 
increase O 
in O 
cytochrome O 
c O 
in O 
the O 
cytoplasmatic O 
fraction O 
of O 
neurons O 
. O 
Pre O 
- O 
treatment O 
with O 
an O 
antibody O 
raised O 
against O 
the O 
5-HT B-SYSTEMATIC 
(2A)-receptor O 
( O 
an O 
irreversible O 
antagonist O 
) O 
greatly O 
attenuated O 
neuronal O 
death O 
promoted O 
by O 
48 O 
h O 
exposure O 
to O 
DOI B-ABBREVIATION 
or O 
MDMA B-ABBREVIATION 
. O 
In O 
conclusion O 
, O 
hallucinogenic O 
amphetamines B-FAMILY 
promoted O 
programmed O 
neuronal O 
death O 
involving O 
both O 
the O 
mitochondria O 
machinery O 
and O 
the O 
extrinsic O 
cell O 
death O 
key O 
regulators O 
. O 
Death O 
was O 
dependent O 
, O 
at O 
least O 
in O 
part O 
, O 
on O 
the O 
stimulation O 
of O 
the O 
5-HT B-SYSTEMATIC 
(2A)-receptors O 
. O 

DFT O 
study O 
on O 
the O 
initial O 
stage O 
of O 
thermal O 
degradation O 
of O 
Poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
/ O 
carbon B-SYSTEMATIC 
nanotube O 
system O 
. O 

calculations O 
, O 
with O 
VWN O 
exchange O 
correlation O 
functional O 
and O 
double O 
numeric O 
basis O 
set O 
, O 
were O 
used O 
to O 
evaluate O 
the O 
energies O 
required O 
for O 
the O 
scission O 
reactions O 
taking O 
place O 
in O 
the O 
initial O 
stage O 
of O 
the O 
thermal O 
degradation O 
of O 
Poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PMMA B-ABBREVIATION 
) O 
in O 
the O 
presence O 
of O 
a O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
CNT O 
) O 
. O 
Side O 
group O 
and O 
main O 
chain O 
scissions O 
were O 
investigated O 
. O 
The O 
results O 
averaged O 
from O 
five O 
configurations O 
of O 
pure O 
PMMA B-ABBREVIATION 
( O 
DP=5 O 
) O 
were O 
used O 
as O 
references O 
and O 
compared O 
to O 
the O 
results O 
obtained O 
for O 
the O 
five O 
same O 
configurations O 
of O 
PMMA B-ABBREVIATION 
grafted O 
on O 
three O 
carbon B-SYSTEMATIC 
nanotubes O 
of O 
similar O 
diameter O 
( O 
1.49 O 
nm O 
) O 
. O 
The O 
bond O 
dissociation O 
energies O 
( O 
BDE O 
) O 
of O 
main O 
chain O 
scission O 
evaluated O 
for O 
grafted O 
PMMA B-ABBREVIATION 
was O 
4 O 
% O 
less O 
endothermic O 
than O 
for O 
pure O 
PMMA B-ABBREVIATION 
. O 
These O 
results O 
seemed O 
independent O 
of O 
the O 
tested O 
chirality O 
( O 
11,11 O 
) O 
; O 
( O 
12,10 O 
) O 
and O 
( O 
16,5 O 
) O 
of O 
the O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 
Comparisons O 
with O 
the O 
BDE O 
of O 
the O 
weakest O 
bonds O 
due O 
to O 
intrinsic O 
defaults O 
( O 
head O 
to O 
head O 
and O 
unsaturated O 
end O 
chain O 
) O 
were O 
performed O 
. O 

cytological O 
responses O 
of O 
lung O 
epithelial O 
and O 
pleural O 
mesothelial O 
cells O 
following O 
in O 
vitro O 
exposure O 
to O 
nanoscale O 
SiO2 B-FORMULA 
. O 

to O 
unique O 
surface O 
chemistries O 
and O 
the O 
ability O 
to O 
easily O 
functionalize O 
their O 
surface O 
, O 
amorphous O 
silica B-TRIVIAL 
nanoparticles O 
are O 
being O 
assimilated O 
into O 
medicinal O 
and O 
consumer O 
products O 
at O 
an O 
increasing O 
rate O 
. O 
Subsequently O 
, O 
there O 
is O 
an O 
emergent O 
need O 
to O 
understand O 
the O 
interactions O 
of O 
these O 
particulates O 
with O 
biological O 
systems O 
in O 
an O 
attempt O 
to O 
mitigate O 
toxicity O 
. O 
The O 
identification O 
of O 
susceptible O 
or O 
resistant O 
cell O 
types O 
of O 
the O 
pulmonary O 
system O 
remains O 
a O 
critical O 
step O 
in O 
the O 
development O 
of O 
toxicity O 
assessments O 
for O 
nanoparticle O 
- O 
based O 
platforms O 
. O 
Specific O 
to O 
this O 
study O 
, O 
the O 
cellular O 
responses O 
of O 
A549 O 
lung O 
epithelial O 
and O 
MeT-5A O 
pleural O 
mesothelial O 
cell O 
lines O 
as O 
a O 
means O 
of O 
detecting O 
nanoparticle O 
- O 
induced O 
oxidative O 
stress O 
were O 
examined O 
. O 
Basal O 
expression O 
and O 
cellular O 
antioxidant O 
activity O 
, O 
including O 
SOD O 
, O 
CAT O 
, O 
and O 
GSH B-ABBREVIATION 
, O 
were O 
examined O 
prior O 
to O 
H(2)O(2) B-FORMULA 
and O 
~30 O 
nm O 
SiO(2) B-FORMULA 
( O 
0.01-100mg O 
/ O 
L O 
) O 
exposures O 
. O 
Dose O 
- O 
response O 
observations O 
were O 
made O 
regarding O 
oxidant O 
production O 
, O 
cytotoxicity O 
, O 
GSH B-ABBREVIATION 
depletion O 
and O 
NRF2 O 
transcription O 
factor O 
activation O 
. O 
Results O 
indicated O 
that O 
, O 
while O 
both O 
cell O 
types O 
exhibited O 
susceptibility O 
to O 
H(2)O(2) B-FORMULA 
and O 
SiO(2) B-FORMULA 
-induced O 
oxidative O 
stress O 
and O 
damage O 
, O 
the O 
A549 O 
cell O 
line O 
was O 
relatively O 
more O 
resilient O 
. O 

treatment O 
and O 
synthesis O 
of O 
sugar B-FAMILY 
alcohol I-FAMILY 
modified O 
Na+ B-FORMULA 
- O 
montmorillonite B-TRIVIAL 
clay O 
. O 

- O 
montmorillonite B-TRIVIAL 
clay O 
( O 
generally O 
referred O 
to O 
as O 
MMT B-ABBREVIATION 
) O 
is O 
very O 
useful O 
for O 
reinforcing O 
polymeric O 
matrix O 
at O 
very O 
low O 
concentrations O 
( O 
typically O 
, O 
2-5% O 
wt O 
) O 
. O 
These O 
clay O 
particles O 
are O 
typically O 
exfoliated O 
before O 
they O 
can O 
demonstrate O 
the O 
significant O 
gains O 
in O 
heat O 
deflection O 
temperature O 
, O 
modulus O 
, O 
and O 
elongation O 
properties O 
. O 
In O 
the O 
case O 
of O 
hydrophilic O 
biopolymer O 
based O 
matrices O 
, O 
such O 
as O 
carbohydrates B-FAMILY 
and O 
chitosan O 
, O 
exfoliating O 
these O 
nanoclay O 
particles O 
needs O 
greater O 
attention O 
because O 
the O 
exfoliation O 
is O 
typically O 
carried O 
out O 
using O 
hydrophobic O 
oligomers O 
through O 
ion O 
- O 
exchange O 
. O 
This O 
study O 
reports O 
a O 
new O 
method O 
of O 
synthesizing O 
completely O 
hydrophilic O 
MMT B-ABBREVIATION 
-assemblages O 
using O 
hydrophilic O 
plasticizers O 
for O 
biopolymers O 
. O 
We O 
used O 
sugar B-FAMILY 
alcohols I-FAMILY 
( O 
glycerol B-TRIVIAL 
, O 
xylitol B-TRIVIAL 
with O 
3 O 
and O 
5 O 
hydroxyl B-SYSTEMATIC 
groups O 
) O 
and O 
polysaccharide O 
maltodextrin O 
to O 
exfoliate O 
the O 
MMT B-ABBREVIATION 
. O 
Sonication O 
was O 
conducted O 
for O 
MMT B-ABBREVIATION 
nanoclay O 
and O 
plasticizers O 
at O 
different O 
weight O 
ratios O 
. O 
It O 
was O 
confirmed O 
that O 
all O 
plasticizer O 
/ O 
modifier O 
led O 
to O 
expansion O 
of O 
MMT B-ABBREVIATION 
gallery O 
spacing O 
( O 
d-spacing O 
) O 
and O 
the O 
change O 
in O 
d-spacing O 
could O 
be O 
related O 
to O 
the O 
molecular O 
structure O 
of O 
the O 
plasticizer O 
. O 
Meanwhile O 
, O 
the O 
extent O 
of O 
exfoliation O 
was O 
maximum O 
with O 
maltodextrin O 
( O 
fully O 
exfoliation O 
with O 
1 O 
: O 
10 O 
and O 
1 O 
: O 
20 O 
ratio O 
of O 
MMT B-ABBREVIATION 
: O 
plasticizer O 
) O 
across O 
all O 
test O 
samples O 
and O 
interestingly O 
, O 
glycerol B-TRIVIAL 
and O 
xylitol B-TRIVIAL 
samples O 
quickly O 
established O 
within O 
the O 
MMT B-ABBREVIATION 
galleries O 
and O 
exhibited O 
minimal O 
influence O 
with O 
further O 
increase O 
in O 
relative O 
concentrations O 
. O 

isoflavones B-FAMILY 
modulate O 
adipokines O 
and O 
myokines O 
to O 
regulate O 
lipid O 
metabolism O 
in O 
adipose O 
tissue O 
, O 
skeletal O 
muscle O 
and O 
liver O 
of O 
male O 
Huanjiang O 
mini O 
- O 
pigs O 
. O 

a O 
growing O 
body O 
of O 
evidence O 
suggests O 
that O 
soy O 
isoflavones B-FAMILY 
help O 
regulate O 
lipid O 
metabolism O 
, O 
the O 
underlying O 
mechanism O 
has O 
not O 
yet O 
been O 
thoroughly O 
clarified O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
determine O 
the O 
effects O 
of O 
soy O 
isoflavones B-FAMILY 
on O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
lipid O 
metabolism O 
in O 
different O 
adipose O 
tissue O 
depots O 
, O 
skeletal O 
muscle O 
and O 
liver O 
of O 
male O 
Huanjiang O 
mini O 
- O 
pigs O 
, O 
as O 
well O 
as O 
the O 
expression O 
of O 
adipokines O 
and O 
myokines O 
. O 
A O 
total O 
of O 
36 O 
male O 
Huanjiang O 
mini O 
- O 
pigs O 
were O 
fed O 
basal O 
diet O 
( O 
control O 
, O 
Con O 
) O 
, O 
low O 
- O 
dose O 
soy O 
isoflavones B-FAMILY 
( O 
LSI O 
) O 
and O 
high O 
- O 
dose O 
soy O 
isoflavones B-FAMILY 
( O 
HSI O 
) O 
. O 
The O 
results O 
showed O 
that O 
LSI O 
and O 
HSI O 
regulated O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
anabolism O 
and O 
catabolism O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
dorsal O 
subcutaneous O 
( O 
DSA O 
) O 
, O 
abdominal O 
subcutaneous O 
( O 
ASA O 
) O 
and O 
perirenal O 
( O 
PRA O 
) O 
adipose O 
tissue O 
depots O 
, O 
as O 
well O 
as O 
longissimus O 
dorsi O 
muscle O 
( O 
LDM O 
) O 
and O 
liver O 
. O 
LSI O 
and O 
HSI O 
also O 
regulated O 
the O 
expression O 
of O 
adipokines O 
in O 
DSA O 
, O 
ASA O 
and O 
PRA O 
, O 
and O 
the O 
expression O 
of O 
myokines O 
in O 
LDM O 
in O 
male O 
Huanjiang O 
mini O 
- O 
pigs O 
. O 
In O 
addition O 
, O 
soy O 
isoflavones B-FAMILY 
regulated O 
plasma O 
glucose B-TRIVIAL 
, O 
leptin O 
and O 
adiponectin O 
contents O 
after O 
treatment O 
for O 
two O 
months O 
. O 
Our O 
results O 
indicate O 
that O 
soy O 
isoflavones B-FAMILY 
, O 
by O 
regulating O 
the O 
expression O 
of O 
adipokines O 
and O 
myokines O 
, O 
may O 
regulate O 
the O 
metabolism O 
of O 
lipids O 
and O 
could O 
have O 
potential O 
therapeutic O 
applications O 
in O 
lipid O 
abnormalities O 
. O 

, O 
a O 
recently O 
discovered O 
adipocytokine O 
plays O 
an O 
important O 
role O 
in O 
obesity O 
and O 
obesity O 
- O 
associated O 
metabolic O 
complications O 
. O 
However O 
, O 
the O 
role O 
of O 
chemerin O 
in O 
the O 
pathogenesis O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
has O 
not O 
fully O 
been O 
elucidated O 
. O 
We O 
compared O 
the O 
serum O 
chemerin O 
levels O 
and O 
metabolic O 
parameters O 
between O 
88 O 
control O 
subjects O 
, O 
86 O 
patients O 
with O 
metabolic O 
syndrome O 
( O 
MS O 
) O 
, O 
and O 
147 O 
patients O 
with O 
T2DM O 
in O 
a O 
Japanese O 
population O 
and O 
further O 
analyzed O 
their O 
correlation O 
. O 
Enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
was O 
used O 
to O 
measure O 
the O 
serum O 
chemerin O 
levels O 
. O 
The O 
chemerin O 
levels O 
were O 
significantly O 
higher O 
in O 
male O 
than O 
in O 
female O 
control O 
subjects O 
( O 
p O 
< O 
0.005 O 
) O 
, O 
with O 
significant O 
decreases O 
in O 
patients O 
with O 
T2DM O 
compared O 
with O 
those O 
with O 
MS O 
and O 
control O 
subjects O 
( O 
164.9 O 
± O 
6.3 O 
ng O 
/ O 
mL O 
vs O 
. O 
209.8 O 
± O 
7.7 O 
and O 
218.7 O 
± O 
7.3 O 
ng O 
/ O 
mL O 
; O 
p O 
< O 
0.0001 O 
vs O 
. O 
p O 
< O 
0.0001 O 
, O 
respectively O 
) O 
but O 
no O 
significant O 
differences O 
in O 
female O 
subjects O 
. O 
The O 
multiple O 
regression O 
analysis O 
revealed O 
that O 
the O 
chemerin O 
levels O 
negatively O 
correlated O 
with O 
the O 
fasting O 
glucose B-TRIVIAL 
and O 
HbA1c O 
levels O 
in O 
total O 
and O 
male O 
subjects O 
. O 
In O 
the O 
patients O 
with O 
T2DM O 
, O 
the O 
chemerin O 
levels O 
negatively O 
correlated O 
with O 
fasting O 
glucose B-TRIVIAL 
and O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
but O 
positively O 
correlated O 
with O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
, O 
and O 
total O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
levels O 
. O 
The O 
negative O 
correlation O 
between O 
the O 
chemerin O 
and O 
fasting O 
glucose B-TRIVIAL 
levels O 
remained O 
significant O 
after O 
adjustment O 
for O 
age O 
, O 
sex O 
, O 
and O 
BMI O 
in O 
the O 
total O 
and O 
male O 
subjects O 
and O 
those O 
with O 
T2DM O 
. O 
These O 
results O 
suggest O 
the O 
role O 
of O 
chemerin O 
in O 
sex O 
dimorphism O 
and O 
a O 
potential O 
link O 
between O 
chemerin O 
levels O 
and O 
T2DM O 
pathogenesis O 
in O 
a O 
Japanese O 
population O 
. O 

antioxidant O 
effects O 
of O 
lycopene O 
, O 
apo-10'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
apo-14'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
human O 
macrophages O 
exposed O 
to O 
H2O2 B-FORMULA 
and O 
cigarette O 
smoke O 
extract O 
. O 

of O 
the O 
beneficial O 
effects O 
of O 
tomato O 
lycopene B-TRIVIAL 
in O 
the O 
prevention O 
of O 
chronic O 
diseases O 
has O 
been O 
attributed O 
to O 
its O 
antioxidant O 
properties O 
, O 
which O 
could O 
be O 
mediated O 
by O 
its O 
metabolites O 
and O 
/ O 
or O 
oxidation O 
products O 
. O 
However O 
, O 
the O 
biological O 
functions O 
of O 
these O 
lycopene B-TRIVIAL 
derivatives O 
remain O 
still O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
and O 
compared O 
the O 
antioxidant O 
efficacy O 
of O 
the O 
lycopene B-TRIVIAL 
eccentric O 
cleavage O 
products O 
apo-10'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
apo-14'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
counteracting O 
the O 
oxidative O 
effects O 
of O 
H(2)O(2) B-FORMULA 
and O 
cigarette O 
smoke O 
extract O 
( O 
CSE O 
) O 
in O 
THP-1 O 
macrophages O 
. O 
Both O 
apo-10'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
apo-14'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
were O 
able O 
to O 
inhibit O 
spontaneous O 
and O 
H(2)O(2) B-FORMULA 
-induced O 
ROS O 
production O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Such O 
an O 
effect O 
was O 
accompanied O 
by O 
an O 
inhibition O 
of O 
MAPK O 
phosphorylation O 
, O 
by O 
NF-κB O 
inactivation O 
, O 
and O 
by O 
inhibition O 
of O 
hsp-70 O 
and O 
hsp-90 O 
expressions O 
. O 
Both O 
apo B-FAMILY 
- I-FAMILY 
lycopenoic I-FAMILY 
acids I-FAMILY 
also O 
decreased O 
CSE-induced O 
ROS O 
production O 
, O 
8-OHdG B-SYSTEMATIC 
formation O 
and O 
reduced O 
the O 
increase O 
in O 
NOX-4 O 
and O 
COX-2 O 
expressions O 
caused O 
by O 
CSE O 
. O 
However O 
, O 
in O 
both O 
the O 
models O 
of O 
oxidative O 
stress O 
, O 
apo-14'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
was O 
much O 
more O 
potent O 
as O 
an O 
antioxidant O 
than O 
apo-10'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
showing O 
antioxidant O 
properties O 
similar O 
to O 
lycopene B-TRIVIAL 
. O 
These O 
data O 
strongly O 
suggest O 
that O 
apo B-FAMILY 
- I-FAMILY 
lycopenoic I-FAMILY 
acids I-FAMILY 
, O 
and O 
particularly O 
apo-14'-lycopenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
may O 
mediate O 
some O 
of O 
the O 
antioxidant O 
functions O 
of O 
lycopene O 
in O 
cells O 
. O 

of O 
all B-SYSTEMATIC 
- I-SYSTEMATIC 
trans I-SYSTEMATIC 
retinoid I-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
preventing O 
nickel B-SYSTEMATIC 
induced O 
cardiotoxicity O 
in O 
myocardial O 
cells O 
of O 
rats O 
. O 

, O 
a O 
metal O 
commonly O 
found O 
in O 
battery O 
plants O 
and O 
welding O 
factories O 
, O 
has O 
potential O 
cardiotoxicity O 
, O 
while O 
all B-SYSTEMATIC 
- I-SYSTEMATIC 
trans I-SYSTEMATIC 
retinoid I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
atRA B-ABBREVIATION 
) O 
can O 
promote O 
cardiovascular O 
repair O 
and O 
myocardial O 
recovery O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
atRA B-ABBREVIATION 
could O 
prevent O 
cardiotoxicity O 
induced O 
by O 
nickel B-SYSTEMATIC 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
In O 
the O 
study O 
, O 
a O 
rat O 
myocardial O 
cell O 
line O 
( O 
H9c2 O 
) O 
exposed O 
to O 
different O 
concentrations O 
of O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
NiCl(2) B-FORMULA 
) O 
displayed O 
apoptotic O 
features O 
accompanied O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generation O 
. O 
In O 
addition O 
, O 
NiCl(2) B-FORMULA 
also O 
caused O 
obvious O 
apoptosis O 
and O 
systolic O 
dysfunction O 
in O 
primary O 
myocardial O 
cells O 
. O 
Treatment O 
with O 
atRA B-ABBREVIATION 
efficiently O 
attenuated O 
the O 
cytotoxicities O 
triggered O 
by O 
NiCl(2) B-FORMULA 
as O 
it O 
significantly O 
mitigated O 
ROS O 
generation O 
and O 
decreased O 
MAP O 
kinases O 
activity O 
in O 
NiCl(2) B-FORMULA 
-treated O 
cardiomyocytes O 
. O 
Additionally O 
, O 
NiCl(2) B-FORMULA 
exposure O 
caused O 
obvious O 
arrhythmia O 
in O 
Sprague-Dawley O 
rats O 
with O 
the O 
maximum O 
tolerance O 
dose O 
of O 
NiCl(2) B-FORMULA 
between O 
2 O 
and O 
3mg O 
/ O 
kg O 
. O 
A O 
combinational O 
intragastric O 
administration O 
of O 
40mg O 
/ O 
kg O 
atRA B-ABBREVIATION 
can O 
partially O 
reverse O 
NiCl(2) B-FORMULA 
-induced O 
arrhythmia O 
in O 
rats O 
. O 
Our O 
results O 
suggested O 
that O 
atRA B-ABBREVIATION 
might O 
have O 
therapeutic O 
potential O 
in O 
alleviating O 
the O 
adverse O 
effects O 
of O 
nickel B-SYSTEMATIC 
on O 
the O 
cardiovascular O 
system O 
. O 

protects O 
against O 
cisplatin B-TRIVIAL 
induced O 
nephrotoxicity O 
in O 
rats O 
and O 
potentiates O 
its O 
anticancer O 
activity O 
against O 
human O 
renal O 
adenocarcinoma O 
cell O 
lines O 
. O 

-induced O 
nephrotoxicity O 
is O 
a O 
serious O 
problem O 
that O 
limits O 
its O 
use O 
in O 
cancer O 
treatment O 
. O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
renal O 
protective O 
capacity O 
of O 
pioglitazone B-TRIVIAL 
to O 
reduce O 
the O 
cisplatin B-TRIVIAL 
- O 
induced O 
nephrotoxicity O 
. O 
The O 
underlying O 
suggested O 
mechanism(s) O 
and O 
whether O 
this O 
nephroprotective O 
effect O 
( O 
if O 
any O 
) O 
interferes O 
with O 
the O 
cytotoxic O 
effect O 
of O 
cisplatin B-TRIVIAL 
on O 
cancer O 
cells O 
were O 
also O 
investigated O 
. O 
Pioglitazone B-TRIVIAL 
, O 
Bisphenol B-SYSTEMATIC 
A I-SYSTEMATIC 
diglycidyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
, O 
BADGE B-ABBREVIATION 
, O 
IP O 
injected O 
( O 
Peroxisome O 
proliferator- O 
activated O 
receptor O 
gamma O 
( O 
PPAR-γ O 
) O 
antagonist O 
) O 
, O 
or O 
their O 
combination O 
were O 
administered O 
to O 
rats O 
one O 
hour O 
before O 
cisplatin B-TRIVIAL 
injection O 
. O 
Moreover O 
, O 
their O 
effects O 
on O 
the O 
cell O 
viability O 
of O 
human O 
renal O 
adenocarcinoma O 
cell O 
models O 
( O 
ACHN O 
) O 
were O 
studied O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
pioglitazone B-TRIVIAL 
improved O 
the O 
renal O 
function O 
, O 
structural O 
changes O 
, O 
renal O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
, O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
genes O 
expression O 
in O 
cisplatin B-TRIVIAL 
injected O 
rats O 
. O 
It O 
increased O 
both O 
renal O 
reduced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
content O 
and O 
PPAR-γ O 
gene O 
expression O 
. O 
In O 
contrast O 
to O 
the O 
data O 
obtained O 
by O 
prior O 
administration O 
of O 
BADGE B-ABBREVIATION 
. O 
Pioglitazone B-TRIVIAL 
also O 
potentiated O 
the O 
cytotoxic O 
effect O 
of O 
cisplatin B-TRIVIAL 
on O 
human O 
renal O 
adenocarcinoma O 
cells O 
and O 
this O 
effect O 
was O 
abolished O 
by O 
BADGE B-ABBREVIATION 
co O 
administration O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
suggested O 
that O 
pioglitazone B-TRIVIAL 
protected O 
against O 
cisplatin B-TRIVIAL 
- O 
induced O 
nephrotoxicity O 
through O 
its O 
interaction O 
with O 
PPAR-γ O 
receptors O 
and O 
antioxidant O 
effects O 
. O 
Furthermore O 
, O 
pioglitazone B-TRIVIAL 
did O 
not O 
interfere O 
but O 
rather O 
potentiated O 
the O 
cytotoxic O 
effects O 
of O 
cisplatin B-TRIVIAL 
on O 
human O 
renal O 
adenocarcinoma O 
cells O 
. O 

effect O 
of O 
calcium B-SYSTEMATIC 
citrate I-SYSTEMATIC 
on O 
serum O 
calcium B-SYSTEMATIC 
and O 
cardiovascular O 
function O 
. O 

supplements O 
have O 
been O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
cardiovascular O 
events O 
. O 
However O 
, O 
the O 
validity O 
of O 
these O 
findings O 
has O 
been O 
questioned O 
. O 
A O 
major O 
concern O 
is O 
that O 
the O 
mechanism O 
underlying O 
an O 
increase O 
in O 
cardiovascular O 
events O 
has O 
not O 
been O 
demonstrated O 
. O 
Calcium B-SYSTEMATIC 
initiates O 
cardiac O 
and O 
vascular O 
contraction O 
following O 
influx O 
of O 
calcium B-SYSTEMATIC 
into O 
cardiac O 
and O 
smooth O 
muscle O 
from O 
extracellular O 
fluid O 
. O 
We O 
have O 
investigated O 
whether O 
the O 
acute O 
rise O 
in O 
serum O 
calcium B-SYSTEMATIC 
following O 
calcium B-SYSTEMATIC 
supplement O 
administration O 
is O 
associated O 
with O 
adverse O 
changes O 
in O 
cardiovascular O 
function O 
. O 
In O 
an O 
open O 
interventional O 
study O 
, O 
we O 
recruited O 
25 O 
volunteers O 
( O 
16 O 
female O 
, O 
age O 
60.3 O 
± O 
6.5 O 
years O 
, O 
body O 
mass O 
index O 
25.7 O 
± O 
2.7 O 
kg O 
/ O 
m2 O 
) O 
from O 
the O 
community O 
who O 
were O 
not O 
taking O 
calcium B-SYSTEMATIC 
supplements O 
. O 
Participants O 
were O 
studied O 
before O 
and O 
3 O 
hours O 
after O 
a O 
single O 
oral O 
dose O 
of O 
1000 O 
mg O 
calcium B-SYSTEMATIC 
citrate I-SYSTEMATIC 
. O 
We O 
assessed O 
well O 
- O 
validated O 
markers O 
of O 
arterial O 
stiffness O 
( O 
pulse O 
wave O 
velocity O 
[ O 
PWV O 
] O 
) O 
, O 
arterial O 
wave O 
reflection O 
( O 
augmentation O 
index O 
[ O 
AIx O 
] O 
) O 
, O 
and O 
myocardial O 
perfusion O 
( O 
subendocardial O 
viability O 
ratio O 
[ O 
SEVR O 
] O 
) O 
by O 
pulse O 
wave O 
analysis O 
and O 
endothelial O 
function O 
( O 
reactive O 
hyperemia O 
index O 
[ O 
RHI O 
] O 
) O 
by O 
peripheral O 
arterial O 
tonometry O 
. O 
Total O 
and O 
ionized O 
serum O 
calcium B-SYSTEMATIC 
were O 
acutely O 
increased O 
by O 
0.1 O 
± O 
0.07 O 
and O 
0.06 O 
± O 
0.03 O 
mmol O 
/ O 
L O 
, O 
respectively O 
, O 
3 O 
hours O 
after O 
calcium B-SYSTEMATIC 
citrate I-SYSTEMATIC 
administration O 
( O 
p O 
< O 
0.0001 O 
for O 
both O 
comparisons O 
) O 
. O 
Following O 
administration O 
of O 
calcium B-SYSTEMATIC 
citrate I-SYSTEMATIC 
there O 
was O 
a O 
fall O 
in O 
AIx O 
from O 
a O 
median O 
of O 
29.7% O 
( O 
23.8% O 
to O 
34.0% O 
) O 
to O 
26.4% O 
( O 
22.7% O 
to O 
34.0% O 
, O 
p O 
= O 
0.03 O 
) O 
and O 
an O 
increase O 
in O 
SEVR O 
from O 
163% O 
( O 
148% O 
to O 
174% O 
) O 
to O 
170% O 
( O 
149% O 
to O 
185% O 
, O 
p O 
= O 
0.007 O 
) O 
. O 
PWV O 
and O 
RHI O 
were O 
not O 
significantly O 
altered O 
. O 
The O 
change O 
in O 
total O 
calcium B-SYSTEMATIC 
was O 
negatively O 
correlated O 
with O 
the O 
change O 
in O 
AIx O 
( O 
r O 
= O 
-0.48 O 
, O 
p O 
= O 
0.02 O 
) O 
. O 
In O 
summary O 
, O 
the O 
acute O 
increase O 
in O 
serum O 
calcium B-SYSTEMATIC 
following O 
calcium B-SYSTEMATIC 
supplement O 
administration O 
is O 
associated O 
with O 
reduced O 
arterial O 
wave O 
reflection O 
and O 
a O 
marker O 
of O 
increased O 
myocardial O 
perfusion O 
. O 
If O 
maintained O 
long O 
- O 
term O 
, O 
these O 
changes O 
would O 
be O 
expected O 
to O 
reduce O 
cardiovascular O 
risk O 
. O 
Acute O 
serum O 
calcium B-SYSTEMATIC 
-mediated O 
changes O 
in O 
these O 
parameters O 
of O 
cardiovascular O 
function O 
are O 
unlikely O 
to O 
underlie O 
an O 
association O 
between O 
calcium B-SYSTEMATIC 
supplementation O 
and O 
cardiovascular O 
events O 
. O 

peripheral O 
blood O 
γδ O 
T O 
cells O 
predict O 
osteonecrosis O 
of O 
the O 
jaw O 
? O 
An O 
immunological O 
perspective O 
on O 
the O 
adverse O 
drug O 
effects O 
of O 
aminobisphosphonate B-FAMILY 
therapy O 
. O 

- I-FAMILY 
bisphosphonates I-FAMILY 
( O 
n-BP B-ABBREVIATION 
) O 
, O 
often O 
referred O 
to O 
as O 
aminobisphosphonates B-FAMILY 
, O 
are O 
the O 
most O 
commonly O 
prescribed O 
drugs O 
for O 
the O 
treatment O 
of O 
disorders O 
of O 
bone O 
fragility O 
. O 
However O 
, O 
long O 
- O 
term O 
continuous O 
treatment O 
predisposes O 
certain O 
individuals O 
to O 
serious O 
rare O 
side O 
effects O 
, O 
such O 
as O 
bisphosphonate B-SYSTEMATIC 
-associated O 
osteonecrosis O 
of O 
the O 
jaw O 
( O 
BAONJ O 
) O 
. O 
n-BP B-ABBREVIATION 
use O 
is O 
known O 
to O 
unintentionally O 
activate O 
a O 
subset O 
of O 
innate O 
T O 
cells O 
called O 
Vγ9Vδ2 O 
T O 
cells O 
, O 
but O 
the O 
consequence O 
of O 
this O 
chronic O 
immune O 
stimulation O 
has O 
remained O 
unexplored O 
. O 
The O 
primary O 
objectives O 
of O 
this O 
study O 
were O 
to O 
1 O 
) O 
determine O 
the O 
fate O 
of O 
Vγ9Vδ2 O 
T O 
cells O 
in O 
osteoporotic O 
patients O 
on O 
n-BP B-ABBREVIATION 
therapy O 
as O 
a O 
function O 
of O 
time O 
and O 
type O 
of O 
therapy O 
; O 
2 O 
) O 
evaluate O 
the O 
proportion O 
of O 
Vγ9Vδ2 O 
T O 
cells O 
in O 
patients O 
who O 
had O 
recently O 
experienced O 
n-BP B-ABBREVIATION 
-associated O 
ONJ O 
. O 
We O 
found O 
there O 
is O 
a O 
notable O 
loss O 
of O 
Vγ9Vδ2 O 
T O 
cells O 
over O 
time O 
in O 
osteoporotic O 
patients O 
on O 
n-BP B-ABBREVIATION 
therapy O 
, O 
particularly O 
those O 
on O 
intravenous O 
(iv) O 
therapy O 
( O 
Spearman O 
r O 
= O 
-0.55 O 
, O 
p O 
< O 
0.0001 O 
iv O 
; O 
r O 
= O 
-0.3 O 
, O 
p O 
< O 
0.03 O 
oral O 
) O 
( O 
n O 
= O 
68 O 
) O 
; O 
no O 
difference O 
was O 
observed O 
in O 
total O 
T O 
cells O 
, O 
monocytes O 
, O 
or O 
granulocytes O 
. O 
Importantly O 
, O 
the O 
observed O 
negative O 
effect O 
on O 
Vγ9Vδ2 O 
T O 
cells O 
coincides O 
with O 
the O 
reported O 
route O 
of O 
administration O 
and O 
timing O 
of O 
the O 
rare O 
occurrence O 
of O 
BAONJ O 
. O 
Patients O 
( O 
n O 
= O 
6 O 
) O 
who O 
had O 
experienced O 
BAONJ O 
were O 
all O 
found O 
to O 
be O 
significantly O 
deficient O 
in O 
Vγ9Vδ2 O 
T O 
cells O 
( O 
median O 
= O 
0.07% O 
) O 
in O 
comparison O 
to O 
age- O 
and O 
sex O 
- O 
matched O 
treatment-naïve O 
controls O 
( O 
N O 
= O 
11 O 
; O 
median O 
= O 
2.40% O 
) O 
, O 
U O 
= O 
0 O 
, O 
p O 
= O 
0.001 O 
; O 
this O 
was O 
the O 
only O 
consistent O 
difference O 
in O 
the O 
leukocytes O 
assessed O 
. O 
All O 
BAONJ O 
cases O 
had O 
an O 
underlying O 
condition O 
that O 
further O 
contributed O 
to O 
impaired O 
immunity O 
. O 
We O 
propose O 
Vγ9Vδ2 O 
T O 
cells O 
show O 
a O 
strong O 
potential O 
to O 
serve O 
as O 
harbingers O 
of O 
possible O 
adverse O 
immune O 
effects O 
of O 
n-BP B-ABBREVIATION 
therapy O 
, O 
particularly O 
in O 
those O 
patients O 
already O 
having O 
a O 
compromised O 
immune O 
system O 
as O 
they O 
may O 
be O 
most O 
vulnerable O 
to O 
the O 
development O 
of O 
conditions O 
such O 
as O 
BAONJ O 
. O 

computerized O 
auditory O 
training O 
results O 
in O 
improved O 
cognition O 
for O 
schizophrenia O 
patients O 
, O 
but O 
participants O 
show O 
variation O 
in O 
their O 
cognitive O 
gains O 
and O 
the O 
biological O 
factors O 
that O 
affect O 
the O 
response O 
to O 
training O 
are O 
unknown O 
. O 
Single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
in O 
the O 
catechol B-TRIVIAL 
- O 
O B-FORMULA 
-methyltransferase O 
( O 
COMT O 
) O 
gene O 
have O 
been O 
related O 
to O 
cognitive O 
function O 
. O 
Here O 
we O 
asked O 
if O 
functional O 
variation O 
in O 
this O 
gene O 
has O 
an O 
impact O 
on O 
the O 
response O 
of O 
schizophrenia O 
patients O 
to O 
cognitive O 
training O 
. O 
We O 
genotyped O 
48 O 
schizophrenia O 
patients O 
who O 
completed O 
50 O 
h O 
of O 
computerized O 
cognitive O 
training O 
and O 
analyzed O 
the O 
association O 
between O 
DNA O 
variants O 
in O 
the O 
COMT O 
gene O 
and O 
the O 
improvement O 
in O 
global O 
cognition O 
. O 
Although O 
conventional O 
analyses O 
did O 
not O 
reveal O 
any O 
significant O 
associations O 
, O 
a O 
set O 
- O 
based O 
analysis O 
examining O 
the O 
aggregate O 
effect O 
of O 
common O 
variation O 
in O 
the O 
COMT O 
gene O 
( O 
42 O 
SNPs O 
) O 
suggested O 
association O 
with O 
improvement O 
in O 
global O 
cognition O 
. O 
Eight O 
SNPs O 
, O 
mostly O 
located O 
in O 
the O 
3 O 
' O 
end O 
of O 
the O 
COMT O 
gene O 
, O 
were O 
nominally O 
associated O 
with O 
improvement O 
in O 
cognition O 
. O 
These O 
data O 
suggest O 
that O 
genotype O 
influences O 
the O 
response O 
to O 
intensive O 
cognitive O 
training O 
in O 
schizophrenia O 
, O 
and O 
may O 
indicate O 
that O 
cognitive O 
training O 
regimens O 
need O 
to O 
be O 
personalized O 
to O 
the O 
underlying O 
biosignatures O 
of O 
each O 
individual O 
patient O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Cognitive O 
Enhancers' O 
. O 

ATGL O 
knockdown O 
uncouples O 
glucose B-TRIVIAL 
intolerance O 
from O 
liver O 
TAG O 
accumulation O 
. O 

triglyceride B-FAMILY 
lipase O 
( O 
ATGL O 
) O 
is O 
the O 
predominant O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
hydrolase O 
in O 
mammals O 
; O 
however O 
, O 
the O 
tissue O 
- O 
specific O 
effects O 
of O 
ATGL O 
outside O 
of O 
adipose O 
tissue O 
have O 
not O 
been O 
well O 
characterized O 
. O 
Hence O 
, O 
we O 
tested O 
the O 
contribution O 
of O 
hepatic O 
ATGL O 
on O 
mediating O 
glucose B-TRIVIAL 
tolerance O 
and O 
insulin O 
action O 
. O 
Glucose B-TRIVIAL 
or O 
insulin O 
tolerance O 
tests O 
and O 
insulin O 
signaling O 
were O 
performed O 
in O 
C57BL O 
/ O 
6 O 
mice O 
administered O 
control O 
( O 
nongene O 
specific O 
shRNA O 
) O 
or O 
Atgl O 
shRNA O 
adenoviruses O 
. O 
Glucose B-TRIVIAL 
and O 
lipid O 
metabolism O 
assays O 
were O 
conducted O 
in O 
primary O 
hepatocytes O 
isolated O 
from O 
mice O 
transduced O 
with O 
control O 
or O 
Atgl O 
shRNA O 
adenoviruses O 
. O 
Knocking O 
down O 
hepatic O 
ATGL O 
completely O 
abrogated O 
the O 
increase O 
in O 
serum O 
insulin O 
following O 
either O 
1 O 
or O 
12 O 
wk O 
of O 
feeding O 
a O 
high O 
- O 
fat O 
( O 
HF O 
) O 
diet O 
despite O 
higher O 
hepatic O 
TAG B-ABBREVIATION 
content O 
. O 
Glucose B-TRIVIAL 
tolerance O 
tests O 
demonstrated O 
that O 
ATGL O 
knockdown O 
normalized O 
glucose B-TRIVIAL 
tolerance O 
in O 
HF-diet O 
- O 
fed O 
mice O 
. O 
The O 
observed O 
improvements O 
in O 
glucose B-TRIVIAL 
tolerance O 
were O 
present O 
despite O 
unaltered O 
hepatic O 
insulin O 
signaling O 
and O 
increased O 
liver O 
TAG B-ABBREVIATION 
. O 
Mice O 
with O 
suppressed O 
hepatic O 
ATGL O 
had O 
reduced O 
hepatic O 
glucose B-TRIVIAL 
production O 
in O 
vivo O 
, O 
and O 
hepatocytes O 
isolated O 
from O 
Atgl O 
shRNA O 
- O 
treated O 
mice O 
displayed O 
a O 
26% O 
decrease O 
in O 
glucose B-TRIVIAL 
production O 
and O 
a O 
38% O 
increase O 
in O 
glucose B-TRIVIAL 
oxidation O 
compared O 
to O 
control O 
cells O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
hepatic O 
ATGL O 
knockdown O 
enhances O 
glucose B-TRIVIAL 
tolerance O 
by O 
increasing O 
hepatic O 
glucose B-TRIVIAL 
utilization O 
and O 
uncouples O 
impairments O 
in O 
insulin O 
action O 
from O 
hepatic O 
TAG B-ABBREVIATION 
accumulation O 
. O 

linear O 
polyethylenimine B-SYSTEMATIC 
enhances O 
delivery O 
of O 
DNA O 
to O 
the O 
cytoplasm O 
. O 

polyethylenimines B-FAMILY 
( O 
PEIs B-ABBREVIATION 
) O 
have O 
been O 
frequently O 
examined O 
over O 
the O 
past O 
decade O 
since O 
they O 
can O 
maintain O 
the O 
transfection O 
efficiency O 
of O 
commercially O 
available O 
, O 
25k O 
branched O 
PEI B-ABBREVIATION 
, O 
but O 
exhibit O 
less O 
cytotoxicity O 
. O 
The O 
argument O 
is O 
often O 
made O 
that O 
the O 
degradability O 
of O 
such O 
polymers O 
, O 
generally O 
synthesized O 
with O 
either O 
disulfide B-SYSTEMATIC 
or O 
hydrolytically O 
degradable O 
crosslinkers O 
, O 
is O 
critical O 
to O 
the O 
high O 
efficiency O 
and O 
low O 
toxicity O 
of O 
the O 
system O 
. O 
In O 
this O 
work O 
, O 
we O 
present O 
a O 
crosslinked O 
linear O 
PEI B-ABBREVIATION 
( O 
xLPEI O 
) O 
system O 
in O 
which O 
either O 
disulfide B-SYSTEMATIC 
-responsive O 
or O 
non-degradable O 
linkages O 
are O 
incorporated O 
. O 
As O 
with O 
previous O 
systems O 
, O 
strong O 
transfection O 
efficiency O 
in O 
comparison O 
with O 
commercial O 
standards O 
was O 
achieved O 
with O 
low O 
cytotoxicity O 
. O 
However O 
, O 
these O 
properties O 
were O 
shown O 
to O 
be O 
present O 
when O 
either O 
the O 
degradable O 
or O 
non-degradable O 
crosslinker O 
was O 
used O 
. O 
Uncomplexed O 
polymer O 
was O 
demonstrated O 
to O 
be O 
the O 
critical O 
factor O 
determining O 
transfection O 
efficiency O 
for O 
these O 
polymers O 
, O 
mediating O 
efficient O 
endosomal O 
escape O 
without O 
signs O 
of O 
cell O 
membrane O 
damage O 
. O 
While O 
several O 
crosslinked O 
PEI B-ABBREVIATION 
systems O 
in O 
the O 
literature O 
have O 
demonstrated O 
the O 
effect O 
of O 
the O 
disulfide B-SYSTEMATIC 
moiety O 
, O 
this O 
work O 
demonstrates O 
that O 
disulfide B-SYSTEMATIC 
-mediated O 
unpackaging O 
may O 
not O 
be O 
as O 
important O 
as O 
conventionally O 
thought O 
for O 
some O 
PEI B-ABBREVIATION 
systems O 
. O 

, O 
or O 
crayfish O 
worms O 
, O 
are O 
ectosymbiotic O 
clitellate O 
annelids O 
associated O 
primarily O 
with O 
freshwater O 
crayfishes O 
. O 
The O 
main O 
objectives O 
of O 
our O 
study O 
were O 
to O 
infer O 
a O 
molecular O 
phylogeny O 
for O 
the O 
North O 
American O 
Branchiobdellida O 
, O 
examine O 
its O 
congruence O 
with O 
morphology O 
- O 
based O 
hypotheses O 
of O 
relationships O 
at O 
the O 
subfamily O 
and O 
genus O 
level O 
, O 
and O 
use O 
our O 
dataset O 
to O 
assess O 
consistency O 
of O 
GenBank O 
- O 
archived O 
branchiobdellidan O 
sequences O 
. O 
We O 
used O 
nucleotide B-FAMILY 
sequence O 
data O 
from O 
two O 
mtDNA O 
genes O 
( O 
COI O 
and O 
16S O 
rDNA O 
) O 
and O 
three O 
nuclear O 
genes O 
( O 
28S O 
rDNA O 
, O 
18S O 
rDNA O 
, O 
and O 
ITS1 O 
) O 
to O 
estimate O 
phylogenetic O 
relationships O 
among O 
47 O 
described O 
and O 
one O 
undescribed O 
species O 
of O 
Branchiobdellida O 
. O 
We O 
recovered O 
a O 
monophyletic O 
branchiobdellidan O 
clade O 
with O 
generally O 
short O 
branch O 
lengths O 
, O 
suggesting O 
that O 
a O 
large O 
portion O 
of O 
the O 
taxon O 
has O 
likely O 
undergone O 
a O 
recent O 
and O 
rapid O 
radiation O 
in O 
North O 
America O 
. O 
Results O 
from O 
our O 
phylogenetic O 
analyses O 
indicate O 
that O 
current O 
taxonomic O 
groupings O 
are O 
largely O 
unsupported O 
by O 
the O 
molecular O 
data O 
. O 
All O 
four O 
subfamilies O 
are O 
either O 
paraphyletic O 
or O 
polyphyletic O 
, O 
and O 
only O 
three O 
of O 
seven O 
sampled O 
non-monotypic O 
genera O 
were O 
monophyletic O 
. O 
We O 
found O 
a O 
high O 
rate O 
( O 
49% O 
) O 
of O 
inconsistency O 
in O 
GenBank O 
- O 
archived O 
sequences O 
, O 
over O 
70% O 
of O 
which O 
can O 
be O 
attributed O 
to O 
field- O 
or O 
laboratory O 
- O 
based O 
error O 
. O 

for O 
substrate O 
- O 
dependent O 
inhibition O 
profiles O 
for O 
human O 
liver O 
aldehyde B-SYSTEMATIC 
oxidase O 
. O 

goal O 
of O 
this O 
study O 
was O 
to O 
provide O 
a O 
reasonable O 
assessment O 
of O 
how O 
probe O 
substrate O 
selection O 
may O 
impact O 
the O 
results O 
of O 
in O 
vitro O 
aldehyde B-SYSTEMATIC 
oxidase O 
( O 
AO O 
) O 
inhibition O 
experiments O 
. O 
Here O 
, O 
we O 
used O 
a O 
previously O 
studied O 
set O 
of O 
seven O 
known O 
AO O 
inhibitors O 
to O 
probe O 
the O 
inhibition O 
profile O 
of O 
a O 
pharmacologically O 
relevant O 
substrate O 
N-[(2-dimethylamino)ethyl]acridine-4-carboxamide B-SYSTEMATIC 
( O 
DACA B-ABBREVIATION 
) O 
. O 
DACA B-ABBREVIATION 
oxidation O 
in O 
human O 
liver O 
cytosol O 
was O 
characterized O 
with O 
a O 
measured O 
V(max) O 
of O 
2.3 O 
± O 
0.08 O 
nmol O 
product O 
· O 
min(-1) O 
· O 
mg(-1) O 
and O 
a O 
K(m) O 
of O 
6.3 O 
± O 
0.8 O 
µM O 
. O 
The O 
K O 
(ii) O 
and O 
K(is) O 
values O 
describing O 
the O 
inhibition O 
of O 
DACA B-ABBREVIATION 
oxidation O 
by O 
the O 
panel O 
of O 
seven O 
inhibitors O 
were O 
tabulated O 
and O 
compared O 
with O 
previous O 
findings O 
with O 
phthalazine B-TRIVIAL 
as O 
the O 
substrate O 
. O 
In O 
every O 
case O 
, O 
the O 
inhibition O 
profile O 
shifted O 
to O 
a O 
much O 
less O 
uncompetitive O 
mode O 
of O 
inhibition O 
for O 
DACA B-ABBREVIATION 
relative O 
to O 
phthalazine B-TRIVIAL 
. O 
With O 
the O 
exception O 
of O 
one O 
inhibitor O 
, O 
raloxifene B-TRIVIAL 
, O 
this O 
change O 
in O 
inhibition O 
profile O 
seems O 
to O 
be O 
a O 
result O 
of O 
a O 
decrease O 
in O 
the O 
uncompetitive O 
mode O 
of O 
inhibition O 
( O 
an O 
affected O 
K O 
(ii) O 
value O 
) O 
, O 
whereas O 
the O 
competitive O 
mode O 
(K(is)) O 
seems O 
to O 
be O 
relatively O 
consistent O 
between O 
substrates O 
. O 
Raloxifene B-TRIVIAL 
was O 
found O 
to O 
inhibit O 
competitively O 
when O 
using O 
DACA B-ABBREVIATION 
as O 
a O 
probe O 
, O 
and O 
a O 
previous O 
report O 
showed O 
that O 
raloxifene B-TRIVIAL 
inhibited O 
uncompetitively O 
with O 
other O 
substrates O 
. O 
The O 
relevance O 
of O 
these O 
data O 
to O 
the O 
mechanistic O 
understanding O 
of O 
aldehyde B-SYSTEMATIC 
oxidase O 
inhibition O 
and O 
potential O 
implications O 
on O 
drug O 
- O 
drug O 
interactions O 
is O 
discussed O 
. O 
Overall O 
, O 
it O 
appears O 
that O 
the O 
choice O 
in O 
substrate O 
may O 
be O 
critical O 
when O 
conducting O 
mechanistic O 
inhibition O 
or O 
in O 
vitro O 
drug O 
- O 
drug O 
interactions O 
prediction O 
studies O 
with O 
AO O 
. O 

of O 
emetic O 
potencies O 
of O 
the O 
8-ketotrichothecenes B-SYSTEMATIC 
deoxynivalenol I-SYSTEMATIC 
, O 
15-acetyldeoxynivalenol B-SYSTEMATIC 
, O 
3-acetyldeoxynivalenol B-SYSTEMATIC 
, O 
fusarenon B-TRIVIAL 
X I-TRIVIAL 
, O 
and O 
nivalenol B-TRIVIAL 
. O 

the O 
acute O 
toxic O 
effects O 
of O 
trichothecene B-FAMILY 
mycotoxin O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
or O 
vomitoxin B-TRIVIAL 
) O 
, O 
a O 
known O 
cause O 
of O 
human O 
food O 
poisoning O 
, O 
have O 
been O 
well O 
characterized O 
in O 
several O 
animal O 
species O 
, O 
much O 
less O 
is O 
known O 
about O 
closely O 
related O 
8-ketotrichothecenes B-FAMILY 
that O 
similarly O 
occur O 
in O 
cereal O 
grains O 
colonized O 
by O 
toxigenic O 
fusaria O 
. O 
To O 
address O 
this O 
, O 
we O 
compared O 
potencies O 
of O 
DON B-ABBREVIATION 
, O 
15-acetyldeoxynivalenol B-SYSTEMATIC 
( O 
15-ADON B-SYSTEMATIC 
) O 
, O 
3-acetyldeoxynivalenol B-SYSTEMATIC 
( O 
3-ADON B-SYSTEMATIC 
) O 
, O 
fusarenon B-TRIVIAL 
X I-TRIVIAL 
( O 
FX O 
) O 
, O 
and O 
nivalenol B-TRIVIAL 
( O 
NIV B-ABBREVIATION 
) O 
in O 
the O 
mink O 
emesis O 
model O 
following O 
intraperitoneal O 
( O 
ip O 
) O 
and O 
oral O 
administration O 
. O 
All O 
five O 
congeners O 
dose O 
- O 
dependently O 
induced O 
emesis O 
by O 
both O 
administration O 
methods O 
. O 
With O 
increasing O 
doses O 
, O 
there O 
were O 
marked O 
decreases O 
in O 
latency O 
to O 
emesis O 
with O 
corresponding O 
increases O 
in O 
emesis O 
duration O 
and O 
number O 
of O 
emetic O 
events O 
. O 
The O 
effective O 
doses O 
resulting O 
in O 
emetic O 
events O 
in O 
50% O 
of O 
the O 
animals O 
for O 
ip O 
exposure O 
to O 
DON B-ABBREVIATION 
, O 
15-ADON B-SYSTEMATIC 
, O 
3-ADON B-SYSTEMATIC 
, O 
FX O 
, O 
and O 
NIV B-ABBREVIATION 
were O 
80 O 
, O 
170 O 
, O 
180 O 
, O 
70 O 
, O 
and O 
60 O 
µg O 
/ O 
kg O 
bw O 
, O 
respectively O 
, O 
and O 
for O 
oral O 
exposure O 
, O 
they O 
were O 
30 O 
, O 
40 O 
, O 
290 O 
, O 
30 O 
, O 
and O 
250 O 
µg O 
/ O 
kg O 
bw O 
, O 
respectively O 
. O 
The O 
emetic O 
potency O 
of O 
DON B-ABBREVIATION 
determined O 
here O 
was O 
comparable O 
to O 
that O 
reported O 
in O 
analogous O 
studies O 
conducted O 
in O 
pigs O 
and O 
dogs O 
, O 
suggesting O 
that O 
the O 
mink O 
is O 
a O 
suitable O 
small O 
animal O 
model O 
for O 
investigating O 
acute O 
trichothecene B-FAMILY 
toxicity O 
. O 
The O 
use O 
of O 
a O 
mouse O 
pica O 
model O 
, O 
based O 
on O 
the O 
consumption O 
of O 
kaolin B-TRIVIAL 
, O 
was O 
also O 
evaluated O 
as O 
a O 
possible O 
surrogate O 
for O 
studying O 
emesis O 
but O 
was O 
found O 
unsuitable O 
. O 
From O 
a O 
public O 
health O 
perspective O 
, O 
comparative O 
emetic O 
potency O 
data O 
derived O 
from O 
small O 
animal O 
models O 
such O 
as O 
the O 
mink O 
should O 
be O 
useful O 
for O 
establishing O 
toxic O 
equivalency O 
factors O 
for O 
DON B-ABBREVIATION 
and O 
other O 
trichothecenes B-FAMILY 
. O 

-CNT O 
composite O 
prepared O 
by O 
electrophoretic O 
codeposition O 
and O 
the O 
polymer O 
infiltration O 
and O 
pyrolysis O 
process O 
. O 

paper O 
reports O 
on O 
the O 
successful O 
anodic O 
codeposition O 
of O 
submicrometer O 
SiC B-FORMULA 
powder O 
and O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
from O 
aqueous O 
suspensions O 
to O 
form O 
SiC B-FORMULA 
-CNT O 
composites O 
. O 
On O 
the O 
basis O 
of O 
the O 
comprehensive O 
analysis O 
of O 
the O 
aqueous O 
suspensions O 
with O 
different O 
pHs O 
, O 
solids O 
contents O 
, O 
and O 
CNT O 
contents O 
, O 
optimal O 
conditions O 
for O 
deposition O 
were O 
determined O 
. O 
Besides O 
having O 
the O 
necessary O 
high O 
absolute O 
value O 
of O 
the O 
ζ-potential O 
, O 
the O 
suspensions O 
that O 
resulted O 
in O 
firm O 
deposits O 
were O 
characterized O 
by O 
limited O 
conductivity O 
( O 
< O 
1 O 
mS O 
/ O 
cm O 
) O 
. O 
Lowering O 
of O 
suspension O 
conductivity O 
was O 
achieved O 
either O 
by O 
dilution O 
of O 
the O 
suspension O 
or O 
by O 
dialysis O 
of O 
the O 
as-received O 
CNT O 
suspension O 
with O 
high O 
intrinsic O 
conductivity O 
. O 
Selected O 
SiC B-FORMULA 
-CNT O 
deposits O 
were O 
further O 
densified O 
by O 
use O 
of O 
the O 
polymer O 
infiltration O 
and O 
pyrolysis O 
process O 
. O 

- O 
finger O 
toxins O 
( O 
TFTs O 
) O 
are O 
the O 
main O 
venom O 
components O 
of O 
snakes O 
from O 
Elapidae O 
family O 
. O 
Amino B-FAMILY 
acid I-FAMILY 
sequences O 
of O 
more O 
than O 
five O 
hundreds O 
TFTs O 
are O 
determined O 
; O 
these O 
toxins O 
form O 
one O 
of O 
the O 
largest O 
protein O 
families O 
present O 
in O 
snake O 
venoms O 
. O 
The O 
first O 
TFT O 
α-bungarotoxin O 
was O 
isolated O 
almost O 
half O 
a O 
century O 
ago O 
and O 
so O 
far O 
it O 
remains O 
a O 
valuable O 
tool O 
in O 
the O 
study O 
of O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
. O 
TFTs O 
possess O 
diverse O 
biological O 
activities O 
; O 
for O 
example O 
, O 
α-neurotoxins O 
bind O 
specifically O 
with O 
high O 
affinity O 
to O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
, O 
while O 
cytotoxins O 
induce O 
non-specific O 
lysis O 
in O 
great O 
variety O 
of O 
cells O 
. O 
These O 
toxins O 
are O 
widely O 
used O 
as O 
instruments O 
in O 
different O 
branches O 
of O 
life O 
sciences O 
. O 
In O 
this O 
review O 
the O 
main O 
landmarks O 
in O 
TFT O 
study O 
are O 
considered O 
. O 
These O 
are O 
the O 
discovery O 
and O 
isolation O 
of O 
TFTs O 
, O 
determination O 
of O 
their O 
structure O 
and O 
mode O 
of O 
action O 
as O 
well O 
as O 
evolution O 
and O 
relationship O 
within O 
the O 
family O 
. O 

of O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
and O 
the O 
cytotoxicity O 
activities O 
of O 
the O 
transformed O 
products O 
. O 

and O 
rutin B-TRIVIAL 
are O 
well O 
- O 
know O 
flavonoids B-FAMILY 
. O 
In O 
spite O 
of O 
this O 
, O 
the O 
comprehension O 
of O 
their O 
metabolism O 
is O 
still O 
incomplete O 
. O 
In O 
this O 
work O 
, O 
the O 
cytotoxic O 
activity O 
of O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
and O 
its O 
metabolites O 
produced O 
by O 
metabolism O 
of O 
filamentous O 
fungi O 
was O 
investigated O 
. O 
Flavonoids B-FAMILY 
metabolism O 
was O 
monitored O 
by O 
HPLC O 
and O 
LC-MS O 
. O 
Both O 
flavonoids B-FAMILY 
were O 
extensively O 
metabolized O 
. O 
Quercetin B-TRIVIAL 
was O 
converted O 
into O 
metabolite O 
methylquercetin B-SYSTEMATIC 
( O 
2 O 
) O 
and O 
quercetin B-TRIVIAL 
glucuronide I-TRIVIAL 
( O 
3 O 
) O 
and O 
rutin B-TRIVIAL 
into O 
metabolite O 
rutin B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
methylrutin B-SYSTEMATIC 
( O 
6 O 
) O 
and O 
rutin B-TRIVIAL 
glucuronide I-TRIVIAL 
( O 
7 O 
) O 
. O 
Cytotoxic O 
effects O 
of O 
rutin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
and O 
its O 
metabolites O 
were O 
measured O 
by O 
MTT B-ABBREVIATION 
tetrazolium B-SYSTEMATIC 
reduction O 
test O 
and O 
the O 
trypan B-TRIVIAL 
blue I-TRIVIAL 
exclusion O 
assay O 
on O 
HL-60 O 
leukemic O 
cells O 
. O 
The O 
results O 
showed O 
similar O 
concentration O 
- O 
dependent O 
cytotoxic O 
effect O 
for O 
rutin B-TRIVIAL 
and O 
rutin B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
while O 
no O 
cytotoxic O 
effect O 
was O 
detected O 
with O 
the O 
metabolites O 
6 O 
and O 
7 O 
. O 
In O 
relation O 
to O 
the O 
quercetin B-TRIVIAL 
and O 
its O 
metabolites O 
the O 
results O 
showed O 
that O 
all O 
compounds O 
have O 
a O 
similar O 
concentration O 
- O 
dependent O 
inhibitory O 
effect O 
on O 
HL-60 O 
cells O 
. O 
These O 
findings O 
corroborate O 
the O 
literature O 
, O 
showing O 
that O 
bioconversion O 
is O 
a O 
useful O 
strategy O 
for O 
production O 
of O 
biological O 
active O 
metabolites O 
. O 

inhibitory O 
effects O 
of O 
mollugin B-TRIVIAL 
on O 
CYP1A2 O 
in O 
human O 
liver O 
microsomes O 
. O 

originally O 
isolated O 
from O 
Rubia O 
cordifolia O 
is O 
a O 
pharmacological O 
compound O 
for O 
its O 
anti-inflammation O 
, O 
anti-cancer O 
, O 
and O 
anti-viral O 
activity O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
cocktail O 
probe O 
assay O 
was O 
performed O 
for O 
determination O 
of O 
the O 
selective O 
inhibitory O 
effect O 
of O 
mollugin B-TRIVIAL 
on O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
enzymes O 
in O 
human O 
liver O 
microsomes O 
( O 
HLM O 
) O 
. O 
Incubation O 
of O 
isoform O 
- O 
specific O 
substrate O 
probes O 
CYPs O 
with O 
mollugin B-TRIVIAL 
( O 
0-25μM O 
) O 
in O 
HLM O 
resulted O 
in O 
strong O 
inhibition O 
of O 
CYP1A2 O 
- O 
catalyzed O 
phenacetin B-TRIVIAL 
O B-FORMULA 
-deethylation O 
, O 
showing O 
IC(50) O 
values O 
of O 
1.03 O 
and O 
3.55μM O 
without O 
and O 
with O 
pre O 
- O 
incubation O 
, O 
respectively O 
. O 
Mollugin B-TRIVIAL 
-caused O 
inhibition O 
of O 
phenacetin B-TRIVIAL 
O B-FORMULA 
-deethylation O 
was O 
concentration O 
- O 
dependent O 
in O 
HLMs O 
, O 
but O 
not O 
time O 
- O 
dependent O 
. O 
In O 
addition O 
, O 
the O 
Lineweaver-Burk O 
plot O 
indicated O 
a O 
typical O 
competitive O 
inhibition O 
. O 
Inhibitory O 
effects O 
of O 
mollugin B-TRIVIAL 
on O 
human O 
recombinant O 
cDNA-expressed O 
CYP1A1 O 
and O 
1A2 O 
were O 
comparable O 
. O 
Taken O 
together O 
, O 
the O 
results O 
suggested O 
that O 
mollugin B-TRIVIAL 
might O 
cause O 
herb O 
- O 
drug O 
interaction O 
through O 
selective O 
inhibition O 
of O 
CYP1A2 O 
in O 
humans O 
receiving O 
herbal O 
medications O 
, O 
including O 
R O 
. O 
cordifolia O 
. O 

90-day O 
feeding O 
study O 
of O 
glyphosate B-TRIVIAL 
-tolerant O 
maize O 
with O 
the O 
G2-aroA O 
gene O 
in O 
Sprague-Dawley O 
rats O 
. O 

is O 
not O 
only O 
a O 
staple O 
food O 
crop O 
but O 
also O 
an O 
important O 
raw O 
material O 
for O 
feed O 
and O 
industry O 
; O 
however O 
, O 
the O 
threat O 
of O 
weeds O 
leads O 
to O 
a O 
serious O 
decline O 
in O 
its O 
output O 
and O 
quality O 
. O 
The O 
G2-aroA O 
gene O 
confers O 
glyphosate B-TRIVIAL 
herbicide O 
tolerance O 
to O 
crops O 
. O 
In O 
this O 
study O 
, O 
the O 
food O 
safety O 
of O 
genetically O 
modified O 
( O 
GM O 
) O 
, O 
glyphosate B-TRIVIAL 
-tolerant O 
maize O 
with O 
the O 
G2-aroA O 
gene O 
was O 
evaluated O 
in O 
a O 
90-day O 
feeding O 
study O 
in O 
Sprague-Dawley O 
( O 
SD O 
) O 
rats O 
. O 
Maize O 
grain O 
from O 
GM O 
or O 
non-GM O 
isogenic O 
control O 
lines O 
were O 
separately O 
formulated O 
into O 
rodent O 
diets O 
at O 
concentrations O 
of O 
12.5% O 
( O 
low O 
level O 
) O 
, O 
25% O 
( O 
middle O 
level O 
) O 
, O 
and O 
50% O 
( O 
high O 
level O 
) O 
. O 
An O 
additional O 
group O 
of O 
rats O 
were O 
fed O 
a O 
commercialized O 
diet O 
as O 
a O 
control O 
. O 
The O 
toxicological O 
response O 
variables O 
, O 
including O 
body O 
weights O 
, O 
food O 
consumption O 
, O 
serum O 
biochemistry O 
, O 
hematology O 
, O 
and O 
absolute O 
and O 
relative O 
organ O 
weights O 
, O 
were O 
compared O 
between O 
rats O 
fed O 
GM O 
maize O 
and O 
those O 
fed O 
non-GM O 
maize O 
after O 
consumption O 
of O 
test O 
diets O 
for O 
90days O 
. O 
In O 
addition O 
, O 
gross O 
and O 
microscopic O 
pathology O 
were O 
conducted O 
among O 
treatment O 
groups O 
. O 
No O 
adverse O 
effects O 
related O 
to O 
the O 
consumption O 
of O 
GM O 
maize O 
were O 
detected O 
in O 
the O 
subchronic O 
feeding O 
study O 
. O 
These O 
results O 
indicated O 
that O 
the O 
GM O 
glyphosate B-TRIVIAL 
-tolerant O 
maize O 
was O 
as O 
safe O 
and O 
nutritious O 
as O 
conventional O 
maize O 
. O 

( O 
AChE O 
) O 
activity O 
has O 
been O 
used O 
to O 
evaluate O 
the O 
exposure O 
of O 
mollusk O 
bivalves O 
to O 
organophosphates B-FAMILY 
, O 
carbamate B-FAMILY 
pesticides O 
, O 
and O 
heavy O 
metals O 
. O 
Crassostrea O 
hongkongensis O 
is O 
a O 
Hong O 
Kong O 
endemic O 
oyster O 
, O 
and O 
has O 
a O 
high O 
commercial O 
value O 
along O 
the O 
coastal O 
area O 
of O 
South O 
China O 
. O 
The O 
use O 
of O 
this O 
species O 
as O 
a O 
bio O 
- O 
indicator O 
of O 
the O 
marine O 
environment O 
, O 
and O 
the O 
use O 
of O 
AChE O 
activity O 
measurements O 
in O 
tissues O 
of O 
C O 
. O 
hongkongensis O 
require O 
prior O 
characterization O 
of O 
AChE O 
in O 
this O 
species O 
. O 
Here O 
, O 
we O 
report O 
that O 
gill O 
tissue O 
contains O 
the O 
highest O 
AChE O 
activity O 
in O 
C O 
. O 
hongkongensis O 
, O 
and O 
that O 
the O 
molecular O 
form O 
of O 
AChE O 
is O 
most O 
likely O 
to O 
be O 
a O 
dimeric O 
form O 
. O 
In O 
addition O 
, O 
the O 
effect O 
of O 
the O 
pesticide O 
acephate O 
on O 
AChE O 
activity O 
in O 
the O 
gill O 
of O 
C O 
. O 
hongkongensis O 
was O 
analyzed O 
, O 
and O 
the O 
mean O 
inhibition O 
concentration O 
( O 
IC50 O 
) O 
value O 
was O 
determined O 
. O 
This O 
study O 
suggests O 
that O 
AChE O 
activity O 
in O 
the O 
gill O 
tissue O 
of O 
C O 
. O 
hongkongensis O 
might O 
be O 
used O 
as O 
a O 
biomarker O 
in O 
monitoring O 
organophosphate B-FAMILY 
contamination O 
in O 
the O 
marine O 
fauna O 
of O 
South O 
China O 
. O 

( O 
BChE O 
) O 
has O 
been O 
associated O 
to O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
, O 
weight O 
, O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
levels O 
. O 
-116A O 
( O 
rs1126680 O 
) O 
and O 
K O 
( O 
A539T O 
, O 
1615A O 
, O 
rs1803274 O 
) O 
BCHE O 
gene O 
variants O 
had O 
previously O 
been O 
associated O 
to O 
BChE O 
activity O 
, O 
weight O 
and O 
BMI O 
variance O 
in O 
adults O 
. O 
The O 
present O 
study O 
examined O 
-116A O 
and O 
K O 
variants O 
, O 
BChE O 
activity O 
, O 
anthropometric O 
and O 
biochemical O 
variables O 
associated O 
with O 
obesity O 
in O 
adolescents O 
( O 
120 O 
obese O 
and O 
150 O 
non-obese O 
from O 
Curitiba O 
, O 
Brazil O 
) O 
. O 
Both O 
-116A O 
and O 
K O 
variants O 
were O 
found O 
with O 
significantly O 
lower O 
frequencies O 
( O 
p O 
< O 
0.05 O 
) O 
in O 
obese O 
adolescents O 
when O 
compared O 
with O 
non-obese O 
adolescents O 
and O 
with O 
the O 
general O 
population O 
. O 
Mean O 
BChE O 
activity O 
( O 
KU O 
/ O 
L O 
) O 
was O 
significantly O 
higher O 
in O 
obese O 
adolescents O 
when O 
compared O 
with O 
non-obese O 
adolescents O 
and O 
with O 
the O 
general O 
population O 
. O 
Analyzing O 
only O 
the O 
obese O 
adolescents O 
, O 
it O 
was O 
found O 
that O 
carriers O 
of O 
the O 
-116A O 
variant O 
showed O 
lower O 
BChE O 
activity O 
and O 
higher O 
triglyceride B-FAMILY 
levels O 
than O 
homozygotes O 
for O 
the O 
usual O 
allele O 
. O 
Indeed O 
, O 
obese O 
carriers O 
of O 
the O 
-116A O 
variant O 
had O 
triglyceride B-FAMILY 
levels O 
considered O 
high O 
according O 
to O 
reference O 
values O 
for O 
serum O 
triglycerides B-FAMILY 
in O 
Brazilian O 
adolescents O 
. O 
These O 
results O 
show O 
: O 
( O 
1 O 
) O 
a O 
protective O 
effect O 
of O 
-116A O 
and O 
K O 
variants O 
on O 
juvenile O 
obesity O 
risk O 
, O 
suggesting O 
a O 
role O 
for O 
the O 
BCHE O 
gene O 
on O 
juvenile O 
onset O 
obesity O 
different O 
from O 
that O 
observed O 
on O 
adult O 
onset O 
obesity O 
and O 
( O 
2 O 
) O 
an O 
association O 
of O 
the O 
-116A O 
variant O 
with O 
hypertriglyceridemia O 
in O 
obese O 
adolescents O 
probably O 
because O 
of O 
its O 
effect O 
on O 
lowering O 
BChE O 
activity O 
and O 
consequently O 
diminishing O 
the O 
enzyme O 
capability O 
of O 
maintaining O 
homeostasis O 
on O 
lipid O 
metabolism O 
during O 
the O 
metabolic O 
stress O 
caused O 
by O 
obesity O 
. O 

as O 
a O 
source O 
of O 
butyrylcholinesterase O 
variants O 
designed O 
for O 
enhanced O 
cocaine B-TRIVIAL 
hydrolase O 
activity O 
. O 

addiction O 
affects O 
millions O 
of O 
people O 
with O 
disastrous O 
personal O 
and O 
social O 
consequences O 
. O 
Cocaine B-TRIVIAL 
is O 
one O 
of O 
the O 
most O 
reinforcing O 
of O 
all O 
drugs O 
of O 
abuse O 
, O 
and O 
even O 
those O 
who O 
undergo O 
rehabilitation O 
and O 
experience O 
long O 
periods O 
of O 
abstinence O 
have O 
more O 
than O 
80% O 
chance O 
of O 
relapse O 
. O 
Yet O 
there O 
is O 
no O 
FDA-approved O 
treatment O 
to O 
decrease O 
the O 
likelihood O 
of O 
relapse O 
in O 
rehabilitated O 
addicts O 
. O 
Recent O 
studies O 
, O 
however O 
, O 
have O 
demonstrated O 
a O 
promising O 
potential O 
treatment O 
option O 
with O 
the O 
help O 
of O 
the O 
serum O 
enzyme O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
, O 
which O 
is O 
capable O 
of O 
breaking O 
down O 
naturally O 
occurring O 
(-)-cocaine B-TRIVIAL 
before O 
the O 
drug O 
can O 
influence O 
the O 
reward O 
centers O 
of O 
the O 
brain O 
or O 
affect O 
other O 
areas O 
of O 
the O 
body O 
. O 
This O 
activity O 
of O 
wild O 
- O 
type O 
( O 
WT O 
) O 
BChE O 
, O 
however O 
, O 
is O 
relatively O 
low O 
. O 
This O 
prompted O 
the O 
design O 
of O 
variants O 
of O 
BChE O 
which O 
exhibit O 
significantly O 
improved O 
catalytic O 
activity O 
against O 
(-)-cocaine B-TRIVIAL 
. O 
Plants O 
are O 
a O 
promising O 
means O 
to O 
produce O 
large O 
amounts O 
of O 
these O 
cocaine B-TRIVIAL 
hydrolase O 
variants O 
of O 
BChE O 
, O 
cheaply O 
, O 
safely O 
with O 
no O 
concerns O 
regarding O 
human O 
pathogens O 
and O 
functionally O 
equivalent O 
to O 
enzymes O 
derived O 
from O 
other O 
sources O 
. O 
Here O 
, O 
in O 
expressing O 
cocaine B-TRIVIAL 
-hydrolyzing O 
mutants O 
of O 
BChE O 
in O 
Nicotiana O 
benthamiana O 
using O 
the O 
MagnICON O 
virus O 
- O 
assisted O 
transient O 
expression O 
system O 
, O 
and O 
in O 
reporting O 
their O 
initial O 
biochemical O 
analysis O 
, O 
we O 
provide O 
proof O 
- O 
of O 
- O 
principle O 
that O 
plants O 
can O 
express O 
engineered O 
BChE O 
proteins O 
with O 
desired O 
properties O 
. O 

tooth O 
movement O 
( O 
ETM O 
) O 
changes O 
the O 
distribution O 
of O 
sensory O 
nerve O 
fibers O 
in O 
periodontal O 
ligament O 
and O 
the O 
bone O 
architecture O 
through O 
the O 
stimulation O 
of O 
bone O 
remodeling O 
. O 
As O 
the O 
sympathetic O 
nervous O 
system O 
is O 
involved O 
in O 
bone O 
remodeling O 
, O 
we O 
examined O 
whether O 
ETM O 
is O 
controlled O 
by O 
sympathetic O 
signaling O 
or O 
not O 
. O 
In O 
male O 
mice O 
, O 
elastic O 
rubber O 
was O 
inserted O 
between O 
upper O 
left O 
first O 
molar O 
( O 
M1 O 
) O 
and O 
second O 
molar O 
( O 
M2 O 
) O 
for O 
3 O 
or O 
5 O 
days O 
. O 
Nerve O 
fibers O 
immunoreactive O 
for O 
not O 
only O 
sensory O 
neuromarkers O 
, O 
such O 
as O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
( O 
CGRP O 
) O 
, O 
but O 
also O 
sympathetic O 
neuromarkers O 
, O 
such O 
as O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
and O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
were O 
increased O 
in O 
the O 
periodontal O 
ligament O 
during O 
ETM O 
. O 
To O 
elucidate O 
the O 
effect O 
of O 
the O 
sympathetic O 
signal O 
mediated O 
by O 
ETM O 
, O 
mice O 
were O 
intraperitoneally O 
injected O 
with O 
a O 
β-antagonist O 
, O 
propranolol B-TRIVIAL 
( O 
PRO B-ABBREVIATION 
: O 
20 O 
μg O 
/ O 
g O 
/ O 
day O 
) O 
, O 
or O 
a O 
β-agonist O 
, O 
isoproterenol B-TRIVIAL 
( O 
ISO B-ABBREVIATION 
: O 
5 O 
μg O 
/ O 
g O 
/ O 
day O 
) O 
from O 
7 O 
days O 
before O 
ETM O 
. O 
PRO B-ABBREVIATION 
treatment O 
suppressed O 
the O 
amount O 
of O 
tooth O 
movement O 
by O 
12.9% O 
in O 
3-day O 
ETM O 
and O 
by O 
32.2% O 
in O 
5-day O 
ETM O 
compared O 
with O 
vehicle O 
treatment O 
. O 
On O 
the O 
other O 
hand O 
, O 
ISO B-ABBREVIATION 
treatment O 
increased O 
it O 
. O 
Furthermore O 
, O 
ETM O 
remarkably O 
increased O 
the O 
osteoclast O 
number O 
on O 
the O 
bone O 
surface O 
( O 
alveolar O 
socket O 
) O 
( O 
Oc.N O 
/ O 
BS O 
) O 
in O 
all O 
drug O 
treatments O 
. O 
PRO B-ABBREVIATION 
treatment O 
suppressed O 
Oc.N O 
/ O 
BS O 
by O 
39.4% O 
in O 
3-day O 
ETM O 
, O 
while O 
ISO B-ABBREVIATION 
treatment O 
increased O 
it O 
by O 
32.1% O 
in O 
3-day O 
ETM O 
compared O 
with O 
vehicle O 
treatment O 
. O 
Chemical O 
sympathectomy O 
using O 
6-hydroxydopamine B-SYSTEMATIC 
( O 
6-OHDA B-SYSTEMATIC 
: O 
250 O 
μg O 
/ O 
g O 
) O 
showed O 
results O 
similar O 
to O 
those O 
for O 
PRO B-ABBREVIATION 
treatment O 
in O 
terms O 
of O 
both O 
the O 
amount O 
of O 
tooth O 
movement O 
and O 
osteoclast O 
parameters O 
. O 
Our O 
data O 
showed O 
that O 
blockade O 
of O 
sympathetic O 
signaling O 
inhibited O 
the O 
tooth O 
movement O 
and O 
osteoclast O 
increase O 
induced O 
by O 
ETM O 
, O 
and O 
stimulation O 
of O 
sympathetic O 
signaling O 
accelerated O 
these O 
responses O 
. O 
These O 
data O 
suggest O 
that O 
the O 
mechano O 
- O 
adaptive O 
response O 
induced O 
by O 
ETM O 
is O 
controlled O 
by O 
sympathetic O 
signaling O 
through O 
osteoclast O 
activation O 
. O 

replacement O 
therapy O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
supplementation O 
prevents O 
oxidative O 
stress O 
and O 
cognitive O 
deficit O 
in O 
experimental O 
hypothyroidism O 
. O 

has O 
a O 
variety O 
of O 
adverse O 
effects O 
on O 
cognitive O 
function O 
. O 
The O 
treatment O 
of O 
levothyroxine B-TRIVIAL 
alone O 
cannot O 
restore O 
cognitive O 
defects O 
of O 
hypothyroid O 
patients O 
. O 
Antioxidant O 
vitamin B-FAMILY 
E I-FAMILY 
supplementation O 
could O 
be O 
useful O 
in O 
disturbances O 
which O 
are O 
associated O 
with O 
oxidative O 
stress O 
and O 
could O 
effectively O 
slow O 
the O 
progression O 
of O 
Alzheimer O 
disease O 
. O 
Thus O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
oxidative O 
stress O 
status O 
of O 
the O 
serum O 
and O 
hippocampus O 
in O 
hypothyroidism O 
and O 
to O 
examine O 
the O 
effects O 
of O 
levothyroxine B-TRIVIAL 
replacement O 
therapy O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
supplementation O 
on O 
cognitive O 
deficit O 
. O 
Sprague-Dawley O 
rats O 
were O 
randomly O 
divided O 
into O 
five O 
groups O 
: O 
control O 
group O 
, O 
PTU B-ABBREVIATION 
group O 
, O 
PTU B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
group O 
, O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
group O 
, O 
and O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
group O 
. O 
Serum O 
and O 
hippocampus O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
were O 
determined O 
using O 
the O 
thiobarbituric B-SYSTEMATIC 
- I-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
method O 
. O 
Serum O 
and O 
hippocampus O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
levels O 
were O 
determined O 
by O 
measuring O 
its O 
ability O 
to O 
inhibit O 
the O 
photoreduction O 
of O 
nitroblue B-TRIVIAL 
tetrazolium I-TRIVIAL 
. O 
Learning O 
and O 
memory O 
was O 
assessed O 
by O 
Morris O 
water O 
maze O 
test O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
found O 
that O 
the O 
rats O 
of O 
PTU B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
group O 
spent O 
less O 
time O 
to O 
find O 
the O 
platform O 
on O 
days O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
and O 
5 O 
than O 
the O 
PTU B-ABBREVIATION 
group O 
. O 
Moreover O 
, O 
the O 
rats O 
of O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
group O 
spent O 
less O 
time O 
to O 
find O 
the O 
platform O 
on O 
days O 
4 O 
and O 
5 O 
than O 
the O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
group O 
. O 
The O 
time O 
spent O 
in O 
the O 
target O 
quadrants O 
was O 
measured O 
in O 
the O 
probe O 
test O 
and O 
no O 
difference O 
was O 
observed O 
in O 
all O 
groups O 
. O 
Oxidative O 
damage O 
has O 
been O 
observed O 
in O 
the O 
serum O 
and O 
hippocampus O 
of O 
hypothyroidism O 
rat O 
. O 
SOD O 
levels O 
of O 
serum O 
and O 
hippocampus O 
tissue O 
were O 
significantly O 
increased O 
and O 
MDA B-ABBREVIATION 
levels O 
were O 
significantly O 
decreased O 
in O 
the O 
PTU B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
and O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
+ O 
Vit B-ABBREVIATION 
E I-ABBREVIATION 
groups O 
than O 
the O 
PTU B-ABBREVIATION 
and O 
PTU B-ABBREVIATION 
+ O 
L-T4 B-ABBREVIATION 
groups O 
. O 
Therefore O 
, O 
these O 
findings O 
indicate O 
that O 
levothyroxine B-TRIVIAL 
replacement O 
therapy O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
supplementation O 
may O 
ameliorate O 
cognitive O 
deficit O 
in O 
PTU B-ABBREVIATION 
-induced O 
hypothyroidism O 
through O 
the O 
decrease O 
of O 
oxidative O 
stress O 
status O 
. O 

This O 
study O 
investigated O 
the O 
association O 
between O 
arterial O 
stiffness O 
and O 
plasma O 
adiponectin O 
in O 
patients O 
with O 
type O 
1 O 
diabetes O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
Participants O 
were O 
normotensive O 
patients O 
with O 
type O 
1 O 
diabetes O 
who O 
were O 
up O 
to O 
age O 
40 O 
years O 
. O 
Subjects O 
on O 
statins B-FAMILY 
with O 
macrovascular O 
disease O 
or O 
overt O 
nephropathy O 
were O 
excluded O 
. O 
Large O 
artery O 
stiffness O 
was O 
assessed O 
by O 
measurement O 
of O 
carotid O 
- O 
femoral O 
pulse O 
wave O 
velocity O 
( O 
PWV O 
) O 
, O 
whereas O 
plasma O 
adiponectin O 
was O 
measured O 
by O 
radioimmunoassay O 
. O 
RESULTS O 
Data O 
from O 
80 O 
patients O 
( O 
age O 
27.1 O 
± O 
6.1 O 
years O 
, O 
BMI O 
24.2 O 
± O 
3.1 O 
kg O 
/ O 
m(2) O 
, O 
HbA(1c) O 
7.5 O 
± O 
1.6% O 
, O 
39 O 
men O 
, O 
adiponectin O 
13.9 O 
± O 
6.7 O 
μg O 
/ O 
mL O 
, O 
and O 
PWV O 
5.6 O 
± O 
0.9 O 
m O 
/ O 
s O 
) O 
were O 
analyzed O 
. O 
Log O 
adiponectin O 
inversely O 
correlated O 
with O 
age O 
- O 
adjusted O 
PWV O 
( O 
r O 
= O 
-0.291 O 
, O 
P O 
= O 
0.009 O 
) O 
and O 
waist O 
circumference O 
( O 
r O 
= O 
-0.427 O 
, O 
P O 
< O 
0.001 O 
) O 
. O 
In O 
a O 
fully O 
adjusted O 
model O 
, O 
age O 
, O 
expiration O 
/ O 
inspiration O 
index O 
, O 
and O 
log O 
adiponectin O 
were O 
independently O 
associated O 
with O 
PWV O 
, O 
explaining O 
39.6% O 
of O 
its O 
variance O 
. O 
CONCLUSIONS O 
Arterial O 
stiffness O 
is O 
inversely O 
related O 
to O 
adiponectin O 
concentration O 
in O 
young O 
patients O 
with O 
type O 
1 O 
diabetes O 
without O 
major O 
complications O 
. O 

of O 
ifenprodil B-TRIVIAL 
on O 
GluN1 O 
/ O 
GluN2B O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptor O 
gating O 
. O 

is O 
an O 
allosteric O 
inhibitor O 
of O 
GluN1 O 
/ O 
GluN2B O 
N-methyl-D-aspartate B-SYSTEMATIC 
receptors O 
. O 
Despite O 
its O 
widespread O 
use O 
as O 
a O 
prototype O 
for O 
drug O 
development O 
and O 
a O 
subtype O 
- O 
selective O 
tool O 
for O 
physiologic O 
experiments O 
, O 
its O 
precise O 
effect O 
on O 
GluN1 O 
/ O 
GluN2B O 
gating O 
is O 
yet O 
to O 
be O 
fully O 
understood O 
. O 
Interestingly O 
, O 
recent O 
crystallographic O 
evidence O 
identified O 
that O 
ifenprodil B-TRIVIAL 
, I-TRIVIAL 
unlike O 
zinc B-SYSTEMATIC 
, O 
binds O 
at O 
the O 
interface O 
of O 
the O 
GluN1 O 
/ O 
GluN2B O 
amino B-FAMILY 
terminal O 
domain O 
dimer O 
by O 
an O 
induced O 
- O 
fit O 
mechanism O 
. O 
To O 
delineate O 
the O 
effect O 
of O 
this O 
unique O 
binding O 
on O 
GluN1 O 
/ O 
GluN2B O 
receptor O 
gating O 
, O 
we O 
recorded O 
steady O 
- O 
state O 
currents O 
from O 
cell O 
- O 
attached O 
and O 
outside-out O 
patches O 
. O 
At O 
pH O 
7.9 O 
in O 
cell O 
- O 
attached O 
patches O 
, O 
ifenprodil B-TRIVIAL 
increased O 
the O 
occupancy O 
of O 
the O 
long O 
- O 
lived O 
shut O 
conformations O 
, O 
thereby O 
reducing O 
the O 
open O 
probability O 
of O 
the O 
receptor O 
with O 
no O 
change O 
in O 
the O 
mean O 
open O 
time O 
. O 
In O 
addition O 
, O 
ifenprodil B-TRIVIAL 
selectively O 
affected O 
the O 
area O 
of O 
shut O 
time O 
constants O 
, O 
but O 
not O 
the O 
time O 
constants O 
themselves O 
. O 
Kinetic O 
analyses O 
suggested O 
that O 
ifenprodil B-TRIVIAL 
prevents O 
the O 
transition O 
of O 
the O 
receptor O 
to O 
an O 
open O 
state O 
and O 
increases O 
its O 
dwell O 
time O 
in O 
an O 
intrinsically O 
occurring O 
closed O 
conformation O 
or O 
desensitized O 
state O 
. O 
We O 
found O 
distinct O 
differences O 
in O 
the O 
action O 
of O 
ifenprodil B-TRIVIAL 
at O 
GluN1 O 
/ O 
GluN2B O 
in O 
comparison O 
with O 
previous O 
studies O 
on O 
the O 
effect O 
of O 
zinc B-SYSTEMATIC 
on O 
GluN1 O 
/ O 
GluN2A O 
gating O 
, O 
which O 
may O 
arise O 
due O 
to O 
their O 
unique O 
binding O 
sites O 
. O 
Our O 
data O 
also O 
uncover O 
the O 
potential O 
pH-dependent O 
action O 
of O 
ifenprodil B-TRIVIAL 
on O 
gating O 
. O 
At O 
a O 
low O 
pH O 
( O 
pH O 
7.4 O 
) O 
, O 
but O 
not O 
pH O 
7.9 O 
, O 
ifenprodil B-TRIVIAL 
reduces O 
the O 
mean O 
open O 
time O 
of O 
GluN1 O 
/ O 
GluN2B O 
receptors O 
, O 
which O 
may O 
be O 
responsible O 
for O 
its O 
usefulness O 
as O 
a O 
context O 
- O 
dependent O 
inhibitor O 
in O 
conditions O 
like O 
ischemia O 
and O 
stroke O 
, O 
when O 
the O 
pH O 
of O 
the O 
extracellular O 
milieu O 
becomes O 
acidic O 
. O 

immunotoxicity O 
of O 
ethanol B-SYSTEMATIC 
in O 
an O 
extended O 
one O 
- O 
generation O 
reproductive O 
toxicity O 
study O 
. O 

susceptibility O 
of O 
developing O 
immune O 
system O 
to O 
chemical O 
disruption O 
warrants O 
the O 
assessment O 
of O 
immune O 
parameters O 
in O 
reproductive O 
and O 
developmental O 
testing O 
protocols O 
. O 
In O 
this O 
study O 
, O 
a O 
wide O 
range O 
of O 
immune O 
endpoints O 
was O 
included O 
in O 
an O 
extended O 
one O 
- O 
generation O 
reproduction O 
toxicity O 
study O 
( O 
EOGRTS O 
) O 
design O 
to O 
determine O 
the O 
relative O 
sensitivity O 
of O 
immune O 
and O 
developmental O 
parameters O 
to O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
) O 
, O 
a O 
well O 
- O 
known O 
developmental O 
toxicant O 
with O 
immunomodulatory O 
properties O 
. O 
Adult O 
Wistar O 
rats O 
were O 
exposed O 
to O 
EtOH B-FORMULA 
via O 
drinking O 
water O 
( O 
0 O 
, O 
1.5 O 
, O 
4 O 
, O 
6.5 O 
, O 
9 O 
, O 
11.5 O 
and O 
14 O 
% O 
( O 
w O 
/ O 
v O 
EtOH B-FORMULA 
) O 
) O 
during O 
premating O 
, O 
mating O 
, O 
gestation O 
and O 
lactation O 
and O 
continuation O 
of O 
exposure O 
of O 
the O 
F(1) O 
from O 
weaning O 
until O 
killed O 
. O 
Immune O 
assessments O 
were O 
performed O 
at O 
postnatal O 
days O 
( O 
PNDs O 
) O 
21 O 
, O 
42 O 
and O 
70 O 
. O 
Keyhole O 
limpet O 
hemocyanin O 
(KLH)-specific O 
immune O 
responses O 
were O 
evaluated O 
following O 
subcutaneous O 
immunizations O 
on O 
PNDs O 
21 O 
and O 
35 O 
. O 
EtOH B-FORMULA 
exposure O 
affected O 
innate O 
as O 
well O 
as O 
adaptive O 
immune O 
responses O 
. O 
The O 
most O 
sensitive O 
immune O 
parameters O 
included O 
white O 
blood O 
cell O 
subpopulations O 
, O 
ConA-stimulated O 
splenocyte O 
proliferation O 
, O 
LPS-induced O 
NO B-FORMULA 
and O 
TNF-α O 
production O 
by O 
adherent O 
splenocytes O 
and O 
KLH-specific O 
immune O 
responses O 
. O 
Most O 
parameters O 
showed O 
recovery O 
after O 
cessation O 
of O 
EtOH B-FORMULA 
exposure O 
after O 
weaning O 
in O 
the O 
14 O 
% O 
exposure O 
group O 
. O 
However O 
, O 
effects O 
on O 
LPS-induced O 
NO B-FORMULA 
and O 
TNF-α O 
production O 
by O 
adherent O 
splenocytes O 
and O 
KLH-specific O 
parameters O 
persisted O 
until O 
PND O 
70 O 
. O 
The O 
results O 
demonstrate O 
the O 
relative O 
sensitivity O 
to O 
EtOH B-FORMULA 
of O 
especially O 
functional O 
immune O 
parameters O 
and O 
confirm O 
the O 
added O 
value O 
of O 
immune O 
parameters O 
in O 
the O 
EOGRTS O 
. O 
Furthermore O 
, O 
this O 
study O 
identified O 
an O 
expanded O 
KLH-specific O 
parameter O 
set O 
and O 
LPS-induced O 
NO B-FORMULA 
and O 
TNF-α O 
production O 
by O 
adherent O 
splenocytes O 
as O 
valuable O 
parameters O 
that O 
can O 
provide O 
additional O 
information O 
on O 
functional O 
immune O 
effects O 
. O 

of O 
enantioselectivity O 
in O 
the O 
SULT1A3 O 
- O 
catalyzed O 
sulfoconjugation O 
of O 
normetanephrine B-TRIVIAL 
enantiomers O 
: O 
an O 
in O 
vitro O 
and O 
computational O 
study O 
. O 

is O 
the O 
natural O 
stereoisomeric O 
substrate O 
for O 
sulfotransferase O 
1A3 O 
( O 
SULT1A3 O 
) O 
- O 
catalyzed O 
sulfonation O 
. O 
Nothing O 
appears O 
known O 
on O 
the O 
enantioselectivity O 
of O 
the O 
reaction O 
despite O 
its O 
potential O 
significance O 
in O 
the O 
metabolism O 
of O 
adrenergic B-FAMILY 
amines I-FAMILY 
and O 
in O 
clinical O 
biochemistry O 
. O 
We O 
confronted O 
the O 
kinetic O 
parameters O 
of O 
the O 
sulfoconjugation O 
of O 
synthetic O 
(1R)-normetanephrine B-TRIVIAL 
and O 
(1S)-normetanephrine B-TRIVIAL 
by O 
recombinant O 
human O 
SULT1A3 O 
to O 
a O 
docking O 
model O 
of O 
each O 
normetanephrine B-TRIVIAL 
enantiomer O 
with O 
SULT1A3 O 
and O 
the O 
3'-phosphoadenosine-5'-phosphosulfate B-SYSTEMATIC 
cofactor O 
on O 
the O 
basis O 
of O 
molecular O 
modeling O 
and O 
molecular O 
dynamics O 
simulations O 
of O 
the O 
stability O 
of O 
the O 
complexes O 
. O 
The O 
K(M) O 
, O 
V(max) O 
, O 
and O 
k(cat) O 
values O 
for O 
the O 
sulfonation O 
of O 
(1R)-normetanephrine B-TRIVIAL 
, O 
(1S)-normetanephrine B-TRIVIAL 
, O 
and O 
racemic O 
normetanephrine B-TRIVIAL 
were O 
similar O 
. O 
In O 
silico O 
models O 
were O 
consistent O 
with O 
these O 
findings O 
as O 
they O 
showed O 
that O 
the O 
binding O 
modes O 
of O 
the O 
two O 
enantiomers O 
were O 
almost O 
identical O 
. O 
In O 
conclusion O 
, O 
SULT1A3 O 
is O 
not O 
substrate O 
- O 
enantioselective O 
toward O 
normetanephrine O 
, O 
an O 
unexpected O 
finding O 
explainable O 
by O 
a O 
mutual O 
adaptability O 
between O 
the O 
ligands O 
and O 
SULT1A3 O 
through O 
an O 
" O 
induced O 
- O 
fit O 
model O 
" O 
in O 
the O 
catalytic O 
pocket O 
. O 

and O 
electronic O 
transport O 
properties O 
of O 
fullerene B-TRIVIAL 
and O 
fullerene B-TRIVIAL 
derivatives O 
in O 
break O 
- O 
junction O 
geometries O 
. O 

are O 
considered O 
anchoring O 
groups O 
for O 
molecular O 
electronics O 
due O 
to O 
a O 
large O 
contact O 
area O 
and O 
their O 
affinity O 
for O 
noble O 
metals O 
. O 
The O 
conductances O 
of O 
fullerene B-TRIVIAL 
-terminated O 
molecules O 
, O 
however O 
, O 
are O 
found O 
to O 
be O 
even O 
lower O 
than O 
for O 
thiol B-FAMILY 
termination O 
. O 
The O 
effects O 
of O 
weak O 
molecule O 
- O 
metal O 
coupling O 
and O 
symmetry O 
breaking O 
are O 
studied O 
by O 
transport O 
measurements O 
of O 
C(60) B-TRIVIAL 
and O 
functionalized O 
C(60) B-TRIVIAL 
. O 
The O 
results O 
demonstrate O 
highy O 
efficient O 
contacts O 
between O 
Au B-FORMULA 
and O 
C(60) B-TRIVIAL 
, O 
despite O 
of O 
deposition O 
from O 
solution O 
. O 

long O 
road O 
of O 
research O 
on O 
snake O 
venom O 
serine B-TRIVIAL 
proteinases O 
. O 

has O 
long O 
been O 
recognized O 
that O 
snake O 
venom O 
serine B-TRIVIAL 
proteinases O 
( O 
SVSPs O 
) O 
affect O 
various O 
physiological O 
functions O 
including O 
blood O 
coagulation O 
, O 
fibrinolysis O 
, O 
blood O 
pressure O 
and O 
platelet O 
aggregation O 
. O 
Therefore O 
, O 
SVSPs O 
have O 
been O 
used O 
as O 
refined O 
tools O 
to O 
study O 
molecular O 
mechanisms O 
involved O 
in O 
the O 
activation O 
of O 
key O 
factors O 
that O 
control O 
hemostasis O 
and O 
as O 
therapeutic O 
agents O 
in O 
various O 
thrombotic O 
and O 
hemostatic O 
conditions O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
highlight O 
the O 
state O 
of O 
our O 
knowledge O 
on O 
the O 
advances O 
made O 
in O 
SVSP O 
research O 
since O 
the O 
18th O 
century O 
. O 
It O 
includes O 
the O 
personal O 
accounts O 
of O 
some O 
distinguished O 
scientists O 
that O 
addressed O 
specific O 
problems O 
and O 
contributed O 
to O 
advance O 
the O 
field O 
. O 

brief O 
review O 
of O 
the O 
scientific O 
history O 
of O 
several O 
lesser O 
- O 
known O 
snake O 
venom O 
proteins O 
: O 
l-amino B-FAMILY 
acid I-FAMILY 
oxidases O 
, O 
hyaluronidases O 
and O 
phosphodiesterases O 
. O 

considering O 
the O 
proteins O 
and O 
toxins O 
in O 
snake O 
venom O 
one's O 
thoughts O 
generally O 
migrate O 
to O 
the O 
proteinases O 
, O 
neurotoxins O 
and O 
phospholipases O 
since O 
these O 
families O 
of O 
proteins O 
are O 
comprised O 
by O 
many O 
of O 
the O 
toxins O 
found O 
in O 
venom O 
. O 
However O 
as O 
modern O 
proteomic O 
and O 
transcriptomic O 
venom O 
research O 
has O 
abundantly O 
shown O 
snake O 
venoms O 
are O 
complex O 
and O 
containing O 
numerous O 
families O 
of O 
protein O 
beyond O 
the O 
" O 
big O 
three O 
" O 
. O 
In O 
this O 
brief O 
review O 
we O 
will O 
discuss O 
three O 
of O 
the O 
lesser O 
discussed O 
proteins O 
typically O 
found O 
in O 
snake O 
venoms O 
: O 
l-amino B-FAMILY 
acid I-FAMILY 
oxidases O 
( O 
LAAO O 
) O 
; O 
hyaluronidases O 
and O 
phosphodiesterases O 
. O 
These O 
proteins O 
have O 
long O 
been O 
known O 
to O 
be O 
part O 
of O 
many O 
venoms O 
' O 
proteomes O 
with O 
reports O 
appearing O 
in O 
the O 
literature O 
as O 
early O 
as O 
1944 O 
for O 
LAAO O 
, O 
1947 O 
for O 
hyaluronidase O 
( O 
spreading O 
factor O 
) O 
, O 
and O 
1932 O 
for O 
venom O 
phosphodiesterase O 
. O 
These O 
are O 
more O 
or O 
less O 
contemporary O 
with O 
the O 
first O 
reports O 
( O 
circa O 
1950 O 
) O 
on O 
snake O 
venom O 
proteases O 
. O 
Thus O 
, O 
the O 
relatively O 
modest O 
literature O 
on O 
these O 
snake O 
venom O 
proteins O 
stems O 
not O 
from O 
lack O 
of O 
early O 
discovery O 
but O 
rather O 
more O 
likely O 
to O 
their O 
ostensibly O 
minor O 
role O 
in O 
snake O 
venom O 
pathophysiology O 
. O 
In O 
this O 
review O 
we O 
will O 
provide O 
an O 
overview O 
of O 
the O 
experimental O 
history O 
of O 
these O 
venom O 
proteins O 
, O 
their O 
biochemical O 
and O 
structural O 
features O 
and O 
their O 
role O 
in O 
snake O 
venom O 
toxinology O 
with O 
the O 
aim O 
of O 
bringing O 
a O 
fuller O 
, O 
more O 
comprehensive O 
, O 
understanding O 
of O 
the O 
history O 
of O 
laboratory O 
research O 
on O 
snake O 
venoms O 
. O 
In O 
addition O 
, O 
there O 
are O 
some O 
comments O 
on O 
these O 
proteins O 
from O 
investigators O 
who O 
were O 
actively O 
engaged O 
in O 
their O 
investigation O 
. O 

and O 
structural O 
interaction O 
of O 
(-)-reboxetine B-TRIVIAL 
with O 
the O 
human O 
α4β2 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
. O 

interaction O 
of O 
the O 
selective O 
norepinephrine B-TRIVIAL 
reuptake O 
inhibitor O 
(-)-reboxetine B-TRIVIAL 
with O 
the O 
human O 
α4β2 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
in O 
different O 
conformational O 
states O 
was O 
studied O 
by O 
several O 
functional O 
and O 
structural O 
approaches O 
. O 
Patch O 
- O 
clamp O 
and O 
Ca(2+) B-FORMULA 
-influx O 
results O 
indicate O 
that O 
(-)-reboxetine B-TRIVIAL 
does O 
not O 
activate O 
hα4β2 O 
nAChRs O 
via O 
interaction O 
with O 
the O 
orthosteric O 
sites O 
, O 
but O 
inhibits O 
agonist O 
- O 
induced O 
hα4β2 O 
activation O 
by O 
a O 
noncompetitive O 
mechanism O 
. O 
Consistently O 
, O 
the O 
results O 
from O 
the O 
electrophysiology O 
- O 
based O 
functional O 
approach O 
suggest O 
that O 
(-)-reboxetine B-TRIVIAL 
may O 
act O 
via O 
open O 
channel O 
block O 
; O 
therefore O 
, O 
it O 
is O 
capable O 
of O 
producing O 
a O 
use O 
- O 
dependent O 
type O 
of O 
inhibition O 
of O 
the O 
hα4β2 O 
nAChR O 
function O 
. O 
We O 
tested O 
whether O 
(-)-reboxetine B-TRIVIAL 
binds O 
to O 
the O 
luminal O 
[(3)H]imipramine B-SYSTEMATIC 
site O 
. O 
The O 
results O 
indicate O 
that O 
, O 
although O 
(-)-reboxetine B-TRIVIAL 
binds O 
with O 
low O 
affinity O 
to O 
this O 
site O 
, O 
it O 
discriminates O 
between O 
the O 
resting O 
and O 
desensitized O 
hα4β2 O 
nAChR O 
ion O 
channels O 
. O 
Patch O 
- O 
clamp O 
results O 
also O 
indicate O 
that O 
(-)-reboxetine B-TRIVIAL 
progressively O 
inhibits O 
the O 
hα4β2 O 
nAChR O 
with O 
two O 
- O 
fold O 
higher O 
potency O 
at O 
the O 
end O 
of O 
one O 
- O 
second O 
application O 
of O 
agonist O 
, O 
compared O 
with O 
the O 
peak O 
current O 
. O 
The O 
molecular O 
docking O 
studies O 
show O 
that O 
(-)-reboxetine B-TRIVIAL 
blocks O 
the O 
ion O 
channel O 
at O 
the O 
level O 
of O 
the O 
imipramine B-TRIVIAL 
locus O 
, O 
between O 
M2 O 
rings O 
6 O 
' O 
and O 
14 O 
' O 
. O 
In O 
addition O 
, O 
we O 
found O 
a O 
(-)-reboxetine B-TRIVIAL 
conformer O 
that O 
docks O 
in O 
the O 
helix O 
bundle O 
of O 
the O 
α4 O 
subunit O 
, O 
near O 
the O 
middle O 
region O 
. O 
According O 
to O 
molecular O 
dynamics O 
simulations O 
, O 
(-)-reboxetine B-TRIVIAL 
binding O 
is O 
stable O 
for O 
both O 
sites O 
, O 
albeit O 
less O 
stable O 
than O 
imipramine B-TRIVIAL 
. O 
The O 
interaction O 
of O 
these O 
drugs O 
with O 
the O 
helix O 
bundle O 
might O 
alter O 
allostericaly O 
the O 
functionality O 
of O 
the O 
channel O 
. O 
In O 
conclusion O 
, O 
the O 
clinical O 
action O 
of O 
(-)-reboxetine B-TRIVIAL 
may O 
be O 
produced O 
( O 
at O 
least O 
partially O 
) O 
by O 
its O 
inhibitory O 
action O 
on O 
hα4β2 O 
nAChRs O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
identify O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
analogs O 
with O 
a O 
broad O 
spectrum O 
of O 
anti-cancer O 
activities O 
and O 
an O 
increased O 
apoptosis O 
- O 
inducing O 
potential O 
compared O 
with O 
the O 
parent O 
VPA B-ABBREVIATION 
, O 
which O 
is O 
enrolled O 
as O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitor O 
in O 
a O 
large O 
number O 
of O 
clinical O 
trials O 
. O 
We O 
identified O 
a O 
chiral O 
VPA B-ABBREVIATION 
derivative O 
, O 
(S)-2-pentyl-4-pentynoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
previously O 
characterized O 
as O 
HDAC O 
inhibitor O 
that O 
induced O 
massive O 
programmed O 
cell O 
death O 
in O 
a O 
strongly O 
enantioselective O 
manner O 
in O 
U937 O 
histiocytic O 
lymphoma O 
cells O 
and O 
NB4 O 
acute O 
promyelocytic O 
leukemia O 
cells O 
. O 
By O 
performing O 
fluorescence O 
- O 
activated O 
cell O 
sorting O 
and O 
Western O 
blotting O 
analyses O 
, O 
we O 
established O 
that O 
enantiomer O 
(S)-2-pentyl-4-pentynoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
has O 
higher O 
apoptosis O 
- O 
inducing O 
potential O 
than O 
VPA B-ABBREVIATION 
itself O 
. O 
The O 
optic O 
antipode O 
(R)-2-pentyl-4-pentynoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
VPA B-ABBREVIATION 
caused O 
under O 
the O 
same O 
conditions O 
only O 
a O 
weak O 
growth O 
inhibition O 
without O 
inducing O 
cell O 
differentiation O 
and O 
apoptosis O 
. O 
(S)-2-pentyl-4-pentynoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
more O 
apoptogenic O 
than O 
VPA B-ABBREVIATION 
and O 
displays O 
enantioselective O 
anti-cancer O 
properties O 
that O 
warrant O 
further O 
research O 
regarding O 
the O 
mechanistic O 
basis O 
of O 
its O 
activity O 
and O 
its O 
potential O 
use O 
in O 
cancer O 
therapy O 
. O 

of O 
pH O 
, O 
light O 
cycle O 
, O 
and O 
temperature O 
on O 
ecotoxicity O 
of O 
four O 
sulfonylurea B-FAMILY 
herbicides O 
towards O 
Lemna O 
gibba O 
. O 

chemical O 
regulation O 
, O 
e.g O 
. O 
the O 
EU O 
Water O 
Framework O 
Directive O 
, O 
REACH O 
, O 
or O 
the O 
Pesticide O 
Directive O 
, O 
standardized O 
ecotoxicological O 
tests O 
are O 
applied O 
to O 
evaluate O 
and O 
rank O 
the O 
hazard O 
of O 
compounds O 
and O 
for O 
deriving O 
environmental O 
quality O 
standards O 
( O 
EQS O 
) O 
. O 
Standardized O 
test O 
methods O 
prescribe O 
fixed O 
testing O 
conditions O 
e.g O 
. O 
specific O 
temperature O 
, O 
pH O 
, O 
light O 
intensity O 
etc O 
. O 
However O 
, O 
environmental O 
conditions O 
under O 
which O 
the O 
organisms O 
live O 
are O 
rarely O 
identical O 
to O 
the O 
standard O 
conditions O 
. O 
Thus O 
, O 
the O 
ecotoxicity O 
of O 
compounds O 
found O 
in O 
standard O 
test O 
is O 
not O 
only O 
a O 
function O 
of O 
the O 
compounds O 
inherent O 
physico O 
- O 
chemical O 
properties O 
but O 
is O 
also O 
affected O 
by O 
test O 
conditions O 
. O 
It O 
is O 
therefore O 
important O 
to O 
study O 
the O 
effect O 
of O 
changes O 
in O 
test O 
conditions O 
in O 
order O 
to O 
get O 
reliable O 
input O 
ecotoxicity O 
data O 
for O 
assessing O 
the O 
potential O 
risk O 
posed O 
by O 
a O 
compound O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
implications O 
of O 
changing O 
test O 
conditions O 
on O 
the O 
toxicity O 
of O 
four O 
sulfonylurea B-FAMILY 
herbicides O 
( O 
SUs O 
) O 
. O 
The O 
toxicity O 
of O 
the O 
four O 
SUs O 
towards O 
Lemna O 
gibba O 
was O 
investigated O 
at O 
three O 
pH O 
levels O 
( O 
6 O 
, O 
7.5 O 
and O 
9 O 
) O 
, O 
at O 
two O 
temperatures O 
( O 
15 O 
and O 
24 O 
°C O 
) O 
and O 
two O 
light O 
regimes O 
( O 
continuous O 
and O 
12 O 
: O 
12 O 
h O 
light O 
: O 
dark O 
cycle O 
) O 
The O 
EC50 O 
increased O 
twofold O 
to O 
tenfold O 
for O 
the O 
four O 
SUs O 
when O 
pH O 
was O 
increased O 
from O 
6 O 
to O 
9 O 
. O 
Decreasing O 
the O 
temperature O 
from O 
24 O 
to O 
15 O 
°C O 
or O 
introducing O 
a O 
dark O 
: O 
light O 
cycle O 
did O 
not O 
cause O 
any O 
trends O 
in O 
changes O 
in O 
toxicity O 
. O 
The O 
results O 
show O 
that O 
test O 
conditions O 
can O 
have O 
an O 
effect O 
on O 
the O 
toxicity O 
and O 
this O 
should O 
be O 
considered O 
when O 
the O 
standard O 
test O 
results O 
are O 
used O 
for O 
derivation O 
of O 
EQS O 
. O 

indices O 
of O 
mercury B-SYSTEMATIC 
exposure O 
in O 
three O 
species O 
of O 
turtles O 
occupying O 
different O 
trophic O 
niches O 
downstream O 
from O 
a O 
former O 
chloralkali O 
facility O 
. O 

are O 
useful O 
for O 
studying O 
bioaccumulative O 
pollutants O 
such O 
as O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
because O 
they O 
have O 
long O 
life O 
spans O 
and O 
feed O 
at O 
trophic O 
levels O 
that O 
result O 
in O 
high O 
exposure O 
to O 
anthropogenic O 
chemicals O 
. O 
We O 
compared O 
total O 
Hg B-FORMULA 
concentrations O 
in O 
blood O 
and O 
toenails O 
of O 
three O 
species O 
of O 
turtles O 
( O 
Chelydra O 
serpentina O 
, O 
Sternotherus O 
odoratus O 
, O 
and O 
Graptemys O 
geographica O 
) O 
with O 
different O 
feeding O 
ecologies O 
from O 
locations O 
up- O 
and O 
downstream O 
of O 
a O 
superfund O 
site O 
in O 
Virginia O 
, O 
USA O 
. O 
Mercury B-SYSTEMATIC 
concentrations O 
in O 
turtle O 
tissues O 
were O 
low O 
at O 
the O 
reference O 
site O 
( O 
average O 
± O 
1SE O 
: O 
blood O 
= O 
48 O 
± O 
6 O 
ng O 
g(-1) O 
; O 
nail O 
= O 
2464 O 
± O 
339 O 
ng O 
g(-1) O 
FW O 
) O 
but O 
rose O 
near O 
the O 
contamination O 
source O 
to O 
concentrations O 
among O 
the O 
highest O 
ever O 
reported O 
in O 
turtles O 
[ O 
up O 
to O 
1800 O 
ng O 
g(-1) O 
( O 
blood O 
) O 
and O 
42250 O 
ng O 
g(-1) O 
( O 
nail O 
) O 
FW O 
] O 
. O 
Tissue O 
concentrations O 
remained O 
elevated O 
~130 O 
km O 
downstream O 
from O 
the O 
source O 
compared O 
to O 
reference O 
concentrations O 
. O 
Tissue O 
Hg B-FORMULA 
concentrations O 
were O 
higher O 
for O 
C O 
. O 
serpentina O 
and O 
S O 
. O 
odoratus O 
than O 
G O 
. O 
geographica O 
, O 
consistent O 
with O 
the O 
feeding O 
ecology O 
and O 
our O 
stable O 
isotope O 
( O 
δ O 
(13)C B-FORMULA 
and O 
δ O 
(15)N B-FORMULA 
) O 
analyses O 
of O 
these O 
species O 
. O 
In O 
addition O 
, O 
we O 
suggest O 
that O 
toenails O 
were O 
a O 
better O 
indication O 
of O 
Hg B-FORMULA 
exposure O 
than O 
blood O 
, O 
probably O 
because O 
this O 
keratinized O 
tissue O 
represents O 
integrated O 
exposure O 
over O 
time O 
. O 
Our O 
results O 
demonstrate O 
that O 
downstream O 
transport O 
of O 
Hg B-FORMULA 
from O 
point O 
sources O 
can O 
persist O 
over O 
vast O 
expanses O 
of O 
river O 
thereby O 
posing O 
potential O 
exposure O 
risks O 
to O 
turtles O 
, O 
but O 
relative O 
exposure O 
varies O 
with O 
trophic O 
level O 
. O 
In O 
addition O 
, O 
our O 
study O 
identifies O 
turtle O 
toenails O 
as O 
a O 
simple O 
, O 
cost O 
- O 
efficient O 
, O 
and O 
minimally O 
invasive O 
tissue O 
for O 
conservation O 
- O 
minded O 
sampling O 
of O 
these O 
long O 
- O 
lived O 
vertebrates O 
. O 

analysis O 
of O 
the O 
protective O 
effects O 
of O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CAPE B-ABBREVIATION 
) O 
on O 
pulmonary O 
contusion O 
lung O 
oxidative O 
stress O 
and O 
serum O 
copper B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
levels O 
in O 
experimental O 
rat O 
model O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CAPE B-ABBREVIATION 
) O 
in O 
the O 
lungs O 
by O 
biochemical O 
and O 
histopathological O 
analyses O 
in O 
an O 
experimental O 
isolated O 
lung O 
contusion O 
model O 
. O 
Eighty O 
- O 
one O 
male O 
Sprague-Dawley O 
rats O 
were O 
used O 
. O 
The O 
animals O 
were O 
divided O 
randomly O 
into O 
four O 
groups O 
: O 
group O 
1 O 
( O 
n O 
= O 
9 O 
) O 
was O 
defined O 
as O 
without O 
contusion O 
and O 
without O 
CAPE B-ABBREVIATION 
injection O 
. O 
Group O 
2 O 
( O 
n O 
= O 
9 O 
) O 
was O 
defined O 
as O 
CAPE B-ABBREVIATION 
10 O 
μmol O 
/ O 
kg O 
injection O 
without O 
lung O 
contusion O 
. O 
Group O 
3 O 
( O 
n O 
= O 
36 O 
) O 
was O 
defined O 
as O 
contusion O 
without O 
CAPE B-ABBREVIATION 
-administrated O 
group O 
which O 
consisted O 
of O 
four O 
subgroups O 
that O 
were O 
created O 
according O 
to O 
analysis O 
between O 
days O 
0 O 
, O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
. O 
Group O 
4 O 
( O 
n O 
= O 
27 O 
) O 
was O 
defined O 
as O 
CAPE B-ABBREVIATION 
10 O 
μmol O 
/ O 
kg O 
administrated O 
after O 
contusion O 
group O 
divided O 
into O 
three O 
subgroups O 
according O 
to O 
analysis O 
on O 
days O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
. O 
CAPE B-ABBREVIATION 
10 O 
μmol O 
/ O 
kg O 
was O 
injected O 
intraperitoneally O 
30 O 
min O 
after O 
trauma O 
and O 
on O 
days O 
1 O 
and O 
2 O 
. O 
Blood O 
samples O 
were O 
obtained O 
to O 
measure O 
catalase O 
( O 
CAT O 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activities O 
and O 
level O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
for O 
blood O 
gas O 
analysis O 
. O 
Trace O 
elements O 
such O 
as O 
zinc B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
were O 
measured O 
in O 
serum O 
. O 
The O 
lung O 
tissue O 
was O 
also O 
removed O 
for O 
histopathological O 
examination O 
. O 
Isolated O 
lung O 
contusion O 
increased O 
serum O 
and O 
tissue O 
SOD O 
and O 
CAT O 
activities O 
and O 
MDA B-ABBREVIATION 
levels O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Both O 
serum O 
and O 
tissue O 
SOD O 
, O 
MDA B-ABBREVIATION 
, O 
and O 
CAT O 
levels O 
on O 
day O 
3 O 
were O 
lower O 
in O 
group O 
4 O 
compared O 
to O 
group O 
3 O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Further O 
, O 
the O 
levels O 
of O 
SOD O 
, O 
MDA B-ABBREVIATION 
, O 
and O 
CAT O 
in O 
group O 
4 O 
were O 
similar O 
compared O 
to O 
group O 
1 O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
CAPE B-ABBREVIATION 
also O 
had O 
a O 
significant O 
beneficial O 
effect O 
on O 
blood O 
gases O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Both O 
serum O 
zinc B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
levels O 
were O 
( O 
p O 
< O 
0.05 O 
) O 
influenced O 
by O 
the O 
administration O 
of O 
CAPE B-ABBREVIATION 
. O 
Histopathological O 
examination O 
revealed O 
lower O 
scores O 
in O 
group O 
4 O 
compared O 
to O 
group O 
3 O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
no O 
significant O 
differences O 
compared O 
to O 
group O 
1 O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
CAPE B-ABBREVIATION 
appears O 
to O 
be O 
effective O 
in O 
protecting O 
against O 
severe O 
oxidative O 
stress O 
and O 
tissue O 
damage O 
caused O 
by O 
pulmonary O 
contusion O 
in O 
an O 
experimental O 
setting O 
. O 
Therefore O 
, O 
we O 
conclude O 
that O 
administration O 
of O 
CAPE B-ABBREVIATION 
may O 
be O 
used O 
for O 
a O 
variety O 
of O 
conditions O 
associated O 
with O 
pulmonary O 
contusion O 
. O 
Clinical O 
use O 
of O 
CAPE B-ABBREVIATION 
may O 
have O 
the O 
advantage O 
of O 
prevention O 
of O 
pulmonary O 
contusion O 
. O 

, O 
the O 
proposed O 
selective O 
blocker O 
of O 
volume O 
- O 
regulated O 
anion O 
channels O 
, O 
inhibits O 
several O 
glutamate B-TRIVIAL 
transport O 
pathways O 
in O 
glial O 
cells O 
. O 

oxobutyric I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DCPIB B-ABBREVIATION 
) O 
was O 
identified O 
as O 
the O 
selective O 
blocker O 
of O 
volume O 
- O 
regulated O 
anion O 
channels O 
( O 
VRAC O 
) O 
. O 
VRAC O 
are O 
permeable O 
to O 
small O 
inorganic O 
and O 
organic O 
anions O 
, O 
including O 
the O 
excitatory O 
neurotransmitter O 
glutamate O 
. O 
In O 
recent O 
years O 
DCPIB B-ABBREVIATION 
has O 
been O 
increasingly O 
used O 
for O 
probing O 
the O 
physiologic O 
and O 
pathologic O 
roles O 
of O 
VRAC O 
and O 
was O 
found O 
to O 
potently O 
suppress O 
pathologic O 
glutamate B-TRIVIAL 
release O 
in O 
cerebral O 
ischemia O 
. O 
Because O 
ischemic O 
glutamate B-TRIVIAL 
release O 
can O 
be O 
mediated O 
by O 
a O 
plethora O 
of O 
mechanisms O 
, O 
in O 
this O 
study O 
we O 
explored O 
the O 
selectivity O 
of O 
DCPIB B-ABBREVIATION 
toward O 
the O 
majority O 
of O 
previously O 
identified O 
glutamate B-TRIVIAL 
transporters O 
and O 
permeability O 
pathways O 
. O 
l-[(3)H]glutamate B-SYSTEMATIC 
, O 
d-[(3)H]aspartate B-SYSTEMATIC 
, O 
and O 
l-[(14)C]cystine B-TRIVIAL 
were O 
used O 
to O 
trace O 
amino B-FAMILY 
acid I-FAMILY 
release O 
and O 
uptake O 
. O 
We O 
found O 
that O 
in O 
addition O 
to O 
its O 
well O 
- O 
characterized O 
effect O 
on O 
VRAC O 
, O 
DCPIB B-ABBREVIATION 
potently O 
inhibited O 
glutamate B-TRIVIAL 
release O 
via O 
connexin O 
hemichannels O 
and O 
glutamate B-TRIVIAL 
uptake O 
via O 
the O 
glutamate B-TRIVIAL 
transporter O 
GLT-1 O 
in O 
rat O 
glial O 
cells O 
. O 
In O 
contrast O 
, O 
DCPIB B-ABBREVIATION 
had O 
no O 
direct O 
effect O 
on O 
vesicular O 
glutamate B-TRIVIAL 
release O 
from O 
rat O 
brain O 
synaptosomes O 
or O 
the O 
cystine B-TRIVIAL 
/ O 
glutamate B-TRIVIAL 
exchange O 
in O 
astrocytes O 
. O 
The O 
compound O 
did O 
not O 
affect O 
the O 
astrocytic O 
glutamate B-TRIVIAL 
transporter O 
GLAST O 
, O 
nor O 
did O 
it O 
block O 
glutamate B-TRIVIAL 
release O 
via O 
the O 
P2X(7) O 
/ O 
pannexin O 
permeability O 
pathway O 
. O 
The O 
ability O 
of O 
DCPIB B-ABBREVIATION 
to O 
directly O 
block O 
connexin O 
hemichannels O 
was O 
confirmed O 
using O 
a O 
gene O 
- O 
specific O 
siRNA O 
knockdown O 
approach O 
. O 
Overall O 
, O 
our O 
data O 
demonstrate O 
that O 
DCPIB B-ABBREVIATION 
influences O 
several O 
glutamate B-TRIVIAL 
transport O 
pathways O 
and O 
that O 
its O 
effects O 
on O 
VRAC O 
in O 
vivo O 
should O 
be O 
verified O 
using O 
additional O 
pharmacological O 
controls O 
. O 

disease O 
( O 
AD O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disorder O 
that O 
is O 
characterized O 
by O 
progressive O 
loss O 
of O 
memory O 
and O 
cognitive O 
impairment O 
. O 
Aggregation O 
of O 
amyloid-β O 
( O 
Aβ O 
) O 
peptides O 
is O 
the O 
crucial O 
factor O 
in O 
the O 
onset O 
of O 
AD O 
. O 
The O 
toxic O 
Aβ O 
peptides O 
Aβ40 O 
and O 
Aβ42 O 
are O 
produced O 
from O 
the O 
Aβ O 
precursor O 
protein O 
( O 
APP O 
) O 
, O 
a O 
transmembrane O 
protein O 
which O 
is O 
folded O 
and O 
modified O 
in O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
. O 
ER O 
is O 
the O 
main O 
organelle O 
for O 
the O 
synthesis O 
and O 
processing O 
of O 
nearly O 
all O 
proteins O 
as O 
well O 
as O 
the O 
main O 
cellular O 
source O 
of O 
Ca2+ B-FORMULA 
. O 
Under O 
stress O 
conditions O 
, O 
three O 
main O 
ER O 
pathways O 
including O 
inositol B-TRIVIAL 
-requiring O 
enzyme O 
1 O 
, O 
protein O 
kinase O 
RNA O 
- O 
like O 
ER O 
kinase O 
, O 
and O 
activating O 
transcription O 
factor O 
6 O 
become O 
activated O 
causing O 
the O 
accumulation O 
of O 
unfolded O 
or O 
misfolded O 
proteins O 
within O 
ER O 
lumen O 
. O 
These O 
pathways O 
manage O 
the O 
stress O 
by O 
regulating O 
the O 
expression O 
of O 
chaperones O 
and O 
enzymes O 
involved O 
in O 
protein O 
folding O 
. O 
Several O 
studies O 
have O 
reported O 
the O 
dysfunction O 
of O 
these O 
stress O 
- O 
sensing O 
pathways O 
in O 
pathological O 
conditions O 
, O 
including O 
neurodegenerative O 
diseases O 
. O 
Recent O 
studies O 
have O 
proposed O 
that O 
neuronal O 
death O 
in O 
AD O 
arises O 
from O 
dysfunction O 
of O 
the O 
ER O 
. O 
Here O 
, O 
we O 
will O 
review O 
recent O 
research O 
findings O 
on O 
the O 
interaction O 
between O 
ER O 
and O 
mitochondria O 
, O 
and O 
its O 
effect O 
on O 
apoptotic O 
pathways O 
. O 
We O 
further O 
provide O 
insights O 
into O 
studies O 
which O 
suggest O 
the O 
role O 
of O 
ER O 
in O 
animal O 
and O 
/ O 
or O 
cellular O 
models O 
of O 
AD O 
. O 
Therapeutic O 
strategies O 
that O 
modulate O 
ER O 
could O 
represent O 
a O 
promising O 
approach O 
for O 
prevention O 
or O 
treatment O 
of O 
AD O 
. O 

officinalis O 
L O 
. O 
( O 
lemon O 
balm O 
) O 
is O 
normally O 
consumed O 
as O 
an O 
infusion O 
and O 
presents O 
therapeutic O 
properties O 
, O 
such O 
as O 
sedative O 
, O 
carminative O 
and O 
antispasmodic O 
, O 
also O 
being O 
included O 
in O 
some O 
pharmaceutical O 
preparations O 
. O 
The O 
phenolic O 
profiles O 
of O 
different O 
samples O 
of O 
lemon O 
balm O 
, O 
prepared O 
as O 
infusions O 
, O 
were O 
evaluated O 
by O 
HPLC-DAD-ESI O 
/ O 
MS O 
. O 
The O 
profiles O 
were O 
compared O 
in O 
order O 
to O 
understand O 
the O 
differences O 
between O 
cultivated O 
, O 
in O 
vitro O 
cultured O 
and O 
commercial O 
( O 
bags O 
and O 
granulated O 
) O 
samples O 
. O 
All O 
the O 
samples O 
showed O 
a O 
similar O 
phenolic O 
profile O 
, O 
presenting O 
differences O 
only O 
in O 
the O 
quantities O 
found O 
of O 
each O 
compound O 
. O 
Rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
was O 
the O 
most O 
abundant O 
compound O 
, O 
being O 
higher O 
in O 
commercial O 
samples O 
, O 
especially O 
in O 
tea O 
bag O 
sample O 
( O 
55.68mg O 
/ O 
g O 
of O 
infusion O 
) O 
and O 
lower O 
in O 
in O 
vitro O 
cultured O 
sample O 
( O 
15.46mg O 
/ O 
g O 
) O 
. O 
Moreover O 
, O 
dimers O 
, O 
trimers O 
and O 
tetramers O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
were O 
identified O 
and O 
quantified O 
for O 
the O 
first O 
time O 
in O 
lemon O 
balm O 
. O 
Only O 
one O 
flavonoid B-FAMILY 
, O 
luteolin-3'-O-glucuronide B-SYSTEMATIC 
was O 
found O 
in O 
all O 
the O 
samples O 
, O 
ranging O 
from O 
8.43mg O 
/ O 
g O 
in O 
commercial O 
granulate O 
sample O 
to O 
1.22mg O 
/ O 
g O 
in O 
in O 
vitro O 
cultured O 
sample O 
. O 
Overall O 
, O 
cultivated O 
and O 
in O 
vitro O 
cultured O 
samples O 
presented O 
the O 
lowest O 
amounts O 
of O 
phenolic O 
compounds O 
( O 
59.59 O 
and O 
30.21mg O 
/ O 
g O 
, O 
respectively O 
) O 
; O 
otherwise O 
, O 
commercial O 
samples O 
showed O 
the O 
highest O 
contents O 
( O 
109.24mg O 
/ O 
g O 
for O 
tea O 
bag O 
and O 
101.03mg O 
/ O 
g O 
for O 
granulate O 
sample O 
) O 
. O 
The O 
present O 
study O 
shows O 
that O 
infusion O 
of O 
lemon O 
balm O 
can O 
be O 
a O 
source O 
of O 
phenolic O 
compounds O 
, O 
known O 
for O 
their O 
bioactive O 
effects O 
. O 

, O 
Pulsatilla B-TRIVIAL 
saponin I-TRIVIAL 
D I-TRIVIAL 
suppresses O 
the O 
proliferation O 
of O 
human O 
colon O 
cancer O 
cells O 
and O 
induces O 
apoptosis O 
by O 
modulating O 
the O 
AKT O 
/ O 
mTOR O 
signalling O 
pathway O 
. O 

koreana O 
has O 
been O 
used O 
as O 
a O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
several O 
diseases O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
determine O 
if O 
SB365 B-IDENTIFIER 
, O 
Pulsatilla B-TRIVIAL 
saponin I-TRIVIAL 
D I-TRIVIAL 
isolated O 
from O 
the O 
root O 
of O 
P O 
. O 
koreana O 
inhibits O 
the O 
progression O 
of O 
colon O 
cancer O 
. O 
We O 
found O 
that O 
SB365 B-IDENTIFIER 
strongly O 
suppressed O 
the O 
growth O 
and O 
proliferation O 
of O 
colon O 
cancer O 
cells O 
and O 
induced O 
their O 
apoptosis O 
. O 
Also O 
, O 
SB365 B-IDENTIFIER 
showed O 
anti-angiogenic O 
activity O 
by O 
decreasing O 
the O 
expression O 
of O 
HIF-1α O 
and O 
VEGF O 
. O 
These O 
results O 
were O 
confirmed O 
by O 
an O 
in O 
vivo O 
study O 
showing O 
that O 
SB365 B-IDENTIFIER 
significantly O 
inhibited O 
tumor O 
growth O 
by O 
the O 
induction O 
of O 
apoptosis O 
and O 
inhibition O 
of O 
angiogenesis O 
with O 
stronger O 
anticancer O 
activity O 
than O 
5-FU B-SYSTEMATIC 
. O 
When O 
further O 
examined O 
for O 
its O 
anticancer O 
mechanism O 
, O 
SB365 B-IDENTIFIER 
effectively O 
suppressed O 
the O 
AKT O 
/ O 
mTOR O 
pathway O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Taken O 
together O 
, O 
our O 
study O 
demonstrated O 
that O 
SB365 B-IDENTIFIER 
inhibits O 
the O 
AKT O 
/ O 
mTOR O 
pathway O 
, O 
leading O 
to O 
the O 
suppression O 
of O 
tumor O 
growth O 
and O 
angiogenesis O 
together O 
with O 
induction O 
of O 
apoptosis O 
. O 
Therefore O 
, O 
SB365 B-IDENTIFIER 
is O 
a O 
good O 
candidate O 
as O 
a O 
natural O 
product O 
for O 
use O 
in O 
the O 
treatment O 
of O 
colon O 
cancer O 
. O 

on O 
the O 
antioxidant O 
potential O 
of O 
flavones B-FAMILY 
of O 
Allium O 
vineale O 
isolated O 
from O 
its O 
water O 
- O 
soluble O 
fraction O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
examine O 
the O 
chemical O 
constituents O 
and O 
antioxidant O 
potential O 
of O 
water O 
- O 
soluble O 
fractions O 
from O 
the O 
commonly O 
consumed O 
vegetable O 
, O 
Allium O 
vineale O 
. O 
The O 
water O 
- O 
soluble O 
fraction O 
, O 
containing O 
phenolic O 
compounds O 
, O 
was O 
extracted O 
with O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
to O 
obtain O 
flavonoids B-FAMILY 
which O 
were O 
separated O 
and O 
purified O 
by O 
repeated O 
column O 
chromatography O 
over O 
Sephadex O 
LH-20 O 
, O 
RP O 
C18 O 
and O 
silica B-TRIVIAL 
gel I-TRIVIAL 
. O 
The O 
isolated O 
compounds O 
were O 
identified O 
according O 
to O 
their O 
physicochemical O 
properties O 
and O 
spectral O 
data O 
( O 
UV O 
, O 
HPLC-TOF O 
/ O 
MS O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
2D O 
NMR O 
) O 
. O 
Three O 
flavonoids O 
were O 
isolated O 
and O 
identified O 
as O 
chrysoeriol-7-O-[2″-O-E-feruloyl]-β-d-glucoside B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
chrysoeriol B-TRIVIAL 
( O 
2 O 
) O 
, O 
and O 
isorhamnetin-3-β-d-glucoside B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Antioxidant O 
studies O 
of O 
the O 
aqueous O 
extract O 
and O 
three O 
isolated O 
compounds O 
, O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
were O 
undertaken O 
and O 
they O 
were O 
found O 
to O 
have O 
significant O 
antioxidant O 
activity O 
. O 
Antioxidant O 
activities O 
were O 
evaluated O 
for O 
total O 
antioxidant O 
activity O 
by O 
the O 
ferric B-SYSTEMATIC 
thiocyanate I-SYSTEMATIC 
method O 
, O 
ferric B-SYSTEMATIC 
ion O 
( O 
Fe(3+) B-FORMULA 
) O 
reducing O 
antioxidant O 
power O 
assay O 
( O 
FRAP O 
) O 
, O 
ferrous B-SYSTEMATIC 
ion O 
( O 
Fe(2+) B-FORMULA 
) O 
metal O 
chelating O 
activity O 
, O 
and O 
DPPH B-ABBREVIATION 
free O 
radical O 
- O 
scavenging O 
activity O 
. O 
The O 
water O 
- O 
soluble O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
extraction O 
methods O 
were O 
also O 
compared O 
using O 
HPLC-TOF O 
/ O 
MS O 
. O 

evaluation O 
of O 
myofibrillar O 
carbonylation O 
in O 
chilled O 
fish O 
mince O 
and O 
its O 
inhibition O 
by O 
catechin B-TRIVIAL 
. O 

present O 
study O 
investigates O 
the O 
susceptibility O 
of O 
individual O 
myofibrillar O 
proteins O 
from O 
mackerel O 
( O 
Scomber O 
scombrus O 
) O 
mince O 
to O 
undergo O 
carbonylation O 
reactions O 
during O 
chilled O 
storage O 
, O 
and O 
the O 
antioxidant O 
capacity O 
of O 
(+)-catechin B-TRIVIAL 
to O 
prevent O 
oxidative O 
processes O 
of O 
proteins O 
. O 
The O 
carbonylation O 
of O 
each O 
particular O 
protein O 
was O 
quantified O 
by O 
combining O 
the O 
labelling O 
of O 
protein O 
carbonyls O 
by O 
fluorescein-5-thiosemicarbazide B-SYSTEMATIC 
( O 
FTSC B-ABBREVIATION 
) O 
with O 
1-D O 
or O 
2-D O 
gel O 
electrophoresis O 
. O 
Alpha O 
skeletal O 
actin O 
, O 
glycogen O 
phosphorylase O 
, O 
unnamed O 
protein O 
product O 
( O 
UNP O 
) O 
similar O 
to O 
enolase O 
, O 
pyruvate B-TRIVIAL 
kinase O 
, O 
isoforms O 
of O 
creatine B-TRIVIAL 
kinase O 
, O 
aldolase O 
A O 
and O 
an O 
isoform O 
of O 
glyceraldehyde B-TRIVIAL 
3-phosphate O 
dehydrogenase O 
( O 
G3PDH O 
) O 
showed O 
elevated O 
oxidation O 
in O 
chilled O 
non-supplemented O 
mince O 
. O 
Myosin O 
heavy O 
chain O 
( O 
MHC O 
) O 
was O 
not O 
carbonylated O 
in O 
chilled O 
muscle O 
, O 
but O 
an O 
extensive O 
MHC O 
degradation O 
was O 
observed O 
in O 
those O 
samples O 
. O 
The O 
supplementation O 
of O 
catechin B-TRIVIAL 
reduced O 
protein O 
oxidation O 
and O 
lipid O 
oxidation O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
: O 
control O 
> O 
25 O 
> O 
100≈200ppm O 
. O 
Therefore O 
, O 
the O 
highest O 
catechin B-TRIVIAL 
concentrations O 
( O 
100 O 
and O 
200ppm O 
) O 
exhibited O 
the O 
strongest O 
antioxidant O 
activity O 
. O 
Catechin B-TRIVIAL 
( O 
200ppm O 
) O 
reduced O 
significantly O 
carbonylation O 
of O 
protein O 
spots O 
identified O 
as O 
glycogen O 
phosphorylase O 
, O 
pyruvate B-TRIVIAL 
kinase O 
muscle O 
isozyme O 
, O 
isoforms O 
of O 
creatine B-TRIVIAL 
kinase O 
. O 
Conversely O 
, O 
catechin B-TRIVIAL 
was O 
ineffective O 
to O 
inhibit O 
the O 
oxidation O 
of O 
actin O 
and O 
UNP O 
similar O 
to O 
enolase O 
. O 
These O 
results O 
draw O 
attention O 
to O 
the O 
inefficiency O 
of O 
catechin B-TRIVIAL 
to O 
prevent O 
actin O 
oxidation O 
, O 
in O 
contrast O 
to O 
the O 
extremely O 
high O 
efficiency O 
of O 
catechin B-TRIVIAL 
in O 
inhibiting O 
oxidation O 
of O 
lipids O 
and O 
other O 
proteins O 
. O 

and O 
dicarboximide B-SYSTEMATIC 
fungicides O 
in O 
infant O 
formulae O 
from O 
the O 
EU O 
market O 
. O 

method O 
based O 
on O 
ultrasonic O 
extraction O 
and O 
purification O 
by O 
solid O 
phase O 
extraction O 
followed O 
by O 
LC-MS O 
/ O 
MS O 
and O 
GC-MS O 
analysis O 
was O 
developed O 
for O 
the O 
determination O 
of O 
genistein B-TRIVIAL 
, O 
genistin B-TRIVIAL 
, O 
iprodione B-TRIVIAL 
, O 
vinclozolin B-TRIVIAL 
and O 
procymidone B-TRIVIAL 
in O 
infant O 
powdered O 
formulas O 
. O 
The O 
method O 
was O 
tested O 
for O 
different O 
formulations O 
: O 
milk O 
, O 
soy O 
and O 
hypoallergenic O 
, O 
and O 
was O 
applied O 
to O 
European O 
pooled O 
samples O 
. O 
Spike O 
recoveries O 
ranged O 
from O 
53.1% O 
to O 
91.5% O 
and O 
the O 
relative O 
standard O 
deviation O 
values O 
for O 
repeatability O 
ranged O 
from O 
9.6% O 
to O 
17.7% O 
, O 
except O 
for O 
iprodione B-TRIVIAL 
in O 
milk O 
formula O 
( O 
22.3% O 
) O 
. O 
None O 
of O 
the O 
fungicides O 
were O 
found O 
in O 
the O 
European O 
pooled O 
formulae O 
, O 
while O 
genistein B-TRIVIAL 
was O 
found O 
at O 
9.7μg O 
/ O 
g O 
in O 
soy O 
formula O 
and O 
the O 
concentration O 
of O 
genistin B-MULTIPLE 
, I-MULTIPLE 
its I-MULTIPLE 
β-glycosylated I-MULTIPLE 
form O 
, O 
was O 
respectively O 
31.4ng O 
/ O 
g O 
and O 
476ng O 
/ O 
g O 
in O 
milk O 
and O 
soy O 
formula O 
. O 

metabolism O 
in O 
relation O 
to O 
chilling O 
tolerance O 
of O 
loquat O 
fruit O 
. O 

relationship O 
between O 
chilling O 
injury O 
and O 
sugar B-FAMILY 
metabolism O 
was O 
investigated O 
in O 
loquat O 
fruit O 
stored O 
at O 
1°C O 
for O 
35days O 
. O 
No O 
symptoms O 
of O 
chilling O 
injury O 
occurred O 
in O 
the O 
fruit O 
, O 
of O 
' O 
Ninghaibai O 
' O 
cultivar O 
, O 
during O 
the O 
whole O 
storage O 
whereas O 
, O 
in O 
' O 
Dahongpao O 
' O 
fruit O 
, O 
severe O 
chilling O 
symptoms O 
were O 
observed O 
after O 
20days O 
of O 
storage O 
at O 
1°C O 
. O 
' O 
Ninghaibai O 
' O 
fruit O 
had O 
higher O 
levels O 
of O 
glucose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
and O 
higher O 
activities O 
of O 
sucrose B-TRIVIAL 
hydrolyzing O 
enzymes O 
, O 
such O 
as O 
sucrose B-TRIVIAL 
synthase O 
- O 
cleavage O 
and O 
invertase O 
, O 
than O 
had O 
' O 
Dahongpao O 
' O 
. O 
Furthermore O 
, O 
the O 
chilling O 
resistant O 
' O 
Ninghaibai O 
' O 
fruit O 
also O 
showed O 
higher O 
activities O 
of O 
hexokinase O 
and O 
fructokinase O 
, O 
involved O 
in O 
hexose B-TRIVIAL 
phoshorylation O 
and O 
sugar B-FAMILY 
signal O 
generation O 
. O 
These O 
results O 
suggest O 
that O 
the O 
higher O 
content O 
of O 
hexoses B-FAMILY 
and O 
activities O 
of O 
hexose B-TRIVIAL 
sensors O 
were O 
likely O 
part O 
of O 
the O 
mechanism O 
for O 
chilling O 
tolerance O 
of O 
loquat O 
fruit O 
. O 

shunt O 
and O 
polyamine B-FAMILY 
degradation O 
pathway O 
on O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
accumulation O 
in O 
germinating O 
fava O 
bean O 
( O 
Vicia O 
faba O 
L O 
. O 
) O 
under O 
hypoxia O 
. O 

shunt O 
and O 
polyamine B-FAMILY 
degradation O 
pathway O 
on O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
accumulation O 
in O 
germinating O 
fava O 
bean O 
under O 
hypoxia O 
was O 
investigated O 
. O 
GABA B-ABBREVIATION 
content O 
, O 
GAD O 
and O 
DAO O 
activity O 
were O 
significantly O 
increased O 
under O 
hypoxia O 
treatment O 
. O 
Glu B-FORMULA 
and O 
polyamine B-FAMILY 
contents O 
enhanced O 
largely O 
and O 
thus O 
supplied O 
as O 
sufficient O 
substrates O 
for O 
GABA B-ABBREVIATION 
formation O 
. O 
In O 
contrast O 
, O 
GABA B-ABBREVIATION 
content O 
decreased O 
, O 
mainly O 
in O 
the O 
embryo O 
, O 
after O 
removing O 
the O 
hypoxia O 
stress O 
. O 
DAO O 
activity O 
, O 
Glu B-FORMULA 
and O 
polyamines B-FAMILY 
contents O 
decreased O 
, O 
while O 
an O 
increment O 
of O 
GAD O 
activity O 
was O 
observed O 
. O 
This O 
indicated O 
that O 
GAD O 
activity O 
can O 
be O 
not O 
only O 
regulated O 
by O 
hypoxia O 
, O 
but O 
by O 
the O 
rapid O 
growth O 
of O 
embryo O 
after O 
the O 
recovery O 
from O 
hypoxia O 
stress O 
. O 
When O 
treated O 
with O 
AG O 
, O 
DAO O 
activity O 
was O 
almost O 
inhibited O 
completely O 
, O 
and O 
the O 
GABA B-ABBREVIATION 
content O 
decreased O 
by O 
32.96% O 
and O 
32.07% O 
after O 
treated O 
for O 
3 O 
and O 
5 O 
days O 
, O 
respectively O 
. O 
Hence O 
, O 
it O 
can O 
be O 
inferred O 
that O 
about O 
30% O 
of O 
GABA B-ABBREVIATION 
formed O 
in O 
germinating O 
fava O 
bean O 
under O 
hypoxia O 
was O 
supplied O 
by O 
polyamine B-FAMILY 
degradation O 
pathway O 
. O 

phenolic B-FAMILY 
compounds O 
, O 
isoflavones B-FAMILY 
and O 
antioxidant O 
activity O 
as O 
affected O 
by O 
in O 
vitro O 
gastrointestinal O 
digestion O 
. O 

aim O 
of O 
this O 
research O 
was O 
to O 
evaluate O 
changes O 
in O 
the O 
phenolic B-FAMILY 
compounds O 
, O 
isoflavones B-FAMILY 
and O 
antioxidant O 
activity O 
of O 
soymilk O 
following O 
in O 
vitro O 
gastrointestinal O 
digestion O 
( O 
including O 
dialysis O 
) O 
. O 
Gastric O 
digestion O 
significantly O 
influenced O 
the O 
release O 
of O 
bioactive O 
substances O 
from O 
the O 
soymilk O 
matrix O 
, O 
increasing O 
the O 
concentration O 
of O 
total O 
phenolic B-FAMILY 
components O 
( O 
35% O 
as O 
the O 
sum O 
of O 
individuals O 
and O 
14% O 
by O 
Folin-Ciocalteu O 
[ O 
F-C O 
] O 
method O 
) O 
, O 
total O 
isoflavone B-FAMILY 
content O 
( O 
22% O 
) O 
and O 
total O 
antioxidant O 
activity O 
( O 
76% O 
) O 
. O 
The O 
concentration O 
of O 
all O 
those O 
compounds O 
was O 
reduced O 
significantly O 
in O 
the O 
duodenal O 
fraction O 
in O 
comparison O 
to O 
gastric O 
digestion O 
and O 
their O 
lowest O 
concentration O 
was O 
observed O 
in O 
the O 
dialysed O 
fraction O 
, O 
where O 
phenolic B-FAMILY 
acids I-FAMILY 
were O 
not O 
detected O 
. O 
The O 
bioaccessibility O 
of O 
soymilk O 
phenolic B-FAMILY 
compounds O 
was O 
15% O 
as O 
the O 
sum O 
of O 
individuals O 
and O 
20% O 
by O 
F-C O 
assay O 
; O 
isoflavones B-FAMILY 
36% O 
and O 
constituents O 
with O 
antioxidant O 
activity O 
27% O 
. O 
Results O 
suggest O 
that O 
most O 
of O 
these O 
compounds O 
were O 
sufficiently O 
available O 
to O 
be O 
absorbed O 
and O 
could O 
contribute O 
health O 
benefits O 
. O 

dehydrated O 
waste O 
grape O 
skins O 
from O 
the O 
juice O 
industry O 
were O 
added O 
into O 
aged O 
and O 
young O 
red O 
wines O 
as O 
an O 
innovative O 
way O 
of O 
compensating O 
for O 
colour O 
loss O 
before O 
bottling O 
. O 
After O 
addition O 
of O 
grape O 
skins O 
, O 
colour O 
intensity O 
of O 
wines O 
increased O 
a O 
mean O 
11% O 
and O 
a O 
maximum O 
of O 
31% O 
with O 
predominance O 
of O 
the O 
red O 
component O 
. O 
Total O 
polyphenols B-FAMILY 
mean O 
increase O 
was O 
10% O 
with O 
a O 
maximum O 
value O 
of O 
20% O 
. O 
Analysis O 
of O 
low O 
molecular O 
weight O 
phenolic O 
compounds O 
by O 
HPLC-DAD O 
showed O 
a O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
content O 
increase O 
of O 
the O 
bioactive O 
compounds O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
(+)-catechin B-TRIVIAL 
, O 
(-)-epicatechin B-SYSTEMATIC 
, O 
and O 
(E)-resveratrol B-TRIVIAL 
. O 
Anthocyanins B-FAMILY 
content O 
also O 
increased O 
at O 
an O 
average O 
of O 
50mg O 
/ O 
l O 
. O 
The O 
volatile O 
profile O 
of O 
wines O 
analysed O 
by O 
SBSE-GC-MS O 
was O 
only O 
moderately O 
influenced O 
by O 
the O 
treatments O 
. O 
Mixtures O 
of O 
dehydrated O 
waste O 
grape O 
skins O 
were O 
useful O 
to O 
improve O 
the O 
colour O 
and O 
polyphenol B-FAMILY 
profile O 
of O 
red O 
wines O 
, O 
considering O 
them O 
a O 
useful O 
tool O 
for O 
correcting O 
colour O 
loss O 
before O 
bottling O 
. O 

exposure O 
during O 
storage O 
preserving O 
soluble O 
sugar B-FAMILY 
and O 
l-ascorbic B-TRIVIAL 
acid I-TRIVIAL 
content O 
of O 
minimally O 
processed O 
romaine O 
lettuce O 
( O 
Lactuca O 
sativa O 
L.var O 
. O 
longifolia O 
) O 
. O 

processed O 
romaine O 
lettuce O 
( O 
MPRL O 
) O 
leaves O 
were O 
stored O 
in O 
light O 
condition O 
( O 
2500lux O 
) O 
or O 
darkness O 
at O 
4°C O 
for O 
7d O 
. O 
Light O 
exposure O 
significantly O 
delayed O 
the O 
degradation O 
of O 
chlorophyll O 
and O 
decrease O 
of O 
glucose B-TRIVIAL 
, O 
reducing O 
sugar B-FAMILY 
, O 
and O 
sucrose B-TRIVIAL 
content O 
, O 
and O 
thus O 
preserved O 
more O 
total O 
soluble O 
solid O 
( O 
TSS O 
) O 
content O 
at O 
the O 
end O 
of O 
storage O 
in O 
comparison O 
with O 
darkness O 
. O 
While O 
, O 
it O 
did O 
not O 
influenced O 
starch O 
content O 
that O 
progressively O 
decreased O 
over O 
time O 
. O 
The O 
l-ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
accumulated O 
in O 
light O 
- O 
stored O 
leaves O 
, O 
but O 
deteriorated O 
in O 
dark O 
- O 
stored O 
leaves O 
during O 
storage O 
. O 
The O 
dehydroascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
DHA B-ABBREVIATION 
) O 
increased O 
in O 
all O 
leaves O 
stored O 
in O 
both O 
light O 
and O 
dark O 
condition O 
, O 
of O 
which O 
light O 
condition O 
resulted O 
in O 
less O 
DHA B-ABBREVIATION 
than O 
darkness O 
. O 
In O 
addition O 
, O 
the O 
fresh O 
weight O 
loss O 
and O 
dry O 
matter O 
significantly O 
increased O 
and O 
these O 
increases O 
were O 
accelerated O 
by O 
light O 
exposure O 
. O 
Conclusively O 
, O 
light O 
exposure O 
in O 
applied O 
intensity O 
effectively O 
alleviated O 
MPRL O 
quality O 
deterioration O 
by O 
delaying O 
the O 
decreases O 
of O 
pigments O 
, O 
soluble O 
sugar B-FAMILY 
, O 
TSS O 
content O 
and O 
accumulating O 
AA O 
. O 

role O 
of O 
personalized O 
medicine O 
in O 
identifying O 
appropriate O 
candidates O 
for O 
menopausal O 
estrogen B-FAMILY 
therapy O 
. O 

estrogen B-FAMILY 
therapy O 
has O 
a O 
complex O 
balance O 
of O 
benefits O 
and O 
risks O 
and O 
is O 
no O 
longer O 
routinely O 
recommended O 
for O 
the O 
majority O 
of O 
women O 
during O 
or O 
after O 
the O 
transition O 
to O 
menopause O 
. O 
Recent O 
findings O 
from O 
the O 
Women's O 
Health O 
Initiative O 
( O 
WHI O 
) O 
and O 
other O 
studies O 
suggest O 
that O 
a O 
woman's O 
clinical O 
and O 
biological O 
characteristics O 
may O 
modify O 
her O 
health O 
outcomes O 
on O 
hormone O 
therapy O 
( O 
HT O 
) O 
and O 
that O 
some O 
women O 
may O 
be O 
more O 
appropriate O 
candidates O 
for O 
therapy O 
than O 
others O 
. O 
An O 
emerging O 
body O 
of O 
evidence O 
suggests O 
that O 
it O 
may O 
be O 
possible O 
to O 
identify O 
women O 
who O 
are O 
more O 
likely O 
to O 
have O 
favorable O 
outcomes O 
and O 
less O 
likely O 
to O 
have O 
adverse O 
events O 
on O 
HT O 
, O 
as O 
well O 
as O 
to O 
tailor O 
the O 
optimal O 
dose O 
, O 
formulation O 
, O 
and O 
route O 
of O 
delivery O 
of O 
treatment O 
, O 
by O 
the O 
use O 
of O 
individual O 
risk O 
stratification O 
and O 
a O 
personalized O 
approach O 
. O 
Several O 
clinical O 
characteristics O 
that O 
have O 
been O 
proposed O 
for O 
this O 
purpose O 
include O 
a O 
woman's O 
age O 
, O 
time O 
since O 
menopause O 
, O 
symptom O 
severity O 
, O 
baseline O 
vascular O 
health O 
, O 
risk O 
for O 
breast O 
cancer O 
, O 
biomarker O 
levels O 
, O 
and O 
genetic O 
predisposition O 
. O 
The O 
underlying O 
rationale O 
for O 
personalized O 
medicine O 
, O 
that O 
each O 
person O 
has O 
a O 
unique O 
biologic O 
profile O 
that O 
can O 
help O 
to O 
guide O 
the O 
choice O 
of O 
therapy O 
, O 
applies O 
well O 
to O 
HT O 
decision O 
making O 
and O 
holds O 
promise O 
for O 
improved O 
treatment O 
efficacy O 
and O 
safety O 
. O 
This O 
report O 
, O 
which O 
focuses O 
on O 
vascular O 
health O 
, O 
reviews O 
the O 
evidence O 
on O 
the O 
role O 
of O 
such O 
markers O 
in O 
tailoring O 
the O 
use O 
of O 
hormone O 
therapy O 
to O 
appropriate O 
candidates O 
, O 
with O 
the O 
ultimate O 
goal O 
of O 
developing O 
a O 
personalized O 
risk O 
: O 
benefit O 
prediction O 
model O 
that O 
takes O 
into O 
account O 
clinical O 
and O 
genetic O 
factors O 
, O 
" O 
patient-centered O 
" O 
outcomes O 
including O 
sense O 
of O 
well O 
being O 
and O 
quality O 
of O 
life O 
, O 
and O 
other O 
variables O 
. O 
The O 
proposed O 
personalized O 
approach O 
to O 
HT O 
decision O 
making O 
has O 
the O 
potential O 
to O 
improve O 
the O 
quality O 
of O 
health O 
care O 
. O 

of O 
dopamine B-TRIVIAL 
D2 O 
agonist O 
- O 
induced O 
inhibition O 
of O 
ventral O 
tegmental O 
area O 
neurons O 
by O 
Gq O 
- O 
linked O 
neurotransmitters O 
is O 
dependent O 
on O 
protein O 
kinase O 
C O 
, O 
G O 
protein O 
- O 
coupled O 
receptor O 
kinase O 
, O 
and O 
dynamin O 
. O 

neurons O 
of O 
the O 
ventral O 
tegmental O 
area O 
are O 
important O 
components O 
of O 
brain O 
pathways O 
related O 
to O 
addiction O 
. O 
Prolonged O 
exposure O 
of O 
these O 
neurons O 
to O 
moderate O 
concentrations O 
of O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
decreases O 
their O 
sensitivity O 
to O 
inhibition O 
by O 
DA O 
, O 
a O 
process O 
called O 
DA-inhibition O 
reversal O 
( O 
DIR O 
) O 
. O 
DIR O 
is O 
mediated O 
by O 
phospholipase O 
C O 
and O 
conventional O 
subtype O 
of O 
protein O 
kinase O 
C O 
( O 
cPKC O 
) O 
through O 
concurrent O 
stimulation O 
of O 
D2 O 
and O 
D1 O 
- O 
like O 
DA O 
receptors O 
, O 
or O 
by O 
D2 O 
stimulation O 
concurrent O 
with O 
activation O 
of O 
5-HT B-SYSTEMATIC 
( O 
2 O 
) O 
or O 
neurotensin B-TRIVIAL 
receptors O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
further O 
characterized O 
this O 
phenomenon O 
by O 
use O 
of O 
extracellular O 
recordings O 
in O 
brain O 
slices O 
to O 
examine O 
whether O 
DIR O 
is O 
linked O 
to O 
G O 
protein O 
- O 
coupled O 
receptor O 
kinase-2 O 
( O 
GRK2 O 
) O 
or O 
dynamin O 
by O 
assessing O 
DIR O 
in O 
the O 
presence O 
of O 
antagonists O 
of O 
these O 
enzymes O 
. O 
DIR O 
was O 
blocked O 
by O 
β-ARK1 O 
inhibitor O 
, O 
which O 
inhibits O 
GRK2 O 
, O 
and O 
by O 
dynasore O 
, O 
which O 
blocks O 
dynamin O 
. O 
Reversal O 
of O 
inhibition O 
by O 
D2 O 
agonist O 
quinpirole B-TRIVIAL 
was O 
produced O 
by O 
serotonin B-TRIVIAL 
( O 
50 O 
µM O 
) O 
and O 
by O 
neurotensin B-TRIVIAL 
( O 
5-10 O 
nM O 
) O 
. O 
Serotonin B-TRIVIAL 
-induced O 
or O 
neurotensin B-TRIVIAL 
-induced O 
reversal O 
was O 
blocked O 
by O 
β-ARK1 O 
inhibitor O 
, O 
dynasore O 
, O 
or O 
cPKC O 
antagonist O 
5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile B-SYSTEMATIC 
( O 
Gö6976 B-IDENTIFIER 
) O 
. O 
This O 
further O 
characterization O 
of O 
DIR O 
indicates O 
that O 
cPKC O 
, O 
GRK2 O 
, O 
and O 
dynamin O 
play O 
important O 
roles O 
in O 
the O 
desensitization O 
of O 
D2 O 
receptors O 
. O 
As O 
drugs O 
of O 
abuse O 
produce O 
persistent O 
increases O 
in O 
DA O 
concentration O 
in O 
the O 
ventral O 
tegmental O 
area O 
, O 
reduction O 
of O 
D2 O 
receptor O 
sensitivity O 
as O 
a O 
result O 
of O 
drug O 
abuse O 
may O 
be O 
a O 
critical O 
factor O 
in O 
the O 
processes O 
of O 
addiction O 
. O 

A I-TRIVIAL 
inhibits O 
myeloid O 
cell O 
leukemia-1 O 
to O 
induce O 
apoptosis O 
in O 
oral O 
squamous O 
cell O 
carcinomas O 
and O 
tumor O 
xenograft O 
through O 
activation O 
of O 
Bax O 
and O 
oligomerization O 
. O 

several O 
human O 
malignancies O 
, O 
overexpression O 
of O 
myeloid O 
cell O 
leukemia-1 O 
( O 
Mcl-1 O 
) O 
confers O 
resistance O 
to O 
induction O 
of O 
apoptosis O 
; O 
however O 
, O 
Mcl-1 O 
- O 
mediated O 
inhibition O 
of O 
apoptosis O 
in O 
oral O 
squamous O 
cell O 
carcinoma O 
( O 
OSCC O 
) O 
is O 
not O 
fully O 
understood O 
and O 
has O 
been O 
investigated O 
in O 
this O 
study O 
. O 
The O 
Mcl-1 O 
promoter O 
activators O 
( O 
TPA O 
) O 
and O 
epidermal O 
growth O 
factor O 
( O 
EGF O 
) O 
enhanced O 
neoplastic O 
transformation O 
of O 
JB6 O 
cells O 
and O 
this O 
response O 
was O 
accompanied O 
by O 
enhanced O 
expression O 
of O 
Mcl-1 O 
, O 
and O 
knockdown O 
of O 
Mcl-1 O 
by O 
RNA O 
interference O 
( O 
RNAi O 
) O 
decreased O 
JB6 O 
cell O 
transformation O 
. O 
In O 
the O 
same O 
cell O 
line O 
, O 
we O 
also O 
demonstrated O 
that O 
mithramycin B-TRIVIAL 
A I-TRIVIAL 
( O 
Mith B-ABBREVIATION 
) O 
decreased O 
TPA-induced O 
JB6 O 
cell O 
transformation O 
and O 
Mcl-1 O 
expression O 
. O 
Mcl-1 O 
was O 
overexpressed O 
in O 
human O 
oral O 
tumors O 
compared O 
with O 
normal O 
oral O 
mucosa O 
and O 
also O 
in O 
several O 
OSCC O 
cell O 
lines O 
including O 
HN22 O 
and O 
HSC-4 O 
cells O 
. O 
Treatment O 
of O 
these O 
cells O 
with O 
Mith B-ABBREVIATION 
also O 
decreased O 
Mcl-1 O 
expression O 
and O 
neoplastic O 
cell O 
transformation O 
, O 
and O 
this O 
was O 
accompanied O 
by O 
induction O 
of O 
several O 
markers O 
of O 
apoptosis O 
. O 
Knockdown O 
of O 
Mcl-1 O 
by O 
RNAi O 
also O 
induced O 
apoptotic O 
cell O 
death O 
. O 
The O 
downregulation O 
of O 
Mcl-1 O 
by O 
Mith B-ABBREVIATION 
and O 
RNAi O 
increased O 
pro O 
- O 
apoptotic O 
protein O 
Bax O 
, O 
resulting O 
in O 
the O 
Bax O 
translocation O 
into O 
mitochondria O 
and O 
its O 
oligomerization O 
. O 
Mith B-ABBREVIATION 
also O 
suppressed O 
tumor O 
growth O 
in O 
vivo O 
and O 
induced O 
apoptosis O 
in O 
tumor O 
by O 
also O 
regulating O 
expression O 
of O 
Mcl-1 O 
and O 
Bax O 
proteins O 
. O 
These O 
indicate O 
a O 
critical O 
role O 
for O 
Mcl-1 O 
in O 
the O 
growth O 
and O 
survival O 
of O 
OSCC O 
and O 
demonstrate O 
that O 
Mith B-ABBREVIATION 
may O 
be O 
a O 
potential O 
anticancer O 
drug O 
candidate O 
for O 
clinical O 
treatment O 
of O 
OSCC O 
. O 

injury O 
molecule-1 O 
( O 
KIM-1 O 
) O 
has O 
been O 
qualified O 
by O 
the O 
Food O 
and O 
Drug O 
Administration O 
and O 
European O 
Medicines O 
Agency O 
as O 
a O 
urinary O 
biomarker O 
to O 
monitor O 
preclinical O 
nephrotoxicity O 
in O 
rats O 
and O 
on O 
a O 
case O 
- O 
by O 
- O 
case O 
basis O 
for O 
the O 
translation O 
of O 
potentially O 
nephrotoxic O 
drugs O 
into O 
first O 
- O 
in O 
human O 
studies O 
. O 
Although O 
mouse O 
models O 
are O 
widely O 
employed O 
in O 
preclinical O 
studies O 
, O 
few O 
urinary O 
biomarker O 
studies O 
have O 
been O 
performed O 
in O 
mice O 
due O 
to O 
limited O 
urine O 
availability O 
and O 
lack O 
of O 
sensitive O 
assays O 
. O 
Here O 
, O 
we O 
report O 
the O 
development O 
and O 
validation O 
of O 
two O 
different O 
assays O 
for O 
quantitative O 
assessment O 
of O 
mouse O 
urinary O 
KIM-1 O 
( O 
uKIM-1 O 
) O 
and O 
compare O 
the O 
sensitivity O 
of O 
KIM-1 O 
relative O 
to O 
other O 
standard O 
markers O 
in O 
ischemia O 
reperfusion O 
and O 
aristolochic B-FAMILY 
acid I-FAMILY 
(AA)-induced O 
kidney O 
injury O 
in O 
mice O 
. O 
A O 
sensitive O 
, O 
reproducible O 
, O 
and O 
quantitative O 
microbead O 
- O 
based O 
KIM-1 O 
ELISA O 
was O 
established O 
, O 
which O 
requires O 
only O 
10 O 
μl O 
urine O 
for O 
triplicate O 
determination O 
with O 
an O 
assay O 
range O 
of O 
12.21 O 
pg O 
/ O 
ml O 
to O 
50 O 
ng O 
/ O 
ml O 
. O 
The O 
second O 
assay O 
is O 
a O 
laminar O 
flow O 
dipstick O 
assay O 
, O 
which O 
has O 
an O 
assay O 
range O 
of O 
195 O 
pg O 
/ O 
ml O 
to O 
50 O 
ng O 
/ O 
ml O 
and O 
provides O 
quantitative O 
assessment O 
of O 
KIM-1 O 
in O 
15 O 
min O 
. O 
uKIM-1 O 
levels O 
increased O 
with O 
increasing O 
time O 
of O 
ischemia O 
or O 
time O 
after O 
AA O 
administration O 
. O 
After O 
only O 
10-min O 
ischemia O 
followed O 
by O 
24-h O 
reperfusion O 
, O 
uKIM-1 O 
was O 
significantly O 
elevated O 
by O 
13-fold O 
, O 
whereas O 
serum O 
creatinine B-TRIVIAL 
( O 
sCr O 
) O 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
, O 
N-acetyl B-SYSTEMATIC 
-β-glucosaminidase O 
( O 
NAG O 
) O 
, O 
and O 
proteinuria O 
levels O 
did O 
not O 
change O 
. O 
After O 
AA O 
administration O 
, O 
uKIM-1 O 
levels O 
were O 
significantly O 
upregulated O 
by O 
greater O 
than O 
threefold O 
within O 
12 O 
h O 
, O 
whereas O 
sCr O 
and O 
NAG O 
levels O 
were O 
unchanged O 
. O 
Mouse O 
KIM-1 O 
was O 
stable O 
for O 
multiple O 
freeze O 
- O 
thaw O 
cycles O 
, O 
for O 
up O 
to O 
5 O 
days O 
at O 
room O 
temperature O 
and O 
up O 
to O 
at O 
least O 
an O 
year O 
when O 
stored O 
at O 
-80°C O 
. O 

of O 
urinary O 
and O 
gene O 
expression O 
biomarkers O 
in O 
detecting O 
the O 
nephrotoxic O 
effects O 
of O 
melamine B-TRIVIAL 
and O 
cyanuric B-TRIVIAL 
acid I-TRIVIAL 
following O 
diverse O 
scenarios O 
of O 
co O 
- O 
exposure O 
. O 

standard O 
nephrotoxicity O 
assessments O 
primarily O 
detect O 
impaired O 
renal O 
function O 
, O 
KIM-1 O 
, O 
clusterin O 
, O 
NGAL O 
, O 
osteopontin O 
and O 
TIMP-1 O 
were O 
recently O 
identified O 
biomarkers O 
proposed O 
to O 
indicate O 
earlier O 
perturbations O 
in O 
renal O 
integrity O 
. O 
The O 
recent O 
adulteration O 
of O 
infant O 
and O 
pet O 
food O 
with O 
melamine B-TRIVIAL 
( O 
MEL B-ABBREVIATION 
) O 
and O 
structurally O 
- O 
related O 
compounds O 
revealed O 
that O 
co O 
- O 
ingestion O 
of O 
MEL B-ABBREVIATION 
and O 
cyanuric B-TRIVIAL 
acid I-TRIVIAL 
( O 
CYA B-ABBREVIATION 
) O 
could O 
form O 
melamine B-TRIVIAL 
- O 
cyanurate B-TRIVIAL 
crystals O 
which O 
obstruct O 
renal O 
tubules O 
and O 
induce O 
acute O 
renal O 
failure O 
. O 
This O 
study O 
concurrently O 
evaluated O 
the O 
ability O 
of O 
multiplexed O 
urinary O 
biomarker O 
immunoassays O 
and O 
biomarker O 
gene O 
expression O 
analysis O 
to O 
detect O 
nephrotoxicity O 
in O 
F344 O 
rats O 
co O 
- O 
administered O 
60ppm O 
each O 
of O 
MEL B-ABBREVIATION 
and O 
CYA B-ABBREVIATION 
in O 
feed O 
or O 
via O 
gavage O 
for O 
28days O 
. O 
The O 
biomarkers O 
were O 
also O 
evaluated O 
for O 
the O 
ability O 
to O 
differentiate O 
the O 
effects O 
of O 
the O 
compounds O 
when O 
co O 
- O 
administered O 
using O 
diverse O 
dosing O 
schedules O 
( O 
i.e O 
. O 
, O 
consecutive O 
vs O 
. O 
staggered O 
gavage O 
) O 
and O 
dosing O 
matrixes O 
( O 
i.e O 
. O 
, O 
feed O 
vs O 
. O 
gavage O 
) O 
. O 
Our O 
results O 
illustrate O 
the O 
ability O 
of O 
both O 
methods O 
to O 
detect O 
and O 
differentiate O 
the O 
severity O 
of O 
adverse O 
effects O 
in O 
the O 
staggered O 
and O 
consecutive O 
gavage O 
groups O 
at O 
much O 
lower O 
doses O 
than O 
previously O 
observed O 
in O 
animals O 
co O 
- O 
exposed O 
to O 
the O 
compounds O 
in O 
feed O 
. O 
We O 
also O 
demonstrate O 
that O 
these O 
urinary O 
biomarkers O 
outperform O 
traditional O 
diagnostic O 
methods O 
and O 
represent O 
a O 
powerful O 
, O 
non-invasive O 
indicator O 
of O 
chemical O 
- O 
induced O 
nephrotoxicity O 
prior O 
to O 
the O 
onset O 
of O 
renal O 
dysfunction O 
. O 

receptor O 
blockade O 
impairs O 
the O 
muscarinic O 
conversion O 
of O 
sub O 
- O 
threshold O 
transient O 
depression O 
into O 
long O 
- O 
lasting O 
LTD O 
in O 
the O 
hippocampus O 
- O 
prefrontal O 
cortex O 
pathway O 
in O 
vivo O 
: O 
correlation O 
with O 
gamma O 
oscillations O 
. O 

fibers O 
from O 
the O 
brainstem O 
and O 
basal O 
forebrain O 
innervate O 
the O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
modulating O 
neuronal O 
activity O 
and O 
synaptic O 
plasticity O 
responses O 
to O 
hippocampal O 
inputs O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
muscarinic O 
and O 
glutamatergic O 
modulation O 
of O 
long O 
- O 
term O 
depression O 
( O 
LTD O 
) O 
in O 
the O 
intact O 
projections O 
from O 
CA1 O 
to O 
mPFC O 
in O 
vivo O 
. O 
Cortical O 
- O 
evoked O 
responses O 
were O 
recorded O 
in O 
urethane B-TRIVIAL 
-anesthetized O 
rats O 
for O 
30 O 
min O 
during O 
baseline O 
and O 
4 O 
h O 
following O 
LTD O 
. O 
In O 
order O 
to O 
test O 
the O 
potentiating O 
effects O 
of O 
pilocarpine B-TRIVIAL 
( O 
PILO B-ABBREVIATION 
) O 
, O 
independent O 
groups O 
of O 
rats O 
received O 
either O 
a O 
microinjection O 
of O 
PILO B-ABBREVIATION 
( O 
40 O 
nmol O 
; O 
i.c.v O 
. O 
) O 
or O 
vehicle O 
, O 
immediately O 
before O 
or O 
20 O 
min O 
after O 
a O 
sub O 
- O 
threshold O 
LTD O 
protocol O 
( O 
600 O 
pulses O 
, O 
1 O 
Hz O 
; O 
LFS600 O 
) O 
. O 
Other O 
groups O 
received O 
either O 
an O 
infusion O 
of O 
the O 
selective O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
( O 
AP7 B-IDENTIFIER 
; O 
10 O 
nmol O 
; O 
intra-mPFC O 
) O 
or O 
vehicle O 
, O 
10 O 
min O 
prior O 
to O 
PILO B-ABBREVIATION 
preceding O 
LFS600 O 
, O 
or O 
prior O 
to O 
a O 
supra O 
- O 
threshold O 
LTD O 
protocol O 
( O 
900 O 
pulses O 
, O 
1 O 
Hz O 
; O 
LFS900 O 
) O 
. O 
Our O 
results O 
show O 
that O 
PILO B-ABBREVIATION 
converts O 
a O 
transient O 
cortical O 
depression O 
induced O 
by O 
LFS600 O 
into O 
a O 
robust O 
LTD O 
, O 
stable O 
for O 
at O 
least O 
4 O 
h O 
. O 
When O 
applied O 
after O 
LFS600 O 
, O 
PILO B-ABBREVIATION 
does O 
not O 
change O 
either O 
mPFC O 
basal O 
neurotransmission O 
or O 
late O 
LTD O 
. O 
Our O 
data O 
also O 
indicate O 
that O 
NMDA B-ABBREVIATION 
receptor O 
pre O 
- O 
activation O 
is O 
essential O 
to O 
the O 
muscarinic O 
enhancement O 
of O 
mPFC O 
synaptic O 
depression O 
, O 
since O 
AP7 B-IDENTIFIER 
microinjection O 
into O 
the O 
mPFC O 
blocked O 
the O 
conversion O 
of O 
transient O 
depression O 
into O 
long O 
- O 
lasting O 
LTD O 
produced O 
by O 
PILO B-ABBREVIATION 
. O 
In O 
addition O 
, O 
AP7 B-IDENTIFIER 
effectively O 
blocked O 
the O 
long O 
- O 
lasting O 
LTD O 
induced O 
by O 
LFS900 O 
. O 
Therefore O 
, O 
our O 
findings O 
suggest O 
that O 
the O 
glutamatergic O 
co O 
- O 
activation O 
of O 
prefrontal O 
neurons O 
is O 
important O 
for O 
the O 
effects O 
of O 
PILO B-ABBREVIATION 
on O 
mPFC O 
synaptic O 
depression O 
, O 
which O 
could O 
play O 
an O 
important O 
role O 
in O 
the O 
control O 
of O 
executive O 
and O 
emotional O 
functions O 
. O 

effects O 
of O 
α-tocopherol B-TRIVIAL 
on O 
oxidative O 
damage O 
and O 
serum O 
levels O 
of O 
Clara O 
cell O 
protein O 
16 O 
in O 
aspiration O 
pneumonitis O 
induced O 
by O 
bile O 
acids O 
. O 

aim O 
in O 
this O 
study O 
is O 
to O 
examine O 
the O 
effects O 
of O 
α-tocopherol B-TRIVIAL 
( O 
AT O 
) O 
on O 
rats O 
with O 
aspiration O 
pneumonitis O 
induced O 
with O 
bile B-FAMILY 
acids I-FAMILY 
( O 
BAs B-ABBREVIATION 
) O 
. O 
The O 
animals O 
were O 
divided O 
in O 
to O 
four O 
groups O 
, O 
namely O 
saline O 
group O 
( O 
n O 
= O 
7 O 
) O 
, O 
saline O 
+ O 
AT O 
group O 
( O 
n O 
= O 
7 O 
) O 
, O 
BA O 
group O 
( O 
n O 
= O 
7 O 
) O 
, O 
and O 
BA O 
+ O 
AT O 
group O 
( O 
n O 
= O 
7 O 
) O 
. O 
Saline O 
and O 
BA O 
groups O 
aspirated O 
intratracheally O 
with O 
1 O 
ml O 
/ O 
kg O 
saline O 
and O 
1 O 
ml O 
/ O 
kg O 
bile B-FAMILY 
acids I-FAMILY 
, O 
respectively O 
. O 
AT O 
was O 
given O 
at O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
dosage O 
for O 
7 O 
days O 
to O 
the O 
groups O 
. O 
AT O 
group O 
was O 
given O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
AT O 
for O 
7 O 
days O 
. O 
Malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
Clara O 
cell O 
protein O 
16 O 
( O 
CC-16 O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
as O 
well O 
as O 
peribronchial O 
inflammatory O 
cell O 
infiltration O 
, O 
alveolar O 
septal O 
infiltration O 
, O 
alveolar O 
edema O 
, O 
alveolar O 
exudate O 
, O 
alveolar O 
histiocytes O 
, O 
and O 
necrosis O 
were O 
evaluated O 
. O 
The O 
CAT O 
activity O 
of O 
the O 
BA O 
group O 
was O 
significantly O 
lower O 
than O 
the O 
saline O 
group O 
. O 
In O 
the O 
BA O 
+ O 
AT O 
group O 
, O 
there O 
was O 
a O 
significant O 
increase O 
in O 
SOD O 
and O 
CAT O 
activities O 
when O 
compared O 
with O 
that O 
of O 
the O 
BA O 
group O 
. O 
The O 
CC-16 O 
and O 
MDA B-ABBREVIATION 
contents O 
in O 
the O 
BA O 
group O 
were O 
significantly O 
higher O 
than O 
in O 
the O 
saline O 
group O 
. O 
The O 
CC-16 O 
and O 
MDA B-ABBREVIATION 
levels O 
of O 
the O 
BA O 
+ O 
AT O 
group O 
were O 
significantly O 
lower O 
than O 
BA O 
group O 
. O 
Histopathologic O 
changes O 
were O 
seen O 
in O 
BA O 
group O 
, O 
and O 
there O 
was O 
a O 
significant O 
decrease O 
in O 
the O 
BA O 
+ O 
AT O 
group O 
. O 
In O 
conclusion O 
, O 
AT O 
might O 
be O 
beneficial O 
in O 
the O 
treatment O 
of O 
aspiration O 
pneumonitis O 
induced O 
by O 
BAs B-ABBREVIATION 
because O 
AT O 
decreased O 
oxidative O 
damage O 
and O 
resulted O 
in O 
a O 
decrease O 
in O 
CC-16 O 
levels O 
. O 

attenuates O 
hepatotoxicity O 
of O 
rats O 
exposed O 
to O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
. O 

trioxide I-SYSTEMATIC 
( O 
As(2)O(3) B-FORMULA 
) O 
is O 
an O 
environmental O 
pollutant O 
and O 
potent O 
toxicant O 
to O 
humans O 
. O 
However O 
, O 
it O 
also O 
shows O 
substantial O 
anti-cancer O 
activity O 
in O 
individuals O 
with O 
acute O 
promyelocytic O 
leukemia O 
( O 
APL O 
) O 
. O 
Unfortunately O 
, O 
As(2)O(3) B-FORMULA 
-treated O 
leukemia O 
patients O 
suffer O 
hepatotoxicity O 
. O 
Resveratrol B-TRIVIAL 
has O 
been O 
demonstrated O 
to O 
have O 
efficient O 
antioxidant O 
and O 
antineoplastic O 
activities O 
. O 
The O 
study O 
that O 
how O 
As(2)O(3) B-FORMULA 
in O 
combination O 
with O 
resveratrol B-TRIVIAL 
affects O 
hepatotoxicity O 
and O 
arsenic B-SYSTEMATIC 
accumulation O 
in O 
the O 
liver O 
is O 
lacking O 
, O 
and O 
the O 
present O 
study O 
tackles O 
this O 
question O 
. O 
Wistar O 
rats O 
were O 
injected O 
with O 
3mg O 
/ O 
kg O 
As(2)O(3) B-FORMULA 
on O 
alternate O 
days O 
; O 
resveratrol B-TRIVIAL 
( O 
8mg O 
/ O 
kg O 
) O 
was O 
administered O 
1h O 
before O 
As(2)O(3) B-FORMULA 
. O 
Rats O 
were O 
killed O 
on O 
the O 
8th O 
day O 
to O 
determine O 
histological O 
liver O 
damage O 
, O 
the O 
antioxidant O 
enzymes O 
in O 
serum O 
, O 
the O 
ratio O 
of O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
to O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSSG B-ABBREVIATION 
) O 
, O 
and O 
arsenic B-SYSTEMATIC 
accumulation O 
in O 
the O 
liver O 
. O 
In O 
the O 
resveratrol B-TRIVIAL 
+ O 
As(2)O(3) B-FORMULA 
group O 
, O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
in O 
serum O 
and O 
GSH B-ABBREVIATION 
/ O 
GSSG B-ABBREVIATION 
were O 
significantly O 
increased O 
, O 
histopathological O 
effects O 
were O 
reduced O 
, O 
and O 
arsenic B-SYSTEMATIC 
accumulation O 
markedly O 
decreased O 
in O 
the O 
liver O 
, O 
compared O 
with O 
the O 
As(2)O(3) B-FORMULA 
-treated O 
group O 
. O 
Thus O 
, O 
resveratrol B-TRIVIAL 
attenuated O 
As(2)O(3) B-FORMULA 
-induced O 
hepatotoxicity O 
by O 
decreasing O 
oxidative O 
stress O 
and O 
arsenic B-SYSTEMATIC 
accumulation O 
in O 
the O 
liver O 
. O 
These O 
data O 
suggest O 
that O 
use O 
of O 
resveratrol B-TRIVIAL 
as O 
post O 
- O 
remission O 
therapy O 
of O 
APL O 
and O 
adjunctive O 
therapy O 
in O 
patients O 
with O 
chronic O 
exposure O 
to O 
arsenic B-SYSTEMATIC 
may O 
decrease O 
arsenic B-SYSTEMATIC 
hepatotoxicity O 
. O 

mechanistic O 
mass O 
balance O 
bioconcentration O 
model O 
is O 
developed O 
and O 
parameterized O 
for O 
ionogenic O 
organic O 
chemicals O 
( O 
IOCs O 
) O 
in O 
fish O 
and O 
evaluated O 
against O 
a O 
compilation O 
of O 
empirical O 
bioconcentration O 
factors O 
( O 
BCFs O 
) O 
. O 
The O 
model O 
is O 
subsequently O 
applied O 
to O 
a O 
set O 
of O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
. O 
Key O 
aspects O 
of O 
model O 
development O 
include O 
revised O 
methods O 
to O 
estimate O 
the O 
chemical O 
absorption O 
efficiency O 
of O 
IOCs O 
at O 
the O 
respiratory O 
surface O 
( O 
E(W) O 
) O 
and O 
the O 
use O 
of O 
distribution O 
ratios O 
to O 
characterize O 
the O 
overall O 
sorption O 
capacity O 
of O 
the O 
organism O 
. O 
Membrane O 
- O 
water O 
distribution O 
ratios O 
( O 
D(MW) O 
) O 
are O 
used O 
to O 
characterize O 
sorption O 
to O 
phospholipids O 
instead O 
of O 
only O 
considering O 
the O 
octanol B-SYSTEMATIC 
-water O 
distribution O 
ratio O 
( O 
D(OW) O 
) O 
. O 
Modeled O 
BCFs O 
are O 
well O 
correlated O 
with O 
the O 
observations O 
( O 
e.g O 
. O 
, O 
r(2) O 
= O 
0.68 O 
and O 
0.75 O 
for O 
organic O 
acids O 
and O 
bases O 
, O 
respectively O 
) O 
and O 
accurate O 
to O 
within O 
a O 
factor O 
of O 
three O 
on O 
average O 
. O 
Model O 
prediction O 
errors O 
appear O 
to O 
be O 
largely O 
the O 
result O 
of O 
uncertainties O 
in O 
the O 
biotransformation O 
rate O 
constant O 
( O 
k(M) O 
) O 
estimates O 
and O 
the O 
generic O 
approaches O 
for O 
estimating O 
sorption O 
capacity O 
( O 
e.g O 
. O 
, O 
D(MW) O 
) O 
. O 
Model O 
performance O 
for O 
the O 
set O 
of O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
considered O 
is O 
highly O 
dependent O 
on O 
the O 
input O 
parameters O 
describing O 
hydrophobicity O 
( O 
i.e O 
. O 
, O 
log O 
K(OW) O 
of O 
the O 
neutral O 
form O 
) O 
. O 
The O 
model O 
applications O 
broadly O 
support O 
the O 
hypothesis O 
that O 
phospholipids O 
contribute O 
substantially O 
to O 
the O 
sorption O 
capacity O 
of O 
fish O 
, O 
particularly O 
for O 
compounds O 
that O 
exhibit O 
a O 
high O 
degree O 
of O 
ionization O 
at O 
biologically O 
relevant O 
pH O 
. O 
Additional O 
empirical O 
data O 
on O 
biotransformation O 
and O 
sorption O 
to O 
phospholipids O 
and O 
subsequent O 
incorporation O 
into O 
property O 
estimation O 
approaches O 
( O 
e.g O 
. O 
, O 
k(M) O 
, O 
D(MW) O 
) O 
are O 
priorities O 
with O 
respect O 
to O 
improving O 
model O 
performance O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effects O 
of O 
Cassia O 
tora O 
seeds O 
on O 
high O 
- O 
fat O 
diet O 
(HFD)-induced O 
hepatic O 
steatosis O 
, O 
and O 
elucidate O 
the O 
molecular O 
mechanisms O 
behind O 
its O 
effects O 
. O 
After O 
being O 
fed O 
a O 
HFD O 
for O 
two O 
weeks O 
, O 
rats O 
were O 
orally O 
dosed O 
with O 
Cassia O 
seed O 
ethanol B-SYSTEMATIC 
extract O 
( O 
CSEE O 
) O 
( O 
100 O 
, O 
200 O 
, O 
or O 
300mg O 
/ O 
kg O 
) O 
once O 
daily O 
for O 
8weeks O 
. O 
CSEE O 
induced O 
dose O 
- O 
dependent O 
reductions O 
in O 
plasma O 
lipid O 
levels O 
, O 
as O 
well O 
as O 
decreased O 
the O 
over O 
hepatic O 
lipid O 
accumulation O 
. O 
Furthermore O 
, O 
CSEE O 
treatment O 
improved O 
HFD-induced O 
hepatic O 
histological O 
lesions O 
. O 
CSEE O 
enhanced O 
the O 
phosphorylation O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
and O 
its O 
primary O 
downstream O 
targeting O 
enzyme O 
, O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
, O 
up O 
- O 
regulated O 
the O 
gene O 
expression O 
of O 
carnitine B-TRIVIAL 
palmitoyl I-TRIVIAL 
transferase O 
1 O 
, O 
and O 
down O 
- O 
regulated O 
sterol B-FAMILY 
regulatory O 
element O 
binding O 
protein O 
1 O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
protein O 
levels O 
in O 
the O 
livers O 
of O 
HFD-fed O 
rats O 
. O 
AMPK O 
inhibition O 
by O 
compound O 
C O 
retarded O 
CSEE-induced O 
reduction O 
in O 
triglyceride B-FAMILY 
accumulation O 
in O 
HepG2 O 
cells O 
stimulated O 
by O 
insulin O 
. O 
Our O 
findings O 
suggest O 
that O 
CSEE O 
may O 
regulate O 
hepatic O 
lipid O 
homeostasis O 
related O 
with O 
an O 
AMPK-dependent O 
signaling O 
pathway O 
. O 
Targeting O 
AMPK O 
activation O 
with O 
CSEE O 
may O 
represent O 
a O 
promising O 
approach O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
obesity O 
- O 
related O 
non-alcoholic O 
fatty O 
liver O 
disease O 
. O 

of O 
CYP3A4 O 
leads O 
to O 
important O 
role O 
of O 
CYP2C8 O 
in O 
imatinib B-TRIVIAL 
metabolism O 
: O 
variability O 
in O 
CYP2C8 O 
activity O 
may O 
alter O 
plasma O 
concentrations O 
and O 
response O 
. O 

data O 
suggest O 
that O 
the O 
role O 
of O 
CYP3A4 O 
in O 
imatinib B-TRIVIAL 
metabolism O 
is O 
smaller O 
than O 
presumed O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
the O 
quantitative O 
importance O 
of O 
different O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzymes O 
in O 
imatinib B-TRIVIAL 
pharmacokinetics O 
. O 
First O 
, O 
the O 
metabolism O 
of O 
imatinib B-TRIVIAL 
was O 
investigated O 
using O 
recombinant O 
P450 O 
enzymes O 
and O 
human O 
liver O 
microsomes O 
with O 
P450 O 
isoform O 
- O 
selective O 
inhibitors O 
. O 
Thereafter O 
, O 
an O 
in O 
silico O 
model O 
for O 
imatinib B-TRIVIAL 
was O 
constructed O 
to O 
perform O 
pharmacokinetic O 
simulations O 
to O 
assess O 
the O 
roles O 
of O 
P450 O 
enzymes O 
in O 
imatinib B-TRIVIAL 
elimination O 
at O 
clinically O 
used O 
imatinib B-TRIVIAL 
doses O 
. O 
In O 
vitro O 
, O 
CYP2C8 O 
inhibitors O 
and O 
CYP3A4 O 
inhibitors O 
inhibited O 
the O 
depletion O 
of O 
0.1 O 
µM O 
imatinib B-TRIVIAL 
by O 
45 O 
and O 
80% O 
, O 
respectively O 
, O 
and O 
the O 
formation O 
of O 
the O 
main O 
metabolite O 
of O 
imatinib B-TRIVIAL 
, O 
N-desmethylimatinib B-SYSTEMATIC 
, O 
by O 
> O 
50% O 
. O 
Likewise O 
, O 
recombinant O 
CYP2C8 O 
and O 
CYP3A4 O 
metabolized O 
imatinib B-TRIVIAL 
extensively O 
, O 
whereas O 
other O 
isoforms O 
had O 
minor O 
effect O 
on O 
imatinib B-TRIVIAL 
concentrations O 
. O 
In O 
the O 
beginning O 
of O 
imatinib B-TRIVIAL 
treatment O 
, O 
the O 
fractions O 
of O 
its O 
hepatic O 
clearance O 
mediated O 
by O 
CYP2C8 O 
and O 
CYP3A4 O 
were O 
predicted O 
to O 
approximate O 
40 O 
and O 
60% O 
, O 
respectively O 
. O 
During O 
long O 
- O 
term O 
treatment O 
with O 
imatinib B-TRIVIAL 
400 O 
mg O 
once O 
or O 
twice O 
daily O 
, O 
up O 
to O 
65 O 
or O 
75% O 
of O 
its O 
hepatic O 
elimination O 
was O 
predicted O 
to O 
occur O 
via O 
CYP2C8 O 
, O 
and O 
only O 
about O 
35 O 
or O 
25% O 
by O 
CYP3A4 O 
, O 
due O 
to O 
dose- O 
and O 
time O 
- O 
dependent O 
autoinactivation O 
of O 
CYP3A4 O 
by O 
imatinib B-TRIVIAL 
. O 
Thus O 
, O 
although O 
CYP2C8 O 
and O 
CYP3A4 O 
are O 
the O 
main O 
enzymes O 
in O 
imatinib B-TRIVIAL 
metabolism O 
in O 
vitro O 
, O 
in O 
silico O 
predictions O 
indicate O 
that O 
imatinib B-TRIVIAL 
inhibits O 
its O 
own O 
CYP3A4 O 
- O 
mediated O 
metabolism O 
, O 
assigning O 
a O 
key O 
role O 
for O 
CYP2C8 O 
. O 
During O 
multiple O 
dosing O 
, O 
pharmacogenetic O 
polymorphisms O 
and O 
drug O 
interactions O 
affecting O 
CYP2C8 O 
activity O 
may O 
cause O 
marked O 
interindividual O 
variation O 
in O 
the O 
exposure O 
and O 
response O 
to O 
imatinib B-TRIVIAL 
. O 

growth O 
of O 
heteroepitaxially O 
strained O 
semiconductors O 
at O 
the O 
nanoscale O 
enables O 
tailoring O 
of O 
material O 
properties O 
for O 
enhanced O 
device O 
performance O 
. O 
For O 
core O 
/ O 
shell O 
nanowires O 
( O 
NWs O 
) O 
, O 
theoretical O 
predictions O 
of O 
the O 
coherency O 
limits O 
and O 
the O 
implications O 
they O 
carry O 
remain O 
uncertain O 
without O 
proper O 
identification O 
of O 
the O 
mechanisms O 
by O 
which O 
strains O 
relax O 
. O 
We O 
present O 
here O 
for O 
the O 
Ge B-FORMULA 
/ O 
Si B-FORMULA 
core O 
/ O 
shell O 
NW O 
system O 
the O 
first O 
experimental O 
measurement O 
of O 
critical O 
shell O 
thickness O 
for O 
strain O 
relaxation O 
in O 
a O 
semiconductor O 
NW O 
heterostructure O 
and O 
the O 
identification O 
of O 
the O 
relaxation O 
mechanisms O 
. O 
Axial O 
and O 
tangential O 
strain O 
relief O 
is O 
initiated O 
by O 
the O 
formation O 
of O 
periodic O 
a O 
/ O 
2 O 
⟨110⟩ O 
perfect O 
dislocations O 
via O 
nucleation O 
and O 
glide O 
on O 
{ O 
111 O 
} O 
slip O 
- O 
planes O 
. O 
Glide O 
of O 
dislocation O 
segments O 
is O 
directly O 
confirmed O 
by O 
real O 
- O 
time O 
in O 
situ O 
transmission O 
electron O 
microscope O 
observations O 
and O 
by O 
dislocation O 
dynamics O 
simulations O 
. O 
Further O 
shell O 
growth O 
leads O 
to O 
roughening O 
and O 
grain O 
formation O 
which O 
provides O 
additional O 
strain O 
relief O 
. O 
As O 
a O 
consequence O 
of O 
core O 
/ O 
shell O 
strain O 
sharing O 
in O 
NWs O 
, O 
a O 
16 O 
nm O 
radius O 
Ge B-FORMULA 
NW O 
with O 
a O 
3 O 
nm O 
Si B-FORMULA 
shell O 
is O 
shown O 
to O 
accommodate O 
3% O 
coherent O 
strain O 
at O 
equilibrium O 
, O 
a O 
factor O 
of O 
3 O 
increase O 
over O 
the O 
1 O 
nm O 
equilibrium O 
critical O 
thickness O 
for O 
planar O 
Si B-FORMULA 
/ O 
Ge B-FORMULA 
heteroepitaxial O 
growth O 
. O 

vitro O 
metabolism O 
of O 
the O 
5-hydroxytryptamine1B O 
receptor O 
antagonist O 
elzasonan B-TRIVIAL 
. O 

metabolism O 
of O 
elzasonan B-TRIVIAL 
has O 
been O 
examined O 
in O 
vitro O 
using O 
hepatic O 
microsomes O 
from O 
human O 
and O 
recombinant O 
heterologously O 
expressed O 
P450 O 
enzymes O 
( O 
rCYP O 
) O 
. O 
Metabolism O 
occurs O 
primarily O 
via O 
oxidative O 
N B-FORMULA 
-demethylation O 
to O 
form O 
M4 O 
and O 
oxidation O 
reactions O 
to O 
form O 
elzasonan B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
( O 
M5 O 
) O 
and O 
5-hydroxyelzasonan B-SYSTEMATIC 
metabolite O 
( O 
M3 O 
) O 
. O 
Additionally O 
, O 
elzasonan B-TRIVIAL 
was O 
shown O 
to O 
be O 
metabolized O 
to O 
the O 
novel O 
cyclized O 
indole B-SYSTEMATIC 
metabolite O 
( O 
M6 O 
) O 
which O 
undergoes O 
subsequent O 
oxidation O 
to O 
form O 
the O 
iminium B-SYSTEMATIC 
ion O 
metabolite O 
( O 
M3a O 
) O 
. O 
The O 
rCYP O 
data O 
was O 
normalized O 
relative O 
to O 
the O 
levels O 
of O 
each O 
CYP O 
form O 
in O 
native O 
human O 
liver O 
microsomes O 
to O 
better O 
assess O 
the O 
contribution O 
of O 
each O 
rCYP O 
in O 
the O 
metabolism O 
of O 
elzasonan B-TRIVIAL 
. O 
Results O 
demonstrated O 
the O 
involvement O 
of O 
CYP3A4 O 
in O 
the O 
pathways O 
leading O 
to O 
M3a O 
, O 
M3 O 
, O 
M5 O 
and O 
M6 O 
and O 
CYP2C8 O 
in O 
the O 
formation O 
of O 
M4 O 
. O 
Kinetic O 
constants O 
for O 
the O 
formation O 
of O 
M3 O 
were O 
determined O 
and O 
correlation O 
and O 
inhibition O 
studies O 
suggested O 
that O 
CYP3A4 O 
is O 
primarily O 
responsible O 
for O 
the O 
formation O 
of O 
M3 O 
and O 
CYP2C19 O 
plays O 
a O 
very O 
minor O 
role O 
in O 
its O 
formation O 
. O 
Cytochrome O 
b5 O 
has O 
shown O 
to O 
be O 
an O 
essential O 
component O 
in O 
P450 O 
3A4 O 
catalyzed O 
5-hydroxyelzasonan B-SYSTEMATIC 
formation O 
and O 
provides O 
insights O 
on O 
the O 
disconnect O 
between O 
human O 
liver O 
microsomes O 
data O 
and O 
that O 
of O 
rCYP O 
. O 
Furthermore O 
, O 
rCYP3A4 O 
containing O 
b5 O 
are O 
useful O 
models O 
for O 
predicting O 
the O 
rates O 
for O 
liver O 
microsomes O 
P450-dependent O 
drug O 
oxidations O 
and O 
should O 
be O 
utilized O 
routinely O 
. O 

cell O 
lines O 
and O 
primary O 
cells O 
in O 
culture O 
, O 
precision O 
- O 
cut O 
tissue O 
slices O 
remain O 
metabolically O 
differentiated O 
for O 
at O 
least O 
24-48 O 
h O 
and O 
allow O 
to O 
study O 
the O 
effect O 
of O 
xenobiotics O 
during O 
short O 
- O 
term O 
and O 
long O 
- O 
term O 
incubations O 
. O 
2.In O 
this O 
article O 
, O 
we O 
illustrate O 
the O 
use O 
of O 
such O 
an O 
experimental O 
model O 
to O 
study O 
the O 
nephrotoxic O 
effects O 
of O 
(i) O 
chloroacetaldehyde B-SYSTEMATIC 
, O 
a O 
metabolite O 
of O 
the O 
anticancer O 
drug O 
ifosfamide B-TRIVIAL 
, O 
(ii) O 
of O 
cobalt B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
a O 
potential O 
leakage O 
product O 
of O 
the O 
cobalt B-SYSTEMATIC 
-containing O 
nanoparticles O 
, O 
and O 
(iii) O 
of O 
valproate B-SYSTEMATIC 
, O 
a O 
widely O 
used O 
antiepileptic O 
drug O 
. O 
3.Since O 
all O 
the O 
latter O 
test O 
compounds O 
, O 
like O 
many O 
toxic O 
compounds O 
, O 
negatively O 
interact O 
with O 
cellular O 
metabolic O 
pathways O 
, O 
we O 
also O 
illustrate O 
our O 
biochemical O 
toxicology O 
approach O 
in O 
which O 
we O 
used O 
not O 
only O 
enzymatic O 
but O 
also O 
carbon B-SYSTEMATIC 
13 I-SYSTEMATIC 
NMR O 
measurements O 
and O 
mathematical O 
modelling O 
of O 
metabolic O 
pathways O 
. O 
4.This O 
original O 
approach O 
, O 
which O 
can O 
be O 
applied O 
to O 
any O 
tissue O 
, O 
allows O 
to O 
predict O 
the O 
nephrotoxic O 
effects O 
of O 
milligram O 
amounts O 
of O 
test O 
compounds O 
very O 
early O 
during O 
the O 
research O 
and O 
development O 
processes O 
of O 
drugs O 
and O 
chemicals O 
. O 
This O 
approach O 
, O 
combined O 
with O 
the O 
use O 
of O 
cells O 
that O 
retain O 
their O 
in O 
vivo O 
metabolic O 
properties O 
and O 
, O 
therefore O 
, O 
are O 
predictive O 
, O 
reduces O 
the O 
risk O 
, O 
the O 
time O 
and O 
cost O 
of O 
such O 
processes O 
. O 

anchored O 
to O 
residue O 
N297 O 
of O 
the O 
antibody O 
IgG O 
Fc O 
domain O 
are O 
critical O 
in O 
mediating O 
binding O 
toward O 
FcγRs O 
to O 
direct O 
both O 
adaptive O 
and O 
innate O 
immune O 
responses O 
. O 
However O 
, O 
using O 
a O 
full O 
length O 
bacterial O 
IgG O 
display O 
system O 
, O 
we O 
have O 
isolated O 
aglycosylated O 
Fc O 
domains O 
with O 
mutations O 
that O 
confer O 
up O 
to O 
a O 
160-fold O 
increase O 
in O 
the O 
affinity O 
toward O 
the O 
low O 
affinity O 
FcγRIIa-R131 O 
allele O 
as O 
well O 
as O 
high O 
selectivity O 
against O 
binding O 
to O 
the O 
remarkably O 
homologous O 
human O 
inhibitory O 
receptor O 
, O 
FcγRIIb O 
. O 
The O 
mutant O 
Fc O 
domain O 
( O 
AglycoT-Fc1004 O 
) O 
contained O 
a O 
total O 
of O 
5 O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
that O 
conferred O 
an O 
activating O 
to O 
inhibitory O 
ratio O 
of O 
25 O 
( O 
A O 
/ O 
I O 
ratio O 
; O 
FcyRIIa-R131 O 
: O 
FcγRIIb O 
) O 
. O 
Incorporation O 
of O 
this O 
engineered O 
Fc O 
into O 
trastuzumab O 
, O 
an O 
anti-Her2 O 
antibody O 
, O 
resulted O 
in O 
a O 
75% O 
increase O 
in O 
tumor O 
cell O 
phagocytosis O 
by O 
macrophages O 
compared O 
to O 
that O 
of O 
the O 
parental O 
glycosylated O 
trastuzumab O 
with O 
both O 
medium O 
and O 
low O 
Her2-expressing O 
cancer O 
cells O 
. O 
A O 
mathematical O 
model O 
has O 
been O 
developed O 
to O 
help O 
explain O 
how O 
receptor O 
affinity O 
and O 
the O 
A O 
/ O 
I O 
ratio O 
relate O 
to O 
improved O 
antibody O 
dependent O 
cell O 
- O 
mediated O 
phagocytosis O 
. O 
Our O 
model O 
provides O 
guidelines O 
for O 
the O 
future O 
engineering O 
of O 
Fc O 
domains O 
with O 
enhanced O 
effector O 
function O 
. O 

isolated O 
from O 
the O 
rhizomes O 
of O 
Reynoutria O 
elliptica O 
exerts O 
neuroprotective O 
effects O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

ganglion O 
cells O 
( O 
RGCs O 
) O 
death O 
caused O 
by O 
oxidative O 
stress O 
is O 
a O 
common O 
risk O 
factor O 
for O 
glaucoma O 
. O 
In O 
the O 
present O 
study O 
, O 
8-hydroxycalamenene B-SYSTEMATIC 
was O 
isolated O 
from O 
the O 
hexane B-SYSTEMATIC 
fraction O 
of O 
Reynoutria O 
elliptica O 
. O 
We O 
showed O 
that O 
8-hydroxycalamenene B-SYSTEMATIC 
attenuated O 
the O 
cell O 
death O 
of O 
transformed O 
RGC-5 O 
cells O 
. O 
This O 
compound O 
also O 
produced O 
a O 
dose O 
- O 
dependent O 
decrease O 
in O 
the O 
expression O 
of O 
apoptotic O 
proteins O 
( O 
cleaved O 
PARP O 
and O 
caspase-3 O 
) O 
induced O 
by O 
l-buthionine-(S,R)-sulfoximine B-SYSTEMATIC 
( O 
BSO B-ABBREVIATION 
) O 
plus O 
glutamate B-TRIVIAL 
and O 
stimulated O 
glutathione B-TRIVIAL 
and O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
activity O 
. O 
Moreover O 
, O 
the O 
addition O 
of O 
8-hydroxycalamenene B-SYSTEMATIC 
to O 
cell O 
cultures O 
restored O 
the O 
reduced O 
mitochondrial O 
membrane O 
potential O 
resulting O 
from O 
glutamate B-TRIVIAL 
/ O 
BSO B-ABBREVIATION 
treatment O 
. O 
The O 
presence O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
in O 
the O 
retina O 
of O 
rats O 
affected O 
the O 
thickness O 
of O 
the O 
inner O 
plexiform O 
layer O 
( O 
IPL O 
) O 
and O 
increased O 
the O 
number O 
of O 
TUNEL-positive O 
RGCs O 
. O 
However O 
, O 
8-hydroxycalamenene B-SYSTEMATIC 
protected O 
against O 
thinning O 
of O 
the O 
IPL O 
and O 
reduced O 
TUNEL-positive O 
cells O 
in O 
the O 
ganglion O 
cell O 
layer O 
. O 
Thus O 
, O 
8-hydroxycalamenene B-SYSTEMATIC 
isolated O 
from O 
R O 
. O 
elliptica O 
exerts O 
neuroprotective O 
effects O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

anion O 
transporting O 
polypeptides O 
( O 
rodents O 
, O 
Oatps O 
; O 
human O 
, O 
OATPs O 
) O 
are O 
primarily O 
involved O 
in O 
the O 
transmembrane O 
transportation O 
of O 
a O 
wide O 
range O 
of O 
endogenous O 
and O 
exogenous O 
compounds O 
. O 
Multiple O 
mouse O 
Oatp1 O 
isoforms O 
are O 
closely O 
located O 
on O 
chromosome O 
6 O 
, O 
where O 
each O 
isoform O 
shows O 
distinct O 
tissue O 
distribution O 
; O 
Oatp1b2 O 
, O 
Oatp1a6 O 
, O 
and O 
Oatp1c1 O 
are O 
expressed O 
exclusively O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
cerebrum O 
, O 
respectively O 
; O 
Oatp1a1 O 
in O 
the O 
liver O 
and O 
kidney O 
; O 
and O 
Oatp1a4 O 
in O 
the O 
liver O 
and O 
cerebrum O 
. O 
We O 
have O 
identified O 
tissue O 
- O 
dependent O 
differentially O 
methylated O 
region O 
( O 
T-DMR O 
) O 
around O 
the O 
transcriptional O 
start O 
site O 
( O 
TSS O 
) O 
of O 
Oatp1b2 O 
, O 
which O 
correlates O 
with O 
its O 
liver O 
- O 
specific O 
expression O 
. O 
Bisulfite B-SYSTEMATIC 
sequencing O 
also O 
demonstrated O 
the O 
presence O 
of O 
T-DMRs O 
around O 
the O 
TSS O 
in O 
other O 
Oatp1 O 
genes O 
: O 
CpG O 
dinucleotides O 
at O 
+ O 
149 O 
relative O 
to O 
the O 
TSS O 
for O 
Oatp1c1 O 
; O 
-48 O 
, O 
+ O 
101 O 
, O 
and O 
+ O 
356 O 
for O 
Oatp1a4 O 
; O 
-572 O 
and O 
-550 O 
for O 
Oatp1a1 O 
; O 
and O 
-122 O 
and O 
+ O 
216 O 
for O 
Oatp1a6 O 
were O 
differentially O 
methylated O 
among O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
cerebrum O 
. O 
These O 
methylation O 
profiles O 
were O 
largely O 
consistent O 
with O 
the O 
tissue O 
distribution O 
of O 
Oatp1 O 
mRNAs O 
. O 
Chromatin O 
immunoprecipitation O 
assay O 
revealed O 
that O 
the O 
mRNA O 
expression O 
of O 
Oatp1 O 
genes O 
was O 
accompanied O 
by O 
acetylated O 
histone O 
H3 O 
. O 
Human O 
OATP1B1 O 
and O 
OATP1B3 O 
are O 
located O 
on O 
chromosome O 
12p12 O 
in O 
the O 
OATP1 O 
cluster O 
; O 
both O 
show O 
predominant O 
expression O 
in O 
the O 
liver O 
. O 
These O 
genes O 
also O 
contained O 
T-DMRs O 
that O 
were O 
hypomethylated O 
in O 
the O 
liver O 
, O 
compared O 
with O 
kidney O 
cortex O 
: O 
-511 O 
, O 
-411 O 
, O 
and O 
+ O 
92 O 
relative O 
to O 
the O 
TSS O 
for O 
OATP1B1 O 
and O 
-331 O 
, O 
+ O 
70 O 
, O 
and O 
+ O 
73 O 
for O 
OATP1B3 O 
. O 
These O 
results O 
suggest O 
that O 
the O 
difference O 
in O 
epigenetic O 
profiles O 
comprising O 
DNA O 
methylation O 
and O 
histone O 
acetylation O 
determines O 
the O 
distinct O 
tissue O 
distribution O 
of O 
Oatp O 
/ O 
OATP O 
mRNAs O 
. O 

and O 
reactive O 
nitrogen B-SYSTEMATIC 
species O 
( O 
RNS O 
) O 
are O 
key O 
regulators O 
of O 
redox O 
homeostasis O 
in O 
living O 
organisms O 
including O 
plants O 
. O 
As O 
control O 
of O 
redox O 
homeostasis O 
plays O 
a O 
central O 
function O 
in O 
plant O 
biology O 
, O 
redox O 
proteomics O 
could O 
help O 
in O 
characterizing O 
the O 
potential O 
roles O 
played O 
by O 
ROS O 
/ O 
RNS-induced O 
posttranslational O 
modification O 
in O 
plant O 
cells O 
. O 
In O 
this O 
review O 
, O 
we O 
focus O 
on O 
two O 
posttranslational O 
modifications O 
: O 
protein O 
carbonylation O 
( O 
a O 
marker O 
of O 
protein O 
oxidation O 
) O 
and O 
protein O 
S B-FORMULA 
-nitrosylation O 
, O 
both O 
of O 
which O 
having O 
recently O 
emerged O 
as O 
important O 
regulatory O 
mechanisms O 
during O 
numerous O 
fundamental O 
biological O 
processes O 
. O 
Here O 
, O 
we O 
describe O 
the O 
recent O 
progress O 
in O 
proteomic O 
analysis O 
of O 
carbonylated O 
and O 
nitrosylated O 
proteins O 
and O 
highlight O 
the O 
achievements O 
made O 
in O 
understanding O 
the O 
physiological O 
basis O 
of O 
these O 
oxy B-SYSTEMATIC 
/ O 
nitro B-SYSTEMATIC 
modifications O 
in O 
plants O 
. O 
In O 
addition O 
, O 
we O 
document O 
the O 
existence O 
of O 
a O 
relationship O 
between O 
ROS O 
- O 
based O 
carbonylation O 
and O 
RNS O 
- O 
based O 
nitrosylation O 
thus O 
supporting O 
the O 
finding O 
that O 
crosstalk O 
between O 
cellular O 
signaling O 
stress O 
pathways O 
induced O 
by O 
ROS O 
and O 
RNS O 
could O 
be O 
mediated O 
by O 
specific O 
protein O 
modifications O 
. O 

the O 
ultimate O 
aim O 
of O 
increasing O 
the O 
utility O 
of O 
in O 
vitro O 
assays O 
for O 
toxicological O 
risk O 
assessment O 
, O 
a O 
method O 
was O 
developed O 
to O 
calculate O 
in O 
vivo O 
estrogenic O 
potencies O 
from O 
in O 
vitro O 
estrogenic O 
potencies O 
of O 
compounds O 
by O 
taking O 
into O 
account O 
systemic O 
availability O 
. O 
In O 
vitro O 
estrogenic O 
potencies O 
of O 
three O 
model O 
compounds O 
( O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
, O 
genistein B-TRIVIAL 
, O 
and O 
4-nonylphenol B-SYSTEMATIC 
) O 
relative O 
to O 
ethinylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
, O 
determined O 
with O 
the O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
transcriptional O 
activation O 
assay O 
using O 
hER-HeLa-9903 O 
cells O 
, O 
were O 
taken O 
from O 
literature O 
and O 
used O 
to O 
calculate O 
the O 
EE2 B-ABBREVIATION 
equivalent O 
( O 
EE2EQ O 
) O 
effect O 
doses O 
in O 
the O 
predominantly O 
ERα-dependent O 
rat O 
uterotrophic O 
assay O 
. O 
Compound O 
- O 
specific O 
differences O 
in O 
hepatic O 
clearance O 
relative O 
to O 
the O 
reference O 
compound O 
EE2 B-ABBREVIATION 
were O 
determined O 
in O 
vitro O 
to O 
examine O 
whether O 
in O 
vivo O 
estrogenic O 
potencies O 
reported O 
in O 
literature O 
could O 
be O 
more O 
accurately O 
estimated O 
. O 
The O 
EE2EQ O 
doses O 
allowed O 
to O 
predict O 
in O 
vivo O 
uterotrophic O 
responses O 
within O 
a O 
factor O 
of O 
6-25 O 
and O 
the O 
inclusion O 
of O 
the O 
hepatic O 
clearance O 
further O 
improved O 
the O 
prediction O 
with O 
a O 
factor O 
1.6-2.1 O 
for O 
especially O 
genistein B-TRIVIAL 
and O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
. O 
Yet O 
, O 
the O 
model O 
compounds O 
still O 
were O 
less O 
potent O 
in O 
vivo O 
than O 
predicted O 
based O 
on O 
their O 
EE2 B-ABBREVIATION 
equivalent O 
estrogenic O 
potency O 
and O 
hepatic O 
clearance O 
. O 
For O 
further O 
improvement O 
of O 
the O 
in O 
vitro O 
to O 
in O 
vivo O 
predictive O 
value O 
of O 
in O 
vitro O 
assays O 
, O 
the O 
relevance O 
of O 
other O 
kinetic O 
characteristics O 
should O 
be O 
studied O 
, O 
including O 
binding O 
to O 
carrier O 
proteins O 
, O 
oral O 
bioavailability O 
and O 
the O 
formation O 
of O 
estrogenic O 
metabolites O 
. O 

photosystem O 
II O 
water O 
oxidation O 
centre O 
analogues O 
in O 
visible O 
light O 
oxygen B-SYSTEMATIC 
and O 
H+ B-FORMULA 
generation O 
. O 

manganese I-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
for O 
application O 
in O 
water O 
oxidation O 
are O 
synthesized O 
by O 
combination O 
with O 
a O 
carboxylated O 
biopolymer O 
stabilizing O 
agent O 
to O 
form O 
very O 
simple O 
but O 
effective O 
analogues O 
of O 
the O 
photosynthetic O 
PSII O 
oxygen B-SYSTEMATIC 
evolving O 
complex O 
. O 
The O 
relative O 
efficiency O 
of O 
these O 
materials O 
for O 
production O 
of O 
O(2) B-FORMULA 
and O 
protons O 
under O 
visible O 
light O 
- O 
promoted O 
reactions O 
is O 
evaluated O 
and O 
prolonged O 
reaction O 
lifetimes O 
are O 
observed O 
. O 

proteins O 
belong O 
to O 
a O 
family O 
of O 
ser B-FORMULA 
/ O 
thr B-FORMULA 
kinases O 
composed O 
of O 
3 O 
members O 
, O 
PIM1 O 
, O 
PIM2 O 
and O 
PIM3 O 
, O 
with O 
greatly O 
overlapping O 
functions O 
. O 
PIM O 
kinases O 
are O 
mainly O 
responsible O 
for O 
cell O 
cycle O 
regulation O 
, O 
antiapoptotic O 
activity O 
and O 
the O 
homing O 
and O 
migration O 
of O 
receptor O 
tyrosine B-TRIVIAL 
kinases O 
mediated O 
via O 
the O 
JAK O 
/ O 
STAT O 
pathway O 
. O 
PIM O 
kinases O 
have O 
been O 
found O 
to O 
be O 
upregulated O 
in O 
many O 
hematological O 
malignancies O 
and O 
solid O 
tumors O 
. O 
Although O 
these O 
kinases O 
have O 
been O 
described O 
as O 
weak O 
oncogenes O 
, O 
they O 
are O 
heavily O 
targeted O 
for O 
anticancer O 
drug O 
discovery O 
. O 
The O 
present O 
review O 
summarizes O 
the O 
discoveries O 
made O 
to O 
date O 
regarding O 
PIM O 
kinases O 
as O 
driving O 
oncogenes O 
in O 
the O 
process O 
of O 
tumorigenesis O 
and O 
their O 
validation O 
as O 
drug O 
targets O 
. O 

of O 
combined O 
treatment O 
with O 
eldecalcitol B-TRIVIAL 
and O 
alendronate B-TRIVIAL 
on O 
bone O 
mass O 
, O 
mechanical O 
properties O 
, O 
and O 
bone O 
histomorphometry O 
in O 
ovariectomized O 
rats O 
: O 
a O 
comparison O 
with O 
alfacalcidol B-TRIVIAL 
and O 
alendronate B-TRIVIAL 
. O 

( O 
ELD B-ABBREVIATION 
) O 
, O 
a O 
2β-hydroxypropyloxy B-SYSTEMATIC 
derivative O 
of O 
1α,25 B-SYSTEMATIC 
( I-SYSTEMATIC 
OH I-SYSTEMATIC 
) I-SYSTEMATIC 
2D3 I-SYSTEMATIC 
, O 
inhibits O 
bone O 
resorption O 
more O 
potently O 
than O 
alfacalcidol B-TRIVIAL 
( O 
ALF B-ABBREVIATION 
) O 
while O 
maintaining O 
osteoblastic O 
function O 
in O 
an O 
ovariectomized O 
( O 
OVX O 
) O 
osteoporosis O 
rat O 
model O 
. O 
Alendronate B-TRIVIAL 
( O 
ALN B-ABBREVIATION 
) O 
, O 
which O 
is O 
the O 
most O 
common O 
bisphosphonate B-SYSTEMATIC 
used O 
for O 
the O 
treatment O 
of O 
osteoporosis O 
, O 
increases O 
the O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
by O 
suppressing O 
bone O 
resorption O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
combination O 
treatments O 
with O 
ELD B-ABBREVIATION 
and O 
ALN B-ABBREVIATION 
or O 
with O 
ALF B-ABBREVIATION 
and O 
ALN B-ABBREVIATION 
on O 
bone O 
mass O 
and O 
strength O 
in O 
OVX O 
rats O 
. O 
Seventy O 
female O 
rats O 
, O 
32 O 
weeks O 
old O 
, O 
were O 
assigned O 
to O 
seven O 
groups O 
: O 
( O 
1 O 
) O 
a O 
sham O 
- O 
operated O 
control O 
group O 
; O 
( O 
2 O 
) O 
an O 
OVX-control O 
group O 
; O 
( O 
3 O 
) O 
an O 
ELD B-ABBREVIATION 
group O 
; O 
( O 
4 O 
) O 
an O 
ALF B-ABBREVIATION 
group O 
; O 
( O 
5 O 
) O 
an O 
ALN B-ABBREVIATION 
group O 
; O 
( O 
6 O 
) O 
an O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
group O 
; O 
and O 
( O 
7 O 
) O 
an O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
group O 
. O 
OVX O 
rats O 
were O 
orally O 
treated O 
with O 
ELD B-ABBREVIATION 
( O 
0.015 O 
μg O 
/ O 
kg O 
) O 
, O 
ALF B-ABBREVIATION 
( O 
0.0375 O 
μg O 
/ O 
kg O 
) O 
, O 
or O 
ALN B-ABBREVIATION 
( O 
0.2mg O 
/ O 
kg O 
) O 
daily O 
for O 
12 O 
weeks O 
. O 
In O 
both O 
the O 
lumbar O 
spine O 
and O 
the O 
femur O 
, O 
ELD B-ABBREVIATION 
and O 
ALF B-ABBREVIATION 
monotherapy O 
significantly O 
increased O 
the O 
BMD O 
, O 
and O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
and O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
significantly O 
increased O 
the O 
BMD O 
, O 
compared O 
with O 
ALN B-ABBREVIATION 
monotherapy O 
, O 
as O 
an O 
additive O 
effect O 
. O 
In O 
particular O 
, O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
resulted O 
in O 
a O 
significantly O 
higher O 
BMD O 
than O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
in O 
the O 
femur O 
. O 
On O 
mechanical O 
testing O 
of O 
the O 
lumbar O 
spine O 
, O 
ELD B-ABBREVIATION 
and O 
ALF B-ABBREVIATION 
monotherapy O 
significantly O 
increased O 
the O 
ultimate O 
load O 
, O 
and O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
and O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
significantly O 
increased O 
the O 
ultimate O 
load O 
compared O 
with O 
ALN B-ABBREVIATION 
monotherapy O 
. O 
In O 
the O 
femur O 
, O 
ELD B-ABBREVIATION 
, O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
, O 
and O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
treatment O 
significantly O 
increased O 
the O 
ultimate O 
load O 
, O 
compared O 
with O 
the O 
OVX-control O 
group O 
, O 
and O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
resulted O 
in O 
a O 
significantly O 
higher O 
ultimate O 
load O 
than O 
ALN B-ABBREVIATION 
monotherapy O 
. O 
A O 
histomorphometric O 
analysis O 
showed O 
that O 
ELD B-ABBREVIATION 
monotherapy O 
and O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
combination O 
therapy O 
had O 
a O 
potent O 
inhibitory O 
effect O 
on O 
bone O 
resorption O 
parameters O 
( O 
osteoclast O 
surface O 
and O 
eroded O 
surface O 
) O 
, O 
while O 
maintaining O 
bone O 
formation O 
parameters O 
( O 
osteoblast O 
surface O 
and O 
osteoid O 
surface O 
) O 
. O 
By O 
contrast O 
, O 
ALF B-ABBREVIATION 
and O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
significantly O 
lowered O 
the O 
histological O 
parameters O 
of O 
both O 
bone O 
resorption O 
and O 
formation O 
. O 
These O 
results O 
suggested O 
that O 
ELD B-ABBREVIATION 
or O 
ALF B-ABBREVIATION 
used O 
in O 
combination O 
with O 
ALN B-ABBREVIATION 
has O 
therapeutic O 
advantages O 
over O 
ALN B-ABBREVIATION 
monotherapy O 
, O 
with O 
ELD B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
combination O 
treatment O 
producing O 
an O 
especially O 
beneficial O 
anti-osteoporotic O 
effect O 
by O 
inhibiting O 
osteoclastic O 
bone O 
resorption O 
and O 
maintaining O 
osteoblastic O 
function O 
, O 
compared O 
with O 
ALF B-ABBREVIATION 
+ O 
ALN B-ABBREVIATION 
combination O 
treatment O 
. O 

- O 
induced O 
synaptic O 
plasticity O 
drives O 
sustained O 
expression O 
of O 
calcium B-SYSTEMATIC 
-permeable O 
AMPA O 
receptors O 
in O 
the O 
hippocampus O 
. O 

lasting O 
enhancement O 
of O 
synaptic O 
transmission O 
can O 
be O 
triggered O 
by O 
brief O 
bursts O 
of O 
afferent O 
stimulation O 
, O 
underlying O 
long O 
- O 
term O 
potentiation O 
( O 
LTP O 
) O 
, O 
and O 
also O 
by O 
brief O 
ischemia O 
in O 
a O 
process O 
known O 
as O 
i-LTP O 
. O 
The O 
extent O 
to O 
which O 
LTP O 
and O 
i-LTP O 
rely O 
on O 
comparable O 
cellular O 
mechanisms O 
remains O 
unclear O 
. O 
Under O 
physiological O 
conditions O 
, O 
LTP O 
induction O 
drives O 
transient O 
expression O 
of O 
calcium B-SYSTEMATIC 
-permeable O 
AMPARs O 
( O 
CP-AMPARs O 
) O 
at O 
synapses O 
, O 
whose O 
ability O 
to O 
undergo O 
plasticity O 
is O 
primed O 
by O 
endogenous O 
activation O 
of O 
adenosine B-TRIVIAL 
A(2A) O 
receptors O 
( O 
A(2A)Rs O 
) O 
. O 
The O 
present O 
work O 
thus O 
addressed O 
the O 
contribution O 
of O 
CP-AMPARs O 
and O 
A(2A)Rs O 
to O 
i-LTP O 
, O 
which O 
was O 
induced O 
in O 
rat O 
hippocampal O 
slices O 
by O 
brief O 
( O 
10 O 
min O 
) O 
oxygen B-SYSTEMATIC 
/ O 
glucose B-TRIVIAL 
deprivation O 
( O 
OGD O 
) O 
. O 
The O 
amplitude O 
of O 
afferent-evoked O 
excitatory O 
postsynaptic O 
currents O 
( O 
EPSCs O 
) O 
recorded O 
from O 
CA1 O 
pyramidal O 
neurons O 
was O 
decreased O 
during O 
OGD O 
but O 
gradually O 
recovered O 
toward O 
values O 
significantly O 
above O 
( O 
157 O 
± O 
17% O 
) O 
the O 
baseline O 
( O 
100% O 
) O 
40-50 O 
min O 
after O 
re O 
- O 
oxygenation O 
. O 
This O 
i-LTP O 
was O 
precluded O 
by O 
CP-AMPAR O 
blockade O 
( O 
internal O 
spermine B-TRIVIAL 
( O 
500 O 
μM O 
) O 
or O 
extracellular O 
NASPM B-ABBREVIATION 
( O 
20 O 
μM O 
) O 
application O 
) O 
as O 
well O 
as O 
by O 
A(2A)R O 
blockade O 
with O 
a O 
selective O 
antagonist O 
( O 
SCH B-IDENTIFIER 
58261 I-IDENTIFIER 
, O 
100 O 
nM O 
) O 
. O 
OGD O 
prompted O 
sustained O 
( O 
> O 
70 O 
min O 
) O 
facilitation O 
of O 
mEPSC O 
amplitude O 
and O 
frequency O 
, O 
and O 
decreased O 
mEPSC O 
decay O 
time O 
, O 
all O 
of O 
which O 
were O 
prevented O 
by O 
SCH B-IDENTIFIER 
58261 I-IDENTIFIER 
( O 
100 O 
nM O 
) O 
. O 
The O 
ability O 
of O 
NASPM B-ABBREVIATION 
( O 
20 O 
μM O 
) O 
to O 
acutely O 
inhibit O 
EPSCs O 
1 O 
h O 
after O 
OGD O 
, O 
but O 
not O 
in O 
control O 
conditions O 
nor O 
in O 
OGD-challenged O 
slices O 
when O 
in O 
the O 
presence O 
of O 
SCH B-IDENTIFIER 
58261 I-IDENTIFIER 
( O 
100 O 
nM O 
) O 
, O 
further O 
supports O 
sustained O 
CP-AMPAR O 
recruitment O 
by O 
i-LTP O 
in O 
an O 
A(2A)R-dependent O 
way O 
. O 
We O 
propose O 
that O 
although O 
i-LTP O 
may O 
initially O 
mimic O 
LTP O 
, O 
failure O 
of O 
auto O 
- O 
regulated O 
CP-AMPAR O 
removal O 
from O 
synapses O 
could O 
constitute O 
an O 
early O 
divergent O 
event O 
between O 
these O 
forms O 
of O 
plasticity O 
. O 

bridge O 
switching O 
from O 
Arg B-FORMULA 
290/ O 
Glu B-FORMULA 
167 O 
to O 
Arg B-FORMULA 
290/ O 
ATP B-ABBREVIATION 
promotes O 
the O 
closed O 
- O 
to O 
- O 
open O 
transition O 
of O 
the O 
P2X2 O 
receptor O 
. O 

receptors O 
are O 
trimeric O 
adenosine-5'-triphosphate B-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
)-gated O 
cation O 
channels O 
involved O 
in O 
fast O 
signal O 
transduction O 
in O 
many O 
cell O 
types O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
homology O 
modeling O 
of O 
the O 
rat O 
P2X2 O 
receptor O 
with O 
the O 
zebrafish O 
P2X4 O 
X-ray O 
template O 
to O 
determine O 
that O 
the O 
side O 
chains O 
of O 
the O 
Glu B-FORMULA 
167 O 
and O 
Arg B-FORMULA 
290 O 
residues O 
are O 
in O 
close O 
spatial O 
vicinity O 
within O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
when O 
the O 
rat O 
P2X2 O 
channel O 
is O 
closed O 
. O 
Through O 
charge O 
reversal O 
mutation O 
analysis O 
and O 
mutant O 
cycle O 
analysis O 
, O 
we O 
obtained O 
evidence O 
that O 
Glu B-FORMULA 
167 O 
and O 
Arg B-FORMULA 
290 O 
form O 
an O 
electrostatic O 
interaction O 
. O 
In O 
addition O 
, O 
disulfide B-SYSTEMATIC 
trapping O 
indicated O 
the O 
close O 
proximity O 
of O 
Glu B-FORMULA 
167 O 
and O 
Arg B-FORMULA 
290 O 
when O 
the O 
channel O 
is O 
in O 
the O 
closed O 
state O 
, O 
but O 
not O 
in O 
the O 
ATP B-ABBREVIATION 
-bound O 
open O 
state O 
. O 
Consistent O 
with O 
a O 
gating O 
- O 
induced O 
movement O 
that O 
disrupts O 
the O 
Glu B-FORMULA 
167/ O 
Arg B-FORMULA 
290 O 
salt O 
bridge O 
, O 
a O 
comparison O 
of O 
the O 
closed O 
and O 
open O 
rat O 
P2X2 O 
receptor O 
models O 
revealed O 
a O 
significant O 
rearrangement O 
of O 
the O 
protein O 
backbone O 
and O 
the O 
side O 
chains O 
of O 
the O 
Glu B-FORMULA 
167 O 
and O 
Arg B-FORMULA 
290 O 
residues O 
during O 
the O 
closed O 
- O 
to O 
- O 
open O 
transition O 
. O 
The O 
associated O 
release O 
of O 
the O 
Glu B-FORMULA 
167/ O 
Arg B-FORMULA 
290 O 
salt O 
bridge O 
during O 
channel O 
opening O 
allows O 
a O 
strong O 
ionic O 
interaction O 
between O 
Arg B-FORMULA 
290 O 
and O 
a O 
γ-phosphate B-SYSTEMATIC 
oxygen I-SYSTEMATIC 
of O 
ATP B-ABBREVIATION 
. O 
We O 
conclude O 
from O 
these O 
results O 
that O 
the O 
state O 
- O 
dependent O 
salt O 
bridge O 
switching O 
from O 
Arg B-FORMULA 
290/ O 
Glu B-FORMULA 
167 O 
to O 
Arg B-FORMULA 
290/ O 
ATP B-ABBREVIATION 
fulfills O 
a O 
dual O 
role O 
: O 
to O 
destabilize O 
the O 
closed O 
state O 
of O 
the O 
receptor O 
and O 
to O 
promote O 
the O 
ionic O 
coordination O 
of O 
ATP B-ABBREVIATION 
in O 
the O 
ATP B-ABBREVIATION 
-binding O 
pocket O 
. O 

dimorphic O 
transcriptomic O 
responses O 
in O 
the O 
teleostean O 
hypothalamus O 
: O 
a O 
case O 
study O 
with O 
the O 
organochlorine B-FAMILY 
pesticide O 
dieldrin B-TRIVIAL 
. O 

pesticides O 
( O 
OCPs O 
) O 
such O 
as O 
dieldrin B-TRIVIAL 
are O 
a O 
persistent O 
class O 
of O 
aquatic O 
pollutants O 
that O 
cause O 
adverse O 
neurological O 
and O 
reproductive O 
effects O 
in O 
vertebrates O 
. O 
In O 
this O 
study O 
, O 
female O 
and O 
male O 
largemouth O 
bass O 
( O 
Micropterus O 
salmoides O 
) O 
( O 
LMB O 
) O 
were O 
exposed O 
to O 
3mg O 
dieldrin B-TRIVIAL 
/ O 
kg O 
feed O 
in O 
a O 
2 O 
month O 
feeding O 
exposure O 
( O 
August-October O 
) O 
to O 
( O 
1 O 
) O 
determine O 
if O 
the O 
hypothalamic O 
transcript O 
responses O 
to O 
dieldrin B-TRIVIAL 
were O 
conserved O 
between O 
the O 
sexes O 
; O 
( O 
2 O 
) O 
characterize O 
cell O 
signaling O 
cascades O 
underlying O 
dieldrin B-TRIVIAL 
neurotoxicity O 
; O 
and O 
( O 
3 O 
) O 
determine O 
whether O 
or O 
not O 
co O 
- O 
feeding O 
with O 
17β-estradiol B-SYSTEMATIC 
(E(2)) O 
, O 
a O 
hormone O 
with O 
neuroprotective O 
roles O 
, O 
mitigates O 
responses O 
in O 
males O 
to O 
dieldrin B-TRIVIAL 
. O 
Despite O 
also O 
being O 
a O 
weak O 
estrogen B-FAMILY 
, O 
dieldrin B-TRIVIAL 
treatments O 
did O 
not O 
elicit O 
changes O 
in O 
reproductive O 
endpoints O 
( O 
e.g O 
. O 
gonadosomatic O 
index O 
, O 
vitellogenin O 
, O 
or O 
plasma O 
E(2) O 
) O 
. O 
Sub O 
- O 
network O 
( O 
SNEA O 
) O 
and O 
gene O 
set O 
enrichment O 
analysis O 
( O 
GSEA O 
) O 
revealed O 
that O 
neuro O 
- O 
hormone O 
networks O 
, O 
neurotransmitter O 
and O 
nuclear O 
receptor O 
signaling O 
, O 
and O 
the O 
activin O 
signaling O 
network O 
were O 
altered O 
by O 
dieldrin B-TRIVIAL 
exposure O 
. O 
Most O 
striking O 
was O 
that O 
the O 
majority O 
of O 
cell O 
pathways O 
identified O 
by O 
the O 
gene O 
set O 
enrichment O 
were O 
significantly O 
increased O 
in O 
females O 
while O 
the O 
majority O 
of O 
cell O 
pathways O 
were O 
significantly O 
decreased O 
in O 
males O 
fed O 
dieldrin B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
( O 
1 O 
) O 
there O 
are O 
sexually O 
dimorphic O 
responses O 
in O 
the O 
teleost O 
hypothalamus O 
; O 
( O 
2 O 
) O 
neurotransmitter O 
systems O 
are O 
a O 
target O 
of O 
dieldrin B-TRIVIAL 
at O 
the O 
transcriptomics O 
level O 
; O 
and O 
( O 
3 O 
) O 
males O 
co O 
- O 
fed O 
dieldrin B-TRIVIAL 
and O 
E(2) O 
had O 
the O 
fewest O 
numbers O 
of O 
genes O 
and O 
cell O 
pathways O 
altered O 
in O 
the O 
hypothalamus O 
, O 
suggesting O 
that O 
E(2) O 
may O 
mitigate O 
the O 
effects O 
of O 
dieldrin B-TRIVIAL 
in O 
the O 
central O 
nervous O 
system O 
. O 

to O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
inhibits O 
chondrogenesis O 
and O 
osteogenesis O 
in O 
mid O 
- O 
organogenesis O 
mouse O 
limbs O 
. O 

utero O 
exposure O 
to O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
, O 
a O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitor O 
, O 
causes O 
neural O 
tube O 
, O 
heart O 
, O 
and O 
limb O 
defects O 
. O 
Valpromide B-TRIVIAL 
( O 
VPD B-ABBREVIATION 
) O 
, O 
the O 
amide B-FAMILY 
derivative O 
of O 
VPA B-ABBREVIATION 
, O 
does O 
not O 
inhibit O 
HDAC O 
activity O 
and O 
is O 
a O 
weak O 
teratogen O 
in O 
vivo O 
. O 
The O 
detailed O 
mechanism O 
of O 
action O 
of O 
VPA B-ABBREVIATION 
as O 
a O 
teratogen O 
is O 
not O 
known O 
. O 
The O 
goal O 
of O 
this O 
study O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
VPA B-ABBREVIATION 
disrupts O 
regulation O 
of O 
the O 
expression O 
of O 
genes O 
that O 
are O 
critical O 
in O 
chondrogenesis O 
and O 
osteogenesis O 
during O 
limb O 
development O 
. O 
Murine O 
gestation O 
day-12 O 
embryonic O 
forelimbs O 
were O 
excised O 
and O 
exposed O 
to O 
VPA B-ABBREVIATION 
or O 
VPD B-ABBREVIATION 
in O 
a O 
limb O 
bud O 
culture O 
system O 
. O 
VPA B-ABBREVIATION 
caused O 
a O 
significant O 
concentration- O 
dependent O 
increase O 
in O 
limb O 
abnormalities O 
, O 
which O 
was O 
correlated O 
with O 
its O 
HDAC O 
inhibitory O 
effect O 
. O 
The O 
signaling O 
of O 
both O 
Sox9 O 
and O 
Runx2 O 
, O 
key O 
regulators O 
of O 
chondrogenesis O 
, O 
was O 
downregulated O 
by O 
VPA B-ABBREVIATION 
. O 
In O 
contrast O 
, O 
VPD B-ABBREVIATION 
had O 
little O 
effect O 
on O 
limb O 
morphology O 
and O 
no O 
significant O 
effect O 
on O 
HDAC O 
activity O 
or O 
the O 
expression O 
of O 
marker O 
genes O 
. O 
Thus O 
, O 
VPA B-ABBREVIATION 
exposure O 
dysregulated O 
the O 
expression O 
of O 
target O 
genes O 
directly O 
involved O 
in O 
chondrogenesis O 
and O 
osteogenesis O 
in O 
the O 
developing O 
limb O 
. O 
Disturbances O 
in O 
these O 
signaling O 
pathways O 
are O 
likely O 
to O 
be O 
a O 
consequence O 
of O 
HDAC O 
inhibition O 
because O 
VPD B-ABBREVIATION 
did O 
not O 
affect O 
their O 
expressions O 
. O 

necrosis O 
factor O 
- O 
alpha O 
potentiates O 
the O 
cytotoxicity O 
of O 
amiodarone B-TRIVIAL 
in O 
Hepa1c1c7 O 
cells O 
: O 
roles O 
of O 
caspase O 
activation O 
and O 
oxidative O 
stress O 
. O 

( O 
AMD B-ABBREVIATION 
) O 
, O 
a O 
class O 
III O 
antiarrhythmic O 
drug O 
, O 
causes O 
idiosyncratic O 
hepatotoxicity O 
in O 
human O 
patients O 
. O 
We O 
demonstrated O 
previously O 
that O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
plays O 
an O 
important O 
role O 
in O 
a O 
rat O 
model O 
of O 
AMD B-ABBREVIATION 
-induced O 
hepatotoxicity O 
under O 
inflammatory O 
stress O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
a O 
model O 
in O 
vitro O 
to O 
study O 
the O 
roles O 
of O 
caspase O 
activation O 
and O 
oxidative O 
stress O 
in O 
TNF O 
potentiation O 
of O 
AMD B-ABBREVIATION 
cytotoxicity O 
. O 
AMD B-ABBREVIATION 
caused O 
cell O 
death O 
in O 
Hepa1c1c7 O 
cells O 
, O 
and O 
TNF O 
cotreatment O 
potentiated O 
its O 
toxicity O 
. O 
Activation O 
of O 
caspases O 
9 O 
and O 
3 O 
/ O 
7 O 
was O 
observed O 
in O 
AMD B-ABBREVIATION 
/ O 
TNF-cotreated O 
cells O 
, O 
and O 
caspase O 
inhibitors O 
provided O 
minor O 
protection O 
from O 
cytotoxicity O 
. O 
Intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
and O 
lipid O 
peroxidation O 
were O 
observed O 
after O 
treatment O 
with O 
AMD B-ABBREVIATION 
and O 
were O 
further O 
elevated O 
by O 
TNF O 
cotreatment O 
. O 
Adding O 
water O 
- O 
soluble O 
antioxidants O 
( O 
trolox B-TRIVIAL 
, O 
N-acetylcysteine B-SYSTEMATIC 
, O 
glutathione B-TRIVIAL 
, O 
or O 
ascorbate B-TRIVIAL 
) O 
produced O 
only O 
minor O 
attenuation O 
of O 
AMD B-ABBREVIATION 
/ O 
TNF-induced O 
cytotoxicity O 
and O 
did O 
not O 
influence O 
the O 
effect O 
of O 
AMD B-ABBREVIATION 
alone O 
. O 
On O 
the O 
other O 
hand O 
, O 
α-tocopherol B-TRIVIAL 
( O 
TOCO B-ABBREVIATION 
) O 
, O 
which O 
reduced O 
lipid O 
peroxidation O 
and O 
ROS O 
generation O 
, O 
prevented O 
AMD B-ABBREVIATION 
toxicity O 
and O 
caused O 
pronounced O 
reduction O 
in O 
cytotoxicity O 
from O 
AMD B-ABBREVIATION 
/ O 
TNF O 
cotreatment O 
. O 
α-TOCO B-SYSTEMATIC 
plus O 
a O 
pancaspase O 
inhibitor O 
completely O 
abolished O 
AMD B-ABBREVIATION 
/ O 
TNF-induced O 
cytotoxicity O 
. O 
In O 
summary O 
, O 
activation O 
of O 
caspases O 
and O 
oxidative O 
stress O 
were O 
observed O 
after O 
AMD B-ABBREVIATION 
/ O 
TNF O 
cotreatment O 
, O 
and O 
caspase O 
inhibitors O 
and O 
a O 
lipid O 
- O 
soluble O 
free O 
- O 
radical O 
scavenger O 
attenuated O 
AMD B-ABBREVIATION 
/ O 
TNF-induced O 
cytotoxicity O 
. O 

inhibits O 
THC B-ABBREVIATION 
-elicited O 
paranoid O 
symptoms O 
and O 
hippocampal O 
- O 
dependent O 
memory O 
impairment O 
. O 

- O 
based O 
studies O 
suggest O 
that O 
cannabis O 
products O 
that O 
are O 
high O 
in O 
Δ⁹-tetrahydrocannabinol B-SYSTEMATIC 
( O 
THC B-ABBREVIATION 
) O 
but O 
low O 
in O 
cannabidiol B-TRIVIAL 
( O 
CBD B-ABBREVIATION 
) O 
are O 
particularly O 
hazardous O 
for O 
mental O 
health O 
. O 
Laboratory O 
- O 
based O 
studies O 
are O 
ideal O 
for O 
clarifying O 
this O 
issue O 
because O 
THC B-ABBREVIATION 
and O 
CBD B-ABBREVIATION 
can O 
be O 
administered O 
in O 
pure O 
form O 
, O 
under O 
controlled O 
conditions O 
. O 
In O 
a O 
between O 
- O 
subjects O 
design O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
pre O 
- O 
treatment O 
with O 
CBD B-ABBREVIATION 
inhibited O 
THC B-ABBREVIATION 
-elicited O 
psychosis O 
and O 
cognitive O 
impairment O 
. O 
Healthy O 
participants O 
were O 
randomised O 
to O 
receive O 
oral O 
CBD B-ABBREVIATION 
600 O 
mg O 
( O 
n=22 O 
) O 
or O 
placebo O 
( O 
n=26 O 
) O 
, O 
210 O 
min O 
ahead O 
of O 
intravenous O 
(IV) O 
THC B-ABBREVIATION 
( O 
1.5 O 
mg O 
) O 
. O 
Post- O 
THC B-ABBREVIATION 
, O 
there O 
were O 
lower O 
PANSS O 
positive O 
scores O 
in O 
the O 
CBD B-ABBREVIATION 
group O 
, O 
but O 
this O 
did O 
not O 
reach O 
statistical O 
significance O 
. O 
However O 
, O 
clinically O 
significant O 
positive O 
psychotic O 
symptoms O 
( O 
defined O 
a O 
priori O 
as O 
increases O 
≥ O 
3 O 
points O 
) O 
were O 
less O 
likely O 
in O 
the O 
CBD B-ABBREVIATION 
group O 
compared O 
with O 
the O 
placebo O 
group O 
, O 
odds O 
ratio O 
(OR)=0.22 O 
( O 
χ²=4.74 O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
agreement O 
, O 
post- O 
THC B-ABBREVIATION 
paranoia O 
, O 
as O 
rated O 
with O 
the O 
State O 
Social O 
Paranoia O 
Scale O 
( O 
SSPS O 
) O 
, O 
was O 
less O 
in O 
the O 
CBD B-ABBREVIATION 
group O 
compared O 
with O 
the O 
placebo O 
group O 
( O 
t=2.28 O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Episodic O 
memory O 
, O 
indexed O 
by O 
scores O 
on O 
the O 
Hopkins O 
Verbal O 
Learning O 
Task O 
- O 
revised O 
( O 
HVLT-R O 
) O 
, O 
was O 
poorer O 
, O 
relative O 
to O 
baseline O 
, O 
in O 
the O 
placebo O 
pre O 
- O 
treated O 
group O 
( O 
-10.6 O 
± O 
18.9% O 
) O 
compared O 
with O 
the O 
CBD B-ABBREVIATION 
group O 
( O 
-0.4% O 
± O 
9.7 O 
% O 
) O 
( O 
t=2.39 O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
These O 
findings O 
support O 
the O 
idea O 
that O 
high- O 
THC B-ABBREVIATION 
/ O 
low- O 
CBD B-ABBREVIATION 
cannabis O 
products O 
are O 
associated O 
with O 
increased O 
risks O 
for O 
mental O 
health O 
. O 

amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
hinge O 
region O 
of O 
the O 
5A O 
apolipoprotein O 
mimetic O 
peptide O 
are O 
essential O 
for O 
promoting O 
cholesterol B-TRIVIAL 
efflux O 
by O 
the O 
ABCA1 O 
transporter O 
. O 

bihelical O 
apolipoprotein O 
mimetic O 
peptide O 
5A O 
effluxes O 
cholesterol B-TRIVIAL 
from O 
cells O 
and O 
reduces O 
inflammation O 
and O 
atherosclerosis O 
in O 
animal O 
models O 
. O 
We O 
investigated O 
how O 
hydrophobic O 
residues O 
in O 
the O 
hinge O 
region O 
between O 
the O 
two O 
helices O 
are O 
important O 
in O 
the O 
structure O 
and O 
function O 
of O 
this O 
peptide O 
. O 
By O 
simulated O 
annealing O 
analysis O 
and O 
molecular O 
dynamics O 
modeling O 
, O 
two O 
hydrophobic O 
amino B-FAMILY 
acids I-FAMILY 
, O 
F-18 O 
and O 
W-21 O 
, O 
in O 
the O 
hinge O 
region O 
were O 
predicted O 
to O 
be O 
relatively O 
surface O 
- O 
exposed O 
and O 
to O 
interact O 
with O 
the O 
aqueous O 
solvent O 
. O 
Using O 
a O 
series O 
of O 
5A O 
peptide O 
analogs O 
in O 
which O 
F-18 O 
or O 
W-21 O 
was O 
changed O 
to O 
either O 
F O 
, O 
W O 
, O 
A O 
, O 
or O 
E O 
, O 
only O 
peptides O 
with O 
hydrophobic O 
amino B-FAMILY 
acids I-FAMILY 
in O 
these O 
two O 
positions O 
were O 
able O 
to O 
readily O 
bind O 
and O 
solubilize O 
phospholipid O 
vesicles O 
. O 
Compared O 
with O 
active O 
peptides O 
containing O 
F O 
or O 
W O 
, O 
peptides O 
containing O 
E O 
in O 
either O 
of O 
these O 
two O 
positions O 
were O 
more O 
than O 
10-fold O 
less O 
effective O 
in O 
effluxing O 
cholesterol B-TRIVIAL 
by O 
the O 
ABCA1 O 
transporter O 
. O 
Intravenous O 
injection O 
of O 
5A O 
in O 
C57BL O 
/ O 
6 O 
mice O 
increased O 
plasma O 
- O 
free O 
cholesterol B-TRIVIAL 
( O 
5A O 
: O 
89.9 O 
± O 
13.6 O 
mg O 
/ O 
dl O 
; O 
control O 
: O 
38.7 O 
± O 
4.3 O 
mg O 
/ O 
dl O 
( O 
mean O 
± O 
S.D O 
. O 
) O 
; O 
P O 
< O 
0.05 O 
) O 
and O 
triglyceride B-FAMILY 
s O 
( O 
5A O 
: O 
887 O 
± O 
172 O 
mg O 
/ O 
dl O 
; O 
control O 
: O 
108.9 O 
± O 
9.9 O 
mg O 
/ O 
dl O 
; O 
P O 
< O 
0.05 O 
) O 
, O 
whereas O 
the O 
EE O 
peptide O 
containing O 
E O 
in O 
both O 
positions O 
had O 
no O 
effect O 
. O 
Finally O 
, O 
5A O 
increased O 
cholestero B-TRIVIAL 
l O 
efflux O 
approximately O 
2.5-fold O 
in O 
vivo O 
from O 
radiolabeled O 
macrophages O 
, O 
whereas O 
the O 
EE O 
peptide O 
was O 
inactive O 
. O 
These O 
results O 
provide O 
a O 
rationale O 
for O 
future O 
design O 
of O 
therapeutic O 
apolipoprotein O 
mimetic O 
peptides O 
and O 
provide O 
new O 
insights O 
into O 
the O 
interaction O 
of O 
hydrophobic O 
residues O 
on O 
apolipoproteins O 
with O 
phospholipids O 
in O 
the O 
lipid O 
microdomain O 
created O 
by O 
the O 
ABCA1 O 
transporter O 
during O 
the O 
cholestero B-TRIVIAL 
l O 
efflux O 
process O 
. O 

of O 
the O 
GluK1/ O 
AMPA B-ABBREVIATION 
receptor O 
antagonist O 
LY293558 B-IDENTIFIER 
against O 
seizures O 
and O 
neuropathology O 
in O 
a O 
soman O 
- O 
exposure O 
model O 
without O 
pretreatment O 
and O 
its O 
pharmacokinetics O 
after O 
intramuscular O 
administration O 
. O 

of O 
brain O 
seizures O 
after O 
exposure O 
to O 
nerve O 
agents O 
is O 
imperative O 
for O 
the O 
prevention O 
of O 
brain O 
damage O 
and O 
death O 
. O 
Animal O 
models O 
of O 
nerve O 
agent O 
exposure O 
make O 
use O 
of O 
pretreatments O 
, O 
or O 
medication O 
administered O 
within O 
1 O 
minute O 
after O 
exposure O 
, O 
in O 
order O 
to O 
prevent O 
rapid O 
death O 
from O 
peripheral O 
toxic O 
effects O 
and O 
respiratory O 
failure O 
, O 
which O 
then O 
allows O 
the O 
testing O 
of O 
anticonvulsant O 
compounds O 
. O 
However O 
, O 
in O 
a O 
real O 
- O 
case O 
scenario O 
of O 
an O 
unexpected O 
attack O 
with O 
nerve O 
agents O 
, O 
pretreatment O 
would O 
not O 
be O 
possible O 
, O 
and O 
medical O 
assistance O 
may O 
not O 
be O 
available O 
immediately O 
. O 
To O 
determine O 
if O 
control O 
of O 
seizures O 
and O 
survival O 
are O 
still O 
possible O 
without O 
pretreatment O 
or O 
immediate O 
pharmacologic O 
intervention O 
, O 
we O 
studied O 
the O 
anticonvulsant O 
efficacy O 
of O 
the O 
GluK1 O 
(GluR5)/ O 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
receptor O 
antagonist O 
(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
LY293558 B-IDENTIFIER 
) O 
in O 
rats O 
that O 
did O 
not O 
receive O 
any O 
treatment O 
until O 
20 O 
minutes O 
after O 
exposure O 
to O 
the O 
nerve O 
agent O 
soman O 
. O 
We O 
injected O 
LY293558 B-IDENTIFIER 
intramuscularly O 
, O 
as O 
this O 
would O 
be O 
the O 
most O 
likely O 
route O 
of O 
administration O 
to O 
humans O 
. O 
LY293558 B-IDENTIFIER 
( O 
15 O 
mg O 
/ O 
kg O 
) O 
, O 
injected O 
along O 
with O 
atropine O 
and O 
the O 
oxime B-SYSTEMATIC 
HI-6 B-IDENTIFIER 
at O 
20 O 
minutes O 
after O 
soman O 
exposure O 
, O 
stopped O 
seizures O 
and O 
increased O 
survival O 
rate O 
from O 
64% O 
to O 
100% O 
. O 
LY293558 B-IDENTIFIER 
also O 
prevented O 
neuronal O 
loss O 
in O 
the O 
amygdala O 
and O 
hippocampus O 
, O 
and O 
reduced O 
neurodegeneration O 
in O 
a O 
number O 
of O 
brain O 
regions O 
studied O 
7 O 
days O 
after O 
soman O 
exposure O 
. O 
Analysis O 
of O 
the O 
LY293558 B-IDENTIFIER 
pharmacokinetics O 
after O 
intramuscular O 
administration O 
showed O 
that O 
this O 
compound O 
readily O 
crosses O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
There O 
was O 
good O 
correspondence O 
between O 
the O 
time O 
course O 
of O 
seizure O 
suppression O 
by O 
LY293558 B-IDENTIFIER 
and O 
the O 
brain O 
levels O 
of O 
the O 
compound O 
. O 

in O 
an O 
adenovirus O 
infection O 
, O 
the O 
viral O 
proteinase O 
( O 
AVP O 
) O 
becomes O 
activated O 
to O 
process O 
virion O 
precursor O 
proteins O 
used O 
in O 
virus O 
assembly O 
. O 
AVP O 
is O 
activated O 
by O 
two O 
cofactors O 
, O 
the O 
viral O 
DNA O 
and O 
pVIc B-ABBREVIATION 
, O 
an O 
11- O 
amino B-FAMILY 
acid I-FAMILY 
peptide O 
originating O 
from O 
the O 
C B-FORMULA 
terminus O 
of O 
the O 
precursor O 
protein O 
pVI O 
. O 
There O 
is O 
a O 
conundrum O 
in O 
the O 
activation O 
of O 
AVP O 
in O 
that O 
AVP O 
and O 
pVI O 
are O 
sequence O 
- O 
independent O 
DNA O 
- O 
binding O 
proteins O 
with O 
nm O 
equilibrium O 
dissociation O 
constants O 
such O 
that O 
in O 
the O 
virus O 
particle O 
, O 
they O 
are O 
predicted O 
to O 
be O 
essentially O 
irreversibly O 
bound O 
to O 
the O 
viral O 
DNA O 
. O 
Here O 
, O 
we O 
resolve O 
that O 
conundrum O 
by O 
showing O 
that O 
activation O 
of O 
AVP O 
takes O 
place O 
on O 
the O 
one O 
- O 
dimensional O 
contour O 
of O 
DNA O 
. O 
In O 
vitro O 
, O 
pVI O 
, O 
a O 
substrate O 
, O 
slides O 
on O 
DNA O 
via O 
one O 
- O 
dimensional O 
diffusion O 
, O 
D(1) O 
= O 
1.45 O 
× O 
10(6) O 
bp(2) O 
/ O 
s O 
, O 
until O 
it O 
binds O 
to O 
AVP O 
also O 
on O 
the O 
same O 
DNA O 
molecule O 
. O 
AVP O 
, O 
partially O 
activated O 
by O 
being O 
bound O 
to O 
DNA O 
, O 
excises O 
pVIc B-ABBREVIATION 
, O 
which O 
binds O 
to O 
the O 
AVP O 
molecule O 
that O 
cut O 
it O 
out O 
. O 
pVIc B-ABBREVIATION 
then O 
forms O 
a O 
disulfide B-SYSTEMATIC 
bond O 
with O 
AVP O 
forming O 
the O 
fully O 
active O 
AVP- O 
pVIc B-ABBREVIATION 
complex O 
bound O 
to O 
DNA O 
. O 
In O 
vivo O 
, O 
in O 
heat O 
- O 
disrupted O 
immature O 
virus O 
, O 
AVP O 
was O 
also O 
activated O 
by O 
pVI O 
in O 
DNA-dependent O 
reactions O 
. O 
This O 
activation O 
mechanism O 
illustrates O 
a O 
new O 
paradigm O 
for O 
virion O 
maturation O 
and O 
a O 
new O 
way O 
, O 
by O 
sliding O 
on O 
DNA O 
, O 
for O 
bimolecular O 
complexes O 
to O 
form O 
among O 
proteins O 
not O 
involved O 
in O 
DNA O 
metabolism O 
. O 

the O 
present O 
study O 
, O 
the O 
two O 
grafting O 
techniques O 
grafting O 
- O 
from O 
- O 
by O 
activators O 
regenerated O 
by O 
electron O 
transfer O 
atom O 
transfer O 
radical O 
polymerization O 
( O 
ARGET O 
ATRP O 
) O 
- O 
and O 
grafting O 
- O 
to O 
- O 
by O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-catalyzed O 
azide-alkyne B-FAMILY 
cycloaddition O 
( O 
CuAAC O 
) O 
- O 
were O 
systematically O 
compared O 
, O 
employing O 
cellulose O 
as O 
a O 
substrate O 
. O 
In O 
order O 
to O 
obtain O 
a O 
meaningful O 
comparison O 
, O 
it O 
is O 
crucial O 
that O 
the O 
graft O 
lengths O 
of O 
the O 
polymers O 
that O 
are O 
grafted O 
from O 
and O 
to O 
the O 
substrates O 
are O 
essentially O 
identical O 
. O 
Herein O 
, O 
this O 
was O 
achieved O 
by O 
utilizing O 
the O 
free O 
polymer O 
formed O 
in O 
parallel O 
to O 
the O 
grafting O 
- O 
from O 
reaction O 
as O 
the O 
polymer O 
for O 
the O 
grafting O 
- O 
to O 
reaction O 
. O 
Four O 
graft O 
lengths O 
were O 
investigated O 
, O 
and O 
the O 
molar O 
masses O 
of O 
the O 
four O 
free O 
polymers O 
( O 
21 O 
≤ O 
M(n) O 
≤ O 
100 O 
kDa O 
; O 
1.07 O 
≤ O 
Đ(M) O 
≤ O 
1.26 O 
) O 
, O 
i.e O 
. O 
the O 
polymers O 
subsequently O 
employed O 
in O 
the O 
grafting O 
- O 
to O 
reaction O 
, O 
were O 
shown O 
to O 
be O 
in O 
the O 
same O 
range O 
as O 
the O 
molar O 
masses O 
of O 
the O 
polymers O 
grafted O 
from O 
the O 
surface O 
( O 
23 O 
≤ O 
M(n) O 
≤ O 
87 O 
kDa O 
; O 
1.08 O 
≤ O 
Đ(M) O 
≤ O 
1.31 O 
) O 
. O 
The O 
molecular O 
weights O 
of O 
the O 
chains O 
grafted O 
from O 
the O 
surface O 
were O 
established O 
after O 
cleavage O 
from O 
the O 
cellulose O 
substrates O 
via O 
size O 
exclusion O 
chromatography O 
( O 
SEC O 
) O 
. O 
High O 
- O 
resolution O 
Fourier O 
transform O 
infrared O 
microscopy O 
( O 
FT-IRM O 
) O 
was O 
employed O 
as O 
an O 
efficient O 
tool O 
to O 
study O 
the O 
spatial O 
distribution O 
of O 
the O 
polymer O 
content O 
on O 
the O 
grafted O 
substrates O 
. O 
In O 
addition O 
, O 
the O 
functionalized O 
substrates O 
were O 
analyzed O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
contact O 
angle O 
( O 
CA O 
) O 
measurements O 
, O 
and O 
field O 
- O 
emission O 
scanning O 
electron O 
microscopy O 
( O 
FE-SEM O 
) O 
. O 
For O 
cellulose O 
substrates O 
modified O 
via O 
the O 
grafting O 
- O 
from O 
approach O 
, O 
the O 
content O 
of O 
polymer O 
on O 
the O 
surfaces O 
increased O 
with O 
increasing O 
graft O 
length O 
, O 
confirming O 
the O 
possibility O 
to O 
tailor O 
not O 
only O 
the O 
length O 
of O 
the O 
polymer O 
grafts O 
but O 
also O 
the O 
polymeric O 
content O 
on O 
the O 
surface O 
. O 
In O 
comparison O 
, O 
for O 
the O 
grafting O 
- O 
to O 
reaction O 
, O 
the O 
grafted O 
content O 
could O 
not O 
be O 
controlled O 
by O 
varying O 
the O 
length O 
of O 
the O 
preformed O 
polymer O 
: O 
the O 
polymer O 
content O 
was O 
essentially O 
the O 
same O 
for O 
the O 
four O 
graft O 
lengths O 
. O 
Consequently O 
, O 
the O 
obtained O 
results O 
, O 
when O 
employing O 
cellulose O 
as O 
a O 
substrate O 
and O 
under O 
these O 
conditions O 
, O 
suggest O 
that O 
the O 
grafting O 
- O 
from O 
approach O 
is O 
superior O 
to O 
the O 
grafting O 
- O 
to O 
technique O 
with O 
respect O 
to O 
controlling O 
the O 
distribution O 
of O 
the O 
polymeric O 
content O 
on O 
the O 
surface O 
. O 

are O 
considered O 
to O 
act O 
as O 
mechanosensory O 
cells O 
in O 
bone O 
. O 
They O 
form O 
a O 
functional O 
synctia O 
in O 
which O 
their O 
processes O 
become O 
interconnected O 
to O 
constitute O 
a O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
network O 
. O 
Previous O 
studies O 
reported O 
that O 
in O 
mice O 
, O 
the O 
two O 
- O 
dimensional O 
osteocyte O 
network O 
becomes O 
progressively O 
more O 
regular O 
as O 
they O 
grow O 
, O 
although O 
the O 
key O 
factors O 
governing O 
the O 
arrangement O 
of O 
the O 
osteocyte O 
network O 
during O 
bone O 
growth O 
remain O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
characterized O 
the O 
3D O 
formation O 
of O 
the O 
osteocyte O 
network O 
during O 
bone O 
growth O 
. O 
Morphological O 
skeletal O 
changes O 
have O 
been O 
reported O 
to O 
occur O 
in O 
response O 
to O 
mechanical O 
loading O 
and O 
unloading O 
. O 
In O 
order O 
to O 
evaluate O 
the O 
effect O 
of O 
mechanical O 
unloading O 
on O 
osteocyte O 
network O 
formation O 
, O 
we O 
subjected O 
newborn O 
mice O 
to O 
sciatic O 
neurectomy O 
in O 
order O 
to O 
immobilize O 
their O 
left O 
hind O 
limb O 
as O 
an O 
unloading O 
model O 
. O 
The O 
osteocyte O 
network O 
was O 
visualized O 
by O 
staining O 
osteocyte O 
cell O 
bodies O 
and O 
processes O 
with O 
fluorescently O 
labeled O 
phalloidin B-TRIVIAL 
. O 
First O 
, O 
we O 
compared O 
the O 
osteocyte O 
network O 
in O 
the O 
femora O 
of O 
embryonic O 
and O 
6-week- O 
old O 
mice O 
in O 
order O 
to O 
understand O 
the O 
morphological O 
changes O 
that O 
occur O 
with O 
normal O 
growth O 
and O 
mechanical O 
loading O 
. O 
In O 
embryonic O 
mice O 
, O 
the O 
osteocyte O 
network O 
in O 
the O 
femur O 
cortical O 
bone O 
displayed O 
a O 
random O 
cell O 
body O 
distribution O 
, O 
non-directional O 
orientation O 
of O 
cell O 
processes O 
, O 
and O 
irregularly O 
shaped O 
cells O 
. O 
In O 
6-week- O 
old O 
mice O 
, O 
the O 
3D O 
network O 
contained O 
spindle O 
- O 
shaped O 
osteocytes O 
, O 
which O 
were O 
arranged O 
parallel O 
to O 
the O 
longitudinal O 
axis O 
of O 
the O 
femur O 
. O 
In O 
addition O 
, O 
more O 
and O 
longer O 
cell O 
processes O 
radiated O 
from O 
each O 
osteocyte O 
. O 
Second O 
, O 
we O 
compared O 
the O 
cortical O 
osteocyte O 
networks O 
of O 
6-week- O 
old O 
mice O 
that O 
had O 
or O 
had O 
not O 
undergone O 
sciatic O 
neurectomy O 
in O 
order O 
to O 
evaluate O 
the O 
effect O 
of O 
unloading O 
on O 
osteocyte O 
network O 
formation O 
. O 
The O 
osteocyte O 
network O 
formation O 
in O 
both O 
cortical O 
bone O 
and O 
cancellous O 
bone O 
was O 
affected O 
by O 
mechanical O 
loading O 
. O 
However O 
, O 
there O 
were O 
differences O 
in O 
the O 
extent O 
of O 
network O 
formation O 
between O 
cortical O 
bone O 
and O 
cancellous O 
bone O 
in O 
response O 
to O 
mechanical O 
loading O 
with O 
regard O 
to O 
the O 
orientation O 
, O 
nuclear O 
shape O 
and O 
branch O 
formation O 
. O 

combinations O 
for O 
the O 
field O 
treatment O 
of O 
soman B-TRIVIAL 
-induced O 
self O 
- O 
sustaining O 
status O 
epilepticus O 
. O 
Review O 
of O 
current O 
data O 
and O 
perspectives O 
. O 

nerve O 
agents O 
( O 
nan O 
) O 
, O 
potent O 
irreversible O 
cholinesterase O 
inhibitors O 
, O 
could O 
induce O 
severe O 
seizures O 
, O 
status O 
epilepticus O 
( O 
SE O 
) O 
, O 
seizure O 
- O 
related O 
brain O 
damage O 
( O 
SRBD O 
) O 
and O 
lethality O 
. O 
Despite O 
the O 
lack O 
of O 
data O 
in O 
the O 
case O 
of O 
nan O 
, O 
clinical O 
evidences O 
suggest O 
that O 
SE O 
survivors O 
could O 
suffer O 
from O 
neurological O 
/ O 
cognitive O 
deficits O 
and O 
impairments O 
such O 
as O 
spontaneous O 
recurrent O 
seizures O 
( O 
epilepsy O 
) O 
after O 
a O 
latent O 
period O 
of O 
epileptogenesis O 
. O 
It O 
is O 
beyond O 
doubt O 
that O 
an O 
effective O 
and O 
quick O 
management O 
of O 
the O 
initial O 
seizures O 
and O 
prevention O 
of O 
SRBD O 
are O 
critical O 
to O 
prevent O 
these O 
long O 
- O 
term O 
consequences O 
, O 
explaining O 
why O 
most O 
experimental O 
data O 
are O 
focusing O 
on O 
the O 
5-40min O 
post O 
- O 
exposure O 
time O 
frame O 
. O 
However O 
, O 
in O 
field O 
conditions O 
, O 
treatment O 
may O 
be O 
delayed O 
and O 
with O 
the O 
exception O 
of O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
, O 
currently O 
no O 
drug O 
provides O 
protection O 
( O 
against O 
lethality O 
, O 
seizures O 
, O 
SRBD O 
and O 
neurological O 
consequences O 
) O 
when O 
seizures O 
are O 
left O 
unabated O 
for O 
one O 
hour O 
or O 
more O 
. O 
Ketamine B-TRIVIAL 
( O 
KET B-ABBREVIATION 
) O 
is O 
the O 
only O 
NMDA B-ABBREVIATION 
antagonist O 
licensed O 
as O 
an O 
injectable O 
drug O 
in O 
different O 
countries O 
and O 
remains O 
an O 
anesthetic O 
of O 
choice O 
in O 
some O 
difficult O 
field O 
conditions O 
. O 
In O 
this O 
short O 
review O 
paper O 
, O 
after O 
a O 
presentation O 
of O 
some O 
of O 
the O 
key O 
points O 
of O 
the O 
pathophysiology O 
of O 
NA-induced O 
SE O 
and O 
a O 
quick O 
survey O 
of O 
the O 
potential O 
therapeutic O 
avenues O 
in O 
the O 
context O 
of O 
delayed O 
treatment O 
of O 
NA-induced O 
SE O 
, O 
we O 
will O 
review O 
the O 
recent O 
data O 
we O 
obtained O 
showing O 
that O 
KET B-ABBREVIATION 
, O 
in O 
combination O 
with O 
atropine B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
AS O 
) O 
, O 
with O 
or O 
without O 
a O 
benzodiazepine B-FAMILY 
, O 
considerably O 
reduces O 
soman B-TRIVIAL 
-induced O 
neuroinflammation O 
, O 
provides O 
neuroprotection O 
, O 
histologically O 
and O 
functionally O 
, O 
and O 
also O 
positively O 
modify O 
soman B-TRIVIAL 
-induced O 
changes O 
in O 
brain O 
metabolism O 
. O 
Finally O 
, O 
we O 
will O 
also O 
mention O 
some O 
results O 
from O 
safety O 
studies O 
including O 
those O 
bringing O 
evidence O 
that O 
, O 
at O 
difference O 
with O 
MK-801 B-IDENTIFIER 
, O 
KET B-ABBREVIATION 
does O 
not O 
impair O 
thermoregulation O 
and O 
even O 
seems O 
to O 
reduce O 
AS-induced O 
heat O 
stress O 
. O 
All O 
in O 
all O 
, O 
KET B-ABBREVIATION 
, O 
in O 
combination O 
, O 
appears O 
a O 
good O 
candidate O 
for O 
the O 
out O 
- O 
of O 
- O 
hospital O 
treatment O 
of O 
severe O 
NA-induced O 
SE O 
. O 

cross O 
- O 
linked O 
polymeric O 
micellar O 
delivery O 
system O 
for O 
cisplatin B-TRIVIAL 
(IV) I-TRIVIAL 
complex O 
. O 

polymeric O 
cisplatin B-TRIVIAL 
(IV) I-TRIVIAL 
prodrug O 
in O 
the O 
form O 
of O 
cross O 
- O 
linked O 
micelles O 
( O 
M( O 
Pt B-FORMULA 
(IV) I-FORMULA 
) O 
was O 
prepared O 
by O 
first O 
constructing O 
MPEG-b-PCL-b-PLL O 
micelles O 
and O 
then O 
attaching O 
a O 
cisplatin B-TRIVIAL 
(IV) I-TRIVIAL 
complex O 
with O 
two O 
axial O 
succinic O 
moieties O 
to O 
the O 
lysine O 
residues O 
of O 
the O 
carrier O 
polymer O 
in O 
aqueous O 
medium O 
. O 
The O 
micelles O 
obtained O 
were O 
characterized O 
by O 
TEM O 
, O 
DLS O 
, O 
and O 
zeta O 
potential O 
measurement O 
. O 
Their O 
in O 
vitro O 
release O 
experiments O 
were O 
carried O 
out O 
at O 
pH O 
7.4 O 
and O 
5 O 
or O 
in O 
the O 
presence O 
of O 
5mM O 
sodium B-SYSTEMATIC 
ascorbate I-SYSTEMATIC 
( O 
NaAsc B-FORMULA 
) O 
. O 
Results O 
showed O 
that O 
the O 
micelles O 
were O 
sensitive O 
to O 
both O 
acidic O 
hydrolysis O 
and O 
mild O 
reducing O 
agents O 
; O 
in O 
the O 
presence O 
of O 
5mM O 
NaAsc O 
, O 
cisplatin B-TRIVIAL 
(II) I-TRIVIAL 
was O 
directly O 
released O 
and O 
the O 
released O 
cisplatin B-TRIVIAL 
(II) I-TRIVIAL 
could O 
chelate O 
with O 
nucleobases B-FAMILY 
; O 
the O 
micelles O 
displayed O 
comparable O 
cytotoxicities O 
to O 
cisplatin B-TRIVIAL 
; O 
and O 
the O 
micelles O 
were O 
much O 
more O 
efficiently O 
internalized O 
by O 
the O 
cells O 
than O 
cisplatin B-TRIVIAL 
(II) I-TRIVIAL 
and O 
cisplatin B-TRIVIAL 
(IV) I-TRIVIAL 
counterparts O 
. O 
Moreover O 
, O 
in O 
vivo O 
study O 
showed O 
accumulation O 
of O 
more O 
Pt O 
species O 
in O 
the O 
tumor O 
site O 
and O 
lower O 
systematic O 
toxicity O 
compared O 
to O 
free O 
cisplatin B-TRIVIAL 
(II) I-TRIVIAL 
and O 
cisplatin B-TRIVIAL 
(IV) I-TRIVIAL 
. O 
This O 
polymeric O 
prodrug O 
of O 
cisplatin B-TRIVIAL 
is O 
expected O 
to O 
be O 
used O 
more O 
for O 
future O 
study O 
and O 
applications O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
benzothiazepinones B-FAMILY 
( O 
BTZs B-ABBREVIATION 
) O 
as O 
novel O 
non- O 
ATP B-ABBREVIATION 
competitive O 
inhibitors O 
of O 
glycogen O 
synthase O 
kinase-3β O 
( O 
GSK-3β O 
) O 
. O 

synthase O 
kinase-3β O 
( O 
GSK-3β O 
) O 
plays O 
a O 
key O 
role O 
in O 
type O 
II O 
diabetes O 
and O 
Alzheimer's O 
diseases O 
, O 
to O 
which O 
non- O 
ATP B-ABBREVIATION 
competitive O 
inhibitors O 
represent O 
an O 
effectively O 
therapeutical O 
approach O 
due O 
to O 
their O 
good O 
specificity O 
. O 
Herein O 
, O 
a O 
series O 
of O 
small O 
molecules O 
benzothiazepinones B-FAMILY 
( O 
BTZs B-ABBREVIATION 
) O 
as O 
novel O 
non- O 
ATP B-ABBREVIATION 
competitive O 
inhibitors O 
of O 
GSK-3β O 
have O 
been O 
designed O 
and O 
synthesized O 
. O 
The O 
in O 
vitro O 
evaluation O 
performed O 
by O 
luminescent O 
assay O 
showed O 
most O 
BTZ B-ABBREVIATION 
derivatives O 
have O 
inhibitory O 
effects O 
in O 
micromolar O 
scale O 
. O 
Among O 
them O 
compounds O 
6l O 
, O 
6t O 
and O 
6v O 
have O 
the O 
IC50 O 
values O 
of O 
25 O 
μM O 
, O 
27.8 O 
μM O 
and O 
23 O 
μM O 
, O 
respectively O 
. O 
Moreover O 
6v O 
is O 
devoid O 
of O 
any O 
inhibitory O 
activity O 
in O 
the O 
assays O 
to O 
other O 
thirteen O 
protein O 
kinases O 
. O 
Besides O 
, O 
SAR O 
is O 
analyzed O 
and O 
a O 
hypothetical O 
enzymatic O 
binding O 
mode O 
is O 
proposed O 
by O 
molecular O 
docking O 
study O 
, O 
which O 
would O 
be O 
useful O 
for O 
new O 
candidates O 
design O 
. O 

cholinergic O 
and O 
non-cholinergic O 
effects O 
of O 
organophosphates B-FAMILY 
and O 
oximes B-FAMILY 
in O 
cultured O 
human O 
myoblasts O 
. O 

compounds O 
( O 
OPs O 
) O 
and O 
oximes B-FAMILY 
may O 
interfere O 
with O 
other O 
molecules O 
than O 
AChE O 
in O 
the O 
living O 
systems O 
, O 
affecting O 
in O 
this O 
way O 
various O 
cellular O 
processes O 
and O 
underlying O 
mechanisms O 
. O 
These O 
non-cholinergic O 
effects O 
may O 
contribute O 
to O 
the O 
clinical O 
status O 
in O 
OP O 
poisoning O 
and O 
therefore O 
deserve O 
equal O 
scientific O 
attention O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
tabun B-TRIVIAL 
and O 
oxime B-SYSTEMATIC 
K048 B-IDENTIFIER 
on O 
the O 
processes O 
known O 
to O 
be O 
involved O 
in O 
muscle O 
response O 
to O 
the O 
environmental O 
factors O 
, O 
like O 
IL-6 O 
release O 
and O 
the O 
regulation O 
of O 
the O 
heat O 
shock O 
proteins O 
( O 
HSPs O 
) O 
. O 
While O 
IL-6 O 
stimulates O 
muscle O 
regeneration O 
, O 
which O 
follows O 
well O 
known O 
OP-induced O 
myopathy O 
, O 
HSPs O 
have O 
cytoprotective O 
effect O 
against O 
various O 
stress O 
factors O 
including O 
xenobiotics O 
. O 
All O 
our O 
experiments O 
were O 
carried O 
out O 
on O 
cultured O 
human O 
myoblasts O 
, O 
as O 
the O 
precursors O 
of O 
muscle O 
regeneration O 
. O 
We O 
found O 
unchanged O 
AChE O 
mRNA O 
level O 
after O 
tabun B-TRIVIAL 
/ O 
K048 B-IDENTIFIER 
treatment O 
meaning O 
that O 
tabun B-TRIVIAL 
and O 
K048 B-IDENTIFIER 
did O 
not O 
interfere O 
with O 
the O 
transcription O 
or O 
stability O 
of O 
this O 
mRNA O 
in O 
the O 
time O 
period O 
tested O 
, O 
even O 
if O 
AChE O 
catalytic O 
activity O 
was O 
significantly O 
affected O 
. O 
On O 
the O 
other O 
hand O 
, O 
after O 
myoblast O 
exposure O 
to O 
tabun B-TRIVIAL 
, O 
we O 
observed O 
significant O 
changes O 
in O 
the O 
protein O 
levels O 
of O 
HSP O 
27 O 
and O 
in O 
the O 
secretion O 
of O 
IL-6 O 
. O 
Namely O 
, O 
secretion O 
of O 
IL-6 O 
decreased O 
to O 
53% O 
and O 
the O 
level O 
of O 
HSP O 
27 O 
increased O 
by O 
34% O 
compared O 
to O 
the O 
control O 
level O 
. O 
Both O 
effects O 
were O 
attenuated O 
if O 
myoblasts O 
were O 
pretreated O 
with O 
oxime B-SYSTEMATIC 
K048 B-IDENTIFIER 
, O 
but O 
not O 
if O 
they O 
were O 
treated O 
with O 
K048 B-IDENTIFIER 
after O 
exposure O 
to O 
tabun B-TRIVIAL 
. O 
The O 
molecular O 
mechanism O 
underlying O 
these O 
effects O 
remains O 
to O 
be O 
elucidated O 
. O 
However O 
, O 
it O 
seems O 
that O 
these O 
effects O 
could O 
be O 
associated O 
with O 
OPs O 
and O 
oximes B-FAMILY 
as O 
a O 
specific O 
group O 
of O 
compounds O 
rather O 
than O 
as O 
a O 
specific O 
compound O 
itself O 
. O 
Overall O 
, O 
the O 
effects O 
of O 
OPs O 
and O 
oximes B-FAMILY 
demonstrated O 
here O 
might O 
play O 
an O 
important O 
role O 
in O 
muscle O 
regeneration O 
which O 
importantly O 
determines O 
the O 
final O 
outcome O 
of O 
OP O 
myotoxicity O 
. O 

versatile O 
multicomponent O 
assembly O 
via O 
β-cyclodextrin B-TRIVIAL 
host O 
- O 
guest O 
chemistry O 
on O 
graphene B-TRIVIAL 
for O 
biomedical O 
applications O 
. O 

multi O 
- O 
component O 
nanosystem O 
based O 
on O 
graphene B-TRIVIAL 
and O 
comprising O 
individual O 
cyclodextrins O 
at O 
its O 
surface O 
is O 
assembled O 
, O 
creating O 
hybrid O 
structures O 
enabling O 
new O 
and O 
important O 
functionalities O 
: O 
optical O 
imaging O 
, O 
drug O 
storage O 
, O 
and O 
cell O 
targeting O 
for O 
medical O 
diagnosis O 
and O 
treatment O 
. O 
These O 
nanohybrids O 
are O 
part O 
of O 
a O 
universal O 
system O 
of O 
interchangeable O 
units O 
, O 
capable O 
of O 
mutilple O 
functionalities O 
. O 
The O 
surface O 
components O 
, O 
made O 
of O 
individual O 
β-cyclodextrin B-TRIVIAL 
molecules O 
, O 
are O 
the O 
" O 
hosts O 
" O 
for O 
functional O 
units O 
, O 
which O 
may O 
be O 
used O 
as O 
imaging O 
agents O 
, O 
for O 
anti-cancer O 
drug O 
delivery O 
, O 
and O 
as O 
tumor O 
- O 
specific O 
ligands O 
. O 
Specifically O 
, O 
individual O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
) O 
, O 
with O 
a O 
known O 
capability O 
to O 
host O 
various O 
molecules O 
, O 
is O 
considered O 
a O 
module O 
unit O 
that O 
is O 
assembled O 
onto O 
graphene B-TRIVIAL 
nanosheet O 
( O 
GNS O 
) O 
. O 
The O 
cyclodextrin O 
- O 
functionalized O 
graphene B-TRIVIAL 
nanosheet O 
( O 
GNS/ O 
β-CD B-ABBREVIATION 
) O 
enables O 
" O 
host O 
- O 
guest O 
" O 
chemistry O 
between O 
the O 
nanohybrid O 
and O 
functional O 
" O 
payloads O 
" O 
. O 
The O 
structure O 
, O 
composition O 
, O 
and O 
morphology O 
of O 
the O 
graphene B-TRIVIAL 
nanosheet O 
hybrid O 
have O 
been O 
investigated O 
. O 
The O 
nanohybrid O 
, O 
GNS/ O 
β-CD B-ABBREVIATION 
, O 
is O 
highly O 
dispersive O 
in O 
various O 
physiological O 
solutions O 
, O 
reflecting O 
the O 
high O 
biostability O 
of O 
cyclodextrin O 
. O 
Regarding O 
the O 
host O 
capability O 
, O 
the O 
nanohybrid O 
is O 
fully O 
capable O 
of O 
selectively O 
accommodating O 
various O 
biological O 
and O 
functional O 
agents O 
in O 
a O 
controlled O 
fashion O 
, O 
including O 
the O 
antivirus O 
drug O 
amantadine B-TRIVIAL 
, O 
fluorescent O 
dye O 
[ O 
5(6)-carboxyfluorescein B-SYSTEMATIC 
] O 
, O 
and O 
Arg-Gly-Asp B-FORMULA 
( O 
RGD O 
) O 
peptide-targeting O 
ligands O 
assisted O 
by O 
an O 
adamantine B-TRIVIAL 
linker O 
. O 
The O 
loading O 
ratio O 
of O 
5(6)-carboxyfluorescein B-SYSTEMATIC 
is O 
as O 
high O 
as O 
110% O 
with O 
a O 
drug O 
concentration O 
of O 
0.45 O 
mg O 
mL(-1) O 
. O 
The O 
cyclic B-TRIVIAL 
RGD I-TRIVIAL 
-functionalized O 
nanohybrid O 
exhibits O 
remarkable O 
targeting O 
for O 
HeLa O 
cells O 
. O 

induced O 
ER O 
stress O 
and O 
enhanced O 
caspase O 
12 O 
cleavage O 
in O 
human O 
neuroblastoma O 
SH-SY5Y O 
cells O 
at O 
low O 
nonexcitotoxic O 
concentrations O 
. O 

cyanobacterial O 
β-N-methylamino-L-alanine B-SYSTEMATIC 
( O 
L-BMAA B-ABBREVIATION 
) O 
is O 
described O 
as O 
a O 
low O 
- O 
potency O 
excitotoxin O 
, O 
possibly O 
a O 
factor O 
in O 
the O 
increased O 
incidence O 
of O 
amyotrophic O 
lateral O 
sclerosis O 
( O 
ALS O 
) O 
and O 
Parkinsonism O 
- O 
dementia O 
complex O 
( O 
PDC O 
) O 
in O 
Guam O 
. O 
The O 
latter O 
association O 
is O 
intensively O 
disputed O 
, O 
as O 
L-BMAA B-ABBREVIATION 
concentrations O 
required O 
for O 
toxic O 
effects O 
exceed O 
those O 
assumed O 
to O 
occur O 
via O 
food O 
. O 
The O 
question O 
thus O 
was O 
raised O 
whether O 
L-BMAA B-ABBREVIATION 
leads O 
to O 
neurodegeneration O 
at O 
nonexcitotoxic O 
conditions O 
. O 
Using O 
human O 
SH-SY5Y O 
neuroblastoma O 
cells O 
, O 
L-BMAA B-ABBREVIATION 
-transport O 
, O 
incorporation O 
into O 
proteins O 
, O 
and O 
subsequent O 
impairment O 
of O 
cellular O 
protein O 
homeostasis O 
were O 
investigated O 
. O 
Binding O 
of O 
L-BMAA B-ABBREVIATION 
to O 
intracellular O 
proteins O 
, O 
but O 
no O 
clear O 
protein O 
incorporation O 
was O 
detected O 
in O 
response O 
to O 
(14)C B-FORMULA 
- O 
L-BMAA B-ABBREVIATION 
exposures O 
. O 
Nevertheless O 
, O 
low O 
L-BMAA B-ABBREVIATION 
concentrations O 
( O 
≥ O 
0.1mM O 
, O 
48 O 
h O 
) O 
increased O 
protein O 
ubiquitination O 
, O 
20S O 
proteasomal O 
and O 
caspase O 
12 O 
activity O 
, O 
expression O 
of O 
the O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
marker O 
CHOP O 
, O 
and O 
enhanced O 
phosphorylation O 
of O 
elf2α O 
in O 
SH-SY5Y O 
cells O 
. O 
In O 
contrast O 
, O 
high O 
L-BMAA B-ABBREVIATION 
concentrations O 
( O 
≥ O 
1mM O 
, O 
48 O 
h O 
) O 
increased O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
protein O 
oxidization O 
, O 
which O 
were O 
partially O 
ameliorated O 
by O 
coincubation O 
with O 
vitamin B-FAMILY 
E I-FAMILY 
. O 
L-BMAA B-ABBREVIATION 
-mediated O 
cytotoxicity O 
was O 
observable O 
48 O 
h O 
following O 
≥ O 
2mM O 
L-BMAA B-ABBREVIATION 
treatment O 
. O 
Consequently O 
, O 
the O 
data O 
presented O 
here O 
suggest O 
that O 
low O 
L-BMAA B-ABBREVIATION 
concentrations O 
result O 
in O 
a O 
dysregulation O 
of O 
the O 
cellular O 
protein O 
homeostasis O 
with O 
ensuing O 
ER O 
stress O 
that O 
is O 
independent O 
from O 
high O 
- O 
concentration O 
effects O 
such O 
as O 
excitotoxicity O 
and O 
oxidative O 
stress O 
. O 
Thus O 
, O 
the O 
latter O 
could O 
be O 
a O 
contributing O 
factor O 
in O 
the O 
onset O 
and O 
slow O 
progression O 
of O 
ALS O 
/ O 
PDC O 
in O 
Guam O 
. O 

-induced O 
intracellular O 
GTP B-ABBREVIATION 
depletion O 
activates O 
transcription O 
elongation O 
in O 
coagulation O 
factor O 
VII O 
gene O 
expression O 
. O 

FVII O 
( O 
Factor O 
VII O 
) O 
is O 
a O 
vitamin B-FAMILY 
K I-FAMILY 
-dependent O 
glycoprotein O 
synthesized O 
in O 
hepatocytes O 
. O 
It O 
was O 
reported O 
previously O 
that O 
FVII O 
gene O 
( O 
F7 O 
) O 
expression O 
was O 
up O 
- O 
regulated O 
by O 
ribavirin B-TRIVIAL 
treatment O 
in O 
hepatitis O 
C O 
virus O 
- O 
infected O 
haemophilia O 
patients O 
; O 
however O 
, O 
its O 
precise O 
mechanism O 
is O 
still O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
molecular O 
mechanism O 
of O 
ribavirin B-TRIVIAL 
-induced O 
up O 
- O 
regulation O 
of O 
F7 O 
expression O 
in O 
HepG2 O 
( O 
human O 
hepatoma O 
cell O 
line O 
) O 
. O 
We O 
found O 
that O 
intracellular O 
GTP B-ABBREVIATION 
depletion O 
by O 
ribavirin B-TRIVIAL 
as O 
well O 
as O 
other O 
IMPDH O 
( O 
inosine-5'-monophosphate B-SYSTEMATIC 
dehydrogenase O 
) O 
inhibitors O 
, O 
such O 
as O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
and O 
6-mercaptopurine B-TRIVIAL 
, O 
up O 
- O 
regulated O 
F7 O 
expression O 
. O 
FVII O 
mRNA O 
transcription O 
was O 
mainly O 
enhanced O 
by O 
accelerated O 
transcription O 
elongation O 
, O 
which O 
was O 
mediated O 
by O 
the O 
P-TEFb O 
( O 
positive O 
- O 
transcription O 
elongation O 
factor O 
b O 
) O 
complex O 
, O 
rather O 
than O 
by O 
promoter O 
activation O 
. O 
Ribavirin B-TRIVIAL 
unregulated O 
ELL O 
( O 
eleven O 
- O 
nineteen O 
lysine B-TRIVIAL 
-rich O 
leukaemia O 
) O 
3 O 
mRNA O 
expression O 
before O 
F7 O 
up O 
- O 
regulation O 
. O 
We O 
observed O 
that O 
ribavirin B-TRIVIAL 
enhanced O 
ELL3 O 
recruitment O 
to O 
F7 O 
, O 
whereas O 
knockdown O 
of O 
ELL3 O 
diminished O 
ribavirin B-TRIVIAL 
-induced O 
FVII O 
mRNA O 
up O 
- O 
regulation O 
. O 
Ribavirin B-TRIVIAL 
also O 
enhanced O 
recruitment O 
of O 
CDK9 O 
( O 
cyclin O 
- O 
dependent O 
kinase O 
9 O 
) O 
and O 
AFF4 O 
to O 
F7 O 
. O 
These O 
data O 
suggest O 
that O 
ribavirin B-TRIVIAL 
-induced O 
intracellular O 
GTP B-ABBREVIATION 
depletion O 
recruits O 
a O 
super O 
elongation O 
complex O 
containing O 
P-TEFb O 
, O 
AFF4 O 
and O 
ELL3 O 
, O 
to O 
F7 O 
, O 
and O 
modulates O 
FVII O 
mRNA O 
transcription O 
elongation O 
. O 
Collectively O 
, O 
we O 
have O 
elucidated O 
a O 
basal O 
mechanism O 
for O 
ribavirin B-TRIVIAL 
-induced O 
FVII O 
mRNA O 
up O 
- O 
regulation O 
by O 
acceleration O 
of O 
transcription O 
elongation O 
, O 
which O 
may O 
be O 
crucial O 
in O 
understanding O 
its O 
pleiotropic O 
functions O 
in O 
vivo O 
. O 

- O 
metal O 
( O 
WC B-FORMULA 
- O 
Co B-FORMULA 
) O 
particles O 
trigger O 
a O 
signaling O 
cascade O 
involving O 
p38 O 
MAPK O 
, O 
HIF-1α O 
, O 
HMOX1 O 
, O 
and O 
p53 O 
activation O 
in O 
human O 
PBMC O 
. O 

- O 
metals O 
are O 
made O 
of O 
tungsten B-SYSTEMATIC 
carbide I-SYSTEMATIC 
( O 
WC B-FORMULA 
) O 
and O 
metallic O 
cobalt B-SYSTEMATIC 
( O 
Co B-FORMULA 
) O 
particles O 
and O 
are O 
important O 
industrial O 
materials O 
produced O 
for O 
their O 
extreme O 
hardness O 
and O 
high O 
wear O 
resistance O 
properties O 
. O 
While O 
occupational O 
exposure O 
to O 
metallic O 
Co B-FORMULA 
alone O 
is O 
apparently O 
not O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
cancer O 
, O 
the O 
WC B-FORMULA 
- O 
Co B-FORMULA 
particle O 
mixture O 
was O 
shown O 
to O 
increase O 
the O 
risk O 
of O 
lung O 
cancer O 
in O 
exposed O 
workers O 
. O 
We O 
have O 
previously O 
shown O 
that O 
WC B-FORMULA 
- O 
Co B-FORMULA 
specifically O 
induces O 
a O 
burst O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
in O 
vitro O 
mutagenic O 
/ O 
apoptogenic O 
effects O 
in O 
human O 
peripheral O 
blood O 
mononucleated O 
cells O 
( O 
PBMC O 
) O 
used O 
as O 
a O 
validated O 
experimental O 
model O 
. O 
In O 
the O 
present O 
study O 
, O 
PBMCs O 
were O 
treated O 
during O 
a O 
short O 
period O 
( O 
15 O 
min O 
) O 
to O 
focus O 
on O 
the O 
very O 
rapid O 
ROS O 
burst O 
induced O 
by O 
WC B-FORMULA 
- O 
Co B-FORMULA 
. O 
We O 
investigated O 
by O 
microarray O 
the O 
response O 
to O 
WC B-FORMULA 
- O 
Co B-FORMULA 
versus O 
Co(2+) B-FORMULA 
ions O 
( O 
CoCl(2) B-FORMULA 
) O 
after O 
15 O 
min O 
exposure O 
and O 
found O 
that O 
the O 
oxidative O 
stress O 
response O 
HMOX1 O 
gene O 
was O 
highly O 
expressed O 
in O 
WC B-FORMULA 
- O 
Co B-FORMULA 
-treated O 
samples O 
. O 
This O 
result O 
was O 
confirmed O 
by O 
qRT-PCR O 
, O 
and O 
western O 
blotting O 
was O 
carried O 
out O 
to O 
analyze O 
translational O 
and O 
post O 
- O 
translational O 
regulation O 
of O 
genes O 
belonging O 
to O 
the O 
HMOX1 O 
pathway O 
. O 
We O 
show O 
here O 
that O 
WC B-FORMULA 
- O 
Co B-FORMULA 
, O 
and O 
metallic O 
Co B-FORMULA 
particles O 
although O 
with O 
slower O 
kinetics O 
, O 
but O 
not O 
CoCl(2) B-FORMULA 
or O 
WC B-FORMULA 
alone O 
, O 
induced O 
a O 
temporally O 
ordered O 
cascade O 
of O 
events O 
. O 
This O 
cascade O 
implies O 
p38 O 
/ O 
MAP O 
kinase O 
activation O 
, O 
HIF-1α O 
stabilization O 
, O 
HMOX1 O 
transcriptional O 
activation O 
, O 
and O 
ATM O 
- O 
independent O 
p53 O 
stabilization O 
. O 
These O 
events O 
, O 
and O 
in O 
particular O 
HIF-1α O 
stabilization O 
, O 
could O 
contribute O 
to O 
the O 
carcinogenic O 
activity O 
of O 
WC B-FORMULA 
- O 
Co B-FORMULA 
dusts O 
. O 

Y O 
Y1 O 
receptor O 
knockdown O 
can O 
modify O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
c-AMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
in O 
phenylpropanolamine B-SYSTEMATIC 
-treated O 
rats O 
. O 

has O 
been O 
reported O 
that O 
antioxidative O 
enzymes O 
, O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
, O 
and O 
c-AMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
( O 
CREB O 
) O 
are O 
involved O 
in O 
regulating O 
phenylpropanolamine B-SYSTEMATIC 
( O 
PPA B-ABBREVIATION 
) O 
- O 
mediated O 
appetite O 
suppression O 
. O 
Here O 
, O 
we O 
investigated O 
whether O 
Y1 O 
receptor O 
( O 
Y1R O 
) O 
might O 
be O 
involved O 
in O 
this O 
regulation O 
. O 
Rats O 
were O 
daily O 
treated O 
with O 
PPA B-ABBREVIATION 
for O 
4 O 
days O 
. O 
Changes O 
in O 
the O 
contents O 
of O 
NPY O 
, O 
Y1R O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GP O 
) O 
, O 
and O 
CREB O 
were O 
assessed O 
and O 
compared O 
. O 
Results O 
showed O 
that O 
Y1R O 
, O 
GP O 
, O 
and O 
CREB O 
increased O 
, O 
with O 
a O 
maximal O 
increase O 
about O 
100 O 
, O 
200 O 
, O 
and O 
150 O 
% O 
, O 
respectively O 
, O 
on O 
Day O 
2 O 
. O 
By O 
contrast O 
, O 
NPY O 
decreased O 
with O 
a O 
biggest O 
reduction O 
about O 
48 O 
% O 
on O 
Day O 
2 O 
and O 
the O 
pattern O 
of O 
expression O 
during O 
PPA B-ABBREVIATION 
treatment O 
was O 
opposite O 
to O 
those O 
of O 
Y1R O 
, O 
GP O 
, O 
and O 
CREB O 
. O 
Central O 
knockdown O 
( O 
using O 
antisense O 
) O 
or O 
inhibition O 
( O 
using O 
antagonist O 
) O 
of O 
Y1R O 
expression O 
modulated O 
the O 
anorectic O 
response O 
of O 
PPA B-ABBREVIATION 
and O 
the O 
reciprocal O 
regulation O 
between O 
NPY O 
and O 
GP O 
( O 
or O 
CREB O 
) O 
, O 
revealing O 
an O 
essential O 
role O 
of O 
Y1R O 
in O 
regulating O 
NPY O 
, O 
GP O 
, O 
and O 
CREB O 
. O 
These O 
results O 
suggest O 
that O 
Y1R O 
participates O 
in O 
the O 
reciprocal O 
regulation O 
of O 
NPY O 
, O 
GP O 
, O 
and O 
CREB O 
in O 
the O 
hypothalamus O 
during O 
PPA B-ABBREVIATION 
treatment O 
in O 
conscious O 
rats O 
. O 
The O 
present O 
results O 
may O 
aid O 
the O 
therapeutic O 
research O 
of O 
PPA B-ABBREVIATION 
and O 
related O 
antiobesity O 
drugs O 
. O 

metallo-dielectric O 
hybrid O 
clusters O 
with O 
subwavelength O 
dimensions O 
are O 
fabricated O 
by O 
template O 
guided O 
self O 
- O 
assembly O 
. O 
Elastic O 
and O 
inelastic O 
scattering O 
spectroscopy O 
and O 
electromagnetic O 
simulations O 
reveal O 
that O 
hybrid O 
clusters O 
comprising O 
TiO(2) B-FORMULA 
nanoparticles O 
on O 
top O 
of O 
a O 
cluster O 
of O 
strongly O 
coupled O 
gold O 
nanoparticles O 
harness O 
synergistic O 
electromagnetic O 
interactions O 
between O 
the O 
building O 
blocks O 
. O 
This O 
results O 
in O 
a O 
boost O 
of O 
the O 
peak O 
electric O 
field O 
intensity O 
and O 
a O 
redistribution O 
of O 
the O 
field O 
in O 
the O 
ambient O 
medium O 
. O 
The O 
complex O 
phase O 
landscape O 
in O 
the O 
clusters O 
features O 
optical O 
vortices O 
that O 
enhance O 
the O 
magnetic O 
field O 
. O 

copolymerization O 
of O 
a O 
conjugated O 
segment O 
and O 
a O 
flexible O 
segment O 
and O 
fabrication O 
of O 
a O 
fluorescent O 
sensing O 
film O 
for O 
HCl B-FORMULA 
in O 
the O 
vapor O 
phase O 
. O 

novel O 
fluorescently O 
active O 
co O 
- O 
oligomer O 
( O 
P1 O 
) O 
was O 
designed O 
and O 
prepared O 
by O 
alternative O 
co O 
- O 
polymerization O 
of O 
oligo(p-phenyleneethynylene) B-SYSTEMATIC 
( O 
OPE B-ABBREVIATION 
) O 
, O 
possessing O 
two O 
cholesterol B-TRIVIAL 
-containing O 
side O 
chains O 
, O 
and O 
ethanediamine B-SYSTEMATIC 
. O 
A O 
control O 
co O 
- O 
oligomer O 
( O 
P2 O 
) O 
possessing O 
similar O 
structure O 
to O 
P1 O 
was O 
also O 
prepared O 
, O 
but O 
in O 
this O 
case O 
the O 
OPE B-ABBREVIATION 
bears O 
no O 
side O 
chains O 
. O 
P1 O 
and O 
P2 O 
have O 
been O 
used O 
for O 
the O 
fabrication O 
of O 
two O 
fluorescent O 
films O 
, O 
film O 
1 O 
and O 
film O 
2 O 
, O 
respectively O 
. O 
Fluorescence O 
studies O 
demonstrated O 
that O 
the O 
emission O 
of O 
film O 
1 O 
is O 
sensitive O 
and O 
selective O 
to O 
the O 
presence O 
of O 
trace O 
amounts O 
of O 
HCl B-FORMULA 
in O 
air O 
. O 
In O 
contrast O 
, O 
film O 
2 O 
shows O 
no O 
such O 
response O 
. O 
The O 
quenching O 
has O 
been O 
attributed O 
to O 
the O 
protonation O 
of O 
the O 
imino B-SYSTEMATIC 
groups O 
within O 
the O 
oligomer O 
chains O 
, O 
and O 
the O 
difference O 
in O 
the O 
sensing O 
behaviors O 
of O 
the O 
two O 
films O 
was O 
rationalized O 
by O 
supposing O 
the O 
existence O 
of O 
molecular O 
channels O 
in O 
film O 
1 O 
. O 
The O 
proposed O 
mechanism O 
is O 
supported O 
by O 
the O 
results O 
from O 
additional O 
experiments O 
and O 
theoretical O 
calculations O 
. O 
Furthermore O 
, O 
the O 
film O 
as O 
fabricated O 
is O 
robust O 
, O 
and O 
thereby O 
it O 
is O 
believed O 
that O 
film O 
1 O 
has O 
the O 
potential O 
to O 
be O 
developed O 
into O 
a O 
new O 
generation O 
of O 
sensitive O 
and O 
selective O 
HCl B-FORMULA 
sensor O 
. O 

of O 
metabolically O 
stabilized O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
analogs O 
as O 
procognitive O 
/ O 
antidementia O 
agents O 
. O 

IV I-TRIVIAL 
( O 
AngIV B-ABBREVIATION 
: O 
VYIHPF O 
) O 
- O 
related O 
peptides O 
have O 
long O 
been O 
recognized O 
as O 
procognitive O 
agents O 
with O 
potential O 
as O 
antidementia O 
therapeutics O 
. O 
Their O 
development O 
as O 
useful O 
therapeutics O 
, O 
however O 
, O 
has O 
been O 
limited O 
by O 
physiochemical O 
properties O 
that O 
make O 
them O 
susceptible O 
to O 
metabolic O 
degradation O 
and O 
impermeable O 
to O 
gut O 
and O 
blood O 
- O 
brain O 
barriers O 
. O 
A O 
previous O 
study O 
demonstrated O 
that O 
the O 
core O 
structural O 
information O 
required O 
to O 
impart O 
the O 
procognitive O 
activity O 
of O 
the O 
AngIV B-ABBREVIATION 
analog O 
, O 
norleucine B-TRIVIAL 
(1)- O 
angiotensin B-TRIVIAL 
IV I-TRIVIAL 
, O 
resides O 
in O 
its O 
three O 
N B-FORMULA 
-terminal O 
amino B-FAMILY 
acids I-FAMILY 
, O 
Nle-Tyr-Ile B-FORMULA 
. O 
The O 
goal O 
of O 
this O 
project O 
was O 
to O 
chemically O 
modify O 
this O 
tripeptide B-FAMILY 
in O 
such O 
a O 
way O 
to O 
enhance O 
its O 
metabolic O 
stability O 
and O 
barrier O 
permeability O 
to O 
produce O 
a O 
drug O 
candidate O 
with O 
potential O 
clinical O 
utility O 
. O 
Initial O 
results O 
demonstrated O 
that O 
several O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
modifications O 
lead O 
to O 
dramatically O 
improved O 
stability O 
while O 
maintaining O 
the O 
capability O 
to O 
reverse O 
scopolamine B-TRIVIAL 
-induced O 
deficits O 
in O 
Morris O 
water O 
maze O 
performance O 
and O 
augment O 
hippocampal O 
synaptogenesis O 
. O 
Subsequent O 
chemical O 
modifications O 
, O 
which O 
were O 
designed O 
to O 
increase O 
hydrophobicity O 
and O 
decrease O 
hydrogen B-SYSTEMATIC 
bonding O 
, O 
yielded O 
an O 
orally O 
active O 
, O 
blood O 
- O 
barrier O 
permeant O 
, O 
metabolically O 
stabilized O 
analog O 
, O 
N-hexanoic-Tyr-Ile-(6) B-SYSTEMATIC 
aminohexanoic I-SYSTEMATIC 
amide I-SYSTEMATIC 
( O 
dihexa B-ABBREVIATION 
) O 
, O 
that O 
exhibits O 
excellent O 
antidementia O 
activity O 
in O 
the O 
scopolamine B-TRIVIAL 
and O 
aged O 
rat O 
models O 
and O 
marked O 
synaptogenic O 
activity O 
. O 
These O 
data O 
suggest O 
that O 
dihexa B-ABBREVIATION 
may O 
have O 
therapeutic O 
potential O 
as O 
a O 
treatment O 
of O 
disorders O 
, O 
such O 
as O 
Alzheimer's O 
disease O 
, O 
where O 
augmented O 
synaptic O 
connectivity O 
may O 
be O 
beneficial O 
. O 

new O 
approach O 
to O 
counteract O 
bacteria O 
resistance O 
: O 
a O 
comparative O 
study O 
between O 
moxifloxacin B-TRIVIAL 
and O 
a O 
new O 
moxifloxacin B-TRIVIAL 
derivative O 
in O 
different O 
model O 
systems O 
of O 
bacterial O 
membrane O 
. O 

drug O 
design O 
has O 
been O 
one O 
of O 
the O 
major O 
challenges O 
to O 
combat O 
bacterial O 
resistance O 
over O 
the O 
past O 
decade O 
. O 
Conventional O 
antibiotics O 
act O 
by O 
destroying O 
bacterial O 
cell O 
wall O 
or O 
by O 
blocking O 
biosynthetic O 
pathways O 
necessary O 
for O 
its O 
survival O 
. O 
Unfortunately O 
, O 
there O 
has O 
been O 
a O 
fast O 
increase O 
in O 
multiresistance O 
, O 
to O 
several O 
conventional O 
antibiotics O 
, O 
in O 
clinical O 
bacterial O 
strains O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
metalloantibiotics O 
, O 
ternary O 
complexes O 
of O 
antibiotic-metal- O 
phenanthroline B-SYSTEMATIC 
, O 
present O 
an O 
increased O 
potential O 
as O 
antimicrobial O 
agents O 
. O 
In O 
this O 
work O 
moxifloxacin B-TRIVIAL 
, O 
a O 
fourth O 
- O 
generation O 
quinolone B-FAMILY 
, O 
with O 
a O 
broad O 
spectrum O 
of O 
action O 
, O 
and O 
its O 
copper B-SYSTEMATIC 
ternary O 
complex O 
( O 
metalloantibiotic O 
) O 
have O 
been O 
study O 
by O 
fluorescence O 
spectroscopy O 
. O 
Partition O 
coefficients O 
were O 
determined O 
and O 
showed O 
that O 
while O 
free O 
moxifloxacin B-TRIVIAL 
exhibits O 
the O 
same O 
behaviour O 
independently O 
of O 
the O 
lipidic O 
system O 
tested O 
, O 
the O 
metalloantibiotic O 
presents O 
higher O 
partition O 
to O 
liposomes O 
, O 
in O 
a O 
lipid O 
composition O 
- O 
dependent O 
way O 
. O 
These O 
significant O 
differences O 
in O 
the O 
interaction O 
of O 
the O 
metalloantibiotic O 
with O 
model O 
bacteria O 
membranes O 
point O 
out O 
for O 
a O 
putative O 
change O 
in O 
its O 
uptake O 
mechanism O 
with O 
increased O 
drug O 
- O 
lipid O 
interaction O 
potentiating O 
metalloantibiotic O 
influx O 
. O 

of O 
nail O 
diseases O 
by O 
topical O 
drug O 
delivery O 
continues O 
to O 
draw O 
much O 
attention O 
in O 
the O 
recent O 
days O 
. O 
This O 
study O 
aims O 
to O 
systematically O 
investigate O 
the O 
effect O 
of O 
constant O 
voltage O 
iontophoresis O 
in O 
the O 
transungual O 
drug O 
delivery O 
, O 
using O 
ciclopirox B-TRIVIAL 
as O 
a O 
model O 
drug O 
. O 
Preliminary O 
permeation O 
studies O 
were O 
carried O 
out O 
by O 
applying O 
constant O 
voltage O 
( O 
6 O 
V O 
for O 
24 O 
h O 
) O 
using O 
a O 
gel O 
formulation O 
across O 
the O 
human O 
nail O 
plate O 
in O 
a O 
Franz O 
diffusion O 
cell O 
. O 
Different O 
protocols O 
have O 
been O 
studied O 
to O 
authenticate O 
the O 
potential O 
of O 
the O 
proposed O 
technique O 
. O 
Antifungal O 
studies O 
were O 
carried O 
out O 
to O 
assess O 
the O 
pharmacodynamic O 
effect O 
of O 
drug O 
depot O 
formed O 
in O 
the O 
nail O 
plate O 
. O 
Initial O 
studies O 
revealed O 
that O 
application O 
of O 
constant O 
voltage O 
iontophoresis O 
enhanced O 
the O 
permeation O 
by O 
an O 
order O 
of O 
magnitude O 
( O 
p O 
= O 
0.019 O 
) O 
and O 
delivered O 
significant O 
amount O 
of O 
drug O 
into O 
the O 
deeper O 
nail O 
layers O 
. O 
Noticeably O 
higher O 
permeation O 
was O 
observed O 
during O 
the O 
active O 
phase O 
in O 
on O 
- O 
off O 
studies O 
. O 
Excellent O 
correlation O 
was O 
observed O 
in O 
permeation O 
( O 
r(2) O 
= O 
0.98 O 
) O 
and O 
drug O 
load O 
( O 
r(2) O 
= O 
0.97 O 
) O 
with O 
the O 
increase O 
in O 
applied O 
voltage O 
( O 
3-12 O 
V O 
) O 
, O 
indicating O 
that O 
the O 
current O 
technique O 
is O 
predictable O 
. O 
The O 
data O 
observed O 
suggest O 
that O 
any O 
further O 
increase O 
in O 
voltage O 
could O 
eventually O 
lead O 
to O 
increase O 
in O 
the O 
permeation O 
and O 
drug O 
load O 
, O 
as O 
the O 
saturation O 
level O 
is O 
very O 
distant O 
. O 
Furthermore O 
, O 
the O 
enhancement O 
in O 
permeation O 
with O 
the O 
applied O 
voltage O 
( O 
3-12 O 
V O 
) O 
was O 
found O 
to O 
be O 
6-20 O 
folds O 
, O 
compared O 
to O 
the O 
passive O 
process O 
. O 
Results O 
of O 
step O 
up O 
and O 
step O 
down O 
studies O 
substantiated O 
the O 
viability O 
of O 
the O 
current O 
technique O 
. O 
Zone O 
of O 
inhibition O 
measured O 
during O 
the O 
antifungal O 
studies O 
demonstrated O 
that O 
the O 
drug O 
molecules O 
loaded O 
into O 
the O 
nail O 
plate O 
by O 
low O 
voltage O 
iontophoresis O 
is O 
active O 
and O 
releases O 
over O 
an O 
extended O 
period O 
of O 
time O 
( O 
~32 O 
days O 
) O 
. O 
Given O 
the O 
excellent O 
results O 
, O 
the O 
current O 
technique O 
could O 
be O 
used O 
as O 
an O 
effective O 
approach O 
for O 
the O 
delivery O 
of O 
antimycotics O 
, O 
which O 
would O 
localize O 
the O 
drug O 
at O 
the O 
infection O 
site O 
and O 
potentially O 
offer O 
higher O 
patient O 
compliance O 
. O 

remodeling O 
is O 
affected O 
by O 
mechanical O 
loading O 
and O 
inflammatory O 
mediators O 
, O 
including O 
chemokines O 
. O 
The O 
chemokine O 
( O 
C-C O 
motif O 
) O 
ligand O 
3 O 
( O 
CCL3 O 
) O 
is O 
involved O 
in O 
bone O 
remodeling O 
by O 
binding O 
to O 
C-C O 
chemokine O 
receptors O 
1 O 
and O 
5 O 
( O 
CCR1 O 
and O 
CCR5 O 
) O 
expressed O 
on O 
osteoclasts O 
and O 
osteoblasts O 
. O 
Our O 
group O 
has O 
previously O 
demonstrated O 
that O 
CCR5 O 
down O 
- O 
regulates O 
mechanical O 
loading O 
- O 
induced O 
bone O 
resorption O 
. O 
Thus O 
, O 
the O 
present O 
study O 
aimed O 
to O 
investigate O 
the O 
role O 
of O 
CCR1 O 
and O 
CCL3 O 
in O 
bone O 
remodeling O 
induced O 
by O 
mechanical O 
loading O 
during O 
orthodontic O 
tooth O 
movement O 
in O 
mice O 
. O 
Our O 
results O 
showed O 
that O 
bone O 
remodeling O 
was O 
significantly O 
decreased O 
in O 
CCL3(- O 
/ O 
- O 
) O 
and O 
CCR1(- O 
/ O 
- O 
) O 
mice O 
and O 
in O 
animals O 
treated O 
with O 
Met B-FORMULA 
-RANTES O 
( O 
an O 
antagonist O 
of O 
CCR5 O 
and O 
CCR1 O 
) O 
. O 
mRNA O 
levels O 
of O 
receptor O 
activator O 
of O 
nuclear O 
factor O 
kappa-B O 
( O 
RANK O 
) O 
, O 
its O 
ligand O 
RANKL O 
, O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
and O 
RANKL O 
/ O 
osteoprotegerin O 
( O 
OPG O 
) O 
ratio O 
were O 
diminished O 
in O 
the O 
periodontium O 
of O 
CCL3(- O 
/ O 
- O 
) O 
mice O 
and O 
in O 
the O 
group O 
treated O 
with O 
Met B-FORMULA 
-RANTES O 
. O 
Met B-FORMULA 
-RANTES O 
treatment O 
also O 
reduced O 
the O 
levels O 
of O 
cathepsin O 
K O 
and O 
metalloproteinase O 
13 O 
( O 
MMP13 O 
) O 
. O 
The O 
expression O 
of O 
the O 
osteoblast O 
markers O 
runt O 
- O 
related O 
transcription O 
factor O 
2 O 
( O 
RUNX2 O 
) O 
and O 
periostin O 
was O 
decreased O 
, O 
while O 
osteocalcin O 
( O 
OCN O 
) O 
was O 
augmented O 
in O 
CCL3(- O 
/ O 
- O 
) O 
and O 
Met B-FORMULA 
-RANTES O 
- O 
treated O 
mice O 
. O 
Altogether O 
, O 
these O 
findings O 
show O 
that O 
CCR1 O 
is O 
pivotal O 
for O 
bone O 
remodeling O 
induced O 
by O 
mechanical O 
loading O 
during O 
orthodontic O 
tooth O 
movement O 
and O 
these O 
actions O 
depend O 
, O 
at O 
least O 
in O 
part O 
, O 
on O 
CCL3 O 
. O 

sensitive O 
H2O2 B-FORMULA 
assay O 
based O 
on O 
dumbbell O 
- O 
like O 
PtPd-Fe3O4 B-FORMULA 
nanoparticles O 
. O 

- O 
like O 
Pt(48)Pd(52)-Fe(3)O(4) B-FORMULA 
nanoparticles O 
are O 
synthesized O 
and O 
functionalized O 
with O 
oleylamine B-SYSTEMATIC 
- O 
polyethyleneglycol B-SYSTEMATIC 
to O 
serve O 
as O 
an O 
efficient O 
catalyst O 
for O 
H(2)O(2) B-FORMULA 
reduction O 
and O 
tetramethylbenzidine B-SYSTEMATIC 
( O 
TMB B-ABBREVIATION 
) O 
oxidation O 
in O 
biological O 
solutions O 
. O 
The O 
Pt(48)Pd(52)-Fe(3)O(4) B-FORMULA 
/ O 
TMB B-ABBREVIATION 
kit O 
is O 
even O 
more O 
active O 
than O 
the O 
natural O 
enzyme O 
for O 
H(2)O(2) B-FORMULA 
detection O 
with O 
a O 
detection O 
limit O 
reaching O 
2 O 
μM O 
, O 
and O 
is O 
successfully O 
used O 
to O 
quantitatively O 
monitor O 
the O 
extracellular O 
H(2)O(2) B-FORMULA 
generated O 
by O 
neutrophils O 
. O 

molecules O 
with O 
medicinal O 
applications O 
. O 

incorporation O 
of O 
silicon B-SYSTEMATIC 
and O 
synthesis O 
of O 
organosilicon B-FAMILY 
small O 
molecules O 
provide O 
unique O 
opportunities O 
for O 
medicinal O 
applications O 
. O 
The O 
biological O 
investigation O 
of O 
organosilicon B-FAMILY 
small O 
molecules O 
is O 
particularly O 
interesting O 
because O 
of O 
differences O 
in O 
their O 
chemical O 
properties O 
that O 
can O 
contribute O 
to O 
enhanced O 
potency O 
and O 
improved O 
pharmacological O 
attributes O 
. O 
Applications O 
such O 
as O 
inhibitor O 
design O 
, O 
imaging O 
, O 
drug O 
release O 
technology O 
, O 
and O 
mapping O 
inhibitor O 
binding O 
are O 
discussed O 
. O 

-- O 
pharmacology O 
of O 
an O 
important O 
naturally O 
medicinal O 
" O 
cool O 
" O 
. O 

, O 
a O 
natural O 
product O 
of O 
the O 
peppermint O 
plant O 
Mentha O 
x O 
piperita O 
( O 
Lamiaceae O 
) O 
, O 
is O 
a O 
monoterpene B-FAMILY 
which O 
is O 
widely O 
used O 
as O 
a O 
natural O 
product O 
in O 
cosmetics O 
, O 
a O 
flavoring O 
agent O 
, O 
and O 
as O 
an O 
intermediate O 
in O 
the O 
production O 
of O 
other O 
compounds O 
. O 
Various O 
extracts O 
from O 
peppermint O 
contain O 
menthol B-TRIVIAL 
as O 
a O 
major O 
active O 
constituent O 
and O 
have O 
been O 
used O 
for O 
centuries O 
as O 
traditional O 
medicines O 
for O 
a O 
number O 
of O 
ailments O 
including O 
infections O 
, O 
insomnia O 
, O 
and O 
irritable O 
bowel O 
syndrome O 
as O 
well O 
as O 
an O 
insect O 
repellent O 
. O 
Menthol B-TRIVIAL 
' O 
s O 
characteristic O 
cooling O 
sensation O 
is O 
due O 
, O 
in O 
part O 
, O 
to O 
the O 
activation O 
of O 
sensory O 
neurons O 
generally O 
termed O 
transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
channels O 
, O 
in O 
particular O 
transient O 
receptor O 
potential O 
melastatin O 
family O 
member O 
8 O 
( O 
TRPM8 O 
) O 
and O 
transient O 
receptor O 
potential O 
subfamily O 
A O 
, O 
member O 
1 O 
( O 
TRPA1 O 
) O 
. O 
Menthol O 
acts O 
upon O 
TRPM8 O 
receptors O 
by O 
rapidly O 
increasing O 
intracellular O 
calcium B-SYSTEMATIC 
and O 
mobilizing O 
calcium B-SYSTEMATIC 
flux O 
through O 
the O 
channels O 
to O 
induce O 
cold O 
response O 
signals O 
at O 
the O 
application O 
site O 
. O 
Aside O 
from O 
its O 
cold O 
- O 
inducing O 
sensation O 
capabilities O 
, O 
menthol B-TRIVIAL 
exhibits O 
cytotoxic O 
effects O 
in O 
cancer O 
cells O 
, O 
induces O 
reduction O 
in O 
malignant O 
cell O 
growth O 
, O 
and O 
engages O 
in O 
synergistic O 
excitation O 
of O 
GABA B-ABBREVIATION 
receptors O 
and O 
sodium B-SYSTEMATIC 
ion O 
channels O 
resulting O 
in O 
analgesia O 
. O 
Notwithstanding O 
its O 
plethora O 
of O 
benefits O 
, O 
menthol B-TRIVIAL 
' O 
s O 
coldsensitivity O 
response O 
mechanism O 
has O 
been O 
shown O 
to O 
inhibit O 
mucosal O 
recognition O 
of O 
nicotine B-TRIVIAL 
and O 
cigarette O 
toxins O 
common O 
in O 
mentholated O 
cigarette O 
brands O 
thus O 
potentially O 
leading O 
to O 
toxic O 
effects O 
. O 
Menthol B-TRIVIAL 
may O 
prove O 
a O 
valuable O 
lead O 
structure O 
for O 
the O 
synthesis O 
of O 
drugs O 
that O 
target O 
multiple O 
receptors O 
involved O 
with O 
a O 
number O 
of O 
pharmacological O 
effects O 
. O 

in O 
marine O 
mussels O 
, O 
Mytilus O 
galloprovincialis O 
, O 
exposed O 
to O 
environmentally O 
relevant O 
levels O 
of O 
the O 
pesticides O 
, O 
chlorpyrifos B-TRIVIAL 
and O 
penoxsulam B-TRIVIAL 
. O 

present O 
study O 
examines O 
the O 
influence O 
of O 
environmentally O 
relevant O 
concentrations O 
of O 
two O 
pesticides O 
, O 
chlorpyrifos B-TRIVIAL 
and O 
penoxsulam B-TRIVIAL 
on O 
mussel O 
physiological O 
status O 
. O 
For O 
this O 
reason O 
, O 
lysosomal O 
membrane O 
stability O 
( O 
LMS O 
) O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
DNA O 
damage O 
, O 
protein O 
carbonylation O 
( O 
PCC O 
) O 
and O 
antioxidant O 
capacity O 
( O 
TAC O 
) O 
in O 
hemaolymph O 
and O 
hemocytes O 
of O 
the O 
mussels O 
was O 
measured O 
. O 
Mussels O 
were O 
exposed O 
to O 
a O 
range O 
of O 
concentrations O 
of O 
the O 
pesticides O 
chlorpyrifos B-TRIVIAL 
and O 
penoxsulam B-TRIVIAL 
and O 
the O 
response O 
of O 
animals O 
to O 
the O 
destabilization O 
of O 
lysosomal O 
membrane O 
in O 
hemocytes O 
( O 
LMS O 
) O 
was O 
studied O 
. O 
Subsequently O 
, O 
the O 
half O 
maximal O 
effective O 
concentration O 
( O 
EC50 O 
) O 
for O 
both O 
pesticides O 
was O 
calculated O 
. O 
The O 
animals O 
were O 
subsequently O 
exposed O 
for O 
0 O 
, O 
1 O 
, O 
3 O 
, O 
5 O 
, O 
7 O 
, O 
15 O 
and O 
30 O 
days O 
to O 
10 O 
times O 
less O 
concentration O 
than O 
EC50 O 
of O 
each O 
pesticide O 
( O 
0.05 O 
μg O 
/ O 
l O 
) O 
and O 
changes O 
in O 
LMS O 
, O 
ROS O 
, O 
DNA O 
damage O 
, O 
protein O 
carbonylation O 
and O 
antioxidant O 
capacity O 
of O 
mussels O 
was O 
evaluated O 
. O 
Our O 
results O 
showed O 
a O 
significant O 
change O 
in O 
the O 
response O 
of O 
mussels O 
for O 
all O 
parameters O 
tested O 
after O 
30 O 
days O 
exposure O 
, O 
in O 
relation O 
to O 
the O 
controls O 
. O 
The O 
pesticides O 
at O 
the O 
environmental O 
concentrations O 
used O 
induced O 
changes O 
to O 
the O 
animal O 
physiology O 
through O 
causing O 
oxidative O 
stress O 
and O 
lysosomal O 
abnormalities O 
and O 
their O 
usage O 
in O 
the O 
agriculture O 
demands O 
great O 
care O 
. O 
In O 
addition O 
, O 
the O 
results O 
show O 
that O 
ROS O 
, O 
DNA O 
damage O 
, O 
protein O 
carbonylation O 
and O 
antioxidant O 
capacity O 
could O 
constitute O 
, O 
after O 
further O 
investigation O 
, O 
reliable O 
biomarkers O 
for O 
the O 
evaluation O 
of O 
pollution O 
or O 
other O 
environmental O 
stressors O 
. O 

change O 
models O 
predict O 
an O 
increase O 
in O 
the O 
frequency O 
and O 
intensity O 
of O 
extreme O 
fluctuations O 
in O 
water O 
level O 
in O 
aquatic O 
habitats O 
. O 
Therefore O 
, O 
it O 
is O 
necessary O 
to O 
understand O 
the O 
combined O 
effects O 
of O 
hydrological O 
fluctuations O 
and O 
toxicants O 
on O 
aquatic O 
biological O 
communities O 
. O 
We O 
investigated O 
the O 
individual O 
and O 
combined O 
effects O 
of O 
the O 
insecticide O 
esfenvalerate B-TRIVIAL 
and O 
recurring O 
fluctuations O 
in O 
water O 
level O 
on O 
zooplankton O 
communities O 
in O 
a O 
system O 
of O 
55 O 
outdoor O 
pond O 
microcosms O 
. O 
The O 
communities O 
were O 
exposed O 
to O 
esfenvalerate B-TRIVIAL 
contamination O 
as O 
a O 
single O 
pulse O 
( O 
at O 
0.03 O 
, O 
0.3 O 
, O 
or O 
3μg O 
/ O 
L O 
) O 
and O 
gradual O 
removal O 
of O 
water O 
and O 
its O 
subsequent O 
replacement O 
over O 
three O 
cycles O 
and O 
monitored O 
until O 
84 O 
days O 
after O 
contamination O 
. O 
The O 
results O 
showed O 
that O 
the O 
sensitivities O 
of O 
the O 
community O 
and O 
its O 
constituent O 
populations O 
to O 
the O 
toxicant O 
were O 
increased O 
by O 
the O 
hydrological O 
stress O 
. O 
Specifically O 
, O 
for O 
both O 
the O 
community O 
structure O 
and O 
abundance O 
of O 
Daphnia O 
spp O 
. O 
the O 
lowest O 
- O 
observed O 
- O 
effect O 
concentrations O 
( O 
LOEC O 
) O 
were O 
0.03 O 
and O 
0.3μg O 
/ O 
L O 
for O 
the O 
series O 
with O 
fluctuating O 
and O 
constant O 
water O 
levels O 
, O 
respectively O 
. O 
Despite O 
these O 
differences O 
in O 
sensitivity O 
, O 
the O 
interactive O 
effects O 
of O 
the O 
two O 
stressors O 
were O 
found O 
to O 
be O 
additive O 
for O 
both O 
the O 
community O 
structure O 
and O 
the O 
abundance O 
of O 
the O 
most O 
affected O 
species O 
. O 
Presumably O 
, O 
it O 
was O 
not O 
possible O 
to O 
detect O 
synergism O 
due O 
to O 
the O 
strong O 
individual O 
effects O 
of O 
the O 
water O 
level O 
fluctuations O 
. O 
Recovery O 
times O 
in O 
the O 
series O 
exposed O 
to O 
the O 
highest O 
pesticide O 
concentration O 
were O 
64 O 
and O 
55 O 
days O 
under O 
fluctuating O 
and O 
constant O 
water O 
level O 
regimes O 
, O 
respectively O 
. O 
Competition O 
and O 
water O 
quality O 
are O 
suggested O 
to O 
be O 
the O 
major O 
factors O 
that O 
underlie O 
the O 
observed O 
effects O 
of O 
fluctuations O 
in O 
the O 
water O 
level O 
. O 
For O 
the O 
ecological O 
risk O 
assessment O 
of O 
toxicants O 
, O 
the O 
present O 
results O 
suggest O 
that O 
(i) O 
community O 
sensitivity O 
may O 
vary O 
substantially O 
, O 
depending O 
on O 
the O 
environmental O 
context O 
, O 
and O 
(ii) O 
this O 
variability O 
can O 
be O 
assessed O 
experimentally O 
to O 
derive O 
safety O 
factors O 
( O 
coefficients O 
used O 
to O 
avoid O 
unexpected O 
effects O 
and O 
define O 
safe O 
concentrations O 
of O 
toxicants O 
) O 
based O 
on O 
empirical O 
findings O 
. O 
This O 
contrasts O 
with O 
the O 
current O 
approach O 
where O 
such O 
factors O 
are O 
usually O 
defined O 
arbitrarily O 
. O 

of O 
toxicity O 
of O 
complex O 
mixtures O 
has O 
been O 
proposed O 
to O 
be O 
one O 
of O 
the O 
most O 
important O 
challenges O 
for O 
modern O 
toxicology O 
. O 
In O 
this O 
study O 
we O 
performed O 
genome O 
wide O 
transcriptome O 
profiling O 
to O 
assess O 
potential O 
toxicant O 
induced O 
changes O 
in O 
gene O 
regulation O 
in O 
zebrafish O 
embryos O 
following O 
parental O 
exposure O 
to O 
two O 
natural O 
mixtures O 
of O 
persistent O 
organic O 
pollutants O 
( O 
POPs O 
) O 
. O 
The O 
mixtures O 
used O 
were O 
extracted O 
from O 
burbot O 
( O 
Lota O 
lota O 
) O 
liver O 
originating O 
from O 
two O 
lakes O 
( O 
Lake O 
Mjøsa O 
and O 
Lake O 
Losna O 
) O 
belonging O 
to O 
the O 
same O 
freshwater O 
system O 
in O 
Norway O 
. O 
The O 
dominating O 
groups O 
of O 
contaminants O 
were O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
, O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
and O 
dichlorodiphenyltrichloroethane B-SYSTEMATIC 
metabolites O 
( O 
DDTs O 
) O 
. O 
Because O 
both O 
mixtures O 
used O 
in O 
the O 
present O 
study O 
induced O 
similar O 
effects O 
, O 
it O 
is O 
likely O 
that O 
the O 
same O 
toxicants O 
are O 
involved O 
. O 
The O 
Mjøsa O 
mixture O 
contains O 
high O 
levels O 
of O 
PBDEs B-ABBREVIATION 
while O 
this O 
group O 
of O 
pollutants O 
is O 
low O 
in O 
the O 
Losna O 
mixture O 
. O 
However O 
, O 
both O 
mixtures O 
contain O 
substantial O 
concentrations O 
of O 
PCB B-ABBREVIATION 
and O 
DDT B-ABBREVIATION 
suggesting O 
these O 
contaminants O 
as O 
the O 
predominant O 
contributors O 
to O 
the O 
toxicity O 
observed O 
. O 
The O 
observed O 
effects O 
included O 
phenotypic O 
traits O 
, O 
like O 
embryo O 
production O 
and O 
survival O 
, O 
and O 
gene O 
transcription O 
changes O 
corresponding O 
with O 
disease O 
and O 
biological O 
functions O 
such O 
as O 
cancer O 
, O 
reproductive O 
system O 
disease O 
, O 
cardiovascular O 
disease O 
, O 
lipid O 
and O 
protein O 
metabolism O 
, O 
small O 
molecule O 
biochemistry O 
and O 
cell O 
cycle O 
. O 
The O 
changes O 
in O 
gene O 
transcription O 
included O 
genes O 
regulated O 
by O 
HNF4A O 
, O 
insulin O 
, O 
LH O 
, O 
FSH O 
and O 
NF-κB O 
which O 
are O 
known O 
to O 
be O 
central O 
regulators O 
of O 
endocrine O 
signaling O 
, O 
metabolism O 
, O 
metabolic O 
homeostasis O 
, O 
immune O 
functions O 
, O 
cancer O 
development O 
and O 
reproduction O 
. O 
The O 
results O 
suggest O 
that O 
relative O 
low O 
concentrations O 
of O 
the O 
natural O 
mixtures O 
of O 
POPs O 
used O 
in O 
the O 
present O 
study O 
might O 
pose O 
a O 
threat O 
to O 
wild O 
freshwater O 
fish O 
living O 
in O 
the O 
lakes O 
from O 
which O 
the O 
POPs O 
mixtures O 
originated O 
. O 

of O 
the O 
roles O 
of O 
ABCB1 O 
, O 
ABCC1 O 
, O 
ABCC2 O 
and O 
ABCG2 O 
in O 
the O 
transport O 
and O 
pharmacokinetics O 
of O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

D I-TRIVIAL 
plays O 
a O 
key O 
role O 
in O 
the O 
successful O 
treatment O 
of O 
Wilms O 
tumour O 
. O 
However O 
, O 
associated O 
liver O 
toxicities O 
remain O 
a O 
drawback O 
to O 
potentially O 
curative O 
treatment O 
. O 
We O 
have O 
used O 
MDCKII O 
cells O 
over O 
- O 
expressing O 
ABCB1 O 
, O 
ABCC1 O 
, O 
ABCC2 O 
and O 
ABCG2 O 
, O 
alongside O 
knockout O 
mouse O 
models O 
to O 
characterise O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
transport O 
and O 
its O 
impact O 
on O 
pharmacokinetics O 
. O 
Growth O 
inhibition O 
, O 
intracellular O 
accumulation O 
and O 
cellular O 
efflux O 
assays O 
were O 
utilised O 
. O 
A O 
59-fold O 
difference O 
in O 
GI(50) O 
was O 
observed O 
between O 
MDCKII-WT O 
and O 
MDCKII-ABCB1 O 
cells O 
( O 
12.7 O 
nM O 
vs O 
. O 
745 O 
nM O 
, O 
p O 
< O 
0.0001 O 
) O 
. O 
Reduced O 
sensitivity O 
was O 
also O 
seen O 
in O 
MDCKII-ABCC1 O 
and O 
ABCC2 O 
cells O 
( O 
GI(50) O 
25.7 O 
and O 
40.4 O 
nM O 
respectively O 
, O 
p O 
< O 
0.0001 O 
) O 
. O 
Lower O 
intracellular O 
accumulation O 
of O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
was O 
observed O 
in O 
MDCKII-ABCB1 O 
cells O 
as O 
compared O 
to O 
MDCKII-WT O 
( O 
0.98 O 
nM O 
vs O 
. O 
0.1 O 
nM O 
, O 
p O 
< O 
0.0001 O 
) O 
, O 
which O 
was O 
reversed O 
upon O 
ABCB1 O 
inhibition O 
. O 
Lower O 
accumulation O 
was O 
also O 
seen O 
in O 
MDCKII-ABCC1 O 
and O 
ABCC2 O 
cells O 
. O 
Actinomycin B-TRIVIAL 
D I-TRIVIAL 
efflux O 
over O 
2 O 
h O 
was O 
most O 
pronounced O 
in O 
MDCKII-ABCB1 O 
cells O 
, O 
with O 
5.5-fold O 
lower O 
intracellular O 
levels O 
compared O 
to O 
WT O 
. O 
In O 
vivo O 
studies O 
showed O 
that O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
plasma O 
concentrations O 
were O 
significantly O 
higher O 
in O 
Abcb1a O 
/ O 
1b(- O 
/ O 
- O 
) O 
as O 
compared O 
to O 
WT O 
mice O 
following O 
administration O 
of O 
0.5 O 
mg O 
/ O 
kg O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
( O 
AUC(0-6 O 
h O 
) O 
242 O 
vs O 
. O 
152 O 
μg O 
/ O 
Lh O 
respectively O 
) O 
. O 
While O 
comparable O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
concentrations O 
were O 
observed O 
in O 
the O 
kidneys O 
and O 
livers O 
of O 
Abcb1a O 
/ O 
1b(- O 
/ O 
- O 
) O 
and O 
Abcc2(- O 
/ O 
- O 
) O 
mice O 
, O 
concentrations O 
in O 
the O 
brain O 
were O 
significantly O 
higher O 
at O 
6h O 
following O 
drug O 
administration O 
in O 
Abcb1a O 
/ O 
1b(- O 
/ O 
- O 
) O 
mice O 
compared O 
to O 
WT O 
. O 
Results O 
confirm O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
as O 
a O 
substrate O 
for O 
ABCB1 O 
, O 
ABCC1 O 
and O 
ABCC2 O 
, O 
and O 
indicate O 
that O 
Abcb1a O 
/ O 
1b O 
and O 
Abcc2 O 
can O 
influence O 
the O 
in O 
vivo O 
disposition O 
of O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
. O 
These O 
data O 
have O 
implications O 
for O 
ongoing O 
clinical O 
pharmacology O 
trials O 
involving O 
children O 
treated O 
with O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
. O 

acid I-TRIVIAL 
inhibits O 
melanogenesis O 
through O 
downregulation O 
of O 
C O 
/ O 
EBP O 
α-dependent O 
expression O 
of O 
HMG-CoA B-ABBREVIATION 
reductase O 
gene O 
. O 

is O 
associated O 
with O 
the O 
regulation O 
of O 
melanogenesis O 
which O 
is O 
the O 
major O 
physiological O 
defense O 
against O 
solar O 
irradiation O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
determine O 
the O 
effects O 
of O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
on O 
melanogenesis O 
and O 
its O 
mechanisms O 
of O 
action O 
in O 
human O 
epidermal O 
melanocytes O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
inhibited O 
melanin O 
content O 
. O 
The O 
mRNA O 
levels O 
of O 
microphthalmia O 
- O 
associated O 
transcription O 
factor O 
( O 
MITF O 
) O 
and O 
its O 
downstream O 
genes O 
tyrosinase O 
, O 
tyrosinase O 
- O 
related O 
protein O 
(TRP)-1 O 
, O 
and O 
TRP-2 O 
were O 
reduced O 
by O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
treatment O 
. O 
Additionally O 
, O 
the O 
mRNA O 
levels O 
of O 
melanogenesis O 
- O 
related O 
genes O 
( O 
c-KIT O 
, O 
stem O 
cell O 
factor O 
( O 
SCF O 
) O 
, O 
and O 
macrophage O 
migration O 
inhibitory O 
factor O 
( O 
MIF O 
) O 
) O 
were O 
down O 
- O 
regulated O 
by O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Furthermore O 
, O 
cAMP B-ABBREVIATION 
production O 
and O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
activity O 
were O 
suppressed O 
by O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Moreover O 
, O 
attempts O 
to O 
elucidate O 
a O 
possible O 
mechanism O 
underlying O 
the O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
-mediated O 
effects O 
revealed O 
that O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
regulated O 
melanogenesis O 
by O 
inhibiting O 
cholesterol B-TRIVIAL 
synthesis O 
through O 
downregulation O 
of O 
the O 
hydroxymethylglutaryl B-SYSTEMATIC 
CoA I-SYSTEMATIC 
( O 
HMG B-ABBREVIATION 
CoA I-ABBREVIATION 
) O 
reductase O 
gene O 
, O 
which O 
was O 
mediated O 
through O 
reduced O 
expression O 
of O 
the O 
CCAAT O 
/ O 
enhancer O 
- O 
binding O 
protein O 
( O 
C O 
/ O 
EBP O 
) O 
α O 
gene O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
indicate O 
that O 
the O 
inhibition O 
of O 
melanogenesis O 
by O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
occurs O 
through O 
reduced O 
expression O 
of O 
the O 
HMG B-ABBREVIATION 
CoA I-ABBREVIATION 
reductase O 
gene O 
, O 
which O 
is O 
mediated O 
by O 
C O 
/ O 
EBP O 
α O 
inhibition O 
and O 
suggest O 
that O 
artemisinic B-TRIVIAL 
acid I-TRIVIAL 
may O 
be O 
useful O 
as O 
a O 
hyperpigmentation O 
inhibitor O 
. O 

induces O 
apoptosis O 
in O 
HepG2 O 
cells O 
: O 
Involvements O 
of O 
ROS O 
and O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 

( O 
HER B-ABBREVIATION 
) O 
is O 
a O 
natural O 
flavonoid B-FAMILY 
compound O 
that O 
can O 
be O 
extracted O 
from O 
Ramose O 
Scouring O 
Rush O 
Herb O 
, O 
and O 
its O 
biological O 
and O 
pharmacological O 
activities O 
lack O 
of O 
corresponding O 
attention O 
. O 
In O 
this O 
study O 
, O 
the O 
apoptotic O 
effect O 
of O 
HER B-ABBREVIATION 
against O 
the O 
human O 
hepatoma O 
cell O 
line O 
( O 
HepG2 O 
) O 
was O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
HepG2 O 
cells O 
apoptosis O 
occurred O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
within O 
48h O 
incubated O 
with O 
HER B-ABBREVIATION 
, O 
which O 
was O 
confirmed O 
by O 
DNA O 
fragmentation O 
, O 
nuclear O 
shrinkage O 
, O 
and O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
) I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
cleavage O 
. O 
HER B-ABBREVIATION 
at O 
25-100μM O 
induced O 
a O 
mitochondria O 
- O 
dependent O 
apoptotic O 
pathway O 
associated O 
with O 
Bcl-2 O 
/ O 
Bax O 
ratio O 
decrease O 
, O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨ O 
) O 
collapse O 
, O 
cytochrome O 
c O 
release O 
, O 
and O 
caspase-3 O 
activation O 
. O 
Increasing O 
expression O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor-γ O 
coactivator O 
1α O 
( O 
PGC-1α O 
) O 
was O 
also O 
observed O 
in O 
HER B-ABBREVIATION 
-treated O 
cells O 
. O 
Furthermore O 
, O 
the O 
addition O 
of O 
a O 
ROS O 
inhibitor O 
( O 
N-Acetyl-l-cysteine B-SYSTEMATIC 
, O 
NAC B-ABBREVIATION 
) O 
significantly O 
attenuated O 
the O 
apoptosis O 
induced O 
by O 
HER B-ABBREVIATION 
and O 
also O 
blocked O 
the O 
expression O 
of O 
PGC-1α O 
protein O 
. O 
Additionally O 
, O 
HER B-ABBREVIATION 
effectively O 
inhibited O 
the O 
phosphorylation O 
of O 
Akt O 
and O 
the O 
phosphatidylinositol B-TRIVIAL 
-3 O 
kinase O 
( O 
PI3K O 
) O 
inhibitor O 
LY294002 B-IDENTIFIER 
increased O 
the O 
inhibition O 
effect O 
of O 
HER B-ABBREVIATION 
on O 
Akt O 
phosphorylation O 
. O 
These O 
findings O 
provide O 
evidences O 
that O 
HER B-ABBREVIATION 
induces O 
HepG2 O 
apoptosis O 
in O 
a O 
ROS O 
- O 
mediated O 
mitochondria O 
- O 
dependent O 
manner O 
that O 
correlate O 
with O 
the O 
inactivation O 
of O 
the O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 

magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
is O 
an O 
essential O 
tool O 
for O 
studying O 
environmental O 
samples O 
but O 
is O 
often O 
hindered O 
by O 
low O 
sensitivity O 
, O 
especially O 
for O 
the O 
direct O 
detection O 
of O 
nuclei O 
such O 
as O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
. O 
In O 
very O 
heterogeneous O 
samples O 
with O 
NMR O 
nuclei O 
at O 
low O 
abundance O 
, O 
such O 
as O 
soils O 
, O 
sediments O 
, O 
and O 
air O 
particulates O 
, O 
it O 
can O 
take O 
days O 
to O 
acquire O 
a O 
conventional O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
spectrum O 
. O 
The O 
present O 
study O 
describes O 
a O 
prescreening O 
method O 
that O 
permits O 
the O 
rapid O 
prediction O 
of O 
experimental O 
run O 
time O 
in O 
natural O 
samples O 
. O 
The O 
approach O 
focuses O 
the O 
NMR O 
chemical O 
shift O 
dispersion O 
into O 
a O 
single O 
spike O 
, O 
and O 
, O 
even O 
in O 
samples O 
with O 
extremely O 
low O 
carbon B-SYSTEMATIC 
content O 
, O 
the O 
spike O 
can O 
be O 
observed O 
in O 
two O 
to O 
three O 
minutes O 
, O 
or O 
less O 
. O 
The O 
intensity O 
of O 
the O 
spike O 
is O 
directly O 
proportional O 
to O 
the O 
total O 
concentration O 
of O 
nuclei O 
of O 
interest O 
in O 
the O 
sample O 
. O 
Consequently O 
, O 
the O 
spike O 
intensity O 
can O 
be O 
used O 
as O 
a O 
powerful O 
prescreening O 
method O 
that O 
answers O 
two O 
key O 
questions O 
: O 
( O 
1 O 
) O 
Will O 
this O 
sample O 
produce O 
a O 
conventional O 
NMR O 
spectrum O 
? O 
( O 
2 O 
) O 
How O 
much O 
instrument O 
time O 
is O 
required O 
to O 
record O 
a O 
spectrum O 
with O 
a O 
specific O 
signal O 
- O 
to O 
- O 
noise O 
( O 
S O 
/ O 
N O 
) O 
ratio O 
? O 
The O 
approach O 
identifies O 
samples O 
to O 
avoid O 
( O 
or O 
pretreat O 
) O 
and O 
permits O 
additional O 
NMR O 
experiments O 
to O 
be O 
performed O 
on O 
samples O 
producing O 
high O 
- O 
quality O 
NMR O 
data O 
. O 
Applications O 
in O 
solid- O 
and O 
liquid O 
- O 
state O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
NMR O 
are O 
demonstrated O 
, O 
and O 
it O 
is O 
shown O 
that O 
the O 
technique O 
is O 
applicable O 
to O 
a O 
range O 
of O 
nuclei O 
. O 

protein O 
directly O 
activated O 
by O 
cAMP B-ABBREVIATION 
( O 
EPAC O 
) O 
and O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
are O 
two O 
intracellular O 
receptors O 
that O 
mediate O 
the O 
effects O 
of O 
the O 
prototypic O 
second O 
messenger O 
cAMP B-ABBREVIATION 
. O 
Identifying O 
pharmacological O 
probes O 
for O 
selectively O 
modulating O 
EPAC O 
activity O 
represents O 
a O 
significant O 
unmet O 
need O 
within O 
the O 
research O 
field O 
. O 
Herein O 
, O 
we O 
report O 
the O 
identification O 
and O 
characterization O 
of O 
3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo- B-SYSTEMATIC 
propionitrile I-SYSTEMATIC 
( O 
ESI-09 B-IDENTIFIER 
) O 
, O 
a O 
novel O 
noncyclic O 
nucleotide B-FAMILY 
EPAC O 
antagonist O 
that O 
is O 
capable O 
of O 
specifically O 
blocking O 
intracellular O 
EPAC O 
- O 
mediated O 
Rap1 O 
activation O 
and O 
Akt O 
phosphorylation O 
, O 
as O 
well O 
as O 
EPAC O 
- O 
mediated O 
insulin O 
secretion O 
in O 
pancreatic O 
β O 
cells O 
. O 
Using O 
this O 
novel O 
EPAC-specific O 
inhibitor O 
, O 
we O 
have O 
probed O 
the O 
functional O 
roles O 
of O 
overexpression O 
of O 
EPAC1 O 
in O 
pancreatic O 
cancer O 
cells O 
. O 
Our O 
studies O 
show O 
that O 
EPAC1 O 
plays O 
an O 
important O 
role O 
in O 
pancreatic O 
cancer O 
cell O 
migration O 
and O 
invasion O 
, O 
and O 
thus O 
represents O 
a O 
potential O 
target O 
for O 
developing O 
novel O 
therapeutic O 
strategies O 
for O 
pancreatic O 
cancer O 
. O 

new O 
alkaloids O 
, O 
callylactam B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
callyimine B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
, O 
along O 
with O 
three O 
known O 
ones O 
( O 
2 O 
, O 
3 O 
and O 
5 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
marine O 
sponge O 
Callyspongia O 
sp O 
. O 
The O 
structures O 
were O 
determined O 
on O 
the O 
basis O 
of O 
NMR O 
and O 
MS O 
analysis O 
. O 

- O 
ligand O 
interaction O 
study O 
of O 
CpOGA O 
in O 
complex O 
with O 
GlcNAcstatin B-FAMILY 
. O 

GlcNAcstatin B-FAMILY 
is O 
a O 
potent O 
inhibitor O 
of O 
O-glycoprotein O 
2-acetamino B-SYSTEMATIC 
-2-deoxy-β-D-glucopyranosidase O 
, O 
which O 
has O 
been O 
related O 
with O 
type O 
II O 
diabetes O 
and O 
neurodegenerative O 
disorders O 
. O 
Herein O 
, O 
hybrid O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
, O 
molecular O 
dynamics O 
simulations O 
, O 
and O 
potential O 
of O 
mean O 
force O 
were O 
employed O 
to O 
study O 
the O 
interactions O 
established O 
between O 
GlcNAcstatin B-FAMILY 
and O 
a O 
bacterial O 
O-GlcNAcase O 
enzyme O 
from O 
Clostridium O 
perfringens O 
. O 
The O 
results O 
reveal O 
that O 
the O 
imidazole B-SYSTEMATIC 
nitrogen B-SYSTEMATIC 
atom O 
of O 
GlcNAcstatin B-FAMILY 
has O 
shown O 
a O 
better O 
interaction O 
with O 
the O 
active O 
site O 
of O 
Clostridium O 
perfringens O 
in O 
its O 
protonated O 
form O 
, O 
which O 
is O 
compatible O 
with O 
a O 
substrate O 
- O 
assisted O 
reaction O 
mechanism O 
involving O 
two O 
conserved O 
aspartate B-TRIVIAL 
residues O 
( O 
297 O 
and O 
298 O 
) O 
. O 
Furthermore O 
, O 
the O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
- O 
molecular O 
dynamics O 
simulations O 
appointed O 
a O 
strong O 
interaction O 
between O 
Asp B-FORMULA 
401 O 
, O 
Asp B-FORMULA 
298 O 
, O 
and O 
Asp B-FORMULA 
297 O 
residues O 
and O 
the O 
GlcNAcstatin B-FAMILY 
inhibitor O 
, O 
which O 
is O 
in O 
accordance O 
with O 
experimental O 
data O 
. O 
Lastly O 
, O 
these O 
results O 
may O 
contribute O 
to O 
understand O 
the O 
molecular O 
mechanism O 
of O 
inhibition O 
of O 
Clostridium O 
perfringens O 
by O 
GlcNAcstatin B-FAMILY 
inhibitor O 
and O 
, O 
consequently O 
, O 
this O 
study O 
might O 
be O 
useful O 
to O 
design O 
new O 
molecules O 
with O 
more O 
interesting O 
inhibitory O 
activity O 
. O 

protects O 
6-hydroxydopamine B-SYSTEMATIC 
-induced O 
neurotoxicity O 
in O 
SH-SY5Y O 
cells O 
and O 
improved O 
behavioral O 
impairments O 
in O 
mouse O 
model O 
of O 
Parkinson's O 
disease O 
. O 

disease O 
( O 
PD O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disorder O 
of O 
unknown O 
etiology O 
. O 
Considerable O 
evidence O 
suggests O 
that O 
free O 
radical O 
formation O 
and O 
oxidative O 
stress O 
might O 
play O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
PD O 
. O 
In O 
the O 
present O 
investigation O 
we O 
evaluated O 
the O 
therapeutic O 
potential O 
of O 
methylparaben B-SYSTEMATIC 
( O 
MP O 
) O 
a O 
well O 
known O 
pharmaceutical O 
preservative O 
against O 
6-hydroxydopamine B-SYSTEMATIC 
( O 
6-OHDA B-SYSTEMATIC 
) O 
neurotoxicity O 
in O 
SH-SY5Y O 
cells O 
and O 
in O 
a O 
mouse O 
model O 
of O 
PD O 
. O 
At O 
nanomolar O 
concentrations O 
MP O 
( O 
0.01 O 
, O 
0.1 O 
and O 
1 O 
nM O 
) O 
significantly O 
attenuated O 
the O 
6-OHDA B-SYSTEMATIC 
- O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
cytotoxicity O 
in O 
SH-SY5Y O 
cells O 
. O 
The O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
generated O 
by O 
6-OHDA B-SYSTEMATIC 
in O 
SH-SY5Y O 
cells O 
was O 
also O 
inhibited O 
by O 
MP O 
in O 
a O 
concentration O 
dependent O 
fashion O 
. O 
Further O 
, O 
intranigral O 
damage O 
induced O 
by O 
stereotaxically O 
injecting O 
6-OHDA B-SYSTEMATIC 
in O 
mouse O 
brain O 
was O 
significantly O 
attenuated O 
by O 
MP O 
treatment O 
. O 
MP O 
( O 
1 O 
, O 
10 O 
or O 
50 O 
μg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
prevented O 
apomorphine B-TRIVIAL 
-induced O 
rotational O 
behavior O 
and O 
significantly O 
improved O 
motor O 
deficits O 
in O 
6-OHDA B-SYSTEMATIC 
-lesioned O 
mice O 
. O 
The O 
cognitive O 
impairments O 
as O 
evaluated O 
by O 
passive O 
avoidance O 
and O 
Y-maze O 
task O 
in O 
mice O 
were O 
also O 
attenuated O 
by O 
MP O 
concentration O 
dependently O 
. O 
Immunohistochemical O 
analysis O 
of O 
substantia O 
nigra O 
in O 
MP O 
treated O 
mice O 
showed O 
significantly O 
higher O 
number O 
of O 
surviving O 
tyrosine B-TRIVIAL 
hydroxylase O 
positive O 
cells O 
. O 
Furthermore O 
, O 
MP O 
also O 
suppressed O 
the O 
lipid O 
peroxidation O 
products O 
in O 
6-OHDA B-SYSTEMATIC 
-lesioned O 
mouse O 
brain O 
tissues O 
. O 
Considering O 
the O 
results O 
obtained O 
, O 
the O 
marked O 
neuroprotection O 
exhibited O 
by O 
MP O 
might O 
be O 
attributed O 
to O 
its O 
potent O 
antioxidant O 
property O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
reports O 
the O 
neuroprotective O 
properties O 
of O 
MP O 
in O 
experimental O 
models O 
of O 
PD O 
for O 
the O 
first O 
time O 
and O 
can O 
be O 
developed O 
as O 
a O 
potential O 
therapeutic O 
agent O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
monitor O 
the O 
amorphous O 
- O 
to O 
- O 
crystalline O 
solid O 
- O 
state O 
phase O 
transformation O 
kinetics O 
of O 
the O 
model O 
drug O 
ibuprofen B-TRIVIAL 
with O 
spectroscopic O 
methods O 
during O 
acoustic O 
levitation O 
. O 
Chemical O 
and O 
physical O 
information O 
was O 
obtained O 
by O 
real O 
- O 
time O 
near O 
infrared O 
( O 
NIRS O 
) O 
and O 
Raman O 
spectroscopy O 
measurements O 
. O 
The O 
recrystallisation O 
kinetic O 
parameters O 
( O 
overall O 
recrystallisation O 
rate O 
constant O 
β O 
and O 
the O 
time O 
needed O 
to O 
reach O 
50% O 
of O 
the O 
equilibrated O 
level O 
t(50) O 
) O 
, O 
were O 
determined O 
using O 
a O 
multivariate O 
curve O 
resolution O 
approach O 
. O 
The O 
acoustic O 
levitation O 
device O 
coupled O 
with O 
non-invasive O 
spectroscopy O 
enabled O 
monitoring O 
of O 
the O 
recrystallisation O 
process O 
of O 
the O 
difficult O 
- O 
to O 
- O 
handle O 
( O 
adhesive O 
) O 
amorphous O 
sample O 
. O 
The O 
application O 
of O 
multivariate O 
curve O 
resolution O 
enabled O 
isolation O 
of O 
the O 
underlying O 
pure O 
spectra O 
, O 
which O 
corresponded O 
well O 
with O 
the O 
reference O 
spectra O 
of O 
amorphous O 
and O 
crystalline O 
ibuprofen B-TRIVIAL 
. O 
The O 
recrystallisation O 
kinetic O 
parameters O 
were O 
estimated O 
from O 
the O 
recrystallisation O 
profiles O 
. O 
While O 
the O 
empirical O 
recrystallisation O 
rate O 
constant O 
determined O 
by O 
NIR O 
and O 
Raman O 
spectroscopy O 
were O 
comparable O 
, O 
the O 
lag O 
time O 
for O 
recrystallisation O 
was O 
significantly O 
lower O 
with O 
Raman O 
spectroscopy O 
as O 
compared O 
to O 
NIRS O 
. O 
This O 
observation O 
was O 
explained O 
by O 
the O 
high O 
energy O 
density O 
of O 
the O 
Raman O 
laser O 
beam O 
, O 
which O 
might O 
have O 
led O 
to O 
local O 
heating O 
effects O 
of O 
the O 
sample O 
and O 
thus O 
reduced O 
the O 
recrystallisation O 
onset O 
time O 
. O 
It O 
was O 
concluded O 
that O 
acoustic O 
levitation O 
with O 
NIR O 
and O 
Raman O 
spectroscopy O 
combined O 
with O 
multivariate O 
curve O 
resolution O 
allowed O 
direct O 
determination O 
of O 
the O 
recrystallisation O 
kinetics O 
of O 
amorphous O 
drugs O 
and O 
thus O 
is O 
a O 
promising O 
technique O 
for O 
monitoring O 
solid O 
- O 
state O 
phase O 
transformations O 
of O 
adhesive O 
small O 
- O 
sized O 
samples O 
during O 
the O 
early O 
phase O 
of O 
drug O 
development O 
. O 

cysteine O 
protease O 
cathepsin O 
K O 
has O 
been O 
implicated O 
in O 
pathogenesis O 
of O 
cardiovascular O 
disease O 
. O 
We O 
hypothesized O 
that O 
ablation O 
of O 
cathepsin O 
K O 
protects O 
against O 
obesity O 
- O 
associated O 
cardiac O 
dysfunction O 
. O 
Wild O 
- O 
type O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
exhibited O 
elevated O 
heart O 
weight O 
, O 
enlarged O 
cardiomyocytes O 
, O 
increased O 
left O 
ventricular O 
wall O 
thickness O 
, O 
and O 
decreased O 
fractional O 
shortening O 
. O 
All O 
these O 
changes O 
were O 
reconciled O 
in O 
cathepsin O 
K O 
knockout O 
mice O 
. O 
Cathepsin O 
K O 
knockout O 
partly O 
reversed O 
the O 
impaired O 
cardiomyocyte O 
contractility O 
and O 
dysregulated O 
calcium B-SYSTEMATIC 
handling O 
associated O 
with O 
high O 
- O 
fat O 
diet O 
. O 
Additionally O 
, O 
cathepsin O 
K O 
knockout O 
alleviated O 
whole O 
- O 
body O 
glucose B-TRIVIAL 
intolerance O 
and O 
improved O 
insulin O 
- O 
stimulated O 
Akt O 
phosphorylation O 
in O 
high O 
- O 
fat O 
diet O 
- O 
fed O 
mice O 
. O 
High O 
- O 
fat O 
feeding O 
increased O 
the O 
expression O 
of O 
cardiac O 
hypertrophic O 
proteins O 
and O 
apoptotic O 
markers O 
, O 
which O 
were O 
inhibited O 
by O 
cathepsin O 
K O 
knockout O 
. O 
Furthermore O 
, O 
high O 
- O 
fat O 
feeding O 
resulted O 
in O 
cathepsin O 
K O 
release O 
from O 
lysosomes O 
into O 
the O 
cytoplasm O 
. O 
In O 
H9c2 O 
myoblasts O 
, O 
silencing O 
of O 
cathepsin O 
K O 
inhibited O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
-induced O 
release O 
of O 
cytochrome O 
c O 
from O 
mitochondria O 
and O 
expression O 
of O 
proapoptotic O 
signaling O 
molecules O 
. O 
Collectively O 
, O 
our O 
data O 
indicate O 
that O 
cathepsin O 
K O 
contributes O 
to O 
the O 
development O 
of O 
obesity O 
- O 
associated O 
cardiac O 
hypertrophy O 
and O 
may O 
represent O 
a O 
potential O 
target O 
for O 
the O 
treatment O 
to O 
obesity O 
- O 
associated O 
cardiac O 
anomalies O 
. O 

control O 
of O 
the O 
giant O 
Rashba O 
effect O 
in O 
bulk O 
GeTe B-FORMULA 
. O 

effects O 
, O 
including O 
the O 
Rashba O 
effect O 
, O 
are O 
increasingly O 
seen O 
as O 
key O 
ingredients O 
in O 
spintronics O 
. O 
A O 
link O 
between O 
Rashba O 
physics O 
and O 
the O 
field O 
of O 
ferroelectrics O 
is O 
established O 
by O 
predicting O 
giant O 
Rashba O 
spin O 
- O 
splitting O 
in O 
bulk O 
GeTe B-FORMULA 
( O 
see O 
the O 
Figure O 
showing O 
the O 
band O 
- O 
structure O 
as O 
well O 
as O 
in O 
- O 
plane O 
and O 
out- O 
of O 
- O 
plane O 
spin O 
polarization O 
for O 
a O 
constant O 
energy O 
cut O 
) O 
. O 

of O 
sulfonylurea B-FAMILY 
action O 
by O 
an O 
EPAC-selective O 
cAMP B-ABBREVIATION 
analog O 
in O 
INS-1 O 
cells O 
: O 
comparison O 
of O 
tolbutamide B-TRIVIAL 
and O 
gliclazide B-TRIVIAL 
and O 
a O 
potential O 
role O 
for O 
EPAC O 
activation O 
of O 
a O 
2-APB-sensitive O 
Ca2+ O 
influx O 
. O 

and O 
gliclazide O 
block O 
the O 
K(ATP) O 
channel O 
K(ir)6.2 O 
/ O 
Sur1 O 
, O 
causing O 
membrane O 
depolarization O 
and O 
stimulating O 
insulin O 
secretion O 
in O 
pancreatic O 
beta O 
cells O 
. O 
We O 
examined O 
the O 
ability O 
of O 
the O 
EPAC-selective O 
cAMP B-ABBREVIATION 
analog O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
to O 
potentiate O 
the O 
action O 
of O 
these O 
drugs O 
and O 
the O 
mechanism O 
that O 
might O 
account O 
for O 
it O 
. O 
Insulin O 
secretion O 
stimulated O 
by O 
both O 
200 O 
μM O 
tolbutamide B-TRIVIAL 
and O 
20 O 
μM O 
gliclazide B-TRIVIAL 
, O 
concentrations O 
that O 
had O 
equivalent O 
effects O 
on O 
membrane O 
potential O 
, O 
was O 
inhibited O 
by O 
thapsigargin B-TRIVIAL 
( O 
1 O 
μM O 
) O 
or O 
the O 
L- O 
type O 
Ca(2+) B-FORMULA 
channel O 
blocker O 
nicardipine B-TRIVIAL 
( O 
2 O 
μM O 
) O 
and O 
was O 
potentiated O 
by O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
at O 
concentrations O 
≥ O 
2 O 
μM O 
in O 
INS-1 O 
cells O 
. O 
Ca(2+) B-FORMULA 
transients O 
stimulated O 
by O 
either O 
tolbutamide B-TRIVIAL 
or O 
gliclazide B-TRIVIAL 
were O 
inhibited O 
by O 
thapsigargin B-TRIVIAL 
or O 
nicardipine B-TRIVIAL 
and O 
were O 
significantly O 
potentiated O 
by O 
8-pCPT-2'-O-Me-cAMP-AM O 
at O 
5 O 
μM O 
but O 
not O 
1 O 
μM O 
. O 
Both O 
tolbutamide B-TRIVIAL 
and O 
gliclazide B-TRIVIAL 
stimulated O 
phospholipase O 
C O 
activity O 
; O 
however O 
, O 
only O 
gliclazide B-TRIVIAL 
did O 
so O 
independently O 
of O 
its O 
activity O 
at O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
, O 
and O 
this O 
activity O 
was O 
partially O 
inhibited O 
by O 
pertussis O 
toxin O 
. O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
alone O 
( O 
5 O 
μM O 
) O 
did O 
not O 
stimulate O 
insulin O 
secretion O 
, O 
but O 
did O 
increase O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
significantly O 
, O 
and O 
this O 
activity O 
was O 
inhibited O 
by O 
25 O 
μM O 
2-aminoethoxydiphenylborate B-SYSTEMATIC 
( O 
2-APB B-SYSTEMATIC 
) O 
or O 
the O 
removal O 
of O 
extracellular O 
Ca(2+) B-FORMULA 
. O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
potentiation O 
of O 
insulin O 
secretion O 
stimulated O 
by O 
tolbutamide B-TRIVIAL 
was O 
markedly O 
inhibited O 
by O 
2-APB B-SYSTEMATIC 
( O 
25 O 
μM O 
) O 
and O 
enhanced O 
by O 
the O 
PKC O 
inhibitor O 
bisindolylmaleimide B-SYSTEMATIC 
I I-SYSTEMATIC 
( O 
1 O 
μM O 
) O 
. O 
Our O 
data O 
demonstrate O 
that O 
the O 
actions O 
of O 
both O 
tolbutamide B-TRIVIAL 
and O 
gliclazide B-TRIVIAL 
are O 
strongly O 
potentiated O 
by O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
, O 
that O 
gliclazide B-TRIVIAL 
can O 
stimulate O 
phospholipase O 
C O 
activity O 
via O 
a O 
partially O 
pertussis O 
toxin O 
- O 
sensitive O 
mechanism O 
, O 
and O 
that O 
8-pCPT-2'-O-Me-cAMP-AM B-SYSTEMATIC 
potentiation O 
of O 
tolbutamide O 
action O 
may O 
involve O 
activation O 
of O 
a O 
2-APB B-SYSTEMATIC 
-sensitive O 
Ca(2+) B-FORMULA 
influx O 
. O 

synthesis O 
of O 
apoE O 
by O 
adipocytes O 
has O 
profound O 
effects O 
on O 
adipose O 
tissue O 
lipid O 
flux O 
and O 
gene O 
expression O 
. O 
Using O 
adipose O 
tissue O 
transplantation O 
from O 
wild O 
- O 
type O 
( O 
WT O 
) O 
to O 
apoE O 
knockout O 
( O 
EKO O 
) O 
mice O 
, O 
we O 
show O 
that O 
adipose O 
tissue O 
also O 
contributes O 
to O 
circulating O 
apoE O 
. O 
Different O 
from O 
circulating O 
apoE O 
produced O 
by O 
bone O 
marrow O 
transplantation O 
( O 
BMT O 
) O 
, O 
however O 
, O 
adipose O 
tissue O 
- O 
derived O 
apoE O 
does O 
not O 
correct O 
hyperlipidemia O 
or O 
suppress O 
atherosclerosis O 
. O 
ApoE O 
secreted O 
by O 
macrophages O 
has O 
a O 
more O 
acidic O 
isoform O 
distribution O 
, O 
and O 
it O 
increases O 
binding O 
of O 
reconstituted O 
VLDL O 
particles O 
to O 
hepatocytes O 
and O 
fibroblasts O 
more O 
effectively O 
than O 
apoE O 
secreted O 
by O 
adipocytes O 
. O 
The O 
incremental O 
binding O 
can O 
be O 
entirely O 
accounted O 
for O 
by O 
binding O 
to O 
the O 
LDL O 
receptor O 
. O 
After O 
BMT O 
into O 
EKO O 
hosts O 
, O 
plasma O 
cholesterol B-TRIVIAL 
and O 
macrophage O 
- O 
derived O 
apoE O 
are O 
largely O 
within O 
IDL O 
/ O 
LDL- O 
and O 
HDL-sized O 
particles O 
. O 
After O 
adipose O 
tissue O 
transplantation O 
, O 
most O 
cholesterol B-TRIVIAL 
and O 
adipocyte O 
apoE O 
remain O 
in O 
VLDL O 
. O 
After O 
BMT O 
, O 
circulating O 
apoE O 
no O 
longer O 
demonstrates O 
predominance O 
of O 
acidic O 
isoforms O 
compared O 
with O 
that O 
circulating O 
after O 
fat O 
transplantation O 
. O 
In O 
conclusion O 
, O 
fat O 
transplantation O 
provides O 
circulating O 
apoE O 
levels O 
similar O 
to O 
those O 
provided O 
by O 
bone O 
marrow O 
transplantation O 
, O 
but O 
it O 
does O 
not O 
suppress O 
hyperlipidemia O 
or O 
atherosclerosis O 
. O 
A O 
potential O 
mechanism O 
contributing O 
to O 
this O 
difference O 
is O 
differential O 
binding O 
to O 
cell O 
surface O 
lipoprotein O 
receptors O 
. O 

of O 
conjugated O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
supplementation O 
and O 
exercise O 
on O 
post O 
- O 
heparin O 
lipoprotein O 
lipase O 
, O 
butyrylcholinesterase O 
, O 
blood O 
lipid O 
profile O 
and O 
glucose B-TRIVIAL 
metabolism O 
in O 
young O 
men O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
the O 
effects O 
of O 
conjugated O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CLA B-ABBREVIATION 
) O 
supplementation O 
and O 
endurance O 
exercise O 
training O 
- O 
induced O 
changes O 
on O 
post O 
- O 
heparin O 
lipoprotein O 
lipase O 
( O 
PH-LPL O 
) O 
and O 
butyrylcholinesterase O 
( O 
BChE O 
) O 
activities O 
along O 
with O 
leptin O 
, O 
insulin O 
and O 
lipid O 
levels O 
in O 
plasma O 
by O 
a O 
randomized O 
double O 
blind O 
experiment O 
. O 
Eighteen O 
sedentary O 
male O 
volunteers O 
were O 
randomly O 
divided O 
into O 
CLA B-ABBREVIATION 
and O 
Placebo O 
( O 
PLC O 
) O 
supplementation O 
groups O 
. O 
Both O 
groups O 
underwent O 
daily O 
supplementation O 
of O 
either O 
3g O 
CLA B-ABBREVIATION 
or O 
3g O 
placebo O 
for O 
30days O 
, O 
respectively O 
, O 
and O 
performed O 
exercise O 
on O 
a O 
bicycle O 
ergometer O 
3 O 
times O 
per O 
week O 
for O 
30-40min O 
at O 
50% O 
VO2 O 
peak O 
workload O 
. O 
For O 
plasma O 
glucose B-TRIVIAL 
, O 
insulin O 
and O 
leptin O 
levels O 
and O 
BChE O 
activity O 
fasting O 
blood O 
was O 
used O 
. O 
For O 
PH-LPL O 
measurements O 
, O 
blood O 
was O 
collected O 
15min O 
after O 
50IU O 
/ O 
kg O 
iv O 
heparin O 
injection O 
. O 
In O 
all O 
groups O 
, O 
there O 
is O 
a O 
statistically O 
significant O 
decrease O 
in O 
BChE O 
( O 
p=0.03 O 
, O 
p=0.02 O 
) O 
and O 
leptin O 
( O 
p=0.002 O 
) O 
, O 
insulin O 
and O 
HOMA-IR O 
levels O 
( O 
p=0.02 O 
) O 
. O 
Exercise O 
with O 
or O 
without O 
CLA B-ABBREVIATION 
supplementation O 
decreased O 
insulin O 
levels O 
and O 
increased O 
insulin O 
sensitivity O 
. O 
PH-LPL O 
activity O 
was O 
increased O 
significantly O 
in O 
both O 
groups O 
, O 
displaying O 
increased O 
fatty O 
acid O 
mobilization O 
. O 
We O 
conclude O 
that O 
though O 
CLA B-ABBREVIATION 
supplementation O 
and O 
exercise O 
can O 
affect O 
these O 
parameters O 
, O 
CLA B-ABBREVIATION 
is O 
not O 
more O 
effective O 
than O 
exercise O 
alone O 
. O 
Hence O 
, O 
a O 
prolonged O 
supplementation O 
regime O 
may O 
be O 
more O 
effective O 
. O 
Taken O 
together O 
in O 
our O 
small O 
study O 
group O 
, O 
our O 
findings O 
display O 
that O 
BChE O 
is O 
a O 
potential O 
marker O 
for O 
synthetic O 
function O 
of O 
liver O 
, O 
fat O 
metabolism O 
, O 
an O 
obesity O 
marker O 
, O 
a O 
function O 
long O 
overlooked O 
. O 

vivo O 
genotoxicity O 
of O 
methyleugenol B-SYSTEMATIC 
in O 
gpt O 
delta O 
transgenic O 
rats O 
following O 
medium O 
- O 
term O 
exposure O 
. O 

( O 
MEG B-ABBREVIATION 
) O 
, O 
which O 
is O 
commonly O 
used O 
as O 
a O 
fragrance O 
and O 
flavoring O 
agent O 
, O 
has O 
been O 
shown O 
to O 
induce O 
hepatocellular O 
tumors O 
in O 
rodents O 
. O 
However O 
, O 
the O 
role O 
of O 
genotoxicity O 
as O 
a O 
possible O 
mechanism O 
of O 
action O 
is O 
not O 
fully O 
understood O 
even O 
though O 
the O 
DNA-reactive O 
metabolite O 
of O 
MEG B-ABBREVIATION 
has O 
been O 
identified O 
. O 
In O 
this O 
study O 
, O 
a O 
gpt O 
delta O 
transgenic O 
rat O 
model O 
was O 
used O 
to O 
clarify O 
whether O 
genotoxic O 
mechanisms O 
are O 
involved O 
in O 
MEG B-ABBREVIATION 
-induced O 
hepatocarcinogenesis O 
following O 
medium O 
- O 
term O 
exposure O 
. O 
F344 O 
gpt O 
delta O 
rats O 
were O 
subjected O 
to O 
repeated O 
oral O 
administration O 
of O 
MEG B-ABBREVIATION 
at O 
dosages O 
of O 
0 O 
, O 
10 O 
, O 
30 O 
, O 
or O 
100mg O 
/ O 
kg O 
( O 
a O 
carcinogenic O 
dose O 
) O 
for O 
13 O 
weeks O 
. O 
The O 
relative O 
weight O 
of O 
the O 
liver O 
of O 
the O 
male O 
and O 
female O 
rats O 
that O 
were O 
administered O 
100mg O 
/ O 
kg O 
MEG B-ABBREVIATION 
and O 
the O 
absolute O 
weight O 
of O 
the O 
liver O 
of O 
the O 
male O 
rats O 
that O 
were O 
administered O 
100mg O 
/ O 
kg O 
MEG B-ABBREVIATION 
were O 
significantly O 
increased O 
. O 
In O 
addition O 
, O 
the O 
number O 
and O 
area O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
placental O 
form O 
( O 
GST-P O 
) O 
positive O 
foci O 
and O 
proliferating O 
cell O 
nuclear O 
antigen O 
( O 
PCNA O 
) O 
positive O 
cell O 
ratios O 
in O 
the O 
hepatocytes O 
were O 
significantly O 
increased O 
in O 
the O 
male O 
and O 
female O 
rats O 
that O 
were O 
administered O 
100mg O 
/ O 
kg O 
MEG B-ABBREVIATION 
compared O 
with O 
the O 
control O 
animals O 
. O 
In O 
the O 
in O 
vivo O 
mutation O 
assays O 
, O 
a O 
significant O 
increase O 
in O 
the O 
gpt O 
and O 
Spi(-) O 
mutant O 
frequencies O 
was O 
observed O 
in O 
both O 
sexes O 
at O 
the O 
carcinogenic O 
dose O 
. O 
These O 
results O 
suggest O 
the O 
possible O 
participation O 
of O 
genotoxic O 
mechanisms O 
in O 
MEG B-ABBREVIATION 
-induced O 
hepatocarcinogenesis O 
. O 

temperature O 
controlled O 
dual O 
water O 
/ O 
oil O 
on O 
- O 
off O 
switch O 
is O 
achieved O 
by O 
using O 
a O 
PMMA-b-PNIPAAm B-ABBREVIATION 
block O 
- O 
copolymer O 
coated O 
mesh O 
, O 
determined O 
by O 
the O 
conformational O 
change O 
of O 
the O 
PNIPAAm B-ABBREVIATION 
chain O 
around O 
the O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
and O 
also O 
the O 
cooperation O 
between O 
PNIPAAm B-ABBREVIATION 
and O 
PMMA B-ABBREVIATION 
. O 
Water O 
can O 
permeate O 
through O 
the O 
BCP O 
- O 
coated O 
mesh O 
, O 
and O 
oil O 
cannot O 
below O 
the O 
LCST O 
, O 
whereas O 
oil O 
can O 
and O 
water O 
cannot O 
above O 
the O 
LCST O 
. O 

- O 
based O 
electrodes O 
for O 
interfacing O 
biological O 
tissues O 
are O 
becoming O 
increasingly O 
sophisticated O 
. O 
Their O 
many O 
functions O 
place O 
them O 
at O 
the O 
cross O 
- O 
roads O 
of O 
electromaterials O 
, O 
biomaterials O 
, O 
and O 
drug O 
- O 
delivery O 
systems O 
. O 
For O 
conducting O 
polymers O 
, O 
the O 
mechanism O 
of O 
conductivity O 
requires O 
doping O 
with O 
anionic O 
molecules O 
such O 
as O 
extracellular O 
matrix O 
molecules O 
, O 
a O 
process O 
that O 
distinguishes O 
them O 
as O 
biomaterials O 
and O 
provides O 
a O 
means O 
to O 
control O 
interactions O 
at O 
the O 
cellular O 
- O 
electrode O 
interface O 
. O 
However O 
, O 
due O 
to O 
their O 
complex O 
structure O 
, O 
directly O 
observing O 
the O 
selective O 
binding O 
of O 
target O 
molecules O 
or O 
proteins O 
has O 
so O 
far O 
eluded O 
researchers O 
. O 
This O 
situation O 
is O 
compounded O 
by O 
the O 
polymer's O 
ability O 
to O 
adopt O 
different O 
electronic O 
states O 
that O 
alter O 
the O 
polymer O 
- O 
dopant O 
interactions O 
. O 
Here O 
, O 
the O 
ability O 
to O 
resolve O 
sub O 
- O 
molecular O 
binding O 
specificity O 
between O 
sulfate O 
and O 
carboxyl B-SYSTEMATIC 
groups O 
of O 
dopants O 
and O 
heparin O 
binding O 
domains O 
of O 
human O 
plasma O 
fibronectin O 
is O 
demonstrated O 
. O 
The O 
interaction O 
exploits O 
a O 
form O 
of O 
biological O 
' O 
charge O 
complementarity O 
' O 
to O 
enable O 
specificity O 
. O 
When O 
an O 
electrical O 
signal O 
is O 
applied O 
to O 
the O 
polymer O 
, O 
the O 
specific O 
interaction O 
is O 
switched O 
to O 
a O 
non-specific O 
, O 
high O 
- O 
affinity O 
binding O 
state O 
that O 
can O 
be O 
reversibly O 
controlled O 
using O 
electrochemical O 
processes O 
. O 
Both O 
the O 
specific O 
and O 
non-specific O 
interactions O 
are O 
integral O 
for O 
controlling O 
protein O 
conformation O 
and O 
dynamics O 
. O 
These O 
details O 
, O 
which O 
represent O 
the O 
first O 
direct O 
measurement O 
of O 
biomolecular O 
recognition O 
between O 
a O 
single O 
protein O 
and O 
any O 
type O 
of O 
organic O 
conductor O 
, O 
give O 
new O 
molecular O 
insight O 
into O 
controlling O 
cellular O 
interactions O 
on O 
these O 
polymer O 
surfaces O 
. O 

iron B-SYSTEMATIC 
chelator O 
, O 
deferasirox B-TRIVIAL 
, O 
as O 
a O 
novel O 
strategy O 
for O 
cancer O 
treatment O 
: O 
oral O 
activity O 
against O 
human O 
lung O 
tumor O 
xenografts O 
and O 
molecular O 
mechanism O 
of O 
action O 
. O 

is O 
an O 
orally O 
effective O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
chelator O 
currently O 
used O 
for O 
the O 
treatment O 
of O 
iron B-SYSTEMATIC 
-overload O 
disease O 
and O 
has O 
been O 
implemented O 
as O 
an O 
alternative O 
to O 
the O 
gold O 
standard O 
chelator O 
, O 
desferrioxamine B-TRIVIAL 
( O 
DFO B-ABBREVIATION 
) O 
. O 
Earlier O 
studies O 
demonstrated O 
that O 
DFO B-ABBREVIATION 
exhibits O 
anticancer O 
activity O 
due O 
to O 
its O 
ability O 
to O 
deplete O 
cancer O 
cells O 
of O 
iron B-SYSTEMATIC 
. O 
In O 
this O 
investigation O 
, O 
we O 
examined O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
activity O 
of O 
deferasirox O 
against O 
cells O 
from O 
human O 
solid O 
tumors O 
. O 
To O 
date O 
, O 
there O 
have O 
been O 
no O 
studies O 
to O 
investigate O 
the O 
effect O 
of O 
deferasirox B-TRIVIAL 
on O 
these O 
types O 
of O 
tumors O 
in O 
vivo O 
. O 
Deferasirox B-TRIVIAL 
demonstrated O 
similar O 
activity O 
at O 
inhibiting O 
proliferation O 
of O 
DMS-53 O 
lung O 
carcinoma O 
and O 
SK-N-MC O 
neuroepithelioma O 
cell O 
lines O 
compared O 
with O 
DFO B-ABBREVIATION 
. O 
Furthermore O 
, O 
deferasirox B-TRIVIAL 
was O 
generally O 
similar O 
or O 
slightly O 
more O 
effective O 
than O 
DFO B-ABBREVIATION 
at O 
mobilizing O 
cellular O 
(59)Fe B-FORMULA 
and O 
inhibiting O 
iron O 
uptake O 
from O 
human O 
transferrin O 
depending O 
on O 
the O 
cell O 
type O 
. O 
However O 
, O 
deferasirox B-TRIVIAL 
potently O 
inhibited O 
DMS-53 O 
xenograft O 
growth O 
in O 
nude O 
mice O 
when O 
given O 
by O 
oral O 
gavage O 
, O 
with O 
no O 
marked O 
alterations O 
in O 
normal O 
tissue O 
histology O 
. O 
To O 
understand O 
the O 
antitumor O 
activity O 
of O 
deferasirox B-TRIVIAL 
, O 
we O 
investigated O 
its O 
effect O 
on O 
the O 
expression O 
of O 
molecules O 
that O 
play O 
key O 
roles O 
in O 
metastasis O 
, O 
cell O 
cycle O 
control O 
, O 
and O 
apoptosis O 
. O 
We O 
demonstrated O 
that O 
deferasirox B-TRIVIAL 
increased O 
expression O 
of O 
the O 
metastasis O 
suppressor O 
protein O 
N-myc O 
downstream O 
- O 
regulated O 
gene O 
1 O 
and O 
upregulated O 
the O 
cyclin O 
- O 
dependent O 
kinase O 
inhibitor O 
p21(CIP1 O 
/ O 
WAF1 O 
) O 
while O 
decreasing O 
cyclin O 
D1 O 
levels O 
. O 
Moreover O 
, O 
this O 
agent O 
increased O 
the O 
expression O 
of O 
apoptosis O 
markers O 
, O 
including O 
cleaved O 
caspase-3 O 
and O 
cleaved O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
1 O 
. O 
Collectively O 
, O 
we O 
demonstrate O 
that O 
deferasirox B-TRIVIAL 
is O 
an O 
orally O 
effective O 
antitumor O 
agent O 
against O 
solid O 
tumors O 
. O 

of O 
halogen B-FAMILY 
bonding O 
. O 
A O 
study O 
based O 
on O 
the O 
topological O 
analysis O 
of O 
the O 
Laplacian O 
of O 
the O 
electron O 
charge O 
density O 
and O 
an O 
energy O 
decomposition O 
analysis O 
. O 

this O 
work O 
we O 
investigate O 
the O 
nature O 
of O 
the O 
Cl B-FORMULA 
··· O 
N B-FORMULA 
interactions O 
in O 
complexes O 
formed O 
between O 
substituted O 
ammonium O 
[ O 
NHn(X3-n) B-FAMILY 
( O 
with O 
n O 
= O 
0 O 
, O 
1 O 
, O 
2 O 
, O 
3 O 
and O 
X O 
= O 
- O 
CH3 B-FORMULA 
, O 
- O 
F B-FORMULA 
] O 
as O 
Lewis B-FAMILY 
bases I-FAMILY 
and O 
F B-FORMULA 
- O 
Cl B-FORMULA 
molecule O 
as O 
Lewis B-FAMILY 
acid I-FAMILY 
. O 
They O 
have O 
been O 
chosen O 
as O 
a O 
study O 
case O 
due O 
to O 
the O 
wide O 
range O 
of O 
variation O 
of O 
their O 
binding O 
energies O 
, O 
BEs O 
. O 
Møller-Plesset O 
[ O 
MP2 O 
/ O 
6-311 O 
+ O 
+ O 
G(2d,2p) O 
] O 
calculations O 
show O 
that O 
the O 
BEs O 
for O 
this O 
set O 
of O 
complexes O 
lie O 
in O 
the O 
range O 
from O 
1.27 O 
kcal O 
/ O 
mol O 
( O 
in O 
F B-FORMULA 
- O 
Cl B-FORMULA 
··· O 
NF3 B-FORMULA 
) O 
to O 
27.62 O 
kcal O 
/ O 
mol O 
[ O 
in O 
F B-FORMULA 
- O 
Cl B-FORMULA 
··· O 
N(CH3)3 B-FORMULA 
] O 
. O 
The O 
intermolecular O 
distribution O 
of O 
the O 
electronic O 
charge O 
density O 
and O 
their O 
L(r) O 
= O 
-¼∇(2)ρ(r) O 
function O 
have O 
been O 
investigated O 
within O 
the O 
framework O 
of O 
the O 
atoms O 
in O 
molecules O 
( O 
AIM O 
) O 
theory O 
. O 
The O 
intermolecular O 
interaction O 
energy O 
decomposition O 
has O 
also O 
been O 
analyzed O 
using O 
the O 
reduced O 
variational O 
space O 
( O 
RVS O 
) O 
method O 
. O 
The O 
topological O 
analysis O 
of O 
the O 
L(r) O 
function O 
reveals O 
that O 
the O 
local O 
topological O 
properties O 
measured O 
at O 
the O 
( O 
3 O 
, O 
+ O 
1 O 
) O 
critical O 
point O 
[ O 
in O 
L(r) O 
topology O 
] O 
are O 
good O 
descriptors O 
of O 
the O 
strength O 
of O 
the O 
halogen B-FAMILY 
bonding O 
interactions O 
. O 
The O 
results O 
obtained O 
from O 
energy O 
decomposition O 
analysis O 
indicate O 
that O 
electrostatic O 
interactions O 
play O 
a O 
key O 
role O 
in O 
these O 
halogen B-FAMILY 
bonding O 
interactions O 
. O 
These O 
results O 
allow O 
us O 
to O 
establish O 
that O 
, O 
when O 
the O 
halogen B-FAMILY 
atom O 
is O 
bonded O 
to O 
a O 
group O 
with O 
high O 
electron O 
- O 
withdrawing O 
capacity O 
, O 
the O 
electrostatic O 
interaction O 
between O 
the O 
electron O 
cloud O 
of O 
the O 
Lewis B-FAMILY 
base I-FAMILY 
and O 
the O 
halogen B-FAMILY 
atom O 
unprotected O 
nucleus O 
of O 
the O 
Lewis B-FAMILY 
acid I-FAMILY 
produces O 
the O 
formation O 
and O 
determines O 
the O 
geometry O 
of O 
the O 
halogen B-FAMILY 
bonded O 
complexes O 
. O 
In O 
addition O 
, O 
a O 
good O 
linear O 
relationship O 
has O 
been O 
established O 
between O 
: O 
the O 
natural O 
logarithm O 
of O 
the O 
BEs O 
and O 
the O 
electrostatic O 
interaction O 
energy O 
between O 
electron O 
charge O 
distribution O 
of O 
N B-FORMULA 
atom O 
and O 
nucleus O 
of O 
Cl B-FORMULA 
atom O 
, O 
denoted O 
as O 
V O 
e-n( O 
N B-FORMULA 
, O 
Cl B-FORMULA 
) O 
within O 
the O 
AIM O 
theory O 
. O 

of O 
hepatic O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
3 O 
by O 
ethynylestradiol B-SYSTEMATIC 
is O 
independent O 
of O 
cholestasis O 
and O 
mediated O 
by O 
estrogen B-FAMILY 
receptor O 
. O 

resistance O 
- O 
associated O 
protein O 
3 O 
( O 
Mrp3 O 
; O 
Abcc3 O 
) O 
expression O 
and O 
activity O 
are O 
up O 
- O 
regulated O 
in O 
rat O 
liver O 
after O 
in O 
vivo O 
repeated O 
administration O 
of O 
ethynylestradiol B-SYSTEMATIC 
( O 
EE O 
) O 
, O 
a O 
cholestatic O 
synthetic O 
estrogen B-FAMILY 
, O 
whereas O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
( O 
Mrp2 O 
) O 
is O 
down O 
- O 
regulated O 
. O 
This O 
study O 
was O 
undertaken O 
to O 
determine O 
whether O 
Mrp3 O 
induction O 
results O 
from O 
a O 
direct O 
effect O 
of O 
EE O 
, O 
independent O 
of O 
accumulation O 
of O 
any O 
endogenous O 
common O 
Mrp2 O 
/ O 
Mrp3 O 
substrates O 
resulting O 
from O 
cholestasis O 
and O 
the O 
potential O 
mediation O 
of O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
. O 
In O 
in O 
vivo O 
studies O 
, O 
male O 
rats O 
were O 
given O 
a O 
single O 
, O 
noncholestatic O 
dose O 
of O 
EE O 
( O 
5 O 
mg O 
/ O 
kg O 
s.c O 
. O 
) O 
, O 
and O 
basal O 
bile O 
flow O 
and O 
the O 
biliary O 
excretion O 
rate O 
of O 
bile B-FAMILY 
salts I-FAMILY 
and O 
glutathione B-TRIVIAL 
were O 
measured O 
5 O 
hours O 
later O 
. O 
This O 
treatment O 
increased O 
Mrp3 O 
mRNA O 
by O 
4-fold O 
, O 
detected O 
by O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
, O 
despite O 
the O 
absence O 
of O 
cholestasis O 
. O 
Primary O 
culture O 
of O 
rat O 
hepatocytes O 
incubated O 
with O 
EE O 
( O 
1-10 O 
µM O 
) O 
for O 
5 O 
hours O 
exhibited O 
a O 
3-fold O 
increase O 
in O 
Mrp3 O 
mRNA O 
( O 
10 O 
µM O 
) O 
, O 
consistent O 
with O 
in O 
vivo O 
findings O 
. O 
The O 
increase O 
in O 
Mrp3 O 
mRNA O 
by O 
EE O 
was O 
prevented O 
by O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
, O 
indicating O 
transcriptional O 
regulation O 
. O 
When O 
hepatocytes O 
were O 
incubated O 
with O 
an O 
ER O 
antagonist O 
[ O 
7α,17β-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol B-SYSTEMATIC 
( O 
ICI182 B-IDENTIFIER 
/ I-IDENTIFIER 
780 I-IDENTIFIER 
) O 
, O 
1 O 
µM O 
] O 
, O 
in O 
addition O 
to O 
EE O 
, O 
induction O 
of O 
Mrp3 O 
mRNA O 
was O 
abolished O 
, O 
implicating O 
ER O 
as O 
a O 
key O 
mediator O 
. O 
EE O 
induced O 
an O 
increase O 
in O 
ER-α O 
phosphorylation O 
at O 
30 O 
minutes O 
and O 
expression O 
of O 
c-Jun O 
, O 
a O 
well O 
- O 
known O 
ER O 
target O 
gene O 
, O 
at O 
60 O 
minutes O 
, O 
as O 
detected O 
by O 
Western O 
blotting O 
of O 
nuclear O 
extracts O 
. O 
These O 
increases O 
were O 
prevented O 
by O 
ICI182 B-IDENTIFIER 
/ I-IDENTIFIER 
780 I-IDENTIFIER 
. O 
In O 
summary O 
, O 
EE O 
increased O 
the O 
expression O 
of O 
hepatic O 
Mrp3 O 
transcriptionally O 
and O 
independently O 
of O 
any O 
cholestatic O 
manifestation O 
and O 
required O 
participation O 
of O 
an O 
ER O 
, O 
most O 
likely O 
ER-α O 
, O 
through O 
its O 
phosphorylation O 
. O 

chromaffin O 
cells O 
exist O 
in O 
both O 
intra- O 
and O 
extra O 
- O 
adrenal O 
locations O 
; O 
the O 
organ O 
of O 
Zuckerkandl O 
( O 
OZ O 
) O 
constitutes O 
the O 
largest O 
accumulation O 
of O 
extra O 
- O 
adrenal O 
chromaffin O 
tissue O 
in O 
mammals O 
. O 
The O 
OZ O 
disappears O 
postnatally O 
by O 
modes O 
that O 
are O 
still O 
enigmatic O 
but O 
can O 
be O 
maintained O 
by O 
treatment O 
with O 
glucocorticoids O 
( O 
GC O 
) O 
. O 
Whether O 
the O 
response O 
to O 
GC O 
reflects O 
a O 
pharmacological O 
or O 
a O 
physiological O 
role O 
of O 
GC O 
has O 
not O 
been O 
clarified O 
. O 
Using O 
mice O 
with O 
a O 
conditional O 
deletion O 
of O 
the O 
GC-receptor O 
( O 
GR O 
) O 
gene O 
restricted O 
to O 
cells O 
expressing O 
the O 
dopamine B-TRIVIAL 
β-hydroxylase O 
( O 
DBH O 
) O 
gene O 
[ O 
GR(fl O 
/ O 
fl O 
) O 
; O 
DBHCre O 
abbreviated O 
( O 
GR(DBHCre) O 
) O 
] O 
, O 
we O 
now O 
present O 
the O 
first O 
evidence O 
for O 
a O 
physiological O 
role O 
of O 
GC O 
signalling O 
in O 
the O 
postnatal O 
maintenance O 
of O 
the O 
OZ O 
: O 
postnatal O 
losses O 
of O 
OZ O 
chromaffin O 
cells O 
in O 
GR(DBHCre) O 
mice O 
are O 
doubled O 
compared O 
to O 
wild O 
- O 
type O 
littermates O 
. O 
We O 
find O 
that O 
postnatal O 
cell O 
loss O 
in O 
the O 
OZ O 
starts O 
at O 
birth O 
and O 
is O 
accompanied O 
by O 
autophagy O 
. O 
Electron O 
microscopy O 
reveals O 
autophagic O 
vacuoles O 
and O 
autophagolysosomes O 
in O 
chromaffin O 
cells O 
. O 
Autophagy O 
in O 
OZ O 
extra O 
- O 
adrenal O 
chromaffin O 
cells O 
is O 
confirmed O 
by O 
showing O 
accumulation O 
of O 
p62 O 
protein O 
, O 
which O 
occurs O 
, O 
when O 
autophagy O 
is O 
blocked O 
by O 
deleting O 
the O 
Atg5 O 
gene O 
( O 
Atg5(DBHCre) O 
mice O 
) O 
. O 
Cathepsin-D O 
, O 
a O 
lysosomal O 
marker O 
, O 
is O 
expressed O 
in O 
cells O 
that O 
surround O 
chromaffin O 
cells O 
and O 
are O 
positive O 
for O 
the O 
macrophage O 
marker O 
BM8 O 
. O 
Macrophages O 
are O 
relatively O 
more O 
abundant O 
in O 
mice O 
lacking O 
the O 
GR O 
, O 
indicating O 
more O 
robust O 
elimination O 
of O 
degenerating O 
chromaffin O 
cells O 
in O 
GR(DBHCre) O 
mice O 
than O 
in O 
wild O 
- O 
type O 
littermates O 
. O 
In O 
summary O 
, O 
our O 
results O 
indicate O 
that O 
extra O 
- O 
adrenal O 
chromaffin O 
cells O 
in O 
the O 
OZ O 
show O 
signs O 
of O 
autophagy O 
, O 
which O 
accompany O 
their O 
postnatal O 
numerical O 
decline O 
, O 
a O 
process O 
that O 
is O 
controlled O 
by O 
GR O 
signalling O 
. O 

immunosuppressive O 
effects O 
of O 
the O 
mTOR O 
inhibitor O 
sirolimus B-TRIVIAL 
and O 
the O 
phytochemical O 
curcumin B-TRIVIAL 
. O 

immunosuppressant O 
sirolimus B-TRIVIAL 
and O 
curcumin B-TRIVIAL 
, O 
the O 
main O 
principle O 
of O 
the O 
turmeric O 
spice O 
, O 
have O 
shown O 
antiproliferative O 
effects O 
on O 
many O 
human O 
and O 
not O 
- O 
human O 
cell O 
lines O 
. O 
Whereas O 
the O 
antiproliferative O 
effect O 
of O 
sirolimus B-TRIVIAL 
is O 
mainly O 
mediated O 
by O 
inhibition O 
of O 
mTOR O 
, O 
curcumin B-TRIVIAL 
is O 
described O 
to O 
affect O 
many O 
molecular O 
targets O 
which O 
makes O 
it O 
unpredictable O 
to O 
appraise O 
if O 
the O 
effects O 
of O 
these O 
both O 
substances O 
on O 
cell O 
proliferation O 
and O 
especially O 
on O 
immunosuppression O 
are O 
additive O 
or O 
synergistic O 
. O 
To O 
answer O 
this O 
question O 
we O 
investigated O 
the O 
interaction O 
of O 
both O 
these O 
substances O 
on O 
OKT3-induced O 
human O 
peripheral O 
blood O 
mononuclear O 
cell O 
( O 
PBMC O 
) O 
proliferation O 
. O 
OKT3-induced O 
human O 
PBMC O 
proliferation O 
was O 
determined O 
by O 
measuring O 
(3)H-thymidine B-SYSTEMATIC 
incorporation O 
. O 
Influence O 
of O 
curcumin B-TRIVIAL 
on O 
interleukin-2 O 
( O 
IL-2 O 
) O 
release O 
and O 
IκB-phosphorylation O 
in O 
PBMC O 
was O 
determined O 
by O 
ELISA O 
and O 
western O 
blot O 
, O 
respectively O 
. O 
Curcumin B-TRIVIAL 
-induced O 
apoptosis O 
and O 
necrosis O 
was O 
analyzed O 
by O 
FACS O 
analysis O 
. O 
Whereas O 
curcumin B-TRIVIAL 
completely O 
inhibited O 
OKT3-induced O 
PBMC O 
proliferation O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
with O 
an O 
IC(50) O 
of O 
2.8 O 
μM O 
, O 
sirolimus B-TRIVIAL 
could O 
reduce O 
PBMC O 
proliferation O 
dose O 
- O 
dependently O 
only O 
to O 
a O 
minimum O 
of O 
28% O 
at O 
a O 
concentration O 
of O 
5 O 
ng O 
/ O 
ml O 
( O 
IC(50) O 
1.1 O 
ng O 
/ O 
ml O 
) O 
. O 
When O 
curcumin B-TRIVIAL 
was O 
combined O 
at O 
concentrations O 
of O 
1.25-2.5 O 
μM O 
with O 
sirolimus B-TRIVIAL 
at O 
concentrations O 
from O 
0.63 O 
to O 
1.25 O 
ng O 
/ O 
ml O 
the O 
effects O 
were O 
synergistic O 
. O 
Combination O 
of O 
curcumin B-TRIVIAL 
( O 
1.25-2.5 O 
μM O 
) O 
with O 
sirolimus B-TRIVIAL 
( O 
5 O 
ng O 
/ O 
ml O 
) O 
showed O 
additive O 
effects O 
. O 
The O 
effects O 
after O 
combination O 
of O 
curcumin B-TRIVIAL 
at O 
5 O 
μM O 
with O 
each O 
sirolimus B-TRIVIAL 
concentration O 
and O 
sirolimus B-TRIVIAL 
at O 
10 O 
ng O 
/ O 
ml O 
with O 
each O 
curcumin B-TRIVIAL 
concentration O 
were O 
presumably O 
antagonistic O 
. O 
We O 
conclude O 
that O 
the O 
immunosuppressive O 
effects O 
of O 
curcumin B-TRIVIAL 
and O 
sirolimus B-TRIVIAL 
in O 
low O 
concentrations O 
are O 
synergistic O 
in O 
OKT3-activated O 
PBMC O 
. O 
Whether O 
curcumin B-TRIVIAL 
and O 
sirolimus B-TRIVIAL 
have O 
also O 
synergistic O 
antiproliferative O 
effects O 
in O 
tumor O 
cells O 
has O 
to O 
be O 
shown O 
in O 
further O 
experiments O 
including O 
animal O 
models O 
. O 

stem O 
cells O 
evade O 
replicative O 
senescence O 
, O 
whereas O 
other O 
primary O 
cells O 
lose O 
their O 
proliferation O 
and O 
differentiation O 
potential O 
after O 
a O 
limited O 
number O 
of O 
cell O 
divisions O 
, O 
and O 
this O 
is O 
accompanied O 
by O 
specific O 
senescence O 
- O 
associated O 
DNA O 
methylation O 
( O 
SA-DNAm O 
) O 
changes O 
. O 
Here O 
, O 
we O 
investigate O 
SA-DNAm O 
changes O 
in O 
mesenchymal O 
stromal O 
cells O 
( O 
MSC O 
) O 
upon O 
long O 
- O 
term O 
culture O 
, O 
irradiation O 
- O 
induced O 
senescence O 
, O 
immortalization O 
, O 
and O 
reprogramming O 
into O 
induced O 
pluripotent O 
stem O 
cells O 
( O 
iPSC O 
) O 
using O 
high O 
- O 
density O 
HumanMethylation450 O 
BeadChips O 
. O 
SA-DNAm O 
changes O 
are O 
highly O 
reproducible O 
and O 
they O 
are O 
enriched O 
in O 
intergenic O 
and O 
nonpromoter O 
regions O 
of O 
developmental O 
genes O 
. O 
Furthermore O 
, O 
SA-hypomethylation O 
in O 
particular O 
appears O 
to O 
be O 
associated O 
with O 
H3K9me3 O 
, O 
H3K27me3 O 
, O 
and O 
Polycomb O 
- O 
group O 
2 O 
target O 
genes O 
. O 
We O 
demonstrate O 
that O 
ionizing O 
irradiation O 
, O 
although O 
associated O 
with O 
a O 
senescence O 
phenotype O 
, O 
does O 
not O 
affect O 
SA-DNAm O 
. O 
Furthermore O 
, O 
overexpression O 
of O 
the O 
catalytic O 
subunit O 
of O 
the O 
human O 
telomerase O 
( O 
TERT O 
) O 
or O 
conditional O 
immortalization O 
with O 
a O 
doxycycline B-TRIVIAL 
-inducible O 
system O 
( O 
TERT O 
and O 
SV40-TAg O 
) O 
result O 
in O 
telomere O 
extension O 
, O 
but O 
do O 
not O 
prevent O 
SA-DNAm O 
. O 
In O 
contrast O 
, O 
we O 
demonstrate O 
that O 
reprogramming O 
into O 
iPSC O 
prevents O 
almost O 
the O 
entire O 
set O 
of O 
SA-DNAm O 
changes O 
. O 
Our O 
results O 
indicate O 
that O 
long O 
- O 
term O 
culture O 
is O 
associated O 
with O 
an O 
epigenetically O 
controlled O 
process O 
that O 
stalls O 
cells O 
in O 
a O 
particular O 
functional O 
state O 
, O 
whereas O 
irradiation O 
- O 
induced O 
senescence O 
and O 
immortalization O 
are O 
not O 
causally O 
related O 
to O 
this O 
process O 
. O 
Absence O 
of O 
SA-DNAm O 
in O 
pluripotent O 
cells O 
may O 
play O 
a O 
central O 
role O 
for O 
their O 
escape O 
from O 
cellular O 
senescence O 
. O 

prochloraz B-TRIVIAL 
and O 
environmental O 
pollutant O 
dioxin B-FAMILY 
induce O 
the O 
ABCG2 O 
transporter O 
in O 
bovine O 
mammary O 
epithelial O 
cells O 
by O 
the O 
arylhydrocarbon B-FAMILY 
receptor O 
signaling O 
pathway O 
. O 

molecular O 
mechanisms O 
by O 
which O 
environmental O 
pollutants O 
including O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
or O 
widely O 
used O 
imidazole B-SYSTEMATIC 
fungicide O 
prochloraz B-TRIVIAL 
display O 
their O 
toxic O 
effects O 
in O 
vertebrates O 
are O 
still O 
not O 
well O 
understood O 
. O 
Using O 
computer O 
analysis O 
, O 
we O 
recently O 
identified O 
nuclear O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
binding O 
sites O 
termed O 
" O 
dioxin B-FAMILY 
response O 
elements O 
" O 
( O 
DREs O 
) O 
in O 
the O 
5'-untranslated O 
region O 
( O 
5'-UTR O 
) O 
of O 
efflux O 
transporter O 
ABCG2 O 
( O 
Accession O 
No O 
. O 
EU570105 O 
) O 
from O 
the O 
bovine O 
mammary O 
gland O 
. O 
As O 
these O 
regulatory O 
motifs O 
mediate O 
regulation O 
of O 
target O 
genes O 
by O 
AhR O 
agonists O 
including O 
TCDD B-ABBREVIATION 
and O 
prochloraz B-TRIVIAL 
, O 
we O 
have O 
systematically O 
investigated O 
the O 
effect O 
of O 
both O 
contaminants O 
on O 
functional O 
ABCG2 O 
transport O 
activity O 
in O 
primary O 
bovine O 
mammary O 
epithelial O 
cells O 
. O 
TCDD B-ABBREVIATION 
or O 
prochloraz B-TRIVIAL 
doubled O 
ABCG2 O 
- O 
mediated O 
Hoechst B-IDENTIFIER 
H33342 I-IDENTIFIER 
secretion O 
. O 
This O 
effect O 
was O 
almost O 
completely O 
reversed O 
by O 
specific O 
ABCG2 O 
inhibitor O 
Ko143 B-IDENTIFIER 
. O 
In O 
further O 
mechanistic O 
studies O 
, O 
we O 
showed O 
that O 
this O 
induction O 
was O 
due O 
to O 
binding O 
of O 
activated O 
AhR O 
to O 
DRE O 
sequences O 
in O 
the O 
ABCG2 O 
5'-UTR O 
. O 
Receptor O 
binding O 
was O 
significantly O 
reduced O 
by O 
specific O 
AhR O 
antagonist O 
salicyl B-TRIVIAL 
amide I-TRIVIAL 
. O 
Induction O 
of O 
AhR O 
by O 
TCDD B-ABBREVIATION 
and O 
prochloraz B-TRIVIAL 
resulted O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
increase O 
of O 
ABCG2 O 
gene O 
expression O 
and O 
transporter O 
protein O 
levels O 
. O 
As O 
ABCG2 O 
represents O 
the O 
main O 
mammary O 
transporter O 
for O 
xenobiotics O 
including O 
drugs O 
and O 
toxins O 
, O 
exposure O 
to O 
prevalent O 
AhR O 
agonists O 
may O 
enhance O 
transporter O 
- O 
mediated O 
secretion O 
of O 
potential O 
harmful O 
compounds O 
into O 
milk O 
. O 
Through O 
identification O 
of O 
mammary O 
ABCG2 O 
as O 
a O 
novel O 
target O 
gene O 
of O 
pesticide O 
prochloraz B-TRIVIAL 
and O 
dioxin B-FAMILY 
, O 
our O 
results O 
may O 
therefore O 
help O 
to O 
improve O 
the O 
protection O 
of O 
breast O 
- O 
feeding O 
infants O 
and O 
the O 
consumer O 
of O 
dairy O 
products O 
. O 

-enhanced O 
surface O 
mobility O 
of O 
Au B-FORMULA 
( O 
100 O 
) O 
. O 

by O 
experimental O 
studies O 
of O 
two O 
- O 
dimensional O 
Ostwald O 
ripening O 
on O 
Au B-FORMULA 
( O 
100 O 
) O 
electrodes O 
in O 
chlorine B-SYSTEMATIC 
-containing O 
electrolytes O 
, O 
we O 
have O 
studied O 
diffusion O 
processes O 
using O 
density O 
functional O 
theory O 
. O 
We O 
find O 
that O 
chlorine B-SYSTEMATIC 
has O 
a O 
propensity O 
to O 
temporary O 
form O 
AuCl B-FORMULA 
complexes O 
, O 
which O 
diffuse O 
significantly O 
faster O 
than O 
gold O 
adatoms O 
. O 
With O 
and O 
without O 
chlorine B-SYSTEMATIC 
, O 
the O 
lowest O 
activation O 
energy O 
is O 
found O 
for O 
the O 
exchange O 
mechanism O 
. O 
Chlorine B-SYSTEMATIC 
furthermore O 
reduces O 
the O 
activation O 
energy O 
for O 
the O 
detachment O 
from O 
kink O 
sites O 
. O 
Kinetic O 
Monte O 
Carlo O 
simulations O 
were O 
performed O 
on O 
the O 
basis O 
of O 
extensive O 
density O 
functional O 
theory O 
calculations O 
. O 
The O 
island O 
- O 
decay O 
rate O 
obtained O 
from O 
these O 
Monte O 
Carlo O 
simulations O 
, O 
as O 
well O 
as O 
the O 
decay O 
rate O 
obtained O 
from O 
the O 
theoretical O 
activation O 
energies O 
and O 
frequency O 
factors O 
when O 
inserted O 
into O 
analytical O 
solutions O 
for O 
Ostwald O 
ripening O 
, O 
are O 
in O 
agreement O 
with O 
experimental O 
island O 
- O 
decay O 
rates O 
in O 
chlorine B-SYSTEMATIC 
-containing O 
electrolytes O 
. O 

deacetylase O 
3 O 
( O 
Hdac3 O 
) O 
is O 
a O 
nuclear O 
enzyme O 
that O 
removes O 
acetyl B-SYSTEMATIC 
groups O 
from O 
lysine B-TRIVIAL 
residues O 
in O 
histones O 
and O 
other O 
proteins O 
to O 
epigenetically O 
regulate O 
gene O 
expression O 
. O 
Hdac3 O 
interacts O 
with O 
bone O 
- O 
related O 
transcription O 
factors O 
and O 
co O 
- O 
factors O 
such O 
as O 
Runx2 O 
and O 
Zfp521 O 
, O 
and O 
thus O 
is O 
poised O 
to O 
play O 
a O 
key O 
role O 
in O 
the O 
skeletal O 
system O 
. O 
To O 
understand O 
the O 
role O 
of O 
Hdac3 O 
in O 
osteoblasts O 
and O 
osteocytes O 
, O 
Hdac3 O 
conditional O 
knockout O 
( O 
CKO O 
) O 
mice O 
were O 
created O 
with O 
the O 
osteocalcin O 
( O 
OCN O 
) O 
promoter O 
driving O 
Cre O 
expression O 
. O 
Hdac3 O 
CKO(OCN) O 
mice O 
were O 
of O 
normal O 
size O 
and O 
weight O 
, O 
but O 
progressively O 
lost O 
trabecular O 
and O 
cortical O 
bone O 
mass O 
with O 
age O 
. O 
The O 
Hdac3 O 
CKO(OCN) O 
mice O 
exhibited O 
reduced O 
cortical O 
bone O 
mineralization O 
and O 
material O 
properties O 
and O 
suffered O 
frequent O 
fractures O 
. O 
Bone O 
resorption O 
was O 
lower O 
, O 
not O 
higher O 
, O 
in O 
the O 
Hdac3 O 
CKO(OCN) O 
mice O 
, O 
suggesting O 
that O 
primary O 
defects O 
in O 
osteoblasts O 
caused O 
the O 
reduced O 
bone O 
mass O 
. O 
Indeed O 
, O 
reductions O 
in O 
bone O 
formation O 
were O 
observed O 
. O 
Osteoblasts O 
and O 
osteocytes O 
from O 
Hdac3 O 
CKO(OCN) O 
mice O 
showed O 
increased O 
DNA O 
damage O 
and O 
reduced O 
functional O 
activity O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
Thus O 
, O 
Hdac3 O 
expression O 
in O 
osteoblasts O 
and O 
osteocytes O 
is O 
essential O 
for O 
bone O 
maintenance O 
during O 
aging O 
. O 

induces O 
NADPH B-ABBREVIATION 
oxidase O 
activation O 
in O 
human O 
neutrophils O 
by O 
inducing O 
the O 
phosphorylation O 
of O 
p47phox O 
and O 
the O 
activation O 
of O 
Rac2 O 
: O 
involvement O 
of O 
protein O 
tyrosine B-TRIVIAL 
kinases O 
, O 
PI3Kinase O 
, O 
PKC O 
, O 
ERK1 O 
/ O 
2 O 
and O 
p38MAPkinase O 
. O 

oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
by O 
the O 
neutrophil O 
NADPH B-ABBREVIATION 
oxidase O 
plays O 
a O 
key O 
role O 
in O 
host O 
defense O 
against O 
pathogens O 
, O 
such O 
as O 
bacteria O 
and O 
fungi O 
. O 
Zymosan O 
a O 
cell O 
- O 
wall O 
preparation O 
from O 
Saccharomyces O 
cerevisiae O 
is O 
largely O 
used O 
to O 
activate O 
neutrophils O 
in O 
its O 
opsonized O 
form O 
. O 
In O 
this O 
study O 
, O 
we O 
show O 
that O 
non-opsonized O 
zymosan O 
alone O 
induced O 
ROS O 
production O 
by O 
human O 
neutrophils O 
. O 
Zymosan O 
- O 
induced O 
ROS O 
production O 
is O 
higher O 
than O 
the O 
formyl-methionyl-leucyl-phenylalanine B-SYSTEMATIC 
( O 
fMLF B-ABBREVIATION 
)- O 
or O 
the O 
phorbol B-SYSTEMATIC 
myristate I-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
PMA B-ABBREVIATION 
)-induced O 
ROS O 
production O 
but O 
is O 
lower O 
than O 
the O 
one O 
induced O 
by O 
opsonized O 
zymosan O 
. O 
Most O 
of O 
the O 
zymosan O 
- O 
induced O 
ROS O 
production O 
is O 
intracellular O 
. O 
Interestingly O 
, O 
zymosan O 
induced O 
the O 
phosphorylation O 
of O 
the O 
NADPH B-ABBREVIATION 
oxidase O 
cytosolic O 
component O 
p47phox O 
on O 
several O 
sites O 
which O 
are O 
Ser B-FORMULA 
315 O 
, O 
Ser B-FORMULA 
328 O 
and O 
Ser B-FORMULA 
345 O 
. O 
Zymosan O 
induced O 
also O 
the O 
activation O 
of O 
the O 
small O 
G O 
- O 
protein O 
Rac2 O 
. O 
Phosphorylation O 
of O 
the O 
p47phox O 
as O 
well O 
as O 
Rac2 O 
activation O 
were O 
inhibited O 
by O 
genistein B-TRIVIAL 
a O 
broad O 
range O 
protein O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
and O 
by O 
wortmannin B-TRIVIAL 
a O 
PI3Kinase O 
inhibitor O 
. O 
GF109203X B-IDENTIFIER 
a O 
PKC O 
inhibitor O 
inhibited O 
phosphorylation O 
of O 
p47phox O 
on O 
Ser B-FORMULA 
315 O 
and O 
Ser B-FORMULA 
328 O 
. O 
SB203580 B-IDENTIFIER 
and O 
UO126 B-IDENTIFIER 
, O 
inhibitors O 
of O 
p38MAPK O 
and O 
ERK1 O 
/ O 
2-pathway O 
, O 
respectively O 
, O 
inhibited O 
phosphorylation O 
of O 
p47phox O 
on O 
Ser B-FORMULA 
345 O 
. O 
Zymosan O 
- O 
induced O 
ROS O 
production O 
was O 
completely O 
inhibited O 
by O 
genistein B-TRIVIAL 
and O 
wortmannin B-TRIVIAL 
and O 
partially O 
inhibited O 
by O 
SB203580 B-IDENTIFIER 
, O 
UO126 B-IDENTIFIER 
and O 
GF109203X B-IDENTIFIER 
. O 
These O 
results O 
show O 
that O 
zymosan O 
alone O 
is O 
able O 
to O 
activate O 
NADPH B-ABBREVIATION 
oxidase O 
in O 
human O 
neutrophils O 
via O 
the O 
phosphorylation O 
of O 
p47phox O 
and O 
Rac2 O 
activation O 
and O 
that O 
a O 
protein O 
tyrosine B-TRIVIAL 
kinase O 
, O 
PI3Kinase O 
, O 
p38MAPK O 
, O 
ERK1 O 
/ O 
2 O 
and O 
PKC O 
are O 
involved O 
in O 
this O 
process O 
. O 
These O 
pathways O 
could O 
be O 
potential O 
pharmacological O 
targets O 
to O 
treat O 
zymosan- O 
and O 
S O 
. O 
cerevisiae O 
- O 
induced O 
inflammation O 
. O 

dispersions O 
for O 
preparation O 
of O 
phototoxic O 
supersaturated O 
solutions O 
for O 
antimicrobial O 
photodynamic O 
therapy O 
( O 
aPDT O 
) O 
: O 
Studies O 
on O 
curcumin B-TRIVIAL 
and O 
curcuminoides O 
L O 
. O 

is O 
under O 
investigation O 
as O 
a O 
potential O 
photosensitizer O 
( O 
PS O 
) O 
in O 
antimicrobial O 
photodynamic O 
therapy O 
( O 
aPDT O 
) O 
. O 
The O 
therapeutic O 
potential O 
of O 
curcumin B-TRIVIAL 
as O 
a O 
PS O 
is O 
limited O 
by O 
its O 
low O 
aqueous O 
solubility O 
, O 
susceptibility O 
to O 
hydrolytic O 
and O 
photolytic O 
degradation O 
, O 
and O 
limited O 
phototoxicity O 
toward O 
Gram O 
negative O 
( O 
G- O 
) O 
bacteria O 
. O 
Supersaturated O 
solutions O 
of O 
curcumin B-TRIVIAL 
have O 
demonstrated O 
high O 
phototoxicity O 
toward O 
several O 
species O 
of O 
Gram O 
positive O 
( O 
G+ O 
) O 
bacteria O 
as O 
well O 
as O 
the O 
G-Escherichia O 
( O 
E O 
) O 
coli O 
. O 
Thus O 
, O 
solid O 
dispersions O 
that O 
can O 
form O 
supersaturated O 
solutions O 
of O 
curcumin B-TRIVIAL 
upon O 
hydration O 
may O 
be O 
beneficial O 
in O 
aPDT O 
. O 
In O 
the O 
present O 
study O 
, O 
solid O 
dispersions O 
of O 
curcumin B-TRIVIAL 
have O 
been O 
prepared O 
through O 
lyophilization O 
of O 
concentrated O 
solutions O 
obtained O 
from O 
dissolution O 
of O 
hydroxypropyl-β-cyclodextrin B-SYSTEMATIC 
( O 
HPβCD B-ABBREVIATION 
)- O 
curcumin B-TRIVIAL 
co O 
- O 
precipitates O 
. O 
Hydroxypropyl B-SYSTEMATIC 
methylcellulose O 
( O 
HPMC O 
) O 
was O 
added O 
to O 
curcumin B-TRIVIAL 
solutions O 
prior O 
to O 
lyophilization O 
. O 
The O 
resulting O 
lyophilizates O 
were O 
porous O 
, O 
amorphous O 
and O 
hydrated O 
and O 
dissolved O 
rapidly O 
in O 
contact O 
with O 
a O 
model O 
physiological O 
salt O 
solution O 
. O 
The O 
detected O 
drug O 
load O 
of O 
the O 
lyophilizates O 
was O 
in O 
the O 
range O 
0.5-1.0% O 
( O 
w O 
/ O 
w O 
) O 
and O 
was O 
dependent O 
on O 
the O 
selected O 
ratio O 
between O 
HPβCD B-ABBREVIATION 
and O 
curcumin B-TRIVIAL 
in O 
the O 
co O 
- O 
precipitate O 
. O 
The O 
lyophilizate O 
with O 
the O 
highest O 
drug O 
load O 
could O 
easily O 
be O 
dissolved O 
in O 
aqueous O 
medium O 
to O 
form O 
curcumin B-TRIVIAL 
solutions O 
of O 
relevant O 
concentrations O 
for O 
aPDT O 
( O 
i.e O 
. O 
, O 
10μM O 
) O 
. O 
Selected O 
solutions O 
of O 
the O 
curcumin B-TRIVIAL 
solid O 
dispersions O 
showed O 
a O 
pronounced O 
decrease O 
in O 
curcumin B-TRIVIAL 
concentration O 
up O 
to O 
90% O 
after O 
storage O 
for O 
168h O 
, O 
which O 
indicated O 
that O 
supersaturated O 
curcumin B-TRIVIAL 
solutions O 
were O 
initially O 
formed O 
upon O 
dissolution O 
of O 
the O 
lyophilizates O 
. O 
Both O 
freshly O 
prepared O 
and O 
2days O 
old O 
solutions O 
of O 
one O 
selected O 
curcumin B-TRIVIAL 
lyophilizate O 
induced O 
significant O 
inactivation O 
of O 
E O 
. O 
coli O 
( O 
∼1% O 
bacterial O 
survival O 
) O 
after O 
exposure O 
to O 
a O 
light O 
dose O 
of O 
only O 
5J O 
/ O 
cm(2) O 
. O 

-containing O 
bisphosphonates B-FAMILY 
induce O 
apoptosis O 
of O 
hematopoietic O 
tumor O 
cells O 
via O 
inhibition O 
of O 
Ras O 
signaling O 
pathways O 
and O 
Bim O 
- O 
mediated O 
activation O 
of O 
the O 
intrinsic O 
apoptotic O 
pathway O 
. O 

-containing O 
bisphosphonates B-FAMILY 
( O 
N B-FORMULA 
- O 
BPs B-ABBREVIATION 
) O 
induce O 
apoptosis O 
in O 
tumor O 
cells O 
by O 
inhibiting O 
the O 
prenylation O 
of O 
small O 
G O 
- O 
proteins O 
. O 
However O 
, O 
the O 
details O 
of O 
the O 
apoptosis O 
- O 
inducing O 
mechanism O 
remain O 
obscure O 
. O 
The O 
present O 
study O 
showed O 
that O 
the O 
induction O 
of O 
apoptosis O 
by O 
N B-FORMULA 
- O 
BPs B-ABBREVIATION 
in O 
hematopoietic O 
tumor O 
cells O 
is O 
mediated O 
by O 
mitochondrial O 
apoptotic O 
signaling O 
pathways O 
, O 
which O 
are O 
activated O 
by O 
the O 
suppression O 
of O 
geranylgeranyl B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
( O 
GGPP B-ABBREVIATION 
) O 
biosynthesis O 
. O 
Furthermore O 
, O 
N B-FORMULA 
- O 
BPs B-ABBREVIATION 
decreased O 
the O 
levels O 
of O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
and O 
mTOR O 
via O 
suppression O 
of O 
Ras O 
prenylation O 
and O 
enhanced O 
Bim O 
expression O 
. O 
The O 
present O 
results O 
indicated O 
that O 
N B-FORMULA 
- O 
BPs B-ABBREVIATION 
induce O 
apoptosis O 
by O 
decreasing O 
the O 
mitochondrial O 
transmembrane O 
potential O 
, O 
increasing O 
the O 
activation O 
of O 
caspase-9 O 
and O 
caspase-3 O 
, O 
and O 
enhancing O 
Bim O 
expression O 
through O 
inhibition O 
of O 
the O 
Ras O 
/ O 
MEK O 
/ O 
ERK O 
and O 
Ras O 
/ O 
mTOR O 
pathways O 
. O 
The O 
accumulation O 
of O 
N B-FORMULA 
- O 
BPs B-ABBREVIATION 
in O 
bones O 
suggests O 
that O 
they O 
may O 
act O 
more O 
effectively O 
on O 
tumors O 
that O 
have O 
spread O 
to O 
bones O 
or O 
on O 
Ras-variable O 
tumors O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
show O 
that O 
the O 
specific O 
molecular O 
pathways O 
of O 
N B-FORMULA 
-BP-induced O 
apoptosis O 
. O 

hydrocarbon I-FAMILY 
receptor O 
- O 
mediated O 
disruption O 
of O 
contact O 
inhibition O 
is O 
associated O 
with O 
connexin43 O 
downregulation O 
and O 
inhibition O 
of O 
gap O 
junctional O 
intercellular O 
communication O 
. O 

aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
contributes O 
to O 
the O 
control O 
of O 
cell O 
- O 
to O 
- O 
cell O 
communication O 
, O 
cell O 
adhesion O 
, O 
migration O 
or O 
proliferation O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
regulation O 
of O 
connexin43 O 
( O 
Cx43 O 
) O 
and O 
Cx43 O 
- O 
mediated O 
gap O 
junctional O 
intercellular O 
communication O 
( O 
GJIC O 
) O 
during O 
the O 
AhR-dependent O 
disruption O 
of O 
contact O 
inhibition O 
in O 
non-tumorigenic O 
liver O 
epithelial O 
cells O 
. O 
The O 
contact O 
inhibition O 
of O 
cell O 
proliferation O 
is O 
a O 
process O 
restricting O 
the O 
cell O 
division O 
of O 
confluent O 
non-transformed O 
cells O 
, O 
which O 
is O 
frequently O 
abolished O 
in O 
cancer O 
cells O 
; O 
however O 
, O 
the O 
mechanisms O 
contributing O 
to O 
its O 
disruption O 
are O 
still O 
only O 
partially O 
understood O 
. O 
Disruption O 
of O 
contact O 
inhibition O 
, O 
which O 
was O 
induced O 
by O 
toxic O 
AhR O 
ligands O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
or O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
in O 
epithelial O 
WB-F344 O 
cells O 
, O 
reduced O 
Cx43 O 
protein O 
levels O 
, O 
possibly O 
via O 
enhanced O 
proteasomal O 
degradation O 
, O 
significantly O 
decreased O 
the O 
amount O 
of O 
gap O 
junction O 
plaques O 
and O 
downregulated O 
GJIC O 
, O 
in O 
an O 
AhR-dependent O 
manner O 
. O 
Although O 
both O 
intracellular O 
and O 
membrane O 
Cx43 O 
pools O 
were O 
markedly O 
reduced O 
in O 
cells O 
released O 
from O 
contact O 
inhibition O 
by O 
TCDD B-ABBREVIATION 
, O 
siRNA O 
- O 
mediated O 
Cx43 O 
knock O 
- O 
down O 
was O 
not O 
sufficient O 
to O 
stimulate O 
proliferation O 
in O 
contact O 
- O 
inhibited O 
cells O 
. O 
Our O 
data O 
suggest O 
that O 
downregulation O 
of O 
Cx43 O 
/ O 
GJIC O 
in O 
non-transformed O 
epithelial O 
cells O 
is O 
an O 
inherent O 
part O 
of O 
disruption O 
of O 
contact O 
inhibition O 
, O 
which O 
occurs O 
at O 
the O 
post O 
- O 
transcriptional O 
level O 
. O 
This O 
process O 
runs O 
in O 
parallel O 
with O 
alterations O 
of O 
other O 
forms O 
of O 
cell O 
- O 
to O 
- O 
cell O 
communication O 
, O 
thus O 
suggesting O 
that O 
toxic O 
AhR O 
agonists O 
may O 
simultaneously O 
abrogate O 
contact O 
inhibition O 
and O 
reduce O 
GJIC O 
, O 
two O 
essential O 
mechanisms O 
linked O 
to O 
deregulation O 
of O 
cell O 
- O 
to O 
- O 
cell O 
communication O 
during O 
tumor O 
promotion O 
and O 
progression O 
. O 

improves O 
glucose B-TRIVIAL 
homeostasis O 
in O 
skeletal O 
muscle O 
in O 
an O 
activity O 
- O 
dependent O 
manner O 
. O 

disorders O 
are O 
a O 
major O 
burden O 
for O 
public O 
health O 
systems O 
globally O 
. O 
Regular O 
exercise O 
improves O 
metabolic O 
health O 
. O 
Pharmacological O 
targeting O 
of O 
exercise O 
mediators O 
might O 
facilitate O 
physical O 
activity O 
or O 
amplify O 
the O 
effects O 
of O 
exercise O 
. O 
The O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
coactivator O 
1α O 
( O 
PGC-1α O 
) O 
largely O 
mediates O 
musculoskeletal O 
adaptations O 
to O 
exercise O 
, O 
including O 
lipid O 
refueling O 
, O 
and O 
thus O 
constitutes O 
such O 
a O 
putative O 
target O 
. O 
Paradoxically O 
, O 
forced O 
expression O 
of O 
PGC-1α O 
in O 
muscle O 
promotes O 
diet O 
- O 
induced O 
insulin O 
resistance O 
in O 
sedentary O 
animals O 
. O 
We O 
show O 
that O 
elevated O 
PGC-1α O 
in O 
combination O 
with O 
exercise O 
preferentially O 
improves O 
glucose B-TRIVIAL 
homeostasis O 
, O 
increases O 
Krebs O 
cycle O 
activity O 
, O 
and O 
reduces O 
the O 
levels O 
of O 
acylcarnitines B-FAMILY 
and O 
sphingosine B-TRIVIAL 
. O 
Moreover O 
, O 
patterns O 
of O 
lipid O 
partitioning O 
are O 
altered O 
in O 
favor O 
of O 
enhanced O 
insulin O 
sensitivity O 
in O 
response O 
to O 
combined O 
PGC-1α O 
and O 
exercise O 
. O 
Our O 
findings O 
reveal O 
how O 
physical O 
activity O 
improves O 
glucose O 
homeostasis O 
. O 
Furthermore O 
, O 
our O 
data O 
suggest O 
that O 
the O 
combination O 
of O 
elevated O 
muscle O 
PGC-1α O 
and O 
exercise O 
constitutes O 
a O 
promising O 
approach O 
for O 
the O 
treatment O 
of O 
metabolic O 
disorders O 
. O 

3-kinase O 
( O 
PI3K O 
) O 
mediates O 
insulin O 
actions O 
by O 
relaying O 
signals O 
from O 
insulin O 
receptors O 
( O 
IRs O 
) O 
to O 
downstream O 
targets O 
. O 
The O 
p110α O 
catalytic O 
subunit O 
of O 
class O 
IA O 
PI3K O 
is O 
the O 
primary O 
insulin O 
- O 
responsive O 
PI3K O 
implicated O 
in O 
insulin O 
signaling O 
. O 
We O 
demonstrate O 
here O 
a O 
new O 
mode O 
of O 
spatial O 
regulation O 
for O 
the O 
p110α O 
subunit O 
of O 
PI3K O 
by O 
PAQR3 O 
that O 
is O 
exclusively O 
localized O 
in O 
the O 
Golgi O 
apparatus O 
. O 
PAQR3 O 
interacts O 
with O 
p110α O 
, O 
and O 
the O 
intracellular O 
targeting O 
of O 
p110α O 
to O 
the O 
Golgi O 
apparatus O 
is O 
reduced O 
by O 
PAQR3 O 
downregulation O 
and O 
increased O 
by O 
PAQR3 O 
overexpression O 
. O 
Insulin O 
- O 
stimulated O 
PI3K O 
activity O 
and O 
phosphoinositide B-SYSTEMATIC 
(3,4,5)-triphosphate I-SYSTEMATIC 
production O 
are O 
enhanced O 
by O 
Paqr3 O 
deletion O 
and O 
reduced O 
by O 
PAQR3 O 
overexpression O 
in O 
hepatocytes O 
. O 
Deletion O 
of O 
Paqr3 O 
enhances O 
insulin O 
- O 
stimulated O 
phosphorylation O 
of O 
AKT O 
and O 
glycogen O 
synthase O 
kinase O 
3β O 
, O 
but O 
not O 
phosphorylation O 
of O 
IR O 
and O 
IR O 
substrate-1 O 
( O 
IRS-1 O 
) O 
, O 
in O 
hepatocytes O 
, O 
mouse O 
liver O 
, O 
and O 
skeletal O 
muscle O 
. O 
Insulin O 
- O 
stimulated O 
GLUT4 O 
translocation O 
to O 
the O 
plasma O 
membrane O 
and O 
glucose B-TRIVIAL 
uptake O 
are O 
enhanced O 
by O 
Paqr3 O 
ablation O 
. O 
Furthermore O 
, O 
PAQR3 O 
interacts O 
with O 
the O 
domain O 
of O 
p110α O 
involved O 
in O 
its O 
binding O 
with O 
p85 O 
, O 
the O 
regulatory O 
subunit O 
of O 
PI3K O 
. O 
Overexpression O 
of O 
PAQR3 O 
dose O 
- O 
dependently O 
reduces O 
the O 
interaction O 
of O 
p85α O 
with O 
p110α O 
. O 
Thus O 
, O 
PAQR3 O 
negatively O 
regulates O 
insulin O 
signaling O 
by O 
shunting O 
cytosolic O 
p110α O 
to O 
the O 
Golgi O 
apparatus O 
while O 
competing O 
with O 
p85 O 
subunit O 
in O 
forming O 
a O 
PI3K O 
complex O 
with O 
p110α O 
. O 

-cytochrome O 
P450 O 
oxidoreductase O 
: O 
roles O 
in O 
physiology O 
, O 
pharmacology O 
, O 
and O 
toxicology O 
. O 

is O 
a O 
report O 
on O 
a O 
symposium O 
sponsored O 
by O 
the O 
American O 
Society O 
for O 
Pharmacology O 
and O 
Experimental O 
Therapeutics O 
and O 
held O 
at O 
the O 
Experimental O 
Biology O 
2012 O 
meeting O 
in O 
San O 
Diego O 
, O 
California O 
, O 
on O 
April O 
25 O 
, O 
2012 O 
. O 
The O 
symposium O 
speakers O 
summarized O 
and O 
critically O 
evaluated O 
our O 
current O 
understanding O 
of O 
the O 
physiologic O 
, O 
pharmacological O 
, O 
and O 
toxicological O 
roles O 
of O 
NADPH B-ABBREVIATION 
-cytochrome O 
P450 O 
oxidoreductase O 
( O 
POR O 
) O 
, O 
a O 
flavoprotein O 
involved O 
in O 
electron O 
transfer O 
to O 
microsomal O 
cytochromes O 
P450 O 
( O 
P450 O 
) O 
, O 
cytochrome O 
b(5) O 
, O 
squalene B-TRIVIAL 
mono-oxygenase O 
, O 
and O 
heme B-FAMILY 
oxygenase O 
. O 
Considerable O 
insight O 
has O 
been O 
derived O 
from O 
the O 
development O 
and O 
characterization O 
of O 
mouse O 
models O 
with O 
conditional O 
Por O 
deletion O 
in O 
particular O 
tissues O 
or O 
partial O 
suppression O 
of O 
POR O 
expression O 
in O 
all O 
tissues O 
. O 
Additional O 
mouse O 
models O 
with O 
global O 
or O 
conditional O 
hepatic O 
deletion O 
of O 
cytochrome O 
b(5) O 
are O 
helping O 
to O 
clarify O 
the O 
P450 O 
isoform- O 
and O 
substrate O 
- O 
specific O 
influences O 
of O 
cytochrome O 
b(5) O 
on O 
P450 O 
electron O 
transfer O 
and O 
catalytic O 
function O 
. O 
This O 
symposium O 
also O 
considered O 
studies O 
using O 
siRNA O 
to O 
suppress O 
POR O 
expression O 
in O 
a O 
hepatoma O 
cell O 
- O 
culture O 
model O 
to O 
explore O 
the O 
basis O 
of O 
the O 
hepatic O 
lipidosis O 
phenotype O 
observed O 
in O 
mice O 
with O 
conditional O 
deletion O 
of O 
Por O 
in O 
liver O 
. O 
The O 
symposium O 
concluded O 
with O 
a O 
strong O 
translational O 
perspective O 
, O 
relating O 
the O 
basic O 
science O 
of O 
human O 
POR O 
structure O 
and O 
function O 
to O 
the O 
impacts O 
of O 
POR O 
genetic O 
variation O 
on O 
human O 
drug O 
and O 
steroid B-FAMILY 
metabolism O 
. O 

of O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
2A2 O 
and O 
2A3 O 
in O 
tobacco O 
carcinogen O 
metabolism O 
. O 

-glucuronosyltransferase O 
A1 O 
( O 
UGT2A1 O 
) O 
is O 
expressed O 
in O 
the O 
lung O 
and O 
exhibits O 
activity O 
against O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
, O 
suggesting O 
UGT2A1 O 
involvement O 
in O 
the O 
local O 
metabolism O 
of O 
PAH B-ABBREVIATION 
tobacco O 
carcinogens O 
. O 
The O 
goal O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
importance O 
of O 
two O 
additional O 
UGT2A O 
enzymes O 
, O 
UGT2A2 O 
and O 
UGT2A3 O 
, O 
in O 
tobacco O 
carcinogen O 
metabolism O 
. O 
Real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
suggested O 
that O 
wild O 
- O 
type O 
UGT2A2 O 
had O 
the O 
highest O 
expression O 
in O 
the O 
breast O 
, O 
followed O 
by O 
trachea O 
> O 
larynx O 
> O 
kidney O 
. O 
A O 
novel O 
splice O 
variant O 
of O 
UGT2A2 O 
lacking O 
exon O 
3 O 
( O 
termed O 
UGT2A2Δexon3 O 
) O 
was O 
investigated O 
, O 
with O 
UGT2A2Δexon3 O 
expression O 
determined O 
to O 
be O 
25-50% O 
that O 
of O 
wild O 
- O 
type O 
UGT2A2 O 
in O 
all O 
tissues O 
examined O 
. O 
UGT2A3 O 
was O 
determined O 
to O 
be O 
well O 
expressed O 
in O 
the O 
liver O 
and O 
colon O 
, O 
followed O 
by O 
pancreas O 
> O 
kidney O 
> O 
lung O 
> O 
tonsil O 
> O 
trachea O 
> O 
larynx O 
. O 
Cell O 
homogenates O 
prepared O 
from O 
human O 
embryonic O 
kidney O 
(HEK)293 O 
cells O 
overexpressing O 
wild O 
- O 
type O 
UGT2A2 O 
( O 
termed O 
UGT2A2_i1 O 
) O 
exhibited O 
glucuronidation O 
activity O 
, O 
as O 
observed O 
by O 
reverse O 
- O 
phase O 
ultra O 
- O 
pressure O 
liquid O 
chromatography O 
, O 
against O 
1-hydroxy-(OH)-pyrene B-SYSTEMATIC 
, O 
1-naphthol B-SYSTEMATIC 
, O 
and O 
hydroxylated B-FAMILY 
benzo(a)pyrene I-FAMILY 
metabolites O 
, O 
whereas O 
homogenates O 
prepared O 
from O 
HEK293 O 
cells O 
overexpressing O 
UGT2A3 O 
only O 
showed O 
activity O 
against O 
simple O 
PAHs B-ABBREVIATION 
like O 
1-OH-pyrene B-SYSTEMATIC 
and O 
1-naphthol B-SYSTEMATIC 
. O 
Activity O 
assays O 
showed O 
the O 
UGT2A2Δexon3 O 
protein O 
( O 
termed O 
UGT2A2_i2 O 
) O 
exhibited O 
no O 
detectable O 
glucuronidation O 
activity O 
against O 
all O 
substrates O 
examined O 
; O 
however O 
, O 
coexpression O 
studies O 
suggested O 
that O 
UGT2A2_i2 O 
negatively O 
modulates O 
UGT2A2_i1 O 
activity O 
. O 
Both O 
UGT2A2 O 
and O 
UGT2A3 O 
exhibited O 
no O 
detectable O 
activity O 
against O 
complex O 
PAH B-ABBREVIATION 
proximate O 
carcinogens O 
, O 
tobacco O 
- O 
specific O 
nitrosamines B-FAMILY 
, O 
or O 
heterocyclic B-FAMILY 
amines I-FAMILY 
. O 
These O 
data O 
suggest O 
that O 
, O 
although O 
UGT2A1 O 
is O 
the O 
only O 
UGT2A O 
enzyme O 
active O 
against O 
PAH B-ABBREVIATION 
proximate O 
carcinogens O 
( O 
including O 
PAH B-ABBREVIATION 
diols B-FAMILY 
) O 
, O 
both O 
UGTs O 
2A1 O 
and O 
2A2 O 
play O 
an O 
important O 
role O 
in O 
the O 
local O 
detoxification O 
of O 
procarcinogenic O 
monohydroxylated B-FAMILY 
PAH I-FAMILY 
metabolites O 
. O 

- O 
molecular O 
- O 
weight O 
CXCR4 O 
ligands O 
based O 
on O 
known O 
lead O 
compounds O 
including O 
the O 
14-mer O 
peptide O 
T140 O 
, O 
the O 
cyclic B-FAMILY 
pentapeptide I-FAMILY 
FC131 B-IDENTIFIER 
, O 
peptide O 
mimetics O 
, O 
and O 
dipicolylamine B-FAMILY 
-containing O 
compounds O 
were O 
designed O 
and O 
synthesized O 
. O 
Three O 
types O 
of O 
aromatic O 
spacers O 
, O 
1,4-phenylenedimethanamine B-SYSTEMATIC 
, O 
naphthalene-2,6-diyldimethanamine B-SYSTEMATIC 
, O 
and O 
[1,1'-biphenyl]-4,4'-diyldimethanamine B-SYSTEMATIC 
, O 
were O 
used O 
to O 
build O 
four O 
pharmacophore O 
groups O 
. O 
As O 
pharmacophore O 
groups O 
, O 
2-pyridylmethyl B-SYSTEMATIC 
and O 
1-naphthylmethyl B-SYSTEMATIC 
are O 
present O 
in O 
all O 
of O 
the O 
compounds O 
, O 
and O 
several O 
aromatic O 
groups O 
and O 
a O 
cationic O 
group O 
from O 
1-propylguanidine B-SYSTEMATIC 
and O 
1,1,3,3-tetramethyl-2-propylguanidine B-SYSTEMATIC 
were O 
also O 
used O 
. O 
Several O 
compounds O 
showed O 
significant O 
CXCR4 O 
binding O 
affinity O 
, O 
and O 
zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexation O 
of O 
bis(pyridin-2-ylmethyl)amine B-SYSTEMATIC 
moieties O 
resulted O 
in O 
a O 
remarkable O 
increase O 
in O 
CXCR4 O 
binding O 
affinity O 
. O 

48- O 
linked O 
polyubiquitination O 
of O 
organic O 
anion O 
transporter-1 O 
is O 
essential O 
for O 
its O 
protein O 
kinase O 
C-regulated O 
endocytosis O 
. O 

anion O 
transporter-1 O 
( O 
OAT1 O 
) O 
mediates O 
the O 
body's O 
disposition O 
of O 
a O 
diverse O 
array O 
of O 
environmental O 
toxins O 
and O 
clinically O 
important O 
drugs O 
. O 
Therefore O 
, O 
understanding O 
the O 
regulation O 
of O 
this O 
transporter O 
has O 
profound O 
clinical O 
significance O 
. O 
We O 
had O 
previously O 
established O 
that O 
OAT1 O 
undergoes O 
constitutive O 
internalization O 
from O 
and O 
recycling O 
back O 
to O 
the O 
cell O 
surface O 
and O 
that O 
acute O 
activation O 
of O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
inhibits O 
OAT1 O 
activity O 
by O 
reducing O 
OAT1 O 
cell O 
- O 
surface O 
expression O 
through O 
accelerating O 
its O 
internalization O 
from O 
cell O 
surface O 
to O 
intracellular O 
compartments O 
. O 
However O 
, O 
the O 
underlying O 
mechanisms O 
are O 
poorly O 
understood O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
provide O 
novel O 
evidence O 
that O 
acute O 
activation O 
of O 
PKC O 
significantly O 
enhances O 
OAT1 O 
ubiquitination O 
both O 
in O 
vitro O 
and O 
ex O 
vivo O 
. O 
We O 
further O 
show O 
that O 
ubiquitination O 
of O 
cell O 
- O 
surface O 
OAT1 O 
increases O 
in O 
cells O 
transfected O 
with O 
dominant O 
negative O 
mutant O 
of O 
dynamin-2 O 
, O 
a O 
maneuver O 
blocking O 
OAT1 O 
internalization O 
, O 
which O 
suggests O 
that O 
OAT1 O 
ubiquitination O 
proceeds O 
before O 
OAT1 O 
internalization O 
. O 
Mass O 
spectroscopy O 
has O 
revealed O 
that O 
ubiquitination O 
of O 
OAT1 O 
consists O 
of O 
polyubiquitin O 
chains O 
, O 
primarily O 
through O 
lysine B-TRIVIAL 
48 O 
linkage O 
. O 
Transfection O 
of O 
cells O 
with O 
the O 
dominant O 
negative O 
mutant O 
of O 
ubiquitin O 
Ub-K48R O 
, O 
which O 
prevents O 
the O 
formation O 
of O 
Lys B-FORMULA 
48- O 
linked O 
polyubiquitin O 
chains O 
, O 
abolishes O 
PKC-stimulated O 
OAT1 O 
ubiquitination O 
and O 
internalization O 
. O 
Together O 
, O 
our O 
findings O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
Lys B-FORMULA 
48- O 
linked O 
polyubiquitination O 
is O 
essential O 
for O 
PKC-regulated O 
OAT1 O 
trafficking O 
. O 

binding O 
cassette O 
transporters O 
in O 
two O 
distinct O 
compartments O 
of O 
the O 
skin O 
contribute O 
to O 
transdermal O 
absorption O 
of O 
a O 
typical O 
substrate O 
. O 

role O 
of O 
two O 
ATP B-ABBREVIATION 
binding O 
cassette O 
transporters O 
, O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
, O 
in O 
transdermal O 
absorption O 
of O 
a O 
typical O 
common O 
substrate O 
was O 
examined O 
in O 
vivo O 
. O 
Skin O 
and O 
plasma O 
concentrations O 
of O 
rhodamine123 B-TRIVIAL 
( O 
Rho123 B-ABBREVIATION 
) O 
after O 
dermal O 
application O 
were O 
reduced O 
in O 
P-gp O 
knockout O 
( O 
mdr1a O 
/ O 
1b⁻ O 
/ O 
⁻ O 
) O 
mice O 
and O 
were O 
below O 
the O 
detection O 
limit O 
in O 
P-gp O 
and O 
BCRP O 
triple O 
- O 
knockout O 
( O 
mdr1a O 
/ O 
1b O 
/ O 
bcrp⁻ O 
/ O 
⁻ O 
) O 
mice O 
. O 
Lower O 
epidermal O 
- O 
to O 
- O 
hypodermal O 
permeation O 
of O 
Rho123 O 
in O 
mdr1a O 
/ O 
1b O 
/ O 
bcrp⁻ O 
/ O 
⁻ O 
mouse O 
skin O 
compared O 
to O 
the O 
wild O 
- O 
type O 
mouse O 
skin O 
was O 
confirmed O 
in O 
an O 
Ussing O 
- O 
type O 
chamber O 
experiment O 
. O 
The O 
reduction O 
in O 
skin O 
concentration O 
after O 
dermal O 
application O 
in O 
mdr1a O 
/ O 
1b O 
/ O 
bcrp⁻ O 
/ O 
⁻ O 
mice O 
was O 
greater O 
in O 
the O 
dermis O 
than O 
in O 
the O 
epidermis O 
, O 
suggesting O 
functional O 
expressions O 
of O 
these O 
transporters O 
in O 
two O 
distinct O 
skin O 
compartments O 
. O 
Coadministration O 
of O 
the O 
inhibitor O 
itraconazole B-TRIVIAL 
reduced O 
the O 
skin O 
and O 
plasma O 
concentrations O 
of O 
Rho123 B-ABBREVIATION 
in O 
the O 
wild O 
- O 
type O 
mice O 
, O 
but O 
not O 
in O 
mdr1a O 
/ O 
1b O 
/ O 
bcrp⁻ O 
/ O 
⁻ O 
mice O 
, O 
and O 
a O 
marked O 
decrease O 
of O 
Rho123 B-ABBREVIATION 
concentration O 
was O 
seen O 
in O 
the O 
dermis O 
, O 
demonstrating O 
that O 
the O 
functional O 
activities O 
of O 
these O 
transporters O 
can O 
be O 
modulated O 
in O 
vivo O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
distribution O 
of O 
Rho123 B-ABBREVIATION 
after O 
intravenous O 
infusion O 
was O 
higher O 
in O 
mdr1a O 
/ O 
1b O 
/ O 
bcrp⁻ O 
/ O 
⁻ O 
mice O 
than O 
in O 
the O 
wild O 
- O 
type O 
mice O 
. O 
This O 
supports O 
the O 
occurrence O 
of O 
vectorial O 
transport O 
from O 
the O 
skin O 
into O 
systemic O 
circulation O 
, O 
and O 
is O 
consistent O 
with O 
the O 
immunohistochemical O 
localization O 
of O 
P-gp O 
and O 
BCRP O 
in O 
mouse O 
dermal O 
endothelial O 
cells O 
. O 
BCRP O 
was O 
immunohistochemically O 
identified O 
in O 
human O 
epidermis O 
and O 
dermal O 
endothelial O 
cells O 
. O 
Thus O 
, O 
our O 
findings O 
show O 
that O 
ABC O 
transporters O 
in O 
different O 
compartments O 
of O 
the O 
skin O 
contribute O 
to O 
transdermal O 
absorption O 
of O 
a O 
typical O 
substrate O 
in O 
vivo O 
and O 
can O 
be O 
modulated O 
by O 
a O 
specific O 
inhibitor O 
. O 
These O 
findings O 
have O 
implications O 
for O 
transdermal O 
drug O 
delivery O 
. O 

molecular O 
events O 
during O 
nongenotoxic O 
carcinogenesis O 
and O 
their O 
temporal O 
order O 
are O 
poorly O 
understood O 
but O 
thought O 
to O 
include O 
long O 
- O 
lasting O 
perturbations O 
of O 
gene O 
expression O 
. O 
Here O 
, O 
we O 
have O 
investigated O 
the O 
temporal O 
sequence O 
of O 
molecular O 
and O 
pathological O 
perturbations O 
at O 
early O 
stages O 
of O 
phenobarbital B-TRIVIAL 
( O 
PB O 
) O 
mediated O 
liver O 
tumor O 
promotion O 
in O 
vivo O 
. O 
Molecular O 
profiling O 
( O 
mRNA O 
, O 
microRNA O 
[ O 
miRNA O 
] O 
, O 
DNA O 
methylation O 
, O 
and O 
proteins O 
) O 
of O 
mouse O 
liver O 
during O 
13 O 
weeks O 
of O 
PB O 
treatment O 
revealed O 
progressive O 
increases O 
in O 
hepatic O 
expression O 
of O 
long O 
noncoding O 
RNAs O 
and O 
miRNAs O 
originating O 
from O 
the O 
Dlk1-Dio3 O 
imprinted O 
gene O 
cluster O 
, O 
a O 
locus O 
that O 
has O 
recently O 
been O 
associated O 
with O 
stem O 
cell O 
pluripotency O 
in O 
mice O 
and O 
various O 
neoplasms O 
in O 
humans O 
. O 
PB O 
induction O 
of O 
the O 
Dlk1-Dio3 O 
cluster O 
noncoding O 
RNA O 
( O 
ncRNA O 
) O 
Meg3 O 
was O 
localized O 
to O 
glutamine B-TRIVIAL 
synthetase O 
- O 
positive O 
hypertrophic O 
perivenous O 
hepatocytes O 
, O 
suggesting O 
a O 
role O 
for O 
β-catenin O 
signaling O 
in O 
the O 
dysregulation O 
of O 
Dlk1-Dio3 O 
ncRNAs O 
. O 
The O 
carcinogenic O 
relevance O 
of O 
Dlk1-Dio3 O 
locus O 
ncRNA O 
induction O 
was O 
further O 
supported O 
by O 
in O 
vivo O 
genetic O 
dependence O 
on O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
and O 
β-catenin O 
pathways O 
. O 
Our O 
data O 
identify O 
Dlk1-Dio3 O 
ncRNAs O 
as O 
novel O 
candidate O 
early O 
biomarkers O 
for O 
mouse O 
liver O 
tumor O 
promotion O 
and O 
provide O 
new O 
opportunities O 
for O 
assessing O 
the O 
carcinogenic O 
potential O 
of O 
novel O 
compounds O 
. O 

mechanism O 
involved O 
in O 
the O 
prolonged O 
high O 
retention O 
of O 
laninamivir B-TRIVIAL 
in O 
mouse O 
respiratory O 
tissues O 
after O 
intranasal O 
administration O 
of O 
its O 
prodrug O 
laninamivir B-SYSTEMATIC 
octanoate I-SYSTEMATIC 
. O 

octanoate I-SYSTEMATIC 
( O 
LO O 
) O 
( O 
Inavir B-TRIVIAL 
; O 
Daiichi O 
Sankyo O 
, O 
Japan O 
) O 
is O 
an O 
ester B-FAMILY 
prodrug O 
of O 
the O 
neuraminidase O 
inhibitor O 
laninamivir B-TRIVIAL 
. O 
We O 
previously O 
reported O 
that O 
a O 
prolonged O 
high O 
retention O 
of O 
laninamivir B-TRIVIAL 
in O 
mouse O 
respiratory O 
tissues O 
was O 
achieved O 
by O 
intranasal O 
administration O 
of O 
LO O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
intrapulmonary O 
pharmacokinetics O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
to O 
investigate O 
the O 
potential O 
mechanism O 
involved O 
in O 
such O 
a O 
preferable O 
retention O 
. O 
After O 
intranasal O 
administration O 
of O 
LO O 
to O 
mice O 
( O 
0.5 O 
μmol O 
/ O 
kg O 
) O 
, O 
the O 
drug O 
was O 
distributed O 
from O 
the O 
airway O 
space O 
into O 
the O 
lungs O 
, O 
and O 
laninamivir B-TRIVIAL 
remained O 
in O 
the O 
lung O 
at O 
24 O 
hours O 
postdose O 
( O 
2680 O 
pmol O 
/ O 
g O 
) O 
, O 
with O 
a O 
higher O 
concentration O 
than O 
that O 
in O 
the O 
epithelial O 
lining O 
fluid O 
. O 
The O 
laninamivir B-TRIVIAL 
was O 
localized O 
mainly O 
on O 
the O 
epithelial O 
cells O 
of O 
airway O 
tracts O 
, O 
determined O 
by O 
microautoradiography O 
using O 
(14)C B-FORMULA 
-labeled O 
LO O 
. O 
In O 
mouse O 
airway O 
epithelial O 
cells O 
, O 
the O 
cellular O 
uptake O 
and O 
hydrolysis O 
of O 
LO O 
were O 
observed O 
over O 
incubation O 
time O 
without O 
any O 
apparent O 
saturation O 
at O 
the O 
highest O 
concentration O 
tested O 
( O 
1000 O 
μM O 
) O 
. O 
Furthermore O 
, O 
after O 
additional O 
incubation O 
in O 
drug O 
- O 
free O 
medium O 
, O 
the O 
intracellular O 
laninamivir B-TRIVIAL 
was O 
released O 
very O 
slowly O 
into O 
the O 
medium O 
with O 
an O 
estimate O 
rate O 
constant O 
of O 
0.0707 O 
h(-1) O 
, O 
which O 
was O 
regarded O 
as O 
a O 
rate O 
- O 
limiting O 
step O 
in O 
the O 
cellular O 
retention O 
. O 
These O 
results O 
demonstrated O 
that O 
the O 
prolonged O 
high O 
retention O 
of O 
laninamivir B-TRIVIAL 
in O 
the O 
respiratory O 
tissues O 
was O 
attributed O 
to O 
a O 
consecutive O 
series O 
of O 
three O 
steps O 
: O 
uptake O 
of O 
LO O 
into O 
the O 
airway O 
epithelial O 
cells O 
, O 
hydrolysis O 
of O 
LO O 
into O 
laninamivir B-TRIVIAL 
by O 
intracellular O 
esterase(s) O 
, O 
and O 
limited O 
efflux O 
of O 
the O 
generated O 
laninamivir B-TRIVIAL 
due O 
to O 
its O 
poor O 
membrane O 
permeability O 
. O 
This O 
prodrug O 
approach O 
could O 
be O 
useful O 
for O 
lung O 
- O 
targeting O 
drug O 
delivery O 
. O 

disease O 
is O 
an O 
X O 
- O 
linked O 
, O 
multisystemic O 
lysosomal O 
storage O 
disorder O 
due O 
to O 
alpha-galactosidase O 
A O 
deficiency O 
. O 
It O 
is O 
characterized O 
by O 
the O 
accumulation O 
of O 
glycosphingolipids O 
, O 
mainly O 
globotriaosylceramide O 
(Gb(3)) O 
, O 
in O 
biological O 
fluids O 
, O 
vascular O 
endothelium O 
, O 
heart O 
, O 
and O 
kidneys O 
. O 
Treatment O 
by O 
enzyme O 
replacement O 
therapy O 
has O 
been O 
shown O 
to O 
be O 
beneficial O 
in O 
both O 
males O 
and O 
females O 
affected O 
with O 
the O 
disease O 
. O 
In O 
addition O 
to O 
Gb(3) O 
, O 
increased O 
concentrations O 
of O 
globotriaosylsphingosine O 
(lyso-Gb(3)) O 
have O 
recently O 
been O 
reported O 
in O 
urine O 
and O 
plasma O 
of O 
Fabry O 
patients O 
. O 
The O 
overall O 
objective O 
of O 
this O 
metabolomic O 
study O 
was O 
to O 
identify O 
and O 
characterize O 
new O 
potential O 
plasma O 
biomarkers O 
in O 
treated O 
and O 
untreated O 
males O 
and O 
females O 
affected O 
with O 
Fabry O 
disease O 
which O 
might O 
better O 
reflect O 
disease O 
severity O 
and O 
progression O 
. O 
We O 
employed O 
a O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
metabolomic O 
approach O 
using O 
plasma O 
samples O 
of O 
Fabry O 
patients O 
compared O 
to O 
age O 
- O 
matched O 
controls O 
. O 
We O 
found O 
three O 
new O 
lyso-Gb(3) O 
analogs O 
in O 
Fabry O 
patients O 
presenting O 
m O 
/ O 
z O 
ratios O 
at O 
802 O 
, O 
804 O 
, O 
and O 
820 O 
. O 
As O 
previously O 
detected O 
by O 
our O 
group O 
, O 
we O 
also O 
found O 
a O 
m O 
/ O 
z O 
ratio O 
of O 
784 O 
corresponding O 
to O 
the O 
lyso-Gb(3) O 
molecule O 
minus O 
two O 
hydrogen B-SYSTEMATIC 
atoms O 
. O 
Using O 
exact O 
mass O 
measurements O 
and O 
tandem O 
mass O 
spectrometry O 
, O 
we O 
confirmed O 
that O 
these O 
analogs O 
result O 
from O 
modifications O 
of O 
the O 
lyso-Gb(3) O 
sphingosine O 
moiety O 
. O 
We O 
evaluated O 
the O 
relative O 
plasma O 
concentration O 
by O 
measuring O 
area O 
counts O 
for O 
each O 
lyso-Gb(3) O 
analog O 
. O 
None O 
of O 
these O 
analogs O 
was O 
detected O 
in O 
the O 
majority O 
of O 
healthy O 
controls O 
. O 
The O 
relative O 
concentration O 
of O 
each O 
analog O 
was O 
higher O 
in O 
males O 
compared O 
to O 
female O 
Fabry O 
patients O 
. O 
We O 
demonstrated O 
that O 
mass O 
spectrometry O 
combined O 
to O 
a O 
metabolomic O 
approach O 
is O 
a O 
powerful O 
tool O 
to O 
detect O 
and O 
identify O 
new O 
potential O 
biomarkers O 
. O 

Microscopy O 
: O 
Spatially O 
Resolved O 
Carrier O 
Dynamics O 
in O 
ZnO B-FORMULA 
Rods O 
and O 
the O 
Influence O 
of O 
Optical O 
Cavity O 
Resonator O 
Modes O 
. O 

pump O 
- O 
probe O 
microscopy O 
is O 
used O 
to O 
investigate O 
the O 
charge O 
recombination O 
dynamics O 
at O 
different O 
points O 
within O 
a O 
single O 
needle O 
- O 
shaped O 
ZnO B-FORMULA 
rod O 
. O 
Recombination O 
in O 
the O 
tips O 
of O 
the O 
rod O 
occurs O 
through O 
an O 
excitonic O 
or O 
electron O 
- O 
hole O 
plasma O 
state O 
, O 
taking O 
place O 
on O 
a O 
picosecond O 
time O 
scale O 
. O 
Photoexcitation O 
in O 
the O 
larger O 
diameter O 
sections O 
of O 
the O 
interior O 
exhibit O 
dramatically O 
slower O 
recombination O 
that O 
occurs O 
primarily O 
through O 
defects O 
sites O 
, O 
i.e O 
. O 
, O 
trap O 
mediated O 
recombination O 
. O 
Transient O 
absorption O 
imaging O 
shows O 
that O 
the O 
spatial O 
variation O 
in O 
the O 
dynamics O 
is O 
also O 
influenced O 
by O 
the O 
cavity O 
resonances O 
supported O 
within O 
the O 
hexagonal O 
cross O 
section O 
of O 
the O 
rod O 
. O 
Finite O 
element O 
simulations O 
suggest O 
that O 
these O 
optical O 
resonator O 
modes O 
produce O 
qualitatively O 
different O 
intensity O 
patterns O 
in O 
the O 
two O 
different O 
locations O 
. O 
Near O 
the O 
end O 
of O 
the O 
rod O 
, O 
the O 
intensity O 
pattern O 
has O 
significant O 
standing O 
- O 
wave O 
character O 
, O 
which O 
leads O 
to O 
the O 
creation O 
of O 
photoexcited O 
carriers O 
in O 
the O 
core O 
of O 
the O 
structure O 
. O 
The O 
larger O 
diameter O 
regions O 
, O 
on O 
the O 
other O 
hand O 
, O 
exhibit O 
intensity O 
distributions O 
in O 
which O 
the O 
whispering O 
gallery O 
( O 
WG O 
) O 
mode O 
character O 
dominates O 
. O 
At O 
these O 
locations O 
, O 
the O 
photoexcited O 
carriers O 
are O 
produced O 
in O 
subsurface O 
depletion O 
zone O 
, O 
where O 
the O 
internal O 
fields O 
separate O 
the O 
electrons O 
and O 
holes O 
and O 
lead O 
to O 
a O 
greater O 
degree O 
of O 
trap O 
recombination O 
on O 
longer O 
time O 
scales O 
. O 

duckeana O 
is O 
popularly O 
known O 
as O 
timbó O 
and O 
used O 
by O 
indigenous O 
people O 
as O 
ictiotoxic O 
. O 
On O 
account O 
of O 
there O 
being O 
no O 
literature O 
pertaining O 
to O 
the O 
chemical O 
profile O 
or O 
biological O 
activity O 
of O 
this O 
plant O 
, O 
the O 
hexane B-SYSTEMATIC 
, O 
methanol B-SYSTEMATIC 
and O 
aqueous O 
crude O 
extracts O 
from O 
leaves O 
, O 
stems O 
and O 
roots O 
were O 
assayed O 
that O 
presented O 
very O 
high O 
cytotoxic O 
potential O 
against O 
Artemia O 
salina O 
, O 
achieving O 
100% O 
mortality O 
in O 
up O 
to O 
5 O 
µg O 
mL(-1) O 
concentration O 
, O 
but O 
lower O 
antioxidant O 
potential O 
on O 
2,2-diphenyl-1-picryl-hydrazyl B-SYSTEMATIC 
and O 
Fe(3+) B-FORMULA 
/ O 
Phenanthroline B-TRIVIAL 
assays O 
. O 
The O 
phytochemical O 
analysis O 
of O 
crude O 
extracts O 
showed O 
the O 
presence O 
of O 
flavonoids B-FAMILY 
and O 
related O 
compounds O 
as O 
major O 
constituents O 
as O 
well O 
as O 
steroids B-FAMILY 
in O 
all O 
of O 
them O 
, O 
and O 
tannins B-FAMILY 
in O 
polar O 
extracts O 
. O 
All O 
the O 
extracts O 
were O 
assayed O 
for O 
antibacterial O 
activity O 
but O 
only O 
the O 
hexane B-SYSTEMATIC 
extract O 
of O 
stems O 
showed O 
moderate O 
activity O 
on O 
Staphylococcus O 
aureus O 
, O 
which O 
was O 
fractionated O 
and O 
yielded O 
a O 
mixture O 
of O 
3,5,4'-trimethoxy-4-prenylstilbene B-SYSTEMATIC 
, O 
lonchocarpine B-TRIVIAL 
, O 
4-hydroxylonchocarpine B-SYSTEMATIC 
and O 
derricidine B-TRIVIAL 
, O 
reported O 
for O 
the O 
first O 
time O 
in O 
D O 
. O 
duckeana O 
and O 
other O 
fraction O 
with O 
β-sitosterol B-TRIVIAL 
and O 
stigmasterol B-TRIVIAL 
mixture O 
. O 

of O 
four O 
plant O 
portions O 
( O 
roots O 
, O 
stems O 
, O 
leaves O 
and O 
flowers O 
) O 
of O 
Urtica O 
dioica O 
( O 
the O 
stinging O 
nettle O 
) O 
were O 
prepared O 
using O 
accelerated O 
solvent O 
extraction O 
( O 
ASE O 
) O 
involving O 
water O 
, O 
hexanes B-FAMILY 
, O 
methanol B-SYSTEMATIC 
and O 
dichloromethane B-SYSTEMATIC 
. O 
The O 
extracts O 
were O 
evaluated O 
for O 
their O 
anti-inflammatory O 
and O 
cytotoxic O 
activities O 
in O 
an O 
NF-κB O 
luciferase O 
and O 
MTT B-ABBREVIATION 
assay O 
using O 
macrophage O 
immune O 
( O 
RAW264.7 O 
) O 
cells O 
. O 
A O 
standardized O 
commercial O 
ethanol B-SYSTEMATIC 
extract O 
of O 
nettle O 
leaves O 
was O 
also O 
evaluated O 
. O 
The O 
methanolic O 
extract O 
of O 
the O 
flowering O 
portions O 
displayed O 
significant O 
anti-inflammatory O 
activity O 
on O 
par O 
with O 
a O 
standard O 
compound O 
celastrol B-TRIVIAL 
( O 
1 O 
) O 
but O 
were O 
moderately O 
cytotoxic O 
. O 
Alternatively O 
, O 
the O 
polar O 
extracts O 
( O 
water O 
, O 
methanol B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
) O 
of O 
the O 
roots O 
, O 
stems O 
and O 
leaves O 
displayed O 
moderate O 
to O 
weak O 
anti-inflammatory O 
activity O 
, O 
while O 
the O 
methanol B-SYSTEMATIC 
and O 
especially O 
the O 
water O 
soluble O 
extracts O 
exhibited O 
noticeable O 
cytotoxicity O 
. O 
In O 
contrast O 
, O 
the O 
lipophilic O 
dichloromethane B-SYSTEMATIC 
extracts O 
of O 
the O 
roots O 
, O 
stems O 
and O 
leaves O 
exhibited O 
potent O 
anti-inflammatory O 
effects O 
greater O 
than O 
or O 
equal O 
to O 
1 O 
with O 
minimal O 
cytotoxicity O 
to O 
RAW264.7 O 
cells O 
. O 
Collectively O 
these O 
results O 
suggest O 
that O 
using O 
lipophilic O 
extracts O 
of O 
stinging O 
nettle O 
may O 
be O 
more O 
effective O 
than O 
traditional O 
tinctures O 
( O 
water O 
, O 
methanol B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
) O 
in O 
clinical O 
evaluations O 
for O 
the O 
treatment O 
of O 
inflammatory O 
disorders O 
especially O 
arthritis O 
. O 
A O 
chemical O 
investigation O 
into O 
the O 
lipophilic O 
extracts O 
of O 
stinging O 
nettle O 
to O 
identify O 
the O 
bioactive O 
compound(s) O 
responsible O 
for O 
their O 
observed O 
anti-inflammatory O 
activity O 
is O 
further O 
warranted O 
. O 

has O 
previously O 
been O 
shown O 
to O 
promote O 
cognitive O 
functions O 
in O 
GH-deficient O 
rodents O 
. O 
In O 
this O 
study O 
we O 
report O 
the O 
effects O 
of O 
GH O 
on O 
learning O 
and O 
memory O 
in O 
intact O 
rats O 
pretreated O 
with O 
the O 
anabolic O 
androgenic O 
steroid B-FAMILY 
nandrolone B-TRIVIAL 
. O 
Male O 
Wistar O 
rats O 
received O 
nandrolone B-SYSTEMATIC 
decanoate I-SYSTEMATIC 
( O 
15 O 
mg O 
/ O 
kg O 
) O 
or O 
peanut O 
oil O 
every O 
third O 
day O 
for O 
3 O 
weeks O 
and O 
were O 
subsequently O 
treated O 
with O 
recombinant O 
human O 
GH O 
( O 
1 O 
IU O 
/ O 
kg O 
) O 
or O 
saline O 
for O 
10 O 
consecutive O 
days O 
. O 
During O 
the O 
GH O 
/ O 
saline O 
treatment O 
spatial O 
learning O 
and O 
memory O 
were O 
tested O 
in O 
the O 
Morris O 
water O 
maze O 
( O 
MWM O 
) O 
. O 
Also O 
, O 
plasma O 
levels O 
of O 
IGF1 O 
were O 
assessed O 
and O 
the O 
gene O 
expression O 
of O 
the O 
GH O 
receptors O 
( O 
Ghr O 
) O 
, O 
Igf1 O 
and O 
Igf2 O 
, O 
in O 
hippocampus O 
and O 
frontal O 
cortex O 
was O 
analyzed O 
. O 
The O 
results O 
demonstrated O 
a O 
significant O 
positive O 
effect O 
of O 
GH O 
on O 
memory O 
functions O 
and O 
increased O 
gene O 
expression O 
of O 
Igf1 O 
in O 
the O 
hippocampus O 
was O 
found O 
in O 
the O 
animals O 
treated O 
with O 
GH O 
. O 
In O 
addition O 
, O 
GH O 
was O 
demonstrated O 
to O 
increase O 
the O 
body O 
weight O 
gain O 
and O 
was O 
able O 
to O 
attenuate O 
the O 
reduced O 
body O 
weight O 
seen O 
in O 
nandrolone B-TRIVIAL 
-treated O 
animals O 
. O 
In O 
general O 
, O 
the O 
rats O 
treated O 
with O 
nandrolone B-TRIVIAL 
alone O 
did O 
not O 
exhibit O 
any O 
pronounced O 
alteration O 
in O 
memory O 
compared O 
with O 
controls O 
in O 
the O 
MWM O 
, O 
and O 
in O 
many O 
cases O 
GH O 
did O 
not O 
induce O 
any O 
alteration O 
. O 
Regarding O 
target O 
zone O 
crossings O 
, O 
considered O 
to O 
be O 
associated O 
with O 
spatial O 
memory O 
, O 
the O 
difference O 
between O 
GH- O 
and O 
steroid O 
- O 
treated O 
animals O 
was O 
significant O 
and O 
administration O 
of O 
GH O 
improved O 
this O 
parameter O 
in O 
the O 
latter O 
group O 
. O 
In O 
conclusion O 
, O 
GH O 
improves O 
spatial O 
memory O 
in O 
intact O 
rats O 
and O 
can O 
reverse O 
certain O 
effects O 
induced O 
by O 
anabolic O 
androgenic O 
steroid B-FAMILY 
. O 

and O 
SPECT O 
tracers O 
for O 
glutamate B-TRIVIAL 
receptors O 
. O 

for O 
PET O 
imaging O 
of O 
glutamate B-TRIVIAL 
receptors O 
will O 
have O 
the O 
potential O 
for O 
studying O 
neurological O 
and O 
neuropsychiatric O 
disorders O 
and O 
their O 
diagnosis O 
and O 
therapeutic O 
intervention O 
. O 
Glutamate B-TRIVIAL 
is O 
the O 
major O 
excitatory O 
neurotransmitter O 
in O 
the O 
brain O 
and O 
is O 
implicated O 
in O 
the O 
pathophysiology O 
of O 
many O 
neurodegenerative O 
and O 
neuropsychiatric O 
disorders O 
. O 
Glutamate B-TRIVIAL 
and O 
its O 
receptors O 
are O 
potential O 
targets O 
in O 
the O 
treatment O 
of O 
these O 
disorders O 
. O 
Glutamate B-TRIVIAL 
signaling O 
is O 
mediated O 
through O 
ionotropic O 
and O 
metabotropic O 
receptors O 
. O 
The O 
abundant O 
concentration O 
of O 
these O 
receptors O 
can O 
facilitate O 
their O 
in O 
vivo O 
quantification O 
using O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
. O 
Glutamate B-TRIVIAL 
receptors O 
are O 
a O 
potentially O 
important O 
set O 
of O 
targets O 
for O 
monitoring O 
disease O 
progression O 
, O 
for O 
evaluating O 
the O 
effect O 
of O 
therapy O 
and O 
for O 
new O 
treatment O 
development O 
based O 
on O 
the O 
quantification O 
of O 
receptor O 
occupancy O 
. O 
Here O 
, O 
we O 
review O 
the O 
PET O 
and O 
single O 
- O 
photon O 
emission O 
computed O 
tomography O 
( O 
SPECT O 
) O 
radioligands O 
that O 
have O 
been O 
developed O 
for O 
imaging O 
glutamate B-TRIVIAL 
receptors O 
in O 
living O 
brain O 
. O 

surface O 
functionalization O 
targeting O 
Si-N B-FORMULA 
linkages O 
. O 

substrates O 
have O 
been O 
a O 
fascinating O 
topic O 
of O 
fundamental O 
and O 
applied O 
research O 
for O 
well O 
over O 
50 O 
years O 
. O 
They O 
have O 
attracted O 
even O 
more O 
attention O 
over O 
the O 
last O 
couple O 
of O 
decades O 
with O 
advances O 
in O 
chemical O 
functionalization O 
that O 
made O 
oxide-free O 
silicon B-SYSTEMATIC 
surfaces O 
a O 
reality O 
. O 
Fundamentally O 
new O 
electronic O 
properties O 
and O 
chemical O 
reactivity O 
became O 
available O 
, O 
and O 
the O 
focus O 
of O 
chemical O 
research O 
turned O 
more O 
toward O 
targeting O 
specific O 
chemical O 
bonds O 
and O 
functionalities O 
on O 
silicon B-SYSTEMATIC 
. O 
Although O 
thermodynamics O 
clearly O 
drives O 
most O 
processes O 
under O 
ambient O 
conditions O 
toward O 
the O 
formation O 
of O 
an O 
oxide O 
layer O 
, O 
kinetic O 
control O 
of O 
the O 
oxidation O 
processes O 
and O 
thermodynamic O 
tricks O 
based O 
on O 
gaining O 
stability O 
of O 
surface O 
monolayers O 
with O 
high O 
- O 
density O 
assembly O 
have O 
allowed O 
for O 
the O 
formation O 
of O 
stable O 
Si-C B-FORMULA 
bonds O 
and O 
Si-O-C B-FORMULA 
linkages O 
on O 
oxide-free O 
silicon B-SYSTEMATIC 
crystals O 
. O 
This O 
feature O 
article O 
targets O 
recent O 
advances O 
in O 
making O 
Si-N B-FORMULA 
linkages O 
on O 
the O 
same O 
oxide-free O 
single O 
crystals O 
. O 
It O 
covers O 
the O 
range O 
of O 
chemical O 
approaches O 
to O 
achieving O 
this O 
goal O 
and O 
offers O 
possible O 
chemistry O 
that O 
can O 
take O 
advantage O 
of O 
the O 
systems O 
produced O 
. O 
The O 
present O 
status O 
of O 
the O 
field O 
and O 
the O 
future O 
directions O 
of O 
its O 
development O 
will O 
be O 
considered O 
. O 

derivatives O 
: O 
a O 
patent O 
review O 
( O 
January O 
2006 O 
- O 
September O 
2012 O 
) O 
. O 

: O 
Tanshinone B-TRIVIAL 
IIA I-TRIVIAL 
( O 
TSIIA B-ABBREVIATION 
) O 
, O 
cryptotanshinone B-TRIVIAL 
and O 
tanshinone B-TRIVIAL 
I I-TRIVIAL 
are O 
major O 
bioactive O 
constituents O 
of O 
Danshen O 
, O 
a O 
Chinese O 
herbal O 
medicine O 
. O 
Sodium B-SYSTEMATIC 
tanshinone I-SYSTEMATIC 
IIA I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
STS B-ABBREVIATION 
) O 
is O 
a O 
water O 
- O 
soluble O 
derivative O 
of O 
TSIIA B-ABBREVIATION 
and O 
it O 
is O 
currently O 
used O 
for O 
treating O 
cardiovascular O 
diseases O 
in O 
China O 
. O 
AREAS O 
COVERED O 
: O 
The O 
article O 
presents O 
a O 
review O 
of O 
the O 
anti-atherosclerosis O 
, O 
cardioprotective O 
effects O 
, O 
neuroprotection O 
and O 
anti-tumor O 
activities O 
of O 
TSIIA B-ABBREVIATION 
and O 
a O 
review O 
of O 
patents O 
on O 
tanshinone B-FAMILY 
derivatives O 
from O 
January O 
2006 O 
to O 
September O 
2012 O 
. O 
EXPERT O 
OPINION O 
: O 
Mechanistic O 
studies O 
have O 
discovered O 
that O 
TSIIA B-ABBREVIATION 
modulates O 
ion O 
channels O 
, O 
kinases O 
, O 
hormone O 
receptors O 
, O 
apoptosis O 
proteins O 
, O 
growth O 
factors O 
, O 
cytokines O 
, O 
microRNA O 
, O 
tumor O 
suppressor O 
and O 
many O 
other O 
targets O 
, O 
revealing O 
an O 
intricate O 
biological O 
network O 
modulated O 
by O 
TSIIA B-ABBREVIATION 
. O 
Many O 
patents O 
have O 
attempted O 
to O 
overcome O 
the O 
low O 
water O 
solubility O 
of O 
TSIIA B-ABBREVIATION 
and O 
tanshinone B-TRIVIAL 
I I-TRIVIAL 
by O 
attaching O 
a O 
polar O 
substituent O 
or O 
by O 
a O 
prodrug O 
strategy O 
. O 
However O 
, O 
biological O 
activities O 
of O 
these O 
tanshinone B-FAMILY 
derivatives O 
need O 
to O 
be O 
further O 
evaluated O 
. O 
Given O 
the O 
extensive O 
in O 
vitro O 
and O 
in O 
vivo O 
biological O 
activities O 
of O 
TSIIA B-ABBREVIATION 
, O 
this O 
compound O 
is O 
a O 
promising O 
candidate O 
to O 
be O 
further O 
developed O 
as O 
a O 
novel O 
therapeutics O 
for O 
treating O 
atherosclerosis O 
, O 
cardiovascular O 
diseases O 
, O 
neurodegenerative O 
diseases O 
and O 
cancer O 
. O 

receptor O 
signaling O 
in O 
pain O 
pathways O 
. O 

and O 
channels O 
that O 
underlie O 
nociceptive O 
signaling O 
constitute O 
potential O 
sites O 
of O 
intervention O 
for O 
treatment O 
of O 
chronic O 
pain O 
states O 
. O 
The O 
kainate B-TRIVIAL 
receptor O 
family O 
of O 
glutamate B-TRIVIAL 
-gated O 
ion O 
channels O 
represents O 
one O 
such O 
candidate O 
set O 
of O 
molecules O 
. O 
They O 
have O 
a O 
prominent O 
role O 
in O 
modulation O 
of O 
excitatory O 
signaling O 
between O 
sensory O 
and O 
spinal O 
cord O 
neurons O 
. O 
Kainate B-TRIVIAL 
receptors O 
are O 
also O 
expressed O 
throughout O 
central O 
pain O 
neuraxis O 
, O 
where O 
their O 
functional O 
contributions O 
to O 
neural O 
integration O 
are O 
less O 
clearly O 
defined O 
. O 
Pharmacological O 
inhibition O 
or O 
genetic O 
ablation O 
of O 
kainate B-TRIVIAL 
receptor O 
activity O 
reduces O 
pain O 
behaviors O 
in O 
a O 
number O 
of O 
animal O 
models O 
of O 
chronic O 
pain O 
, O 
and O 
small O 
clinical O 
trials O 
have O 
been O 
conducted O 
using O 
several O 
orthosteric O 
antagonists O 
. O 
This O 
review O 
will O 
cover O 
kainate B-TRIVIAL 
receptor O 
function O 
and O 
participation O 
in O 
pain O 
signaling O 
as O 
well O 
as O 
the O 
pharmacological O 
studies O 
supporting O 
further O 
consideration O 
as O 
potential O 
targets O 
for O 
therapeutic O 
development O 
. O 

effects O 
of O 
ecstasy B-TRIVIAL 
on O 
mood O 
: O 
an O 
exploration O 
of O 
associated O 
risk O 
factors O 
. O 

use O 
may O 
result O 
in O 
lowered O 
mood O 
, O 
anxiety O 
or O 
aggression O 
in O 
the O 
days O 
following O 
use O 
. O 
Yet O 
, O 
few O 
studies O 
have O 
investigated O 
what O 
factors O 
increase O 
the O 
risk O 
of O 
experiencing O 
such O 
symptoms O 
. O 
Ecstasy B-TRIVIAL 
users O 
( O 
at O 
least O 
once O 
in O 
the O 
last O 
12 O 
months O 
) O 
who O 
subsequently O 
took O 
ecstasy B-TRIVIAL 
( O 
n=35 O 
) O 
over O 
the O 
period O 
of O 
one O 
week O 
, O 
were O 
compared O 
on O 
measures O 
of O 
mood O 
, O 
sleep O 
, O 
stress O 
and O 
drug O 
use O 
, O 
with O 
those O 
who O 
abstained O 
from O 
ecstasy B-TRIVIAL 
( O 
n=21 O 
) O 
that O 
week O 
. O 
Measures O 
were O 
administered O 
the O 
week O 
prior O 
to O 
ecstasy B-TRIVIAL 
use O 
and O 
one O 
and O 
three O 
days O 
following O 
use O 
, O 
or O 
the O 
equivalent O 
day O 
for O 
abstainers O 
. O 
Mood O 
symptoms O 
were O 
assessed O 
using O 
the O 
Kessler-10 O 
self O 
- O 
report O 
psychological O 
distress O 
scale O 
, O 
a O 
subjective O 
mood O 
rating O 
( O 
1-10 O 
) O 
, O 
and O 
using O 
the O 
depression O 
, O 
anxiety O 
and O 
hostility O 
items O 
from O 
the O 
clinician O 
- O 
rated O 
Brief O 
Psychiatric O 
Rating O 
Scale O 
. O 
Timeline O 
Followback O 
methods O 
were O 
used O 
to O 
collect O 
information O 
on O 
drug O 
use O 
and O 
life O 
stress O 
in O 
the O 
past O 
month O 
. O 
Self O 
- O 
reported O 
sleep O 
quality O 
was O 
also O 
assessed O 
. O 
Ecstasy B-TRIVIAL 
use O 
was O 
not O 
associated O 
with O 
subacute O 
depressive O 
, O 
anxiety O 
or O 
aggressive O 
symptoms O 
. O 
Rather O 
, O 
lowered O 
mood O 
and O 
increased O 
psychological O 
distress O 
were O 
associated O 
with O 
self O 
- O 
reported O 
hours O 
and O 
quality O 
of O 
sleep O 
obtained O 
during O 
the O 
three O 
- O 
day O 
follow O 
- O 
up O 
. O 
These O 
findings O 
highlight O 
the O 
importance O 
of O 
considering O 
sleep O 
disruption O 
in O 
understanding O 
the O 
short O 
- O 
term O 
mood O 
effects O 
of O 
ecstasy B-TRIVIAL 
use O 
. O 

from O 
ground O 
- O 
based O 
animal O 
studies O 
using O 
tail O 
- O 
suspended O 
hindlimb O 
unloaded O 
rats O 
model O 
has O 
clearly O 
demonstrated O 
that O 
simulated O 
microgravity O 
- O 
induced O 
smooth O 
muscle O 
cell O 
phenotype O 
conversion O 
, O 
a O 
characteristic O 
vascular O 
structural O 
and O 
functional O 
remodeling O 
, O 
may O 
be O 
one O 
of O 
the O 
key O 
contributors O 
to O 
postspaceflight O 
orthostatic O 
intolerance O 
. O 
However O 
, O 
the O 
rats O 
model O 
involves O 
multiple O 
collective O 
effects O 
of O 
microgravity O 
including O 
cephalic O 
fluid O 
shift O 
and O 
postural O 
muscle O 
unloading O 
on O 
smooth O 
muscle O 
cells O 
( O 
SMCs O 
) O 
. O 
It O 
cannot O 
isolate O 
a O 
single O 
factor O 
from O 
the O 
collective O 
ones O 
and O 
therefore O 
is O 
not O 
ideal O 
to O 
study O 
the O 
effects O 
of O 
gravitational O 
vector O 
alteration O 
alone O 
on O 
SMCs O 
. O 
To O 
test O 
the O 
hypothesis O 
that O 
gravitational O 
vector O 
alteration O 
per O 
se O 
might O 
affect O 
smooth O 
muscle O 
cell O 
phenotype O 
, O 
a O 
roller O 
culture O 
apparatus O 
was O 
employed O 
to O 
expose O 
cultured O 
rat O 
aortic O 
smooth O 
muscle O 
cells O 
( O 
RASMCs O 
) O 
to O 
simulated O 
microgravity O 
. O 
Cell O 
proliferation O 
, O 
cell O 
cycle O 
distribution O 
, O 
apoptosis O 
, O 
migration O 
, O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
rates O 
were O 
measured O 
and O 
compared O 
between O 
the O 
control O 
and O 
the O 
simulated O 
microgravity O 
groups O 
. O 
Cell O 
cytoskeleton O 
reorganization O 
induced O 
by O 
simulated O 
microgravity O 
was O 
observed O 
by O 
confocal O 
microscopy O 
. O 
Specific O 
contractile O 
and O 
synthetic O 
Gene O 
expression O 
at O 
the O 
mRNA O 
level O 
was O 
quantified O 
by O 
reverse O 
transcriptional O 
polymerase O 
chain O 
reaction O 
. O 
It O 
was O 
observed O 
that O 
simulated O 
microgravity O 
suppressed O 
RASMC O 
proliferation O 
and O 
migration O 
, O 
enhanced O 
cell O 
apoptosis O 
, O 
stimulated O 
NO B-FORMULA 
release O 
, O 
and O 
destroyed O 
the O 
original O 
well O 
- O 
organized O 
cytoskeleton O 
. O 
Moreover O 
, O 
at O 
the O 
mRNA O 
level O 
, O 
long O 
- O 
time O 
exposure O 
( O 
≥ O 
72 O 
h O 
) O 
to O 
simulated O 
microgravity O 
induced O 
a O 
contractile O 
phenotype O 
tendency O 
by O 
up O 
- O 
regulating O 
smMHC O 
expression O 
. O 
All O 
these O 
findings O 
suggest O 
that O 
the O 
phenotype O 
modulation O 
of O 
vascular O 
smooth O 
muscle O 
cells O 
may O 
be O 
gravity O 
dependent O 
. O 

activities O 
of O 
the O 
extracts O 
and O 
isolated O 
flavonoids B-FAMILY 
of O 
Euphorbia O 
cuneata O 
Vahl O 
. O 

total O 
alcohol B-FAMILY 
extracts O 
of O 
Euphorbia O 
cuneata O 
Vahl O 
. O 
( O 
Euphorbiaceae O 
) O 
were O 
screened O 
for O 
antiulcerogenic O 
activity O 
using O 
an O 
ethano B-SYSTEMATIC 
l-induced O 
ulcer O 
model O 
at O 
doses O 
of O 
125 O 
, O 
250 O 
and O 
500 O 
mg O 
/ O 
kg O 
. O 
The O 
extracts O 
possessed O 
antiulcerogenic O 
activity O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Four O 
flavonoida B-FAMILY 
l O 
compounds O 
were O 
isolated O 
and O 
identified O 
as O 
naringeni B-TRIVIAL 
n O 
, O 
aromadendri B-TRIVIAL 
n O 
, O 
apigeni B-TRIVIAL 
n O 
and O 
4'-O-methoxy-luteolin-7-O-rhamnoglucosid B-SYSTEMATIC 
e O 
, O 
each O 
demonstrating O 
antiulcerogenic O 
activity O 
with O 
curative O 
ratios O 
ranging O 
from O 
75.78% O 
to O 
88.23% O 
. O 
In O 
addition O 
, O 
the O 
alcoho B-FAMILY 
l O 
extracts O 
and O 
isolated O 
compounds O 
were O 
shown O 
to O 
scavenge O 
the O 
1,1-diphenyl,2-picrylhydrazy B-SYSTEMATIC 
l O 
radical O 
by O 
different O 
ratio O 
, O 
with O 
the O 
most O 
effective O 
being O 
4'-O-methoxy-luteolin-7-O-rhamnoglucosid B-SYSTEMATIC 
e O 
( O 
91.14% O 
) O 
. O 
The O 
antioxidant O 
activity O 
of O 
the O 
alcoho B-FAMILY 
l O 
extracts O 
and O 
the O 
isolated O 
compounds O 
may O 
explain O 
the O 
antiulcerogenic O 
properties O 
. O 
No O 
side O 
effects O 
were O 
observed O 
on O 
either O 
liver O 
or O 
kidney O 
functions O 
. O 

of O 
menstrual O 
cycle O 
phase O 
on O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
in O 
rhesus O 
macaques O 
. O 

findings O 
suggest O 
that O 
men O 
and O 
women O 
vary O 
in O 
their O 
pattern O 
of O 
cocaine B-TRIVIAL 
use O 
resulting O 
in O 
differences O 
in O 
cocaine B-TRIVIAL 
dependence O 
and O 
relapse O 
rates O 
. O 
Preclinical O 
laboratory O 
studies O 
have O 
demonstrated O 
that O 
female O 
rodents O 
are O 
indeed O 
more O 
sensitive O 
to O 
cocaine B-TRIVIAL 
' O 
s O 
reinforcing O 
effects O 
than O 
males O 
, O 
with O 
estrous O 
cycle O 
stage O 
as O 
a O 
key O 
determinant O 
of O 
this O 
effect O 
. O 
The O 
current O 
study O 
sought O 
to O 
extend O 
these O 
findings O 
to O 
normally O 
cycling O 
female O 
rhesus O 
macaques O 
, O 
a O 
species O 
that O 
shares O 
a O 
nearly O 
identical O 
menstrual O 
cycle O 
to O 
humans O 
. O 
Dose O 
- O 
dependent O 
intravenous O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
( O 
0.0125 O 
, O 
0.025 O 
, O 
and O 
0.05 O 
mg O 
/ O 
kg O 
/ O 
infusion O 
) O 
using O 
a O 
progressive O 
- O 
ratio O 
schedule O 
of O 
reinforcement O 
was O 
determined O 
across O 
the O 
menstrual O 
cycle O 
. O 
The O 
menstrual O 
cycle O 
was O 
divided O 
into O 
5 O 
discrete O 
phases O 
- O 
menses O 
, O 
follicular O 
, O 
periovulatory O 
, O 
luteal O 
, O 
and O 
late O 
luteal O 
phases O 
- O 
verified O 
by O 
the O 
onset O 
of O 
menses O 
and O 
plasma O 
levels O 
of O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
. O 
Dependent O 
variables O 
including O 
number O 
of O 
infusions O 
self O 
- O 
administered O 
per O 
session O 
, O 
progressive O 
ratio O 
breakpoint O 
, O 
and O 
cocaine B-TRIVIAL 
intake O 
were O 
analyzed O 
according O 
to O 
cocaine B-TRIVIAL 
dose O 
and O 
menstrual O 
cycle O 
phase O 
. O 
Analysis O 
of O 
plasma O 
hormone O 
levels O 
verified O 
phase O 
- O 
dependent O 
fluctuations O 
of O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
, O 
with O 
estrogen B-FAMILY 
levels O 
peaking O 
during O 
the O 
periovulatory O 
phase O 
, O 
and O 
progesterone B-TRIVIAL 
peaking O 
during O 
the O 
luteal O 
phase O 
. O 
Progressive O 
ratio O 
breakpoint O 
, O 
infusions O 
self O 
- O 
administered O 
, O 
and O 
cocaine B-TRIVIAL 
intake O 
did O 
not O 
consistently O 
vary O 
based O 
on O 
menstrual O 
cycle O 
phase O 
. O 
These O 
findings O 
demonstrate O 
that O 
under O 
the O 
current O 
experimental O 
parameters O 
, O 
the O 
reinforcing O 
effects O 
of O 
cocaine B-TRIVIAL 
did O 
not O 
vary O 
across O 
the O 
menstrual O 
cycle O 
in O 
a O 
systematic O 
fashion O 
in O 
normally O 
cycling O 
rhesus O 
macaques O 
. O 

catalytic O 
competence O 
of O 
cytochrome O 
P450 O 
in O 
the O 
synthesis O 
of O 
serotonin B-TRIVIAL 
from O 
5-methoxytryptamine B-SYSTEMATIC 
in O 
the O 
brain O 
: O 
an O 
in O 
vitro O 
study O 
. O 

serotonin B-TRIVIAL 
has O 
been O 
implicated O 
in O 
the O 
pathophysiology O 
of O 
a O 
wide O 
spectrum O 
of O 
psychiatric O 
disorders O 
, O 
as O 
well O 
as O 
in O 
the O 
mechanism O 
of O 
action O 
of O 
psychotropic O 
drugs O 
. O 
The O 
aim O 
of O 
present O 
study O 
was O 
to O 
identify O 
rat O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
isoforms O 
which O 
can O 
catalyze O 
the O 
O B-FORMULA 
-demethylation O 
of O 
5-methoxytryptamine B-SYSTEMATIC 
to O 
serotonin B-TRIVIAL 
, O 
and O 
to O 
find O 
out O 
whether O 
that O 
alternative O 
pathway O 
of O 
serotonin B-TRIVIAL 
synthesis O 
may O 
take O 
place O 
in O 
the O 
brain O 
. O 
The O 
study O 
was O 
conducted O 
on O 
cDNA-expressed O 
CYPs O 
( O 
rat O 
CYP1A1 O 
/ O 
2 O 
, O 
2A1 O 
/ O 
2 O 
, O 
2B1 O 
, O 
2C6 O 
/ O 
11 O 
/ O 
13 O 
, O 
2D1 O 
/ O 
2 O 
/ O 
4 O 
/ O 
18 O 
, O 
20 O 
, O 
3A2 O 
and O 
human O 
CYP2D6 O 
) O 
, O 
on O 
rat O 
brain O 
and O 
liver O 
microsomes O 
and O 
on O 
human O 
liver O 
microsomes O 
( O 
the O 
wild O 
- O 
type O 
CYP2D6 O 
or O 
the O 
allelic O 
variant O 
2D6*4*4 O 
) O 
. O 
Of O 
the O 
rat O 
CYP O 
isoforms O 
studied O 
, O 
CYP2D O 
isoforms O 
were O 
the O 
most O 
efficient O 
in O 
catalyzing O 
the O 
O B-FORMULA 
-demethylation O 
of O 
5-methoxytryptamine B-SYSTEMATIC 
to O 
serotonin B-TRIVIAL 
, O 
but O 
they O 
were O 
less O 
effective O 
than O 
the O 
human O 
isoform O 
CYP2D6 O 
. O 
Microsomes O 
from O 
different O 
brain O 
regions O 
were O 
capable O 
of O 
metabolizing O 
5-methoxytryptamine B-SYSTEMATIC 
to O 
serotonin B-TRIVIAL 
. O 
The O 
reaction O 
was O 
inhibited O 
by O 
the O 
specific O 
CYP2D O 
inhibitors O 
quinine B-TRIVIAL 
and O 
fluoxetine B-TRIVIAL 
. O 
Human O 
liver O 
microsomes O 
of O 
the O 
wild O 
- O 
type O 
CYP2D6 O 
metabolized O 
5-methoxytryptamine B-SYSTEMATIC 
to O 
serotonin B-TRIVIAL 
more O 
effectively O 
than O 
did O 
the O 
defective O 
CYP2D6*4*4 O 
ones O 
. O 
The O 
obtained O 
results O 
indicate O 
that O 
rat O 
brain O 
CYP2D O 
isoforms O 
catalyze O 
the O 
formation O 
of O 
serotonin B-TRIVIAL 
from O 
5-methoxytryptamine B-SYSTEMATIC 
, O 
and O 
that O 
the O 
deficit O 
or O 
genetic O 
defect O 
of O 
CYP2D O 
may O 
affect O 
serotonin B-TRIVIAL 
metabolism O 
in O 
the O 
brain O 
. O 
The O 
results O 
are O 
discussed O 
in O 
the O 
context O 
of O 
their O 
possible O 
physiological O 
and O 
pharmacological O 
significance O 
in O 
vivo O 
. O 

novel O 
furanoeremophilane B-FAMILY 
with O 
an O 
unusual O 
oxygen B-SYSTEMATIC 
bridge O 
from O 
Senecio O 
nemorensis O 
. O 

new O 
furanoeremophilanes B-FAMILY 
, O 
1α B-SYSTEMATIC 
, I-SYSTEMATIC 
6α-epoxy-9-oxo-10β-hydroxyl-furanoeremophilane I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
and O 
9-oxo-1α B-SYSTEMATIC 
, I-SYSTEMATIC 
6β I-SYSTEMATIC 
, I-SYSTEMATIC 
10β-trihydroxy-furanoeremophilane I-SYSTEMATIC 
( O 
2 O 
) O 
were O 
isolated O 
from O 
Senecio O 
nemorensis O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
and O 
X-ray O 
crystallography O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
the O 
isolation O 
of O 
the O 
C1-C6 B-FORMULA 
oxygen B-SYSTEMATIC 
bridge O 
of O 
furanoeremophilane B-FAMILY 
. O 
Their O 
cytotoxic O 
effects O 
on O 
BEL7402 O 
and O 
NF-KB O 
cell O 
lines O 
were O 
tested O 
. O 

receptor O 
potential O 
ankyrin O 
1 O 
( O 
TRPA1 O 
) O 
is O 
a O 
nonselective O 
cation O 
channel O 
important O 
in O 
setting O 
nociceptive O 
threshold O 
. O 
It O 
is O 
expressed O 
in O 
nociceptive O 
C-fibers O 
and O 
in O 
non-neuronal O 
cells O 
involved O 
in O 
pro O 
- O 
inflammatory O 
mediators O 
' O 
release O 
. O 
We O 
asked O 
whether O 
TRPA1 O 
contributes O 
to O 
carrageenan O 
- O 
induced O 
hyperalgesia O 
in O 
rats O 
, O 
and O 
if O 
so O 
, O 
whether O 
this O 
contribution O 
is O 
mediated O 
by O 
mechanisms O 
involved O 
in O 
inflammation O 
such O 
as O 
cytokine O 
release O 
and O 
neutrophil O 
migration O 
and O 
/ O 
or O 
by O 
a O 
direct O 
sensitization O 
of O 
the O 
primary O 
afferent O 
nociceptors O 
. O 
Pharmacological O 
blockade O 
of O 
local O 
TRPA1 O 
by O 
its O 
selective O 
antagonist O 
HC B-IDENTIFIER 
30031 I-IDENTIFIER 
prevented O 
and O 
reversed O 
carrageenan O 
- O 
induced O 
hyperalgesia O 
, O 
which O 
was O 
detected O 
either O 
by O 
a O 
mechanical O 
or O 
chemical O 
( O 
low O 
dose O 
of O 
capsaicin B-TRIVIAL 
) O 
stimulus O 
. O 
However O 
, O 
it O 
did O 
not O 
affect O 
either O 
carrageenan O 
- O 
induced O 
cytokines O 
expression O 
or O 
neutrophil O 
migration O 
. O 
The O 
neuronal O 
TRPA1 O 
gene O 
silencing O 
induced O 
by O 
intrathecal O 
pre O 
- O 
treatment O 
with O 
antisense O 
oligodoexynucleotide O 
completely O 
prevented O 
carrageenan O 
- O 
induced O 
hyperalgesia O 
over O 
24 O 
h O 
and O 
significantly O 
reduced O 
TRPA1 O 
expression O 
in O 
the O 
dorsal O 
root O 
ganglia O 
cells O 
( O 
L5-6 O 
) O 
, O 
which O 
was O 
not O 
affected O 
by O 
carrageenan O 
treatment O 
. O 
We O 
conclude O 
that O 
TRPA1 O 
plays O 
an O 
important O 
role O 
in O 
the O 
development O 
and O 
maintenance O 
of O 
carrageenan O 
- O 
induced O 
inflammatory O 
hyperalgesia O 
by O 
directly O 
contributing O 
to O 
nociceptor O 
excitability O 
. O 

reduces O 
cadmium B-SYSTEMATIC 
accumulation O 
in O 
the O 
organism O 
and O 
enhances O 
the O 
levels O 
of O 
antioxidant O 
protein O 
expression O 
in O 
the O 
epididymis O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
caffeine B-TRIVIAL 
( O 
20 O 
mg O 
/ O 
L O 
) O 
intake O 
on O 
cadmium B-SYSTEMATIC 
( O 
15 O 
mg O 
/ O 
L O 
) O 
accumulation O 
in O 
the O 
rat O 
blood O 
, O 
testes O 
, O 
epididymis O 
and O 
prostate O 
as O 
well O 
as O 
cadmium B-SYSTEMATIC 
-induced O 
changes O 
to O 
the O 
antioxidant O 
defense O 
system O 
of O 
the O 
epididymis O 
. O 
Caffeine B-TRIVIAL 
reduced O 
the O 
cadmium B-SYSTEMATIC 
concentration O 
in O 
all O 
tissues O 
analyzed O 
. O 
Meanwhile O 
, O 
cadmium B-SYSTEMATIC 
reduced O 
catalase O 
activity O 
and O 
increased O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
in O 
the O 
epididymis O 
. O 
Caffeine B-TRIVIAL 
increased O 
SOD O 
activity O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
tissue O 
expression O 
and O 
sustains O 
the O 
cadmium B-SYSTEMATIC 
' O 
s O 
effect O 
on O 
catalase O 
and O 
GSP-Px O 
activity O 
. O 
No O 
differences O 
in O 
the O 
expression O 
of O 
metallothionein O 
and O 
lipid O 
peroxidation O 
were O 
observed O 
among O 
the O 
different O 
treatments O 
in O 
the O 
epididymis O 
. O 
In O 
conclusion O 
, O 
low O 
doses O 
of O 
cadmium B-SYSTEMATIC 
alter O 
the O 
antioxidant O 
enzymatic O 
profile O 
of O 
the O 
epididymis O 
, O 
but O 
not O 
induced O 
oxidative O 
lipid O 
damage O 
. O 
Caffeine B-TRIVIAL 
intake O 
reduces O 
overall O 
cadmium B-SYSTEMATIC 
accumulation O 
in O 
the O 
organism O 
and O 
enhances O 
the O 
levels O 
of O 
antioxidant O 
protein O 
expression O 
in O 
the O 
epididymis O 
, O 
thus O 
exerting O 
a O 
protective O 
effect O 
against O 
this O 
metal O 
. O 

effects O 
of O 
diabetic O 
conditions O 
in O 
chick O 
heart O 
in O 
ovo O 
and O 
in O 
micromass O 
culture O 
may O 
be O 
prevented O 
by O 
addition O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
and O 
folic B-TRIVIAL 
acid I-TRIVIAL 
. O 

diseases O 
like O 
diabetes O 
mellitus O 
may O 
cause O 
developmental O 
defects O 
. O 
Supplementation O 
with O 
folic B-TRIVIAL 
acid I-TRIVIAL 
and O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
during O 
the O 
periconceptional O 
period O 
has O 
been O 
shown O 
to O 
prevent O 
some O 
neural O 
tube O 
and O 
congenital O 
heart O 
defects O 
. O 
Hearts O 
were O 
dissected O 
from O 
5 O 
days O 
- O 
old O 
White O 
Leghorn O 
chick O 
embryos O 
, O 
the O 
cells O 
isolated O 
and O 
cultured O 
in O 
micromass O 
under O 
diabetic O 
conditions O 
, O 
with O 
and O 
without O 
folic B-TRIVIAL 
acid I-TRIVIAL 
and O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
. O 
Contractile O 
activity O 
, O 
cell O 
viability O 
( O 
resazurin B-TRIVIAL 
reduction O 
) O 
and O 
protein O 
assays O 
were O 
performed O 
. O 
Results O 
indicated O 
diabetic O 
conditions O 
reduced O 
contractile O 
activity O 
and O 
cell O 
viability O 
, O 
whilst O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
( O 
100 O 
μM O 
) O 
and O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
mM O 
) O 
administered O 
concurrently O 
significantly O 
improved O 
them O 
to O 
values O 
comparable O 
with O 
the O 
control O 
. O 
Day O 
3 O 
chick O 
embryos O 
in O 
ovo O 
were O 
injected O 
with O 
glucose B-TRIVIAL 
+ O 
hydroxybutyrate B-SYSTEMATIC 
or O 
a O 
combination O 
of O 
these O 
and O 
vitamins O 
. O 
Diabetic O 
conditions O 
caused O 
gross O 
and O 
histological O 
malformations O 
, O 
but O 
these O 
effects O 
were O 
abrogated O 
by O 
vitamin O 
supplement O 
. O 
Teratogenic O 
effects O 
on O 
heart O 
development O 
could O 
possibly O 
be O 
prevented O 
by O 
vitamin O 
supplementation O 
during O 
pregnancy O 
. O 

( O 
N-myc O 
downstream O 
- O 
regulated O 
gene O 
1 O 
) O 
plays O 
a O 
role O 
in O 
cell O 
differentiation O 
and O 
suppression O 
of O 
tumor O 
metastasis O 
. O 
This O 
study O 
aims O 
to O 
determine O 
the O 
expression O 
of O 
NDRG1 O 
mRNA O 
and O 
protein O 
in O 
gastric O 
cancer O 
cell O 
lines O 
and O 
tissue O 
specimens O 
and O 
then O 
assess O 
the O 
possible O 
cause O 
of O 
its O 
aberrant O 
expression O 
. O 
Six O 
gastric O 
cancer O 
cell O 
lines O 
and O 
20 O 
pairs O 
of O 
normal O 
and O 
gastric O 
cancer O 
tissue O 
samples O 
were O 
used O 
to O 
assess O 
NDRG1 O 
expression O 
using O 
Real O 
- O 
time O 
PCR O 
and O 
Western O 
blot O 
. O 
High O 
- O 
resolution O 
melting O 
analysis O 
( O 
HRM O 
) O 
and O 
methylation O 
- O 
specific O 
PCR O 
( O 
MSP O 
) O 
were O 
performed O 
to O 
detect O 
gene O 
mutation O 
and O 
methylation O 
, O 
respectively O 
, O 
in O 
cell O 
lines O 
and O 
tissues O 
samples O 
. O 
Expression O 
of O 
NDRG1 O 
mRNA O 
and O 
protein O 
was O 
downregulated O 
in O 
gastric O 
cancer O 
cell O 
lines O 
and O 
tissues O 
. O 
Specifically O 
, O 
expression O 
of O 
NDRG1 O 
mRNA O 
and O 
protein O 
was O 
lower O 
in O 
all O 
six O 
gastric O 
cancer O 
cell O 
lines O 
than O 
that O 
of O 
normal O 
gastric O 
cells O 
, O 
while O 
15 O 
out O 
of O 
20 O 
cases O 
of O 
gastric O 
cancer O 
tissues O 
had O 
the O 
reduced O 
levels O 
of O 
NDRG1 O 
mRNA O 
and O 
protein O 
. O 
HRM O 
data O 
showed O 
that O 
there O 
was O 
no O 
mutation O 
in O 
NDRG1 O 
gene O 
, O 
but O 
MSP O 
data O 
showed O 
high O 
levels O 
of O 
NDRG1 O 
gene O 
promoter O 
methylation O 
in O 
the O 
CpG O 
islands O 
in O 
both O 
cell O 
lines O 
and O 
tissue O 
samples O 
. O 
Moreover O 
, O 
treatment O 
with O 
the O 
DNA O 
methyltransferase O 
inhibitor O 
5-Aza-2'-deoxycytidine B-SYSTEMATIC 
upregulated O 
NDRG1 O 
expression O 
in O 
gastric O 
cancer O 
HGC27 O 
cells O 
, O 
but O 
not O 
in O 
the O 
histone O 
deacetylase O 
inhibitor O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
-treated O 
HGC27 O 
cells O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
has O 
shown O 
that O 
expression O 
of O 
NDRG1 O 
mRNA O 
and O 
protein O 
was O 
reduced O 
in O 
gastric O 
cancer O 
cell O 
lines O 
and O 
tissues O 
, O 
which O 
is O 
due O 
to O 
methylation O 
of O 
NDRG1 O 
gene O 
promoter O 
. O 
Further O 
study O 
will O 
unearth O 
the O 
clinical O 
significance O 
of O 
the O 
reduced O 
NDRG1 O 
protein O 
in O 
gastric O 
cancer O 
. O 

of O 
dietary O 
carbon B-SYSTEMATIC 
on O 
mercury B-SYSTEMATIC 
bioaccumulation O 
in O 
streams O 
of O 
the O 
Adirondack O 
Mountains O 
of O 
New O 
York O 
and O 
the O 
Coastal O 
Plain O 
of O 
South O 
Carolina O 
, O 
USA O 
. O 

studied O 
lower O 
food O 
webs O 
in O 
streams O 
of O 
two O 
mercury B-SYSTEMATIC 
-sensitive O 
regions O 
to O 
determine O 
whether O 
variations O 
in O 
consumer O 
foraging O 
strategy O 
and O 
resultant O 
dietary O 
carbon B-SYSTEMATIC 
signatures O 
accounted O 
for O 
observed O 
within O 
- O 
site O 
and O 
among O 
- O 
site O 
variations O 
in O 
consumer O 
mercury B-SYSTEMATIC 
concentration O 
. O 
We O 
collected O 
macroinvertebrates O 
( O 
primary O 
consumers O 
and O 
predators O 
) O 
and O 
selected O 
forage O 
fishes O 
from O 
three O 
sites O 
in O 
the O 
Adirondack O 
Mountains O 
of O 
New O 
York O 
, O 
and O 
three O 
sites O 
in O 
the O 
Coastal O 
Plain O 
of O 
South O 
Carolina O 
, O 
for O 
analysis O 
of O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
and O 
stable O 
isotopes O 
of O 
carbon B-SYSTEMATIC 
( O 
δ O 
(13)C B-FORMULA 
) O 
and O 
nitrogen B-SYSTEMATIC 
( O 
δ O 
(15)N B-FORMULA 
) O 
. O 
Among O 
primary O 
consumers O 
, O 
scrapers O 
and O 
filterers O 
had O 
higher O 
MeHg B-FORMULA 
and O 
more O 
depleted O 
δ O 
(13)C B-FORMULA 
than O 
shredders O 
from O 
the O 
same O 
site O 
. O 
Variation O 
in O 
δ O 
(13)C B-FORMULA 
accounted O 
for O 
up O 
to O 
34 O 
% O 
of O 
within O 
- O 
site O 
variation O 
in O 
MeHg B-FORMULA 
among O 
primary O 
consumers O 
, O 
beyond O 
that O 
explained O 
by O 
δ O 
(15)N B-FORMULA 
, O 
an O 
indicator O 
of O 
trophic O 
position O 
. O 
Consumer O 
δ O 
(13)C B-FORMULA 
accounted O 
for O 
10 O 
% O 
of O 
the O 
variation O 
in O 
Hg B-FORMULA 
among O 
predatory O 
macroinvertebrates O 
and O 
forage O 
fishes O 
across O 
these O 
six O 
sites O 
, O 
after O 
accounting O 
for O 
environmental O 
aqueous O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
, O 
5 O 
% O 
of O 
variation O 
) O 
and O 
base- O 
N B-FORMULA 
adjusted O 
consumer O 
trophic O 
position O 
( O 
Δδ O 
(15)N B-FORMULA 
, O 
22 O 
% O 
of O 
variation O 
) O 
. O 
The O 
δ O 
(13)C B-FORMULA 
spatial O 
pattern O 
within O 
consumer O 
taxa O 
groups O 
corresponded O 
to O 
differences O 
in O 
benthic O 
habitat O 
shading O 
among O 
sites O 
. O 
Consumers O 
from O 
relatively O 
more O 
- O 
shaded O 
sites O 
had O 
more O 
enriched O 
δ O 
(13)C B-FORMULA 
that O 
was O 
more O 
similar O 
to O 
typical O 
detrital O 
δ O 
(13)C B-FORMULA 
, O 
while O 
those O 
from O 
the O 
relatively O 
more O 
- O 
open O 
sites O 
had O 
more O 
depleted O 
δ O 
(13)C B-FORMULA 
. O 
Although O 
we O 
could O 
not O 
clearly O 
attribute O 
these O 
differences O 
strictly O 
to O 
differences O 
in O 
assimilation O 
of O 
carbon B-SYSTEMATIC 
from O 
terrestrial O 
or O 
in O 
- O 
channel O 
sources O 
, O 
greater O 
potential O 
for O 
benthic O 
primary O 
production O 
at O 
more O 
open O 
sites O 
might O 
play O 
a O 
role O 
. O 
We O 
found O 
significant O 
variation O 
among O 
consumers O 
within O 
and O 
among O 
sites O 
in O 
carbon B-SYSTEMATIC 
source O 
; O 
this O 
may O 
be O 
related O 
to O 
within O 
- O 
site O 
differences O 
in O 
diet O 
and O 
foraging O 
habitat O 
, O 
and O 
to O 
among O 
- O 
site O 
differences O 
in O 
environmental O 
conditions O 
that O 
influence O 
primary O 
production O 
. O 
These O 
observations O 
suggest O 
that O 
different O 
foraging O 
strategies O 
and O 
habitats O 
influence O 
MeHg B-FORMULA 
bioaccumulation O 
in O 
streams O 
, O 
even O 
at O 
relatively O 
small O 
spatial O 
scales O 
. O 
Such O 
influence O 
must O 
be O 
considered O 
when O 
selecting O 
lower O 
trophic O 
level O 
consumers O 
as O 
sentinels O 
of O 
MeHg B-FORMULA 
bioaccumulation O 
for O 
comparison O 
within O 
and O 
among O 
sites O 
. O 

kinetic O 
and O 
molecular O 
docking O 
studies O 
for O 
the O 
inhibitions O 
of O 
miltirone B-TRIVIAL 
on O 
major O 
human O 
cytochrome O 
P450 O 
isozymes O 
. O 

studies O 
have O 
shown O 
that O 
major O 
tanshinones B-FAMILY 
isolated O 
from O 
Danshen O 
( O 
Salvia O 
miltiorrhiza O 
) O 
inhibited O 
human O 
and O 
rat O 
CYP450 O 
enzymes O 
- O 
mediated O 
metabolism O 
of O 
model O 
probe O 
substrates O 
, O 
with O 
potential O 
in O 
causing O 
herb O 
- O 
drug O 
interactions O 
. O 
Miltirone B-TRIVIAL 
, O 
another O 
abietane B-TRIVIAL 
type- O 
diterpene B-FAMILY 
quinone I-FAMILY 
isolated O 
from O 
Danshen O 
, O 
has O 
been O 
reported O 
for O 
its O 
anti-oxidative O 
, O 
anxiolytic O 
and O 
anti-cancer O 
effects O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
study O 
the O 
effect O 
of O 
miltirone B-TRIVIAL 
on O 
the O 
metabolism O 
of O 
model O 
probe O 
substrates O 
of O 
CYP1A2 O 
, O 
2C9 O 
, O 
2D6 O 
and O 
3A4 O 
in O 
pooled O 
human O 
liver O 
microsomes O 
. O 
Miltirone B-TRIVIAL 
showed O 
moderate O 
inhibition O 
on O 
CYP1A2 O 
( O 
IC(50)=1.73 O 
μM O 
) O 
and O 
CYP2C9 O 
( O 
IC(50)=8.61 O 
μM O 
) O 
, O 
and O 
weak O 
inhibition O 
on O 
CYP2D6 O 
( O 
IC(50)=30.20 O 
μM O 
) O 
and O 
CYP3A4 O 
( O 
IC(50)=33.88 O 
μM O 
) O 
. O 
Enzyme O 
kinetic O 
studies O 
showed O 
that O 
miltirone B-TRIVIAL 
competitively O 
inhibited O 
CYP2C9 O 
( O 
K(i)=1.48 O 
μM O 
) O 
, O 
and O 
displayed O 
mixed O 
type O 
inhibitions O 
on O 
CYP1A2 O 
, O 
CYP2D6 O 
and O 
CYP3A4 O 
with O 
K O 
(i) O 
values O 
of O 
3.17 O 
μM O 
, O 
24.25 O 
μM O 
and O 
35.09 O 
μM O 
, O 
respectively O 
. O 
Molecular O 
docking O 
study O 
further O 
confirmed O 
the O 
ligand O 
- O 
binding O 
conformations O 
of O 
miltirone B-TRIVIAL 
in O 
the O 
active O 
sites O 
of O 
these O 
human O 
CYP450 O 
isoforms O 
, O 
and O 
provided O 
some O 
information O 
on O 
structure O 
- O 
activity O 
relationships O 
for O 
the O 
CYPs O 
inhibition O 
by O 
tanshinones B-FAMILY 
. O 
Taken O 
together O 
, O 
CYPs O 
inhibitions O 
of O 
miltirone B-TRIVIAL 
were O 
weaker O 
than O 
dihydrotanshinone B-SYSTEMATIC 
, O 
but O 
stronger O 
than O 
cryptotanshinone B-TRIVIAL 
, O 
tanshinone B-TRIVIAL 
I I-TRIVIAL 
and O 
tanshinone B-TRIVIAL 
IIA I-TRIVIAL 
. O 

: O 
antispasmodic O 
effect O 
and O 
mode O 
of O 
action O 
. O 

is O 
a O 
monoterpene B-FAMILY 
ketone I-FAMILY 
found O 
in O 
spearmint O 
( O 
Mentha O 
spicata O 
var O 
. O 
crispa O 
) O 
essential O 
oil O 
that O 
is O 
widely O 
used O 
as O 
an O 
odor O 
and O 
flavor O 
additive O 
. O 
An O 
intestinal O 
antispasmodic O 
effect O 
was O 
recently O 
reported O 
for O 
(-)-carvone B-TRIVIAL 
, O 
and O 
it O 
has O 
been O 
shown O 
to O 
be O 
more O 
potent O 
than O 
its O 
(+)-antipode O 
. O 
The O 
mechanism O 
of O 
(-)-carvone B-TRIVIAL 
action O 
in O 
the O 
intestines O 
has O 
not O 
been O 
investigated O 
. O 
To O 
gain O 
a O 
better O 
understanding O 
of O 
the O 
(-)-carvone B-TRIVIAL 
antispasmodic O 
effect O 
, O 
we O 
investigated O 
its O 
pharmacological O 
effects O 
in O 
the O 
guinea O 
pig O 
ileum O 
. O 
Terminal O 
portions O 
of O 
the O 
ileum O 
were O 
mounted O 
for O 
isotonic O 
contraction O 
recordings O 
. O 
The O 
effect O 
of O 
(-)-carvone B-TRIVIAL 
was O 
compared O 
with O 
that O 
of O 
the O 
classical O 
calcium B-SYSTEMATIC 
channel O 
blocker O 
( O 
CCB O 
) O 
verapamil B-TRIVIAL 
. O 
In O 
isolated O 
ileal O 
smooth O 
muscle O 
, O 
(-)-carvone B-TRIVIAL 
did O 
not O 
produce O 
direct O 
contractile O 
or O 
relaxation O 
responses O 
and O 
did O 
not O 
modify O 
electrically O 
elicited O 
contractions O 
or O 
low O 
K(+) B-FORMULA 
-evoked O 
contractions O 
. O 
The O 
submaximal O 
contractions O 
induced O 
by O 
histamine B-TRIVIAL 
( O 
p O 
< O 
0.001 O 
) O 
, O 
BaCl2 B-FORMULA 
( O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
carbachol B-TRIVIAL 
( O 
p O 
< O 
0.01 O 
) O 
were O 
significantly O 
reduced O 
by O 
(-)-carvone B-TRIVIAL 
. O 
The O 
contractile O 
response O 
elicited O 
by O 
high O 
concentrations O 
of O 
carbachol B-TRIVIAL 
was O 
reduced O 
but O 
not O 
abolished O 
by O 
(-)-carvone B-TRIVIAL 
. O 
No O 
additive O 
action O 
was O 
detected O 
with O 
co O 
- O 
incubation O 
of O 
(-)-carvone B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
on O 
carbachol B-TRIVIAL 
-induced O 
contraction O 
. O 
(-)-Carvone B-TRIVIAL 
reduced O 
the O 
contraction O 
induced O 
by O 
high O 
K(+) B-FORMULA 
and O 
was O 
almost O 
100 O 
times O 
more O 
potent O 
than O 
verapamil B-TRIVIAL 
. O 
Thus O 
, O 
(-)-carvone B-TRIVIAL 
showed O 
a O 
typical O 
and O 
potent O 
CCB O 
- O 
like O 
action O 
. O 
Many O 
effects O 
described O 
for O 
both O 
(-)-carvone B-TRIVIAL 
and O 
spearmint O 
oil O 
can O 
be O 
explained O 
as O 
a O 
CCB O 
- O 
like O 
mode O 
of O 
action O 
. O 

electron O 
transfer O 
chain O 
complexes O 
inhibition O 
by O 
different O 
organochalcogens B-FAMILY 
. O 

dysfunction O 
plays O 
a O 
pivotal O 
role O 
in O 
the O 
cell O 
toxicology O 
and O 
death O 
decision O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
three O 
organocompounds O 
( O 
ebselen O 
[ O 
Ebs O 
] O 
, O 
diphenyl B-SYSTEMATIC 
diselenide I-SYSTEMATIC 
[ O 
(PhSe)(2) B-FORMULA 
] O 
and O 
diphenyl B-SYSTEMATIC 
ditelluride I-SYSTEMATIC 
[ O 
(PhTe)(2) B-FORMULA 
] O 
) O 
on O 
mitochondrial O 
complexes O 
( O 
I O 
, O 
II O 
, O 
I-III O 
, O 
II-III O 
and O 
IV O 
) O 
activity O 
from O 
rat O 
liver O 
and O 
kidney O 
to O 
determine O 
their O 
potential O 
role O 
as O 
molecular O 
targets O 
of O 
organochalcogens B-FAMILY 
. O 
All O 
studied O 
organochalcogens B-FAMILY 
caused O 
a O 
statistically O 
significant O 
inhibition O 
of O 
the O 
mitochondrial O 
complex O 
I O 
activity O 
. O 
Ebs O 
and O 
(PhTe)(2) B-FORMULA 
caused O 
a O 
statistically O 
significant O 
inhibition O 
of O 
the O 
mitochondrial O 
complex O 
II O 
activity O 
in O 
both O 
hepatic O 
and O 
renal O 
membranes O 
. O 
Hepatic O 
mitochondrial O 
complex O 
II O 
activity O 
was O 
practically O 
unchanged O 
by O 
(PhSe)(2) B-FORMULA 
, O 
whereas O 
it O 
significantly O 
inhibited O 
renal O 
complex O 
II O 
activity O 
. O 
Mitochondrial O 
complex O 
IV O 
activity O 
was O 
practically O 
unchanged O 
by O 
the O 
organochalcogens B-FAMILY 
. O 
Furthermore O 
, O 
organochalcogens B-FAMILY 
inhibited O 
the O 
mitochondrial O 
respiration O 
supported O 
by O 
complex O 
I O 
or O 
complex O 
II O 
substrates O 
. O 
The O 
inhibitory O 
effect O 
of O 
Ebs O 
, O 
(PhSe)(2) B-FORMULA 
and O 
(PhTe)(2) B-FORMULA 
on O 
mitochondrial O 
complex O 
I O 
was O 
prevented O 
by O 
NADH B-ABBREVIATION 
, O 
but O 
it O 
was O 
not O 
prevented O 
by O 
catalase O 
( O 
CAT O 
) O 
and O 
/ O 
or O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
. O 
Additionally O 
, O 
the O 
organochalcogens B-FAMILY 
-induced O 
inhibition O 
of O 
complex O 
I O 
and O 
II O 
was O 
completely O 
reversed O 
by O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
. O 
In O 
conclusion O 
, O 
Ebs O 
, O 
(PhSe)(2) B-FORMULA 
and O 
(PhTe)(2) B-FORMULA 
were O 
more O 
effective O 
inhibitors O 
of O 
renal O 
and O 
hepatic O 
mitochondrial O 
complex O 
I O 
than O 
complex O 
II O 
, O 
whereas O 
complexes O 
III O 
and O 
IV O 
were O 
little O 
modified O 
by O 
these O 
compounds O 
. O 
Taking O 
into O 
account O 
the O 
presented O 
results O 
, O 
we O 
suggest O 
that O 
organochalcogen B-FAMILY 
-induced O 
mitochondrial O 
complexes O 
I O 
and O 
II O 
inhibition O 
can O 
be O 
mediated O 
by O 
their O 
thiol B-FAMILY 
oxidation O 
activity O 
, O 
i.e O 
. O 
, O 
Ebs O 
, O 
(PhSe)(2) B-FORMULA 
and O 
(PhTe)(2) B-FORMULA 
can O 
oxidize O 
critical O 
thiol O 
groups O 
from O 
mitochondrial O 
complexes O 
I O 
and O 
II O 
. O 
So O 
, O 
mitochondrial O 
dysfunction O 
can O 
be O 
considered O 
an O 
important O 
factor O 
in O 
the O 
toxicity O 
of O 
Ebs O 
, O 
(PhSe)(2) B-FORMULA 
and O 
(PhTe)(2) B-FORMULA 
. O 

receptor O 
signaling O 
as O 
a O 
target O 
for O 
novel O 
breast O 
cancer O 
therapeutics O 
. O 

breast O 
cancer O 
( O 
BC O 
) O 
epithelial O 
cells O 
, O 
the O 
mitogenic O 
action O 
of O 
estradiol B-TRIVIAL 
is O 
transduced O 
through O 
binding O 
to O 
two O 
receptors O 
, O 
ERα O 
and O 
ERβ O 
, O 
which O 
act O 
as O 
transcription O 
factors O 
. O 
Anti- O 
estrogens B-FAMILY 
( O 
AEs O 
) O 
and O 
aromatase O 
inhibitors O 
( O 
AIs O 
) O 
are O 
used O 
clinically O 
to O 
arrest O 
the O 
estrogen B-FAMILY 
-dependent O 
growth O 
of O 
BC O 
. O 
In O 
the O 
case O 
of O 
AE O 
or O 
AI O 
resistance O 
, O 
Herceptin O 
or O 
lapatinib B-TRIVIAL 
may O 
be O 
used O 
to O 
inhibit O 
growth O 
factors O 
. O 
Estrogen B-FAMILY 
effects O 
are O 
mediated O 
not O 
only O 
through O 
nuclear O 
ERs O 
but O 
also O 
through O 
cytoplasmic O 
/ O 
membrane O 
ERs O 
and O 
G O 
- O 
protein O 
- O 
coupled O 
ERs O 
. O 
These O 
estrogen B-FAMILY 
-binding O 
systems O 
associate O 
with O 
various O 
proteins O 
that O 
direct O 
cell O 
cycle O 
signaling O 
, O 
proliferation O 
and O 
survival O 
. O 
The O 
partners O 
of O 
nuclear O 
ER O 
include O 
SRC1-3 O 
, O 
HDACs O 
and O 
ERβ O 
itself O 
as O 
well O 
as O 
newly O 
identified O 
proteins O 
, O 
such O 
as O 
E6-AP O 
, O 
LKB1 O 
, O 
PELP1 O 
, O 
PAX-2 O 
and O 
FOXA1 O 
. O 
The O 
partners O 
of O 
extra O 
- O 
nuclear O 
ERα O 
include O 
PI3K O 
and O 
the O 
tyrosine B-TRIVIAL 
kinase O 
Src O 
. O 
These O 
various O 
factors O 
are O 
all O 
potential O 
targets O 
for O 
therapeutic O 
intervention O 
. O 
In O 
addition O 
, O 
BC O 
proliferation O 
is O 
enhanced O 
by O 
insulin O 
and O 
EGF O 
, O 
which O 
stimulate O 
signaling O 
through O 
the O 
MAPK O 
and O 
PI3K O 
/ O 
AKT O 
pathways O 
by O 
activation O 
of O 
the O 
IGF-1R O 
and O 
EGFR O 
axes O 
, O 
respectively O 
. O 
These O 
pathways O 
are O 
tightly O 
interconnected O 
with O 
ER-activated O 
signaling O 
, O 
and O 
membrane O 
ERα O 
forms O 
complexes O 
with O 
Src O 
and O 
PI3K O 
. O 
Chemokine O 
- O 
mediated O 
signaling O 
also O 
modulates O 
the O 
estrogen B-FAMILY 
response O 
. O 
Inhibiting O 
these O 
pathways O 
with O 
specific O 
inhibitors O 
or O 
activating O 
some O 
of O 
the O 
pathways O 
by O 
gene O 
manipulation O 
may O 
be O 
therapeutically O 
valuable O 
for O 
arresting O 
BC O 
cell O 
cycle O 
progression O 
and O 
for O 
inducing O 
apoptosis O 
to O 
antagonize O 
hormone O 
- O 
resistance O 
. O 
Here O 
, O 
we O 
review O 
some O 
newly O 
identified O 
putatively O 
targetable O 
ER O 
partners O 
and O 
highlight O 
the O 
need O 
to O 
develop O 
tumor O 
- O 
targeting O 
drug O 
carrier O 
systems O 
affecting O 
both O 
the O 
tumor O 
cells O 
and O 
the O 
tumor O 
environment O 
. O 

evaluated O 
the O 
herb O 
- O 
drug O 
interaction O 
potential O 
of O 
Galgeun O 
- O 
tang O 
( O 
GGT O 
) O 
extracts O 
, O 
mediated O 
by O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
inhibition O 
/ O 
induction O 
. O 
Further O 
, O 
the O 
effects O 
of O 
fermentation O 
on O 
the O 
CYP O 
- O 
mediated O 
herb O 
- O 
drug O 
interaction O 
potential O 
of O 
GGT O 
extracts O 
were O 
determined O 
. O 
As O 
measured O 
by O 
LC-ESI O 
/ O 
MS O 
/ O 
MS O 
, O 
GGT O 
extracts O 
( O 
0-300μg O 
/ O 
mL O 
) O 
showed O 
no O 
inhibitory O 
activity O 
toward O 
eight O 
CYP O 
isoforms O 
( O 
1A2 O 
, O 
2A6 O 
, O 
2B6 O 
, O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
20 O 
, O 
and O 
3A4 O 
) O 
in O 
pooled O 
human O 
liver O 
microsomes O 
, O 
suggesting O 
that O 
GGT O 
may O 
have O 
low O 
potential O 
for O 
herb O 
- O 
drug O 
interactions O 
mediated O 
by O 
CYP O 
inhibition O 
. O 
Hepatic O 
CYP O 
expression O 
and O 
activity O 
in O 
rats O 
treated O 
with O 
GGT O 
extracts O 
twice O 
per O 
day O 
for O 
1week O 
was O 
examined O 
. O 
Among O 
the O 
tested O 
CYP O 
isoforms O 
( O 
1A1 O 
, O 
1A2 O 
, O 
1B1 O 
, O 
2B1 O 
, O 
2C11 O 
, O 
20 O 
, O 
3A1 O 
, O 
3A2 O 
, O 
and O 
4A1 O 
) O 
, O 
CYP1B1 O 
and O 
4A1 O 
were O 
increased O 
by O 
GGT O 
extracts O 
. O 
Hepatic O 
activities O 
of O 
7-ethoxyresorufin B-SYSTEMATIC 
- O 
O B-FORMULA 
-deethylase O 
, O 
7-pentoxyresorufin B-SYSTEMATIC 
- O 
O B-FORMULA 
-depentylase O 
, O 
and O 
chlorzoxazone B-SYSTEMATIC 
6-hydroxylase O 
, O 
but O 
not O 
midazolam B-TRIVIAL 
hydroxylase O 
were O 
also O 
elevated O 
. O 
These O 
results O 
raise O 
the O 
possibility O 
that O 
GGT O 
extracts O 
may O 
increase O 
the O 
toxicity O 
of O 
environmental O 
toxicants O 
through O 
the O 
elevating O 
CYP-dependent O 
metabolic O 
activation O 
. O 
Interestingly O 
, O 
the O 
increases O 
in O 
CYP1B1 O 
and O 
CYP4A1 O 
levels O 
, O 
and O 
7-ethoxyresorufin B-SYSTEMATIC 
-O-deethylase O 
, O 
7-pentoxyresorufin B-SYSTEMATIC 
-O-depentylase O 
, O 
and O 
chlorzoxazone B-SYSTEMATIC 
6-hydroxylase O 
activities O 
were O 
attenuated O 
by O 
fermentation O 
of O 
GGT O 
extract O 
using O 
Lactobacillus O 
plantarum O 
KFRI O 
402 O 
, O 
but O 
not O 
144 O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
identify O 
the O 
CYP O 
regulatory O 
component(s) O 
from O 
GGT O 
and O 
determination O 
its O 
metabolism O 
. O 

study O 
of O 
equimolar O 
doses O 
of O 
gamma-hydroxybutyrate B-SYSTEMATIC 
( O 
GHB B-ABBREVIATION 
) O 
, O 
1,4-butanediol B-SYSTEMATIC 
( O 
1,4-BD B-SYSTEMATIC 
) O 
and O 
gamma-butyrolactone B-SYSTEMATIC 
( O 
GBL B-ABBREVIATION 
) O 
on O 
catalepsy O 
after O 
acute O 
and O 
chronic O 
administration O 
. O 

( O 
GHB B-ABBREVIATION 
) O 
, O 
and O 
its O 
precursors O 
1,4-butanediol B-SYSTEMATIC 
( O 
1,4-BD B-SYSTEMATIC 
) O 
and O 
gamma-butyrolactone O 
( O 
GBL B-ABBREVIATION 
) O 
are O 
known O 
drugs O 
of O 
abuse O 
. O 
The O 
ability O 
of O 
acute O 
and O 
chronic O 
administration O 
of O 
equimolar O 
doses O 
of O 
GHB B-ABBREVIATION 
( O 
200mg O 
/ O 
kg O 
) O 
, O 
1,4-BD B-SYSTEMATIC 
( O 
174mg O 
/ O 
kg O 
) O 
and O 
GBL B-ABBREVIATION 
( O 
166mg O 
/ O 
kg O 
) O 
to O 
produce O 
catalepsy O 
in O 
male O 
Swiss O 
Webster O 
mice O 
was O 
examined O 
. O 
GHB B-ABBREVIATION 
, O 
1,4-BD B-SYSTEMATIC 
, O 
GBL B-ABBREVIATION 
produced O 
catalepsy O 
when O 
injected O 
acutely O 
. O 
Drug O 
treatment O 
was O 
then O 
continued O 
for O 
14days O 
. O 
Tolerance O 
development O 
was O 
determined O 
on O 
days O 
6 O 
, O 
14 O 
, O 
and O 
challenged O 
with O 
a O 
higher O 
dose O 
on O 
day O 
15 O 
in O 
those O 
chronically O 
pretreated O 
mice O 
, O 
and O 
compared O 
with O 
naïve O 
mice O 
. O 
Chronic O 
GHB B-ABBREVIATION 
produced O 
tolerance O 
to O 
catalepsy O 
, O 
as O 
evidenced O 
from O 
area O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
of O 
catalepsy O 
versus O 
time O 
( O 
min O 
- O 
sec O 
) O 
on O 
days O 
6 O 
( O 
678±254 O 
) O 
, O 
14 O 
( O 
272±247 O 
) O 
, O 
which O 
were O 
less O 
than O 
those O 
on O 
day O 
1 O 
( O 
1923±269 O 
) O 
. O 
However O 
, O 
less O 
tolerance O 
was O 
seen O 
from O 
GBL B-ABBREVIATION 
or O 
1,4-BD B-SYSTEMATIC 
, O 
as O 
AUCs O 
on O 
days O 
6 O 
and O 
14 O 
were O 
not O 
significantly O 
lower O 
than O 
that O 
of O 
day O 
1 O 
. O 
In O 
conclusion O 
, O 
although O 
equimolar O 
doses O 
were O 
used O 
, O 
expecting O 
similar O 
levels O 
of O 
GHB B-ABBREVIATION 
in O 
the O 
body O 
, O 
1,4-BD B-SYSTEMATIC 
and O 
GBL B-ABBREVIATION 
shared O 
only O 
some O 
of O 
the O 
in O 
vivo O 
effects O 
of O 
GHB B-ABBREVIATION 
. O 
The O 
rate O 
of O 
metabolic O 
conversion O 
of O 
1,4-BD B-SYSTEMATIC 
and O 
GBL B-ABBREVIATION 
into O 
GHB B-ABBREVIATION 
might O 
be O 
responsible O 
for O 
the O 
differences O 
in O 
the O 
tolerance O 
development O 
to O 
these O 
drugs O 
. O 

gestational O 
and O 
neonatal O 
hypothyroidism O 
- O 
induced O 
specific O 
changes O 
in O 
androgen B-FAMILY 
receptor O 
expression O 
in O 
skeletal O 
and O 
cardiac O 
muscles O 
of O 
adult O 
rat O 
. O 

present O 
study O 
aims O 
to O 
identify O 
the O 
association O 
between O 
androgen B-FAMILY 
status O 
and O 
metabolic O 
activity O 
in O 
skeletal O 
and O 
cardiac O 
muscles O 
of O 
adult O 
rats O 
with O 
transient O 
gestational O 
/ O 
neonatal O 
- O 
onset O 
hypothyroidism O 
. O 
Pregnant O 
and O 
lactating O 
rats O 
were O 
made O 
hypothyroid O 
by O 
exposing O 
to O 
0.05% O 
methimazole B-TRIVIAL 
in O 
drinking O 
water O 
; O 
gestational O 
exposure O 
was O 
from O 
embryonic O 
day O 
9-14 O 
( O 
group O 
II O 
) O 
or O 
21 O 
( O 
group O 
III O 
) O 
, O 
lactational O 
exposure O 
was O 
from O 
postnatal O 
day O 
1-14 O 
( O 
group O 
IV O 
) O 
or O 
29 O 
( O 
group O 
V O 
) O 
. O 
Serum O 
was O 
collected O 
for O 
hormone O 
assay O 
. O 
Androgen B-FAMILY 
receptor O 
status O 
, O 
Glu-4 O 
expression O 
, O 
and O 
enzyme O 
activities O 
were O 
assessed O 
in O 
the O 
skeletal O 
and O 
cardiac O 
muscles O 
. O 
Serum O 
testosterone B-TRIVIAL 
and O 
estradiol B-TRIVIAL 
levels O 
decreased O 
in O 
adult O 
rats O 
of O 
groups O 
II O 
and O 
III O 
, O 
whereas O 
testosterone B-TRIVIAL 
remained O 
normal O 
but O 
estradiol B-TRIVIAL 
increased O 
in O 
group O 
IV O 
and O 
V O 
, O 
when O 
compared O 
to O 
coeval O 
control O 
. O 
Androgen B-FAMILY 
receptor O 
ligand O 
binding O 
activity O 
increased O 
in O 
both O 
muscle O 
phenotypes O 
with O 
a O 
consistent O 
increase O 
in O 
the O 
expression O 
level O 
of O 
its O 
mRNA O 
and O 
protein O 
expressions O 
except O 
in O 
the O 
forelimb O 
of O 
adult O 
rats O 
with O 
transient O 
hypothyroidism O 
( O 
group O 
II-V O 
) O 
. O 
Glut-4 O 
expression O 
remained O 
normal O 
in O 
skeletal O 
and O 
cardiac O 
muscle O 
of O 
experimental O 
rats O 
. O 
Specific O 
activity O 
of O 
hexokinase O 
and O 
lactate B-FAMILY 
dehydrogenase O 
increased O 
in O 
both O 
muscle O 
phenotypes O 
whereas O 
, O 
creatine B-TRIVIAL 
kinase O 
activity O 
increased O 
in O 
skeletal O 
muscles O 
alone O 
. O 
It O 
is O 
concluded O 
that O 
transient O 
gestational O 
/ O 
lactational O 
exposure O 
to O 
methimazole B-TRIVIAL 
results O 
in O 
hypothyroidism O 
during O 
prepuberal O 
life O 
whereas O 
it O 
increases O 
AR O 
status O 
and O 
glycolytic O 
activity O 
in O 
skeletal O 
and O 
cardiac O 
muscles O 
even O 
at O 
adulthood O 
. O 
Thus O 
, O 
the O 
present O 
study O 
suggests O 
that O 
euthyroid O 
status O 
during O 
prenatal O 
and O 
early O 
postnatal O 
life O 
is O 
essential O 
to O 
have O 
optimal O 
AR O 
status O 
and O 
metabolic O 
activity O 
at O 
adulthood O 
. O 

activation O 
protein O 
( O 
FAP O 
) O 
is O 
a O 
serine B-TRIVIAL 
protease O 
selectively O 
expressed O 
on O 
tumor O 
stromal O 
fibroblasts O 
in O 
epithelial O 
carcinomas O 
and O 
is O 
important O 
in O 
cancer O 
growth O 
, O 
adhesion O 
, O 
and O 
metastases O 
. O 
As O 
FAP O 
enzymatic O 
activity O 
is O 
a O 
potent O 
therapeutic O 
target O 
, O 
we O 
aimed O 
to O 
identify O 
inhibitory O 
antibodies O 
. O 
Using O 
a O 
competitive O 
inhibition O 
strategy O 
, O 
we O 
used O 
phage O 
display O 
techniques O 
to O 
identify O 
53 O 
single O 
- O 
chain O 
variable O 
fragments O 
( O 
scFvs O 
) O 
after O 
three O 
rounds O 
of O 
panning O 
against O 
FAP O 
. O 
These O 
scFvs O 
were O 
expressed O 
and O 
characterized O 
for O 
binding O 
to O 
FAP O 
by O 
surface O 
plasmon O 
resonance O 
and O 
flow O 
cytometry O 
. O 
Functional O 
assessment O 
of O 
these O 
antibodies O 
yielded O 
an O 
inhibitory O 
scFv O 
antibody O 
, O 
named O 
E3 O 
, O 
which O 
could O 
attenuate O 
35% O 
of O 
FAP O 
cleavage O 
of O 
the O 
fluorescent O 
substrate O 
Ala-Pro-7-amido-4-trifluoromethylcoumarin B-SYSTEMATIC 
compared O 
with O 
nonfunctional O 
scFv O 
control O 
. O 
Furthermore O 
, O 
a O 
mutant O 
E3 O 
scFv O 
was O 
identified O 
by O 
yeast O 
affinity O 
maturation O 
. O 
It O 
had O 
higher O 
affinity O 
( O 
4-fold O 
) O 
and O 
enhanced O 
inhibitory O 
effect O 
on O 
FAP O 
enzyme O 
activity O 
( O 
3-fold O 
) O 
than O 
E3 O 
. O 
The O 
application O 
of O 
both O 
inhibitory O 
anti-FAP O 
scFvs O 
significantly O 
affected O 
the O 
formation O 
of O 
3-dimensional O 
FAP-positive O 
cell O 
matrix O 
, O 
as O 
demonstrated O 
by O 
reducing O 
the O 
fibronectin O 
fiber O 
orientation O 
from O 
41.18% O 
( O 
negative O 
antibody O 
control O 
) O 
to O 
34.06% O 
( O 
E3 O 
) O 
and O 
36.15% O 
( O 
mutant O 
E3 O 
) O 
, O 
respectively O 
. O 
Thus O 
, O 
we O 
have O 
identified O 
and O 
affinity O 
- O 
maturated O 
the O 
first O 
scFv O 
antibody O 
capable O 
of O 
inhibiting O 
FAP O 
function O 
. O 
This O 
scFv O 
antibody O 
has O 
the O 
potential O 
to O 
disrupt O 
the O 
role O 
of O 
FAP O 
in O 
tumor O 
invasion O 
and O 
metastasis O 
. O 

pathogens O 
provoke O 
devastating O 
losses O 
in O 
agricultural O 
production O 
, O 
contaminate O 
food O 
with O 
mycotoxins O 
and O 
give O 
rise O 
to O 
life O 
- O 
threatening O 
infections O 
in O 
humans O 
. O 
The O 
soil O 
- O 
borne O 
ascomycete O 
Fusarium O 
oxysporum O 
attacks O 
over O 
100 O 
different O 
crops O 
and O 
can O 
cause O 
systemic O 
fusariosis O 
in O 
immunocompromised O 
individuals O 
. O 
Here O 
we O 
functionally O 
characterized O 
VeA O 
, O 
VelB O 
, O 
VelC O 
and O 
LaeA O 
, O 
four O 
components O 
of O 
the O 
velvet O 
protein O 
complex O 
which O 
regulates O 
fungal O 
development O 
and O 
secondary O 
metabolism O 
. O 
Deletion O 
of O 
veA O 
, O 
velB O 
and O 
to O 
a O 
minor O 
extent O 
velC O 
caused O 
a O 
derepression O 
of O 
conidiation O 
as O 
well O 
as O 
alterations O 
in O 
the O 
shape O 
and O 
size O 
of O 
microconidia O 
. O 
VeA O 
and O 
LaeA O 
were O 
required O 
for O 
full O 
virulence O 
of O 
F. O 
oxysporum O 
on O 
tomato O 
plants O 
and O 
on O 
immunodepressed O 
mice O 
. O 
A O 
critical O 
contribution O 
of O 
velvet O 
consists O 
in O 
promoting O 
chromatin O 
accessibility O 
and O 
expression O 
of O 
the O 
biosynthetic O 
gene O 
cluster O 
for O 
beauvericin B-TRIVIAL 
, O 
a O 
depsipeptide B-FAMILY 
mycotoxin O 
that O 
functions O 
as O 
a O 
virulence O 
determinant O 
. O 
These O 
results O 
reveal O 
a O 
conserved O 
role O 
of O 
the O 
velvet O 
complex O 
during O 
fungal O 
infection O 
on O 
plants O 
and O 
mammals O 
. O 

novel O 
pyrrolidine B-FAMILY 
alkaloid I-FAMILY 
, O 
(2R*,3S*,5S*)-N,2-dimethyl-3-hydroxy-5-(10-phenyldecyl)pyrrolidine B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
and O 
17 O 
known O 
compounds O 
were O 
isolated O 
from O 
Arisaema O 
franchetianum O 
Engl O 
. O 
( O 
Araceae O 
) O 
tubers O 
. O 
The O 
17 O 
compounds O 
were O 
bergenin B-TRIVIAL 
( O 
2 O 
) O 
, O 
emodin B-TRIVIAL 
( O 
3 O 
) O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
4 O 
) O 
, O 
nobiletin B-TRIVIAL 
( O 
5 O 
) O 
, O 
3-O-β-d-galactopyranosyl-hederagenin B-SYSTEMATIC 
28-O-β-d-xylopyranosyl(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
6)-β-d-galactopyranosyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
coniferin B-TRIVIAL 
( O 
7 O 
) O 
, O 
qingyangshengenin B-TRIVIAL 
( O 
8 O 
) O 
, O 
methylconiferin B-SYSTEMATIC 
( O 
9 O 
) O 
, O 
syringaresinol B-SYSTEMATIC 
4'-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
10 O 
) O 
, O 
gagaminine B-TRIVIAL 
( O 
11 O 
) O 
, O 
perlolyrine B-TRIVIAL 
( O 
12 O 
) O 
, O 
(S)-1-(1'-hydroxyethyl)-β-carboline B-SYSTEMATIC 
( O 
13 O 
) O 
, O 
1-(β-carboline-1-yl)-3,4,5-trihydroxy-1-pentanone B-SYSTEMATIC 
( O 
14 O 
) O 
, O 
1-methoxycarbonyl-β-carboline B-SYSTEMATIC 
( O 
15 O 
) O 
, O 
indolo[2,3-α]carbazole B-SYSTEMATIC 
( O 
16 O 
) O 
, O 
4-hydroxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
17 O 
) O 
, O 
and O 
methyl B-SYSTEMATIC 
4-[2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-(hydroxymethyl)ethyl] I-SYSTEMATIC 
ferulate I-SYSTEMATIC 
( O 
18 O 
) O 
. O 
The O 
inhibitory O 
activities O 
of O 
compound O 
1 O 
and O 
its O 
N-methyl B-SYSTEMATIC 
derivative O 
( O 
1a O 
) O 
against O 
porcine O 
respiratory O 
and O 
reproductive O 
syndrome O 
virus O 
( O 
PRRSV O 
) O 
, O 
human O 
leukemic O 
K562 O 
cells O 
, O 
and O 
human O 
breast O 
cancer O 
MCF-7 O 
cells O 
were O 
evaluated O 
. O 
Compounds O 
1 O 
[ O 
50% O 
inhibited O 
concentration O 
(IC(50)) O 
= O 
12.5 O 
± O 
0.6 O 
μM O 
] O 
and O 
1a O 
( O 
IC(50) O 
= O 
15.7 O 
± O 
0.9 O 
μM O 
) O 
were O 
cytotoxic O 
against O 
K562 O 
cells O 
. O 
Compound O 
1a O 
also O 
had O 
a O 
weak O 
effect O 
on O 
PRRSV O 
with O 
an O 
IC(50) O 
value O 
of O 
31.9 O 
± O 
6 O 
μM O 
[ O 
selectivity O 
index O 
(SI) O 
= O 
18.7 O 
] O 
. O 

quercifolia O 
( O 
L O 
. O 
) O 
J O 
. O 
Sm O 
. O 
, O 
is O 
an O 
ethnomedicinal O 
plant O 
used O 
widely O 
in O 
Tamil O 
Nadu O 
to O 
treat O 
arthritis O 
. O 
The O 
present O 
study O 
was O 
aimed O 
to O 
evaluate O 
the O 
traditional O 
claim O 
of O 
D O 
. O 
quercifolia O 
rhizome O 
water O 
extract O 
in O 
adjuvant O 
induced O 
arthritic O 
animals O 
. O 
Anti-arthritic O 
effect O 
was O 
studied O 
by O 
assessing O 
the O 
levels O 
of O 
lysosomal O 
enzymes O 
, O 
protein O 
bound O 
carbohydrates B-FAMILY 
, O 
urinary O 
degradative O 
collagen O 
and O 
serum O 
cytokines O 
on O 
control O 
and O 
adjuvant O 
induced O 
arthritis O 
. O 
The O 
paw O 
swelling O 
and O 
body O 
weight O 
were O 
also O 
analyzed O 
. O 
The O 
levels O 
of O 
ROS O 
and O 
lysosomal O 
enzymes O 
in O 
neutrophils O 
of O 
control O 
and O 
adjuvant O 
induced O 
animals O 
were O 
also O 
estimated O 
. O 
D O 
. O 
quercifolia O 
rhizome O 
water O 
extract O 
at O 
doses O 
of O 
100 O 
and O 
200mg O 
/ O 
kg O 
reduced O 
the O 
paw O 
thickness O 
and O 
elevated O 
the O 
mean O 
body O 
weight O 
of O 
arthritic O 
rats O 
. O 
The O 
treatment O 
with O 
extract O 
showed O 
a O 
significant O 
reduction O 
in O 
the O 
levels O 
of O 
plasma O 
and O 
liver O 
lysosomal O 
enzymes O 
as O 
well O 
as O 
protein O 
bound O 
carbohydrates O 
and O 
urinary O 
degradative O 
collagen O 
levels O 
. O 
The O 
treatment O 
reduced O 
the O 
levels O 
of O 
ROS O 
and O 
lysosomal O 
enzymes O 
in O 
neutrophils O 
significantly O 
. O 
The O 
significant O 
reduction O 
in O 
the O 
levels O 
of O 
serum O 
pro O 
- O 
inflammatory O 
cytokines O 
( O 
TNF-α O 
and O 
IL-1β O 
) O 
and O 
the O 
increment O 
in O 
the O 
levels O 
of O 
anti-inflammatory O 
cytokine O 
( O 
IL-10 O 
) O 
were O 
also O 
observed O 
by O 
the O 
treatment O 
. O 
The O 
present O 
study O 
supports O 
the O 
traditional O 
claim O 
of O 
using O 
D O 
. O 
quercifolia O 
to O 
treat O 
rheumatism O 
. O 

toxicity O 
of O 
binary O 
metal O 
mixtures O 
( O 
Cu(2+) B-FORMULA 
-Ag(+) I-FORMULA 
, O 
Cu(2+) B-FORMULA 
-Zn(2+) I-FORMULA 
) O 
to O 
lettuce O 
, O 
Lactuca O 
sativa O 
, O 
with O 
the O 
biotic O 
ligand O 
model O 
. O 

biotic O 
ligand O 
model O 
( O 
BLM O 
) O 
was O 
applied O 
to O 
predict O 
metal O 
toxicity O 
to O 
lettuce O 
, O 
Lactuca O 
sativa O 
. O 
Cu(2+) B-FORMULA 
had O 
the O 
lowest O 
median O 
effective O 
activity O 
( O 
EA50(M) O 
) O 
, O 
compared O 
with O 
Ag(+) B-FORMULA 
and O 
Zn(2+) B-FORMULA 
( O 
EA50( O 
Cu B-FORMULA 
) O 
= O 
2.6 O 
× O 
10(-8) O 
M O 
, O 
EA50( O 
Ag B-FORMULA 
) O 
= O 
1.34 O 
× O 
10(-7) O 
M O 
, O 
EA50( O 
Zn B-FORMULA 
) O 
= O 
1.06 O 
× O 
10(-4) O 
M O 
) O 
. O 
At O 
the O 
50% O 
response O 
level O 
, O 
the O 
fraction O 
of O 
the O 
total O 
number O 
of O 
biotic O 
ligands O 
occupied O 
by O 
ions O 
( O 
f50(M) O 
) O 
was O 
lowest O 
for O 
Ag(+) B-FORMULA 
among O 
the O 
metals O 
( O 
f50( O 
Ag B-FORMULA 
) O 
= O 
0.22 O 
, O 
f50( O 
Cu B-FORMULA 
) O 
= O 
0.36 O 
, O 
f50( O 
Zn B-FORMULA 
) O 
= O 
0.42 O 
) O 
. O 
Cu(2+) B-FORMULA 
had O 
the O 
highest O 
affinity O 
for O 
biotic O 
ligands O 
compared O 
with O 
Ag(+) B-FORMULA 
and O 
Zn(2+) B-FORMULA 
, O 
as O 
shown O 
by O 
stability O 
constants O 
of O 
the O 
cation O 
- O 
biotic O 
ligand O 
binding O 
, O 
expressed O 
as O 
log O 
K(MBL) O 
( O 
log O 
K( O 
Cu B-FORMULA 
BL O 
) O 
= O 
7.4 O 
, O 
log O 
K( O 
Ag B-FORMULA 
BL O 
) O 
= O 
6.39 O 
, O 
log O 
K( O 
Zn B-FORMULA 
BL O 
) O 
= O 
4 O 
) O 
. O 
Furthermore O 
, O 
the O 
BLM O 
was O 
combined O 
with O 
the O 
toxic O 
equivalency O 
factor O 
approach O 
in O 
predicting O 
toxicity O 
of O 
mixtures O 
of O 
Cu(2+) B-FORMULA 
-Zn(2+) I-FORMULA 
and O 
Cu(2+) B-FORMULA 
-Ag(+) I-FORMULA 
. O 
The O 
fraction O 
of O 
biotic O 
ligands O 
occupied O 
by O 
ions O 
was O 
used O 
to O 
determine O 
the O 
relative O 
toxic O 
potency O 
of O 
metals O 
and O 
the O 
toxic O 
equivalency O 
quotient O 
( O 
TEQ O 
) O 
of O 
mixtures O 
. O 
This O 
approach O 
allowed O 
for O 
including O 
interactions O 
in O 
estimating O 
mixture O 
toxicity O 
and O 
showed O 
good O 
predictive O 
power O 
( O 
r(2) O 
= O 
0.64-0.84 O 
) O 
. O 
The O 
TEQ O 
at O 
the O 
50% O 
response O 
level O 
( O 
TEQ50 O 
, O 
Cu(2+) B-FORMULA 
equivalents O 
) O 
for O 
Cu(2+) B-FORMULA 
-Zn(2+) I-FORMULA 
mixtures O 
was O 
significantly O 
lower O 
than O 
the O 
value O 
for O 
Cu(2+) B-FORMULA 
-Ag(+) I-FORMULA 
mixtures O 
. O 
Joint O 
toxicity O 
depended O 
on O 
both O 
TEQ O 
and O 
specific O 
composition O 
of O 
the O 
mixture O 
. O 
The O 
present O 
study O 
supports O 
the O 
use O 
of O 
the O 
accumulation O 
of O 
metal O 
ions O 
at O 
the O 
biotic O 
ligands O 
as O 
a O 
predictor O 
of O 
toxicity O 
of O 
single O 
metals O 
and O 
mixtures O 
. O 

toxicity O 
and O 
bioaccumulation O 
of O 
fipronil B-TRIVIAL 
in O 
fathead O 
minnows O 
( O 
Pimephales O 
promelas O 
) O 
following O 
water O 
and O 
sediment O 
exposures O 
. O 

is O 
a O 
widely O 
used O 
, O 
broad O 
- O 
spectrum O 
pesticide O 
that O 
is O 
applied O 
as O 
an O 
equal O 
mixture O 
of O 
two O 
enantiomers O 
. O 
As O 
regulations O 
on O 
older O 
pesticides O 
become O 
more O 
stringent O 
, O 
production O 
and O 
application O 
of O 
fipronil B-TRIVIAL 
is O 
expected O 
to O 
grow O 
, O 
leading O 
to O 
increased O 
inputs O 
into O 
aquatic O 
environments O 
and O 
complex O 
exposures O 
to O 
biota O 
. O 
To O 
better O 
understand O 
the O 
potential O 
exposures O 
introduced O 
by O 
fipronil B-TRIVIAL 
contamination O 
, O 
we O 
conducted O 
subchronic O 
toxicity O 
tests O 
with O 
larval O 
fathead O 
minnows O 
( O 
Pimephales O 
promelas O 
) O 
and O 
waterborne O 
fipronil B-TRIVIAL 
and O 
its O 
enantiomers O 
and O 
exposed O 
juvenile O 
fathead O 
minnows O 
to O 
fipronil B-TRIVIAL 
-spiked O 
sediment O 
. O 
Enantioselective O 
toxicity O 
was O 
observed O 
in O 
fish O 
after O 
the O 
7-d O 
subchronic O 
exposure O 
, O 
with O 
increased O 
toxicity O 
of O 
the O 
racemate O 
and O 
( O 
+ O 
) O 
enantiomer O 
observed O 
compared O 
with O 
the O 
( O 
- O 
) O 
enantiomer O 
. O 
Curiously O 
, O 
toxicities O 
of O 
the O 
racemate O 
and O 
( O 
+ O 
) O 
enantiomer O 
were O 
not O 
significantly O 
different O 
, O 
even O 
though O 
the O 
racemate O 
contains O 
50% O 
of O 
the O 
( O 
+ O 
) O 
enantiomer O 
and O 
50% O 
of O 
the O 
less O 
toxic O 
( O 
- O 
) O 
enantiomer O 
. O 
During O 
the O 
sediment O 
exposure O 
, O 
racemic O 
fipronil B-TRIVIAL 
in O 
sediment O 
was O 
transformed O 
primarily O 
to O 
fipronil B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
, O 
while O 
exposed O 
fish O 
rapidly O 
accumulated O 
fipronil B-TRIVIAL 
and O 
/ O 
or O 
fipronil B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
and O 
transformed O 
the O 
majority O 
to O 
fipronil B-SYSTEMATIC 
sulfone I-SYSTEMATIC 
. O 
Using O 
the O 
results O 
of O 
the O 
sediment-exposure O 
experiment O 
, O 
the O 
authors O 
explored O 
a O 
mechanism O 
that O 
may O 
contribute O 
to O 
the O 
interesting O 
trends O 
in O 
enantioselective O 
toxicity O 
observed O 
during O 
the O 
waterborne O 
exposures O 
. O 
In O 
tandem O 
, O 
the O 
aquatic O 
toxicity O 
experiment O 
and O 
the O 
spiked O 
sediment O 
exposure O 
demonstrate O 
the O 
potentially O 
complex O 
behavior O 
of O 
fipronil B-TRIVIAL 
in O 
sediment O 
and O 
fish O 
. O 

- O 
scale O 
production O 
of O 
edge O 
- O 
selectively O 
functionalized O 
graphene B-TRIVIAL 
nanoplatelets O 
via O 
ball O 
milling O 
and O 
their O 
use O 
as O 
metal O 
- O 
free O 
electrocatalysts O 
for O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
. O 

- O 
selectively O 
functionalized O 
graphene B-TRIVIAL 
nanoplatelets O 
( O 
EFGnPs O 
) O 
with O 
different O 
functional O 
groups O 
were O 
efficiently O 
prepared O 
simply O 
by O 
dry O 
ball O 
milling O 
graphite B-TRIVIAL 
in O 
the O 
presence O 
of O 
hydrogen B-SYSTEMATIC 
, O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
, O 
sulfur B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
, O 
or O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
/ O 
sulfur B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
mixture O 
. O 
Upon O 
exposure O 
to O 
air O 
moisture O 
, O 
the O 
resultant O 
hydrogen B-SYSTEMATIC 
- O 
( O 
HGnP O 
) O 
, O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
- O 
( O 
CGnP O 
) O 
, O 
sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
- O 
( O 
SGnP O 
) O 
, O 
and O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
/ O 
sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
- O 
( O 
CSGnP O 
) O 
functionalized O 
GnPs O 
readily O 
dispersed O 
into O 
various O 
polar O 
solvents O 
, O 
including O 
neutral O 
water O 
. O 
The O 
resultant O 
EFGnPs O 
were O 
then O 
used O 
as O 
electrocatalysts O 
for O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
in O 
an O 
alkaline O 
electrolyte O 
. O 
It O 
was O 
found O 
that O 
the O 
edge O 
polar O 
nature O 
of O 
the O 
newly O 
prepared O 
EFGnPs O 
without O 
heteroatom O 
doping O 
into O 
their O 
basal O 
plane O 
played O 
an O 
important O 
role O 
in O 
regulating O 
the O 
ORR O 
efficiency O 
with O 
the O 
electrocatalytic O 
activity O 
in O 
the O 
order O 
of O 
SGnP O 
> O 
CSGnP O 
> O 
CGnP O 
> O 
HGnP O 
> O 
pristine O 
graphite B-TRIVIAL 
. O 
More O 
importantly O 
, O 
the O 
sulfur B-SYSTEMATIC 
-containing O 
SGnP O 
and O 
CSGnP O 
were O 
found O 
to O 
have O 
a O 
superior O 
ORR O 
performance O 
to O 
commercially O 
available O 
platinum B-SYSTEMATIC 
-based O 
electrocatalyst O 
. O 

exact O 
mechanism O 
of O 
chilling O 
injury O 
( O 
by O 
a O 
decrease O 
of O 
temperature O 
to O 
sub O 
- O 
physiological O 
values O 
) O 
, O 
especially O 
in O 
the O 
intact O 
organ O 
, O 
is O 
yet O 
unknown O 
. O 
Precision O 
- O 
cut O 
liver O 
slices O 
( O 
PCLS O 
) O 
, O 
which O 
closely O 
resemble O 
the O 
organ O 
from O 
which O 
they O 
are O 
derived O 
, O 
are O 
an O 
ideal O 
in O 
vitro O 
model O 
to O 
study O 
the O 
mechanism O 
of O 
chilling O 
injury O 
in O 
the O 
intact O 
organ O 
. O 
In O 
the O 
present O 
study O 
we O 
were O 
able O 
to O 
separate O 
chilling O 
injury O 
from O 
other O 
damaging O 
events O 
such O 
as O 
cryoprotectant O 
toxicity O 
and O 
ice O 
- O 
crystal O 
injury O 
and O 
performed O 
micro O 
- O 
array O 
analysis O 
of O 
regulated O 
genes O 
. O 
Pathway O 
analysis O 
revealed O 
that O 
different O 
stress O 
responses O 
, O 
lipid/ O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
cholesterol B-TRIVIAL 
biosynthesis O 
and O 
metabolism O 
were O 
affected O 
by O 
chilling O 
. O 
This O 
indicates O 
that O 
the O 
cell O 
- O 
membrane O 
might O 
be O 
the O 
primary O 
site O 
and O 
sensor O 
for O 
chilling O 
, O 
which O 
may O 
initiate O 
and O 
amplify O 
downstream O 
intracellular O 
signaling O 
events O 
. O 
Most O 
importantly O 
, O 
we O 
were O 
able O 
to O 
identify O 
gene O 
expression O 
responses O 
from O 
stellate O 
cells O 
and O 
Kupffer O 
cells O 
suggesting O 
the O 
involvement O 
of O 
all O 
liver O 
cell O 
types O 
in O 
the O 
injury O 
. O 
In O 
conclusion O 
, O 
a O 
broad O 
spectrum O 
of O 
previously O 
unknown O 
gene O 
expression O 
changes O 
induced O 
by O 
chilling O 
was O 
identified O 
in O 
the O 
tissue O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
a O 
systematic O 
investigation O 
on O 
the O 
mechanism O 
of O 
chilling O 
injury O 
in O 
integrated O 
tissue O 
by O 
micro O 
- O 
array O 
analysis O 
under O 
conditions O 
in O 
which O 
other O 
sources O 
of O 
injury O 
are O 
minimal O 
. O 

and O 
in O 
vitro O 
evaluations O 
of O 
uncharged O 
reactivators O 
for O 
human O 
acetylcholinesterase O 
inhibited O 
by O 
organophosphorus B-FAMILY 
nerve O 
agents O 
. O 

nerve O 
agents O 
( O 
OPNAs O 
) O 
are O 
highly O 
toxic O 
compounds O 
that O 
represent O 
a O 
threat O 
to O 
both O 
military O 
and O 
civilian O 
populations O 
. O 
They O 
cause O 
an O 
irreversible O 
inhibition O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
, O 
by O 
the O 
formation O 
of O 
a O 
covalent O 
P-O B-FORMULA 
bond O 
with O 
the O 
catalytic O 
serine B-TRIVIAL 
. O 
Among O 
the O 
present O 
treatment O 
of O 
nerve O 
agents O 
poisoning O 
, O 
pyridinium B-MULTIPLE 
and I-MULTIPLE 
bis-pyridinium I-MULTIPLE 
aldoximes I-MULTIPLE 
are O 
used O 
to O 
reactivate O 
this O 
inhibited O 
enzyme O 
but O 
these O 
compounds O 
do O 
not O 
readily O 
cross O 
the O 
blood O 
brain O 
barrier O 
( O 
BBB O 
) O 
due O 
to O 
their O 
permanent O 
cationic O 
charge O 
and O 
thus O 
cannot O 
efficiently O 
reactivate O 
cholinesterases O 
in O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
. O 
In O 
this O 
study O 
, O 
a O 
series O 
of O 
seven O 
new O 
uncharged O 
oximes B-FAMILY 
reactivators O 
have O 
been O 
synthesized O 
and O 
their O 
in O 
vitro O 
ability O 
to O 
reactivate O 
VX O 
and O 
tabun B-TRIVIAL 
-inhibited O 
human O 
acetylcholinesterase O 
( O 
hAChE O 
) O 
has O 
been O 
evaluated O 
. O 
The O 
dissociation O 
constant O 
KD O 
of O 
inhibited O 
enzyme- O 
oxime B-SYSTEMATIC 
complex O 
, O 
the O 
reactivity O 
rate O 
constant O 
kr O 
and O 
the O 
second O 
order O 
reactivation O 
rate O 
constant O 
kr2 O 
have O 
been O 
determined O 
and O 
have O 
been O 
compared O 
to O 
reference O 
oximes B-FAMILY 
HI-6 B-IDENTIFIER 
, O 
Obidoxime B-TRIVIAL 
and O 
2-Pralidoxime B-SYSTEMATIC 
( O 
2-PAM B-SYSTEMATIC 
) O 
. O 
Regarding O 
the O 
reactivation O 
of O 
VX-inhibited O 
hAChE O 
, O 
all O 
compounds O 
show O 
a O 
better O 
reactivation O 
potency O 
than O 
those O 
of O 
2-PAM B-SYSTEMATIC 
, O 
nevertheless O 
they O 
are O 
less O 
efficient O 
than O 
obidoxime B-TRIVIAL 
and O 
HI-6 B-IDENTIFIER 
. O 
Moreover O 
, O 
one O 
of O 
seven O 
described O 
compounds O 
presents O 
an O 
ability O 
to O 
reactivate O 
tabun O 
- O 
inhibited O 
hAChE O 
equivalent O 
to O 
those O 
of O 
2-PAM B-SYSTEMATIC 
. O 

investigation O 
of O 
a O 
novel O 
high O 
density O 
cage O 
compound O 
4,8,11,14,15-pentanitro-2,6,9,13-tetraoxa-4,8,11,14,15-pentaazaheptacyclo[5.5.1.1(3,11).1(5,9)] B-SYSTEMATIC 
pentadecane I-SYSTEMATIC 
. O 

novel O 
polynitro O 
cage O 
compound O 
4,8,11,14,15-pentanitro-2,6,9,13-tetraoxa-4,8,11,14,15-pentaazaheptacyclo B-SYSTEMATIC 
[5.5.1.1(3,11).1(5,9)]pentadecane I-SYSTEMATIC 
( O 
PNTOPAHP B-ABBREVIATION 
) O 
has O 
been O 
designed O 
and O 
investigated O 
at O 
the O 
DFT-B3LYP O 
/ O 
6-31(d) O 
level O 
. O 
Properties O 
, O 
such O 
as O 
electronic O 
structure O 
, O 
IR O 
spectrum O 
, O 
heat O 
of O 
formation O 
, O 
thermodynamic O 
properties O 
and O 
crystal O 
structure O 
have O 
been O 
predicted O 
. O 
This O 
compound O 
is O 
most O 
likely O 
to O 
crystallize O 
in O 
C2 O 
/ O 
c O 
space O 
group O 
, O 
and O 
the O 
corresponding O 
cell O 
parameters O 
are O 
Z O 
= O 
8 O 
, O 
a O 
= O 
29.78 O 
Å O 
, O 
b O 
= O 
6.42 O 
Å O 
, O 
c O 
= O 
32.69 O 
Å O 
, O 
α O 
= O 
90.00° O 
, O 
β O 
= O 
151.05° O 
, O 
γ O 
= O 
90.00° O 
and O 
ρ O 
= O 
1.94 O 
g O 
/ O 
cm(3) O 
. O 
In O 
addition O 
, O 
the O 
detonation O 
velocity O 
and O 
pressure O 
have O 
also O 
been O 
calculated O 
by O 
the O 
empirical O 
Kamlet-Jacobs O 
equation O 
. O 
As O 
a O 
result O 
, O 
the O 
detonation O 
velocity O 
and O 
pressure O 
of O 
this O 
compound O 
are O 
9.82 O 
km O 
/ O 
s O 
, O 
44.67 O 
GPa O 
, O 
respectively O 
, O 
a O 
little O 
higher O 
than O 
those O 
of O 
4,10-dinitro-2,6,8,12-tetraoxa-4,10-diazaisowurtzitane B-SYSTEMATIC 
( O 
TEX B-ABBREVIATION 
, O 
9.28 O 
km O 
/ O 
s O 
, O 
40.72 O 
GPa O 
) O 
. O 
This O 
compound O 
has O 
a O 
comparable O 
chemical O 
stability O 
to O 
TEX B-ABBREVIATION 
, O 
based O 
on O 
the O 
N-NO(2) B-FORMULA 
trigger O 
bond O 
length O 
analysis O 
. O 
The O 
bond O 
dissociation O 
energy O 
ranges O 
from O 
153.09 O 
kJ O 
mol(-1) O 
to O 
186.04 O 
kJ O 
mol(-1) O 
, O 
which O 
indicates O 
that O 
this O 
compound O 
meets O 
the O 
thermal O 
stability O 
requirement O 
as O 
an O 
exploitable O 
HEDM O 
. O 

do O 
not O 
consume O 
/ O 
do O 
not O 
use O 
concentrations O 
for O 
ferric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
in O 
drinking O 
water O 
. O 

U.S O 
. O 
Congress O 
[ O 
PL O 
107-188 O 
] O 
amended O 
the O 
Safe O 
Drinking O 
Water O 
Act O 
and O 
required O 
each O 
community O 
water O 
system O 
serving O 
more O 
than O 
3000 O 
people O 
to O 
conduct O 
vulnerability O 
assessments O 
. O 
These O 
assessments O 
address O 
potential O 
circumstances O 
that O 
could O 
compromise O 
the O 
safety O 
and O 
reliability O 
of O 
municipal O 
water O 
. O 
Ferric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
is O 
used O 
in O 
coagulation O 
and O 
flocculation O 
, O 
and O 
it O 
is O 
used O 
to O 
treat O 
raw O 
water O 
with O 
high O 
viral O 
loads O 
, O 
elevated O 
dissolved O 
solids O 
or O 
high O 
bromide B-SYSTEMATIC 
. O 
Iron B-SYSTEMATIC 
is O 
an O 
essential O 
nutrient O 
, O 
but O 
elevated O 
concentrations O 
of O 
FeCl3 B-FORMULA 
are O 
corrosive O 
as O 
a O 
result O 
of O 
hydrolysis O 
to O 
HCl B-FORMULA 
. O 
Based O 
on O 
a O 
no O 
- O 
observed O 
- O 
adverse O 
effect O 
level O 
( O 
NOAEL O 
) O 
of O 
0.5% O 
FeCl3 B-FORMULA 
• I-FORMULA 
6H2O I-FORMULA 
administered O 
in O 
drinking O 
water O 
to O 
male O 
and O 
female O 
F344 O 
rats O 
for O 
up O 
to O 
2 O 
years O 
, O 
a O 
do O 
not O 
consume O 
concentration O 
of O 
200 O 
mg O 
FeCl3 B-FORMULA 
/L O 
can O 
be O 
derived O 
. O 
Since O 
instillation O 
of O 
0.3 O 
M O 
( O 
48.7 O 
g O 
/ O 
L O 
) O 
FeCl3 B-FORMULA 
in O 
saline O 
to O 
rodent O 
vagina O 
failed O 
to O 
elicit O 
damage O 
, O 
a O 
topical O 
do O 
not O 
use O 
concentration O 
of O 
2000 O 
mg O 
FeCl3 B-FORMULA 
/L O 
( O 
600 O 
mg O 
Fe B-FORMULA 
/L O 
) O 
can O 
be O 
assigned O 
. O 
The O 
only O 
FeCl3 B-FORMULA 
data O 
available O 
to O 
quantify O 
ocular O 
toxicity O 
involved O 
a O 
pH O 
1 O 
solution O 
in O 
rabbit O 
eyes O 
, O 
but O 
HCl B-FORMULA 
instillation O 
( O 
pH O 
2.5 O 
) O 
to O 
rabbit O 
eyes O 
found O 
permanent O 
corneal O 
ulceration O 
after O 
10 O 
min O 
. O 
The O 
pH O 
of O 
FeCl3 B-FORMULA 
in O 
water O 
at O 
the O 
do O 
not O 
use O 
limit O 
( O 
2.4-2.6 O 
) O 
is O 
near O 
the O 
pH O 
( O 
2 O 
) O 
considered O 
corrosive O 
by O 
regulatory O 
agencies O 
. O 
As O 
direct O 
eye O 
contact O 
with O 
water O 
at O 
pH O 
4.5 O 
or O 
below O 
increases O 
complaints O 
of O 
ocular O 
discomfort O 
, O 
emergency O 
response O 
plans O 
that O 
address O 
FeCl3 B-FORMULA 
in O 
drinking O 
water O 
must O 
account O 
for O 
Fe B-FORMULA 
levels O 
and O 
the O 
pH O 
of O 
the O 
affected O 
water O 
. O 

of O 
cadmium B-SYSTEMATIC 
and O 
protective O 
effect O 
of O 
bee O 
honey O 
, O 
vitamins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
complex O 
. O 

present O 
work O 
aimed O 
to O 
study O 
the O 
toxic O 
effect O 
of O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
on O 
rabbits O 
' O 
blood O 
indices O 
, O 
as O 
well O 
as O 
the O 
therapeutic O 
effect O 
of O 
the O 
antioxidant O 
agents O 
, O 
vitamins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
complex O 
and O 
bee O 
honey O 
on O 
Cd B-FORMULA 
intoxicated O 
rabbits O 
. O 
Cadmium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
CdCl2 B-FORMULA 
) O 
was O 
injected O 
subcutaneously O 
at O 
a O 
dose O 
of O 
3 O 
mg O 
/ O 
kg O 
of O 
body O 
weight O 
. O 
The O 
results O 
showed O 
a O 
significant O 
increase O 
in O 
serum O 
glucose B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
cholesterol B-TRIVIAL 
, O 
total O 
protein O 
, O 
albumin O 
, O 
globulin O 
, O 
urea B-TRIVIAL 
and O 
creatinine B-TRIVIAL 
, O 
compared O 
to O 
the O 
control O 
group O 
. O 
In O 
addition O 
, O 
CdCl2 B-FORMULA 
intoxication O 
increased O 
the O 
levels O 
of O 
uric B-TRIVIAL 
acid I-TRIVIAL 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
alkaline O 
phosphatase O 
and O 
bilirubin B-TRIVIAL 
. O 
Concerning O 
haematological O 
parameters O 
, O 
the O 
more O 
obvious O 
changes O 
were O 
an O 
increase O 
in O 
mean O 
corpuscular O 
volume O 
and O 
a O 
decrease O 
in O 
white O 
blood O 
cells O 
count O 
, O 
platelets O 
, O 
lymphocytes O 
, O 
heamatocrit O 
, O 
haemoglobin O 
and O 
red O 
blood O 
cells O 
count O 
. O 
Treatment O 
of O 
CdCl2 B-FORMULA 
-intoxicated O 
animals O 
with O 
vitamins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
complex O 
and O 
bee O 
honey O 
showed O 
a O 
decrease O 
in O 
the O 
harmful O 
effects O 
of O 
Cd B-FORMULA 
by O 
restoring O 
haematological O 
and O 
biochemical O 
changes O 
. O 
Bee O 
honey O 
treatment O 
was O 
the O 
most O 
effective O 
in O 
providing O 
recoveries O 
in O 
the O 
altered O 
blood O 
parameters O 
. O 

of O 
BDNF O 
gene O 
polymorphism O 
and O 
predisposition O 
to O 
dependence O 
development O 
for O 
selected O 
psychoactive O 
compounds O 
: O 
genetic O 
aspects O 
of O 
addiction O 
with O 
the O 
selected O 
drugs O 
, O 
amphetamine B-TRIVIAL 
, O 
tetrahydrocannabinol B-SYSTEMATIC 
and O 
opiates O 
. O 

etiology O 
of O 
drug O 
addiction O 
, O 
a O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
disease O 
, O 
is O 
not O 
fully O 
known O 
. O 
This O 
complex O 
problem O 
is O 
believed O 
to O 
be O 
connected O 
with O 
concurrently O 
affecting O 
genetic O 
, O 
psychological O 
and O 
environmental O 
factors O 
. O 
The O 
development O 
of O 
addiction O 
is O 
connected O 
with O 
CNS O 
reinforcement O 
system O 
and O 
dopaminergic O 
neurotransmission O 
. O 
Molecular O 
processes O 
are O 
postulated O 
to O 
be O 
of O 
universal O 
character O 
and O 
allow O 
to O 
presume O 
a O 
similar O 
mechanism O 
of O 
dependence O 
for O 
both O 
ethanol B-SYSTEMATIC 
and O 
other O 
substances O 
. O 
Therefore O 
, O 
elements O 
of O 
dopaminergic O 
transmission O 
become O 
excellent O 
candidates O 
for O 
the O 
examination O 
of O 
genetic O 
influence O 
on O 
the O 
development O 
of O 
addiction O 
. O 
A O 
relationship O 
between O 
alcoholic O 
disease O 
and O 
the O 
presence O 
of O 
TaqIA1 O 
and O 
DRD2 O 
alleles O 
permits O 
to O 
initiate O 
another O 
investigation O 
of O 
gene O 
- O 
coding O 
DRD2 O 
dopamine O 
receptor O 
. O 
The O 
latest O 
results O 
indicate O 
the O 
importance O 
of O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
in O 
the O 
regulation O 
of O 
dopaminergic O 
route O 
. O 
The O 
purpose O 
of O 
this O 
research O 
was O 
to O 
reveal O 
the O 
relationship O 
between O 
the O 
Val66Met O 
BDNF O 
gene O 
polymorphism O 
and O 
dependence O 
of O 
psychoactive O 
agent O 
. O 
The O 
examinations O 
were O 
performed O 
with O 
the O 
Local O 
Research O 
Ethics O 
Committee O 
approval O 
and O 
patient's O 
consent O 
. O 
The O 
study O 
group O 
consisted O 
of O 
100 O 
patients O 
( O 
88 O 
men O 
and O 
12 O 
women O 
) O 
aged O 
18-52 O 
years O 
, O 
qualified O 
for O 
research O 
program O 
according O 
to O 
the O 
International O 
Classification O 
of O 
Diseases O 
, O 
Tenth O 
Revision O 
( O 
ICD-10 O 
) O 
requirements O 
, O 
medical O 
examination O 
and O 
detailed O 
questionnaire O 
. O 

low O 
cytotoxic O 
elastic O 
niosomal O 
formulation O 
loaded O 
with O 
salmon O 
calcitonin O 
was O 
developed O 
. O 
The O 
elastic O 
niosomes O 
were O 
prepared O 
from O 
Tween B-TRIVIAL 
61 I-TRIVIAL 
mixed O 
with O 
cholesterol B-TRIVIAL 
at O 
various O 
concentrations O 
of O 
the O 
edge O 
activators O 
( O 
sodium B-SYSTEMATIC 
cholate I-SYSTEMATIC 
( O 
NaC B-ABBREVIATION 
) O 
and O 
sodium B-SYSTEMATIC 
deoxycholate I-SYSTEMATIC 
( O 
NaDC B-FORMULA 
) O 
; O 
0.25 O 
, O 
0.5 O 
, O 
2.5 O 
, O 
5 O 
and O 
10% O 
mole O 
) O 
or O 
ethanol B-SYSTEMATIC 
( O 
10-30% O 
v O 
/ O 
v O 
) O 
. O 
The O 
effects O 
of O 
the O 
niosomal O 
concentrations O 
( O 
5 O 
, O 
10 O 
and O 
20 O 
mM O 
) O 
and O 
phosphate B-SYSTEMATIC 
buffer O 
at O 
pH O 
7 O 
( O 
5 O 
, O 
10 O 
, O 
20 O 
and O 
30 O 
mM O 
) O 
on O 
the O 
physical O 
characteristics O 
of O 
niosomes O 
were O 
investigated O 
. O 
The O 
5 O 
mM O 
elastic O 
niosomes O 
in O 
5 O 
mM O 
phosphate B-SYSTEMATIC 
buffer O 
containing O 
calcitonin O 
0.22 O 
mg O 
/ O 
mL O 
gave O 
the O 
highest O 
elasticity O 
( O 
deformability O 
index O 
( O 
DI O 
) O 
) O 
at O 
6.79 O 
± O 
2.03 O 
determined O 
by O 
the O 
extrusion O 
method O 
. O 
The O 
blank O 
elastic O 
niosomes O 
comprised O 
2.5% O 
mole O 
NaDC B-FORMULA 
, O 
5% O 
mole O 
NaC B-ABBREVIATION 
or O 
20% O 
v O 
/ O 
v O 
ethanol B-SYSTEMATIC 
showed O 
the O 
highest O 
elasticity O 
. O 
The O 
5% O 
mole O 
NaC B-ABBREVIATION 
elastic O 
niosomes O 
loaded O 
with O 
calcitonin O 
gave O 
the O 
highest O 
DI O 
( O 
21.59 O 
± O 
0.91 O 
) O 
and O 
percentages O 
of O 
calcitonin O 
entrapment O 
efficiency O 
( O 
60.11 O 
± O 
4.98 O 
) O 
. O 
This O 
study O 
has O 
demonstrated O 
that O 
this O 
NaC B-ABBREVIATION 
elastic O 
niosome O 
did O 
not O 
only O 
reduce O 
the O 
cytotoxicity O 
of O 
the O 
loaded O 
calcitonin O 
but O 
also O 
gave O 
superior O 
cell O 
viability O 
to O 
the O 
ethanolic O 
elastic O 
niosome O 
as O 
well O 
. O 

cases O 
of O 
acute O 
dexmedetomidine B-TRIVIAL 
withdrawal O 
syndrome O 
following O 
prolonged O 
infusion O 
in O 
the O 
intensive O 
care O 
unit O 
: O 
Report O 
of O 
cases O 
and O 
review O 
of O 
the O 
literature O 
. O 

infusion O 
of O 
dexmedetomidine B-TRIVIAL 
, O 
an O 
α(2)-adrenoreceptor O 
agonist O 
anesthetic O 
used O 
in O 
the O 
intensive O 
care O 
unit O 
, O 
produces O 
a O 
withdrawal O 
syndrome O 
of O 
sympathetic O 
over O 
- O 
activity O 
, O 
characterized O 
by O 
tachycardia O 
, O 
hypertension O 
and O 
agitation O 
, O 
but O 
there O 
is O 
no O 
recommended O 
standard O 
treatment O 
for O 
this O 
syndrome O 
. O 
We O 
describe O 
two O 
patients O 
with O 
a O 
clinical O 
diagnosis O 
of O 
acute O 
dexmedetomidine B-TRIVIAL 
withdrawal O 
and O 
its O 
management O 
with O 
oral O 
clonidine B-TRIVIAL 
. O 
We O 
utilized O 
the O 
principle O 
of O 
managing O 
acute O 
drug O 
withdrawal O 
with O 
longer O 
acting O 
medications O 
. O 
These O 
two O 
cases O 
demonstrated O 
the O 
benefit O 
of O 
using O 
oral O 
, O 
longer O 
acting O 
clonidine B-TRIVIAL 
to O 
manage O 
acute O 
withdrawal O 
from O 
shorter O 
- O 
acting O 
, O 
intravenous O 
dexmedetomidine B-TRIVIAL 
. O 

of O 
hypothermia O 
on O 
the O 
disposition O 
of O 
morphine B-TRIVIAL 
, O 
midazolam B-TRIVIAL 
, O 
fentanyl B-TRIVIAL 
, O 
and O 
propofol B-TRIVIAL 
in O 
intensive O 
care O 
unit O 
patients O 
. O 

hypothermia O 
( O 
TH O 
) O 
may O 
induce O 
pharmacokinetic O 
changes O 
that O 
may O 
affect O 
the O 
level O 
of O 
sedation O 
. O 
We O 
have O 
compared O 
the O 
disposition O 
of O 
morphine B-TRIVIAL 
, O 
midazolam B-TRIVIAL 
, O 
fentanyl B-TRIVIAL 
, O 
and O 
propofol B-TRIVIAL 
in O 
TH O 
with O 
normothermia O 
in O 
man O 
. O 
Fourteen O 
patients O 
treated O 
with O 
TH O 
following O 
cardiac O 
arrest O 
( O 
33-34°C O 
) O 
were O 
compared O 
with O 
eight O 
matched O 
critically O 
ill O 
patients O 
( O 
36-38°C O 
) O 
. O 
Continuous O 
infusions O 
of O 
morphine B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
were O 
stopped O 
and O 
replaced O 
with O 
infusions O 
of O 
fentanyl B-TRIVIAL 
and O 
propofol B-TRIVIAL 
to O 
describe O 
elimination O 
and O 
start O 
of O 
infusion O 
pharmacokinetics O 
, O 
respectively O 
. O 
Serial O 
serum O 
and O 
urine O 
samples O 
were O 
collected O 
for O 
6-8 O 
hours O 
for O 
validated O 
quantification O 
and O 
subsequent O 
pharmacokinetic O 
analysis O 
. O 
During O 
TH O 
, O 
morphine B-TRIVIAL 
elimination O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
was O 
significantly O 
higher O 
, O 
while O 
total O 
clearance O 
(CL(tot)) O 
was O 
significantly O 
lower O 
( O 
median O 
[ O 
semi-interquartile O 
range O 
( O 
s-iqr O 
) O 
] O 
) O 
: O 
t(1 O 
/ O 
2 O 
) O 
, O 
266 O 
( O 
43 O 
) O 
versus O 
168 O 
( O 
11 O 
) O 
minutes O 
, O 
P O 
< O 
0.01 O 
; O 
CL(tot) O 
, O 
1201 O 
( O 
283 O 
) O 
versus O 
1687 O 
( O 
200 O 
) O 
ml O 
/ O 
min O 
, O 
P O 
< O 
0.01 O 
. O 
No O 
significant O 
differences O 
were O 
seen O 
for O 
midazolam B-TRIVIAL 
. O 
CL(tot) O 
of O 
fentanyl B-TRIVIAL 
and O 
propofol B-TRIVIAL 
was O 
significantly O 
lower O 
in O 
hypothermic O 
patients O 
[ O 
median O 
( O 
s-iqr O 
) O 
] O 
: O 
fentanyl B-TRIVIAL 
, O 
726 O 
( O 
230 O 
) O 
versus O 
1331 O 
( O 
678 O 
) O 
ml O 
/ O 
min O 
, O 
P O 
< O 
0.05 O 
; O 
propofol B-TRIVIAL 
, O 
2046 O 
( O 
305 O 
) O 
versus O 
2665 O 
( O 
223 O 
) O 
ml O 
/ O 
min O 
, O 
P O 
< O 
0.05 O 
. O 
Compared O 
with O 
the O 
matched O 
, O 
normothermic O 
intensive O 
care O 
unit O 
patients O 
, O 
t(1 O 
/ O 
2 O 
) O 
of O 
morphine B-TRIVIAL 
was O 
significantly O 
higher O 
during O 
TH O 
. O 
CL(tot) O 
was O 
lower O 
during O 
TH O 
for O 
morphine B-TRIVIAL 
, O 
fentanyl B-TRIVIAL 
, O 
and O 
propofol B-TRIVIAL 
but O 
not O 
for O 
midazolam B-TRIVIAL 
. O 
Reducing O 
the O 
infusion O 
rates O 
of O 
morphine B-TRIVIAL 
, O 
fentanyl B-TRIVIAL 
, O 
and O 
propofol B-TRIVIAL 
during O 
TH O 
is O 
encouraged O 
. O 

statistical O 
analysis O 
of O 
aromatic O 
rings O 
program O 
allows O 
for O 
an O 
automated O 
search O 
for O 
anion-π O 
interactions O 
between O 
phenylalanine B-TRIVIAL 
residues O 
and O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
moieties O 
of O 
neighboring O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
or O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
residues O 
in O 
protein O 
data O 
bank O 
( O 
PDB O 
) O 
structures O 
. O 
The O 
program O 
is O 
written O 
in O 
C O 
+ O 
+ O 
and O 
is O 
available O 
both O 
as O 
a O 
standalone O 
code O 
and O 
through O 
a O 
web O 
implementation O 
that O 
allows O 
users O 
to O 
upload O 
and O 
analyze O 
biomolecular O 
structures O 
in O 
PDB O 
format O 
. O 
The O 
program O 
outputs O 
lists O 
of O 
Phe B-FORMULA 
/ O 
Glu B-FORMULA 
or O 
Phe B-FORMULA 
/ O 
Asp B-FORMULA 
pairs O 
involved O 
in O 
potential O 
anion-π O 
interactions O 
, O 
together O 
with O 
geometrical O 
( O 
distance O 
and O 
angle O 
between O 
the O 
Phe B-FORMULA 
' O 
s O 
center O 
of O 
mass O 
and O 
Glu B-FORMULA 
or O 
Asp B-FORMULA 
' O 
s O 
center O 
of O 
charge O 
) O 
and O 
energetic O 
( O 
quantum O 
mechanical O 
Kitaura-Morokuma O 
interaction O 
energy O 
between O 
the O 
residues O 
) O 
descriptions O 
of O 
each O 
anion-π O 
interaction O 
. O 
Application O 
of O 
the O 
program O 
on O 
the O 
latest O 
content O 
of O 
the O 
PDB O 
shows O 
that O 
anion-π O 
interactions O 
are O 
present O 
in O 
thousands O 
of O 
protein O 
structures O 
and O 
can O 
possess O 
strong O 
energies O 
, O 
as O 
low O 
as O 
-8.72 O 
kcal O 
/ O 
mol O 
. O 

bromodomain O 
proteins O 
mediate O 
downstream O 
signaling O 
events O 
following O 
growth O 
factor O 
stimulation O 
in O 
human O 
lung O 
fibroblasts O 
and O 
are O 
involved O 
in O 
bleomycin B-FAMILY 
-induced O 
pulmonary O 
fibrosis O 
. O 

alterations O 
, O 
such O 
as O 
histone O 
acetylation O 
, O 
regulate O 
the O 
signaling O 
outcomes O 
and O 
phenotypic O 
responses O 
of O 
fibroblasts O 
after O 
growth O 
factor O 
stimulation O 
. O 
The O 
bromodomain O 
and O 
extra O 
- O 
terminal O 
domain O 
- O 
containing O 
proteins O 
( O 
Brd O 
) O 
bind O 
to O 
acetylated O 
histone O 
residues O 
, O 
resulting O 
in O 
recruitment O 
of O 
components O 
of O 
the O 
transcriptional O 
machinery O 
and O 
subsequent O 
gene O 
transcription O 
. O 
Given O 
the O 
central O 
importance O 
of O 
fibroblasts O 
in O 
tissue O 
fibrosis O 
, O 
this O 
study O 
sought O 
to O 
determine O 
the O 
role O 
of O 
Brd O 
proteins O 
in O 
human O 
lung O 
fibroblasts O 
( O 
LFs O 
) O 
after O 
growth O 
factor O 
stimulation O 
and O 
in O 
the O 
murine O 
bleomycin B-FAMILY 
model O 
of O 
lung O 
fibrosis O 
. O 
Using O 
small O 
interfering O 
RNA O 
against O 
human O 
Brd2 O 
and O 
Brd4 O 
and O 
pharmacologic O 
Brd O 
inhibitors O 
, O 
this O 
study O 
found O 
that O 
Brd2 O 
and O 
Brd4 O 
are O 
essential O 
in O 
mediating O 
the O 
phenotypic O 
responses O 
of O 
LFs O 
downstream O 
of O 
multiple O 
growth O 
factor O 
pathways O 
. O 
Growth O 
factor O 
stimulation O 
of O 
LFs O 
causes O 
increased O 
histone O 
acetylation O 
, O 
association O 
of O 
Brd4 O 
with O 
growth O 
factor O 
- O 
responsive O 
genes O 
, O 
and O 
enhanced O 
transcription O 
of O 
these O 
genes O 
that O 
could O 
be O 
attenuated O 
with O 
pharmacologic O 
Brd O 
inhibitors O 
. O 
Of O 
note O 
, O 
lung O 
fibrosis O 
induced O 
after O 
intratracheal O 
bleomycin B-FAMILY 
challenge O 
in O 
mice O 
could O 
be O 
prevented O 
by O 
pretreatment O 
of O 
animals O 
with O 
pharmacologic O 
inhibitors O 
of O 
Brd O 
proteins O 
. O 
This O 
study O 
is O 
the O 
first O 
demonstration O 
of O 
a O 
role O 
for O 
Brd2 O 
and O 
Brd4 O 
proteins O 
in O 
mediating O 
the O 
responses O 
of O 
LFs O 
after O 
growth O 
factor O 
stimulation O 
and O 
in O 
driving O 
the O 
induction O 
of O 
lung O 
fibrosis O 
in O 
mice O 
in O 
response O 
to O 
bleomycin B-FAMILY 
challenge O 
. O 

sulfide I-SYSTEMATIC 
as O 
an O 
allosteric O 
modulator O 
of O 
ATP B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
channels O 
in O 
colonic O 
inflammation O 
. O 

ATP B-ABBREVIATION 
-sensitive O 
potassium B-SYSTEMATIC 
channel O 
( O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
) O 
in O 
mouse O 
colonic O 
smooth O 
muscle O 
cell O 
is O 
a O 
complex O 
containing O 
a O 
pore O 
- O 
forming O 
subunit O 
( O 
Kir6.1 O 
) O 
and O 
a O 
sulfonylurea B-FAMILY 
receptor O 
subunit O 
( O 
SUR2B O 
) O 
. O 
These O 
channels O 
contribute O 
to O 
the O 
cellular O 
excitability O 
of O 
smooth O 
muscle O 
cells O 
and O 
hence O 
regulate O 
the O 
motility O 
patterns O 
in O 
the O 
colon O 
. O 
Whole O 
- O 
cell O 
voltage O 
- O 
clamp O 
techniques O 
were O 
used O 
to O 
study O 
the O 
alterations O 
in O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channels O 
in O 
smooth O 
muscle O 
cells O 
in O 
experimental O 
colitis O 
. O 
Colonic O 
inflammation O 
was O 
induced O 
in O 
BALB O 
/ O 
C O 
mice O 
after O 
intracolonic O 
administration O 
of O 
trinitrobenzene B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
currents O 
were O 
measured O 
at O 
a O 
holding O 
potential O 
of O 
-60 O 
mV O 
in O 
high O 
K(+) B-FORMULA 
external O 
solution O 
. O 
The O 
concentration O 
response O 
to O 
levcromakalim B-TRIVIAL 
( O 
LEVC B-ABBREVIATION 
) O 
, O 
a O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
channel O 
opener O 
, O 
was O 
significantly O 
shifted O 
to O 
the O 
left O 
in O 
the O 
inflamed O 
smooth O 
- O 
muscle O 
cells O 
. O 
Both O 
the O 
potency O 
and O 
maximal O 
currents O 
induced O 
by O 
LEVC B-ABBREVIATION 
were O 
enhanced O 
in O 
inflammation O 
. O 
The O 
EC(50) O 
values O 
in O 
control O 
were O 
6259 O 
nM O 
( O 
n O 
= O 
10 O 
) O 
and O 
422 O 
nM O 
( O 
n O 
= O 
8 O 
) O 
in O 
inflamed O 
colon O 
, O 
and O 
the O 
maximal O 
currents O 
were O 
9.9 O 
± O 
0.71 O 
pA O 
/ O 
pF O 
( O 
60 O 
μM O 
) O 
in O 
control O 
and O 
39.7 O 
± O 
8.8 O 
pA O 
/ O 
pF O 
( O 
3 O 
μM O 
) O 
after O 
inflammation O 
. O 
As O 
was O 
seen O 
with O 
LEVC B-ABBREVIATION 
, O 
the O 
potency O 
and O 
efficacy O 
of O 
sodium B-SYSTEMATIC 
hydrogen I-SYSTEMATIC 
sulfide I-SYSTEMATIC 
( O 
NaHS B-FORMULA 
) O 
( O 
10-1000 O 
μM O 
) O 
on O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
currents O 
were O 
significantly O 
greater O 
in O 
inflamed O 
colon O 
compared O 
with O 
controls O 
. O 
In O 
control O 
cells O 
, O 
pretreatment O 
with O 
100 O 
µM O 
NaHS B-FORMULA 
shifted O 
the O 
EC(50) O 
for O 
LEV-induced O 
currents O 
from O 
2838 O 
( O 
n O 
= O 
6 O 
) O 
to O 
154 O 
( O 
n O 
= O 
8 O 
) O 
nM O 
. O 
Sulfhydration O 
of O 
sulfonylurea B-FAMILY 
receptor O 
2B O 
( O 
SUR2B O 
) O 
was O 
induced O 
by O 
NaHS B-FORMULA 
and O 
colonic O 
inflammation O 
. O 
These O 
data O 
suggest O 
that O 
sulfhydration O 
of O 
SUR2B O 
induces O 
allosteric O 
modulation O 
of O 
K B-FORMULA 
( O 
ATP B-ABBREVIATION 
) O 
currents O 
in O 
colonic O 
inflammation O 
. O 

acid I-TRIVIAL 
ameliorates O 
acute O 
liver O 
damage O 
and O 
fibrogenesis O 
in O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-intoxicated O 
mice O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
therapeutic O 
potential O 
of O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
, O 
a O 
natural O 
phenolic O 
, O 
in O 
the O 
treatment O 
of O 
acute O 
liver O 
toxicity O 
. O 
RA O 
at O 
10 O 
, O 
25 O 
and O 
50mg O 
/ O 
kg O 
was O 
administered O 
by O 
gavage O 
once O 
daily O 
for O 
2 O 
consecutive O 
days O 
, O 
6h O 
after O 
CCl(4) B-FORMULA 
intoxication O 
. O 
CCl(4) B-FORMULA 
intoxication O 
caused O 
hepatic O 
necrosis O 
and O 
increased O 
serum O 
ALT O 
activity O 
. O 
In O 
the O 
livers O 
, O 
oxidative O 
/ O 
nitrosative O 
stress O 
was O 
evidenced O 
by O 
increased O 
3-nitrotyrosine B-SYSTEMATIC 
( O 
3-NT B-SYSTEMATIC 
) O 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
( O 
TBARS O 
) O 
formation O 
and O 
a O 
significant O 
decrease O 
in O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
. O 
CCl(4) B-FORMULA 
administration O 
triggered O 
inflammatory O 
response O 
in O 
mice O 
livers O 
by O 
activating O 
nuclear O 
factor-kappaB O 
( O 
NF-κB O 
) O 
, O 
which O 
coincided O 
with O 
the O 
induction O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
. O 
RA O 
improved O 
histological O 
and O 
serum O 
markers O 
of O 
liver O 
damage O 
and O 
significantly O 
ameliorated O 
oxidative O 
/ O 
nitrosative O 
stress O 
and O 
inflammatory O 
response O 
in O 
liver O 
tissue O 
. O 
Additionally O 
, O 
RA O 
prevented O 
transforming O 
growth O 
factor-beta1 O 
( O 
TGF-β1 O 
) O 
and O 
alpha-smooth O 
muscle O 
actin O 
( O 
α-SMA O 
) O 
expression O 
, O 
suggesting O 
suppression O 
of O 
profibrotic O 
response O 
. O 
Furthermore O 
, O 
RA O 
significantly O 
inhibited O 
the O 
CCl(4) B-FORMULA 
-induced O 
apoptosis O 
, O 
which O 
was O 
evident O 
from O 
decreased O 
cleavage O 
of O 
caspase-3 O 
. O 
The O 
hepatoprotective O 
activity O 
of O 
RA O 
coincided O 
with O 
enhanced O 
NF-E2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
and O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
expression O 
. O 
The O 
results O 
of O 
this O 
study O 
indicates O 
that O 
RA O 
possesses O 
antioxidant O 
, O 
anti-inflammatory O 
, O 
antiapoptotic O 
and O 
antifibrotic O 
activity O 
against O 
acute O 
liver O 
toxicity O 
. O 

suppresses O 
postischemic O 
glucose B-TRIVIAL 
intolerance O 
and O 
neuronal O 
damage O 
through O 
hypothalamic O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
. O 

( O 
a O 
glucose B-TRIVIAL 
-sensing O 
neuropeptide O 
in O 
the O 
hypothalamus O 
) O 
and O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
; O 
a O 
member O 
of O 
the O 
neurotrophin O 
family O 
) O 
play O 
roles O 
in O 
many O 
physiologic O 
functions O 
, O 
including O 
regulation O 
of O 
glucose B-TRIVIAL 
metabolism O 
. O 
We O 
previously O 
showed O 
that O 
the O 
development O 
of O 
postischemic O 
glucose B-TRIVIAL 
intolerance O 
is O 
one O 
of O 
the O 
triggers O 
of O 
ischemic O 
neuronal O 
damage O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
there O 
was O 
an O 
interaction O 
between O 
orexin-A O 
and O 
BDNF O 
functions O 
in O 
the O 
hypothalamus O 
after O 
cerebral O 
ischemic O 
stress O 
. O 
Male O 
ddY O 
mice O 
were O 
subjected O 
to O 
2 O 
hours O 
of O 
middle O 
cerebral O 
artery O 
occlusion O 
( O 
MCAO O 
) O 
. O 
Neuronal O 
damage O 
was O 
estimated O 
by O 
histologic O 
and O 
behavioral O 
analyses O 
. O 
Expression O 
of O 
protein O 
levels O 
was O 
analyzed O 
by O 
Western O 
blot O 
. O 
Small O 
interfering O 
RNA O 
directed O 
BDNF O 
, O 
orexin-A O 
, O 
and O 
SB334867 B-IDENTIFIER 
[ O 
N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl B-SYSTEMATIC 
urea I-SYSTEMATIC 
; O 
a O 
specific O 
orexin-1 O 
receptor O 
antagonist O 
] O 
were O 
administered O 
directly O 
into O 
the O 
hypothalamus O 
. O 
The O 
level O 
of O 
hypothalamic O 
orexin-A O 
, O 
detected O 
by O 
immunohistochemistry O 
, O 
was O 
decreased O 
on O 
day O 
1 O 
after O 
MCAO O 
. O 
Intrahypothalamic O 
administration O 
of O 
orexin-A O 
( O 
1 O 
or O 
5 O 
pmol O 
/ O 
mouse O 
) O 
significantly O 
and O 
dose O 
- O 
dependently O 
suppressed O 
the O 
development O 
of O 
postischemic O 
glucose B-TRIVIAL 
intolerance O 
on O 
day O 
1 O 
and O 
development O 
of O 
neuronal O 
damage O 
on O 
day O 
3 O 
. O 
The O 
MCAO-induced O 
decrease O 
in O 
insulin O 
receptor O 
levels O 
in O 
the O 
liver O 
and O 
skeletal O 
muscle O 
on O 
day O 
1 O 
was O 
recovered O 
to O 
control O 
levels O 
by O 
orexin-A O 
, O 
and O 
this O 
effect O 
of O 
orexin-A O 
was O 
reversed O 
by O 
the O 
administration O 
of O 
SB334867 B-IDENTIFIER 
as O 
well O 
as O 
by O 
hypothalamic O 
BDNF O 
knockdown O 
. O 
These O 
results O 
suggest O 
that O 
suppression O 
of O 
postischemic O 
glucose B-TRIVIAL 
intolerance O 
by O 
orexin-A O 
assists O 
in O 
the O 
prevention O 
of O 
cerebral O 
ischemic O 
neuronal O 
damage O 
. O 
In O 
addition O 
, O 
hypothalamic O 
BDNF O 
may O 
play O 
an O 
important O 
role O 
in O 
this O 
effect O 
of O 
orexin-A O 
. O 

of O 
5-hydroxytryptamine B-SYSTEMATIC 
1B O 
( O 
5-HT1B O 
) O 
receptors O 
in O 
the O 
regulation O 
of O 
ethanol B-SYSTEMATIC 
intake O 
in O 
rodents O 
. O 

indicates O 
that O 
the O 
serotonergic O 
system O 
is O 
important O 
in O 
mediating O 
dependence O 
on O 
and O 
craving O 
for O 
alcohol B-FAMILY 
. O 
Among O 
serotonin B-TRIVIAL 
receptors O 
, O 
5-hydroxytryptamine B-SYSTEMATIC 
1B O 
( O 
5-HT1B O 
) O 
receptors O 
have O 
been O 
associated O 
with O 
drug O 
abuse O 
including O 
alcohol B-FAMILY 
. O 
In O 
this O 
review O 
, O 
the O 
neurocircuitry O 
involving O 
5-HT1B O 
receptors O 
in O 
central O 
reward O 
brain O 
regions O 
related O 
to O 
alcohol B-FAMILY 
intake O 
are O 
discussed O 
in O 
detail O 
. O 
Emphasis O 
has O 
been O 
placed O 
on O 
the O 
pharmacological O 
manipulations O 
of O 
5-HT1B O 
receptor O 
- O 
mediated O 
alcohol B-FAMILY 
intake O 
. O 
Furthermore O 
, O 
5-HT1B O 
auto- O 
and O 
hetero O 
- O 
receptors O 
regulate O 
alcohol B-FAMILY 
intake O 
through O 
the O 
regulatory O 
mechanism O 
involving O 
release O 
of O 
5-HT B-SYSTEMATIC 
, O 
gamma-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
, O 
dopamine B-TRIVIAL 
, O 
and O 
glutamate B-TRIVIAL 
is O 
evaluated O 
. O 
Thus O 
, O 
interactions O 
between O 
5-HT1B O 
receptors O 
and O 
these O 
neurotransmitter O 
systems O 
are O 
suggested O 
to O 
modulate O 
alcohol B-FAMILY 
-drinking O 
behavior O 
. O 
This O 
review O 
on O 
the O 
role O 
of O 
5-HT1B O 
receptors O 
in O 
neurotransmitter O 
release O 
and O 
consequent O 
alcohol B-FAMILY 
intake O 
provides O 
important O 
information O 
about O 
the O 
potential O 
therapeutic O 
role O 
of O 
5-HT1B O 
receptors O 
for O 
the O 
treatment O 
of O 
alcohol B-FAMILY 
dependence O 
. O 

vivo O 
and O 
in O 
vitro O 
characterization O 
of O 
naltrindole B-TRIVIAL 
-derived O 
ligands O 
at O 
the O 
κ-opioid O 
receptor O 
. O 

evidence O 
supports O 
a O 
role O 
for O 
κ-opioid O 
receptor O 
antagonists O 
in O 
the O 
treatment O 
of O 
mood O 
disorders O 
. O 
Standard O 
κ-antagonists O 
have O 
an O 
unusual O 
pharmacodynamic O 
action O 
, O 
with O 
a O 
single O 
injection O 
blocking O 
receptor O 
signaling O 
for O 
several O 
weeks O 
. O 
Here O 
, O 
we O 
have O 
characterized O 
the O 
κ-selective O 
properties O 
of O 
two O 
ligands O 
, O 
5'-(2-aminomethyl) B-SYSTEMATIC 
naltrindole I-SYSTEMATIC 
( O 
5'-AMN B-FORMULA 
) O 
and O 
N-((Naltrindol-5-yl) B-SYSTEMATIC 
methyl I-SYSTEMATIC 
) I-SYSTEMATIC 
pentanimidamide I-SYSTEMATIC 
( O 
5'-MABN B-FORMULA 
) O 
, O 
to O 
identify O 
whether O 
modifications O 
of O 
the O 
naltrindole B-TRIVIAL 
side O 
chain O 
produces O 
short O 
- O 
acting O 
κ-antagonists O 
. O 
Opioid O 
receptor O 
binding O 
affinity O 
and O 
activity O 
were O 
assessed O 
using O 
[(3)H]-diprenorphine B-SYSTEMATIC 
binding O 
, O 
guanosine-5'-O-(3-[35S]-thio) B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
[(35)S]-GTPγS B-SYSTEMATIC 
) O 
binding O 
and O 
isolated O 
guinea O 
- O 
pig O 
ileum O 
. O 
Pharmacodynamic O 
profiles O 
of O 
5'-AMN B-FORMULA 
and O 
5'-MABN B-FORMULA 
( O 
1-10 O 
mg O 
/ O 
kg O 
) O 
were O 
investigated O 
using O 
the O 
tail O 
- O 
withdrawal O 
assay O 
and O 
diuresis O 
. O 
Efficacy O 
was O 
also O 
determined O 
in O 
depression- O 
and O 
anxiety O 
- O 
related O 
behavioral O 
paradigms O 
in O 
CD-1 O 
mice O 
. O 
Both O 
5'-AMN B-FORMULA 
and O 
5'-MABN B-FORMULA 
had O 
high O 
affinity O 
for O 
κ-receptors O 
( O 
K O 
(i) O 
1.36 O 
± O 
0.98 O 
and O 
0.27 O 
± O 
0.08 O 
, O 
respectively O 
) O 
and O 
were O 
revealed O 
as O 
potent O 
κ-antagonists O 
( O 
pA(2) O 
7.43 O 
and O 
8.18 O 
, O 
respectively O 
) O 
and O 
μ-receptor O 
antagonists O 
( O 
pA(2) O 
7.62 O 
and O 
7.85 O 
, O 
respectively O 
) O 
in O 
the O 
ileum O 
. O 
Contrary O 
to O 
our O 
hypothesis O 
, O 
in O 
vivo O 
, O 
5'-AMN B-FORMULA 
and O 
5'-MABN B-FORMULA 
displayed O 
long O 
- O 
lasting O 
antagonist O 
effects O 
in O 
mice O 
, O 
reducing O 
the O 
antinociceptive O 
actions O 
of O 
U50,488 B-IDENTIFIER 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
at O 
28 O 
and O 
21 O 
days O 
post O 
- O 
injection O 
, O 
respectively O 
. O 
Interestingly O 
, O 
while O 
5'-AMN B-FORMULA 
and O 
5'-MABN B-FORMULA 
were O 
not O 
κ-selective O 
, O 
both O 
compounds O 
did O 
show O 
significant O 
antidepressant- O 
and O 
anxiolytic O 
- O 
like O 
effects O 
at O 
7-14 O 
days O 
post O 
- O 
injection O 
in O 
mice O 
. O 

essential O 
anion O 
exchanger O 
( O 
AE O 
) O 
involved O 
in O 
bicarbonate B-SYSTEMATIC 
secretion O 
is O 
AE2 O 
/ O 
SLC4A2 O 
, O 
a O 
membrane O 
protein O 
recognized O 
to O 
be O 
relevant O 
for O 
the O 
regulation O 
of O 
the O 
intracellular O 
pH O 
in O 
several O 
cell O 
types O 
. O 
Here O 
we O 
report O 
that O 
gastrin O 
, O 
a O 
major O 
gastrointestinal O 
hormone O 
, O 
upregulates O 
the O 
expression O 
of O 
AE2 O 
mRNA O 
and O 
protein O 
in O 
a O 
cholecystokinin O 
B O 
receptor O 
dependent O 
manner O 
in O 
gastric O 
cancer O 
cells O 
. O 
The O 
upregulated O 
species O 
of O 
AE2 O 
mRNA O 
originates O 
from O 
the O 
classical O 
upstream O 
promoter O 
of O 
the O 
AE2 O 
gene O 
( O 
here O 
referred O 
to O 
as O 
AE2a1 O 
) O 
which O 
provides O 
the O 
binding O 
site O 
for O 
transcription O 
factors O 
early O 
growth O 
response O 
1 O 
( O 
EGR1 O 
) O 
and O 
SP1 O 
. O 
EGR1 O 
upregulated O 
the O 
AE2 O 
expression O 
that O 
can O 
be O 
competitively O 
inhibited O 
by O 
SP1 O 
in O 
co O 
- O 
transfection O 
experiments O 
. O 
This O 
competitive O 
inhibition O 
was O 
avoided O 
in O 
cells O 
because O 
the O 
SP1 O 
expression O 
was O 
time O 
- O 
staggered O 
to O 
EGR1 O 
in O 
response O 
to O 
gastrin O 
. O 
Overexpression O 
or O 
knockdown O 
of O 
EGR1 O 
consistently O 
increased O 
or O 
decreased O 
the O 
expression O 
of O 
AE2 O 
. O 
Our O 
data O 
linked O 
a O 
novel O 
signal O 
pathway O 
involved O 
in O 
gastrin O 
- O 
stimulated O 
AE2 O 
expression O 
. O 

and O 
evaluation O 
of O 
a O 
series O 
of O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
as O 
potential O 
antinarcotic O 
agents O 
. O 

series O 
of O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
was O 
prepared O 
and O 
evaluated O 
for O 
antinarcotic O 
effects O 
on O 
morphine B-TRIVIAL 
dependence O 
in O 
mice O 
and O 
binding O 
affinities O 
on O 
serotonergic O 
receptors O 
. O 
The O 
key O 
synthetic O 
strategies O 
involve O 
generation O 
of O 
ketones B-FAMILY 
6-7 O 
, O 
esters B-FAMILY 
9-12 O 
through O 
condensation O 
reaction O 
, O 
and O 
amides B-FAMILY 
13-19 O 
via O 
coupling O 
reaction O 
using O 
1-hydroxybenzotriazole B-SYSTEMATIC 
/ O 
ethyl(dimethylaminopropryl)carbodiimide B-SYSTEMATIC 
system O 
in O 
high O 
yield O 
. O 
We O 
found O 
that O 
the O 
naloxone B-TRIVIAL 
-induced O 
morphine B-TRIVIAL 
withdrawal O 
syndrome O 
was O 
significantly O 
suppressed O 
by O 
new O 
synthetic O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
( O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
. O 
Most O 
of O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
were O 
found O 
to O 
have O 
high O 
affinity O 
to O 
5-HT(1A) O 
receptor O 
. O 
The O 
naloxone B-TRIVIAL 
-induced O 
morphine B-TRIVIAL 
withdrawal O 
syndrome O 
was O 
attenuated O 
by O 
(+)8-OH-DPAT B-SYSTEMATIC 
( O 
0.1 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
i.p O 
. O 
) O 
, O 
a O 
5-HT(1A) O 
receptor O 
agonist O 
. O 
In O 
cortical O 
neuronal O 
cells O 
, O 
(+)8-OH-DPA B-SYSTEMATIC 
T O 
( O 
1 O 
μM O 
) O 
produced O 
an O 
elevation O 
of O 
the O 
pERK O 
1 O 
/ O 
2 O 
expression O 
, O 
and O 
the O 
elevated O 
pERK O 
levels O 
were O 
inhibited O 
by O 
WAY B-IDENTIFIER 
10063 I-IDENTIFIER 
5 O 
, O 
a O 
5-HT(1A) O 
receptor O 
- O 
specific O 
antagonist O 
. O 
Interestingly O 
, O 
the O 
pERK O 
levels O 
were O 
increased O 
by O 
the O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
aci I-SYSTEMATIC 
d O 
derivatives O 
and O 
the O 
derivatives O 
- O 
mediated O 
changes O 
in O 
pERK O 
levels O 
were O 
blocked O 
by O 
the O 
WAY B-IDENTIFIER 
10063 I-IDENTIFIER 
5 O 
. O 
These O 
results O 
suggested O 
that O 
new O 
synthetic O 
3,4,5-trimethoxycinnamic B-SYSTEMATIC 
aci I-SYSTEMATIC 
d O 
derivatives O 
have O 
a O 
potential O 
antinarcotic O 
effect O 
through O 
acting O 
as O 
a O 
5-HT(1A) O 
receptor O 
agonist O 
in O 
mice O 
. O 

novel O 
mechanism O 
for O 
the O 
promotion O 
of O 
quercetin B-FAMILY 
glycoside I-FAMILY 
absorption O 
by O 
megalo O 
α-1,6-glucosaccharide O 
in O 
the O 
rat O 
small O 
intestine O 
. O 

presence O 
of O 
an O 
α-1,6-glucosaccharide O 
enhances O 
absorption O 
of O 
water O 
- O 
soluble O 
quercetin B-FAMILY 
glycosides I-FAMILY 
, O 
a O 
mixture O 
of O 
quercetin-3-O-β-d-glucoside B-SYSTEMATIC 
( O 
Q3G B-SYSTEMATIC 
, O 
31.8% O 
) O 
, O 
mono O 
( O 
23.3% O 
) O 
, O 
di O 
( O 
20.3% O 
) O 
and O 
more O 
d-glucose B-TRIVIAL 
adducts O 
with O 
α-1,4-linkage O 
to O 
a O 
d-glucose B-TRIVIAL 
moiety O 
of O 
Q3G B-SYSTEMATIC 
, O 
in O 
a O 
ligated O 
small O 
intestinal O 
loop O 
of O 
anesthetized O 
rats O 
. O 
We O 
prepared O 
α-1,6-glucosaccharides O 
with O 
different O 
degrees O 
of O 
polymerization O 
( O 
DP O 
) O 
enzymatically O 
and O 
separated O 
them O 
into O 
a O 
megalo O 
- O 
isomaltosaccharide O 
- O 
containing O 
fraction O 
( O 
M-IM O 
, O 
average O 
DP=11.0 O 
) O 
and O 
an O 
oligo O 
- O 
isomaltosaccharide O 
- O 
containing O 
fraction O 
( O 
O-IM O 
, O 
average O 
DP=3.6 O 
) O 
. O 
Luminal O 
injection O 
of O 
either O 
saccharide B-FAMILY 
fraction O 
promoted O 
the O 
absorption O 
of O 
total O 
quercetin B-TRIVIAL 
-derivatives O 
from O 
the O 
small O 
intestinal O 
segment O 
and O 
this O 
effect O 
was O 
greater O 
for O 
M-IM O 
than O 
O-IM O 
addition O 
. O 
M-IM O 
also O 
increased O 
Q3G B-SYSTEMATIC 
, O 
but O 
not O 
the O 
quercetin B-TRIVIAL 
aglycone O 
, O 
concentration O 
in O 
the O 
water O 
- O 
phase O 
of O 
the O 
luminal O 
contents O 
more O 
strongly O 
than O 
O-IM O 
. O 
The O 
enhancement O 
of O 
Q3G B-SYSTEMATIC 
solubilization O 
in O 
the O 
luminal O 
contents O 
may O 
be O 
responsible O 
for O 
the O 
increases O 
in O 
the O 
quercetin B-TRIVIAL 
glucoside I-TRIVIAL 
absorption O 
promoted O 
by O 
α-1,6-glucosaccharides O 
, O 
especially O 
that O 
by O 
M-IM O 
. O 
These O 
results O 
suggest O 
that O 
the O 
ingestion O 
of O 
α-1,6-glucosaccharides O 
promotes O 
Q3G B-SYSTEMATIC 
bioavailability O 
. O 

bioassay O 
- O 
guided O 
fractionation O 
of O 
an O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Buthus O 
martensi O 
Karsch O 
led O 
to O 
the O 
isolation O 
of O 
a O 
potent O 
α-glucosidase O 
inhibitor O 
( O 
compound O 
S O 
) O 
. O 
The O 
structure O 
was O 
elucidated O 
as O 
a O 
novel O 
β-carboline B-TRIVIAL 
glucoalkaloid B-FAMILY 
, O 
harmanyl B-TRIVIAL 
β-d-glucopyranoside I-TRIVIAL 
, O 
on O 
the O 
basis O 
of O 
spectral O 
data O 
, O 
including O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
NOESY O 
, O 
and O 
HMBC O 
. O 
Compound O 
S O 
showed O 
potent O 
inhibitory O 
activity O 
against O 
α-glucosidase O 
, O 
with O 
an O 
IC(50) O 
value O 
of O 
24 O 
μM O 
. O 
A O 
Lineweaver-Burk O 
plot O 
indicated O 
that O 
its O 
inhibition O 
of O 
α-glucosidase O 
was O 
uncompetitive O 
, O 
with O 
a O 
Ki O 
value O 
of O 
16.1 O 
μM O 
. O 

examined O 
the O 
thermal O 
stability O 
of O 
yeast O 
hydrolysates O 
before O 
and O 
after O 
ultrafiltration O 
( O 
UF O 
) O 
in O 
vitro O 
, O 
and O 
the O 
anti-obesity O 
activity O 
of O 
yeast O 
hydrolysates O 
before O 
and O 
after O 
heat O 
treatment O 
in O 
vivo O 
. O 
Yeast O 
hydrolysate O 
after O 
UF O 
showed O 
significantly O 
higher O 
thermal O 
stability O 
than O 
before O 
UF O 
. O 
Yeast O 
hydrolysates O 
before O 
and O 
after O 
UF O 
showed O 
3 O 
and O 
4 O 
thermal O 
transition O 
peaks O 
in O 
their O 
thermograms O 
, O 
respectively O 
, O 
and O 
the O 
total O 
thermal O 
denaturation O 
enthalpies O 
of O 
yeast O 
hydrolysates O 
before O 
and O 
after O 
UF O 
were O 
69.5 O 
and O 
36.5 O 
J O 
/ O 
g O 
, O 
respectively O 
. O 
For O 
the O 
anti-obesity O 
activity O 
study O 
, O 
yeast O 
hydrolysates O 
before O 
and O 
after O 
heating O 
were O 
administered O 
ad O 
libitum O 
with O 
water O 
to O 
7-week- O 
old O 
male O 
SD O 
rats O 
. O 
The O 
administration O 
of O 
yeast O 
hydrolysate O 
( O 
YH-control O 
; O 
no O 
heat O 
treatment O 
, O 
YH-1 O 
; O 
heat O 
treatment O 
at O 
140°C O 
, O 
and O 
YH-2 O 
; O 
heat O 
treatment O 
at O 
160°C O 
) O 
significantly O 
increased O 
mRNA O 
expression O 
of O 
cocaine B-TRIVIAL 
- O 
and O 
amphetamine B-TRIVIAL 
-regulated O 
transcript O 
( O 
CART O 
) O 
compared O 
with O 
control O 
rats O 
( O 
saline O 
administration O 
) O 
. O 
However O 
, O 
there O 
was O 
no O 
significant O 
difference O 
between O 
the O 
heat O 
- O 
treated O 
groups O 
and O 
YH-control O 
and O 
there O 
was O 
no O 
significant O 
difference O 
in O 
neuropeptide O 
Y O 
expression O 
between O 
the O 
heat O 
- O 
treated O 
groups O 
and O 
YH-control O 
. O 
These O 
results O 
suggest O 
that O 
yeast O 
hydrolysate O 
can O 
be O 
use O 
an O 
anti-obesity O 
material O 
after O 
heat O 
treatment O 
. O 

explore O 
the O 
hypocholesterolaemic O 
components O 
in O 
the O 
fat O 
fraction O 
of O 
freshwater O 
clam O 
extract O 
( O 
FCE O 
) O 
, O 
we O 
further O 
fractionated O 
the O 
fat O 
fraction O 
by O 
silica B-TRIVIAL 
gel I-TRIVIAL 
column O 
chromatography O 
into O 
nine O 
fat O 
subfractions O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
used O 
exogenous O 
hypercholesterolaemic O 
rats O 
induced O 
by O 
feeding O 
a O 
high- O 
cholesterol B-TRIVIAL 
diet O 
; O 
the O 
doses O 
of O 
the O 
added O 
fat O 
subfractions O 
were O 
equivalent O 
to O 
those O 
in O 
30% O 
FCE O 
. O 
Two O 
( O 
FF1 O 
, O 
FF2 O 
) O 
out O 
of O 
the O 
nine O 
fat O 
subfractions O 
strongly O 
reduced O 
serum O 
cholesterol B-TRIVIAL 
levels O 
in O 
the O 
rats O 
fed O 
a O 
high- O 
cholesterol B-TRIVIAL 
diet O 
. O 
Both O 
FF1 O 
and O 
FF2 O 
up O 
- O 
regulated O 
the O 
hepatic O 
gene O 
expression O 
of O 
cholesterol B-TRIVIAL 
7α-hydroxylase O 
, O 
a O 
rate O 
- O 
limiting O 
enzyme O 
of O 
bile B-FAMILY 
acid I-FAMILY 
biosynthesis O 
. O 
Thin O 
- O 
layer O 
chromatography O 
showed O 
that O 
FF1 O 
primarily O 
contained O 
sphingolipids B-FAMILY 
, O 
while O 
FF2 O 
mainly O 
contained O 
triacylglycerols B-FAMILY 
and O 
sterol B-FAMILY 
esters I-FAMILY 
. O 
These O 
results O 
indicate O 
that O 
fractions O 
containing O 
sphingolipids B-FAMILY 
, O 
triacylglycerols B-FAMILY 
, O 
and O 
sterol B-FAMILY 
esters I-FAMILY 
are O 
possibly O 
responsible O 
for O 
the O 
hypocholesterolaemic O 
action O 
in O 
a O 
novel O 
manner O 
through O 
the O 
up O 
- O 
regulation O 
of O 
the O 
hepatic O 
biosynthesis O 
of O 
bile O 
acids O 
. O 

and O 
purification O 
of O 
sulforaphene B-TRIVIAL 
from O 
radish O 
seeds O 
using O 
macroporous O 
resin O 
and O 
preparative O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 

present O 
study O 
described O 
a O 
rapid O 
and O 
cost O 
- O 
effective O 
method O 
for O 
the O 
separation O 
and O 
purification O 
of O 
natural O 
sulforaphene B-TRIVIAL 
from O 
radish O 
seeds O 
by O 
SP-700 O 
macroporous O 
resin O 
and O 
preparative O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
. O 
Sulforaphene B-TRIVIAL 
with O 
high O 
purity O 
and O 
recovery O 
was O 
obtained O 
by O 
preparative O 
HPLC O 
with O 
a O 
C18 O 
column O 
and O 
30% O 
methanol B-SYSTEMATIC 
in O 
ultra O 
- O 
pure O 
water O 
as O 
the O 
mobile O 
phase O 
. O 
12.5 O 
kg O 
of O 
radish O 
seeds O 
, O 
which O 
contained O 
87.5 O 
g O 
of O 
sulforaphene B-TRIVIAL 
, O 
produced O 
117.5 O 
g O 
of O 
sulforaphene B-TRIVIAL 
-rich O 
extract O 
of O 
65.8% O 
sulforaphene B-TRIVIAL 
after O 
primary O 
separation O 
by O 
SP-700 O 
macroporous O 
resin O 
. O 
5.9 O 
g O 
of O 
96.5% O 
sulforaphene B-TRIVIAL 
was O 
obtained O 
from O 
9.5 O 
g O 
of O 
the O 
sulforaphene B-TRIVIAL 
-rich O 
extract O 
after O 
purification O 
by O 
preparative O 
HPLC O 
. O 
The O 
purified O 
compound O 
was O 
assessed O 
by O 
analytical O 
HPLC O 
and O 
characterised O 
by O 
ESI O 
/ O 
MS O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
(13)C B-FORMULA 
NMR O 
. O 
Standard O 
curve O 
was O 
developed O 
using O 
the O 
purified O 
sulforaphene B-TRIVIAL 
to O 
allow O 
quantification O 
of O 
sulforaphene B-TRIVIAL 
in O 
the O 
extracts O 
of O 
radish O 
seeds O 
by O 
analytical O 
HPLC O 
. O 

biocontrol O 
effects O 
of O 
Bacillus O 
cereus O 
AR156 O 
on O 
Rhizopus O 
rot O 
caused O 
by O 
Rhizopus O 
stolonifer O 
in O 
postharvest O 
peach O 
fruit O 
and O 
the O 
possible O 
mechanisms O 
were O 
investigated O 
. O 
The O 
results O 
showed O 
that O 
fruit O 
treated O 
with O 
B O 
. O 
cereus O 
AR156 O 
had O 
significantly O 
lower O 
disease O 
incidence O 
and O 
smaller O 
lesion O 
diameter O 
than O 
the O 
control O 
fruit O 
did O 
. O 
B O 
. O 
cereus O 
AR156 O 
treatment O 
remarkably O 
enhanced O 
activities O 
of O 
chitinase O 
and O 
β-1,3-glucanase O 
, O 
promoted O 
accumulation O 
of O 
H(2)O(2) B-FORMULA 
, O 
and O 
improved O 
total O 
phenolic O 
content O 
and O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
radical O 
- O 
scavenging O 
activity O 
. O 
Transcripts O 
of O 
four O 
defense O 
related O 
genes O 
were O 
only O 
significantly O 
enhanced O 
in O 
fruit O 
both O 
treated O 
with O 
B O 
. O 
cereus O 
AR156 O 
and O 
inoculated O 
with O 
R O 
. O 
stolonifer O 
compared O 
with O 
those O 
that O 
were O 
only O 
treated O 
with O 
B O 
. O 
cereus O 
AR156 O 
or O 
inoculated O 
with O 
R O 
. O 
stolonifer O 
. O 
These O 
results O 
suggest O 
that O 
B O 
. O 
cereus O 
AR156 O 
can O 
effectively O 
inhibit O 
Rhizopus O 
rot O 
caused O 
by O 
R O 
. O 
stolonifer O 
and O 
enhance O 
antioxidant O 
activity O 
in O 
peach O 
fruit O 
through O 
the O 
priming O 
of O 
defense O 
responses O 
. O 

against O 
diacylglycerol B-FAMILY 
ethers I-FAMILY 
in O 
lipase O 
- O 
catalysed O 
ethanolysis O 
of O 
shark O 
liver O 
oil O 
. O 

- O 
catalysed O 
ethanolysis O 
of O 
squalene B-TRIVIAL 
-free O 
shark O 
liver O 
oil O 
was O 
investigated O 
. O 
The O 
mentioned O 
shark O 
liver O 
oil O 
was O 
comprised O 
mainly O 
of O 
diacylglycerol B-FAMILY 
ether I-FAMILY 
and O 
triacylglycerols B-FAMILY 
. O 
In O 
order O 
to O 
test O 
discrimination O 
against O 
diacylglycerol B-FAMILY 
ether I-FAMILY 
, O 
up O 
to O 
10 O 
different O 
lipases O 
were O 
compared O 
. O 
The O 
ratio O 
of O 
oil O 
to O 
ethanol B-SYSTEMATIC 
and O 
lipase O 
stability O 
were O 
also O 
evaluated O 
. O 
Surprisingly O 
, O 
lipase O 
from O 
Pseudomonas O 
stutzeri O 
was O 
the O 
fastest O 
biocatalyst O 
among O 
all O 
assayed O 
, O 
although O 
poor O 
discrimination O 
against O 
diacylglycerol B-FAMILY 
ether I-FAMILY 
was O 
observed O 
. O 
The O 
best O 
results O 
in O 
terms O 
of O 
selectivity O 
and O 
stability O 
were O 
obtained O 
with O 
immobilised O 
lipase O 
from O 
Candida O 
antarctica O 
( O 
Novozym O 
435 O 
) O 
. O 
Ethanolysis O 
reaction O 
after O 
24h O 
in O 
the O 
presence O 
of O 
Novozym O 
435 O 
produced O 
total O 
disappearance O 
of O 
triacylglycerol B-FAMILY 
and O 
a O 
final O 
reaction O 
mixture O 
comprised O 
mainly O 
of O 
diacylglycerol B-FAMILY 
ethers I-FAMILY 
( O 
10.6% O 
) O 
, O 
monoacylglycerol B-FAMILY 
ethers I-FAMILY 
( O 
32.9% O 
) O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
ethyl I-FAMILY 
esters I-FAMILY 
( O 
46.0% O 
) O 
. O 
In O 
addition O 
, O 
when O 
an O 
excess O 
of O 
ethanol B-SYSTEMATIC 
was O 
used O 
, O 
diacylglycerol B-FAMILY 
ethers I-FAMILY 
completely O 
disappeared O 
after O 
15 O 
h O 
, O 
giving O 
a O 
final O 
product O 
mainly O 
composed O 
of O 
monoacylglycerol B-FAMILY 
ethers I-FAMILY 
( O 
36.6% O 
) O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
ethyl I-FAMILY 
esters I-FAMILY 
( O 
46.4% O 
) O 
. O 

application O 
of O 
high O 
hydrostatic O 
pressure O 
technology O 
for O 
enzymatic O 
extraction O 
of O 
pectin O 
was O 
evaluated O 
. O 
Cellulase O 
and O 
xylanase O 
under O 
five O 
different O 
combinations O 
( O 
cellulase O 
/ O 
xylanase O 
: O 
50 O 
/ O 
0 O 
, O 
50 O 
/ O 
25 O 
, O 
50 O 
/ O 
50 O 
, O 
25 O 
/ O 
50 O 
, O 
and O 
0 O 
/ O 
50 O 
U O 
/ O 
g O 
lime O 
peel O 
) O 
at O 
ambient O 
pressure O 
, O 
100 O 
and O 
200 O 
MPa O 
were O 
used O 
to O 
extract O 
pectin O 
from O 
dried O 
lime O 
peel O 
. O 
Extraction O 
yield O 
, O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GalA B-ABBREVIATION 
) O 
content O 
, O 
average O 
molecular O 
weight O 
(M(w,ave)) O 
, O 
intrinsic O 
viscosity O 
[η](w) O 
, O 
and O 
degree O 
of O 
esterification O 
( O 
DE O 
) O 
were O 
compared O 
to O 
those O 
parameters O 
obtained O 
for O 
pectins O 
extracted O 
using O 
acid O 
and O 
aqueous O 
processes O 
. O 
Pressure O 
level O 
, O 
type O 
and O 
concentration O 
of O 
enzyme O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
influenced O 
yield O 
and O 
DE O 
of O 
pectin O 
. O 
Enzyme O 
and O 
high O 
pressure O 
extraction O 
resulted O 
in O 
yields O 
which O 
were O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
higher O 
than O 
those O 
using O 
acid O 
and O 
aqueous O 
extraction O 
. O 
Although O 
pressure O 
- O 
induced O 
enzymatic O 
treatment O 
improves O 
pectin O 
yield O 
, O 
it O 
does O 
not O 
have O 
any O 
significant O 
effect O 
on O 
M(w,ave) O 
and O 
[η](w) O 
of O 
pectin O 
extracts O 
indicating O 
the O 
potential O 
of O 
high O 
pressure O 
treatment O 
for O 
enzymatic O 
pectin O 
production O 
as O 
a O 
novel O 
and O 
sustainable O 
process O 
. O 

soy O 
germ O 
( O 
GSG O 
) O 
were O 
developed O 
and O 
evaluated O 
for O 
their O 
nutritional O 
value O 
. O 
Separated O 
soy O 
germ O 
was O 
germinated O 
at O 
room O 
temperature O 
for O 
24h O 
under O 
running O 
water O 
. O 
As O 
germination O 
progressed O 
, O 
the O 
protein O 
and O 
fibre O 
content O 
of O 
GSG O 
increased O 
slightly O 
, O 
while O 
the O 
lipid O 
and O 
carbon B-SYSTEMATIC 
to O 
nitrogen B-SYSTEMATIC 
( O 
C B-FORMULA 
/ O 
N B-FORMULA 
) O 
ratio O 
decreased O 
; O 
free O 
amino B-FAMILY 
acids I-FAMILY 
including O 
GABA B-ABBREVIATION 
increased O 
considerably O 
while O 
free O 
sugars B-FAMILY 
decreased O 
. O 
Linoleic B-MULTIPLE 
and I-MULTIPLE 
linolenic I-MULTIPLE 
acid I-MULTIPLE 
were O 
the O 
most O 
abundant O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
soy O 
germ O 
, O 
and O 
slight O 
changes O 
were O 
observed O 
in O 
GSG O 
. O 
The O 
tocopherol B-FAMILY 
and O 
isoflavone B-FAMILY 
contents O 
showed O 
a O 
rapid O 
increase O 
of O 
32.4% O 
and O 
27.9% O 
, O 
respectively O 
, O 
during O 
germination O 
. O 
The O 
abundance O 
of O 
GABA B-ABBREVIATION 
, O 
isoflavones B-FAMILY 
and O 
tocopherols B-FAMILY 
demonstrates O 
the O 
high O 
nutritional O 
value O 
of O 
GSG O 
and O 
suggests O 
that O 
GSG O 
can O 
be O 
utilised O 
as O 
a O 
reasonable O 
and O 
effective O 
source O 
of O 
healthy O 
foods O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
evaluate O 
the O 
effect O 
of O 
freezing O 
black O 
truffles O 
( O 
Tuber O 
melanosporum O 
) O 
on O 
their O 
aroma O 
both O 
in O 
sensory O 
and O 
chemical O 
terms O 
. O 
The O 
truffles O 
were O 
frozen O 
at O 
temperatures O 
of O 
-20 O 
to O 
-80°C O 
. O 
Descriptive O 
and O 
discriminative O 
sensory O 
and O 
chemical O 
analyses O 
, O 
based O 
on O 
headspace O 
solid O 
phase O 
microextraction O 
followed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
analysis O 
( O 
HS-SPME-GC-MS O 
) O 
, O 
were O 
carried O 
out O 
after O 
1 O 
, O 
20 O 
, O 
40 O 
and O 
60 O 
days O 
. O 
Fifteen O 
compounds O 
with O 
high O 
aromatic O 
potential O 
in O 
truffles O 
were O 
determined O 
. O 
Their O 
selective O 
ion O 
peak O 
areas O 
were O 
calculated O 
, O 
summed O 
and O 
expressed O 
as O 
percentage O 
of O 
active O 
odour O 
compound O 
, O 
in O 
order O 
to O 
monitor O 
changes O 
in O 
odour O 
profile O 
. O 
The O 
aroma O 
of O 
frozen O 
truffles O 
differed O 
significantly O 
from O 
the O 
aroma O 
of O 
fresh O 
truffles O 
. O 
Volatile O 
composition O 
data O 
revealed O 
that O 
T O 
. O 
melanosporum O 
aromatic O 
profile O 
is O 
deeply O 
modified O 
as O 
a O 
consequence O 
of O 
a O 
freezing O 
process O 
. O 
These O 
aromatic O 
changes O 
could O 
explain O 
the O 
loss O 
of O 
freshness O 
observed O 
in O 
all O 
frozen O 
truffles O 
. O 
Methional B-TRIVIAL 
and O 
some O 
phenols B-FAMILY 
were O 
suggested O 
as O 
markers O 
of O 
freezing O 
time O 
. O 
Interestingly O 
, O 
1-octen-3-one B-SYSTEMATIC 
appeared O 
as O 
a O 
general O 
marker O 
of O 
freezing O 
process O 
. O 

in O 
Rabdosia O 
serra O 
were O 
investigated O 
by O 
headspace O 
solid O 
phase O 
microextraction O 
( O 
HS-SPME O 
) O 
and O 
simultaneous O 
- O 
distillation O 
extraction O 
( O 
SDE O 
) O 
. O 
The O 
HS-SPME O 
technique O 
was O 
previously O 
evaluated O 
to O 
optimise O 
sampling O 
conditions O 
. O 
A O 
total O 
of O 
56 O 
and O 
48 O 
compounds O 
including O 
alcohols B-FAMILY 
, O 
aldehydes B-FAMILY 
, O 
hydrocarbons B-FAMILY 
, O 
ketones B-FAMILY 
, O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
ester B-FAMILY 
, O 
and O 
aromatics O 
were O 
identified O 
in O 
leaf O 
and O 
stem O 
by O 
optimised O 
HS-SPME O 
method O 
( O 
CAR O 
/ O 
PDMS O 
fibre O 
; O 
incubation O 
time O 
, O 
10 O 
min O 
; O 
extraction O 
temperature O 
, O 
50°C O 
; O 
extraction O 
time O 
, O 
40 O 
min O 
) O 
, O 
respectively O 
. O 
1-Octen-3-ol B-SYSTEMATIC 
and O 
(2E)-hexenal B-SYSTEMATIC 
had O 
significant O 
contribution O 
to O 
R O 
. O 
serra O 
aroma O 
. O 
Cluster O 
analysis O 
indicated O 
that O 
leaf O 
and O 
stem O 
exhibited O 
different O 
volatile O 
diversity O 
. O 
Air O 
drying O 
was O 
favourable O 
for O 
the O 
retention O 
of O 
the O 
volatiles O 
, O 
while O 
freeze- O 
and O 
sun O 
- O 
drying O 
led O 
to O 
the O 
loss O 
of O 
volatiles O 
. O 
SDE O 
method O 
preferred O 
to O 
the O 
analysis O 
of O 
compounds O 
with O 
low O 
volatility O 
including O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
esters B-FAMILY 
. O 
HS-SPME O 
was O 
a O 
useful O 
technique O 
for O 
the O 
analysis O 
of O 
readily O 
volatile O 
components O 
for O 
the O 
characteristics O 
of O 
R O 
. O 
serra O 
aroma O 
. O 

screening O 
of O 
Allura B-TRIVIAL 
Red I-TRIVIAL 
AC I-TRIVIAL 
photodegradation O 
products O 
in O 
a O 
beverage O 
through O 
ultra O 
high O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
hybrid O 
triple O 
quadrupole O 
/ O 
linear O 
ion O 
trap O 
mass O 
spectrometry O 
. O 

study O 
deals O 
with O 
the O 
identification O 
of O 
the O 
degradation O 
products O 
formed O 
by O 
simulated O 
sunlight O 
photoirradiation O 
in O 
a O 
commercial O 
beverage O 
that O 
contains O 
Allura B-TRIVIAL 
Red I-TRIVIAL 
AC I-TRIVIAL 
dye O 
. O 
An O 
UHPLC-MS O 
/ O 
MS O 
method O 
, O 
that O 
makes O 
use O 
of O 
hybrid O 
triple O 
quadrupole O 
/ O 
linear O 
ion O 
trap O 
, O 
was O 
developed O 
. O 
In O 
the O 
identification O 
step O 
the O 
software O 
tool O 
information O 
dependent O 
acquisition O 
( O 
IDA O 
) O 
was O 
used O 
to O 
automatically O 
obtain O 
information O 
about O 
the O 
species O 
present O 
and O 
to O 
build O 
a O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
method O 
with O 
the O 
MS O 
/ O 
MS O 
fragmentation O 
pattern O 
of O 
the O 
species O 
considered O 
. O 
The O 
results O 
indicate O 
that O 
the O 
identified O 
degradation O 
products O 
are O 
formed O 
from O 
side-reactions O 
and O 
/ O 
or O 
interactions O 
among O 
the O 
dye O 
and O 
other O 
ingredients O 
present O 
in O 
the O 
beverage O 
( O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
citric B-TRIVIAL 
acid I-TRIVIAL 
, O 
sucrose B-TRIVIAL 
, O 
aromas O 
, O 
strawberry O 
juice O 
, O 
and O 
extract O 
of O 
chamomile O 
flowers O 
) O 
. O 
The O 
presence O 
of O 
aromatic B-MULTIPLE 
amine I-MULTIPLE 
or I-MULTIPLE 
amide I-MULTIPLE 
functionalities O 
in O 
the O 
chemical O 
structures O 
proposed O 
for O 
the O 
degradation O 
products O 
might O 
suggest O 
potential O 
hazards O 
to O 
consumer O 
health O 
. O 

polyphenols B-FAMILY 
, O 
ginnalins B-MULTIPLE 
A-C I-MULTIPLE 
, O 
induce O 
S- O 
and O 
G2 O 
/ O 
M-cell O 
cycle O 
arrest O 
in O 
colon O 
and O 
breast O 
cancer O 
cells O 
mediated O 
by O 
decreasing O 
cyclins O 
A O 
and O 
D1 O 
levels O 
. O 

are O 
bioactive O 
compounds O 
found O 
in O 
plant O 
foods O 
. O 
Ginnalins B-MULTIPLE 
A-C I-MULTIPLE 
are O 
polyphenols B-FAMILY 
present O 
in O 
the O 
sap O 
and O 
other O 
parts O 
of O 
the O 
sugar B-FAMILY 
and O 
red O 
maple O 
species O 
which O 
are O 
used O 
to O 
produce O 
maple O 
syrup O 
. O 
Here O 
we O 
evaluated O 
the O 
antiproliferative O 
effects O 
of O 
ginnalins B-MULTIPLE 
A-C I-MULTIPLE 
on O 
colon O 
( O 
HCT-116 O 
) O 
and O 
breast O 
( O 
MCF-7 O 
) O 
tumourigenic O 
and O 
non-tumourigenic O 
colon O 
( O 
CCD-18Co O 
) O 
cells O 
and O 
investigated O 
whether O 
these O 
effects O 
were O 
mediated O 
through O 
cell O 
cycle O 
arrest O 
and O 
/ O 
or O 
apoptosis O 
. O 
Ginnalins B-MULTIPLE 
A-C I-MULTIPLE 
were O 
twofold O 
more O 
effective O 
against O 
the O 
tumourigenic O 
than O 
non-tumourigenic O 
cells O 
. O 
Among O 
the O 
polyphenols B-FAMILY 
, O 
ginnalin B-TRIVIAL 
A I-TRIVIAL 
( O 
84% O 
, O 
HCT-116 O 
; O 
49% O 
, O 
MCF-7 O 
) O 
was O 
more O 
effective O 
than O 
ginnalins B-MULTIPLE 
B I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
( O 
50% O 
, O 
HCT-116 O 
; O 
30% O 
, O 
MCF-7 O 
) O 
at O 
50 O 
μM O 
concentrations O 
. O 
Ginnalin B-TRIVIAL 
A I-TRIVIAL 
did O 
not O 
induce O 
apoptosis O 
of O 
the O 
cancer O 
cells O 
but O 
arrested O 
cell O 
cycle O 
( O 
in O 
the O 
S- O 
and O 
G(2) O 
/ O 
M-phases O 
) O 
and O 
decreased O 
cyclins O 
A O 
and O 
D1 O 
protein O 
levels O 
. O 
These O 
results O 
suggest O 
that O 
maple O 
polyphenols B-FAMILY 
may O 
have O 
potential O 
cancer O 
chemopreventive O 
effects O 
mediated O 
through O 
cell O 
cycle O 
arrest O 
. O 

mercury B-SYSTEMATIC 
levels O 
and O 
food O 
consumption O 
in O 
residents O 
from O 
the O 
Pearl O 
River O 
Delta O 
: O 
South O 
China O 
. O 

Pearl O 
River O 
Delta O 
( O 
PRD O 
) O 
is O 
located O 
in O 
the O 
Southern O 
part O 
of O 
China O 
and O 
is O 
the O 
main O 
region O 
for O 
fish O 
culture O 
in O 
Guangdong O 
Province O 
. O 
In O 
order O 
to O 
assess O 
the O 
potential O 
health O 
risks O 
associated O 
with O 
dietary O 
consumption O 
of O 
mercury B-SYSTEMATIC 
, O 
hair O 
samples O 
from O 
91 O 
urban O 
, O 
town O 
and O 
fishing O 
village O 
residents O 
, O 
37 O 
species O 
of O 
fish O 
, O 
cereal O 
, O 
vegetables O 
, O 
and O 
meat O 
samples O 
were O 
collected O 
. O 
The O 
average O 
total O 
mercury B-SYSTEMATIC 
( O 
THg O 
) O 
and O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
) O 
concentrations O 
in O 
hair O 
were O 
1.08 O 
± O 
0.94 O 
and O 
0.58 O 
± O 
0.59 O 
μg O 
/ O 
g O 
, O 
respectively O 
. O 
Daily O 
Hg B-FORMULA 
intake O 
via O 
fish O 
consumption O 
is O 
significantly O 
correlated O 
with O 
THg O 
and O 
MeHg B-FORMULA 
accumulated O 
in O 
human O 
hair O 
( O 
r=0.48 O 
, O 
p O 
< O 
0.01 O 
; O 
r=0.43 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
estimated O 
daily O 
intake O 
of O 
Hg B-FORMULA 
via O 
different O 
food O 
types O 
showed O 
that O 
both O 
fish O 
and O 
cereal O 
consumption O 
were O 
the O 
two O 
main O 
routes O 
of O 
Hg B-FORMULA 
exposure O 
for O 
residents O 
in O 
the O 
sampling O 
areas O 
. O 
Besides O 
food O 
intake O 
, O 
smoking O 
was O 
also O 
an O 
important O 
source O 
for O 
daily O 
THg O 
intake O 
in O 
the O 
smoke O 
group O 
, O 
contributing O 
11-18% O 
to O 
EDI O 
of O 
THg O 
. O 

analysis O 
of O 
fungicide O 
azoxystrobin B-TRIVIAL 
in O 
agricultural O 
samples O 
with O 
rapid O 
, O 
simple O 
and O 
reliable O 
monoclonal O 
immunoassay O 
. O 

work O 
presents O 
analytical O 
performance O 
of O 
a O 
kit O 
- O 
based O 
direct O 
competitive O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
dc-ELISA O 
) O 
for O 
azoxystrobin B-TRIVIAL 
detection O 
in O 
agricultural O 
products O 
. O 
The O 
dc-ELISA O 
was O 
sufficiently O 
sensitive O 
for O 
analysis O 
of O 
residue O 
levels O 
close O 
to O 
the O 
maximum O 
residue O 
limits O 
. O 
The O 
dc-ELISA O 
did O 
not O 
show O 
cross O 
- O 
reactivity O 
to O 
other O 
strobilurin B-FAMILY 
analogues O 
. O 
Absorbance O 
decreased O 
with O 
the O 
increase O 
of O 
methanol B-SYSTEMATIC 
concentration O 
in O 
sample O 
solution O 
from O 
2% O 
to O 
40% O 
, O 
while O 
the O 
standard O 
curve O 
became O 
most O 
linear O 
when O 
the O 
sample O 
solution O 
contained O 
10% O 
methanol B-SYSTEMATIC 
. O 
Agricultural O 
samples O 
were O 
extracted O 
with O 
methanol B-SYSTEMATIC 
, O 
and O 
the O 
extracts O 
were O 
diluted O 
with O 
water O 
to O 
10% O 
methanol B-SYSTEMATIC 
adequate O 
. O 
No O 
significant O 
matrix O 
interference O 
was O 
observed O 
. O 
Satisfying O 
recovery O 
was O 
found O 
for O 
all O 
of O 
spiked O 
samples O 
and O 
the O 
results O 
were O 
well O 
agreed O 
with O 
the O 
analysis O 
with O 
liquid O 
chromatography O 
. O 
These O 
results O 
clearly O 
indicate O 
that O 
the O 
kit O 
- O 
based O 
dc-ELISA O 
is O 
suitable O 
for O 
the O 
rapid O 
, O 
simple O 
, O 
quantitative O 
and O 
reliable O 
determination O 
of O 
the O 
fungicide O 
. O 

eleven O 
organophosphorus B-FAMILY 
pesticides O 
screening O 
in O 
multiple O 
commodities O 
using O 
headspace O 
- O 
solid O 
phase O 
microextraction O 
- O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 

headspace O 
- O 
solid O 
phase O 
microextraction O 
- O 
gas O 
chromatography O 
- O 
mass O 
spectrometric O 
( O 
HS-SPME-GC-MS O 
, O 
hereafter O 
abbreviated O 
as O 
" O 
SPME O 
" O 
) O 
method O 
was O 
developed O 
for O 
dedicated O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
pesticides O 
assessment O 
in O 
multiple O 
vegetable O 
and O 
fruit O 
commodities O 
. O 
Specific O 
extraction O 
variables O 
were O 
optimised O 
to O 
achieve O 
harmonised O 
extraction O 
performance O 
of O 
eleven O 
OPs O 
in O 
a O 
great O 
span O 
of O 
seven O 
characteristic O 
commodities O 
cataloged O 
in O 
Codex O 
Alimentarius O 
Commission O 
. O 
Comprehensive O 
validation O 
study O 
confirmed O 
analytical O 
robustness O 
of O 
the O 
SPME O 
treatment O 
in O 
turnip O 
, O 
green O 
cabbage O 
, O 
French O 
beans O 
, O 
eggplant O 
, O 
apple O 
, O 
nectarine O 
and O 
grapes O 
. O 
Based O 
on O 
range O 
- O 
specific O 
evaluation O 
, O 
extraction O 
of O 
individual O 
OPs O 
was O 
characterised O 
by O 
sub O 
- O 
ppb O 
level O 
sensitivity O 
and O 
a O 
wide O 
0.01-2.5 O 
mg O 
L(-1) O 
dynamic O 
range O 
. O 
Effective O 
sample O 
clean O 
- O 
up O 
afforded O 
precise O 
quantification O 
( O 
0.5-10.9% O 
R.S.D O 
. O 
) O 
within O 
a O 
70-120% O 
recovery O 
range O 
at O 
the O 
MRL O 
levels O 
specified O 
for O 
individual O 
commodities O 
. O 
Compared O 
to O 
conventional O 
methods O 
currently O 
used O 
, O 
the O 
SPME O 
treatment O 
developed O 
here O 
is O 
quick O 
, O 
accurate O 
, O 
and O 
relatively O 
environmental O 
friendly O 
; O 
it O 
represents O 
an O 
attractive O 
, O 
practical O 
way O 
to O 
deliver O 
international O 
standards O 
in O 
OP O 
screening O 
routines O 
. O 

sensitivity O 
of O 
D-galactose B-TRIVIAL 
-binding O 
lectins O 
from O 
fruits O 
of O 
dwarf O 
elder O 
( O 
Sambucus O 
ebulus O 
L O 
. O 
) O 
to O 
a O 
simulated O 
gastric O 
fluid O 
. O 

lectins O 
from O 
Sambucus O 
spp O 
. O 
share O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
with O 
the O 
pollen O 
Sam O 
n1 O 
allergen O 
. O 
The O 
lectins O 
ebulin O 
f O 
and O 
SELfd O 
from O 
the O 
early O 
stages O 
of O 
growth O 
were O 
isolated O 
and O 
subjected O 
to O 
analysis O 
by O 
MALDI-TOF O 
mass O 
spectrometry O 
, O 
tryptic O 
peptide O 
fingerprinting O 
, O 
molecular O 
characterization O 
and O 
pepsin O 
digestibility O 
. O 
The O 
molecular O 
mass O 
( O 
33.214 O 
) O 
and O 
other O 
structural O 
features O 
of O 
the O 
Sam O 
n1 O 
allergen O 
fit O 
best O 
with O 
a O 
monomeric O 
lectin O 
like O 
SELlm O 
( O 
Mr O 
34.2 O 
kDa O 
) O 
found O 
in O 
shoots O 
of O 
dwarf O 
elder O 
. O 
Ebulin O 
f O 
toxicity O 
to O 
mice O 
was O 
higher O 
intraperitoneally O 
than O 
orally O 
at O 
the O 
same O 
dose O 
( O 
5mg O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
In O 
contrast O 
SELfd O 
at O 
the O 
same O 
dose O 
lacks O 
of O 
apparent O 
toxicity O 
. O 
Ebulin O 
f O 
, O 
but O 
not O 
SELfd O 
, O 
undergoes O 
extensive O 
pepsin O 
proteolysis O 
, O 
which O 
could O 
explain O 
the O 
differences O 
in O 
toxicity O 
. O 
The O 
present O 
study O 
supports O 
our O 
hypothesis O 
that O 
the O 
Sam O 
n1 O 
allergen O 
could O 
be O 
a O 
sequence O 
- O 
related O 
monomeric O 
lectin O 
like O 
SELlm O 
present O 
in O 
shoots O 
of O 
Sambucus O 
ebulus O 
rather O 
than O 
ebulin O 
. O 

present O 
research O 
was O 
the O 
first O 
to O 
investigate O 
phenolic O 
compound O 
profiles O 
and O 
antioxidant O 
properties O 
in O 
the O 
seeds O 
of O 
various O 
perilla O 
( O 
Perilla O 
frutescens O 
) O 
cultivars O 
. O 
The O 
80% O 
methanol B-SYSTEMATIC 
extract O 
( O 
50 O 
μg O 
/ O 
ml O 
) O 
of O 
this O 
species O 
showed O 
potent O 
antioxidant O 
activities O 
against O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
and O 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
ABTS B-ABBREVIATION 
) O 
radicals O 
. O 
Phenolic O 
compounds O 
were O 
characterised O 
by O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
, O 
and O 
ultra O 
performance O 
liquid O 
chromatography O 
with O 
photodiode O 
array O 
detector O 
and O 
electrospray O 
ionisation O 
/ O 
mass O 
( O 
UPLC-PDA-ESI O 
/ O 
MS O 
) O 
analysis O 
. O 
Nine O 
compounds O 
were O 
elucidated O 
as O 
caffeic B-SYSTEMATIC 
acid-3-O-glucoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
2 O 
) O 
, O 
luteolin-7-O-glucoside B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
apigenin-7-O-glucoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
rosmarinic B-SYSTEMATIC 
acid-3-O-glucoside I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
6 O 
) O 
, O 
luteolin B-TRIVIAL 
( O 
7 O 
) O 
, O 
apigenin B-TRIVIAL 
( O 
8 O 
) O 
, O 
and O 
chrysoeriol B-TRIVIAL 
( O 
9 O 
) O 
. O 
The O 
individual O 
and O 
total O 
phenolic O 
contents O 
were O 
remarkably O 
different O 
, O 
especially O 
rosmarinic B-SYSTEMATIC 
acid-3-O-glucoside I-SYSTEMATIC 
( O 
5 O 
) O 
and O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
6 O 
) O 
which O 
were O 
the O 
predominant O 
compounds O 
( O 
> O 
95% O 
) O 
in O 
all O 
perilla O 
cultivars O 
. O 
Additionally O 
, O 
Yeupsil O 
cultivar O 
exhibited O 
the O 
highest O 
phenolic O 
content O 
( O 
5029 O 
μg O 
/ O 
g O 
) O 
and O 
antioxidant O 
activity O 
, O 
whereas O 
the O 
lowest O 
was O 
shown O 
by O 
Dasil O 
( O 
2138.7 O 
μg O 
/ O 
g O 
) O 
. O 
Therefore O 
, O 
these O 
results O 
suggest O 
that O 
antioxidant O 
effects O 
of O 
perilla O 
seeds O 
are O 
correlated O 
with O 
phenolic O 
contents O 
. O 

kinetics O 
of O 
anthocyanins B-FAMILY 
in O 
acerola O 
pulp O 
: O 
comparison O 
between O 
ohmic O 
and O 
conventional O 
heat O 
treatment O 
. O 

kinetics O 
of O 
monomeric O 
anthocyanins B-FAMILY 
in O 
acerola O 
pulp O 
during O 
thermal O 
treatment O 
by O 
ohmic O 
and O 
conventional O 
heating O 
was O 
evaluated O 
at O 
different O 
temperatures O 
( O 
75-90°C O 
) O 
. O 
Anthocyanin O 
degradation O 
fitted O 
a O 
first O 
- O 
order O 
reaction O 
model O 
and O 
the O 
rate O 
constants O 
ranged O 
from O 
5.9 O 
to O 
19.7 O 
× O 
10(-3)min(-1) O 
. O 
There O 
were O 
no O 
significant O 
differences O 
between O 
the O 
rate O 
constants O 
of O 
the O 
ohmic O 
and O 
the O 
conventional O 
heating O 
processes O 
at O 
all O 
evaluated O 
temperatures O 
. O 
D-Values O 
ranged O 
from O 
116.7 O 
to O 
374.5 O 
for O 
ohmic O 
heating O 
and O 
from O 
134.9 O 
to O 
390.4 O 
for O 
conventional O 
heating O 
. O 
Values O 
of O 
the O 
free O 
energy O 
of O 
inactivation O 
were O 
within O 
the O 
range O 
of O 
100.19 O 
and O 
101.35 O 
kJ O 
mol(-1) O 
. O 
The O 
enthalpy O 
of O 
activation O 
presented O 
values O 
between O 
71.79 O 
and O 
71.94 O 
kJ O 
mol(-1) O 
and O 
the O 
entropy O 
of O 
activation O 
ranged O 
from O 
-80.15 O 
to O 
-82.63 O 
J O 
mol(-1)K(-1) O 
. O 
Both O 
heating O 
technologies O 
showed O 
activation O 
energy O 
of O 
74.8 O 
kJ O 
mol(-1) O 
and O 
close O 
values O 
for O 
all O 
thermodynamic O 
parameters O 
, O 
indicating O 
similar O 
mechanisms O 
of O 
degradation O 
. O 

and O 
hypoglycemic O 
effects O 
of O 
vescalagin B-TRIVIAL 
from O 
Pink O 
wax O 
apple O 
[ O 
Syzygium O 
samarangense O 
( O 
Blume O 
) O 
Merrill O 
and O 
Perry O 
cv O 
. O 
Pink O 
] O 
in O 
high- O 
fructose B-TRIVIAL 
diet O 
- O 
induced O 
diabetic O 
rats O 
. O 

, O 
an O 
active O 
component O 
from O 
Pink O 
wax O 
apple O 
[ O 
Syzygium O 
samarangense O 
( O 
Blume O 
) O 
Merrill O 
and O 
Perry O 
cv O 
. O 
Pink O 
] O 
fruit O 
, O 
with O 
glucose B-TRIVIAL 
uptake O 
enhancing O 
ability O 
in O 
insulin O 
- O 
resistant O 
FL83B O 
mouse O 
hepatocytes O 
, O 
as O 
shown O 
in O 
our O 
previous O 
study O 
, O 
was O 
further O 
evaluated O 
for O 
its O 
hypotriglyceridemic O 
and O 
hypoglycemic O 
effects O 
in O 
high- O 
fructose B-TRIVIAL 
diet O 
(HFD)-induced O 
diabetic O 
rats O 
. O 
Wistar O 
rats O 
were O 
fed O 
HFD O 
for O 
16 O 
weeks O 
and O 
orally O 
administered O 
with O 
vescalagin B-TRIVIAL 
from O 
Pink O 
wax O 
apple O 
daily O 
during O 
the O 
last O 
4 O 
weeks O 
. O 
The O 
results O 
of O 
biochemical O 
parameters O 
showed O 
that O 
fasting O 
blood O 
glucose B-TRIVIAL 
, O 
C- O 
peptide O 
, O 
fructosamine B-SYSTEMATIC 
, O 
triglyceride B-FAMILY 
and O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
contents O 
decreased O 
by O 
44.7% O 
, O 
46.2% O 
, O 
4.0% O 
, O 
42.5% O 
, O 
and O 
10.8% O 
, O 
respectively O 
, O 
in O 
the O 
HFD-induced O 
diabetic O 
rats O 
administered O 
with O 
vescalagin B-TRIVIAL 
at O 
30 O 
mg O 
/ O 
kg O 
body O 
weight O 
in O 
comparison O 
with O 
those O 
of O 
control O 
HFD-induced O 
diabetic O 
rats O 
. O 
However O 
, O 
high-density-lipoprotein- O 
cholesterol B-TRIVIAL 
content O 
increased O 
by O 
14.4% O 
in O 
the O 
HFD O 
rats O 
treated O 
with O 
vescalagin B-TRIVIAL 
. O 
The O 
present O 
study O 
reveals O 
that O 
vescalagin B-TRIVIAL 
could O 
have O 
therapeutic O 
value O 
against O 
diabetic O 
progression O 
via O 
its O 
anti-hypertriglyceridemic O 
and O 
anti-hyperglycemic O 
effects O 
. O 

compositions O 
of O 
coloured O 
tomato O 
cultivars O 
and O 
contribution O 
to O 
antioxidant O 
activities O 
and O 
protection O 
against O 
H(2)O(2) B-FORMULA 
-induced O 
cell O 
death O 
in O 
H9c2 O 
. O 

carotenoid O 
compositions O 
, O 
antioxidant O 
activities O 
and O 
the O 
potential O 
cardio O 
- O 
protective O 
role O 
of O 
13 O 
tomato O 
cultivars O 
with O 
distinct O 
colour O 
were O 
studied O 
. O 
Colour O 
coordinates O 
were O 
evaluated O 
by O 
colorimeter O 
and O 
the O 
carotenoid O 
compositions O 
were O 
analysed O 
by O 
UPLC O 
. O 
Red O 
tomatoes O 
had O 
the O 
highest O 
total O 
carotenoid O 
contents O 
( O 
TCC O 
) O 
and O 
antioxidant O 
activities O 
, O 
followed O 
by O 
purple O 
, O 
orange O 
, O 
pink O 
and O 
yellow O 
ones O 
. O 
The O 
TCC O 
were O 
120.5-278.0 O 
μg O 
/ O 
gDW O 
, O 
and O 
the O 
antioxidant O 
activities O 
were O 
21.32-40.07 O 
μmolTE O 
/ O 
gDW O 
( O 
PCL O 
) O 
, O 
64.42-89.98% O 
( O 
DPPH B-ABBREVIATION 
) O 
and O 
10.47-13.76 O 
μmolTE O 
/ O 
g O 
DW O 
( O 
ORAC O 
) O 
, O 
respectively O 
. O 
The O 
lipophilic O 
extracts O 
were O 
also O 
found O 
to O 
prevent O 
cell O 
death O 
in O 
a O 
cell O 
- O 
based O 
model O 
system O 
using O 
cardiac O 
H9c2 O 
cells O 
and O 
H(2)O(2) B-FORMULA 
, O 
via O 
attenuation O 
of O 
the O 
caspase-3 O 
and O 
matrix O 
metalloproteinase-2 O 
activities O 
. O 
The O 
extracts O 
of O 
different O 
tomatoes O 
showed O 
strong O 
but O 
different O 
antioxidant O 
activities O 
. O 
Roles O 
of O 
total O 
and O 
individual O 
carotenoids O 
in O 
the O 
antioxidant O 
activities O 
were O 
studied O 
and O 
lycopene O 
showed O 
the O 
highest O 
correlation O 
. O 
Results O 
of O 
this O 
study O 
can O 
be O 
used O 
to O 
guide O 
the O 
development O 
of O 
new O 
tomato O 
cultivars O 
and O 
functional O 
foods O 
, O 
and O 
benefit O 
the O 
consumers O 
. O 

chain O 
and O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
incorporated O 
structured O 
lipids O 
from O 
sal O 
, O 
mango O 
and O 
kokum O 
fats O 
by O 
lipase O 
acidolysis O 
. O 

chain O 
( O 
MC O 
) O 
and O 
behenic O 
fatty B-FAMILY 
acids I-FAMILY 
were O 
incorporated O 
into O 
kokum O 
, O 
sal O 
and O 
mango O 
fats O 
using O 
1,3-specific O 
lipase O 
catalysed O 
acidolysis O 
. O 
The O 
incorporation O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
increased O 
with O 
increase O 
in O 
concentration O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
duration O 
of O 
reaction O 
. O 
The O 
order O 
of O 
incorporation O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
was O 
C22 O 
: O 
0 O 
> O 
C10 O 
: O 
0 O 
> O 
C8 O 
: O 
0 O 
, O 
to O 
the O 
extent O 
of O 
53% O 
, O 
42.5% O 
, O 
35.8% O 
, O 
respectively O 
, O 
after O 
16 O 
h O 
, O 
using O 
kokum O 
as O 
substrate O 
. O 
The O 
same O 
trend O 
was O 
observed O 
with O 
sal O 
or O 
mango O 
fats O 
as O 
substrates O 
though O 
the O 
percentages O 
incorporated O 
were O 
different O 
. O 
The O 
modified O 
products O 
with O 
higher O 
contents O 
of O 
MC O 
were O 
liquids O 
with O 
no O 
solid O 
fats O 
, O 
even O 
at O 
0°C O 
, O 
and O 
which O 
showed O 
low O 
cloud O 
point O 
due O 
to O 
an O 
increase O 
in O 
triacylglycerols B-FAMILY 
containing O 
lower O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
The O 
modified O 
products O 
after O 
incorporating O 
both O 
MC O 
and O 
C22 O 
: O 
0 O 
showed O 
long O 
melting O 
ranges O 
and O 
were O 
suitable O 
for O 
use O 
in O 
bakery O 
, O 
confectionery O 
, O 
etc O 
. O 
as O 
vanaspati O 
substitutes O 
. O 

of O 
the O 
affinity O 
and O 
selectivity O 
of O 
insoluble O 
fibres O 
and O 
commercial O 
proteins O 
for O 
wine O 
proanthocyanidins B-FAMILY 
. O 

fining O 
action O 
of O 
commercial O 
proteins O 
and O 
insoluble O 
fibres O 
for O 
wine O 
proanthocyanidin B-FAMILY 
( O 
PA O 
) O 
were O 
compared O 
. O 
Fibres O 
were O 
prepared O 
from O 
fresh O 
apple O 
and O 
grape O 
sources O 
, O 
and O 
their O 
corresponding O 
pomaces O 
. O 
PA O 
removal O 
by O 
fibre O 
was O 
via O 
adsorption O 
, O 
and O 
required O 
a O 
higher O 
dose O 
to O 
achieve O 
a O 
fining O 
effect O 
comparable O 
with O 
proteins O 
. O 
A O 
principal O 
component O 
analysis O 
data O 
model O 
revealed O 
that O 
PA O 
molecular O 
mass O 
was O 
significant O 
in O 
defining O 
the O 
fining O 
response O 
, O 
and O 
reflected O 
changes O 
in O 
the O 
proportion O 
of O 
the O 
dominant O 
terminal O 
PA O 
subunits O 
catechin B-TRIVIAL 
and O 
epicatechin B-TRIVIAL 
, O 
but O 
not O 
epicatechin-3-O-gallate B-SYSTEMATIC 
. O 
For O 
PA O 
extension O 
subunits O 
, O 
changes O 
in O 
epigallocatechin B-TRIVIAL 
were O 
inversely O 
correlated O 
with O 
epicatechin B-TRIVIAL 
and O 
epicatechin-3-O-gallate B-SYSTEMATIC 
. O 
Generally O 
, O 
the O 
application O 
of O 
proteins O 
and O 
fibres O 
reduced O 
PA O 
molecular O 
mass O 
. O 
Selectivity O 
for O 
PAs O 
by O 
subunit O 
composition O 
was O 
variable O 
between O 
treatments O 
, O 
but O 
differences O 
were O 
minor O 
. O 
This O 
work O 
demonstrates O 
the O 
potential O 
use O 
of O 
fibres O 
as O 
an O 
alternative O 
to O 
proteins O 
in O 
winemaking O 
. O 
Benefits O 
, O 
and O 
possible O 
limitations O 
of O 
such O 
an O 
approach O 
are O 
discussed O 
. O 

effect O 
of O 
the O 
malaxation O 
temperature O 
under O 
sealed O 
conditions O 
on O 
the O 
qualitative O 
and O 
quantitative O 
composition O 
of O 
the O 
phenolic O 
compounds O 
in O 
virgin O 
olive O 
oils O 
produced O 
from O 
four O 
Italian O 
cultivars O 
was O 
assessed O 
for O 
two O 
atmospheric O 
conditions O 
. O 
In O 
both O 
cases O 
, O 
the O 
results O 
show O 
a O 
positive O 
relationship O 
between O 
temperature O 
and O 
the O 
concentration O 
of O 
the O 
derivatives O 
of O 
the O 
secoiridoid B-FAMILY 
aglycones I-FAMILY 
; O 
the O 
effect O 
of O 
the O 
temperature O 
on O 
the O 
oxidoreductases O 
that O 
promote O 
oxidation O 
( O 
polyphenoloxidase O 
and O 
peroxidase O 
) O 
was O 
investigated O 
to O 
determine O 
their O 
optimal O 
temperatures O 
and O 
thermal O 
stability O 
. O 
While O 
olive O 
peroxidase O 
( O 
POD O 
) O 
showed O 
the O 
highest O 
activity O 
at O 
37°C O 
and O 
high O 
stability O 
in O 
the O 
temperature O 
range O 
tested O 
, O 
polyphenoloxidase O 
( O 
PPO O 
) O 
exhibited O 
the O 
optimum O 
activity O 
at O 
approximately O 
50°C O 
, O 
but O 
showed O 
low O 
stability O 
at O 
40°C O 
, O 
with O 
a O 
large O 
variation O 
in O 
stability O 
according O 
to O 
the O 
olive O 
cultivar O 
. O 
These O 
results O 
may O 
contribute O 
to O 
an O 
understanding O 
of O 
the O 
increase O 
in O 
the O 
phenol B-SYSTEMATIC 
concentration O 
found O 
in O 
virgin O 
olive O 
oils O 
obtained O 
following O 
higher O 
temperatures O 
of O 
malaxation O 
. O 

- O 
like O 
effects O 
of O 
fractions O 
, O 
essential O 
oil O 
, O 
carnosol B-TRIVIAL 
and O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
isolated O 
from O 
Rosmarinus O 
officinalis O 
L O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
antidepressant O 
- O 
like O 
effect O 
of O 
fractions O 
from O 
Rosmarinus O 
officinalis O 
L O 
. O 
: O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
1 O 
and O 
2 O 
( O 
AcOEt B-FORMULA 
1 O 
and O 
2 O 
) O 
, O 
hexane B-SYSTEMATIC 
( O 
HEX B-ABBREVIATION 
) O 
, O 
ethanolic O 
( O 
ET O 
) O 
, O 
and O 
essential O 
oil O 
- O 
free O 
( O 
EOF O 
) O 
fractions O 
, O 
as O 
well O 
as O 
essential O 
oil O 
, O 
the O 
isolated O 
compounds O 
carnosol B-TRIVIAL 
and O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
tail O 
suspension O 
test O 
, O 
a O 
predictive O 
test O 
of O 
antidepressant O 
activity O 
. O 
Swiss O 
mice O 
were O 
acutely O 
administered O 
by O 
oral O 
route O 
( O 
p.o O 
. O 
) O 
with O 
fractions O 
, O 
essential O 
oil O 
or O 
isolated O 
compounds O 
, O 
60 O 
min O 
before O 
the O 
tail O 
suspension O 
test O 
or O 
open O 
- O 
field O 
test O 
. O 
All O 
of O 
them O 
produced O 
a O 
significant O 
antidepressant O 
- O 
like O 
effect O 
: O 
AcOEt B-FORMULA 
1 O 
, O 
ET O 
, O 
EOF O 
fractions O 
and O 
essential O 
oil O 
( O 
0.1-100mg O 
/ O 
kg O 
, O 
p.o O 
) O 
; O 
HEX B-ABBREVIATION 
( O 
0.1-10mg O 
/ O 
kg O 
, O 
p.o O 
) O 
and O 
AcOEt B-FORMULA 
2 O 
fraction O 
( O 
0.1-1mg O 
/ O 
kg O 
, O 
p.o O 
) O 
, O 
carnosol B-TRIVIAL 
( O 
0.01-0.1mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
isolated O 
from O 
the O 
HEX B-ABBREVIATION 
fraction O 
and O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
10mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
isolated O 
from O 
the O 
AcOE B-FORMULA 
t1 O 
and O 
AcOE B-FORMULA 
t2 O 
fractions O 
. O 
No O 
psychostimulant O 
effect O 
was O 
shown O 
in O 
the O 
open O 
- O 
field O 
test O 
, O 
indicating O 
that O 
the O 
effects O 
in O 
the O 
tail O 
suspension O 
test O 
are O 
specific O 
. O 
This O 
study O 
suggests O 
that O 
carnoso B-TRIVIAL 
l O 
and O 
betulinic B-TRIVIAL 
aci I-TRIVIAL 
d O 
could O 
be O 
responsible O 
for O 
the O 
anti-immobility O 
effect O 
of O 
extracts O 
from O 
R O 
. O 
officinalis O 
. O 

and O 
application O 
of O 
an O 
HPLC O 
/ O 
UVD O 
to O 
determine O 
dinotefuran B-TRIVIAL 
and O 
its O 
shorter O 
wavelength O 
metabolites O 
residues O 
in O 
melon O 
with O 
tandem O 
mass O 
confirmation O 
. O 

new O 
analytical O 
method O 
was O 
developed O 
for O 
dinotefuran B-TRIVIAL 
and O 
its O 
metabolites O 
, O 
MNG B-ABBREVIATION 
, O 
UF O 
, O 
and O 
DN O 
, O 
in O 
melon O 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
coupled O 
with O 
an O 
ultraviolet O 
detector O 
( O 
UVD O 
) O 
. O 
Due O 
to O 
shorter O 
wavelength O 
, O 
lower O 
sensitivity O 
to O 
UV O 
detection O 
, O 
and O 
high O 
water O 
miscibility O 
of O 
some O 
metabolites O 
, O 
QuEChERs O 
acetate O 
- O 
buffered O 
version O 
was O 
modified O 
for O 
extraction O 
and O 
purification O 
. O 
Mobile O 
phases O 
with O 
different O 
ion O 
pairing O 
or O 
ionisation O 
agents O 
were O 
tested O 
in O 
different O 
reverse O 
phase O 
columns O 
, O 
and O 
ammonium B-SYSTEMATIC 
bicarbonate I-SYSTEMATIC 
buffer O 
was O 
found O 
as O 
the O 
best O 
choice O 
to O 
increase O 
the O 
sensitivity O 
of O 
target O 
analytes O 
to O 
the O 
UV O 
detector O 
. O 
After O 
failure O 
of O 
dispersive O 
SPE O 
clean O 
- O 
up O 
with O 
primary B-MULTIPLE 
secondary I-MULTIPLE 
amine I-MULTIPLE 
, O 
different O 
solid O 
phase O 
extraction O 
cartridges O 
( O 
SPE O 
) O 
were O 
used O 
to O 
check O 
the O 
protecting O 
capability O 
of O 
analytes O 
against O 
matrix O 
interference O 
. O 
Finally O 
, O 
samples O 
were O 
extracted O 
with O 
a O 
simple O 
and O 
rapid O 
method O 
using O 
acetonitrile B-MULTIPLE 
and I-MULTIPLE 
salts I-MULTIPLE 
, O 
and O 
purified O 
through O 
C(18)SPE O 
. O 
The O 
method O 
was O 
validated O 
at O 
two O 
spiking O 
levels O 
( O 
three O 
replicates O 
for O 
each O 
) O 
in O 
the O 
matrix O 
. O 
Good O 
recoveries O 
were O 
observed O 
for O 
all O 
of O 
the O 
analytes O 
and O 
ranged O 
between O 
70.6% O 
and O 
93.5% O 
, O 
with O 
relative O 
standard O 
deviations O 
of O 
less O 
than O 
10% O 
. O 
Calibration O 
curves O 
were O 
linear O 
over O 
the O 
calibration O 
ranges O 
for O 
all O 
the O 
analytes O 
with O 
r(2)≥ O 
0.998 O 
. O 
Limits O 
of O 
detection O 
ranged O 
from O 
0.02 O 
to O 
0.05 O 
mg O 
kg(-1) O 
, O 
whereas O 
limits O 
of O 
quantitation O 
ranged O 
from O 
0.06 O 
to O 
0.16 O 
mg O 
kg(-1) O 
for O 
dinotefuran B-TRIVIAL 
and O 
its O 
metabolites O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
to O 
real O 
samples O 
, O 
where O 
dinotefuran B-TRIVIAL 
and O 
UF O 
residues O 
were O 
found O 
in O 
the O 
field O 
- O 
incurred O 
melon O 
samples O 
. O 
Residues O 
were O 
confirmed O 
via O 
LC-tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
in O 
positive O 
- O 
ion O 
electrospray O 
ionisation O 
(ESI(+)) O 
mode O 
. O 

and O 
sensory O 
perception O 
of O 
Z-2-(β-d-glucopyranosyloxy)-3-phenylpropenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
rooibos O 
( O 
Aspalathus O 
linearis O 
) O 
. O 

acid I-SYSTEMATIC 
( O 
PPAG B-ABBREVIATION 
) O 
, O 
a O 
compound O 
postulated O 
to O 
contribute O 
to O 
the O 
taste O 
and O 
mouthfeel O 
of O 
fermented O 
rooibos O 
tea O 
( O 
Aspalathus O 
linearis O 
) O 
, O 
was O 
isolated O 
from O 
unfermented O 
rooibos O 
plant O 
material O 
. O 
Its O 
structure O 
was O 
unequivocally O 
confirmed O 
by O 
LC-MS O 
, O 
-MS(2) O 
, O 
FT-IR O 
and O 
NMR O 
of O 
the O 
underivatised O 
natural O 
product O 
, O 
and O 
optical O 
rotation O 
measurements O 
of O 
the O 
hydrolysed O 
sugar B-FAMILY 
moiety O 
. O 
A O 
similar O 
compound O 
, O 
postulated O 
to O 
be O 
E-2-(β-d-glucopyranosyloxy)-3-phenylpropenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
was O 
also O 
detected O 
. O 
Analysis O 
of O 
the O 
leaves O 
of O 
a O 
large O 
number O 
of O 
rooibos O 
plants O 
( O 
n=54 O 
) O 
, O 
sampled O 
at O 
commercial O 
plantations O 
, O 
showed O 
that O 
PPAG B-ABBREVIATION 
is O 
not O 
ubiquitously O 
present O 
in O 
detectable O 
quantities O 
in O 
the O 
leaves O 
of O 
different O 
plants O 
. O 
This O 
leads O 
to O 
large O 
variation O 
in O 
the O 
fermented O 
plant O 
material O 
, O 
infusions O 
and O 
food O 
- O 
grade O 
extracts O 
. O 
PPAG B-ABBREVIATION 
was O 
shown O 
to O 
have O 
a O 
slightly O 
bitter O 
to O 
astringent O 
taste O 
and O 
a O 
detection O 
threshold O 
of O 
0.4 O 
mg O 
/ O 
l O 
in O 
water O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
: O 
a O 
new O 
class O 
of O 
nortriterpenoids B-FAMILY 
from O 
the O 
fruits O 
of O 
Schisandra O 
arisanensis O 
. O 

novel O 
highly O 
oxygenated O 
nortriterpenoids B-FAMILY 
, O 
schisarisanlactones B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
, O 
have O 
been O 
isolated O 
from O 
the O 
fruits O 
of O 
Schisandra O 
arisanensis O 
, O 
an O 
endemic O 
plant O 
of O 
Taiwan O 
. O 
Compounds O 
1 O 
and O 
2 O 
possess O 
an O 
unprecedented O 
5 O 
/ O 
5 O 
/ O 
7 O 
/ O 
5 O 
/ O 
5-fused O 
pentacyclic O 
ring O 
system O 
. O 
The O 
structures O 
of O 
both O 
compounds O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
analyses O 
, O 
especially O 
2D O 
NMR O 
and O 
MS O 
. O 
A O 
plausible O 
biogenetic O 
pathway O 
of O 
1 O 
was O 
proposed O 
. O 
Schisarisanlactone B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
showed O 
significant O 
anti-HIV O 
activity O 
. O 

diterpenoids B-FAMILY 
from O 
Isodon O 
lophanthoides O 
var O 
. O 
graciliflorus O 
and O 
their O 
cytotoxicity O 
. O 

new O 
( O 
1-7 O 
) O 
and O 
three O 
known O 
( O 
8-10 O 
) O 
abietane B-TRIVIAL 
diterpenoids B-FAMILY 
were O 
isolated O 
from O 
the O 
methanolic O 
extract O 
of O 
the O 
aerial O 
parts O 
of O 
Isodon O 
lophanthoides O 
var O 
. O 
graciliflorus O 
( O 
Lamiaceae O 
) O 
, O 
a O 
folk O 
Chinese O 
medicine O 
and O 
an O 
herb O 
for O 
functional O 
beverages O 
. O 
They O 
were O 
identified O 
as O 
16-acetoxylsugiol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
graciliflorin B-TRIVIAL 
E I-TRIVIAL 
( O 
2 O 
) O 
, O 
graciliflorin B-TRIVIAL 
F I-TRIVIAL 
( O 
3 O 
) O 
, O 
15-O-methylgraciliflorin B-SYSTEMATIC 
F I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
15-hydroxy-20-deoxocarnosol B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
3β-hydroxysempervirol B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
15-hydroxy-1-oxosalvibretol B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
abieta-8,11,13-triene-14,19-diol B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
6,12,15-trihydroxy-5,8,11,13-abietatetraen-7-one B-SYSTEMATIC 
( O 
9 O 
) O 
, O 
and O 
3α-hinokiol B-TRIVIAL 
( O 
10 O 
) O 
based O 
on O 
the O 
spectroscopic O 
data O 
including O 
COSY O 
( O 
correlated O 
spectroscopy O 
) O 
, O 
HMBC O 
( O 
heteronuclear O 
multiple O 
bond O 
correlation O 
) O 
, O 
and O 
HR-ESI-MS O 
( O 
high O 
- O 
resolution O 
electrospray O 
ionization O 
mass O 
spectrometry O 
) O 
. O 
All O 
the O 
compounds O 
except O 
10 O 
were O 
obtained O 
from O 
I O 
. O 
lophanthoides O 
for O 
the O 
first O 
time O 
. O 
Compounds O 
1 O 
, O 
2 O 
, O 
5 O 
, O 
6 O 
, O 
8 O 
, O 
and O 
9 O 
exhibited O 
in O 
vitro O 
cytotoxicity O 
against O 
A549 O 
( O 
human O 
lung O 
adenocarcinoma O 
) O 
, O 
MCF-7 O 
( O 
human O 
breast O 
adenocarcinoma O 
) O 
, O 
and O 
HeLa O 
( O 
human O 
cervical O 
carcinoma O 
) O 
cell O 
lines O 
with O 
the O 
IC(50) O 
values O 
of O 
1.79-52.67 O 
μM O 
. O 

therapy O 
by O 
extended O 
release O 
of O 
timolol B-TRIVIAL 
from O 
nanoparticle O 
loaded O 
silicone O 
- O 
hydrogel O 
contact O 
lenses O 
. O 

is O 
the O 
second O 
major O 
cause O 
of O 
blindness O 
in O 
the O 
world O 
after O 
cataract O 
. O 
Glaucoma O 
management O 
through O 
eye O 
drops O 
that O 
reduce O 
the O 
intraocular O 
pressure O 
( O 
IOP O 
) O 
has O 
major O 
deficiencies O 
including O 
low O 
patient O 
compliance O 
and O 
low O 
bioavailability O 
. O 
Extended O 
wear O 
contact O 
lenses O 
that O 
deliver O 
glaucoma O 
drugs O 
for O 
extended O 
periods O 
could O 
increase O 
patient O 
compliance O 
, O 
while O 
also O 
increasing O 
the O 
bioavailability O 
. O 
To O 
develop O 
extended O 
wear O 
contact O 
lenses O 
that O 
can O 
also O 
provide O 
extended O 
glaucoma O 
therapy O 
, O 
we O 
disperse O 
nanoparticles O 
of O 
PGT B-ABBREVIATION 
( O 
propoxylated B-FAMILY 
glyceryl I-FAMILY 
triacylate I-FAMILY 
) O 
that O 
contain O 
a O 
glaucoma O 
drug O 
timolol B-TRIVIAL 
. O 
The O 
particles O 
can O 
also O 
be O 
loaded O 
into O 
prefabricated O 
lenses O 
by O 
soaking O 
the O 
lenses O 
in O 
a O 
solution O 
of O 
particles O 
in O 
ethanol B-SYSTEMATIC 
. O 
The O 
particle O 
loaded O 
gels O 
can O 
release O 
timolol B-TRIVIAL 
in O 
phosphate B-SYSTEMATIC 
buffered O 
saline O 
( O 
PBS O 
) O 
for O 
about O 
a O 
month O 
at O 
room O 
temperature O 
. O 
The O 
most O 
likely O 
rate O 
controlling O 
mechanism O 
is O 
hydrolysis O 
of O 
the O 
ester O 
bond O 
that O 
links O 
timolol B-TRIVIAL 
to O 
the O 
PGT B-ABBREVIATION 
matrix O 
, O 
but O 
other O 
mechanisms O 
such O 
as O 
water O 
and O 
drug O 
diffusion O 
, O 
drug O 
dissolution O 
, O 
drug O 
- O 
polymer O 
chain O 
cleavage O 
, O 
time O 
- O 
dependent O 
drug O 
permeability O 
within O 
the O 
polymeric O 
matrix O 
, O 
etc O 
. O 
may O 
also O 
be O 
important O 
. O 
Nanoparticle O 
incorporation O 
in O 
the O 
silicone O 
hydrogels O 
results O 
in O 
reduction O 
in O 
ion O 
and O 
oxygen B-SYSTEMATIC 
permeabilities O 
, O 
and O 
an O 
increase O 
in O 
modulus O 
, O 
and O 
the O 
impact O 
on O 
each O 
of O 
these O 
properties O 
is O 
proportional O 
to O 
the O 
particle O 
loading O 
. O 
A O 
gel O 
with O 
5% O 
particle O 
loading O 
can O 
deliver O 
timolol B-TRIVIAL 
at O 
therapeutic O 
doses O 
for O 
about O 
a O 
month O 
at O 
room O 
temperature O 
, O 
with O 
a O 
minimal O 
impact O 
on O 
critical O 
lens O 
properties O 
. O 
Preliminary O 
animal O 
studies O 
in O 
Beagle O 
dogs O 
conducted O 
with O 
lenses O 
in O 
which O 
particles O 
are O 
loaded O 
by O 
soaking O 
the O 
lenses O 
in O 
ethanol O 
show O 
a O 
reduction O 
in O 
IOP O 
. O 

( O 
CEs O 
) O 
are O 
ubiquitously O 
expressed O 
proteins O 
that O 
are O 
responsible O 
for O 
the O 
detoxification O 
of O 
xenobiotics O 
. O 
They O 
tend O 
to O 
be O 
expressed O 
in O 
tissues O 
likely O 
to O 
be O 
exposed O 
to O 
such O 
agents O 
( O 
e.g O 
. O 
, O 
lung O 
and O 
gut O 
epithelia O 
, O 
liver O 
) O 
and O 
can O 
hydrolyze O 
numerous O 
agents O 
, O 
including O 
many O 
clinically O 
used O 
drugs O 
. O 
Due O 
to O 
the O 
considerable O 
structural O 
similarity O 
between O 
cholinesterases O 
( O 
ChE O 
) O 
and O 
CEs O 
, O 
we O 
have O 
assessed O 
the O 
ability O 
of O 
a O 
series O 
of O 
ChE O 
inhibitors O 
to O 
modulate O 
the O 
activity O 
of O 
the O 
human O 
liver O 
( O 
hCE1 O 
) O 
and O 
the O 
human O 
intestinal O 
CE O 
( O 
hiCE O 
) O 
isoforms O 
. O 
We O 
observed O 
inhibition O 
of O 
hCE1 O 
and O 
hiCE O 
by O 
carbamate B-FAMILY 
-containing O 
small O 
molecules O 
, O 
including O 
those O 
used O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 
For O 
example O 
, O 
rivastigmine B-TRIVIAL 
resulted O 
in O 
greater O 
than O 
95% O 
inhibition O 
of O 
hiCE O 
that O 
was O 
irreversible O 
under O 
the O 
conditions O 
used O 
. O 
Hence O 
, O 
the O 
administration O 
of O 
esterified O 
drugs O 
, O 
in O 
combination O 
with O 
these O 
carbamates B-FAMILY 
, O 
may O 
inadvertently O 
result O 
in O 
decreased O 
hydrolysis O 
of O 
the O 
former O 
, O 
thereby O 
limiting O 
their O 
efficacy O 
. O 
Therefore O 
drug O 
: O 
drug O 
interactions O 
should O 
be O 
carefully O 
evaluated O 
in O 
individuals O 
receiving O 
ChE O 
inhibitors O 
. O 

paraoxonase-1 O 
( O 
HuPON1 O 
) O 
has O 
been O 
proposed O 
as O 
a O 
catalytic O 
bioscavenger O 
of O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
pesticides O 
and O 
nerve O 
agents O 
. O 
We O 
assessed O 
the O 
potential O 
of O 
this O 
enzyme O 
to O 
protect O 
against O 
OP O 
poisoning O 
using O 
two O 
different O 
paradigms O 
. O 
First O 
, O 
recombinant O 
HuPON1 O 
purified O 
from O 
cabbage O 
loopers O 
( O 
iPON1 O 
; O 
Trichoplusia O 
ni O 
) O 
was O 
administered O 
to O 
guinea O 
pigs O 
, O 
followed O 
by O 
exposure O 
to O 
at O 
least O 
2times O 
the O 
median O 
lethal O 
dose O 
( O 
LD50 O 
) O 
of O 
the O 
OP O 
nerve O 
agents O 
tabun B-TRIVIAL 
( O 
GA O 
) O 
, O 
sarin B-TRIVIAL 
( O 
GB O 
) O 
, O 
soman B-TRIVIAL 
( O 
GD O 
) O 
, O 
and O 
cyclosarin B-TRIVIAL 
( O 
GF O 
) O 
, O 
or O 
chlorpyrifos B-TRIVIAL 
oxon I-TRIVIAL 
, O 
the O 
toxic O 
metabolite O 
of O 
the O 
OP O 
pesticide O 
chlorpyrifos B-TRIVIAL 
. O 
In O 
the O 
second O 
model O 
, O 
mice O 
were O 
infected O 
with O 
an O 
adenovirus O 
that O 
induced O 
expression O 
of O 
HuPON1 O 
and O 
then O 
exposed O 
to O 
sequential O 
doses O 
of O 
GD O 
, O 
VX O 
, O 
or O 
( O 
as O 
reported O 
previously O 
) O 
diazoxon B-TRIVIAL 
, O 
the O 
toxic O 
metabolite O 
of O 
the O 
OP O 
pesticide O 
diazinon B-TRIVIAL 
. O 
In O 
both O 
animal O 
models O 
, O 
the O 
exogenously O 
added O 
HuPON1 O 
protected O 
animals O 
against O 
otherwise O 
lethal O 
doses O 
of O 
the O 
OP O 
pesticides O 
but O 
not O 
against O 
the O 
nerve O 
agents O 
. O 
Together O 
, O 
the O 
results O 
support O 
prior O 
modeling O 
and O 
in O 
vitro O 
activity O 
data O 
which O 
suggest O 
that O 
wild O 
- O 
type O 
HuPON1 O 
does O 
not O 
have O 
sufficient O 
catalytic O 
activity O 
to O 
provide O 
in O 
vivo O 
protection O 
against O 
nerve O 
agents O 
. O 

- O 
two O 
- O 
hour O 
release O 
formulation O 
of O 
the O 
poorly O 
soluble O 
drug O 
silybin B-TRIVIAL 
based O 
on O 
porous O 
silica B-TRIVIAL 
nanoparticles O 
: O 
in O 
vitro O 
release O 
kinetics O 
and O 
in O 
vitro O 
/ O 
in O 
vivo O 
correlations O 
in O 
beagle O 
dogs O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
prepare O 
a O 
72 O 
h-release O 
formulation O 
of O 
silybin B-TRIVIAL 
( O 
72 O 
h- O 
SLB B-ABBREVIATION 
) O 
using O 
a O 
combination O 
of O 
solid O 
dispersion O 
, O 
gel O 
matrix O 
and O 
porous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
PSNs O 
) O 
and O 
to O 
investigate O 
the O 
in O 
vitro O 
/ O 
in O 
vivo O 
correlations O 
( O 
IVIVCs O 
) O 
. O 
The O 
results O 
of O 
scanning O 
electron O 
microscopy O 
and O 
N(2) O 
adsorption O 
demonstrated O 
that O 
empty O 
PSNs O 
possessed O 
a O 
spherical O 
shape O 
, O 
a O 
highly O 
porous O 
structure O 
, O 
a O 
large O 
specific O 
surface O 
area O 
( O 
385.89 O 
± O 
1.12 O 
m(2) O 
/ O 
g O 
) O 
and O 
a O 
small O 
pore O 
size O 
( O 
2.74 O 
nm O 
on O 
average O 
) O 
. O 
The O 
in O 
vitro O 
dissolution O 
profiles O 
of O 
both O 
72 O 
h- O 
SLB B-ABBREVIATION 
and O 
silybin B-TRIVIAL 
-loaded O 
PSNs O 
in O 
different O 
concentrations O 
( O 
0.01 O 
, O 
0.06 O 
and O 
0.08M O 
) O 
of O 
Na(2)CO(3) B-FORMULA 
solutions O 
revealed O 
that O 
0.06 O 
M O 
Na(2)CO(3) B-FORMULA 
solution O 
was O 
the O 
optimal O 
medium O 
in O 
which O 
silybin B-TRIVIAL 
could O 
be O 
released O 
from O 
72 O 
h- O 
SLB B-ABBREVIATION 
with O 
first O 
- O 
order O 
release O 
kinetics O 
and O 
from O 
PSNs O 
with O 
Higuchi O 
kinetics O 
. O 
Furthermore O 
, O 
the O 
IVIVCs O 
of O 
72 O 
h- O 
SLB B-ABBREVIATION 
and O 
silybin B-TRIVIAL 
-loaded O 
PSNs O 
in O 
beagle O 
dogs O 
were O 
also O 
established O 
. O 
Using O 
0.06 O 
M O 
Na(2)CO(3) B-FORMULA 
solution O 
as O 
the O 
in O 
vitro O 
dissolution O 
medium O 
, O 
a O 
good O 
linear O 
relationship O 
could O 
be O 
achieved O 
for O 
both O 
72 O 
h- O 
SLB B-ABBREVIATION 
and O 
silybin B-TRIVIAL 
-loaded O 
PSNs O 
. O 
The O 
findings O 
support O 
the O 
fact O 
that O 
the O 
72 O 
h- O 
SLB B-ABBREVIATION 
( O 
consisting O 
of O 
solid O 
dispersion O 
, O 
regular O 
gel O 
matrix O 
and O 
PSNs O 
) O 
together O 
with O 
Na(2)CO(3) B-FORMULA 
solution O 
as O 
an O 
in O 
vitro O 
dissolution O 
medium O 
can O 
be O 
developed O 
into O 
a O 
promising O 
formulation O 
for O 
poorly O 
soluble O 
drugs O 
, O 
which O 
enjoys O 
a O 
good O 
IVIVC O 
. O 

hyperstimulation O 
syndrome O 
( O 
OHSS O 
) O 
is O 
a O 
disorder O 
associated O 
with O 
ovarian O 
stimulation O 
. O 
OHSS O 
features O 
are O 
ovarian O 
enlargement O 
with O 
fluid O 
shifting O 
to O 
the O 
third O 
space O 
. O 
Disturbances O 
in O 
the O 
vasculature O 
are O 
considered O 
the O 
main O 
changes O 
that O 
lead O 
to O 
OHSS O 
. O 
Our O 
aim O 
was O 
to O 
analyze O 
the O 
levels O 
of O 
angiopoietins O 
1 O 
and O 
2 O 
( O 
ANGPT1 O 
and O 
2 O 
) O 
and O 
their O 
soluble O 
and O 
membrane O 
receptors O 
( O 
s O 
/ O 
mTie-2 O 
) O 
in O 
follicular O 
fluid O 
( O 
FF O 
) O 
and O 
in O 
granulosa- O 
lutein B-TRIVIAL 
cells O 
culture O 
( O 
GLCs O 
) O 
from O 
women O 
at O 
risk O 
of O 
developing O 
OHSS O 
. O 
We O 
also O 
evaluated O 
the O 
effect O 
of O 
ANGPT1 O 
on O 
endothelial O 
cell O 
migration O 
. O 
In O 
ovaries O 
from O 
an O 
OHSS O 
rat O 
model O 
, O 
we O 
analyzed O 
the O 
protein O 
concentration O 
of O 
ANGPTs O 
, O 
their O 
mTie-2 O 
receptor O 
, O 
and O 
platelet O 
- O 
derived O 
growth O 
factor O 
PDGF-B O 
, O 
-D O 
and O 
PDGFR-β O 
. O 
ANGPT1 O 
levels O 
were O 
increased O 
in O 
both O 
FF O 
and O 
GLCs O 
from O 
women O 
at O 
risk O 
of O 
OHSS O 
. O 
Incubation O 
of O 
these O 
FF O 
with O 
an O 
ANGPT1 O 
neutralizing O 
antibody O 
decreased O 
endothelial O 
cell O 
migration O 
. O 
In O 
the O 
ovaries O 
of O 
OHSS O 
rat O 
model O 
, O 
mTie-2 O 
protein O 
levels O 
increased O 
and O 
PDGF-B O 
and O 
-D O 
decreased O 
. O 
In O 
summary O 
, O 
these O 
results O 
suggest O 
that O 
ANGPT1 O 
could O 
be O 
another O 
mediator O 
in O 
the O 
development O 
of O 
OHSS O 
. O 

receptor O 
ESR1 O 
regulates O 
the O 
phospholipase O 
C- O 
inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
signaling O 
in O 
the O 
hippocampus O 
from O 
rats O 
in O 
proestrous O 
and O 
estrous O 
phases O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
involvement O 
of O 
estrogen B-FAMILY 
receptors O 
in O 
the O 
activation O 
of O 
phospholipase O 
C O 
(PLC)-phosphoinositide O 
hydrolysis O 
in O 
the O 
hippocampus O 
from O 
rats O 
in O 
estrous O 
and O 
proestrous O 
phases O 
. O 
17β-Estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
and O 
ESR1-selective O 
agonist O 
PPT B-ABBREVIATION 
, O 
but O 
not O 
ESR2-selective O 
agonist O 
DPN B-ABBREVIATION 
, O 
induced O 
a O 
rapid O 
increase O 
on O 
total O 
[³H]-inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
accumulation O 
in O 
the O 
hippocampus O 
from O 
both O 
rats O 
. O 
These O 
effects O 
are O 
mediated O 
by O 
PLC O 
activation O 
, O 
since O 
the O 
inhibition O 
of O 
this O 
protein O 
decreased O 
the O 
total O 
[³H]-inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
accumulation O 
. O 
The O 
pretreatment O 
with O 
ESR1 O 
and O 
ESR2 O 
antagonist O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
, O 
but O 
not O 
with O 
GPER O 
antagonist O 
G B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
, O 
blocked O 
the O 
total O 
[³H]-inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
accumulation O 
induced O 
by O 
E2 O 
and O 
PPT B-ABBREVIATION 
, O 
confirming O 
that O 
ESR1 O 
is O 
upstream O 
component O 
regulating O 
this O 
rapid O 
effect O 
. O 
SRC O 
family O 
of O 
protein O 
tyrosine B-TRIVIAL 
kinases O 
inhibitor O 
PP2 B-ABBREVIATION 
blocked O 
the O 
total O 
[³H]-inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
accumulation O 
induced O 
by O 
E2 O 
and O 
PPT B-ABBREVIATION 
in O 
hippocampus O 
, O 
suggesting O 
that O 
ESR1 O 
undergoes O 
translocation O 
from O 
the O 
nuclei O 
to O 
the O 
plasma O 
membrane O 
region O 
via O 
SRC O 
to O 
activate O 
rapid O 
signaling O 
pathways O 
. O 
Furthermore O 
, O 
the O 
magnitude O 
of O 
the O 
response O 
to O 
E2 O 
and O 
PPT B-ABBREVIATION 
was O 
higher O 
in O 
hippocampus O 
from O 
rats O 
in O 
proestrous O 
than O 
in O 
estrous O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
expression O 
of O 
the O 
ESR1 O 
is O 
higher O 
in O 
hippocampus O 
from O 
rats O 
in O 
estrous O 
than O 
in O 
proestrous O 
, O 
indicating O 
that O 
the O 
regulation O 
of O 
this O 
receptor O 
by O 
estrous O 
cycle O 
does O 
not O 
play O 
a O 
role O 
in O 
the O 
magnitude O 
of O 
the O 
response O 
to O 
E2 O 
and O 
PPT B-ABBREVIATION 
in O 
hippocampus O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
indicate O 
that O 
E2 O 
activates O 
SRC O 
- O 
mediated O 
translocation O 
of O 
ESR1 O 
to O 
the O 
plasma O 
membrane O 
, O 
which O 
results O 
in O 
the O 
activation O 
of O 
PLC- O 
inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
signaling O 
pathway O 
in O 
rat O 
hippocampus O 
. O 
Thus O 
, O 
these O 
rapid O 
estrogen B-FAMILY 
actions O 
in O 
hippocampus O 
might O 
be O 
a O 
key O 
step O 
mediating O 
cellular O 
events O 
important O 
for O 
learning O 
and O 
memory O 
. O 

exposure O 
to O 
the O 
herbicide O 
atrazine B-TRIVIAL 
alters O 
locomotor O 
activity O 
and O 
the O 
nigrostriatal O 
dopaminergic O 
system O 
of O 
the O 
albino O 
rat O 
. O 

( O 
ATR B-ABBREVIATION 
) O 
is O 
used O 
as O 
a O 
pre- O 
and O 
post O 
- O 
emergent O 
herbicide O 
; O 
although O 
banned O 
in O 
several O 
countries O 
of O 
the O 
European O 
Community O 
, O 
it O 
is O 
still O 
used O 
extensively O 
around O 
the O 
world O 
. O 
A O 
recent O 
study O 
in O 
rats O 
has O 
shown O 
that O 
chronic O 
, O 
daily O 
exposure O 
to O 
10 O 
mg O 
ATR B-ABBREVIATION 
/ O 
kg O 
BW O 
causes O 
hyperactivity O 
, O 
disrupts O 
motor O 
coordination O 
and O 
learning O 
of O 
behavioral O 
tasks O 
, O 
and O 
decreases O 
dopamine B-TRIVIAL 
levels O 
in O 
the O 
brain O 
. O 
In O 
order O 
to O 
evaluate O 
the O 
short O 
- O 
term O 
effect O 
of O 
ATR B-ABBREVIATION 
exposure O 
on O 
locomotor O 
activity O 
, O 
monoamine B-FAMILY 
markers O 
, O 
and O 
antioxidants O 
, O 
adult O 
male O 
Sprague-Dawley O 
rats O 
received O 
six O 
IP O 
injections O 
of O 
100 O 
mg O 
ATR B-ABBREVIATION 
/ O 
kg O 
BW O 
or O 
vehicle O 
over O 
two O 
weeks O 
. O 
After O 
every O 
ATR B-ABBREVIATION 
injection O 
we O 
found O 
hypoactivity O 
that O 
lasted O 
up O 
to O 
five O 
days O 
, O 
and O 
it O 
was O 
accompanied O 
by O 
reductions O 
in O 
levels O 
of O 
striatal O 
DA O 
, O 
DOPAC B-ABBREVIATION 
, O 
and O 
HVA B-ABBREVIATION 
without O 
any O 
alteration O 
in O 
the O 
striatal O 
expression O 
of O 
the O 
mRNAs O 
for O 
Mn B-FORMULA 
-SOD O 
, O 
Trx-1 O 
, O 
DAR-D(1) O 
, O 
or O 
DAR-D(2) O 
. O 
In O 
contrast O 
, O 
in O 
the O 
nucleus O 
accumbens O 
no O 
changes O 
in O 
monoamine B-FAMILY 
markers O 
were O 
observed O 
, O 
and O 
a O 
down O 
- O 
regulation O 
of O 
Trx-1 O 
expression O 
was O 
detected O 
shortly O 
after O 
the O 
ATR B-ABBREVIATION 
treatment O 
. O 
Moreover O 
, O 
in O 
the O 
ventral O 
midbrain O 
, O 
we O 
found O 
that O 
ATR B-ABBREVIATION 
induced O 
a O 
down O 
- O 
regulation O 
of O 
mRNA O 
for O 
Th O 
and O 
DAT O 
, O 
but O 
it O 
increased O 
VMAT2 O 
mRNA O 
expression O 
. O 
Decreases O 
of O 
monoamine B-FAMILY 
levels O 
and O 
of O 
locomotor O 
activity O 
disappeared O 
three O 
months O 
after O 
ATR B-ABBREVIATION 
treatment O 
; O 
however O 
, O 
an O 
amphetamine B-TRIVIAL 
challenge O 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
given O 
two O 
months O 
after O 
the O 
ATR B-ABBREVIATION 
treatment O 
resulted O 
in O 
a O 
significant O 
stimulation O 
in O 
the O 
exposed O 
group O 
, O 
revealing O 
hidden O 
effects O 
of O 
ATR B-ABBREVIATION 
on O 
dopaminergic O 
systems O 
. O 
These O 
results O 
indicate O 
that O 
ATR B-ABBREVIATION 
exposure O 
differentially O 
modifies O 
the O 
dopaminergic O 
systems O 
, O 
and O 
these O 
modifications O 
may O 
underlie O 
the O 
behavioral O 
changes O 
observed O 
. O 

chelation O 
by O 
frustulins O 
: O 
a O 
novel O 
metal O 
tolerance O 
mechanism O 
in O 
Nitzschia O 
palea O 
( O 
Kützing O 
) O 
W O 
. O 
Smith O 
. O 

ubiquity O 
of O 
diatom O 
distribution O 
, O 
species O 
richness O 
, O 
short O 
generation O 
time O 
, O 
and O 
specific O 
sensitivity O 
to O 
several O 
environmental O 
stressors O 
such O 
as O 
metals O 
, O 
make O 
diatoms O 
particularly O 
useful O 
for O 
scientific O 
studies O 
. O 
Anthropogenic O 
activities O 
have O 
increased O 
the O 
concentration O 
of O 
metals O 
in O 
air O 
, O 
soil O 
and O 
water O 
. O 
Due O 
to O 
their O 
toxicity O 
and O 
persistent O 
character O 
, O 
the O 
effects O 
of O 
metals O 
on O 
organisms O 
have O 
been O 
extensively O 
studied O 
. O 
In O 
this O 
work O 
, O 
the O 
association O 
of O 
cadmium B-SYSTEMATIC 
to O 
different O 
extracellular O 
molecules O 
of O 
Nitzschia O 
palea O 
cells O 
was O 
investigated O 
. O 
Cells O 
were O 
grown O 
in O 
the O 
absence O 
and O 
presence O 
( O 
0.2 O 
mg O 
l(-1) O 
) O 
of O 
cadmium B-SYSTEMATIC 
in O 
Chu O 
no O 
. O 
10 O 
medium O 
. O 
Extracellular O 
polysaccharides O 
were O 
extracted O 
, O 
and O 
subsamples O 
were O 
used O 
for O 
polysaccharide O 
and O 
Cd B-FORMULA 
determination O 
. O 
The O 
frustules O 
were O 
broken O 
mechanically O 
under O 
liquid O 
nitrogen B-SYSTEMATIC 
and O 
the O 
intracellular O 
and O 
frustule O 
fractions O 
separated O 
. O 
Frustulins O 
, O 
a O 
protein O 
family O 
found O 
on O 
the O 
outmost O 
frustule O 
layer O 
, O 
constituting O 
a O 
protection O 
coating O 
to O 
environmental O 
stress O 
, O 
were O 
extracted O 
. O 
In O 
each O 
fraction O 
proteins O 
were O 
quantified O 
by O 
the O 
BCA O 
method O 
and O 
separated O 
by O 
gel O 
electrophoresis O 
( O 
SDS-PAGE O 
) O 
. O 
Cadmium B-SYSTEMATIC 
associated O 
to O 
each O 
fraction O 
was O 
quantified O 
by O 
Inductively O 
Coupled O 
Plasma O 
Mass O 
Spectrometry O 
( O 
ICP-MS O 
) O 
analysis O 
. O 
Exposure O 
of O 
Nitzschia O 
palea O 
to O 
cadmium B-SYSTEMATIC 
decreased O 
extracellular O 
polysaccharides O 
by O 
52.8 O 
% O 
and O 
increased O 
6 O 
times O 
the O 
amount O 
of O 
frustulins O 
. O 
Cadmium B-SYSTEMATIC 
was O 
mostly O 
retained O 
extracellularly O 
: O 
85.4 O 
% O 
was O 
bound O 
to O 
the O 
frustulin O 
fraction O 
, O 
and O 
11.1 O 
% O 
to O 
polysaccharides O 
. O 
The O 
ability O 
of O 
Nitzschia O 
palea O 
to O 
increase O 
the O 
production O 
of O 
frustulins O 
due O 
to O 
the O 
presence O 
of O 
Cd B-FORMULA 
, O 
the O 
extracellular O 
location O 
of O 
this O 
frustulin O 
coating O 
and O 
the O 
ability O 
of O 
these O 
proteins O 
to O 
bind O 
Cd B-FORMULA 
, O 
suggests O 
a O 
new O 
cellular O 
defense O 
mechanism O 
to O 
metals O 
unknown O 
until O 
now O 
. O 

the O 
monomolecular O 
film O 
technique O 
, O 
we O 
studied O 
interfacial O 
properties O 
of O 
Fusarium O 
solani O 
lipase O 
( O 
FSL O 
) O 
. O 
This O 
lipolytic O 
enzyme O 
was O 
found O 
to O 
be O 
unique O 
among O 
the O 
fungal O 
lipases O 
possessing O 
not O 
only O 
a O 
lipase O 
activity O 
but O 
also O 
a O 
high O 
phospholipase O 
one.The O 
FSL O 
was O 
able O 
to O 
hydrolyze O 
dicaprin B-TRIVIAL 
films O 
at O 
various O 
surface O 
pressures O 
. O 
The O 
surface O 
pressure O 
dependency O 
, O 
the O 
stereospecificity O 
, O 
and O 
the O 
regioselectivity O 
of O 
FSL O 
were O 
performed O 
using O 
optically O 
pure O 
stereoisomers O 
of O 
diglyceride B-FAMILY 
( O 
1,2-sn- B-SYSTEMATIC 
dicaprin I-SYSTEMATIC 
and O 
2,3-sn-dicaprin B-SYSTEMATIC 
) O 
and O 
a O 
prochiral O 
isomer O 
( O 
1,3-sn-dicaprin B-SYSTEMATIC 
) O 
spread O 
as O 
monomolecular O 
films O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 
The O 
FSL O 
prefers O 
adjacent O 
ester B-FAMILY 
groups O 
of O 
the O 
diglyceride B-FAMILY 
isomers O 
( O 
1,2-sn-dicaprin B-SYSTEMATIC 
and O 
2,3-sn-dicaprin B-SYSTEMATIC 
) O 
at O 
low O 
and O 
high O 
surface O 
pressures O 
. O 
Furthermore O 
, O 
FSL O 
was O 
found O 
to O 
be O 
markedly O 
stereospecific O 
for O 
the O 
sn-1 O 
position O 
of O 
the O 
1,2-sn-enantiomer O 
of O 
dicaprin B-TRIVIAL 
at O 
both O 
low O 
and O 
high O 
surface O 
pressures.Moreover O 
, O 
FSL O 
shows O 
high O 
activities O 
on O 
phospholipids O 
monolayers O 
. O 
However O 
, O 
this O 
enzyme O 
displays O 
high O 
preference O 
to O 
zwitterionic O 
phospholipids O 
compared O 
to O 
the O 
negatively O 
charged O 
ones O 
. O 

work O 
presents O 
an O 
inexpensive O 
and O 
easily O 
manufacturable O 
, O 
highly O 
conductive O 
and O 
transparent O 
nanowire O 
network O 
electrode O 
for O 
textured O 
semiconductors O 
. O 
It O 
is O 
based O 
on O 
lines O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
transformed O 
into O 
a O 
nanowire O 
network O 
by O 
microwave O 
or O 
furnace O 
sintering O 
. O 
The O 
nanonetwork O 
electrode O 
on O 
crystalline O 
silicon B-SYSTEMATIC 
is O 
demonstrated O 
experimentally O 
, O 
with O 
the O 
nanoparticles O 
self O 
- O 
assembling O 
in O 
the O 
valleys O 
between O 
the O 
pyramids O 
of O 
the O 
textured O 
surface O 
. O 
Optical O 
experiments O 
show O 
that O 
this O 
conductive O 
nanowire O 
network O 
electrode O 
can O 
be O 
essentially O 
' O 
invisible O 
' O 
when O 
covered O 
with O 
the O 
conventional O 
anti-reflection O 
coating O 
( O 
ARC O 
) O 
, O 
and O 
thus O 
could O 
be O 
employed O 
in O 
photovoltaic O 
applications O 
. O 

of O 
Leydig O 
and O 
Sertoli O 
cells O 
to O 
testosterone B-TRIVIAL 
production O 
in O 
mouse O 
fetal O 
testes O 
. O 

is O 
a O 
final O 
product O 
of O 
androgenic O 
hormone O 
biosynthesis O 
, O 
and O 
Leydig O 
cells O 
are O 
known O 
to O 
be O 
the O 
primary O 
source O 
of O 
androgens O 
. O 
In O 
the O 
mammalian O 
testis O 
, O 
two O 
distinct O 
populations O 
of O 
Leydig O 
cells O 
, O 
the O 
fetal O 
and O 
the O 
adult O 
Leydig O 
cells O 
, O 
develop O 
sequentially O 
, O 
and O 
these O 
two O 
cell O 
types O 
differ O 
both O 
morphologically O 
and O 
functionally O 
. O 
It O 
is O 
well O 
known O 
that O 
the O 
adult O 
Leydig O 
cells O 
maintain O 
male O 
reproductive O 
function O 
by O 
producing O 
testosterone B-TRIVIAL 
. O 
However O 
, O 
it O 
has O 
been O 
controversial O 
whether O 
fetal O 
Leydig O 
cells O 
can O 
produce O 
testosterone B-TRIVIAL 
, O 
and O 
the O 
synthetic O 
pathway O 
of O 
testosterone B-TRIVIAL 
in O 
the O 
fetal O 
testis O 
is O 
not O 
fully O 
understood O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
generated O 
transgenic O 
mice O 
in O 
which O 
enhanced O 
green O 
fluorescence O 
protein O 
was O 
expressed O 
under O 
the O 
control O 
of O 
a O 
fetal O 
Leydig O 
cell O 
- O 
specific O 
enhancer O 
of O 
the O 
Ad4BP O 
/ O 
SF-1 O 
( O 
Nr5a1 O 
) O 
gene O 
. O 
The O 
transgene O 
construct O 
was O 
prepared O 
by O 
mutating O 
the O 
LIM O 
homeodomain O 
transcription O 
factor O 
( O 
LHX9 O 
) O 
- O 
binding O 
sequence O 
in O 
the O 
promoter O 
, O 
which O 
abolished O 
promoter O 
activity O 
in O 
the O 
undifferentiated O 
testicular O 
cells O 
. O 
These O 
transgenic O 
mice O 
were O 
used O 
to O 
collect O 
highly O 
pure O 
fetal O 
Leydig O 
cells O 
. O 
Gene O 
expression O 
and O 
steroidogenic O 
enzyme O 
activities O 
in O 
the O 
fetal O 
Leydig O 
cells O 
as O 
well O 
as O 
in O 
the O 
fetal O 
Sertoli O 
cells O 
and O 
adult O 
Leydig O 
cells O 
were O 
analyzed O 
. O 
Our O 
results O 
revealed O 
that O 
the O 
fetal O 
Leydig O 
cells O 
synthesize O 
only O 
androstenedione B-TRIVIAL 
because O 
they O 
lack O 
expression O 
of O 
Hsd17b3 O 
, O 
and O 
fetal O 
Sertoli O 
cells O 
convert O 
androstenedione B-TRIVIAL 
to O 
testosterone B-TRIVIAL 
, O 
whereas O 
adult O 
Leydig O 
cells O 
synthesize O 
testosterone B-TRIVIAL 
by O 
themselves O 
. O 
The O 
current O 
study O 
demonstrated O 
that O 
both O 
Leydig O 
and O 
Sertoli O 
cells O 
are O 
required O 
for O 
testosterone B-TRIVIAL 
synthesis O 
in O 
the O 
mouse O 
fetal O 
testis O 
. O 

of O 
triphenylmethane B-SYSTEMATIC 
dyes O 
Brilliant B-TRIVIAL 
Blue I-TRIVIAL 
and O 
Patent B-TRIVIAL 
Blue I-TRIVIAL 
through O 
intact O 
skin O 
, O 
shaven O 
skin O 
and O 
lingual O 
mucosa O 
from O 
daily O 
life O 
products O 
. O 

, O 
there O 
is O 
evidence O 
of O 
health O 
risks O 
of O 
triphenylmethane B-SYSTEMATIC 
dyes O 
after O 
systemic O 
absorption O 
. O 
This O 
paper O 
investigates O 
the O 
fate O 
of O 
Brilliant B-TRIVIAL 
Blue I-TRIVIAL 
( O 
BB O 
) O 
and O 
Patent B-TRIVIAL 
Blue I-TRIVIAL 
( O 
PB O 
) O 
after O 
24-h O 
in O 
vitro O 
diffusion O 
, O 
firstly O 
through O 
intact O 
and O 
secondly O 
through O 
shaven O 
pig O 
- O 
ear O 
skin O 
( O 
stored O 
by O 
freezing O 
) O 
from O 
four O 
leave O 
- O 
on O 
cosmetics O 
under O 
in O 
- O 
use O 
conditions O 
. O 
Both O 
dyes O 
showed O 
no O 
measurable O 
permeation O 
through O 
intact O 
skin O 
but O 
significant O 
permeation O 
was O 
found O 
through O 
shaven O 
skin O 
. O 
From O 
250 O 
ng O 
/ O 
cm(2) O 
of O 
dye O 
in O 
one O 
applied O 
dose O 
there O 
were O 
found O 
52 O 
ng O 
/ O 
cm(2) O 
of O 
BB O 
and O 
91 O 
ng O 
/ O 
cm(2) O 
of O 
PB O 
from O 
ethanol B-SYSTEMATIC 
-based O 
after O 
- O 
shave O 
, O 
39 O 
ng O 
/ O 
cm(2) O 
of O 
BB O 
and O 
86 O 
ng O 
/ O 
cm(2) O 
of O 
PB O 
from O 
ethanol B-SYSTEMATIC 
-free O 
facial O 
- O 
cleanser O 
, O 
35 O 
ng O 
/ O 
cm(2) O 
of O 
BB O 
and O 
43 O 
ng O 
/ O 
cm(2) O 
of O 
PB O 
from O 
O O 
/ O 
W O 
emulsion O 
, O 
and O 
no O 
amount O 
from O 
W O 
/ O 
O O 
emulsion O 
, O 
as O 
available O 
to O 
become O 
systemically O 
absorbed O 
. O 
Thirdly O 
, O 
the O 
paper O 
focuses O 
on O 
lingual O 
mucosa O 
after O 
licking O 
lollipops O 
. O 
Ex O 
vivo O 
porcine O 
tongue O 
dorsum O 
was O 
exposed O 
to O 
human O 
saliva O 
with O 
15000 O 
ng O 
/ O 
cm(2) O 
of O 
dye O 
for O 
20 O 
min O 
. O 
24-h O 
diffusion O 
resulted O 
in O 
34 O 
ng O 
/ O 
cm(2) O 
of O 
BB O 
and O 
86 O 
ng O 
/ O 
cm(2) O 
of O 
PB O 
which O 
can O 
be O 
directly O 
absorbed O 
into O 
the O 
blood O 
system O 
. O 
Findings O 
are O 
troubling O 
, O 
particularly O 
with O 
regard O 
to O 
the O 
frequent O 
use O 
of O 
after O 
- O 
shave O 
products O 
by O 
the O 
male O 
population O 
and O 
repeated O 
lollipops O 
licking O 
by O 
children O 
. O 

effects O 
of O 
resveratrol B-TRIVIAL 
on O 
nonalcoholic O 
fatty O 
liver O 
disease O 
are O 
associated O 
with O 
up O 
regulation O 
of O 
hepatic O 
low O 
density O 
lipoprotein O 
receptor O 
and O 
scavenger O 
receptor O 
class O 
B O 
type O 
I O 
gene O 
expressions O 
in O 
rats O 
. O 

metabolic O 
disorders O 
are O 
widely O 
considered O 
to O 
be O 
one O 
of O 
the O 
most O 
critical O 
and O 
basic O 
link O 
in O 
the O 
pathogenesis O 
of O 
nonalcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
illustrate O 
the O 
alleviation O 
function O 
of O 
resveratrol B-TRIVIAL 
( O 
Res B-ABBREVIATION 
) O 
on O 
NAFLD O 
and O 
the O 
roles O 
of O 
hepatic O 
fatty B-FAMILY 
acid I-FAMILY 
synthase O 
( O 
FAS O 
) O 
, O 
low O 
density O 
lipoprotein O 
receptor O 
( O 
LDLr O 
) O 
, O 
scavenger O 
receptor O 
class O 
B O 
type O 
I O 
( O 
SR-BI O 
) O 
, O 
and O 
thyroid O 
hormone O 
receptor O 
β1 O 
( O 
TRβ1 O 
) O 
, O 
which O 
are O 
the O 
key O 
molecules O 
involved O 
in O 
lipid O 
metabolism O 
. O 
Adult O 
male O 
Wistar O 
rats O 
were O 
fed O 
a O 
normal O 
diet O 
or O 
high O 
fat/ O 
sucrose B-TRIVIAL 
diet O 
( O 
HFS O 
) O 
with O 
or O 
without O 
resveratrol B-TRIVIAL 
for O 
13 O 
weeks O 
. O 
HFS O 
induced O 
NAFLD O 
formation O 
and O 
increased O 
the O 
lipids O 
concentrations O 
in O 
serum O 
and O 
livers O 
of O 
rats O 
, O 
while O 
noticeable O 
improvement O 
has O 
been O 
reached O 
by O 
Res B-ABBREVIATION 
intervention O 
. O 
Moreover O 
, O 
Res B-ABBREVIATION 
protected O 
against O 
HFS-induced O 
decrease O 
in O 
hepatic O 
LDLr O 
and O 
SR-BI O 
mRNA O 
and O 
protein O 
expressions O 
, O 
whereas O 
TRβ1 O 
expressions O 
were O 
impervious O 
with O 
/ O 
without O 
Res B-ABBREVIATION 
. O 
Unexpectedly O 
, O 
hepatic O 
FAS O 
gene O 
expressions O 
were O 
markedly O 
diminished O 
in O 
NAFLD O 
rats O 
and O 
were O 
gradually O 
increased O 
by O 
treatment O 
with O 
Res B-ABBREVIATION 
. O 
These O 
data O 
indicate O 
that O 
the O 
alleviative O 
effects O 
of O 
Res B-ABBREVIATION 
on O 
NAFLD O 
are O 
associated O 
with O 
up O 
regulation O 
of O 
hepatic O 
LDLr O 
and O 
SR-BI O 
gene O 
expressions O 
, O 
which O 
provide O 
new O 
insights O 
into O 
the O 
pharmacological O 
targets O 
of O 
Res B-ABBREVIATION 
in O 
the O 
prevention O 
of O 
NAFLD O 
. O 

of O 
tomato O 
products O 
is O 
associated O 
with O 
lower O 
blood O 
mercury B-SYSTEMATIC 
levels O 
in O 
Inuit O 
preschool O 
children O 
. O 

evidence O 
suggests O 
that O 
various O 
diet O 
components O 
and O 
nutrients O 
, O 
including O 
vegetables O 
, O 
fruit O 
and O 
food O 
- O 
derived O 
antioxidants O 
, O 
could O 
mitigate O 
contaminant O 
exposure O 
and O 
/ O 
or O 
adverse O 
health O 
effects O 
of O 
contaminants O 
. O 
To O 
examine O 
the O 
effect O 
of O 
the O 
consumption O 
of O 
tomato O 
products O 
on O 
blood O 
mercury B-SYSTEMATIC 
levels O 
in O 
Inuit O 
preschool O 
children O 
, O 
155 O 
Inuit O 
children O 
( O 
25.0±9.1months O 
) O 
were O 
recruited O 
from O 
2006-2008 O 
in O 
Nunavik O 
childcare O 
centers O 
( O 
northern O 
Québec O 
, O 
Canada O 
) O 
. O 
Food O 
frequency O 
questionnaires O 
were O 
completed O 
at O 
home O 
and O 
at O 
the O 
childcare O 
center O 
, O 
and O 
total O 
blood O 
mercury B-SYSTEMATIC 
concentration O 
was O 
measured O 
by O 
inductively O 
coupled O 
plasma O 
- O 
mass O 
spectrometry O 
. O 
Multivariate O 
regression O 
analysis O 
was O 
performed O 
after O 
multiple O 
imputation O 
. O 
The O 
median O 
blood O 
concentration O 
of O 
mercury B-SYSTEMATIC 
was O 
9.5nmol O 
/ O 
L O 
. O 
Age O 
, O 
duration O 
of O 
breastfeeding O 
, O 
annual O 
consumption O 
frequency O 
of O 
seal O 
meat O 
, O 
and O 
monthly O 
consumption O 
frequency O 
of O 
tomato O 
products O 
were O 
significant O 
predictors O 
of O 
blood O 
mercury B-SYSTEMATIC 
levels O 
, O 
whereas O 
annual O 
consumption O 
frequencies O 
of O 
beluga O 
muktuk O 
, O 
walrus O 
, O 
Arctic O 
char O 
, O 
and O 
caribou O 
meat O 
were O 
not O 
. O 
Each O 
time O 
a O 
participant O 
consumed O 
tomato O 
products O 
during O 
the O 
month O 
before O 
the O 
interview O 
was O 
associated O 
with O 
a O 
4.6% O 
lower O 
blood O 
mercury B-SYSTEMATIC 
level O 
( O 
p=0.0005 O 
) O 
. O 
All O 
other O 
significant O 
predictors O 
in O 
the O 
model O 
were O 
positively O 
associated O 
with O 
blood O 
mercury B-SYSTEMATIC 
levels O 
. O 
Further O 
studies O 
should O 
explore O 
interactions O 
between O 
consumption O 
of O 
healthy O 
store O 
- O 
bought O 
foods O 
available O 
in O 
Arctic O 
regions O 
and O 
contaminant O 
exposure O 
. O 

- O 
based O 
design O 
of O 
flavone B-TRIVIAL 
derivatives O 
as O 
c-myc O 
oncogene O 
down O 
- O 
regulators O 
. O 

on O 
molecular O 
docking O 
analysis O 
of O 
complexes O 
between O 
flavone B-TRIVIAL 
and O 
the O 
c-myc O 
G-quadruplex O 
, O 
we O 
designed O 
and O 
screened O 
30 O 
flavone B-TRIVIAL 
derivatives O 
containing O 
various O 
side O 
chains O 
that O 
could O 
potentially O 
form O 
interactions O 
with O 
the O 
G-quadruplex O 
grooves O 
. O 
As O 
a O 
proof O 
- O 
of O 
- O 
concept O 
, O 
the O 
highest O 
- O 
scoring O 
flavone B-TRIVIAL 
derivatives O 
containing O 
cationic O 
pyridinium B-SYSTEMATIC 
side O 
chains O 
were O 
synthesized O 
and O 
their O 
interactions O 
with O 
the O 
c-myc O 
G-quadruplex O 
were O 
examined O 
using O 
a O 
PCR-stop O 
assay O 
. O 
The O 
stabilizing O 
effects O 
of O 
the O 
flavone B-TRIVIAL 
derivatives O 
were O 
found O 
to O 
be O 
selective O 
towards O 
the O 
c-myc O 
G-quadruplex O 
over O 
other O 
biologically O 
relevant O 
G-quadruplex O 
structures O 
, O 
such O 
as O 
the O 
human O 
telomeric O 
sequence O 
( O 
HTS O 
) O 
. O 
The O 
interaction O 
between O 
the O 
most O 
potent O 
compound O 
of O 
the O 
series O 
and O 
the O 
c-myc O 
G-quadruplex O 
was O 
examined O 
in O 
depth O 
using O 
UV-Vis O 
titration O 
, O 
molecular O 
modeling O 
and O 
CD O 
spectroscopy O 
. O 
Our O 
results O 
suggest O 
that O 
in O 
addition O 
to O 
stabilizing O 
the O 
c-myc O 
G-quadruplex O 
, O 
the O 
flavone B-TRIVIAL 
derivatives O 
were O 
capable O 
of O 
inducing O 
the O 
formation O 
of O 
the O 
G-quadruplex O 
structure O 
even O 
in O 
the O 
absence O 
of O 
monovalent O 
cations O 
. O 
The O 
flavone B-TRIVIAL 
derivatives O 
were O 
found O 
to O 
be O 
potent O 
inhibitors O 
of O 
c-myc O 
promoters O 
within O 
the O 
cellular O 
environment O 
and O 
displayed O 
promising O 
cytotoxic O 
behavior O 
against O 
human O 
cancer O 
cell O 
lines O 
. O 

leaves O 
of O 
coca O 
( O 
Erythroxylum O 
coca O 
var O 
. O 
coca O 
) O 
, O 
a O 
South O 
American O 
shrub O 
which O 
contains O 
cocaine B-TRIVIAL 
, O 
other O 
alkaloids O 
and O 
phenolics O 
are O 
widely O 
used O 
by O 
indigenous O 
populations O 
of O 
the O 
Andes O 
. O 
It O 
is O 
currently O 
not O 
known O 
if O 
coca O 
consumption O 
causes O 
genotoxic O 
effects O 
in O 
humans O 
. O 
This O 
information O 
is O 
important O 
to O 
predict O 
potential O 
long O 
- O 
term O 
toxic O 
effects O 
such O 
as O 
cancer O 
induction O 
. O 
Therefore O 
, O 
the O 
buccal O 
cytome O 
assay O 
was O 
used O 
to O 
analyze O 
oral O 
cells O 
from O 
45 O 
uni- O 
and O 
bilateral O 
chewers O 
and O 
23 O 
controls O 
living O 
in O 
the O 
Altiplano O 
of O 
the O 
Peruvian O 
Andes O 
. O 
In O 
total O 
, O 
123471 O 
cells O 
were O 
evaluated O 
from O 
chewers O 
and O 
57916 O 
from O 
controls O 
. O 
Information O 
concerning O 
the O 
consumption O 
levels O 
and O 
habits O 
and O 
also O 
use O 
of O 
lime O 
were O 
collected O 
with O 
questionnaires O 
. O 
Chewing O 
of O 
the O 
leaves O 
did O 
not O 
induce O 
nuclear O 
anomalies O 
reflecting O 
genetic O 
damage O 
such O 
as O 
micronuclei O 
( O 
MNi O 
) O 
and O 
nuclear O 
buds O 
; O 
in O 
the O 
highest O 
exposure O 
group O 
( O 
but O 
not O 
in O 
the O 
overall O 
group O 
) O 
even O 
a O 
significant O 
decrease O 
in O 
the O 
frequencies O 
of O 
cells O 
with O 
MNi O 
( O 
by O 
64 O 
% O 
) O 
was O 
observed O 
. O 
However O 
, O 
we O 
found O 
significantly O 
elevated O 
levels O 
of O 
other O 
nuclear O 
anomalies O 
( O 
karyorrhexis O 
and O 
karyolysis O 
) O 
which O 
reflect O 
cytotoxic O 
effects O 
in O 
the O 
coca O 
users O 
. O 
The O 
frequencies O 
of O 
these O 
anomalies O 
increased O 
with O 
the O 
daily O 
consumption O 
and O 
when O 
lime O 
was O 
used O 
to O 
improve O 
the O 
release O 
of O 
the O 
alkaloids O 
. O 
In O 
contrast O 
to O 
other O 
chewing O 
habits O 
( O 
betel O 
, O 
tobacco O 
and O 
khat O 
) O 
, O 
consumption O 
of O 
coca O 
leaves O 
does O 
not O 
induce O 
genetic O 
instability O 
in O 
cells O 
from O 
the O 
oral O 
cavity O 
and O 
our O 
findings O 
indicate O 
that O 
no O 
adverse O 
health O 
effects O 
take O 
place O 
in O 
chewers O 
which O 
are O 
associated O 
with O 
DNA O 
damage O 
. O 
However O 
, O 
the O 
significant O 
increase O 
in O 
certain O 
anomalies O 
shows O 
that O 
acute O 
toxic O 
effects O 
are O 
caused O 
by O 
coca O 
consumption O 
. O 

of O 
substituted O 
phenylpropylamides B-FAMILY 
as O 
highly O 
selective O 
agonists O 
at O 
the O 
melatonin B-TRIVIAL 
MT2 O 
receptor O 
. O 

is O 
a O 
widely O 
distributed O 
hormone O 
that O 
regulates O 
several O 
major O 
physiological O 
processes O 
, O 
including O 
the O 
circadian O 
rhythm O 
and O 
seasonal O 
adaptation O 
. O 
The O 
two O 
subtypes O 
of O 
mammalian O 
G O 
protein O 
- O 
coupled O 
melatonin O 
receptors O 
are O 
primarily O 
responsible O 
for O 
mediating O 
the O 
actions O 
of O 
melatonin B-TRIVIAL 
. O 
Because O 
synthetic O 
melatonin B-TRIVIAL 
agonists O 
have O 
considerable O 
therapeutic O 
potentials O 
in O 
modulating O 
insomnia O 
and O 
circadian- O 
related O 
sleep O 
disorders O 
, O 
it O 
is O 
highly O 
desirable O 
to O 
develop O 
subtype O 
- O 
selective O 
melatoninergic O 
compounds O 
. O 
The O 
pharmacological O 
potencies O 
of O 
a O 
series O 
of O 
substituted O 
N-[3-(3-methoxyphenyl)propyl] B-FAMILY 
amides I-FAMILY 
towards O 
human O 
melatonin B-TRIVIAL 
MT(1) O 
and O 
MT(2) O 
receptors O 
were O 
evaluated O 
by O 
the O 
FLIPR O 
high O 
- O 
throughput O 
screening O 
assay O 
, O 
whilst O 
their O 
subtype O 
- O 
selectivity O 
was O 
subsequently O 
verified O 
with O 
ERK O 
phosphorylation O 
and O 
cAMP B-ABBREVIATION 
assays O 
. O 
Structure O 
- O 
activity O 
relationship O 
analysis O 
of O 
highly O 
potent O 
subtype O 
- O 
selective O 
ligands O 
( O 
MT(2) O 
EC(50) O 
10-90 O 
pM O 
) O 
revealed O 
that O 
a O 
benzyloxyl B-SYSTEMATIC 
substituent O 
incorporated O 
at O 
C6 O 
position O 
of O 
the O 
3-methoxyphenyl B-SYSTEMATIC 
ring O 
dramatically O 
enhanced O 
the O 
MT(2) O 
potency O 
and O 
at O 
the O 
same O 
time O 
decreased O 
MT(1) O 
potency O 
. O 
Incorporation O 
of O 
structural O 
moieties O 
conferring O 
the O 
subtype O 
selectivity O 
produced O 
several O 
extremely O 
potent O 
MT(2)-selective O 
ligands O 
. O 
The O 
most O 
potent O 
subtype O 
- O 
selective O 
ligand O 
, O 
2q O 
had O 
a O 
substantially O 
higher O 
potency O 
for O 
MT(2) O 
receptor O 
than O 
melatonin B-TRIVIAL 
for O 
elevation O 
of O 
[ O 
Ca(2+) B-FORMULA 
]i O 
and O 
inhibition O 
of O 
forskolin O 
- O 
elevated O 
cAMP O 
. O 
Representative O 
MT(2)-selective O 
ligands O 
also O 
induced O 
ERK O 
phosphorylation O 
in O 
both O 
recombinant O 
and O 
native O 
cell O 
lines O 
, O 
and O 
no O 
cross O 
- O 
reactivity O 
to O 
17 O 
other O 
GPCRs O 
could O 
be O 
detected O 
. O 
These O 
ligands O 
represent O 
invaluable O 
tools O 
for O 
delineating O 
the O 
functional O 
roles O 
of O 
distinct O 
melatonin B-TRIVIAL 
receptor O 
subtypes O 
and O 
are O 
viable O 
candidates O 
for O 
drug O 
development O 
. O 

is O 
a O 
crucial O 
parameter O 
in O 
drug O 
development O 
since O 
it O 
impacts O 
both O 
ADME O 
properties O 
and O 
target O 
affinity O 
of O 
drug O 
candidates O 
. O 
In O 
early O 
drug O 
discovery O 
stage O 
, O 
accurate O 
tools O 
for O 
logP O 
prediction O 
are O 
highly O 
desired O 
. O 
Many O 
calculation O 
methods O 
were O 
developed O 
to O 
aid O 
pharmaceutical O 
scientists O 
in O 
drug O 
research O 
; O 
however O 
almost O 
all O 
suffer O 
from O 
insufficient O 
accuracy O 
and O 
variation O 
of O 
performance O 
in O 
several O 
regions O 
of O 
the O 
chemical O 
space O 
associated O 
with O 
new O 
chemical O 
entities O 
. O 
The O 
low O 
predictive O 
power O 
of O 
existing O 
software O 
packages O 
can O 
be O 
explained O 
by O 
limited O 
availability O 
and O 
/ O 
or O 
variable O 
quality O 
of O 
experimental O 
logP O 
values O 
associated O 
with O 
training O 
set O 
used O 
, O 
which O 
stem O 
from O 
various O 
protocols O 
and O 
poorly O 
cover O 
chemical O 
space O 
. O 
In O 
this O 
study O 
, O 
a O 
dataset O 
of O 
1000 O 
diverse O 
test O 
compounds O 
out O 
of O 
4.5 O 
million O 
was O 
generated O 
; O 
logP O 
values O 
of O 
759 O 
purchasable O 
compounds O 
( O 
46% O 
non-ionizable O 
, O 
30% O 
basic O 
, O 
17% O 
acidic O 
, O 
0.5% O 
zwitterionic O 
and O 
6.5% O 
ampholytes O 
) O 
from O 
this O 
selected O 
set O 
were O 
experimentally O 
determined O 
by O 
UHPLC O 
followed O 
by O 
UV O 
detection O 
or O 
MS O 
detection O 
when O 
necessary O 
. O 
Finally O 
, O 
a O 
data O 
collection O 
of O 
707 O 
validated O 
logP O 
values O 
ranging O 
from O 
0.3 O 
to O 
7.5 O 
is O 
now O 
available O 
for O 
benchmarking O 
of O 
existing O 
and O 
development O 
of O 
new O 
approaches O 
to O 
predict O 
octanol B-SYSTEMATIC 
/ O 
water O 
partition O 
coefficients O 
of O 
chemical O 
compounds O 
. O 

of O 
novel O 
cannabinoid O 
receptor O 
ligands O 
by O 
a O 
virtual O 
screening O 
approach O 
: O 
further O 
development O 
of O 
2,4,6- B-FAMILY 
trisubstituted I-FAMILY 
1,3,5-triazines I-FAMILY 
as O 
CB2 O 
agonists O 
. O 

ligand O 
- O 
based O 
virtual O 
screening O 
was O 
employed O 
to O 
identify O 
novel O 
scaffolds O 
for O 
cannabinoid O 
receptor O 
ligand O 
development O 
. O 
A O 
total O 
of O 
112 O 
compounds O 
with O 
diverse O 
structures O 
were O 
purchased O 
from O 
commercial O 
vendors O 
. O 
12 O 
CB1 O 
receptor O 
antagonists O 
/ O 
inverse O 
agonists O 
and O 
10 O 
CB2 O 
receptor O 
agonists O 
were O 
identified O 
in O 
vitro O 
. O 
One O 
of O 
the O 
CB2 O 
agonists O 
, O 
N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine B-SYSTEMATIC 
( O 
19 O 
, O 
-logEC(50)=7.5 O 
, O 
E(max)=255% O 
) O 
was O 
selected O 
for O 
further O 
development O 
. O 
As O 
far O 
as O 
we O 
are O 
aware O 
, O 
the O 
compound's O 
1,3,5-triazine B-SYSTEMATIC 
scaffold O 
represents O 
a O 
new O 
core O 
structure O 
for O 
CB2 O 
agonists O 
. O 
A O 
library O 
of O 
fifty O 
- O 
seven O 
2,4,6- B-FAMILY 
trisubstituted-1,3,5-triazines I-FAMILY 
was O 
created O 
to O 
clarify O 
the O 
structure O 
- O 
activity O 
relationship O 
study O 
of O 
the O 
analogs O 
. O 

vitro O 
investigations O 
into O 
the O 
roles O 
of O 
drug O 
transporters O 
and O 
metabolizing O 
enzymes O 
in O 
the O 
disposition O 
and O 
drug O 
interactions O 
of O 
dolutegravir B-TRIVIAL 
, O 
a O 
HIV O 
integrase O 
inhibitor O 
. O 

( O 
DTG B-ABBREVIATION 
; O 
S B-IDENTIFIER 
/ I-IDENTIFIER 
GSK1349572 I-IDENTIFIER 
) O 
is O 
a O 
potent O 
HIV-1 O 
integrase O 
inhibitor O 
with O 
a O 
distinct O 
resistance O 
profile O 
and O 
a O 
once O 
- O 
daily O 
dose O 
regimen O 
that O 
does O 
not O 
require O 
pharmacokinetic O 
boosting O 
. O 
This O 
work O 
investigated O 
the O 
in O 
vitro O 
drug O 
transport O 
and O 
metabolism O 
of O 
DTG B-ABBREVIATION 
and O 
assessed O 
the O 
potential O 
for O 
clinical O 
drug O 
- O 
drug O 
interactions O 
. O 
DTG B-ABBREVIATION 
is O 
a O 
substrate O 
for O 
the O 
efflux O 
transporters O 
P-glycoprotein O 
( O 
Pgp O 
) O 
and O 
human O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
. O 
Its O 
high O 
intrinsic O 
membrane O 
permeability O 
limits O 
the O 
impact O 
these O 
transporters O 
have O 
on O 
DTG B-ABBREVIATION 
' O 
s O 
intestinal O 
absorption O 
. O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
1A1 O 
is O 
the O 
main O 
enzyme O 
responsible O 
for O 
the O 
metabolism O 
of O 
DTG B-ABBREVIATION 
in O 
vivo O 
, O 
with O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
3A4 O 
being O 
a O 
notable O 
pathway O 
and O 
UGT1A3 O 
and O 
UGT1A9 O 
being O 
only O 
minor O 
pathways O 
. O 
DTG B-ABBREVIATION 
demonstrated O 
little O 
or O 
no O 
inhibition O 
( O 
IC(50) O 
values O 
> O 
30 O 
μM O 
) O 
in O 
vitro O 
of O 
the O 
transporters O 
Pgp O 
, O 
BCRP O 
, O 
multidrug O 
resistance O 
protein O 
2 O 
, O 
organic O 
anion O 
transporting O 
polypeptide O 
1B1 O 
/ O 
3 O 
, O 
organic O 
cation O 
transporter O 
( O 
OCT O 
) O 
1 O 
, O 
or O 
the O 
drug O 
metabolizing O 
enzymes O 
CYP1A2 O 
, O 
2A6 O 
, O 
2B6 O 
, O 
2C8 O 
, O 
2C9 O 
, O 
2C19 O 
, O 
2D6 O 
, O 
3A4 O 
, O 
UGT1A1 O 
, O 
or O 
2B7 O 
. O 
Further O 
, O 
DTG B-ABBREVIATION 
did O 
not O 
induce O 
CYP1A2 O 
, O 
2B6 O 
, O 
or O 
3A4 O 
mRNA O 
in O 
vitro O 
using O 
human O 
hepatocytes O 
. O 
DTG B-ABBREVIATION 
does O 
inhibit O 
the O 
renal O 
OCT2 O 
( O 
IC(50) O 
= O 
1.9 O 
μM O 
) O 
transporter O 
, O 
which O 
provides O 
a O 
mechanistic O 
basis O 
for O 
the O 
mild O 
increases O 
in O 
serum O 
creatinine B-TRIVIAL 
observed O 
in O 
clinical O 
studies O 
. O 
These O 
in O 
vitro O 
studies O 
demonstrate O 
a O 
low O 
propensity O 
for O 
DTG B-ABBREVIATION 
to O 
be O 
a O 
perpetrator O 
of O 
clinical O 
drug O 
interactions O 
and O 
provide O 
a O 
basis O 
for O 
predicting O 
when O 
other O 
drugs O 
could O 
result O 
in O 
a O 
drug O 
interaction O 
with O 
DTG B-ABBREVIATION 
. O 

- O 
dependent O 
actions O 
of O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
are O 
required O 
for O 
activation O 
of O 
TGF-β O 
signaling O 
during O 
the O 
inflammatory O 
response O 
to O 
cutaneous O 
injury O 
. O 

vitamin B-FAMILY 
D I-FAMILY 
receptor O 
( O 
VDR O 
) O 
has O 
both O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
-dependent O 
and O 
-independent O 
actions O 
in O 
the O 
epidermis O 
. O 
Ligand O 
- O 
dependent O 
actions O 
of O 
the O 
VDR O 
have O 
been O 
shown O 
to O 
promote O 
keratinocyte O 
differentiation O 
and O 
to O 
regulate O 
formation O 
of O 
the O 
epidermal O 
barrier O 
. O 
In O 
contrast O 
, O 
the O 
actions O 
of O 
the O 
VDR O 
that O 
regulate O 
postmorphogenic O 
hair O 
cycling O 
do O 
not O 
require O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
. O 
The O 
VDR O 
also O 
has O 
immunomodulatory O 
actions O 
that O 
are O 
dependent O 
on O 
its O 
ligand O 
, O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
. O 
To O 
determine O 
whether O 
the O 
ligand O 
- O 
dependent O 
or O 
-independent O 
actions O 
of O 
the O 
VDR O 
regulate O 
the O 
inflammatory O 
response O 
to O 
cutaneous O 
injury O 
, O 
studies O 
were O 
performed O 
in O 
control O 
, O 
VDR O 
knockout O 
, O 
and O 
vitamin B-FAMILY 
D I-FAMILY 
-deficient O 
mice O 
. O 
These O 
investigations O 
demonstrate O 
that O 
absence O 
of O 
receptor O 
or O 
ligand O 
impairs O 
the O 
dermal O 
response O 
to O 
cutaneous O 
injury O 
. O 
Although O 
neutrophil O 
recruitment O 
is O 
not O 
affected O 
, O 
the O 
absence O 
of O 
VDR O 
signaling O 
leads O 
to O 
defects O 
in O 
macrophage O 
recruitment O 
and O 
granulation O 
tissue O 
formation O 
. O 
Studies O 
performed O 
to O 
identify O 
the O 
molecular O 
basis O 
for O 
this O 
phenotype O 
demonstrate O 
that O 
absence O 
of O 
the O 
VDR O 
, O 
or O 
its O 
ligand O 
, O 
impairs O 
TGF-β O 
signaling O 
in O 
the O 
dermis O 
, O 
characterized O 
by O 
decreased O 
expression O 
of O 
monocyte O 
chemotactic O 
protein-1 O 
and O 
reduced O 
phosphorylation O 
of O 
phosphorylated O 
Smad-3 O 
as O 
well O 
as O 
attenuated O 
phosphorylated O 
Smad-3 O 
phosphorylation O 
in O 
response O 
to O 
TGF-β O 
in O 
primary O 
dermal O 
fibroblasts O 
lacking O 
the O 
VDR O 
. O 
Thus O 
, O 
these O 
data O 
demonstrate O 
that O 
the O 
liganded O 
VDR O 
interacts O 
with O 
the O 
TGF-β O 
signaling O 
pathway O 
to O 
promote O 
the O 
normal O 
inflammatory O 
response O 
to O 
cutaneous O 
injury O 
. O 

activation O 
of O 
CaO B-FORMULA 
-based O 
adsorbents O 
for O 
CO(2) B-FORMULA 
capture O 
. O 

reversible O 
cycling O 
of O 
CaO B-FORMULA 
adsorbents O 
to O 
CaCO(3) B-FORMULA 
for O 
high O 
- O 
temperature O 
CO(2) B-FORMULA 
capture O 
is O 
substantially O 
improved O 
by O 
mechanical O 
treatment O 
. O 
The O 
mechanical O 
milling O 
intensity O 
and O 
conditions O 
of O 
grinding O 
( O 
e.g O 
. O 
, O 
wet O 
vs O 
. O 
dry O 
, O 
planetary O 
vs O 
. O 
vibratory O 
milling O 
) O 
were O 
determined O 
to O 
be O 
the O 
main O 
factors O 
that O 
control O 
the O 
effectiveness O 
of O 
the O 
mechanochemical O 
synthesis O 
to O 
enhance O 
the O 
recycling O 
stability O 
of O 
the O 
sorbents O 
prepared O 
. O 
In O 
addition O 
, O 
MgO B-FORMULA 
was O 
used O 
as O 
an O 
example O 
of O 
an O 
inert O 
binder O 
to O 
help O 
mitigate O 
CaCO(3) B-FORMULA 
sintering O 
. O 
Wet O 
planetary O 
milling O 
of O 
MgO B-FORMULA 
into O 
CaCO(3) B-FORMULA 
allowed O 
efficient O 
particle O 
size O 
reduction O 
and O 
the O 
effective O 
dispersion O 
of O 
MgO B-FORMULA 
throughout O 
the O 
particles O 
. O 
Wet O 
planetary O 
milling O 
yielded O 
the O 
most O 
stable O 
sorbents O 
during O 
50 O 
cycles O 
of O 
carbonation O 
- O 
calcination O 
. O 

and O 
evaluation O 
of O 
3,4-dihydropyrimidin-2(1H)-ones B-FAMILY 
as O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
inhibitors O 
. O 

sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
( O 
NIS O 
) O 
is O 
responsible O 
for O 
the O 
accumulation O 
of O 
iodide B-SYSTEMATIC 
in O 
the O 
thyroid O 
gland O 
. O 
This O 
transport O 
process O 
is O 
involved O 
in O 
numerous O 
thyroid O 
dysfunctions O 
and O 
is O 
the O 
basis O 
for O 
human O 
contamination O 
in O 
the O 
case O 
of O 
exposure O 
to O 
radioactive O 
iodine B-SYSTEMATIC 
species O 
. O 
4-Aryl-3,4-dihydropyrimidin-2(1H)-ones B-FAMILY 
were O 
recently O 
discovered O 
by O 
high O 
- O 
throughput O 
screening O 
as O 
the O 
first O 
NIS O 
inhibitors O 
. O 
Described O 
herein O 
are O 
the O 
synthesis O 
and O 
evaluation O 
of O 
115 O 
derivatives O 
with O 
structural O 
modifications O 
at O 
five O 
key O 
positions O 
on O 
the O 
pyrimidone B-SYSTEMATIC 
core O 
. O 
This O 
study O 
provides O 
extensive O 
structure O 
- O 
activity O 
relationships O 
for O 
this O 
new O 
class O 
of O 
inhibitors O 
that O 
will O 
serve O 
as O 
a O 
basis O 
for O 
further O 
development O 
of O 
compounds O 
with O 
in O 
vivo O 
efficacy O 
and O 
adequate O 
pharmacokinetic O 
properties O 
. O 
In O 
addition O 
, O 
the O 
SAR O 
investigation O 
provided O 
a O 
more O 
potent O 
compound O 
, O 
which O 
exhibits O 
an O 
IC(50) O 
value O 
of O 
3.2 O 
nM O 
in O 
a O 
rat O 
thyroid O 
cell O 
line O 
( O 
FRTL5 O 
) O 
. O 

of O 
hepatocellular O 
toxicity O 
associated O 
with O 
dronedarone B-TRIVIAL 
-- O 
a O 
comparison O 
to O 
amiodarone B-TRIVIAL 
. O 

is O 
a O 
new O 
antiarrhythmic O 
drug O 
with O 
an O 
amiodarone B-TRIVIAL 
-like O 
benzofuran B-SYSTEMATIC 
structure O 
. O 
Shortly O 
after O 
its O 
introduction O 
, O 
dronedarone B-TRIVIAL 
became O 
implicated O 
in O 
causing O 
severe O 
liver O 
injury O 
. O 
Amiodarone B-TRIVIAL 
is O 
a O 
well O 
- O 
known O 
mitochondrial O 
toxicant O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
investigate O 
mechanisms O 
of O 
hepatotoxicity O 
of O 
dronedarone B-TRIVIAL 
in O 
vitro O 
and O 
to O 
compare O 
them O 
with O 
amiodarone B-TRIVIAL 
. O 
We O 
used O 
isolated O 
rat O 
liver O 
mitochondria O 
, O 
primary O 
human O 
hepatocytes O 
, O 
and O 
the O 
human O 
hepatoma O 
cell O 
line O 
HepG2 O 
, O 
which O 
were O 
exposed O 
acutely O 
or O 
up O 
to O 
24h O 
. O 
After O 
exposure O 
of O 
primary O 
hepatocytes O 
or O 
HepG2 O 
cells O 
for O 
24h O 
, O 
dronedarone B-TRIVIAL 
and O 
amiodarone B-TRIVIAL 
caused O 
cytotoxicity O 
and O 
apoptosis O 
starting O 
at O 
20 O 
and O 
50 O 
µM O 
, O 
respectively O 
. O 
The O 
cellular O 
ATP B-ABBREVIATION 
content O 
started O 
to O 
decrease O 
at O 
20 O 
µM O 
for O 
both O 
drugs O 
, O 
suggesting O 
mitochondrial O 
toxicity O 
. O 
Inhibition O 
of O 
the O 
respiratory O 
chain O 
required O 
concentrations O 
of O 
~10 O 
µM O 
and O 
was O 
caused O 
by O 
an O 
impairment O 
of O 
complexes O 
I O 
and O 
II O 
for O 
both O 
drugs O 
. O 
In O 
parallel O 
, O 
mitochondrial O 
accumulation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
was O 
observed O 
. O 
In O 
isolated O 
rat O 
liver O 
mitochondria O 
, O 
acute O 
treatment O 
with O 
dronedarone B-TRIVIAL 
decreased O 
the O 
mitochondrial O 
membrane O 
potential O 
, O 
inhibited O 
complex O 
I O 
, O 
and O 
uncoupled O 
the O 
respiratory O 
chain O 
. O 
Furthermore O 
, O 
in O 
acutely O 
treated O 
rat O 
liver O 
mitochondria O 
and O 
in O 
HepG2 O 
cells O 
exposed O 
for O 
24h O 
, O 
dronedarone B-TRIVIAL 
started O 
to O 
inhibit O 
mitochondrial O 
β-oxidation O 
at O 
10 O 
µM O 
and O 
amiodarone B-TRIVIAL 
at O 
20 O 
µM O 
. O 
Similar O 
to O 
amiodarone B-TRIVIAL 
, O 
dronedarone B-TRIVIAL 
is O 
an O 
uncoupler O 
and O 
an O 
inhibitor O 
of O 
the O 
mitochondrial O 
respiratory O 
chain O 
and O 
of O 
β-oxidation O 
both O 
acutely O 
and O 
after O 
exposure O 
for O 
24h O 
. O 
Inhibition O 
of O 
mitochondrial O 
function O 
leads O 
to O 
accumulation O 
of O 
ROS O 
and O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
eventually O 
leading O 
to O 
apoptosis O 
and O 
/ O 
or O 
necrosis O 
of O 
hepatocytes O 
. O 
Mitochondrial O 
toxicity O 
may O 
be O 
an O 
explanation O 
for O 
hepatotoxicity O 
of O 
dronedarone O 
in O 
vivo O 
. O 

inhibits O 
zebrafish O 
epicardium O 
and O 
proepicardium O 
development O 
. O 

exposure O 
to O 
the O 
environmental O 
contaminant O 
and O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
agonist O 
, O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
, O 
dioxin B-FAMILY 
) O 
, O 
disrupts O 
cardiac O 
development O 
and O 
function O 
in O 
fish O 
, O 
birds O 
, O 
and O 
mammals O 
. O 
In O 
zebrafish O 
, O 
the O 
temporal O 
window O 
of O 
sensitivity O 
to O 
the O 
cardiotoxic O 
effects O 
of O 
TCDD B-ABBREVIATION 
coincides O 
with O 
epicardium O 
formation O 
. O 
We O 
hypothesized O 
that O 
this O 
TCDD B-ABBREVIATION 
-induced O 
heart O 
failure O 
results O 
from O 
disruption O 
of O 
epicardial O 
development O 
. O 
To O 
determine O 
whether O 
embryonic O 
TCDD B-ABBREVIATION 
exposure O 
inhibits O 
epicardium O 
and O 
proepicardium O 
( O 
PE O 
) O 
development O 
in O 
zebrafish O 
, O 
we O 
used O 
histology O 
and O 
fluorescence O 
immunocytochemistry O 
to O 
examine O 
the O 
epicardium O 
formation O 
in O 
fish O 
exposed O 
to O 
TCDD B-ABBREVIATION 
. O 
TCDD B-ABBREVIATION 
exposure O 
prevented O 
epicardium O 
formation O 
. O 
Using O 
live O 
imaging O 
and O 
in O 
situ O 
hybridization O 
, O 
we O 
found O 
that O 
TCDD B-ABBREVIATION 
exposure O 
blocked O 
the O 
formation O 
of O 
the O 
PE O 
cluster O 
. O 
In O 
situ O 
hybridization O 
experiments O 
showed O 
that O 
TCDD B-ABBREVIATION 
exposure O 
also O 
prevented O 
the O 
expression O 
of O 
the O 
PE O 
marker O 
tcf21 O 
at O 
the O 
site O 
where O 
the O 
PE O 
normally O 
forms O 
. O 
TCDD B-ABBREVIATION 
also O 
inhibited O 
expansion O 
of O 
the O 
epicardial O 
layer O 
across O 
the O 
developing O 
heart O 
: O 
Exposure O 
after O 
PE O 
formation O 
was O 
completed O 
prevented O 
further O 
expansion O 
of O 
the O 
epicardium O 
. O 
However O 
, O 
TCDD B-ABBREVIATION 
exposure O 
did O 
not O 
affect O 
epicardial O 
cells O 
already O 
present O 
. O 
Because O 
TCDD B-ABBREVIATION 
blocks O 
epicardium O 
formation O 
, O 
but O 
is O 
not O 
directly O 
toxic O 
to O 
the O 
epicardium O 
once O 
complete O 
, O 
we O 
propose O 
that O 
inhibition O 
of O 
epicardium O 
formation O 
can O 
account O 
for O 
the O 
window O 
of O 
sensitivity O 
to O 
TCDD B-ABBREVIATION 
cardiotoxicity O 
in O 
developing O 
zebrafish O 
. O 
Epicardium O 
development O 
is O 
crucial O 
to O 
heart O 
development O 
. O 
Loss O 
of O 
this O 
layer O 
during O 
development O 
may O 
account O 
for O 
most O 
if O 
not O 
all O 
of O 
the O 
TCDD B-ABBREVIATION 
-induced O 
cardiotoxicity O 
in O 
zebrafish O 
. O 

of O 
resveratrol B-TRIVIAL 
on O 
rheumatoid O 
fibroblast O 
- O 
like O 
synoviocytes O 
analysed O 
with O 
gene O 
chip O 
transcription O 
. O 

arthritis O 
( O 
RA O 
) O 
is O 
a O 
chronic O 
, O 
systemic O 
autoimmune O 
disease O 
that O 
primarily O 
attacks O 
joints O 
and O 
is O 
therefore O 
a O 
common O 
cause O 
of O 
chronic O 
disability O 
and O 
articular O 
destruction O 
. O 
The O 
hyperplastic O 
growth O 
of O 
RA-fibroblast O 
- O 
like O 
synoviocytes O 
( O 
FLSs O 
) O 
and O 
their O 
resistance O 
against O 
apoptosis O 
are O 
considered O 
pathological O 
hallmarks O 
of O 
RA O 
. O 
The O 
natural O 
antioxidant O 
resveratrol B-TRIVIAL 
is O 
known O 
for O 
its O 
antiproliferative O 
and O 
pro O 
- O 
apoptotic O 
properties O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
resveratrol B-TRIVIAL 
on O 
RA-FLS O 
. O 
RA-FLS O 
were O 
isolated O 
from O 
the O 
synovium O 
of O 
10 O 
RA O 
patients O 
undergoing O 
synovectomy O 
or O 
joint O 
replacement O 
surgery O 
. O 
RA-FLS O 
were O 
first O 
stressed O 
by O 
pre O 
- O 
incubation O 
with O 
interleukin O 
1beta O 
( O 
IL-1β O 
) O 
and O 
then O 
treated O 
with O 
100 O 
μM O 
resveratrol B-TRIVIAL 
for O 
24h O 
. O 
In O 
order O 
to O 
evaluate O 
the O 
influence O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
transcription O 
of O 
genes O 
, O 
a O 
Gene O 
Chip O 
Human O 
Gene O 
1 O 
ST O 
Array O 
was O 
applied O 
. O 
In O 
addition O 
, O 
the O 
effect O 
of O 
dexamethasone B-TRIVIAL 
on O 
proliferation O 
and O 
apoptosis O 
of O 
RA-FLS O 
was O 
compared O 
with O 
that O 
of O 
resveratrol B-TRIVIAL 
. O 
Gene O 
array O 
analysis O 
showed O 
highly O 
significant O 
effects O 
of O 
resveratrol B-TRIVIAL 
on O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
mitosis O 
, O 
cell O 
cycle O 
, O 
chromosome O 
segregation O 
and O 
apoptosis O 
. O 
qRT-PCR O 
, O 
caspase-3 O 
/ O 
7 O 
and O 
proliferation O 
assays O 
confirmed O 
the O 
results O 
of O 
gene O 
array O 
analysis O 
. O 
In O 
comparison O 
, O 
dexamethasone B-TRIVIAL 
showed O 
little O 
to O 
no O 
effect O 
on O 
reducing O 
cell O 
proliferation O 
and O 
apoptosis O 
. O 
Our O 
in O 
vitro O 
findings O 
point O 
towards O 
resveratrol B-TRIVIAL 
as O 
a O 
promising O 
new O 
therapeutic O 
approach O 
for O 
local O 
intra O 
- O 
articular O 
application O 
against O 
RA O 
, O 
and O 
further O 
clinical O 
studies O 
will O 
be O 
necessary O 
. O 

are O 
produced O 
in O 
plants O 
by O 
micro O 
- O 
fungi O 
species O 
, O 
and O 
naturally O 
contaminated O 
the O 
food O 
chain O 
. O 
In O 
the O 
second O 
French O 
total O 
diet O 
study O 
( O 
TDS O 
) O 
, O 
mycotoxins O 
were O 
analyzed O 
in O 
577 O 
food O 
samples O 
collected O 
in O 
mainland O 
France O 
to O 
be O 
representative O 
of O 
the O 
population O 
diet O 
and O 
prepared O 
( O 
( O 
as O 
consumed O 
) O 
) O 
. O 
Highest O 
mean O 
concentrations O 
were O 
found O 
in O 
wheat O 
and O 
cereal O 
- O 
based O 
products O 
( O 
bread O 
, O 
breakfast O 
cereals O 
, O 
pasta O 
, O 
pastries O 
, O 
pizzas O 
and O 
savoury O 
pastries… O 
) O 
. O 
Exposure O 
of O 
adult O 
and O 
child O 
populations O 
was O 
assessed O 
by O 
combining O 
national O 
consumption O 
data O 
with O 
analytical O 
results O 
, O 
using O 
lowerbound O 
( O 
LB O 
) O 
and O 
upperbound O 
( O 
UB O 
) O 
assumptions O 
for O 
left O 
- O 
censorship O 
management O 
. O 
Individual O 
exposures O 
were O 
compared O 
with O 
available O 
health O 
- O 
based O 
guidance O 
values O 
( O 
HBGV O 
) O 
. O 
Only O 
the O 
exposure O 
to O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
and O 
its O 
acetylated O 
derivatives O 
was O 
found O 
to O 
significantly O 
exceed O 
the O 
HBGV O 
in O 
LB O 
in O 
adults O 
( O 
0.5% O 
[ O 
0.1 O 
; O 
0.8 O 
] O 
) O 
and O 
children O 
( O 
5% O 
[ O 
4 O 
; O 
6 O 
] O 
) O 
. O 
HBGV O 
was O 
exceeded O 
in O 
UB O 
only O 
for O 
T-2 O 
and O 
HT-2 O 
toxins O 
by O 
, O 
respectively O 
, O 
0.2% O 
[ O 
0.02 O 
; O 
0.05 O 
] O 
and O 
4% O 
[ O 
3 O 
; O 
5 O 
] O 
of O 
adults O 
, O 
and O 
11% O 
[ O 
9 O 
; O 
12 O 
] O 
and O 
35% O 
[ O 
32 O 
; O 
37 O 
] O 
of O 
children O 
. O 
Although O 
the O 
exposures O 
assessed O 
were O 
generally O 
lower O 
than O 
the O 
previous O 
French O 
TDS O 
, O 
the O 
results O 
indicated O 
a O 
health O 
concern O 
for O 
trichothecenes B-FAMILY 
and O 
a O 
need O 
to O 
reduce O 
dietary O 
exposure O 
as O 
well O 
as O 
analytical O 
limits O 
. O 

effect O 
of O 
copper B-SYSTEMATIC 
on O 
different O 
phototrophic O 
microorganisms O 
determined O 
in O 
vivo O 
and O 
at O 
cellular O 
level O 
by O 
confocal O 
laser O 
microscopy O 
. O 

mats O 
are O 
coastal O 
ecosystems O 
that O 
consist O 
mainly O 
of O 
cyanobacteria O 
, O 
primary O 
producers O 
in O 
these O 
habitats O 
that O 
play O 
an O 
important O 
role O 
in O 
stabilising O 
delta O 
sediments O 
. O 
However O 
, O 
these O 
ecosystems O 
are O 
subject O 
to O 
various O 
kinds O 
of O 
pollution O 
, O 
including O 
metal O 
contamination O 
, O 
placing O 
their O 
survival O 
at O 
risk O 
. O 
Among O 
heavy O 
metals O 
, O 
copper B-SYSTEMATIC 
is O 
an O 
essential O 
metal O 
at O 
low O 
doses O 
and O 
toxic O 
at O 
high O 
doses O 
. O 
This O 
metal O 
is O 
present O 
in O 
different O 
pesticides O 
used O 
in O 
rice O 
production O 
, O 
a O 
thriving O 
agro O 
- O 
industry O 
in O 
the O 
Ebro O 
Delta O 
( O 
Spain O 
) O 
. O 
For O 
several O 
years O 
, O 
our O 
group O 
has O 
been O 
studying O 
the O 
Ebro O 
Delta O 
microbial O 
mats O 
and O 
has O 
developed O 
a O 
method O 
for O 
determining O 
the O 
effect O 
that O 
metals O 
cause O 
on O 
cyanobacteria O 
populations O 
. O 
This O 
method O 
is O 
based O 
on O 
confocal O 
laser O 
microscopy O 
coupled O 
to O 
a O 
spectrofluorometer O 
, O 
which O 
rapidly O 
provides O 
simultaneous O 
three O 
- O 
dimensional O 
information O 
on O 
photosynthetic O 
microorganisms O 
and O 
their O 
fluorescence O 
spectra O 
profiles O 
. O 
The O 
current O 
study O 
determines O 
the O 
copper B-SYSTEMATIC 
effect O 
on O 
different O 
photosynthetic O 
microorganisms O 
from O 
culture O 
collection O 
( O 
Chroococcus O 
sp O 
. O 
PCC O 
9106 O 
and O 
Spirulina O 
sp O 
. O 
PCC O 
6313 O 
) O 
and O 
isolated O 
from O 
the O 
environment O 
( O 
Microcoleus O 
- O 
like O 
and O 
the O 
microalga O 
DE2009 O 
) O 
. O 
Comparing O 
all O 
results O 
obtained O 
it O 
can O 
be O 
observed O 
that O 
the O 
minimum O 
dose O 
of O 
Cu B-FORMULA 
that O 
is O 
capable O 
of O 
significantly O 
altering O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
( O 
chl B-ABBREVIATION 
a I-ABBREVIATION 
) O 
fluorescence O 
intensity O 
were O 
1 O 
× O 
10(-7) O 
M O 
in O 
Chroococcus O 
sp O 
. O 
PCC O 
9106 O 
; O 
1 O 
× O 
10(-7) O 
M O 
in O 
Spirulina O 
sp O 
. O 
PCC O 
6313 O 
; O 
3 O 
× O 
10(-7) O 
M O 
in O 
Microcoleus O 
and O 
5 O 
× O 
10(-6) O 
M O 
in O 
the O 
microalga O 
DE2009 O 
. O 
Moreover O 
, O 
the O 
sensitivity O 
of O 
the O 
technique O 
used O 
was O 
1 O 
× O 
10(-7) O 
M O 
. O 

results O 
on O 
formaldehyde B-SYSTEMATIC 
: O 
the O 
2nd O 
International O 
Formaldehyde B-SYSTEMATIC 
Science O 
Conference O 
( O 
Madrid O 
, O 
19-20 O 
April O 
2012 O 
) O 
. O 

toxicology O 
and O 
epidemiology O 
of O 
formaldehyde B-SYSTEMATIC 
were O 
discussed O 
on O 
the O 
2nd O 
International O 
Formaldehyde B-SYSTEMATIC 
Science O 
Conference O 
in O 
Madrid O 
, O 
19-20 O 
April O 
2012 O 
. O 
It O 
was O 
noted O 
that O 
a O 
substantial O 
amount O 
of O 
new O 
scientific O 
data O 
has O 
appeared O 
within O 
the O 
last O 
years O 
since O 
the O 
1st O 
conference O 
in O 
2007 O 
. O 
Progress O 
has O 
been O 
made O 
in O 
characterisation O 
of O 
genotoxicity O 
, O 
toxicokinetics O 
, O 
formation O 
of O 
exogenous O 
and O 
endogenous O 
DNA O 
adducts O 
, O 
controlled O 
human O 
studies O 
and O 
epidemiology O 
. O 
Thus O 
, O 
new O 
research O 
results O 
are O 
now O 
at O 
hand O 
to O 
be O 
incorporated O 
into O 
existing O 
evaluations O 
on O 
formaldehyde B-SYSTEMATIC 
by O 
official O 
bodies O 
. O 

palladium B-SYSTEMATIC 
-catalyzed O 
asymmetric O 
hydrogenation O 
. O 

transition O 
metal O 
catalyzed O 
asymmetric O 
hydrogenation O 
of O 
unsaturated O 
compounds O 
arguably O 
presents O 
one O 
of O 
the O 
most O 
attractive O 
methods O 
for O 
the O 
synthesis O 
of O 
chiral O 
compounds O 
. O 
Over O 
the O 
last O 
few O 
decades O 
, O 
Pd B-FORMULA 
has O 
gradually O 
grown O 
up O 
as O 
a O 
new O 
and O 
popular O 
metal O 
catalyst O 
in O 
homogeneous O 
asymmetric O 
hydrogenation O 
the O 
same O 
as O 
traditional O 
Ru B-FORMULA 
, O 
Rh B-FORMULA 
and O 
Ir B-FORMULA 
catalysts O 
. O 
Much O 
progress O 
has O 
been O 
successfully O 
achieved O 
in O 
the O 
asymmetric O 
reduction O 
of O 
imines B-FAMILY 
, O 
enamines B-FAMILY 
, O 
olefins B-FAMILY 
, O 
ketones B-FAMILY 
and O 
heteroarenes B-FAMILY 
. O 
It O 
was O 
also O 
found O 
that O 
palladium B-SYSTEMATIC 
catalyzed O 
asymmetric O 
hydrogenation O 
could O 
be O 
used O 
as O 
a O 
key O 
step O 
in O 
tandem O 
reactions O 
to O 
quickly O 
synthesize O 
chiral O 
compounds O 
. O 
This O 
tutorial O 
review O 
intends O 
to O 
offer O 
an O 
overview O 
of O 
recent O 
progress O 
in O 
homogeneous O 
palladium B-SYSTEMATIC 
catalyzed O 
asymmetric O 
hydrogenation O 
and O 
should O 
serve O 
as O 
an O 
inspiration O 
for O 
further O 
advances O 
in O 
this O 
area O 
. O 

of O 
the O 
dominant O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
cytochrome O 
p450 O 
monooxygenases O 
in O 
rat O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
: O 
protein O 
expression O 
and O 
metabolite O 
kinetics O 
. O 

P450 O 
( O 
P450 O 
) O 
- O 
derived O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
metabolites O 
serve O 
pivotal O 
physiological O 
roles O 
. O 
Therefore O 
, O 
it O 
is O 
important O 
to O 
determine O 
the O 
dominant O 
P450 O 
AA O 
monooxygenases O 
in O 
different O 
organs O 
. O 
We O 
investigated O 
the O 
P450 O 
AA O 
monooxygenases O 
protein O 
expression O 
as O 
well O 
as O 
regioselectivity O 
, O 
immunoinhibition O 
, O 
and O 
kinetic O 
profile O 
of O 
AA O 
epoxygenation O 
and O 
hydroxylation O 
in O 
rat O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
. O 
Thereafter O 
, O 
the O 
predominant O 
P450 O 
epoxygenases O 
and O 
P450 O 
hydroxylases O 
in O 
these O 
organs O 
were O 
characterized O 
. O 
Microsomes O 
from O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
were O 
incubated O 
with O 
AA O 
. O 
The O 
protein O 
expression O 
of O 
CYP2B1 O 
/ O 
2 O 
, O 
CYP2C11 O 
, O 
CYP2C23 O 
, O 
CYP2J3 O 
, O 
CYP4A1 O 
/ O 
2 O 
/ O 
3 O 
, O 
and O 
CYP4Fs O 
in O 
the O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
were O 
determined O 
by O 
Western O 
blot O 
analysis O 
. O 
The O 
levels O 
of O 
AA O 
metabolites O 
were O 
determined O 
by O 
liquid O 
chromatography O 
- O 
electrospray O 
ionization O 
mass O 
spectroscopy O 
. O 
This O 
was O 
followed O 
by O 
determination O 
of O 
regioselectivity O 
, O 
immunoinhibition O 
effect O 
, O 
and O 
the O 
kinetic O 
profile O 
of O 
AA O 
metabolism O 
. O 
AA O 
was O 
metabolized O 
to O 
epoxyeicosatrienoic B-FAMILY 
acids I-FAMILY 
and O 
19- B-MULTIPLE 
and I-MULTIPLE 
20-hydroxyeicosatetraenoic I-MULTIPLE 
acid I-MULTIPLE 
in O 
the O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
but O 
with O 
varying O 
metabolic O 
activities O 
and O 
regioselectivity O 
. O 
Anti-P450 O 
antibodies O 
were O 
found O 
to O 
differentially O 
inhibit O 
AA O 
epoxygenation O 
and O 
hydroxylation O 
in O 
these O 
organs O 
. O 
Our O 
data O 
suggest O 
that O 
the O 
predominant O 
epoxygenases O 
are O 
CYP2C11 O 
, O 
CYP2B1 O 
, O 
CYP2C23 O 
, O 
and O 
CYP2C11 O 
/ O 
CYP2C23 O 
for O 
the O 
heart O 
, O 
lung O 
, O 
kidney O 
, O 
and O 
liver O 
, O 
respectively O 
. O 
On O 
the O 
other O 
hand O 
, O 
CYP4A1 O 
is O 
the O 
major O 
ω-hydroxylase O 
in O 
the O 
heart O 
and O 
kidney O 
; O 
whereas O 
CYP4A2 O 
and O 
/ O 
or O 
CYP4F1 O 
/ O 
4 O 
are O 
probably O 
the O 
major O 
hydroxlases O 
in O 
the O 
lung O 
and O 
liver O 
. O 
These O 
results O 
provide O 
important O 
insights O 
into O 
the O 
activities O 
of O 
P450 O 
epoxygenases O 
and O 
P450 O 
hydroxylases O 
- O 
mediated O 
AA O 
metabolism O 
in O 
different O 
organs O 
and O 
their O 
associated O 
P450 O 
protein O 
levels O 
. O 

of O 
the O 
repaglinide O 
concentration O 
increase O 
produced O 
by O 
gemfibrozil B-TRIVIAL 
and O 
itraconazole B-TRIVIAL 
based O 
on O 
the O 
inhibition O 
of O 
the O 
hepatic O 
uptake O 
transporter O 
and O 
metabolic O 
enzymes O 
. O 

plasma O 
concentration O 
of O 
repaglinide B-TRIVIAL 
is O 
reported O 
to O 
increase O 
greatly O 
when O 
given O 
after O 
repeated O 
oral O 
administration O 
of O 
itraconazole B-TRIVIAL 
and O 
gemfibrozil B-TRIVIAL 
. O 
The O 
present O 
study O 
analyzed O 
this O 
interaction O 
based O 
on O 
a O 
physiologically O 
based O 
pharmacokinetic O 
( O 
PBPK O 
) O 
model O 
incorporating O 
inhibition O 
of O 
the O 
hepatic O 
uptake O 
transporter O 
and O 
metabolic O 
enzymes O 
involved O 
in O 
repaglinide O 
disposition O 
. O 
Firstly O 
, O 
the O 
plasma O 
concentration O 
profiles O 
of O 
inhibitors O 
( O 
itraconazole B-TRIVIAL 
, O 
gemfibrozil B-TRIVIAL 
, O 
and O 
gemfibrozil B-TRIVIAL 
glucuronide I-TRIVIAL 
) O 
were O 
reproduced O 
by O 
a O 
PBPK O 
model O 
to O 
obtain O 
their O 
pharmacokinetic O 
parameters O 
. O 
The O 
plasma O 
concentration O 
profiles O 
of O 
repaglinide B-TRIVIAL 
were O 
then O 
analyzed O 
by O 
a O 
PBPK O 
model O 
, O 
together O 
with O 
those O 
of O 
the O 
inhibitors O 
, O 
assuming O 
a O 
competitive O 
inhibition O 
of O 
CYP3A4 O 
by O 
itraconazole B-TRIVIAL 
, O 
mechanism O 
- O 
based O 
inhibition O 
of O 
CYP2C8 O 
by O 
gemfibrozil B-TRIVIAL 
glucuronide I-TRIVIAL 
, O 
and O 
inhibition O 
of O 
organic O 
anion O 
transporting O 
polypeptide O 
( O 
OATP O 
) O 
1B1 O 
by O 
gemfibrozil B-MULTIPLE 
and I-MULTIPLE 
its I-MULTIPLE 
glucuronide I-MULTIPLE 
. O 
The O 
plasma O 
concentration O 
profiles O 
of O 
repaglinide B-TRIVIAL 
were O 
well O 
reproduced O 
by O 
the O 
PBPK O 
model O 
based O 
on O 
the O 
above O 
assumptions O 
, O 
and O 
the O 
optimized O 
values O 
for O 
the O 
inhibition O 
constants O 
( O 
0.0676 O 
nM O 
for O 
itraconazole B-TRIVIAL 
against O 
CYP3A4 O 
; O 
14.2 O 
μM O 
for O 
gemfibrozil B-TRIVIAL 
against O 
OATP1B1 O 
; O 
and O 
5.48 O 
μM O 
for O 
gemfibrozil B-TRIVIAL 
glucuronide I-TRIVIAL 
against O 
OATP1B1 O 
) O 
and O 
the O 
fraction O 
of O 
repaglinide B-TRIVIAL 
metabolized O 
by O 
CYP2C8 O 
( O 
0.801 O 
) O 
were O 
consistent O 
with O 
the O 
reported O 
values O 
. O 
The O 
validity O 
of O 
the O 
obtained O 
parameters O 
was O 
further O 
confirmed O 
by O 
sensitivity O 
analyses O 
and O 
by O 
reproducing O 
the O 
repaglinide B-TRIVIAL 
concentration O 
increase O 
produced O 
by O 
concomitant O 
gemfibrozil B-TRIVIAL 
administration O 
at O 
various O 
timings O 
/ O 
doses O 
. O 
The O 
present O 
findings O 
suggested O 
that O 
the O 
reported O 
concentration O 
increase O 
of O 
repaglinide B-TRIVIAL 
, O 
suggestive O 
of O 
synergistic O 
effects O 
of O 
the O 
coadministered O 
inhibitors O 
, O 
can O 
be O 
quantitatively O 
explained O 
by O 
the O 
simultaneous O 
inhibition O 
of O 
the O 
multiple O 
clearance O 
pathways O 
of O 
repaglinide B-TRIVIAL 
. O 

topology O 
of O 
the O 
second O 
extracellular O 
loop O 
( O 
ECL2 O 
) O 
and O 
its O 
interaction O 
with O 
ligands O 
is O 
unique O 
in O 
each O 
G O 
protein O 
- O 
coupled O 
receptor O 
. O 
When O 
the O 
orthosteric O 
ligand O 
pocket O 
located O 
in O 
the O 
transmembrane O 
( O 
TM O 
) O 
domain O 
is O 
occupied O 
, O 
ligand O 
- O 
specific O 
conformational O 
changes O 
occur O 
in O 
the O 
ECL2 O 
. O 
In O 
more O 
than O 
90% O 
of O 
G O 
protein O 
- O 
coupled O 
receptors O 
, O 
ECL2 O 
is O 
tethered O 
to O 
the O 
third O 
TM O 
helix O 
via O 
a O 
disulfide O 
bond O 
. O 
Therefore O 
, O 
understanding O 
the O 
extent O 
to O 
which O 
the O 
TM O 
domain O 
and O 
ECL2 O 
conformations O 
are O 
coupled O 
is O 
useful O 
. O 
To O 
investigate O 
this O 
, O 
we O 
examined O 
conformational O 
changes O 
in O 
ECL2 O 
of O 
the O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
( O 
AT1R O 
) O 
by O 
introducing O 
mutations O 
in O 
distant O 
sites O 
that O 
alter O 
the O 
activation O 
state O 
equilibrium O 
of O 
the O 
AT1R O 
. O 
Differential O 
accessibility O 
of O 
reporter O 
cysteines B-FAMILY 
introduced O 
at O 
four O 
conformation O 
- O 
sensitive O 
sites O 
in O 
ECL2 O 
of O 
these O 
mutants O 
was O 
measured O 
. O 
Binding O 
of O 
the O 
agonist O 
angiotensin O 
II O 
( O 
AngII O 
) O 
and O 
inverse O 
agonist O 
losartan B-TRIVIAL 
in O 
wild O 
- O 
type O 
AT1R O 
changed O 
the O 
accessibility O 
of O 
reporter O 
cysteines B-FAMILY 
, O 
and O 
the O 
pattern O 
was O 
consistent O 
with O 
ligand O 
- O 
specific O 
" O 
lid O 
" O 
conformations O 
of O 
ECL2 O 
. O 
Without O 
agonist O 
stimulation O 
, O 
the O 
ECL2 O 
in O 
the O 
gain O 
of O 
function O 
mutant O 
N111G O 
assumed O 
a O 
lid O 
conformation O 
similar O 
to O 
AngII O 
- O 
bound O 
wild O 
- O 
type O 
AT1R O 
. O 
In O 
the O 
presence O 
of O 
inverse O 
agonists O 
, O 
the O 
conformation O 
of O 
ECL2 O 
in O 
the O 
N111G O 
mutant O 
was O 
similar O 
to O 
the O 
inactive O 
state O 
of O 
wild O 
- O 
type O 
AT1R O 
. O 
In O 
contrast O 
, O 
AngII O 
did O 
not O 
induce O 
a O 
lid O 
conformation O 
in O 
ECL2 O 
in O 
the O 
loss O 
of O 
function O 
D281A O 
mutant O 
, O 
which O 
is O 
consistent O 
with O 
the O 
reduced O 
AngII O 
binding O 
affinity O 
in O 
this O 
mutant O 
. O 
However O 
, O 
a O 
lid O 
conformation O 
was O 
induced O 
by O 
[ O 
Sar B-ABBREVIATION 
( O 
1 O 
) O 
, O 
Gln B-FORMULA 
( O 
2 O 
) O 
, O 
Ile B-FORMULA 
( O 
8 O 
) O 
] O 
AngII O 
, O 
a O 
specific O 
analog O 
that O 
binds O 
to O 
the O 
D281A O 
mutant O 
with O 
better O 
affinity O 
than O 
AngII O 
. O 
These O 
results O 
provide O 
evidence O 
for O 
the O 
emerging O 
paradigm O 
of O 
domain O 
coupling O 
facilitated O 
by O 
long O 
range O 
interactions O 
at O 
distant O 
sites O 
on O 
the O 
same O 
receptor O 
. O 

tea O 
has O 
been O 
shown O 
to O 
have O 
thermogenic O 
and O 
antiobesity O 
properties O 
. O 
Therefore O 
, O 
it O 
is O 
important O 
to O 
investigate O 
its O 
effect O 
on O 
weight O 
loss O 
in O 
humans O 
, O 
especially O 
in O 
women O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
green O 
tea O 
consumption O 
combined O 
with O 
resistance O 
training O 
on O 
the O 
body O 
composition O 
and O 
the O 
resting O 
metabolic O 
rate O 
( O 
RMR O 
) O 
in O 
women O 
who O 
were O 
overweight O 
or O 
obese O 
( O 
grade O 
I O 
) O 
. O 
After O 
4 O 
weeks O 
on O 
an O 
adaptive O 
diet O 
, O 
36 O 
women O 
were O 
divided O 
into O 
four O 
groups O 
( O 
group O 
1 O 
green O 
tea O 
; O 
group O 
2 O 
placebo O 
; O 
group O 
3 O 
green O 
tea O 
plus O 
resistance O 
training O 
; O 
group O 
4 O 
placebo O 
plus O 
resistance O 
training O 
) O 
. O 
The O 
study O 
was O 
double O 
- O 
blinded O 
and O 
placebo O 
- O 
controlled O 
. O 
The O 
RMR O 
and O 
body O 
composition O 
were O 
ascertained O 
for O 
each O 
volunteer O 
, O 
blood O 
tests O 
were O 
performed O 
, O 
and O 
subjects O 
in O 
groups O 
3 O 
and O 
4 O 
were O 
tested O 
for O 
their O 
one O 
repetition O 
maximum O 
. O 
Each O 
subject O 
followed O 
the O 
protocol O 
and O 
continued O 
the O 
diet O 
for O 
eight O 
additional O 
weeks O 
, O 
and O 
periodic O 
evaluations O 
were O 
administered O 
. O 
The O 
mean O 
RMR O 
of O 
group O 
1 O 
decreased O 
significantly O 
and O 
was O 
accompanied O 
by O 
weight O 
loss O 
, O 
maintenance O 
of O 
lean O 
body O 
mass O 
, O 
and O 
decreases O 
in O 
both O 
waist O 
circumference O 
and O 
body O 
mass O 
index O 
. O 
Group O 
2 O 
showed O 
no O 
variations O 
in O 
anthropometric O 
or O 
blood O 
variables O 
and O 
significantly O 
decreased O 
their O 
mean O 
RMR O 
. O 
Group O 
3 O 
showed O 
significant O 
increases O 
in O 
RMR O 
, O 
lean O 
body O 
mass O 
, O 
and O 
muscle O 
strength O 
, O 
and O 
significant O 
decreases O 
in O 
body O 
fat O 
, O 
triglycerides B-FAMILY 
, O 
and O 
waist O 
circumference O 
as O 
compared O 
to O 
group O 
4 O 
. O 
Green O 
tea O 
combined O 
with O 
resistance O 
training O 
its O 
potential O 
is O 
increased O 
with O 
decreasing O 
body O 
fat O 
, O 
waist O 
circumference O 
, O 
and O 
triacylglyceride B-FAMILY 
levels O 
and O 
by O 
increasing O 
lean O 
body O 
mass O 
and O 
muscle O 
strength O 
. O 

inhibits O 
CTGF O 
expression O 
via O 
blocking O 
NF-κB O 
activation O 
in O 
cardiac O 
fibroblast O 
. O 

tissue O 
growth O 
factor O 
( O 
CTGF O 
) O 
has O 
been O 
reported O 
to O 
play O 
an O 
important O 
role O 
in O 
tissue O 
fibrosis O 
and O 
presents O 
a O 
promising O 
therapeutic O 
target O 
for O 
fibrotic O 
diseases O 
. O 
In O 
heart O 
, O 
inappropriate O 
increase O 
in O 
level O 
of O 
CTGF O 
promotes O 
fibroblast O 
proliferation O 
and O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
accumulation O 
, O 
thereby O 
exacerbating O 
cardiac O 
hypertrophy O 
and O 
subsequent O 
failure O 
. O 
Epigallocatechin-3-gallate B-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
the O 
major O 
polyphenol B-FAMILY 
found O 
in O 
green O 
tea O 
, O 
possesses O 
multiple O 
protective O 
effects O 
on O 
the O 
cardiovascular O 
system O 
including O 
cardiac O 
fibrosis O 
. O 
However O 
, O 
the O 
molecular O 
mechanism O 
by O 
which O 
EGCG B-ABBREVIATION 
exerts O 
its O 
anti-fibrotic O 
effects O 
has O 
not O 
been O 
well O 
investigated O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
EGCG B-ABBREVIATION 
could O 
significantly O 
reduce O 
collagen O 
synthesis O 
, O 
fibronectin O 
( O 
FN O 
) O 
expression O 
and O 
cell O 
proliferation O 
in O 
rat O 
cardiac O 
fibroblasts O 
stimulated O 
with O 
angiotensinII O 
( O 
AngII O 
) O 
. O 
It O 
also O 
ameliorated O 
cardiac O 
fibrosis O 
in O 
rats O 
submitted O 
to O 
abdominal O 
aortic O 
constriction O 
( O 
AAC O 
) O 
. O 
Moreover O 
, O 
EGCG B-ABBREVIATION 
attenuated O 
the O 
excessive O 
expression O 
of O 
CTGF O 
induced O 
by O 
AAC O 
or O 
AngII O 
, O 
and O 
reduced O 
the O 
nuclear O 
translocation O 
of O 
NF-κB O 
p65 O 
subunit O 
and O 
degradation O 
of O 
IκB-α O 
. O 
Subsequently O 
, O 
we O 
demonstrated O 
that O 
in O 
cardiac O 
fibroblasts O 
NF-κB O 
inhibition O 
could O 
suppress O 
AngII-induced O 
CTGF O 
expression O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
provide O 
the O 
first O 
evidence O 
that O 
the O 
effect O 
of O 
EGCG B-ABBREVIATION 
against O 
cardiac O 
fibrosis O 
may O 
be O 
attributed O 
to O 
its O 
inhibition O 
on O 
NF-κB O 
activation O 
and O 
subsequent O 
CTGF O 
overexpression O 
, O 
suggesting O 
the O 
therapeutic O 
potential O 
of O 
EGCG B-ABBREVIATION 
on O 
the O 
prevention O 
of O 
cardiac O 
remodeling O 
in O 
patients O 
with O 
pressure O 
overload O 
hypertrophy O 
. O 

soluble O 
guanylate O 
cyclase O 
stimulator O 
, O 
BAY B-IDENTIFIER 
41-8543 I-IDENTIFIER 
, O 
preserves O 
right O 
ventricular O 
function O 
in O 
experimental O 
pulmonary O 
embolism O 
. O 

embolism O 
( O 
PE O 
) O 
increases O 
pulmonary O 
vascular O 
resistance O 
, O 
causing O 
right O 
ventricular O 
( O 
RV O 
) O 
dysfunction O 
, O 
and O 
poor O 
clinical O 
outcome O 
. O 
Present O 
studies O 
test O 
if O 
the O 
soluble O 
guanylate O 
cyclase O 
stimulator O 
BAY B-IDENTIFIER 
41-8543 I-IDENTIFIER 
reduces O 
pulmonary O 
vascular O 
resistance O 
and O 
protects O 
RV O 
function O 
. O 
Experimental O 
PE O 
was O 
induced O 
in O 
anesthetized O 
, O 
male O 
Sprague-Dawley O 
rats O 
by O 
infusing O 
25 O 
μm O 
polystyrene B-SYSTEMATIC 
microspheres O 
( O 
1.95 O 
million O 
/ O 
100 O 
g O 
body O 
wt O 
, O 
right O 
jugular O 
vein O 
) O 
producing O 
moderate O 
PE O 
. O 
Pulmonary O 
artery O 
vascular O 
resistance O 
, O 
estimated O 
as O 
RVPSP O 
/ O 
CO O 
, O 
increased O 
3-fold O 
after O 
5 O 
h O 
of O 
PE O 
. O 
Treatment O 
with O 
BAY B-IDENTIFIER 
41-8543 I-IDENTIFIER 
( O 
50 O 
μg O 
/ O 
kg O 
, O 
I.V O 
. O 
; O 
given O 
at O 
the O 
time O 
of O 
PE O 
induction O 
) O 
normalized O 
this O 
index O 
by O 
reducing O 
RVPSP O 
and O 
markedly O 
increasing O 
CO O 
, O 
via O 
preservation O 
of O 
heart O 
rate O 
and O 
stroke O 
volume O 
. O 
Ex O 
vivo O 
RV O 
heart O 
function O 
showed O 
minimal O 
changes O 
at O 
5 O 
h O 
of O 
PE O 
, O 
but O 
decreased O 
significantly O 
after O 
18 O 
h O 
of O 
PE O 
, O 
including O 
peak O 
systolic O 
pressure O 
( O 
PSP O 
, O 
Control O 
39 O 
± O 
1 O 
mmHg O 
vs O 
. O 
19 O 
± O 
3 O 
PE), O 
+dP O 
/ O 
dt O 
( O 
1192 O 
± O 
93 O 
mmHg O 
/ O 
s O 
vs O 
. O 
444 O 
± O 
64 O 
) O 
and O 
-dP O 
/ O 
dt O 
( O 
-576 O 
± O 
60 O 
mmHg O 
/ O 
s O 
vs. O 
-278 O 
± O 
40 O 
) O 
. O 
BAY O 
41-8543 O 
significantly O 
improved O 
all O 
three O 
indices O 
of O 
RV O 
heart O 
function O 
( O 
PSP O 
35 O 
± O 
3.5, O 
+ O 
dP O 
/ O 
dt O 
1129 O 
± O 
100 O 
, O 
-dP O 
/ O 
dt O 
-568 O 
± O 
87 O 
) O 
. O 
Experimental O 
PE O 
produced O 
increased O 
PVR O 
and O 
RV O 
dysfunction O 
, O 
which O 
were O 
ameliorated O 
by O 
treatment O 
with O 
BAY B-IDENTIFIER 
41-854 I-IDENTIFIER 
3 O 
. O 
Thus O 
, O 
there O 
is O 
vasodilator O 
reserve O 
in O 
this O 
model O 
of O 
experimental O 
PE O 
that O 
can O 
be O 
exploited O 
to O 
reduce O 
the O 
stress O 
upon O 
the O 
heart O 
and O 
preserve O 
RV O 
contractile O 
function O 
. O 

of O 
developmental O 
dioxin B-FAMILY 
exposure O 
on O 
methylation O 
and O 
expression O 
of O 
specific O 
imprinted O 
genes O 
in O 
mice O 
. O 

( O 
TCDD B-ABBREVIATION 
) O 
is O 
an O 
endocrine O 
disruptor O 
affecting O 
the O 
reproductive O 
system O 
in O 
humans O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
TCDD B-ABBREVIATION 
administered O 
to O 
pregnant O 
mice O 
at O 
two O 
different O 
doses O 
( O 
2-10 O 
ng O 
/ O 
kg O 
/ O 
day O 
) O 
, O 
on O 
imprinted O 
genes O 
in O 
the O 
male O 
offspring O 
. O 
The O 
degree O 
of O 
methylation O 
and O 
the O 
mRNA O 
expression O 
of O 
Snrpn O 
, O 
Peg3 O 
and O 
Igf2r O 
were O 
analyzed O 
in O 
the O 
sperm O 
, O 
skeletal O 
muscle O 
and O 
liver O 
. O 
TCDD B-ABBREVIATION 
administration O 
( O 
10 O 
ng O 
/ O 
kg O 
/ O 
day O 
) O 
decreased O 
the O 
sperm O 
count O 
in O 
the O 
male O 
offspring O 
. O 
It O 
did O 
not O 
affect O 
methylation O 
but O 
increased O 
mRNA O 
expression O 
of O 
Snrpn O 
, O 
Peg3 O 
, O 
Igf2r O 
and O 
Air O 
ncRNA O 
. O 
In O 
muscle O 
and O 
liver O 
, O 
TCDD B-ABBREVIATION 
( O 
10 O 
ng O 
/ O 
kg O 
/ O 
day O 
) O 
induced O 
increases O 
in O 
methylation O 
and O 
decreases O 
in O 
mRNA O 
expression O 
of O 
Igf2r O 
. O 
These O 
results O 
show O 
that O 
the O 
robust O 
effects O 
of O 
TCDD B-ABBREVIATION 
on O 
the O 
mRNA O 
expression O 
of O 
Snrpn O 
, O 
Peg3 O 
and O 
Igf2r O 
genes O 
in O 
the O 
sperm O 
and O 
of O 
Igf2r O 
in O 
the O 
muscle O 
and O 
liver O 
are O 
unrelated O 
to O 
changes O 
in O 
methylation O 
in O 
their O 
respective O 
genes O 
. O 

17-β-oestradiol B-SYSTEMATIC 
inhibits O 
osteoclast O 
activity O 
by O 
increasing O 
the O 
cannabinoid O 
CB2 O 
receptor O 
expression O 
. O 

is O 
a O 
highly O 
metabolically O 
active O 
tissue O 
and O 
its O 
formation O 
and O 
resorption O 
is O 
at O 
the O 
base O 
of O 
bone O 
remodelling O 
. O 
The O 
critical O 
importance O 
of O 
a O 
balanced O 
bone O 
remodelling O 
is O 
demonstrated O 
by O 
human O 
diseases O 
, O 
i.e O 
. O 
osteoporosis O 
, O 
in O 
which O 
a O 
net O 
increase O 
in O 
bone O 
resorption O 
is O 
responsible O 
of O 
skeleton O 
weakening O 
and O 
fracture O 
risk O 
. O 
Oestrogens B-FAMILY 
display O 
anti-resorptive O 
properties O 
on O 
bone O 
metabolism O 
. O 
Indeed O 
, O 
the O 
so O 
- O 
called O 
post O 
- O 
menopausal O 
osteoporosis O 
occurs O 
after O 
interruption O 
of O 
gonad O 
function O 
and O 
benefits O 
from O 
hormonal O 
replacement O 
treatment O 
. O 
Recently O 
, O 
an O 
important O 
role O 
for O 
the O 
endocannabinoid O 
system O 
in O 
the O 
regulation O 
of O 
skeletal O 
remodelling O 
in O 
human O 
has O 
also O 
been O 
shown O 
. O 
In O 
particular O 
, O 
we O 
showed O 
that O 
CB2 O 
stimulation O 
is O 
able O 
to O 
reduce O 
the O 
number O 
of O 
human O 
OCs O 
in O 
vitro O 
. O 
Here O 
, O 
we O 
provide O 
unprecedented O 
evidence O 
that O 
17-β-oestradiol B-SYSTEMATIC 
administration O 
inhibits O 
activity O 
and O 
formation O 
of O 
human O 
OCs O 
in O 
vitro O 
, O 
demonstrating O 
that O 
oestrogens B-FAMILY 
are O 
able O 
to O 
induce O 
an O 
increase O 
of O 
CB2 O 
expression O 
probably O 
through O 
the O 
recruitment O 
of O 
a O 
putative O 
oestrogens B-FAMILY 
responsive O 
element O 
in O 
the O 
CB2 O 
encoding O 
for O 
gene O 
. O 

- O 
oncogene O 
PIM-1 O 
is O 
a O 
novel O 
estrogen B-FAMILY 
receptor O 
target O 
associating O 
with O 
high O 
grade O 
breast O 
tumors O 
. O 

searched O 
ERα O 
cistromes O 
of O 
MCF-7 O 
breast O 
cancer O 
cells O 
for O 
previously O 
unrecognized O 
ERα O 
targets O 
and O 
identified O 
proto O 
- O 
oncogene O 
PIM-1 O 
as O 
a O 
novel O 
potential O 
target O 
gene O 
. O 
We O 
show O 
that O 
the O 
expression O 
of O 
PIM-1 O 
is O 
induced O 
in O 
response O 
to O 
estradiol B-TRIVIAL 
in O 
MCF-7 O 
cells O 
and O 
that O 
the O 
induction O 
is O 
mediated O 
by O 
ERα-regulated O 
enhancers O 
located O 
distally O 
upstream O 
from O 
the O 
gene O 
. O 
In O 
keeping O 
with O 
the O 
growth O 
- O 
promoting O 
role O 
of O 
the O 
PIM-1 O 
, O 
depletion O 
of O 
the O 
PIM-1 O 
attenuated O 
the O 
proliferation O 
of O 
the O 
MCF-7 O 
cells O 
, O 
which O 
was O 
paralleled O 
with O 
up O 
- O 
regulation O 
of O 
cyclin O 
- O 
dependent O 
protein O 
kinase O 
inhibitor O 
CDKN1A O 
and O 
CDKN2B O 
expression O 
. O 
Analysis O 
of O 
PIM-1 O 
expression O 
between O 
invasive O 
breast O 
tumors O 
and O 
benign O 
breast O 
tissue O 
samples O 
showed O 
that O 
elevated O 
PIM-1 O 
expression O 
is O 
associated O 
with O 
malignancy O 
and O 
a O 
higher O 
tumor O 
grade O 
. O 
In O 
sum O 
, O 
identification O 
of O 
PIM-1 O 
as O 
an O 
ERα O 
target O 
gene O 
adds O 
a O 
novel O 
potential O 
mechanism O 
by O 
which O 
estrogens B-FAMILY 
can O 
contribute O 
to O 
breast O 
cancer O 
cell O 
proliferation O 
and O 
carcinogenesis O 
. O 

( O 
DDT B-ABBREVIATION 
) O 
, O 
DDT B-ABBREVIATION 
metabolites O 
and O 
pregnancy O 
outcomes O 
. O 

pesticides O 
( O 
OCPs O 
) O 
are O 
persistent O 
endocrine O 
disruptors O 
. O 
OCPs O 
cross O 
the O 
placenta O 
; O 
this O 
prenatal O 
exposure O 
has O 
been O 
associated O 
with O 
adverse O 
pregnancy O 
outcomes O 
. O 
We O 
investigated O 
associations O 
between O 
prenatal O 
exposure O 
to O 
OCPs O 
and O 
gestational O 
age O 
and O 
birth O 
weight O 
in O 
600 O 
infants O 
born O 
between O 
1960 O 
and O 
1963 O 
. O 
The O 
primary O 
OCP O 
was O 
1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane B-SYSTEMATIC 
( O 
p,p'-DDT B-ABBREVIATION 
) O 
, O 
its O 
primary O 
metabolite O 
, O 
1,1'-dichloro-2,2'-bis(p-chlorophenyl)ethylene B-SYSTEMATIC 
( O 
p,p'-DDE B-SYSTEMATIC 
) O 
and O 
the O 
contaminant O 
, O 
1,1,1-trichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)-ethane B-SYSTEMATIC 
( O 
o,p'-DDT B-ABBREVIATION 
) O 
. O 
Regression O 
analysis O 
indicated O 
that O 
for O 
each O 
natural O 
log O 
unit O 
increase O 
in O 
p,p'-DDT B-ABBREVIATION 
, O 
birth O 
weight O 
increased O 
by O 
274 O 
g O 
( O 
95% O 
CI O 
: O 
122 O 
, O 
425 O 
) O 
when O 
controlling O 
for O 
p,p'-DDE B-SYSTEMATIC 
and O 
o,p'-DDT B-ABBREVIATION 
. O 
At O 
a O 
given O 
level O 
of O 
p,p'-DDT B-ABBREVIATION 
exposure O 
, O 
o,p'-DDT B-ABBREVIATION 
and O 
p,p'-DDE B-SYSTEMATIC 
were O 
associated O 
with O 
decreased O 
birth O 
weight O 
. O 
p,p'-DDE B-SYSTEMATIC 
was O 
negatively O 
associated O 
with O 
length O 
of O 
gestation O 
, O 
controlling O 
for O 
p,p'-DDT B-ABBREVIATION 
and O 
o,p'-DDT B-ABBREVIATION 
. O 
These O 
findings O 
suggest O 
opposing O 
associations O 
between O 
exposure O 
to O 
p,p'-DDT B-ABBREVIATION 
and O 
p,p'-DDE B-SYSTEMATIC 
and O 
birth O 
weight O 
. O 
We O 
did O 
not O 
find O 
evidence O 
to O 
support O 
mediation O 
by O 
maternal O 
thyroid O 
hormone O 
status O 
nor O 
that O 
the O 
association O 
differed O 
by O 
sex O 
. O 

( O 
Cd B-FORMULA 
)-induced O 
oxidative O 
stress O 
down O 
- O 
regulates O 
the O 
gene O 
expression O 
of O 
DNA O 
mismatch O 
recognition O 
proteins O 
MutS O 
homolog O 
2 O 
( O 
MSH2 O 
) O 
and O 
MSH6 O 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
embryos O 
. O 

mismatch O 
repair O 
( O 
MMR O 
) O 
of O 
simple O 
base O 
mismatches O 
and O 
small O 
insertion O 
- O 
deletion O 
loops O 
in O 
eukaryotes O 
is O 
initiated O 
by O 
the O 
binding O 
of O 
the O 
MutS O 
homolog O 
2 O 
(MSH2)-MSH6 O 
heterodimer O 
to O 
mismatched O 
DNA O 
. O 
Cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
is O 
a O 
genotoxic O 
heavy O 
metal O 
that O 
has O 
been O 
recognized O 
as O 
a O 
human O 
carcinogen O 
. O 
Oxidant O 
stress O 
and O 
inhibition O 
of O 
DNA O 
repair O 
have O 
been O 
proposed O 
as O 
major O 
factors O 
underlying O 
Cd B-FORMULA 
genotoxicity O 
. O 
Our O 
previous O 
studies O 
indicated O 
the O 
ability O 
of O 
Cd B-FORMULA 
to O 
disturb O 
the O 
gene O 
expression O 
of O 
MSH6 O 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
embryos O 
. O 
This O 
study O 
was O 
undertaken O 
to O 
explore O 
if O 
Cd B-FORMULA 
-induced O 
oxidative O 
stress O 
down O 
- O 
regulated O 
MSH O 
gene O 
activities O 
. O 
Following O 
the O 
exposure O 
of O 
zebrafish O 
embryos O 
at O 
1 O 
h O 
post O 
fertilization O 
( O 
hpf O 
) O 
to O 
sublethal O 
concentrations O 
of O 
Cd B-FORMULA 
at O 
3-5 O 
μM O 
for O 
4 O 
or O 
9 O 
h O 
, O 
a O 
parallel O 
down O 
- O 
regulation O 
of O 
MSH2 O 
, O 
MSH6 O 
and O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
superoxide B-TRIVIAL 
dismutase O 
( O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
-SOD O 
) O 
gene O 
expression O 
was O 
detected O 
by O 
real O 
- O 
time O 
RT-PCR O 
and O 
the O 
expression O 
levels O 
were O 
40-50% O 
of O 
control O 
after O 
a O 
9-h O 
exposure O 
. O 
Cd B-FORMULA 
exposure O 
also O 
induced O 
oxidative O 
stress O 
, O 
yet O 
no O 
inhibition O 
of O 
catalase O 
gene O 
activity O 
was O 
observed O 
. O 
Whole O 
mount O 
in O 
situ O 
hybridization O 
revealed O 
a O 
wide O 
distribution O 
of O 
msh6 O 
mRNA O 
in O 
the O 
head O 
regions O 
of O 
10 O 
hpf O 
embryos O 
and O 
pretreatment O 
of O 
embryos O 
with O 
antioxidants O 
butylhydroxytoluene B-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
, O 
d-mannitol B-TRIVIAL 
or O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
at O 
1-10 O 
μM O 
restored O 
Cd B-FORMULA 
-suppressed O 
msh6 O 
expression O 
. O 
QPCR O 
confirmed O 
the O 
protective O 
effects O 
of O 
antioxidants O 
on O 
Cd B-FORMULA 
-suppressed O 
msh2 O 
/ O 
msh6 O 
mRNA O 
production O 
. O 
Down O 
- O 
regulated O 
MSH O 
gene O 
activities O 
reaching O 
about O 
50% O 
of O 
control O 
were O 
also O 
induced O 
in O 
embryos O 
exposed O 
to O 
paraquat B-TRIVIAL 
, O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
(ROS)-generating O 
herbicide O 
, O 
or O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
at O 
200 O 
μM O 
. O 
Hence O 
, O 
Cd B-FORMULA 
at O 
sublethal O 
levels O 
down O 
- O 
regulates O 
msh2 O 
/ O 
msh6 O 
expression O 
primarily O 
via O 
ROS O 
as O 
signaling O 
molecules O 
. O 
The O 
transcriptional O 
activation O 
of O 
human O 
msh6 O 
is O 
known O 
to O 
be O 
fully O 
dependent O 
on O 
the O 
specificity O 
factor O 
1 O 
( O 
Sp1 O 
) O 
. O 
Cd B-FORMULA 
failed O 
to O 
inhibit O 
the O 
DNA O 
binding O 
activity O 
of O 
zebrafish O 
Sp1 O 
unless O 
at O 
lethal O 
concentrations O 
based O 
on O 
band O 
shift O 
assay O 
, O 
therefore O 
excluding O 
the O 
involvement O 
of O 
Sp1 O 
inactivation O 
in O 
Cd B-FORMULA 
-induced O 
MSH O 
gene O 
inhibition O 
in O 
zebrafish O 
embryos O 
. O 

dependence O 
of O 
long O 
- O 
term O 
cadmium B-SYSTEMATIC 
toxicity O 
in O 
the O 
zebrafish O 
is O 
not O 
explained O 
by O 
liver O 
oxidative O 
stress O 
: O 
evidence O 
from O 
transcript O 
expression O 
to O 
physiology O 
. O 

ecotoxicity O 
tests O 
are O 
performed O 
at O 
species O 
' O 
specific O 
standard O 
temperatures O 
, O 
but O 
temperature O 
is O 
known O 
to O 
affect O 
chemical O 
toxicity O 
. O 
A O 
temperature O 
increase O 
has O 
been O 
shown O 
to O 
increase O 
cadmium B-SYSTEMATIC 
toxicity O 
in O 
several O 
aquatic O 
species O 
but O 
information O 
in O 
fish O 
is O 
scarce O 
. O 
Based O 
on O 
literature O 
we O 
hypothesize O 
that O 
with O 
increasing O 
temperature O 
, O 
cadmium B-SYSTEMATIC 
accumulation O 
and O 
oxidative O 
stress O 
increase O 
, O 
resulting O 
in O 
increased O 
toxicity O 
. O 
In O 
this O 
study O 
zebrafish O 
acclimated O 
to O 
12 O 
, O 
18 O 
, O 
26 O 
( O 
standard O 
temperature O 
) O 
or O 
34°C O 
for O 
one O 
month O 
, O 
were O 
exposed O 
to O 
5 O 
μM O 
cadmium B-SYSTEMATIC 
for O 
4 O 
or O 
28 O 
days O 
at O 
the O 
respective O 
acclimation O 
temperature O 
. O 
Cadmium B-SYSTEMATIC 
toxicity O 
( O 
mortality O 
) O 
increased O 
with O 
increasing O 
temperature O 
. O 
PCA O 
showed O 
that O 
the O 
high O 
mortality O 
at O 
34°C O 
was O 
closely O 
correlated O 
to O 
an O 
increasing O 
tissue O 
cadmium B-SYSTEMATIC 
accumulation O 
with O 
increasing O 
temperature O 
, O 
but O 
not O 
to O 
liver O 
oxidative O 
damage O 
under O 
the O 
form O 
of O 
protein O 
carbonyl B-FAMILY 
content O 
or O 
lipid O 
peroxidation O 
( O 
measured O 
as O 
malondialdehyde B-TRIVIAL 
levels O 
) O 
or O 
liver O 
antioxidative O 
potential O 
. O 
Instead O 
, O 
acclimation O 
to O 
12°C O 
induced O 
the O 
highest O 
oxidative O 
damage O 
to O 
liver O 
proteins O 
and O 
lipids O 
, O 
and O 
transcript O 
levels O 
of O 
glucose B-TRIVIAL 
-6P-dehydrogenase O 
, O 
6P- O 
gluconate B-TRIVIAL 
-dehydrogenase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
were O 
particularly O 
good O 
markers O 
of O 
cold O 
- O 
induced O 
oxidative O 
stress O 
. O 
At O 
this O 
low O 
temperature O 
there O 
was O 
no O 
interaction O 
with O 
cadmium B-SYSTEMATIC 
exposure O 
and O 
there O 
was O 
no O 
sign O 
of O 
cadmium B-SYSTEMATIC 
sensitivity O 
. O 
Contrastingly O 
, O 
the O 
combined O 
effect O 
of O 
high O 
temperature O 
and O 
cadmium B-SYSTEMATIC 
exposure O 
on O 
mortality O 
proved O 
synergistic O 
. O 
Therefore O 
we O 
conclude O 
that O 
interactions O 
between O 
temperature O 
and O 
cadmium B-SYSTEMATIC 
toxicity O 
increased O 
with O 
increasing O 
temperature O 
and O 
that O 
this O 
probably O 
played O 
part O 
in O 
increasing O 
cadmium B-SYSTEMATIC 
sensitivity O 
. O 
Increased O 
cadmium B-SYSTEMATIC 
compartmentalization O 
and O 
protein O 
carbonyl B-FAMILY 
content O 
in O 
liver O 
of O 
zebrafish O 
acclimated O 
to O 
the O 
standard O 
temperature O 
of O 
26°C O 
probably O 
played O 
part O 
in O 
increased O 
sensitivity O 
towards O 
the O 
same O 
cadmium B-SYSTEMATIC 
body O 
burden O 
compared O 
to O 
lower O 
temperatures O 
. O 
On O 
the O 
one O 
hand O 
we O 
recognize O 
and O 
this O 
study O 
even O 
confirms O 
the O 
importance O 
of O 
applying O 
standard O 
temperatures O 
in O 
standard O 
ecotoxicity O 
tests O 
to O 
ensure O 
inter O 
- O 
study O 
comparability O 
. O 
On O 
the O 
other O 
hand O 
temperatures O 
in O 
the O 
field O 
may O 
deviate O 
from O 
standard O 
temperatures O 
and O 
accounting O 
for O 
deviating O 
temperatures O 
, O 
which O 
can O 
alter O 
chemical O 
sensitivity O 
, O 
in O 
regulation O 
can O 
improve O 
environmental O 
protection O 
. O 

in O 
vitro O 
DNA O 
microarray O 
studies O 
have O 
shown O 
the O 
importance O 
of O 
nuclear O 
factor O 
( O 
erythroid O 
- O 
derived O 
2 O 
) O 
- O 
like O 
2 O 
( O 
Nrf2 O 
) O 
in O 
skin O 
sensitization O 
. O 
Nevertheless O 
, O 
the O 
exact O 
in O 
vivo O 
role O 
of O 
the O 
Nrf2-Keap1 O 
pathway O 
during O 
the O 
induction O 
of O 
skin O 
sensitization O 
remains O 
unknown O 
. O 
To O 
study O 
the O 
function O 
of O 
Nrf2 O 
, O 
a O 
local O 
lymph O 
node O 
assay O 
was O 
performed O 
in O 
wild O 
- O 
type O 
and O 
Nrf2-deficient O 
mice O 
using O 
2,4-dinitrochlorobenzene B-SYSTEMATIC 
. O 
The O 
Nrf2-deficient O 
mice O 
show O 
a O 
more O 
pronounced O 
response O 
, O 
indicating O 
that O 
Nrf2 O 
is O 
involved O 
in O 
dampening O 
the O 
induction O 
of O 
skin O 
sensitization O 
. O 

differences O 
in O 
drug O 
metabolism O 
have O 
made O 
it O 
difficult O 
to O 
use O 
preclinical O 
animal O 
testing O 
data O 
to O 
predict O 
the O 
drug O 
metabolites O 
or O 
potential O 
drug O 
- O 
drug O 
interactions O 
( O 
DDIs O 
) O 
that O 
will O 
occur O 
in O 
humans O 
. O 
Although O 
chimeric O 
mice O 
with O 
humanized O 
livers O 
can O 
produce O 
known O 
human O 
metabolites O 
for O 
test O 
substrates O 
, O 
we O 
do O 
not O 
know O 
whether O 
chimeric O 
mice O 
can O 
be O 
used O 
to O 
prospectively O 
predict O 
human O 
drug O 
metabolism O 
or O 
a O 
possible O 
DDI O 
. O 
Therefore O 
, O 
we O 
investigated O 
whether O 
they O 
could O 
provide O 
a O 
more O 
predictive O 
assessment O 
for O 
clemizole B-TRIVIAL 
, O 
a O 
drug O 
in O 
clinical O 
development O 
for O 
the O 
treatment O 
of O 
hepatitis O 
C O 
virus O 
( O 
HCV O 
) O 
infection O 
. O 
Our O 
results O 
demonstrate O 
, O 
for O 
the O 
first O 
time O 
, O 
that O 
analyses O 
performed O 
in O 
chimeric O 
mice O 
can O 
correctly O 
identify O 
the O 
predominant O 
human O 
drug O 
metabolite O 
before O 
human O 
testing O 
. O 
The O 
differences O 
in O 
the O 
rodent O 
and O 
human O 
pathways O 
for O 
clemizole B-TRIVIAL 
metabolism O 
were O 
of O 
importance O 
, O 
because O 
the O 
predominant O 
human O 
metabolite O 
was O 
found O 
to O 
have O 
synergistic O 
anti-HCV O 
activity O 
. O 
Moreover O 
, O 
studies O 
in O 
chimeric O 
mice O 
also O 
correctly O 
predicted O 
that O 
a O 
DDI O 
would O 
occur O 
in O 
humans O 
when O 
clemizole B-TRIVIAL 
was O 
coadministered O 
with O 
a O 
CYP3A4 O 
inhibitor O 
. O 
These O 
results O 
demonstrate O 
that O 
using O 
chimeric O 
mice O 
can O 
improve O 
the O 
quality O 
of O 
preclinical O 
drug O 
assessment O 
. O 

- O 
time O 
fluorescence O 
turn O 
- O 
on O 
detection O 
of O 
alkaline O 
phosphatase O 
activity O 
with O 
a O 
novel O 
perylene B-SYSTEMATIC 
probe O 
. O 

tetracationic O 
perylene B-SYSTEMATIC 
probe O 
( O 
probe O 
1 O 
) O 
was O 
designed O 
and O 
synthesized O 
. O 
Probe O 
1 O 
was O 
used O 
for O 
the O 
real O 
- O 
time O 
fluorescence O 
turn O 
- O 
on O 
assay O 
of O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
activity O 
and O 
inhibitor O 
screening O 
. O 
Probe O 
1 O 
monomer O 
fluorescence O 
could O 
be O 
very O 
efficiently O 
quenched O 
by O 
ATP O 
through O 
the O 
formation O 
of O 
an O 
ATP O 
/ O 
probe O 
1 O 
complex O 
. O 
ALP O 
triggered O 
the O 
degradation O 
of O 
ATP O 
, O 
the O 
breakdown O 
of O 
the O 
ATP O 
/ O 
probe O 
1 O 
complex O 
, O 
and O 
the O 
recovery O 
of O 
the O 
probe O 
1 O 
monomer O 
fluorescence O 
. O 
In O 
the O 
presence O 
of O 
an O 
ALP O 
inhibitor O 
, O 
a O 
decrease O 
in O 
fluorescence O 
recovery O 
was O 
observed O 
. O 

of O 
transcriptional O 
response O 
to O 
phorbol B-FAMILY 
ester I-FAMILY 
, O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
, O 
and O 
bryostatin B-FAMILY 
analogs O 
in O 
LNCaP O 
and O 
U937 O 
cancer O 
cell O 
lines O 
provides O 
insight O 
into O 
their O 
differential O 
mechanism O 
of O 
action O 
. O 

1 I-TRIVIAL 
, O 
like O 
the O 
phorbol B-FAMILY 
esters I-FAMILY 
, O 
binds O 
to O 
and O 
activates O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
but O 
paradoxically O 
antagonizes O 
many O 
but O 
not O 
all O 
phorbol B-FAMILY 
ester I-FAMILY 
responses O 
. O 
Previously O 
, O 
we O 
have O 
compared O 
patterns O 
of O 
biological O 
response O 
to O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
, O 
phorbol B-FAMILY 
ester I-FAMILY 
, O 
and O 
the O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
derivative O 
Merle B-IDENTIFIER 
23 I-IDENTIFIER 
in O 
two O 
human O 
cancer O 
cell O 
lines O 
, O 
LNCaP O 
and O 
U937 O 
. O 
Bryostatin B-TRIVIAL 
1 I-TRIVIAL 
fails O 
to O 
induce O 
a O 
typical O 
phorbol B-FAMILY 
ester I-FAMILY 
biological O 
response O 
in O 
either O 
cell O 
line O 
, O 
whereas O 
Merle B-IDENTIFIER 
23 I-IDENTIFIER 
resembles O 
phorbol B-FAMILY 
ester I-FAMILY 
in O 
the O 
U937 O 
cells O 
and O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
in O 
the O 
LNCaP O 
cells O 
. O 
Here O 
, O 
we O 
have O 
compared O 
the O 
pattern O 
of O 
their O 
transcriptional O 
response O 
in O 
both O 
cell O 
lines O 
. O 
We O 
examined O 
by O 
qPCR O 
the O 
transcriptional O 
response O 
as O 
a O 
function O 
of O 
dose O 
and O 
time O 
for O 
a O 
series O 
of O 
genes O 
regulated O 
by O 
PKCs O 
. O 
In O 
both O 
cell O 
lines O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
differed O 
primarily O 
from O 
phorbol B-FAMILY 
ester I-FAMILY 
in O 
having O 
a O 
shorter O 
duration O 
of O 
transcriptional O 
modulation O 
. O 
This O 
was O 
not O 
due O 
to O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
instability O 
, O 
since O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
suppressed O 
the O 
phorbol B-FAMILY 
ester I-FAMILY 
response O 
. O 
In O 
both O 
cell O 
lines O 
Merle B-IDENTIFIER 
23 I-IDENTIFIER 
induced O 
a O 
pattern O 
of O 
transcription O 
largely O 
like O 
that O 
of O 
phorbol B-FAMILY 
ester I-FAMILY 
although O 
with O 
a O 
modest O 
reduction O 
at O 
later O 
times O 
in O 
the O 
LNCaP O 
cells O 
, O 
suggesting O 
that O 
the O 
difference O 
in O 
biological O 
response O 
of O 
the O 
two O 
cell O 
lines O 
to O 
Merle B-IDENTIFIER 
23 I-IDENTIFIER 
lies O 
downstream O 
of O 
this O 
transcriptional O 
regulation O 
. O 
For O 
a O 
series O 
of O 
bryostatins B-FAMILY 
and O 
analogs O 
which O 
ranged O 
from O 
bryostatin B-TRIVIAL 
1 I-TRIVIAL 
-like O 
to O 
phorbol B-FAMILY 
ester I-FAMILY 
-like O 
in O 
activity O 
on O 
the O 
U937 O 
cells O 
, O 
the O 
duration O 
of O 
transcriptional O 
response O 
correlated O 
with O 
the O 
pattern O 
of O 
biological O 
activity O 
, O 
suggesting O 
that O 
this O 
may O 
provide O 
a O 
robust O 
platform O 
for O 
structure O 
activity O 
analysis O 
. O 

anti-cancer O 
effects O 
of O 
resveratrol B-TRIVIAL 
and O 
chemotherapeutic O 
agent O 
clofarabine B-TRIVIAL 
against O 
human O 
malignant O 
mesothelioma O 
MSTO-211H O 
cells O 
. O 

phytochemicals O 
as O 
adjuvants O 
have O 
been O 
suggested O 
to O 
play O 
important O 
roles O 
in O 
enhancing O 
chemotherapeutic O 
potential O 
owing O 
to O 
multitargeted O 
chemopreventive O 
properties O 
and O 
lack O 
of O 
substantial O 
toxicity O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
efficacy O 
of O 
the O 
combined O 
treatment O 
of O 
various O 
phytochemicals O 
with O 
the O 
anticancer O 
drug O 
clofarabine B-TRIVIAL 
in O 
malignant O 
mesothelioma O 
MSTO-211H O 
cells O 
and O 
normal O 
mesothelial O 
MeT-5A O 
cells O 
. O 
The O 
combined O 
treatment O 
of O 
resveratrol B-TRIVIAL 
and O 
clofarabine B-TRIVIAL 
produced O 
a O 
synergistic O 
antiproliferative O 
effect O 
in O 
MSTO-211H O 
cells O 
, O 
but O 
not O 
in O 
MeT-5A O 
cells O 
. O 
In O 
MSTO-211H O 
cells O 
, O 
the O 
nuclear O 
accumulation O 
of O 
Sp1 O 
and O 
the O 
levels O 
of O 
p-Akt O 
, O 
Sp1 O 
, O 
c-Met O 
, O 
cyclin O 
D1 O 
, O 
and O 
p21 O 
were O 
effectively O 
decreased O 
by O 
the O 
combined O 
treatment O 
of O 
them O 
. O 
In O 
combination O 
with O 
clofarabine B-TRIVIAL 
, O 
the O 
ability O 
of O 
resveratrol B-TRIVIAL 
to O 
reduce O 
the O 
contents O 
of O 
Sp1 O 
and O 
its O 
target O 
gene O 
products O 
was O 
also O 
evident O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
experiment O 
. O 
The O 
inhibition O 
of O 
phosphoinositide B-FAMILY 
3-kinase O 
using O 
Ly294002 B-IDENTIFIER 
augmented O 
a O 
decrease O 
in O 
the O 
p21 O 
level O 
induced O 
by O 
their O 
combination O 
, O 
but O 
it O 
showed O 
no O 
significant O 
effects O 
on O 
expression O 
of O 
Sp1 O 
and O 
cyclin O 
D1 O 
. O 
Taken O 
together O 
, O 
the O 
data O 
provide O 
evidence O 
that O 
the O 
synergistic O 
antiproliferative O 
effect O 
of O 
resveratrol B-TRIVIAL 
and O 
clofarabine B-TRIVIAL 
is O 
linked O 
to O 
the O 
inhibition O 
of O 
Akt O 
and O 
Sp1 O 
activities O 
, O 
and O 
suggest O 
that O 
this O 
combination O 
may O 
have O 
therapeutic O 
value O 
in O 
treatment O 
of O 
malignant O 
mesothelioma O 
. O 

investigated O 
the O 
effects O 
of O 
bioactive O 
- O 
peptides O 
from O 
hydrolysates O 
of O 
flounder O 
fish O 
muscle O 
( O 
FFM O 
) O 
on O 
antioxidant O 
activity O 
. O 
The O 
hydrolysates O 
were O 
prepared O 
by O 
enzymatic O 
reactions O 
of O 
FFM O 
using O 
eight O 
commercial O 
proteases O 
such O 
as O 
papain O 
, O 
pepsin O 
, O 
trypsin O 
, O 
neutrase O 
, O 
alcalase O 
, O 
kojizyme O 
, O 
protamex O 
, O 
and O 
α-chymotrypsin O 
. O 
The O 
α-chymotrypsin O 
hydrolysate O 
showed O 
the O 
strongest O 
antioxidant O 
activity O 
among O 
the O 
eight O 
enzymatic O 
hydrolysates O 
. O 
Further O 
separation O 
of O 
the O 
α-chymotrypsin O 
hydrolysate O 
was O 
performed O 
by O 
ultrafiltration O 
, O 
gel O 
filtration O 
, O 
and O 
reverse O 
- O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
. O 
Consequently O 
, O 
two O 
novel O 
peptides O 
with O 
high O 
antioxidant O 
activity O 
were O 
purified O 
, O 
and O 
their O 
amino B-FAMILY 
acid I-FAMILY 
sequences O 
were O 
determined O 
( O 
Val-Cys-Ser-Val B-FORMULA 
[ O 
VCSV B-ABBREVIATION 
] O 
and O 
Cys-Ala-Ala-Pro B-FORMULA 
[ O 
CAAP B-ABBREVIATION 
] O 
, O 
respectively O 
) O 
. O 
The O 
two O 
peptides O 
showed O 
good O 
scavenging O 
activity O 
against O 
the O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
free O 
radical O 
( O 
IC(50) O 
values O 
, O 
111.32 O 
and O 
26.89 O 
μM O 
, O 
respectively O 
) O 
and O 
high O 
cytoprotective O 
activities O 
against O 
2,2-azobis-(2-amidino-propane) B-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
AAPH B-ABBREVIATION 
) O 
without O 
cytotoxicity O 
and O 
scavenged O 
total O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
Vero O 
cells O 
. O 
In O 
particular O 
, O 
apoptotic O 
bodies O 
produced O 
by O 
AAPH B-ABBREVIATION 
dose O 
- O 
dependently O 
decreased O 
following O 
treatment O 
with O 
the O 
CAAP B-ABBREVIATION 
peptide O 
. O 
These O 
results O 
revealed O 
firstly O 
the O 
two O 
peptides O 
with O 
strong O 
antioxidative O 
effects O 
from O 
FFM O 
. O 

A I-TRIVIAL 
inhibits O 
proliferation O 
and O 
induces O 
apoptosis O 
in O 
micromass O 
cultures O 
of O 
rat O 
embryonic O 
midbrain O 
cells O 
through O 
the O 
JNK O 
, O 
CREB O 
and O 
p53 O 
signaling O 
pathways O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
has O 
been O 
widely O 
used O 
in O 
the O 
manufacture O 
of O 
polycarbonate B-FAMILY 
plastic O 
, O 
water O 
bottles O 
and O 
food O 
containers O 
. O 
Previous O 
studies O 
have O 
established O 
that O 
BPA B-ABBREVIATION 
could O 
cause O 
developmental O 
toxicity O 
by O 
inhibiting O 
the O 
proliferation O 
and O 
differentiation O 
of O 
rat O 
embryonic O 
midbrain O 
( O 
MB O 
) O 
cells O 
in O 
vitro O 
. O 
However O 
, O 
the O 
underlying O 
mechanisms O 
have O 
not O 
been O 
well O 
studied O 
yet O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
examined O 
the O 
proliferation O 
and O 
differentiation O 
of O 
MB O 
cells O 
treated O 
with O 
10(-12)-10(-4)M O 
BPA B-ABBREVIATION 
and O 
found O 
that O 
only O 
10(-4)M O 
BPA B-ABBREVIATION 
inhibited O 
proliferation O 
and O 
differentiation O 
. O 
Then O 
, O 
we O 
investigated O 
the O 
cell O 
cycle O 
progression O 
and O 
apoptosis O 
of O 
MB O 
cells O 
; O 
10(-4)M O 
BPA B-ABBREVIATION 
caused O 
an O 
explicit O 
S O 
phase O 
and O 
G2 O 
/ O 
M O 
phase O 
arrest O 
in O 
the O 
cell O 
cycle O 
and O 
increased O 
the O 
percentage O 
of O 
apoptotic O 
cells O 
. O 
Moreover O 
, O 
the O 
phosphorylation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
and O 
cyclic-AMP O 
response O 
binding O 
protein O 
( O 
CREB O 
) O 
and O 
the O 
expression O 
of O 
some O 
apoptotic O 
regulatory O 
genes O 
were O 
investigated O 
. O 
BPA B-ABBREVIATION 
( O 
10(-4)M O 
) O 
reduced O 
the O 
phosphorylation O 
of O 
C-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
( O 
JNK O 
) O 
and O 
CREB O 
, O 
and O 
increased O 
the O 
mRNA O 
expression O 
level O 
of O 
Bax O 
and O 
p53 O 
. O 
Our O 
findings O 
demonstrated O 
that O 
BPA B-ABBREVIATION 
could O 
cause O 
developmental O 
toxicity O 
through O 
anti-proliferation O 
and O 
pro O 
- O 
apoptosis O 
in O 
MB O 
cells O 
. O 
Multiple O 
signaling O 
pathways O 
, O 
such O 
as O 
the O 
JNK O 
, O 
CREB O 
and O 
p53-mitochondrial O 
apoptosis O 
pathways O 
, O 
participate O 
in O 
these O 
effects O 
. O 

NMR O 
- O 
based O 
metabonomics O 
approach O 
in O 
a O 
rat O 
model O 
of O 
acute O 
liver O 
injury O 
and O 
regeneration O 
induced O 
by O 
CCl4 O 
administration O 
. O 

administration O 
of O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl(4) B-FORMULA 
) O 
has O 
been O 
established O 
as O 
a O 
model O 
of O 
toxin O 
- O 
induced O 
acute O 
and O 
chronic O 
liver O 
injury O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigate O 
the O 
progression O 
of O 
the O 
biochemical O 
response O 
to O 
acute O 
CCl(4) B-FORMULA 
-induced O 
liver O 
injury O 
, O 
capturing O 
metabolic O 
variations O 
during O 
both O 
toxic O 
insult O 
and O 
regeneration O 
using O 
NMR O 
- O 
based O 
metabonomic O 
analysis O 
of O 
liver O 
tissue O 
and O 
plasma O 
. O 
A O 
single O 
dose O 
of O 
CCl(4) B-FORMULA 
( O 
1 O 
mL O 
/ O 
kg O 
BW O 
) O 
was O 
intraperitoneally O 
administered O 
to O 
male O 
Wister O 
rats O 
sacrificed O 
every O 
12h O 
up O 
to O 
72 O 
h O 
post O 
treatment O 
, O 
while O 
healthy O 
animals O 
served O 
as O 
controls O 
. O 
Acquired O 
(1)H B-FORMULA 
NMR O 
spectra O 
of O 
liver O 
tissue O 
extracts O 
and O 
plasma O 
samples O 
were O 
explored O 
with O 
multivariate O 
analysis O 
and O 
the O 
resulted O 
models O 
were O 
correlated O 
with O 
conventional O 
biochemical O 
and O 
histopathological O 
indices O 
of O 
toxicity O 
for O 
monitoring O 
the O 
progression O 
of O 
experimental O 
injury O 
. O 
The O 
metabonomic O 
analysis O 
resulted O 
in O 
discrimination O 
between O 
the O 
subjects O 
under O 
toxic O 
insult O 
( O 
up O 
to O 
36 O 
h O 
) O 
and O 
those O 
at O 
the O 
regenerative O 
phase O 
( O 
peaked O 
at O 
48 O 
h O 
) O 
. O 
At O 
72 O 
h O 
normalization O 
of O 
liver's O 
pathology O 
similar O 
to O 
the O 
controls O 
group O 
was O 
apparent O 
. O 
Principal O 
component O 
analysis O 
( O 
PCA O 
) O 
trajectories O 
highlighted O 
the O 
time O 
points O 
of O 
the O 
greater O 
degree O 
of O 
toxic O 
insult O 
and O 
the O 
regenerative O 
state O 
. O 
A O 
number O 
of O 
metabolites O 
such O 
as O 
glucose B-TRIVIAL 
, O 
lactate B-FAMILY 
, O 
choline B-FAMILY 
, O 
formate B-SYSTEMATIC 
exhibited O 
variations O 
suggesting O 
CCl(4) B-FORMULA 
induced O 
impairment O 
in O 
essential O 
biochemical O 
pathways O 
as O 
energy O 
metabolism O 
, O 
lipid O 
biosynthesis O 
and O 
transmethylation O 
reactions O 
. O 
The O 
latter O 
provides O 
new O 
evidence O 
of O 
B12 B-TRIVIAL 
and O 
folate B-TRIVIAL 
pathways O 
deficiency O 
, O 
indicative O 
of O 
new O 
mechanistic O 
implications O 
possibly O 
by O 
direct O 
inhibition O 
of O 
B12 B-TRIVIAL 
dependent O 
enzymes O 
by O 
the O 
chlorinated O 
radicals O 
of O 
CCl(4) B-FORMULA 
metabolism O 
. O 

based O 
toxicokinetics O 
of O 
serum O 
aflatoxin B-TRIVIAL 
B1 I-TRIVIAL 
- O 
lysine B-TRIVIAL 
adduct O 
in O 
F344 O 
rats O 
. O 

B(1) I-TRIVIAL 
- O 
lysine B-TRIVIAL 
adduct O 
( O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
) O 
is O 
a O 
reliable O 
biomarker O 
for O 
aflatoxin B-FAMILY 
exposure O 
; O 
however O 
, O 
a O 
systematic O 
toxicokinetic O 
evaluation O 
has O 
not O 
been O 
reported O 
. O 
In O 
this O 
study O 
, O 
male O 
F344 O 
rats O 
were O 
orally O 
exposed O 
to O 
single O 
, O 
or O 
repeated O 
, O 
doses O 
of O 
AFB(1) B-ABBREVIATION 
and O 
the O 
toxicokinetics O 
of O 
serum O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
that O 
followed O 
treatments O 
were O 
investigated O 
. O 
A O 
single O 
- O 
dose O 
of O 
AFB(1) B-ABBREVIATION 
increased O 
serum O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
levels O 
rapidly O 
peaking O 
at O 
4h O 
, O 
followed O 
by O 
first O 
- O 
order O 
elimination O 
, O 
through O 
which O 
the O 
half O 
- O 
life O 
was O 
estimated O 
to O 
be O 
2.31 O 
days O 
. O 
A O 
physiologically O 
based O 
pharmacokinetic O 
model O 
showed O 
that O 
approximately O 
3.00-3.90% O 
and O 
1.12-1.98% O 
of O 
the O 
administered O 
AFB(1) B-ABBREVIATION 
doses O 
were O 
converted O 
to O 
serum O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
adducts O 
at O 
2h O 
and O 
24h O 
post O 
treatment O 
, O 
respectively O 
. O 
Repeated O 
AFB(1) B-ABBREVIATION 
exposure O 
at O 
5-25 O 
μg O 
/ O 
kg O 
body O 
weight O 
linearly O 
increased O 
serum O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
levels O 
for O 
5 O 
weeks O 
in O 
animals O 
, O 
resulting O 
in O 
a O 
1-1.5 O 
times O 
higher O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
level O 
overall O 
. O 
This O 
indicates O 
the O 
potential O 
of O 
this O 
adduct O 
as O 
a O 
reliable O 
biomarker O 
for O 
repeated O 
low O 
dose O 
exposure O 
. O 
Higher O 
dose O 
exposure O 
at O 
75 O 
μg O 
/ O 
kg O 
increased O 
the O 
level O 
of O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
to O 
a O 
maximum O 
at O 
2 O 
weeks O 
, O 
followed O 
by O 
a O 
gradual O 
decrease O 
to O 
near O 
plateau O 
level O 
up O 
to O 
5 O 
weeks O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
systematically O 
evaluated O 
the O 
toxicokinetics O 
of O 
serum O 
AFB B-ABBREVIATION 
- O 
Lys B-FORMULA 
adduct O 
in O 
F344 O 
rats O 
using O 
a O 
physiologically O 
based O 
pharmacokinetic O 
model O 
and O 
robust O 
statistical O 
modeling O 
analysis O 
and O 
provided O 
a O 
firm O 
and O 
clear O 
understanding O 
of O 
the O 
toxicokinetics O 
of O 
this O 
biomarker O 
. O 

of O 
ovarian O 
and O 
non-ovarian O 
estrogens B-FAMILY 
on O 
weight O 
gain O 
in O 
response O 
to O 
disruption O 
of O 
sweet O 
taste O 
-- O 
calorie O 
relations O 
in O 
female O 
rats O 
. O 

of O 
energy O 
balance O 
in O 
female O 
rats O 
is O 
known O 
to O 
differ O 
along O 
a O 
number O 
of O 
dimensions O 
compared O 
to O 
male O 
rats O 
. O 
Previous O 
work O 
from O 
our O 
lab O 
has O 
demonstrated O 
that O 
in O 
female O 
rats O 
fed O 
dietary O 
supplements O 
containing O 
high O 
- O 
intensity O 
sweeteners O 
that O 
may O 
disrupt O 
a O 
predictive O 
relation O 
between O 
sweet O 
tastes O 
and O 
calories O 
, O 
excess O 
weight O 
gain O 
is O 
demonstrated O 
only O 
when O 
females O 
are O 
also O 
fed O 
a O 
diet O 
high O 
in O 
fat O 
and O 
sugar B-FAMILY 
, O 
and O 
is O 
evidenced O 
primarily O 
in O 
animals O 
already O 
prone O 
to O 
gain O 
excess O 
weight O 
. O 
In O 
contrast O 
, O 
male O 
rats O 
show O 
excess O 
weight O 
gain O 
when O 
fed O 
saccharin B-TRIVIAL 
-sweetened O 
yogurt O 
supplements O 
when O 
fed O 
both O 
standard O 
chow O 
diets O 
and O 
diets O 
high O 
in O 
fat O 
and O 
sugar B-FAMILY 
, O 
and O 
regardless O 
of O 
their O 
proneness O 
to O 
excess O 
weight O 
gain O 
. O 
The O 
goal O 
of O 
the O 
present O 
experiments O 
was O 
to O 
determine O 
whether O 
ovarian O 
, O 
or O 
other O 
sources O 
of O 
estrogens B-FAMILY 
, O 
contributes O 
to O 
the O 
resistance O 
to O 
excess O 
weight O 
gain O 
in O 
female O 
rats O 
fed O 
standard O 
chow O 
diets O 
along O 
with O 
dietary O 
supplements O 
sweetened O 
with O 
yogurt O 
. O 
Results O 
of O 
the O 
first O 
experiment O 
indicated O 
that O 
when O 
the O 
ovaries O 
were O 
removed O 
surgically O 
in O 
adult O 
female O 
rats O 
, O 
patterns O 
of O 
weight O 
gain O 
were O 
similar O 
in O 
animals O 
fed O 
saccharin B-TRIVIAL 
-sweetened O 
compared O 
to O 
glucose B-TRIVIAL 
-sweetened O 
yogurt O 
supplements O 
. O 
In O 
the O 
second O 
experiment O 
, O 
when O 
the O 
ovaries O 
were O 
surgically O 
removed O 
in O 
adult O 
female O 
rats O 
, O 
and O 
local O 
production O 
of O 
estrogens B-FAMILY 
was O 
suppressed O 
with O 
the O 
aromatase O 
inhibitor O 
anastrozole B-TRIVIAL 
, O 
females O 
fed O 
the O 
saccharin B-TRIVIAL 
-sweetened O 
yogurt O 
consumed O 
more O 
energy O 
and O 
gained O 
more O 
weight O 
than O 
females O 
fed O 
the O 
glucose B-TRIVIAL 
-sweetened O 
yogurt O 
. O 
However O 
, O 
when O 
the O 
ovaries O 
were O 
surgically O 
removed O 
prior O 
to O 
the O 
onset O 
of O 
puberty O 
( O 
at O 
24-25 O 
days O 
of O 
age O 
) O 
, O 
females O 
given O 
saccharin B-TRIVIAL 
-sweetened O 
yogurt O 
along O 
with O 
vehicle O 
gained O 
excess O 
weight O 
. O 
In O 
contrast O 
, O 
weight O 
gain O 
was O 
similar O 
in O 
those O 
given O 
saccharin B-TRIVIAL 
-sweetened O 
and O 
glucose B-TRIVIAL 
-sweetened O 
yogurt O 
along O 
with O 
anastrozole B-TRIVIAL 
. O 
The O 
results O 
suggest O 
that O 
behavioral O 
differences O 
between O 
males O 
and O 
females O 
in O 
response O 
to O 
disruption O 
of O 
sweet→calorie O 
relations O 
may O 
result O 
from O 
differences O 
in O 
patterns O 
of O 
local O 
estrogen B-FAMILY 
production O 
. O 
These O 
differences O 
may O 
be O 
established O 
developmentally O 
during O 
the O 
pubertal O 
period O 
in O 
females O 
. O 

transport O 
via O 
the O 
transferrin O 
mechanism O 
. O 

manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
uptake O 
by O 
brain O 
cells O 
, O 
particularly O 
in O 
regions O 
like O 
the O 
basal O 
ganglia O 
, O 
can O 
lead O 
to O 
toxicity O 
. O 
Mn(2+) B-FORMULA 
is O 
transported O 
into O 
cells O 
via O 
a O 
number O 
of O 
mechanisms O 
, O 
while O 
Mn(3+) B-FORMULA 
is O 
believed O 
to O 
be O 
transported O 
similarly O 
to O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
via O 
the O 
transferrin O 
( O 
Tf O 
) O 
mechanism O 
. O 
Cellular O 
Mn B-FORMULA 
uptake O 
is O 
therefore O 
determined O 
by O 
the O 
activity O 
of O 
the O 
mechanisms O 
transporting O 
Mn B-FORMULA 
into O 
each O 
type O 
of O 
cell O 
and O 
by O 
the O 
amounts O 
of O 
Mn(2+) B-FORMULA 
, O 
Mn(3+) B-FORMULA 
and O 
their O 
complexes O 
to O 
which O 
these O 
cells O 
are O 
exposed O 
; O 
this O 
complicates O 
understanding O 
the O 
contributions O 
of O 
each O 
transporter O 
to O 
Mn B-FORMULA 
toxicity O 
. O 
While O 
uptake O 
of O 
Fe(3+) B-FORMULA 
via O 
the O 
Tf O 
mechanism O 
is O 
well O 
understood O 
, O 
uptake O 
of O 
Mn(3+) B-FORMULA 
via O 
this O 
mechanism O 
has O 
not O 
been O 
systematically O 
studied O 
. O 
The O 
stability O 
of O 
the O 
Mn(3+) B-FORMULA 
Tf O 
complex O 
allowed O 
us O 
to O 
form O 
and O 
purify O 
this O 
complex O 
and O 
label O 
it O 
with O 
a O 
fluorescent O 
( O 
Alexa B-TRIVIAL 
green I-TRIVIAL 
) O 
tag O 
. O 
Using O 
purified O 
and O 
labeled O 
Mn(3+) B-FORMULA 
Tf O 
and O 
biophysical O 
tools O 
, O 
we O 
have O 
developed O 
a O 
novel O 
approach O 
to O 
study O 
Mn(3+) B-FORMULA 
Tf O 
transport O 
independently O 
of O 
other O 
Mn B-FORMULA 
transport O 
mechanisms O 
. O 
This O 
approach O 
was O 
used O 
to O 
compare O 
the O 
uptake O 
of O 
Mn(3+) B-FORMULA 
Tf O 
into O 
neuronal O 
cell O 
lines O 
with O 
published O 
descriptions O 
of O 
Fe(3+) B-FORMULA 
uptake O 
via O 
the O 
Tf O 
mechanism O 
, O 
and O 
to O 
obtain O 
quantitative O 
information O 
on O 
Mn B-FORMULA 
uptake O 
via O 
the O 
Tf O 
mechanism O 
. O 
Results O 
confirm O 
that O 
in O 
these O 
cell O 
lines O 
significant O 
Mn(3+) B-FORMULA 
is O 
transported O 
by O 
the O 
Tf O 
mechanism O 
similarly O 
to O 
Fe(3+) B-FORMULA 
Tf O 
transport O 
; O 
although O 
Mn(3+) B-FORMULA 
Tf O 
transport O 
is O 
markedly O 
slower O 
than O 
other O 
Mn B-FORMULA 
transport O 
mechanisms O 
. O 
This O 
novel O 
approach O 
may O 
prove O 
useful O 
for O 
studying O 
Mn B-FORMULA 
toxicity O 
in O 
other O 
systems O 
and O 
cell O 
types O 
. O 

of O 
the O 
BcgI O 
restriction O 
- O 
modification O 
protein O 
for O 
the O 
cleavage O 
of O 
eight O 
phosphodiester B-SYSTEMATIC 
bonds O 
in O 
DNA O 
. O 

IIB O 
restriction O 
- O 
modification O 
systems O 
, O 
such O 
as O 
BcgI O 
, O 
feature O 
a O 
single O 
protein O 
with O 
both O 
endonuclease O 
and O 
methyltransferase O 
activities O 
. O 
Type O 
IIB O 
nucleases O 
require O 
two O 
recognition O 
sites O 
and O 
cut O 
both O 
strands O 
on O 
both O 
sides O 
of O 
their O 
unmodified O 
sites O 
. O 
BcgI O 
cuts O 
all O 
eight O 
target O 
phosphodiester B-SYSTEMATIC 
bonds O 
before O 
dissociation O 
. O 
The O 
BcgI O 
protein O 
contains O 
A O 
and O 
B O 
polypeptides O 
in O 
a O 
2 O 
: O 
1 O 
ratio O 
: O 
A O 
has O 
one O 
catalytic O 
centre O 
for O 
each O 
activity O 
; O 
B O 
recognizes O 
the O 
DNA O 
. O 
We O 
show O 
here O 
that O 
BcgI O 
is O 
organized O 
as O 
A(2)B O 
protomers O 
, O 
with O 
B O 
at O 
its O 
centre O 
, O 
but O 
that O 
these O 
protomers O 
self O 
- O 
associate O 
to O 
assemblies O 
containing O 
several O 
A(2)B O 
units O 
. O 
Moreover O 
, O 
like O 
the O 
well O 
known O 
FokI O 
nuclease O 
, O 
BcgI O 
bound O 
to O 
its O 
site O 
has O 
to O 
recruit O 
additional O 
protomers O 
before O 
it O 
can O 
cut O 
DNA O 
. O 
DNA O 
- O 
bound O 
BcgI O 
can O 
alternatively O 
be O 
activated O 
by O 
excess O 
A O 
subunits O 
, O 
much O 
like O 
the O 
activation O 
of O 
FokI O 
by O 
its O 
catalytic O 
domain O 
. O 
Eight O 
A O 
subunits O 
, O 
each O 
with O 
one O 
centre O 
for O 
nuclease O 
activity O 
, O 
are O 
presumably O 
needed O 
to O 
cut O 
the O 
eight O 
bonds O 
cleaved O 
by O 
BcgI O 
. O 
Its O 
nuclease O 
reaction O 
may O 
thus O 
involve O 
two O 
A(2)B O 
units O 
, O 
each O 
bound O 
to O 
a O 
recognition O 
site O 
, O 
with O 
two O 
more O 
A(2)B O 
units O 
bridging O 
the O 
complexes O 
by O 
protein O 
- O 
protein O 
interactions O 
between O 
the O 
nuclease O 
domains O 
. O 

, O 
exposure O 
to O 
particulate O 
air O 
pollution O 
is O 
associated O 
with O 
increases O 
in O 
morbidity O 
and O 
mortality O 
, O 
and O 
diabetics O 
are O 
especially O 
vulnerable O 
to O 
effects O 
of O 
particles O 
. O 
This O 
study O 
was O 
carried O 
out O 
to O 
determine O 
the O 
respiratory O 
effect O 
of O 
diesel O 
exhaust O 
particles O 
( O 
DEP O 
; O 
0.4mg O 
/ O 
kg O 
) O 
on O 
mice O 
rendered O 
diabetic O 
by O 
the O 
injection O 
of O 
streptozotocin B-TRIVIAL 
or O 
vehicle O 
( O 
control O 
) O 
. O 
Four O 
weeks O 
following O 
induction O 
of O 
diabetes O 
, O 
the O 
animals O 
were O 
intratracheally O 
instilled O 
( O 
i.t O 
. O 
) O 
with O 
DEP O 
( O 
0.4mg O 
/ O 
kg O 
) O 
or O 
saline O 
. O 
24h O 
later O 
, O 
the O 
measurement O 
of O 
airway O 
reactivity O 
to O 
methacholine B-TRIVIAL 
in O 
vivo O 
by O 
a O 
forced O 
oscillation O 
technique O 
showed O 
a O 
significant O 
and O 
dose O 
- O 
dependent O 
increase O 
in O 
airway O 
resistance O 
in O 
non-diabetic O 
mice O 
exposed O 
to O 
DEP O 
versus O 
non-diabetic O 
mice O 
exposed O 
to O 
saline O 
. O 
Similarly O 
, O 
the O 
airway O 
resistance O 
was O 
significantly O 
increased O 
in O 
diabetic O 
mice O 
exposed O 
to O 
DEP O 
versus O 
diabetic O 
mice O 
exposed O 
to O 
saline O 
. O 
Nevertheless O 
, O 
there O 
was O 
no O 
difference O 
in O 
the O 
airway O 
resistance O 
between O 
diabetic O 
and O 
non-diabetic O 
mice O 
after O 
i.t O 
. O 
administration O 
of O 
DEP O 
. O 
Following O 
DEP O 
administration O 
there O 
were O 
neutrophil O 
polymorphs O 
infiltration O 
of O 
pulmonary O 
interalveolar O 
septae O 
and O 
the O 
alveolar O 
spaces O 
with O 
many O 
macrophages O 
containing O 
DEP O 
in O 
both O 
diabetic O 
and O 
non-diabetic O 
mice O 
. O 
Interestingly O 
, O 
apoptotic O 
cells O 
were O 
only O 
found O 
in O 
the O 
examined O 
lung O 
sections O 
from O 
diabetic O 
mice O 
exposed O 
to O 
DEP O 
. O 
Total O 
proteins O 
and O 
albumin O 
concentrations O 
in O 
bronchoalveolar O 
lavage O 
( O 
BAL O 
) O 
fluid O 
, O 
markers O 
for O 
increase O 
of O 
epithelial O 
permeability O 
, O 
were O 
significantly O 
increased O 
in O 
diabetic O 
mice O 
exposed O 
to O 
DEP O 
compared O 
to O 
saline O 
- O 
treated O 
diabetic O 
and O 
DEP O 
- O 
treated O 
non O 
diabetic O 
mice O 
. O 
Superoxide B-TRIVIAL 
dismutase O 
activity O 
and O 
reduced O 
glutathione O 
concentration O 
in O 
BAL O 
were O 
significantly O 
decreased O 
in O 
diabetic O 
mice O 
exposed O 
to O 
DEP O 
compared O 
to O 
saline O 
- O 
treated O 
diabetic O 
and O 
DEP O 
- O 
treated O 
non O 
diabetic O 
mice O 
. O 
Moreover O 
, O 
tumor O 
necrosis O 
factor O 
α O 
( O 
TNFα O 
) O 
concentrations O 
were O 
significantly O 
increased O 
in O 
diabetic O 
mice O 
exposed O 
to O 
DEP O 
compared O 
to O 
saline O 
- O 
treated O 
diabetic O 
and O 
DEP O 
- O 
treated O 
non O 
diabetic O 
mice O 
. O 
We O 
conclude O 
that O 
, O 
at O 
the O 
dose O 
and O 
time O 
point O 
investigated O 
, O 
DEP O 
equally O 
increased O 
airway O 
resistance O 
and O 
caused O 
infiltration O 
of O 
inflammatory O 
cells O 
in O 
the O 
lung O 
of O 
both O 
diabetic O 
and O 
non-diabetic O 
mice O 
. O 
However O 
, O 
the O 
occurrence O 
of O 
oxidative O 
stress O 
, O 
the O 
presence O 
lung O 
apoptotic O 
cells O 
and O 
the O 
increase O 
of O 
total O 
proteins O 
, O 
albumin O 
and O 
TNFα O 
in O 
BAL O 
fluid O 
were O 
only O 
seen O 
in O 
DEP-exposed O 
diabetic O 
mice O 
suggesting O 
an O 
increased O 
respiratory O 
susceptibility O 
to O 
particulate O 
air O 
pollution O 
. O 

oxide I-SYSTEMATIC 
particles O 
modulate O 
the O 
ovalbumin O 
- O 
induced O 
Th2 O 
immune O 
response O 
in O 
mice O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
the O 
modulatory O 
effects O 
of O 
submicron O 
and O 
nanosized O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
Fe(2)O(3) B-FORMULA 
) O 
particles O 
on O 
the O 
ovalbumin O 
(OVA)-induced O 
immune O 
Th2 O 
response O 
in O 
BALB O 
/ O 
c O 
mice O 
. O 
Particles O 
were O 
intratracheally O 
administered O 
four O 
times O 
to O 
mice O 
before O 
and O 
during O 
the O 
OVA O 
sensitization O 
period O 
. O 
For O 
each O 
particle O 
type O 
, O 
three O 
different O 
doses O 
, O 
namely O 
4×100 O 
, O 
4×250 O 
or O 
4×500 O 
μg O 
/ O 
mouse O 
, O 
were O 
used O 
and O 
for O 
each O 
dose O 
, O 
four O 
groups O 
of O 
mice O 
, O 
i.e O 
. O 
group O 
saline O 
solution O 
( O 
1 O 
) O 
, O 
OVA O 
( O 
2 O 
) O 
, O 
particles O 
( O 
3 O 
) O 
, O 
and O 
OVA O 
plus O 
particles O 
( O 
4 O 
) O 
, O 
were O 
constituted O 
. O 
Mice O 
exposed O 
to O 
OVA O 
alone O 
exhibited O 
an O 
allergic O 
Th2-dominated O 
response O 
with O 
a O 
consistent O 
increase O 
in O 
inflammatory O 
scores O 
, O 
eosinophil O 
numbers O 
, O 
specific O 
IgE O 
levels O 
and O 
IL-4 O 
production O 
. O 
When O 
the O 
mice O 
were O 
exposed O 
to O 
OVA O 
and O 
to O 
high O 
and O 
intermediate O 
doses O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
submicron- O 
or O 
nanoparticles O 
, O 
the O 
OVA-induced O 
allergic O 
response O 
was O 
significantly O 
inhibited O 
, O 
as O 
evidenced O 
by O 
the O 
decrease O 
in O 
eosinophil O 
cell O 
influx O 
and O 
specific O 
IgE O 
levels O 
. O 
However O 
, O 
the O 
low O 
dose O 
( O 
4×100 O 
μg O 
) O 
of O 
submicron O 
particles O 
had O 
no O 
significant O 
effect O 
on O 
the O 
OVA O 
allergic O 
response O 
while O 
the O 
same O 
dose O 
of O 
nanoparticles O 
had O 
an O 
adjuvant O 
effect O 
on O 
the O 
Th2 O 
response O 
to O 
OVA O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
demonstrate O 
that O 
the O 
pulmonary O 
immune O 
response O 
to O 
OVA O 
is O 
a O 
sensitive O 
target O 
for O 
intratracheally O 
instilled O 
particles O 
. O 
Depending O 
on O 
the O 
particle O 
dose O 
and O 
size O 
, O 
the O 
allergic O 
response O 
was O 
suppressed O 
or O 
enhanced O 
. O 

impaired O 
central O 
cholinergic O 
system O 
is O 
at O 
least O 
partly O 
involved O 
in O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
pathogenesis O 
, O 
with O 
cholinergic O 
markers O 
such O 
as O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
and O 
protein O 
levels O 
decreasing O 
as O 
cognitive O 
decline O 
progresses O 
. O 
AD O 
patients O 
receive O 
AChE O 
inhibitor O 
drugs O 
to O 
enhance O 
cholinergic O 
responses O 
in O 
the O 
brain O 
. O 
The O 
present O 
study O 
characterises O 
the O 
cholinergic O 
system O 
of O 
mice O 
heterozygous O 
for O 
AChE O 
( O 
HZ O 
) O 
as O 
a O 
suitable O 
in O 
vivo O 
model O 
for O 
permanently O 
reduced O 
AChE O 
activity O 
. O 
In O 
comparison O 
to O 
homozygous O 
, O 
wild O 
type O 
( O 
WT O 
) O 
mice O 
, O 
HZ O 
mice O 
show O 
a O 
40% O 
reduction O 
of O 
AChE O 
activity O 
in O 
the O 
brain O 
, O 
while O 
their O 
hippocampal O 
ACh O 
levels O 
are O 
increased O 
by O 
56% O 
as O 
measured O 
by O 
microdialysis O 
; O 
choline B-FAMILY 
acetyltransferase O 
levels O 
remain O 
unaltered O 
, O 
and O 
choline B-FAMILY 
uptake O 
increases O 
2-fold O 
. O 
We O 
demonstrate O 
that O 
HZ O 
mice O 
are O 
significantly O 
more O 
sensitive O 
to O 
local O 
AChE O 
inhibition O 
( O 
BW284c51 B-IDENTIFIER 
) O 
, O 
but O 
remain O 
insensitive O 
to O 
butyrylcholinesterase O 
( O 
BuChE O 
) O 
inhibition O 
( O 
bambuterol B-TRIVIAL 
) O 
. O 
HZ O 
mice O 
are O 
also O 
more O 
sensitive O 
to O 
the O 
peripheral O 
application O 
of O 
the O 
selective O 
AChE O 
inhibitor O 
donepezil B-TRIVIAL 
or O 
the O 
mixed O 
inhibitor O 
physostigmine B-TRIVIAL 
; O 
extracellular O 
ACh O 
levels O 
rise O 
significantly O 
after O 
administration O 
of O 
both O 
drugs O 
; O 
also O 
glucose B-TRIVIAL 
levels O 
are O 
moderately O 
increased O 
indicating O 
potentially O 
non-cholinergic O 
effects O 
of O 
donepezil B-TRIVIAL 
. O 
Behavioural O 
tests O 
show O 
comparable O 
cognitive O 
function O 
in O 
both O 
mouse O 
strains O 
. O 
Our O 
results O 
are O 
discussed O 
in O 
relation O 
to O 
the O 
use O 
of O 
AChE O 
/ O 
BuChE O 
inhibitors O 
in O 
AD O 
patients O 
. O 

are O 
small O 
chemotactic O 
cytokines O 
that O 
elicit O 
many O 
physiological O 
and O 
pathological O 
effects O 
through O 
binding O 
to O 
their O 
corresponding O 
receptors O 
. O 
Recent O 
studies O 
have O 
suggested O 
that O 
C-C O 
chemokine O 
receptor O 
( O 
CCR O 
) O 
5 O 
interacts O 
with O 
μ-opioid O 
receptor O 
and O 
modifies O 
a O 
nociceptive O 
reaction O 
. O 
We O 
examined O 
effects O 
of O 
CCR5 O 
deficiency O 
on O 
pain O 
responses O 
by O 
employing O 
CCR5 O 
knockout O 
( O 
KO O 
) O 
mice O 
. O 
We O 
found O 
that O 
pain O 
responses O 
of O 
CCR5 O 
KO O 
mice O 
to O 
chemical O 
or O 
inflammation O 
stimuli O 
were O 
milder O 
than O 
those O 
of O 
CCR5 O 
wild O 
type O 
( O 
WT O 
) O 
mice O 
. O 
However O 
, O 
there O 
was O 
no O 
remarkable O 
change O 
in O 
thermal O 
nociception O 
. O 
To O 
prove O 
the O 
involvement O 
of O 
CCR5 O 
deletion O 
in O 
lowered O 
nociception O 
, O 
we O 
examined O 
pain O 
reactions O 
with O 
CCR5 O 
WT O 
mice O 
following O 
treatment O 
of O 
a O 
CCR5 O 
antagonist O 
( O 
D-Ala(1)- B-FORMULA 
peptide I-FORMULA 
T-NH(2,) I-FORMULA 
DAPTA B-ABBREVIATION 
) O 
. O 
Chemical O 
or O 
inflammatory O 
pain O 
behavior O 
was O 
significantly O 
relieved O 
by O 
intracerebroventricular O 
infusion O 
of O 
the O 
inhibitor O 
. O 
When O 
we O 
assessed O 
expression O 
level O 
of O 
μ-opioid O 
receptor O 
( O 
MOR O 
) O 
in O 
the O 
periaqueductal O 
gray O 
where O 
the O 
receptors O 
are O 
critical O 
for O 
analgesic O 
effects O 
, O 
immunoreactivity O 
of O 
MOR O 
was O 
significantly O 
higher O 
in O 
CCR5 O 
KO O 
mice O 
than O 
WT O 
mice O 
without O 
change O 
in O 
phosphorylation O 
level O 
of O 
the O 
receptor O 
. O 
Reduced O 
nociceptive O 
responses O 
in O 
CCR5 O 
KO O 
mice O 
were O 
moderated O 
by O 
administration O 
of O 
naloxone B-TRIVIAL 
and O 
d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2 B-FORMULA 
( O 
CTAP B-ABBREVIATION 
) O 
, O 
MOR O 
antagonists O 
. O 
Our O 
data O 
indicate O 
that O 
CCR5 O 
deficiency O 
is O 
related O 
to O 
up O 
- O 
regulation O 
of O 
MOR O 
without O 
an O 
increase O 
in O 
the O 
receptor O 
desensitization O 
which O 
might O 
result O 
in O 
increased O 
analgesic O 
effects O 
against O 
chemical O 
or O 
inflammatory O 
stimuli O 
. O 
Alternatively O 
, O 
higher O 
amount O 
of O 
opioid O 
ligands O 
in O 
CCR5 O 
mice O 
might O 
be O 
linked O 
to O 
these O 
results O 
. O 
Therefore O 
, O 
CCR5 O 
appears O 
to O 
be O 
a O 
therapeutic O 
target O 
for O 
treatment O 
of O 
pain O 
related O 
diseases O 
such O 
as O 
inflammatory O 
hyperalgesia O 
. O 

- O 
principles O 
simulation O 
of O 
the O 
absorption O 
bands O 
of O 
fluorenone B-SYSTEMATIC 
in O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
. O 

absorption O 
spectrum O 
of O 
fluorenone B-SYSTEMATIC 
in O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
is O 
calculated O 
from O 
first O 
- O 
principles O 
simulations O 
. O 
The O 
broadening O 
of O 
each O 
band O 
is O 
obtained O 
from O 
the O 
explicit O 
treatment O 
of O 
the O 
interactions O 
between O 
the O 
chromophore O 
and O 
its O 
environment O 
in O 
the O 
statistical O 
ensemble O 
. O 
The O 
comparison O 
between O 
the O 
simulated O 
and O 
measured O 
spectra O 
reveals O 
the O 
main O 
factors O 
affecting O 
the O 
spectrum O 
of O 
the O 
chromophore O 
in O 
hydrated O 
zeolite B-TRIVIAL 
L I-TRIVIAL 
. O 
Whereas O 
each O 
distinguishable O 
band O 
is O 
found O 
to O 
originate O 
from O 
a O 
single O 
electronic O 
transition O 
, O 
the O 
bandwidth O 
is O 
determined O 
by O 
the O 
statistical O 
nature O 
of O 
the O 
environment O 
of O 
the O 
fluorenone B-SYSTEMATIC 
molecule O 
. O 
The O 
K(+) B-FORMULA 
··· O 
O=C B-FORMULA 
motif O 
is O 
retained O 
in O 
all O 
conformations O 
. O 
Although O 
the O 
interactions O 
between O 
K(+) B-FORMULA 
and O 
the O 
fluorenone B-SYSTEMATIC 
carbonyl I-SYSTEMATIC 
group O 
result O 
in O 
an O 
average O 
lengthening O 
of O 
the O 
C B-FORMULA 
[ O 
double O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
O B-FORMULA 
bond O 
and O 
in O 
a O 
redshift O 
of O 
the O 
lowest O 
energy O 
absorption O 
band O 
compared O 
to O 
gas O 
phase O 
or O 
non-polar O 
solvents O 
, O 
the O 
magnitude O 
of O 
this O 
shift O 
is O 
noticeably O 
smaller O 
than O 
the O 
total O 
shift O 
. O 
An O 
important O 
factor O 
affecting O 
the O 
shape O 
of O 
the O 
band O 
is O 
fluorenone B-SYSTEMATIC 
' O 
s O 
orientation O 
, O 
which O 
is O 
strongly O 
affected O 
by O 
the O 
presence O 
of O 
water O 
. O 
The O 
effect O 
of O 
direct O 
interactions O 
between O 
fluorenone B-SYSTEMATIC 
and O 
water O 
is O 
, O 
however O 
, O 
negligible O 
. O 

and O 
toxicity O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
in O 
terrestrial O 
springtails O 
-- O 
studying O 
bioconcentration O 
kinetics O 
and O 
linking O 
toxicity O 
to O 
chemical O 
activity O 
. O 

dosing O 
applies O 
a O 
polymer O 
loaded O 
with O 
test O 
compound(s) O 
to O 
establish O 
and O 
maintain O 
constant O 
exposure O 
in O 
laboratory O 
experiments O 
. O 
Passive O 
dosing O 
with O 
the O 
silicone O 
poly(dimethylsiloxane) B-SYSTEMATIC 
was O 
used O 
to O 
control O 
exposure O 
of O 
the O 
terrestrial O 
springtail O 
Folsomia O 
candida O 
to O 
six O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
in O 
bioconcentration O 
and O 
toxicity O 
experiments O 
. O 
Folsomia O 
candida O 
could O 
move O 
freely O 
on O 
the O 
PAH B-ABBREVIATION 
-loaded O 
silicone B-FAMILY 
, O 
resulting O 
in O 
exposure O 
via O 
air O 
and O 
direct O 
contact O 
. O 
The O 
bioconcentration O 
kinetics O 
indicated O 
efficient O 
uptake O 
of O 
naphthalene B-SYSTEMATIC 
, O 
anthracene B-SYSTEMATIC 
, O 
and O 
pyrene B-SYSTEMATIC 
through O 
air O 
and O 
( O 
near O 
) O 
equilibrium O 
partitioning O 
of O 
these O 
PAHs O 
to O 
lipids O 
and O 
possibly O 
the O 
waxy O 
layer O 
of O 
the O 
springtail O 
cuticle O 
. O 
Toxicities O 
of O 
naphthalene B-SYSTEMATIC 
, O 
phenanthrene B-SYSTEMATIC 
, O 
and O 
pyrene B-SYSTEMATIC 
were O 
related O 
to O 
chemical O 
activity O 
, O 
which O 
quantifies O 
the O 
energetic O 
level O 
and O 
drives O 
spontaneous O 
processes O 
including O 
diffusive O 
biouptake O 
. O 
Chemical O 
activity O 
- O 
response O 
relationships O 
yielded O 
effective O 
lethal O 
chemical O 
activities O 
( O 
La50s O 
) O 
well O 
within O 
the O 
expected O 
range O 
for O 
baseline O 
toxicity O 
( O 
0.01-0.1 O 
) O 
. O 
Effective O 
lethal O 
body O 
burdens O 
for O 
naphthalene B-SYSTEMATIC 
and O 
pyrene B-SYSTEMATIC 
exceeded O 
the O 
expected O 
range O 
of O 
2 O 
to O 
8 O 
mmol O 
kg(-1) O 
fresh O 
weight O 
, O 
which O 
again O 
indicated O 
the O 
waxy O 
layer O 
to O 
be O 
a O 
sorbing O 
phase O 
. O 
Finally O 
, O 
chemical O 
activities O 
were O 
converted O 
into O 
equilibrium O 
partitioning O 
concentrations O 
in O 
lipids O 
yielding O 
effective O 
lethal O 
concentrations O 
for O 
naphthalene B-SYSTEMATIC 
and O 
phenanthrene B-SYSTEMATIC 
in O 
good O 
correspondence O 
with O 
the O 
lethal O 
membrane O 
burden O 
for O 
baseline O 
toxicity O 
( O 
40-160 O 
mmol O 
kg(-1) O 
lipid O 
) O 
. O 
Passive O 
dosing O 
was O 
a O 
practical O 
approach O 
for O 
tightly O 
controlling O 
PAH O 
exposure O 
, O 
which O 
in O 
turn O 
provided O 
new O 
experimental O 
possibilities O 
and O 
findings O 
. O 

induced O 
formation O 
of O 
chromium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
from O 
dissolved O 
dichromate B-SYSTEMATIC 
. O 

formation O 
of O 
chromium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
by O 
gamma O 
radiolysis O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
( O 
CrO(4)(2-) B-FORMULA 
or O 
Cr(2)O(7)(2-) B-FORMULA 
) O 
solutions O 
was O 
investigated O 
as O 
a O 
function O 
of O 
pH O 
and O 
initial O 
Cr B-FORMULA 
(VI) I-FORMULA 
concentration O 
by O 
measuring O 
[ O 
Cr B-FORMULA 
(VI) I-FORMULA 
] O 
, O 
the O 
particle O 
concentration O 
( O 
[ O 
Cr B-FORMULA 
(III) I-FORMULA 
( O 
col O 
) O 
] O 
) O 
and O 
[ O 
H(2) B-FORMULA 
] O 
, O 
and O 
by O 
characterizing O 
the O 
particles O 
using O 
TEM O 
, O 
Raman O 
, O 
FTIR O 
and O 
XPS O 
. O 
The O 
results O 
show O 
that O 
Cr B-FORMULA 
(VI) I-FORMULA 
is O 
easily O 
reduced O 
to O 
Cr B-FORMULA 
(III) I-FORMULA 
by O 
a O 
homogeneous O 
aqueous O 
reaction O 
with O 
˙e(aq)(-) O 
, O 
but O 
, O 
due O 
to O 
the O 
stability O 
of O 
Cr B-FORMULA 
(III) I-FORMULA 
colloids O 
, O 
the O 
growth O 
of O 
the O 
Cr(OH)(3) B-FORMULA 
particles O 
is O 
very O 
slow O 
. O 
As O 
the O 
particles O 
grow O 
the O 
interior O 
of O 
the O 
particle O 
dehydrates O 
to O 
form O 
Cr(2)O(3 B-FORMULA 
) O 
while O 
the O 
outer O 
layer O 
remains O 
hydrated O 
. O 
When O 
most O 
of O 
the O 
Cr B-FORMULA 
(VI) I-FORMULA 
that O 
is O 
initially O 
present O 
in O 
the O 
solution O 
is O 
converted O 
to O 
Cr(OH)(3) B-FORMULA 
further O 
redox O 
reactions O 
of O 
chromium B-SYSTEMATIC 
species O 
occur O 
on O 
the O 
particle O 
surfaces O 
. O 
The O 
redox O 
system O 
reaches O 
a O 
pseudo O 
- O 
equilibrium O 
state O 
due O 
to O 
cyclic O 
reactions O 
of O 
Cr B-FORMULA 
(III) I-FORMULA 
with O 
˙ O 
OH B-FORMULA 
and O 
H(2)O(2) B-FORMULA 
, O 
and O 
reactions O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
with O 
˙e(aq)(-) O 
and O 
H(2)O(2) B-FORMULA 
. O 
The O 
size O 
distribution O 
of O 
the O 
particles O 
that O 
are O 
formed O 
is O 
controlled O 
by O 
these O 
solution O 
- O 
solid O 
interface O 
reactions O 
. O 

ionic O 
concentrations O 
are O 
associated O 
with O 
the O 
impairment O 
of O 
benthic O 
invertebrate O 
assemblages O 
. O 
However O 
, O 
the O 
causal O 
nature O 
of O 
that O 
relationship O 
must O 
be O 
demonstrated O 
so O 
that O 
it O 
can O 
be O 
used O 
to O 
derive O 
a O 
benchmark O 
for O 
conductivity O 
. O 
The O 
available O 
evidence O 
is O 
organized O 
in O 
terms O 
of O 
six O 
characteristics O 
of O 
causation O 
: O 
co O 
- O 
occurrence O 
, O 
preceding O 
causation O 
, O 
interaction O 
, O 
alteration O 
, O 
sufficiency O 
, O 
and O 
time O 
order O 
. O 
The O 
inferential O 
approach O 
is O 
to O 
weight O 
the O 
lines O 
of O 
evidence O 
using O 
a O 
consistent O 
scoring O 
system O 
, O 
weigh O 
the O 
evidence O 
for O 
each O 
causal O 
characteristic O 
, O 
and O 
then O 
assess O 
the O 
body O 
of O 
evidence O 
. O 
Through O 
this O 
assessment O 
, O 
the O 
authors O 
found O 
that O 
a O 
mixture O 
containing O 
the O 
ions O 
Ca(+) B-FORMULA 
, O 
Mg(+) B-FORMULA 
, O 
HCO B-FORMULA 
3(-) I-FORMULA 
, O 
and O 
SO B-FORMULA 
4(-) I-FORMULA 
, O 
as O 
measured O 
by O 
conductivity O 
, O 
is O 
a O 
common O 
cause O 
of O 
extirpation O 
of O 
aquatic O 
macroinvertebrates O 
in O 
Appalachia O 
where O 
surface O 
coal B-TRIVIAL 
mining O 
is O 
prevalent O 
. O 
The O 
mixture O 
of O 
ions O 
is O 
implicated O 
as O 
the O 
cause O 
rather O 
than O 
any O 
individual O 
constituent O 
of O 
the O 
mixture O 
. O 
The O 
authors O 
also O 
expect O 
that O 
ionic O 
concentrations O 
sufficient O 
to O 
cause O 
extirpations O 
would O 
occur O 
with O 
a O 
similar O 
salt O 
mixture O 
containing O 
predominately O 
HCO B-FORMULA 
3(-) I-FORMULA 
, O 
SO B-FORMULA 
4(2-) I-FORMULA 
, O 
Ca(2+) B-FORMULA 
, O 
and O 
Mg(2+) B-FORMULA 
in O 
other O 
regions O 
with O 
naturally O 
low O 
conductivity O 
. O 
This O 
case O 
demonstrates O 
the O 
utility O 
of O 
the O 
method O 
for O 
determining O 
whether O 
relationships O 
identified O 
in O 
the O 
field O 
are O 
causal O 
. O 

exposure O 
of O 
eggs O 
to O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
BDE-47 B-ABBREVIATION 
and O 
BDE-99 B-ABBREVIATION 
in O 
red O 
- O 
eared O 
sliders O 
( O 
Trachemys O 
scripta O 
elegans O 
) O 
and O 
snapping O 
turtles O 
( O 
Chelydra O 
serpentina O 
) O 
and O 
possible O 
species O 
- O 
specific O 
differences O 
in O 
debromination O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
are O 
a O 
bioaccumulative O 
, O 
persistent O 
, O 
and O 
toxic O 
class O 
of O 
flame O 
retardants O 
that O 
can O 
potentially O 
impact O 
turtles O 
in O 
natural O 
habitats O 
via O 
exposure O 
through O 
maternal O 
transfer O 
. O 
To O 
simulate O 
maternal O 
transfer O 
in O 
the O 
present O 
study O 
, O 
PBDE B-ABBREVIATION 
congeners O 
BDE-47 B-ABBREVIATION 
and O 
BDE-99 B-ABBREVIATION 
were O 
topically O 
applied O 
to O 
the O 
eggshell O 
and O 
were O 
allowed O 
to O 
diffuse O 
into O 
the O 
egg O 
contents O 
of O 
the O 
red O 
- O 
eared O 
slider O 
( O 
Trachemys O 
scripta O 
elegans O 
) O 
and O 
snapping O 
turtle O 
( O 
Chelydra O 
serpentina O 
) O 
. O 
Eggs O 
were O 
topically O 
dosed O 
over O 
8 O 
d O 
to O 
achieve O 
a O 
target O 
concentration O 
of O 
40 O 
ng O 
/ O 
g O 
in O 
the O 
egg O 
contents O 
. O 
Transfer O 
efficiency O 
was O 
higher O 
for O 
BDE-47 B-ABBREVIATION 
than O 
for O 
BDE-99 B-ABBREVIATION 
in O 
the O 
red O 
- O 
eared O 
sliders O 
( O 
25.8 O 
± O 
1.9% O 
vs O 
9.9 O 
± O 
1.1% O 
) O 
and O 
snapping O 
turtles O 
( O 
31.3 O 
± O 
1.6% O 
vs O 
12.5 O 
± O 
1.4% O 
) O 
, O 
resulting O 
in O 
greater O 
BDE-47 B-ABBREVIATION 
and O 
lower O 
BDE-99 B-ABBREVIATION 
egg O 
content O 
concentrations O 
relative O 
to O 
the O 
40 O 
ng O 
/ O 
g O 
target O 
. O 
However O 
, O 
only O 
25.8 O 
and O 
31.3% O 
of O 
the O 
total O 
BDE-47 B-ABBREVIATION 
and O 
9.9 O 
and O 
12.5% O 
of O 
the O 
total O 
BDE-99 B-ABBREVIATION 
dose O 
applied O 
could O 
be O 
accounted O 
for O 
in O 
the O 
red O 
- O 
eared O 
slider O 
and O 
snapping O 
turtle O 
egg O 
contents O 
, O 
respectively O 
. O 
Additionally O 
, O 
increased O 
BDE-47 B-ABBREVIATION 
in O 
red O 
- O 
eared O 
slider O 
egg O 
contents O 
dosed O 
with O 
only O 
BDE-99 B-ABBREVIATION 
indicate O 
that O 
BDE-99 B-ABBREVIATION 
might O 
have O 
been O 
debrominated O 
to O 
BDE-47 B-ABBREVIATION 
. O 
The O 
efficacy O 
of O 
topical O 
dosing O 
for O 
administering O 
desired O 
embryonic O 
exposures O 
is O 
clearly O 
affected O 
by O 
the O 
chemical O 
properties O 
of O 
the O 
applied O 
compounds O 
and O 
was O 
more O 
successful O 
for O 
BDE-47 B-ABBREVIATION 
in O 
both O 
species O 
. O 

adenosine B-TRIVIAL 
receptors O 
differentially O 
limit O 
antigen O 
- O 
induced O 
mast O 
cell O 
activation O 
. O 

cell O 
activation O 
results O 
in O 
the O 
immediate O 
release O 
of O 
proinflammatory O 
mediators O 
prestored O 
in O 
cytoplasmic O 
granules O 
, O 
as O 
well O 
as O 
initiation O 
of O 
lipid O 
mediator O 
production O 
and O 
cytokine O 
synthesis O 
by O 
these O 
resident O 
tissue O 
leukocytes O 
. O 
Allergen O 
- O 
induced O 
mast O 
cell O 
activation O 
is O 
central O 
to O 
the O 
pathogenesis O 
of O 
asthma O 
and O 
other O 
allergic O 
diseases O 
. O 
Presently O 
, O 
most O 
pharmacological O 
agents O 
for O 
the O 
treatment O 
of O 
allergic O 
disease O 
target O 
receptors O 
for O 
inflammatory O 
mediators O 
. O 
Many O 
of O 
these O 
mediators O 
, O 
such O 
as O 
histamine B-TRIVIAL 
, O 
are O 
released O 
by O 
mast O 
cells O 
. O 
Targeting O 
pathways O 
that O 
limit O 
antigen O 
- O 
induced O 
mast O 
cell O 
activation O 
may O 
have O 
greater O 
therapeutic O 
efficacy O 
by O 
inhibiting O 
the O 
synthesis O 
and O 
release O 
of O 
many O 
proinflammatory O 
mediators O 
produced O 
in O 
the O 
mast O 
cell O 
. O 
In O 
vitro O 
studies O 
using O 
cultured O 
human O 
and O 
mouse O 
mast O 
cells O 
, O 
and O 
studies O 
of O 
mice O 
lacking O 
A(2B) O 
receptors O 
, O 
suggest O 
that O 
adenosine B-TRIVIAL 
receptors O 
, O 
specifically O 
the O 
G(s)-coupled O 
A(2A) O 
and O 
A(2B) O 
receptors O 
, O 
might O 
provide O 
such O 
a O 
target O 
. O 
Here O 
, O 
using O 
a O 
panel O 
of O 
mice O 
lacking O 
various O 
combinations O 
of O 
adenosine B-TRIVIAL 
receptors O 
, O 
and O 
mast O 
cells O 
derived O 
from O 
these O 
animals O 
, O 
we O 
show O 
that O 
adenosine B-TRIVIAL 
receptor O 
agonists O 
provide O 
an O 
effective O 
means O 
of O 
inhibition O 
of O 
mast O 
cell O 
degranulation O 
and O 
induction O 
of O 
cytokine O 
production O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
We O 
identify O 
A(2B) O 
as O 
the O 
primary O 
receptor O 
limiting O 
mast O 
cell O 
degranulation O 
, O 
whereas O 
the O 
combined O 
activity O 
of O 
A(2A) O 
and O 
A(2B) O 
is O 
required O 
for O 
the O 
inhibition O 
of O 
cytokine O 
synthesis O 
. O 

is O 
a O 
rare O 
condition O 
caused O 
by O 
a O 
pituitary O 
adenoma O 
that O 
secretes O 
growth O 
hormone O 
. O 
The O 
mortality O 
rate O 
is O 
72 O 
% O 
higher O 
in O 
patients O 
with O 
acromegaly O 
than O 
in O 
the O 
general O 
population O 
according O 
to O 
meta-analyses O 
. O 
Mortality O 
analysis O 
has O 
shown O 
as O 
many O 
as O 
60 O 
% O 
of O 
acromegalic O 
patients O 
die O 
due O 
to O 
cardiovascular O 
disease O 
. O 
Sudden O 
cardiac O 
death O 
may O 
occur O 
in O 
patients O 
with O 
acromegaly O 
and O 
malignant O 
ventricular O 
arrhythmia O 
may O 
play O 
an O 
important O 
role O 
in O 
this O 
fatal O 
complication O 
; O 
however O 
, O 
the O 
precise O 
mechanism O 
is O 
not O 
fully O 
known O 
. O 
QT O 
dispersion O 
( O 
dQT O 
) O 
is O 
an O 
electrophysiological O 
factor O 
known O 
to O 
be O 
associated O 
with O 
a O 
tendency O 
for O 
ventricular O 
arrhythmia O 
and O 
sudden O 
cardiac O 
death O 
. O 
This O 
study O 
aimed O 
to O 
evaluate O 
dQT O 
as O 
an O 
early O 
predictor O 
of O 
ventricular O 
tachyarrhythmia O 
, O 
as O 
sudden O 
cardiac O 
death O 
commonly O 
occurs O 
in O 
acromegalic O 
patients O 
. O 
This O 
cross O 
- O 
sectional O 
case O 
- O 
control O 
study O 
enrolled O 
20 O 
patients O 
( O 
10 O 
female O 
and O 
10 O 
male O 
) O 
with O 
acromegaly O 
and O 
20 O 
healthy O 
controls O 
( O 
11 O 
female O 
and O 
9 O 
male O 
) O 
after O 
exclusion O 
criteria O 
were O 
applied O 
. O 
Each O 
participant O 
underwent O 
12-lead O 
electrocardiography O 
, O 
including O 
≥3 O 
QRS O 
complexes O 
, O 
at O 
a O 
speed O 
of O 
25 O 
mm O 
/ O 
s O 
after O 
a O 
15-min O 
rest O 
. O 
In O 
each O 
participant O 
, O 
the O 
QT O 
interval O 
( O 
beginning O 
of O 
the O 
Q O 
wave O 
to O 
the O 
end O 
of O 
the O 
T O 
wave O 
) O 
was O 
corrected O 
( O 
QTc O 
) O 
for O 
heart O 
rate O 
using O 
Bazett's O 
formula O 
[ O 
Formula O 
: O 
see O 
text O 
] O 
QTc O 
dispersion O 
( O 
dQTc O 
) O 
( O 
QTc O 
max O 
- O 
QTc O 
min O 
) O 
was O 
also O 
calculated O 
. O 
There O 
was O 
no O 
significant O 
difference O 
in O 
median O 
dQTc O 
between O 
the O 
acromegalic O 
patients O 
( O 
0.79 O 
s O 
) O 
and O 
the O 
controls O 
( O 
0.45 O 
s O 
) O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
Active O 
acromegalic O 
patients O 
( O 
n O 
= O 
14 O 
) O 
were O 
estimated O 
to O 
have O 
a O 
median O 
dQTc O 
of O 
0.82 O 
s O 
, O 
after O 
excluding O 
from O 
the O 
analysis O 
six O 
patients O 
that O 
were O 
under O 
full O 
biochemical O 
control O 
, O 
and O 
that O 
had O 
randomly O 
obtained O 
growth O 
hormone O 
levels O 
< O 
0.4 O 
ng O 
/ O 
mL O 
, O 
GH O 
< O 
1 O 
ng O 
/ O 
mL O 
based O 
on O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
and O 
normal O 
IGF-I O 
for O 
age O 
and O 
gender O 
. O 
A O 
significant O 
difference O 
was O 
noted O 
in O 
median O 
dQTc O 
between O 
the O 
active O 
acromegalic O 
patients O 
and O 
the O 
controls O 
( O 
p O 
= O 
0.015 O 
) O 
. O 
The O 
dQT O 
in O 
active O 
acromegalic O 
patients O 
was O 
longer O 
than O 
that O 
in O 
the O 
control O 
group O 
, O 
which O 
indicates O 
that O 
patients O 
with O 
active O 
acromegaly O 
might O 
have O 
an O 
elevated O 
risk O 
for O 
ventricular O 
arrhythmia O 
. O 
We O 
think O 
that O 
a O 
non-invasive O 
, O 
simple O 
and O 
inexpensive O 
marker O 
- O 
measurement O 
of O 
dQT-as O 
part O 
of O 
cardiac O 
monitoring O 
could O 
be O 
valuable O 
for O 
screening O 
complications O 
in O 
acromegalic O 
patients O 
. O 

and O 
fetal O 
exposure O 
to O 
bisphenol B-TRIVIAL 
a I-TRIVIAL 
is O 
associated O 
with O 
alterations O 
of O 
thyroid O 
function O 
in O 
pregnant O 
ewes O 
and O 
their O 
newborn O 
lambs O 
. O 

putative O 
thyroid O 
- O 
disrupting O 
properties O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
highlight O 
the O 
need O 
for O 
an O 
evaluation O 
of O 
fetal O 
exposure O 
and O 
its O 
consequence O 
on O 
the O 
mother O 
/ O 
newborn O 
thyroid O 
functions O 
in O 
models O 
relevant O 
to O 
human O 
. O 
The O 
goals O 
of O 
this O 
study O 
were O 
to O 
characterize O 
in O 
sheep O 
a O 
relevant O 
model O 
for O 
human O 
pregnancy O 
and O 
thyroid O 
physiology O 
, O 
the O 
internal O 
exposures O 
of O 
the O 
fetuses O 
and O 
their O 
mothers O 
to O 
BPA B-ABBREVIATION 
and O 
its O 
main O 
metabolite O 
BPA-glucuronide B-SYSTEMATIC 
( O 
Gluc O 
) O 
, O 
and O 
to O 
determine O 
to O 
what O 
extent O 
it O 
might O 
be O 
associated O 
with O 
thyroid O 
disruption O 
. O 
Ewes O 
were O 
treated O 
with O 
BPA B-ABBREVIATION 
[ O 
5 O 
mg O 
/ O 
( O 
kg O 
· O 
d O 
) O 
sc O 
] O 
or O 
vehicle O 
from O 
d O 
28 O 
until O 
the O 
end O 
of O 
pregnancy O 
. O 
Unconjugated O 
BPA B-ABBREVIATION 
did O 
not O 
appear O 
to O 
accumulate O 
in O 
pregnant O 
ewes O 
, O 
and O 
its O 
concentration O 
was O 
similar O 
in O 
the O 
newborns O 
and O 
their O 
mothers O 
( O 
0.13 O 
± O 
0.02 O 
and O 
0.18 O 
± O 
0.03 O 
nmol O 
/ O 
ml O 
in O 
cord O 
and O 
maternal O 
blood O 
, O 
respectively O 
) O 
. O 
In O 
amniotic O 
fluid O 
and O 
cord O 
blood O 
, O 
BPA-Gluc B-ABBREVIATION 
concentrations O 
were O 
about O 
1300-fold O 
higher O 
than O 
those O 
of O 
BPA B-ABBREVIATION 
. O 
Total O 
T(4) O 
concentrations O 
were O 
decreased O 
in O 
BPA B-ABBREVIATION 
-treated O 
pregnant O 
ewes O 
and O 
in O 
the O 
cord O 
and O 
the O 
jugular O 
blood O 
of O 
their O 
newborns O 
( O 
30% O 
decrease O 
) O 
. O 
A O 
similar O 
difference O 
was O 
observed O 
for O 
free O 
T(4) O 
plasma O 
concentrations O 
in O 
the O 
jugular O 
blood O 
of O 
the O 
newborns O 
. O 
Our O 
results O 
show O 
in O 
a O 
long O 
- O 
gestation O 
species O 
with O 
a O 
similar O 
regulatory O 
scheme O 
of O 
thyroid O 
function O 
as O 
humans O 
that O 
BPA B-ABBREVIATION 
in O 
utero O 
exposure O 
can O 
be O 
associated O 
with O 
hypothyroidism O 
in O 
the O 
newborns O 
. O 
If O 
such O 
an O 
effect O 
were O 
to O 
be O 
confirmed O 
for O 
a O 
more O 
relevant O 
exposure O 
scheme O 
to O 
BPA B-ABBREVIATION 
, O 
this O 
would O 
constitute O 
a O 
major O 
issue O 
for O 
BPA O 
risk O 
assessment O 
. O 

is O 
broad O 
evidence O 
that O 
association O 
of O 
transmembrane O 
receptors O 
and O 
signalling O 
molecules O 
with O 
lipid O 
rafts O 
/ O 
caveolae O 
provides O 
an O 
enriched O 
environment O 
for O 
protein O 
- O 
protein O 
interactions O 
necessary O 
for O 
signal O 
transduction O 
, O 
and O 
a O 
mechanism O 
for O 
the O 
modulation O 
of O 
neurotransmitter O 
and O 
/ O 
or O 
growth O 
factor O 
receptor O 
function O 
. O 
Several O 
receptors O 
translocate O 
into O 
submembrane O 
compartments O 
after O 
ligand O 
binding O 
, O 
while O 
others O 
move O 
in O 
the O 
opposite O 
direction O 
. O 
The O 
role O 
of O 
such O 
a O 
dynamic O 
localization O 
and O 
functional O 
facilitation O 
is O 
signalling O 
modulation O 
and O 
receptor O 
desensitization O 
or O 
internalization O 
. O 
Purine B-TRIVIAL 
and O 
pyrimidine B-SYSTEMATIC 
nucleotides B-FAMILY 
have O 
been O 
viewed O 
as O 
primordial O 
precursors O 
in O 
the O 
evolution O 
of O 
all O 
forms O 
of O 
intercellular O 
communication O 
, O 
and O 
they O 
are O 
now O 
regarded O 
as O 
fundamental O 
extracellular O 
signalling O 
molecules O 
. O 
They O 
propagate O 
the O 
purinergic O 
signalling O 
by O 
binding O 
to O 
ionotropic O 
and O 
metabotropic O 
receptors O 
expressed O 
on O 
the O 
plasma O 
membrane O 
of O 
almost O 
all O 
cell O 
types O 
, O 
tissues O 
and O 
organs O 
. O 
Here O 
, O 
we O 
have O 
illustrated O 
the O 
localization O 
in O 
lipid O 
rafts O 
/ O 
caveolae O 
of O 
G O 
protein O 
- O 
coupled O 
P1 O 
receptors O 
for O 
adenosine B-TRIVIAL 
and O 
P2Y O 
receptors O 
for O 
nucleoside B-MULTIPLE 
tri- I-MULTIPLE 
and I-MULTIPLE 
di I-MULTIPLE 
- I-MULTIPLE 
phosphates I-MULTIPLE 
. O 
We O 
have O 
highlighted O 
that O 
microdomain O 
partitioning O 
of O 
these O 
purinergic O 
GPCRs O 
is O 
cell O 
- O 
specific O 
, O 
as O 
is O 
the O 
overall O 
expression O 
levels O 
of O 
these O 
same O 
receptors O 
. O 
Moreover O 
, O 
we O 
have O 
described O 
that O 
disruption O 
of O 
submembrane O 
compartments O 
can O 
shift O 
the O 
purinergic O 
receptors O 
from O 
raft O 
/ O 
caveolar O 
to O 
non-raft O 
/ O 
non-caveolar O 
fractions O 
, O 
and O 
then O 
abolish O 
their O 
ability O 
to O 
activate O 
lipid O 
signalling O 
pathways O 
and O 
to O 
integrate O 
with O 
additional O 
lipid O 
- O 
controlled O 
signalling O 
events O 
. O 
This O 
modulates O 
the O 
biological O 
response O 
to O 
purinergic O 
ligands O 
and O 
most O 
of O 
all O 
indicates O 
that O 
the O 
topology O 
of O 
the O 
various O 
purinergic O 
components O 
at O 
the O 
cell O 
surface O 
not O 
only O 
organizes O 
the O 
signal O 
transduction O 
machinery O 
, O 
but O 
also O 
controls O 
the O 
final O 
cellular O 
response O 
. O 

hundred O 
years O 
of O 
helicene B-FAMILY 
chemistry O 
. O 
Part O 
2 O 
: O 
stereoselective O 
syntheses O 
and O 
chiral O 
separations O 
of O 
carbohelicenes B-FAMILY 
. O 

generally O 
incorporate O 
a O 
helical O 
, O 
distorted O 
, O 
conjugated O 
, O 
polyaromatic O 
system O 
with O 
ortho-fused O 
benzenoid B-FAMILY 
rings O 
, O 
which O 
is O 
a O 
fundamental O 
molecular O 
characteristic O 
of O 
this O 
class O 
of O 
compounds O 
. O 
They O 
have O 
been O 
described O 
as O 
" O 
molecules O 
in O 
distress O 
" O 
due O 
to O 
their O 
distortion O 
. O 
The O 
generation O 
of O 
a O 
chiral O 
helicity O 
in O 
helicenes B-FAMILY 
was O 
observed O 
because O 
of O 
a O 
severe O 
intramolecular O 
steric O 
strain O 
. O 
Helicity O 
is O 
a O 
molecular O 
necessity O 
in O 
the O 
higher O 
series O 
of O 
carbohelicenes B-FAMILY 
, O 
when O 
at O 
some O 
point O 
, O 
a O 
helical O 
pitch O 
occurs O 
when O 
a O 
second O 
coil O 
is O 
formed O 
. O 
The O 
most O 
interesting O 
properties O 
resulting O 
from O 
such O 
molecular O 
distortion O 
are O 
the O 
very O 
high O 
chiroptical O 
and O 
circular O 
dichroism O 
values O 
. O 
For O 
instance O 
, O 
the O 
resolution O 
of O 
some O 
helicene B-FAMILY 
racemates O 
by O 
" O 
hand O 
picking O 
" O 
of O 
a O 
few O 
homochiral O 
single O 
enantiomeric O 
crystals O 
allowed O 
for O 
a O 
measurement O 
of O 
their O 
optical O 
rotation O 
. O 
Due O 
to O 
that O 
intrinsic O 
chirality O 
spanned O 
over O 
a O 
large O 
polyaromatic O 
template O 
, O 
preliminary O 
results O 
clearly O 
established O 
the O 
efficiency O 
of O 
carbohelicenes B-FAMILY 
to O 
induce O 
asymmetry O 
and O 
chirality O 
in O 
organic O 
synthesis O 
and O 
in O 
supramolecular O 
chemistry O 
. O 
Additionally O 
, O 
they O 
have O 
some O 
potential O 
uses O 
in O 
several O 
fields O 
: O 
materials O 
science O 
, O 
nanoscience O 
, O 
chemical O 
biology O 
and O 
supramolecular O 
chemistry O 
. O 
It O 
has O 
encouraged O 
many O 
attempts O 
to O 
develop O 
new O 
asymmetric O 
syntheses O 
of O 
carbohelicenes B-FAMILY 
, O 
as O 
well O 
as O 
some O 
chiral O 
separations O 
of O 
enantiomers O 
and O 
diastereoisomers O 
. O 
This O 
review O 
is O 
thus O 
dedicated O 
to O 
carbohelicene B-FAMILY 
chirality O 
. O 
It O 
gathered O 
a O 
substantial O 
collection O 
of O 
data O 
, O 
and O 
a O 
comprehensive O 
review O 
on O 
the O 
preparations O 
of O 
enantioenriched O 
helicenes B-FAMILY 
, O 
either O 
from O 
an O 
asymmetric O 
synthesis O 
or O 
from O 
a O 
chiral O 
separation O 
. O 
Utilizations O 
of O 
non-racemic O 
helicenes B-FAMILY 
and O 
their O 
applications O 
will O 
be O 
treated O 
in O 
the O 
following O 
review O 
( O 
Part O 
3 O 
) O 
, O 
and O 
will O 
not O 
be O 
the O 
subject O 
of O 
this O 
manuscript O 
. O 

- O 
like O 
effect O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
mice O 
exposed O 
to O 
the O 
repeated O 
forced O 
swimming O 
test O 
. O 

study O 
aimed O 
to O 
explore O 
the O 
antidepressant O 
- O 
like O 
effect O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
and O 
its O 
possible O 
mechanism O 
related O 
to O 
the O 
monoaminergic O 
system O 
and O 
neurotrophin O 
in O 
mice O 
exposed O 
to O 
the O 
repeated O 
forced O 
swimming O 
test O 
( O 
FST O 
) O 
. O 
Both O 
the O 
duration O 
and O 
the O 
latency O 
of O 
immobility O 
affected O 
by O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
10 O 
, O 
20 O 
and O 
40 O 
mg O 
/ O 
kg O 
) O 
were O 
evaluated O 
in O 
the O 
FST O 
repeated O 
at O 
intervals O 
on O 
days O 
1 O 
, O 
7 O 
and O 
14 O 
, O 
followed O 
by O 
neurochemical O 
and O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
analyses O 
in O 
the O 
mouse O 
brain O 
regions O 
of O 
frontal O 
cortex O 
and O 
whole O 
hippocampus O 
. O 
A O 
repeated O 
analysis O 
of O 
variance O 
( O 
ANOVA O 
) O 
indicated O 
that O 
over O 
retesting O 
the O 
immobility O 
time O 
increased O 
, O 
whereas O 
latency O 
to O 
immobility O 
tended O 
to O 
decrease O 
. O 
Minute O 
- O 
by O 
- O 
minute O 
analysis O 
showed O 
that O 
immobility O 
time O 
also O 
increased O 
during O 
the O 
4-min O 
course O 
of O 
the O 
test O 
. O 
In O 
addition O 
, O 
post O 
- O 
hoc O 
Dunnett's O 
test O 
demonstrated O 
that O 
sub O 
- O 
chronic O 
and O 
chronic O 
, O 
but O 
not O 
acute O 
, O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
treatment O 
reduced O 
the O 
immobility O 
time O 
( O 
sub O 
- O 
chronic O 
: O 
20 O 
mg O 
/ O 
kg O 
, O 
43.5% O 
; O 
chronic O 
: O 
10 O 
mg O 
/ O 
kg O 
, O 
19.3% O 
; O 
20 O 
mg O 
/ O 
kg O 
, O 
31.8% O 
) O 
and O 
increased O 
the O 
latency O 
to O 
immobility O 
( O 
sub O 
- O 
chronic O 
: O 
10 O 
mg O 
/ O 
kg O 
, O 
60.6% O 
; O 
20 O 
mg O 
/ O 
kg O 
, O 
80.1% O 
; O 
chronic O 
: O 
10 O 
mg O 
/ O 
kg O 
, O 
121.8% O 
; O 
20 O 
mg O 
/ O 
kg O 
, O 
140.8% O 
; O 
40 O 
mg O 
/ O 
kg O 
, O 
80.0% O 
) O 
. O 
Furthermore O 
, O 
chronic O 
administration O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
significantly O 
increased O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
levels O 
( O 
frontal O 
cortex O 
: O 
44.5% O 
, O 
41.9% O 
, O 
27.5% O 
for O 
10 O 
, O 
20 O 
, O 
40 O 
mg O 
/ O 
kg O 
; O 
hippocampus O 
: O 
57.2% O 
, O 
80.9% O 
for O 
10 O 
, O 
20 O 
mg O 
/ O 
kg O 
) O 
, O 
decreased O 
5-hydroxyindoleacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
5-HIAA B-SYSTEMATIC 
)/ O 
5-HT B-SYSTEMATIC 
ratio O 
( O 
frontal O 
cortex O 
: O 
31.6% O 
, O 
30.1% O 
, O 
23.5% O 
; O 
hippocampus O 
: O 
40.6% O 
, O 
47.7% O 
, O 
29.2% O 
for O 
10 O 
, O 
20 O 
, O 
40 O 
mg O 
/ O 
kg O 
) O 
and O 
elevated O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
levels O 
( O 
hippocampus O 
: O 
20 O 
mg O 
/ O 
kg O 
, O 
45.4% O 
) O 
but O 
did O 
not O 
alter O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
levels O 
. O 
Moreover O 
, O 
BDNF O 
levels O 
in O 
the O 
two O 
brain O 
regions O 
were O 
also O 
elevated O 
by O 
chronic O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
treatment O 
( O 
frontal O 
cortex O 
: O 
20 O 
mg O 
/ O 
kg O 
, O 
67.2% O 
; O 
hippocampus O 
: O 
10 O 
mg O 
/ O 
kg O 
, O 
36.4% O 
; O 
20 O 
mg O 
/ O 
kg O 
, O 
55.1% O 
) O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
imply O 
that O 
functions O 
of O 
5-HT B-SYSTEMATIC 
, O 
NE O 
and O 
BDNF O 
may O 
be O 
involved O 
in O 
the O 
antidepressant O 
- O 
like O 
effect O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
. O 

is O 
a O 
chronic O 
debilitating O 
mental O 
disorder O 
that O 
affects O 
about O 
1% O 
of O 
the O 
US O 
population O 
. O 
The O 
pathophysiology O 
and O 
etiology O 
remain O 
unknown O 
, O 
thus O 
new O 
treatment O 
targets O 
have O 
been O 
challenging O 
and O 
few O 
novel O 
treatments O 
with O 
new O 
mechanisms O 
of O 
action O 
have O 
come O 
to O 
market O 
in O 
the O 
past O 
few O 
decades O 
. O 
Increasing O 
attention O 
has O 
been O 
paid O 
to O 
the O 
role O 
of O 
inflammation O 
in O 
schizophrenia O 
and O 
new O 
data O 
suggests O 
that O 
decreasing O 
inflammation O 
and O 
inflammatory O 
biomarkers O 
may O 
play O 
some O 
role O 
in O 
schizophrenia O 
treatment O 
. O 
This O 
review O 
summarizes O 
the O 
clinical O 
trial O 
literature O 
regarding O 
medications O 
that O 
possess O 
anti-inflammatory O 
properties O 
that O 
have O 
been O 
tested O 
for O 
schizophrenia O 
symptoms O 
and O 
covers O 
such O 
medications O 
as O 
non- O 
steroidal B-FAMILY 
anti-inflammatory O 
agents O 
, O 
such O 
as O 
the O 
cyclo-oxygenase-2 O 
( O 
COX-2 O 
) O 
inhibitors O 
and O 
aspirin B-TRIVIAL 
, O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
neurosteroids B-FAMILY 
and O 
minocycline B-TRIVIAL 
. O 
Overall O 
, O 
there O 
is O 
accumulating O 
evidence O 
, O 
albeit O 
mostly O 
adjunctive O 
treatments O 
, O 
that O 
agents O 
working O 
on O 
inflammatory O 
pathways O 
have O 
some O 
benefits O 
in O 
people O 
with O 
schizophrenia O 
. O 
In O 
the O 
next O 
few O 
years O 
the O 
field O 
will O 
begin O 
to O 
see O 
data O 
on O 
many O 
treatments O 
with O 
anti-inflammatory O 
properties O 
that O 
are O 
currently O 
under O 
study O 
. O 
Hopefully O 
advancements O 
in O 
understanding O 
inflammation O 
and O 
effective O 
treatments O 
having O 
anti-inflammatory O 
properties O 
may O 
help O 
revolutionize O 
our O 
understanding O 
and O 
provide O 
new O 
targets O 
for O 
prevention O 
and O 
treatment O 
in O 
schizophrenia O 
. O 

activates O 
endothelin-1 O 
Gi O 
protein O 
- O 
coupled O 
receptor O 
signaling O 
to O 
inhibit O 
stem O 
cell O 
differentiation O 
in O 
adipogenesis O 
. O 

lipid O 
and O 
glucose B-TRIVIAL 
metabolism O 
contribute O 
to O 
metabolic O 
syndrome-a O 
major O 
public O 
health O 
concern O 
that O 
enhances O 
cardiovascular O 
disease O 
risk O 
. O 
Arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
(III) I-FORMULA 
) O 
exposure O 
may O 
increase O 
metabolic O 
syndrome O 
and O 
cardiovascular O 
disease O 
risk O 
by O 
impairing O 
adipose O 
tissue O 
differentiation O 
, O 
function O 
, O 
and O 
insulin O 
sensitivity O 
through O 
pathogenic O 
mechanisms O 
that O 
remain O 
unclear O 
. O 
We O 
hypothesized O 
that O 
As B-FORMULA 
(III) I-FORMULA 
signals O 
through O 
the O 
Pertussis O 
toxin O 
( O 
Ptx O 
) O 
sensitive O 
, O 
Gi O 
protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
to O 
impair O 
adipogenesis O 
, O 
as O 
previously O 
demonstrated O 
for O 
its O 
stimulation O 
of O 
vascular O 
oxidant O 
generation O 
, O 
angiogenesis O 
, O 
and O 
remodeling O 
. O 
Because O 
both O 
As B-FORMULA 
(III) I-FORMULA 
and O 
GPCR O 
ligands O 
inhibit O 
progenitor O 
cell O 
differentiation O 
into O 
adipocytes O 
, O 
we O 
investigated O 
the O 
hypothesis O 
in O 
a O 
model O 
of O 
low O 
- O 
passage O 
human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSC O 
) O 
. O 
As B-FORMULA 
(III) I-FORMULA 
( O 
0.1-1.0 O 
µM O 
) O 
suppressed O 
dexamethasone B-TRIVIAL 
/ O 
insulin O 
- O 
induced O 
hMSC O 
adipogenesis O 
, O 
as O 
indicated O 
by O 
decreased O 
transcriptional O 
promoters O 
of O 
differentiation O 
, O 
decreased O 
fat O 
droplet O 
formation O 
, O 
and O 
decreased O 
expression O 
of O 
differentiated O 
adipocyte O 
markers O 
, O 
such O 
as O 
adiponectin O 
and O 
perilipin O 
. O 
Preincubating O 
hMSC O 
with O 
Ptx O 
prevented O 
90% O 
of O 
the O 
suppressive O 
effect O 
of O 
As B-FORMULA 
(III) I-FORMULA 
. O 
Selective O 
competitive O 
antagonists O 
of O 
Gi-coupled O 
endothelin-1 O 
type O 
A O 
and O 
B O 
receptors O 
were O 
~60% O 
effective O 
in O 
blocking O 
As B-FORMULA 
(III) I-FORMULA 
inhibition O 
and O 
combination O 
of O 
antagonists O 
to O 
both O 
receptors O 
were O 
85% O 
effective O 
. O 
In O 
contrast O 
, O 
antagonists O 
to O 
the O 
sphingosine-1-phosphate B-SYSTEMATIC 
type O 
1 O 
receptor O 
( O 
previously O 
shown O 
to O 
mediate O 
As B-FORMULA 
(III) I-FORMULA 
vascular O 
effects O 
) O 
or O 
the O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
were O 
ineffective O 
in O 
blocking O 
As B-FORMULA 
(III) I-FORMULA 
effects O 
. O 
These O 
studies O 
suggest O 
a O 
majority O 
of O 
arsenic B-SYSTEMATIC 
-inhibited O 
adipocyte O 
differentiation O 
, O 
and O 
metabolism O 
requires O 
endothelin-1 O 
GPCRs O 
and O 
that O 
As B-FORMULA 
(III) I-FORMULA 
effects O 
on O 
GPCR O 
signaling O 
are O 
tissue O 
and O 
context O 
specific O 
. O 
This O 
may O 
represent O 
a O 
significant O 
mechanism O 
for O 
the O 
contribution O 
of O 
arsenic B-SYSTEMATIC 
exposure O 
to O 
increased O 
metabolic O 
and O 
cardiovascular O 
diseases O 
. O 

progesterone B-TRIVIAL 
positive O 
feedback O 
effect O 
in O 
women O 
after O 
ovariectomy O 
. O 

ovarian O 
substances O 
regulate O 
the O 
secretion O 
of O 
gonadotrophins O 
during O 
the O 
menstrual O 
cycle O 
, O 
but O 
there O 
are O 
still O 
several O 
unclarified O 
issues O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
positive O 
feedback O 
effect O 
of O 
progesterone B-TRIVIAL 
during O 
the O 
immediate O 
period O 
following O 
ovariectomy O 
. O 
Experiments O 
were O 
performed O 
in O 
12 O 
normally O 
cycling O 
women O 
( O 
aged O 
39-49 O 
years O 
) O 
. O 
Following O 
abdominal O 
hysterectomy O 
plus O 
bilateral O 
ovariectomy O 
performed O 
on O 
cycle O 
day O 
3 O 
( O 
day O 
0 O 
) O 
, O 
the O 
women O 
received O 
either O 
estradiol B-TRIVIAL 
via O 
skin O 
patches O 
( O 
days O 
0-7 O 
, O 
n O 
= O 
6 O 
, O 
group O 
1 O 
) O 
or O 
estradiol B-TRIVIAL 
as O 
above O 
plus O 
vaginal O 
progesterone O 
( O 
days O 
1-7 O 
, O 
n O 
= O 
6 O 
, O 
group O 
2 O 
) O 
. O 
Serum O 
estradiol B-TRIVIAL 
values O 
increased O 
similarly O 
in O 
the O 
two O 
groups O 
. O 
After O 
the O 
operation O 
, O 
serum O 
progesterone B-TRIVIAL 
levels O 
decreased O 
significantly O 
in O 
group O 
1 O 
, O 
while O 
in O 
group O 
2 O 
they O 
remained O 
stable O 
becoming O 
higher O 
than O 
in O 
group O 
1 O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
An O 
LH O 
and O 
an O 
FSH O 
surge O 
occurred O 
in O 
group O 
2 O 
with O 
the O 
values O 
after O 
the O 
peak O 
returning O 
to O 
the O 
pre O 
- O 
surge O 
baseline O 
. O 
In O 
contrast O 
, O 
in O 
group O 
1 O 
LH O 
and O 
FSH O 
levels O 
following O 
an O 
initial O 
decrease O 
, O 
increased O 
gradually O 
until O 
the O 
end O 
of O 
the O 
experiment O 
. O 
These O 
results O 
demonstrate O 
that O 
, O 
despite O 
a O 
variable O 
response O 
to O 
estrogens B-FAMILY 
, O 
the O 
positive O 
feedback O 
effect O 
of O 
progesterone B-TRIVIAL 
remained O 
intact O 
immediately O 
after O 
ovariectomy O 
in O 
women O 
. O 
It O 
is O 
suggested O 
that O 
it O 
is O 
the O 
combining O 
action O 
of O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
that O 
can O 
ensure O 
the O 
expression O 
of O 
a O 
positive O 
feedback O 
mechanism O 
in O 
women O 
. O 

. O 
Focusing O 
on O 
the O 
genetic O 
similarity O 
of O 
CYP3A O 
subfamily O 
enzymes O 
( O 
CYP3A4 O 
and O 
CYP3A5 O 
) O 
between O 
monkeys O 
and O 
humans O 
, O 
we O 
have O 
attempted O 
to O 
provide O 
a O 
single O 
- O 
species O 
approach O 
to O 
predicting O 
human O 
hepatic O 
clearance O 
( O 
CLh O 
) O 
of O 
CYP3A4 O 
substrates O 
using O 
pharmacokinetic O 
parameters O 
in O 
cynomolgus O 
monkeys O 
following O 
intravenous O 
administrations O 
. O 
2 O 
. O 
Hepatic O 
intrinsic O 
clearance O 
( O 
CLint,h O 
) O 
of O 
six O 
CYP3A4 O 
substrates O 
( O 
alprazolam B-TRIVIAL 
, O 
clonazepam B-TRIVIAL 
, O 
diltiazem B-TRIVIAL 
, O 
midazolam B-TRIVIAL 
, O 
nifedipine B-TRIVIAL 
, O 
and O 
quinidine B-TRIVIAL 
) O 
, O 
covering O 
a O 
wide O 
range O 
of O 
clearance O 
, O 
in O 
monkeys O 
correlated O 
well O 
with O 
that O 
cited O 
in O 
literature O 
for O 
humans O 
( O 
R O 
= O 
0.9 O 
) O 
with O 
a O 
simple O 
equation O 
of O 
Y O 
= O 
0.165X O 
( O 
Y O 
: O 
human O 
CLint,h O 
, O 
X O 
: O 
monkey O 
CLint,h O 
, O 
represented O 
in O 
mL O 
/ O 
min O 
/ O 
kg O 
) O 
. O 
3 O 
. O 
To O 
verify O 
the O 
predictability O 
of O 
human O 
CLint,h O 
, O 
monkey O 
CLint,h O 
of O 
a O 
test O 
set O 
of O 
CYP3A4 O 
substrates O 
cited O 
in O 
literature O 
( O 
dexamethasone B-TRIVIAL 
, O 
nifedipine B-TRIVIAL 
, O 
midazolam B-TRIVIAL 
, O 
quinidine B-TRIVIAL 
, O 
tacrolimus B-TRIVIAL 
, O 
and O 
verapamil B-TRIVIAL 
) O 
was O 
applied O 
to O 
the O 
equation O 
and O 
human O 
CLint,h O 
was O 
calculated O 
. O 
The O 
human O 
CLint,h O 
of O 
all O 
the O 
substrates O 
was O 
predicted O 
within O 
3-fold O 
error O 
( O 
fold O 
error O 
: O 
0.35-2.77 O 
) O 
. O 
4 O 
. O 
The O 
predictability O 
of O 
human O 
CLh O 
by O 
our O 
method O 
was O 
superior O 
to O 
common O 
in O 
vivo O 
prediction O 
methods O 
( O 
allometry O 
and O 
liver O 
blood O 
flow O 
method O 
) O 
. O 
These O 
results O 
suggest O 
that O 
human O 
hepatic O 
clearance O 
of O 
CYP3A4 O 
substrates O 
can O 
be O 
predicted O 
by O 
applying O 
cynomolgus O 
monkey O 
CLint,h O 
obtained O 
following O 
intravenous O 
administrations O 
in O 
each O 
laboratory O 
to O 
the O 
simple O 
equation O 
. O 

. O 
A O 
fast O 
, O 
straightforward O 
and O 
cost O 
- O 
effective O 
assay O 
was O 
validated O 
for O 
the O 
assessment O 
of O 
CYP O 
induction O 
in O 
cryopreserved O 
human O 
hepatocytes O 
cultured O 
in O 
48-well O 
plates O 
. O 
The O 
cocktail O 
strategy O 
( O 
in O 
situ O 
incubation O 
) O 
was O 
used O 
to O 
assess O 
the O 
induction O 
of O 
CYP1A2 O 
, O 
CYP2B6 O 
, O 
CYP2C9 O 
and O 
CYP3A4 O 
by O 
using O 
the O 
recommended O 
probe O 
substrate O 
, O 
i.e O 
. O 
phenacetin B-TRIVIAL 
, O 
bupropion B-TRIVIAL 
, O 
diclofenac B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
, O 
respectively O 
. O 
2 O 
. O 
Cryopreserved O 
human O 
hepatocytes O 
were O 
treated O 
for O 
72 O 
h O 
with O 
prototypical O 
reference O 
inducers O 
, O 
β-naphthoflavone B-TRIVIAL 
( O 
25 O 
µM O 
) O 
, O 
phenobarbital B-TRIVIAL 
( O 
500 O 
µM O 
) O 
and O 
rifampicin B-TRIVIAL 
( O 
10 O 
µM O 
) O 
as O 
positive O 
controls O 
for O 
CYP O 
induction O 
. O 
The O 
use O 
of O 
a O 
cocktail O 
strategy O 
has O 
been O 
validated O 
and O 
compared O 
to O 
the O 
classical O 
approach O 
( O 
single O 
incubation O 
) O 
. O 
The O 
need O 
of O 
using O 
phase O 
II O 
inhibitor O 
( O 
salicylamide B-TRIVIAL 
) O 
in O 
CYP O 
induction O 
assay O 
was O 
also O 
investigated O 
. O 
3 O 
. O 
By O 
using O 
three O 
different O 
batches O 
of O 
cryopreserved O 
human O 
hepatocytes O 
and O 
our O 
conditions O 
of O 
incubations O 
, O 
we O 
showed O 
that O 
there O 
was O 
no O 
relevant O 
drug O 
- O 
drug O 
interaction O 
using O 
the O 
cocktail O 
strategy O 
. O 
The O 
same O 
conclusions O 
were O 
observed O 
when O 
a O 
broad O 
range O 
of O 
enzyme O 
activity O 
has O 
to O 
be O 
assessed O 
( O 
wide O 
range O 
of O 
reference O 
inducers O 
, O 
i.e O 
. O 
EC50-Emax O 
experiment O 
) O 
. O 
In O 
addition O 
, O 
the O 
interassay O 
reproducibility O 
assessment O 
showed O 
that O 
the O 
day O 
- O 
to O 
- O 
day O 
variability O 
was O 
minimal O 
. O 
4 O 
. O 
In O 
summary O 
, O 
the O 
study O 
showed O 
that O 
the O 
conditions O 
used O 
( O 
probe O 
substrates O 
, O 
concentration O 
of O 
probe O 
substrate O 
and O 
time O 
of O 
incubation O 
) O 
for O 
the O 
cocktail O 
approach O 
were O 
appropriate O 
for O 
investigations O 
of O 
CYP O 
induction O 
potential O 
of O 
new O 
chemical O 
entities O 
. O 
In O 
addition O 
, O 
it O 
was O 
also O 
clear O 
that O 
the O 
use O 
of O 
salicylamide B-TRIVIAL 
in O 
the O 
incubation O 
media O 
was O 
not O 
mandatory O 
and O 
could O 
generate O 
drug O 
- O 
drug O 
interactions O 
. O 
For O 
this O 
reason O 
, O 
we O 
recommend O 
to O 
not O 
use O 
salicylamide B-TRIVIAL 
in O 
CYP O 
induction O 
assay O 
. O 

gland O 
function O 
5 O 
years O 
after O 
radioactive B-SYSTEMATIC 
iodine I-SYSTEMATIC 
ablation O 
in O 
patients O 
with O 
differentiated O 
thyroid O 
cancer O 
: O 
direct O 
comparison O 
of O 
pre- O 
and O 
postablation O 
scintigraphies O 
and O 
their O 
relation O 
to O 
xerostomia O 
symptoms O 
. O 

: O 
Chronic O 
sialadenitis O 
is O 
one O 
of O 
the O 
most O 
frequent O 
chronic O 
complications O 
after O 
radioactive B-SYSTEMATIC 
iodine I-SYSTEMATIC 
( O 
RAI B-ABBREVIATION 
) O 
therapy O 
for O 
thyroid O 
cancer O 
. O 
To O 
evaluate O 
the O 
long O 
- O 
term O 
effects O 
of O 
RAI B-ABBREVIATION 
ablation O 
on O 
salivary O 
gland O 
function O 
, O 
we O 
investigated O 
scintigraphic O 
changes O 
in O 
salivary O 
glands O 
by O 
direct O 
comparison O 
of O 
two O 
salivary O 
gland O 
scintigraphies O 
( O 
SGSs O 
) O 
taken O 
before O 
and O 
at O 
5 O 
years O 
after O 
an O 
RAI B-ABBREVIATION 
ablation O 
. O 
Methods O 
: O 
SGS O 
was O 
performed O 
just O 
before O 
RAI B-ABBREVIATION 
ablation O 
( O 
pre-SGS O 
) O 
and O 
∼5 O 
years O 
after O 
RAI B-ABBREVIATION 
ablation O 
( O 
F O 
/ O 
U O 
SGS O 
) O 
in O 
213 O 
subjects O 
who O 
underwent O 
thyroidectomy O 
for O 
thyroid O 
cancer O 
. O 
The O 
uptake O 
score O 
( O 
U O 
score O 
) O 
was O 
graded O 
, O 
and O 
the O 
ejection O 
fraction O 
( O 
EF O 
) O 
was O 
quantified O 
for O 
the O 
parotid O 
and O 
submandibular O 
glands O 
at O 
pre-SGS O 
and O 
F O 
/ O 
U O 
SGS O 
. O 
Changes O 
in O 
salivary O 
gland O 
function O 
were O 
graded O 
as O 
mild O 
, O 
moderate O 
, O 
or O 
severe O 
according O 
to O 
the O 
differences O 
in O 
U O 
score O 
and O 
EF O 
between O 
the O 
two O 
SGSs O 
. O 
Xerostomia O 
was O 
assessed O 
and O 
compared O 
with O 
the O 
SGS O 
findings O 
. O 
Results O 
: O 
Worsening O 
of O 
the O 
U O 
score O 
was O 
observed O 
in O 
182 O 
of O 
852 O 
salivary O 
glands O 
( O 
total O 
: O 
21.3% O 
; O 
mild O 
: O 
4.2% O 
, O 
moderate O 
: O 
7.4% O 
, O 
severe O 
: O 
9.7% O 
) O 
, O 
and O 
47.4% O 
of O 
the O 
patients O 
had O 
a O 
worsening O 
U O 
score O 
for O 
at O 
least O 
one O 
of O 
four O 
salivary O 
glands O 
. O 
A O 
decrease O 
in O 
EF O 
was O 
observed O 
in O 
173 O 
of O 
852 O 
salivary O 
glands O 
( O 
total O 
: O 
20.3% O 
; O 
mild O 
: O 
5.4% O 
, O 
moderate O 
: O 
6.8% O 
, O 
severe O 
: O 
8.1% O 
) O 
, O 
and O 
43.7% O 
of O 
the O 
patients O 
experienced O 
a O 
decrease O 
in O 
the O 
EF O 
of O 
at O 
least O 
one O 
of O 
the O 
four O 
salivary O 
glands O 
. O 
Bilateral O 
parotid O 
gland O 
dysfunction O 
was O 
the O 
most O 
commonly O 
observed O 
condition O 
. O 
Thirty O 
- O 
five O 
( O 
16.4% O 
) O 
patients O 
complained O 
of O 
xerostomia O 
at O 
5 O 
years O 
after O 
RAI B-ABBREVIATION 
ablation O 
. O 
Scintigraphic O 
changes O 
in O 
salivary O 
gland O 
function O 
and O 
xerostomia O 
were O 
more O 
common O 
in O 
patients O 
receiving O 
5.55 O 
GBq O 
, O 
compared O 
with O 
3.7 O 
GBq O 
. O 
Xerostomia O 
was O 
more O 
common O 
in O 
patients O 
with O 
submandibular O 
gland O 
dysfunction O 
than O 
those O 
with O 
parotid O 
gland O 
dysfunction O 
( O 
68.8% O 
vs O 
. O 
33.3% O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
number O 
of O 
dysfunctional O 
salivary O 
glands O 
was O 
correlated O 
with O 
xerostomia O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Conclusion O 
: O 
About O 
20% O 
of O 
the O 
salivary O 
glands O 
were O 
dysfunctional O 
on O 
SGS O 
5 O 
years O 
after O 
a O 
single O 
RAI B-ABBREVIATION 
ablation O 
, O 
especially O 
in O 
patients O 
who O 
received O 
higher O 
doses O 
of O 
RAI B-ABBREVIATION 
. O 
While O 
parotid O 
glands O 
are O 
more O 
susceptible O 
to O 
(131)I O 
- O 
related O 
damage O 
, O 
xerostomia O 
was O 
more O 
associated O 
with O 
submandibular O 
gland O 
dysfunction O 
and O 
the O 
prevalence O 
of O 
dysfunctional O 
salivary O 
glands O 
. O 

their O 
antiviral O 
activity O 
, O 
type O 
I O 
Interferons O 
( O 
IFN O 
) O 
display O 
context O 
- O 
specific O 
immunomodulation O 
. O 
In O 
contrast O 
to O 
long O 
- O 
known O 
IFNα O 
/ O 
β O 
, O 
Interleukin O 
(IL)-22 O 
is O 
an O 
anti-bacterial O 
, O 
largely O 
tissue O 
protective O 
cytokine O 
that O 
recently O 
gained O 
attention O 
. O 
Herein O 
, O 
cellular O 
IFNα O 
/ O 
IL-22 O 
interactions O 
are O 
investigated O 
. O 
We O 
report O 
that O 
pre O 
- O 
conditioning O 
of O 
epithelial O 
cells O 
with O 
IFNα O 
initiated O 
dramatic O 
changes O 
in O 
IL-22 O 
signaling O 
normally O 
dominated O 
by O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
(STAT)-3 O 
. O 
Specifically O 
, O 
by O 
using O 
human O 
DLD1 O 
colon O 
epithelial O 
/ O 
carcinoma O 
cells O 
we O 
demonstrate O 
that O 
, O 
upon O 
IFNα O 
, O 
IL-22 O 
converts O 
into O 
a O 
cytokine O 
robustly O 
activating O 
STAT1 O 
and O 
its O 
downstream O 
pro O 
- O 
inflammatory O 
targets O 
CXCL9 O 
, O 
CXCL10 O 
, O 
and O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
. O 
Accordingly O 
, O 
only O 
after O 
IFNα O 
pre O 
- O 
incubation O 
was O 
IL-22-induced O 
STAT1 O 
binding O 
to O 
the O 
CXCL10 O 
promoter O 
detectable O 
. O 
Using O 
the O 
viral O 
mimic O 
polyinosinic B-MULTIPLE 
: I-MULTIPLE 
polycytidylic I-MULTIPLE 
acid I-MULTIPLE 
and O 
the O 
IFNα O 
/ O 
β O 
antagonist O 
B18R O 
we O 
furthermore O 
demonstrate O 
the O 
capability O 
of O 
endogenous O 
IFN O 
to O 
promote O 
IL-22-induced O 
STAT1 O 
activation O 
and O 
expression O 
of O 
CXCL10 O 
. O 
IL-22-induced O 
STAT1 O 
activation O 
subsequent O 
to O 
IFNα O 
priming O 
became O 
likewise O 
apparent O 
in O 
human O 
Caco2 O 
colon O 
epithelial O 
/ O 
carcinoma O 
cells O 
, O 
HepG2 O 
hepatoma O 
cells O 
, O 
and O 
primary O 
keratinocytes O 
. O 
Current O 
observations O 
may O 
relate O 
to O 
characteristics O 
of O 
IFNα O 
/ O 
β O 
in O 
clinical O 
therapy O 
and O 
expose O 
margins O 
of O 
tissue O 
protection O 
by O 
IL-22 O 
application O 
. O 

model O 
for O 
in O 
vitro O 
interaction O 
between O 
fenitrothion B-TRIVIAL 
and O 
DNA O 
, O 
by O 
using O 
competitive O 
fluorescence O 
, O 
(31)P B-FORMULA 
NMR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
FT-IR O 
, O 
CD O 
and O 
molecular O 
modeling O 
. O 

this O 
work O 
we O 
proposed O 
a O 
model O 
for O 
in O 
vitro O 
interaction O 
of O 
fenitrothion B-TRIVIAL 
( O 
FEN B-ABBREVIATION 
) O 
with O 
calf O 
thymus-DNA O 
by O 
combination O 
of O 
multispectroscopic O 
and O 
two O 
dimensional O 
molecular O 
modeling O 
( O 
ONIOM O 
) O 
methods O 
. O 
The O 
circular O 
dichroism O 
results O 
showed O 
that O 
FEN B-ABBREVIATION 
changes O 
the O 
conformation O 
of O 
B-DNA O 
and O 
caused O 
some O 
changes O 
to O 
C-DNA O 
form O 
. O 
The O 
FT-IR O 
results O 
confirmed O 
a O 
partial O 
intercalation O 
between O 
FEN B-ABBREVIATION 
and O 
edges O 
of O 
all O 
base O 
pairs O 
. O 
The O 
competitive O 
fluorescence O 
, O 
using O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
as O 
fluorescence O 
probe O 
, O 
in O 
the O 
presence O 
of O 
increasing O 
amounts O 
of O 
FEN B-ABBREVIATION 
, O 
revealed O 
that O 
FEN B-ABBREVIATION 
is O 
able O 
to O 
release O 
the O 
non-intercalated O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
from O 
the O 
DNA O 
. O 
The O 
weak O 
chemical O 
shift O 
and O 
peak O 
broadening O 
of O 
(1)H B-FORMULA 
NMR O 
spectrum O 
of O 
FEN B-ABBREVIATION 
in O 
the O 
presence O 
of O 
DNA O 
confirmed O 
a O 
non-intercalation O 
mode O 
. O 
The O 
(31)P B-FORMULA 
NMR O 
showed O 
that O 
FEN B-ABBREVIATION 
interacts O 
more O 
with O 
DNA O 
via O 
its O 
- O 
NO2 B-FORMULA 
moiety O 
. O 
The O 
ONIOM O 
, O 
based O 
on O 
the O 
hybridization O 
of O 
QM O 
/ O 
MM O 
( O 
DFT O 
, O 
6.31 O 
+ O 
+G O 
( O 
d,p O 
) O 
/ O 
UFF O 
) O 
methodology O 
, O 
was O 
also O 
performed O 
by O 
Gaussian O 
2003 O 
package O 
. O 
The O 
results O 
revealed O 
that O 
the O 
interaction O 
is O 
base O 
sequence O 
dependent O 
, O 
and O 
FEN B-ABBREVIATION 
interacts O 
more O 
with O 
AT O 
base O 
sequences O 
. O 

of O 
the O 
cellular O 
redox O 
status O 
by O 
the O 
Alternaria O 
toxins O 
alternariol B-TRIVIAL 
and O 
alternariol B-SYSTEMATIC 
monomethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
. O 

mycotoxin O 
alternariol B-TRIVIAL 
( O 
AOH B-FORMULA 
) O 
has O 
been O 
reported O 
to O 
possess O 
genotoxic O 
properties O 
, O 
inducing O 
enhanced O 
levels O 
of O 
DNA O 
damage O 
after O 
only O 
1 O 
h O 
of O 
incubation O 
. O 
In O 
the O 
present O 
study O 
we O 
addressed O 
the O 
question O 
whether O 
the O 
induction O 
of O 
oxidative O 
stress O 
might O 
contribute O 
to O 
the O 
genotoxic O 
effects O 
of O 
AOH B-FORMULA 
or O 
its O 
naturally O 
occurring O 
monomethylether B-SYSTEMATIC 
( O 
AME B-ABBREVIATION 
) O 
. O 
In O 
the O 
dichlorofluorescein B-SYSTEMATIC 
( O 
DCF B-ABBREVIATION 
) O 
assay O 
, O 
treatment O 
of O 
HT29 O 
cells O 
for O 
1 O 
h O 
enhanced O 
the O 
formation O 
of O 
dichlorofluorescein B-SYSTEMATIC 
, O 
indicative O 
for O 
ROS O 
formation O 
. O 
The O 
total O 
glutathione B-TRIVIAL 
( O 
tGSH O 
) O 
was O 
transiently O 
decreased O 
. O 
In O 
accordance O 
with O 
the O 
results O 
of O 
the O 
DCF B-ABBREVIATION 
assay O 
, O 
AOH B-FORMULA 
and O 
AME B-ABBREVIATION 
enhanced O 
the O 
proportion O 
of O 
the O 
transcription O 
factor O 
Nrf2 O 
in O 
the O 
nucleus O 
. O 
Concomitantly O 
, O 
the O 
Nrf2 O 
/ O 
ARE-dependent O 
genes O 
γ-glutamylcysteine B-SYSTEMATIC 
ligase O 
( O 
γ-GCL O 
) O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GSTA1 O 
/ O 
2 O 
) O 
showed O 
enhanced O 
transcript O 
levels O 
. O 
After O 
24 O 
h O 
of O 
incubation O 
this O 
effect O 
was O 
also O 
reflected O 
on O 
the O 
protein O 
level O 
by O 
an O 
increase O 
of O 
GST O 
activity O 
. O 
However O 
, O 
in O 
spite O 
of O 
the O 
positive O 
DCF B-ABBREVIATION 
assay O 
and O 
the O 
activation O 
of O 
the O 
redox O 
- O 
sensitive O 
Nrf2 O 
/ O 
ARE-pathway O 
, O 
the O 
level O 
of O 
oxidative O 
DNA O 
damage O 
, O 
measured O 
in O 
the O 
comet O 
assay O 
by O 
the O 
addition O 
of O 
formamidopyrimidine B-SYSTEMATIC 
-DNA-glycosylase O 
( O 
fpg O 
) O 
remained O 
unaffected O 
. O 
Of O 
note O 
, O 
after O 
3 O 
h O 
of O 
incubation O 
no O 
significant O 
DNA O 
damaging O 
potential O 
of O 
AOH B-FORMULA 
and O 
AME B-ABBREVIATION 
was O 
detectable O 
, O 
indicating O 
either O 
inactivation O 
of O 
the O 
compounds O 
or O 
enhanced O 
DNA O 
repair O 
. O 
In O 
summary O 
, O 
the O 
mycotoxins O 
AOH B-FORMULA 
and O 
AME B-ABBREVIATION 
were O 
found O 
to O 
modulate O 
the O 
redox O 
balance O 
of O 
HT29 O 
cells O 
but O 
without O 
apparent O 
negative O 
effect O 
on O 
DNA O 
integrity O 
. O 

of O 
novel O 
indole B-FAMILY 
hydrazone I-FAMILY 
derivatives O 
and O 
evaluation O 
of O 
their O 
antiplatelet O 
aggregation O 
activity O 
. O 

on O 
the O 
existing O 
reports O 
regarding O 
the O 
antiplatelet O 
aggregation O 
activity O 
of O 
hydrazone B-FAMILY 
derivatives O 
, O 
a O 
series O 
of O 
indole B-FAMILY 
hydrazone I-FAMILY 
derivatives O 
were O 
considered O 
as O 
potential O 
antiplatelet O 
agents O 
and O 
synthesized O 
. O 
The O 
structures O 
of O 
the O 
synthesized O 
compounds O 
were O 
confirmed O 
by O 
spectral O 
data O 
and O 
elemental O 
analysis O 
. O 
The O 
new O 
indole B-FAMILY 
hydrazone I-FAMILY 
derivatives O 
were O 
evaluated O 
for O 
their O 
ability O 
to O 
inhibit O 
platelet O 
aggregation O 
induced O 
by O 
adenosine B-TRIVIAL 
diphosphate I-TRIVIAL 
( O 
ADP B-ABBREVIATION 
) O 
and O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
. O 
Compounds O 
1h O 
and O 
3h O 
exhibited O 
remarkable O 
activity O 
against O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
induced O 
platelet O 
aggregation O 
with O 
IC(50) O 
values O 
comparable O 
to O 
that O 
of O 
indomethacin B-TRIVIAL 
and O 
compound O 
1i O 
efficiently O 
inhibited O 
platelet O 
aggregation O 
induced O 
by O 
both O 
ADP B-ABBREVIATION 
and O 
AA O 
. O 

Cell O 
Lymphoma-2 O 
( O 
Bcl-2 O 
) O 
protein O 
suppresses O 
ionizing O 
radiation O 
- O 
induced O 
apoptosis O 
in O 
hemato O 
- O 
lymphoid O 
system O 
. O 
To O 
enhance O 
the O 
survival O 
of O 
irradiated O 
cells O 
, O 
we O 
have O 
compared O 
the O 
effects O 
and O 
mechanism O 
of O 
Bcl-2 O 
and O 
its O 
functional O 
variants O 
, O 
D34A O 
( O 
caspase-3 O 
resistant O 
) O 
and O 
S70E O 
( O 
mimics O 
phosphorylation O 
on O 
S70 O 
) O 
. O 
Bcl-2 O 
and O 
its O 
mutants O 
were O 
transfected O 
into O 
hematopoietic O 
cell O 
line O 
and O 
assessed O 
for O 
cell O 
survival O 
, O 
clonogenicity O 
and O 
cell O 
cycle O 
perturbations O 
upon O 
exposure O 
to O 
ionizing O 
radiation O 
. O 
The O 
electrostatic O 
potential O 
of O 
BH3 B-FORMULA 
cleft O 
of O 
Bcl-2 O 
/ O 
mutants O 
and O 
their O 
heterodimerization O 
with O 
Bcl-2 O 
associated O 
X O 
protein O 
( O 
Bax O 
) O 
were O 
computationally O 
evaluated O 
. O 
Correspondingly O 
, O 
these O 
results O 
were O 
verified O 
by O 
co O 
- O 
immunoprecipitation O 
and O 
western O 
blotting O 
. O 
The O 
mutants O 
afford O 
higher O 
radioprotective O 
effect O 
than O 
Bcl-2 O 
in O 
apoptotic O 
and O 
clonogenic O 
assays O 
at O 
D(0) O 
( O 
radiation O 
dose O 
at O 
which O 
37 O 
% O 
cell O 
survival O 
was O 
observed O 
) O 
. O 
The O 
computational O 
and O 
functional O 
analysis O 
indicates O 
that O 
mutants O 
have O 
higher O 
propensity O 
to O 
neutralize O 
Bax O 
protein O 
by O 
heterodimerization O 
and O 
have O 
increased O 
caspase-9 O 
suppression O 
capability O 
, O 
which O 
is O 
responsible O 
for O 
enhanced O 
survival O 
. O 
This O 
study O 
implies O 
potential O 
of O 
Bcl-2 O 
mutants O 
or O 
their O 
chemical O 
/ O 
peptide O 
mimics O 
to O 
elicit O 
radioprotective O 
effect O 
in O 
cells O 
exposed O 
to O 
radiation O 
. O 

: O 
We O 
aimed O 
to O 
evaluate O 
the O 
articular O 
involvements O 
in O 
pediatric O 
patients O 
with O 
familial O 
Mediterranean O 
fever O 
( O 
FMF O 
) O 
with O 
joint O 
symptoms O 
by O 
bone O 
scintigraphy O 
and O 
to O 
correlate O 
the O 
involved O 
joints O 
with O 
the O 
gene O 
mutations O 
. O 
Materials O 
and O 
methods O 
: O 
A O 
total O 
of O 
41 O 
newly O 
diagnosed O 
patients O 
in O 
pediatric O 
age O 
group O 
( O 
28 O 
girls O 
and O 
13 O 
boys O 
; O 
mean O 
age O 
9.14 O 
± O 
2.91 O 
years O 
) O 
with O 
joint O 
involvement O 
symptoms O 
were O 
included O 
in O 
this O 
study O 
. O 
Scintigraphic O 
images O 
were O 
obtained O 
at O 
5th O 
min O 
( O 
blood O 
pool O 
or O 
early O 
phase O 
) O 
and O 
starting O 
at O 
3 O 
h O 
( O 
late O 
phase O 
) O 
after O 
( O 
after O 
tracer O 
injection O 
) O 
intravenous O 
administration O 
of O 
technetium-99m B-SYSTEMATIC 
( O 
99mTc B-FORMULA 
)- O 
methylendiphosphonate B-SYSTEMATIC 
( O 
MDP B-ABBREVIATION 
) O 
. O 
Genomic O 
DNA O 
was O 
isolated O 
from O 
leukocytes O 
using O 
standard O 
salting O 
out O 
procedure O 
. O 
The O 
sequencing O 
data O 
were O 
analyzed O 
. O 
Results O 
: O 
Of O 
the O 
41 O 
patients O 
, O 
arthritis O 
was O 
found O 
in O 
21 O 
( O 
51.2% O 
) O 
patients O 
. O 
Of O 
the O 
21 O 
patients O 
, O 
there O 
was O 
single O 
joint O 
involvement O 
in O 
15 O 
( O 
71.4% O 
) O 
patients O 
and O 
multiple O 
joint O 
involvement O 
in O 
six O 
( O 
28.6% O 
) O 
patients O 
. O 
The O 
mean O 
age O 
of O 
patients O 
with O 
joint O 
involvement O 
( O 
8 O 
± O 
2.3 O 
years O 
) O 
were O 
considerably O 
lower O 
than O 
the O 
patients O 
without O 
joint O 
involvement O 
( O 
10.35 O 
± O 
3.04 O 
years O 
) O 
, O 
and O 
this O 
was O 
statistically O 
significant O 
( O 
p O 
= O 
0.008 O 
) O 
. O 
The O 
most O 
commonly O 
involved O 
joints O 
were O 
ankles O 
and O 
knees O 
. O 
Multiple O 
joint O 
involvements O 
were O 
most O 
frequently O 
observed O 
in O 
the O 
M694V O 
and O 
M694I O 
gene O 
mutations O 
( O 
16.7% O 
) O 
. O 
Conclusions O 
: O 
We O 
use O 
and O 
recommend O 
the O 
bone O 
scintigraphy O 
in O 
patients O 
with O 
FMF O 
to O 
determine O 
the O 
presence O 
and O 
distribution O 
of O 
arthritis O 
, O 
since O 
bone O 
scintigraphy O 
is O 
inexpensive O 
, O 
noninvasive O 
, O 
easy O 
- O 
to O 
- O 
use O 
, O 
and O 
also O 
is O 
more O 
sensitive O 
in O 
the O 
diagnosis O 
and O 
distribution O 
of O 
arthritis O 
than O 
conventional O 
radiological O 
methods O 
and O 
clinical O 
examination O 
. O 

acid O 
( O 
HA O 
) O 
hydrogels O 
were O 
structured O 
in O 
the O 
form O 
of O 
porous O 
monoliths O 
by O 
means O 
of O 
the O 
ice O 
- O 
segregation O 
- O 
induced O 
self O 
- O 
assembly O 
( O 
ISISA O 
) O 
method O 
coupled O 
with O 
freeze O 
- O 
drying O 
. O 
Physical O 
and O 
chemical O 
parameters O 
were O 
explored O 
in O 
order O 
to O 
fine O 
- O 
tune O 
the O 
microstructure O 
and O 
the O 
incidence O 
on O 
both O 
swelling O 
and O 
dissolution O 
behavior O 
in O 
aqueous O 
media O 
. O 
Gentamicin B-FAMILY 
-loaded O 
HA O 
matrices O 
with O 
tuned O 
drug O 
release O 
properties O 
were O 
also O 
prepared O 
; O 
their O 
inherent O 
properties O 
and O 
behavior O 
in O 
solution O 
are O 
discussed O 
in O 
the O 
framework O 
of O 
thermal O 
analysis O 
and O 
scanning O 
electron O 
microscopy O 
inspection O 
. O 

evidence O 
that O 
antipsychotics O 
improve O 
brain O 
function O 
and O 
reduce O 
symptoms O 
in O 
schizophrenia O 
is O 
unmistakable O 
, O 
but O 
how O 
antipsychotics O 
change O 
brain O 
function O 
is O 
poorly O 
understood O 
, O 
especially O 
within O 
neuronal O 
systems O 
. O 
In O 
this O 
review O 
, O 
we O 
investigated O 
the O 
hypothesized O 
normalization O 
of O 
the O 
functional O 
magnetic O 
resonance O 
imaging O 
( O 
fMRI O 
) O 
blood O 
oxygen B-SYSTEMATIC 
level O 
dependent O 
signal O 
in O 
the O 
context O 
of O 
antipsychotic O 
treatment O 
. O 
First O 
, O 
we O 
conducted O 
a O 
systematic O 
PubMed O 
search O 
to O 
identify O 
eight O 
fMRI O 
investigations O 
that O 
met O 
the O 
following O 
inclusion O 
criteria O 
: O 
case O 
- O 
control O 
, O 
longitudinal O 
design O 
; O 
pre- O 
and O 
post O 
- O 
treatment O 
contrasts O 
with O 
a O 
healthy O 
comparison O 
group O 
; O 
and O 
antipsychotic O 
- O 
free O 
or O 
antipsychotic O 
- O 
naive O 
patients O 
with O 
schizophrenia O 
at O 
the O 
start O 
of O 
the O 
investigation O 
. O 
We O 
hypothesized O 
that O 
aberrant O 
activation O 
patterns O 
or O 
connectivity O 
between O 
patients O 
with O 
schizophrenia O 
and O 
healthy O 
comparisons O 
at O 
the O 
first O 
imaging O 
assessment O 
would O 
no O 
longer O 
be O 
apparent O 
or O 
" O 
normalize O 
" O 
at O 
the O 
second O 
imaging O 
assessment O 
. O 
The O 
included O 
studies O 
differed O 
by O 
analysis O 
method O 
and O 
fMRI O 
task O 
but O 
demonstrated O 
normalization O 
of O 
fMRI O 
activation O 
or O 
connectivity O 
during O 
the O 
treatment O 
interval O 
. O 
Second O 
, O 
we O 
reviewed O 
putative O 
mechanisms O 
from O 
animal O 
studies O 
that O 
support O 
normalization O 
of O 
the O 
BOLD O 
signal O 
in O 
schizophrenia O 
. O 
We O 
provided O 
several O 
neuronal O 
- O 
based O 
interpretations O 
of O 
these O 
changes O 
of O 
the O 
BOLD O 
signal O 
that O 
may O 
be O 
attributable O 
to O 
long O 
- O 
term O 
antipsychotic O 
administration O 
. O 

Magnetic O 
Resonance O 
Imaging O 
( O 
FMRI O 
) O 
is O 
a O 
non-invasive O 
technique O 
for O 
brain O 
mapping O 
and O 
mostly O 
performed O 
using O 
changes O 
of O 
the O 
blood- O 
oxygen B-SYSTEMATIC 
-level O 
- O 
dependent O 
(BOLD)-signal O 
. O 
It O 
has O 
been O 
widely O 
used O 
to O 
investigate O 
patients O 
with O 
schizophrenia O 
. O 
Most O 
of O 
the O 
studies O 
examine O 
patients O 
treated O 
with O 
antipsychotic O 
drugs O 
, O 
although O 
little O 
is O 
known O 
about O 
the O 
effects O 
of O 
these O 
drugs O 
on O 
the O 
BOLDsignal O 
. O 
Here O 
we O 
examined O 
studies O 
of O 
patients O 
with O 
schizophrenia O 
treated O 
with O 
different O 
antipsychotics O 
to O 
address O 
the O 
question O 
whether O 
and O 
to O 
what O 
extent O 
antipsychotic O 
drugs O 
in O 
themselves O 
produce O 
BOLD-signal O 
changes O 
. O 
We O 
performed O 
a O 
PubMed O 
- O 
search O 
for O 
the O 
period O 
from O 
1999 O 
until O 
January O 
2012 O 
with O 
the O 
search O 
items O 
" O 
schizophrenia O 
" O 
and O 
" O 
Magnetic O 
Resonance O 
Imaging O 
" O 
and O 
" O 
Antipsychotic O 
Agents O 
; O 
or O 
" O 
Magnetic O 
Resonance O 
Imaging O 
" O 
and O 
" O 
Antipsychotic O 
Agents O 
" O 
; O 
or O 
" O 
schizophrenia O 
" O 
and O 
" O 
Antipsychotic O 
Agents O 
" O 
and O 
" O 
FMRI O 
" O 
. O 
We O 
extracted O 
articles O 
that O 
examined O 
at O 
least O 
two O 
patient O 
groups O 
with O 
different O 
treatments O 
, O 
or O 
patients O 
examined O 
on O 
different O 
medications O 
at O 
different O 
times O 
and O 
that O 
provided O 
information O 
about O 
drug O 
effects O 
. O 
No O 
common O 
effect O 
of O 
antipsychotics O 
on O 
BOLD-signal O 
was O 
found O 
. O 
However O 
, O 
based O 
on O 
the O 
results O 
for O 
different O 
antipsychotics O 
( O 
haloperidol B-TRIVIAL 
, O 
olanzapine B-TRIVIAL 
, O 
quetiapine B-TRIVIAL 
and O 
risperidone B-TRIVIAL 
) O 
we O 
found O 
evidence O 
that O 
the O 
affinity O 
to O 
the O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
D(2)-receptor O 
may O 
influence O 
BOLD-signal O 
. O 

( O 
miRNAs O 
) O 
translationally O 
repressing O 
their O 
target O 
messenger O 
RNAs O 
due O 
to O 
their O 
gene O 
- O 
regulatory O 
functions O 
play O 
an O 
important O 
but O 
not O 
unexpected O 
role O 
in O 
a O 
tumour O 
development O 
. O 
More O 
surprising O 
are O 
the O 
findings O 
that O 
levels O 
of O 
various O 
miRNAs O 
are O 
well O 
correlated O 
with O 
presence O 
of O 
specific O 
tumours O 
and O 
formation O 
of O 
metastases O 
. O 
Moreover O 
, O 
these O 
small O 
regulatory O 
molecules O 
play O 
a O 
role O 
in O 
the O 
resistance O 
of O 
cancer O 
cells O 
to O 
commonly O 
used O 
anti-cancer O 
drugs O 
, O 
such O 
as O 
cisplatin B-TRIVIAL 
, O 
anthracyclines B-FAMILY 
, O 
and O 
taxanes B-FAMILY 
. O 
In O 
that O 
respect O 
, O 
miRNAs O 
become O 
very O 
attractive O 
target O 
for O 
potential O 
therapeutic O 
interventions O 
. O 
Improvements O 
in O 
the O 
sensitivity O 
of O 
miRNAs O 
detection O 
techniques O 
led O 
to O 
discovery O 
of O 
circulating O 
miRNAs O 
which O 
became O 
very O 
attractive O 
non-invasive O 
biomarker O 
of O 
cancer O 
with O 
a O 
substantial O 
predictive O 
value O 
. O 
In O 
this O 
review O 
, O 
the O 
authors O 
focus O 
on O 
i O 
) O 
oncogenic O 
and O 
anti-tumour O 
acting O 
miRNAs O 
, O 
ii O 
) O 
function O 
of O 
miRNAs O 
in O 
tumour O 
progression O 
, O 
iii O 
) O 
possible O 
role O 
of O 
miRNAs O 
in O 
resistance O 
to O 
anticancer O 
drugs O 
, O 
and O 
iv O 
) O 
diagnostic O 
potential O 
of O 
miRNAs O 
for O 
identification O 
of O 
cancer O 
from O 
circulating O 
miRNAs O 
with O 
special O 
emphasis O 
on O 
prostate O 
cancer O 
. O 
Moreover O 
, O 
relationship O 
between O 
miRNAs O 
and O 
expression O 
of O 
metallothionein O 
is O 
discussed O 
as O 
a O 
possible O 
explanation O 
of O 
resistance O 
against O 
platinum B-SYSTEMATIC 
based O 
drugs O 
. O 

modulates O 
the O 
neurovascular O 
coupling O 
. O 

some O 
evidence O 
of O 
the O 
underlying O 
molecular O 
mechanisms O 
the O 
neuronal O 
basis O 
of O 
ethanol B-SYSTEMATIC 
-induced O 
effects O 
on O 
the O 
neurovascular O 
coupling O 
that O 
forms O 
the O 
BOLD O 
( O 
blood O 
oxygenation O 
level O 
dependent O 
) O 
signal O 
is O 
poorly O 
understood O 
. O 
In O 
a O 
recent O 
fMRI O 
( O 
functional O 
magnetic O 
resonance O 
imaging O 
) O 
study O 
monitoring O 
ethanol B-SYSTEMATIC 
-induced O 
changes O 
of O 
the O 
BOLD O 
signal O 
a O 
reduction O 
of O 
the O 
amplitude O 
and O 
a O 
prolongation O 
of O 
the O 
BOLD O 
signal O 
were O 
observed O 
. O 
However O 
, O 
the O 
BOLD O 
signal O 
is O 
assumed O 
to O 
consist O 
of O 
a O 
complex O 
superposition O 
of O 
different O 
underlying O 
signals O 
. O 
To O 
gain O 
insight O 
how O 
ethanol B-SYSTEMATIC 
influences O 
stimulus O 
efficacy O 
, O 
oxygen B-SYSTEMATIC 
extraction O 
, O 
transit O 
time O 
and O 
vessel O 
- O 
related O 
parameters O 
the O 
fMRI O 
time O 
series O 
from O 
the O 
sensori O 
- O 
motor O 
and O 
the O 
visual O 
cortex O 
were O 
analyzed O 
using O 
the O 
balloon O 
model O 
. O 
The O 
results O 
show O 
a O 
region O 
- O 
dependent O 
decrease O 
of O 
the O 
stimulus O 
efficacy O 
to O 
trigger O 
a O 
post O 
- O 
stimulus O 
neurovascular O 
response O 
as O 
well O 
as O 
a O 
prolongation O 
of O 
the O 
transit O 
time O 
through O 
the O 
venous O 
compartment O 
. O 
Oxygen B-SYSTEMATIC 
extraction O 
, O 
feedback O 
mechanisms O 
and O 
other O 
vessel O 
- O 
related O 
parameters O 
were O 
not O 
affected O 
. O 
The O 
results O 
may O 
be O 
interpreted O 
as O 
follows O 
: O 
the O 
overall O 
mechanisms O 
of O 
the O 
neurovascular O 
coupling O 
are O 
still O 
acting O 
well O 
at O 
the O 
moderate O 
ethanol B-SYSTEMATIC 
level O 
of O 
about O 
0.8‰ O 
( O 
in O 
particular O 
the O 
vessel O 
- O 
related O 
parts O 
) O 
, O 
but O 
the O 
potency O 
to O 
evoke O 
a O 
neurovascular O 
response O 
is O 
already O 
compromised O 
most O 
obviously O 
in O 
the O 
supplementary O 
motor O 
area O 
responsible O 
for O 
complex O 
synchronizing O 
and O 
planning O 
processes O 
. O 

behavior O 
in O 
rats O 
with O 
methamphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 

induces O 
monoamine O 
depletions O 
thought O 
to O 
contribute O 
to O 
cognitive O 
and O 
behavioral O 
dysfunctions O 
. O 
Previously O 
, O 
we O 
reported O 
that O 
methamphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
is O 
associated O 
with O 
impaired O 
formation O 
of O 
stimulus O 
- O 
response O 
associations O 
. O 
Additionally O 
, O 
subjective O 
observations O 
suggested O 
that O 
behavioral O 
flexibility O 
might O 
be O 
affected O 
. O 
Thus O 
, O 
the O 
present O 
study O 
examined O 
whether O 
methamphetamine B-TRIVIAL 
neurotoxicity O 
induces O 
perseverative O 
behavior O 
. O 
Rats O 
were O 
pretreated O 
with O 
(±)-methamphetamine B-TRIVIAL 
( O 
4 O 
× O 
10 O 
mg O 
/ O 
kg O 
, O 
2-hr O 
intervals O 
) O 
or O 
saline O 
. O 
Three O 
weeks O 
later O 
, O 
rats O 
were O 
trained O 
to O 
press O 
a O 
lever O 
on O 
one O 
side O 
of O 
an O 
operant O 
chamber O 
and O 
then O 
retrieve O 
the O 
reinforcer O 
from O 
a O 
magazine O 
on O 
the O 
opposite O 
side O 
until O 
they O 
reached O 
criterion O 
( O 
> O 
50 O 
reinforcers O 
/ O 
30-min O 
) O 
. O 
After O 
four O 
consecutive O 
sessions O 
performing O 
the O 
task O 
at O 
criterion O 
, O 
rats O 
were O 
sacrificed O 
and O 
brains O 
removed O 
for O 
monoamine O 
determinations O 
. O 
Methamphetamine B-TRIVIAL 
-pretreated O 
rats O 
had O 
∼50% O 
loss O 
of O 
striatal O 
dopamine B-TRIVIAL 
and O 
prefrontal O 
serotonin B-TRIVIAL 
. O 
Methamphetamine B-TRIVIAL 
- O 
and O 
saline O 
- O 
pretreated O 
rats O 
were O 
not O 
different O 
in O 
the O 
number O 
of O 
sessions O 
required O 
to O 
reach O 
criterion O 
or O 
in O 
the O 
total O 
numbers O 
of O 
lever O 
presses O 
and O 
/ O 
or O 
head O 
entries O 
made O 
across O 
the O 
four O 
consecutive O 
sessions O 
at O 
criterion O 
- O 
level O 
performance O 
. O 
However O 
, O 
methamphetamine B-TRIVIAL 
-pretreated O 
rats O 
earned O 
fewer O 
reinforcers O 
, O 
because O 
they O 
made O 
extra O 
lever O 
- O 
presses O 
and O 
head O 
entries O 
when O 
they O 
should O 
have O 
been O 
retrieving O 
the O 
reinforcer O 
or O 
returning O 
to O 
the O 
lever O 
. O 
Latencies O 
for O 
methamphetamine B-TRIVIAL 
-pretreated O 
rats O 
to O 
switch O 
between O 
the O 
two O 
behaviors O 
also O 
were O 
significantly O 
slower O 
than O 
latencies O 
for O 
controls O 
. O 
Interestingly O 
, O 
the O 
degree O 
of O 
additional O 
lever O 
- O 
presses O 
negatively O 
correlated O 
with O 
serotonin B-TRIVIAL 
-transporter O 
binding O 
in O 
the O 
prefrontal O 
cortex O 
, O 
even O 
in O 
saline O 
- O 
pretreated O 
controls O 
. O 
These O 
data O 
suggest O 
that O 
methamphetamine B-TRIVIAL 
-induced O 
partial O 
monoamine O 
toxicity O 
is O 
associated O 
with O 
perseveration O 
and O 
that O 
the O 
degree O 
of O 
perseveration O 
may O 
depend O 
on O 
serotonin B-TRIVIAL 
innervation O 
of O 
the O 
frontal O 
cortex O 
. O 

describe O 
the O 
subcellular O 
localization O 
of O 
horse O 
F(ab')(2) O 
and O 
IgG O 
, O 
and O 
ostrich O 
IgY O 
labeled O 
with O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
( O 
FITC B-ABBREVIATION 
) O 
administered O 
IV O 
to O 
mice O 
. O 
We O 
used O 
wide O 
field O 
high O 
sensitivity O 
fluorescence O 
microscopy O 
deblurred O 
by O 
3-dimensional O 
blind O 
deconvolution O 
of O 
kidney O 
, O 
liver O 
, O 
lungs O 
and O 
brain O 
sections O 
. O 
Sections O 
were O 
obtained O 
from O 
mice O 
sacrificed O 
15 O 
min O 
, O 
1 O 
or O 
5 O 
h O 
after O 
receiving O 
FITC B-ABBREVIATION 
-immunoproteins O 
, O 
counter O 
- O 
stained O 
with O 
DAPI B-ABBREVIATION 
( O 
4',6'-diamidino-2-phenylindole B-SYSTEMATIC 
) O 
and O 
Evans B-TRIVIAL 
blue I-TRIVIAL 
. O 
FITC B-ABBREVIATION 
-IgG O 
and O 
its O 
fractions O 
are O 
rapidly O 
taken O 
up O 
and O 
extravasated O 
by O 
vascular O 
endothelium O 
. O 
FITC B-ABBREVIATION 
-IgG O 
and O 
FITC B-ABBREVIATION 
-F(ab')(2) O 
appear O 
to O 
be O 
quickly O 
secreted O 
by O 
glomeruli O 
endothelium O 
and O 
to O 
be O 
reabsorbed O 
along O 
all O 
nephron O 
segments O 
. O 
FITC B-ABBREVIATION 
-IgG O 
and O 
FITC B-ABBREVIATION 
-F(ab')(2) O 
appeared O 
15 O 
min O 
after O 
IV O 
injection O 
within O 
bronchial O 
, O 
alveolar O 
and O 
bile O 
duct O 
epithelium O 
. O 
Hepatocytes O 
were O 
loaded O 
with O 
fluorescence O 
after O 
15 O 
min O 
of O 
administration O 
. O 
Fluorescence O 
was O 
absent O 
from O 
brain O 
slices O 
, O 
except O 
for O 
the O 
endothelium O 
of O 
some O 
vessels O 
in O 
brain O 
ventricles O 
which O 
appeared O 
intensely O 
fluorescent O 
. O 
Fluorescence O 
appeared O 
in O 
intracellular O 
vesicles O 
which O 
conferred O 
the O 
tissues O 
a O 
glowing O 
foamy O 
aspect O 
for O 
up O 
to O 
5 O 
h O 
after O 
inoculation O 
. O 
Arterial O 
elastic O 
layers O 
were O 
intensely O 
green O 
after O 
horse O 
FITC B-ABBREVIATION 
-Ig O 
inoculation O 
. O 
Ostrich O 
FITC B-ABBREVIATION 
-IgY O 
behaved O 
completely O 
differently O 
to O 
horse O 
Ig's O 
; O 
only O 
1 O 
h O 
after O 
injection O 
it O 
was O 
possible O 
to O 
observe O 
small O 
brightly O 
green O 
scarce O 
vesicles O 
in O 
vascular O 
endothelium O 
of O 
arteries O 
, O 
interstitial O 
kidney O 
capillaries O 
between O 
nephron O 
tubules O 
and O 
were O 
also O 
scarce O 
in O 
glomeruli O 
endothelium O 
; O 
FITC B-ABBREVIATION 
-IgY O 
appeared O 
only O 
in O 
hepatic O 
sinusoids O 
in O 
the O 
liver O 
. O 
No O 
IgY O 
was O 
seen O 
in O 
bronchial O 
and O 
alveolar O 
endothelium O 
, O 
in O 
bile O 
ducts O 
or O 
in O 
hepatocytes O 
. O 

envenoming O 
by O 
Bothrops O 
caribbaeus O 
, O 
an O 
endemic O 
viperid O 
from O 
the O 
Lesser O 
Antillean O 
island O 
of O 
Saint O 
Lucia O 
, O 
is O 
clinically O 
characterized O 
by O 
local O 
tissue O 
damage O 
and O 
systemic O 
thrombosis O 
that O 
can O 
lead O 
to O 
cerebral O 
, O 
myocardial O 
or O 
pulmonary O 
infarctions O 
and O 
venous O 
thromboses O 
. O 
Systemic O 
effects O 
( O 
lethality O 
, O 
pulmonary O 
hemorrhage O 
, O 
thrombocytopenia O 
and O 
coagulopathy O 
) O 
induced O 
by O 
intravenous O 
( O 
i.v O 
. O 
) O 
administration O 
of O 
B O 
. O 
caribbaeus O 
venom O 
were O 
studied O 
in O 
mice O 
. O 
The O 
role O 
of O 
snake O 
venom O 
metalloproteinases O 
( O 
SVMPs O 
) O 
in O 
these O 
systemic O 
alterations O 
was O 
assessed O 
by O 
inhibition O 
with O 
the O 
chelating O 
agent O 
calcium B-SYSTEMATIC 
disodium I-SYSTEMATIC 
ethylenediaminetetraacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CaNa(2)EDTA B-FORMULA 
) O 
. O 
A O 
snake O 
C- O 
type O 
lectin O 
- O 
like O 
( O 
snaclec O 
) O 
and O 
a O 
type O 
P-III O 
hemorrhagic O 
SVMP O 
were O 
isolated O 
and O 
characterized O 
from O 
this O 
venom O 
, O 
and O 
the O 
effect O 
of O 
venom O 
and O 
the O 
isolated O 
snaclec O 
on O 
human O 
platelet O 
aggregation O 
was O 
studied O 
in O 
vitro O 
. O 
Results O 
indicate O 
that O 
SVMPs O 
play O 
an O 
important O 
role O 
in O 
the O 
overall O 
toxicity O 
of O 
B. O 
caribbaeus O 
venom O 
, O 
being O 
responsible O 
for O 
systemic O 
hemorrhage O 
and O 
lethality O 
, O 
but O 
not O 
thrombocytopenia O 
, O 
whereas O 
the O 
isolated O 
snaclec O 
is O 
involved O 
in O 
the O 
thrombocytopenic O 
effect O 
. O 
Both O 
venom O 
and O 
snaclec O 
induce O 
platelet O 
aggregation O 
/ O 
agglutination O 
. O 
Moreover O 
, O 
the O 
snaclec O 
binds O 
directly O 
to O 
glycoprotein O 
Ib O 
( O 
GPIb O 
) O 
and O 
induces O 
agglutination O 
in O 
washed O 
fixed O 
platelets O 
. O 
On O 
the O 
other O 
hand O 
, O 
B O 
. O 
caribbaeus O 
venom O 
hydrolyzed O 
fibrinogen O 
in O 
vitro O 
and O 
induced O 
a O 
partial O 
drop O 
of O 
fibrinogen O 
levels O 
with O 
an O 
increase O 
in O 
fibrin O 
/ O 
fibrinogen O 
degradation O 
products O 
( O 
FDP O 
) O 
levels O 
in O 
vivo O 
. O 
The O 
negative O 
result O 
for O 
D-dimer O 
( O 
DD O 
) O 
in O 
plasma O 
is O 
consistent O 
with O 
the O 
lack O 
of O 
microscopic O 
evidence O 
of O 
pulmonary O 
thrombosis O 
and O 
endothelial O 
cell O 
damage O 
. O 
Likewise O 
, O 
no O 
increments O 
in O 
plasma O 
sE-selectin O 
levels O 
were O 
detected O 
. O 
The O 
absence O 
of O 
thrombosis O 
in O 
this O 
murine O 
model O 
suggests O 
that O 
this O 
effect O 
may O 
be O 
species O 
- O 
specific O 
. O 

impact O 
of O 
oxytocin B-TRIVIAL 
administration O 
and O 
maternal O 
love O 
withdrawal O 
on O 
event O 
- O 
related O 
potential O 
( O 
ERP O 
) O 
responses O 
to O 
emotional O 
faces O 
with O 
performance O 
feedback O 
. O 

is O 
the O 
first O 
experimental O 
study O 
on O 
the O 
effect O 
of O 
oxytocin B-TRIVIAL 
administration O 
on O 
the O 
neural O 
processing O 
of O 
facial O 
stimuli O 
conducted O 
with O 
female O 
participants O 
that O 
uses O 
event O 
- O 
related O 
potentials O 
( O 
ERPs O 
) O 
. O 
Using O 
a O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
within O 
- O 
subjects O 
design O 
, O 
we O 
studied O 
the O 
effects O 
of O 
16 O 
IU O 
of O 
intranasal O 
oxytocin B-TRIVIAL 
on O 
ERPs O 
to O 
pictures O 
combining O 
performance O 
feedback O 
with O 
emotional O 
facial O 
expressions O 
in O 
48 O 
female O 
undergraduate O 
students O 
. O 
Participants O 
also O 
reported O 
on O 
the O 
amount O 
of O 
love O 
withdrawal O 
they O 
experienced O 
from O 
their O 
mothers O 
. O 
Vertex O 
positive O 
potential O 
( O 
VPP O 
) O 
and O 
late O 
positive O 
potential O 
( O 
LPP O 
) O 
amplitudes O 
were O 
more O 
positive O 
after O 
oxytocin B-TRIVIAL 
compared O 
to O 
placebo O 
administration O 
. O 
This O 
suggests O 
that O 
oxytocin B-TRIVIAL 
increased O 
attention O 
to O 
the O 
feedback O 
stimuli O 
( O 
LPP O 
) O 
and O 
enhanced O 
the O 
processing O 
of O 
emotional O 
faces O 
( O 
VPP O 
) O 
. O 
Oxytocin B-TRIVIAL 
heightened O 
processing O 
of O 
the O 
happy O 
and O 
disgusted O 
faces O 
primarily O 
for O 
those O 
reporting O 
less O 
love O 
withdrawal O 
. O 
Significant O 
associations O 
with O 
LPP O 
amplitude O 
suggest O 
that O 
more O 
maternal O 
love O 
withdrawal O 
relates O 
to O 
the O 
allocation O 
of O 
attention O 
toward O 
the O 
motivationally O 
relevant O 
combination O 
of O 
negative O 
feedback O 
with O 
a O 
disgusted O 
face O 
. O 

- O 
albumin O 
nanoparticles O 
( O 
NANAPs O 
) O 
for O 
the O 
delivery O 
of O 
a O 
multikinase O 
inhibitor O 
17864 B-IDENTIFIER 
to O 
EGFR O 
overexpressing O 
tumor O 
cells O 
. O 

novel O 
, O 
EGFR-targeted O 
nanomedicine O 
has O 
been O 
developed O 
in O 
the O 
current O 
study O 
. O 
Glutaraldehyde B-TRIVIAL 
crosslinked O 
albumin O 
nanoparticles O 
with O 
a O 
size O 
of O 
approximately O 
100nm O 
were O 
loaded O 
with O 
the O 
multikinase O 
inhibitor O 
17864 B-IDENTIFIER 
-L(x)-a O 
platinum B-SYSTEMATIC 
-bound O 
sunitinib B-TRIVIAL 
analogue O 
- O 
which O 
couples O 
the O 
drug O 
to O 
methionine B-TRIVIAL 
residues O 
of O 
albumin O 
and O 
is O 
released O 
in O 
a O 
reductive O 
environment O 
. O 
Albumin O 
nanoparticles O 
were O 
surface O 
- O 
coated O 
with O 
bifunctional O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
3500 O 
( O 
PEG B-ABBREVIATION 
) O 
and O 
a O 
nanobody O 
- O 
the O 
single O 
variable O 
domain O 
of O 
an O 
antibody-(Ega1) O 
against O 
the O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
. O 
EGa1- O 
PEG B-ABBREVIATION 
functionalized O 
nanoparticles O 
showed O 
a O 
40-fold O 
higher O 
binding O 
to O 
EGFR-positive O 
14C B-FORMULA 
squamous O 
head O 
and O 
neck O 
cancer O 
cells O 
in O 
comparison O 
to O 
PEGylated O 
nanoparticles O 
. O 
17864 B-IDENTIFIER 
-L O 
(x) O 
loaded O 
EGa1- O 
PEG B-ABBREVIATION 
nanoparticles O 
were O 
internalized O 
by O 
clathrin O 
- O 
mediated O 
endocytosis O 
and O 
ultimately O 
digested O 
in O 
lysosomes O 
. O 
The O 
intracellular O 
routing O 
of O 
EGa1 O 
targeted O 
nanoparticles O 
leads O 
to O 
a O 
successful O 
release O 
of O 
the O 
kinase O 
inhibitor O 
in O 
the O 
cell O 
and O 
inhibition O 
of O 
proliferation O 
whereas O 
the O 
non-targeted O 
formulations O 
had O 
no O 
antiproliferative O 
effects O 
on O 
14C B-FORMULA 
cells O 
. O 
The O 
drug O 
loaded O 
targeted O 
nanoparticles O 
were O 
as O 
effective O 
as O 
the O 
free O 
drug O 
in O 
vitro O 
. O 
These O 
results O 
demonstrate O 
that O 
multikinase O 
inhibitor O 
loaded O 
nanoparticles O 
are O 
interesting O 
nanomedicines O 
for O 
the O 
treatment O 
of O 
EGFR-positive O 
cancers O 
. O 

vivo O 
permeation O 
characteristics O 
of O 
venlafaxine B-TRIVIAL 
through O 
sheep O 
nasal O 
mucosa O 
. O 

, O 
a O 
dual O 
acting O 
antidepressant O 
is O 
a O 
new O 
therapeutic O 
option O 
for O 
chronic O 
depression O 
. O 
Depression O 
is O 
a O 
common O 
mental O 
disorder O 
associated O 
with O 
the O 
abnormalities O 
in O 
neuronal O 
transport O 
in O 
the O 
brain O 
. O 
Since O 
the O 
nose O 
- O 
to O 
- O 
brain O 
pathway O 
has O 
been O 
indicated O 
for O 
delivering O 
drugs O 
to O 
the O 
brain O 
, O 
we O 
analyzed O 
the O 
transport O 
of O 
venlafaxine B-TRIVIAL 
through O 
sheep O 
nasal O 
mucosa O 
. O 
Transmucosal O 
permeation O 
kinetics O 
of O 
venlafaxine B-TRIVIAL 
were O 
examined O 
using O 
sheep O 
nasal O 
mucosa O 
mounted O 
onto O 
static O 
vertical O 
Franz O 
diffusion O 
cells O 
. O 
Nasal O 
mucosa O 
was O 
treated O 
with O 
venlafaxine B-TRIVIAL 
in O 
situ O 
gel O 
( O 
100 O 
μl O 
; O 
1% O 
w O 
/ O 
v O 
) O 
for O 
7h O 
. O 
Amount O 
of O 
venlafaxine B-TRIVIAL 
diffused O 
through O 
mucosa O 
was O 
measured O 
using O 
validated O 
RP-HPLC O 
method O 
. O 
After O 
the O 
completion O 
of O 
the O 
study O 
histopathological O 
investigation O 
of O 
mucosa O 
was O 
carried O 
out O 
. O 
Ex O 
vivo O 
studies O 
through O 
sheep O 
nasal O 
mucosa O 
showed O 
sustained O 
diffusion O 
of O 
venlafaxine B-TRIVIAL 
with O 
66.5% O 
permeation O 
in O 
7h O 
. O 
Transnasal O 
transport O 
of O 
venlafaxine B-TRIVIAL 
followed O 
a O 
non-Fickian O 
diffusion O 
process O 
. O 
Permeability O 
coefficient O 
and O 
steady O 
state O 
flux O 
were O 
found O 
to O 
be O 
21.11×10(-3) O 
cmh(-1) O 
and O 
21.118 O 
μg O 
cm(-2)h(-1) O 
respectively O 
. O 
Cumulative O 
amount O 
permeated O 
through O 
mucosa O 
at O 
7h O 
was O 
found O 
to O 
be O 
664.8 O 
μg O 
through O 
an O 
area O 
of O 
3.14 O 
cm(2) O 
. O 
Total O 
recovery O 
of O 
venlafaxine B-TRIVIAL 
at O 
the O 
end O 
of O 
the O 
permeation O 
study O 
was O 
87.3% O 
of O 
initial O 
dose O 
distributed O 
(i) O 
at O 
the O 
mucosal O 
surface O 
( O 
208.4 O 
μg O 
; O 
20.8% O 
) O 
and O 
(ii) O 
through O 
mucosa O 
( O 
664.8 O 
μg O 
; O 
66.5% O 
) O 
. O 
Histopathological O 
examinations O 
showed O 
no O 
significant O 
adverse O 
effects O 
confirming O 
that O 
the O 
barrier O 
function O 
of O 
nasal O 
mucosa O 
remains O 
unaffected O 
even O 
after O 
treatment O 
with O 
venlafaxine B-TRIVIAL 
in O 
situ O 
gel O 
. O 
Permeation O 
through O 
sheep O 
nasal O 
mucosa O 
using O 
in O 
situ O 
gel O 
demonstrated O 
a O 
harmless O 
nasal O 
delivery O 
of O 
venlafaxine B-TRIVIAL 
, O 
providing O 
new O 
dimension O 
to O 
the O 
treatment O 
of O 
chronic O 
depression O 
. O 

conjugation O 
does O 
not O 
increase O 
the O 
efficiency O 
of O 
liposomal O 
Foscan B-TRIVIAL 
during O 
in O 
vitro O 
photodynamic O 
therapy O 
of O 
oesophageal O 
cancer O 
. O 

therapy O 
( O 
PDT O 
) O 
is O 
based O 
on O 
the O 
delivery O 
of O 
photocytotoxic O 
agents O 
to O 
a O 
target O 
tissue O 
, O 
followed O 
by O 
irradiation O 
. O 
In O 
order O 
to O 
increase O 
the O 
efficiency O 
of O 
PDT O 
in O 
oesophageal O 
cancer O 
therapy O 
, O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
)-grafted O 
, O 
transferrin O 
(Tf)-conjugated O 
liposome O 
formulations O 
of O 
5,10,15,20-tetra(m-hydroxyphenyl)chlorin B-SYSTEMATIC 
( O 
Foscan B-TRIVIAL 
) O 
, O 
a O 
second O 
- O 
generation O 
photosensitiser O 
, O 
were O 
prepared O 
. O 
Expression O 
of O 
transferrin O 
receptors O 
( O 
CD71 O 
) O 
in O 
the O 
oesophageal O 
cancer O 
cell O 
line O 
, O 
OE21 O 
, O 
was O 
confirmed O 
by O 
immunoblot O 
and O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
The O 
anti-proliferative O 
effect O 
of O 
Foscan B-TRIVIAL 
liposomes O 
was O 
evaluated O 
and O 
compared O 
with O 
plain O 
formulations O 
( O 
i.e O 
. O 
, O 
without O 
Tf O 
) O 
as O 
well O 
as O 
with O 
free O 
drug O 
. O 
In O 
addition O 
, O 
the O 
intracellular O 
accumulation O 
was O 
studied O 
using O 
high O 
content O 
analysis O 
. O 
Surprisingly O 
, O 
delivering O 
Foscan B-TRIVIAL 
by O 
transferrin O 
- O 
conjugated O 
PEG B-ABBREVIATION 
-liposomes O 
to O 
oesophageal O 
cancer O 
cells O 
did O 
not O 
improve O 
the O 
photocytotoxicity O 
or O 
the O 
intracellular O 
accumulation O 
of O 
Foscan B-TRIVIAL 
when O 
compared O 
to O 
unmodified O 
liposomes O 
or O 
indeed O 
free O 
photosensitiser O 
. O 
Tf-targeted O 
drugs O 
and O 
drug O 
delivery O 
systems O 
have O 
shown O 
improved O 
the O 
therapy O 
of O 
many O 
cancers O 
. O 
Our O 
study O 
, O 
however O 
, O 
did O 
not O 
corroborate O 
these O 
findings O 
. O 
If O 
this O 
is O 
due O 
to O 
the O 
tumour O 
type O 
, O 
the O 
choice O 
of O 
in O 
vitro O 
model O 
or O 
the O 
delivery O 
systems O 
remains O 
to O 
be O 
confirmed O 
. O 

novel O 
approach O 
to O 
improve O 
the O 
pharmacokinetic O 
properties O 
of O 
8-chloro- B-SYSTEMATIC 
adenosine I-SYSTEMATIC 
by O 
the O 
dual O 
combination O 
of O 
lipophilic O 
derivatisation O 
and O 
liposome O 
formulation O 
. O 

adenosine I-SYSTEMATIC 
( O 
8CA B-SYSTEMATIC 
) O 
has O 
shown O 
promise O 
in O 
hematologic O 
and O 
solid O 
tumor O 
models O 
and O 
is O 
in O 
a O 
phase O 
I O 
clinical O 
trial O 
. O 
However O 
, O 
8CA B-SYSTEMATIC 
is O 
intensively O 
metabolized O 
shortly O 
after O 
i.v O 
. O 
administration O 
, O 
with O 
a O 
t(1 O 
/ O 
2β O 
) O 
of O 
approximately O 
1h O 
. O 
Many O 
carriers O 
have O 
failed O 
to O 
encapsulate O 
8CA B-SYSTEMATIC 
efficiently O 
. O 
To O 
improve O 
its O 
pharmacokinetic O 
properties O 
, O 
8-chloro-adenosine-5'-O-stearate B-SYSTEMATIC 
( O 
8CAS B-SYSTEMATIC 
) O 
, O 
a O 
lipophilic O 
octadecanoyl B-SYSTEMATIC 
analogue O 
of O 
8CA B-SYSTEMATIC 
, O 
was O 
synthesized O 
and O 
incorporated O 
into O 
pegylated O 
liposomes O 
. O 
The O 
liposomes O 
, O 
comprising O 
egg O 
phosphatidylcholine B-FAMILY 
, O 
cholesterol B-TRIVIAL 
and O 
poly B-SYSTEMATIC 
( I-SYSTEMATIC 
ethylene I-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
2000- O 
distearoyl B-SYSTEMATIC 
phosphatidylethanolamine I-SYSTEMATIC 
( O 
PEG-DSPE B-ABBREVIATION 
) O 
, O 
had O 
mean O 
diameters O 
of O 
approximately O 
100 O 
nm O 
and O 
an O 
entrapment O 
efficiency O 
of O 
69-86% O 
. O 
MTT B-ABBREVIATION 
assays O 
showed O 
that O 
the O 
cytotoxicity O 
of O 
8CAS B-SYSTEMATIC 
and O 
its O 
pegylated O 
liposomes O 
( O 
8CAS B-SYSTEMATIC 
-PL O 
) O 
were O 
retained O 
, O 
with O 
IC(50) O 
values O 
of O 
1 O 
μM O 
and O 
1.9 O 
μM O 
at O 
72 O 
h O 
on O 
MCF-7 O 
cells O 
, O 
respectively O 
, O 
slightly O 
higher O 
than O 
that O 
of O 
8CA B-SYSTEMATIC 
( O 
0.6 O 
μM O 
) O 
. O 
Pharmacokinetic O 
studies O 
in O 
rats O 
after O 
i.v O 
. O 
injection O 
showed O 
that O 
both O 
8CAS B-SYSTEMATIC 
and O 
8 O 
CAS-PL O 
had O 
increased O 
elimination O 
half O 
- O 
lives O 
( O 
t(1 O 
/ O 
2 O 
) O 
, O 
128.4 O 
, O 
249.2 O 
vs O 
. O 
74.7 O 
min O 
) O 
, O 
decreased O 
clearance O 
rates O 
( O 
Cl O 
, O 
0.0135 O 
, O 
0.00875 O 
vs O 
. O 
0.2398 O 
L O 
/ O 
min O 
/ O 
kg O 
) O 
and O 
increased O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
( O 
AUC(0-∞) O 
, O 
741.4 O 
, O 
1163.6 O 
vs O 
. O 
42 O 
mg O 
min O 
/ O 
L O 
) O 
compared O 
to O 
8CA B-SYSTEMATIC 
. O 
No O 
obvious O 
hematological O 
toxicity O 
was O 
seen O 
for O 
Kunming O 
mice O 
receiving O 
i.v O 
. O 
8CA B-SYSTEMATIC 
or O 
8CAS B-SYSTEMATIC 
-PL O 
at O 
a O 
dosage O 
of O 
10mg O 
/ O 
kg O 
daily O 
. O 
These O 
results O 
indicate O 
that O 
the O 
lipophilic O 
derivation O 
of O 
8CA B-SYSTEMATIC 
and O 
the O 
incorporation O 
of O 
8CAS B-SYSTEMATIC 
is O 
an O 
effective O 
strategy O 
to O 
improve O 
the O 
bioavailability O 
of O 
8CA B-SYSTEMATIC 
. O 

multiparticulate O 
patch O 
for O 
the O 
intrabuccal O 
controlled O 
delivery O 
of O 
lidocaine B-TRIVIAL 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
prepare O 
and O 
evaluate O 
patches O 
for O 
the O 
controlled O 
release O 
of O 
lidocaine B-TRIVIAL 
in O 
the O 
oral O 
cavity O 
. O 
Mucoadhesive O 
buccal O 
patches O 
, O 
containing O 
8 O 
mg O 
/ O 
cm(2) O 
lidocaine B-TRIVIAL 
base O 
, O 
were O 
formulated O 
and O 
developed O 
by O 
solvent O 
casting O 
method O 
technique O 
, O 
using O 
a O 
number O 
of O 
different O 
bio O 
- O 
adhesive O 
and O 
film O 
- O 
forming O 
semi-synthetic O 
and O 
synthetic O 
polymers O 
( O 
Carbopol B-TRIVIAL 
, O 
Poloxamer B-TRIVIAL 
, O 
different O 
type O 
Methocel O 
) O 
and O 
plasticizers O 
( O 
PEG B-ABBREVIATION 
400 I-ABBREVIATION 
, O 
triethyl B-SYSTEMATIC 
citrate I-SYSTEMATIC 
) O 
; O 
the O 
patches O 
were O 
evaluated O 
for O 
bioadhesion O 
, O 
in O 
vitro O 
drug O 
release O 
and O 
permeation O 
using O 
a O 
modified O 
Franz O 
diffusion O 
cell O 
. O 
A O 
lidocaine B-TRIVIAL 
/ O 
Compritol B-TRIVIAL 
solid O 
dispersion O 
in O 
the O 
form O 
of O 
microspheres O 
, O 
embedded O 
inside O 
the O 
patch O 
, O 
alone O 
or O 
together O 
with O 
free O 
lidocaine B-TRIVIAL 
, O 
was O 
also O 
examined O 
to O 
prolong O 
the O 
drug O 
release O 
. O 
The O 
effects O 
of O 
the O 
composition O 
were O 
evaluated O 
considering O 
a O 
number O 
of O 
technological O 
parameters O 
and O 
the O 
release O 
of O 
the O 
drug O 
. O 
All O 
the O 
formulations O 
tested O 
offer O 
a O 
variety O 
of O 
drug O 
release O 
mechanisms O 
, O 
obtaining O 
a O 
quick O 
or O 
delayed O 
or O 
prolonged O 
anesthetic O 
local O 
activity O 
with O 
simple O 
changes O 
of O 
the O 
formulation O 
parameters O 
. O 

effects O 
of O 
oil O 
sands O 
- O 
derived O 
naphthenic B-FAMILY 
acids I-FAMILY 
to O 
rainbow O 
trout O 
. O 

acids I-FAMILY 
are O 
the O 
major O 
organic O 
constituents O 
in O 
waters O 
impacted O 
by O 
oil O 
sands O 
. O 
To O 
investigate O 
their O 
immunotoxicity O 
, O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
were O 
injected O 
with O 
naphthenic B-FAMILY 
acids I-FAMILY 
extracted O 
from O 
aged O 
oil O 
sands O 
tailings O 
water O 
. O 
In O 
two O 
experiments O 
, O 
rainbow O 
trout O 
were O 
injected O 
intraperitoneally O 
with O 
0 O 
, O 
10 O 
, O 
or O 
100 O 
mg O 
/ O 
kg O 
of O 
naphthenic B-FAMILY 
acids I-FAMILY 
, O 
and O 
sampled O 
after O 
5 O 
or O 
21 O 
d O 
. O 
Half O 
of O 
the O 
fish O 
from O 
the O 
21 O 
d O 
exposure O 
were O 
co O 
- O 
exposed O 
to O 
inactivated O 
Aeromonas O 
salmonicida O 
( O 
A.s O 
. O 
) O 
to O 
induce O 
an O 
immune O 
response O 
. O 
A O 
positive O 
control O 
experiment O 
was O 
conducted O 
using O 
an O 
intraperitoneal O 
injection O 
of O 
100 O 
mg O 
/ O 
kg O 
of O 
benzo[a]pyrene B-SYSTEMATIC 
, O 
a O 
known O 
immune O 
suppressing O 
compound O 
. O 
T-lymphocytes O 
, O 
B-lymphocytes O 
, O 
thrombocytes O 
, O 
and O 
myeloid O 
cells O 
were O 
counted O 
in O 
blood O 
and O 
lymphatic O 
tissue O 
using O 
flow O 
cytometry O 
. O 
In O 
the O 
5d O 
exposure O 
, O 
there O 
was O 
a O 
reduction O 
in O 
blood O 
leucocytes O 
and O 
spleen O 
thrombocytes O 
at O 
the O 
100 O 
mg O 
/ O 
kg O 
dose O 
. O 
However O 
, O 
at O 
21 O 
d O 
, O 
leucocyte O 
populations O 
showed O 
no O 
effects O 
of O 
exposure O 
with O 
the O 
exception O 
that O 
spleen O 
thrombocyte O 
populations O 
increase O 
at O 
the O 
100 O 
mg O 
/ O 
kg O 
dose O 
. O 
In O 
the O 
21 O 
d O 
exposure O 
, O 
B- O 
and O 
T-lymphocytes O 
in O 
blood O 
showed O 
a O 
significant O 
Dose O 
× O 
A.s O 
. O 
interaction O 
, O 
indicating O 
stimulated O 
blood O 
cell O 
proliferation O 
due O 
to O 
naphthenic B-FAMILY 
acids I-FAMILY 
alone O 
as O 
well O 
as O 
due O 
to O 
A.s O 
. O 
Naphthenic B-FAMILY 
acid I-FAMILY 
injections O 
did O 
not O 
result O 
in O 
elevated O 
bile O 
fluorescent O 
metabolites O 
or O 
elevated O 
hepatic O 
EROD O 
activity O 
. O 
In O 
contrast O 
to O 
naphthenic B-FAMILY 
acids I-FAMILY 
exposures O 
, O 
as O 
similar O 
dose O 
of O 
benzo[a]pyrene B-SYSTEMATIC 
caused O 
a O 
significant O 
decrease O 
in O 
B- O 
and O 
T-lymphocyte O 
absolute O 
counts O 
in O 
blood O 
and O 
relative O 
B-lymphocyte O 
counts O 
in O 
spleen O 
. O 
Results O 
suggest O 
that O 
the O 
naphthenic B-FAMILY 
acids I-FAMILY 
may O 
act O 
via O 
a O 
generally O 
toxic O 
mechanism O 
rather O 
than O 
by O 
specific O 
toxic O 
effects O 
on O 
immune O 
cells O 
. O 

specific O 
interaction O 
of O 
the O 
photosensitizer O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
with O 
acetylcholinesterase O 
provides O 
a O 
model O 
system O 
for O 
studying O 
the O 
molecular O 
consequences O 
of O 
photodynamic O 
therapy O 
. O 

photosensitizer O 
, O 
methylene B-TRIVIAL 
blue I-TRIVIAL 
( O 
MB O 
) O 
, O 
generates O 
singlet O 
oxygen B-SYSTEMATIC 
( O 
( O 
1 O 
) O 
O2 B-FORMULA 
) O 
that O 
irreversibly O 
inhibits O 
Torpedo O 
californica O 
acetylcholinesterase O 
( O 
TcAChE O 
) O 
. O 
In O 
the O 
dark O 
MB O 
inhibits O 
reversibly O 
, O 
binding O 
being O 
accompanied O 
by O 
a O 
bathochromic O 
shift O 
that O 
can O 
be O 
used O 
to O 
show O 
its O 
displacement O 
by O 
other O 
reversible O 
inhibitors O 
binding O 
to O 
the O 
catalytic O 
' O 
anionic O 
' O 
subsite O 
( O 
CAS O 
) O 
, O 
the O 
peripheral O 
' O 
anionic O 
' O 
subsite O 
( O 
PAS O 
) O 
, O 
or O 
bridging O 
them O 
. O 
Data O 
concerning O 
both O 
reversible O 
and O 
irreversible O 
inhibition O 
are O 
here O 
reviewed O 
. O 
MB O 
protects O 
TcAChE O 
from O 
thermal O 
denaturation O 
, O 
and O 
differential O 
scanning O 
calorimetry O 
reveals O 
a O 
∼8°C O 
increase O 
in O 
the O 
denaturation O 
temperature O 
. O 
The O 
crystal O 
structure O 
of O 
the O 
MB O 
/ O 
TcAChE O 
complex O 
reveals O 
a O 
single O 
MB O 
stacked O 
against O 
W279 O 
in O 
the O 
PAS O 
, O 
pointing O 
down O 
the O 
gorge O 
towards O 
the O 
CAS O 
. O 
The O 
intrinsic O 
fluorescence O 
of O 
the O 
irreversibly O 
inhibited O 
enzyme O 
displays O 
new O 
emission O 
bands O 
that O 
can O 
be O 
ascribed O 
to O 
N'- B-TRIVIAL 
formylkynurenine I-TRIVIAL 
( O 
NFK B-ABBREVIATION 
) O 
; O 
this O 
was O 
indeed O 
confirmed O 
using O 
anti- O 
NFK B-ABBREVIATION 
antibodies O 
. O 
Mass O 
spectroscopy O 
revealed O 
that O 
two O 
Trp B-FORMULA 
residues O 
, O 
Trp B-FORMULA 
84 O 
in O 
the O 
CAS O 
, O 
and O 
Trp B-FORMULA 
279 O 
in O 
the O 
PAS O 
, O 
were O 
the O 
only O 
Trp B-FORMULA 
residues O 
, O 
out O 
of O 
a O 
total O 
of O 
14 O 
, O 
significantly O 
modified O 
by O 
photo O 
- O 
oxidation O 
, O 
both O 
being O 
converted O 
to O 
NFK B-ABBREVIATION 
. O 
In O 
the O 
presence O 
of O 
competitive O 
inhibitors O 
that O 
displace O 
MB O 
from O 
the O 
gorge O 
, O 
their O 
modification O 
is O 
completely O 
prevented O 
. O 
Thus O 
, O 
photo O 
- O 
oxidative O 
damage O 
caused O 
by O 
MB O 
involves O 
targeted O 
release O 
of O 
( O 
1 O 
) O 
O2 B-FORMULA 
by O 
the O 
bound O 
photosensitizer O 
within O 
the O 
aqueous O 
milieu O 
of O 
the O 
active O 
- O 
site O 
gorge O 
. O 

Thai O 
banded O 
tiger O 
wasp O 
( O 
Vespa O 
affinis O 
) O 
is O 
one O 
of O 
the O 
most O 
dangerous O 
vespid O 
species O 
in O 
Southeast O 
Asia O 
, O 
and O 
stinging O 
accidents O 
involving O 
this O 
species O 
still O 
cause O 
fatalities O 
. O 
In O 
the O 
present O 
study O 
, O 
four O 
forms O 
of O 
V O 
. O 
affinis O 
phospholipase O 
A(1) O 
were O 
identified O 
through O 
a O 
proteomics O 
approach O 
. O 
Two O 
of O 
these O 
enzymes O 
were O 
purified O 
by O 
reverse O 
- O 
phase O 
chromatography O 
, O 
and O 
their O 
biochemical O 
properties O 
were O 
characterised O 
. O 
These O 
enzymes O 
, O 
designated O 
Ves O 
a O 
1s O 
, O 
are O 
not O 
glycoproteins O 
and O 
exist O 
as O 
33441.5 O 
and O 
33474.4 O 
Da O 
proteins O 
, O 
which O 
corresponded O 
with O 
the O 
34-kDa O 
band O 
observed O 
via O 
SDS-PAGE O 
. O 
The O 
thermal O 
stabilities O 
of O 
these O 
enzymes O 
were O 
stronger O 
than O 
snake O 
venom O 
. O 
Using O 
an O 
in O 
vivo O 
assay O 
, O 
no O 
difference O 
was O 
found O 
in O 
the O 
toxicities O 
of O 
the O 
different O 
isoforms O 
. O 
Furthermore O 
, O 
the O 
toxicity O 
of O 
these O 
enzymes O 
does O 
not O 
appear O 
to O 
be O 
correlated O 
with O 
their O 
PLA(1) O 
activity O 
. O 
The O 
cDNAs O 
of O 
the O 
full O 
- O 
length O 
version O 
of O 
Ves O 
a O 
1s O 
revealed O 
that O 
the O 
Ves O 
a O 
1 O 
gene O 
consists O 
of O 
a O 
1005-bp O 
ORF O 
, O 
which O 
encodes O 
334 O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
, O 
and O 
67- O 
and O 
227-bp O 
5 O 
' O 
and O 
3 O 
' O 
UTRs O 
, O 
respectively O 
. O 
The O 
two O 
isoforms O 
are O 
different O 
by O 
three O 
nucleotide B-FAMILY 
substitutions O 
, O 
resulting O 
in O 
the O 
replacement O 
of O 
two O 
amino B-FAMILY 
acids I-FAMILY 
. O 
Through O 
sequence O 
alignment O 
, O 
these O 
enzymes O 
were O 
classified O 
as O 
members O 
of O 
the O 
pancreatic O 
lipase O 
family O 
. O 
The O 
structural O 
modelling O 
of O 
Ves O 
a O 
1 O 
used O 
the O 
rat O 
pancreatic O 
lipase O 
- O 
related O 
protein O 
2 O 
( O 
1bu8A O 
) O 
as O 
a O 
template O 
because O 
it O 
has O 
PLA(1) O 
activity O 
, O 
which O 
demonstrated O 
that O 
this O 
enzyme O 
belongs O 
to O 
the O 
α O 
/ O 
β O 
hydrolase O 
fold O 
family O 
. O 
The O 
Ves O 
a O 
1 O 
structure O 
, O 
which O 
is O 
composed O 
of O 
seven O 
α-helixes O 
and O 
eleven O 
β-strands O 
, O 
contains O 
the O 
β-strand O 
/ O 
ɛSer O 
/ O 
α-helix O 
structural O 
motif O 
, O 
which O 
contains O 
the O 
Gly B-FORMULA 
-X- O 
Ser B-FORMULA 
-X- O 
Gly B-FORMULA 
consensus O 
sequence O 
. O 
The O 
typical O 
surface O 
structures O 
that O 
play O 
important O 
roles O 
in O 
substrate O 
selectivity O 
( O 
the O 
lid O 
domain O 
and O 
the O 
β9 O 
loop O 
) O 
were O 
shortened O 
in O 
the O 
Ves O 
a O 
1 O 
structure O 
, O 
which O 
suggests O 
that O 
this O 
enzyme O 
may O 
only O 
exhibit O 
phospholipase O 
activity O 
. O 
Moreover O 
, O 
the O 
observed O 
insertion O 
of O 
proline B-TRIVIAL 
into O 
the O 
lid O 
domain O 
of O 
the O 
Ves O 
a O 
1 O 
structure O 
is O 
rare O 
. O 
We O 
therefore O 
propose O 
that O 
this O 
proline B-TRIVIAL 
residue O 
might O 
be O 
involved O 
in O 
the O 
stability O 
and O 
activity O 
of O 
Ves O 
a O 
1s O 
. O 

of O 
mammalian O 
alcohol B-FAMILY 
dehydrogenase O 
5 O 
( O 
ADH5 O 
) O 
: O 
characterisation O 
of O 
rat O 
ADH5 O 
with O 
comparisons O 
to O 
the O 
corresponding O 
human O 
variant O 
. O 

dehydrogenase O 
5 O 
( O 
ADH5 O 
) O 
is O 
a O 
member O 
of O 
the O 
mammalian O 
alcohol B-FAMILY 
dehydrogenase O 
family O 
of O 
yet O 
undefined O 
functions O 
. O 
ADH5 O 
was O 
first O 
identified O 
at O 
the O 
DNA O 
level O 
in O 
human O 
and O 
deer O 
mouse O 
. O 
A O 
rat O 
alcohol B-FAMILY 
dehydrogenase O 
structure O 
of O 
similar O 
type O 
has O 
been O 
isolated O 
at O 
the O 
cDNA O 
level O 
using O 
human O 
ADH5 O 
as O 
a O 
screening O 
probe O 
, O 
where O 
the O 
rat O 
cDNA O 
structure O 
displayed O 
several O 
atypical O 
properties O 
. O 
mRNA O 
for O 
rat O 
ADH5 O 
was O 
found O 
in O 
multiple O 
tissues O 
, O 
especially O 
in O 
the O 
kidney O 
. O 
In O 
vitro O 
translation O 
experiments O 
indicated O 
that O 
rat O 
ADH5 O 
is O 
expressed O 
as O 
efficiently O 
as O 
ADH1 O 
and O 
furthermore O 
, O 
rat O 
ADH5 O 
was O 
readily O 
expressed O 
in O 
COS O 
cells O 
fused O 
to O 
Green O 
Fluorescent O 
Protein O 
. O 
However O 
, O 
no O 
soluble O 
ADH5 O 
protein O 
could O 
be O 
heterologously O 
expressed O 
in O 
Escherichia O 
coli O 
cells O 
with O 
expression O 
systems O 
successfully O 
used O 
for O 
other O 
mammalian O 
ADHs O 
, O 
including O 
fused O 
to O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
. O 
Molecular O 
modelling O 
of O 
the O 
enzyme O 
indicated O 
that O 
the O 
protein O 
does O 
not O 
fold O 
in O 
a O 
productive O 
way O 
, O 
which O 
can O 
be O 
the O 
explanation O 
why O 
no O 
stable O 
and O 
active O 
ADH5 O 
has O 
been O 
isolated O 
. O 
These O 
results O 
indicate O 
that O 
ADH5 O 
, O 
while O 
readily O 
expressed O 
at O 
the O 
mRNA O 
level O 
, O 
does O 
not O 
behave O 
similarly O 
to O 
other O 
mammalian O 
ADHs O 
investigated O 
. O 
The O 
results O 
, O 
in O 
vitro O 
and O 
in O 
silico O 
, O 
suggest O 
an O 
unstable O 
ADH5 O 
structure O 
, O 
which O 
can O 
explain O 
for O 
why O 
no O 
active O 
and O 
stable O 
protein O 
can O 
be O 
isolated O 
. O 
Further O 
possibilities O 
are O 
conceivable O 
: O 
the O 
ADH5 O 
protein O 
may O 
have O 
to O 
interact O 
with O 
a O 
stabiliser O 
, O 
or O 
the O 
gene O 
is O 
actually O 
a O 
pseudogene O 
. O 

has O 
exploited O 
medium O 
- O 
sized O 
8- O 
to O 
11-membered O 
rings O 
in O 
a O 
variety O 
of O 
natural O 
products O 
to O 
address O 
diverse O 
and O 
challenging O 
biological O 
targets O 
. O 
However O 
, O 
owing O 
to O 
the O 
limitations O 
of O 
conventional O 
cyclization O 
- O 
based O 
approaches O 
to O 
medium O 
- O 
ring O 
synthesis O 
, O 
these O 
structures O 
remain O 
severely O 
underrepresented O 
in O 
current O 
probe O 
and O 
drug O 
discovery O 
efforts O 
. O 
To O 
address O 
this O 
problem O 
, O 
we O 
have O 
established O 
an O 
alternative O 
, O 
biomimetic O 
ring O 
expansion O 
approach O 
to O 
the O 
diversity O 
- O 
oriented O 
synthesis O 
of O 
medium O 
- O 
ring O 
libraries O 
. O 
Oxidative O 
dearomatization O 
of O 
bicyclic B-FAMILY 
phenols I-FAMILY 
affords O 
polycyclic B-FAMILY 
cyclohexadienones I-FAMILY 
that O 
undergo O 
efficient O 
ring O 
expansion O 
to O 
form O 
benzannulated O 
medium O 
- O 
ring O 
scaffolds O 
found O 
in O 
natural O 
products O 
. O 
The O 
ring O 
expansion O 
reaction O 
can O 
be O 
induced O 
using O 
three O 
complementary O 
reagents O 
that O 
avoid O 
competing O 
dienone B-SYSTEMATIC 
- I-SYSTEMATIC 
phenol I-SYSTEMATIC 
rearrangements O 
and O 
is O 
driven O 
by O 
rearomatization O 
of O 
a O 
phenol B-SYSTEMATIC 
ring O 
adjacent O 
to O 
the O 
scissile O 
bond O 
. O 
Cheminformatic O 
analysis O 
of O 
the O 
resulting O 
first O 
- O 
generation O 
library O 
confirms O 
that O 
these O 
molecules O 
occupy O 
chemical O 
space O 
overlapping O 
with O 
medium O 
- O 
ring O 
natural O 
products O 
and O 
distinct O 
from O 
that O 
of O 
synthetic O 
drugs O 
and O 
drug O 
- O 
like O 
libraries O 
. O 

new O 
chromone B-FAMILY 
glycosides I-FAMILY 
from O 
Drynaria O 
fortunei O 
. O 

new O 
chromone B-FAMILY 
glycosides I-FAMILY 
, O 
drynachromoside B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
drynachromoside B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
along O 
with O 
three O 
known O 
flavanones B-FAMILY 
, O 
5,7,3',5'-tetrahydroxy-flavanone B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
5,7,3',5'-tetrahydroxy-flavanone-7-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
5,7,3',5'-tetrahydroxy-flavanone-7-O-neohesperidoside B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
dry O 
rhizomes O 
of O 
Drynaria O 
fortunei O 
by O 
means O 
of O 
bio O 
- O 
active O 
screening O 
. O 
The O 
two O 
former O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
physico O 
- O 
chemical O 
property O 
and O 
spectroscopic O 
data O 
. O 
The O 
osteoblastic O 
proliferation O 
activities O 
of O 
these O 
flavonoids B-FAMILY 
were O 
evaluated O 
by O 
the O 
method O 
of O 
MTT B-ABBREVIATION 
. O 
The O 
results O 
showed O 
that O 
compound O 
1 O 
exhibited O 
the O 
biochemical O 
effects O 
on O 
the O 
proliferation O 
of O 
MC3T3-E1 O 
cells O 
, O 
while O 
Compound O 
2 O 
showed O 
inhibitory O 
effects O 
against O 
MC3T3-E1 O 
cells O 
. O 

of O 
the O 
extracts O 
and O 
an O 
active O 
compound O 
curcumenone B-TRIVIAL 
isolated O 
from O 
Curcuma O 
zedoaria O 
rhizomes O 
on O 
alcohol B-FAMILY 
-induced O 
drunkenness O 
in O 
mice O 
. O 

Curcuma O 
zedoaria O 
rhizome O 
has O 
been O 
used O 
traditionally O 
to O 
treat O 
gastrointestinal O 
diseases O 
as O 
an O 
aromatic O 
stomachic O 
drug O 
, O 
and O 
this O 
is O 
currently O 
used O 
to O 
treat O 
alcohol B-FAMILY 
-induced O 
loss O 
of O 
appetite O 
and O 
nausea O 
in O 
Japan O 
. O 
We O 
examined O 
the O 
effects O 
of O 
various O 
fractions O 
and O 
isolated O 
compounds O 
on O 
alcohol B-FAMILY 
-induced O 
drunkenness O 
and O 
blood O 
alcohol B-FAMILY 
concentrations O 
in O 
mice O 
. O 
The O 
30% O 
ethanol B-SYSTEMATIC 
-extract O 
( O 
1000mg O 
/ O 
kg O 
) O 
of O 
C O 
. O 
zedoaria O 
rhizome O 
prevented O 
drunkenness O 
60 O 
and O 
120min O 
after O 
40% O 
alcohol B-FAMILY 
administration O 
. O 
The O 
n-hexane B-SYSTEMATIC 
-soluble O 
fraction O 
( O 
300mg O 
/ O 
kg O 
) O 
and O 
an O 
isolated O 
compound O 
( O 
3 O 
, O 
10 O 
or O 
30mg O 
/ O 
kg O 
) O 
prevented O 
drunkenness O 
at O 
30 O 
, O 
60 O 
or O 
120min O 
. O 
The O 
extract O 
, O 
n-hexane B-SYSTEMATIC 
-soluble O 
fraction O 
and O 
isolated O 
compound O 
reduced O 
the O 
elevation O 
in O 
blood O 
alcohol B-FAMILY 
concentrations O 
30 O 
and O 
60min O 
after O 
40% O 
alcohol B-FAMILY 
administration O 
. O 
The O 
isolated O 
compound O 
( O 
10 O 
and O 
30mg O 
/ O 
kg O 
) O 
enhanced O 
liver O 
ADH O 
activity O 
30 O 
and O 
60min O 
after O 
40% O 
alcohol B-FAMILY 
administration O 
. O 
The O 
compound O 
was O 
identified O 
as O 
curcumenone B-TRIVIAL 
by O 
a O 
direct O 
comparison O 
of O 
(1)H B-FORMULA 
- O 
and O 
(13)C B-FORMULA 
-NMR O 
spectral O 
data O 
. O 
In O 
conclusion O 
, O 
the O 
protective O 
effect O 
of O 
the O 
C O 
. O 
zedoaria O 
extract O 
on O 
drunkenness O 
might O 
be O 
due O 
to O 
an O 
active O 
substance O 
, O 
curcumenone B-TRIVIAL 
, O 
and O 
decreases O 
in O 
the O 
elevation O 
of O 
blood O 
alcohol B-FAMILY 
concentrations O 
through O 
increased O 
liver O 
alcohol B-FAMILY 
dehydrogenase O 
activity O 
. O 

dioxide I-SYSTEMATIC 
at O 
the O 
air O 
- O 
water O 
interface O 
: O 
trapping O 
, O 
absorption O 
, O 
and O 
solvation O 
in O 
the O 
bulk O 
and O 
at O 
the O 
surface O 
. O 

interaction O 
of O 
NO(2) B-FORMULA 
with O 
water O 
surfaces O 
in O 
the O 
troposphere O 
is O 
of O 
major O 
interest O 
in O 
atmospheric O 
chemistry O 
. O 
We O 
examined O 
an O 
initial O 
step O 
in O 
this O 
process O 
, O 
the O 
uptake O 
of O 
NO(2) B-FORMULA 
by O 
water O 
through O 
the O 
use O 
of O 
molecular O 
dynamics O 
simulations O 
. O 
An O 
NO(2) B-FORMULA 
- O 
H(2)O B-FORMULA 
intermolecular O 
potential O 
was O 
obtained O 
by O 
fitting O 
to O 
high O 
- O 
level O 
ab O 
initio O 
calculations O 
. O 
We O 
determined O 
the O 
binding O 
of O 
NO(2) B-FORMULA 
- O 
H(2)O B-FORMULA 
to O 
be O 
about O 
two O 
times O 
stronger O 
than O 
that O 
previously O 
calculated O 
. O 
From O 
scattering O 
simulations O 
of O 
an O 
NO(2) B-FORMULA 
molecule O 
interacting O 
with O 
a O 
water O 
slab O 
we O 
observed O 
that O 
the O 
majority O 
of O 
the O 
scattering O 
events O 
resulted O 
in O 
outcomes O 
in O 
which O 
the O 
NO(2) B-FORMULA 
molecule O 
became O 
trapped O 
at O 
the O 
surface O 
or O 
in O 
the O 
interior O 
of O 
the O 
water O 
slab O 
. O 
Typical O 
surface O 
- O 
trapped O 
/ O 
adsorbed O 
and O 
bulk O 
- O 
solvated O 
/ O 
absorbed O 
trajectories O 
were O 
analyzed O 
to O 
obtain O 
radial O 
distribution O 
functions O 
and O 
the O 
orientational O 
propensity O 
of O 
NO(2) B-FORMULA 
with O 
respect O 
to O 
the O 
water O 
surface O 
. O 
We O 
observed O 
an O 
affinity O 
of O 
the O 
nitrogen B-SYSTEMATIC 
atom O 
for O 
the O 
oxygen B-SYSTEMATIC 
in O 
water O 
, O 
rather O 
than O 
hydrogen B-SYSTEMATIC 
-bonding O 
which O 
was O 
rare O 
. O 
The O 
water O 
solvation O 
shell O 
was O 
less O 
tight O 
for O 
the O 
bulk O 
- O 
absorbed O 
NO(2) B-FORMULA 
than O 
for O 
the O 
surface O 
- O 
adsorbed O 
NO(2) B-FORMULA 
. O 
Adsorbed O 
NO(2) B-FORMULA 
demonstrated O 
a O 
marked O 
orientational O 
preference O 
, O 
with O 
the O 
oxygens B-FAMILY 
pointing O 
into O 
the O 
vacuum O 
. O 
Such O 
behavior O 
is O 
expected O 
for O 
a O 
mildly O 
hydrophobic O 
and O 
surfactant O 
molecule O 
like O 
NO(2) B-FORMULA 
. O 
Estimates O 
based O 
on O 
our O 
results O 
suggest O 
that O 
at O 
high O 
NO(2) B-FORMULA 
concentrations O 
encountered O 
, O 
for O 
example O 
, O 
in O 
some O 
sampling O 
systems O 
, O 
adsorption O 
and O 
reaction O 
of O 
NO(2) B-FORMULA 
at O 
the O 
surface O 
may O 
contribute O 
to O 
the O 
formation O 
of O 
gas-phase O 
HONO B-FORMULA 
. O 

is O 
a O 
critical O 
regulator O 
of O 
glucose B-TRIVIAL 
homeostasis O 
; O 
however O 
, O 
mechanisms O 
regulating O 
glucagon O 
action O 
and O 
α-cell O 
function O 
and O 
number O 
are O 
incompletely O 
understood O 
. O 
To O 
elucidate O 
the O 
role O 
of O 
the O 
hepatic O 
glucagon O 
receptor O 
( O 
Gcgr O 
) O 
in O 
glucagon O 
action O 
, O 
we O 
generated O 
mice O 
with O 
hepatocyte O 
- O 
specific O 
deletion O 
of O 
the O 
glucagon O 
receptor O 
. O 
Gcgr(Hep)(- O 
/ O 
- O 
) O 
mice O 
exhibited O 
reductions O 
in O 
fasting O 
blood O 
glucose B-TRIVIAL 
and O 
improvements O 
in O 
insulin O 
sensitivity O 
and O 
glucose B-TRIVIAL 
tolerance O 
compared O 
with O 
wild O 
- O 
type O 
controls O 
, O 
similar O 
in O 
magnitude O 
to O 
changes O 
observed O 
in O 
Gcgr(- O 
/ O 
- O 
) O 
mice O 
. O 
Despite O 
preservation O 
of O 
islet O 
Gcgr O 
signaling O 
, O 
Gcgr(Hep)(- O 
/ O 
- O 
) O 
mice O 
developed O 
hyperglucagonemia O 
and O 
α-cell O 
hyperplasia O 
. O 
To O 
investigate O 
mechanisms O 
by O 
which O 
signaling O 
through O 
the O 
Gcgr O 
regulates O 
α-cell O 
mass O 
, O 
wild O 
- O 
type O 
islets O 
were O 
transplanted O 
into O 
Gcgr(- O 
/ O 
- O 
) O 
or O 
Gcgr(Hep)(- O 
/ O 
- O 
) O 
mice O 
. O 
Wild O 
- O 
type O 
islets O 
beneath O 
the O 
renal O 
capsule O 
of O 
Gcgr(- O 
/ O 
- O 
) O 
or O 
Gcgr(Hep)(- O 
/ O 
- O 
) O 
mice O 
exhibited O 
an O 
increased O 
rate O 
of O 
α-cell O 
proliferation O 
and O 
expansion O 
of O 
α-cell O 
area O 
, O 
consistent O 
with O 
changes O 
exhibited O 
by O 
endogenous O 
α-cells O 
in O 
Gcgr(- O 
/ O 
- O 
) O 
and O 
Gcgr(Hep)(- O 
/ O 
- O 
) O 
pancreata O 
. O 
These O 
results O 
suggest O 
that O 
a O 
circulating O 
factor O 
generated O 
after O 
disruption O 
of O 
hepatic O 
Gcgr O 
signaling O 
can O 
increase O 
α-cell O 
proliferation O 
independent O 
of O 
direct O 
pancreatic O 
input O 
. O 
Identification O 
of O 
novel O 
factors O 
regulating O 
α-cell O 
proliferation O 
and O 
mass O 
may O 
facilitate O 
the O 
generation O 
and O 
expansion O 
of O 
α-cells O 
for O 
transdifferentiation O 
into O 
β-cells O 
and O 
the O 
treatment O 
of O 
diabetes O 
. O 

investigated O 
whether O 
HLA-A*24 O 
typing O 
complements O 
screening O 
for O 
HLA-DQ O 
and O 
for O 
antibodies O 
( O 
Abs O 
) O 
against O 
insulin O 
, O 
GAD O 
, O 
IA-2 O 
( O 
IA-2A O 
) O 
, O 
and O 
zinc B-SYSTEMATIC 
transporter-8 O 
( O 
ZnT8A O 
) O 
for O 
prediction O 
of O 
rapid O 
progression O 
to O 
type O 
1 O 
diabetes O 
( O 
T1D O 
) O 
. O 
Persistently O 
Ab(+) O 
siblings O 
/ O 
offspring O 
( O 
n O 
= O 
288 O 
; O 
aged O 
0-39 O 
years O 
) O 
of O 
T1D O 
patients O 
were O 
genotyped O 
for O 
HLA-DQA1-DQB1 O 
and O 
HLA-A*24 O 
and O 
monitored O 
for O 
development O 
of O 
diabetes O 
within O 
5 O 
years O 
of O 
first O 
Ab(+) O 
. O 
HLA-A*24 O 
( O 
P O 
= O 
0.009 O 
) O 
, O 
HLA-DQ2 O 
/ O 
DQ8 O 
( O 
P O 
= O 
0.001 O 
) O 
, O 
and O 
positivity O 
for O 
IA-2A O 
± O 
ZnT8A O 
( O 
P O 
< O 
0.001 O 
) O 
were O 
associated O 
with O 
development O 
of O 
T1D O 
in O 
multivariate O 
analysis O 
. O 
The O 
5-year O 
risk O 
increased O 
with O 
the O 
number O 
of O 
the O 
above O 
three O 
markers O 
present O 
( O 
n O 
= O 
0 O 
: O 
6% O 
; O 
n O 
= O 
1 O 
: O 
18% O 
; O 
n O 
= O 
2 O 
: O 
46% O 
; O 
n O 
= O 
3 O 
: O 
100% O 
) O 
. O 
Positivity O 
for O 
one O 
or O 
more O 
markers O 
identified O 
a O 
subgroup O 
of O 
171 O 
( O 
59% O 
) O 
containing O 
88% O 
of O 
rapid O 
progressors O 
. O 
The O 
combined O 
presence O 
of O 
HLA-A*24 O 
and O 
IA-2A(+) O 
± O 
ZnT8A(+) O 
defined O 
a O 
subgroup O 
of O 
18 O 
( O 
6% O 
) O 
with O 
an O 
82% O 
diabetes O 
risk O 
. O 
Among O 
IA-2A(+) O 
± O 
ZnT8A(+) O 
relatives O 
, O 
identification O 
of O 
HLA-A*24 O 
carriers O 
in O 
addition O 
to O 
HLA-DQ2 O 
/ O 
DQ8 O 
carriers O 
increased O 
screening O 
sensitivity O 
for O 
relatives O 
at O 
high O 
Ab- O 
and O 
HLA-inferred O 
risk O 
( O 
64% O 
progression O 
; O 
P O 
= O 
0.002 O 
) O 
. O 
In O 
conclusion O 
, O 
HLA-A*24 O 
independently O 
predicts O 
rapid O 
progression O 
to O 
T1D O 
in O 
Ab(+) O 
relatives O 
and O 
complements O 
IA-2A O 
, O 
ZnT8A O 
, O 
and O 
HLA-DQ2 O 
/ O 
DQ8 O 
for O 
identifying O 
participants O 
in O 
immunointervention O 
trials O 
. O 

of O 
the O 
structural O 
characteristics O 
of O 
Cu(2+) B-FORMULA 
-bound O 
and O 
unbound O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
obtained O 
in O 
simulations O 
using O 
different O 
force O 
fields O 
. O 

effects O 
of O 
Cu(2+) B-FORMULA 
binding O 
and O 
the O 
utilization O 
of O 
different O 
force O 
fields O 
when O 
modeling O 
the O 
structural O 
characteristics O 
of O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
were O 
investigated O 
. O 
To O 
this O 
end O 
, O 
we O 
performed O 
extensive O 
temperature O 
replica O 
exchange O 
molecular O 
dynamics O 
( O 
T-REMD O 
) O 
simulations O 
on O 
Cu(2+) B-FORMULA 
-bound O 
and O 
unbound O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
using O 
the O 
GROMOS O 
43A1 O 
, O 
OPLS-AA O 
, O 
and O 
AMBER03 O 
force O 
fields O 
. O 
Each O 
replica O 
was O 
run O 
for O 
300 O 
ns O 
. O 
The O 
structural O 
characteristics O 
of O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
were O 
studied O 
based O 
on O 
backbone O 
dihedral O 
angle O 
distributions O 
, O 
free O 
- O 
energy O 
surfaces O 
obtained O 
with O 
different O 
reaction O 
coordinates O 
, O 
favored O 
conformations O 
, O 
the O 
formation O 
of O 
different O 
Turn O 
structures O 
, O 
and O 
the O 
solvent O 
exposure O 
of O 
the O 
hydrophobic O 
residues O 
. O 
The O 
findings O 
show O 
that O 
AMBER03 O 
prefers O 
to O 
sample O 
helical O 
structures O 
for O 
the O 
unbound O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
and O 
does O 
not O 
sample O 
any O 
β-hairpin O 
structure O 
for O 
the O 
Cu(2+) B-FORMULA 
-bound O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
. O 
In O 
contrast O 
, O 
the O 
central O 
structure O 
of O 
the O 
major O 
conformational O 
clusters O 
for O 
the O 
Cu(2+) B-FORMULA 
-bound O 
and O 
unbound O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
according O 
to O 
simulations O 
performed O 
using O 
the O 
GROMOS O 
43A1 O 
and O 
OPLS-AA O 
force O 
fields O 
is O 
a O 
β-hairpin O 
with O 
Turn(9-6) O 
. O 
Cu(2+) B-FORMULA 
can O 
also O 
promote O 
the O 
formation O 
of O 
the O 
β-hairpin O 
and O 
increase O 
the O 
solvent O 
exposure O 
of O 
hydrophobic O 
residues O 
, O 
which O 
promotes O 
the O 
aggregation O 
of O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
. O 
This O 
study O 
can O 
help O 
us O 
to O 
understand O 
the O 
mechanisms O 
through O 
which O 
Cu(2+) B-FORMULA 
participates O 
in O 
the O 
fibrillation O 
of O 
α-syn12 B-TRIVIAL 
peptide I-TRIVIAL 
at O 
the O 
atomic O 
level O 
, O 
which O 
in O 
turn O 
represents O 
a O 
step O 
towards O 
elucidating O 
the O 
nosogenesis O 
of O 
Parkinson's O 
disease O 
. O 

have O 
previously O 
identified O 
allosteric O 
modulators O 
of O 
the O 
cannabinoid O 
CB(1) O 
receptor O 
( O 
Org B-IDENTIFIER 
27569 I-IDENTIFIER 
, O 
PSNCBAM-1 B-IDENTIFIER 
) O 
that O 
display O 
a O 
contradictory O 
pharmacological O 
profile O 
: O 
increasing O 
the O 
specific O 
binding O 
of O 
the O 
CB(1) O 
receptor O 
agonist O 
[(3)H]CP55940 B-IDENTIFIER 
but O 
producing O 
a O 
decrease O 
in O 
CB(1) O 
receptor O 
agonist O 
efficacy O 
. O 
Here O 
we O 
investigated O 
the O 
effect O 
one O 
or O 
both O 
compounds O 
in O 
a O 
broad O 
range O 
of O 
signaling O 
endpoints O 
linked O 
to O 
CB(1) O 
receptor O 
activation O 
. O 
We O 
assessed O 
the O 
effect O 
of O 
these O 
compounds O 
on O 
CB(1) O 
receptor O 
agonist O 
- O 
induced O 
[(35)S]GTPγS B-SYSTEMATIC 
binding O 
, O 
inhibition O 
, O 
and O 
stimulation O 
of O 
forskolin B-TRIVIAL 
-stimulated O 
cAMP B-ABBREVIATION 
production O 
, O 
phosphorylation O 
of O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
( O 
ERK O 
) O 
, O 
and O 
β-arrestin O 
recruitment O 
. O 
We O 
also O 
investigated O 
the O 
effect O 
of O 
these O 
allosteric O 
modulators O 
on O 
CB(1) O 
agonist O 
binding O 
kinetics O 
. O 
Both O 
compounds O 
display O 
ligand O 
dependence O 
, O 
being O 
significantly O 
more O 
potent O 
as O 
modulators O 
of O 
CP55940 B-IDENTIFIER 
signaling O 
as O 
compared O 
with O 
WIN55212 B-IDENTIFIER 
and O 
having O 
little O 
effect O 
on O 
[(3)H]WIN55212 B-IDENTIFIER 
binding O 
. O 
Org B-IDENTIFIER 
27569 I-IDENTIFIER 
displays O 
biased O 
antagonism O 
whereby O 
it O 
inhibits O 
: O 
agonist O 
- O 
induced O 
guanosine B-SYSTEMATIC 
5'-O-(3-[(35)S]thio)triphosphate I-SYSTEMATIC 
( O 
[(35)S]GTPγS B-SYSTEMATIC 
) O 
binding O 
, O 
simulation O 
( O 
Gα(s) O 
- O 
mediated O 
) O 
, O 
and O 
inhibition O 
( O 
Gα O 
(i) O 
- O 
mediated O 
) O 
of O 
cAMP B-ABBREVIATION 
production O 
and O 
β-arrestin O 
recruitment O 
. O 
In O 
contrast O 
, O 
it O 
acts O 
as O 
an O 
enhancer O 
of O 
agonist O 
- O 
induced O 
ERK O 
phosphorylation O 
. O 
Alone O 
, O 
the O 
compound O 
can O 
act O 
also O 
as O 
an O 
allosteric O 
agonist O 
, O 
increasing O 
cAMP B-ABBREVIATION 
production O 
and O 
ERK O 
phosphorylation O 
. O 
We O 
find O 
that O 
in O 
both O 
saturation O 
and O 
kinetic O 
- O 
binding O 
experiments O 
, O 
the O 
Org B-IDENTIFIER 
27569 I-IDENTIFIER 
and O 
PSNCBAM-1 B-IDENTIFIER 
appeared O 
to O 
influence O 
only O 
orthosteric O 
ligand O 
maximum O 
occupancy O 
rather O 
than O 
affinity O 
. O 
The O 
data O 
indicate O 
that O 
the O 
allosteric O 
modulators O 
share O 
a O 
common O 
mechanism O 
whereby O 
they O 
increase O 
available O 
high O 
- O 
affinity O 
CB(1) O 
agonist O 
binding O 
sites O 
. O 
The O 
receptor O 
conformation O 
stabilized O 
by O 
the O 
allosterics O 
appears O 
to O 
induce O 
signaling O 
and O 
also O 
selectively O 
traffics O 
orthosteric O 
agonist O 
signaling O 
via O 
the O 
ERK O 
phosphorylation O 
pathway O 
. O 

is O 
a O 
gastrointestinal O 
peptide O 
hormone O 
that O 
is O 
present O 
in O 
blood O 
mostly O 
in O 
a O 
non-posttranslationally O 
modified O 
form O 
, O 
with O 
a O 
minor O 
proportion O 
acylated O 
at O 
Ser B-FORMULA 
( O 
3 O 
) O 
. O 
Both O 
ghrelin O 
forms O 
were O 
initially O 
assigned O 
a O 
role O 
in O 
the O 
control O 
of O 
food O 
intake O 
but O 
there O 
is O 
accumulating O 
evidence O 
for O 
their O 
involvement O 
in O 
fat O 
allocation O 
and O 
utilization O 
. O 
We O 
investigated O 
changes O 
in O 
the O 
ghrelin O 
system O 
in O 
dairy O 
cows O 
, O 
exhibiting O 
differences O 
in O 
body O 
fat O 
mobilization O 
and O 
fatty O 
liver O 
, O 
from O 
late O 
pregnancy O 
to O 
early O 
lactation O 
. O 
Sixteen O 
dairy O 
cows O 
underwent O 
liver O 
biopsy O 
and O 
were O 
retrospectively O 
grouped O 
based O 
on O 
high O 
( O 
H O 
) O 
or O 
low O 
( O 
L O 
) O 
liver O 
fat O 
content O 
post O 
- O 
partum O 
. O 
Both O 
groups O 
had O 
a O 
comparable O 
feed O 
intake O 
in O 
week O 
-6 O 
( O 
before O 
parturition O 
) O 
and O 
week O 
2 O 
( O 
after O 
parturition O 
) O 
. O 
Only O 
before O 
parturition O 
was O 
preprandial O 
total O 
ghrelin O 
concentration O 
higher O 
in O 
L O 
than O 
in O 
H O 
cows O 
and O 
only O 
after O 
parturition O 
was O 
the O 
basal O 
plasma O 
concentration O 
of O 
non-esterified O 
fatty B-FAMILY 
acids I-FAMILY 
higher O 
in O 
H O 
than O 
in O 
L O 
cows O 
. O 
Both O 
before O 
and O 
after O 
parturition O 
, O 
H O 
cows O 
had O 
higher O 
preprandial O 
plasma O 
concentrations O 
of O 
acyl B-FAMILY 
ghrelin O 
, O 
a O 
higher O 
acyl B-FAMILY 
: O 
total O 
ghrelin O 
ratio O 
, O 
lower O 
plasma O 
triacylglyceride B-FAMILY 
concentrations O 
and O 
a O 
lower O 
respiratory O 
quotient O 
compared O 
with O 
L O 
cows O 
. O 
These O 
group O 
differences O 
could O 
not O 
be O 
attributed O 
to O 
an O 
allelic O 
variant O 
of O 
the O 
acyl B-FAMILY 
ghrelin O 
receptor O 
. O 
Rather O 
, O 
the O 
ratio O 
of O 
acyl B-FAMILY 
: O 
total O 
ghrelin O 
correlated O 
with O 
several O 
aspects O 
of O 
fat O 
metabolism O 
and O 
with O 
respiratory O 
quotient O 
but O 
not O 
with O 
feed O 
intake O 
. O 
These O 
results O 
show O 
that O 
endogenous O 
ghrelin O 
forms O 
are O 
associated O 
with O 
fat O 
allocation O 
, O 
fatty O 
liver O 
, O 
and O 
utilization O 
of O 
fat O 
during O 
the O 
periparturient O 
period O 
. O 

D3 I-SYSTEMATIC 
upregulates O 
leptin O 
expression O 
in O 
mouse O 
adipose O 
tissue O 
. O 

is O 
an O 
adipose O 
tissue O 
- O 
derived O 
hormone O 
that O 
plays O 
a O 
critical O 
role O 
in O 
energy O 
homeostasis O 
. O 
Vitamin B-FAMILY 
D I-FAMILY 
has O 
been O 
shown O 
to O 
regulate O 
energy O 
metabolism O 
, O 
but O 
the O 
relationship O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
and O 
leptin O 
is O 
unclear O 
. O 
Leptin O 
expression O 
and O 
secretion O 
was O 
reduced O 
in O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
(VDR)-null O 
mice O 
and O 
increased O 
in O 
transgenic O 
( O 
Tg O 
) O 
mice O 
overexpressing O 
the O 
VDR O 
in O 
adipocytes O 
; O 
however O 
, O 
as O 
leptin O 
is O 
mainly O 
determined O 
by O 
fat O 
mass O 
, O 
it O 
is O 
unclear O 
whether O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
hormone O 
directly O 
regulates O 
leptin O 
expression O 
. O 
To O 
address O 
this O 
question O 
, O 
we O 
determined O 
the O 
effect O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
on O 
leptin O 
expression O 
in O 
vivo O 
and O 
ex O 
vivo O 
. O 
One O 
- O 
week O 
treatment O 
of O 
WT O 
mice O 
with O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
analog O 
RO-27-5646 B-IDENTIFIER 
led O 
to O 
a O 
significant O 
increase O 
in O 
adipose O 
leptin O 
mRNA O 
transcript O 
and O 
serum O 
leptin O 
levels O 
. O 
Moreover O 
, O 
in O 
adipose O 
tissue O 
cultures O 
, O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
markedly O 
stimulated O 
mRNA O 
expression O 
and O 
secretion O 
of O 
leptin O 
, O 
but O 
not O 
resistin O 
, O 
in O 
adipose O 
tissues O 
obtained O 
from O 
WT O 
mice O 
, O 
but O 
not O 
from O 
VDR-null O 
mice O 
, O 
and O 
leptin O 
upregulation O 
induced O 
by O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
was O 
more O 
robust O 
in O 
adipose O 
tissues O 
obtained O 
from O 
VDR O 
Tg O 
mice O 
compared O 
with O 
WT O 
mice O 
. O 
These O 
data O 
demonstrate O 
that O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
stimulates O 
adipose O 
leptin O 
production O 
in O 
a O 
VDR-dependent O 
manner O 
, O 
suggesting O 
that O 
vitamin B-FAMILY 
D I-FAMILY 
may O 
affect O 
energy O 
homeostasis O 
through O 
direct O 
regulation O 
of O 
leptin O 
expression O 
. O 

decreases O 
injury O 
and O 
improves O 
regeneration O 
of O 
ethanol B-SYSTEMATIC 
-induced O 
steatotic O 
partial O 
liver O 
grafts O 
. O 

grafts O 
are O 
excluded O 
for O 
use O 
in O 
partial O 
liver O 
transplantation O 
( O 
LT O 
) O 
because O 
of O 
the O 
increased O 
risk O 
of O 
primary O 
nonfunction O 
. O 
This O 
study O 
investigated O 
the O 
effects O 
of O 
suramin B-TRIVIAL 
, O 
a O 
polysulfonated B-FAMILY 
naphthylurea I-FAMILY 
, O 
on O 
the O 
outcome O 
of O 
steatotic O 
partial O 
LT O 
. O 
Rat O 
livers O 
were O 
harvested O 
after O 
acute O 
ethanol B-SYSTEMATIC 
treatment O 
( O 
6 O 
g O 
/ O 
kg O 
, O 
intragastric O 
administration O 
) O 
, O 
reduced O 
in O 
size O 
to O 
≈ O 
1 O 
/ O 
3 O 
, O 
and O 
transplanted O 
. O 
Serum O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
and O 
total O 
bilirubin B-TRIVIAL 
levels O 
as O 
well O 
as O 
hepatic O 
necrosis O 
and O 
apoptosis O 
were O 
significantly O 
higher O 
after O 
transplantation O 
of O 
fatty O 
partial O 
grafts O 
( O 
FPG O 
) O 
than O 
lean O 
partial O 
grafts O 
( O 
LPG O 
) O 
. O 
Suramin B-TRIVIAL 
( O 
5 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
decreased O 
ALT O 
by O 
≈ O 
60% O 
, O 
hyperbilirubinemia O 
by O 
75% O 
, O 
necrosis O 
by O 
83% O 
, O 
and O 
apoptosis O 
by O 
70% O 
after O 
FPG O 
transplantation O 
. O 
Hepatic O 
cellular O 
5-bromo-2'-deoxyuridine B-SYSTEMATIC 
( O 
BrdU B-ABBREVIATION 
) O 
incorporation O 
increased O 
to O 
28% O 
in O 
LPG O 
but O 
was O 
only O 
2% O 
in O 
FPG O 
at O 
48 O 
hours O 
, O 
and O 
the O 
mitotic O 
index O 
increased O 
to O 
7% O 
in O 
LPG O 
but O 
was O 
only O 
0.2% O 
in O 
FPG O 
, O 
indicating O 
suppressed O 
regeneration O 
in O 
FPG O 
. O 
Suramin B-TRIVIAL 
increased O 
BrdU B-ABBREVIATION 
incorporation O 
and O 
the O 
mitotic O 
index O 
to O 
43% O 
and O 
9% O 
, O 
respectively O 
, O 
in O 
FPG O 
. O 
All O 
FPG O 
recipients O 
died O 
within O 
5 O 
days O 
. O 
Suramin B-TRIVIAL 
recovered O 
survival O 
of O 
FPG O 
to O 
62% O 
. O 
Tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
mRNA O 
was O 
2.2-fold O 
higher O 
in O 
FPG O 
than O 
in O 
LPG O 
and O 
was O 
associated O 
with O 
activation O 
of O 
caspase-8 O 
and O 
caspase-3 O 
in O 
FPG O 
. O 
Suramin B-TRIVIAL 
decreased O 
TNF-α O 
and O 
caspase O 
activation O 
in O 
FPG O 
. O 
Transforming O 
growth O 
factor-β O 
( O 
TGF-β O 
) O 
, O 
phospho B-SYSTEMATIC 
-Smad2 O 
/ O 
3 O 
and O 
p21Cip1 O 
were O 
significantly O 
higher O 
in O 
FPG O 
than O 
in O 
LPG O 
and O 
suramin B-TRIVIAL 
blocked O 
TGF-β O 
formation O 
and O 
its O 
down O 
- O 
stream O 
signaling O 
pathway O 
. O 
Taken O 
together O 
, O 
suramin B-TRIVIAL 
improves O 
the O 
outcome O 
of O 
FPG O 
transplantation O 
, O 
most O 
likely O 
by O 
inhibition O 
of O 
TNF-α O 
and O 
TGF-β O 
formation O 
. O 

I O 
inhibitor O 
evodiamine B-TRIVIAL 
acts O 
as O 
an O 
antibacterial O 
agent O 
against O 
drug O 
- O 
resistant O 
Klebsiella O 
pneumoniae O 
. O 

inhibitors O 
have O 
been O 
developed O 
in O 
a O 
variety O 
of O 
clinical O 
applications O 
. O 
We O 
investigated O 
the O 
inhibitory O 
effect O 
of O 
evodiamine B-TRIVIAL 
on O 
E O 
. O 
coli O 
topoisomerase O 
I O 
, O 
which O 
may O 
lead O 
to O 
an O 
anti-bacterial O 
effect O 
. O 
Evodiamine B-TRIVIAL 
inhibits O 
the O 
supercoiled O 
plasmid O 
DNA O 
relaxation O 
that O 
is O 
catalyzed O 
by O 
E O 
. O 
coli O 
topoisomerase O 
I O 
, O 
and O 
computer O 
- O 
aided O 
docking O 
has O 
shown O 
that O 
the O 
Arg B-FORMULA 
161 O 
and O 
Asp B-FORMULA 
551 O 
residues O 
of O 
topoisomerase O 
I O 
interact O 
with O 
evodiamine B-TRIVIAL 
. O 
We O 
investigated O 
the O 
bactericidal O 
effect O 
of O 
evodiamine B-TRIVIAL 
against O 
multidrug O 
- O 
resistant O 
Klebsiella O 
pneumoniae O 
. O 
Evodiamine B-TRIVIAL 
showed O 
a O 
significantly O 
lower O 
minimal O 
inhibitory O 
concentration O 
value O 
( O 
MIC O 
128 O 
µg O 
/ O 
mL O 
) O 
compared O 
with O 
antibiotics O 
( O 
> O 
512 O 
µg O 
/ O 
mL O 
) O 
against O 
the O 
clinical O 
isolate O 
of O 
K O 
. O 
pneumoniae O 
. O 
The O 
results O 
suggested O 
that O 
evodiamine B-TRIVIAL 
is O 
a O 
potential O 
agent O 
against O 
drug O 
- O 
resistant O 
bacteria O 
. O 

increased O 
ionic O 
strength O 
has O 
caused O 
deleterious O 
ecological O 
changes O 
in O 
freshwater O 
streams O 
, O 
thresholds O 
for O 
effects O 
are O 
needed O 
to O 
inform O 
resource O 
- O 
management O 
decisions O 
. O 
In O 
particular O 
, O 
effluents O 
from O 
surface O 
coal B-TRIVIAL 
mining O 
raise O 
the O 
ionic O 
strength O 
of O 
receiving O 
streams O 
. O 
The O 
authors O 
developed O 
an O 
aquatic O 
life O 
benchmark O 
for O 
specific O 
conductance O 
as O 
a O 
measure O 
of O 
ionic O 
strength O 
that O 
is O 
expected O 
to O 
prevent O 
the O 
local O 
extirpation O 
of O 
95% O 
of O 
species O 
from O 
neutral O 
to O 
alkaline O 
waters O 
containing O 
a O 
mixture O 
of O 
dissolved O 
ions O 
in O 
which O 
the O 
mass O 
of O 
SO B-FORMULA 
(4)2- I-FORMULA 
+ O 
HCO B-FORMULA 
(3)- I-FORMULA 
≥ O 
Cl(-) B-FORMULA 
. O 
Extirpation O 
concentrations O 
of O 
specific O 
conductance O 
were O 
estimated O 
from O 
the O 
presence O 
and O 
absence O 
of O 
benthic O 
invertebrate O 
genera O 
from O 
2210 O 
stream O 
samples O 
in O 
West O 
Virginia O 
. O 
The O 
extirpation O 
concentration O 
is O 
the O 
95th O 
percentile O 
of O 
the O 
distribution O 
of O 
the O 
probability O 
of O 
occurrence O 
of O 
a O 
genus O 
with O 
respect O 
to O 
specific O 
conductance O 
. O 
In O 
a O 
region O 
with O 
a O 
background O 
of O 
116 O 
µS O 
/ O 
cm O 
, O 
the O 
5th O 
percentile O 
of O 
the O 
species O 
sensitivity O 
distribution O 
of O 
extirpation O 
concentrations O 
for O 
163 O 
genera O 
is O 
300 O 
µS O 
/ O 
cm O 
. O 
Because O 
the O 
benchmark O 
is O 
not O 
protective O 
of O 
all O 
genera O 
and O 
protects O 
against O 
extirpation O 
rather O 
than O 
reduction O 
in O 
abundance O 
, O 
this O 
level O 
may O 
not O 
fully O 
protect O 
sensitive O 
species O 
or O 
higher O 
- O 
quality O 
, O 
exceptional O 
waters O 
. O 

- O 
response O 
element O 
(HRE)-directed O 
transcriptional O 
regulation O 
of O 
the O 
rat O 
lysyl B-TRIVIAL 
oxidase O 
gene O 
in O 
response O 
to O 
cobalt B-SYSTEMATIC 
and O 
cadmium B-SYSTEMATIC 
. O 

oxidase O 
( O 
LO O 
) O 
catalyzes O 
crosslink O 
of O 
collagen O 
, O 
elastin O 
, O 
and O 
histone O 
H1 O 
, O 
stabilizing O 
the O 
extracellular O 
matrix O 
and O 
cell O 
nucleus O 
. O 
This O 
enzyme O 
displays O 
dual O 
functions O 
for O 
tumorigenesis O 
, O 
i.e O 
. O 
, O 
as O 
a O 
tumor O 
suppressor O 
inactivating O 
the O 
ras O 
oncogene O 
and O 
as O 
a O 
tumor O 
promoter O 
enhancing O 
malignant O 
cell O 
metastasis O 
. O 
To O 
elucidate O 
LO O 
transcriptional O 
regulation O 
, O 
we O 
have O 
cloned O 
the O 
804 O 
base O 
pair O 
region O 
upstream O 
of O 
the O 
translation O 
start O 
site O 
( O 
ATG O 
) O 
of O 
the O 
rat O 
LO O 
gene O 
with O 
the O 
maximal O 
promoter O 
activity O 
. O 
Computer O 
analysis O 
indicated O 
that O 
at O 
least O 
four O 
hypoxia O 
- O 
response O 
element O 
( O 
HRE O 
) O 
consensuses O 
( O 
5'-ACGTG-3 O 
' O 
) O 
exist O 
in O 
the O 
cloned O 
LO O 
promoter O 
. O 
Treatment O 
of O 
rat O 
lung O 
fibroblasts O 
( O 
RFL6 O 
) O 
with O 
CoCl2 B-FORMULA 
( O 
Co B-FORMULA 
, O 
10-100 O 
μM O 
) O 
, O 
a O 
chemical O 
hypoxia O 
reagent O 
, O 
enhanced O 
LO O 
mRNA O 
expression O 
and O 
promoter O 
activities O 
. O 
Overexpression O 
of O 
LO O 
was O 
associated O 
with O 
upregulation O 
of O 
hypoxia O 
- O 
inducible O 
factor O 
(HIF)-1α O 
at O 
mRNA O 
levels O 
in O 
cobalt B-SYSTEMATIC 
( O 
Co B-FORMULA 
) O 
- O 
treated O 
cells O 
. O 
Thus O 
, O 
LO O 
is O 
a O 
hypoxia O 
- O 
responsive O 
gene O 
. O 
Dominant O 
negative-HIF-1α O 
inhibited O 
LO O 
promoter O 
activities O 
stimulated O 
by O 
Co B-FORMULA 
. O 
Electrophoretic O 
mobility O 
shift O 
, O 
oligonucleotide O 
competition O 
, O 
and O 
in O 
vitro O 
translated O 
HIF-1α O 
binding O 
assays O 
indicated O 
that O 
only O 
one O 
HRE O 
mapped O 
at O 
-387 O 
/ O 
-383 O 
relative O 
to O 
ATG O 
was O 
functionally O 
active O 
among O 
four O 
consensuses O 
. O 
Site O 
- O 
directed O 
mutation O 
of O 
this O 
HRE O 
significantly O 
diminished O 
the O 
Co B-FORMULA 
-induced O 
and O 
LO O 
promoter O 
- O 
directed O 
expression O 
of O 
the O 
reporter O 
gene O 
. O 
Cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
, O 
an O 
inducer O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
inhibited O 
HIF-1α O 
mRNA O 
expression O 
and O 
HIF-1α O 
binding O 
to O 
the O 
LO O 
gene O 
in O 
Co B-FORMULA 
-treated O 
cells O 
as O 
revealed O 
by O 
RT-PCR O 
and O 
ChIP O 
assays O 
, O 
respectively O 
. O 
Thus O 
, O 
modulation O 
of O 
the O 
HRE O 
activity O 
by O 
Co B-FORMULA 
and O 
Cd B-FORMULA 
plays O 
a O 
critical O 
role O 
in O 
LO O 
gene O 
transactivation O 
. O 

of O 
differentially O 
expressed O 
subnetworks O 
from O 
protein O 
- O 
protein O 
interaction O 
( O 
PPI O 
) O 
networks O 
has O 
become O 
increasingly O 
important O 
to O 
our O 
global O 
understanding O 
of O 
the O 
molecular O 
mechanisms O 
that O 
drive O 
cancer O 
. O 
Several O 
methods O 
have O 
been O 
proposed O 
for O 
PPI O 
subnetwork O 
identification O 
, O 
but O 
the O 
dependency O 
among O 
network O 
member O 
genes O 
is O 
not O 
explicitly O 
considered O 
, O 
leaving O 
many O 
important O 
hub O 
genes O 
largely O 
unidentified O 
. O 
We O 
present O 
a O 
new O 
method O 
, O 
based O 
on O 
a O 
bagging O 
Markov O 
random O 
field O 
( O 
BMRF O 
) O 
framework O 
, O 
to O 
improve O 
subnetwork O 
identification O 
for O 
mechanistic O 
studies O 
of O 
breast O 
cancer O 
. O 
The O 
method O 
follows O 
a O 
maximum O 
a O 
posteriori O 
principle O 
to O 
form O 
a O 
novel O 
network O 
score O 
that O 
explicitly O 
considers O 
pairwise O 
gene O 
interactions O 
in O 
PPI O 
networks O 
, O 
and O 
it O 
searches O 
for O 
subnetworks O 
with O 
maximal O 
network O 
scores O 
. O 
To O 
improve O 
their O 
robustness O 
across O 
data O 
sets O 
, O 
a O 
bagging O 
scheme O 
based O 
on O 
bootstrapping O 
samples O 
is O 
implemented O 
to O 
statistically O 
select O 
high O 
confidence O 
subnetworks O 
. O 
We O 
first O 
compared O 
the O 
BMRF O 
- O 
based O 
method O 
with O 
existing O 
methods O 
on O 
simulation O 
data O 
to O 
demonstrate O 
its O 
improved O 
performance O 
. O 
We O 
then O 
applied O 
our O 
method O 
to O 
breast O 
cancer O 
data O 
to O 
identify O 
PPI O 
subnetworks O 
associated O 
with O 
breast O 
cancer O 
progression O 
and O 
/ O 
or O 
tamoxifen B-TRIVIAL 
resistance O 
. O 
The O 
experimental O 
results O 
show O 
that O 
not O 
only O 
an O 
improved O 
prediction O 
performance O 
can O 
be O 
achieved O 
by O 
the O 
BMRF O 
approach O 
when O 
tested O 
on O 
independent O 
data O 
sets O 
, O 
but O 
biologically O 
meaningful O 
subnetworks O 
can O 
also O 
be O 
revealed O 
that O 
are O 
relevant O 
to O 
breast O 
cancer O 
and O 
tamoxifen B-TRIVIAL 
resistance O 
. O 

G-quadruplex O 
ligands O 
database O 
( O 
G4LDB O 
, O 
http O 
: O 
/ O 
/ O 
www.g4ldb.org O 
) O 
provides O 
a O 
unique O 
collection O 
of O 
reported O 
G-quadruplex O 
ligands O 
to O 
streamline O 
ligand O 
/ O 
drug O 
discovery O 
targeting O 
G-quadruplexes O 
. O 
G-quadruplexes O 
are O 
guanine B-TRIVIAL 
-rich O 
nucleic B-FAMILY 
acid I-FAMILY 
sequences O 
in O 
human O 
telomeres O 
and O 
gene O 
promoter O 
regions O 
. O 
There O 
is O 
a O 
growing O 
recognition O 
for O 
their O 
profound O 
roles O 
in O 
a O 
wide O 
spectrum O 
of O 
diseases O 
, O 
such O 
as O 
cancer O 
, O 
diabetes O 
and O 
cardiovascular O 
disease O 
. O 
Ligands O 
that O 
affect O 
the O 
structure O 
and O 
activity O 
of O 
G-quadruplexes O 
can O 
shed O 
light O 
on O 
the O 
search O 
for O 
G-quadruplex O 
- O 
targeting O 
drugs O 
. O 
Therefore O 
, O 
we O 
built O 
the O 
G4LDB O 
to O 
(i) O 
compile O 
a O 
data O 
set O 
covering O 
various O 
physical O 
properties O 
and O 
3D O 
structure O 
of O 
G-quadruplex O 
ligands O 
; O 
(ii) O 
provide O 
Web O 
- O 
based O 
tools O 
for O 
G-quadruplex O 
ligand O 
design O 
; O 
and O 
(iii) O 
to O 
facilitate O 
the O 
discovery O 
of O 
novel O 
therapeutic O 
and O 
diagnostic O 
agents O 
targeting O 
G-quadruplexes O 
. O 
G4LDB O 
currently O 
contains O 
> O 
800 O 
G-quadruplex O 
ligands O 
with O 
∼4000 O 
activity O 
records O 
, O 
which O 
, O 
to O 
our O 
knowledge O 
, O 
is O 
the O 
most O 
extensive O 
collection O 
of O 
its O 
kind O 
. O 
It O 
offers O 
a O 
user O 
friendly O 
interface O 
that O 
can O 
meet O 
a O 
variety O 
of O 
data O 
inquiries O 
from O 
researchers O 
. O 
For O 
example O 
, O 
ligands O 
can O 
be O 
searched O 
for O 
by O 
name O 
, O 
molecular O 
properties O 
, O 
structures O 
, O 
ligand O 
activities O 
and O 
so O 
on O 
. O 
Building O 
on O 
the O 
reported O 
data O 
, O 
the O 
database O 
also O 
provides O 
an O 
online O 
ligand O 
design O 
module O 
that O 
can O 
predict O 
ligand O 
binding O 
affinity O 
in O 
real O 
time O 
. O 

discrimination O 
of O 
isoxazoline B-SYSTEMATIC 
fused O 
β-amino B-FAMILY 
acid I-FAMILY 
derivatives O 
using O 
(18-crown-6)-2,3,11,12-tetracarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
chiral O 
NMR O 
solvating O 
agent O 
. O 

acid I-SYSTEMATIC 
is O 
a O 
useful O 
chiral O 
NMR O 
solvating O 
agent O 
for O 
isoxazoline B-SYSTEMATIC 
-fused O 
β-amino B-FAMILY 
acid I-FAMILY 
derivatives O 
. O 
Isoxazoline B-FAMILY 
substrates O 
are O 
analyzed O 
as O 
their O 
hydrochloride B-FAMILY 
salts O 
in O 
methanol B-SYSTEMATIC 
-d(4) O 
. O 
The O 
crown O 
ether O 
and O 
substrate O 
associate O 
through O 
the O 
formation O 
of O 
three O 
hydrogen B-SYSTEMATIC 
bonds O 
between O 
the O 
protonated O 
amine B-SYSTEMATIC 
and O 
crown B-FAMILY 
ether I-FAMILY 
oxygen B-SYSTEMATIC 
atoms O 
. O 
Enantiomeric O 
discrimination O 
is O 
observed O 
for O 
two O 
or O 
more O 
resonances O 
of O 
every O 
substrate O 
. O 
At O 
least O 
one O 
of O 
these O 
resonances O 
is O 
free O 
of O 
overlap O 
with O 
other O 
resonances O 
in O 
the O 
spectrum O 
and O 
has O 
large O 
enough O 
enantiomeric O 
discrimination O 
to O 
enable O 
the O 
determination O 
of O 
enantiomeric O 
purity O 
. O 
2D O 
COSY O 
methods O 
can O 
be O 
used O 
to O 
identify O 
additional O 
resonances O 
that O 
exhibit O 
enantiomeric O 
discrimination O 
in O 
the O 
NMR O 
spectrum O 
. O 

homeostasis O 
and O 
oligomerization O 
of O 
the O 
amyloid-β O 
( O 
Aβ O 
) O 
peptide O 
in O 
the O 
brain O 
are O 
hallmarks O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
Microglia O 
and O 
macrophages O 
play O 
a O 
critical O 
role O 
in O 
the O 
etiology O 
of O 
AD O 
either O 
by O 
clearing O 
Aβ O 
from O 
the O 
brain O 
or O 
inducing O 
inflammation O 
. O 
Recent O 
evidence O 
suggests O 
that O 
clearance O 
of O 
Aβ O 
by O 
microglia O 
/ O 
macrophages O 
via O 
the O 
phagocytic O 
pathway O 
is O 
defective O 
in O 
AD O 
, O 
which O 
can O 
contribute O 
to O 
the O 
accumulation O 
of O 
Aβ O 
in O 
the O 
brain O 
. O 
We O 
have O 
recently O 
demonstrated O 
that O 
protein O 
microspheres O 
modified O 
at O 
their O 
surface O 
with O 
multiple O 
copies O 
of O 
an O 
Aβ-recognition O 
motif O 
can O 
strongly O 
bind O 
Aβ O 
, O 
inhibit O 
its O 
aggregation O 
, O 
and O 
directly O 
reduce O 
its O 
toxicity O 
by O 
sequestering O 
it O 
from O 
the O 
medium O 
. O 
Here O 
, O 
we O 
describe O 
how O 
microsphere O 
- O 
bound O 
Aβ O 
can O 
stimulate O 
microglial O 
cells O 
and O 
be O 
phagocytosed O 
through O 
a O 
mechanism O 
that O 
is O 
distinct O 
from O 
that O 
of O 
Aβ O 
removal O 
and O 
, O 
thus O 
, O 
contribute O 
to O 
the O 
clearance O 
of O 
Aβ O 
, O 
even O 
by O 
defective O 
microglial O 
cells O 
. O 
The O 
phagocytosis O 
was O 
most O 
effective O 
, O 
with O 
microspheres O 
having O 
a O 
diameter O 
of O 
< O 
1 O 
μm O 
. O 
The O 
introduction O 
of O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
to O 
the O 
surface O 
of O 
the O 
microspheres O 
changed O 
the O 
kinetics O 
of O 
the O 
phagocytosis O 
. O 
Moreover O 
, O 
while O 
aggregated O 
Aβ O 
induced O 
a O 
significant O 
inflammatory O 
response O 
that O 
was O 
manifested O 
by O 
the O 
release O 
of O 
TNF-α O 
, O 
the O 
microsphere O 
- O 
bound O 
Aβ O 
dramatically O 
reduced O 
the O 
amount O 
of O 
cytokine O 
released O 
from O 
microglial O 
cells O 
. O 

are O 
a O 
key O 
phylum O 
of O 
marine O 
protists O 
, O 
including O 
~300 O 
described O 
morphospecies O 
and O 
80 O 
morphogenera O 
. O 
We O 
used O 
454 O 
pyrosequencing O 
on O 
large O 
subunit O 
ribosomal O 
DNA O 
( O 
LSU O 
rDNA O 
) O 
fragments O 
to O 
assess O 
the O 
diversity O 
from O 
size O 
- O 
fractioned O 
plankton O 
samples O 
collected O 
in O 
the O 
Bay O 
of O 
Naples O 
. O 
One O 
group O 
- O 
specific O 
primer O 
set O 
targeting O 
the O 
LSU O 
rDNA O 
D1 O 
/ O 
D2 O 
region O 
was O 
designed O 
to O 
amplify O 
Haptophyte O 
sequences O 
from O 
nucleic O 
acid O 
extracts O 
( O 
total O 
DNA O 
or O 
RNA O 
) O 
of O 
two O 
size O 
fractions O 
( O 
0.8-3 O 
or O 
3-20 O 
μm O 
) O 
and O 
two O 
sampling O 
depths O 
[ O 
subsurface O 
, O 
at O 
1 O 
m O 
, O 
or O 
deep O 
chlorophyll B-FAMILY 
maximum O 
( O 
DCM O 
) O 
at O 
23 O 
m O 
] O 
. O 
454 O 
reads O 
were O 
identified O 
using O 
a O 
database O 
covering O 
the O 
entire O 
Haptophyta O 
diversity O 
currently O 
sequenced O 
. O 
Our O 
data O 
set O 
revealed O 
several O 
hundreds O 
of O 
Haptophyte O 
clusters O 
. O 
However O 
, O 
most O 
of O 
these O 
clusters O 
could O 
not O 
be O 
linked O 
to O 
taxonomically O 
known O 
sequences O 
: O 
considering O 
OTUs(97%) O 
( O 
clusters O 
build O 
at O 
a O 
sequence O 
identity O 
level O 
of O 
97% O 
) O 
on O 
our O 
global O 
data O 
set O 
, O 
less O 
than O 
1% O 
of O 
the O 
reads O 
clustered O 
with O 
sequences O 
from O 
cultures O 
, O 
and O 
less O 
than O 
12% O 
clustered O 
with O 
reference O 
sequences O 
obtained O 
previously O 
from O 
cloning O 
and O 
Sanger O 
sequencing O 
of O 
environmental O 
samples O 
. O 
Thus O 
, O 
we O 
highlighted O 
a O 
large O 
uncharacterized O 
environmental O 
genetic O 
diversity O 
, O 
which O 
clearly O 
shows O 
that O 
currently O 
cultivated O 
species O 
poorly O 
reflect O 
the O 
actual O 
diversity O 
present O 
in O 
the O 
natural O 
environment O 
. O 
Haptophyte O 
community O 
appeared O 
to O 
be O 
significantly O 
structured O 
according O 
to O 
the O 
depth O 
. O 
The O 
highest O 
diversity O 
and O 
evenness O 
were O 
obtained O 
in O 
samples O 
from O 
the O 
DCM O 
, O 
and O 
samples O 
from O 
the O 
large O 
size O 
fraction O 
( O 
3-20 O 
μm O 
) O 
taken O 
at O 
the O 
DCM O 
shared O 
a O 
lower O 
proportion O 
of O 
common O 
OTUs(97%) O 
with O 
the O 
other O 
samples O 
. O 
Reads O 
from O 
the O 
species O 
Chrysoculter O 
romboideus O 
were O 
notably O 
found O 
at O 
the O 
DCM O 
, O 
while O 
they O 
could O 
be O 
detected O 
at O 
the O 
subsurface O 
. O 
The O 
highest O 
proportion O 
of O 
totally O 
unknown O 
OTUs(97%) O 
was O 
collected O 
at O 
the O 
DCM O 
in O 
the O 
smallest O 
size O 
fraction O 
( O 
0.8-3 O 
μm O 
) O 
. O 
Overall O 
, O 
this O 
study O 
emphasized O 
several O 
technical O 
and O 
theoretical O 
barriers O 
inherent O 
to O 
the O 
exploration O 
of O 
the O 
large O 
and O 
largely O 
unknown O 
diversity O 
of O 
unicellular O 
eukaryotes O 
. O 

present O 
study O 
aimed O 
to O 
investigate O 
the O 
distribution O 
of O 
the O 
octadecaneuropeptide O 
( O 
ODN O 
) O 
in O 
the O 
goldfish O 
brain O 
and O 
to O 
look O 
for O 
a O 
possible O 
effect O 
of O 
ODN O 
on O 
somatolactin O 
( O 
SL O 
) O 
release O 
from O 
pituitary O 
cells O 
. O 
A O 
discrete O 
population O 
of O 
ODN-immunoreactive O 
neurones O 
was O 
localised O 
in O 
the O 
lateral O 
part O 
of O 
the O 
nucleus O 
lateralis O 
tuberis O 
. O 
These O 
neurones O 
sent O 
projections O 
through O 
the O 
neurohypophyseal O 
tract O 
towards O 
the O 
neurohypophysis O 
, O 
and O 
nerve O 
fibres O 
were O 
seen O 
in O 
the O 
close O 
vicinity O 
of O 
SL-producing O 
cells O 
in O 
the O 
pars O 
intermedia O 
. O 
Incubation O 
of O 
cultured O 
goldfish O 
pituitary O 
cells O 
with O 
graded O 
concentrations O 
of O 
ODN O 
( O 
10(-9) O 
-10(-5 O 
) O 
m O 
) O 
induced O 
a O 
dose O 
- O 
dependent O 
stimulation O 
of O 
SL-β O 
, O 
but O 
not O 
SL-α O 
, O 
release O 
. O 
ODN-evoked O 
SL O 
release O 
was O 
blocked O 
by O 
the O 
metabotrophic O 
endozepine O 
receptor O 
antagonist O 
cyclo(1-8) B-FORMULA 
[ I-FORMULA 
DLeu(5) I-FORMULA 
]OP I-FORMULA 
but O 
was O 
not O 
affected O 
by O 
the O 
central O 
- O 
type O 
benzodiazepine B-FAMILY 
receptor O 
antagonist O 
flumazenil B-TRIVIAL 
. O 
ODN-induced O 
SL O 
release O 
was O 
suppressed O 
by O 
treatment O 
with O 
the O 
phospholipase O 
C O 
( O 
PLC O 
) O 
inhibitor O 
U-73122 B-IDENTIFIER 
but O 
not O 
with O 
the O 
protein O 
kinase O 
A O 
( O 
PKA O 
) O 
inhibitor O 
H-89 B-TRIVIAL 
. O 
These O 
results O 
indicate O 
that O 
, O 
in O 
fish O 
, O 
ODN O 
produced O 
by O 
hypothalamic O 
neurones O 
acts O 
as O 
a O 
hypophysiotrophic O 
neuropeptide O 
stimulating O 
SL O 
release O 
. O 
The O 
effect O 
of O 
ODN O 
is O 
mediated O 
through O 
a O 
metabotrophic O 
endozepine O 
receptor O 
positively O 
coupled O 
to O 
the O 
PLC/ O 
inositol B-SYSTEMATIC 
1,4,5-trisphosphate I-SYSTEMATIC 
/ O 
protein O 
kinase O 
C-signalling O 
pathway O 
. O 

serotonin B-TRIVIAL 
receptor O 
7 O 
promotes O 
neurite O 
outgrowth O 
via O 
ERK O 
and O 
Cdk5 O 
signaling O 
pathways O 
. O 

neurotransmission O 
is O 
mediated O 
by O 
at O 
least O 
14 O 
subtypes O 
of O 
5-HT B-SYSTEMATIC 
receptors O 
. O 
Among O 
these O 
, O 
the O 
CNS O 
serotonin B-TRIVIAL 
receptor O 
7 O 
( O 
5-HTR7 O 
) O 
is O 
involved O 
in O 
diverse O 
physiological O 
processes O 
. O 
Here O 
we O 
show O 
that O 
treatment O 
of O 
murine O 
striatal O 
and O 
cortical O 
neuronal O 
cultures O 
with O 
5-HTR7 O 
agonists O 
( O 
8-OH-DPAT B-SYSTEMATIC 
and O 
LP-211 B-IDENTIFIER 
) O 
significantly O 
enhances O 
neurite O 
outgrowth O 
. O 
This O 
effect O 
is O 
abolished O 
by O 
the O 
selective O 
5-HTR7 O 
antagonist O 
SB-269970 B-IDENTIFIER 
, O 
by O 
the O 
ERK O 
inhibitor O 
U0126 B-IDENTIFIER 
, O 
by O 
the O 
cyclin O 
- O 
dependent O 
kinase O 
5 O 
( O 
Cdk5 O 
) O 
inhibitor O 
roscovitine B-TRIVIAL 
, O 
as O 
well O 
as O 
by O 
cycloheximide B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
protein O 
synthesis O 
. O 
These O 
data O 
indicate O 
that O 
5-HTR7 O 
activation O 
stimulates O 
extensive O 
neurite O 
elongation O 
in O 
CNS O 
primary O 
cultures O 
, O 
subserved O 
by O 
ERK O 
and O 
Cdk5 O 
activation O 
, O 
and O 
de O 
novo O 
protein O 
synthesis O 
. O 
Two O 
- O 
dimensional O 
( O 
2D O 
) O 
gel O 
electrophoresis O 
coupled O 
to O 
Western O 
blot O 
analyses O 
reveals O 
both O 
qualitative O 
and O 
quantitative O 
expression O 
changes O 
in O 
selected O 
cytoskeletal O 
proteins O 
, O 
following O 
treatment O 
of O 
striatal O 
primary O 
cultures O 
with O 
LP-211 O 
. O 
In O 
particular O 
, O 
the O 
34 O 
kDa O 
isoform O 
of O 
MAP1B O 
is O 
selectively O 
expressed O 
in O 
stimulated O 
cultures O 
, O 
consistent O 
with O 
a O 
role O 
of O 
this O 
protein O 
in O 
tubulin O 
polymerization O 
and O 
neurite O 
elongation O 
. O 
In O 
summary O 
, O 
our O 
results O 
show O 
that O 
agonist O 
- O 
dependent O 
activation O 
of O 
the O 
endogenous O 
5-HTR7 O 
in O 
CNS O 
neuronal O 
primary O 
cultures O 
stimulates O 
ERK- O 
and O 
Cdk5-dependent O 
neurite O 
outgrowth O 
, O 
sustained O 
by O 
modifications O 
of O 
cytoskeletal O 
proteins O 
. O 
These O 
data O 
support O 
the O 
hypothesis O 
that O 
the O 
5-HTR7 O 
might O 
play O 
a O 
crucial O 
role O 
in O 
shaping O 
neuronal O 
morphology O 
and O 
behaviorally O 
relevant O 
neuronal O 
networks O 
, O 
paving O 
the O 
way O 
to O 
new O 
approaches O 
able O 
to O 
modulate O 
CNS O 
connectivity O 
. O 

modulation O 
of O 
retinal O 
ganglion O 
cell O 
light O 
responses O 
by O 
orthosteric O 
and O 
allosteric O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
8 O 
compounds O 
. O 

investigate O 
the O 
role O 
of O 
mGluR8 O 
in O 
modulating O 
the O 
synaptic O 
responses O 
of O 
retinal O 
ganglion O 
cells O 
, O 
we O 
used O 
a O 
recently O 
identified O 
positive O 
allosteric O 
modulator O 
of O 
mGluR8 O 
, O 
AZ12216052 B-IDENTIFIER 
( O 
AZ O 
) O 
and O 
the O 
mGluR8-specific O 
orthosteric O 
agonist O 
(S)-3,4-dicarboxyphenylglycine B-SYSTEMATIC 
( O 
DCPG B-ABBREVIATION 
) O 
. O 
These O 
agents O 
were O 
applied O 
to O 
whole O 
- O 
cell O 
voltage O 
- O 
clamped O 
ganglion O 
cells O 
from O 
an O 
isolated O 
, O 
superfused O 
mouse O 
retina O 
preparation O 
. O 
DCPG B-ABBREVIATION 
reduced O 
OFF-ganglion O 
cell O 
excitatory O 
currents O 
, O 
whereas O 
AZ O 
enhanced O 
the O 
peak O 
excitatory O 
currents O 
in O 
ON- O 
, O 
OFF- O 
, O 
and O 
ON-OFF-ganglion O 
cells O 
. O 
The O 
effects O 
on O 
ganglion O 
cell O 
inhibitory O 
currents O 
were O 
more O 
varied O 
. O 
The O 
effects O 
of O 
the O 
allosteric O 
modulator O 
were O 
stronger O 
for O 
bright O 
stimuli O 
than O 
for O 
dim O 
stimuli O 
, O 
consistent O 
with O 
receptor O 
stimulation O 
by O 
endogenous O 
glutamate B-TRIVIAL 
being O 
stronger O 
during O 
bright O 
light O 
stimulation O 
and O 
with O 
mGluR8 O 
receptors O 
mainly O 
being O 
localized O 
away O 
from O 
glutamate B-TRIVIAL 
release O 
sites O 
, O 
immuno O 
- O 
labeled O 
with O 
VGLUT1 O 
. O 
The O 
differential O 
sensitivity O 
of O 
ganglion O 
cell O 
light O 
responses O 
to O 
DCPG B-ABBREVIATION 
and O 
AZ O 
supports O 
multiple O 
sites O 
where O 
mGluR8 O 
modulates O 
the O 
light O 
responses O 
of O 
ganglion O 
cells O 
. O 

design O 
of O 
sulfated O 
, O 
small O 
, O 
nonsaccharide O 
molecules O 
as O 
modulators O 
of O 
proteins O 
is O 
still O 
in O 
its O 
infancy O 
as O 
standard O 
drug O 
discovery O 
tools O 
such O 
as O 
library O 
of O 
diverse O 
sulfated O 
molecules O 
and O 
in O 
silico O 
docking O 
and O 
scoring O 
protocol O 
have O 
not O 
been O 
firmly O 
established O 
. O 
Databases O 
, O 
such O 
as O 
ZINC B-SYSTEMATIC 
, O 
contain O 
too O 
few O 
sulfate B-SYSTEMATIC 
-containing O 
nonsaccharide O 
molecules O 
, O 
which O 
severely O 
limits O 
the O 
identification O 
of O 
new O 
hits O 
. O 
Lack O 
of O 
a O 
generally O 
applicable O 
protocol O 
for O 
scaffold O 
hopping O 
limits O 
the O 
development O 
of O 
sulfated O 
small O 
molecules O 
as O 
synthetic O 
mimetics O 
of O 
the O 
highly O 
sulfated O 
glycosaminoglycans O 
. O 
We O 
explored O 
a O 
sequential O 
ligand O 
- O 
based O 
( O 
LBVS O 
) O 
and O 
structure O 
- O 
based O 
virtual O 
screening O 
( O 
SBVS O 
) O 
approach O 
starting O 
from O 
our O 
initial O 
discovery O 
of O 
monosulfated B-FAMILY 
benzofurans I-FAMILY 
to O 
discover O 
alternative O 
scaffolds O 
as O 
allosteric O 
modulators O 
of O 
thrombin O 
, O 
a O 
key O 
coagulation O 
enzyme O 
. O 
Screening O 
the O 
ZINC B-SYSTEMATIC 
database O 
containing O 
nearly O 
1 O 
million O 
nonsulfated O 
small O 
molecules O 
using O 
a O 
pharmacophore O 
developed O 
from O 
the O 
parent O 
sulfated B-FAMILY 
benzofurans I-FAMILY 
followed O 
by O 
a O 
genetic O 
algorithm O 
- O 
based O 
dual O 
- O 
filter O 
docking O 
and O 
scoring O 
screening O 
identified O 
a O 
group O 
of O 
10 O 
promising O 
hits O 
, O 
of O 
which O 
three O 
top O 
- O 
scoring O 
hits O 
were O 
synthesized O 
. O 
Each O 
was O 
found O 
to O 
selectively O 
inhibit O 
human O 
alpha-thrombin O 
suggesting O 
the O 
possibility O 
of O 
this O 
approach O 
for O 
scaffold O 
hopping O 
. O 
Michaelis-Menten O 
kinetics O 
showed O 
allosteric O 
inhibition O 
mechanism O 
for O 
the O 
best O 
molecule O 
and O 
human O 
plasma O 
studies O 
confirmed O 
good O 
anticoagulation O 
potential O 
as O 
expected O 
. O 
Our O 
simple O 
sequential O 
LBVS O 
and O 
SBVS O 
approach O 
is O 
likely O 
to O 
be O 
useful O 
as O 
a O 
general O 
strategy O 
for O 
identification O 
of O 
sulfated O 
small O 
molecules O 
hits O 
as O 
modulators O 
of O 
glycosaminoglycan O 
- O 
protein O 
interactions O 
. O 

of O 
anticonvulsants O 
into O 
the O 
perirhinal O 
cortex O 
through O 
1 O 
guide O 
cannula O 
in O 
each O 
hemisphere O 
only O 
invades O 
a O 
small O 
area O 
of O 
this O 
seizure O 
controlling O 
site O 
in O 
rats O 
exposed O 
to O 
soman O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
whether O 
infusions O 
made O 
through O 
2 O 
cannulas O 
in O 
each O 
perirhinal O 
cortex O 
may O 
produce O 
more O 
efficacious O 
anticonvulsant O 
action O 
against O 
soman O 
intoxication O 
than O 
the O 
use O 
of O 
1 O 
cannula O 
only O 
in O 
rats O 
infused O 
with O 
the O 
ionotropic O 
antagonists O 
procyclidine B-TRIVIAL 
and O 
caramiphen B-TRIVIAL 
or O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
modulators O 
DCG-IV B-IDENTIFIER 
and O 
MPEP B-ABBREVIATION 
. O 
The O 
results O 
showed O 
that O 
the O 
mere O 
presence O 
of O 
indwelling O 
double O 
cannulas O 
caused O 
proconvulsant O 
effect O 
in O 
response O 
to O 
subsequent O 
systemic O 
administration O 
of O 
soman O 
. O 
Both O 
the O 
control O 
and O 
caramiphen B-TRIVIAL 
groups O 
with O 
double O 
cannulas O 
had O 
significantly O 
shorter O 
latencies O 
to O 
seizure O 
onset O 
than O 
the O 
corresponding O 
groups O 
with O 
single O 
cannula O 
. O 
Procyclidine B-TRIVIAL 
resulted O 
in O 
anticonvulsant O 
efficacy O 
, O 
even O 
in O 
rats O 
with O 
double O 
cannulas O 
. O 
In O 
rats O 
that O 
received O 
twin O 
infusions O 
of O 
DCG-IV B-IDENTIFIER 
or O 
MPEP B-ABBREVIATION 
, O 
the O 
anticonvulsant O 
impact O 
was O 
very O 
high O 
, O 
inasmuch O 
as O 
a O 
majority O 
of O 
the O 
rats O 
in O 
each O 
group O 
was O 
protected O 
against O 
seizure O 
activity O 
. O 
Drugs O 
possessing O 
powerful O 
anticonvulsant O 
potency O 
can O 
apparently O 
counteract O 
the O 
proconvulsant O 
effect O 
of O 
double O 
cannulas O 
, O 
and O 
some O 
can O 
even O 
gain O 
enhanced O 
anticonvulsant O 
capacity O 
when O 
invading O 
a O 
larger O 
area O 
of O 
the O 
perirhinal O 
cortex O 
. O 
Perirhinal O 
EEG O 
recordings O 
( O 
electrodes O 
in O 
indwelling O 
cannulas O 
) O 
in O 
a O 
separate O 
set O 
of O 
rats O 
not O 
exposed O 
to O 
soman O 
or O 
drugs O 
showed O 
no O 
differences O 
in O 
basal O 
electrical O 
activity O 
( O 
total O 
power O 
0.5-25Hz O 
or O 
the O 
theta O 
band O 
4-12Hz O 
) O 
between O 
groups O 
with O 
single O 
or O 
double O 
cannulas O 
. O 
The O 
intrinsic O 
excitability O 
and O 
synaptic O 
connectivity O 
of O 
the O 
perirhinal O 
cortex O 
may O 
be O 
associated O 
with O 
the O 
proconvulsant O 
impact O 
observed O 
in O 
rats O 
with O 
double O 
cannulas O 
when O 
exposed O 
to O 
soman O 
. O 

concentrations O 
of O 
mercury B-SYSTEMATIC 
, O 
lead O 
, O 
cadmium B-SYSTEMATIC 
, O 
and O 
arsenic B-SYSTEMATIC 
and O 
the O 
risk O 
of O 
neural O 
tube O 
defects O 
in O 
a O 
Chinese O 
population O 
. O 

examine O 
whether O 
in O 
utero O 
exposure O 
to O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
, O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
, O 
lead O 
( O 
Pb B-FORMULA 
) O 
and O 
arsenic B-SYSTEMATIC 
( O 
As B-FORMULA 
) O 
is O 
associated O 
with O 
an O 
elevated O 
neural O 
tube O 
defects O 
( O 
NTDs O 
) O 
risk O 
, O 
placental O 
concentrations O 
of O 
total O 
Hg B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Pb B-FORMULA 
and O 
As B-FORMULA 
were O 
measured O 
with O 
an O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometer O 
( O 
ICP-MS O 
) O 
in O 
36 O 
anencephaly O 
and O 
44 O 
spina O 
bifida O 
cases O 
as O 
well O 
as O 
in O 
50 O 
healthy O 
controls O 
. O 
The O 
median O 
Hg B-FORMULA 
concentration O 
in O 
the O 
NTD O 
cases O 
( O 
2.25 O 
ng O 
/ O 
g O 
) O 
was O 
higher O 
than O 
that O 
of O 
the O 
controls O 
( O 
1.16 O 
ng O 
/ O 
g O 
) O 
. O 
The O 
odds O 
ratio O 
( O 
OR O 
) O 
for O 
an O 
Hg O 
concentration O 
above O 
the O 
median O 
was O 
8.8 O 
( O 
95% O 
CI O 
3.80-20.36 O 
) O 
for O 
the O 
NTD O 
cases O 
. O 
NTD O 
risks O 
increased O 
for O 
the O 
second O 
and O 
third O 
high O 
levels O 
of O 
the O 
concentrations O 
, O 
with O 
ORs O 
of O 
2.7 O 
( O 
95% O 
CI O 
1.13-6.43 O 
) O 
and O 
18.2 O 
( O 
95% O 
CI O 
5.45-60.73 O 
) O 
, O 
respectively O 
. O 
Therefore O 
, O 
higher O 
placental O 
levels O 
of O 
Hg B-FORMULA 
are O 
associated O 
with O 
an O 
elevated O 
risk O 
of O 
NTDs O 
. O 

of O 
quinacrine B-TRIVIAL 
in O 
the O 
decrease O 
of O 
ingested O 
sulfite B-SYSTEMATIC 
-induced O 
toxic O 
action O 
in O 
rat O 
brain O 
. O 

aimed O 
at O 
investigating O 
the O 
effects O 
of O 
sulfite B-SYSTEMATIC 
-induced O 
lipid O 
peroxidation O 
and O 
apoptosis O 
mediated O 
by O 
secretory O 
phospholipase O 
A2 O 
( O 
sPLA2 O 
) O 
on O 
somatosensory O 
evoked O 
potentials O 
( O 
SEP O 
) O 
alterations O 
in O 
rats O 
. O 
Thirty O 
male O 
albino O 
Wistar O 
rats O 
were O 
randomized O 
into O 
three O 
experimental O 
groups O 
as O 
follows O 
; O 
control O 
( O 
C O 
) O 
, O 
sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
treated O 
( O 
S O 
) O 
, O 
sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
+ O 
quinacrine B-TRIVIAL 
treated O 
( O 
SQ O 
) O 
. O 
Sodium B-SYSTEMATIC 
metabisulfite I-SYSTEMATIC 
( O 
100 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
was O 
given O 
by O 
gastric O 
gavage O 
for O 
5 O 
weeks O 
and O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
quinacrine B-TRIVIAL 
was O 
applied O 
as O 
a O 
single O 
dose O 
of O 
intraperitoneal O 
injection O 
for O 
the O 
same O 
period O 
. O 
The O 
latencies O 
of O 
SEP O 
components O 
were O 
significantly O 
prolonged O 
in O 
the O 
S O 
group O 
and O 
returned O 
to O 
control O 
levels O 
following O 
quinacrine B-TRIVIAL 
administration O 
. O 
Plasma- O 
S B-FORMULA 
- O 
sulfonate B-SYSTEMATIC 
level O 
was O 
increased O 
in O 
S O 
and O 
SQ O 
groups O 
. O 
TBARS O 
levels O 
in O 
the O 
S O 
group O 
were O 
significantly O 
higher O 
than O 
those O 
detected O 
in O 
controls O 
. O 
Quinacrine B-TRIVIAL 
significantly O 
decreased O 
brain O 
TBARS O 
levels O 
in O 
the O 
SQ O 
group O 
compared O 
with O 
the O 
S O 
group O 
. O 
Quinacrine B-TRIVIAL 
treatment O 
did O 
not O 
have O 
an O 
effect O 
on O 
the O 
increased O 
sPLA2 O 
level O 
of O 
the O 
sulfite B-SYSTEMATIC 
administered O 
group O 
. O 
Immunohistochemistry O 
showed O 
that O 
sulfite B-SYSTEMATIC 
caused O 
an O 
increase O 
in O 
caspase-3 O 
and O 
TUNEL O 
positive O 
cells O 
, O 
restored O 
to O 
control O 
levels O 
via O 
quinacrine B-TRIVIAL 
administration O 
. O 
This O 
study O 
showed O 
that O 
sPLA2 O 
might O 
play O 
a O 
role O 
in O 
ingested O 
sulfite B-SYSTEMATIC 
-induced O 
SEP O 
alterations O 
, O 
oxidative O 
stress O 
, O 
apoptotic O 
cell O 
death O 
and O 
DNA O 
damage O 
in O 
the O 
brain O 
. O 

transformations O 
during O 
the O 
reduction O 
of O 
hollow O 
and O 
porous O 
nickel B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 

- O 
dependent O 
nanostructural O 
transformations O 
occurring O 
during O 
the O 
H(2) B-FORMULA 
-mediated O 
reduction O 
of O 
hollow O 
and O 
porous O 
NiO B-FORMULA 
nanoparticles O 
were O 
investigated O 
for O 
controlled O 
nanoparticle O 
sizes O 
of O 
~10 O 
to O 
100 O 
nm O 
. O 
Transmission O 
electron O 
microscopy O 
reveals O 
that O 
the O 
location O 
and O 
number O 
of O 
reduction O 
sites O 
strongly O 
depend O 
on O 
the O 
nanoparticle O 
size O 
and O 
structure O 
. O 

do O 
the O 
electrical O 
properties O 
of O 
graphene B-TRIVIAL 
change O 
with O 
its O 
functionalization O 
? O 

of O 
graphene B-TRIVIAL 
is O 
essential O 
to O 
interface O 
it O 
with O 
other O 
moieties O 
to O 
expand O 
the O 
scope O 
of O 
its O 
electrical O 
/ O 
electronic O 
applications O 
. O 
However O 
, O 
chemical O 
functionalization O 
and O 
/ O 
or O 
molecular O 
interactions O 
on O 
graphene B-TRIVIAL 
sensitively O 
modulate O 
its O 
electrical O 
properties O 
. O 
To O 
evaluate O 
and O 
take O 
advantage O 
of O 
the O 
properties O 
of O 
functionalized O 
graphene B-TRIVIAL 
, O 
it O 
is O 
important O 
to O 
understand O 
how O 
its O 
electrical O 
attributes O 
( O 
such O 
as O 
carrier O 
scattering O 
, O 
carrier O 
concentration O 
, O 
charge O 
polarity O 
, O 
quantum O 
- O 
capacitance O 
enhanced O 
doping O 
, O 
energy O 
levels O 
, O 
transport O 
mechanisms O 
, O 
and O 
orbital O 
hybridization O 
of O 
energy O 
- O 
bands O 
) O 
are O 
influenced O 
by O 
a O 
change O 
in O 
carbon B-SYSTEMATIC 
' O 
s O 
structural O 
conformation O 
, O 
hybridization O 
state O 
, O 
chemical O 
potential O 
, O 
local O 
energy O 
levels O 
, O 
and O 
dopant O 
/ O 
interface O 
coupling O 
induced O 
via O 
functionalization O 
or O 
molecular O 
interactions O 
. O 
Here O 
, O 
a O 
detailed O 
and O 
integrated O 
model O 
describes O 
factors O 
influencing O 
these O 
electrical O 
characteristics O 
of O 
functionalized O 
graphene B-TRIVIAL 
( O 
covalent O 
bonds O 
, O 
adsorption O 
, O 
π-π O 
bonds O 
, O 
and O 
lattice O 
incorporation O 
) O 
. O 
The O 
electrical O 
properties O 
are O 
governed O 
via O 
three O 
mechanisms O 
: O 
( O 
a O 
) O 
conversion O 
of O 
carbon B-SYSTEMATIC 
' O 
s O 
hybridized O 
state O 
, O 
( O 
b O 
) O 
dipole O 
interactions O 
enhanced O 
via O 
quantum O 
capacitance O 
, O 
and O 
( O 
c O 
) O 
orbital O 
hybridization O 
with O 
an O 
interfacing O 
molecule O 
. O 
A O 
few O 
graphenic O 
materials O 
are O 
also O 
identified O 
where O 
further O 
studies O 
are O 
essential O 
to O 
understand O 
the O 
effect O 
of O 
their O 
functionalization O 
. O 

mediated O 
mitochondrial O 
cytoprotection O 
: O 
premises O 
for O 
therapy O 
of O 
cerebrovascular O 
and O 
neurodegenerative O 
diseases O 
. O 

the O 
last O 
decades O 
, O 
emerging O 
molecular O 
targets O 
for O 
ischemic O 
neuroprotection O 
and O 
regeneration O 
have O 
been O 
postulated O 
. O 
This O 
fact O 
allowed O 
that O 
classical O 
drugs O 
with O 
well O 
established O 
therapeutic O 
applications O 
might O 
be O 
used O 
in O 
cerebrovascular O 
diseases O 
as O 
well O 
as O 
neurodegenerative O 
diseases O 
. O 
Minocycline B-TRIVIAL 
is O 
a O 
commonly O 
used O 
antibiotic O 
of O 
the O 
tetracycline B-FAMILY 
family O 
( O 
7-dimethylamino-6-dimethyl-6-deoxytetracycline B-SYSTEMATIC 
) O 
which O 
reveals O 
cytoprotective O 
capability O 
and O 
potential O 
use O 
in O 
treatment O 
of O 
different O 
diseases O 
. O 
Here O 
, O 
we O 
discuss O 
the O 
literature O 
concerning O 
minocycline B-TRIVIAL 
. O 
The O 
available O 
data O 
indicate O 
that O 
the O 
antibiotic O 
has O 
multi O 
- O 
faceted O 
effects O 
on O 
cell O 
functions O 
and O 
, O 
consequently O 
, O 
a O 
number O 
of O 
clinical O 
properties O 
that O 
are O 
useful O 
and O 
/ O 
or O 
could O 
be O 
useful O 
for O 
treatment O 
of O 
different O 
diseases O 
including O 
bacterial O 
infections O 
, O 
cancer O 
, O 
autoimmune O 
disorders O 
, O 
ischemia O 
as O 
well O 
as O 
neurodegenerative O 
and O 
psychiatric O 
diseases O 
. O 
Thus O 
, O 
application O 
of O 
minocycline B-TRIVIAL 
as O 
a O 
therapeutic O 
agent O 
is O 
the O 
subject O 
of O 
clinical O 
trials O 
for O 
various O 
diseases O 
. O 
It O 
is O 
also O 
evident O 
that O 
minocycline B-TRIVIAL 
-mediated O 
cytoprotection O 
, O 
including O 
neuroprotection O 
, O 
is O 
an O 
important O 
aspect O 
of O 
its O 
clinical O 
application O 
. O 
Here O 
, O 
we O 
have O 
reviewed O 
the O 
basis O 
of O 
the O 
minocycline B-TRIVIAL 
activity O 
as O 
well O 
as O 
different O 
studies O 
indicating O 
that O 
minocycline B-TRIVIAL 
can O 
be O 
used O 
as O 
potential O 
therapeutic O 
agent O 
in O 
both O 
cerebrovascular O 
and O 
neurodegenerative O 
diseases O 
in O 
human O 
. O 

& O 
mechanism O 
of O 
ethanol B-SYSTEMATIC 
in O 
stroke O 
and O 
traumatic O 
brain O 
injury O 
therapy O 
: O 
new O 
prospects O 
for O 
an O 
ancient O 
drug O 
. O 

efforts O 
to O 
screen O 
for O 
agents O 
that O 
protect O 
against O 
the O 
devastating O 
effects O 
of O 
stroke O 
have O 
not O 
produced O 
viable O 
results O 
thus O 
far O 
. O 
As O 
a O 
result O 
this O 
article O 
reviews O 
the O 
possible O 
role O 
of O 
ethanol B-SYSTEMATIC 
as O 
a O 
neuroprotective O 
agent O 
in O 
stroke O 
and O 
traumatic O 
brain O 
injury O 
( O 
TBI O 
) O 
. O 
Previous O 
studies O 
have O 
associated O 
ethanol O 
consumption O 
with O 
a O 
decreased O 
risk O 
of O 
ischemic O 
stroke O 
, O 
suggesting O 
a O 
neuroprotective O 
mechanism O 
. O 
The O 
translation O 
of O 
this O 
clinical O 
knowledge O 
into O 
basic O 
science O 
research O 
with O 
the O 
goal O 
of O 
new O 
therapy O 
for O 
acute O 
stroke O 
patients O 
remains O 
in O 
its O 
initial O 
stages O 
. O 
In O 
a O 
recent O 
study O 
involving O 
rats O 
, O 
we O 
have O 
shown O 
that O 
ethanol B-SYSTEMATIC 
administration O 
, O 
in O 
the O 
correct O 
dose O 
after O 
stroke O 
onset O 
, O 
protects O 
against O 
ischemia O 
- O 
induced O 
brain O 
injury O 
. O 
The O 
purpose O 
of O 
this O 
paper O 
is O 
to O 
discuss O 
ethanol B-SYSTEMATIC 
' O 
s O 
neuroprotective O 
properties O 
in O 
stroke O 
when O 
consumed O 
as O 
a O 
preconditioning O 
agent O 
, O 
in O 
TBI O 
with O 
a O 
positive O 
blood O 
alcohol O 
content O 
, O 
and O 
finally O 
in O 
stroke O 
treatment O 
, O 
with O 
the O 
goal O 
of O 
using O 
post O 
- O 
ischemia O 
ethanol B-SYSTEMATIC 
( O 
PIE O 
) O 
therapy O 
to O 
ameliorate O 
brain O 
damage O 
in O 
the O 
future O 
. O 

2-(aryloxy)-3-phenylpropanoic B-FAMILY 
acids I-FAMILY 
as O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
/ O 
γ O 
dual O 
agonists O 
able O 
to O 
upregulate O 
mitochondrial O 
carnitine B-TRIVIAL 
shuttle O 
system O 
gene O 
expression O 
. O 

preparation O 
of O 
a O 
series O 
of O 
2-(aryloxy)-3-phenylpropanoic B-FAMILY 
acids I-FAMILY 
, O 
resulting O 
from O 
the O 
introduction O 
of O 
different O 
substituents O 
into O 
the O 
biphenyl B-SYSTEMATIC 
system O 
of O 
the O 
previously O 
reported O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
α O 
/ O 
γ O 
( O 
PPARα O 
/ O 
γ O 
) O 
dual O 
agonist O 
1 O 
, O 
allowed O 
the O 
identification O 
of O 
new O 
ligands O 
with O 
higher O 
potency O 
on O 
PPARα O 
and O 
fine O 
- O 
tuned O 
moderate O 
PPARγ O 
activity O 
. O 
For O 
the O 
most O 
promising O 
stereoisomer O 
(S)-16 O 
, O 
X-ray O 
and O 
calorimetric O 
studies O 
in O 
PPARγ O 
revealed O 
, O 
at O 
high O 
ligand O 
concentration O 
, O 
the O 
presence O 
of O 
two O 
molecules O 
simultaneously O 
bound O 
to O 
the O 
receptor O 
. O 
On O 
the O 
basis O 
of O 
these O 
results O 
and O 
docking O 
experiments O 
in O 
both O 
receptor O 
subtypes O 
, O 
a O 
molecular O 
explanation O 
was O 
provided O 
for O 
its O 
different O 
behavior O 
as O 
a O 
full O 
and O 
partial O 
agonist O 
of O 
PPARα O 
and O 
PPARγ O 
, O 
respectively O 
. O 
The O 
effects O 
of O 
(S)-16 O 
on O 
mitochondrial O 
acylcarnitine B-SYSTEMATIC 
carrier O 
and O 
carnitine B-TRIVIAL 
- O 
palmitoyl B-TRIVIAL 
-transferase O 
1 O 
gene O 
expression O 
, O 
two O 
key O 
components O 
of O 
the O 
carnitine B-TRIVIAL 
shuttle O 
system O 
, O 
were O 
also O 
investigated O 
, O 
allowing O 
the O 
hypothesis O 
of O 
a O 
more O 
beneficial O 
pharmacological O 
profile O 
of O 
this O 
compound O 
compared O 
to O 
the O 
less O 
potent O 
PPARα O 
agonist O 
fibrates O 
currently O 
used O 
in O 
therapy O 
. O 

method O 
for O 
predicting O 
the O 
isosteric O 
heat O 
of O 
gas O 
adsorption O 
on O 
solid O 
materials O 
is O 
developed O 
which O 
requires O 
the O 
measurement O 
of O 
a O 
single O 
isotherm O 
- O 
where O 
previous O 
methods O 
, O 
such O 
as O 
the O 
Clausius-Clapeyron O 
approach O 
, O 
require O 
either O 
multiple O 
isotherms O 
or O 
complex O 
calorimetric O 
measurement O 
. O 
The O 
Tóth O 
potential O 
function O 
, O 
stemming O 
from O 
the O 
Polanyi O 
potential O 
function O 
, O 
is O 
evaluated O 
using O 
the O 
Langmuir O 
and O 
Tóth O 
isotherm O 
equations O 
to O 
generate O 
new O 
equations O 
for O 
the O 
isosteric O 
heat O 
. O 
These O 
new O 
isosteric O 
heat O 
equations O 
share O 
common O 
parameters O 
with O 
the O 
isotherm O 
equations O 
and O 
are O 
determined O 
from O 
isotherm O 
fitting O 
. O 
This O 
method O 
is O 
demonstrated O 
in O 
the O 
literature O 
for O 
gas O 
adsorption O 
onto O 
solid O 
adsorbates O 
including O 
zeolites O 
of O 
various O 
surface O 
charge O 
character O 
and O 
non-porous O 
rutile O 
phase O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
. O 
Predictions O 
are O 
made O 
using O 
the O 
new O 
isosteric O 
heat O 
equations O 
and O 
then O 
compared O 
to O 
calorimetric O 
data O 
. O 

CNT- O 
polyurethane B-SYSTEMATIC 
nanocomposite O 
: O 
synthesis O 
, O 
performance O 
and O 
assessment O 
of O 
fragments O 
released O 
during O 
use O 
. O 

for O 
use O 
in O 
high O 
performance O 
applications O 
where O 
electrical O 
conductivity O 
is O 
required O 
, O 
we O 
developed O 
a O 
CNT-TPU O 
composite O 
. O 
Such O 
a O 
composite O 
can O 
be O 
prepared O 
by O 
melt O 
processing O 
( O 
extrusion O 
) O 
on O 
an O 
industrial O 
scale O 
. O 
Due O 
to O 
the O 
known O 
hazard O 
upon O 
inhalation O 
of O 
CNTs O 
, O 
we O 
assessed O 
three O 
degradation O 
scenarios O 
that O 
may O 
lead O 
to O 
the O 
release O 
of O 
CNTs O 
from O 
the O 
composite O 
: O 
normal O 
use O 
, O 
machining O 
and O 
outdoor O 
weathering O 
. O 
Unexpectedly O 
, O 
we O 
find O 
that O 
the O 
relative O 
softness O 
of O 
the O 
material O 
actually O 
enhances O 
the O 
embedding O 
of O 
CNTs O 
also O 
in O 
its O 
degradation O 
fragments O 
. O 
A O 
release O 
of O 
free O 
CNTs O 
was O 
not O 
detected O 
under O 
any O 
condition O 
using O 
several O 
detection O 
methods O 
. O 
However O 
, O 
since O 
machining O 
may O 
induce O 
a O 
high O 
acute O 
dose O 
of O 
human O 
exposure O 
, O 
we O 
assessed O 
the O 
cytotoxicity O 
potential O 
of O 
released O 
fragments O 
in O 
the O 
in O 
vitro O 
model O 
of O 
precision O 
- O 
cut O 
lung O 
slices O 
, O 
and O 
found O 
no O 
additional O 
toxicity O 
due O 
to O 
the O 
presence O 
of O 
CNTs O 
. O 
At O 
very O 
low O 
rates O 
over O 
years O 
, O 
weathering O 
degrades O 
the O 
polymer O 
matrix O 
as O 
expected O 
for O 
polyurethanes B-FAMILY 
, O 
thus O 
exposing O 
a O 
network O 
of O 
entangled O 
CNTs O 
. O 
In O 
a O 
preliminary O 
risk O 
assessment O 
, O 
we O 
conclude O 
that O 
this O 
material O 
is O 
safe O 
for O 
humans O 
in O 
professional O 
and O 
consumer O 
use O 
. O 

-dependent O 
reconstitution O 
of O 
respiratory O 
supercomplexes O 
from O 
purified O 
Saccharomyces O 
cerevisiae O 
complexes O 
III O 
and O 
IV O 
. O 

, O 
we O 
report O 
for O 
the O 
first O 
time O 
in O 
vitro O 
reconstitution O 
of O 
the O 
respiratory O 
supercomplexes O 
from O 
individual O 
complexes O 
III O 
and O 
IV O 
. O 
Complexes O 
III O 
and O 
IV O 
were O 
purified O 
from O 
Saccharomyces O 
cerevisiae O 
mitochondria O 
. O 
Complex O 
III O 
contained O 
eight O 
molecules O 
of O 
cardiolipin B-TRIVIAL 
, O 
and O 
complex O 
IV O 
contained O 
two O 
molecules O 
of O 
cardiolipin B-TRIVIAL 
, O 
as O 
determined O 
by O 
electrospray O 
ionization O 
- O 
mass O 
spectrometry O 
. O 
Complex O 
IV O 
also O 
contained O 
Rcf1p O 
. O 
No O 
supercomplexes O 
were O 
formed O 
upon O 
mixing O 
of O 
the O 
purified O 
complexes O 
, O 
and O 
low O 
amounts O 
of O 
the O 
supercomplex O 
trimer O 
III(2)IV(1) O 
were O 
formed O 
after O 
reconstitution O 
into O 
proteoliposomes O 
containing O 
only O 
phosphatidylcholine B-FAMILY 
and O 
phosphatidylethanolamine B-SYSTEMATIC 
. O 
Further O 
addition O 
of O 
cardiolipin O 
to O 
the O 
proteoliposome O 
reconstitution O 
mixture O 
resulted O 
in O 
distinct O 
formation O 
of O 
both O 
the O 
III(2)IV(1) O 
supercomplex O 
trimer O 
and O 
III(2)IV(2) O 
supercomplex O 
tetramer O 
. O 
No O 
other O 
anionic O 
phospholipid O 
was O 
as O 
effective O 
as O 
cardiolipin B-TRIVIAL 
in O 
supporting O 
tetramer O 
formation O 
. O 
Phospholipase O 
treatment O 
of O 
complex O 
IV O 
prevented O 
trimer O 
formation O 
in O 
the O 
absence O 
of O 
cardiolipin B-TRIVIAL 
. O 
Both O 
trimer O 
and O 
tetramer O 
formations O 
were O 
restored O 
by O 
cardiolipin B-TRIVIAL 
. O 
Analysis O 
of O 
the O 
reconstituted O 
tetramer O 
by O 
single O 
particle O 
electron O 
microscopy O 
confirmed O 
native O 
organization O 
of O 
individual O 
complexes O 
within O 
the O 
supercomplex O 
. O 
In O 
conclusion O 
, O 
although O 
some O 
trimer O 
formation O 
occurred O 
dependent O 
only O 
on O 
tightly O 
bound O 
cardiolipin B-TRIVIAL 
, O 
tetramer O 
formation O 
required O 
additional O 
cardiolipin B-TRIVIAL 
. O 
This O 
is O 
consistent O 
with O 
the O 
high O 
cardiolipin B-TRIVIAL 
content O 
in O 
the O 
native O 
tetramer O 
. O 
The O 
dependence O 
on O 
cardiolipin B-TRIVIAL 
for O 
supercomplex O 
formation O 
suggests O 
that O 
changes O 
in O 
cardiolipin B-TRIVIAL 
levels O 
resulting O 
from O 
changes O 
in O 
physiological O 
conditions O 
may O 
control O 
the O 
equilibrium O 
between O 
individual O 
respiratory O 
complexes O 
and O 
supercomplexes O 
in O 
vivo O 
. O 

( O 
OP O 
) O 
is O 
an O 
inherited O 
disorder O 
of O 
defective O 
bone O 
resorption O 
, O 
which O 
can O 
be O 
accompanied O 
by O 
impaired O 
skeletal O 
mineralization O 
, O 
a O 
phenotype O 
termed O 
osteopetrorickets O 
( O 
OPR O 
) O 
. O 
Since O 
individuals O 
with O 
dysfunctional O 
osteoclasts O 
often O 
develop O 
osteomyelitis O 
of O 
the O 
jaw O 
, O 
we O 
have O 
analyzed O 
, O 
if O 
dentin O 
and O 
enamel O 
mineralization O 
are O 
differentially O 
affected O 
in O 
OP O 
and O 
OPR O 
. O 
Therefore O 
, O 
we O 
have O 
applied O 
non-decalcified O 
histology O 
and O 
quantitative O 
backscattered O 
electron O 
imaging O 
( O 
qBEI O 
) O 
to O 
compare O 
the O 
dental O 
phenotypes O 
of O 
Src(- O 
/ O 
- O 
) O 
, O 
oc O 
/ O 
oc O 
and O 
Hyp(- O 
/ O 
0 O 
) O 
mice O 
, O 
which O 
serve O 
as O 
models O 
for O 
OP O 
, O 
OPR O 
and O 
hypophosphatemic O 
rickets O 
, O 
respectively O 
. O 
While O 
both O 
, O 
Src(- O 
/ O 
- O 
) O 
and O 
oc O 
/ O 
oc O 
mice O 
, O 
were O 
characterized O 
by O 
defects O 
of O 
molar O 
root O 
formation O 
, O 
only O 
oc O 
/ O 
oc O 
mice O 
displayed O 
a O 
severe O 
defect O 
of O 
dentin O 
mineralization O 
, O 
similar O 
to O 
Hyp(- O 
/ O 
0 O 
) O 
mice O 
. O 
Most O 
importantly O 
, O 
while O 
enamel O 
thickness O 
was O 
not O 
affected O 
in O 
either O 
mouse O 
model O 
, O 
the O 
calcium B-SYSTEMATIC 
content O 
within O 
the O 
enamel O 
phase O 
was O 
significantly O 
reduced O 
in O 
oc O 
/ O 
oc O 
, O 
but O 
not O 
in O 
Src(- O 
/ O 
- O 
) O 
or O 
Hyp(- O 
/ O 
0 O 
) O 
mice O 
. O 
Taken O 
together O 
, O 
these O 
data O 
demonstrate O 
that O 
dentin O 
and O 
enamel O 
mineralization O 
are O 
differentially O 
affected O 
in O 
Src(- O 
/ O 
- O 
) O 
and O 
oc O 
/ O 
oc O 
mice O 
. O 
Moreover O 
, O 
since O 
defects O 
of O 
dental O 
mineralization O 
may O 
trigger O 
premature O 
tooth O 
decay O 
and O 
thereby O 
osteomyelitis O 
of O 
the O 
jaw O 
, O 
they O 
further O 
underscore O 
the O 
importance O 
of O 
discriminating O 
between O 
OP O 
and O 
OPR O 
in O 
the O 
respective O 
individuals O 
. O 

modulates O 
the O 
kinetic O 
properties O 
of O 
an O 
archaeal O 
member O 
of O 
the O 
PLL O 
family O 
. O 

we O 
reported O 
on O 
the O 
characterization O 
of O 
an O 
archaeal O 
member O 
of O 
the O 
amidohydrolase O 
superfamily O 
, O 
namely O 
Sulfolobus O 
acidocaldarius O 
lactonase O 
, O 
showing O 
low O 
but O 
significant O 
and O 
extremely O 
thermostable O 
paraoxonase O 
activity O 
. O 
This O 
enzyme O 
, O 
that O 
we O 
have O 
named O 
SacPox O 
, O 
is O 
a O 
member O 
of O 
the O 
new O 
described O 
family O 
of O 
phosphotriesterase O 
- O 
like O 
lactonases O 
( O 
PLLs O 
) O 
. O 
In O 
this O 
family O 
the O 
binuclear O 
metal O 
centre O 
, O 
which O 
is O 
involved O 
in O 
the O 
catalytic O 
machinery O 
, O 
has O 
been O 
poorly O 
studied O 
up O 
to O 
now O 
. O 
In O 
this O 
work O 
we O 
describe O 
the O 
expression O 
of O 
the O 
protein O 
in O 
presence O 
of O 
different O 
metals O 
showing O 
Mn(2+) B-FORMULA 
to O 
support O 
the O 
higher O 
activity O 
. O 
The O 
enzyme O 
has O 
been O 
over O 
- O 
expressed O 
, O 
purified O 
and O 
characterized O 
as O 
a O 
Mn(2+) B-FORMULA 
-containing O 
enzyme O 
by O 
inductive O 
plasma O 
coupled O 
mass O 
spectrometry O 
( O 
ICP-MS O 
) O 
, O 
showing O 
also O 
surprising O 
kinetic O 
differences O 
in O 
comparison O 
with O 
the O 
cadmium B-SYSTEMATIC 
-containing O 
enzyme O 
. O 
The O 
Mn(2+) B-FORMULA 
containing O 
enzyme O 
was O 
about O 
30-fold O 
more O 
efficient O 
with O 
paraoxon B-TRIVIAL 
as O 
substrate O 
and O 
more O 
stable O 
than O 
the O 
Cd(2+) B-FORMULA 
counterpart O 
, O 
even O 
though O 
the O 
Mn(2+) B-FORMULA 
affinity O 
for O 
the O 
binuclear O 
metal O 
centre O 
is O 
apparently O 
lower O 
. O 
These O 
results O 
increase O 
our O 
knowledge O 
of O 
the O 
biochemical O 
characteristics O 
of O 
SacPox O 
mainly O 
with O 
regard O 
to O 
the O 
metal O 
- O 
ions O 
modulation O 
of O 
function O 
. O 

of O 
early O 
life O 
permethrin B-TRIVIAL 
exposure O 
on O 
spatial O 
working O 
memory O 
and O 
on O 
monoamine B-FAMILY 
levels O 
in O 
different O 
brain O 
areas O 
of O 
pre O 
- O 
senescent O 
rats O 
. O 

exposure O 
during O 
brain O 
development O 
could O 
represent O 
an O 
important O 
risk O 
factor O 
for O 
the O 
onset O 
of O 
neurodegenerative O 
diseases O 
. O 
Previous O 
studies O 
investigated O 
the O 
effect O 
of O 
permethrin B-TRIVIAL 
( O 
PERM B-ABBREVIATION 
) O 
administered O 
at O 
34 O 
mg O 
/ O 
kg O 
, O 
a O 
dose O 
close O 
to O 
the O 
no O 
observable O 
adverse O 
effect O 
level O 
( O 
NOAEL O 
) O 
from O 
post O 
natal O 
day O 
( O 
PND O 
) O 
6 O 
to O 
PND O 
21 O 
in O 
rats O 
. O 
Despite O 
the O 
PERM B-ABBREVIATION 
dose O 
did O 
not O 
elicited O 
overt O 
signs O 
of O 
toxicity O 
( O 
i.e O 
. O 
normal O 
body O 
weight O 
gain O 
curve O 
) O 
, O 
it O 
was O 
able O 
to O 
induce O 
striatal O 
neurodegeneration O 
( O 
dopamine B-TRIVIAL 
and O 
Nurr1 O 
reduction O 
, O 
and O 
lipid O 
peroxidation O 
increase O 
) O 
. O 
The O 
present O 
study O 
was O 
designed O 
to O 
characterize O 
the O 
cognitive O 
deficits O 
in O 
the O 
current O 
animal O 
model O 
. O 
When O 
during O 
late O 
adulthood O 
PERM B-ABBREVIATION 
treated O 
rats O 
were O 
tested O 
for O 
spatial O 
working O 
memory O 
performances O 
in O 
a O 
T-maze O 
- O 
rewarded O 
alternation O 
task O 
they O 
took O 
longer O 
to O 
choose O 
for O 
the O 
correct O 
arm O 
in O 
comparison O 
to O 
age O 
matched O 
controls O 
. O 
No O 
differences O 
between O 
groups O 
were O 
found O 
in O 
anxiety O 
- O 
like O 
state O 
, O 
locomotor O 
activity O 
, O 
feeding O 
behavior O 
and O 
spatial O 
orientation O 
task O 
. O 
Our O 
findings O 
showing O 
a O 
selective O 
effect O 
of O 
PERM B-ABBREVIATION 
treatment O 
on O 
the O 
T-maze O 
task O 
point O 
to O 
an O 
involvement O 
of O 
frontal O 
cortico O 
- O 
striatal O 
circuitry O 
rather O 
than O 
to O 
a O 
role O 
for O 
the O 
hippocampus O 
. O 
The O 
predominant O 
disturbances O 
concern O 
the O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
depletion O 
in O 
the O 
striatum O 
and O 
, O 
the O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
and O 
noradrenaline B-TRIVIAL 
( O 
NE O 
) O 
unbalance O 
together O 
with O 
a O 
hypometabolic O 
state O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
area O 
. O 
In O 
the O 
hippocampus O 
, O 
an O 
increase O 
of O 
NE O 
and O 
a O 
decrease O 
of O 
DA O 
were O 
observed O 
in O 
PERM B-ABBREVIATION 
treated O 
rats O 
as O 
compared O 
to O 
controls O 
. O 
The O 
concentration O 
of O 
the O 
most O 
representative O 
marker O 
for O 
pyrethroid B-FAMILY 
exposure O 
( O 
3-phenoxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
measured O 
in O 
the O 
urine O 
of O 
rodents O 
12 O 
h O 
after O 
the O 
last O 
treatment O 
was O 
41.5 O 
μg O 
/ O 
L O 
and O 
it O 
was O 
completely O 
eliminated O 
after O 
96 O 
h O 
. O 

dyskinesia O 
induced O 
by O 
nasal O 
Ritalin B-TRIVIAL 
( O 
R O 
) O 
( O 
methylphenidate B-SYSTEMATIC 
) O 
sniffing O 
: O 
a O 
rare O 
case O 
report O 
from O 
Switzerland O 
. O 

® O 
( O 
methylphenidate B-SYSTEMATIC 
) O 
is O 
an O 
amphetamine B-TRIVIAL 
-like O 
prescription O 
stimulant O 
commonly O 
used O 
in O 
the O 
treatment O 
of O 
attention O 
deficit O 
hyperactivity O 
disorder O 
in O 
children O 
and O 
adults O 
. O 
Recently O 
, O 
the O 
recreational O 
use O 
of O 
Ritalin B-TRIVIAL 
has O 
increased O 
, O 
particularly O 
among O 
young O 
adults O 
. O 
Well O 
- O 
known O 
symptoms O 
of O 
intoxication O 
include O 
signs O 
of O 
sympathetic O 
nervous O 
stimulation O 
, O 
such O 
as O 
agitation O 
, O 
anxiety O 
, O 
tachycardia O 
, O 
hypertension O 
, O 
headache O 
, O 
tremor O 
, O 
and O 
dizziness O 
. O 
This O 
case O 
report O 
describes O 
oral O 
dyskinesia O 
as O 
a O 
rare O 
presentation O 
of O 
Ritalin B-TRIVIAL 
intoxication O 
, O 
with O 
the O 
review O 
of O 
pathophysiology O 
and O 
some O 
epidemiological O 
data O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
glucose B-TRIVIAL 
-containing O 
scutellarein B-TRIVIAL 
derivatives O 
as O 
neuroprotective O 
agents O 
based O 
on O 
metabolic O 
mechanism O 
of O 
scutellarin B-TRIVIAL 
in O 
vivo O 
. O 

on O 
metabolic O 
mechanism O 
of O 
scutellarin B-TRIVIAL 
in O 
vivo O 
that O 
scutellarin B-TRIVIAL 
could O 
be O 
hydrolyzed O 
into O 
scutellarein B-TRIVIAL 
by O 
β-glucuronide O 
enzyme O 
, O 
some O 
glucose B-TRIVIAL 
-containing O 
scutellarein B-TRIVIAL 
derivatives O 
were O 
designed O 
and O 
synthesized O 
through O 
the O 
introduction O 
of O 
glucose B-TRIVIAL 
moiety O 
at O 
C-7 O 
position O 
of O 
scutellarein B-TRIVIAL 
via O 
a O 
glucosidic O 
bond O 
. O 
Biological O 
activity O 
evaluation O 
showed O 
that O 
these O 
glucose B-TRIVIAL 
-containing O 
scutellarein B-TRIVIAL 
derivatives O 
exhibited O 
potent O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
activities O 
. O 
Furthermore O 
, O 
the O 
improvement O 
of O 
physicochemical O 
properties O 
such O 
as O 
anticoagulant O 
and O 
neuroprotective O 
activities O 
alongside O 
with O 
the O 
water O 
solubility O 
was O 
achieved O 
by O 
introducing O 
glucose B-TRIVIAL 
. O 
These O 
findings O 
suggest O 
that O 
the O 
introduction O 
of O 
the O 
glucose B-TRIVIAL 
moiety O 
to O 
scutellarein B-TRIVIAL 
wattants O 
further O 
development O 
of O 
this O 
kind O 
of O 
compounds O 
as O 
neuroprotective O 
agents O 
. O 

identification O 
of O 
c-Myc O 
inhibitor O 
10074-G5 B-IDENTIFIER 
. O 

structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
study O 
of O 
the O 
c-Myc O 
( O 
Myc O 
) O 
inhibitor O 
10074-G5 B-IDENTIFIER 
( O 
N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine B-SYSTEMATIC 
, O 
1 O 
) O 
- O 
which O 
targets O 
a O 
hydrophobic O 
domain O 
of O 
the O 
Myc O 
oncoprotein O 
that O 
is O 
flanked O 
by O 
arginine B-TRIVIAL 
residues O 
- O 
was O 
executed O 
in O 
order O 
to O 
determine O 
its O 
pharmacophore O 
. O 
Whilst O 
the O 
7-nitrobenzofurazan B-SYSTEMATIC 
was O 
found O 
to O 
be O 
critical O 
for O 
inhibitory O 
activity O 
, O 
the O 
ortho-biphenyl B-SYSTEMATIC 
could O 
be O 
replaced O 
with O 
a O 
para-carboxyphenyl B-SYSTEMATIC 
group O 
to O 
furnish O 
the O 
new O 
inhibitor O 
JY-3-094 B-IDENTIFIER 
( O 
3q O 
) O 
. O 
Around O 
five O 
times O 
as O 
potent O 
as O 
the O 
lead O 
with O 
an O 
IC(50) O 
of O 
33 O 
μM O 
for O 
disruption O 
of O 
the O 
Myc-Max O 
heterodimer O 
, O 
JY-3-094 B-IDENTIFIER 
demonstrated O 
excellent O 
selectivity O 
over O 
Max-Max O 
homodimers O 
, O 
with O 
no O 
apparent O 
effect O 
at O 
100 O 
μM O 
. O 
Importantly O 
, O 
the O 
carboxylic O 
acid O 
of O 
JY-3-094 B-IDENTIFIER 
improves O 
the O 
physicochemical O 
properties O 
of O 
the O 
lead O 
compound O 
, O 
which O 
will O 
facilitate O 
the O 
incorporation O 
of O 
additional O 
hydrophobicity O 
that O 
might O 
enhance O 
Myc O 
inhibitory O 
activity O 
further O 
still O 
. O 

5'-6-locked O 
phenanthroline B-SYSTEMATIC 
-derived O 
nucleosides B-FAMILY 
chelated O 
to O 
ruthenium B-SYSTEMATIC 
and O 
europium B-SYSTEMATIC 
ions O 
. O 

describe O 
complexes O 
of O 
ruthenium B-SYSTEMATIC 
and O 
europium B-SYSTEMATIC 
with O 
rigid O 
, O 
5'-6-locked O 
1,10-phenanthroline B-SYSTEMATIC 
-containing O 
nucleosides B-FAMILY 
. O 
Both O 
nucleosides O 
were O 
synthesized O 
from O 
condensation O 
of O 
5-amino-2'-deoxycytidine B-SYSTEMATIC 
with O 
the O 
corresponding O 
diketone B-SYSTEMATIC 
. O 
The O 
ruthenium B-SYSTEMATIC 
nucleoside O 
displayed O 
fluorescence O 
characteristic O 
of O 
polypyridine B-SYSTEMATIC 
ruthenium I-SYSTEMATIC 
complexes O 
with O 
a O 
maximum O 
at O 
616 O 
nm O 
and O 
a O 
quantum O 
yield O 
of O 
0.011 O 
. O 
Binding O 
of O 
europium B-SYSTEMATIC 
to O 
the O 
1,10-phenanthroline-2,9-diacid B-SYSTEMATIC 
moiety O 
of O 
the O 
lanthanide B-FAMILY 
binding O 
nucleoside B-FAMILY 
showed O 
formation O 
of O 
a O 
1 O 
: O 
1 O 
complex O 
with O 
emission O 
at O 
570-630 O 
nm O 
, O 
whose O 
emission O 
was O 
enhanced O 
by O 
addition O 
of O 
two O 
phenanthroline B-SYSTEMATIC 
ligands O 
. O 
The O 
lanthanide B-FAMILY 
-binding O 
nucleoside B-FAMILY 
was O 
incorporated O 
into O 
DNA O 
oligonucleotides O 
and O 
shown O 
to O 
selectively O 
bind O 
one O 
equivalent O 
of O 
europium B-SYSTEMATIC 
ions O 
. O 

of O 
a O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
: O 
Kv7.4 O 
( O 
KCNQ4 O 
) O 
B-helix O 
complex O 
provides O 
insight O 
into O 
M O 
current O 
modulation O 
. O 

( O 
CaM O 
) O 
is O 
an O 
important O 
regulator O 
of O 
Kv7.x O 
( O 
KCNQx O 
) O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
channels O 
. O 
Channels O 
from O 
this O 
family O 
produce O 
neuronal O 
M O 
currents O 
and O 
cardiac O 
and O 
auditory O 
I(KS) O 
currents O 
and O 
harbor O 
mutations O 
that O 
cause O 
arrhythmias O 
, O 
epilepsy O 
, O 
and O 
deafness O 
. O 
Despite O 
extensive O 
functional O 
characterization O 
, O 
biochemical O 
and O 
structural O 
details O 
of O 
the O 
interaction O 
between O 
CaM O 
and O 
the O 
channel O 
have O 
remained O 
elusive O 
. O 
Here O 
, O 
we O 
show O 
that O 
both O 
apo-CaM O 
and O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
bind O 
to O 
the O 
C B-FORMULA 
-terminal O 
tail O 
of O 
the O 
neuronal O 
channel O 
Kv7.4 O 
( O 
KCNQ4 O 
) O 
, O 
which O 
is O 
involved O 
in O 
both O 
hearing O 
and O 
mechanosensation O 
. O 
Interactions O 
between O 
apo-CaM O 
and O 
the O 
Kv7.4 O 
tail O 
involve O 
two O 
C B-FORMULA 
-terminal O 
tail O 
segments O 
, O 
known O 
as O 
the O 
A O 
and O 
B O 
segments O 
, O 
whereas O 
the O 
interaction O 
between O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
and O 
the O 
Kv7.4 O 
C B-FORMULA 
-terminal O 
tail O 
requires O 
only O 
the O 
B O 
segment O 
. O 
Biochemical O 
studies O 
show O 
that O 
the O 
calcium B-SYSTEMATIC 
dependence O 
of O 
the O 
CaM O 
: O 
B O 
segment O 
interaction O 
is O 
conserved O 
in O 
all O 
Kv7 O 
subtypes O 
. O 
X-ray O 
crystallographic O 
determination O 
of O 
the O 
structure O 
of O 
the O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
: O 
Kv7.4 O 
B O 
segment O 
complex O 
shows O 
that O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
wraps O 
around O 
the O 
Kv7.4 O 
B O 
segment O 
, O 
which O 
forms O 
an O 
α-helix O 
, O 
in O 
an O 
antiparallel O 
orientation O 
that O 
embodies O 
a O 
variation O 
of O 
the O 
classic O 
1-14 O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
interaction O 
motif O 
. O 
Taken O 
together O 
with O 
the O 
context O 
of O 
prior O 
studies O 
, O 
our O 
data O 
suggest O 
a O 
model O 
for O 
modulation O 
of O 
neuronal O 
Kv7 O 
channels O 
involving O 
a O 
calcium B-SYSTEMATIC 
-dependent O 
conformational O 
switch O 
from O 
an O 
apo-CaM O 
form O 
that O 
bridges O 
the O 
A O 
and O 
B O 
segments O 
to O 
a O 
Ca(2+) B-FORMULA 
/ O 
CaM O 
form O 
bound O 
to O 
the O 
B-helix O 
. O 
The O 
structure O 
presented O 
here O 
also O 
provides O 
a O 
context O 
for O 
a O 
number O 
of O 
disease O 
- O 
causing O 
mutations O 
and O 
for O 
further O 
dissection O 
of O 
the O 
mechanisms O 
by O 
which O 
CaM O 
controls O 
Kv7 O 
function O 
. O 

alterations O 
in O 
swimming O 
speed O 
distributions O 
of O 
rainbow O 
trout O 
exposed O 
to O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
are O 
associated O 
with O 
gill O 
rather O 
than O 
brain O 
injury O 
. O 

effects O 
of O 
engineered O 
nanomaterials O 
on O 
fish O 
behaviours O 
are O 
poorly O 
understood O 
. O 
The O 
present O 
study O 
aimed O 
to O 
determine O 
the O 
locomotor O 
behaviours O 
of O 
trout O 
during O 
waterborne O 
exposure O 
to O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
( O 
TiO(2) B-FORMULA 
NPs O 
) O 
as O 
well O 
as O 
inform O 
on O 
the O 
underlying O 
physiological O 
mechanisms O 
involved O 
. O 
Trout O 
were O 
exposed O 
to O 
either O 
control O 
( O 
without O 
TiO(2) B-FORMULA 
) O 
, O 
1 O 
mg O 
l(-1) O 
TiO(2) B-FORMULA 
NPs O 
or O 
1 O 
mg O 
l(-1) O 
bulk O 
TiO(2) B-FORMULA 
for O 
14 O 
days O 
. O 
Titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
exposure O 
resulted O 
in O 
31 O 
( O 
bulk O 
) O 
and O 
22 O 
fold O 
( O 
nano O 
) O 
increases O 
in O 
the O 
Ti B-FORMULA 
concentrations O 
of O 
gill O 
tissue O 
compared O 
to O 
controls O 
, O 
but O 
there O 
were O 
no O 
measurable O 
increases O 
of O 
Ti B-FORMULA 
in O 
the O 
internal O 
organs O 
including O 
the O 
brain O 
. O 
Gill O 
pathologies O 
were O 
observed O 
in O 
both O 
TiO(2) B-FORMULA 
treatments O 
. O 
Locomotor O 
behaviours O 
were O 
quantified O 
using O 
video O 
tracking O 
software O 
and O 
the O 
proportion O 
of O 
time O 
spent O 
swimming O 
at O 
high O 
speed O 
( O 
> O 
20 O 
cms(-1) O 
) O 
was O 
significantly O 
decreased O 
in O 
fish O 
exposed O 
to O 
TiO(2) B-FORMULA 
NPs O 
, O 
compared O 
to O 
controls O 
, O 
but O 
not O 
fish O 
exposed O 
to O 
bulk O 
TiO(2) B-FORMULA 
. O 
The O 
shift O 
in O 
swimming O 
speed O 
distribution O 
in O 
the O 
TiO(2) B-FORMULA 
NP-exposed O 
fish O 
was O 
associated O 
with O 
decreased O 
area O 
of O 
red O 
pulp O 
in O 
the O 
spleen O 
, O 
increases O 
in O 
haematocrit O 
and O 
whole O 
blood O 
haemoglobin O 
, O 
all O 
consistent O 
with O 
a O 
compensation O 
for O 
respiratory O 
hypoxia O 
without O 
the O 
accumulation O 
of O 
plasma O 
lactate B-FAMILY 
. O 
Fish O 
exposed O 
to O 
TiO(2) B-FORMULA 
NPs O 
also O 
retained O 
competitive O 
abilities O 
when O 
paired O 
with O 
controls O 
in O 
aggressive O 
social O 
encounters O 
. O 
The O 
duration O 
of O 
competitive O 
contests O 
, O 
the O 
level O 
of O 
aggression O 
and O 
contest O 
outcome O 
were O 
not O 
affected O 
by O 
NP O 
exposure O 
. O 
Neurological O 
injury O 
did O 
not O 
explain O 
the O 
changes O 
in O 
locomotor O 
behaviour O 
, O 
although O 
there O 
was O 
some O 
apparent O 
enlargement O 
of O 
the O 
blood O 
vessels O 
on O 
the O 
brain O 
. O 
Whole O 
brain O 
homogenates O 
showed O 
a O 
statistically O 
significant O 
increase O 
in O 
oxidative O 
stress O 
defences O 
such O 
as O 
the O 
total O 
glutathione B-TRIVIAL 
pool O 
, O 
but O 
without O 
loss O 
of O 
Na(+)K(+) B-FORMULA 
-ATPase O 
or O 
acetylcholinesterase O 
activities O 
. O 

of O 
the O 
thyroid O 
hormone O 
pathway O 
in O 
Xenopus O 
laevis O 
by O 
2-mercaptobenzothiazole B-SYSTEMATIC 
. O 

the O 
effects O 
of O 
chemicals O 
on O 
the O 
thyroid O 
system O 
is O 
an O 
important O 
aspect O 
of O 
evaluating O 
chemical O 
safety O 
from O 
an O 
endocrine O 
disrupter O 
perspective O 
. O 
Since O 
there O 
are O 
numerous O 
chemicals O 
to O 
test O 
and O 
limited O 
resources O 
, O 
prioritizing O 
chemicals O 
for O 
subsequent O 
in O 
vivo O 
testing O 
is O 
critical O 
. O 
2-Mercaptobenzothiazole B-SYSTEMATIC 
( O 
MBT B-ABBREVIATION 
) O 
, O 
a O 
high O 
production O 
volume O 
chemical O 
, O 
was O 
tested O 
and O 
shown O 
to O 
inhibit O 
thyroid O 
peroxidase O 
( O 
TPO O 
) O 
enzyme O 
activity O 
in O 
vitro O 
, O 
a O 
key O 
enzyme O 
necessary O 
for O 
the O 
synthesis O 
of O 
thyroid O 
hormone O 
. O 
To O 
determine O 
the O 
thyroid O 
disrupting O 
activity O 
of O 
MBT B-ABBREVIATION 
in O 
vivo O 
, O 
Xenopus O 
laevis O 
larvae O 
were O 
exposed O 
using O 
7- O 
and O 
21-day O 
protocols O 
. O 
The O 
7-day O 
protocol O 
used O 
18-357 O 
μg O 
/ O 
L O 
MBT B-ABBREVIATION 
concentrations O 
and O 
evaluated O 
: O 
metamorphic O 
development O 
, O 
thyroid O 
histology O 
, O 
circulating O 
T4 O 
, O 
circulating O 
thyroid O 
stimulating O 
hormone O 
, O 
thyroidal O 
sodium B-SYSTEMATIC 
- I-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
gene O 
expression O 
, O 
and O 
thyroidal O 
T4 O 
, O 
T3 O 
, O 
and O 
related O 
iodo B-FAMILY 
- I-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
. O 
The O 
21-day O 
protocol O 
used O 
23-435 O 
μg O 
/ O 
L O 
MBT B-ABBREVIATION 
concentrations O 
and O 
evaluated O 
metamorphic O 
development O 
and O 
thyroid O 
histology O 
. O 
Both O 
protocols O 
demonstrated O 
that O 
MBT B-ABBREVIATION 
is O 
a O 
thyroid O 
disrupting O 
chemical O 
at O 
the O 
lowest O 
concentrations O 
tested O 
. O 
These O 
studies O 
complement O 
the O 
in O 
vitro O 
study O 
used O 
to O 
identify O 
MBT B-ABBREVIATION 
as O 
a O 
high O 
priority O 
for O 
in O 
vivo O 
testing O 
, O 
supporting O 
the O 
utility O 
/ O 
predictive O 
potential O 
of O 
a O 
tiered O 
approach O 
to O 
testing O 
chemicals O 
for O 
TPO O 
activity O 
inhibition O 
. O 
The O 
7-day O 
study O 
, O 
with O 
more O 
comprehensive O 
, O 
sensitive O 
, O 
and O 
diagnostic O 
endpoints O 
, O 
provides O 
information O 
at O 
intermediate O 
biological O 
levels O 
that O 
enables O 
linking O 
various O 
endpoints O 
in O 
a O 
robust O 
and O 
integrated O 
pathway O 
for O 
thyroid O 
hormone O 
disruption O 
associated O 
with O 
TPO O 
inhibition O 
. O 

, O 
a O 
dimeric O 
inhibitor O 
of O 
PSD-95 O 
, O 
reduces O 
inflammatory O 
pain O 
without O 
disrupting O 
cognitive O 
or O 
motor O 
performance O 
: O 
comparison O 
with O 
the O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
MK-801 B-IDENTIFIER 
. O 

N-Methyl-d-aspartate B-SYSTEMATIC 
receptor O 
(NMDAR)-dependent O 
production O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
is O 
involved O 
in O 
the O 
development O 
and O 
maintenance O 
of O 
chronic O 
pain O 
states O 
, O 
and O 
is O 
mediated O 
by O 
postsynaptic O 
density O 
protein-95 O 
( O 
PSD-95 O 
) O 
. O 
By O 
binding O 
to O 
both O 
the O 
NMDAR O 
and O 
neuronal O 
NO B-FORMULA 
synthase O 
( O 
nNOS O 
) O 
, O 
PSD-95 O 
mediates O 
a O 
specific O 
coupling O 
between O 
NMDAR O 
activation O 
and O 
NO B-FORMULA 
production O 
. O 
NMDAR O 
antagonism O 
shows O 
anti-nociceptive O 
action O 
in O 
humans O 
and O 
animal O 
models O 
of O 
chronic O 
pain O 
but O 
is O 
associated O 
with O 
severe O 
disturbances O 
of O 
cognitive O 
and O 
motor O 
functions O 
. O 
An O 
alternative O 
approach O 
to O 
modulate O 
the O 
NMDAR O 
- O 
related O 
activity O 
is O 
to O 
perturb O 
the O 
NMDAR O 
/ O 
PSD-95 O 
/ O 
nNOS O 
complex O 
by O 
targeting O 
PSD-95 O 
, O 
thereby O 
decreasing O 
NO B-FORMULA 
production O 
without O 
interfering O 
with O 
the O 
NMDAR O 
ion O 
channel O 
function O 
. O 
Here O 
, O 
we O 
compared O 
the O 
effects O 
of O 
a O 
dimeric O 
PSD-95 O 
inhibitor O 
, O 
UCCB01-125 B-IDENTIFIER 
, O 
and O 
the O 
NMDAR O 
antagonist O 
, O 
MK-801 B-IDENTIFIER 
, O 
on O 
mechanical O 
hypersensitivity O 
in O 
the O 
complete O 
Freund's O 
adjuvant O 
( O 
CFA O 
) O 
model O 
of O 
inflammatory O 
pain O 
. O 
To O 
examine O 
side-effect O 
profiles O 
we O 
also O 
compared O 
the O 
effects O 
of O 
UCCB01-125 B-IDENTIFIER 
and O 
MK-801 B-IDENTIFIER 
in O 
tests O 
of O 
attention O 
, O 
long O 
- O 
term O 
memory O 
, O 
and O 
motor O 
performance O 
. O 
When O 
administered O 
concurrently O 
with O 
CFA O 
, O 
both O 
MK-801 B-IDENTIFIER 
and O 
UCCB01-125 B-IDENTIFIER 
prevented O 
the O 
development O 
of O 
CFA-induced O 
mechanical O 
hypersensitivity O 
1 O 
and O 
24 O 
h O 
after O 
treatment O 
. O 
Moreover O 
, O 
UCCB01-125 B-IDENTIFIER 
was O 
found O 
to O 
reverse O 
CFA-induced O 
hypersensitivity O 
when O 
administered O 
24 O 
h O 
after O 
CFA O 
treatment O 
, O 
an O 
effect O 
lasting O 
for O 
at O 
least O 
3 O 
days O 
. O 
At O 
the O 
dose O 
reducing O 
hypersensitivity O 
, O 
MK-801 B-IDENTIFIER 
disrupted O 
attention O 
, O 
long O 
- O 
term O 
memory O 
, O 
and O 
motor O 
performance O 
. O 
By O 
contrast O 
, O 
even O 
high O 
doses O 
of O 
UCCB01-125 B-IDENTIFIER 
were O 
devoid O 
of O 
side-effects O 
in O 
these O 
tests O 
. O 
The O 
data O 
suggest O 
that O 
PSD-95 O 
inhibition O 
is O 
a O 
feasible O 
strategy O 
to O 
prevent O 
both O 
development O 
and O 
maintenance O 
of O 
chronic O 
inflammatory O 
pain O 
, O 
while O 
avoiding O 
NMDAR O 
antagonism O 
- O 
related O 
side-effects O 
. O 

regioselective O 
glycosylation O 
of O 
xylosyl B-FAMILY 
- I-FAMILY 
containing I-FAMILY 
taxanes I-FAMILY 
by O 
Enterobacter O 
cloaceae O 
. O 

new O 
diglycoside B-FAMILY 
taxanes I-FAMILY 
( O 
4-6 O 
) O 
containing O 
an O 
additional O 
α-d-glucose B-TRIVIAL 
unit O 
were O 
obtained O 
via O 
Enterobacter O 
cloaceae O 
- O 
mediated O 
, O 
highly O 
regioselective O 
glycosylations O 
at O 
OH B-FORMULA 
-4 O 
of O 
the O 
xylosyl B-TRIVIAL 
moieties O 
in O 
7-xylosyl B-FAMILY 
taxanes I-FAMILY 
( O 
1-3 O 
) O 
. O 
Their O 
structures O 
were O 
determined O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
and O 
chemical O 
reactivity O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
an O 
enzymatic O 
elongation O 
of O 
the O 
saccharide O 
chain O 
in O 
taxanes O 
, O 
and O 
the O 
glycosylation O 
reaction O 
is O 
the O 
first O 
described O 
example O 
of O 
a O 
transformation O 
effected O 
by O 
E O 
. O 
cloaceae O 
. O 

on O 
local O 
genotoxicity O 
after O 
particle O 
exposure O 
are O 
crucial O 
to O 
resolve O 
mechanistic O 
aspects O 
such O 
as O 
the O 
impact O 
of O 
chronic O 
inflammation O 
, O 
types O 
of O 
DNA O 
damage O 
, O 
and O 
their O 
role O 
in O 
lung O 
carcinogenesis O 
. O 
We O 
established O 
immunohistochemical O 
methods O 
to O 
quantify O 
the O 
DNA O 
damage O 
markers O 
poly(ADP-ribose) B-SYSTEMATIC 
( O 
PAR B-ABBREVIATION 
) O 
, O 
phosphorylated O 
H2AX O 
( O 
γ-H2AX O 
) O 
, O 
8-hydroxyguanosine B-SYSTEMATIC 
( O 
8-OH-dG B-SYSTEMATIC 
) O 
, O 
and O 
8-oxoguanine B-SYSTEMATIC 
DNA O 
glycosylase O 
( O 
OGG1 O 
) O 
in O 
paraffin B-FAMILY 
-embedded O 
tissue O 
from O 
particle O 
- O 
exposed O 
rats O 
. O 
The O 
study O 
was O 
based O 
on O 
lungs O 
from O 
a O 
subchronic O 
study O 
that O 
was O 
part O 
of O 
an O 
already O 
published O 
carcinogenicity O 
study O 
where O 
rats O 
had O 
been O 
intratracheally O 
instilled O 
with O 
saline O 
, O 
quartz O 
DQ12 O 
, O 
amorphous O 
silica B-TRIVIAL 
( O 
Aerosil B-TRIVIAL 
( O 
® O 
) O 
150 O 
) O 
, O 
or O 
carbon B-TRIVIAL 
black I-TRIVIAL 
( O 
Printex B-TRIVIAL 
( O 
® O 
) O 
90 O 
) O 
at O 
monthly O 
intervals O 
for O 
3 O 
months O 
. O 
Lung O 
sections O 
were O 
stained O 
immunohistochemically O 
and O 
markers O 
were O 
quantified O 
in O 
alveolar O 
lining O 
cells O 
. O 
Local O 
genotoxicity O 
was O 
then O 
correlated O 
with O 
already O 
defined O 
endpoints O 
, O 
i.e O 
. O 
mean O 
inflammation O 
score O 
, O 
bronchoalveolar O 
lavage O 
parameters O 
, O 
and O 
carcinogenicity O 
. O 
Genotoxicity O 
was O 
most O 
pronounced O 
in O 
quartz O 
DQ12 O 
- O 
treated O 
rats O 
, O 
where O 
all O 
genotoxicity O 
markers O 
gave O 
statistically O 
significant O 
positive O 
results O 
, O 
indicating O 
considerable O 
genotoxic O 
stress O 
such O 
as O 
occurrence O 
of O 
DNA O 
double O 
- O 
strand O 
breaks O 
( O 
DSB O 
) O 
, O 
and O 
oxidative O 
damage O 
with O 
subsequent O 
repair O 
activity O 
. O 
Genotoxicity O 
was O 
less O 
pronounced O 
for O 
Printex B-TRIVIAL 
( O 
® O 
) O 
90 O 
, O 
but O 
significant O 
increases O 
in O 
γ-H2AX- O 
and O 
8-OH-dG B-SYSTEMATIC 
-positive O 
nuclei O 
and O 
OGG1-positive O 
cytoplasm O 
were O 
nevertheless O 
detected O 
. O 
In O 
contrast O 
, O 
Aerosil B-TRIVIAL 
( O 
® O 
) O 
150 O 
significantly O 
enhanced O 
only O 
8-OH-dG B-SYSTEMATIC 
-positive O 
nuclei O 
and O 
oxidative O 
damage O 
- O 
related O 
repair O 
activity O 
( O 
OGG1 O 
) O 
in O 
cytoplasm O 
. O 
In O 
the O 
present O 
study O 
, O 
γ-H2AX O 
was O 
the O 
most O 
sensitive O 
genotoxicity O 
marker O 
, O 
differentiating O 
best O 
between O 
the O 
three O 
types O 
of O 
particles O 
. O 
The O 
mean O 
number O 
of O 
8-OH-dG B-SYSTEMATIC 
-positive O 
nuclei O 
, O 
however O 
, O 
correlated O 
best O 
with O 
the O 
mean O 
inflammation O 
score O 
at O 
the O 
same O 
time O 
point O 
. O 
This O 
methodological O 
approach O 
enables O 
integration O 
of O 
local O 
genotoxicity O 
testing O 
in O 
subchronic O 
inhalation O 
studies O 
and O 
makes O 
immunohistochemical O 
detection O 
, O 
in O 
particular O 
of O 
γ-H2AX O 
and O 
8-hydroxyguanine B-SYSTEMATIC 
, O 
a O 
very O 
promising O 
approach O 
for O 
local O 
genotoxicity O 
testing O 
in O 
lungs O 
, O 
with O 
prognostic O 
value O 
for O 
the O 
long O 
- O 
term O 
outcome O 
of O 
particle O 
exposure O 
. O 

receptor O 
( O 
GR O 
) O 
concentrations O 
and O 
the O 
ability O 
of O 
the O 
GR O 
to O 
dimerize O 
are O 
factors O 
which O 
influence O 
sensitivity O 
to O 
glucocorticoids O 
. O 
Upon O 
glucocorticoid O 
binding O 
, O 
the O 
GR O 
is O 
actively O 
transported O 
into O 
the O 
nucleus O 
, O 
a O 
crucial O 
step O 
in O 
determining O 
GR O 
function O 
. O 
We O 
examined O 
the O 
effects O 
of O 
GR O 
concentration O 
and O 
the O 
ability O 
to O 
dimerize O 
on O 
GR O 
nuclear O 
import O 
, O 
export O 
and O 
nuclear O 
distribution O 
using O 
both O 
live O 
cell O 
microscopy O 
of O 
GFP-tagged O 
GR O 
and O 
immunofluorescence O 
of O 
untagged O 
GR O 
, O 
with O 
both O 
wild O 
type O 
GR O 
( O 
GRwt O 
) O 
and O 
dimerization O 
deficient O 
GR O 
( O 
GRdim O 
) O 
. O 
We O 
found O 
that O 
the O 
observed O 
rate O 
of O 
GR O 
nuclear O 
import O 
increases O 
significantly O 
at O 
higher O 
GR O 
concentrations O 
, O 
at O 
saturating O 
concentrations O 
of O 
dexamethasone B-TRIVIAL 
( O 
10(-6) O 
M O 
) O 
using O 
GFP-tagged O 
GR O 
, O 
while O 
with O 
untagged O 
GR O 
it O 
is O 
only O 
discernable O 
at O 
sub O 
- O 
saturating O 
ligand O 
concentrations O 
( O 
10(-10)-10(-9) O 
M O 
) O 
. O 
Loss O 
of O 
dimerization O 
results O 
in O 
a O 
slower O 
observed O 
rate O 
of O 
nuclear O 
import O 
( O 
2.5- O 
to O 
3.3-fold O 
decrease O 
for O 
GFP-GRdim O 
) O 
as O 
well O 
as O 
a O 
decreased O 
extent O 
of O 
GR O 
nuclear O 
localization O 
( O 
18-27% O 
decrease O 
for O 
untagged O 
GRdim O 
) O 
. O 
These O 
results O 
were O 
linked O 
to O 
an O 
increased O 
rate O 
of O 
GR O 
export O 
at O 
low O 
GR O 
concentrations O 
( O 
1.4- O 
to O 
1.6-fold O 
increase O 
for O 
untagged O 
GR O 
) O 
and O 
where O 
GR O 
dimerization O 
is O 
abrogated O 
( O 
1.5- O 
to O 
1.7-fold O 
increase O 
for O 
GFP-GRdim O 
) O 
. O 
Furthermore O 
, O 
GR O 
dimerization O 
was O 
shown O 
to O 
be O 
required O 
for O 
the O 
appearance O 
of O 
discrete O 
GC-dependent O 
GR O 
nuclear O 
foci O 
, O 
the O 
loss O 
of O 
which O 
may O 
explain O 
the O 
increased O 
rate O 
of O 
GR O 
export O 
for O 
the O 
GRdim O 
. O 
The O 
reduction O 
in O 
the O 
observed O 
rate O 
of O 
nuclear O 
import O 
and O 
increased O 
rate O 
of O 
nuclear O 
export O 
displayed O 
at O 
low O 
GR O 
concentrations O 
and O 
by O 
the O 
GRdim O 
could O 
explain O 
the O 
lowered O 
glucocorticoid O 
response O 
under O 
these O 
conditions O 
. O 

approach O 
to O 
improve O 
encapsulation O 
and O 
antitumor O 
activity O 
of O 
doxorubicin B-TRIVIAL 
loaded O 
in O 
solid O 
lipid O 
nanoparticles O 
. O 

work O 
aimed O 
to O 
develop O 
solid O 
lipid O 
nanoparticles O 
( O 
SLNs O 
) O 
loaded O 
with O 
doxorubicin B-TRIVIAL 
evaluating O 
the O 
influence O 
of O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
, O 
a O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
that O 
enhances O 
the O 
activity O 
of O 
anticancer O 
drugs O 
, O 
on O 
drug O 
encapsulation O 
efficiency O 
( O 
EE O 
) O 
. O 
The O 
SLN O 
were O 
characterized O 
for O 
size O 
, O 
zeta O 
potential O 
, O 
entrapment O 
efficiency O 
( O 
EE O 
) O 
and O 
drug O 
release O 
. O 
Studies O 
of O 
in O 
vitro O 
antitumor O 
activity O 
and O 
cellular O 
uptake O 
were O 
also O 
conducted O 
. O 
The O 
reduction O 
in O 
particle O 
size O 
( O 
from O 
127 O 
± O 
14 O 
to O 
94 O 
± O 
1 O 
nm O 
) O 
and O 
negative O 
charges O 
were O 
obtained O 
for O 
SLN O 
loaded O 
with O 
DHA B-ABBREVIATION 
and O 
triethanolamine B-SYSTEMATIC 
( O 
TEA B-ABBREVIATION 
) O 
, O 
amine B-SYSTEMATIC 
used O 
to O 
increase O 
the O 
solubility O 
of O 
doxorubicin B-TRIVIAL 
in O 
melted O 
lipid O 
. O 
The O 
EE O 
was O 
significantly O 
improved O 
from O 
36 O 
± O 
4% O 
to O 
99 O 
± O 
2% O 
for O 
SLN O 
without O 
and O 
with O 
DHA B-ABBREVIATION 
at O 
0.4% O 
, O 
respectively O 
. O 
The O 
doxorubicin B-TRIVIAL 
release O 
in O 
a O 
slightly O 
acid O 
medium O 
( O 
pH O 
5 O 
) O 
was O 
higher O 
than O 
that O 
observed O 
at O 
physiological O 
pH O 
. O 
The O 
in O 
vitro O 
studies O 
clearly O 
showed O 
the O 
higher O 
cytotoxicity O 
of O 
doxorubicin B-TRIVIAL 
- O 
DHA B-ABBREVIATION 
-loaded O 
SLN O 
than O 
free O 
doxorubicin B-TRIVIAL 
+ O 
DHA B-ABBREVIATION 
on O 
human O 
lung O 
tumor O 
cell O 
line O 
( O 
A549 O 
) O 
and O 
the O 
improved O 
cellular O 
uptake O 
achieved O 
with O 
the O 
drug O 
encapsulation O 
can O 
be O 
an O 
explanation O 
. O 
These O 
findings O 
suggest O 
that O 
DHA B-ABBREVIATION 
- O 
doxorubicin B-TRIVIAL 
-loaded O 
SLN O 
is O 
a O 
promising O 
alternative O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 

toxin O 
A O 
( O 
BT O 
) O 
is O 
used O 
therapeutically O 
for O 
the O 
treatment O 
of O 
primary O 
focal O 
hyperhidrosis O 
, O 
a O 
chronic O 
debilitating O 
condition O 
characterised O 
by O 
over O 
- O 
activity O 
of O 
the O 
eccrine O 
sweat O 
glands O 
. O 
Systemic O 
toxicity O 
concerns O 
require O 
BT O 
to O 
be O 
administered O 
by O 
local O 
injection O 
, O 
which O 
in O 
the O 
case O 
of O 
hyperhidrosis O 
means O 
multiple O 
painful O 
intradermal O 
injections O 
by O 
a O 
skilled O 
clinician O 
at O 
6-monthly O 
intervals O 
. O 
This O 
study O 
investigates O 
the O 
potential O 
of O 
a O 
liquid O 
- O 
loaded O 
pocketed O 
microneedle O 
device O 
to O 
deliver O 
botulinum O 
toxin O 
A O 
into O 
the O 
human O 
dermis O 
with O 
the O 
aim O 
of O 
reducing O 
patient O 
pain O 
, O 
improving O 
therapeutic O 
targeting O 
and O 
simplifying O 
the O 
administration O 
procedure O 
. O 
Initially O 
, O 
β-galactosidase O 
was O 
employed O 
as O 
a O 
detectable O 
model O 
for O 
BT O 
to O 
(i) O 
visualise O 
liquid O 
loading O 
of O 
the O 
microneedles O 
, O 
(ii) O 
determine O 
residence O 
time O 
of O 
a O 
liquid O 
formulation O 
on O 
the O 
device O 
and O 
(iii) O 
quantify O 
loaded O 
doses O 
. O 
An O 
array O 
of O 
five O 
stainless O 
steel O 
pocketed O 
microneedles O 
was O 
shown O 
to O 
possess O 
sufficient O 
capacity O 
to O 
deliver O 
therapeutic O 
doses O 
of O 
the O 
potent O 
BT O 
protein O 
. O 
Microneedle O 
- O 
mediated O 
intradermal O 
delivery O 
of O 
β-galactosidase O 
and O 
formaldehyde B-SYSTEMATIC 
-inactivated O 
botulinum O 
toxoid O 
revealed O 
effective O 
deposition O 
and O 
subsequent O 
diffusion O 
within O 
the O 
dermis O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
characterise O 
pocketed O 
microneedle O 
delivery O 
of O 
a O 
liquid O 
formulation O 
into O 
human O 
skin O 
and O 
illustrates O 
the O 
potential O 
of O 
such O 
systems O 
for O 
the O 
cutaneous O 
administration O 
of O 
potent O 
proteins O 
such O 
as O 
BT O 
. O 
A O 
clinically O 
appropriate O 
microneedle O 
delivery O 
system O 
for O 
BT O 
could O 
have O 
a O 
significant O 
impact O 
in O 
both O 
the O 
medical O 
and O 
cosmetic O 
industries O 
. O 

of O 
the O 
serum O 
cytokine O 
contents O 
in O 
broilers O 
fed O 
on O 
diets O 
supplemented O 
with O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 

are O 
immunoregulatory O 
proteins O 
which O 
play O 
an O 
important O 
role O 
in O 
the O 
immune O 
system O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
serum O 
cytokine O 
contents O 
including O 
interleukin-2 O 
( O 
IL-2 O 
) O 
, O 
interleukin-4 O 
( O 
IL-4 O 
) O 
, O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
interleukin-10 O 
( O 
IL-10 O 
) O 
, O 
interferon O 
gamma O 
( O 
IFN-γ O 
) O 
, O 
and O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
induced O 
by O 
dietary O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
in O 
broilers O 
by O 
enzyme O 
- O 
linked O 
immunospecific O 
assay O 
. O 
A O 
total O 
of O 
240 O 
one O 
- O 
day O 
- O 
old O 
avian O 
broilers O 
were O 
divided O 
into O 
four O 
groups O 
and O 
fed O 
on O 
a O 
corn O 
- O 
soybean O 
basal O 
diet O 
as O 
control O 
diet O 
or O 
the O 
same O 
basal O 
diet O 
supplemented O 
with O 
300 O 
, O 
600 O 
, O 
and O 
900 O 
mg O 
/ O 
kg O 
of O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 
During O 
the O 
experimental O 
period O 
of O 
42 O 
days O 
, O 
the O 
results O 
showed O 
that O 
the O 
serum O 
IL-2 O 
, O 
IL-4 O 
, O 
IL-6 O 
, O 
IL-10 O 
, O 
IFN-γ O 
and O 
TNF-α O 
contents O 
were O 
lower O 
( O 
p O 
< O 
0.05 O 
or O 
p O 
< O 
0.01 O 
) O 
in O 
the O 
300 O 
, O 
600 O 
, O 
900 O 
mg O 
/ O 
kg O 
groups O 
than O 
those O 
in O 
the O 
control O 
group O 
. O 
It O 
was O 
concluded O 
that O 
dietary O 
nickel B-SYSTEMATIC 
chloride I-SYSTEMATIC 
in O 
the O 
range O 
of O 
300 O 
to O 
900 O 
mg O 
/ O 
kg O 
could O 
reduce O 
the O 
serum O 
cytokine O 
contents O 
, O 
which O 
could O 
finally O 
impact O 
the O 
immune O 
function O 
in O 
broilers O 
. O 

of O 
benzene B-SYSTEMATIC 
-water O 
and O 
pyrrole B-SYSTEMATIC 
-water O 
interactions O 
in O 
the O 
forms O 
of O 
σ O 
and O 
π O 
types O 
: O 
theoretical O 
studies O 
from O 
clusters O 
to O 
liquid O 
mixture O 
. O 

combined O 
and O 
sequential O 
use O 
of O 
quantum O 
mechanical O 
( O 
QM O 
) O 
calculations O 
and O 
classical O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
was O 
made O 
to O 
investigate O 
the O 
σ O 
and O 
π O 
types O 
of O 
hydrogen B-SYSTEMATIC 
bond O 
( O 
HB O 
) O 
in O 
benzene B-SYSTEMATIC 
-water O 
and O 
pyrrole B-SYSTEMATIC 
-water O 
as O 
clusters O 
and O 
as O 
their O 
liquid O 
mixture O 
, O 
respectively O 
. O 
This O 
paper O 
aims O 
at O 
analyzing O 
similarities O 
and O 
differences O 
of O 
these O 
HBs O 
resulted O 
from O 
QM O 
and O 
MD O 
on O 
an O 
equal O 
footing O 
. O 
Based O 
on O 
the O 
optimized O 
geometry O 
at O 
ωb97xD O 
/ O 
aug-cc-pVTZ O 
level O 
of O 
theory O 
, O 
the O 
nature O 
and O 
property O 
of O 
σ O 
and O 
π O 
types O 
of O 
HBs O 
are O 
unveiled O 
by O 
means O 
of O 
atoms O 
in O 
molecules O 
( O 
AIM O 
) O 
, O 
natural O 
bond O 
orbital O 
( O 
NBO O 
) O 
and O 
energy O 
decomposition O 
analysis O 
( O 
EDA O 
) O 
. O 
In O 
light O 
of O 
the O 
above O 
findings O 
, O 
MD O 
simulation O 
with O 
OPLS-AA O 
and O 
SPC O 
model O 
was O 
applied O 
to O 
study O 
the O 
liquid O 
mixture O 
at O 
different O 
temperatures O 
. O 
The O 
MD O 
results O 
further O 
characterize O 
the O 
behavior O 
and O 
structural O 
properties O 
of O 
σ O 
and O 
π O 
types O 
HBs O 
, O 
which O 
are O 
somewhat O 
different O 
but O 
reasonable O 
for O 
the O 
clusters O 
by O 
QM O 
. O 
Finally O 
, O 
we O 
provide O 
a O 
reasonable O 
explanation O 
for O 
the O 
different O 
solubility O 
between O 
benzene B-SYSTEMATIC 
/ O 
water O 
and O 
pyrrole B-SYSTEMATIC 
/ O 
water O 
. O 

- O 
glutamate B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
- O 
dopamine B-TRIVIAL 
reciprocal O 
interactions O 
as O 
putative O 
molecular O 
targets O 
for O 
novel O 
antipsychotic O 
treatments O 
: O 
from O 
receptor O 
heterodimers O 
to O 
postsynaptic O 
scaffolding O 
and O 
effector O 
proteins O 
. O 

physical O 
and O 
functional O 
interactions O 
between O 
serotonin B-TRIVIAL 
- O 
glutamate B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
- O 
dopamine B-TRIVIAL 
signaling O 
have O 
been O 
suggested O 
to O 
be O 
involved O 
in O 
psychosis O 
pathophysiology O 
and O 
are O 
supposed O 
to O 
be O 
relevant O 
for O 
antipsychotic O 
treatment O 
. O 
Type O 
II O 
metabotropic O 
glutamate B-TRIVIAL 
receptors O 
( O 
mGluRs O 
) O 
and O 
serotonin B-TRIVIAL 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
have O 
been O 
reported O 
to O 
form O 
heterodimers O 
that O 
modulate O 
G O 
- O 
protein O 
- O 
mediated O 
intracellular O 
signaling O 
differentially O 
compared O 
to O 
mGluR2 O 
and O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
homomers O 
. O 
Additionally O 
, O 
direct O 
evidence O 
has O 
been O 
provided O 
that O 
D(2) O 
and O 
5-HT B-SYSTEMATIC 
( O 
2A O 
) O 
receptors O 
form O 
physical O 
heterocomplexes O 
which O 
exert O 
a O 
functional O 
cross O 
- O 
talk O 
, O 
as O 
demonstrated O 
by O 
studies O 
on O 
hallucinogen O 
- O 
induced O 
signaling O 
. O 
Moving O 
from O 
receptors O 
to O 
postsynaptic O 
density O 
( O 
PSD O 
) O 
scenario O 
, O 
the O 
scaffolding O 
protein O 
PSD-95 O 
is O 
known O 
to O 
interact O 
with O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
, O 
D(2) O 
and O 
5-HT B-SYSTEMATIC 
( O 
2 O 
) O 
receptors O 
, O 
regulating O 
their O 
activation O 
state O 
. O 
Homer1a O 
, O 
the O 
inducible O 
member O 
of O 
the O 
Homer O 
family O 
of O 
PSD O 
proteins O 
that O 
is O 
implicated O 
in O 
glutamatergic O 
signal O 
transduction O 
, O 
is O 
induced O 
in O 
striatum O 
by O 
antipsychotics O 
with O 
high O 
dopamine B-TRIVIAL 
receptor O 
affinity O 
and O 
in O 
the O 
cortex O 
by O 
antipsychotics O 
with O 
mixed O 
serotonergic O 
/ O 
dopaminergic O 
profile O 
. O 
Signaling O 
molecules O 
, O 
such O 
as O 
Akt O 
and O 
glycogen-synthase-kinase-3 O 
( O 
GSK-3 O 
) O 
, O 
could O 
be O 
involved O 
in O 
the O 
mechanism O 
of O 
action O 
of O 
antipsychotics O 
, O 
targeting O 
dopamine B-TRIVIAL 
, O 
serotonin B-TRIVIAL 
, O 
and O 
glutamate B-TRIVIAL 
neurotransmission O 
. O 
Altogether O 
, O 
these O 
proteins O 
stand O 
at O 
the O 
crossroad O 
of O 
glutamate B-TRIVIAL 
- O 
dopamine B-TRIVIAL 
- O 
serotonin B-TRIVIAL 
signaling O 
pathways O 
and O 
may O 
be O 
considered O 
as O 
valuable O 
molecular O 
targets O 
for O 
current O 
and O 
new O 
antipsychotics O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
provide O 
a O 
critical O 
appraisal O 
on O 
serotonin B-TRIVIAL 
- O 
glutamate B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
- O 
dopamine B-TRIVIAL 
interplay O 
to O 
support O 
the O 
idea O 
that O 
next O 
generation O 
schizophrenia O 
pharmacotherapy O 
should O 
not O 
exclusively O 
rely O 
on O 
receptor O 
targeting O 
strategies O 
. O 

Athabasca O 
River O 
basin O 
, O 
located O 
in O 
Alberta O 
, O 
Canada O 
, O 
covers O 
157 O 
, O 
0 O 
km(2) O 
and O 
holds O 
significant O 
cultural O 
and O 
economic O 
importance O 
. O 
Recent O 
research O 
assessed O 
changes O 
in O 
several O 
water O 
quality O 
and O 
quantity O 
parameters O 
that O 
have O 
changed O 
both O 
spatially O 
( O 
along O 
the O 
river O 
continuum O 
) O 
and O 
temporally O 
( O 
pre O 
- O 
development O 
and O 
present O 
day O 
) O 
in O 
the O 
Athabasca O 
River O 
Basin O 
. O 
In O 
particular O 
, O 
parameters O 
such O 
as O 
salinity O 
and O 
dissolved O 
sulphate B-SYSTEMATIC 
have O 
changed O 
significantly O 
across O 
the O 
Athabasca O 
River O 
mainstem O 
over O 
the O 
past O 
five O 
decades O 
. O 
Further O 
laboratory O 
testing O 
has O 
linked O 
concentrations O 
of O 
these O 
parameters O 
to O 
changes O 
in O 
fathead O 
minnow O 
reproduction O 
. O 
Research O 
is O 
required O 
to O 
determine O 
whether O 
these O 
changes O 
observed O 
in O 
the O 
laboratory O 
can O 
be O 
applied O 
to O 
actual O 
in O 
- O 
river O 
conditions O 
. O 
The O 
objectives O 
of O 
the O 
present O 
study O 
were O 
to O 
twofold O 
: O 
assess O 
changes O 
in O 
fathead O 
minnow O 
response O 
metrics O 
( O 
i.e O 
. O 
, O 
condition O 
, O 
liver O 
and O 
gonad O 
size O 
, O 
egg O 
production O 
, O 
and O 
gill O 
histology O 
) O 
associated O 
with O 
increasing O 
concentrations O 
of O 
salinity O 
and O 
dissolved O 
sulphate B-SYSTEMATIC 
and O 
determine O 
whether O 
sublethal O 
effect O 
thresholds O 
established O 
in O 
laboratory O 
experiments O 
correspond O 
to O 
actual O 
in O 
- O 
river O 
concentrations O 
using O 
water O 
from O 
the O 
mouth O 
and O 
headwaters O 
of O 
the O 
Athabasca O 
River O 
. O 
Three O 
dose O 
- O 
response O 
experiments O 
( O 
NaCl B-FORMULA 
, O 
SO4 B-FORMULA 
, O 
and O 
water O 
sampled O 
from O 
the O 
mouth O 
of O 
the O 
Athabasca O 
River O 
) O 
were O 
conducted O 
at O 
Jasper O 
National O 
Park O 
, O 
Alberta O 
, O 
Canada O 
. O 
Significant O 
increases O 
in O 
mean O 
eggs O 
per O 
female O 
per O 
day O 
occurred O 
at O 
the O 
50% O 
treatment O 
for O 
the O 
mouth O 
experiment O 
and O 
thresholds O 
previously O 
developed O 
in O 
the O 
laboratory O 
were O 
verified O 
. O 

graphenes B-FAMILY 
: O 
an O 
emerging O 
class O 
of O 
functional O 
soft O 
materials O 
. O 

a O 
materials O 
science O 
point O 
of O 
view O 
, O 
graphene B-TRIVIAL 
is O 
essentially O 
a O 
polymer O 
having O 
a O 
giant O 
, O 
two O 
- O 
dimensional O 
molecular O 
configuration O 
. O 
In O 
this O 
Progress O 
Report O 
, O 
solvated O 
graphene B-TRIVIAL 
and O 
its O 
derivatives O 
are O 
illustrated O 
from O 
the O 
perspective O 
of O 
soft O 
matter O 
. O 
Firstly O 
, O 
the O 
key O 
appealing O 
features O 
of O 
graphene B-TRIVIAL 
as O 
a O 
molecular O 
building O 
block O 
for O 
assembling O 
bulk O 
soft O 
materials O 
are O 
highlighed O 
. O 
It O 
is O 
then O 
demonstrated O 
how O 
the O 
intersheet O 
interactions O 
in O 
solution O 
are O 
correlated O 
with O 
the O 
molecular O 
structure O 
of O 
graphene B-TRIVIAL 
, O 
and O 
how O 
a O 
combination O 
of O 
the O 
unique O 
molecular O 
structure O 
and O 
colloidal O 
interactions O 
can O 
lead O 
to O 
simple O 
, O 
solution O 
- O 
phase O 
approaches O 
for O 
assembling O 
graphenes B-FAMILY 
into O 
a O 
variety O 
of O 
macroscopic O 
nanoarchitectures O 
. O 
A O 
number O 
of O 
new O 
exciting O 
functions O 
and O 
applications O 
are O 
also O 
highlighted O 
, O 
which O 
are O 
enabled O 
by O 
the O 
solvation O 
effect O 
and O 
in O 
particular O 
, O 
it O 
is O 
discussed O 
why O 
and O 
how O 
solvated O 
graphenes B-FAMILY 
can O 
offer O 
exciting O 
functions O 
that O 
are O 
unattainable O 
with O 
the O 
dried O 
, O 
hard O 
counterpart O 
. O 
The O 
discussion O 
is O 
concluded O 
with O 
some O 
personal O 
perspectives O 
on O 
the O 
future O 
directions O 
in O 
which O 
this O 
emerging O 
class O 
of O 
functional O 
soft O 
materials O 
could O 
be O 
pursued O 
. O 

stability O 
of O 
24 O 
chemicals O 
, O 
including O 
pharmaceuticals O 
and O 
personal O 
care O 
products O 
, O 
and O 
some O 
agrochemicals O 
on O 
extraction O 
media O 
was O 
evaluated O 
by O 
preloading O 
them O 
onto O 
Oasis O 
hydrophilic O 
lipophilic O 
balanced O 
solid O 
- O 
phase O 
extraction O 
( O 
SPE O 
) O 
cartridges O 
and O 
polar O 
organic O 
chemical O 
integrative O 
samplers O 
( O 
POCIS O 
) O 
followed O 
by O 
storage O 
at O 
-20°C O 
over O 
time O 
. O 
After O 
20 O 
months O 
, O 
the O 
average O 
loss O 
was O 
11% O 
on O 
POCIS O 
, O 
with O 
only O 
2,4-dichlorophenoxyacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
atrazine B-TRIVIAL 
, O 
chlorpyrifos B-TRIVIAL 
, O 
and O 
gemfibrozil B-TRIVIAL 
showing O 
a O 
statistically O 
significant O 
decline O 
compared O 
with O 
initial O 
concentrations O 
. O 
Losses O 
on O 
SPE O 
cartridges O 
were O 
below O 
19% O 
, O 
with O 
an O 
average O 
loss O 
of O 
9% O 
. O 
In O 
addition O 
to O 
laboratory O 
spiked O 
samples O 
, O 
multiple O 
POCIS O 
deployed O 
in O 
wastewater O 
- O 
impacted O 
surface O 
waters O 
and O 
SPE O 
extracts O 
of O 
these O 
waters O 
were O 
stored O 
in O 
their O 
original O 
coextracted O 
matrix O 
for O 
nearly O 
two O 
years O 
with O 
minimal O 
observed O 
losses O 
. O 
Errors O 
from O 
typical O 
sampling O 
, O 
handling O 
, O 
and O 
concentration O 
estimates O 
from O 
POCIS O 
sampling O 
rates O 
were O 
typically O 
± O 
15 O 
to O 
30% O 
relative O 
standard O 
deviation O 
, O 
so O 
observed O 
storage O 
losses O 
are O 
minimal O 
for O 
most O 
POCIS O 
applications O 
. O 
While O 
losses O 
during O 
storage O 
on O 
SPE O 
cartridges O 
for O 
20 O 
months O 
were O 
small O 
but O 
statistically O 
significant O 
for O 
many O 
compounds O 
, O 
addition O 
of O 
labeled O 
internal O 
standards O 
prior O 
to O 
freezing O 
should O 
correct O 
for O 
such O 
losses O 
. O 
Thus O 
, O 
storage O 
of O 
processed O 
water O 
samples O 
for O 
analysis O 
of O 
polar O 
organic O 
pollutants O 
is O 
viable O 
for O 
archival O 
purposes O 
or O 
studies O 
for O 
which O 
samples O 
cannot O 
be O 
analyzed O 
in O 
the O 
short O 
term O 
. O 

ecotoxicology O 
, O 
appreciation O 
is O 
growing O 
for O 
the O 
influence O 
that O 
ecological O 
interactions O 
have O 
on O 
the O 
toxicity O 
of O 
contaminants O 
, O 
such O 
as O 
insecticides O 
, O 
to O 
sensitive O 
species O 
. O 
Most O 
previous O 
studies O 
, O 
however O 
, O 
have O 
focused O 
on O 
factors O 
that O 
exacerbate O 
insecticide O 
effects O 
on O 
species O 
, O 
while O 
factors O 
that O 
may O 
mitigate O 
these O 
effects O 
have O 
been O 
relatively O 
ignored O 
. O 
In O 
aquatic O 
habitats O 
, O 
a O 
small O 
number O 
of O 
studies O 
have O 
shown O 
that O 
submersed O 
macrophytes O 
can O 
remove O 
some O 
insecticides O 
from O 
the O 
water O 
column O 
via O 
sorption O 
. O 
Although O 
examining O 
sorption O 
dynamics O 
is O 
important O 
for O 
understanding O 
the O 
environmental O 
fate O 
of O 
insecticides O 
, O 
whether O 
and O 
to O 
what O 
extent O 
macrophytes O 
actually O 
mitigate O 
insecticide O 
effects O 
on O 
aquatic O 
species O 
remains O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
authors O 
examined O 
how O 
much O 
and O 
how O 
quickly O 
several O 
realistic O 
densities O 
of O 
the O 
macrophyte O 
Elodea O 
canadensis O 
decreased O 
the O 
toxicity O 
of O 
the O 
insecticide O 
malathion B-TRIVIAL 
to O 
Daphnia O 
magna O 
, O 
a O 
keystone O 
aquatic O 
herbivore O 
. O 
To O 
do O 
this O 
, O 
the O 
authors O 
quantified O 
Daphnia O 
survival O 
in O 
outdoor O 
test O 
systems O 
( O 
0.95 O 
L O 
) O 
exposed O 
to O 
a O 
factorial O 
combination O 
of O 
five O 
Elodea O 
densities O 
crossed O 
with O 
five O 
malathion B-TRIVIAL 
concentrations O 
. O 
The O 
authors O 
discovered O 
that O 
malathion B-TRIVIAL 
' O 
s O 
lethality O 
to O 
Daphnia O 
decreased O 
with O 
increasing O 
Elodea O 
density O 
. O 
Furthermore O 
, O 
the O 
rate O 
at O 
which O 
Elodea O 
reduced O 
malathion B-TRIVIAL 
' O 
s O 
toxicity O 
in O 
the O 
water O 
column O 
increased O 
with O 
macrophyte O 
density O 
. O 
These O 
results O 
provide O 
strong O 
evidence O 
that O 
submersed O 
macrophytes O 
can O 
mitigate O 
the O 
ecological O 
impacts O 
of O 
a O 
popular O 
insecticide O 
and O 
further O 
support O 
that O 
ecological O 
interactions O 
can O 
strongly O 
influence O 
contaminant O 
environmental O 
effects O 
. O 

is O 
a O 
transcription O 
factor O 
that O 
regulates O 
the O 
ttd O 
operon O 
encoding O 
tartrate B-TRIVIAL 
dehydratase O 
. O 
During O 
anaerobic O 
conditions O 
, O 
its O 
copy O 
number O 
increases O 
by O 
100-fold O 
, O 
making O 
Dan O 
an O 
abundant O 
nucleoid O 
- O 
associated O 
protein O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
mode O 
of O 
Dan-DNA O 
interaction O 
. O 
To O 
understand O 
its O 
cellular O 
functions O 
, O 
we O 
used O 
single O 
- O 
molecule O 
manipulation O 
and O 
imaging O 
techniques O 
to O 
show O 
that O 
Dan O 
binds O 
cooperatively O 
along O 
DNA O 
, O 
resulting O 
in O 
formation O 
of O 
a O 
rigid O 
periodic O 
nucleoprotein O 
filament O 
that O 
strongly O 
restricts O 
accessibility O 
to O 
DNA O 
. O 
Furthermore O 
, O 
in O 
the O 
presence O 
of O 
physiologic O 
levels O 
of O 
magnesium B-SYSTEMATIC 
, O 
these O 
filaments O 
interact O 
with O 
each O 
other O 
to O 
cause O 
global O 
DNA O 
condensation O 
. O 
Overall O 
, O 
these O 
results O 
shed O 
light O 
on O 
the O 
architectural O 
role O 
of O 
Dan O 
in O 
the O 
compaction O 
of O 
Escherichia O 
coli O 
chromosomal O 
DNA O 
under O 
anaerobic O 
conditions O 
. O 
Formation O 
of O 
the O 
nucleoprotein O 
filament O 
provides O 
a O 
basis O 
in O 
understanding O 
how O 
Dan O 
may O 
play O 
roles O 
in O 
both O 
chromosomal O 
DNA O 
protection O 
and O 
gene O 
regulation O 
. O 

landscape O 
of O 
diisopropyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
: O 
quantum O 
chemical O 
calculations O 
validated O 
by O 
microwave O 
spectroscopy O 
. O 

report O 
on O 
the O 
gas-phase O 
structure O 
of O 
the O 
most O 
abundant O 
conformer O 
of O 
diisopropyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
, O 
(CH(3))(2)HC-CO-CH(CH(3))(2) B-FORMULA 
, O 
as O 
observed O 
by O 
molecular O 
beam O 
Fourier O 
transform O 
microwave O 
spectroscopy O 
. O 
The O 
gas-phase O 
structures O 
of O 
five O 
conformers O 
of O 
diisopropyl B-SYSTEMATIC 
ketone I-SYSTEMATIC 
were O 
optimized O 
using O 
ab O 
initio O 
calculations O 
at O 
the O 
MP2 O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
level O 
of O 
theory O 
. O 
The O 
natures O 
of O 
the O 
stationary O 
points O 
were O 
verified O 
using O 
harmonic O 
frequency O 
calculations O 
. O 
The O 
only O 
conformer O 
observed O 
in O 
the O 
supersonic O 
jet O 
possesses O 
C(2) O 
symmetry O 
and O 
appears O 
as O 
an O 
enantiomeric O 
pair O 
. O 
From O 
the O 
microwave O 
spectrum O 
, O 
a O 
set O 
of O 
three O 
highly O 
accurate O 
rotational O 
constants O 
, O 
five O 
centrifugal O 
distortion O 
constants O 
, O 
and O 
three O 
sextic O 
centrifugal O 
distortion O 
constants O 
were O 
determined O 
. O 
The O 
structure O 
of O 
the O 
observed O 
conformer O 
was O 
optimized O 
again O 
at O 
different O 
levels O 
of O 
theory O 
using O 
the O 
HF O 
, O 
MP2 O 
, O 
and O 
B3LYP O 
methods O 
. O 
The O 
theoretical O 
constants O 
of O 
the O 
C(2) O 
conformer O 
were O 
subsequently O 
validated O 
using O 
the O 
experimental O 
constants O 
. O 
To O 
understand O 
the O 
transitions O 
of O 
one O 
conformer O 
to O 
the O 
others O 
, O 
the O 
isopropyl B-SYSTEMATIC 
groups O 
were O 
rotated O 
against O 
each O 
other O 
. O 
The O 
resulting O 
two O 
- O 
dimensional O 
potential O 
energy O 
surface O 
shows O 
nicely O 
the O 
symmetry O 
of O 
the O 
conformational O 
landscape O 
and O 
also O 
indicates O 
the O 
enantiomeric O 
pairs O 
of O 
the O 
conformers O 
. O 
The O 
barriers O 
to O 
internal O 
rotation O 
of O 
the O 
methyl B-SYSTEMATIC 
groups O 
were O 
determined O 
to O 
be O 
1052 O 
and O 
905 O 
cm(-1) O 
at O 
the O 
MP2 O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
and O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
levels O 
, O 
respectively O 
. O 
In O 
agreement O 
with O 
the O 
theoretical O 
predictions O 
, O 
no O 
internal O 
rotation O 
patterns O 
could O 
be O 
observed O 
in O 
the O 
microwave O 
spectrum O 
. O 

effects O 
on O 
expression O 
of O 
AKR1C1-AKR1C3 O 
, O 
SRD5A1 O 
and O 
PGR O 
in O 
the O 
Z-12 O 
endometriotic O 
epithelial O 
cell O 
line O 
. O 

is O 
defined O 
as O 
the O 
presence O 
of O 
endometrial O 
glands O 
and O 
stroma O 
outside O 
the O 
uterine O 
cavity O 
. O 
This O 
disease O 
is O 
associated O 
with O 
diminished O 
protective O 
effects O 
of O 
progesterone B-TRIVIAL 
, O 
which O 
are O 
usually O 
explained O 
by O 
inadequate O 
activation O 
of O 
progesterone B-TRIVIAL 
receptors O 
and O 
also O 
enhanced O 
pre O 
- O 
receptor O 
metabolism O 
of O 
progesterone B-TRIVIAL 
. O 
Endometriosis O 
is O 
often O 
treated O 
with O 
progestins B-FAMILY 
, O 
which O 
act O 
as O 
progesterone B-TRIVIAL 
receptor O 
agonists O 
, O 
although O 
their O 
exact O 
mechanisms O 
of O 
action O 
are O 
not O 
completely O 
understood O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
how O 
the O 
progestins B-FAMILY 
medroxyprogesterone B-TRIVIAL 
acetate I-TRIVIAL 
, O 
dydrogesterone B-TRIVIAL 
and O 
dienogest B-TRIVIAL 
, O 
as O 
well O 
as O 
progesterone B-TRIVIAL 
, O 
impact O 
on O 
the O 
expression O 
of O 
genes O 
of O 
pre O 
- O 
receptor O 
progesterone B-TRIVIAL 
metabolism O 
in O 
Z-12 O 
epithelial O 
cell O 
line O 
, O 
a O 
model O 
system O 
of O 
peritoneal O 
endometriosis O 
. O 
Our O 
data O 
demonstrate O 
that O 
these O 
progestins B-FAMILY 
affect O 
local O 
pre O 
- O 
receptor O 
metabolism O 
to O 
a O 
different O 
extent O 
. O 
The O 
most O 
favorable O 
effects O 
were O 
seen O 
for O 
dydrogesterone B-TRIVIAL 
and O 
dienogest B-TRIVIAL 
, O 
where O 
the O 
first O 
, O 
dydrogesterone B-TRIVIAL 
, O 
significantly O 
reduced O 
SRD5A1 O 
, O 
AKR1C2 O 
and O 
AKR1C3 O 
expression O 
, O 
and O 
additionally O 
had O 
a O 
nonsignificant O 
impact O 
on O 
progesterone B-TRIVIAL 
receptor O 
B O 
( O 
PR-B O 
) O 
protein O 
levels O 
. O 
This O 
might O 
slow O 
down O 
the O 
first O 
step O 
of O 
pre O 
- O 
receptor O 
metabolism O 
, O 
the O 
conversion O 
of O 
progesterone B-TRIVIAL 
to O 
5α-dihydroprogestrone B-SYSTEMATIC 
by O 
SRD5A1 O 
, O 
and O 
it O 
might O 
also O 
affect O 
further O 
reduction O 
of O 
3-keto B-SYSTEMATIC 
and O 
20-keto B-SYSTEMATIC 
groups O 
catalyzed O 
by O 
AKR1C2 O 
and O 
AKR1C3 O 
. O 
Similarly O 
favorable O 
effects O 
were O 
seen O 
for O 
dienogest B-TRIVIAL 
, O 
which O 
promoted O 
significant O 
reduction O 
of O 
AKR1C1 O 
and O 
AKR1C2 O 
expression O 
and O 
also O 
showed O 
no O 
effect O 
on O 
PR-B O 
protein O 
levels O 
. O 
Different O 
effects O 
were O 
seen O 
for O 
progesterone B-TRIVIAL 
, O 
which O 
significantly O 
decreased O 
SRD5A1 O 
, O 
PR-B O 
and O 
HSD17B2 O 
protein O 
levels O 
. O 
In O 
contrast O 
, O 
treatment O 
with O 
medroxyprogesterone B-TRIVIAL 
acetate I-TRIVIAL 
resulted O 
in O 
increased O 
AKR1C1 O 
expression O 
and O 
decreased O 
levels O 
of O 
PR-B O 
, O 
which O 
might O 
lead O 
to O 
enhanced O 
progesterone B-TRIVIAL 
metabolism O 
and O 
reduced O 
signaling O 
through O 
progesterone B-TRIVIAL 
receptors O 
. O 
Altogether O 
, O 
our O 
data O 
in O 
this O 
Z-12 O 
cell O 
model O 
suggest O 
that O 
the O 
beneficial O 
effects O 
of O 
treatment O 
with O 
progestin B-FAMILY 
observed O 
in O 
endometriosis O 
patients O 
might O 
arise O 
from O 
decreased O 
pre O 
- O 
receptor O 
metabolism O 
of O 
the O 
protective O 
progesterone B-TRIVIAL 
by O 
the O 
SRD5A1 O 
and O 
AKR1C O 
enzymes O 
. O 

protein O 
kinase O 
1 O 
( O 
Pak1 O 
) O 
mediates O 
the O 
cross O 
talk O 
between O 
insulin O 
and O 
β-catenin O 
on O 
proglucagon O 
gene O 
expression O 
and O 
its O 
ablation O 
affects O 
glucose B-TRIVIAL 
homeostasis O 
in O 
male O 
C57BL O 
/ O 
6 O 
mice O 
. O 

gut O 
endocrine O 
L O 
cells O 
, O 
the O 
Wnt O 
signaling O 
pathway O 
effector O 
β-catenin O 
( O 
β-cat O 
) O 
/ O 
transcription O 
factor O 
7- O 
like O 
2 O 
mediates O 
the O 
stimulatory O 
effect O 
of O 
insulin O 
on O 
proglucagon O 
( O 
gcg O 
) O 
expression O 
and O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
production O 
. O 
In O 
several O 
other O 
cell O 
lineages O 
, O 
insulin O 
is O 
able O 
to O 
stimulate O 
p21-activated O 
protein O 
kinase O 
1 O 
( O 
Pak1 O 
) O 
. O 
Here O 
we O 
determined O 
the O 
role O 
of O 
Pak1 O 
in O 
gcg O 
expression O 
and O 
the O 
effect O 
of O 
Pak1 O 
deletion O 
on O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Insulin O 
stimulated O 
Pak1 O 
activation O 
through O 
increasing O 
its O 
Thr B-FORMULA 
423 O 
phosphorylation O 
in O 
gut O 
gcg O 
- O 
expressing O 
cell O 
lines O 
, O 
associated O 
with O 
increased O 
gcg O 
mRNA O 
levels O 
. O 
This O 
stimulation O 
was O 
attenuated O 
by O 
the O 
Pak O 
inhibitor O 
2,2'-dihydroxy-1,1'-dinaphthyldisulfide B-SYSTEMATIC 
( O 
IPA3 B-ABBREVIATION 
) O 
or O 
dominant O 
- O 
negative O 
Pak1 O 
. O 
Both O 
insulin O 
and O 
cAMP B-ABBREVIATION 
-promoting O 
agents O 
activated O 
β-cat O 
Ser B-FORMULA 
675 O 
phosphorylation O 
, O 
which O 
was O 
attenuated O 
by O 
IPA3 O 
or O 
protein O 
kinase O 
A O 
inhibition O 
, O 
respectively O 
. O 
Gut O 
gcg O 
levels O 
were O 
reduced O 
in O 
male O 
Pak1(- O 
/ O 
- O 
) O 
mice O 
, O 
associated O 
with O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
after O 
an O 
ip O 
or O 
oral O 
glucose B-TRIVIAL 
challenge O 
. O 
These O 
mice O 
had O 
lower O 
circulating O 
active O 
GLP-1 O 
levels O 
after O 
a O 
glucose B-TRIVIAL 
challenge O 
as O 
well O 
as O 
reduced O 
distal O 
ileum O 
GLP-1 O 
content O 
after O 
insulin O 
treatment O 
. O 
Finally O 
, O 
the O 
Pak1(- O 
/ O 
- O 
) O 
mice O 
exhibited O 
reduced O 
brainstem O 
gcg O 
level O 
and O 
abolished O 
β-cat O 
Ser B-FORMULA 
675 O 
phosphorylation O 
in O 
brain O 
neurons O 
after O 
insulin O 
treatment O 
. O 
We O 
suggest O 
that O 
Pak1 O 
mediates O 
the O 
cross O 
talk O 
between O 
insulin O 
and O 
Wnt O 
signaling O 
pathways O 
on O 
gut O 
and O 
brain O 
gcg O 
expression O 
, O 
and O 
its O 
ablation O 
impairs O 
glucose B-TRIVIAL 
homeostasis O 
. O 

, O 
bioaccumulation O 
and O 
physiological O 
responses O 
in O 
juvenile O 
freshwater O 
mussels O 
( O 
Lampsilis O 
siliquoidea O 
) O 
chronically O 
exposed O 
to O 
copper B-SYSTEMATIC 
. O 

studies O 
have O 
indicated O 
that O 
the O 
early O 
life O 
stages O 
of O 
freshwater O 
mussels O 
are O 
among O 
the O 
most O 
sensitive O 
aquatic O 
organisms O 
to O 
inorganic O 
chemicals O 
, O 
including O 
copper B-SYSTEMATIC 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
toxic O 
mode O 
of O 
action O 
and O 
sub O 
- O 
lethal O 
effects O 
of O 
copper B-SYSTEMATIC 
exposure O 
in O 
this O 
group O 
of O 
imperiled O 
animals O 
. O 
In O 
this O 
study O 
, O 
the O 
physiological O 
effects O 
of O 
long O 
- O 
term O 
copper B-SYSTEMATIC 
exposure O 
( O 
survival O 
, O 
growth O 
, O 
copper B-SYSTEMATIC 
bioaccumulation O 
, O 
whole O 
- O 
body O 
ion O 
content O 
, O 
oxygen B-SYSTEMATIC 
consumption O 
, O 
filtration O 
rate O 
, O 
ATPase O 
activities O 
, O 
and O 
biomarkers O 
of O 
oxidative O 
stress O 
) O 
were O 
evaluated O 
in O 
juvenile O 
( O 
6 O 
month O 
old O 
) O 
mussels O 
( O 
Lampsilis O 
siliquoidea O 
) O 
. O 
The O 
mussels O 
' O 
recovery O 
capacity O 
and O 
their O 
ability O 
to O 
withstand O 
further O 
acute O 
copper B-SYSTEMATIC 
challenge O 
were O 
also O 
evaluated O 
in O 
secondary O 
experiments O 
following O 
the O 
28 O 
day O 
exposure O 
by O 
assessing O 
survival O 
, O 
copper B-SYSTEMATIC 
bioaccumulation O 
and O 
whole O 
- O 
body O 
ion O 
content O 
. O 
Mussels O 
chronically O 
exposed O 
to O 
2 O 
and O 
12 O 
μg O 
Cu O 
/ O 
L O 
showed O 
significantly O 
higher O 
mortality O 
than O 
those O 
held O 
under O 
control O 
conditions O 
( O 
mortality O 
20.9 O 
, O 
69.9 O 
and O 
12.5% O 
, O 
respectively O 
) O 
, O 
indicating O 
that O 
juvenile O 
L O 
. O 
siliquoidea O 
is O 
underprotected O 
by O 
the O 
U.S O 
. O 
Environmental O 
Protection O 
Agency O 
( O 
USEPA O 
) O 
biotic O 
ligand O 
model O 
( O 
BLM O 
) O 
- O 
derived O 
chronic O 
water O 
quality O 
criteria O 
( O 
WQC O 
) O 
( O 
2.18 O 
μg O 
Cu O 
/ O 
L O 
) O 
and O 
the O 
hardness O 
- O 
derived O 
USEPA O 
WQC O 
( O 
12.16 O 
μg O 
Cu O 
/ O 
L O 
) O 
. O 
Soft O 
tissue O 
copper B-SYSTEMATIC 
burden O 
increased O 
equally O 
for O 
both O 
copper B-SYSTEMATIC 
exposures O 
, O 
suggesting O 
that O 
chronic O 
toxicity O 
is O 
not O 
associated O 
with O 
copper B-SYSTEMATIC 
bioaccumulation O 
. O 
Several O 
physiological O 
disturbances O 
were O 
also O 
observed O 
during O 
chronic O 
copper B-SYSTEMATIC 
exposure O 
. O 
Most O 
relevant O 
was O 
a O 
decrease O 
in O 
whole O 
- O 
body O 
sodium B-SYSTEMATIC 
content O 
paralleled O 
by O 
an O 
inhibition O 
of O 
Na(+) B-FORMULA 
K(+) B-FORMULA 
-ATPase O 
activity O 
, O 
indicating O 
a O 
metal O 
- O 
induced O 
ionoregulatory O 
disturbance O 
. O 
Filtration O 
and O 
oxygen B-SYSTEMATIC 
consumption O 
rates O 
were O 
also O 
affected O 
. O 
Redox O 
parameters O 
( O 
reactive O 
oxygen B-SYSTEMATIC 
production O 
, O 
antioxidant O 
capacity O 
against O 
peroxyl B-SYSTEMATIC 
radicals O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
activity O 
, O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
concentration O 
) O 
did O 
not O 
show O 
clear O 
responses O 
, O 
but O 
membrane O 
damage O 
as O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
was O 
observed O 
in O 
both O 
copper B-SYSTEMATIC 
exposures O 
. O 
Mussels O 
previously O 
held O 
in O 
control O 
conditions O 
or O 
pre O 
- O 
exposed O 
to O 
2 O 
μg O 
dissolved O 
Cu B-FORMULA 
/L O 
were O 
able O 
to O 
maintain O 
their O 
ionic O 
homeostasis O 
and O 
did O 
not O 
experience O 
mortality O 
after O 
the O 
4-d O 
recovery O 
period O 
. O 
In O 
contrast O 
, O 
those O 
previously O 
exposed O 
to O 
12 O 
μg O 
dissolved O 
Cu B-FORMULA 
/L O 
exhibited O 
50% O 
mortality O 
indicating O 
that O 
they O 
had O 
already O 
reached O 
a O 
' O 
point O 
of O 
no O 
return O 
' O 
. O 
Pre O 
- O 
exposure O 
to O 
copper B-SYSTEMATIC 
did O 
not O 
influence O 
mussel O 
response O 
to O 
the O 
copper B-SYSTEMATIC 
challenge O 
test O 
. O 
As O 
observed O 
for O 
the O 
chronic O 
exposure O 
, O 
mortality O 
of O 
mussels O 
held O 
in O 
the O 
absence O 
of O 
copper B-SYSTEMATIC 
and O 
submitted O 
to O 
the O 
challenge O 
test O 
was O 
also O 
associated O 
with O 
an O 
ionoregulatory O 
disturbance O 
. O 
These O 
results O 
indicate O 
that O 
ionoregulatory O 
disruption O 
in O 
freshwater O 
mussels O 
chronically O 
exposed O 
to O 
copper B-SYSTEMATIC 
is O 
the O 
main O 
mechanism O 
of O 
toxicity O 
and O 
that O 
redox O 
parameters O 
do O 
not O 
appear O 
to O 
be O 
useful O 
as O 
indicators O 
of O 
sub O 
- O 
lethal O 
copper B-SYSTEMATIC 
toxicity O 
in O 
these O 
animals O 
. O 

luminal O 
nitrogen B-SYSTEMATIC 
metabolism O 
: O 
role O 
of O 
the O 
gut O 
microbiota O 
and O 
consequences O 
for O 
the O 
host O 
. O 

and O 
endogenous O 
proteins O 
are O 
mixed O 
in O 
the O 
small O 
intestinal O 
lumen O 
with O 
the O 
microbiota O 
. O 
Although O 
experimental O 
evidences O 
suggest O 
that O 
the O 
intestinal O 
microbiota O 
is O 
able O 
to O 
incorporate O 
and O 
degrade O 
some O 
of O 
the O 
available O 
amino B-FAMILY 
acids I-FAMILY 
, O 
it O 
appears O 
that O 
the O 
microbiota O 
is O 
also O 
able O 
to O 
synthesize O 
amino B-FAMILY 
acids I-FAMILY 
raising O 
the O 
view O 
that O 
amino B-FAMILY 
acid I-FAMILY 
exchange O 
between O 
the O 
microbiota O 
and O 
host O 
can O 
proceed O 
in O 
both O 
directions O 
. O 
Although O 
the O 
net O 
result O 
of O 
such O 
exchanges O 
remains O 
to O 
be O 
determined O 
, O 
it O 
is O 
likely O 
that O 
a O 
significant O 
part O 
of O 
the O 
amino B-FAMILY 
acids I-FAMILY 
recovered O 
from O 
the O 
alimentary O 
proteins O 
are O 
used O 
by O 
the O 
microbiota O 
. O 
In O 
the O 
large O 
intestine O 
, O 
where O 
the O 
density O 
of O 
bacteria O 
is O 
much O 
higher O 
than O 
in O 
the O 
small O 
intestine O 
and O 
the O 
transit O 
time O 
much O 
longer O 
, O 
the O 
residual O 
undigested O 
luminal O 
proteins O 
and O 
peptides O 
can O 
be O 
degraded O 
in O 
amino B-FAMILY 
acids I-FAMILY 
by O 
the O 
microbiota O 
. O 
These O 
amino B-FAMILY 
acids I-FAMILY 
cannot O 
be O 
absorbed O 
to O 
a O 
significant O 
extent O 
by O 
the O 
colonic O 
epithelium O 
, O 
but O 
are O 
precursors O 
for O 
the O 
synthesis O 
of O 
numerous O 
metabolic O 
end O 
products O 
in O 
reactions O 
made O 
by O 
the O 
microbiota O 
. O 
Among O 
these O 
products O 
, O 
some O 
like O 
short O 
- O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
organic O 
acids O 
are O 
energy O 
substrates O 
for O 
the O 
colonic O 
mucosa O 
and O 
several O 
peripheral O 
tissues O 
while O 
others O 
like O 
sulfide B-SYSTEMATIC 
and O 
ammonia B-SYSTEMATIC 
can O 
affect O 
the O 
energy O 
metabolism O 
of O 
colonic O 
epithelial O 
cells O 
. O 
More O 
work O 
is O 
needed O 
to O 
clarify O 
the O 
overall O 
effects O 
of O 
the O 
intestinal O 
microbiota O 
on O 
nitrogenous O 
compound O 
metabolism O 
and O 
consequences O 
on O 
gut O 
and O 
more O 
generally O 
host O 
health O 
. O 

members O 
of O 
the O 
nudix O 
hydrolase O 
family O 
exhibit O 
considerable O 
substrate O 
multispecificity O 
and O 
ambiguity O 
, O 
which O 
raises O 
significant O 
issues O 
when O 
assessing O 
their O 
functions O 
in O 
vivo O 
and O 
gives O 
rise O 
to O 
errors O 
in O 
database O 
annotation O 
. O 
Several O 
display O 
low O 
antimutator O 
activity O 
when O 
expressed O 
in O 
bacterial O 
tester O 
strains O 
as O 
well O 
as O 
some O 
degree O 
of O 
activity O 
in O 
vitro O 
towards O 
mutagenic O 
, O 
oxidized B-FAMILY 
nucleotides I-FAMILY 
such O 
as O 
8-oxo-dGTP B-SYSTEMATIC 
. O 
However O 
, O 
many O 
of O 
these O 
show O 
greater O 
activity O 
towards O 
other O 
nucleotides B-FAMILY 
such O 
as O 
ADP B-ABBREVIATION 
- O 
ribose B-TRIVIAL 
or O 
diadenosine B-SYSTEMATIC 
tetraphosphate I-SYSTEMATIC 
( O 
Ap(4)A B-ABBREVIATION 
) O 
. O 
The O 
antimutator O 
activities O 
have O 
tended O 
to O 
gain O 
prominence O 
in O 
the O 
literature O 
, O 
whereas O 
they O 
may O 
in O 
fact O 
represent O 
the O 
residual O 
activity O 
of O 
an O 
ancestral O 
antimutator O 
enzyme O 
that O 
has O 
become O 
secondary O 
to O 
the O 
more O 
recently O 
evolved O 
major O 
activity O 
after O 
gene O 
duplication O 
. O 
Whether O 
any O 
meaningful O 
antimutagenic O 
function O 
has O 
also O 
been O 
retained O 
in O 
vivo O 
requires O 
very O 
careful O 
assessment O 
. O 
Then O 
again O 
, O 
other O 
examples O 
of O 
substrate O 
ambiguity O 
may O 
indicate O 
as O 
yet O 
unexplored O 
regulatory O 
systems O 
. O 
For O 
example O 
, O 
bacterial O 
Ap(4)A B-ABBREVIATION 
hydrolases O 
also O 
efficiently O 
remove O 
pyrophosphate B-SYSTEMATIC 
from O 
the O 
5 O 
' O 
termini O 
of O 
mRNAs O 
, O 
suggesting O 
a O 
potential O 
role O 
for O 
Ap(4)A B-ABBREVIATION 
in O 
the O 
control O 
of O 
bacterial O 
mRNA O 
turnover O 
, O 
while O 
the O 
ability O 
of O 
some O 
eukaryotic O 
mRNA O 
decapping O 
enzymes O 
to O 
degrade O 
IDP B-ABBREVIATION 
and O 
dIDP B-ABBREVIATION 
or O 
diphosphoinositol B-FAMILY 
polyphosphates I-FAMILY 
( O 
DIPs B-ABBREVIATION 
) O 
may O 
also O 
be O 
indicative O 
of O 
new O 
regulatory O 
networks O 
in O 
RNA O 
metabolism O 
. O 
DIP B-ABBREVIATION 
phosphohydrolases O 
also O 
degrade O 
diadenosine B-FAMILY 
polyphosphates I-FAMILY 
and O 
inorganic O 
polyphosphates B-FAMILY 
, O 
suggesting O 
further O 
avenues O 
for O 
investigation O 
. O 
This O 
article O 
uses O 
these O 
and O 
other O 
examples O 
to O 
highlight O 
the O 
need O 
for O 
a O 
greater O 
awareness O 
of O 
the O 
possible O 
significance O 
of O 
substrate O 
ambiguity O 
among O 
the O 
nudix O 
hydrolases O 
as O 
well O 
as O 
the O 
need O 
to O 
exert O 
caution O 
when O 
interpreting O 
incomplete O 
analyses O 
. O 

hydrolysis O 
enhances O 
RNA O 
recognition O 
and O 
antiviral O 
signal O 
transduction O 
by O 
the O 
innate O 
immune O 
sensor O 
, O 
laboratory O 
of O 
genetics O 
and O 
physiology O 
2 O 
( O 
LGP2 O 
) O 
. O 

of O 
genetics O 
and O 
physiology O 
2 O 
( O 
LGP2 O 
) O 
is O 
a O 
member O 
of O 
the O 
RIG-I O 
- O 
like O 
receptor O 
family O 
of O 
cytoplasmic O 
pattern O 
recognition O 
receptors O 
that O 
detect O 
molecular O 
signatures O 
of O 
virus O 
infection O 
and O 
initiate O 
antiviral O 
signal O 
transduction O 
cascades O 
. O 
The O 
ATP B-ABBREVIATION 
hydrolysis O 
activity O 
of O 
LGP2 O 
is O 
essential O 
for O 
antiviral O 
signaling O 
, O 
but O 
it O 
has O 
been O 
unclear O 
how O 
the O 
enzymatic O 
properties O 
of O 
LGP2 O 
regulate O 
its O 
biological O 
response O 
. O 
Quantitative O 
analysis O 
of O 
the O 
dsRNA O 
binding O 
and O 
enzymatic O 
activities O 
of O 
LGP2 O 
revealed O 
high O 
dsRNA O 
- O 
independent O 
ATP B-ABBREVIATION 
hydrolysis O 
activity O 
. O 
Biochemical O 
assays O 
and O 
single O 
- O 
molecule O 
analysis O 
of O 
LGP2 O 
and O 
mutant O 
variants O 
that O 
dissociate O 
basal O 
from O 
dsRNA-stimulated O 
ATP B-ABBREVIATION 
hydrolysis O 
demonstrate O 
that O 
LGP2 O 
utilizes O 
basal O 
ATP B-ABBREVIATION 
hydrolysis O 
to O 
enhance O 
and O 
diversify O 
its O 
RNA O 
recognition O 
capacity O 
, O 
enabling O 
the O 
protein O 
to O 
associate O 
with O 
intrinsically O 
poor O 
substrates O 
. O 
This O 
property O 
is O 
required O 
for O 
LGP2 O 
to O 
synergize O 
with O 
another O 
RIG-I O 
- O 
like O 
receptor O 
, O 
MDA5 O 
, O 
to O 
potentiate O 
IFNβ O 
transcription O 
in O 
vivo O 
during O 
infection O 
with O 
encephalomyocarditis O 
virus O 
or O 
transfection O 
with O 
poly(I:C) O 
. O 
These O 
results O 
demonstrate O 
previously O 
unrecognized O 
properties O 
of O 
LGP2 O 
ATP O 
hydrolysis O 
and O 
RNA O 
interaction O 
and O 
provide O 
a O 
mechanistic O 
basis O 
for O 
a O 
positive O 
regulatory O 
role O 
for O 
LGP2 O 
in O 
antiviral O 
signaling O 
. O 

-tRNA O 
Substrate O 
and O 
Enzyme O 
Backbone O 
Atoms O 
Contribute O 
to O 
Translational O 
Quality O 
Control O 
by O 
YbaK O 
. O 

acids I-FAMILY 
are O 
covalently O 
attached O 
to O 
their O 
corresponding O 
transfer O 
RNAs O 
( O 
tRNAs O 
) O 
by O 
aminoacyl B-SYSTEMATIC 
-tRNA O 
synthetases O 
. O 
Proofreading O 
mechanisms O 
exist O 
to O 
ensure O 
that O 
high O 
fidelity O 
is O 
maintained O 
in O 
this O 
key O 
step O 
in O 
protein O 
synthesis O 
. O 
Prolyl B-TRIVIAL 
-tRNA O 
synthetase O 
( O 
ProRS O 
) O 
can O 
misacylate O 
cognate O 
tRNA( O 
Pro B-FORMULA 
) O 
with O 
Ala B-FORMULA 
and O 
Cys B-FORMULA 
. O 
The O 
cis-editing O 
domain O 
of O 
ProRS O 
( O 
INS O 
) O 
hydrolyzes O 
Ala B-FORMULA 
-tRNA(Pro) O 
, O 
whereas O 
Cys B-FORMULA 
-tRNA( O 
Pro B-FORMULA 
) O 
is O 
hydrolyzed O 
by O 
a O 
single O 
domain O 
editing O 
protein O 
, O 
YbaK O 
, O 
in O 
trans O 
. O 
Previous O 
studies O 
have O 
proposed O 
a O 
model O 
of O 
substrate O 
- O 
binding O 
by O 
bacterial O 
YbaK O 
and O 
elucidated O 
a O 
substrate O 
- O 
assisted O 
mechanism O 
of O 
catalysis O 
. O 
However O 
, O 
the O 
microscopic O 
steps O 
in O 
this O 
mechanism O 
have O 
not O 
been O 
investigated O 
. O 
In O 
this O 
work O 
, O 
we O 
carried O 
out O 
biochemical O 
experiments O 
together O 
with O 
a O 
detailed O 
hybrid O 
quantum O 
mechanics O 
/ O 
molecular O 
mechanics O 
study O 
to O 
investigate O 
the O 
mechanism O 
of O 
catalysis O 
by O 
Escherichia O 
coli O 
YbaK O 
. O 
The O 
results O 
support O 
a O 
mechanism O 
wherein O 
cyclization O 
of O 
the O 
substrate O 
Cys B-FORMULA 
results O 
in O 
cleavage O 
of O 
the O 
Cys B-FORMULA 
-tRNA O 
ester B-FAMILY 
bond O 
. O 
Protein O 
side O 
chains O 
do O 
not O 
play O 
a O 
significant O 
role O 
in O 
YbaK O 
catalysis O 
. O 
Instead O 
, O 
protein O 
backbone O 
atoms O 
play O 
crucial O 
roles O 
in O 
stabilizing O 
the O 
transition O 
state O 
, O 
while O 
the O 
product O 
is O 
stabilized O 
by O 
the O 
2'-OH B-SYSTEMATIC 
of O 
the O 
tRNA O 
. O 

- O 
associated O 
changes O 
in O 
the O 
internal O 
distribution O 
of O 
tetrodotoxin B-TRIVIAL 
in O 
the O 
female O 
goby O 
Yongeichthys O 
criniger O 
. O 

- O 
associated O 
changes O 
in O 
the O 
internal O 
distribution O 
of O 
tetrodotoxin B-TRIVIAL 
( O 
TTX B-ABBREVIATION 
) O 
in O 
the O 
goby O 
Yongeichthys O 
criniger O 
were O 
investigated O 
in O 
29 O 
and O 
40 O 
female O 
specimens O 
collected O 
from O 
Okinawa O 
, O 
Japan O 
, O 
from O 
August O 
2008 O 
to O 
June O 
2009 O 
( O 
Group O 
I O 
) O 
, O 
and O 
from O 
November O 
2009 O 
to O 
August O 
2010 O 
( O 
Group O 
II O 
) O 
, O 
respectively O 
. O 
In O 
Group O 
I O 
, O 
based O 
on O 
changes O 
in O 
the O 
gonadosomatic O 
index O 
( O 
GSI O 
) O 
and O 
histologic O 
observation O 
of O 
the O 
ovary O 
, O 
the O 
period O 
from O 
October O 
2008 O 
through O 
January O 
2009 O 
was O 
estimated O 
to O 
be O 
the O 
' O 
previtelline O 
- O 
forming O 
period O 
' O 
, O 
February O 
through O 
March O 
2009 O 
the O 
' O 
vitelline O 
- O 
forming O 
period O 
' O 
, O 
April O 
through O 
June O 
2009 O 
the O 
' O 
spawning O 
period O 
' O 
, O 
and O 
August O 
2008 O 
the O 
' O 
end O 
of O 
spawning O 
period O 
' O 
of O 
the O 
preceding O 
year O 
. O 
The O 
TTX B-ABBREVIATION 
content O 
( O 
mouse O 
unit O 
[ O 
MU O 
] O 
per O 
gram O 
tissue O 
) O 
of O 
each O 
Y O 
. O 
criniger O 
tissue O 
( O 
skin O 
, O 
muscle O 
, O 
liver O 
, O 
and O 
ovary O 
) O 
quantified O 
by O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
) O 
was O 
generally O 
high O 
during O 
the O 
spawning O 
period O 
and O 
continued O 
to O 
rise O 
until O 
the O 
end O 
of O 
spawning O 
period O 
, O 
especially O 
in O 
the O 
ovary O 
. O 
Total O 
TTX B-ABBREVIATION 
per O 
individual O 
increased O 
considerably O 
during O 
the O 
spawning O 
period O 
, O 
most O 
of O 
which O 
located O 
in O 
the O 
ovary O 
, O 
indicating O 
that O 
Y O 
. O 
criniger O 
obtains O 
a O 
high O 
amount O 
of O 
TTX B-ABBREVIATION 
during O 
the O 
spawning O 
period O 
, O 
and O 
accumulates O 
most O 
of O 
it O 
in O 
the O 
ovary O 
. O 
In O 
contrast O 
, O 
the O 
TTX B-ABBREVIATION 
content O 
of O 
the O 
skin O 
was O 
highest O 
at O 
the O 
end O 
of O 
spawning O 
period O 
, O 
and O 
most O 
of O 
the O 
total O 
TTX B-ABBREVIATION 
located O 
in O 
the O 
skin O 
during O 
this O 
period O 
as O 
well O 
as O 
during O 
the O 
previtelline O 
- O 
forming O 
period O 
. O 
In O 
Group O 
II O 
, O 
the O 
maturation O 
stage O 
of O 
the O 
ovaries O 
of O 
all O 
specimens O 
was O 
determined O 
, O 
and O 
the O 
specimens O 
were O 
grouped O 
accordingly O 
. O 
In O 
the O 
perinucleolus O 
stage O 
, O 
yolk O 
vesicle O 
stage O 
, O 
and O 
yolk O 
globule O 
stage O 
I O 
, O 
most O 
of O 
the O 
TTX B-ABBREVIATION 
was O 
localized O 
in O 
the O 
skin O 
, O 
but O 
the O 
TTX B-ABBREVIATION 
in O 
the O 
ovary O 
greatly O 
increased O 
as O 
the O 
maturation O 
stage O 
advanced O 
from O 
yolk O 
globule O 
stage O 
I O 
to O 
yolk O 
globule O 
stage O 
III O 
. O 

of O 
clonidine B-TRIVIAL 
in O 
mice O 
injected O 
with O 
Tityus O 
discrepans O 
scorpion O 
venom O 
. O 

study O 
was O 
conducted O 
to O 
assess O 
the O 
effect O 
of O 
clonidine B-TRIVIAL 
( O 
α(2)-adrenoceptor O 
selective O 
agonist O 
) O 
on O 
glycemia O 
, O 
serum O 
and O 
urine O 
α-amylase O 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
, O 
serum O 
creatinine B-TRIVIAL 
, O 
white O 
blood O 
cell O 
count O 
, O 
kidney O 
histology O 
and O 
zymogen O 
granule O 
content O 
in O 
pancreatic O 
acini O 
, O 
in O 
mice O 
under O 
the O 
effect O 
of O 
Tityus O 
discrepans O 
( O 
Td O 
) O 
scorpion O 
venom O 
. O 
BALB O 
/ O 
c O 
male O 
mice O 
( O 
20 O 
± O 
2 O 
g O 
, O 
n O 
= O 
7-11 O 
) O 
were O 
intraperitoneally O 
( O 
ip O 
) O 
injected O 
with O 
a O 
sublethal O 
dose O 
( O 
1 O 
μg O 
/ O 
g O 
) O 
of O 
Td O 
venom O 
, O 
and O 
were O 
treated O 
( O 
ip O 
) O 
with O 
0.1 O 
μg O 
/ O 
g O 
of O 
clonidine B-TRIVIAL 
( O 
Catapresan B-TRIVIAL 
( O 
® O 
) O 
) O 
or O 
0.9% O 
NaCl B-FORMULA 
30 O 
min O 
after O 
the O 
venom O 
injection O 
, O 
and O 
then O 
every O 
2 O 
h O 
. O 
Six O 
hours O 
later O 
, O 
mice O 
were O 
anesthetized O 
with O 
diethylether B-SYSTEMATIC 
and O 
urine O 
and O 
blood O 
samples O 
were O 
withdrawn O 
by O 
cystocentesis O 
and O 
cardiocentesis O 
, O 
respectively O 
. O 
Tissue O 
samples O 
were O 
obtained O 
and O 
fixed O 
immediately O 
in O 
buffered O 
formalin B-TRIVIAL 
( O 
2% O 
, O 
pH O 
7.4 O 
) O 
and O 
then O 
processed O 
for O 
stain O 
H&E O 
. O 
Td O 
venom O 
did O 
not O 
cause O 
hyperglycemia O 
by O 
itself O 
. O 
However O 
, O 
clonidine B-TRIVIAL 
induced O 
hyperglycemia O 
, O 
which O 
was O 
synergized O 
by O 
Td O 
venom O 
. O 
Although O 
the O 
venom O 
did O 
not O 
produce O 
hyperamylasemia O 
, O 
clonidine B-TRIVIAL 
significantly O 
diminished O 
serum O 
α-amylase O 
activity O 
in O 
envenomed O 
mice O 
. O 
Td O 
venom O 
did O 
not O 
significantly O 
increase O 
urinary O 
α-amylase O 
activity O 
, O 
which O 
was O 
unaffected O 
by O 
clonidine B-TRIVIAL 
. O 
Morphometric O 
analysis O 
using O 
microphotographs O 
of O 
pancreata O 
from O 
mice O 
injected O 
with O 
Td O 
venom O 
showed O 
a O 
reduced O 
zymogen O 
granule O 
content O 
as O 
judged O 
by O 
the O 
acidophilic O 
bidimensional O 
area O 
of O 
acini O 
. O 
This O 
effect O 
was O 
significantly O 
reduced O 
by O 
clonidine B-TRIVIAL 
. O 
Kidney O 
samples O 
showed O 
histological O 
changes O 
which O 
were O 
partially O 
affected O 
by O 
the O 
drug O 
. O 
Clonidine B-TRIVIAL 
reduced O 
the O 
increase O 
in O 
BUN O 
and O 
serum O 
creatinine B-TRIVIAL 
concentration O 
in O 
envenomed O 
mice O 
. O 
Td O 
venom O 
produced O 
neutrophilia O 
and O 
lymphopenia O 
, O 
which O 
were O 
clonidine B-TRIVIAL 
-resistant O 
at O 
the O 
assayed O 
dose O 
. O 
These O 
results O 
suggest O 
that O 
α(2)-adrenoceptor O 
selective O 
agonists O 
would O 
be O 
able O 
to O 
reduce O 
some O 
scorpion O 
venom O 
- O 
induced O 
renal O 
and O 
pancreatic O 
disturbances O 
, O 
possibly O 
through O 
the O 
inhibition O 
of O 
neurotransmitter O 
release O 
from O 
presynaptic O 
cholinergic O 
and O 
noradrenergic O 
terminals O 
, O 
as O 
well O 
as O 
from O 
adrenal O 
medulla O 
. O 

salvage O 
in O 
Trypanosoma O 
brucei O 
bloodstream O 
forms O 
and O 
the O 
trypanocidal O 
action O 
of O 
halogenated B-FAMILY 
pyrimidines I-FAMILY 
. O 

trypanosomes O 
are O 
capable O 
of O 
both O 
pyrimidine B-SYSTEMATIC 
biosynthesis O 
and O 
salvage O 
of O 
preformed O 
pyrimidines B-FAMILY 
from O 
the O 
host O 
. O 
However O 
, O 
uptake O 
of O 
pyrimidines B-FAMILY 
in O 
bloodstream O 
form O 
trypanosomes O 
has O 
not O 
been O 
investigated O 
, O 
making O 
it O 
difficult O 
to O 
judge O 
the O 
relative O 
importance O 
of O 
salvage O 
and O 
synthesis O 
or O 
to O 
design O 
a O 
pyrimidine B-SYSTEMATIC 
-based O 
chemotherapy O 
. O 
Detailed O 
characterization O 
of O 
pyrimidine B-SYSTEMATIC 
transport O 
activities O 
in O 
bloodstream O 
form O 
Trypanosoma O 
brucei O 
brucei O 
found O 
that O 
these O 
cells O 
express O 
a O 
high O 
- O 
affinity O 
uracil B-TRIVIAL 
transporter O 
( O 
designated O 
TbU3 O 
) O 
that O 
is O 
clearly O 
distinct O 
from O 
the O 
procyclic O 
pyrimidine B-SYSTEMATIC 
transporters O 
. O 
This O 
transporter O 
had O 
low O 
affinity O 
for O 
uridine B-TRIVIAL 
and O 
2'deoxyuridine B-SYSTEMATIC 
and O 
was O 
the O 
sole O 
pyrimidine B-SYSTEMATIC 
transporter O 
expressed O 
in O 
these O 
cells O 
. O 
In O 
addition O 
, O 
thymidine B-TRIVIAL 
was O 
taken O 
up O 
inefficiently O 
through O 
a O 
P1 O 
- O 
type O 
nucleoside B-FAMILY 
transporter O 
. O 
Of O 
importance O 
, O 
the O 
anticancer O 
drug O 
5-fluorouracil B-SYSTEMATIC 
was O 
an O 
excellent O 
substrate O 
for O 
TbU3 O 
, O 
and O 
several O 
5-fluoropyrimidine B-SYSTEMATIC 
analogs O 
were O 
investigated O 
for O 
uptake O 
and O 
trypanocidal O 
activity O 
; O 
5F-orotic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
5F-2'deoxyuridine B-SYSTEMATIC 
displayed O 
activity O 
in O 
the O 
low O 
micromolar O 
range O 
. O 
The O 
metabolism O 
and O 
mode O 
of O 
action O 
of O 
these O 
analogs O 
was O 
determined O 
using O 
metabolomic O 
assessments O 
of O 
T O 
. O 
brucei O 
clonal O 
lines O 
adapted O 
to O 
high O 
levels O 
of O 
these O 
pyrimidine B-SYSTEMATIC 
analogs O 
, O 
and O 
of O 
the O 
sensitive O 
parental O 
strains O 
. O 
The O 
analysis O 
showed O 
that O 
5-fluorouracil B-SYSTEMATIC 
is O 
incorporated O 
into O 
a O 
large O 
number O 
of O 
metabolites O 
but O 
likely O 
exerts O 
toxicity O 
through O 
incorporation O 
into O 
RNA O 
. O 
5F-2'dUrd B-SYSTEMATIC 
and O 
5F-2'dCtd B-SYSTEMATIC 
are O 
not O 
incorporated O 
into O 
nucleic O 
acids O 
but O 
act O 
as O 
prodrugs O 
by O 
inhibiting O 
thymidylate O 
synthase O 
as O 
5F-dUMP B-SYSTEMATIC 
. O 
We O 
present O 
the O 
most O 
complete O 
model O 
of O 
pyrimidine B-SYSTEMATIC 
salvage O 
in O 
T O 
. O 
brucei O 
to O 
date O 
, O 
supported O 
by O 
genome O 
- O 
wide O 
profiling O 
of O 
the O 
predicted O 
pyrimidine B-SYSTEMATIC 
biosynthesis O 
and O 
conversion O 
enzymes O 
. O 

: O 
Although O 
thyroid O 
diseases O 
exist O 
in O 
patients O 
with O 
renal O 
failure O 
, O 
thyroid O 
function O 
tests O 
are O 
not O 
routine O 
tests O 
in O 
patients O 
on O 
chronic O 
hemodialysis O 
( O 
HD O 
) O 
. O 
Therefore O 
, O 
the O 
impact O 
of O 
thyroid O 
diseases O 
on O 
erythropoietin O 
( O 
EPO O 
) O 
dosage O 
in O 
HD O 
patients O 
is O 
not O 
well O 
defined O 
. O 
This O 
study O 
evaluated O 
the O 
relationship O 
between O 
the O 
dose O 
of O 
EPO O 
and O 
the O 
presence O 
or O 
absence O 
of O 
thyroid O 
dysfunction O 
in O 
HD O 
patients O 
. O 
Methods O 
: O 
This O 
study O 
included O 
1013 O 
adult O 
patients O 
on O 
HD O 
who O 
did O 
not O 
have O 
a O 
malignancy O 
, O 
liver O 
cirrhosis O 
, O 
thalassemia O 
, O 
iron B-SYSTEMATIC 
deficiency O 
, O 
gastrointestinal O 
bleeding O 
, O 
or O 
a O 
major O 
operation O 
within O 
6 O 
months O 
. O 
Patients O 
were O 
characterized O 
as O 
being O 
euthyroid O 
, O 
or O 
having O 
the O 
sick O 
euthyroid O 
syndrome O 
, O 
primary O 
hypothyroidism O 
, O 
subclinical O 
hypothyroidism O 
, O 
hyperthyroidism O 
, O 
or O 
subclinical O 
hyperthyroidism O 
based O 
on O 
thyroid O 
function O 
tests O 
. O 
Routine O 
biochemistry O 
profiles O 
including O 
an O 
index O 
of O 
the O 
efficiency O 
of O 
HD O 
, O 
along O 
with O 
clinical O 
data O 
over O 
the O 
previous O 
6-month O 
period O 
, O 
were O 
collected O 
and O 
analyzed O 
. O 
Multiple O 
regression O 
models O 
were O 
employed O 
to O 
assess O 
the O 
relationship O 
between O 
the O 
dose O 
of O 
EPO O 
and O 
the O 
presence O 
or O 
absence O 
of O 
thyroid O 
status O 
. O 
Results O 
: O 
The O 
mean O 
monthly O 
EPO O 
dosages O 
were O 
77.7±37.0 O 
, O 
70.2±40.6 O 
, O 
90.8±68.4 O 
, O 
78.5±46.7 O 
, O 
and O 
82.3±41.2 O 
μg O 
, O 
respectively O 
, O 
in O 
the O 
sick O 
euthyroid O 
syndrome O 
, O 
euthyroid O 
patients O 
, O 
hypothyroidism O 
, O 
subclinical O 
hypothyroidism O 
, O 
and O 
subclinical O 
hyperthyroidism O 
groups O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
After O 
adjustment O 
of O 
all O 
other O 
variables O 
in O 
multiple O 
regression O 
, O 
the O 
mean O 
monthly O 
EPO O 
dosage O 
was O 
19.00±8.59 O 
μg O 
more O 
in O 
hypothyroid O 
patients O 
compared O 
with O 
euthyroid O 
patients O 
( O 
p=0.027 O 
) O 
. O 
Further O 
, O 
considering O 
an O 
interaction O 
with O 
the O 
presence O 
of O 
diabetes O 
, O 
the O 
mean O 
monthly O 
EPO O 
dosage O 
in O 
patients O 
with O 
either O 
hypothyroidism O 
or O 
subclinical O 
hypothyroidism O 
and O 
diabetes O 
was O 
54.66±17.12 O 
μg O 
( O 
p=0.001 O 
) O 
and O 
31.51±10.38 O 
μg O 
more O 
than O 
that O 
of O 
euthyroid O 
patients O 
, O 
respectively O 
( O 
p=0.002 O 
) O 
. O 
Conclusions O 
: O 
In O 
HD O 
patients O 
, O 
the O 
EPO O 
dosage O 
required O 
to O 
maintain O 
the O 
target O 
hemoglobin O 
level O 
is O 
significantly O 
higher O 
in O 
patients O 
having O 
both O 
hypothyroidism O 
or O 
subclinical O 
hypothyroidism O 
and O 
diabetes O 
than O 
in O 
euthyroid O 
patients O 
. O 

compounds O 
: O 
the O 
role O 
of O 
redox O 
regulation O 
in O 
neurodegenerative O 
disease O 
and O 
cancer O 
. O 

work O 
has O 
been O 
carried O 
out O 
in O 
the O 
last O 
two O 
decades O 
on O 
the O 
role O 
of O 
oxidative O 
stress O 
and O 
antioxidants O 
deficiency O 
in O 
the O 
pathophysiology O 
of O 
civilization O 
diseases O 
. O 
A O 
considerable O 
amount O 
of O 
chemical O 
, O 
biochemical O 
, O 
epidemiological O 
and O 
clinical O 
evidence O 
indicates O 
that O 
(poly)phenolic B-FAMILY 
compounds O 
widely O 
distributed O 
in O 
the O 
plant O 
kingdom O 
, O 
exhibit O 
a O 
wide O 
range O 
effects O 
on O 
biomolecules O 
. O 
The O 
beneficial O 
effects O 
on O 
human O 
health O 
, O 
many O 
of O 
phenolics O 
have O 
been O 
described O 
to O 
their O 
reactive O 
oxygen B-SYSTEMATIC 
( O 
ROS O 
) O 
and O 
nitrogen B-SYSTEMATIC 
species O 
( O 
RNS O 
) O 
scavenging O 
and O 
antioxidant O 
capacity O 
. O 
The O 
consumption O 
of O 
vegetables O 
, O 
fruits O 
and O 
flavonoid B-FAMILY 
-rich O 
beverages O 
has O 
been O 
reported O 
to O 
prevent O 
against O 
neurodegenerative O 
diseases O 
, O 
cancer O 
, O 
and O 
ageing O 
. O 
This O 
paper O 
reviews O 
the O 
recent O 
data O 
on O 
( O 
1 O 
) O 
the O 
role O 
oxidative O 
stress O 
in O 
the O 
pathology O 
of O 
civilization O 
diseases O 
; O 
( O 
2 O 
) O 
the O 
protection O 
against O 
oxidative O 
damage O 
due O 
to O 
the O 
toxicity O 
of O 
ROS O 
/ O 
RNS O 
; O 
( O 
3 O 
) O 
the O 
cellular O 
and O 
molecular O 
interactions O 
of O 
the O 
(poly)phenolic B-FAMILY 
compounds O 
relevant O 
to O 
the O 
prevention O 
of O 
neurodegenerative O 
diseases O 
and O 
cancer O 
, O 
and O 
( O 
4 O 
) O 
the O 
methods O 
for O 
assessing O 
antioxidant O 
capacity O 
. O 

anti-inflammatory O 
effects O 
in O 
primary O 
astrocytes O 
require O 
oestrogen B-FAMILY 
receptor O 
β- O 
mediated O 
neuroglobin O 
up O 
- O 
regulation O 
. O 

( O 
Ngb O 
) O 
, O 
so O 
named O 
after O 
its O 
initial O 
discovery O 
in O 
brain O 
neurones O 
, O 
has O 
received O 
great O 
attention O 
as O 
a O 
result O 
of O 
its O 
neuroprotective O 
effects O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Recently O 
, O 
we O 
demonstrated O 
that O 
, O 
in O 
neurones O 
, O 
Ngb O 
is O 
a O 
17β-oestradiol B-SYSTEMATIC 
( O 
E(2) O 
) O 
inducible O 
protein O 
that O 
is O 
pivotal O 
for O 
hormone O 
- O 
induced O 
anti-apoptotic O 
effects O 
against O 
H(2) B-FORMULA 
O(2) I-FORMULA 
toxicity O 
. O 
The O 
involvement O 
of O 
Ngb O 
in O 
other O 
brain O 
cell O 
populations O 
, O 
as O 
well O 
as O 
in O 
other O 
neuroprotective O 
effects O 
of O 
E(2) O 
, O 
is O 
completely O 
unknown O 
at O 
present O 
. O 
We O 
demonstrate O 
Ngb O 
immunoreactivity O 
in O 
reactive O 
astrocytes O 
located O 
in O 
the O 
proximity O 
of O 
a O 
penetrating O 
cortical O 
injury O 
in O 
vivo O 
and O 
the O 
involvement O 
of O 
Ngb O 
in O 
the O 
E(2) O 
-mediated O 
anti-inflammatory O 
effect O 
in O 
primary O 
cortical O 
astrocytes O 
. O 
Upon O 
binding O 
to O 
oestrogen B-FAMILY 
receptor O 
(ER)β O 
, O 
E(2) O 
enhances O 
Ngb O 
levels O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Although O 
with O 
a O 
lesser O 
degree O 
than O 
E(2) O 
, O 
the O 
pro O 
- O 
inflammatory O 
stimulation O 
with O 
lipopolysaccharide O 
( O 
LPS O 
) O 
also O 
induces O 
the O 
increase O 
of O 
Ngb O 
protein O 
levels O 
via O 
nuclear O 
factor-(NF)κB O 
signal(s) O 
. O 
Moreover O 
, O 
a O 
negative O 
cross O 
- O 
talk O 
between O 
ER O 
subtypes O 
and O 
NFκB O 
signal(s) O 
has O 
been O 
demonstrated O 
. O 
In O 
particular O 
, O 
ERα-activated O 
signals O 
prevent O 
the O 
NFκB O 
- O 
mediated O 
Ngb O 
increase O 
, O 
whereas O 
LPS O 
impairs O 
the O 
ERβ-induced O 
up O 
- O 
regulation O 
of O 
Ngb O 
. O 
Therefore O 
, O 
the O 
co O 
- O 
expression O 
of O 
both O 
ERα O 
and O 
ERβ O 
is O 
pivotal O 
for O 
mediating O 
E(2) O 
-induced O 
Ngb O 
expression O 
in O 
the O 
presence O 
of O 
NFκB-activated O 
signals O 
. O 
Interestingly O 
, O 
Ngb O 
silencing O 
prevents O 
the O 
effect O 
of O 
E(2) O 
on O 
the O 
expression O 
of O 
inflammatory O 
markers O 
( O 
i.e O 
. O 
interleukin O 
6 O 
and O 
interferon O 
γ-inducible O 
protein O 
10 O 
) O 
. O 
Ngb O 
can O 
be O 
regarded O 
as O 
a O 
key O 
mediator O 
of O 
the O 
different O 
protective O 
effects O 
of O 
E(2) O 
in O 
the O 
brain O 
, O 
including O 
protection O 
against O 
oxidative O 
stress O 
and O 
the O 
control O 
of O 
inflammation O 
, O 
both O 
of O 
which O 
are O 
at O 
the O 
root O 
of O 
several O 
neurodegenerative O 
diseases O 
. O 

and O 
thermal O 
decomposition O 
behaviors O 
of O 
magnesium B-FAMILY 
borohydride I-FAMILY 
ammoniates I-FAMILY 
with O 
controllable O 
composition O 
as O 
hydrogen B-SYSTEMATIC 
storage O 
materials O 
. O 

ammonia B-SYSTEMATIC 
-redistribution O 
strategy O 
for O 
synthesizing O 
metal B-FAMILY 
borohydride I-FAMILY 
ammoniates I-FAMILY 
with O 
controllable O 
coordination O 
number O 
of O 
NH(3) B-FORMULA 
was O 
proposed O 
, O 
and O 
a O 
series O 
of O 
magnesium B-FAMILY 
borohydride I-FAMILY 
ammoniates I-FAMILY 
were O 
easily O 
synthesized O 
by O 
a O 
mechanochemical O 
reaction O 
between O 
Mg(BH(4))(2) B-FORMULA 
and O 
its O 
hexaammoniate B-SYSTEMATIC 
. O 
A O 
strong O 
dependence O 
of O 
the O 
dehydrogenation O 
temperature O 
and O 
purity O 
of O 
the O 
released O 
hydrogen B-SYSTEMATIC 
upon O 
heating O 
on O 
the O 
coordination O 
number O 
of O 
NH(3) B-FORMULA 
was O 
elaborated O 
for O 
Mg(BH(4))(2)·xNH(3) B-FAMILY 
owing O 
to O 
the O 
change O 
in O 
the O 
molar O 
ratio O 
of O 
H(δ+) B-FORMULA 
and O 
H(δ-) B-FORMULA 
, O 
the O 
charge O 
distribution O 
on O 
H(δ+) B-FORMULA 
and O 
H(δ-) B-FORMULA 
, O 
and O 
the O 
strength O 
of O 
the O 
coordinate O 
bond O 
N B-FORMULA 
: I-FORMULA 
→Mg(2+) I-FORMULA 
. O 
The O 
monoammoniate O 
of O 
magnesium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
( O 
Mg(BH(4))(2)·NH(3) B-FORMULA 
) O 
was O 
obtained O 
for O 
the O 
first O 
time O 
. O 
It O 
can O 
release O 
6.5% O 
pure O 
hydrogen B-SYSTEMATIC 
within O 
50 O 
minutes O 
at O 
180 O 
°C O 
. O 

histone O 
methylases O 
regulate O 
expression O 
of O 
HDLR-SR-B1 O 
in O 
presence O 
of O 
estrogen B-FAMILY 
and O 
control O 
plasma O 
cholesterol B-TRIVIAL 
in O 
vivo O 
. O 

- O 
density O 
lipoprotein O 
receptors O 
scavenger O 
receptor O 
class O 
B O 
type O 
I O 
[ O 
HDLR-SR-B1 O 
( O 
SR-B1 O 
) O 
] O 
is O 
a O 
key O 
player O 
in O 
reverse O 
cholesterol B-TRIVIAL 
transport O 
and O 
maintaining O 
blood O 
cholesterol B-TRIVIAL 
. O 
We O 
demonstrated O 
that O 
human O 
SR-B1 O 
is O 
transcriptionally O 
activated O 
by O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
in O 
HEPG2 O 
and O 
JAR O 
cells O 
. O 
SR-B1 O 
promoter O 
contains O 
multiple O 
estrogen B-FAMILY 
response O 
elements O 
( O 
ERE O 
half O 
- O 
sites O 
) O 
along O 
with O 
some O 
Sp1 O 
binding O 
sites O 
. O 
Knockdown O 
of O 
estrogen B-FAMILY 
receptor O 
(ER)α O 
and O 
ERβ O 
down O 
- O 
regulated O 
E2-induced O 
SR-B1 O 
expression O 
. O 
ERs O 
were O 
bound O 
to O 
SR-B1 O 
promoter O 
EREs O 
in O 
an O 
E2-dependent O 
manner O 
. O 
Along O 
with O 
ERs O 
, O 
mixed O 
- O 
lineage O 
leukemia O 
( O 
MLL O 
) O 
histone O 
methylases O 
, O 
especially O 
MLL1 O 
and O 
MLL2 O 
, O 
play O 
key O 
roles O 
in O 
E2 O 
- O 
mediated O 
SR-B1 O 
activation O 
. O 
MLL1 O 
and O 
MLL2 O 
bind O 
to O 
SR-B1 O 
promoter O 
in O 
an O 
E2-dependent O 
manner O 
and O 
control O 
the O 
assembly O 
of O 
transcription O 
pre O 
- O 
initiation O 
complex O 
and O 
RNA O 
polymerase O 
II O 
( O 
RNAPII O 
) O 
recruitment O 
. O 
ERs O 
and O 
MLLs O 
play O 
critical O 
roles O 
in O 
determining O 
the O 
cholesterol B-TRIVIAL 
uptake O 
by O 
steroidogenic O 
tissues O 
/ O 
cells O 
, O 
and O 
their O 
knockdown O 
suppressed O 
the O 
E2-induced O 
cholesterol B-TRIVIAL 
uptake O 
efficiencies O 
of O 
the O 
cells O 
. O 
Intriguingly O 
, O 
MLL2 O 
knockdown O 
in O 
mice O 
resulted O 
in O 
a O 
33% O 
increase O 
in O 
plasma O 
cholesterol B-TRIVIAL 
level O 
and O 
also O 
reduced O 
SR-B1 O 
expression O 
in O 
mice O 
liver O 
, O 
demonstrating O 
its O 
crucial O 
functions O 
in O 
controlling O 
plasma O 
cholesterol B-TRIVIAL 
in O 
vivo O 
. O 

identification O 
of O 
orthologous O 
genes O 
in O 
an O 
increasing O 
number O 
of O 
fully O 
sequenced O 
genomes O 
is O 
a O 
challenging O 
issue O 
in O 
recent O 
genome O 
science O 
. O 
Here O 
we O 
present O 
KEGG O 
OC O 
( O 
http O 
: O 
/ O 
/ O 
www.genome.jp O 
/ O 
tools O 
/ O 
oc/ O 
) O 
, O 
a O 
novel O 
database O 
of O 
ortholog O 
clusters O 
( O 
OCs O 
) O 
. O 
The O 
current O 
version O 
of O 
KEGG O 
OC O 
contains O 
1 O 
176 O 
30 O 
OCs O 
, O 
obtained O 
by O 
clustering O 
8 O 
357 O 
175 O 
genes O 
in O 
2112 O 
complete O 
genomes O 
( O 
153 O 
eukaryotes O 
, O 
1830 O 
bacteria O 
and O 
129 O 
archaea O 
) O 
. O 
The O 
OCs O 
were O 
constructed O 
by O 
applying O 
the O 
quasi O 
- O 
clique O 
- O 
based O 
clustering O 
method O 
to O 
all O 
possible O 
protein O 
coding O 
genes O 
in O 
all O 
complete O 
genomes O 
, O 
based O 
on O 
their O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
similarities O 
. O 
It O 
is O 
computationally O 
efficient O 
to O 
calculate O 
OCs O 
, O 
which O 
enables O 
to O 
regularly O 
update O 
the O 
contents O 
. O 
KEGG O 
OC O 
has O 
the O 
following O 
two O 
features O 
: O 
(i) O 
It O 
consists O 
of O 
all O 
complete O 
genomes O 
of O 
a O 
wide O 
variety O 
of O 
organisms O 
from O 
three O 
domains O 
of O 
life O 
, O 
and O 
the O 
number O 
of O 
organisms O 
is O 
the O 
largest O 
among O 
the O 
existing O 
databases O 
; O 
and O 
(ii) O 
It O 
is O 
compatible O 
with O 
the O 
KEGG O 
database O 
by O 
sharing O 
the O 
same O 
sets O 
of O 
genes O 
and O 
identifiers O 
, O 
which O 
leads O 
to O 
seamless O 
integration O 
of O 
OCs O 
with O 
useful O 
components O 
in O 
KEGG O 
such O 
as O 
biological O 
pathways O 
, O 
pathway O 
modules O 
, O 
functional O 
hierarchy O 
, O 
diseases O 
and O 
drugs O 
. O 
The O 
KEGG O 
OC O 
resources O 
are O 
accessible O 
via O 
OC O 
Viewer O 
that O 
provides O 
an O 
interactive O 
visualization O 
of O 
OCs O 
at O 
different O 
taxonomic O 
levels O 
. O 

isoquinoline B-FAMILY 
alkaloid I-FAMILY 
from O 
the O 
Chinese O 
herbal O 
plant O 
Corydalis O 
yanhusuo O 
W.T O 
. O 
Wang O 
inhibits O 
P-glycoprotein O 
and O 
multidrug O 
resistance O 
- O 
associate O 
protein O 
1 O 
. O 

of O 
P-glycoprotein O 
( O 
P-gp O 
) O 
and O 
multidrug O 
resistance O 
- O 
associate O 
protein O 
1 O 
( O 
MRP1 O 
) O 
is O 
a O 
major O 
mechanism O 
leading O 
to O 
multidrug O 
resistance O 
( O 
MDR O 
) O 
of O 
cancer O 
cells O 
. O 
These O 
transporters O 
expel O 
anti-cancer O 
drugs O 
and O 
greatly O 
impair O 
therapeutic O 
efficacy O 
of O 
chemotherapy O 
. O 
A O 
Chinese O 
herbal O 
plant O 
Yanhusuo O 
( O 
Corydalis O 
yanhusuo O 
W.T O 
. O 
Wang O 
, O 
YHS O 
) O 
is O 
frequently O 
used O 
in O 
functional O 
food O 
and O 
traditional O 
Chinese O 
medicine O 
to O 
improve O 
the O 
efficacy O 
of O 
chemotherapy O 
. O 
The O 
objective O 
of O 
this O 
work O 
was O 
to O 
study O 
effects O 
of O 
glaucine B-TRIVIAL 
, O 
an O 
alkaloid O 
component O 
of O 
YHS O 
, O 
on O 
P-gp O 
and O 
MRP1 O 
in O 
resistant O 
cancer O 
cells O 
. O 
The O 
resistant O 
cancer O 
cell O 
line O 
, O 
MCF-7 O 
/ O 
ADR O 
and O 
corresponding O 
parental O 
sensitive O 
cells O 
were O 
employed O 
to O 
determine O 
reversal O 
properties O 
of O 
glaucine B-TRIVIAL 
. O 
Glaucine B-TRIVIAL 
inhibits O 
P-gp O 
and O 
MRP1 O 
- O 
mediated O 
efflux O 
and O 
activates O 
ATPase O 
activities O 
of O 
the O 
transporters O 
, O 
indicating O 
that O 
it O 
is O 
a O 
substrate O 
and O 
inhibits O 
P-gp O 
and O 
MRP1 O 
competitively O 
. O 
Furthermore O 
, O 
glaucine O 
suppresses O 
expression O 
of O 
ABC O 
transporter O 
genes O 
. O 
It O 
reverses O 
the O 
resistance O 
of O 
MCF-7 O 
/ O 
ADR O 
to O 
adriamycin B-TRIVIAL 
and O 
mitoxantrone B-TRIVIAL 
effectively O 
. O 

antioxidant O 
activity O 
and O 
the O 
flavonoids B-FAMILY 
of O 
mature O 
and O 
immature O 
calamondin O 
( O 
Citrus O 
mitis O 
Blanco O 
) O 
peel O 
were O 
investigated O 
. O 
The O 
hot O 
water O 
extract O 
of O 
immature O 
calamondin O 
peel O 
exhibited O 
the O 
highest O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
, O 
reducing O 
power O 
, O 
and O 
superoxide B-TRIVIAL 
scavenging O 
effect O 
. O 
3',5'-Di-C-β-glucopyranosylphloretin B-SYSTEMATIC 
, O 
naringin B-TRIVIAL 
, O 
hesperidin B-TRIVIAL 
, O 
nobiletin B-TRIVIAL 
, O 
and O 
tangeretin B-TRIVIAL 
are O 
the O 
five O 
major O 
flavonoids B-FAMILY 
found O 
in O 
hot O 
water O 
extract O 
with O 
the O 
levels O 
of O 
6888±522 O 
, O 
2333±157 O 
, O 
1350±94 O 
, O 
165±13 O 
, O 
and O 
8±4 O 
mg O 
/ O 
100 O 
g O 
dry O 
basis O 
, O 
respectively O 
. O 
The O 
contents O 
of O 
nobiletin B-TRIVIAL 
and O 
tangeretin B-TRIVIAL 
increased O 
after O 
ripening O 
. O 
The O 
hot O 
water O 
extract O 
of O 
immature O 
calamondin O 
peel O 
was O 
fractionated O 
using O 
a O 
semi-preparative O 
HPLC O 
. O 
Fraction O 
VI O 
showed O 
the O 
highest O 
ORAC O 
value O 
( O 
28.02±2.73 O 
mmol O 
Trolox B-TRIVIAL 
equivalents O 
( O 
TE O 
) O 
/ O 
g O 
fraction O 
) O 
and O 
two O 
compounds O 
, O 
naringin B-TRIVIAL 
and O 
hesperidin B-TRIVIAL 
, O 
were O 
identified O 
as O 
the O 
major O 
active O 
components O 
attributed O 
to O 
the O 
antioxidant O 
activity O 
. O 
Fraction O 
V O 
contained O 
3',5'-di-C-β-glucopyranosylphloretin B-SYSTEMATIC 
, O 
which O 
revealed O 
low O 
ORAC O 
value O 
with O 
7.43 O 
mmol O 
TE O 
/ O 
g O 
fraction O 
. O 
However O 
, O 
it O 
might O 
also O 
contribute O 
to O 
antioxidant O 
activity O 
in O 
immature O 
calamondin O 
peel O 
due O 
to O 
its O 
greatest O 
quantity O 
. O 

kinetics O 
of O 
a O 
batch O 
solid O 
- O 
liquid O 
extraction O 
of O 
total O 
phenolic O 
compounds O 
( O 
PC O 
) O 
from O 
milled O 
grape O 
seed O 
( O 
Vitis O 
vinifera O 
L O 
. O 
cv O 
. O 
" O 
Frankovka O 
" O 
) O 
using O 
50% O 
ethanol B-SYSTEMATIC 
at O 
different O 
extraction O 
temperatures O 
( O 
25-80°C O 
) O 
was O 
studied O 
. O 
The O 
maximum O 
yield O 
of O 
PC O 
was O 
0.13 O 
kg(GAE) O 
/ O 
kg(db) O 
after O 
200 O 
min O 
of O 
extraction O 
in O 
agitated O 
vessel O 
at O 
80°C O 
. O 
A O 
new O 
model O 
based O 
on O 
the O 
assumptions O 
of O 
a O 
first O 
order O 
kinetics O 
mechanism O 
for O 
the O 
solid O 
- O 
liquid O 
extraction O 
and O 
a O 
linear O 
equilibrium O 
at O 
the O 
solid O 
- O 
liquid O 
interface O 
was O 
developed O 
. O 
The O 
model O 
involves O 
the O 
concept O 
of O 
broken O 
and O 
intact O 
cells O 
in O 
order O 
to O 
describe O 
two O 
successive O 
extraction O 
periods O 
: O 
a O 
very O 
fast O 
surface O 
washing O 
process O 
followed O 
by O 
slow O 
diffusion O 
of O 
phenolic O 
compounds O 
from O 
grape O 
seeds O 
to O 
the O 
solvent O 
. O 
The O 
proposed O 
model O 
is O 
suited O 
to O 
fit O 
experimental O 
data O 
and O 
to O 
simulate O 
the O 
extraction O 
of O 
phenolic O 
compounds O 
, O 
which O 
was O 
confirmed O 
by O 
the O 
correlation O 
coefficient O 
( O 
r≥0.965 O 
) O 
, O 
the O 
root O 
mean O 
square O 
error O 
( O 
RMSE≤0.003 O 
kg(GAE) O 
/ O 
kg(db) O 
) O 
and O 
the O 
mean O 
relative O 
deviation O 
modulus O 
( O 
E≤2.149% O 
) O 
. O 
The O 
temperature O 
influenced O 
both O 
equilibrium O 
partition O 
coefficients O 
of O 
phenolic O 
compounds O 
and O 
transport O 
properties O 
, O 
which O 
is O 
manifested O 
by O 
a O 
relatively O 
high O 
value O 
of O 
activation O 
energy O 
( O 
23-24 O 
) O 
kJ O 
/ O 
mol O 
and O 
by O 
values O 
of O 
effective O 
diffusivity O 
in O 
seed O 
particles O 
. O 

major O 
carotenoids O 
of O 
high O 
nutritional O 
significance O 
, O 
including O 
β-carotene B-TRIVIAL 
, O 
lycopene B-TRIVIAL 
, O 
lutein B-TRIVIAL 
and O 
zeaxanthin B-TRIVIAL 
were O 
determined O 
in O 
three O 
isolates O 
of O 
heterocystous O 
cyanobacteria O 
, O 
belonging O 
to O 
the O 
genera O 
Anabaena O 
and O 
Nostoc O 
, O 
isolated O 
from O 
Iranian O 
terrestrial O 
and O 
aquatic O 
ecosystems O 
, O 
for O 
the O 
first O 
time O 
. O 
The O 
ultrasonically O 
extracted O 
carotenoids O 
were O 
identified O 
and O 
quantified O 
by O 
a O 
rapid O 
and O 
sensitive O 
isocratic O 
HPLC O 
method O 
and O 
identification O 
was O 
further O 
confirmed O 
by O 
spiking O 
authentic O 
standards O 
and O 
the O 
pattern O 
of O 
the O 
UV-Vis O 
spectra O 
obtained O 
from O 
photo O 
- O 
diode O 
array O 
detector O 
. O 
The O 
results O 
showed O 
that O 
these O 
isolates O 
contain O 
large O 
amounts O 
of O 
four O 
major O 
carotenoids O 
, O 
especially O 
lycopene B-TRIVIAL 
( O 
up O 
to O 
24570 O 
μg O 
/ O 
g O 
dry O 
weight O 
, O 
DW O 
) O 
which O 
appears O 
to O 
be O 
the O 
highest O 
reported O 
amount O 
until O 
present O 
; O 
and O 
β-carotene B-TRIVIAL 
( O 
up O 
to O 
8133 O 
μg O 
/ O 
g O 
DW O 
) O 
which O 
is O 
comparable O 
with O 
the O 
best O 
natural O 
sources O 
of O 
β-carotene B-TRIVIAL 
. O 
Meanwhile O 
, O 
they O 
are O 
rich O 
in O 
the O 
cis- B-MULTIPLE 
isomers I-MULTIPLE 
of I-MULTIPLE 
lycopene I-MULTIPLE 
and I-MULTIPLE 
β-carotene I-MULTIPLE 
which O 
is O 
important O 
in O 
their O 
bioavailability O 
and O 
health O 
benefits O 
. O 

of O 
carcinogenic O 
4(5)-methylimidazole B-MULTIPLE 
in O 
caramel O 
model O 
systems O 
: O 
a O 
role O 
of O 
sulphite B-SYSTEMATIC 
. O 

caramel O 
model O 
systems O 
consisted O 
the O 
D-glucose B-SYSTEMATIC 
/ O 
NH(3) B-FORMULA 
/ O 
sulphite B-SYSTEMATIC 
were O 
heated O 
at O 
100°C O 
for O 
2 O 
h O 
and O 
amounts O 
of O 
carcinogenic O 
4(5)-methylimidazole B-MULTIPLE 
( O 
4-MI B-SYSTEMATIC 
) O 
formed O 
were O 
determined O 
. O 
The O 
amount O 
formed O 
ranged O 
from O 
7 O 
to O 
155 O 
ppm O 
. O 
A O 
system O 
with O 
0.1 O 
M O 
sulphite B-SYSTEMATIC 
yielded O 
the O 
greatest O 
amount O 
of O 
4-MI B-SYSTEMATIC 
, O 
which O 
was O 
54% O 
more O 
than O 
that O 
yielded O 
from O 
a O 
system O 
without O 
sulphite B-SYSTEMATIC 
. O 
When O 
the O 
amount O 
of O 
sulphite B-SYSTEMATIC 
increased O 
over O 
0.1 O 
M O 
, O 
the O 
amount O 
of O 
4-MI B-SYSTEMATIC 
reduced O 
. O 
The O 
greatest O 
reduction O 
was O 
achieved O 
with O 
0.2 O 
M O 
sulphite B-SYSTEMATIC 
by O 
68% O 
compared O 
to O 
0 O 
M O 
sulphite B-SYSTEMATIC 
, O 
suggesting O 
that O 
sulphite B-SYSTEMATIC 
plays O 
an O 
important O 
role O 
in O 
the O 
formation O 
of O 
carcinogenic O 
4-MI B-SYSTEMATIC 
in O 
caramel O 
colour O 
. O 
Also O 
, O 
a O 
system O 
with O 
0.1 O 
M O 
sulphite B-SYSTEMATIC 
yielded O 
the O 
most O 
intense O 
caramel O 
colour O 
but O 
the O 
other O 
levels O 
of O 
sulphite B-SYSTEMATIC 
did O 
not O 
change O 
the O 
colour O 
intensity O 
significantly O 
. O 
Sulphite B-SYSTEMATIC 
contributed O 
slightly O 
to O 
the O 
level O 
of O 
flavour O 
chemicals O 
evaluated O 
using O 
pyrazine B-SYSTEMATIC 
formation O 
. O 
The O 
results O 
suggest O 
that O 
sulphite B-SYSTEMATIC 
addition O 
at O 
appropriate O 
amount O 
reduces O 
4-MI B-SYSTEMATIC 
formation O 
in O 
caramel O 
colour O 
without O 
sacrificing O 
flavour O 
and O 
colour O 
formation O 
. O 

, O 
isopimarane B-TRIVIAL 
, O 
and O 
abietane B-TRIVIAL 
diterpenoids B-FAMILY 
from O 
Isodon O 
lophanthoides O 
var O 
. O 
graciliflorus O 
. O 

new O 
diterpenoids B-FAMILY 
including O 
two O 
podocarpanes B-FAMILY 
, O 
graciliflorins B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
2 O 
) O 
, O 
an O 
isopimarane B-SYSTEMATIC 
acetal I-SYSTEMATIC 
, O 
graciliflorin B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
, O 
and O 
a O 
rearranged O 
abietane B-TRIVIAL 
, O 
graciliflorin B-TRIVIAL 
D I-TRIVIAL 
( O 
4 O 
) O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Isodon O 
lophanthoides O 
var O 
. O 
graciliflorus O 
( O 
Lamiaceae O 
) O 
along O 
with O 
podocarpa-8,11,13-triene-3α,13-diol B-SYSTEMATIC 
( O 
5 O 
) O 
and O 
micranthin B-TRIVIAL 
B I-TRIVIAL 
( O 
6 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
based O 
on O 
the O 
spectroscopic O 
data O 
. O 
The O 
in O 
vitro O 
cytotoxicity O 
of O 
compounds O 
1-4 O 
and O 
6 O 
against O 
human O 
carcinoma O 
A549 O 
, O 
MCF-7 O 
, O 
and O 
HeLa O 
cell O 
lines O 
were O 
evaluated O 
using O 
the O 
MTT B-ABBREVIATION 
colourimetric O 
assay O 
. O 
Micranthin B-TRIVIAL 
B I-TRIVIAL 
( O 
6 O 
) O 
showed O 
moderate O 
activity O 
against O 
all O 
the O 
cells O 
with O 
IC(50) O 
values O 
of O 
16.29 O 
, O 
18.2 O 
, O 
and O 
22.25 O 
μM O 
, O 
while O 
compounds O 
1-4 O 
were O 
inactive O 
( O 
IC(50) O 
> O 
50 O 
μg O 
/ O 
ml O 
) O 
. O 

fish O 
meal O 
and O 
oil O 
have O 
increasingly O 
been O 
replaced O 
with O 
proteins O 
and O 
oils O 
from O 
vegetable O 
sources O 
in O 
the O 
diets O 
of O 
farmed O 
salmonids O 
, O 
but O 
the O 
consequences O 
for O 
the O 
oxidative O 
stability O 
of O 
the O 
resulting O 
fish O 
products O 
have O 
not O 
been O 
investigated O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
influence O 
of O 
feeding O 
regime O 
on O 
composition O 
of O 
rainbow O 
trout O 
fillets O 
, O 
as O 
well O 
as O 
on O 
lipid O 
and O 
protein O 
oxidation O 
during O 
storage O 
on O 
ice O 
. O 
Rainbow O 
trout O 
were O 
fed O 
six O 
different O 
diets O 
, O 
which O 
differed O 
in O 
their O 
levels O 
of O 
marine O 
oil O 
and O 
proteins O 
vs O 
. O 
vegetable O 
oil O 
and O 
protein O 
. O 
Fish O 
fillets O 
were O 
characterised O 
by O 
measurement O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
amino B-FAMILY 
acid I-FAMILY 
composition O 
, O 
primary O 
and O 
secondary O 
lipid O 
oxidation O 
products O 
, O 
astaxanthin B-TRIVIAL 
and O 
tocopherol B-FAMILY 
content O 
. O 
Protein O 
oxidation O 
was O 
assessed O 
by O 
measuring O 
protein O 
carbonyl B-FAMILY 
content O 
, O 
oxidised O 
amino B-FAMILY 
acids I-FAMILY 
, O 
sulfhydryl B-FAMILY 
groups O 
and O 
immuno O 
- O 
blotting O 
against O 
carbonyl B-FAMILY 
groups O 
. O 
Feeding O 
regimes O 
significantly O 
influenced O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
. O 
Replacement O 
of O 
fish O 
oil O 
with O 
vegetable O 
oil O 
reduced O 
formation O 
of O 
primary O 
oxidation O 
products O 
, O 
but O 
the O 
effect O 
on O 
secondary O 
oxidation O 
products O 
differed O 
between O 
different O 
types O 
of O 
volatiles O 
. O 
The O 
differences O 
in O 
protein O 
and O 
amino B-FAMILY 
acid I-FAMILY 
composition O 
were O 
not O 
significant O 
, O 
and O 
there O 
were O 
no O 
clear O 
effects O 
of O 
diets O 
on O 
protein O 
oxidation O 
, O 
but O 
data O 
indicated O 
that O 
compounds O 
present O 
in O 
the O 
marine O 
ingredients O 
might O 
have O 
had O 
an O 
effect O 
on O 
protein O 
oxidation O 
. O 

affinity O 
between O 
dietary O 
polyphenols B-FAMILY 
and O 
β-lactoglobulin O 
negatively O 
correlates O 
with O 
the O 
protein O 
susceptibility O 
to O 
digestion O 
and O 
total O 
antioxidant O 
activity O 
of O 
complexes O 
formed O 
. O 

interactions O 
between O 
β-lactoglobulin O 
( O 
BLG O 
) O 
and O 
polyphenol B-FAMILY 
extracts O 
of O 
teas O 
, O 
coffee O 
and O 
cocoa O 
were O 
studied O 
by O 
fluorescence O 
and O 
CD O 
spectroscopy O 
at O 
pH O 
values O 
of O 
the O 
gastrointestinal O 
tract O 
( O 
GIT O 
) O 
. O 
The O 
biological O 
implications O 
of O 
non-covalent O 
binding O 
of O 
polyphenols B-FAMILY 
to O 
BLG O 
were O 
investigated O 
by O 
in O 
vitro O 
pepsin O 
and O 
pancreatin O 
digestibility O 
assay O 
and O 
ABTS B-ABBREVIATION 
radical O 
scavenging O 
activity O 
of O 
complexes O 
formed O 
. O 
The O 
polyphenol B-FAMILY 
-BLG O 
systems O 
were O 
stable O 
at O 
pH O 
values O 
of O 
the O 
GIT O 
. O 
The O 
most O 
profound O 
effect O 
of O 
pH O 
on O 
binding O 
affinity O 
was O 
observed O 
for O 
polyphenol B-FAMILY 
extracts O 
rich O 
in O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 
Stronger O 
non-covalent O 
interactions O 
delayed O 
pepsin O 
and O 
pancreatin O 
digestion O 
of O 
BLG O 
and O 
induced O 
β-sheet O 
to O 
α-helix O 
transition O 
at O 
neutral O 
pH O 
. O 
All O 
polyphenols B-FAMILY 
tested O 
protected O 
protein O 
secondary O 
structure O 
at O 
an O 
extremely O 
acidic O 
pH O 
of O 
1.2 O 
. O 
A O 
positive O 
correlation O 
was O 
found O 
between O 
the O 
strength O 
of O 
protein- O 
polyphenol B-FAMILY 
interactions O 
and O 
( O 
a O 
) O 
half O 
time O 
of O 
protein O 
decay O 
in O 
gastric O 
conditions O 
( O 
R(2)=0.85 O 
) O 
, O 
( O 
b O 
) O 
masking O 
of O 
total O 
antioxidant O 
capacity O 
of O 
protein- O 
polyphenol B-FAMILY 
complexes O 
( O 
R(2)=0.95 O 
) O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
complexly O 
constituted O 
phenolic O 
extracts O 
from O 
apple O 
seeds O 
may O 
be O 
utilised O 
for O 
the O 
recovery O 
of O 
natural O 
coloured O 
antioxidant O 
preparations O 
, O 
which O 
might O 
serve O 
as O 
potential O 
food O 
or O 
cosmetic O 
ingredients O 
. O 
In O 
a O 
first O 
step O 
, O 
the O 
recovery O 
of O 
phenolic O 
compounds O 
was O 
optimised O 
by O 
varying O 
crucial O 
extraction O 
parameters O 
. O 
A O 
single O 
extraction O 
step O 
at O 
25°C O 
using O 
an O 
acetone B-SYSTEMATIC 
-water O 
mixture O 
( O 
60 O 
: O 
40 O 
, O 
v O 
/ O 
v O 
) O 
and O 
a O 
solid O 
- O 
to O 
- O 
solvent O 
ratio O 
of O 
1 O 
: O 
8 O 
( O 
w O 
/ O 
v O 
) O 
for O 
1 O 
h O 
was O 
found O 
to O 
be O 
appropriate O 
to O 
achieve O 
both O 
high O 
phenolic O 
yields O 
and O 
antioxidant O 
activities O 
. O 
In O 
a O 
second O 
step O 
, O 
differently O 
produced O 
apple O 
seed O 
extracts O 
and O 
a O 
phloridzin B-TRIVIAL 
model O 
solution O 
were O 
enzymatically O 
treated O 
by O 
mushroom O 
polyphenol B-FAMILY 
oxidase O 
to O 
investigate O 
the O 
rate O 
of O 
pigment O 
synthesis O 
. O 
Depending O 
on O 
the O 
extraction O 
procedure O 
applied O 
, O 
synthesis O 
rates O 
, O 
pigment O 
yields O 
and O 
colour O 
properties O 
significantly O 
differed O 
. O 
Compared O 
to O 
the O 
phloridzin B-TRIVIAL 
model O 
solution O 
, O 
extracts O 
recovered O 
from O 
the O 
seeds O 
showed O 
comparable O 
and O 
even O 
better O 
results O 
, O 
thus O 
indicating O 
such O 
preparations O 
to O 
be O 
a O 
promising O 
alternative O 
to O 
synthetic O 
yellow O 
dyes O 
. O 

nutritional O 
supplement O 
Active O 
Hexose B-TRIVIAL 
Correlated O 
Compound O 
( O 
AHCC O 
) O 
has O 
direct O 
immunomodulatory O 
actions O 
on O 
intestinal O 
epithelial O 
cells O 
and O 
macrophages O 
involving O 
TLR O 
/ O 
MyD88 O 
and O 
NF-κB O 
/ O 
MAPK O 
activation O 
. O 

Hexose B-TRIVIAL 
Correlated O 
Compound O 
( O 
AHCC O 
) O 
is O 
an O 
immunostimulatory O 
nutritional O 
supplement O 
. O 
AHCC O 
effects O 
and O 
mechanism O 
of O 
action O 
on O 
intestinal O 
epithelial O 
cells O 
or O 
monocytes O 
are O 
poorly O 
described O 
. O 
AHCC O 
was O 
added O 
to O 
the O 
culture O 
medium O 
of O 
intestinal O 
epithelial O 
cells O 
( O 
IEC18 O 
and O 
HT29 O 
cells O 
) O 
and O 
monocytes O 
( O 
THP-1 O 
cells O 
) O 
and O 
assessed O 
the O 
secretion O 
of O 
proinflammatory O 
cytokines O 
by O 
ELISA O 
. O 
Inhibitors O 
of O 
NFκB O 
and O 
MAPKs O 
were O 
used O 
to O 
study O 
signal O 
transduction O 
pathways O 
while O 
TLR4 O 
and O 
MyD88 O 
were O 
silenced O 
in O 
IEC18 O 
cells O 
using O 
shRNA O 
. O 
It O 
was O 
found O 
that O 
AHCC O 
induced O 
GROα O 
and O 
MCP1 O 
secretion O 
in O 
IEC18 O 
and O 
IL-8 O 
in O 
HT29 O 
cells O 
. O 
These O 
effects O 
depended O 
on O 
NFκB O 
activation O 
, O 
and O 
partly O 
on O 
MAPKs O 
activation O 
and O 
on O 
the O 
presence O 
of O 
MyD88 O 
and O 
TLR4 O 
. O 
In O 
THP-1 O 
cells O 
AHCC O 
evoked O 
IL-8 O 
, O 
IL-1β O 
and O 
TNF-α O 
secretion O 
. O 
The O 
induction O 
of O 
IL-8 O 
depended O 
on O 
JNK O 
and O 
NFκB O 
activation O 
. O 
Therefore O 
, O 
AHCC O 
exerts O 
immunostimulatory O 
effects O 
on O 
intestinal O 
epithelial O 
cells O 
and O 
monocytes O 
involving O 
TLR4 O 
/ O 
MyD88 O 
and O 
NFκB O 
/ O 
MAPK O 
signal O 
transduction O 
pathways O 
. O 

is O 
a O 
well O 
established O 
risk O 
factor O 
for O 
cardiac O 
cell O 
apoptosis O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
evaluate O 
the O 
effects O 
of O 
garlic O 
oil O 
on O 
cardiac O 
apoptosis O 
induced O 
by O 
a O 
hypercholesterol O 
diet O 
. O 
Twenty O 
- O 
four O 
male O 
Golden-Syrian O 
hamsters O 
at O 
3 O 
months O 
of O 
age O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
, O 
control O 
, O 
cholesterol B-TRIVIAL 
and O 
garlic O 
oil O 
groups O 
received O 
a O 
chow O 
diet O 
, O 
chow O 
diet O 
with O 
2% O 
cholesterol B-TRIVIAL 
, O 
and O 
chow O 
diet O 
with O 
2% O 
cholesterol B-TRIVIAL 
and O 
1% O 
garlic O 
oil O 
for O 
8 O 
weeks O 
, O 
respectively O 
. O 
The O 
TUNEL-positive O 
apoptotic O 
cells O 
, O 
and O 
several O 
apoptotic O 
proteins O 
were O 
significantly O 
induced O 
in O 
the O 
excised O 
left O 
ventricle O 
in O 
cholesterol B-TRIVIAL 
group O 
, O 
whereas O 
significant O 
reduction O 
was O 
observed O 
in O 
cholesterol B-TRIVIAL 
plus O 
garlic O 
oil O 
group O 
. O 
The O 
IGFI O 
receptor O 
dependent O 
survival O 
pathway O 
was O 
inhibited O 
in O 
cholesterol B-TRIVIAL 
group O 
whereas O 
it O 
was O 
obviously O 
reversed O 
in O 
cholesterol B-TRIVIAL 
plus O 
garlic O 
oil O 
group O 
. O 
Our O 
results O 
suggest O 
that O 
administration O 
of O 
garlic O 
oil O 
shows O 
protective O 
effects O 
on O 
cardiac O 
apoptosis O 
in O 
rats O 
with O 
high O 
cholesterol B-TRIVIAL 
intake O 
. O 

of O 
silver B-SYSTEMATIC 
, O 
gold O 
, O 
aged O 
and O 
extra O 
- O 
aged O 
tequila O 
using O 
1-propanol B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
2-methyl-1-propanol B-SYSTEMATIC 
, O 
3-methyl-1-butanol B-SYSTEMATIC 
and O 
2-methyl-1-butanol B-SYSTEMATIC 
and O 
furan B-SYSTEMATIC 
derivatives O 
like O 
5-(hydroxymethyl)-2-furaldehyde B-SYSTEMATIC 
and O 
2-furaldehyde B-SYSTEMATIC 
has O 
been O 
carried O 
out O 
. O 
The O 
content O 
of O 
1-propanol B-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
2-methyl-1-propanol B-SYSTEMATIC 
, O 
3-methyl-1-butanol B-SYSTEMATIC 
and O 
2-methyl-1-butanol B-SYSTEMATIC 
was O 
determined O 
by O 
means O 
of O 
head O 
space O 
solid O 
phase O 
microextraction O 
gas O 
chromatography O 
mass O 
- O 
spectrometry O 
. O 
5-(Hydroxymethyl)-2-furaldehyde B-SYSTEMATIC 
and O 
2-furaldehyde B-SYSTEMATIC 
were O 
determined O 
by O 
high O 
performance O 
liquid O 
chromatography O 
with O 
diode O 
array O 
detection O 
. O 
Kruskal-Wallis O 
test O 
was O 
used O 
to O 
highlight O 
significant O 
differences O 
between O 
types O 
of O 
tequila O 
. O 
Principal O 
component O 
analysis O 
was O 
applied O 
as O 
visualisation O 
technique O 
. O 
Linear O 
discriminant O 
analysis O 
and O 
multilayer O 
perceptron O 
artificial O 
neural O 
networks O 
were O 
used O 
to O 
construct O 
classification O 
models O 
. O 
The O 
best O 
classification O 
performance O 
was O 
obtained O 
when O 
multilayer O 
perceptron O 
model O 
was O 
applied O 
. O 

- O 
electric O 
- O 
field O 
- O 
assisted O 
extraction O 
of O 
anthocyanins B-FAMILY 
from O 
purple O 
- O 
fleshed O 
potato O 
. O 

influence O 
of O 
pulsed O 
electric O 
field O 
( O 
PEF O 
) O 
treatment O 
on O 
the O 
anthocyanin B-FAMILY 
extraction O 
yield O 
( O 
AEY O 
) O 
from O 
purple O 
- O 
fleshed O 
potato O 
( O 
PFP O 
) O 
at O 
different O 
extraction O 
times O 
( O 
60-480 O 
min O 
) O 
and O 
temperatures O 
( O 
10-40°C O 
) O 
using O 
water O 
and O 
ethanol B-SYSTEMATIC 
( O 
48% O 
and O 
96% O 
) O 
as O 
solvents O 
has O 
been O 
investigated O 
. O 
Response O 
surface O 
methodology O 
was O 
used O 
to O 
determine O 
optimal O 
PEF O 
treatment O 
and O 
optimise O 
anthocyanin B-FAMILY 
extraction O 
. O 
A O 
PEF O 
treatment O 
of O 
3.4 O 
kV O 
/ O 
cm O 
and O 
105 O 
μs O 
( O 
35 O 
pulses O 
of O 
3 O 
μs O 
) O 
resulted O 
in O 
the O 
highest O 
cell O 
disintegration O 
index O 
( O 
Z(p)=1 O 
) O 
at O 
the O 
lowest O 
specific O 
energy O 
requirements O 
( O 
8.92 O 
kJ O 
/ O 
kg O 
) O 
. O 
This O 
PEF O 
treatment O 
increased O 
the O 
AEY O 
, O 
the O 
effect O 
being O 
higher O 
at O 
lower O 
extraction O 
temperature O 
with O 
water O 
as O 
solvent O 
. O 
After O 
480 O 
min O 
at O 
40°C O 
, O 
the O 
AEY O 
obtained O 
for O 
the O 
untreated O 
sample O 
using O 
96% O 
ethanol B-SYSTEMATIC 
as O 
the O 
solvent O 
( O 
63.9 O 
mg O 
/ O 
100 O 
g O 
fw O 
) O 
was O 
similar O 
to O 
that O 
obtained O 
in O 
the O 
PEF O 
- O 
treated O 
sample O 
using O 
water O 
( O 
65.8 O 
mg O 
/ O 
100 O 
g O 
fw O 
) O 
. O 
Therefore O 
, O 
PEF O 
was O 
possible O 
with O 
water O 
, O 
a O 
more O 
environmental O 
- O 
friendly O 
solvent O 
than O 
ethanol B-SYSTEMATIC 
, O 
without O 
decreasing O 
the O 
AEY O 
from O 
PFP O 
. O 

of O 
medium O 
chain O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
with O 
enhanced O 
antimicrobial O 
activity O 
from O 
crude O 
coconut O 
fat O 
by O 
solid O 
state O 
cultivation O 
of O 
Yarrowia O 
lipolytica O 
. O 

acids I-FAMILY 
profiles O 
and O 
antimicrobial O 
activity O 
of O 
crude O 
coconut O 
fat O 
hydrolysates O 
obtained O 
in O 
solid O 
- O 
state O 
cultivation O 
system O 
with O 
a O 
selected O 
yeast O 
strain O 
Yarrowia O 
lipolytica O 
RO13 O 
were O 
performed O 
. O 
A O 
preliminary O 
step O 
regarding O 
extracellular O 
lipase O 
production O 
and O 
solid O 
state O 
enzymatic O 
hydrolysis O 
of O 
crude O 
fat O 
at O 
different O 
water O 
activity O 
and O 
time O 
intervals O 
up O 
to O 
7 O 
days O 
was O 
also O 
applied O 
. O 
Gas O 
chromatography O 
- O 
mass O 
spectrometry O 
analysis O 
was O 
used O 
for O 
quantification O 
of O 
medium O 
chain O 
saturated O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
MCSFAs O 
) O 
and O 
the O 
results O 
revealed O 
a O 
higher O 
concentration O 
of O 
about O 
70% O 
lauric B-TRIVIAL 
acid I-TRIVIAL 
from O 
total O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
Further O 
, O 
antimicrobial O 
activity O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
against O 
some O 
food O 
- O 
borne O 
pathogens O 
( O 
Salmonella O 
enteritidis O 
, O 
Escherichia O 
coli O 
, O 
Listeria O 
monocytogenes O 
and O 
Bacillus O 
cereus O 
) O 
was O 
evaluated O 
. O 
The O 
minimum O 
inhibitory O 
concentration O 
of O 
the O 
obtained O 
hydrolysates O 
varied O 
from O 
12.5 O 
to O 
1.56 O 
ppm O 
, O 
significantly O 
lower O 
than O 
values O 
reported O 
in O 
literature O 
. O 
The O 
results O 
provide O 
substantial O 
evidence O 
for O 
obtaining O 
biopreservative O 
effects O 
by O 
coconut O 
fat O 
enzymatic O 
hydrolysis O 
. O 

method O 
for O 
the O 
residues O 
of O 
boscalid O 
in O 
blueberries O 
was O 
developed O 
. O 
Fungicide O 
residues O 
were O 
determined O 
by O 
solid O 
- O 
phase O 
microextraction O 
( O 
SPME O 
) O 
coupled O 
to O 
gas O 
chromatography O 
with O 
micro O 
- O 
electron O 
capture O 
( O 
μ-ECD O 
) O 
detector O 
. O 
The O 
effect O 
of O 
pH O 
values O 
and O 
fiber O 
coatings O 
were O 
studied O 
. O 
The O 
SPME O 
fiber O 
coating O 
selected O 
was O 
100 O 
μm O 
PDMS O 
. O 
The O 
method O 
is O 
selective O 
with O 
adequate O 
precision O 
and O 
high O 
accuracy O 
and O 
sensitivity O 
. O 
Recoveries O 
ranged O 
within O 
the O 
98-104% O 
range O 
, O 
and O 
detection O 
and O 
quantification O 
limits O 
were O 
1.33 O 
and O 
4.42 O 
μg O 
/ O 
kg O 
, O 
respectively O 
. O 
Statistical O 
parameters O 
indicated O 
the O 
occurrence O 
of O 
matrix O 
effect O 
; O 
consequently O 
calibration O 
was O 
performed O 
on O 
spiked O 
samples O 
. O 
Degradation O 
of O 
boscalid B-TRIVIAL 
was O 
studied O 
in O 
a O 
blueberry O 
field O 
located O 
in O 
Concordia O 
, O 
Argentina O 
, O 
with O 
fruits O 
from O 
Emerald O 
and O 
Jewel O 
varieties O 
. O 
The O 
degradation O 
of O 
boscalid B-TRIVIAL 
in O 
both O 
blueberry O 
varieties O 
studied O 
followed O 
a O 
first O 
order O 
rate O 
kinetics O 
and O 
the O 
half O 
- O 
life O 
for O 
boscalid B-TRIVIAL 
was O 
5.3 O 
and O 
6.3 O 
days O 
for O 
Emerald O 
and O 
Jewel O 
cultivars O 
, O 
respectively O 
. O 

starch O 
, O 
potato O 
starch O 
, O 
pea O 
starch O 
were O 
impregnated O 
with O 
ionic O 
gums O 
( O 
sodium B-SYSTEMATIC 
alginate O 
, O 
CMC O 
, O 
and O 
xanthan O 
, O 
1% O 
based O 
on O 
starch O 
solids O 
) O 
and O 
heat O 
- O 
treated O 
in O 
a O 
dry O 
state O 
for O 
0 O 
, O 
2 O 
, O 
or O 
4 O 
h O 
at O 
130°C O 
. O 
Effects O 
of O 
the O 
dry O 
heating O 
on O 
paste O 
viscosity O 
( O 
RVA O 
) O 
, O 
microstructure O 
and O 
thermal O 
properties O 
were O 
examined O 
. O 
Dry O 
heat O 
treatment O 
with O 
ionic O 
gums O 
reduced O 
the O 
pasting O 
temperature O 
of O 
the O 
three O 
starches O 
. O 
Heating O 
with O 
xanthan O 
increased O 
the O 
paste O 
viscosity O 
of O 
corn O 
and O 
potato O 
starch O 
. O 
With O 
heat O 
treatment O 
, O 
the O 
paste O 
viscosity O 
of O 
all O 
the O 
starch- O 
sodium B-SYSTEMATIC 
alginate O 
mixtures O 
decreased O 
. O 
Heating O 
with O 
CMC O 
increased O 
the O 
paste O 
viscosity O 
of O 
potato O 
starch O 
, O 
but O 
decreased O 
that O 
of O 
corn O 
and O 
pea O 
starch O 
. O 
After O 
dry O 
- O 
heating O 
, O 
To O 
, O 
Tp O 
and O 
Tc O 
of O 
potato O 
starch O 
with O 
ionic O 
gums O 
decreased O 
significantly O 
. O 
SEM O 
of O 
potato O 
starch O 
with O 
CMC O 
showed O 
that O 
the O 
gel O 
structure O 
got O 
compacter O 
after O 
drying O 
- O 
heating O 
. O 
Heat O 
treatment O 
obviously O 
improved O 
the O 
functional O 
properties O 
of O 
the O 
three O 
starches O 
. O 

of O 
acrylamide B-TRIVIAL 
in O 
local O 
and O 
commercial O 
cultivar O 
of O 
potatoes O 
from O 
biological O 
farm O 
. O 

paper O 
reports O 
the O 
results O 
of O 
a O 
preliminary O 
study O 
on O 
the O 
characterization O 
of O 
parameters O 
influencing O 
formation O 
of O 
acrylamide B-TRIVIAL 
in O 
fried O 
potatoes O 
, O 
from O 
biological O 
cultivation O 
. O 
The O 
formation O 
of O 
acrylamide B-TRIVIAL 
was O 
investigated O 
in O 
relation O 
to O 
frying O 
in O 
biological O 
extra O 
virgin O 
olive O 
oil O 
and O 
commercial O 
seed O 
oil O 
. O 
Three O 
different O 
cultivars O 
( O 
Rossa O 
di O 
Colfiorito O 
, O 
Quarantina O 
bianca O 
genovese O 
and O 
Kennebec O 
) O 
were O 
chosen O 
. O 
Asparagine B-TRIVIAL 
, O 
glucose B-TRIVIAL 
, O 
fructose B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
concentrations O 
were O 
determined O 
in O 
potato O 
slice O 
before O 
frying O 
, O 
while O 
acrylamide B-TRIVIAL 
content O 
was O 
analysed O 
by O 
LC-ESI-MS O 
/ O 
MS O 
in O 
the O 
slices O 
fried O 
in O 
seed O 
and O 
extra O 
virgin O 
olive O 
oil O 
. O 
The O 
Kennebec O 
cultivar O 
showed O 
differences O 
in O 
its O 
potential O 
for O 
acrylamide B-TRIVIAL 
formation O 
, O 
which O 
was O 
primarily O 
related O 
to O 
its O 
relatively O 
high O 
asparagine B-TRIVIAL 
and O 
reducing O 
sugars B-FAMILY 
contents O 
, O 
respect O 
the O 
other O 
local O 
cultivars O 
( O 
particulary O 
Quarantina O 
) O 
. O 
Values O 
of O 
acrylamide B-TRIVIAL 
below O 
detection O 
limit O 
( O 
LOD O 
) O 
were O 
found O 
in O 
Quarantina O 
bianca O 
genovese O 
cultivar O 
samples O 
fried O 
in O 
extra O 
virgin O 
olive O 
oil O 
and O 
peanuts O 
seed O 
oil O 
and O 
higher O 
in O 
peanuts O 
seed O 
oil O 
fried O 
potatoes O 
of O 
Kennebec O 
cultivar O 
. O 

kinetics O 
, O 
thermodynamics O 
and O 
isotherm O 
of O 
Hg B-FORMULA 
(II) I-FORMULA 
from O 
aqueous O 
solutions O 
using O 
buckwheat O 
hulls O 
from O 
Jiaodong O 
of O 
China O 
. O 

adsorption O 
kinetics O 
and O 
adsorption O 
isotherms O 
of O 
buckwheat O 
hulls O 
in O 
the O 
region O 
of O 
Jiaodong O 
, O 
China O 
( O 
BHJC O 
) O 
for O 
Hg B-FORMULA 
(II) I-FORMULA 
were O 
investigated O 
. O 
Results O 
revealed O 
that O 
the O 
adsorption O 
kinetics O 
of O 
BHJC O 
for O 
Hg B-FORMULA 
(II) I-FORMULA 
were O 
well O 
described O 
by O 
a O 
pseudo O 
second O 
- O 
order O 
reaction O 
model O 
, O 
and O 
the O 
adsorption O 
thermodynamic O 
parameters O 
ΔG O 
, O 
ΔH O 
and O 
ΔS O 
were O 
-5.83 O 
kJ O 
mol(-1)(35°C) O 
, O 
73.1 O 
, O 
and O 
256 O 
JK(-1) O 
mol(-1) O 
, O 
respectively O 
. O 
Moreover O 
, O 
Langmuir O 
, O 
Freundlich O 
and O 
Redlich-Peterson O 
isotherm O 
models O 
were O 
applied O 
to O 
analyse O 
the O 
experimental O 
data O 
and O 
to O 
predict O 
the O 
relevant O 
isotherm O 
parameters O 
. O 
The O 
best O 
interpretation O 
for O 
the O 
experimental O 
data O 
was O 
given O 
by O 
the O 
Langmuir O 
isotherm O 
equation O 
, O 
and O 
the O 
maximum O 
adsorption O 
capacity O 
for O 
Hg B-FORMULA 
(II) I-FORMULA 
is O 
243.9 O 
mg O 
/ O 
g O 
at O 
35°C O 
. O 
Furthermore O 
, O 
investigation O 
of O 
the O 
adsorption O 
selectivity O 
showed O 
that O 
BHJC O 
displayed O 
strong O 
affinity O 
for O 
mercury B-SYSTEMATIC 
in O 
the O 
aqueous O 
solutions O 
and O 
exhibited O 
100% O 
selectivity O 
for O 
mercury B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
Zn B-FORMULA 
(II) I-FORMULA 
and O 
Cd B-FORMULA 
(II) I-FORMULA 
. O 

of O 
sample O 
preparation O 
methods O 
, O 
validation O 
of O 
an O 
UPLC-MS O 
/ O 
MS O 
procedure O 
for O 
the O 
quantification O 
of O 
tetrodotoxin B-TRIVIAL 
present O 
in O 
marine O 
gastropods O 
and O 
analysis O 
of O 
pufferfish O 
. O 

( O 
TTX B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
potent O 
marine O 
neurotoxins O 
reported O 
. O 
The O 
global O 
distribution O 
of O 
this O 
toxin O 
is O 
spreading O 
with O 
the O 
European O 
Atlantic O 
coastline O 
now O 
being O 
affected O 
. O 
Climate O 
change O 
and O 
increasing O 
pollution O 
have O 
been O 
suggested O 
as O 
underlying O 
causes O 
for O 
this O 
. O 
In O 
the O 
present O 
study O 
, O 
two O 
different O 
sample O 
preparation O 
techniques O 
were O 
used O 
to O 
extract O 
TTX B-ABBREVIATION 
from O 
Trumpet O 
shells O 
and O 
pufferfish O 
samples O 
. O 
Both O 
extraction O 
procedures O 
( O 
accelerated O 
solvent O 
extraction O 
( O 
ASE O 
) O 
and O 
a O 
simple O 
solvent O 
extraction O 
) O 
were O 
shown O 
to O 
provide O 
good O 
recoveries O 
( O 
80-92% O 
) O 
. O 
A O 
UPLC-MS O 
/ O 
MS O 
method O 
was O 
developed O 
for O 
the O 
analysis O 
of O 
TTX B-ABBREVIATION 
and O 
validated O 
following O 
the O 
guidelines O 
contained O 
in O 
the O 
Commission O 
Decision O 
2002 O 
/ O 
657 O 
/ O 
EC O 
for O 
chemical O 
contaminant O 
analysis O 
. O 
The O 
performance O 
of O 
this O 
procedure O 
was O 
demonstrated O 
to O 
be O 
fit O 
for O 
purpose O 
. O 
This O 
study O 
is O 
the O 
first O 
report O 
on O 
the O 
use O 
of O 
ASE O 
as O 
a O 
mean O 
for O 
TTX B-ABBREVIATION 
extraction O 
, O 
the O 
use O 
of O 
UPLC-MS O 
/ O 
MS O 
for O 
TTX B-ABBREVIATION 
analysis O 
, O 
and O 
the O 
validation O 
of O 
this O 
method O 
for O 
TTX B-ABBREVIATION 
in O 
gastropods O 
. O 

inhibition O 
of O 
vasoconstriction O 
by O 
thiazolidinediones B-FAMILY 
related O 
to O 
PI3K O 
/ O 
Akt O 
inhibition O 
in O 
vascular O 
smooth O 
muscle O 
cells O 
. O 

( O 
also O 
referred O 
to O 
as O 
glitazones B-FAMILY 
) O 
, O 
agonists O 
for O 
Peroxisome O 
Proliferator-Activated O 
Receptor O 
gamma O 
( O 
PPARγ O 
) O 
, O 
are O 
used O 
for O 
treating O 
type O 
2 O 
diabetes O 
mellitus O 
, O 
where O 
they O 
decrease O 
insulin O 
resistance O 
and O 
cardiovascular O 
risk O 
. O 
Compounds O 
bearing O 
the O 
thiazolidinedione B-FAMILY 
structure O 
have O 
also O 
been O 
shown O 
to O 
inhibit O 
phosphoinositide O 
3-kinase O 
( O 
PI3K O 
) O 
. O 
Here O 
we O 
tried O 
to O 
elucidate O 
the O 
poorly O 
defined O 
role O 
of O 
PI3K O 
/ O 
Akt O 
in O 
the O 
physiology O 
of O 
vascular O 
smooth O 
muscle O 
cell O 
contraction O 
and O 
tested O 
the O 
hypothesis O 
that O 
thiazolidinediones B-FAMILY 
, O 
by O 
affecting O 
the O 
PI3K O 
/ O 
Akt O 
pathway O 
, O 
may O 
influence O 
vascular O 
physiology O 
. O 
Isolated O 
rat O 
femoral O 
arteries O 
segments O 
were O 
mounted O 
in O 
a O 
wire O 
myograph O 
and O 
challenged O 
with O 
100mM O 
KCl B-FORMULA 
or O 
phenylephrine B-TRIVIAL 
( O 
PE O 
) O 
, O 
in O 
the O 
absence O 
or O 
presence O 
of O 
troglitazone B-TRIVIAL 
, O 
rosiglitazone B-TRIVIAL 
, O 
pioglitazone B-TRIVIAL 
, O 
LY294002 B-IDENTIFIER 
( O 
PI3K O 
inhibitor O 
) O 
and O 
10-DEBC B-SYSTEMATIC 
( O 
Akt O 
inhibitor O 
) O 
. O 
All O 
these O 
compounds O 
dose O 
- O 
dependently O 
inhibited O 
vasoconstriction O 
to O 
KCl B-FORMULA 
or O 
PE O 
; O 
their O 
effect O 
was O 
reversible O 
( O 
after O 
60-120 O 
min O 
washout O 
) O 
and O 
not O 
affected O 
by O 
GW9662 B-IDENTIFIER 
( O 
a O 
PPARγ O 
antagonist O 
) O 
or O 
by O 
N(G)-nitro-L-arginine B-SYSTEMATIC 
( O 
LNNA B-ABBREVIATION 
, O 
an O 
inhibitor O 
of O 
NO B-FORMULA 
biosynthesis O 
) O 
. O 
Analysis O 
of O 
phospho-Akt O 
( O 
ser B-FORMULA 
473 O 
) O 
in O 
lysates O 
from O 
rat O 
arteries O 
( O 
by O 
immunoblot O 
) O 
revealed O 
that O 
thiazolidinediones B-FAMILY 
, O 
LY294002 B-IDENTIFIER 
and O 
10-DEBC B-SYSTEMATIC 
, O 
at O 
the O 
same O 
concentration O 
and O 
kinetics O 
inhibiting O 
vasoconstriction O 
, O 
produced O 
a O 
similar O 
decrease O 
of O 
Akt O 
phosphorylation O 
. O 
PI3K O 
/ O 
Akt O 
pathway O 
therefore O 
appears O 
to O 
be O 
an O 
important O 
, O 
fast O 
acting O 
, O 
modulator O 
of O 
contraction O 
of O 
vascular O 
smooth O 
muscle O 
. O 
Thiazolidinediones B-FAMILY 
decrease O 
vasoconstriction O 
of O 
isolated O 
vessels O 
possibly O 
by O 
inhibiting O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 
Such O 
an O 
effect O 
of O 
glitazones B-FAMILY 
, O 
if O 
occurring O 
in O 
vivo O 
, O 
may O 
impact O 
cardiovascular O 
syndromes O 
related O 
to O 
vasospasm O 
in O 
diabetic O 
patients O 
. O 

of O 
" O 
ecstasy B-TRIVIAL 
" O 
and O 
its O 
metabolites O 
in O 
human O 
dopaminergic O 
differentiated O 
SH-SY5Y O 
cells O 
. O 

Ecstasy B-TRIVIAL 
" O 
( O 
3,4-methylenedioxymethamphetamine B-SYSTEMATIC 
or O 
MDMA B-ABBREVIATION 
) O 
is O 
a O 
widely O 
abused O 
recreational O 
drug O 
, O 
reported O 
to O 
produce O 
neurotoxic O 
effects O 
, O 
both O 
in O 
laboratory O 
animals O 
and O 
in O 
humans O 
. O 
MDMA B-ABBREVIATION 
metabolites O 
can O 
be O 
major O 
contributors O 
for O 
MDMA B-ABBREVIATION 
neurotoxicity O 
. O 
This O 
work O 
studied O 
the O 
neurotoxicity O 
of O 
MDMA B-ABBREVIATION 
and O 
its O 
catechol B-TRIVIAL 
metabolites O 
, O 
α-methyldopamine B-SYSTEMATIC 
( O 
α-MeDA B-ABBREVIATION 
) O 
and O 
N-methyl-α-methyldopamine B-SYSTEMATIC 
( O 
N-Me-α-MeDA B-ABBREVIATION 
) O 
in O 
human O 
dopaminergic O 
SH-SY5Y O 
cells O 
differentiated O 
with O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
and O 
12-O-tetradecanoyl-phorbol-13-acetate B-SYSTEMATIC 
. O 
Differentiation O 
led O 
to O 
SH-SY5Y O 
neurons O 
with O 
higher O 
ability O 
to O 
accumulate O 
dopamine B-TRIVIAL 
and O 
higher O 
resistance O 
towards O 
dopamine B-TRIVIAL 
neurotoxicity O 
. O 
MDMA B-ABBREVIATION 
catechol B-TRIVIAL 
metabolites O 
were O 
neurotoxic O 
to O 
SH-SY5Y O 
neurons O 
, O 
leading O 
to O 
caspase O 
3- O 
independent O 
cell O 
death O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
MDMA B-ABBREVIATION 
did O 
not O 
show O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
death O 
. O 
Pre O 
- O 
treatment O 
with O 
the O 
antioxidant O 
and O 
glutathione B-TRIVIAL 
precursor O 
, O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
resulted O 
in O 
strong O 
protection O 
against O 
the O 
MDMA B-ABBREVIATION 
metabolites O 
' O 
neurotoxicity O 
. O 
Neither O 
the O 
superoxide B-TRIVIAL 
radical O 
scavenger O 
, O 
tiron O 
, O 
nor O 
the O 
inhibitor O 
of O 
the O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
transporter O 
, O 
GBR B-IDENTIFIER 
12909 I-IDENTIFIER 
, O 
prevented O 
the O 
metabolites O 
' O 
toxicity O 
. O 
Cells O 
exposed O 
to O 
α-MeDA B-ABBREVIATION 
showed O 
an O 
increase O 
in O 
intracellular O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
, O 
which O 
, O 
at O 
the O 
48 O 
h O 
time O 
- O 
point O 
, O 
was O 
not O 
dependent O 
in O 
the O 
activity O 
increase O 
of O 
γ-glutamylcysteine B-SYSTEMATIC 
synthetase O 
( O 
γ-GCS O 
) O 
, O 
revealing O 
a O 
possible O 
transient O 
effect O 
. O 
Importantly O 
, O 
pre O 
- O 
treatment O 
with O 
buthionine B-SYSTEMATIC 
sulfoximine I-SYSTEMATIC 
( O 
BSO B-ABBREVIATION 
) O 
, O 
an O 
inhibitor O 
of O 
γ-GCS O 
, O 
prevented O 
α-MeDA B-ABBREVIATION 
induced O 
increase O 
in O 
GSH B-ABBREVIATION 
levels O 
, O 
but O 
did O 
not O 
augment O 
this O 
metabolite O 
cytotoxicity O 
. O 
Even O 
so O 
, O 
BSO B-ABBREVIATION 
pre O 
- O 
treatment O 
abolished O 
NAC B-ABBREVIATION 
protective O 
effects O 
against O 
α-MeDA B-ABBREVIATION 
neurotoxicity O 
, O 
which O 
were O 
, O 
at O 
least O 
partially O 
, O 
due O 
to O 
GSH B-ABBREVIATION 
de O 
novo O 
synthesis O 
. O 
Inversely O 
, O 
pre O 
- O 
treatment O 
of O 
cells O 
with O 
BSO B-ABBREVIATION 
augmented O 
N-Me-α-MeDA B-ABBREVIATION 
-induced O 
neurotoxicity O 
, O 
but O 
only O 
slightly O 
affected O 
NAC B-ABBREVIATION 
neuroprotection O 
. O 
In O 
conclusion O 
, O 
MDMA B-ABBREVIATION 
catechol B-TRIVIAL 
metabolites O 
promote O 
differential O 
toxic O 
effects O 
to O 
differentiated O 
dopaminergic O 
human O 
SH-SY5Y O 
cells O 
. O 

protease O 
activity O 
of O 
calnuc O 
: O 
regulation O 
by O 
Zn2+ B-FORMULA 
and O 
G O 
proteins O 
. O 

functions O 
of O 
calnuc O 
, O 
a O 
novel O 
Ca(2+) B-FORMULA 
-binding O 
protein O 
with O 
multiple O 
structural O 
domains O 
and O 
diverse O 
interacting O 
partners O 
, O 
are O 
yet O 
unknown O 
. O 
We O 
demonstrate O 
unknown O 
facets O 
of O 
calnuc O 
, O 
which O 
is O 
a O 
serine B-TRIVIAL 
protease O 
in O 
which O 
Ser B-FORMULA 
-378 O 
of O 
GXSXG O 
motif O 
, O 
Asp B-FORMULA 
-328 O 
of O 
DTG O 
motif O 
, O 
and O 
His B-FORMULA 
-339 O 
form O 
the O 
" O 
catalytic O 
triad O 
, O 
" O 
locating O 
the O 
enzyme O 
active O 
site O 
in O 
the O 
C B-FORMULA 
-terminal O 
region O 
. O 
Analogous O 
to O 
the O 
active O 
site O 
of O 
Zn(2+) B-FORMULA 
carboxypeptidases O 
, O 
calnuc O 
has O 
two O 
high O 
affinity O 
( O 
K(d) O 
∼ O 
20 O 
nm O 
) O 
, O 
well O 
conserved O 
Zn(2+) B-FORMULA 
-binding O 
sites O 
near O 
its O 
N B-FORMULA 
terminus O 
, O 
although O 
it O 
is O 
inactive O 
as O 
a O 
peptidase O 
. O 
Zn(2+) B-FORMULA 
binding O 
allosterically O 
and O 
negatively O 
regulates O 
the O 
serine B-TRIVIAL 
protease O 
activity O 
of O 
calnuc O 
, O 
inhibition O 
being O 
caused O 
by O 
an O 
" O 
open O 
to O 
close O 
" O 
change O 
in O 
its O 
conformation O 
not O 
seen O 
upon O 
Ca(2+) B-FORMULA 
binding O 
. O 
Most O 
strikingly O 
, O 
interaction O 
with O 
G O 
protein O 
α O 
subunit O 
completely O 
inhibits O 
the O 
enzymatic O 
activity O 
of O 
calnuc O 
. O 
We O 
thus O 
illustrate O 
that O 
G O 
proteins O 
and O 
Zn(2+) B-FORMULA 
act O 
as O 
two O 
" O 
keys O 
" O 
that O 
control O 
enzymatic O 
activity O 
of O 
calnuc O 
, O 
arresting O 
it O 
in O 
" O 
locked O 
" O 
state O 
. O 
Calnuc O 
, O 
therefore O 
, O 
exists O 
dynamically O 
in O 
two O 
different O 
forms O 
, O 
(i) O 
as O 
a O 
Ca(2+) B-FORMULA 
-binding O 
protein O 
in O 
Zn(2+) B-FORMULA 
-bound O 
form O 
and O 
(ii) O 
as O 
a O 
protease O 
in O 
Zn(2+) B-FORMULA 
-free O 
form O 
, O 
commissioning O 
it O 
to O 
perform O 
multiple O 
functions O 
. O 

specific O 
and O 
essential O 
role O 
for O 
Na B-FORMULA 
, O 
K B-FORMULA 
-ATPase O 
α3 O 
in O 
neurons O 
co O 
- O 
expressing O 
α1 O 
and O 
α3 O 
. O 

neurons O 
co O 
- O 
express O 
two O 
catalytic O 
isoforms O 
of O 
Na B-FORMULA 
, O 
K B-FORMULA 
-ATPase O 
, O 
the O 
ubiquitous O 
α1 O 
, O 
and O 
the O 
more O 
selectively O 
expressed O 
α3 O 
. O 
Although O 
neurological O 
syndromes O 
are O 
associated O 
with O 
α3 O 
mutations O 
, O 
the O 
specific O 
role O 
of O 
this O 
isoform O 
is O 
not O 
completely O 
understood O 
. O 
Here O 
, O 
we O 
used O 
electrophysiological O 
and O 
Na(+) B-FORMULA 
imaging O 
techniques O 
to O 
study O 
the O 
role O 
of O 
α3 O 
in O 
central O 
nervous O 
system O 
neurons O 
expressing O 
both O 
isoforms O 
. O 
Under O 
basal O 
conditions O 
, O 
selective O 
inhibition O 
of O 
α3 O 
using O 
a O 
low O 
concentration O 
of O 
the O 
cardiac O 
glycoside O 
, O 
ouabain B-TRIVIAL 
, O 
resulted O 
in O 
a O 
modest O 
increase O 
in O 
intracellular O 
Na(+) B-FORMULA 
concentration O 
( O 
[ O 
Na(+) B-FORMULA 
](i O 
) O 
) O 
accompanied O 
by O 
membrane O 
potential O 
depolarization O 
. O 
When O 
neurons O 
were O 
challenged O 
with O 
a O 
large O 
rapid O 
increase O 
in O 
[ O 
Na(+) B-FORMULA 
](i O 
) O 
, O 
similar O 
to O 
what O 
could O 
be O 
expected O 
following O 
suprathreshold O 
neuronal O 
activity O 
, O 
selective O 
inhibition O 
of O 
α3 O 
almost O 
completely O 
abolished O 
the O 
capacity O 
to O 
restore O 
[ O 
Na(+) B-FORMULA 
](i O 
) O 
in O 
soma O 
and O 
dendrite O 
. O 
Recordings O 
of O 
Na B-FORMULA 
, O 
K B-FORMULA 
-ATPase O 
specific O 
current O 
supported O 
the O 
notion O 
that O 
when O 
[ O 
Na(+) B-FORMULA 
](i O 
) O 
is O 
elevated O 
in O 
the O 
neuron O 
, O 
α3 O 
is O 
the O 
predominant O 
isoform O 
responsible O 
for O 
rapid O 
extrusion O 
of O 
Na(+) B-FORMULA 
. O 
Low O 
concentrations O 
of O 
ouabain B-TRIVIAL 
were O 
also O 
found O 
to O 
disrupt O 
cortical O 
network O 
oscillations O 
, O 
providing O 
further O 
support O 
for O 
the O 
importance O 
of O 
α3 O 
function O 
in O 
the O 
central O 
nervous O 
system O 
. O 
The O 
α O 
isoforms O 
express O 
a O 
well O 
conserved O 
protein O 
kinase O 
A O 
consensus O 
site O 
, O 
which O 
is O 
structurally O 
associated O 
with O 
an O 
Na(+) B-FORMULA 
binding O 
site O 
. O 
Following O 
activation O 
of O 
protein O 
kinase O 
A O 
, O 
both O 
the O 
α3-dependent O 
current O 
and O 
restoration O 
of O 
dendritic O 
[ O 
Na(+) B-FORMULA 
](i O 
) O 
were O 
significantly O 
attenuated O 
, O 
indicating O 
that O 
α3 O 
is O 
a O 
target O 
for O 
phosphorylation O 
and O 
may O 
participate O 
in O 
short O 
term O 
regulation O 
of O 
neuronal O 
function O 
. O 

picosecond O 
laser O 
ablation O 
approach O 
has O 
been O 
developed O 
for O 
the O 
synthesis O 
of O 
ligand O 
- O 
free O 
AuAg B-FORMULA 
bimetallic O 
NPs O 
where O 
the O 
relative O 
amount O 
of O 
Ag B-FORMULA 
is O 
controlled O 
in O 
situ O 
through O 
a O 
laser O 
shielding O 
effect O 
. O 
Various O 
measurements O 
, O 
such O 
as O 
optical O 
spectroscopy O 
, O 
transmission O 
electron O 
microscopy O 
combined O 
with O 
energy O 
dispersive O 
X-ray O 
spectroscopy O 
and O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
, O 
revealed O 
the O 
generation O 
of O 
homogenous O 
15 O 
nm O 
average O 
size O 
bimetallic O 
NPs O 
with O 
different O 
compositions O 
and O 
tunable O 
localized O 
surface O 
plasmon O 
resonance O 
. O 
Furthermore O 
, O 
ligand O 
- O 
free O 
metallic O 
nanoparticles O 
with O 
respect O 
to O 
chemically O 
synthesized O 
nanoparticles O 
display O 
outstanding O 
properties O 
, O 
i.e O 
. O 
featureless O 
Raman O 
background O 
spectrum O 
, O 
which O 
is O 
a O 
basic O 
requirement O 
in O 
many O 
plasmonic O 
applications O 
such O 
as O 
Surface O 
Enhanced O 
Raman O 
Spectroscopy O 
. O 
Various O 
molecules O 
were O 
chemisorbed O 
on O 
the O 
nanoparticle O 
and O 
SERS O 
investigations O 
were O 
carried O 
out O 
, O 
by O 
varying O 
the O 
laser O 
wavelength O 
. O 
The O 
SERS O 
enhancement O 
factor O 
for O 
AuAg B-FORMULA 
bimetallic O 
NPs O 
shows O 
an O 
enhancement O 
factor O 
of O 
about O 
5.7 O 
× O 
10(5) O 
with O 
respect O 
to O 
the O 
flat O 
AuAg B-FORMULA 
surface O 
. O 

receptors O 
exclusively O 
activated O 
by O 
designer O 
drugs O 
( O 
DREADDs O 
) O 
are O 
chemogenetically O 
modified O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
mAChRs O 
) O 
that O 
have O 
minimal O 
responsiveness O 
to O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
but O 
are O 
potently O 
and O 
efficaciously O 
activated O 
by O 
an O 
otherwise O 
inert O 
synthetic O 
ligand O 
, O 
clozapine-N-oxide B-SYSTEMATIC 
( O 
CNO B-ABBREVIATION 
) O 
. O 
DREADDs O 
have O 
been O 
used O 
as O 
tools O 
for O 
selectively O 
modulating O 
signal O 
transduction O 
pathways O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Recent O 
comprehensive O 
studies O 
have O 
validated O 
how O 
the O 
pharmacology O 
of O 
a O 
CNO B-ABBREVIATION 
-bound O 
DREADD O 
mirrors O 
that O 
of O 
an O 
ACh B-ABBREVIATION 
-bound O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mAChR O 
. O 
However O 
, O 
nothing O 
is O 
known O 
about O 
whether O 
this O 
equivalence O 
extends O 
to O 
the O 
allosteric O 
modulation O 
of O 
DREADDs O 
by O 
small O 
molecules O 
. O 
To O 
address O 
this O 
, O 
we O 
investigated O 
the O 
actions O 
at O 
an O 
M(1) O 
DREADD O 
of O 
benzyl B-SYSTEMATIC 
quinolone I-SYSTEMATIC 
carboxylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
BQCA B-ABBREVIATION 
) O 
, O 
a O 
positive O 
allosteric O 
modulator O 
of O 
ACh B-ABBREVIATION 
binding O 
and O 
function O 
that O 
is O 
known O 
to O 
behave O 
according O 
to O 
a O 
simple O 
two O 
- O 
state O 
mechanism O 
at O 
the O 
WT O 
receptor O 
. O 
We O 
found O 
that O 
allosteric O 
modulation O 
of O 
the O 
CNO B-ABBREVIATION 
-bound O 
DREADD O 
receptor O 
is O 
not O 
equivalent O 
to O 
the O 
corresponding O 
modulation O 
of O 
the O 
ACh B-ABBREVIATION 
-bound O 
WT O 
receptor O 
. O 
We O 
also O 
found O 
that O 
BQCA B-ABBREVIATION 
engenders O 
stimulus O 
bias O 
at O 
the O 
M(1) O 
DREADD O 
, O 
having O 
differential O 
types O 
of O 
cooperativity O 
depending O 
on O 
the O 
signaling O 
pathway O 
. O 
Furthermore O 
, O 
the O 
modulation O 
of O 
ACh B-ABBREVIATION 
itself O 
by O 
BQCA B-ABBREVIATION 
at O 
the O 
DREADD O 
is O 
not O 
compatible O 
with O 
the O 
two O 
- O 
state O 
model O 
that O 
we O 
previously O 
applied O 
to O 
the O 
M(1) O 
WT O 
receptor O 
. O 

of O 
Mer O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
signaling O 
attenuated O 
lipopolysaccharide-induced O 
lung O 
inflammation O 
. O 

receptor O 
tyrosine B-TRIVIAL 
kinase O 
( O 
Mer O 
) O 
signaling O 
plays O 
a O 
central O 
role O 
in O 
the O 
intrinsic O 
inhibition O 
of O 
the O 
inflammatory O 
response O 
to O 
Toll O 
- O 
like O 
receptor O 
activation O 
. O 
Previously O 
, O 
we O 
found O 
that O 
lung O 
Mer O 
protein O 
expression O 
decreased O 
after O 
lipopolysaccharide O 
( O 
LPS O 
) O 
treatment O 
due O 
to O 
enhanced O 
Mer O 
cleavage O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
examine O 
whether O 
pharmacologically O 
restored O 
membrane O 
- O 
bound O 
Mer O 
expression O 
upregulates O 
the O 
Mer O 
signaling O 
pathways O 
and O 
suppresses O 
lung O 
inflammatory O 
responses O 
. O 
Pretreatment O 
with O 
the O 
ADAM17 O 
( O 
a O 
disintegrin O 
and O 
metalloproteinase-17 O 
) O 
inhibitor O 
TAPI-0 B-IDENTIFIER 
( O 
tumor O 
necrosis O 
factor O 
alpha O 
protease O 
inhibitor-0 O 
) O 
reduced O 
LPS-induced O 
production O 
of O 
soluble O 
Mer O 
protein O 
in O 
bronchoalveolar O 
lavage O 
( O 
BAL O 
) O 
fluid O 
, O 
restored O 
membrane O 
- O 
bound O 
Mer O 
expression O 
, O 
and O 
increased O 
Mer O 
activation O 
in O 
alveolar O 
macrophages O 
and O 
lungs O 
after O 
LPS O 
treatment O 
. O 
TAPI-0 B-IDENTIFIER 
also O 
enhanced O 
Mer O 
downstream O 
signaling O 
, O 
including O 
phosphorylation O 
of O 
protein O 
kinase O 
b O 
, O 
focal O 
adhesion O 
kinase O 
, O 
and O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
1 O 
. O 
As O 
expected O 
from O 
enhanced O 
Mer O 
signaling O 
, O 
TAPI-0 B-IDENTIFIER 
also O 
augmented O 
suppressor O 
of O 
cytokine O 
signaling-1 O 
and O 
-3 O 
mRNA O 
and O 
protein O 
levels O 
and O 
inhibited O 
nuclear O 
factor O 
κB O 
activation O 
at O 
4 O 
and O 
24 O 
hours O 
after O 
LPS O 
treatment O 
. O 
TAPI-0 B-IDENTIFIER 
suppressed O 
LPS-induced O 
inflammatory O 
cell O 
accumulation O 
, O 
total O 
protein O 
level O 
elevation O 
in O 
BAL O 
fluid O 
, O 
and O 
production O 
of O 
inflammatory O 
mediators O 
, O 
including O 
tumor O 
necrosis O 
factor-α O 
, O 
interleukin-1β O 
, O 
and O 
macrophage O 
inflammatory O 
protein-2 O 
. O 
Additionally O 
, O 
the O 
effects O 
of O 
TAPI-0 B-IDENTIFIER 
on O 
the O 
activation O 
of O 
Mer O 
signaling O 
and O 
the O 
production O 
of O 
inflammatory O 
responses O 
could O 
be O 
reversed O 
by O 
cotreatment O 
with O 
specific O 
Mer O 
- O 
neutralizing O 
antibody O 
. O 
Restored O 
Mer O 
protein O 
expression O 
by O 
treatment O 
with O 
TAPI-0 B-IDENTIFIER 
efficiently O 
prevents O 
the O 
inflammatory O 
cascade O 
during O 
acute O 
lung O 
injury O 
. O 

the O 
vision O 
of O 
identifying O 
and O 
quantifying O 
cancer O 
- O 
related O 
events O 
and O 
targets O 
for O 
future O 
personalized O 
oncology O 
is O 
predicated O 
on O 
the O 
existence O 
of O 
synthetically O 
accessible O 
and O 
economically O 
viable O 
probe O 
molecules O 
fully O 
able O 
to O 
report O 
the O 
presence O 
of O 
these O 
events O 
and O 
targets O 
in O 
a O 
rapid O 
and O 
highly O 
selective O 
and O 
sensitive O 
fashion O 
. O 
Delineated O 
here O 
are O 
the O 
design O 
and O 
evaluation O 
of O 
a O 
newly O 
synthesized O 
turn O 
- O 
on O 
probe O 
whose O 
intense O 
fluorescent O 
reporter O 
signature O 
is O 
revealed O 
only O 
through O 
probe O 
activation O 
by O 
a O 
specific O 
intracellular O 
enzyme O 
present O 
in O 
tumor O 
cells O 
of O 
multiple O 
origins O 
. O 
Quenching O 
of O 
molecular O 
probe O 
fluorescence O 
is O 
achieved O 
through O 
unique O 
photoinduced O 
electron O 
transfer O 
between O 
the O 
naphthalimide B-FAMILY 
dye O 
reporter O 
and O 
a O 
covalently O 
attached O 
, O 
quinone B-FAMILY 
-based O 
enzyme O 
substrate O 
. O 
Fluorescence O 
of O 
the O 
reporter O 
dye O 
is O 
turned O 
on O 
by O 
rapid O 
removal O 
of O 
the O 
quinone B-FAMILY 
quencher O 
, O 
an O 
event O 
that O 
immediately O 
occurs O 
only O 
after O 
highly O 
selective O 
, O 
two O 
- O 
electron O 
reduction O 
of O 
the O 
sterically O 
and O 
conformationally O 
restricted O 
quinone B-FAMILY 
substrate O 
by O 
the O 
cancer O 
- O 
associated O 
human O 
NAD(P)H O 
: O 
quinone B-FAMILY 
oxidoreductase O 
isozyme O 
1 O 
( O 
hNQO1 O 
) O 
. O 
Successes O 
of O 
the O 
approach O 
include O 
rapid O 
differentiation O 
of O 
NQO1-expressing O 
and O 
-nonexpressing O 
cancer O 
cell O 
lines O 
via O 
the O 
unaided O 
eye O 
, O 
flow O 
cytometry O 
, O 
fluorescence O 
imaging O 
, O 
and O 
two O 
- O 
photon O 
microscopy O 
. O 
The O 
potential O 
for O 
use O 
of O 
the O 
turn O 
- O 
on O 
probe O 
in O 
longer O 
- O 
term O 
cellular O 
studies O 
is O 
indicated O 
by O 
its O 
lack O 
of O 
influence O 
on O 
cell O 
viability O 
and O 
its O 
in O 
vitro O 
stability O 
. O 

development O 
of O 
clay O 
bionanocomposites O 
requires O 
processing O 
routes O 
with O 
nanostructural O 
control O 
. O 
Moreover O 
, O 
moisture O 
durability O 
is O 
a O 
concern O 
with O 
water O 
- O 
soluble O 
biopolymers O 
. O 
Here O 
, O 
oriented O 
bionanocomposite O 
coatings O 
with O 
strong O 
in O 
- O 
plane O 
orientation O 
of O 
clay O 
platelets O 
are O 
for O 
the O 
first O 
time O 
prepared O 
by O 
continuous O 
water O 
- O 
based O 
processing O 
. O 
Montmorillonite B-TRIVIAL 
( O 
MTM B-ABBREVIATION 
) O 
and O 
a O 
" O 
new O 
" O 
unmodified O 
biological O 
polymer O 
( O 
xyloglucan O 
( O 
XG O 
) O 
) O 
are O 
combined O 
. O 
The O 
resulting O 
nanocomposites O 
are O 
characterized O 
by O 
FE-SEM O 
, O 
TEM O 
, O 
and O 
XRD O 
. O 
XG O 
adsorption O 
on O 
MTM B-ABBREVIATION 
is O 
measured O 
by O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
analysis O 
. O 
Mechanical O 
and O 
gas O 
barrier O 
properties O 
are O 
measured O 
, O 
also O 
at O 
high O 
relative O 
humidity O 
. O 
The O 
reinforcement O 
effects O 
are O 
modeled O 
. O 
XG O 
dimensions O 
in O 
composites O 
are O 
estimated O 
using O 
atomistic O 
simulations O 
. O 
The O 
nanostructure O 
shows O 
highly O 
oriented O 
and O 
intercalated O 
clay O 
platelets O 
. O 
The O 
reinforcement O 
efficiency O 
and O 
effects O 
on O 
barrier O 
properties O 
are O 
remarkable O 
and O 
are O 
likely O 
to O 
be O 
due O 
to O 
highly O 
oriented O 
and O 
well O 
- O 
dispersed O 
MTM B-ABBREVIATION 
and O 
strong O 
XG- O 
MTM B-ABBREVIATION 
interactions O 
. O 
Properties O 
are O 
well O 
preserved O 
in O 
humid O 
conditions O 
and O 
the O 
reasons O 
for O 
this O 
are O 
discussed O 
. O 

evolution O 
from O 
Pt B-FORMULA 
/ O 
Ru B-FORMULA 
-coated O 
p- O 
type O 
WSe2 O 
photocathodes O 
. O 

p- O 
type O 
WSe(2) O 
has O 
been O 
grown O 
by O 
a O 
chemical O 
vapor O 
transport O 
method O 
. O 
After O 
deposition O 
of O 
noble O 
metal O 
catalysts O 
, O 
p-WSe(2) O 
photocathodes O 
exhibited O 
thermodynamically O 
based O 
photoelectrode O 
energy O 
- O 
conversion O 
efficiencies O 
of O 
> O 
7% O 
for O 
the O 
hydrogen B-SYSTEMATIC 
evolution O 
reaction O 
under O 
mildly O 
acidic O 
conditions O 
, O 
and O 
were O 
stable O 
under O 
cathodic O 
conditions O 
for O 
at O 
least O 
2 O 
h O 
in O 
acidic O 
as O 
well O 
as O 
in O 
alkaline O 
electrolytes O 
. O 
The O 
open O 
circuit O 
potentials O 
of O 
the O 
photoelectrodes O 
in O 
contact O 
with O 
the O 
H(+) B-FORMULA 
/ O 
H(2) B-FORMULA 
redox O 
couple O 
were O 
very O 
close O 
to O 
the O 
bulk O 
recombination O 
/ O 
diffusion O 
limit O 
predicted O 
from O 
the O 
Shockley O 
diode O 
equation O 
. O 
Only O 
crystals O 
with O 
a O 
prevalence O 
of O 
surface O 
step O 
edges O 
exhibited O 
a O 
shift O 
in O 
flat O 
- O 
band O 
potential O 
as O 
the O 
pH O 
was O 
varied O 
. O 
Spectral O 
response O 
data O 
indicated O 
effective O 
minority O 
- O 
carrier O 
diffusion O 
lengths O 
of O 
∼1 O 
μm O 
, O 
which O 
limited O 
the O 
attainable O 
photocurrent O 
densities O 
in O 
the O 
samples O 
to O 
∼15 O 
mA O 
cm(-2) O 
under O 
100 O 
mW O 
cm(-2) O 
of O 
Air O 
Mass O 
1.5G O 
illumination O 
. O 

this O 
Letter O 
, O 
we O 
present O 
narrow O 
line O 
width O 
( O 
7 O 
μeV O 
) O 
, O 
nearly O 
background O 
- O 
free O 
single O 
- O 
photon O 
emission O 
( O 
g((2))(0) O 
= O 
0.02 O 
) O 
and O 
highly O 
indistinguishable O 
photons O 
( O 
V O 
= O 
0.73 O 
) O 
from O 
site O 
- O 
controlled O 
In(Ga)As B-FORMULA 
/ O 
GaAs B-FORMULA 
quantum O 
dots O 
. O 
These O 
excellent O 
properties O 
have O 
been O 
achieved O 
by O 
combining O 
overgrowth O 
on O 
ex O 
situ O 
pit O 
- O 
patterned O 
substrates O 
with O 
vertical O 
stacking O 
of O 
spectrally O 
distinct O 
quantum O 
dot O 
layers O 
. O 
Our O 
study O 
paves O 
the O 
way O 
for O 
large O 
- O 
scale O 
integration O 
of O 
quantum O 
dots O 
into O 
quantum O 
photonic O 
circuits O 
as O 
indistinguishable O 
single O 
- O 
photon O 
sources O 
. O 

, O 
biological O 
evaluation O 
, O 
and O 
molecular O 
modeling O 
of O 
glycyrrhizin B-TRIVIAL 
derivatives O 
as O 
potent O 
high O 
- O 
mobility O 
group O 
box-1 O 
inhibitors O 
with O 
anti-heart- O 
failure O 
activity O 
in O 
vivo O 
. O 

glycyrrhizin B-TRIVIAL 
( O 
GL O 
) O 
derivatives O 
were O 
designed O 
and O 
synthesized O 
by O 
introducing O 
various O 
amine B-SYSTEMATIC 
or O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
into O 
the O 
carbohydrate B-FAMILY 
chain O 
and O 
at O 
C-30 O 
. O 
Their O 
inhibitory O 
effects O 
on O 
high O 
- O 
mobility O 
group O 
box O 
1 O 
( O 
HMGB1 O 
) O 
were O 
evaluated O 
using O 
a O 
cell O 
- O 
based O 
lipopolysaccharide O 
( O 
LPS O 
) O 
induced O 
tumor O 
necrosis O 
factor O 
α O 
( O 
TNF-α O 
) O 
release O 
study O 
. O 
Compounds O 
10 O 
, O 
12 O 
, O 
18-20 O 
, O 
23 O 
, O 
and O 
24 O 
, O 
which O 
had O 
substituents O 
introduced O 
at O 
C-30 O 
, O 
demonstrated O 
moderate O 
HMGB1 O 
inhibition O 
with O 
ED₅₀ O 
values O 
ranging O 
from O 
337 O 
to O 
141 O 
μM O 
, O 
which O 
are O 
values O 
comparable O 
to O 
that O 
of O 
the O 
leading O 
GL O 
compound O 
( O 
1 O 
) O 
( O 
ED₅₀ O 
= O 
70 O 
μM O 
) O 
. O 
Compounds O 
23 O 
and O 
24 O 
emerged O 
as O 
novel O 
and O 
interesting O 
HMGB1 O 
inhibitors O 
. O 
These O 
compounds O 
were O 
able O 
to O 
extend O 
the O 
survival O 
of O 
mice O 
with O 
chronic O 
heart O 
failure O 
( O 
CHF O 
) O 
and O 
acute O 
heart O 
failure O 
( O 
AHF O 
) O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
molecular O 
modeling O 
studies O 
were O 
performed O 
to O 
support O 
the O 
biological O 
data O 
. O 

of O 
1-lactulose B-SYSTEMATIC 
and O 
lactulose B-TRIVIAL 
using O 
commercial O 
β-galactosidase O 
from O 
Kluyveromyces O 
lactis O 
in O 
the O 
presence O 
of O 
fructose B-TRIVIAL 
. O 

of O 
1-lactulose B-SYSTEMATIC 
and O 
lactulose B-TRIVIAL 
using O 
commercial O 
β-galactosidase O 
DSM O 
Maxilact O 
® O 
5000 O 
in O 
the O 
presence O 
of O 
fructose B-TRIVIAL 
was O 
investigated O 
. O 
Experiments O 
were O 
performed O 
at O 
40 O 
°C O 
and O 
pH O 
7.5 O 
. O 
Lactose B-TRIVIAL 
starting O 
concentration O 
was O 
constantly O 
250 O 
g O 
/ O 
l O 
. O 
A O 
novel O 
transgalactosylation O 
product O 
1-lactulose B-SYSTEMATIC 
was O 
detected O 
besides O 
lactulose B-TRIVIAL 
. O 
Effects O 
of O 
fructose B-TRIVIAL 
concentration O 
, O 
reaction O 
time O 
and O 
enzyme O 
concentration O 
on O 
transgalactosylation O 
reactions O 
were O 
discussed O 
. O 
In O 
all O 
reactions O 
, O 
the O 
yield O 
ratio O 
1-lactulose B-SYSTEMATIC 
: O 
lactulose B-TRIVIAL 
was O 
close O 
to O 
3 O 
: O 
1 O 
due O 
to O 
the O 
regioselectivity O 
of O 
β-galactosidase O 
. O 
The O 
maximum O 
production O 
of O 
1-lactulose B-SYSTEMATIC 
and O 
lactulose B-TRIVIAL 
was O 
approximately O 
22 O 
and O 
8 O 
g O 
/ O 
l O 
, O 
respectively O 
, O 
when O 
fructose B-TRIVIAL 
concentration O 
was O 
increased O 
to O 
100 O 
g O 
/ O 
l O 
. O 
Lactose B-TRIVIAL 
hydrolysis O 
was O 
significantly O 
retarded O 
since O 
fructose B-TRIVIAL 
strongly O 
attracted O 
water O 
molecules O 
. O 
Higher O 
enzyme O 
concentration O 
can O 
accelerate O 
transgalactosylation O 
reactions O 
without O 
affecting O 
the O 
maximum O 
production O 
of O 
transgalactosylation O 
products O 
. O 
Fructose B-TRIVIAL 
was O 
a O 
more O 
preferred O 
galactosyl B-TRIVIAL 
acceptor O 
than O 
lactose B-TRIVIAL 
, O 
since O 
the O 
synthesis O 
of O 
galactooligosacchairdes O 
was O 
found O 
to O 
be O 
absolutely O 
inhibited O 
in O 
the O 
presence O 
of O 
fructose B-TRIVIAL 
. O 

of O 
chemical O 
interesterification O 
on O 
the O 
physicochemical O 
, O 
microstructural O 
and O 
thermal O 
properties O 
of O 
palm O 
stearin B-TRIVIAL 
, O 
palm O 
kernel O 
oil O 
and O 
soybean O 
oil O 
blends O 
. O 

of O 
palm O 
stearin B-TRIVIAL 
( O 
PS O 
) O 
, O 
palm O 
kernel O 
oil O 
( O 
PKO O 
) O 
and O 
soybean O 
oil O 
( O 
SBO O 
) O 
at O 
certain O 
proportions O 
were O 
formulated O 
using O 
a O 
mixture O 
design O 
based O 
on O 
simplex O 
- O 
lattice O 
( O 
Design O 
Expert O 
8.0.4 O 
Stat-Ease O 
Inc O 
. O 
, O 
Minneapolis O 
, O 
2010 O 
) O 
. O 
All O 
the O 
10 O 
oil O 
blends O 
were O 
subjected O 
to O 
chemical O 
interesterification O 
( O 
CIE O 
) O 
using O 
sodium B-SYSTEMATIC 
methoxide I-SYSTEMATIC 
as O 
the O 
catalyst O 
. O 
The O 
solid O 
fat O 
content O 
( O 
SFC O 
) O 
, O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
composition O 
, O 
thermal O 
properties O 
( O 
DSC O 
) O 
, O 
polymorphism O 
and O 
microstructural O 
properties O 
were O 
studied O 
. O 
Palm O 
- O 
based O 
trans-free O 
table O 
margarine O 
containing O 
ternary O 
mixture O 
of O 
PS O 
/ O 
PKO O 
/ O 
SBO O 
[ O 
49 O 
/ O 
20 O 
/ O 
31 O 
( O 
w O 
/ O 
w O 
) O 
] O 
, O 
was O 
optimally O 
formulated O 
through O 
analysis O 
of O 
multiple O 
isosolid O 
diagrams O 
and O 
was O 
found O 
to O 
have O 
quite O 
similar O 
SMP O 
and O 
SFC O 
profile O 
as O 
compared O 
to O 
the O 
commercial O 
table O 
margarine O 
. O 
This O 
study O 
has O 
shown O 
chemical O 
interesterification O 
are O 
effective O 
in O 
modifying O 
the O 
physicochemical O 
properties O 
of O 
palm O 
stearin B-TRIVIAL 
, O 
palm O 
kernel O 
oil O 
, O 
soybean O 
oil O 
and O 
their O 
mixtures O 
. O 

of O 
cabbage O 
( O 
Brassica O 
rapa O 
ssp O 
. O 
pekinensis O 
) O 
cultivars O 
grown O 
in O 
different O 
geographical O 
areas O 
using O 
¹H B-FORMULA 
NMR O 
- O 
based O 
metabolomics O 
. O 

( O 
Brassica O 
rapa O 
ssp O 
. O 
pekinensis O 
) O 
is O 
one O 
of O 
the O 
most O 
popular O 
foods O 
in O 
Asia O 
and O 
is O 
widely O 
cultivated O 
in O 
many O 
countries O 
for O 
the O 
production O 
of O 
lightly O 
fermented O 
vegetables O 
. O 
In O 
this O 
study O 
, O 
metabolomic O 
analysis O 
was O 
performed O 
to O 
distinguish O 
two O 
cultivars O 
of O 
cabbage O 
grown O 
in O 
different O 
geographical O 
areas O 
, O 
Korea O 
and O 
China O 
, O 
using O 
¹H B-FORMULA 
NMR O 
spectroscopy O 
coupled O 
with O 
multivariate O 
statistical O 
analysis O 
. O 
Principal O 
component O 
analysis O 
( O 
PCA O 
) O 
showed O 
clear O 
discrimination O 
between O 
extracts O 
of O 
cabbage O 
grown O 
in O 
Korea O 
and O 
China O 
for O 
two O 
different O 
cultivars O 
( O 
Chunmyeong O 
and O 
Chunjung O 
) O 
. O 
The O 
major O 
biochemicals O 
( O 
metabolites O 
) O 
that O 
contributed O 
to O 
discrimination O 
between O 
cabbages O 
grown O 
in O 
the O 
two O 
regions O 
were O 
4-aminobutyrate B-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
, O 
acetate B-SYSTEMATIC 
, O 
asparagine B-TRIVIAL 
, O 
leucine B-TRIVIAL 
, O 
isoleucine B-TRIVIAL 
, O 
O-phosphocholine B-SYSTEMATIC 
, O 
phenylacetate B-SYSTEMATIC 
, O 
phenylalanine B-TRIVIAL 
, O 
succinate B-TRIVIAL 
, O 
sucrose B-TRIVIAL 
, O 
tyrosine B-TRIVIAL 
, O 
and O 
valine B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
the O 
levels O 
of O 
the O 
major O 
metabolites O 
that O 
differ O 
significantly O 
between O 
cabbages O 
grown O 
in O 
these O 
two O 
areas O 
were O 
influenced O 
by O 
environmental O 
factors O 
such O 
as O 
climate O 
and O 
geology O 
. O 
Our O 
study O 
demonstrates O 
that O 
¹H B-FORMULA 
NMR O 
based O 
on O 
metabolomics O 
, O 
coupled O 
with O 
multivariate O 
statistics O 
, O 
can O 
be O 
applied O 
to O 
identify O 
the O 
regions O 
of O 
cultivation O 
of O 
various O 
cabbage O 
cultivars O 
. O 

is O 
not O 
known O 
if O 
there O 
is O 
a O 
correlation O 
between O 
in O 
vitro O 
and O 
in O 
vivo O 
antioxidant O 
activity O 
of O 
wines O 
. O 
Thus O 
, O 
in O 
the O 
present O 
study O 
, O 
rats O 
were O 
fed O 
with O 
a O 
high O 
- O 
fat O 
diet O 
to O 
induce O 
inflammation O 
and O 
oxidative O 
stress O 
, O 
and O 
received O 
supplementation O 
( O 
1 O 
mL O 
/ O 
day O 
) O 
containing O 
water O 
or O 
three O 
red O 
wine O 
samples O 
characterised O 
by O 
high O 
( O 
41.1 O 
mmol O 
TE O 
/ O 
L O 
) O 
, O 
medium O 
( O 
35.7 O 
mmol O 
TE O 
/ O 
L O 
) O 
and O 
low O 
( O 
14.4 O 
mmol O 
TE O 
/ O 
L O 
) O 
in O 
vitro O 
antioxidant O 
activity O 
. O 
A O 
correlation O 
was O 
observed O 
between O 
in O 
vitro O 
antioxidant O 
activity O 
measured O 
in O 
the O 
wines O 
and O 
in O 
vivo O 
antioxidant O 
activity O 
measured O 
in O 
plasma O 
( O 
r= O 
+ O 
0.49 O 
, O 
p=0.011 O 
) O 
. O 
In O 
liver O 
, O 
only O 
the O 
wine O 
containing O 
the O 
highest O 
in O 
vitro O 
antioxidant O 
activity O 
was O 
able O 
to O 
reduce O 
malondialdehyde B-TRIVIAL 
concentration O 
. O 
Groups O 
supplemented O 
with O 
wines O 
containing O 
lower O 
in O 
vitro O 
antioxidant O 
activity O 
showed O 
an O 
increase O 
in O 
antioxidant O 
enzyme O 
activity O 
. O 
We O 
concluded O 
that O 
the O 
correlation O 
between O 
in O 
vitro O 
and O 
in O 
vivo O 
antioxidant O 
activity O 
depends O 
on O 
the O 
biomarker O 
selected O 
to O 
evaluate O 
the O 
oxidative O 
stress O 
. O 

of O 
mercury B-SYSTEMATIC 
in O 
rice O 
by O 
MSFIA O 
and O 
cold O 
vapour O 
atomic O 
fluorescence O 
spectrometry O 
. O 

the O 
present O 
paper O 
the O 
use O 
of O 
a O 
MSFIA O 
system O 
for O 
determination O 
of O 
mercury B-SYSTEMATIC 
in O 
rice O 
by O 
cold O 
vapour O 
atomic O 
fluorescence O 
spectrometry O 
( O 
CV O 
AFS O 
) O 
is O 
proposed O 
. O 
The O 
sample O 
digestion O 
is O 
performed O 
in O 
a O 
microwave O 
oven O 
using O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 
The O 
experimental O 
conditions O 
for O 
vapour O 
generation O 
were O 
determined O 
using O 
a O 
full O 
two O 
- O 
level O 
factorial O 
design O 
involving O 
the O 
following O 
factors O 
: O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
tin B-SYSTEMATIC 
chloride I-SYSTEMATIC 
concentrations O 
and O 
sample O 
flow O 
rate O 
. O 
Employing O 
the O 
conditions O 
optimised O 
, O 
the O 
method O 
allows O 
the O 
determination O 
of O 
mercury B-SYSTEMATIC 
using O 
the O 
external O 
calibration O 
technique O 
with O 
aqueous O 
standards O 
. O 
The O 
reached O 
limits O 
of O 
detection O 
and O 
quantification O 
were O 
0.48 O 
and O 
1.61 O 
ng O 
g⁻¹ O 
respectively O 
, O 
and O 
the O 
precision O 
( O 
as O 
relative O 
standard O 
deviation O 
) O 
was O 
3.28% O 
and O 
1.56% O 
for O 
rice O 
samples O 
with O 
a O 
mercury B-SYSTEMATIC 
content O 
of O 
3.63 O 
and O 
5.81 O 
ng O 
g⁻¹ O 
, O 
respectively O 
. O 
The O 
method O 
accuracy O 
was O 
confirmed O 
analysing O 
a O 
certified O 
reference O 
material O 
of O 
rice O 
flour O 
furnished O 
by O 
National O 
Institute O 
of O 
Standard O 
and O 
Technology O 
. O 
The O 
interference O 
of O 
nitrous B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
nitrous B-FAMILY 
oxides I-FAMILY 
are O 
removed O 
using O 
potassium B-SYSTEMATIC 
dichromate I-SYSTEMATIC 
. O 
The O 
method O 
was O 
applied O 
to O 
mercury B-SYSTEMATIC 
determination O 
in O 
twelve O 
rice O 
samples O 
acquired O 
in O 
Palma O 
de O 
Mallorca O 
( O 
Spain O 
) O 
between O 
the O 
months O 
of O 
January O 
and O 
April O 
of O 
2012 O 
. O 
The O 
mercury B-SYSTEMATIC 
content O 
found O 
varied O 
from O 
2.15 O 
to O 
7.25 O 
ng O 
g⁻¹ O 
. O 
These O 
results O 
agree O 
with O 
those O 
reported O 
by O 
others O 
authors O 
. O 

and O 
distribution O 
of O 
the O 
main O 
active O 
components O 
in O 
selenium B-SYSTEMATIC 
-enriched O 
fruit O 
bodies O 
of O 
Cordyceps O 
militaris O 
link O 
. O 

-enriched O 
Cordyceps O 
militaris O 
fruit O 
bodies O 
are O 
industrially O 
cultivated O 
as O 
functional O 
food O 
or O 
medicinal O 
food O 
in O 
China O 
and O 
southeast O 
Asia O 
. O 
However O 
, O 
composition O 
of O 
selenium B-SYSTEMATIC 
compounds O 
and O 
distribution O 
of O 
the O 
main O 
bioactive O 
components O 
are O 
still O 
unknown O 
. O 
In O 
the O 
selenium B-SYSTEMATIC 
-enriched O 
fruit O 
bodies O 
, O 
the O 
main O 
soluble O 
selenium B-SYSTEMATIC 
compounds O 
of O 
low O 
molecular O 
weight O 
were O 
identified O 
as O 
SeMet B-FORMULA 
( O 
selenomethionine B-SYSTEMATIC 
) O 
, O 
and O 
the O 
main O 
selenium B-SYSTEMATIC 
compounds O 
bound O 
in O 
proteins O 
were O 
identified O 
as O 
SeMet B-FORMULA 
and O 
SeCys B-FORMULA 
( O 
methylselenocysteine B-SYSTEMATIC 
) O 
. O 
Trace O 
minerals O 
as O 
Se B-FORMULA 
( O 
selenium B-SYSTEMATIC 
) O 
, O 
Zn B-FORMULA 
( O 
zinc B-SYSTEMATIC 
) O 
, O 
Fe B-FORMULA 
( O 
iron B-SYSTEMATIC 
) O 
and O 
the O 
main O 
active O 
components O 
as O 
adenosine B-TRIVIAL 
, O 
cordycepin B-TRIVIAL 
and O 
carotenoids O 
were O 
mostly O 
distributed O 
in O 
the O 
terminal O 
of O 
fruit O 
bodies O 
, O 
while O 
P B-FORMULA 
( O 
phosphorus B-SYSTEMATIC 
) O 
and O 
K B-FORMULA 
( O 
potassium B-SYSTEMATIC 
) O 
were O 
evenly O 
distributed O 
in O 
the O 
fruit O 
bodies O 
. O 
The O 
results O 
indicated O 
that O 
terminal O 
of O 
the O 
fruit O 
bodies O 
should O 
be O 
the O 
better O 
materials O 
for O 
production O 
of O 
advanced O 
functional O 
food O 
. O 
So O 
cultivation O 
of O 
relatively O 
short O 
and O 
thick O 
fruit O 
bodies O 
with O 
bigger O 
terminals O 
deserves O 
further O 
research O 
. O 

of O 
trace O 
metal O 
in O 
distilled O 
alcoholic B-FAMILY 
drinks O 
. O 

presence O 
of O 
trace O 
metal O 
cadmium B-SYSTEMATIC 
assay O 
was O 
investigated O 
with O 
a O 
copper B-SYSTEMATIC 
immobilized O 
on O 
a O 
graphite B-TRIVIAL 
carbon B-SYSTEMATIC 
electrode O 
( O 
GPC O 
) O 
, O 
the O 
modified O 
property O 
of O 
which O 
was O 
determined O 
with O 
handheld O 
voltammetric O 
systems O 
. O 
Following O 
the O 
determination O 
of O 
the O 
analytical O 
stripping O 
conditions O 
of O 
0.45 O 
V O 
amplitude O 
, O 
30 O 
Hz O 
frequency O 
, O 
-1.4 O 
V O 
initial O 
potential O 
, O 
and O 
4 O 
mV O 
increment O 
potential O 
, O 
only O 
a O 
60-s O 
experimental O 
accumulation O 
time O 
was O 
used O 
. O 
Using O 
these O 
conditions O 
, O 
the O 
analytical O 
detection O 
limit O 
approached O 
the O 
nano O 
range O 
. O 
At O 
this O 
condition O 
, O 
the O 
analytical O 
application O 
was O 
performed O 
on O 
distilled O 
alcoholic B-FAMILY 
drinks O 
for O 
food O 
manufacturing O 
systems O 
. O 
This O 
developed O 
technique O 
is O 
faster O 
and O 
less O 
costly O 
than O 
the O 
common O 
voltammetric O 
and O 
spectrophotometric O 
methods O 
. O 

norditerpenoids B-FAMILY 
from O 
the O 
soft O 
coral O 
Sinularia O 
maxima O 
. O 

investigation O 
of O 
the O 
soft O 
coral O 
Sinularia O 
maxima O 
resulted O 
in O 
the O 
isolation O 
of O 
seven O 
norditerpenoids B-FAMILY 
, O 
including O 
two O 
new O 
compounds O 
, O 
12-hydroxy-scabrolide B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
13-epi-scabrolide B-SYSTEMATIC 
C I-SYSTEMATIC 
( O 
6 O 
) O 
. O 
The O 
structures O 
of O 
the O 
isolated O 
compounds O 
were O 
elucidated O 
based O 
on O 
extensive O 
spectroscopic O 
evidence O 
including O 
Fourier O 
transform O 
ion O 
cyclotron O 
resonance O 
mass O 
spectrometry O 
( O 
FTICR-MS O 
) O 
and O 
both O 
one- O 
and O 
two O 
- O 
dimensional O 
nuclear O 
magnetic O 
resonance O 
( O 
1D O 
and O 
2D O 
NMR O 
, O 
respectively O 
) O 
, O 
in O 
comparison O 
with O 
reported O 
data O 
. O 
Compound O 
6 O 
potently O 
inhibited O 
IL-12 O 
and O 
IL-6 O 
production O 
in O 
LPS-stimulated O 
bone O 
marrow O 
derived O 
dendritic O 
( O 
BMDCs O 
) O 
with O 
IC(50) O 
values O 
of O 
5.3 O 
± O 
0.21 O 
and O 
13.12 O 
± O 
0.64 O 
μM O 
, O 
respectively O 
. O 
Compound O 
1 O 
exhibited O 
moderate O 
inhibitory O 
activity O 
against O 
IL-12 O 
and O 
IL-6 O 
production O 
with O 
IC(50) O 
values O 
of O 
23.52 O 
± O 
1.37 O 
and O 
69.85 O 
± O 
4.11 O 
μM O 
, O 
respectively O 
. O 

letter O 
describes O 
the O 
further O 
exploration O 
of O 
two O 
series O 
of O 
M(1) O 
allosteric O 
agonists O 
, O 
TBPB B-ABBREVIATION 
and O 
VU0357017 B-IDENTIFIER 
, O 
previously O 
reported O 
from O 
our O 
lab O 
. O 
Within O 
the O 
TPBP B-ABBREVIATION 
scaffold O 
, O 
either O 
electronic O 
or O 
steric O 
perturbations O 
to O 
the O 
central O 
piperidine B-SYSTEMATIC 
ring O 
led O 
to O 
a O 
loss O 
of O 
selective O 
M(1) O 
allosteric O 
agonism O 
and O 
afforded O 
pan-mAChR O 
antagonism O 
, O 
which O 
was O 
demonstrated O 
to O 
be O 
mediated O 
via O 
the O 
orthosteric O 
site O 
. O 
Additional O 
SAR O 
around O 
a O 
related O 
M(1) O 
allosteric O 
agonist O 
family O 
( O 
VU0357017 B-IDENTIFIER 
) O 
identified O 
similar O 
, O 
subtle O 
' O 
molecular O 
switches O 
' O 
that O 
modulated O 
modes O 
of O 
pharmacology O 
from O 
allosteric O 
agonism O 
to O 
pan-mAChR O 
orthosteric O 
antagonism O 
. O 
Therefore O 
, O 
all O 
of O 
these O 
ligands O 
are O 
best O 
classified O 
as O 
bi O 
- O 
topic O 
ligands O 
that O 
possess O 
high O 
affinity O 
binding O 
at O 
an O 
allosteric O 
site O 
to O 
engender O 
selective O 
M(1) O 
activation O 
, O 
but O 
all O 
bind O 
, O 
at O 
higher O 
concentrations O 
, O 
to O 
the O 
orthosteric O 
ACh O 
site O 
, O 
leading O 
to O 
non-selective O 
orthosteric O 
site O 
binding O 
and O 
mAChR O 
antagonism O 
. O 

compounds O 
( O 
OPs O 
) O 
cause O 
neurotoxic O 
disorders O 
through O 
interactions O 
with O 
well O 
- O 
known O 
target O 
esterases O 
, O 
such O 
as O 
acetylcholinesterase O 
and O 
neuropathy O 
target O 
esterase O 
( O 
NTE O 
) O 
. O 
However O 
, O 
the O 
OPs O 
can O 
potentially O 
interact O 
with O 
other O 
esterases O 
of O 
unknown O 
significance O 
. O 
Therefore O 
, O 
identifying O 
, O 
characterizing O 
and O 
elucidating O 
the O 
nature O 
and O 
functional O 
significance O 
of O 
the O 
OP-sensitive O 
pool O 
of O 
esterases O 
in O 
the O 
central O 
and O 
peripheral O 
nervous O 
systems O 
need O 
to O 
be O 
investigated O 
. O 
Kinetic O 
models O 
have O 
been O 
developed O 
and O 
applied O 
by O 
considering O 
multi O 
- O 
enzymatic O 
systems O 
, O 
inhibition O 
, O 
spontaneous O 
reactivation O 
, O 
the O 
chemical O 
hydrolysis O 
of O 
the O 
inhibitor O 
and O 
" O 
ongoing O 
inhibition O 
" O 
( O 
inhibition O 
during O 
the O 
substrate O 
reaction O 
time O 
) O 
. O 
These O 
models O 
have O 
been O 
applied O 
to O 
discriminate O 
enzymatic O 
components O 
among O 
the O 
esterases O 
in O 
nerve O 
tissues O 
of O 
adult O 
chicken O 
, O 
this O 
being O 
the O 
experimental O 
model O 
for O 
delayed O 
neuropathy O 
and O 
to O 
identify O 
different O 
modes O 
of O 
interactions O 
between O 
OPs O 
and O 
soluble O 
brain O 
esterases O 
. O 
The O 
covalent O 
interaction O 
with O 
the O 
substrate O 
catalytic O 
site O 
has O 
been O 
demonstrated O 
by O 
time O 
- O 
progressive O 
inhibition O 
during O 
ongoing O 
inhibition O 
. O 
The O 
interaction O 
of O 
sequential O 
exposure O 
to O 
an O 
esterase O 
inhibitor O 
has O 
been O 
tested O 
in O 
brain O 
soluble O 
fraction O 
where O 
exposure O 
to O 
one O 
inhibitor O 
at O 
a O 
non O 
inhibitory O 
concentration O 
has O 
been O 
seen O 
to O 
modify O 
sensitivity O 
to O 
further O 
exposure O 
to O 
others O 
. O 
The O 
effect O 
has O 
been O 
suggested O 
to O 
be O 
caused O 
by O 
interaction O 
with O 
sites O 
other O 
than O 
the O 
inhibition O 
site O 
at O 
the O 
substrate O 
catalytic O 
site O 
. O 
This O 
kind O 
of O 
interaction O 
among O 
esterase O 
inhibitors O 
should O 
be O 
considered O 
to O 
study O 
the O 
potentiation O 
/ O 
promotion O 
phenomenon O 
, O 
which O 
is O 
observed O 
when O 
some O 
esterase O 
inhibitors O 
enhance O 
the O 
severity O 
of O 
the O 
OP O 
induced O 
neuropathy O 
if O 
they O 
are O 
dosed O 
after O 
a O 
non O 
neuropathic O 
low O 
dose O 
of O 
a O 
neuropathy O 
inducer O 
. O 

induction O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
in O 
round O 
spermatids O 
from O 
the O 
Brown-Norway O 
rat O 
by O 
the O 
chemotherapeutic O 
regimen O 
for O 
testicular O 
cancer O 
. O 

drugs O 
can O 
affect O 
DNA O 
in O 
male O 
germ O 
cells O 
, O 
thereby O 
impacting O 
on O 
the O 
integrity O 
of O 
the O 
genome O 
transmitted O 
to O 
offspring O 
. O 
Drug O 
metabolizing O 
enzymes O 
can O 
protect O 
cells O 
from O 
xenobiotic O 
insult O 
. O 
We O 
analyzed O 
the O 
expression O 
pattern O 
of O 
such O 
enzymes O 
in O 
isolated O 
round O 
spermatids O 
from O 
rats O 
exposed O 
to O 
drugs O 
used O 
to O 
treat O 
testicular O 
cancer O 
: O 
bleomycin B-FAMILY 
, O 
etoposide B-TRIVIAL 
, O 
and O 
cisplatin B-TRIVIAL 
( O 
BEP B-ABBREVIATION 
) O 
. O 
The O 
number O 
of O 
isozymes O 
expressed O 
and O 
the O 
overall O 
relative O 
expression O 
values O 
were O 
highest O 
for O 
the O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
( O 
GSTs O 
) O 
. O 
Moreover O 
, O 
BEP B-ABBREVIATION 
treatment O 
significantly O 
increased O 
the O 
expression O 
of O 
8 O 
GSTs O 
and O 
3 O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
. O 
Increased O 
expression O 
of O 
GST O 
isozymes O 
was O 
confirmed O 
by O 
qRT-PCR O 
and O 
Western O 
blot O 
analysis O 
. O 
Although O 
Gst O 
genes O 
can O 
be O 
targets O 
for O 
epigenetic O 
modifications O 
, O 
promoter O 
DNA O 
methylation O 
was O 
not O 
affected O 
by O 
BEP B-ABBREVIATION 
treatment O 
. O 
As O 
GSTs O 
are O 
involved O 
in O 
drug O 
resistance O 
mechanisms O 
, O 
we O 
hypothesize O 
that O 
BEP B-ABBREVIATION 
induction O 
of O 
GST O 
expression O 
may O 
lead O 
to O 
the O 
survival O 
of O 
damaged O 
germ O 
cells O 
and O 
the O 
production O 
of O 
abnormal O 
sperm O 
. O 

affects O 
differently O 
rat O 
liver O 
and O 
brain O 
mitochondrial O 
bioenergetics O 
and O 
oxidative O 
stress O 
in O 
vitro O 
: O 
investigation O 
of O 
the O 
role O 
of O 
gender O 
. O 

( O 
3,5,4'-trihydroxy-trans B-SYSTEMATIC 
stilbene I-SYSTEMATIC 
) O 
is O 
commonly O 
recognized O 
by O 
its O 
antioxidant O 
properties O 
. O 
Despite O 
its O 
beneficial O 
qualities O 
, O 
the O 
toxic O 
effects O 
of O 
this O 
natural O 
compound O 
are O 
still O 
unknown O 
. O 
Since O 
mitochondria O 
are O 
essential O 
to O 
support O 
the O 
energy O 
- O 
dependent O 
regulation O 
of O 
several O 
cell O 
functions O 
, O 
the O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
resveratrol B-TRIVIAL 
effects O 
on O 
rat O 
brain O 
and O 
liver O 
mitochondrial O 
fractions O 
from O 
male O 
and O 
females O 
regarding O 
oxidative O 
stress O 
and O 
bioenergetics O 
. O 
No O 
basal O 
differences O 
were O 
observed O 
between O 
mitochondrial O 
fractions O 
from O 
males O 
and O 
females O 
, O 
except O 
in O 
liver O 
mitochondria O 
, O 
the O 
generation O 
of O 
H(2)O(2) B-FORMULA 
by O 
the O 
respiratory O 
chain O 
is O 
lower O 
for O 
female O 
preparations O 
. O 
Resveratrol B-TRIVIAL 
inhibited O 
lipid O 
peroxidation O 
in O 
preparations O 
from O 
both O 
genders O 
and O 
organs O 
. O 
Furthermore O 
, O 
brain O 
mitochondria O 
in O 
both O 
gender O 
groups O 
appeared O 
susceptible O 
to O 
resveratrol B-TRIVIAL 
as O 
seen O 
by O 
a O 
decrease O 
in O 
state O 
3 O 
respiration O 
and O 
alterations O 
in O 
mitochondrial O 
membrane O 
potential O 
fluctuations O 
during O 
ADP B-ABBREVIATION 
phosphorylation O 
. O 
As O 
opposed O 
, O 
liver O 
mitochondria O 
were O 
less O 
affected O 
by O 
resveratrol B-TRIVIAL 
. O 
Our O 
data O 
also O 
demonstrates O 
that O 
resveratrol B-TRIVIAL 
inhibits O 
complex O 
I O 
activity O 
in O 
all O 
mitochondrial O 
preparations O 
. O 
The O 
results O 
suggest O 
that O 
brain O 
mitochondria O 
appear O 
to O 
be O 
more O 
susceptible O 
to O 
resveratrol B-TRIVIAL 
effects O 
, O 
and O 
gender O 
appears O 
to O 
play O 
a O 
minor O 
role O 
. O 
It O 
remains O 
to O 
be O 
determined O 
if O 
resveratrol B-TRIVIAL 
effects O 
on O 
brain O 
mitochondria O 
contribute O 
to O 
deterioration O 
of O 
mitochondrial O 
function O 
or O 
instead O 
to O 
mediate O 
hormesis O 
- O 
mediated O 
events O 
. O 

role O 
of O 
efflux O 
transporters O 
on O 
the O 
transport O 
of O 
highly O 
toxic O 
aconitine B-TRIVIAL 
, O 
mesaconitine B-TRIVIAL 
, O 
hypaconitine B-TRIVIAL 
, O 
and O 
their O 
hydrolysates O 
, O 
as O 
determined O 
in O 
cultured O 
Caco-2 O 
and O 
transfected O 
MDCKII O 
cells O 
. O 

alkaloids I-FAMILY 
including O 
aconitine B-TRIVIAL 
( O 
AC O 
) O 
, O 
mesaconitine B-TRIVIAL 
( O 
MA O 
) O 
, O 
hypaconitine B-TRIVIAL 
( O 
HA O 
) O 
, O 
are O 
highly O 
toxic O 
. O 
Their O 
hydrolysates O 
, O 
such O 
as O 
benzoylaconine B-SYSTEMATIC 
( O 
BAC B-ABBREVIATION 
) O 
, O 
benzoylmesaconine B-SYSTEMATIC 
( O 
BMA B-ABBREVIATION 
) O 
, O 
benzoylhypaconine B-TRIVIAL 
( O 
BHA B-ABBREVIATION 
) O 
, O 
aconine B-TRIVIAL 
, O 
and O 
mesaconine B-TRIVIAL 
, O 
are O 
considerably O 
less O 
toxic O 
. O 
Efflux O 
transporters O 
, O 
including O 
P-glycoprotein O 
( O 
P-gp O 
) O 
, O 
breast O 
cancer O 
resistance O 
protein O 
( O 
BCRP O 
) O 
, O 
and O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
isoform O 
2 O 
( O 
MRP2 O 
) O 
, O 
act O 
as O 
a O 
first O 
line O 
of O 
defence O 
and O 
play O 
key O 
roles O 
in O 
toxicity O 
prevention O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
role O 
of O 
efflux O 
transporters O 
in O 
the O 
transport O 
of O 
Aconitum B-FAMILY 
alkaloids I-FAMILY 
using O 
cultured O 
Caco-2 O 
, O 
MDR1-MDCKII O 
and O 
BCRP-MDCKII O 
cells O 
. O 
Bidirectional O 
transport O 
assays O 
of O 
the O 
Aconitum B-FAMILY 
alkaloids I-FAMILY 
were O 
performed O 
with O 
or O 
without O 
P-gp O 
( O 
cyclosporine B-TRIVIAL 
A I-TRIVIAL 
and O 
verapamil B-TRIVIAL 
) O 
, O 
BCRP O 
( O 
Ko143 B-IDENTIFIER 
) O 
and O 
MRP2 O 
( O 
MK571 B-IDENTIFIER 
) O 
inhibitors O 
. O 
The O 
efflux O 
ratios O 
( O 
Er O 
) O 
of O 
AC O 
, O 
MA O 
, O 
and O 
HA O 
in O 
Caco-2 O 
cells O 
were O 
34.6±4.2 O 
, O 
29.7±2.1 O 
, O 
and O 
15.6±2.1 O 
, O 
respectively O 
; O 
those O 
of O 
BAC B-ABBREVIATION 
, O 
BMA B-ABBREVIATION 
, O 
and O 
BHA B-ABBREVIATION 
were O 
approximately O 
4 O 
, O 
and O 
those O 
of O 
aconine B-TRIVIAL 
and O 
mesaconine B-TRIVIAL 
were O 
equal O 
to O 
1 O 
. O 
The O 
Er O 
values O 
of O 
AC O 
, O 
MA O 
, O 
and O 
HA O 
in O 
MDR1-MDCKII O 
and O 
BCRP-MDCKII O 
cells O 
were O 
significantly O 
higher O 
than O 
those O 
in O 
parental O 
MDCKII O 
cells O 
. O 
Taken O 
together O 
the O 
results O 
of O 
Er O 
values O 
and O 
intracellular O 
amounts O 
in O 
the O 
presence O 
of O 
inhibitors O 
, O 
P-gp O 
and O 
BCRP O 
were O 
involved O 
in O 
the O 
transport O 
of O 
AC O 
, O 
MA O 
and O 
HA O 
; O 
and O 
MRP2 O 
might O 
transport O 
AC O 
, O 
MA O 
, O 
HA O 
, O 
BAC B-ABBREVIATION 
, O 
BMA B-ABBREVIATION 
and O 
BHA B-ABBREVIATION 
. O 

effect O 
of O 
1α,25-dihydroxyvitamin B-SYSTEMATIC 
D₃ I-SYSTEMATIC 
on O 
excretion O 
of O 
JBP485 B-IDENTIFIER 
via O 
organic O 
anion O 
transporters O 
in O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
pharmacokinetic O 
mechanism O 
of O 
interaction O 
between O 
JBP485 B-IDENTIFIER 
and O 
1α,25-dihydroxyvitamin B-SYSTEMATIC 
D(3) I-SYSTEMATIC 
[ O 
1,25(OH)(2)D(3) B-FORMULA 
] O 
. O 
Rats O 
were O 
injected O 
intraperitoneally O 
with O 
0.64 O 
nmol O 
/ O 
kg O 
/ O 
day O 
1,25(OH)(2)D(3) B-FORMULA 
in O 
1 O 
ml O 
/ O 
kg O 
corn O 
oil O 
for O 
5 O 
days O 
. O 
The O 
plasma O 
and O 
urine O 
concentrations O 
of O 
JBP485 B-IDENTIFIER 
after O 
intravenous O 
administration O 
and O 
the O 
uptake O 
of O 
JBP485 B-IDENTIFIER 
in O 
kidney O 
slices O 
in O 
vitro O 
were O 
determined O 
by O 
liquid O 
chromatography O 
/ O 
tandem O 
mass O 
spectrometry O 
. O 
Quantitative O 
polymerase O 
chain O 
reaction O 
, O 
western O 
blotting O 
, O 
immunohistochemical O 
analysis O 
and O 
immunofluorescence O 
were O 
used O 
to O 
determine O 
the O 
changes O 
in O 
the O 
expression O 
of O 
organic O 
anion O 
transporter O 
(Oat)1 O 
and O 
Oat3 O 
in O 
rat O 
kidney O 
in O 
response O 
to O 
1,25(OH)(2)D(3) B-FORMULA 
treatment O 
. O 
The O 
plasma O 
concentrations O 
and O 
AUCs O 
of O 
JBP485 B-IDENTIFIER 
were O 
significantly O 
increased O 
, O 
while O 
the O 
renal O 
clearance O 
of O 
JBP485 B-IDENTIFIER 
and O 
uptake O 
of O 
JBP485 B-IDENTIFIER 
in O 
kidney O 
slices O 
were O 
significantly O 
decreased O 
after O 
1,25(OH)(2)D(3) B-FORMULA 
treatment O 
. O 
These O 
results O 
confirmed O 
that O 
1,25(OH)(2)D(3) B-FORMULA 
inhibited O 
renal O 
excretion O 
of O 
JBP485 B-IDENTIFIER 
. O 
Moreover O 
, O 
1,25(OH)(2)D(3) B-FORMULA 
decreased O 
expression O 
of O 
Oat1 O 
and O 
Oat3 O 
in O 
rat O 
kidney O 
. O 
Our O 
results O 
are O 
novel O 
in O 
demonstrating O 
an O 
interaction O 
between O 
JBP485 B-IDENTIFIER 
and O 
1,25(OH)(2)D(3) B-FORMULA 
when O 
they O 
are O 
co O 
- O 
administered O 
. O 
The O 
mechanism O 
of O 
interaction O 
between O 
JBP485 B-IDENTIFIER 
and O 
1,25(OH)(2)D(3) B-FORMULA 
could O 
be O 
explained O 
at O 
least O 
in O 
part O 
by O 
inhibitory O 
effect O 
of O 
1,25(OH)(2)D(3) B-FORMULA 
on O 
expression O 
of O 
Oats O 
in O 
rat O 
kidney O 
. O 

of O 
encapsulation O 
of O 
a O 
synthetic O 
long O 
peptide O 
in O 
PLGA B-ABBREVIATION 
nanoparticles O 
: O 
low O 
- O 
burst O 
release O 
is O 
crucial O 
for O 
efficient O 
CD8(+) O 
T O 
cell O 
activation O 
. O 

synthetic O 
long O 
peptides O 
( O 
SLPs O 
) O 
hold O 
great O 
promise O 
for O 
immunotherapy O 
of O 
cancer O 
. O 
Poly(lactic B-SYSTEMATIC 
- I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
glycolic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
nanoparticles O 
( O 
NPs O 
) O 
are O 
being O 
developed O 
as O 
delivery O 
systems O 
to O 
improve O 
the O 
potency O 
of O 
peptide O 
- O 
based O 
therapeutic O 
cancer O 
vaccines O 
. O 
Our O 
aim O 
was O 
to O 
optimize O 
PLGA B-ABBREVIATION 
NP O 
for O 
SLP O 
delivery O 
with O 
respect O 
to O 
encapsulation O 
and O 
release O 
, O 
using O 
OVA24 O 
, O 
a O 
24-residue O 
long O 
synthetic O 
antigenic O 
peptide O 
covering O 
a O 
CTL O 
epitope O 
of O 
ovalbumin O 
( O 
SIINFEKL O 
) O 
, O 
as O 
a O 
model O 
antigen O 
. O 
Peptide-loaded O 
PLGA B-ABBREVIATION 
NPs O 
were O 
prepared O 
by O 
a O 
double O 
emulsion O 
/ O 
solvent O 
evaporation O 
technique O 
. O 
Using O 
standard O 
conditions O 
( O 
acidic O 
inner O 
aqueous O 
phase O 
) O 
, O 
we O 
observed O 
that O 
either O 
encapsulation O 
was O 
very O 
low O 
( O 
1-30% O 
) O 
, O 
or O 
burst O 
release O 
extremely O 
high O 
( O 
> O 
70% O 
) O 
upon O 
resuspension O 
of O 
NP O 
in O 
physiological O 
buffers O 
. O 
By O 
adjusting O 
formulation O 
and O 
process O 
parameters O 
, O 
we O 
uncovered O 
that O 
the O 
pH O 
of O 
the O 
first O 
emulsion O 
was O 
critical O 
to O 
efficient O 
encapsulation O 
and O 
controlled O 
release O 
. O 
In O 
particular O 
, O 
an O 
alkaline O 
inner O 
aqueous O 
phase O 
resulted O 
in O 
circa O 
330 O 
nm O 
sized O 
NP O 
with O 
approximately O 
40% O 
encapsulation O 
efficiency O 
and O 
low O 
( O 
< O 
10% O 
) O 
burst O 
release O 
. O 
These O 
NP O 
showed O 
enhanced O 
MHC O 
class O 
I O 
restricted O 
T O 
cell O 
activation O 
in O 
vitro O 
when O 
compared O 
to O 
high O 
- O 
burst O 
releasing O 
NP O 
and O 
soluble O 
OVA24 O 
, O 
proving O 
that O 
efficient O 
entrapment O 
of O 
the O 
antigen O 
is O 
crucial O 
to O 
induce O 
a O 
potent O 
cellular O 
immune O 
response O 
. O 

of O 
Apoptosis O 
Protein O 
( O 
IAPs O 
) O 
are O 
guardian O 
ubiquitin O 
ligases O 
that O 
keep O 
classic O 
proapoptotic O 
proteins O 
in O 
check O 
. O 
Systematic O 
identification O 
of O 
additional O 
IAP O 
substrates O 
is O 
challenged O 
by O 
the O 
heterogeneity O 
and O 
sheer O 
number O 
of O 
ubiquitinated O 
proteins O 
( O 
> O 
5000 O 
) O 
. O 
Here O 
we O 
report O 
a O 
powerful O 
catalytic O 
tagging O 
tool O 
, O 
the O 
NEDDylator O 
, O 
which O 
fuses O 
a O 
NEDD8 O 
E2-conjugating O 
enzyme O 
, O 
Ubc12 O 
, O 
to O 
the O 
ubiquitin O 
ligase O 
, O 
XIAP O 
or O 
cIAP1 O 
. O 
This O 
permits O 
transfer O 
of O 
the O 
rare O 
ubiquitin O 
homolog O 
NEDD8 O 
to O 
the O 
ubiquitin O 
E3 O 
substrates O 
, O 
allowing O 
them O 
to O 
be O 
efficiently O 
purified O 
for O 
LC-MS O 
/ O 
MS O 
identification O 
. O 
We O 
have O 
identified O 
> O 
50 O 
potential O 
IAP O 
substrates O 
of O 
both O 
cytosolic O 
and O 
mitochondrial O 
origin O 
that O 
bear O 
hallmark O 
N B-FORMULA 
-terminal O 
IAP O 
binding O 
motifs O 
. O 
These O 
substrates O 
include O 
the O 
recently O 
discovered O 
protein O 
phosphatase O 
PGAM5 O 
, O 
which O 
we O 
show O 
is O 
proteolytically O 
processed O 
, O 
accumulates O 
in O 
cytosol O 
during O 
apoptosis O 
, O 
and O 
sensitizes O 
cells O 
to O 
death O 
. O 
These O 
studies O 
reveal O 
mechanisms O 
and O 
antagonistic O 
partners O 
for O 
specific O 
IAPs O 
, O 
and O 
provide O 
a O 
powerful O 
technology O 
for O 
labeling O 
binding O 
partners O 
in O 
transient O 
protein O 
- O 
protein O 
complexes O 
. O 

of O 
kinases O 
on O 
the O 
activation O 
of O 
tenofovir B-TRIVIAL 
, O 
an O 
anti-HIV O 
agent O 
. O 

analogues O 
, O 
used O 
in O 
HIV O 
- O 
therapy O 
, O 
need O 
to O 
be O 
phosphorylated O 
by O 
cellular O 
enzymes O 
in O 
order O 
to O 
become O 
potential O 
substrates O 
for O 
HIV O 
reverse O 
transcriptase O 
. O 
After O 
incorporation O 
into O 
the O 
viral O 
DNA O 
chain O 
, O 
because O 
of O 
lacking O 
of O 
their O 
3'-hydroxyl B-SYSTEMATIC 
groups O 
, O 
they O 
stop O 
the O 
elongation O 
process O 
and O 
lead O 
to O 
the O 
death O 
of O 
the O 
virus O 
. O 
Phosphorylation O 
of O 
the O 
HIV-drug O 
derivative O 
, O 
tenofovir B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
was O 
tested O 
with O 
the O 
recombinant O 
mammalian O 
nucleoside B-FAMILY 
diphosphate I-FAMILY 
kinase O 
( O 
NDPK O 
) O 
, O 
3-phosphoglycerate B-SYSTEMATIC 
kinase O 
( O 
PGK O 
) O 
, O 
creatine B-TRIVIAL 
kinase O 
( O 
CK O 
) O 
and O 
pyruvate B-TRIVIAL 
kinase O 
( O 
PK O 
) O 
. O 
Among O 
them O 
, O 
only O 
CK O 
was O 
found O 
to O 
phosphorylate O 
tenofovir B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
with O 
a O 
reasonable O 
rate O 
( O 
about O 
45-fold O 
lower O 
than O 
with O 
its O 
natural O 
substrate O 
, O 
ADP B-ABBREVIATION 
) O 
, O 
while O 
PK O 
exhibits O 
even O 
lower O 
, O 
but O 
still O 
detectable O 
activity O 
( O 
about O 
1000-fold O 
lower O 
compared O 
to O 
the O 
value O 
with O 
ADP B-ABBREVIATION 
) O 
. O 
On O 
the O 
other O 
hand O 
, O 
neither O 
NDPK O 
nor O 
PGK O 
has O 
any O 
detectable O 
activity O 
on O 
tenofovir B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
. O 
The O 
absence O 
of O 
activity O 
with O 
PGK O 
is O 
surprising O 
, O 
since O 
the O 
drug O 
tenofovir B-TRIVIAL 
competitively O 
inhibits O 
both O 
CK O 
and O 
PGK O 
towards O 
their O 
nucleotide B-FAMILY 
substrates O 
, O 
with O 
similar O 
inhibitory O 
constants O 
, O 
K O 
(I) O 
of O 
2.9 O 
and O 
4.8mM O 
, O 
respectively O 
. O 
Computer O 
modelling O 
( O 
docking O 
) O 
of O 
tenofovir B-MULTIPLE 
mono- I-MULTIPLE 
or I-MULTIPLE 
diphosphate I-MULTIPLE 
forms O 
to O 
these O 
four O 
kinases O 
suggests O 
that O 
the O 
requirement O 
of O 
large O 
- O 
scale O 
domain O 
closure O 
for O 
functioning O 
( O 
as O 
for O 
PGK O 
) O 
may O 
largely O 
restrict O 
their O 
applicability O 
for O 
phosphorylation O 
/ O 
activation O 
of O 
pro O 
- O 
drugs O 
having O 
a O 
structure O 
similar O 
to O 
tenofovir B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
. O 

effects O 
of O 
sweroside B-TRIVIAL 
on O 
human O 
MG-63 O 
cells O 
and O 
rat O 
osteoblasts O 
. O 

Fructus O 
Corni O 
is O 
a O 
folk O 
medicine O 
with O 
a O 
long O 
history O 
of O 
safe O 
use O 
for O 
treating O 
osteoporosis O 
in O 
postmenopausal O 
women O 
or O 
elderly O 
men O 
in O 
Asia O 
. O 
Sweroside B-TRIVIAL 
is O 
a O 
bioactive O 
herbal O 
ingredient O 
isolated O 
from O 
Fructus O 
Corni O 
, O 
which O 
has O 
been O 
widely O 
used O 
for O 
the O 
treatment O 
of O 
osteoporosis O 
in O 
traditional O 
Chinese O 
medicine O 
( O 
TCM O 
) O 
. O 
Unfortunately O 
, O 
the O 
working O 
mechanisms O 
of O 
this O 
compound O 
are O 
difficult O 
to O 
determine O 
and O 
thus O 
remain O 
unclear O 
. O 
The O 
aim O 
of O 
the O 
study O 
was O 
performed O 
to O 
determine O 
the O 
potential O 
molecular O 
mechanism O 
of O 
the O 
anti-osteoporotic O 
effect O 
of O 
sweroside B-TRIVIAL 
on O 
the O 
human O 
MG-63 O 
cells O 
and O 
rat O 
osteoblasts O 
. O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
test O 
was O 
used O 
to O 
observe O 
the O 
effect O 
of O 
sweroside B-TRIVIAL 
on O 
cell O 
proliferation O 
. O 
The O 
activity O 
of O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
and O 
the O 
amount O 
of O 
osteocalcin O 
were O 
also O 
assayed O 
the O 
cell O 
differentiation O 
. O 
Sweroside B-TRIVIAL 
significantly O 
increased O 
the O 
proliferation O 
of O 
human O 
MG-63 O 
cells O 
and O 
rat O 
osteoblasts O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
It O 
increased O 
the O 
activity O 
of O 
ALP O 
, O 
and O 
osteocalcin O 
was O 
also O 
elevated O 
in O 
response O 
to O 
sweroside B-TRIVIAL 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Of O 
note O 
, O 
flowcytometer O 
assay O 
showed O 
that O 
sweroside B-TRIVIAL 
can O 
attenuate O 
and O 
inhibit O 
apoptosis O 
. O 
Sweroside B-TRIVIAL 
has O 
a O 
direct O 
osteogenic O 
effect O 
on O 
the O 
proliferation O 
and O 
differentiation O 
of O 
cultured O 
human O 
MG-63 O 
cells O 
and O 
rat O 
osteoblasts O 
in O 
vitro O 
. O 
These O 
data O 
will O 
help O 
in O 
understanding O 
the O 
molecular O 
mechanisms O 
of O 
therapeutic O 
efficacy O 
of O 
sweroside B-TRIVIAL 
, O 
and O 
highlight O 
insights O 
into O 
drug O 
discovery O 
. O 
In O 
the O 
current O 
study O 
, O 
sweroside B-TRIVIAL 
has O 
been O 
suggested O 
to O 
be O 
a O 
promising O 
osteoporosis O 
therapeutic O 
natural O 
product O 
. O 

present O 
study O 
investigated O 
the O 
acute O 
, O 
subchronic O 
and O 
genotoxicity O 
of O 
turmeric O 
essential O 
oil O 
( O 
TEO O 
) O 
from O 
Curcuma O 
longa O 
L O 
. O 
Acute O 
administration O 
of O 
TEO O 
was O 
done O 
as O 
single O 
dose O 
up O 
to O 
5 O 
g O 
of O 
TEO O 
per O 
kg O 
body O 
weight O 
and O 
subchronic O 
toxicity O 
study O 
for O 
thirteen O 
weeks O 
was O 
done O 
by O 
daily O 
oral O 
administration O 
of O 
TEO O 
at O 
doses O 
0.1 O 
, O 
0.25 O 
and O 
0.5 O 
g O 
/ O 
kg O 
b.wt O 
. O 
in O 
Wistar O 
rats O 
. O 
There O 
were O 
no O 
mortality O 
, O 
adverse O 
clinical O 
signs O 
or O 
changes O 
in O 
body O 
weight O 
; O 
water O 
and O 
food O 
consumption O 
during O 
acute O 
as O 
well O 
as O 
subchronic O 
toxicity O 
studies O 
. O 
Indicators O 
of O 
hepatic O 
function O 
such O 
as O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
, O 
alanine B-TRIVIAL 
amino B-FAMILY 
transferase O 
( O 
ALT O 
) O 
and O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
were O 
unchanged O 
in O 
treated O 
animals O 
compared O 
to O 
untreated O 
animals O 
. O 
Oral O 
administration O 
of O 
TEO O 
for O 
13 O 
weeks O 
did O 
not O 
alter O 
total O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
markers O 
of O 
renal O 
function O 
, O 
serum O 
electrolyte O 
parameters O 
and O 
histopathology O 
of O 
tissues O 
. O 
TEO O 
did O 
not O 
produce O 
any O 
mutagenicity O 
to O 
Salmonella O 
typhimurium O 
TA-98 O 
, O 
TA-100 O 
, O 
TA-102 O 
and O 
TA-1535 O 
with O 
or O 
without O 
metabolic O 
activation O 
. O 
Administration O 
of O 
TEO O 
to O 
rats O 
( O 
1 O 
g O 
/ O 
kg O 
b.wt O 
. O 
) O 
for O 
14 O 
days O 
did O 
not O 
produce O 
any O 
chromosome O 
aberration O 
or O 
micronuclei O 
in O 
rat O 
bone O 
marrow O 
cells O 
and O 
did O 
not O 
produce O 
any O 
DNA O 
damage O 
as O 
seen O 
by O 
comet O 
assay O 
confirming O 
the O 
non O 
toxicity O 
of O 
TEO O 
. O 

modified O 
β-cyclodextrin B-TRIVIAL 
derivatives O 
as O 
detoxifying O 
agents O 
of O 
chemical O 
warfare O 
agents O 
(I) O 
. O 
Synthesis O 
and O 
preliminary O 
screening O 
: O 
evaluation O 
of O 
the O 
detoxification O 
using O 
a O 
half O 
- O 
quantitative O 
enzymatic O 
assay O 
. O 

treatments O 
of O 
organophosphorus B-FAMILY 
nerve O 
agents O 
poisoning O 
are O 
imperfect O 
, O 
and O 
more O 
efficient O 
medical O 
countermeasures O 
need O 
to O 
be O 
developed O 
. O 
Chemical O 
scavengers O 
based O 
on O 
β-cyclodextrin B-TRIVIAL 
displayed O 
promising O 
results O 
, O 
but O 
further O 
investigations O 
have O 
to O 
be O 
performed O 
to O 
evaluate O 
the O 
possibility O 
of O 
application O 
of O 
substituted O 
cyclodextrins O 
as O 
potential O 
detoxification O 
agents O 
. O 
Herein O 
, O 
five O 
new O 
cyclodextrins O 
scavengers O 
were O 
synthesized O 
. O 
New O 
optimal O 
conditions O 
for O 
regioselectively O 
monosubstitution O 
of O 
β-cyclodextrin B-TRIVIAL 
at O 
O-2 O 
position O 
were O 
then O 
studied O 
to O 
access O 
to O 
key O 
intermediates O 
. O 
After O 
these O 
optimizations O 
, O 
a O 
new O 
series O 
of O 
three O 
permethylated O 
derivatives O 
was O 
developed O 
, O 
and O 
two O 
compounds O 
bearing O 
an O 
α-nucleophilic O 
group O 
via O 
a O 
three O 
carbon B-SYSTEMATIC 
atoms O 
linker O 
were O 
prepared O 
. O 
The O 
ability O 
of O 
these O 
five O 
scavengers O 
to O 
detoxify O 
nerve O 
agents O 
( O 
cyclosarin B-TRIVIAL 
, O 
soman O 
, O 
tabun O 
and O 
VX O 
) O 
was O 
evaluated O 
by O 
a O 
semi-quantitative O 
biological O 
assay O 
. O 
All O 
the O 
modified O 
cyclodextrins O 
significantly O 
decreased O 
the O 
inhibitory O 
effect O 
of O 
chemical O 
warfare O 
G O 
agents O 
on O 
acetylcholinesterase O 
activity O 
. O 
For O 
this O 
purpose O 
, O 
we O 
showed O 
that O 
the O 
specific O 
interactions O 
between O 
the O 
organophosphorus B-FAMILY 
compound O 
and O 
the O 
oligosaccharidic O 
moiety O 
of O 
the O 
scavenger O 
played O 
a O 
pivotal O 
role O 
in O 
the O 
detoxification O 
process O 
. O 

affects O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
in O 
livers O 
from O 
ovariectomized O 
rats O 
by O 
acting O 
as O 
a O 
pro O 
- O 
oxidant O 
agent O 
. O 

deficiency O 
accelerates O 
the O 
development O 
of O 
several O 
disorders O 
including O 
visceral O 
obesity O 
and O 
hepatic O 
steatosis O 
. O 
The O 
predisposing O 
factors O 
can O 
be O 
exacerbated O 
by O 
drugs O 
that O 
affect O 
hepatic O 
lipid O 
metabolism O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
was O 
to O 
determine O 
if O 
raloxifene B-TRIVIAL 
, O 
a O 
selective O 
estrogen B-FAMILY 
receptor O 
modulator O 
( O 
SERM O 
) O 
used O 
extensively O 
by O 
postmenopausal O 
women O 
, O 
affects O 
hepatic O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
pathways O 
. O 
Fatty B-FAMILY 
acids I-FAMILY 
oxidation O 
was O 
measured O 
in O 
the O 
livers O 
, O 
mitochondria O 
and O 
peroxisomes O 
of O 
ovariectomized O 
( O 
OVX O 
) O 
rats O 
. O 
Mitochondrial O 
and O 
peroxisomal O 
β-oxidation O 
was O 
inhibited O 
by O 
raloxifene B-TRIVIAL 
at O 
a O 
concentration O 
range O 
of O 
2.5-25 O 
μM O 
. O 
In O 
perfused O 
livers O 
, O 
raloxifene B-TRIVIAL 
reduced O 
the O 
ketogenesis O 
from O 
endogenous O 
and O 
exogenous O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
increased O 
the O 
β-hydroxybutyrate B-SYSTEMATIC 
/ O 
acetoacetate B-SYSTEMATIC 
ratio O 
. O 
An O 
increase O 
in O 
¹⁴CO₂ B-FORMULA 
production O 
without O 
a O 
parallel O 
increase O 
in O 
the O 
oxygen B-SYSTEMATIC 
consumption O 
indicated O 
that O 
raloxifene B-TRIVIAL 
caused O 
a O 
diversion O 
of O 
NADH B-ABBREVIATION 
from O 
the O 
mitochondrial O 
respiratory O 
chain O 
to O 
another O 
oxidative O 
reaction O 
. O 
It O 
was O 
found O 
that O 
raloxifene B-TRIVIAL 
has O 
a O 
strong O 
ability O 
to O 
react O 
with O 
H₂O₂ B-FORMULA 
in O 
the O 
presence O 
of O 
peroxidase O 
. O 
It O 
is O 
likely O 
that O 
the O 
generation O 
of O 
phenoxyl B-SYSTEMATIC 
radical O 
derivatives O 
of O 
raloxifene B-TRIVIAL 
in O 
intact O 
livers O 
led O 
to O 
the O 
co O 
- O 
oxidation O 
of O 
NADH B-ABBREVIATION 
and O 
a O 
shift O 
of O 
the O 
cellular O 
redox O 
state O 
to O 
an O 
oxidised O 
condition O 
. O 
This O 
change O 
can O 
perturb O 
other O 
important O 
liver O 
metabolic O 
processes O 
dependent O 
on O 
cellular O 
NADH B-ABBREVIATION 
/ O 
NAD⁺ B-ABBREVIATION 
ratio O 
. O 

of O 
OECD O 
Guideline O 
423 O 
in O 
assessing O 
the O 
acute O 
oral O 
toxicity O 
of O 
moniliformin B-TRIVIAL 
. O 

is O 
a O 
Fusarium O 
mycotoxin O 
highly O 
prevalent O 
in O 
grains O 
and O 
grain O 
- O 
based O 
products O 
worldwide O 
. O 
In O 
this O 
study O 
, O 
the O 
acute O 
oral O 
toxicity O 
of O 
moniliformin B-TRIVIAL 
was O 
assessed O 
in O 
Sprague-Dawley O 
male O 
rats O 
according O 
to O 
OECD O 
Guideline O 
423 O 
with O 
a O 
single O 
- O 
dose O 
exposure O 
. O 
Clinical O 
observations O 
and O 
histopathological O 
changes O 
were O 
recorded O 
together O 
with O 
the O 
excretion O 
of O 
moniliformin B-TRIVIAL 
via O 
urine O 
and O 
feces O 
, O 
utilizing O 
a O 
novel O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
method O 
. O 
According O 
to O 
our O 
study O 
, O 
moniliformin B-TRIVIAL 
is O 
acutely O 
toxic O 
to O 
rats O 
with O 
a O 
rather O 
narrow O 
range O 
of O 
toxicity O 
. O 
Moniliformin B-TRIVIAL 
can O 
be O 
classified O 
into O 
category O 
2 O 
( O 
LD(50) O 
cut O 
- O 
off O 
value O 
25 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
, O 
according O 
to O 
the O 
Globally O 
Harmonized O 
System O 
for O 
the O 
classification O 
of O 
chemicals O 
. O 
The O 
clinical O 
observations O 
included O 
muscular O 
weakness O 
, O 
respiratory O 
distress O 
and O 
heart O 
muscle O 
damage O 
. O 
Pathological O 
findings O 
confirmed O 
that O 
heart O 
is O 
the O 
main O 
target O 
tissue O 
of O 
acute O 
moniliformi B-TRIVIAL 
n O 
toxicity O 
. O 
A O 
significant O 
proportion O 
( O 
about O 
38% O 
) O 
of O 
the O 
administered O 
moniliformi B-TRIVIAL 
n O 
was O 
rapidly O 
excreted O 
in O 
urine O 
in O 
less O 
than O 
6 O 
h O 
. O 
However O 
, O 
the O 
toxicokinetics O 
of O 
the O 
majority O 
of O 
the O 
administered O 
dose O 
still O 
requires O 
clarification O 
, O 
as O 
the O 
total O 
excretion O 
was O 
only O 
close O 
to O 
42% O 
. O 
Considering O 
the O 
worldwide O 
occurrence O 
of O 
moniliformi B-TRIVIAL 
n O 
together O 
with O 
its O 
high O 
acute O 
toxicity O 
, O 
research O 
into O 
the O 
subchronic O 
toxicity O 
is O 
of O 
vital O 
importance O 
to O 
identify O 
the O 
possible O 
risk O 
in O 
human O 
/ O 
animal O 
health O 
. O 

increasing O 
use O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
( O 
n O 
TiO(2) B-FORMULA 
) O 
inevitably O 
results O 
in O 
their O 
release O 
into O 
the O 
environment O 
, O 
raising O 
concerns O 
about O 
potential O 
adverse O 
effects O 
in O 
wildlife O 
. O 
By O 
following O 
standard O 
test O 
protocols O 
, O 
several O 
studies O 
investigated O 
the O 
ecotoxicity O 
of O 
n O 
TiO(2) B-FORMULA 
among O 
others O 
to O 
Daphnia O 
magna O 
. O 
These O 
studies O 
indicated O 
a O 
large O 
variability O 
- O 
several O 
orders O 
of O 
magnitude O 
- O 
in O 
the O 
response O 
variables O 
. O 
However O 
, O 
other O 
factors O 
, O 
like O 
nanoparticle O 
characteristics O 
and O 
test O 
design O 
, O 
potentially O 
triggering O 
these O 
differences O 
, O 
were O 
largely O 
ignored O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
assessed O 
the O 
chronic O 
ecotoxicity O 
of O 
two O 
n O 
TiO(2) B-FORMULA 
products O 
with O 
varying O 
crystalline O 
structure O 
( O 
A-100 O 
; O 
P25 O 
) O 
to O 
D O 
. O 
magna O 
. O 
A O 
semi-static O 
and O 
a O 
flow O 
- O 
through O 
exposure O 
scenario O 
were O 
compared O 
, O 
ensuring O 
that O 
both O 
contained O 
environmentally O 
relevant O 
concentrations O 
of O 
dissolved O 
organic O 
carbon B-SYSTEMATIC 
. O 
Utilizing O 
the O 
semi-static O 
test O 
design O 
, O 
a O 
concentration O 
as O 
low O 
as O 
0.06 O 
mg O 
/ O 
L O 
A-100 O 
( O 
∼330 O 
nm O 
) O 
significantly O 
reduced O 
the O 
reproduction O 
of O 
daphnia O 
indicating O 
environmental O 
risk O 
. O 
In O 
contrast O 
, O 
no O 
implication O 
in O 
the O 
number O 
of O 
released O 
offspring O 
was O 
observed O 
during O 
the O 
flow O 
- O 
through O 
experiment O 
with O 
A-100 O 
( O 
∼140 O 
nm O 
) O 
. O 
Likewise O 
, O 
P25 O 
( O 
∼130 O 
nm O 
) O 
did O 
not O 
adversely O 
affect O 
reproduction O 
irrespective O 
of O 
the O 
test O 
design O 
utilized O 
. O 
Given O 
the O 
present O 
study's O 
results O 
, O 
the O 
particle O 
size O 
, O 
the O 
product O 
composition O 
, O 
i.e O 
. O 
the O 
crystalline O 
structure O 
, O 
and O 
the O 
accumulation O 
of O 
n O 
TiO(2) B-FORMULA 
at O 
the O 
bottom O 
of O 
the O 
test O 
vessel O 
- O 
the O 
latter O 
is O 
relevant O 
for O 
a O 
semi-static O 
test O 
design O 
- O 
may O 
be O 
suggested O 
as O 
factors O 
potentially O 
triggering O 
differences O 
in O 
n O 
TiO(2) B-FORMULA 
toxicity O 
to O 
D O 
. O 
magna O 
. O 
Hence O 
, O 
these O 
factors O 
should O 
be O 
considered O 
to O 
improve O 
environmental O 
risk O 
assessment O 
of O 
nanoparticles O 
. O 

slides O 
nucleosomes O 
along O 
DNA O 
, O 
enabling O 
the O 
structural O 
changes O 
of O 
chromatin O 
required O 
for O 
the O 
regulated O 
use O 
of O 
eukaryotic O 
genomes O 
. O 
Prominent O 
mechanistic O 
models O 
imply O 
cooperation O 
of O 
the O 
ISWI O 
ATPase O 
domain O 
with O 
a O 
C B-FORMULA 
-terminal O 
DNA O 
- O 
binding O 
function O 
residing O 
in O 
the O 
HAND-SANT-SLIDE O 
( O 
HSS O 
) O 
domain O 
. O 
Contrary O 
to O 
these O 
models O 
, O 
we O 
show O 
by O 
quantitative O 
biochemical O 
means O 
that O 
all O 
fundamental O 
aspects O 
of O 
nucleosome O 
remodeling O 
are O 
contained O 
within O 
the O 
compact O 
ATPase O 
module O 
of O 
Drosophila O 
ISWI O 
. O 
This O 
domain O 
can O 
independently O 
associate O 
with O 
DNA O 
and O 
nucleosomes O 
, O 
which O 
in O 
turn O 
activate O 
ATP B-ABBREVIATION 
turnover O 
by O 
inducing O 
a O 
conformational O 
change O 
in O 
the O 
enzyme O 
, O 
and O 
it O 
can O 
autonomously O 
reposition O 
nucleosomes O 
. O 
The O 
role O 
of O 
the O 
HSS O 
domain O 
is O 
to O 
increase O 
the O 
affinity O 
and O 
specificity O 
for O 
nucleosomes O 
. O 
Nucleosome O 
- O 
remodeling O 
enzymes O 
may O 
thus O 
have O 
evolved O 
directly O 
from O 
ancestral O 
helicase O 
- O 
type O 
motors O 
, O 
and O 
peripheral O 
domains O 
have O 
furnished O 
regulatory O 
capabilities O 
that O 
bias O 
the O 
remodeling O 
reaction O 
toward O 
different O 
structural O 
outcomes O 
. O 

of O 
rates O 
and O 
products O 
in O 
the O 
reaction O 
of O 
NO3 B-FORMULA 
with O 
submicron O 
squalane B-TRIVIAL 
and O 
squalene B-TRIVIAL 
aerosol O 
. O 

reactive O 
uptake O 
coefficients O 
γ O 
, O 
for O 
nitrate B-SYSTEMATIC 
radical O 
, O 
NO(3) B-FORMULA 
, O 
on O 
∼100 O 
nm O 
diameter O 
squalane B-TRIVIAL 
and O 
squalene B-TRIVIAL 
aerosol O 
were O 
measured O 
( O 
1 O 
atm O 
pressure O 
of O 
N(2) B-FORMULA 
and O 
293 O 
K O 
) O 
. O 
For O 
squalane B-TRIVIAL 
, O 
a O 
branched B-FAMILY 
alkane I-FAMILY 
, O 
γ( O 
NO(3) B-FORMULA 
) O 
of O 
2.8 O 
× O 
10(-3) O 
was O 
estimated O 
. O 
For O 
squalene B-TRIVIAL 
which O 
contains O 
6 O 
double O 
bonds O 
, O 
γ( O 
NO(3) B-FORMULA 
) O 
was O 
found O 
to O 
be O 
a O 
function O 
of O 
degree O 
of O 
oxidation O 
with O 
an O 
initial O 
value O 
of O 
0.18 O 
± O 
0.03 O 
on O 
fresh O 
particles O 
increasing O 
to O 
0.82 O 
± O 
0.11 O 
on O 
average O 
of O 
over O 
3 O 
NO(3) B-FORMULA 
reactions O 
per O 
squalene B-TRIVIAL 
molecule O 
in O 
the O 
aerosol O 
. O 
Synchrotron O 
VUV-ionization O 
aerosol O 
mass O 
spectrometry O 
was O 
used O 
to O 
detect O 
the O 
particle O 
phase O 
oxidation O 
products O 
that O 
include O 
as O 
many O 
as O 
3 O 
NO(3) B-FORMULA 
subunits O 
added O 
to O 
the O 
squalene B-TRIVIAL 
backbone O 
. O 
The O 
fraction O 
of O 
squalene B-TRIVIAL 
remaining O 
in O 
the O 
aerosol O 
follows O 
first O 
order O 
kinetics O 
under O 
oxidation O 
, O 
even O 
at O 
very O 
high O 
oxidation O 
equivalents O 
, O 
which O 
suggests O 
that O 
the O 
matrix O 
remains O 
a O 
liquid O 
upon O 
oxidation O 
. O 
Our O 
calculation O 
indicates O 
a O 
much O 
shorter O 
chemical O 
lifetime O 
for O 
squalene B-TRIVIAL 
-like O 
particle O 
with O 
respect O 
to O 
NO(3) B-FORMULA 
than O 
its O 
atmospheric O 
lifetime O 
to O 
deposition O 
or O 
wet O 
removal O 
. O 

of O 
the O 
plasticizer O 
and O 
phthalate B-FAMILY 
substitute O 
diisononyl-cyclohexane-1,2-dicarboxylate B-SYSTEMATIC 
( O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
) O 
in O 
humans O 
after O 
single O 
oral O 
doses O 
. O 

( O 
® O 
) O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
( O 
diisononyl-cyclohexane-1,2-dicarboxylate B-SYSTEMATIC 
) O 
is O 
a O 
new O 
high O 
- O 
molecular O 
- O 
weight O 
plasticizer O 
and O 
a O 
phthalate B-FAMILY 
substitute O 
. O 
In O 
this O 
study O 
, O 
the O 
metabolism O 
of O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
was O 
investigated O 
by O 
oral O 
dosage O 
of O 
three O 
male O 
volunteers O 
with O 
approximately O 
50 O 
mg O 
Hexamoll B-TRIVIAL 
( O 
® O 
) O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
( O 
resulting O 
in O 
individual O 
doses O 
between O 
0.552 O 
and O 
0.606 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
Their O 
urine O 
samples O 
were O 
consecutively O 
collected O 
over O 
48 O 
h O 
. O 
In O 
analogy O 
to O 
di-iso-nonylphthalate B-SYSTEMATIC 
( O 
DINP B-ABBREVIATION 
) O 
metabolism O 
, O 
we O 
quantified O 
the O 
simple O 
monoester B-SYSTEMATIC 
mono-isononyl-cyclohexane-1,2-dicarboxylate B-SYSTEMATIC 
( O 
MINCH B-ABBREVIATION 
) O 
and O 
its O 
secondary O 
oxidized O 
metabolites O 
with O 
HPLC-MS O 
/ O 
MS O 
via O 
isotope O 
dilution O 
analysis O 
. O 
Additionally O 
, O 
we O 
quantified O 
the O 
unspecific O 
full O 
breakdown O 
product O 
, O 
cyclohexane-1,2-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CHDA B-ABBREVIATION 
) O 
, O 
via O 
standard O 
addition O 
. O 
All O 
postulated O 
metabolites O 
were O 
present O 
in O 
all O 
samples O 
analyzed O 
. O 
The O 
unspecific O 
CHDA B-ABBREVIATION 
was O 
identified O 
as O 
the O 
major O 
urinary O 
metabolite O 
representing O 
23.7 O 
% O 
of O 
the O 
dose O 
as O 
the O 
mean O 
of O 
the O 
three O 
volunteers O 
( O 
range O 
20.0-26.5 O 
% O 
) O 
. O 
14.8 O 
% O 
( O 
11.3-16.7 O 
% O 
) O 
of O 
the O 
dose O 
was O 
excreted O 
as O 
monoesters B-FAMILY 
with O 
oxidative O 
modifications O 
, O 
in O 
particular O 
OH B-FORMULA 
- O 
MINCH B-ABBREVIATION 
10.7 O 
% O 
( O 
7.7-12.9 O 
% O 
) O 
, O 
oxo B-SYSTEMATIC 
- O 
MINCH B-ABBREVIATION 
2 O 
% O 
( O 
1.5-2.6 O 
% O 
) O 
and O 
carboxy B-SYSTEMATIC 
- O 
MINCH B-ABBREVIATION 
2 O 
% O 
( O 
1.8-2.3 O 
% O 
) O 
. O 
Less O 
than O 
1 O 
% O 
was O 
excreted O 
as O 
the O 
simple O 
monoester B-SYSTEMATIC 
MINCH B-ABBREVIATION 
. O 
In O 
sum O 
, O 
39.2 O 
% O 
( O 
35.9-42.4 O 
% O 
) O 
of O 
the O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
dose O 
was O 
excreted O 
as O 
these O 
metabolites O 
in O 
urine O 
within O 
48 O 
h O 
. O 
Over O 
90 O 
% O 
of O 
the O 
metabolites O 
investigated O 
were O 
excreted O 
within O 
24 O 
h O 
after O 
application O 
. O 
The O 
secondary O 
oxidized O 
metabolites O 
, O 
with O 
elimination O 
half O 
- O 
times O 
between O 
10 O 
and O 
18 O 
h O 
, O 
proved O 
to O 
be O 
apt O 
and O 
specific O 
biomarkers O 
to O 
determine O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
exposure O 
. O 
With O 
this O 
study O 
, O 
we O 
provide O 
reliable O 
urinary O 
excretion O 
factors O 
to O 
calculate O 
DINCH B-ABBREVIATION 
( O 
® O 
) O 
intakes O 
based O 
on O 
these O 
metabolites O 
in O 
environmental O 
and O 
occupational O 
studies O 
. O 

report O 
here O 
the O 
construction O 
of O 
engineered O 
endonuclease O 
database O 
( O 
EENdb O 
) O 
( O 
http O 
: O 
/ O 
/ O 
eendb.zfgenetics.org/ O 
) O 
, O 
a O 
searchable O 
database O 
and O 
knowledge O 
base O 
for O 
customizable O 
engineered O 
endonucleases O 
( O 
EENs O 
) O 
, O 
including O 
zinc B-SYSTEMATIC 
finger O 
nucleases O 
( O 
ZFNs O 
) O 
and O 
transcription O 
activator O 
- O 
like O 
effector O 
nucleases O 
( O 
TALENs O 
) O 
. O 
EENs O 
are O 
artificial O 
nucleases O 
designed O 
to O 
target O 
and O 
cleave O 
specific O 
DNA O 
sequences O 
. O 
EENs O 
have O 
been O 
shown O 
to O 
be O 
a O 
very O 
useful O 
genetic O 
tool O 
for O 
targeted O 
genome O 
modification O 
and O 
have O 
shown O 
great O 
potentials O 
in O 
the O 
applications O 
in O 
basic O 
research O 
, O 
clinical O 
therapies O 
and O 
agricultural O 
utilities O 
, O 
and O 
they O 
are O 
specifically O 
essential O 
for O 
reverse O 
genetics O 
research O 
in O 
species O 
where O 
no O 
other O 
gene O 
targeting O 
techniques O 
are O 
available O 
. O 
EENdb O 
contains O 
over O 
700 O 
records O 
of O 
all O 
the O 
reported O 
ZFNs O 
and O 
TALENs O 
and O 
related O 
information O 
, O 
such O 
as O 
their O 
target O 
sequences O 
, O 
the O 
peptide O 
components O 
[ O 
zinc O 
finger O 
protein- O 
/ O 
transcription O 
activator O 
- O 
like O 
effector O 
( O 
TALE O 
) O 
- O 
binding O 
domains O 
, O 
FokI O 
variants O 
and O 
linker O 
peptide O 
/ O 
framework O 
] O 
, O 
the O 
efficiency O 
and O 
specificity O 
of O 
their O 
activities O 
. O 
The O 
database O 
also O 
lists O 
EEN O 
engineering O 
tools O 
and O 
resources O 
as O 
well O 
as O 
information O 
about O 
forms O 
and O 
types O 
of O 
EENs O 
, O 
EEN O 
screening O 
and O 
construction O 
methods O 
, O 
detection O 
methods O 
for O 
targeting O 
efficiency O 
and O 
many O 
other O 
utilities O 
. O 
The O 
aim O 
of O 
EENdb O 
is O 
to O 
represent O 
a O 
central O 
hub O 
for O 
EEN O 
information O 
and O 
an O 
integrated O 
solution O 
for O 
EEN O 
engineering O 
. O 
These O 
studies O 
may O 
help O 
to O 
extract O 
in O 
- O 
depth O 
properties O 
and O 
common O 
rules O 
regarding O 
ZFN O 
or O 
TALEN O 
efficiency O 
through O 
comparison O 
of O 
the O 
known O 
ZFNs O 
or O 
TALENs O 
. O 

the O 
widespread O 
occurrence O 
of O 
bacterial O 
resistance O 
to O 
antibiotics O 
, O 
the O 
development O 
of O 
new O 
strategies O 
beyond O 
conventional O 
treatments O 
is O 
a O 
pursuit O 
taken O 
by O 
public O 
health O 
institutions O 
worldwide O 
. O 
LasR O 
, O 
a O 
transcription O 
factor O 
that O 
controls O 
quorum O 
sensing O 
in O 
Pseudomonas O 
aeruginosa O 
, O 
has O 
emerged O 
as O 
an O 
attractive O 
therapeutic O 
target O 
for O 
the O 
next O 
generation O 
of O 
antimicrobial O 
agents O 
. O 
In O 
the O 
present O 
study O 
, O 
a O 
virtual O 
screening O 
workflow O 
combining O 
pharmacophore- O 
and O 
structure O 
- O 
based O 
approaches O 
was O 
used O 
to O 
identify O 
new O 
LasR O 
ligands O 
. O 
Five O 
novel O 
inducers O 
and O 
three O 
inhibitors O 
of O 
LasR O 
activity O 
were O 
validated O 
experimentally O 
by O 
use O 
of O 
a O 
cell O 
- O 
based O 
assay O 
. O 
Interestingly O 
, O 
these O 
compounds O 
are O 
molecularly O 
distinct O 
from O 
the O 
native O 
signal O 
molecule O 
, O 
N-3-oxododecanoyl-L-homoserine B-SYSTEMATIC 
lactone I-SYSTEMATIC 
( O 
OHN B-ABBREVIATION 
) O 
, O 
and O 
may O 
serve O 
as O 
lead O 
structures O 
for O 
the O 
design O 
of O 
new O 
drugs O 
. O 
The O 
binding O 
modes O 
of O 
these O 
compounds O 
to O 
the O 
OHN B-ABBREVIATION 
binding O 
site O 
in O 
LasR O 
were O 
predicted O 
and O 
used O 
to O 
identify O 
the O 
key O 
interactions O 
that O 
contribute O 
to O 
the O 
induction O 
and O 
inhibition O 
of O 
LasR O 
activity O 
. O 

increased O 
insulin O 
secretory O 
burden O 
placed O 
on O 
pancreatic O 
β-cells O 
during O 
obesity O 
and O 
insulin O 
resistance O 
can O 
ultimately O 
lead O 
to O 
β-cell O 
dysfunction O 
and O 
death O 
and O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
. O 
Mitogen O 
- O 
inducible O 
gene O 
6 O 
( O 
Mig6 O 
) O 
is O 
a O 
cellular O 
stress O 
- O 
responsive O 
protein O 
that O 
can O 
negatively O 
regulate O 
the O 
duration O 
and O 
intensity O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
signaling O 
and O 
has O 
been O 
classically O 
viewed O 
as O 
a O 
molecular O 
brake O 
for O 
proliferation O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
Mig6 O 
heterozygous O 
knockout O 
mice O 
( O 
Mig6(+ O 
/ O 
- O 
) O 
) O 
to O 
study O 
the O 
role O 
of O 
Mig6 O 
in O 
regulating O 
β-cell O 
proliferation O 
and O 
survival O 
. O 
Surprisingly O 
, O 
the O 
proliferation O 
rate O 
of O 
Mig6(+ O 
/ O 
- O 
) O 
pancreatic O 
islets O 
was O 
lower O 
than O 
wild O 
- O 
type O 
islets O 
despite O 
having O 
comparable O 
β-cell O 
mass O 
and O 
glucose B-TRIVIAL 
tolerance O 
. O 
We O 
thus O 
speculated O 
that O 
Mig6 O 
regulates O 
cellular O 
death O 
. O 
Using O 
adenoviral O 
vectors O 
to O 
overexpress O 
or O 
knockdown O 
Mig6 O 
, O 
we O 
found O 
that O 
caspase O 
3 O 
activation O 
during O 
apoptosis O 
was O 
dependent O 
on O 
the O 
level O 
of O 
Mig6 O 
. O 
Interestingly O 
, O 
Mig6 O 
expression O 
was O 
induced O 
during O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
, O 
and O 
its O 
protein O 
levels O 
were O 
maintained O 
throughout O 
ER O 
stress O 
. O 
Using O 
polyribosomal O 
profiling O 
, O 
we O 
identified O 
that O 
Mig6 O 
protein O 
translation O 
was O 
maintained O 
, O 
whereas O 
the O 
global O 
protein O 
translation O 
was O 
inhibited O 
during O 
ER O 
stress O 
. O 
In O 
addition O 
, O 
Mig6 O 
overexpression O 
exacerbated O 
ER O 
stress O 
- O 
induced O 
caspase O 
3 O 
activation O 
in O 
vitro O 
. O 
In O 
conclusion O 
, O 
Mig6 O 
is O 
transcriptionally O 
up O 
- O 
regulated O 
and O 
resistant O 
to O 
global O 
translational O 
inhibition O 
during O 
stressed O 
conditions O 
in O 
β-cells O 
and O 
mediates O 
apoptosis O 
in O 
the O 
form O 
of O 
caspase O 
3 O 
activation O 
. O 
The O 
sustained O 
production O 
of O 
Mig6 O 
protein O 
exacerbates O 
ER O 
stress O 
- O 
induced O 
β-cell O 
death O 
. O 
Thus O 
, O 
preventing O 
the O 
induction O 
, O 
translation O 
, O 
and O 
/ O 
or O 
function O 
of O 
Mig6 O 
is O 
warranted O 
for O 
increasing O 
β-cell O 
survival O 
. O 

1-phosphate I-SYSTEMATIC 
receptor O 
1 O 
(S1P(1)) O 
upregulation O 
and O 
amelioration O 
of O 
experimental O 
autoimmune O 
encephalomyelitis O 
by O 
an O 
S1P(1) O 
antagonist O 
. O 

1-phosphate I-SYSTEMATIC 
receptor O 
1 O 
(S1P(1)) O 
is O 
a O 
G O 
protein O 
- O 
coupled O 
receptor O 
that O 
is O 
critical O 
for O 
proper O 
lymphocyte O 
development O 
and O 
recirculation O 
. O 
Agonists O 
to O 
S1P(1) O 
are O 
currently O 
in O 
use O 
clinically O 
for O 
the O 
treatment O 
of O 
multiple O 
sclerosis O 
, O 
and O 
these O 
drugs O 
may O 
act O 
on O 
both O 
S1P(1) O 
expressed O 
on O 
lymphocytes O 
and O 
S1P(1) O 
expressed O 
within O 
the O 
central O 
nervous O 
system O 
. O 
Agonists O 
to O 
S1P(1) O 
and O 
deficiency O 
in O 
S1P(1) O 
both O 
cause O 
lymphocyte O 
sequestration O 
in O 
the O 
lymph O 
nodes O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
show O 
that O 
S1P(1) O 
antagonism O 
induces O 
lymphocyte O 
sequestration O 
in O 
the O 
lymph O 
nodes O 
similar O 
to O 
that O 
observed O 
with O 
S1P(1) O 
agonists O 
while O 
upregulating O 
S1P(1) O 
on O 
lymphocytes O 
and O 
endothelial O 
cells O 
. O 
Additionally O 
, O 
we O 
show O 
that O 
S1P(1) O 
antagonism O 
reverses O 
experimental O 
autoimmune O 
encephalomyelitis O 
in O 
mice O 
without O 
acting O 
on O 
S1P(1) O 
expressed O 
within O 
the O 
central O 
nervous O 
system O 
, O 
demonstrating O 
that O 
lymphocyte O 
sequestration O 
via O 
S1P(1) O 
antagonism O 
is O 
sufficient O 
to O 
alleviate O 
autoimmune O 
pathology O 
. O 

, O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationship O 
of O 
new O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
analogues O 
containing O 
proline B-TRIVIAL 
derivatives O 
in O 
position O 
2 O 
. O 

this O 
study O 
, O 
we O 
present O 
the O 
synthesis O 
and O 
pharmacological O 
properties O 
of O 
new O 
analogues O 
of O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
modified O 
in O 
the O 
N B-FORMULA 
-terminal O 
part O 
of O 
the O 
molecule O 
with O 
proline B-TRIVIAL 
derivatives O 
: O 
indoline-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
Ica B-ABBREVIATION 
) O 
and O 
(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
All O 
the O 
peptides O 
were O 
tested O 
for O 
pressor O 
, O 
antidiuretic O 
and O 
in O 
vitro O 
uterotonic O 
activities O 
. O 
We O 
also O 
determined O 
their O 
binding O 
affinity O 
to O 
the O 
human O 
oxytocin B-TRIVIAL 
receptor O 
. O 
The O 
Ica B-ABBREVIATION 
( O 
2 O 
) O 
substitution O 
resulted O 
in O 
two O 
moderately O 
potent O 
and O 
selective O 
antioxytocic O 
agents O 
: O 
[ B-FORMULA 
Mpa(1) I-FORMULA 
, I-FORMULA 
Ica(2) I-FORMULA 
, I-FORMULA 
D-Arg(8)]VP I-FORMULA 
and O 
[Mpa(1),Ica(2),Val(4),D-Arg(8)]VP B-FORMULA 
( O 
pA(2) O 
= O 
7.09 O 
and O 
7.5 O 
, O 
respectively O 
) O 
. O 
On O 
the O 
other O 
hand O 
, O 
peptides O 
modified O 
with O 
(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
apart O 
from O 
their O 
moderate O 
antioxytocic O 
activity O 
, O 
turned O 
out O 
to O 
be O 
weak O 
antagonists O 
of O 
the O 
pressor O 
response O 
to O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
. O 
The O 
results O 
of O 
this O 
study O 
provide O 
useful O 
information O 
about O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
arginine B-TRIVIAL 
vasopressin I-TRIVIAL 
analogues O 
and O 
can O 
help O 
to O 
design O 
compounds O 
with O 
desired O 
biological O 
properties O 
. O 

nanoclusters O 
with O 
chemical O 
, O 
magnetic O 
, O 
and O 
biofunctionality O 
offer O 
broad O 
opportunities O 
for O 
targeted O 
cellular O 
imaging O 
. O 
A O 
key O 
challenge O 
is O 
to O 
load O 
a O 
high O 
degree O 
of O 
targeting O 
, O 
imaging O 
, O 
and O 
therapeutic O 
functionality O 
onto O 
stable O 
metal B-FAMILY 
- I-FAMILY 
oxide I-FAMILY 
nanoparticles O 
. O 
Here O 
we O 
report O 
a O 
route O 
for O 
producing O 
magnetic O 
nanoclusters O 
( O 
MNCs O 
) O 
with O 
alkyne B-FAMILY 
surface O 
functionality O 
that O 
can O 
be O 
utilized O 
as O 
multimodal O 
imaging O 
probes O 
. O 
We O 
form O 
MNCs O 
composed O 
of O 
magnetic O 
Fe(3)O(4) O 
nanoparticles O 
and O 
poly(acrylic O 
acid O 
- O 
co O 
- O 
propargyl O 
acrylate O 
) O 
by O 
the O 
co O 
- O 
precipitation O 
of O 
iron O 
salts O 
in O 
the O 
presence O 
of O 
copolymer O 
stabilizers O 
. O 
The O 
MNCs O 
were O 
surface O 
- O 
modified O 
with O 
near O 
- O 
infrared O 
( O 
NIR O 
) O 
emitting O 
fluorophore O 
used O 
in O 
photodynamic O 
therapy O 
, O 
an O 
azide B-SYSTEMATIC 
-modified O 
indocyanine B-TRIVIAL 
green I-TRIVIAL 
. O 
The O 
fluorophores O 
engaged O 
and O 
complexed O 
with O 
bovine O 
serum O 
albumin O 
, O 
forming O 
an O 
extended O 
coverage O 
of O 
serum O 
proteins O 
on O 
the O 
MNCs O 
. O 
These O 
proteins O 
isolated O 
indocyanine B-TRIVIAL 
green I-TRIVIAL 
fluorophores O 
from O 
the O 
aqueous O 
environment O 
and O 
induced O 
an O 
effective O 
" O 
turn O 
- O 
on O 
" O 
of O 
NIR O 
emission O 
. O 

potentials O 
for O 
phase O 
equilibria O 
. O 
10 O 
. O 
Explicit- O 
hydrogen B-SYSTEMATIC 
description O 
of O 
substituted O 
benzenes B-FAMILY 
and O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
compounds O 
. O 

explicit- O 
hydrogen B-SYSTEMATIC 
version O 
of O 
the O 
transferable O 
potentials O 
for O 
phase O 
equilibria O 
( O 
TraPPE-EH O 
) O 
force O 
field O 
is O 
extended O 
to O 
various O 
substituted O 
benzenes B-FAMILY 
through O 
the O 
parametrization O 
of O 
the O 
exocyclic O 
groups O 
- O 
F B-FORMULA 
, O 
- O 
Cl B-FORMULA 
, O 
- O 
Br B-FORMULA 
, O 
- O 
C≡N B-FORMULA 
, O 
and O 
- O 
OH B-FORMULA 
and O 
to O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
through O 
the O 
parametrization O 
of O 
the O 
aromatic O 
linker O 
carbon B-SYSTEMATIC 
atom O 
for O 
multiple O 
rings O 
. O 
The O 
linker O 
carbon B-SYSTEMATIC 
together O 
with O 
the O 
TraPPE-EH O 
parameters O 
for O 
aromatic B-FAMILY 
heterocycles I-FAMILY 
constitutes O 
a O 
force O 
field O 
for O 
fused B-FAMILY 
- I-FAMILY 
ring I-FAMILY 
heterocycles I-FAMILY 
. O 
Configurational O 
- O 
bias O 
Monte O 
Carlo O 
simulations O 
in O 
the O 
Gibbs O 
ensemble O 
were O 
carried O 
out O 
to O 
compute O 
vapor O 
- O 
liquid O 
coexistence O 
curves O 
for O 
fluorobenzene B-SYSTEMATIC 
; O 
chlorobenzene B-SYSTEMATIC 
; O 
bromobenzene B-SYSTEMATIC 
; O 
di- B-MULTIPLE 
, I-MULTIPLE 
tri- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
hexachlorobenzene I-MULTIPLE 
isomers O 
; O 
2-chlorofuran B-SYSTEMATIC 
; O 
2-chlorothiophene B-SYSTEMATIC 
; O 
benzonitrile B-SYSTEMATIC 
; O 
phenol B-SYSTEMATIC 
; O 
dihydroxybenzene B-FAMILY 
isomers O 
; O 
1,4-benzoquinone B-SYSTEMATIC 
; O 
naphthalene B-SYSTEMATIC 
; O 
naphthalene-2-carbonitrile B-SYSTEMATIC 
; O 
naphthalen-2-ol B-SYSTEMATIC 
; O 
quinoline B-SYSTEMATIC 
; O 
benzo[b]thiophene B-SYSTEMATIC 
; O 
benzo[c]thiophene B-SYSTEMATIC 
; O 
benzoxazole B-SYSTEMATIC 
; O 
benzisoxazole B-SYSTEMATIC 
; O 
benzimidazole B-SYSTEMATIC 
; O 
benzothiazole B-SYSTEMATIC 
; O 
indole B-SYSTEMATIC 
; O 
isoindole B-SYSTEMATIC 
; O 
indazole B-SYSTEMATIC 
; O 
purine B-TRIVIAL 
; O 
anthracene B-SYSTEMATIC 
; O 
and O 
phenanthrene B-SYSTEMATIC 
. O 
The O 
agreement O 
with O 
the O 
limited O 
experimental O 
data O 
is O 
very O 
satisfactory O 
, O 
with O 
saturated O 
liquid O 
densities O 
and O 
vapor O 
pressures O 
reproduced O 
to O 
within O 
1.5% O 
and O 
15% O 
, O 
respectively O 
. O 
The O 
mean O 
unsigned O 
percentage O 
errors O 
in O 
the O 
normal O 
boiling O 
points O 
, O 
critical O 
temperatures O 
, O 
and O 
critical O 
densities O 
are O 
0.9% O 
, O 
1.2% O 
, O 
and O 
1.4% O 
, O 
respectively O 
. O 
Additional O 
simulations O 
were O 
carried O 
out O 
for O 
binary O 
systems O 
of O 
benzene B-SYSTEMATIC 
/ O 
benzonitrile B-SYSTEMATIC 
, O 
benzene B-SYSTEMATIC 
/ O 
phenol B-SYSTEMATIC 
, O 
and O 
naphthalene B-SYSTEMATIC 
/ O 
methanol B-SYSTEMATIC 
to O 
illustrate O 
the O 
transferability O 
of O 
the O 
developed O 
potentials O 
to O 
binary O 
systems O 
containing O 
compounds O 
of O 
different O 
polarity O 
and O 
hydrogen B-SYSTEMATIC 
-bonding O 
ability O 
. O 
A O 
detailed O 
analysis O 
of O 
the O 
liquid O 
- O 
phase O 
structures O 
is O 
provided O 
for O 
selected O 
neat O 
systems O 
and O 
binary O 
mixtures O 
. O 

action O 
of O 
N-palmitoylethanolamine B-SYSTEMATIC 
through O 
CB1 O 
and O 
PPAR-α O 
receptor O 
activation O 
in O 
a O 
genetic O 
model O 
of O 
absence O 
epilepsy O 
. O 

( O 
PEA B-ABBREVIATION 
) O 
, O 
an O 
endogenous O 
fatty B-FAMILY 
acid I-FAMILY 
ethanolamide I-FAMILY 
, O 
plays O 
a O 
key O 
role O 
in O 
the O 
regulation O 
of O 
the O 
inflammatory O 
response O 
and O 
pain O 
through O 
, O 
among O 
others O 
, O 
activation O 
of O 
nuclear O 
peroxisome O 
proliferator O 
- O 
activated O 
receptors O 
( O 
PPAR-α O 
) O 
. O 
Endogenous O 
cannabinoids B-FAMILY 
play O 
a O 
protective O 
role O 
in O 
several O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
disorders O 
, O 
particularly O 
those O 
associated O 
with O 
neuronal O 
hyperexcitability O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
PEA B-ABBREVIATION 
and O 
the O 
role O 
of O 
PPAR-α O 
in O 
absence O 
epilepsy O 
using O 
the O 
WAG O 
/ O 
Rij O 
rat O 
model O 
. O 
PEA B-ABBREVIATION 
, O 
anandamide B-TRIVIAL 
( O 
AEA B-ABBREVIATION 
) O 
, O 
a O 
PPAR-α O 
antagonist O 
( O 
GW6471 B-IDENTIFIER 
) O 
and O 
a O 
synthetic O 
CB1 O 
receptor O 
antagonist O 
/ O 
inverse O 
agonist O 
( O 
SR141716 B-IDENTIFIER 
) O 
were O 
administered O 
to O 
WAG O 
/ O 
Rij O 
rats O 
in O 
order O 
to O 
evaluate O 
the O 
effects O 
on O 
epileptic O 
spike O 
- O 
wave O 
discharges O 
( O 
SWDs O 
) O 
on O 
EEG O 
recordings O 
. O 
We O 
studied O 
also O 
the O 
effects O 
of O 
PEA B-ABBREVIATION 
co O 
- O 
administration O 
with O 
SR141716 B-IDENTIFIER 
and O 
GW6471 B-IDENTIFIER 
and O 
compared O 
these O 
effects O 
with O 
those O 
of O 
AEA B-ABBREVIATION 
to O 
evaluate O 
PEA B-ABBREVIATION 
mechanism O 
of O 
action O 
and O 
focusing O 
on O 
CB1 O 
receptors O 
and O 
PPAR-α O 
. O 
Both O 
PEA B-ABBREVIATION 
and O 
AEA B-ABBREVIATION 
administration O 
significantly O 
decreased O 
SWDs O 
parameters O 
( O 
absence O 
seizures O 
) O 
. O 
In O 
contrast O 
, O 
GW6471 B-IDENTIFIER 
was O 
devoid O 
of O 
effects O 
while O 
SR141716 B-IDENTIFIER 
had O 
pro O 
- O 
absence O 
effects O 
. O 
The O 
co O 
- O 
administration O 
of O 
SR141716 B-IDENTIFIER 
with O 
PEA B-ABBREVIATION 
or O 
AEA B-ABBREVIATION 
completely O 
blocked O 
the O 
anti-absence O 
effects O 
of O 
these O 
compounds O 
. O 
GW6471 B-IDENTIFIER 
antagonized O 
PEA B-ABBREVIATION 
' O 
s O 
effects O 
whereas O 
it O 
did O 
not O 
modify O 
AEA B-ABBREVIATION 
' O 
s O 
effects O 
. O 
Furthermore O 
, O 
we O 
have O 
also O 
measured O 
PEA B-ABBREVIATION 
, O 
AEA B-ABBREVIATION 
and O 
2-AG B-ABBREVIATION 
( O 
2-arachidonoylglycerol B-SYSTEMATIC 
) O 
brain O 
levels O 
identifying O 
significant O 
differences O 
between O 
epileptic O 
and O 
control O 
rats O 
such O 
as O 
decreased O 
PEA B-ABBREVIATION 
levels O 
in O 
both O 
thalamus O 
and O 
cortex O 
that O 
might O 
contribute O 
to O 
absence O 
epilepsy O 
. O 
Our O 
data O 
demonstrate O 
that O 
PEA B-ABBREVIATION 
has O 
anti-absence O 
properties O 
in O 
the O 
WAG O 
/ O 
Rij O 
rat O 
model O 
and O 
that O 
such O 
properties O 
depend O 
on O 
PPAR-α O 
and O 
indirect O 
activation O 
of O 
CB1 O 
receptors O 
. O 
This O 
article O 
is O 
part O 
of O 
the O 
Special O 
Issue O 
entitled O 
' O 
New O 
Targets O 
and O 
Approaches O 
to O 
the O 
Treatment O 
of O 
Epilepsy O 
' O 
. O 

derivatives O 
targeting O 
fatty B-FAMILY 
acid I-FAMILY 
amide I-FAMILY 
hydrolase O 
( O 
FAAH O 
) O 
and O 
transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
channels O 
. O 

series O 
of O 
twenty O 
- O 
five O 
derivatives O 
of O 
tetrahydro-β-carbolines B-FAMILY 
1-3 O 
was O 
synthesized O 
and O 
assayed O 
on O 
FAAH O 
and O 
TRPV1 O 
and O 
TRPA1 O 
channels O 
. O 
Four O 
carbamates B-FAMILY 
, O 
that O 
is O 
, O 
5a,c,e O 
, O 
and O 
9b O 
inhibited O 
FAAH O 
with O 
significant O 
potency O 
and O 
interacted O 
also O 
effectively O 
with O 
TRPV1 O 
and O 
TRPA1 O 
nociceptive O 
receptors O 
, O 
while O 
ureas O 
7b,d,f O 
, O 
and O 
8a,b O 
were O 
endowed O 
with O 
specific O 
submicromolar O 
TRPV1 O 
modulating O 
activities O 
. O 

reporting O 
associations O 
between O 
genetic O 
factors O 
and O 
mood O 
- O 
related O 
traits O 
have O 
often O 
been O 
criticized O 
(i) O 
for O 
failing O 
to O 
take O 
into O 
account O 
the O 
role O 
of O 
the O 
social O 
environment O 
in O 
which O 
individuals O 
act O 
and O 
(ii) O 
for O 
not O 
maintaining O 
a O 
' O 
transparent O 
narrative O 
connection O 
' O 
between O 
genes O 
and O 
outcomes O 
. O 
In O 
a O 
sample O 
of O 
adolescents O 
, O 
we O 
analyzed O 
whether O 
PvuII O 
and O 
XbaI O 
, O 
two O 
polymorphisms O 
on O 
the O 
ESR1 O 
( O 
Estrogen B-FAMILY 
Receptor O 
Gene O 
α O 
) O 
were O 
related O 
to O 
depressive O 
symptoms O 
, O 
and O 
considered O 
whether O 
daily O 
hassles O 
moderated O 
this O 
relationship O 
and O 
whether O 
anger O 
expression O 
style O 
mediated O 
this O 
relationship O 
. O 
Analyses O 
suggested O 
that O 
ESR1 O 
polymorphisms O 
are O 
relevant O 
to O 
the O 
intra O 
- O 
sexual O 
variability O 
in O 
depressive O 
symptoms O 
in O 
boys O 
and O 
that O 
the O 
experience O 
of O 
daily O 
hassles O 
moderated O 
this O 
relationship O 
. O 
No O 
such O 
relationships O 
were O 
found O 
in O 
girls O 
. O 
Additionally O 
, O 
ESR1 O 
polymorphisms O 
are O 
related O 
to O 
anger O 
expression O 
styles O 
in O 
girls O 
. O 
Anger O 
- O 
related O 
variables O 
, O 
however O 
, O 
did O 
not O 
mediate O 
the O 
relationship O 
between O 
ESR1 O 
polymorphisms O 
and O 
depressive O 
symptoms O 
, O 
in O 
boys O 
nor O 
in O 
girls O 
. O 

defects O 
after O 
exposure O 
to O 
misoprostol B-TRIVIAL 
in O 
the O 
first O 
trimester O 
of O 
pregnancy O 
: O 
prospective O 
follow O 
- O 
up O 
study O 
. O 

during O 
the O 
first O 
trimester O 
of O 
pregnancy O 
is O 
associated O 
with O 
a O 
specific O 
malformative O 
pattern O 
( O 
Moebius O 
sequence O 
and O 
limb O 
defects O 
) O 
whose O 
incidence O 
remains O 
unknown O 
. O 
Data O 
originate O 
mostly O 
from O 
illegal O 
use O 
for O 
abortion O 
and O 
are O 
mainly O 
retrospective O 
. O 
The O 
present O 
prospective O 
controlled O 
study O 
analyses O 
outcomes O 
of O 
first O 
trimester O 
misoprostol B-TRIVIAL 
exposures O 
after O 
medical O 
prescriptions O 
. O 
Malformation O 
rate O 
was O 
higher O 
among O 
236 O 
pregnancies O 
exposed O 
before O 
12 O 
gestational O 
weeks O 
( O 
4% O 
) O 
than O 
in O 
255 O 
controls O 
( O 
1.8% O 
) O 
, O 
although O 
not O 
statistically O 
significant O 
( O 
OR=2.2 O 
[ O 
95% O 
CI=0.6-7.7 O 
] O 
) O 
. O 
Three O 
malformations O 
( O 
2% O 
) O 
in O 
the O 
exposed O 
group O 
were O 
consistent O 
with O 
the O 
misoprostol B-TRIVIAL 
malformative O 
pattern O 
. O 
This O 
is O 
the O 
largest O 
prospective O 
study O 
on O 
first O 
trimester O 
misoprostol B-TRIVIAL 
exposure O 
and O 
the O 
first O 
one O 
relying O 
on O 
prescriptions O 
. O 
A O 
trend O 
toward O 
a O 
doubling O 
of O 
the O 
overall O 
rate O 
of O 
malformations O 
was O 
observed O 
and O 
for O 
the O 
first O 
time O 
an O 
estimation O 
of O 
the O 
incidence O 
of O 
misoprostol B-TRIVIAL 
specific O 
spectrum O 
is O 
proposed O 
( O 
2% O 
) O 
. O 
Brainstem O 
injuries O 
including O 
severe O 
trismus O 
might O 
be O 
added O 
to O 
this O 
specific O 
pattern O 
. O 

progenitor O 
cells O 
( O 
EPCs O 
) O 
are O 
known O 
to O 
repair O 
vascular O 
injuries O 
. O 
Recent O 
studies O 
suggest O 
that O 
Saiko-ka-ryukotsu-borei-To O 
( O 
SKRBT O 
) O 
, O 
a O 
traditional O 
herbal O 
medicine O 
that O 
has O 
been O 
used O 
to O 
treat O 
stress O 
- O 
related O 
neuropsychiatric O 
disorders O 
, O 
has O 
protective O 
effects O 
on O 
cardiovascular O 
diseases O 
such O 
as O 
hypertension O 
and O 
arteriosclerosis O 
. O 
Spontaneously O 
hypertensive O 
rats O 
( O 
SHRs O 
) O 
were O 
fed O 
diets O 
containing O 
lyophilized O 
SKRBT O 
extract O 
for O 
6 O 
weeks O 
. O 
Peripheral O 
blood O 
mononuclear O 
cells O 
( O 
MNCs O 
) O 
were O 
isolated O 
and O 
cultured O 
to O 
assay O 
EPC O 
colony O 
formation O 
. O 
Oxidative O 
stress O 
in O 
MNCs O 
was O 
evaluated O 
by O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substance O 
( O 
TBARS O 
) O 
assay O 
and O 
flowcytometric O 
analyses O 
. O 
Treatment O 
with O 
SKRBT O 
increased O 
EPC O 
colony O 
numbers O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
with O 
decrease O 
in O 
oxidative O 
stress O 
and O 
without O 
affecting O 
blood O 
pressure O 
in O 
SHRs O 
. O 
Treatment O 
with O 
SKRBT O 
did O 
not O 
reduce O 
the O 
expression O 
of O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
NADPH B-ABBREVIATION 
) O 
oxidase O 
subunits O 
in O 
cardiovascular O 
organs O 
. O 
Serum O 
IL-6 O 
level O 
was O 
significantly O 
reduced O 
. O 
SKRBT O 
is O 
a O 
feasible O 
herbal O 
medicine O 
that O 
protects O 
against O 
cardiovascular O 
diseases O 
through O 
an O 
increase O 
in O 
EPC O 
function O 
along O 
with O 
anti-oxidative O 
effects O 
, O 
and O 
may O 
affect O 
the O 
link O 
between O 
chronic O 
inflammation O 
and O 
cardiovascular O 
disease O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
mucoadhesive O 
stimuli O 
- O 
sensitive O 
drug O 
delivery O 
system O 
for O 
nasal O 
administration O 
of O 
zidovudine B-TRIVIAL 
( O 
AZT B-ABBREVIATION 
) O 
. O 
The O 
system O 
was O 
prepared O 
by O 
formulating O 
a O 
low O 
viscosity O 
precursor O 
of O 
a O 
liquid O 
crystal O 
phase O 
, O 
taking O 
advantage O 
of O 
its O 
lyotropic O 
phase O 
behavior O 
. O 
Flow O 
rheology O 
measurements O 
showed O 
that O 
the O 
formulation O 
composed O 
of O 
PPG-5-CETETH-20 B-FORMULA 
, O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
and O 
water O 
( O 
55 O 
, O 
30 O 
, O 
15% O 
w O 
/ O 
w O 
) O 
, O 
denominated O 
P O 
, O 
has O 
Newtonian O 
flow O 
behavior O 
. O 
Polarized O 
light O 
microscopy O 
( O 
PLM O 
) O 
revealed O 
that O 
formulation O 
P O 
is O 
isotropic O 
, O 
whereas O 
its O 
1 O 
: O 
1 O 
( O 
w O 
/ O 
w O 
) O 
dilution O 
with O 
artificial O 
nasal O 
mucus O 
( O 
ANM O 
) O 
changed O 
the O 
system O 
to O 
an O 
anisotropic O 
lamellar O 
phase O 
( O 
PD O 
) O 
. O 
Oscillatory O 
frequency O 
sweep O 
analysis O 
showed O 
that O 
PD O 
has O 
a O 
high O 
storage O 
modulus O 
( O 
G O 
' O 
) O 
at O 
nasal O 
temperatures O 
. O 
Measurement O 
of O 
the O 
mucoadhesive O 
force O 
against O 
excised O 
porcine O 
nasal O 
mucosa O 
or O 
a O 
mucin O 
disk O 
proved O 
that O 
the O 
transition O 
to O 
the O 
lamellar O 
phase O 
tripled O 
the O 
work O 
of O 
mucoadhesion O 
. O 
Ex O 
vivo O 
permeation O 
studies O 
across O 
porcine O 
nasal O 
mucosa O 
exhibited O 
an O 
18-fold O 
rise O 
in O 
the O 
permeability O 
of O 
AZT B-ABBREVIATION 
from O 
the O 
formulation O 
. O 
The O 
Weibull O 
mathematical O 
model O 
suggested O 
that O 
the O 
AZT B-ABBREVIATION 
is O 
released O 
by O 
Fickian O 
diffusion O 
mechanisms O 
. O 
Hence O 
, O 
the O 
physicochemical O 
characterization O 
, O 
combined O 
with O 
ex O 
vivo O 
studies O 
, O 
revealed O 
that O 
the O 
PPG-5-CETETH-20 B-FORMULA 
, O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
water O 
formulation O 
could O 
form O 
a O 
mucoadhesive O 
matrix O 
in O 
contact O 
with O 
nasal O 
mucus O 
that O 
promoted O 
nasal O 
absorption O 
of O 
the O 
AZT B-ABBREVIATION 
. O 
For O 
an O 
in O 
vivo O 
assessment O 
, O 
the O 
plasma O 
concentrations O 
of O 
AZT B-ABBREVIATION 
in O 
rats O 
were O 
determined O 
by O 
HPLC O 
method O 
following O 
intravenous O 
and O 
intranasal O 
administration O 
of O 
AZT B-ABBREVIATION 
-loaded O 
P O 
formulation O 
( O 
PA O 
) O 
and O 
AZT B-ABBREVIATION 
solution O 
, O 
respectively O 
, O 
at O 
a O 
dose O 
of O 
8mg O 
/ O 
kg O 
. O 
The O 
intranasal O 
administration O 
of O 
PA O 
resulted O 
in O 
a O 
fast O 
absorption O 
process O 
( O 
Tmax=6.7min O 
) O 
. O 
Therefore O 
, O 
a O 
liquid O 
crystal O 
precursor O 
formulation O 
administered O 
by O 
the O 
nasal O 
route O 
might O 
represent O 
a O 
promising O 
novel O 
tool O 
for O 
the O 
systemic O 
delivery O 
of O 
AZT B-ABBREVIATION 
and O 
other O 
antiretroviral O 
drugs O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
uptake O 
of O 
AZT B-ABBREVIATION 
absorption O 
in O 
the O 
nasal O 
mucosa O 
was O 
demonstrated O 
, O 
providing O 
new O 
foundations O 
for O 
clinical O 
trials O 
in O 
patients O 
with O 
AIDS O 
. O 

whole O 
blood O 
concentrations O 
in O 
healthy O 
adult O 
male O 
volunteers O 
following O 
two O 
- O 
weeks O 
of O 
ingesting O 
a O 
cobalt B-SYSTEMATIC 
supplement O 
. O 

, O 
there O 
has O 
been O 
an O 
increase O 
in O 
the O 
marketing O 
and O 
sales O 
of O 
dietary O 
supplements O 
, O 
energy O 
drinks O 
, O 
and O 
other O 
consumer O 
products O 
that O 
may O 
contain O 
relatively O 
high O 
concentrations O 
of O 
essential O 
elements O 
. O 
Cobalt B-SYSTEMATIC 
-containing O 
supplements O 
are O 
readily O 
available O 
in O 
the O 
U.S O 
. O 
and O 
have O 
been O 
marketed O 
to O 
consumers O 
as O 
energy O 
enhancers O 
. O 
However O 
, O 
little O 
information O 
is O 
available O 
regarding O 
cobalt B-SYSTEMATIC 
( O 
Co B-FORMULA 
) O 
body O 
burden O 
and O 
steady O 
- O 
state O 
blood O 
concentrations O 
following O 
the O 
intake O 
of O 
Co B-FORMULA 
dietary O 
supplements O 
. O 
We O 
assessed O 
Co B-FORMULA 
whole O 
blood O 
concentrations O 
in O 
four O 
healthy O 
adult O 
male O 
volunteers O 
who O 
ingested O 
a O 
commercially O 
available O 
Co B-FORMULA 
supplement O 
( O 
0.4 O 
mg O 
Co B-FORMULA 
/ O 
day O 
) O 
for O 
15 O 
or O 
16 O 
days O 
. O 
Pre O 
- O 
supplementation O 
blood O 
Co B-FORMULA 
concentrations O 
were O 
less O 
than O 
the O 
reporting O 
limit O 
of O 
0.5 O 
μg O 
/ O 
L O 
, O 
consistent O 
with O 
background O 
concentrations O 
reported O 
to O 
range O 
between O 
0.1 O 
and O 
0.4 O 
μg O 
/ O 
L O 
. O 
The O 
mean O 
whole O 
blood O 
Co B-FORMULA 
concentration O 
in O 
the O 
volunteers O 
after O 
15 O 
or O 
16 O 
days O 
of O 
dosing O 
was O 
3.6 O 
μg O 
Co B-FORMULA 
/L O 
and O 
ranged O 
from O 
1.8 O 
to O 
5.1 O 
μg O 
Co B-FORMULA 
/L O 
. O 
The O 
mean O 
observed O 
concentration O 
in O 
the O 
study O 
group O 
was O 
approximately O 
9-36 O 
times O 
greater O 
than O 
background O 
concentrations O 
. O 
Further O 
studies O 
of O 
Co B-FORMULA 
whole O 
blood O 
concentrations O 
following O 
supplementation O 
over O 
longer O 
time O 
periods O 
with O 
additional O 
monitoring O 
of O 
physiological O 
parameters O 
may O 
provide O 
useful O 
information O 
for O 
evaluating O 
the O 
health O 
of O 
persons O 
who O 
take O 
various O 
doses O 
of O 
Co B-FORMULA 
. O 

acid O 
( O 
polySia O 
) O 
is O 
a O 
large O 
, O 
cell O 
- O 
surface O 
linear O 
homopolymer O 
composed O 
of O 
α2,8 O 
- O 
linked O 
sialic B-TRIVIAL 
acid I-TRIVIAL 
residues O 
. O 
Most O 
extensively O 
studied O 
in O 
the O 
nervous O 
system O 
, O 
this O 
unique O 
glycan O 
modulates O 
development O 
by O 
enhancing O 
cell O 
migration O 
and O 
regulating O 
differentiation O 
. O 
PolySia O 
also O 
functions O 
in O 
developing O 
and O 
adult O 
immune O 
systems O 
and O 
is O 
a O 
signature O 
of O 
many O 
cancers O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrated O 
that O 
human O 
placental O 
trophoblasts O 
, O 
an O 
epithelial O 
lineage O 
, O 
also O 
display O 
this O 
glycan O 
. O 
Cytotrophoblasts O 
and O 
syncytiotrophoblasts O 
expressed O 
polySia O 
in O 
the O 
first O 
trimester O 
and O 
downregulated O 
it O 
during O 
the O 
course O 
of O 
pregnancy O 
. O 
PolySia O 
promoted O 
cytotrophoblast O 
migration O 
in O 
an O 
explant O 
model O 
of O 
chorionic O 
villous O 
growth O 
. O 
Removal O 
of O 
this O 
glycan O 
also O 
reduced O 
cytotrophoblast O 
penetration O 
of O 
basement O 
membranes O 
in O 
an O 
in O 
vitro O 
model O 
of O 
invasion O 
. O 
Finally O 
, O 
we O 
showed O 
that O 
polySia O 
was O 
overexpressed O 
in O 
biopsies O 
from O 
patients O 
with O 
gestational O 
trophoblastic O 
diseases O 
, O 
including O 
benign O 
molar O 
pregnancies O 
and O 
malignant O 
choriocarcinomas O 
. O 
These O 
results O 
demonstrated O 
, O 
for O 
the O 
first O 
time O 
, O 
functional O 
roles O 
for O 
polySia O 
during O 
normal O 
human O 
placental O 
development O 
and O 
implicated O 
these O 
unusual O 
oligosaccharides O 
in O 
the O 
unrestrained O 
invasion O 
of O 
trophoblast O 
tumors O 
. O 

- O 
disrupting O 
effects O 
of O 
thioxanthone B-SYSTEMATIC 
photoinitiators O 
. O 

used O 
in O 
food O 
packaging O 
ink O 
, O 
such O 
as O 
2-isopropylthioxanthone B-SYSTEMATIC 
( O 
2-ITX B-SYSTEMATIC 
) O 
, O 
have O 
been O 
shown O 
to O 
migrate O 
into O 
food O 
and O 
beverages O 
. O 
Recently O 
, O 
several O 
studies O 
indicated O 
that O 
2-ITX B-SYSTEMATIC 
might O 
be O 
an O 
endocrine O 
- O 
disrupting O 
chemical O 
. O 
In O 
this O 
work O 
, O 
the O 
effects O 
of O 
2-ITX B-SYSTEMATIC 
, O 
4-isopropylthioxanthone B-SYSTEMATIC 
( O 
4-ITX B-SYSTEMATIC 
) O 
, O 
2,4-diethylthio B-SYSTEMATIC 
xanthone I-SYSTEMATIC 
( O 
2,4-diethyl-TX B-SYSTEMATIC 
) O 
, O 
2-chlorothioxanthone B-SYSTEMATIC 
( O 
2-chloro-TX B-SYSTEMATIC 
) O 
, O 
and O 
1-chloro-4-propoxythioxanthone B-SYSTEMATIC 
( O 
1-chloro-4-propoxy-TX B-SYSTEMATIC 
) O 
on O 
steroidogenesis O 
and O 
androgen B-FAMILY 
and O 
estrogen B-FAMILY 
receptor O 
- O 
mediated O 
transcription O 
activation O 
have O 
been O 
studied O 
using O 
human O 
H295R O 
adrenocarcinoma O 
cells O 
and O 
yeast O 
hormone O 
bioassays O 
, O 
respectively O 
. O 
None O 
of O 
the O 
compounds O 
showed O 
androgenic O 
or O 
estrogenic O 
activities O 
, O 
but O 
clear O 
antiandrogenic O 
and O 
antiestrogenic O 
activities O 
were O 
observed O 
for O 
2-ITX B-SYSTEMATIC 
, O 
4-ITX B-SYSTEMATIC 
, O 
and O 
2,4-diethyl-TX B-SYSTEMATIC 
, O 
whereas O 
2-chloro-TX B-SYSTEMATIC 
showed O 
only O 
antiandrogenic O 
activity O 
. O 
In O 
an O 
adapted O 
version O 
of O 
the O 
H295R O 
steroidogenesis O 
assay O 
, O 
using O 
gas O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
analysis O 
of O 
H295R O 
media O 
, O 
all O 
five O 
compounds O 
increased O 
levels O 
of O 
17ß-estradiol B-SYSTEMATIC 
and O 
estrone B-TRIVIAL 
. O 
H295R O 
cells O 
incubated O 
with O 
2-ITX B-SYSTEMATIC 
also O 
showed O 
significantly O 
reduced O 
androgen B-FAMILY 
and O 
increased O 
pregnenolone B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
levels O 
. O 
Expression O 
of O 
particular O 
steroidogenic O 
genes O 
, O 
including O 
the O 
one O 
encoding O 
for O 
aromatase O 
( O 
CYP19A1 O 
) O 
, O 
was O 
significantly O 
upregulated O 
after O 
incubation O 
of O 
H295R O 
cells O 
with O 
2-ITX B-SYSTEMATIC 
, O 
4-ITX B-SYSTEMATIC 
, O 
and O 
2,4-diethyl-TX B-SYSTEMATIC 
. O 
In O 
line O 
with O 
the O 
increased O 
CYP19A1 O 
mRNA O 
expression O 
, O 
2-ITX B-SYSTEMATIC 
increased O 
catalytic O 
activity O 
of O 
aromatase O 
in O 
H295R O 
cells O 
as O 
measured O 
by O 
cognate O 
aromatase O 
assays O 
. O 
The O 
results O 
indicate O 
that O 
thioxanthone B-SYSTEMATIC 
derivatives O 
can O 
act O 
as O 
potential O 
endocrine O 
disruptors O 
both O 
at O 
the O 
level O 
of O 
nuclear O 
receptor O 
signaling O 
and O 
steroid B-FAMILY 
hormone O 
production O 
. O 

-derived O 
contact O 
biocides O 
: O 
contributions O 
to O 
the O 
understanding O 
of O 
antimicrobial O 
activity O 
. O 

set O 
of O 
poly(2-oxazoline) B-SYSTEMATIC 
-derived O 
(co-)polymers O 
was O 
prepared O 
by O 
microwave O 
- O 
assisted O 
polymerizations O 
and O 
acid O 
- O 
mediated O 
hydrolysis O 
and O 
tested O 
for O 
antimicrobial O 
activity O 
in O 
50 O 
× O 
50 O 
× O 
2 O 
mm O 
PP O 
compound O 
plates O 
containing O 
5 O 
wt% O 
of O 
the O 
polymers O 
. O 
Antimicrobial O 
activity O 
against O 
gram O 
- O 
negative O 
E O 
. O 
coli O 
and O 
P O 
. O 
aeruginosa O 
as O 
well O 
as O 
C O 
. O 
albicans O 
depended O 
only O 
on O 
the O 
degree O 
of O 
hydrolysis O 
, O 
while O 
antimicrobial O 
activity O 
against O 
gram O 
- O 
positive O 
S O 
. O 
aureus O 
was O 
only O 
observed O 
for O 
hydrolyzed O 
poly(2-nonyl-2-oxazoline)s B-FAMILY 
. O 
The O 
surface O 
energies O 
of O 
the O 
compound O 
plates O 
compared O 
to O 
pure O 
PP O 
were O 
hardly O 
altered O 
, O 
and O 
the O 
compounds O 
can O 
be O 
considered O 
as O 
alternatives O 
for O 
PP O 
. O 
The O 
presence O 
of O 
the O 
biocide O 
additives O 
at O 
the O 
surface O 
of O 
the O 
PP O 
compound O 
plates O 
could O 
be O 
shown O 
by O 
combined O 
ATR-IR O 
, O 
zeta O 
potential O 
, O 
and O 
SEM-EDX O 
measurements O 
. O 
Antimicrobial O 
activity O 
was O 
maintained O 
during O 
double O 
incubation O 
as O 
well O 
as O 
for O 
lowered O 
amounts O 
of O 
the O 
biocide O 
additive O 
of O 
1% O 
in O 
PP O 
compound O 
plates O 
. O 

in O 
human O 
placenta O 
predicts O 
induction O 
of O 
gene O 
expression O 
in O 
fetal O 
tissues O 
. O 

cigarette O 
smoking O 
during O 
pregnancy O 
is O 
associated O 
with O 
increased O 
risk O 
of O 
perinatal O 
morbidity O 
and O 
mortality O 
. O 
However O 
, O 
the O 
mechanisms O 
underlying O 
adverse O 
birth O 
outcomes O 
following O 
prenatal O 
exposure O 
to O 
cigarette O 
smoke O 
remain O 
unknown O 
due O 
, O 
in O 
part O 
, O 
to O 
the O 
absence O 
or O 
unreliability O 
of O 
information O 
regarding O 
maternal O 
cigarette O 
smoke O 
exposure O 
during O 
pregnancy O 
. O 
Our O 
goal O 
was O 
to O 
determine O 
if O 
placental O 
cotinine B-TRIVIAL 
could O 
be O 
a O 
reliable O 
biomarker O 
of O 
fetal O 
cigarette O 
smoke O 
exposure O 
during O 
pregnancy O 
. O 
Cotinine B-TRIVIAL 
levels O 
were O 
determined O 
in O 
placentas O 
from O 
47 O 
women O 
who O 
reported O 
smoking O 
during O 
pregnancy O 
and O 
from O 
10 O 
women O 
who O 
denied O 
cigarette O 
smoke O 
exposure O 
. O 
Cotinine B-TRIVIAL 
levels O 
were O 
significantly O 
higher O 
in O 
placentas O 
from O 
women O 
reporting O 
cigarette O 
smoking O 
( O 
median O 
= O 
27.2 O 
ng O 
/ O 
g O 
) O 
versus O 
women O 
who O 
reported O 
no O 
smoke O 
exposure O 
( O 
2.3 O 
ng O 
/ O 
g O 
, O 
P O 
< O 
0.001 O 
) O 
. O 
Receiver O 
operating O 
characteristic O 
curve O 
analysis O 
identified O 
an O 
optimal O 
cut O 
point O 
of O 
7.5 O 
ng O 
/ O 
g O 
( O 
sensitivity O 
= O 
78.7% O 
, O 
specificity O 
= O 
100% O 
) O 
to O 
classify O 
placenta O 
samples O 
from O 
mothers O 
who O 
smoked O 
versus O 
those O 
from O 
mothers O 
who O 
did O 
not O 
. O 
Among O 
415 O 
placentas O 
for O 
which O 
maternal O 
cigarette O 
smoking O 
status O 
was O 
unavailable O 
, O 
167 O 
had O 
cotinine B-TRIVIAL 
levels O 
> O 
7.5 O 
ng O 
/ O 
g O 
and O 
would O 
be O 
considered O 
positive O 
for O 
cigarette O 
smoke O 
exposure O 
. O 
Data O 
from O 
quantitative O 
reverse O 
- O 
transcription O 
polymerase O 
chain O 
reaction O 
analyses O 
demonstrated O 
that O 
in O 
utero O 
cigarette O 
smoke O 
exposure O 
predicted O 
by O 
cotinine B-TRIVIAL 
in O 
placenta O 
is O 
associated O 
with O 
changes O 
in O 
the O 
expression O 
of O 
xenobiotic O 
- O 
metabolizing O 
enzymes O 
in O 
fetal O 
tissues O 
. O 
CYP1A1 O 
mRNA O 
in O 
fetal O 
lung O 
and O 
liver O 
tissue O 
and O 
CYP1B1 O 
mRNA O 
in O 
fetal O 
lung O 
tissue O 
were O 
significantly O 
induced O 
when O 
cotinine B-TRIVIAL 
was O 
detected O 
in O 
placenta O 
. O 
These O 
findings O 
indicate O 
that O 
cotinine B-TRIVIAL 
in O 
placenta O 
is O 
a O 
reliable O 
biomarker O 
for O 
fetal O 
exposure O 
and O 
response O 
to O 
maternal O 
cigarette O 
smoking O 
during O 
pregnancy O 
. O 

of O 
vizantin B-TRIVIAL 
, O 
a O 
safe O 
immunostimulant O 
, O 
based O 
on O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
trehalose-6,6'-dicorynomycolate B-SYSTEMATIC 
. O 

, O 
6,6'-bis-O-(3-nonyldodecanoyl)-α,α'-trehalose B-SYSTEMATIC 
, O 
was O 
developed O 
as O 
a O 
safe O 
immunostimulator O 
on O 
the O 
basis O 
of O 
a O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
study O 
with O 
trehalose B-SYSTEMATIC 
6,6'-dicorynomycolate I-SYSTEMATIC 
( O 
TDCM B-ABBREVIATION 
) O 
. O 
It O 
was O 
possible O 
to O 
synthesize O 
vizantin B-TRIVIAL 
on O 
a O 
large O 
scale O 
more O 
easily O 
than O 
in O 
the O 
case O 
of O 
TDCM B-ABBREVIATION 
, O 
and O 
the O 
compound O 
exhibited O 
more O 
potent O 
prophylactic O 
effect O 
on O 
experimental O 
lung O 
metastasis O 
of O 
B16-F0 O 
melanoma O 
cells O 
. O 
Because O 
vizantin B-TRIVIAL 
stimulated O 
human O 
macrophages O 
, O 
it O 
is O 
a O 
promising O 
candidate O 
for O 
clinical O 
application O 
. O 

explicit O 
formula O 
for O 
optical O 
oscillator O 
strength O 
of O 
excitons O 
in O 
semiconducting O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
: O 
family O 
behavior O 
. O 

sensitive O 
structural O 
dependence O 
of O 
the O 
optical O 
properties O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
, O 
which O 
are O 
dominated O 
by O 
excitons O 
and O 
tunable O 
by O 
changing O 
diameter O 
and O 
chirality O 
, O 
makes O 
them O 
excellent O 
candidates O 
for O 
optical O 
devices O 
. O 
Because O 
of O 
strong O 
many O 
- O 
electron O 
interaction O 
effects O 
, O 
the O 
detailed O 
dependence O 
of O 
the O 
optical O 
oscillator O 
strength O 
f(s) O 
of O 
excitons O 
on O 
nanotube O 
diameter O 
d O 
, O 
chiral O 
angle O 
θ O 
, O 
and O 
electronic O 
subband O 
index O 
P O 
( O 
the O 
so O 
- O 
called O 
family O 
behavior O 
) O 
, O 
however O 
, O 
has O 
been O 
unclear O 
. O 
In O 
this O 
study O 
, O 
based O 
on O 
results O 
from O 
an O 
extended O 
Hubbard O 
Hamiltonian O 
with O 
parameters O 
derived O 
from O 
ab O 
initio O 
GW O 
plus O 
Bethe-Salpeter O 
equation O 
( O 
GW-BSE O 
) O 
calculations O 
, O 
we O 
have O 
obtained O 
an O 
explicit O 
formula O 
for O 
the O 
family O 
behavior O 
of O 
the O 
oscillator O 
strengths O 
of O 
excitons O 
in O 
semiconducting O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
, O 
incorporating O 
environmental O 
screening O 
. O 
The O 
formula O 
explains O 
recent O 
measurements O 
well O 
and O 
is O 
expected O 
to O 
be O 
useful O 
in O 
the O 
understanding O 
and O 
design O 
of O 
possible O 
SWCNT O 
optical O 
and O 
optoelectronic O 
devices O 
. O 

describe O 
the O 
synthesis O 
of O 
a O 
core O 
- O 
shell O 
biohybrid O 
consisting O 
of O 
a O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
core O 
that O 
serves O 
as O 
a O 
reservoir O 
for O 
lipophilic O 
molecules O 
and O 
a O 
cationized O 
shell O 
region O 
consisting O 
of O 
ethynyl B-SYSTEMATIC 
-G2.0- O 
PAMAM B-ABBREVIATION 
or O 
ethynyl B-SYSTEMATIC 
-G3.0- O 
PAMAM B-ABBREVIATION 
dendrons O 
. O 
The O 
binding O 
capacity O 
of O 
lipophilic O 
guests O 
was O 
quantified O 
applying O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spectroscopy O 
, O 
and O 
five O 
to O 
six O 
out O 
of O 
seven O 
pockets O 
were O 
still O 
available O 
compared O 
with O 
HSA O 
. O 
The O 
attachment O 
of O 
ethynyl B-SYSTEMATIC 
-G2.0- O 
PAMAM B-ABBREVIATION 
dendrons O 
to O 
HSA O 
yielded O 
a O 
nontoxic O 
core O 
- O 
shell O 
macromolecule O 
that O 
was O 
clearly O 
uptaken O 
by O 
A549 O 
human O 
epithelial O 
cells O 
due O 
to O 
the O 
presence O 
of O 
the O 
dendritic O 
PAMAM B-ABBREVIATION 
shell O 
. O 
Significantly O 
higher O 
loading O 
of O 
doxorubicin B-TRIVIAL 
was O 
observed O 
for O 
dendronized O 
G2-DHSA O 
compared O 
with O 
the O 
native O 
protein O 
due O 
to O 
the O 
availability O 
of O 
binding O 
pockets O 
of O 
the O 
HSA O 
core O 
, O 
and O 
interaction O 
with O 
the O 
dendritic O 
shell O 
. O 
Dendronized O 
G2-DHSA- O 
doxorubicin B-TRIVIAL 
displayed O 
significant O 
cytotoxicity O 
resulting O 
from O 
high O 
drug O 
loading O 
and O 
high O 
stability O 
under O 
different O 
conditions O 
, O 
thus O 
demonstrating O 
its O 
great O 
potential O 
as O 
a O 
transporter O 
for O 
drug O 
molecules O 
. O 

topoisomerases O 
comprise O 
an O 
important O 
family O 
of O 
enzymes O 
that O 
catalyse O 
the O 
induction O 
of O 
topological O 
changes O 
( O 
e.g O 
. O 
relaxation/ O 
supercoiling O 
, O 
catenation O 
/ O 
decatenation O 
and O 
knotting O 
/ O 
unknotting O 
) O 
in O 
the O 
DNA O 
molecule O 
. O 
These O 
enzymes O 
perform O 
their O 
functions O 
by O 
creating O 
transient O 
either O 
single O 
- O 
stranded O 
or O 
double O 
- O 
stranded O 
breaks O 
in O 
the O 
DNA O 
molecule O 
. O 
Due O 
to O 
their O 
ability O 
to O 
modulate O 
the O 
topology O 
of O 
the O 
DNA O 
molecule O 
, O 
DNA O 
topoisomerases O 
play O 
vital O 
roles O 
in O 
replication O 
, O 
transcription O 
, O 
chromosome O 
separation O 
and O 
segregation O 
, O 
and O 
thus O 
represent O 
an O 
important O 
collection O 
of O 
design O 
targets O 
for O 
novel O 
anticancer O 
drugs O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
provide O 
an O 
overview O 
of O 
the O 
development O 
of O 
catalytic O 
inhibitors O 
of O 
the O 
human O 
topoisomerase O 
IIα O 
enzyme O 
-- O 
an O 
important O 
member O 
of O 
the O 
DNA O 
topoisomerase O 
family O 
-- O 
as O 
potential O 
novel O 
anticancer O 
agents O 
. O 
The O 
group O 
of O 
catalytic O 
topoII O 
inhibitors O 
is O 
classified O 
into O 
four O 
types O 
according O 
to O 
their O 
molecular O 
mechanism O 
of O 
action O 
: O 
inhibitors O 
that O 
bind O 
to O 
the O 
ATP B-ABBREVIATION 
binding O 
site O 
, O 
inhibitors O 
that O 
prevent O 
the O 
ATP B-ABBREVIATION 
hydrolysis O 
step O 
and O 
trap O 
the O 
enzyme O 
in O 
a O 
closed O 
clamp O 
, O 
inhibitors O 
that O 
block O 
the O 
DNA O 
cleavage O 
and O 
inhibitors O 
that O 
prevent O 
the O 
enzyme O 
binding O 
to O 
the O 
DNA O 
. O 
One O 
of O 
the O 
important O 
considerations O 
highlighted O 
throughout O 
this O 
review O 
is O 
the O 
structure O 
- O 
based O 
perspective O 
of O 
inhibitor O 
design O 
, O 
giving O 
the O 
reader O 
a O 
medicinal O 
chemist's O 
perspective O 
on O 
this O 
vibrant O 
and O 
active O 
field O 
of O 
drug O 
design O 
research O 
. O 

is O 
an O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
blocker O 
( O 
ARB O 
) O 
that O 
has O 
been O 
to O 
shown O 
to O 
limit O 
ischemic O 
stroke O 
and O 
improve O 
stroke O 
outcome O 
. O 
In O 
experimental O 
stroke O 
, O 
candesartan B-TRIVIAL 
induces O 
a O 
proangiogenic O 
effect O 
that O 
is O 
partly O 
attributable O 
to O 
vascular O 
endothelial O 
growth O 
factor O 
. O 
Brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
is O 
a O 
member O 
of O 
the O 
neurotrophin O 
family O 
that O 
has O 
been O 
reported O 
to O 
have O 
angiogenic O 
effects O 
and O 
play O 
an O 
important O 
role O 
in O 
recovery O 
after O 
stroke O 
. O 
The O 
purpose O 
of O 
this O 
investigation O 
was O 
to O 
determine O 
the O 
role O 
of O 
BDNF O 
in O 
the O 
proangiogenic O 
effect O 
of O 
candesartan O 
in O 
the O 
brain O 
under O 
hypertensive O 
conditions O 
. O 
Accordingly O 
, O 
spontaneously O 
hypertensive O 
rats O 
were O 
treated O 
with O 
candesartan B-TRIVIAL 
, O 
and O 
brain O 
tissue O 
samples O 
were O 
collected O 
for O 
quantification O 
of O 
BDNF O 
expression O 
. O 
In O 
addition O 
, O 
human O 
cerebromicrovascular O 
endothelial O 
cells O 
were O 
treated O 
with O 
either O 
low O 
- O 
dose O 
( O 
1 O 
ƒM O 
) O 
or O 
high O 
- O 
dose O 
( O 
1 O 
µM O 
) O 
angiotensin O 
II O 
alone O 
or O 
in O 
combination O 
with O 
candesartan B-TRIVIAL 
( O 
0.16 O 
µM O 
) O 
to O 
assess O 
the O 
effect O 
of O 
candesartan B-TRIVIAL 
treatment O 
and O 
BDNF O 
involvement O 
in O 
the O 
behavior O 
of O 
endothelial O 
cells O 
. O 
Candesartan B-TRIVIAL 
significantly O 
increased O 
the O 
expression O 
of O 
BDNF O 
in O 
the O 
SHR O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
In O 
addition O 
, O 
candesartan B-TRIVIAL 
reversed O 
the O 
antiangiogenic O 
effect O 
of O 
the O 
1-µM O 
dose O 
of O 
AngII O 
( O 
P O 
= O 
0.0001 O 
) O 
. O 
The O 
observed O 
effects O 
of O 
candesartan B-TRIVIAL 
were O 
ablated O 
by O 
neutralizing O 
the O 
effects O 
of O 
BDNF O 
. O 
Treatment O 
with O 
the O 
AT2 O 
antagonist O 
PD-123319 B-IDENTIFIER 
significantly O 
reduced O 
tube O 
- O 
like O 
formation O 
in O 
endothelial O 
cells O 
. O 
AT2 O 
stimulation O 
induced O 
the O 
BDNF O 
expression O 
and O 
migration O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
candesartan B-TRIVIAL 
exerts O 
a O 
proangiogenic O 
effect O 
on O 
brain O 
microvascular O 
endothelial O 
cells O 
treated O 
with O 
angiotensin O 
II O 
. O 
This O 
response O 
is O 
attributable O 
to O 
increased O 
BDNF O 
expression O 
and O 
is O 
mediated O 
through O 
stimulation O 
of O 
the O 
AT2 O 
receptor O 
. O 

of O 
the O 
human O 
hydroxysteroid B-FAMILY 
sulfotransferase O 
( O 
SULT2A1 O 
) O 
by O 
RORα O 
and O 
RORγ O 
and O 
its O 
potential O 
relevance O 
to O 
human O 
liver O 
diseases O 
. O 

retinoid B-FAMILY 
-related O 
orphan O 
receptors O 
( O 
RORs O 
) O 
were O 
postulated O 
to O 
have O 
functions O 
in O 
tissue O 
development O 
and O 
circadian O 
rhythm O 
. O 
In O 
this O 
study O 
, O 
we O 
revealed O 
a O 
novel O 
function O 
of O 
RORα O 
( O 
NR1F1 O 
) O 
and O 
RORγ O 
( O 
NR1F3 O 
) O 
in O 
regulating O 
the O 
human O 
hydroxysteroid B-FAMILY 
sulfotransferase O 
( O 
SULT2A1 O 
) O 
, O 
a O 
phase O 
II O 
conjugating O 
enzyme O 
known O 
to O 
sulfonate B-FAMILY 
bile I-FAMILY 
acids I-FAMILY 
, O 
hydroxysteroid B-FAMILY 
dehydroepiandrosterone B-TRIVIAL 
, O 
and O 
related O 
androgens B-FAMILY 
. O 
A O 
combination O 
of O 
promoter O 
reporter O 
gene O 
assay O 
and O 
EMSA O 
and O 
chromatin O 
immunoprecipitation O 
( O 
ChIP O 
) O 
assays O 
showed O 
that O 
both O 
RORα O 
and O 
RORγ O 
transactivated O 
the O 
SULT2A1 O 
gene O 
promoter O 
through O 
their O 
binding O 
to O 
a O 
ROR O 
response O 
element O 
found O 
in O 
the O 
SULT2A1 O 
gene O 
promoter O 
. O 
Interestingly O 
, O 
this O 
ROR O 
response O 
element O 
overlaps O 
with O 
a O 
previously O 
reported O 
constitutive O 
androstane O 
receptor O 
response O 
element O 
on O 
the O 
same O 
promoter O 
. O 
Down O 
- O 
regulation O 
of O 
RORα O 
and O 
/ O 
or O 
RORγ O 
by O 
small O 
interfering O 
RNA O 
inhibited O 
the O 
expression O 
of O 
endogenous O 
SULT2A1 O 
. O 
In O 
primary O 
human O 
hepatocytes O 
and O 
human O 
livers O 
, O 
we O 
found O 
a O 
positive O 
correlation O 
between O 
the O 
expression O 
of O 
SULT2A1 O 
and O 
RORs O 
, O 
which O 
further O 
supported O 
the O 
regulation O 
of O 
SULT2A1 O 
by O 
RORs O 
. O 
We O 
also O 
found O 
that O 
the O 
expression O 
of O 
RORα O 
and O 
RORγ O 
was O 
impaired O 
in O 
several O 
liver O 
disease O 
conditions O 
, O 
such O 
as O 
steatosis O 
/ O 
steatohepatitis O 
, O 
fibrosis O 
, O 
and O 
hepatocellular O 
carcinoma O 
. O 
The O 
positive O 
regulation O 
of O 
human O 
SULT2A1 O 
by O 
RORs O 
is O 
opposite O 
to O 
the O 
negative O 
regulation O 
of O 
Sult2a1 O 
by O 
RORs O 
in O 
rodents O 
. O 
In O 
summary O 
, O 
our O 
results O 
established O 
SULT2A1 O 
as O 
a O 
novel O 
ROR O 
target O 
gene O 
. O 
The O 
expression O 
of O 
RORs O 
is O 
a O 
potential O 
predictor O 
for O 
the O 
expression O 
of O 
SULT2A1 O 
as O 
well O 
as O 
disease O 
conditions O 
. O 

desorption O 
atmospheric O 
pressure O 
chemical O 
ionization O 
mass O 
spectrometry O 
was O 
developed O 
as O 
a O 
rapid O 
online O 
detection O 
technology O 
for O 
the O 
chemical O 
fingerprints O 
of O 
ginseng O 
products O 
without O 
any O 
sample O 
pretreatment O 
. O 
More O 
than O 
20 O 
ginsenosides B-FAMILY 
were O 
detected O 
in O 
the O 
ginseng O 
tissue O 
and O 
identified O 
by O 
their O 
tandem O 
mass O 
spectrometry O 
. O 
Data O 
were O 
well O 
matched O 
with O 
their O 
reference O 
compounds O 
. O 
Herein O 
, O 
surface O 
desorption O 
atmospheric O 
pressure O 
chemical O 
ionization O 
mass O 
spectrometry O 
was O 
first O 
applied O 
to O 
study O 
the O 
nonvolatile O 
compounds O 
in O 
ginseng O 
. O 
White O 
and O 
red O 
ginseng O 
have O 
been O 
successfully O 
differentiated O 
from O 
their O 
counterfeits O 
using O 
some O 
ginsenosides B-FAMILY 
as O 
chemical O 
markers O 
. O 
Ginsenoside B-FAMILY 
can O 
be O 
used O 
to O 
differentiate O 
between O 
white O 
ginseng O 
, O 
red O 
ginseng O 
, O 
unboiled O 
ginseng O 
, O 
and O 
their O 
counterfeits O 
. O 
Ginsenosides B-MULTIPLE 
Ra1-3 I-MULTIPLE 
, I-MULTIPLE 
Rb2-3 I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
Rc I-MULTIPLE 
might O 
be O 
used O 
to O 
differentiate O 
between O 
white O 
ginseng O 
and O 
boiled O 
ginseng O 
. O 
Our O 
result O 
showed O 
that O 
surface O 
desorption O 
atmospheric O 
pressure O 
chemical O 
ionization O 
mass O 
spectrometry O 
not O 
only O 
could O 
be O 
used O 
for O 
fast O 
screening O 
authentic O 
ginseng O 
products O 
but O 
also O 
might O 
become O 
a O 
useful O 
promising O 
technique O 
for O 
the O 
characterization O 
of O 
nonvolatile O 
compounds O 
in O 
medicinal O 
herbs O 
to O 
save O 
researchers O 
the O 
laborious O 
effort O 
of O 
sample O 
pretreatment O 
. O 

- O 
based O 
biodegradable O 
and O 
biocompatible O 
hyperbranched O 
polyurethane B-SYSTEMATIC 
: O 
a O 
scaffold O 
for O 
tissue O 
engineering O 
. O 

polyurethanes B-FAMILY 
are O 
synthesized O 
using O 
TDI B-ABBREVIATION 
, O 
PCL B-SYSTEMATIC 
diol I-SYSTEMATIC 
, O 
butanediol B-SYSTEMATIC 
, O 
and O 
pentaerythritol B-SYSTEMATIC 
( O 
1-5 O 
wt% O 
) O 
as O 
the O 
B(4) O 
reactant O 
with O 
and O 
without O 
the O 
monoglyceride B-SYSTEMATIC 
of O 
sunflower O 
oil O 
. O 
The O 
biodegradation O 
, O 
physico O 
- O 
mechanical O 
, O 
and O 
thermal O 
properties O 
are O 
found O 
to O 
be O 
tailored O 
by O 
varying O 
the O 
percentage O 
weight O 
of O 
the O 
branching O 
unit O 
. O 
An O 
MTT B-ABBREVIATION 
/ O 
hemolytic O 
assay O 
and O 
subcutaneous O 
implantation O 
in O 
Wistar O 
rats O 
followed O 
by O 
cytokine O 
/ O 
ALP O 
assay O 
and O 
histopathology O 
studies O 
confirm O 
a O 
better O 
biocompatibility O 
of O 
HBPU O 
with O 
MG O 
than O 
without O 
MG O 
. O 
HBPU O 
supports O 
the O 
proliferation O 
of O 
dermatocytes O 
with O 
no O 
toxic O 
effect O 
in O 
major O 
organs O 
, O 
in O 
addition O 
the O 
in O 
vitro O 
degraded O 
products O 
are O 
non-toxic O 
. O 
Cell O 
adherence O 
and O 
proliferation O 
endorse O 
the O 
bio O 
- O 
based O 
HBPU O 
as O 
a O 
prospective O 
scaffold O 
material O 
in O 
the O 
niche O 
of O 
tissue O 
engineering O 
. O 

-modified O 
surfaces O 
for O 
biomedical O 
applications O 
. O 

( O 
PVP B-ABBREVIATION 
) O 
, O 
an O 
important O 
water O 
soluble O 
synthetic O 
polymer O 
, O 
has O 
many O 
desirable O 
properties O 
including O 
low O 
toxicity O 
, O 
chemical O 
stability O 
, O 
and O 
good O 
biocompatibility O 
. O 
Since O 
PVP B-ABBREVIATION 
is O 
hemocompatible O 
and O 
physiologically O 
inactive O 
, O 
it O 
has O 
been O 
used O 
as O 
a O 
blood O 
plasma O 
substitute O 
. O 
Surface O 
modification O 
with O 
PVP B-ABBREVIATION 
has O 
been O 
investigated O 
extensively O 
over O 
the O 
past O 
few O 
years O 
as O 
a O 
means O 
of O 
preventing O 
nonspecific O 
protein O 
adsorption O 
. O 
PVP B-ABBREVIATION 
may O 
therefore O 
be O 
seen O 
as O 
a O 
promising O 
antifouling O 
surface O 
modifier O 
comparable O 
to O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
. O 
In O 
this O 
review O 
, O 
various O 
approaches O 
for O 
the O 
design O 
and O 
preparation O 
of O 
PVP B-ABBREVIATION 
-modified O 
surfaces O 
are O 
summarized O 
and O 
potential O 
biomedical O 
applications O 
of O 
these O 
PVP B-ABBREVIATION 
-modified O 
materials O 
are O 
indicated O 
. O 
Finally O 
, O 
some O 
perspectives O 
on O 
future O 
research O 
on O 
PVP B-ABBREVIATION 
for O 
surface O 
modification O 
are O 
discussed O 
. O 

of O 
mixed O 
PEO B-ABBREVIATION 
/ O 
PAA B-ABBREVIATION 
brushes O 
with O 
switchable O 
properties O 
toward O 
protein O 
adsorption O 
. O 

of O 
proteins O 
at O 
interfaces O 
is O 
an O 
ubiquitous O 
phenomenon O 
of O 
prime O 
importance O 
. O 
Layers O 
of O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
) O 
are O 
widely O 
used O 
to O 
repel O 
proteins O 
. O 
Conversely O 
, O 
proteins O 
were O 
shown O 
to O 
adsorb O 
deeply O 
into O 
brushes O 
of O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAA B-ABBREVIATION 
) O 
, O 
and O 
their O 
subsequent O 
partial O 
release O 
could O 
be O 
triggered O 
by O 
a O 
change O 
of O 
pH O 
and O 
/ O 
or O 
ionic O 
strength O 
(I) O 
. O 
Mixed O 
brushes O 
of O 
these O 
polymers O 
are O 
thus O 
promising O 
candidates O 
to O 
tune O 
protein O 
adsorption O 
onto O 
new O 
smart O 
surfaces O 
. O 
In O 
this O 
work O 
, O 
the O 
synthesis O 
of O 
such O 
mixed O 
brushes O 
was O 
performed O 
based O 
on O 
a O 
" O 
grafting O 
to O 
" O 
approach O 
, O 
the O 
two O 
polymers O 
being O 
either O 
grafted O 
sequentially O 
or O 
simultaneously O 
. O 
Detailed O 
characterization O 
of O 
the O 
obtained O 
brushes O 
using O 
static O 
water O 
contact O 
angle O 
measurements O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
, O 
electrochemical O 
impedance O 
spectroscopy O 
, O 
and O 
polarization O 
- O 
modulation O 
reflection O 
- O 
absorption O 
infrared O 
spectroscopy O 
is O 
presented O 
. O 
While O 
sequential O 
grafting O 
of O 
the O 
two O 
polymers O 
for O 
different O 
reactions O 
times O 
did O 
not O 
give O 
rise O 
to O 
a O 
broad O 
range O 
of O 
composition O 
of O 
mixed O 
brushes O 
, O 
simultaneous O 
grafting O 
of O 
the O 
polymers O 
from O 
solutions O 
with O 
different O 
compositions O 
allows O 
for O 
the O 
synthesis O 
of O 
a O 
range O 
of O 
mixed O 
brushes O 
( O 
mass O 
fraction O 
of O 
PEO B-ABBREVIATION 
in O 
the O 
mixed O 
brushes O 
from O 
0.35 O 
to O 
0.65 O 
) O 
. O 
A O 
key O 
example O 
is O 
then O 
chosen O 
to O 
illustrate O 
the O 
switchable O 
behavior O 
of O 
a O 
selected O 
mixed O 
PEO B-ABBREVIATION 
/ O 
PAA B-ABBREVIATION 
brush O 
toward O 
albumin O 
adsorption O 
. O 
The O 
adsorption O 
behavior O 
was O 
monitored O 
with O 
a O 
quartz O 
crystal O 
microbalance O 
. O 
The O 
mixed O 
brush O 
could O 
adsorb O 
high O 
amounts O 
of O 
albumin O 
, O 
but O 
86% O 
of O 
the O 
adsorbed O 
protein O 
could O 
then O 
be O 
desorbed O 
upon O 
pH O 
and O 
I O 
change O 
. O 
The O 
obtained O 
properties O 
are O 
thus O 
a O 
combination O 
of O 
the O 
ones O 
of O 
PEO B-ABBREVIATION 
and O 
PAA B-ABBREVIATION 
, O 
and O 
a O 
highly O 
switchable O 
behavior O 
is O 
observed O 
toward O 
protein O 
adsorption O 
. O 

of O 
chemical O 
bonding O 
in O 
semifluorinated O 
graphite B-TRIVIAL 
C2F B-FORMULA 
revealed O 
with O 
angle O 
- O 
resolved O 
X-ray O 
absorption O 
spectroscopy O 
. O 

oriented O 
pyrolytic O 
graphite B-TRIVIAL 
characterized O 
by O 
a O 
low O 
misorientation O 
of O 
crystallites O 
is O 
fluorinated O 
using O 
a O 
gaseous O 
mixture O 
of O 
BrF(3) B-FORMULA 
with O 
Br(2) B-FORMULA 
at O 
room O 
temperature O 
. O 
The O 
golden O 
- O 
colored O 
product O 
, O 
easily O 
delaminating O 
into O 
micrometer O 
- O 
size O 
transparent O 
flakes O 
, O 
is O 
an O 
intercalation O 
compound O 
where O 
Br(2) B-FORMULA 
molecules O 
are O 
hosted O 
between O 
fluorinated O 
graphene B-TRIVIAL 
layers O 
of O 
approximate O 
C(2)F B-FORMULA 
composition O 
. O 
To O 
unravel O 
the O 
chemical O 
bonding O 
in O 
semifluorinated O 
graphite B-TRIVIAL 
, O 
we O 
apply O 
angle O 
- O 
resolved O 
near O 
- O 
edge O 
X-ray O 
absorption O 
fine O 
structure O 
( O 
NEXAFS O 
) O 
spectroscopy O 
and O 
quantum O 
- O 
chemical O 
modeling O 
. O 
The O 
strong O 
angular O 
dependence O 
of O 
the O 
CK O 
and O 
FK O 
edge O 
NEXAFS O 
spectra O 
on O 
the O 
incident O 
radiation O 
indicates O 
that O 
room O 
- O 
temperature O 
- O 
produced O 
graphite B-TRIVIAL 
fluoride I-TRIVIAL 
is O 
a O 
highly O 
anisotropic O 
material O 
, O 
where O 
half O 
of O 
the O 
carbon B-SYSTEMATIC 
atoms O 
are O 
covalently O 
bonded O 
with O 
fluorine B-SYSTEMATIC 
, O 
while O 
the O 
rest O 
of O 
the O 
carbon O 
atoms O 
preserve O 
π O 
electrons O 
. O 
Comparison O 
of O 
the O 
experimental O 
CK O 
edge O 
spectrum O 
with O 
theoretical O 
spectra O 
plotted O 
for O 
C(2)F B-FORMULA 
models O 
reveals O 
that O 
fluorine B-SYSTEMATIC 
atoms O 
are O 
more O 
likely O 
to O 
form O 
chains O 
. O 
This O 
conclusion O 
agrees O 
with O 
the O 
atomic O 
force O 
microscopy O 
observation O 
of O 
a O 
chain O 
- O 
like O 
pattern O 
on O 
the O 
surface O 
of O 
graphite B-TRIVIAL 
fluoride I-TRIVIAL 
layers O 
. O 

the O 
existence O 
of O 
any O 
direct O 
spectral O 
relationship O 
between O 
the O 
far O 
- O 
field O 
scattering O 
properties O 
and O 
the O 
near O 
- O 
field O 
Raman O 
- O 
enhancing O 
properties O 
of O 
surface O 
- O 
enhanced O 
Raman O 
spectroscopy O 
( O 
SERS O 
) O 
substrates O 
has O 
been O 
a O 
challenging O 
task O 
with O 
only O 
a O 
few O 
significant O 
results O 
to O 
date O 
. O 
Here O 
, O 
we O 
prove O 
that O 
hot O 
spot O 
dominated O 
systems O 
show O 
little O 
dependence O 
on O 
the O 
far O 
- O 
field O 
scattering O 
properties O 
because O 
of O 
differences O 
between O 
near- O 
and O 
far O 
- O 
field O 
localized O 
surface O 
plasmon O 
resonance O 
( O 
LSPR O 
) O 
effects O 
as O 
well O 
as O 
excitation O 
of O 
new O 
plasmon O 
modes O 
via O 
a O 
localized O 
emitter O 
. O 
We O 
directly O 
probe O 
the O 
relationship O 
between O 
the O 
near- O 
and O 
far O 
- O 
field O 
light O 
interactions O 
using O 
a O 
correlated O 
LSPR-transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
surface O 
- O 
enhanced O 
Raman O 
excitation O 
spectroscopy O 
( O 
SERES O 
) O 
technique O 
. O 
Fourteen O 
individual O 
SERS O 
nanoantennas O 
, O 
Au B-FORMULA 
nanoparticle O 
aggregates O 
ranging O 
from O 
dimers O 
to O 
undecamers O 
, O 
coated O 
in O 
a O 
reporter O 
molecule O 
and O 
encased O 
in O 
a O 
protective O 
silica B-TRIVIAL 
shell O 
, O 
were O 
excited O 
using O 
eight O 
laser O 
wavelengths O 
. O 
We O 
observed O 
no O 
correlation O 
between O 
the O 
spectral O 
position O 
of O 
the O 
LSPR O 
maxima O 
and O 
the O 
maximum O 
enhancement O 
factor O 
( O 
EF O 
) O 
. O 
The O 
single O 
nanoantenna O 
data O 
reveal O 
EFs O 
ranging O 
from O 
( O 
2.5 O 
± O 
0.6 O 
) O 
× O 
10(4) O 
to O 
( O 
4.5 O 
± O 
0.6 O 
) O 
× O 
10(8) O 
with O 
maximum O 
enhancement O 
for O 
excitation O 
wavelengths O 
of O 
785 O 
nm O 
and O 
lower O 
energy O 
. O 
The O 
magnitude O 
of O 
maximum O 
EF O 
was O 
not O 
correlated O 
to O 
the O 
number O 
of O 
cores O 
in O 
the O 
nanoantenna O 
or O 
the O 
spectral O 
position O 
of O 
the O 
LSPR O 
, O 
suggesting O 
a O 
separation O 
between O 
near O 
- O 
field O 
SERS O 
enhancement O 
and O 
far O 
- O 
field O 
Rayleigh O 
scattering O 
. O 
Computational O 
electrodynamics O 
confirms O 
the O 
decoupling O 
of O 
maximum O 
SERS O 
enhancement O 
from O 
the O 
peak O 
of O 
the O 
scattering O 
spectrum O 
. O 
It O 
also O 
points O 
to O 
the O 
importance O 
of O 
a O 
localized O 
emitter O 
for O 
radiating O 
Raman O 
photons O 
to O 
the O 
far O 
- O 
field O 
which O 
, O 
in O 
nonsymmetric O 
systems O 
, O 
allows O 
for O 
the O 
excitation O 
of O 
radiative O 
plasmon O 
modes O 
that O 
are O 
difficult O 
to O 
excite O 
with O 
plane O 
waves O 
. O 
Once O 
these O 
effects O 
are O 
considered O 
, O 
we O 
are O 
able O 
to O 
fully O 
explain O 
the O 
hot O 
spot O 
dominated O 
SERS O 
response O 
of O 
the O 
nanoantennas O 
. O 

of O 
homogeneous O 
reduction O 
of O 
CO2 B-FORMULA 
by O 
pyridine B-SYSTEMATIC 
: O 
proton O 
relay O 
in O 
aqueous O 
solvent O 
and O 
aromatic O 
stabilization O 
. O 

employ O 
quantum O 
chemical O 
calculations O 
to O 
investigate O 
the O 
mechanism O 
of O 
homogeneous O 
CO(2) B-FORMULA 
reduction O 
by O 
pyridine B-SYSTEMATIC 
( O 
Py O 
) O 
in O 
the O 
Py O 
/ O 
p-GaP O 
system O 
. O 
We O 
find O 
that O 
CO(2) B-FORMULA 
reduction O 
by O 
Py O 
commences O 
with O 
PyCOOH(0) B-FORMULA 
formation O 
where O 
: O 
( O 
a O 
) O 
protonated O 
Py O 
( O 
PyH(+) B-FORMULA 
) O 
is O 
reduced O 
to O 
PyH(0) B-FORMULA 
, O 
( O 
b O 
) O 
PyH(0) B-FORMULA 
then O 
reduces O 
CO(2) B-FORMULA 
by O 
one O 
electron O 
transfer O 
( O 
ET O 
) O 
via O 
nucleophilic O 
attack O 
by O 
its O 
N B-FORMULA 
lone O 
pair O 
on O 
the O 
C B-FORMULA 
of O 
CO(2) B-FORMULA 
, O 
and O 
finally O 
( O 
c O 
) O 
proton O 
transfer O 
( O 
PT O 
) O 
from O 
PyH(0) B-FORMULA 
to O 
CO(2) B-FORMULA 
produces O 
PyCOOH(0) B-FORMULA 
. O 
The O 
predicted O 
enthalpic O 
barrier O 
for O 
this O 
proton O 
- O 
coupled O 
ET O 
( O 
PCET O 
) O 
reaction O 
is O 
45.7 O 
kcal O 
/ O 
mol O 
for O 
direct O 
PT O 
from O 
PyH(0) B-FORMULA 
to O 
CO(2) B-FORMULA 
. O 
However O 
, O 
when O 
PT O 
is O 
mediated O 
by O 
one O 
to O 
three O 
water O 
molecules O 
acting O 
as O 
a O 
proton O 
relay O 
, O 
the O 
barrier O 
decreases O 
to O 
29.5 O 
, O 
20.4 O 
, O 
and O 
18.5 O 
kcal O 
/ O 
mol O 
, O 
respectively O 
. O 
The O 
water O 
proton O 
relay O 
reduces O 
strain O 
in O 
the O 
transition O 
state O 
( O 
TS O 
) O 
and O 
facilitates O 
more O 
complete O 
ET O 
. O 
For O 
PT O 
mediated O 
by O 
a O 
three O 
water O 
molecule O 
proton O 
relay O 
, O 
adding O 
water O 
molecules O 
to O 
explicitly O 
solvate O 
the O 
core O 
reaction O 
system O 
reduces O 
the O 
barrier O 
to O 
13.6-16.5 O 
kcal O 
/ O 
mol O 
, O 
depending O 
on O 
the O 
number O 
and O 
configuration O 
of O 
the O 
solvating O 
waters O 
. O 
This O 
agrees O 
with O 
the O 
experimentally O 
determined O 
barrier O 
of O 
16.5 O 
± O 
2.4 O 
kcal O 
/ O 
mol O 
. O 
We O 
calculate O 
a O 
pK(a) O 
for O 
PyH(0) B-FORMULA 
of O 
31 O 
indicating O 
that O 
PT O 
preceding O 
ET O 
is O 
highly O 
unfavorable O 
. O 
Moreover O 
, O 
we O 
demonstrate O 
that O 
ET O 
precedes O 
PT O 
in O 
PyCOOH(0) B-FORMULA 
formation O 
, O 
confirming O 
PyH(0) B-FORMULA 
' O 
s O 
pK(a) O 
as O 
irrelevant O 
for O 
predicting O 
PT O 
from O 
PyH(0) B-FORMULA 
to O 
CO(2) B-FORMULA 
. O 
Furthermore O 
, O 
we O 
calculate O 
adiabatic O 
electron O 
affinities O 
in O 
aqueous O 
solvent O 
for O 
CO(2) B-FORMULA 
, O 
Py O 
, O 
and O 
Py·CO(2) B-FORMULA 
of O 
47.4 O 
, O 
37.9 O 
, O 
and O 
66.3 O 
kcal O 
/ O 
mol O 
respectively O 
, O 
indicating O 
that O 
the O 
anionic O 
complex O 
PyCOO(-) B-FORMULA 
stabilizes O 
the O 
anionic O 
radicals O 
CO(2)(-) B-FORMULA 
and O 
Py(-) B-ABBREVIATION 
to O 
facilitate O 
low O 
barrier O 
ET O 
. O 
As O 
the O 
reduction O 
of O 
CO(2) B-FORMULA 
proceeds O 
through O 
ET O 
and O 
then O 
PT O 
, O 
the O 
pyridine B-SYSTEMATIC 
ring O 
becomes O 
aromatic O 
, O 
and O 
thus O 
Py O 
catalyzes O 
CO(2) B-FORMULA 
reduction O 
by O 
stabilizing O 
the O 
PCET O 
TS O 
and O 
the O 
PyCOOH(0) B-FORMULA 
product O 
through O 
aromatic O 
resonance O 
stabilization O 
. O 
Our O 
results O 
suggest O 
that O 
Py O 
catalyzes O 
the O 
homogeneous O 
reductions O 
of O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
formaldehyde B-SYSTEMATIC 
en O 
route O 
to O 
formation O 
of O 
CH(3)OH B-FORMULA 
through O 
a O 
series O 
of O 
one O 
- O 
electron O 
reductions O 
analogous O 
to O 
the O 
PCET O 
reduction O 
of O 
CO(2) B-FORMULA 
examined O 
here O 
, O 
where O 
the O 
electrode O 
only O 
acts O 
to O 
reduce O 
PyH(+) B-FORMULA 
to O 
PyH(0) B-FORMULA 
. O 

synthesis O 
of O 
AMF-26 B-IDENTIFIER 
, O 
an O 
antitumor O 
agent O 
for O 
inhibition O 
of O 
the O 
Golgi O 
system O 
, O 
targeting O 
ADP B-ABBREVIATION 
-ribosylation O 
factor O 
1 O 
. O 

effective O 
method O 
for O 
the O 
total O 
synthesis O 
of O 
1 O 
( O 
AMF-26 B-IDENTIFIER 
) O 
, O 
a O 
potentially O 
promising O 
new O 
anticancer O 
drug O 
that O 
disrupts O 
the O 
Golgi O 
system O 
by O 
inhibiting O 
the O 
ADP B-ABBREVIATION 
-ribosylation O 
factor O 
1 O 
( O 
Arf1 O 
) O 
activation O 
, O 
has O 
been O 
developed O 
for O 
the O 
first O 
time O 
. O 
The O 
construction O 
of O 
the O 
chiral O 
linear O 
precursor O 
( O 
a O 
key O 
to O 
the O 
synthesis O 
) O 
was O 
achieved O 
by O 
the O 
asymmetric O 
aldol O 
reaction O 
followed O 
by O 
the O 
computer O 
- O 
assisted O 
predictive O 
stereoselective O 
intramolecular O 
Diels-Alder O 
reaction O 
. O 
The O 
global O 
antitumor O 
activity O 
of O 
the O 
totally O 
synthetic O 
1 O 
against O 
a O 
variety O 
of O 
human O 
cancer O 
cells O 
was O 
assessed O 
using O 
a O 
panel O 
of O 
39 O 
human O 
cancer O 
cell O 
lines O 
( O 
JFCR39 O 
) O 
, O 
and O 
it O 
was O 
shown O 
that O 
the O 
synthetic O 
1 O 
strongly O 
inhibited O 
the O 
growth O 
of O 
several O 
cancer O 
cell O 
lines O 
at O 
concentrations O 
of O 
less O 
than O 
0.04 O 
μM O 
. O 
Biological O 
assays O 
of O 
novel O 
derivatives O 
, O 
26 O 
and O 
31 O 
, O 
which O 
have O 
different O 
side O 
- O 
chains O 
at O 
the O 
C-4 O 
positions O 
in O 
the O 
Δ¹,²-octalin B-TRIVIAL 
backbone O 
, O 
disclosed O 
the O 
importance O 
of O 
the O 
suitable O 
structure O 
of O 
the O 
side-chain O 
containing O 
conjugated O 
multidouble O 
bonds O 
. O 

pyrrolopyrazine I-SYSTEMATIC 
JAK O 
kinase O 
inhibitors O 
: O 
development O 
of O 
a O 
JAK3 O 
vs O 
JAK1 O 
selective O 
inhibitor O 
and O 
evaluation O 
in O 
cellular O 
and O 
in O 
vivo O 
models O 
. O 

Janus O 
kinases O 
( O 
JAKs O 
) O 
are O 
involved O 
in O 
multiple O 
signaling O 
networks O 
relevant O 
to O 
inflammatory O 
diseases O 
, O 
and O 
inhibition O 
of O 
one O 
or O 
more O 
members O 
of O 
this O 
class O 
may O 
modulate O 
disease O 
activity O 
or O 
progression O 
. O 
We O 
optimized O 
a O 
new O 
inhibitor O 
scaffold O 
, O 
3-amido-5-cyclopropylpyrrolopyrazines B-SYSTEMATIC 
, O 
to O 
a O 
potent O 
example O 
with O 
reasonable O 
kinome O 
selectivity O 
, O 
including O 
selectivity O 
for O 
JAK3 O 
versus O 
JAK1 O 
, O 
and O 
good O 
biopharmaceutical O 
properties O 
. O 
Evaluation O 
of O 
this O 
analogue O 
in O 
cellular O 
and O 
in O 
vivo O 
models O 
confirmed O 
functional O 
selectivity O 
for O 
modulation O 
of O 
a O 
JAK3 O 
/ O 
JAK1-dependent O 
IL-2 O 
stimulated O 
pathway O 
over O 
a O 
JAK1 O 
/ O 
JAK2 O 
/ O 
Tyk2-dependent O 
IL-6 O 
stimulated O 
pathway O 
. O 

adsorption O 
mechanisms O 
determine O 
the O 
efficiency O 
of O 
thermally O 
controlled O 
cell O 
adhesion O 
on O 
poly(N-isopropyl B-SYSTEMATIC 
acrylamide I-SYSTEMATIC 
) I-SYSTEMATIC 
brushes O 
. O 

study O 
investigated O 
the O 
impact O 
of O 
the O 
protein O 
adsorption O 
mechanism(s) O 
on O 
the O 
efficiency O 
of O 
thermally O 
controlled O 
cell O 
adhesion O 
and O 
release O 
from O 
poly(N-isopropyl B-SYSTEMATIC 
acrylamide I-SYSTEMATIC 
) I-SYSTEMATIC 
brushes O 
. O 
Large O 
format O 
polymer O 
gradients O 
were O 
used O 
to O 
screen O 
for O 
grafting O 
densities O 
and O 
substrate O 
chemistries O 
that O 
alter O 
both O 
cell O 
adhesion O 
at O 
37 O 
°C O 
and O 
rapid O 
cell O 
release O 
at O 
25 O 
°C O 
. O 
In O 
particular O 
, O 
the O 
grafting O 
conditions O 
investigated O 
allowed O 
protein O 
adsorption O 
to O 
the O 
underlying O 
substrate O 
, O 
penetration O 
of O 
the O 
brush O 
only O 
, O 
or O 
adsorption O 
to O 
the O 
outer O 
edge O 
of O 
the O 
film O 
. O 
At O 
an O 
average O 
molecular O 
weight O 
of O 
30 O 
kDa O 
( O 
degree O 
of O 
polymerization O 
N O 
∼ O 
270 O 
) O 
, O 
the O 
results O 
show O 
that O 
robust O 
protein O 
adsorption O 
to O 
polymer O 
brushes O 
impairs O 
rapid O 
cell O 
release O 
below O 
the O 
lower O 
critical O 
solution O 
temperature O 
. O 
Conversely O 
, O 
grafting O 
conditions O 
that O 
permit O 
protein O 
penetration O 
of O 
the O 
brush O 
but O 
block O 
strong O 
adsorption O 
to O 
the O 
underlying O 
substrate O 
support O 
cell O 
adhesion O 
above O 
the O 
transition O 
temperature O 
and O 
ensure O 
efficient O 
cell O 
recovery O 
at O 
lower O 
temperature O 
. O 
These O 
findings O 
demonstrate O 
the O 
impact O 
of O 
protein O 
adsorption O 
mechanisms O 
, O 
surface O 
chemistry O 
, O 
and O 
polymer O 
properties O 
on O 
thermally O 
controlled O 
cell O 
capture O 
and O 
release O 
. O 

of O 
uracils B-FAMILY 
. O 
Experimental O 
and O 
computational O 
enthalpies O 
of O 
formation O 
of O 
5,6-dimethyl- B-MULTIPLE 
, I-MULTIPLE 
1,3,5-trimethyl- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
1,3,5,6-tetramethyluracils I-MULTIPLE 
. O 

describe O 
in O 
the O 
current O 
paper O 
an O 
experimental O 
and O 
computational O 
study O 
of O 
three O 
methylated O 
uracils O 
, O 
in O 
particular O 
, O 
the O 
5,6-dimethyl- B-MULTIPLE 
, I-MULTIPLE 
1,3,5-trimethyl- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
1,3,5,6-tetramethyl I-MULTIPLE 
derivatives O 
. O 
The O 
values O 
of O 
the O 
standard O 
( O 
p(0) O 
= O 
0.1 O 
MPa O 
) O 
molar O 
enthalpies O 
of O 
formation O 
in O 
the O 
gas O 
phase O 
at O 
T O 
= O 
298.15 O 
K O 
have O 
been O 
determined O 
. O 
The O 
energies O 
of O 
combustion O 
were O 
measured O 
by O 
static O 
bomb O 
combustion O 
calorimetry O 
, O 
and O 
from O 
the O 
results O 
obtained O 
, O 
the O 
standard O 
molar O 
enthalpies O 
of O 
formation O 
in O 
the O 
crystalline O 
state O 
at O 
T O 
= O 
298.15 O 
K O 
were O 
calculated O 
. O 
The O 
enthalpies O 
of O 
sublimation O 
were O 
determined O 
using O 
the O 
transpiration O 
method O 
in O 
a O 
saturated O 
N(2) B-FORMULA 
stream O 
. O 
Values O 
of O 
-(376.2 O 
± O 
2.6 O 
) O 
, O 
-(355.9 O 
± O 
3 O 
) O 
, O 
and O 
-(381.7 O 
± O 
2.8 O 
) O 
kJ·mol(-1) O 
for O 
the O 
gas-phase O 
enthalpies O 
of O 
formation O 
at O 
T O 
= O 
298.15 O 
K O 
of O 
5,6-dimethyluracil B-SYSTEMATIC 
, O 
1,3,5-trimethyluracil B-SYSTEMATIC 
, O 
and O 
1,3,5,6-tetramethyluracil B-SYSTEMATIC 
, O 
respectively O 
, O 
were O 
obtained O 
from O 
the O 
experimental O 
thermochemical O 
study O 
. O 
An O 
extended O 
theoretical O 
study O 
with O 
the O 
G3 O 
and O 
the O 
G4 O 
quantum O 
- O 
chemical O 
methods O 
has O 
been O 
carried O 
out O 
for O 
all O 
the O 
possible O 
methylated B-FAMILY 
uracils I-FAMILY 
. O 
There O 
is O 
a O 
very O 
good O 
agreement O 
between O 
experimental O 
and O 
calculated O 
enthalpies O 
of O 
formation O 
for O 
the O 
three O 
derivatives O 
studied O 
. O 
A O 
Free-Wilson O 
analysis O 
on O 
G4-calculated O 
enthalpies O 
of O 
formation O 
has O 
been O 
carried O 
out O 
, O 
and O 
the O 
contribution O 
of O 
methylation O 
in O 
the O 
different O 
positions O 
of O 
the O 
uracil O 
ring O 
has O 
been O 
estimated O 
. O 

- O 
reorganization O 
- O 
induced O 
morphology O 
alteration O 
in O 
asymmetric O 
substrate O 
- O 
supported O 
lipid O 
bilayers O 
( O 
SLBs O 
) O 
was O 
directly O 
visualized O 
by O 
means O 
of O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
and O 
total O 
internal O 
reflection O 
fluorescence O 
( O 
TIRF O 
) O 
microscopy O 
. O 
SLB O 
samples O 
were O 
fabricated O 
on O 
mica O 
- O 
on O 
- O 
glass O 
and O 
glass O 
substrates O 
by O 
Langmuir-Blodgett O 
( O 
LB O 
) O 
/ O 
Langmuir-Schaeffer O 
( O 
LS O 
) O 
using O 
binary O 
lipid O 
mixtures O 
, O 
namely O 
, O 
1,2-dioleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DOPC B-ABBREVIATION 
)/ O 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DPPC B-ABBREVIATION 
) O 
and O 
ternary O 
mixtures O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
/ O 
1,2-dioleoyl-sn-glycero-3-phospho-L-serine B-SYSTEMATIC 
( O 
DOPS B-ABBREVIATION 
) O 
, O 
labeled O 
with O 
0.2 O 
mol O 
% O 
Texas B-TRIVIAL 
Red I-TRIVIAL 
1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine B-SYSTEMATIC 
triethylammonium I-SYSTEMATIC 
salt O 
( O 
TR-DHPE B-ABBREVIATION 
) O 
dye O 
. O 
Phase O 
segregations O 
were O 
characterized O 
by O 
TIRF O 
imaging O 
, O 
and O 
DPPC B-ABBREVIATION 
-enriched O 
domain O 
structures O 
were O 
also O 
observed O 
. O 
Interestingly O 
for O 
∼40% O 
( O 
n O 
= O 
6 O 
) O 
of O 
the O 
samples O 
with O 
binary O 
mixtures O 
in O 
the O 
LB O 
leaflet O 
and O 
a O 
single O 
component O 
in O 
the O 
LS O 
leaflet O 
, O 
that O 
is O 
, O 
( O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
)(LB)+ O 
DOPC B-ABBREVIATION 
( O 
LS O 
) O 
, O 
the O 
contrast O 
of O 
the O 
DPPC B-ABBREVIATION 
domains O 
changed O 
from O 
the O 
original O 
dark O 
( O 
without O 
dye O 
) O 
to O 
bright O 
( O 
more O 
TR O 
dye O 
partitioning O 
) O 
on O 
TIRF O 
images O 
, O 
returning O 
to O 
dark O 
again O 
. O 
This O 
contrast O 
reverse O 
was O 
also O 
correlated O 
to O 
AFM O 
height O 
images O 
, O 
where O 
a O 
DPPC B-ABBREVIATION 
- O 
DPPC B-ABBREVIATION 
gel O 
phase O 
was O 
spotted O 
after O 
the O 
TIRF O 
image O 
contrast O 
returned O 
to O 
dark O 
. O 
The O 
rupture O 
force O 
mapping O 
results O 
measured O 
on O 
these O 
binary O 
mixture O 
samples O 
also O 
confirmed O 
unambiguously O 
the O 
formation O 
of O 
DPPC B-ABBREVIATION 
- O 
DPPC B-ABBREVIATION 
gel O 
domain O 
components O 
during O 
the O 
contrast O 
change O 
. O 
The O 
samples O 
were O 
tracked O 
over O 
48 O 
h O 
to O 
investigate O 
the O 
lipid O 
molecule O 
movements O 
in O 
both O 
the O 
DPPC B-ABBREVIATION 
domains O 
and O 
the O 
DOPC B-ABBREVIATION 
fluid O 
phase O 
. O 
The O 
fluorescence O 
contrast O 
changes O 
from O 
bright O 
to O 
dark O 
in O 
SLBs O 
indicate O 
that O 
the O 
movement O 
of O 
dye O 
molecules O 
was O 
independent O 
of O 
the O 
movement O 
of O 
lipid O 
molecules O 
. O 
In O 
addition O 
, O 
correlated O 
multimodal O 
imaging O 
using O 
AFM O 
, O 
force O 
mapping O 
, O 
and O 
fluorescence O 
provides O 
a O 
novel O 
route O 
to O 
uncover O 
the O 
reorganization O 
of O 
lipid O 
molecules O 
at O 
the O 
solid O 
- O 
liquid O 
interface O 
, O 
suggesting O 
that O 
the O 
dynamics O 
of O 
dye O 
molecules O 
is O 
highly O 
structure O 
dependent O 
. O 

, O 
we O 
report O 
the O 
preparation O 
and O 
characterization O 
of O 
hollow O 
polymer O 
microspheres O 
based O 
on O 
the O 
preprecipitation O 
of O 
porous O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
cores O 
with O 
an O 
average O 
size O 
of O 
5 O 
μm O 
and O 
their O 
use O 
for O 
encapsulation O 
of O 
living O 
microorganisms O 
. O 
The O 
microspheres O 
filled O 
with O 
individual O 
living O 
E O 
. O 
coli O 
cells O 
were O 
prepared O 
by O 
layer O 
- O 
by O 
- O 
layer O 
( O 
LbL O 
) O 
deposition O 
of O 
different O 
polyelectrolytes O 
and O 
proteins O 
onto O 
the O 
porous O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
cores O 
leading O 
to O 
the O 
formation O 
of O 
matrix O 
- O 
like O 
complexes O 
of O 
the O 
compounds O 
followed O 
by O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
core O 
dissolution O 
using O 
EDTA B-ABBREVIATION 
. O 
Both O 
the O 
influence O 
of O 
the O 
encapsulation O 
process O 
as O 
well O 
as O 
of O 
the O 
used O 
polyelectrolytes O 
on O 
the O 
survival O 
rate O 
of O 
the O 
cells O 
were O 
determined O 
by O 
confocal O 
laser O 
scanning O 
microscopy O 
( O 
CLSM O 
) O 
and O 
microtiter O 
plate O 
fluorescence O 
tests O 
. O 
After O 
the O 
encapsulation O 
process O 
~40% O 
of O 
the O 
cells O 
were O 
alive O 
. O 
Cultivation O 
tests O 
indicated O 
that O 
the O 
lag O 
phase O 
of O 
cells O 
treated O 
with O 
polyelectrolytes O 
increases O 
and O 
the O 
encapsulated O 
E O 
. O 
coli O 
cells O 
were O 
able O 
to O 
produce O 
green O 
fluorescent O 
protein O 
inside O 
the O 
microcapsules O 
. O 

fibrinogen O 
is O 
a O 
biomaterial O 
used O 
in O 
surgical O 
tissue O 
sealants O 
, O 
scaffolding O 
for O 
tissue O 
engineering O 
, O 
and O 
wound O 
healing O 
. O 
Here O 
we O 
report O 
on O 
the O 
post O 
- O 
translational O 
structure O 
and O 
functionality O 
of O 
recombinant O 
human O 
FI O 
( O 
rFI O 
) O 
made O 
at O 
commodity O 
levels O 
in O 
the O 
milk O 
of O 
transgenic O 
dairy O 
cows O 
. O 
Relative O 
to O 
plasma O 
- O 
derived O 
fibrinogen O 
( O 
pdFI O 
) O 
, O 
rFI O 
predominately O 
contained O 
a O 
simplified O 
, O 
neutral O 
carbohydrate B-FAMILY 
structure O 
and O 
> O 
4-fold O 
higher O 
levels O 
of O 
the O 
γ'-chain O 
transcriptional O 
variant O 
that O 
has O 
been O 
reported O 
to O 
bind O 
thrombin O 
and O 
Factor O 
XIII O 
. O 
In O 
spite O 
of O 
these O 
differences O 
, O 
rFI O 
and O 
pdFI O 
were O 
kinetically O 
similar O 
with O 
respect O 
to O 
the O 
thrombin O 
- O 
catalyzed O 
formation O 
of O 
protofibrils O 
and O 
Factor O 
XIIIa O 
- O 
mediated O 
formation O 
of O 
cross O 
- O 
linked O 
fibrin O 
polymer O 
. O 
However O 
, O 
electron O 
microscopy O 
showed O 
rFI O 
produced O 
fibrin O 
with O 
much O 
thicker O 
fibers O 
with O 
less O 
branching O 
than O 
pdFI O 
. O 
In O 
vivo O 
studies O 
in O 
a O 
swine O 
liver O 
transection O 
model O 
showed O 
that O 
, O 
relative O 
to O 
pdFI O 
, O 
rFI O 
made O 
a O 
denser O 
, O 
more O 
strongly O 
wound O 
- O 
adherent O 
fibrin O 
clot O 
that O 
more O 
rapidly O 
established O 
hemostasis O 
. O 

substantial O 
proportion O 
of O 
women O 
with O 
the O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
are O 
obese O 
and O 
obesity O 
is O 
considered O 
as O 
a O 
prothrombotic O 
state O 
. O 
Platelet O 
- O 
derived O 
microparticles O 
( O 
PMPs O 
) O 
might O 
be O 
implicated O 
in O 
the O 
activation O 
of O 
the O 
coagulation O 
cascade O 
. O 
We O 
aimed O 
to O 
assess O 
plasma O 
PMPs O 
in O 
overweight O 
/ O 
obese O 
women O 
with O 
PCOS O 
. O 
We O 
measured O 
plasma O 
PMPs O 
and O 
determined O 
anthropometric O 
, O 
metabolic O 
, O 
hormonal O 
and O 
ultrasonographic O 
features O 
of O 
PCOS O 
in O 
67 O 
overweight O 
/ O 
obese O 
women O 
with O 
PCOS O 
( O 
with O 
body O 
mass O 
index O 
[ O 
BMI O 
] O 
> O 
25 O 
kg O 
/ O 
m(2) O 
) O 
and O 
in O 
21 O 
BMI-matched O 
healthy O 
women O 
. O 
Circulating O 
androgens B-FAMILY 
and O 
markers O 
of O 
insulin O 
resistance O 
( O 
IR O 
) O 
were O 
higher O 
in O 
women O 
with O 
PCOS O 
than O 
in O 
controls O 
. O 
Plasma O 
PMPs O 
were O 
also O 
higher O 
in O 
women O 
with O 
PCOS O 
than O 
in O 
controls O 
( O 
p O 
= O 
0.046 O 
) O 
. O 
In O 
women O 
with O 
PCOS O 
, O 
plasma O 
PMPs O 
correlated O 
with O 
the O 
mean O 
number O 
of O 
follicles O 
in O 
the O 
ovaries O 
( O 
r O 
= O 
0.343 O 
; O 
p O 
= O 
0.006 O 
) O 
. O 
In O 
controls O 
, O 
plasma O 
PMPs O 
did O 
not O 
correlate O 
with O 
any O 
of O 
the O 
studied O 
parameters O 
. O 
In O 
conclusion O 
, O 
plasma O 
PMPs O 
are O 
elevated O 
in O 
overweight O 
/ O 
obese O 
women O 
with O 
PCOS O 
compared O 
with O 
BMI-matched O 
controls O 
. O 
The O 
cause O 
of O 
this O 
increase O 
is O 
unclear O 
but O 
both O 
IR O 
and O 
hyperandrogenemia O 
might O 
be O 
implicated O 
. O 
More O 
studies O 
are O 
required O 
to O 
elucidate O 
the O 
pathogenesis O 
of O 
the O 
elevation O 
of O 
PMPs O 
in O 
PCOS O 
and O 
to O 
assess O 
its O 
implications O 
on O 
the O 
cardiovascular O 
risk O 
of O 
these O 
patients O 
. O 

- O 
activity O 
relationship O 
study O 
on O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
part O 
of O 
diphenylamine B-SYSTEMATIC 
-based O 
retinoids B-FAMILY 
. O 

on O 
structure O 
- O 
activity O 
relationship O 
studies O 
of O 
the O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
part O 
of O 
diphenylamine B-SYSTEMATIC 
-based O 
retinoids B-FAMILY 
, O 
the O 
potent O 
RXR O 
agonist O 
4 O 
was O 
derivatized O 
to O 
obtain O 
retinoid B-FAMILY 
agonists O 
, O 
synergists O 
, O 
and O 
an O 
antagonist O 
. O 
Cinnamic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
5 O 
and O 
phenylpropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
6 O 
showed O 
retinoid B-FAMILY 
agonistic O 
and O 
synergistic O 
activities O 
, O 
respectively O 
. O 
The O 
difference O 
of O 
the O 
activities O 
is O 
considered O 
to O 
be O 
due O 
to O 
differences O 
in O 
the O 
flexibility O 
of O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-containing O 
substituent O 
on O 
the O 
diphenylamine B-SYSTEMATIC 
skeleton O 
. O 
Compound O 
7 O 
, O 
bearing O 
a O 
methyl B-SYSTEMATIC 
group O 
at O 
the O 
meta O 
position O 
to O 
the O 
carboxyl B-SYSTEMATIC 
group O 
, O 
was O 
an O 
antagonist O 
, O 
dose O 
- O 
dependently O 
inhibiting O 
HL-60 O 
cell O 
differentiation O 
induced O 
by O 
3.3 O 
× O 
10(-10)M O 
Am80 B-IDENTIFIER 
. O 

of O 
a O 
novel O 
phenylethyl B-SYSTEMATIC 
benzamide I-SYSTEMATIC 
glucokinase O 
activator O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
. O 

benzamide B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
tested O 
at O 
in O 
vitro O 
assay O 
by O 
measuring O 
fold O 
increase O 
of O 
glucokinase O 
activity O 
at O 
5 O 
mM O 
glucose B-TRIVIAL 
concentration O 
. O 
Among O 
the O 
prepared O 
compounds O 
, O 
YH-GKA B-IDENTIFIER 
was O 
found O 
to O 
be O 
an O 
active O 
glucokinase O 
activator O 
with O 
EC(50) O 
of O 
70 O 
nM O 
. O 
YH-GKA B-IDENTIFIER 
showed O 
similar O 
glucose B-TRIVIAL 
AUC O 
reduction O 
of O 
29.6% O 
( O 
50 O 
mg O 
/ O 
kg O 
) O 
in O 
an O 
OGTT O 
study O 
with O 
C57BL O 
/ O 
J6 O 
mice O 
compared O 
to O 
29.9% O 
for O 
metformin O 
( O 
300 O 
mg O 
/ O 
kg O 
) O 
. O 
Acute O 
treatment O 
of O 
the O 
compound O 
in O 
C57BL O 
/ O 
J6 O 
and O 
ob O 
/ O 
ob O 
mice O 
elicited O 
basal O 
glucose B-TRIVIAL 
lowering O 
activity O 
. O 
In O 
subchronic O 
study O 
with O 
ob O 
/ O 
ob O 
mice O 
, O 
YH-GKA B-IDENTIFIER 
showed O 
significant O 
decrease O 
in O 
blood O 
glucose B-TRIVIAL 
levels O 
and O 
no O 
adverse O 
effects O 
on O 
serum O 
lipids O 
or O 
body O 
weight O 
. O 
In O 
addition O 
, O 
YH-GKA B-IDENTIFIER 
exhibited O 
high O 
bioavailability O 
and O 
moderate O 
elimination O 
in O 
preclinical O 
species O 
. O 

of O 
norovirus O 
3CL O 
protease O 
by O 
bisulfite B-SYSTEMATIC 
adducts O 
of O 
transition O 
state O 
inhibitors O 
. O 

are O 
the O 
most O 
common O 
cause O 
of O 
acute O 
viral O 
gastroenteritis O 
, O 
accounting O 
for O 
> O 
21 O 
million O 
cases O 
annually O 
in O 
the O 
US O 
alone O 
. O 
Norovirus O 
infections O 
constitute O 
an O 
important O 
health O 
problem O 
for O 
which O 
there O 
are O 
no O 
specific O 
antiviral O 
therapeutics O 
or O 
vaccines O 
. O 
In O 
this O 
study O 
, O 
a O 
series O 
of O 
bisulfite B-SYSTEMATIC 
adducts O 
derived O 
from O 
representative O 
transition O 
state O 
inhibitors O 
( O 
dipeptidyl B-FAMILY 
aldehydes I-FAMILY 
and O 
α-ketoamides B-FAMILY 
) O 
was O 
synthesized O 
and O 
shown O 
to O 
exhibit O 
anti-norovirus O 
activity O 
in O 
a O 
cell O 
- O 
based O 
replicon O 
system O 
. O 
The O 
ED(50) O 
of O 
the O 
most O 
effective O 
inhibitor O 
was O 
60 O 
nM O 
. O 
This O 
study O 
demonstrates O 
for O 
the O 
first O 
time O 
the O 
utilization O 
of O 
bisulfite B-SYSTEMATIC 
adducts O 
of O 
transition O 
state O 
inhibitors O 
in O 
the O 
inhibition O 
of O 
norovirus O 
3C O 
- O 
like O 
protease O 
in O 
vitro O 
and O 
in O 
a O 
cell O 
- O 
based O 
replicon O 
system O 
. O 
The O 
approach O 
described O 
herein O 
can O 
be O 
extended O 
to O 
the O 
synthesis O 
of O 
the O 
bisulfite B-SYSTEMATIC 
adducts O 
of O 
other O 
classes O 
of O 
transition O 
state O 
inhibitors O 
of O 
serine B-TRIVIAL 
and O 
cysteine B-TRIVIAL 
proteases O 
, O 
such O 
as O 
α-ketoheterocycles B-FAMILY 
and O 
α-ketoesters B-FAMILY 
. O 

2,3-dioxygenase O 
inhibitory O 
activity O 
of O 
derivatives O 
of O 
marine O 
alkaloid O 
tsitsikammamine B-TRIVIAL 
A I-TRIVIAL 
. O 

are O 
marine O 
alkaloids O 
whose O 
structure O 
is O 
based O 
on O 
the O 
pyrroloiminoquinone B-SYSTEMATIC 
scaffold O 
. O 
These O 
and O 
related O 
compounds O 
have O 
attracted O 
attention O 
due O 
to O 
various O 
interesting O 
biological O 
properties O 
, O 
including O 
cytotoxicity O 
, O 
topoisomerase O 
inhibition O 
, O 
antimicrobial O 
, O 
antifungal O 
and O 
antimalarial O 
activity O 
. O 
Indoleamine B-SYSTEMATIC 
2,3-dioxygenase O 
( O 
IDO1 O 
) O 
is O 
a O 
well O 
- O 
established O 
therapeutic O 
target O 
as O 
an O 
important O 
factor O 
in O 
the O 
tumor O 
immune O 
evasion O 
mechanism O 
. O 
In O 
this O 
preliminary O 
communication O 
, O 
we O 
report O 
the O 
inhibitory O 
activity O 
of O 
tsitsikammamine B-FAMILY 
derivatives O 
against O 
IDO1 O 
. O 
Tsitsikammamine B-TRIVIAL 
A I-TRIVIAL 
analogue O 
11b O 
displays O 
submicromolar O 
potency O 
in O 
an O 
enzymatic O 
assay O 
. O 
A O 
number O 
of O 
derivatives O 
are O 
also O 
active O 
in O 
a O 
cellular O 
assay O 
while O 
showing O 
little O 
or O 
no O 
activity O 
towards O 
tryptophan B-TRIVIAL 
2,3-dioxygenase O 
( O 
TDO O 
) O 
, O 
a O 
functionally O 
related O 
enzyme O 
. O 
This O 
IDO1 O 
inhibitory O 
activity O 
is O 
rationalized O 
by O 
molecular O 
modeling O 
studies O 
. O 
An O 
interest O 
is O 
thus O 
established O 
in O 
this O 
class O 
of O 
compounds O 
as O 
a O 
potential O 
source O 
of O 
lead O 
compounds O 
for O 
the O 
development O 
of O 
new O 
pharmaceutically O 
useful O 
IDO1 O 
inhibitors O 
. O 

and O 
insecticidal O 
evaluation O 
of O 
novel O 
N-pyridylpyrazolecarboxamides B-FAMILY 
containing O 
cyano B-FAMILY 
substituent O 
in O 
the O 
ortho- O 
position O 
. O 

an O 
attempt O 
to O 
search O 
for O 
potent O 
insecticides O 
targeting O 
the O 
ryanodine B-TRIVIAL 
receptor O 
( O 
RyR O 
) O 
, O 
a O 
series O 
of O 
novel O 
N-pyridylpyrazolecarboxamides B-FAMILY 
containing O 
cyano B-FAMILY 
substituent O 
in O 
the O 
ortho- O 
position O 
were O 
designed O 
and O 
synthesized O 
. O 
Their O 
insecticidal O 
activities O 
of O 
target O 
compounds O 
against O 
oriental O 
armyworm O 
( O 
Mythimna O 
separata O 
) O 
and O 
diamondback O 
moth O 
( O 
Plutella O 
xylostella O 
) O 
indicated O 
that O 
most O 
of O 
the O 
compounds O 
showed O 
moderate O 
to O 
high O 
activities O 
at O 
the O 
tested O 
concentrations O 
. O 
In O 
particular O 
, O 
compound O 
6l O 
and O 
6o O 
showed O 
86% O 
larvicidal O 
activities O 
against O 
Plutella O 
xylostella O 
at O 
the O 
concentration O 
of O 
0.1mg O 
/ O 
L O 
, O 
while O 
the O 
activity O 
of O 
compound O 
6h O 
against O 
Mythimna O 
separate O 
was O 
80% O 
at O 
1mg O 
/ O 
L O 
. O 
The O 
calcium B-SYSTEMATIC 
imaging O 
technique O 
was O 
applied O 
to O 
investigate O 
the O 
effects O 
of O 
some O 
title O 
compounds O 
on O 
the O 
intracellular O 
calcium B-SYSTEMATIC 
ion O 
concentration O 
( O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
) O 
, O 
experimental O 
results O 
demonstrated O 
that O 
compound O 
6h O 
stimulates O 
a O 
transient O 
elevation O 
in O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
in O 
the O 
absence O 
of O 
external O 
calcium B-SYSTEMATIC 
after O 
the O 
central O 
neurons O 
dye O 
loading O 
with O 
fluo-3 B-TRIVIAL 
AM I-TRIVIAL 
. O 
However O 
, O 
when O 
the O 
central O 
neurons O 
were O 
dyed O 
with O 
fluo-5N O 
and O 
incubated O 
with O 
2-APB B-SYSTEMATIC 
, O 
[ O 
Ca(2+) B-FORMULA 
]i O 
decreased O 
transiently O 
by O 
treated O 
of O 
compound O 
6h O 
. O 
All O 
of O 
the O 
calcium B-SYSTEMATIC 
imaging O 
technique O 
experiments O 
demonstrated O 
that O 
these O 
novel O 
compounds O 
deliver O 
calcium B-SYSTEMATIC 
from O 
endoplasmic O 
reticulum O 
to O 
cytoplasm O 
, O 
which O 
proved O 
that O 
the O 
title O 
compounds O 
were O 
the O 
possible O 
activators O 
of O 
insect O 
RyR O 
. O 

mammalian O 
cells O 
, O 
POLQ O 
( O 
pol O 
θ O 
) O 
is O 
an O 
unusual O 
specialized O 
DNA O 
polymerase O 
whose O 
in O 
vivo O 
function O 
is O 
under O 
active O 
investigation O 
. O 
POLQ O 
has O 
been O 
implicated O 
by O 
different O 
experiments O 
to O 
play O 
a O 
role O 
in O 
resistance O 
to O 
ionizing O 
radiation O 
and O 
defense O 
against O 
genomic O 
instability O 
, O 
in O 
base O 
excision O 
repair O 
, O 
and O 
in O 
immunological O 
diversification O 
. O 
The O 
protein O 
is O 
formed O 
by O 
an O 
N B-FORMULA 
-terminal O 
helicase O 
- O 
like O 
domain O 
, O 
a O 
C B-FORMULA 
-terminal O 
DNA O 
polymerase O 
domain O 
, O 
and O 
a O 
large O 
central O 
domain O 
that O 
spans O 
between O 
the O 
two O 
. O 
This O 
arrangement O 
is O 
also O 
found O 
in O 
the O 
Drosophila O 
Mus308 O 
protein O 
, O 
which O 
functions O 
in O 
resistance O 
to O 
DNA O 
interstrand O 
crosslinking O 
agents O 
. O 
Homologs O 
of O 
POLQ O 
and O 
Mus308 O 
are O 
found O 
in O 
multicellular O 
eukaryotes O 
, O 
including O 
plants O 
, O 
but O 
a O 
comparison O 
of O 
phenotypes O 
suggests O 
that O 
not O 
all O 
of O 
these O 
genes O 
are O 
functional O 
orthologs O 
. O 
Flies O 
defective O 
in O 
Mus308 O 
are O 
sensitive O 
to O 
DNA O 
interstrand O 
crosslinking O 
agents O 
, O 
while O 
mammalian O 
cells O 
defective O 
in O 
POLQ O 
are O 
primarily O 
sensitive O 
to O 
DNA O 
double O 
- O 
strand O 
breaking O 
agents O 
. O 
Cells O 
from O 
Polq(- O 
/ O 
- O 
) O 
mice O 
are O 
hypersensitive O 
to O 
radiation O 
and O 
peripheral O 
blood O 
cells O 
display O 
increased O 
spontaneous O 
and O 
ionizing O 
radiation O 
- O 
induced O 
levels O 
of O 
micronuclei O 
( O 
a O 
hallmark O 
of O 
gross O 
chromosomal O 
aberrations O 
) O 
, O 
though O 
mice O 
apparently O 
develop O 
normally O 
. O 
Loss O 
of O 
POLQ O 
in O 
human O 
and O 
mouse O 
cells O 
causes O 
sensitivity O 
to O 
ionizing O 
radiation O 
and O 
other O 
double O 
strand O 
breaking O 
agents O 
and O 
increased O 
DNA O 
damage O 
signaling O 
. O 
Retrospective O 
studies O 
of O 
clinical O 
samples O 
show O 
that O 
higher O 
levels O 
of O 
POLQ O 
gene O 
expression O 
in O 
breast O 
and O 
colorectal O 
cancer O 
are O 
correlated O 
with O 
poorer O 
outcomes O 
for O 
patients O 
. O 
A O 
clear O 
understanding O 
of O 
the O 
mechanism O 
of O 
action O 
and O 
physiologic O 
function O 
of O 
POLQ O 
in O 
the O 
cell O 
is O 
likely O 
to O 
bear O 
clinical O 
relevance O 
. O 

cinnoline B-TRIVIAL 
-based O 
inhibitors O 
of O 
LRRK2 O 
kinase O 
activity O 
. O 

rich O 
repeat O 
kinase O 
2 O 
( O 
LRRK2 O 
) O 
has O 
been O 
implicated O 
in O 
the O 
pathogenesis O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
Inhibition O 
of O 
LRRK2 O 
kinase O 
activity O 
is O 
a O 
therapeutic O 
approach O 
that O 
may O 
lead O 
to O 
new O 
treatments O 
for O 
PD O 
. O 
Herein O 
we O 
report O 
the O 
discovery O 
of O 
a O 
series O 
of O 
cinnoline-3-carboxamides B-FAMILY 
that O 
are O 
potent O 
against O 
both O 
wild O 
- O 
type O 
and O 
mutant O 
LRRK2 O 
kinase O 
activity O 
in O 
biochemical O 
assays O 
. O 
These O 
compounds O 
are O 
also O 
shown O 
to O 
be O 
potent O 
inhibitors O 
in O 
a O 
cellular O 
assay O 
and O 
to O 
have O 
good O 
to O 
excellent O 
CNS O 
penetration O 
. O 

effects O 
of O 
oxymatrine B-TRIVIAL 
against O 
excitotoxicity O 
partially O 
through O 
down O 
- O 
regulation O 
of O 
NR2B O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
. O 

( O 
OMT B-ABBREVIATION 
) O 
is O 
a O 
major O 
bioactive O 
component O 
derived O 
from O 
Sophora O 
flavescens O 
Ait O 
( O 
kushen O 
) O 
, O 
which O 
is O 
widely O 
used O 
in O 
Chinese O 
medicine O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
it O 
has O 
neuroprotective O 
effects O 
; O 
however O 
, O 
its O 
underlying O 
mechanisms O 
remain O 
unclear O 
. O 
We O 
focus O 
on O 
the O 
mechanisms O 
of O 
pharmacologic O 
action O 
in O 
OMT B-ABBREVIATION 
by O 
detecting O 
its O 
pharmacological O 
properties O 
against O 
focal O 
cerebral O 
ischemia O 
in O 
vivo O 
and O 
NMDA B-ABBREVIATION 
-induced O 
neurotoxicity O 
in O 
vitro O 
. O 
OMT B-ABBREVIATION 
prevented O 
cerebral O 
ischemic O 
injury O 
in O 
mice O 
induced O 
via O 
a O 
2 O 
h O 
middle O 
cerebral O 
artery O 
occlusion O 
and O 
a O 
24 O 
h O 
reperfusion O 
, O 
in O 
vivo O 
. O 
In O 
vitro O 
cultured O 
neurons O 
challenged O 
with O 
N-methyl-D-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
, O 
200 O 
μM O 
) O 
for O 
30 O 
min O 
showed O 
significant O 
decrease O 
in O 
the O 
viability O 
of O 
neurons O 
; O 
however O 
, O 
OMT B-ABBREVIATION 
was O 
able O 
to O 
protect O 
neurons O 
against O 
induced O 
neurotoxicity O 
via O 
NMDA B-ABBREVIATION 
exposure O 
. O 
Western O 
blot O 
analysis O 
revealed O 
that O 
OMT B-ABBREVIATION 
decreased O 
the O 
expression O 
of O 
Bax O 
and O 
repaired O 
the O 
balance O 
of O 
pro- O 
and O 
anti-apoptotic O 
proteins O 
. O 
Furthermore O 
, O 
OMT B-ABBREVIATION 
significantly O 
reversed O 
the O 
up O 
- O 
regulation O 
of O 
NR2B O 
and O 
inhibited O 
the O 
calcium B-SYSTEMATIC 
overload O 
in O 
the O 
cultured O 
neurons O 
after O 
challenging O 
the O 
NMDA B-ABBREVIATION 
. O 
OMT B-ABBREVIATION 
showed O 
partial O 
protection O 
in O 
the O 
cortical O 
neurons O 
via O 
down O 
- O 
regulation O 
of O 
NR2B O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
and O 
up O 
- O 
regulation O 
of O 
Bcl-2 O 
family O 
. O 
Our O 
results O 
provide O 
new O 
insights O 
into O 
the O 
development O 
of O 
natural O 
therapeutic O 
anti-oxidants O 
against O 
ischemia O 
. O 

transmembrane O 
interaction O 
between O 
actin O 
and O 
the O 
pore O 
- O 
competent O 
, O 
cholesterol B-TRIVIAL 
-dependent O 
cytolysin O 
pneumolysin O 
. O 

eukaryotic O 
actin O 
cytoskeleton O 
is O 
an O 
evolutionarily O 
well O 
- O 
established O 
pathogen O 
target O 
, O 
as O 
a O 
large O 
number O 
of O 
bacterial O 
factors O 
disturb O 
its O 
dynamics O 
to O 
alter O 
the O 
function O 
of O 
the O 
host O 
cells O 
. O 
These O 
pathogenic O 
factors O 
modulate O 
or O 
mimic O 
actin O 
effector O 
proteins O 
or O 
they O 
modify O 
actin O 
directly O 
, O 
leading O 
to O 
an O 
imbalance O 
of O 
the O 
precisely O 
regulated O 
actin O 
turnover O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
pore O 
- O 
forming O 
, O 
cholesterol B-TRIVIAL 
-dependent O 
cytolysin O 
pneumolysin O 
( O 
PLY O 
) O 
, O 
a O 
major O 
neurotoxin O 
of O 
Streptococcus O 
pneumoniae O 
, O 
has O 
the O 
capacity O 
to O 
bind O 
actin O 
directly O 
and O 
to O 
enhance O 
actin O 
polymerisation O 
in O 
vitro O 
. O 
In O 
cells O 
, O 
the O 
toxin O 
co O 
- O 
localised O 
with O 
F-actin O 
shortly O 
after O 
exposure O 
, O 
and O 
this O 
direct O 
interaction O 
was O 
verified O 
by O 
Förster O 
resonance O 
energy O 
transfer O 
. O 
PLY O 
was O 
capable O 
of O 
exerting O 
its O 
effect O 
on O 
actin O 
through O 
the O 
lipid O 
bilayer O 
of O 
giant O 
unilamellar O 
vesicles O 
, O 
but O 
only O 
when O 
its O 
pore O 
competence O 
was O 
preserved O 
. O 
The O 
dissociation O 
constant O 
of O 
G-actin O 
binding O 
to O 
PLY O 
in O 
a O 
biochemical O 
environment O 
was O 
170-190 O 
nM O 
, O 
which O 
is O 
indicative O 
of O 
a O 
high O 
- O 
affinity O 
interaction O 
, O 
comparable O 
to O 
the O 
affinity O 
of O 
other O 
intracellular O 
actin O 
- O 
binding O 
factors O 
. O 
Our O 
results O 
demonstrate O 
the O 
first O 
example O 
of O 
a O 
direct O 
interaction O 
of O 
a O 
pore O 
- O 
forming O 
toxin O 
with O 
cytoskeletal O 
components O 
, O 
suggesting O 
that O 
the O 
cross O 
talk O 
between O 
pore O 
- O 
forming O 
cytolysins O 
and O 
cells O 
is O 
more O 
complex O 
than O 
previously O 
thought O 
. O 

of O 
sildenafil B-TRIVIAL 
and O 
tadalafil O 
on O 
the O 
enzyme- O 
and O 
transporter O 
- O 
inducing O 
effects O 
of O 
bosentan B-TRIVIAL 
and O 
ambrisentan B-TRIVIAL 
in O 
LS180 O 
cells O 
. O 

combinations O 
of O 
the O 
endothelin-1 O 
receptor O 
antagonists O 
bosentan B-TRIVIAL 
or O 
ambrisentan B-TRIVIAL 
with O 
the O 
phosphodiesterase O 
5 O 
inhibitors O 
sildenafil B-TRIVIAL 
or O 
tadalafil B-TRIVIAL 
are O 
current O 
standard O 
therapies O 
of O 
advanced O 
pulmonary O 
arterial O 
hypertension O 
. O 
However O 
, O 
these O 
drugs O 
have O 
a O 
number O 
of O 
drug O 
interactions O 
. O 
Changes O 
of O 
bosentan B-TRIVIAL 
pharmacokinetics O 
by O 
sildenafil B-TRIVIAL 
are O 
attributed O 
to O 
reduced O 
hepatic O 
uptake O 
as O 
a O 
consequence O 
of O 
inhibition O 
of O 
organic O 
anion O 
transporting O 
polypeptides O 
. O 
We O 
therefore O 
tested O 
in O 
vitro O 
the O 
hypothesis O 
that O 
sildenafil B-TRIVIAL 
and O 
tadalafil B-TRIVIAL 
reduce O 
the O 
enzyme- O 
and O 
transporter O 
- O 
inducing O 
effects O 
of O 
bosentan B-TRIVIAL 
or O 
ambrisentan B-TRIVIAL 
by O 
preventing O 
cellular O 
access O 
. O 
Although O 
intracellular O 
concentrations O 
of O 
bosentan B-TRIVIAL 
and O 
ambrisentan B-TRIVIAL 
( O 
measured O 
by O 
high O 
pressure O 
liquid O 
chromatography O 
coupled O 
with O 
tandem O 
mass O 
- O 
spectrometry O 
) O 
after O 
four O 
days O 
of O 
incubation O 
of O 
LS180 O 
cells O 
were O 
lower O 
when O 
sildenafil B-TRIVIAL 
or O 
tadalafil B-TRIVIAL 
were O 
present O 
, O 
quantification O 
of O 
mRNA O 
expression O 
in O 
these O 
cells O 
by O 
real O 
- O 
time O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
revealed O 
that O 
bosentan B-TRIVIAL 
and O 
ambrisentan B-TRIVIAL 
-mediated O 
induction O 
was O 
stable O 
or O 
even O 
increased O 
in O 
combination O 
with O 
sildenafil B-TRIVIAL 
or O 
tadalafil B-TRIVIAL 
. O 
For O 
the O 
drug O 
transporter O 
P-glycoprotein O 
this O 
was O 
confirmed O 
at O 
the O 
protein O 
and O 
functional O 
level O 
with O 
highly O 
significant O 
correlations O 
between O 
P-gp O 
mRNA O 
, O 
protein O 
, O 
and O 
function O 
. O 
Moreover O 
, O 
using O 
a O 
reporter O 
gene O 
assay O 
in O 
LS180 O 
cells O 
, O 
our O 
study O 
demonstrates O 
for O 
the O 
first O 
time O 
that O 
tadalafil B-TRIVIAL 
is O 
a O 
potent O 
, O 
ambrisentan B-TRIVIAL 
a O 
weak O 
, O 
and O 
sildenafil B-TRIVIAL 
no O 
activator O 
of O 
pregnane B-TRIVIAL 
X O 
receptor O 
. O 
In O 
conclusion O 
, O 
our O 
study O 
demonstrates O 
that O 
although O 
sildenafil B-TRIVIAL 
and O 
tadalafil B-TRIVIAL 
indeed O 
reduce O 
intracellular O 
concentrations O 
of O 
bosentan B-TRIVIAL 
and O 
ambrisentan B-TRIVIAL 
in O 
LS180 O 
cells O 
, O 
they O 
do O 
not O 
mitigate O 
the O 
inducing O 
effects O 
of O 
these O 
endothelin-1 O 
receptor O 
antagonists O 
. O 

of O 
maprotiline B-TRIVIAL 
-induced O 
apoptosis O 
: O 
role O 
of O 
[ O 
Ca2+ B-FORMULA 
](i O 
) O 
, O 
ERK O 
, O 
JNK O 
and O 
caspase-3 O 
signaling O 
pathways O 
. O 

are O 
generally O 
used O 
for O 
treatment O 
of O 
various O 
mood O 
and O 
anxiety O 
disorders O 
. O 
Several O 
studies O 
have O 
shown O 
the O 
anti-tumor O 
and O 
cytotoxic O 
activities O 
of O 
some O 
antidepressants O 
, O 
but O 
the O 
underlying O 
mechanisms O 
were O 
unclear O 
. O 
Maprotiline B-TRIVIAL 
is O 
a O 
tetracyclic O 
antidepressant O 
and O 
possesses O 
a O 
highly O 
selective O 
norepinephrine B-TRIVIAL 
reuptake O 
ability O 
. O 
We O 
found O 
that O 
maprotiline B-TRIVIAL 
decreased O 
cell O 
viability O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
in O 
Neuro-2a O 
cells O 
. O 
Maprotiline B-TRIVIAL 
induced O 
apoptosis O 
and O 
increased O 
caspase-3 O 
activation O 
. O 
The O 
activation O 
of O 
caspase-3 O 
by O 
maprotiline B-TRIVIAL 
appears O 
to O 
depend O 
on O 
the O 
activation O 
of O 
JNK O 
and O 
the O 
inactivation O 
of O 
ERK O 
. O 
Maprotiline B-TRIVIAL 
also O 
induced O 
[ O 
Ca(2+) B-FORMULA 
](i O 
) O 
increases O 
which O 
involved O 
the O 
mobilization O 
of O 
intracellular O 
Ca(2+) B-FORMULA 
stored O 
in O 
the O 
endoplasmic O 
reticulum O 
. O 
Pretreatment O 
with O 
BAPTA B-ABBREVIATION 
/ O 
AM O 
, O 
a O 
Ca(2+) B-FORMULA 
chelator O 
, O 
suppressed O 
maprotiline B-TRIVIAL 
-induced O 
ERK O 
phosphorylation O 
, O 
enhanced O 
caspase-3 O 
activation O 
and O 
increased O 
maprotiline B-TRIVIAL 
-induced O 
apoptosis O 
. O 
In O 
conclusion O 
, O 
maprotiline B-TRIVIAL 
induced O 
apoptosis O 
in O 
Neuro-2a O 
cells O 
through O 
activation O 
of O 
JNK-associated O 
caspase-3 O 
pathways O 
. O 
Maprotiline B-TRIVIAL 
also O 
evoked O 
an O 
anti-apoptotic O 
response O 
that O 
was O 
both O 
Ca(2+) B-FORMULA 
- O 
and O 
ERK-dependent O 
. O 

blocking O 
the O 
tissue O 
plasminogen O 
activator O 
- O 
dependent O 
activation O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
glutamate B-TRIVIAL 
receptors O 
improves O 
hemorrhagic O 
stroke O 
outcome O 
. O 

and O 
hemorrhagic O 
strokes O 
have O 
different O 
etiologies O 
, O 
but O 
share O 
some O 
pathogenic O 
mechanisms O 
, O 
including O 
a O 
pro O 
- O 
neurotoxic O 
effect O 
of O 
endogenous O 
tissue O 
plasminogen O 
activator O 
( O 
tPA O 
) O 
via O 
N-methyl-d-Aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
. O 
Thus O 
, O 
in O 
a O 
model O 
of O 
intracerebral O 
hemorrhage O 
in O 
rats O 
, O 
we O 
investigated O 
the O 
therapeutic O 
value O 
of O 
a O 
strategy O 
of O 
immunotherapy O 
( O 
αATD-GluN1 O 
antibody O 
) O 
preventing O 
the O 
interaction O 
of O 
tPA O 
with O 
NMDA B-ABBREVIATION 
receptors O 
. O 
We O 
found O 
that O 
a O 
single O 
intravenous O 
injection O 
of O 
αATD-GluN1 O 
reduced O 
brain O 
edema O 
, O 
neuronal O 
death O 
, O 
microglial O 
activation O 
and O 
functional O 
deficits O 
following O 
intracerebral O 
hemorrhage O 
, O 
without O 
affecting O 
the O 
hematoma O 
volume O 
. O 

mollusks O 
use O 
vertebrate O 
sex O 
steroids B-FAMILY 
as O 
reproductive O 
hormones O 
? O 
II O 
. O 
Critical O 
review O 
of O 
the O 
evidence O 
that O 
steroids B-FAMILY 
have O 
biological O 
effects O 
. O 

assessing O 
the O 
evidence O 
as O 
to O 
whether O 
vertebrate O 
sex O 
steroids B-FAMILY 
( O 
e.g O 
. O 
testosterone B-TRIVIAL 
, O 
estradiol B-TRIVIAL 
, O 
progesterone B-TRIVIAL 
) O 
have O 
hormonal O 
actions O 
in O 
mollusks O 
, O 
ca O 
. O 
85% O 
of O 
research O 
papers O 
report O 
at O 
least O 
one O 
biological O 
effect O 
; O 
and O 
18 O 
out O 
of O 
21 O 
review O 
papers O 
( O 
published O 
between O 
1970 O 
and O 
2012 O 
) O 
express O 
a O 
positive O 
view O 
. O 
However O 
, O 
just O 
under O 
half O 
of O 
the O 
research O 
studies O 
can O 
be O 
rejected O 
on O 
the O 
grounds O 
that O 
they O 
did O 
not O 
actually O 
test O 
steroids B-FAMILY 
, O 
but O 
compounds O 
or O 
mixtures O 
that O 
were O 
only O 
presumed O 
to O 
behave O 
as O 
steroids B-FAMILY 
( O 
or O 
modulators O 
of O 
steroids B-FAMILY 
) O 
on O 
the O 
basis O 
of O 
their O 
effects O 
in O 
vertebrates O 
( O 
e.g O 
. O 
Bisphenol-A B-TRIVIAL 
, O 
nonylphenol B-SYSTEMATIC 
and O 
sewage O 
treatment O 
effluents O 
) O 
. O 
Of O 
the O 
remaining O 
55 O 
papers O 
, O 
some O 
can O 
be O 
criticized O 
for O 
having O 
no O 
statistical O 
analysis O 
; O 
some O 
for O 
using O 
only O 
a O 
single O 
dose O 
of O 
steroid B-FAMILY 
; O 
others O 
for O 
having O 
irregular O 
dose O 
- O 
response O 
curves O 
; O 
40 O 
out O 
of O 
the O 
55 O 
for O 
not O 
replicating O 
the O 
treatments O 
; O 
and O 
50 O 
out O 
of O 
55 O 
for O 
having O 
no O 
within O 
- O 
study O 
repetition O 
. O 
Furthermore O 
, O 
most O 
studies O 
had O 
very O 
low O 
effect O 
sizes O 
in O 
comparison O 
to O 
fish O 
- O 
based O 
bioassays O 
for O 
steroids B-FAMILY 
( O 
i.e O 
. O 
they O 
had O 
a O 
very O 
weak O 
' O 
signal O 
- O 
to O 
- O 
noise O 
' O 
ratio O 
) O 
. O 
When O 
these O 
facts O 
are O 
combined O 
with O 
the O 
fact O 
that O 
none O 
of O 
the O 
studies O 
were O 
conducted O 
with O 
rigorous O 
randomization O 
or O 
' O 
blinding O 
' O 
procedures O 
( O 
implying O 
the O 
possibility O 
of O 
' O 
operator O 
bias O 
' O 
) O 
one O 
must O 
conclude O 
that O 
there O 
is O 
no O 
indisputable O 
bioassay O 
evidence O 
that O 
vertebrate O 
sex O 
steroids B-FAMILY 
have O 
endocrinological O 
or O 
reproductive O 
roles O 
in O 
mollusks O 
. O 
The O 
only O 
observation O 
that O 
has O 
been O 
independently O 
validated O 
is O 
the O 
ability O 
of O 
estradiol B-TRIVIAL 
to O 
trigger O 
rapid O 
( O 
1-5 O 
min O 
) O 
lysosomal O 
membrane O 
breakdown O 
in O 
hemocytes O 
of O 
Mytilus O 
spp O 
. O 
This O 
is O 
a O 
typical O 
' O 
inflammatory O 
' O 
response O 
, O 
however O 
, O 
and O 
is O 
not O 
proof O 
that O 
estradiol B-TRIVIAL 
is O 
a O 
hormone O 
- O 
especially O 
when O 
taken O 
in O 
conjunction O 
with O 
the O 
evidence O 
( O 
discussed O 
in O 
a O 
previous O 
review O 
) O 
that O 
mollusks O 
have O 
neither O 
the O 
enzymes O 
necessary O 
to O 
synthesize O 
vertebrate O 
steroids B-FAMILY 
nor O 
nuclear O 
receptors O 
with O 
which O 
to O 
respond O 
to O 
them O 
. O 

effects O 
of O 
Tartary O 
buckwheat O 
( O 
TB O 
) O 
and O 
common O 
buckwheat O 
( O 
CB O 
) O 
on O 
amyloid O 
beta O 
(Aβ)-induced O 
impairment O 
of O 
cognition O 
and O 
memory O 
function O 
were O 
investigated O 
in O 
vivo O 
in O 
order O 
to O 
identify O 
potential O 
therapeutic O 
agents O 
against O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
and O 
its O 
associated O 
progressive O 
memory O 
deficits O 
, O 
cognitive O 
impairment O 
, O 
and O 
personality O 
changes O 
. O 
An O 
in O 
vivo O 
mouse O 
model O 
of O 
AD O 
was O 
created O 
by O 
injecting O 
the O 
brains O 
of O 
ICR O 
mice O 
with O 
Aβ(25-35) O 
, O 
a O 
fragment O 
of O 
the O 
full O 
- O 
length O 
Aβ O 
protein O 
. O 
Damage O 
of O 
mice O 
recognition O 
ability O 
through O 
following O 
Aβ(25-35) O 
brain O 
injections O 
was O 
confirmed O 
using O 
the O 
T-maze O 
test O 
, O 
the O 
object O 
recognition O 
test O 
, O 
and O 
the O 
Morris O 
water O 
maze O 
test O 
. O 
Results O 
of O 
behavior O 
tests O 
in O 
AD O 
model O 
showed O 
that O 
oral O 
administration O 
of O 
the O 
methanol B-SYSTEMATIC 
( O 
MeOH B-FORMULA 
) O 
extracts O 
of O 
TB O 
and O 
CB O 
improved O 
cognition O 
and O 
memory O 
function O 
following O 
Aβ(25-35) O 
injections O 
. O 
Furthermore O 
, O 
in O 
groups O 
receiving O 
the O 
MeOH B-FORMULA 
extracts O 
of O 
TB O 
and O 
CB O 
, O 
lipid O 
peroxidation O 
was O 
significantly O 
inhibited O 
, O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
levels O 
in O 
tissue O 
, O 
which O 
are O 
elevated O 
by O 
injection O 
of O 
Aβ(25-35) O 
, O 
were O 
also O 
decrease O 
. O 
In O 
particular O 
, O 
the O 
MeOH B-FORMULA 
extract O 
of O 
TB O 
exerted O 
a O 
stronger O 
protective O 
activity O 
than O 
CB O 
against O 
Aβ(25-35)-induced O 
memory O 
and O 
cognition O 
impairment O 
. O 
The O 
results O 
indicate O 
that O 
TB O 
may O 
play O 
a O 
promising O 
role O 
in O 
preventing O 
or O 
reversing O 
memory O 
and O 
cognition O 
loss O 
associated O 
with O 
Aβ(25-35)-induced O 
AD O 
. O 

cis-stilbenoids B-FAMILY 
from O 
the O 
tubers O 
of O 
Scirpus O 
yagara O 
. O 

new O 
cis-stilbenoids B-FAMILY 
, O 
sciryagarol B-MULTIPLE 
I I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
II I-MULTIPLE 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
EtOAc B-FORMULA 
extract O 
of O 
the O 
tubers O 
of O 
Scirpus O 
yagara O 
, O 
together O 
with O 
four O 
known O 
compounds O 
. O 
The O 
structures O 
of O 
all O 
compounds O 
were O 
determined O 
by O 
comprehensive O 
analyses O 
of O 
their O 
spectroscopic O 
data O 
and O 
comparison O 
with O 
literature O 
information O 
. O 
The O 
compounds O 
3 O 
, O 
4 O 
and O 
6 O 
were O 
isolated O 
for O 
the O 
first O 
time O 
from O 
this O 
genus O 
. O 
Some O 
compounds O 
were O 
tested O 
for O 
their O 
cytotoxicity O 
against O 
human O 
tumor O 
cell O 
lines O 
and O 
antimicrobial O 
activity O 
. O 
Compounds O 
1-4 O 
showed O 
significant O 
cytotoxicity O 
against O 
the O 
Hela O 
cell O 
lines O 
with O 
IC(50) O 
values O 
ranging O 
from O 
7.21 O 
to O 
61.21μM O 
. O 
1 O 
and O 
2 O 
exhibited O 
some O 
antimicrobial O 
activity O 
against O 
Staphylococcus O 
aureus O 
and O 
Candida O 
albicans O 
with O 
uniform O 
MICs O 
of O 
79.3μl O 
/ O 
ml O 
for O 
2 O 
, O 
and O 
152μl O 
/ O 
ml O 
for O 
1 O 
, O 
respectively O 
. O 

target O 
esterase O 
( O 
NTE O 
) O 
was O 
discovered O 
by O 
M.K O 
. O 
Johnson O 
in O 
his O 
quest O 
for O 
the O 
entity O 
responsible O 
for O 
the O 
striking O 
and O 
mysterious O 
paralysis O 
brought O 
about O 
by O 
certain O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
esters B-FAMILY 
. O 
His O 
pioneering O 
work O 
on O 
OP O 
neuropathy O 
led O 
to O 
the O 
view O 
that O 
the O 
biochemical O 
lesion O 
consisted O 
of O 
NTE O 
that O 
had O 
undergone O 
OP O 
inhibition O 
and O 
aging O 
. O 
Indeed O 
, O 
nonaging O 
NTE O 
inhibitors O 
failed O 
to O 
produce O 
disease O 
but O 
protected O 
against O 
neuropathy O 
from O 
subsequently O 
administered O 
aging O 
inhibitors O 
. O 
Thus O 
, O 
inhibition O 
of O 
NTE O 
activity O 
was O 
not O 
the O 
culprit O 
; O 
rather O 
, O 
formation O 
of O 
an O 
abnormal O 
protein O 
was O 
the O 
agent O 
of O 
the O 
disorder O 
. O 
More O 
recently O 
, O 
however O 
, O 
Paul O 
Glynn O 
and O 
colleagues O 
showed O 
that O 
whereas O 
conventional O 
knockout O 
of O 
the O 
NTE O 
gene O 
was O 
embryonic O 
lethal O 
, O 
conditional O 
knockout O 
of O 
central O 
nervous O 
system O 
NTE O 
produced O 
neurodegeneration O 
, O 
suggesting O 
to O 
these O 
authors O 
that O 
the O 
absence O 
of O 
NTE O 
rather O 
than O 
its O 
presence O 
in O 
some O 
altered O 
form O 
caused O 
disease O 
. O 
We O 
now O 
know O 
that O 
NTE O 
is O 
the O 
6th O 
member O 
of O 
a O 
9- O 
protein O 
family O 
called O 
patatin O 
- O 
like O 
phospholipase O 
domain O 
- O 
containing O 
proteins O 
, O 
PNPLA1-9 O 
. O 
Mutations O 
in O 
the O 
catalytic O 
domain O 
of O 
NTE O 
( O 
PNPLA6 O 
) O 
are O 
associated O 
with O 
a O 
slowly O 
developing O 
disease O 
akin O 
to O 
OP O 
neuropathy O 
and O 
hereditary O 
spastic O 
paraplegia O 
called O 
NTE O 
- O 
related O 
motor O 
neuron O 
disorder O 
( O 
NTE-MND O 
) O 
. O 
Furthermore O 
, O 
the O 
NTE O 
protein O 
from O 
affected O 
individuals O 
has O 
altered O 
enzymological O 
characteristics O 
. O 
Moreover O 
, O 
closely O 
related O 
PNPLA7 O 
is O 
regulated O 
by O 
insulin O 
and O 
glucose B-TRIVIAL 
. O 
These O 
seemingly O 
disparate O 
findings O 
are O 
not O 
necessarily O 
mutually O 
exclusive O 
, O 
but O 
we O 
need O 
to O 
reconcile O 
recent O 
genetic O 
findings O 
with O 
the O 
historical O 
body O 
of O 
toxicological O 
data O 
indicating O 
that O 
inhibition O 
and O 
aging O 
of O 
NTE O 
are O 
both O 
necessary O 
in O 
order O 
to O 
produce O 
neuropathy O 
from O 
exposure O 
to O 
certain O 
OP O 
compounds O 
. O 
Solving O 
this O 
mystery O 
will O 
be O 
satisfying O 
in O 
itself O 
, O 
but O 
it O 
is O 
also O 
an O 
enterprise O 
likely O 
to O 
pay O 
dividends O 
by O 
enhancing O 
our O 
understanding O 
of O 
the O 
physiological O 
and O 
pathogenic O 
roles O 
of O 
the O 
PNPLA O 
family O 
of O 
proteins O 
in O 
neurological O 
health O 
and O 
disease O 
, O 
including O 
a O 
potential O 
role O 
for O 
NTE O 
in O 
diabetic O 
neuropathy O 
. O 

and O 
methylglyoxal B-SYSTEMATIC 
: O 
autoxidation O 
from O 
dihydroxyacetone B-SYSTEMATIC 
and O 
polyphenol B-FAMILY 
cytoprotective O 
antioxidant O 
mechanisms O 
. O 

, O 
this O 
laboratory O 
had O 
shown O 
that O 
fructose B-TRIVIAL 
and O 
its O 
downstream O 
metabolites O 
can O 
be O 
enzymatically O 
metabolized O 
to O 
form O 
glyoxal B-TRIVIAL 
and O 
methylglyoxal B-SYSTEMATIC 
. O 
Fructose B-TRIVIAL 
metabolites O 
, O 
glycoaldehyde B-SYSTEMATIC 
, O 
glyceraldehyde B-TRIVIAL 
and O 
hydroxypyruvate B-SYSTEMATIC 
have O 
also O 
been O 
shown O 
to O 
be O 
autoxidizable O 
. O 
In O 
this O 
study O 
, O 
however O 
, O 
fructose B-TRIVIAL 
did O 
not O 
cause O 
protein O 
carbonylation O 
itself O 
and O 
instead O 
protected O 
against O 
apparent O 
carbonylation O 
by O 
Fenton's O 
reagent O 
; O 
fructose B-TRIVIAL 
did O 
not O 
form O 
significant O 
levels O 
of O 
dicarbonyl B-SYSTEMATIC 
compounds O 
over O 
a O 
period O 
of O 
6 O 
days O 
under O 
standard O 
conditions O 
( O 
37°C O 
, O 
pH O 
7.4 O 
) O 
. O 
In O 
contrast O 
, O 
dihydroxyacetone B-SYSTEMATIC 
, O 
a O 
fructose B-TRIVIAL 
metabolite O 
, O 
caused O 
protein O 
carbonylation O 
and O 
autoxidized O 
to O 
form O 
dicarbonyls B-FAMILY 
, O 
which O 
effects O 
were O 
further O 
potentiated O 
under O 
oxidative O 
stress O 
conditions O 
( O 
Fenton's O 
reaction O 
) O 
. O 
Natural O 
polyphenols B-FAMILY 
were O 
tested O 
for O 
their O 
ability O 
to O 
protect O 
against O 
glyoxal B-TRIVIAL 
- O 
and O 
methylglyoxal B-SYSTEMATIC 
-induced O 
cytotoxicity O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
formation O 
and O 
improved O 
mitochondrial O 
membrane O 
potential O 
maintenance O 
. O 
The O 
polyphenols B-FAMILY 
investigated O 
were O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
methyl B-SYSTEMATIC 
gallate I-SYSTEMATIC 
, O 
ethyl B-SYSTEMATIC 
gallate I-SYSTEMATIC 
, O 
propyl B-SYSTEMATIC 
gallate I-SYSTEMATIC 
, O 
rutin B-TRIVIAL 
and O 
curcumin B-TRIVIAL 
. O 
The O 
polyphenols B-FAMILY 
were O 
assayed O 
using O 
primary O 
and O 
GSH B-ABBREVIATION 
-depleted O 
hepatocytes O 
. O 
The O 
polyphenols B-FAMILY 
were O 
also O 
investigated O 
for O 
their O 
rescuing O 
ability O 
and O 
were O 
found O 
to O 
provide O 
greater O 
hepatoprotection O 
when O 
toxins O 
were O 
pre O 
- O 
incubated O 
for O 
30 O 
min O 
before O 
adding O 
the O 
polyphenols B-FAMILY 
. O 
However O 
, O 
rutin B-TRIVIAL 
was O 
less O 
protective O 
when O 
rescuing O 
hepatocytes O 
, O 
perhaps O 
, O 
because O 
rutin B-TRIVIAL 
metabolites O 
may O 
scavenge O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
more O 
effectively O 
than O 
rutin B-TRIVIAL 
itself O 
. O 
The O 
longer O 
the O 
alkyl B-FAMILY 
group O 
attached O 
to O 
the O 
gallate B-TRIVIAL 
compound O 
, O 
the O 
more O 
cytoprotective O 
the O 
polyphenol B-FAMILY 
was O 
. O 
However O 
, O 
the O 
gallates B-FAMILY 
with O 
longer O 
alkyl B-FAMILY 
groups O 
were O 
less O 
able O 
to O 
scavenge O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
and O 
to O 
maintain O 
the O 
mitochondrial O 
membrane O 
potential O 
. O 

- O 
keto O 
reductases O 
in O 
retinoid B-FAMILY 
metabolism O 
: O 
search O 
for O 
substrate O 
specificity O 
and O 
inhibitor O 
selectivity O 
. O 

activity O 
of O 
natural O 
retinoids B-FAMILY 
requires O 
the O 
oxidation O 
of O 
retinol B-TRIVIAL 
to O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
and O 
its O 
binding O 
to O 
specific O 
nuclear O 
receptors O 
in O 
target O 
tissues O 
. O 
The O 
first O 
step O 
of O 
this O 
pathway O 
, O 
the O 
reversible O 
oxidoreduction O 
of O 
retinol B-TRIVIAL 
to O 
retinaldehyde B-TRIVIAL 
, O 
is O 
essential O 
to O 
control O 
RA O 
levels O 
. O 
The O 
enzymes O 
of O 
retinol B-TRIVIAL 
oxidation O 
are O 
NAD B-ABBREVIATION 
-dependent O 
dehydrogenases O 
of O 
the O 
cytosolic O 
medium O 
- O 
chain O 
( O 
MDR O 
) O 
and O 
the O 
membrane O 
- O 
bound O 
short O 
- O 
chain O 
( O 
SDR O 
) O 
dehydrogenases O 
/ O 
reductases O 
. O 
Retinaldehyde B-TRIVIAL 
reduction O 
can O 
be O 
performed O 
by O 
SDR O 
and O 
aldo O 
- O 
keto O 
reductases O 
( O 
AKR O 
) O 
, O 
while O 
its O 
oxidation O 
to O 
RA O 
is O 
carried O 
out O 
by O 
aldehyde B-SYSTEMATIC 
dehydrogenases O 
( O 
ALDH O 
) O 
. O 
In O 
contrast O 
to O 
SDR O 
, O 
AKR O 
and O 
ALDH O 
are O 
cytosolic O 
. O 
A O 
common O 
property O 
of O 
these O 
enzymes O 
is O 
that O 
they O 
only O 
use O 
free O 
retinoid B-FAMILY 
, O 
but O 
not O 
retinoid B-FAMILY 
bound O 
to O 
cellular O 
retinol B-TRIVIAL 
binding O 
protein O 
( O 
CRBP O 
) O 
. O 
The O 
relative O 
contribution O 
of O 
each O 
enzyme O 
type O 
in O 
retinoid B-FAMILY 
metabolism O 
is O 
discussed O 
in O 
terms O 
of O 
the O 
different O 
subcellular O 
localization O 
, O 
topology O 
of O 
membrane O 
- O 
bound O 
enzymes O 
, O 
kinetic O 
constants O 
, O 
binding O 
affinity O 
of O 
CRBP O 
for O 
retinol B-TRIVIAL 
and O 
retinaldehyde B-TRIVIAL 
, O 
and O 
partition O 
of O 
retinoid B-FAMILY 
pools O 
between O 
membranes O 
and O 
cytoplasm O 
. O 
The O 
development O 
of O 
selective O 
inhibitors O 
for O 
AKR O 
enzymes O 
1B1 O 
and O 
1B10 O 
, O 
of O 
clinical O 
relevance O 
in O 
diabetes O 
and O 
cancer O 
, O 
granted O 
the O 
investigation O 
of O 
some O 
structure O 
- O 
activity O 
relationships O 
. O 
Kinetics O 
with O 
the O 
4-methyl B-SYSTEMATIC 
derivatives O 
of O 
retinaldehyde B-TRIVIAL 
isomers O 
was O 
performed O 
to O 
identify O 
structural O 
features O 
for O 
substrate O 
specificity O 
. O 
Hydrophilic O 
derivatives O 
were O 
better O 
substrates O 
than O 
the O 
more O 
hydrophobic O 
compounds O 
. O 
We O 
also O 
explored O 
the O 
inhibitory O 
properties O 
of O 
some O 
synthetic O 
retinoids B-FAMILY 
, O 
known O 
for O 
binding O 
to O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
receptors O 
( O 
RAR O 
) O 
and O 
retinoid B-FAMILY 
X O 
receptors O 
( O 
RXR O 
) O 
. O 
Consistent O 
with O 
its O 
substrate O 
specificity O 
towards O 
retinaldehyde B-TRIVIAL 
, O 
AKR1B10 O 
was O 
more O 
effectively O 
inhibited O 
by O 
synthetic O 
retinoids B-FAMILY 
than O 
AKR1B1 O 
. O 
A O 
RARβ O 
/ O 
γ O 
agonist O 
( O 
UVI2008 B-IDENTIFIER 
) O 
inhibited O 
AKR1B10 O 
with O 
the O 
highest O 
potency O 
and O 
selectivity O 
, O 
and O 
docking O 
simulations O 
predicted O 
that O 
its O 
carboxyl B-SYSTEMATIC 
group O 
binds O 
to O 
the O 
anion O 
- O 
binding O 
pocket O 
. O 

analysis O 
of O 
limonene B-TRIVIAL 
reaction O 
products O 
using O 
an O 
in O 
vitro O 
exposure O 
system O 
. O 

investigations O 
suggest O 
a O 
link O 
between O 
exposure O 
to O 
indoor O 
air O 
chemicals O 
and O 
adverse O 
health O 
effects O 
. O 
Consumer O 
products O 
contain O 
reactive O 
chemicals O 
which O 
can O 
form O 
secondary O 
pollutants O 
which O 
may O 
contribute O 
to O 
these O 
effects O 
. O 
The O 
reaction O 
of O 
limonene B-TRIVIAL 
and O 
ozone B-TRIVIAL 
is O 
a O 
well O 
characterized O 
example O 
of O 
this O 
type O 
of O 
indoor O 
air O 
chemistry O 
. O 
The O 
studies O 
described O 
here O 
characterize O 
an O 
in O 
vitro O 
model O 
using O 
an O 
epithelial O 
cell O 
line O 
( O 
A549 O 
) O 
or O 
differentiated O 
epithelial O 
tissue O 
( O 
MucilAir O 
™ O 
) O 
. O 
The O 
model O 
is O 
used O 
to O 
investigate O 
adverse O 
effects O 
following O 
exposure O 
to O 
combinations O 
of O 
limonene B-TRIVIAL 
and O 
ozone B-TRIVIAL 
. O 
In O 
A549 O 
cells O 
, O 
exposure O 
to O 
both O 
the O 
parent O 
compounds O 
and O 
reaction O 
products O 
resulted O 
in O 
alterations O 
in O 
inflammatory O 
cytokine O 
production O 
. O 
A O 
one O 
hour O 
exposure O 
to O 
limonene B-TRIVIAL 
+ O 
ozone B-TRIVIAL 
resulted O 
in O 
decreased O 
proliferation O 
when O 
compared O 
to O 
cells O 
exposed O 
to O 
limonene B-TRIVIAL 
alone O 
. O 
Repeated O 
dose O 
exposures O 
of O 
limonene B-TRIVIAL 
or O 
limonene B-TRIVIAL 
+ O 
ozone B-TRIVIAL 
were O 
conducted O 
on O 
MucilAir O 
™ O 
tissue O 
. O 
No O 
change O 
in O 
proliferation O 
was O 
observed O 
but O 
increases O 
in O 
cytokine O 
production O 
were O 
observed O 
for O 
both O 
the O 
parent O 
compounds O 
and O 
reaction O 
products O 
. O 
Factors O 
such O 
as O 
exposure O 
duration O 
, O 
chemical O 
concentration O 
, O 
and O 
sampling O 
time O 
point O 
were O 
identified O 
to O 
influence O 
result O 
outcome O 
. O 
These O 
findings O 
suggest O 
that O 
exposure O 
to O 
reaction O 
products O 
may O 
produce O 
more O 
severe O 
effects O 
compared O 
to O 
the O 
parent O 
compound O 
. O 

monoamines B-FAMILY 
and O 
antidepressant O 
- O 
like O 
responses O 
in O 
MRL O 
/ O 
MpJ O 
versus O 
C57BL O 
/ O 
6J O 
mice O 
. O 

MRL O 
/ O 
MpJ O 
mouse O 
demonstrates O 
enhanced O 
wound O 
healing O 
and O 
tissue O 
regeneration O 
and O 
increased O 
neurotrophic O 
mobilization O 
to O 
chronic O 
antidepressant O 
drug O 
treatments O 
. O 
This O 
study O 
compared O 
brain O 
monoamine B-FAMILY 
systems O 
between O 
MRL O 
/ O 
MpJ O 
and O 
C57BL O 
/ O 
6J O 
mice O 
as O 
a O 
potential O 
basis O 
for O 
strain O 
differences O 
after O 
chronic O 
antidepressant O 
treatment O 
. O 
MRL O 
/ O 
MpJ O 
mice O 
had O 
significantly O 
higher O 
tissue O 
levels O 
of O 
serotonin B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
in O 
multiple O 
brain O 
regions O 
. O 
Microdialysis O 
studies O 
demonstrated O 
that O 
baseline O 
levels O 
of O 
extracellular O 
serotonin B-TRIVIAL 
did O 
not O 
differ O 
between O 
strains O 
. O 
However O 
, O 
acute O 
administration O 
of O 
the O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
citalopram B-TRIVIAL 
produced O 
an O 
increase O 
in O 
extracellular O 
serotonin B-TRIVIAL 
in O 
the O 
ventral O 
hippocampus O 
of O 
MRL O 
/ O 
MpJ O 
mice O 
that O 
was O 
twice O 
as O 
large O 
as O 
achieved O 
in O 
C57BL O 
/ O 
6J O 
mice O 
. O 
The O 
greater O 
effects O 
in O 
MRL O 
/ O 
MpJ O 
mice O 
on O 
5-HT B-SYSTEMATIC 
levels O 
were O 
not O 
maintained O 
after O 
local O 
perfusion O 
of O 
citalopram B-TRIVIAL 
, O 
suggesting O 
that O 
mechanisms O 
outside O 
of O 
the O 
hippocampus O 
were O 
responsible O 
for O 
the O 
greater O 
effect O 
of O 
citalopram B-TRIVIAL 
after O 
systemic O 
injection O 
. O 
The O 
density O 
of O 
serotonin B-TRIVIAL 
and O 
norepinephrine B-TRIVIAL 
transporters O 
in O 
the O 
hippocampus O 
was O 
significantly O 
higher O 
in O 
MRL O 
/ O 
MpJ O 
mice O 
. O 
In O 
addition O 
, O 
the O 
expression O 
of O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
mRNA O 
was O 
lower O 
in O 
the O 
hippocampus O 
, O 
5-HT B-SYSTEMATIC 
( O 
1B O 
) O 
mRNA O 
was O 
higher O 
in O 
the O 
hippocampus O 
and O 
brainstem O 
and O 
SERT O 
mRNA O 
was O 
higher O 
in O 
the O 
brain O 
stem O 
of O 
MRL O 
/ O 
MpJ O 
mice O 
. O 
The O 
exaggerated O 
neurotransmitter O 
release O 
in O 
MRL O 
/ O 
MpJ O 
mice O 
was O 
accompanied O 
by O 
reduced O 
baseline O 
immobility O 
in O 
the O 
tail O 
suspension O 
test O 
and O 
a O 
greater O 
reduction O 
of O 
immobility O 
produced O 
by O 
citalopram B-TRIVIAL 
or O 
the O 
tricyclic O 
antidepressant O 
desipramine B-TRIVIAL 
. O 
These O 
data O 
suggest O 
that O 
differences O 
in O 
the O 
response O 
to O 
acute O 
and O 
chronic O 
antidepressant O 
treatments O 
between O 
the O 
two O 
strains O 
could O 
be O 
attributed O 
to O 
differences O 
in O 
serotonin B-TRIVIAL 
or O 
catecholamine B-TRIVIAL 
transmission O 
. O 

of O 
adolescent O 
social O 
defeat O 
on O 
adult O 
amphetamine B-TRIVIAL 
-induced O 
locomotion O 
and O 
corticoaccumbal O 
dopamine B-TRIVIAL 
release O 
in O 
male O 
rats O 
. O 

of O 
mesocorticolimbic O 
dopamine B-TRIVIAL 
systems O 
occurs O 
during O 
adolescence O 
, O 
and O 
exposure O 
to O 
social O 
stress O 
during O 
this O 
period O 
results O 
in O 
behavioral O 
dysfunction O 
including O 
substance O 
abuse O 
disorders O 
. O 
Adult O 
male O 
rats O 
exposed O 
to O 
repeated O 
social O 
defeat O 
in O 
adolescence O 
exhibit O 
reduced O 
basal O 
dopamine B-TRIVIAL 
tissue O 
content O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
, O 
altered O 
dopamine B-TRIVIAL 
tissue O 
content O 
in O 
corticoaccumbal O 
dopamine B-TRIVIAL 
regions O 
following O 
acute O 
amphetamine B-TRIVIAL 
, O 
and O 
increased O 
amphetamine B-TRIVIAL 
conditioned O 
place O 
preference O 
following O 
repeated O 
amphetamine B-TRIVIAL 
treatment O 
. O 
Such O 
changes O 
may O 
reflect O 
altered O 
amphetamine B-TRIVIAL 
-induced O 
extracellular O 
dopamine B-TRIVIAL 
release O 
in O 
the O 
corticoaccumbal O 
regions O 
. O 
Therefore O 
, O 
we O 
used O 
in O 
vivo O 
microdialysis O 
to O 
measure O 
extracellular O 
dopamine B-TRIVIAL 
simultaneously O 
within O 
the O 
medial O 
prefrontal O 
cortex O 
and O 
nucleus O 
accumbens O 
core O 
of O 
previously O 
defeated O 
rats O 
and O 
controls O 
, O 
in O 
response O 
to O 
either O 
acute O 
or O 
repeated O 
( O 
7 O 
daily O 
injections O 
) O 
of O 
amphetamine B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
. O 
Locomotion O 
responses O 
to O 
acute O 
/ O 
repeated O 
amphetamine B-TRIVIAL 
were O 
also O 
assessed O 
the O 
day O 
prior O 
to O 
taking O 
dopamine B-TRIVIAL 
measurements O 
. O 
Adolescent O 
defeat O 
potentiated O 
adult O 
locomotion O 
responses O 
to O 
acute O 
amphetamine B-TRIVIAL 
, O 
which O 
was O 
negatively O 
correlated O 
with O 
attenuated O 
amphetamine B-TRIVIAL 
-induced O 
dopamine B-TRIVIAL 
release O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
, O 
but O 
there O 
was O 
no O 
difference O 
in O 
amphetamine B-TRIVIAL 
-induced O 
accumbal O 
dopamine B-TRIVIAL 
release O 
. O 
However O 
, O 
both O 
locomotion O 
and O 
corticoaccumbal O 
dopamine B-TRIVIAL 
responses O 
to O 
repeated O 
amphetamine B-TRIVIAL 
were O 
equivalent O 
between O 
previously O 
defeated O 
rats O 
and O 
controls O 
. O 
These O 
data O 
suggest O 
adolescent O 
defeat O 
enhances O 
behavioral O 
responses O 
to O 
initial O 
amphetamine B-TRIVIAL 
exposure O 
as O 
a O 
function O 
of O 
diminished O 
prefrontal O 
cortex O 
dopamine B-TRIVIAL 
activity O 
, O 
which O 
may O 
be O 
sufficient O 
to O 
promote O 
subsequently O 
enhanced O 
seeking O 
of O 
drug O 
- O 
associated O 
cues O 
. O 
Interestingly O 
, O 
repeated O 
amphetamine B-TRIVIAL 
treatment O 
appears O 
to O 
normalize O 
amphetamine B-TRIVIAL 
-elicited O 
locomotion O 
and O 
cortical O 
dopamine B-TRIVIAL 
responses O 
observed O 
in O 
adult O 
rats O 
exposed O 
to O 
adolescent O 
social O 
defeat O 
, O 
providing O 
implications O 
for O 
treating O 
stress O 
- O 
induced O 
dopamine B-TRIVIAL 
dysfunction O 
. O 

responses O 
of O 
two O 
species O 
of O 
marine O 
phytoplankton O 
to O 
metolachlor B-TRIVIAL 
exposure O 
. O 

, O 
a O 
chloroacetanilide B-SYSTEMATIC 
herbicide O 
, O 
has O 
been O 
frequently O 
detected O 
in O 
coastal O 
waters O 
. O 
This O 
study O 
examined O 
the O 
growth O 
, O 
photosynthesis O 
, O 
and O 
detoxification O 
responses O 
of O 
chlorophyte O 
Dunaliella O 
tertiolecta O 
( O 
DT O 
) O 
and O 
brown O 
tide O 
alga O 
Aureococcus O 
anophagefferens O 
( O 
AA O 
) O 
upon O 
5-day O 
exposure O 
to O 
0.5-5 O 
mg O 
L(-1) O 
metolachlor B-TRIVIAL 
. O 
Growth O 
was O 
assessed O 
with O 
exponential O 
growth O 
rate O 
, O 
and O 
5th O 
day O 
in O 
vivo O 
chlorophyll O 
fluorescence O 
, O 
chlorophyll B-MULTIPLE 
a I-MULTIPLE 
, I-MULTIPLE 
b I-MULTIPLE 
or I-MULTIPLE 
c I-MULTIPLE 
, O 
cell O 
density O 
and O 
cell O 
size O 
. O 
The O 
photosynthesis O 
function O 
was O 
assessed O 
with O 
photochemical O 
parameters O 
of O 
photosystem O 
II O 
( O 
PSII O 
) O 
during O 
the O 
mid O 
- O 
exponential O 
growth O 
phase O 
( O 
i.e O 
. O 
2-4 O 
day O 
metolachlor B-TRIVIAL 
exposure O 
) O 
. O 
The O 
biochemical O 
detoxification O 
was O 
analyzed O 
with O 
glutathione B-TRIVIAL 
production O 
and O 
metolachlor B-TRIVIAL 
degradation O 
. O 
Results O 
show O 
that O 
metolachlor B-TRIVIAL 
caused O 
up O 
to O 
∼9% O 
inhibition O 
in O 
growth O 
rate O 
in O 
both O 
species O 
and O 
an O 
expected O 
∼35% O 
and O 
25% O 
inhibition O 
in O 
chlorophyll O 
based O 
endpoints O 
in O 
DT O 
and O 
AA O 
respectively O 
. O 
DT O 
had O 
an O 
up O 
to O 
70% O 
inhibition O 
in O 
cell O 
density O 
, O 
but O 
AA O 
a O 
35% O 
hormesis O 
at O 
1 O 
mg O 
L(-1) O 
metolachlor B-TRIVIAL 
and O 
no O 
significant O 
inhibition O 
, O 
as O 
compared O 
to O 
the O 
controls O 
. O 
Both O 
DT O 
and O 
AA's O 
cell O 
sizes O 
were O 
enlarged O 
by O 
metolachlor B-TRIVIAL 
exposure O 
, O 
but O 
greater O 
in O 
DT O 
( O 
1.2% O 
per O 
mg O 
L(-1) O 
) O 
than O 
in O 
AA O 
( O 
0.68% O 
per O 
mg O 
L(-1) O 
) O 
. O 
On O 
PSII O 
photochemistry O 
, O 
maximum O 
quantum O 
yield O 
was O 
not O 
affected O 
in O 
both O 
species O 
; O 
PSII O 
optical O 
cross O 
section O 
and O 
connectivity O 
factor O 
increased O 
in O 
DT O 
but O 
decreased O 
in O 
AA O 
, O 
suggesting O 
species O 
specific O 
impact O 
on O 
PSII O 
function O 
. O 
On O 
detoxification O 
responses O 
, O 
glutathione B-TRIVIAL 
production O 
, O 
when O 
normalized O 
to O 
total O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
, O 
was O 
not O 
affected O 
by O 
metolachlor B-TRIVIAL 
in O 
both O 
species O 
; O 
further O 
, O 
despite O 
of O 
heterotrophic O 
capacity O 
of O 
A O 
. O 
anophagefferens O 
metolachlor B-TRIVIAL 
was O 
not O 
significantly O 
degraded O 
by O 
this O 
alga O 
during O 
the O 
5-day O 
incubation O 
. O 
The O 
species O 
specific O 
effects O 
on O 
algal O 
growth O 
have O 
ecological O 
implications O 
of O 
potential O 
selective O 
inhibition O 
of O 
chlorophytes O 
by O 
metolachlor B-TRIVIAL 
herbicide O 
. O 

of O 
zebrafish O 
embryos O 
/ O 
larvae O 
to O 
TDCPP B-ABBREVIATION 
alters O 
concentrations O 
of O 
thyroid O 
hormones O 
and O 
transcriptions O 
of O 
genes O 
involved O 
in O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
thyroid O 
axis O 
. O 

phosphate I-SYSTEMATIC 
( O 
TDCPP B-ABBREVIATION 
) O 
has O 
been O 
frequently O 
detected O 
in O 
the O 
environment O 
and O 
in O 
various O 
biota O 
, O 
including O 
fish O 
, O 
and O 
has O 
been O 
implicated O 
in O 
disruption O 
of O 
the O 
thyroid O 
endocrine O 
system O 
. O 
In O 
the O 
present O 
study O 
, O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
embryos O 
were O 
exposed O 
to O 
different O 
concentrations O 
of O 
TDCPP B-ABBREVIATION 
( O 
10 O 
, O 
50 O 
, O 
100 O 
, O 
300 O 
and O 
600 O 
μg O 
/ O 
L O 
) O 
from O 
2 O 
h O 
post O 
- O 
fertilization O 
( O 
hpf O 
) O 
to O 
144 O 
hpf O 
. O 
Developmental O 
endpoints O 
, O 
and O 
whole O 
- O 
body O 
concentrations O 
of O 
thyroid O 
hormones O 
and O 
transcriptional O 
profiles O 
of O 
genes O 
involved O 
in O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
thyroid O 
( O 
HPT O 
) O 
axis O 
were O 
examined O 
. O 
Exposure O 
to O 
TDCPP B-ABBREVIATION 
caused O 
a O 
dose O 
- O 
dependent O 
developmental O 
toxicity O 
, O 
including O 
decreased O 
body O 
weight O 
, O 
reduced O 
hatching O 
, O 
survival O 
and O 
heartbeat O 
rates O 
, O 
and O 
increased O 
malformation O 
( O 
spinal O 
curvature O 
) O 
. O 
Treatment O 
with O 
the O 
positive O 
control O 
chemical O 
3,3',5-triiodo-l-thyronine B-SYSTEMATIC 
( O 
T3 O 
) O 
significantly O 
decreased O 
whole O 
- O 
body O 
thyroxin B-TRIVIAL 
( I-TRIVIAL 
T4 I-TRIVIAL 
) I-TRIVIAL 
concentrations O 
, O 
increased O 
whole O 
- O 
body O 
T3 O 
concentrations O 
, O 
and O 
upregulated O 
mRNA O 
expression O 
involved O 
in O 
the O 
HPT O 
axis O 
as O 
a O 
compensatory O 
mechanism O 
. O 
These O 
results O 
suggested O 
that O 
the O 
HPT O 
axis O 
in O 
144-hpf O 
zebrafish O 
larvae O 
was O 
responsive O 
to O 
chemical O 
exposure O 
and O 
could O 
be O 
used O 
to O 
evaluate O 
the O 
effects O 
of O 
chemicals O 
on O 
the O 
thyroid O 
endocrine O 
system O 
. O 
TDCPP B-ABBREVIATION 
exposure O 
significantly O 
decreased O 
whole O 
- O 
body O 
T4 O 
concentrations O 
and O 
increased O 
whole O 
- O 
body O 
T3 O 
concentrations O 
, O 
indicating O 
thyroid O 
endocrine O 
disruption O 
. O 
The O 
upregulation O 
of O 
genes O 
related O 
to O 
thyroid O 
hormone O 
metabolism O 
( O 
dio1 O 
and O 
ugt1ab O 
) O 
might O 
be O 
responsible O 
for O 
decreased O 
T4 O 
concentrations O 
. O 
Treatment O 
with O 
TDCPP B-ABBREVIATION 
also O 
significantly O 
increased O 
transcription O 
of O 
genes O 
involved O 
in O 
thyroid O 
hormone O 
synthesis O 
( O 
tshβ O 
, O 
slc5a5 O 
and O 
tg O 
) O 
and O 
thyroid O 
development O 
( O 
hhex O 
, O 
nkx2.1 O 
and O 
pax8 O 
) O 
as O 
a O 
compensatory O 
mechanism O 
for O 
decreased O 
T4 O 
concentrations O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
TDCPP B-ABBREVIATION 
alters O 
the O 
transcription O 
of O 
genes O 
involved O 
in O 
the O 
HPT O 
axis O 
and O 
changes O 
whole O 
- O 
body O 
concentrations O 
of O 
thyroid O 
hormones O 
in O 
zebrafish O 
embryos O 
/ O 
larvae O 
, O 
thus O 
causing O 
an O 
endocrine O 
disruption O 
of O 
the O 
thyroid O 
system O 
. O 

hepatocellular O 
cancer O 
initiating O 
effects O 
in O 
rat O 
liver O 
. O 

( O 
MEG B-ABBREVIATION 
) O 
, O 
a O 
constituent O 
of O 
plants O 
used O 
in O 
the O 
human O 
diet O 
, O 
is O 
hepatocarcinogenic O 
in O 
rodents O 
. O 
In O 
an O 
experiment O 
to O 
elucidate O 
its O 
mode O 
of O 
action O 
in O 
rat O 
liver O 
, O 
male O 
F344 O 
rats O 
were O 
administered O 
MEG B-ABBREVIATION 
intragastrically O 
at O 
3 O 
doses O 
per O 
week O 
for O 
up O 
to O 
16 O 
weeks O 
in O 
an O 
initiation O 
phase O 
, O 
after O 
which O 
half O 
the O 
rats O 
were O 
fed O 
500 O 
ppm O 
phenobarbital B-TRIVIAL 
( O 
PB O 
) O 
in O 
the O 
diet O 
to O 
promote O 
liver O 
neoplasia O 
and O 
the O 
other O 
half O 
were O 
maintained O 
on O 
control O 
diet O 
for O 
24 O 
weeks O 
. O 
At O 
8 O 
and O 
16 O 
week O 
interim O 
terminations O 
, O 
(32)P B-FORMULA 
-nucleotide O 
postlabeling O 
assay O 
revealed O 
3 O 
adducts O 
in O 
livers O 
of O 
all O 
MEG B-ABBREVIATION 
groups O 
. O 
The O 
hepatocellular O 
replicating O 
fractions O 
, O 
measured O 
by O 
proliferating O 
cell O 
nuclear O 
antigen O 
immunohistochemistry O 
, O 
were O 
doubled O 
or O 
more O 
in O 
all O 
MEG B-ABBREVIATION 
groups O 
. O 
Hepatocellular O 
altered O 
foci O 
, O 
detected O 
by O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
- O 
placental O 
type O 
( O 
π O 
) O 
immunohistochemistry O 
, O 
were O 
present O 
beginning O 
with O 
the O 
high O 
dose O 
group O 
at O 
8 O 
weeks O 
and O 
extending O 
to O 
all O 
MEG B-ABBREVIATION 
groups O 
at O 
16 O 
weeks O 
. O 
At O 
the O 
end O 
of O 
maintenance O 
/ O 
promotion O 
phase O 
, O 
the O 
incidences O 
, O 
multiplicity O 
and O 
size O 
of O 
foci O 
was O 
similar O 
between O 
control O 
and O 
low O 
dose O 
groups O 
, O 
while O 
those O 
of O 
mid O 
and O 
high O 
dose O 
groups O 
were O 
increased O 
. O 
Hepatocellular O 
adenomas O 
occurred O 
in O 
the O 
mid O 
and O 
high O 
dose O 
groups O 
, O 
attaining O 
higher O 
multiplicity O 
and O 
size O 
with O 
PB O 
. O 
Thus O 
, O 
MEG B-ABBREVIATION 
had O 
rapid O 
initiating O 
activity O 
, O 
reflecting O 
the O 
formation O 
of O 
DNA O 
adducts O 
and O 
possibly O 
cell O 
proliferation O 
. O 

of O 
linalool B-TRIVIAL 
as O 
a O 
component O 
of O 
Humulus O 
lupulus O 
on O 
doxorubicin B-TRIVIAL 
-induced O 
antitumor O 
activity O 
. O 

malignant O 
neoplasm O 
is O 
a O 
major O 
public O 
health O 
problem O 
, O 
there O 
is O 
a O 
need O 
for O 
the O 
development O 
of O 
a O 
novel O 
modulator O 
that O 
enhances O 
antitumor O 
activity O 
and O 
reduces O 
adverse O 
reactions O 
to O 
antitumor O 
agents O 
. O 
In O 
this O 
study O 
, O 
the O 
effects O 
of O 
some O 
volatile O 
oil O 
components O 
in O 
Humulus O 
lupulus O 
on O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
permeability O 
in O 
tumor O 
cells O 
and O 
DOX B-ABBREVIATION 
-induced O 
antitumor O 
activity O 
were O 
examined O 
. O 
In O 
vitro O 
, O 
DOX B-ABBREVIATION 
levels O 
in O 
tumor O 
cells O 
by O 
combined O 
linalool B-TRIVIAL 
as O 
its O 
component O 
significantly O 
increased O 
in O 
the O 
DOX B-ABBREVIATION 
influx O 
system O 
, O 
and O 
the O 
increased O 
effect O 
by O 
linalool B-TRIVIAL 
on O 
DOX B-ABBREVIATION 
cytotoxicity O 
was O 
shown O 
. O 
In O 
vivo O 
, O 
the O 
combination O 
of O 
DOX B-ABBREVIATION 
with O 
linalool B-TRIVIAL 
significantly O 
decreased O 
tumor O 
weight O 
compared O 
with O 
that O 
of O 
DOX B-ABBREVIATION 
alone O 
treated O 
group O 
. O 
The O 
promotion O 
of O 
DOX B-ABBREVIATION 
influx O 
level O 
by O 
combined O 
linalool B-TRIVIAL 
did O 
not O 
depend O 
on O 
energy O 
, O 
whereas O 
it O 
was O 
suppressed O 
by O 
the O 
absence O 
of O 
Na(+) B-FORMULA 
. O 
This O 
promoting O 
effect O 
was O 
suppressed O 
by O 
the O 
presence O 
of O 
S-(4-nitrobenzyl)-6-thioinosine B-SYSTEMATIC 
and O 
inhibited O 
dependently O 
on O 
phlorizin B-TRIVIAL 
concentration O 
. O 
It O 
is O 
considered O 
that O 
linalool B-TRIVIAL 
promoted O 
DOX B-ABBREVIATION 
influx O 
in O 
tumor O 
cells O 
because O 
of O 
its O 
action O 
on O 
DOX B-ABBREVIATION 
transport O 
through O 
concentrative O 
Na(+) B-FORMULA 
-dependent O 
nucleoside B-FAMILY 
transporter O 
3 O 
, O 
which O 
increased O 
DOX B-ABBREVIATION 
concentration O 
in O 
tumor O 
cells O 
and O 
thus O 
enhanced O 
the O 
antitumor O 
activity O 
of O 
DOX B-ABBREVIATION 
. O 
Therefore O 
, O 
linalool B-TRIVIAL 
as O 
a O 
food O 
component O 
is O 
anticipated O 
to O 
be O 
an O 
effective O 
DOX B-ABBREVIATION 
modulator O 
. O 

level O 
prenatal O 
exposure O 
to O 
methylmercury B-SYSTEMATIC 
disrupts O 
neuronal O 
migration O 
in O 
the O 
developing O 
rat O 
cerebral O 
cortex O 
. O 

determined O 
the O 
effects O 
of O 
low O 
- O 
level O 
prenatal O 
MeHg B-FORMULA 
exposure O 
on O 
neuronal O 
migration O 
in O 
the O 
developing O 
rat O 
cerebral O 
cortex O 
using O 
in O 
utero O 
electroporation O 
. O 
We O 
used O 
offspring O 
rats O 
born O 
to O 
dams O 
that O 
had O 
been O 
exposed O 
to O 
saline O 
or O 
various O 
doses O 
of O 
MeHg B-FORMULA 
( O 
0.01 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
0.1 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
and O 
1 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
from O 
gestational O 
day O 
( O 
GD O 
) O 
11-21 O 
. O 
Immunohistochemical O 
examination O 
of O 
the O 
brains O 
of O 
the O 
offspring O 
was O 
conducted O 
on O 
postnatal O 
day O 
( O 
PND O 
) O 
0 O 
, O 
PND3 O 
, O 
and O 
PND7 O 
. O 
Our O 
results O 
showed O 
that O 
prenatal O 
exposure O 
to O 
low O 
levels O 
of O 
MeHg B-FORMULA 
( O 
0.1 O 
mg O 
/ O 
kg O 
/ O 
day O 
or O 
1 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
during O 
the O 
critical O 
stage O 
in O 
neuronal O 
migration O 
resulted O 
in O 
migration O 
defects O 
of O 
the O 
cerebrocortical O 
neurons O 
in O 
offspring O 
rats O 
. O 
Importantly O 
, O 
our O 
data O 
revealed O 
that O 
the O 
abnormal O 
neuronal O 
distribution O 
induced O 
by O 
MeHg B-FORMULA 
was O 
not O 
caused O 
by O 
altered O 
proliferation O 
of O 
neural O 
progenitor O 
cells O 
( O 
NPCs O 
) O 
, O 
induction O 
of O 
apoptosis O 
of O 
NPCs O 
and O 
/ O 
or O 
newborn O 
neurons O 
, O 
abnormal O 
differentiation O 
of O 
NPCs O 
, O 
and O 
the O 
morphological O 
changes O 
of O 
radial O 
glial O 
scaffold O 
, O 
indicating O 
that O 
the O 
defective O 
neuronal O 
positioning O 
triggered O 
by O 
exposure O 
to O 
low O 
- O 
dose O 
of O 
MeHg B-FORMULA 
is O 
due O 
to O 
the O 
impacts O 
of O 
MeHg B-FORMULA 
on O 
the O 
process O 
of O 
neuronal O 
migration O 
itself O 
. O 
Moreover O 
, O 
we O 
demonstrated O 
that O 
in O 
utero O 
exposure O 
to O 
low O 
- O 
level O 
MeHg B-FORMULA 
suppresses O 
the O 
expression O 
of O 
Rac1 O 
, O 
Cdc42 O 
, O 
and O 
RhoA O 
, O 
which O 
play O 
key O 
roles O 
in O 
the O 
migration O 
of O 
cerebrocortical O 
neurons O 
during O 
the O 
early O 
stage O 
of O 
brain O 
development O 
, O 
suggesting O 
that O 
the O 
MeHg B-FORMULA 
-induced O 
migratory O 
disturbance O 
of O 
cerebrocortical O 
neurons O 
is O 
likely O 
associated O 
with O 
the O 
Rho O 
GTPases O 
signal O 
pathway O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
provide O 
a O 
novel O 
perspective O 
on O 
clarifying O 
the O 
mechanisms O 
underlying O 
the O 
impairment O 
of O 
neuronal O 
migration O 
induced O 
by O 
MeHg B-FORMULA 
. O 

expression O 
of O 
the O 
tight O 
junction O 
proteins O 
is O 
involved O 
in O 
clopidogrel B-TRIVIAL 
-induced O 
gastric O 
injury O 
through O 
p38 O 
MAPK O 
activation O 
. O 

complications O 
and O 
delayed O 
healing O 
of O 
gastric O 
ulcer O 
associated O 
with O 
use O 
of O 
clopidogrel B-TRIVIAL 
is O 
a O 
common O 
clinical O 
concern O 
; O 
however O 
, O 
the O 
underlying O 
mechanisms O 
remain O 
to O 
be O 
determined O 
. O 
This O 
study O 
aimed O 
to O 
clarify O 
whether O 
clopidogrel B-TRIVIAL 
could O 
cause O 
the O 
damage O 
of O 
the O 
human O 
gastric O 
epithelial O 
cells O 
and O 
to O 
further O 
elucidate O 
the O 
mechanisms O 
involved O 
. O 
After O 
human O 
gastric O 
epithelial O 
cell O 
line O 
GES-1 O 
had O 
been O 
treated O 
with O 
clopidogrel B-TRIVIAL 
( O 
0.5-2.5 O 
mM O 
) O 
, O 
the O 
cell O 
proliferation O 
was O 
examined O 
by O 
MTT B-ABBREVIATION 
assay O 
, O 
apoptosis O 
was O 
measured O 
with O 
DAPI B-ABBREVIATION 
staining O 
and O 
flow O 
cytometry O 
analysis O 
, O 
and O 
the O 
barrier O 
function O 
of O 
the O 
tight O 
junctions O 
( O 
TJ O 
) O 
was O 
evaluated O 
by O 
permeability O 
measurement O 
and O 
transmission O 
electron O 
microscopy O 
. O 
Moreover O 
, O 
expression O 
of O 
the O 
TJ O 
proteins O 
occludin O 
and O 
ZO-1 O 
and O 
the O 
phosphorylation O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPK O 
) O 
p38 O 
, O 
ERK O 
, O 
and O 
JNK O 
were O 
examined O 
by O 
western O 
blot O 
. O 
In O 
addition O 
, O 
three O 
MAPK O 
inhibitors O 
specific O 
to O 
p38 O 
, O 
ERK O 
and O 
JNK O 
were O 
used O 
, O 
respectively O 
, O 
to O 
verify O 
the O 
signaling O 
pathways O 
responsible O 
for O 
regulating O 
the O 
expression O 
of O 
the O 
TJ O 
proteins O 
being O 
tested O 
. O 
Results O 
showed O 
that O 
clopidogrel B-TRIVIAL 
significantly O 
increased O 
dextran O 
permeability O 
, O 
induced O 
apoptosis O 
, O 
suppressed O 
GES-1 O 
cell O 
viability O 
, O 
and O 
reduced O 
the O 
expression O 
of O 
the O 
TJ O 
proteins O 
( O 
occludin O 
and O 
ZO-1 O 
) O 
, O 
acting O 
through O 
p38 O 
MAPK O 
phosphorylation O 
. O 
Furthermore O 
, O 
these O 
observed O 
effects O 
were O 
partially O 
abolished O 
by O 
SB-203580 B-IDENTIFIER 
( O 
a O 
p38 O 
MAPK O 
inhibitor O 
) O 
, O 
rather O 
than O 
by O 
either O 
U-0126 B-IDENTIFIER 
( O 
an O 
ERK O 
inhibitor O 
) O 
or O 
SP-600125 B-IDENTIFIER 
( O 
a O 
JNK O 
inhibitor O 
) O 
, O 
suggesting O 
that O 
clopidogrel B-TRIVIAL 
-induced O 
disruption O 
in O 
the O 
gastric O 
epithelial O 
cells O 
is O 
mediated O 
by O 
the O 
p38 O 
MAPK O 
pathway O 
. O 
It O 
is O 
concluded O 
that O 
attenuated O 
expression O 
of O 
the O 
TJ O 
proteins O 
occludin O 
and O 
ZO-1 O 
in O 
human O 
gastric O 
epithelial O 
cells O 
could O 
be O 
involved O 
in O 
clopidogrel B-TRIVIAL 
-induced O 
gastric O 
mucosal O 
injury O 
through O 
activation O 
of O 
the O 
p38 O 
MAPK O 
pathway O 
. O 

of O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
conjugation O 
on O 
the O 
circulatory O 
stability O 
of O 
plasma O 
- O 
derived O 
human O 
butyrylcholinesterase O 
in O 
mice O 
. O 

administered O 
human O 
serum O 
butyrylcholinesterase O 
( O 
Hu O 
BChE O 
) O 
was O 
demonstrated O 
to O 
function O 
as O 
a O 
bioscavenger O 
of O 
highly O 
toxic O 
organophosphorus B-FAMILY 
( O 
OP O 
) O 
compounds O 
in O 
several O 
animal O 
species O 
. O 
Since O 
the O 
enzyme O 
is O 
isolated O 
from O 
human O 
serum O 
, O 
it O 
is O 
currently O 
the O 
most O 
suitable O 
pretreatment O 
for O 
human O 
use O 
. O 
A O 
dose O 
of O 
200-300mg O 
/ O 
70kg O 
human O 
adult O 
is O 
projected O 
to O 
provide O 
protection O 
from O 
2 O 
X O 
LD50 O 
of O 
soman B-TRIVIAL 
. O 
Due O 
to O 
the O 
limited O 
supply O 
of O 
Hu O 
BChE O 
, O 
strategies O 
aimed O 
at O 
reducing O 
the O 
dose O 
of O 
enzyme O 
are O 
being O 
explored O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
modification O 
with O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
on O 
the O 
in O 
vivo O 
stability O 
of O 
Hu O 
BChE O 
. O 
Mice O 
were O 
given O 
two O 
injections O 
of O 
either O 
Hu O 
BChE O 
or O 
Hu O 
BChE O 
modified O 
with O 
PEG B-ABBREVIATION 
-5K O 
or O 
PEG B-ABBREVIATION 
-20K O 
, O 
six O 
weeks O 
apart O 
. O 
Pharmacokinetic O 
parameters O 
, O 
such O 
as O 
mean O 
residence O 
time O 
( O 
MRT O 
) O 
, O 
maximal O 
concentration O 
( O 
Cmax O 
) O 
, O 
elimination O 
half O 
- O 
life O 
( O 
T1 O 
/ O 
2 O 
) O 
, O 
and O 
area O 
under O 
the O 
plasma O 
concentration O 
time O 
curve O 
extrapolated O 
to O 
infinity O 
( O 
AUC O 
) O 
, O 
were O 
determined O 
. O 
For O 
the O 
first O 
injection O 
, O 
values O 
for O 
MRT O 
, O 
T1 O 
/ O 
2 O 
, O 
Cmax O 
, O 
and O 
AUC O 
for O 
PEG B-ABBREVIATION 
-5K-Hu O 
BChE O 
and O 
PEG B-ABBREVIATION 
-20K-Hu O 
BChE O 
were O 
similar O 
to O 
those O 
for O 
Hu O 
BChE O 
. O 
These O 
values O 
for O 
the O 
second O 
injection O 
of O 
Hu O 
BChE O 
as O 
well O 
as O 
PEG B-ABBREVIATION 
-Hu O 
BChEs O 
were O 
lower O 
as O 
compared O 
to O 
those O 
for O 
the O 
first O 
injections O 
, O 
likely O 
due O 
to O 
antibody O 
- O 
mediated O 
clearance O 
. O 

and O 
chloroacetaldehyde B-SYSTEMATIC 
: O 
an O 
examination O 
of O 
the O 
cell O 
and O 
cell O 
- O 
free O 
biomarkers O 
of O 
toxicity O 
. O 

and O 
ifosfamide B-TRIVIAL 
are O 
two O 
commonly O 
used O 
DNA-alkylating O 
agents O 
in O 
cancer O 
chemotherapy O 
that O 
undergo O 
biotransformation O 
to O 
several O 
toxic O 
and O 
non-toxic O 
metabolites O 
, O 
including O 
acrolein B-TRIVIAL 
and O 
chloroacetaldehyde B-SYSTEMATIC 
( O 
CAA B-ABBREVIATION 
) O 
. O 
Acrolein B-TRIVIAL 
and O 
CAA B-ABBREVIATION 
toxicities O 
occur O 
by O 
several O 
different O 
mechanisms O 
, O 
including O 
ROS O 
formation O 
and O 
protein O 
damage O 
( O 
oxidation O 
) O 
, O 
however O 
, O 
these O 
pathways O 
of O 
toxicity O 
and O 
protecting O 
agents O 
used O 
to O 
prevent O 
them O 
have O 
yet O 
to O 
be O 
compared O 
and O 
ranked O 
in O 
a O 
single O 
study O 
. O 
This O 
research O 
focused O 
on O 
the O 
molecular O 
targets O 
of O 
acrolein B-TRIVIAL 
and O 
CAA B-ABBREVIATION 
toxicities O 
and O 
strategies O 
to O 
decrease O 
toxicities O 
. O 
Hepatocyte O 
viability O 
( O 
cytotoxicity O 
) O 
was O 
assessed O 
using O 
Trypan B-TRIVIAL 
blue I-TRIVIAL 
uptake O 
; O 
formation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
endogenous O 
H2O2 B-FORMULA 
were O 
also O 
assessed O 
in O 
the O 
hepatocyte O 
model O 
. O 
In O 
cell O 
- O 
free O 
models O 
( O 
bovine O 
serum O 
albumin O 
and O 
hepatic O 
microsomes O 
) O 
, O 
protein O 
carbonylation O 
was O 
the O 
measurement O 
of O 
toxicity O 
. O 
The O 
present O 
study O 
demonstrated O 
that O 
acrolein B-TRIVIAL 
was O 
a O 
more O 
potent O 
toxin O 
than O 
CAA B-ABBREVIATION 
for O 
freshly O 
isolated O 
rat O 
hepatocytes O 
, O 
bovine O 
serum O 
albumin O 
and O 
rat O 
hepatic O 
microsomes O 
. O 
Acrolein B-TRIVIAL 
protein O 
carbonylation O 
was O 
dependent O 
on O 
its O 
concentration O 
; O 
as O 
acrolein B-TRIVIAL 
concentration O 
increased O 
, O 
protein O 
carbonylation O 
increased O 
in O 
a O 
linear O 
trend O 
, O 
whereas O 
, O 
CAA B-ABBREVIATION 
deviated O 
from O 
the O 
trend O 
and O 
did O 
not O 
cause O 
protein O 
carbonylation O 
at O 
lower O 
concentrations O 
( O 
< O 
400 O 
μM O 
) O 
. O 
Aldehyde B-SYSTEMATIC 
dehydrogenase O 
( O 
ALDH O 
) O 
is O 
a O 
major O 
pathway O 
for O 
detoxifying O 
pathway O 
for O 
CAA B-ABBREVIATION 
in O 
hepatocytes O 
, O 
as O 
a O 
3-fold O 
increase O 
in O 
cytotoxicity O 
occurred O 
when O 
cells O 
were O 
incubated O 
with O 
cyanamide B-SYSTEMATIC 
, O 
an O 
ALDH O 
inhibitor O 
. O 
Inhibiting O 
ALDH O 
or O 
depleting O 
GSH O 
in O 
hepatocytes O 
increased O 
cytotoxicity O 
by O 
about O 
3-fold O 
in O 
acrolein B-TRIVIAL 
-treated O 
hepatocytes O 
. O 
The O 
overall O 
effectiveness O 
of O 
protecting O 
agents O 
to O 
prevent O 
or O 
suppress O 
acrolein B-TRIVIAL 
or O 
CAA B-ABBREVIATION 
toxicities O 
in O 
cell O 
and O 
cell O 
- O 
free O 
models O 
were O 
ranked O 
in O 
order O 
of O 
most O 
effective O 
to O 
least O 
effective O 
: O 
reducing O 
agents O 
( O 
sodium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
, O 
sodium B-SYSTEMATIC 
bisulfite I-SYSTEMATIC 
)> O 
thiol B-FAMILY 
-containing O 
compounds O 
( O 
N-acetylcysteine B-SYSTEMATIC 
, O 
cysteine B-TRIVIAL 
, O 
glutathione B-TRIVIAL 
, O 
2-mercaptoethane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
[ O 
MESNA B-ABBREVIATION 
] O 
, O 
penicillamine B-TRIVIAL 
)> O 
carbonyl B-FAMILY 
scavengers/ O 
amines B-FAMILY 
( O 
aminoguanidine B-SYSTEMATIC 
, O 
hydralazine B-SYSTEMATIC 
, O 
hydroxylamine B-SYSTEMATIC 
) O 
> O 
antioxidants O 
/ O 
ROS O 
scavengers O 
( O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
Trolox B-TRIVIAL 
; O 
only O 
utilized O 
in O 
hepatocyte O 
system O 
) O 
. O 
An O 
understanding O 
of O 
acrolein B-TRIVIAL 
and O 
CAA B-ABBREVIATION 
toxicities O 
and O 
the O 
ability O 
of O 
protecting O 
agents O 
to O 
protect O 
against O 
toxicities O 
may O 
help O 
to O 
establish O 
or O 
improve O 
existing O 
therapeutic O 
interventions O 
against O 
the O 
side O 
effects O 
associated O 
with O 
acrolein B-TRIVIAL 
or O 
CAA B-ABBREVIATION 
in O 
cyclophosphamide B-TRIVIAL 
or O 
ifosfamide B-TRIVIAL 
treatment O 
. O 

compounds O 
( O 
OPC O 
) O 
were O 
developed O 
as O 
warfare O 
nerve O 
agents O 
. O 
They O 
are O 
also O 
widely O 
used O 
as O 
pesticides O 
. O 
The O 
drug O 
therapy O 
of O 
intoxication O 
with O 
OPC O 
includes O 
mainly O 
combination O 
of O 
cholinesterase O 
( O 
ChE O 
) O 
reactivators O 
and O 
cholinolytics O 
. O 
There O 
is O 
no O 
single O 
ChE O 
reactivator O 
having O 
an O 
ability O 
to O 
reactivate O 
sufficiently O 
the O 
inhibited O 
enzyme O 
due O 
to O 
the O 
high O 
variability O 
of O 
chemical O 
structure O 
of O 
the O 
inhibitors O 
. O 
The O 
difficulties O 
in O 
reactivation O 
of O 
ChE O 
activity O 
and O 
slight O 
antidote O 
effect O 
regarding O 
intoxication O 
with O 
some O 
OPC O 
are O 
some O 
of O 
the O 
reasons O 
for O 
continuous O 
efforts O 
to O 
obtain O 
new O 
reactivators O 
of O 
ChE O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
efficacy O 
of O 
some O 
ChE O 
reactivators O 
against O 
OPC O 
intoxication O 
( O 
tabun B-TRIVIAL 
, O 
paraoxon B-TRIVIAL 
and O 
dichlorvos B-TRIVIAL 
) O 
in O 
in O 
vitro O 
experiments O 
and O 
to O 
compare O 
their O 
activity O 
to O 
that O 
known O 
for O 
some O 
currently O 
used O 
oximes B-FAMILY 
( O 
obidoxime B-TRIVIAL 
, O 
HI-6 B-IDENTIFIER 
, O 
2-PAM B-SYSTEMATIC 
) O 
. O 
Experiments O 
were O 
carried O 
out O 
using O 
rat O 
brain O 
acetylcholinesterase O 
( O 
AChE O 
) O 
. O 
Reactivators O 
showed O 
different O 
activity O 
in O 
the O 
reactivation O 
of O 
rat O 
brain O 
AChE O 
after O 
dichlorvos B-TRIVIAL 
, O 
paraoxon B-TRIVIAL 
and O 
tabun B-TRIVIAL 
inhibition O 
. O 
AChE O 
was O 
easier O 
reactivated O 
after O 
paraoxon B-TRIVIAL 
treatment O 
. O 
The O 
best O 
effect O 
showed O 
BT-07-4M B-NO_CLASS 
, O 
obidoxime B-TRIVIAL 
, O 
TMB-4 B-IDENTIFIER 
and O 
BT-08 B-NO_CLASS 
from O 
the O 
group O 
of O 
symmetric O 
oximes B-FAMILY 
, O 
and O 
Toxidin B-NO_CLASS 
, O 
BT-05 B-NO_CLASS 
and O 
BT-03 B-NO_CLASS 
from O 
asymmetric O 
compounds O 
. O 
The O 
reactivation O 
of O 
brain O 
AChE O 
inhibited O 
with O 
tabun O 
demonstrated O 
better O 
activity O 
of O 
new O 
compound O 
BT-07-4M B-NO_CLASS 
, O 
TMB-4 B-IDENTIFIER 
and O 
obidoxime B-TRIVIAL 
from O 
symmetric O 
oximes B-FAMILY 
, O 
and O 
BT-05 B-NO_CLASS 
and O 
BT-03 B-NO_CLASS 
possessing O 
asymmetric O 
structure O 
. O 
All O 
compounds O 
showed O 
low O 
activity O 
toward O 
inhibition O 
of O 
AChE O 
caused O 
by O 
dichlorvos B-TRIVIAL 
. O 
Comparison O 
of O 
two O 
main O 
structure O 
types O 
( O 
symmetric O 
/ O 
asymmetric O 
) O 
showed O 
that O 
the O 
symmetric O 
compounds O 
reactivated O 
better O 
AChE O 
, O 
inhibited O 
with O 
this O 
OPC O 
, O 
than O 
asymmetric O 
ones O 
. O 

radical O 
products O 
including O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
are O 
potent O 
to O 
oxidize O 
lipids O 
and O 
reliable O 
measurements O 
have O 
been O 
established O 
mostly O 
in O 
human O 
and O 
rodent O 
. O 
To O 
date O 
, O 
robust O 
biomarkers O 
were O 
not O 
used O 
to O 
assess O 
the O 
peroxidation O 
in O 
marine O 
fish O 
. O 
The O 
changes O 
of O 
oxidized O 
lipid O 
products O 
from O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
and O 
cholesterol B-TRIVIAL 
were O 
assessed O 
after O 
exposure O 
of O 
H(2)O(2) B-FORMULA 
to O 
fish O 
( O 
medaka O 
) O 
. O 
Oxidized O 
lipid O 
products O 
released O 
by O 
free O 
radical O 
reaction O 
( O 
F(2)- O 
isoprostanes B-FAMILY 
and O 
metabolites O 
, O 
F(3)- O 
isoprostanes B-FAMILY 
, O 
neuroprostanes B-FAMILY 
, O 
7-ketocholesterol B-SYSTEMATIC 
, O 
7β-hydroxycholesterol B-SYSTEMATIC 
) O 
, O 
by O 
lipoxygenase O 
enzymes O 
( O 
5(S)- B-MULTIPLE 
, I-MULTIPLE 
8(S)- I-MULTIPLE 
, I-MULTIPLE 
12(S)- I-MULTIPLE 
and I-MULTIPLE 
15(S)-HETE I-MULTIPLE 
, O 
and O 
resolvin B-TRIVIAL 
D1 I-TRIVIAL 
) O 
and O 
by O 
cytochrome O 
P450 O 
( O 
9(S)- B-MULTIPLE 
, I-MULTIPLE 
11(S)- I-MULTIPLE 
and I-MULTIPLE 
20-HETE I-MULTIPLE 
, O 
and O 
27-hydroxycholestrol B-SYSTEMATIC 
) O 
were O 
measured O 
in O 
fish O 
muscle O 
using O 
LC O 
/ O 
MS O 
/ O 
MS O 
. O 
Arachidonate B-TRIVIAL 
, O 
docosahexaenoate B-SYSTEMATIC 
, O 
eicosapentaenoate B-SYSTEMATIC 
and O 
cholesterol B-TRIVIAL 
levels O 
, O 
and O 
antioxidant O 
enzymes O 
activity O 
( O 
catalase O 
, O 
SOD O 
and O 
gluthathione B-TRIVIAL 
reductase O 
) O 
measurement O 
were O 
also O 
determined O 
. O 
Activity O 
of O 
antioxidant O 
enzymes O 
especially O 
catalase O 
were O 
elevated O 
in O 
presence O 
of O 
H(2)O(2) B-FORMULA 
however O 
longer O 
exposure O 
time O 
suppressed O 
the O 
antioxidant O 
activities O 
. O 
Arachidonate B-TRIVIAL 
, O 
docosahexaenoate B-SYSTEMATIC 
, O 
eicosapentaenoate B-SYSTEMATIC 
and O 
cholesterol B-TRIVIAL 
levels O 
were O 
reduced O 
in O 
presence O 
of O 
H(2)O(2) B-FORMULA 
and O 
oxidized O 
lipid O 
products O 
( O 
isoprostanes B-FAMILY 
, O 
neuroprostanes B-FAMILY 
5(S)-HETE B-SYSTEMATIC 
, O 
20-HETE B-SYSTEMATIC 
, O 
7-ketocholesterol B-SYSTEMATIC 
, O 
27-hydroxycholesterol B-SYSTEMATIC 
and O 
resolvin B-TRIVIAL 
D1 I-TRIVIAL 
) O 
were O 
rapidly O 
released O 
in O 
the O 
fish O 
muscle O 
. O 
This O 
study O 
validates O 
oxidized O 
lipid O 
products O 
, O 
noticeably O 
isoprostanes B-FAMILY 
are O 
measurable O 
in O 
marine O 
fish O 
muscle O 
and O 
should O 
be O 
considered O 
when O 
assessing O 
oxidative O 
stress O 
especially O 
due O 
to O 
exogenous O 
factors O 
. O 

breast O 
cancer O 
patients O 
( O 
before O 
and O 
during O 
anti-cancer O 
therapy O 
) O 
oxidative O 
/ O 
nitrative O 
damage O 
to O 
various O 
molecules O 
is O 
observed O 
. O 
Furthermore O 
, O 
anti-cancer O 
treatments O 
may O 
also O 
influence O 
the O 
hemostatic O 
properties O 
of O 
blood O 
platelets O 
and O 
plasma O 
. O 
The O 
aim O 
of O 
our O 
study O 
was O 
to O 
assess O 
the O 
effect O 
of O 
oxidative O 
/ O 
nitrative O 
stress O 
( O 
estimated O 
by O 
measurements O 
of O 
the O 
levels O 
of O 
carbonyl B-FAMILY 
groups O 
and O 
3-nitrotyrosine B-SYSTEMATIC 
in O 
proteins O 
-- O 
ELISA O 
and O 
C-ELISA O 
methods O 
, O 
respectively O 
; O 
lipid O 
peroxidation O 
and O 
total O 
antioxidant O 
level O 
-- O 
TAS O 
) O 
on O 
the O 
selected O 
parameters O 
of O 
hemostatic O 
activity O 
of O 
plasma O 
( O 
the O 
process O 
of O 
fibrin O 
polymerization O 
and O 
lysis O 
) O 
collected O 
from O 
breast O 
cancer O 
patients O 
after O 
surgery O 
and O 
after O 
various O 
phases O 
of O 
chemotherapy O 
( O 
doxorubicin B-TRIVIAL 
and O 
cyclophosphamide B-TRIVIAL 
) O 
. O 
Subsequently O 
, O 
we O 
also O 
evaluated O 
the O 
level O 
of O 
oxidative O 
/ O 
nitrative O 
stress O 
and O 
hemostatic O 
activity O 
in O 
plasma O 
from O 
these O 
patients O 
in O 
the O 
presence O 
of O 
the O 
commercial O 
extract O 
of O 
Aronia O 
melanocarpa O 
( O 
Aronox O 
® O 
) O 
in O 
vitro O 
. O 
Patients O 
were O 
hospitalized O 
in O 
Department O 
of O 
Oncological O 
Surgery O 
and O 
Department O 
of O 
Chemotherapy O 
in O 
Medical O 
University O 
of O 
Lodz O 
, O 
Poland O 
. O 
We O 
observed O 
increased O 
levels O 
of O 
biomarkers O 
of O 
oxidative O 
/ O 
nitrative O 
stress O 
in O 
plasma O 
from O 
patients O 
with O 
breast O 
cancer O 
( O 
before O 
or O 
after O 
surgery O 
and O 
after O 
various O 
phases O 
of O 
chemotherapy O 
) O 
in O 
comparison O 
to O 
healthy O 
group O 
. O 
Our O 
further O 
experiments O 
demonstrated O 
the O 
hemostatic O 
activity O 
of O 
plasma O 
from O 
the O 
investigated O 
patients O 
differs O 
from O 
hemostatic O 
properties O 
of O 
plasma O 
obtained O 
from O 
healthy O 
volunteers O 
. O 
We O 
also O 
recognize O 
the O 
existence O 
of O 
a O 
relationship O 
between O 
oxidative O 
stress O 
( O 
measured O 
by O 
the O 
level O 
of O 
carbonyl O 
groups O 
) O 
and O 
changes O 
of O 
hemostasis O 
in O 
breast O 
cancer O 
patients O 
after O 
I O 
and O 
IV O 
phases O 
of O 
chemotherapy O 
. O 
Moreover O 
, O 
the O 
obtained O 
results O 
showed O 
that O 
the O 
commercial O 
extract O 
from O 
A O 
. O 
melanocarpa O 
berries O 
significantly O 
reduced O 
, O 
in O 
in O 
vitro O 
system O 
, O 
the O 
oxidative O 
/ O 
nitrative O 
stress O 
and O 
hemostasis O 
changes O 
in O 
plasma O 
from O 
breast O 
cancer O 
patients O 
, O 
after O 
surgery O 
and O 
different O 
phases O 
of O 
chemotherapy O 
. O 
Considering O 
the O 
data O 
presented O 
in O 
this O 
study O 
, O 
we O 
suggest O 
that O 
the O 
oxidative O 
/ O 
nitrative O 
stress O 
in O 
plasma O 
obtained O 
from O 
breast O 
cancer O 
patients O 
( O 
not O 
only O 
before O 
or O 
after O 
the O 
surgery O 
, O 
but O 
also O 
after O 
various O 
phases O 
of O 
doxorubicin B-TRIVIAL 
and O 
cyclophosphamide B-TRIVIAL 
chemotherapy O 
) O 
may O 
induce O 
changes O 
of O 
hemostatic O 
activity O 
, O 
which O 
may O 
contribute O 
to O 
thrombosis O 
in O 
these O 
patients O 
. O 
Our O 
results O 
also O 
suggest O 
that O 
the O 
commercial O 
extract O 
of O 
A O 
. O 
melanocarpa O 
may O 
be O 
regarded O 
as O 
a O 
promising O 
new O 
source O 
of O 
bioactive O 
antioxidant O 
natural O 
compounds O 
for O 
breast O 
cancer O 
patients O 
. O 

aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
is O 
a O 
transcription O 
factor O 
which O 
is O 
activated O 
by O 
diverse O 
compounds O 
and O 
regulates O 
the O 
expression O 
of O 
xenobiotic O 
metabolism O 
genes O 
. O 
Recent O 
studies O 
have O 
unraveled O 
unsuspected O 
physiological O 
roles O 
and O 
novel O 
alternative O 
ligand O 
- O 
specific O 
pathways O 
for O 
this O 
receptor O 
. O 
In O 
this O 
review O 
, O 
we O 
discuss O 
these O 
novel O 
aspects O 
and O 
focus O 
on O 
the O 
different O 
responses O 
elicited O 
by O 
the O 
diverse O 
endogenous O 
and O 
/ O 
or O 
exogenous O 
AhR O 
ligands O 
. O 
In O 
addition O 
to O 
challenging O 
the O 
relevance O 
of O 
the O 
' O 
agonist O 
/ O 
antagonist O 
' O 
classification O 
of O 
ligands O 
, O 
we O 
introduce O 
the O 
concept O 
of O 
AhR O 
plasticity O 
as O 
a O 
primordial O 
factor O 
in O 
the O 
generation O 
of O 
these O 
pathways O 
. O 
Finally O 
, O 
we O 
suggest O 
several O 
promising O 
perspectives O 
for O 
the O 
pharmacological O 
modulation O 
of O 
these O 
responses O 
. O 

of O 
5-hydroxytryptamines B-FAMILY 
as O 
dual O 
function O 
inhibitors O 
targeting O 
phospholipase O 
A2 O 
and O 
leukotriene O 
A4 O 
hydrolase O 
. O 

function O 
inhibitors O 
targeting O 
phospholipase O 
A(2) O 
(PLA(2)) O 
and O 
leukotriene O 
A(4) O 
hydrolase O 
( O 
LTA(4)H O 
) O 
may O 
balance O 
the O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
metabolic O 
network O 
and O 
be O 
used O 
as O 
new O 
anti-inflammatory O 
drugs O 
. O 
In O 
previous O 
study O 
, O 
we O 
discovered O 
multi O 
- O 
target O 
drugs O 
towards O 
the O 
AA O 
metabolic O 
network O 
, O 
among O 
which O 
a O 
dual O 
- O 
target O 
inhibitor O 
( O 
JMC08-4 B-IDENTIFIER 
) O 
for O 
human O 
nonpancreatic O 
secretory O 
phospholipase O 
A(2) O 
(hnps-PLA(2)) O 
and O 
human O 
leukotriene O 
A(4) O 
hydrolase O 
( O 
LTA(4)H-h O 
) O 
was O 
found O 
. O 
Based O 
on O 
the O 
structure O 
of O 
compound O 
JMC08-4 B-IDENTIFIER 
, O 
new O 
dual O 
- O 
target O 
inhibitors O 
were O 
designed O 
assisted O 
by O 
molecular O 
docking O 
. O 
In O 
this O 
report O 
, O 
a O 
series O 
of O 
5-hydroxytryptamine B-SYSTEMATIC 
compounds O 
were O 
synthesized O 
; O 
and O 
most O 
of O 
these O 
title O 
compounds O 
showed O 
more O 
potent O 
inhibitory O 
activity O 
than O 
compound O 
JMC08-4 B-IDENTIFIER 
in O 
the O 
in O 
vitro O 
bioassay O 
against O 
these O 
two O 
enzymes O 
. O 
The O 
best O 
one O 
inhibited O 
hnps-PLA(2) O 
and O 
LTA(4)H-h O 
with O 
IC(50) O 
values O 
of O 
9.2 O 
± O 
0.5 O 
μM O 
and O 
2.4 O 
± O 
1.4 O 
μM O 
, O 
respectively O 
. O 

and O 
synthesis O 
of O 
novel O 
benzoheterocyclic B-FAMILY 
derivatives O 
as O 
human O 
acrosin O 
inhibitors O 
by O 
scaffold O 
hopping O 
. O 

acrosin O 
is O 
an O 
attracting O 
target O 
for O 
the O 
development O 
of O 
novel O 
male O 
contraceptives O 
. O 
Scaffold O 
hopping O 
was O 
used O 
to O 
optimize O 
the O 
isoxazolecarbaldehyde B-SYSTEMATIC 
human O 
acrosin O 
inhibitors O 
and O 
extend O 
their O 
structure O 
- O 
activity O 
relationships O 
. O 
Four O 
kinds O 
of O 
scaffolds O 
, O 
namely O 
benzimidazole B-SYSTEMATIC 
, O 
benzothiazole B-SYSTEMATIC 
, O 
3H-indazole B-SYSTEMATIC 
, O 
and O 
5-phenyl-1H-pyrazole B-SYSTEMATIC 
, O 
were O 
designed O 
and O 
synthesized O 
. O 
Most O 
of O 
the O 
synthesized O 
compounds O 
showed O 
potent O 
human O 
acrosin O 
inhibitory O 
activity O 
and O 
their O 
binding O 
modes O 
were O 
investigated O 
by O 
molecular O 
docking O 
. O 
The O 
scaffold O 
of O 
the O 
compounds O 
was O 
found O 
to O 
be O 
important O 
for O 
the O 
inhibitory O 
activity O 
. O 
Several O 
compounds O 
were O 
more O 
active O 
than O 
the O 
positive O 
control O 
TLCK B-ABBREVIATION 
, O 
suggesting O 
that O 
they O 
can O 
serve O 
as O 
good O 
starting O 
points O 
for O 
the O 
discovery O 
of O 
novel O 
male O 
contraceptive O 
agents O 
. O 

of O 
organic O 
cation/ O 
carnitine B-TRIVIAL 
transporter O 
1 O 
in O 
uptake O 
of O 
phenformin B-TRIVIAL 
and O 
inhibitory O 
effect O 
on O 
complex O 
I O 
respiration O 
in O 
mitochondria O 
. O 

causes O 
lactic O 
acidosis O 
in O 
clinical O 
situations O 
due O 
to O 
inhibition O 
of O 
mitochondrial O 
respiratory O 
chain O 
complex O 
I O 
. O 
It O 
is O 
reportedly O 
taken O 
up O 
by O 
hepatocytes O 
and O 
exhibits O 
mitochondrial O 
toxicity O 
in O 
the O 
liver O 
. O 
In O 
this O 
study O 
, O 
uptake O 
of O 
phenformin B-TRIVIAL 
and O 
[(14)C]tetraethylammonium B-SYSTEMATIC 
( O 
TEA B-ABBREVIATION 
) O 
and O 
complex O 
I O 
inhibition O 
by O 
phenformin B-TRIVIAL 
were O 
examined O 
in O 
isolated O 
liver O 
and O 
heart O 
mitochondria O 
. O 
Uptake O 
of O 
phenformin B-TRIVIAL 
into O 
isolated O 
rat O 
liver O 
mitochondria O 
was O 
higher O 
than O 
that O 
into O 
heart O 
mitochondria O 
. O 
It O 
was O 
inhibited O 
by O 
several O 
cat O 
ionic O 
compounds O 
, O 
which O 
suggests O 
the O 
involvement O 
of O 
multispecific O 
transport O 
system(s) O 
. O 
Similar O 
characteristics O 
were O 
also O 
observed O 
for O 
uptake O 
of O 
TEA B-ABBREVIATION 
; O 
however O 
, O 
uptake O 
of O 
phenformin B-TRIVIAL 
into O 
mitochondria O 
of O 
organic O 
cation/ O 
carnitine B-TRIVIAL 
transporter O 
1 O 
( O 
OCTN1 O 
) O 
knockout O 
mice O 
was O 
lower O 
than O 
that O 
in O 
wild O 
- O 
type O 
mice O 
, O 
whereas O 
uptake O 
of O 
TEA B-ABBREVIATION 
was O 
comparable O 
between O 
the O 
two O 
strains O 
, O 
suggesting O 
the O 
involvement O 
of O 
distinct O 
transport O 
mechanisms O 
for O 
these O 
two O 
cations O 
in O 
mitochondria O 
. O 
Inhibition O 
by O 
phenformin B-TRIVIAL 
of O 
oxygen B-SYSTEMATIC 
consumption O 
via O 
complex O 
I O 
respiration O 
in O 
isolated O 
rat O 
liver O 
mitochondria O 
was O 
greater O 
than O 
that O 
in O 
heart O 
mitochondria O 
, O 
whereas O 
inhibitory O 
effect O 
of O 
phenformin B-TRIVIAL 
on O 
complex O 
I O 
respiration O 
was O 
similar O 
in O 
inside-out O 
structured O 
submitochondrial O 
particles O 
prepared O 
from O 
rat O 
livers O 
and O 
hearts O 
. O 
Lactic O 
acidosis O 
provoked O 
by O 
iv O 
infusion O 
of O 
phenformin B-TRIVIAL 
was O 
weaker O 
in O 
octn1(- O 
/ O 
- O 
) O 
mice O 
than O 
that O 
in O 
wild O 
- O 
type O 
mice O 
. O 
These O 
observations O 
suggest O 
that O 
uptake O 
of O 
phenformin B-TRIVIAL 
into O 
liver O 
mitochondria O 
is O 
at O 
least O 
partly O 
mediated O 
by O 
OCTN1 O 
and O 
functionally O 
relevant O 
to O 
its O 
inhibition O 
potential O 
of O 
complex O 
I O 
respiration O 
. O 
This O 
study O 
was O 
, O 
thus O 
, O 
the O 
first O 
to O 
demonstrate O 
OCTN1 O 
- O 
mediated O 
mitochondrial O 
transport O 
and O 
toxicity O 
of O 
biguanide O 
in O 
vivo O 
in O 
rodents O 
. O 

damage O 
from O 
ionizing O 
radiation O 
( O 
IR O 
) O 
is O 
in O 
part O 
due O 
to O 
DNA O 
damage O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
which O 
activate O 
DNA O 
damage O 
response O 
( O 
DDR O 
) O 
and O 
cytokine O 
signaling O 
pathways O 
, O 
including O 
the O 
ataxia O 
telangiectasia O 
mutated O 
( O 
ATM O 
) O 
and O 
transforming O 
growth O 
factor O 
(TGF)β O 
/ O 
Smad O 
pathways O 
. O 
Using O 
classic O 
double O 
- O 
strand O 
breaks O 
( O 
DSBs O 
) O 
markers O 
, O 
we O 
studied O 
the O 
roles O 
of O 
Smad O 
proteins O 
in O 
DDR O 
and O 
the O 
crosstalk O 
between O 
TGFβ O 
and O 
ATM O 
pathways O 
. O 
We O 
observed O 
co O 
- O 
localization O 
of O 
phospho B-SYSTEMATIC 
-Smad2 O 
( O 
pSmad2 O 
) O 
and O 
Smad7 O 
with O 
DSB O 
repair O 
proteins O 
following O 
low O 
and O 
high O 
linear O 
energy O 
transfer O 
( O 
LET O 
) O 
radiation O 
in O 
human O 
fibroblasts O 
and O 
epithelial O 
cells O 
. O 
The O 
decays O 
of O 
both O 
foci O 
were O 
similar O 
to O 
that O 
of O 
γH2AX O 
foci O 
. O 
Irradiation O 
with O 
high O 
LET O 
particles O 
induced O 
pSmad2 O 
and O 
Smad7 O 
foci O 
tracks O 
indicating O 
the O 
particle O 
trajectory O 
through O 
cells O 
. O 
pSmad2 O 
foci O 
were O 
absent O 
in O 
S O 
phase O 
cells O 
, O 
while O 
Smad7 O 
foci O 
were O 
present O 
in O 
all O 
phases O 
of O 
cell O 
cycle O 
. O 
pSmad2 O 
( O 
but O 
not O 
Smad7 O 
) O 
foci O 
were O 
completely O 
abolished O 
when O 
ATM O 
was O 
depleted O 
or O 
inactivated O 
. O 
In O 
contrast O 
, O 
a O 
TGFβ O 
receptor O 
1 O 
( O 
TGFβR1 O 
) O 
inhibitor O 
abrogated O 
Smad7 O 
, O 
but O 
not O 
pSmad2 O 
foci O 
at O 
DSBs O 
sites O 
. O 
In O 
summary O 
, O 
we O 
suggest O 
that O 
Smad2 O 
and O 
Smad7 O 
contribute O 
to O 
IR-induced O 
DSB O 
signaling O 
in O 
an O 
ATM O 
or O 
TGFβR1-dependent O 
manner O 
, O 
respectively O 
. O 

of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
by O 
plasmapheresis O 
in O 
a O 
patient O 
treated O 
for O 
multiple O 
sclerosis O 
. O 

present O 
a O 
case O 
of O 
a O 
patient O 
with O 
multiple O 
sclerosis O 
who O 
was O 
treated O 
with O 
plasmapheresis O 
and O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
. O 
We O 
used O 
therapeutic O 
drug O 
monitoring O 
to O 
determine O 
whether O 
plasma O 
concentrations O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
were O 
kept O 
within O 
the O 
therapeutic O 
window O 
and O 
to O 
determine O 
the O 
amount O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
that O 
was O 
removed O 
by O 
plasmapheresis O 
. O 

of O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
concentration O 
impairs O 
endothelial O 
progenitor O 
cell O 
and O 
bone O 
marrow O 
- O 
derived O 
progenitor O 
cell O 
bioavailability O 
: O 
role O 
of O 
the O 
STAT5 O 
/ O 
PPARγ O 
transcriptional O 
complex O 
. O 

profiling O 
of O 
plasma O 
nonesterified O 
fatty B-FAMILY 
acids I-FAMILY 
discovered O 
that O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
( O 
PA O 
) O 
, O 
a O 
natural O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
γ O 
( O 
PPARγ O 
) O 
ligand O 
, O 
is O 
a O 
reliable O 
type O 
2 O 
diabetes O 
biomarker O 
. O 
We O 
investigated O 
whether O 
and O 
how O 
PA O 
diabetic O 
( O 
d-PA O 
) O 
concentrations O 
affected O 
endothelial O 
progenitor O 
cell O 
( O 
EPC O 
) O 
and O 
bone O 
marrow O 
- O 
derived O 
hematopoietic O 
cell O 
( O 
BM-HC O 
) O 
biology O 
. O 
PA O 
physiologic O 
( O 
n-PA O 
) O 
and O 
d-PA O 
concentrations O 
were O 
used O 
. O 
Proliferating O 
cell O 
nuclear O 
antigen O 
content O 
and O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
5 O 
( O 
STAT5 O 
) O 
, O 
PPARγ O 
, O 
cyclin O 
D1 O 
, O 
and O 
p21(Waf) O 
expression O 
were O 
evaluated O 
. O 
Small O 
interfering O 
RNA O 
technology O 
, O 
gene O 
reporter O 
luciferase O 
assay O 
, O 
electrophoretic O 
mobility O 
shift O 
assay O 
, O 
chromatin O 
immunoprecipitation O 
assay O 
, O 
and O 
coimmunoprecipitation O 
were O 
exploited O 
. O 
In O 
vivo O 
studies O 
and O 
migration O 
assays O 
were O 
also O 
performed O 
. O 
d-PA O 
, O 
unlike O 
n-PA O 
or O 
physiological O 
and O 
diabetic O 
oleic B-MULTIPLE 
and I-MULTIPLE 
stearic I-MULTIPLE 
acid I-MULTIPLE 
concentrations O 
, O 
impaired O 
EPC O 
migration O 
and O 
EPC O 
/ O 
BM-HC O 
proliferation O 
through O 
a O 
PPARγ O 
- O 
mediated O 
STAT5 O 
transcription O 
inhibition O 
. O 
This O 
event O 
did O 
not O 
prevent O 
the O 
formation O 
of O 
a O 
STAT5 O 
/ O 
PPARγ O 
transcriptional O 
complex O 
but O 
was O 
crucial O 
for O 
gene O 
targeting O 
, O 
as O 
p21(Waf) O 
gene O 
promoter O 
, O 
unlike O 
cyclin O 
D1 O 
, O 
was O 
the O 
STAT5 O 
/ O 
PPARγ O 
transcriptional O 
target O 
. O 
Similar O 
molecular O 
events O 
could O 
be O 
detected O 
in O 
EPCs O 
isolated O 
from O 
type O 
2 O 
diabetic O 
patients O 
. O 
By O 
expressing O 
a O 
constitutively O 
activated O 
STAT5 O 
form O 
, O 
we O 
demonstrated O 
that O 
STAT5 O 
content O 
is O 
crucial O 
for O 
gene O 
targeting O 
and O 
EPC O 
fate O 
. O 
Finally O 
, O 
we O 
also O 
provide O 
in O 
vivo O 
data O 
that O 
d-PA O 
- O 
mediated O 
EPC O 
dysfunction O 
could O 
be O 
rescued O 
by O 
PPARγ O 
blockade O 
. O 
These O 
data O 
provide O 
first O 
insights O 
on O 
how O 
mechanistically O 
d-PA O 
drives O 
EPC O 
/ O 
BM-HC O 
dysfunction O 
in O 
diabetes O 
. O 

fidelity O 
of O 
RNA O 
synthesis O 
depends O 
on O 
both O 
accurate O 
template O 
- O 
mediated O 
nucleotide B-FAMILY 
selection O 
and O 
proper O 
maintenance O 
of O 
register O 
between O 
template O 
and O 
RNA O 
. O 
Loss O 
of O 
register O 
, O 
or O 
transcriptional O 
slippage O 
, O 
is O 
particularly O 
likely O 
on O 
homopolymeric O 
runs O 
in O 
the O 
template O 
. O 
Transcriptional O 
slippage O 
can O 
alter O 
the O 
coding O 
capacity O 
of O 
mRNAs O 
and O 
is O 
used O 
as O 
a O 
regulatory O 
mechanism O 
. O 
Here O 
we O 
describe O 
mutations O 
in O 
the O 
largest O 
subunit O 
of O 
Saccharomyces O 
cerevisiae O 
RNA O 
polymerase O 
II O 
that O 
substantially O 
increase O 
the O 
level O 
of O 
transcriptional O 
slippage O 
. O 
Alleles O 
of O 
RPB1 O 
( O 
RPO21 O 
) O 
with O 
elevated O 
slippage O 
rates O 
were O 
identified O 
among O 
6-azauracil B-SYSTEMATIC 
-sensitive O 
mutants O 
and O 
were O 
also O 
isolated O 
using O 
a O 
slippage O 
- O 
dependent O 
reporter O 
gene O 
. O 
Biochemical O 
characterization O 
of O 
polymerase O 
II O 
isolated O 
from O 
these O 
mutants O 
confirms O 
elevated O 
levels O 
of O 
transcriptional O 
slippage O 
. O 

Effects O 
of O 
Carbohydrate B-FAMILY 
, O 
Unsaturated O 
Fat O 
, O 
and O 
Protein O 
Intake O 
on O 
Measures O 
of O 
Insulin O 
Sensitivity O 
: O 
Results O 
from O 
the O 
OmniHeart O 
Trial O 
. O 

Impaired O 
insulin O 
sensitivity O 
increases O 
the O 
risk O 
of O 
cardiovascular O 
disease O 
. O 
Although O 
calorie O 
restriction O 
and O 
weight O 
loss O 
increase O 
insulin O 
sensitivity O 
, O 
the O 
effects O 
of O 
modifying O 
macronutrient O 
composition O 
on O 
insulin O 
sensitivity O 
are O 
uncertain O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
determine O 
the O 
effects O 
on O 
insulin O 
sensitivity O 
of O 
a O 
carbohydrate B-FAMILY 
-rich O 
diet O 
( O 
CARB B-ABBREVIATION 
; O 
similar O 
to O 
the O 
Dietary O 
Approaches O 
to O 
Stop O 
Hypertension O 
[ O 
DASH O 
] O 
diet O 
) O 
, O 
a O 
protein O 
- O 
rich O 
diet O 
( O 
PROT O 
; O 
protein O 
predominantly O 
from O 
plant O 
sources O 
) O 
, O 
and O 
an O 
unsaturated O 
fat O 
- O 
rich O 
diet O 
( O 
UNSAT O 
; O 
predominantly O 
monounsaturated O 
) O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
This O 
study O 
was O 
a O 
randomized O 
, O 
controlled O 
, O 
three O 
- O 
period O 
, O 
crossover O 
feeding O 
study O 
. O 
The O 
study O 
participants O 
were O 
164 O 
individuals O 
with O 
prehypertension O 
or O 
stage O 
1 O 
hypertension O 
without O 
diabetes O 
. O 
Diets O 
were O 
administered O 
for O 
6 O 
weeks O 
each O 
, O 
with O 
a O 
washout O 
period O 
between O 
diets O 
of O 
2-4 O 
weeks O 
. O 
Weight O 
was O 
held O 
constant O 
throughout O 
the O 
study O 
. O 
For O 
our O 
primary O 
outcome O 
, O 
we O 
calculated O 
the O 
quantitative O 
insulin O 
sensitivity O 
check O 
index O 
( O 
QUICKI O 
) O 
using O 
the O 
end O 
- O 
of O 
- O 
period O 
fasting O 
serum O 
glucose B-TRIVIAL 
and O 
insulin O 
. O 
QUICKI O 
is O 
a O 
validated O 
measure O 
of O 
insulin O 
sensitivity O 
. O 
The O 
primary O 
analyses O 
used O 
generalized O 
estimating O 
equations O 
. O 
RESULTS O 
At O 
baseline O 
, O 
mean O 
( O 
SD O 
) O 
BMI O 
was O 
30.2 O 
( O 
6.1 O 
) O 
kg O 
/ O 
m(2) O 
, O 
and O 
mean O 
( O 
SD O 
) O 
QUICKI O 
was O 
0.35 O 
( O 
0.04 O 
) O 
. O 
The O 
UNSAT O 
diet O 
increased O 
QUICKI O 
by O 
0.005 O 
, O 
more O 
than O 
the O 
CARB B-ABBREVIATION 
diet O 
( O 
P O 
= O 
0.04 O 
) O 
. O 
PROT O 
had O 
no O 
significant O 
effect O 
compared O 
with O 
CARB B-ABBREVIATION 
. O 
CONCLUSIONS O 
A O 
diet O 
that O 
partially O 
replaces O 
carbohydrate B-FAMILY 
with O 
unsaturated O 
fat O 
may O 
improve O 
insulin O 
sensitivity O 
in O 
a O 
population O 
at O 
risk O 
for O 
cardiovascular O 
disease O 
. O 
Given O 
the O 
well O 
- O 
recognized O 
challenges O 
of O 
sustaining O 
weight O 
loss O 
, O 
our O 
results O 
suggest O 
an O 
alternative O 
approach O 
for O 
improving O 
insulin O 
sensitivity O 
. O 

chemical O 
study O 
of O 
the O 
catalytic O 
activation O 
of O 
methane B-SYSTEMATIC 
by O 
copper B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
cations O 
. O 

activation O 
of O 
methane B-SYSTEMATIC 
and O 
its O 
subsequent O 
conversion O 
into O 
more O 
valuable O 
feedstocks O 
under O 
ambient O 
conditions O 
are O 
regarded O 
as O 
one O 
of O 
the O 
major O 
challenges O 
in O 
contemporary O 
catalysis O 
, O 
due O 
to O 
its O 
thermodynamically O 
strong O 
and O 
kinetically O 
inert O 
C-H B-FORMULA 
bond O 
. O 
Several O 
enzymes O 
and O 
synthetic O 
bioinorganic O 
systems O 
perform O 
the O 
activation O 
of O 
C-H B-FORMULA 
bonds O 
in O 
methane B-SYSTEMATIC 
and O 
small O 
hydrocarbons B-FAMILY 
, O 
mediated O 
by O 
transition B-FAMILY 
metal I-FAMILY 
mononuclear O 
centers O 
. O 
Among O 
them O 
, O 
monocopper O 
cores O 
and O 
, O 
in O 
particular O 
, O 
CuO(+) B-FORMULA 
and O 
CuOH(+) B-FORMULA 
have O 
been O 
suggested O 
as O 
efficient O 
catalytic O 
centers O 
; O 
this O 
activity O 
has O 
not O 
been O 
experimentally O 
proven O 
until O 
very O 
recently O 
, O 
mainly O 
due O 
to O 
the O 
difficulty O 
to O 
produce O 
sufficient O 
amounts O 
of O 
active O 
species O 
to O 
demonstrate O 
the O 
bond O 
activation O 
processes O 
. O 
The O 
theoretical O 
study O 
presented O 
here O 
provides O 
a O 
thorough O 
quantum O 
chemical O 
description O 
of O 
the O 
activity O 
of O 
both O 
species O 
, O 
together O 
with O 
molecular O 
level O 
insight O 
into O 
the O 
elementary O 
steps O 
of O 
the O 
experimentally O 
observed O 
reactions O 
. O 
Post-HF O 
( O 
CCSD(T) O 
, O 
CASPT2 O 
) O 
and O 
Density O 
Functional O 
Theory O 
( O 
DFT O 
) O 
methods O 
have O 
been O 
used O 
to O 
unravel O 
detailed O 
electronic O 
and O 
mechanistic O 
aspects O 
of O 
the O 
reaction O 
paths O 
. O 
Our O 
study O 
reveals O 
the O 
decisive O 
role O 
of O 
the O 
oxygen B-SYSTEMATIC 
-centered O 
radical O 
in O 
the O 
reactivity O 
of O 
both O 
species O 
, O 
and O 
the O 
improvement O 
of O 
the O 
reactivity O 
as O 
a O 
result O 
of O 
the O 
protonation O 
of O 
the O 
active O 
species O 
. O 

report O 
an O 
array O 
of O 
polymeric O 
nanowires O 
for O 
effectively O 
immobilizing O 
biomolecules O 
on O 
biochips O 
owing O 
to O 
the O 
large O 
surface O 
area O 
. O 
The O 
nanowires O 
were O 
fabricated O 
in O 
predesigned O 
patterns O 
using O 
an O 
inductively O 
coupled O 
plasma O 
( O 
ICP O 
) O 
etching O 
process O 
. O 
Microfluidic O 
biochips O 
integrated O 
using O 
the O 
substrates O 
with O 
arrays O 
of O 
nanowires O 
and O 
polydimethylsiloxane B-SYSTEMATIC 
channels O 
have O 
been O 
demonstrated O 
to O 
be O 
effective O 
for O 
detecting O 
antigens O 
, O 
and O 
a O 
detection O 
limit O 
of O 
antigens O 
at O 
0.2 O 
μg O 
mL(-1) O 
has O 
been O 
achieved O 
, O 
which O 
is O 
improved O 
by O 
a O 
factor O 
of O 
50 O 
compared O 
to O 
that O 
based O 
on O 
flat O 
substrates O 
without O 
the O 
nanowires O 
. O 
In O 
addition O 
, O 
the O 
high O 
sensitivity O 
for O 
clinical O 
detection O 
of O 
human O 
immunodeficiency O 
virus O 
( O 
HIV O 
) O 
antibody O 
has O 
also O 
been O 
demonstrated O 
, O 
showing O 
a O 
20 O 
times O 
enhancement O 
in O 
fluorescent O 
signal O 
intensity O 
between O 
the O 
samples O 
with O 
positive O 
and O 
negative O 
HIV O 
. O 

- O 
mesoporous O 
materials O 
obtained O 
by O 
zeolite B-TRIVIAL 
recrystallization O 
: O 
synthesis O 
, O 
characterization O 
and O 
catalytic O 
applications O 
. O 

review O 
covers O 
the O 
recent O 
developments O 
in O 
the O 
field O 
of O 
novel O 
micro O 
- O 
mesoporous O 
materials O 
obtained O 
by O 
zeolite B-TRIVIAL 
recrystallization O 
. O 
The O 
materials O 
are O 
classified O 
into O 
three O 
distinctly O 
different O 
groups O 
depending O 
on O 
the O 
degree O 
of O 
recrystallization O 
: O 
(i) O 
coated O 
mesoporous O 
zeolites B-FAMILY 
( O 
RZEO-1 O 
) O 
; O 
(ii) O 
micro O 
- O 
mesoporous O 
nanocomposites O 
( O 
RZEO-2 O 
) O 
; O 
and O 
(iii) O 
mesoporous O 
materials O 
with O 
zeolitic O 
fragments O 
in O 
the O 
walls O 
( O 
RZEO-3 O 
) O 
. O 
The O 
first O 
part O 
of O 
the O 
review O 
is O 
focused O 
on O 
the O 
analysis O 
of O 
the O 
synthetic O 
strategies O 
leading O 
to O 
different O 
types O 
of O 
recrystallized O 
materials O 
. O 
In O 
the O 
second O 
part O 
, O 
a O 
comprehensive O 
view O 
on O 
their O 
structure O 
, O 
texture O 
and O 
porosity O 
in O 
connection O 
with O 
acidic O 
and O 
diffusion O 
properties O 
is O 
given O 
. O 
The O 
last O 
part O 
is O 
devoted O 
to O 
the O 
catalytic O 
applications O 
of O 
recrystallized O 
materials O 
. O 
The O 
advantages O 
and O 
disadvantages O 
with O 
respect O 
to O 
pure O 
micro- O 
and O 
mesoporous O 
molecular O 
sieves O 
and O 
other O 
hierarchical O 
zeolites B-FAMILY 
are O 
critically O 
analyzed O 
and O 
the O 
future O 
opportunities O 
and O 
perspectives O 
are O 
discussed O 
. O 

asymmetric O 
ultrafiltration O 
PVDF B-ABBREVIATION 
membranes O 
: O 
an O 
alternative O 
separator O 
for O 
VFB O 
with O 
excellent O 
stability O 
. O 

fluoride I-SYSTEMATIC 
( O 
PVDF B-ABBREVIATION 
) O 
ultrafiltration O 
membranes O 
were O 
investigated O 
for O 
the O 
first O 
time O 
in O 
vanadium B-SYSTEMATIC 
redox O 
flow O 
battery O 
( O 
VFB O 
) O 
applications O 
. O 
Surprisingly O 
, O 
PVDF B-ABBREVIATION 
ultrafiltration O 
membranes O 
with O 
hydrophobic O 
pore O 
walls O 
and O 
relatively O 
large O 
pore O 
sizes O 
of O 
several O 
tens O 
of O 
nanometers O 
proved O 
able O 
to O 
separate O 
vanadium B-SYSTEMATIC 
ions O 
and O 
protons O 
efficiently O 
, O 
thus O 
being O 
suitable O 
as O 
a O 
VFB O 
separator O 
. O 
The O 
ion O 
selectivity O 
of O 
this O 
new O 
type O 
of O 
VFB O 
membrane O 
could O 
be O 
tuned O 
readily O 
by O 
controlling O 
the O 
membrane O 
morphology O 
via O 
changes O 
in O 
the O 
composition O 
of O 
the O 
membrane O 
casting O 
solution O 
, O 
and O 
the O 
casting O 
thickness O 
. O 
The O 
results O 
showed O 
that O 
the O 
PVDF B-ABBREVIATION 
membranes O 
offered O 
good O 
performances O 
and O 
excellent O 
stability O 
in O 
VFB O 
applications O 
, O 
where O 
it O 
could O 
, O 
performance O 
- O 
wise O 
, O 
truly O 
substitute O 
Nafion B-TRIVIAL 
in O 
VFB O 
applications O 
, O 
but O 
at O 
a O 
much O 
lower O 
cost O 
. O 

-doped O 
luminescent O 
nano O 
- O 
bioprobes O 
: O 
from O 
fundamentals O 
to O 
biodetection O 
. O 

lanthanide I-FAMILY 
( O 
Ln(3+) B-FORMULA 
)-doped O 
luminescent O 
inorganic O 
nanoparticles O 
( O 
NPs O 
) O 
, O 
characterized O 
by O 
long O 
- O 
lived O 
luminescence O 
, O 
large O 
Stokes O 
and O 
/ O 
or O 
anti-Stokes O 
shifts O 
, O 
narrow O 
emission O 
bands O 
and O 
high O 
photochemical O 
stability O 
, O 
are O 
considered O 
to O 
be O 
promising O 
candidates O 
as O 
luminescent O 
bioprobes O 
in O 
biomedicine O 
and O 
biotechnology O 
. O 
In O 
this O 
feature O 
article O 
, O 
we O 
provide O 
a O 
brief O 
overview O 
of O 
the O 
most O 
recent O 
advances O 
in O 
Ln(3+) B-FORMULA 
-doped O 
luminescent O 
inorganic O 
NPs O 
as O 
sensors O 
, O 
which O 
covers O 
from O 
their O 
chemical O 
and O 
physical O 
fundamentals O 
to O 
biodetection O 
, O 
such O 
as O 
controlled O 
synthesis O 
methodology O 
, O 
surface O 
modification O 
chemistry O 
, O 
optical O 
physics O 
, O 
and O 
their O 
promising O 
applications O 
in O 
diverse O 
bioassays O 
, O 
with O 
an O 
emphasis O 
on O 
heterogeneous O 
and O 
homogeneous O 
in O 
vitro O 
biodetection O 
. O 
Finally O 
, O 
some O 
of O 
the O 
most O 
important O 
emerging O 
trends O 
and O 
future O 
efforts O 
toward O 
this O 
active O 
research O 
field O 
are O 
also O 
proposed O 
. O 

carbon B-SYSTEMATIC 
nanotubes O 
in O 
neural O 
regeneration O 
: O 
a O 
mini O 
- O 
review O 
. O 

nanotubes O 
( O 
CNTs O 
) O 
have O 
become O 
an O 
intriguing O 
and O 
promising O 
biomaterial O 
platform O 
for O 
the O 
regeneration O 
and O 
functional O 
recovery O 
of O 
damaged O 
nerve O 
tissues O 
. O 
The O 
unique O 
electrical O 
, O 
structural O 
and O 
mechanical O 
properties O 
, O 
diversity O 
of O 
available O 
surface O 
chemistry O 
and O 
cell O 
- O 
penetrating O 
ability O 
of O 
CNTs O 
have O 
made O 
them O 
useful O 
implantable O 
matrices O 
or O 
carriers O 
for O 
the O 
delivery O 
of O 
therapeutic O 
molecules O 
. O 
Although O 
there O 
are O 
still O 
challenges O 
being O 
faced O 
in O 
the O 
clinical O 
applications O 
of O 
CNTs O 
mainly O 
due O 
to O 
their O 
toxicity O 
, O 
many O 
studies O 
to O 
overcome O 
this O 
issue O 
have O 
been O 
published O 
. O 
Modification O 
of O 
CNTs O 
with O 
chemical O 
groups O 
to O 
ensure O 
their O 
dissolution O 
in O 
aqueous O 
media O 
is O 
one O 
possible O 
solution O 
. O 
Functionalization O 
of O 
CNTs O 
with O 
biologically O 
relevant O 
and O 
effective O 
molecules O 
( O 
biofunctionalization O 
) O 
is O 
also O 
a O 
promising O 
strategy O 
to O 
provide O 
better O 
biocompatibility O 
and O 
selectivity O 
for O 
neural O 
regeneration O 
. O 
Here O 
, O 
we O 
review O 
recent O 
advances O 
in O 
the O 
use O 
of O 
CNTs O 
to O 
promote O 
neural O 
regeneration O 
. O 

established O 
cultures O 
of O 
primary O 
hepatocytes O 
progressively O 
adopt O 
a O 
foetal O 
- O 
like O 
phenotype O 
and O 
display O 
increased O 
production O 
of O 
connexin43 O 
. O 
The O 
latter O 
is O 
a O 
multifaceted O 
cellular O 
entity O 
with O 
variable O 
subcellular O 
locations O 
, O 
including O 
the O 
mitochondrial O 
compartment O 
. O 
Cx43 O 
forms O 
hemichannels O 
and O 
gap O 
junctions O 
that O 
are O 
involved O 
in O 
a O 
plethora O 
of O 
physiological O 
and O 
pathological O 
processes O 
, O 
such O 
as O 
apoptosis O 
. O 
The O 
present O 
study O 
was O 
conducted O 
with O 
the O 
goal O 
of O 
shedding O 
more O 
light O 
onto O 
the O 
role O 
of O 
connexin43 O 
in O 
primary O 
hepatocyte O 
cultures O 
. O 
Connexin43 O 
expression O 
was O 
suppressed O 
by O 
means O 
of O 
RNA O 
interference O 
technology O 
, O 
and O 
the O 
overall O 
outcome O 
of O 
this O 
treatment O 
on O 
the O 
hepatocellular O 
proteome O 
and O 
metabolome O 
was O 
investigated O 
using O 
tandem O 
mass O 
tag O 
- O 
based O 
differential O 
protein O 
profiling O 
and O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
, O 
respectively O 
. O 
Global O 
protein O 
profiling O 
revealed O 
a O 
number O 
of O 
targets O 
of O 
the O 
connexin43 O 
knock O 
- O 
down O 
procedure O 
, O 
including O 
mitochondrial O 
proteins O 
( O 
heat O 
shock O 
protein O 
60 O 
, O 
glucose B-TRIVIAL 
-regulated O 
protein O 
75 O 
, O 
thiosulphate B-SYSTEMATIC 
sulphurtransferase O 
and O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
synthase O 
) O 
and O 
detoxifying O 
enzymes O 
( O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
μ O 
2 O 
and O 
cytochrome O 
P450 O 
2C70 O 
) O 
. O 
At O 
the O 
metabolomic O 
level O 
, O 
connexin43 O 
silencing O 
caused O 
no O 
overt O 
changes O 
, O 
though O 
there O 
was O 
some O 
evidence O 
for O 
a O 
subtle O 
increase O 
in O 
intracellular O 
glycine B-TRIVIAL 
quantities O 
. O 
Collectively O 
, O 
these O 
data O 
could O 
further O 
substantiate O 
the O 
established O 
existence O 
of O 
a O 
mitochondrial O 
connexin O 
pool O 
and O 
could O 
be O 
reconciled O 
with O 
the O 
previously O 
reported O 
involvement O 
of O 
connexin43 O 
signalling O 
in O 
spontaneously O 
occurring O 
apoptosis O 
in O 
primary O 
hepatocyte O 
cultures O 
. O 

parameters O 
related O 
to O 
the O 
photoelectrochemical O 
properties O 
, O 
such O 
as O 
ground O 
state O 
geometries O 
, O 
electronic O 
structures O 
, O 
oxidation O 
potential O 
and O 
electron O 
driving O 
force O 
, O 
of O 
cochineal O 
insect O 
dyes O 
were O 
investigated O 
by O 
DFT O 
and O 
TDDFT O 
at O 
the O 
B3LYP O 
/ O 
6-31 O 
+ O 
G(d,p) O 
level O 
of O 
the O 
theory O 
. O 
The O 
results O 
show O 
that O 
the O 
major O 
charge O 
flow O 
dynamic O 
for O 
all O 
dyes O 
is O 
the O 
HOMO→LUMO O 
transition O 
. O 
The O 
bi O 
- O 
coordinated O 
binding O 
mode O 
, O 
in O 
which O 
the O 
dye O 
uses O 
one O 
carboxyl- B-MULTIPLE 
and I-MULTIPLE 
hydroxyl I-MULTIPLE 
oxygen I-MULTIPLE 
bound O 
to O 
Ti B-FORMULA 
(IV) I-FORMULA 
, O 
is O 
found O 
for O 
all O 
dye- O 
TiO(2) B-FORMULA 
systems O 
. O 
Additionally O 
, O 
the O 
doubly O 
bi O 
- O 
coordinated O 
binding O 
mode O 
in O 
which O 
the O 
dye O 
used O 
both O 
carboxyl B-SYSTEMATIC 
groups O 
bound O 
to O 
two O 
Ti B-FORMULA 
(IV) I-FORMULA 
is O 
also O 
possible O 
due O 
to O 
high O 
energy O 
distribution O 
occupied O 
at O 
anchoring O 
groups O 
. O 
This O 
study O 
highlights O 
that O 
most O 
of O 
these O 
insect O 
dyes O 
can O 
be O 
good O 
photosensitizers O 
in O 
dye O 
- O 
sensitized O 
solar O 
cells O 
based O 
on O 
their O 
strong O 
binding O 
to O 
the O 
TiO(2) B-FORMULA 
surface O 
, O 
good O 
computed O 
excited O 
state O 
oxidation O 
potential O 
and O 
thermodynamically O 
favored O 
electron O 
driving O 
force O 
. O 

vibrational O 
spectroscopy O 
characterization O 
of O 
epoxy B-SYSTEMATIC 
graphene I-SYSTEMATIC 
oxide I-SYSTEMATIC 
from O 
density O 
functional O 
calculations O 
. O 

further O 
understand O 
the O 
structure O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
several O 
structures O 
of O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
were O 
systematically O 
investigated O 
using O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
. O 
Our O 
models O 
consisted O 
of O 
a O 
hexagonal O 
in O 
- O 
plane O 
structure O 
of O 
graphene B-TRIVIAL 
with O 
epoxy B-SYSTEMATIC 
groups O 
, O 
and O 
different O 
oxidation O 
levels O 
. O 
We O 
found O 
that O 
different O 
arrangements O 
of O 
these O 
units O 
yielded O 
a O 
range O 
of O 
vibrational O 
spectra O 
. O 
Raman O 
positions O 
of O 
the O 
D O 
and O 
G O 
bands O 
depend O 
sensitively O 
on O 
the O 
local O 
atomic O 
configurations O 
. O 
Both O 
structure O 
energy O 
and O 
spectra O 
computations O 
indicate O 
that O 
the O 
oxidation O 
functional O 
groups O 
are O 
energetically O 
favorable O 
to O 
aggregate O 
together O 
and O 
to O 
be O 
close O 
to O 
one O 
another O 
on O 
the O 
opposite O 
side O 
of O 
graphene B-TRIVIAL 
surface O 
. O 

lateral O 
sclerosis O 
( O 
ALS O 
) O 
is O 
a O 
progressive O 
and O 
fatal O 
degenerative O 
disorder O 
of O 
motor O 
neurons O 
. O 
The O 
cause O 
of O 
this O 
degeneration O 
is O 
unknown O 
, O 
and O 
different O 
causal O 
hypotheses O 
include O 
genetic O 
, O 
viral O 
, O 
traumatic O 
and O 
environmental O 
mechanisms O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
analyzed O 
metal O 
concentrations O 
in O 
cerebrospinal O 
fluid O 
( O 
CSF O 
) O 
and O 
blood O 
plasma O 
in O 
a O 
well O 
- O 
defined O 
cohort O 
( O 
n O 
= O 
17 O 
) O 
of O 
ALS O 
patients O 
diagnosed O 
with O 
quantitative O 
electromyography O 
. O 
Metal O 
analyses O 
were O 
performed O 
with O 
high O 
- O 
resolution O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
. O 
Statistically O 
significant O 
higher O 
concentrations O 
of O 
manganese B-SYSTEMATIC 
, O 
aluminium B-SYSTEMATIC 
, O 
cadmium B-SYSTEMATIC 
, O 
cobalt B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
, O 
lead O 
, O 
vanadium B-SYSTEMATIC 
and O 
uranium B-SYSTEMATIC 
were O 
found O 
in O 
ALS O 
CSF O 
compared O 
to O 
control O 
CSF O 
. O 
We O 
also O 
report O 
higher O 
concentrations O 
of O 
these O 
metals O 
in O 
ALS O 
CSF O 
than O 
in O 
ALS O 
blood O 
plasma O 
, O 
which O 
indicate O 
mechanisms O 
of O 
accumulation O 
, O 
e.g O 
. O 
inward O 
directed O 
transport O 
. O 
A O 
pattern O 
of O 
multiple O 
toxic O 
metals O 
is O 
seen O 
in O 
ALS O 
CSF O 
. O 
The O 
results O 
support O 
the O 
hypothesis O 
that O 
metals O 
with O 
neurotoxic O 
effects O 
are O 
involved O 
in O 
the O 
pathogenesis O 
of O 
ALS O 
. O 

Stimulates O 
Hepatic O 
Fat O 
and O 
Cholesterol B-TRIVIAL 
Accumulation O 
in O 
High O 
- O 
fat O 
Diet O 
- O 
fed O 
Rats O 
. O 

study O 
was O 
designed O 
to O 
determine O 
how O 
estrogens B-FAMILY 
withdrawal O 
during O 
a O 
high O 
- O 
fat O 
( O 
HF O 
) O 
diet O 
regimen O 
affects O 
liver O 
triacylglycerol B-FAMILY 
( O 
TAG B-ABBREVIATION 
) O 
and O 
cholesterol B-TRIVIAL 
accumulation O 
. O 
Female O 
Sprague-Dawley O 
rats O 
were O 
submitted O 
to O 
a O 
HF O 
( O 
42% O 
energy O 
as O 
fat O 
) O 
or O 
a O 
standard O 
( O 
SD O 
) O 
diet O 
for O 
6 O 
weeks O 
before O 
being O 
either O 
ovariectomized O 
( O 
Ovx O 
) O 
or O 
sham O 
operated O 
( O 
Sham O 
) O 
. O 
Thereafter O 
, O 
Ovx O 
and O 
Sham O 
rats O 
were O 
kept O 
on O 
the O 
same O 
diet O 
for O 
another O 
6 O 
weeks O 
leading O 
to O 
euthanasia O 
. O 
Liver O 
TAG B-ABBREVIATION 
content O 
was O 
increased O 
( O 
p O 
< O 
0.01 O 
) O 
in O 
Ovx O 
rats O 
but O 
not O 
by O 
the O 
HF O 
diet O 
alone O 
. O 
However O 
, O 
the O 
combination O 
of O 
HF O 
diet O 
and O 
Ovx O 
resulted O 
in O 
a O 
greater O 
liver O 
TAG B-ABBREVIATION 
accumulation O 
( O 
p O 
< O 
0.06 O 
) O 
than O 
that O 
observed O 
in O 
Ovx-SD O 
/ O 
SD O 
. O 
Measurement O 
of O 
molecular O 
markers O 
of O 
liver O 
lipid O 
metabolism O 
revealed O 
an O 
increase O 
in O 
transcripts O 
of O 
markers O 
of O 
lipid O 
oxidation O 
( O 
CPT-1 O 
and O 
PGC1 O 
; O 
p O 
< O 
0.05 O 
) O 
in O 
rats O 
fed O 
the O 
HF O 
diet O 
. O 
This O 
increase O 
was O 
, O 
however O 
, O 
substantially O 
less O 
if O 
HF O 
fed O 
rats O 
were O 
Ovx O 
. O 
Liver O 
total O 
cholesterol B-TRIVIAL 
levels O 
were O 
increased O 
( O 
p O 
< O 
0.01 O 
) O 
only O 
in O 
the O 
Ovx-HF O 
/ O 
HF O 
rats O 
while O 
plasma O 
cholesterol B-TRIVIAL 
levels O 
were O 
increased O 
in O 
Ovx-SD O 
/ O 
SD O 
and O 
in O 
SHAM-HF O 
/ O 
HF O 
and O 
Ovx-HF O 
/ O 
HF O 
rats O 
. O 
Transcripts O 
of O 
molecular O 
markers O 
of O 
cholesterol B-TRIVIAL 
metabolism O 
suggest O 
that O 
biliary B-FAMILY 
acids I-FAMILY 
synthesis O 
( O 
CYP7a-1 O 
) O 
was O 
reduced O 
in O 
Ovx-SD O 
/ O 
SD O 
and O 
Sham-HF O 
/ O 
HF O 
rats O 
and O 
even O 
more O 
so O 
in O 
Ovx-HF O 
/ O 
HF O 
rats O 
. O 
It O 
is O 
concluded O 
that O 
the O 
effects O 
of O 
a O 
HF O 
diet O 
on O 
liver O 
TAG B-ABBREVIATION 
accumulation O 
are O 
especially O 
observed O 
in O 
Ovx O 
rats O 
possibly O 
through O 
a O 
reduction O 
in O 
hepatic O 
lipid O 
oxidation O 
. O 
The O 
combination O 
of O 
Ovx O 
and O 
HF O 
diet O 
also O 
acts O 
synergistically O 
to O 
favor O 
liver O 
cholesterol B-TRIVIAL 
accumulation O 
. O 

vitro O 
antileishmanial O 
activity O 
of O 
resveratrol B-TRIVIAL 
originates O 
from O 
its O 
cytotoxic O 
potential O 
against O 
host O 
cells O 
. O 

addition O 
to O 
a O 
range O 
of O 
beneficial O 
pharmacological O 
activities O 
, O 
resveratrol B-TRIVIAL 
is O 
recently O 
reported O 
to O 
have O 
potential O 
antileishmanial O 
activities O 
in O 
vitro O 
. O 
The O 
present O 
study O 
was O 
conducted O 
to O 
evaluate O 
the O 
effect O 
of O 
resveratrol B-TRIVIAL 
on O 
promastigotes O 
and O 
amastigotes O 
of O 
transgenic O 
Leishmania O 
major O 
expressing O 
green O 
fluorescent O 
protein O 
in O 
comparison O 
with O 
its O 
direct O 
cytotoxic O 
effects O 
on O 
host O 
cells O 
( O 
bone O 
marrow O 
- O 
derived O 
and O 
J774-G8 O 
macrophages O 
, O 
respectively O 
) O 
. O 
As O 
assessed O 
by O 
FACS O 
analysis O 
, O 
resveratrol B-TRIVIAL 
showed O 
moderate O 
antipromastigote O 
activity O 
at O 
< O 
35 O 
µg O 
/ O 
mL O 
( O 
153.2 O 
µM O 
) O 
and O 
promising O 
effects O 
at O 
higher O 
sample O 
concentrations O 
. O 
In O 
contrast O 
, O 
the O 
green O 
fluorescent O 
protein O 
signal O 
as O 
a O 
measure O 
of O 
the O 
intracellular O 
parasites O 
' O 
viability O 
was O 
reduced O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Resveratrol B-TRIVIAL 
strongly O 
inhibited O 
NO B-FORMULA 
production O 
, O 
but O 
did O 
not O 
display O 
direct O 
NO B-FORMULA 
-scavenging O 
activity O 
in O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
solution O 
. O 
Western O 
blotting O 
indicated O 
that O 
resveratrol B-TRIVIAL 
reduced O 
recombinant O 
interferon-γ O 
/ O 
LPS-induced O 
expression O 
of O 
iNOS O 
protein O 
. O 
Microscopic O 
studies O 
, O 
MTT B-ABBREVIATION 
evaluation O 
, O 
and O 
FACS O 
analysis O 
showed O 
significant O 
cytotoxic O 
effects O 
on O 
host O 
cells O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
This O 
finding O 
suggests O 
that O 
the O 
in O 
vitro O 
antileishmanial O 
activity O 
of O 
resveratrol B-TRIVIAL 
is O 
due O 
to O 
cytotoxic O 
effects O 
on O 
host O 
cells O 
rather O 
than O 
attributable O 
to O 
a O 
specific O 
antiparasitic O 
potential O 
. O 

cycloartane B-TRIVIAL 
triterpenes B-FAMILY 
of O 
the O 
traditional O 
Chinese O 
medicine O 
" O 
shengma O 
" O 
( O 
Cimicifuga O 
dahurica O 
) O 
. O 

new O 
9,19-cycloartane B-SYSTEMATIC 
triterpenes B-FAMILY 
( O 
1-12 O 
) O 
, O 
together O 
with O 
fourteen O 
known O 
compounds O 
( O 
13-26 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Cimicifuga O 
dahurica O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
application O 
of O 
spectroscopic O 
analyses O 
and O 
chemical O 
methods O 
. O 
Biological O 
evaluation O 
of O 
the O 
compounds O 
against O 
human O 
HL-60 O 
, O 
SMMC-7721 O 
, O 
A549 O 
, O 
MCF-7 O 
, O 
and O 
SW-480 O 
cell O 
lines O 
indicated O 
that O 
cimigenol B-TRIVIAL 
-type O 
glycosides O 
( O 
1-3 O 
, O 
19 O 
, O 
and O 
20 O 
) O 
showed O 
broad O 
- O 
spectrum O 
and O 
moderate O 
cytotoxicities O 
, O 
with O 
IC50 O 
values O 
ranging O 
from O 
4.2 O 
to O 
14.5 O 
µM O 
. O 
Meanwhile O 
, O 
cimigenol B-TRIVIAL 
-type O 
aglycones O 
( O 
6-8 O 
, O 
15 O 
, O 
16 O 
, O 
and O 
18 O 
) O 
exhibited O 
broad O 
- O 
spectrum O 
and O 
week O 
cytotoxicities O 
, O 
having O 
IC50 O 
values O 
around O 
20 O 
µM O 
. O 
In O 
addition O 
, O 
the O 
key O 
points O 
of O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
aglycones O 
with O 
a O 
cimigenol B-TRIVIAL 
skeleton O 
were O 
discussed O 
. O 

toxicity O 
of O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
and O 
heavy O 
metals O 
to O 
biochemical O 
and O 
antioxidant O 
responses O 
of O 
free O 
and O 
immobilized O 
Selenastrum O 
capricornutum O 
. O 

aquatic O 
environment O 
often O 
contains O 
different O 
groups O 
of O 
contaminants O 
, O 
but O 
their O 
combined O 
toxicity O 
on O 
microalgae O 
has O 
seldom O 
been O 
reported O 
. O 
The O 
present O 
study O 
compared O 
the O 
toxic O 
effects O 
of O 
combined O 
mixed O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
PAHs B-ABBREVIATION 
) O 
and O 
heavy O 
metals O 
on O 
growth O 
and O 
antioxidant O 
responses O 
of O 
free O 
and O 
immobilized O 
microalga O 
, O 
Selenastrum O 
capricornutum O 
. O 
Five O 
PAHs B-ABBREVIATION 
- O 
phenanthrene B-SYSTEMATIC 
, O 
fluorene B-SYSTEMATIC 
, O 
fluoranthene B-SYSTEMATIC 
, O 
pyrene B-SYSTEMATIC 
, O 
and O 
benzo[a]pyrene B-SYSTEMATIC 
-and O 
four O 
heavy O 
metals O 
at O 
different O 
concentrations-0.05 O 
to O 
0.1 O 
µg O 
Cd(2+) B-FORMULA 
ml(-1) O 
, O 
0.05 O 
to O 
1 O 
µg O 
Cu(2+) B-FORMULA 
ml(-1) O 
, O 
0.05 O 
to O 
1 O 
µg O 
Zn(2+) B-FORMULA 
ml(-1) O 
, O 
and O 
0.5 O 
to O 
2.5 O 
µg O 
Ni(2+) B-FORMULA 
ml(-1) O 
-were O 
examined O 
. O 
Results O 
showed O 
that O 
the O 
chlorophyll B-TRIVIAL 
a I-TRIVIAL 
content O 
of O 
free O 
and O 
immobilized O 
S O 
. O 
capricornutum O 
was O 
not O 
affected O 
by O 
PAHs B-ABBREVIATION 
but O 
was O 
significantly O 
inhibited O 
by O 
heavy O 
metals O 
. O 
Conversely O 
, O 
the O 
antioxidant O 
parameters O 
, O 
including O 
the O 
content O 
of O 
reduced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
and O 
peroxidase O 
, O 
were O 
significantly O 
induced O 
by O 
both O 
PAHs B-ABBREVIATION 
and O 
metals O 
. O 
For O 
the O 
combined O 
toxic O 
effects O 
of O 
PAHs B-ABBREVIATION 
and O 
heavy O 
metals O 
, O 
cell O 
growth O 
and O 
antioxidant O 
responses O 
varied O 
with O 
exposure O 
time O 
and O 
contaminants O 
and O 
differed O 
between O 
free O 
and O 
immobilized O 
cells O 
. O 
The O 
effects O 
of O 
cocontaminants O 
on O 
the O 
GSH B-ABBREVIATION 
content O 
in O 
free O 
cells O 
were O 
mainly O 
synergistic O 
but O 
changed O 
to O 
antagonistic O 
in O 
immobilized O 
cells O 
. O 
The O 
toxic O 
effects O 
of O 
cocontamination O 
on O 
free O 
cells O 
were O 
also O 
more O 
obvious O 
than O 
those O 
on O 
immobilized O 
cells O 
. O 
These O 
findings O 
suggest O 
that O 
immobilization O 
offers O 
some O 
protection O 
to O 
microalgal O 
cells O 
against O 
toxic O 
contaminants O 
causing O 
differences O 
in O 
the O 
interaction O 
and O 
responses O 
to O 
combined O 
toxicants O 
between O 
free O 
and O 
immobilized O 
cells O 
. O 
Immobilized O 
cells O 
might O 
be O 
more O 
suitable O 
for O 
treating O 
wastewater O 
containing O 
toxic O 
contaminants O 
than O 
free O 
cells O 
. O 

uniform O 
core O 
- O 
shell O 
Fe3O4 B-FORMULA 
@mSiO2 O 
mesoporous O 
nanoparticles O 
for O 
bimodal O 
imaging O 
and O 
photothermal O 
therapy O 
. O 

imaging O 
and O 
simultaneous O 
therapy O 
is O 
highly O 
desirable O 
because O 
it O 
can O 
provide O 
complementary O 
information O 
from O 
each O 
imaging O 
modality O 
for O 
accurate O 
diagnosis O 
and O 
, O 
at O 
the O 
same O 
time O 
, O 
afford O 
an O 
imaging O 
- O 
guided O 
focused O 
tumor O 
therapy O 
. O 
In O 
this O 
study O 
, O 
indocyanine B-TRIVIAL 
green I-TRIVIAL 
( O 
ICG B-ABBREVIATION 
) O 
, O 
a O 
near O 
- O 
infrared O 
( O 
NIR O 
) O 
imaging O 
agent O 
and O 
perfect O 
NIR O 
light O 
absorber O 
for O 
laser O 
- O 
mediated O 
photothermal O 
therapy O 
, O 
was O 
successfully O 
incorporated O 
into O 
superparamagnetic O 
Fe(3)O(4) B-FORMULA 
@mSiO(2) O 
core O 
- O 
shell O 
nanoparticles O 
to O 
combine O 
the O 
merit O 
of O 
NIR O 
/ O 
magnetic O 
resonance O 
( O 
MR O 
) O 
bimodal O 
imaging O 
properties O 
with O 
NIR O 
photothermal O 
therapy O 
. O 
The O 
resultant O 
nanoparticles O 
were O 
homogenously O 
coated O 
with O 
poly(allylamine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAH B-ABBREVIATION 
) O 
to O 
make O 
the O 
surface O 
of O 
the O 
composite O 
nanoparticles O 
positively O 
charged O 
, O 
which O 
would O 
enhance O 
cellular O 
uptake O 
driven O 
by O 
electrostatic O 
interactions O 
between O 
the O 
positive O 
surface O 
of O 
the O 
nanoparticles O 
and O 
the O 
negative O 
surface O 
of O 
the O 
cancer O 
cell O 
. O 
A O 
high O 
biocompatibility O 
of O 
the O 
achieved O 
nanoparticles O 
was O 
demonstrated O 
by O 
using O 
a O 
cell O 
cytotoxicity O 
assay O 
. O 
Moreover O 
, O 
confocal O 
laser O 
scanning O 
microscopy O 
( O 
CLSM O 
) O 
observations O 
indicated O 
excellent O 
NIR O 
fluorescent O 
imaging O 
properties O 
of O 
the O 
ICG B-ABBREVIATION 
-loaded O 
nanoparticles O 
. O 
The O 
relatively O 
high O 
r(2) O 
value O 
( O 
171.6 O 
mM(-1) O 
s(-1) O 
) O 
of O 
the O 
nanoparticles O 
implies O 
its O 
excellent O 
capability O 
as O 
a O 
contrast O 
agent O 
for O 
MRI O 
. O 
More O 
importantly O 
, O 
the O 
ICG B-ABBREVIATION 
-loaded O 
nanoparticles O 
showed O 
perfect O 
NIR O 
photothermal O 
therapy O 
properties O 
, O 
thus O 
indicating O 
their O 
potential O 
for O 
simultaneous O 
cancer O 
diagnosis O 
as O 
highly O 
effective O 
NIR O 
/ O 
MR O 
bimodal O 
imaging O 
probes O 
and O 
for O 
NIR O 
photothermal O 
therapy O 
of O 
cancerous O 
cells O 
. O 

new O 
class O 
of O 
non-ionic O 
dendronized O 
multiamphiphilic O 
polymers O 
is O 
prepared O 
from O 
a O 
biodegradable O 
(AB)n O 
- O 
type O 
diblock O 
polymer O 
synthesized O 
from O 
2-azido-1,3-propanediol B-SYSTEMATIC 
( O 
azido B-SYSTEMATIC 
glycerol I-SYSTEMATIC 
) O 
and O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
)-600 O 
diethylester B-SYSTEMATIC 
using O 
Novozym-435 O 
( O 
Candida O 
antarctica O 
lipase O 
) O 
as O 
a O 
biocatalyst O 
, O 
following O 
a O 
well O 
- O 
established O 
biocatalytic O 
route O 
. O 
These O 
polymers O 
are O 
functionalized O 
with O 
dendritic O 
polyglycerols B-FAMILY 
( O 
G1 O 
and O 
G2 O 
) O 
and O 
octadecyl B-SYSTEMATIC 
chains O 
in O 
different O 
functionalization O 
levels O 
via O 
click O 
chemistry O 
to O 
generate O 
dendronized O 
multiamphiphilic O 
polymers O 
. O 
Surface O 
tension O 
measurements O 
and O 
dynamic O 
light O 
scattering O 
studies O 
reveal O 
that O 
all O 
of O 
the O 
multiamphiphilic O 
polymers O 
spontaneously O 
self O 
- O 
assemble O 
in O 
aqueous O 
solution O 
. O 
Cryogenic O 
transmission O 
electron O 
microscopy O 
further O 
proves O 
the O 
formation O 
of O 
multiamphiphiles O 
towards O 
monodisperse O 
spherical O 
micelles O 
of O 
about O 
7-9 O 
nm O 
in O 
diameter O 
. O 
The O 
evidence O 
from O 
UV-vis O 
and O 
fluorescence O 
spectroscopy O 
suggests O 
the O 
effective O 
solubilization O 
of O 
hydrophobic O 
guests O 
like O 
pyrene B-SYSTEMATIC 
and O 
1-anilinonaphthalene-8-sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
within O 
the O 
hydrophobic O 
core O 
of O 
the O 
micelles O 
. O 
These O 
results O 
demonstrate O 
the O 
potential O 
of O 
these O 
dendronized O 
multiamphiphilic O 
polymers O 
for O 
the O 
development O 
of O 
prospective O 
drug O 
delivery O 
systems O 
for O 
the O 
solubilization O 
of O 
poorly O 
water O 
soluble O 
drugs O 
. O 

ancestors O 
of O 
RNA O 
? O 
There O 
is O 
a O 
long O 
- O 
standing O 
proposal O 
that O 
contemporary O 
nucleic B-FAMILY 
acids I-FAMILY 
might O 
have O 
evolved O 
from O 
RNA O 
- O 
like O 
polymers O 
that O 
utilized O 
only O 
purine B-TRIVIAL 
- O 
purine B-TRIVIAL 
base O 
pairs O 
. O 
Here O 
we O 
demonstrate O 
the O 
great O 
advantage O 
that O 
increased O 
nucleobase O 
stacking O 
area O 
provides O 
for O 
nonenzymatic O 
ligation O 
. O 

of O 
functional O 
water O 
- O 
soluble O 
low O 
- O 
cytotoxic O 
poly(methacrylate)s B-FAMILY 
with O 
pendant O 
cationic O 
L-lysines B-FAMILY 
for O 
efficient O 
gene O 
delivery O 
. O 

this O 
work O 
, O 
we O 
present O 
the O 
preparation O 
of O 
water O 
- O 
soluble O 
poly(methacrylate)s B-FAMILY 
with O 
pendant O 
cationic O 
L-lysines B-FAMILY 
PHMLs(6-30 O 
K) O 
. O 
Plasmid O 
DNA O 
binding O 
affinity O 
as O 
well O 
as O 
particle O 
sizes O 
and O 
zeta O 
potentials O 
of O 
the O 
polyplexes O 
were O 
examined O 
for O 
these O 
PHML O 
vectors O 
, O 
and O 
their O 
cytotoxicities O 
were O 
assayed O 
with O 
HeLa O 
cells O 
by O 
CCK-8 O 
and O 
lactate O 
dehydrogenase O 
kits O 
. O 
Gene O 
transfection O 
efficacy O 
and O 
intracellular O 
uptake O 
of O 
the O 
polyplexes O 
by O 
the O 
PHML O 
vectors O 
were O 
also O 
studied O 
with O 
HeLa O 
cells O 
. O 
As O 
a O 
result O 
, O 
it O 
was O 
revealed O 
that O 
the O 
low O 
cytotoxic O 
PHMLs O 
tended O 
to O 
exhibit O 
gene O 
transfection O 
efficiencies O 
significantly O 
higher O 
than O 
those O 
of O 
the O 
linear O 
structural O 
PLL O 
( O 
15-30 O 
K O 
) O 
control O 
, O 
in O 
particular O 
the O 
molecular O 
weight O 
of O 
a O 
PHML O 
vector O 
remarkably O 
influenced O 
its O 
pDNA O 
binding O 
affinity O 
, O 
transfection O 
efficacy O 
and O 
intracellular O 
uptake O 
of O 
the O 
polyplexes O 
. O 

fibrous O 
networks O 
of O 
cellulose O 
nanofibres O 
and O 
collagen O 
crosslinked O 
using O 
genipin B-TRIVIAL 
: O 
potential O 
as O 
artificial O 
ligament O 
/ O 
tendons O 
. O 

- O 
based O 
fibrous O 
nanocomposites O 
of O 
cellulose O 
nanofibres O 
and O 
non-crosslinked O 
/ O 
crosslinked O 
collagen O 
were O 
prepared O 
by O 
in O 
situ O 
pH-induced O 
fibrillation O 
of O 
collagen O 
phase O 
and O 
sterilized O 
using O 
gamma O 
rays O 
at O 
25 O 
KGy O 
. O 
Collagen O 
phase O 
is O 
crosslinked O 
using O 
genipin B-TRIVIAL 
, O 
a O 
bio O 
- O 
based O 
crosslinker O 
that O 
introduces O 
flexible O 
crosslinks O 
. O 
Microscopy O 
studies O 
of O 
the O 
prepared O 
materials O 
showed O 
nanostructured O 
fibrous O 
collagen O 
and O 
cellulose O 
dispersed O 
in O 
collagen O 
matrix O 
. O 
Mechanical O 
performance O 
of O 
the O 
sterilized O 
nanocomposites O 
was O 
close O 
to O 
that O 
of O 
natural O 
ligament O 
and O 
tendon O 
, O 
in O 
simulated O 
body O 
conditions O 
. O 
Cytocompatibility O 
studies O 
indicated O 
that O 
these O 
nanocomposites O 
allowed O 
human O 
ligament O 
cell O 
and O 
human O 
endothelial O 
cell O 
adhesion O 
, O 
growth O 
, O 
and O 
differentiation O 
; O 
which O 
is O 
eminently O 
favourable O 
to O 
ligament O 
tissue O 
engineering O 
. O 

sulfoximines I-FAMILY 
: O 
COX O 
inhibition O 
, O 
anticancer O 
activity O 
, O 
cellular O 
toxicity O 
, O 
and O 
mutagenicity O 
. O 

insects O 
to O 
cancer O 
: O 
N-Cyano B-FAMILY 
sulfoximines I-FAMILY 
were O 
evaluated O 
for O 
COX O 
inhibition O 
and O 
antiproliferative O 
activity O 
against O 
a O 
panel O 
of O 
cancer O 
cell O 
lines O 
. O 
The O 
most O 
active O 
compound O 
exhibited O 
potent O 
COX-2 O 
inhibition O 
, O 
some O 
selectivity O 
for O 
COX-2 O 
over O 
COX-1 O 
, O 
only O 
slight O 
cytotoxicity O 
towards O 
healthy O 
cells O 
( O 
HaCaT O 
skin O 
cells O 
) O 
, O 
and O 
no O 
mutagenic O 
potential O 
( O 
as O 
determined O 
by O 
an O 
Ames O 
assay O 
) O 
. O 

nervous O 
system O 
disposition O 
and O 
metabolism O 
of O 
Fosdevirine B-TRIVIAL 
( O 
GSK2248761 B-IDENTIFIER 
) O 
, O 
a O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitor O 
: O 
an O 
LC-MS O 
and O 
Matrix O 
- O 
assisted O 
laser O 
desorption O 
/ O 
ionization O 
imaging O 
MS O 
investigation O 
into O 
central O 
nervous O 
system O 
toxicity O 
. O 

CNS O 
disposition O 
and O 
metabolism O 
of O 
Fosdevirine B-TRIVIAL 
( O 
FDV B-ABBREVIATION 
) O 
, O 
an O 
HIV O 
non- O 
nucleoside B-FAMILY 
reverse O 
transcriptase O 
inhibitor O 
, O 
was O 
investigated O 
in O 
four O 
patients O 
who O 
unexpectedly O 
experienced O 
seizures O 
after O 
at O 
least O 
4 O 
weeks O 
of O 
treatment O 
in O 
a O 
Phase O 
IIb O 
, O 
HIV-1 O 
treatment O 
experienced O 
study O 
. O 
In O 
addition O 
, O 
the O 
CNS O 
disposition O 
and O 
metabolism O 
of O 
FDV B-ABBREVIATION 
was O 
examined O 
in O 
samples O 
from O 
rabbit O 
, O 
minipig O 
, O 
and O 
monkey O 
studies O 
. O 
LC-MS O 
was O 
used O 
to O 
characterize O 
and O 
estimate O 
the O 
concentrations O 
of O 
FDV B-ABBREVIATION 
and O 
its O 
metabolites O 
in O 
cerebral O 
spinal O 
fluid O 
( O 
seizure O 
patients O 
, O 
rabbit O 
, O 
and O 
monkey O 
) O 
and O 
brain O 
homogenate O 
( O 
rabbit O 
, O 
minipig O 
, O 
and O 
monkey O 
) O 
. O 
The O 
application O 
of O 
matrix O 
- O 
assisted O 
laser O 
desorption O 
/ O 
ionization O 
imaging O 
mass O 
spectrometry O 
( O 
MALDI O 
IMS O 
) O 
provided O 
the O 
spatial O 
distribution O 
of O 
FDV B-ABBREVIATION 
and O 
its O 
metabolites O 
in O 
brain O 
tissue O 
( O 
rabbit O 
, O 
minipig O 
, O 
and O 
monkey O 
) O 
. O 
A O 
cysteine B-TRIVIAL 
conjugate O 
metabolite O 
resulting O 
from O 
an O 
initial O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
Michael O 
addition O 
to O 
the O 
trans-phenyl B-SYSTEMATIC 
acrylonitrile I-SYSTEMATIC 
moiety O 
of O 
FDV B-ABBREVIATION 
was O 
the O 
predominant O 
drug O 
- O 
related O 
component O 
in O 
the O 
samples O 
from O 
seizure O 
patients O 
, O 
rabbits O 
, O 
and O 
minipigs O 
. O 
This O 
metabolite O 
persisted O 
in O 
the O 
CNS O 
for O 
an O 
extended O 
period O 
of O 
time O 
after O 
the O 
last O 
dose O 
in O 
both O 
seizure O 
patients O 
and O 
minipigs O 
. O 
Furthermore O 
, O 
the O 
localization O 
of O 
this O 
metabolite O 
was O 
found O 
to O 
be O 
highly O 
associated O 
with O 
the O 
white O 
matter O 
in O 
rabbit O 
and O 
minipig O 
brain O 
sections O 
by O 
MALDI O 
IMS O 
. O 
In O 
contrast O 
, O 
the O 
predominant O 
component O 
in O 
monkey O 
CNS O 
was O 
FDV B-ABBREVIATION 
, O 
which O 
was O 
shown O 
to O 
be O 
highly O 
associated O 
with O 
the O 
gray O 
matter O 
. O 
On O 
the O 
basis O 
of O 
these O 
data O 
, O 
several O 
hypothesizes O 
are O 
considered O 
, O 
which O 
might O 
provide O 
insights O 
into O 
species O 
differences O 
in O 
CNS O 
toxicity O 
/ O 
seizures O 
observed O 
after O 
FDV B-ABBREVIATION 
dosing O 
. O 

electrical O 
properties O 
of O 
metal O 
- O 
doped O 
In2O3 B-FORMULA 
nanowires O 
for O 
high O 
- O 
performance O 
enhancement-mode O 
transistors O 
. O 

recent O 
years O 
, O 
In(2)O(3) B-FORMULA 
nanowires O 
( O 
NWs O 
) O 
have O 
been O 
widely O 
explored O 
in O 
many O 
technological O 
areas O 
due O 
to O 
their O 
excellent O 
electrical O 
and O 
optical O 
properties O 
; O 
however O 
, O 
most O 
of O 
these O 
devices O 
are O 
based O 
on O 
In(2)O(3) B-FORMULA 
NW O 
field O 
- O 
effect O 
transistors O 
( O 
FETs O 
) O 
operating O 
in O 
the O 
depletion O 
mode O 
, O 
which O 
induces O 
relatively O 
higher O 
power O 
consumption O 
and O 
fancier O 
circuit O 
integration O 
design O 
. O 
Here O 
, O 
n O 
- O 
type O 
enhancement-mode O 
In(2)O(3) B-FORMULA 
NW O 
FETs O 
are O 
successfully O 
fabricated O 
by O 
doping O 
different O 
metal O 
elements O 
( O 
Mg B-FORMULA 
, O 
Al B-FORMULA 
, O 
and O 
Ga B-FORMULA 
) O 
in O 
the O 
NW O 
channels O 
. O 
Importantly O 
, O 
the O 
resulting O 
threshold O 
voltage O 
can O 
be O 
effectively O 
modulated O 
through O 
varying O 
the O 
metal O 
( O 
Mg B-FORMULA 
, O 
Ga B-FORMULA 
, O 
and O 
Al B-FORMULA 
) O 
content O 
in O 
the O 
NWs O 
. O 
A O 
series O 
of O 
scaling O 
effects O 
in O 
the O 
mobility O 
, O 
transconductance O 
, O 
threshold O 
voltage O 
, O 
and O 
source O 
- O 
drain O 
current O 
with O 
respect O 
to O 
the O 
device O 
channel O 
length O 
are O 
also O 
observed O 
. O 
Specifically O 
, O 
a O 
small O 
gate O 
delay O 
time O 
( O 
0.01 O 
ns O 
) O 
and O 
high O 
on O 
- O 
current O 
density O 
( O 
0.9 O 
mA O 
/ O 
μm O 
) O 
are O 
obtained O 
at O 
300 O 
nm O 
channel O 
length O 
. O 
Furthermore O 
, O 
Mg B-FORMULA 
-doped O 
In(2)O(3) B-FORMULA 
NWs O 
are O 
then O 
employed O 
to O 
fabricate O 
NW O 
parallel O 
array O 
FETs O 
with O 
a O 
high O 
saturation O 
current O 
( O 
0.5 O 
mA O 
) O 
, O 
on O 
/ O 
off O 
ratio O 
( O 
> O 
10(9) O 
) O 
, O 
and O 
field O 
- O 
effect O 
mobility O 
( O 
110 O 
cm(2) O 
/ O 
V·s O 
) O 
, O 
while O 
the O 
subthreshold O 
slope O 
and O 
threshold O 
voltage O 
do O 
not O 
show O 
any O 
significant O 
changes O 
. O 
All O 
of O 
these O 
results O 
indicate O 
the O 
great O 
potency O 
for O 
metal O 
- O 
doped O 
In(2)O(3) B-FORMULA 
NWs O 
used O 
in O 
the O 
low O 
- O 
power O 
, O 
high O 
- O 
performance O 
thin O 
- O 
film O 
transistors O 
. O 

new O 
antibacterial O 
phenanthrenequinone B-SYSTEMATIC 
from O 
Dendrobium O 
sinense O 
. O 

new O 
phenanthrenequinone B-SYSTEMATIC 
, O 
named O 
denbinobin B-TRIVIAL 
B I-TRIVIAL 
( O 
1 O 
) O 
, O 
together O 
with O 
three O 
known O 
phenanthrenes B-FAMILY 
was O 
isolated O 
from O 
the O 
whole O 
plant O 
of O 
Dendrobium O 
sinense O 
T O 
. O 
Tang O 
et O 
F.T O 
. O 
Wang O 
, O 
an O 
endemic O 
and O 
endangered O 
orchid O 
to O 
Hainan O 
Island O 
. O 
The O 
new O 
compound O 
was O 
elucidated O 
using O 
a O 
combination O 
of O 
1D O 
, O 
2D O 
NMR O 
( O 
COSY O 
, O 
HMQC O 
, O 
and O 
HMBC O 
) O 
techniques O 
, O 
and O 
HR-ESI-MS O 
analyses O 
. O 
Compound O 
1 O 
exhibited O 
moderate O 
antibacterial O 
activity O 
against O 
Staphylococcus O 
aureus O 
with O 
the O 
diameter O 
of O 
the O 
inhibition O 
zone O 
of O 
16.5 O 
mm O 
. O 

novel O 
cytotoxin O 
3,5-bis(4-chlorobenzylidene)-1-[4-{2-(4-morpholinyl)ethoxy}phenyl-carbonyl]-4-piperidone B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
2 O 
demonstrated O 
potent O 
antimalarial O 
properties O 
with O 
IC(50) O 
values O 
of O 
0.6 O 
and O 
1.97 O 
μM O 
against O 
the O 
drug O 
sensitive O 
D6 O 
strain O 
and O 
the O 
C235 O 
drug O 
- O 
resistant O 
strain O 
of O 
Plasmodium O 
falciparum O 
. O 
This O 
compound O 
concentrates O 
in O 
red O 
blood O 
cells O 
, O 
lowers O 
glutathione B-TRIVIAL 
concentrations O 
in O 
erythrocytes O 
and O 
permeates O 
across O 
CACO-2 O 
cells O 
. O 
These O 
data O 
reveal O 
2 O 
to O 
be O 
a O 
promising O 
lead O 
compound O 
in O 
the O 
quest O 
for O 
novel O 
antimalarial O 
agents O 
. O 

regioselective O 
synthesis O 
of O 
novel O 
bioactive O 
thiazolyl-pyrazoline B-FAMILY 
derivatives O 
via O 
a O 
three O 
- O 
component O 
reaction O 
and O 
their O 
antimicrobial O 
activity O 
. O 

series O 
of O 
novel O 
2-(3,5-diphenyl-4,5-dihydro-1H-pyrazol-1-yl)-4-phenylthiazoles B-FAMILY 
have O 
been O 
prepared O 
by O 
a O 
three O 
- O 
component O 
cyclo-condensation O 
of O 
various O 
chalcones B-FAMILY 
, O 
thiosemicarbazide B-SYSTEMATIC 
and O 
phenacyl B-FAMILY 
bromide I-FAMILY 
. O 
The O 
easy O 
work O 
- O 
up O 
of O 
the O 
products O 
, O 
rapid O 
reaction O 
, O 
and O 
mild O 
conditions O 
are O 
notable O 
features O 
of O 
this O 
protocol O 
. O 
The O 
reaction O 
was O 
efficiently O 
catalyzed O 
in O 
one O 
- O 
pot O 
by O 
a O 
few O 
drops O 
of O 
HCl B-FORMULA 
in O 
EtOH B-FORMULA 
under O 
reflux O 
conditions O 
providing O 
the O 
title O 
compounds O 
in O 
moderate O 
to O 
high O 
yields O 
. O 
The O 
antibacterial O 
activity O 
of O 
the O 
selected O 
products O 
was O 
examined O 
. O 
Some O 
products O 
exhibit O 
promising O 
activities O 
. O 

as O 
an O 
activator O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
. O 

is O 
a O 
pyrimidinamine B-TRIVIAL 
fungicide O 
, O 
used O 
worldwide O 
by O 
agriculture O 
. O 
It O 
is O 
used O 
to O 
protect O 
fruit O 
plants O 
and O 
vegetables O 
from O 
a O 
wide O 
range O 
of O 
pathogens O 
. O 
Benzo[a]pyrene B-SYSTEMATIC 
( O 
BaP B-ABBREVIATION 
) O 
and O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
are O 
toxic O 
environmental O 
pollutants O 
and O 
are O 
prototypes O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AHR O 
) O 
ligands O 
. O 
Although O 
the O 
structure O 
of O 
cyprodinil B-TRIVIAL 
distinctly O 
differs O 
from O 
those O 
of O 
BaP B-ABBREVIATION 
and O 
TCDD B-ABBREVIATION 
, O 
our O 
results O 
show O 
that O 
cyprodinil B-TRIVIAL 
induced O 
nuclear O 
translocation O 
of O 
the O 
AHR O 
, O 
and O 
induced O 
the O 
transcriptional O 
activity O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
response O 
element O 
( O 
AHRE O 
) O 
. O 
Cyprodinil B-TRIVIAL 
induced O 
the O 
expression O 
of O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
1A1 O 
, O 
a O 
well O 
- O 
known O 
AHR-targeted O 
gene O 
, O 
in O 
ovarian O 
granulosa O 
cells O 
, O 
HO23 O 
, O 
and O 
hepatoma O 
cells O 
, O 
Hepa-1c1c7 O 
. O 
Its O 
induction O 
did O 
not O 
appear O 
in O 
AHR O 
signal O 
- O 
deficient O 
cells O 
, O 
and O 
was O 
blocked O 
by O 
the O 
AHR O 
antagonist O 
, O 
CH-223191 O 
. O 
Cyprodinil B-TRIVIAL 
decreased O 
AHR O 
expression O 
in O 
HO23 O 
cells O 
, O 
resulting O 
in O 
CYP1A1 O 
expression O 
decreasing O 
after O 
it O 
peaked O 
at O 
9h O 
of O 
treatment O 
in O 
HO23 O 
cells O 
. O 
Dexamethasone B-TRIVIAL 
is O 
a O 
synthetic O 
agonist O 
of O 
glucocorticoids O 
. O 
Cyprodinil B-TRIVIAL 
enhanced O 
dexamethasone B-TRIVIAL 
-induced O 
gene O 
expression O 
, O 
and O 
conversely O 
, O 
its O 
induction O 
of O 
CYP1A1 O 
expression O 
was O 
decreased O 
by O 
dexamethasone B-TRIVIAL 
in O 
HO23 O 
cells O 
, O 
indicating O 
its O 
induction O 
of O 
crosstalk O 
between O 
the O 
AHR O 
and O 
glucocorticoid O 
receptor O 
and O 
its O 
role O 
as O 
a O 
potential O 
endocrine O 
disrupter O 
. O 
In O 
addition O 
to O 
BaP B-ABBREVIATION 
, O 
TCDD B-ABBREVIATION 
, O 
and O 
an O 
AHR O 
agonist O 
, O 
β-NF O 
, O 
cyprodinil B-TRIVIAL 
also O 
phosphorylated O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
in O 
HO23 O 
and O 
Hepa-1c1c7 O 
cells O 
, O 
indicating O 
its O 
deregulation O 
of O 
ERK O 
activity O 
. O 
In O 
summary O 
, O 
our O 
results O 
demonstrate O 
that O 
cyprodinil B-TRIVIAL 
, O 
similar O 
to O 
BaP B-ABBREVIATION 
, O 
acts O 
as O 
an O 
AHR O 
activator O 
, O 
a O 
potential O 
endocrine O 
disrupter O 
, O 
and O 
an O 
ERK O 
disrupter O 
. O 

-mediated O 
downregulation O 
of O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
- O 
dependent O 
excision O 
repair O 
cross O 
- O 
complementing O 
1 O 
decreases O 
DNA O 
repair O 
capacity O 
and O 
sensitizes O 
human O 
lung O 
cancer O 
cells O 
to O 
paclitaxel B-TRIVIAL 
. O 

, O 
an O 
extensively O 
used O 
and O 
well O 
- O 
tolerated O 
drug O 
for O 
treating O 
individuals O 
with O 
type O 
2 O 
diabetes O 
, O 
has O 
recently O 
gained O 
significant O 
attention O 
as O 
an O 
anticancer O 
drug O 
. O 
On O 
the O 
other O 
hand O 
, O 
paclitaxel B-TRIVIAL 
( O 
Taxol B-TRIVIAL 
) O 
is O 
a O 
new O 
antineoplastic O 
drug O 
that O 
has O 
shown O 
promise O 
in O 
the O 
treatment O 
of O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
. O 
High O 
expression O 
levels O 
of O 
excision O 
repair O 
cross O 
- O 
complementary O 
1 O 
( O 
ERCC1 O 
) O 
in O 
cancers O 
have O 
been O 
positively O 
associated O 
with O 
the O 
DNA O 
repair O 
capacity O 
and O 
a O 
poor O 
prognosis O 
in O 
NSCLC O 
patients O 
treated O 
with O 
platinum B-SYSTEMATIC 
-containing O 
chemotherapy O 
. O 
In O 
this O 
current O 
study O 
, O 
paclitaxel B-TRIVIAL 
was O 
found O 
to O 
increase O 
phosphorylation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
kinase O 
3 O 
/ O 
6 O 
( O 
MKK3 O 
/ O 
6)-p38 O 
MAPK O 
as O 
well O 
as O 
protein O 
and O 
mRNA O 
levels O 
of O 
ERCC1 O 
in O 
H1650 O 
and O 
H1703 O 
cells O 
. O 
Moreover O 
, O 
paclitaxel B-TRIVIAL 
-induced O 
ERCC1 O 
protein O 
and O 
mRNA O 
levels O 
significantly O 
decreased O 
via O 
the O 
downregulation O 
of O 
p38 O 
activity O 
by O 
either O 
a O 
p38 O 
MAPK O 
inhibitor O 
SB202190 B-IDENTIFIER 
or O 
p38 O 
knockdown O 
with O 
specific O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
. O 
Specific O 
inhibition O 
of O 
ERCC1 O 
with O 
siRNA O 
was O 
found O 
to O 
enhance O 
the O 
paclitaxel B-TRIVIAL 
-induced O 
cytotoxic O 
effect O 
and O 
growth O 
inhibition O 
. O 
Furthermore O 
, O 
metformin B-TRIVIAL 
was O 
able O 
to O 
not O 
only O 
decrease O 
the O 
paclitaxel B-TRIVIAL 
-induced O 
p38 O 
MAPK O 
- O 
mediated O 
ERCC1 O 
expression O 
, O 
but O 
also O 
augment O 
the O 
cytotoxic O 
effect O 
induced O 
by O 
paclitaxel B-TRIVIAL 
. O 
Finally O 
, O 
expression O 
of O 
constitutive O 
activate O 
MKK6 O 
or O 
HA-p38 O 
MAPK O 
vectors O 
in O 
lung O 
cancer O 
cells O 
was O 
able O 
to O 
abrogate O 
ERCC1 O 
downregulation O 
by O 
metformin B-TRIVIAL 
and O 
paclitaxel B-TRIVIAL 
as O 
well O 
as O 
cell O 
viability O 
and O 
DNA O 
repair O 
capacity O 
. O 
Overall O 
, O 
our O 
results O 
suggest O 
that O 
inhibition O 
of O 
the O 
p38 O 
MAPK O 
signaling O 
by O 
metformin B-TRIVIAL 
coupled O 
with O 
paclitaxel B-TRIVIAL 
therapy O 
in O 
human O 
NSCLC O 
cells O 
may O 
be O 
a O 
clinically O 
useful O 
combination O 
, O 
which O 
however O 
will O 
require O 
further O 
validation O 
. O 

is O 
a O 
highly O 
sensitive O 
target O 
of O 
the O 
antiobesity O 
agent O 
orlistat B-TRIVIAL 
with O 
profound O 
implications O 
in O 
the O 
activation O 
of O 
anticancer O 
prodrugs O 
. O 

has O 
been O 
the O 
most O 
used O 
anti-obesity O 
drug O 
and O 
the O 
mechanism O 
of O 
its O 
action O 
is O 
to O 
reduce O 
lipid O 
absorption O 
by O 
inhibiting O 
gastrointestinal O 
lipases O 
. O 
These O 
enzymes O 
, O 
like O 
carboxylesterases O 
( O 
CESs O 
) O 
, O 
structurally O 
belong O 
to O 
the O 
α O 
/ O 
β O 
hydrolase O 
fold O 
superfamily O 
. O 
Lipases O 
and O 
CESs O 
are O 
functionally O 
related O 
as O 
well O 
. O 
Some O 
CESs O 
( O 
e.g O 
. O 
, O 
human O 
CES1 O 
) O 
have O 
been O 
shown O 
to O 
hydrolyze O 
lipids O 
. O 
This O 
study O 
was O 
designed O 
to O 
test O 
the O 
hypothesis O 
that O 
orlistat B-TRIVIAL 
inhibits O 
CESs O 
with O 
higher O 
potency O 
toward O 
CES1 O 
than O 
CES2 O 
, O 
a O 
carboxylesterase O 
with O 
little O 
lipase O 
activity O 
. O 
Liver O 
microsomes O 
and O 
recombinant O 
CESs O 
were O 
tested O 
for O 
the O 
inhibition O 
of O 
the O 
hydrolysis O 
of O 
standard O 
substrates O 
and O 
the O 
anticancer O 
prodrugs O 
pentyl B-SYSTEMATIC 
carbamate I-SYSTEMATIC 
of O 
p-aminobenzyl B-SYSTEMATIC 
carbamate I-SYSTEMATIC 
of O 
doxazolidine B-TRIVIAL 
( O 
PPD B-ABBREVIATION 
) O 
and O 
irinotecan B-TRIVIAL 
. O 
Contrary O 
to O 
the O 
hypothesis O 
, O 
orlistat O 
at O 
1 O 
nM O 
inhibited O 
CES2 O 
activity O 
by O 
75% O 
but O 
no O 
inhibition O 
on O 
CES1 O 
, O 
placing O 
CES2 O 
one O 
of O 
the O 
most O 
sensitive O 
targets O 
of O 
orlistat B-TRIVIAL 
. O 
The O 
inhibition O 
varied O 
among O 
some O 
CES2 O 
polymorphic O 
variants O 
. O 
Pretreatment O 
with O 
orlistat B-TRIVIAL 
reduced O 
the O 
cell O 
killing O 
activity O 
of O 
PPD B-ABBREVIATION 
. O 
Certain O 
mouse O 
but O 
not O 
rat O 
CESs O 
were O 
also O 
highly O 
sensitive O 
. O 
CES2 O 
is O 
responsible O 
for O 
the O 
hydrolysis O 
of O 
many O 
common O 
drugs O 
and O 
abundantly O 
expressed O 
in O 
the O 
gastrointestinal O 
track O 
and O 
liver O 
. O 
Inhibition O 
of O 
this O 
carboxylesterase O 
probably O 
presents O 
a O 
major O 
source O 
for O 
altered O 
therapeutic O 
activity O 
of O 
these O 
medicines O 
if O 
co O 
- O 
administered O 
with O 
orlistat B-TRIVIAL 
. O 
In O 
addition O 
, O 
orlistat B-TRIVIAL 
has O 
been O 
linked O 
to O 
various O 
types O 
of O 
organ O 
toxicities O 
, O 
and O 
this O 
study O 
provides O 
an O 
alternative O 
target O 
potentially O 
involved O 
in O 
these O 
toxicological O 
responses O 
. O 

synthesis O 
, O 
characterization O 
and O 
bio O 
- O 
efficacy O 
evaluation O 
of O 
novel O 
chalcone B-FAMILY 
based O 
6-carbethoxy-2-cyclohexen-1-one B-SYSTEMATIC 
and O 
2H-indazol-3-ol B-SYSTEMATIC 
derivatives O 
. O 

chalcone B-FAMILY 
based O 
6-carbethoxy-2-cyclohexen-1-one B-SYSTEMATIC 
and O 
2H-indazol-3-ol B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
characterized O 
by O 
using O 
spectral O 
techniques O 
like O 
IR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
COSY O 
, O 
DEPT O 
, O 
and O 
GC-MS O 
. O 
All O 
these O 
compounds O 
were O 
screened O 
for O 
anti-fungal O 
, O 
anti-bacterial O 
and O 
anti-oxidant O 
activity O 
. O 
Cyclohexenone B-SYSTEMATIC 
derivatives O 
, O 
in O 
general O 
, O 
showed O 
better O 
anti-fungal O 
and O 
anti-bacterial O 
activity O 
than O 
parent O 
chalcones B-FAMILY 
. O 
Whereas O 
, O 
all O 
the O 
Indazole B-SYSTEMATIC 
derivatives O 
showed O 
very O 
good O 
anti-oxidant O 
activity O 
and O 
some O 
were O 
also O 
found O 
to O 
be O 
active O 
as O 
anti-bacterial O 
agent O 
. O 
Among O 
the O 
screened O 
compounds O 
, O 
15 O 
was O 
found O 
to O 
be O 
most O 
active O 
as O 
anti-fungal O 
agent O 
( O 
against O 
Rhizoctonia O 
solani O 
, O 
LC(50) O 
= O 
2.36 O 
μg O 
mL(-1) O 
) O 
, O 
15b O 
was O 
found O 
to O 
be O 
most O 
active O 
anti-bacterial O 
agent O 
( O 
against O 
Klebsiella O 
pneumonia O 
, O 
MIC O 
= O 
24.68 O 
μg O 
mL(-1) O 
) O 
and O 
14b O 
emerged O 
as O 
most O 
active O 
anti-oxidant O 
(IC(50) O 
= O 
19.81 O 
μg O 
mL(-1)) O 
. O 

hydrocarbon I-FAMILY 
receptor O 
is O 
a O 
target O 
of O 
17-Allylamino-17-demethoxygeldanamycin B-SYSTEMATIC 
and O 
enhances O 
its O 
anticancer O 
activity O 
in O 
lung O 
adenocarcinoma O 
cells O 
. O 

have O 
demonstrated O 
that O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
is O 
overexpressed O 
in O 
lung O 
adenocarcinoma O 
( O 
AD O 
) O 
. O 
AhR O 
is O 
usually O 
associated O 
with O 
heat O 
shock O 
protein O 
90 O 
( O 
Hsp90 O 
) O 
in O 
the O 
cytoplasm O 
. O 
17-Allylamino-17-demethoxygeldanamycin B-SYSTEMATIC 
( O 
17-AAG B-SYSTEMATIC 
) O 
, O 
an O 
Hsp90 O 
inhibitor O 
, O 
is O 
currently O 
under O 
evaluation O 
for O 
its O 
anticancer O 
activity O 
in O 
clinical O 
trials O 
. O 
Here O 
we O 
investigated O 
whether O 
AhR O 
plays O 
a O 
role O 
in O 
17-AAG B-SYSTEMATIC 
-mediated O 
anticancer O 
activity O 
by O 
functioning O 
as O 
a O 
downstream O 
target O 
or O 
by O 
modulating O 
its O 
anticancer O 
efficacy O 
. O 
AhR O 
expression O 
in O 
lung O 
AD O 
cells O 
was O 
modulated O 
by O 
siRNA O 
interference O 
or O 
overexpression O 
. O 
Tumor O 
growth O 
was O 
determined O 
with O 
colony O 
formation O 
in O 
vitro O 
or O 
in O 
vivo O 
. O 
Anticancer O 
activity O 
of O 
17-AAG B-SYSTEMATIC 
was O 
determined O 
by O 
measuring O 
cell O 
viability O 
, O 
cell O 
cycle O 
distribution O 
, O 
and O 
expression O 
of O 
cell O 
cycle O 
regulators O 
. O 
Proteins O 
and O 
mRNA O 
levels O 
were O 
examined O 
by O 
immunoblotting O 
and O 
the O 
real O 
- O 
time O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
, O 
respectively O 
. O 
In O 
this O 
study O 
, O 
AhR O 
overexpression O 
positively O 
modulated O 
growth O 
of O 
lung O 
AD O 
cells O 
, O 
at O 
least O 
partially O 
, O 
via O 
RelA-dependent O 
mechanisms O 
. O 
Although O 
treatment O 
with O 
17-AAG B-SYSTEMATIC 
reduced O 
AhR O 
levels O 
and O 
AhR-regulated O 
gene O 
expression O 
in O 
lung O 
AD O 
cells O 
, O 
AhR O 
expression O 
increased O 
anticancer O 
activity O 
of O 
17-AAG B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
17-AAG B-SYSTEMATIC 
treatment O 
reduced O 
cell O 
viability O 
, O 
CDK2 O 
, O 
CDK4 O 
, O 
cyclin O 
E O 
, O 
cyclin O 
D1 O 
, O 
and O 
phosphorylated O 
Rb O 
levels O 
in O 
AhR-expressing O 
lung O 
AD O 
cells O 
. O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
( O 
NQO1 O 
) O 
, O 
which O 
is O 
regulated O 
by O 
AhR O 
, O 
was O 
shown O 
to O 
increase O 
anticancer O 
activity O 
of O 
17-AAG B-SYSTEMATIC 
in O 
cells O 
. O 
Knockdown O 
of O 
NQO1 O 
expression O 
attenuated O 
the O 
reduction O 
of O 
cell O 
cycle O 
regulators O 
by O 
17-AAG B-SYSTEMATIC 
treatment O 
in O 
AhR O 
overexpressed O 
cells O 
. O 
We O 
demonstrated O 
that O 
AhR O 
protein O 
not O 
only O 
functions O 
as O 
a O 
downstream O 
target O 
of O 
17-AAG B-SYSTEMATIC 
, O 
but O 
also O 
enhances O 
anticancer O 
activity O 
of O 
17-AAG B-SYSTEMATIC 
in O 
lung O 
AD O 
cells O 
. O 

cognitive O 
dysfunction O 
( O 
POCD O 
) O 
is O 
recognized O 
as O 
a O 
complication O 
after O 
surgery O 
in O 
the O 
elderly O 
. O 
The O 
exact O 
pathogenic O 
mechanisms O 
of O 
POCD O 
are O 
still O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
role O 
of O 
iron B-SYSTEMATIC 
accumulation O 
within O 
the O 
central O 
nervous O 
system O 
in O 
the O 
development O 
of O 
cognitive O 
dysfunction O 
in O 
rats O 
following O 
splenectomy O 
. O 
Cognitive O 
function O 
was O 
assessed O 
using O 
a O 
Morris O 
water O 
maze O 
on O 
postoperative O 
days O 
1 O 
, O 
3 O 
, O 
and O 
7 O 
. O 
Impaired O 
cognitive O 
function O 
was O 
observed O 
on O 
days O 
1 O 
and O 
3 O 
after O 
splenectomy O 
, O 
while O 
an O 
anesthesia O 
- O 
alone O 
group O 
showed O 
no O 
significant O 
difference O 
from O 
the O 
control O 
. O 
Serum O 
iron O 
levels O 
decreased O 
and O 
brain O 
iron O 
content O 
increased O 
on O 
days O 
1 O 
and O 
3 O 
after O 
surgery O 
, O 
which O 
was O 
in O 
parallel O 
with O 
the O 
impairment O 
of O 
cognitive O 
function O 
. O 
Furthermore O 
, O 
the O 
levels O 
of O 
proteins O 
involved O 
in O 
the O 
maintenance O 
of O 
brain O 
iron B-SYSTEMATIC 
homeostasis O 
, O 
including O 
ferritin O 
, O 
transferrin O 
receptor O 
1 O 
, O 
and O 
iron B-SYSTEMATIC 
regulatory O 
protein O 
2 O 
, O 
were O 
significantly O 
different O 
at O 
postoperative O 
days O 
1 O 
and O 
3 O 
in O 
the O 
hippocampus O 
of O 
splenectomized O 
animals O 
when O 
compared O 
with O 
those O 
of O 
the O 
control O 
. O 
The O 
alterations O 
in O 
iron B-SYSTEMATIC 
homeostasis O 
were O 
accompanied O 
by O 
intensified O 
oxidative O 
stress O 
as O 
measured O 
by O 
increases O 
in O 
the O 
lipid O 
peroxidation O 
product O 
, O 
malondialdehyde B-TRIVIAL 
, O 
and O 
a O 
decrease O 
in O 
the O 
levels O 
of O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
. O 
Overall O 
, O 
these O 
findings O 
suggest O 
that O 
the O 
impaired O 
cognitive O 
function O 
was O 
primarily O 
due O 
to O 
surgical O 
trauma O 
rather O 
than O 
anesthesia O 
. O 
Increased O 
iron O 
accumulation O 
and O 
oxidative O 
stress O 
in O 
the O 
brain O 
, O 
especially O 
in O 
the O 
hippocampus O 
, O 
may O 
be O 
involved O 
in O 
the O 
pathogenesis O 
of O 
POCD O 
. O 

of O 
gemcitabine B-TRIVIAL 
metabolism O 
: O 
functional O 
analysis O 
of O 
genetic O 
variants O 
in O 
cytidine B-TRIVIAL 
deaminase O 
and O 
deoxycytidine B-TRIVIAL 
kinase O 
. O 

( O 
dFdC B-ABBREVIATION 
, O 
2',2'-difluorodeoxycytidine B-SYSTEMATIC 
) O 
is O 
metabolized O 
by O 
cytidine B-TRIVIAL 
deaminase O 
( O 
CDA O 
) O 
and O 
deoxycytidine B-TRIVIAL 
kinase O 
( O 
DCK O 
) O 
, O 
but O 
the O 
contribution O 
of O 
genetic O 
variation O 
in O 
these O 
enzymes O 
to O 
the O 
variability O 
in O 
systemic O 
exposure O 
and O 
response O 
observed O 
in O 
cancer O 
patients O 
is O 
unclear O 
. O 
Wild O 
- O 
type O 
enzymes O 
and O 
variants O 
of O 
CDA O 
( O 
Lys27Gln O 
and O 
Ala70Thr O 
) O 
and O 
DCK O 
( O 
Ile24Val O 
, O 
Ala119Gly O 
, O 
and O 
Pro122Ser O 
) O 
were O 
expressed O 
in O 
and O 
purified O 
from O 
Escherichia O 
coli O 
, O 
and O 
enzyme O 
kinetic O 
parameters O 
were O 
estimated O 
for O 
cytarabine B-TRIVIAL 
( O 
Ara-C B-ABBREVIATION 
) O 
, O 
dFdC B-ABBREVIATION 
, O 
and O 
its O 
metabolite O 
2',2'-difluorodeoxyuridine B-SYSTEMATIC 
( O 
dFdU B-ABBREVIATION 
) O 
as O 
substrates O 
. O 
All O 
three O 
CDA O 
proteins O 
showed O 
similar O 
K(m) O 
and O 
V(max) O 
for O 
Ara-C B-ABBREVIATION 
and O 
dFdC B-ABBREVIATION 
deamination O 
, O 
except O 
for O 
CDA70Thr O 
, O 
which O 
had O 
a O 
2.5-fold O 
lower O 
K(m) O 
and O 
6-fold O 
lower O 
V(max) O 
for O 
Ara-C B-ABBREVIATION 
deamination O 
. O 
All O 
four O 
DCK O 
proteins O 
yielded O 
comparable O 
metabolic O 
activity O 
for O 
Ara-C B-ABBREVIATION 
and O 
dFdC B-ABBREVIATION 
monophosphorylation O 
, O 
except O 
for O 
DCK24Val O 
, O 
which O 
demonstrated O 
an O 
approximately O 
2-fold O 
increase O 
( O 
P O 
< O 
0.05 O 
) O 
in O 
the O 
intrinsic O 
clearance O 
of O 
dFdC B-ABBREVIATION 
monophosphorylation O 
due O 
to O 
a O 
40% O 
decrease O 
in O 
K(m) O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
DCK O 
did O 
not O 
significantly O 
contribute O 
to O 
dFdU B-ABBREVIATION 
monophosphorylation O 
. O 
In O 
conclusion O 
, O 
the O 
Lys27Gln O 
substitution O 
does O 
not O 
significantly O 
modulate O 
CDA O 
activity O 
toward O 
dFdC B-ABBREVIATION 
, O 
and O 
therefore O 
would O 
not O 
contribute O 
to O 
interindividual O 
variability O 
in O 
response O 
to O 
gemcitabine B-TRIVIAL 
. O 
The O 
higher O 
in O 
vitro O 
catalytic O 
efficiency O 
of O 
DCK24Val O 
toward O 
dFdC B-ABBREVIATION 
monophosphorylation O 
may O 
be O 
relevant O 
to O 
dFdC B-ABBREVIATION 
clinical O 
response O 
. O 
The O 
substrate O 
- O 
dependent O 
alterations O 
in O 
activities O 
of O 
CDA70Thr O 
and O 
DCK24Val O 
in O 
vitro O 
were O 
observed O 
for O 
the O 
first O 
time O 
, O 
and O 
demonstrate O 
that O 
the O 
in O 
vivo O 
consequences O 
of O 
these O 
genetic O 
variations O 
should O 
not O 
be O 
extrapolated O 
from O 
one O 
substrate O 
of O 
these O 
enzymes O 
to O 
another O 
. O 

granules O 
inhibit O 
apoptosis O 
by O 
reducing O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
. O 

can O 
undergo O 
two O 
alternative O 
fates O 
following O 
exposure O 
to O 
environmental O 
stress O 
: O 
they O 
either O 
induce O 
apoptosis O 
or O 
inhibit O 
apoptosis O 
and O 
then O 
repair O 
the O 
stress O 
- O 
induced O 
alterations O 
. O 
These O 
processes O 
minimize O 
cell O 
loss O 
and O 
prevent O 
the O 
survival O 
of O 
cells O 
with O 
aberrant O 
DNA O 
and O 
protein O 
alterations O 
. O 
These O 
two O 
alternative O 
fates O 
are O 
partly O 
controlled O 
by O 
stress O 
granules O 
( O 
SGs O 
) O 
. O 
While O 
arsenite B-SYSTEMATIC 
, O 
hypoxia O 
, O 
and O 
heat O 
shock O 
induce O 
the O 
formation O 
of O 
SGs O 
that O 
inhibit O 
apoptosis O 
, O 
X-ray O 
irradiation O 
and O 
genotoxic O 
drugs O 
do O 
not O 
induce O 
SGs O 
, O 
and O 
they O 
are O 
more O 
prone O 
to O 
trigger O 
apoptosis O 
. O 
However O 
, O 
it O 
is O 
unclear O 
precisely O 
how O 
SGs O 
control O 
apoptosis O 
. O 
This O 
study O 
found O 
that O 
SGs O 
suppress O 
the O 
elevation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
and O 
this O 
suppression O 
is O 
essential O 
for O 
inhibiting O 
ROS-dependent O 
apoptosis O 
. O 
This O 
antioxidant O 
activity O 
of O 
SGs O 
is O 
controlled O 
by O 
two O 
SG O 
components O 
, O 
GTPase O 
- O 
activating O 
protein O 
SH3 O 
domain O 
binding O 
protein O 
1 O 
( O 
G3BP1 O 
) O 
and O 
ubiquitin O 
- O 
specific O 
protease O 
10 O 
( O 
USP10 O 
) O 
. O 
G3BP1 O 
elevates O 
the O 
steady O 
- O 
state O 
ROS O 
level O 
by O 
inhibiting O 
the O 
antioxidant O 
activity O 
of O 
USP10 O 
. O 
However O 
, O 
following O 
exposure O 
to O 
arsenite B-SYSTEMATIC 
, O 
G3BP1 O 
and O 
USP10 O 
induce O 
the O 
formation O 
of O 
SGs O 
, O 
which O 
uncovers O 
the O 
antioxidant O 
activity O 
of O 
USP10 O 
. O 
We O 
also O 
found O 
that O 
the O 
antioxidant O 
activity O 
of O 
USP10 O 
requires O 
the O 
protein O 
kinase O 
activity O 
of O 
ataxia O 
telangiectasia O 
mutated O 
( O 
ATM O 
) O 
. O 
This O 
work O 
reveals O 
that O 
SGs O 
are O 
critical O 
redox O 
regulators O 
that O 
control O 
cell O 
fate O 
under O 
stress O 
conditions O 
. O 

- O 
onset O 
preeclampsia O 
( O 
EPE O 
) O 
is O 
a O 
severe O 
form O 
of O 
preeclampsia O 
that O 
involves O 
life O 
- O 
threatening O 
neurological O 
complications O 
. O 
However O 
, O 
the O 
underlying O 
mechanism O 
by O 
which O 
EPE O 
affects O 
the O 
maternal O 
brain O 
is O 
not O 
known O 
. O 
We O 
hypothesized O 
that O 
plasma O 
from O 
women O 
with O 
EPE O 
increases O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
permeability O 
vs O 
. O 
plasma O 
from O 
women O 
with O 
late O 
- O 
onset O 
preeclampsia O 
( O 
LPE O 
) O 
or O 
normal O 
pregnancy O 
( O 
NP O 
) O 
and O 
investigated O 
its O 
underlying O 
mechanism O 
by O 
perfusing O 
cerebral O 
veins O 
from O 
nonpregnant O 
rats O 
( O 
n=6-7 O 
/ O 
group O 
) O 
with O 
human O 
plasma O 
from O 
women O 
with O 
EPE O 
, O 
LPE O 
, O 
or O 
NP O 
and O 
measuring O 
permeability O 
. O 
We O 
show O 
that O 
plasma O 
from O 
women O 
with O 
EPE O 
significantly O 
increased O 
BBB O 
permeability O 
vs O 
. O 
plasma O 
from O 
women O 
with O 
LPE O 
or O 
NP O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
BBB O 
disruption O 
in O 
response O 
to O 
EPE O 
plasma O 
was O 
due O 
to O 
a O 
260% O 
increase O 
of O 
circulating O 
oxidized O 
LDL O 
( O 
oxLDL O 
) O 
binding O 
to O 
its O 
receptor O 
, O 
LOX-1 O 
, O 
and O 
subsequent O 
generation O 
of O 
peroxynitrite B-SYSTEMATIC 
( O 
P O 
< O 
0.001 O 
) O 
. O 
A O 
rat O 
model O 
with O 
pathologically O 
high O 
lipid O 
levels O 
in O 
pregnancy O 
showed O 
symptoms O 
of O 
preeclampsia O 
, O 
including O 
elevated O 
blood O 
pressure O 
, O 
growth O 
- O 
restricted O 
fetuses O 
, O 
and O 
LOX-1-dependent O 
BBB O 
disruption O 
, O 
similar O 
to O 
EPE O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Thus O 
, O 
we O 
have O 
identified O 
LOX-1 O 
activation O 
by O 
oxLDL O 
and O 
subsequent O 
peroxynitrite B-SYSTEMATIC 
generation O 
as O 
a O 
novel O 
mechanism O 
by O 
which O 
disruption O 
of O 
the O 
BBB O 
occurs O 
in O 
EPE O 
. O 
As O 
increased O 
BBB O 
permeability O 
is O 
a O 
primary O 
means O 
by O 
which O 
seizure O 
and O 
other O 
neurological O 
symptoms O 
ensue O 
, O 
our O 
findings O 
highlight O 
oxLDL O 
, O 
LOX-1 O 
, O 
and O 
peroxynitrite B-SYSTEMATIC 
as O 
important O 
therapeutic O 
targets O 
in O 
EPE O 
. O 

differentiation O 
of O 
embryonic O 
stem O 
cells O 
( O 
ESC O 
) O 
is O 
considered O 
a O 
promising O 
model O 
to O 
perform O 
in O 
vitro O 
testing O 
for O 
neuroactive O 
and O 
neurotoxic O 
compounds O 
. O 
We O 
studied O 
the O 
potential O 
of O 
a O 
dual O 
reporter O 
murine O 
ESC O 
line O 
to O 
identify O 
bioactive O 
and O 
/ O 
or O 
toxic O 
compounds O 
. O 
This O 
line O 
expressed O 
firefly O 
luciferase O 
under O 
the O 
control O 
of O 
the O 
neural O 
cell O 
- O 
specific O 
tubulin O 
alpha O 
promoter O 
( O 
TUBA1A O 
) O 
, O 
and O 
renilla O 
luciferase O 
under O 
the O 
control O 
of O 
the O 
ubiquitous O 
translation O 
elongation O 
factor O 
1-alpha-1 O 
( O 
EEF1A1 O 
) O 
promoter O 
. O 
During O 
neural O 
differentiation O 
, O 
TUBA1A O 
activity O 
increased O 
, O 
while O 
EEF1A1 O 
activity O 
decreased O 
. O 
We O 
first O 
validated O 
our O 
test O 
system O 
using O 
the O 
known O 
neurotoxin O 
methyl B-SYSTEMATIC 
mercury I-SYSTEMATIC 
. O 
This O 
compound O 
altered O 
expression O 
of O 
both O 
reporter O 
genes O 
, O 
with O 
ESC O 
- O 
derived O 
neural O 
precursors O 
being O 
affected O 
at O 
markedly O 
lower O 
concentrations O 
than O 
undifferentiated O 
ESCs O 
. O 
Analysis O 
of O 
a O 
library O 
of O 
1040 O 
bioactive O 
compounds O 
picked O 
up O 
127 O 
compounds O 
with O 
altered O 
EEF1A1 O 
and O 
/ O 
or O 
TUBA1A O 
promoter O 
activity O 
, O 
which O 
were O 
classified O 
in O 
4 O 
clusters O 
. O 
Cluster O 
1 O 
( O 
low O 
EEF1A1 O 
and O 
TUBA1A O 
) O 
was O 
the O 
largest O 
cluster O 
, O 
containing O 
many O 
cytostatic O 
drugs O 
, O 
as O 
well O 
as O 
known O 
neurodevelopmental O 
toxicants O 
, O 
psychotropic O 
drugs O 
and O 
endocrine O 
disruptors O 
. O 
Cluster O 
2 O 
( O 
high O 
EEF1A1 O 
, O 
stable O 
TUBA1A O 
) O 
was O 
limited O 
to O 
three O 
sulfonamides B-FAMILY 
. O 
Cluster O 
3 O 
( O 
high O 
EEF1A1 O 
and O 
TUBA1A O 
) O 
was O 
small O 
, O 
but O 
markedly O 
enriched O 
in O 
neuroactive O 
and O 
neurotoxic O 
compounds O 
. O 
Cluster O 
4 O 
( O 
stable O 
EEF1A1 O 
, O 
high O 
TUBA1A O 
) O 
was O 
heterogeneous O 
, O 
containing O 
endocrine O 
disruptors O 
, O 
neurotoxic O 
and O 
cytostatic O 
drugs O 
. O 
The O 
dual O 
reporter O 
gene O 
assay O 
described O 
here O 
might O 
be O 
a O 
useful O 
addition O 
to O 
in O 
vitro O 
drug O 
testing O 
panels O 
. O 
Our O 
two O 
- O 
dimensional O 
testing O 
strategy O 
provides O 
information O 
on O 
complex O 
response O 
patterns O 
, O 
which O 
could O 
not O 
be O 
achieved O 
by O 
a O 
single O 
marker O 
approach O 
. O 

, O 
synthesis O 
, O 
and O 
structure O 
- O 
based O 
optimization O 
of O 
a O 
series O 
of O 
N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) B-FAMILY 
acetamides I-FAMILY 
( O 
ML188 B-IDENTIFIER 
) O 
as O 
potent O 
noncovalent O 
small O 
molecule O 
inhibitors O 
of O 
the O 
severe O 
acute O 
respiratory O 
syndrome O 
coronavirus O 
( O 
SARS-CoV O 
) O 
3CL O 
protease O 
. O 

high O 
- O 
throughput O 
screen O 
of O 
the O 
NIH O 
molecular O 
libraries O 
sample O 
collection O 
and O 
subsequent O 
optimization O 
of O 
a O 
lead O 
dipeptide B-FAMILY 
-like O 
series O 
of O 
severe O 
acute O 
respiratory O 
syndrome O 
( O 
SARS O 
) O 
main O 
protease O 
( O 
3CLpro O 
) O 
inhibitors O 
led O 
to O 
the O 
identification O 
of O 
probe O 
compound O 
ML188 B-IDENTIFIER 
( O 
16- O 
( O 
R O 
) O 
, O 
(R)-N-(4-(tert-butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide B-SYSTEMATIC 
, O 
Pubchem O 
CID B-IDENTIFIER 
: I-IDENTIFIER 
46897844 I-IDENTIFIER 
) O 
. O 
Unlike O 
the O 
majority O 
of O 
reported O 
coronavirus O 
3CLpro O 
inhibitors O 
that O 
act O 
via O 
covalent O 
modification O 
of O 
the O 
enzyme O 
, O 
16- O 
( O 
R O 
) O 
is O 
a O 
noncovalent O 
SARS-CoV O 
3CLpro O 
inhibitor O 
with O 
moderate O 
MW O 
and O 
good O 
enzyme O 
and O 
antiviral O 
inhibitory O 
activity O 
. O 
A O 
multicomponent O 
Ugi O 
reaction O 
was O 
utilized O 
to O 
rapidly O 
explore O 
structure O 
- O 
activity O 
relationships O 
within O 
S(1') O 
, O 
S(1) O 
, O 
and O 
S(2) O 
enzyme O 
binding O 
pockets O 
. O 
The O 
X-ray O 
structure O 
of O 
SARS-CoV O 
3CLpro O 
bound O 
with O 
16- O 
( O 
R O 
) O 
was O 
instrumental O 
in O 
guiding O 
subsequent O 
rounds O 
of O 
chemistry O 
optimization O 
. O 
16- O 
( O 
R O 
) O 
provides O 
an O 
excellent O 
starting O 
point O 
for O 
the O 
further O 
design O 
and O 
refinement O 
of O 
3CLpro O 
inhibitors O 
that O 
act O 
by O 
a O 
noncovalent O 
mechanism O 
of O 
action O 
. O 

encapsulation O 
technology O 
holds O 
promise O 
for O 
the O 
sustained O 
and O 
controlled O 
delivery O 
of O 
different O 
therapeutic O 
proteins O 
. O 
Alginate- O 
poly-L-lysine B-SYSTEMATIC 
-alginate O 
( O 
APA O 
) O 
microcapsules O 
represent O 
one O 
of O 
the O 
most O 
widely O 
studied O 
alginate O 
- O 
polycation O 
microcapsules O 
. O 
On O 
the O 
basis O 
of O 
this O 
technology O 
, O 
two O 
types O 
of O 
hydrogel O 
- O 
based O 
scaffolds O 
have O 
been O 
developed O 
and O 
analyzed O 
with O 
the O 
aim O 
of O 
improving O 
the O 
retention O 
and O 
the O 
retrieval O 
of O 
erythropoietin O 
( O 
Epo O 
) O 
secreting O 
cell O 
- O 
loaded O 
microcapsules O 
in O 
the O 
tissue O 
where O 
they O 
are O 
implanted O 
. O 
Furthermore O 
, O 
these O 
hydrogels O 
may O 
help O 
to O 
reduce O 
the O 
post O 
- O 
transplant O 
inflammation O 
and O 
pericapsular O 
fibrotic O 
overgrowth O 
typically O 
observed O 
around O 
capsules O 
. O 
The O 
hydrogel O 
- O 
based O 
scaffolds O 
could O 
be O 
administered O 
as O 
implantable O 
forms O 
( O 
preformed O 
scaffolds O 
) O 
or O 
injectable O 
forms O 
( O 
in O 
situ O 
formed O 
scaffolds O 
) O 
. O 
The O 
in O 
vitro O 
studies O 
confirmed O 
the O 
correct O 
adaptation O 
of O 
the O 
enclosed O 
cells O 
to O 
the O 
scaffolds O 
in O 
terms O 
of O 
viability O 
and O 
protein O 
expression O 
. O 
The O 
posterior O 
implantation O 
of O 
the O 
cell O 
- O 
loaded O 
capsules O 
containing O 
hydrogel O 
- O 
based O 
scaffolds O 
in O 
mice O 
revealed O 
that O 
the O 
hematocrit O 
levels O 
were O 
maintained O 
up O 
to O 
80% O 
for O 
at O 
least O 
2 O 
months O 
. O 
The O 
histological O 
analysis O 
of O 
the O 
explanted O 
microcapsules O 
performed O 
at O 
that O 
point O 
showed O 
that O 
pericapsular O 
overgrowth O 
was O 
reduced O 
when O 
cell O 
- O 
loaded O 
microcapsules O 
were O 
enclosed O 
in O 
the O 
hydrogels O 
scaffolds O 
. O 
Incorporating O 
microencapsulated O 
cells O 
within O 
hydrogel O 
- O 
based O 
scaffolds O 
may O 
help O 
to O 
improve O 
their O 
administration O 
protocol O 
and O 
retention O 
while O 
reducing O 
post O 
- O 
transplantation O 
inflammation O 
. O 

facilitates O 
dendritic O 
spine O 
formation O 
by O 
cultured O 
striatal O 
medium O 
spiny O 
neurons O 
through O 
both O 
D1 O 
and O 
D2 O 
dopamine B-TRIVIAL 
receptors O 
. O 

of O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
levels O 
induced O 
by O 
drugs O 
of O 
abuse O 
or O 
in O 
the O 
context O 
of O 
Parkinson's O 
disease O 
modulate O 
the O 
number O 
of O 
dendritic O 
spines O 
in O 
medium O 
spiny O 
neurons O 
( O 
MSNs O 
) O 
of O 
the O 
striatum O 
, O 
showing O 
that O 
DA O 
plays O 
a O 
major O 
role O 
in O 
the O 
structural O 
plasticity O 
of O 
MSNs O 
. O 
However O 
, O 
little O 
is O 
presently O 
known O 
regarding O 
early O 
spine O 
development O 
in O 
MSNs O 
occurring O 
before O 
the O 
arrival O 
of O 
cortical O 
inputs O 
and O 
in O 
particular O 
about O 
the O 
role O 
of O 
DA O 
and O 
D1 O 
( O 
D1R O 
) O 
and O 
D2 O 
( O 
D2R O 
) O 
DA O 
receptors O 
. O 
A O 
cell O 
culture O 
model O 
reconstituting O 
early O 
cellular O 
interactions O 
between O 
MSNs O 
, O 
intrinsic O 
cholinergic O 
interneurons O 
and O 
DA O 
neurons O 
was O 
used O 
to O 
study O 
the O 
role O 
of O 
DA O 
in O 
spine O 
formation O 
. O 
After O 
5 O 
or O 
10 O 
days O 
in O 
vitro O 
, O 
the O 
presence O 
of O 
DA O 
neurons O 
increased O 
the O 
number O 
of O 
immature O 
spine O 
- O 
like O 
protrusions O 
. O 
In O 
MSN O 
monocultures O 
, O 
chronic O 
activation O 
of O 
D1R O 
or O 
D2R O 
also O 
increased O 
the O 
number O 
of O 
spines O 
and O 
spinophilin O 
expression O 
in O 
MSNs O 
, O 
suggesting O 
a O 
direct O 
role O 
for O 
these O 
receptors O 
. O 
In O 
DA-MSN O 
cocultures O 
, O 
chronic O 
blockade O 
of O 
D1R O 
or O 
D2R O 
reduced O 
the O 
number O 
of O 
dendritic O 
spines O 
. O 
Interestingly O 
, O 
the O 
combined O 
activation O 
or O 
blockade O 
of O 
both O 
D1R O 
and O 
D2R O 
failed O 
to O 
elicit O 
more O 
extensive O 
spine O 
formation O 
, O 
suggesting O 
that O 
both O 
receptors O 
act O 
through O 
a O 
mechanism O 
that O 
is O 
not O 
additive O 
. O 
Finally O 
, O 
we O 
found O 
increased O 
ionotropic O 
glutamate O 
receptor O 
responsiveness O 
and O 
miniature O 
excitatory O 
postsynaptic O 
current O 
( O 
EPSC O 
) O 
frequency O 
in O 
DA-MSN O 
co O 
- O 
cultures O 
, O 
in O 
parallel O 
with O 
a O 
higher O 
number O 
of O 
spines O 
containing O 
PSD-95 O 
, O 
suggesting O 
that O 
the O 
newly O 
formed O 
spines O 
present O 
functional O 
post O 
- O 
synaptic O 
machinery O 
preparing O 
the O 
MSNs O 
to O 
receive O 
additional O 
glutamatergic O 
contacts O 
. O 
These O 
results O 
represent O 
a O 
first O 
step O 
in O 
the O 
understanding O 
of O 
how O 
dopamine B-TRIVIAL 
neurons O 
promote O 
the O 
structural O 
plasticity O 
of O 
MSNs O 
during O 
the O 
development O 
of O 
basal O 
ganglia O 
circuits O 
. O 

and O 
potent O 
adenosine B-TRIVIAL 
A3 O 
receptor O 
antagonists O 
by O 
methoxyaryl B-FAMILY 
substitution O 
on O 
the O 
N-(2,6-diarylpyrimidin-4-yl)acetamide B-FAMILY 
scaffold O 
. O 

influence O 
of O 
diverse O 
methoxyphenyl B-SYSTEMATIC 
substitution O 
patterns O 
on O 
the O 
N-(2,6-diarylpyrimidin-4-yl)acetamide B-FAMILY 
scaffold O 
is O 
herein O 
explored O 
in O 
order O 
to O 
modulate O 
the O 
A(3) O 
adenosine B-TRIVIAL 
receptor O 
antagonistic O 
profile O 
. O 
As O 
a O 
result O 
, O 
novel O 
ligands O 
exhibiting O 
excellent O 
potency O 
( O 
K O 
(i) O 
on O 
A(3) O 
AR O 
< O 
20 O 
nM O 
) O 
and O 
selectivity O 
profiles O 
( O 
above O 
100-fold O 
within O 
the O 
adenosine B-TRIVIAL 
receptors O 
family O 
) O 
are O 
reported O 
. O 
Moreover O 
, O 
our O 
joint O 
theoretical O 
and O 
experimental O 
approach O 
allows O 
the O 
identification O 
of O 
novel O 
pharmacophoric O 
elements O 
conferring O 
A(3)AR O 
selectivity O 
, O 
first O 
established O 
by O 
a O 
robust O 
computational O 
model O 
and O 
thereafter O 
characterizing O 
the O 
most O 
salient O 
features O 
of O 
the O 
structure O 
- O 
activity O 
and O 
structure O 
- O 
selectivity O 
relationships O 
in O 
this O 
series O 
. O 

molecule O 
amides B-FAMILY 
as O 
potent O 
ROR-γ O 
selective O 
modulators O 
. O 

structure O 
- O 
activity O 
relationship O 
study O 
of O 
a O 
diphenylpropanamide B-FAMILY 
series O 
of O 
ROR-γ O 
selective O 
modulators O 
is O 
reported O 
. O 
Compounds O 
were O 
screened O 
using O 
chimeric O 
receptor O 
Gal4 O 
DNA O 
- O 
binding O 
domain O 
(DBD)-NR O 
ligand O 
binding O 
domain O 
cotransfection O 
assay O 
in O 
a O 
two O 
- O 
step O 
format O 
. O 
Three O 
different O 
regions O 
of O 
the O 
scaffold O 
were O 
modified O 
to O 
assess O 
the O 
effects O 
on O 
repression O 
of O 
ROR-γ O 
transcriptional O 
activity O 
and O 
potency O 
. O 
The O 
lead O 
compound O 
1 O 
exhibits O 
modest O 
mouse O 
pharmacokinetics O 
and O 
an O 
acceptable O 
in O 
vitro O 
profile O 
which O 
makes O 
it O 
a O 
suitable O 
in O 
vivo O 
probe O 
to O 
interrogate O 
the O 
functions O 
of O 
ROR-γ O 
in O 
animal O 
models O 
of O 
disease O 
. O 

from O 
Cynara O 
scolymus O 
L O 
. O 
suppresses O 
photoaging O 
of O 
skin O 
by O 
inhibiting O 
the O 
transcription O 
activity O 
of O 
nuclear O 
factor O 
- O 
kappa O 
B O 
. O 

of O 
skin O 
is O 
characterized O 
by O 
skin O 
wrinkling O 
, O 
laxity O 
, O 
and O 
pigmentation O 
induced O 
by O 
several O 
environmental O 
stress O 
factors O 
. O 
Histological O 
changes O 
during O 
the O 
photoaging O 
of O 
skin O 
include O 
hyperproliferation O 
of O 
keratinocytes O 
and O 
melanocytes O 
causing O 
skin O 
wrinkles O 
and O 
pigmentation O 
. O 
Nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
is O 
one O 
of O 
the O 
representative O 
transcription O 
factors O 
active O 
in O 
conjunction O 
with O 
inflammation O 
. O 
NF-κB O 
is O 
activated O 
by O 
stimulation O 
such O 
as O 
ultraviolet O 
rays O 
and O 
inflammatory O 
cytokines O 
and O 
induces O 
the O 
expression O 
of O 
various O 
genes O 
such O 
as O 
those O 
of O 
basic O 
fibroblast O 
growth O 
factor O 
( O 
bFGF O 
) O 
and O 
matrix O 
metalloprotease-1 O 
( O 
MMP-1 O 
) O 
. O 
We O 
screened O 
several O 
plant O 
extracts O 
for O 
their O 
possible O 
inhibitory O 
effect O 
on O 
the O 
transcriptional O 
activity O 
of O 
NF-κB O 
. O 
One O 
of O 
them O 
, O 
an O 
extract O 
from O 
Cynara O 
scolymus O 
L O 
. O 
, O 
showed O 
a O 
greatest O 
effect O 
on O 
the O 
suppression O 
of O 
NF-κB O 
transactivation O 
. O 
As O 
a O 
result O 
, O 
we O 
found O 
that O 
cynaropicrin B-TRIVIAL 
, O 
which O 
is O 
a O 
sesquiterpene B-FAMILY 
lactone I-FAMILY 
, O 
inhibited O 
the O 
NF-κB O 
- O 
mediated O 
transactivation O 
of O 
bFGF O 
and O 
MMP-1 O 
. O 
Furthermore O 
, O 
it O 
was O 
confirmed O 
that O 
in O 
an O 
in O 
vivo O 
mouse O 
model O 
cynaropicrin B-TRIVIAL 
prevented O 
skin O 
photoaging O 
processes O 
leading O 
to O 
the O 
hyperproliferation O 
of O 
keratinocytes O 
and O 
melanocytes O 
. O 
These O 
findings O 
taken O 
together O 
indicate O 
that O 
cynaropicrin B-TRIVIAL 
is O 
an O 
effective O 
antiphotoaging O 
agent O 
that O 
acts O 
by O 
inhibiting O 
NF-κB O 
- O 
mediated O 
transactivation O 
. O 

and O 
characterization O 
of O 
eight O 
estradiol B-TRIVIAL 
inducible O 
genes O 
and O 
a O 
strong O 
promoter O 
from O 
the O 
steroid B-FAMILY 
degrading O 
marine O 
bacterial O 
strain O 
S19-1 O 
. O 

strain O 
S19-1 O 
is O 
a O 
new O 
marine O 
bacterium O 
, O 
isolated O 
from O 
the O 
Baltic O 
Sea O 
, O 
which O 
can O 
degrade O 
steroids B-FAMILY 
. O 
In O 
this O 
report O 
, O 
a O 
meta-genomic O 
approach O 
was O 
used O 
to O 
isolate O 
estradiol B-TRIVIAL 
inducible O 
genes O 
from O 
S19-1 O 
. O 
SalI-fragments O 
from O 
the O 
chromosomal O 
DNA O 
of O 
S19-1 O 
were O 
ligated O 
into O 
plasmid O 
pKEGFP2 O 
bearing O 
an O 
EGFP O 
gene O 
as O 
the O 
reporter O 
system O 
. O 
All O 
resulting O 
plasmids O 
harboring O 
SalI-fragments O 
were O 
transformed O 
into O 
Escherichia O 
coli O 
HB101 O 
to O 
measure O 
the O 
relative O 
fluorescent O 
units O 
( O 
RFU O 
) O 
. O 
E O 
. O 
coli O 
cells O 
showing O 
higher O 
RFU O 
after O 
estradiol B-TRIVIAL 
induction O 
than O 
those O 
without O 
estradiol B-TRIVIAL 
induction O 
, O 
were O 
selected O 
and O 
the O 
respective O 
plasmids O 
were O 
sequenced O 
. O 
Sequences O 
of O 
8 O 
positive O 
plasmids O 
were O 
analyzed O 
and O 
aligned O 
by O 
BLAST O 
. O 
Among O 
the O 
predicted O 
genes O 
we O 
found O 
similarities O 
to O 
the O 
major O 
facilitator O 
superfamily O 
, O 
glycerol B-TRIVIAL 
dehydratase O 
activator O 
, O 
formate B-SYSTEMATIC 
acetyltransferase O 
activating O 
enzyme O 
, O 
histidinol B-SYSTEMATIC 
- I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
/ O 
aromatic O 
aminotransferase O 
, O 
ABC-transporter O 
, O 
transcriptional O 
regulator O 
nadR O 
, O 
lipoate O 
- O 
protein O 
ligase O 
A O 
, O 
and O 
alcohol B-FAMILY 
phosphatidyl-transferase O 
. O 
Interestingly O 
, O 
one O 
of O 
the O 
E O 
. O 
coli O 
cell O 
clones O 
( O 
containing O 
plasmid O 
p302 O 
) O 
showed O 
up O 
in O 
green O 
color O 
by O 
normal O 
light O 
microscopy O 
, O 
which O 
indicated O 
that O 
a O 
strong O 
promoter O 
was O 
present O 
in O 
this O 
plasmid O 
. O 
Sequencing O 
and O 
deletion O 
- O 
mutagenesis O 
revealed O 
that O 
the O 
putative O 
promoter O 
comprises O 
a O 
108 O 
bp O 
DNA O 
fragment O 
within O 
p302 O 
, O 
from O 
which O 
the O 
putative O 
-10 O 
and O 
-35 O 
regions O 
are O 
TTTGAT O 
and O 
TTGGTT O 
, O 
respectively O 
. O 
The O 
promoter O 
might O 
be O 
used O 
to O 
construct O 
S19-1 O 
mutants O 
in O 
which O 
steroid B-FAMILY 
degradation O 
occurs O 
at O 
high O 
levels O 
. O 

constraints O 
and O 
parental O 
care O 
: O 
is O 
corticosterone B-TRIVIAL 
indicative O 
of O 
energetic O 
costs O 
of O 
incubation O 
in O 
a O 
precocial O 
bird O 
? O 

of O 
the O 
adrenocortical O 
response O 
( O 
e.g O 
. O 
, O 
corticosterone B-TRIVIAL 
release O 
) O 
to O 
an O 
acute O 
stressor O 
is O 
a O 
physiological O 
adjustment O 
thought O 
to O 
decrease O 
the O 
likelihood O 
of O 
avian O 
parents O 
abandoning O 
their O 
nests O 
. O 
However O 
, O 
some O 
periods O 
of O 
parental O 
care O 
, O 
like O 
incubation O 
, O 
are O 
energetically O 
costly O 
, O 
thus O 
corticosterone B-TRIVIAL 
could O 
increase O 
during O 
these O 
stages O 
to O 
allow O 
incubating O 
parents O 
to O 
utilize O 
energy O 
reserves O 
. O 
Wood O 
ducks O 
( O 
Aix O 
sponsa O 
) O 
have O 
~30 O 
day O 
incubation O 
periods O 
and O 
only O 
the O 
female O 
incubates O 
the O 
eggs O 
. O 
We O 
hypothesized O 
that O 
corticosterone B-TRIVIAL 
would O 
be O 
important O 
in O 
regulating O 
energy O 
availability O 
during O 
incubation O 
in O 
this O 
species O 
. O 
Because O 
resources O 
invested O 
in O 
reproduction O 
increase O 
with O 
clutch O 
size O 
, O 
we O 
also O 
hypothesized O 
that O 
clutch O 
size O 
would O 
influence O 
plasma O 
corticosterone B-TRIVIAL 
during O 
incubation O 
. O 
We O 
measured O 
baseline O 
and O 
stress O 
- O 
induced O 
corticosterone B-TRIVIAL 
in O 
incubating O 
females O 
during O 
early O 
and O 
late O 
stages O 
of O 
incubation O 
. O 
At O 
both O 
stages O 
of O 
incubation O 
all O 
hens O 
had O 
low O 
baseline O 
corticosterone B-TRIVIAL 
levels O 
. O 
However O 
, O 
we O 
found O 
that O 
stress O 
- O 
induced O 
corticosterone B-TRIVIAL 
was O 
105% O 
greater O 
late O 
in O 
incubation O 
than O 
early O 
in O 
incubation O 
. O 
We O 
also O 
detected O 
a O 
significant O 
negative O 
correlation O 
between O 
female O 
body O 
mass O 
and O 
stress O 
- O 
induced O 
corticosterone B-TRIVIAL 
late O 
in O 
incubation O 
, O 
but O 
not O 
during O 
the O 
early O 
stages O 
of O 
incubation O 
. O 
Furthermore O 
, O 
we O 
found O 
a O 
significant O 
positive O 
relationship O 
between O 
stress O 
- O 
induced O 
corticosterone B-TRIVIAL 
and O 
clutch O 
size O 
. O 
These O 
lines O 
of O 
evidence O 
support O 
the O 
hypothesis O 
that O 
incubation O 
in O 
wood O 
ducks O 
is O 
energetically O 
costly O 
and O 
corticosterone B-TRIVIAL 
is O 
important O 
in O 
supporting O 
the O 
energetic O 
demands O 
of O 
incubating O 
hens O 
. O 
Our O 
findings O 
suggest O 
that O 
corticosterone B-TRIVIAL 
' O 
s O 
role O 
in O 
supporting O 
parental O 
care O 
behaviors O 
are O 
dynamic O 
and O 
are O 
influenced O 
by O 
several O 
factors O 
and O 
that O 
there O 
is O 
a O 
greater O 
physiological O 
cost O 
associated O 
with O 
incubating O 
larger O 
clutches O 
. O 

of O 
organotin B-FAMILY 
compounds O 
: O 
shared O 
and O 
unshared O 
biochemical O 
targets O 
and O 
mechanisms O 
in O 
animal O 
cells O 
. O 

biochemical O 
effects O 
of O 
organotin B-FAMILY 
compounds O 
leading O 
to O 
toxicity O 
are O 
astonishingly O 
similar O 
in O 
different O 
animal O 
species O 
. O 
In O 
vitro O 
tests O 
, O 
designed O 
to O 
explore O 
organotin B-FAMILY 
action O 
modes O 
at O 
cell O 
level O 
by O 
minimizing O 
interfering O 
factors O 
, O 
point O 
out O 
akin O 
responses O 
to O 
these O 
man O 
- O 
made O 
environmental O 
pollutants O 
from O 
prokaryotes O 
to O 
mammals O 
. O 
On O 
the O 
other O 
hand O 
, O 
a O 
broad O 
susceptibility O 
range O 
to O 
organotin B-FAMILY 
toxicants O 
of O 
animal O 
cells O 
and O 
variegated O 
action O 
mechanisms O 
of O 
these O 
compounds O 
have O 
been O 
reported O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
studies O 
. O 
Endocrine O 
and O 
lipid O 
homeostasis O 
perturbations O 
span O 
from O 
mollusks O 
to O 
mammals O 
, O 
in O 
which O 
organotins B-FAMILY 
mainly O 
favor O 
fat O 
accumulation O 
. O 
Lipid O 
changes O 
were O 
also O 
found O 
in O 
Bacteria O 
. O 
Organotin B-FAMILY 
are O 
immunotoxic O 
both O 
in O 
invertebrates O 
and O 
humans O 
. O 
Mitochondria O 
and O 
membrane O 
functions O 
seem O 
to O 
be O 
a O 
preferred O 
target O 
of O 
these O 
lipophilic O 
pollutants O 
. O 
The O 
inhibition O 
of O 
key O 
membrane O 
- O 
bound O 
enzyme O 
complexes O 
such O 
as O 
Na B-FORMULA 
, O 
K B-FORMULA 
-and O 
F0F1-ATPases O 
, O 
accompanied O 
by O 
perturbation O 
of O 
hydromineral O 
balance O 
, O 
membrane O 
potential O 
and O 
bioenergetics O 
, O 
has O 
been O 
widely O 
reported O 
. O 
Highly O 
conserved O 
mechanisms O 
could O 
be O 
involved O 
in O 
organotin B-FAMILY 
binding O 
to O 
nuclear O 
receptors O 
, O 
membrane O 
components O 
and O 
intracellular O 
proteins O 
as O 
well O 
as O 
in O 
promoting O 
DNA O 
damage O 
, O 
all O 
widely O 
shared O 
action O 
modes O 
of O 
these O 
toxicants O 
. O 
Accordingly O 
, O 
the O 
different O 
responsiveness O 
/ O 
refractoriness O 
to O 
organotins B-FAMILY 
, O 
here O 
overviewed O 
, O 
may O 
mirror O 
the O 
biochemical O 
- O 
physiological O 
selectivity O 
of O 
biomembranes O 
, O 
signalling O 
pathways O 
and O 
intracellular O 
protein O 
components O 
. O 

stimulation O 
of O 
nervous O 
tissue O 
is O 
used O 
clinically O 
for O 
the O 
treatment O 
of O 
multiple O 
neurological O 
disorders O 
and O 
experimentally O 
for O 
basic O 
research O 
. O 
With O 
the O 
increase O 
of O 
optical O 
probes O 
to O 
record O 
neuronal O 
activity O 
, O 
simple O 
and O 
user O 
- O 
friendly O 
methods O 
are O 
desired O 
to O 
stimulate O 
neurons O 
and O 
their O 
subcellular O 
compartments O 
for O 
biological O 
experimentation O 
. O 
Here O 
we O 
describe O 
the O 
novel O 
integration O 
of O 
liquid O 
metal O 
electrodes O 
with O 
microfluidic O 
culture O 
platforms O 
to O 
accomplish O 
this O 
goal O 
. O 
We O 
integrated O 
electrode O 
and O 
cell O 
channels O 
into O 
a O 
single O 
poly(dimethylsiloxane) B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
chip O 
, O 
eliminating O 
entirely O 
the O 
need O 
to O 
align O 
electrodes O 
with O 
microchannels O 
. O 
We O 
designed O 
the O 
electrode O 
channels O 
such O 
that O 
the O 
metal O 
can O 
be O 
injected O 
by O 
hand O 
and O 
when O 
the O 
device O 
is O 
non-covalently O 
bound O 
to O 
glass O 
. O 
We O 
demonstrated O 
the O 
biocompatibility O 
of O 
the O 
electrodes O 
for O 
long O 
- O 
term O 
cultures O 
( O 
12 O 
days O 
) O 
using O 
hippocampal O 
neurons O 
. O 
We O 
demonstrated O 
the O 
use O 
of O 
these O 
electrodes O 
to O 
depolarize O 
neurons O 
and O 
recorded O 
neuronal O 
activity O 
using O 
the O 
calcium B-SYSTEMATIC 
indicator O 
dye O 
, O 
Fluo-4 B-ABBREVIATION 
. O 
We O 
established O 
optimal O 
stimulation O 
parameters O 
that O 
induce O 
neuronal O 
spiking O 
without O 
inducing O 
damage O 
. O 
We O 
showed O 
that O 
the O 
liquid O 
metal O 
electrode O 
evoked O 
larger O 
calcium B-SYSTEMATIC 
responses O 
in O 
somata O 
than O 
bath O 
electrodes O 
using O 
the O 
same O 
stimulus O 
parameters O 
. O 
Lastly O 
we O 
demonstrated O 
the O 
use O 
of O 
these O 
liquid O 
metal O 
electrodes O 
to O 
target O 
and O 
depolarize O 
axons O 
. O 
In O 
summary O 
, O 
the O 
integration O 
of O 
liquid O 
metal O 
electrodes O 
with O 
neuronal O 
culture O 
platforms O 
provides O 
a O 
user O 
- O 
friendly O 
and O 
targeted O 
method O 
to O 
stimulate O 
neurons O 
and O 
their O 
subcellular O 
compartments O 
, O 
thus O 
providing O 
a O 
novel O 
tool O 
for O 
future O 
biological O 
investigations O 
. O 

functional O 
theory O 
study O 
of O 
the O 
structure O 
and O 
vibrational O 
modes O 
of O 
acrylonitrile B-SYSTEMATIC 
adsorbed O 
on O 
Cu(100) B-FORMULA 
. O 

present O 
a O 
theoretical O 
study O 
of O 
the O 
structure O 
and O 
vibrations O 
of O 
acrylonitrile B-SYSTEMATIC 
adsorbed O 
on O 
a O 
Cu(100) B-FORMULA 
metal O 
surface O 
. O 
Simulations O 
have O 
been O 
carried O 
out O 
by O 
means O 
of O 
the O 
density O 
functional O 
theory O 
adopting O 
periodic O 
boundary O 
conditions O 
and O 
including O 
van O 
der O 
Waals O 
dispersion O 
forces O 
. O 
The O 
two O 
most O 
stable O 
structures O 
( O 
which O 
are O 
almost O 
degenerate O 
in O 
energy O 
) O 
correspond O 
to O 
the O 
molecule O 
adsorbed O 
parallel O 
to O 
the O 
metal O 
surface O 
. O 
In O 
both O 
geometries O 
, O 
the O 
vinyl B-FAMILY 
( O 
C=C B-FORMULA 
) O 
and O 
the O 
cyano B-FAMILY 
( O 
C≡N B-FORMULA 
) O 
groups O 
are O 
the O 
anchorage O 
sites O 
to O 
the O 
surface O 
atoms O 
. O 
Low O 
energy O 
transition O 
barriers O 
allow O 
fast O 
isomerization O 
between O 
both O 
structures O 
. O 
Molecular O 
adsorption O 
shifts O 
some O 
of O 
their O 
vibrational O 
frequencies O 
with O 
respect O 
to O 
the O 
gas O 
phase O 
, O 
mainly O 
the O 
C=C B-FORMULA 
and O 
the O 
C≡N B-FORMULA 
stretching O 
modes O 
, O 
in O 
agreement O 
with O 
recent O 
experimental O 
measurements O 
[ O 
Tornero O 
et O 
al O 
. O 
, O 
Phys O 
. O 
Chem O 
. O 
Chem O 
. O 
Phys O 
. O 
, O 
2011 O 
, O 
13 O 
, O 
8475 O 
] O 
. O 

analysis O 
in O 
the O 
near O 
infrared O 
region O 
is O 
of O 
significant O 
biological O 
importance O 
due O 
to O 
better O 
tissue O 
penetration O 
and O 
reduced O 
autofluorescence O 
. O 
In O 
this O 
work O 
, O 
an O 
improved O 
synthesis O 
of O 
hollow O 
gold O 
nanospheres O 
( O 
HGNs O 
) O 
, O 
which O 
provides O 
a O 
tunable O 
localized O 
surface O 
plasmon O 
resonance O 
( O 
LSPR O 
) O 
from O 
610 O 
nm O 
up O 
to O 
1320 O 
nm O 
, O 
is O 
demonstrated O 
. O 
The O 
scattering O 
properties O 
of O 
these O 
nanoparticles O 
are O 
shown O 
using O 
surface O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
at O 
1064 O 
nm O 
excitation O 
wavelength O 
and O 
are O 
compared O 
to O 
citrate B-FAMILY 
reduced O 
gold O 
and O 
silver B-SYSTEMATIC 
nanoparticles O 
of O 
similar O 
physical O 
sizes O 
and O 
surface O 
properties O 
. O 
After O 
the O 
addition O 
of O 
salts O 
, O 
a O 
strong O 
signal O 
was O 
observed O 
from O 
hollow O 
gold O 
with O 
a O 
LSPR O 
of O 
650 O 
nm O 
and O 
a O 
weaker O 
, O 
yet O 
observable O 
, O 
signal O 
from O 
HGNs O 
with O 
a O 
LSPR O 
of O 
775 O 
nm O 
. O 
However O 
, O 
no O 
obvious O 
signals O 
were O 
observed O 
in O 
the O 
case O 
of O 
standard O 
citrate B-FAMILY 
reduced O 
gold O 
, O 
silver B-SYSTEMATIC 
or O 
HGNs O 
with O 
a O 
LSPR O 
of O 
1080 O 
nm O 
. O 
The O 
absorption O 
properties O 
of O 
HGNs O 
were O 
investigated O 
by O 
monitoring O 
their O 
photothermal O 
activity O 
. O 
In O 
this O 
case O 
, O 
different O 
nanoparticle O 
suspensions O 
including O 
citrate B-FAMILY 
reduced O 
gold O 
, O 
silver B-SYSTEMATIC 
, O 
and O 
HGNs O 
were O 
illuminated O 
by O 
a O 
continuous O 
laser O 
at O 
785 O 
nm O 
excitation O 
wavelength O 
and O 
the O 
absorption O 
efficiency O 
of O 
HGNs O 
with O 
a O 
LSPR O 
of O 
775 O 
nm O 
was O 
calculated O 
to O 
be O 
0.81% O 
which O 
is O 
more O 
than O 
5 O 
times O 
higher O 
than O 
the O 
absorption O 
efficiency O 
of O 
citrate B-FAMILY 
reduced O 
gold O 
nanoparticles O 
under O 
similar O 
conditions O 
. O 

vitro O 
transfection O 
mediated O 
by O 
dendrigraft O 
poly(L-lysines) B-SYSTEMATIC 
: O 
the O 
effect O 
of O 
structure O 
and O 
molecule O 
size O 
. O 

poly(L-lysines) I-SYSTEMATIC 
( O 
DGL B-ABBREVIATION 
) O 
constitute O 
promising O 
nanomaterials O 
applicable O 
as O 
a O 
nonviral O 
gene O 
- O 
delivery O 
vector O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluate O 
the O 
transfection O 
abilities O 
of O 
four O 
DGL B-ABBREVIATION 
generations O 
with O 
special O 
emphasis O 
on O 
the O 
systematic O 
description O 
of O 
the O 
relationship O 
of O 
how O 
generation O 
( O 
i.e O 
. O 
, O 
molecule O 
size O 
) O 
affects O 
the O 
transfection O 
efficacy O 
. O 
Using O 
Hep2 O 
cells O 
, O 
we O 
demonstrated O 
that O 
the O 
capability O 
of O 
unmodified O 
DGL B-ABBREVIATION 
to O 
deliver O 
plasmid O 
is O 
of O 
a O 
magnitude O 
lower O 
than O 
that O 
of O 
jetPEI B-TRIVIAL 
. O 
On O 
the O 
other O 
hand O 
, O 
employing O 
the O 
Hep2 O 
cell O 
line O 
stably O 
transduced O 
with O 
eGFP O 
, O 
we O 
observed O 
that O 
DGL B-ABBREVIATION 
G5 O 
delivers O 
the O 
siRNA O 
oligonucleotide O 
with O 
the O 
same O 
efficiency O 
as O 
Lipofectamine O 
2000 O 
. O 
In O 
further O 
experiments O 
, O 
it O 
was O 
shown O 
that O 
DGL B-ABBREVIATION 
affords O 
excellent O 
ability O 
to O 
bind O 
DNA O 
, O 
protect O 
it O 
against O 
DNase O 
I O 
attack O 
, O 
and O 
internalize O 
it O 
into O 
cells O 
. O 

and O 
SAR O 
of O 
novel O 
Re B-FORMULA 
/ O 
99mTc B-FORMULA 
-labeled O 
benzenesulfonamide B-SYSTEMATIC 
carbonic O 
anhydrase O 
IX O 
inhibitors O 
for O 
molecular O 
imaging O 
of O 
tumor O 
hypoxia O 
. O 

anhydrase O 
IX O 
( O 
CA-IX O 
) O 
is O 
upregulated O 
in O 
cancer O 
in O 
response O 
to O 
the O 
hypoxic O 
tumor O 
microenvironment O 
, O 
making O 
it O 
an O 
attractive O 
molecular O 
target O 
for O 
the O 
detection O 
of O 
hypoxic O 
solid O 
tumors O 
. O 
A O 
series O 
of O 
small O 
molecule O 
benzenesulfonamide B-SYSTEMATIC 
based O 
CA-IX O 
inhibitors O 
containing O 
novel O 
tridentate O 
chelates O 
complexed O 
with O 
the O 
M(CO)(3) B-FAMILY 
core O 
( O 
M O 
= O 
Re B-FORMULA 
or O 
(99m)Tc B-FORMULA 
) O 
were O 
designed O 
and O 
synthesized O 
. O 
The O 
in O 
vitro O 
binding O 
affinity O 
of O 
the O 
benzenesulfonamide B-SYSTEMATIC 
rhenium I-SYSTEMATIC 
complexes O 
yielded O 
IC(50) O 
values O 
ranging O 
from O 
3 O 
to O 
116 O 
nM O 
in O 
hypoxic O 
CA-IX O 
expressing O 
HeLa O 
cells O 
. O 
One O 
of O 
the O 
most O 
potent O 
compounds O 
, O 
3d O 
( O 
IC(50) O 
= O 
9 O 
nM O 
) O 
, O 
was O 
radiolabeled O 
with O 
technetium B-SYSTEMATIC 
tricarbonyl I-SYSTEMATIC 
( O 
{(99m)Tc(CO)(3)}(+) B-FORMULA 
) O 
to O 
afford O 
the O 
{ O 
( B-FORMULA 
99m)Tc(CO)(3)}(+ I-FORMULA 
) I-FORMULA 
complex O 
in O 
excellent O 
yield O 
and O 
high O 
purity O 
. O 
(99m)Tc(CO)(3) B-FORMULA 
-3d O 
bound O 
specifically O 
to O 
CA-IX O 
expressing O 
hypoxic O 
HeLa O 
cells O 
. O 
This O 
effort O 
led O 
to O 
the O 
identification O 
of O 
a O 
diverse O 
series O 
of O 
promising O 
high O 
affinity O 
{(99m)Tc(CO)(3)}(+) B-FORMULA 
radiolabeled O 
CA-IX O 
inhibitors O 
with O 
the O 
potential O 
to O 
significantly O 
impact O 
diagnosis O 
, O 
staging O 
, O 
and O 
treatment O 
selection O 
of O 
hypoxic O 
solid O 
tumors O 
. O 

of O 
surface O 
groups O 
on O 
poly(propylene B-SYSTEMATIC 
imine I-SYSTEMATIC 
) I-SYSTEMATIC 
dendrimers O 
antiprion O 
activity O 
. O 

diseases O 
are O 
characterized O 
by O 
the O 
accumulation O 
of O 
PrP(Sc) O 
, O 
an O 
aberrantly O 
folded O 
isoform O 
of O 
the O 
host O 
protein O 
PrP(C) O 
. O 
Specific O 
forms O 
of O 
synthetic O 
molecules O 
known O 
as O 
dendrimers O 
are O 
able O 
to O 
eliminate O 
protease O 
- O 
resistant O 
PrP(Sc) O 
in O 
both O 
an O 
intracellular O 
and O 
in O 
vitro O 
setting O 
. O 
The O 
properties O 
of O 
a O 
dendrimer O 
which O 
govern O 
this O 
ability O 
are O 
unknown O 
. O 
We O 
addressed O 
the O 
issue O 
by O 
comparing O 
the O 
in O 
vitro O 
antiprion O 
ability O 
of O 
numerous O 
modified O 
poly(propylene-imine) B-SYSTEMATIC 
dendrimers O 
, O 
which O 
varied O 
in O 
size O 
, O 
structure O 
, O 
charge O 
, O 
and O 
surface O 
group O 
composition O 
. O 
Several O 
of O 
the O 
modified O 
dendrimers O 
, O 
including O 
an O 
anionic O 
glycodendrimer O 
, O 
reduced O 
the O 
level O 
of O 
protease O 
resistant O 
PrP(Sc) O 
in O 
a O 
prion O 
strain O 
- O 
dependent O 
manner O 
. O 
This O 
led O 
to O 
the O 
formulation O 
of O 
a O 
new O 
working O 
model O 
for O 
dendrimer O 
/ O 
prion O 
interactions O 
which O 
proposes O 
dendrimers O 
eliminate O 
PrP(Sc) O 
by O 
destabilizing O 
the O 
protein O 
and O 
rendering O 
it O 
susceptible O 
to O 
proteolysis O 
. O 
This O 
ability O 
is O 
not O 
dependent O 
on O 
any O 
particular O 
charge O 
of O 
dendrimer O 
, O 
but O 
does O 
require O 
a O 
high O 
density O 
of O 
reactive O 
surface O 
groups O 
. O 

carbon B-SYSTEMATIC 
nanotube O 
networks O 
as O 
efficient O 
hole O 
extraction O 
layers O 
for O 
organic O 
photovoltaics O 
. O 

, O 
highly O 
percolated O 
networks O 
of O 
regioregular O 
poly(3-hexylthiophene) B-SYSTEMATIC 
( O 
rr- O 
P3HT B-ABBREVIATION 
)-wrapped O 
semiconducting O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
s-SWNTs O 
) O 
are O 
deposited O 
, O 
and O 
the O 
charge O 
transfer O 
processes O 
of O 
these O 
nanohybrids O 
are O 
studied O 
using O 
spectroscopic O 
and O 
electrical O 
measurements O 
. O 
The O 
data O 
disclose O 
hole O 
doping O 
of O 
s-SWNTs O 
by O 
the O 
polymer O 
, O 
challenging O 
the O 
prevalent O 
electron O 
- O 
doping O 
hypothesis O 
. O 
Through O 
controlled O 
fabrication O 
, O 
high- O 
to O 
low O 
- O 
density O 
nanohybrid O 
networks O 
are O 
achieved O 
, O 
with O 
low O 
- O 
density O 
hybrid O 
carbon B-SYSTEMATIC 
nanotube O 
networks O 
tested O 
as O 
hole O 
transport O 
layers O 
( O 
HTLs O 
) O 
for O 
bulk O 
heterojunction O 
( O 
BHJ O 
) O 
organic O 
photovoltaics O 
( O 
OPV O 
) O 
. O 
OPVs O 
incorporating O 
these O 
rr- O 
P3HT B-ABBREVIATION 
/ O 
s-SWNT O 
networks O 
as O 
the O 
HTL O 
demonstrate O 
the O 
best O 
large O 
area O 
( O 
70 O 
mm(2) O 
) O 
carbon B-SYSTEMATIC 
nanotube O 
incorporated O 
organic O 
solar O 
cells O 
to O 
date O 
with O 
a O 
power O 
conversion O 
efficiency O 
of O 
7.6% O 
. O 
This O 
signifies O 
the O 
strong O 
capability O 
of O 
nanohybrids O 
as O 
an O 
efficient O 
hole O 
extraction O 
layer O 
, O 
and O 
we O 
believe O 
that O 
dense O 
nanohybrid O 
networks O 
have O 
the O 
potential O 
to O 
replace O 
expensive O 
and O 
material O 
scarce O 
inorganic O 
transparent O 
electrodes O 
in O 
large O 
area O 
electronics O 
toward O 
the O 
realization O 
of O 
low O 
- O 
cost O 
flexible O 
electronics O 
. O 

ligand O 
NMR O 
screening O 
method O 
for O 
2-oxoglutarate B-SYSTEMATIC 
oxygenase O 
inhibitors O 
. O 

human O 
2-oxoglutarate B-SYSTEMATIC 
( O 
2OG B-ABBREVIATION 
) O 
dependent O 
oxygenases O 
belong O 
to O 
a O 
family O 
of O 
structurally O 
related O 
enzymes O 
that O 
play O 
important O 
roles O 
in O 
many O 
biological O 
processes O 
. O 
We O 
report O 
that O 
competition O 
- O 
based O 
NMR O 
methods O 
, O 
using O 
2OG B-ABBREVIATION 
as O 
a O 
reporter O 
ligand O 
, O 
can O 
be O 
used O 
for O 
quantitative O 
and O 
site O 
- O 
specific O 
screening O 
of O 
ligand O 
binding O 
to O 
2OG B-ABBREVIATION 
oxygenases O 
. O 
The O 
method O 
was O 
demonstrated O 
using O 
hypoxia O 
inducible O 
factor O 
hydroxylases O 
and O 
histone O 
demethylases O 
, O 
and O 
K(D) O 
values O 
were O 
determined O 
for O 
inhibitors O 
that O 
compete O 
with O 
2OG B-ABBREVIATION 
at O 
the O 
metal O 
center O 
. O 
This O 
technique O 
is O 
also O 
useful O 
as O 
a O 
screening O 
or O 
validation O 
tool O 
for O 
inhibitor O 
discovery O 
, O 
as O 
exemplified O 
by O 
work O 
with O 
protein O 
- O 
directed O 
dynamic O 
combinatorial O 
chemistry O 
. O 

Ranelate I-SYSTEMATIC 
affects O 
signaling O 
from O 
mechanically O 
- O 
stimulated O 
osteocytes O 
towards O 
osteoclasts O 
and O 
osteoblasts O 
. O 

Ranelate I-SYSTEMATIC 
( O 
SrRan B-FORMULA 
) O 
is O 
used O 
to O 
decrease O 
the O 
risk O 
of O 
bone O 
fractures O 
. O 
Any O 
factor O 
that O 
alters O 
the O 
release O 
of O 
paracrine O 
signals O 
by O 
osteocytes O 
in O 
response O 
to O 
mechanical O 
stimuli O 
potentially O 
affects O 
bone O 
mass O 
and O 
structure O 
, O 
and O 
thus O 
fracture O 
resistance O 
. O 
We O 
hypothesized O 
that O 
SrRan B-FORMULA 
affects O 
paracrine O 
signaling O 
from O 
mechanically O 
- O 
stimulated O 
osteocytes O 
towards O 
osteoclast O 
- O 
precursors O 
and O 
osteoblasts O 
. O 
MLO-Y4 O 
osteocytes O 
were O 
cultured O 
for O 
24h O 
with O 
SrRan B-FORMULA 
( O 
0.1-3mM O 
) O 
and O 
either O 
or O 
not O 
mechanically O 
stimulated O 
by O 
pulsating O 
fluid O 
flow O 
( O 
PFF O 
; O 
0.7 O 
± O 
0.3 O 
Pa O 
, O 
5 O 
Hz O 
) O 
for O 
60 O 
min O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
( O 
PGE(2) B-ABBREVIATION 
) O 
release O 
, O 
and O 
expression O 
of O 
mechanoresponsive O 
genes O 
were O 
quantified O 
. O 
Conditioned O 
medium O 
( O 
CM O 
) O 
from O 
osteocytes O 
was O 
added O 
to O 
mouse O 
bone O 
marrow O 
cells O 
for O 
7 O 
days O 
to O 
assess O 
osteoclastogenesis O 
, O 
or O 
MC3T3-E1 O 
osteoblasts O 
for O 
4-16 O 
days O 
to O 
measure O 
osteogenic O 
gene O 
expression O 
. O 
SrRan B-FORMULA 
( O 
3mM O 
) O 
enhanced O 
NO B-FORMULA 
and O 
PGE(2) B-ABBREVIATION 
release O 
to O 
the O 
same O 
extent O 
in O 
static O 
osteocytes O 
( O 
NO B-FORMULA 
: O 
1.6-fold O 
; O 
PGE(2) B-ABBREVIATION 
: O 
2.8-fold O 
) O 
and O 
PFF-stimulated O 
osteocytes O 
( O 
NO B-FORMULA 
: O 
1.3-fold O 
; O 
PGE(2) B-ABBREVIATION 
: O 
2.6-fold O 
) O 
. O 
CM O 
from O 
PFF O 
- O 
treated O 
osteocytes O 
without O 
SrRan B-FORMULA 
enhanced O 
Ki67 O 
expression O 
but O 
reduced O 
Runx2 O 
and O 
Ocn O 
expression O 
in O 
osteoblasts O 
. O 
This O 
effect O 
on O 
gene O 
expression O 
was O 
not O 
observed O 
with O 
CM O 
obtained O 
from O 
osteocytes O 
treated O 
with O 
the O 
combination O 
of O 
PFF O 
and O 
3mM O 
SrRan B-FORMULA 
. O 
CM O 
from O 
PFF O 
- O 
treated O 
osteocytes O 
inhibited O 
osteoclastogenesis O 
by O 
1.9-fold O 
. O 
The O 
combination O 
of O 
PFF O 
and O 
3mM O 
SrRan B-FORMULA 
reduced O 
osteocyte O 
- O 
stimulated O 
osteoclastogenesis O 
even O 
more O 
strongly O 
( O 
4.3-fold O 
) O 
. O 
In O 
conclusion O 
, O 
SrRan B-FORMULA 
affects O 
paracrine O 
signaling O 
between O 
mechanically O 
- O 
stimulated O 
MLO-Y4 O 
osteocytes O 
and O 
both O 
osteoblasts O 
and O 
osteoclast O 
precursors O 
. O 
The O 
positive O 
effects O 
of O 
SrRan B-FORMULA 
on O 
bone O 
fracture O 
resistance O 
may O 
thus O 
be O 
partly O 
explained O 
by O 
altered O 
paracrine O 
signaling O 
by O 
osteocytes O 
. O 

of O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
functionalities O 
in O 
ruthenium B-FAMILY 
(II) I-FAMILY 
polypyridyl I-FAMILY 
complexes I-FAMILY 
on O 
DNA O 
binding O 
, O 
cytotoxicity O 
and O 
antioxidant O 
activity O 
: O 
synthesis O 
, O 
structure O 
and O 
in O 
vitro O 
anticancer O 
activity O 
. O 

new O 
Ru B-FORMULA 
(II) I-FORMULA 
complexes O 
[RuHCl(bpy)(PPh(3))(CO)] B-FORMULA 
( O 
1 O 
) O 
, O 
[RuHCl(bpy)(AsPh(3))(CO)] B-FORMULA 
( O 
2 O 
) O 
( O 
bpy B-ABBREVIATION 
= O 
2,2'-bipyridine B-SYSTEMATIC 
) O 
, O 
[RuCl(HL)(PPh(3))(2)(CO)] B-FORMULA 
( O 
3 O 
) O 
and O 
[RuCl(HL)(AsPh(3))(2)(CO)] B-FORMULA 
( O 
4 O 
) O 
( O 
HL O 
= O 
2,2'-bipyridine-4,4'-dicarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
were O 
synthesized O 
and O 
characterized O 
. O 
X-ray O 
diffraction O 
was O 
used O 
to O 
characterize O 
3 O 
in O 
solid O 
state O 
. O 
The O 
interactions O 
of O 
these O 
complexes O 
with O 
DNA O 
were O 
explored O 
by O 
different O 
techniques O 
which O 
revealed O 
that O 
the O 
complexes O 
could O 
bind O 
to O 
CT-DNA O 
through O 
non-intercalation O 
. O 
The O 
in O 
vitro O 
cytotoxic O 
and O 
antioxidant O 
activities O 
of O 
the O 
complexes O 
validated O 
against O 
a O 
panel O 
of O 
cancer O 
cell O 
lines O 
and O 
free O 
radicals O 
showed O 
that O 
3 O 
and O 
4 O 
possess O 
quite O 
high O 
anticancer O 
and O 
antioxidant O 
activities O 
over O 
1 O 
, O 
2 O 
and O 
standard O 
drugs O 
. O 
An O 
apparent O 
dependence O 
of O 
biological O 
activities O 
on O 
incorporation O 
of O 
COOH B-FORMULA 
in O 
bipyridine B-SYSTEMATIC 
moiety O 
was O 
noticed O 
: O 
Inclusion O 
of O 
COOH B-FORMULA 
caused O 
significant O 
differences O 
in O 
DNA O 
binding O 
, O 
cytotoxicity O 
and O 
antioxidant O 
activity O 
. O 

cells O 
are O 
derived O 
from O 
hematopoietic O 
progenitors O 
that O 
are O 
known O 
to O 
migrate O 
to O 
and O 
reside O 
within O 
connective O 
and O 
mucosal O 
tissues O 
, O 
where O 
they O 
differentiate O 
and O 
respond O 
to O 
various O 
stimuli O 
by O 
releasing O 
pro O 
- O 
inflammatory O 
mediators O 
, O 
including O 
histamine B-TRIVIAL 
, O 
growth O 
factors O 
, O 
and O 
proteases O 
. O 
This O 
study O 
demonstrated O 
that O 
primary O 
human O 
mast O 
cells O 
as O 
well O 
as O 
the O 
rat O 
and O 
human O 
mast O 
cell O 
lines O 
, O 
RBL-2H3 O 
and O 
HMC-1 O 
, O 
produce O 
the O 
heparan O 
sulfate B-SYSTEMATIC 
proteoglycan O 
, O 
perlecan O 
, O 
with O 
a O 
molecular O 
mass O 
of O 
640 O 
kDa O 
as O 
well O 
as O 
smaller O 
molecular O 
mass O 
species O 
of O 
300 O 
and O 
130 O 
kDa O 
. O 
Utilizing O 
domain O 
- O 
specific O 
antibodies O 
coupled O 
with O 
N B-FORMULA 
-terminal O 
sequencing O 
, O 
it O 
was O 
confirmed O 
that O 
both O 
forms O 
contained O 
the O 
C B-FORMULA 
-terminal O 
module O 
of O 
the O 
protein O 
core O 
known O 
as O 
endorepellin O 
, O 
which O 
were O 
generated O 
by O 
mast O 
cell O 
- O 
derived O 
proteases O 
. O 
Domain O 
- O 
specific O 
RT-PCR O 
experiments O 
demonstrated O 
that O 
transcripts O 
corresponding O 
to O 
domains O 
I O 
and O 
V O 
, O 
including O 
endorepellin O 
, O 
were O 
present O 
; O 
however O 
, O 
mRNA O 
transcripts O 
corresponding O 
to O 
regions O 
of O 
domain O 
III O 
were O 
not O 
present O 
, O 
suggesting O 
that O 
these O 
cells O 
were O 
capable O 
of O 
producing O 
spliced O 
forms O 
of O 
the O 
protein O 
core O 
. O 
Fractions O 
from O 
mast O 
cell O 
cultures O 
that O 
were O 
enriched O 
for O 
these O 
fragments O 
were O 
shown O 
to O 
bind O 
endothelial O 
cells O 
via O 
the O 
α(2)β(1) O 
integrin O 
and O 
stimulate O 
the O 
migration O 
of O 
cells O 
in O 
" O 
scratch O 
assays O 
, O 
" O 
both O 
activities O 
of O 
which O 
were O 
inhibited O 
by O 
incubation O 
with O 
either O 
anti-endorepellin O 
or O 
anti-perlecan O 
antibodies O 
. O 
This O 
study O 
shows O 
for O 
the O 
first O 
time O 
that O 
mast O 
cells O 
secrete O 
and O 
process O 
the O 
extracellular O 
proteoglycan O 
perlecan O 
into O 
fragments O 
containing O 
the O 
endorepellin O 
C B-FORMULA 
-terminal O 
region O 
that O 
regulate O 
angiogenesis O 
and O 
matrix O 
turnover O 
, O 
which O 
are O 
both O 
key O 
events O 
in O 
wound O 
healing O 
. O 

- O 
decolorizing O 
peroxidases O 
( O 
DyPs O 
) O 
belong O 
to O 
the O 
large O 
group O 
of O 
heme B-FAMILY 
peroxidases O 
. O 
They O 
utilize O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
to O 
catalyze O 
oxidations O 
of O 
various O 
organic O 
compounds O 
. O 
AauDyPI O 
from O 
Auricularia O 
auricula O 
- O 
judae O 
( O 
fungi O 
) O 
was O 
crystallized O 
, O 
and O 
its O 
crystal O 
structure O 
was O 
determined O 
at O 
2.1 O 
Å O 
resolution O 
. O 
The O 
mostly O 
helical O 
structure O 
also O 
shows O 
a O 
β-sheet O 
motif O 
typical O 
for O 
DyPs O 
and O 
Cld O 
( O 
chlorite B-SYSTEMATIC 
dismutase O 
) O 
- O 
related O 
structures O 
and O 
includes O 
the O 
complete O 
polypeptide O 
chain O 
. O 
At O 
the O 
distal O 
side O 
of O 
the O 
heme B-FAMILY 
molecule O 
, O 
a O 
flexible O 
aspartate B-TRIVIAL 
residue O 
( O 
Asp B-FORMULA 
-168 O 
) O 
plays O 
a O 
key O 
role O 
in O 
catalysis O 
. O 
It O 
guides O 
incoming O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
toward O 
the O 
heme B-FAMILY 
iron B-SYSTEMATIC 
and O 
mediates O 
proton O 
rearrangement O 
in O 
the O 
process O 
of O 
Compound O 
I O 
formation O 
. O 
Afterward O 
, O 
its O 
side O 
chain O 
changes O 
its O 
conformation O 
, O 
now O 
pointing O 
toward O 
the O 
protein O 
backbone O 
. O 
We O 
propose O 
an O 
extended O 
functionality O 
of O 
Asp B-FORMULA 
-168 O 
, O 
which O 
acts O 
like O 
a O 
gatekeeper O 
by O 
altering O 
the O 
width O 
of O 
the O 
heme B-FAMILY 
cavity O 
access O 
channel O 
. O 
Chemical O 
modifications O 
of O 
potentially O 
redox O 
- O 
active O 
amino B-FAMILY 
acids I-FAMILY 
show O 
that O 
a O 
tyrosine B-TRIVIAL 
is O 
involved O 
in O 
substrate O 
interaction O 
. O 
Using O 
spin O 
- O 
trapping O 
experiments O 
, O 
a O 
transient O 
radical O 
on O 
the O 
surface O 
- O 
exposed O 
Tyr B-FORMULA 
-337 O 
was O 
identified O 
as O 
the O 
oxidation O 
site O 
for O 
bulky O 
substrates O 
. O 
A O 
possible O 
long O 
- O 
range O 
electron O 
transfer O 
pathway O 
from O 
the O 
surface O 
of O 
the O 
enzyme O 
to O 
the O 
redox O 
cofactor O 
( O 
heme B-FAMILY 
) O 
is O 
discussed O 
. O 

study O 
of O 
the O 
spin O 
- O 
state O 
energies O 
and O 
UV-Vis O 
spectra O 
of O 
bis(1,4,7-triazacyclononane) B-SYSTEMATIC 
complexes O 
of O 
some O 
first O 
- O 
row O 
transition B-FAMILY 
metal I-FAMILY 
cations O 
. O 

report O 
here O 
computed O 
spin O 
- O 
state O 
energies O 
and O 
UV-Vis O 
spectra O 
for O 
several O 
transition B-FAMILY 
metal I-FAMILY 
complexes O 
with O 
a O 
triazacyclononane B-SYSTEMATIC 
ligand O 
. O 
Our O 
results O 
show O 
that O 
the O 
spin O 
ground O 
- O 
state O 
is O 
correctly O 
obtained O 
with O 
either O 
OPBE O 
or O 
SSB-D O 
, O 
except O 
for O 
the O 
high O 
- O 
spin O 
ground O 
- O 
state O 
of O 
the O 
Co B-FORMULA 
(ii) I-FORMULA 
complex O 
that O 
was O 
properly O 
described O 
only O 
by O 
SSB-D O 
. O 
The O 
UV-Vis O 
spectra O 
from O 
TD-DFT O 
reproduce O 
in O 
general O 
rather O 
well O 
the O 
experimental O 
spectra O 
, O 
but O 
in O 
cases O 
of O 
the O 
Cr B-FORMULA 
(iii) I-FORMULA 
and O 
Co B-FORMULA 
(ii) I-FORMULA 
complexes O 
it O 
clearly O 
failed O 
. O 
Better O 
results O 
for O 
the O 
UV-Vis O 
spectra O 
have O 
been O 
obtained O 
by O 
using O 
Ligand O 
Field O 
DFT O 
. O 

shape O 
optimization O 
by O 
changing O 
from O 
an O 
isotropic O 
to O 
an O 
anisotropic O 
nanostructure O 
: O 
preparation O 
of O 
highly O 
active O 
and O 
stable O 
supported O 
Pt B-FORMULA 
catalysts O 
in O 
microemulsions O 
. O 

recently O 
introduced O 
a O 
new O 
method O 
to O 
synthesize O 
an O 
active O 
and O 
stable O 
Pt B-FORMULA 
catalyst O 
, O 
namely O 
thermo O 
- O 
destabilization O 
of O 
microemulsions O 
( O 
see O 
R O 
. O 
Y O 
. O 
Parapat O 
, O 
V O 
. O 
Parwoto O 
, O 
M O 
. O 
Schwarze O 
, O 
B O 
. O 
Zhang O 
, O 
D O 
. O 
S O 
. O 
Su O 
and O 
R O 
. O 
Schomäcker O 
, O 
J O 
. O 
Mater O 
. O 
Chem O 
. O 
, O 
2012 O 
, O 
22 O 
( O 
23 O 
) O 
, O 
11605-11614 O 
) O 
. O 
We O 
are O 
able O 
to O 
produce O 
Pt B-FORMULA 
nanocrystals O 
with O 
a O 
small O 
size O 
( O 
2.5 O 
nm O 
) O 
of O 
an O 
isotropic O 
structure O 
i.e O 
. O 
truncated O 
octahedral O 
and O 
deposit O 
them O 
well O 
on O 
support O 
materials O 
. O 
Although O 
we O 
have O 
obtained O 
good O 
results O 
, O 
the O 
performance O 
of O 
the O 
catalyst O 
still O 
needed O 
to O 
be O 
improved O 
and O 
optimized O 
. O 
We O 
followed O 
the O 
strategy O 
to O 
retain O 
the O 
small O 
size O 
but O 
change O 
the O 
shape O 
to O 
an O 
anisotropic O 
structure O 
of O 
Pt B-FORMULA 
nanocrystals O 
which O 
produces O 
more O 
active O 
sites O 
by O 
means O 
of O 
a O 
weaker O 
reducing O 
agent O 
. O 
We O 
found O 
that O 
our O 
catalysts O 
are O 
more O 
active O 
than O 
those O 
we O 
reported O 
before O 
and O 
even O 
show O 
the O 
potential O 
to O 
be O 
applied O 
in O 
a O 
challenging O 
reaction O 
such O 
as O 
hydrogenation O 
of O 
levulinic B-TRIVIAL 
acid I-TRIVIAL 
. O 

the O 
light O 
emission O 
from O 
GaAs B-FORMULA 
nanowires O 
over O 
290 O 
meV O 
with O 
uniaxial O 
strain O 
. O 

engineering O 
has O 
been O 
used O 
to O 
increase O 
the O 
charge O 
carrier O 
mobility O 
of O 
complementary O 
metal-oxide-semiconductor O 
transistors O 
as O 
well O 
as O 
to O 
boost O 
and O 
tune O 
the O 
performance O 
of O 
optoelectronic O 
devices O 
, O 
enabling O 
wavelength O 
tuning O 
, O 
polarization O 
selectivity O 
and O 
suppression O 
of O 
temperature O 
drifts O 
. O 
Semiconducting O 
nanowires O 
benefit O 
from O 
enhanced O 
mechanical O 
properties O 
, O 
such O 
as O 
increased O 
yield O 
strength O 
, O 
that O 
turn O 
out O 
to O 
be O 
beneficial O 
to O 
amplify O 
strain O 
effects O 
. O 
Here O 
we O 
use O 
photoluminescence O 
( O 
PL O 
) O 
to O 
study O 
the O 
effect O 
of O 
uniaxial O 
stress O 
on O 
the O 
electronic O 
properties O 
of O 
GaAs B-FORMULA 
/ O 
Al0.3Ga0.7 O 
As B-FORMULA 
/ O 
GaAs B-FORMULA 
core O 
/ O 
shell O 
nanowires O 
. O 
Both O 
compressive O 
and O 
tensile O 
mechanical O 
stress O 
were O 
applied O 
continuously O 
and O 
reversibly O 
to O 
the O 
nanowire O 
, O 
resulting O 
in O 
a O 
remarkable O 
decrease O 
of O 
the O 
bandgap O 
of O 
up O 
to O 
296 O 
meV O 
at O 
3.5% O 
of O 
strain O 
. O 
Raman O 
spectra O 
were O 
measured O 
and O 
analyzed O 
to O 
determine O 
the O 
axial O 
strain O 
in O 
the O 
nanowire O 
and O 
the O 
Poisson O 
ratio O 
in O 
the O 
< O 
111> O 
direction O 
. O 
In O 
both O 
PL O 
and O 
Raman O 
spectra O 
, O 
we O 
observe O 
fingerprints O 
of O 
symmetry O 
breaking O 
due O 
to O 
anisotropic O 
deformation O 
of O 
the O 
nanowire O 
. O 
The O 
shifts O 
observed O 
in O 
the O 
PL O 
and O 
Raman O 
spectra O 
are O 
well O 
described O 
by O 
bulk O 
deformation O 
potentials O 
for O 
band O 
structure O 
and O 
phonon O 
energies O 
. O 
The O 
fact O 
that O 
exceptionally O 
high O 
elastic O 
strain O 
can O 
be O 
applied O 
to O 
semiconducting O 
nanowires O 
makes O 
them O 
ideally O 
suited O 
for O 
novel O 
device O 
applications O 
that O 
require O 
a O 
tuning O 
of O 
the O 
band O 
structure O 
over O 
a O 
broad O 
range O 
. O 

use O 
of O 
plasmonic O 
nanoparticle O 
complexes O 
for O 
biomedical O 
applications O 
such O 
as O 
imaging O 
, O 
gene O 
therapy O 
, O 
and O 
cancer O 
treatment O 
is O 
a O 
rapidly O 
emerging O 
field O 
expected O 
to O 
significantly O 
improve O 
conventional O 
medical O 
practices O 
. O 
In O 
contrast O 
, O 
the O 
use O 
of O 
these O 
types O 
of O 
nanoparticles O 
to O 
noninvasively O 
trigger O 
biochemical O 
pathways O 
has O 
been O 
largely O 
unexplored O 
. O 
Here O 
we O 
report O 
the O 
light O 
- O 
induced O 
activation O 
of O 
the O 
thermophilic O 
enzyme O 
Aeropyrum O 
pernix O 
glucokinase O 
, O 
a O 
key O 
enzyme O 
for O 
the O 
decomposition O 
of O 
glucose B-TRIVIAL 
via O 
the O 
glycolysis O 
pathway O 
, O 
increasing O 
its O 
rate O 
of O 
reaction O 
60% O 
with O 
light O 
by O 
conjugating O 
the O 
enzyme O 
onto O 
Au B-FORMULA 
nanorods O 
. O 
The O 
observed O 
increase O 
in O 
enzyme O 
activity O 
corresponded O 
to O 
a O 
local O 
temperature O 
increase O 
within O 
a O 
calcium B-SYSTEMATIC 
alginate O 
encapsulate O 
of O 
~20 O 
°C O 
when O 
compared O 
to O 
the O 
bulk O 
medium O 
maintained O 
at O 
standard O 
, O 
nonthermophilic O 
temperatures O 
. O 
The O 
encapsulated O 
nanocomplexes O 
were O 
reusable O 
and O 
stable O 
for O 
several O 
days O 
, O 
making O 
them O 
potentially O 
useful O 
in O 
industrial O 
applications O 
. O 
This O 
approach O 
could O 
significantly O 
improve O 
how O 
biochemical O 
pathways O 
are O 
controlled O 
for O 
in O 
vitro O 
and O 
, O 
quite O 
possibly O 
, O 
in O 
vivo O 
use O 
. O 

flow O 
of O 
water O 
through O 
silica B-TRIVIAL 
colloidal O 
crystals O 
was O 
investigated O 
experimentally O 
for O 
eight O 
different O 
particle O 
diameters O 
, O 
which O 
have O 
hydraulic O 
channel O 
radii O 
ranging O 
from O 
15 O 
to O 
800 O 
nm O 
. O 
The O 
particle O 
surfaces O 
were O 
silylated O 
to O 
be O 
low O 
in O 
energy O 
, O 
with O 
a O 
water O 
contact O 
angle O 
of O 
83° O 
, O 
as O 
determined O 
for O 
a O 
silylated O 
flat O 
surface O 
. O 
Flow O 
rates O 
through O 
centimeter O 
lengths O 
of O 
colloidal O 
crystal O 
were O 
measured O 
using O 
a O 
commercial O 
liquid O 
chromatograph O 
for O 
accurate O 
comparisons O 
of O 
water O 
and O 
toluene O 
flow O 
rates O 
using O 
pressure O 
gradients O 
as O 
high O 
as O 
10(10) O 
Pa O 
/ O 
m O 
. O 
Toluene O 
exhibited O 
no O 
- O 
slip O 
Hagen-Poiseuille O 
flow O 
for O 
all O 
hydraulic O 
channel O 
radii O 
. O 
For O 
water O 
, O 
the O 
slip O 
flow O 
enhancement O 
as O 
a O 
function O 
of O 
hydraulic O 
channel O 
radius O 
was O 
described O 
well O 
by O 
the O 
expected O 
slip O 
flow O 
correction O 
for O 
Hagen-Poiseuille O 
flow O 
, O 
and O 
the O 
data O 
revealed O 
a O 
constant O 
slip O 
length O 
of O 
63 O 
± O 
3 O 
nm O 
. O 
A O 
flow O 
enhancement O 
of O 
20 O 
± O 
2 O 
was O 
observed O 
for O 
the O 
smallest O 
hydraulic O 
channel O 
radius O 
of O 
15 O 
nm O 
. O 
The O 
amount O 
of O 
slip O 
flow O 
was O 
found O 
to O 
be O 
independent O 
of O 
shear O 
rate O 
over O 
a O 
range O 
of O 
fluid O 
velocities O 
from O 
0.7 O 
to O 
5.8 O 
mm O 
/ O 
s O 
. O 
The O 
results O 
support O 
the O 
applicability O 
of O 
the O 
slip O 
flow O 
correction O 
for O 
channel O 
radii O 
as O 
small O 
as O 
15 O 
nm O 
. O 
The O 
work O 
demonstrates O 
that O 
packed O 
beds O 
of O 
submicrometer O 
particles O 
enable O 
slip O 
flow O 
to O 
be O 
employed O 
for O 
high O 
- O 
volume O 
flow O 
rates O 
. O 

stimulates O 
suppressor O 
of O 
cytokine O 
signaling-3 O 
gene O 
expression O 
in O 
3T3-L1 O 
adipocytes O 
via O 
the O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
pathway O 
. O 

of O 
cytokine O 
signaling O 
(SOCS)-3 O 
can O 
act O 
as O 
a O 
regulator O 
of O 
energy O 
metabolism O 
and O 
cytokine O 
signaling O 
in O 
fat O 
cells O 
. O 
It O 
is O 
regulated O 
by O 
hormones O 
and O 
toxicological O 
factors O 
. O 
However O 
, O 
the O 
action O 
of O 
cycloheximide B-TRIVIAL 
on O 
expression O 
of O 
adipocyte O 
SOCS-3 O 
gene O 
is O 
unknown O 
. O 
Using O 
3T3-L1 O 
adipocytes O 
, O 
we O 
found O 
that O 
cycloheximide B-TRIVIAL 
up O 
- O 
regulated O 
SOCS-3 O 
mRNA O 
expression O 
in O 
dose- O 
and O 
time O 
- O 
dependent O 
manners O 
. O 
Treatment O 
with O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
prevented O 
cycloheximide B-TRIVIAL 
-stimulated O 
SOCS-3 O 
mRNA O 
expression O 
, O 
suggesting O 
that O 
the O 
effect O 
of O 
cycloheximide B-TRIVIAL 
requires O 
new O 
mRNA O 
synthesis O 
. O 
While O 
cycloheximide B-TRIVIAL 
was O 
shown O 
to O 
increase O 
activities O 
of O 
MEK1 O 
and O 
JNK O 
, O 
signaling O 
was O 
demonstrated O 
to O 
be O 
inhibited O 
by O 
pretreatment O 
with O 
either O 
MEK1 O 
inhibitors O 
U0126 B-IDENTIFIER 
and O 
PD98059 B-IDENTIFIER 
, O 
or O 
with O 
the O 
JNK O 
inhibitor O 
SP600125 B-IDENTIFIER 
. O 
U0126 B-IDENTIFIER 
and O 
PD98059 B-IDENTIFIER 
, O 
respectively O 
, O 
reduced O 
cycloheximide B-TRIVIAL 
-stimulated O 
SOCS-3 O 
mRNA O 
expression O 
, O 
but O 
SP600125 B-IDENTIFIER 
did O 
not O 
antagonize O 
cycloheximide B-TRIVIAL 
effect O 
. O 
Moreover O 
, O 
cycloheximide B-TRIVIAL 
was O 
observed O 
to O 
up O 
- O 
regulate O 
expression O 
of O 
other O 
SOCS O 
family O 
members O 
, O 
such O 
as O 
SOCS-1 O 
, O 
-2 O 
, O 
-4 O 
, O 
-5 O 
, O 
-6 O 
, O 
-7 O 
, O 
and O 
cytokine O 
- O 
inducible O 
SH2 O 
- O 
containing O 
protein O 
(CIS)-1 O 
mRNAs O 
. O 
Such O 
effects O 
varied O 
with O 
the O 
dosage O 
and O 
duration O 
of O 
cycloheximide B-TRIVIAL 
treatment O 
. O 
These O 
results O 
imply O 
the O 
functional O 
MEK1 O 
/ O 
ERK O 
- O 
mediated O 
pathway O 
is O 
necessary O 
for O 
the O 
cycloheximide B-TRIVIAL 
stimulation O 
of O 
SOCS-3 O 
gene O 
expression O 
. O 

S O 
and O 
G2 O 
phase O 
mammalian O 
cells O 
DNA O 
double O 
strand O 
breaks O 
( O 
DSBs O 
) O 
can O 
potentially O 
be O 
repaired O 
by O 
homologous O 
recombination O 
( O 
HR O 
) O 
or O 
non-homologous O 
end O 
- O 
joining O 
( O 
NHEJ O 
) O 
. O 
Results O 
of O 
several O 
studies O 
suggest O 
that O 
these O 
two O 
mechanistically O 
distinct O 
repair O 
pathways O 
can O 
compete O 
for O 
DNA O 
ends O 
. O 
Because O 
HR O 
and O 
NHEJ O 
differ O 
with O 
respect O 
to O 
error O 
susceptibility O 
, O 
generation O 
of O 
chromosome O 
rearrangements O 
, O 
which O 
are O 
potentially O 
carcinogenic O 
products O 
of O 
DSB O 
repair O 
, O 
may O 
depend O 
on O 
the O 
pathway O 
choice O 
. O 
To O 
investigate O 
this O 
hypothesis O 
, O 
the O 
influence O 
of O 
HR O 
and O 
NHEJ O 
inhibition O 
on O 
the O 
frequencies O 
of O 
chromosome O 
aberrations O 
in O 
G2 O 
phase O 
cells O 
was O 
investigated O 
. O 
SW-1573 O 
and O 
RKO O 
cells O 
were O 
treated O 
with O 
mild O 
( O 
41 O 
°C O 
) O 
hyperthermia O 
in O 
order O 
to O 
disable O 
HR O 
and O 
/ O 
or O 
NU7441 B-IDENTIFIER 
/ O 
cisplatin B-TRIVIAL 
to O 
inactivate O 
NHEJ O 
and O 
frequencies O 
of O 
chromosomal O 
fragments O 
( O 
resulting O 
from O 
unrepaired O 
DSBs O 
) O 
and O 
translocations O 
( O 
products O 
of O 
erroneous O 
DSB O 
rejoining O 
) O 
were O 
studied O 
using O 
premature O 
chromosome O 
condensation O 
( O 
PCC O 
) O 
combined O 
with O 
fluorescence O 
in O 
situ O 
hybridization O 
( O 
FISH O 
) O 
. O 
It O 
is O 
shown O 
here O 
that O 
temporary O 
inhibition O 
of O 
HR O 
by O 
hyperthermia O 
results O 
in O 
increased O 
frequency O 
of O 
ionizing O 
- O 
radiation O 
(IR)-induced O 
chromosomal O 
translocations O 
and O 
that O 
this O 
effect O 
is O 
abrogated O 
by O 
NU7441 B-IDENTIFIER 
- O 
or O 
cisplatin B-TRIVIAL 
-mediated O 
inhibition O 
of O 
NHEJ O 
. O 
The O 
results O 
suggest O 
that O 
in O 
the O 
absence O 
of O 
HR O 
, O 
DSB O 
repair O 
is O 
shifted O 
to O 
the O 
error O 
- O 
prone O 
NHEJ O 
pathway O 
resulting O 
in O 
increased O 
frequencies O 
of O 
chromosomal O 
rearrangements O 
. O 
These O 
results O 
might O 
be O 
of O 
consequence O 
for O 
clinical O 
cancer O 
treatment O 
approaches O 
that O 
aim O 
at O 
inhibition O 
of O 
one O 
or O 
more O 
DSB O 
repair O 
pathways O 
. O 

from O 
Schisandra O 
sphenathera O 
Rehd O 
. O 
et O 
Wils O 
. O 
and O 
semisynthetic O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
analogues O 
: O 
absolute O 
configuration O 
, O 
and O 
their O 
estrogenic O 
and O 
anti-proliferative O 
activity O 
. O 

new O 
dibenzocyclooctene B-SYSTEMATIC 
-type O 
lignan B-FAMILY 
, O 
named O 
schisandrin B-TRIVIAL 
A1 I-TRIVIAL 
( O 
1 O 
) O 
, O 
together O 
with O 
nine O 
known O 
lignans O 
( O 
2-10 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
stems O 
of O 
Schisandra O 
sphenathera O 
. O 
The O 
structure O 
of O 
schisandrin B-TRIVIAL 
A1 I-TRIVIAL 
, O 
which O 
contains O 
a O 
spirocyclic O 
epoxy B-SYSTEMATIC 
unit O 
, O 
was O 
established O 
by O 
means O 
of O 
spectroscopic O 
methods O 
. O 
The O 
absolute O 
configurations O 
of O 
schisandrin B-TRIVIAL 
A1 I-TRIVIAL 
( O 
1 O 
) O 
and O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
were O 
determined O 
by O 
electronic O 
circular O 
dichroism O 
( O 
CD O 
) O 
and O 
TDDFT O 
calculations O 
, O 
with O 
2 O 
further O 
confirmed O 
by O 
X-ray O 
crystallographic O 
data O 
. O 
Ten O 
new O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
derivatives O 
( O 
11-20 O 
) O 
and O 
6,7-secoschisantherol B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
2b O 
) O 
were O 
synthesized O 
. O 
In O 
addition O 
, O 
natural O 
lignans B-FAMILY 
and O 
semisynthetic O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
derivatives O 
showed O 
the O 
antiproliferative O 
activity O 
on O 
four O 
human O 
cancer O 
cell O 
lines O 
and O 
Id1 O 
( O 
an O 
inhibitor O 
of O 
DNA O 
binding O 
protein O 
) O 
and O 
estrogenic O 
potency O 
. O 
Compounds O 
5 O 
, O 
7 O 
, O 
and O 
8 O 
exhibited O 
very O 
potent O 
estrogenic O 
activity O 
. O 

new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
from O 
the O 
leaves O 
of O 
Panax O 
japonicus O 
grown O 
in O 
southern O 
Miyazaki O 
Prefecture O 
( O 
4 O 
) O 
. O 

new O 
dammarane B-TRIVIAL 
-type O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
such O 
as O 
chikusetsusaponin B-TRIVIAL 
LM3 I-TRIVIAL 
( O 
1 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
LM4 I-TRIVIAL 
( O 
2 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
LM5 I-TRIVIAL 
( O 
3 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
LM6 I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
twenty O 
known O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
such O 
as O 
ginsenoside B-TRIVIAL 
Rb3 I-TRIVIAL 
( O 
5 O 
) O 
, O 
ginsenoside B-TRIVIAL 
Rc I-TRIVIAL 
( O 
6 O 
) O 
, O 
ginsenoside B-TRIVIAL 
Rd I-TRIVIAL 
( O 
7 O 
) O 
, O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
( O 
8 O 
) O 
, O 
ginsenoside B-TRIVIAL 
Rg1 I-TRIVIAL 
( O 
9 O 
) O 
, O 
ginsenoside B-TRIVIAL 
F3 I-TRIVIAL 
( O 
10 O 
) O 
, O 
ginsenoside B-TRIVIAL 
F5 I-TRIVIAL 
( O 
11 O 
) O 
, O 
ginsenoside B-TRIVIAL 
F6 I-TRIVIAL 
( O 
12 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
IVa I-TRIVIAL 
( O 
13 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
V I-TRIVIAL 
( O 
14 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
L5 I-TRIVIAL 
( O 
15 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
L9a I-TRIVIAL 
( O 
16 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
L9bc I-TRIVIAL 
( O 
17 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
L10 I-TRIVIAL 
( O 
18 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
FK2 I-TRIVIAL 
( O 
19 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
FK6 I-TRIVIAL 
( O 
20 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
FK7 I-TRIVIAL 
( O 
21 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
FT1 I-TRIVIAL 
( O 
22 O 
) O 
, O 
chikusetsusaponin B-TRIVIAL 
LM1 I-TRIVIAL 
( O 
23 O 
) O 
, O 
and O 
chikusetsusaponin B-TRIVIAL 
LM2 I-TRIVIAL 
( O 
24 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Panax O 
japonicus O 
C O 
. O 
A O 
. O 
MEYER O 
collected O 
in O 
Miyazaki O 
prefecture O 
, O 
Japan O 
. O 
The O 
structures O 
of O 
new O 
chikusetsusaponins B-FAMILY 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectral O 
and O 
physicochemical O 
evidences O 
. O 

human O 
diet O 
is O 
an O 
important O 
factor O 
in O 
the O 
development O 
of O 
different O 
diseases O 
. O 
Lipid O 
peroxidation O 
during O 
frying O 
in O 
edible O 
vegetable O 
liquid O 
oils O 
of O 
food O 
components O 
is O 
a O 
mechanism O 
leading O 
to O 
the O 
formation O 
of O 
free O 
radicals O 
. O 
Such O 
radicals O 
induce O 
tissue O 
damage O 
and O 
are O 
implicated O 
in O 
diverse O 
pathological O 
conditions O 
, O 
including O 
aging O 
, O 
atherosclerosis O 
, O 
brain O 
disorders O 
, O 
cancer O 
, O 
lung O 
disorders O 
and O 
various O 
liver O 
disorders O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
decided O 
to O 
investigate O 
the O 
genotoxic O 
effects O 
of O 
four O 
lipid O 
peroxidation O 
products O 
in O 
the O 
in O 
vivo O 
Drosophila O 
wing O 
somatic O 
mutation O 
and O 
recombination O 
test O 
. O 
In O 
this O 
test O 
, O 
point O 
mutation O 
, O 
chromosome O 
breakage O 
and O 
mitotic O 
recombination O 
produce O 
single O 
spots O 
; O 
while O 
twin O 
spots O 
are O 
produced O 
only O 
by O 
mitotic O 
recombination O 
. O 
Drosophila O 
is O 
a O 
suitable O 
eukaryotic O 
organism O 
for O 
mutagenicity O 
studies O 
and O 
also O 
its O 
metabolism O 
is O 
quite O 
similar O 
to O 
that O 
of O 
mammalians O 
. O 
Since O 
conflicting O 
data O 
exist O 
on O 
the O 
possible O 
risk O 
of O 
several O 
lipid O 
peroxidation O 
products O 
for O 
humans O 
, O 
we O 
have O 
selected O 
four O 
of O 
them O 
, O 
namely O 
acrolein B-TRIVIAL 
, O 
crotonaldehyde B-TRIVIAL 
, O 
4-hydroxy-hexenal B-SYSTEMATIC 
( O 
4-HHE B-SYSTEMATIC 
) O 
and O 
4-oxo-2-nonenal B-SYSTEMATIC 
( O 
4-ONE B-SYSTEMATIC 
) O 
. O 
Especially O 
at O 
the O 
highest O 
concentrations O 
tested O 
all O 
exert O 
both O 
mutagenic O 
and O 
recombinogenic O 
effects O 
in O 
the O 
Drosophila O 
SMART O 
assay O 
, O 
showing O 
a O 
direct O 
dose O 
- O 
effect O 
relationship O 
. O 
This O 
is O 
the O 
first O 
study O 
reporting O 
genotoxicity O 
data O 
in O 
Drosophila O 
for O 
these O 
compounds O 
. O 

annuum O 
L O 
. O 
is O 
reported O 
to O 
be O 
the O 
most O 
widely O 
cultivated O 
species O 
. O 
Recently O 
, O 
waste O 
of O 
vegetable O 
processing O 
, O 
like O 
seeds O 
, O 
has O 
been O 
the O 
subject O 
of O 
many O 
studies O 
as O 
an O 
attempt O 
to O 
find O 
new O 
, O 
alternative O 
and O 
cheap O 
resources O 
of O 
bioactive O 
compounds O 
with O 
application O 
in O 
several O 
industries O 
. O 
Despite O 
their O 
chemical O 
, O 
biological O 
and O 
ecological O 
importance O 
, O 
C O 
. O 
annuum O 
seeds O 
are O 
still O 
poorly O 
studied O 
. O 
To O 
improve O 
the O 
knowledge O 
on O 
the O 
metabolic O 
profile O 
of O 
this O 
matrix O 
, O 
a O 
targeted O 
metabolite O 
analysis O 
was O 
performed O 
in O 
" O 
sweet O 
Italian O 
" O 
and O 
" O 
Reus O 
long O 
pairal O 
" O 
pepper O 
seeds O 
. O 
Sterols B-FAMILY 
, O 
triterpenes B-FAMILY 
, O 
organic O 
acids O 
, O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
volatile O 
compounds O 
were O 
determined O 
by O 
different O 
chromatographic O 
methods O 
. O 
The O 
antioxidant O 
activity O 
was O 
assessed O 
against O 
DPPH(·) B-ABBREVIATION 
, O 
superoxide B-TRIVIAL 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
radicals O 
. O 
A O 
concentration O 
- O 
dependent O 
activity O 
was O 
noticed O 
against O 
all O 
radicals O 
. O 
Acetylcholinesterase O 
inhibitory O 
capacity O 
was O 
also O 
evaluated O 
, O 
but O 
no O 
effect O 
was O 
found O 
. O 
Data O 
provide O 
evidence O 
of O 
great O 
similarities O 
between O 
" O 
sweet O 
Italian O 
" O 
and O 
" O 
Reus O 
long O 
pairal O 
" O 
pepper O 
seeds O 
. O 
The O 
present O 
study O 
indicates O 
that O 
C O 
. O 
annuum O 
seeds O 
are O 
a O 
potential O 
source O 
of O 
valuable O 
bioactive O 
compounds O 
that O 
could O 
be O 
used O 
in O 
food O 
industry O 
. O 

insight O 
into O 
the O 
ZnO B-FORMULA 
sulfidation O 
reaction O 
: O 
mechanism O 
and O 
kinetics O 
modeling O 
of O 
the O 
ZnS B-FORMULA 
outward O 
growth O 
. O 

oxide I-SYSTEMATIC 
based O 
materials O 
are O 
commonly O 
used O 
for O 
the O 
final O 
desulfurization O 
of O 
synthesis O 
gas O 
in O 
Fischer-Tropsch O 
based O 
XTL O 
processes O 
. O 
Although O 
the O 
ZnO B-FORMULA 
sulfidation O 
reaction O 
has O 
been O 
widely O 
studied O 
, O 
little O 
is O 
known O 
about O 
the O 
transformation O 
at O 
the O 
crystal O 
scale O 
, O 
its O 
detailed O 
mechanism O 
and O 
kinetics O 
. O 
A O 
model O 
ZnO B-FORMULA 
material O 
with O 
well O 
- O 
determined O 
characteristics O 
( O 
particle O 
size O 
and O 
shape O 
) O 
has O 
been O 
synthesized O 
to O 
perform O 
this O 
study O 
. O 
Characterizations O 
of O 
sulfided O 
samples O 
( O 
using O 
XRD O 
, O 
TEM O 
and O 
electron O 
diffraction O 
) O 
have O 
shown O 
the O 
formation O 
of O 
oriented O 
polycrystalline O 
ZnS B-FORMULA 
nanoparticles O 
with O 
a O 
predominant O 
hexagonal O 
form O 
( O 
wurtzite B-TRIVIAL 
phase O 
) O 
. O 
TEM O 
observations O 
also O 
have O 
evidenced O 
an O 
outward O 
development O 
of O 
the O 
ZnS B-FORMULA 
phase O 
, O 
showing O 
zinc B-SYSTEMATIC 
and O 
oxygen B-SYSTEMATIC 
diffusion O 
from O 
the O 
ZnO B-FORMULA 
- O 
ZnS B-FORMULA 
internal O 
interface O 
to O 
the O 
surface O 
of O 
the O 
ZnS B-FORMULA 
particle O 
. O 
The O 
kinetics O 
of O 
ZnO B-FORMULA 
sulfidation O 
by O 
H(2)S B-FORMULA 
has O 
been O 
investigated O 
using O 
isothermal O 
and O 
isobaric O 
thermogravimetry O 
. O 
Kinetic O 
tests O 
have O 
been O 
performed O 
that O 
show O 
that O 
nucleation O 
of O 
ZnS B-FORMULA 
is O 
instantaneous O 
compared O 
to O 
the O 
growth O 
process O 
. O 
A O 
reaction O 
mechanism O 
composed O 
of O 
eight O 
elementary O 
steps O 
has O 
been O 
proposed O 
to O 
account O 
for O 
these O 
results O 
, O 
and O 
various O 
possible O 
rate O 
laws O 
have O 
been O 
determined O 
upon O 
approximation O 
of O 
the O 
rate O 
- O 
determining O 
step O 
. O 
Thermogravimetry O 
experiments O 
performed O 
in O 
a O 
wide O 
range O 
of O 
H(2)S B-FORMULA 
and O 
H(2)O B-FORMULA 
partial O 
pressures O 
have O 
shown O 
that O 
the O 
ZnO B-FORMULA 
sulfidation O 
reaction O 
rate O 
has O 
a O 
nonlinear O 
variation O 
with O 
H(2)S B-FORMULA 
partial O 
pressure O 
at O 
the O 
same O 
time O 
no O 
significant O 
influence O 
of O 
water O 
vapor O 
on O 
reaction O 
kinetics O 
has O 
been O 
observed O 
. O 
From O 
these O 
observations O 
, O 
a O 
mixed O 
kinetics O 
of O 
external O 
interface O 
reaction O 
with O 
water O 
desorption O 
and O 
oxygen B-SYSTEMATIC 
diffusion O 
has O 
been O 
determined O 
to O 
control O 
the O 
reaction O 
kinetics O 
and O 
the O 
proposed O 
mechanism O 
has O 
been O 
validated O 
. O 
However O 
, O 
the O 
formation O 
of O 
voids O 
at O 
the O 
ZnO B-FORMULA 
- O 
ZnS B-FORMULA 
internal O 
interface O 
, O 
characterized O 
by O 
TEM O 
and O 
electron O 
tomography O 
, O 
strongly O 
slows O 
down O 
the O 
reaction O 
rate O 
. O 
Therefore O 
, O 
the O 
impact O 
of O 
the O 
decreasing O 
ZnO B-FORMULA 
- O 
ZnS B-FORMULA 
internal O 
interface O 
on O 
reaction O 
kinetics O 
has O 
been O 
taken O 
into O 
account O 
in O 
the O 
reaction O 
rate O 
expression O 
. O 
In O 
this O 
way O 
the O 
void O 
formation O 
at O 
the O 
interface O 
has O 
been O 
modeled O 
considering O 
a O 
random O 
nucleation O 
followed O 
by O 
an O 
isotropic O 
growth O 
of O 
cavities O 
. O 
Very O 
good O 
agreement O 
has O 
been O 
observed O 
between O 
both O 
experimental O 
and O 
calculated O 
rates O 
after O 
taking O 
into O 
account O 
the O 
decrease O 
in O 
the O 
ZnO B-FORMULA 
- O 
ZnS B-FORMULA 
internal O 
interface O 
. O 

presence O 
of O 
hydrophilic O 
SO3H B-FORMULA 
nanoclusters O 
on O 
the O 
surface O 
of O 
dry O 
ultrathin O 
Nafion B-TRIVIAL 
® O 
films O 
: O 
a O 
positron O 
annihilation O 
study O 
. O 

of O 
Nafion B-TRIVIAL 
® O 
with O 
an O 
ion O 
exchange O 
capacity O 
( O 
IEC O 
) O 
of O 
0.91 O 
meq O 
g(-1) O 
, O 
which O 
are O 
on O 
the O 
verge O 
of O 
the O 
formation O 
of O 
SO(3)H B-FORMULA 
nanoclusters O 
, O 
were O 
spin O 
coated O 
on O 
silicon B-SYSTEMATIC 
( O 
Si B-FORMULA 
) O 
, O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
( O 
GC O 
) O 
and O 
platinum B-SYSTEMATIC 
/ O 
silicon B-SYSTEMATIC 
( O 
Pt B-FORMULA 
/ O 
Si B-FORMULA 
) O 
substrates O 
to O 
form O 
films O 
of O 
up O 
to O 
256 O 
nm O 
thickness O 
. O 
Nanostructure O 
of O 
the O 
films O 
was O 
studied O 
using O 
Doppler O 
broadening O 
of O 
annihilation O 
radiation O 
( O 
DBAR O 
) O 
, O 
positron O 
annihilation O 
lifetime O 
( O 
PAL O 
) O 
, O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
, O 
an O 
atomic O 
force O 
microscope O 
( O 
AFM O 
) O 
and O 
contact O 
angle O 
measurements O 
. O 
Contact O 
angles O 
as O 
low O 
as O 
10 O 
degrees O 
indicate O 
that O 
the O 
surface O 
of O 
dry O 
ultrathin O 
Nafion B-TRIVIAL 
® O 
films O 
on O 
Si B-FORMULA 
is O 
highly O 
hydrophilic O 
. O 
XPS O 
data O 
of O 
10 O 
nm O 
thick O 
, O 
ultrathin O 
film O 
on O 
Si B-FORMULA 
show O 
that O 
oxygen B-SYSTEMATIC 
concentration O 
is O 
enhanced O 
and O 
the O 
SO(3)H B-FORMULA 
group O 
concentration O 
, O 
in O 
other O 
words O 
, O 
IEC O 
on O 
the O 
surface O 
is O 
much O 
higher O 
than O 
other O 
films O 
. O 
The O 
S O 
parameter O 
measured O 
by O 
DBAR O 
of O 
an O 
ultrathin O 
Nafion B-TRIVIAL 
® O 
film O 
on O 
Si B-FORMULA 
is O 
much O 
higher O 
than O 
that O 
of O 
the O 
films O 
on O 
the O 
other O 
substrates O 
. O 
We O 
consider O 
that O 
a O 
large O 
number O 
of O 
hydrophilic O 
, O 
reversed O 
micelle O 
like O 
SO(3)H B-FORMULA 
groups O 
are O 
on O 
the O 
surface O 
of O 
the O 
ultrathin O 
Nafion B-TRIVIAL 
® O 
film O 
on O 
Si B-FORMULA 
but O 
not O 
on O 
the O 
surface O 
of O 
other O 
films O 
. O 
Positrons O 
implanted O 
into O 
the O 
film O 
are O 
trapped O 
by O 
the O 
SO(3)H B-FORMULA 
clusters O 
, O 
annihilating O 
with O 
the O 
electrons O 
of O 
oxygen B-SYSTEMATIC 
and O 
exhibit O 
the O 
high O 
S O 
parameter O 
. O 
The O 
SO(3)H B-FORMULA 
concentration O 
on O 
the O 
surface O 
of O 
thin O 
Nafion B-TRIVIAL 
® O 
films O 
on O 
GC O 
and O 
Pt B-FORMULA 
/ O 
Si B-FORMULA 
substrates O 
may O 
not O 
be O 
so O 
high O 
as O 
the O 
threshold O 
for O 
the O 
formation O 
of O 
a O 
large O 
number O 
of O 
SO(3)H B-FORMULA 
clusters O 
. O 
Positrons O 
implanted O 
into O 
the O 
films O 
annihilate O 
mostly O 
with O 
fluorine B-SYSTEMATIC 
atoms O 
, O 
resulting O 
in O 
a O 
low O 
S O 
parameter O 
. O 
The O 
film O 
- O 
substrate O 
interaction O 
plays O 
an O 
essential O 
role O 
in O 
nanostructuring O 
of O 
Nafion B-TRIVIAL 
® O 
thin O 
films O 
, O 
which O 
may O 
also O 
be O 
the O 
case O 
for O 
Nafion B-TRIVIAL 
® O 
on O 
the O 
catalysts O 
of O 
polymer O 
electrolyte O 
fuel O 
cells O 
. O 

intake O 
of O 
magnesium B-SYSTEMATIC 
may O 
modulate O 
depression O 
. O 

symptoms O 
are O 
frequent O 
in O 
students O 
and O 
may O 
lead O 
to O 
countless O 
problems O 
. O 
Several O 
hypotheses O 
associate O 
magnesium B-SYSTEMATIC 
with O 
depression O 
because O 
of O 
the O 
presence O 
of O 
this O 
mineral O 
in O 
several O 
enzymes O 
, O 
hormones O 
, O 
and O 
neurotransmitters O 
, O 
which O 
may O 
play O 
a O 
key O 
role O 
in O 
the O 
pathological O 
pathways O 
of O 
depression O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
assess O 
whether O 
magnesium B-SYSTEMATIC 
intake O 
could O 
modulate O 
depressive O 
symptoms O 
. O 
A O 
cross O 
- O 
sectional O 
study O 
was O 
conducted O 
on O 
a O 
convenience O 
sample O 
of O 
402 O 
Iranian O 
postgraduate O 
students O 
studying O 
in O 
Malaysia O 
to O 
assess O 
the O 
relationship O 
between O 
magnesium B-SYSTEMATIC 
intake O 
and O 
depressive O 
symptoms O 
. O 
The O 
mean O 
age O 
of O 
the O 
participants O 
was O 
32.54 O 
± O 
6.22 O 
years O 
. O 
The O 
results O 
of O 
the O 
study O 
demonstrated O 
an O 
inverse O 
relationship O 
between O 
magnesium B-SYSTEMATIC 
intake O 
and O 
depressive O 
symptoms O 
, O 
which O 
persisted O 
even O 
after O 
adjustments O 
for O 
sex O 
, O 
age O 
, O 
body O 
mass O 
index O 
, O 
monthly O 
expenses O 
, O 
close O 
friends O 
, O 
living O 
on O 
campus O 
, O 
smoking O 
( O 
current O 
and O 
former O 
) O 
, O 
education O 
, O 
physical O 
activity O 
, O 
and O 
marital O 
status O 
. O 

Recent O 
evidence O 
indicates O 
that O 
heat O 
- O 
enhanced O 
food O 
advanced O 
glycation O 
end O 
products O 
( O 
AGEs O 
) O 
adversely O 
affect O 
vascular O 
function O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
acute O 
effects O 
of O 
an O 
oral O 
load O 
of O 
heat O 
- O 
treated O 
, O 
AGE O 
- O 
modified O 
β-lactoglobulins O 
( O 
AGE-BLG O 
) O 
compared O 
with O 
heat O 
- O 
treated O 
, O 
nonglycated O 
BLG O 
( O 
C-BLG O 
) O 
on O 
vascular O 
function O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
In O 
a O 
double O 
- O 
blind O 
, O 
controlled O 
, O 
randomized O 
, O 
crossover O 
study O 
, O 
19 O 
patients O 
with O 
T2DM O 
received O 
, O 
on O 
two O 
different O 
occasions O 
, O 
beverages O 
containing O 
either O 
AGE-BLG O 
or O 
C-BLG O 
. O 
We O 
measured O 
macrovascular O 
[ O 
brachial O 
ultrasound O 
of O 
flow O 
- O 
mediated O 
dilatation O 
( O 
FMD O 
) O 
] O 
and O 
microvascular O 
( O 
laser-Doppler O 
measurements O 
of O 
reactive O 
hyperemia O 
in O 
the O 
hand O 
) O 
functions O 
at O 
baseline O 
( O 
T0 O 
) O 
, O 
90 O 
( O 
T90 O 
) O 
, O 
and O 
180 O 
( O 
T180 O 
) O 
min O 
. O 
RESULTS O 
Following O 
the O 
AGE-BLG O 
, O 
FMD O 
decreased O 
at O 
T90 O 
by O 
80% O 
from O 
baseline O 
and O 
remained O 
decreased O 
by O 
42% O 
at O 
T180 O 
( O 
P O 
< O 
0.05 O 
vs O 
. O 
baseline O 
, O 
P O 
< O 
0.05 O 
vs O 
. O 
C-BLG O 
at O 
T90 O 
) O 
. O 
By O 
comparison O 
, O 
following O 
C-BLG O 
, O 
FMD O 
decreased O 
by O 
27% O 
at O 
T90 O 
and O 
51% O 
at O 
T180 O 
( O 
P O 
< O 
0.05 O 
vs O 
. O 
baseline O 
at O 
T180 O 
) O 
. O 
A O 
significant O 
decrease O 
in O 
nitrite B-SYSTEMATIC 
( O 
T180 O 
) O 
and O 
nitrate B-SYSTEMATIC 
( O 
T90 O 
and O 
T180 O 
) O 
, O 
as O 
well O 
as O 
a O 
significant O 
increase O 
in O 
N(ε)-carboxymethyllisine B-SYSTEMATIC 
, O 
accompanied O 
intake O 
of O 
AGE-BLG O 
. O 
There O 
was O 
no O 
change O 
in O 
microvascular O 
function O 
caused O 
by O 
either O 
beverage O 
. O 
CONCLUSIONS O 
In O 
patients O 
with O 
T2DM O 
, O 
acute O 
oral O 
administration O 
of O 
a O 
single O 
AGE O 
- O 
modified O 
protein O 
class O 
significantly O 
though O 
transiently O 
impaired O 
macrovascular O 
function O 
in O 
concert O 
with O 
decreased O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
bioavailability O 
. O 
These O 
AGE O 
- O 
related O 
changes O 
were O 
independent O 
of O 
heat O 
treatment O 
. O 

We O 
sought O 
to O 
investigate O 
whether O 
elevated O 
levels O 
of O 
acute O 
- O 
phase O 
serum O 
amyloid O 
A O 
( O 
A-SAA O 
) O 
protein O 
precede O 
the O 
onset O 
of O 
type O 
2 O 
diabetes O 
independently O 
of O 
other O 
risk O 
factors O 
, O 
including O 
parameters O 
of O 
glucose B-TRIVIAL 
metabolism O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
Within O 
the O 
population O 
- O 
based O 
Cooperative O 
Health O 
Research O 
in O 
the O 
Region O 
of O 
Augsburg O 
( O 
KORA O 
) O 
S4 O 
study O 
, O 
we O 
measured O 
A-SAA O 
concentrations O 
in O 
836 O 
initially O 
nondiabetic O 
subjects O 
( O 
55-74 O 
years O 
of O 
age O 
) O 
without O 
clinically O 
overt O 
inflammation O 
who O 
participated O 
in O 
a O 
7-year O 
follow O 
- O 
up O 
examination O 
including O 
an O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
. O 
RESULTS O 
A-SAA O 
concentrations O 
were O 
significantly O 
associated O 
with O 
incident O 
type O 
2 O 
diabetes O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
for O 
a O 
one-SD O 
increase O 
of O 
A-SAA O 
adjusted O 
for O 
age O 
and O 
sex O 
= O 
1.28 O 
[ O 
95% O 
CI O 
1.08-1.53 O 
] O 
, O 
P O 
= O 
0.005 O 
) O 
, O 
particularly O 
in O 
younger O 
subjects O 
( O 
P O 
value O 
for O 
interaction O 
= O 
0.047 O 
) O 
. O 
The O 
association O 
attenuated O 
when O 
adjusting O 
for O 
parameters O 
of O 
glucose B-TRIVIAL 
metabolism O 
( O 
fasting O 
glucose B-TRIVIAL 
, O 
fasting O 
insulin O 
, O 
HbA1c O 
, O 
and O 
2-h O 
glucose B-TRIVIAL 
; O 
OR O 
1.16 O 
[ O 
0.95-1.42 O 
] O 
, O 
P O 
= O 
0.15 O 
) O 
. O 
Similar O 
analyses O 
for O 
high O 
- O 
sensitive O 
C-reactive O 
protein O 
( O 
hs-CRP O 
) O 
yielded O 
the O 
following O 
ORs O 
: O 
1.39 O 
( O 
1.10-1.68 O 
, O 
P O 
= O 
0.0006 O 
) O 
and O 
1.13 O 
( O 
0.88-1.45 O 
, O 
P O 
= O 
0.34 O 
) O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
A-SAA O 
concentrations O 
were O 
significantly O 
associated O 
with O 
2-h O 
glucose B-TRIVIAL 
levels O 
at O 
follow O 
- O 
up O 
even O 
after O 
adjustment O 
for O 
parameters O 
of O 
glucose B-TRIVIAL 
metabolism O 
( O 
P O 
= O 
0.008 O 
, O 
n O 
= O 
803 O 
) O 
. O 
CONCLUSIONS O 
Our O 
findings O 
indicate O 
similarly O 
strong O 
prospective O 
associations O 
with O 
type O 
2 O 
diabetes O 
for O 
A-SAA O 
and O 
hs-CRP O 
and O 
suggest O 
a O 
potential O 
causal O 
link O 
via O 
postchallenge O 
hyperglycemia O 
. O 

influence O 
of O 
sex O 
, O 
ethnicity O 
, O 
and O 
CYP2B6 O 
genotype O 
on O 
bupropion B-TRIVIAL 
metabolism O 
as O 
an O 
index O 
of O 
hepatic O 
CYP2B6 O 
activity O 
in O 
humans O 
. O 

effects O 
of O 
sex O 
, O 
ethnicity O 
, O 
and O 
genetic O 
polymorphism O 
on O 
hepatic O 
CYP2B6 O 
( O 
cytochrome O 
P450 O 
2B6 O 
) O 
expression O 
and O 
activity O 
were O 
previously O 
demonstrated O 
in O 
vitro O 
. O 
Race O 
/ O 
ethnic O 
differences O 
in O 
CYP2B6 O 
genotype O 
and O 
phenotype O 
were O 
observed O 
only O 
in O 
women O 
. O 
To O 
identify O 
important O 
covariates O 
associated O 
with O 
interindividual O 
variation O 
in O 
CYP2B6 O 
activity O 
in O 
vivo O 
, O 
we O 
evaluated O 
these O 
effects O 
in O 
healthy O 
volunteers O 
using O 
bupropion B-TRIVIAL 
( O 
Wellbutrin B-TRIVIAL 
SR I-TRIVIAL 
GlaxoSmithKline O 
, O 
Research O 
Triangle O 
Park O 
, O 
NC O 
) O 
as O 
a O 
CYP2B6 O 
probe O 
substrate O 
. O 
A O 
fixed O 
150-mg O 
oral O 
sustained O 
- O 
release O 
dose O 
of O 
bupropion B-TRIVIAL 
was O 
administered O 
to O 
100 O 
healthy O 
volunteers O 
comprising O 
four O 
sex O 
/ O 
ethnicity O 
cohorts O 
( O 
n O 
= O 
25 O 
each O 
) O 
: O 
Caucasian O 
men O 
and O 
Caucasian O 
, O 
African O 
American O 
, O 
and O 
Hispanic O 
women O 
. O 
Blood O 
samples O 
were O 
obtained O 
at O 
0 O 
and O 
6 O 
hours O 
postdose O 
for O 
the O 
measurement O 
of O 
serum O 
bupropion B-TRIVIAL 
( O 
BU O 
) O 
and O 
hydroxybupropion B-SYSTEMATIC 
( O 
HB O 
) O 
concentrations O 
. O 
Whole O 
blood O 
was O 
obtained O 
at O 
baseline O 
for O 
CYP2B6 O 
genotyping O 
. O 
To O 
characterize O 
the O 
relationship O 
between O 
CYP2B6 O 
activity O 
and O 
ethnicity O 
, O 
sex O 
, O 
and O 
genotype O 
when O 
accounting O 
for O 
serum O 
BU O 
concentrations O 
( O 
dose O 
- O 
adjusted O 
log(10)-transformed O 
) O 
, O 
analysis O 
of O 
covariance O 
model O 
was O 
fitted O 
in O 
which O 
the O 
dependent O 
variable O 
was O 
CYP2B6 O 
activity O 
represented O 
as O 
the O 
log(10)-transformed O 
, O 
metabolic O 
ratio O 
of O 
HB O 
to O 
BU O 
concentrations O 
. O 
Several O 
CYP2B6 O 
polymorphisms O 
were O 
associated O 
with O 
CYP2B6 O 
activity O 
. O 
Evidence O 
of O 
dependence O 
of O 
CYP2B6 O 
activity O 
on O 
ethnicity O 
or O 
genotype O 
- O 
by O 
- O 
ethnicity O 
interactions O 
was O 
not O 
detected O 
in O 
women O 
. O 
These O 
results O 
suggest O 
that O 
CYP2B6 O 
genotype O 
is O 
the O 
most O 
important O 
patient O 
variable O 
for O 
predicting O 
the O 
level O 
of O 
CYP2B6 O 
activity O 
in O 
women O 
, O 
when O 
measured O 
by O 
the O 
metabolism O 
of O 
bupropion B-TRIVIAL 
. O 
The O 
bupropion B-TRIVIAL 
metabolic O 
ratio O 
appears O 
to O 
detect O 
known O 
differences O 
in O 
CYP2B6 O 
activity O 
associated O 
with O 
genetic O 
polymorphism O 
, O 
across O 
different O 
ethnic O 
groups O 
. O 
Prospective O 
studies O 
will O 
be O 
needed O 
to O 
validate O 
the O 
use O 
of O 
bupropion B-TRIVIAL 
as O 
a O 
probe O 
substrate O 
for O 
clinical O 
use O 
. O 

( O 
Walterinnesia O 
aegyptia O 
) O 
venom O 
- O 
loaded O 
silica B-TRIVIAL 
nanoparticles O 
induce O 
apoptosis O 
and O 
growth O 
arrest O 
in O 
human O 
prostate O 
cancer O 
cells O 
. O 

cancer O 
( O 
PCa O 
) O 
is O 
the O 
most O 
commonly O 
diagnosed O 
cancer O 
in O 
men O 
. O 
The O 
progression O 
and O 
invasion O 
of O 
PCa O 
are O 
normally O 
mediated O 
by O 
the O 
overexpression O 
of O 
chemokine O 
receptors O 
( O 
CKRs O 
) O 
and O 
the O 
interaction O 
between O 
CKRs O 
and O 
their O 
cognate O 
ligands O 
. O 
We O 
recently O 
demonstrated O 
that O 
venom O 
extracted O 
from O 
Walterinnesia O 
aegyptia O 
( O 
WEV O 
) O 
either O 
alone O 
or O 
in O 
combination O 
with O 
silica B-TRIVIAL 
nanoparticles O 
( O 
WEV O 
+ O 
NP O 
) O 
mediated O 
the O 
growth O 
arrest O 
and O 
apoptosis O 
of O 
breast O 
cancer O 
cells O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
impact O 
of O 
WEV O 
alone O 
and O 
WEV O 
+ O 
NP O 
on O 
the O 
migration O 
, O 
invasion O 
, O 
proliferation O 
and O 
apoptosis O 
of O 
prostate O 
cancer O 
cells O 
. O 
We O 
found O 
that O 
WEV O 
alone O 
and O 
WEV O 
+ O 
NP O 
decreased O 
the O 
viability O 
of O 
all O 
cell O 
types O 
tested O 
( O 
PCa O 
cells O 
isolated O 
from O 
patient O 
samples O 
, O 
PC3 O 
cells O 
and O 
LNCaP O 
cells O 
) O 
using O 
an O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
IC(50) O 
values O 
were O 
determined O 
to O 
be O 
10 O 
and O 
5 O 
μg O 
/ O 
mL O 
for O 
WEV O 
alone O 
and O 
WEV O 
+ O 
NP O 
, O 
respectively O 
. O 
WEV O 
+ O 
NP O 
decreased O 
the O 
surface O 
expression O 
of O 
the O 
CKRs O 
CXCR3 O 
, O 
CXCR4 O 
, O 
CXCR5 O 
and O 
CXCR6 O 
to O 
a O 
greater O 
extent O 
than O 
WEV O 
alone O 
and O 
subsequently O 
reduced O 
migration O 
and O 
the O 
invasion O 
response O 
of O 
the O 
cells O 
to O 
the O 
cognate O 
ligands O 
of O 
the O 
CKRs O 
( O 
CXCL10 O 
, O 
CXCL12 O 
, O 
CXCL13 O 
and O 
CXCL16 O 
, O 
respectively O 
) O 
. O 
Using O 
a O 
CFSE B-ABBREVIATION 
proliferation O 
assay O 
, O 
we O 
found O 
that O 
WEV O 
+ O 
NP O 
strongly O 
inhibited O 
epidermal O 
growth O 
factor O 
- O 
mediated O 
PCa O 
cell O 
proliferation O 
. O 
Furthermore O 
, O 
analysis O 
of O 
the O 
cell O 
cycle O 
indicated O 
that O 
WEV O 
+ O 
NP O 
strongly O 
altered O 
the O 
cell O 
cycle O 
of O 
PCa O 
cells O 
and O 
enhanced O 
the O 
induction O 
of O 
apoptosis O 
. O 
Finally O 
, O 
we O 
demonstrated O 
that O 
WEV O 
+ O 
NP O 
robustly O 
decreased O 
the O 
expression O 
of O 
anti-apoptotic O 
effectors O 
, O 
such O 
as O 
B O 
cell O 
Lymphoma-2 O 
( O 
Bcl-2 O 
) O 
, O 
B O 
cell O 
Lymphoma O 
- O 
extra O 
large O 
(Bcl-(XL)) O 
and O 
myeloid O 
cell O 
leukemia O 
sequence-1 O 
( O 
Mcl-1 O 
) O 
, O 
and O 
increased O 
the O 
expression O 
of O 
pro O 
- O 
apoptotic O 
effectors O 
, O 
such O 
as O 
Bcl-2 O 
homologous O 
antagonist O 
/ O 
killer O 
( O 
Bak O 
) O 
, O 
Bcl-2-associated O 
X O 
protein O 
( O 
Bax O 
) O 
and O 
Bcl-2-interacting O 
mediator O 
of O 
cell O 
death O 
( O 
Bim O 
) O 
. O 
WEV O 
+ O 
NP O 
also O 
altered O 
the O 
membrane O 
potential O 
of O 
mitochondria O 
in O 
the O 
PCa O 
cells O 
. O 
Our O 
data O 
reveal O 
the O 
potential O 
of O 
nanoparticle O 
- O 
sustained O 
delivery O 
of O 
snake O 
venom O 
as O 
effective O 
treatments O 
for O 
prostate O 
cancer O 
. O 

Tetraarylporphycene I-FAMILY 
Platform-Synthesis O 
of O 
Octacationic B-FAMILY 
Derivatives O 
Towards O 
the O 
Layer O 
- O 
by O 
- O 
Layer O 
Design O 
of O 
Versatile O 
Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Photoelectrodes O 
. O 

most O 
highly O 
charged O 
water O 
- O 
soluble O 
poly B-FAMILY 
- I-FAMILY 
ortho I-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
tetraarylporphycene I-FAMILY 
( O 
Pc(8+) B-FORMULA 
) O 
has O 
been O 
synthetized O 
. O 
The O 
latter O 
, O 
which O 
interacts O 
in O 
aqueous O 
solutions O 
with O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GO O 
) O 
forming O 
a O 
photoactive O 
ensemble O 
Pc(8+) B-FORMULA 
/ O 
GO O 
, O 
is O 
immobilized O 
by O 
means O 
of O 
the O 
Layer O 
- O 
by O 
- O 
Layer O 
( O 
LbL O 
) O 
technique O 
onto O 
ITO O 
electrodes O 
to O 
afford O 
novel O 
solar O 
energy O 
conversion O 
devices O 
. O 

nanoparticles O 
produced O 
in O 
situ O 
mediate O 
bioelectricity O 
and O 
hydrogen B-SYSTEMATIC 
production O 
in O 
a O 
microbial O 
fuel O 
cell O 
by O 
quantized O 
capacitance O 
charging O 
. O 

quantized O 
style O 
: O 
By O 
adding O 
a O 
gold O 
precursor O 
at O 
its O 
cathode O 
, O 
a O 
microbial O 
fuel O 
cell O 
( O 
MFC O 
) O 
is O 
demonstrated O 
to O 
form O 
gold O 
nanoparticles O 
that O 
can O 
be O 
used O 
to O 
simultaneously O 
produce O 
bioelectricity O 
and O 
hydrogen B-SYSTEMATIC 
. O 
By O 
exploiting O 
the O 
quantized O 
capacitance O 
charging O 
effect O 
, O 
the O 
gold O 
nanoparticles O 
mediate O 
the O 
production O 
of O 
hydrogen B-SYSTEMATIC 
without O 
requiring O 
an O 
external O 
power O 
supply O 
, O 
while O 
the O 
MFC O 
produces O 
a O 
stable O 
power O 
density O 
. O 

of O 
maleimide B-SYSTEMATIC 
-functionalyzed O 
HPMA B-ABBREVIATION 
-copolymers O 
and O 
in O 
vitro O 
characterization O 
of O 
the O 
aRAGE- O 
and O 
human O 
immunoglobulin O 
(huIgG)-polymer O 
conjugates O 
. O 

the O 
synthesis O 
of O 
antibody O 
- O 
polymer O 
conjugates O 
, O 
with O 
a O 
quite O 
narrow O 
dispersity O 
based O 
on O 
the O 
polymer O 
HPMA B-ABBREVIATION 
, O 
are O 
reported O 
. O 
These O 
conjugates O 
are O 
synthesized O 
by O 
coupling O 
antibodies O 
to O 
maleimide B-SYSTEMATIC 
-functionalized O 
poly(N-(2-hydroxypropyl)-methacrylamide) B-SYSTEMATIC 
( O 
poly-HPMA B-ABBREVIATION 
) O 
copolymers O 
derived O 
through O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
( O 
RAFT O 
) O 
polymerization O 
of O 
pentafluorophenyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
via O 
the O 
intermediate O 
step O 
of O 
an O 
activated O 
ester B-FAMILY 
polymer O 
. O 
We O 
develop O 
a O 
protocol O 
that O 
allows O 
the O 
attachment O 
of O 
two O 
different O 
model O 
antibodies O 
, O 
monoclonal O 
anti-RAGE O 
( O 
receptor O 
for O 
advanced O 
glycation O 
end O 
- O 
products O 
) O 
antibody O 
, O 
and O 
polyclonal O 
human O 
immunoglobulin O 
( O 
huIgG O 
) O 
. O 
Modification O 
of O 
the O 
antibody O 
and O 
conjugation O 
is O 
monitored O 
by O 
SDS B-ABBREVIATION 
-PAGE O 
electrophoresis O 
. O 
Preserved O 
affinity O 
is O 
demonstrated O 
by O 
Western O 
Blott O 
and O 
cell O 
- O 
uptake O 
analysis O 
, O 
for O 
example O 
, O 
to O 
cells O 
of O 
the O 
immune O 
system O 
. O 

in O 
the O 
ability O 
of O 
opioid O 
drugs O 
to O 
promote O 
regulated O 
endocytosis O 
of O 
μ-opioid O 
receptors O 
are O 
related O 
to O 
their O 
tendency O 
to O 
produce O 
drug O 
tolerance O 
and O 
dependence O 
. O 
Here O 
we O 
show O 
that O 
drug O 
- O 
specific O 
differences O 
in O 
receptor O 
internalization O 
are O 
determined O 
by O 
a O 
conserved O 
, O 
10-residue O 
sequence O 
in O 
the O 
receptor's O 
carboxyl B-SYSTEMATIC 
-terminal O 
cytoplasmic O 
tail O 
. O 
Diverse O 
opioids O 
induce O 
receptor O 
phosphorylation O 
at O 
serine B-TRIVIAL 
(S)375 O 
, O 
present O 
in O 
the O 
middle O 
of O 
this O 
sequence O 
, O 
but O 
opioids O 
differ O 
markedly O 
in O 
their O 
ability O 
to O 
drive O 
higher O 
- O 
order O 
phosphorylation O 
on O 
flanking O 
residues O 
[ O 
threonine B-TRIVIAL 
(T)370 O 
, O 
T376 O 
, O 
and O 
T379 O 
] O 
. O 
Multi O 
- O 
phosphorylation O 
is O 
required O 
for O 
the O 
endocytosis O 
- O 
promoting O 
activity O 
of O 
this O 
sequence O 
and O 
occurs O 
both O 
sequentially O 
and O 
hierarchically O 
, O 
with O 
S375 O 
representing O 
the O 
initiating O 
site O 
. O 
Higher O 
- O 
order O 
phosphorylation O 
involving O 
T370 O 
, O 
T376 O 
, O 
and O 
T379 O 
specifically O 
requires O 
GRK2 O 
/ O 
3 O 
isoforms O 
, O 
and O 
the O 
same O 
sequence O 
controls O 
opioid O 
receptor O 
internalization O 
in O 
neurons O 
. O 
These O 
results O 
reveal O 
a O 
biochemical O 
mechanism O 
differentiating O 
the O 
endocytic O 
activity O 
of O 
opioid O 
drugs O 
. O 

performance O 
multilayer O 
MoS2 B-FORMULA 
transistors O 
with O 
scandium B-SYSTEMATIC 
contacts O 
. O 

there O 
has O 
been O 
growing O 
interest O 
in O 
two O 
- O 
dimensional O 
( O 
2-D O 
) O 
crystals O 
other O 
than O 
graphene B-TRIVIAL 
, O 
evaluating O 
their O 
potential O 
usefulness O 
for O 
electronic O 
applications O 
is O 
still O 
in O 
its O 
infancy O 
due O 
to O 
the O 
lack O 
of O 
a O 
complete O 
picture O 
of O 
their O 
performance O 
potential O 
. O 
The O 
focus O 
of O 
this O 
article O 
is O 
on O 
contacts O 
. O 
We O 
demonstrate O 
that O 
through O 
a O 
proper O 
understanding O 
and O 
design O 
of O 
source O 
/ O 
drain O 
contacts O 
and O 
the O 
right O 
choice O 
of O 
number O 
of O 
MoS(2) B-FORMULA 
layers O 
the O 
excellent O 
intrinsic O 
properties O 
of O 
this O 
2-D O 
material O 
can O 
be O 
harvested O 
. O 
Using O 
scandium B-SYSTEMATIC 
contacts O 
on O 
10-nm- O 
thick O 
exfoliated O 
MoS(2) B-FORMULA 
flakes O 
that O 
are O 
covered O 
by O 
a O 
15 O 
nm O 
Al(2)O(3) B-FORMULA 
film O 
, O 
high O 
effective O 
mobilities O 
of O 
700 O 
cm(2) O 
/ O 
( O 
V O 
s O 
) O 
are O 
achieved O 
at O 
room O 
temperature O 
. O 
This O 
breakthrough O 
is O 
largely O 
attributed O 
to O 
the O 
fact O 
that O 
we O 
succeeded O 
in O 
eliminating O 
contact O 
resistance O 
effects O 
that O 
limited O 
the O 
device O 
performance O 
in O 
the O 
past O 
unrecognized O 
. O 
In O 
fact O 
, O 
the O 
apparent O 
linear O 
dependence O 
of O 
current O 
on O 
drain O 
voltage O 
had O 
mislead O 
researchers O 
to O 
believe O 
that O 
a O 
truly O 
Ohmic O 
contact O 
had O 
already O 
been O 
achieved O 
, O 
a O 
misconception O 
that O 
we O 
also O 
elucidate O 
in O 
the O 
present O 
article O 
. O 

of O 
pillared O 
clays O 
studied O 
by O 
hyperpolarized O 
129Xe B-FORMULA 
NMR O 
spectroscopy O 
and O 
Xe B-FORMULA 
adsorption O 
isotherms O 
. O 

influence O 
of O 
the O 
layer O 
charge O 
on O 
the O 
microstructure O 
was O 
studied O 
for O 
a O 
series O 
of O 
three O 
hybrid O 
pillared O 
interlayered O 
clays O 
based O 
on O 
the O 
organic O 
dication O 
Me(2)DABCO(2+) B-FORMULA 
and O 
charge O 
reduced O 
synthetic O 
fluorohectorites O 
. O 
To O 
get O 
a O 
detailed O 
picture O 
of O 
the O 
local O 
arrangements O 
within O 
the O 
interlayer O 
space O 
, O 
multinuclear O 
solid O 
- O 
state O 
NMR O 
spectroscopy O 
was O 
performed O 
in O 
conjunction O 
with O 
high O 
- O 
resolution O 
(129)Xe B-FORMULA 
MAS O 
NMR O 
, O 
temperature O 
- O 
dependent O 
wide-line O 
1D O 
and O 
2D O 
(129)Xe B-FORMULA 
NMR O 
, O 
and O 
Ar B-FORMULA 
/ O 
Ar(l) B-FORMULA 
and O 
Xe B-FORMULA 
/ O 
Xe(l) B-FORMULA 
physisorption O 
measurements O 
. O 
The O 
resulting O 
layer O 
charge O 
(x) O 
for O 
the O 
three O 
samples O 
are O 
0.48 O 
, O 
0.44 O 
, O 
and O 
0.39 O 
per O 
formula O 
unit O 
( O 
pfu O 
) O 
. O 
The O 
samples O 
exhibit O 
BET O 
equivalent O 
surfaces O 
between O 
150 O 
and O 
220 O 
m(2) O 
/ O 
g O 
and O 
pore O 
volumes O 
which O 
increase O 
from O 
0.06 O 
to O 
0.11 O 
cm(3) O 
/ O 
g O 
while O 
the O 
layer O 
charge O 
reduces O 
. O 
1D O 
and O 
2D O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
, O 
(19)F B-FORMULA 
, O 
and O 
(29)Si B-FORMULA 
MAS O 
data O 
reveal O 
that O 
the O 
postsynthetic O 
charge O 
reduction O 
induces O 
regions O 
with O 
higher O 
defect O 
concentrations O 
within O 
the O 
silicate O 
layers O 
. O 
Although O 
the O 
pillars O 
tend O 
to O 
avoid O 
these O 
defect O 
- O 
rich O 
regions O 
, O 
a O 
homogeneous O 
and O 
regular O 
spacing O 
of O 
the O 
Me(2)DABCO(2+) B-FORMULA 
pillars O 
is O 
established O 
. O 
Both O 
the O 
Ar B-FORMULA 
/ O 
Ar(l) B-FORMULA 
physisorption O 
and O 
(129)Xe B-FORMULA 
NMR O 
measurements O 
reveal O 
comparable O 
pore O 
dimensions O 
. O 
The O 
trend O 
of O 
the O 
temperature O 
- O 
dependent O 
wide-line O 
(129)Xe B-FORMULA 
spectra O 
as O 
well O 
as O 
the O 
exchange O 
in O 
the O 
EXSY O 
spectra O 
is O 
typical O 
for O 
a O 
narrow O 
2D O 
pore O 
system O 
. O 
(129)Xe B-FORMULA 
high O 
- O 
resolution O 
experiments O 
allow O 
for O 
a O 
detailed O 
description O 
of O 
the O 
microstructure O 
. O 
For O 
x O 
= O 
0.48 O 
a O 
bimodal O 
distribution O 
with O 
pore O 
diameters O 
between O 
5.9 O 
and O 
6.4 O 
Å O 
is O 
observed O 
. O 
Reducing O 
the O 
layer O 
charge O 
leads O 
to O 
a O 
more O 
homogeneous O 
pore O 
structure O 
with O 
a O 
mean O 
diameter O 
of O 
6.6 O 
Å O 
( O 
x O 
= O 
0.39 O 
) O 
. O 
The O 
adsorption O 
enthalpies O 
ΔH(ads) O 
determined O 
from O 
the O 
temperature O 
- O 
dependent O 
(129)Xe B-FORMULA 
chemical O 
shift O 
data O 
fit O 
well O 
to O 
the O 
ones O 
derived O 
from O 
the O 
Xe B-FORMULA 
/ O 
Xe(l) B-FORMULA 
physisorption O 
measurements O 
in O 
the O 
high O 
- O 
pressure O 
limit O 
while O 
the O 
magnitude O 
of O 
ΔH(ads) O 
in O 
the O 
low O 
- O 
pressure O 
limit O 
is O 
significantly O 
larger O 
. O 
Thus O 
, O 
the O 
(129)Xe B-FORMULA 
data O 
are O 
influenced O 
by O 
adsorbate O 
- O 
adsorbent O 
as O 
well O 
as O 
adsorbate O 
- O 
adsorbate O 
interactions O 
. O 

the O 
charge O 
density O 
study O 
of O 
9-diphenylthiophosphinoylanthracene B-SYSTEMATIC 
the O 
thermal O 
motion O 
of O 
several O 
atoms O 
needed O 
an O 
anharmonic O 
description O 
via O 
Gram-Charlier O 
coefficients O 
even O 
for O 
data O 
collected O 
at O 
15 O 
K O 
. O 
As O 
several O 
data O 
sets O 
at O 
different O 
temperatures O 
were O 
measured O 
, O 
this O 
anharmonic O 
model O 
could O 
be O 
proved O 
to O 
be O 
superior O 
to O 
a O 
disorder O 
model O 
. O 
Refinements O 
against O 
theoretical O 
data O 
showed O 
the O 
resemblance O 
of O 
an O 
anharmonic O 
model O 
and O 
a O 
disorder O 
model O 
with O 
two O 
positions O 
very O 
close O 
to O 
each O 
other O 
( O 
~0.2 O 
Å O 
) O 
, O 
whereas O 
these O 
two O 
models O 
could O 
be O 
clearly O 
distinguished O 
if O 
the O 
second O 
position O 
is O 
0.5 O 
Å O 
apart O 
. O 
The O 
refined O 
multipole O 
parameters O 
were O 
distorted O 
when O 
the O 
anharmonic O 
motion O 
was O 
not O 
properly O 
refined O 
. O 
Therefore O 
, O 
this O 
study O 
reveals O 
the O 
importance O 
of O 
detecting O 
and O 
properly O 
handling O 
anharmonic O 
motion O 
. O 
Unrefined O 
anharmonic O 
motion O 
leads O 
to O 
typical O 
shashlik O 
- O 
like O 
residual O 
density O 
patterns O 
. O 
Therefore O 
, O 
careful O 
analysis O 
of O 
the O 
residual O 
density O 
and O 
the O 
derived O 
probability O 
density O 
function O 
after O 
the O 
refinement O 
of O 
the O 
Gram-Charlier O 
coefficients O 
proved O 
to O 
be O 
the O 
most O 
useful O 
tools O 
to O 
indicate O 
the O 
presence O 
of O 
anharmonic O 
motion O 
. O 

Interactions O 
of O 
small O 
- O 
molecule O 
inhibitors O 
affecting O 
the O 
YopH O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
. O 

have O 
developed O 
competitive O 
and O 
direct O 
binding O 
methods O 
to O 
examine O 
small O 
- O 
molecule O 
inhibitors O 
of O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
activity O 
. O 
Focusing O 
on O 
the O 
Yersinia O 
pestis O 
outer O 
protein O 
H O 
, O 
a O 
potent O 
bacterial O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
, O 
we O 
describe O 
how O 
an O 
understanding O 
of O 
the O 
kinetic O 
interactions O 
involving O 
Yersinia O 
pestis O 
outer O 
protein O 
H O 
, O 
peptide O 
substrates O 
, O 
and O 
small O 
- O 
molecule O 
inhibitors O 
of O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
activity O 
can O 
be O 
beneficial O 
for O 
inhibitor O 
screening O 
, O 
and O 
we O 
further O 
translate O 
these O 
results O 
into O 
a O 
microarray O 
assay O 
for O 
high O 
- O 
throughput O 
screening O 
. O 

- O 
like O 
Ni(OH)2 B-FORMULA 
- O 
NiF2 B-FORMULA 
composite O 
film O 
with O 
excellent O 
electrochemical O 
performance O 
. O 

- O 
like O 
porous O 
Ni(OH)(2) B-FORMULA 
- O 
NiF(2) B-FORMULA 
composite O 
( O 
PNC O 
) O 
film O 
was O 
successfully O 
synthesized O 
by O 
the O 
anodization O 
of O 
nickel B-SYSTEMATIC 
in O 
a O 
NH(4)F B-FORMULA 
and O 
H(3)PO(4) B-FORMULA 
containing O 
electrolyte O 
. O 
Thanks O 
to O 
the O 
good O 
conductivity O 
and O 
the O 
highly O 
porous O 
architecture O 
, O 
PNC O 
exhibited O 
not O 
only O 
a O 
high O 
specific O 
capacitance O 
, O 
but O 
also O 
a O 
superior O 
rate O 
capability O 
and O 
a O 
good O 
cyclability O 
( O 
2090 O 
F O 
g(-1) O 
at O 
10 O 
mV O 
s(-1) O 
, O 
capacitance O 
> O 
1200 O 
F O 
g(-1) O 
at O 
100 O 
A O 
g(-1) O 
after O 
2000 O 
cycles O 
) O 
. O 
Anodization O 
of O 
nickel B-SYSTEMATIC 
is O 
proven O 
to O 
be O 
fast O 
and O 
facile O 
and O 
can O 
be O 
easily O 
scaled O 
up O 
. O 
The O 
method O 
described O 
here O 
is O 
promising O 
for O 
the O 
fabrication O 
of O 
supercapacitor O 
electrodes O 
with O 
excellent O 
performance O 
. O 

dissociative O 
electron O 
attachment O 
to O 
flavonoids B-FAMILY 
and O 
possible O 
similarities O 
to O 
their O 
metabolic O 
pathways O 
. O 

gas-phase O 
empty O 
- O 
level O 
structures O 
and O 
formation O 
of O 
anion O 
states O 
via O 
resonance O 
attachment O 
of O 
low O 
- O 
energy O 
electrons O 
to O 
the O 
flavonoids B-FAMILY 
naringenin B-TRIVIAL 
(III) O 
, O 
quercetin B-TRIVIAL 
(IV) O 
and O 
myricetin B-TRIVIAL 
(V) O 
and O 
the O 
smaller O 
reference O 
molecules O 
chromone B-TRIVIAL 
(I) O 
and O 
flavone B-TRIVIAL 
(II) O 
are O 
investigated O 
experimentally O 
for O 
the O 
first O 
time O 
. O 
Dissociative O 
electron O 
attachment O 
spectroscopy O 
( O 
DEAS O 
) O 
is O 
used O 
to O 
measure O 
the O 
fragment O 
anion O 
currents O 
generated O 
through O 
dissociative O 
decay O 
channels O 
of O 
the O 
molecular O 
anions O 
of O 
compounds O 
I–V O 
, O 
detected O 
with O 
a O 
mass O 
filter O 
as O 
a O 
function O 
of O 
the O 
incident O 
electron O 
energy O 
in O 
the O 
0– O 
14 O 
eV O 
energy O 
range O 
. O 
Due O 
to O 
the O 
insufficient O 
volatility O 
of O 
flavonoids B-FAMILY 
III–V O 
, O 
the O 
energies O 
of O 
vertical O 
electron O 
attachment O 
associated O 
with O 
temporary O 
occupation O 
of O 
the O 
lower O 
- O 
lying O 
virtual O 
orbitals O 
are O 
measured O 
with O 
electron O 
transmission O 
spectroscopy O 
( O 
ETS O 
) O 
only O 
in O 
the O 
smaller O 
reference O 
molecules O 
I O 
and O 
II O 
. O 
The O 
experimental O 
findings O 
are O 
interpreted O 
with O 
the O 
support O 
of O 
appropriate O 
density O 
functional O 
theory O 
calculations O 
with O 
the O 
B3LYP O 
functional O 
. O 
The O 
experimental O 
vertical O 
electron O 
attachment O 
energies O 
measured O 
in O 
the O 
ET O 
spectra O 
of O 
I O 
and O 
II O 
are O 
compared O 
with O 
the O 
orbital O 
energies O 
of O 
the O 
neutral O 
molecules O 
scaled O 
using O 
an O 
empirically O 
calibrated O 
linear O 
equation O 
. O 
The O 
vertical O 
and O 
adiabatic O 
electron O 
affinities O 
are O 
evaluated O 
at O 
the O 
B3LYP O 
/ O 
6-31 O 
+ O 
G(d) O 
level O 
as O 
the O 
anion O 
/ O 
neutral O 
total O 
energy O 
difference O 
. O 
The O 
latter O 
theoretical O 
method O 
is O 
also O 
used O 
for O 
evaluation O 
of O 
the O 
most O 
stable O 
conformers O 
of O 
the O 
neutral O 
molecules O 
, O 
O–H B-FORMULA 
bond O 
dissociation O 
energies O 
and O 
thermodynamic O 
energy O 
thresholds O 
for O 
production O 
of O 
the O 
anion O 
fragments O 
observed O 
in O 
the O 
DEA O 
spectra O 
. O 
A O 
possible O 
role O 
played O 
by O 
loss O 
of O 
an O 
H(2) B-FORMULA 
molecule O 
from O 
the O 
parent O 
molecular O 
anion O 
in O 
vivo O 
in O 
the O 
mitochondrial O 
respiratory O 
chain O 
is O 
briefly O 
discussed O 
. O 

methods O 
for O 
micrometer- O 
and O 
nanometer O 
- O 
scale O 
surface O 
derivatization O 
based O 
on O 
photochemical O 
coupling O 
of O 
primary B-FAMILY 
amines I-FAMILY 
to O 
monolayers O 
of O 
aryl B-FAMILY 
azides I-FAMILY 
on O 
gold O 
and O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
surfaces O 
. O 

series O 
of O 
aryl B-FAMILY 
azide I-FAMILY 
terminated O 
thiols B-FAMILY 
and O 
phosphonic B-FAMILY 
acids I-FAMILY 
has O 
been O 
synthesized O 
, O 
and O 
used O 
to O 
prepare O 
self O 
- O 
assembled O 
monolayers O 
on O 
( O 
respectively O 
) O 
gold O 
and O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
surfaces O 
. O 
The O 
rates O 
of O 
photoactivation O 
were O 
determined O 
using O 
contact O 
angle O 
measurement O 
and O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
The O 
behavior O 
of O 
a O 
diazirine B-SYSTEMATIC 
functionalized O 
aryl B-FAMILY 
thiol I-FAMILY 
was O 
also O 
studied O 
. O 
The O 
rates O 
of O 
activation O 
were O 
found O 
to O 
be O 
similar O 
for O 
all O 
five O 
adsorbates O 
. O 
However O 
, O 
the O 
extent O 
of O 
photochemical O 
coupling O 
of O 
a O 
primary B-FAMILY 
amine I-FAMILY 
was O 
significantly O 
greater O 
for O 
the O 
aryl B-FAMILY 
azides I-FAMILY 
than O 
for O 
the O 
diazirine B-SYSTEMATIC 
. O 
A O 
range O 
of O 
primary B-FAMILY 
amines I-FAMILY 
was O 
successfully O 
coupled O 
to O 
all O 
of O 
the O 
azides B-FAMILY 
with O 
high O 
yield O 
. O 
Little O 
difference O 
in O 
reactivity O 
was O 
observed O 
following O 
perfluorination O 
of O 
the O 
aromatic O 
ring O 
. O 
Micrometer O 
- O 
scale O 
patterns O 
were O 
fabricated O 
by O 
carrying O 
out O 
exposures O 
of O 
the O 
aryl B-FAMILY 
azide I-FAMILY 
terminated O 
SAMs O 
through O 
a O 
mask O 
submerged O 
under O 
a O 
film O 
of O 
primary B-FAMILY 
amine I-FAMILY 
. O 
Contrasting O 
amines B-FAMILY 
could O 
be O 
introduced O 
to O 
unreacted O 
regions O 
in O 
a O 
subsequent O 
maskless O 
step O 
. O 
A O 
scanning O 
near O 
- O 
field O 
optical O 
microscope O 
was O 
used O 
to O 
fabricate O 
nanopatterns O 
. O 
Exposure O 
of O 
the O 
azides B-FAMILY 
to O 
irradiation O 
at O 
325 O 
nm O 
in O 
air O 
enabled O 
selective O 
deactivation O 
of O 
azides B-FAMILY 
. O 
The O 
surrounding O 
surface O 
was O 
functionalized O 
with O 
a O 
primary B-FAMILY 
amine I-FAMILY 
in O 
a O 
maskless O 
process O 
; O 
when O 
a O 
protein O 
- O 
resistant O 
oligo(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
functionalized O 
amine B-SYSTEMATIC 
was O 
used O 
it O 
was O 
possible O 
to O 
produce O 
protein O 
nanopatterns O 
, O 
by O 
adsorbing O 
protein O 
to O 
features O 
defined O 
using O 
near O 
- O 
field O 
exposure O 
. O 

plasma O 
and O 
its O 
fractions O 
/ O 
derivatives O 
are O 
frequently O 
used O 
materials O 
in O 
biomedicine O 
as O 
it O 
contains O 
thousands O 
and O 
thousands O 
of O 
proteins O 
representing O 
the O 
majority O 
of O 
human O 
proteome O 
. O 
Several O 
important O 
methods O 
were O 
developed O 
in O 
the O 
past O 
for O 
the O 
fractionation O 
of O 
this O 
important O 
biological O 
fluid O 
and O 
its O 
use O 
for O 
medicinal O 
purposes O 
. O 
One O 
of O 
the O 
greatest O 
challenges O 
is O 
the O 
very O 
large O 
dynamic O 
range O 
of O 
plasma O 
proteins O 
ranging O 
up O 
to O 
10-12 O 
orders O 
of O 
magnitude O 
. O 
Early O 
attempts O 
were O 
mainly O 
based O 
on O 
methods O 
such O 
as O 
salting O 
out O 
or O 
cold O 
ethanol B-SYSTEMATIC 
precipitation O 
, O 
as O 
well O 
as O 
chromatography O 
utilizing O 
affinity O 
, O 
size O 
exclusion O 
, O 
ion O 
exchange O 
and O 
hydrophobic O 
interaction O 
techniques O 
. O 
More O 
recently O 
, O 
fractionation O 
applications O 
started O 
with O 
the O 
depletion O 
of O 
the O 
high O 
abundant O 
plasma O 
components O 
, O 
such O 
as O 
serum O 
albumin O 
and O 
immunoglobulins O 
, O 
before O 
isolating O 
lower O 
abundant O 
proteins O 
of O 
interest O 
. O 
Plasma O 
volumes O 
were O 
utilized O 
from O 
the O 
milliliter O 
scale O 
for O 
diagnostic O 
applications O 
to O 
hundreds O 
of O 
liters O 
for O 
industrial O 
scale O 
plasma O 
fractionation O 
( O 
e.g O 
. O 
, O 
medicinal O 
product O 
manufacturing O 
) O 
. O 
In O 
this O 
paper O 
we O 
review O 
this O 
important O 
part O 
of O 
medicinal O 
chemistry O 
, O 
highlighting O 
the O 
traditional O 
methods O 
along O 
with O 
some O 
of O 
their O 
variations O 
as O 
well O 
as O 
the O 
most O 
significant O 
recent O 
achievements O 
of O 
the O 
field O 
. O 

- O 
like O 
and O 
peroxidase O 
- O 
like O 
catalytic O 
activities O 
of O 
silicon B-SYSTEMATIC 
nanowire O 
arrays O 
. O 

nanowire O 
arrays O 
( O 
SiNWAs O 
) O 
were O 
found O 
to O 
have O 
catalytic O 
activities O 
similar O 
to O 
those O 
of O 
biological O 
enzymes O 
catalase O 
and O 
peroxidase O 
. O 
Thus O 
not O 
only O 
can O 
these O 
materials O 
catalyze O 
the O 
decomposition O 
reaction O 
of O 
H(2)O(2) B-FORMULA 
into O 
water O 
and O 
oxygen B-SYSTEMATIC 
, O 
but O 
they O 
can O 
also O 
catalyze O 
the O 
oxidation O 
of O 
o-phenylenediamine B-SYSTEMATIC 
( O 
OPD B-ABBREVIATION 
) O 
, O 
a O 
common O 
substrate O 
for O 
peroxidases O 
, O 
by O 
H(2)O(2) B-FORMULA 
. O 
The O 
presence O 
of O 
Si B-FORMULA 
- O 
H B-FORMULA 
bonds O 
and O 
the O 
morphology O 
of O 
the O 
SiNWAs O 
are O 
found O 
to O 
be O 
crucial O 
to O 
the O 
occurrence O 
of O 
such O 
catalytic O 
activity O 
. O 
When O 
the O 
SiNWAs O 
are O 
reacted O 
with O 
H(2)O(2) B-FORMULA 
, O 
the O 
data O 
from O 
Raman O 
spectroscopy O 
suggests O 
the O 
formation O 
of O 
(Si-H)(2) B-FORMULA 
···( O 
O B-FORMULA 
species O 
) O 
( O 
(Si-H)(2) B-FORMULA 
···Os O 
) O 
, O 
which O 
is O 
presumably O 
responsible O 
for O 
the O 
catalytic O 
activity O 
. O 
These O 
findings O 
suggest O 
the O 
potential O 
use O 
of O 
SiNWAs O 
as O 
enzyme O 
mimics O 
in O 
medicine O 
, O 
biotechnology O 
, O 
and O 
environmental O 
chemistry O 
. O 

series O 
of O 
novel O 
glycopyranosyl B-FAMILY 
azides I-FAMILY 
were O 
synthesised O 
wherein O 
the O 
carbohydrate B-FAMILY 
moiety O 
was O 
peracylated O 
with O 
four O 
acetyl B-SYSTEMATIC 
, O 
propionyl B-SYSTEMATIC 
, O 
butanoyl B-SYSTEMATIC 
, O 
pentanoyl B-SYSTEMATIC 
( O 
valeryl B-SYSTEMATIC 
) O 
or O 
3-methylbutanoyl B-SYSTEMATIC 
( O 
isovaleryl B-TRIVIAL 
) O 
ester B-FAMILY 
linked O 
groups O 
. O 
A O 
panel O 
of O 
glycoconjugates O 
was O 
synthesised O 
from O 
these O 
glycopyranosyl B-FAMILY 
azides I-FAMILY 
using O 
copper B-SYSTEMATIC 
-catalysed O 
azide B-SYSTEMATIC 
- O 
alkyne B-FAMILY 
cycloaddition O 
. O 
The O 
in O 
vitro O 
metabolic O 
stability O 
, O 
plasma O 
stability O 
and O 
plasma O 
protein O 
binding O 
was O 
then O 
measured O 
to O 
establish O 
the O 
impact O 
of O 
the O 
different O 
acyl B-FAMILY 
group O 
when O 
presented O 
on O 
a O 
common O 
scaffold O 
. O 
The O 
acetyl B-MULTIPLE 
, I-MULTIPLE 
propionyl I-MULTIPLE 
and I-MULTIPLE 
butanoyl I-MULTIPLE 
esters I-MULTIPLE 
exhibited O 
metabolism O 
consistent O 
with O 
esterase O 
processing O 
, O 
and O 
various O 
mono- B-MULTIPLE 
, I-MULTIPLE 
di- I-MULTIPLE 
and I-MULTIPLE 
tri I-MULTIPLE 
- I-MULTIPLE 
acylated I-MULTIPLE 
hydrolysis O 
products O 
as O 
well O 
as O 
the O 
fully O 
hydrolysed O 
compound O 
were O 
detected O 
. O 
In O 
contrast O 
, O 
the O 
pentanoyl B-MULTIPLE 
and I-MULTIPLE 
3-methylbutanoyl I-MULTIPLE 
esters I-MULTIPLE 
were O 
stable O 
. O 

of O 
perylene B-FAMILY 
bisimide I-FAMILY 
-centered O 
glycodendrimer O 
and O 
its O 
interactions O 
with O 
concanavalin O 
A O 
. O 

novel O 
glycodendrimer O 
based O 
on O 
18 O 
peripheral O 
α-D-mannoses B-FAMILY 
functionalized O 
perylene B-SYSTEMATIC 
bisimide O 
derivative O 
PBI-18-Man B-TRIVIAL 
was O 
synthesized O 
and O 
its O 
selectively O 
binding O 
interactions O 
for O 
Con O 
A O 
were O 
investigated O 
by O 
CD O 
spectra O 
and O 
turbidity O 
assay O 
, O 
which O 
exhibited O 
strong O 
binding O 
affinity O 
for O 
Con O 
A O 
with O 
the O 
binding O 
constant O 
of O 
1.3×10(8) O 
M(-1) O 
( O 
7.2×10(6) O 
M(-1) O 
for O 
monomeric O 
mannose B-TRIVIAL 
, O 
valency O 
corrected O 
) O 
, O 
3 O 
orders O 
of O 
magnitude O 
higher O 
affinity O 
than O 
the O 
monovalent O 
mannose B-TRIVIAL 
ligand O 
. O 
Furthermore O 
, O 
the O 
inhibitory O 
activity O 
for O 
Con O 
A O 
was O 
studied O 
by O 
ELLA O 
experiment O 
, O 
showed O 
2 O 
times O 
inhibitor O 
activity O 
than O 
the O 
reference O 
compound O 
( O 
α-MMP O 
) O 
. O 

incorporation O 
, O 
proofreading O 
and O 
bypass O 
by O 
human O 
DNA O 
polymerase O 
δ O 
. O 

both O 
budding O 
and O 
fission O 
yeast O 
, O 
a O 
large O 
number O 
of O 
ribonucleotides B-FAMILY 
are O 
incorporated O 
into O 
DNA O 
during O 
replication O 
by O 
the O 
major O 
replicative O 
polymerases O 
( O 
Pols O 
α O 
, O 
δ O 
and O 
ɛ O 
) O 
. O 
They O 
are O 
subsequently O 
removed O 
by O 
RNase O 
H2-dependent O 
repair O 
, O 
which O 
if O 
defective O 
leads O 
to O 
replication O 
stress O 
and O 
genome O 
instability O 
. O 
To O 
extend O 
these O 
studies O 
to O 
humans O 
, O 
where O 
an O 
RNase O 
H2 O 
defect O 
results O 
in O 
an O 
autoimmune O 
disease O 
, O 
here O 
we O 
compare O 
the O 
ability O 
of O 
human O 
and O 
yeast O 
Pol O 
δ O 
to O 
incorporate O 
, O 
proofread O 
, O 
and O 
bypass O 
ribonucleotides B-FAMILY 
during O 
DNA O 
synthesis O 
. O 
In O 
reactions O 
containing O 
nucleotide B-FAMILY 
concentrations O 
estimated O 
to O 
be O 
present O 
in O 
mammalian O 
cells O 
, O 
human O 
Pol O 
δ O 
stably O 
incorporates O 
one O 
rNTP B-ABBREVIATION 
for O 
approximately O 
2000 O 
dNTPs B-ABBREVIATION 
, O 
a O 
ratio O 
similar O 
to O 
that O 
for O 
yeast O 
Pol O 
δ O 
. O 
This O 
result O 
predicts O 
that O 
human O 
Pol O 
δ O 
may O 
introduce O 
more O 
than O 
a O 
million O 
ribonucleotides B-FAMILY 
into O 
the O 
nuclear O 
genome O 
per O 
replication O 
cycle O 
, O 
an O 
amount O 
recently O 
reported O 
to O 
be O 
present O 
in O 
the O 
genome O 
of O 
RNase O 
H2-defective O 
mouse O 
cells O 
. O 
Consistent O 
with O 
such O 
abundant O 
stable O 
incorporation O 
, O 
we O 
show O 
that O 
the O 
3'-exonuclease O 
activity O 
of O 
yeast O 
and O 
human O 
Pol O 
δ O 
largely O 
fails O 
to O 
edit O 
ribonucleotides B-FAMILY 
during O 
polymerization O 
. O 
We O 
also O 
show O 
that O 
, O 
like O 
yeast O 
Pol O 
δ O 
, O 
human O 
Pol O 
δ O 
pauses O 
as O 
it O 
bypasses O 
ribonucleotides B-FAMILY 
in O 
DNA O 
templates O 
, O 
with O 
four O 
consecutive O 
ribonucleotides B-FAMILY 
in O 
a O 
DNA O 
template O 
being O 
more O 
problematic O 
than O 
single O 
ribonucleotides B-FAMILY 
. O 
In O 
conjunction O 
with O 
recent O 
studies O 
in O 
yeast O 
and O 
mice O 
, O 
this O 
ribonucleotide B-FAMILY 
incorporation O 
may O 
be O 
relevant O 
to O 
impaired O 
development O 
and O 
disease O 
when O 
RNase O 
H2 O 
is O 
defective O 
in O 
mammals O 
. O 
As O 
one O 
tool O 
to O 
investigate O 
ribonucleotide B-FAMILY 
incorporation O 
by O 
Pol O 
δ O 
in O 
human O 
cells O 
, O 
we O 
show O 
that O 
human O 
Pol O 
δ O 
containing O 
a O 
Leu606Met O 
substitution O 
in O 
the O 
polymerase O 
active O 
site O 
incorporates O 
7-fold O 
more O 
ribonucleotides B-FAMILY 
into O 
DNA O 
than O 
does O 
wild O 
type O 
Pol O 
δ O 
. O 

/ O 
HSMS O 
/ O 
MS(E) O 
- O 
based O 
metabonomics O 
for O 
adenine B-TRIVIAL 
-induced O 
changes O 
in O 
metabolic O 
profiles O 
of O 
rat O 
faeces O 
and O 
intervention O 
effects O 
of O 
ergosta-4,6,8(14),22-tetraen-3-one B-SYSTEMATIC 
. O 

( O 
ergone B-TRIVIAL 
) O 
, O 
isolated O 
from O 
the O 
medicinal O 
fungus O 
Polyporus O 
umbellatus O 
, O 
has O 
been O 
proven O 
to O 
prevent O 
the O 
progression O 
of O 
renal O 
injury O 
and O 
the O 
subsequent O 
renal O 
fibrosis O 
. O 
Ultra O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
high O 
- O 
sensitivity O 
mass O 
spectrometry O 
and O 
a O 
novel O 
mass O 
spectrometry(Elevated O 
Energy O 
) O 
(MS(E)) O 
data O 
collection O 
technique O 
was O 
employed O 
to O 
investigate O 
metabonomic O 
characters O 
of O 
chronic O 
renal O 
failure O 
( O 
CRF O 
) O 
induced O 
adenine B-TRIVIAL 
and O 
the O 
protective O 
effects O 
of O 
ergosta-4,6,8(14),22-tetraen-3-one B-SYSTEMATIC 
( O 
ergone B-TRIVIAL 
) O 
. O 
Coupled O 
with O 
blood O 
biochemistry O 
and O 
kidney O 
histopathology O 
results O 
, O 
the O 
significant O 
difference O 
in O 
metabolic O 
profiling O 
between O 
adenine B-TRIVIAL 
-induced O 
CRF O 
group O 
and O 
ergone B-TRIVIAL 
-treated O 
CRF O 
group O 
by O 
using O 
pattern O 
recognition O 
analysis O 
indicated O 
that O 
changes O 
in O 
global O 
faecal O 
metabolites O 
were O 
occurred O 
. O 
Seven O 
endogenous O 
metabolites O 
were O 
identified O 
by O 
using O 
metabonomic O 
method O 
combined O 
with O 
multivariate O 
data O 
analysis O 
, O 
the O 
accurate O 
mass O 
, O 
isotopic O 
pattern O 
, O 
MS(E) O 
fragments O 
information O 
and O 
MassLynx O 
i-FIT O 
algorithm O 
. O 
These O 
biochemical O 
changes O 
in O 
faecal O 
metabolites O 
are O 
related O 
to O 
the O 
perturbations O 
of O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
and O 
phospholipid O 
metabolism O 
, O 
which O 
may O 
be O 
helpful O 
to O 
further O 
understand O 
the O 
CRF O 
and O 
therapeutic O 
mechanisms O 
of O 
ergone B-TRIVIAL 
. O 
This O 
research O 
proved O 
that O 
MS(E) O 
can O 
simultaneous O 
acquire O 
precursor O 
ion O 
information O 
and O 
fragment O 
ion O 
data O 
at O 
high O 
and O 
low O 
collision O 
energy O 
in O 
one O 
analytical O 
run O 
, O 
which O 
facilitated O 
the O 
fast O 
structural O 
characterization O 
of O 
metabolites O 
. O 

switches O 
are O 
critical O 
components O 
of O 
developmental O 
circuits O 
. O 
Because O 
temperate O 
bacteriophages O 
are O 
vastly O 
abundant O 
and O 
greatly O 
diverse O 
, O 
they O 
are O 
rich O 
resources O 
for O 
understanding O 
the O 
mechanisms O 
and O 
evolution O 
of O 
switches O 
and O 
the O 
molecular O 
control O 
of O 
genetic O 
circuitry O 
. O 
Here O 
, O 
we O 
describe O 
a O 
new O 
class O 
of O 
small O 
, O 
compact O 
, O 
and O 
simple O 
switches O 
that O 
use O 
site O 
- O 
specific O 
recombination O 
as O 
the O 
key O 
decision O 
point O 
. O 
The O 
phage O 
attachment O 
site O 
attP O 
is O 
located O 
within O 
the O 
phage O 
repressor O 
gene O 
such O 
that O 
chromosomal O 
integration O 
results O 
in O 
removal O 
of O 
a O 
C B-FORMULA 
-terminal O 
tag O 
that O 
destabilizes O 
the O 
virally O 
encoded O 
form O 
of O 
the O 
repressor O 
. O 
Integration O 
thus O 
not O 
only O 
confers O 
prophage O 
stability O 
but O 
also O 
is O 
a O 
requirement O 
for O 
lysogenic O 
establishment O 
. O 
The O 
variety O 
of O 
these O 
self O 
- O 
contained O 
integration O 
- O 
dependent O 
immunity O 
systems O 
in O 
different O 
genomic O 
contexts O 
suggests O 
that O 
these O 
represent O 
ancestral O 
states O 
in O 
switch O 
evolution O 
from O 
which O 
more O 
- O 
complex O 
switches O 
have O 
evolved O 
. O 
They O 
also O 
provide O 
a O 
powerful O 
toolkit O 
for O 
building O 
synthetic O 
biological O 
circuits O 
. O 

novel O 
δ O 
opioid O 
receptor O 
agonist O 
KNT-127 B-IDENTIFIER 
produces O 
distinct O 
anxiolytic O 
- O 
like O 
effects O 
in O 
rats O 
without O 
producing O 
the O 
adverse O 
effects O 
associated O 
with O 
benzodiazepines B-FAMILY 
. O 

previously O 
reported O 
that O 
a O 
δ O 
opioid O 
receptor O 
agonist O 
SNC80 B-IDENTIFIER 
produced O 
potent O 
anxiolytic O 
- O 
like O 
effects O 
in O 
rodents O 
. O 
Recently O 
, O 
we O 
succeeded O 
in O 
synthesizing O 
a O 
novel O 
δ O 
opioid O 
receptor O 
agonist O 
KNT-127 B-IDENTIFIER 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
anxiolytic O 
- O 
like O 
effects O 
of O 
KNT-127 B-IDENTIFIER 
using O 
three O 
different O 
rat O 
models O 
of O 
innate O 
anxiety O 
. O 
In O 
an O 
elevated O 
plus O 
- O 
maze O 
test O 
, O 
KNT-127 B-IDENTIFIER 
( O 
0.3 O 
, O 
1 O 
, O 
and O 
3 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
significantly O 
and O 
dose O 
- O 
dependently O 
increased O 
the O 
time O 
rats O 
spent O 
in O 
the O 
open O 
arms O 
30 O 
min O 
after O 
administration O 
. O 
The O 
magnitude O 
of O 
the O 
KNT-127 B-IDENTIFIER 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
s.c.)-induced O 
anxiolytic O 
- O 
like O 
effects O 
was O 
similar O 
to O 
that O 
produced O 
by O 
diazepam B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
, O 
a O 
benzodiazepine B-FAMILY 
anxiolytic O 
. O 
The O 
anxiolytic O 
- O 
like O 
effects O 
of O 
KNT-127 B-IDENTIFIER 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
were O 
abolished O 
by O 
pretreatment O 
with O 
naltrindole B-TRIVIAL 
( O 
0.1 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
, O 
a O 
selective O 
δ O 
opioid O 
receptor O 
antagonist O 
, O 
suggesting O 
that O 
KNT-127 B-IDENTIFIER 
-induced O 
anxiolytic O 
- O 
like O 
effects O 
are O 
mediated O 
by O 
δ O 
opioid O 
receptors O 
. O 
These O 
findings O 
were O 
supported O 
by O 
results O 
obtained O 
from O 
light O 
/ O 
dark O 
and O 
open O 
- O 
field O 
tests O 
. O 
Interestingly O 
, O 
in O 
contrast O 
to O 
diazepam B-TRIVIAL 
( O 
1 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
, O 
KNT-127 B-IDENTIFIER 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
caused O 
no O 
significant O 
performance O 
changes O 
in O 
the O 
Y-maze O 
test O 
, O 
the O 
ethanol B-SYSTEMATIC 
-induced O 
sleeping O 
test O 
, O 
and O 
footprint O 
test O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
demonstrate O 
that O 
the O 
novel O 
δ O 
opioid O 
receptor O 
agonist O 
KNT-127 B-IDENTIFIER 
produces O 
distinct O 
anxiolytic O 
- O 
like O 
effects O 
in O 
rats O 
, O 
without O 
producing O 
the O 
adverse O 
effects O 
associated O 
with O 
benzodiazepines B-FAMILY 
. O 

and O 
di-(2-ethylhexyl) B-SYSTEMATIC 
adipate I-SYSTEMATIC 
( O 
DEHA B-ABBREVIATION 
) O 
intake O 
by O 
German O 
infants O 
based O 
on O 
the O 
results O 
of O 
a O 
duplicate O 
diet O 
study O 
and O 
biomonitoring O 
data O 
( O 
INES O 
2 O 
) O 
. O 

as O 
well O 
as O 
di-(2-ethylhexyl) B-SYSTEMATIC 
adipate I-SYSTEMATIC 
( O 
DEHA B-ABBREVIATION 
) O 
are O 
used O 
as O 
plasticizers O 
in O 
diverse O 
applications O 
and O 
are O 
of O 
toxicological O 
concern O 
. O 
The O 
study O 
was O 
conducted O 
with O 
a O 
study O 
population O 
of O 
25 O 
German O 
subjects O 
aged O 
between O 
15 O 
and O 
21 O 
months O 
. O 
Overall O 
, O 
16 O 
phthalates B-FAMILY 
and O 
DEHA B-ABBREVIATION 
were O 
measured O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
in O 
a O 
total O 
of O 
171 O 
duplicate O 
diet O 
samples O 
collected O 
over O 
7 O 
consecutive O 
days O 
, O 
and O 
20 O 
phthalate B-FAMILY 
metabolites O 
were O 
analyzed O 
in O 
the O 
urine O 
samples O 
collected O 
over O 
7 O 
consecutive O 
days O 
using O 
a O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
method O 
. O 
The O 
median O 
" O 
high O 
" O 
daily O 
dietary O 
intake O 
based O 
on O 
95th O 
percentiles O 
was O 
4.66 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
di-2-ethylhexyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
, O 
1.03 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
isobutyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DiBP B-ABBREVIATION 
) O 
, O 
and O 
0.7 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
di-n-butyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DnBP B-ABBREVIATION 
) O 
, O 
and O 
1 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
DEHA B-ABBREVIATION 
. O 
The O 
" O 
high O 
" O 
daily O 
total O 
intake O 
from O 
biomonitoring O 
data O 
was O 
4.9 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
DEHP B-ABBREVIATION 
, O 
2.2 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
DnBP B-ABBREVIATION 
, O 
3.9 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
DiBP B-ABBREVIATION 
, O 
and O 
2.6 O 
μg O 
/ O 
kg O 
b.w O 
. O 
for O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
isononyl I-SYSTEMATIC 
phthalate I-SYSTEMATIC 
. O 
The O 
comparison O 
of O 
the O 
two O 
intake O 
estimates O 
indicates O 
that O 
the O 
dominant O 
intake O 
source O 
of O 
DEHP B-ABBREVIATION 
was O 
food O 
ingestion O 
, O 
whereas O 
other O 
sources O 
considerably O 
contributed O 
to O 
the O 
total O 
intake O 
of O 
other O 
phthalates B-FAMILY 
. O 
Using O 
our O 
" O 
high O 
" O 
intake O 
scenario O 
, O 
none O 
of O 
the O 
analyzed O 
phthalates B-FAMILY 
reached O 
the O 
recommended O 
tolerable O 
daily O 
intake O 
levels O 
. O 

protective O 
role O 
of O 
curcumin B-TRIVIAL 
on O 
perfluorooctane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
-induced O 
genotoxicity O 
: O 
single O 
cell O 
gel O 
electrophoresis O 
and O 
micronucleus O 
test O 
. O 

sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
is O 
a O 
man O 
- O 
made O 
fluorosurfactant O 
and O 
global O 
pollutant O 
. O 
PFOS B-ABBREVIATION 
a O 
persistent O 
and O 
bioaccumulative O 
compound O 
, O 
is O 
widely O 
distributed O 
in O 
humans O 
and O 
wildlife O 
. O 
Therefore O 
, O 
it O 
was O 
added O 
to O 
Annex O 
B O 
of O 
the O 
Stockholm O 
Convention O 
on O 
Persistent O 
Organic O 
Pollutants O 
in O 
May O 
2009 O 
. O 
Curcumin B-TRIVIAL 
is O 
a O 
natural O 
polyphenolic B-FAMILY 
compound O 
abundant O 
in O 
the O 
rhizome O 
of O 
the O 
perennial O 
herb O 
turmeric O 
. O 
It O 
is O 
commonly O 
used O 
as O 
a O 
dietary O 
spice O 
and O 
coloring O 
agent O 
in O 
cooking O 
and O 
anecdotally O 
as O 
an O 
herb O 
in O 
traditional O 
Asian O 
medicine O 
. O 
In O 
this O 
study O 
, O 
male O 
rats O 
were O 
treated O 
with O 
three O 
different O 
PFOS B-ABBREVIATION 
doses O 
( O 
0.6 O 
, O 
1.25 O 
and O 
2.5 O 
mg O 
/ O 
kg O 
) O 
and O 
one O 
dose O 
of O 
curcumin O 
, O 
from O 
Curcuma O 
longa O 
( O 
80 O 
mg O 
/ O 
kg O 
) O 
and O 
combined O 
three O 
doses O 
of O 
PFOS O 
with O 
80 O 
mg O 
/ O 
kg O 
dose O 
of O 
curcumin B-TRIVIAL 
by O 
gavage O 
for O 
30 O 
days O 
at O 
48 O 
h O 
intervals O 
. O 
Here O 
, O 
we O 
evaluated O 
the O 
DNA O 
damage O 
via O 
single O 
cell O 
gel O 
electrophoresis O 
or O 
comet O 
assay O 
and O 
micronucleus O 
test O 
in O 
bone O 
marrow O 
in O 
vivo O 
. O 
PFOS B-ABBREVIATION 
induced O 
micronucleus O 
frequency O 
and O 
decreased O 
the O 
ratio O 
of O 
polychromatic O 
erythrocyte O 
to O 
normochromatic O 
erythrocyte O 
in O 
bone O 
marrow O 
. O 
Using O 
the O 
alkaline O 
comet O 
assay O 
, O 
we O 
showed O 
that O 
all O 
doses O 
of O 
the O 
PFOS B-ABBREVIATION 
strongly O 
induced O 
DNA O 
damage O 
in O 
rat O 
bone O 
marrow O 
and O 
curcumin B-TRIVIAL 
prevented O 
the O 
formation O 
of O 
DNA O 
damage O 
induced O 
by O 
PFOS B-ABBREVIATION 
. O 

- O 
induced O 
neurodegenerative O 
events O 
and O 
abnormal O 
behaviors O 
occur O 
via O 
ORXRergic/ O 
GABA B-ABBREVIATION 
(A)Rergic O 
mechanisms O 
in O 
a O 
marine O 
teleost O 
. O 

hindering O 
effects O 
of O 
metals O 
and O 
in O 
particular O 
lead O 
( O 
Pb B-FORMULA 
) O 
are O 
representing O 
a O 
growing O 
threat O 
to O 
aquatic O 
organisms O 
such O 
as O 
fish O 
. O 
This O 
observation O 
derives O 
from O 
toxic O 
concentrations O 
of O 
Pb B-FORMULA 
accounting O 
for O 
altered O 
neurophysiological O 
activities O 
of O 
some O 
interesting O 
teleost O 
models O 
like O 
Thalassoma O 
pavo O 
, O 
a O 
fish O 
species O 
highly O 
known O 
for O 
its O 
host O 
- O 
cleaning O 
symbiosis O 
. O 
In O 
this O 
study O 
, O 
the O 
nominal O 
PbNO(3) B-FORMULA 
concentration O 
of O 
1.6 O 
mg O 
/ O 
L O 
was O 
capable O 
of O 
reducing O 
feeding O 
and O 
resting O 
bouts O 
as O 
early O 
as O 
24 O 
h O 
of O 
exposure O 
while O 
hyperactive O 
swimming O 
episodes O 
were O 
also O 
detected O 
. O 
Such O 
abnormal O 
behaviors O 
were O 
tightly O 
correlated O 
to O 
up O 
- O 
regulated O 
orexin O 
receptor O 
( O 
ORXR O 
) O 
mRNA O 
expression O 
levels O 
in O 
some O 
brain O 
areas O 
such O 
as O 
the O 
lateral O 
thalamic O 
nucleus O 
( O 
+ O 
213% O 
) O 
and O 
the O 
optic O 
tectum O 
( O 
+ O 
90% O 
) O 
with O 
respect O 
to O 
controls O 
. O 
Interestingly O 
, O 
these O 
transcriptional O 
effects O 
seemed O 
to O 
be O 
attenuated O 
when O 
Pb B-FORMULA 
-exposed O 
fish O 
received O 
either O 
100 O 
ng O 
/ O 
g O 
of O 
ORX-A O 
( O 
-70% O 
) O 
or O 
0.1 O 
μg O 
/ O 
g O 
of O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
A O 
) O 
receptor O 
( O 
GABA B-ABBREVIATION 
(A)R O 
) O 
agonist O 
muscimol B-TRIVIAL 
( O 
MUS B-ABBREVIATION 
; O 
-97% O 
) O 
compared O 
to O 
fish O 
exposed O 
to O 
Pb B-FORMULA 
alone O 
. O 
Moreover O 
, O 
a O 
net O 
neurodegenerative O 
process O 
of O 
the O 
different O 
brain O 
areas O 
was O 
reported O 
after O 
Pb B-FORMULA 
exposure O 
as O 
displayed O 
by O 
their O 
marked O 
amino B-SYSTEMATIC 
cupric I-SYSTEMATIC 
silver I-SYSTEMATIC 
stained O 
cells O 
while O 
these O 
cells O 
were O 
devoid O 
of O 
any O 
staining O 
reaction O 
after O 
treatment O 
with O 
MUS B-ABBREVIATION 
only O 
. O 
Conversely O 
, O 
addition O 
of O 
the O 
GABA B-ABBREVIATION 
(A)R O 
antagonist O 
bicuculline B-TRIVIAL 
( O 
BIC B-ABBREVIATION 
; O 
1 O 
μg O 
/ O 
g O 
) O 
moderately O 
( O 
p O 
< O 
0.05 O 
) O 
enhanced O 
Pb B-FORMULA 
-dependent O 
behavioral O 
and O 
neurodegenerative O 
actions O 
. O 
Overall O 
, O 
these O 
first O 
indications O 
strongly O 
point O 
to O 
altered O 
ORXR/ O 
GABA B-ABBREVIATION 
(A)R O 
interactions O 
during O 
neurotoxic O 
events O 
of O 
a O 
metal O 
that O 
by O 
evoking O 
harmful O 
neurobiological O 
dysfunctions O 
may O 
endanger O 
the O 
survival O 
of O 
commercially O 
valuable O 
fish O 
with O 
eventual O 
repercussions O 
on O 
human O 
health O 
. O 

islet O 
studies O 
implicate O 
an O 
important O 
signaling O 
role O 
for O 
the O 
Cdc42 O 
effector O 
protein O 
p21-activated O 
kinase O 
( O 
PAK1 O 
) O 
in O 
the O 
sustained O 
/ O 
second O 
- O 
phase O 
of O 
insulin O 
secretion O 
. O 
Because O 
human O 
islets O 
from O 
type O 
2 O 
diabetic O 
donors O 
lack O 
∼80% O 
of O 
normal O 
PAK1 O 
protein O 
levels O 
, O 
the O 
mechanistic O 
requirement O 
for O 
PAK1 O 
signaling O 
in O 
islet O 
function O 
was O 
interrogated O 
. O 
Similar O 
to O 
MIN6 O 
β O 
cells O 
, O 
human O 
islets O 
elicited O 
glucose B-TRIVIAL 
-stimulated O 
PAK1 O 
activation O 
that O 
was O 
sensitive O 
to O 
the O 
PAK1 O 
inhibitor O 
, O 
IPA3 B-ABBREVIATION 
. O 
Given O 
that O 
sustained O 
insulin O 
secretion O 
has O 
been O 
correlated O 
with O 
glucose B-TRIVIAL 
-induced O 
filamentous O 
actin O 
( O 
F-actin O 
) O 
remodeling O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
a O 
Cdc42-activated O 
PAK1 O 
signaling O 
cascade O 
is O 
required O 
to O 
elicit O 
F-actin O 
remodeling O 
to O 
mobilize O 
granules O 
to O 
the O 
cell O 
surface O 
. O 
Live O 
- O 
cell O 
imaging O 
captured O 
the O 
glucose B-TRIVIAL 
-induced O 
cortical O 
F-actin O 
remodeling O 
in O 
MIN6 O 
β O 
cells O 
; O 
IPA3 B-ABBREVIATION 
-mediated O 
inhibition O 
of O 
PAK1 O 
abolished O 
this O 
remodeling O 
. O 
IPA3 B-ABBREVIATION 
also O 
ablated O 
glucose B-TRIVIAL 
-stimulated O 
insulin O 
granule O 
accumulation O 
at O 
the O 
plasma O 
membrane O 
, O 
consistent O 
with O 
its O 
role O 
in O 
sustained O 
/ O 
second O 
- O 
phase O 
insulin O 
release O 
. O 
Both O 
IPA3 B-ABBREVIATION 
and O 
a O 
selective O 
inhibitor O 
of O 
the O 
Cdc42 O 
GTPase O 
, O 
ML-141 B-IDENTIFIER 
, O 
blunted O 
the O 
glucose B-TRIVIAL 
-stimulated O 
activation O 
of O 
Raf-1 O 
, O 
suggesting O 
Raf-1 O 
to O 
be O 
downstream O 
of O 
Cdc42→PAK1 O 
. O 
IPA3 B-ABBREVIATION 
also O 
inhibited O 
MEK1 O 
/ O 
2 O 
activation O 
, O 
implicating O 
the O 
MEK1 O 
/ O 
2→ERK1 O 
/ O 
2 O 
cascade O 
to O 
occur O 
downstream O 
of O 
PAK1 O 
. O 
Importantly O 
, O 
PD0325901 B-IDENTIFIER 
, O 
a O 
new O 
selective O 
inhibitor O 
of O 
MEK1 O 
/ O 
2→ERK1 O 
/ O 
2 O 
activation O 
, O 
impaired O 
F-actin O 
remodeling O 
and O 
the O 
sustained O 
/ O 
amplification O 
pathway O 
of O 
insulin O 
release O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
glucose B-TRIVIAL 
-mediated O 
activation O 
of O 
Cdc42 O 
leads O 
to O 
activation O 
of O 
PAK1 O 
and O 
prompts O 
activation O 
of O 
its O 
downstream O 
targets O 
Raf-1 O 
, O 
MEK1 O 
/ O 
2 O 
and O 
ERK1 O 
/ O 
2 O 
to O 
elicit O 
F-actin O 
remodeling O 
and O 
recruitment O 
of O 
insulin O 
granules O 
to O 
the O 
plasma O 
membrane O 
to O 
support O 
the O 
sustained O 
phase O 
of O 
insulin O 
release O 
. O 

reduces O 
the O 
expression O 
of O 
lipopolysaccharide-induced O 
inflammatory O 
markers O 
by O 
inhibition O 
of O 
aldose B-FAMILY 
reductase O 
in O 
murine O 
macrophages O 
and O 
ocular O 
tissues O 
. O 

reductase O 
( O 
AR O 
) O 
catalyzes O 
the O 
reduction O 
of O 
toxic O 
lipid O 
aldehydes B-FAMILY 
to O 
their O 
alcohol B-FAMILY 
products O 
and O 
mediates O 
inflammatory O 
signals O 
triggered O 
by O 
lipopolysaccharide O 
( O 
LPS O 
) O 
. O 
Beta-glucogallin B-TRIVIAL 
( O 
BGG B-ABBREVIATION 
) O 
, O 
a O 
recently O 
described O 
AR O 
inhibitor O 
, O 
was O 
purified O 
from O 
extracts O 
of O 
the O 
Indian O 
gooseberry O 
( O 
Emblica O 
officinalis O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
BGG B-ABBREVIATION 
showed O 
low O 
cytotoxicity O 
in O 
Raw264.7 O 
murine O 
macrophages O 
and O 
effectively O 
inhibited O 
AR O 
activity O 
as O 
measured O 
by O 
a O 
decrease O 
in O 
sorbitol B-TRIVIAL 
accumulation O 
. O 
In O 
addition O 
, O 
BGG B-ABBREVIATION 
-mediated O 
inhibition O 
of O 
AR O 
prevented O 
LPS-induced O 
activation O 
of O 
JNK O 
and O 
p38 O 
and O 
lowered O 
ROS O 
levels O 
, O 
which O 
could O 
inhibit O 
LPS-induced O 
apoptosis O 
. O 
Uveitis O 
is O 
a O 
disease O 
of O 
the O 
eye O 
associated O 
with O 
chronic O 
inflammation O 
. O 
In O 
this O 
study O 
, O 
we O 
also O 
demonstrated O 
that O 
treatment O 
with O 
BGG B-ABBREVIATION 
decreased O 
the O 
number O 
of O 
inflammatory O 
cells O 
that O 
infiltrate O 
the O 
ocular O 
media O 
of O 
mice O 
with O 
experimental O 
uveitis O 
. O 
Accordingly O 
, O 
these O 
results O 
suggest O 
BGG B-ABBREVIATION 
is O 
a O 
potential O 
therapy O 
for O 
inflammatory O 
diseases O 
. O 

of O 
human O 
carbonyl B-FAMILY 
reductase O 
1 O 
( O 
CBR1 O 
, O 
SDR21C1 O 
) O 
gene O 
by O 
transcription O 
factor O 
Nrf2 O 
. O 

carbonyl B-FAMILY 
reductase O 
1 O 
( O 
CBR1 O 
, O 
SDR21C1 O 
) O 
is O 
a O 
member O 
of O 
the O 
short O 
- O 
chain O 
dehydrogenase O 
/ O 
reductase O 
superfamily O 
and O 
is O 
involved O 
in O 
the O 
metabolism O 
of O 
anthracycline B-FAMILY 
anti-cancer O 
drugs O 
, O 
prostaglandins B-FAMILY 
, O 
and O 
isatin B-TRIVIAL 
, O 
which O 
is O 
an O 
endogenous O 
inhibitor O 
of O 
monoamine B-FAMILY 
oxidases O 
. O 
Additionally O 
, O 
cancer O 
progression O 
may O 
be O 
partly O 
regulated O 
by O 
CBR1 O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
screened O 
more O 
than O 
10 O 
drugs O 
for O 
the O 
induction O 
of O 
the O 
human O 
CBR1 O 
gene O 
to O 
investigate O 
its O 
regulation O 
. O 
Of O 
the O 
drugs O 
, O 
butylated B-SYSTEMATIC 
hydroxyanisole I-SYSTEMATIC 
( O 
BHA B-ABBREVIATION 
) O 
was O 
found O 
to O 
be O 
an O 
inducer O 
. O 
BHA B-ABBREVIATION 
induced O 
the O 
mRNA O 
and O 
protein O 
expression O 
of O 
CBR1 O 
in O 
hepatoma O 
HepG2 O 
cells O 
. O 
In O 
a O 
luciferase O 
reporter O 
gene O 
assay O 
, O 
the O 
promoter O 
region O 
between O 
-2062 O 
bp O 
and O 
the O 
transcription O 
start O 
site O 
of O 
CBR1 O 
was O 
also O 
activated O 
by O 
BHA O 
. O 
The O 
transcription O 
factor O 
Nrf2 O 
is O 
known O 
to O 
be O 
activated O 
by O 
BHA B-ABBREVIATION 
. O 
There O 
are O 
2 O 
anti-oxidant O 
responsive O 
elements O 
( O 
ARE O 
) O 
that O 
are O 
bound O 
by O 
Nrf2 O 
in O 
this O 
region O 
. O 
Mutation O 
analyses O 
revealed O 
that O 
one O 
of O 
the O 
AREs O 
participates O 
in O 
the O 
gene O 
regulation O 
of O 
CBR1 O 
by O 
Nrf2 O 
. O 
Electrophoretic O 
mobility O 
shift O 
assay O 
revealed O 
that O 
Nrf2 O 
binds O 
the O 
site O 
. O 
Moreover O 
, O 
to O 
determine O 
whether O 
the O 
functional O 
ARE O 
of O 
CBR1 O 
is O 
conserved O 
with O 
the O 
promoter O 
region O 
of O 
homologues O 
in O 
other O 
species O 
, O 
the O 
nucleotide B-FAMILY 
sequences O 
of O 
the O 
functional O 
AREs O 
of O 
the O 
Chcr1 O 
and O 
Chcr2 O 
genes O 
, O 
which O 
are O 
the O 
Chinese O 
hamster O 
homologues O 
of O 
CBR1 O 
, O 
were O 
determined O 
. O 
The O 
region O 
has O 
2 O 
AREs O 
, O 
and O 
these O 
genes O 
were O 
also O 
induced O 
by O 
the O 
forced O 
expression O 
of O 
Nrf2 O 
( O 
cotransfection O 
of O 
pNrf2 O 
) O 
in O 
the O 
luciferase O 
reporter O 
gene O 
assay O 
. O 
In O 
conclusion O 
, O 
Nrf2 O 
is O 
a O 
novel O 
transcriptional O 
regulator O 
of O 
CBR1 O 
genes O 
in O 
humans O 
and O 
the O 
Chinese O 
hamster O 
. O 
Because O 
the O 
regulation O 
of O 
CBR1 O 
appears O 
to O 
be O 
important O 
for O 
diseases O 
, O 
the O 
induction O 
of O 
CBR1 O 
by O 
Nrf2 O 
may O 
be O 
a O 
therapeutic O 
target O 
. O 

sought O 
to O 
modify O 
adenoviral O 
( O 
Ad O 
) O 
particles O 
by O 
incorporating O 
the O 
advantageous O 
characteristics O 
of O 
non-viral O 
gene O 
delivery O 
vehicles O 
to O 
complement O 
the O 
viral O 
vectors O 
. O 
α-Amino B-FAMILY 
acid-N-carboxyanhydride I-FAMILY 
chemistry O 
was O 
used O 
to O 
synthesize O 
homopolypeptides O 
and O 
diblock O 
copolypeptides O 
that O 
possess O 
well O 
- O 
defined O 
secondary O 
structures O 
. O 
Using O 
cryo O 
- O 
electron O 
and O 
fluorescence O 
microscopy O 
, O 
we O 
showed O 
that O 
these O 
polypeptides O 
can O 
coat O 
the O 
surfaces O 
of O 
Ad O 
particles O 
in O 
a O 
non-covalent O 
manner O 
to O 
modify O 
their O 
transduction O 
properties O 
. O 
The O 
coated O 
Ad O 
particles O 
were O 
found O 
to O 
bind O 
to O 
and O 
be O 
internalized O 
by O 
cells O 
. O 
In O 
contrast O 
to O 
reports O 
using O 
covalently O 
PEGylated O 
Ad O 
particles O 
, O 
we O 
found O 
that O 
our O 
physically O 
coated O 
Ad O 
hybrid O 
complexes O 
facilitate O 
gene O 
transfer O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
We O 
showed O 
that O 
our O 
polypeptide O 
coating O 
was O 
able O 
to O 
shield O 
the O 
Ad O 
particles O 
from O 
the O 
neutralizing O 
effect O 
of O 
antibodies O 
and O 
mitigate O 
the O 
binding O 
of O 
blood O 
coagulation O 
factor O 
( O 
Factor O 
X O 
) O 
in O 
vitro O 
. O 
The O 
coating O 
also O 
reduced O 
the O 
antigenicity O 
of O 
Ad O 
in O 
immunocompetent O 
mice O 
. O 
The O 
biodistribution O 
of O 
the O 
systemically O 
administered O 
hybrid O 
complexes O 
mirrored O 
the O 
behavior O 
of O 
both O 
viral O 
and O 
non-viral O 
vectors O 
, O 
exhibiting O 
liver O 
tropism O 
as O 
well O 
as O 
enhanced O 
lung O 
transduction O 
. O 
These O 
data O 
demonstrated O 
that O 
our O 
non-covalent O 
modification O 
was O 
able O 
to O 
alter O 
Ad's O 
interactions O 
with O 
cells O 
and O 
organs O 
with O 
retention O 
of O 
transduction O 
efficiency O 
. O 
Advantages O 
such O 
as O 
facile O 
coating O 
of O 
the O 
Ad O 
vector O 
, O 
design O 
flexibility O 
and O 
ease O 
of O 
attaching O 
ligands O 
to O 
the O 
polypeptides O 
make O 
this O 
system O 
potentially O 
useful O 
as O 
a O 
platform O 
for O 
adding O 
functionalities O 
to O 
Ad O 
to O 
target O 
cancer O 
metastasis O 
. O 

recognition O 
of O 
the O 
protonated O 
serine B-TRIVIAL 
dimer O 
and O 
octamer O 
by O 
infrared O 
multiphoton O 
dissociation O 
spectroscopy O 
. O 

multiphoton O 
dissociation O 
( O 
IRMPD O 
) O 
spectroscopy O 
has O 
been O 
used O 
to O 
record O 
IR O 
signatures O 
of O 
chirality O 
recognition O 
in O 
the O 
protonated O 
serine B-TRIVIAL 
dimer O 
and O 
octamer O 
in O 
the O 
3200-3800 O 
cm(-1) O 
region O 
. O 
This O 
is O 
the O 
first O 
IRMPD O 
study O 
to O 
investigate O 
the O 
heterochiral O 
biomolecular O 
system O 
by O 
utilizing O 
the O 
isotope O 
- O 
labelled O 
species O 
. O 
Noticeable O 
differences O 
in O 
the O 
homo- O 
versus O 
heterochiral O 
IRMPD O 
spectra O 
have O 
been O 
obtained O 
experimentally O 
for O 
both O 
the O 
dimer O 
and O 
octamer O 
. O 
Different O 
dissociation O 
patterns O 
have O 
been O 
noted O 
not O 
only O 
between O 
the O 
homo- O 
and O 
heterochiral O 
octamers O 
, O 
but O 
also O 
between O 
the O 
two O 
- O 
OH B-FORMULA 
stretching O 
vibrational O 
bands O 
of O 
the O 
same O 
chirality O 
species O 
. O 
Systematic O 
theoretical O 
searches O 
have O 
been O 
carried O 
out O 
to O 
identify O 
the O 
most O 
stable O 
conformers O 
of O 
both O 
the O 
homo- O 
and O 
heterochiral O 
protonated O 
serine B-TRIVIAL 
dimer O 
and O 
octamer O 
. O 
The O 
final O 
geometry O 
optimization O 
and O 
harmonic O 
vibrational O 
calculations O 
have O 
been O 
performed O 
at O 
the O 
MP2 O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
level O 
for O 
the O 
homo- O 
and O 
heterochiral O 
protonated O 
serine B-TRIVIAL 
dimer O 
and O 
at O 
the O 
B3LYP O 
/ O 
6-31G(d) O 
level O 
for O 
the O 
homo- O 
and O 
heterochiral O 
protonated O 
serine O 
octamer O 
. O 
For O 
the O 
homo- O 
and O 
heterochiral O 
dimer O 
, O 
good O 
agreement O 
between O 
the O 
experimental O 
and O 
theoretical O 
spectra O 
has O 
been O 
achieved O 
and O 
the O 
major O 
conformers O 
have O 
been O 
identified O 
. O 
For O 
the O 
homo- O 
and O 
heterochiral O 
octamer O 
, O 
the O 
main O 
IR O 
features O 
observed O 
have O 
been O 
satisfactorily O 
reproduced O 
theoretically O 
and O 
the O 
dominant O 
conformers O 
identified O 
. O 
More O 
than O 
one O 
main O 
conformer O 
has O 
been O 
identified O 
for O 
the O 
homochiral O 
octamer O 
. O 
This O 
conclusion O 
has O 
been O 
further O 
supported O 
by O 
the O 
analysis O 
of O 
the O 
wavelength O 
specific O 
dissociation O 
products O 
. O 

- O 
functionalized O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 

iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
NP O 
) O 
have O 
been O 
synthesized O 
in O 
a O 
one O 
and O 
a O 
two O 
- O 
step O 
method O 
using O 
a O 
natural O 
functional O 
glycolipid O 
belonging O 
to O 
the O 
family O 
of O 
sophorolipids O 
( O 
SL O 
) O 
. O 
These O 
compounds O 
, O 
whose O 
open O 
acidic O 
form O 
is O 
highly O 
suitable O 
for O 
nanoparticle O 
stabilization O 
, O 
are O 
readily O 
obtained O 
by O 
a O 
fermentation O 
process O 
of O 
the O 
yeast O 
Candida O 
bombicola O 
( O 
polymorph O 
Starmerella O 
bombicola O 
) O 
in O 
large O 
amounts O 
. O 
The O 
final O 
carbohydrate B-FAMILY 
coated O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
represent O 
interesting O 
potentially O 
biocompatible O 
materials O 
for O 
biomedical O 
applications O 
. O 
According O 
to O 
the O 
synthesis O 
strategy O 
, O 
magnetic O 
properties O 
can O 
eventually O 
be O 
tuned O 
, O 
thus O 
putting O 
in O 
evidence O 
the O 
direct O 
effect O 
of O 
the O 
glycolipid O 
on O 
the O 
final O 
material's O 
structure O 
( O 
maghemite B-TRIVIAL 
and O 
ferrihydrite B-TRIVIAL 
have O 
been O 
obtained O 
here O 
) O 
. O 
A O 
combination O 
of O 
FT-IR O 
, O 
Dynamic O 
Light O 
Scattering O 
( O 
DLS O 
) O 
and O 
UV-Vis O 
experiments O 
shows O 
that O 
SL O 
complex O 
the O 
nanoparticle O 
surface O 
via O 
their O 
accessible O 
COOH B-FORMULA 
group O 
thus O 
forming O 
stable O 
colloids O 
, O 
whose O 
hydrodynamic O 
diameter O 
mostly O 
varies O 
between O 
10 O 
nm O 
and O 
30 O 
nm O 
, O 
both O 
in O 
water O 
and O 
in O 
KCl B-FORMULA 
-containing O 
( O 
0.01 O 
M O 
and O 
2 O 
M O 
) O 
solutions O 
. O 
The O 
materials O 
can O 
stand O 
multiple O 
filtration O 
steps O 
( O 
up O 
to O 
10 O 
) O 
at O 
different O 
extents O 
, O 
where O 
the O 
largest O 
recorded O 
average O 
aggregate O 
size O 
is O 
100 O 
nm O 
. O 
In O 
general O 
, O 
materials O 
synthesized O 
at O 
T O 
= O 
80 O 
°C O 
display O 
better O 
stability O 
and O 
smaller O 
size O 
distribution O 
than O 
those O 
obtained O 
at O 
room O 
temperature O 
. O 

nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
are O 
ligand O 
- O 
gated O 
ion O 
channels O 
that O 
consist O 
of O 
pentameric O 
combinations O 
of O 
α O 
and O 
β O 
subunits O 
. O 
These O 
receptors O 
are O 
widely O 
distributed O 
throughout O 
the O 
brain O 
and O 
are O 
highly O 
expressed O 
in O 
addiction O 
circuitry O 
. O 
The O 
role O 
of O 
nAChRs O 
in O 
regulating O 
neuronal O 
activity O 
and O 
motivated O 
behavior O 
is O 
complex O 
and O 
varies O 
both O 
in O 
and O 
among O 
brain O 
regions O 
. O 
The O 
rich O 
diversity O 
of O 
central O 
nAChRs O 
has O 
hampered O 
the O 
characterization O 
of O 
their O 
structure O 
and O 
function O 
with O 
use O 
of O 
classic O 
pharmacological O 
techniques O 
. O 
However O 
, O 
recent O 
molecular O 
approaches O 
using O 
nan O 
mutant O 
mice O 
with O 
specific O 
regional O 
lentiviral O 
re O 
- O 
expression O 
, O 
in O 
combination O 
with O 
neuroanatomical O 
and O 
electrophysiological O 
techniques O 
, O 
have O 
allowed O 
the O 
elucidation O 
of O 
the O 
influence O 
of O 
different O 
nAChR O 
types O 
on O 
neuronal O 
circuit O 
activity O 
and O 
behavior O 
. O 
This O 
review O 
will O 
address O 
the O 
influence O 
of O 
nAChRs O 
on O 
limbic O 
dopamine B-TRIVIAL 
circuitry O 
and O 
the O 
medial O 
habenula O 
- O 
interpeduncular O 
nucleus O 
complex O 
, O 
which O 
are O 
critical O 
mediators O 
of O 
reinforced O 
behavior O 
. O 
Characterization O 
of O 
the O 
mechanisms O 
underlying O 
regulation O 
of O 
addiction O 
pathways O 
by O 
endogenous O 
cholinergic O 
transmission O 
and O 
by O 
nicotine B-TRIVIAL 
may O 
lead O 
to O 
the O 
identification O 
of O 
new O 
therapeutic O 
targets O 
for O 
treating O 
tobacco O 
dependence O 
and O 
other O 
addictions O 
. O 

and O 
restoration O 
of O 
a O 
functional O 
β-cell O 
mass O 
are O 
fundamental O 
strategies O 
for O 
prevention O 
and O 
treatment O 
of O 
diabetes O 
. O 
Consequently O 
, O 
knowledge O 
of O 
signals O 
that O 
determine O 
the O 
functional O 
β-cell O 
mass O 
is O 
of O 
immense O 
clinical O 
relevance O 
. O 
Transforming O 
growth O 
factor O 
β O 
( O 
TGFβ O 
) O 
superfamily O 
signaling O 
pathways O 
play O 
a O 
critical O 
role O 
in O 
development O 
and O 
tissue O 
specification O 
. O 
Nevertheless O 
, O 
the O 
role O 
of O 
these O 
pathways O 
in O 
adult O 
β-cell O 
homeostasis O 
is O 
not O 
well O 
defined O 
. O 
Here O 
, O 
we O 
ablated O 
TGFβ O 
receptor O 
I O 
and O 
II O 
genes O 
in O 
mice O 
undergoing O 
two O 
surgical O 
β-cell O 
replication O 
models O 
( O 
partial O 
pancreatectomy O 
or O 
partial O 
duct O 
ligation O 
) O 
, O 
representing O 
two O 
triggers O 
for O 
β-cell O 
proliferation O 
, O 
increased O 
β-cell O 
workload O 
and O 
local O 
inflammation O 
, O 
respectively O 
. O 
Our O 
data O 
suggest O 
that O 
TGFβ O 
receptor O 
signaling O 
is O 
necessary O 
for O 
baseline O 
β-cell O 
proliferation O 
. O 
By O 
either O 
provision O 
of O 
excess O 
glucose B-TRIVIAL 
or O 
treatment O 
with O 
exogenous O 
insulin O 
, O 
we O 
further O 
demonstrated O 
that O 
inflammation O 
and O 
increased O 
β-cell O 
workload O 
are O 
both O 
stimulants O 
for O 
β-cell O 
proliferation O 
but O 
are O 
TGFβ O 
receptor O 
signaling O 
dependent O 
and O 
independent O 
, O 
respectively O 
. O 
Collectively O 
, O 
by O 
using O 
a O 
pancreas-specific O 
TGFβ O 
receptor O 
- O 
deleted O 
mouse O 
model O 
, O 
we O 
have O 
identified O 
two O 
distinct O 
pathways O 
that O 
regulate O 
adult O 
β-cell O 
proliferation O 
. O 
Our O 
study O 
thus O 
provides O 
important O 
information O 
for O 
understanding O 
β-cell O 
proliferation O 
during O 
normal O 
growth O 
and O 
in O 
pancreatic O 
diseases O 
. O 

and O 
Risk O 
of O 
Diabetes O 
: O 
An O 
analysis O 
of O 
electronic O 
medical O 
records O 
to O 
evaluate O 
possible O 
bias O 
due O 
to O 
differential O 
survival O 
. O 

Two O 
meta-analyses O 
of O 
randomized O 
trials O 
of O 
statins B-FAMILY 
found O 
increased O 
risk O 
of O 
type O 
2 O 
diabetes O 
. O 
One O 
possible O 
explanation O 
is O 
bias O 
due O 
to O 
differential O 
survival O 
when O 
patients O 
who O 
are O 
at O 
higher O 
risk O 
of O 
diabetes O 
survive O 
longer O 
under O 
statin B-FAMILY 
treatment O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
We O 
used O 
electronic O 
medical O 
records O 
from O 
500 O 
general O 
practices O 
in O 
the O 
U.K O 
. O 
and O 
included O 
data O 
from O 
285864 O 
men O 
and O 
women O 
aged O 
50-84 O 
years O 
from O 
January O 
2000 O 
to O 
December O 
2010 O 
. O 
We O 
emulated O 
the O 
design O 
and O 
analysis O 
of O 
a O 
hypothetical O 
randomized O 
trial O 
of O 
statins B-FAMILY 
, O 
estimated O 
the O 
observational O 
analog O 
of O 
the O 
intention O 
- O 
to O 
- O 
treat O 
effect O 
, O 
and O 
adjusted O 
for O 
differential O 
survival O 
bias O 
using O 
inverse O 
- O 
probability O 
weighting O 
. O 
RESULTS O 
During O 
1.2 O 
million O 
person O 
- O 
years O 
of O 
follow O 
- O 
up O 
, O 
there O 
were O 
13455 O 
cases O 
of O 
type O 
2 O 
diabetes O 
and O 
8932 O 
deaths O 
. O 
Statin B-FAMILY 
initiation O 
was O 
associated O 
with O 
increased O 
risk O 
of O 
type O 
2 O 
diabetes O 
. O 
The O 
hazard O 
ratio O 
( O 
95% O 
CI O 
) O 
of O 
diabetes O 
was O 
1.45 O 
( O 
1.39-1.50 O 
) O 
before O 
adjusting O 
for O 
potential O 
confounders O 
and O 
1.14 O 
( O 
1.10-1.19 O 
) O 
after O 
adjustment O 
. O 
Adjusting O 
for O 
differential O 
survival O 
did O 
not O 
change O 
the O 
estimates O 
. O 
Initiating O 
atorvastatin B-TRIVIAL 
and O 
simvastatin B-TRIVIAL 
was O 
associated O 
with O 
increased O 
risk O 
of O 
type O 
2 O 
diabetes O 
. O 
CONCLUSIONS O 
In O 
this O 
sample O 
of O 
the O 
general O 
population O 
, O 
statin B-FAMILY 
therapy O 
was O 
associated O 
with O 
14% O 
increased O 
risk O 
of O 
type O 
2 O 
diabetes O 
. O 
Differential O 
survival O 
did O 
not O 
explain O 
this O 
increased O 
risk O 
. O 

of O 
bacterial O 
thioredoxin O 
reductase O 
: O 
an O 
antibiotic O 
mechanism O 
targeting O 
bacteria O 
lacking O 
glutathione B-TRIVIAL 
. O 

antibiotic O 
resistance O 
makes O 
the O 
identification O 
of O 
new O 
antibacterial O 
principles O 
an O 
urgent O 
task O 
. O 
The O 
thioredoxin O 
system O 
including O 
thioredoxin O 
reductase O 
( O 
TrxR O 
) O 
, O 
thioredoxin O 
( O 
Trx O 
) O 
, O 
and O 
NADPH B-ABBREVIATION 
plays O 
critical O 
roles O 
in O 
cellular O 
DNA O 
synthesis O 
and O 
defense O 
against O 
oxidative O 
stress O 
. O 
Notably O 
, O 
TrxR O 
is O 
very O 
different O 
in O 
structure O 
and O 
mechanism O 
in O 
mammals O 
and O 
bacteria O 
. O 
Ebselen B-TRIVIAL 
[ O 
2-phenyl-1,2 B-SYSTEMATIC 
benzisoselenazol-3(2H)-one I-SYSTEMATIC 
] O 
, O 
a O 
well O 
- O 
known O 
antioxidant O 
and O 
a O 
substrate O 
for O 
mammalian O 
TrxR O 
and O 
Trx O 
, O 
is O 
rapidly O 
bacteriocidal O 
for O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
by O 
an O 
unknown O 
mechanism O 
. O 
We O 
have O 
discovered O 
that O 
ebselen B-TRIVIAL 
is O 
a O 
competitive O 
inhibitor O 
of O 
Escherichia O 
coli O 
TrxR O 
with O 
a O 
Ki O 
of O 
0.52 O 
± O 
0.13 O 
μM O 
, O 
through O 
reaction O 
with O 
the O 
active O 
site O 
dithiol B-SYSTEMATIC 
of O 
the O 
enzyme O 
. O 
Bacteria O 
lacking O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
glutaredoxin O 
, O 
in O 
which O 
TrxR O 
and O 
Trx O 
are O 
essential O 
for O 
DNA O 
synthesis O 
, O 
were O 
particularly O 
sensitive O 
to O 
ebselen O 
. O 
In O 
growth O 
- O 
inhibited O 
E O 
. O 
coli O 
strains O 
, O 
Trx1 O 
and O 
Trx2 O 
were O 
oxidized O 
, O 
demonstrating O 
that O 
electron O 
transfer O 
via O 
thioredoxin O 
was O 
blocked O 
. O 
Ebselen B-TRIVIAL 
and O 
its O 
sulfur B-SYSTEMATIC 
analog O 
ebsulfur B-TRIVIAL 
were O 
bactericidal O 
for O 
GSH B-ABBREVIATION 
-negative O 
pathogens O 
. O 
Ebsulfur B-TRIVIAL 
inhibited O 
a O 
clinically O 
isolated O 
Helicobacter O 
pylori O 
strain O 
with O 
a O 
minimum O 
inhibitory O 
concentration O 
value O 
as O 
low O 
as O 
0.39 O 
μg O 
/ O 
ml O 
. O 
These O 
results O 
demonstrate O 
that O 
bacterial O 
Trx O 
and O 
TrxR O 
are O 
viable O 
antibacterial O 
drug O 
targets O 
using O 
benzisoselenazol B-SYSTEMATIC 
and O 
benzisothiazol B-SYSTEMATIC 
derivates.-Lu O 
, O 
J O 
. O 
, O 
Vlamis-Gardikas O 
, O 
A O 
. O 
, O 
Kandasamy O 
, O 
K O 
. O 
, O 
Zhao O 
, O 
R O 
. O 
, O 
Gustafsson O 
, O 
T O 
. O 
N O 
. O 
, O 
Engstrand O 
, O 
L O 
. O 
, O 
Hoffner O 
, O 
S O 
. O 
, O 
Engman O 
, O 
L O 
. O 
, O 
Holmgren O 
, O 
A O 
. O 
Inhibition O 
of O 
bacterial O 
thioredoxin O 
reductase O 
: O 
an O 
antibiotic O 
mechanism O 
targeting O 
bacteria O 
lacking O 
glutathione O 
. O 

ultrafast O 
intramolecular O 
charge O 
transfer O 
dynamics O 
of O 
4-(dimethylamino)benzonitrile B-SYSTEMATIC 
( O 
DMABN B-ABBREVIATION 
) O 
. O 

charge O 
transfer O 
( O 
ICT O 
) O 
of O 
DMABN B-ABBREVIATION 
has O 
been O 
the O 
subject O 
of O 
extensive O 
investigations O 
. O 
Through O 
the O 
measurements O 
of O 
highly O 
time O 
- O 
resolved O 
fluorescence O 
spectra O 
( O 
TRFS O 
) O 
over O 
the O 
whole O 
emission O 
region O 
, O 
we O 
have O 
examined O 
the O 
ICT O 
dynamics O 
of O 
DMABN B-ABBREVIATION 
in O 
acetonitrile B-SYSTEMATIC 
free O 
from O 
the O 
solvation O 
dynamics O 
and O 
vibronic O 
relaxation O 
. O 
The O 
ICT O 
dynamics O 
was O 
found O 
to O 
be O 
characterized O 
by O 
a O 
broad O 
range O 
of O 
time O 
scales O 
; O 
nearly O 
instantaneous O 
( O 
< O 
30 O 
fs O 
) O 
, O 
160 O 
fs O 
, O 
and O 
3.3 O 
ps O 
. O 
TRFS O 
revealed O 
that O 
an O 
ICT O 
state O 
with O 
partially O 
twisted O 
geometry O 
, O 
ICT(P) O 
, O 
is O 
formed O 
within O 
a O 
few O 
hundred O 
femtoseconds O 
either O 
directly O 
from O 
the O 
initial O 
photoexcited O 
state O 
or O 
via O 
the O 
locally O 
excited O 
( O 
LE O 
) O 
state O 
. O 
The O 
ICT(P) O 
state O 
undergoes O 
further O 
relaxation O 
along O 
the O 
intramolecular O 
nuclear O 
coordinate O 
to O 
reach O 
the O 
twisted O 
ICT O 
( O 
TICT O 
) O 
state O 
with O 
the O 
time O 
constant O 
of O 
4.8 O 
ps O 
. O 
A O 
conformational O 
diversity O 
along O 
the O 
rotation O 
of O 
the O 
dimethylamino B-SYSTEMATIC 
group O 
was O 
speculated O 
to O 
account O 
for O 
the O 
observed O 
diffusive O 
dynamics O 
. O 

- O 
harvesting O 
and O 
ultrafast O 
energy O 
migration O 
in O 
porphyrin B-FAMILY 
-based O 
metal O 
- O 
organic O 
frameworks O 
. O 

that O 
energy O 
( O 
exciton O 
) O 
migration O 
in O 
natural O 
photosynthesis O 
primarily O 
occurs O 
in O 
highly O 
ordered O 
porphyrin B-FAMILY 
-like O 
pigments O 
( O 
chlorophylls B-FAMILY 
) O 
, O 
equally O 
highly O 
ordered O 
porphyrin B-FAMILY 
-based O 
metal O 
- O 
organic O 
frameworks O 
( O 
MOFs O 
) O 
might O 
be O 
expected O 
to O 
exhibit O 
similar O 
behavior O 
, O 
thereby O 
facilitating O 
antenna O 
- O 
like O 
light O 
- O 
harvesting O 
and O 
positioning O 
such O 
materials O 
for O 
use O 
in O 
solar O 
energy O 
conversion O 
schemes O 
. O 
Herein O 
, O 
we O 
report O 
the O 
first O 
example O 
of O 
directional O 
, O 
long O 
- O 
distance O 
energy O 
migration O 
within O 
a O 
MOF O 
. O 
Two O 
MOFs O 
, O 
namely O 
F-MOF O 
and O 
DA-MOF O 
that O 
are O 
composed O 
of O 
two O 
Zn B-FORMULA 
(II) I-FORMULA 
porphyrin B-FAMILY 
struts O 
[5,15-dipyridyl-10,20-bis(pentafluorophenyl)porphinato]zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
and O 
[5,15-bis[4-(pyridyl)ethynyl]-10,20-diphenylporphinato]zinc B-SYSTEMATIC 
(II) I-SYSTEMATIC 
, O 
respectively O 
, O 
were O 
investigated O 
. O 
From O 
fluorescence O 
quenching O 
experiments O 
and O 
theoretical O 
calculations O 
, O 
we O 
find O 
that O 
the O 
photogenerated O 
exciton O 
migrates O 
over O 
a O 
net O 
distance O 
of O 
up O 
to O 
~45 O 
porphyrin B-FAMILY 
struts O 
within O 
its O 
lifetime O 
in O 
DA-MOF O 
( O 
but O 
only O 
~3 O 
in O 
F-MOF O 
) O 
, O 
with O 
a O 
high O 
anisotropy O 
along O 
a O 
specific O 
direction O 
. O 
The O 
remarkably O 
efficient O 
exciton O 
migration O 
in O 
DA-MOF O 
is O 
attributed O 
to O 
enhanced O 
π-conjugation O 
through O 
the O 
addition O 
of O 
two O 
acetylene B-SYSTEMATIC 
moieties O 
in O 
the O 
porphyrin B-FAMILY 
molecule O 
, O 
which O 
leads O 
to O 
greater O 
Q-band O 
absorption O 
intensity O 
and O 
much O 
faster O 
exciton O 
- O 
hopping O 
( O 
energy O 
transfer O 
between O 
adjacent O 
porphyrin B-FAMILY 
struts O 
) O 
. O 
The O 
long O 
distance O 
and O 
directional O 
energy O 
migration O 
in O 
DA-MOF O 
suggests O 
promising O 
applications O 
of O 
this O 
compound O 
or O 
related O 
compounds O 
in O 
solar O 
energy O 
conversion O 
schemes O 
as O 
an O 
efficient O 
light O 
- O 
harvesting O 
and O 
energy O 
- O 
transport O 
component O 
. O 

of O 
OH B-FORMULA 
radicals O 
with O 
Arizona O 
Test O 
Dust O 
: O 
uptake O 
and O 
products O 
. O 

and O 
products O 
of O 
the O 
interaction O 
of O 
OH B-FORMULA 
radicals O 
with O 
solid O 
films O 
of O 
Arizona O 
Test O 
Dust O 
( O 
ATD O 
) O 
were O 
studied O 
using O 
a O 
low O 
pressure O 
flow O 
reactor O 
( O 
0.5-3 O 
Torr O 
) O 
combined O 
with O 
a O 
modulated O 
molecular O 
beam O 
mass O 
spectrometer O 
for O 
monitoring O 
of O 
the O 
gaseous O 
species O 
involved O 
. O 
The O 
reactive O 
uptake O 
coefficient O 
of O 
OH B-FORMULA 
was O 
measured O 
from O 
the O 
kinetics O 
of O 
OH B-FORMULA 
consumption O 
on O 
Pyrex O 
rods O 
coated O 
with O 
ATD O 
as O 
a O 
function O 
of O 
OH B-FORMULA 
concentration O 
( O 
( O 
0.4-5.2 O 
) O 
× O 
10(12) O 
molecules O 
cm(-3) O 
) O 
, O 
relative O 
humidity O 
( O 
RH O 
= O 
0.03-25.9% O 
) O 
, O 
temperature O 
( O 
T O 
= O 
275-320 O 
K O 
) O 
, O 
and O 
UV O 
irradiance O 
intensity O 
( O 
J( O 
NO(2) B-FORMULA 
) O 
= O 
0-0.012 O 
s(-1) O 
) O 
. O 
Deactivation O 
of O 
ATD O 
surface O 
upon O 
exposure O 
to O 
OH B-FORMULA 
was O 
observed O 
. O 
The O 
initial O 
uptake O 
coefficient O 
was O 
found O 
to O 
be O 
independent O 
of O 
temperature O 
and O 
irradiation O 
conditions O 
and O 
to O 
decrease O 
with O 
relative O 
humidity O 
: O 
γ(0) O 
= O 
0.2 O 
/ O 
( O 
1 O 
+ O 
RH(0.36) O 
) O 
( O 
calculated O 
using O 
geometric O 
surface O 
area O 
, O 
with O 
30% O 
estimated O 
conservative O 
uncertainty O 
) O 
. O 
H(2)O(2) B-FORMULA 
and O 
H(2)O B-FORMULA 
were O 
observed O 
in O 
the O 
gas O 
phase O 
as O 
products O 
of O 
the O 
OH B-FORMULA 
reaction O 
with O 
ATD O 
surface O 
with O 
yields O 
of O 
( O 
10 O 
± O 
3 O 
) O 
and O 
( O 
98 O 
± O 
25 O 
) O 
% O 
, O 
respectively O 
. O 

and O 
8-OH-DPAT B-SYSTEMATIC 
induce O 
compulsive O 
checking O 
behavior O 
in O 
male O 
rats O 
by O 
acting O 
on O 
different O 
functional O 
parts O 
of O 
an O 
OCD O 
neurocircuit O 
. O 

study O 
investigated O 
whether O 
the O 
serotonin B-TRIVIAL 
5-HT1A O 
receptor O 
agonist O 
8-hydroxy-2-(di-n-propylamino) B-SYSTEMATIC 
tetralin I-SYSTEMATIC 
( O 
8-OH-DPAT B-SYSTEMATIC 
) O 
can O 
induce O 
compulsive O 
checking O 
in O 
a O 
large O 
open O 
field O 
, O 
as O 
does O 
the O 
dopamine B-TRIVIAL 
D2 O 
/ O 
D3 O 
receptor O 
agonist O 
quinpirole B-TRIVIAL 
. O 
To O 
induce O 
compulsive O 
checking O 
, O 
male O 
rats O 
were O 
exposed O 
to O 
eight O 
injections O 
of O 
either O 
8-OH-DPAT B-SYSTEMATIC 
( O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
quinpirole B-TRIVIAL 
( O 
0.2 O 
mg O 
/ O 
kg O 
) O 
, O 
or O 
saline O 
. O 
Subsequently O 
, O 
to O 
assess O 
cross O 
- O 
sensitization O 
, O 
rats O 
received O 
an O 
acute O 
challenge O 
of O 
8-OH-DPAT B-SYSTEMATIC 
or O 
quinpirole B-TRIVIAL 
. O 
The O 
results O 
showed O 
that O 
treatment O 
with O 
8-OH-DPAT B-SYSTEMATIC 
induces O 
compulsive O 
checking O 
and O 
may O 
have O 
a O 
stronger O 
effect O 
on O 
this O 
behavior O 
compared O 
with O 
quinpirole B-TRIVIAL 
. O 
However O 
, O 
there O 
was O 
no O 
cross O 
- O 
sensitization O 
between O 
8-OH-DPAT B-SYSTEMATIC 
and O 
quinpirole B-TRIVIAL 
on O 
measures O 
of O 
compulsive O 
checking O 
and O 
locomotion O 
. O 
Moreover O 
, O 
the O 
spatial O 
distribution O 
of O 
locomotor O 
paths O 
in O 
8-OH-DPAT B-SYSTEMATIC 
animals O 
was O 
more O 
confined O 
and O 
invariant O 
than O 
in O 
quinpirole B-TRIVIAL 
rats O 
; O 
their O 
rate O 
of O 
locomotor O 
sensitization O 
was O 
also O 
faster O 
than O 
that O 
in O 
quinpirole B-TRIVIAL 
animals O 
. O 
Thus O 
, O 
although O 
8-OH-DPAT B-SYSTEMATIC 
and O 
quinpirole B-TRIVIAL 
can O 
induce O 
compulsive O 
checking O 
in O 
a O 
large O 
open O 
field O 
, O 
the O 
results O 
suggest O 
that O 
they O 
do O 
so O 
differently O 
. O 
It O 
is O 
suggested O 
that O 
8-OH-DPAT B-SYSTEMATIC 
and O 
quinpirole B-TRIVIAL 
probably O 
produce O 
compulsive O 
behavior O 
by O 
acting O 
on O 
different O 
parts O 
of O 
a O 
security O 
motivation O 
circuit O 
underlying O 
obsessive O 
- O 
compulsive O 
disorder O 
. O 
Quinpirole B-TRIVIAL 
may O 
induce O 
compulsive O 
checking O 
behavior O 
by O 
directly O 
driving O 
dopaminergic O 
activity O 
mediating O 
the O 
motivational O 
drive O 
to O 
check O 
. O 
Conversely O 
, O 
8-OH-DPAT B-SYSTEMATIC 
may O 
perpetuate O 
the O 
activated O 
motivational O 
state O 
by O 
inhibiting O 
the O 
serotonergic O 
- O 
negative O 
feedback O 
signals O 
that O 
normally O 
deactivate O 
the O 
obsessive O 
- O 
compulsive O 
disorder O 
circuit O 
. O 

the O 
absence O 
of O 
elongation O 
factor O 
EF-G O 
, O 
ribosomes O 
undergo O 
spontaneous O 
, O 
thermally O 
driven O 
fluctuation O 
between O 
the O 
pre O 
- O 
translocation O 
( O 
classical O 
) O 
and O 
intermediate O 
( O 
hybrid O 
) O 
states O 
of O 
translocation O 
. O 
These O 
fluctuations O 
do O 
not O 
result O 
in O 
productive O 
mRNA O 
translocation O 
. O 
Extending O 
previous O 
findings O 
that O 
the O 
antibiotic O 
sparsomycin B-TRIVIAL 
induces O 
translocation O 
, O 
we O 
identify O 
additional O 
peptidyl O 
transferase O 
inhibitors O 
that O 
trigger O 
productive O 
mRNA O 
translocation O 
. O 
We O 
find O 
that O 
antibiotics O 
that O 
bind O 
the O 
peptidyl O 
transferase O 
A O 
site O 
induce O 
mRNA O 
translocation O 
, O 
whereas O 
those O 
that O 
do O 
not O 
occupy O 
the O 
A O 
site O 
fail O 
to O 
induce O 
translocation O 
. O 
Using O 
single O 
- O 
molecule O 
FRET O 
, O 
we O 
show O 
that O 
translocation O 
- O 
inducing O 
antibiotics O 
do O 
not O 
accelerate O 
intersubunit O 
rotation O 
, O 
but O 
act O 
solely O 
by O 
converting O 
the O 
intrinsic O 
, O 
thermally O 
driven O 
dynamics O 
of O 
the O 
ribosome O 
into O 
translocation O 
. O 
Our O 
results O 
support O 
the O 
idea O 
that O 
the O 
ribosome O 
is O 
a O 
Brownian O 
ratchet O 
machine O 
, O 
whose O 
intrinsic O 
dynamics O 
can O 
be O 
rectified O 
into O 
unidirectional O 
translocation O 
by O 
ligand O 
binding O 
. O 

effect O 
of O 
a O 
bile B-FAMILY 
acid I-FAMILY 
sequestrant O 
on O 
glucose B-TRIVIAL 
metabolism O 
in O 
subjects O 
with O 
type O 
2 O 
diabetes O 
. O 

designed O 
an O 
experiment O 
to O 
examine O 
the O 
effect O 
of O 
bile B-FAMILY 
acid I-FAMILY 
sequestration O 
with O 
Colesevelam B-TRIVIAL 
on O 
fasting O 
and O 
postprandial O 
glucose B-TRIVIAL 
metabolism O 
in O 
type O 
2 O 
diabetes O 
. O 
To O 
do O 
so O 
, O 
we O 
tested O 
the O 
hypothesis O 
that O 
Colesevelam B-TRIVIAL 
increases O 
the O 
disposition O 
index O 
( O 
DI O 
) O 
, O 
and O 
this O 
increase O 
is O 
associated O 
with O 
increased O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
concentrations O 
. O 
Thirty O 
- O 
eight O 
subjects O 
on O 
metformin B-TRIVIAL 
monotherapy O 
were O 
studied O 
using O 
a O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
, O 
parallel O 
- O 
group O 
design O 
. O 
Subjects O 
were O 
studied O 
before O 
and O 
after O 
12 O 
weeks O 
of O 
Colesevelam B-TRIVIAL 
or O 
placebo O 
using O 
a O 
labeled O 
triple O 
- O 
tracer O 
mixed O 
meal O 
to O 
measure O 
the O 
rate O 
of O 
meal O 
appearance O 
( O 
Meal O 
Ra O 
) O 
, O 
endogenous O 
glucose B-TRIVIAL 
production O 
( O 
EGP O 
) O 
, O 
and O 
glucose B-TRIVIAL 
disappearance O 
( O 
Rd O 
) O 
. O 
Insulin O 
sensitivity O 
and O 
β-cell O 
responsivity O 
indices O 
were O 
estimated O 
using O 
the O 
oral O 
minimal O 
model O 
and O 
then O 
used O 
to O 
calculate O 
DI O 
. O 
Therapy O 
with O 
Colesevelam B-TRIVIAL 
was O 
associated O 
with O 
a O 
decrease O 
in O 
fasting O 
( O 
7 O 
± O 
0.2 O 
vs O 
. O 
6.6 O 
± O 
0.2 O 
mmol O 
/ O 
L O 
; O 
P O 
= O 
0.004 O 
) O 
and O 
postprandial O 
glucose B-TRIVIAL 
concentrations O 
( O 
3145 O 
± O 
138 O 
vs O 
. O 
2896 O 
± O 
127 O 
mmol O 
/ O 
6 O 
h O 
; O 
P O 
= O 
0.01 O 
) O 
in O 
the O 
absence O 
of O 
a O 
change O 
in O 
insulin O 
concentrations O 
. O 
Minimal O 
model O 
- O 
derived O 
indices O 
of O 
insulin O 
secretion O 
and O 
action O 
were O 
unchanged O 
. O 
Postprandial O 
GLP-1 O 
concentrations O 
were O 
not O 
altered O 
by O 
Colesevelam B-TRIVIAL 
. O 
Although O 
EGP O 
and O 
Rd O 
were O 
unchanged O 
, O 
integrated O 
Meal O 
Ra O 
was O 
decreased O 
by O 
Colesevelam B-TRIVIAL 
( O 
5191 O 
± O 
204 O 
vs O 
. O 
5817 O 
± O 
204 O 
μmol O 
/ O 
kg O 
/ O 
6 O 
h O 
; O 
P O 
= O 
0.04 O 
) O 
, O 
suggesting O 
increased O 
splanchnic O 
sequestration O 
of O 
meal O 
- O 
derived O 
glucose B-TRIVIAL 
. O 

of O 
tissue O 
metal O 
concentrations O 
in O 
Zucker O 
lean O 
, O 
Zucker O 
obese O 
, O 
and O 
Zucker O 
diabetic O 
fatty B-FAMILY 
rats I-FAMILY 
and O 
the O 
effects O 
of O 
chromium B-SYSTEMATIC 
supplementation O 
on O 
tissue O 
metal O 
concentrations O 
. O 

results O 
in O 
several O 
metabolic O 
changes O 
, O 
including O 
alterations O 
in O 
the O 
transport O 
, O 
distribution O 
, O 
excretion O 
, O 
and O 
accumulation O 
of O 
metals O 
. O 
While O 
changes O 
have O 
been O 
examined O 
in O 
several O 
rat O 
models O 
of O 
insulin O 
resistance O 
and O 
diabetes O 
, O 
the O 
metal O 
ion O 
concentrations O 
in O 
the O 
tissues O 
of O 
Zucker O 
lean O 
, O 
Zucker O 
obese O 
( O 
an O 
insulin O 
resistance O 
and O 
early O 
stage O 
diabetes O 
model O 
) O 
, O 
and O 
Zucker O 
diabetic O 
fatty O 
( O 
ZDF O 
, O 
a O 
type O 
2 O 
diabetes O 
model O 
) O 
have O 
not O 
previously O 
been O 
examined O 
in O 
detail O 
. O 
The O 
concentration O 
of O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mg B-FORMULA 
, O 
and O 
Ca B-FORMULA 
were O 
examined O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
heart O 
and O 
spleen O 
, O 
and O 
Cr B-FORMULA 
concentration O 
in O 
the O 
liver O 
and O 
kidney O 
of O 
these O 
rats O 
were O 
examined O 
. O 
Zucker O 
obese O 
rats O 
have O 
a O 
reduction O 
in O 
the O 
concentration O 
of O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Mg B-FORMULA 
in O 
the O 
liver O 
compared O 
to O 
ZDF O 
and O 
/ O 
or O 
lean O 
Zucker O 
rats O 
, O 
presumably O 
as O 
a O 
result O 
of O 
the O 
increased O 
fat O 
content O 
of O 
the O 
liver O 
of O 
the O 
obese O 
rats O 
. O 
ZDF O 
rats O 
have O 
increased O 
concentrations O 
of O 
kidney O 
Cu B-FORMULA 
compared O 
to O 
the O 
lean O 
rats O 
, O 
while O 
kidney O 
Ca B-FORMULA 
concentrations O 
are O 
increased O 
in O 
the O 
Zucker O 
obese O 
rats O 
. O 
Spleen O 
Fe B-FORMULA 
concentrations O 
are O 
decreased O 
in O 
Zucker O 
obese O 
rats O 
compared O 
to O 
the O 
lean O 
rats O 
. O 
No O 
effects O 
on O 
metal O 
concentrations O 
in O 
the O 
heart O 
were O 
observed O 
between O 
the O 
lean O 
, O 
obese O 
, O 
and O 
ZDF O 
rats O 
, O 
and O 
no O 
effects O 
on O 
Cr B-FORMULA 
concentrations O 
were O 
identified O 
. O 
Cr B-FORMULA 
(III) I-FORMULA 
complexes O 
have O 
previously O 
been O 
shown O 
to O 
have O 
beneficial O 
effects O 
on O 
the O 
signs O 
of O 
insulin O 
resistance O 
in O 
Zucker O 
obese O 
and O 
ZDF O 
rats O 
. O 
The O 
effects O 
of O 
daily O 
gavage O 
administration O 
of O 
chromium B-SYSTEMATIC 
picolinate I-SYSTEMATIC 
( O 
[Cr(pic)(3)] B-FORMULA 
) O 
( O 
1 O 
mg O 
Cr B-FORMULA 
/ O 
kg O 
body O 
mass O 
) O 
, O 
CrCl(3) B-FORMULA 
( O 
1 O 
mg O 
Cr B-FORMULA 
/ O 
kg O 
body O 
mass O 
) O 
, O 
and O 
Cr3 B-FORMULA 
([Cr(3)O(propionate)(6)(H(2)O)(3)](+)) I-FORMULA 
( O 
33 O 
μg O 
and O 
1 O 
mg O 
Cr B-FORMULA 
/ O 
kg O 
body O 
mass O 
) O 
on O 
metal O 
concentrations O 
in O 
these O 
tissues O 
were O 
examined O 
. O 
Treatment O 
with O 
CrCl(3) B-FORMULA 
and O 
Cr3 B-FORMULA 
, O 
but O 
not O 
[Cr(pic)(3)] B-FORMULA 
, O 
at O 
1 O 
mg O 
Cr B-FORMULA 
/ O 
kg O 
resulted O 
in O 
a O 
statistically O 
significant O 
accumulation O 
of O 
Cr B-FORMULA 
in O 
the O 
kidney O 
of O 
lean O 
and O 
obese O 
but O 
not O 
ZDF O 
rats O 
but O 
resulted O 
in O 
lowering O 
the O 
elevated O 
levels O 
of O 
kidney O 
Cu B-FORMULA 
in O 
ZDF O 
rats O 
, O 
suggesting O 
a O 
beneficial O 
effect O 
on O 
this O 
symptom O 
of O 
type O 
2 O 
diabetes O 
. O 

improves O 
TNBS-induced O 
colitis O 
in O 
rats O 
by O 
inhibiting O 
IL-27 O 
expression O 
via O 
the O 
TLR4 O 
/ O 
NF-κB O 
signaling O 
pathway O 
. O 

is O 
a O 
widely O 
used O 
spice O 
with O 
anti-inflammatory O 
and O 
anticancer O 
properties O 
. O 
It O 
has O 
been O 
reported O 
to O 
have O 
beneficial O 
effects O 
in O 
experimental O 
colitis O 
. O 
This O 
study O 
explored O 
whether O 
curcumin B-TRIVIAL 
improves O 
colonic O 
inflammation O 
in O 
a O 
rat O 
colitis O 
model O 
through O 
inhibition O 
of O 
the O 
TLR4 O 
/ O 
NF-κB O 
signaling O 
pathway O 
and O 
IL-27 O 
expression O 
. O 
After O 
induction O 
of O 
colitis O 
with O 
2,4,6-trinitrobenzene B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
rats O 
were O 
intragastrically O 
administered O 
with O 
curcumin B-TRIVIAL 
or O 
sulfasalazine B-TRIVIAL 
daily O 
for O 
one O 
week O 
. O 
Rat O 
intestinal O 
mucosa O 
was O 
collected O 
for O 
evaluation O 
of O 
the O 
disease O 
activity O 
index O 
, O 
colonic O 
mucosa O 
damage O 
index O 
, O 
and O 
histological O 
score O 
. O 
Myeloperoxidase O 
activity O 
was O 
detected O 
by O 
immunohistochemistry O 
, O 
and O 
mRNA O 
and O 
protein O 
expression O 
levels O 
of O 
TLR4 O 
, O 
NF-κB O 
, O 
and O 
IL-27 O 
in O 
colonic O 
mucosa O 
were O 
detected O 
by O 
RT-PCR O 
and O 
Western O 
blot O 
. O 
Compared O 
with O 
the O 
untreated O 
colitis O 
group O 
, O 
the O 
curcumin B-TRIVIAL 
-treated O 
group O 
showed O 
significant O 
decreases O 
in O 
the O 
disease O 
activity O 
index O 
, O 
colonic O 
mucosa O 
damage O 
index O 
, O 
histological O 
score O 
, O 
myeloperoxidase O 
activity O 
, O 
and O 
expressions O 
of O 
NF-κB O 
mRNA O 
, O 
IL-27 O 
mRNA O 
, O 
TLR4 O 
protein O 
, O 
NF-κB O 
p65 O 
protein O 
, O 
and O 
IL-27 O 
p28 O 
protein O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
TLR4 O 
mRNA O 
expression O 
did O 
not O 
differ O 
between O 
groups O 
. O 
Disease O 
activity O 
index O 
decreased O 
more O 
rapidly O 
in O 
the O 
curcumin B-TRIVIAL 
-treated O 
group O 
than O 
in O 
the O 
sulfasalazine B-TRIVIAL 
-treated O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
There O 
was O 
no O 
significant O 
difference O 
in O 
TLR4 O 
, O 
NF-κB O 
, O 
and O 
IL-27 O 
mRNA O 
and O 
proteins O 
between O 
curcumin B-TRIVIAL 
-treated O 
and O 
sulfasalazine B-TRIVIAL 
-treated O 
groups O 
. O 
Curcumin B-TRIVIAL 
shows O 
significant O 
therapeutic O 
effects O 
on O 
2,4,6-trinitrobenzene B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
colitis O 
that O 
are O 
comparable O 
to O 
sulfasalazine B-TRIVIAL 
. O 
The O 
anti-inflammatory O 
actions O 
of O 
curcumin B-TRIVIAL 
on O 
colitis O 
may O 
involve O 
inhibition O 
of O 
the O 
TLR4 O 
/ O 
NF-κB O 
signaling O 
pathway O 
and O 
of O 
IL-27 O 
expression O 
. O 

lightweight O 
and O 
strong O 
porous O 
cellulose O 
material O 
has O 
been O 
prepared O 
by O 
drying O 
aqueous O 
foams O 
stabilized O 
with O 
surface O 
- O 
modified O 
nanofibrillated O 
cellulose O 
( O 
NFC O 
) O 
. O 
This O 
material O 
differs O 
from O 
other O 
dry O 
, O 
particle O 
stabilized O 
foams O 
in O 
that O 
renewable O 
cellulose O 
is O 
used O 
as O 
stabilizing O 
particles O 
. O 
Confocal O 
microscopy O 
and O 
high O 
speed O 
video O 
imaging O 
show O 
that O 
the O 
octylamine B-SYSTEMATIC 
-coated O 
, O 
rod O 
- O 
shaped O 
NFC O 
nanoparticles O 
residing O 
at O 
the O 
air O 
- O 
liquid O 
interface O 
prevent O 
the O 
air O 
bubbles O 
from O 
collapsing O 
or O 
coalescing O 
. O 
Stable O 
wet O 
foams O 
can O 
be O 
achieved O 
at O 
solids O 
content O 
around O 
1% O 
by O 
weight O 
. O 
Careful O 
removal O 
of O 
the O 
water O 
results O 
in O 
a O 
cellulose O 
- O 
based O 
material O 
with O 
a O 
porosity O 
of O 
98% O 
and O 
a O 
density O 
of O 
30 O 
mg O 
cm(-3) O 
. O 
These O 
porous O 
cellulose O 
materials O 
have O 
a O 
higher O 
Young's O 
modulus O 
than O 
porous O 
cellulose O 
materials O 
made O 
from O 
freeze O 
- O 
drying O 
, O 
at O 
comparable O 
densities O 
, O 
and O 
have O 
a O 
compressive O 
energy O 
absorption O 
of O 
56 O 
kJ O 
m(-3) O 
at O 
80% O 
strain O 
. O 
Measurement O 
with O 
the O 
aid O 
of O 
an O 
autoporosimeter O 
revealed O 
that O 
most O 
pores O 
are O 
in O 
the O 
range O 
of O 
300 O 
to O 
500 O 
μm O 
. O 

synthesis O 
and O 
evaluation O 
of O 
vinblastine B-TRIVIAL 
analogues O 
containing O 
systematic O 
deep O 
- O 
seated O 
modifications O 
in O 
the O 
vindoline B-TRIVIAL 
subunit O 
ring O 
system O 
: O 
core O 
redesign O 
. O 

total O 
synthesis O 
of O 
a O 
systematic O 
series O 
of O 
vinblastine B-TRIVIAL 
analogues O 
that O 
contain O 
deep O 
- O 
seated O 
structural O 
modifications O 
to O 
the O 
core O 
ring O 
system O 
of O 
the O 
lower O 
vindoline B-TRIVIAL 
subunit O 
is O 
described O 
. O 
Complementary O 
to O 
the O 
vindoline B-TRIVIAL 
6,5 O 
DE O 
ring O 
system O 
, O 
compounds O 
with O 
5,5 O 
, O 
6,6 O 
, O 
and O 
the O 
reversed O 
5,6 O 
membered O 
DE O 
ring O 
systems O 
were O 
prepared O 
. O 
Both O 
the O 
natural O 
cis O 
and O 
unnatural O 
trans O 
6,6-membered O 
ring O 
systems O 
proved O 
accessible O 
, O 
with O 
the O 
latter O 
representing O 
a O 
surprisingly O 
effective O 
class O 
for O 
analogue O 
design O 
. O 
Following O 
Fe B-FORMULA 
(III) I-FORMULA 
-promoted O 
coupling O 
with O 
catharanthine B-TRIVIAL 
and O 
in O 
situ O 
oxidation O 
to O 
provide O 
the O 
corresponding O 
vinblastine B-TRIVIAL 
analogues O 
, O 
their O 
evaluation O 
provided O 
unanticipated O 
insights O 
into O 
how O 
the O 
structure O 
of O 
the O 
vindoline B-TRIVIAL 
subunit O 
contributes O 
to O 
activity O 
. O 
Two O 
potent O 
analogues O 
( O 
81 O 
and O 
44 O 
) O 
possessing O 
two O 
different O 
unprecedented O 
modifications O 
to O 
the O 
vindoline B-TRIVIAL 
subunit O 
core O 
architecture O 
were O 
discovered O 
that O 
matched O 
the O 
potency O 
of O 
the O 
comparison O 
natural O 
products O 
and O 
both O 
lack O 
the O 
6,7-double O 
bond O 
whose O 
removal O 
in O 
vinblastine B-TRIVIAL 
leads O 
to O 
a O 
100-fold O 
drop O 
in O 
activity O 
. O 

of O 
4-Hydroxy-1-(3-pyridyl)-1-butanone B-SYSTEMATIC 
( O 
HPB B-ABBREVIATION 
)-Releasing O 
DNA O 
Adducts O 
in O 
Human O 
Exfoliated O 
Oral O 
Mucosa O 
Cells O 
by O 
Liquid O 
Chromatography-Electrospray O 
Ionization-Tandem O 
Mass O 
Spectrometry O 
. O 

of O 
DNA O 
adducts O 
could O 
provide O 
critical O 
information O 
on O 
the O 
relationship O 
between O 
exposure O 
to O 
tobacco O 
smoke O 
and O 
cancer O 
risk O 
in O 
smokers O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
a O 
robust O 
and O 
sensitive O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
method O 
for O 
the O 
analysis O 
of O 
4-hydroxy-1-(3-pyridyl)-1-butanone B-SYSTEMATIC 
( O 
HPB B-ABBREVIATION 
)-releasing O 
DNA O 
adducts O 
in O 
human O 
oral O 
cells O 
, O 
a O 
noninvasive O 
source O 
of O 
DNA O 
for O 
biomarker O 
studies O 
. O 
Isolated O 
DNA O 
undergoes O 
acid O 
hydrolysis O 
, O 
after O 
which O 
samples O 
are O 
purified O 
by O 
solid O 
- O 
phase O 
extraction O 
and O 
analyzed O 
by O 
LC-ESI-MS O 
/ O 
MS O 
. O 
The O 
developed O 
method O 
was O 
applied O 
to O 
the O 
analysis O 
of O 
samples O 
obtained O 
via O 
collection O 
with O 
a O 
commercial O 
mouthwash O 
from O 
30 O 
smokers O 
and O 
15 O 
nonsmokers O 
. O 
In O 
smokers O 
, O 
the O 
levels O 
of O 
HPB B-ABBREVIATION 
-releasing O 
DNA O 
adducts O 
averaged O 
12 O 
pmol O 
HPB B-ABBREVIATION 
/ O 
mg O 
DNA O 
( O 
detected O 
in O 
20 O 
out O 
of O 
28 O 
samples O 
with O 
quantifiable O 
DNA O 
yield O 
) O 
, O 
and O 
in O 
nonsmokers O 
, O 
the O 
levels O 
of O 
adducts O 
averaged O 
0.23 O 
pmol O 
/ O 
mg O 
DNA O 
( O 
detected O 
in O 
3 O 
out O 
of O 
15 O 
samples O 
) O 
. O 
For O 
the O 
30 O 
smoking O 
subjects O 
, O 
matching O 
buccal O 
brushings O 
were O 
also O 
analyzed O 
, O 
and O 
HPB B-ABBREVIATION 
-releasing O 
DNA O 
adducts O 
were O 
detected O 
in O 
24 O 
out O 
of O 
27 O 
samples O 
with O 
quantifiable O 
DNA O 
yield O 
, O 
averaging O 
44.7 O 
pmol O 
HPB B-ABBREVIATION 
/ O 
mg O 
DNA O 
. O 
The O 
levels O 
of O 
adducts O 
in O 
buccal O 
brushings O 
correlated O 
with O 
those O 
in O 
mouthwash O 
samples O 
of O 
smokers O 
( O 
R O 
= O 
0.73 O 
, O 
p O 
< O 
0.0001 O 
) O 
. O 
Potentially O 
, O 
the O 
method O 
can O 
be O 
applied O 
in O 
studies O 
of O 
individual O 
susceptibility O 
to O 
tobacco O 
- O 
induced O 
cancers O 
in O 
humans O 
. O 

-linker- O 
glucono B-TRIVIAL 
gelators O 
. O 
Correlations O 
of O 
gel O 
properties O 
with O 
gelator O 
structures O 
and O 
characterization O 
of O 
solvent O 
effects O 
. O 

series O 
of O 
glucono B-TRIVIAL 
-appended O 
1-pyrenesulfonyl B-SYSTEMATIC 
derivatives O 
containing O 
α,ω-diaminoalkane B-FAMILY 
spacers O 
( O 
Pn O 
, O 
where O 
n O 
, O 
the O 
number O 
of O 
methylene B-SYSTEMATIC 
units O 
separating O 
the O 
amino B-FAMILY 
groups O 
, O 
is O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
6 O 
, O 
7 O 
, O 
and O 
8 O 
) O 
have O 
been O 
prepared O 
. O 
Careful O 
analyses O 
of O 
correlations O 
between O 
the O 
structures O 
of O 
these O 
molecules O 
and O 
their O 
gels O 
have O 
provided O 
important O 
insights O 
into O 
the O 
factors O 
responsible O 
for O 
one O 
- O 
dimensional O 
aggregation O 
of O 
small O 
molecules O 
containing O 
both O 
lipophilic O 
and O 
hydrophilic O 
parts O 
. O 
The O 
gelation O 
behavior O 
has O 
been O 
examined O 
in O 
30 O 
liquids O 
of O 
diverse O 
structure O 
and O 
polarity O 
, O 
and O 
the O 
properties O 
of O 
their O 
gels O 
and O 
the O 
gelation O 
mechanisms O 
have O 
been O 
investigated O 
using O 
a O 
variety O 
of O 
techniques O 
. O 
Possible O 
reasons O 
are O 
discussed O 
regarding O 
why O 
the O 
Pn O 
are O 
better O 
gelators O 
than O 
the O 
corresponding O 
naphthyl B-SYSTEMATIC 
analogues O 
( O 
Nn O 
) O 
which O 
had O 
been O 
investigated O 
previously O 
. O 
P2 O 
and O 
P3 O 
are O 
ambidextrous O 
gelators O 
( O 
i.e O 
. O 
, O 
they O 
gelate O 
both O 
water O 
and O 
some O 
organic O 
liquids O 
) O 
, O 
and O 
P4-P8 O 
gelate O 
some O 
organic O 
liquids O 
which O 
are O 
protic O 
and O 
aprotic O 
, O 
but O 
not O 
water O 
. O 
In O 
at O 
least O 
one O 
of O 
the O 
liquids O 
examined O 
, O 
P3 O 
, O 
P4 O 
, O 
P6 O 
, O 
P7 O 
, O 
and O 
P8 O 
form O 
gels O 
at O 
less O 
than O 
1 O 
w O 
/ O 
v O 
% O 
concentrations O 
, O 
and O 
some O 
of O 
the O 
gels O 
in O 
1-decanol B-SYSTEMATIC 
are O 
thixotropic O 
. O 
Analyses O 
of O 
the O 
gelation O 
abilities O 
using O 
Hansen O 
solubility O 
parameters O 
yield O 
both O 
qualitative O 
and O 
quantitative O 
insights O 
into O 
the O 
role O 
of O 
liquid O 
- O 
gelator O 
interactions O 
. O 
For O 
example O 
, O 
the O 
critical O 
gelation O 
concentrations O 
increase O 
generally O 
with O 
increasing O 
polar O 
and O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
between O 
the O 
gelators O 
and O 
their O 
liquid O 
components O 
. O 
As O 
revealed O 
by O 
FT-IR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
UV-vis O 
, O 
and O 
fluorescence O 
spectra O 
, O 
hydrogen B-SYSTEMATIC 
-bonding O 
between O 
glucono B-TRIVIAL 
units O 
and O 
π-π O 
stacking O 
between O 
pyrenyl B-SYSTEMATIC 
groups O 
are O 
important O 
in O 
the O 
formation O 
and O 
maintenance O 
of O 
the O 
gel O 
networks O 
. O 
The O 
results O 
from O 
this O 
study O 
, O 
especially O 
those O 
relating O 
the O 
aggregation O 
modes O 
and O 
liquid O 
properties O 
, O 
offer O 
insights O 
for O 
the O 
design O 
of O 
new O 
surfactant O 
- O 
containing O 
low O 
- O 
molecular O 
- O 
mass O 
gelators O 
with O 
predefined O 
gelating O 
abilities O 
. O 

withanolides B-FAMILY 
from O 
Datura O 
wrightii O 
. O 

new O 
withanolide B-TRIVIAL 
, O 
named O 
withawrightolide B-TRIVIAL 
( O 
1 O 
) O 
, O 
and O 
four O 
known O 
withanolides B-FAMILY 
( O 
2-5 O 
) O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Datura O 
wrightii O 
. O 
The O 
structure O 
of O 
compound O 
1 O 
was O 
elucidated O 
through O 
2D O 
NMR O 
and O 
other O 
spectroscopic O 
techniques O 
. O 
In O 
addition O 
, O 
the O 
structure O 
of O 
withametelin B-TRIVIAL 
L I-TRIVIAL 
( O 
2 O 
) O 
was O 
confirmed O 
by O 
X-ray O 
crystallographic O 
analysis O 
. O 
Using O 
MTS B-ABBREVIATION 
viability O 
assays O 
, O 
withanolides B-MULTIPLE 
1-5 I-MULTIPLE 
showed O 
antiproliferative O 
activities O 
against O 
human O 
glioblastoma O 
( O 
U251 O 
and O 
U87 O 
) O 
, O 
head O 
and O 
neck O 
squamous O 
cell O 
carcinoma O 
( O 
MDA-1986 O 
) O 
, O 
and O 
normal O 
fetal O 
lung O 
fibroblast O 
( O 
MRC-5 O 
) O 
cells O 
with O 
IC50 O 
values O 
in O 
the O 
range O 
between O 
0.56 O 
and O 
5.6 O 
μM O 
. O 

discovery O 
of O 
fused O 
oxadiazepines B-FAMILY 
as O 
gamma O 
secretase O 
modulators O 
for O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 

an O 
attempt O 
to O 
further O 
improve O 
overall O 
profiles O 
of O 
the O 
oxadiazine B-FAMILY 
series O 
of O 
GSMs O 
, O 
in O 
particular O 
the O 
hERG O 
activity O 
, O 
conformational O 
modifications O 
of O 
the O 
core O 
structure O 
resulted O 
in O 
the O 
identification O 
of O 
fused O 
oxadiazepines B-FAMILY 
such O 
as O 
7i O 
which O 
had O 
an O 
improved O 
hERG O 
inhibition O 
profile O 
and O 
was O 
a O 
highly O 
efficacious O 
GSM O 
in O 
vitro O 
and O 
in O 
vivo O 
in O 
rats O 
. O 
These O 
SAR O 
explorations O 
offer O 
opportunities O 
to O 
identify O 
potential O 
drugs O 
to O 
treat O 
Alzheimer's O 
disease O 
. O 

functions O 
of O 
human O 
RECQ O 
helicases O 
WRN O 
and O 
BLM O 
in O 
replication O 
fork O 
recovery O 
and O 
progression O 
after O 
hydroxyurea B-SYSTEMATIC 
-induced O 
stalling O 
. O 

WRN O 
and O 
BLM O 
genes O 
are O 
members O 
of O 
the O 
conserved O 
RECQ O 
helicase O 
family O 
. O 
Mutations O 
in O 
these O 
genes O 
are O 
associated O 
with O 
Werner O 
and O 
Bloom O 
syndromes O 
. O 
WRN O 
and O 
BLM O 
proteins O 
are O 
implicated O 
in O 
DNA O 
replication O 
, O 
recombination O 
, O 
repair O 
, O 
telomere O 
maintenance O 
, O 
and O 
transcription O 
. O 
Using O 
microfluidics O 
- O 
assisted O 
display O 
of O 
DNA O 
for O 
replication O 
track O 
analysis O 
( O 
ma-RTA O 
) O 
, O 
we O 
show O 
that O 
WRN O 
and O 
BLM O 
contribute O 
additively O 
to O 
normal O 
replication O 
fork O 
progression O 
, O 
and O 
non-additively O 
, O 
in O 
a O 
RAD51-dependent O 
pathway O 
, O 
to O 
resumption O 
of O 
replication O 
after O 
arrest O 
by O 
hydroxyurea B-SYSTEMATIC 
( O 
HU O 
) O 
, O 
a O 
replication O 
- O 
stalling O 
drug O 
. O 
WRN O 
but O 
not O 
BLM O 
is O 
required O 
to O 
support O 
fork O 
progression O 
after O 
HU O 
. O 
Resumption O 
of O 
replication O 
by O 
forks O 
may O 
be O 
necessary O 
but O 
is O 
not O 
sufficient O 
for O 
timely O 
completion O 
of O 
the O 
cell O 
cycle O 
after O 
HU O 
arrest O 
, O 
as O 
depletion O 
of O 
WRN O 
or O 
BLM O 
compromises O 
fork O 
recovery O 
to O 
a O 
similar O 
degree O 
, O 
but O 
only O 
BLM O 
depletion O 
leads O 
to O 
extensive O 
delay O 
of O 
cell O 
division O 
after O 
HU O 
, O 
as O 
well O 
as O 
more O 
pronounced O 
chromatin O 
bridging O 
. O 
Finally O 
, O 
we O 
show O 
that O 
recovery O 
from O 
HU O 
includes O 
apparent O 
removal O 
of O 
some O 
of O 
the O 
DNA O 
that O 
was O 
synthesized O 
immediately O 
after O 
release O 
from O 
HU O 
, O 
a O 
novel O 
phenomenon O 
that O 
we O 
refer O 
to O 
as O 
nascent O 
strand O 
processing O 
, O 
NSP O 
. O 

genistein B-TRIVIAL 
protects O 
against O 
endothelial O 
barrier O 
dysfunction O 
in O 
vascular O 
endothelial O 
cells O 
through O 
PKA O 
- O 
mediated O 
suppression O 
of O 
RhoA O 
signaling O 
. O 

soy O 
- O 
derived O 
phytoestrogen O 
genistein B-TRIVIAL 
has O 
received O 
attention O 
for O 
its O 
potential O 
to O 
improve O 
vascular O 
function O 
, O 
but O 
its O 
mechanism O 
remains O 
unclear O 
. O 
Here O 
, O 
we O 
report O 
that O 
genistein B-TRIVIAL 
at O 
physiologically O 
relevant O 
concentrations O 
( O 
0.1-10 O 
μM O 
) O 
significantly O 
inhibited O 
thrombin O 
- O 
induced O 
increase O 
in O 
endothelial O 
monolayer O 
permeability O 
. O 
Genistein B-TRIVIAL 
also O 
reduced O 
the O 
formation O 
of O 
stress O 
fibers O 
by O 
thrombin O 
and O 
suppressed O 
thrombin O 
- O 
induced O 
phosphorylation O 
of O 
myosin O 
light O 
chain O 
( O 
MLC O 
) O 
on O 
Ser B-FORMULA 
(19)/ O 
Thr B-FORMULA 
( O 
18 O 
) O 
in O 
endothelial O 
cells O 
( O 
ECs O 
) O 
. O 
Genistein B-TRIVIAL 
had O 
no O 
effect O 
on O 
resting O 
intracellular O 
[ O 
Ca(2+) B-FORMULA 
] O 
or O 
thrombin O 
- O 
induced O 
increase O 
in O 
Ca(2+) B-FORMULA 
mobilization O 
. O 
Addition O 
of O 
the O 
inhibitors O 
of O 
endothelial O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
or O 
estrogen B-FAMILY 
receptor O 
did O 
not O 
alter O 
the O 
protective O 
effect O 
of O 
genistein B-TRIVIAL 
. O 
RhoA O 
is O 
a O 
small O 
GTPase O 
that O 
plays O 
an O 
important O 
role O 
in O 
actin O 
- O 
myosin O 
contraction O 
and O 
endothelial O 
barrier O 
dysfunction O 
. O 
RhoA O 
inhibitor O 
blocked O 
the O 
protective O 
effect O 
of O 
genistein B-TRIVIAL 
on O 
endothelial O 
permeability O 
and O 
also O 
ablated O 
thrombin O 
- O 
induced O 
MLC-phosphorylation O 
in O 
ECs O 
. O 
Inhibition O 
of O 
PKA O 
significantly O 
attenuated O 
the O 
effect O 
of O 
genistein B-TRIVIAL 
on O 
thrombin O 
- O 
induced O 
EC O 
permeability O 
, O 
MLC O 
phosphorylation O 
, O 
and O 
RhoA O 
membrane O 
translocation O 
in O 
ECs O 
. O 
Furthermore O 
, O 
thrombin O 
diminished O 
cAMP B-ABBREVIATION 
production O 
in O 
ECs O 
, O 
which O 
were O 
prevented O 
by O 
treatment O 
with O 
genistein B-TRIVIAL 
. O 
These O 
findings O 
demonstrated O 
that O 
genistein B-TRIVIAL 
improves O 
thrombin O 
- O 
induced O 
endothelial O 
barrier O 
dysfunction O 
in O 
ECs O 
through O 
PKA O 
- O 
mediated O 
suppression O 
of O 
RhoA O 
signaling O 
. O 

green O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
? O 
From O 
synthesis O 
via O 
(eco-)toxicology O 
to O 
scenario O 
modelling O 
. O 

oxide I-SYSTEMATIC 
nanoparticles O 
( O 
IONP O 
) O 
are O 
currently O 
being O 
studied O 
as O 
green O 
magnet O 
resonance O 
imaging O 
( O 
MRI O 
) O 
contrast O 
agents O 
. O 
They O 
are O 
also O 
used O 
in O 
huge O 
quantities O 
for O 
environmental O 
remediation O 
and O 
water O 
treatment O 
purposes O 
, O 
although O 
very O 
little O 
is O 
known O 
on O 
the O 
consequences O 
of O 
such O 
applications O 
for O 
organisms O 
and O 
ecosystems O 
. O 
In O 
order O 
to O 
address O 
these O 
questions O 
, O 
we O 
synthesised O 
polyvinylpyrrolidone B-SYSTEMATIC 
-coated O 
IONP O 
, O 
characterised O 
the O 
particle O 
dispersion O 
in O 
various O 
media O 
and O 
investigated O 
the O 
consequences O 
of O 
an O 
IONP O 
exposure O 
using O 
an O 
array O 
of O 
biochemical O 
and O 
biological O 
assays O 
. O 
Several O 
theoretical O 
approaches O 
complemented O 
the O 
measurements O 
. O 
In O 
aqueous O 
dispersion O 
IONP O 
had O 
an O 
average O 
hydrodynamic O 
diameter O 
of O 
25 O 
nm O 
and O 
were O 
stable O 
over O 
six O 
days O 
in O 
most O 
test O 
media O 
, O 
which O 
could O 
also O 
be O 
predicted O 
by O 
stability O 
modelling O 
. O 
The O 
particles O 
were O 
tested O 
in O 
concentrations O 
of O 
up O 
to O 
100 O 
mg O 
Fe B-FORMULA 
per O 
L O 
. O 
The O 
activity O 
of O 
the O 
enzymes O 
glutathione B-TRIVIAL 
reductase O 
and O 
acetylcholine B-SYSTEMATIC 
esterase O 
was O 
not O 
affected O 
, O 
nor O 
were O 
proliferation O 
, O 
morphology O 
or O 
vitality O 
of O 
mammalian O 
OLN-93 O 
cells O 
although O 
exposure O 
of O 
the O 
cells O 
to O 
100 O 
mg O 
Fe B-FORMULA 
per O 
L O 
increased O 
the O 
cellular O 
iron B-SYSTEMATIC 
content O 
substantially O 
. O 
Only O 
at O 
this O 
concentration O 
, O 
acute O 
toxicity O 
tests O 
with O 
the O 
freshwater O 
flea O 
Daphnia O 
magna O 
revealed O 
slightly O 
, O 
yet O 
insignificantly O 
increased O 
mortality O 
. O 
Two O 
fundamentally O 
different O 
bacterial O 
assays O 
, O 
anaerobic O 
activated O 
sludge O 
bacteria O 
inhibition O 
and O 
a O 
modified O 
sediment O 
contact O 
test O 
with O 
Arthrobacter O 
globiformis O 
, O 
both O 
rendered O 
results O 
contrary O 
to O 
the O 
other O 
assays O 
: O 
at O 
the O 
lowest O 
test O 
concentration O 
( O 
1 O 
mg O 
Fe O 
per O 
L O 
) O 
, O 
IONP O 
caused O 
a O 
pronounced O 
inhibition O 
whereas O 
higher O 
concentrations O 
were O 
not O 
effective O 
or O 
even O 
stimulating O 
. O 
Preliminary O 
and O 
prospective O 
risk O 
assessment O 
was O 
exemplified O 
by O 
comparing O 
the O 
application O 
of O 
IONP O 
with O 
gadolinium B-SYSTEMATIC 
-based O 
nanoparticles O 
as O 
MRI O 
contrast O 
agents O 
. O 
Predicted O 
environmental O 
concentrations O 
were O 
modelled O 
in O 
two O 
different O 
scenarios O 
, O 
showing O 
that O 
IONP O 
could O 
reduce O 
the O 
environmental O 
exposure O 
of O 
toxic O 
Gd B-FORMULA 
-based O 
particles O 
by O 
more O 
than O 
50% O 
. O 
Application O 
of O 
the O 
Swiss O 
" O 
Precautionary O 
Matrix O 
for O 
Synthetic O 
Nanomaterials O 
" O 
rendered O 
a O 
low O 
precautionary O 
need O 
for O 
using O 
our O 
IONP O 
as O 
MRI O 
agents O 
and O 
a O 
higher O 
one O 
when O 
using O 
them O 
for O 
remediation O 
or O 
water O 
treatment O 
. O 
Since O 
IONP O 
and O 
( O 
considerably O 
more O 
reactive O 
) O 
zerovalent O 
iron B-SYSTEMATIC 
nanoparticles O 
are O 
being O 
used O 
in O 
huge O 
quantities O 
for O 
environmental O 
remediation O 
purposes O 
, O 
it O 
has O 
to O 
be O 
ascertained O 
that O 
these O 
particles O 
pose O 
no O 
risk O 
to O 
either O 
human O 
health O 
or O 
to O 
the O 
environment O 
. O 

of O 
RNA O 
phosphodiester B-SYSTEMATIC 
bond O 
by O 
histidine B-TRIVIAL 
-containing O 
dipeptides B-FAMILY 
. O 

new O 
scenario O 
for O 
prebiotic O 
formation O 
of O 
nucleic O 
acid O 
oligomers O 
is O 
presented O 
. O 
Peptide O 
catalysis O 
is O 
applied O 
to O 
achieve O 
condensation O 
of O 
activated O 
RNA O 
monomers O 
into O 
short O 
RNA O 
chains O 
. O 
As O 
catalysts O 
, O 
L- B-FAMILY 
dipeptides I-FAMILY 
containing O 
a O 
histidine B-TRIVIAL 
residue O 
, O 
primarily O 
Ser-His B-FORMULA 
, O 
were O 
used O 
. O 
Reactions O 
were O 
carried O 
out O 
in O 
self O 
- O 
organised O 
environment O 
, O 
a O 
water O 
- O 
ice O 
eutectic O 
phase O 
, O 
with O 
low O 
concentrations O 
of O 
reactants O 
. O 
Incubation O 
periods O 
up O 
to O 
30 O 
days O 
resulted O 
in O 
the O 
formation O 
of O 
short O 
oligomers O 
of O 
RNA O 
. O 
During O 
the O 
oligomerisation O 
, O 
an O 
active O 
intermediate O 
( O 
dipeptide-mononucleotide B-FAMILY 
) O 
is O 
produced O 
, O 
which O 
is O 
the O 
reactive O 
species O 
. O 
Details O 
of O 
the O 
mechanism O 
and O 
kinetics O 
, O 
which O 
were O 
elucidated O 
with O 
a O 
set O 
of O 
control O 
experiments O 
, O 
further O 
establish O 
that O 
the O 
imidazole B-SYSTEMATIC 
side O 
chain O 
of O 
a O 
histidine B-TRIVIAL 
at O 
the O 
carboxyl B-SYSTEMATIC 
end O 
of O 
the O 
dipeptide B-FAMILY 
plays O 
a O 
crucial O 
role O 
in O 
the O 
catalysis O 
. O 
These O 
results O 
suggest O 
that O 
this O 
oligomerisation O 
catalysis O 
occurs O 
by O 
a O 
transamination O 
mechanism O 
. O 
Because O 
peptides O 
are O 
much O 
more O 
likely O 
products O 
of O 
spontaneous O 
condensation O 
than O 
nucleotide B-FAMILY 
chains O 
, O 
their O 
potential O 
as O 
catalysts O 
for O 
the O 
formation O 
of O 
RNA O 
is O 
interesting O 
from O 
the O 
origin O 
- O 
of O 
- O 
life O 
perspective O 
. O 
Finally O 
, O 
the O 
formation O 
of O 
the O 
dipeptide-mononucleotide B-FAMILY 
intermediate O 
and O 
its O 
significance O 
for O 
catalysis O 
might O 
also O 
be O 
viewed O 
as O 
the O 
tell O 
- O 
tale O 
signs O 
of O 
a O 
new O 
example O 
of O 
organocatalysis O 
. O 

and O 
stereochemical O 
studies O 
of O 
hydroxyanthraquinone B-SYSTEMATIC 
derivatives O 
from O 
the O 
endophytic O 
fungus O 
Coniothyrium O 
sp O 
. O 

known O 
hydroxyanthraquinones B-FAMILY 
( O 
1-4 O 
) O 
together O 
with O 
four O 
new O 
derivatives O 
having O 
a O 
tetralone B-TRIVIAL 
moiety O 
, O 
namely O 
coniothyrinones B-MULTIPLE 
A-D I-MULTIPLE 
( O 
5-8 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
culture O 
of O 
Coniothyrium O 
sp O 
. O 
, O 
an O 
endophytic O 
fungus O 
isolated O 
from O 
Salsola O 
oppostifolia O 
from O 
Gomera O 
in O 
the O 
Canary O 
Islands O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
detailed O 
spectroscopic O 
analysis O 
and O 
comparison O 
with O 
reported O 
data O 
. O 
The O 
absolute O 
configurations O 
of O 
coniothyrinones B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
5 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
( I-MULTIPLE 
6 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
( O 
8 O 
) O 
were O 
determined O 
by O 
TDDFT O 
calculations O 
of O 
CD O 
spectra O 
, O 
allowing O 
the O 
determination O 
of O 
the O 
absolute O 
configuration O 
of O 
coniothyrinone B-TRIVIAL 
C I-TRIVIAL 
( O 
7 O 
) O 
as O 
well O 
. O 
Coniothyrinones B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
5 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
( I-MULTIPLE 
6 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
( O 
8 O 
) O 
could O 
be O 
used O 
as O 
ECD O 
reference O 
compounds O 
in O 
the O 
determination O 
of O 
absolute O 
configuration O 
for O 
related O 
tetralone B-TRIVIAL 
derivatives O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
anthraquinones B-FAMILY 
and O 
derivatives O 
from O 
an O 
isolate O 
of O 
the O 
genus O 
Coniothyrium O 
sp O 
. O 
These O 
compounds O 
showed O 
inhibitory O 
effects O 
against O 
the O 
fungus O 
Microbotryum O 
violaceum O 
, O 
the O 
alga O 
Chlorella O 
fusca O 
, O 
and O 
the O 
bacteria O 
Escherichia O 
coli O 
and O 
Bacillus O 
megaterium O 
. O 

carbide I-SYSTEMATIC 
nanoparticles O 
as O 
efficient O 
cocatalysts O 
for O 
photocatalytic O 
overall O 
water O 
splitting O 
. O 

carbide I-SYSTEMATIC 
exhibits O 
platinum B-SYSTEMATIC 
-like O 
behavior O 
, O 
which O 
makes O 
it O 
an O 
interesting O 
potential O 
substitute O 
for O 
noble O 
metals O 
in O 
catalytic O 
applications O 
. O 
Tungsten B-SYSTEMATIC 
carbide I-SYSTEMATIC 
nanocrystals O 
( O 
≈5 O 
nm O 
) O 
are O 
directly O 
synthesized O 
through O 
the O 
reaction O 
of O 
tungsten B-SYSTEMATIC 
precursors O 
with O 
mesoporous O 
graphitic O 
C(3)N(4) B-FORMULA 
( O 
mpg- O 
C(3)N(4) B-FORMULA 
) O 
as O 
the O 
reactive O 
template O 
in O 
a O 
flow O 
of O 
inert O 
gas O 
at O 
high O 
temperatures O 
. O 
Systematic O 
experiments O 
that O 
vary O 
the O 
precursor O 
compositions O 
and O 
temperatures O 
used O 
in O 
the O 
synthesis O 
selectively O 
generate O 
different O 
compositions O 
and O 
structures O 
for O 
the O 
final O 
nanocarbide O 
( O 
W(2)C B-FORMULA 
or O 
WC B-FORMULA 
) O 
products O 
. O 
Electrochemical O 
measurements O 
demonstrate O 
that O 
the O 
WC B-FORMULA 
phase O 
with O 
a O 
high O 
surface O 
area O 
exhibits O 
both O 
high O 
activity O 
and O 
stability O 
in O 
hydrogen B-SYSTEMATIC 
evolution O 
over O 
a O 
wide O 
pH O 
range O 
. O 
The O 
WC B-FORMULA 
sample O 
also O 
shows O 
excellent O 
hydrogen B-SYSTEMATIC 
oxidation O 
activity O 
, O 
whereas O 
its O 
activity O 
in O 
oxygen B-SYSTEMATIC 
reduction O 
is O 
poor O 
. O 
These O 
tungsten B-FAMILY 
carbides I-FAMILY 
are O 
successful O 
cocatalysts O 
for O 
overall O 
water O 
splitting O 
and O 
give O 
H(2) B-FORMULA 
and O 
O(2) B-FORMULA 
in O 
a O 
stoichiometric O 
ratio O 
from O 
H(2)O B-FORMULA 
decomposition O 
when O 
supported O 
on O 
a O 
Na B-FORMULA 
-doped O 
SrTiO(3) B-FORMULA 
photocatalyst O 
. O 
Herein O 
, O 
we O 
present O 
tungsten B-SYSTEMATIC 
carbide I-SYSTEMATIC 
( O 
on O 
a O 
small O 
scale O 
) O 
as O 
a O 
promising O 
and O 
durable O 
catalyst O 
substitute O 
for O 
platinum B-SYSTEMATIC 
and O 
other O 
scarce O 
noble O 
- O 
metal O 
catalysts O 
in O 
catalytic O 
reaction O 
systems O 
used O 
for O 
renewable O 
energy O 
generation O 
. O 

leaf O 
extract O 
protects O 
against O 
liver O 
injury O 
induced O 
by O 
methionine B-TRIVIAL 
- O 
and O 
choline B-FAMILY 
-deficient O 
diet O 
in O 
mice O 
. O 

investigated O 
the O 
hepatoprotective O 
effects O 
of O 
the O 
extract O 
of O 
dandelion O 
leaves O 
( O 
EDL O 
) O 
on O 
a O 
murine O 
model O 
of O 
methionine B-TRIVIAL 
- O 
and O 
choline B-FAMILY 
-deficient O 
( O 
MCD O 
) O 
diet O 
- O 
induced O 
nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
. O 
C57BL O 
/ O 
6 O 
mice O 
were O 
fed O 
for O 
4 O 
weeks O 
with O 
one O 
of O 
the O 
following O 
diets O 
: O 
control O 
diet O 
( O 
Cont O 
) O 
, O 
MCD O 
diet O 
( O 
MCD O 
) O 
, O 
MCD O 
diet O 
supplemented O 
with O 
EDL O 
at O 
200 O 
mg O 
/ O 
kg O 
body O 
weight·daily O 
( O 
MCD O 
+ O 
D200 O 
) O 
, O 
and O 
MCD O 
diet O 
supplemented O 
with O 
EDL O 
at O 
500 O 
mg O 
/ O 
kg O 
body O 
weight·daily O 
( O 
MCD O 
+ O 
D500 O 
) O 
. O 
Hepatic O 
function O 
was O 
assessed O 
by O 
evaluating O 
the O 
following O 
parameters O 
: O 
liver O 
histology O 
; O 
plasma O 
levels O 
of O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
triglyceride B-FAMILY 
( O 
TG O 
) O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
and O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
; O 
expression O 
levels O 
of O 
TNF-α O 
and O 
IL-6 O 
; O 
and O 
levels O 
of O 
caspase-3 O 
and O 
pJNK O 
/ O 
JNK O 
protein O 
. O 
Histopathological O 
evaluations O 
revealed O 
that O 
addition O 
of O 
EDL O 
to O 
the O 
MCD O 
diet O 
dampens O 
the O 
severity O 
of O 
the O 
clinical O 
signs O 
of O 
NASH O 
. O 
Moreover O 
, O 
EDL O 
led O 
to O 
a O 
significant O 
decrease O 
in O 
the O 
serum O 
levels O 
of O 
ALT O 
, O 
hepatic O 
TG O 
, O 
and O 
MDA B-ABBREVIATION 
, O 
and O 
in O 
the O 
expression O 
levels O 
of O 
TNF-α O 
, O 
and O 
IL-6 O 
; O 
on O 
the O 
contrary O 
, O 
the O 
levels O 
of O 
reduced B-ABBREVIATION 
GSH I-ABBREVIATION 
increased O 
. O 
At O 
the O 
post O 
- O 
transcriptional O 
level O 
, O 
EDL O 
significantly O 
decreased O 
the O 
activation O 
of O 
procaspase-3 O 
to O 
active O 
caspase-3 O 
, O 
and O 
the O 
phosphorylation O 
of O 
JNK O 
. O 
These O 
results O 
suggest O 
that O 
the O 
beneficial O 
effects O 
of O 
EDL O 
on O 
NASH O 
are O 
mainly O 
due O 
to O 
its O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
. O 

ameliorates O 
oxidative O 
stress O 
in O 
type O 
2 O 
diabetic O 
Goto-Kakizaki O 
rats O 
. O 

, O 
we O 
showed O 
that O 
trigonelline B-TRIVIAL 
( O 
TRG B-ABBREVIATION 
) O 
exerts O 
antidiabetic O 
effects O 
in O 
type O 
2 O 
diabetic O 
Goto-Kakizaki O 
( O 
GK O 
) O 
rats O 
and O 
also O 
lowers O 
blood O 
and O 
liver O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
and O 
urinary O 
8-hydroxydeoxyguanosine B-SYSTEMATIC 
when O 
compared O 
with O 
those O 
levels O 
in O 
GK O 
control O 
rats O 
without O 
TRG O 
. O 
These O 
results O 
suggested O 
that O 
TRG B-ABBREVIATION 
also O 
mitigates O 
oxidative O 
stress O 
, O 
which O 
accelerates O 
diabetes O 
. O 
In O 
this O 
study O 
, O 
the O 
mechanisms O 
of O 
TRG B-ABBREVIATION 
prevention O 
of O 
oxidative O 
stress O 
were O 
determined O 
by O 
measuring O 
erythrocyte O 
and O 
liver O 
antioxidant O 
enzyme O 
activities O 
, O 
and O 
expressions O 
of O 
genes O 
associated O 
with O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
, O 
and O 
carbohydrate B-FAMILY 
and O 
lipid O 
metabolisms O 
by O 
DNA O 
microarray O 
. O 
Erythrocyte O 
and O 
liver O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
and O 
liver O 
catalase O 
activities O 
in O 
the O 
GK O 
rats O 
fed O 
with O 
TRG B-ABBREVIATION 
were O 
significantly O 
lower O 
than O 
those O 
of O 
the O 
GK O 
control O 
rats O 
. O 
TRG B-ABBREVIATION 
downregulated O 
the O 
gene O 
expressions O 
involved O 
with O 
NADPH B-ABBREVIATION 
oxidase O 
and O 
mitochondrial O 
electron O 
transfer O 
system O 
when O 
compared O 
with O 
those O 
of O 
the O 
GK O 
control O 
group O 
. O 
These O 
results O 
suggested O 
that O 
mitigation O 
of O 
diabetes O 
by O 
TRG B-ABBREVIATION 
is O 
mediated O 
by O 
its O 
ameliorating O 
effects O 
on O 
oxidative O 
stress O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
metabolic O 
effects O 
of O 
12-week O 
honey O 
consumption O 
on O 
patients O 
suffering O 
from O 
type O 
1 O 
diabetes O 
mellitus O 
( O 
DM O 
) O 
. O 
This O 
was O 
a O 
randomized O 
crossover O 
clinical O 
trial O 
done O 
in O 
the O 
National O 
Institute O 
for O 
Diabetes O 
and O 
Endocrinology O 
, O 
Cairo O 
, O 
Egypt O 
. O 
Twenty O 
patients O 
of O 
both O 
sexes O 
aged O 
4-18 O 
years O 
with O 
type O 
1 O 
DM O 
and O 
HbA1C O 
< O 
10% O 
participated O 
in O 
the O 
study O 
. O 
They O 
were O 
randomized O 
into O 
two O 
equal O 
groups O 
( O 
intervention O 
to O 
control O 
and O 
control O 
to O 
intervention O 
) O 
. O 
The O 
dietary O 
intervention O 
was O 
12-week O 
honey O 
consumption O 
in O 
a O 
dose O 
of O 
0.5 O 
mL O 
/ O 
kg O 
body O 
weight O 
per O 
day O 
. O 
The O 
main O 
outcome O 
measures O 
were O 
serum O 
glucose B-TRIVIAL 
, O 
lipids O 
, O 
and O 
C- O 
peptide O 
, O 
and O 
anthropometric O 
measurements O 
. O 
None O 
of O 
participants O 
were O 
lost O 
in O 
follow O 
- O 
up O 
. O 
The O 
intervention O 
resulted O 
in O 
significant O 
decreases O 
in O 
subscapular O 
skin O 
fold O 
thickness O 
( O 
SSFT O 
; O 
P=.002 O 
) O 
, O 
fasting O 
serum O 
glucose B-TRIVIAL 
( O 
FSG O 
; O 
P=.001 O 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
P=.0001 O 
) O 
, O 
serum O 
triglycerides B-FAMILY 
( O 
TG O 
; O 
P=.0001 O 
) O 
, O 
and O 
low O 
- O 
density O 
lipoprotein O 
( O 
P=.0009 O 
) O 
, O 
and O 
significant O 
increases O 
in O 
fasting O 
C- O 
peptide O 
( O 
FCP O 
; O 
P=.0004 O 
) O 
and O 
2-h O 
postprandial O 
C- O 
peptide O 
( O 
PCP O 
; O 
P=.002 O 
) O 
. O 
As O 
possible O 
long O 
- O 
term O 
effects O 
of O 
honey O 
after O 
its O 
withdrawal O 
, O 
statistically O 
significant O 
reductions O 
in O 
midarm O 
circumference O 
( O 
P=.000 O 
) O 
, O 
triceps O 
skin O 
fold O 
thickness O 
( O 
P=.006 O 
) O 
, O 
SSFT O 
( O 
P=.003 O 
) O 
, O 
FSG O 
( O 
P=.005 O 
) O 
, O 
2-h O 
postprandial O 
serum O 
glucose B-TRIVIAL 
( O 
P=.000 O 
) O 
, O 
TG O 
( O 
P=.003 O 
) O 
, O 
and O 
HbA1C O 
( O 
P=.043 O 
) O 
, O 
and O 
significant O 
increases O 
in O 
FCP O 
( O 
P=.002 O 
) O 
and O 
PCP O 
( O 
P=.003 O 
) O 
were O 
observed O 
. O 
This O 
small O 
clinical O 
trial O 
suggests O 
that O 
long O 
- O 
term O 
consumption O 
of O 
honey O 
might O 
have O 
positive O 
effects O 
on O 
the O 
metabolic O 
derangements O 
of O 
type O 
1 O 
DM O 
. O 

show O 
that O 
local O 
structural O 
variation O 
affects O 
the O 
rate O 
of O 
aging O 
in O 
nanostructured O 
polymer O 
solar O 
cells O 
by O 
comparing O 
time O 
- O 
resolved O 
electrostatic O 
force O 
microscopy O 
( O 
trEFM O 
) O 
and O 
conventional O 
device O 
measurements O 
on O 
model O 
polymer O 
blends O 
. O 
Specifically O 
, O 
we O 
study O 
photovoltaic O 
devices O 
made O 
from O 
1 O 
: O 
1 O 
blends O 
of O 
the O 
polyfluorene B-SYSTEMATIC 
copolymers O 
poly(9,9'-dioctylfluorene-co-bis-N,N'-(4-butylphenyl)-bis-N,N'-phenyl-1,4-phenylene B-SYSTEMATIC 
- I-SYSTEMATIC 
diamine I-SYSTEMATIC 
) O 
( O 
PFB B-ABBREVIATION 
) O 
and O 
poly(9,9'-dioctylfluorene B-SYSTEMATIC 
- I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
benzothiadiazole I-SYSTEMATIC 
) O 
( O 
F8BT B-ABBREVIATION 
) O 
. O 
We O 
photooxidize O 
these O 
films O 
in O 
situ O 
using O 
365 O 
, O 
405 O 
, O 
and O 
455 O 
nm O 
illumination O 
under O 
ambient O 
conditions O 
, O 
with O 
the O 
wavelengths O 
chosen O 
to O 
preferentially O 
excite O 
the O 
different O 
components O 
. O 
During O 
photooxidation O 
, O 
we O 
observe O 
a O 
faster O 
loss O 
of O 
photocurrent O 
generation O 
from O 
F8BT B-ABBREVIATION 
-rich O 
domains O 
, O 
leaving O 
the O 
PFB B-ABBREVIATION 
-rich O 
phases O 
to O 
show O 
higher O 
photoresponse O 
even O 
at O 
wavelengths O 
absorbed O 
predominantly O 
by O 
F8BT B-ABBREVIATION 
. O 
We O 
propose O 
that O 
this O 
effect O 
is O 
due O 
to O 
the O 
more O 
rapid O 
degradation O 
of O 
PFB B-ABBREVIATION 
hole O 
- O 
transport O 
pathways O 
in O 
the O 
F8BT B-ABBREVIATION 
-rich O 
regions O 
, O 
resulting O 
in O 
a O 
loss O 
of O 
percolation O 
pathways O 
for O 
hole O 
transport O 
in O 
the O 
F8BT B-ABBREVIATION 
-rich O 
phase O 
. O 

- O 
principles O 
prediction O 
of O 
the O 
effects O 
of O 
temperature O 
and O 
solvent O 
selection O 
on O 
the O 
dimerization O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

introduce O 
a O 
procedure O 
of O 
quantum O 
chemical O 
calculations O 
( O 
B3P86 O 
/ O 
6-31G** O 
) O 
to O 
study O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
dimerization O 
and O 
its O 
correlation O 
with O 
temperature O 
and O 
properties O 
of O 
the O 
solvent O 
. O 
Benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
chosen O 
as O 
a O 
model O 
system O 
for O 
studying O 
dimerization O 
via O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
Organic O 
solvents O 
are O 
simulated O 
using O 
the O 
self O 
- O 
consistent O 
reaction O 
field O 
( O 
SCRF O 
) O 
method O 
with O 
the O 
polarized O 
continuum O 
model O 
( O 
PCM O 
) O 
. O 
The O 
cyclic O 
dimer O 
is O 
the O 
most O 
stable O 
structure O 
both O 
in O 
gas O 
phase O 
and O 
solution O 
. O 
Dimer O 
mono- B-MULTIPLE 
and I-MULTIPLE 
dihydrates I-MULTIPLE 
could O 
be O 
found O 
in O 
the O 
gas O 
phase O 
if O 
acid O 
molecules O 
are O 
in O 
contact O 
with O 
water O 
vapor O 
. O 
However O 
, O 
the O 
formation O 
of O 
these O 
hydrated O 
conformers O 
is O 
very O 
limited O 
and O 
cyclic O 
dimer O 
is O 
the O 
principal O 
conformer O 
to O 
coexist O 
with O 
monomer O 
acid O 
in O 
solution O 
. O 
Solvation O 
of O 
the O 
cyclic O 
dimer O 
is O 
more O 
favorable O 
compared O 
to O 
other O 
complexes O 
, O 
partially O 
due O 
to O 
the O 
diminishing O 
of O 
hydrogen B-SYSTEMATIC 
bonding O 
capability O 
and O 
annihilation O 
of O 
dipole O 
moments O 
. O 
Solvents O 
have O 
a O 
strong O 
effect O 
on O 
inducing O 
dimer O 
dissociation O 
and O 
this O 
dependence O 
is O 
more O 
pronounced O 
at O 
low O 
dielectric O 
constants O 
. O 
By O 
accounting O 
for O 
selected O 
terms O 
in O 
the O 
total O 
free O 
energy O 
of O 
solvation O 
, O 
the O 
solvation O 
entropy O 
could O 
be O 
incorporated O 
to O 
predict O 
the O 
dimer O 
behavior O 
at O 
elevated O 
temperatures O 
. O 
The O 
temperature O 
dependence O 
of O 
benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
dimerization O 
obtained O 
by O 
this O 
technique O 
is O 
in O 
good O 
agreement O 
with O 
available O 
experimental O 
measurements O 
, O 
in O 
which O 
a O 
tendency O 
of O 
dimer O 
to O 
dissociate O 
is O 
observed O 
with O 
increased O 
temperatures O 
. O 
In O 
addition O 
, O 
dimer O 
breakup O 
is O 
more O 
sensitive O 
to O 
temperature O 
in O 
low O 
dielectric O 
environments O 
rather O 
than O 
in O 
solvents O 
with O 
a O 
higher O 
dielectric O 
constant O 
. O 

concept O 
for O 
the O 
implementation O 
of O 
a O 
single O 
cleavable O 
unit O 
at O 
tunable O 
position O 
in O 
functional O 
poly(ethylene B-FAMILY 
glycol)s I-FAMILY 
. O 

glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
with O 
acid O 
- O 
sensitive O 
moieties O 
gained O 
attention O 
particularly O 
for O 
various O 
biomedical O 
applications O 
, O 
such O 
as O 
the O 
covalent O 
attachment O 
of O 
PEG B-ABBREVIATION 
( O 
PEGylation O 
) O 
to O 
protein O 
therapeutics O 
, O 
the O 
synthesis O 
of O 
stealth O 
liposomes O 
, O 
and O 
polymeric O 
carriers O 
for O 
low O 
- O 
molecular O 
- O 
weight O 
drugs O 
. O 
Cleavable O 
PEGs B-ABBREVIATION 
are O 
favored O 
over O 
their O 
inert O 
analogues O 
because O 
of O 
superior O 
pharmacodynamic O 
and O 
/ O 
or O 
pharmacokinetic O 
properties O 
of O 
their O 
formulations O 
. O 
However O 
, O 
synthetic O 
routes O 
to O 
acetal B-SYSTEMATIC 
-containing O 
PEGs B-ABBREVIATION 
published O 
up O 
to O 
date O 
either O 
require O 
enormous O 
efforts O 
or O 
result O 
in O 
ill O 
- O 
defined O 
materials O 
with O 
a O 
lack O 
of O 
control O 
over O 
the O 
molecular O 
weight O 
. O 
Herein O 
, O 
we O 
describe O 
a O 
novel O 
methodology O 
to O 
implement O 
a O 
single O 
acetaldehyde B-SYSTEMATIC 
acetal I-SYSTEMATIC 
in O 
well O 
- O 
defined O 
(hetero)functional B-FAMILY 
poly(ethylene I-FAMILY 
glycol)s I-FAMILY 
with O 
total O 
control O 
over O 
its O 
position O 
. O 
To O 
underline O 
its O 
general O 
applicability O 
, O 
a O 
diverse O 
set O 
of O 
initiators O 
for O 
the O 
anionic O 
polymerization O 
of O 
ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
cholesterol B-TRIVIAL 
, O 
dibenzylamino B-SYSTEMATIC 
ethanol I-SYSTEMATIC 
, O 
and O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
monomethyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
mPEG B-ABBREVIATION 
) O 
) O 
was O 
modified O 
and O 
used O 
to O 
synthesize O 
the O 
analogous O 
labile O 
PEGs B-ABBREVIATION 
. O 
The O 
polyether B-SYSTEMATIC 
bearing O 
the O 
cleavable O 
lipid O 
had O 
a O 
degree O 
of O 
polymerization O 
of O 
46 O 
, O 
was O 
amphiphilic O 
and O 
exhibited O 
a O 
critical O 
micelle O 
concentration O 
of O 
4.2 O 
mg·L(-1) O 
. O 
From O 
dibenzylamino B-SYSTEMATIC 
ethanol I-SYSTEMATIC 
, O 
three O 
heterofunctional O 
PEGs B-ABBREVIATION 
with O 
different O 
molecular O 
weights O 
and O 
labile O 
amino B-FAMILY 
termini O 
were O 
generated O 
. O 
The O 
transformation O 
of O 
the O 
amino B-FAMILY 
functionality O 
into O 
the O 
corresponding O 
squaric B-SYSTEMATIC 
acid I-SYSTEMATIC 
ester I-SYSTEMATIC 
amide I-SYSTEMATIC 
demonstrated O 
the O 
accessibility O 
of O 
the O 
cleavable O 
functional O 
group O 
and O 
activated O 
the O 
PEG B-ABBREVIATION 
for O 
protein O 
PEGylation O 
, O 
which O 
was O 
exemplarily O 
shown O 
by O 
the O 
attachment O 
to O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
. O 
Furthermore O 
, O 
turning O 
mPEG B-ABBREVIATION 
into O 
a O 
macroinitiator O 
with O 
a O 
cleavable O 
hydroxyl B-SYSTEMATIC 
group O 
granted O 
access O 
to O 
a O 
well O 
- O 
defined O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
derivative O 
bearing O 
a O 
single O 
cleavable O 
moiety O 
within O 
its O 
backbone O 
. O 
All O 
the O 
acetal B-SYSTEMATIC 
-containing O 
PEGs B-ABBREVIATION 
and O 
PEG B-ABBREVIATION 
/ O 
protein O 
conjugates O 
were O 
proven O 
to O 
degrade O 
upon O 
acidic O 
treatment O 
. O 

correlation O 
for O 
rational O 
design O 
of O 
Mn B-FORMULA 
(II) I-FORMULA 
hybrid O 
- O 
spin O 
complexes O 
. O 

magnetic O 
properties O 
of O 
a O 
series O 
of O 
manganese B-MULTIPLE 
(II) I-MULTIPLE 
diacetylacetonate I-MULTIPLE 
and I-MULTIPLE 
dihexafluoroacetylacetonate I-MULTIPLE 
hybrid O 
- O 
spin O 
complexes O 
with O 
neutral O 
pyridine B-SYSTEMATIC 
-based O 
organic O 
radicals O 
were O 
characterized O 
theoretically O 
by O 
DFT O 
calculations O 
. O 
Three O 
stable O 
radicals O 
, O 
in O 
which O 
a O 
radical O 
group O 
is O 
bound O 
in O 
either O 
para O 
or O 
meta O 
position O 
with O 
respect O 
to O 
the O 
pyridine B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
atom O 
, O 
were O 
considered O 
. O 
The O 
correct O 
stable O 
structures O 
and O 
multiplets O 
of O 
the O 
complexes O 
were O 
obtained O 
by O 
full O 
geometry O 
optimization O 
starting O 
from O 
an O 
ideal O 
structure O 
. O 
A O 
total O 
of O 
three O 
important O 
geometry O 
descriptors O 
of O 
the O 
complexes O 
were O 
monitored O 
and O 
related O 
to O 
their O 
magnetic O 
characteristics O 
. O 
These O 
structural O 
parameters O 
are O 
(i) O 
the O 
torsion O 
angle O 
governing O 
the O 
conjugation O 
of O 
the O 
organic O 
radical O 
m-PyNO B-FORMULA 
( O 
anti O 
versus O 
gauche O 
) O 
, O 
(ii) O 
the O 
coordination O 
geometry O 
of O 
the O 
acetyl B-SYSTEMATIC 
acetonate I-SYSTEMATIC 
ligands O 
around O 
the O 
metal O 
ion O 
( O 
square O 
versus O 
rhombic O 
) O 
, O 
and O 
(iii) O 
the O 
relative O 
orientation O 
of O 
the O 
organic O 
radical O 
with O 
respect O 
to O 
the O 
acetyl B-SYSTEMATIC 
acetonate I-SYSTEMATIC 
plane O 
( O 
parallel O 
versus O 
perpendicular O 
) O 
. O 
It O 
was O 
found O 
that O 
the O 
magnetic O 
properties O 
are O 
not O 
sensitive O 
to O 
the O 
orientation O 
of O 
the O 
radicals O 
with O 
respect O 
to O 
the O 
equatorial O 
plane O 
but O 
do O 
depend O 
on O 
the O 
conformation O 
of O 
the O 
organic O 
radicals O 
. O 
Even O 
a O 
spin O 
switch O 
between O 
the O 
ferromagnetic O 
( O 
S O 
= O 
( O 
7 O 
) O 
/ O 
( O 
2 O 
) O 
) O 
and O 
antiferromagnetic O 
( O 
S O 
= O 
( O 
3 O 
) O 
/ O 
( O 
2 O 
) O 
) O 
ground O 
state O 
was O 
found O 
to O 
be O 
feasible O 
for O 
one O 
of O 
the O 
complexes O 
upon O 
variation O 
of O 
the O 
organic O 
radical O 
geometry O 
, O 
namely O 
, O 
the O 
dihedral O 
angle O 
between O 
the O 
organic O 
radical O 
moiety O 
and O 
the O 
pyridine B-SYSTEMATIC 
ring O 
. O 
The O 
pattern O 
of O 
molecular O 
orbital O 
overlap O 
was O 
determined O 
to O 
be O 
the O 
key O 
factor O 
governing O 
the O 
exchange O 
coupling O 
in O 
the O 
modeled O 
systems O 
. O 
Bonding O 
π- O 
type O 
overlap O 
provides O 
antiferromagnetic O 
coupling O 
in O 
all O 
complexes O 
of O 
the O 
para O 
radicals O 
. O 
In O 
the O 
meta O 
analogues O 
, O 
the O 
spins O 
are O 
coupled O 
through O 
the O 
σ O 
orbitals O 
. O 
A O 
low O 
- O 
spin O 
ground O 
state O 
occurs O 
whenever O 
a O 
continuous O 
σ-overlap O 
pathway O 
is O 
present O 
in O 
the O 
complex O 
. O 
Ferromagnetic O 
interaction O 
requires O 
σ-π O 
orthogonality O 
of O 
the O 
pyridine B-SYSTEMATIC 
atomic O 
orbitals O 
and O 
/ O 
or O 
π-antibonding O 
Mn B-FORMULA 
- O 
pyridine B-SYSTEMATIC 
natural O 
orbital O 
overlap O 
. O 
Using O 
an O 
estimate O 
of O 
the O 
donor-acceptor O 
energy O 
stabilization O 
, O 
the O 
affinity O 
of O 
a O 
given O 
Mn B-FORMULA 
(II) I-FORMULA 
d-orbital O 
to O 
mix O 
with O 
the O 
sp(2) O 
orbital O 
from O 
pyridine B-SYSTEMATIC 
can O 
be O 
predicted O 
. O 

obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
is O 
a O 
major O 
cause O 
of O 
morbidity O 
and O 
mortality O 
worldwide O 
. O 
Oxidative O 
stress O 
is O 
an O 
important O 
mechanism O 
in O 
the O 
pathogenesis O 
of O 
this O 
disease O 
. O 
The O 
oxidant/ O 
antioxidant O 
imbalance O 
occurring O 
in O 
smokers O 
and O 
patients O 
with O 
COPD O 
is O 
well O 
established O 
. O 
Thus O 
, O 
therapeutic O 
strategies O 
targeting O 
oxidative O 
stress O 
with O 
pharmacological O 
antioxidant O 
agents O 
or O 
boosting O 
the O 
endogenous O 
levels O 
of O 
antioxidants O 
is O 
likely O 
to O 
be O 
beneficial O 
as O 
an O 
adjunctive O 
tool O 
in O 
the O 
treatment O 
of O 
COPD O 
patients O 
. O 
Thiol B-SYSTEMATIC 
compounts O 
such O 
as O 
N-acetyl-L-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
carbocysteine B-TRIVIAL 
, O 
erdosteine B-TRIVIAL 
, O 
and O 
fudosteine B-TRIVIAL 
have O 
been O 
extensively O 
studied O 
. O 
Although O 
some O 
results O 
remain O 
controversial O 
, O 
NAC B-ABBREVIATION 
and O 
carbocysteine B-TRIVIAL 
seem O 
to O 
have O 
beneficial O 
effect O 
in O 
patients O 
not O 
receiving O 
inhaled O 
corticosteroids B-FAMILY 
who O 
suffer O 
from O 
frequent O 
exacerbations O 
. O 
In O 
addition O 
, O 
other O 
antioxidants O 
like O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
mimetics O 
and O 
nuclear O 
factor O 
- O 
erythroid O 
2 O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
are O 
shown O 
to O 
decrease O 
markers O 
of O 
oxidative O 
stress O 
in O 
patients O 
with O 
emphysema O 
, O 
while O 
others O 
like O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
mimetics O 
and O 
NO B-FORMULA 
synthase O 
( O 
iNOS O 
) O 
can O 
prevent O 
both O 
inflammation O 
and O 
oxidative O 
stress O 
in O 
clinical O 
trials O 
in O 
vivo O 
( O 
or O 
in O 
mouse O 
models O 
) O 
. O 
In O 
this O 
article O 
we O 
review O 
the O 
effectiveness O 
of O 
various O 
antioxidant O 
factors O 
in O 
COPD O 
and O 
their O 
potential O 
beneficial O 
effect O 
in O 
the O 
treatment O 
of O 
the O 
disease O 
. O 

for O 
the O 
treatment O 
of O 
panic O 
disorder O 
. O 

was O 
initially O 
licensed O 
as O 
an O 
anti-epileptic O 
agent O 
, O 
but O 
its O 
use O 
in O 
a O 
wide O 
variety O 
of O 
psychiatric O 
conditions O 
, O 
including O 
panic O 
disorder O 
( O 
PD O 
) O 
has O 
now O 
been O 
well O 
established O 
. O 
This O 
overview O 
evaluates O 
the O 
current O 
role O 
of O 
clonazepam B-TRIVIAL 
alone O 
or O 
in O 
combination O 
with O 
antidepressants O 
and O 
/ O 
or O 
behavioral O 
therapy O 
in O 
the O 
treatment O 
of O 
PD O 
. O 
We O 
review O 
the O 
data O 
establishing O 
the O 
use O 
of O 
clonazepam B-TRIVIAL 
in O 
the O 
treatment O 
of O 
PD O 
as O 
well O 
as O 
new O 
information O 
, O 
particularly O 
confirmation O 
of O 
longterm O 
efficacy O 
and O 
safety O 
. O 
We O 
also O 
discuss O 
a O 
regimen O 
for O 
safely O 
tapered O 
withdrawal O 
of O 
clonazepam B-TRIVIAL 
, O 
the O 
characteristics O 
of O 
the O 
respiratory O 
subtype O 
of O 
PD O 
, O 
and O 
CO2 B-FORMULA 
-induced O 
panic O 
attacks O 
as O 
a O 
diagnostic O 
measure O 
and O 
predictor O 
for O 
therapeutic O 
success O 
. O 
It O 
has O 
been O 
shown O 
that O 
panic O 
attacks O 
can O 
more O 
readily O 
be O 
induced O 
by O 
CO2 B-FORMULA 
in O 
PD O 
patients O 
with O 
the O 
respiratory O 
subtype O 
than O 
those O 
with O 
the O 
non-respiratory O 
subtype O 
. O 
More O 
than O 
25 O 
years O 
after O 
the O 
first O 
report O 
of O 
efficacy O 
in O 
PD O 
in O 
1984 O 
, O 
clonazepam B-TRIVIAL 
, O 
alone O 
or O 
combined O 
with O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
SSRIs O 
) O 
and O 
/ O 
or O 
behavioral O 
therapy O 
, O 
remains O 
an O 
important O 
therapeutic O 
modality O 
for O 
the O 
management O 
of O 
PD O 
. O 

of O 
formation O 
conditions O 
on O 
the O 
physicochemical O 
properties O 
, O 
aggregation O 
, O 
and O 
phase O 
transformation O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
. O 

this O 
work O 
, O 
hematite B-TRIVIAL 
transformation O 
from O 
a O 
precursor O 
6-line O 
ferrihydrite B-TRIVIAL 
phase O 
was O 
investigated O 
by O 
systematically O 
altering O 
the O 
forced O 
hydrolysis O 
hematite B-TRIVIAL 
synthesis O 
. O 
Specifically O 
, O 
we O 
used O 
a O 
combination O 
of O 
in O 
situ O 
and O 
ex O 
situ O 
characterization O 
techniques O 
to O 
examine O 
the O 
effects O 
of O 
varying O 
the O 
Fe B-FORMULA 
(III) I-FORMULA 
injection O 
rates O 
and O 
cooling O 
methods O 
on O 
the O 
hematite B-TRIVIAL 
and O 
6-line O 
ferrihydrite B-TRIVIAL 
nanoparticle O 
size O 
, O 
isoelectric O 
point O 
, O 
mineral O 
phase O 
, O 
and O 
aggregation O 
. O 
Finally O 
, O 
As B-FORMULA 
(V) I-FORMULA 
adsorption O 
experiments O 
were O 
performed O 
to O 
determine O 
how O 
the O 
two O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
phases O 
existed O 
in O 
the O 
reaction O 
system O 
. O 
Nanoparticle O 
synthesis O 
thermodynamics O 
and O 
kinetics O 
were O 
found O 
to O 
control O 
the O 
extent O 
of O 
distinct O 
6-line O 
ferrihydrite B-TRIVIAL 
phases O 
in O 
the O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
solutions O 
, O 
as O 
well O 
as O 
the O 
particle O 
size O 
and O 
isoelectric O 
point O 
. O 
Conversion O 
of O 
6-line O 
ferrihydrite B-TRIVIAL 
to O 
hematite B-TRIVIAL 
was O 
greatly O 
influenced O 
by O 
the O 
degree O 
of O 
aggregation O 
( O 
determined O 
by O 
synthesis O 
conditions O 
) O 
during O 
drying O 
. O 
As B-FORMULA 
(V) I-FORMULA 
adsorption O 
experiments O 
revealed O 
that O 
6-line O 
ferrihydrite B-TRIVIAL 
and O 
hematite B-TRIVIAL 
exist O 
as O 
a O 
linear O 
combination O 
of O 
two O 
separate O 
phases O 
. O 
These O 
results O 
provide O 
unique O 
information O 
regarding O 
how O 
in O 
situ O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
properties O 
can O 
direct O 
their O 
ex O 
situ O 
behavior O 
. O 

melanoma O 
continues O 
to O 
be O 
an O 
extremely O 
fatal O 
cancer O 
due O 
to O 
a O 
lack O 
of O 
viable O 
treatment O 
options O 
for O 
patients O 
. O 
The O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
S100B O 
has O 
long O 
been O 
used O 
as O 
a O 
clinical O 
biomarker O 
, O 
aiding O 
in O 
malignant O 
melanoma O 
staging O 
and O 
patient O 
prognosis O 
. O 
However O 
, O 
the O 
discovery O 
of O 
p53 O 
as O 
a O 
S100B O 
target O 
and O 
the O 
consequent O 
impact O 
on O 
cell O 
apoptosis O 
redirected O 
research O 
efforts O 
towards O 
the O 
development O 
of O 
inhibitors O 
of O 
this O 
S100B-p53 O 
interaction O 
. O 
Several O 
approaches O 
, O 
including O 
computer O 
- O 
aided O 
drug O 
design O 
, O 
fluorescence O 
polarization O 
competition O 
assays O 
, O 
NMR O 
, O 
x-ray O 
crystallography O 
and O 
cell O 
- O 
based O 
screens O 
have O 
been O 
performed O 
to O 
identify O 
compounds O 
that O 
block O 
the O 
S100B-p53 O 
association O 
, O 
reactivate O 
p53 O 
transcriptional O 
activities O 
and O 
induce O 
cancer O 
cell O 
death O 
. O 
Eight O 
promising O 
compounds O 
, O 
including O 
pentamidine B-TRIVIAL 
, O 
are O 
presented O 
in O 
this O 
review O 
and O 
the O 
potential O 
for O 
future O 
modifications O 
is O 
discussed O 
. O 
Synthesis O 
of O 
compound O 
derivatives O 
will O 
likely O 
exhibit O 
increased O 
S100B O 
affinity O 
and O 
mimic O 
important O 
S100B-target O 
dynamic O 
properties O 
that O 
will O 
result O 
in O 
high O 
specificity O 
. O 

NMR O 
Spectroscopy O 
of O 
Reconstructed O 
Human O 
Epidermis O 
: O 
Potential O 
for O 
the O 
in O 
Situ O 
Investigation O 
of O 
the O 
Chemical O 
Interactions O 
between O 
Skin O 
Allergens O 
and O 
Nucleophilic O 
Amino B-FAMILY 
Acids I-FAMILY 
. O 

- O 
resolution O 
magic O 
angle O 
spinning O 
( O 
HR-MAS O 
) O 
is O 
a O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
technique O 
that O 
enables O 
the O 
characterization O 
of O 
metabolic O 
phenotypes O 
/ O 
metabolite O 
profiles O 
of O 
cells O 
, O 
tissues O 
, O 
and O 
organs O 
, O 
under O 
both O 
normal O 
and O 
pathological O 
conditions O 
, O 
without O 
resorting O 
to O 
time O 
- O 
consuming O 
extraction O 
techniques O 
. O 
In O 
this O 
article O 
, O 
we O 
explore O 
a O 
new O 
domain O 
of O 
application O 
of O 
HR-MAS O 
, O 
namely O 
, O 
reconstructed O 
human O 
epidermis O 
( O 
RHE O 
) O 
and O 
the O 
in O 
situ O 
observation O 
of O 
chemical O 
interactions O 
between O 
skin O 
sensitizers O 
and O 
nucleophilic O 
amino B-FAMILY 
acids I-FAMILY 
. O 
First O 
, O 
the O 
preparation O 
, O 
storage O 
, O 
and O 
analysis O 
of O 
RHE O 
were O 
optimized O 
, O 
and O 
this O 
work O 
demonstrated O 
that O 
HR-MAS O 
NMR O 
was O 
well O 
adapted O 
for O 
investigating O 
RHE O 
with O 
spectra O 
of O 
good O 
quality O 
allowing O 
qualitative O 
as O 
well O 
as O 
quantitative O 
studies O 
of O 
metabolites O 
. O 
Second O 
, O 
in O 
order O 
to O 
study O 
the O 
response O 
of O 
RHE O 
to O 
chemical O 
sensitizers O 
, O 
the O 
((13)C)methyldodecanesulfonate B-SYSTEMATIC 
was O 
chosen O 
as O 
an O 
NMR O 
probe O 
, O 
and O 
we O 
compared O 
adducts O 
formed O 
on O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
in O 
solution O 
and O 
adducts O 
formed O 
in O 
RHE O 
. O 
Thus O 
, O 
while O 
the O 
modification O 
of O 
proteins O 
or O 
peptides O 
in O 
solution O 
takes O 
several O 
days O 
to O 
lead O 
to O 
a O 
significant O 
amount O 
of O 
modification O 
, O 
in O 
RHE O 
the O 
modifications O 
of O 
nucleophilic O 
amino B-FAMILY 
acids I-FAMILY 
were O 
observable O 
already O 
at O 
24 O 
h O 
. O 
The O 
chemioselectivity O 
also O 
appeared O 
to O 
be O 
different O 
with O 
major O 
modifications O 
taking O 
place O 
on O 
histidine B-TRIVIAL 
, O 
methionine B-TRIVIAL 
, O 
and O 
cysteine B-TRIVIAL 
residues O 
in O 
RHE O 
, O 
while O 
on O 
HSA O 
, O 
significant O 
modifications O 
were O 
observed O 
on O 
lysine B-TRIVIAL 
residues O 
with O 
the O 
formation O 
of O 
methylated O 
and O 
dimethylated O 
amino B-FAMILY 
groups O 
. O 
We O 
thus O 
demonstrated O 
that O 
RHE O 
could O 
be O 
used O 
to O 
investigate O 
in O 
situ O 
chemical O 
interactions O 
taking O 
place O 
between O 
skin O 
sensitizers O 
and O 
nucleophilic O 
amino B-FAMILY 
acids I-FAMILY 
. O 
This O 
opens O 
perspectives O 
for O 
the O 
molecular O 
understanding O 
of O 
the O 
skin O 
immune O 
system O 
activation O 
by O 
sensitizing O 
chemicals O 
. O 

single O 
subunit O 
DNA-dependent O 
RNA O 
polymerase O 
was O 
identified O 
and O 
purified O 
to O 
apparent O 
homogeneity O 
from O 
cyanophage O 
Syn5 O 
that O 
infects O 
the O 
marine O 
cyanobacteria O 
Synechococcus O 
. O 
Syn5 O 
is O 
homologous O 
to O 
bacteriophage O 
T7 O 
that O 
infects O 
Escherichia O 
coli O 
. O 
Using O 
the O 
purified O 
enzyme O 
its O 
promoter O 
has O 
been O 
identified O 
by O 
examining O 
transcription O 
of O 
segments O 
of O 
Syn5 O 
DNA O 
and O 
sequencing O 
the O 
5'-termini O 
of O 
the O 
transcripts O 
. O 
Only O 
two O 
Syn5 O 
RNAP O 
promoters O 
, O 
having O 
the O 
sequence O 
5'-ATTGGGCACCCGTAA-3 O 
' O 
, O 
are O 
found O 
within O 
the O 
Syn5 O 
genome O 
. O 
One O 
promoter O 
is O 
located O 
within O 
the O 
Syn5 O 
RNA O 
polymerase O 
gene O 
and O 
the O 
other O 
is O 
located O 
close O 
to O 
the O 
right O 
genetic O 
end O 
of O 
the O 
genome O 
. O 
The O 
purified O 
enzyme O 
and O 
its O 
promoter O 
have O 
enabled O 
a O 
determination O 
of O 
the O 
requirements O 
for O 
transcription O 
. O 
Unlike O 
the O 
salt O 
- O 
sensitive O 
bacteriophage O 
T7 O 
RNA O 
polymerase O 
, O 
this O 
marine O 
RNA O 
polymerase O 
requires O 
160 O 
mm O 
potassium B-SYSTEMATIC 
for O 
maximal O 
activity O 
. O 
The O 
optimal O 
temperature O 
for O 
Syn5 O 
RNA O 
polymerase O 
is O 
24 O 
°C O 
, O 
much O 
lower O 
than O 
that O 
for O 
T7 O 
RNA O 
polymerase O 
. O 
Magnesium B-SYSTEMATIC 
is O 
required O 
as O 
a O 
cofactor O 
although O 
some O 
activity O 
is O 
observed O 
with O 
ferrous B-SYSTEMATIC 
ions O 
. O 
Syn5 O 
RNA O 
polymerase O 
is O 
more O 
efficient O 
in O 
utilizing O 
low O 
concentrations O 
of O 
ribonucleotides B-FAMILY 
than O 
T7 O 
RNA O 
polymerase O 
. O 

- O 
stable O 
ultrafine O 
beta-tungsten B-SYSTEMATIC 
nanocrystals O 
with O 
metastable O 
phase O 
and O 
related O 
magnetism O 
. O 

tungsten B-SYSTEMATIC 
nanocrystals O 
( O 
average O 
size O 
of O 
3 O 
nm O 
) O 
with O 
a O 
metastable O 
phase O 
( O 
beta-tungsten B-SYSTEMATIC 
with O 
A15 O 
structure O 
, O 
β- O 
W B-FORMULA 
) O 
have O 
been O 
prepared O 
by O 
laser O 
ablation O 
of O 
tungsten B-SYSTEMATIC 
in O 
liquid O 
nitrogen B-SYSTEMATIC 
. O 
The O 
as-prepared O 
metastable O 
nanocrystals O 
exhibited O 
super O 
- O 
stablity O 
, O 
and O 
can O 
keep O 
the O 
same O 
metastable O 
structure O 
over O 
a O 
period O 
of O 
6 O 
months O 
at O 
room O 
temperature O 
. O 
This O 
super O 
- O 
stability O 
is O 
attributed O 
to O 
the O 
nanosized O 
confinement O 
effect O 
of O 
ultrafine O 
nanocrystals O 
. O 
The O 
magnetism O 
measurements O 
showed O 
that O 
the O 
β- O 
W B-FORMULA 
nanocrystals O 
have O 
weak O 
ferromagnetic O 
properties O 
at O 
2 O 
K O 
, O 
which O 
may O 
arise O 
from O 
surface O 
defects O 
and O 
unpaired O 
electrons O 
on O 
the O 
surface O 
of O 
the O 
ultrafine O 
nanocrystals O 
. O 
These O 
findings O 
provided O 
useful O 
information O 
for O 
the O 
application O 
of O 
ultrafine O 
β- O 
W B-FORMULA 
nanocrystals O 
in O 
microelectronics O 
and O 
spintronics O 
. O 

three O 
- O 
generational O 
study O 
of O 
In O 
ovo O 
exposure O 
to O 
PBDE-99 B-ABBREVIATION 
in O 
the O 
zebra O 
finch O 
. O 

on O 
a O 
literature O 
review O 
of O 
avian O 
data O 
for O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
, O 
ecologically O 
relevant O 
doses O 
, O 
low O 
( O 
10 O 
ng O 
/ O 
egg O 
) O 
, O 
medium O 
( O 
100 O 
ng O 
/ O 
egg O 
) O 
, O 
and O 
high O 
( O 
1000 O 
ng O 
/ O 
egg O 
) O 
of O 
the O 
2,2',4,4',5-pentabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
BDE-99 B-ABBREVIATION 
) O 
congener O 
along O 
with O 
dimethylsulfoxide B-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
control O 
were O 
injected O 
into O 
the O 
yolk O 
sac O 
of O 
un O 
- O 
incubated O 
eggs O 
of O 
zebra O 
finch O 
, O 
Taeniopygia O 
guttata O 
. O 
Offspring O 
development O 
and O 
adult O 
phenotype O 
were O 
followed O 
over O 
three O 
generations O 
. O 
No O 
effects O 
of O 
in O 
ovo O 
PBDE B-ABBREVIATION 
exposure O 
on O 
hatching O 
success O 
, O 
chick O 
growth O 
, O 
thyroid O 
hormone O 
levels O 
, O 
or O 
hematological O 
traits O 
were O 
measured O 
at O 
sexual O 
maturity O 
( O 
90 O 
d O 
posthatching O 
) O 
. O 
However O 
, O 
the O 
authors O 
did O 
detect O 
significant O 
effects O 
of O 
BDE-99 B-ABBREVIATION 
treatment O 
on O 
adult O 
phenotype O 
of O 
in O 
ovo O 
- O 
exposed O 
birds O 
by O 
breeding O 
observations O 
, O 
in O 
which O 
clutch O 
size O 
was O 
significantly O 
smaller O 
in O 
all O 
PBDE B-ABBREVIATION 
-dosed O 
birds O 
( O 
low O 
, O 
medium O 
, O 
and O 
high O 
) O 
compared O 
with O 
controls O 
. O 
A O 
trend O 
was O 
also O 
seen O 
for O 
longer O 
laying O 
intervals O 
in O 
PBDE B-ABBREVIATION 
-dosed O 
birds O 
( O 
13-14 O 
d O 
) O 
compared O 
with O 
control O 
birds O 
( O 
8 O 
d O 
) O 
. O 
In O 
addition O 
, O 
a O 
significant O 
effect O 
of O 
PBDE B-ABBREVIATION 
was O 
found O 
on O 
growth O 
of O 
the O 
second O 
- O 
generation O 
offspring O 
of O 
in O 
ovo O 
- O 
treated O 
females O 
; O 
body O 
mass O 
was O 
significantly O 
lower O 
in O 
the O 
high- O 
PBDE B-ABBREVIATION 
dosed O 
birds O 
compared O 
with O 
controls O 
from O 
hatch O 
through O 
to O 
fledging O 
( O 
day O 
30 O 
) O 
. O 
The O 
authors O 
found O 
no O 
evidence O 
of O 
effects O 
over O 
the O 
longer O 
term O 
and O 
in O 
successive O 
generations O 
, O 
whether O 
in O 
adult O 
, O 
reproductive O 
phenotype O 
of O 
the O 
second O 
- O 
generation O 
offspring O 
of O 
in O 
ovo O 
- O 
treated O 
birds O 
, O 
or O 
in O 
the O 
growth O 
of O 
their O 
( O 
third O 
- O 
generation O 
) O 
offspring O 
. O 
Their O 
results O 
suggest O 
that O 
egg O 
levels O 
as O 
low O 
as O 
10 O 
ng O 
/ O 
g O 
BDE-99 B-ABBREVIATION 
may O 
affect O 
reproduction O 
in O 
small O 
passerines O 
by O 
reducing O 
clutch O 
size O 
. O 

ongoing O 
sources O 
of O 
dissolved O 
- O 
phase O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
in O 
a O 
contaminated O 
stream O 
. O 

studies O 
assess O 
the O 
potential O 
of O 
ongoing O 
sources O 
of O 
" O 
fresh O 
" O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
to O 
aquatic O 
systems O 
when O 
direct O 
discharge O 
to O 
the O 
environment O 
has O 
been O 
eliminated O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
authors O 
used O 
single O 
- O 
layered O 
, O 
low O 
- O 
density O 
polyethylene B-SYSTEMATIC 
samplers O 
( O 
PEs O 
) O 
to O 
measure O 
total O 
PCB B-ABBREVIATION 
concentrations O 
, O 
congener O 
profiles O 
, O 
and O 
enantiomeric O 
fractions O 
( O 
EFs O 
) O 
in O 
a O 
contaminated O 
stream O 
and O 
to O 
provide O 
multiple O 
lines O 
of O 
evidence O 
for O 
assessing O 
ongoing O 
inputs O 
of O 
PCB B-ABBREVIATION 
. O 
Concentrations O 
were O 
well O 
above O 
background O 
levels O 
that O 
have O 
been O 
monitored O 
for O 
years O 
. O 
Concentrations O 
significantly O 
increased O 
with O 
distance O 
, O 
the O 
farthest O 
downstream O 
PE O 
concentrations O 
being O 
almost O 
five O 
times O 
greater O 
than O 
those O 
at O 
79 O 
m O 
downstream O 
of O 
a O 
historical O 
point O 
source O 
. O 
The O 
PCBs B-ABBREVIATION 
in O 
the O 
PEs O 
at O 
79 O 
m O 
downstream O 
of O 
the O 
contamination O 
source O 
were O 
dominated O 
by O 
low O 
K(OW) O 
congeners O 
, O 
similar O 
to O 
those O 
in O 
the O 
mixture O 
of O 
Aroclors B-MULTIPLE 
1016 I-MULTIPLE 
and I-MULTIPLE 
1254 I-MULTIPLE 
( O 
4 O 
: O 
1 O 
v O 
/ O 
v O 
) O 
historically O 
released O 
from O 
the O 
former O 
capacitor O 
manufacturer O 
. O 
The O 
only O 
two O 
chiral O 
congeners O 
detected O 
in O 
the O 
PEs O 
downstream O 
were O 
PCBs B-ABBREVIATION 
91 O 
and O 
95 O 
. O 
The O 
EF O 
values O 
were O 
nonracemic O 
for O 
PCB B-ABBREVIATION 
91 O 
, O 
while O 
the O 
values O 
were O 
either O 
racemic O 
or O 
near O 
racemic O 
for O 
PCB B-ABBREVIATION 
95 O 
. O 
Increased O 
PCB B-ABBREVIATION 
concentrations O 
with O 
distance O 
and O 
a O 
congener O 
composition O 
of O 
predominantly O 
low O 
- O 
weight O 
congeners O 
in O 
the O 
PEs O 
at O 
79 O 
m O 
downstream O 
of O 
the O 
plant O 
site O 
suggested O 
an O 
ongoing O 
PCB B-ABBREVIATION 
source O 
from O 
the O 
plant O 
site O 
. O 
Chiral O 
signatures O 
suggested O 
aerobic O 
biotransformation O 
of O 
dissolved O 
PCBs B-ABBREVIATION 
but O 
did O 
not O 
shed O 
any O 
light O 
on O 
possible O 
ongoing O 
PCB B-ABBREVIATION 
inputs O 
. O 

may O 
be O 
reversibly O 
photoisomerized O 
between O 
two O 
metastable O 
states O 
and O 
their O 
properties O 
can O 
influence O 
, O 
and O 
be O 
influenced O 
by O 
, O 
other O 
chromophores O 
in O 
the O 
same O 
molecule O 
through O 
energy O 
or O 
electron O 
transfer O 
. O 
In O 
the O 
photochemically O 
active O 
molecular O 
tetrad O 
described O 
here O 
, O 
a O 
porphyrin B-FAMILY 
has O 
been O 
covalently O 
linked O 
to O 
a O 
fullerene B-TRIVIAL 
electron O 
acceptor O 
, O 
a O 
quinoline B-SYSTEMATIC 
-derived O 
dihydroindolizine B-SYSTEMATIC 
photochrome O 
, O 
and O 
a O 
dithienylethene B-SYSTEMATIC 
photochrome O 
. O 
The O 
porphyrin B-FAMILY 
first O 
excited O 
singlet O 
state O 
undergoes O 
photoinduced O 
electron O 
transfer O 
to O 
the O 
fullerene B-TRIVIAL 
to O 
generate O 
a O 
charge O 
- O 
separated O 
state O 
. O 
The O 
quantum O 
yield O 
of O 
charge O 
separation O 
is O 
modulated O 
by O 
the O 
two O 
photochromes O 
: O 
one O 
isomer O 
of O 
each O 
quenches O 
the O 
porphyrin B-FAMILY 
excited O 
state O 
, O 
reducing O 
the O 
quantum O 
yield O 
of O 
electron O 
transfer O 
to O 
near O 
zero O 
. O 
Interestingly O 
, O 
when O 
the O 
molecule O 
is O 
illuminated O 
with O 
white O 
light O 
, O 
the O 
quantum O 
yield O 
decreases O 
as O 
the O 
white O 
light O 
intensity O 
is O 
increased O 
, O 
generating O 
an O 
out O 
- O 
of O 
- O 
phase O 
response O 
of O 
the O 
quantum O 
yield O 
to O 
white O 
light O 
. O 
However O 
, O 
when O 
the O 
same O 
experiment O 
is O 
performed O 
in O 
the O 
presence O 
of O 
additional O 
, O 
steady O 
- O 
state O 
UV O 
illumination O 
, O 
a O 
phase O 
inversion O 
occurs O 
. O 
The O 
quantum O 
yield O 
of O 
electron O 
transfer O 
now O 
increases O 
with O 
increasing O 
white O 
light O 
intensity O 
. O 
Such O 
effects O 
illustrate O 
emergent O 
complexity O 
in O 
a O 
relatively O 
simple O 
system O 
and O 
could O 
find O 
applications O 
in O 
molecular O 
logic O 
, O 
photochemical O 
labeling O 
and O 
drug O 
delivery O 
, O 
and O 
photoprotection O 
for O 
artificial O 
photosynthetic O 
molecules O 
. O 
The O 
photochemistry O 
leading O 
to O 
this O 
behavior O 
is O 
discussed O 
. O 

- O 
based O 
multivalent O 
vancomycin B-TRIVIAL 
nanoplatform O 
for O 
targeting O 
the O 
drug O 
- O 
resistant O 
bacterial O 
surface O 
. O 

represents O 
the O 
preferred O 
ligand O 
for O 
bacteria O 
- O 
targeting O 
nanosystems O 
. O 
However O 
, O 
it O 
is O 
inefficient O 
for O 
emerging O 
vancomycin B-TRIVIAL 
-resistant O 
species O 
because O 
of O 
its O 
poor O 
affinity O 
to O 
the O 
reprogrammed O 
cell O 
wall O 
structure O 
. O 
This O 
study O 
demonstrates O 
the O 
use O 
of O 
a O 
multivalent O 
strategy O 
as O 
an O 
effective O 
way O 
for O 
overcoming O 
such O 
an O 
affinity O 
limitation O 
in O 
bacteria O 
targeting O 
. O 
We O 
designed O 
a O 
series O 
of O 
fifth O 
generation O 
( O 
G5 O 
) O 
poly(amidoamine) B-SYSTEMATIC 
( O 
PAMAM B-ABBREVIATION 
) O 
dendrimers O 
tethered O 
with O 
vancomycin B-TRIVIAL 
at O 
the O 
C B-FORMULA 
-terminus O 
at O 
different O 
valencies O 
. O 
We O 
performed O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
studies O 
to O 
determine O 
their O 
binding O 
avidity O 
to O 
two O 
cell O 
wall O 
models O 
, O 
each O 
made O 
with O 
either O 
a O 
vancomycin B-TRIVIAL 
-susceptible O 
(D)-Ala-(D)-Ala B-FORMULA 
or O 
vancomycin B-TRIVIAL 
-resistant O 
(D)-Ala-(D)-Lac B-FORMULA 
cell O 
wall O 
precursor O 
. O 
These O 
conjugates O 
showed O 
remarkable O 
enhancement O 
in O 
avidity O 
in O 
the O 
cell O 
wall O 
models O 
tested O 
, O 
including O 
the O 
vancomycin B-TRIVIAL 
-resistant O 
model O 
, O 
which O 
had O 
an O 
increase O 
in O 
avidity O 
of O 
four O 
to O 
five O 
orders O 
of O 
magnitude O 
greater O 
than O 
free O 
vancomycin B-TRIVIAL 
. O 
The O 
tight O 
adsorption O 
of O 
the O 
conjugate O 
to O 
the O 
model O 
surface O 
corresponded O 
with O 
its O 
ability O 
to O 
bind O 
vancomycin B-TRIVIAL 
-susceptible O 
Staphylococcus O 
aureus O 
bacterial O 
cells O 
in O 
vitro O 
as O 
imaged O 
by O 
confocal O 
fluorescent O 
microscopy O 
. O 
This O 
vancomycin B-TRIVIAL 
platform O 
was O 
then O 
used O 
to O 
fabricate O 
the O 
surface O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
by O 
coating O 
them O 
with O 
the O 
dendrimer O 
conjugates O 
, O 
and O 
the O 
resulting O 
dendrimer O 
- O 
covered O 
magnetic O 
nanoparticles O 
were O 
demonstrated O 
to O 
rapidly O 
sequester O 
bacterial O 
cells O 
. O 
In O 
summary O 
, O 
this O 
article O 
investigates O 
the O 
biophysical O 
basis O 
of O 
the O 
tight O 
, O 
multivalent O 
association O 
of O 
dendrimer O 
- O 
based O 
vancomycin B-TRIVIAL 
conjugates O 
to O 
the O 
bacterial O 
cell O 
wall O 
, O 
and O 
proposes O 
a O 
potential O 
new O 
use O 
of O 
this O 
nanoplatform O 
in O 
targeting O 
Gram O 
- O 
positive O 
bacteria O 
. O 

- O 
channel O 
transistors O 
constructed O 
with O 
solution O 
- O 
processed O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

develop O 
short O 
- O 
channel O 
transistors O 
using O 
solution O 
- O 
processed O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNTs O 
) O 
to O 
evaluate O 
the O 
feasibility O 
of O 
those O 
SWNTs O 
for O 
high O 
- O 
performance O 
applications O 
. O 
Our O 
results O 
show O 
that O 
even O 
though O 
the O 
intrinsic O 
field O 
- O 
effect O 
mobility O 
is O 
lower O 
than O 
the O 
mobility O 
of O 
CVD O 
nanotubes O 
, O 
the O 
electrical O 
contact O 
between O 
the O 
nanotube O 
and O 
metal O 
electrodes O 
is O 
not O 
significantly O 
affected O 
. O 
It O 
is O 
this O 
contact O 
resistance O 
which O 
often O 
limits O 
the O 
performance O 
of O 
ultrascaled O 
transistors O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
the O 
contact O 
resistance O 
is O 
lowered O 
by O 
the O 
introduction O 
of O 
oxygen B-SYSTEMATIC 
treatment O 
. O 
Therefore O 
, O 
high O 
- O 
performance O 
solution O 
- O 
processed O 
nanotube O 
transistors O 
with O 
a O 
15 O 
nm O 
channel O 
length O 
were O 
obtained O 
by O 
combining O 
a O 
top O 
- O 
gate O 
structure O 
and O 
gate O 
insulators O 
made O 
of O 
a O 
high O 
- O 
dielectric O 
- O 
constant O 
ZrO(2) B-FORMULA 
film O 
. O 
The O 
combination O 
of O 
these O 
elements O 
yields O 
a O 
performance O 
comparable O 
to O 
that O 
obtained O 
with O 
CVD O 
nanotube O 
transistors O 
, O 
which O 
indicates O 
the O 
potential O 
for O 
using O 
solution O 
- O 
processed O 
SWNTs O 
for O 
future O 
aggressively O 
scaled O 
transistor O 
technology O 
. O 

fracture O 
approach O 
to O 
directly O 
visualize O 
wetting O 
transitions O 
on O 
nanopatterned O 
superhydrophobic O 
silicon B-SYSTEMATIC 
surfaces O 
: O 
more O 
than O 
a O 
proof O 
of O 
principle O 
. O 

fracturing O 
is O 
applied O 
to O 
make O 
the O 
wetting O 
behavior O 
of O 
artificially O 
nanopatterned O 
Si B-FORMULA 
surfaces O 
directly O 
visible O 
. O 
For O 
this O 
purpose O 
, O 
almost O 
hexagonally O 
arranged O 
nanopillars O 
of O 
fixed O 
areal O 
density O 
( O 
127 O 
μm(-2) O 
) O 
and O 
diameters O 
( O 
35 O 
nm O 
) O 
but O 
varying O 
heights O 
( O 
40-150 O 
nm O 
) O 
were O 
fabricated O 
on O 
silicon B-SYSTEMATIC 
. O 
Measurement O 
of O 
contact O 
angles O 
( O 
CAs O 
) O 
including O 
hysteresis O 
allowed O 
to O 
distinguish O 
between O 
the O 
Wenzel O 
( O 
W O 
) O 
and O 
the O 
Cassie-Baxter O 
( O 
CB O 
) O 
states O 
with O 
droplets O 
completely O 
wetting O 
the O 
pillars O 
or O 
residing O 
on O 
top O 
of O 
them O 
, O 
respectively O 
. O 
Providing O 
additional O 
depth O 
contrast O 
by O 
evaporating O 
the O 
ice O 
replica O 
with O 
thin O 
carbon B-SYSTEMATIC 
and O 
( O 
typically O 
3 O 
nm O 
) O 
platinum B-SYSTEMATIC 
layers O 
under O 
45° O 
allowed O 
resolving O 
3D O 
features O 
of O 
5 O 
nm O 
within O 
the O 
ice O 
replica O 
. O 
In O 
this O 
way O 
, O 
laterally O 
sharp O 
transitions O 
from O 
CB- O 
to O 
W-states O 
could O 
be O 
revealed O 
, O 
indicating O 
the O 
formation O 
of O 
zero O 
- O 
curvature O 
water O 
surfaces O 
even O 
on O 
the O 
nanoscale O 
. O 

and O 
biological O 
evaluation O 
of O 
indenoisoquinolines B-FAMILY 
that O 
inhibit O 
both O 
tyrosyl-DNA O 
phosphodiesterase O 
I O 
( O 
Tdp1 O 
) O 
and O 
topoisomerase O 
I O 
( O 
Top1 O 
) O 
. O 

phosphodiesterase O 
I O 
( O 
Tdp1 O 
) O 
plays O 
a O 
key O 
role O 
in O 
the O 
repair O 
of O 
damaged O 
DNA O 
resulting O 
from O 
the O 
topoisomerase O 
I O 
( O 
Top1 O 
) O 
inhibitor O 
camptothecin B-TRIVIAL 
and O 
a O 
variety O 
of O 
other O 
DNA-damaging O 
anticancer O 
agents O 
. O 
This O 
report O 
documents O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
evaluation O 
of O 
new O 
indenoisoquinolines B-FAMILY 
that O 
are O 
dual O 
inhibitors O 
of O 
both O 
Tdp1 O 
and O 
Top1 O 
. O 
Enzyme O 
inhibitory O 
data O 
and O 
cytotoxicity O 
data O 
from O 
human O 
cancer O 
cell O 
cultures O 
were O 
used O 
to O 
establish O 
structure O 
- O 
activity O 
relationships O 
. O 
The O 
potencies O 
of O 
the O 
indenoisoquinolines B-FAMILY 
against O 
Tdp1 O 
ranged O 
from O 
5 O 
μM O 
to O 
111 O 
μM O 
, O 
which O 
places O 
the O 
more O 
active O 
compounds O 
among O 
the O 
most O 
potent O 
known O 
inhibitors O 
of O 
this O 
target O 
. O 
The O 
cytotoxicity O 
mean O 
graph O 
midpoints O 
ranged O 
from O 
0.02 O 
to O 
2.34 O 
μM O 
. O 
Dual O 
Tdp1-Top1 O 
inhibitors O 
are O 
of O 
interest O 
because O 
the O 
Top1 O 
and O 
Tdp1 O 
inhibitory O 
activities O 
could O 
theoretically O 
work O 
synergistically O 
to O 
create O 
more O 
effective O 
anticancer O 
agents O 
. O 

of O 
ABC O 
triblock O 
terpolymer O 
melts O 
containing O 
poly(cyclohexadiene) B-SYSTEMATIC 
: O 
effects O 
of O 
conformational O 
asymmetry O 
. O 

have O 
synthesized O 
linear O 
ABC O 
triblock O 
terpolymers O 
containing O 
poly(1,3-cyclohexadiene) B-SYSTEMATIC 
, O 
PCHD B-ABBREVIATION 
, O 
as O 
an O 
end O 
block O 
and O 
characterized O 
their O 
morphologies O 
in O 
the O 
melt O 
. O 
Specifically O 
, O 
we O 
have O 
studied O 
terpolymers O 
containing O 
polystyrene B-SYSTEMATIC 
( O 
PS O 
) O 
, O 
polybutadiene B-SYSTEMATIC 
( O 
PB O 
) O 
, O 
and O 
polyisoprene B-SYSTEMATIC 
( O 
PI O 
) O 
as O 
the O 
other O 
blocks O 
. O 
Systematically O 
varying O 
the O 
ratio O 
of O 
1,2- O 
/ O 
1,4-microstructures O 
of O 
poly(1,3-cyclohexadiene) B-SYSTEMATIC 
, O 
we O 
have O 
studied O 
the O 
effects O 
of O 
conformational O 
asymmetry O 
among O 
the O 
three O 
blocks O 
on O 
the O 
morphologies O 
using O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
small O 
- O 
angle O 
X-ray O 
scattering O 
( O 
SAXS O 
) O 
, O 
and O 
self O 
- O 
consistent O 
field O 
theory O 
( O 
SCFT O 
) O 
performed O 
with O 
PolySwift O 
+ O 
+ O 
. O 
Our O 
work O 
reveals O 
that O 
the O 
triblock O 
terpolymer O 
melts O 
containing O 
a O 
high O 
percentage O 
of O 
1,2-microstructures O 
in O 
the O 
PCHD B-ABBREVIATION 
block O 
are O 
disordered O 
at O 
110 O 
°C O 
for O 
all O 
the O 
samples O 
, O 
independent O 
of O 
sequence O 
and O 
volume O 
fraction O 
of O 
the O 
blocks O 
. O 
In O 
contrast O 
, O 
the O 
triblock O 
terpolymer O 
melts O 
containing O 
a O 
high O 
percentage O 
of O 
1,4-microstructure O 
form O 
regular O 
morphologies O 
known O 
from O 
the O 
literature O 
. O 
The O 
accuracy O 
of O 
the O 
SCFT O 
calculations O 
depends O 
on O 
calculating O 
the O 
χ O 
parameters O 
that O 
quantify O 
the O 
repulsive O 
interactions O 
between O 
different O 
monomers O 
. O 
Simulations O 
using O 
χ O 
values O 
obtained O 
from O 
solubility O 
parameters O 
and O 
group O 
contribution O 
methods O 
are O 
unable O 
to O 
reproduce O 
the O 
morphologies O 
as O 
seen O 
in O 
the O 
experiments O 
. O 
However O 
, O 
SCFT O 
calculations O 
accounting O 
for O 
the O 
enhancement O 
of O 
the O 
χ O 
parameter O 
with O 
an O 
increase O 
in O 
the O 
conformational O 
asymmetry O 
lead O 
to O 
an O 
excellent O 
agreement O 
between O 
theory O 
and O 
experiments O 
. O 
These O 
results O 
highlight O 
the O 
importance O 
of O 
conformational O 
asymmetry O 
in O 
tuning O 
the O 
χ O 
parameter O 
and O 
, O 
in O 
turn O 
, O 
morphologies O 
in O 
block O 
copolymers O 
. O 

polymers O 
as O 
a O 
determining O 
factor O 
for O 
polyplex B-TRIVIAL 
decomplexation O 
rate O 
and O 
transfection O 
. O 

formation O 
( O 
complexation O 
) O 
and O 
gene O 
release O 
from O 
the O 
polyplexes B-FAMILY 
( O 
decomplexation O 
) O 
are O 
major O 
events O 
in O 
polymeric O 
gene O 
delivery O 
; O 
however O 
, O 
the O 
effect O 
of O 
the O 
decomplexation O 
rate O 
on O 
transfection O 
has O 
been O 
rarely O 
investigated O 
. O 
This O 
study O 
employed O 
mixed O 
polymers O 
of O 
poly((L)-lysine) B-SYSTEMATIC 
( O 
PLL B-ABBREVIATION 
: O 
MW O 
~7.4 O 
kDa O 
) O 
and O 
reducible O 
PLL B-ABBREVIATION 
( O 
RPLL O 
) O 
( O 
MW O 
~6.7 O 
kDa O 
) O 
to O 
design O 
decomplexation O 
rate O 
- O 
controllable O 
PLL B-ABBREVIATION 
(100-x)RPLL O 
(x) O 
/ O 
pDNA O 
complexes O 
( O 
PRL O 
(x) O 
polyplexes B-FAMILY 
) O 
. O 
The O 
transfection O 
efficiency O 
of O 
a O 
model O 
gene O 
( O 
luciferase O 
) O 
in O 
MCF7 O 
and O 
HEK293 O 
cell O 
lines O 
increased O 
with O 
increasing O 
x O 
( O 
RPLL O 
content O 
) O 
in O 
the O 
PRL O 
(x) O 
polyplexes B-FAMILY 
until O 
peaking O 
at O 
x O 
= O 
2.5 O 
and O 
10 O 
, O 
respectively O 
, O 
after O 
which O 
point O 
transfection O 
efficiency O 
declined O 
rapidly O 
. O 
In O 
MCF7 O 
cells O 
, O 
PRL(2.5) O 
polyplex B-TRIVIAL 
produced O 
3 O 
or O 
223 O 
times O 
higher O 
gene O 
expression O 
than O 
PLL B-ABBREVIATION 
or O 
RPLL O 
polyplexes B-FAMILY 
, O 
respectively O 
. O 
Similarly O 
, O 
the O 
transfection O 
efficiency O 
of O 
PRL(10) O 
polyplex B-TRIVIAL 
-transfected O 
HEK293 O 
cells O 
was O 
3.8 O 
or O 
67 O 
times O 
higher O 
than O 
that O 
of O 
PLL B-ABBREVIATION 
or O 
RPLL O 
polyplexes B-FAMILY 
, O 
respectively O 
. O 
The O 
transfection O 
results O 
were O 
not O 
apparently O 
related O 
to O 
the O 
particle O 
size O 
, O 
surface O 
charge O 
, O 
complexation O 
/ O 
compactness O 
, O 
cellular O 
uptake O 
, O 
or O 
cytotoxicity O 
of O 
the O 
tested O 
polyplexes B-FAMILY 
. O 
However O 
, O 
the O 
decomplexation O 
rate O 
varied O 
by O 
RPLL O 
content O 
in O 
the O 
polyplexes B-FAMILY 
, O 
which O 
in O 
turn O 
influenced O 
the O 
gene O 
transfection O 
. O 
The O 
nuclear O 
localization O 
of O 
pDNA O 
delivered O 
by O 
PRL O 
(x) O 
polyplexes B-FAMILY 
showed O 
a O 
similar O 
trend O 
to O 
their O 
transfection O 
efficiencies O 
. O 
This O 
study O 
suggests O 
that O 
an O 
optimum O 
decomplexation O 
rate O 
may O 
result O 
in O 
high O 
nuclear O 
localization O 
of O 
pDNA O 
and O 
transfection O 
. O 
Understanding O 
in O 
decomplexation O 
and O 
intracellular O 
localization O 
of O 
pDNA O 
may O 
help O 
develop O 
more O 
effective O 
polyplexes B-FAMILY 
. O 

the O 
Toxicity O 
of O 
a O 
Bismuth B-SYSTEMATIC 
- O 
Asparagine B-TRIVIAL 
Coordination O 
Polymer O 
on O 
the O 
Early O 
Development O 
of O 
Zebrafish O 
Embryos O 
. O 

are O 
widely O 
used O 
in O 
nanomedicine O 
, O 
raising O 
concerns O 
about O 
their O 
toxicity O 
. O 
In O 
this O 
study O 
, O 
the O 
toxicity O 
of O 
bismuth B-SYSTEMATIC 
- O 
asparagine B-TRIVIAL 
coordination O 
polymer O 
spheres O 
( O 
BACP-2 O 
) O 
was O 
assessed O 
in O 
zebrafish O 
embryos O 
. O 
Injection O 
of O 
1-4 O 
cell O 
stage O 
embryos O 
with O 
BACP-2 O 
resulted O 
in O 
smaller O 
head O 
size O 
( O 
particularly O 
smaller O 
eye O 
size O 
) O 
, O 
shorter O 
body O 
length O 
, O 
and O 
pericardial O 
edemas O 
. O 
The O 
severity O 
and O 
occurrence O 
of O 
the O 
resulting O 
phenotype O 
were O 
concentration O 
- O 
dependent O 
. O 
The O 
expression O 
of O 
genes O 
such O 
as O 
krox20 O 
, O 
orthodenticle O 
homeobox O 
2 O 
( O 
otx2 O 
) O 
, O 
and O 
cardiac O 
myosin O 
light O 
chain-2 O 
( O 
cmlc2 O 
) O 
indicates O 
that O 
the O 
effects O 
of O 
BACP-2 O 
on O 
the O 
head O 
and O 
heart O 
were O 
related O 
to O 
changes O 
in O 
gene O 
expression O 
patterns O 
. O 
A O 
delay O 
in O 
epiboly O 
was O 
observed O 
, O 
and O 
the O 
expression O 
levels O 
of O 
the O 
no O 
tail O 
( O 
ntl O 
) O 
gene O 
indicated O 
that O 
the O 
delay O 
in O 
epiboly O 
resulted O 
both O 
from O 
the O 
effect O 
of O 
BACP-2 O 
on O 
cell O 
migration O 
during O 
epiboly O 
and O 
from O 
slow O 
growth O 
. O 
These O 
findings O 
indicate O 
that O 
BACP-2 O 
exhibits O 
concentration O 
- O 
dependent O 
developmental O 
toxicity O 
, O 
providing O 
insight O 
into O 
the O 
nanotoxicity O 
of O 
bismuth B-SYSTEMATIC 
derivatives O 
, O 
which O 
must O 
be O 
rigorously O 
evaluated O 
with O 
respect O 
to O 
toxicity O 
before O 
their O 
application O 
in O 
nanomedicine O 
. O 

and O 
evaluation O 
of O 
diphenylphosphinic B-FAMILY 
amides I-FAMILY 
and O 
diphenylphosphine B-FAMILY 
oxides I-FAMILY 
as O 
inhibitors O 
of O 
Kv1.5 O 
. O 

amides I-FAMILY 
and O 
diphenylphosphine B-FAMILY 
oxides I-FAMILY 
have O 
been O 
synthesized O 
and O 
tested O 
as O 
inhibitors O 
of O 
the O 
Kv1.5 O 
potassium B-SYSTEMATIC 
ion O 
channel O 
as O 
a O 
possible O 
treatment O 
for O 
atrial O 
fibrillation O 
. O 
In O 
vitro O 
structure O 
- O 
activity O 
relationships O 
are O 
discussed O 
and O 
several O 
compounds O 
with O 
Kv1.5 O 
IC(50) O 
values O 
of O 
< O 
0.5 O 
μM O 
were O 
discovered O 
. O 
Selectivity O 
over O 
the O 
ventricular O 
IKs O 
current O 
was O 
monitored O 
and O 
selective O 
compounds O 
were O 
found O 
. O 
Results O 
from O 
a O 
rabbit O 
PD-model O 
are O 
included O 
. O 

in O 
vivo O 
active O 
anti-malarials O 
based O 
on O 
a O 
hydroxy-ethyl-amine B-SYSTEMATIC 
scaffold O 
. O 

novel O 
series O 
of O 
anti-malarials O 
, O 
based O 
on O 
a O 
hydroxy-ethyl-amine B-SYSTEMATIC 
scaffold O 
, O 
initially O 
identified O 
as O 
peptidomimetic O 
protease O 
inhibitors O 
is O 
described O 
. O 
Combination O 
of O 
the O 
hydroxy-ethyl-amine B-SYSTEMATIC 
anti-malarial O 
phramacophore O 
with O 
the O 
known O 
Mannich B-FAMILY 
base I-FAMILY 
pharmacophore O 
of O 
amodiaquine B-TRIVIAL 
( O 
57 O 
) O 
resulted O 
in O 
promising O 
in O 
vivo O 
active O 
novel O 
derivatives O 
. O 

plays O 
an O 
important O 
role O 
in O 
regulating O 
a O 
wide O 
variety O 
of O 
cellular O 
processes O 
, O 
such O 
as O 
cell O 
cycle O 
arrest O 
and O 
/ O 
or O 
apoptosis O 
. O 
Dysfunction O 
of O 
p53 O 
is O 
frequently O 
associated O 
with O 
several O 
pathologies O 
, O 
such O 
as O 
cancer O 
and O 
neurodegenerative O 
diseases O 
. O 
In O 
recent O 
years O 
substantial O 
progress O 
has O 
been O 
made O 
in O 
developing O 
novel O 
p53-activating O 
molecules O 
. O 
Importantly O 
, O 
modulation O 
of O 
p53 O 
interaction O 
with O 
its O 
main O 
inhibitor O 
, O 
Mdm2 O 
, O 
has O 
been O 
highlighted O 
as O 
a O 
promising O 
therapeutic O 
target O 
. O 
In O 
this O 
regard O 
, O 
bimolecular O 
fluorescence O 
complementation O 
( O 
BiFC O 
) O 
analysis O 
, O 
by O 
providing O 
direct O 
visualization O 
of O 
protein O 
interactions O 
in O 
living O 
cells O 
, O 
offers O 
a O 
straightforward O 
method O 
to O 
identify O 
potential O 
modulators O 
of O 
protein O 
interactions O 
. O 
In O 
this O 
study O 
, O 
we O 
developed O 
a O 
simple O 
and O 
robust O 
Venus O 
- O 
based O 
BiFC O 
system O 
to O 
screen O 
for O 
modulators O 
of O 
p53-p53 O 
and O 
p53-Mdm2 O 
interactions O 
in O 
live O 
mammalian O 
cells O 
. O 
We O 
used O 
nutlin-3 B-TRIVIAL 
, O 
a O 
well O 
- O 
known O 
disruptor O 
of O 
p53-Mdm2 O 
interaction O 
, O 
to O 
validate O 
the O 
specificity O 
of O 
the O 
assay O 
. O 
The O 
reduction O 
of O 
BiFC O 
signal O 
mediated O 
by O 
nutlin-3 B-TRIVIAL 
was O 
correlated O 
with O 
an O 
increase O 
in O 
Puma O 
transactivation O 
, O 
PARP O 
cleavage O 
, O 
and O 
cell O 
death O 
. O 
Finally O 
, O 
this O 
novel O 
BiFC O 
approach O 
was O 
exploited O 
to O 
identify O 
potential O 
modulators O 
of O 
p53-Mdm2 O 
complex O 
formation O 
among O 
a O 
commercially O 
available O 
chemical O 
library O 
of O 
33 O 
protein O 
phosphatase O 
inhibitors O 
. O 
Our O 
results O 
constitute O 
" O 
proof O 
- O 
of O 
- O 
concept O 
" O 
that O 
this O 
model O 
has O 
strong O 
potential O 
as O 
an O 
alternative O 
to O 
traditional O 
target O 
- O 
based O 
drug O 
discovery O 
strategies O 
. O 
Identification O 
of O 
new O 
modulators O 
of O 
p53-p53 O 
and O 
p53-Mdm2 O 
interactions O 
will O 
be O 
useful O 
to O 
achieve O 
synergistic O 
drug O 
efficacy O 
with O 
currently O 
used O 
anti-tumor O 
therapies O 
. O 

use O 
of O 
prostaglandins B-FAMILY 
and O 
NSAIDS O 
in O 
the O 
clinic O 
has O 
proven O 
that O 
lipid O 
mediators O 
and O 
their O 
associated O 
pathways O 
make O 
attractive O 
therapeutic O 
targets O 
. O 
When O 
contemplating O 
therapies O 
involving O 
lipid O 
pathways O 
, O 
several O 
basic O 
agents O 
come O 
to O 
mind O 
. O 
There O 
are O 
the O 
enzymes O 
and O 
accessory O 
proteins O 
that O 
lead O 
to O 
the O 
metabolism O 
of O 
lipid O 
substrates O 
, O 
provided O 
through O 
diet O 
or O 
through O 
actions O 
of O 
lipases O 
, O 
the O 
subsequent O 
lipid O 
products O 
, O 
and O 
finally O 
the O 
lipid O 
sensors O 
or O 
receptors O 
. O 
There O 
is O 
abundant O 
evidence O 
that O 
molecules O 
along O 
this O 
lipid O 
continuum O 
can O 
serve O 
as O 
prognostic O 
and O 
diagnostic O 
indicators O 
and O 
are O 
in O 
fact O 
viable O 
therapeutic O 
targets O 
. O 
Furthermore O 
, O 
lipids O 
themselves O 
can O 
be O 
used O 
as O 
therapeutics O 
. O 
Despite O 
this O 
, O 
the O 
vernacular O 
dialog O 
pertaining O 
to O 
" O 
biomarkers O 
" O 
does O 
not O 
routinely O 
include O 
mention O 
of O 
lipids O 
, O 
though O 
this O 
is O 
rapidly O 
changing O 
. O 
Collectively O 
these O 
agents O 
are O 
becoming O 
more O 
appreciated O 
for O 
their O 
respective O 
roles O 
in O 
diverse O 
disease O 
processes O 
from O 
cancer O 
to O 
preterm O 
labor O 
and O 
are O 
receiving O 
their O 
due O 
appreciation O 
after O 
decades O 
of O 
ground O 
work O 
in O 
the O 
lipid O 
field O 
. O 
By O 
relating O 
examples O 
of O 
disease O 
processes O 
that O 
result O 
from O 
dysfunction O 
along O 
the O 
lipid O 
continuum O 
, O 
as O 
well O 
as O 
examples O 
of O 
lipid O 
therapies O 
and O 
emerging O 
technologies O 
, O 
this O 
review O 
is O 
meant O 
to O 
inspire O 
further O 
reading O 
and O 
discovery O 
. O 

of O 
Th1 O 
/ O 
Th17 O 
responses O 
via O 
suppression O 
of O 
STAT1 O 
and O 
STAT3 O 
activation O 
contributes O 
to O 
the O 
amelioration O 
of O 
murine O 
experimental O 
colitis O 
by O 
a O 
natural O 
flavonoid B-FAMILY 
glucoside O 
icariin B-TRIVIAL 
. O 

bowel O 
disease O 
( O 
IBD O 
) O 
is O 
a O 
chronic O 
inflammatory O 
disorder O 
in O 
the O 
intestine O 
which O 
involves O 
overproduction O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
and O 
excessive O 
functions O 
of O 
inflammatory O 
cells O 
. O 
However O 
, O 
current O 
treatments O 
for O 
IBD O 
may O 
have O 
potential O 
adverse O 
effects O 
including O 
steroid B-FAMILY 
dependence O 
, O 
infections O 
and O 
lymphoma O 
. O 
Therefore O 
new O 
therapies O 
or O 
drug O 
candidates O 
for O 
the O 
treatment O 
of O 
IBD O 
are O 
desperately O 
needed O 
. O 
In O 
the O 
present O 
study O 
we O 
found O 
that O 
icariin B-TRIVIAL 
, O 
a O 
major O 
bioactive O 
compound O 
from O 
plants O 
in O 
Epimedium O 
family O 
, O 
exerted O 
protective O 
effect O 
on O 
intestinal O 
inflammation O 
in O 
mice O 
induced O 
by O 
dextran O 
sulfate B-SYSTEMATIC 
sodium B-SYSTEMATIC 
. O 
Oral O 
administration O 
of O 
icariin B-TRIVIAL 
significantly O 
attenuated O 
the O 
disease O 
progression O 
and O 
alleviated O 
the O 
pathological O 
changes O 
of O 
colitis O 
. O 
It O 
also O 
inhibited O 
the O 
production O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
and O 
expression O 
of O 
p-p65 O 
, O 
p-STAT1 O 
and O 
p-STAT3 O 
in O 
colon O 
tissues O 
. O 
Further O 
study O 
showed O 
that O 
icariin B-TRIVIAL 
dose O 
- O 
dependently O 
inhibited O 
the O 
proliferation O 
and O 
activation O 
of O 
T O 
lymphocytes O 
, O 
and O 
suppressed O 
pro O 
- O 
inflammatory O 
cytokine O 
levels O 
of O 
activated O 
T O 
cells O 
. O 
Moreover O 
, O 
icariin B-TRIVIAL 
treatment O 
inhibited O 
the O 
phosphorylations O 
of O 
STAT1 O 
and O 
STAT3 O 
in O 
CD4(+) O 
T O 
cells O 
, O 
which O 
were O 
the O 
crucial O 
transcription O 
factors O 
for O 
Th1 O 
and O 
Th17 O 
respectively O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
icariin B-TRIVIAL 
is O 
a O 
potential O 
therapeutic O 
agent O 
for O 
IBD O 
. O 

and O 
long O 
- O 
term O 
exposure O 
of O 
CNS O 
cell O 
lines O 
to O 
BPA-f O 
a O 
radiosensitizer O 
for O 
Boron B-SYSTEMATIC 
Neutron O 
Capture O 
Therapy O 
: O 
safety O 
dose O 
evaluation O 
by O 
a O 
battery O 
of O 
cytotoxicity O 
tests O 
. O 

the O 
current O 
clinical O 
use O 
of O 
boronophenylalanine B-SYSTEMATIC 
- O 
fructose B-TRIVIAL 
( O 
BPA-f B-ABBREVIATION 
) O 
, O 
as O 
radiosensitizer O 
, O 
in O 
BNCT O 
application O 
for O 
brain O 
tumors O 
, O 
still O 
remains O 
to O 
be O 
determined O 
the O 
safety O 
dose O 
of O 
this O 
agent O 
. O 
We O 
evaluated O 
the O 
potential O 
risk O 
of O 
primary O 
BPA-f B-ABBREVIATION 
toxicity O 
before O 
neutronic O 
irradiation O 
at O 
different O 
concentrations O 
( O 
0-100μgBeq O 
/ O 
ml O 
) O 
after O 
short- O 
and O 
long O 
- O 
term O 
exposure O 
( O 
4-48h O 
and O 
7-10 O 
days O 
) O 
, O 
using O 
a O 
battery O 
of O 
tests O 
( O 
i.e O 
. O 
MTT B-ABBREVIATION 
assay O 
, O 
calcein-AM B-TRIVIAL 
/ O 
Propidium B-SYSTEMATIC 
Iodide I-SYSTEMATIC 
staining O 
, O 
clonogenic O 
test O 
) O 
in O 
CNS O 
cell O 
models O 
( O 
D384 O 
and O 
SH-SY5Y O 
) O 
, O 
and O 
non-neuronal O 
primary O 
human O 
fibroblasts O 
( O 
F26 O 
) O 
. O 
MTT B-ABBREVIATION 
data O 
showed O 
: O 
(i) O 
no O 
cytotoxic O 
effects O 
after O 
short O 
- O 
term O 
exposure O 
( O 
4h O 
) O 
to O 
any O 
of O 
BPA-f B-ABBREVIATION 
concentrations O 
tested O 
in O 
all O 
cell O 
models O 
; O 
(ii) O 
dose- O 
and O 
time O 
- O 
dependent O 
mitochondrial O 
activity O 
impairment O 
in O 
D384 O 
and O 
SH-SY5Y O 
cells O 
only O 
( O 
with O 
60% O 
and O 
40% O 
cell O 
death O 
in O 
D384 O 
and O 
SH-SY5Y O 
, O 
respectively O 
, O 
after O 
48h O 
exposure O 
to O 
BPA-f B-ABBREVIATION 
100μgBeq O 
/ O 
ml O 
) O 
. O 
By O 
Calcein-AM B-TRIVIAL 
/ O 
PI O 
staining O 
, O 
BPA-f B-ABBREVIATION 
treatment O 
was O 
specific O 
toward O 
SH-SY5Y O 
cells O 
only O 
: O 
a O 
dose O 
- O 
dependent O 
cell O 
density O 
reduction O 
was O 
observed O 
, O 
with O 
a O 
more O 
pronounced O 
effect O 
after O 
48h O 
exposure O 
( O 
15-40% O 
at O 
doses O 
ranging O 
20-100μgBeq O 
/ O 
ml O 
) O 
. O 
Clonogenic O 
data O 
revealed O 
dose O 
- O 
dependent O 
decrease O 
of O 
cell O 
proliferative O 
capacity O 
in O 
all O 
cell O 
lines O 
, O 
still O 
the O 
SH-SY5Y O 
cells O 
were O 
the O 
most O 
sensitive O 
ones O 
: O 
the O 
lowest O 
dose O 
( O 
20μgBeq O 
/ O 
ml O 
) O 
produced O 
90% O 
cell O 
decrease O 
. O 
These O 
results O 
indicate O 
dose- O 
and O 
time O 
- O 
dependent O 
cytotoxic O 
effects O 
of O 
BPA-f B-ABBREVIATION 
, O 
with O 
CNS O 
cells O 
showing O 
a O 
lower O 
tolerance O 
compared O 
to O 
fibroblasts O 
. O 
Long O 
- O 
term O 
exposure O 
to O 
BPA-f B-ABBREVIATION 
compromised O 
the O 
proliferative O 
capacity O 
regardless O 
of O 
cell O 
model O 
type O 
( O 
cell O 
sensitivity O 
being O 
SH-SY5Y O 
> O 
D384 O 
> O 
F26 O 
) O 
. O 
In O 
short O 
- O 
time O 
exposure O 
, O 
BPA-f B-ABBREVIATION 
exhibits O 
a O 
safe O 
dosage O 
up O 
to O 
40μgBeq O 
/ O 
ml O 
for O 
the O 
viability O 
of O 
CNS O 
cell O 
lines O 
. O 

A I-TRIVIAL 
suppresses O 
amyloid-β O 
oligomer O 
- O 
induced O 
microglia O 
activation O 
and O 
thereby O 
protects O 
PC-12 O 
cells O 
from O 
inflammation O 
- O 
mediated O 
toxicity O 
. O 

pathological O 
hallmark O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
aggregation O 
and O 
deposition O 
of O 
amyloid-β O 
peptides O 
, O 
has O 
been O 
recognized O 
as O 
a O 
potent O 
activator O 
of O 
microglia O 
- O 
mediated O 
neuroinflammation O 
and O 
neuronal O 
dysfunction O 
. O 
Therefore O 
, O 
downregulation O 
of O 
microglial O 
activation O 
has O 
a O 
significant O 
therapeutic O 
demand O 
. O 
In O 
this O 
study O 
, O 
focus O 
was O 
given O 
to O 
evaluate O 
the O 
ability O 
of O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
, O 
an O 
indole B-SYSTEMATIC 
alkaloid O 
isolated O 
from O 
marine O 
- O 
derived O 
Microsporum O 
sp O 
. O 
, O 
to O 
attenuate O 
microglial O 
activation O 
by O 
oligomeric O 
amyloid-β O 
1-42 O 
( O 
Aβ42 O 
) O 
. O 
Neoechinulin B-TRIVIAL 
A I-TRIVIAL 
treatment O 
significantly O 
inhibited O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
in O 
Aβ42-activated O 
BV-2 O 
microglia O 
cells O 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
significantly O 
suppressed O 
the O 
production O 
of O 
neurotoxic O 
inflammatory O 
mediator O 
tumour O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
interleukin-1β O 
( O 
IL-1β O 
) O 
, O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
in O 
activated O 
BV-2 O 
cells O 
. O 
Moreover O 
, O 
the O 
treatment O 
downregulated O 
the O 
protein O 
and O 
gene O 
expressions O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
TNF-α O 
, O 
IL-1β O 
and O 
IL-6 O 
. O 
Further O 
, O 
activated O 
microglia O 
- O 
mediated O 
apoptosis O 
of O 
PC-12 O 
pheochromocytoma O 
cells O 
was O 
significantly O 
repressed O 
by O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
. O 
The O 
molecular O 
mechanism O 
studies O 
suggested O 
that O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
may O 
block O 
the O 
phosphorylation O 
of O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
molecule O 
p38 O 
, O 
apoptosis O 
signal O 
- O 
regulating O 
kinase O 
1 O 
( O 
ASK-1 O 
) O 
and O 
nuclear O 
translocation O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
p65 O 
and O 
p50 O 
subunits O 
. O 
Regulation O 
of O 
these O 
signalling O 
pathways O 
have O 
most O 
probably O 
contributed O 
to O 
the O 
anti-inflammatory O 
activity O 
of O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
with O 
further O 
studies O 
neoechinulin B-TRIVIAL 
A I-TRIVIAL 
have O 
a O 
potential O 
to O 
be O 
developed O 
as O 
a O 
modulator O 
of O 
neuroinflammatory O 
process O 
in O 
AD O 
. O 

serious O 
limitation O 
of O 
the O 
conventional O 
comet O 
assay O 
( O 
single O 
cell O 
gel O 
electrophoresis O 
) O 
is O 
the O 
restriction O 
on O 
the O 
number O 
of O 
samples O 
that O 
can O 
be O 
processed O 
in O 
one O 
experiment O 
, O 
imposed O 
by O 
the O 
size O 
of O 
the O 
electrophoresis O 
platform O 
. O 
One O 
approach O 
to O 
increasing O 
throughput O 
is O 
to O 
reduce O 
the O 
size O 
of O 
gels O 
. O 
We O 
here O 
compare O 
the O 
conventional O 
system O 
of O 
two O 
large O 
gels O 
on O 
a O 
microscope O 
slide O 
, O 
with O 
two O 
recent O 
developments O 
, O 
namely O 
12 O 
minigels O 
per O 
slide O 
, O 
and O 
a O 
format O 
with O 
96 O 
minigels O 
on O 
GelBond O 
® O 
film O 
. O 
We O 
used O 
cells O 
treated O 
with O 
X-rays O 
or O 
methylmethanesulphonate B-SYSTEMATIC 
( O 
MMS B-ABBREVIATION 
) O 
. O 
The O 
level O 
of O 
damage O 
detected O 
( O 
% O 
tail O 
DNA O 
) O 
in O 
X-irradiated O 
or O 
MMS B-ABBREVIATION 
-treated O 
cells O 
was O 
not O 
affected O 
by O 
the O 
format O 
used O 
. O 
Parallel O 
experiments O 
, O 
using O 
all O 
three O 
formats O 
, O 
were O 
performed O 
with O 
MMS B-ABBREVIATION 
-treated O 
cells O 
in O 
two O 
independent O 
laboratories O 
; O 
the O 
difference O 
in O 
results O 
between O 
the O 
two O 
laboratories O 
was O 
of O 
borderline O 
significance O 
. O 
The O 
potential O 
problem O 
of O 
anomalous O 
comets O 
seen O 
at O 
the O 
border O 
of O 
the O 
gel O 
, O 
the O 
so O 
- O 
called O 
' O 
edge O 
effects O 
' O 
, O 
has O 
been O 
addressed O 
. O 
A O 
reliable O 
, O 
high O 
throughput O 
comet O 
assay O 
has O 
applications O 
in O 
genotoxicity O 
testing O 
( O 
particularly O 
for O 
in O 
vivo O 
studies O 
with O 
samples O 
from O 
different O 
organs O 
) O 
as O 
well O 
as O 
ecogenotoxicology O 
and O 
human O 
biomonitoring O 
, O 
where O 
the O 
numbers O 
of O 
samples O 
collected O 
can O 
be O 
considerable O 
. O 

effects O 
of O 
jaspamide B-TRIVIAL 
on O 
human O 
cardiomyocyte O 
function O 
and O 
cardiac O 
ion O 
channel O 
activity O 
. O 

( O 
jasplakinolide B-TRIVIAL 
; O 
NSC-613009 B-IDENTIFIER 
) O 
is O 
a O 
cyclodepsipeptide B-FAMILY 
that O 
has O 
antitumor O 
activity O 
. O 
A O 
narrow O 
margin O 
of O 
safety O 
was O 
observed O 
between O 
doses O 
required O 
for O 
efficacy O 
in O 
mouse O 
tumor O 
models O 
and O 
doses O 
that O 
caused O 
severe O 
acute O 
toxicity O 
in O 
rats O 
and O 
dogs O 
. O 
We O 
explored O 
the O 
hypothesis O 
that O 
the O 
observed O 
toxicity O 
was O 
due O 
to O 
cardiotoxicity O 
. O 
Jaspamide B-TRIVIAL 
was O 
tested O 
in O 
a O 
patch O 
clamp O 
assay O 
to O 
determine O 
its O 
effect O 
on O 
selected O 
cardiac O 
ion O 
channels O 
. O 
Jaspamide B-TRIVIAL 
( O 
10 O 
μM O 
) O 
inhibited O 
Kv1.5 O 
activity O 
by O 
98.5% O 
. O 
Jaspamide B-TRIVIAL 
also O 
inhibited O 
other O 
channels O 
including O 
Cav1.2 O 
, O 
Cav3.2 O 
, O 
and O 
HCN2 O 
; O 
however O 
, O 
the O 
Kv11.1 O 
( O 
hERG O 
) O 
channel O 
was O 
minimally O 
affected O 
. O 
Using O 
spontaneously O 
contracting O 
human O 
cardiomyocytes O 
derived O 
from O 
induced O 
pluripotent O 
stem O 
cells O 
, O 
effects O 
on O 
cardiomyocyte O 
contraction O 
and O 
viability O 
were O 
also O 
examined O 
. O 
Jaspamide B-TRIVIAL 
( O 
30 O 
nM O 
to O 
30 O 
μM O 
) O 
decreased O 
cardiomyocyte O 
cell O 
indices O 
and O 
beat O 
amplitude O 
, O 
putative O 
measurements O 
of O 
cell O 
viability O 
and O 
cardiac O 
contractility O 
, O 
respectively O 
. O 
Concentration O 
- O 
dependent O 
increases O 
in O 
rhythmic O 
beating O 
rate O 
were O 
noted O 
at O 
≤ O 
6 O 
h O 
of O 
treatment O 
, O 
followed O 
by O 
dose O 
- O 
dependent O 
decreases O 
after O 
6 O 
and O 
72 O 
h O 
exposure O 
. O 
The O 
toxic O 
effects O 
of O 
jaspamide B-TRIVIAL 
were O 
compared O 
with O 
that O 
of O 
the O 
known O 
cardiotoxicant O 
mitoxantrone B-TRIVIAL 
, O 
and O 
confirmed O 
by O 
multiparameter O 
fluorescence O 
imaging O 
analysis O 
. O 
These O 
results O 
support O 
the O 
hypothesis O 
that O 
the O 
toxicity O 
observed O 
in O 
rats O 
and O 
dogs O 
is O 
due O 
to O 
toxic O 
effects O 
of O 
jaspamide B-TRIVIAL 
on O 
cardiomyocytes O 
. O 

- O 
term O 
incubation O 
of O 
adult O 
Nereis O 
virens O 
( O 
Annelida O 
: O 
Polychaeta O 
) O 
in O 
copper B-SYSTEMATIC 
-spiked O 
sediment O 
: O 
the O 
effects O 
on O 
adult O 
mortality O 
, O 
gametogenesis O 
, O 
spawning O 
and O 
embryo O 
development O 
. O 

gametogenic O 
Nereis O 
virens O 
were O 
incubated O 
for O 
up O 
to O 
2.5 O 
months O 
in O 
environmentally O 
relevant O 
concentrations O 
of O 
copper B-SYSTEMATIC 
-spiked O 
sediment O 
. O 
Sequential O 
extraction O 
confirmed O 
that O 
much O 
more O 
labile O 
copper B-SYSTEMATIC 
( O 
in O 
actual O 
and O 
percentage O 
terms O 
) O 
was O 
present O 
as O 
spiked O 
concentrations O 
increased O 
, O 
although O 
the O 
residual O 
fractions O 
contained O 
similar O 
amounts O 
across O 
concentrations O 
. O 
This O 
is O 
also O 
reflected O 
in O 
the O 
tissue O 
concentration O 
of O 
the O 
worms O 
which O 
increased O 
in O 
line O 
with O 
the O 
sediment O 
concentrations O 
. O 
Adult O 
mortality O 
was O 
not O 
dependent O 
on O 
the O 
exposure O 
time O 
, O 
but O 
higher O 
concentrations O 
usually O 
induced O 
greater O 
mortality O 
for O 
both O 
sexes O 
. O 
Oocytes O 
were O 
significantly O 
smaller O 
at O 
higher O 
concentrations O 
although O 
pairwise O 
comparisons O 
did O 
not O 
show O 
specific O 
differences O 
. O 
Spawning O 
of O 
males O 
occurred O 
a O 
number O 
of O 
days O 
earlier O 
in O 
the O 
higher O 
concentrations O 
. O 
Differences O 
in O 
the O 
number O 
of O 
embryos O 
developing O 
normally O 
after O 
in O 
vitro O 
fertilizations O 
of O 
oocytes O 
fertilized O 
with O 
sperm O 
from O 
exposed O 
males O 
and O 
non-exposed O 
males O 
showed O 
that O 
sperm O 
were O 
more O 
susceptible O 
to O 
toxicity O 
, O 
but O 
oocytes O 
were O 
also O 
affected O 
at O 
the O 
highest O 
concentration O 
. O 
These O 
results O 
show O 
that O 
there O 
are O 
direct O 
and O 
indirect O 
reproductive O 
consequences O 
of O 
parental O 
exposure O 
to O 
copper B-SYSTEMATIC 
with O 
implications O 
for O 
recruitment O 
and O 
subsequent O 
colonization O 
of O 
polluted O 
sediments O 
for O 
this O 
ecologically O 
and O 
commercially O 
important O 
species O 
. O 

- I-TRIVIAL 
) I-TRIVIAL 
Epicatechin I-TRIVIAL 
attenuates O 
mitochondrial O 
damage O 
by O 
enhancing O 
mitochondrial O 
multi O 
- O 
marker O 
enzymes O 
, O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
and O 
lowering O 
calcium B-SYSTEMATIC 
in O 
isoproterenol B-TRIVIAL 
induced O 
myocardial O 
infarcted O 
rats O 
. O 

mitochondrial O 
damage O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathology O 
of O 
myocardial O 
infarction O 
. O 
The O 
protective O 
effects O 
of O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
on O 
cardiac O 
mitochondrial O 
damage O 
in O 
isoproterenol B-TRIVIAL 
induced O 
myocardial O 
infarction O 
were O 
evaluated O 
in O 
rats O 
. O 
Rats O 
were O 
pretreated O 
with O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
( O 
20 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
daily O 
for O 
a O 
period O 
of O 
21 O 
days O 
. O 
After O 
the O 
pretreatment O 
period O 
, O 
isoproterenol B-TRIVIAL 
( O 
100 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
was O 
injected O 
subcutaneously O 
into O 
rats O 
twice O 
at O 
an O 
interval O 
of O 
24 O 
h O 
to O 
induce O 
myocardial O 
infarction O 
. O 
Isoproterenol B-TRIVIAL 
induced O 
myocardial O 
infarcted O 
rats O 
showed O 
a O 
significant O 
increase O 
in O 
the O 
levels O 
of O 
cardiac O 
diagnostic O 
markers O 
, O 
heart O 
mitochondrial O 
lipid O 
peroxidation O 
, O 
calcium B-SYSTEMATIC 
, O 
and O 
a O 
significant O 
decrease O 
in O 
the O 
activities O 
/ O 
levels O 
of O 
heart O 
mitochondrial O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
, O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
, O 
isocitrate B-TRIVIAL 
, O 
succinate B-TRIVIAL 
, O 
malate B-TRIVIAL 
, O 
α-ketoglutarate B-TRIVIAL 
and O 
NADH B-ABBREVIATION 
-dehydrogenases O 
, O 
cytochrome-C-oxidase O 
and O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
. O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
Epicatechin I-TRIVIAL 
pretreatment O 
showed O 
significant O 
protective O 
effects O 
on O 
all O 
the O 
biochemical O 
parameters O 
evaluated O 
. O 
The O 
in O 
vitro O 
study O 
revealed O 
the O 
superoxide B-TRIVIAL 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
scavenging O 
activity O 
of O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
. O 
The O 
possible O 
mechanisms O 
for O 
the O 
beneficial O 
effects O 
of O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
on O 
cardiac O 
mitochondria O 
could O 
be O 
attributed O 
to O 
scavenging O 
of O 
free O 
radicals O 
, O 
decreasing O 
calcium B-SYSTEMATIC 
, O 
increasing O 
multi O 
- O 
enzymes O 
( O 
antioxidant O 
, O 
tricarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
cycle O 
and O 
respiratory O 
chain O 
enzymes O 
) O 
, O 
reduced O 
glutathione B-TRIVIAL 
and O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
. O 
Thus O 
, O 
( B-TRIVIAL 
- I-TRIVIAL 
) I-TRIVIAL 
epicatechin I-TRIVIAL 
attenuated O 
mitochondrial O 
damage O 
in O 
isoproterenol B-TRIVIAL 
induced O 
myocardial O 
infarcted O 
rats O 
. O 

present O 
study O 
examined O 
the O 
effect O 
of O 
insulin O 
- O 
mediated O 
activation O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
complex O 
1 O 
( O 
MTORC1 O 
) O 
signaling O 
network O 
on O 
the O 
proliferation O 
of O 
primary O 
culture O 
of O 
theca O 
- O 
interstitial O 
( O 
T-I O 
) O 
cells O 
. O 
Our O 
results O 
show O 
that O 
insulin O 
treatment O 
increased O 
proliferation O 
of O 
the O 
T-I O 
cells O 
through O 
the O 
MTORC1-dependent O 
signaling O 
pathway O 
by O 
increasing O 
cell O 
cycle O 
regulatory O 
proteins O 
. O 
Inhibition O 
of O 
ERK1 O 
/ O 
2 O 
signaling O 
caused O 
partial O 
reduction O 
of O 
insulin O 
- O 
induced O 
phosphorylation O 
of O 
RPS6KB1 O 
and O 
RPS6 O 
whereas O 
inhibition O 
of O 
PI3-kinase O 
signaling O 
completely O 
blocked O 
the O 
insulin O 
response O 
. O 
Pharmacological O 
inhibition O 
of O 
MTORC1 O 
with O 
rapamycin B-TRIVIAL 
abrogated O 
the O 
insulin O 
- O 
induced O 
phosphorylation O 
of O 
EIF4EBP1 O 
, O 
RPS6KB1 O 
and O 
its O 
downstream O 
effector O 
, O 
RPS6 O 
. O 
These O 
results O 
were O 
further O 
confirmed O 
by O 
demonstrating O 
that O 
knockdown O 
of O 
Mtor O 
using O 
siRNA O 
reduced O 
the O 
insulin O 
- O 
stimulated O 
MTORC1 O 
signaling O 
. O 
Furthermore O 
, O 
insulin O 
- O 
stimulated O 
T-I O 
cell O 
proliferation O 
and O 
the O 
expression O 
of O 
cell O 
cycle O 
regulatory O 
proteins O 
CDK4 O 
, O 
CCND3 O 
and O 
PCNA O 
were O 
also O 
blocked O 
by O 
rapamycin B-TRIVIAL 
. O 
Taken O 
together O 
, O 
the O 
present O 
studies O 
show O 
that O 
insulin O 
stimulates O 
cell O 
proliferation O 
and O 
cell O 
cycle O 
regulatory O 
proteins O 
in O 
T-I O 
cells O 
via O 
activation O 
of O 
the O 
MTORC1 O 
signaling O 
pathway O 
. O 

of O 
activity O 
and O 
inhibitor O 
sensitivity O 
of O 
rabbit O 
aldose B-FAMILY 
reductase O 
- O 
like O 
protein O 
( O 
AKR1B19 O 
) O 
by O 
oxidized B-TRIVIAL 
glutathione I-TRIVIAL 
and O 
SH B-FORMULA 
-reagents O 
. O 

aldo O 
- O 
keto O 
reductase O 
( O 
AKR O 
) O 
1B19 O 
is O 
an O 
ortholog O 
of O 
human O 
aldose B-FAMILY 
reductase O 
- O 
like O 
protein O 
( O 
ARLP O 
) O 
, O 
AKR1B10 O 
, O 
showing O 
86% O 
amino B-FAMILY 
acid I-FAMILY 
sequence O 
identity O 
. O 
AKR1B19 O 
exhibits O 
the O 
highest O 
catalytic O 
efficiency O 
for O 
4-oxo-2-nonenal B-SYSTEMATIC 
, O 
a O 
major O 
product O 
of O 
lipid O 
peroxidation O 
, O 
compared O 
to O 
known O 
reductases O 
of O 
this O 
aldehyde B-SYSTEMATIC 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
the O 
reductase O 
activity O 
of O 
AKR1B19 O 
was O 
activated O 
to O 
about O 
5-fold O 
immediately O 
after O 
the O 
addition O 
of O 
10 O 
μM O 
SH B-FORMULA 
-reagents O 
( O 
p-chloromercuriphenylsulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
p-chloromercuribenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
in O 
the O 
absence O 
or O 
presence O 
of O 
NADPH B-ABBREVIATION 
. O 
In O 
addition O 
, O 
a O 
maximum O 
of O 
3-fold O 
activation O 
of O 
AKR1B19 O 
was O 
induced O 
by O 
incubation O 
with O 
glutathione B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
GSSG B-ABBREVIATION 
) O 
for O 
1h O 
. O 
The O 
activated O 
enzyme O 
was O 
converted O 
into O 
the O 
native O 
enzyme O 
by O 
further O 
incubation O 
with O 
dithiothreitol B-SYSTEMATIC 
and O 
glutathione B-TRIVIAL 
. O 
The O 
activation O 
was O 
abolished O 
by O 
the O 
C299S O 
mutation O 
of O 
AKR1B19 O 
, O 
and O 
the O 
glutathionylated O 
Cys B-FORMULA 
299 O 
was O 
identified O 
by O 
mass O 
spectrometry O 
analysis O 
. O 
The O 
Cys B-FORMULA 
299- O 
modified O 
enzyme O 
displayed O 
different O 
kinetic O 
alterations O 
depending O 
on O 
substrates O 
and O 
inhibitors O 
. O 
In O 
the O 
reduction O 
of O 
4-oxo-2-nonenal B-SYSTEMATIC 
, O 
the O 
catalytic O 
efficiency O 
was O 
increased O 
. O 
Thus O 
, O 
AKR1B10 O 
may O 
be O 
modulated O 
by O 
cellular O 
ratio O 
of O 
GSSG B-ABBREVIATION 
/ O 
glutathione B-TRIVIAL 
and O 
more O 
efficiently O 
act O 
as O 
a O 
detoxifying O 
enzyme O 
for O 
the O 
cytotoxic O 
aldehyde B-SYSTEMATIC 
under O 
oxidatively O 
stressed O 
conditions O 
. O 
Furthermore O 
, O 
such O 
an O 
activity O 
alteration O 
by O 
GSSG B-ABBREVIATION 
was O 
not O 
detected O 
in O 
AKR1B10 O 
and O 
rat O 
ARLPs O 
, O 
suggesting O 
the O 
presence O 
of O 
a O 
GSSG B-ABBREVIATION 
-binding O 
site O 
near O 
Cys B-FORMULA 
299 O 
in O 
AKR1B19 O 
. O 

effect O 
of O 
triclosan B-TRIVIAL 
on O 
the O 
uterotrophic O 
response O 
to O 
extended O 
doses O 
of O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
in O 
the O 
weanling O 
rat O 
. O 

( O 
TCS B-ABBREVIATION 
) O 
, O 
an O 
antibacterial O 
, O 
has O 
been O 
shown O 
to O 
be O 
an O 
endocrine O 
disruptor O 
in O 
the O 
rat O 
. O 
We O 
reported O 
previously O 
that O 
TCS B-ABBREVIATION 
potentiated O 
the O 
estrogenic O 
effect O 
of O 
ethinyl B-TRIVIAL 
estradiol I-TRIVIAL 
( O 
EE O 
) O 
on O 
uterine O 
growth O 
in O 
rats O 
exposed O 
to O 
EE O 
and O 
TCS B-ABBREVIATION 
in O 
the O 
uterotrophic O 
assay O 
, O 
whereas O 
TCS B-ABBREVIATION 
alone O 
had O 
no O 
effect O 
. O 
To O 
further O 
characterize O 
this O 
potentiation O 
, O 
we O 
evaluated O 
the O 
effect O 
of O 
co O 
- O 
exposure O 
with O 
lower O 
doses O 
of O 
EE O 
that O 
are O 
comparable O 
to O 
the O 
concentrations O 
in O 
hormone O 
replacement O 
regimens O 
and O 
began O 
to O 
assess O 
the O 
mechanisms O 
by O 
which O 
this O 
potentiation O 
occurs O 
. O 
Changes O 
in O 
uterine O 
weight O 
, O 
epithelial O 
cell O 
growth O 
, O 
and O 
estrogen B-FAMILY 
-sensitive O 
gene O 
expression O 
were O 
assessed O 
. O 
TCS B-ABBREVIATION 
expectedly O 
enhanced O 
the O 
uterotrophic O 
response O 
to O 
EE O 
, O 
however O 
at O 
significantly O 
lower O 
doses O 
of O 
EE O 
. O 
Similarly O 
, O 
TCS B-ABBREVIATION 
increased O 
the O 
EE-induced O 
stimulation O 
of O 
epithelial O 
cell O 
height O 
following O 
cotreatment O 
. O 
Cotreatment O 
also O 
enhanced O 
the O 
estrogen B-FAMILY 
-induced O 
change O 
in O 
gene O 
expression O 
, O 
which O 
was O 
reversed O 
with O 
an O 
ER O 
antagonist O 
. O 
Furthermore O 
, O 
the O 
TCS B-ABBREVIATION 
-induced O 
potentiation O 
was O 
independent O 
of O 
ER O 
activation O 
, O 
as O 
no O 
effects O 
were O 
observed O 
in O 
the O 
ER O 
TA O 
assay O 
. O 

, O 
a O 
natural O 
product O 
, O 
has O 
been O 
reported O 
to O 
have O 
antioxidant O 
activities O 
such O 
as O 
the O 
scavenging O 
of O 
free O 
radicals O 
. O 
This O 
compound O 
could O 
be O 
used O 
in O 
the O 
dermocosmetic O 
field O 
to O 
protect O 
the O 
skin O 
from O 
oxidative O 
stress O 
. O 
In O 
this O 
work O 
, O 
the O 
percutaneous O 
profile O 
of O 
resveratrol B-TRIVIAL 
in O 
ethanol B-SYSTEMATIC 
solutions O 
through O 
pig O 
skin O 
was O 
determinated O 
by O 
an O 
in O 
vitro O 
methodology O 
. O 
The O 
percutaneous O 
absorption O 
of O 
resveratrol B-TRIVIAL 
was O 
measured O 
and O 
compared O 
with O 
trolox B-TRIVIAL 
, O 
an O 
analogous O 
of O 
Vitamin B-FAMILY 
E I-FAMILY 
. O 
Both O 
antioxidants O 
were O 
found O 
in O 
all O 
skin O 
sections O 
( O 
stratum O 
corneum O 
, O 
epidermis O 
, O 
and O 
dermis O 
) O 
. O 
Besides O 
, O 
the O 
free O 
radical O 
scavenging O 
activity O 
of O 
resveratrol B-TRIVIAL 
and O 
trolox B-TRIVIAL 
has O 
been O 
evaluated O 
using O 
DPPH B-ABBREVIATION 
method O 
. O 
The O 
effective O 
dose O 
( O 
ED50 O 
) O 
of O 
compounds O 
and O 
DPPH B-ABBREVIATION 
radical O 
inhibition O 
in O 
each O 
skin O 
layer O 
were O 
evaluated O 
. O 
Under O 
the O 
conditions O 
used O 
for O 
these O 
experiments O 
, O 
it O 
can O 
be O 
deduced O 
that O 
resveratrol B-TRIVIAL 
is O 
more O 
efficient O 
than O 
trolox B-TRIVIAL 
as O 
an O 
antioxidant O 
, O 
also O 
in O 
the O 
inner O 
skin O 
layers O 
. O 
The O 
cosmeto O 
- O 
textiles O 
with O 
an O 
active O 
substance O 
incorporated O 
into O 
their O 
structure O 
are O 
increasingly O 
used O 
in O 
the O 
cosmetics O 
and O 
pharmaceutical O 
industries O 
. O 
The O 
action O 
of O 
several O 
cosmeto O 
- O 
textiles O 
on O 
the O 
skin O 
was O 
assessed O 
by O 
in O 
vitro O 
and O 
in O 
vivo O 
methodologies O 
. O 
Samples O 
of O 
these O 
cosmeto O 
- O 
textiles O 
were O 
prepared O 
with O 
resveratrol B-TRIVIAL 
incorporated O 
into O 
cotton O 
and O 
polyamide B-FAMILY 
fabrics O 
. O 
An O 
in O 
vitro O 
percutaneous O 
absorption O 
was O 
used O 
to O 
demonstrate O 
the O 
delivery O 
of O 
the O 
resveratrol B-TRIVIAL 
from O 
the O 
textile O 
to O 
the O 
different O 
skin O 
layers O 
( O 
stratum O 
corneum O 
, O 
epidermis O 
, O 
and O 
dermis O 
) O 
. O 
Additionally O 
, O 
these O 
cosmeto O 
- O 
textiles O 
containing O 
the O 
antioxidant O 
were O 
applied O 
onto O 
the O 
forearms O 
of O 
volunteers O 
to O 
evaluate O 
the O 
textiles O 
' O 
efficacy O 
in O 
skin O 
penetration O 
. O 
The O 
antioxidant's O 
antiradical O 
capacity O 
was O 
evaluated O 
using O 
the O 
DPPH B-ABBREVIATION 
method O 
. O 
Results O 
showed O 
that O 
resveratrol B-TRIVIAL 
could O 
be O 
detected O 
in O 
the O 
dermis O 
, O 
epidermis O 
, O 
and O 
stratum O 
corneum O 
( O 
SC O 
) O 
by O 
an O 
in O 
vitro O 
percutaneous O 
absorption O 
method O 
and O 
was O 
also O 
detected O 
in O 
the O 
outermost O 
layers O 
of O 
the O 
SC O 
by O 
an O 
in O 
vivo O 
method O 
( O 
stripping O 
) O 
. O 
A O 
smaller O 
amount O 
of O 
resveratrol B-TRIVIAL 
was O 
penetrated O 
through O 
the O 
skin O 
layers O 
when O 
cosmeto O 
- O 
textiles O 
were O 
used O 
compared O 
to O 
direct O 
topical O 
application O 
of O 
the O 
antioxidant O 
solution O 
. O 
The O 
cosmeto O 
- O 
textiles O 
investigated O 
can O 
act O 
as O 
a O 
reservoir O 
system O 
capable O 
of O 
progressively O 
deliver O 
the O 
active O 
substance O 
to O 
the O 
skin O 
layers O 
. O 
From O 
the O 
skin O 
penetration O 
profiles O 
and O 
the O 
antioxidant O 
efficacy O 
assessment O 
of O 
resveratrol B-TRIVIAL 
, O 
it O 
is O 
possible O 
to O 
ameliorate O 
the O 
inherent O 
antioxidant O 
capacity O 
of O 
skin O 
. O 

photothermal O 
therapy O 
increases O 
the O 
tumor O 
mass O 
penetration O 
of O 
HPMA B-ABBREVIATION 
copolymers O 
. O 

drug O 
delivery O 
to O 
tumors O 
requires O 
both O 
transport O 
through O 
the O 
vasculature O 
and O 
tumor O 
interstitium O 
. O 
Previously O 
, O 
it O 
was O 
shown O 
that O 
gold O 
nanorod O 
( O 
GNR O 
) O 
mediated O 
plasmonic O 
photothermal O 
therapy O 
( O 
PPTT O 
) O 
is O 
capable O 
of O 
increasing O 
the O 
overall O 
accumulation O 
of O 
N-(2-hydroxypropyl)methacrylamide B-SYSTEMATIC 
( O 
HPMA B-ABBREVIATION 
) O 
copolymers O 
in O 
prostate O 
tumors O 
. O 
In O 
the O 
present O 
study O 
, O 
it O 
is O 
demonstrated O 
that O 
PPTT O 
is O 
also O 
capable O 
of O 
increasing O 
the O 
distribution O 
of O 
these O 
conjugates O 
in O 
tumors O 
. O 
Gadolinium B-SYSTEMATIC 
labeled O 
HPMA B-ABBREVIATION 
copolymers O 
were O 
administered O 
to O 
mice O 
bearing O 
prostate O 
tumors O 
immediately O 
before O 
treatment O 
of O 
the O 
right O 
tumor O 
with O 
PPTT O 
. O 
The O 
left O 
tumor O 
served O 
as O 
internal O 
, O 
untreated O 
control O 
. O 
Magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
of O 
both O 
tumors O 
showed O 
that O 
PPTT O 
was O 
capable O 
of O 
improving O 
the O 
tumor O 
mass O 
penetration O 
of O 
HPMA B-ABBREVIATION 
copolymers O 
. O 
Thermal O 
enhancement O 
of O 
delivery O 
, O 
roughly O 
1.5-fold O 
, O 
to O 
both O 
the O 
tumor O 
center O 
and O 
periphery O 
was O 
observed O 
. O 
Confocal O 
microscopy O 
of O 
fluorescently O 
labeled O 
copolymers O 
corroborates O 
these O 
findings O 
in O 
that O 
PPTT O 
is O 
capable O 
of O 
delivering O 
more O 
HPMA B-ABBREVIATION 
copolymers O 
to O 
the O 
tumor's O 
center O 
and O 
periphery O 
. O 
These O 
results O 
further O 
demonstrate O 
that O 
PPTT O 
is O 
a O 
useful O 
tool O 
to O 
improve O 
the O 
delivery O 
of O 
polymer O 
- O 
drug O 
conjugates O 
. O 

targeting O 
the O 
orphan O 
receptor O 
GPR35 O 
have O 
potential O 
therapeutic O 
application O 
in O 
a O 
number O 
of O 
disease O 
areas O 
, O 
including O 
inflammation O 
, O 
metabolic O 
disorders O 
, O 
nociception O 
, O 
and O 
cardiovascular O 
disease O 
. O 
Currently O 
available O 
surrogate O 
GPR35 O 
agonists O 
identified O 
from O 
pharmacologically O 
relevant O 
compound O 
libraries O 
have O 
limited O 
utility O 
due O 
to O 
the O 
likelihood O 
of O 
off O 
- O 
target O 
effects O 
in O 
vitro O 
and O 
in O 
vivo O 
and O 
the O 
variable O 
potency O 
that O 
such O 
ligands O 
exhibit O 
across O 
species O 
. O 
We O 
sought O 
to O 
identify O 
and O 
characterize O 
novel O 
GPR35 O 
agonists O 
to O 
facilitate O 
studies O 
aimed O 
at O 
defining O 
the O 
physiologic O 
role O 
of O 
GPR35 O 
. O 
PathHunter O 
β-arrestin O 
recruitment O 
technology O 
was O 
validated O 
as O 
a O 
human O 
GPR35 O 
screening O 
assay O 
, O 
and O 
a O 
high O 
- O 
throughput O 
screen O 
of O 
100000 O 
diverse O 
low O 
molecular O 
weight O 
compounds O 
was O 
conducted O 
. O 
Confirmed O 
GPR35 O 
agonists O 
from O 
five O 
distinct O 
chemotypes O 
were O 
selected O 
for O 
detailed O 
characterization O 
using O 
both O 
β-arrestin O 
recruitment O 
and O 
G O 
protein O 
- O 
dependent O 
assays O 
and O 
each O 
of O 
the O 
human O 
, O 
mouse O 
, O 
and O 
rat O 
GPR35 O 
orthologs O 
. O 
These O 
studies O 
identified O 
4-{(Z)-[(2Z)-2-(2-fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl}benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
compound O 
1 O 
) O 
as O 
the O 
highest O 
potency O 
full O 
agonist O 
of O 
human O 
GPR35 O 
yet O 
described O 
. O 
As O 
with O 
certain O 
other O 
GPR35 O 
agonists O 
, O 
compound O 
1 O 
was O 
markedly O 
selective O 
for O 
human O 
GPR35 O 
, O 
but O 
displayed O 
elements O 
of O 
signal O 
bias O 
between O 
β-arrestin-2 O 
and O 
G O 
protein O 
- O 
dependent O 
assays O 
. O 
Compound O 
1 O 
also O 
displayed O 
competitive O 
behavior O 
when O 
assessed O 
against O 
the O 
human O 
GPR35 O 
antagonist O 
, O 
ML-145 B-IDENTIFIER 
( O 
2-hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
. O 
Of O 
the O 
other O 
chemotypes O 
studied O 
, O 
compounds O 
2 O 
and O 
3 O 
were O 
selective O 
for O 
the O 
human O 
receptor O 
, O 
but O 
compounds O 
4 O 
and O 
5 O 
demonstrated O 
similar O 
activity O 
at O 
human O 
, O 
rat O 
, O 
and O 
mouse O 
GPR35 O 
orthologs O 
. O 
Further O 
characterization O 
of O 
these O 
compounds O 
and O 
related O 
analogs O 
is O 
likely O 
to O 
facilitate O 
a O 
better O 
understanding O 
of O 
GPR35 O 
in O 
health O 
and O 
disease O 
. O 

exposure O 
induces O 
α-synuclein O 
aggregation O 
in O 
the O 
frontal O 
cortex O 
of O 
non-human O 
primates O 
. O 

of O 
α-synuclein O 
( O 
α-syn O 
) O 
in O 
the O 
brain O 
is O 
a O 
defining O 
pathological O 
feature O 
of O 
neurodegenerative O 
disorders O 
classified O 
as O 
synucleinopathies O 
. O 
They O 
include O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
, O 
dementia O 
with O 
Lewy O 
bodies O 
( O 
DLB O 
) O 
, O 
and O 
multiple O 
system O 
atrophy O 
( O 
MSA O 
) O 
. O 
Occupational O 
and O 
environmental O 
exposure O 
to O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
is O 
associated O 
with O 
a O 
neurological O 
syndrome O 
consisting O 
of O 
psychiatric O 
symptoms O 
, O 
cognitive O 
impairment O 
and O 
parkinsonism O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
α-syn O 
immunoreactivity O 
in O 
the O 
frontal O 
cortex O 
of O 
Cynomolgus O 
macaques O 
as O 
part O 
of O 
a O 
multidisciplinary O 
assessment O 
of O 
the O 
neurological O 
effects O 
produced O 
by O 
exposure O 
to O 
moderate O 
levels O 
of O 
Mn B-FORMULA 
. O 
We O 
found O 
increased O 
α-syn-positive O 
cells O 
in O 
the O 
gray O 
matter O 
of O 
Mn B-FORMULA 
-exposed O 
animals O 
, O 
typically O 
observed O 
in O 
pyramidal O 
and O 
medium O 
- O 
sized O 
neurons O 
in O 
deep O 
cortical O 
layers O 
. O 
Some O 
of O 
these O 
neurons O 
displayed O 
loss O 
of O 
Nissl O 
staining O 
with O 
α-syn-positive O 
spherical O 
aggregates O 
. O 
In O 
the O 
white O 
matter O 
we O 
also O 
observed O 
α-syn-positive O 
glial O 
cells O 
and O 
in O 
some O 
cases O 
α-syn-positive O 
neurites O 
. O 
These O 
findings O 
suggest O 
that O 
Mn B-FORMULA 
exposure O 
promotes O 
α-syn O 
aggregation O 
in O 
neuronal O 
and O 
glial O 
cells O 
that O 
may O 
ultimately O 
lead O 
to O 
degeneration O 
in O 
the O 
frontal O 
cortex O 
gray O 
and O 
white O 
matter O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
Mn B-FORMULA 
-induced O 
neuronal O 
and O 
glial O 
cell O 
α-syn O 
accumulation O 
and O 
aggregation O 
in O 
the O 
frontal O 
cortex O 
of O 
non-human O 
primates O 
. O 

leptin O 
sensitivity O 
, O 
reduced O 
adiposity O 
, O 
and O 
improved O 
glucose B-TRIVIAL 
homeostasis O 
in O 
mice O 
lacking O 
exchange O 
protein O 
directly O 
activated O 
by O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
isoform O 
1 O 
. O 

prototypic O 
second O 
messenger O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
( O 
cAMP B-ABBREVIATION 
) O 
is O 
essential O 
for O 
controlling O 
cellular O 
metabolism O 
, O 
including O 
glucose B-TRIVIAL 
and O 
lipid O 
homeostasis O 
. O 
In O 
mammals O 
, O 
the O 
majority O 
of O 
cAMP O 
functions O 
are O 
mediated O 
by O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
and O 
exchange O 
proteins O 
directly O 
activated O 
by O 
cAMP B-ABBREVIATION 
( O 
Epacs O 
) O 
. O 
To O 
explore O 
the O 
physiological O 
functions O 
of O 
Epac1 O 
, O 
we O 
generated O 
Epac1 O 
knockout O 
mice O 
. O 
Here O 
we O 
report O 
that O 
Epac1 O 
nan O 
mutants O 
have O 
reduced O 
white O 
adipose O 
tissue O 
and O 
reduced O 
plasma O 
leptin O 
levels O 
but O 
display O 
heightened O 
leptin O 
sensitivity O 
. O 
Epac1-deficient O 
mice O 
are O 
more O 
resistant O 
to O 
high O 
- O 
fat O 
diet O 
- O 
induced O 
obesity O 
, O 
hyperleptinemia O 
, O 
and O 
glucose B-TRIVIAL 
intolerance O 
. O 
Furthermore O 
, O 
pharmacological O 
inhibition O 
of O 
Epac O 
by O 
use O 
of O 
an O 
Epac O 
- O 
specific O 
inhibitor O 
reduces O 
plasma O 
leptin O 
levels O 
in O 
vivo O 
and O 
enhances O 
leptin O 
signaling O 
in O 
organotypic O 
hypothalamic O 
slices O 
. O 
Taken O 
together O 
, O 
our O 
results O 
demonstrate O 
that O 
Epac1 O 
plays O 
an O 
important O 
role O 
in O 
regulating O 
adiposity O 
and O 
energy O 
balance O 
. O 

of O 
fluoxetine B-TRIVIAL 
on O 
the O 
swimming O 
and O 
behavioural O 
responses O 
of O 
the O 
Arabian O 
killifish O 
. O 

selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
fluoxetine B-TRIVIAL 
has O 
frequently O 
been O 
detected O 
in O 
surface O 
waters O 
around O 
the O 
world O 
. O 
Fluoxetine B-TRIVIAL 
modulates O 
levels O 
of O 
serotonin B-TRIVIAL 
, O 
a O 
neurotransmitter O 
that O 
regulates O 
several O 
important O 
physiological O 
and O 
behavioural O 
processes O 
including O 
fear O 
and O 
anxiety O 
, O 
aggression O 
, O 
locomotion O 
and O 
feeding O 
. O 
In O 
this O 
study O 
, O 
groups O 
of O 
sub O 
- O 
adult O 
Arabian O 
killifish O 
( O 
Aphanius O 
dispar O 
) O 
were O 
exposed O 
to O 
either O 
0 O 
, O 
0.03 O 
, O 
0.3 O 
or O 
3 O 
μg O 
/ O 
L O 
fluoxetine B-TRIVIAL 
hydrochloride B-FAMILY 
for O 
7 O 
days O 
and O 
their O 
swimming O 
behaviour O 
and O 
social O 
interactions O 
videotaped O 
in O 
a O 
circular O 
arena O 
. O 
The O 
fish O 
were O 
subsequently O 
exposed O 
to O 
a O 
predator O 
alarm O 
chemical O 
( O 
from O 
dragonfly O 
larvae O 
fed O 
with O 
A O 
. O 
dispar O 
) O 
and O 
their O 
short O 
- O 
term O 
responses O 
recorded O 
. O 
The O 
video O 
was O 
analysed O 
using O 
the O 
open O 
- O 
sourced O 
software O 
program O 
Ctrax O 
which O 
objectively O 
quantified O 
swimming O 
and O 
social O 
behaviours O 
. O 
Aggression O 
( O 
chasing O 
behaviour O 
was O 
significantly O 
reduced O 
at O 
3 O 
μg O 
/ O 
L O 
fluoxetine B-TRIVIAL 
. O 
After O 
the O 
addition O 
of O 
the O 
predator O 
alarm O 
chemicals O 
fish O 
responded O 
quickly O 
, O 
increasing O 
the O 
percentage O 
of O 
time O 
spent O 
drifting O 
or O 
motionless O 
and O 
reducing O 
average O 
swimming O 
velocity O 
. O 
Controls O 
and O 
fish O 
exposed O 
to O 
0.03 O 
or O 
3 O 
μg O 
/ O 
L O 
fluoxetine B-TRIVIAL 
reduced O 
swimming O 
speed O 
by O 
20-30 O 
% O 
but O 
returned O 
to O 
pre O 
- O 
exposure O 
velocities O 
within O 
6 O 
min O 
. O 
Fish O 
exposed O 
to O 
0.3 O 
μg O 
/ O 
L O 
fluoxetine B-TRIVIAL 
reduced O 
swimming O 
speed O 
by O 
38 O 
% O 
after O 
addition O 
of O 
the O 
predator O 
alarm O 
and O 
did O 
not O 
return O 
to O 
pre O 
- O 
exposure O 
speeds O 
during O 
the O 
recording O 
period O 
( O 
19 O 
min O 
) O 
. O 
Schooling O 
behaviour O 
was O 
also O 
affected O 
by O 
fluoxetine B-TRIVIAL 
and O 
predator O 
alarm O 
with O 
fish O 
exposed O 
to O 
0.3 O 
μg O 
/ O 
L O 
fluoxetine B-TRIVIAL 
significantly O 
reducing O 
nearest O 
neighbour O 
distance O 
and O 
swimming O 
speed O 
relative O 
to O 
nearest O 
neighbour O 
the O 
following O 
addition O 
of O 
the O 
predator O 
alarm O 
. O 

and O 
interferon O 
tau O 
regulation O 
of O 
endometrial O 
function O 
and O 
conceptus O 
development O 
in O 
female O 
sheep O 
. O 

early O 
pregnancy O 
in O 
sheep O 
, O 
the O 
elongating O 
conceptus O 
secretes O 
interferon-τ O 
( O 
IFNT O 
) O 
and O 
the O 
conceptus O 
as O 
well O 
as O 
endometrial O 
epithelia O 
produce O 
prostaglandins B-FAMILY 
( O 
PG O 
) O 
via O 
PG O 
synthase O 
2 O 
( O 
PTGS2 O 
) O 
and O 
cortisol B-TRIVIAL 
via O 
hydroxysteroid B-FAMILY 
( O 
11-β O 
) O 
dehydrogenase O 
1 O 
( O 
HSD11B1 O 
) O 
. O 
Ovarian O 
progesterone B-TRIVIAL 
induces O 
and O 
PG O 
and O 
IFNT O 
stimulates O 
endometrial O 
HSD11B1 O 
expression O 
and O 
keto B-SYSTEMATIC 
-reductase O 
activity O 
as O 
well O 
as O 
many O 
epithelial O 
genes O 
that O 
govern O 
trophectoderm O 
proliferation O 
, O 
migration O 
, O 
and O 
attachment O 
during O 
elongation O 
. O 
The O 
primary O 
aim O 
of O 
these O 
studies O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
HSD11B1 O 
- O 
derived O 
cortisol B-TRIVIAL 
has O 
a O 
biological O 
role O 
in O 
endometrial O 
function O 
and O 
conceptus O 
development O 
during O 
early O 
pregnancy O 
in O 
sheep O 
. O 
In O 
study O 
1 O 
, O 
cyclic O 
ewes O 
received O 
vehicle O 
, O 
cortisol B-TRIVIAL 
, O 
PF B-IDENTIFIER 
915275 I-IDENTIFIER 
( O 
PF O 
; O 
a O 
selective O 
inhibitor O 
of O 
HSD11B1 O 
) O 
, O 
cortisol B-TRIVIAL 
and O 
PF O 
, O 
meloxicam B-TRIVIAL 
( O 
a O 
selective O 
inhibitor O 
of O 
PTGS2 O 
) O 
, O 
cortisol B-TRIVIAL 
and O 
meloxicam B-TRIVIAL 
, O 
recombinant O 
ovine O 
IFNT O 
, O 
or O 
IFNT O 
and O 
PF O 
into O 
the O 
uterus O 
from O 
day O 
10 O 
to O 
day14 O 
after O 
estrus O 
. O 
Cortisol B-TRIVIAL 
and O 
IFNT O 
stimulated O 
endometrial O 
HSD11B1 O 
expression O 
and O 
activity O 
, O 
increased O 
endometrial O 
PTGS2 O 
activity O 
and O 
the O 
amount O 
of O 
PG O 
in O 
the O 
uterine O 
lumen O 
, O 
and O 
up O 
- O 
regulated O 
many O 
conceptus O 
elongation O 
- O 
related O 
genes O 
in O 
the O 
endometrium O 
. O 
Some O 
effects O 
of O 
cortisol B-TRIVIAL 
and O 
IFNT O 
were O 
mediated O 
by O 
PTGS2 O 
- O 
derived O 
PG O 
. O 
In O 
study O 
2 O 
, O 
bred O 
ewes O 
received O 
PF B-IDENTIFIER 
915275 I-IDENTIFIER 
or O 
recombinant O 
ovine O 
IFNT O 
and O 
into O 
the O 
uterus O 
from O 
day O 
10 O 
to O 
day O 
14 O 
after O 
mating O 
. O 
Inhibition O 
of O 
HSD11B1 O 
activity O 
in O 
utero O 
prevented O 
conceptus O 
elongation O 
, O 
whereas O 
IFNT O 
rescued O 
conceptus O 
elongation O 
in O 
PF-infused O 
ewes O 
. O 
These O 
results O 
suggest O 
that O 
HSD11B1 O 
- O 
derived O 
cortisol B-TRIVIAL 
mediates O 
, O 
in O 
part O 
, O 
actions O 
of O 
ovarian O 
progesterone B-TRIVIAL 
and O 
the O 
conceptus O 
on O 
endometrial O 
function O 
and O 
support O 
the O 
hypothesis O 
that O 
IFNT O 
, O 
PG O 
, O 
and O 
cortisol B-TRIVIAL 
coordinately O 
regulate O 
endometrial O 
functions O 
important O 
for O 
conceptus O 
elongation O 
and O 
implantation O 
during O 
early O 
pregnancy O 
in O 
sheep O 
. O 

modified O 
proteins O 
are O 
invaluable O 
tools O 
for O 
studying O 
the O 
molecular O 
details O 
of O 
biological O 
processes O 
, O 
and O 
they O 
also O 
hold O 
great O 
potential O 
as O 
new O 
therapeutic O 
agents O 
. O 
Several O 
methods O 
have O 
been O 
developed O 
for O 
the O 
site O 
- O 
specific O 
modification O 
of O 
proteins O 
, O 
one O 
of O 
the O 
most O 
widely O 
used O 
being O 
expressed O 
protein O 
ligation O 
( O 
EPL O 
) O 
in O 
which O 
a O 
recombinant O 
α-thioester B-FAMILY 
is O 
ligated O 
to O 
an O 
N B-FORMULA 
-terminal O 
Cys B-FORMULA 
-containing O 
peptide O 
. O 
Despite O 
the O 
widespread O 
use O 
of O 
EPL O 
, O 
the O 
generation O 
and O 
isolation O 
of O 
the O 
required O 
recombinant O 
protein O 
α-thioesters B-FAMILY 
remain O 
challenging O 
. O 
We O 
describe O 
here O 
a O 
new O 
method O 
for O 
the O 
preparation O 
and O 
purification O 
of O 
recombinant O 
protein O 
α-thioesters B-FAMILY 
using O 
engineered O 
versions O 
of O 
naturally O 
split O 
DnaE O 
inteins O 
. O 
This O 
family O 
of O 
autoprocessing O 
enzymes O 
is O 
closely O 
related O 
to O 
the O 
inteins O 
currently O 
used O 
for O 
protein O 
α-thioester B-FAMILY 
generation O 
, O 
but O 
they O 
feature O 
faster O 
kinetics O 
and O 
are O 
split O 
into O 
two O 
inactive O 
polypeptides O 
that O 
need O 
to O 
associate O 
to O 
become O 
active O 
. O 
Taking O 
advantage O 
of O 
the O 
strong O 
affinity O 
between O 
the O 
two O 
split O 
intein O 
fragments O 
, O 
we O 
devised O 
a O 
streamlined O 
procedure O 
for O 
the O 
purification O 
and O 
generation O 
of O 
protein O 
α-thioesters B-FAMILY 
from O 
cell O 
lysates O 
and O 
applied O 
this O 
strategy O 
for O 
the O 
semisynthesis O 
of O 
a O 
variety O 
of O 
proteins O 
including O 
an O 
acetylated O 
histone O 
and O 
a O 
site O 
- O 
specifically O 
modified O 
monoclonal O 
antibody O 
. O 

brush O 
layers O 
based O 
on O 
block O 
copolymers O 
of O 
poly(oligo(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
POEGMA B-ABBREVIATION 
) O 
and O 
poly(glycidyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PGMA B-ABBREVIATION 
) O 
were O 
formed O 
on O 
silicon B-SYSTEMATIC 
wafers O 
by O 
activators O 
generated O 
by O 
electron O 
transfer O 
atom O 
transfer O 
radical O 
polymerization O 
( O 
AGET O 
ATRP O 
) O 
. O 
Different O 
types O 
of O 
biomolecule O 
can O 
be O 
conjugated O 
to O 
these O 
brush O 
layers O 
by O 
reaction O 
of O 
PGMA B-ABBREVIATION 
epoxide B-SYSTEMATIC 
groups O 
with O 
amino B-FAMILY 
groups O 
in O 
the O 
biomolecule O 
, O 
while O 
POEGMA B-ABBREVIATION 
, O 
which O 
resists O 
nonspecific O 
protein O 
adsorption O 
, O 
provides O 
an O 
antifouling O 
environment O 
. O 
Surfaces O 
were O 
characterized O 
by O 
water O 
contact O 
angle O 
, O 
ellipsometry O 
, O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
to O 
confirm O 
the O 
modification O 
reactions O 
. O 
Phase O 
segregation O 
of O 
the O 
copolymer O 
blocks O 
in O 
the O 
layers O 
was O 
observed O 
by O 
AFM O 
. O 
The O 
effect O 
of O 
surface O 
properties O 
on O 
protein O 
conjugation O 
was O 
investigated O 
using O 
radiolabeling O 
methods O 
. O 
It O 
was O 
shown O 
that O 
surfaces O 
with O 
POEGMA B-ABBREVIATION 
layers O 
were O 
protein O 
resistant O 
, O 
while O 
the O 
quantity O 
of O 
protein O 
conjugated O 
to O 
the O 
diblock O 
copolymer O 
modified O 
surfaces O 
increased O 
with O 
increasing O 
PGMA B-ABBREVIATION 
layer O 
thickness O 
. O 
The O 
activity O 
of O 
lysozyme O 
conjugated O 
on O 
the O 
surface O 
could O 
also O 
be O 
controlled O 
by O 
varying O 
the O 
thickness O 
of O 
the O 
copolymer O 
layer O 
. O 
When O 
biotin B-TRIVIAL 
was O 
conjugated O 
to O 
the O 
block O 
copolymer O 
grafts O 
, O 
the O 
surface O 
remained O 
resistant O 
to O 
nonspecific O 
protein O 
adsorption O 
but O 
showed O 
specific O 
binding O 
of O 
avidin O 
. O 
These O 
properties O 
, O 
that O 
is O 
, O 
well O 
- O 
controlled O 
quantity O 
and O 
activity O 
of O 
conjugated O 
biomolecules O 
and O 
specificity O 
of O 
interaction O 
with O 
target O 
biomolecules O 
may O 
be O 
exploited O 
for O 
the O 
improvement O 
of O 
signal O 
- O 
to O 
- O 
noise O 
ratio O 
in O 
sensor O 
applications O 
. O 
More O 
generally O 
, O 
such O 
surfaces O 
may O 
be O 
useful O 
as O 
biological O 
recognition O 
elements O 
of O 
high O 
specificity O 
for O 
functional O 
biomaterials O 
. O 

of O 
crystalline O 
GaAs B-FORMULA 
on O 
liquid O 
gallium B-SYSTEMATIC 
electrodes O 
in O 
aqueous O 
electrolytes O 
. O 

GaAs B-FORMULA 
( O 
c- O 
GaAs B-FORMULA 
) O 
has O 
been O 
prepared O 
directly O 
through O 
electroreduction O 
of O 
As(2)O(3) B-FORMULA 
dissolved O 
in O 
an O 
alkaline O 
aqueous O 
solution O 
at O 
a O 
liquid O 
gallium B-SYSTEMATIC 
( O 
Ga(l) B-FORMULA 
) O 
electrode O 
at O 
modest O 
temperatures O 
( O 
T O 
≥ O 
80 O 
°C O 
) O 
. O 
Ga(l) B-FORMULA 
pool O 
electrodes O 
yielded O 
consistent O 
electrochemical O 
behavior O 
, O 
affording O 
repetitive O 
measurements O 
that O 
illustrated O 
the O 
interdependences O 
of O 
applied O 
potential O 
, O 
concentration O 
of O 
dissolved O 
As(2)O(3) B-FORMULA 
, O 
and O 
electrodeposition O 
temperature O 
on O 
the O 
quality O 
of O 
the O 
resultant O 
c- O 
GaAs B-FORMULA 
( O 
s O 
) O 
. O 
Raman O 
spectra O 
indicated O 
the O 
composition O 
of O 
the O 
resultant O 
film O 
was O 
strongly O 
dependent O 
on O 
both O 
the O 
electrodeposition O 
temperature O 
and O 
dissolved O 
concentration O 
of O 
As(2)O(3) B-FORMULA 
but O 
not O 
to O 
the O 
applied O 
bias O 
. O 
For O 
electrodepositions O 
performed O 
either O 
at O 
room O 
temperature O 
or O 
with O 
high O 
( O 
≥ O 
0.01 O 
M O 
) O 
concentrations O 
of O 
dissolved O 
As(2)O(3) B-FORMULA 
, O 
Raman O 
spectra O 
of O 
the O 
electrodeposited O 
films O 
were O 
consistent O 
with O 
amorphous O 
As B-FORMULA 
( O 
s O 
) O 
. O 
X-ray O 
diffractograms O 
of O 
As B-FORMULA 
( O 
s O 
) O 
films O 
collected O 
after O 
thermal O 
annealing O 
indicated O 
metallurgical O 
alloying O 
occurred O 
only O 
at O 
temperatures O 
in O 
excess O 
of O 
200 O 
°C O 
. O 
Optical O 
images O 
and O 
Raman O 
spectra O 
separately O 
showed O 
the O 
composition O 
of O 
the O 
as B-FORMULA 
-electrodeposited O 
film O 
in O 
dilute O 
( O 
≤ O 
0.001 O 
M O 
) O 
solutions O 
of O 
dissolved O 
As(2)O(3) B-FORMULA 
( O 
aq O 
) O 
was O 
pure O 
c- O 
GaAs B-FORMULA 
( O 
s O 
) O 
at O 
much O 
lower O 
temperatures O 
than O 
200 O 
°C O 
. O 
Diffractograms O 
and O 
transmission O 
electron O 
microscopy O 
performed O 
on O 
as-prepared O 
films O 
confirmed O 
the O 
identity O 
of O 
c- O 
GaAs B-FORMULA 
( O 
s O 
) O 
. O 
The O 
collective O 
results O 
thus O 
provide O 
the O 
first O 
clear O 
demonstration O 
of O 
an O 
electrochemical O 
liquid O 
- O 
liquid O 
- O 
solid O 
( O 
ec-LLS O 
) O 
process O 
involving O 
a O 
liquid O 
metal O 
that O 
serves O 
simultaneously O 
as O 
an O 
electrode O 
, O 
a O 
solvent O 
/ O 
medium O 
for O 
crystal O 
growth O 
, O 
and O 
a O 
coreactant O 
for O 
the O 
synthesis O 
of O 
a O 
polycrystalline O 
semiconductor O 
. O 
The O 
presented O 
data O 
serve O 
as O 
impetus O 
for O 
the O 
further O 
development O 
of O 
the O 
ec-LLS O 
process O 
as O 
a O 
controllable O 
, O 
simple O 
, O 
and O 
direct O 
route O 
for O 
technologically O 
important O 
optoelectronic O 
materials O 
such O 
as O 
c- O 
GaAs B-FORMULA 
( O 
s O 
) O 
. O 

profiles O 
of O 
44 O 
unifloral O 
Serbian O 
honeys O 
were O 
analyzed O 
using O 
ultra O 
- O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
UHPLC O 
) O 
coupled O 
with O 
hybrid O 
mass O 
spectrometer O 
which O 
combines O 
the O 
Linear O 
Trap O 
Quadrupole O 
( O 
LTQ O 
) O 
and O 
OrbiTrap O 
mass O 
analyzer O 
. O 
Rapid O 
UHPLC O 
method O 
was O 
developed O 
in O 
combination O 
with O 
a O 
high O 
sensitivity O 
accurate O 
mass O 
scan O 
and O 
a O 
simultaneous O 
data O 
dependent O 
scan O 
. O 
The O 
honey O 
samples O 
were O 
of O 
different O 
botanical O 
origin O 
: O 
acacia O 
( O 
Robinia O 
pseudoacacia O 
) O 
, O 
sunflower O 
( O 
Helianthus O 
annuus O 
) O 
, O 
linden O 
( O 
Tilia O 
cordata O 
) O 
, O 
basil O 
( O 
Ocimum O 
basilicum O 
) O 
, O 
buckwheat O 
( O 
Fagopyrum O 
esculentum O 
) O 
, O 
oilseed O 
rape O 
( O 
Brassica O 
napus O 
) O 
, O 
and O 
goldenrod O 
( O 
Solidago O 
virgaurea O 
) O 
. O 
The O 
presence O 
of O 
43 O 
compounds O 
, O 
mainly O 
flavonoids B-FAMILY 
, O 
was O 
proven O 
in O 
all O 
honey O 
samples O 
by O 
their O 
characteristic O 
mass O 
spectra O 
and O 
fragmentation O 
pattern O 
. O 
Relatively O 
high O 
amounts O 
of O 
chrysin B-TRIVIAL 
, O 
pinocembrin B-TRIVIAL 
and O 
galangin B-TRIVIAL 
were O 
identified O 
in O 
all O 
honey O 
extracts O 
. O 
p-Coumaric B-TRIVIAL 
acid I-TRIVIAL 
was O 
not O 
detected O 
in O 
basil O 
, O 
buckwheat O 
and O 
goldenrod O 
honey O 
extracts O 
. O 
A O 
larger O 
amount O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
( O 
max O 
value O 
1.45 O 
mg O 
/ O 
kg O 
) O 
was O 
found O 
in O 
the O 
sunflower O 
honey O 
, O 
while O 
a O 
larger O 
amount O 
of O 
apigenin B-TRIVIAL 
( O 
0.97 O 
mg O 
/ O 
kg O 
) O 
was O 
determined O 
in O 
the O 
buckwheat O 
honey O 
in O 
comparison O 
with O 
other O 
honeys O 
. O 
The O 
samples O 
were O 
classified O 
according O 
to O 
the O 
botanical O 
origin O 
using O 
pattern O 
recognition O 
technique O 
, O 
Principal O 
Component O 
Analysis O 
( O 
PCA O 
) O 
. O 
The O 
LTQ O 
OrbiTrap O 
technique O 
was O 
proven O 
to O 
be O 
reliable O 
for O 
the O 
unambiguous O 
detection O 
of O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
their O 
derivatives O 
, O 
and O 
flavonoid B-FAMILY 
aglycones O 
based O 
on O 
their O 
molecular O 
masses O 
and O 
fragmentation O 
pattern O 
. O 

HPLC-DAD O 
quantification O 
of O 
nine O 
polyphenols B-FAMILY 
in O 
honey O 
by O 
using O 
second O 
- O 
order O 
calibration O 
method O 
based O 
on O 
trilinear O 
decomposition O 
algorithm O 
. O 

paper O 
describes O 
the O 
use O 
of O 
second O 
- O 
order O 
calibration O 
for O 
development O 
of O 
HPLC-DAD O 
method O 
to O 
quantify O 
nine O 
polyphenols B-FAMILY 
in O 
five O 
kinds O 
of O 
honey O 
samples O 
. O 
The O 
sample O 
treatment O 
procedure O 
was O 
simplified O 
effectively O 
relative O 
to O 
the O 
traditional O 
ways O 
. O 
Baselines O 
drift O 
was O 
also O 
overcome O 
by O 
means O 
of O 
regarding O 
the O 
drift O 
as O 
additional O 
factor(s) O 
as O 
well O 
as O 
the O 
analytes O 
of O 
interest O 
in O 
the O 
mathematical O 
model O 
. O 
The O 
contents O 
of O 
polyphenols B-FAMILY 
obtained O 
by O 
the O 
alternating O 
trilinear O 
decomposition O 
( O 
ATLD O 
) O 
method O 
have O 
been O 
successfully O 
used O 
to O 
distinguish O 
different O 
types O 
of O 
honey O 
. O 
This O 
method O 
shows O 
good O 
linearity O 
( O 
r O 
> O 
0.99 O 
) O 
, O 
rapidity O 
( O 
t O 
< O 
7.6 O 
min O 
) O 
and O 
accuracy O 
, O 
which O 
may O 
be O 
extremely O 
promising O 
as O 
an O 
excellent O 
routine O 
strategy O 
for O 
identification O 
and O 
quantification O 
of O 
polyphenols B-FAMILY 
in O 
the O 
complex O 
matrices O 
. O 

curcas O 
L O 
. O 
protein O 
hydrolysates O 
were O 
produced O 
by O 
treatment O 
of O 
a O 
non-toxic O 
genotype O 
with O 
Alcalase O 
as O 
well O 
as O 
the O 
digestive O 
enzymes O 
pepsin O 
and O 
pancreatin O 
. O 
The O 
J O 
. O 
curcas O 
protein O 
hydrolysate O 
produced O 
with O 
the O 
pepsin O 
- O 
pancreatin O 
system O 
from O 
protein O 
isolate O 
had O 
the O 
highest O 
TEAC O 
value O 
and O 
was O 
shown O 
to O 
undergo O 
single O 
- O 
electron O 
transfer O 
reactions O 
in O 
the O 
ABTS(+) B-ABBREVIATION 
reduction O 
assay O 
, O 
demonstrating O 
its O 
antioxidant O 
capacity O 
. O 
Testing O 
of O 
antimicrobial O 
activity O 
in O 
the O 
J O 
. O 
curcas O 
protein O 
hydrolysates O 
against O 
seven O 
bacterial O 
pathogens O 
showed O 
no O 
growth O 
inhibitory O 
effect O 
in O 
Gram O 
- O 
negative O 
and O 
Gram O 
- O 
positive O 
bacteria O 
. O 
More O 
ACE-I O 
inhibitory O 
active O 
peptides O 
were O 
produced O 
in O 
the O 
Alcalase O 
hydrolysates O 
obtained O 
from O 
J O 
. O 
curcas O 
protein O 
isolate O 
. O 
The O 
protein O 
hydrolysate O 
obtained O 
with O 
Alcalase O 
from O 
defatted O 
J O 
. O 
curcas O 
flour O 
as O 
well O 
as O 
from O 
the O 
protein O 
isolate O 
showed O 
the O 
highest O 
inhibitory O 
effect O 
of O 
ADP B-ABBREVIATION 
-induced O 
aggregation O 
of O 
human O 
platelets O 
in O 
platelet O 
- O 
rich O 
plasma O 
. O 
It O 
is O 
expected O 
that O 
the O 
information O 
collated O 
will O 
facilitate O 
new O 
applications O 
of O 
proteins O 
present O 
in O 
Jatropha O 
plant O 
. O 

transport O 
of O 
6-O-caffeoylsophorose B-SYSTEMATIC 
across O 
Caco-2 O 
cell O 
monolayers O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
clarify O 
the O 
transport O 
behaviour O 
and O 
mechanism O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
analogue O 
bearing O 
a O 
sugar B-FAMILY 
-moiety O 
, O 
6-O-caffeoylsophorose B-SYSTEMATIC 
( O 
CS O 
) O 
, O 
in O 
Caco-2 O 
cells O 
. O 
The O 
absorption O 
of O 
CS O 
was O 
investigated O 
by O 
its O 
transport O 
across O 
Caco-2 O 
cell O 
monolayers O 
using O 
a O 
high O 
- O 
performance O 
liquid O 
chromatography O 
- O 
time O 
- O 
of O 
- O 
flight O 
- O 
mass O 
spectrometry O 
( O 
LC-TOF-MS O 
) O 
. O 
The O 
permeation O 
of O 
CS O 
was O 
concentration O 
- O 
dependent O 
and O 
reached O 
the O 
plateau O 
at O 
> O 
6 O 
mM O 
. O 
The O 
apparent O 
permeability O 
(P(app)) O 
of O 
CS O 
in O 
the O 
apical O 
- O 
to O 
- O 
basolateral O 
direction O 
was O 
5.4×10(-7) O 
cm O 
/ O 
s O 
, O 
while O 
in O 
the O 
reversed O 
direction O 
the O 
P(app) O 
value O 
was O 
significantly O 
reduced O 
( O 
1.9×10(-7) O 
cm O 
/ O 
s O 
) O 
. O 
CS O 
transport O 
was O 
competitively O 
inhibited O 
by O 
phloretin B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
monocarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
transporter O 
( O 
MCT O 
) O 
. O 
Benzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
an O 
MCT O 
substrate O 
, O 
also O 
reduced O 
CS O 
transport O 
. O 
A O 
less O 
significant O 
change O 
of O 
CS O 
transport O 
was O 
observed O 
across O 
Caco-2 O 
cell O 
monolayers O 
pretreated O 
with O 
quercetin B-TRIVIAL 
, O 
a O 
suppressor O 
of O 
tight O 
- O 
junction O 
. O 
These O 
findings O 
strongly O 
indicate O 
that O 
CS O 
, O 
a O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
analogue O 
bearing O 
sophorose B-TRIVIAL 
moiety O 
, O 
can O 
be O 
transported O 
across O 
Caco-2 O 
cell O 
monolayers O 
via O 
the O 
MCT O 
pathway O 
. O 

bagasse O 
treated O 
with O 
hydrous B-SYSTEMATIC 
ferric I-SYSTEMATIC 
oxide I-SYSTEMATIC 
as O 
a O 
potential O 
adsorbent O 
for O 
the O 
removal O 
of O 
As B-FORMULA 
(V) I-FORMULA 
from O 
aqueous O 
solutions O 
. O 

mechanism O 
of O 
As B-FORMULA 
(V) I-FORMULA 
removal O 
from O 
aqueous O 
solutions O 
by O 
means O 
of O 
hydrated B-SYSTEMATIC 
ferric I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
HFO B-ABBREVIATION 
) O 
- O 
treated O 
sugarcane O 
bagasse O 
( O 
SCB- O 
HFO B-ABBREVIATION 
) O 
( O 
Saccharum O 
officinarum O 
L O 
. O 
) O 
was O 
investigated O 
. O 
Effects O 
of O 
different O 
parameters O 
, O 
such O 
as O 
pH O 
value O 
, O 
initial O 
arsenic B-SYSTEMATIC 
concentration O 
, O 
adsorbent O 
dosage O 
, O 
contact O 
time O 
and O 
ionic O 
strength O 
, O 
on O 
the O 
As B-FORMULA 
(V) I-FORMULA 
adsorption O 
were O 
studied O 
. O 
The O 
adsorption O 
capacity O 
of O 
SCB- O 
HFO B-ABBREVIATION 
for O 
As B-FORMULA 
(V) I-FORMULA 
was O 
found O 
to O 
be O 
22.1 O 
mg O 
/ O 
g O 
under O 
optimum O 
conditions O 
of O 
pH O 
4 O 
, O 
contact O 
time O 
3h O 
and O 
temperature O 
22 O 
°C O 
. O 
Initial O 
As B-FORMULA 
(V) I-FORMULA 
concentration O 
influenced O 
the O 
removal O 
efficiency O 
of O 
SCB- O 
HFO B-ABBREVIATION 
. O 
The O 
desorption O 
of O 
As B-FORMULA 
(V) I-FORMULA 
from O 
the O 
adsorbent O 
was O 
17% O 
when O 
using O 
30% O 
HCl B-FORMULA 
and O 
85% O 
with O 
1M O 
NaOH B-FORMULA 
solution O 
. O 
FTIR O 
analyses O 
evidenced O 
two O 
potential O 
binding O 
sites O 
associated O 
with O 
carboxyl B-SYSTEMATIC 
and O 
hydroxyl B-SYSTEMATIC 
groups O 
which O 
are O 
responsible O 
for O 
As B-FORMULA 
(V) I-FORMULA 
removal O 
. O 
Adsorption O 
, O 
surface O 
precipitation O 
, O 
ion O 
exchange O 
and O 
complexation O 
can O 
be O 
suggested O 
as O 
mechanisms O 
for O 
the O 
As B-FORMULA 
(V) I-FORMULA 
removal O 
from O 
the O 
solution O 
phase O 
onto O 
the O 
surface O 
of O 
SCB- O 
HFO B-ABBREVIATION 
. O 

work O 
is O 
focused O 
on O 
the O 
synthesis O 
of O 
the O 
fructooligosaccharides O 
( O 
FOS O 
) O 
from O 
sucrose B-TRIVIAL 
and O 
inulin O 
, O 
using O 
free O 
, O 
immobilized O 
and O 
pre O 
- O 
treated O 
immobilized O 
inulinase O 
from O 
Kluyveromyces O 
marxianus O 
NRRL O 
Y O 
7571 O 
and O 
Aspergillus O 
niger O 
in O 
an O 
aqueous O 
- O 
organic O 
system O 
. O 
Initially O 
, O 
the O 
influence O 
of O 
pre O 
- O 
treatment O 
using O 
four O 
different O 
gases O 
, O 
propane B-SYSTEMATIC 
, O 
n-butane B-SYSTEMATIC 
, O 
CO(2) B-FORMULA 
and O 
liquefied O 
petroleum O 
gas O 
( O 
LPG O 
) O 
, O 
was O 
investigated O 
towards O 
FOS O 
production O 
and O 
best O 
results O 
were O 
found O 
when O 
both O 
enzymes O 
were O 
previously O 
treated O 
with O 
LPG O 
. O 
The O 
best O 
reaction O 
yields O 
were O 
obtained O 
when O 
the O 
immobilized O 
enzymes O 
were O 
treated O 
with O 
LPG O 
. O 
Considering O 
FOS O 
synthesis O 
using O 
the O 
enzyme O 
from O 
A O 
. O 
niger O 
, O 
yields O 
of O 
26.62% O 
of O 
GF2 O 
( O 
kestose B-TRIVIAL 
) O 
, O 
30.62% O 
of O 
GF3 O 
( O 
nystose B-TRIVIAL 
) O 
and O 
8.47% O 
of O 
GF4 O 
( O 
fructosyl B-TRIVIAL 
nystose I-TRIVIAL 
) O 
were O 
achieved O 
using O 
sucrose B-TRIVIAL 
as O 
substrate O 
. O 
Using O 
inulinases O 
from O 
K O 
. O 
marxianus O 
NRRL O 
Y O 
7571 O 
, O 
11.89% O 
of O 
GF2 O 
and O 
20.83% O 
of O 
GF3 O 
were O 
obtained O 
, O 
using O 
inulin O 
as O 
substrate O 
. O 
However O 
, O 
promising O 
results O 
were O 
achieved O 
using O 
the O 
free O 
form O 
of O 
inulinase O 
from O 
A O 
. O 
niger O 
( O 
77.19% O 
of O 
GF2 O 
; O 
14.03% O 
of O 
GF3 O 
and O 
0.07% O 
of O 
GF4 O 
) O 
using O 
inulin O 
as O 
substrate O 
. O 

: O 
on O 
published O 
data O 
and O 
methods O 
for O 
selenium B-SYSTEMATIC 
in O 
mushrooms O 
. O 

data O 
published O 
on O 
selenium B-SYSTEMATIC 
in O 
several O 
species O 
of O 
mushrooms O 
are O 
outlined O 
and O 
discussed O 
in O 
light O 
of O 
performance O 
of O 
analytical O 
methods O 
employed O 
. O 
Data O 
was O 
shown O 
to O 
be O 
either O 
dubious O 
or O 
concentrations O 
too O 
high O 
to O 
be O 
credible O 
and O 
valid O 
in O 
some O 
data O 
reported O 
by O 
authors O 
. O 
Examples O 
of O 
methods O 
and O 
specifically O 
the O 
measurement O 
techniques O 
of O 
Se B-FORMULA 
as O 
reported O 
by O 
authors O 
studying O 
mushrooms O 
are O 
outlined O 
. O 
Also O 
examples O 
of O 
valid O 
and O 
incorrect O 
data O 
on O 
Se B-FORMULA 
in O 
a O 
given O 
mushroom O 
species O 
with O 
data O 
by O 
two O 
or O 
more O 
analytical O 
methods O 
are O 
illustrated O 
. O 
Excessive O 
values O 
reported O 
due O 
to O 
selection O 
of O 
improper O 
method O 
of O 
determination O 
of O 
Se B-FORMULA 
in O 
mushrooms O 
relate O 
largely O 
to O 
improper O 
use O 
of O 
flame O 
atomic O 
absorption O 
spectroscopy O 
( O 
AAS O 
) O 
and O 
inductively O 
coupled O 
plasma O 
- O 
atomic O 
emission O 
spectroscopy O 
( O 
ICP-AES O 
) O 
. O 
The O 
biased O 
analytical O 
data O 
published O 
gave O 
a O 
false O 
picture O 
on O 
the O 
composition O 
and O 
nutritional O 
value O 
of O 
mushrooms O 
with O 
respect O 
to O 
selenium B-SYSTEMATIC 
. O 

aim O 
of O 
our O 
study O 
was O 
to O 
investigate O 
the O 
mechanisms O 
by O 
which O 
rhubarb O 
regulates O 
β-catenin O 
as O 
well O 
as O 
metastasis O 
of O 
hepatocellular O 
carcinomas O 
. O 
Our O 
results O 
revealed O 
that O 
rhubarb O 
extract O 
inhibited O 
HA22T O 
cell O 
migration O 
ability O 
in O 
wound O 
healing O 
, O 
migration O 
and O 
invasion O 
assays O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Rhubarb O 
also O 
reduced O 
β-catenin O 
protein O 
level O 
, O 
downregulated O 
its O 
downstream O 
proteins O 
, O 
cyclin O 
D O 
, O 
Tbx3 O 
and O 
c-Myc O 
, O 
and O 
attenuated O 
the O 
expression O 
of O 
MMP9 O 
and O 
contactin-1 O 
metastatic O 
factors O 
. O 
Additionally O 
, O 
rhubarb O 
inhibited O 
β-catenin O 
nuclear O 
accumulation O 
and O 
induced O 
its O 
degradation O 
via O 
proteasome O 
- O 
mediated O 
pathway O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
rhubarb O 
suppressed O 
the O 
p- O 
ser B-FORMULA 
( O 
9 O 
) O 
GSK-3-β O 
protein O 
level O 
to O 
inactivate O 
Wnt O 
signalling O 
and O 
reduce O 
β-catenin O 
protein O 
level O 
. O 
Taken O 
together O 
; O 
we O 
found O 
that O 
rhubarb O 
blocked O 
the O 
metastatic O 
process O 
of O 
HA22T O 
hepatocellular O 
carcinoma O 
cells O 
mediated O 
through O 
GSK-3-β O 
activation O 
, O 
and O 
enhancement O 
of O 
protein O 
degradation O 
as O 
well O 
as O 
reduction O 
of O 
the O 
nuclear O 
accumulation O 
of O 
β-catenin O 
. O 

of O 
biological O 
activities O 
of O 
a O 
groundnut O 
( O 
Apios O 
americana O 
Medik O 
) O 
extract O 
containing O 
a O 
novel O 
isoflavone B-FAMILY 
. O 

( O 
Apios O 
americana O 
Medik O 
) O 
contains O 
a O 
novel O 
isoflavone B-FAMILY 
, O 
genistein-7-O-gentiobioside B-SYSTEMATIC 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
biological O 
activities O 
of O 
an O 
alcohol B-FAMILY 
extract O 
of O 
groundnut O 
containing O 
genistein-7-O-gentiobioside B-SYSTEMATIC 
as O 
the O 
main O 
component O 
. O 
Although O 
the O 
groundnut O 
extract O 
by O 
itself O 
did O 
not O 
show O 
antioxidative O 
activity O 
, O 
it O 
drove O 
the O 
antioxidative O 
system O 
in O 
cells O 
. O 
Pretreatment O 
of O 
human O 
breast O 
carcinoma O 
MCF-7 O 
cells O 
for O 
24 O 
h O 
with O 
the O 
groundnut O 
extract O 
and O 
soybean O 
isoflavone B-FAMILY 
increased O 
gene O 
expression O 
of O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
, O 
a O 
major O 
antioxidative O 
stress O 
enzyme O 
. O 
These O 
groundnut O 
extract O 
- O 
treated O 
cells O 
showed O 
antioxidative O 
activity O 
against O 
free O 
radicals O 
derived O 
from O 
a O 
radical O 
initiator O 
. O 
Pretreatment O 
of O 
cells O 
with O 
100 O 
μg O 
/ O 
mL O 
groundnut O 
extract O 
prevented O 
the O 
depletion O 
of O 
glutathione B-TRIVIAL 
by O 
the O 
radical O 
initiator O 
; O 
however O 
, O 
treatment O 
with O 
100 O 
μg O 
/ O 
mL O 
of O 
soybean O 
isoflavone B-FAMILY 
injured O 
the O 
cell O 
membrane O 
, O 
indicating O 
that O 
glutathione B-TRIVIAL 
might O 
be O 
released O 
to O 
the O 
extracellular O 
environment O 
. O 
These O 
results O 
suggest O 
that O 
the O 
groundnut O 
extract O 
had O 
isoflavone B-FAMILY 
-like O 
activity O 
. O 
Like O 
soybean O 
, O 
groundnuts O 
are O 
a O 
good O 
source O 
of O 
isoflavones B-FAMILY 
. O 

sulphated O 
polysaccharides O 
, O 
coded O 
as O 
BEMPA O 
, O 
BEMPB(1) O 
, O 
BEMPB(2) O 
, O 
were O 
extracted O 
from O 
the O 
mucilage O 
of O 
mud O 
snail O 
of O 
Bullacta O 
exarata O 
and O 
purified O 
by O 
DEAE B-ABBREVIATION 
-cellulose O 
ion O 
- O 
exchange O 
and O 
size O 
- O 
exclusion O 
chromatography O 
. O 
Structural O 
analysis O 
of O 
purified O 
polysaccharides O 
by O 
chemical O 
and O 
biochemical O 
methods O 
revealed O 
BEMPA O 
was O 
a O 
high O 
( O 
1→3,4 O 
) O 
- O 
linked O 
mannose B-TRIVIAL 
-containing O 
polysaccharide O 
with O 
molecular O 
weight O 
of O 
22977 O 
Da O 
. O 
BEMPB(1) O 
, O 
with O 
molecular O 
weight O 
of O 
64117 O 
Da O 
, O 
was O 
a O 
high O 
( O 
1→3 O 
) O 
- O 
linked O 
arabinose B-TRIVIAL 
-containing O 
polysaccharide O 
. O 
BEMPB(2) O 
was O 
mainly O 
composed O 
of O 
( O 
1→3,4 O 
) O 
- O 
linked O 
mannose B-TRIVIAL 
with O 
molecular O 
weight O 
of O 
47,507Da O 
. O 
The O 
comparison O 
between O 
sulphated O 
polysaccharides O 
and O 
their O 
desulphated O 
products O 
showed O 
that O 
sulphate B-SYSTEMATIC 
substitutions O 
of O 
BEMPB(1) O 
were O 
deduced O 
to O 
be O 
at O 
the O 
C-3 O 
of O 
( O 
1→4 O 
) O 
- O 
linked O 
mannose B-TRIVIAL 
, O 
while O 
sulphate B-SYSTEMATIC 
substitutions O 
of O 
BEMPA O 
and O 
BEMPB(2) O 
were O 
at O 
C-4 O 
of O 
( O 
1→3 O 
) O 
- O 
linked O 
mannose B-TRIVIAL 
. O 
Furthermore O 
, O 
BEMPA O 
exhibited O 
highest O 
inhibitory O 
effects O 
on O 
growth O 
of O 
B-16 O 
melanoma O 
cells O 
, O 
and O 
IC(50) O 
were O 
31.1 O 
μg O 
/ O 
mL O 
. O 

strawberry O 
fruits O 
( O 
Cv O 
. O 
' O 
Albion O 
' O 
) O 
were O 
harvested O 
at O 
six O 
different O 
ripening O 
stages O 
and O 
evaluated O 
for O 
physical O 
and O 
chemical O 
parameters O 
. O 
Biometrical O 
characteristics O 
and O 
moisture O 
content O 
did O 
not O 
change O 
significantly O 
during O 
ripening O 
. O 
Total O 
soluble O 
solids O 
, O 
pH O 
and O 
colour O 
development O 
increased O 
while O 
titratable O 
acidity O 
and O 
fruit O 
firmness O 
decreased O 
14.7% O 
and O 
91% O 
, O 
respectively O 
. O 
Fructose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
, O 
and O 
sucrose B-TRIVIAL 
followed O 
similar O 
tendencies O 
. O 
Final O 
contents O 
of O 
these O 
sugars B-FAMILY 
were O 
2323.4 O 
, O 
1988.5 O 
, O 
and O 
1578.4 O 
mg O 
/ O 
100 O 
g O 
. O 
Citric B-MULTIPLE 
, I-MULTIPLE 
malic I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
ascorbic I-MULTIPLE 
acids I-MULTIPLE 
followed O 
a O 
descending O 
, O 
irregular O 
, O 
and O 
increasing O 
tendency O 
during O 
ripening O 
, O 
respectively O 
. O 
Final O 
contents O 
of O 
these O 
acids O 
were O 
822.8 O 
, O 
245.8 O 
, O 
and O 
78.1 O 
mg O 
/ O 
100 O 
g O 
. O 
Total O 
anthocyanins B-FAMILY 
content O 
( O 
TAC O 
) O 
increased O 
during O 
ripening O 
, O 
while O 
the O 
opposite O 
was O 
observed O 
for O 
total O 
phenolic O 
content O 
( O 
TPC O 
) O 
. O 
TAC O 
and O 
TPC O 
in O 
ripe O 
fruit O 
were O 
56.4 O 
mg O 
/ O 
100g O 
and O 
196 O 
mg O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
equivalents O 
( O 
GAE O 
) O 
/ O 
100 O 
g O 
. O 
Twenty O 
eight O 
phenolic O 
compounds O 
, O 
mainly O 
glycosides O 
, O 
were O 
identified O 
and O 
quantified O 
by O 
HPLC-DAD-MS O 
analysis O 
. O 
The O 
concentration O 
of O 
these O 
compounds O 
was O 
ripening O 
dependent O 
. O 

acid I-TRIVIAL 
, O 
nitrate B-SYSTEMATIC 
, O 
and O 
nitrite B-SYSTEMATIC 
concentration O 
relationship O 
to O 
the O 
24hour O 
light O 
/ O 
dark O 
cycle O 
for O 
spinach O 
grown O 
in O 
different O 
conditions O 
. O 

, O 
nitrite B-SYSTEMATIC 
and O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
( O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
) O 
concentrations O 
were O 
determined O 
for O 
spinach O 
( O 
Spinacia O 
oleracea O 
L O 
. O 
) O 
over O 
a O 
24 O 
h O 
period O 
to O 
determine O 
if O 
light O 
intensity O 
( O 
including O 
dark O 
periods O 
) O 
at O 
time O 
of O 
harvest O 
impacts O 
concentrations O 
in O 
raw O 
vegetables O 
. O 
Nitrate B-SYSTEMATIC 
, O 
nitrate B-SYSTEMATIC 
and O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
concentrations O 
varied O 
significantly O 
over O 
the O 
24 O 
h O 
period O 
and O 
appeared O 
to O 
be O 
related O 
to O 
changes O 
in O 
light O 
intensity O 
. O 
Light O 
intensity O 
at O 
the O 
time O 
an O 
experimental O 
sample O 
is O 
collected O 
may O 
affect O 
the O 
concentration O 
of O 
some O 
constituents O 
that O 
a O 
researcher O 
is O 
studying O 
. O 
Also O 
, O 
nitrate B-SYSTEMATIC 
and O 
nitrite B-SYSTEMATIC 
concentrations O 
in O 
raw O 
spinach O 
can O 
be O 
reduced O 
by O 
harvesting O 
at O 
the O 
best O 
time O 
of O 
day O 
. O 
The O 
highest O 
nitrate B-SYSTEMATIC 
concentrations O 
in O 
spinach O 
occurred O 
in O 
the O 
dark O 
just O 
prior O 
to O 
an O 
increase O 
in O 
light O 
intensity O 
. O 
Ascorbic B-TRIVIAL 
acid I-TRIVIAL 
was O 
near O 
its O 
highest O 
level O 
for O 
the O 
24 O 
h O 
period O 
when O 
the O 
light O 
intensity O 
initially O 
increased O 
, O 
then O 
decreased O 
to O 
its O 
lowest O 
level O 
around O 
3-6 O 
h O 
later O 
. O 

principal O 
mango O 
cultivars O 
( O 
Tainong O 
No.1 O 
, O 
Irwin O 
, O 
JinHwang O 
and O 
Keitt O 
) O 
grown O 
in O 
southern O 
China O 
were O 
selected O 
, O 
and O 
their O 
physico O 
- O 
chemical O 
and O 
antioxidant O 
properties O 
were O 
characterized O 
and O 
compared O 
. O 
Of O 
all O 
the O 
four O 
cultivars O 
, O 
Tainong O 
No.1 O 
had O 
highest O 
content O 
of O 
total O 
phenols B-FAMILY 
, O 
ρ-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
titratable O 
acidity O 
, O 
citric B-TRIVIAL 
acid I-TRIVIAL 
, O 
malic B-TRIVIAL 
acid I-TRIVIAL 
, O 
fructose B-TRIVIAL 
, O 
higher O 
antioxidant O 
activities O 
( O 
DPPH B-ABBREVIATION 
, O 
FRAP O 
) O 
and O 
L(*) O 
, O 
lower O 
pH O 
, O 
PPO O 
activity O 
and O 
individual O 
weight O 
. O 
Keitt O 
mangoes O 
showed O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
higher O 
contents O 
of O 
β-carotene B-TRIVIAL 
, O 
ρ-hydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
sucrose B-TRIVIAL 
, O 
total O 
sugar B-FAMILY 
, O 
total O 
soluble O 
solid O 
, O 
catechin B-TRIVIAL 
, O 
succinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
higher O 
PPO O 
activity O 
. O 
JinHwang O 
mangoes O 
exhibited O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
higher O 
individual O 
weight O 
and O 
PPO O 
activity O 
, O 
but O 
had O 
lower O 
content O 
of O 
total O 
phenols B-FAMILY 
, O 
β-carotene B-TRIVIAL 
and O 
lower O 
antioxidant O 
activity O 
. O 
Principal O 
component O 
analysis O 
( O 
PCA O 
) O 
allowed O 
the O 
four O 
mango O 
cultivars O 
to O 
be O 
differentiated O 
clearly O 
based O 
on O 
all O 
these O 
physico O 
- O 
chemical O 
and O 
antioxidant O 
properties O 
determined O 
in O 
the O 
study O 
. O 

estimation O 
of O 
antioxidant O 
activity O 
in O 
DPPH· B-ABBREVIATION 
assay O 
using O 
several O 
statistical O 
programs O 
. O 

assay O 
is O 
a O 
reliable O 
method O 
to O 
determine O 
the O 
antioxidant O 
capacity O 
of O 
biological O 
substrates O 
. O 
The O 
DPPH(·) B-ABBREVIATION 
radical O 
scavenging O 
activity O 
is O 
generally O 
quantified O 
in O 
terms O 
of O 
inhibition O 
percentage O 
of O 
the O 
pre O 
- O 
formed O 
free O 
radical O 
by O 
antioxidants O 
, O 
and O 
the O 
EC(50) O 
( O 
concentration O 
required O 
to O 
obtain O 
a O 
50% O 
antioxidant O 
effect O 
) O 
is O 
a O 
typically O 
employed O 
parameter O 
to O 
express O 
the O 
antioxidant O 
capacity O 
and O 
to O 
compare O 
the O 
activity O 
of O 
different O 
compounds O 
. O 
In O 
this O 
study O 
, O 
the O 
EC(50) O 
estimation O 
was O 
performed O 
using O 
a O 
comparative O 
approach O 
based O 
on O 
various O 
regression O 
models O 
implemented O 
in O 
six O 
specialized O 
computer O 
programs O 
: O 
GraphPad O 
Prism O 
® O 
version O 
5.01 O 
, O 
BLeSq O 
, O 
OriginPro O 
® O 
8.5.1 O 
, O 
SigmaPlot O 
® O 
12 O 
, O 
BioDataFit O 
® O 
1.02 O 
, O 
and O 
IBM O 
SPSS O 
Statistics O 
® O 
Desktop O 
19 O 
. O 
For O 
this O 
project O 
, O 
quercetin B-TRIVIAL 
, O 
catechin B-TRIVIAL 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
and O 
acetylcysteine B-SYSTEMATIC 
were O 
screened O 
as O 
antioxidant O 
standards O 
with O 
DPPH(·) B-ABBREVIATION 
assay O 
to O 
define O 
the O 
EC(50) O 
parameters O 
. O 
All O 
the O 
statistical O 
programs O 
gave O 
similar O 
EC(50) O 
values O 
, O 
but O 
GraphPad O 
Prism O 
® O 
five O 
- O 
parameter O 
analysis O 
pointed O 
out O 
a O 
best O 
performance O 
, O 
also O 
showing O 
a O 
minor O 
variance O 
in O 
relation O 
to O 
the O 
actual O 
EC(50) O 
. O 

: O 
no O 
trans B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
in O 
Spanish O 
bakery O 
products O 
. O 

fatty I-FAMILY 
acids I-FAMILY 
( O 
TFA B-ABBREVIATION 
) O 
are O 
strongly O 
correlated O 
with O 
an O 
increased O 
risk O 
of O 
cardiovascular O 
and O 
other O 
chronic O 
diseases O 
. O 
Current O 
dietary O 
recommendations O 
exclude O 
bakery O 
products O 
from O 
frequent O 
consumption O 
basically O 
due O 
to O 
their O 
traditionally O 
high O 
content O 
of O 
TFA B-ABBREVIATION 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
analyse O 
the O 
lipid O 
profile O 
of O 
different O 
bakery O 
products O 
currently O 
commercialised O 
in O 
Spain O 
and O 
with O 
a O 
conventionally O 
high O 
fat O 
and O 
TFA B-ABBREVIATION 
content O 
. O 
Premium O 
and O 
store O 
brands O 
for O 
each O 
product O 
were O 
included O 
in O 
the O 
study O 
. O 
No O 
significant O 
amounts O 
of O 
TFA B-ABBREVIATION 
were O 
found O 
in O 
any O 
of O 
the O 
analysed O 
products O 
, O 
regardless O 
the O 
brand O 
. O 
TFA B-ABBREVIATION 
content O 
ranged O 
between O 
0.17 O 
g O 
and O 
0.22 O 
g O 
/ O 
100 O 
g O 
product O 
( O 
mean=0.19 O 
g O 
/ O 
100 O 
g O 
product O 
) O 
. O 
Expressed O 
on O 
percentage O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
the O 
maximum O 
value O 
was O 
0.87 O 
g O 
/ O 
100 O 
g O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
the O 
mean O 
value O 
was O 
0.68% O 
. O 
These O 
data O 
are O 
significantly O 
lower O 
than O 
those O 
observed O 
in O 
previously O 
published O 
papers O 
for O 
these O 
types O 
of O 
products O 
, O 
and O 
highlighted O 
the O 
importance O 
of O 
updating O 
food O 
composition O 
databases O 
in O 
order O 
to O 
accurately O 
estimate O 
the O 
real O 
and O 
current O 
intake O 
of O 
TFA B-ABBREVIATION 
. O 

- O 
term O 
supplementation O 
of O 
high O 
pigmented O 
rice O 
bran O 
oil O 
( O 
Oryza O 
sativa O 
L O 
. O 
) O 
on O 
amelioration O 
of O 
oxidative O 
stress O 
and O 
histological O 
changes O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
fed O 
a O 
high O 
fat O 
diet O 
; O 
Riceberry O 
bran O 
oil O 
. O 

is O 
a O 
serious O 
health O 
problem O 
. O 
Searching O 
for O 
alternative O 
natural O 
antioxidants O 
is O 
considered O 
important O 
strategy O 
to O 
manage O 
diabetes O 
. O 
This O 
study O 
evaluated O 
the O 
effect O 
of O 
Riceberry O 
bran O 
oil O 
( O 
RBBO O 
) O 
supplementation O 
on O 
oxidative O 
stress O 
and O 
organ O 
histology O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
fed O 
a O 
high O 
fat O 
( O 
HF O 
) O 
diet O 
. O 
Adult O 
male O 
Sprague-Dawley O 
rats O 
with O 
hyperglycemia O 
were O 
divided O 
into O 
four O 
groups O 
: O 
DM O 
group O 
fed O 
a O 
HF O 
diet O 
alone O 
; O 
DMRL O 
group O 
fed O 
a O 
HF O 
diet O 
and O 
5% O 
RBBO O 
; O 
DMRM O 
group O 
fed O 
a O 
HF O 
diet O 
and O 
7.5% O 
RBBO O 
; O 
DMRH O 
group O 
fed O 
a O 
HF O 
diet O 
and O 
15% O 
RBBO O 
. O 
Normal O 
rats O 
were O 
used O 
as O 
normal O 
control O 
and O 
were O 
divided O 
into O 
NC O 
and O 
NR O 
group O 
fed O 
a O 
normal O 
diet O 
containing O 
either O 
5% O 
corn O 
oil O 
or O 
5% O 
RBBO O 
, O 
respectively O 
. O 
After O 
12 O 
weeks O 
, O 
RBBO O 
significantly O 
decreased O 
malondialdehyde B-TRIVIAL 
and O 
restored O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
coenzyme O 
Q(10) O 
and O 
ORAC O 
levels O 
in O 
diabetic O 
rats O 
. O 
RBBO O 
additionally O 
improved O 
the O 
regenerative O 
changes O 
of O 
the O 
pancreas O 
, O 
kidneys O 
, O 
heart O 
and O 
liver O 
. O 
These O 
findings O 
indicate O 
that O 
pigmented O 
RBBO O 
could O 
provide O 
beneficial O 
effect O 
on O 
diabetes O 
by O 
decreasing O 
oxidative O 
stress O 
and O 
recovering O 
organ O 
histology O 
. O 

study O 
proposes O 
a O 
FRAP O 
assay O 
adapted O 
to O 
FIA O 
system O 
with O 
a O 
merging O 
zones O 
configuration O 
. O 
The O 
FIA O 
system O 
conditions O 
were O 
optimised O 
with O 
the O 
response O 
surface O 
methodology O 
using O 
the O 
central O 
composite O 
rotatable O 
design O 
. O 
The O 
optimisation O 
parameters O 
studied O 
were O 
: O 
the O 
carrier O 
flow O 
rate O 
, O 
the O 
lengths O 
of O 
the O 
sample O 
and O 
reagent O 
loops O 
, O 
and O 
reactor O 
length O 
. O 
The O 
conditions O 
selected O 
in O 
accordance O 
with O 
the O 
results O 
were O 
: O 
carrier O 
flow O 
rate O 
of O 
1 O 
ml O 
/ O 
min O 
, O 
length O 
of O 
the O 
loops O 
18.2 O 
cm O 
and O 
length O 
of O 
the O 
reaction O 
coil O 
210.1 O 
cm O 
. O 
The O 
detection O 
and O 
quantification O 
limits O 
were O 
, O 
respectively O 
, O 
28.6 O 
and O 
86.8 O 
μmol O 
/ O 
l O 
Fe(2+) B-FORMULA 
, O 
and O 
the O 
precision O 
was O 
1.27% O 
. O 
The O 
proposed O 
method O 
had O 
an O 
analytical O 
frequency O 
of O 
30 O 
samples O 
/ O 
h O 
and O 
about O 
95% O 
less O 
volume O 
of O 
FRAP O 
reagent O 
was O 
consumed O 
. O 
The O 
FRAP O 
assay O 
adapted O 
to O 
the O 
FIA O 
system O 
under O 
the O 
optimised O 
conditions O 
was O 
utilised O 
to O 
determine O 
the O 
antioxidant O 
activity O 
of O 
tea O 
samples O 
. O 

single O 
quadrupole O 
GC-MS O 
method O 
was O 
optimized O 
for O 
multiresidue O 
determination O 
of O 
47 O 
pesticides O 
in O 
grapes O 
with O 
limit O 
of O 
quantifications O 
of O 
each O 
compound O 
in O 
compliance O 
with O 
the O 
EU-MRL O 
requirements O 
. O 
Sample O 
preparation O 
involved O 
extraction O 
of O 
10 O 
g O 
sample O 
with O 
10 O 
ml O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
+ O 
10 O 
g O 
sodium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
) O 
by O 
homogenization O 
at O 
15000 O 
rpm O 
followed O 
by O 
centrifugation O 
at O 
3000 O 
rpm O 
. O 
The O 
supernatant O 
was O 
cleaned O 
by O 
dispersive O 
solid O 
phase O 
extraction O 
with O 
primary B-MULTIPLE 
secondary I-MULTIPLE 
amine I-MULTIPLE 
and O 
acidified O 
with O 
0.1% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Residues O 
were O 
estimated O 
in O 
selected O 
ion O 
monitoring O 
mode O 
with O 
programmable O 
temperature O 
vaporizer O 
- O 
large O 
volume O 
injection O 
( O 
8 O 
μl O 
) O 
. O 
All O 
the O 
GC O 
and O 
MS O 
parameters O 
were O 
thoroughly O 
optimized O 
to O 
achieve O 
satisfactory O 
linearity O 
( O 
R(2) O 
> O 
0.99 O 
) O 
within O 
0.01-0.25 O 
mg O 
kg(-1) O 
with O 
minimum O 
matrix O 
interferences O 
. O 
Recoveries O 
at O 
0.01 O 
and O 
0.02 O 
mg O 
kg(-1) O 
were O 
within O 
67-120% O 
with O 
associated O 
precision O 
RSD O 
below O 
19% O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
for O 
analysis O 
of O 
the O 
real O 
world O 
samples O 
for O 
incurred O 
residues O 
. O 

behaviour O 
of O 
oat O 
β-glucan/ O 
sodium B-SYSTEMATIC 
caseinate O 
mixtures O 
varying O 
in O 
molecular O 
weight O 
. O 

isothermal O 
phase O 
behaviour O 
at O 
5 O 
°C O 
of O 
mixtures O 
of O 
sodium B-SYSTEMATIC 
caseinate O 
and O 
oat O 
β-glucan O 
isolates O 
varying O 
in O 
molecular O 
weight O 
( O 
MW O 
) O 
was O 
investigated O 
by O 
means O 
of O 
phase O 
diagram O 
construction O 
, O 
rheometry O 
, O 
fluorescence O 
microscopy O 
and O 
electrophoresis O 
. O 
Phase O 
diagrams O 
indicated O 
that O 
the O 
compatibility O 
of O 
the O 
β-glucan/ O 
sodium B-SYSTEMATIC 
caseinate O 
system O 
increases O 
as O 
β-glucan O 
MW O 
decreases O 
. O 
Images O 
of O 
mixtures O 
taken O 
at O 
various O 
biopolymer O 
concentrations O 
revealed O 
phase O 
separated O 
domains O 
. O 
Results O 
also O 
revealed O 
that O 
at O 
the O 
state O 
of O 
thermodynamic O 
equilibrium O 
, O 
lower O 
MW O 
samples O 
yielded O 
considerable O 
viscosity O 
in O 
the O 
mixture O 
. O 
At O 
equivalent O 
hydrodynamic O 
volume O 
of O 
β-glucan O 
in O 
the O 
mixtures O 
, O 
samples O 
varying O 
in O 
molecular O 
weight O 
exhibited O 
similar O 
flow O 
behaviour O 
. O 
A O 
deviation O 
dependent O 
on O 
the O 
protein O 
concentration O 
was O 
observed O 
for O 
the O 
high O 
MW O 
sample O 
in O 
the O 
concentrated O 
regime O 
due O 
to O 
the O 
size O 
of O 
β-glucan O 
aggregates O 
formed O 
. O 
Results O 
demonstrate O 
that O 
by O 
controlling O 
the O 
structural O 
features O 
of O 
β-glucan O 
in O 
mixtures O 
with O 
sodium B-SYSTEMATIC 
caseinate O 
, O 
informed O 
manipulation O 
of O 
rheological O 
properties O 
in O 
these O 
systems O 
can O 
be O 
achieved O 
. O 

oil O 
from O 
the O 
aerial O 
parts O 
of O 
Artemisia O 
indica O 
was O 
analysed O 
by O 
GC-FID O 
and O 
GC-MS O 
. O 
A O 
total O 
of O 
43 O 
compounds O 
representing O 
96.8% O 
of O 
the O 
oil O 
were O 
identified O 
and O 
the O 
major O 
components O 
were O 
found O 
to O 
be O 
artemisia B-TRIVIAL 
ketone I-TRIVIAL 
( O 
42.1% O 
) O 
, O 
germacrene B-TRIVIAL 
B I-TRIVIAL 
( O 
8.6% O 
) O 
, O 
borneol B-TRIVIAL 
( O 
6.1% O 
) O 
and O 
cis-chrysanthenyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
4.8% O 
) O 
. O 
Antimicrobial O 
activity O 
of O 
the O 
oil O 
was O 
evaluated O 
against O 
seven O 
clinically O 
significant O 
bacterial O 
and O 
two O 
fungal O 
strains O 
. O 
The O 
essential O 
oil O 
and O 
its O 
major O 
constituents O 
exhibited O 
moderate O 
to O 
potent O 
, O 
broad O 
- O 
spectrum O 
antibacterial O 
and O 
antifungal O 
activities O 
targeting O 
both O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
In O 
vitro O 
cytotoxicity O 
evaluation O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
THP-1 O 
( O 
leukemia O 
) O 
, O 
A-549 O 
( O 
lung O 
) O 
, O 
HEP-2 O 
( O 
liver O 
) O 
and O 
Caco-2 O 
( O 
colon O 
) O 
showed O 
that O 
the O 
essential O 
oil O 
exhibited O 
concentration O 
dependant O 
growth O 
inhibition O 
in O 
the O 
10-100 O 
μg O 
/ O 
ml O 
dilution O 
range O 
, O 
with O 
IC(50) O 
values O 
of O 
10 O 
μg O 
/ O 
ml O 
( O 
THP-1 O 
) O 
, O 
25 O 
μg O 
/ O 
ml O 
( O 
A-549 O 
) O 
, O 
15.5 O 
μg O 
/ O 
ml O 
( O 
HEP-2 O 
) O 
and O 
19.5 O 
μg O 
/ O 
ml O 
( O 
Caco-2 O 
) O 
. O 
It O 
was O 
interesting O 
to O 
note O 
that O 
the O 
essential O 
oil O 
also O 
exhibited O 
potent O 
antioxidant O 
activity O 
. O 

volatile O 
compounds O 
of O 
four O 
peach O 
cultivars O 
( O 
Prunus O 
persica O 
L O 
. O 
) O 
were O 
studied O 
: O 
Sudanell O 
, O 
San O 
Lorenzo O 
, O 
Miraflores O 
and O 
Calanda O 
( O 
two O 
clones O 
, O 
Calante O 
and O 
Jesca O 
) O 
. O 
17-23 O 
Samples O 
of O 
each O 
cultivar O 
with O 
the O 
same O 
maturity O 
level O 
were O 
analyzed O 
, O 
measuring O 
color O 
, O 
firmness O 
, O 
and O 
soluble O 
solids O 
content O 
. O 
The O 
pulp O 
was O 
crushed O 
and O 
mixed O 
with O 
water O 
prior O 
to O 
HS-SPME O 
analysis O 
, O 
and O 
GC-MS O 
was O 
used O 
to O 
determine O 
the O 
volatile O 
compounds O 
. O 
Sixty O 
- O 
five O 
compounds O 
were O 
identified O 
using O 
spectral O 
library O 
matching O 
, O 
Kovat's O 
indices O 
and O 
, O 
when O 
available O 
, O 
pure O 
standards O 
. O 
The O 
main O 
components O 
were O 
lactones B-FAMILY 
and O 
C6 O 
compounds O 
. O 
From O 
the O 
distribution O 
of O 
these O 
compounds O 
, O 
Principal O 
Component O 
Analysis O 
led O 
to O 
the O 
clustering O 
of O 
the O 
samples O 
according O 
to O 
their O 
different O 
cultivars O 
. O 
Finally O 
, O 
Canonical O 
Component O 
Analysis O 
was O 
used O 
to O 
create O 
a O 
classification O 
function O 
that O 
identifies O 
the O 
origin O 
of O 
an O 
unknown O 
sample O 
from O 
its O 
volatile O 
composition O 
. O 
The O 
results O 
obtained O 
will O 
help O 
to O 
avoid O 
fraud O 
and O 
protect O 
the O 
European O 
Designation O 
of O 
Origin O 
' O 
Melocotón O 
de O 
Calanda O 
' O 
. O 

from O 
Lindera O 
erythrocarpa O 
Makino O 
fruits O 
suppresses O 
adipogenesis O 
in O 
3T3-L1 O 
cells O 
and O 
attenuates O 
obesity O 
and O 
consequent O 
metabolic O 
disorders O 
in O 
high O 
- O 
fat O 
diet O 
C57BL O 
/ O 
6 O 
mice O 
. O 

is O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
development O 
of O 
numerous O 
diseases O 
including O 
type O 
2 O 
diabetes O 
, O 
hypertension O 
, O 
hyperlipidemia O 
, O 
and O 
cardiovascular O 
disease O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
lucidone B-TRIVIAL 
in O 
vitro O 
on O 
gene O 
expression O 
during O 
adipogenesis O 
in O 
3T3-L1 O 
cells O 
and O 
in O 
vivo O 
on O 
high O 
- O 
fat O 
diet O 
induced O 
obesity O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 
Lucidone B-TRIVIAL 
at O 
40 O 
μmol O 
/ O 
L O 
suppressed O 
adipogenesis O 
in O 
3T3-L1 O 
cells O 
by O 
reducing O 
transcription O 
levels O 
of O 
adipogenic O 
genes O 
, O 
including O 
PPARγ O 
, O 
C O 
/ O 
EBPα O 
, O 
LXR-α O 
, O 
LPL O 
, O 
aP2 O 
, O 
GLUT4 O 
and O 
adiponectin O 
. O 
Five O 
- O 
week O 
- O 
old O 
male O 
C57BL O 
/ O 
6 O 
mice O 
fed O 
a O 
high O 
fat O 
diet O 
( O 
60% O 
energy O 
from O 
fat O 
) O 
supplemented O 
with O 
lucidone B-TRIVIAL 
at O 
a O 
dosage O 
of O 
1250 O 
mg O 
/ O 
kg O 
of O 
diet O 
for O 
12 O 
weeks O 
had O 
reduced O 
body O 
and O 
liver O 
weight O 
, O 
reduced O 
epididymal O 
and O 
perirenal O 
adipose O 
tissue O 
, O 
decreased O 
food O 
efficiency O 
( O 
percentage O 
of O 
weight O 
gain O 
divided O 
by O 
food O 
intake O 
) O 
, O 
and O 
lowered O 
plasma O 
cholesterol B-TRIVIAL 
, O 
triglyceride B-FAMILY 
, O 
glucose B-TRIVIAL 
, O 
and O 
insulin O 
levels O 
. O 
Dissection O 
of O 
adipose O 
tissue O 
from O 
lucidone B-TRIVIAL 
-treated O 
mice O 
showed O 
a O 
reduction O 
in O 
the O 
average O 
fat O 
- O 
cell O 
size O 
and O 
percentage O 
of O 
large O 
adipocytes O 
. O 
These O 
results O 
provide O 
evidence O 
that O 
dietary O 
intake O 
of O 
lucidone B-TRIVIAL 
alleviates O 
high O 
fat O 
diet O 
- O 
induced O 
obesity O 
in O 
C57BL O 
/ O 
6 O 
mice O 
and O 
reveals O 
the O 
potential O 
of O 
lucidone B-TRIVIAL 
as O 
a O 
nutraceutical O 
to O 
prevent O 
obesity O 
and O 
consequent O 
metabolic O 
disorders O 
. O 

new O 
single O 
- O 
photon O 
emission O 
computed O 
tomography O 
( O 
SPECT O 
) O 
imaging O 
agent O 
for O 
serotonin B-TRIVIAL 
transporters O 
: O 
[(125)I]Flip-IDAM B-SYSTEMATIC 
, O 
(2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol B-SYSTEMATIC 
. O 

ligands O 
for O 
in O 
vivo O 
brain O 
imaging O 
of O 
serotonin B-TRIVIAL 
transporter O 
( O 
SERT O 
) O 
with O 
single O 
photon O 
emission O 
tomography O 
( O 
SPECT O 
) O 
were O 
prepared O 
and O 
evaluated O 
. O 
An O 
efficient O 
synthesis O 
and O 
radiolabeling O 
of O 
a O 
biphenylthiol B-SYSTEMATIC 
, O 
FLIP-IDAM B-ABBREVIATION 
, O 
4 O 
, O 
was O 
accomplished O 
. O 
The O 
affinity O 
of O 
FLIP-IDAM B-ABBREVIATION 
was O 
evaluated O 
by O 
an O 
in O 
vitro O 
inhibitory O 
binding O 
assay O 
using O 
[(125)I]-IDAM B-SYSTEMATIC 
as O 
radioligand O 
in O 
rat O 
brain O 
tissue O 
homogenates O 
( O 
K O 
(i) O 
= O 
0.03 O 
nM O 
) O 
. O 
New O 
[(125)I]Flip-IDAM B-SYSTEMATIC 
exhibited O 
excellent O 
binding O 
affinity O 
to O 
SERT O 
binding O 
sites O 
with O 
a O 
high O 
hypothalamus O 
to O 
cerebellum O 
ratio O 
of O 
4 O 
at O 
30 O 
min O 
post O 
iv O 
injection O 
. O 
The O 
faster O 
in O 
vivo O 
kinetics O 
for O 
brain O 
uptake O 
and O 
a O 
rapid O 
washout O 
from O 
non-specific O 
regions O 
provide O 
excellent O 
signal O 
to O 
noise O 
ratio O 
. O 
This O 
new O 
agent O 
, O 
when O 
labeled O 
with O 
(123)I B-FORMULA 
, O 
may O 
be O 
a O 
useful O 
imaging O 
agent O 
for O 
mapping O 
SERT O 
binding O 
sites O 
in O 
the O 
human O 
brain O 
. O 

activity O 
relationship O 
studies O 
of O 
tricyclic B-FAMILY 
bispyran I-FAMILY 
sulfone I-FAMILY 
γ-secretase O 
inhibitors O 
. O 

investigation O 
is O 
detailed O 
of O 
the O 
structure O 
activity O 
relationships O 
( O 
SAR O 
) O 
of O 
two O 
sulfone B-SYSTEMATIC 
side O 
chains O 
of O 
compound O 
(-)-1a O 
( O 
SCH B-IDENTIFIER 
900229 I-IDENTIFIER 
) O 
, O 
a O 
potent O 
, O 
PS1-selective O 
γ-secretase O 
inhibitor O 
and O 
clinical O 
candidate O 
for O 
the O 
treatment O 
of O 
Alzheimer's O 
disease O 
. O 
Specifically O 
, O 
4-CF(3) B-FORMULA 
and O 
4-Br B-FORMULA 
substituted O 
arylsulfone B-FAMILY 
analogs O 
, O 
(-)-1b O 
and O 
(-)-1c O 
, O 
are O 
equipotent O 
to O 
compound O 
(-)-1a O 
. O 
On O 
the O 
right O 
hand O 
side O 
chain O 
, O 
linker O 
size O 
and O 
terminal O 
substituents O 
of O 
the O 
pendant O 
sulfone B-SYSTEMATIC 
group O 
are O 
also O 
investigated O 
. O 

synthesis O 
of O 
5- B-MULTIPLE 
and I-MULTIPLE 
6-methoxybenzimidazole-1,3,5-triazines I-MULTIPLE 
as O 
inhibitors O 
of O 
phosphoinositide O 
3-kinase O 
. O 

3-kinases O 
( O 
PI3K O 
) O 
hold O 
significant O 
therapeutic O 
potential O 
as O 
novel O 
targets O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
ZSTK474 B-IDENTIFIER 
( O 
4a O 
) O 
is O 
a O 
potent O 
, O 
pan-PI3K O 
inhibitor O 
currently O 
under O 
clinical O 
evaluation O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 
Structural O 
studies O 
have O 
shown O 
that O 
derivatisation O 
at O 
the O 
5- O 
or O 
6- O 
position O 
of O 
the O 
benzimidazole B-SYSTEMATIC 
ring O 
may O 
influence O 
potency O 
and O 
isoform O 
selectivity O 
. O 
However O 
, O 
synthesis O 
of O 
these O 
derivatives O 
by O 
the O 
traditional O 
route O 
results O 
in O 
a O 
mixture O 
of O 
the O 
two O 
regioisomers O 
. O 
We O 
have O 
developed O 
a O 
straightforward O 
regioselective O 
synthesis O 
that O 
gave O 
convenient O 
access O 
to O 
5- B-MULTIPLE 
and I-MULTIPLE 
6-methoxysubstituted I-MULTIPLE 
benzimidazole I-MULTIPLE 
derivatives O 
of O 
ZSTK474 B-IDENTIFIER 
. O 
While O 
5-methoxy B-SYSTEMATIC 
substitution O 
abolished O 
activity O 
at O 
all O 
isoforms O 
, O 
the O 
6-methoxy B-SYSTEMATIC 
substitution O 
is O 
consistently O 
10-fold O 
more O 
potent O 
. O 
This O 
synthesis O 
will O 
allow O 
convenient O 
access O 
to O 
further O 
6- O 
position O 
derivatives O 
, O 
thus O 
allowing O 
the O 
full O 
scope O 
of O 
the O 
structure O 
- O 
activity O 
relationships O 
of O 
ZSTK474 B-IDENTIFIER 
to O 
be O 
probed O 
. O 

of O 
DNA O 
oligonucleotides O 
containing O 
C5-ethynylbenzenesulfonamide- B-FAMILY 
modified I-FAMILY 
nucleotides I-FAMILY 
( O 
EBNA B-ABBREVIATION 
) O 
by O 
polymerases O 
towards O 
the O 
construction O 
of O 
base O 
functionalized O 
nucleic O 
acids O 
. O 

modified I-FAMILY 
nucleotide I-FAMILY 
( O 
EBNA B-ABBREVIATION 
) O 
was O 
investigated O 
as O 
substrate O 
of O 
various O 
DNA O 
polymerases O 
. O 
The O 
experiments O 
revealed O 
that O 
KOD O 
, O 
Phusion O 
and O 
Klenow O 
DNA O 
polymerases O 
successfully O 
accepted O 
EBNA B-ABBREVIATION 
-T O 
nucleotide B-FAMILY 
as O 
a O 
substrate O 
and O 
yielded O 
the O 
fully O 
extended O 
DNA O 
. O 
KOD O 
DNA O 
polymerase O 
was O 
found O 
to O 
be O 
the O 
most O 
efficient O 
enzyme O 
to O 
furnish O 
EBNA B-ABBREVIATION 
-T O 
containing O 
DNA O 
in O 
good O 
yields O 
. O 
Phusion O 
DNA O 
polymerase O 
efficiently O 
amplified O 
the O 
template O 
containing O 
EBNA B-ABBREVIATION 
-T O 
nucleotides B-FAMILY 
by O 
PCR O 
. O 

and O 
evaluation O 
of O 
8-oxoadenine B-FAMILY 
derivatives O 
as O 
potent O 
Toll O 
- O 
like O 
receptor O 
7 O 
agonists O 
with O 
high O 
water O 
solubility O 
. O 

report O 
the O 
discovery O 
of O 
novel O 
series O 
of O 
highly O 
potent O 
TLR7 O 
agonists O 
based O 
on O 
8-oxoadenines B-FAMILY 
, O 
1 O 
and O 
2 O 
by O 
introducing O 
and O 
optimizing O 
various O 
tertiary B-FAMILY 
amines I-FAMILY 
onto O 
the O 
N B-FORMULA 
( O 
9 O 
) O 
- O 
position O 
of O 
the O 
adenine B-TRIVIAL 
moiety O 
. O 
The O 
introduction O 
of O 
the O 
amino B-FAMILY 
group O 
resulted O 
in O 
not O 
only O 
improved O 
water O 
solubility O 
but O 
also O 
enhanced O 
TLR7 O 
agonistic O 
activity O 
. O 
In O 
particular O 
compound O 
20 O 
( O 
DSR-6434 B-IDENTIFIER 
) O 
indicated O 
an O 
optimal O 
balance O 
between O 
the O 
agonistic O 
potency O 
and O 
high O 
water O 
solubility O 
. O 
It O 
also O 
demonstrated O 
a O 
strong O 
antitumor O 
effect O 
in O 
vivo O 
by O 
intravenous O 
administration O 
in O 
a O 
tumor O 
bearing O 
mice O 
model O 
. O 

modification O 
of O 
SCH B-IDENTIFIER 
900229 I-IDENTIFIER 
and O 
related O 
chromene O 
sulfone B-SYSTEMATIC 
γ-secretase O 
inhibitors O 
. O 

to O 
block O 
metabolism O 
by O 
incorporating O 
a O 
9-fluoro B-SYSTEMATIC 
substituent O 
at O 
the O 
A-ring O 
of O 
compound O 
1 O 
( O 
SCH B-IDENTIFIER 
900229 I-IDENTIFIER 
) O 
using O 
electrophilic O 
Selectfluor B-TRIVIAL 
™ O 
led O 
to O 
an O 
unexpected O 
oxidation O 
of O 
the O 
A-ring O 
to O 
give O 
difluoroquinone B-FAMILY 
analog O 
1a O 
. O 
Oxidation O 
of O 
other O 
related O 
chromene O 
γ-secretase O 
inhibitors O 
2-8 O 
resulted O 
in O 
similar O 
difluoroquinone B-FAMILY 
analogs O 
2a-8a O 
, O 
respectively O 
. O 
These O 
quinone B-FAMILY 
products O 
exhibited O 
comparable O 
in O 
vitro O 
potency O 
in O 
a O 
γ-scretase O 
membrane O 
assay O 
, O 
but O 
were O 
several O 
fold O 
less O 
potent O 
in O 
a O 
cell O 
- O 
based O 
assay O 
in O 
lowering O 
Aβ40-42 O 
, O 
compared O 
to O 
their O 
parent O 
compounds O 
. O 

of O 
the O 
β-carbonic O 
anhydrases O 
from O 
Mycobacterium O 
tuberculosis O 
with O 
C-cinnamoyl B-FAMILY 
glycosides I-FAMILY 
: O 
identification O 
of O 
the O 
first O 
inhibitor O 
with O 
anti-mycobacterial O 
activity O 
. O 

small O 
series O 
of O 
C-cinnamoyl B-FAMILY 
glycoside I-FAMILY 
containing O 
the O 
phenol B-SYSTEMATIC 
moiety O 
was O 
tested O 
for O 
the O 
inhibition O 
of O 
the O 
three O 
Mycobacterium O 
tuberculosis O 
β-carbonic O 
anhydrases O 
( O 
CAs O 
, O 
EC O 
4.2.1.1 O 
) O 
with O 
activities O 
in O 
the O 
low O 
micromolar O 
range O 
detected O 
. O 
The O 
compounds O 
were O 
also O 
tested O 
for O 
the O 
inhibition O 
of O 
growth O 
of O 
M O 
. O 
tuberculosis O 
H(37)Rv O 
strain O 
, O 
leading O 
to O 
the O 
identification O 
of O 
(E)-1-(2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl)-4-(3-hydroxyphenyl)but-3-en-2-one B-SYSTEMATIC 
( O 
1 O 
) O 
as O 
the O 
first O 
carbonic O 
anhydrase O 
inhibitor O 
with O 
anti-tubercular O 
activity O 
. O 

of O 
liver O 
- O 
targeted O 
inhibitors O 
of O 
stearoyl-CoA B-TRIVIAL 
desaturase O 
( O 
SCD1 O 
) O 
. O 

based O 
on O 
a O 
benzo B-FAMILY 
- I-FAMILY 
fused I-FAMILY 
spirocyclic I-FAMILY 
oxazepine I-FAMILY 
scaffold O 
were O 
discovered O 
for O 
stearoyl-coenzyme B-TRIVIAL 
A I-TRIVIAL 
( O 
CoA B-ABBREVIATION 
) O 
desaturase O 
1 O 
( O 
SCD1 O 
) O 
and O 
subsequently O 
optimized O 
to O 
potent O 
compounds O 
with O 
favorable O 
pharmacokinetic O 
profiles O 
and O 
in O 
vivo O 
efficacy O 
in O 
reducing O 
the O 
desaturation O 
index O 
in O 
a O 
mouse O 
model O 
. O 
Initial O 
optimization O 
revealed O 
potency O 
preferences O 
for O 
the O 
oxazepine B-TRIVIAL 
core O 
and O 
benzylic B-TRIVIAL 
positions O 
, O 
while O 
substituents O 
on O 
the O 
piperidine B-SYSTEMATIC 
portions O 
were O 
more O 
tolerant O 
and O 
allowed O 
for O 
tuning O 
of O 
potency O 
and O 
PK O 
properties O 
. O 
After O 
preparation O 
and O 
testing O 
of O 
a O 
range O 
of O 
functional O 
groups O 
on O 
the O 
piperidine B-SYSTEMATIC 
nitrogen B-SYSTEMATIC 
, O 
three O 
classes O 
of O 
analogs O 
were O 
identified O 
with O 
single O 
digit O 
nanomolar O 
potency O 
: O 
glycine B-FAMILY 
amides I-FAMILY 
, O 
heterocycle O 
- O 
linked O 
amides B-FAMILY 
, O 
and O 
thiazoles B-FAMILY 
. O 
Responding O 
to O 
concerns O 
about O 
target O 
localization O 
and O 
potential O 
mechanism O 
- O 
based O 
side O 
effects O 
, O 
an O 
initial O 
effort O 
was O 
also O 
made O 
to O 
improve O 
liver O 
concentration O 
in O 
an O 
available O 
rat O 
PK O 
model O 
. O 
An O 
advanced O 
compound O 
17m O 
with O 
a O 
5-carboxy-2-thiazole B-SYSTEMATIC 
substructure O 
appended O 
to O 
the O 
spirocyclic B-FAMILY 
piperidine I-FAMILY 
scaffold O 
was O 
developed O 
which O 
satisfied O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
requirements O 
for O 
more O 
detailed O 
studies O 
. O 

examine O 
by O 
both O 
experimental O 
and O 
computational O 
means O 
the O 
diffusion O 
of O 
macromolecules O 
through O 
the O 
skin O 
strata O 
( O 
both O 
the O 
epidermis O 
and O 
dermis O 
) O 
. O 
Using O 
mouse O 
skin O 
as O 
a O 
test O 
case O 
, O 
we O 
present O 
a O 
novel O 
high O 
- O 
resolution O 
technique O 
to O 
characterize O 
the O 
diffusion O 
properties O 
of O 
heterogeneous O 
biomaterials O 
using O 
3D O 
imaging O 
of O 
fluorescent O 
probes O 
, O 
precisely O 
- O 
deposited O 
in O 
minimally O 
- O 
perturbed O 
in O 
vivo O 
skin O 
layers O 
. O 
We O 
find O 
the O 
diffusivity O 
of O 
the O 
delivered O 
macromolecules O 
( O 
70 O 
kDa O 
and O 
2 O 
MDa O 
rhodamine B-TRIVIAL 
-dextrans O 
) O 
low O 
within O 
the O 
packed O 
cellular O 
arrangement O 
of O 
the O 
epidermis O 
, O 
while O 
gradually O 
increasing O 
( O 
by O 
~an O 
order O 
of O 
magnitude O 
) O 
through O 
the O 
dermis O 
-- O 
as O 
pores O 
in O 
the O 
fibrillar O 
network O 
enlarge O 
from O 
the O 
papillary O 
to O 
the O 
reticular O 
dermis O 
. O 
Our O 
experimental O 
and O 
computational O 
approaches O 
for O 
investigating O 
the O 
diffusion O 
through O 
skin O 
strata O 
help O 
in O 
the O 
assessment O 
and O 
optimization O 
of O 
controlled O 
delivery O 
of O 
drugs O 
( O 
e.g O 
. O 
vaccines O 
) O 
to O 
specific O 
sites O 
( O 
e.g O 
. O 
antigen O 
presenting O 
cells O 
) O 
. O 

functionalized O 
mixed O 
micellar O 
nanoparticles O 
for O 
targeted O 
delivery O 
of O 
siRNA O 
to O 
liver O 
. O 

to O 
its O 
efficient O 
and O 
specific O 
gene O 
silencing O 
ability O 
, O 
RNA O 
interference O 
has O 
shown O 
great O 
potential O 
in O 
the O 
treatment O 
of O 
liver O 
diseases O 
. O 
However O 
, O 
achieving O 
in O 
vivo O 
delivery O 
of O 
siRNA O 
to O 
critical O 
liver O 
cells O 
remains O 
the O 
biggest O 
obstacle O 
for O 
this O 
technique O 
to O 
be O 
a O 
real O 
clinic O 
therapeutic O 
modality O 
. O 
Here O 
, O 
we O 
describe O 
a O 
promising O 
liver O 
targeting O 
siRNA O 
delivery O 
system O 
based O 
on O 
N-acetylgalactosamine B-SYSTEMATIC 
functionalized O 
mixed O 
micellar O 
nanoparticles O 
( O 
Gal-MNP O 
) O 
, O 
which O 
can O 
efficiently O 
deliver O 
siRNA O 
to O 
hepatocytes O 
and O 
silence O 
the O 
target O 
gene O 
expression O 
after O 
systemic O 
administration O 
. O 
The O 
Gal-MNP O 
were O 
assembled O 
in O 
aqueous O 
solution O 
from O 
mixed O 
N-acetylgalactosamine B-SYSTEMATIC 
functionalized O 
poly(ethylene B-SYSTEMATIC 
glycol)-b-poly(ε-caprolactone I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
cationic O 
poly(ε-caprolactone)-b-poly(2-aminoethyl B-SYSTEMATIC 
ethylene I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PCL-b-PPEEA B-ABBREVIATION 
) O 
; O 
the O 
properties O 
of O 
nanoparticles O 
, O 
including O 
particle O 
size O 
, O 
zeta O 
potential O 
and O 
the O 
density O 
of O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
could O 
be O 
easily O 
regulated O 
. O 
The O 
hepatocyte O 
- O 
targeting O 
effect O 
of O 
Gal-MNP O 
was O 
demonstrated O 
by O 
significant O 
enriching O 
of O 
fluorescent O 
siRNA O 
in O 
primary O 
hepatocytes O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Successful O 
down O 
- O 
regulation O 
of O 
liver O 
- O 
specific O 
apolipoprotein O 
B O 
( O 
apoB O 
) O 
expression O 
was O 
achieved O 
in O 
mouse O 
liver O 
, O 
at O 
both O 
the O 
transcriptional O 
and O 
protein O 
level O 
, O 
following O 
intravenous O 
injection O 
of O 
Gal-MNP O 
/ O 
siapoB O 
to O 
BALB O 
/ O 
c O 
mice O 
. O 
Systemic O 
delivery O 
of O 
Gal-MNP O 
/ O 
siRNA O 
did O 
not O 
induce O 
the O 
innate O 
immune O 
response O 
or O 
positive O 
hepatotoxicity O 
. O 
The O 
results O 
of O 
this O 
study O 
suggested O 
therapeutic O 
potential O 
for O 
the O 
Gal-MNP O 
/ O 
siRNA O 
system O 
in O 
liver O 
disease O 
. O 

chronic O 
inflammatory O 
diseases O 
the O 
endothelium O 
expresses O 
mediators O 
responsible O 
for O 
harmful O 
leukocyte O 
infiltration O 
. O 
We O 
investigated O 
whether O 
targeted O 
delivery O 
of O 
a O 
therapeutic O 
transgene O 
that O 
inhibits O 
nuclear O 
factor O 
κB O 
signal O 
transduction O 
could O 
silence O 
the O 
proinflammatory O 
activation O 
status O 
of O 
endothelial O 
cells O 
. O 
For O 
this O 
, O 
an O 
adenovirus O 
encoding O 
dominant O 
- O 
negative O 
IκB O 
( O 
dnIκB O 
) O 
as O 
a O 
therapeutic O 
transgene O 
was O 
employed O 
. O 
Selectivity O 
for O 
the O 
endothelial O 
cells O 
was O 
achieved O 
by O 
introduction O 
of O 
antibodies O 
specific O 
for O 
inflammatory O 
endothelial O 
adhesion O 
molecules O 
E-selectin O 
or O 
VCAM-1 O 
chemically O 
linked O 
to O 
the O 
virus O 
via O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
. O 
In O 
vitro O 
, O 
the O 
retargeted O 
adenoviruses O 
selectively O 
infected O 
cytokine O 
- O 
activated O 
endothelial O 
cells O 
to O 
express O 
functional O 
transgene O 
. O 
The O 
comparison O 
of O 
transductional O 
capacity O 
of O 
both O 
retargeted O 
viruses O 
revealed O 
that O 
E-selectin O 
based O 
transgene O 
delivery O 
exerted O 
superior O 
pharmacological O 
effects O 
. O 
Targeted O 
delivery O 
mediated O 
dnIκB O 
transgene O 
expression O 
in O 
endothelial O 
cells O 
inhibited O 
the O 
induced O 
expression O 
of O 
several O 
inflammatory O 
genes O 
, O 
including O 
adhesion O 
molecules O 
, O 
cytokines O 
, O 
and O 
chemokines O 
. O 
In O 
vivo O 
, O 
in O 
mice O 
suffering O 
from O 
glomerulonephritis O 
, O 
E-selectin- O 
retargeted O 
adenovirus O 
selectively O 
homed O 
in O 
the O 
kidney O 
to O 
microvascular O 
glomerular O 
endothelium O 
. O 
Subsequent O 
downregulation O 
of O 
endothelial O 
adhesion O 
molecule O 
expression O 
2 O 
days O 
after O 
induction O 
of O 
inflammation O 
demonstrated O 
the O 
pharmacological O 
potential O 
of O 
this O 
gene O 
therapy O 
approach O 
. O 
The O 
data O 
justify O 
further O 
studies O 
towards O 
therapeutic O 
virus O 
design O 
and O 
optimization O 
of O 
treatment O 
schedules O 
to O 
investigate O 
their O 
capacity O 
to O 
interfere O 
with O 
inflammatory O 
disease O 
progression O 
. O 

vitro O 
anti-inflammatory O 
effect O 
of O 
apigenin B-TRIVIAL 
in O 
the O 
Helicobacter O 
pylori O 
- O 
infected O 
gastric O 
adenocarcinoma O 
cells O 
. O 

with O 
Helicobacter O 
pylori O 
causes O 
extensive O 
gastric O 
epithelial O 
cell O 
inflammation O 
which O 
may O 
progress O 
to O 
atrophic O 
gastritis O 
, O 
intestinal O 
metaplasia O 
, O 
and O 
even O 
gastric O 
adenocarcinoma O 
. O 
Apigenin B-TRIVIAL 
( O 
4',5,7-trihydroxyflavone B-SYSTEMATIC 
) O 
is O 
widely O 
distributed O 
in O 
fruits O 
and O 
vegetables O 
, O 
and O 
is O 
a O 
well O 
- O 
known O 
antiinflammatory O 
supplement O 
with O 
low O 
cytotoxicity O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
anti-inflammatory O 
effects O 
of O 
apigenin B-TRIVIAL 
in O 
H O 
. O 
pylori O 
- O 
infected O 
MKN45 O 
cells O 
, O 
for O 
which O 
IκBα O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
intercellular O 
adhesion O 
molecule-1 O 
( O 
ICAM-1 O 
) O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
interleukin-8 O 
( O 
IL-8 O 
) O 
, O 
IL-6 O 
, O 
IL-1β O 
, O 
and O 
mucin-2 O 
( O 
MUC-2 O 
) O 
expressions O 
were O 
examined O 
. O 
Apigenin B-TRIVIAL 
treatments O 
( O 
9.3-74 O 
μM O 
) O 
significantly O 
increased O 
the O 
IκBα O 
expression O 
, O 
and O 
thus O 
inhibited O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
activation O 
, O 
and O 
the O 
inflammatory O 
factor O 
( O 
COX-2 O 
, O 
ICAM-1 O 
, O 
ROS O 
, O 
IL-6 O 
, O 
and O 
IL-8 O 
) O 
expressions O 
decreased O 
. O 
The O 
ROS O 
levels O 
decreased O 
partially O 
based O 
on O 
the O 
intrinsic O 
scavenging O 
property O 
of O 
apigenin B-TRIVIAL 
. O 
In O 
summary O 
, O 
apigenin B-TRIVIAL 
treatments O 
effectively O 
inhibited O 
NF-κB O 
activation O 
and O 
the O 
related O 
inflammatory O 
factor O 
expressions O 
, O 
as O 
well O 
as O 
increased O 
MUC-2 O 
expression O 
in O 
the O 
H O 
. O 
pylori O 
- O 
infected O 
MKN45 O 
cells O 
. O 
The O 
compound O 
shows O 
great O 
potential O 
as O 
a O 
candidate O 
agent O 
for O 
the O 
inhibition O 
of O 
H O 
. O 
pylori O 
- O 
induced O 
extensive O 
gastric O 
epithelial O 
cell O 
inflammation O 
. O 

insecticide O 
methomyl B-TRIVIAL 
confers O 
cytotoxicity O 
through O 
DNA O 
damage O 
induction O 
. O 

insecticide O 
methomyl B-TRIVIAL 
could O 
induce O 
genotoxic O 
effects O 
, O 
including O 
micronuclei O 
, O 
chromosome O 
aberrations O 
and O 
sister O 
- O 
chromatid O 
exchanges O 
. O 
However O 
, O 
methomyl B-TRIVIAL 
induction O 
of O 
cytotoxicity O 
through O 
DNA O 
damage O 
is O 
largely O 
unknown O 
. O 
Here O 
we O 
identify O 
cytotoxicity O 
and O 
potential O 
genotoxicity O 
of O 
methomyl B-TRIVIAL 
in O 
vitro O 
. O 
We O 
have O 
employed O 
alkaline O 
comet O 
assay O 
, O 
γH2AX O 
foci O 
formation O 
and O 
DNA O 
ladder O 
assay O 
to O 
detected O 
DNA O 
damage O 
and O 
apoptosis O 
of O 
Drosophila O 
S2 O 
, O 
HeLa O 
and O 
HEK293 O 
cells O 
. O 
The O 
alkaline O 
comet O 
assay O 
was O 
used O 
to O 
evaluate O 
total O 
DNA O 
single O 
strand O 
breaks O 
( O 
SSBs O 
) O 
in O 
the O 
target O 
cells O 
exposed O 
in O 
vitro O 
to O 
sublethal O 
concentrations O 
of O 
methomyl B-TRIVIAL 
. O 
As O 
expected O 
, O 
methomyl B-TRIVIAL 
induced O 
significant O 
concentration O 
- O 
dependent O 
increases O 
in O 
DNA O 
damage O 
of O 
target O 
cells O 
compared O 
with O 
the O 
negative O 
control O 
, O 
as O 
measured O 
by O 
increases O 
in O 
tail O 
length O 
( O 
μm O 
) O 
, O 
tail O 
DNA O 
( O 
percentage O 
of O 
the O 
comet O 
tail O 
) O 
and O 
tail O 
moment O 
( O 
arbitrary O 
units O 
) O 
. O 
In O 
agreement O 
with O 
the O 
comet O 
assay O 
data O 
, O 
the O 
percentage O 
of O 
γH2AX O 
positive O 
reaction O 
in O 
HeLa O 
cells O 
also O 
revealed O 
methomyl B-TRIVIAL 
caused O 
DNA O 
double O 
strand O 
breaks O 
( O 
DSBs O 
) O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
. O 
Moreover O 
, O 
methomyl B-TRIVIAL 
induced O 
a O 
significant O 
increase O 
of O 
apoptosis O 
in O 
Drosophila O 
S2 O 
, O 
HeLa O 
and O 
HEK293 O 
cells O 
in O 
a O 
concentration- O 
and O 
time O 
- O 
dependent O 
manner O 
, O 
as O 
determined O 
by O 
Urea B-TRIVIAL 
PAGE O 
DNA O 
fragmentation O 
analysis O 
. O 
In O 
conclusion O 
, O 
methomyl B-TRIVIAL 
is O 
a O 
strongly O 
genotoxic O 
agent O 
that O 
induces O 
cell O 
DNA O 
damage O 
and O 
apoptosis O 
in O 
vitro O 
at O 
these O 
sublethal O 
concentrations O 
. O 

of O 
constitutive O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
signaling O 
attenuates O 
androgen B-FAMILY 
independent O 
signaling O 
and O 
growth O 
in O 
( O 
C4-2 O 
) O 
prostate O 
cancer O 
cells O 
. O 

aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
is O 
a O 
member O 
of O 
the O 
basic O 
- O 
helix O 
- O 
loop O 
- O 
helix O 
family O 
of O 
transcription O 
factors O 
. O 
AhR O 
mediates O 
the O 
biochemical O 
and O 
toxic O 
effects O 
of O 
a O 
number O 
of O 
polyaromatic B-FAMILY 
hydrocarbons I-FAMILY 
such O 
as O 
2,3,7,8,-tetrachloro-dibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
. O 
AhR O 
is O 
widely O 
known O 
for O 
regulating O 
the O 
transcription O 
of O 
drug O 
metabolizing O 
enzymes O 
involved O 
in O 
the O 
xenobiotic O 
metabolism O 
of O 
carcinogens O 
and O 
therapeutic O 
agents O 
, O 
such O 
as O 
cytochrome O 
P450-1B1 O 
( O 
CYP1B1 O 
) O 
. O 
Additionally O 
, O 
AhR O 
has O 
also O 
been O 
reported O 
to O 
interact O 
with O 
multiple O 
signaling O 
pathways O 
during O 
prostate O 
development O 
. O 
Here O 
we O 
investigate O 
the O 
effect O 
of O 
sustained O 
AhR O 
signaling O 
on O 
androgen B-FAMILY 
receptor O 
function O 
in O 
prostate O 
cancer O 
cells O 
. O 
Immunoblot O 
analysis O 
shows O 
that O 
AhR O 
expression O 
is O 
increased O 
in O 
androgen B-FAMILY 
independent O 
( O 
C4-2 O 
) O 
prostate O 
cancer O 
cells O 
when O 
compared O 
to O 
androgen B-FAMILY 
sensitive O 
( O 
LNCaP O 
) O 
cells O 
. O 
RT-PCR O 
studies O 
revealed O 
constitutive O 
AhR O 
signaling O 
in O 
C4-2 O 
cells O 
without O 
the O 
ligand O 
induced O 
activation O 
required O 
in O 
LNCaP O 
cells O 
. O 
A O 
reduction O 
of O 
AhR O 
activity O 
by O 
short O 
RNA O 
mediated O 
silencing O 
in O 
C4-2 O 
cells O 
reduced O 
expression O 
of O 
both O 
AhR O 
and O 
androgen B-FAMILY 
responsive O 
genes O 
. O 
The O 
decrease O 
in O 
androgen B-FAMILY 
responsive O 
genes O 
correlates O 
to O 
a O 
decrease O 
in O 
phosphorylated O 
androgen B-FAMILY 
receptor O 
and O 
androgen B-FAMILY 
receptor O 
expression O 
in O 
the O 
nucleus O 
. O 
Furthermore O 
, O 
the O 
forced O 
decrease O 
in O 
AhR O 
expression O 
resulted O 
in O 
a O 
50% O 
decline O 
in O 
the O 
growth O 
rate O 
of O 
C4-2 O 
cells O 
. O 
These O 
data O 
indicates O 
that O 
AhR O 
is O 
required O 
to O 
maintain O 
hormone O 
independent O 
signaling O 
and O 
growth O 
by O 
the O 
androgen B-FAMILY 
receptor O 
in O 
C4-2 O 
cells O 
. O 
Collectively O 
, O 
these O 
data O 
provide O 
evidence O 
of O 
a O 
direct O 
role O 
for O 
AhR O 
in O 
androgen B-FAMILY 
independent O 
signaling O 
and O 
provides O 
insight O 
into O 
the O 
molecular O 
mechanisms O 
responsible O 
for O 
sustained O 
androgen B-FAMILY 
receptor O 
signaling O 
in O 
hormone O 
refractory O 
prostate O 
cancer O 
. O 

properties O 
of O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
in O 
peripheral O 
blood O 
mononuclear O 
cells O 
from O 
healthy O 
subjects O 
and O 
allergic O 
patients O 
. O 

the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
immunomodulatory O 
activity O 
of O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNTs O 
) O 
in O 
peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMCs O 
) O 
from O 
healthy O 
donors O 
and O 
mite O 
- O 
allergic O 
subjects O 
. O 
Freshly O 
prepared O 
PBMCs O 
, O 
stimulated O 
or O 
not O 
with O 
Toll O 
- O 
like O 
receptor O 
(TLR)1-9 O 
agonists O 
, O 
a O 
T O 
cell O 
mitogen O 
( O 
phytohemagglutinin O 
A O 
) O 
or O 
mite O 
allergen O 
extract O 
were O 
cultured O 
in O 
the O 
presence O 
or O 
absence O 
of O 
MWCNTs O 
. O 
Secretion O 
of O 
TNF-α O 
, O 
IL-2 O 
, O 
IL-5 O 
, O 
IL-6 O 
, O 
IL-12 O 
/ O 
23p40 O 
or O 
IFN-γ O 
was O 
quantified O 
in O 
the O 
culture O 
supernatants O 
by O 
ELISA O 
. O 
Basal O 
secretion O 
of O 
all O 
the O 
cytokines O 
was O 
not O 
altered O 
by O 
MWCNTs O 
in O 
PBMCs O 
from O 
both O 
healthy O 
donors O 
and O 
allergic O 
subjects O 
. O 
In O 
PBMCs O 
from O 
healthy O 
donors O 
, O 
TNF-α O 
, O 
IL-6 O 
and O 
IL-12 O 
/ O 
23p40 O 
secretion O 
in O 
response O 
to O 
the O 
TLR4 O 
agonist O 
, O 
lipopolysaccharide O 
was O 
however O 
increased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
by O 
MWCNTs O 
. O 
Significant O 
increases O 
in O 
the O 
release O 
of O 
these O 
cytokines O 
were O 
also O 
observed O 
in O 
PBMCs O 
stimulated O 
with O 
a O 
TLR2 O 
or O 
TLR3 O 
agonist O 
. O 
MWCNTs O 
also O 
increased O 
the O 
release O 
of O 
IL-2 O 
and O 
IFN-γ O 
by O 
PBMCs O 
stimulated O 
with O 
a O 
T O 
cell O 
mitogen O 
. O 
In O 
contrast O 
, O 
MWCNTs O 
inhibited O 
allergen O 
- O 
induced O 
IL-5 O 
secretion O 
by O 
PBMCs O 
from O 
mite O 
- O 
allergic O 
subjects O 
. O 
As O 
well O 
, O 
MWCNTs O 
altered O 
the O 
capacity O 
of O 
PBMC O 
- O 
derived O 
monocytes O 
to O 
differentiate O 
into O 
functional O 
dendritic O 
cells O 
. O 
All O 
together O 
, O 
our O 
data O 
suggest O 
that O 
according O 
to O 
its O 
immune O 
cell O 
target O 
, O 
MWCNTs O 
may O 
either O 
promote O 
or O 
suppress O 
immune O 
responses O 
in O 
humans O 
. O 
Further O 
investigations O 
are O 
necessary O 
to O 
fully O 
understand O 
the O 
complexity O 
behind O 
interactions O 
of O 
engineered O 
nanoparticles O 
with O 
the O 
immune O 
system O 
. O 

a O 
frontier O 
organ O 
, O 
skin O 
is O 
exposed O 
to O 
different O 
environmental O 
and O 
/ O 
or O 
occupational O 
chemicals O 
which O 
cause O 
cutaneous O 
cancers O 
in O 
experimental O 
animals O 
. O 
In O 
mice O 
, O 
7,12-dimethylbenz[a]anthrancene B-SYSTEMATIC 
( O 
DMBA B-ABBREVIATION 
) O 
and O 
the O 
phorbol B-FAMILY 
ester I-FAMILY 
12-O-tetradecanoylphorbol-13-acetate B-SYSTEMATIC 
( O 
TPA B-ABBREVIATION 
) O 
are O 
frequently O 
used O 
as O 
skin O 
model O 
tumor O 
initiator O 
and O 
promoter O 
, O 
respectively O 
. O 
The O 
sequential O 
administration O 
of O 
DMBA B-ABBREVIATION 
and O 
TPA B-ABBREVIATION 
leads O 
to O 
the O 
appearance O 
of O 
a O 
large O 
number O 
of O 
benign O 
papillomas O 
, O 
of O 
which O 
some O 
convert O 
later O 
into O 
invasive O 
squamous O 
cell O 
carcinomas O 
( O 
SCC O 
) O 
. O 
At O 
the O 
molecular O 
level O 
, O 
initiation O 
of O 
carcinogenesis O 
in O 
mouse O 
skin O 
consists O 
in O 
the O 
mutational O 
activation O 
of O 
the O 
Ha-ras O 
oncoprotein O 
. O 
HA-RAS O 
mutations O 
are O 
rare O 
in O 
human O 
SCC O 
, O 
but O 
HA-RAS-mutated O 
tumors O 
appear O 
in O 
melanoma O 
patients O 
treated O 
with O 
B-raf O 
inhibitors O 
, O 
indicating O 
that O 
initiated O 
, O 
HA-RAS-mutated O 
stem O 
cells O 
also O 
reside O 
in O 
human O 
skin O 
. O 
Similarly O 
, O 
UV-induced O 
human O 
SCC O 
show O 
footprint O 
mutations O 
in O 
the O 
tumor O 
suppressor O 
gene O 
TP53 O 
which O 
are O 
also O 
observed O 
in O 
UV-induced O 
mouse O 
SCC O 
. O 
Strong O 
species O 
differences O 
exist O 
with O 
respect O 
to O 
phorbol B-FAMILY 
ester I-FAMILY 
-mediated O 
tumor O 
promotion O 
. O 
While O 
certain O 
mouse O 
strains O 
are O 
very O 
susceptible O 
, O 
other O 
rodent O 
species O 
are O 
much O 
less O 
sensitive O 
. O 
Likewise O 
, O 
humans O 
appear O 
to O 
be O 
much O 
more O 
resistant O 
to O 
phorbol B-FAMILY 
ester I-FAMILY 
-mediated O 
skin O 
toxicity O 
. O 
Papilloma O 
formation O 
as O 
a O 
result O 
of O 
a O 
chemical O 
insult O 
is O 
uncommon O 
in O 
men O 
, O 
questioning O 
the O 
relevance O 
of O 
this O 
preneoplastic O 
lesion O 
for O 
humans O 
. O 
However O 
, O 
skin O 
tumorigenesis O 
in O 
the O 
experimental O 
situation O 
and O 
in O 
humans O 
appears O 
to O 
follow O 
common O 
molecular O 
mechanisms O 
, O 
even O 
though O 
there O 
are O 
species O 
differences O 
in O 
the O 
morphological O 
correlates O 
to O 
the O 
preneoplastic O 
state O 
. O 
Therefore O 
, O 
we O 
recommend O 
not O 
simply O 
labeling O 
them O 
as O 
irrelevant O 
for O 
human O 
risk O 
assessment O 
. O 

- O 
healing O 
plants O 
from O 
Traditional O 
Chinese O 
Medicine O 
and O 
described O 
for O 
wound O 
healing O 
in O 
the O 
Pharmacopoeia O 
of O 
People's O 
Republic O 
of O 
China O 
( O 
2005 O 
ed O 
. O 
) O 
were O 
investigated O 
by O 
in O 
vitro O 
bioassay O 
on O 
human O 
skin O 
cells O 
. O 
Therefore O 
water O 
and O 
EtOH B-FORMULA 
-water O 
extracts O 
( O 
6 O 
: O 
4 O 
, O 
v O 
/ O 
v O 
) O 
from O 
12 O 
plants O 
were O 
tested O 
on O 
human O 
primary O 
dermal O 
fibroblasts O 
( O 
pNHDF O 
) O 
and O 
human O 
HaCaT O 
keratinocyte O 
cell O 
line O 
by O 
quantification O 
of O 
cell O 
viability O 
( O 
MTT B-ABBREVIATION 
assay O 
) O 
and O 
cellular O 
proliferation O 
( O 
BrdU O 
incorporation O 
ELISA O 
) O 
. O 
No O 
functional O 
activity O 
was O 
found O 
for O 
extracts O 
from O 
Achyranthis O 
bidentatae O 
rhizoma O 
, O 
Cimicifugae O 
rhizoma O 
, O 
Corydalis O 
rhizoma O 
, O 
Gardeniae O 
fructus O 
, O 
Houttuyniae O 
herba O 
, O 
Lonicerae O 
japonicae O 
caulis O 
, O 
Paeoniae O 
rubrae O 
radix O 
and O 
Rehmanniae O 
radix O 
. O 
Extracts O 
from O 
Notoginseng O 
radix O 
et O 
rhizoma O 
, O 
Angelicae O 
sinensis O 
radix O 
and O 
Lonicerae O 
japonicae O 
flos O 
showed O 
moderate O 
activity O 
, O 
while O 
extracts O 
from O 
Moutan O 
cortex O 
( O 
the O 
root O 
bark O 
of O 
Paeonia O 
suffruticosa O 
Andr O 
. O 
, O 
Ranunculaceae O 
) O 
increased O 
cell O 
viability O 
of O 
HaCaT O 
keratinocytes O 
and O 
pNHDF O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
significantly O 
. O 
Bioassay O 
- O 
guided O 
fractionation O 
yielded O 
paeonol B-TRIVIAL 
1 O 
, O 
the O 
flavan-3-ols B-FAMILY 
catechin B-TRIVIAL 
2 O 
and O 
epicatechin-3-O-gallate B-SYSTEMATIC 
3 O 
, O 
the O 
dimeric O 
proanthocyanidin B-FAMILY 
epicatechin-(4β→8)-catechin B-SYSTEMATIC 
4 O 
, O 
a O 
mixture O 
of O 
trigalloyl-glucoses B-FAMILY 
5 O 
and O 
1,2,3,4,6-penta-O-galloyl-β-d-glucose B-SYSTEMATIC 
( O 
PGG B-ABBREVIATION 
) O 
6 O 
. O 
The O 
proanthocyanidin B-FAMILY 
-containing O 
fractions O 
as O 
well O 
as O 
PGG B-ABBREVIATION 
-containing O 
fractions O 
contributed O 
substantially O 
to O 
the O 
stimulating O 
effects O 
. O 
Especially O 
PGG B-ABBREVIATION 
-containing O 
fractions O 
enhanced O 
cell O 
viability O 
and O 
cellular O 
proliferation O 
of O 
HaCaT O 
keratinocytes O 
at O 
concentration O 
of O 
100nM O 
. O 
From O 
these O 
data O 
we O 
conclude O 
that O 
indication O 
claims O 
for O 
TCM O 
herbal O 
materials O 
must O 
be O 
carefully O 
investigated O 
in O 
order O 
to O 
establish O 
evidence O 
- O 
driven O 
use O 
of O 
such O 
plants O 
. O 
In O 
case O 
of O 
Moutan O 
cortex O 
skin O 
cell O 
stimulating O 
effects O 
have O 
clearly O 
been O 
proven O 
. O 
These O 
effects O 
can O 
be O 
related O 
to O 
the O 
polyphenol B-FAMILY 
fractions O 
of O 
condensed O 
and O 
hydrolysable O 
tannins O 
. O 

Mate O 
tea O 
( O 
Mate O 
) O 
, O 
an O 
infusion O 
made O 
from O 
the O 
leaves O 
of O 
the O 
tree O 
Ilex O 
paraguariensis O 
, O 
is O 
a O 
widely O 
consumed O 
beverage O 
in O 
South O 
America O 
. O 
This O 
study O 
was O 
performed O 
to O 
investigate O 
the O 
effect O 
of O 
Mate O 
tea O 
on O 
vascular O 
endothelial O 
dysfunction O 
and O 
liver O 
lipoprotein O 
receptor O 
gene O 
expression O 
in O 
hyperlipidemic O 
rats O 
, O 
with O 
the O 
aim O 
of O 
gaining O 
insight O 
into O 
its O 
known O 
lipid O 
- O 
lowering O 
protective O 
mechanisms O 
. O 
Sixty O 
male O 
Sprague-Dawley O 
rats O 
were O 
randomly O 
divided O 
into O 
five O 
groups O 
: O 
a O 
normal O 
control O 
group O 
( O 
NC O 
) O 
, O 
a O 
high O 
- O 
fat O 
diet O 
group O 
( O 
HC O 
) O 
, O 
and O 
three O 
Mate O 
tea O 
- O 
treated O 
groups O 
. O 
In O 
the O 
NC O 
group O 
, O 
rats O 
were O 
fed O 
with O 
standard O 
diet O 
while O 
in O 
the O 
other O 
groups O 
the O 
rats O 
were O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
for O 
8weeks O 
. O 
In O 
the O 
Mate O 
tea O 
- O 
treated O 
groups O 
, O 
the O 
rats O 
were O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
supplemented O 
with O 
low O 
, O 
moderate O 
or O 
high O 
concentrations O 
of O 
aqueous O 
Mate O 
tea O 
extract O 
for O 
the O 
final O 
4weeks O 
. O 
Compared O 
to O 
the O 
HC O 
group O 
, O 
aqueous O 
Mate O 
tea O 
extract O 
significantly O 
reduced O 
endothelin O 
( O 
ET O 
) O 
and O 
thromboxane B-TRIVIAL 
B(2) I-TRIVIAL 
( O 
TXB(2) B-ABBREVIATION 
) O 
levels O 
and O 
increased O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
6-keto B-SYSTEMATIC 
prostaglandin I-SYSTEMATIC 
F(1α) I-SYSTEMATIC 
( O 
6-keto-PGF(1α) B-SYSTEMATIC 
) O 
levels O 
in O 
the O 
blood O 
, O 
reduced O 
the O 
pathological O 
damage O 
of O 
vascular O 
endothelial O 
cells O 
, O 
decreased O 
intercellular O 
adhesion O 
molecule-1 O 
( O 
ICAM-1 O 
) O 
protein O 
expression O 
in O 
the O 
thoracic O 
aorta O 
, O 
and O 
upregulated O 
mRNA O 
expression O 
of O 
hepatic O 
low O 
density O 
lipoprotein O 
receptor O 
( O 
LDLR O 
) O 
and O 
scavenger O 
receptor O 
B1 O 
( O 
SR-B1 O 
) O 
. O 
These O 
findings O 
indicate O 
that O 
Mate O 
tea O 
administration O 
might O 
have O 
a O 
regulatory O 
effect O 
on O 
blood O 
fat O 
and O 
endothelial O 
function O 
in O 
hyperlipidemia O 
rats O 
. O 
The O 
mechanism O 
may O 
involve O 
protecting O 
vascular O 
endothelial O 
cell O 
function O 
and O 
upregulating O 
the O 
expression O 
of O 
LDLR O 
and O 
SR-B1 O 
genes O 
, O 
thereby O 
inhibiting O 
the O 
occurrence O 
of O 
atherosclerosis O 
. O 

saponins I-FAMILY 
from O 
Clematis O 
tangutica O 
and O 
their O 
cardioprotective O 
activities O 
. O 

investigation O 
of O 
the O 
whole O 
plants O 
of O 
Clematis O 
tangutica O 
led O 
to O 
the O 
isolation O 
of O 
three O 
new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
( O 
1-3 O 
) O 
, O 
together O 
with O 
four O 
known O 
saponins B-FAMILY 
( O 
4-7 O 
) O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
extensive O 
spectral O 
analysis O 
and O 
chemical O 
evidences O 
. O 
Compounds O 
1-7 O 
were O 
evaluated O 
for O 
their O 
cardioprotective O 
activities O 
in O 
cardiomyocytes O 
anoxia O 
/ O 
reoxygenation O 
( O 
A O 
/ O 
R O 
) O 
model O 
. O 
The O 
results O 
showed O 
that O 
those O 
saponins B-FAMILY 
exhibited O 
cardioprotective O 
effects O 
by O 
decreasing O 
the O 
levels O 
of O 
creatine B-TRIVIAL 
kinase-MB O 
( O 
CK-MB O 
) O 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
. O 

is O 
a O 
rare O 
but O 
potentially O 
lethal O 
chromaffin O 
cell O 
tumor O 
with O 
currently O 
no O 
effective O 
treatment O 
. O 
Peptide O 
hormone O 
receptors O 
are O 
frequently O 
overexpressed O 
on O 
endocrine O 
tumor O 
cells O 
and O 
can O 
be O 
specifically O 
targeted O 
by O 
various O 
anti-tumor O 
peptide O 
analogs O 
. O 
The O 
present O 
study O 
carried O 
out O 
on O 
mouse O 
pheochromocytoma O 
cells O 
( O 
MPCs O 
) O 
and O 
a O 
more O 
aggressive O 
mouse O 
tumor O 
tissue O 
- O 
derived O 
( O 
MTT O 
) O 
cell O 
line O 
revealed O 
that O 
these O 
cells O 
are O 
characterized O 
by O 
pronounced O 
expression O 
of O 
the O 
somatostatin B-TRIVIAL 
receptor O 
2 O 
( O 
sst2 O 
) O 
, O 
growth O 
hormone O 
- O 
releasing O 
hormone O 
( O 
GHRH O 
) O 
receptor O 
and O 
the O 
luteinizing O 
hormone O 
- O 
releasing O 
hormone O 
( O 
LHRH O 
) O 
receptor O 
. O 
We O 
further O 
demonstrated O 
significant O 
anti-tumor O 
effects O 
mediated O 
by O 
cytotoxic O 
somatostatin B-TRIVIAL 
analogs O 
, O 
AN-162 O 
and O 
AN-238 O 
, O 
by O 
LHRH O 
antagonist O 
, O 
Cetrorelix B-TRIVIAL 
, O 
by O 
the O 
cytotoxic O 
LHRH O 
analog O 
, O 
AN-152 O 
, O 
and O 
by O 
recently O 
developed O 
GHRH O 
antagonist O 
, O 
MIA-602 O 
, O 
on O 
MPC O 
and O 
for O 
AN-152 O 
and O 
MIA-602 O 
on O 
MTT O 
cells O 
. O 
Studies O 
of O 
novel O 
anti-tumor O 
compounds O 
on O 
these O 
mouse O 
cell O 
lines O 
serve O 
as O 
an O 
important O 
basis O 
for O 
mouse O 
models O 
of O 
metastatic O 
pheochromocytoma O 
, O 
which O 
we O 
are O 
currently O 
establishing O 
. O 

effect O 
of O 
novel O 
promoter O 
variants O 
in O 
MATE1 O 
and O 
MATE2 O 
on O 
the O 
pharmacokinetics O 
and O 
pharmacodynamics O 
of O 
metformin B-TRIVIAL 
. O 

variation O 
in O 
response O 
to O 
metformin B-TRIVIAL 
, O 
first O 
- O 
line O 
therapy O 
for O 
type O 
2 O 
diabetes O 
, O 
is O 
substantial O 
. O 
Given O 
that O 
transporters O 
are O 
determinants O 
of O 
metformin B-TRIVIAL 
pharmacokinetics O 
, O 
we O 
examined O 
the O 
effects O 
of O 
promoter O 
variants O 
in O 
both O 
multidrug O 
and O 
toxin O 
extrusion O 
protein O 
1 O 
( O 
MATE1 O 
) O 
( O 
g.-66T O 
→ O 
C O 
, O 
rs2252281 O 
) O 
and O 
MATE2 O 
( O 
g.-130G O 
→ O 
A O 
, O 
rs12943590 O 
) O 
on O 
variation O 
in O 
metformin B-TRIVIAL 
disposition O 
and O 
response O 
. O 
The O 
pharmacokinetics O 
and O 
glucose B-TRIVIAL 
-lowering O 
effects O 
of O 
metformin B-TRIVIAL 
were O 
assessed O 
in O 
healthy O 
volunteers O 
( O 
n O 
= O 
57 O 
) O 
receiving O 
metformin B-TRIVIAL 
. O 
The O 
renal O 
and O 
secretory O 
clearances O 
of O 
metformin B-TRIVIAL 
were O 
higher O 
( O 
22% O 
and O 
26% O 
, O 
respectively O 
) O 
in O 
carriers O 
of O 
variant O 
MATE2 O 
who O 
were O 
also O 
MATE1 O 
reference O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Both O 
MATE O 
genotypes O 
were O 
associated O 
with O 
altered O 
post- O 
metformin B-TRIVIAL 
glucose B-TRIVIAL 
tolerance O 
, O 
with O 
variant O 
carriers O 
of O 
MATE1 O 
and O 
MATE2 O 
having O 
an O 
enhanced O 
( O 
P O 
< O 
0.01 O 
) O 
and O 
reduced O 
( O 
P O 
< O 
0.05 O 
) O 
response O 
, O 
respectively O 
. O 
Consistent O 
with O 
these O 
results O 
, O 
patients O 
with O 
diabetes O 
( O 
n O 
= O 
145 O 
) O 
carrying O 
the O 
MATE1 O 
variant O 
showed O 
enhanced O 
metformin B-TRIVIAL 
response O 
. O 
These O 
findings O 
suggest O 
that O 
promoter O 
variants O 
of O 
MATE1 O 
and O 
MATE2 O 
are O 
important O 
determinants O 
of O 
metformin B-TRIVIAL 
disposition O 
and O 
response O 
in O 
healthy O 
volunteers O 
and O 
diabetic O 
patients O 
. O 

of O 
providing O 
a O 
detailed O 
thermodynamic O 
picture O 
of O 
noncovalent O 
association O 
reactions O 
, O 
isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
has O 
become O 
a O 
popular O 
method O 
for O 
studying O 
protein O 
- O 
ligand O 
interactions O 
. O 
We O 
routinely O 
employ O 
the O 
technique O 
to O 
study O 
divalent O 
ion O 
- O 
binding O 
by O 
two O 
- O 
site O 
EF-hand O 
proteins O 
from O 
the O 
parvalbumin- O 
and O 
polcalcin O 
lineages O 
. O 
The O 
combination O 
of O 
high O 
Ca(2+) B-FORMULA 
affinity O 
and O 
relatively O 
low O 
Mg(2+) B-FORMULA 
affinity O 
, O 
and O 
the O 
attendant O 
complication O 
of O 
parameter O 
correlation O 
, O 
conspire O 
to O 
make O 
the O 
simultaneous O 
extraction O 
of O 
binding O 
constants O 
and O 
-enthalpies O 
for O 
both O 
ions O 
challenging O 
. O 
Although O 
global O 
analysis O 
of O 
multiple O 
ITC O 
experiments O 
can O 
overcome O 
these O 
hurdles O 
, O 
our O 
current O 
experimental O 
protocol O 
includes O 
upwards O 
of O 
10 O 
titrations O 
- O 
requiring O 
a O 
substantial O 
investment O 
in O 
labor O 
, O 
machine O 
time O 
, O 
and O 
material O 
. O 
This O 
paper O 
explores O 
the O 
potential O 
for O 
using O 
a O 
smaller O 
suite O 
of O 
experiments O 
that O 
includes O 
simultaneous O 
titrations O 
with O 
Ca(2+) B-FORMULA 
and O 
Mg(2+) B-FORMULA 
at O 
different O 
ratios O 
of O 
the O 
two O 
ions O 
. O 
The O 
results O 
obtained O 
for O 
four O 
proteins O 
, O 
differing O 
substantially O 
in O 
their O 
divalent O 
ion O 
- O 
binding O 
properties O 
, O 
suggest O 
that O 
the O 
approach O 
has O 
merit O 
. O 
The O 
Ca(2+) B-FORMULA 
- O 
and O 
Mg(2+) B-FORMULA 
-binding O 
constants O 
afforded O 
by O 
the O 
streamlined O 
analysis O 
are O 
in O 
reasonable O 
agreement O 
with O 
those O 
obtained O 
from O 
the O 
standard O 
analysis O 
protocol O 
. O 
Likewise O 
, O 
the O 
abbreviated O 
analysis O 
provides O 
comparable O 
values O 
for O 
the O 
Ca(2+) B-FORMULA 
-binding O 
enthalpies O 
. O 
However O 
, O 
the O 
streamlined O 
analysis O 
can O 
yield O 
divergent O 
values O 
for O 
the O 
Mg(2+) B-FORMULA 
-binding O 
enthalpies O 
- O 
particularly O 
those O 
for O 
lower O 
affinity O 
sites O 
. O 
This O 
shortcoming O 
can O 
be O 
remedied O 
, O 
in O 
large O 
measure O 
, O 
by O 
including O 
data O 
from O 
a O 
direct O 
Ca(2+) B-FORMULA 
titration O 
in O 
the O 
presence O 
of O 
a O 
high O 
, O 
fixed O 
Mg(2+) B-FORMULA 
concentration O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
clarify O 
the O 
association O 
between O 
C- O 
peptide O 
immunoreactivity O 
( O 
CPR O 
) O 
, O 
a O 
marker O 
of O 
beta O 
cell O 
function O 
, O 
and O 
future O 
glycemic O 
control O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 
We O 
conducted O 
a O 
retrospective O 
analysis O 
of O 
513 O 
consecutive O 
patients O 
with O 
type O 
2 O 
diabetes O 
who O 
were O 
admitted O 
to O 
our O 
hospital O 
between O 
2000 O 
and O 
2007 O 
and O 
followed O 
up O 
for O 
2 O 
years O 
. O 
Serum O 
and O 
urinary O 
CPR O 
levels O 
were O 
measured O 
during O 
admission O 
, O 
and O 
CPR O 
index O 
was O 
calculated O 
as O 
the O 
ratio O 
of O 
CPR O 
to O 
plasma O 
glucose B-TRIVIAL 
. O 
The O 
associations O 
between O 
these O 
markers O 
at O 
baseline O 
and O 
glycemic O 
control O 
after O 
2 O 
years O 
were O 
assessed O 
by O 
means O 
of O 
logistic O 
regression O 
models O 
. O 
After O 
2 O 
years O 
, O 
167 O 
patients O 
( O 
32.6% O 
) O 
showed O 
good O 
glycemic O 
control O 
( O 
HbA1c O 
< O 
6.9% O 
) O 
. O 
Baseline O 
serum O 
and O 
urinary O 
CPR O 
indices O 
were O 
significantly O 
associated O 
with O 
good O 
glycemic O 
control O 
after O 
2 O 
years O 
, O 
and O 
the O 
postprandial O 
CPR O 
to O 
plasma O 
glucose B-TRIVIAL 
ratio O 
( O 
postprandial O 
CPR O 
index O 
) O 
showed O 
the O 
strongest O 
association O 
( O 
odds O 
ratio O 
( O 
OR O 
) O 
1.29 O 
, O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
1.12-1.50 O 
, O 
P O 
= O 
0.001 O 
) O 
among O 
CPR O 
indices O 
. O 
Multivariate O 
analyses O 
showed O 
consistent O 
results O 
( O 
OR O 
1.23 O 
, O 
95%CI O 
1.03-1.48 O 
, O 
P O 
= O 
0.021 O 
) O 
. O 
In O 
conclusion O 
, O 
preserved O 
beta O 
cell O 
function O 
at O 
baseline O 
was O 
associated O 
with O 
better O 
glycemic O 
control O 
thereafter O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 

we O 
report O 
the O 
construction O 
and O 
characterization O 
of O 
a O 
recoverable O 
, O 
thermoresponsive O 
polymer O 
- O 
endoglucanase O 
bioconjugate O 
that O 
matches O 
the O 
activity O 
of O 
unmodified O 
enzymes O 
on O 
insoluble O 
cellulose O 
substrates O 
. O 
Two O 
copolymers O 
exhibiting O 
a O 
thermoresponsive O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
were O 
created O 
through O 
the O 
copolymerization O 
of O 
an O 
aminooxy B-SYSTEMATIC 
-bearing O 
methacrylamide B-SYSTEMATIC 
with O 
N-isopropylacrylamide B-SYSTEMATIC 
( O 
NIPAm B-ABBREVIATION 
) O 
or O 
N-isopropylmethacrylamide B-SYSTEMATIC 
( O 
NIPMa B-ABBREVIATION 
) O 
. O 
The O 
aminooxy B-SYSTEMATIC 
group O 
provided O 
a O 
handle O 
through O 
which O 
the O 
LCST O 
was O 
adjusted O 
through O 
small O 
- O 
molecule O 
quenching O 
. O 
This O 
allowed O 
materials O 
with O 
LCSTs O 
ranging O 
from O 
20.9 O 
to O 
60.5 O 
°C O 
to O 
be O 
readily O 
obtained O 
after O 
polymerization O 
. O 
The O 
thermostable O 
endoglucanase O 
EGPh O 
from O 
the O 
hypothermophilic O 
Pyrococcus O 
horikoshii O 
was O 
transaminated O 
with O 
pyridoxal-5'-phosphate B-SYSTEMATIC 
to O 
produce O 
a O 
ketone B-SYSTEMATIC 
-bearing O 
protein O 
, O 
which O 
was O 
then O 
site O 
- O 
selectively O 
modified O 
through O 
oxime B-SYSTEMATIC 
linkage O 
with O 
benzylalkoxyamine B-FAMILY 
or O 
5 O 
kDa- O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
- O 
alkoxyamine B-FAMILY 
. O 
These O 
modified O 
proteins O 
showed O 
activity O 
comparable O 
to O 
the O 
controls O 
when O 
assayed O 
on O 
an O 
insoluble O 
cellulosic O 
substrate O 
. O 
Two O 
polymer O 
bioconjugates O 
were O 
then O 
constructed O 
using O 
transaminated O 
EGPh O 
and O 
the O 
aminooxy B-SYSTEMATIC 
-bearing O 
copolymers O 
. O 
After O 
12 O 
h O 
, O 
both O 
bioconjugates O 
produced O 
an O 
equivalent O 
amount O 
of O 
free O 
reducing O 
sugars B-FAMILY 
as O 
the O 
unmodified O 
control O 
using O 
insoluble O 
cellulose O 
as O 
a O 
substrate O 
. O 
The O 
recycling O 
ability O 
of O 
the O 
NIPAm B-ABBREVIATION 
copolymer-EGPh O 
conjugate O 
was O 
determined O 
through O 
three O 
rounds O 
of O 
activity O 
, O 
maintaining O 
over O 
60% O 
activity O 
after O 
two O 
cycles O 
of O 
reuse O 
and O 
affording O 
significantly O 
more O 
soluble O 
carbohydrates B-FAMILY 
than O 
unmodified O 
enzyme O 
alone O 
. O 
When O 
assayed O 
on O 
acid O 
- O 
pretreated O 
Miscanthus O 
, O 
this O 
bioconjugate O 
increased O 
the O 
amount O 
of O 
reducing O 
sugars B-FAMILY 
by O 
2.8-fold O 
over O 
three O 
rounds O 
of O 
activity O 
. O 
The O 
synthetic O 
strategy O 
of O 
this O 
bioconjugate O 
allows O 
the O 
LCST O 
of O 
the O 
material O 
to O 
be O 
changed O 
readily O 
from O 
a O 
common O 
stock O 
of O 
copolymer O 
and O 
the O 
method O 
of O 
attachment O 
is O 
applicable O 
to O 
a O 
variety O 
of O 
proteins O 
, O 
enabling O 
the O 
same O 
approach O 
to O 
be O 
amenable O 
to O 
thermophile O 
- O 
derived O 
cellulases O 
or O 
to O 
the O 
separation O 
of O 
multiple O 
species O 
using O 
polymers O 
with O 
different O 
recovery O 
temperatures O 
. O 

and O 
raisanberine B-TRIVIAL 
alleviate O 
intermittent O 
hypoxia O 
induced O 
abnormal O 
StAR O 
and O 
3β-HSD O 
and O 
low O 
testosterone B-TRIVIAL 
by O 
suppressing O 
endoplasmic O 
reticulum O 
stress O 
and O 
activated O 
p66Shc O 
in O 
rat O 
testes O 
. O 

hypothesized O 
that O 
hypoxia O 
induced O 
testicular O 
damage O 
is O 
mediated O 
by O 
an O 
activated O 
NADPH B-ABBREVIATION 
oxidase O 
( O 
NOX O 
) O 
, O 
therefore O 
, O 
APO B-ABBREVIATION 
( O 
apocynin B-TRIVIAL 
) O 
an O 
inhibitor O 
of O 
NOX O 
and O 
raisanberine B-TRIVIAL 
( O 
RS O 
) O 
, O 
a O 
calcium B-SYSTEMATIC 
influx O 
inhibitor O 
were O 
tested O 
if O 
they O 
could O 
attenuate O 
hypoxic O 
toxicity O 
to O 
the O 
testis O 
. O 
Male O 
Sprague-Dawley O 
rats O 
were O 
exposed O 
to O 
hypoxia O 
( O 
10±0.5% O 
O2 O 
) O 
for O 
17d O 
and O 
intervened O 
with O 
APO B-ABBREVIATION 
and O 
RS O 
in O 
the O 
last O 
6d O 
. O 
Histological O 
changes O 
and O 
expression O 
of O 
pro O 
- O 
inflammation O 
factors O 
were O 
evaluated O 
in O 
vivo O 
. O 
Biomarkers O 
in O 
isolated O 
Leydig O 
cells O 
incubated O 
with O 
H2O2 B-FORMULA 
were O 
also O 
assayed O 
in O 
vitro O 
. O 
Hypoxic O 
rats O 
displayed O 
lower O 
serum O 
testosterone B-TRIVIAL 
and O 
higher O 
LH O 
and O 
FSH O 
. O 
Upregulation O 
of O 
p22 O 
/ O 
p47(phox) O 
, O 
NOX2 O 
, O 
MMP9 O 
, O 
PERK O 
and O 
p66Shc O 
was O 
associated O 
with O 
downregulation O 
of O 
StAR O 
, O 
3β-HSD O 
and O 
Cx43 O 
in O 
the O 
hypoxia O 
testis O 
, O 
revealed O 
by O 
Western O 
blot O 
and O 
immunohistochemical O 
assay O 
, O 
respectively O 
. O 
APO B-ABBREVIATION 
and O 
RS O 
at O 
least O 
partially O 
normalize O 
hypoxia O 
caused O 
male O 
hypogonadism O 
by O 
suppressing O 
ER O 
stress O 
, O 
and O 
p66Shc O 
in O 
testes O 
. O 

acid I-TRIVIAL 
as O 
an O 
antagonist O 
of O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
in O 
the O 
brain O 
: O 
facts O 
and O 
challenges O 
. O 

acid I-TRIVIAL 
( O 
KYNA B-ABBREVIATION 
) O 
, O 
a O 
major O 
tryptophan B-TRIVIAL 
metabolite O 
, O 
is O 
a O 
glutamate B-TRIVIAL 
receptor O 
antagonist O 
, O 
which O 
is O 
also O 
reported O 
to O 
inhibit O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
α7nAChRs O 
) O 
. O 
Due O 
to O 
variations O 
in O 
experimental O 
approaches O 
, O 
controversy O 
has O 
arisen O 
regarding O 
the O 
ability O 
of O 
KYNA B-ABBREVIATION 
to O 
directly O 
influence O 
α7nAChR O 
function O 
. O 
Here O 
we O 
summarize O 
current O 
concepts O 
of O 
KYNA B-ABBREVIATION 
neurobiology O 
and O 
review O 
evidence O 
pertaining O 
to O 
the O 
proposed O 
role O 
of O 
KYNA B-ABBREVIATION 
as O 
an O 
endogenous O 
modulator O 
of O 
α7nAChRs O 
and O 
synaptic O 
transmission O 
. O 
As O 
dysfunction O 
of O 
α7nAChRs O 
plays O 
a O 
major O 
role O 
in O 
the O 
pathophysiology O 
of O 
central O 
nervous O 
system O 
disorders O 
, O 
elucidation O 
of O 
KYNA B-ABBREVIATION 
' O 
s O 
action O 
on O 
this O 
receptor O 
subtype O 
has O 
significant O 
therapeutic O 
implications O 
. O 

optimizing O 
the O 
resistance O 
profile O 
of O 
an O 
inhibitor O 
can O 
be O 
challenging O 
, O 
it O 
is O 
potentially O 
important O 
for O 
improving O 
the O 
long O 
term O 
effectiveness O 
of O 
antiviral O 
therapy O 
. O 
This O 
work O 
describes O 
our O 
rational O 
approach O 
toward O 
the O 
identification O 
of O 
a O 
macrocyclic O 
acylsulfonamide B-FAMILY 
that O 
is O 
a O 
potent O 
inhibitor O 
of O 
the O 
NS3-NS4A O 
proteases O 
of O 
all O 
hepatitis O 
C O 
virus O 
genotypes O 
and O 
of O 
a O 
panel O 
of O 
genotype O 
1-resistant O 
variants O 
. O 
The O 
enhanced O 
potency O 
of O 
this O 
compound O 
versus O 
variants O 
D168V O 
and O 
R155K O 
facilitated O 
x-ray O 
determination O 
of O 
the O 
inhibitor O 
- O 
variant O 
complexes O 
. O 
In O 
turn O 
, O 
these O 
structural O 
studies O 
revealed O 
a O 
complex O 
molecular O 
basis O 
of O 
resistance O 
and O 
rationalized O 
how O 
such O 
compounds O 
are O 
able O 
to O 
circumvent O 
these O 
mechanisms O 
. O 

suppresses O 
cell O 
survival O 
via O 
Pirh2 O 
- O 
mediated O 
proteasomal O 
degradation O 
of O 
ΔNp63 O 
protein O 
. O 

factor O 
p63 O 
, O 
a O 
member O 
of O 
the O 
p53 O 
family O 
, O 
shares O 
a O 
high O 
degree O 
of O 
sequence O 
similarity O 
with O 
p53 O 
. O 
Because O 
of O 
transcription O 
from O 
two O 
distinct O 
promoters O 
, O 
the O 
p63 O 
gene O 
encodes O 
two O 
isoforms O 
, O 
TAp63 O 
and O 
ΔNp63 O 
. O 
Although O 
TAp63 O 
acts O 
as O 
a O 
tumor O 
suppressor O 
, O 
ΔNp63 O 
functions O 
as O 
an O 
oncogene O 
and O 
is O 
often O 
overexpressed O 
in O 
squamous O 
cell O 
carcinomas O 
. O 
Thus O 
, O 
therapeutic O 
agents O 
targeting O 
ΔNp63 O 
might O 
be O 
used O 
to O 
manage O 
tumors O 
that O 
overexpress O 
ΔNp63 O 
. O 
Here O 
we O 
found O 
that O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
, O 
a O 
frontline O 
agent O 
for O 
acute O 
promyelocytic O 
leukemia O 
, O 
inhibits O 
ΔNp63 O 
but O 
not O 
TAp63 O 
expression O 
in O 
time- O 
and O 
dose O 
- O 
dependent O 
manners O 
. O 
In O 
addition O 
, O 
we O 
found O 
that O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
decreases O 
the O 
stability O 
of O 
ΔNp63 O 
protein O 
via O 
a O 
proteasome O 
- O 
dependent O 
pathway O 
but O 
has O 
little O 
effect O 
on O 
the O 
level O 
of O 
ΔNp63 O 
transcript O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
arsenic B-SYSTEMATIC 
trioxide I-SYSTEMATIC 
activates O 
the O 
Pirh2 O 
promoter O 
and O 
consequently O 
induces O 
Pirh2 O 
expression O 
. O 
Consistent O 
with O 
this O 
, O 
we O 
found O 
that O 
knockdown O 
of O 
Pirh2 O 
inhibits O 
, O 
whereas O 
ectopic O 
expression O 
of O 
Pirh2 O 
enhances O 
, O 
arsenic B-SYSTEMATIC 
-induced O 
degradation O 
of O 
ΔNp63 O 
protein O 
. O 
Importantly O 
, O 
we O 
found O 
that O 
knockdown O 
of O 
ΔNp63 O 
sensitizes O 
, O 
whereas O 
ectopic O 
expression O 
of O 
ΔNp63 O 
inhibits O 
, O 
growth O 
suppression O 
induced O 
by O 
arsenic B-SYSTEMATIC 
. O 
Together O 
, O 
these O 
data O 
suggest O 
that O 
arsenic B-SYSTEMATIC 
degrades O 
ΔNp63 O 
protein O 
at O 
least O 
in O 
part O 
via O 
Pirh2-dependent O 
proteolysis O 
and O 
that O 
inhibition O 
of O 
ΔNp63 O 
expression O 
facilitates O 
tumor O 
cells O 
to O 
arsenic B-SYSTEMATIC 
-induced O 
death O 
. O 

natural O 
and O 
fundamental O 
proclivities O 
of O 
interaction O 
between O 
a O 
pair O 
of O 
peptide O 
units O 
are O 
examined O 
using O 
high O 
- O 
level O 
ab O 
initio O 
calculations O 
. O 
The O 
NH B-FORMULA 
··· O 
O B-FORMULA 
H I-FORMULA 
-bonded O 
structure O 
is O 
found O 
to O 
be O 
the O 
most O 
stable O 
configuration O 
of O 
the O 
N-methylacetamide B-SYSTEMATIC 
( O 
NMA B-ABBREVIATION 
) O 
model O 
dimer O 
, O 
but O 
only O 
slightly O 
more O 
so O 
than O 
a O 
stacked O 
arrangement O 
. O 
The O 
H B-FORMULA 
-bonded O 
geometry O 
is O 
destabilized O 
by O 
only O 
a O 
small O 
amount O 
if O 
the O 
NH B-FORMULA 
group O 
is O 
lifted O 
out O 
of O 
the O 
plane O 
of O 
the O 
proton O 
- O 
accepting O 
amide B-FAMILY 
. O 
This O 
out O 
- O 
of O 
- O 
plane O 
motion O 
is O 
facilitated O 
by O 
a O 
stabilizing O 
charge O 
transfer O 
from O 
the O 
CO B-FORMULA 
π O 
bond O 
to O 
the O 
NH B-FORMULA 
σ* O 
antibonding O 
orbital O 
. O 
The O 
parallel O 
and O 
antiparallel O 
stacked O 
dimers O 
are O 
nearly O 
equal O 
in O 
energy O 
, O 
both O 
only O 
slightly O 
less O 
stable O 
than O 
the O 
NH B-FORMULA 
··· O 
O B-FORMULA 
H I-FORMULA 
-bonded O 
structure O 
. O 
Both O 
are O 
stabilized O 
by O 
a O 
combination O 
of O 
CH B-FORMULA 
··· O 
O B-FORMULA 
H I-FORMULA 
-bonding O 
and O 
a O 
π→π* O 
transfer O 
between O 
the O 
two O 
CO B-FORMULA 
bonds O 
. O 
There O 
are O 
no O 
minima O 
on O 
the O 
surface O 
that O 
are O 
associated O 
with O 
O B-FORMULA 
( O 
lp)→π*( O 
CO B-FORMULA 
) O 
transfers O 
, O 
due O 
in O 
large O 
part O 
to O 
strong O 
electrostatic O 
repulsion O 
between O 
the O 
two O 
O B-FORMULA 
atoms O 
, O 
which O 
resists O 
an O 
approach O 
of O 
a O 
carbonyl B-FAMILY 
O B-FORMULA 
from O 
above O 
the O 
C=O B-FORMULA 
bond O 
of O 
the O 
other O 
amide B-FAMILY 
. O 

Porphyrin B-FAMILY 
Nanoarchitectures O 
at O 
Solid O 
Interfaces O 
. O 

complementary O 
examples O 
of O 
porphyrin B-FAMILY 
nanoarchitectonics O 
are O 
presented O 
. O 
The O 
fabrication O 
of O 
binary O 
molecular O 
monolayers O 
using O 
two O 
different O 
porphyrin B-FAMILY 
molecules O 
, O 
tetrakis(3,5-di-t-butyl-4-hydroxyphenyl)porphyrin B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
tetrakis(4-pyridyl)porphyrin B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
by O 
deposition O 
in O 
ultrahigh O 
vacuum O 
was O 
demonstrated O 
. O 
Two O 
unusual O 
heteromolecular O 
monolayer O 
structures O 
were O 
observed O 
, O 
with O 
one O 
exhibiting O 
good O 
separation O 
of O 
1 O 
molecules O 
within O 
the O 
monolayer O 
. O 
Also O 
, O 
a O 
synthetic O 
nanoarchitectonic O 
approach O 
was O 
used O 
to O 
prepare O 
self O 
- O 
assembled O 
molecular O 
nanowires O 
at O 
a O 
mica O 
substrate O 
. O 
The O 
nanowires O 
could O 
be O 
observed O 
to O 
grow O 
using O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
, O 
and O 
the O 
network O 
structures O 
of O 
the O 
nanowires O 
could O 
be O 
influenced O 
by O 
manipulation O 
using O 
the O 
AFM O 
probe O 
tip O 
. O 

and O 
antioxidant O 
activity O 
of O 
thymol B-TRIVIAL 
and O 
carvacrol B-TRIVIAL 
based O 
Schiff B-FAMILY 
bases I-FAMILY 
. O 

and O 
carvacrol B-TRIVIAL 
are O 
well O 
known O 
antioxidants O 
found O 
in O 
the O 
extract O 
of O 
the O 
plants O 
of O 
thyme O 
species O 
. O 
The O 
Schiff B-FAMILY 
bases I-FAMILY 
of O 
2-iso-propyl-5-methyl-phenol B-SYSTEMATIC 
( O 
thymol B-TRIVIAL 
/ O 
1a O 
) O 
, O 
2-tert-butyl-5-methyl-phenol B-SYSTEMATIC 
( O 
1b O 
) O 
and O 
5-iso-propyl-2-methyl-phenol B-SYSTEMATIC 
( O 
carvacrol B-TRIVIAL 
/ O 
1c O 
) O 
exhibited O 
much O 
better O 
antioxidant O 
activity O 
than O 
thymol B-TRIVIAL 
and O 
carvacrol B-TRIVIAL 
in O 
DPPH B-ABBREVIATION 
assay O 
. O 
Ten O 
compounds O 
( O 
4k O 
, O 
4l O 
, O 
4r O 
, O 
5k O 
, O 
5l O 
, O 
5q O 
, O 
5r O 
, O 
6k O 
, O 
6l O 
and O 
6r O 
) O 
showed O 
better O 
or O 
similar O 
activity O 
as O 
compared O 
to O 
the O 
reference O 
compound O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Twenty O 
- O 
four O 
most O 
active O 
compounds O 
were O 
also O 
screened O 
by O 
ABTS B-ABBREVIATION 
method O 
and O 
showed O 
60-90% O 
inhibition O 
at O 
5 O 
μg O 
/ O 
mL O 
concentration O 
. O 

freshwater O 
pulmonate O 
snail O 
, O 
Lymnaea O 
stagnalis O 
, O 
is O 
the O 
most O 
sensitive O 
freshwater O 
organism O 
tested O 
to O 
date O 
for O 
several O 
metals O 
( O 
Co B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Pb B-FORMULA 
, O 
Ni B-FORMULA 
) O 
based O 
on O 
28 O 
d O 
early O 
life O 
- O 
stage O 
( O 
ELS O 
) O 
tests O 
in O 
which O 
growth O 
was O 
the O 
most O 
sensitive O 
endpoint O 
. O 
The O 
United O 
States O 
Environmental O 
Protection O 
Agency O 
( O 
USEPA O 
) O 
has O 
expressed O 
concern O 
that O 
growth O 
in O 
28 O 
d O 
ELS O 
tests O 
with O 
mollusks O 
may O 
overpredict O 
toxicity O 
because O 
of O 
the O 
potential O 
for O 
recovery O 
in O 
a O 
full O 
life O 
- O 
cycle O 
( O 
LC O 
) O 
test O 
. O 
Consequently O 
, O 
the O 
USEPA O 
only O 
accepts O 
the O 
survival O 
endpoint O 
for O 
these O 
tests O 
in O 
establishing O 
water O 
quality O 
criteria O 
( O 
WQC O 
) O 
. O 
To O 
address O 
this O 
concern O 
, O 
the O 
current O 
study O 
aimed O 
to O 
test O 
the O 
sensitivity O 
of O 
L O 
. O 
stagnalis O 
to O 
Pb O 
in O 
a O 
56 O 
d O 
full O 
LC O 
test O 
evaluating O 
survival O 
, O 
growth O 
, O 
reproductive O 
and O 
embryonic O 
growth O 
endpoints O 
and O 
compare O 
the O 
estimated O 
effect O 
levels O 
to O 
those O 
established O 
using O 
the O 
28 O 
d O 
ELS O 
test O 
design O 
. O 
The O 
most O 
sensitive O 
endpoints O 
in O 
this O 
study O 
were O 
28 O 
d O 
growth O 
and O 
56 O 
d O 
egg O 
mass O 
production O 
, O 
both O 
with O 
a O 
NOEC O 
of O 
< O 
1 O 
μg O 
L(-1) O 
and O 
a O 
LOEC O 
of O 
1 O 
μg O 
L(-1) O 
, O 
showing O 
that O 
the O 
ELS O 
growth O 
endpoint O 
is O 
predictive O 
of O 
the O 
56 O 
d O 
reproduction O 
endpoint O 
. O 
Snails O 
exposed O 
to O 
1 O 
and O 
2.7 O 
μg O 
L(-1) O 
Pb B-FORMULA 
showed O 
full O 
and O 
partial O 
recovery O 
from O 
growth O 
inhibition O 
between O 
28 O 
and O 
56 O 
d O 
. O 
While O 
this O 
recovery O 
supports O 
the O 
USEPA's O 
concern O 
about O 
the O 
28 O 
d O 
growth O 
endpoint O 
; O 
considering O 
the O 
reproductive O 
lifespan O 
of O 
L O 
. O 
stagnalis O 
and O 
the O 
recovery O 
dose O 
- O 
response O 
, O 
we O 
conclude O 
that O 
the O 
28 O 
d O 
growth O 
endpoint O 
will O 
be O 
within O 
a O 
factor O 
of O 
3 O 
of O 
full O 
LC O 
endpoints O 
. O 
This O 
is O 
consistent O 
with O 
the O 
level O 
of O 
precision O 
previously O 
determined O 
for O 
fish O 
ELS O 
tests O 
, O 
which O 
the O 
USEPA O 
accepts O 
for O 
WQC O 
derivation O 
, O 
and O 
suggests O 
that O 
tests O 
using O 
28 O 
d O 
ELS O 
growth O 
endpoint O 
for O 
L O 
. O 
stagnalis O 
may O 
be O 
acceptable O 
for O 
inclusion O 
in O 
WQC O 
derivation O 
. O 

in O 
physiological O 
responses O 
of O 
an O 
Antarctic O 
fish O 
, O 
the O 
emerald O 
rock O 
cod O 
( O 
Trematomus O 
bernacchii O 
) O 
, O 
following O 
exposure O 
to O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
. O 

polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
have O 
the O 
ability O 
to O 
undergo O 
long O 
- O 
range O 
atmospheric O 
transport O 
to O 
remote O 
ecosystems O 
like O 
Antarctica O 
, O 
a O 
recent O 
study O 
found O 
evidence O 
for O 
a O 
local O 
source O 
within O 
the O 
Antarctic O 
. O 
PBDEs O 
from O 
sewage O 
treatment O 
outfalls O 
of O 
McMurdo O 
Station O 
and O 
Scott O 
Base O 
on O 
Ross O 
Island O 
have O 
been O 
attributed O 
to O 
the O 
high O 
concentrations O 
measured O 
in O 
emerald O 
rock O 
cod O 
( O 
Trematomus O 
bernacchii O 
) O 
. O 
The O 
potential O 
impact O 
of O 
PBDEs O 
on O 
Antarctic O 
fish O 
physiology O 
is O 
unknown O 
and O 
therefore O 
, O 
the O 
aim O 
of O 
this O 
study O 
was O 
to O 
obtain O 
a O 
greater O 
understanding O 
of O 
physiological O 
responses O 
of O 
emerald O 
rock O 
cod O 
for O 
assessing O 
changes O 
in O 
ecosystem O 
quality O 
. O 
A O 
PBDE B-ABBREVIATION 
mixture O 
( O 
ΣPBDE O 
8 O 
congeners O 
) O 
was O 
administered O 
fortnightly O 
over O 
42 O 
days O 
and O 
physiological O 
changes O 
were O 
observed O 
throughout O 
this O 
period O 
and O 
for O 
a O 
further O 
14 O 
days O 
thereafter O 
. O 
Changes O 
in O 
liver O 
composition O 
, O 
molecular O 
level O 
changes O 
and O 
enzyme O 
activities O 
of O 
selected O 
detoxification O 
- O 
mediated O 
and O 
antioxidant O 
defence O 
markers O 
were O 
measured O 
. O 
Changes O 
in O 
total O 
lipid O 
, O 
lipid O 
peroxide B-SYSTEMATIC 
and O 
protein O 
carbonyl B-FAMILY 
concentrations O 
in O 
emerald O 
rock O 
cod O 
liver O 
were O 
consistent O 
with O 
increases O 
in O 
nucleus O 
surface O 
area O 
in O 
the O 
PBDE B-ABBREVIATION 
-treated O 
groups O 
, O 
suggesting O 
alterations O 
in O 
cellular O 
function O 
. O 
Changes O 
in O 
the O 
activities O 
of O 
selected O 
antioxidant O 
enzymes O 
indirectly O 
indicated O 
oxidative O 
stress O 
, O 
possibly O 
resulting O 
in O 
the O 
changes O 
in O 
liver O 
composition O 
. O 
Additionally O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
activity O 
reached O 
its O 
peak O 
faster O 
than O 
that O 
of O 
ethoxyresorufin B-SYSTEMATIC 
- O 
O B-FORMULA 
-deethylase O 
( O 
EROD O 
) O 
, O 
suggesting O 
that O 
during O 
the O 
early O 
response O 
to O 
PBDE B-ABBREVIATION 
exposures O 
there O 
could O 
be O 
a O 
greater O 
involvement O 
of O 
GST O 
- O 
mediated O 
detoxification O 
. O 
Thus O 
, O 
for O 
at O 
least O 
the O 
species O 
examined O 
here O 
, O 
protein O 
carbonyl B-FAMILY 
and O 
lipid O 
peroxides O 
were O 
useful O 
and O 
informative O 
biomarkers O 
for O 
cellular O 
level O 
responses O 
following O 
PBDE B-ABBREVIATION 
-related O 
exposure O 
. O 
Furthermore O 
, O 
our O 
findings O 
suggest O 
that O 
emerald O 
rock O 
cod O 
exposed O 
to O 
PBDEs B-ABBREVIATION 
develop O 
oxidative O 
stress O 
- O 
a O 
condition O 
with O 
potential O 
consequences O 
for O 
fish O 
growth O 
, O 
health O 
and O 
reproduction O 
. O 

leaves O 
are O 
used O 
in O 
traditional O 
medicine O 
as O 
an O 
herbal O 
medicament O 
for O 
the O 
treatment O 
of O 
hepatic O 
related O 
diseases O 
, O 
as O 
well O 
as O 
choleretic O 
and O 
diuretic O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
capacity O 
of O 
Cynara O 
scolymus O 
L O 
. O 
leaves O 
extract O 
( O 
LE O 
) O 
to O 
cause O 
chromosomal O 
instability O 
and O 
cytotoxicity O 
in O 
Chinese O 
hamster O 
ovary O 
cells O 
( O 
CHO O 
) O 
employing O 
the O 
cytokinesis O 
- O 
block O 
micronucleus O 
( O 
CBMN O 
) O 
cytome O 
assay O 
. O 
Cells O 
were O 
treated O 
with O 
four O 
concentrations O 
of O 
C O 
. O 
scolymus O 
for O 
two O 
exposure O 
times O 
: O 
1h O 
and O 
24h O 
. O 
Our O 
findings O 
showed O 
that O 
LE O 
did O 
not O 
increase O 
the O 
frequencies O 
of O 
nucleoplasmic O 
bridges O 
( O 
NPBs O 
) O 
and O 
nuclear O 
bud O 
( O 
NBUD O 
) O 
. O 
However O 
, O 
all O 
concentrations O 
of O 
the O 
extract O 
produced O 
increments O 
in O 
micronuclei O 
frequencies O 
( O 
MNi O 
) O 
in O 
both O 
exposure O 
times O 
, O 
when O 
compared O 
to O 
the O 
negative O 
control O 
. O 
No O 
significant O 
differences O 
were O 
observed O 
in O 
the O 
nuclear O 
division O 
cytotoxicity O 
index O 
( O 
NDCI O 
) O 
, O 
reflecting O 
the O 
absence O 
of O 
cytotoxic O 
effects O 
associated O 
to O 
LE O 
. O 
The O 
results O 
demonstrated O 
the O 
ability O 
of O 
C O 
. O 
scolymus O 
LE O 
to O 
promote O 
chromosomal O 
mutations O 
which O 
are O 
, O 
probably O 
, O 
a O 
result O 
of O 
the O 
pro O 
- O 
oxidant O 
activity O 
of O 
LE O 
constituents O 
such O 
as O 
flavonoids B-FAMILY 
and O 
chlorogenic B-FAMILY 
acids I-FAMILY 
. O 
The O 
data O 
obtained O 
in O 
this O 
study O 
suggests O 
that O 
high O 
concentrations O 
of O 
artichoke O 
can O 
pose O 
a O 
risk O 
associated O 
to O 
its O 
consumption O 
. O 

of O 
zinc B-SYSTEMATIC 
on O 
epithelial O 
barrier O 
properties O 
and O 
viability O 
in O 
a O 
human O 
and O 
a O 
porcine O 
intestinal O 
cell O 
culture O 
model O 
. O 

is O 
an O 
essential O 
trace O 
element O 
with O 
a O 
variety O 
of O 
physiological O 
and O 
biochemical O 
functions O 
. O 
Piglets O 
are O 
commonly O 
supplemented O 
, O 
during O 
the O 
weaning O 
period O 
, O 
with O 
doses O 
of O 
zinc B-SYSTEMATIC 
above O 
dietary O 
requirements O 
with O 
positive O 
effects O 
on O 
health O 
and O 
performance O 
that O 
might O 
be O 
attributed O 
to O 
anti-secretory O 
and O 
barrier O 
- O 
enhancing O 
effects O 
in O 
the O 
intestine O 
. O 
For O 
a O 
better O 
understanding O 
of O 
these O 
observations O 
increasing O 
zinc B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
ZnSO4 B-FORMULA 
; O 
0-200μM O 
) O 
concentrations O 
were O 
used O 
in O 
an O 
in O 
vitro O 
culture O 
model O 
of O 
porcine O 
( O 
IPEC-J2 O 
) O 
and O 
human O 
( O 
Caco-2 O 
) O 
intestinal O 
epithelial O 
cells O 
and O 
effects O 
on O 
barrier O 
function O 
, O 
viability O 
, O 
and O 
the O 
mRNA O 
expression O 
of O 
one O 
selected O 
heat O 
shock O 
protein O 
( O 
Hsp O 
) O 
were O 
assessed O 
. O 
When O 
treated O 
apically O 
with O 
zinc B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
the O 
transepithelial O 
electrical O 
resistance O 
( O 
TEER O 
) O 
did O 
not O 
change O 
significantly O 
. O 
In O 
contrast O 
, O 
cell O 
viability O 
measured O 
by O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
leakage O 
, O 
by O 
ATP B-ABBREVIATION 
and O 
by O 
WST-1 O 
conversion O 
in O 
postconfluent O 
IPEC-J2 O 
monolayers O 
was O 
affected O 
after O 
a O 
24-h O 
treatment O 
with O 
200μM O 
ZnSO4 B-FORMULA 
. O 
Caco-2 O 
cells O 
were O 
more O 
resistant O 
to O 
Zn B-FORMULA 
. O 
ZnSO4 B-FORMULA 
did O 
not O 
induce O 
any O 
effect O 
on O 
viability O 
, O 
except O 
when O 
it O 
was O 
used O 
at O 
the O 
highest O 
concentration O 
( O 
200μM O 
) O 
, O 
and O 
only O 
in O 
preconfluent O 
cells O 
. O 
Furthermore O 
, O 
ZnSO4 B-FORMULA 
induced O 
Hsp70 O 
mRNA O 
expression O 
at O 
200μM O 
and O 
was O 
more O 
pronounced O 
in O 
preconfluent O 
cells O 
. O 
The O 
observed O 
dose O 
- O 
related O 
effects O 
of O 
zinc B-SYSTEMATIC 
are O 
cell O 
- O 
line O 
specific O 
and O 
depended O 
on O 
the O 
differentiation O 
status O 
of O 
the O 
cells O 
. O 
The O 
IPEC-J2 O 
cell O 
line O 
appears O 
to O 
be O 
a O 
suitable O 
in O 
vitro O 
model O 
to O 
characterize O 
specific O 
effects O 
on O 
porcine O 
intestinal O 
cells O 
. O 

in O 
the O 
circadian O 
system O 
are O 
associated O 
with O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
Here O 
, O 
we O 
studied O 
the O 
direct O 
contribution O 
of O 
the O 
suprachiasmatic O 
nucleus O 
( O 
SCN O 
) O 
, O 
the O 
central O 
pacemaker O 
in O 
the O 
circadian O 
system O 
, O 
in O 
the O 
development O 
of O 
insulin O 
resistance O 
. O 
Exclusive O 
bilateral O 
SCN O 
lesions O 
in O 
male O 
C57Bl O 
/ O 
6J O 
mice O 
, O 
as O 
verified O 
by O 
immunochemistry O 
, O 
showed O 
a O 
small O 
but O 
significant O 
increase O 
in O 
body O 
weight O 
( O 
+ O 
17% O 
) O 
, O 
which O 
was O 
accounted O 
for O 
by O 
an O 
increase O 
in O 
fat O 
mass O 
. O 
In O 
contrast O 
, O 
mice O 
with O 
collateral O 
damage O 
to O 
the O 
ventromedial O 
hypothalamus O 
and O 
paraventricular O 
nucleus O 
showed O 
severe O 
obesity O 
and O 
insulin O 
resistance O 
. O 
Mice O 
with O 
exclusive O 
SCN O 
ablation O 
revealed O 
a O 
loss O 
of O 
circadian O 
rhythm O 
in O 
activity O 
, O 
oxygen B-SYSTEMATIC 
consumption O 
, O 
and O 
food O 
intake O 
. O 
Hyperinsulinemic O 
- O 
euglycemic O 
clamp O 
analysis O 
8 O 
weeks O 
after O 
lesioning O 
showed O 
that O 
the O 
glucose B-TRIVIAL 
infusion O 
rate O 
was O 
significantly O 
lower O 
in O 
SCN O 
lesioned O 
mice O 
compared O 
with O 
sham O 
- O 
operated O 
mice O 
( O 
-63% O 
) O 
. O 
Although O 
insulin O 
potently O 
inhibited O 
endogenous O 
glucose B-TRIVIAL 
production O 
( O 
-84% O 
) O 
, O 
this O 
was O 
greatly O 
reduced O 
in O 
SCN O 
lesioned O 
mice O 
( O 
-7% O 
) O 
, O 
indicating O 
severe O 
hepatic O 
insulin O 
resistance O 
. O 
Our O 
data O 
show O 
that O 
SCN O 
malfunctioning O 
plays O 
an O 
important O 
role O 
in O 
the O 
disturbance O 
of O 
energy O 
balance O 
and O 
suggest O 
that O 
an O 
absence O 
of O 
central O 
clock O 
activity O 
, O 
in O 
a O 
genetically O 
intact O 
animal O 
, O 
may O 
lead O 
to O 
the O 
development O 
of O 
insulin O 
resistance O 
. O 

- O 
cut O 
lung O 
slices O 
( O 
PCLSs O 
) O 
are O 
an O 
organotypic O 
lung O 
model O 
that O 
is O 
widely O 
used O 
in O 
pharmacological O 
, O 
physiological O 
, O 
and O 
toxicological O 
studies O 
. O 
Genotoxicity O 
testing O 
, O 
as O 
a O 
pivotal O 
part O 
of O 
early O 
risk O 
assessment O 
, O 
is O 
currently O 
established O 
in O 
vivo O 
in O 
various O 
organs O 
including O 
lung O 
, O 
brain O 
, O 
or O 
liver O 
, O 
and O 
in O 
vitro O 
in O 
cell O 
lines O 
or O 
primary O 
cells O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
provide O 
the O 
three O 
- O 
dimensional O 
organ O 
culture O 
PCLS O 
as O 
a O 
new O 
ex O 
vivo O 
model O 
for O 
determination O 
of O 
genotoxicity O 
using O 
the O 
Comet O 
assay O 
. O 
Murine O 
PCLS O 
were O 
exposed O 
to O 
increasing O 
concentrations O 
of O 
ethyl B-SYSTEMATIC 
methane I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
' O 
EMS B-ABBREVIATION 
' O 
( O 
0.03-0.4% O 
) O 
and O 
formalin B-TRIVIAL 
( O 
0.5-5mM O 
) O 
. O 
Tissue O 
was O 
subsequently O 
dissociated O 
, O 
and O 
DNA O 
single O 
- O 
strand O 
breaks O 
were O 
quantified O 
using O 
the O 
Comet O 
assay O 
. O 
Number O 
of O 
viable O 
dissociated O 
lung O 
cells O 
was O 
between O 
4×10(5) O 
and O 
6.7×10(5)cells O 
/ O 
slice O 
. O 
Even O 
treatment O 
with O 
EMS B-ABBREVIATION 
did O 
not O 
induce O 
toxicity O 
compared O 
to O 
untreated O 
tissue O 
control O 
. O 
As O 
expected O 
, O 
DNA O 
single O 
- O 
strand O 
breaks O 
were O 
increased O 
dose O 
- O 
dependently O 
and O 
significantly O 
after O 
exposure O 
to O 
EMS B-ABBREVIATION 
. O 
Here O 
, O 
tail O 
length O 
rose O 
from O 
24μm O 
to O 
75μm O 
. O 
In O 
contrast O 
, O 
formalin B-TRIVIAL 
resulted O 
in O 
a O 
significant O 
induction O 
of O 
DNA O 
cross O 
- O 
links O 
. O 
The O 
effects O 
induced O 
by O 
EMS B-ABBREVIATION 
and O 
formalin B-TRIVIAL 
demonstrate O 
the O 
usefulness O 
of O 
PCLS O 
as O 
a O 
new O 
ex O 
vivo O 
lung O 
model O 
for O 
genotoxicity O 
testing O 
in O 
the O 
early O 
risk O 
assessment O 
of O 
airborne O 
substances O 
in O 
the O 
future O 
. O 

- I-SYSTEMATIC 
polymethacrylate I-SYSTEMATIC 
supramolecular O 
aggregates O 
for O 
protein O 
oral O 
delivery O 
. O 

calcitonin O 
( O 
sCT O 
) O 
is O 
characterized O 
by O 
a O 
poor O 
oral O 
availability O 
. O 
A O 
new O 
copolymer O 
, O 
β-poly(N-2-hydroxyethyl)-graft-{N-2-ethylene[2-poly(methacrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
sodium I-SYSTEMATIC 
salt)isobutyrate]}-d,l-aspartamide I-SYSTEMATIC 
( O 
PHEA-IB-p(MANa(+)) B-FORMULA 
) O 
, O 
was O 
designed O 
for O 
the O 
oral O 
administration O 
of O 
sCT O 
through O 
the O 
formation O 
of O 
supramolecular O 
aggregates O 
( O 
SAs O 
) O 
based O 
on O 
electrostatic O 
interactions O 
. O 
Several O 
sCT/ O 
PHEA-IB-p(MANa(+)) B-FORMULA 
weight O 
ratios O 
were O 
characterized O 
by O 
turbidimetry O 
, O 
DLS O 
, O 
zeta O 
potential O 
, O 
and O 
microscopy O 
analysis O 
. O 
After O 
the O 
incubation O 
of O 
sCT/ O 
PHEA-IB-p(MANa(+)) B-FORMULA 
complex O 
with O 
digestive O 
enzymes O 
, O 
10% O 
( O 
w O 
/ O 
w O 
) O 
of O 
loaded O 
sCT O 
was O 
released O 
in O 
the O 
native O 
form O 
. O 
In O 
vitro O 
investigation O 
was O 
carried O 
out O 
to O 
determine O 
the O 
copolymer O 
effect O 
on O 
the O 
permeability O 
of O 
sCT O 
in O 
Caco-2 O 
cell O 
monolayers O 
. O 
sCT O 
pharmacokinetic O 
profile O 
and O 
the O 
pharmacodynamic O 
effect O 
on O 
calcium B-SYSTEMATIC 
plasma O 
level O 
were O 
determined O 
following O 
an O 
oral O 
administration O 
of O 
the O 
lead O 
sCT/ O 
PHEA-IB-p(MANa(+)) B-FORMULA 
SA O 
( O 
1 O 
/ O 
5 O 
ratio O 
) O 
in O 
rats O 
. O 
The O 
SA O 
yielded O 
a O 
marked O 
prolongation O 
of O 
the O 
sCT O 
lowering O 
calcium B-SYSTEMATIC 
effect O 
. O 
The O 
maximum O 
decrease O 
, O 
35% O 
with O 
respect O 
the O 
basal O 
calcium B-SYSTEMATIC 
plasma O 
level O 
at O 
time O 
0h O 
, O 
was O 
achieved O 
after O 
4h O 
post O 
- O 
administration O 
, O 
and O 
after O 
7h O 
, O 
a O 
decrease O 
of O 
20% O 
was O 
still O 
present O 
. O 
Differently O 
, O 
sCT O 
yielded O 
a O 
transient O 
calcium B-SYSTEMATIC 
decrease O 
that O 
was O 
completely O 
restored O 
after O 
5h O 
. O 
The O 
higher O 
bioavailability O 
of O 
sCT O 
administered O 
as O 
SA O 
was O 
confirmed O 
by O 
the O 
pharmacokinetic O 
studies O 
. O 
In O 
fact O 
, O 
the O 
AUC O 
and O 
the O 
Cmax O 
were O 
about O 
15 O 
times O 
higher O 
for O 
the O 
sCT O 
formulated O 
as O 
SA O 
than O 
the O 
free O 
sCT O 
. O 
This O 
study O 
indicates O 
the O 
potentials O 
of O 
PHEA-IB-p(MANa(+)) B-FORMULA 
as O 
carrier O 
of O 
sCT O 
for O 
oral O 
delivery O 
. O 

release O 
kinetics O 
, O 
cell O 
uptake O 
, O 
and O 
tumor O 
toxicity O 
of O 
hybrid O 
VVVVVVKK O 
peptide-assembled O 
polylactide B-FAMILY 
nanoparticles O 
. O 

exciting O 
approach O 
to O 
tumor O 
delivery O 
is O 
encapsulation O 
of O 
the O 
drug O 
in O 
self O 
- O 
assembled O 
polymer O 
- O 
peptide O 
nanoparticles O 
. O 
The O 
objective O 
of O 
this O 
work O 
was O 
to O 
synthesize O 
a O 
conjugate O 
of O 
low O 
molecular O 
weight O 
polylactide B-FAMILY 
( O 
LMW O 
PLA O 
) O 
and O 
V6K2 O 
peptide O 
and O 
investigate O 
self O 
- O 
assembly O 
, O 
drug O 
release O 
kinetics O 
, O 
cell O 
uptake O 
and O 
toxicity O 
, O 
drug O 
pharmacokinetics O 
, O 
and O 
tumor O 
cell O 
invasion O 
with O 
Doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
or O 
paclitaxel B-TRIVIAL 
( O 
PTX B-ABBREVIATION 
) O 
. O 
The O 
results O 
for O 
PLA B-ABBREVIATION 
-V6K2 O 
self O 
- O 
assembled O 
NPs O 
were O 
compared O 
with O 
those O 
of O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
stabilized O 
PLA B-ABBREVIATION 
( O 
PLA B-ABBREVIATION 
-EG O 
) O 
NPs O 
. O 
The O 
size O 
of O 
PLA B-ABBREVIATION 
-V6K2 O 
and O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
was O 
100±20 O 
and O 
130±50nm O 
, O 
respectively O 
, O 
with O 
polydispersity O 
index O 
of O 
1.04 O 
and O 
1.14 O 
. O 
The O 
encapsulation O 
efficiency O 
of O 
DOX B-ABBREVIATION 
in O 
PLA B-ABBREVIATION 
-V6K2 O 
and O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
was O 
44±9% O 
and O 
55±5% O 
, O 
respectively O 
, O 
and O 
that O 
of O 
PTX B-ABBREVIATION 
was O 
> O 
90 O 
for O 
both O 
NP O 
types O 
. O 
The O 
release O 
of O 
DOX B-ABBREVIATION 
and O 
PTX B-ABBREVIATION 
from O 
PLA B-ABBREVIATION 
-V6K2 O 
was O 
slower O 
than O 
that O 
of O 
PLA B-ABBREVIATION 
-EG O 
, O 
and O 
the O 
release O 
rate O 
was O 
relatively O 
constant O 
with O 
time O 
. O 
Based O 
on O 
molecular O 
dynamic O 
simulation O 
, O 
the O 
less O 
hydrophobic O 
DOX B-ABBREVIATION 
was O 
distributed O 
in O 
the O 
lactide B-TRIVIAL 
core O 
as O 
well O 
as O 
the O 
peptide O 
shell O 
, O 
while O 
the O 
hydrophobic O 
PTX B-ABBREVIATION 
was O 
localized O 
mainly O 
to O 
the O 
lactide B-TRIVIAL 
core O 
. O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
had O 
significantly O 
higher O 
cell O 
uptake O 
by O 
4T1 O 
mouse O 
breast O 
carcinoma O 
cells O 
compared O 
to O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
, O 
which O 
was O 
attributed O 
to O 
the O 
electrostatic O 
interactions O 
between O 
the O 
peptide O 
and O 
negatively O 
charged O 
moieties O 
on O 
the O 
cell O 
membrane O 
. O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
showed O 
no O 
toxicity O 
to O 
marrow O 
stromal O 
cells O 
. O 
DOX B-ABBREVIATION 
-loaded O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
showed O 
higher O 
toxicity O 
to O 
4T1 O 
cells O 
and O 
the O 
DNA O 
damage O 
response O 
, O 
and O 
apoptosis O 
was O 
delayed O 
compared O 
to O 
the O 
free O 
DOX B-ABBREVIATION 
. O 
DOX B-ABBREVIATION 
or O 
PTX B-ABBREVIATION 
encapsulated O 
in O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
significantly O 
reduced O 
invasion O 
of O 
4T1 O 
cells O 
compared O 
to O 
those O 
cells O 
treated O 
with O 
the O 
drug O 
in O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
. O 
Invasion O 
of O 
4T1 O 
cells O 
treated O 
with O 
DOX B-ABBREVIATION 
in O 
PLA B-ABBREVIATION 
-V6K2 O 
and O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
was O 
5±1% O 
and O 
30±5% O 
, O 
respectively O 
, O 
and O 
that O 
of O 
PTX B-ABBREVIATION 
was O 
11±2% O 
and O 
40±7% O 
. O 
The O 
AUC O 
of O 
DOX B-ABBREVIATION 
in O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
was O 
67% O 
and O 
21% O 
higher O 
than O 
those O 
of O 
free O 
DOX B-ABBREVIATION 
and O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
, O 
respectively O 
. O 
DOX B-ABBREVIATION 
-loaded O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
injected O 
in O 
C3HeB O 
/ O 
FeJ O 
mice O 
inoculated O 
with O 
MTCL O 
syngeneic O 
breast O 
cancer O 
cells O 
displayed O 
higher O 
tumor O 
toxicity O 
than O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
and O 
lower O 
host O 
toxicity O 
than O 
the O 
free O 
DOX B-ABBREVIATION 
. O 
Cationic O 
PLA B-ABBREVIATION 
-V6K2 O 
NPs O 
with O 
higher O 
tumor O 
toxicity O 
than O 
the O 
PLA B-ABBREVIATION 
-EG O 
NPs O 
are O 
potentially O 
useful O 
in O 
chemotherapy O 
. O 

lipid O 
formulation O 
systems O 
are O 
used O 
to O 
overcome O 
oral O 
bioavailability O 
problems O 
of O 
poorly O 
water O 
- O 
soluble O 
drugs O 
. O 
One O 
promising O 
process O 
is O 
the O 
conversion O 
of O 
a O 
liquid O 
lipid O 
system O 
in O 
a O 
free O 
flowing O 
powder O 
by O 
use O 
of O 
adsorbing O 
excipients O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
the O 
detailed O 
characterization O 
of O 
solid O 
- O 
liquid O 
interactions O 
in O 
oil O 
adsorbed O 
to O 
Fujicalin B-TRIVIAL 
® O 
and O 
Neusilin B-TRIVIAL 
® O 
which O 
were O 
manufactured O 
by O 
means O 
of O 
dual O 
asymmetric O 
centrifugation O 
or O 
conventional O 
mortar O 
/ O 
pestle O 
blending O 
. O 
The O 
adsorption O 
strength O 
of O 
the O 
excipients O 
was O 
investigated O 
by O 
Benchtop-NMR O 
and O 
ESR O 
spectroscopy O 
revealing O 
the O 
highest O 
adsorption O 
power O 
for O 
the O 
Neusilin B-TRIVIAL 
® O 
products O 
. O 
The O 
adsorbate O 
production O 
methods O 
as O 
well O 
as O 
the O 
storage O 
of O 
the O 
excipients O 
impact O 
their O 
adsorption O 
properties O 
. O 
Environmental O 
scanning O 
electron O 
microscopy O 
( O 
ESEM O 
) O 
and O 
confocal O 
laser O 
scanning O 
microscopy O 
( O 
CLSM O 
) O 
show O 
that O 
dual O 
asymmetric O 
centrifugation O 
leads O 
to O 
a O 
smoothing O 
of O 
the O 
particle O 
surface O 
, O 
whereas O 
the O 
mortar O 
/ O 
pestle O 
blending O 
results O 
in O 
an O 
uneven O 
surface O 
and O 
particle O 
destruction O 
. O 
The O 
oil O 
distribution O 
at O 
the O 
particles O 
is O 
inhomogeneous O 
for O 
both O 
production O 
methods O 
. O 
The O 
micropolarity O 
of O 
the O 
adsorbed O 
oil O 
was O 
investigated O 
by O 
ESR O 
spectroscopy O 
and O 
multispectral O 
fluorescence O 
imaging O 
. O 
The O 
adsorbing O 
process O 
on O 
Neusilin B-TRIVIAL 
® O 
leads O 
to O 
an O 
increased O 
micropolarity O 
of O 
the O 
oil O 
component O 
. O 
The O 
release O 
of O 
the O 
oil O 
component O 
in O 
aqueous O 
media O 
could O 
be O 
verified O 
by O 
Benchtop-NMR O 
and O 
multispectral O 
fluorescence O 
imaging O 
. O 

review O 
summarized O 
the O 
progress O 
of O 
glyconanoparticles O 
in O 
the O 
aspects O 
of O 
types O 
, O 
synthesis O 
, O 
and O 
applications O 
for O 
recent O 
five O 
years O 
. O 
A O 
major O 
challenge O 
in O 
the O 
development O 
of O 
Au B-FORMULA 
glyconanoparticles O 
for O 
the O 
study O 
of O 
cellular O 
interactions O 
is O 
to O 
span O 
the O 
cellular O 
membrane O 
, O 
which O 
is O 
used O 
for O 
the O 
drug O 
delivery O 
. O 
A O 
majority O 
of O 
glyco O 
- O 
functionalized O 
quantum O 
dots O 
have O 
been O 
utilized O 
as O 
fluorescent O 
probes O 
for O 
biolabeling O 
, O 
imaging O 
and O 
biosensing O 
. O 
Recently O 
, O 
magnetic O 
nanoparticles O 
have O 
been O 
more O 
frequently O 
used O 
in O 
biomedical O 
applications O 
. O 
The O 
application O 
of O 
these O 
new O 
multivalent O 
systems O 
of O 
glyconanoparticles O 
is O 
to O 
mainly O 
study O 
carbohydrate B-FAMILY 
-mediated O 
interactions O 
, O 
which O 
opens O 
the O 
new O 
field O 
in O 
glycobiology O 
. O 

complexity O 
of O 
the O 
molecular O 
recognition O 
and O 
assembly O 
of O 
biotic O 
- O 
abiotic O 
interfaces O 
on O 
a O 
scale O 
of O 
1 O 
to O 
1000 O 
nm O 
can O 
be O 
understood O 
more O 
effectively O 
using O 
simulation O 
tools O 
along O 
with O 
laboratory O 
instrumentation O 
. O 
We O 
discuss O 
the O 
current O 
capabilities O 
and O 
limitations O 
of O 
atomistic O 
force O 
fields O 
and O 
explain O 
a O 
strategy O 
to O 
obtain O 
dependable O 
parameters O 
for O 
inorganic O 
compounds O 
that O 
has O 
been O 
developed O 
and O 
tested O 
over O 
the O 
past O 
decade O 
. O 
Parameter O 
developments O 
include O 
several O 
silicates B-FAMILY 
, O 
aluminates B-FAMILY 
, O 
metals O 
, O 
oxides B-FAMILY 
, O 
sulfates B-FAMILY 
, O 
and O 
apatites B-FAMILY 
that O 
are O 
summarized O 
in O 
what O 
we O 
call O 
the O 
INTERFACE O 
force O 
field O 
. O 
The O 
INTERFACE O 
force O 
field O 
operates O 
as O 
an O 
extension O 
of O 
common O 
harmonic O 
force O 
fields O 
( O 
PCFF O 
, O 
COMPASS O 
, O 
CHARMM O 
, O 
AMBER O 
, O 
GROMACS O 
, O 
and O 
OPLS-AA O 
) O 
by O 
employing O 
the O 
same O 
functional O 
form O 
and O 
combination O 
rules O 
to O 
enable O 
simulations O 
of O 
inorganic O 
- O 
organic O 
and O 
inorganic O 
- O 
biomolecular O 
interfaces O 
. O 
The O 
parametrization O 
builds O 
on O 
an O 
in O 
- O 
depth O 
understanding O 
of O 
physical O 
- O 
chemical O 
properties O 
on O 
the O 
atomic O 
scale O 
to O 
assign O 
each O 
parameter O 
, O 
especially O 
atomic O 
charges O 
and O 
van O 
der O 
Waals O 
constants O 
, O 
as O 
well O 
as O 
on O 
the O 
validation O 
of O 
macroscale O 
physical O 
- O 
chemical O 
properties O 
for O 
each O 
compound O 
in O 
comparison O 
to O 
measurements O 
. O 
The O 
approach O 
eliminates O 
large O 
discrepancies O 
between O 
computed O 
and O 
measured O 
bulk O 
and O 
surface O 
properties O 
of O 
up O 
to O 
2 O 
orders O 
of O 
magnitude O 
using O 
other O 
parametrization O 
protocols O 
and O 
increases O 
the O 
transferability O 
of O 
the O 
parameters O 
by O 
introducing O 
thermodynamic O 
consistency O 
. O 
As O 
a O 
result O 
, O 
a O 
wide O 
range O 
of O 
properties O 
can O 
be O 
computed O 
in O 
quantitative O 
agreement O 
with O 
experiment O 
, O 
including O 
densities O 
, O 
surface O 
energies O 
, O 
solid O 
- O 
water O 
interface O 
tensions O 
, O 
anisotropies O 
of O 
interfacial O 
energies O 
of O 
different O 
crystal O 
facets O 
, O 
adsorption O 
energies O 
of O 
biomolecules O 
, O 
and O 
thermal O 
and O 
mechanical O 
properties O 
. O 
Applications O 
include O 
insight O 
into O 
the O 
assembly O 
of O 
inorganic O 
- O 
organic O 
multiphase O 
materials O 
, O 
the O 
recognition O 
of O 
inorganic O 
facets O 
by O 
biomolecules O 
, O 
growth O 
and O 
shape O 
preferences O 
of O 
nanocrystals O 
and O 
nanoparticles O 
, O 
as O 
well O 
as O 
thermal O 
transitions O 
and O 
nanomechanics O 
. O 
Limitations O 
and O 
opportunities O 
for O 
further O 
development O 
are O 
also O 
described O 
. O 

1-methyladenine B-SYSTEMATIC 
( O 
1-meA B-SYSTEMATIC 
) O 
and O 
3-methylcytosine B-SYSTEMATIC 
( O 
3-meC B-SYSTEMATIC 
) O 
lesions O 
induced O 
in O 
DNA O 
and O 
RNA O 
in O 
vitro O 
and O 
in O 
pre O 
- O 
damaged O 
DNA O 
and O 
RNA O 
bacteriophages O 
in O 
vivo O 
are O 
repaired O 
by O 
the O 
Escherichia O 
coli O 
( O 
E O 
. O 
coli O 
) O 
protein O 
AlkB O 
and O 
a O 
human O 
homolog O 
, O 
ALKBH3 O 
. O 
However O 
, O 
it O 
is O 
not O 
known O 
whether O 
endogenous O 
RNA O 
is O 
repaired O 
in O 
vivo O 
by O 
repair O 
proteins O 
present O 
at O 
physiological O 
concentrations O 
. O 
The O 
concept O 
of O 
RNA O 
repair O 
as O 
a O 
biologically O 
relevant O 
process O 
has O 
therefore O 
remained O 
elusive O 
. O 
Here O 
, O 
we O 
demonstrate O 
AlkB O 
- O 
mediated O 
repair O 
of O 
endogenous O 
RNA O 
in O 
vivo O 
by O 
measuring O 
differences O 
in O 
lesion O 
- O 
accumulation O 
in O 
two O 
independent O 
AlkB-proficient O 
and O 
deficient O 
E O 
. O 
coli O 
strains O 
during O 
exposure O 
to O 
methyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
( O 
MMS B-ABBREVIATION 
) O 
. O 
Repair O 
was O 
observed O 
both O 
in O 
AlkB-overproducing O 
strains O 
and O 
in O 
the O 
wild O 
- O 
type O 
strains O 
after O 
AlkB O 
induction O 
. O 
RNA O 
repair O 
appeared O 
to O 
be O 
highest O 
in O 
RNA O 
species O 
below O 
200 O 
nucleotides B-FAMILY 
in O 
size O 
, O 
mainly O 
comprising O 
tRNAs O 
. O 
Strikingly O 
, O 
at O 
least O 
10-fold O 
more O 
lesions O 
were O 
repaired O 
in O 
RNA O 
than O 
in O 
DNA O 
. O 
This O 
may O 
be O 
a O 
consequence O 
of O 
some O 
30-fold O 
higher O 
levels O 
of O 
aberrant O 
methylation O 
in O 
RNA O 
than O 
in O 
DNA O 
after O 
exposure O 
to O 
MMS B-ABBREVIATION 
. O 
A O 
high O 
primary O 
kinetic O 
isotope O 
effect O 
( O 
> O 
10 O 
) O 
was O 
measured O 
using O 
a O 
deuterated O 
methylated O 
RNA O 
substrate O 
, O 
D3-1me(rA) O 
, O 
demonstrating O 
that O 
it O 
is O 
the O 
catalytic O 
step O 
, O 
and O 
not O 
the O 
search O 
step O 
that O 
is O 
rate O 
- O 
limiting O 
. O 
Our O 
results O 
demonstrate O 
that O 
RNA O 
repair O 
by O 
AlkB O 
takes O 
place O 
in O 
endogenous O 
RNA O 
as O 
part O 
of O 
an O 
adaptive O 
response O 
in O 
wild O 
- O 
type O 
E O 
. O 
coli O 
cells O 
. O 

metabolites O 
mediate O 
its O 
effects O 
on O 
myocardial O 
damage O 
induced O 
by O 
ischemia O 
/ O 
reperfusion O 
in O 
male O 
Wistar O 
rats O 
. O 

role O 
of O 
testosterone B-TRIVIAL 
in O 
cardiovascular O 
( O 
CV O 
) O 
homeostasis O 
is O 
in O 
controversy O 
, O 
and O 
the O 
exact O 
effects O 
of O 
testosterone B-TRIVIAL 
on O 
the O 
cardiovascular O 
system O 
remain O 
poorly O 
understood O 
. O 
Testosterone B-TRIVIAL 
is O 
metabolized O 
by O 
aromatase O 
into O 
17β-estradiol B-SYSTEMATIC 
and O 
by O 
5α-reductase O 
into O 
dihydrotestosterone B-SYSTEMATIC 
( O 
DHT B-ABBREVIATION 
) O 
. O 
Thus O 
, O 
identification O 
of O 
these O 
metabolites O 
in O 
the O 
heart O 
may O 
help O 
to O 
explain O 
the O 
controversy O 
regarding O 
the O 
cardiovascular O 
effects O 
of O 
testosterone B-TRIVIAL 
. O 
We O 
analyzed O 
the O 
expression O 
patterns O 
of O 
these O 
testosterone B-TRIVIAL 
-metabolizing O 
enzymes O 
and O 
assessed O 
the O 
effect O 
of O 
its O 
enzymatic O 
activity O 
inhibition O 
on O 
ischemia O 
( O 
40 O 
min O 
) O 
/ O 
reperfusion O 
( O 
4h O 
, O 
I O 
/ O 
R O 
) O 
via O 
the O 
left O 
anterior O 
descendent O 
coronary O 
artery O 
in O 
intact O 
and O 
gonadectomized O 
male O 
rats O 
. O 
Myocardial O 
damage O 
was O 
measured O 
as O 
percentage O 
of O 
infarcted O 
area O 
vs O 
. O 
area O 
at O 
risk O 
. O 
Aromatase O 
and O 
5α-reductase O 
protein O 
expression O 
was O 
found O 
in O 
the O 
left O 
ventricle O 
of O 
intact O 
and O 
orchidectomized O 
rats O 
. O 
Exogenous O 
testosterone B-TRIVIAL 
had O 
no O 
effect O 
on O 
I O 
/ O 
R O 
induced O 
myocardial O 
damage O 
in O 
intact O 
male O 
rats O 
, O 
meanwhile O 
exogenous O 
testosterone B-TRIVIAL 
protects O 
against O 
I O 
/ O 
R O 
injury O 
in O 
orchidectomized O 
rats O 
. O 
However O 
, O 
enzymatic O 
inhibition O 
of O 
aromatase O 
increased O 
myocardial O 
damage O 
in O 
the O 
presence O 
of O 
testosterone B-TRIVIAL 
, O 
while O 
enzymatic O 
inhibition O 
of O 
5α-reductase O 
significantly O 
decreased O 
the O 
level O 
of O 
myocardial O 
damage O 
. O 
Our O 
results O 
also O 
showed O 
that O 
sub O 
- O 
chronic O 
inhibition O 
of O 
5α-reductase O 
resulted O 
in O 
myocardial O 
protection O 
in O 
both O 
groups O 
. O 
Furthermore O 
, O 
in O 
orchidectomized O 
and O 
intact O 
male O 
rats O 
IV O 
treatment O 
with O 
DHT O 
induces O 
a O 
significant O 
increase O 
in O 
the O 
myocardial O 
damage O 
induced O 
by O 
I O 
/ O 
R O 
. O 
Thus O 
, O 
the O 
effect O 
of O 
testosterone B-TRIVIAL 
on O 
cardiovascular O 
pathophysiology O 
could O 
be O 
related O 
, O 
at O 
least O 
in O 
part O 
to O 
changes O 
in O 
the O 
balance O 
of O 
testosterone B-TRIVIAL 
5α-reduction O 
and O 
aromatization O 
. O 

sequencing O 
projects O 
over O 
the O 
last O 
several O 
years O 
have O 
aided O 
the O 
discovery O 
of O 
previously O 
uncharacterized O 
invertebrate O 
sequences O 
, O 
including O 
new O 
cytochrome O 
P450 O 
genes O 
( O 
CYPs O 
) O 
. O 
Here O 
we O 
present O 
data O 
on O 
the O 
identification O 
and O 
characterization O 
of O 
two O 
CYP1 O 
- O 
like O 
and O 
three O 
CYP3 O 
- O 
like O 
genes O 
from O 
the O 
bivalve O 
mollusk O 
Mytilus O 
edulis O 
, O 
and O 
assess O 
their O 
potential O 
as O 
biomarkers O 
based O 
on O 
their O 
responses O 
to O 
several O 
known O 
vertebrate O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AHR O 
) O 
agonists O 
. O 
Quantitative O 
real O 
- O 
time O 
PCR O 
was O 
used O 
to O 
measure O 
CYP O 
transcript O 
levels O 
in O 
digestive O 
gland O 
, O 
labial O 
palps O 
, O 
adductor O 
muscle O 
, O 
gill O 
, O 
foot O 
, O 
and O 
different O 
regions O 
of O 
the O 
mantle O 
. O 
Levels O 
of O 
both O 
CYP1 O 
- O 
like O 
genes O 
were O 
highest O 
in O 
digestive O 
gland O 
, O 
whereas O 
labial O 
palps O 
had O 
the O 
highest O 
expression O 
levels O 
of O 
the O 
three O 
CYP3 O 
- O 
like O 
genes O 
followed O 
by O 
digestive O 
gland O 
and O 
outer O 
margin O 
of O 
the O 
mantle O 
. O 
Mussels O 
were O 
exposed O 
by O 
injection O 
to O 
the O 
AHR O 
agonists O 
, O 
β-naphthoflavone B-TRIVIAL 
( O 
BNF B-ABBREVIATION 
; O 
25 O 
μg O 
g(-1) O 
) O 
, O 
3,3',4,4',5-polychlorinated B-SYSTEMATIC 
biphenyl I-SYSTEMATIC 
( O 
PCB126 B-TRIVIAL 
; O 
2 O 
μg O 
g(-1) O 
) O 
, O 
or O 
6- B-SYSTEMATIC 
formylindolo[3,2-b]carbazole I-SYSTEMATIC 
( O 
FICZ B-ABBREVIATION 
; O 
0.1 O 
μg O 
g(-1) O 
) O 
, O 
or O 
to O 
Aroclor B-TRIVIAL 
1254 I-TRIVIAL 
( O 
a O 
mixture O 
of O 
PCBs B-ABBREVIATION 
; O 
50 O 
μg O 
g(-1) O 
) O 
for O 
24 O 
h O 
, O 
followed O 
by O 
CYP O 
expression O 
analysis O 
. O 
There O 
was O 
no O 
statistically O 
significant O 
change O 
in O 
expression O 
of O 
either O 
of O 
the O 
CYP1 O 
- O 
like O 
genes O 
after O 
exposure O 
to O 
the O 
various O 
AHR O 
agonists O 
. O 
The O 
CYP3 O 
- O 
like-1 O 
gene O 
was O 
significantly O 
up O 
- O 
regulated O 
by O 
BNF B-ABBREVIATION 
in O 
gill O 
tissues O 
and O 
the O 
CYP3 O 
- O 
like-2 O 
gene O 
was O 
up O 
- O 
regulated O 
in O 
digestive O 
gland O 
by O 
PCB126 B-TRIVIAL 
and O 
in O 
gill O 
tissue O 
by O 
BNF O 
. O 
These O 
results O 
suggest O 
that O 
distinct O 
mechanisms O 
of O 
CYP O 
gene O 
activation O 
could O 
be O 
present O 
in O 
M O 
. O 
edulis O 
, O 
although O 
the O 
importance O 
of O 
the O 
CYP1 O 
- O 
like O 
and O 
CYP3 O 
- O 
like O 
genes O 
for O 
xenobiotic O 
and O 
endogenous O 
lipids O 
biotransformation O 
requires O 
additional O 
investigation O 
. O 

averts O 
oxidative O 
stress O 
in O 
pancreatic O 
tissues O 
of O 
streptozotocin B-TRIVIAL 
-induced O 
diabetic O 
rats O 
. O 

hyperglycemia O 
is O 
associated O 
with O 
chronic O 
oxidative O 
stress O 
which O 
contributes O 
to O 
the O 
development O 
and O 
progression O 
of O 
diabetes O 
- O 
associated O 
complications O 
. O 
The O 
sensitivity O 
of O 
pancreatic O 
β-cells O 
to O 
oxidative O 
stress O 
has O 
been O 
attributed O 
to O 
their O 
low O 
content O 
of O 
antioxidants O 
compared O 
with O 
other O 
tissues O 
. O 
Bioactive O 
compounds O 
with O 
potent O 
antidiabetic O 
properties O 
have O 
been O 
shown O 
to O 
ameliorate O 
hyperglycemia O 
mediated O 
oxidative O 
stress O 
. O 
Recently O 
, O 
we O 
have O 
reported O 
that O 
oral O 
administration O 
of O 
fisetin B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
Kg O 
b.w O 
. O 
) O 
, O 
a O 
bioflavonoi B-FAMILY 
d O 
found O 
to O 
be O 
present O 
in O 
strawberries O 
, O 
persimmon O 
, O 
to O 
ST B-ABBREVIATION 
Z-induced O 
experimental O 
diabetic O 
rats O 
significantly O 
improved O 
normoglycemia O 
. O 
The O 
present O 
study O 
was O 
aimed O 
to O 
evaluate O 
the O 
antioxidant O 
potential O 
of O 
fiseti B-TRIVIAL 
n O 
in O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Diabetes O 
was O 
induced O 
by O 
single O 
intraperitoneal O 
injection O 
of O 
streptozotoci B-TRIVIAL 
n O 
( O 
50 O 
mg O 
/ O 
kg O 
body O 
weight O 
) O 
. O 
Fisetin O 
was O 
administered O 
orally O 
for O 
30 O 
days O 
. O 
At O 
the O 
end O 
of O 
the O 
study O 
, O 
all O 
animals O 
were O 
killed O 
. O 
Blood O 
samples O 
were O 
collected O 
for O 
the O 
biochemical O 
estimations O 
. O 
The O 
antioxidant O 
status O 
was O 
evaluated O 
. O 
Histological O 
examinations O 
were O 
performed O 
on O 
pancreatic O 
tissues O 
. O 
Fisetin O 
treatment O 
showed O 
a O 
significant O 
decline O 
in O 
the O 
levels O 
of O 
blood O 
glucos B-TRIVIAL 
e O 
, O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
, O 
NF-kB O 
p65 O 
unit O 
( O 
in O 
pancreas O 
) O 
and O 
IL-1β O 
( O 
plasma O 
) O 
, O 
serum O 
nitric B-SYSTEMATIC 
oxid I-SYSTEMATIC 
e O 
( B-FORMULA 
N I-FORMULA 
O O 
) O 
with O 
an O 
elevation O 
in O 
plasma O 
insulin O 
. O 
The O 
treatment O 
also O 
improved O 
the O 
antioxidant O 
status O 
in O 
pancreas O 
as O 
well O 
as O 
plasma O 
of O 
diabetic O 
rats O 
indicating O 
the O 
antioxidant O 
potential O 
of O 
fiseti B-TRIVIAL 
n O 
. O 
In O 
addition O 
, O 
the O 
results O 
of O 
DPP B-ABBREVIATION 
H O 
and O 
ABT B-ABBREVIATION 
S O 
assays O 
substantiate O 
the O 
free O 
radical O 
scavenging O 
activity O 
of O 
fiseti B-TRIVIAL 
n O 
. O 
Histological O 
studies O 
of O 
the O 
pancreas O 
also O 
evidenced O 
the O 
tissue O 
protective O 
nature O 
of O 
fiseti B-TRIVIAL 
n O 
. O 
It O 
is O 
concluded O 
that O 
, O 
fiseti B-TRIVIAL 
n O 
possesses O 
antioxidant O 
and O 
anti-inflammatory O 
property O 
and O 
may O 
be O 
considered O 
as O 
an O 
adjunct O 
for O 
the O 
treatment O 
of O 
diabetes O 
. O 

lateral O 
sclerosis O 
( O 
ALS O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disorder O 
characterised O 
by O 
the O 
selective O 
dysfunction O 
and O 
death O 
of O 
the O 
upper O 
and O 
lower O 
motor O 
neurons O 
. O 
Median O 
survival O 
rates O 
are O 
between O 
3 O 
and O 
5 O 
years O 
after O 
diagnosis O 
. O 
Mutations O 
in O 
the O 
gene O 
encoding O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD1 O 
) O 
have O 
been O 
linked O 
to O 
a O 
subset O 
of O 
familial O 
forms O 
of O 
ALS O 
( O 
fALS O 
) O 
. O 
Herein O 
, O 
we O 
describe O 
a O 
fragment- O 
based O 
drug O 
discovery O 
( O 
FBDD O 
) O 
approach O 
for O 
the O 
investigation O 
of O 
small O 
molecule O 
binding O 
sites O 
in O 
SOD1 O 
. O 
X-ray O 
crystallography O 
has O 
been O 
used O 
as O 
the O 
primary O 
screening O 
method O 
and O 
has O 
been O 
shown O 
to O 
directly O 
detect O 
protein O 
- O 
ligand O 
interactions O 
which O 
cannot O 
be O 
unambiguously O 
identified O 
using O 
other O 
biophysical O 
methods O 
. O 
The O 
structural O 
requirements O 
for O 
effective O 
binding O 
at O 
Trp B-FORMULA 
32 O 
are O 
detailed O 
for O 
a O 
series O 
of O 
quinazoline B-SYSTEMATIC 
-containing O 
compounds O 
. O 
The O 
investigation O 
of O 
an O 
additional O 
site O 
that O 
binds O 
a O 
range O 
of O 
catecholamines B-FAMILY 
and O 
the O 
use O 
of O 
computational O 
modelling O 
to O 
assist O 
fragment O 
evolution O 
is O 
discussed O 
. O 
This O 
study O 
also O 
highlights O 
the O 
importance O 
of O 
ligand O 
solubility O 
for O 
successful O 
Xray O 
crystallographic O 
campaigns O 
in O 
lead O 
compound O 
design O 
. O 

of O 
N(3) B-FAMILY 
- I-FAMILY 
Substituted I-FAMILY 
Xanthines I-FAMILY 
in O 
the O 
Solid O 
State O 
and O 
at O 
the O 
Solid-Liquid O 
Interface O 
. O 

self O 
- O 
assembly O 
of O 
small O 
molecular O 
modules O 
interacting O 
through O 
noncovalent O 
forces O 
is O 
increasingly O 
being O 
used O 
to O 
generate O 
functional O 
structures O 
and O 
materials O 
for O 
electronic O 
, O 
catalytic O 
, O 
and O 
biomedical O 
applications O 
. O 
The O 
greatest O 
control O 
over O 
the O 
geometry O 
in O 
H B-FORMULA 
-bond O 
supramolecular O 
architectures O 
, O 
especially O 
in O 
H B-FORMULA 
-bonded O 
supramolecular O 
polymers O 
, O 
can O 
be O 
achieved O 
by O 
exploiting O 
the O 
rich O 
programmability O 
of O 
artificial O 
nucleobases B-FAMILY 
undergoing O 
self O 
- O 
assembly O 
through O 
strong O 
H B-FORMULA 
bonds O 
. O 
Here O 
N(3)-functionalized O 
xanthine B-TRIVIAL 
modules O 
are O 
described O 
, O 
which O 
are O 
capable O 
of O 
self O 
- O 
associating O 
through O 
self O 
- O 
complementary O 
H B-FORMULA 
-bonding O 
patterns O 
to O 
form O 
H B-FORMULA 
-bonded O 
supramolecular O 
ribbons O 
. O 
The O 
self O 
- O 
association O 
of O 
xanthines B-FAMILY 
through O 
directional O 
H B-FORMULA 
bonding O 
between O 
neighboring O 
molecules O 
allows O 
the O 
controlled O 
generation O 
of O 
highly O 
compact O 
1D O 
supramolecular O 
polymeric O 
ribbons O 
on O 
graphite B-TRIVIAL 
. O 
These O 
architectures O 
have O 
been O 
characterized O 
by O 
scanning O 
tunneling O 
microscopy O 
at O 
the O 
solid O 
- O 
liquid O 
interface O 
, O 
corroborated O 
by O 
dispersion O 
- O 
corrected O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
studies O 
and O 
X-ray O 
diffraction O 
. O 

and O 
quantum O 
chemical O 
studies O 
of O 
new O 
4-aminoquinazoline B-SYSTEMATIC 
derivatives O 
as O 
Aurora O 
A O 
/ O 
B O 
kinase O 
inhibitors O 
. O 

novel O 
4-aminoquinazoline B-SYSTEMATIC 
derivatives O 
were O 
designed O 
and O 
synthesized O 
. O 
Biochemical O 
and O 
cellular O 
analyses O 
demonstrated O 
that O 
most O 
of O 
the O 
derivatives O 
exhibited O 
a O 
strong O 
activity O 
to O 
inhibit O 
Aurora O 
A O 
and O 
B O 
kinases O 
and O 
to O 
suppress O 
the O 
proliferation O 
of O 
a O 
panel O 
of O 
human O 
tumor O 
cell O 
lines O 
( O 
U937 O 
, O 
K562 O 
, O 
A549 O 
, O 
LoVo O 
, O 
and O 
HT29 O 
) O 
. O 
Quantum O 
chemical O 
studies O 
were O 
also O 
carried O 
out O 
to O 
determine O 
the O 
structural O 
features O 
of O 
these O 
compounds O 
engaged O 
in O 
the O 
inhibition O 
of O 
Aurora O 
kinases O 
. O 

action O 
of O 
ethanolic O 
extract O 
of O 
Rosmarinus O 
officinalis O 
L O 
. O 
in O 
gastric O 
ulcer O 
prevention O 
induced O 
by O 
ethanol B-SYSTEMATIC 
in O 
rats O 
. O 

pathology O 
of O 
a O 
gastric O 
ulcer O 
is O 
complex O 
and O 
multifactorial O 
. O 
Gastric O 
ulcers O 
affect O 
many O 
people O 
around O 
the O 
world O 
and O 
its O 
development O 
is O 
a O 
result O 
of O 
the O 
imbalance O 
between O 
aggressive O 
and O 
protective O 
factors O 
in O 
the O 
gastric O 
mucosa O 
. O 
In O 
this O 
study O 
, O 
we O 
evaluated O 
the O 
ethanolic O 
extract O 
of O 
Rosmarinus O 
officinalis O 
L O 
. O 
( O 
eeRo O 
) O 
; O 
this O 
plant O 
, O 
more O 
commonly O 
known O 
as O 
rosemary O 
, O 
has O 
attracted O 
the O 
interest O 
of O 
the O 
scientific O 
community O 
due O 
to O 
its O 
numerous O 
pharmacological O 
properties O 
and O 
their O 
potential O 
therapeutic O 
applications O 
. O 
Here O 
, O 
we O 
tested O 
the O 
preventive O 
effects O 
of O 
eeRo O 
against O 
gastric O 
ulcer O 
induced O 
by O 
70% O 
ethanol B-SYSTEMATIC 
in O 
male O 
Wistar O 
rats O 
. O 
In O 
addition O 
, O 
we O 
aimed O 
to O 
clarify O 
the O 
mechanism O 
involved O 
in O 
the O 
preventive O 
action O 
of O 
the O 
eeRo O 
in O 
gastric O 
ulcers O 
. O 
Based O 
on O 
the O 
analysis O 
of O 
markers O 
of O 
oxidative O 
damage O 
and O 
enzymatic O 
antioxidant O 
defense O 
systems O 
, O 
the O 
measurement O 
of O 
nitrite B-SYSTEMATIC 
and O 
nitrate B-SYSTEMATIC 
levels O 
and O 
the O 
assessment O 
of O 
the O 
inflammatory O 
response O 
, O 
the O 
eeRo O 
exhibited O 
significant O 
antioxidant O 
, O 
vasodilator O 
and O 
antiinflammatory O 
properties O 
. O 

of O 
the O 
flavonoid B-FAMILY 
fraction O 
from O 
Rosa O 
laevigata O 
Michx O 
fruit O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-induced O 
acute O 
liver O 
injury O 
in O 
mice O 
. O 

effect O 
of O 
the O 
total O 
flavonoids B-FAMILY 
( O 
TFs O 
) O 
from O 
Rosa O 
laevigata O 
Michx O 
fruit O 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl4 B-FORMULA 
)-induced O 
hepatotoxicity O 
in O 
mice O 
was O 
investigated O 
. O 
Pretreatment O 
with O 
TFs O 
significantly O 
decreased O 
CCl4 B-FORMULA 
-induced O 
elevation O 
of O 
serum O 
aspartate B-TRIVIAL 
transaminase O 
( O 
AST O 
) O 
and O 
alanine B-TRIVIAL 
transaminase O 
( O 
ALT O 
) O 
activities O 
as O 
well O 
as O 
the O 
relative O 
liver O 
weight O 
. O 
Histopathological O 
observation O 
also O 
revealed O 
that O 
TFs O 
reduced O 
the O 
incidence O 
of O 
liver O 
lesions O 
and O 
improved O 
hepatocyte O 
abnormality O 
. O 
Moreover O 
, O 
oral O 
administration O 
of O 
TFs O 
significantly O 
enhanced O 
antioxidant O 
enzyme O 
activities O 
( O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
) O 
, O 
increased O 
the O 
content O 
of O 
glutathione B-TRIVIAL 
and O 
decreased O 
the O 
content O 
of O 
malondialdehyde B-TRIVIAL 
. O 
Further O 
research O 
indicated O 
that O 
TFs O 
prevented O 
the O 
DNA O 
fragmentation O 
and O 
mitochondrial O 
ultrastructural O 
alterations O 
caused O 
by O 
CCl4 B-FORMULA 
based O 
on O 
TUNEL O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
assays O 
. O 
Moreover O 
, O 
pretreatment O 
with O 
TFs O 
down O 
- O 
regulated O 
the O 
protein O 
expressions O 
of O 
CYP2E1 O 
, O 
iNOS O 
, O 
NF-κB O 
, O 
Bak O 
and O 
Caspase-3 O 
. O 
Quantitative O 
Real O 
- O 
time O 
PCR O 
assay O 
suggested O 
that O 
TFs O 
markedly O 
decreased O 
the O 
levels O 
of O 
TNF-α O 
, O 
Fas O 
/ O 
FasL O 
and O 
Bax O 
gene O 
expressions O 
, O 
and O 
increased O 
the O 
level O 
of O 
Bcl-2 O 
. O 
This O 
is O 
the O 
first O 
time O 
to O 
report O 
the O 
significant O 
hepatoprotective O 
effect O 
of O 
TFs O 
from O 
R O 
. O 
laevigata O 
Michx O 
fruit O 
against O 
CCl4 B-FORMULA 
-induced O 
liver O 
injury O 
in O 
mice O 
and O 
the O 
action O 
should O 
be O 
through O 
reducing O 
oxidative O 
stress O 
and O 
suppressing O 
inflammation O 
and O 
apoptosis O 
. O 

study O 
aimed O 
to O 
assess O 
whether O 
maifanite O 
can O 
improve O 
the O 
learning O 
and O 
memory O 
, O 
and O 
antioxidant O 
abilities O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
rats O 
. O 
The O 
70 O 
rats O 
were O 
divided O 
into O 
seven O 
groups O 
: O 
[ O 
A O 
] O 
normal O 
control O 
group O 
, O 
[ O 
B O 
] O 
AD O 
model O 
group O 
, O 
[ O 
C O 
] O 
sham O 
group O 
, O 
[ O 
D O 
] O 
positive O 
control O 
group O 
( O 
donepezil B-TRIVIAL 
) O 
, O 
[ O 
E O 
] O 
low O 
- O 
dose O 
maifanite O 
group O 
, O 
[ O 
F O 
] O 
middle O 
- O 
dose O 
maifanite O 
group O 
, O 
[ O 
G O 
] O 
high O 
- O 
dose O 
maifanite O 
group O 
. O 
For O 
[ O 
B O 
] O 
, O 
[ O 
D O 
] O 
, O 
[ O 
E O 
] O 
, O 
[ O 
F O 
] O 
, O 
and O 
[ O 
G O 
] O 
groups O 
, O 
Aβ(25-35) O 
ventricle O 
injection O 
was O 
carried O 
out O 
, O 
then O 
respective O 
medicine O 
were O 
administered O 
once O 
a O 
day O 
for O 
60 O 
consecutive O 
days O 
. O 
The O 
step O 
- O 
down O 
and O 
step O 
- O 
through O 
test O 
were O 
used O 
to O 
measure O 
learning O 
and O 
memory O 
ability O 
. O 
The O 
hippocampus O 
levels O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
, O 
and O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
were O 
assayed O 
. O 
The O 
hippocampus O 
contents O 
of O 
Al B-FORMULA 
, O 
Fe B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
, O 
Se B-FORMULA 
, O 
and O 
Mn B-FORMULA 
were O 
analyzed O 
by O 
inductively O 
coupled O 
plasma O 
- O 
atomic O 
emission O 
spectrometer O 
. O 
Maifanite O 
decreased O 
the O 
acquisition O 
errors O 
and O 
the O 
retention O 
errors O 
while O 
prolonging O 
the O 
step O 
- O 
down O 
latency O 
, O 
and O 
decreased O 
the O 
number O 
of O 
electric O 
shocks O 
while O 
prolonging O 
the O 
first O 
latency O 
of O 
AD O 
rats O 
. O 
Aβ(25-35) O 
ventricle O 
injection O 
initiated O 
the O 
decrease O 
of O 
SOD O 
and O 
GSH B-ABBREVIATION 
-Px O 
activities O 
and O 
the O 
increase O 
of O 
MDA B-ABBREVIATION 
content O 
, O 
and O 
triggered O 
the O 
rise O 
of O 
Al B-FORMULA 
, O 
Fe B-FORMULA 
, O 
and O 
Cu B-FORMULA 
levels O 
and O 
the O 
decline O 
of O 
Mn B-FORMULA 
, O 
Zn B-FORMULA 
, O 
and O 
Se B-FORMULA 
levels O 
. O 
The O 
SOD O 
and O 
GSH B-ABBREVIATION 
-Px O 
activities O 
were O 
enhanced O 
followed O 
by O 
reduced O 
MDA B-ABBREVIATION 
level O 
, O 
and O 
the O 
levels O 
of O 
Mn B-FORMULA 
, O 
Zn B-FORMULA 
, O 
and O 
Se B-FORMULA 
increased O 
accompanied O 
by O 
Al B-FORMULA 
, O 
Fe B-FORMULA 
, O 
and O 
Cu B-FORMULA 
decreased O 
in O 
the O 
maifanite O 
treat O 
groups O 
. O 
Maifanite O 
could O 
improve O 
the O 
learning O 
and O 
memory O 
, O 
and O 
the O 
antioxidant O 
abilities O 
of O 
AD O 
rats O 
. O 
Maifanite O 
had O 
the O 
potential O 
prevention O 
and O 
treatment O 
for O 
AD O 
. O 

therapy O 
( O 
SDT O 
) O 
has O 
shown O 
great O 
potential O 
in O 
target O 
cancer O 
therapy O 
, O 
but O 
it O 
induced O 
cell O 
death O 
modes O 
has O 
not O 
been O 
fully O 
investigated O 
. O 
This O 
study O 
was O 
to O 
examine O 
autophagic O 
and O 
apoptotic O 
responses O 
to O 
protoporphyrin B-TRIVIAL 
IX I-TRIVIAL 
( O 
PpIX B-ABBREVIATION 
) O 
mediated O 
SDT O 
in O 
murine O 
leukemia O 
L1210 O 
cells O 
. O 
After O 
SDT O 
, O 
the O 
occurrence O 
of O 
autophagy O 
was O 
identified O 
by O 
morphological O 
observation O 
and O 
biochemical O 
analysis O 
. O 
Meanwhile O 
, O 
the O 
mitochondria O 
dependent O 
apoptosis O 
pathway O 
was O 
examined O 
to O 
participate O 
in O 
SDT O 
induced O 
cell O 
death O 
. O 
The O 
relationship O 
between O 
autophagy O 
and O 
apoptosis O 
was O 
further O 
investigated O 
by O 
applying O 
pharmacological O 
inhibition O 
studies O 
, O 
which O 
indicated O 
that O 
impairment O 
of O 
autophagy O 
enhanced O 
the O 
anti-tumor O 
effect O 
of O 
SDT O 
through O 
induction O 
of O 
apoptosis O 
and O 
necrosis O 
, O 
while O 
caspase O 
inhibition O 
did O 
not O 
affect O 
autophagic O 
vacuoles O 
formation O 
or O 
protect O 
SDT O 
induced O 
cytotoxicity O 
. O 
The O 
findings O 
supported O 
that O 
autophagic O 
vacuoles O 
formed O 
upstream O 
and O 
independently O 
from O 
caspase O 
- O 
dependent O 
cell O 
death O 
. O 
Additionally O 
, O 
the O 
possible O 
mechanism O 
of O 
SDT-induced O 
autophagy O 
was O 
evaluated O 
by O 
measurement O 
of O 
ROS O 
( O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
) O 
formation O 
. O 
Result O 
suggested O 
ROS O 
play O 
important O 
role O 
in O 
initiating O 
autophagy O 
, O 
possibly O 
through O 
the O 
sono O 
- O 
damaged O 
mitochondria O 
being O 
enclosed O 
by O 
autophagic O 
vacuoles O 
. O 
All O 
together O 
, O 
these O 
data O 
indicate O 
that O 
autophagy O 
may O 
be O 
cytoprotective O 
in O 
our O 
experimental O 
system O 
, O 
and O 
point O 
to O 
an O 
important O 
insight O 
into O 
how O 
autophagy O 
inhibitors O 
, O 
in O 
combination O 
with O 
SDT O 
may O 
contribute O 
a O 
regimen O 
for O 
cancer O 
therapy O 
. O 

of O 
impaired O 
health O 
in O 
yellow O 
perch O 
( O 
Perca O 
flavescens O 
) O 
from O 
a O 
biological O 
mercury B-SYSTEMATIC 
hotspot O 
in O 
northeastern O 
North O 
America O 
. O 

studies O 
have O 
investigated O 
the O 
effects O 
of O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
on O 
wild O 
fish O 
from O 
remote O 
areas O 
, O 
even O 
though O 
these O 
fish O 
can O 
have O 
high O 
total O 
Hg B-FORMULA 
concentrations O 
. O 
In O 
Kejimkujik O 
National O 
Park O 
and O 
National O 
Historic O 
Site O 
( O 
KNPNHS O 
) O 
, O 
Nova O 
Scotia O 
, O 
Canada O 
, O 
concentrations O 
of O 
total O 
Hg B-FORMULA 
in O 
many O 
yellow O 
perch O 
( O 
Perca O 
flavescens O 
) O 
currently O 
exceed O 
the O 
estimated O 
threshold O 
level O 
for O 
adverse O 
effects O 
in O 
fish O 
( O 
0.2 O 
µg O 
Hg B-FORMULA 
g(-1) O 
( O 
wet O 
wt O 
) O 
, O 
whole O 
body O 
) O 
. O 
To O 
determine O 
whether O 
Hg B-FORMULA 
exposure O 
is O 
adversely O 
affecting O 
the O 
general O 
health O 
of O 
these O 
fish O 
, O 
the O 
authors O 
collected O 
male O 
and O 
female O 
perch O 
in O 
the O 
fall O 
of O 
2009 O 
and O 
2010 O 
from O 
12 O 
lakes O 
within O 
KNPNHS O 
. O 
The O 
health O 
endpoints O 
condition O 
, O 
liver O 
somatic O 
index O 
( O 
LSI O 
) O 
, O 
and O 
macrophage O 
aggregates O 
( O 
MAs O 
; O 
indicators O 
of O 
oxidative O 
stress O 
and O 
tissue O 
damage O 
) O 
in O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
spleen O 
were O 
examined O 
, O 
and O 
in O 
female O 
perch O 
were O 
compared O 
between O 
lakes O 
and O 
related O 
to O 
Hg B-FORMULA 
concentrations O 
measured O 
in O 
the O 
muscle O 
and O 
liver O 
tissue O 
. O 
No O 
negative O 
relationships O 
between O 
fish O 
condition O 
or O 
LSI O 
and O 
Hg B-FORMULA 
were O 
found O 
. O 
However O 
, O 
within O 
the O 
liver O 
, O 
kidney O 
, O 
and O 
spleen O 
tissues O 
of O 
females O 
, O 
the O 
relative O 
area O 
occupied O 
by O 
MAs O 
was O 
positively O 
related O 
to O 
both O 
muscle O 
and O 
liver O 
Hg B-FORMULA 
concentrations O 
, O 
indicating O 
the O 
health O 
of O 
these O 
perch O 
was O 
adversely O 
affected O 
at O 
the O 
cellular O 
level O 
. O 
These O 
findings O 
raise O 
concerns O 
for O 
the O 
health O 
of O 
these O 
perch O 
as O 
well O 
as O 
for O 
other O 
wild O 
fish O 
populations O 
known O 
to O 
have O 
similarly O 
elevated O 
Hg B-FORMULA 
concentrations O 
. O 

U.S O 
. O 
Environmental O 
Protection O 
Agency O 
laboratory O 
tests O 
are O 
used O 
to O 
monitor O 
water O 
column O 
toxicity O 
in O 
U.S O 
. O 
surface O 
waters O 
. O 
The O 
water O 
flea O 
Ceriodaphnia O 
dubia O 
is O 
among O 
the O 
most O 
sensitive O 
test O 
species O 
for O 
detecting O 
insecticide O 
toxicity O 
in O 
freshwater O 
environments.Its O 
usefulness O 
is O 
limited O 
, O 
however O 
, O 
when O 
water O 
conductivity O 
exceeds O 
2000 O 
µS O 
/ O 
cm O 
( O 
approximately O 
1 O 
ppt O 
salinity O 
) O 
and O 
test O 
effectiveness O 
is O 
insufficient O 
. O 
Water O 
column O 
toxicity O 
tests O 
using O 
the O 
euryhaline O 
amphipod O 
Hyalella O 
azteca O 
could O 
complement O 
C O 
. O 
dubia O 
tests O 
; O 
however O 
, O 
standard O 
chronic O 
protocols O 
do O 
not O 
exist O 
. O 
The O 
present O 
study O 
compares O 
the O 
effectiveness O 
of O 
two O 
water O 
column O 
toxicity O 
tests O 
in O 
detecting O 
the O 
toxicity O 
of O 
two O 
organophosphate B-FAMILY 
( O 
OP O 
) O 
and O 
two O 
pyrethroid B-FAMILY 
insecticides O 
: O 
the O 
short O 
- O 
term O 
chronic O 
C O 
. O 
dubia O 
test O 
, O 
which O 
measures O 
mortality O 
and O 
fecundity O 
, O 
and O 
a O 
10-d O 
H O 
. O 
azteca O 
test O 
, O 
which O 
measures O 
mortality O 
and O 
growth O 
. O 
Sensitivity O 
was O 
evaluated O 
by O 
comparing O 
effect O 
data O 
, O 
and O 
end O 
point O 
variability O 
was O 
evaluated O 
by O 
comparing O 
minimum O 
significant O 
differences O 
. O 
Tests O 
were O 
performed O 
in O 
synthetic O 
water O 
and O 
filtered O 
ambient O 
water O 
to O 
quantify O 
the O 
influence O 
of O 
water O 
matrix O 
on O 
effect O 
concentrations O 
. O 
The O 
H O 
. O 
azteca O 
test O 
detected O 
pyrethroid B-FAMILY 
toxicity O 
far O 
more O 
effectively O 
, O 
while O 
the O 
C O 
. O 
dubia O 
test O 
was O 
more O 
sensitive O 
to O 
OPs O 
. O 
Among O 
endpoints O 
, O 
H O 
. O 
azteca O 
mortality O 
was O 
most O 
robust O 
. O 
The O 
results O 
demonstrate O 
that O 
the O 
H O 
. O 
azteca O 
test O 
is O 
preferable O 
when O 
conductivity O 
of O 
water O 
samples O 
is O 
2000 O 
to O 
10000 O 
µS O 
/ O 
cm O 
or O 
if O 
contaminants O 
of O 
concern O 
include O 
pyrethroid B-FAMILY 
insecticides O 
. O 

impact O 
of O 
structure O 
on O 
oxidatively O 
generated O 
DNA O 
damage O 
products O 
resulting O 
from O 
the O 
C3'-thymidinyl B-SYSTEMATIC 
radical O 
. O 

the O 
damage O 
? O 
Trapping O 
the O 
C3'-thymidinyl B-SYSTEMATIC 
radical O 
in O 
biologically O 
significant O 
architectures O 
delivers O 
both O 
the O 
repaired O 
oligomer O 
and O 
1-(2'-deoxy-β-D-threo-pentofuranosyl)thymidine B-SYSTEMATIC 
-containing O 
substrates O 
. O 
The O 
stereoselectivity O 
of O 
the O 
reduction O 
was O 
found O 
to O 
be O 
dependent O 
upon O 
the O 
DNA O 
structure O 
. O 

investigate O 
the O 
quantum O 
- O 
mechanical O 
delocalization O 
of O 
hydrogen B-SYSTEMATIC 
in O 
rotational O 
symmetric O 
molecular O 
systems O 
. O 
To O 
this O 
purpose O 
, O 
we O 
perform O 
ab O 
initio O 
path O 
integral O 
molecular O 
dynamics O 
simulations O 
of O 
a O 
methanol B-SYSTEMATIC 
molecule O 
to O 
characterize O 
the O 
quantum O 
properties O 
of O 
hydrogen B-SYSTEMATIC 
atoms O 
in O 
a O 
representative O 
system O 
by O 
means O 
of O 
their O 
real O 
- O 
space O 
and O 
momentum O 
- O 
space O 
densities O 
. O 
In O 
particular O 
, O 
we O 
compute O 
the O 
spherically O 
averaged O 
momentum O 
distribution O 
n(k) O 
and O 
the O 
pseudoangular O 
momentum O 
distribution O 
n(kθ) O 
. O 
We O 
interpret O 
our O 
results O 
by O 
comparing O 
them O 
to O 
path O 
integral O 
samplings O 
of O 
a O 
bare O 
proton O 
in O 
an O 
ideal O 
torus O 
potential O 
. O 
We O 
find O 
that O 
the O 
hydroxyl B-SYSTEMATIC 
hydrogen I-SYSTEMATIC 
exhibits O 
a O 
toroidal O 
delocalization O 
, O 
which O 
leads O 
to O 
characteristic O 
fingerprints O 
in O 
the O 
line O 
shapes O 
of O 
the O 
momentum O 
distributions O 
. O 
We O 
can O 
describe O 
these O 
specific O 
spectroscopic O 
patterns O 
quantitatively O 
and O 
compute O 
their O 
onset O 
as O 
a O 
function O 
of O 
temperature O 
and O 
potential O 
energy O 
landscape O 
. O 
The O 
delocalization O 
patterns O 
in O 
the O 
projected O 
momentum O 
distribution O 
provide O 
a O 
promising O 
computational O 
tool O 
to O 
address O 
the O 
intriguing O 
phenomenon O 
of O 
quantum O 
delocalization O 
in O 
condensed O 
matter O 
and O 
its O 
spectroscopic O 
characterization O 
. O 
As O 
the O 
momentum O 
distribution O 
n(k) O 
is O 
also O 
accessible O 
through O 
Nuclear O 
Compton O 
Scattering O 
experiments O 
, O 
our O 
results O 
will O 
help O 
to O 
interpret O 
and O 
understand O 
future O 
measurements O 
more O 
thoroughly O 
. O 

deposition O 
of O 
CdSe B-FORMULA 
/ O 
ZnS B-FORMULA 
quantum O 
dots O 
for O 
light O 
- O 
emitting O 
devices O 
. O 

electrophoretic O 
deposition O 
of O 
thin O 
films O 
of O 
colloidal O 
quantum O 
dots O 
is O 
an O 
alternative O 
to O 
spin O 
- O 
casting O 
and O 
printing O 
for O 
large O 
- O 
area O 
, O 
high O 
- O 
throughput O 
processing O 
of O 
quantum O 
- O 
dot O 
( O 
QD O 
) O 
optoelectronics O 
. O 
In O 
this O 
study O 
, O 
QD O 
light O 
- O 
emitting O 
diodes O 
( O 
QD-LEDs O 
) O 
fabricated O 
with O 
electrophoretically O 
deposited O 
films O 
of O 
CdSe B-FORMULA 
/ O 
ZnS B-FORMULA 
core O 
/ O 
shell O 
QDs O 
are O 
demonstrated O 
for O 
the O 
first O 
time O 
. O 

and O 
biological O 
evaluation O 
of O 
diaryl B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
carboranes I-FAMILY 
as O 
inhibitors O 
of O 
hypoxia O 
inducible O 
factor O 
(HIF)-1 O 
transcriptional O 
activity O 
. O 

- I-MULTIPLE 
substituted I-MULTIPLE 
ortho- I-MULTIPLE 
and I-MULTIPLE 
meta-carboranes I-MULTIPLE 
were O 
synthesized O 
as O 
mimics O 
of O 
manassantin B-TRIVIAL 
A I-TRIVIAL 
. O 
Among O 
the O 
carboranes B-FAMILY 
synthesized O 
, O 
compounds O 
1 O 
and O 
2 O 
showed O 
significant O 
inhibition O 
of O 
hypoxia O 
- O 
induced O 
HIF-1 O 
transcriptional O 
activity O 
, O 
with O 
IC(50) O 
values O 
of O 
3.2 O 
and O 
2.2 O 
μM O 
, O 
respectively O 
. O 
Compounds O 
1 O 
and O 
2 O 
similarly O 
suppressed O 
hypoxia O 
- O 
induced O 
HIF-1α O 
accumulation O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
without O 
affecting O 
the O 
expression O 
level O 
of O 
HIF-1α O 
mRNA O 
. O 
The O 
hypoxia O 
- O 
induced O 
accumulation O 
and O 
translocation O 
of O 
HIF-1α O 
into O 
nuclei O 
were O 
not O 
observed O 
in O 
HeLa O 
cells O 
treated O 
with O 
compounds O 
1 O 
and O 
2 O 
by O 
immunofluorescence O 
analysis O 
, O 
revealing O 
that O 
the O 
inhibition O 
of O 
hypoxia O 
- O 
induced O 
HIF-1 O 
transcriptional O 
activity O 
is O 
induced O 
by O 
compounds O 
1 O 
and O 
2 O 
through O 
a O 
degradation O 
pathway O 
of O 
the O 
HIF-1α O 
protein O 
under O 
hypoxic O 
conditions O 
. O 

(IV) I-FAMILY 
benzoates I-FAMILY 
: O 
inhibition O 
of O 
thioredoxin O 
reductase O 
, O 
tumor O 
cell O 
growth O 
inhibition O 
, O 
and O 
interactions O 
with O 
proteins O 
. O 

reductase O 
( O 
TrxR O 
) O 
is O 
overexpressed O 
in O 
cancer O 
cells O 
and O 
is O 
therefore O 
a O 
putative O 
cancer O 
target O 
. O 
Inhibition O 
of O 
this O 
enzyme O 
is O 
considered O 
an O 
important O 
strategy O 
for O 
the O 
development O 
of O 
new O 
chemotherapeutic O 
agents O 
with O 
a O 
specific O 
mechanism O 
of O 
action O 
. O 
Organotin B-FAMILY 
compounds O 
have O 
been O 
described O 
as O 
experimental O 
antitumor O 
agents O 
, O 
yet O 
their O 
mechanism O 
of O 
action O 
remains O 
largely O 
unknown O 
. O 
Based O 
on O 
the O 
outcome O 
of O 
a O 
virtual O 
screening O 
study O 
, O 
various O 
di- B-MULTIPLE 
and I-MULTIPLE 
tri-n-butyltin I-MULTIPLE 
(IV) I-MULTIPLE 
carboxylates I-MULTIPLE 
were O 
synthesized O 
, O 
and O 
their O 
biological O 
properties O 
were O 
evaluated O 
. O 
All O 
synthesized O 
compounds O 
were O 
able O 
to O 
inhibit O 
TrxR O 
selectively O 
within O 
the O 
micromolar O 
range O 
and O 
showed O 
potent O 
antitumor O 
activity O 
against O 
HT-29 O 
and O 
MCF-7 O 
cancer O 
cell O 
lines O 
. O 
Moreover O 
, O 
tin B-SYSTEMATIC 
(IV) I-SYSTEMATIC 
organometallics O 
were O 
found O 
to O 
strongly O 
induce O 
apoptosis O 
in O 
the O 
BJAB O 
lymphoma O 
cell O 
line O 
. O 
Mass O 
spectrometry O 
and O 
atomic O 
absorption O 
spectroscopy O 
experiments O 
revealed O 
metal O 
binding O 
to O 
proteins O 
, O 
and O 
efficient O 
cellular O 
uptake O 
was O 
observed O 
using O 
a O 
di-n-butyltin B-SYSTEMATIC 
(IV) I-SYSTEMATIC 
complex O 
as O 
an O 
example O 
. O 

metallic O 
cells O 
: O 
design O 
of O 
uniformly O 
sized O 
hollow O 
mesoporous O 
pt B-FORMULA 
- O 
ru B-FORMULA 
particles O 
with O 
tunable O 
shell O 
thicknesses O 
. O 

new O 
class O 
of O 
hollow O 
mesoporous O 
Pt B-FORMULA 
- O 
Ru B-FORMULA 
and O 
Pt B-FORMULA 
particles O 
with O 
uniform O 
size O 
, O 
named O 
' O 
mesoporous O 
metallic O 
cells O 
' O 
, O 
are O 
synthesized O 
through O 
a O 
dual O 
- O 
templating O 
approach O 
using O 
colloidal O 
silica B-TRIVIAL 
particles O 
and O 
non-ionic O 
surfactants O 
. O 
To O 
realize O 
the O 
full O 
potential O 
of O 
mesoporous O 
metals O 
as O 
electrocatalysts O 
, O 
the O 
shell O 
thicknesses O 
, O 
compositions O 
, O 
and O 
hollow O 
cavity O 
sizes O 
are O 
precisely O 
controlled O 
. O 

of O 
hybrid O 
diesel O 
fuel O 
precursors O 
from O 
carbohydrates B-FAMILY 
and O 
petrochemicals O 
using O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
reactive O 
solvent O 
. O 

report O 
the O 
one O 
- O 
pot O 
alkylation O 
of O 
mesitylene B-TRIVIAL 
with O 
carbohydrate B-FAMILY 
-derived O 
5-(hydroxymethyl)furfural B-SYSTEMATIC 
( O 
HMF B-ABBREVIATION 
) O 
as O 
a O 
step O 
toward O 
diesel O 
- O 
range O 
liquids O 
. O 
Using O 
FeCl(3) B-FORMULA 
as O 
a O 
catalyst O 
, O 
HMF B-ABBREVIATION 
is O 
shown O 
to O 
alkylate O 
toluene B-TRIVIAL 
, O 
xylene B-FAMILY 
, O 
and O 
mesitylene B-TRIVIAL 
in O 
high O 
yields O 
in O 
CH(2)Cl(2) B-FORMULA 
and O 
MeNO(2) B-FORMULA 
solvents O 
. O 
Efforts O 
to O 
extend O 
this O 
reaction O 
to O 
greener O 
or O 
safer O 
solvents O 
showed O 
that O 
most O 
ether B-SYSTEMATIC 
-based O 
solvents O 
are O 
unsatisfactory O 
. O 
Acid O 
catalysts O 
( O 
e.g O 
, O 
p-TsOH B-FORMULA 
) O 
also O 
proved O 
to O 
be O 
ineffective O 
. O 
Using O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
a O 
reactive O 
solvent O 
, O 
mesitylene B-TRIVIAL 
could O 
be O 
alkylated O 
to O 
give O 
mesitylmethylfurfural B-SYSTEMATIC 
( O 
MMF B-ABBREVIATION 
) O 
starting O 
from O 
fructose B-TRIVIAL 
with O 
yields O 
up O 
to O 
approximately O 
70 O 
% O 
. O 
The O 
reaction O 
of O 
fructose B-TRIVIAL 
with O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
the O 
absence O 
of O 
mesitylene B-TRIVIAL 
gave O 
rise O 
to O 
low O 
yields O 
of O 
the O 
formate B-SYSTEMATIC 
ester I-SYSTEMATIC 
of O 
HMF B-ABBREVIATION 
, O 
which O 
indicates O 
the O 
stabilizing O 
effect O 
of O 
replacing O 
the O 
hydroxyl B-SYSTEMATIC 
substituent O 
with O 
mesityl B-TRIVIAL 
. O 
The O 
arene B-FAMILY 
also O 
serves O 
as O 
a O 
second O 
phase O 
into O 
which O 
the O 
product O 
is O 
extracted O 
. O 
Even O 
by O 
using O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
the O 
mesitylation O 
of O 
less O 
expensive O 
precursors O 
such O 
as O 
glucose B-TRIVIAL 
and O 
cellulose O 
proceeded O 
only O 
in O 
modest O 
yields O 
( O 
ca O 
. O 
20 O 
% O 
) O 
. O 
These O 
simpler O 
substrates O 
were O 
found O 
to O 
undergo O 
mesitylation O 
by O 
using O 
hydrogen B-SYSTEMATIC 
chloride I-SYSTEMATIC 
/ O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
via O 
the O 
intermediate O 
chloromethylfurfural B-SYSTEMATIC 
. O 

inhibit O 
viral O 
infection O 
. O 

- O 
soluble O 
glycofullerenes O 
based O 
on O 
a O 
hexakis B-TRIVIAL 
- I-TRIVIAL 
adduct I-TRIVIAL 
of I-TRIVIAL 
[60]fullerene I-TRIVIAL 
with O 
an O 
octahedral O 
addition O 
pattern O 
are O 
very O 
attractive O 
compounds O 
providing O 
a O 
spherical O 
presentation O 
of O 
carbohydrates B-FAMILY 
. O 
These O 
tools O 
have O 
been O 
recently O 
described O 
and O 
they O 
have O 
been O 
used O 
to O 
interact O 
with O 
lectins O 
in O 
a O 
multivalent O 
manner O 
. O 
Here O 
, O 
we O 
present O 
the O 
use O 
of O 
these O 
glycofullerenes B-FAMILY 
, O 
including O 
new O 
members O 
with O 
36 O 
mannoses B-FAMILY 
, O 
as O 
compounds O 
able O 
to O 
inhibit O 
a O 
DC-SIGN-dependent O 
cell O 
infection O 
by O 
pseudotyped O 
viral O 
particles O 
. O 
The O 
results O 
obtained O 
in O 
these O 
experiments O 
demonstrate O 
for O 
the O 
first O 
time O 
that O 
these O 
glycoconjugates O 
are O 
adequate O 
to O 
inhibit O 
efficiently O 
an O 
infection O 
process O 
, O 
and O 
therefore O 
, O 
they O 
can O 
be O 
considered O 
as O 
very O 
promising O 
and O 
interesting O 
tools O 
to O 
interfere O 
in O 
biological O 
events O 
where O 
lectins O 
such O 
as O 
DC-SIGN O 
are O 
involved O 
. O 

new O 
ent-3,4-seco- B-FAMILY 
labdane I-FAMILY 
diterpenoids I-FAMILY 
from O 
Callicarpa O 
nudiflora O 
. O 

new O 
ent-3,4-seco- B-FAMILY 
labdane I-FAMILY 
diterpenoids I-FAMILY 
, O 
methylcallicarpate B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
callicarpic B-TRIVIAL 
acid I-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Callicarpa O 
nudiflora O 
Hook O 
et O 
Arn O 
. O 
Their O 
structures O 
and O 
relative O 
configurations O 
were O 
established O 
by O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
Their O 
absolute O 
configurations O 
were O 
assigned O 
by O 
the O 
application O 
of O 
the O 
CD O 
technique O 
for O 
the O 
first O 
time O 
among O 
the O 
ent-3,4-seco- B-SYSTEMATIC 
labdane I-SYSTEMATIC 
-type O 
diterpenes B-FAMILY 
. O 

acts O 
as O 
a O 
liver O 
X O 
receptor O 
agonist O 
. O 

is O 
one O 
of O 
the O 
active O 
ingredients O 
of O 
Paeonia O 
lactiflora O 
Pall O 
. O 
, O 
a O 
novel O 
traditional O 
herbal O 
medicine O 
exerting O 
pharmacological O 
effects O 
including O 
antihyperlipidemic O 
, O 
neuroprotective O 
, O 
and O 
anti-hepatofibrosis O 
effects O 
. O 
Liver O 
X O 
receptor O 
( O 
LXR O 
) O 
acts O 
as O 
a O 
ligand O 
- O 
activated O 
transcription O 
factor O 
to O 
exhibit O 
antihyperlipidemic O 
and O 
neuroprotective O 
effects O 
. O 
In O 
this O 
study O 
, O 
the O 
activity O 
of O 
paeoniflorin B-TRIVIAL 
against O 
LXR O 
was O 
evaluated O 
by O 
the O 
mammalian O 
one O 
- O 
hybrid O 
and O 
transient O 
transfection O 
reporter O 
assays O 
. O 
The O 
results O 
showed O 
that O 
paeoniflorin B-TRIVIAL 
transactivated O 
GAL4 O 
, O 
rat O 
cholesterol B-TRIVIAL 
7 O 
α-hydroxylase O 
, O 
phospholipid O 
transfer O 
protein O 
, O 
and O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
A1 O 
gene O 
promoters O 
in O 
dose O 
- O 
dependent O 
manner O 
. O 
Furthermore O 
, O 
the O 
docking O 
study O 
demonstrated O 
that O 
paeoniflorin B-TRIVIAL 
resided O 
in O 
the O 
LXR O 
ligand O 
- O 
binding O 
pocket O 
in O 
the O 
similar O 
manner O 
as O 
GSK B-IDENTIFIER 
3987 I-IDENTIFIER 
, O 
a O 
novel O 
LXR O 
agonist O 
. O 
These O 
results O 
indicated O 
that O 
paeoniflorin B-TRIVIAL 
might O 
exert O 
pharmacological O 
effects O 
through O 
LXR O 
pathway O 
. O 

wetting O 
behavior O 
of O 
superhydrophilic O 
polyelectrolyte O 
brushes O 
was O 
investigated O 
. O 
Reflection O 
interference O 
contrast O 
microscopy O 
demonstrated O 
that O 
the O 
contact O 
angles O 
of O 
water O 
on O 
the O 
polyelectrolyte O 
brushes O 
were O 
extremely O 
low O 
but O 
remained O 
finite O 
in O 
the O 
range O 
of O 
< O 
3° O 
. O 
The O 
presence O 
of O 
water O 
molecules O 
was O 
evident O 
, O 
even O 
outside O 
the O 
macroscopic O 
water O 
droplet O 
. O 
These O 
water O 
molecules O 
were O 
confined O 
to O 
the O 
thin O 
brush O 
layers O 
and O 
contained O 
a O 
highly O 
ordered O 
hydrogen B-SYSTEMATIC 
bond O 
network O 
, O 
which O 
was O 
identified O 
as O 
structural O 
water O 
. O 
The O 
presence O 
of O 
the O 
thin O 
film O 
and O 
the O 
structural O 
water O 
changed O 
the O 
surface O 
energies O 
, O 
which O 
prevented O 
the O 
complete O 
wetting O 
of O 
the O 
surface O 
. O 

and O 
development O 
of O 
multiple O 
emulsion O 
for O 
enhancement O 
of O 
oral O 
bioavailability O 
of O 
acyclovir B-TRIVIAL 
. O 

objective O 
of O 
this O 
investigation O 
was O 
to O 
design O 
and O 
develop O 
water O 
- O 
in O 
- O 
oil O 
- O 
in O 
- O 
water O 
type O 
multiple O 
emulsions O 
( O 
w O 
/ O 
o O 
/ O 
w O 
emulsions O 
) O 
entrapping O 
acyclovir B-TRIVIAL 
for O 
improving O 
its O 
oral O 
bioavailability O 
. O 
Multiple O 
emulsions O 
( O 
MEs O 
) O 
were O 
prepared O 
and O 
optimized O 
using O 
Span-80 B-TRIVIAL 
and O 
Span-83 B-TRIVIAL 
as O 
lipophilic O 
surfactant O 
and O 
Brij-35 B-TRIVIAL 
as O 
hydrophilic O 
surfactant O 
. O 
The O 
physio O 
- O 
chemical O 
properties O 
of O 
the O 
w O 
/ O 
o O 
/ O 
w O 
emulsions O 
- O 
particle O 
size O 
, O 
viscosity O 
, O 
phase O 
separation O 
( O 
centrifugation O 
test O 
) O 
and O 
entrapment O 
efficiency O 
were O 
measured O 
and O 
evaluated O 
along O 
with O 
macroscopic O 
and O 
microscopic O 
observations O 
to O 
confirm O 
multiple O 
nature O 
, O 
homogeneity O 
and O 
globule O 
size O 
. O 
Stability O 
study O 
, O 
in O 
vitro O 
and O 
ex O 
vivo O 
release O 
studies O 
were O 
performed O 
followed O 
by O 
in O 
vivo O 
studies O 
in O 
rats O 
. O 
Stable O 
w O 
/ O 
o O 
/ O 
w O 
emulsions O 
with O 
a O 
particle O 
size O 
of O 
33.098 O 
± O 
2.985 O 
µm O 
and O 
85.25 O 
± O 
4.865% O 
entrapment O 
efficiency O 
were O 
obtained O 
. O 
Stability O 
studies O 
showed O 
that O 
the O 
concentration O 
of O 
lipophilic O 
surfactant O 
was O 
very O 
important O 
for O 
stability O 
of O 
MEs O 
. O 
Drug O 
release O 
from O 
the O 
prepared O 
formulations O 
showed O 
initial O 
rapid O 
release O 
followed O 
by O 
a O 
much O 
slower O 
release O 
. O 
In O 
vivo O 
studies O 
in O 
rats O 
indicated O 
prolonged O 
release O 
and O 
better O 
oral O 
bioavailability O 
as O 
compared O 
to O 
drug O 
solution O 
. O 
The O 
overall O 
results O 
of O 
this O 
study O 
show O 
the O 
potential O 
of O 
the O 
w O 
/ O 
o O 
/ O 
w O 
emulsions O 
as O 
promising O 
drug O 
delivery O 
systems O 
for O 
acyclovir B-TRIVIAL 
. O 

studies O 
of O 
mixed O 
glass O 
former O 
0.35 O 
Na2O B-FORMULA 
+ O 
0.65 O 
[ B-FAMILY 
xB2O3 I-FAMILY 
+ I-FAMILY 
( I-FAMILY 
1 I-FAMILY 
- I-FAMILY 
x)P2O5 I-FAMILY 
] I-FAMILY 
glasses O 
by O 
Raman O 
and O 
11B B-FORMULA 
and O 
31P B-FORMULA 
magic O 
angle O 
spinning O 
nuclear O 
magnetic O 
resonance O 
spectroscopies O 
. O 

mixed O 
glass O 
former O 
( O 
MGF O 
) O 
effect O 
( O 
MGFE O 
) O 
is O 
defined O 
as O 
a O 
nonlinear O 
and O 
nonadditive O 
change O 
in O 
the O 
ionic O 
conductivity O 
with O 
changing O 
glass O 
former O 
composition O 
at O 
constant O 
modifier O 
composition O 
. O 
In O 
this O 
study O 
, O 
sodium B-SYSTEMATIC 
borophosphate I-SYSTEMATIC 
0.35 O 
Na(2)O B-FORMULA 
+ O 
0.65 O 
[ B-FAMILY 
xB(2)O(3) I-FAMILY 
+ I-FAMILY 
( I-FAMILY 
1 I-FAMILY 
- I-FAMILY 
x)P(2)O(5 I-FAMILY 
) I-FAMILY 
] I-FAMILY 
, O 
0 O 
≤ O 
x O 
≤ O 
1 O 
, O 
glasses O 
which O 
have O 
been O 
shown O 
to O 
exhibit O 
a O 
positive O 
MGFE O 
have O 
been O 
prepared O 
and O 
examined O 
using O 
Raman O 
and O 
(11)B B-FORMULA 
and O 
(31)P B-FORMULA 
magic O 
angle O 
spinning O 
nuclear O 
magnetic O 
resonance O 
( O 
MAS O 
NMR O 
) O 
spectroscopies O 
. O 
Through O 
examination O 
of O 
the O 
short O 
- O 
range O 
order O 
( O 
SRO O 
) O 
structures O 
found O 
in O 
the O 
ternary O 
glasses O 
, O 
it O 
was O 
determined O 
that O 
the O 
minority O 
glass O 
former O 
, O 
B B-FORMULA 
for O 
0.1 O 
≤ O 
x O 
≤ O 
0.7 O 
and O 
P B-FORMULA 
for O 
0.7 O 
≤ O 
x O 
≤ O 
0.9 O 
, O 
is O 
" O 
overmodified O 
" O 
and O 
contains O 
more O 
Na(+) B-FORMULA 
ions O 
than O 
would O 
be O 
expected O 
from O 
simple O 
linear O 
mixing O 
of O 
the O 
binary O 
sodium B-SYSTEMATIC 
borate I-SYSTEMATIC 
, O 
x O 
= O 
1 O 
, O 
and O 
sodium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
, O 
x O 
= O 
0 O 
, O 
glasses O 
, O 
respectively O 
. O 
Changes O 
in O 
the O 
intermediate O 
range O 
order O 
( O 
IRO O 
) O 
structures O 
were O 
suggested O 
by O 
changes O 
in O 
the O 
NMR O 
spectral O 
chemical O 
shifts O 
and O 
Raman O 
spectra O 
wavenumber O 
shifts O 
over O 
the O 
full O 
composition O 
range O 
x O 
in O 
the O 
Raman O 
and O 
MAS O 
NMR O 
spectra O 
. O 
The O 
changes O 
observed O 
in O 
the O 
chemical O 
shifts O 
of O 
(31)P B-FORMULA 
MAS O 
NMR O 
spectra O 
with O 
x O 
are O 
found O 
to O 
be O 
too O 
large O 
to O 
be O 
caused O 
solely O 
by O 
changing O 
sodium B-SYSTEMATIC 
modification O 
of O 
the O 
phosphate O 
SRO O 
structural O 
groups O 
, O 
and O 
this O 
indicates O 
that O 
internetwork O 
bonding O 
between O 
phosphorus B-SYSTEMATIC 
and O 
boron B-SYSTEMATIC 
through O 
bridging O 
oxygens B-FAMILY 
( O 
BOs O 
) O 
, O 
P-O-B B-FAMILY 
, O 
must O 
be O 
a O 
major O 
contributor O 
to O 
the O 
IRO O 
structure O 
of O 
these O 
glasses O 
. O 
While O 
not O 
fully O 
developed O 
, O 
a O 
first O 
- O 
order O 
thermodynamic O 
analysis O 
based O 
upon O 
the O 
Gibbs O 
free O 
energies O 
of O 
formation O 
of O 
the O 
various O 
SRO O 
structural O 
units O 
in O 
this O 
system O 
has O 
been O 
developed O 
and O 
can O 
be O 
used O 
to O 
account O 
for O 
the O 
preferential O 
formation O 
of O 
tetrahedral O 
boron B-SYSTEMATIC 
groups O 
, O 
B B-FORMULA 
( O 
4 O 
) O 
, O 
by O 
the O 
reaction O 
of O 
B B-FORMULA 
( O 
3 O 
) O 
with O 
P B-FORMULA 
( O 
2 O 
) O 
groups O 
to O 
form O 
B B-FORMULA 
( O 
4 O 
) O 
and O 
P B-FORMULA 
( O 
3 O 
) O 
groups O 
, O 
respectively O 
, O 
where O 
the O 
superscript O 
denotes O 
the O 
number O 
of O 
BOs O 
on O 
these O 
units O 
, O 
in O 
these O 
glasses O 
. O 
This O 
preference O 
for O 
B B-FORMULA 
( O 
4 O 
) O 
units O 
appears O 
to O 
be O 
a O 
predominate O 
cause O 
of O 
the O 
changing O 
modifier O 
to O 
glass O 
former O 
ratio O 
with O 
composition O 
x O 
in O 
these O 
ternary O 
MGF O 
glasses O 
and O 
appears O 
to O 
be O 
associated O 
with O 
the O 
large O 
negative O 
value O 
of O 
the O 
Gibbs O 
free O 
energy O 
of O 
formation O 
of O 
this O 
group O 
. O 

absorption O 
near O 
edge O 
structure O 
spectroscopy O 
to O 
resolve O 
the O 
in O 
vivo O 
chemistry O 
of O 
the O 
redox O 
- O 
active O 
indazolium B-SYSTEMATIC 
trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] I-SYSTEMATIC 
( O 
KP1019 B-IDENTIFIER 
) O 
. O 

trans-[tetrachlorobis(1H-indazole)ruthenate(III)] I-SYSTEMATIC 
( O 
1 O 
, O 
KP1019 B-IDENTIFIER 
) O 
and O 
its O 
analogue O 
sodium B-SYSTEMATIC 
trans-[tetrachlorobis(1H-indazole)ruthenate(III)] I-SYSTEMATIC 
( O 
2 O 
, O 
KP1339 B-IDENTIFIER 
) O 
are O 
promising O 
redox O 
- O 
active O 
anticancer O 
drug O 
candidates O 
that O 
were O 
investigated O 
with O 
X-ray O 
absorption O 
near O 
edge O 
structure O 
spectroscopy O 
. O 
The O 
analysis O 
was O 
based O 
on O 
the O 
concept O 
of O 
the O 
coordination O 
charge O 
and O 
ruthenium B-SYSTEMATIC 
model O 
compounds O 
representing O 
possible O 
coordinations O 
and O 
oxidation O 
states O 
in O 
vivo O 
. O 
1 O 
was O 
investigated O 
in O 
citrate B-FAMILY 
saline O 
buffer O 
( O 
pH O 
3.5 O 
) O 
and O 
in O 
carbonate B-FAMILY 
buffer O 
( O 
pH O 
7.4 O 
) O 
at O 
37 O 
°C O 
for O 
different O 
time O 
intervals O 
. O 
Interaction O 
studies O 
on O 
1 O 
with O 
glutathione B-TRIVIAL 
in O 
saline O 
buffer O 
and O 
apo O 
- O 
transferrin O 
in O 
carbonate B-FAMILY 
buffer O 
were O 
undertaken O 
, O 
and O 
the O 
coordination O 
of O 
1 O 
and O 
2 O 
in O 
tumor O 
tissues O 
was O 
studied O 
too O 
. O 
The O 
most O 
likely O 
coordinations O 
and O 
oxidation O 
states O 
of O 
the O 
compound O 
under O 
the O 
above O 
mentioned O 
conditions O 
were O 
assigned O 
. O 
Microprobe O 
X-ray O 
fluorescence O 
of O 
tumor O 
thin O 
sections O 
showed O 
the O 
strong O 
penetration O 
of O 
ruthenium B-SYSTEMATIC 
into O 
the O 
tumor O 
tissue O 
, O 
with O 
the O 
highest O 
concentrations O 
near O 
blood O 
vessels O 
and O 
in O 
the O 
edge O 
regions O 
of O 
the O 
tissue O 
samples O 
. O 

of O 
animal O 
models O 
for O 
intestinal O 
first O 
- O 
pass O 
metabolism O 
of O 
drug O 
candidates O 
to O 
be O 
metabolized O 
by O 
CYP3A O 
enzymes O 
via O 
in O 
vivo O 
and O 
in O 
vitro O 
oxidation O 
of O 
midazolam B-TRIVIAL 
and O 
triazolam B-TRIVIAL 
. O 

1 O 
. O 
To O 
search O 
an O 
appropriate O 
evaluation O 
methodology O 
for O 
the O 
intestinal O 
first O 
- O 
pass O 
metabolism O 
of O 
new O 
drug O 
candidates O 
, O 
grapefruit O 
juice O 
(GFJ)- O 
and O 
vehicle O 
( O 
tap O 
water O 
) O 
- O 
pretreated O 
mice O 
or O 
rats O 
were O 
orally O 
administered O 
midazolam B-TRIVIAL 
( O 
MDZ B-ABBREVIATION 
) O 
or O 
triazolam B-TRIVIAL 
( O 
TRZ B-ABBREVIATION 
) O 
, O 
and O 
blood O 
levels O 
of O 
the O 
parent O 
compounds O 
and O 
their O 
metabolites O 
were O 
measured O 
by O 
liquid O 
chromatography O 
/ O 
MS O 
/ O 
MS O 
. O 
A O 
significant O 
effect O 
of O 
GFJ O 
to O 
elevate O 
the O 
blood O 
levels O 
was O 
observed O 
only O 
for O 
TRZ B-ABBREVIATION 
in O 
mice O 
. O 
2 O 
. O 
In O 
vitro O 
experiments O 
using O 
mouse O 
, O 
rat O 
and O 
human O 
intestinal O 
and O 
hepatic O 
microsomal O 
fractions O 
demonstrated O 
that O 
GFJ O 
suppressed O 
the O 
intestinal O 
microsomal O 
oxidation O 
of O 
MDZ B-ABBREVIATION 
and O 
especially O 
TRZ B-ABBREVIATION 
. O 
Substrate O 
inhibition O 
by O 
MDZ B-ABBREVIATION 
caused O 
reduction O 
in O 
1'-hydroxylation O 
but O 
not O 
4-hydroxylation O 
in O 
both O 
intestinal O 
and O 
hepatic O 
microsomal O 
fractions O 
. O 
The O 
kinetic O 
profiles O 
of O 
MDZ B-ABBREVIATION 
oxidation O 
and O 
the O 
substrate O 
inhibition O 
in O 
mouse O 
intestinal O 
and O 
hepatic O 
microsomal O 
fractions O 
were O 
very O 
similar O 
to O 
those O 
in O 
human O 
microsomes O 
but O 
were O 
different O 
from O 
those O 
in O 
rat O 
microsomes O 
. O 
Furthermore O 
, O 
MDZ B-ABBREVIATION 
caused O 
mechanism O 
- O 
based O 
inactivation O 
of O 
cytochrome O 
P450 O 
3A-dependent O 
TRZ B-ABBREVIATION 
1'-hydroxylation O 
in O 
mouse O 
, O 
rat O 
and O 
human O 
intestinal O 
microsomes O 
with O 
similar O 
potencies O 
. O 
3 O 
. O 
These O 
results O 
are O 
useful O 
information O 
in O 
the O 
analysis O 
of O 
data O 
obtained O 
in O 
mouse O 
and O 
rat O 
for O 
the O 
evaluation O 
of O 
first O 
- O 
pass O 
effects O 
of O 
drug O 
candidates O 
to O 
be O 
metabolized O 
by O 
CYP3A O 
enzymes O 
. O 

enantioselective O 
cyclization O 
and O 
C3-fluorination O 
of O 
polyenes B-FAMILY 
. O 

in O 
combination O 
with O 
XeF(2) B-FORMULA 
mediates O 
the O 
consecutive O 
diastereoselective O 
cation- O 
olefin B-FAMILY 
cyclization O 
/ O 
fluorination O 
of O 
polyene B-SYSTEMATIC 
substrates O 
. O 
Isolated O 
yields O 
were O 
typically O 
in O 
the O 
60-69% O 
range O 
while O 
enantioselectivities O 
reached O 
as O 
high O 
as O 
87% O 
. O 
The O 
data O 
are O 
consistent O 
with O 
a O 
stereoretentive O 
fluorination O 
of O 
a O 
P(2)Pt-alkyl B-FAMILY 
cation O 
intermediate O 
. O 

sensors O 
have O 
been O 
extensively O 
explored O 
as O 
a O 
promising O 
technique O 
for O 
real O 
- O 
time O 
and O 
label O 
- O 
free O 
analyses O 
in O 
biological O 
systems O 
. O 
A O 
major O 
sensing O 
principle O 
utilized O 
by O 
state O 
- O 
of O 
- O 
the O 
- O 
art O 
cantilever O 
sensors O 
is O 
based O 
on O 
analyte O 
- O 
induced O 
surface O 
stress O 
changes O 
, O 
which O 
result O 
in O 
static O 
bending O 
of O 
a O 
cantilever O 
. O 
The O 
sensor O 
performance O 
, O 
however O 
, O 
suffers O 
from O 
the O 
intrinsically O 
small O 
change O 
in O 
surface O 
stress O 
induced O 
by O 
analytes O 
, O 
especially O 
for O 
molecular O 
recognition O 
such O 
as O 
antigen O 
- O 
antibody O 
binding O 
. O 
Through O 
the O 
contact O 
angle O 
change O 
on O 
a O 
tailored O 
solid O 
surface O 
, O 
it O 
is O 
possible O 
to O 
convert O 
a O 
tiny O 
surface O 
stress O 
into O 
a O 
capillary O 
force-a O 
much O 
larger O 
physical O 
quantity O 
needed O 
for O 
a O 
practical O 
sensor O 
application O 
. O 
In O 
this O 
work O 
, O 
a O 
micro O 
- O 
cantilever O 
sensor O 
based O 
on O 
contact O 
angle O 
analysis O 
( O 
CAMCS O 
) O 
was O 
proposed O 
to O 
effectively O 
enhance O 
the O 
sensitivity O 
of O 
a O 
sensor O 
in O 
proportion O 
to O 
the O 
square O 
of O 
the O 
length O 
to O 
thickness O 
ratio O 
of O 
the O 
cantilever O 
structure O 
. O 
CAMCS O 
chips O 
were O 
fabricated O 
using O 
a O 
standard O 
complementary- O 
metal B-FAMILY 
- I-FAMILY 
oxide I-FAMILY 
-semiconductor O 
( O 
CMOS O 
) O 
process O 
to O 
demonstrate O 
a O 
1250-fold O 
enhancement O 
in O 
the O 
sensitivity O 
of O 
surface O 
stress O 
to O 
bioanalyte O 
adsorption O 
using O 
a O 
piezoresistive O 
sensing O 
method O 
. O 
A O 
real O 
- O 
time O 
and O 
label O 
- O 
free O 
troponin O 
I O 
( O 
cTnI O 
) O 
immunoassay O 
, O 
which O 
is O 
now O 
widely O 
used O 
in O 
clinics O 
and O 
considered O 
a O 
gold O 
standard O 
for O 
the O 
early O 
diagnosis O 
and O 
prognosis O 
of O 
cardiovascular O 
disease O 
, O 
was O 
performed O 
to O 
demonstrate O 
cTnI O 
detection O 
levels O 
as O 
low O 
as O 
1 O 
pg O 
mL(-1) O 
. O 
The O 
short O 
detection O 
time O 
of O 
this O 
assay O 
was O 
within O 
several O 
minutes O 
, O 
which O 
matches O 
the O 
detection O 
time O 
of O 
commercially O 
available O 
instruments O 
that O 
are O 
based O 
on O 
fluorescence O 
- O 
labeling O 
techniques O 
. O 

sulphate I-SYSTEMATIC 
and O 
vitamin B-FAMILY 
E I-FAMILY 
alleviate O 
reproductive O 
toxicity O 
caused O 
by O 
aluminium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
in O 
male O 
albino O 
rats O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
the O 
reproductive O 
toxicity O 
of O 
aluminium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
and O 
the O 
therapeutic O 
effects O 
of O 
administration O 
of O 
zinc B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
and O 
vitamin B-FAMILY 
E I-FAMILY 
individually O 
or O 
in O 
combination O 
against O 
the O 
toxic O 
effect O 
caused O 
by O 
aluminium B-SYSTEMATIC 
( O 
Al B-FORMULA 
) O 
in O 
male O 
albino O 
rats O 
. O 
The O 
animals O 
were O 
divided O 
into O 
five O 
groups O 
: O 
group O 
1 O 
received O 
distilled O 
water O 
and O 
served O 
as O 
control O 
; O 
group O 
2 O 
received O 
only O 
aluminium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
50 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
) O 
; O 
group O 
3 O 
received O 
aluminium B-SYSTEMATIC 
sulphat I-SYSTEMATIC 
e O 
( O 
50 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
plus O 
zinc B-SYSTEMATIC 
sulphat I-SYSTEMATIC 
e O 
( O 
50 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
; O 
group O 
4 O 
receive O 
d B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
sulpha I-SYSTEMATIC 
te O 
( O 
50 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
an O 
d B-FAMILY 
vitamin I-FAMILY 
E O 
( O 
15 O 
mg O 
/ O 
kg O 
b.w O 
. O 
) O 
; O 
group O 
5 O 
receiv O 
ed B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
plus O 
a O 
combination O 
of B-SYSTEMATIC 
zinc I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
a O 
nd B-FAMILY 
vitami I-FAMILY 
n O 
E O 
in O 
similar O 
doses O 
as O 
above O 
. O 
Doses O 
were O 
administered O 
orally O 
once O 
daily O 
for O 
45 O 
consecutive O 
days O 
. O 
The O 
results O 
revealed O 
th O 
at B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
induced O 
significant O 
decrease O 
in O 
body O 
weight O 
gain O 
and O 
testis O 
weight O 
and O 
significant O 
increase O 
in B-FORMULA 
Al O 
level O 
in O 
both O 
serum O 
and O 
testes O 
of O 
male O 
rats O 
. O 
Biochemical O 
analysis O 
showed O 
significant O 
decrease O 
in O 
serum O 
total O 
protein O 
and O 
phospholipids O 
levels O 
, O 
while O 
serum O 
total O 
lipid O 
was O 
significantly O 
elevated O 
po O 
st B-FORMULA 
Al O 
treatment O 
. O 
In O 
addition O 
, O 
significant O 
decrease O 
in O 
total O 
protein O 
, O 
phospholipids O 
a O 
nd B-TRIVIAL 
choleste I-TRIVIAL 
rol O 
levels O 
in O 
the O 
testes O 
of B-FORMULA 
Al O 
- O 
treated O 
rats O 
was O 
recorded O 
. O 
The O 
data O 
also O 
showed O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
ser O 
um B-TRIVIAL 
testoster I-TRIVIAL 
one O 
, O 
leutinizing O 
hormone O 
and O 
follicle O 
stimulating O 
hormone O 
and O 
significant O 
increase O 
in O 
the O 
level O 
of O 
serum O 
prolactin O 
in B-FORMULA 
Al-intoxicated O 
rats O 
. O 
Moreover O 
, O 
histological O 
examination O 
showed O 
th O 
at B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
caused O 
apparent O 
alterations O 
in O 
the O 
testicular O 
structure O 
of O 
the O 
treated O 
animals O 
. O 
Treatment O 
wi O 
th B-SYSTEMATIC 
zinc I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
a O 
nd B-FAMILY 
vitami I-FAMILY 
n O 
E O 
individually O 
or O 
in O 
combination O 
ameliorated O 
the O 
harmful O 
effects O 
of B-FORMULA 
Al O 
, O 
which O 
was O 
proved O 
histopathologically O 
by O 
the O 
noticeable O 
improvement O 
in O 
the O 
testicular O 
tissues O 
. O 
We O 
can O 
conclude O 
that O 
the O 
tested O 
dose O 
of B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
induced O 
toxic O 
effect O 
on O 
the O 
reproductive O 
system O 
of O 
male O 
albino O 
rats O 
and O 
the O 
treatment O 
wi O 
th B-SYSTEMATIC 
zinc I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
and/ O 
or B-FAMILY 
vitami I-FAMILY 
n O 
E O 
alleviated O 
these O 
toxic O 
effects O 
. O 
In O 
some O 
case O 
s B-FAMILY 
, I-FAMILY 
vitami I-FAMILY 
n O 
E O 
exerted O 
a O 
more O 
potent O 
effect O 
, O 
while O 
in O 
other O 
cases O 
, O 
the O 
more O 
potent O 
effect O 
is O 
related O 
to B-SYSTEMATIC 
zinc I-SYSTEMATIC 
sulph I-SYSTEMATIC 
ate O 
and O 
the O 
combination O 
of O 
both O 
at O 
most O 
of O 
the O 
recorded O 
data O 
. O 

A I-TRIVIAL 
inhibits O 
transforming O 
growth O 
factor-β-induced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
accumulation O 
and O 
myofibroblast O 
differentiation O 
via O 
enhanced O 
NF-E2 O 
- O 
related O 
factor O 
2-antioxidant O 
response O 
element O 
signaling O 
. O 

A I-TRIVIAL 
( O 
TSA B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
prevent O 
fibrosis O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
present O 
study O 
aimed O 
at O 
investigating O 
the O 
role O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
scavenging O 
by O 
TSA B-ABBREVIATION 
on O 
transforming O 
growth O 
factor-β O 
(TGF-β)-induced O 
myofibroblast O 
differentiation O 
of O 
corneal O 
fibroblasts O 
in O 
vitro O 
. O 
Human O 
immortalized O 
corneal O 
fibroblasts O 
were O 
treated O 
with O 
TGF-β O 
in O 
the O 
presence O 
of O 
TSA B-ABBREVIATION 
, O 
the O 
NAD(P)H B-ABBREVIATION 
oxidase O 
inhibitor O 
diphenyleneiodonium B-TRIVIAL 
( O 
DPI B-ABBREVIATION 
) O 
, O 
the O 
antioxidant O 
N-acetyl-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
the O 
NF-E2 O 
- O 
related O 
factor O 
2-antioxidant O 
response O 
element O 
( O 
Nrf2-ARE O 
) O 
activator O 
sulforaphane B-TRIVIAL 
, O 
or O 
small O 
interfering O 
RNA O 
. O 
Myofibroblast O 
differentiation O 
was O 
assessed O 
by O 
α-smooth O 
muscle O 
actin O 
( O 
α-SMA O 
) O 
expression O 
, O 
F-actin O 
bundle O 
formation O 
, O 
and O 
collagen O 
gel O 
contraction O 
. O 
ROS O 
, O 
H(2)O(2) B-FORMULA 
, O 
intracellular O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
level O 
, O 
cellular O 
total O 
antioxidant O 
capacity O 
, O 
and O 
the O 
activation O 
of O 
Nrf2-ARE O 
signaling O 
were O 
determined O 
with O 
various O 
assays O 
. O 
Treatment O 
with O 
TSA B-ABBREVIATION 
and O 
the O 
Nrf2-ARE O 
activator O 
resulted O 
in O 
increased O 
inhibition O 
of O 
the O 
TGF-β-induced O 
myofibroblast O 
differentiation O 
as O 
compared O 
with O 
treatment O 
with O 
DPI B-ABBREVIATION 
or O 
NAC B-ABBREVIATION 
. O 
Furthermore O 
, O 
TSA B-ABBREVIATION 
also O 
decreased O 
cellular O 
ROS O 
and O 
H(2)O(2) B-FORMULA 
accumulation O 
induced O 
by O 
TGF-β O 
, O 
whereas O 
it O 
elevated O 
intracellular O 
GSH B-ABBREVIATION 
level O 
and O 
cellular O 
total O 
antioxidant O 
capacity O 
. O 
In O 
addition O 
, O 
TSA B-ABBREVIATION 
induced O 
Nrf2 O 
nuclear O 
translocation O 
and O 
up O 
- O 
regulated O 
the O 
expression O 
of O 
Nrf2-ARE O 
downstream O 
antioxidant O 
genes O 
, O 
whereas O 
Nrf2 O 
knockdown O 
by O 
RNA O 
interference O 
blocked O 
the O 
inhibition O 
of O 
TSA B-ABBREVIATION 
on O 
myofibroblast O 
differentiation O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
provides O 
the O 
first O 
evidence O 
implicating O 
that O 
TSA B-ABBREVIATION 
inhibits O 
TGF-β-induced O 
ROS O 
accumulation O 
and O 
myofibroblast O 
differentiation O 
via O 
enhanced O 
Nrf2-ARE O 
signaling O 
. O 

hydrolysis O 
of O 
a O 
novel O 
chemical O 
series O 
of O 
microsomal O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase-1 O 
inhibitors O 
induces O 
kidney O 
toxicity O 
in O 
the O 
rat O 
. O 

novel O 
microsomal O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase O 
1 O 
( O 
mPGES-1 O 
) O 
inhibitor O 
induced O 
kidney O 
injury O 
at O 
exposures O 
representing O 
less O 
than O 
4 O 
times O 
the O 
anticipated O 
efficacious O 
exposure O 
in O 
man O 
during O 
a O 
7-day O 
toxicity O 
study O 
in O 
rats O 
. O 
The O 
findings O 
consisted O 
mainly O 
of O 
tubular O 
lesions O 
and O 
the O 
presence O 
of O 
crystalline O 
material O 
and O 
increases O 
in O 
plasma O 
urea B-TRIVIAL 
and O 
creatinine B-TRIVIAL 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
metabolic O 
profiling O 
generated O 
a O 
working O 
hypothesis O 
that O 
a O 
bis-sulfonamide B-SYSTEMATIC 
metabolite O 
( O 
determined O 
M1 O 
) O 
formed O 
by O 
amide B-FAMILY 
hydrolysis O 
caused O 
this O 
toxicity O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
rats O 
were O 
subjected O 
to O 
a O 
7-day O 
study O 
and O 
were O 
administered O 
the O 
suspected O 
metabolite O 
and O 
two O 
low O 
- O 
potency O 
mPGES-1 O 
inhibitor O 
analogs O 
, O 
where O 
amide B-FAMILY 
hydrolysis O 
was O 
undetectable O 
in O 
rat O 
hepatocyte O 
experiments O 
. O 
The O 
results O 
suggested O 
that O 
compounds O 
with O 
a O 
reduced O 
propensity O 
to O 
undergo O 
amide B-FAMILY 
hydrolysis O 
, O 
thus O 
having O 
less O 
ability O 
to O 
form O 
M1 O 
, O 
reduced O 
the O 
risk O 
of O 
inducing O 
kidney O 
toxicity O 
. O 
Rats O 
treated O 
with O 
M1 O 
alone O 
showed O 
no O 
histopathologic O 
change O 
in O 
the O 
kidney O 
, O 
which O 
was O 
likely O 
related O 
to O 
underexposure O 
to O 
M1 O 
. O 
To O 
circumvent O 
rat O 
kidney O 
toxicity O 
, O 
we O 
identified O 
a O 
potent O 
mPGES-1 O 
inhibitor O 
with O 
a O 
low O 
propensity O 
for O 
amide B-FAMILY 
hydrolysis O 
and O 
superior O 
rat O 
pharmacokinetic O 
properties O 
. O 
A O 
subsequent O 
14-day O 
rat O 
toxicity O 
study O 
showed O 
that O 
this O 
compound O 
was O 
associated O 
with O 
kidney O 
toxicity O 
at O 
42 O 
, O 
but O 
not O 
21 O 
, O 
times O 
the O 
anticipated O 
efficacious O 
exposure O 
in O 
humans O 
. O 
In O 
conclusion O 
, O 
by O 
including O 
metabolic O 
profiling O 
and O 
exploratory O 
rat O 
toxicity O 
studies O 
, O 
a O 
new O 
and O 
active O 
mPGES-1 O 
inhibitor O 
with O 
improved O 
margins O 
to O 
chemically O 
induced O 
kidney O 
toxicity O 
in O 
rats O 
has O 
been O 
identified O 
. O 

report O 
a O 
dramatically O 
improved O 
synthesis O 
of O 
colloidal O 
gold O 
nanorods O 
( O 
NRs O 
) O 
using O 
a O 
binary O 
surfactant O 
mixture O 
composed O 
of O 
hexadecyltrimethylammonium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
CTAB B-ABBREVIATION 
) O 
and O 
sodium B-SYSTEMATIC 
oleate I-SYSTEMATIC 
( O 
NaOL B-ABBREVIATION 
) O 
. O 
Both O 
thin O 
( O 
diameter O 
< O 
25 O 
nm O 
) O 
and O 
thicker O 
( O 
diameter O 
> O 
30 O 
nm O 
) O 
gold O 
NRs O 
with O 
exceptional O 
monodispersity O 
and O 
broadly O 
tunable O 
longitudinal O 
surface O 
plasmon O 
resonance O 
can O 
be O 
synthesized O 
using O 
seeded O 
growth O 
at O 
reduced O 
CTAB B-ABBREVIATION 
concentrations O 
( O 
as O 
low O 
as O 
0.037 O 
M O 
) O 
. O 
The O 
CTAB B-ABBREVIATION 
- O 
NaOL B-ABBREVIATION 
binary O 
surfactant O 
mixture O 
overcomes O 
the O 
difficulty O 
of O 
growing O 
uniform O 
thick O 
gold O 
NRs O 
often O 
associated O 
with O 
the O 
single O 
- O 
component O 
CTAB B-ABBREVIATION 
system O 
and O 
greatly O 
expands O 
the O 
dimensions O 
of O 
gold O 
NRs O 
that O 
are O 
accessible O 
through O 
a O 
one O 
- O 
pot O 
seeded O 
growth O 
process O 
. O 
Gold O 
NRs O 
with O 
large O 
overall O 
dimensions O 
and O 
thus O 
high O 
scattering O 
/ O 
absorption O 
ratios O 
are O 
ideal O 
for O 
scattering O 
- O 
based O 
applications O 
such O 
as O 
biolabeling O 
as O 
well O 
as O 
the O 
enhancement O 
of O 
optical O 
processes O 
. O 

and O 
antiplasmodial O 
dimeric B-FAMILY 
phloroglucinols I-FAMILY 
from O 
Mallotus O 
oppositifolius O 
from O 
the O 
Madagascar O 
Dry O 
Forest O 
( O 
1 O 
) O 
. O 

- O 
guided O 
fractionation O 
of O 
an O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
leaves O 
and O 
inflorescence O 
of O 
Mallotus O 
oppositifolius O 
collected O 
in O 
Madagascar O 
led O 
to O 
the O 
isolation O 
of O 
the O 
two O 
new O 
bioactive O 
dimeric B-FAMILY 
phloroglucinols I-FAMILY 
mallotojaponins B-MULTIPLE 
B I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
, O 
together O 
with O 
the O 
known O 
mallotophenone B-TRIVIAL 
( O 
3 O 
) O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
determined O 
on O 
the O 
basis O 
of O 
spectroscopic O 
evidence O 
, O 
including O 
their O 
1D- O 
and O 
2D-NMR O 
spectra O 
, O 
mass O 
spectrometry O 
, O 
and O 
an O 
X-ray O 
crystal O 
structure O 
. O 
Compounds O 
1 O 
and O 
2 O 
showed O 
potent O 
antimalarial O 
activity O 
against O 
chloroquine B-TRIVIAL 
-resistant O 
Plasmodium O 
falciparum O 
, O 
with O 
IC50 O 
values O 
of O 
0.75 O 
± O 
0.3 O 
and O 
0.14 O 
± O 
0.04 O 
μM O 
, O 
while O 
3 O 
was O 
inactive O 
in O 
this O 
assay O 
. O 
Compounds O 
1-3 O 
also O 
displayed O 
strong O 
antiproliferative O 
activity O 
against O 
the O 
A2780 O 
human O 
ovarian O 
cancer O 
cell O 
line O 
( O 
IC50 O 
1.1 O 
± O 
0.05 O 
, O 
1.3 O 
± O 
0.1 O 
and O 
6.3 O 
± O 
0.4 O 
μM O 
, O 
respectively O 
) O 
. O 

of O 
copper B-FAMILY 
salts I-FAMILY 
is O 
dependent O 
on O 
solubility O 
profile O 
and O 
cell O 
type O 
tested O 
. O 

( O 
Cu B-FORMULA 
) O 
is O 
considered O 
an O 
essential O 
metal O 
for O 
living O 
organisms O 
. O 
However O 
, O 
disruption O 
of O 
Cu B-FORMULA 
homeostasis O 
is O 
toxic O 
and O 
can O 
lead O 
to O 
disorders O 
such O 
as O 
Menkes O 
and O 
Wilson's O 
diseases O 
. O 
The O 
brain O 
appears O 
to O 
be O 
a O 
vulnerable O 
target O 
organ O 
. O 
This O 
study O 
investigated O 
the O 
toxicity O 
of O 
Cu B-FORMULA 
based O 
on O 
its O 
solubility O 
profile O 
and O 
cell O 
type O 
tested O 
. O 
Human O 
A-172 O 
( O 
glioblastoma O 
) O 
, O 
SK-N-SH O 
( O 
neuroblastoma O 
) O 
and O 
CCF-STTG1 O 
( O 
astrocytoma O 
) O 
cells O 
were O 
assessed O 
after O 
exposure O 
to O 
different O 
concentrations O 
( O 
0.5-500μM O 
) O 
of O 
copper B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
CuSO4 B-FORMULA 
) O 
or O 
copper B-SYSTEMATIC 
(II) I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
CuO B-FORMULA 
) O 
. O 
Since O 
Cu B-FORMULA 
is O 
a O 
redox O 
active O 
transition B-FAMILY 
metal I-FAMILY 
, O 
we O 
hypothesized O 
that O 
oxidative O 
stress O 
would O 
be O 
the O 
main O 
mechanism O 
underlying O 
cell O 
toxicity O 
. O 
Therefore O 
, O 
cell O 
viability O 
was O 
correlated O 
with O 
the O 
extent O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
formation O 
. O 
Cell O 
viability O 
decreased O 
at O 
the O 
higher O 
concentrations O 
of O 
the O 
Cu B-FAMILY 
salts I-FAMILY 
and O 
CuO B-FORMULA 
was O 
more O 
toxic O 
compared O 
to O 
CuSO4 B-FORMULA 
. O 
The O 
astrocytoma O 
and O 
glioblastoma O 
cells O 
were O 
more O 
vulnerable O 
compared O 
to O 
the O 
neuronal O 
cells O 
. O 
Furthermore O 
, O 
it O 
appears O 
that O 
oxidative O 
stress O 
only O 
partially O 
accounts O 
for O 
Cu B-FORMULA 
-induced O 
cell O 
toxicity O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
better O 
understand O 
the O 
unique O 
susceptibility O 
of O 
glial O 
cells O 
and O 
determine O 
the O 
physicochemical O 
properties O 
of O 
insoluble O 
Cu B-FORMULA 
which O 
accounts O 
for O 
its O 
enhanced O 
toxicity O 
. O 

and O 
biological O 
evaluation O 
of O 
new O 
N-alkylcarbazole B-FAMILY 
derivatives O 
as O 
STAT3 O 
inhibitors O 
: O 
preliminary O 
study O 
. O 

signalling O 
pathway O 
of O 
Janus O 
tyrosine B-TRIVIAL 
Kinases-Signal O 
Transducers O 
and O 
Activators O 
of O 
Transcription O 
( O 
JAK-STAT O 
) O 
is O 
activated O 
by O 
a O 
number O 
of O 
cytokines O 
, O 
hormones O 
( O 
GH O 
, O 
erythropoietin O 
and O 
prolactin O 
) O 
, O 
and O 
growth O 
factors O 
. O 
JAK-STAT O 
signalling O 
is O 
involved O 
in O 
regulation O 
of O 
cell O 
proliferation O 
, O 
differentiation O 
and O 
apoptosis O 
. O 
These O 
activities O 
are O 
due O 
to O 
different O 
members O 
of O 
JAK-STAT O 
family O 
consisting O 
of O 
: O 
JAK1 O 
, O 
JAK2 O 
, O 
JAK3 O 
, O 
Tyk2 O 
and O 
STAT1 O 
, O 
STAT2 O 
, O 
STAT3 O 
, O 
STAT4 O 
, O 
STAT5a O 
, O 
STAT5b O 
, O 
STAT6 O 
. O 
Recent O 
studies O 
suggest O 
a O 
key O 
role O 
for O 
STAT O 
family O 
proteins O 
, O 
in O 
particular O 
for O 
STAT3 O 
, O 
in O 
selectively O 
inducing O 
and O 
maintaining O 
a O 
pro O 
- O 
carcinogenic O 
inflammatory O 
microenvironment O 
, O 
that O 
promote O 
tumour O 
cells O 
transformation O 
. O 
Moreover O 
, O 
a O 
striking O 
correlation O 
between O 
cancer O 
development O 
/ O 
progression O 
and O 
STAT3 O 
persistent O 
activation O 
exists O 
, O 
probably O 
due O 
to O 
STAT3 O 
promoting O 
of O 
the O 
pro O 
- O 
oncogenic O 
inflammatory O 
pathways O 
, O 
like O 
NF-kB O 
, O 
IL-6 O 
and O 
JAK O 
family O 
kinases O 
. O 
Recent O 
study O 
demonstrated O 
that O 
carbazoles B-FAMILY 
can O 
inhibit O 
STAT3 O 
mediated O 
transcription O 
. O 
From O 
these O 
evidences O 
, O 
STAT3 O 
represents O 
a O 
therapeutic O 
target O 
, O 
so O 
we O 
have O 
synthesized O 
a O 
new O 
set O 
of O 
N-alkylcarbazole B-FAMILY 
derivatives O 
substituted O 
in O 
positions O 
2 O 
, O 
4 O 
and O 
6 O 
, O 
to O 
evaluate O 
their O 
activity O 
on O 
STAT3 O 
. O 
Some O 
of O 
these O 
compounds O 
showed O 
an O 
interesting O 
activity O 
as O 
STAT3 O 
selective O 
inhibitors O 
; O 
in O 
particular O 
, O 
compounds O 
9a O 
9b O 
and O 
9c O 
revealed O 
to O 
inhibit O 
the O 
STAT3 O 
activation O 
for O 
the O 
50% O 
, O 
90% O 
and O 
95% O 
, O 
respectively O 
. O 

dose O 
- O 
dependent O 
behavioral O 
and O 
cognitive O 
disturbances O 
after O 
a O 
single O 
neonatal O 
PFHxS B-ABBREVIATION 
dose O 
. O 

acids I-FAMILY 
, O 
including O 
perfluorohexane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFHxS B-ABBREVIATION 
) O 
, O 
are O 
fluorinated O 
organic O 
compounds O 
used O 
as O 
surfactants O 
and O 
water O 
and O 
stain O 
repellents O 
in O 
carpets O 
, O 
paper O 
, O 
and O 
textiles O 
, O 
with O 
characteristics O 
to O 
bioaccumulate O 
and O 
biomagnify O 
in O 
the O 
food O 
chain O 
. O 
PFHxS B-ABBREVIATION 
is O 
found O 
in O 
umbilical O 
cord O 
blood O 
, O 
human O 
milk O 
and O 
child O 
serum O 
from O 
all O 
over O 
the O 
world O 
. O 
We O 
have O 
recently O 
reported O 
that O 
neonatal O 
exposure O 
to O 
certain O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
, O 
PFOS B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
, O 
can O 
induce O 
persistent O 
aberrations O 
in O 
spontaneous O 
behavior O 
and O 
also O 
affect O 
learning O 
and O 
memory O 
functions O 
in O 
the O 
adult O 
animal O 
. O 
The O 
present O 
study O 
indicates O 
that O 
a O 
single O 
exposure O 
to O 
PFHxS B-ABBREVIATION 
on O 
postnatal O 
day O 
10 O 
, O 
during O 
a O 
vulnerable O 
period O 
of O 
brain O 
development O 
can O 
alter O 
adult O 
spontaneous O 
behavior O 
and O 
cognitive O 
function O 
in O 
both O 
male O 
and O 
female O 
mice O 
, O 
effects O 
that O 
are O 
both O 
dose O 
- O 
response O 
related O 
and O 
long O 
- O 
lasting O 
/ O 
irreversible O 
. O 
PFHxS B-ABBREVIATION 
affected O 
the O 
cholinergic O 
system O 
, O 
manifested O 
as O 
altered O 
nicotine B-TRIVIAL 
-induced O 
behavior O 
in O 
adult O 
animals O 
. O 
This O 
is O 
also O 
in O 
agreement O 
with O 
earlier O 
studies O 
on O 
neonatal O 
exposure O 
to O 
PFOS B-ABBREVIATION 
and O 
PFOA B-ABBREVIATION 
. O 
The O 
present O 
findings O 
show O 
that O 
PFHxS B-ABBREVIATION 
, O 
a O 
member O 
of O 
the O 
perfluoroalkyl B-FAMILY 
acid I-FAMILY 
group O 
, O 
can O 
act O 
as O 
a O 
developmental O 
neurotoxicant O 
and O 
affect O 
the O 
cholinergic O 
system O 
and O 
cognitive O 
function O 
and O 
the O 
effects O 
show O 
similarities O 
with O 
effects O 
earlier O 
reported O 
after O 
neonatal O 
exposure O 
to O 
other O 
POPs O 
, O 
such O 
as O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
, O 
PBDEs B-ABBREVIATION 
and O 
PCBs B-ABBREVIATION 
. O 

alcohol O 
binge O 
drinking O 
constitutes O 
a O 
major O 
vulnerability O 
factor O 
to O 
develop O 
alcoholism O 
. O 
However O 
, O 
mechanisms O 
underlying O 
this O 
susceptibility O 
remain O 
unknown O 
. O 
We O 
evaluated O 
the O 
effect O 
of O 
adolescent O 
binge O 
- O 
like O 
ethanol B-SYSTEMATIC 
intoxication O 
on O 
vulnerability O 
to O 
alcohol O 
abuse O 
in O 
Sprague-Dawley O 
rats O 
. O 
To O 
model O 
binge O 
- O 
like O 
ethanol B-SYSTEMATIC 
intoxication O 
, O 
every O 
2 O 
days O 
, O 
rats O 
received O 
an O 
ethanol B-SYSTEMATIC 
injection O 
( O 
3 O 
g O 
/ O 
kg O 
) O 
for O 
2 O 
consecutive O 
days O 
across O 
14 O 
days O 
either O 
from O 
postnatal O 
day O 
30 O 
( O 
PND30 O 
) O 
to O 
43 O 
( O 
early O 
adolescence O 
) O 
or O 
from O 
PND O 
45 O 
to O 
PND O 
58 O 
( O 
late O 
adolescence O 
) O 
. O 
In O 
young O 
adult O 
animals O 
, O 
we O 
measured O 
free O 
ethanol B-SYSTEMATIC 
consumption O 
in O 
the O 
two O 
- O 
bottle O 
choice O 
paradigm O 
, O 
motivation O 
for O 
ethanol B-SYSTEMATIC 
in O 
the O 
operant O 
self O 
- O 
administration O 
task O 
and O 
both O 
ethanol B-SYSTEMATIC 
' O 
s O 
rewarding O 
and O 
aversive O 
properties O 
in O 
the O 
conditioned O 
place O 
preference O 
( O 
CPP O 
) O 
and O 
taste O 
aversion O 
( O 
CTA O 
) O 
paradigms O 
. O 
While O 
intermittent O 
ethanol B-SYSTEMATIC 
intoxications O 
( O 
IEI O 
) O 
during O 
late O 
adolescence O 
had O 
no O 
effect O 
on O 
free O 
- O 
choice O 
10% O 
ethanol B-SYSTEMATIC 
consumption O 
, O 
we O 
found O 
that O 
IEI O 
during O 
early O 
adolescence O 
promoted O 
free O 
- O 
choice O 
10% O 
ethanol B-SYSTEMATIC 
consumption O 
, O 
enhanced O 
motivation O 
for O 
ethanol B-SYSTEMATIC 
in O 
the O 
self O 
- O 
administration O 
paradigm O 
and O 
induced O 
a O 
loss O 
of O 
both O 
ethanol B-SYSTEMATIC 
-induced O 
CPP O 
and O 
CTA O 
in O 
young O 
adults O 
. O 
No O 
modification O 
in O 
either O 
sucrose B-TRIVIAL 
self O 
- O 
administration O 
or O 
amphetamine B-TRIVIAL 
-induced O 
CPP O 
was O 
observed O 
. O 
As O 
the O 
nucleus O 
accumbens O 
( O 
Nac O 
) O 
is O 
particularly O 
involved O 
in O 
addictive O 
behavior O 
, O 
we O 
analyzed O 
IEI-induced O 
long O 
- O 
term O 
neuroadaptations O 
in O 
the O 
Nac O 
using O 
c-Fos O 
immunohistochemistry O 
and O 
an O 
array O 
of O 
neurotransmission O 
- O 
related O 
genes O 
. O 
This O 
vulnerability O 
to O 
ethanol B-SYSTEMATIC 
abuse O 
was O 
associated O 
with O 
a O 
lower O 
c-Fos O 
immunoreactivity O 
in O 
the O 
Nac O 
and O 
enduring O 
alterations O 
of O 
the O 
expression O 
of O 
Penk O 
and O 
Slc6a4 O 
, O 
2 O 
neurotransmission O 
- O 
related O 
genes O 
that O 
have O 
been O 
shown O 
to O 
play O 
critical O 
roles O 
in O 
the O 
behavioral O 
effects O 
of O 
ethanol B-SYSTEMATIC 
and O 
alcoholism O 
. O 

discrimination O 
and O 
antagonism O 
by O 
CB(1) O 
neutral O 
and O 
inverse O 
agonist O 
antagonists O 
. O 

receptor O 
1 O 
(CB(1)) O 
inverse O 
agonists O 
( O 
e.g O 
. O 
, O 
rimonabant B-TRIVIAL 
) O 
have O 
been O 
reported O 
to O 
produce O 
adverse O 
effects O 
including O 
nausea O 
, O 
emesis O 
, O 
and O 
anhedonia O 
that O 
limit O 
their O 
clinical O 
applications O 
. O 
Recent O 
laboratory O 
studies O 
suggest O 
that O 
the O 
effects O 
of O 
CB(1) O 
neutral O 
antagonists O 
differ O 
from O 
those O 
of O 
such O 
inverse O 
agonists O 
, O 
raising O 
the O 
possibility O 
of O 
improved O 
clinical O 
utility O 
. O 
However O 
, O 
little O 
is O 
known O 
regarding O 
the O 
antagonist O 
properties O 
of O 
neutral O 
antagonists O 
. O 
In O 
the O 
present O 
studies O 
, O 
the O 
CB(1) O 
inverse O 
agonist O 
SR141716A B-IDENTIFIER 
( O 
rimonabant B-TRIVIAL 
) O 
and O 
the O 
CB(1) O 
neutral O 
antagonist O 
AM4113 B-IDENTIFIER 
were O 
compared O 
for O 
their O 
ability O 
to O 
modify O 
CB(1) O 
receptor O 
- O 
mediated O 
discriminative O 
stimulus O 
effects O 
in O 
nonhuman O 
primates O 
trained O 
to O 
discriminate O 
the O 
novel O 
CB(1) O 
full O 
agonist O 
AM4054 B-IDENTIFIER 
. O 
Results O 
indicate O 
that O 
AM4054 B-IDENTIFIER 
serves O 
as O 
an O 
effective O 
CB(1) O 
discriminative O 
stimulus O 
, O 
with O 
an O 
onset O 
and O 
time O 
course O 
of O 
action O 
comparable O 
with O 
that O 
of O 
the O 
CB(1) O 
agonist O 
Δ(9)-tetrahydrocannabinol B-SYSTEMATIC 
, O 
and O 
that O 
the O 
inverse O 
agonist O 
rimonabant B-TRIVIAL 
and O 
the O 
neutral O 
antagonist O 
AM4113 B-IDENTIFIER 
produce O 
dose O 
- O 
related O 
rightward O 
shifts O 
in O 
the O 
AM4054 B-IDENTIFIER 
dose O 
- O 
effect O 
curve O 
, O 
indicating O 
that O 
both O 
drugs O 
surmountably O 
antagonize O 
the O 
discriminative O 
stimulus O 
effects O 
of O 
AM4054 B-IDENTIFIER 
. O 
Schild O 
analyses O 
further O 
show O 
that O 
rimonabant B-TRIVIAL 
and O 
AM4113 B-IDENTIFIER 
produce O 
highly O 
similar O 
antagonist O 
effects O 
, O 
as O 
evident O 
in O 
comparable O 
pA(2) O 
values O 
( O 
6.9 O 
) O 
. O 
Taken O 
together O 
with O 
previous O 
studies O 
, O 
the O 
present O 
data O 
suggest O 
that O 
the O 
improved O 
safety O 
profile O 
suggested O 
for O 
CB(1) O 
neutral O 
antagonists O 
over O 
inverse O 
agonists O 
is O 
not O 
accompanied O 
by O 
a O 
loss O 
of O 
antagonist O 
action O 
at O 
CB(1) O 
receptors O 
. O 

dependent O 
molecular O 
effects O 
of O 
acrylamide B-TRIVIAL 
and O 
glycidamide B-TRIVIAL 
in O 
human O 
cancer O 
cell O 
lines O 
and O 
human O 
primary O 
hepatocytes O 
. O 

published O 
studies O 
suggest O 
a O 
weak O 
positive O 
correlation O 
between O 
increased O 
dietary O 
acrylamide B-TRIVIAL 
intake O 
and O 
the O 
increased O 
risk O 
of O 
endometrial O 
and O 
ovarian O 
cancer O 
. O 
However O 
, O 
risk O 
assessment O 
of O 
acrylamide B-TRIVIAL 
remains O 
difficult O 
because O 
the O 
carcinogenic O 
mechanisms O 
are O 
still O 
unknown O 
and O 
in O 
particular O 
the O 
molecular O 
effects O 
of O 
low O 
level O 
acrylamide B-TRIVIAL 
exposure O 
as O 
seen O 
by O 
dietary O 
intake O 
are O 
not O 
well O 
understood O 
. O 
Therefore O 
, O 
we O 
analyzed O 
in O 
ovarian O 
and O 
endometrial O 
cancer O 
cell O 
lines O 
as O 
well O 
as O 
in O 
primary O 
hepatocytes O 
the O 
expression O 
of O 
genes O 
involved O 
in O 
cancer O 
development O 
and O 
xenobiotic O 
metabolism O 
after O 
high O 
and O 
low O 
dose O 
exposure O 
( O 
1-0.001mM O 
) O 
of O 
acrylamide B-TRIVIAL 
and O 
its O 
metabolite O 
glycidamide B-TRIVIAL 
. O 
In O 
conclusion O 
our O 
in O 
vitro O 
results O 
demonstrate O 
that O 
exposure O 
to O 
high O 
doses O 
of O 
glycidamide B-TRIVIAL 
/ O 
acrylamide B-TRIVIAL 
- O 
exceeding O 
the O 
dietary O 
exposure O 
of O 
the O 
general O 
population O 
by O 
far O 
- O 
can O 
induce O 
genes O 
with O 
growth O 
promoting O 
potential O 
like O 
the O 
oncogene O 
cMYC O 
and O 
genes O 
involved O 
in O 
the O 
MAPK O 
pathway O 
. O 
However O 
, O 
low O 
- O 
dose O 
exposure O 
seems O 
to O 
activate O 
primarily O 
genes O 
involved O 
in O 
the O 
elimination O 
of O 
the O 
toxicant O 
. O 

and O 
characterization O 
of O 
an O 
antibacterial O 
L-amino B-FAMILY 
acid I-FAMILY 
oxidase O 
from O 
Crotalus O 
durissus O 
cumanensis O 
venom O 
. O 

L-amino B-FAMILY 
acid I-FAMILY 
oxidase O 
( O 
LAAO O 
) O 
from O 
Crotalus O 
durissus O 
cumanensis O 
venom O 
( O 
CdcLAAO O 
) O 
was O 
purified O 
to O 
homogeneity O 
using O 
a O 
combination O 
of O 
size O 
- O 
exclusion O 
and O 
ion O 
exchange O 
chromatographies O 
. O 
CdcLAAO O 
is O 
a O 
monomeric O 
protein O 
exhibiting O 
an O 
apparent O 
molecular O 
mass O 
of O 
55 O 
kDa O 
and O 
a O 
calculated O 
pI O 
of O 
8 O 
. O 
Its O 
complete O 
498- O 
amino-acid B-FAMILY 
sequence O 
was O 
deduced O 
through O 
cDNA O 
and O 
protein O 
sequencing O 
. O 
The O 
enzyme O 
oxidized O 
L-Leu B-FORMULA 
with O 
K(m) O 
and O 
a O 
V(Max) O 
of O 
9.23 O 
μM O 
and O 
0.46 O 
μM O 
/ O 
min O 
respectively O 
, O 
and O 
exhibited O 
Kcat O 
and O 
a O 
Kcat O 
/ O 
K(m) O 
of O 
1.8 O 
s(-1) O 
and O 
195 O 
mM(-1)s(-1) O 
. O 
CdcLAAO O 
inhibited O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
the O 
growth O 
of O 
Staphylococcus O 
aureus O 
and O 
Acinetobacter O 
baumannii O 
. O 
The O 
inhibitory O 
effect O 
was O 
more O 
significant O 
on O 
S O 
. O 
aureus O 
, O 
with O 
a O 
Minimal O 
Inhibitory O 
Concentration O 
( O 
MIC O 
) O 
of O 
8 O 
μg O 
/ O 
mL O 
and O 
Minimal O 
Bactericidal O 
Concentration O 
( O 
MBC O 
) O 
of O 
16 O 
μg O 
/ O 
mL O 
, O 
than O 
against O 
A O 
. O 
baumannii O 
, O 
with O 
a O 
MIC O 
of O 
16 O 
μg O 
/ O 
mL O 
and O 
MBC O 
of O 
32 O 
μg O 
/ O 
mL O 
. O 
However O 
, O 
against O 
Escherichia O 
coli O 
CdcLAAO O 
did O 
not O 
show O 
inhibitory O 
capacity O 
at O 
the O 
concentrations O 
tested O 
( O 
2-128 O 
μg O 
/ O 
mL O 
) O 
. O 
CdcLAAO O 
did O 
not O 
exhibit O 
cytotoxic O 
activity O 
on O 
the O 
mouse O 
myoblast O 
cell O 
line O 
C(2)C(12) O 
and O 
on O 
peripheral O 
blood O 
mononuclear O 
cell O 
( O 
PBMC O 
) O 
. O 

of O 
the O 
flame O 
- O 
retardant O 
BDE-49 B-ABBREVIATION 
on O 
brain O 
mitochondria O 
and O 
neuronal O 
progenitor O 
striatal O 
cells O 
enhanced O 
by O 
a O 
PTEN-deficient O 
background O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
represent O 
an O 
important O 
group O 
of O 
flame O 
retardants O 
extensively O 
used O 
, O 
tonnage O 
of O 
which O 
in O 
the O 
environment O 
has O 
been O 
steadily O 
increasing O 
over O 
the O 
past O 
25 O 
years O 
. O 
PBDEs B-ABBREVIATION 
or O 
metabolites O 
can O 
induce O 
neurotoxicity O 
and O 
mitochondrial O 
dysfunction O 
( O 
MD O 
) O 
through O 
a O 
variety O 
of O 
mechanisms O 
. O 
Recently O 
, O 
PBDEs B-ABBREVIATION 
with O 
< O 
5 O 
Br B-FORMULA 
substitutions O 
( O 
i.e O 
. O 
, O 
2,2',4,4'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
[ O 
BDE-47 B-ABBREVIATION 
] O 
and O 
2,2',4,5'-tetrabromodiphenyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
[ O 
BDE-49 B-ABBREVIATION 
] O 
) O 
have O 
gained O 
interest O 
because O 
of O 
their O 
high O 
bioaccumulation O 
. O 
In O 
particular O 
, O 
congeners O 
such O 
as O 
BDE-49 B-ABBREVIATION 
arise O 
as O 
one O 
of O 
the O 
most O 
biologically O 
active O 
, O 
with O 
concentrations O 
typically O 
lower O 
than O 
those O 
observed O 
for O 
BDE-47 B-ABBREVIATION 
in O 
biological O 
tissues O 
; O 
however O 
, O 
its O 
potential O 
to O 
cause O 
MD O 
at O 
biologically O 
relevant O 
concentrations O 
is O 
unknown O 
. O 
To O 
this O 
end O 
, O 
the O 
effect O 
of O 
BDE-49 B-ABBREVIATION 
was O 
studied O 
in O 
brain O 
mitochondria O 
and O 
neuronal O 
progenitor O 
striatal O 
cells O 
( O 
NPC O 
) O 
. O 
BDE-49 B-ABBREVIATION 
uncoupled O 
mitochondria O 
at O 
concentrations O 
< O 
0.1 O 
nM O 
, O 
whereas O 
at O 
> O 
1 O 
nM O 
, O 
it O 
inhibited O 
the O 
electron O 
transport O 
at O 
Complex O 
V O 
( O 
mixed O 
type O 
inhibition O 
; O 
IC(50) O 
= O 
6 O 
nM O 
) O 
and O 
Complex O 
IV O 
( O 
noncompetitive O 
inhibition O 
; O 
IC(50) O 
= O 
40 O 
nM O 
) O 
. O 
These O 
concentrations O 
are O 
easily O 
achieved O 
in O 
plasma O 
concentrations O 
considering O 
that O 
BDE-49 B-ABBREVIATION 
( O 
this O 
study O 
, O 
400-fold O 
) O 
and O 
other O 
PBDEs B-ABBREVIATION 
accumulate O 
1-3 O 
orders O 
of O 
magnitude O 
in O 
the O 
cells O 
, O 
particularly O 
in O 
mitochondria O 
and O 
microsomes O 
. O 
Similar O 
effects O 
were O 
observed O 
in O 
NPC O 
and O 
exacerbated O 
with O 
PTEN O 
( O 
negative O 
modulator O 
of O 
the O 
PI3K O 
/ O 
Akt O 
pathway O 
) O 
deficiency O 
, O 
background O 
associated O 
with O 
autism O 
- O 
like O 
behavior O 
, O 
schizophrenia O 
, O 
and O 
epilepsy O 
. O 
PBDE B-ABBREVIATION 
-mediated O 
MD O 
per O 
se O 
or O 
enhanced O 
by O 
a O 
background O 
that O 
confers O 
susceptibility O 
to O 
this O 
exposure O 
may O 
have O 
profound O 
implications O 
in O 
the O 
energy O 
balance O 
of O 
brain O 
. O 

carcinoma O 
( O 
HCC O 
) O 
mostly O 
develops O 
in O 
patients O 
with O 
advanced O 
fibrosis O 
; O 
however O 
, O 
the O 
mechanisms O 
of O 
interaction O 
between O 
a O 
genotoxic O 
insult O 
and O 
fibrogenesis O 
are O 
not O 
well O 
understood O 
. O 
This O 
study O 
tested O 
a O 
hypothesis O 
that O 
fibrosis O 
promotes O 
HCC O 
via O 
a O 
mechanism O 
that O 
involves O 
activation O 
of O 
liver O 
stem O 
cells O 
. O 
First O 
, O 
B6C3F1 O 
mice O 
were O 
administered O 
diethylnitrosamine B-SYSTEMATIC 
( O 
DEN B-ABBREVIATION 
; O 
single O 
ip O 
injection O 
of O 
1mg O 
/ O 
kg O 
at O 
14 O 
days O 
of O 
age O 
) O 
. O 
Second O 
, O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl(4) B-FORMULA 
; O 
0.2ml O 
/ O 
kg O 
, O 
2 O 
/ O 
week O 
ip O 
starting O 
at O 
8 O 
weeks O 
of O 
age O 
) O 
was O 
administered O 
for O 
9 O 
or O 
14 O 
weeks O 
to O 
develop O 
advanced O 
liver O 
fibrosis O 
. O 
In O 
animals O 
treated O 
with O 
DEN B-ABBREVIATION 
as O 
neonates O 
, O 
presence O 
of O 
liver O 
fibrosis O 
led O 
to O 
more O 
than O 
doubling O 
( O 
to O 
100% O 
) O 
of O 
the O 
liver O 
tumor O 
incidence O 
as O 
early O 
as O 
5 O 
months O 
of O 
age O 
. O 
This O 
effect O 
was O 
associated O 
with O 
activation O 
of O 
cells O 
with O 
progenitor O 
features O 
in O 
noncancerous O 
liver O 
tissue O 
, O 
including O 
markers O 
of O 
replicative O 
senescence O 
( O 
p16 O 
) O 
, O 
oncofetal O 
transformation O 
( O 
Afp O 
, O 
H19 O 
, O 
and O 
Bex1 O 
) O 
, O 
and O 
increased O 
" O 
stemness O 
" O 
( O 
Prom1 O 
and O 
Epcam O 
) O 
. O 
In O 
contrast O 
, O 
the O 
dose O 
of O 
DEN B-ABBREVIATION 
used O 
did O 
not O 
modify O 
the O 
extent O 
of O 
liver O 
inflammation O 
, O 
fibrogenesis O 
, O 
oxidative O 
stress O 
, O 
proliferation O 
, O 
or O 
apoptosis O 
induced O 
by O 
subchronic O 
CCl(4) B-FORMULA 
administration O 
. O 
This O 
study O 
demonstrates O 
the O 
potential O 
role O 
of O 
liver O 
stem O 
- O 
like O 
cells O 
in O 
the O 
mechanisms O 
of O 
chemical O 
- O 
induced O 
, O 
fibrosis O 
- O 
promoted O 
HCC O 
. O 
We O 
posit O 
that O 
the O 
combination O 
of O 
genotoxic O 
and O 
fibrogenic O 
insults O 
is O 
a O 
sensible O 
approach O 
to O 
model O 
liver O 
carcinogenesis O 
in O 
experimental O 
animals O 
. O 
These O 
results O 
may O 
contribute O 
to O 
identification O 
of O 
cirrhotic O 
patients O 
predisposed O 
to O 
HCC O 
by O 
analyzing O 
the O 
expression O 
of O 
hepatic O 
progenitor O 
cell O 
markers O 
in O 
the O 
noncancerous O 
liver O 
tissue O 
. O 

( O 
serum O 
/ O 
plasma O 
) O 
antiepileptic O 
drug O 
( O 
AED O 
) O 
therapeutic O 
drug O 
monitoring O 
( O 
TDM O 
) O 
has O 
proven O 
to O 
be O 
an O 
invaluable O 
surrogate O 
marker O 
for O 
individualizing O 
and O 
optimizing O 
the O 
drug O 
management O 
of O 
patients O 
with O 
epilepsy O 
. O 
Since O 
1989 O 
, O 
there O 
has O 
been O 
an O 
exponential O 
increase O 
in O 
AEDs O 
with O 
23 O 
currently O 
licensed O 
for O 
clinical O 
use O 
, O 
and O 
recently O 
, O 
there O 
has O 
been O 
renewed O 
and O 
extensive O 
interest O 
in O 
the O 
use O 
of O 
saliva O 
as O 
an O 
alternative O 
matrix O 
for O 
AED O 
TDM O 
. O 
The O 
advantages O 
of O 
saliva O 
include O 
the O 
fact O 
that O 
for O 
many O 
AEDs O 
it O 
reflects O 
the O 
free O 
( O 
pharmacologically O 
active O 
) O 
concentration O 
in O 
serum O 
; O 
it O 
is O 
readily O 
sampled O 
, O 
can O 
be O 
sampled O 
repetitively O 
, O 
and O 
sampling O 
is O 
noninvasive O 
; O 
does O 
not O 
require O 
the O 
expertise O 
of O 
a O 
phlebotomist O 
; O 
and O 
is O 
preferred O 
by O 
many O 
patients O 
, O 
particularly O 
children O 
and O 
the O 
elderly O 
. O 
For O 
each O 
AED O 
, O 
this O 
review O 
summarizes O 
the O 
key O 
pharmacokinetic O 
characteristics O 
relevant O 
to O 
the O 
practice O 
of O 
TDM O 
, O 
discusses O 
the O 
use O 
of O 
other O 
biological O 
matrices O 
with O 
particular O 
emphasis O 
on O 
saliva O 
and O 
the O 
evidence O 
that O 
saliva O 
concentration O 
reflects O 
those O 
in O 
serum O 
. O 
Also O 
discussed O 
are O 
the O 
indications O 
for O 
salivary O 
AED O 
TDM O 
, O 
the O 
key O 
factors O 
to O 
consider O 
when O 
saliva O 
sampling O 
is O 
to O 
be O 
undertaken O 
, O 
and O 
finally O 
, O 
a O 
practical O 
protocol O 
is O 
described O 
so O 
as O 
to O 
enable O 
AED O 
TDM O 
to O 
be O 
applied O 
optimally O 
and O 
effectively O 
in O 
the O 
clinical O 
setting O 
. O 
Overall O 
, O 
there O 
is O 
compelling O 
evidence O 
that O 
salivary O 
TDM O 
can O 
be O 
usefully O 
applied O 
so O 
as O 
to O 
optimize O 
the O 
treatment O 
of O 
epilepsy O 
with O 
carbamazepine B-TRIVIAL 
, O 
clobazam B-TRIVIAL 
, O 
ethosuximide B-TRIVIAL 
, O 
gabapentin B-TRIVIAL 
, O 
lacosamide B-TRIVIAL 
, O 
lamotrigine B-TRIVIAL 
, O 
levetiracetam B-TRIVIAL 
, O 
oxcarbazepine B-SYSTEMATIC 
, O 
phenobarbital B-TRIVIAL 
, O 
phenytoin B-TRIVIAL 
, O 
primidone B-TRIVIAL 
, O 
topiramate B-TRIVIAL 
, O 
and O 
zonisamide B-TRIVIAL 
. O 
Salivary O 
TDM O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
is O 
probably O 
not O 
helpful O 
, O 
whereas O 
for O 
clonazepam B-TRIVIAL 
, O 
eslicarbazepine B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
felbamate B-TRIVIAL 
, O 
pregabalin B-TRIVIAL 
, O 
retigabine B-TRIVIAL 
, O 
rufinamide B-TRIVIAL 
, O 
stiripentol B-TRIVIAL 
, O 
tiagabine B-TRIVIAL 
, O 
and O 
vigabatrin B-TRIVIAL 
, O 
the O 
data O 
are O 
sparse O 
or O 
nonexistent O 
. O 

new O 
hematite B-TRIVIAL 
photoanode O 
doping O 
strategy O 
for O 
solar O 
water O 
splitting O 
: O 
oxygen B-SYSTEMATIC 
vacancy O 
generation O 
. O 

enhancement O 
of O 
the O 
electrical O 
conductivity O 
by O 
doping O 
is O 
important O 
in O 
hematite B-TRIVIAL 
( O 
α-Fe(2)O(3) B-FORMULA 
) O 
photoanodes O 
for O 
efficient O 
solar O 
water O 
oxidation O 
. O 
However O 
, O 
in O 
spite O 
of O 
many O 
successful O 
demonstrations O 
using O 
extrinsic O 
dopants O 
, O 
such O 
as O 
Sn B-FORMULA 
, O 
Ti B-FORMULA 
, O 
and O 
Si B-FORMULA 
, O 
the O 
achieved O 
photocurrent O 
is O 
still O 
lower O 
than O 
the O 
practical O 
requirement O 
. O 
There O 
is O 
still O 
lack O 
of O 
our O 
understanding O 
of O 
how O 
intrinsic O 
oxygen B-SYSTEMATIC 
defects O 
can O 
change O 
the O 
photocurrent O 
and O 
interact O 
with O 
the O 
extrinsic O 
dopants O 
. O 
In O 
this O 
study O 
, O 
we O 
systematically O 
investigate O 
the O 
interplay O 
of O 
oxygen B-SYSTEMATIC 
vacancies O 
and O 
extrinsic O 
Sn B-FORMULA 
dopants O 
in O 
the O 
context O 
of O 
photoanodic O 
properties O 
. O 
As O 
a O 
result O 
, O 
we O 
demonstrate O 
that O 
the O 
controlled O 
generation O 
of O 
oxygen B-SYSTEMATIC 
vacancies O 
can O 
activate O 
the O 
photoactivity O 
of O 
pure O 
hematite B-TRIVIAL 
remarkably O 
and O 
further O 
enhance O 
the O 
Sn B-FORMULA 
doping O 
effects O 
synergistically O 
. O 
Furthermore O 
, O 
the O 
correlated O 
behavior O 
of O 
oxygen B-SYSTEMATIC 
vacancies O 
and O 
Sn B-FORMULA 
dopants O 
is O 
closely O 
linked O 
to O 
the O 
variation O 
of O 
electrical O 
conductance O 
and O 
results O 
in O 
the O 
optimum O 
concentration O 
region O 
to O 
show O 
the O 
high O 
photocurrent O 
and O 
low O 
onset O 
voltage O 
. O 

increases O 
portal O 
bioavailability O 
of O 
loperamide B-TRIVIAL 
in O 
mouse O 
by O 
reducing O 
first O 
- O 
pass O 
intestinal O 
metabolism O 
. O 

( O 
P-gp O 
) O 
and O 
CYP3A O 
( O 
cytochrome O 
P450 O 
3A O 
, O 
generally O 
; O 
Cyp3a O 
, O 
rodent O 
enzyme O 
) O 
in O 
the O 
intestine O 
can O 
attenuate O 
absorption O 
of O 
orally O 
administered O 
drugs O 
. O 
While O 
some O 
suggest O 
that O 
P-gp O 
enhances O 
intestinal O 
metabolism O 
by O 
CYP3A O 
/ O 
Cyp3a O 
during O 
absorption O 
of O 
a O 
dual O 
substrate O 
, O 
others O 
suggest O 
that O 
P-gp O 
reduces O 
the O 
metabolism O 
in O 
the O 
intestine O 
when O 
substrates O 
are O 
at O 
subsaturating O 
concentrations O 
. O 
Hence O 
, O 
to O 
elucidate O 
the O 
cellular O 
mechanisms O 
that O 
can O 
address O 
these O 
divergent O 
reports O 
, O 
we O 
studied O 
intestinal O 
absorption O 
of O 
the O 
dual O 
substrate O 
loperamide B-TRIVIAL 
in O 
portal O 
vein O 
- O 
cannulated O 
P-gp O 
- O 
competent O 
and O 
P-gp O 
- O 
deficient O 
mice O 
. O 
These O 
studies O 
showed O 
that O 
at O 
low O 
doses O 
of O 
loperamide B-TRIVIAL 
, O 
which O 
produced O 
intestinal O 
concentrations O 
near O 
the O 
apparent O 
K(m) O 
for O 
oxidative O 
metabolism O 
, O 
the O 
bioavailability O 
across O 
the O 
intestine O 
(F(G)) O 
was O 
6-fold O 
greater O 
in O 
the O 
P-gp O 
- O 
competent O 
mice O 
than O 
in O 
P-gp O 
- O 
deficient O 
mice O 
. O 
The O 
higher O 
F(G) O 
of O 
loperamide B-TRIVIAL 
in O 
the O 
presence O 
of O 
P-gp O 
was O 
attributed O 
to O 
lower O 
loperamide B-TRIVIAL 
intestinal O 
metabolism O 
. O 
However O 
, O 
at O 
high O 
doses O 
of O 
loperamide B-TRIVIAL 
, O 
the O 
sparing O 
of O 
first O 
- O 
pass O 
metabolism O 
by O 
P-gp O 
was O 
balanced O 
against O 
the O 
attenuation O 
of O 
absorption O 
by O 
apical O 
efflux O 
, O 
resulting O 
in O 
no O 
net O 
effect O 
on O 
F(G) O 
. O 
In O 
vitro O 
studies O 
with O 
intestinal O 
tissue O 
from O 
P-gp O 
- O 
competent O 
and O 
-deficient O 
mice O 
confirmed O 
that O 
P-gp O 
reduced O 
the O 
metabolic O 
rate O 
of O 
loperamide B-TRIVIAL 
during O 
absorptive O 
flux O 
at O 
concentrations O 
near O 
K(m) O 
but O 
had O 
little O 
effect O 
on O 
metabolism O 
at O 
higher O 
( O 
saturating O 
) O 
concentrations O 
. O 
Further O 
, O 
studies O 
in O 
which O 
Cyp3a O 
was O 
chemically O 
inactivated O 
by O 
aminobenzotriazole B-SYSTEMATIC 
in O 
P-gp O 
- O 
competent O 
and O 
-deficient O 
mice O 
, O 
showed O 
that O 
P-gp O 
and O 
Cyp3a O 
individually O 
attenuated O 
F(G) O 
by O 
8-fold O 
and O 
70-fold O 
, O 
respectively O 
. O 
These O 
results O 
confirmed O 
that O 
P-gp O 
effectively O 
protects O 
loperamide B-TRIVIAL 
at O 
low O 
doses O 
from O 
intestinal O 
first O 
- O 
pass O 
metabolism O 
during O 
intestinal O 
absorption O 
. O 

- O 
cross O 
- O 
linkable O 
polyelectrolyte O 
films O 
, O 
whose O 
nanomechanical O 
properties O 
can O 
be O 
varied O 
under O 
UV O 
light O 
illumination O 
, O 
were O 
prepared O 
from O 
poly(l-lysine) B-SYSTEMATIC 
( O 
PLL B-ABBREVIATION 
) O 
and O 
a O 
hyaluronan O 
derivative O 
modified O 
with O 
photoreactive O 
vinylbenzyl B-SYSTEMATIC 
groups O 
( O 
HAVB O 
) O 
. O 
The O 
adhesion O 
and O 
the O 
growth O 
of O 
two O 
model O 
bacteria O 
, O 
namely O 
Escherichia O 
coli O 
and O 
Lactococcus O 
lactis O 
, O 
were O 
studied O 
on O 
non-cross O 
- O 
linked O 
and O 
cross O 
- O 
linked O 
films O 
to O 
investigate O 
how O 
the O 
film O 
stiffness O 
influences O 
the O 
bacterial O 
behavior O 
. O 
While O 
the O 
Gram O 
positive O 
L O 
. O 
lactis O 
was O 
shown O 
to O 
grow O 
slowly O 
on O 
both O 
films O 
, O 
independently O 
of O 
their O 
rigidity O 
, O 
the O 
Gram O 
negative O 
E O 
. O 
coli O 
exhibited O 
a O 
more O 
rapid O 
growth O 
on O 
non-cross O 
- O 
linked O 
softer O 
films O 
compared O 
to O 
the O 
stiffer O 
ones O 
. O 
Experiments O 
performed O 
on O 
photopatterned O 
films O 
showing O 
both O 
soft O 
and O 
stiff O 
regions O 
, O 
confirmed O 
a O 
faster O 
development O 
of O 
E O 
. O 
coli O 
colonies O 
on O 
softer O 
regions O 
. O 
Interestingly O 
, O 
this O 
behavior O 
is O 
opposite O 
to O 
the O 
one O 
reported O 
before O 
for O 
mammalian O 
cells O 
. O 
Therefore O 
, O 
the O 
photo O 
- O 
cross O 
- O 
linked O 
( O 
PLL O 
/ O 
HAVB O 
) O 
films O 
are O 
interesting O 
coatings O 
for O 
tissue O 
engineering O 
since O 
they O 
promote O 
the O 
growth O 
of O 
mammalian O 
cells O 
while O 
limiting O 
the O 
bacterial O 
colonization O 
. O 

1H-1,2,3- B-MULTIPLE 
, I-MULTIPLE 
2H-1,2,3- I-MULTIPLE 
, I-MULTIPLE 
1H-1,2,4- I-MULTIPLE 
and I-MULTIPLE 
4H-1,2,4-triazole I-MULTIPLE 
derivatives O 
: O 
a O 
patent O 
review O 
( O 
2008 O 
- O 
2011 O 
) O 
. O 

: O 
The O 
triazoles B-FAMILY 
represent O 
a O 
class O 
of O 
five O 
- O 
membered O 
heterocyclic O 
compounds O 
of O 
great O 
importance O 
for O 
the O 
preparation O 
of O 
new O 
drugs O 
with O 
diverse O 
biological O 
activities O 
because O 
they O 
may O 
present O 
several O 
structural O 
variations O 
with O 
the O 
same O 
numbers O 
of O 
carbon B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
atoms O 
. O 
Due O 
to O 
the O 
success O 
of O 
various O 
triazoles B-FAMILY 
that O 
entered O 
the O 
pharmaceutical O 
market O 
and O 
are O 
still O 
being O 
used O 
in O 
medicines O 
, O 
many O 
companies O 
and O 
research O 
groups O 
have O 
shown O 
interest O 
in O 
developing O 
new O 
methods O 
of O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
potential O 
uses O 
for O 
these O 
compounds O 
. O 
In O 
this O 
review O 
, O 
the O 
authors O 
explored O 
aspects O 
of O 
patents O 
for O 
the O 
1H-1,2,3- B-MULTIPLE 
, I-MULTIPLE 
2H-1,2,3- I-MULTIPLE 
, I-MULTIPLE 
1H-1,2,4- I-MULTIPLE 
and I-MULTIPLE 
4H-1,2,4-triazole I-MULTIPLE 
families O 
, O 
including O 
prototypes O 
being O 
considered O 
in O 
clinical O 
studies O 
between O 
2008 O 
and O 
2011 O 
. O 
AREAS O 
COVERED O 
: O 
The O 
triazoles B-FAMILY 
have O 
been O 
studied O 
for O 
over O 
a O 
century O 
as O 
an O 
important O 
class O 
of O 
heterocyclic O 
compounds O 
and O 
still O 
attract O 
considerable O 
attention O 
due O 
to O 
their O 
broad O 
range O 
of O 
biological O 
activities O 
. O 
More O 
recently O 
, O 
there O 
has O 
been O 
considerable O 
interest O 
in O 
the O 
development O 
of O 
novel O 
triazoles B-FAMILY 
with O 
anti-inflammatory O 
, O 
antiplatelet O 
, O 
antimicrobial O 
, O 
antimycobacterial O 
, O 
antitumoral O 
and O 
antiviral O 
properties O 
and O 
activity O 
against O 
several O 
neglected O 
diseases O 
. O 
This O 
review O 
emphasizes O 
recent O 
perspective O 
and O 
advances O 
in O 
the O 
therapeutically O 
active O 
1H-1,2,3- B-MULTIPLE 
, I-MULTIPLE 
2H-1,2,3- I-MULTIPLE 
, I-MULTIPLE 
1H-1,2,4- I-MULTIPLE 
and I-MULTIPLE 
4H-1,2,4-triazole I-MULTIPLE 
derivative O 
patents O 
between O 
2008 O 
and O 
2011 O 
, O 
covering O 
the O 
development O 
of O 
new O 
chemical O 
entities O 
and O 
new O 
pharmaceuticals O 
. O 
Many O 
studies O 
have O 
focused O 
on O 
these O 
compounds O 
as O 
target O 
structures O 
and O 
evaluated O 
them O 
in O 
several O 
biological O 
targets O 
. O 
EXPERT O 
OPINION O 
: O 
The O 
preparation O 
of O 
1H-1,2,3- B-MULTIPLE 
, I-MULTIPLE 
2H-1,2,3- I-MULTIPLE 
, I-MULTIPLE 
1H-1,2,4- I-MULTIPLE 
and I-MULTIPLE 
4H-1,2,4-triazole I-MULTIPLE 
derivatives O 
brings O 
to O 
light O 
several O 
issues O 
. O 
There O 
is O 
a O 
need O 
to O 
find O 
new O 
, O 
more O 
efficient O 
preparations O 
for O 
these O 
triazoles B-FAMILY 
that O 
take O 
into O 
consideration O 
current O 
issues O 
in O 
green O 
chemistry O 
, O 
energy O 
saving O 
and O 
sustainability O 
. O 
New O 
diseases O 
are O 
discovered O 
and O 
new O 
viruses O 
and O 
bacteria O 
continue O 
to O 
challenge O 
mankind O 
, O 
so O 
it O 
is O 
imperative O 
to O 
find O 
new O 
prototypes O 
for O 
these O 
new O 
diseases O 
. O 
Of O 
great O 
urgency O 
is O 
finding O 
prototypes O 
against O 
bacteria O 
that O 
continue O 
to O 
increase O 
resistance O 
and O 
for O 
neglected O 
diseases O 
that O 
affect O 
a O 
large O 
part O 
of O 
humanity O 
, O 
especially O 
the O 
poor O 
and O 
vulnerable O 
. O 

multiple O 
photon O 
dissociation O 
action O 
spectroscopy O 
of O 
deprotonated O 
DNA O 
mononucleotides B-FAMILY 
: O 
gas-phase O 
conformations O 
and O 
energetics O 
. O 

gas O 
phase O 
structures O 
of O 
the O 
deprotonated O 
2'-deoxymononucleotides B-FAMILY 
including O 
2'-deoxyadenosine-5'-monophosphate B-SYSTEMATIC 
( O 
dA5'p B-SYSTEMATIC 
) O 
, O 
2'-deoxycytidine-5'-monophosphate B-SYSTEMATIC 
( O 
dC5'p B-SYSTEMATIC 
) O 
, O 
2'-deoxyguanosine-5'-monophosphate B-SYSTEMATIC 
( O 
dG5'p B-SYSTEMATIC 
) O 
, O 
and O 
thymidine-5'-monophosphate B-SYSTEMATIC 
( O 
T5'p B-SYSTEMATIC 
) O 
are O 
examined O 
via O 
infrared O 
multiple O 
photon O 
dissociation O 
( O 
IRMPD O 
) O 
action O 
spectroscopy O 
and O 
theoretical O 
electronic O 
structure O 
calculations O 
. O 
The O 
measured O 
IRMPD O 
action O 
spectra O 
of O 
all O 
four O 
deprotonated O 
DNA O 
mononucleotides B-FAMILY 
exhibit O 
unique O 
spectral O 
features O 
in O 
the O 
region O 
extending O 
from O 
~600 O 
to O 
1800 O 
cm(-1) O 
such O 
that O 
they O 
can O 
be O 
readily O 
differentiated O 
from O 
one O 
another O 
. O 
The O 
measured O 
IRMPD O 
action O 
spectra O 
are O 
compared O 
to O 
the O 
linear O 
IR O 
spectra O 
calculated O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G(d,p) O 
level O 
of O 
theory O 
to O 
determine O 
the O 
conformations O 
of O 
these O 
species O 
accessed O 
in O 
the O 
experiments O 
. O 
On O 
the O 
basis O 
of O 
these O 
comparisons O 
and O 
the O 
computed O 
energetic O 
information O 
, O 
the O 
most O 
stable O 
conformations O 
of O 
the O 
deprotonated O 
forms O 
of O 
dA5'p B-SYSTEMATIC 
, O 
dC5'p B-SYSTEMATIC 
, O 
and O 
T5'p B-SYSTEMATIC 
are O 
conformers O 
where O 
the O 
ribose B-TRIVIAL 
moiety O 
adopts O 
a O 
C3 O 
' O 
endo O 
conformation O 
and O 
the O 
nucleobase B-FAMILY 
is O 
in O 
an O 
anti O 
conformation O 
. O 
By O 
contrast O 
, O 
the O 
most O 
stable O 
conformations O 
of O 
the O 
deprotonated O 
form O 
of O 
dG5'p B-SYSTEMATIC 
are O 
conformers O 
where O 
the O 
ribose O 
adapts O 
a O 
C3 O 
' O 
endo O 
conformation O 
and O 
the O 
nucleobase B-FAMILY 
is O 
in O 
a O 
syn O 
conformation O 
. O 
In O 
addition O 
to O 
the O 
ground O 
- O 
state O 
conformers O 
, O 
several O 
stable O 
low O 
- O 
energy O 
excited O 
conformers O 
that O 
differ O 
slightly O 
in O 
the O 
orientation O 
of O 
the O 
phosphate B-SYSTEMATIC 
ester I-SYSTEMATIC 
moiety O 
were O 
also O 
accessed O 
in O 
the O 
experiments O 
. O 

new O 
method O 
is O 
described O 
that O 
combines O 
a O 
microfluidic O 
device O 
for O 
the O 
controlled O 
formation O 
of O 
liposomes O 
with O 
instantaneous O 
immobilization O 
by O 
means O 
of O 
ultrarapid O 
cooling O 
. O 
The O 
microfluidic O 
device O 
is O 
composed O 
of O 
capillaries O 
to O 
hydrodynamically O 
focus O 
a O 
stream O 
of O 
lipids O 
dissolved O 
in O 
2-propanol B-SYSTEMATIC 
by O 
two O 
adjacent O 
aqueous O 
buffer O 
streams O 
before O 
rapidly O 
cooling O 
by O 
propane O 
jet O 
- O 
freezing O 
. O 
The O 
capillary O 
containing O 
the O 
frozen O 
sheath O 
- O 
flow O 
is O 
subsequently O 
separated O 
from O 
the O 
flow O 
- O 
focusing O 
unit O 
and O 
trimmed O 
with O 
cryo O 
- O 
ultramicrotomy O 
for O 
imaging O 
with O 
cryo O 
- O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
. O 
The O 
emergence O 
of O 
liposomes O 
could O 
be O 
visualized O 
by O 
cryo-SEM O 
without O 
the O 
need O 
for O 
chemical O 
fixation O 
or O 
labeling O 
. O 
We O 
demonstrate O 
that O 
the O 
method O 
is O 
capable O 
of O 
revealing O 
in O 
more O 
detail O 
the O 
formation O 
of O 
nonequilibrium O 
liposomes O 
. O 
Partially O 
and O 
completely O 
formed O 
liposomes O 
were O 
observed O 
at O 
the O 
miscible O 
alcohol B-FAMILY 
-buffer O 
interface O 
. O 
The O 
number O 
density O 
of O 
lipid O 
vesicles O 
varied O 
along O 
the O 
focused O 
interface O 
, O 
and O 
we O 
frequently O 
found O 
clusters O 
of O 
liposomes O 
. O 
Additionally O 
, O 
evidence O 
for O 
the O 
formation O 
of O 
disclike O 
transient O 
intermediates O 
is O 
presented O 
. O 
The O 
method O 
is O 
not O 
limited O 
to O 
studying O 
self O 
- O 
assembly O 
processes O 
only O 
. O 
It O 
can O 
be O 
extended O 
to O 
other O 
biochemical O 
reactions O 
, O 
crystallization O 
processes O 
, O 
and O 
even O 
systematic O 
interfacial O 
mixing O 
studies O 
between O 
different O 
solvents O 
. O 

and O 
seasonal O 
variation O 
in O 
hypothalamic O 
RF- O 
amide B-FAMILY 
peptides O 
in O 
a O 
semi-desert O 
rodent O 
, O 
the O 
jerboa O 
. O 

jerboa O 
is O 
a O 
semi-desert O 
rodent O 
, O 
in O 
which O 
reproductive O 
activity O 
depends O 
on O 
the O 
seasons O 
, O 
being O 
sexually O 
active O 
in O 
the O 
spring O 
- O 
summer O 
. O 
The O 
present O 
study O 
aimed O 
to O 
determine O 
whether O 
the O 
expression O 
of O 
two O 
RF- O 
amide B-FAMILY 
peptides O 
recently O 
described O 
to O 
regulate O 
gonadotrophin O 
- O 
releasing O 
hormone O 
neurone O 
activity O 
, O 
kisspeptin O 
( O 
Kp O 
) O 
and O 
RF- O 
amide B-FAMILY 
-related O 
peptide O 
(RFRP)-3 O 
, O 
displays O 
seasonal O 
variation O 
in O 
jerboa O 
. O 
Kp O 
and O 
/ O 
or O 
RFRP-3 O 
immunoreactivity O 
was O 
investigated O 
in O 
the O 
hypothalamus O 
of O 
jerboas O 
captured O 
in O 
the O 
field O 
of O 
the O 
Middle O 
Atlas O 
mountain O 
( O 
Morocco O 
) O 
, O 
either O 
in O 
the O 
spring O 
or O 
autumn O 
. O 
As O 
in O 
other O 
rodents O 
, O 
the O 
Kp-immunoreactive O 
( O 
-IR O 
) O 
neurones O 
were O 
found O 
in O 
the O 
anteroventro O 
- O 
periventricular O 
and O 
arcuate O 
nuclei O 
. O 
RFRP-3 O 
neurones O 
were O 
noted O 
within O 
the O 
dorso O 
/ O 
ventromedial O 
hypothalamus O 
. O 
A O 
marked O 
sexual O 
dimorphism O 
in O 
the O 
expression O 
of O 
Kp O 
( O 
but O 
not O 
RFRP-3 O 
) O 
was O 
observed O 
. O 
The O 
number O 
of O 
Kp-IR O 
neurones O 
was O 
nine O 
- O 
fold O 
higher O 
, O 
and O 
the O 
density O 
of O 
Kp-IR O 
fibres O 
and O 
terminal O 
- O 
like O 
elements O 
in O 
the O 
median O 
eminence O 
was O 
two O 
- O 
fold O 
higher O 
in O 
females O 
than O 
in O 
males O 
. O 
Furthermore O 
, O 
a O 
significant O 
seasonal O 
variation O 
in O 
peptide O 
expression O 
was O 
obtained O 
with O 
an O 
increase O 
in O 
both O 
Kp- O 
and O 
RFRP-3-IR O 
cell O 
bodies O 
in O 
sexually O 
active O 
male O 
jerboas O 
captured O 
in O 
the O 
spring O 
compared O 
to O 
sexually O 
inactive O 
autumn O 
animals O 
. O 
In O 
the O 
arcuate O 
nucleus O 
, O 
the O 
level O 
of O 
Kp-IR O 
cells O 
and O 
fibres O 
was O 
significant O 
higher O 
during O 
the O 
sexually O 
active O 
period O 
in O 
the O 
spring O 
than O 
during O 
the O 
autumnal O 
sexual O 
quiescence O 
. O 
Similarly O 
, O 
the O 
number O 
of O 
RFRP-3-IR O 
neurones O 
in O 
the O 
ventro O 
/ O 
dorsomedial O 
hypothalamus O 
was O 
approximately O 
three O 
- O 
fold O 
higher O 
in O 
sexually O 
active O 
jerboa O 
captured O 
in O 
the O 
spring O 
compared O 
to O 
sexually O 
inactive O 
autumn O 
animals O 
. O 
Altogether O 
, O 
the O 
present O 
study O 
reports O 
the O 
distribution O 
of O 
Kp O 
and O 
RFRP-3 O 
neurones O 
in O 
the O 
hypothalamus O 
of O 
a O 
desert O 
species O 
and O 
reveals O 
a O 
seasonal O 
difference O 
in O 
their O 
expression O 
that O 
correlates O 
with O 
sexual O 
activity O 
. O 
These O 
findings O 
suggest O 
that O 
these O 
two O 
RF-amide O 
peptides O 
may O 
act O 
in O 
concert O 
to O 
synchronise O 
the O 
gonadotrophic O 
activity O 
of O 
jerboas O 
with O 
the O 
seasons O 
. O 

the O 
dynamic O 
behavior O 
of O 
molecular O 
self O 
- O 
assemblies O 
with O 
higher O 
- O 
dimensional O 
structures O 
remains O 
a O 
key O 
challenge O 
to O 
obtaining O 
well O 
- O 
controlled O 
and O 
monodispersed O 
structures O 
. O 
Nonetheless O 
, O 
there O 
exist O 
few O 
systems O 
capable O 
of O 
realizing O 
the O 
mechanism O 
of O 
supramolecular O 
polymerization O 
at O 
higher O 
dimensions O 
. O 
Herein O 
, O 
we O 
report O 
the O 
unique O 
self O 
- O 
assembling O 
behavior O 
of O 
polyion O 
complexes O 
( O 
PICs O 
) O 
consisting O 
of O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-polyelectrolyte O 
block O 
copolymer O 
as O 
an O 
example O 
of O 
two O 
- O 
dimensional O 
supramolecular O 
living O 
polymerization O 
. O 
Monodispersed O 
and O 
submicrometer O 
unilamellar O 
PIC O 
vesicles O 
( O 
nano-PICsomes O 
) O 
displayed O 
time O 
- O 
dependent O 
growth O 
while O 
maintaining O 
a O 
narrow O 
size O 
distribution O 
and O 
a O 
unilamellar O 
structure O 
. O 
Detailed O 
analysis O 
of O 
the O 
system O 
revealed O 
that O 
vesicle O 
growth O 
proceeded O 
through O 
the O 
consumption O 
of O 
unit O 
PICs O 
( O 
uPICs O 
) O 
composed O 
of O 
a O 
single O 
polycation O 
/ O 
polyanion O 
pair O 
and O 
was O 
able O 
to O 
restart O 
upon O 
the O 
further O 
addition O 
of O 
isolated O 
uPICs O 
. O 
Interestingly O 
, O 
the O 
resulting O 
vesicles O 
underwent O 
dissociation O 
into O 
uPICs O 
in O 
response O 
to O 
mechanical O 
stress O 
. O 
These O 
results O 
clearly O 
frame O 
the O 
growth O 
as O 
a O 
two O 
- O 
dimensional O 
supramolecular O 
living O 
polymerization O 
of O 
uPICs O 
. O 

Trit1 O 
is O 
a O 
tRNA([ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
)- O 
isopentenyl B-SYSTEMATIC 
transferase O 
required O 
for O 
full O 
selenoprotein O 
expression O 
. O 

are O 
proteins O 
carrying O 
the O 
rare O 
amino B-FAMILY 
acid I-FAMILY 
Sec B-FORMULA 
( O 
selenocysteine B-TRIVIAL 
) O 
. O 
Full O 
expression O 
of O 
selenoproteins O 
requires O 
modification O 
of O 
tRNA([ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
) O 
, O 
including O 
N(6)-isopentenylation O 
of O 
base O 
A(37) O 
. O 
We O 
show O 
that O 
Trit1 O 
is O 
a O 
dimethylallyl B-SYSTEMATIC 
:tRNA([ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
) O 
transferase O 
. O 
Knockdown O 
of O 
Trit1 O 
reduces O 
expression O 
of O 
selenoproteins O 
. O 
Incubation O 
of O 
in O 
vitro O 
transcribed O 
tRNA[ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
with O 
recombinant O 
Trit1 O 
transfers O 
[(14)C]dimethylallyl B-SYSTEMATIC 
pyrophosphate I-SYSTEMATIC 
to O 
tRNA([ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
) O 
. O 
37A O 
> O 
G O 
tRNA([ O 
Ser B-FORMULA 
] O 
Sec B-FORMULA 
) O 
is O 
resistant O 
to O 
isopentenylation O 
by O 
Trit1 O 
. O 

of O 
CF3 B-FORMULA 
group O 
in O 
N-H B-FORMULA 
··· O 
F-C B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
in O 
the O 
solution O 
state O 
: O 
NMR O 
spectroscopy O 
and O 
MD O 
simulation O 
studies O 
. O 

evidence O 
for O 
the O 
engagement O 
of O 
CF(3) B-FORMULA 
group O 
in O 
N-H B-FORMULA 
··· O 
F-C B-FORMULA 
hydrogen B-SYSTEMATIC 
bond O 
in O 
a O 
low O 
polarity O 
solvent O 
, O 
the O 
first O 
observation O 
of O 
its O 
kind O 
, O 
is O 
reported O 
. O 
The O 
presence O 
of O 
such O 
weak O 
molecular O 
interactions O 
in O 
the O 
solution O 
state O 
is O 
convincingly O 
established O 
by O 
one O 
and O 
two O 
- O 
dimensional O 
(1)H B-FORMULA 
, O 
(19)F B-FORMULA 
, O 
and O 
natural O 
abundant O 
(15)N B-FORMULA 
NMR O 
spectroscopic O 
studies O 
. O 
The O 
strong O 
and O 
direct O 
evidence O 
is O 
derived O 
by O 
the O 
observation O 
of O 
through O 
- O 
space O 
couplings O 
, O 
such O 
as O 
, O 
( O 
1h)J( O 
FH B-FORMULA 
) O 
, O 
( O 
1h)J( O 
FN B-FORMULA 
) O 
, O 
and O 
( O 
2h)J( O 
FF B-FORMULA 
) O 
, O 
where O 
the O 
spin O 
polarization O 
is O 
transmitted O 
through O 
hydrogen B-SYSTEMATIC 
bond O 
. O 
In O 
an O 
interesting O 
example O 
of O 
a O 
molecule O 
containing O 
two O 
CF(3) B-FORMULA 
groups O 
getting O 
simultaneously O 
involved O 
in O 
hydrogen B-SYSTEMATIC 
bond O 
, O 
where O 
hydrogen B-SYSTEMATIC 
bond O 
mediated O 
couplings O 
are O 
not O 
reflected O 
in O 
the O 
NMR O 
spectrum O 
, O 
(19)F B-FORMULA 
- O 
(19)F B-FORMULA 
NOESY O 
experiment O 
yielded O 
confirmatory O 
evidence O 
. O 
Significant O 
deviations O 
in O 
the O 
strengths O 
of O 
( O 
1)J( O 
NH B-FORMULA 
) O 
, O 
variable O 
temperature O 
, O 
and O 
the O 
solvent O 
induced O 
perturbations O 
yielded O 
additional O 
support O 
. O 
The O 
NMR O 
results O 
are O 
corroborated O 
by O 
both O 
DFT O 
calculations O 
and O 
MD O 
simulations O 
, O 
where O 
the O 
quantitative O 
information O 
on O 
different O 
ways O 
of O 
involvement O 
of O 
fluorine B-SYSTEMATIC 
in O 
two O 
and O 
three O 
centered O 
hydrogen B-SYSTEMATIC 
bonds O 
, O 
their O 
percentage O 
of O 
occurrences O 
, O 
and O 
geometries O 
have O 
been O 
obtained O 
. O 
The O 
hydrogen B-SYSTEMATIC 
bond O 
interaction O 
energies O 
have O 
also O 
been O 
calculated O 
. O 

the O 
preparation O 
of O 
indoxyl B-TRIVIAL 
red I-TRIVIAL 
from O 
indican O 
and O 
some O 
new O 
characteristics O 
. O 

indole B-SYSTEMATIC 
compound O 
with O 
a O 
strong O 
purple O 
- O 
red O 
color O 
was O 
produced O 
by O 
boiling O 
a O 
solution O 
of O 
indican O 
under O 
acidic O 
conditions O 
and O 
purified O 
by O 
chromatographies O 
on O 
DEAE-650S O 
Toyopearl O 
TSK-gel O 
and O 
silica B-TRIVIAL 
-gel O 
columns O 
. O 
The O 
purple O 
- O 
red O 
compound O 
purified O 
was O 
identified O 
as O 
indoxyl B-TRIVIAL 
red I-TRIVIAL 
, O 
on O 
the O 
basis O 
of O 
FAB O 
Mass O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
UV-visible O 
spectra O 
, O 
and O 
IR O 
spectra O 
. O 
Although O 
indoxyl B-TRIVIAL 
red I-TRIVIAL 
was O 
first O 
synthesized O 
by O 
Seidel(9) O 
70 O 
years O 
ago O 
, O 
very O 
little O 
information O 
has O 
been O 
available O 
on O 
its O 
characteristics O 
. O 
We O 
repot O 
here O 
that O 
the O 
compound O 
was O 
purple O 
- O 
red O 
colored O 
at O 
acidic O 
pH O 
and O 
green O 
at O 
pH O 
13 O 
, O 
and O 
showed O 
antiproliferative O 
and O 
cytotoxic O 
activities O 
to O 
the O 
mouse O 
B O 
cell O 
lymphoma O 
cell O 
line O 
NSF202 O 
. O 

DNA O 
glycosylase O 
( O 
AAG O 
) O 
localizes O 
to O 
mitochondria O 
and O 
interacts O 
with O 
mitochondrial O 
single O 
- O 
stranded O 
binding O 
protein O 
( O 
mtSSB O 
) O 
. O 

to O 
a O 
harsh O 
environment O 
mitochondrial O 
genomes O 
accumulate O 
high O 
levels O 
of O 
DNA O 
damage O 
, O 
in O 
particular O 
oxidation O 
, O 
hydrolytic O 
deamination O 
, O 
and O 
alkylation O 
adducts O 
. O 
While O 
repair O 
of O 
alkylated O 
bases O 
in O 
nuclear O 
DNA O 
has O 
been O 
explored O 
in O 
detail O 
, O 
much O 
less O 
is O 
known O 
about O 
the O 
repair O 
of O 
DNA O 
alkylation O 
damage O 
in O 
mitochondria O 
. O 
Alkyladenine B-FAMILY 
DNA O 
glycosylase O 
( O 
AAG O 
) O 
recognizes O 
and O 
removes O 
numerous O 
alkylated O 
bases O 
, O 
but O 
to O 
date O 
AAG O 
has O 
only O 
been O 
detected O 
in O 
the O 
nucleus O 
, O 
even O 
though O 
mammalian O 
mitochondria O 
are O 
known O 
to O 
repair O 
DNA O 
lesions O 
that O 
are O 
specific O 
substrates O 
of O 
AAG O 
. O 
Here O 
we O 
use O 
immunofluorescence O 
to O 
show O 
that O 
AAG O 
localizes O 
to O 
mitochondria O 
, O 
and O 
we O 
find O 
that O 
native O 
AAG O 
is O 
present O 
in O 
purified O 
human O 
mitochondrial O 
extracts O 
, O 
as O 
well O 
as O 
that O 
exposure O 
to O 
alkylating O 
agent O 
promotes O 
AAG O 
accumulation O 
in O 
the O 
mitochondria O 
. O 
We O 
identify O 
mitochondrial O 
single O 
- O 
stranded O 
binding O 
protein O 
( O 
mtSSB O 
) O 
as O 
a O 
novel O 
interacting O 
partner O 
of O 
AAG O 
; O 
interaction O 
between O 
mtSSB O 
and O 
AAG O 
is O 
direct O 
and O 
increases O 
upon O 
methyl B-SYSTEMATIC 
methanesulfonate I-SYSTEMATIC 
( O 
MMS B-ABBREVIATION 
) O 
treatment O 
. O 
The O 
consequence O 
of O 
this O 
interaction O 
is O 
specific O 
inhibition O 
of O 
AAG O 
glycosylase O 
activity O 
in O 
the O 
context O 
of O 
a O 
single O 
- O 
stranded O 
DNA O 
( O 
ssDNA O 
) O 
, O 
but O 
not O 
a O 
double O 
- O 
stranded O 
DNA O 
( O 
dsDNA O 
) O 
substrate O 
. O 
By O 
inhibiting O 
AAG O 
- O 
initiated O 
processing O 
of O 
damaged O 
bases O 
, O 
mtSSB O 
potentially O 
prevents O 
formation O 
of O 
DNA O 
breaks O 
in O 
ssDNA O 
, O 
ensuring O 
that O 
base O 
removal O 
primarily O 
occurs O 
in O 
dsDNA O 
. O 
In O 
summary O 
, O 
our O 
findings O 
suggest O 
the O 
existence O 
of O 
AAG O 
- O 
initiated O 
BER O 
in O 
mitochondria O 
and O 
further O 
support O 
a O 
role O 
for O 
mtSSB O 
in O 
DNA O 
repair O 
. O 

drives O 
a O 
tertiary O 
fold O 
in O 
the O 
prion O 
protein O 
with O 
familial O 
disease O 
mutation O 
sites O 
at O 
the O 
interface O 
. O 

cellular O 
prion O 
protein O 
PrP(C) O 
consists O 
of O 
two O 
domains O 
-- O 
a O 
flexible O 
N B-FORMULA 
-terminal O 
domain O 
, O 
which O 
participates O 
in O 
copper B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
regulation O 
, O 
and O 
a O 
largely O 
helical O 
C B-FORMULA 
-terminal O 
domain O 
that O 
converts O 
to O 
β O 
sheet O 
in O 
the O 
course O 
of O 
prion O 
disease O 
. O 
These O 
two O 
domains O 
are O 
thought O 
to O 
be O 
fully O 
independent O 
and O 
noninteracting O 
. O 
Compelling O 
cellular O 
and O 
biophysical O 
studies O 
, O 
however O 
, O 
suggest O 
a O 
higher O 
order O 
structure O 
that O 
is O 
relevant O 
to O 
both O 
PrP(C) O 
function O 
and O 
misfolding O 
in O 
disease O 
. O 
Here O 
, O 
we O 
identify O 
a O 
Zn²⁺ B-FORMULA 
-driven O 
N B-FORMULA 
-terminal O 
to O 
C B-FORMULA 
-terminal O 
tertiary O 
interaction O 
in O 
PrP(C) O 
. O 
The O 
C B-FORMULA 
-terminal O 
surface O 
participating O 
in O 
this O 
interaction O 
carries O 
the O 
majority O 
of O 
the O 
point O 
mutations O 
that O 
confer O 
familial O 
prion O 
disease O 
. O 
Investigation O 
of O 
mutant O 
PrPs O 
finds O 
a O 
systematic O 
relationship O 
between O 
the O 
type O 
of O 
mutation O 
and O 
the O 
apparent O 
strength O 
of O 
this O 
domain O 
structure O 
. O 
The O 
structural O 
features O 
identified O 
here O 
suggest O 
mechanisms O 
by O 
which O 
physiologic O 
metal O 
ions O 
trigger O 
PrP(C) O 
trafficking O 
and O 
control O 
prion O 
disease O 
. O 

and O 
evaluation O 
of O 
the O 
antioxidant O 
activity O 
of O 
novel O 
methoxypsoralen B-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
5- B-MULTIPLE 
and I-MULTIPLE 
8-methoxypsoralen I-MULTIPLE 
( O 
MOP B-ABBREVIATION 
) O 
analogs O 
, O 
suitable O 
for O 
structure O 
- O 
antioxidative O 
/ O 
anti-inflammatory O 
activity O 
relationship O 
studies O 
, O 
were O 
synthesized O 
using O 
as O 
key O 
- O 
reactions O 
the O 
selective O 
monobromination O 
of O 
MOPs B-ABBREVIATION 
with O 
N-bromosaccharin B-SYSTEMATIC 
and O 
either O 
a O 
Heck O 
reaction O 
or O 
a O 
Suzuki O 
coupling O 
or O 
a O 
Suzuki O 
coupling O 
followed O 
by O 
a O 
Wittig O 
reaction O 
to O 
install O 
side O 
- O 
chains O 
of O 
the O 
acrylate B-SYSTEMATIC 
- O 
or O 
benzoate B-SYSTEMATIC 
- O 
or O 
cinnamate B-SYSTEMATIC 
-type O 
, O 
respectively O 
. O 
The O 
8-MOP B-SYSTEMATIC 
analogs O 
19 O 
and O 
24 O 
, O 
incorporating O 
at O 
position O 
5 O 
of O 
the O 
psoralen B-TRIVIAL 
nucleus O 
a O 
butyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
or O 
a O 
tert-butyl B-SYSTEMATIC 
cinnamate I-SYSTEMATIC 
moiety O 
, O 
were O 
the O 
most O 
powerful O 
inhibitors O 
of O 
soybean O 
LOX O 
and O 
inhibited O 
effectively O 
lipid O 
peroxidation O 
. O 
Analog O 
19 O 
was O 
a O 
more O 
potent O 
anti-inflammatory O 
agent O 
than O 
the O 
reference O 
compound O 
indomethacin B-TRIVIAL 
and O 
of O 
comparable O 
cytocompatibility O 
to O 
8-MOP B-SYSTEMATIC 
whereas O 
analog O 
24 O 
was O 
a O 
weaker O 
inhibitor O 
of O 
inflammation O 
than O 
indomethacin B-TRIVIAL 
and O 
significantly O 
more O 
cytotoxic O 
than O 
8-MOP B-SYSTEMATIC 
. O 
The O 
results O 
of O 
the O 
biological O 
tests O 
are O 
discussed O 
in O 
terms O 
of O 
structural O 
characteristics O 
. O 

chemokine O 
( O 
C-C O 
motif O 
) O 
ligand O 
2 O 
( O 
monocyte O 
chemotactic O 
protein-1 O 
) O 
as O 
a O 
tubular O 
injury O 
marker O 
for O 
early O 
detection O 
of O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
. O 

of O 
the O 
difficulty O 
in O 
detecting O 
segment-specific O 
response O 
in O 
the O 
kidney O 
, O 
we O 
investigated O 
the O 
molecular O 
events O 
underlying O 
acute O 
kidney O 
injury O 
in O 
the O 
proximal O 
tubules O 
of O 
rats O 
with O 
cisplatin B-TRIVIAL 
( O 
cis-diamminedichloroplatinum B-SYSTEMATIC 
II I-SYSTEMATIC 
)-induced O 
nephrotoxicity O 
. O 
Microarray O 
analysis O 
revealed O 
that O 
mRNA O 
levels O 
of O 
several O 
cytokines O 
and O 
chemokines O 
, O 
such O 
as O 
interleukin-1beta O 
, O 
chemokine O 
( O 
C-C O 
motif O 
) O 
ligand O 
( O 
CCL O 
) O 
2 O 
, O 
CCL20 O 
, O 
chemokine O 
( O 
C-X-C O 
motif O 
) O 
ligand O 
( O 
CXCL O 
) O 
1 O 
, O 
and O 
CXCL10 O 
were O 
significantly O 
increased O 
after O 
cisplatin B-TRIVIAL 
treatment O 
in O 
both O 
isolated O 
proximal O 
tubules O 
and O 
whole O 
kidney O 
. O 
Interestingly O 
, O 
tubular O 
CCL2 O 
mRNA O 
levels O 
increased O 
soon O 
after O 
cisplatin B-TRIVIAL 
administration O 
, O 
whereas O 
CCL2 O 
mRNA O 
levels O 
in O 
whole O 
kidney O 
first O 
decreased O 
and O 
then O 
increased O 
. O 
Levels O 
of O 
both O 
CCL2 O 
and O 
kidney O 
injury O 
molecule-1 O 
( O 
KIM-1 O 
) O 
in O 
the O 
whole O 
kidney O 
increased O 
after O 
cisplatin B-TRIVIAL 
administration O 
. O 
Immunofluorescence O 
analysis O 
revealed O 
CCL2 O 
changes O 
in O 
the O 
proximal O 
tubular O 
cells O 
initially O 
and O 
then O 
in O 
the O 
medullary O 
interstitium O 
. O 
Urinary O 
CCL2 O 
excretion O 
significantly O 
increased O 
approximately O 
3-fold O 
compared O 
with O 
controls O 
the O 
day O 
after O 
cisplatin B-TRIVIAL 
administration O 
( O 
5mg O 
/ O 
kg O 
) O 
, O 
when O 
no O 
changes O 
were O 
observed O 
plasma O 
creatinine B-TRIVIAL 
and O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
levels O 
. O 
Urinary O 
levels O 
of O 
KIM-1 O 
also O 
increased O 
3-fold O 
after O 
cisplatin B-TRIVIAL 
administration O 
. O 
In O 
addition O 
, O 
urinary O 
CCL2 O 
rather O 
than O 
KIM-1 O 
increased O 
in O 
chronic O 
renal O 
failure O 
rats O 
after O 
administration O 
of O 
low O 
- O 
dose O 
cisplatin B-TRIVIAL 
( O 
2mg O 
/ O 
kg O 
) O 
, O 
suggesting O 
that O 
urinary O 
CCL2 O 
was O 
selective O 
for O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
in O 
renal O 
impairment O 
. O 
These O 
results O 
indicated O 
that O 
the O 
increase O 
in O 
cytokine O 
and O 
chemokine O 
expression O 
in O 
renal O 
epithelial O 
cells O 
might O 
be O 
responsible O 
for O 
kidney O 
deterioration O 
in O 
cisplatin B-TRIVIAL 
-induced O 
nephrotoxicity O 
, O 
and O 
that O 
urinary O 
CCL2 O 
is O 
associated O 
with O 
tubular O 
injury O 
and O 
serves O 
as O 
a O 
sensitive O 
and O 
noninvasive O 
marker O 
for O 
the O 
early O 
detection O 
of O 
cisplatin B-TRIVIAL 
-induced O 
tubular O 
injury O 
. O 

long O 
- O 
standing O 
question O 
in O 
evolutionary O 
biology O 
is O 
how O 
organisms O 
adapt O 
to O 
novel O 
environments O 
. O 
In O 
North O 
American O 
hot O 
springs O 
, O 
diversification O 
of O 
a O 
clade O 
of O 
the O 
cyanobacterium O 
Synechococcus O 
into O 
hotter O 
environments O 
has O 
resulted O 
in O 
the O 
unique O 
innovation O 
of O 
a O 
light O 
- O 
driven O 
ecosystem O 
at O 
temperatures O 
up O 
to O 
74°C O 
, O 
and O 
temperature O 
adaptation O 
of O 
photosynthetic O 
carbon O 
fixation O 
with O 
the O 
Calvin O 
cycle O 
contributed O 
to O 
this O 
process O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
evolution O 
of O 
thermostability O 
of O 
the O 
Calvin O 
cycle O 
enzyme O 
ribulose-1 B-SYSTEMATIC 
, I-SYSTEMATIC 
5-bisphosphate I-SYSTEMATIC 
carboxylase O 
/ O 
oxygenase O 
( O 
RuBisCO O 
) O 
during O 
Synechococcus O 
divergence O 
. O 
Circular O 
dichroism O 
thermal O 
scans O 
revealed O 
that O 
the O 
RuBisCO O 
of O 
the O 
most O 
thermotolerant O 
Synechococcus O 
lineage O 
is O 
more O 
stable O 
than O 
those O 
of O 
other O 
lineages O 
or O 
of O 
resurrected O 
ancestral O 
enzymes O 
. O 
Using O 
site O 
- O 
directed O 
mutagenesis O 
, O 
we O 
next O 
identified O 
four O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
that O 
together O 
increased O 
stability O 
and O 
activity O 
of O 
this O 
enzyme O 
at O 
higher O 
temperatures O 
. O 
These O 
are O 
clustered O 
near O 
critical O 
subunit O 
interfaces O 
distant O 
from O 
the O 
active O 
site O 
. O 
Each O 
of O 
the O 
four O 
amino B-FAMILY 
acids I-FAMILY 
is O 
also O 
observed O 
in O 
a O 
less O 
thermostable O 
Synechococcus O 
RuBisCO O 
, O 
and O 
the O 
impact O 
on O 
stability O 
of O 
three O 
of O 
these O 
appears O 
to O 
be O 
epistatic O 
. O 
Recombination O 
analyses O 
that O 
allow O 
for O 
recurrent O 
mutation O 
as O 
well O 
as O 
patterns O 
of O 
synonymous O 
variation O 
surrounding O 
these O 
sites O 
suggest O 
that O 
the O 
evolution O 
of O 
a O 
more O 
thermostable O 
RuBisCO O 
may O 
have O 
involved O 
homologous O 
recombination O 
. O 
Our O 
results O 
provide O 
insights O 
on O 
the O 
molecular O 
evolutionary O 
processes O 
that O 
shape O 
niche O 
differentiation O 
and O 
ecosystem O 
function O 
. O 

oral O 
anticoagulants O 
: O 
comparative O 
pharmacology O 
with O 
vitamin B-FAMILY 
K I-FAMILY 
antagonists O 
. O 

oral O 
anticoagulants O 
( O 
OACs O 
) O 
that O 
directly O 
inhibit O 
Factor O 
Xa O 
( O 
FXa O 
) O 
or O 
thrombin O 
have O 
been O 
developed O 
for O 
the O 
long O 
- O 
term O 
prevention O 
of O 
thromboembolic O 
disorders O 
. O 
These O 
novel O 
agents O 
provide O 
numerous O 
benefits O 
over O 
older O 
vitamin B-FAMILY 
K I-FAMILY 
antagonists O 
( O 
VKAs O 
) O 
due O 
to O 
major O 
pharmacological O 
differences O 
. O 
VKAs O 
are O 
economical O 
and O 
very O 
well O 
characterized O 
, O 
but O 
have O 
important O 
limitations O 
that O 
can O 
outweigh O 
these O 
advantages O 
, O 
such O 
as O 
slow O 
onset O 
of O 
action O 
, O 
narrow O 
therapeutic O 
window O 
and O 
unpredictable O 
anticoagulant O 
effect O 
. O 
VKA-associated O 
dietary O 
precautions O 
, O 
monitoring O 
and O 
dosing O 
adjustments O 
to O 
maintain O 
international O 
normalized O 
ratio O 
( O 
INR O 
) O 
within O 
therapeutic O 
range O 
, O 
and O 
bridging O 
therapy O 
, O 
are O 
inconvenient O 
for O 
patients O 
, O 
expensive O 
, O 
and O 
may O 
result O 
in O 
inappropriate O 
use O 
of O 
VKA O 
therapy O 
. O 
This O 
may O 
lead O 
to O 
increased O 
bleeding O 
risk O 
or O 
reduced O 
anticoagulation O 
and O 
increased O 
risk O 
of O 
thrombotic O 
events O 
. O 
The O 
new O 
OACs O 
have O 
rapid O 
onset O 
of O 
action O 
, O 
low O 
potential O 
for O 
food O 
and O 
drug O 
interactions O 
, O 
and O 
predictable O 
anticoagulant O 
effect O 
that O 
removes O 
the O 
need O 
for O 
routine O 
monitoring O 
. O 
FXa O 
inhibitors O 
, O 
e.g O 
. O 
rivaroxaban B-TRIVIAL 
and O 
apixaban B-TRIVIAL 
, O 
are O 
potent O 
, O 
oral O 
direct O 
inhibitors O 
of O 
prothrombinase O 
- O 
bound O 
, O 
clot O 
- O 
associated O 
or O 
free O 
FXa O 
. O 
Both O 
agents O 
have O 
a O 
rapid O 
onset O 
of O 
action O 
, O 
a O 
wide O 
therapeutic O 
window O 
, O 
little O 
or O 
no O 
interaction O 
with O 
food O 
and O 
other O 
drugs O 
, O 
minimal O 
inter O 
- O 
patient O 
variability O 
, O 
and O 
display O 
similar O 
pharmacokinetics O 
in O 
different O 
patient O 
populations O 
. O 
Since O 
both O 
are O 
substrates O 
, O 
co O 
- O 
administration O 
of O 
rivaroxaban B-TRIVIAL 
and O 
apixaban B-TRIVIAL 
with O 
strong O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
3A4 O 
and O 
permeability O 
glycoprotein O 
( O 
P-gp O 
) O 
inhibitors O 
and O 
inducers O 
can O 
result O 
in O 
substantial O 
changes O 
in O 
plasma O 
concentrations O 
due O 
to O 
altered O 
clearance O 
rates O 
; O 
consequently O 
, O 
their O 
concomitant O 
use O 
is O 
contraindicated O 
and O 
caution O 
is O 
required O 
when O 
used O 
concomitantly O 
with O 
strong O 
CYP3A4 O 
and O 
P-gp O 
inducers O 
. O 
Although O 
parenteral O 
oral O 
direct O 
thrombin O 
inhibitors O 
( O 
DTIs O 
) O 
, O 
such O 
as O 
argatroban B-TRIVIAL 
and O 
bivalirudin O 
, O 
have O 
been O 
on O 
the O 
market O 
for O 
years O 
, O 
DTIs O 
such O 
as O 
dabigatran B-TRIVIAL 
are O 
novel O 
synthetic O 
thrombin O 
antagonists O 
. O 
Dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
is O 
a O 
low O 
- O 
molecular O 
- O 
weight O 
non-active O 
pro O 
- O 
drug O 
that O 
is O 
administered O 
orally O 
and O 
converted O 
rapidly O 
to O 
its O 
active O 
form O 
, O 
dabigatran B-TRIVIAL 
-- O 
a O 
potent O 
, O 
competitive O 
and O 
reversible O 
DTI O 
. O 
Dabigatran B-TRIVIAL 
has O 
an O 
advantage O 
over O 
the O 
indirect O 
thrombin O 
inhibitors O 
, O 
unfractionated O 
heparin O 
and O 
low O 
- O 
molecular O 
- O 
weight O 
heparin O 
, O 
in O 
that O 
it O 
inhibits O 
free O 
and O 
fibrin O 
- O 
bound O 
thrombin O 
. O 
The O 
reversible O 
binding O 
of O 
dabigatran B-TRIVIAL 
may O 
provide O 
safer O 
and O 
more O 
predictable O 
anticoagulant O 
treatment O 
than O 
seen O 
with O 
irreversible O 
, O 
non-covalent O 
thrombin O 
inhibitors O 
, O 
e.g O 
. O 
hirudin O 
. O 
Dabigatran B-TRIVIAL 
shows O 
a O 
very O 
low O 
potential O 
for O 
drug O 
- O 
drug O 
interactions O 
. O 
However O 
, O 
co O 
- O 
administration O 
of O 
dabigatran B-TRIVIAL 
etexilate I-TRIVIAL 
with O 
other O 
anticoagulants O 
and O 
antiplatelet O 
agents O 
can O 
increase O 
the O 
bleeding O 
risk O 
. O 
Although O 
the O 
new O 
agents O 
are O 
pharmacologically O 
better O 
than O 
VKAs O 
-- O 
particularly O 
in O 
terms O 
of O 
fixed O 
dosing O 
, O 
rapid O 
onset O 
of O 
action O 
, O 
no O 
INR O 
monitoring O 
and O 
lower O 
risk O 
of O 
drug O 
interactions O 
-- O 
there O 
are O 
some O 
differences O 
between O 
them O 
: O 
the O 
bioavailability O 
of O 
dabigatran B-TRIVIAL 
is O 
lower O 
than O 
rivaroxaban B-TRIVIAL 
and O 
apixaban B-TRIVIAL 
, O 
and O 
so O 
the O 
dabigatran B-TRIVIAL 
dosage O 
required O 
is O 
higher O 
; O 
lower O 
protein O 
binding O 
of O 
dabigatran B-TRIVIAL 
reduces O 
the O 
variability O 
related O 
to O 
albuminaemia O 
. O 
The O 
risk O 
of O 
metabolic O 
drug O 
- O 
drug O 
interactions O 
also O 
appears O 
to O 
differ O 
between O 
OACs O 
: O 
VKAs O 
> O 
rivaroxaban B-TRIVIAL 
> O 
apixaban B-TRIVIAL 
> O 
dabigatran B-TRIVIAL 
. O 
The O 
convenience O 
of O 
the O 
new O 
OACs O 
has O 
translated O 
into O 
improvements O 
in O 
efficacy O 
and O 
safety O 
as O 
shown O 
in O 
phase O 
III O 
randomized O 
trials O 
. O 
The O 
new O 
anticoagulants O 
so O 
far O 
offer O 
the O 
greatest O 
promise O 
and O 
opportunity O 
for O 
the O 
replacement O 
of O 
VKAs O 
. O 

live O 
- O 
cell O 
imaging O 
of O 
metabolically O 
incorporated O 
unnatural O 
cyclopropene B-SYSTEMATIC 
- O 
mannosamine B-FAMILY 
derivatives O 
. O 

coated O 
: O 
We O 
recently O 
developed O 
methylcyclopropenes B-FAMILY 
as O 
low O 
- O 
molecular O 
- O 
weight O 
tetrazine B-FAMILY 
coupling O 
partners O 
. O 
Here O 
, O 
we O 
demonstrate O 
that O 
methylcyclopropenes B-FAMILY 
can O 
meet O 
the O 
stringent O 
steric O 
demands O 
required O 
for O 
metabolic O 
imaging O 
of O 
unnatural O 
mannosamines B-FAMILY 
on O 
live O 
cells O 
. O 
Using O 
sequential O 
azide B-SYSTEMATIC 
- O 
alkyne B-FAMILY 
chemistry O 
, O 
we O 
also O 
demonstrate O 
multicolor O 
imaging O 
of O 
two O 
different O 
metabolically O 
incorporated O 
unnatural O 
sugars B-FAMILY 
. O 

spectroscopic O 
and O 
atoms O 
in O 
molecules O 
theoretical O 
investigations O 
on O 
the O 
Ar··· O 
propargyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
complex O 
: O 
Ar··· O 
H-O B-FORMULA 
, O 
Ar···π O 
, O 
and O 
Ar··· O 
C B-FORMULA 
interactions O 
. O 

structure O 
of O 
the O 
Ar··· O 
propargyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
Ar···PA O 
) O 
complex O 
is O 
determined O 
from O 
the O 
rotational O 
spectra O 
of O 
the O 
parent O 
complex O 
and O 
its O 
two O 
deuterated O 
isotopologues O 
, O 
namely O 
Ar···PA- O 
D B-FORMULA 
( O 
OD B-FORMULA 
) O 
and O 
Ar···PA- O 
D B-FORMULA 
( O 
CD B-FORMULA 
) O 
. O 
The O 
spectra O 
confirm O 
a O 
geometry O 
in O 
which O 
PA O 
exists O 
in O 
the O 
gauche O 
form O 
with O 
Ar O 
located O 
in O 
between O 
- O 
OH B-FORMULA 
and O 
- O 
C≡C-H B-FORMULA 
groups O 
. O 
All O 
a O 
, O 
b O 
and O 
c O 
types O 
of O 
transitions O 
show O 
small O 
splitting O 
due O 
to O 
some O 
large O 
- O 
amplitude O 
motion O 
dominated O 
by O 
C-OH B-FORMULA 
torsion O 
, O 
as O 
in O 
the O 
monomer O 
. O 
Splittings O 
in O 
a- O 
and O 
b O 
- O 
type O 
transitions O 
are O 
of O 
the O 
order O 
of O 
a O 
few O 
kilohertz O 
, O 
whereas O 
splitting O 
in O 
the O 
c O 
- O 
type O 
transitions O 
is O 
relatively O 
larger O 
( O 
0.9-2.6 O 
MHz O 
) O 
and O 
decreases O 
in O 
the O 
order O 
Ar···PA O 
> O 
Ar···PA- O 
D B-FORMULA 
( O 
CD B-FORMULA 
) O 
> O 
Ar···PA- O 
D B-FORMULA 
( O 
OD B-FORMULA 
) O 
. O 
The O 
assignments O 
are O 
well O 
supported O 
by O 
ab O 
initio O 
calculations O 
. O 
Atoms O 
in O 
molecules O 
( O 
AIM O 
) O 
and O 
electrostatic O 
potential O 
calculations O 
are O 
used O 
to O 
explore O 
the O 
nature O 
of O 
the O 
interactions O 
in O 
this O 
complex O 
. O 
AIM O 
calculations O 
not O 
only O 
reveal O 
the O 
expected O 
O-H B-FORMULA 
···Ar O 
and O 
π···Ar O 
interactions O 
in O 
the O 
Ar···gauche-PA O 
complex O 
, O 
but O 
also O 
novel O 
C B-FORMULA 
···Ar O 
( O 
of O 
CH2OH B-FORMULA 
group O 
) O 
and O 
O-H B-FORMULA 
···Ar O 
interactions O 
in O 
the O 
Ar···trans-PA O 
complex O 
. O 
Similar O 
interactions O 
are O 
also O 
present O 
in O 
the O 
Ar··· O 
methanol B-SYSTEMATIC 
complex O 
. O 

( O 
Smo O 
) O 
is O 
a O 
7-transmembrane O 
protein O 
essential O 
to O 
the O 
activation O 
of O 
Gli O 
transcription O 
factors O 
( O 
Gli O 
) O 
by O 
hedgehog O 
morphogens O 
. O 
The O 
structure O 
of O 
Smo O 
implies O 
interactions O 
with O 
heterotrimeric O 
G O 
proteins O 
, O 
but O 
the O 
degree O 
to O 
which O 
G O 
proteins O 
participate O 
in O 
the O 
actions O 
of O 
hedgehogs O 
remains O 
controversial O 
. O 
We O 
posit O 
that O 
the O 
G O 
(i) O 
family O 
of O 
G O 
proteins O 
provides O 
to O 
hedgehogs O 
the O 
ability O 
to O 
expand O 
well O 
beyond O 
the O 
bounds O 
of O 
Gli O 
. O 
In O 
this O 
regard O 
, O 
we O 
evaluate O 
here O 
the O 
efficacy O 
of O 
Smo O 
as O 
it O 
relates O 
to O 
the O 
activation O 
of O 
G O 
(i) O 
, O 
by O 
comparing O 
Smo O 
with O 
the O 
5-hydroxytryptamine B-SYSTEMATIC 
( O 
1A O 
) O 
( O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
) O 
receptor O 
, O 
a O 
quintessential O 
G(i)-coupled O 
receptor O 
. O 
We O 
find O 
that O 
with O 
use O 
of O 
[(35)S]guanosine B-SYSTEMATIC 
5'-(3-O-thio)triphosphate I-SYSTEMATIC 
, O 
first O 
, O 
with O 
forms O 
of O 
G O 
(i) O 
endogenous O 
to O 
human O 
embryonic O 
kidney O 
(HEK)-293 O 
cells O 
made O 
to O 
express O 
epitope O 
- O 
tagged O 
receptors O 
and O 
, O 
second O 
, O 
with O 
individual O 
forms O 
of O 
Gα O 
(i) O 
fused O 
to O 
the O 
C O 
terminus O 
of O 
each O 
receptor O 
, O 
Smo O 
is O 
equivalent O 
to O 
the O 
5-HT B-SYSTEMATIC 
( O 
1A O 
) O 
receptor O 
in O 
the O 
assay O 
as O 
it O 
relates O 
to O 
capacity O 
to O 
activate O 
G O 
(i) O 
. O 
This O 
finding O 
is O 
true O 
regardless O 
of O 
subtype O 
of O 
G O 
(i) O 
( O 
e.g O 
. O 
, O 
G(i2) O 
, O 
G O 
(o) O 
, O 
and O 
G(z) O 
) O 
tested O 
. O 
We O 
also O 
find O 
that O 
Smo O 
endogenous O 
to O 
HEK-293 O 
cells O 
, O 
ostensibly O 
through O 
inhibition O 
of O 
adenylyl B-TRIVIAL 
cyclase O 
, O 
decreases O 
intracellular O 
levels O 
of O 
cAMP B-ABBREVIATION 
. O 
The O 
results O 
indicate O 
that O 
Smo O 
is O 
a O 
receptor O 
that O 
can O 
engage O 
not O 
only O 
Gli O 
but O 
also O 
other O 
more O 
immediate O 
effectors O 
. O 

nanoscale O 
chemical O 
imaging O 
of O 
the O 
distribution O 
of O 
aluminum B-SYSTEMATIC 
coordination O 
environments O 
in O 
zeolites B-FAMILY 
with O 
soft O 
X-ray O 
microscopy O 
. O 

side O 
are O 
you O 
on O 
? O 
Scanning O 
transmission O 
X-ray O 
microscopy O 
is O 
used O 
for O 
the O 
first O 
time O 
to O 
elucidate O 
the O 
coordination O 
and O 
distribution O 
of O 
aluminum B-SYSTEMATIC 
in O 
industrial O 
- O 
relevant O 
zeolites B-FAMILY 
at O 
the O 
single O 
- O 
particle O 
level O 
. O 
Extended O 
regions O 
of O 
a O 
few O 
hundred O 
nanometers O 
, O 
rich O 
in O 
higher O 
aluminum B-SYSTEMATIC 
coordination O 
environments O 
, O 
are O 
heterogeneously O 
embedded O 
within O 
the O 
zeolite B-TRIVIAL 
particle O 
, O 
before O 
and O 
after O 
a O 
steaming O 
post O 
- O 
treatment O 
. O 

doping O 
by O 
charge O 
transfer O 
at O 
LaFeO3 B-FORMULA 
/ O 
Sm2CuO4 B-FORMULA 
epitaxial O 
interfaces O 
. O 

X-ray O 
absorption O 
spectroscopy O 
and O 
electron O 
energy O 
loss O 
spectroscopy O 
with O 
atomic O 
- O 
scale O 
spatial O 
resolution O 
, O 
experimental O 
evidence O 
for O 
charge O 
transfer O 
at O 
the O 
interface O 
between O 
the O 
Mott O 
insulators O 
Sm2 B-FORMULA 
CuO4 I-FORMULA 
and O 
LaFeO3 B-FORMULA 
is O 
obtained O 
. O 
As O 
a O 
consequence O 
of O 
the O 
charge O 
transfer O 
, O 
the O 
Sm2 B-FORMULA 
CuO4 I-FORMULA 
is O 
doped O 
with O 
electrons O 
and O 
thus O 
epitaxial O 
Sm2 B-FORMULA 
CuO4 I-FORMULA 
/ O 
LaFeO3 B-FORMULA 
heterostructures O 
become O 
metallic O 
. O 

human O 
telomeric O 
DNA O 
sequence O 
with O 
four O 
repeats O 
can O 
fold O 
into O 
a O 
parallel O 
- O 
stranded O 
propeller O 
- O 
type O 
topology O 
. O 
NMR O 
structures O 
solved O 
under O 
molecular O 
crowding O 
experiments O 
correlate O 
with O 
the O 
crystal O 
structures O 
found O 
with O 
crystal O 
- O 
packing O 
interactions O 
that O 
are O 
effectively O 
equivalent O 
to O 
molecular O 
crowding O 
. O 
This O 
topology O 
has O 
been O 
used O 
for O 
rationalization O 
of O 
ligand O 
design O 
and O 
occurs O 
experimentally O 
in O 
a O 
number O 
of O 
complexes O 
with O 
a O 
diversity O 
of O 
ligands O 
, O 
at O 
least O 
in O 
the O 
crystalline O 
state O 
. O 
Although O 
G-quartet O 
stems O 
have O 
been O 
well O 
characterized O 
, O 
the O 
interactions O 
of O 
the O 
TTA O 
loop O 
with O 
the O 
G-quartets O 
are O 
much O 
less O 
defined O 
. O 
To O 
better O 
understand O 
the O 
conformational O 
variability O 
and O 
structural O 
dynamics O 
of O 
the O 
propeller O 
- O 
type O 
topology O 
, O 
we O 
performed O 
molecular O 
dynamics O 
simulations O 
in O 
explicit O 
solvent O 
up O 
to O 
1.5 O 
μs O 
. O 
The O 
analysis O 
provides O 
a O 
detailed O 
atomistic O 
account O 
of O 
the O 
dynamic O 
nature O 
of O 
the O 
TTA O 
loops O 
highlighting O 
their O 
interactions O 
with O 
the O 
G-quartets O 
including O 
formation O 
of O 
an O 
A O 
: O 
A O 
base O 
pair O 
, O 
triad O 
, O 
pentad O 
and O 
hexad O 
. O 
The O 
results O 
present O 
a O 
threshold O 
in O 
quadruplex O 
simulations O 
, O 
with O 
regards O 
to O 
understanding O 
the O 
flexible O 
nature O 
of O 
the O 
sugar B-FAMILY 
- O 
phosphate B-SYSTEMATIC 
backbone O 
in O 
formation O 
of O 
unusual O 
architecture O 
within O 
the O 
topology O 
. O 
Furthermore O 
, O 
this O 
study O 
stresses O 
the O 
importance O 
of O 
simulation O 
time O 
in O 
sampling O 
conformational O 
space O 
for O 
this O 
topology O 
. O 

effects O 
of O 
feeding O 
farm O 
- O 
raised O 
mink O 
( O 
Mustela O 
vison O 
) O 
diets O 
containing O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB B-ABBREVIATION 
)-contaminated O 
fish O 
from O 
the O 
upper O 
Hudson O 
River O 
( O 
New O 
York O 
, O 
USA O 
) O 
on O 
adult O 
reproductive O 
performance O 
and O 
kit O 
growth O 
and O 
mortality O 
were O 
evaluated O 
. O 
Diets O 
contained O 
2.5 O 
to O 
20% O 
Hudson O 
River O 
fish O 
, O 
providing O 
0.72 O 
to O 
6.1 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
4.8-38 O 
pg O 
toxic O 
equivalents O 
[ O 
TEQWHO O 
2005 O 
] O 
/ O 
g O 
feed O 
) O 
. O 
The O 
percentage O 
of O 
stillborn O 
kits O 
per O 
litter O 
was O 
significantly O 
increased O 
by O 
dietary O 
concentrations O 
of O 
4.5 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
28 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
and O 
greater O 
. O 
All O 
offspring O 
exposed O 
to O 
dietary O 
concentrations O 
of O 
4.5 O 
and O 
6.1 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
28 O 
and O 
38 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
died O 
by O 
10 O 
weeks O 
of O 
age O 
, O 
and O 
all O 
offspring O 
exposed O 
to O 
1.5 O 
and O 
2.8 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
10 O 
and O 
18 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
died O 
by O 
31 O 
weeks O 
of O 
age O 
, O 
leaving O 
juveniles O 
in O 
the O 
control O 
and O 
0.72 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
0.41- O 
and O 
4.8 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
groups O 
only O 
. O 
The O 
dietary O 
concentration O 
predicted O 
to O 
result O 
in O 
20% O 
kit O 
mortality O 
( O 
LC20 O 
) O 
at O 
six O 
weeks O 
of O 
age O 
was O 
0.34 O 
µg O 
∑PCBs O 
/ O 
g O 
feed O 
( O 
2.6 O 
pg O 
TEQWHO O 
2005 O 
/g O 
feed O 
) O 
. O 
The O 
corresponding O 
maternal O 
hepatic O 
concentration O 
was O 
0.8 O 
µg O 
∑PCBs O 
/ O 
g O 
liver O 
, O 
wet O 
weight O 
( O 
13 O 
pg O 
TEQWHO O 
2005 O 
/g O 
liver O 
, O 
wet O 
wt O 
) O 
. O 
Mink O 
residing O 
in O 
the O 
upper O 
Hudson O 
River O 
would O 
be O 
expected O 
to O 
consume O 
species O 
of O 
fish O 
that O 
contain O 
an O 
average O 
of O 
4 O 
µg O 
∑PCBs O 
/ O 
g O 
tissue O 
. O 
Thus O 
, O 
a O 
daily O 
diet O 
composed O 
of O 
less O 
than O 
10% O 
Hudson O 
River O 
fish O 
could O 
provide O 
a O 
dietary O 
concentration O 
of O 
∑PCBs O 
that O 
resulted O 
in O 
20% O 
kit O 
mortality O 
in O 
the O 
present O 
study O 
. O 

enhancement O 
of O 
pyrene B-SYSTEMATIC 
/ O 
dispersant O 
nanoarrays O 
driven O 
by O 
the O 
nanoscale O 
spatial O 
effect O 
on O 
mixing O 
. O 

, O 
a O 
recently O 
identified O 
cell O 
surface O 
protease O 
, O 
is O 
the O 
key O 
enzyme O 
of O 
iron B-SYSTEMATIC 
homoeostasis O 
modulating O 
the O 
expression O 
of O 
the O 
liver O 
peptide O 
hormone O 
hepcidin O 
. O 
HAI O 
( O 
hepatocyte O 
growth O 
factor O 
activator O 
inhibitor O 
) O 
types O 
1 O 
and O 
2 O 
( O 
HAI-1 O 
and O 
HAI-2 O 
respectively O 
) O 
have O 
been O 
shown O 
to O 
inhibit O 
the O 
close O 
homologue O 
, O 
i.e O 
. O 
matriptase O 
. O 
By O 
co O 
- O 
expressing O 
matriptase-2 O 
and O 
the O 
inhibitor O 
HAI-2 O 
we O 
have O 
identified O 
HAI-2 O 
displaying O 
high O 
inhibitory O 
potential O 
against O 
matriptase-2 O 
at O 
the O 
cell O 
surface O 
as O 
well O 
as O 
in O 
conditioned O 
medium O 
. O 
Accordingly O 
, O 
complex O 
formation O 
between O 
matriptase-2 O 
and O 
HAI-2 O 
was O 
demonstrated O 
by O 
isolation O 
of O 
the O 
complex O 
via O 
immobilizing O 
either O 
HAI-2 O 
or O 
matriptase-2 O 
from O 
lysates O 
and O 
conditioned O 
medium O 
of O 
co O 
- O 
expressing O 
cells O 
. O 
Furthermore O 
, O 
HAI-2 O 
indirectly O 
influences O 
the O 
expression O 
of O 
the O 
hepcidin O 
- O 
encoding O 
gene O 
HAMP O 
. O 
The O 
inhibitor O 
abrogates O 
the O 
matriptase-2 O 
- O 
mediated O 
suppression O 
of O 
HAMP O 
expression O 
, O 
presumably O 
by O 
inhibiting O 
the O 
supposed O 
potential O 
of O 
matriptase-2 O 
to O 
cleave O 
membrane O 
- O 
bound O 
HJV O 
( O 
haemojuvelin O 
) O 
. O 
Taken O 
together O 
, O 
the O 
results O 
of O 
the O 
present O 
study O 
have O 
characterized O 
HAI-2 O 
as O 
an O 
inhibitor O 
of O 
matriptase-2 O 
that O 
modulates O 
the O 
synthesis O 
of O 
hepcidin O 
and O 
provides O 
new O 
insights O 
into O 
the O 
regulatory O 
mechanism O 
of O 
iron B-SYSTEMATIC 
homoeostasis O 
, O 
with O 
clinical O 
importance O 
for O 
a O 
treatment O 
of O 
iron B-SYSTEMATIC 
overload O 
diseases O 
. O 

and O 
characterization O 
of O 
quarteranthene B-TRIVIAL 
: O 
elucidating O 
the O 
characteristics O 
of O 
the O 
edge O 
state O 
of O 
graphene B-TRIVIAL 
nanoribbons O 
at O 
the O 
molecular O 
level O 
. O 

characteristics O 
of O 
the O 
edge O 
state O 
, O 
which O 
is O 
a O 
peculiar O 
magnetic O 
state O 
in O 
zigzag O 
- O 
edged O 
graphene B-TRIVIAL 
nanoribbons O 
( O 
ZGNRs O 
) O 
that O 
originates O 
from O 
electron O 
- O 
electron O 
correlation O 
in O 
an O 
edge O 
- O 
localized O 
π-state O 
, O 
are O 
investigated O 
by O 
preparing O 
and O 
characterizing O 
quarteranthene B-TRIVIAL 
molecules O 
. O 
The O 
molecular O 
geometry O 
that O 
was O 
determined O 
from O 
the O 
X-ray O 
analysis O 
is O 
consistent O 
with O 
a O 
zigzag O 
- O 
edge O 
- O 
localized O 
structure O 
of O 
unpaired O 
electrons O 
. O 
The O 
localized O 
electrons O 
are O 
responsible O 
for O 
the O 
peculiar O 
magnetic O 
( O 
room O 
- O 
temperature O 
ferromagnetic O 
correlation O 
) O 
, O 
optical O 
( O 
the O 
lowest O 
- O 
lying O 
doubly O 
excited O 
state O 
) O 
, O 
and O 
chemical O 
( O 
peroxide B-SYSTEMATIC 
bond O 
formation O 
) O 
behaviors O 
. O 
On O 
the O 
basis O 
of O 
these O 
distinguishing O 
properties O 
and O 
a O 
careful O 
consideration O 
of O 
the O 
valence O 
bonding O 
, O 
insight O 
into O 
the O 
edge O 
state O 
of O 
ZGNRs O 
can O 
be O 
gained O 
. O 

smoke O 
modulates O 
ozone B-TRIVIAL 
-induced O 
toxicity O 
in O 
rat O 
lungs O 
and O 
central O 
nervous O 
system O 
. O 

Sprague-Dawley O 
( O 
SD O 
) O 
male O 
rats O 
were O 
exposed O 
for O 
a O 
single O 
3 O 
h O 
period O 
to O 
air O 
, O 
ozone B-TRIVIAL 
( O 
O₃ B-FORMULA 
) O 
or O 
O₃ B-FORMULA 
) O 
followed O 
by O 
tobacco O 
smoke O 
( O 
O₃ B-FORMULA 
/ O 
TS O 
) O 
. O 
For O 
pulmonary O 
effects O 
, O 
bronchoalveolar O 
lavage O 
( O 
BAL O 
) O 
cells O 
and O 
fluid O 
were O 
analyzed O 
. O 
Data O 
revealed O 
a O 
significant O 
increase O 
in O 
polymorphonuclear O 
leukocytes O 
( O 
PMN O 
) O 
, O 
total O 
protein O 
and O 
albumin O 
concentrations O 
in O 
the O 
O₃ B-FORMULA 
group O 
, O 
reflecting O 
inflammatory O 
and O 
toxic O 
responses O 
. O 
A O 
subsequent O 
exposure O 
to O 
TS O 
attenuated O 
PMN O 
infiltration O 
into O 
the O 
airspaces O 
and O 
their O 
recovery O 
in O 
the O 
BAL O 
. O 
A O 
similar O 
reduction O 
was O 
observed O 
for O 
BAL O 
protein O 
and O 
albumin O 
in O 
the O 
O₃ B-FORMULA 
/ O 
TS O 
group O 
, O 
but O 
it O 
was O 
not O 
statistically O 
significant O 
. O 
We O 
also O 
observed O 
a O 
significant O 
increase O 
in O 
BAL O 
total O 
antioxidant O 
capacity O 
following O 
O₃ B-FORMULA 
exposure O 
, O 
suggesting O 
development O 
of O 
protective O 
mechanisms O 
for O 
oxidative O 
stress O 
damage O 
from O 
O₃ B-FORMULA 
. O 
Exposure O 
to O 
TS O 
attenuated O 
the O 
levels O 
of O 
total O 
antioxidant O 
capacity O 
. O 
Lung O 
tissue O 
protein O 
analysis O 
showed O 
a O 
significant O 
reduction O 
of O 
extracellular O 
superoxide B-TRIVIAL 
dismutase O 
( O 
EC-SOD O 
) O 
in O 
the O 
O₃ B-FORMULA 
or O 
O₃ B-FORMULA 
/ O 
TS O 
group O 
and O 
catalase O 
in O 
the O 
O₃ B-FORMULA 
/ O 
TS O 
group O 
. O 
TS O 
further O 
altered O 
O₃ B-FORMULA 
-induced O 
EC-SOD O 
and O 
catalase O 
protein O 
expression O 
, O 
but O 
the O 
reductions O 
were O 
not O 
significant O 
. O 
For O 
effects O 
in O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
, O 
we O 
measured O 
striatal O 
dopamine B-TRIVIAL 
levels O 
by O 
HPLC O 
with O 
electrochemical O 
detection O 
. O 
O₃ B-FORMULA 
exposure O 
produced O 
a O 
nonsignificant O 
decrease O 
in O 
the O 
striatal O 
dopamine O 
content O 
. O 
The O 
effect O 
was O 
partially O 
reversed O 
in O 
the O 
O₃ B-FORMULA 
/ O 
TS O 
group O 
. O 
Overall O 
, O 
the O 
results O 
show O 
that O 
the O 
toxicity O 
of O 
O₃ B-FORMULA 
in O 
the O 
lung O 
is O 
modulated O 
by O 
TS O 
exposure O 
, O 
and O 
the O 
attenuating O 
trend O 
, O 
though O 
nonsignificant O 
in O 
many O 
cases O 
, O 
is O 
contrary O 
to O 
the O 
synergistic O 
toxicity O 
predicted O 
for O 
TS O 
and O 
O₃ B-FORMULA 
, O 
suggesting O 
limited O 
cross O 
- O 
tolerance O 
following O 
such O 
exposures O 
. O 

of O 
dose O 
- O 
response O 
relations O 
between O 
4-week O 
inhalation O 
and O 
intratracheal O 
instillation O 
of O 
NiO B-FORMULA 
nanoparticles O 
using O 
polimorphonuclear O 
neutrophils O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
as O 
a O 
biomarker O 
of O 
pulmonary O 
inflammation O 
. O 

studies O 
and O 
intratracheal O 
instillation O 
studies O 
using O 
laboratory O 
animals O 
are O 
commonly O 
conducted O 
for O 
pulmonary O 
toxicity O 
tests O 
of O 
nanomaterials O 
. O 
In O 
our O 
study O 
, O 
male O 
Wister O 
rats O 
were O 
exposed O 
to O 
nickel B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NiO B-FORMULA 
) O 
particles O 
including O 
a O 
nano O 
- O 
scale O 
, O 
even O 
for O 
aerosols O 
and O 
suspensions O 
, O 
in O 
a O 
4-week O 
inhalation O 
and O 
intratracheal O 
instillation O 
. O 
Using O 
polymorphonuclear O 
neutrophils O 
( O 
PMNs O 
) O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
as O 
a O 
biomarker O 
of O 
inflammation O 
, O 
we O 
attempted O 
to O 
quantify O 
the O 
relationship O 
between O 
responses O 
to O 
inhalation O 
and O 
intratracheal O 
instillation O 
of O 
the O 
nanoparticles O 
, O 
based O 
on O 
surface O 
area O 
doses O 
. O 
Four O 
kinds O 
of O 
NiO B-FORMULA 
suspension O 
samples O 
with O 
different O 
specific O 
surface O 
areas O 
were O 
singly O 
injected O 
via O 
the O 
tracheas O 
of O 
the O 
rats O 
. O 
The O 
relationship O 
between O 
the O 
instilled O 
doses O 
and O 
PMN O 
production O 
was O 
examined O 
3 O 
days O 
and O 
1 O 
month O 
after O 
the O 
instillation O 
. O 
In O 
parallel O 
, O 
4-week O 
inhalation O 
studies O 
, O 
using O 
two O 
of O 
the O 
suspensions O 
, O 
were O 
conducted O 
for O 
aerosols O 
generated O 
by O 
a O 
pressurized O 
nebulizer O 
. O 
NiO B-FORMULA 
samples O 
induced O 
PMN O 
responses O 
3 O 
days O 
after O 
instillation O 
according O 
to O 
the O 
surface O 
area O 
doses O 
, O 
but O 
not O 
the O 
mass O 
doses O 
, O 
as O 
has O 
been O 
reported O 
in O 
many O 
studies O 
. O 
When O 
the O 
same O 
NiO B-FORMULA 
samples O 
were O 
tested O 
in O 
a O 
4-week O 
inhalation O 
and O 
intratracheal O 
instillation O 
, O 
the O 
amount O 
of O 
pulmonary O 
deposition O 
of O 
the O 
sample O 
after O 
the O 
4-week O 
inhalation O 
, O 
and O 
an O 
intratracheally O 
instilled O 
dose O 
about O 
ten O 
- O 
times O 
higher O 
, O 
induced O 
similar O 
PMN O 
responses O 
3 O 
days O 
after O 
termination O 
of O 
inhalation O 
and O 
instillation O 
. O 
Using O 
the O 
relationship O 
between O 
these O 
responses O 
to O 
4-week O 
inhalation O 
and O 
intratracheal O 
instillation O 
, O 
it O 
may O 
be O 
possible O 
to O 
estimate O 
what O 
aerosol O 
concentrations O 
of O 
other O 
nanomaterials O 
might O 
cause O 
the O 
same O 
responses O 
of O 
PMN O 
production O 
as O 
intratracheal O 
instillation O 
tests O 
. O 

deposition O 
of O 
amyloid O 
β- O 
protein O 
( O 
Aβ O 
) O 
is O 
a O 
pathological O 
hallmark O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
We O 
previously O 
found O 
that O 
the O 
ganglioside B-TRIVIAL 
-enriched O 
microdomains O 
( O 
ganglioside B-TRIVIAL 
clusters O 
) O 
in O 
presynaptic O 
neuronal O 
membranes O 
play O 
a O 
key O 
role O 
in O 
the O 
initiation O 
of O 
the O 
Aβ O 
assembly O 
process O 
. O 
However O 
, O 
not O 
all O 
ganglioside B-TRIVIAL 
clusters O 
accelerate O 
Aβ O 
assembly O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
directly O 
observed O 
a O 
spherical O 
Aβ O 
in O 
an O 
atomic O 
force O 
microscopic O 
study O 
on O 
the O 
morphology O 
of O 
a O 
reconstituted O 
lipid O 
bilayer O 
composed O 
of O 
lipids O 
that O 
were O 
extracted O 
from O 
a O 
detergent-resistant O 
membrane O 
microdomain O 
( O 
DRM O 
) O 
fraction O 
of O 
synaptosomes O 
prepared O 
from O 
aged O 
mouse O 
brain O 
. O 
The O 
Aβ O 
assembly O 
was O 
generated O 
on O 
a O 
distinctive O 
GM1 O 
domain O 
, O 
which O 
was O 
characterized O 
as O 
the O 
Aβ-sensitive O 
ganglioside B-TRIVIAL 
nanocluster O 
( O 
ASIGN O 
) O 
. O 
By O 
using O 
an O 
artificial O 
GM1 O 
cluster O 
- O 
binding O 
peptide O 
, O 
ASIGN O 
was O 
found O 
to O 
have O 
a O 
high O 
density O 
of O 
GM1 O 
; O 
therefore O 
, O 
there O 
would O 
be O 
a O 
critical O 
density O 
of O 
GM1 O 
in O 
nanoclusters O 
to O 
induce O 
Aβ O 
binding O 
and O 
assembly O 
. O 
These O 
results O 
suggest O 
that O 
ganglioside B-TRIVIAL 
-bound O 
Aβ O 
( O 
GAβ O 
) O 
, O 
which O 
acts O 
as O 
an O 
endogenous O 
seed O 
for O 
Aβ O 
fibril O 
formation O 
in O 
AD O 
brains O 
, O 
is O 
generated O 
on O 
ASIGN O 
on O 
synaptosomal O 
membranes O 
. O 

gradient O 
2 O 
and O 
3 O 
-- O 
two O 
prototype O 
androgen B-FAMILY 
-responsive O 
genes O 
transcriptionally O 
upregulated O 
by O 
androgens B-FAMILY 
and O 
by O 
oestrogens B-FAMILY 
in O 
prostate O 
cancer O 
cells O 
. O 

and O 
oestrogens B-FAMILY 
have O 
been O 
implicated O 
in O 
prostatic O 
carcinogenesis O 
and O 
tumour O 
progression O 
. O 
Although O 
the O 
actions O 
of O 
androgens B-FAMILY 
have O 
been O 
studied O 
extensively O 
, O 
the O 
mechanisms O 
underlying O 
oestrogen B-FAMILY 
signalling O 
in O 
prostate O 
cancer O 
are O 
not O 
fully O 
understood O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
analyzed O 
the O 
effect O 
of O 
androgens B-FAMILY 
and O 
oestrogens B-FAMILY 
on O 
the O 
expression O 
of O 
anterior O 
gradient O 
2 O 
( O 
AGR2 O 
) O 
and O 
anterior O 
gradient O 
3 O 
( O 
AGR3 O 
) O 
, O 
comprising O 
two O 
highly O 
- O 
related O 
genes O 
encoding O 
secretory O 
proteins O 
that O 
are O 
expressed O 
in O 
prostate O 
cancer O 
and O 
one O 
of O 
which O 
( O 
AGR2 O 
) O 
has O 
been O 
associated O 
with O 
tumour O 
metastasis O 
. O 
Quantitative O 
reverse O 
- O 
transcriptase O 
PCR O 
and O 
western O 
blot O 
analysis O 
showed O 
androgen B-FAMILY 
induction O 
of O 
AGR2 O 
and O 
AGR3 O 
in O 
three O 
androgen B-FAMILY 
receptor O 
positive O 
cell O 
lines O 
, O 
starting O 
at O 
concentrations O 
of O 
0.1 O 
nm O 
. O 
Both O 
AGR O 
genes O 
were O 
also O 
transcriptionally O 
activated O 
by O 
≥ O 
5 O 
nM O 
oestradiol B-TRIVIAL 
but O 
not O 
by O 
isotype O 
selective O 
or O 
nonselective O 
oestrogen B-FAMILY 
receptor O 
agonists O 
in O 
DUCaP O 
cells O 
that O 
harbour O 
a O 
high O 
- O 
level O 
of O 
wild O 
- O 
type O 
androgen B-FAMILY 
receptor O 
. O 
A O 
functional O 
androgen B-FAMILY 
receptor O 
but O 
not O 
oestrogen B-FAMILY 
receptor O 
turned O 
out O 
to O 
be O 
required O 
for O 
both O 
androgen B-FAMILY 
and O 
oestrogen B-FAMILY 
regulation O 
. O 
This O 
pattern O 
of O 
androgen B-FAMILY 
and O 
oestrogen B-FAMILY 
regulation O 
was O 
confirmed O 
in O 
VCaP O 
cells O 
and O 
was O 
also O 
observed O 
for O 
FKBP5 O 
, O 
a O 
well O 
- O 
characterized O 
androgen B-FAMILY 
-regulated O 
gene O 
. O 
Genome O 
- O 
wide O 
chromatin O 
- O 
immunoprecipitation O 
studies O 
coupled O 
with O 
deep O 
sequencing O 
identified O 
androgen B-FAMILY 
receptor O 
binding O 
sites O 
localized O 
in O 
the O 
distal O 
promoter O 
and O 
intron O 
regions O 
of O 
the O 
AGR2 O 
and O 
AGR3 O 
genes O 
, O 
respectively O 
. O 
The O 
androgen B-FAMILY 
responsiveness O 
of O 
these O 
enhancers O 
was O 
verified O 
by O 
luciferase O 
reporter O 
gene O 
assays O 
and O 
site O 
- O 
directed O 
mutagenesis O 
analysis O 
. O 
Androgen B-FAMILY 
treatment O 
also O 
induced O 
p300 O 
and O 
RNA O 
Pol O 
II O 
recruitment O 
to O 
androgen B-FAMILY 
receptor O 
enhancers O 
of O 
AGR2 O 
and O 
initiated O 
local O 
chromatin O 
remodelling O 
and O 
the O 
formation O 
of O 
RNA O 
Pol O 
II O 
- O 
containing O 
androgen B-FAMILY 
receptor O 
transcription O 
complexes O 
. O 

hemiacetal I-FAMILY 
sterol I-FAMILY 
with O 
antifouling O 
and O 
cytotoxic O 
activities O 
from O 
the O 
soft O 
coral O 
Nephthea O 
sp O 
. O 

novel O 
unusual O 
pentacyclic B-FAMILY 
hemiacetal I-FAMILY 
sterol I-FAMILY 
nephthoacetal B-TRIVIAL 
( O 
1 O 
) O 
, O 
was O 
isolated O 
from O 
soft O 
coral O 
Nephthea O 
sp O 
. O 
The O 
structure O 
of O 
this O 
sterol B-FAMILY 
was O 
inferred O 
from O 
its O 
two O 
acetyl B-SYSTEMATIC 
derivatives O 
( O 
2 O 
) O 
and O 
( O 
3 O 
) O 
, O 
by O 
means O 
of O 
spectroscopic O 
methods O 
, O 
and O 
quantum O 
chemical O 
calculations O 
. O 
Anti-fouling O 
activity O 
of O 
compounds O 
1-3 O 
against O 
Bugula O 
neritina O 
larvae O 
was O 
evaluated O 
, O 
sterol B-FAMILY 
( O 
1 O 
) O 
exhibited O 
significant O 
inhibitory O 
effect O 
with O 
EC(50) O 
value O 
of O 
2.5 O 
μg O 
/ O 
mL O 
, O 
while O 
having O 
low O 
toxicity O 
with O 
LC(50) O 
> O 
25 O 
μg O 
/ O 
mL O 
. O 
The O 
in O 
vitro O 
cytotoxic O 
activity O 
of O 
compounds O 
1-3 O 
against O 
HeLa O 
cells O 
was O 
also O 
evaluated O 
, O 
all O 
of O 
them O 
exhibited O 
moderate O 
cytotoxicity O 
with O 
IC(50) O 
values O 
of O 
12.3 O 
( O 
1 O 
) O 
, O 
10.1 O 
( O 
2 O 
) O 
, O 
and O 
19.6 O 
μg O 
/ O 
mL O 
( O 
3 O 
) O 
, O 
respectively O 
. O 

and O 
aspirin B-TRIVIAL 
resistance O 
in O 
coronary O 
artery O 
disease O 
. O 

is O 
still O 
the O 
mainstay O 
of O 
antiplatelet O 
therapy O 
in O 
the O 
secondary O 
prevention O 
of O 
coronary O 
artery O 
disease O 
. O 
However O 
certain O 
patients O 
do O 
not O 
benefit O 
from O 
the O 
antithrombotic O 
effects O 
of O 
aspirin B-TRIVIAL 
. O 
The O 
phenomenon O 
of O 
so O 
- O 
called O 
aspirin B-TRIVIAL 
resistance O 
can O 
be O 
considered O 
from O 
the O 
clinical O 
and O 
laboratory O 
perspective O 
. O 
A O 
variety O 
of O 
methods O 
have O 
emerged O 
for O 
the O 
laboratory O 
diagnosis O 
of O 
aspirin B-TRIVIAL 
resistance O 
. O 
None O 
of O 
them O 
is O 
considered O 
ideal O 
as O 
they O 
provide O 
conflicting O 
information O 
with O 
significant O 
inter O 
- O 
individual O 
variability O 
and O 
weak O 
correlation O 
between O 
them O 
. O 
With O 
the O 
mechanisms O 
of O 
aspirin B-TRIVIAL 
resistance O 
not O 
fully O 
understood O 
and O 
the O 
phenomenon O 
commonly O 
observed O 
in O 
individuals O 
with O 
poor O 
compliance O 
, O 
the O 
existence O 
of O 
aspirin B-TRIVIAL 
resistance O 
has O 
been O 
challenged O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
present O 
recent O 
data O 
on O 
the O 
impact O 
of O 
aspirin B-TRIVIAL 
resistance O 
in O 
primary O 
and O 
secondary O 
prevention O 
of O 
coronary O 
artery O 
disease O 
. O 

protects O 
against O 
arterial O 
hypertension O 
- O 
related O 
cardiac O 
fibrosis O 
through O 
modulation O 
of O 
PPAR-γ O 
expression O 
. O 

fibrosis O 
is O 
a O 
pathogenic O 
factor O 
in O 
a O 
variety O 
of O 
cardiovascular O 
diseases O 
and O 
is O 
characterized O 
by O 
an O 
abnormal O 
accumulation O 
of O 
extracellular O 
matrix O 
protein O 
that O 
leads O 
to O 
cardiac O 
dysfunction O 
. O 
l-Carnitine B-TRIVIAL 
( O 
LC O 
) O 
plays O 
an O 
essential O 
role O 
in O 
the O 
β-oxidation O 
of O 
long O 
- O 
chain O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
lipid O 
metabolism O 
. O 
We O 
have O 
previously O 
demonstrated O 
the O 
beneficial O 
effects O 
of O 
LC O 
in O 
hypertensive O 
rats O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
analyze O 
the O 
effect O 
of O 
LC O 
on O 
arterial O 
hypertension O 
- O 
associated O 
cardiac O 
fibrosis O 
and O 
to O 
explore O 
the O 
mechanisms O 
of O 
LC O 
action O 
. O 
To O 
this O 
end O 
, O 
four O 
groups O 
of O 
rats O 
were O 
used O 
: O 
Wistar O 
( O 
control O 
) O 
, O 
rats O 
treated O 
with O 
400mg O 
/ O 
kg O 
/ O 
day O 
of O 
LC O 
, O 
rats O 
treated O 
with O 
25mg O 
/ O 
kg O 
/ O 
day O 
of O 
l-NAME B-ABBREVIATION 
( O 
to O 
induce O 
hypertension O 
) O 
, O 
and O 
rats O 
treated O 
with O 
LC+ O 
l-NAME B-ABBREVIATION 
simultaneously O 
. O 
We O 
found O 
an O 
elevation O 
in O 
the O 
myocardial O 
expression O 
of O 
profibrotic O 
factors O 
( O 
TGF-β1 O 
and O 
CTGF O 
) O 
, O 
types O 
I O 
and O 
III O 
of O 
collagen O 
, O 
and O 
NADPH B-ABBREVIATION 
oxidase O 
subunits O 
( O 
NOX2 O 
and O 
NOX4 O 
) O 
, O 
in O 
hypertensive O 
rats O 
when O 
compared O 
with O 
normotensive O 
ones O 
. O 
In O 
addition O 
, O 
an O 
increase O 
in O 
myocardial O 
fibrosis O 
was O 
also O 
found O 
in O 
the O 
l-NAME B-ABBREVIATION 
group O 
. O 
These O 
results O 
were O 
accompanied O 
by O 
a O 
down O 
- O 
regulation O 
of O 
PPAR-γ O 
in O 
the O 
heart O 
of O 
hypertensive O 
animals O 
. O 
When O 
hypertensive O 
rats O 
were O 
treated O 
with O 
LC O 
, O 
all O 
these O 
alterations O 
were O 
reversed O 
. O 
Moreover O 
, O 
a O 
significant O 
negative O 
correlation O 
was O 
observed O 
between O 
myocardial O 
interstitial O 
fibrosis O 
and O 
mRNA O 
expression O 
of O 
PPAR-γ O 
. O 
In O 
conclusion O 
, O 
the O 
reduction O 
of O 
cardiac O 
fibrosis O 
and O 
the O 
down O 
- O 
regulation O 
of O 
NOX2 O 
, O 
NOX4 O 
, O 
TGF-β1 O 
and O 
CTGF O 
induced O 
by O 
LC O 
might O 
be O 
, O 
at O 
least O 
in O 
part O 
, O 
mediated O 
by O 
an O 
upregulation O 
of O 
PPAR-γ O 
, O 
which O 
leads O 
to O 
a O 
reduction O 
on O 
hypertension O 
- O 
related O 
cardiac O 
fibrosis O 
. O 

novel O 
transcriptional O 
repressor O 
PhaR O 
for O 
the O 
steroid B-FAMILY 
-inducible O 
expression O 
of O 
the O 
3,17β-hydroxysteroid B-FAMILY 
dehydrogenase O 
gene O 
in O 
Comamonas O 
testosteroni O 
ATCC11996 O 
. O 

testosteroni O 
is O 
able O 
to O 
catabolize O 
a O 
variety O 
of O 
steroids B-FAMILY 
and O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
and O 
might O 
be O 
used O 
in O 
the O 
bioremediation O 
of O 
contaminated O 
environments O 
. O 
3,17β-Hydroxysteroid B-FAMILY 
dehydrogenase O 
( O 
3,17β-HSD O 
) O 
from O 
C O 
. O 
testosteroni O 
is O 
a O 
member O 
of O 
the O 
short O 
- O 
chain O 
dehydrogenase O 
/ O 
reductase O 
( O 
SDR O 
) O 
superfamily O 
and O 
a O 
key O 
enzyme O 
in O 
steroid B-FAMILY 
degradation O 
. O 
The O 
genome O 
of O 
C O 
. O 
testosteroni O 
ATCC11996 O 
was O 
sequenced O 
in O 
our O 
previous O 
work O 
. O 
In O 
addition O 
to O 
the O 
gene O 
coding O 
for O 
3,17β-HSD O 
( O 
βhsd O 
) O 
, O 
a O 
novel O 
transcriptional O 
repressor O 
phaR O 
gene O 
( O 
phaR O 
) O 
which O 
locates O 
2290 O 
bp O 
upstream O 
of O 
the O 
βhsd O 
gene O 
was O 
found O 
. O 
PhaR O 
knock O 
- O 
out O 
mutants O 
of O 
C O 
. O 
testosteroni O 
were O 
prepared O 
and O 
shown O 
to O 
grow O 
better O 
than O 
wild O 
- O 
type O 
C O 
. O 
testosteroni O 
in O 
the O 
presence O 
of O 
1 O 
mM O 
testosterone B-TRIVIAL 
, O 
0.5 O 
mM O 
estradiol B-TRIVIAL 
or O 
0.5 O 
mM O 
cholesterol B-TRIVIAL 
in O 
both O 
Standard O 
1 O 
Nutrient O 
( O 
SIN O 
) O 
medium O 
and O 
1 O 
: O 
10 O 
diluted O 
SIN O 
medium O 
. O 
After O 
1 O 
mM O 
testosterone B-TRIVIAL 
induction O 
, O 
3,17β-HSD O 
expression O 
in O 
the O 
mutant O 
was O 
2.5 O 
times O 
higher O 
than O 
in O 
wild O 
type O 
C O 
. O 
testosteroni O 
. O 
Accordingly O 
, O 
PhaR O 
is O 
a O 
repressor O 
that O 
controls O 
3,17β-HSD O 
expression O 
. O 
Moreover O 
, O 
phaR O 
knock O 
- O 
out O 
mutants O 
grow O 
at O 
higher O 
rates O 
and O 
produce O 
more O 
protein O 
in O 
the O 
presence O 
of O 
steroids B-FAMILY 
as O 
carbon B-SYSTEMATIC 
source O 
. O 
However O 
, O 
ELISA O 
results O 
showed O 
that O 
0.5 O 
mM O 
estradiol B-TRIVIAL 
and O 
cholesterol B-TRIVIAL 
could O 
not O 
induce O 
βhsd O 
gene O 
expression O 
in O 
both O 
wild O 
- O 
type O 
and O 
mutant O 
C O 
. O 
testosteroni O 
. O 
Probably O 
, O 
in O 
addition O 
to O 
the O 
βhsd O 
gene O 
, O 
PhaR O 
regulates O 
some O 
other O 
genes O 
that O 
relate O 
to O 
steroid B-FAMILY 
degradation O 
. O 
The O 
genes O 
coding O 
for O 
PhaR O 
and O 
3,17β-HSD O 
together O 
with O 
their O 
promoter O 
domains O 
were O 
cloned O 
into O 
plasmids O 
pK18 O 
and O 
pUC19 O 
. O 
Escherichia O 
coli O 
HB101 O 
was O 
co O 
- O 
transformed O 
with O 
these O 
plasmids O 
. O 
The O 
results O 
suggest O 
that O 
PhaR O 
is O 
a O 
repressor O 
, O 
which O 
might O 
bind O 
on O 
a O 
special O 
βhsd O 
promoter O 
domain O 
( O 
214 O 
bp O 
) O 
. O 
A O 
2509 O 
bp O 
DNA O 
fragment O 
that O 
contained O 
a O 
putative O 
promoter O 
for O 
the O 
βhsd O 
gene O 
( O 
without O 
the O 
phaR O 
gene O 
) O 
was O 
cloned O 
into O 
plasmid O 
pUC2.5-3 O 
. O 
The O 
plasmid O 
was O 
transformed O 
into O 
HB101 O 
( O 
E O 
. O 
coli O 
) O 
and O 
induced O 
with O 
testosterone B-TRIVIAL 
. O 
As O 
a O 
result O 
, O 
3,17β-HSD O 
expression O 
was O 
at O 
a O 
high O 
level O 
, O 
but O 
could O 
not O 
be O 
further O 
enhanced O 
by O 
testosterone B-TRIVIAL 
. O 
Taken O 
together O 
, O 
phaR O 
knock O 
- O 
out O 
mutants O 
have O 
better O 
ability O 
to O 
degrade O 
steroids B-FAMILY 
than O 
wild O 
- O 
type O 
C O 
. O 
testosteroni O 
ATCC11996 O 
and O 
might O 
therefore O 
be O 
used O 
in O 
bioremediation O 
. O 

production O 
of O 
alpha-hydroxy B-FAMILY 
ketones I-FAMILY 
and O 
vicinal B-FAMILY 
diols I-FAMILY 
by O 
yeast O 
and O 
human O 
aldo O 
- O 
keto O 
reductases O 
. O 

α-hydroxy B-FAMILY 
ketones I-FAMILY 
are O 
used O 
as O 
building O 
blocks O 
for O 
compounds O 
of O 
pharmaceutical O 
interest O 
( O 
such O 
as O 
antidepressants O 
, O 
HIV-protease O 
inhibitors O 
and O 
antitumorals O 
) O 
. O 
They O 
can O 
be O 
obtained O 
by O 
the O 
action O 
of O 
enzymes O 
or O 
whole O 
cells O 
on O 
selected O 
substrates O 
, O 
such O 
as O 
diketones B-FAMILY 
. O 
We O 
have O 
studied O 
the O 
enantiospecificities O 
of O 
several O 
fungal O 
( O 
AKR3C1 O 
, O 
AKR5F O 
and O 
AKR5G O 
) O 
and O 
human O 
( O 
AKR1B1 O 
and O 
AKR1B10 O 
) O 
aldo O 
- O 
keto O 
reductases O 
in O 
the O 
production O 
of O 
α-hydroxy B-FAMILY 
ketones I-FAMILY 
and O 
diols B-FAMILY 
from O 
vicinal B-FAMILY 
diketones I-FAMILY 
. O 
The O 
reactions O 
have O 
been O 
carried O 
out O 
with O 
pure O 
enzymes O 
and O 
with O 
an O 
NADPH B-ABBREVIATION 
-regenerating O 
system O 
consisting O 
of O 
glucose-6-phosphate B-SYSTEMATIC 
and O 
glucose-6-phosphate B-SYSTEMATIC 
dehydrogenase O 
. O 
To O 
ascertain O 
the O 
regio O 
and O 
stereoselectivity O 
of O 
the O 
reduction O 
reactions O 
catalyzed O 
by O 
the O 
AKRs O 
, O 
we O 
have O 
separated O 
and O 
characterized O 
the O 
reaction O 
products O 
by O 
means O 
of O 
a O 
gas O 
chromatograph O 
equipped O 
with O 
a O 
chiral O 
column O 
and O 
coupled O 
to O 
a O 
mass O 
spectrometer O 
as O 
a O 
detector O 
. O 
According O 
to O 
the O 
regioselectivity O 
and O 
stereoselectivity O 
, O 
the O 
AKRs O 
studied O 
can O 
be O 
divided O 
in O 
two O 
groups O 
: O 
one O 
of O 
them O 
showed O 
preference O 
for O 
the O 
reduction O 
of O 
the O 
proximal O 
keto B-SYSTEMATIC 
group O 
, O 
resulting O 
in O 
the O 
S-enantiomer O 
of O 
the O 
corresponding O 
α-hydroxy B-FAMILY 
ketones I-FAMILY 
. O 
The O 
other O 
group O 
favored O 
the O 
reduction O 
of O 
the O 
distal O 
keto B-SYSTEMATIC 
group O 
and O 
yielded O 
the O 
corresponding O 
R-enantiomer O 
. O 
Three O 
of O 
the O 
AKRs O 
used O 
( O 
AKR1B1 O 
, O 
AKR1B10 O 
and O 
AKR3C1 O 
) O 
could O 
produce O 
2,3-butanediol B-SYSTEMATIC 
from O 
acetoin B-TRIVIAL 
. O 
We O 
have O 
explored O 
the O 
structure O 
/ O 
function O 
relationships O 
in O 
the O 
reactivity O 
between O 
several O 
yeast O 
and O 
human O 
AKRs O 
and O 
various O 
diketones B-FAMILY 
and O 
acetoin B-TRIVIAL 
. O 
In O 
addition O 
, O 
we O 
have O 
demonstrated O 
the O 
utility O 
of O 
these O 
AKRs O 
in O 
the O 
synthesis O 
of O 
selected O 
α-hydroxy B-FAMILY 
ketones I-FAMILY 
and O 
diols B-FAMILY 
. O 

lifetime O 
analysis O 
and O 
effect O 
of O 
magnesium B-SYSTEMATIC 
ions O 
on O 
binding O 
of O 
NADH B-ABBREVIATION 
to O 
human O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
1 O 
. O 

dehydrogenase O 
1 O 
( O 
ALDH1A1 O 
) O 
catalyzes O 
the O 
oxidation O 
of O 
toxic O 
aldehydes B-FAMILY 
to O 
carboxylic B-FAMILY 
acids I-FAMILY 
. O 
Physiologic O 
levels O 
of O 
Mg(2+) B-FORMULA 
ions O 
decrease O 
ALDH1 O 
activity O 
in O 
part O 
by O 
increasing O 
NADH B-ABBREVIATION 
binding O 
affinity O 
to O 
the O 
enzyme O 
. O 
By O 
using O 
time O 
- O 
resolved O 
fluorescence O 
spectroscopy O 
, O 
we O 
have O 
resolved O 
the O 
fluorescent O 
lifetimes O 
( O 
τ O 
) O 
of O 
free O 
NADH B-ABBREVIATION 
in O 
solution O 
( O 
τ=0.4 O 
ns O 
) O 
and O 
two O 
enzyme O 
- O 
bound O 
NADH B-ABBREVIATION 
states O 
( O 
τ=2.0 O 
ns O 
and O 
τ=7.7 O 
ns O 
) O 
. O 
We O 
used O 
this O 
technique O 
to O 
investigate O 
the O 
effects O 
of O 
Mg(2+) B-FORMULA 
ions O 
on O 
the O 
ALDH1A1- O 
NADH B-ABBREVIATION 
binding O 
characteristics O 
and O 
enzyme O 
catalysis O 
. O 
From O 
the O 
resolved O 
free O 
and O 
bound O 
NADH B-ABBREVIATION 
fluorescence O 
signatures O 
, O 
the O 
KD O 
values O 
for O 
both O 
NADH B-ABBREVIATION 
conformations O 
in O 
ALDH1A1 O 
ranged O 
from O 
about O 
24 O 
μM O 
to O 
1 O 
μM O 
for O 
Mg(2+) B-FORMULA 
ion O 
concentrations O 
of O 
0-6000 O 
μM O 
, O 
respectively O 
. O 
The O 
rate O 
constants O 
for O 
dissociation O 
of O 
the O 
enzyme- O 
NADH B-ABBREVIATION 
complex O 
ranged O 
from O 
0.03 O 
s(-1) O 
( O 
6000 O 
μM O 
Mg(2+) B-FORMULA 
) O 
to O 
0.30s(-1) O 
( O 
0 O 
μM O 
Mg(2+) B-FORMULA 
) O 
as O 
determined O 
by O 
addition O 
of O 
excess O 
NAD(+) B-ABBREVIATION 
to O 
prevent O 
re O 
- O 
association O 
of O 
NADH B-ABBREVIATION 
and O 
resolving O 
the O 
real O 
- O 
time O 
NADH B-ABBREVIATION 
fluorescence O 
signal O 
. O 
During O 
the O 
initial O 
reaction O 
of O 
enzyme O 
with O 
NAD(+) B-ABBREVIATION 
and O 
butyraldehyde B-SYSTEMATIC 
, O 
there O 
was O 
an O 
immediate O 
rise O 
in O 
the O 
NADH B-ABBREVIATION 
fluorescence O 
, O 
due O 
to O 
the O 
formation O 
of O 
bound O 
NADH B-ABBREVIATION 
complexes O 
, O 
with O 
a O 
constant O 
steady O 
- O 
state O 
rate O 
of O 
production O 
of O 
free O 
NADH B-ABBREVIATION 
. O 
As O 
the O 
Mg(2+) B-FORMULA 
ion O 
concentration O 
was O 
increased O 
, O 
there O 
was O 
a O 
consistent O 
decrease O 
of O 
the O 
enzyme O 
catalytic O 
turnover O 
from O 
0.31 O 
s(-1) O 
( O 
0 O 
μM O 
Mg(2+) B-FORMULA 
) O 
to O 
0.05 O 
s(-1) O 
( O 
6000 O 
μM O 
Mg(2+) B-FORMULA 
) O 
and O 
a O 
distinct O 
shift O 
in O 
steady O 
- O 
state O 
conformational O 
population O 
from O 
one O 
that O 
favors O 
the O 
ALDH1- O 
NADH B-ABBREVIATION 
complex O 
with O 
the O 
shorter O 
fluorescence O 
lifetime O 
( O 
33% O 
excess O 
) O 
in O 
the O 
absence O 
of O 
magnesium B-SYSTEMATIC 
ion O 
to O 
one O 
that O 
favors O 
the O 
ALDH1- O 
NADH B-ABBREVIATION 
complex O 
with O 
the O 
longer O 
fluorescence O 
lifetime O 
( O 
13% O 
excess O 
) O 
at O 
6000 O 
μM O 
Mg(2+) B-FORMULA 
. O 
This O 
shift O 
in O 
conformational O 
population O 
at O 
higher O 
Mg(2+) B-FORMULA 
ion O 
concentrations O 
and O 
to O 
lower O 
enzyme O 
activity O 
may O 
be O 
due O 
to O 
longer O 
residence O 
time O 
of O 
the O 
NADH B-ABBREVIATION 
in O 
the O 
ALDH1 O 
pocket O 
. O 
The O 
results O 
from O 
monitoring O 
enzyme O 
catalysis O 
in O 
the O 
absence O 
of O 
magnesium B-SYSTEMATIC 
suggests O 
that O 
the O 
ALDH1- O 
NADH B-ABBREVIATION 
complex O 
with O 
the O 
shorter O 
fluorescence O 
lifetime O 
is O 
the O 
form O 
initially O 
produced O 
, O 
and O 
the O 
complex O 
with O 
the O 
longer O 
fluorescence O 
lifetime O 
is O 
produced O 
through O 
isomerization O 
. O 

topical O 
formulations O 
of O 
Terbinafine B-TRIVIAL 
- O 
HCl B-FORMULA 
for O 
treatment O 
of O 
onychomycosis O 
. O 

hydrochloride I-TRIVIAL 
( O 
TBF B-ABBREVIATION 
- O 
HCl B-FORMULA 
) O 
is O 
an O 
active O 
substance O 
that O 
is O 
using O 
for O 
treatment O 
of O 
onychomycosis O 
. O 
Onychomycosis O 
is O 
a O 
fungal O 
infection O 
which O 
is O 
the O 
most O 
common O 
disease O 
of O 
nail O 
plate O 
. O 
The O 
nail O 
plate O 
is O 
a O 
barrier O 
which O 
prevents O 
effective O 
topical O 
treatment O 
of O 
ungual O 
disorders O 
. O 
In O 
this O 
study O 
, O 
TBF B-ABBREVIATION 
- O 
HCl B-FORMULA 
loaded O 
liposome O 
and O 
ethosome O 
formulations O 
and O 
also O 
gel O 
form O 
of O 
these O 
formulations O 
were O 
prepared O 
. O 
The O 
formulations O 
were O 
characterized O 
and O 
in O 
vitro O 
and O 
ex O 
vivo O 
release O 
studies O 
were O 
performed O 
. O 
Nail O 
characterization O 
studies O 
were O 
also O 
performed O 
to O 
examine O 
the O 
effect O 
of O 
formulations O 
and O 
experimental O 
conditions O 
on O 
nail O 
surface O 
. O 
As O 
a O 
result O 
, O 
all O 
formulations O 
can O 
serve O 
as O 
efficient O 
formulations O 
for O 
ungual O 
application O 
of O 
TBF B-ABBREVIATION 
- O 
HCl B-FORMULA 
. O 
By O 
the O 
way O 
, O 
the O 
results O 
of O 
the O 
accumulation O 
studies O 
suggested O 
that O 
liposome O 
poloxamer B-TRIVIAL 
gel I-TRIVIAL 
formulation O 
could O 
be O 
promising O 
system O 
for O 
ungual O 
drug O 
delivery O 
due O 
to O 
the O 
better O 
accumulation O 
and O 
easier O 
application O 
of O 
the O 
formulation O 
. O 

represents O 
a O 
period O 
of O 
marked O 
adaptation O 
of O 
the O 
hypothalamo O 
- O 
pituitary O 
- O 
adrenal O 
HPA O 
axis O 
. O 
We O 
characterized O 
basal O 
and O 
stress O 
- O 
induced O 
HPA O 
activity O 
during O 
lactation O 
and O 
experimental O 
weaning O 
using O 
dynamic O 
blood O 
sampling O 
in O 
rats O 
. O 
Pulsatile O 
and O 
diurnal O 
corticosterone B-TRIVIAL 
release O 
occurred O 
at O 
all O 
reproductive O 
stages O 
studied O 
( O 
virgin O 
; O 
day O 
10 O 
of O 
lactation O 
; O 
3 O 
and O 
14 O 
days O 
after O 
experimental O 
weaning O 
on O 
day O 
10 O 
of O 
lactation O 
) O 
. O 
However O 
, O 
in O 
lactating O 
rats O 
the O 
diurnal O 
peak O 
was O 
significantly O 
reduced O 
, O 
resulting O 
in O 
a O 
flattened O 
rhythm O 
, O 
and O 
three O 
days O 
after O 
weaning O 
, O 
basal O 
HPA O 
activity O 
was O 
markedly O 
suppressed O 
: O 
the O 
number O 
of O 
pulses O 
and O 
underlying O 
basal O 
levels O 
of O 
corticosterone B-TRIVIAL 
were O 
reduced O 
and O 
the O 
diurnal O 
rise O 
phase O 
delayed O 
. O 
Marked O 
changes O 
in O 
the O 
HPA O 
response O 
to O 
10 O 
min O 
noise O 
stress O 
also O 
occurred O 
at O 
these O 
times O 
: O 
being O 
completely O 
absent O 
in O 
lactating O 
animals O 
, O 
but O 
restored O 
and O 
highly O 
prolonged O 
in O 
early O 
weaned O 
animals O 
. O 
Injection O 
of O 
methylprednisolone B-SYSTEMATIC 
( O 
2 O 
mg O 
, O 
iv O 
) O 
was O 
used O 
to O 
determine O 
whether O 
changes O 
in O 
fast O 
glucocorticoid O 
suppression O 
correlated O 
with O 
these O 
adaptive O 
changes O 
. O 
Methylprednisolone B-SYSTEMATIC 
induced O 
a O 
rapid O 
suppression O 
of O 
corticosterone B-TRIVIAL 
in O 
virgin O 
animals O 
, O 
but O 
this O 
effect O 
was O 
markedly O 
attenuated O 
in O 
lactating O 
and O 
early O 
weaned O 
animals O 
and O 
was O 
accompanied O 
by O 
significant O 
changes O 
in O 
relative O 
expression O 
of O 
hippocampal O 
glucocorticoid O 
and O 
mineralocorticoid O 
receptor O 
mRNA O 
. O 
All O 
effects O 
were O 
reversed O 
or O 
partially O 
reversed O 
14 O 
days O 
after O 
experimental O 
weaning O 
. O 
Thus O 
, O 
the O 
presence O 
of O 
the O 
pups O 
has O 
an O 
important O 
influence O 
on O 
regulation O 
of O 
the O 
HPA O 
axis O 
, O 
and O 
while O 
postpartum O 
adaptations O 
are O 
reversible O 
, O 
acute O 
weaning O 
evokes O 
marked O 
reorganisation O 
of O 
basal O 
and O 
stress O 
- O 
induced O 
HPA O 
activity O 
. O 

represses O 
miR-200 O 
microRNAs O 
and O 
promotes O 
epithelial O 
- O 
to O 
- O 
mesenchymal O 
transition O 
by O 
up O 
- O 
regulating O 
c-Myc O 
in O 
endometrial O 
carcinoma O 
cell O 
lines O 
. O 

tamoxifen B-TRIVIAL 
( O 
TAM B-ABBREVIATION 
) O 
, O 
a O 
selective O 
estrogen B-FAMILY 
receptor O 
modulator O 
, O 
has O 
been O 
widely O 
used O 
in O 
the O 
treatment O 
of O 
hormone O 
- O 
responsive O 
breast O 
cancer O 
, O 
its O 
estrogen B-FAMILY 
-like O 
effect O 
increases O 
the O 
risk O 
of O 
endometrial O 
cancer O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
of O 
TAM B-ABBREVIATION 
-induced O 
endometrial O 
carcinoma O 
still O 
remain O 
unclear O 
. O 
In O 
this O 
report O 
, O 
we O 
explored O 
the O 
role O 
of O 
microRNAs O 
( O 
miRNAs O 
) O 
in O 
TAM B-ABBREVIATION 
-induced O 
epithelial O 
- O 
mesenchymal O 
transition O 
( O 
EMT O 
) O 
in O 
ECC-1 O 
and O 
Ishikawa O 
endometrial O 
cancer O 
cell O 
lines O 
and O 
found O 
miR-200 O 
is O 
involved O 
in O 
this O 
process O 
via O 
the O 
regulation O 
of O 
c-Myc O 
. O 
When O 
treated O 
with O 
TAM B-ABBREVIATION 
, O 
ECC-1 O 
and O 
Ishikawa O 
cells O 
were O 
characterized O 
by O 
higher O 
invasiveness O 
and O 
motility O 
and O 
underwent O 
EMT O 
. O 
miR-200 O 
, O 
a O 
miRNA O 
family O 
with O 
tumor O 
suppressive O 
functions O 
in O 
a O 
wide O 
range O 
of O 
cancers O 
, O 
was O 
found O 
reduced O 
in O 
response O 
to O 
TAM B-ABBREVIATION 
treatment O 
. O 
Consistent O 
with O 
zinc B-SYSTEMATIC 
finger O 
E-box O 
binding O 
homeobox O 
2 O 
, O 
which O 
was O 
confirmed O 
as O 
a O 
direct O 
target O 
of O 
miR-200b O 
in O 
endometrial O 
cancer O 
cell O 
lines O 
, O 
some O 
other O 
key O 
factors O 
of O 
EMT O 
such O 
as O 
Snail O 
and O 
N-cadherin O 
increased O 
, O 
whereas O 
E-cadherin O 
decreased O 
in O 
the O 
TAM B-ABBREVIATION 
-treated O 
cells O 
, O 
contributing O 
to O 
TAM B-ABBREVIATION 
-induced O 
EMT O 
in O 
these O 
endometrial O 
cancer O 
cells O 
. O 
In O 
addition O 
, O 
we O 
showed O 
that O 
c-Myc O 
directly O 
binds O 
to O 
and O 
represses O 
the O 
promoter O 
of O 
miR-200 O 
miRNAs O 
, O 
and O 
its O 
up O 
- O 
regulation O 
in O 
TAM B-ABBREVIATION 
-treated O 
endometrial O 
cancer O 
cells O 
leads O 
to O 
the O 
down O 
- O 
regulation O 
of O 
miR-200 O 
and O 
eventually O 
to O 
EMT O 
. O 
Collectively O 
, O 
our O 
data O 
suggest O 
that O 
TAM B-ABBREVIATION 
can O 
repress O 
the O 
miR-200 O 
family O 
and O 
induce O 
EMT O 
via O 
the O 
up O 
- O 
regulation O 
of O 
c-Myc O 
in O 
endometrial O 
cancer O 
cells O 
. O 
These O 
findings O 
describe O 
a O 
possible O 
mechanism O 
of O 
TAM B-ABBREVIATION 
-induced O 
EMT O 
in O 
endometrial O 
cancer O 
and O 
provide O 
a O 
potential O 
new O 
therapeutic O 
strategy O 
for O 
it O 
. O 

combined O 
application O 
of O 
different O 
biophysical O 
techniques O 
- O 
analytical O 
ultracentrifugation O 
, O 
light O 
scattering O 
and O 
fluorescence O 
- O 
based O 
assays O 
- O 
to O 
study O 
the O 
ligand O 
- O 
linked O 
self O 
- O 
association O 
and O 
assembly O 
properties O 
of O 
the O 
cell O 
division O 
protein O 
FtsZ O 
from O 
Escherichia O 
coli O 
is O 
described O 
. O 
These O 
reactions O 
are O 
thought O 
to O 
be O 
important O 
for O 
the O 
formation O 
of O 
the O 
dynamic O 
division O 
ring O 
that O 
drives O 
bacterial O 
cytokinesis O 
. O 
In O 
addition O 
, O 
the O 
use O 
of O 
this O 
orthogonal O 
experimental O 
approach O 
to O 
measure O 
the O 
interactions O 
between O 
FtsZ O 
oligomers O 
( O 
GDP B-ABBREVIATION 
forms O 
) O 
and O 
polymers O 
( O 
GTP B-ABBREVIATION 
forms O 
) O 
with O 
two O 
variants O 
( O 
a O 
soluble O 
form O 
and O 
a O 
full O 
- O 
length O 
protein O 
incorporated O 
in O 
phospholipid O 
bilayer O 
nanodiscs O 
) O 
of O 
the O 
ZipA O 
protein O 
, O 
which O 
provides O 
membrane O 
tethering O 
to O 
FtsZ O 
, O 
is O 
described O 
as O 
well O 
. O 
The O 
power O 
of O 
a O 
global O 
analysis O 
of O 
the O 
results O 
obtained O 
from O 
complementary O 
biophysical O 
methods O 
to O 
discriminate O 
among O 
alternative O 
self- O 
and O 
hetero O 
- O 
associating O 
schemes O 
and O 
to O 
propose O 
a O 
more O 
robust O 
description O 
of O 
the O 
association O 
reactions O 
involved O 
is O 
emphasized O 
. O 
This O 
orthogonal O 
approach O 
will O 
contribute O 
to O 
complete O 
our O 
quantitative O 
understanding O 
of O 
the O 
initial O 
events O 
of O 
bacterial O 
division O 
. O 

-induced O 
oxidative O 
DNA O 
damage O 
in O 
neuronal O 
SH-SY5Y O 
cells O 
: O 
attenuation O 
of O 
thymine B-TRIVIAL 
base O 
lesions O 
by O 
glutathione B-TRIVIAL 
and O 
N-acetylcysteine B-SYSTEMATIC 
. O 

( O 
Mn B-FORMULA 
) O 
is O 
an O 
essential O 
trace O 
element O 
required O 
for O 
normal O 
function O 
and O 
development O 
. O 
However O 
, O 
exposure O 
to O 
this O 
metal O 
at O 
elevated O 
levels O 
may O 
cause O 
manganism O 
, O 
a O 
progressive O 
neurodegenerative O 
disorder O 
with O 
neurological O 
symptoms O 
similar O 
to O 
idiopathic O 
Parkinson's O 
disease O 
( O 
IPD O 
) O 
. O 
Elevated O 
body O 
burdens O 
of O 
Mn B-FORMULA 
from O 
exposure O 
to O 
parental O 
nutrition O 
, O 
vapors O 
in O 
mines O 
and O 
smelters O 
and O 
welding O 
fumes O 
have O 
been O 
associated O 
with O 
neurological O 
health O 
concerns O 
. O 
The O 
underlying O 
mechanism O 
of O 
Mn B-FORMULA 
neurotoxicity O 
remains O 
unclear O 
. O 
Accordingly O 
, O 
the O 
present O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
toxic O 
effects O 
of O 
Mn(2+) B-FORMULA 
in O 
human O 
neuroblastoma O 
SH-SY5Y O 
cells O 
. O 
Mn(2+) B-FORMULA 
caused O 
a O 
concentration O 
dependent O 
decrease O 
in O 
SH-SY5Y O 
cellular O 
viability O 
compared O 
to O 
controls O 
. O 
The O 
LD50 O 
value O 
was O 
12.98 O 
μM O 
Mn(2+) B-FORMULA 
( O 
p O 
< O 
0.001 O 
for O 
control O 
vs O 
. O 
24h O 
Mn B-FORMULA 
treatment O 
) O 
. O 
Both O 
TUNEL O 
and O 
annexin O 
V/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
apoptosis O 
assays O 
confirmed O 
the O 
induction O 
of O 
apoptosis O 
in O 
the O 
cells O 
following O 
exposure O 
to O 
Mn(2+) B-FORMULA 
( O 
2 O 
μM O 
, O 
62 O 
μM O 
or O 
125 O 
μM O 
) O 
. O 
In O 
addition O 
, O 
Mn(2+) B-FORMULA 
induced O 
both O 
the O 
formation O 
and O 
accumulation O 
of O 
DNA O 
single O 
strand O 
breaks O 
( O 
via O 
alkaline O 
comet O 
assay O 
analysis O 
) O 
and O 
oxidatively O 
modified O 
thymine B-TRIVIAL 
bases O 
( O 
via O 
gas O 
chromatography O 
/ O 
mass O 
spectrometry O 
analysis O 
) O 
. O 
Pre O 
- O 
incubation O 
of O 
the O 
cells O 
with O 
characteristic O 
antioxidants O 
, O 
either O 
1mM O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
or O 
1mM O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
reduced O 
the O 
level O 
of O 
DNA O 
strand O 
breaks O 
and O 
the O 
formation O 
of O 
thymine B-TRIVIAL 
base O 
lesions O 
, O 
suggesting O 
protection O 
against O 
oxidative O 
cellular O 
damage O 
. O 
Our O 
findings O 
indicate O 
that O 
( O 
1 O 
) O 
exposure O 
of O 
SH-SY5Y O 
cells O 
to O 
Mn B-FORMULA 
promotes O 
both O 
the O 
formation O 
and O 
accumulation O 
of O 
oxidative O 
DNA O 
damage O 
, O 
( O 
2 O 
) O 
SH-SY5Y O 
cells O 
with O 
accumulated O 
DNA O 
damage O 
are O 
more O 
likely O 
to O 
die O 
via O 
an O 
apoptotic O 
pathway O 
and O 
( O 
3 O 
) O 
the O 
accumulated O 
levels O 
of O 
DNA O 
damage O 
can O 
be O 
abrogated O 
by O 
the O 
addition O 
of O 
exogenous O 
chemical O 
antioxidants O 
. O 
This O 
is O 
the O 
first O 
known O 
report O 
of O 
Mn(2+) B-FORMULA 
-induction O 
and O 
antioxidant O 
protection O 
of O 
thymine B-TRIVIAL 
lesions O 
in O 
this O 
SH-SY5Y O 
cell O 
line O 
and O 
contributes O 
new O 
information O 
to O 
the O 
potential O 
use O 
of O 
antioxidants O 
as O 
a O 
therapeutic O 
strategy O 
for O 
protection O 
against O 
Mn(2+) B-FORMULA 
-induced O 
oxidative O 
DNA O 
damage O 
. O 

induces O 
Alzheimer's O 
disease O 
- O 
like O 
pathologies O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

pathologic O 
mechanisms O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
have O 
not O 
been O 
fully O 
uncovered O 
. O 
Acrolein B-TRIVIAL 
, O 
a O 
ubiquitous O 
dietary O 
pollutant O 
and O 
by O 
- O 
product O 
of O 
oxidative O 
stress O 
, O 
can O 
induce O 
cytotoxicity O 
in O 
neurons O 
, O 
which O 
might O 
play O 
an O 
important O 
role O 
in O 
the O 
etiology O 
of O 
AD O 
. O 
Here O 
, O 
we O 
examined O 
the O 
effects O 
of O 
Acrolein B-TRIVIAL 
on O 
the O 
AD O 
pathologies O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
We O 
found O 
Acrolein B-TRIVIAL 
induced O 
HT22 O 
cells O 
death O 
in O 
concentration- O 
and O 
time O 
- O 
dependent O 
manners O 
. O 
Interestingly O 
, O 
Acrolein B-TRIVIAL 
increased O 
proteins O 
' O 
levels O 
of O 
amyloid O 
precursor O 
protein O 
( O 
APP O 
) O 
, O 
β-secretase O 
( O 
BACE-1 O 
) O 
and O 
the O 
amyloid O 
β- O 
peptide O 
transporter O 
receptor O 
for O 
advanced O 
glycation O 
end O 
products O 
, O 
and O 
decreased O 
A-disintegrin O 
and O 
metalloprotease O 
( O 
ADAM O 
) O 
10 O 
levels O 
. O 
In O 
vivo O 
, O 
chronic O 
oral O 
exposure O 
to O 
Acrolein B-TRIVIAL 
( O 
2.5 O 
mg O 
/ O 
kg O 
/ O 
day O 
by O 
intragastric O 
gavage O 
for O 
8 O 
weeks O 
) O 
induced O 
mild O 
cognitive O 
declination O 
and O 
pyknosis O 
/ O 
atrophy O 
of O 
hippocampal O 
neurons O 
. O 
The O 
activity O 
of O 
superoxide B-TRIVIAL 
dismutase O 
was O 
down O 
- O 
regulated O 
while O 
the O 
level O 
of O 
malondialdehyde B-TRIVIAL 
was O 
up O 
- O 
regulated O 
in O 
rat O 
brain O 
. O 
Moreover O 
, O 
Acrolein B-TRIVIAL 
resulted O 
in O 
activation O 
of O 
astrocytes O 
, O 
up O 
- O 
regulation O 
of O 
BACE-1 O 
in O 
cortex O 
and O 
down O 
- O 
regulation O 
of O 
ADAM-10 O 
in O 
hippocampus O 
and O 
cortex O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
suggest O 
that O 
exposure O 
to O 
Acrolein B-TRIVIAL 
induces O 
AD O 
- O 
like O 
pathology O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Scavenging O 
Acrolein B-TRIVIAL 
might O 
be O 
beneficial O 
for O 
the O 
therapy O 
of O 
AD O 
. O 

of O 
uranium B-SYSTEMATIC 
nanoparticles O 
: O 
respiratory O 
tract O 
deposition O 
and O 
translocation O 
to O 
secondary O 
target O 
organs O 
in O 
rats O 
. O 

nanoparticles O 
( O 
< O 
100 O 
nm O 
) O 
can O 
be O 
released O 
into O 
the O 
atmosphere O 
during O 
industrial O 
stages O 
of O 
the O 
nuclear O 
fuel O 
cycle O 
and O 
during O 
remediation O 
and O 
decommissioning O 
of O 
nuclear O 
facilities O 
. O 
Explosions O 
and O 
fires O 
in O 
nuclear O 
reactors O 
and O 
the O 
use O 
of O 
ammunition O 
containing O 
depleted O 
uranium B-SYSTEMATIC 
can O 
also O 
produce O 
such O 
aerosols O 
. O 
The O 
risk O 
of O 
accidental O 
inhalation O 
of O 
uranium B-SYSTEMATIC 
nanoparticles O 
by O 
nuclear O 
workers O 
, O 
military O 
personnel O 
or O 
civilian O 
populations O 
must O 
therefore O 
be O 
taken O 
into O 
account O 
. O 
In O 
order O 
to O 
address O 
this O 
issue O 
, O 
the O 
absorption O 
rate O 
of O 
inhaled O 
uranium B-SYSTEMATIC 
nanoparticles O 
needs O 
to O 
be O 
characterised O 
experimentally O 
. O 
For O 
this O 
purpose O 
, O 
rats O 
were O 
exposed O 
to O 
an O 
aerosol O 
containing O 
10⁷ O 
particles O 
of O 
uranium B-SYSTEMATIC 
per O 
cm³ O 
( O 
CMD=38 O 
nm O 
) O 
for O 
1h O 
in O 
a O 
nose O 
- O 
only O 
inhalation O 
exposure O 
system O 
. O 
Uranium B-SYSTEMATIC 
concentrations O 
deposited O 
in O 
the O 
respiratory O 
tract O 
, O 
blood O 
, O 
brain O 
, O 
skeleton O 
and O 
kidneys O 
were O 
determined O 
by O 
ICP-MS O 
. O 
Twenty O 
- O 
seven O 
percent O 
of O 
the O 
inhaled O 
mass O 
of O 
uranium B-SYSTEMATIC 
nanoparticles O 
was O 
deposited O 
in O 
the O 
respiratory O 
tract O 
. O 
One O 
- O 
fifth O 
of O 
UO₂ B-FORMULA 
nanoparticles O 
were O 
rapidly O 
cleared O 
from O 
lung O 
( O 
T(½)=2.4 O 
h O 
) O 
and O 
translocated O 
to O 
extrathoracic O 
organs O 
. O 
However O 
, O 
the O 
majority O 
of O 
the O 
particles O 
were O 
cleared O 
slowly O 
( O 
T(½)=141.5 O 
d O 
) O 
. O 
Future O 
long O 
- O 
term O 
experimental O 
studies O 
concerning O 
uranium B-SYSTEMATIC 
nanoparticles O 
should O 
focus O 
on O 
the O 
potential O 
lung O 
toxicity O 
of O 
the O 
large O 
fraction O 
of O 
particles O 
cleared O 
slowly O 
from O 
the O 
respiratory O 
tract O 
after O 
inhalation O 
exposure O 
. O 

RASSCF O 
study O 
of O 
free O 
base O 
, O 
magnesium B-MULTIPLE 
and I-MULTIPLE 
zinc I-MULTIPLE 
porphyrins I-MULTIPLE 
: O 
accuracy O 
versus O 
efficiency O 
. O 

restricted O 
- O 
active O 
- O 
space O 
self-consistent-field O 
methodology O 
is O 
successfully O 
applied O 
to O 
the O 
study O 
of O 
free O 
base- O 
and O 
regular O 
metalloporphyrins B-FAMILY 
, O 
the O 
latter O 
containing O 
magnesium B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
central O 
ions O 
. O 
It O 
is O 
shown O 
that O 
inclusion O 
of O 
all O 
excitations O 
involving O 
the O 
Gouterman O 
frontier O 
orbitals O 
in O 
the O 
RAS2 O 
subspace O 
results O 
in O 
a O 
numerically O 
stable O 
approach O 
, O 
producing O 
highly O 
accurate O 
results O 
at O 
a O 
fraction O 
of O 
the O 
computational O 
cost O 
of O 
the O 
complete O 
- O 
active O 
- O 
space O 
self-consistent-field O 
method O 
, O 
whereas O 
increasing O 
RAS2 O 
beyond O 
this O 
size O 
leads O 
to O 
only O 
modest O 
improvement O 
. O 
Topological O 
and O 
orbital O 
analysis O 
shows O 
that O 
the O 
approach O 
is O 
also O 
able O 
to O 
give O 
a O 
highly O 
accurate O 
description O 
of O 
the O 
electronic O 
wavefunction O 
. O 
Inclusion O 
of O 
the O 
entire O 
π-conjugated O 
subsystem O 
in O 
the O 
active O 
space O 
results O 
in O 
more O 
accurate O 
excitation O 
energies O 
and O 
a O 
reduction O 
in O 
the O 
dependence O 
on O 
the O 
exact O 
form O 
of O 
the O 
perturbational O 
Hamiltonian O 
used O 
to O 
include O 
dynamic O 
correlation O 
. O 
The O 
larger O 
active O 
space O 
also O 
resolves O 
a O 
quantitative O 
disagreement O 
in O 
results O 
obtained O 
with O 
and O 
without O 
the O 
inclusion O 
of O 
dynamic O 
correlation O 
. O 

- O 
dependent O 
cellular O 
cytotoxicity O 
( O 
ADCC O 
) O 
, O 
which O 
is O 
activated O 
by O 
effector O 
cells O 
via O 
immunoglobulin O 
G O 
( O 
IgG O 
) O 
fragment O 
C O 
receptors O 
( O 
FcRs O 
) O 
, O 
was O 
proposed O 
as O 
a O 
mechanism O 
of O 
cetuximab O 
efficacy O 
. O 
Peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMCs O 
) O 
from O 
23 O 
healthy O 
donors O 
and O 
13 O 
patients O 
with O 
metastatic O 
colorectal O 
cancer O 
( O 
mCRC O 
) O 
treated O 
with O 
cetuximab O 
were O 
tested O 
for O 
FcγR O 
polymorphisms O 
and O 
cetuximab O 
- O 
mediated O 
ADCC O 
. O 
ADCC O 
was O 
measured O 
by O 
chromium-51 B-SYSTEMATIC 
release O 
on O 
a O 
epidermal O 
growth O 
factor O 
receptor O 
(EGFR)-positive O 
human O 
colon O 
cancer O 
cell O 
line O 
. O 
Overall O 
, O 
86 O 
mCRC O 
patients O 
were O 
genotyped O 
for O 
study O 
purposes O 
. O 
PBMCs O 
harbouring O 
the O 
FcγRIIIa O 
158 O 
V O 
/ O 
V O 
genotype O 
had O 
a O 
significantly O 
higher O 
cetuximab O 
- O 
mediated O 
ADCC O 
. O 
No O 
correlation O 
was O 
found O 
between O 
FcγR O 
polymorphisms O 
and O 
response O 
rate O 
or O 
time O 
to O 
progression O 
after O 
cetuximab O 
- O 
based O 
therapy O 
. O 
Despite O 
the O 
in O 
vitro O 
analysis O 
showing O 
that O 
the O 
FcγRIIIa O 
158 O 
V O 
/ O 
V O 
genotype O 
is O 
associated O 
with O 
higher O 
ADCC O 
, O 
clinical O 
data O 
do O 
not O 
support O 
a O 
predictive O 
role O 
of O 
FcγRIIIa O 
polymorphisms O 
in O 
mCRC O 
treated O 
with O 
cetuximab.The O 
Pharmacogenomics O 
Journal O 
advance O 
online O 
publication O 
, O 
8 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
tpj.2012.54 O 
. O 

errors O 
of O 
metabolism O 
with O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
as O 
discriminative O 
feature O 
: O 
proper O 
classification O 
and O 
nomenclature O 
. O 

urinary O 
3-methylglutaconic B-SYSTEMATIC 
aci I-SYSTEMATIC 
d O 
excretion O 
is O 
a O 
relatively O 
common O 
finding O 
in O 
metabolic O 
disorders O 
, O 
especially O 
in O 
mitochondrial O 
disorders O 
. O 
In O 
most O 
cases O 
3-methylglutaconic B-SYSTEMATIC 
acid I-SYSTEMATIC 
is O 
only O 
slightly O 
elevated O 
and O 
accompanied O 
by O 
other O 
( O 
disease O 
specific O 
) O 
metabolites O 
. O 
There O 
is O 
, O 
however O 
, O 
a O 
group O 
of O 
disorders O 
with O 
significantly O 
and O 
consistently O 
increased O 
3-methylglutaconic B-SYSTEMATIC 
acid I-SYSTEMATIC 
excretion O 
, O 
where O 
the O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
is O 
a O 
hallmark O 
of O 
the O 
phenotype O 
and O 
the O 
key O 
to O 
diagnosis O 
. O 
Until O 
now O 
these O 
disorders O 
were O 
labelled O 
by O 
roman O 
numbers O 
( O 
I-V O 
) O 
in O 
the O 
order O 
of O 
discovery O 
regardless O 
of O 
pathomechanism O 
. O 
Especially O 
, O 
the O 
so O 
called O 
" O 
unspecified O 
" O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
type O 
IV O 
has O 
been O 
ever O 
growing O 
, O 
leading O 
to O 
biochemical O 
and O 
clinical O 
diagnostic O 
confusion O 
. O 
Therefore O 
, O 
we O 
propose O 
the O 
following O 
pathomechanism O 
based O 
classification O 
and O 
a O 
simplified O 
diagnostic O 
flow O 
chart O 
for O 
these O 
" O 
inborn O 
errors O 
of O 
metabolism O 
with O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
as O 
discriminative O 
feature O 
" O 
. O 
One O 
should O 
distinguish O 
between O 
" O 
primary O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
" O 
formerly O 
known O 
as O 
type O 
I O 
( O 
3-methylglutaconyl-CoA B-SYSTEMATIC 
hydratase O 
deficiency O 
, O 
AUH O 
defect O 
) O 
due O 
to O 
defective O 
leucine B-TRIVIAL 
catabolism O 
and O 
the O 
- O 
currently O 
known O 
- O 
three O 
groups O 
of O 
" O 
secondary O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
" O 
. O 
The O 
latter O 
should O 
be O 
further O 
classified O 
and O 
named O 
by O 
their O 
defective O 
protein O 
or O 
the O 
historical O 
name O 
as O 
follows O 
: O 
i O 
) O 
defective O 
phospholipid O 
remodelling O 
( O 
TAZ O 
defect O 
or O 
Barth O 
syndrome O 
, O 
SERAC1 O 
defect O 
or O 
MEGDEL O 
syndrome O 
) O 
and O 
ii O 
) O 
mitochondrial O 
membrane O 
associated O 
disorders O 
( O 
OPA3 O 
defect O 
or O 
Costeff O 
syndrome O 
, O 
DNAJC19 O 
defect O 
or O 
DCMA O 
syndrome O 
, O 
TMEM70 O 
defect O 
) O 
. O 
The O 
remaining O 
patients O 
with O 
significant O 
and O 
consistent O 
3-methylglutaconic B-SYSTEMATIC 
aciduria O 
in O 
whom O 
the O 
above O 
mentioned O 
syndromes O 
have O 
been O 
excluded O 
, O 
should O 
be O 
referred O 
to O 
as O 
" O 
not O 
otherwise O 
specified O 
( O 
NOS O 
) O 
3-MGA B-SYSTEMATIC 
-uria O 
" O 
until O 
elucidation O 
of O 
the O 
underlying O 
pathomechanism O 
enables O 
proper O 
( O 
possibly O 
extended O 
) O 
classification O 
. O 

and O 
anti-inflammatory O 
properties O 
of O 
a O 
coffee O 
component O 
in O 
the O 
MPTP B-ABBREVIATION 
model O 
of O 
Parkinson's O 
disease O 
. O 

of O 
coffee O 
is O 
associated O 
with O 
reduced O 
risk O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
, O 
an O 
effect O 
that O 
has O 
largely O 
been O 
attributed O 
to O 
caffeine O 
. O 
However O 
, O 
coffee O 
contains O 
numerous O 
components O 
that O 
may O 
also O 
be O 
neuroprotective O 
. O 
One O 
of O 
these O 
compounds O 
is O 
eicosanoyl-5-hydroxytryptamide B-SYSTEMATIC 
( O 
EHT B-ABBREVIATION 
) O 
, O 
which O 
ameliorates O 
the O 
phenotype O 
of O 
α-synuclein O 
transgenic O 
mice O 
associated O 
with O 
decreased O 
protein O 
aggregation O 
and O 
phosphorylation O 
, O 
improved O 
neuronal O 
integrity O 
and O 
reduced O 
neuroinflammation O 
. O 
Here O 
, O 
we O 
sought O 
to O 
investigate O 
if O 
EHT B-ABBREVIATION 
has O 
an O 
effect O 
in O 
the O 
MPTP B-ABBREVIATION 
model O 
of O 
PD O 
. O 
Mice O 
fed O 
a O 
diet O 
containing O 
EHT B-ABBREVIATION 
for O 
four O 
weeks O 
exhibited O 
dose O 
- O 
dependent O 
preservation O 
of O 
nigral O 
dopaminergic O 
neurons O 
following O 
MPTP B-ABBREVIATION 
challenge O 
compared O 
to O 
animals O 
given O 
control O 
feed O 
. O 
Reductions O 
in O 
striatal O 
dopamine B-TRIVIAL 
and O 
tyrosine B-TRIVIAL 
hydroxylase O 
content O 
were O 
also O 
less O 
pronounced O 
with O 
EHT B-ABBREVIATION 
treatment O 
. O 
The O 
neuroinflammatory O 
response O 
to O 
MPTP B-ABBREVIATION 
was O 
markedly O 
attenuated O 
, O 
and O 
indices O 
of O 
oxidative O 
stress O 
and O 
JNK O 
activation O 
were O 
significantly O 
prevented O 
with O 
EHT B-ABBREVIATION 
. O 
In O 
cultured O 
primary O 
microglia O 
and O 
astrocytes O 
, O 
EHT B-ABBREVIATION 
had O 
a O 
direct O 
anti-inflammatory O 
effect O 
demonstrated O 
by O 
repression O 
of O 
lipopolysaccharide-induced O 
NFκB O 
activation O 
, O 
iNOS O 
induction O 
, O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
. O 
EHT B-ABBREVIATION 
also O 
exhibited O 
a O 
robust O 
anti-oxidant O 
activity O 
in O 
vitro O 
. O 
Additionally O 
, O 
in O 
SH-SY5Y O 
cells O 
, O 
MPP(+) B-ABBREVIATION 
-induced O 
demethylation O 
of O 
phosphoprotein O 
phosphatase O 
2A O 
( O 
PP2A O 
) O 
, O 
the O 
master O 
regulator O 
of O 
the O 
cellular O 
phosphoregulatory O 
network O 
, O 
and O 
cytotoxicity O 
were O 
ameliorated O 
by O 
EHT B-ABBREVIATION 
. O 
These O 
findings O 
indicate O 
that O 
the O 
neuroprotective O 
effect O 
of O 
EHT B-ABBREVIATION 
against O 
MPTP B-ABBREVIATION 
is O 
through O 
several O 
mechanisms O 
including O 
its O 
anti-inflammatory O 
and O 
antioxidant O 
activities O 
as O 
well O 
as O 
its O 
ability O 
to O 
modulate O 
the O 
methylation O 
and O 
hence O 
activity O 
of O 
PP2A O 
. O 
Our O 
data O 
, O 
therefore O 
, O 
reveal O 
a O 
strong O 
beneficial O 
effect O 
of O 
a O 
novel O 
component O 
of O 
coffee O 
in O 
multiple O 
endpoints O 
relevant O 
to O 
PD O 
. O 

chromium B-SYSTEMATIC 
excretion O 
in O 
response O 
to O 
an O 
insulin O 
challenge O 
is O 
not O 
a O 
biomarker O 
for O 
chromium B-SYSTEMATIC 
status O 
. O 

50 O 
years O 
ago O 
, O 
chromium B-SYSTEMATIC 
( O 
Cr B-FORMULA 
) O 
was O 
proposed O 
to O 
be O 
an O 
essential O 
trace O 
element O 
; O 
however O 
, O 
recent O 
studies O 
indicate O 
that O 
this O 
status O 
should O 
be O 
removed O 
as O 
the O 
effects O 
of O 
Cr B-FORMULA 
supplementation O 
appear O 
to O 
be O 
pharmacological O 
rather O 
than O 
nutritional O 
. O 
The O 
pharmacological O 
basis O 
for O 
Cr B-FORMULA 
' O 
s O 
effects O 
can O 
explain O 
the O 
inability O 
of O 
investigators O 
to O 
discover O 
a O 
biomarker O 
for O 
Cr B-FORMULA 
status O 
. O 
One O 
potential O 
biomarker O 
has O 
not O 
been O 
examined O 
to O 
date O 
. O 
Cr B-FORMULA 
is O 
known O 
to O 
be O 
mobilized O 
in O 
the O 
body O 
in O 
response O 
to O 
insulin O 
( O 
or O 
insulin O 
release O 
in O 
response O 
to O 
a O 
glucose B-TRIVIAL 
challenge O 
) O 
, O 
resulting O 
in O 
an O 
increase O 
in O 
urinary O 
Cr B-FORMULA 
excretion O 
. O 
The O 
magnitude O 
of O 
increase O 
in O 
urinary O 
Cr B-FORMULA 
loss O 
as O 
a O 
function O 
of O 
dietary O 
Cr B-FORMULA 
intake O 
was O 
tested O 
as O 
a O 
potential O 
biomarker O 
for O 
Cr B-FORMULA 
. O 
Zucker O 
lean O 
rats O 
housed O 
in O 
carefully O 
controlled O 
metal O 
- O 
free O 
conditions O 
were O 
provided O 
a O 
series O 
of O 
purified O 
diets O 
containing O 
variable O 
Cr B-FORMULA 
contents O 
( O 
from O 
16 O 
μg O 
/ O 
kg O 
diet O 
to O 
2000 O 
μg O 
/ O 
kg O 
) O 
for O 
23 O 
weeks O 
. O 
The O 
16 O 
μg O 
/ O 
kg O 
diet O 
contained O 
less O 
Cr B-FORMULA 
than O 
any O 
diet O 
examined O 
to O 
date O 
. O 
Urine O 
samples O 
were O 
collected O 
before O 
and O 
after O 
insulin O 
and O 
glucose B-TRIVIAL 
challenges O 
( O 
0 O 
, O 
2 O 
, O 
6 O 
, O 
and O 
12 O 
h O 
postinjection O 
) O 
. O 
Urinary O 
Cr B-FORMULA 
levels O 
were O 
analyzed O 
by O 
the O 
standard O 
method O 
of O 
addition O 
using O 
graphite B-TRIVIAL 
furnace O 
atomic O 
absorption O 
. O 
The O 
rate O 
of O 
urinary O 
Cr B-FORMULA 
loss O 
after O 
a O 
glucose B-TRIVIAL 
or O 
insulin O 
challenge O 
was O 
found O 
to O 
not O 
be O 
dependent O 
on O 
the O 
Cr B-FORMULA 
content O 
of O 
the O 
rats O 
' O 
diets O 
. O 
Blood O 
iron B-SYSTEMATIC 
levels O 
of O 
the O 
rats O 
were O 
also O 
measured O 
to O 
determine O 
if O 
the O 
addition O 
of O 
Cr B-FORMULA 
to O 
the O 
diet O 
altered O 
iron B-SYSTEMATIC 
status O 
. O 
The O 
Cr B-FORMULA 
content O 
of O 
the O 
diet O 
was O 
found O 
to O 
have O 
no O 
affect O 
on O 
blood O 
iron B-SYSTEMATIC 
levels O 
. O 
Overall O 
, O 
the O 
study O 
demonstrated O 
that O 
insulin O 
- O 
stimulated O 
urinary O 
Cr B-FORMULA 
excretion O 
cannot O 
be O 
used O 
as O 
a O 
biomarker O 
for O 
Cr B-FORMULA 
status O 
. O 

and O 
Luteolin B-TRIVIAL 
Attenuate O 
Diabetes-Induced O 
Impairment O 
in O 
Endothelial-Dependent O 
Relaxation O 
: O 
Effect O 
on O 
Lipid O 
Profile O 
, O 
AGEs O 
and O 
NO B-FORMULA 
Generation O 
. O 

and O 
luteolin B-TRIVIAL 
are O 
two O 
important O 
plant O 
flavonoids B-FAMILY 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
hypothesized O 
that O 
they O 
protect O 
against O 
deleterious O 
vascular O 
effects O 
of O 
diabetes O 
. O 
Diabetes O 
was O 
induced O 
in O 
rats O 
by O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
injection O 
, O 
while O 
chrysin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
were O 
administered O 
two O 
weeks O 
after O 
STZ B-ABBREVIATION 
administration O 
for O 
6 O 
weeks O 
. O 
Then O 
, O 
blood O 
pressure O 
( O 
BP O 
) O 
and O 
serum O 
levels O 
of O 
glucose B-TRIVIAL 
, O 
advanced O 
glycation O 
end O 
products O 
( O 
AGEs O 
) O 
, O 
triglycerides B-FAMILY 
( O 
TGs B-ABBREVIATION 
) O 
, O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
density O 
lipoprotein- O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
were O 
determined O 
. O 
Concentration O 
response O 
curves O 
for O 
KCl B-FORMULA 
, O 
phenylephrine B-TRIVIAL 
( O 
PE O 
) O 
, O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
and O 
ACh B-ABBREVIATION 
-induced O 
NO B-FORMULA 
generation O 
were O 
obtained O 
in O 
isolated O 
aorta O 
. O 
Compared O 
with O 
control O 
, O 
diabetes O 
increased O 
diastolic O 
and O 
systolic O 
BP O 
, O 
while O 
chrysin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
attenuated O 
diastolic O 
BP O 
elevation O 
without O 
affecting O 
the O 
developed O 
hyperglycemia O 
. O 
Diabetes O 
increased O 
contractile O 
response O 
of O 
aorta O 
to O 
KCl B-FORMULA 
, O 
PE O 
, O 
decreased O 
relaxation O 
response O 
to O 
ACh B-ABBREVIATION 
, O 
while O 
chrysin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
prevented O 
the O 
impaired O 
response O 
to O 
ACh B-ABBREVIATION 
. O 
In O 
addition O 
, O 
diabetes O 
was O 
accompanied O 
by O 
elevated O 
levels O 
of O 
TGs B-ABBREVIATION 
, O 
total O 
and O 
LDL O 
cholesterol B-TRIVIAL 
, O 
while O 
both O 
chrysin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
prevented O 
this O 
dyslipidemia O 
. O 
Furthermore O 
, O 
chrysin B-TRIVIAL 
decreased O 
the O 
elevated O 
AGEs O 
level O 
in O 
serum O 
of O 
diabetic O 
animals O 
, O 
while O 
luteolin B-TRIVIAL 
abrogated O 
the O 
impaired O 
NO B-FORMULA 
generation O 
in O 
diabetic O 
aorta O 
. O 
Collectively O 
, O 
chrysin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
attenuate O 
diabetes O 
- O 
evoked O 
impairment O 
in O 
endothelial O 
- O 
dependent O 
relaxation O 
possibly O 
via O 
ameliorating O 
detrimental O 
changes O 
in O 
lipid O 
profile O 
, O 
AGEs O 
and O 
NO B-FORMULA 
generation O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Activity O 
of O 
Erythro-(7S,8R)-7-acetoxy-3,4,3`,5`-tetramethoxy-8-O-4`-neolignan B-SYSTEMATIC 
from O 
Myristica O 
fragrans O 
. O 

play O 
a O 
critical O 
role O 
in O 
pathogenesis O 
of O 
cardiovascular O 
disorders O 
and O 
strokes O 
. O 
The O 
inhibition O 
of O 
platelet O 
function O 
is O 
beneficial O 
for O 
the O 
treatment O 
and O 
prevention O 
of O 
these O 
diseases O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
anti-platelet O 
activity O 
of O 
erythro-(7S,8R)-7-acetoxy-3,4,3`,5`-tetramethoxy-8-O-4`-neolignan B-SYSTEMATIC 
( O 
EATN B-ABBREVIATION 
) O 
, O 
a O 
neolignan B-FAMILY 
isolated O 
from O 
Myristica O 
fragrans O 
, O 
using O 
human O 
platelets O 
. O 
EATN B-ABBREVIATION 
preferentially O 
inhibited O 
thrombin- O 
and O 
platelet O 
- O 
activating O 
factor O 
(PAF)-induced O 
platelet O 
aggregation O 
without O 
affecting O 
platelet O 
damage O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
with O 
IC(50) O 
values O 
of O 
3.2 O 
± O 
0.4 O 
and O 
3.4 O 
± O 
0.3 O 
μM O 
, O 
respectively O 
. O 
However O 
, O 
much O 
higher O 
concentrations O 
of O 
EATN B-ABBREVIATION 
were O 
required O 
to O 
inhibit O 
platelet O 
aggregation O 
induced O 
by O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
. O 
EATN B-ABBREVIATION 
also O 
inhibited O 
thrombin O 
- O 
induced O 
serotonin B-TRIVIAL 
and O 
ATP B-ABBREVIATION 
release O 
, O 
and O 
thromboxane B-TRIVIAL 
B(2) I-TRIVIAL 
formation O 
in O 
human O 
platelets O 
. O 
Moreover O 
, O 
EATN B-ABBREVIATION 
caused O 
an O 
increase O 
in O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
( O 
cAMP B-ABBREVIATION 
) O 
levels O 
and O 
attenuated O 
intracellular O 
Ca(2+) B-FORMULA 
mobilization O 
in O 
thrombin O 
- O 
activated O 
human O 
platelets O 
. O 
Therefore O 
, O 
we O 
conclude O 
that O 
the O 
inhibitory O 
mechanism O 
of O 
EATN B-ABBREVIATION 
on O 
platelet O 
aggregation O 
may O 
increase O 
cAMP B-ABBREVIATION 
levels O 
and O 
subsequently O 
inhibit O 
intracellular O 
Ca(2+) B-FORMULA 
mobilization O 
by O 
interfering O 
with O 
a O 
common O 
signaling O 
pathway O 
rather O 
than O 
by O 
directly O 
inhibiting O 
the O 
binding O 
of O 
thrombin O 
or O 
PAF O 
to O 
their O 
receptors O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
the O 
anti-platelet O 
activity O 
of O 
EATN B-ABBREVIATION 
isolated O 
from O 
M O 
. O 
fragrans O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

sulfide I-SYSTEMATIC 
, O 
the O 
next O 
potent O 
preventive O 
and O 
therapeutic O 
agent O 
in O 
aging O 
and O 
age O 
- O 
associated O 
diseases O 
. O 

sulfide I-SYSTEMATIC 
( O 
H(2)S B-FORMULA 
) O 
is O 
the O 
third O 
endogenous O 
signaling O 
gasotransmitter O 
, O 
following O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
. O 
It O 
is O 
physiologically O 
generated O 
by O 
cystathionine B-TRIVIAL 
-γ-lyase O 
, O 
cystathionine B-TRIVIAL 
-β-synthase O 
, O 
and O 
3-mercaptopyruvate B-SYSTEMATIC 
sulfurtransferase O 
. O 
H(2)S B-FORMULA 
has O 
been O 
gaining O 
increasing O 
attention O 
as O 
an O 
important O 
endogenous O 
signaling O 
molecule O 
because O 
of O 
its O 
significant O 
effects O 
on O 
the O 
cardiovascular O 
and O 
nervous O 
systems O 
. O 
Substantial O 
evidence O 
shows O 
that O 
H(2)S B-FORMULA 
is O 
involved O 
in O 
aging O 
by O 
inhibiting O 
free O 
- O 
radical O 
reactions O 
, O 
activating O 
SIRT1 O 
, O 
and O 
probably O 
interacting O 
with O 
the O 
age O 
- O 
related O 
gene O 
Klotho O 
. O 
Moreover O 
, O 
H(2)S B-FORMULA 
has O 
been O 
shown O 
to O 
have O 
therapeutic O 
potential O 
in O 
age O 
- O 
associated O 
diseases O 
. O 
This O 
article O 
provides O 
an O 
overview O 
of O 
the O 
physiological O 
functions O 
and O 
effects O 
of O 
H(2)S B-FORMULA 
in O 
aging O 
and O 
age O 
- O 
associated O 
diseases O 
, O 
and O 
proposes O 
the O 
potential O 
health O 
and O 
therapeutic O 
benefits O 
of O 
H(2)S B-FORMULA 
. O 

study O 
describes O 
the O 
chemical O 
composition O 
and O 
antibacterial O 
activities O 
of O 
essential O 
oils O 
of O 
Moroccan O 
Juniperus O 
thurifera O 
L O 
. O 
var O 
. O 
Africana O 
( O 
Cupressaceae O 
) O 
. O 
The O 
essential O 
oil O 
of O 
dried O 
leaves O 
was O 
isolated O 
by O 
hydrodistillation O 
, O 
vapohydrodistillation O 
and O 
microwaves O 
. O 
Sixty O 
- O 
four O 
compounds O 
in O 
J O 
. O 
thurifera O 
L O 
. O 
var O 
. O 
Africana O 
oils O 
were O 
identified O 
( O 
79.9% O 
, O 
92.4% O 
and O 
98.4% O 
of O 
the O 
oil O 
, O 
respectively O 
) O 
. O 
The O 
most O 
abundant O 
compound O 
in O 
J O 
. O 
thurifera O 
L O 
. O 
var O 
. O 
Africana O 
oils O 
is O 
sabinene B-TRIVIAL 
( O 
38% O 
, O 
36.2% O 
and O 
39.4% O 
) O 
. O 
Antibacterial O 
activities O 
of O 
J O 
. O 
thurifera O 
essential O 
oils O 
was O 
tested O 
against O 
bacteria O 
Gram O 
( O 
- O 
) O 
and O 
Gram O 
( O 
+ O 
) O 
. O 
The O 
oil O 
is O 
very O 
active O 
against O 
all O 
bacteria O 
tested O 
except O 
Pseudomonas O 
, O 
which O 
turned O 
out O 
to O 
be O 
very O 
resistant O 
. O 

essential O 
oil O 
from O 
the O 
leaves O 
of O 
Annona O 
sylvatica O 
( O 
EOAS O 
) O 
was O 
extracted O 
by O 
hydrodistillation O 
, O 
and O 
the O 
analysis O 
was O 
performed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
The O 
main O 
compounds O 
identified O 
in O 
the O 
EOAS O 
were O 
sesquiterpenes B-FAMILY 
, O 
such O 
as O 
hinesol B-TRIVIAL 
, O 
z-caryophyllene B-TRIVIAL 
, O 
β-maaliene B-TRIVIAL 
, O 
γ-gurjunene B-TRIVIAL 
, O 
silphiperfol-5-en-3-ol B-SYSTEMATIC 
, O 
ledol B-TRIVIAL 
, O 
cubecol-1-epi B-SYSTEMATIC 
, O 
and O 
muurola-3,5-diene B-SYSTEMATIC 
. O 
Oral O 
administration O 
of O 
the O 
EOAS O 
( O 
20 O 
and O 
200 O 
mg O 
/ O 
kg O 
) O 
and O 
subcutaneous O 
injection O 
of O 
dexamethasone B-TRIVIAL 
( O 
0.5 O 
mg O 
/ O 
kg O 
, O 
reference O 
drug O 
) O 
significantly O 
inhibited O 
carrageenan- O 
and O 
complete O 
Freund's O 
adjuvant O 
- O 
induced O 
mouse O 
paw O 
edema O 
. O 
The O 
anticancer O 
activity O 
the O 
EOAS O 
showed O 
growth O 
inhibitory O 
activity O 
on O 
all O 
cell O 
lines O 
when O 
administered O 
in O 
a O 
high O 
concentration O 
. O 
The O 
EOAS O 
inhibited O 
the O 
growth O 
of O 
human O 
cancer O 
cell O 
lines O 
with O 
GI(50) O 
values O 
in O 
the O 
range O 
of O 
36.04-45.37 O 
μg O 
/ O 
mL O 
on O 
all O 
of O 
the O 
cell O 
lines O 
tested O 
. O 
This O 
work O 
describes O 
for O 
the O 
first O 
time O 
the O 
anti-inflammatory O 
and O 
anticancer O 
effects O 
of O 
the O 
essential O 
oil O 
of O 
A O 
. O 
sylvatica O 
and O 
its O 
composition O 
. O 
Considering O 
that O 
drugs O 
currently O 
available O 
for O 
the O 
treatment O 
of O 
inflammatory O 
and O 
cancer O 
conditions O 
show O 
undesirable O 
side-effects O 
, O 
the O 
present O 
results O 
may O 
have O 
clinical O 
relevance O 
and O 
open O 
new O 
possibilities O 
for O 
the O 
development O 
of O 
novel O 
anti-inflammatory O 
and O 
anticancer O 
drugs O 
. O 

surveys O 
indicated O 
that O 
in O 
the O 
traditional O 
medicines O 
worldwide O 
, O 
several O 
Juniperus O 
species O 
are O 
utilized O 
as O 
antihelmintic O 
, O 
diuretic O 
, O 
stimulant O 
, O 
antiseptic O 
, O 
carminative O 
, O 
stomachic O 
, O 
antirheumatic O 
, O 
antifungal O 
, O 
and O 
for O 
wound O 
healing O 
. O 
In O 
the O 
present O 
study O 
, O 
essential O 
oils O 
obtained O 
from O 
heartwood O 
samples O 
of O 
Juniperus O 
virginiana O 
L O 
. O 
, O 
Juniperus O 
occidentalis O 
Hook O 
. O 
and O 
Juniperus O 
ashei O 
J O 
. O 
Buchholz O 
were O 
evaluated O 
for O 
wound O 
healing O 
and O 
anti-inflammatory O 
activities O 
by O 
using O 
in O 
vivo O 
experimental O 
methods O 
. O 
The O 
essential O 
oils O 
were O 
obtained O 
by O 
the O 
supercritical O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
extraction O 
method O 
. O 
Linear O 
incision O 
and O 
circular O 
excision O 
wound O 
models O 
were O 
performed O 
for O 
the O 
wound O 
- O 
healing O 
activity O 
assessment O 
. O 
The O 
tissues O 
were O 
also O 
evaluated O 
for O 
the O 
hydroxyproline B-SYSTEMATIC 
content O 
as O 
well O 
as O 
histopathologically O 
. O 
To O 
evaluate O 
the O 
anti-inflammatory O 
activity O 
of O 
the O 
essential O 
oils O 
, O 
the O 
test O 
used O 
was O 
an O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
increase O 
in O 
capillary O 
permeability O 
. O 
The O 
essential O 
oil O 
of O 
J O 
. O 
occidentalis O 
showed O 
the O 
highest O 
activity O 
on O 
the O 
in O 
vivo O 
biological O 
activity O 
models O 
. O 
Additionaly O 
, O 
the O 
oil O 
of O 
J O 
. O 
virginiana O 
was O 
found O 
highly O 
effective O 
in O 
the O 
anti-inflammatory O 
activity O 
method O 
. O 
The O 
experimental O 
data O 
demonstrated O 
that O 
essential O 
oil O 
of O 
J O 
. O 
occidentalis O 
displayed O 
significant O 
wound O 
- O 
healing O 
and O 
anti-inflammatory O 
activities O 
. O 

and O 
anti-HIV-1 O 
activity O 
of O 
a O 
new O 
sesquiterpene B-FAMILY 
lactone I-FAMILY 
from O 
Calocephalus O 
brownii O 
F O 
. O 
Muell O 
. O 

part O 
of O 
our O 
ongoing O 
collaborative O 
effort O 
to O 
discover O 
potential O 
anti-HIV-1 O 
agents O 
from O 
plants O 
, O 
the O 
CH(2)Cl(2) B-FORMULA 
extract O 
of O 
Calocephalus O 
brownii O 
F O 
. O 
Muell O 
. O 
was O 
phytochemically O 
investigated O 
, O 
which O 
resulted O 
in O 
the O 
isolation O 
of O 
two O 
sesquiterpene B-FAMILY 
lactones I-FAMILY 
of O 
the O 
cis-fused B-FAMILY 
guaianolides I-FAMILY 
type O 
, O 
one O 
new O 
identified O 
as O 
1α-hydroxy-3βH-3α,4α-epoxy-4,10-dimethyl-5αH,7αH,8βH,10αH-guai-11(13)-ene-7,8-olide B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
one O 
known O 
identified O 
1αH-4α-hydroxy-4,10-dimethyl-5αH,7αH,8βH,10αH-guai-11(13)-ene-7,8-olide B-SYSTEMATIC 
( O 
2 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
bases O 
of O 
IR O 
, O 
UV O 
, O 
1D-NMR O 
, O 
2D-NMR O 
, O 
DIFNOE O 
and O 
high O 
- O 
resolution O 
ESI-TOF-MS O 
. O 
The O 
anti-HIV-1 O 
activity O 
was O 
evaluated O 
and O 
revealed O 
that O 
STLs O 
( O 
1 O 
and O 
2 O 
) O 
caused O 
a O 
reduction O 
for O 
the O 
viability O 
of O 
mock O 
- O 
infected O 
MT-4 O 
cells O 
by O 
CC(50) O 
= O 
29.1 O 
and O 
0.5 O 
μg O 
/ O 
mL O 
, O 
respectively O 
, O 
and O 
caused O 
50% O 
protection O 
of O 
MT-4 O 
cells O 
against O 
HIV-1 O 
induced O 
cytopathogeneticy O 
by O 
EC(50) O 
= O 
29.1 O 
and O 
0.5 O 
μg O 
/ O 
mL O 
, O 
respectively O 
, O 
as O 
compared O 
with O 
Efavirenz B-TRIVIAL 
( O 
EFV B-ABBREVIATION 
) O 
as O 
positive O 
control O 
that O 
showed O 
a O 
CC(50) O 
= O 
11.6 O 
and O 
EC(50) O 
= O 
0.0006 O 
μg O 
/ O 
mL O 
, O 
using O 
the O 
3-(4 B-SYSTEMATIC 
, I-SYSTEMATIC 
5-dimethylthiazol-2-yl)-2 I-SYSTEMATIC 
, I-SYSTEMATIC 
5-diphenyltetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
method O 
. O 

oxidation O 
on O 
colloidal O 
Au(0.80)Pd(0.20)-Fe(x)O(y) B-FAMILY 
dumbbell O 
nanocrystals O 
. O 

report O 
a O 
colloidal O 
synthesis O 
of O 
Au(0.80)Pd(0.20)-Fe(x)O(y) B-FAMILY 
dumbbell O 
nanocrystals O 
( O 
NCs O 
) O 
derived O 
from O 
Au(0.75)Pd(0.25) B-FORMULA 
NCs O 
by O 
metal B-FAMILY 
oxide I-FAMILY 
overgrowth O 
. O 
We O 
compared O 
the O 
catalytic O 
activity O 
of O 
the O 
two O 
types O 
of O 
NCs O 
in O 
the O 
CO B-FORMULA 
oxidation O 
reaction O 
( O 
CO B-FORMULA 
+ O 
1 B-FORMULA 
/ I-FORMULA 
2O(2) I-FORMULA 
→ O 
CO(2) B-FORMULA 
) O 
, O 
after O 
they O 
had O 
been O 
dispersed O 
on O 
an O 
alumina B-TRIVIAL 
nanopowder O 
support O 
. O 
In O 
both O 
cases O 
, O 
the O 
surface O 
active O 
sites O 
were O 
identified O 
by O 
means O 
of O 
in O 
situ O 
diffuse O 
reflectance O 
infrared O 
Fourier O 
transform O 
spectroscopy O 
( O 
DRIFTS O 
) O 
. O 
The O 
enhanced O 
catalytic O 
performance O 
of O 
the O 
dumbbell O 
NCs O 
( O 
Au(0.80)Pd(0.20)-Fe(x)O(y) B-FAMILY 
) O 
catalyst O 
over O 
that O 
of O 
the O 
initial O 
Au(0.75)Pd(0.25) B-FORMULA 
NCs O 
could O 
be O 
correlated O 
to O 
the O 
presence O 
of O 
the O 
epitaxial O 
connection O 
between O 
the O 
Fe(x)O(y) B-FAMILY 
and O 
the O 
Au(0.80)Pd(0.20) B-FORMULA 
domains O 
( O 
as O 
the O 
main O 
factor O 
) O 
. O 
Such O 
connection O 
should O 
result O 
in O 
an O 
electron O 
flow O 
from O 
the O 
metal B-FAMILY 
oxide I-FAMILY 
( O 
Fe(x)O(y) B-FAMILY 
) O 
domain O 
to O 
the O 
noble O 
metal O 
( O 
Au(0.80)Pd(0.20) B-FORMULA 
) O 
domain O 
and O 
appears O 
to O 
influence O 
favorably O 
the O 
nature O 
and O 
composition O 
of O 
the O 
catalytically O 
active O 
surface O 
sites O 
of O 
the O 
dumbbells O 
. O 
Our O 
experiments O 
indicate O 
indeed O 
that O 
, O 
when O 
the O 
metal O 
alloy O 
domain O 
is O 
attached O 
to O 
the O 
metal B-FAMILY 
oxide I-FAMILY 
domain O 
( O 
that O 
is O 
, O 
in O 
the O 
dumbbell O 
) O 
, O 
surface O 
Pd B-FORMULA 
species O 
are O 
more O 
active O 
than O 
in O 
the O 
case O 
of O 
the O 
initial O 
Au(0.75)Pd(0.25) B-FORMULA 
NCs O 
and O 
also O 
Au B-FORMULA 
( O 
δ- O 
) O 
sites O 
are O 
formed O 
that O 
were O 
not O 
present O 
on O 
the O 
initial O 
Au(0.75)Pd(0.25) B-FORMULA 
NCs O 
. O 

the O 
long O 
human O 
tradition O 
honey O 
has O 
been O 
used O 
not O 
only O 
as O 
a O 
nutrient O 
but O 
also O 
as O 
a O 
medicine O 
. O 
Its O 
composition O 
is O 
rather O 
variable O 
and O 
depends O 
on O 
the O 
floral O 
source O 
and O 
on O 
external O 
factors O 
, O 
such O 
as O 
seasonal O 
, O 
environmental O 
conditions O 
and O 
processing O 
. O 
In O 
this O 
review O 
, O 
specific O 
attention O 
is O 
focused O 
on O 
absorption O 
, O 
metabolism O 
, O 
and O 
beneficial O 
biological O 
activities O 
of O 
honey O 
compounds O 
in O 
human O 
. O 
Honey O 
is O 
a O 
supersaturated O 
solution O 
of O 
sugars B-FAMILY 
, O 
mainly O 
composed O 
of O 
fructose B-TRIVIAL 
( O 
38% O 
) O 
and O 
glucose B-TRIVIAL 
( O 
31% O 
) O 
, O 
containing O 
also O 
minerals O 
, O 
proteins O 
, O 
free B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
, O 
enzymes O 
, O 
vitamins O 
and O 
polyphenols B-FAMILY 
. O 
Among O 
polyphenols B-FAMILY 
, O 
flavonoids B-FAMILY 
are O 
the O 
most O 
abundant O 
and O 
are O 
closely O 
related O 
to O 
its O 
biological O 
functions O 
. O 
Honey O 
positively O 
affects O 
risk O 
factors O 
for O 
cardiovascular O 
diseases O 
by O 
inhibiting O 
inflammation O 
, O 
improving O 
endothelial O 
function O 
, O 
as O 
well O 
as O 
the O 
plasma O 
lipid O 
profile O 
, O 
and O 
increasing O 
low O 
- O 
density O 
lipoprotein O 
resistance O 
to O 
oxidation O 
. O 
Honey O 
also O 
displays O 
an O 
important O 
antitumoral O 
capacity O 
, O 
where O 
polyphenols B-FAMILY 
again O 
are O 
considered O 
responsible O 
for O 
its O 
complementary O 
and O 
overlapping O 
mechanisms O 
of O 
chemopreventive O 
activity O 
in O 
multistage O 
carcinogenesis O 
, O 
by O 
inhibiting O 
mutagenesis O 
or O 
inducing O 
apoptosis O 
. O 
Moreover O 
, O 
honey O 
positively O 
modulates O 
the O 
glycemic O 
response O 
by O 
reducing O 
blood O 
glucose B-TRIVIAL 
, O 
serum O 
fructosamine B-SYSTEMATIC 
or O 
glycosylated O 
hemoglobin O 
concentrations O 
and O 
exerts O 
antibacterial O 
properties O 
caused O 
by O 
its O 
consistent O 
amount O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
non- O 
peroxide B-SYSTEMATIC 
factors O 
as O 
flavonoids B-FAMILY 
, O 
methylglyoxal B-SYSTEMATIC 
and O 
defensin-1 O 
peptide O 
. O 
In O 
conclusion O 
, O 
the O 
evidence O 
of O 
the O 
biological O 
actions O 
of O 
honey O 
can O 
be O 
ascribed O 
to O 
its O 
polyphenolic O 
contents O 
which O 
, O 
in O 
turn O 
, O 
are O 
usually O 
associated O 
to O 
its O 
antioxidant O 
and O 
anti-inflammatory O 
actions O 
, O 
as O 
well O 
as O 
to O 
its O 
cardiovascular O 
, O 
antiproliferative O 
and O 
antimicrobial O 
benefits O 
. O 

Electrical O 
Conductivity O 
in O 
Poly(3-hexylthiophene) B-SYSTEMATIC 
/ O 
Fluorinated B-FAMILY 
Tetracyanoquinodimethane I-FAMILY 
Nanowires O 
Grown O 
with O 
a O 
Porous O 
Alumina B-TRIVIAL 
Template O 
. O 

report O 
on O 
improved O 
electrical O 
conductivity O 
in O 
poly(3-hexylthiophene) B-SYSTEMATIC 
( O 
P3HT B-ABBREVIATION 
)/ O 
2,3,5,6-tetrafluoro-7,7,8,8-tetracyanoquinodimethane B-SYSTEMATIC 
( O 
F4-TCNQ B-FORMULA 
) O 
composite O 
nanowires O 
grown O 
using O 
an O 
anodized O 
aluminum B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
AAO O 
) O 
template O 
. O 
The O 
electrical O 
conductivity O 
of O 
individual O 
nanowire O 
measured O 
by O 
four O 
- O 
probe O 
scanning O 
tunneling O 
microscopy O 
shows O 
that O 
F4-TCNQ B-FORMULA 
molecules O 
are O 
effectively O 
doped O 
into O 
P3HT B-ABBREVIATION 
by O 
capillary O 
force O 
. O 
The O 
resistivity O 
is O 
tuned O 
in O 
the O 
0.1-10 O 
Ω O 
cm O 
range O 
by O 
changing O 
the O 
F4-TCNQ B-FORMULA 
concentration O 
from O 
10 O 
to O 
0.1 O 
wt O 
% O 
and O 
is O 
2-4 O 
orders O 
of O 
magnitude O 
smaller O 
than O 
that O 
of O 
the O 
corresponding O 
P3HT B-ABBREVIATION 
/ O 
F4-TNCQ B-FORMULA 
thin O 
film O 
composites O 
. O 
The O 
AAO O 
template O 
- O 
assisted O 
synthesis O 
approach O 
thus O 
appears O 
to O 
be O 
effective O 
for O 
high O 
chemical O 
doping O 
and O 
for O 
improving O 
the O 
electrical O 
conductivity O 
of O 
the O 
molecular O 
wires O 
. O 

- O 
release O 
of O 
encapsulated O 
therapeutics O 
from O 
nanoparticles O 
without O 
remote O 
or O 
environmental O 
triggers O 
was O 
demonstrated O 
in O 
this O 
work O 
. O 
Disassembly O 
of O 
the O 
polymer O 
nanoparticles O 
to O 
unimers O 
at O 
precise O 
times O 
allowed O 
the O 
controlled O 
release O 
of O 
oligo O 
DNA O 
. O 
The O 
polymers O 
used O 
in O 
this O 
study O 
consisted O 
of O 
a O 
hydrophilic O 
block O 
for O 
stabilization O 
and O 
second O 
thermoresponsive O 
block O 
for O 
self O 
- O 
assembly O 
and O 
disassembly O 
. O 
At O 
temperatures O 
below O 
the O 
second O 
block's O 
LCST O 
( O 
i.e O 
. O 
, O 
below O 
37 O 
°C O 
for O 
in O 
vitro O 
assays O 
) O 
, O 
the O 
diblock O 
copolymer O 
was O 
fully O 
water O 
- O 
soluble O 
, O 
and O 
when O 
heated O 
to O 
37 O 
°C O 
, O 
the O 
polymer O 
self O 
- O 
assembled O 
into O 
a O 
narrow O 
size O 
distribution O 
of O 
nanoparticles O 
with O 
an O 
average O 
diameter O 
of O 
approximately O 
25 O 
nm O 
. O 
The O 
thermoresponsive O 
nature O 
of O 
the O 
second O 
block O 
could O 
be O 
manipulated O 
in O 
situ O 
by O 
the O 
self O 
- O 
catalyzed O 
degradation O 
of O 
cationic O 
2-(dimethylamino)ethyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
( O 
DMAEA B-ABBREVIATION 
) O 
units O 
to O 
negatively O 
charged O 
acrylic B-TRIVIAL 
acid I-TRIVIAL 
groups O 
and O 
when O 
the O 
amount O 
of O 
acid O 
groups O 
was O 
sufficiently O 
high O 
to O 
increase O 
the O 
LCST O 
of O 
the O 
second O 
block O 
above O 
37 O 
°C O 
. O 
The O 
disassembly O 
of O 
the O 
nanoparticles O 
could O 
be O 
controlled O 
from O 
10 O 
to O 
70 O 
h O 
. O 
The O 
use O 
of O 
these O 
nanoparticles O 
as O 
a O 
combined O 
therapy O 
, O 
in O 
which O 
one O 
or O 
more O 
agents O 
can O 
be O 
released O 
in O 
a O 
predetermined O 
way O 
, O 
has O 
the O 
potential O 
to O 
improve O 
the O 
personal O 
point O 
of O 
care O 
treatment O 
of O 
patients O 
. O 

and O 
biological O 
evaluation O 
of O 
substituted O 
benzoxazoles B-FAMILY 
as O 
inhibitors O 
of O 
mPGES-1 O 
: O 
use O 
of O 
a O 
conformation O 
- O 
based O 
hypothesis O 
to O 
facilitate O 
compound O 
design O 
. O 

prostaglandin B-TRIVIAL 
E(2) I-TRIVIAL 
synthase-1 O 
( O 
mPGES-1 O 
) O 
is O 
a O 
novel O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
inflammation O 
and O 
pain O 
. O 
In O 
the O 
preceding O 
letter O 
, O 
we O 
detailed O 
the O 
discovery O 
of O 
clinical O 
candidate O 
PF-04693627 B-IDENTIFIER 
, O 
a O 
potent O 
mPGES-1 O 
inhibitor O 
possessing O 
a O 
novel O 
benzoxazole B-SYSTEMATIC 
structure O 
. O 
While O 
PF-04693627 B-IDENTIFIER 
was O 
undergoing O 
further O 
preclinical O 
profiling O 
, O 
we O 
sought O 
to O 
identify O 
a O 
back O 
- O 
up O 
mPGES-1 O 
inhibitor O 
that O 
differentiated O 
itself O 
from O 
PF-04693627 B-IDENTIFIER 
. O 
The O 
design O 
, O 
synthesis O 
, O 
mPGES-1 O 
activity O 
and O 
in O 
vivo O 
PK O 
of O 
a O 
novel O 
set O 
of O 
substituted O 
benzoxazoles B-FAMILY 
are O 
described O 
herein O 
. O 
Also O 
described O 
is O 
a O 
conformation O 
- O 
based O 
hypothesis O 
for O 
mPGES-1 O 
activity O 
based O 
on O 
the O 
preferred O 
conformation O 
of O 
the O 
cyclohexane B-SYSTEMATIC 
ring O 
within O 
this O 
class O 
of O 
inhibitors O 
. O 

of O 
asymmetric O 
dimethylarginine B-SYSTEMATIC 
on O 
inflammatory O 
cytokines O 
( O 
TNF-α O 
, O 
IL-6 O 
and O 
IL-10 O 
) O 
in O 
rats O 
. O 

study O 
is O 
intended O 
to O 
examine O 
the O 
effects O 
of O 
administration O 
of O 
asymmetric O 
dimethylarginine B-SYSTEMATIC 
( O 
ADMA O 
) O 
on O 
the O 
levels O 
of O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
interleukin-6 O 
( O 
IL-6 O 
) O 
and O 
IL-10 O 
. O 
A O 
total O 
of O 
30 O 
Wistar O 
adult O 
albino O 
rats O 
were O 
used O 
. O 
Group O 
I O 
was O 
administrated O 
( O 
n O 
= O 
10 O 
) O 
with O 
1 O 
mg O 
/ O 
kg O 
/ O 
day O 
of O 
ADMA O 
, O 
group O 
II O 
( O 
n O 
= O 
10 O 
) O 
was O 
administrated O 
with O 
2 O 
mg O 
/ O 
kg O 
/ O 
day O 
of O 
ADMA O 
and O 
the O 
control O 
group O 
was O 
administrated O 
( O 
n O 
= O 
10 O 
) O 
with O 
0.9% O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 
ADMA O 
was O 
intraperitoneally O 
administrated O 
for O 
7 O 
days O 
. O 
The O 
serum O 
levels O 
of O 
IL-6 O 
, O 
TNF-α O 
and O 
IL-10 O 
were O 
measured O 
. O 
There O 
was O 
a O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
TNF-α O 
, O 
IL-6 O 
and O 
IL-10 O 
in O 
group O 
I O 
compared O 
with O 
that O 
of O 
the O 
control O 
group O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
There O 
was O 
also O 
a O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
IL-10 O 
in O 
group O 
II O 
compared O 
with O 
that O 
of O 
the O 
control O 
group O 
( O 
p O 
< O 
0.05 O 
) O 
but O 
the O 
increase O 
was O 
much O 
more O 
distinct O 
in O 
the O 
levels O 
of O 
IL-6 O 
and O 
TNF-α O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
When O 
comparing O 
the O 
groups O 
by O 
the O 
doses O 
given O 
, O 
no O 
difference O 
between O 
the O 
levels O 
of O 
IL-6 O 
and O 
IL-10 O 
in O 
groups O 
I O 
and O 
II O 
( O 
p O 
> O 
0.05 O 
) O 
was O 
observed O 
; O 
the O 
levels O 
of O 
TNF-α O 
in O 
group O 
II O 
were O 
significantly O 
lower O 
than O 
those O 
of O 
group O 
I O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
A O 
significant O 
decrease O 
in O 
the O 
serum O 
levels O 
of O 
inflammatory O 
cytokines O 
IL-6 O 
, O 
TNF-α O 
and O 
IL-10 O 
, O 
after O 
administration O 
of O 
1 O 
mg O 
/ O 
kg O 
/ O 
day O 
and O 
2 O 
mg O 
/ O 
kg O 
/ O 
day O 
of O 
ADMA O 
, O 
indicates O 
that O 
ADMA O 
has O 
an O 
effect O 
on O 
inflammation O 
. O 
Increase O 
in O 
ADMA O 
levels O 
in O 
the O 
rats O 
shows O 
that O 
the O 
effects O 
of O 
inflammatory O 
cytokines O 
were O 
suppressed O 
. O 

relevance O 
: O 
Lygodium O 
flexuosum O 
( O 
Linn O 
) O 
Sw O 
. O 
is O 
a O 
climbing O 
fern O 
, O 
and O 
it O 
is O 
the O 
sole O 
genus O 
in O 
the O 
family O 
Lygodiaceae O 
. O 
It O 
commonly O 
grows O 
epiphytically O 
on O 
moss O 
covered O 
tree O 
trunks O 
and O 
branches O 
as O 
lithophytes O 
on O 
shady O 
boulders O 
along O 
with O 
moss O 
. O 
It O 
has O 
been O 
reported O 
as O 
a O 
traditional O 
folkloric O 
medicine O 
for O 
a O 
variety O 
of O 
ailments O 
particularly O 
useful O 
for O 
carbuncles O 
, O 
inflammation O 
, O 
ulcer O 
, O 
various O 
respiratory O 
diseases O 
, O 
general O 
disorders O 
, O 
muscle O 
sprains O 
and O 
acts O 
as O 
panacea O 
for O 
wounds O 
. O 
However O 
, O 
there O 
are O 
no O 
scientific O 
reports O 
on O 
wound O 
healing O 
activity O 
of O 
the O 
plant O 
L O 
. O 
flexuosum O 
( O 
Linn O 
) O 
Sw.Aim O 
of O 
the O 
study O 
: O 
To O 
explore O 
the O 
protective O 
effect O 
of O 
L O 
. O 
flexuosum O 
against O 
excision O 
, O 
incision O 
and O 
dead O 
space O 
wounds O 
models O 
in O 
experimental O 
rats O 
. O 
METHODS O 
: O 
Wistar O 
albino O 
rats O 
of O 
either O 
sex O 
weighing O 
between O 
180 O 
and O 
220 O 
g O 
were O 
topically O 
treated O 
with O 
extract O 
formulated O 
in O 
ointment O 
using O 
simple O 
ointment O 
BP O 
as O 
base O 
. O 
Ointments O 
, O 
4% O 
and O 
5% O 
( O 
w O 
/ O 
w O 
) O 
, O 
were O 
applied O 
once O 
daily O 
in O 
excision O 
wound O 
model O 
. O 
L O 
. O 
flexuosum O 
ethanolic O 
extract O 
was O 
given O 
orally O 
at O 
a O 
dose O 
of O 
100 O 
, O 
200 O 
and O 
400 O 
mg O 
/ O 
kg O 
in O 
incision O 
and O 
dead O 
space O 
wound O 
healing O 
models O 
. O 
Rats O 
of O 
standard O 
groups O 
were O 
treated O 
with O 
0.2% O 
nitrofurazone B-SYSTEMATIC 
ointment O 
topically O 
. O 
The O 
percentage O 
wound O 
contraction O 
, O 
epithelization O 
time O 
in O 
excision O 
wound O 
model O 
; O 
breaking O 
strength O 
in O 
incision O 
wound O 
model O 
and O 
wet O 
and O 
dry O 
granulation O 
weight O 
, O 
hydroxyproline B-SYSTEMATIC 
content O 
were O 
measured O 
. O 
RESULTS O 
: O 
Topical O 
application O 
of O 
L O 
. O 
flexuosum O 
in O 
excision O 
wound O 
model O 
increased O 
the O 
percentage O 
of O 
wound O 
contraction O 
, O 
and O 
the O 
epithelization O 
time O 
was O 
decreased O 
. O 
In O 
the O 
incision O 
wound O 
model O 
, O 
the O 
breaking O 
strength O 
of O 
wounds O 
increased O 
and O 
in O 
dead O 
space O 
model O 
the O 
weight O 
of O 
dry O 
and O 
wet O 
granuloma O 
of O 
wounds O 
and O 
hydroxyproline B-SYSTEMATIC 
was O 
increased O 
. O 
Conclusively O 
, O 
the O 
data O 
of O 
present O 
study O 
indicated O 
that O 
the O 
leaf O 
extract O 
of O 
L O 
. O 
flexuosum O 
accelerated O 
wound O 
healing O 
in O 
rats O 
and O 
thus O 
supports O 
its O 
traditional O 
use O 
. O 

mineral O 
density O 
( O 
BMD O 
) O 
declines O 
significantly O 
in O 
HIV O 
patients O 
on O 
antiretroviral O 
therapy O 
( O 
ART O 
) O 
. O 
We O 
compared O 
the O 
effects O 
of O 
intermittent O 
versus O 
continuous O 
ART O 
on O 
markers O 
of O 
bone O 
turnover O 
in O 
the O 
Body O 
Composition O 
substudy O 
of O 
the O 
Strategies O 
for O 
Management O 
of O 
AntiRetroviral O 
Therapy O 
( O 
SMART O 
) O 
trial O 
and O 
determined O 
whether O 
early O 
changes O 
in O 
markers O 
predicted O 
subsequent O 
change O 
in O 
BMD O 
. O 
For O 
202 O 
participants O 
( O 
median O 
age O 
44 O 
years O 
, O 
17% O 
female O 
, O 
74% O 
on O 
ART O 
) O 
randomised O 
to O 
continuous O 
or O 
intermittent O 
ART O 
, O 
plasma O 
markers O 
of O 
inflammation O 
and O 
bone O 
turnover O 
were O 
evaluated O 
at O 
baseline O 
, O 
months O 
4 O 
and O 
12 O 
; O 
BMD O 
at O 
the O 
spine O 
( O 
dual O 
X-ray O 
absorptiometry O 
[ O 
DXA O 
] O 
and O 
computed O 
tomography O 
) O 
and O 
hip O 
( O 
DXA O 
) O 
was O 
evaluated O 
annually O 
. O 
Compared O 
to O 
the O 
continuous O 
ART O 
group O 
, O 
mean O 
bone O 
- O 
specific O 
alkaline O 
phosphatase O 
( O 
bALP O 
) O 
, O 
osteocalcin O 
, O 
procollagen O 
type O 
1 O 
N B-FORMULA 
-terminal O 
propeptide O 
( O 
P1NP O 
) O 
, O 
N B-FORMULA 
-terminal O 
cross O 
- O 
linking O 
telopeptide O 
of O 
type O 
1 O 
collagen O 
( O 
NTX O 
) O 
, O 
and O 
C- O 
terminal O 
cross O 
- O 
linking O 
telopeptide O 
of O 
type O 
1 O 
collagen O 
( O 
βCTX O 
) O 
decreased O 
significantly O 
in O 
the O 
intermittent O 
ART O 
group O 
, O 
whereas O 
RANKL O 
and O 
the O 
RANKL O 
: O 
osteoprotegerin O 
( O 
OPG O 
) O 
ratio O 
increased O 
( O 
all O 
p O 
< O 
0.002 O 
at O 
month O 
4 O 
and O 
month O 
12 O 
) O 
. O 
Increases O 
in O 
bALP O 
, O 
osteocalcin O 
, O 
P1NP O 
, O 
NTX O 
, O 
and O 
βCTX O 
at O 
month O 
4 O 
predicted O 
decrease O 
in O 
hip O 
BMD O 
at O 
month O 
12 O 
, O 
while O 
increases O 
in O 
RANKL O 
and O 
the O 
RANKL O 
: O 
OPG O 
ratio O 
at O 
month O 
4 O 
predicted O 
increase O 
in O 
hip O 
and O 
spine O 
BMD O 
at O 
month O 
12 O 
. O 
This O 
study O 
has O 
shown O 
that O 
compared O 
with O 
continuous O 
ART O 
, O 
interruption O 
of O 
ART O 
results O 
in O 
a O 
reduction O 
in O 
markers O 
of O 
bone O 
turnover O 
and O 
increase O 
in O 
BMD O 
at O 
hip O 
and O 
spine O 
, O 
and O 
that O 
early O 
changes O 
in O 
markers O 
of O 
bone O 
turnover O 
predict O 
BMD O 
changes O 
at O 
12 O 
months O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

effects O 
of O 
rare O 
earth O 
elements O 
( O 
REEs O 
) O 
not O 
only O 
on O 
cell O 
growth O 
and O 
flavonoid B-FAMILY 
accumulation O 
of O 
Tetrastigma O 
hemsleyanum O 
suspension O 
cells O 
but O 
also O 
on O 
the O 
isoenzyme O 
patterns O 
and O 
activities O 
of O 
related O 
enzymes O 
were O 
studied O 
in O 
this O 
paper O 
. O 
There O 
were O 
no O 
significant O 
differences O 
in O 
enhancement O 
of O 
flavonoid B-FAMILY 
accumulation O 
in O 
T O 
. O 
hemsleyanum O 
suspension O 
cells O 
among O 
La(3+) B-FORMULA 
, O 
Ce(3+) B-FORMULA 
, O 
and O 
Nd(3+) B-FORMULA 
. O 
Whereas O 
their O 
inductive O 
effects O 
on O 
cell O 
proliferation O 
varied O 
greatly O 
. O 
The O 
most O 
significant O 
effects O 
were O 
achieved O 
with O 
100 O 
μM O 
Ce(3+) B-FORMULA 
and O 
Nd(3+) B-FORMULA 
. O 
Under O 
treatment O 
over O 
a O 
25-day O 
culture O 
period O 
, O 
the O 
maximal O 
biomass O 
levels O 
reached O 
1.92- O 
and O 
1.74-fold O 
and O 
the O 
total O 
flavonoid B-FAMILY 
contents O 
are O 
1.45- O 
and O 
1.49-fold O 
, O 
than O 
that O 
of O 
control O 
, O 
respectively O 
. O 
Catalase O 
, O 
phenylalanine B-TRIVIAL 
ammonia B-SYSTEMATIC 
-lyase O 
( O 
PAL O 
) O 
, O 
and O 
peroxidase O 
( O 
POD O 
) O 
activity O 
was O 
activated O 
significantly O 
when O 
the O 
REE O 
concentration O 
range O 
from O 
0 O 
to O 
300 O 
μM O 
, O 
whereas O 
no O 
significant O 
changes O 
were O 
found O 
in O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
. O 
Differences O 
of O 
esterase O 
isozymes O 
under O 
REE O 
treatment O 
only O 
laid O 
in O 
expression O 
level O 
, O 
and O 
there O 
were O 
no O 
specific O 
bands O 
. O 
The O 
expression O 
level O 
of O 
some O 
POD O 
isozymes O 
strengthened O 
with O 
increasing O 
concentration O 
of O 
REEs O 
within O 
the O 
range O 
of O 
50-200 O 
μM O 
. O 
When O 
REE O 
concentration O 
was O 
higher O 
than O 
300 O 
μM O 
, O 
the O 
expression O 
of O 
some O 
POD O 
isozymes O 
was O 
inhibited O 
; O 
meanwhile O 
, O 
some O 
other O 
new O 
POD O 
isozymes O 
were O 
induced O 
. O 
Our O 
results O 
also O 
showed O 
REEs O 
did O 
not O 
directly O 
influence O 
PAL O 
activity O 
. O 
So O 
, O 
we O 
speculated O 
that O 
50-200 O 
μM O 
REEs O 
could O 
activate O 
some O 
of O 
antioxidant O 
enzymes O 
, O 
adjust O 
some O 
isozymes O 
expression O 
, O 
trigger O 
the O 
defense O 
responses O 
of O 
T O 
. O 
hemsleyanum O 
suspension O 
cells O 
, O 
and O 
stimulate O 
flavonoid O 
accumulation O 
by O 
inducing O 
PAL O 
activity O 
. O 

of O 
key O 
receptor O 
- O 
ligand O 
interactions O 
of O 
dopaminergic O 
arylpiperazines B-FAMILY 
and O 
the O 
dopamine B-TRIVIAL 
D2 O 
receptor O 
homology O 
model O 
. O 

in O 
structure O 
- O 
based O 
G O 
- O 
protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
ligand O 
discovery O 
is O 
huge O 
, O 
given O 
that O 
almost O 
30 O 
% O 
of O 
all O 
approved O 
drugs O 
belong O 
to O 
this O 
category O 
of O 
active O 
compounds O 
. O 
The O 
GPCR O 
family O 
includes O 
the O 
dopamine B-TRIVIAL 
receptor O 
subtype O 
D2 O 
( O 
D2DR O 
) O 
, O 
but O 
unfortunately O 
-- O 
as O 
is O 
true O 
of O 
most O 
GPCRs O 
-- O 
no O 
experimental O 
structures O 
are O 
available O 
for O 
these O 
receptors O 
. O 
In O 
this O 
publication O 
, O 
we O 
present O 
the O 
molecular O 
model O 
of O 
D2DR O 
based O 
on O 
the O 
previously O 
published O 
crystal O 
structure O 
of O 
the O 
dopamine B-TRIVIAL 
D3 O 
receptor O 
( O 
D3DR O 
) O 
. O 
A O 
molecular O 
modeling O 
study O 
using O 
homology O 
modeling O 
and O 
docking O 
simulation O 
provided O 
a O 
rational O 
explanation O 
for O 
the O 
behavior O 
of O 
the O 
arylpiperazine B-FAMILY 
ligand O 
. O 
The O 
observed O 
binding O 
modes O 
and O 
receptor O 
- O 
ligand O 
interactions O 
provided O 
us O 
with O 
fresh O 
clues O 
about O 
how O 
to O 
optimize O 
selectivity O 
for O 
D2DR O 
receptors O 
. O 

G O 
protein O 
- O 
biased O 
ligand O 
at O 
the O 
μ-opioid O 
receptor O 
is O 
potently O 
analgesic O 
with O 
reduced O 
gastrointestinal O 
and O 
respiratory O 
dysfunction O 
compared O 
with O 
morphine B-TRIVIAL 
. O 

concept O 
of O 
ligand O 
bias O 
at O 
G O 
protein O 
- O 
coupled O 
receptors O 
broadens O 
the O 
possibilities O 
for O 
agonist O 
activities O 
and O 
provides O 
the O 
opportunity O 
to O 
develop O 
safer O 
, O 
more O 
selective O 
therapeutics O 
. O 
Morphine B-TRIVIAL 
pharmacology O 
in O 
β-arrestin-2 O 
knockout O 
mice O 
suggested O 
that O 
a O 
ligand O 
that O 
promotes O 
coupling O 
of O 
the O 
μ-opioid O 
receptor O 
( O 
MOR O 
) O 
to O 
G O 
proteins O 
, O 
but O 
not O 
β-arrestins O 
, O 
would O 
result O 
in O 
higher O 
analgesic O 
efficacy O 
, O 
less O 
gastrointestinal O 
dysfunction O 
, O 
and O 
less O 
respiratory O 
suppression O 
than O 
morphine B-TRIVIAL 
. O 
Here O 
we O 
report O 
the O 
discovery O 
of O 
TRV130 B-IDENTIFIER 
( O 
[(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine B-SYSTEMATIC 
) O 
, O 
a O 
novel O 
MOR O 
G O 
protein O 
- O 
biased O 
ligand O 
. O 
In O 
cell O 
- O 
based O 
assays O 
, O 
TRV130 B-IDENTIFIER 
elicits O 
robust O 
G O 
protein O 
signaling O 
, O 
with O 
potency O 
and O 
efficacy O 
similar O 
to O 
morphine B-TRIVIAL 
, O 
but O 
with O 
far O 
less O 
β-arrestin O 
recruitment O 
and O 
receptor O 
internalization O 
. O 
In O 
mice O 
and O 
rats O 
, O 
TRV130 B-IDENTIFIER 
is O 
potently O 
analgesic O 
while O 
causing O 
less O 
gastrointestinal O 
dysfunction O 
and O 
respiratory O 
suppression O 
than O 
morphine B-TRIVIAL 
at O 
equianalgesic O 
doses O 
. O 
TRV130 B-IDENTIFIER 
successfully O 
translates O 
evidence O 
that O 
analgesic O 
and O 
adverse O 
MOR O 
signaling O 
pathways O 
are O 
distinct O 
into O 
a O 
biased O 
ligand O 
with O 
differentiated O 
pharmacology O 
. O 
These O 
preclinical O 
data O 
suggest O 
that O 
TRV130 B-IDENTIFIER 
may O 
be O 
a O 
safer O 
and O 
more O 
tolerable O 
therapeutic O 
for O 
treating O 
severe O 
pain O 
. O 

is O 
a O 
central O 
node O 
in O 
the O 
phosphoinositide-3 O 
kinase-Akt O 
- O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
pathway O 
and O 
is O 
activated O 
by O 
a O 
multistep O 
process O 
in O 
response O 
to O 
growth O 
factor O 
stimulation O 
. O 
An O 
additional O 
layer O 
of O 
posttranslational O 
modification O 
has O 
emerged O 
as O 
a O 
new O 
paradigm O 
in O 
the O 
regulation O 
of O 
Akt O 
. O 
The O 
identification O 
of O 
an O 
E3 O 
ligase O 
for O 
Lys B-FORMULA 
( O 
63 O 
) O 
- O 
linked O 
ubiquitination O 
of O 
Akt O 
has O 
now O 
been O 
complemented O 
with O 
the O 
discovery O 
of O 
the O 
tumor O 
suppressor O 
cylindromatosis O 
as O 
a O 
deubiquitinating O 
enzyme O 
( O 
DUB O 
) O 
for O 
Akt O 
. O 
Thus O 
, O 
like O 
phosphorylation O 
and O 
dephosphorylation O 
, O 
cycles O 
of O 
ubiquitination O 
and O 
deubiquitination O 
provide O 
additional O 
on O 
- O 
off O 
switches O 
that O 
keep O 
Akt O 
activity O 
in O 
balance O 
, O 
and O 
disturbances O 
in O 
this O 
balance O 
have O 
pathological O 
consequences O 
. O 

sensitised O 
solar O 
cells O 
with O 
nickel B-SYSTEMATIC 
oxide I-SYSTEMATIC 
photocathodes O 
prepared O 
via O 
scalable O 
microwave O 
sintering O 
. O 

NiO B-FORMULA 
electrodes O 
for O 
cathodic O 
dye O 
- O 
sensitised O 
solar O 
cells O 
( O 
p-DSCs O 
) O 
have O 
been O 
prepared O 
with O 
thicknesses O 
ranging O 
between O 
0.4 O 
and O 
3 O 
μm O 
by O 
spray O 
- O 
depositing O 
pre O 
- O 
formed O 
NiO B-FORMULA 
nanoparticles O 
on O 
fluorine B-SYSTEMATIC 
-doped O 
tin B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
FTO B-ABBREVIATION 
) O 
coated O 
glass O 
substrates O 
. O 
The O 
larger O 
thicknesses O 
were O 
obtained O 
in O 
sequential O 
sintering O 
steps O 
using O 
a O 
conventional O 
furnace O 
( O 
CS O 
) O 
and O 
a O 
newly O 
developed O 
rapid O 
discharge O 
sintering O 
( O 
RDS O 
) O 
method O 
. O 
The O 
latter O 
procedure O 
is O 
employed O 
for O 
the O 
first O 
time O 
for O 
the O 
preparation O 
of O 
p-DSCs O 
. O 
In O 
particular O 
, O 
RDS O 
represents O 
a O 
scalable O 
procedure O 
that O 
is O 
based O 
on O 
microwave O 
- O 
assisted O 
plasma O 
formation O 
that O 
allows O 
the O 
production O 
in O 
series O 
of O 
mesoporous O 
NiO B-FORMULA 
electrodes O 
with O 
large O 
surface O 
areas O 
for O 
p- O 
type O 
cell O 
photocathodes O 
. O 
RDS O 
possesses O 
the O 
unique O 
feature O 
of O 
transmitting O 
heat O 
from O 
the O 
bulk O 
of O 
the O 
system O 
towards O 
its O 
outer O 
interfaces O 
with O 
controlled O 
confinement O 
of O 
the O 
heating O 
zone O 
. O 
The O 
use O 
of O 
RDS O 
results O 
in O 
a O 
drastic O 
reduction O 
of O 
processing O 
times O 
with O 
respect O 
to O 
other O 
deposition O 
methods O 
that O 
involve O 
heating O 
/ O 
calcination O 
steps O 
with O 
associated O 
reduced O 
costs O 
in O 
terms O 
of O 
energy O 
. O 
P1-dye O 
sensitized O 
NiO B-FORMULA 
electrodes O 
obtained O 
via O 
the O 
RDS O 
procedure O 
have O 
been O 
tested O 
in O 
DSC O 
devices O 
and O 
their O 
performances O 
have O 
been O 
analysed O 
and O 
compared O 
with O 
those O 
of O 
cathodic O 
DSCs O 
derived O 
from O 
CS-deposited O 
samples O 
. O 
The O 
largest O 
conversion O 
efficiencies O 
( O 
0.12% O 
) O 
and O 
incident O 
photon O 
- O 
to O 
- O 
current O 
conversion O 
efficiencies O 
, O 
IPCEs O 
( O 
50% O 
) O 
, O 
were O 
obtained O 
with O 
sintered O 
NiO B-FORMULA 
electrodes O 
having O 
thicknesses O 
of O 
~1.5-2.0 O 
μm O 
. O 
In O 
all O 
the O 
devices O 
, O 
the O 
photogenerated O 
holes O 
in O 
NiO B-FORMULA 
live O 
significantly O 
longer O 
( O 
τ(h) O 
~ O 
1 O 
s O 
) O 
than O 
have O 
previously O 
been O 
reported O 
for O 
P1-sensitized O 
NiO B-FORMULA 
photocathodes O 
. O 
In O 
addition O 
, O 
P1-sensitised O 
sintered O 
electrodes O 
give O 
rise O 
to O 
relatively O 
high O 
photovoltages O 
( O 
up O 
to O 
135 O 
mV O 
) O 
when O 
the O 
triiodide B-SYSTEMATIC 
- O 
iodide B-SYSTEMATIC 
redox O 
couple O 
is O 
used O 
. O 

antidotes O 
for O 
mass O 
casualties O 
: O 
water O 
- O 
soluble O 
salts O 
of O 
the O 
dithiane B-SYSTEMATIC 
( O 
sulfanegen B-TRIVIAL 
) O 
from O 
3-mercaptopyruvate B-SYSTEMATIC 
for O 
intramuscular O 
administration O 
. O 

cyanide O 
antidotes O 
are O 
administered O 
by O 
IV O 
infusion O 
, O 
which O 
is O 
suboptimal O 
for O 
mass O 
casualties O 
. O 
Therefore O 
, O 
in O 
a O 
cyanide B-SYSTEMATIC 
disaster O 
, O 
intramuscular O 
( O 
IM O 
) O 
injectable O 
antidotes O 
would O 
be O 
more O 
appropriate O 
. O 
We O 
report O 
the O 
discovery O 
of O 
the O 
highly O 
water O 
- O 
soluble O 
sulfanegen B-TRIVIAL 
triethanolamine B-SYSTEMATIC 
as O 
a O 
promising O 
lead O 
for O 
development O 
as O 
an O 
IM O 
injectable O 
cyanide B-SYSTEMATIC 
antidote O 
. O 

of O 
water O 
concentration O 
on O 
the O 
structural O 
and O 
diffusion O 
properties O 
of O 
imidazolium B-SYSTEMATIC 
-based O 
ionic O 
liquid O 
- O 
water O 
mixtures O 
. O 

have O 
used O 
molecular O 
dynamics O 
simulations O 
to O 
study O 
the O 
properties O 
of O 
three O 
ionic O 
liquid O 
(IL)-water O 
systems O 
: O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
[bmim]Cl B-FORMULA 
) O 
, O 
1-ethyl-3-methylimidazolium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
[emim][Ac] B-ABBREVIATION 
) O 
, O 
and O 
1,3-dimethylimidazolium B-SYSTEMATIC 
dimethylphosphate I-SYSTEMATIC 
( O 
[dmim][DMP] B-ABBREVIATION 
) O 
. O 
We O 
observe O 
the O 
transition O 
of O 
those O 
mixtures O 
from O 
pure O 
IL O 
to O 
aqueous O 
solution O 
by O 
analyzing O 
the O 
changes O 
in O 
important O 
bulk O 
properties O 
( O 
density O 
) O 
and O 
structural O 
and O 
bonding O 
properties O 
( O 
radial O 
distribution O 
functions O 
, O 
water O 
clustering O 
, O 
hydrogen O 
bonding O 
, O 
and O 
cationic O 
stacking O 
) O 
as O 
well O 
as O 
dynamical O 
properties O 
( O 
diffusion O 
coefficients O 
) O 
at O 
12 O 
different O 
concentration O 
samplings O 
of O 
each O 
mixture O 
, O 
ranging O 
from O 
0 O 
to O 
99.95 O 
mol O 
% O 
water O 
. O 
Our O 
simulations O 
revealed O 
across O 
all O 
of O 
the O 
different O 
structural O 
, O 
bonding O 
, O 
and O 
dynamical O 
properties O 
major O 
structural O 
changes O 
consistent O 
with O 
a O 
transition O 
from O 
IL-water O 
mixture O 
to O 
aqueous O 
solution O 
in O 
all O 
three O 
ILs O 
at O 
water O 
concentrations O 
around O 
75 O 
mol O 
% O 
. O 
Among O 
the O 
structural O 
changes O 
observed O 
were O 
rapid O 
increase O 
in O 
the O 
frequency O 
of O 
hydrogen B-SYSTEMATIC 
bonds O 
, O 
both O 
water O 
- O 
water O 
and O 
water O 
- O 
anion O 
. O 
Similarly O 
, O 
at O 
these O 
critical O 
concentrations O 
, O 
the O 
water O 
clusters O 
formed O 
begin O 
to O 
span O 
the O 
entire O 
simulation O 
box O 
, O 
rather O 
than O 
existing O 
as O 
isolated O 
networks O 
of O 
molecules O 
. O 
At O 
the O 
same O 
time O 
, O 
there O 
is O 
a O 
sudden O 
decrease O 
in O 
cationic O 
stacking O 
at O 
the O 
transition O 
point O 
, O 
followed O 
by O 
a O 
rapid O 
increase O 
near O 
90 O 
mol O 
% O 
water O 
. O 
Finally O 
, O 
the O 
diffusion O 
coefficients O 
of O 
individual O 
cations O 
and O 
anions O 
show O 
a O 
rapid O 
transition O 
from O 
rates O 
consistent O 
with O 
diffusion O 
in O 
IL's O 
to O 
rates O 
consistent O 
with O 
diffusion O 
in O 
water O 
beginning O 
at O 
75 O 
mol O 
% O 
water O 
. O 
The O 
location O 
of O 
this O 
transition O 
is O 
consistent O 
, O 
for O 
[bmim]Cl B-FORMULA 
and O 
[dmim][DMP] B-ABBREVIATION 
, O 
with O 
the O 
water O 
concentration O 
limit O 
above O 
which O 
the O 
ILs O 
are O 
unable O 
to O 
dissolve O 
cellulose O 
. O 

and O 
terphenyl B-FAMILY 
compounds O 
as O 
phosphodiesterase-4B O 
inhibitors O 
from O 
a O 
fungus O 
of O 
the O 
order O 
Chaetothyriales O 
( O 
MSX O 
47445 O 
) O 
. O 

bioactive O 
compounds O 
were O 
isolated O 
from O 
an O 
organic O 
extract O 
of O 
an O 
ascomycete O 
fungus O 
of O 
the O 
order O 
Chaetothyriales O 
( O 
MSX O 
47445 O 
) O 
using O 
bioactivity O 
- O 
directed O 
fractionation O 
as O 
part O 
of O 
a O 
search O 
for O 
anticancer O 
leads O 
from O 
filamentous O 
fungi O 
. O 
Of O 
these O 
, O 
two O 
were O 
benzoquinones B-FAMILY 
[ O 
betulinan B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
betulinan B-TRIVIAL 
C I-TRIVIAL 
( O 
3 O 
) O 
] O 
, O 
and O 
the O 
third O 
was O 
a O 
terphenyl B-FAMILY 
compound O 
, O 
BTH-II0204-207 B-IDENTIFIER 
: I-IDENTIFIER 
A I-IDENTIFIER 
( O 
2 O 
) O 
. O 
The O 
structures O 
were O 
elucidated O 
using O 
a O 
set O 
of O 
spectroscopic O 
and O 
spectrometric O 
techniques O 
; O 
the O 
structure O 
of O 
the O 
new O 
compound O 
( O 
3 O 
) O 
was O 
confirmed O 
via O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
. O 
Compounds O 
1-3 O 
were O 
evaluated O 
for O 
cytotoxicity O 
against O 
a O 
human O 
cancer O 
cell O 
panel O 
, O 
for O 
antimicrobial O 
activity O 
against O 
Staphylococcus O 
aureus O 
and O 
Candida O 
albicans O 
, O 
and O 
for O 
phosphodiesterase O 
( O 
PDE4B2 O 
) O 
inhibitory O 
activities O 
. O 
The O 
putative O 
binding O 
mode O 
of O 
1-3 O 
with O 
PDE4B2 O 
was O 
examined O 
using O 
a O 
validated O 
docking O 
protocol O 
, O 
and O 
the O 
binding O 
and O 
enzyme O 
inhibitory O 
activities O 
were O 
correlated O 
. O 

work O 
in O 
this O 
article O 
describes O 
a O 
spectral O 
signature O 
for O 
the O 
detection O 
of O 
a O 
C(α) O 
radical O 
damaged O 
peptide O 
, O 
which O 
should O 
enable O 
the O 
use O 
of O 
infrared O 
spectroscopic O 
methods O 
to O 
directly O 
monitor O 
oxidative O 
events O 
. O 
Spectra O 
for O 
radical O 
damaged O 
peptides O 
are O 
computed O 
with O 
ab O 
initio O 
methods O 
. O 
The O 
amide B-FAMILY 
bands O 
A O 
, O 
I O 
, O 
II O 
, O 
and O 
III O 
are O 
analyzed O 
for O 
trends O 
in O 
the O 
damage O 
site O 
. O 
The O 
spectral O 
signature O 
is O 
found O 
in O 
a O 
region O 
( O 
i.e O 
. O 
, O 
1700-1620 O 
cm(-1) O 
) O 
normally O 
void O 
of O 
vibrational O 
absorption O 
bands O 
from O 
stable O 
undamaged O 
beta O 
peptides O 
. O 
An O 
analysis O 
of O 
the O 
vibrational O 
motions O 
of O 
the O 
spectral O 
signature O 
is O 
described O 
. O 
The O 
uniqueness O 
of O 
the O 
spectral O 
signature O 
is O 
explored O 
by O 
an O 
examination O 
and O 
comparison O 
with O 
C(α) O 
monoradicals O 
and O 
polyradicals O 
, O 
as O 
well O 
as O 
with O 
other O 
bioradicals O 
that O 
could O 
act O 
as O 
spectral O 
interferences O 
. O 
The O 
identification O 
of O 
unique O 
infrared O 
spectral O 
features O 
for O 
C(α) O 
damage O 
could O 
have O 
important O 
implications O 
in O 
diagnostics O 
for O 
beta O 
conformational O 
peptides O 
damaged O 
by O 
oxidative O 
stress O 
processes O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
novel O 
7-mercaptocoumarin B-SYSTEMATIC 
derivatives O 
as O 
α(1)-adrenoceptor O 
antagonists O 
. O 

on O 
the O 
pharmacophore O 
model O 
of O 
α(1)-adrenoceptor O 
( O 
α(1)-AR O 
) O 
antagonists O 
led O 
to O 
design O 
a O 
series O 
of O 
novel O 
7-mercaptocoumarin B-SYSTEMATIC 
derivatives O 
as O 
α(1)-AR O 
antagonists O 
. O 
All O 
designed O 
compounds O 
have O 
been O 
synthesized O 
and O 
biologically O 
evaluated O 
. O 
The O 
results O 
showed O 
that O 
most O 
of O 
them O 
exhibited O 
strong O 
antagonistic O 
activity O 
. O 
Especially O 
compound O 
6 O 
showed O 
excellent O 
activity O 
, O 
which O 
was O 
better O 
than O 
that O 
of O 
the O 
reference O 
compound O 
prazosin B-TRIVIAL 
. O 
Structure O 
- O 
activity O 
relationship O 
studies O 
revealed O 
that O 
small O 
hydrophobic O 
group O 
at O 
the O 
terminal O 
heterocyclic O 
ring O 
and O 
ortho O 
substituents O 
on O 
the O 
phenyl O 
ring O 
of O 
phenylpiperazine B-SYSTEMATIC 
moiety O 
were O 
the O 
essential O 
structural O 
factors O 
for O 
α(1)-AR O 
antagonistic O 
activity O 
. O 
The O 
pharmacophore O 
modeling O 
studies O 
further O 
clarified O 
their O 
structural O 
contributions O 
to O 
antagonistic O 
activity O 
and O 
also O 
demonstrated O 
that O 
7-mercaptocoumarin B-SYSTEMATIC 
moiety O 
could O 
be O 
a O 
useful O 
scaffold O 
for O 
design O 
of O 
α(1)-AR O 
antagonists O 
. O 

acids I-MULTIPLE 
E-G I-MULTIPLE 
, O 
new O 
4-pyridone B-SYSTEMATIC 
derivatives O 
from O 
a O 
culture O 
of O 
Aspergillus O 
sp O 
. O 

new O 
himeic B-MULTIPLE 
acids I-MULTIPLE 
E-G I-MULTIPLE 
were O 
isolated O 
from O 
a O 
marine O 
- O 
derived O 
fungus O 
, O 
Aspergillus O 
sp O 
. O 
, O 
and O 
their O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
analysis O 
. O 
Although O 
himeic B-TRIVIAL 
acid I-TRIVIAL 
A I-TRIVIAL 
inhibited O 
the O 
activity O 
of O 
ubiquitin O 
- O 
activating O 
enzyme O 
( O 
E1 O 
) O 
, O 
the O 
three O 
new O 
derivatives O 
did O 
not O 
. O 

synthase O 
1 O 
( O 
HAS1 O 
) O 
requires O 
higher O 
cellular O 
UDP B-ABBREVIATION 
- O 
GlcNAc B-FORMULA 
concentration O 
than O 
HAS2 O 
and O 
HAS3 O 
. O 

have O 
three O 
homologous O 
genes O 
encoding O 
proteins O 
with O 
hyaluronan O 
synthase O 
activity O 
( O 
Has1-3 O 
) O 
, O 
all O 
producing O 
an O 
identical O 
polymer O 
from O 
UDP B-ABBREVIATION 
- O 
N-acetylglucosamine B-SYSTEMATIC 
and O 
UDP B-ABBREVIATION 
- O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
. O 
To O 
compare O 
the O 
properties O 
of O 
these O 
isoenzymes O 
, O 
COS-1 O 
cells O 
, O 
with O 
minor O 
endogenous O 
hyaluronan O 
synthesis O 
, O 
were O 
transfected O 
with O 
human O 
Has1-3 O 
isoenzymes O 
. O 
HAS1 O 
was O 
almost O 
unable O 
to O 
secrete O 
hyaluronan O 
or O 
form O 
a O 
hyaluronan O 
coat O 
, O 
in O 
contrast O 
to O 
HAS2 O 
and O 
HAS3 O 
. O 
This O 
failure O 
of O 
HAS1 O 
to O 
synthesize O 
hyaluronan O 
was O 
compensated O 
by O 
increasing O 
the O 
cellular O 
content O 
of O 
UDP B-ABBREVIATION 
- O 
N-acetyl B-SYSTEMATIC 
glucosamine I-SYSTEMATIC 
by O 
∼10-fold O 
with O 
1 O 
mm O 
glucosamine B-TRIVIAL 
in O 
the O 
growth O 
medium O 
. O 
Hyaluronan O 
synthesis O 
driven O 
by O 
HAS2 O 
was O 
less O 
affected O 
by O 
glucosamine B-TRIVIAL 
addition O 
, O 
and O 
HAS3 O 
was O 
not O 
affected O 
at O 
all O 
. O 
Glucose B-TRIVIAL 
-free O 
medium O 
, O 
leading O 
to O 
depletion O 
of O 
the O 
UDP B-ABBREVIATION 
- O 
sugars B-FAMILY 
, O 
markedly O 
reduced O 
hyaluronan O 
synthesis O 
by O 
all O 
HAS O 
isoenzymes O 
while O 
raising O 
its O 
concentration O 
from O 
5 O 
to O 
25 O 
mm O 
had O 
a O 
moderate O 
stimulatory O 
effect O 
. O 
The O 
results O 
indicate O 
that O 
HAS1 O 
is O 
almost O 
inactive O 
in O 
cells O 
with O 
low O 
UDP B-ABBREVIATION 
- O 
sugar B-FAMILY 
supply O 
, O 
HAS2 O 
activity O 
increases O 
with O 
UDP B-ABBREVIATION 
- O 
sugars B-FAMILY 
, O 
and O 
HAS3 O 
produces O 
hyaluronan O 
at O 
high O 
speed O 
even O 
with O 
minimum O 
substrate O 
content O 
. O 
Transfected O 
Has2 O 
and O 
particularly O 
Has3 O 
consumed O 
enough O 
UDP B-ABBREVIATION 
- O 
sugars B-FAMILY 
to O 
reduce O 
their O 
content O 
in O 
COS-1 O 
cells O 
. O 
Comparison O 
of O 
different O 
human O 
cell O 
types O 
revealed O 
∼50-fold O 
differences O 
in O 
the O 
content O 
of O 
UDP B-ABBREVIATION 
- O 
N-acetylhexosamines B-FAMILY 
and O 
UDP B-ABBREVIATION 
- O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
, O 
correlating O 
with O 
the O 
expression O 
level O 
of O 
Has1 O 
, O 
suggesting O 
cellular O 
coordination O 
between O 
Has1 O 
expression O 
and O 
the O 
content O 
of O 
UDP B-ABBREVIATION 
- O 
sugars B-FAMILY 
. O 

and O 
metabolic O 
effects O 
of O 
high O 
- O 
dose O 
olmesartan B-TRIVIAL 
and O 
telmisartan B-TRIVIAL 
in O 
type O 
2 O 
diabetes O 
patients O 
with O 
hypertension O 
. O 

performed O 
a O 
crossover O 
study O 
in O 
hypertensive O 
patients O 
with O 
type O 
2 O 
diabetes O 
to O 
compare O 
olmesartan B-TRIVIAL 
( O 
40 O 
mg O 
/ O 
day O 
) O 
with O 
telmisartan B-TRIVIAL 
( O 
80 O 
mg O 
/ O 
day O 
) O 
in O 
terms O 
of O 
their O 
antihypertensive O 
and O 
metabolic O 
effects O 
. O 
The O 
subjects O 
were O 
36 O 
patients O 
( O 
20 O 
men O 
and O 
16 O 
women O 
) O 
with O 
type O 
2 O 
diabetes O 
who O 
did O 
not O 
achieve O 
a O 
blood O 
pressure O 
< O 
130 O 
/ O 
80 O 
mmHg O 
following O 
treatment O 
with O 
olmesartan B-TRIVIAL 
at O 
40 O 
mg O 
/ O 
day O 
or O 
telmisartan B-TRIVIAL 
at O 
80 O 
mg O 
/ O 
day O 
for O 
8 O 
weeks O 
or O 
more O 
. O 
The O 
primary O 
endpoint O 
was O 
the O 
blood O 
pressure O 
reduction O 
rate O 
, O 
while O 
the O 
secondary O 
endpoints O 
were O 
BMI O 
, O 
parameters O 
of O 
glucose B-TRIVIAL 
metabolism O 
, O 
HMW-adiponectin O 
, O 
hs-CRP O 
and O 
lipids O 
metabolism O 
. O 
All O 
parameters O 
were O 
measured O 
in O 
Weeks O 
0 O 
, O 
12 O 
, O 
and O 
24 O 
. O 
Treatments O 
were O 
switched O 
in O 
Week O 
0 O 
, O 
and O 
Week O 
12 O 
and O 
the O 
following O 
results O 
were O 
obtained O 
. O 
There O 
were O 
1 O 
) O 
no O 
significant O 
differences O 
in O 
baseline O 
characteristics O 
; O 
2 O 
) O 
no O 
significant O 
difference O 
of O 
the O 
blood O 
pressure O 
reduction O 
rate O 
; O 
3 O 
) O 
significant O 
reductions O 
of O 
HbA1c O 
( O 
NGSP O 
) O 
, O 
FPG O 
and O 
HOMA-IR O 
in O 
olmesartan B-TRIVIAL 
group O 
; O 
4 O 
) O 
a O 
significant O 
increase O 
of O 
HDL-C O 
in O 
olmesartan B-TRIVIAL 
group O 
; O 
5 O 
) O 
a O 
decrease O 
of O 
hs-CRP O 
and O 
a O 
increase O 
of O 
HMW-adiponectin O 
in O 
olmesartan B-TRIVIAL 
group O 
; O 
and O 
6 O 
) O 
a O 
positive O 
correlation O 
between O 
the O 
percent O 
changes O 
of O 
HOMA-IR O 
and O 
hs-CRP O 
in O 
olmesartan B-TRIVIAL 
group O 
. O 
In O 
conclusion O 
, O 
there O 
was O 
no O 
difference O 
of O 
the O 
blood O 
pressure O 
reduction O 
achieved O 
at O 
the O 
highest O 
dose O 
in O 
olmesartan B-TRIVIAL 
group O 
and O 
telmisartan B-TRIVIAL 
group O 
. O 
But O 
improvement O 
of O 
glycemic O 
control O 
and O 
insulin O 
resistance O 
was O 
only O 
observed O 
in O 
olmesartan B-TRIVIAL 
group O 
. O 
Because O 
there O 
was O 
a O 
correlation O 
between O 
the O 
percent O 
changes O 
of O 
HOMA-IR O 
and O 
hs-CRP O 
, O 
these O 
effects O 
of O 
olmesartan B-TRIVIAL 
might O 
be O 
mediated O 
by O 
an O 
anti-inflammatory O 
action O 
. O 

of O 
hepatic O 
disposition O 
of O 
paroxetine B-TRIVIAL 
using O 
sandwich O 
- O 
cultured O 
rat O 
and O 
human O 
hepatocytes O 
. O 

, O 
a O 
selective O 
serotonin O 
reuptake O 
inhibitor O 
, O 
is O 
metabolized O 
in O 
the O 
liver O 
and O 
excreted O 
into O 
bile O 
and O 
urine O 
as O 
metabolites O 
, O 
but O 
species O 
differences O 
have O 
been O 
observed O 
in O 
hepatic O 
disposition O 
between O 
rats O 
and O 
humans O 
. O 
A O 
major O 
metabolite O 
in O 
rats O 
is O 
M1-glucuronide O 
, O 
whereas O 
M1-glucuronide O 
and O 
M1- O 
sulfate B-SYSTEMATIC 
are O 
found O 
in O 
humans O 
. O 
The O 
primary O 
excretion O 
route O 
of O 
paroxetine B-TRIVIAL 
-derived O 
radioactivity O 
in O 
rats O 
and O 
humans O 
is O 
bile O 
and O 
urine O 
, O 
respectively O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
usefulness O 
of O 
sandwich O 
- O 
cultured O 
hepatocytes O 
( O 
SCH O 
) O 
to O 
evaluate O 
in O 
vivo O 
species O 
differences O 
of O 
the O 
hepatic O 
disposition O 
of O 
paroxetine B-TRIVIAL 
between O 
rats O 
and O 
humans O 
. O 
The O 
metabolite O 
profile O 
of O 
[(3)H]paroxetine B-SYSTEMATIC 
in O 
SCH O 
was O 
similar O 
to O 
that O 
in O 
hepatocytes O 
in O 
suspension O 
, O 
and O 
the O 
in O 
vitro O 
metabolite O 
profiles O 
were O 
similar O 
to O 
the O 
published O 
in O 
vivo O 
metabolic O 
pathways O 
for O 
both O 
species O 
. O 
Furthermore O 
, O 
the O 
biliary O 
excretion O 
index O 
( O 
BEI O 
) O 
of O 
formed O 
M1-glucuronide O 
in O 
rat O 
SCH O 
( O 
25.8-50.9% O 
) O 
was O 
higher O 
than O 
that O 
in O 
human O 
SCH O 
( O 
15.1-16.7% O 
) O 
. O 
The O 
BEI O 
of O 
formed O 
M1- O 
sulfate B-SYSTEMATIC 
( O 
16.4-29.1% O 
) O 
was O 
comparable O 
to O 
that O 
of O 
M1-glucuronide O 
in O 
human O 
SCH O 
, O 
whereas O 
the O 
BEIs O 
of O 
paroxetine B-TRIVIAL 
were O 
negligible O 
in O 
SCH O 
of O 
both O 
species O 
. O 
Moreover O 
, O 
M1-glucuronide O 
was O 
demonstrated O 
to O 
be O 
a O 
multidrug O 
resistance O 
- O 
associated O 
protein O 
2 O 
substrate O 
in O 
both O 
species O 
, O 
as O 
determined O 
by O 
its O 
uptake O 
into O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
- O 
expressing O 
membrane O 
vesicles O 
. O 
SCH O 
should O 
prove O 
to O 
be O 
useful O 
to O 
evaluate O 
the O 
processes O 
of O 
hepatic O 
uptake O 
and O 
metabolism O 
of O 
parent O 
drugs O 
and O 
the O 
simultaneous O 
examination O 
of O 
the O 
biliary O 
excretion O 
of O 
both O 
parent O 
drug O 
and O 
liver O 
- O 
derived O 
metabolites O 
. O 

, O 
the O 
functional O 
appendage O 
of O 
a O 
biotin B-TRIVIAL 
moiety O 
to O 
a O 
bioactive O 
compound O 
( O 
including O 
small O 
molecules O 
and O 
biological O 
macromolecules O 
) O 
, O 
represents O 
a O 
common O 
technique O 
for O 
identification O 
of O 
the O 
intracellular O 
binding O 
partners O 
that O 
underlie O 
the O 
foundation O 
of O 
observed O 
biological O 
activity O 
. O 
Introduction O 
of O 
an O 
attachment O 
tether O 
to O 
the O 
framework O 
of O 
a O 
compound O 
of O 
interest O 
must O 
be O 
planned O 
at O 
an O 
early O 
stage O 
of O 
development O 
, O 
and O 
many O 
considerations O 
apply O 
: O 
1 O 
) O 
region O 
of O 
attachment O 
, O 
so O 
as O 
not O 
to O 
impede O 
the O 
pharmacophore O 
; O 
2 O 
) O 
stability O 
of O 
the O 
parent O 
molecular O 
architecture O 
to O 
biotinylation O 
conditions O 
; O 
3 O 
) O 
regioselectivity O 
for O 
the O 
chosen O 
tethering O 
location O 
over O 
other O 
reactive O 
functionalities O 
; O 
4 O 
) O 
toxicity O 
of O 
reagents O 
if O 
biotinylation O 
is O 
to O 
be O 
performed O 
in O 
vitro O 
; O 
and O 
5 O 
) O 
overall O 
ease O 
of O 
synthesis O 
. O 
This O 
review O 
is O 
intended O 
to O 
serve O 
as O 
a O 
guide O 
for O 
the O 
selection O 
of O 
appropriate O 
tethering O 
modalities O 
. O 
Examples O 
of O 
the O 
common O 
techniques O 
used O 
to O 
affix O 
biotin B-TRIVIAL 
, O 
including O 
amide B-FAMILY 
bond O 
formation O 
, O 
[ O 
3 O 
+ O 
2 O 
] O 
cycloadditions O 
through O 
" O 
click O 
" O 
chemistry O 
, O 
Staudinger O 
ligation O 
, O 
and O 
thioether B-SYSTEMATIC 
formation O 
will O 
be O 
discussed O 
, O 
along O 
with O 
analysis O 
of O 
the O 
wider O 
applications O 
of O 
synthetic O 
methodology O 
that O 
have O 
been O 
applied O 
toward O 
the O 
biotinylation O 
of O 
small O 
molecules O 
. O 

marine O 
polyketide O 
myriaporone B-MULTIPLE 
3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
stalls O 
translation O 
by O 
targeting O 
the O 
elongation O 
phase O 
. O 

3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
, O 
a O 
cytotoxic O 
polyketide O 
, O 
has O 
been O 
reported O 
as O 
an O 
inhibitor O 
of O 
eukaryotic O 
protein O 
synthesis O 
. O 
However O 
, O 
the O 
mechanism O 
by O 
which O 
it O 
inhibits O 
translation O 
was O 
unknown O 
. O 
Here O 
we O 
show O 
that O 
myriaporone B-MULTIPLE 
3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
stalls O 
protein O 
synthesis O 
in O 
the O 
elongation O 
phase O 
by O 
inducing O 
phosphorylation O 
of O 
eukaryotic O 
elongation O 
factor O 
2 O 
. O 
The O 
phosphorylation O 
results O 
from O 
direct O 
binding O 
of O 
myriaporone B-MULTIPLE 
3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
to O 
eukaryotic O 
elongation O 
factor O 
2 O 
kinase O 
. O 
Our O 
study O 
also O 
shows O 
that O 
myriaporone B-MULTIPLE 
3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
in O 
the O 
nanomolar O 
range O 
inhibits O 
in O 
vitro O 
tube O 
formation O 
by O 
endothelial O 
cells O 
without O 
being O 
cytotoxic O 
. O 
In O 
general O 
, O 
myriaporone B-MULTIPLE 
3 I-MULTIPLE 
/ I-MULTIPLE 
4 I-MULTIPLE 
was O 
at O 
least O 
300 O 
times O 
less O 
toxic O 
to O 
primary O 
cells O 
than O 
to O 
tumor O 
cells O 
. O 

high O 
mobility O 
in O 
LaAlO3 B-FORMULA 
/ O 
SrTiO3 B-FORMULA 
nanowires O 
. O 

control O 
of O 
the O 
metal O 
- O 
insulator O 
transition O 
at O 
the O 
interface O 
between O 
LaAlO(3) B-FORMULA 
and O 
SrTiO(3) B-FORMULA 
provides O 
a O 
pathway O 
for O 
reconfigurable O 
, O 
oxide O 
- O 
based O 
nanoelectronics O 
. O 
Four O 
- O 
terminal O 
transport O 
measurements O 
of O 
LaAlO(3) B-FORMULA 
/ O 
SrTiO(3) B-FORMULA 
nanowires O 
at O 
room O 
temperature O 
( O 
T O 
= O 
300 O 
K O 
) O 
reveal O 
an O 
equivalent O 
2D O 
Hall O 
mobility O 
greatly O 
surpassing O 
that O 
of O 
bulk O 
SrTiO(3) B-FORMULA 
and O 
approaching O 
that O 
of O 
n O 
- O 
type O 
Si B-FORMULA 
nanowires O 
of O 
comparable O 
dimensions O 
. O 
This O 
large O 
enhancement O 
of O 
mobility O 
is O 
relevant O 
for O 
room O 
- O 
temperature O 
device O 
applications O 
. O 

-ion O 
- O 
conducting O 
solid O 
electrolytes O 
hold O 
promise O 
for O 
enabling O 
high O 
- O 
energy O 
battery O 
chemistries O 
and O 
circumventing O 
safety O 
issues O 
of O 
conventional O 
lithium B-SYSTEMATIC 
batteries O 
. O 
Achieving O 
the O 
combination O 
of O 
high O 
ionic O 
conductivity O 
and O 
a O 
broad O 
electrochemical O 
window O 
in O 
solid O 
electrolytes O 
is O 
a O 
grand O 
challenge O 
for O 
the O 
synthesis O 
of O 
battery O 
materials O 
. O 
Herein O 
we O 
show O 
an O 
enhancement O 
of O 
the O 
room O 
- O 
temperature O 
lithium B-SYSTEMATIC 
-ion O 
conductivity O 
by O 
3 O 
orders O 
of O 
magnitude O 
through O 
the O 
creation O 
of O 
nanostructured O 
Li(3)PS(4) B-FORMULA 
. O 
This O 
material O 
has O 
a O 
wide O 
electrochemical O 
window O 
( O 
5 O 
V O 
) O 
and O 
superior O 
chemical O 
stability O 
against O 
lithium B-SYSTEMATIC 
metal O 
. O 
The O 
nanoporous O 
structure O 
of O 
Li(3)PS(4) B-FORMULA 
reconciles O 
two O 
vital O 
effects O 
that O 
enhance O 
the O 
ionic O 
conductivity O 
: O 
( O 
1 O 
) O 
the O 
reduction O 
of O 
the O 
dimensions O 
to O 
a O 
nanometer O 
- O 
sized O 
framework O 
stabilizes O 
the O 
high O 
- O 
conduction O 
β O 
phase O 
that O 
occurs O 
at O 
elevated O 
temperatures O 
, O 
and O 
( O 
2 O 
) O 
the O 
high O 
surface O 
- O 
to O 
- O 
bulk O 
ratio O 
of O 
nanoporous O 
β- O 
Li(3)PS(4) B-FORMULA 
promotes O 
surface O 
conduction O 
. O 
Manipulating O 
the O 
ionic O 
conductivity O 
of O 
solid O 
electrolytes O 
has O 
far O 
- O 
reaching O 
implications O 
for O 
materials O 
design O 
and O 
synthesis O 
in O 
a O 
broad O 
range O 
of O 
applications O 
, O 
including O 
batteries O 
, O 
fuel O 
cells O 
, O 
sensors O 
, O 
photovoltaic O 
systems O 
, O 
and O 
so O 
forth O 
. O 

and O 
evaluation O 
of O 
novel O 
inhibitors O 
of O 
mycobacterium O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
B O 
from O 
the O 
6-Hydroxy-benzofuran-5-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
scaffold O 
. O 

tuberculosis O 
( O 
Mtb O 
) O 
protein O 
tyrosine O 
phosphatase O 
B O 
( O 
mPTPB O 
) O 
is O 
a O 
virulence O 
factor O 
secreted O 
by O 
the O 
pathogen O 
and O 
mediates O 
mycobacterial O 
survival O 
in O 
macrophages O 
by O 
targeting O 
host O 
cell O 
immune O 
responses O 
. O 
Consequently O 
, O 
mPTPB O 
represents O 
an O 
exciting O 
new O 
target O 
to O 
combat O 
tuberculosis O 
( O 
TB O 
) O 
infection O 
. O 
We O 
describe O 
a O 
medicinal O 
chemistry O 
oriented O 
approach O 
that O 
transforms O 
a O 
benzofuran B-SYSTEMATIC 
salicylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
scaffold O 
into O 
a O 
highly O 
potent O 
( O 
IC(50) O 
= O 
38 O 
nM O 
) O 
and O 
selective O 
mPTPB O 
inhibitor O 
( O 
> O 
50 O 
fold O 
against O 
a O 
large O 
panel O 
of O 
PTPs O 
) O 
. O 
Importantly O 
, O 
the O 
inhibitor O 
is O 
capable O 
of O 
reversing O 
the O 
altered O 
host O 
immune O 
responses O 
induced O 
by O 
the O 
bacterial O 
phosphatase O 
and O 
restoring O 
the O 
macrophage's O 
full O 
capacity O 
to O 
secrete O 
IL-6 O 
and O 
undergo O 
apoptosis O 
in O 
response O 
to O 
interferon-γ O 
stimulation O 
, O 
validating O 
the O 
concept O 
that O 
chemical O 
inhibition O 
of O 
mPTPB O 
may O 
be O 
therapeutically O 
useful O 
for O 
novel O 
TB O 
treatment O 
. O 
The O 
study O 
further O 
demonstrates O 
that O 
bicyclic O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
pharmacophores O 
can O 
be O 
used O 
to O 
deliver O 
PTP O 
inhibitors O 
with O 
high O 
potency O 
, O 
selectivity O 
, O 
and O 
cellular O 
efficacy O 
. O 

pigments O 
from O 
the O 
basidiomycete O 
Albatrellus O 
ovinus O 
. O 

grifolin B-TRIVIAL 
derivatives O 
, O 
involving O 
three O 
new O 
monomers O 
, O 
albatrelins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
three O 
novel O 
dimers O 
( O 
meroterpenoid B-FAMILY 
pigments O 
) O 
, O 
albatrelins B-MULTIPLE 
D-F I-MULTIPLE 
( O 
4-6 O 
) O 
, O 
and O 
two O 
known O 
ones O 
, O 
6a,7,8,9,10,10a-hexahydro-3,6,9-trimethyl-6-(4-methyl-3-penten-1-yl)-1,9-epoxy-6H-dibenzo[b,d]pyran B-SYSTEMATIC 
( O 
7 O 
) O 
and O 
confluentin B-TRIVIAL 
( O 
8 O 
) O 
, O 
were O 
isolated O 
from O 
Albatrellus O 
ovinus O 
. O 
Their O 
structures O 
were O 
established O 
by O 
extensive O 
spectroscopic O 
analysis O 
. O 
The O 
absolute O 
configurations O 
of O 
compounds O 
2-4 O 
were O 
determined O 
as O 
9R O 
by O 
comparing O 
their O 
optical O 
rotations O 
with O 
data O 
reported O 
in O 
the O 
literature O 
. O 
Albatrelin B-TRIVIAL 
F I-TRIVIAL 
( O 
6 O 
) O 
was O 
isolated O 
as O 
a O 
pair O 
of O 
C-2 O 
' O 
tautomers O 
with O 
a O 
ratio O 
of O 
1.3 O 
: O 
1 O 
. O 
Confluentin B-TRIVIAL 
( O 
8 O 
) O 
showed O 
weak O 
cytotoxicity O 
against O 
four O 
human O 
tumor O 
cell O 
lines O 
, O 
HL-60 O 
, O 
SMMC-7712 O 
, O 
A-549 O 
, O 
and O 
MCF-7 O 
, O 
in O 
vitro O 
. O 

from O 
leaves O 
of O 
Miliusa O 
mollis O 
. O 

the O 
leaves O 
of O 
Miliusa O 
mollis O 
Pierre O 
( O 
Annonaceae O 
) O 
, O 
five O 
new O 
dihydrobenzofuran B-FAMILY 
neolignans I-FAMILY 
, O 
namely O 
miliumollin B-TRIVIAL 
, O 
7-methoxymiliumollin B-SYSTEMATIC 
, O 
3'-methoxymiliumollin B-SYSTEMATIC 
, O 
4'-O-methylmiliumollin B-SYSTEMATIC 
and O 
miliumollinone B-TRIVIAL 
, O 
and O 
a O 
new O 
8-O-4 B-SYSTEMATIC 
' I-SYSTEMATIC 
neolignan I-SYSTEMATIC 
named O 
miliusamollin B-TRIVIAL 
were O 
isolated O 
, O 
and O 
their O 
structures O 
were O 
elucidated O 
through O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
Miliumollin B-TRIVIAL 
, O 
3'-methoxymiliumollin B-SYSTEMATIC 
, O 
miliumollinone B-TRIVIAL 
and O 
decurrenal O 
exhibited O 
weak O 
cytotoxicity O 
against O 
KB O 
, O 
MCF7 O 
and O 
NCI-H187 O 
cells O 
. O 
Miliumollinone B-TRIVIAL 
possessed O 
weak O 
inhibitory O 
effects O 
against O 
herpes O 
simplex O 
virus O 
types O 
1 O 
and O 
2 O 
. O 
None O 
of O 
the O 
isolates O 
displayed O 
inhibitory O 
activity O 
against O 
avian O 
influenza O 
H5N1 O 
neuraminidase O 
. O 

effect O 
of O 
resveratrol B-TRIVIAL 
against O 
ethinylestradiol B-SYSTEMATIC 
-induced O 
liver O 
cholestasis O 
. O 

, O 
and O 
particularly O 
glucuronides O 
such O 
as O 
ethinylestradiol B-SYSTEMATIC 
( O 
EE O 
) O 
, O 
have O 
been O 
shown O 
to O 
cause O 
cholestasis O 
in O 
animal O 
studies O 
, O 
by O 
reducing O 
bile B-FAMILY 
acid I-FAMILY 
uptake O 
by O 
hepatocytes O 
. O 
The O 
aim O 
of O 
the O 
present O 
article O 
was O 
to O 
investigate O 
anticholestatic O 
activity O 
of O 
resveratrol B-TRIVIAL 
( O 
RES B-ABBREVIATION 
) O 
against O 
liver O 
cholestasis O 
induced O 
by O 
EE O 
in O 
adult O 
female O 
rats O 
. O 
The O 
daily O 
oral O 
administration O 
of O 
the O 
RES B-ABBREVIATION 
at O 
a O 
concentration O 
of O 
25 O 
mg O 
/ O 
kg O 
body O 
weight O 
for O 
15 O 
days O 
to O 
rats O 
treated O 
with O 
EE O 
( O 
100 O 
μg O 
/ O 
kg O 
body O 
weight O 
for O 
5 O 
days O 
) O 
resulted O 
in O 
a O 
significant O 
protection O 
against O 
EE-induced O 
decrease O 
in O 
both O 
serum O 
cholesterol O 
and O 
bile B-FAMILY 
acid I-FAMILY 
levels O 
as O 
well O 
as O 
against O 
an O 
increase O 
of O 
serum O 
bilirubin B-TRIVIAL 
concentration O 
. O 
The O 
treatment O 
also O 
resulted O 
in O 
a O 
significant O 
increase O 
in O 
hepatic O 
superoxide B-TRIVIAL 
dismutase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
reductase O 
, O 
and O 
catalase O 
activities O 
as O 
well O 
as O 
hepatic O 
protein O 
- O 
bound O 
and O 
nonprotein O 
sulfhydryl B-FAMILY 
groups O 
. O 
RES B-ABBREVIATION 
inhibited O 
serum O 
alkaline O 
phosphatase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
pi- O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
, O 
gamma- O 
glutamyl B-TRIVIAL 
transpeptidase O 
, O 
and O 
alpha- O 
glutathione B-TRIVIAL 
-S-transferase O 
activities O 
, O 
as O 
well O 
as O 
reduced O 
serum O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
and O 
hepatic O 
malondialdehyde B-TRIVIAL 
as O 
compared O 
to O 
EE O 
- O 
treated O 
rats O 
. O 
The O 
results O 
clearly O 
suggest O 
that O 
RES B-ABBREVIATION 
has O 
a O 
powerful O 
prophylactic O 
action O 
in O 
cholestasis O 
induced O 
by O 
EE O 
. O 
Taken O 
together O 
, O 
RES B-ABBREVIATION 
has O 
potential O 
as O 
a O 
preventive O 
and O 
therapeutic O 
agent O 
for O 
cholestasis O 
and O 
deserves O 
clinical O 
trial O 
in O 
the O 
near O 
future O 
as O 
an O 
adjuvant O 
therapy O 
in O 
women O 
treated O 
with O 
estrogen B-FAMILY 
. O 

first O 
total O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
marine O 
natural O 
products O 
ma'edamines B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
. O 

have O 
developed O 
the O 
first O 
total O 
syntheses O 
of O 
marine O 
natural O 
products O 
ma'edamines B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
18 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( O 
20 O 
) O 
. O 
Structurally O 
, O 
they O 
contain O 
a O 
pyrazine-2-(1H)-one B-SYSTEMATIC 
core O 
and O 
were O 
screened O 
for O 
antiproliferative O 
activity O 
on O 
several O 
cancer O 
cell O 
lines O 
. O 
Out O 
of O 
the O 
six O 
cell O 
lines O 
tested O 
, O 
ma'edamines B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
showed O 
significant O 
cytotoxicity O 
against O 
human O 
colon O 
cancer O 
line O 
COLO O 
205 O 
( O 
IC(50) O 
7.9 O 
and O 
10.3 O 
μM O 
, O 
respectively O 
) O 
, O 
breast O 
cancer O 
cell O 
line O 
MCF-7 O 
( O 
IC(50) O 
: O 
6.9 O 
and O 
10.5 O 
μM O 
, O 
respectively O 
) O 
and O 
human O 
lung O 
adenocarcinoma O 
cell O 
line O 
A549 O 
( O 
IC(50) O 
: O 
12.2 O 
and O 
15.4 O 
μM O 
, O 
respectively O 
) O 
. O 
The O 
apoptotic O 
effect O 
of O 
ma'edamines B-FAMILY 
was O 
confirmed O 
by O 
comet O 
assay O 
. O 
Hence O 
ma'edamines B-FAMILY 
are O 
likely O 
to O 
be O 
useful O 
as O 
leads O 
for O 
development O 
of O 
a O 
new O 
class O 
of O 
anti-cancer O 
agents O 
. O 

compound O 
(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione B-SYSTEMATIC 
( O 
LYSO-7 B-ABBREVIATION 
) O 
was O 
synthesised O 
in O 
order O 
to O 
obtain O 
a O 
new O 
type O 
of O 
anti-inflammatory O 
drug O 
, O 
designed O 
with O 
hybrid O 
features O 
to O 
inhibit O 
cyclooxygenase O 
( O 
COX O 
) O 
and O 
also O 
to O 
activate O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
( O 
PPAR O 
) O 
. O 
Results O 
obtained O 
from O 
docking O 
( O 
in O 
silico O 
) O 
studies O 
corroborated O 
with O 
experimental O 
data O 
, O 
showing O 
the O 
potential O 
affinity O 
between O 
the O 
studied O 
ligand O 
and O 
targets O 
. O 
The O 
specificity O 
of O 
LYSO-7 B-ABBREVIATION 
for O 
COX O 
- O 
enzymes O 
was O 
detected O 
by O 
the O 
inhibition O 
of O 
COX-1 O 
and O 
COX-2 O 
activities O 
by O 
30% O 
and O 
20% O 
, O 
respectively O 
. O 
In O 
transactivation O 
reporter O 
gene O 
assays O 
LYSO-07 B-ABBREVIATION 
showed O 
a O 
pan O 
partial O 
agonist O 
effect O 
on O 
the O 
three O 
PPAR O 
subtypes O 
( O 
PPARγ O 
, O 
PPARα O 
and O 
PPARβ O 
/ O 
δ O 
) O 
. O 
The O 
agonist O 
action O 
on O 
PPARγ O 
was O 
also O 
observed O 
by O 
a O 
pharmacological O 
approach O 
, O 
as O 
the O 
reduction O 
in O 
the O 
Escherichia O 
coli O 
lipopolysaccharide O 
(LPS)-induced O 
interleukin O 
1 O 
beta O 
( O 
IL-1β O 
) O 
secretion O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
by O 
mouse O 
neutrophils O 
was O 
blocked O 
by O 
GW9962 B-IDENTIFIER 
, O 
a O 
specific O 
PPARγ O 
antagonist O 
. O 
Additionally O 
, O 
the O 
in O 
vivo O 
effect O 
was O 
measured O 
by O 
reduced O 
carrageenan O 
- O 
induced O 
neutrophil O 
influx O 
into O 
the O 
subcutaneous O 
tissue O 
of O 
mice O 
. O 
Taken O 
together O 
, O 
these O 
data O 
show O 
that O 
LYSO-7 B-ABBREVIATION 
displays O 
a O 
potent O 
in O 
vivo O 
anti-inflammatory O 
effect O 
during O 
the O 
innate O 
acute O 
response O 
, O 
which O 
is O 
dependent O 
on O 
its O 
associated O 
COX O 
inhibitory O 
activities O 
and O 
PPAR O 
activation O 
. O 

new O 
spatane B-TRIVIAL 
diterpenoid B-FAMILY 
from O 
the O 
cultured O 
soft O 
coral O 
Sinularia O 
leptoclados O 
. O 

new O 
spatane B-TRIVIAL 
diterpenoid B-FAMILY 
, O 
leptoclalin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
along O 
with O 
two O 
previously O 
reported O 
known O 
norcembranoid B-FAMILY 
diterpenes B-FAMILY 
( O 
2 O 
and O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
a O 
cultured O 
soft O 
coral O 
Sinularia O 
leptoclados O 
. O 
The O 
structures O 
were O 
determined O 
by O 
extensive O 
spectroscopic O 
analyses O 
and O 
by O 
comparison O 
with O 
the O 
spectral O 
data O 
of O 
related O 
known O 
compounds O 
. O 
Metabolite O 
1 O 
is O 
rarely O 
found O 
in O 
spatane O 
skeletons O 
reported O 
from O 
soft O 
corals O 
. O 
In O 
addition O 
, O 
compound O 
1 O 
exhibited O 
weak O 
cytotoxicity O 
towards O 
human O 
tumor O 
cell O 
lines O 
T-47 O 
D O 
and O 
K-562 O 
. O 

polyketides O 
from O 
the O 
marine O 
alga O 
- O 
derived O 
endophitic O 
Streptomyces O 
sundarbansensis O 
: O 
a O 
study O 
on O 
hydroxypyrone B-SYSTEMATIC 
tautomerism O 
. O 

13 O 
[ O 
= O 
2-hydroxy-5-((6-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-2- B-SYSTEMATIC 
propylchroman-4-one I-SYSTEMATIC 
] O 
and O 
three O 
related O 
known O 
compounds O 
7 O 
, O 
9 O 
and O 
11 O 
were O 
obtained O 
and O 
structurally O 
characterized O 
from O 
Streptomyces O 
sundarbansensis O 
strain O 
, O 
an O 
endophytic O 
actinomycete O 
isolated O 
from O 
the O 
Algerian O 
marine O 
brown O 
algae O 
Fucus O 
sp O 
. O 
Compound O 
13 O 
was O 
obtained O 
as O 
the O 
major O 
metabolite O 
from O 
optimized O 
culture O 
conditions O 
, O 
by O 
using O 
Agar O 
state O 
fermentation O 
. O 
Due O 
to O 
tautomeric O 
equilibrium O 
, O 
13 O 
in O 
CD(3)OD B-FORMULA 
solution O 
was O 
able O 
to O 
incorporate O 
five O 
deuterium B-SYSTEMATIC 
atoms O 
, O 
as O 
deduced O 
by O 
NMR O 
and O 
ESI-MS O 
/ O 
MS O 
analysis O 
. O 
The O 
2-hydroxy-γ-pyrone B-SYSTEMATIC 
form O 
was O 
established O 
for O 
these O 
metabolites O 
based O 
on O 
the O 
comparison O 
of O 
their O 
experimental O 
IR O 
spectra O 
with O 
the O 
DFT O 
calculated O 
ones O 
, O 
for O 
both O 
the O 
corresponding O 
4-hydroxy-α-pyrone B-SYSTEMATIC 
and O 
2-hydroxy-γ-pyrone B-SYSTEMATIC 
forms O 
. O 
During O 
antibacterial O 
evaluation O 
, O 
compound O 
13 O 
stood O 
out O 
as O 
the O 
most O 
active O 
of O 
the O 
series O 
, O 
showing O 
a O 
selective O 
activity O 
against O 
the O 
gram O 
positive O 
pathogenic O 
methicillin B-TRIVIAL 
-resistant O 
S O 
. O 
aureus O 
( O 
MRSA O 
, O 
MIC O 
= O 
6 O 
μΜ O 
) O 
, O 
with O 
a O 
bacteriostatic O 
effect O 
. O 

A I-TRIVIAL 
enhances O 
TRAIL-induced O 
apoptosis O 
via O 
NF-κB O 
- O 
mediated O 
Fas O 
overexpression O 
. O 

investigated O 
whether O 
verrucarin B-TRIVIAL 
A I-TRIVIAL 
( O 
VA O 
) O 
sensitizes O 
HepG2 O 
hepatoma O 
cells O 
to O 
tumor O 
necrosis O 
factor O 
- O 
related O 
apoptosis O 
inducing O 
ligand O 
( O 
TRAIL O 
) O 
- O 
mediated O 
apoptosis O 
. O 
We O 
found O 
that O 
VA O 
alone O 
induces O 
little O 
apoptosis O 
, O 
but O 
when O 
combined O 
with O 
TRAIL O 
( O 
VA O 
/ O 
TRAIL O 
) O 
, O 
it O 
triggered O 
significant O 
apoptosis O 
, O 
causing O 
little O 
or O 
no O 
toxicity O 
in O 
normal O 
mouse O 
splenocytes O 
. O 
VA O 
/ O 
TRAIL-induced O 
cell O 
death O 
is O 
involved O 
in O 
the O 
loss O 
of O 
mitochondrial O 
transmembrane O 
potential O 
and O 
the O 
consequent O 
activation O 
of O 
caspases O 
. O 
Because O 
nuclear O 
factor O 
(NF)-κB O 
inhibition O 
has O 
been O 
known O 
as O 
a O 
critical O 
target O 
in O 
TRAIL O 
- O 
mediated O 
apoptosis O 
, O 
we O 
also O 
investigated O 
the O 
role O 
of O 
NF-κB O 
in O 
VA O 
/ O 
TRAIL O 
treatment O 
. O 
We O 
found O 
that O 
VA O 
upregulated O 
the O 
DNA O 
binding O 
activity O 
of O 
NF-κB O 
, O 
but O 
that O 
the O 
antioxidants O 
glutathione B-TRIVIAL 
and O 
N-acetyl-l-cysteine B-SYSTEMATIC 
, O 
as O 
well O 
as O 
NF-κB O 
inhibitor O 
MG132 B-IDENTIFIER 
, O 
and O 
mutant-IκB O 
( O 
m-IκB O 
) O 
transfection O 
, O 
significantly O 
downregulated O 
VA O 
/ O 
TRAIL-induced O 
cell O 
death O 
by O 
inhibiting O 
caspase-3 O 
and O 
NF-κB O 
activities O 
. O 
Transfection O 
of O 
mutant-eIF2α O 
also O 
resulted O 
in O 
a O 
decrease O 
in O 
VA O 
/ O 
TRAIL-induced O 
cell O 
death O 
by O 
inhibiting O 
of O 
caspase-3 O 
, O 
but O 
not O 
NF-κB O 
activity O 
. O 
Although O 
VA O 
/ O 
TRAIL O 
treatment O 
led O 
to O 
an O 
increase O 
of O 
DR5 O 
expression O 
, O 
transfection O 
of O 
m-IκB O 
had O 
no O 
influence O 
on O 
the O 
DR5 O 
expressional O 
level O 
. O 
Finally O 
, O 
we O 
showed O 
that O 
NF-κB O 
- O 
mediated O 
Fas O 
expression O 
is O 
critical O 
to O 
VA O 
/ O 
TRAIL-induced O 
apoptosis O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
VA O 
/ O 
TRAIL O 
sensitizes O 
HepG2 O 
cells O 
to O 
apoptosis O 
via O 
NF-κB O 
- O 
mediated O 
overexpression O 
of O 
Fas O 
. O 

glycol I-SYSTEMATIC 
-g- O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
grafted O 
copolymer O 
: O 
Reproductive O 
toxicity O 
study O 
in O 
Wistar O 
rats O 
. O 

glycol I-SYSTEMATIC 
-g- O 
polyvinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
PEG-PVA B-ABBREVIATION 
) O 
grafted O 
copolymer O 
was O 
administered O 
by O 
gavage O 
to O 
groups O 
of O 
25 O 
male O 
and O 
25 O 
female O 
young O 
Wistar O 
rats O 
at O 
doses O 
of O 
0 O 
( O 
vehicle O 
control O 
) O 
, O 
100 O 
, O 
300 O 
, O 
or O 
1000mg O 
/ O 
kg O 
bw O 
/ O 
day O 
for O 
one O 
generation O 
( O 
F0 O 
) O 
. O 
The O 
study O 
followed O 
the O 
treated O 
F0 O 
generation O 
through O 
mating O 
, O 
gestation O 
, O 
lactation O 
, O 
and O 
weaning O 
of O 
the O 
F1 O 
generation O 
. O 
F1 O 
animals O 
were O 
mated O 
and O 
followed O 
to O 
gestation O 
day O 
( O 
GD O 
) O 
15-17 O 
at O 
which O 
time O 
F2 O 
implants O 
were O 
evaluated O 
. O 
There O 
were O 
no O 
indications O 
from O 
the O 
various O 
clinical O 
and O 
gross O 
pathological O 
examinations O 
that O 
the O 
oral O 
administration O 
of O 
PEG-PVA B-ABBREVIATION 
grafted O 
copolymer O 
to O 
the O 
F0-parental O 
rats O 
produced O 
any O 
signs O 
of O 
general O 
, O 
reproductive O 
, O 
or O 
developmental O 
toxicity O 
in O 
the O 
F0 O 
or O 
F1 O 
animals O 
or O 
F2 O 
implants O 
. O 
Based O 
on O 
the O 
lack O 
of O 
any O 
dose O 
- O 
related O 
or O 
biologically O 
relevant O 
effects O 
on O 
fertility O 
, O 
reproduction O 
, O 
development O 
, O 
and O 
overall O 
health O 
of O 
rats O 
gavaged O 
with O 
PEG-PVA B-ABBREVIATION 
grafted O 
copolymer O 
and O 
their O 
progeny O 
, O 
the O 
no O 
- O 
observed O 
- O 
adverse O 
effect O 
level O 
( O 
NOAEL O 
) O 
was O 
determined O 
to O 
be O 
the O 
highest O 
dose O 
tested O 
of O 
1000mg O 
/ O 
kg O 
bw O 
/ O 
day O 
. O 

the O 
recent O 
interest O 
of O 
protease O 
- O 
activated O 
receptors O 
( O 
PAR O 
) O 
1 O 
and O 
PAR4 O 
as O 
possible O 
targets O 
for O 
the O 
treatment O 
of O 
thrombotic O 
disorders O 
, O 
we O 
compared O 
the O 
efficacy O 
of O 
protease O 
- O 
activated O 
receptor O 
(PAR)1 O 
and O 
PAR4 O 
in O 
the O 
generation O 
of O 
procoagulant O 
phenotypes O 
on O 
platelet O 
membranes O 
. O 
PAR4-activating O 
peptide O 
(AP)-stimulated O 
platelets O 
promoted O 
thrombin O 
generation O 
in O 
plasma O 
up O 
to O 
5 O 
minutes O 
earlier O 
than O 
PAR1-AP-stimulated O 
platelets O 
. O 
PAR4-AP O 
- O 
mediated O 
factor O 
V O 
( O 
FV O 
) O 
association O 
with O 
the O 
platelet O 
surface O 
was O 
1.6-fold O 
greater O 
than O 
for O 
PAR1-AP O 
. O 
Moreover O 
, O 
PAR4 O 
stimulation O 
resulted O 
in O 
a O 
3-fold O 
greater O 
release O 
of O 
microparticles O 
, O 
compared O 
with O 
PAR1 O 
stimulation O 
. O 
More O 
robust O 
FV O 
secretion O 
and O 
microparticle O 
generation O 
with O 
PAR4-AP O 
was O 
attributable O 
to O 
stronger O 
and O 
more O 
sustained O 
phosphorylation O 
of O 
myosin O 
light O 
chain O 
at O 
serine B-TRIVIAL 
19 O 
and O 
threonine B-TRIVIAL 
18 O 
. O 
Inhibition O 
of O 
Rho-kinase O 
reduced O 
PAR4-AP O 
- O 
mediated O 
FV O 
secretion O 
and O 
microparticle O 
generation O 
to O 
PAR1-AP O 
- O 
mediated O 
levels O 
. O 
Thrombin O 
generation O 
assays O 
measuring O 
prothrombinase O 
complex O 
activity O 
demonstrated O 
1.5-fold O 
higher O 
peak O 
thrombin O 
levels O 
on O 
PAR4-AP-stimulated O 
platelets O 
, O 
compared O 
with O 
PAR1-AP-stimulated O 
platelets O 
. O 
Rho-kinase O 
inhibition O 
reduced O 
PAR4-AP O 
- O 
mediated O 
peak O 
thrombin O 
generation O 
by O 
25% O 
but O 
had O 
no O 
significant O 
effect O 
on O 
PAR1-AP O 
- O 
mediated O 
thrombin O 
generation O 
. O 
In O 
conclusion O 
, O 
stimulation O 
of O 
PAR4 O 
on O 
platelets O 
leads O 
to O 
faster O 
and O 
more O 
robust O 
thrombin O 
generation O 
, O 
compared O 
with O 
PAR1 O 
stimulation O 
. O 
The O 
greater O 
procoagulant O 
potential O 
is O 
related O 
to O 
more O 
efficient O 
FV O 
release O 
from O 
intracellular O 
stores O 
and O 
microparticle O 
production O 
driven O 
by O 
stronger O 
and O 
more O 
sustained O 
myosin O 
light O 
chain O 
phosphorylation O 
. O 
These O 
data O 
have O 
implications O 
about O 
the O 
role O 
of O 
PAR4 O 
during O 
hemostasis O 
and O 
are O 
clinically O 
relevant O 
in O 
light O 
of O 
recent O 
efforts O 
to O 
develop O 
PAR O 
antagonists O 
to O 
treat O 
thrombotic O 
disorders O 
. O 

weeks O 
of O 
high O 
- O 
fat O 
diet O 
feeding O 
causes O 
ghrelin O 
resistance O 
in O 
arcuate O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
/ O 
agouti O 
- O 
related O 
protein O 
( O 
AgRP O 
) O 
neurons O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
investigated O 
whether O 
diet O 
- O 
induced O 
weight O 
loss O 
could O 
restore O 
NPY O 
/ O 
AgRP O 
neuronal O 
responsiveness O 
to O 
ghrelin O 
and O 
whether O 
ghrelin O 
mediates O 
rebound O 
weight O 
gain O 
after O 
calorie O 
- O 
restricted O 
( O 
CR O 
) O 
weight O 
loss O 
. O 
Diet O 
- O 
induced O 
obese O 
( O 
DIO O 
) O 
mice O 
were O 
allocated O 
to O 
one O 
of O 
two O 
dietary O 
interventions O 
until O 
they O 
reached O 
the O 
weight O 
of O 
age O 
- O 
matched O 
lean O 
controls O 
. O 
DIO O 
mice O 
received O 
chow O 
diet O 
ad O 
libitum O 
or O 
chow O 
diet O 
with O 
40% O 
CR O 
. O 
Chow O 
- O 
fed O 
and O 
high O 
- O 
fat O 
- O 
fed O 
mice O 
served O 
as O 
controls O 
. O 
Both O 
dietary O 
interventions O 
normalized O 
body O 
weight O 
, O 
glucose B-TRIVIAL 
tolerance O 
, O 
and O 
plasma O 
insulin O 
. O 
We O 
show O 
that O 
diet O 
- O 
induced O 
weight O 
loss O 
with O 
CR O 
increases O 
total O 
plasma O 
ghrelin O 
, O 
restores O 
ghrelin O 
sensitivity O 
, O 
and O 
increases O 
hypothalamic O 
NPY O 
and O 
AgRP O 
mRNA O 
expression O 
. O 
We O 
propose O 
that O 
long O 
- O 
term O 
DIO O 
creates O 
a O 
higher O 
body O 
weight O 
set O 
- O 
point O 
and O 
that O 
weight O 
loss O 
induced O 
by O 
CR O 
, O 
as O 
seen O 
in O 
the O 
high O 
- O 
fat O 
CR O 
group O 
, O 
provokes O 
the O 
brain O 
to O 
protect O 
the O 
new O 
higher O 
set O 
- O 
point O 
. O 
This O 
adaptation O 
to O 
weight O 
loss O 
likely O 
contributes O 
to O 
rebound O 
weight O 
gain O 
by O 
increasing O 
peripheral O 
ghrelin O 
concentrations O 
and O 
restoring O 
the O 
function O 
of O 
ghrelin O 
- O 
responsive O 
neuronal O 
populations O 
in O 
the O 
hypothalamic O 
arcuate O 
nucleus O 
. O 
Indeed O 
, O 
we O 
also O 
show O 
that O 
DIO O 
ghrelin O 
- O 
knockout O 
mice O 
exhibit O 
reduced O 
body O 
weight O 
regain O 
after O 
CR O 
weight O 
loss O 
compared O 
with O 
ghrelin O 
wild O 
- O 
type O 
mice O 
, O 
suggesting O 
ghrelin O 
mediates O 
rebound O 
weight O 
gain O 
after O 
CR O 
weight O 
loss O 
. O 

of O 
bundled O 
and O 
individual O 
triple O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
by O 
resonant O 
Raman O 
spectroscopy O 
. O 

optical O 
characterization O 
of O 
bundled O 
and O 
individual O 
triple O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
was O 
studied O 
for O 
the O 
first O 
time O 
in O 
detail O 
by O 
using O 
resonant O 
Raman O 
spectroscopy O 
. O 
In O 
our O 
approach O 
, O 
the O 
outer O 
tube O 
of O 
a O 
triple O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
system O 
protects O 
the O 
two O 
inner O 
tubes O 
( O 
or O 
equivalently O 
the O 
inner O 
double O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
) O 
from O 
external O 
environment O 
interactions O 
making O 
them O 
a O 
partially O 
isolated O 
system O 
. O 
Following O 
the O 
spectral O 
changes O 
and O 
line O 
- O 
widths O 
of O 
the O 
radial O 
breathing O 
modes O 
and O 
G-band O 
by O 
performing O 
laser O 
energy O 
dependent O 
Raman O 
spectroscopy O 
, O 
it O 
is O 
possible O 
to O 
extract O 
important O 
information O 
as O 
regards O 
to O 
the O 
electronic O 
and O 
vibrational O 
properties O 
, O 
tube O 
diameters O 
, O 
wall O 
- O 
to O 
- O 
wall O 
distances O 
, O 
radial O 
breathing O 
mode O 
, O 
and O 
G-band O 
resonance O 
evolutions O 
as O 
well O 
as O 
high O 
- O 
curvature O 
intertube O 
interactions O 
in O 
isolated O 
double- O 
and O 
triple O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
systems O 
. O 

describe O 
the O 
outcome O 
of O 
patients O 
with O 
poorly O 
differentiated O 
thyroid O 
cancer O 
( O 
PDTC O 
) O 
presenting O 
with O 
gross O 
extrathyroidal O 
extension O 
( O 
ETE O 
) O 
. O 
After O 
IRB O 
approval O 
we O 
performed O 
retrospective O 
review O 
of O 
consecutive O 
series O 
of O 
thyroid O 
cancer O 
patients O 
treated O 
by O 
primary O 
surgical O 
resection O 
with O 
or O 
without O 
adjuvant O 
therapy O 
at O 
MSKCC O 
from O 
1986-2009 O 
. O 
Out O 
of O 
91 O 
PDTC O 
patients O 
, O 
27 O 
( O 
30% O 
) O 
had O 
gross O 
ETE O 
( O 
T4a O 
) O 
and O 
they O 
formed O 
the O 
basis O 
of O 
our O 
study O 
. O 
Of O 
27 O 
patients O 
, O 
52% O 
were O 
female O 
. O 
The O 
median O 
age O 
was O 
70 O 
( O 
range O 
27-87 O 
) O 
. O 
Ten O 
patients O 
( O 
37% O 
) O 
presented O 
with O 
distant O 
metastases O 
; O 
four O 
to O 
the O 
bone O 
, O 
three O 
to O 
lung O 
and O 
three O 
had O 
both O 
bone O 
and O 
lung O 
metastases O 
. O 
All O 
patients O 
had O 
extended O 
total O 
thyroidectomy O 
except O 
two O 
who O 
had O 
subtotal O 
thyroidectomy O 
. O 
20 O 
patients O 
( O 
74% O 
) O 
had O 
central O 
compartment O 
neck O 
dissection O 
and O 
11 O 
also O 
had O 
lateral O 
neck O 
dissection O 
. O 
Four O 
patients O 
had O 
pN0 O 
, O 
6 O 
( O 
30% O 
) O 
pN1a O 
and O 
10 O 
( O 
50% O 
) O 
pN1b O 
neck O 
disease O 
. O 
21 O 
patients O 
( O 
77% O 
) O 
had O 
adjuvant O 
therapy O 
: O 
15 O 
( O 
55% O 
) O 
RAI B-ABBREVIATION 
only O 
, O 
3 O 
( O 
11% O 
) O 
postoperative O 
external O 
beam O 
radiation O 
( O 
PORT O 
) O 
only O 
and O 
3 O 
( O 
11% O 
) O 
had O 
both O 
RAI B-ABBREVIATION 
and O 
PORT O 
. O 
Overall O 
survival O 
( O 
OS O 
) O 
, O 
disease O 
specific O 
survival O 
( O 
DSS O 
) O 
, O 
local O 
recurrence O 
free O 
survival O 
( O 
LRFS O 
) O 
and O 
regional O 
recurrence O 
free O 
survival O 
( O 
RRFS O 
) O 
were O 
calculated O 
by O 
the O 
Kaplan O 
Meier O 
method O 
. O 
Median O 
follow O 
- O 
up O 
time O 
was O 
57 O 
months O 
( O 
range O 
1-197 O 
months O 
) O 
. O 
The O 
5 O 
year O 
OS O 
and O 
DSS O 
were O 
47% O 
and O 
49% O 
respectively O 
. O 
This O 
poor O 
outcome O 
was O 
due O 
to O 
distant O 
metastatic O 
disease O 
; O 
10 O 
patients O 
had O 
distant O 
metastases O 
at O 
presentation O 
and O 
a O 
further O 
6 O 
developed O 
distant O 
metastases O 
during O 
follow O 
up O 
. O 
Locoregional O 
control O 
was O 
good O 
with O 
5 O 
year O 
LRFS O 
and O 
RRFS O 
of O 
70% O 
and O 
62% O 
respectively O 
. O 
Overall O 
, O 
8 O 
patients O 
( O 
30% O 
) O 
had O 
recurrences O 
: O 
2 O 
had O 
distant O 
alone O 
, O 
2 O 
regional O 
, O 
2 O 
regional O 
and O 
distant O 
, O 
1 O 
local O 
and O 
distant O 
, O 
and O 
1 O 
had O 
local O 
, O 
regional O 
and O 
distant O 
recurrence O 
. O 
Aggressive O 
surgery O 
in O 
patients O 
with O 
PDTC O 
showing O 
gross O 
ETE O 
resulted O 
in O 
satisfactory O 
locoregional O 
control O 
. O 
Due O 
to O 
the O 
small O 
proportion O 
of O 
patients O 
who O 
received O 
PORT O 
( O 
22% O 
) O 
, O 
it O 
is O 
not O 
possible O 
to O 
analyze O 
its O 
benefit O 
on O 
locoregional O 
control O 
. O 
Of O 
significance O 
is O 
the O 
observation O 
that O 
the O 
majority O 
of O 
patients O 
( O 
60% O 
) O 
who O 
presented O 
with O 
or O 
subsequently O 
developed O 
distant O 
metastases O 
eventually O 
died O 
of O 
distant O 
disease O 
. O 
New O 
systemic O 
therapies O 
to O 
target O 
distant O 
metastatic O 
disease O 
are O 
required O 
for O 
improvements O 
in O 
outcome O 
. O 

method O 
developed O 
for O 
the O 
first O 
time O 
, O 
to O 
create O 
a O 
huge O 
number O 
of O 
ionic O 
liquid O 
(IL)-in O 
- O 
oil O 
microemulsions O 
has O 
been O 
discussed O 
in O 
our O 
earlier O 
publication O 
( O 
Rao O 
, O 
V O 
. O 
G O 
. O 
; O 
Ghosh O 
, O 
S O 
. O 
; O 
Ghatak O 
, O 
C O 
. O 
; O 
Mandal O 
, O 
S O 
. O 
; O 
Brahmachari O 
, O 
U O 
. O 
; O 
Sarkar O 
, O 
N O 
. O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
B O 
2012 O 
, O 
116 O 
, O 
2850-2855 O 
) O 
. O 
Here O 
, O 
we O 
present O 
facile O 
methods O 
to O 
adjust O 
the O 
structural O 
parameters O 
of O 
microemulsions O 
using O 
different O 
ionic O 
liquids O 
( O 
ILs O 
) O 
as O 
additives O 
( O 
polar O 
phase O 
) O 
. O 
We O 
have O 
characterized O 
ILs/ O 
[C(4)mim][AOT] B-FORMULA 
/ O 
benzene B-SYSTEMATIC 
ternary O 
system O 
by O 
performing O 
a O 
phase O 
behavior O 
study O 
, O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
measurements O 
, O 
and O 
(1)H B-FORMULA 
NMR O 
measurements O 
. O 
The O 
IL O 
loading O 
capacity O 
of O 
microemulsions O 
( O 
area O 
of O 
single O 
phase O 
region O 
) O 
(i) O 
increases O 
with O 
increase O 
in O 
alkyl O 
chain O 
length O 
of O 
cation O 
of O 
ILs O 
and O 
follows O 
the O 
trend O 
[C(6)mim][TF(2)N] B-FORMULA 
> O 
[C(4)mim][TF(2)N] B-FORMULA 
> O 
[C(2)mim][TF(2)N] B-FORMULA 
, O 
(ii) O 
increases O 
with O 
decrease O 
in O 
cation O 
anion O 
interaction O 
strength O 
of O 
added O 
ILs O 
and O 
follows O 
the O 
trend O 
[C(4)mim][TF(2)N] B-FORMULA 
> O 
[C(4)mim][PF(6)] B-FORMULA 
> O 
[C(4)mim][BF(4)] B-FORMULA 
. O 
So O 
depending O 
on O 
the O 
IL O 
used O 
, O 
the O 
amount O 
of O 
IL O 
within O 
the O 
core O 
of O 
microemulsions O 
can O 
be O 
easily O 
manipulated O 
to O 
directly O 
affect O 
the O 
size O 
of O 
aggregates O 
in O 
microemulsions O 
. O 
The O 
size O 
increase O 
with O 
increasing O 
R O 
value O 
( O 
R O 
value O 
is O 
defined O 
as O 
the O 
molar O 
ratio O 
of O 
RTILs O 
to O 
[C(4)mim][AOT] B-FORMULA 
) O 
was O 
found O 
to O 
be O 
maximum O 
in O 
the O 
case O 
of O 
[C(2)mim][TF(2)N] B-FORMULA 
/ O 
[C(4)mim][AOT] B-FORMULA 
/ O 
benzene B-SYSTEMATIC 
microemulsions O 
and O 
follows O 
the O 
trend O 
[C(2)mim][TF(2)N] B-FORMULA 
> O 
[C(4)mim][TF(2)N] B-FORMULA 
> O 
[C(6)mim][TF(2)N] B-FORMULA 
. O 
However O 
, O 
the O 
size O 
increase O 
was O 
almost O 
the O 
same O 
with O 
increase O 
in O 
R O 
value O 
in O 
the O 
case O 
of O 
ILs O 
with O 
different O 
anions O 
. O 
The O 
most O 
promising O 
fact O 
about O 
IL-in O 
- O 
oil O 
microemulsions O 
is O 
their O 
high O 
thermal O 
stability O 
compared O 
to O 
that O 
of O 
aqueous O 
microemulsions O 
, O 
so O 
we O 
investigated O 
the O 
effect O 
of O 
temperature O 
on O 
size O 
of O 
aggregates O 
in O 
microemulsions O 
at O 
R O 
= O 
1 O 
. O 
It O 
is O 
evident O 
from O 
dynamic O 
light O 
scattering O 
measurements O 
that O 
the O 
aggregates O 
in O 
microemulsions O 
remain O 
monodisperse O 
in O 
nature O 
with O 
increasing O 
temperature O 
, O 
and O 
in O 
all O 
the O 
cases O 
, O 
the O 
size O 
of O 
aggregates O 
in O 
microemulsions O 
decreases O 
with O 
increasing O 
temperature O 
. O 
The O 
effect O 
of O 
water O 
addition O 
on O 
IL-in O 
- O 
oil O 
( O 
IL O 
/ O 
O O 
) O 
microemulsions O 
was O 
also O 
studied O 
in O 
detail O 
. O 
By O 
far O 
, O 
this O 
is O 
the O 
first O 
report O 
where O 
the O 
effect O 
of O 
water O 
addition O 
on O 
microemulsions O 
containing O 
hydrophobic O 
ILs O 
is O 
being O 
reported O 
and O 
compared O 
with O 
microemulsions O 
containing O 
hydrophilic O 
ILs O 
. O 
We O 
observed O 
that O 
the O 
added O 
water O 
has O 
a O 
prominent O 
effect O 
on O 
the O 
microstructure O 
of O 
the O 
microemulsions O 
. O 
In O 
all O 
the O 
cases O 
, O 
(1)H B-FORMULA 
NMR O 
spectra O 
provide O 
more O 
detailed O 
information O 
about O 
intra O 
/ O 
intermolecular O 
interactions O 
thus O 
affording O 
a O 
clear O 
picture O 
of O 
locations O 
of O 
(i) O 
the O 
RTILs O 
in O 
RTILs/ O 
[C(4)mim][AOT] B-FORMULA 
/ O 
benzene B-SYSTEMATIC 
microemulsions O 
and O 
(ii) O 
the O 
added O 
water O 
molecules O 
in O 
microemulsions O 
. O 

- O 
like O 
V2O5 B-FORMULA 
/ O 
poly(3,4-ethylenedioxythiophene) B-SYSTEMATIC 
& O 
MnO2 B-FORMULA 
nanowires O 
with O 
enhanced O 
electrochemical O 
cyclability O 
. O 

by O 
the O 
cucumber O 
- O 
like O 
structure O 
, O 
by O 
combining O 
the O 
in O 
situ O 
chemical O 
oxidative O 
polymerization O 
with O 
facile O 
soaking O 
process O 
, O 
we O 
designed O 
the O 
heterostructured O 
nanomaterial O 
with O 
PEDOT B-ABBREVIATION 
as O 
the O 
shell O 
and O 
MnO(2) B-FORMULA 
nanoparticles O 
as O 
the O 
protuberance O 
and O 
synthesized O 
the O 
novel O 
cucumber O 
- O 
like O 
MnO(2) B-FORMULA 
nanoparticles O 
enriched O 
vanadium B-SYSTEMATIC 
pentoxide I-SYSTEMATIC 
/ O 
poly(3,4-ethylenedioxythiophene) B-SYSTEMATIC 
( O 
PEDOT B-ABBREVIATION 
) O 
coaxial O 
nanowires O 
. O 
This O 
heterostructured O 
nanomaterial O 
exhibits O 
enhanced O 
electrochemical O 
cycling O 
performance O 
with O 
the O 
decreases O 
of O 
capacity O 
fading O 
during O 
200 O 
cycles O 
from O 
0.557 O 
to O 
0.173% O 
over O 
V(2)O(5) B-FORMULA 
nanowires O 
at O 
the O 
current O 
density O 
of O 
100 O 
mA O 
/ O 
g O 
. O 
This O 
method O 
is O 
proven O 
to O 
be O 
an O 
effective O 
technique O 
for O 
improving O 
the O 
electrochemical O 
cycling O 
performance O 
and O 
stability O 
of O 
nanowire O 
electrodes O 
especially O 
at O 
low O 
rate O 
for O 
application O 
in O 
rechargeable O 
lithium B-SYSTEMATIC 
batteries O 
. O 

chlorination O 
of O 
isoquinolines B-FAMILY 
by O 
a O 
fungal O 
flavin B-FAMILY 
-dependent O 
halogenase O 
. O 

is O 
the O 
first O 
flavin B-FAMILY 
-dependent O 
halogenase O 
identified O 
from O 
fungi O 
. O 
Based O 
on O 
the O 
reported O 
structure O 
of O 
the O 
bacterial O 
halogenase O 
CmlS O 
, O 
we O 
have O 
built O 
a O 
homology O 
model O 
for O 
Rdc2 O 
. O 
The O 
model O 
suggests O 
an O 
open O 
substrate O 
binding O 
site O 
that O 
is O 
capable O 
of O 
binding O 
the O 
natural O 
substrate O 
, O 
monocillin B-TRIVIAL 
II I-TRIVIAL 
, O 
and O 
possibly O 
other O 
molecules O 
such O 
as O 
4-hydroxyisoquinoline B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
6-hydroxyisoquinoline B-SYSTEMATIC 
( O 
2 O 
) O 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
halogenation O 
experiments O 
confirmed O 
that O 
1 O 
and O 
2 O 
can O 
be O 
halogenated O 
at O 
the O 
position O 
ortho O 
to O 
the O 
hydroxyl B-SYSTEMATIC 
group O 
, O 
leading O 
to O 
the O 
synthesis O 
of O 
the O 
chlorinated O 
isoquinolines B-FAMILY 
1a O 
and O 
2a O 
, O 
respectively O 
, O 
which O 
further O 
expands O 
the O 
spectrum O 
of O 
identified O 
substrates O 
of O 
Rdc2 O 
. O 
This O 
work O 
revealed O 
that O 
Rdc2 O 
is O 
a O 
useful O 
biocatalyst O 
for O 
the O 
synthesis O 
of O 
various O 
halogenated O 
compounds O 
. O 

such O 
as O 
nucleic O 
acids O 
, O 
proteins O 
/ O 
peptides O 
, O 
vaccines O 
, O 
anti-cancer O 
, O 
and O 
other O 
drugs O 
have O 
disadvantages O 
of O 
low O 
bio O 
- O 
availability O 
, O 
rapid O 
clearance O 
, O 
and O 
high O 
toxicity O 
. O 
Thus O 
, O 
there O 
is O 
a O 
significant O 
need O 
for O 
the O 
development O 
of O 
efficient O 
delivery O 
methods O 
and O 
carriers O 
. O 
Injectable O 
nanocarriers O 
have O 
received O 
much O 
attention O 
due O 
to O 
their O 
vast O 
range O 
of O 
structures O 
and O 
ability O 
to O 
contain O 
multiple O 
functional O 
groups O 
, O 
both O 
within O 
the O 
bulk O 
material O 
and O 
on O 
the O 
surface O 
of O 
the O 
particles O 
. O 
Nanocarriers O 
may O 
be O 
tailored O 
to O 
control O 
drug O 
release O 
and O 
/ O 
or O 
increase O 
selective O 
cell O 
targeting O 
, O 
cellular O 
uptake O 
, O 
drug O 
solubility O 
, O 
and O 
circulation O 
time O 
, O 
all O 
of O 
which O 
lead O 
to O 
a O 
more O 
efficacious O 
delivery O 
and O 
action O 
of O 
therapeutics O 
. O 
The O 
focus O 
of O 
this O 
review O 
is O 
injectable O 
, O 
targeted O 
nanoparticle O 
drug O 
delivery O 
carriers O 
highlighting O 
the O 
diversity O 
of O 
nanoparticle O 
materials O 
and O 
structures O 
as O 
well O 
as O 
highlighting O 
current O 
therapeutics O 
and O 
targeting O 
moieties O 
. O 
Structures O 
and O 
materials O 
discussed O 
include O 
liposomes O 
, O 
polymersomes O 
, O 
dendrimers B-FAMILY 
, O 
cyclodextrin O 
- O 
containing O 
polymers O 
( O 
CDPs O 
) O 
, O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
, O 
and O 
gold O 
nanoparticles O 
. O 
Additionally O 
, O 
current O 
clinical O 
trial O 
information O 
and O 
details O 
such O 
as O 
trial O 
phase O 
, O 
treatment O 
, O 
active O 
drug O 
, O 
carrier O 
sponsor O 
, O 
and O 
clinical O 
trial O 
identifier O 
for O 
different O 
materials O 
and O 
structures O 
are O 
presented O 
and O 
discussed O 
. O 

diaryl B-FAMILY 
ureas I-FAMILY 
with O 
efficacy O 
in O 
a O 
mouse O 
model O 
of O 
malaria O 
. O 

of O 
triclosan O 
analogs O 
has O 
led O 
to O 
novel O 
diaryl B-FAMILY 
ureas I-FAMILY 
with O 
significant O 
potency O 
against O 
in O 
vitro O 
cultures O 
of O 
drug O 
- O 
resistant O 
and O 
drug O 
- O 
sensitive O 
strains O 
of O 
the O 
human O 
malaria O 
parasite O 
Plasmodium O 
falciparum O 
. O 
Compound O 
18 O 
demonstrated O 
EC(50) O 
values O 
of O 
37 O 
and O 
55 O 
nM O 
versus O 
in O 
vitro O 
cultured O 
parasite O 
strains O 
and O 
promising O 
in O 
vivo O 
efficacy O 
in O 
a O 
Plasmodium O 
berghei O 
antimalarial O 
mouse O 
model O 
, O 
with O 
> O 
50% O 
survival O 
at O 
day O 
31 O 
post O 
- O 
treatment O 
when O 
administered O 
subcutaneously O 
at O 
256 O 
mg O 
/ O 
kg O 
. O 
This O 
series O 
of O 
compounds O 
provides O 
a O 
chemical O 
scaffold O 
of O 
novel O 
architecture O 
, O 
as O 
validated O 
by O 
cheminformatics O 
analysis O 
, O 
to O 
pursue O 
antimalarial O 
drug O 
discovery O 
efforts O 
. O 

exerts O 
antitumor O 
activity O 
against O 
human O 
osteosarcoma O 
cells O 
by O 
inhibiting O 
the O 
JAK2 O 
/ O 
STAT3 O 
signaling O 
pathway O 
. O 

is O 
a O 
high O 
- O 
grade O 
malignant O 
bone O 
tumor O 
. O 
Pterostilbene B-TRIVIAL 
( O 
PTE B-ABBREVIATION 
) O 
is O 
a O 
natural O 
, O 
dimethylated O 
analog O 
of O 
resveratrol B-TRIVIAL 
with O 
higher O 
bioavailability O 
. O 
While O 
PTE B-ABBREVIATION 
has O 
been O 
shown O 
to O 
have O 
potent O 
antitumor O 
activity O 
against O 
various O 
types O 
of O 
cancer O 
, O 
the O 
molecular O 
mechanisms O 
underlying O 
the O 
effects O 
of O 
PTE B-ABBREVIATION 
remain O 
largely O 
unknown O 
. O 
The O 
Janus O 
kinase O 
2 O 
/ O 
Signal O 
Transducer O 
and O 
Activator O 
of O 
Transcription O 
3 O 
( O 
JAK2 O 
/ O 
STAT3 O 
) O 
signaling O 
pathway O 
plays O 
a O 
crucial O 
role O 
in O 
tumorigenesis O 
and O 
immune O 
development O 
. O 
In O 
this O 
study O 
, O 
we O 
assessed O 
the O 
antitumor O 
activity O 
of O 
PTE B-ABBREVIATION 
against O 
human O 
osteosarcoma O 
cells O 
and O 
explored O 
the O 
role O 
of O 
JAK2 O 
/ O 
STAT3 O 
and O 
apoptosis O 
- O 
related O 
signaling O 
pathways O 
on O 
the O 
activity O 
of O 
PTE B-ABBREVIATION 
. O 
PTE B-ABBREVIATION 
treatment O 
resulted O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
inhibition O 
of O 
osteosarcoma O 
cell O 
viability O 
. O 
Additionally O 
, O 
PTE B-ABBREVIATION 
exhibited O 
strong O 
antitumor O 
activity O 
, O 
as O 
evidenced O 
not O 
only O 
by O 
reductions O 
in O 
tumor O 
cell O 
adhesion O 
, O 
migration O 
and O 
mitochondrial O 
membrane O 
potential O 
( O 
MMP O 
) O 
but O 
also O 
by O 
increases O 
in O 
the O 
apoptotic O 
index O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
several O 
biochemical O 
parameters O 
. O 
Furthermore O 
, O 
PTE B-ABBREVIATION 
treatment O 
directly O 
inhibited O 
the O 
phosphorylation O 
of O 
JAK2 O 
at O 
Tyr B-FORMULA 
1007 O 
and O 
the O 
downstream O 
activation O 
of O 
STAT3 O 
. O 
PTE B-ABBREVIATION 
also O 
down O 
- O 
regulated O 
the O 
expression O 
of O 
STAT3 O 
target O 
genes O 
, O 
including O 
the O 
anti-apoptotic O 
proteins O 
Bcl-xL O 
and O 
Mcl-1 O 
, O 
leading O 
to O 
the O 
up O 
- O 
regulation O 
of O 
mitochondrial O 
apoptosis O 
pathway O 
- O 
related O 
proteins O 
( O 
Bax O 
, O 
Bak O 
, O 
cytosolic O 
Cytochrome O 
c O 
, O 
and O 
cleaved O 
Caspase3 O 
) O 
and O 
cyclin O 
- O 
dependent O 
kinase O 
inhibitors O 
such O 
as O 
p21 O 
and O 
p27 O 
. O 
PTE B-ABBREVIATION 
, O 
used O 
in O 
combination O 
with O 
a O 
known O 
JAK2 O 
/ O 
STAT3 O 
inhibitor O 
, O 
AG490 B-TRIVIAL 
, O 
further O 
decreased O 
the O 
viability O 
of O 
osteosarcoma O 
cells O 
. O 
Taken O 
together O 
, O 
PTE B-ABBREVIATION 
is O 
a O 
potent O 
inhibitor O 
of O 
osteosarcoma O 
cell O 
growth O 
that O 
targets O 
the O 
JAK2 O 
/ O 
STAT3 O 
signaling O 
pathway O 
. O 
These O 
data O 
suggest O 
that O 
inhibition O 
of O 
JAK2 O 
/ O 
STAT3 O 
signaling O 
is O 
a O 
novel O 
mechanism O 
of O 
action O 
for O 
PTE B-ABBREVIATION 
during O 
therapeutic O 
intervention O 
in O 
osteosarcoma O 
cancers O 
. O 

5 O 
' O 
truncated O 
snake O 
venom O 
metalloproteinase O 
was O 
identified O 
from O 
a O 
cDNA O 
library O 
constructed O 
from O 
venom O 
glands O 
of O 
an O 
eastern O 
diamondback O 
rattlesnake O 
( O 
Crotalus O 
adamanteus O 
) O 
. O 
The O 
5'-rapid O 
amplification O 
of O 
cDNA O 
ends O 
( O 
RACE O 
) O 
was O 
used O 
to O 
obtain O 
the O 
1865 O 
bp O 
full O 
- O 
length O 
cDNA O 
sequence O 
of O 
a O 
snake O 
venom O 
metalloproteinase O 
( O 
CamVMPII O 
) O 
. O 
CamVMPII O 
encodes O 
an O 
open O 
reading O 
frame O 
of O 
488 O 
amino B-FAMILY 
acids I-FAMILY 
, O 
which O 
includes O 
a O 
signal O 
peptide O 
, O 
a O 
pro O 
- O 
domain O 
, O 
a O 
metalloproteinase O 
domain O 
, O 
a O 
spacer O 
, O 
and O 
an O 
RGD-disintegrin O 
domain O 
. O 
The O 
predicted O 
amino O 
acid O 
sequence O 
of O 
CamVMPII O 
showed O 
a O 
91% O 
, O 
90% O 
, O 
83% O 
, O 
and O 
82% O 
sequence O 
homology O 
to O 
the O 
P-II O 
class O 
enzymes O 
of O 
C O 
. O 
adamanteus O 
metalloproteinase O 
2 O 
, O 
Crotalus O 
atrox O 
CaVMP-II O 
, O 
Gloydius O 
halys O 
agkistin O 
, O 
and O 
Protobothrops O 
jerdonii O 
jerdonitin O 
, O 
respectively O 
. O 
Disintegrins O 
are O 
potent O 
inhibitors O 
of O 
both O 
platelet O 
aggregation O 
and O 
integrin O 
- O 
dependent O 
cell O 
adhesion O 
. O 
Therefore O 
, O 
the O 
disintegrin O 
domain O 
( O 
Cam O 
- O 
dis O 
) O 
of O 
CamVMPII O 
was O 
amplified O 
by O 
PCR O 
, O 
cloned O 
into O 
a O 
pET-43.1a O 
vector O 
, O 
and O 
expressed O 
in O 
Escherichia O 
coli O 
BL21 O 
. O 
Affinity O 
purified O 
recombinantly O 
modified O 
Cam O 
- O 
dis O 
( O 
r-Cam O 
- O 
dis O 
) O 
with O 
a O 
yield O 
of O 
8.5 O 
mg O 
/ O 
L O 
culture O 
medium O 
was O 
cleaved O 
from O 
the O 
fusion O 
tags O 
by O 
enterokinase O 
cleavage O 
. O 
r-Cam O 
- O 
dis O 
was O 
further O 
purified O 
by O 
two O 
- O 
step O 
chromatography O 
consisting O 
of O 
HiTrap O 
™ O 
Benzamidine O 
FF O 
column O 
, O 
followed O 
by O 
Talon O 
Metal O 
affinity O 
column O 
with O 
a O 
final O 
yield O 
of O 
1 O 
mg O 
/ O 
L O 
culture O 
. O 
r-Cam O 
- O 
dis O 
was O 
able O 
to O 
inhibit O 
all O 
three O 
processes O 
of O 
platelet O 
thrombus O 
formation O 
including O 
platelet O 
adhesion O 
with O 
an O 
estimated O 
IC(50) O 
of O 
1 O 
nM O 
, O 
collagen- O 
and O 
ADP B-ABBREVIATION 
-induced O 
platelet O 
aggregation O 
with O 
the O 
estimated O 
IC(50)s O 
of O 
18 O 
and O 
6 O 
nM O 
, O 
respectively O 
, O 
and O 
platelet O 
function O 
on O 
clot O 
retraction O 
. O 
It O 
is O 
a O 
potent O 
anti-platelet O 
inhibitor O 
, O 
which O 
should O 
be O 
further O 
investigated O 
for O 
drug O 
discovery O 
to O 
treat O 
stroke O 
patients O 
or O 
patients O 
with O 
thrombotic O 
disorders O 
. O 

effects O 
of O 
1-nitro-2-phenylethane B-SYSTEMATIC 
, O 
the O 
main O 
constituent O 
of O 
the O 
essential O 
oil O 
of O 
Aniba O 
canelilla O 
, O 
in O 
superior O 
mesenteric O 
arteries O 
from O 
spontaneously O 
hypertensive O 
rats O 
. O 

present O 
study O 
investigated O 
the O 
mechanisms O 
underlying O 
the O 
vasorelaxant O 
effects O 
of O 
the O 
essential O 
oil O 
of O 
Aniba O 
canelilla O 
( O 
EOAC O 
) O 
and O 
its O 
main O 
constituent O 
1-nitro-2-phenylethane B-SYSTEMATIC 
( O 
NP O 
) O 
in O 
isolated O 
superior O 
mesenteric O 
artery O 
from O 
spontaneously O 
hypertensive O 
rats O 
( O 
SHRs O 
) O 
. O 
At O 
0.1-1000 O 
μg O 
/ O 
mL O 
, O 
EOAC O 
and O 
NP O 
relaxed O 
SMA O 
preparations O 
pre O 
- O 
contracted O 
with O 
75 O 
mM O 
KCl B-FORMULA 
with O 
IC(50) O 
( O 
geometric O 
mean O 
[ O 
95% O 
confidence O 
interval O 
] O 
) O 
values O 
of O 
294.19 O 
[ O 
158.20-94.64 O 
] O 
and O 
501.27 O 
[ O 
378.60-624.00 O 
] O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
; O 
or O 
with O 
phenylephrine B-TRIVIAL 
( O 
PHE B-ABBREVIATION 
) O 
( O 
IC(50)s=11.07 O 
[ O 
6.40-15.68 O 
] O 
and O 
7.91 O 
[4.08-11.74) O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
. O 
All O 
these O 
effects O 
were O 
reversible O 
and O 
remained O 
unaltered O 
by O 
vascular O 
endothelium O 
removal O 
. O 
In O 
preparations O 
maintained O 
under O 
Ca(2+) B-FORMULA 
-free O 
conditions O 
, O 
EOAC O 
and O 
NP O 
( O 
both O 
at O 
600 O 
μg O 
/ O 
mL O 
) O 
reduced O 
the O 
PHE- O 
, O 
but O 
not O 
the O 
caffeine B-TRIVIAL 
-induced O 
contraction O 
. O 
In O 
Ca(2+) B-FORMULA 
-free O 
and O 
high O 
K(+) B-FORMULA 
( O 
75 O 
mM O 
) O 
medium O 
, O 
the O 
contractions O 
produced O 
by O 
CaCl(2) B-FORMULA 
or O 
BaCl(2) B-FORMULA 
were O 
reduced O 
or O 
even O 
abolished O 
by O 
EOAC O 
and O 
NP O 
at O 
100 O 
and O 
600 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 
EOAC O 
and O 
NP O 
( O 
both O 
at O 
10-1000 O 
μg O 
/ O 
mL O 
) O 
also O 
relaxed O 
the O 
contraction O 
evoked O 
by O 
phorbol B-SYSTEMATIC 
dibutyrate I-SYSTEMATIC 
( O 
IC(50)=52.66 O 
[ O 
10.82-94.64 O 
] O 
and O 
39.13 O 
[ O 
31.55-46.72 O 
] O 
μg O 
/ O 
mL O 
, O 
respectively O 
) O 
. O 
It O 
is O 
concluded O 
that O 
NP O 
has O 
a O 
myogenic O 
endothelium O 
- O 
independent O 
vasorelaxant O 
effects O 
and O 
appears O 
to O 
be O 
the O 
active O 
principle O 
of O 
the O 
EOAC O 
. O 
Vasorelaxant O 
effect O 
induced O 
by O 
both O 
EOAC O 
and O 
NP O 
is O 
preferential O 
to O 
receptor O 
- O 
activated O 
pathways O 
and O 
it O 
appears O 
to O 
occur O 
intracellularly O 
more O 
than O 
a O 
superficial O 
action O 
restricted O 
to O 
the O 
membrane O 
environment O 
such O 
as O 
a O 
simple O 
blocking O 
activity O 
on O 
a O 
given O 
receptor O 
or O 
ion O 
channel O 
. O 

synthesis O 
of O 
bicyclic O 
depsipeptides O 
spiruchostatins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
and O 
investigation O 
of O 
their O 
histone O 
deacetylase O 
inhibitory O 
and O 
antiproliferative O 
activities O 
. O 

bicyclic O 
depsipeptide O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitors O 
spiruchostatins B-MULTIPLE 
C I-MULTIPLE 
and I-MULTIPLE 
D I-MULTIPLE 
were O 
synthesized O 
for O 
the O 
first O 
time O 
in O 
a O 
highly O 
convergent O 
and O 
unified O 
manner O 
. O 
The O 
method O 
features O 
the O 
amide B-FAMILY 
coupling O 
of O 
a O 
D-leucine-D-cysteine B-TRIVIAL 
- O 
or O 
D-valine-D-cysteine B-TRIVIAL 
-containing O 
segment O 
with O 
a O 
D-alanine B-TRIVIAL 
- O 
or O 
D-valine B-TRIVIAL 
-containing O 
segment O 
to O 
directly O 
assemble O 
the O 
corresponding O 
seco O 
- O 
acids O 
, O 
key O 
precursors O 
of O 
macrolactonization O 
. O 
The O 
HDAC O 
inhibitory O 
assay O 
and O 
cell O 
- O 
growth O 
inhibition O 
analysis O 
of O 
the O 
synthesized O 
depsipeptides O 
determined O 
the O 
order O 
of O 
potency O 
of O 
spiruchostatins B-MULTIPLE 
A-D I-MULTIPLE 
in O 
comparison O 
with O 
the O 
clinically O 
approved O 
depsipeptide O 
FK228 B-IDENTIFIER 
( O 
romidepsin B-TRIVIAL 
) O 
. O 
Novel O 
aspects O 
of O 
structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
were O 
revealed O 
. O 

and O 
synthesis O 
of O 
biaryl B-FAMILY 
aryl I-FAMILY 
stilbenes I-FAMILY 
/ O 
ethylenes B-FAMILY 
as O 
antimicrotubule O 
agents O 
. O 

new O 
series O 
of O 
compounds O 
E-2,3,4-trimethoxy-6-styrylbiphenyls B-FAMILY 
and O 
2,3,4-trimethoxy-6-(1-phenylvinyl)biphenyls B-FAMILY 
were O 
designed O 
, O 
synthesized O 
and O 
evaluated O 
for O 
antitubulin O 
activity O 
. O 
A O 
common O 
intermediate O 
4,5,6-trimethoxybiphenyl-2-carbaldehydes B-FAMILY 
was O 
employed O 
to O 
generate O 
the O 
two O 
scaffolds O 
. O 
Majority O 
of O 
the O 
analogs O 
inhibited O 
cell O 
proliferation O 
and O 
those O 
functionalized O 
with O 
3,4-(1,3-dioxolane) B-SYSTEMATIC 
and O 
3,4-difluoro B-SYSTEMATIC 
groups O 
were O 
identified O 
as O 
effective O 
inhibitors O 
in O 
both O 
the O 
series O 
. O 
Treatments O 
with O 
19b O 
, O 
19c O 
, O 
22b O 
and O 
22c O 
arrested O 
cells O 
at O 
G2 O 
/ O 
M O 
phase O 
, O 
disrupted O 
microtubule O 
network O 
, O 
accumulated O 
tubulin O 
in O 
the O 
soluble O 
fraction O 
and O 
manifested O 
an O 
increased O 
expression O 
of O 
the O 
G2 O 
/ O 
M O 
marker O 
, O 
Cyclin O 
B1 O 
. O 
Molecular O 
docking O 
analysis O 
demonstrated O 
the O 
interaction O 
of O 
these O 
compounds O 
at O 
the O 
colchicine B-TRIVIAL 
binding O 
site O 
of O 
tubulin O 
. O 

of O 
polyhexamethylene B-SYSTEMATIC 
biguanide I-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
PHMB B-ABBREVIATION 
) O 
with O 
phosphatidylcholine B-FAMILY 
containing O 
o O 
/ O 
w O 
emulsion O 
and O 
consequences O 
for O 
microbicidal O 
efficacy O 
and O 
cytotoxicity O 
. O 

- O 
in O 
- O 
water O 
( O 
o O 
/ O 
w O 
) O 
emulsions O 
containing O 
egg O 
yolk O 
phosphatidylcholine B-FAMILY 
( O 
EPC O 
) O 
were O 
combined O 
with O 
aqueous O 
polyhexamethylene B-SYSTEMATIC 
biguanide I-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
PHMB B-ABBREVIATION 
) O 
. O 
The O 
PHMB B-ABBREVIATION 
concentration O 
in O 
the O 
aqueous O 
phase O 
was O 
estimated O 
by O 
filtration O 
centrifugation O 
experiments O 
. O 
In O 
parallel O 
, O 
PHMB B-ABBREVIATION 
concentration O 
was O 
assessed O 
utilizing O 
cytotoxicity O 
assays O 
( O 
neutral B-TRIVIAL 
red I-TRIVIAL 
) O 
on O 
cultured O 
murine O 
fibroblasts O 
( O 
L929 O 
cells O 
) O 
and O 
tests O 
of O 
bactericidal O 
efficacy O 
on O 
either O 
Pseudomonas O 
aeruginosa O 
or O 
Staphylococcus O 
aureus O 
. O 
Biological O 
tests O 
were O 
performed O 
in O 
cell O 
culture O 
medium O 
. O 
Filtration O 
centrifugation O 
experiments O 
demonstrated O 
much O 
higher O 
aqueous O 
PHMB B-ABBREVIATION 
concentrations O 
than O 
did O 
the O 
assays O 
for O 
biologically O 
effective O 
PHMB B-ABBREVIATION 
. O 
Therefore O 
, O 
biological O 
test O 
systems O 
should O 
preferably O 
be O 
used O 
to O 
verify O 
effective O 
PHMB B-ABBREVIATION 
concentrations O 
. O 
Tests O 
of O 
microbicidal O 
efficacy O 
in O 
which O 
the O 
same O 
0.05% O 
PHMB B-ABBREVIATION 
o O 
/ O 
w O 
emulsion O 
was O 
re O 
- O 
used O 
8 O 
times O 
revealed O 
a O 
drug O 
delivery O 
system O 
activated O 
by O 
the O 
presence O 
of O 
test O 
bacteria O 
. O 

effects O 
of O 
resveratrol B-TRIVIAL 
on O 
embryonic O 
dorsal O 
root O 
ganglion O 
neurons O 
with O 
neurotoxicity O 
induced O 
by O 
ethanol B-SYSTEMATIC 
. O 

have O 
established O 
that O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
) O 
consumption O 
results O 
in O 
damage O 
to O 
the O 
peripheral O 
nervous O 
systems O 
. O 
Although O 
the O 
pathobiological O 
mechanism O 
is O 
still O 
unclear O 
, O 
oxidative O 
stress O 
is O 
known O 
to O 
play O 
an O 
important O 
role O 
in O 
EtOH B-FORMULA 
-induced O 
neurotoxicity O 
. O 
Because O 
resveratrol B-TRIVIAL 
( O 
Res B-ABBREVIATION 
) O 
is O 
attracting O 
increased O 
attention O 
due O 
to O 
its O 
antioxidative O 
properties O 
, O 
we O 
investigated O 
the O 
neuroprotective O 
efficacy O 
of O 
Res B-ABBREVIATION 
in O 
ethanol B-SYSTEMATIC 
-treated O 
embryonic O 
dorsal O 
root O 
ganglion O 
( O 
DRG O 
) O 
neurons O 
in O 
vitro O 
. O 
Organotypic O 
DRG O 
explants O 
and O 
a O 
dispersed O 
cell O 
culture O 
model O 
were O 
used O 
to O 
evaluate O 
the O 
effects O 
of O 
Res B-ABBREVIATION 
on O 
EtOH B-FORMULA 
-induced O 
neurotoxicity O 
. O 
Res B-ABBREVIATION 
increased O 
the O 
number O 
of O 
extended O 
nerve O 
fibers O 
and O 
neurons O 
that O 
migrated O 
from O 
the O 
DRG O 
explants O 
. O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
staining O 
and O 
terminal O 
deoxynucleotidyl-transferase O 
- O 
mediated O 
dUTP B-ABBREVIATION 
nick O 
- O 
end O 
- O 
labeling O 
analysis O 
showed O 
that O 
the O 
EtOH B-FORMULA 
-induced O 
apoptosis O 
was O 
inhibited O 
by O 
Res B-ABBREVIATION 
. O 
The O 
effects O 
of O 
Res B-ABBREVIATION 
were O 
blocked O 
by O 
the O 
5'-adenosine B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
-activated O 
protein O 
kinase O 
inhibitor O 
Compound O 
C O 
and O 
the O 
sirtuin O 
1 O 
inhibitor O 
nicotinamide B-TRIVIAL 
. O 
The O 
elevation O 
of O 
oxidative O 
/ O 
nitrosative O 
stress O 
, O 
as O 
measured O 
by O 
the O 
amount O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
malondialdehyde B-TRIVIAL 
, O 
nitrite B-SYSTEMATIC 
, O 
glutathione B-TRIVIAL 
and O 
superoxide B-TRIVIAL 
dismutase O 
activity O 
, O 
was O 
also O 
attenuated O 
by O 
Res B-ABBREVIATION 
. O 
The O 
data O 
from O 
the O 
present O 
study O 
indicate O 
that O 
Res B-ABBREVIATION 
protects O 
DRG O 
neurons O 
from O 
EtOH B-FORMULA 
-induced O 
neurotoxicity O 
. O 
Res B-ABBREVIATION 
and O 
its O 
derivative O 
may O 
be O 
effective O 
for O 
the O 
treatment O 
of O 
diseases O 
characterized O 
by O 
axonopathy O 
and O 
neuron O 
loss O 
induced O 
by O 
EtOH B-FORMULA 
. O 

uptake O 
of O 
folate B-TRIVIAL 
-decorated O 
triamcinolone B-TRIVIAL 
-encapsulating O 
nanoparticles O 
by O 
retinal O 
pigment O 
epithelium O 
cells O 
enhances O 
and O 
prolongs O 
antiangiogenic O 
activity O 
. O 

are O 
proposing O 
folate B-TRIVIAL 
-decorated O 
polymeric O 
nanoparticles O 
as O 
carriers O 
of O 
poorly O 
soluble O 
drug O 
molecules O 
for O 
intracellular O 
and O 
prolonged O 
delivery O 
to O 
retinal O 
pigment O 
epithelium O 
( O 
RPE O 
) O 
cells O 
. O 
RPE O 
is O 
a O 
monolayer O 
of O 
epithelial O 
cells O 
that O 
forms O 
the O 
outer O 
blood O 
- O 
retinal O 
barrier O 
in O 
the O 
posterior O 
segment O 
of O 
the O 
eye O 
, O 
and O 
is O 
also O 
implicated O 
in O 
the O 
pathology O 
of O 
, O 
such O 
as O 
neovascularization O 
in O 
age O 
- O 
related O 
macular O 
degeneration O 
( O 
AMD O 
) O 
. O 
In O 
this O 
study O 
, O 
folate B-TRIVIAL 
-functionalized O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-b- O 
polycaprolactone B-SYSTEMATIC 
( O 
folate B-TRIVIAL 
- O 
PEG B-ABBREVIATION 
-b- O 
PCL B-ABBREVIATION 
) O 
were O 
synthesized O 
for O 
assembling O 
into O 
nanoparticles O 
of O 
~130nm O 
. O 
These O 
nanoparticles O 
were O 
internalized O 
into O 
ARPE-19 O 
( O 
human O 
RPE O 
cell O 
line O 
) O 
via O 
receptor O 
- O 
mediated O 
endocytosis O 
, O 
and O 
the O 
cellular O 
uptake O 
was O 
significantly O 
higher O 
than O 
particles O 
without O 
folate B-TRIVIAL 
modification O 
. O 
Triamcinolone B-SYSTEMATIC 
acetonide I-SYSTEMATIC 
( O 
TA O 
) O 
was O 
efficiently O 
encapsulated O 
( O 
> O 
97% O 
) O 
into O 
the O 
folate B-TRIVIAL 
-decorated O 
nanoparticles O 
and O 
was O 
slowly O 
released O 
over O 
a O 
period O 
of O 
4 O 
weeks O 
at O 
pH O 
5.5 O 
and O 
8 O 
weeks O 
at O 
pH O 
7.4 O 
. O 
The O 
enhanced O 
uptake O 
and O 
controlled O 
release O 
resulted O 
in O 
prolonged O 
anti-angiogenic O 
gene O 
expression O 
of O 
RPE O 
cells O 
. O 
In O 
cell O 
culture O 
, O 
the O 
down O 
- O 
regulation O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
and O 
up O 
- O 
regulation O 
of O 
pigment O 
epithelium O 
derived O 
factor O 
( O 
PEDF O 
) O 
lasted O 
for O 
at O 
least O 
3 O 
weeks O 
. O 
Unlike O 
benzyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
, O 
the O 
surfactant O 
found O 
in O 
commercial O 
formulation O 
, O 
folate B-TRIVIAL 
-modified O 
nanoparticles O 
were O 
non-toxic O 
. O 
Furthermore O 
, O 
TA O 
became O 
less O 
cytotoxic O 
by O 
being O 
encapsulated O 
in O 
the O 
nanoparticles O 
. O 
Our O 
findings O 
suggest O 
that O 
folate B-TRIVIAL 
- O 
PEG B-ABBREVIATION 
- O 
PCL B-ABBREVIATION 
nanoparticles O 
are O 
promising O 
drug O 
carriers O 
for O 
RPE O 
targeting O 
. O 

of O 
temoporfin B-TRIVIAL 
-loaded O 
liposome O 
formulations O 
: O 
correlation O 
of O 
liposome O 
and O 
temoporfin B-TRIVIAL 
blood O 
concentration O 
. O 

formulations O 
of O 
the O 
highly O 
hydrophobic O 
photosensitizer O 
temoporfin B-TRIVIAL 
were O 
developed O 
in O 
order O 
to O 
overcome O 
solubility O 
- O 
related O 
problems O 
associated O 
with O 
the O 
current O 
therapy O 
scheme O 
. O 
We O 
have O 
incorporated O 
temoporfin B-TRIVIAL 
into O 
liposomes O 
of O 
varying O 
membrane O 
composition O 
, O 
cholesterol B-TRIVIAL 
content O 
, O 
and O 
vesicle O 
size O 
. O 
Specifically O 
, O 
two O 
phosphatidyl O 
oligoglycerols O 
were O 
compared O 
to O 
PEG2000-DSPE B-ABBREVIATION 
with O 
respect O 
to O 
the O 
ability O 
to O 
prolong O 
circulation O 
half O 
life O 
of O 
the O 
liposomal O 
carrier O 
. O 
We O 
measured O 
the O 
resulting O 
pharmacokinetic O 
profile O 
of O 
the O 
liposomal O 
carrier O 
and O 
the O 
incorporated O 
temoporfin B-TRIVIAL 
in O 
a O 
rat O 
model O 
employing O 
a O 
radioactive O 
lipid O 
label O 
and O 
(14)C-temoporfin B-SYSTEMATIC 
. O 
The O 
data O 
for O 
the O 
removal O 
of O 
liposomes O 
and O 
temoporfin B-TRIVIAL 
were O 
analyzed O 
in O 
terms O 
of O 
classical O 
pharmacokinetic O 
theory O 
assuming O 
a O 
two O 
- O 
compartment O 
model O 
. O 
This O 
model O 
, O 
however O 
, O 
does O 
not O 
allow O 
in O 
a O 
straightforward O 
manner O 
to O 
distinguish O 
between O 
temoporfin B-TRIVIAL 
eliminated O 
together O 
with O 
the O 
liposomal O 
carrier O 
and O 
temoporfin B-TRIVIAL 
that O 
is O 
first O 
transferred O 
to O 
other O 
blood O 
components O 
( O 
e O 
. O 
g O 
. O 
plasma O 
proteins O 
) O 
before O 
being O 
eliminated O 
from O 
the O 
blood O 
. O 
We O 
therefore O 
additionally O 
analyzed O 
the O 
data O 
based O 
on O 
two O 
separate O 
one O 
- O 
compartment O 
models O 
for O 
the O 
liposomes O 
and O 
temoporfin B-TRIVIAL 
. O 
The O 
model O 
yields O 
the O 
ratio O 
of O 
the O 
rate O 
constant O 
of O 
temoporfin B-TRIVIAL 
elimination O 
together O 
with O 
the O 
liposomal O 
carrier O 
and O 
the O 
rate O 
constant O 
of O 
temoporfin B-TRIVIAL 
elimination O 
following O 
the O 
transfer O 
to O 
e O 
. O 
g O 
. O 
plasma O 
proteins O 
. O 
Our O 
analysis O 
using O 
this O 
model O 
demonstrates O 
that O 
a O 
fraction O 
of O 
temoporfin B-TRIVIAL 
is O 
released O 
from O 
the O 
liposomes O 
prior O 
to O 
being O 
eliminated O 
from O 
the O 
blood O 
. O 
In O 
case O 
of O 
unmodified O 
liposomes O 
this O 
temoporfin B-TRIVIAL 
release O 
was O 
observed O 
to O 
increase O 
with O 
decreasing O 
bilayer O 
fluidity O 
, O 
indicating O 
an O 
accelerated O 
temoporfin B-TRIVIAL 
transfer O 
from O 
gel O 
- O 
phase O 
liposomes O 
to O 
e O 
. O 
g O 
. O 
plasma O 
proteins O 
. O 
Interestingly O 
, O 
liposomes O 
carrying O 
either O 
one O 
of O 
the O 
three O 
investigated O 
surface O 
- O 
modifying O 
agents O 
did O 
not O 
adhere O 
to O 
the O 
tendencies O 
observed O 
for O 
unmodified O 
liposomes O 
. O 
Although O 
surface O 
- O 
modified O 
liposomes O 
exhibited O 
improved O 
pharmacokinetic O 
properties O 
with O 
regard O 
to O 
the O 
liposomal O 
carrier O 
, O 
an O 
enhanced O 
temoporfin B-TRIVIAL 
loss O 
and O 
elimination O 
from O 
the O 
PEGylated O 
- O 
liposomes O 
was O 
observed O 
. O 
This O 
effect O 
was O 
more O 
pronounced O 
for O 
PEGylated O 
liposomes O 
than O 
for O 
the O 
two O 
oligo- O 
glycerols B-FAMILY 
. O 
Our O 
combined O 
experimental O 
- O 
theoretical O 
approach O 
for O 
in O 
vivo O 
plasma O 
re O 
- O 
distribution O 
of O 
liposomal O 
drugs O 
may O 
help O 
to O 
optimize O 
colloidal O 
drug O 
carrier O 
systems O 
. O 

of O 
protein O 
glycation O 
by O 
urea B-TRIVIAL 
and O 
thiourea B-SYSTEMATIC 
derivatives O 
of O 
glycine B-TRIVIAL 
/ O 
proline B-TRIVIAL 
conjugated O 
benzisoxazole B-SYSTEMATIC 
analogue O 
- O 
synthesis O 
and O 
structure O 
- O 
activity O 
studies O 
. O 

of O 
a O 
new O 
series O 
of O 
urea B-TRIVIAL 
/ O 
thiourea B-SYSTEMATIC 
derivatives O 
of O 
Gly B-FORMULA 
/ O 
Pro B-FORMULA 
conjugated O 
benzisoxazole B-SYSTEMATIC 
has O 
been O 
reported O 
. O 
Structure O 
of O 
the O 
compounds O 
was O 
characterized O 
by O 
physical O 
and O 
spectroscopical O 
data O 
and O 
has O 
been O 
screened O 
for O 
their O 
in O 
vitro O 
antiglycation O 
activity O 
. O 
Several O 
compounds O 
showed O 
promising O 
activity O 
with O 
IC(50) O 
< O 
5 O 
μM O 
compared O 
to O 
standard O 
rutin B-TRIVIAL 
( O 
IC(50) O 
= O 
41.9 O 
μM O 
) O 
. O 
Further O 
, O 
it O 
was O 
found O 
that O 
compounds O 
containing O 
methoxy B-SYSTEMATIC 
and O 
bromine B-SYSTEMATIC 
substituents O 
have O 
exerted O 
highly O 
potent O 
activity O 
. O 
Thus O 
, O 
the O 
title O 
compounds O 
represent O 
novel O 
class O 
of O 
potent O 
antiglycating O 
agents O 
. O 

of O 
17β-trenbolone B-SYSTEMATIC 
on O 
Eastern O 
and O 
Western O 
mosquitofish O 
( O 
Gambusia O 
holbrooki O 
and O 
G O 
. O 
affinis O 
) O 
anal O 
fin O 
growth O 
and O 
gene O 
expression O 
patterns O 
. O 

Eastern O 
and O 
Western O 
mosquitofish O 
( O 
Gambusia O 
holbrooki O 
and O 
G O 
. O 
affinis O 
) O 
are O 
potential O 
bioindicator O 
organisms O 
for O 
endocrine O 
disruptors O 
. O 
Male O 
mosquitofish O 
have O 
an O 
elongated O 
anal O 
fin O 
( O 
gonopodium O 
) O 
used O 
for O 
internal O 
fertilization O 
whose O 
formation O 
is O 
driven O 
by O 
androgens B-FAMILY 
. O 
Normal O 
female O 
mosquitofish O 
have O 
a O 
normal O 
, O 
rounded O 
anal O 
fin O 
which O 
undergoes O 
elongation O 
into O 
a O 
gonopodium O 
structure O 
when O 
female O 
mosquitofish O 
are O 
exposed O 
to O 
androgenic O 
chemicals O 
. O 
Significant O 
issues O 
with O 
using O 
mosquitofish O 
as O 
a O 
bioindicator O 
include O 
the O 
lack O 
of O 
knowledge O 
on O 
how O 
anal O 
fin O 
growth O 
in O 
females O 
corresponds O 
to O 
endpoints O 
relevant O 
to O 
biological O 
integrity O 
and O 
the O 
lack O 
of O 
information O 
on O 
the O 
molecular O 
pathways O 
that O 
regulate O 
anal O 
fin O 
growth O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
to O 
understand O 
how O 
androgen B-FAMILY 
-induced O 
anal O 
fin O 
elongation O 
relates O 
to O 
changes O 
in O 
endpoints O 
related O 
to O 
the O 
female O 
reproductive O 
system O 
and O 
to O 
understand O 
how O 
anal O 
fin O 
elongation O 
occurs O 
in O 
androgen B-FAMILY 
-exposed O 
female O 
mosquitofish O 
. O 
To O 
achieve O 
these O 
objectives O 
, O 
adult O 
female O 
G O 
. O 
holbrooki O 
were O 
exposed O 
to O 
a O 
vehicle O 
control O 
or O 
one O 
of O 
three O 
doses O 
of O 
the O 
androgen B-FAMILY 
17β-trenbolone B-SYSTEMATIC 
( O 
TB O 
) O 
at O 
nominal O 
concentrations O 
of O 
0.1 O 
, O 
1 O 
or O 
10 O 
μg O 
TB O 
/ O 
L O 
. O 
Anal O 
fin O 
measurements O 
were O 
taken O 
and O 
livers O 
were O 
used O 
for O 
quantitative O 
polymerase O 
chain O 
reaction O 
analysis O 
of O 
vitellogenin O 
( O 
vtg O 
) O 
mRNA O 
expression O 
at O 
multiple O 
time O 
points O 
. O 
10 O 
μg O 
TB O 
/ O 
L O 
induced O 
anal O 
fin O 
elongation O 
after O 
7 O 
days O 
of O 
treatment O 
( O 
one O 
- O 
way O 
ANOVA O 
, O 
p O 
< O 
0.05 O 
) O 
as O 
did O 
0.1 O 
and O 
1 O 
μg O 
TB O 
/ O 
L O 
at O 
later O 
time O 
points O 
( O 
one O 
- O 
way O 
ANOVA O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
10 O 
μg O 
TB O 
/ O 
L O 
significantly O 
reduced O 
hepatic O 
vtg O 
gene O 
expression O 
at O 
all O 
time O 
points O 
assessed O 
( O 
one O 
- O 
way O 
ANOVA O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
There O 
was O 
no O 
correlation O 
between O 
anal O 
fin O 
elongation O 
levels O 
and O 
vtg O 
gene O 
expression O 
( O 
Spearman's O 
ρ O 
, O 
p O 
> O 
0.05 O 
) O 
. O 
In O 
a O 
separate O 
experiment O 
, O 
female O 
G O 
. O 
holbrooki O 
and O 
G O 
. O 
affinis O 
were O 
exposed O 
to O 
the O 
vehicle O 
control O 
or O 
1 O 
μg O 
TB O 
/ O 
L O 
. O 
Anal O 
fins O 
were O 
used O 
for O 
qualitative O 
gene O 
expression O 
analysis O 
of O 
the O 
genes O 
sonic O 
hedgehog O 
( O 
shh O 
) O 
, O 
muscle O 
segment O 
homeobox O 
C O 
( O 
msxC O 
) O 
, O 
and O 
fibroblast O 
growth O 
factor O 
receptor O 
1 O 
( O 
fgfr1 O 
) O 
by O 
in O 
situ O 
hybridization O 
. O 
Shh O 
was O 
expressed O 
in O 
the O 
distal O 
tip O 
of O 
the O 
gonopodium O 
while O 
msxC O 
and O 
fgfr1 O 
were O 
more O 
widely O 
expressed O 
along O 
the O 
same O 
anal O 
fin O 
rays O 
during O 
androgen B-FAMILY 
exposure O 
. O 
These O 
data O 
provide O 
insight O 
into O 
the O 
molecular O 
pathways O 
involved O 
in O 
anal O 
fin O 
elongation O 
and O 
pave O 
the O 
way O 
for O 
future O 
work O 
toward O 
developing O 
the O 
mosquitofish O 
into O 
a O 
bioindicator O 
organism O 
for O 
endocrine O 
disruptors O 
. O 

and O 
metabolic O 
effects O 
of O 
a O 
short O 
- O 
term O 
exposure O 
to O 
nanoparticles O 
of O 
titanium B-SYSTEMATIC 
silicate I-SYSTEMATIC 
in O 
tadpoles O 
of O 
Pelophylax O 
perezi O 
( O 
Seoane O 
) O 
. O 

study O 
aimed O 
to O 
evaluate O 
sublethal O 
effects O 
of O 
a O 
short O 
- O 
term O 
exposure O 
( O 
96 O 
h O 
) O 
to O 
titanium B-SYSTEMATIC 
silicate I-SYSTEMATIC 
nanoparticles O 
( O 
TiSiO(4) B-FORMULA 
-NP O 
) O 
on O 
Pelophylax O 
perezi O 
tadpoles O 
. O 
Tadpoles O 
were O 
exposed O 
to O 
five O 
concentrations O 
of O 
TiSiO(4) B-FORMULA 
-NP O 
( O 
8.2 O 
, O 
10.2 O 
, O 
12.8 O 
, O 
16 O 
and O 
20 O 
mg O 
/ O 
L O 
) O 
plus O 
a O 
control O 
. O 
Effect O 
criteria O 
were O 
: O 
mortality O 
, O 
cholinesterases O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
, O 
lactate B-FAMILY 
dehydrogenase O 
, O 
and O 
catalase O 
activities O 
, O 
and O 
alanine B-TRIVIAL 
and O 
lactate B-FAMILY 
contents O 
. O 
Light O 
scattering O 
was O 
used O 
for O 
physical O 
characterization O 
of O 
TiSiO(4) B-FORMULA 
-NP O 
suspensions O 
, O 
revealing O 
a O 
high O 
aggregation O 
state O 
of O 
the O 
NP O 
, O 
consistent O 
with O 
low O 
z-potential O 
values O 
( O 
< O 
30 O 
mV O 
) O 
. O 
Mortality O 
among O 
TiSiO(4) B-FORMULA 
-NP O 
treatments O 
was O 
< O 
11% O 
. O 
Significant O 
differences O 
relatively O 
to O 
the O 
control O 
were O 
observed O 
at O 
the O 
biochemical O 
level O 
( O 
for O 
CAT O 
and O 
LDH O 
) O 
and O 
in O 
lactate O 
and O 
alanine O 
contents O 
, O 
which O 
may O 
end O 
- O 
up O 
in O 
increased O 
oxidative O 
stress O 
. O 
Overall O 
, O 
some O 
of O 
the O 
monitored O 
endpoints O 
suggest O 
metabolic O 
alterations O 
in O 
TiSiO(4) B-FORMULA 
-NP O 
exposed O 
tadpoles O 
, O 
highlighting O 
the O 
potential O 
of O 
TiSiO(4) B-FORMULA 
-NP O 
long O 
- O 
term O 
effects O 
on O 
these O 
organisms O 
. O 

induced O 
upregulation O 
of O 
apoptosis O 
related O 
genes O 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
gill O 
. O 

( O 
Cu B-FORMULA 
) O 
is O 
an O 
essential O 
micronutrient O 
that O 
, O 
when O 
present O 
in O 
high O 
concentrations O 
, O 
becomes O 
toxic O 
to O 
aquatic O 
organisms O 
. O 
It O 
is O 
known O 
that O 
Cu B-FORMULA 
toxicity O 
may O 
induce O 
apoptotic O 
cell O 
death O 
. O 
However O 
, O 
the O 
precise O 
mechanism O 
and O 
the O 
pathways O 
that O 
are O 
activated O 
, O 
in O 
fish O 
, O 
are O 
still O 
unclear O 
. O 
Thus O 
, O 
this O 
study O 
aimed O 
to O 
assess O 
which O 
apoptotic O 
pathways O 
are O 
triggered O 
by O 
Cu B-FORMULA 
, O 
in O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
gill O 
, O 
the O 
main O 
target O 
of O 
waterborne O 
pollutants O 
. O 
Fish O 
where O 
exposed O 
to O 
12.5 O 
and O 
100 O 
μg O 
/ O 
L O 
of O 
Cu B-FORMULA 
during O 
6 O 
, O 
12 O 
, O 
24 O 
and O 
48 O 
h O 
. O 
Fish O 
gills O 
were O 
collected O 
to O 
TUNEL O 
assay O 
and O 
mRNA O 
expression O 
analysis O 
of O 
selected O 
genes O 
by O 
real O 
time O 
PCR O 
. O 
An O 
approach O 
to O 
different O 
apoptosis O 
pathways O 
was O 
done O 
selecting O 
p53 O 
, O 
caspase-8 O 
, O 
caspase-9 O 
and O 
apoptosis O 
inducing O 
factor O 
( O 
AIF O 
) O 
genes O 
. O 
The O 
higher O 
incidence O 
of O 
TUNEL-positive O 
cells O 
, O 
in O 
gill O 
epithelia O 
of O 
the O 
exposed O 
fish O 
, O 
proved O 
that O 
Cu B-FORMULA 
induced O 
apoptosis O 
. O 
The O 
results O 
suggest O 
that O 
different O 
apoptosis O 
pathways O 
are O 
triggered O 
by O 
Cu B-FORMULA 
at O 
different O 
time O 
points O 
of O 
the O 
exposure O 
period O 
, O 
as O 
the O 
increase O 
in O 
transcripts O 
was O 
sequential O 
, O 
instead O 
of O 
simultaneous O 
. O 
Apoptosis O 
seems O 
to O 
be O 
initiated O 
via O 
intrinsic O 
pathway O 
( O 
caspase-9 O 
) O 
, O 
through O 
p53 O 
activation O 
; O 
then O 
followed O 
by O 
the O 
extrinsic O 
pathway O 
( O 
caspase-8 O 
) O 
and O 
finally O 
by O 
the O 
caspase O 
- O 
independent O 
pathway O 
( O 
AIF O 
) O 
. O 
A O 
possible O 
model O 
for O 
Cu B-FORMULA 
-induce O 
apoptosis O 
pathways O 
is O 
proposed O 
. O 

report O 
a O 
simple O 
and O 
effective O 
approach O 
for O 
the O 
preparation O 
of O 
double O 
layer O 
- O 
encapsulated O 
quantum O 
dots O 
( O 
DL-Qdots O 
) O 
composed O 
of O 
alkyl-capping O 
ligands O 
to O 
interdigitate O 
with O 
hydrophobic O 
, O 
protective O 
agents O 
on O 
the O 
surface O 
of O 
AgInS(2) B-FORMULA 
/ O 
ZnS B-FORMULA 
quantum O 
dots O 
( O 
Qdots O 
) O 
, O 
which O 
allow O 
phase O 
transfer O 
of O 
hydrophobic O 
Qdots O 
from O 
the O 
organic O 
phase O 
into O 
the O 
aqueous O 
phase O 
. O 
The O 
alkyl-capping O 
ligands O 
consist O 
of O 
a O 
hydrophobic O 
, O 
aliphatic O 
chain O 
and O 
different O 
functional O 
terminal O 
groups O 
( O 
e.g O 
. O 
, O 
carboxyl B-SYSTEMATIC 
, O 
amine B-SYSTEMATIC 
, O 
hydroxyl B-SYSTEMATIC 
, O 
and O 
thiol B-FAMILY 
groups O 
) O 
that O 
can O 
serve O 
as O 
reactive O 
sites O 
to O 
chemically O 
couple O 
with O 
other O 
materials O 
. O 
The O 
resulting O 
DL-Qdots O 
bearing O 
various O 
functional O 
groups O 
retain O 
good O 
fluorescence O 
properties O 
and O 
show O 
excellent O 
solubility O 
as O 
well O 
as O 
stability O 
over O 
a O 
range O 
of O 
pH O 
in O 
the O 
aqueous O 
phase O 
. O 
Cytotoxicity O 
studies O 
of O 
DL-Qdots O 
bearing O 
carboxyl B-SYSTEMATIC 
groups O 
( O 
DL-Qdots- O 
COOH B-FORMULA 
) O 
were O 
carried O 
out O 
against O 
human O 
cervical O 
( O 
HeLa O 
) O 
cancer O 
cells O 
to O 
elicit O 
no O 
apparent O 
toxicity O 
even O 
at O 
high O 
concentrations O 
of O 
300 O 
μg O 
mL(-1) O 
and O 
24 O 
h O 
of O 
incubation O 
. O 
To O 
demonstrate O 
their O 
potential O 
biomedical O 
application O 
, O 
DL-Qdots- O 
COOH B-FORMULA 
were O 
further O 
conjugated O 
with O 
folate B-TRIVIAL 
for O 
staining O 
in O 
HeLa O 
, O 
human O 
liver O 
carcinoma O 
( O 
HepG2 O 
) O 
, O 
and O 
human O 
breast O 
( O 
MCF-7 O 
) O 
cancer O 
cells O 
. O 
Confocal O 
imaging O 
characterization O 
revealed O 
that O 
folate B-TRIVIAL 
-conjugated O 
DL-Qdots O 
could O 
target O 
most O 
specifically O 
and O 
effectively O 
HeLa O 
cells O 
via O 
folate B-TRIVIAL 
receptor O 
- O 
mediated O 
targeted O 
delivery O 
compared O 
to O 
HepG2 O 
and O 
MCF-7 O 
cells O 
. O 
The O 
generality O 
and O 
simplicity O 
of O 
this O 
newly O 
developed O 
strategy O 
can O 
possibly O 
be O 
extended O 
to O 
a O 
large O 
variety O 
of O 
hydrophobic O 
Qdots O 
and O 
nanocrystals O 
whose O 
surface O 
protective O 
agents O 
have O 
a O 
long O 
aliphatic O 
chain O 
. O 

hypolipidemic O 
effect O 
of O 
10% O 
fruit O 
fibers O 
in O 
rats O 
fed O 
with O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
was O 
evaluated O 
. O 
This O 
study O 
was O 
conducted O 
on O 
a O 
total O 
of O 
50 O 
male O 
Albino O 
rats O 
divided O 
into O 
10 O 
equal O 
groups O 
fed O 
with O 
different O 
types O 
of O 
dietary O 
fruits O 
. O 
The O 
feeding O 
period O 
lasted O 
for O 
24 O 
weeks O 
. O 
Fasting O 
blood O 
samples O 
were O 
collected O 
and O 
sera O 
separated O 
and O 
subjected O 
to O 
lipid O 
profile O 
assay O 
and O 
atherogenic O 
index O 
. O 
In O 
addition O 
, O 
total O 
antioxidant O 
activity O 
of O 
different O 
fruits O 
was O 
determined O 
. O 
The O 
results O 
obtained O 
showed O 
that O 
pomegranate O 
had O 
higher O 
content O 
of O 
antioxidants O 
followed O 
by O 
apple O 
, O 
strawberry O 
and O 
guava O 
compared O 
with O 
other O 
fruits O 
. O 
Rats O 
fed O 
with O 
20% O 
coconut O 
oil O 
showed O 
a O 
highly O 
significant O 
elevation O 
in O 
the O 
levels O 
of O 
serum O 
total O 
cholesterol B-TRIVIAL 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
and O 
atherogenic O 
factor O 
while O 
the O 
level O 
of O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
was O 
significantly O 
decreased O 
when O 
compared O 
with O 
control O 
rats O 
. O 
Histological O 
examination O 
revealed O 
that O 
there O 
was O 
a O 
large O 
lipid O 
and O 
cholesterol B-TRIVIAL 
deposition O 
in O 
the O 
livers O 
of O 
rats O 
fed O 
with O 
HFD O 
. O 
The O 
potential O 
in O 
lowering O 
the O 
levels O 
of O 
plasma O 
total O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
is O 
in O 
the O 
following O 
order O 
: O 
pomegranate O 
> O 
apple O 
> O 
strawberry O 
> O 
guava O 
> O 
papaya O 
> O 
mandarin O 
and O 
orange O 
. O 
Accumulation O 
of O 
hepatic O 
lipid O 
droplets O 
was O 
diminished O 
when O 
compared O 
with O 
the O 
HFD O 
group O 
. O 
Also O 
, O 
antiatherogenic O 
is O 
better O 
than O 
the O 
untreated O 
groups O 
. O 
Accordingly O 
these O 
hypolipidemic O 
effects O 
may O 
be O 
due O 
to O 
high O 
- O 
fiber O 
content O 
and O 
antioxidant O 
activity O 
of O 
these O 
fruits O 
. O 

: O 
Transaldolase O 
deficiency O 
is O 
a O 
recently O 
described O 
inborn O 
error O 
of O 
pentose B-FAMILY 
phosphate I-FAMILY 
pathway O 
. O 
We O 
conducted O 
this O 
study O 
to O 
further O 
delineate O 
the O 
associated O 
phenotype O 
. O 
METHODS O 
AND O 
RESULTS O 
: O 
We O 
report O 
on O 
12 O 
new O 
cases O 
representing O 
six O 
families O 
with O 
this O 
metabolic O 
defect O 
that O 
were O 
observed O 
over O 
an O 
8 O 
year O 
span O 
. O 
None O 
of O 
these O 
cases O 
received O 
the O 
correct O 
diagnosis O 
initially O 
because O 
of O 
significant O 
overlap O 
in O 
the O 
presenting O 
symptoms O 
( O 
growth O 
retardation O 
, O 
dysmorphic O 
features O 
, O 
cutis O 
laxa O 
, O 
congenital O 
heart O 
disease O 
, O 
hepatosplenomegaly O 
, O 
pancytopenia O 
, O 
and O 
bleeding O 
tendency O 
) O 
with O 
a O 
wide O 
range O 
of O 
genetic O 
disorders O 
. O 
However O 
, O 
the O 
consanguineous O 
nature O 
of O 
these O 
families O 
allowed O 
us O 
to O 
pursue O 
autozygome O 
analysis O 
, O 
which O 
highlighted O 
TALDO O 
as O 
the O 
likely O 
candidate O 
gene O 
and O 
sequencing O 
confirmed O 
segregation O 
of O 
a O 
novel O 
homozygous O 
mutation O 
with O 
the O 
disease O 
in O 
all O 
the O 
studied O 
families O 
. O 
Biochemical O 
analysis O 
was O 
also O 
consistent O 
with O 
transaldolase O 
deficiency O 
. O 
CONCLUSION O 
: O 
This O 
study O 
expands O 
the O 
clinical O 
definition O 
of O 
transaldolase O 
deficiency O 
, O 
and O 
adds O 
to O 
its O 
allelic O 
heterogeneity O 
. O 
In O 
addition O 
, O 
we O 
emphasize O 
the O 
diagnostic O 
challenge O 
posed O 
by O 
this O 
rare O 
and O 
pleiotropic O 
metabolic O 
disorder O 
. O 

of O 
the O 
purinergic O 
inhibitor O 
oxidized O 
ATP B-ABBREVIATION 
in O 
a O 
model O 
of O 
islet O 
allograft O 
rejection O 
. O 

lymphocytic O 
ionotropic O 
purinergic O 
P2X O 
receptors O 
( O 
P2X1R-P2X7R O 
, O 
or O 
P2XRs O 
) O 
sense O 
ATP B-ABBREVIATION 
released O 
during O 
cell O 
damage O 
- O 
activation O 
, O 
thus O 
regulating O 
T-cell O 
activation O 
. O 
We O 
aim O 
to O 
define O 
the O 
role O 
of O 
P2XRs O 
during O 
islet O 
allograft O 
rejection O 
and O 
to O 
establish O 
a O 
novel O 
anti-P2XRs O 
strategy O 
to O 
achieve O 
long O 
- O 
term O 
islet O 
allograft O 
function O 
. O 
Our O 
data O 
demonstrate O 
that O 
P2X1R O 
and O 
P2X7R O 
are O 
induced O 
in O 
islet O 
allograft O 
- O 
infiltrating O 
cells O 
, O 
that O 
only O 
P2X7R O 
is O 
increasingly O 
expressed O 
during O 
alloimmune O 
response O 
, O 
and O 
that O 
P2X1R O 
is O 
augmented O 
in O 
both O 
allogeneic O 
and O 
syngeneic O 
transplantation O 
. O 
In O 
vivo O 
short O 
- O 
term O 
P2X7R O 
targeting O 
( O 
using O 
periodate O 
- O 
oxidized O 
ATP B-ABBREVIATION 
[ O 
oATP B-ABBREVIATION 
] O 
) O 
delays O 
islet O 
allograft O 
rejection O 
, O 
reduces O 
the O 
frequency O 
of O 
Th1 O 
/ O 
Th17 O 
cells O 
, O 
and O 
induces O 
hyporesponsiveness O 
toward O 
donor O 
antigens O 
. O 
oATP B-ABBREVIATION 
-treated O 
mice O 
displayed O 
preserved O 
islet O 
grafts O 
with O 
reduced O 
Th1 O 
transcripts O 
. O 
P2X7R O 
targeting O 
and O 
rapamycin B-TRIVIAL 
synergized O 
in O 
inducing O 
long O 
- O 
term O 
islet O 
function O 
in O 
80% O 
of O 
transplanted O 
mice O 
and O 
resulted O 
in O 
reshaping O 
of O 
the O 
recipient O 
immune O 
system O 
. O 
In O 
vitro O 
P2X7R O 
targeting O 
using O 
oATP B-ABBREVIATION 
reduced O 
T-cell O 
activation O 
and O 
diminished O 
Th1 O 
/ O 
Th17 O 
cytokine O 
production O 
. O 
Peripheral O 
blood O 
mononuclear O 
cells O 
obtained O 
from O 
long O 
- O 
term O 
islet O 
- O 
transplanted O 
patients O 
showed O 
an O 
increased O 
percentage O 
of O 
P2X7R(+)CD4(+) O 
T O 
cells O 
compared O 
with O 
controls O 
. O 
The O 
beneficial O 
effects O 
of O 
oATP B-ABBREVIATION 
treatment O 
revealed O 
a O 
role O 
for O 
the O 
purinergic O 
system O 
in O 
islet O 
allograft O 
rejection O 
, O 
and O 
the O 
targeting O 
of O 
P2X7R O 
is O 
a O 
novel O 
strategy O 
to O 
induce O 
long O 
- O 
term O 
islet O 
allograft O 
function O 
. O 

- O 
level O 
domoic B-TRIVIAL 
acid I-TRIVIAL 
protects O 
mouse O 
cerebellar O 
granule O 
neurons O 
from O 
acute O 
neurotoxicity O 
: O 
role O 
of O 
glutathione B-TRIVIAL 
. O 

acid I-TRIVIAL 
( O 
DomA B-ABBREVIATION 
) O 
is O 
a O 
potent O 
marine O 
neurotoxin O 
. O 
By O 
activating O 
α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
/ O 
kainate B-TRIVIAL 
receptors O 
, O 
DomA B-ABBREVIATION 
induces O 
oxidative O 
stress O 
- O 
mediated O 
apoptotic O 
cell O 
death O 
in O 
neurons O 
. O 
The O 
effect O 
of O 
prolonged O 
( O 
10 O 
days O 
) O 
exposure O 
to O 
a O 
low O 
, O 
nontoxic O 
concentration O 
( O 
5nM O 
) O 
of O 
DomA B-ABBREVIATION 
on O 
acute O 
( O 
intermediate O 
concentration O 
) O 
neurotoxicity O 
of O 
this O 
toxin O 
was O 
investigated O 
in O 
cerebellar O 
granule O 
neurons O 
( O 
CGNs O 
) O 
from O 
wild O 
- O 
type O 
mice O 
and O 
mice O 
lacking O 
the O 
glutamate B-TRIVIAL 
cysteine B-TRIVIAL 
ligase O 
( O 
GCL O 
) O 
modifier O 
subunit O 
( O 
Gclm O 
( O 
/ O 
) O 
) O 
. O 
CGNs O 
from O 
Gclm O 
( O 
/ O 
) O 
mice O 
have O 
very O 
low O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
and O 
are O 
very O 
sensitive O 
to O 
DomA B-ABBREVIATION 
toxicity O 
. O 
In O 
CGNs O 
from O 
wild O 
- O 
type O 
mice O 
, O 
prolonged O 
exposure O 
to O 
5nM O 
DomA B-ABBREVIATION 
did O 
not O 
cause O 
any O 
overt O 
toxicity O 
but O 
reduced O 
oxidative O 
stress O 
- O 
mediated O 
apoptotic O 
cell O 
death O 
induced O 
by O 
exposure O 
to O 
an O 
intermediate O 
concentration O 
( O 
100nM O 
for O 
24h O 
) O 
of O 
DomA B-ABBREVIATION 
. O 
This O 
protection O 
was O 
not O 
observed O 
in O 
CGNs O 
from O 
Gclm O 
( O 
/ O 
) O 
mice O 
. O 
Prolonged O 
DomA B-ABBREVIATION 
exposure O 
increased O 
GSH B-ABBREVIATION 
levels O 
in O 
CGNs O 
of O 
wild O 
- O 
type O 
but O 
not O 
Gclm O 
( O 
/ O 
) O 
mice O 
. O 
Levels O 
of O 
GCLC O 
( O 
the O 
catalytic O 
subunit O 
of O 
GCL O 
) O 
protein O 
and O 
mRNA O 
were O 
increased O 
in O 
CGNs O 
of O 
both O 
mouse O 
strains O 
, O 
whereas O 
levels O 
of O 
GCLM O 
protein O 
and O 
mRNA O 
, O 
activity O 
of O 
GCL O 
, O 
and O 
levels O 
of O 
GCL O 
holoenzyme O 
were O 
only O 
increased O 
in O 
CGNs O 
of O 
wild O 
- O 
type O 
mice O 
. O 
Chronic O 
DomA B-ABBREVIATION 
exposure O 
also O 
protected O 
wild O 
- O 
type O 
CGNs O 
from O 
acute O 
toxicity O 
of O 
other O 
oxidants O 
. O 
The O 
results O 
indicate O 
that O 
CGNs O 
from O 
Gclm O 
( O 
/ O 
) O 
mice O 
, O 
which O 
are O 
already O 
more O 
sensitive O 
to O 
DomA B-ABBREVIATION 
toxicity O 
, O 
are O 
unable O 
to O 
upregulate O 
their O 
GSH B-ABBREVIATION 
levels O 
. O 
As O 
Gclm O 
( O 
/ O 
) O 
mice O 
may O 
represent O 
a O 
model O 
for O 
a O 
common O 
human O 
polymorphism O 
in O 
GCLM O 
, O 
such O 
individuals O 
may O 
be O 
at O 
particular O 
risk O 
for O 
DomA B-ABBREVIATION 
-induced O 
neurotoxicity O 
. O 

Glucose B-TRIVIAL 
During O 
an O 
Oral O 
Glucose B-TRIVIAL 
Challenge O 
Prospectively O 
Predicts O 
β-Cell O 
Deterioration O 
and O 
Prediabetes O 
in O 
Obese O 
Hispanic O 
Youth O 
. O 

adults O 
, O 
1-h O 
glucose B-TRIVIAL 
during O 
an O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
predicts O 
the O 
development O 
of O 
type O 
2 O 
diabetes O 
independent O 
of O 
fasting O 
and O 
2-h O 
glucose B-TRIVIAL 
concentrations O 
. O 
The O 
purpose O 
of O 
the O 
current O 
investigation O 
was O 
to O 
examine O 
the O 
utility O 
of O 
elevated O 
1-h O 
glucose B-TRIVIAL 
levels O 
to O 
prospectively O 
predict O 
deterioration O 
in O 
β-cell O 
function O 
and O 
the O 
development O 
of O 
prediabetes O 
in O 
high O 
- O 
risk O 
youth.RESEARCH O 
DESIGN O 
AND O 
METHODSObese O 
Latino O 
youth O 
with O 
a O 
family O 
history O 
of O 
type O 
2 O 
diabetes O 
( O 
133 O 
male O 
and O 
100 O 
female O 
; O 
age O 
11.1 O 
± O 
1.7 O 
years O 
) O 
completed O 
a O 
baseline O 
OGTT O 
and O 
were O 
divided O 
into O 
two O 
groups O 
based O 
upon O 
a O 
1-h O 
glucose B-TRIVIAL 
threshold O 
of O 
155 O 
mg O 
/ O 
dL O 
( O 
< O 
155 O 
mg O 
/ O 
dL O 
, O 
n O 
= O 
151 O 
, O 
or O 
≥ O 
155 O 
mg O 
/ O 
dL O 
, O 
n O 
= O 
82 O 
) O 
. O 
Youth O 
were O 
followed O 
annually O 
for O 
up O 
to O 
8 O 
years O 
for O 
assessment O 
of O 
glucose B-TRIVIAL 
tolerance O 
, O 
body O 
composition O 
by O 
dual O 
- O 
energy O 
X-ray O 
absorptiometry O 
, O 
and O 
insulin O 
sensitivity O 
, O 
insulin O 
secretion O 
, O 
and O 
the O 
disposition O 
index O 
by O 
the O 
frequently O 
sampled O 
intravenous O 
glucose B-TRIVIAL 
tolerance O 
test.RESULTSOver O 
time O 
, O 
the O 
≥ O 
155 O 
mg O 
/ O 
dL O 
group O 
exhibited O 
a O 
significantly O 
greater O 
decline O 
in O 
β-cell O 
function O 
compared O 
with O 
youth O 
with O 
a O 
1-h O 
glucose B-TRIVIAL 
< O 
155 O 
mg O 
/ O 
dL O 
( O 
β O 
= O 
-327.8 O 
± O 
126.2 O 
, O 
P O 
= O 
0.01 O 
) O 
. O 
Moreover O 
, O 
this O 
decline O 
was O 
independent O 
of O 
fasting O 
or O 
2-h O 
glucose B-TRIVIAL 
and O 
body O 
composition O 
. O 
When O 
the O 
data O 
were O 
restricted O 
to O 
only O 
participants O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
at O 
baseline O 
, O 
a O 
1-h O 
glucose B-TRIVIAL 
≥ O 
155 O 
mg O 
/ O 
dL O 
was O 
independently O 
associated O 
with O 
a O 
2.5 O 
times O 
greater O 
likelihood O 
of O 
developing O 
prediabetes O 
during O 
follow O 
- O 
up O 
( O 
95% O 
CI O 
1.6-4.1 O 
, O 
P O 
= O 
0.0001).CONCLUSIONSThese O 
data O 
suggest O 
that O 
a O 
1-h O 
glucose B-TRIVIAL 
≥ O 
155 O 
mg O 
/ O 
dL O 
during O 
an O 
OGTT O 
is O 
an O 
independent O 
predictor O 
of O 
β-cell O 
deterioration O 
and O 
progression O 
to O 
prediabetes O 
among O 
obese O 
Latino O 
youth O 
. O 

incorporation O 
of O 
InP B-FORMULA 
quantum-dot/ O 
N B-FORMULA 
-doped O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotube O 
( O 
QD O 
: O 
NCNT O 
) O 
nanohybrids O 
in O 
the O 
active O 
layer O 
of O 
poly(3-hexylthiophene) B-SYSTEMATIC 
/ O 
indene B-TRIVIAL 
- O 
C60 B-TRIVIAL 
bisadduct B-FAMILY 
( O 
P3HT B-ABBREVIATION 
/ O 
ICBA B-ABBREVIATION 
) O 
bulk O 
- O 
heterojuction O 
solar O 
cells O 
enhances O 
VOC O 
and O 
JSC O 
. O 
The O 
QDs O 
encourage O 
exciton O 
dissociation O 
by O 
promoting O 
electron O 
transfer O 
, O 
while O 
the O 
NCNTs O 
enhance O 
the O 
transport O 
of O 
the O 
separated O 
electrons O 
and O 
eventual O 
charge O 
collection O 
. O 
Such O 
a O 
synergistic O 
effect O 
successfully O 
improves O 
the O 
power O 
conversion O 
efficiency O 
( O 
PCE O 
) O 
from O 
4.68% O 
( O 
reference O 
cells O 
) O 
to O 
6.11% O 
. O 

protected I-FAMILY 
1,2-diphenylethylenediamine I-FAMILY 
-based O 
dendritic O 
organogels O 
with O 
multiple O 
- O 
stimulus O 
- O 
responsive O 
properties O 
. O 

new O 
class O 
of O 
poly(benzyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
) I-SYSTEMATIC 
dendrimers O 
, O 
decorated O 
in O 
their O 
cores O 
with O 
N-Boc- B-FAMILY 
protected I-FAMILY 
1,2-diphenylethylenediamine I-FAMILY 
groups O 
, O 
were O 
synthesized O 
and O 
fully O 
characterized O 
. O 
It O 
was O 
found O 
that O 
the O 
gelation O 
capability O 
of O 
these O 
dendrimers O 
was O 
highly O 
dependent O 
on O 
dendrimer O 
generation O 
, O 
and O 
the O 
second O 
- O 
generation O 
dendrimer O 
(R,R)-G(2)DPENBoc B-FORMULA 
proved O 
to O 
be O 
a O 
highly O 
efficient O 
organogelator O 
. O 
A O 
number O 
of O 
experiments O 
( O 
SEM O 
, O 
TEM O 
, O 
FTIR O 
spectroscopy O 
, O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
, O 
rheological O 
measurements O 
, O 
UV O 
/ O 
Vis O 
absorption O 
spectroscopy O 
, O 
CD O 
, O 
and O 
XRD O 
) O 
revealed O 
that O 
these O 
dendritic O 
molecules O 
self O 
- O 
assembled O 
into O 
elastically O 
interpenetrating O 
one O 
- O 
dimensional O 
nanostructures O 
in O 
organogels O 
. O 
The O 
hydrogen B-SYSTEMATIC 
bonding O 
, O 
π-π O 
, O 
and O 
solvophobic O 
interactions O 
were O 
found O 
to O 
be O 
the O 
main O 
driving O 
forces O 
for O 
formation O 
of O 
the O 
gels O 
. O 
Most O 
interestingly O 
, O 
these O 
dendritic O 
organogels O 
exhibited O 
smart O 
multiple O 
- O 
stimulus O 
- O 
responsive O 
behavior O 
upon O 
exposure O 
to O 
environmental O 
stimuli O 
such O 
as O 
temperature O 
, O 
anions O 
, O 
and O 
mechanical O 
stress O 
. O 

resource O 
: O 
tissue- O 
and O 
pathway O 
- O 
specific O 
metabolomic O 
profiles O 
of O 
the O 
steroid B-FAMILY 
receptor O 
coactivator O 
( O 
SRC O 
) O 
family O 
. O 

rapidly O 
growing O 
family O 
of O 
transcriptional O 
coregulators O 
includes O 
coactivators O 
that O 
promote O 
transcription O 
and O 
corepressors O 
that O 
harbor O 
the O 
opposing O 
function O 
. O 
In O 
recent O 
years O 
, O 
coregulators O 
have O 
emerged O 
as O 
important O 
regulators O 
of O 
metabolic O 
homeostasis O 
, O 
including O 
the O 
p160 O 
steroid B-FAMILY 
receptor O 
coactivator O 
( O 
SRC O 
) O 
family O 
. O 
Members O 
of O 
the O 
SRC O 
family O 
have O 
been O 
ascribed O 
important O 
roles O 
in O 
control O 
of O 
gluconeogenesis O 
, O 
fat O 
absorption O 
and O 
storage O 
in O 
the O 
liver O 
, O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
in O 
skeletal O 
muscle O 
. O 
To O 
provide O 
a O 
deeper O 
and O 
more O 
granular O 
understanding O 
of O 
the O 
metabolic O 
impact O 
of O 
the O 
SRC O 
family O 
members O 
, O 
we O 
performed O 
targeted O 
metabolomic O 
analyses O 
of O 
key O 
metabolic O 
byproducts O 
of O 
glucose B-TRIVIAL 
, O 
fatty B-FAMILY 
acid I-FAMILY 
, O 
and O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
in O 
mice O 
with O 
global O 
knockouts O 
( O 
KOs O 
) O 
of O 
SRC-1 O 
, O 
SRC-2 O 
, O 
or O 
SRC-3 O 
. O 
We O 
measured O 
amino B-FAMILY 
acids I-FAMILY 
, O 
acyl B-FAMILY 
carnitines I-FAMILY 
, O 
and O 
organic O 
acids O 
in O 
five O 
tissues O 
with O 
key O 
metabolic O 
functions O 
( O 
liver O 
, O 
heart O 
, O 
skeletal O 
muscle O 
, O 
brain O 
, O 
plasma O 
) O 
isolated O 
from O 
SRC-1 O 
, O 
-2 O 
, O 
or O 
-3 O 
KO O 
mice O 
and O 
their O 
wild O 
- O 
type O 
littermates O 
under O 
fed O 
and O 
fasted O 
conditions O 
, O 
thereby O 
unveiling O 
unique O 
metabolic O 
functions O 
of O 
each O 
SRC O 
. O 
Specifically O 
, O 
SRC-1 O 
ablation O 
revealed O 
the O 
most O 
significant O 
impact O 
on O 
hepatic O 
metabolism O 
, O 
whereas O 
SRC-2 O 
appeared O 
to O 
impact O 
cardiac O 
metabolism O 
. O 
Conversely O 
, O 
ablation O 
of O 
SRC-3 O 
primarily O 
affected O 
brain O 
and O 
skeletal O 
muscle O 
metabolism O 
. O 
Surprisingly O 
, O 
we O 
identified O 
very O 
few O 
metabolites O 
that O 
changed O 
universally O 
across O 
the O 
three O 
SRC O 
KO O 
models O 
. O 
The O 
findings O 
of O 
this O 
Research O 
Resource O 
demonstrate O 
that O 
coactivator O 
function O 
has O 
very O 
limited O 
metabolic O 
redundancy O 
even O 
within O 
the O 
homologous O 
SRC O 
family O 
. O 
Furthermore O 
, O 
this O 
work O 
also O 
demonstrates O 
the O 
use O 
of O 
metabolomics O 
as O 
a O 
means O 
for O 
identifying O 
novel O 
metabolic O 
regulatory O 
functions O 
of O 
transcriptional O 
coregulators O 
. O 

Pd B-FORMULA 
nanoparticle O 
- O 
containing O 
polymer O 
microsphere O 
moves O 
with O 
increasing O 
speed O 
across O 
a O 
pH O 
gradient O 
, O 
following O 
differential O 
catalytic O 
decomposition O 
of O 
aqueous O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 
The O 
directional O 
motion O 
is O 
akin O 
to O 
the O 
pH O 
taxis O 
of O 
living O 
microorganisms O 
. O 
The O 
artificial O 
pH O 
taxis O 
exhibits O 
random O 
walk O 
, O 
translation O 
, O 
vertical O 
, O 
hopping O 
, O 
and O 
pulsed O 
motion O 
, O 
when O 
the O 
size O 
of O 
the O 
motor O 
and O 
the O 
imposed O 
pH O 
gradient O 
are O 
modulated O 
. O 

- O 
and O 
manganite O 
- O 
based O 
contrast O 
agents O 
with O 
fluorescent O 
probes O 
for O 
both O 
magnetic O 
resonance O 
and O 
fluorescence O 
imaging O 
of O 
pancreatic O 
islets O 
: O 
a O 
comparative O 
study O 
. O 

magnetic O 
resonance O 
( O 
MR O 
) O 
/ O 
fluorescence O 
imaging O 
probes O 
were O 
tested O 
for O 
visualization O 
, O 
cellular O 
distribution O 
, O 
and O 
survival O 
of O 
labeled O 
pancreatic O 
islets O 
in O 
vitro O 
and O 
following O 
transplantation O 
. O 
As O 
T(1) O 
contrast O 
agents O 
( O 
CAs O 
) O 
, O 
gadolinium B-SYSTEMATIC 
(III) I-SYSTEMATIC 
complexes O 
linked O 
to O 
β-cyclodextrin B-TRIVIAL 
( O 
Gd-F-βCD B-FORMULA 
) O 
or O 
bound O 
to O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
@RhdGd O 
) O 
were O 
tested O 
. O 
As O 
a O 
T(2) O 
CA O 
, O 
perovskite O 
manganite O 
nanoparticles O 
( O 
LSMO@siF@si O 
) O 
were O 
examined O 
. O 
Fluorescein B-TRIVIAL 
or O 
rhodamine B-TRIVIAL 
was O 
incorporated O 
as O 
a O 
fluorescent O 
marker O 
in O 
all O 
probes O 
. O 
Islets O 
labeled O 
with O 
gadolinium B-SYSTEMATIC 
(III) I-SYSTEMATIC 
CAs O 
were O 
visible O 
as O 
hyperintense O 
spots O 
on O 
MR O 
in O 
vitro O 
, O 
but O 
detection O 
in O 
vivo O 
was O 
inconclusive O 
. O 
Islets O 
labeled O 
with O 
LSMO@siF@si O 
CA O 
were O 
clearly O 
visible O 
as O 
hypointense O 
spots O 
or O 
areas O 
on O 
MR O 
scans O 
in O 
vitro O 
as O 
well O 
as O 
in O 
vivo O 
. O 
All O 
CAs O 
were O 
detected O 
inside O 
the O 
islet O 
cells O 
by O 
fluorescence O 
. O 
Although O 
the O 
vitality O 
and O 
function O 
of O 
the O 
labeled O 
islets O 
was O 
not O 
impaired O 
by O 
any O 
of O 
the O 
tested O 
CAs O 
, O 
results O 
indicate O 
that O 
LSMO@siF@si O 
CA O 
is O 
a O 
superior O 
marker O 
for O 
islet O 
labeling O 
, O 
as O 
it O 
provides O 
better O 
contrast O 
enhancement O 
within O 
a O 
shorter O 
scan O 
time O 
. O 

quantum O 
efficiency O 
of O 
highly O 
efficient O 
perovskite B-TRIVIAL 
BaSnO₃ B-FORMULA 
-based O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

oxides B-FAMILY 
are O 
potential O 
candidates O 
as O 
an O 
electron O 
- O 
transporting O 
material O 
that O 
can O 
replace O 
TiO₂ B-FORMULA 
in O 
dye O 
- O 
sensitized O 
solar O 
cells O 
( O 
DSSCs O 
) O 
, O 
as O 
their O 
electronic O 
/ O 
optical O 
properties O 
can O 
be O 
easily O 
controlled O 
by O 
manipulating O 
the O 
composition O 
and O 
/ O 
or O 
by O 
doping O 
. O 
Here O 
, O 
we O 
report O 
a O 
new O 
highly O 
efficient O 
DSSC O 
using O 
perovskite B-TRIVIAL 
BaSnO₃ B-FORMULA 
( O 
BSO B-ABBREVIATION 
) O 
nanoparticles O 
. O 
In O 
addition O 
, O 
the O 
effects O 
of O 
a O 
TiCl₄ B-FORMULA 
treatment O 
on O 
the O 
physical O 
, O 
chemical O 
, O 
and O 
photovoltaic O 
properties O 
of O 
the O 
BSO B-ABBREVIATION 
-based O 
DSSCs O 
are O 
investigated O 
. O 
The O 
TiCl₄ B-FORMULA 
treatment O 
was O 
found O 
to O 
form O 
an O 
ultrathin O 
TiO₂ B-FORMULA 
layer O 
on O 
the O 
BSO B-ABBREVIATION 
surface O 
, O 
the O 
thickness O 
of O 
which O 
increases O 
with O 
the O 
treatment O 
time O 
. O 
The O 
formation O 
of O 
the O 
TiO₂ B-FORMULA 
shell O 
layer O 
improved O 
the O 
charge O 
- O 
collection O 
efficiency O 
by O 
enhancing O 
the O 
charge O 
transport O 
and O 
suppressing O 
the O 
charge O 
recombination O 
. O 
It O 
was O 
also O 
found O 
that O 
the O 
TiCl₄ B-FORMULA 
treatment O 
significantly O 
reduces O 
the O 
amount O 
of O 
surface O 
OH B-FORMULA 
species O 
, O 
resulting O 
in O 
reduced O 
dye O 
adsorption O 
and O 
reduced O 
light O 
- O 
harvesting O 
efficiency O 
. O 
The O 
trade-off O 
effect O 
between O 
the O 
charge O 
- O 
collection O 
and O 
light O 
- O 
harvesting O 
efficiencies O 
resulted O 
in O 
the O 
highest O 
quantum O 
efficiency O 
( O 
i.e O 
. O 
, O 
short O 
- O 
circuit O 
photocurrent O 
density O 
) O 
, O 
leading O 
to O 
the O 
highest O 
conversion O 
efficiency O 
of O 
5.5% O 
after O 
a O 
TiCl₄ B-FORMULA 
treatment O 
of O 
3 O 
min O 
( O 
cf O 
. O 
4.5% O 
for O 
bare O 
BSO B-ABBREVIATION 
) O 
. O 
The O 
conversion O 
efficiency O 
could O 
be O 
increased O 
further O 
to O 
6.2% O 
by O 
increasing O 
the O 
thickness O 
of O 
the O 
BSO B-ABBREVIATION 
film O 
, O 
which O 
is O 
one O 
of O 
the O 
highest O 
efficiencies O 
from O 
non- O 
TiO₂ B-FORMULA 
-based O 
DSSCs O 
. O 

group O 
of O 
proteases O 
, O 
the O 
matrix O 
metalloproteinases O 
( O 
MMPs O 
) O 
are O 
well O 
known O 
for O 
their O 
capacity O 
to O 
degrade O 
extracellular O 
matrix O 
( O 
ECM O 
) O 
proteins O 
. O 
Particularly O 
MMP-2 O 
and O 
MMP-9 O 
contribute O 
to O 
the O 
degradation O 
and O 
reorganization O 
of O 
the O 
ECM O 
components O 
and O 
are O 
involved O 
in O 
the O 
pathophysiology O 
of O 
cardiovascular O 
remodeling O 
. O 
Imbalanced O 
MMP O 
activity O 
promotes O 
vascular O 
smooth O 
muscle O 
cells O 
and O 
migration O 
and O 
proliferation O 
and O 
endothelial O 
dysfunction O 
, O 
thus O 
resulting O 
in O 
increased O 
cardiovascular O 
stiffness O 
and O 
hypertrophy O 
. O 
Furthermore O 
, O 
MMP-2 O 
cleaves O 
non-ECM O 
protein O 
substrates O 
including O 
cellular O 
receptors O 
and O 
intracellular O 
proteins O 
, O 
thus O 
causing O 
cardiac O 
and O 
vascular O 
dysfunction O 
. O 
It O 
is O 
now O 
becoming O 
clear O 
that O 
increased O 
MMP O 
activity O 
promotes O 
long O 
- O 
lasting O 
cardiovascular O 
structural O 
and O 
functional O 
alterations O 
in O 
both O 
experimental O 
and O 
clinical O 
hypertension O 
, O 
and O 
this O 
alteration O 
may O 
contribute O 
to O 
sustained O 
hypertension O 
and O 
its O 
complications O 
. O 
Other O 
pathogenic O 
mechanisms O 
including O 
activation O 
of O 
the O 
renin O 
- O 
angiotensin O 
- O 
aldosterone O 
system O 
and O 
oxidative O 
stress O 
activate O 
and O 
upregulate O 
MMPs O 
. O 
Therefore O 
, O 
MMP O 
inhibition O 
may O 
prevent O 
the O 
deleterious O 
consequences O 
of O 
hypertension O 
to O 
the O 
cardiovascular O 
system O 
. O 
This O 
review O 
article O 
will O 
focus O 
on O 
growing O 
evidence O 
supporting O 
the O 
relevance O 
of O 
MMPs O 
in O 
hypertension O 
and O 
the O 
effects O 
of O 
MMP O 
inhibitors O 
. O 
Particularly O 
, O 
the O 
effects O 
of O 
doxycycline B-TRIVIAL 
used O 
as O 
a O 
non O 
selective O 
MMP O 
inhibitor O 
in O 
experimental O 
and O 
clinical O 
studies O 
will O 
be O 
discussed O 
. O 

pulmonary O 
embolism O 
is O 
a O 
critical O 
condition O 
associated O 
with O 
increased O 
mortality O 
. O 
Lung O 
embolization O 
causes O 
acute O 
pulmonary O 
hypertension O 
and O 
right O 
ventricle O 
afterload O 
. O 
Global O 
heart O 
ischemia O 
supervenes O 
and O 
may O 
lead O 
to O 
severe O 
shock O 
and O 
death O 
. O 
In O 
this O 
article O 
, O 
we O 
reviewed O 
current O 
literature O 
supporting O 
the O 
idea O 
that O 
abnormal O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
activity O 
contributes O 
to O 
acute O 
pulmonary O 
embolism O 
- O 
induced O 
hemodynamic O 
changes O 
. O 
While O 
low O 
MMP O 
levels O 
are O 
usually O 
found O 
in O 
normal O 
lung O 
tissues O 
, O 
it O 
is O 
well O 
known O 
that O 
inflammation O 
and O 
lung O 
injury O 
increase O 
MMP O 
expression O 
and O 
activity O 
. O 
This O 
is O 
probably O 
due O 
to O 
recruitment O 
and O 
migration O 
of O 
inflammatory O 
cells O 
from O 
the O 
circulation O 
to O 
lung O 
tissues O 
. O 
In O 
addition O 
, O 
recent O 
studies O 
have O 
shown O 
increased O 
MMP O 
levels O 
and O 
activity O 
in O 
the O 
right O 
ventricle O 
from O 
animals O 
with O 
acute O 
pulmonary O 
embolism O 
. O 
Such O 
increases O 
in O 
proteolytic O 
activity O 
were O 
associated O 
with O 
increased O 
cardiac O 
troponin O 
I O 
in O 
serum O 
, O 
suggesting O 
a O 
possible O 
role O 
for O 
MMPs O 
in O 
cardiomyocyte O 
injury O 
during O 
acute O 
pulmonary O 
embolism O 
. O 
These O 
alterations O 
have O 
justified O 
the O 
use O 
of O 
doxycycline B-TRIVIAL 
as O 
an O 
MMP O 
inhibitor O 
in O 
acute O 
pulmonary O 
embolism O 
. O 
We O 
review O 
current O 
evidence O 
indicating O 
that O 
MMPs O 
are O 
targets O 
in O 
this O 
critical O 
condition O 
. O 
MMP O 
inhibition O 
apparently O 
exerts O 
antihypertensive O 
effects O 
and O 
protects O 
against O 
cardiomyocyte O 
injury O 
caused O 
by O 
acute O 
pulmonary O 
embolism O 
. O 

Novel O 
Marine O 
Drug O 
, O 
SZ-685C B-IDENTIFIER 
, O 
Induces O 
Apoptosis O 
of O 
MMQ O 
Pituitary O 
Tumor O 
Cells O 
by O 
Downregulating O 
miR-200c O 
. O 

: O 
We O 
found O 
a O 
novel O 
marine O 
drug O 
, O 
SZ-685C B-IDENTIFIER 
, O 
that O 
was O 
isolated O 
from O 
the O 
secondary O 
metabolites O 
of O 
a O 
mangrove O 
endophytic O 
fungus O 
( O 
No O 
. O 
1403 O 
) O 
collected O 
from O 
the O 
South O 
China O 
Sea O 
, O 
which O 
has O 
been O 
reported O 
to O 
inhibit O 
the O 
proliferation O 
of O 
certain O 
tumor O 
cells O 
. O 
However O 
, O 
its O 
anticancer O 
mechanism O 
remains O 
unknown O 
. O 
The O 
aims O 
of O 
this O 
study O 
were O 
to O 
observe O 
the O 
effectiveness O 
of O 
SZ-685C B-IDENTIFIER 
on O 
pituitary O 
adenoma O 
cells O 
and O 
determine O 
the O 
underlying O 
mechanisms O 
of O 
action O 
. O 
Methods O 
: O 
A O 
rat O 
prolactinoma O 
cell O 
line O 
, O 
MMQ O 
, O 
was O 
used O 
in O 
this O 
study O 
. O 
A O 
dose O 
escalation O 
of O 
SZ-685C B-IDENTIFIER 
was O 
performed O 
on O 
this O 
cell O 
line O 
, O 
and O 
cell O 
viability O 
was O 
assessed O 
using O 
an O 
MTT B-ABBREVIATION 
assay O 
. O 
Hoechst O 
33342 O 
, O 
Annexin O 
V- O 
FITC B-ABBREVIATION 
/ O 
PI O 
, O 
TUNEL O 
staining O 
and O 
flow O 
cytometry O 
were O 
used O 
to O 
evaluate O 
the O 
extent O 
of O 
apoptosis O 
at O 
each O 
concentration O 
of O 
SZ-685C B-IDENTIFIER 
. O 
The O 
effect O 
of O 
SZ-685C B-IDENTIFIER 
on O 
prolactin O 
expression O 
was O 
also O 
evaluated O 
using O 
RT-PCR O 
and O 
immunoblotting O 
. O 
Quantitative O 
RT-PCR O 
was O 
used O 
to O 
detect O 
the O 
expression O 
of O 
miR-200c O 
in O 
SZ-685C B-IDENTIFIER 
-stimulated O 
MMQ O 
cells O 
and O 
pituitary O 
adenoma O 
tissues O 
. O 
This O 
miRNA O 
was O 
then O 
overexpressed O 
in O 
MMQ O 
cells O 
via O 
transfection O 
of O 
a O 
miR-200c O 
mimic O 
to O 
identify O 
the O 
mechanism O 
underling O 
the O 
anti-tumor O 
effect O 
of O 
SZ-685C B-IDENTIFIER 
. O 
Results O 
: O 
SZ-685C B-IDENTIFIER 
inhibited O 
MMQ O 
cell O 
growth O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
but O 
showed O 
little O 
toxicity O 
toward O 
rat O 
pituitary O 
cells O 
( O 
RPCs O 
) O 
. O 
The O 
IC50s O 
of O 
SZ-685C B-IDENTIFIER 
in O 
MMQ O 
cells O 
and O 
RPCs O 
were O 
13.2 O 
± O 
1.3 O 
mM O 
and O 
49.1 O 
± O 
11.5 O 
mM O 
, O 
respectively O 
, O 
which O 
was O 
statistically O 
significant O 
. O 
Increasing O 
numbers O 
of O 
apoptotic O 
cells O 
were O 
observed O 
in O 
response O 
to O 
escalating O 
concentrations O 
of O 
SZ-685C B-IDENTIFIER 
, O 
and O 
the O 
expression O 
level O 
of O 
prolactin O 
( O 
PRL O 
) O 
was O 
inhibited O 
. O 
Nevertheless O 
, O 
the O 
level O 
of O 
PRL O 
mRNA O 
was O 
unchanged O 
. O 
Additionally O 
, O 
miR-200c O 
was O 
upregulated O 
in O 
MMQ O 
cells O 
compared O 
with O 
RPCs O 
, O 
and O 
downregulation O 
of O 
miR- O 
200c O 
was O 
observed O 
in O 
SZ-685C B-IDENTIFIER 
-treated O 
MMQ O 
cells O 
. O 
Furthermore O 
, O 
the O 
overexpression O 
of O 
miR-200c O 
weakened O 
the O 
effect O 
of O 
SZ-685C B-IDENTIFIER 
-induced O 
apoptosis O 
of O 
MMQ O 
cells O 
. O 
Conclusions O 
: O 
Our O 
results O 
suggest O 
that O 
SZ-685C B-IDENTIFIER 
induces O 
MMQ O 
cell O 
apoptosis O 
in O 
a O 
miR-200c-dependent O 
manner O 
. O 
Therefore O 
, O 
SZ-685C B-IDENTIFIER 
might O 
be O 
a O 
useful O 
alternative O 
treatment O 
for O 
pituitary O 
adenoma O 
. O 

Janus O 
family O 
kinases O 
( O 
JAKs O 
) O 
, O 
JAK1 O 
, O 
JAK2 O 
, O 
JAK3 O 
, O 
and O 
TYK2 O 
, O 
are O 
involved O 
in O 
cell O 
growth O 
, O 
survival O 
, O 
development O 
, O 
and O 
differentiation O 
of O 
a O 
variety O 
of O 
cells O 
, O 
particularly O 
immune O 
cells O 
and O 
hematopoietic O 
cells O 
. O 
They O 
form O 
a O 
subgroup O 
of O 
the O 
non-receptor O 
protein O 
tyrosine B-TRIVIAL 
kinases O 
. O 
Activating O 
mutations O 
within O 
each O 
of O 
the O 
JAKs O 
is O 
associated O 
with O 
malignant O 
transformations O 
; O 
the O 
most O 
common O 
are O 
mutations O 
of O 
JAK2 O 
in O 
polycythemia O 
vera O 
( O 
PV O 
) O 
and O 
other O 
myeloproliferative O 
neoplasms O 
( O 
MPN O 
) O 
. O 
Identification O 
of O 
the O 
V617F O 
mutation O 
of O 
the O 
JAK2 O 
gene O 
( O 
JAK2 O 
V617F O 
) O 
led O 
to O 
an O 
important O 
breakthrough O 
in O 
the O 
understanding O 
of O 
MPN O 
disease O 
pathogenesis O 
. O 
The O 
JAK2 O 
V617F O 
mutation O 
is O 
present O 
in O 
the O 
majority O 
of O 
PV O 
patients O 
, O 
and O 
about O 
50% O 
of O 
patients O 
with O 
essential O 
thrombocythemia O 
( O 
ET O 
) O 
and O 
primary O 
myelofibrosis O 
( O 
PMF O 
) O 
are O 
affected O 
. O 
This O 
mutation O 
leads O 
to O 
hyperactivation O 
of O 
JAK2 O 
, O 
cytokine O 
- O 
independent O 
signaling O 
, O 
and O 
subsequent O 
activation O 
of O 
downstream O 
signaling O 
networks O 
. O 
JAK2 O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
that O 
indirectly O 
inhibit O 
the O 
JAK-STAT O 
pathway O 
are O 
new O 
candidates O 
for O 
the O 
treatment O 
of O 
MPN O 
. O 
JAK2 O 
inhibitors O 
in O 
development O 
for O 
the O 
treatment O 
of O 
MPN O 
have O 
demonstrated O 
clinical O 
activity O 
with O 
minimal O 
toxicity O 
. O 
These O 
agents O 
consistently O 
alleviate O 
constitutional O 
symptoms O 
and O 
reduce O 
spleen O 
size O 
in O 
PMF O 
and O 
other O 
MPN O 
. O 
However O 
, O 
some O 
of O 
these O 
inhibitors O 
have O 
additional O 
unique O 
effects O 
. O 
Ruxolitinib B-TRIVIAL 
causes O 
a O 
significant O 
reduction O 
in O 
the O 
level O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
. O 
Another O 
inhibitor O 
, O 
CYT387 O 
, O 
improves O 
anemia O 
. O 
Many O 
other O 
JAK2 O 
inhibitors O 
such O 
as O 
TG101348 B-IDENTIFIER 
or O 
SAR302503 B-IDENTIFIER 
, O 
SB1518 B-IDENTIFIER 
, O 
CEP701 B-IDENTIFIER 
and O 
LY2784544 B-IDENTIFIER 
are O 
now O 
under O 
investigation O 
for O 
MPN O 
development O 
. O 
In O 
contrast O 
tasocitinib B-TRIVIAL 
, O 
a O 
predominantly O 
JAK3 O 
inhibitor O 
, O 
is O 
being O 
evaluated O 
in O 
a O 
number O 
of O 
inflammatory O 
and O 
immunological O 
diseases O 
, O 
including O 
rheumatoid O 
arthritis O 
, O 
psoriasis O 
, O 
ulcerative O 
colitis O 
, O 
dry O 
eye O 
disease O 
and O 
in O 
kidney O 
transplant O 
patients O 
. O 
In O 
conclusion O 
the O 
use O 
of O 
JAK O 
inhibitors O 
in O 
MPN O 
and O 
some O 
of O 
the O 
immune O 
- O 
mediated O 
disorders O 
is O 
a O 
promising O 
new O 
strategy O 
for O 
therapy O 
. O 
However O 
, O 
definitive O 
data O 
from O 
ongoing O 
and O 
future O 
preclinical O 
and O 
clinical O 
trials O 
will O 
aid O 
in O 
better O 
defining O 
the O 
status O 
of O 
these O 
drugs O 
in O 
the O 
treatment O 
of O 
these O 
diseases O 
. O 

, O 
genomics O 
and O 
proteomics O 
have O 
been O 
utilized O 
as O 
advanced O 
tools O 
for O 
investigation O 
of O 
cellular O 
signaling O 
pathways O 
and O 
molecular O 
interactions O 
, O 
and O 
elucidated O 
promiscuous O 
networks O 
composed O 
of O 
numerous O 
interactions O 
among O 
pathways O 
. O 
However O 
, O 
some O 
of O 
these O 
interactions O 
are O 
considered O 
to O 
be O 
simply O 
contributing O 
to O 
background O 
' O 
noise O 
' O 
and O 
others O 
are O 
as O 
' O 
crosstalk O 
' O 
biologically O 
- O 
relevant O 
to O 
cellular O 
physiology O 
, O 
leading O 
to O 
synergy O 
effects O 
more O 
than O 
additive O 
responses O 
in O 
an O 
entire O 
organism O 
. O 
Effort O 
is O 
now O 
required O 
to O 
determine O 
which O 
interactions O 
truly O 
contribute O 
to O 
final O 
physiological O 
output O 
. O 
A O 
receptor O 
is O 
the O 
prime O 
example O 
of O 
connectors O 
among O 
the O 
networks O 
. O 
It O 
functions O 
, O 
not O 
simply O 
as O 
a O 
signaling O 
gateway O 
, O 
but O 
also O 
as O 
an O 
active O 
trader O 
by O 
forming O 
inter O 
- O 
receptor O 
dimers O 
. O 
Furthermore O 
, O 
various O 
receptors O 
can O 
modulate O 
the O 
function O 
of O 
the O 
other O 
receptors O 
by O 
input O 
to O 
common O 
intracellular O 
signaling O 
pathways O 
, O 
establishing O 
functional O 
crosstalk O 
among O 
networks O 
. O 
Our O 
findings O 
by O 
combined O 
analyses O 
of O 
gene O 
polymorphisms O 
of O 
two O 
separate O 
genes O 
present O 
evidences O 
that O 
such O 
is O 
the O 
case O 
with O 
human O 
body O 
in O 
a O 
clinical O 
setting O 
: O 
1 O 
) O 
an O 
integrated O 
effect O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
and O 
protease O 
activated O 
receptor-1 O 
( O 
PAR-1 O 
) O 
on O 
susceptibility O 
to O 
airway O 
hyperresponsiveness O 
( O 
AHR O 
) O 
, O 
and O 
2 O 
) O 
a O 
crosstalk O 
effect O 
between O 
muscarinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
mAChRs O 
) O 
and O 
β(2) O 
adrenoceptor O 
( O 
β(2)AR O 
) O 
on O 
bronchodilatory O 
response O 
to O 
anticholinergic O 
agents O 
in O 
patients O 
with O 
COPD O 
. O 
These O 
results O 
indicate O 
that O 
these O 
interactions O 
are O 
unlikely O 
to O 
be O 
' O 
noise O 
' O 
but O 
functionally O 
- O 
relevant O 
' O 
crosstalk O 
' O 
in O 
a O 
human O 
body O 
. O 
This O 
review O 
attempts O 
to O 
highlight O 
the O 
clinically O 
- O 
relevant O 
' O 
crosstalk O 
' O 
paradigm O 
in O 
a O 
human O 
body O 
which O 
provides O 
us O 
a O 
novel O 
insight O 
necessary O 
to O 
investigate O 
pathophysiology O 
in O 
common O 
multifactorial O 
diseases O 
and O 
to O 
develop O 
new O 
drugs O 
. O 

of O 
copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
/ O 
TEMPO O 
- O 
catalyzed O 
aerobic O 
alcohol B-FAMILY 
oxidation O 
. O 

Cu B-FORMULA 
/ O 
TEMPO B-ABBREVIATION 
catalyst O 
systems O 
( O 
TEMPO B-ABBREVIATION 
= O 
2,2,6,6-tetramethylpiperidine-N-oxyl B-SYSTEMATIC 
) O 
have O 
emerged O 
as O 
some O 
of O 
the O 
most O 
versatile O 
and O 
practical O 
catalysts O 
for O 
aerobic O 
alcohol B-FAMILY 
oxidation O 
. O 
Recently O 
, O 
we O 
disclosed O 
a O 
( O 
bpy O 
) O 
Cu B-FORMULA 
(I) I-FORMULA 
/ O 
TEMPO B-ABBREVIATION 
/ O 
NMI B-ABBREVIATION 
catalyst O 
system O 
( O 
NMI B-ABBREVIATION 
= O 
N-methylimidazole B-SYSTEMATIC 
) O 
that O 
exhibits O 
fast O 
rates O 
and O 
high O 
selectivities O 
, O 
even O 
with O 
unactivated O 
aliphatic O 
alcohols B-FAMILY 
. O 
Here O 
, O 
we O 
present O 
a O 
mechanistic O 
investigation O 
of O 
this O 
catalyst O 
system O 
, O 
in O 
which O 
we O 
compare O 
the O 
reactivity O 
of O 
benzylic B-MULTIPLE 
and I-MULTIPLE 
aliphatic I-MULTIPLE 
alcohols I-MULTIPLE 
. O 
This O 
work O 
includes O 
analysis O 
of O 
catalytic O 
rates O 
by O 
gas-uptake O 
and O 
in O 
situ O 
IR O 
kinetic O 
methods O 
and O 
characterization O 
of O 
the O 
catalyst O 
speciation O 
during O 
the O 
reaction O 
by O 
EPR O 
and O 
UV-visible O 
spectroscopic O 
methods O 
. O 
The O 
data O 
support O 
a O 
two O 
- O 
stage O 
catalytic O 
mechanism O 
consisting O 
of O 
( O 
1 O 
) O 
" O 
catalyst O 
oxidation O 
" O 
in O 
which O 
Cu B-FORMULA 
(I) I-FORMULA 
and O 
TEMPO B-ABBREVIATION 
- O 
H B-FORMULA 
are O 
oxidized O 
by O 
O(2) B-FORMULA 
via O 
a O 
binuclear O 
Cu(2)O(2) B-FORMULA 
intermediate O 
and O 
( O 
2 O 
) O 
" O 
substrate O 
oxidation O 
" O 
mediated O 
by O 
Cu B-FORMULA 
(II) I-FORMULA 
and O 
the O 
nitroxyl B-SYSTEMATIC 
radical O 
of O 
TEMPO O 
via O 
a O 
Cu B-FORMULA 
(II) I-FORMULA 
- O 
alkoxide B-FAMILY 
intermediate O 
. O 
Catalytic O 
rate O 
laws O 
, O 
kinetic O 
isotope O 
effects O 
, O 
and O 
spectroscopic O 
data O 
show O 
that O 
reactions O 
of O 
benzylic B-MULTIPLE 
and I-MULTIPLE 
aliphatic I-MULTIPLE 
alcohols I-MULTIPLE 
have O 
different O 
turnover O 
- O 
limiting O 
steps O 
. O 
Catalyst O 
oxidation O 
by O 
O(2) B-FORMULA 
is O 
turnover O 
limiting O 
with O 
benzylic B-FAMILY 
alcohols I-FAMILY 
, O 
while O 
numerous O 
steps O 
contribute O 
to O 
the O 
turnover O 
rate O 
in O 
the O 
oxidation O 
of O 
aliphatic B-FAMILY 
alcohols I-FAMILY 
. O 

progress O 
in O 
biological O 
activities O 
and O 
synthetic O 
methodologies O 
of O 
pyrroloquinoxalines B-FAMILY 
. O 

have O 
proved O 
to O 
be O 
a O 
very O 
attractive O 
scaffold O 
for O 
medicinal O 
chemist O 
in O 
the O 
recent O 
past O 
. O 
These O 
compounds O 
were O 
extensively O 
studied O 
as O 
bioactive O 
compounds O 
and O 
many O 
of O 
them O 
are O 
known O 
to O 
be O 
biologically O 
and O 
medicinally O 
useful O 
molecules O 
, O 
such O 
as O 
anti-HIV O 
agents O 
, O 
antimalarial O 
agents O 
, O 
antagonist O 
agents O 
, O 
anticancer O 
agents O 
, O 
and O 
PARP-1 O 
inhibitors O 
. O 
Additionally O 
, O 
pyrroloquinoxalines B-FAMILY 
are O 
also O 
important O 
intermediates O 
for O 
the O 
construction O 
of O 
5-HT3 O 
receptor O 
agonists O 
. O 
In O 
this O 
review O 
the O 
developments O 
in O 
biological O 
activities O 
and O 
synthetic O 
methodologies O 
of O 
pyrroloquinoxalines B-FAMILY 
are O 
discussed O 
. O 

B O 
virus O 
( O 
HBV O 
) O 
infection O 
is O 
a O 
serious O 
health O 
problem O 
worldwide O 
, O 
and O 
the O 
current O 
treatment O 
methods O 
including O 
vaccines O 
, O 
immunomodulators O 
, O 
interferons O 
and O 
nucleoside B-FAMILY 
analogs O 
are O 
far O 
from O 
satisfactory O 
. O 
For O 
the O 
search O 
of O 
new O 
anti-HBV O 
agents O 
, O 
much O 
investigation O 
has O 
revealed O 
a O 
large O 
number O 
of O 
small O 
- O 
molecule O 
compounds O 
with O 
various O 
skeletons O 
and O 
promising O 
anti-HBV O 
activities O 
. O 
Although O 
some O 
reviews O 
on O 
anti-HBV O 
progress O 
have O 
been O 
published O 
, O 
they O 
are O 
mainly O 
concentrated O 
on O 
the O 
results O 
reported O 
in O 
journal O 
articles O 
. O 
This O 
review O 
provides O 
an O 
overview O 
of O 
the O 
structural O 
features O 
and O 
anti-HBV O 
properties O 
of O 
the O 
small O 
- O 
molecule O 
anti-HBV O 
inhibitors O 
claimed O 
in O 
recent O 
patents O 
( O 
from O 
2001 O 
to O 
2010 O 
) O 
. O 
These O 
small O 
- O 
molecules O 
can O 
be O 
structurally O 
classified O 
as O 
two O 
main O 
types O 
, O 
nucleoside B-FAMILY 
analogs O 
( O 
cyclic O 
and O 
acyclic O 
nucleosides B-FAMILY 
) O 
and O 
non- O 
nucleosides B-FAMILY 
( O 
natural O 
and O 
synthesized O 
compounds O 
) O 
, O 
which O 
are O 
declared O 
with O 
the O 
activity O 
inhibiting O 
the O 
secretion O 
of O 
HBsAg O 
and O 
HBeAg O 
and O 
HBV O 
DNA O 
replication O 
in O 
vitro O 
, O 
as O 
well O 
as O 
anti-DHBV O 
DNA O 
in O 
vivo O 
. O 
Especially O 
, O 
the O 
non- O 
nucleosides B-FAMILY 
with O 
diverse O 
skeletons O 
and O 
novel O 
mechanism O 
offer O 
prolific O 
candidates O 
for O 
anti-HBV O 
drug O 
discovery O 
, O 
which O 
are O 
preferred O 
to O 
be O 
used O 
as O 
adjuvant O 
therapy O 
for O 
HBV O 
infection O 
. O 
This O 
paper O 
will O 
provide O 
valuable O 
information O 
for O 
understanding O 
the O 
current O 
anti-HBV O 
investigation O 
and O 
developing O 
new O 
anti-HBV O 
agents O 
. O 

transformation O 
of O 
rotenone B-TRIVIAL 
with O 
potential O 
anti-adipogenic O 
activity O 
. O 

transformation O 
of O 
the O 
isoflavonoid B-TRIVIAL 
rotenone I-TRIVIAL 
( O 
1 O 
) O 
with O 
γ-irradiation O 
afforded O 
two O 
new O 
degraded O 
products O 
, O 
rotenoisins B-FAMILY 
A I-FAMILY 
( O 
2 O 
) O 
and O 
( O 
3 O 
) O 
. O 
The O 
structures O 
of O 
the O 
two O 
new O 
rotenone B-TRIVIAL 
derivatives O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
methods O 
. O 
The O 
new O 
products O 
2 O 
and O 
3 O 
exhibited O 
significantly O 
enhanced O 
inhibitory O 
activities O 
against O 
pancreatic O 
lipase O 
and O 
adipocyte O 
differentiation O 
in O 
3T3-L1 O 
cells O 
when O 
compared O 
to O 
parent O 
rotenone B-TRIVIAL 
. O 

stimulates O 
PGE(2) B-ABBREVIATION 
/ O 
cyclin O 
D1-dependent O 
VSMCs O 
proliferation O 
via O 
STAT3 O 
activation O 
: O 
role O 
of O 
PKCs-dependent O 
NADPH B-ABBREVIATION 
oxidase O 
/ O 
ROS O 
generation O 
. O 

smooth O 
muscle O 
cells O 
( O 
VSMCs O 
) O 
that O 
function O 
as O 
synthetic O 
units O 
play O 
important O 
roles O 
in O 
cardiovascular O 
diseases O 
. O 
Extracellular O 
nucleotides B-FAMILY 
, O 
such O 
as O 
ATP B-ABBREVIATION 
, O 
have O 
been O 
shown O 
to O 
act O 
via O 
activation O 
of O 
P2 O 
purinoceptors O 
implicated O 
in O 
various O 
inflammatory O 
diseases O 
, O 
we O 
hypothesized O 
that O 
extracellular O 
nucleotides B-FAMILY 
contribute O 
to O 
vascular O 
diseases O 
via O 
up O 
- O 
regulation O 
of O 
inflammatory O 
proteins O 
, O 
including O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
and O 
cytosolic O 
phospholipase O 
A2 O 
( O 
cPLA2 O 
) O 
in O 
VSMCs O 
. O 
However O 
, O 
the O 
mechanisms O 
of O 
ATP B-ABBREVIATION 
-induced O 
cPLA2 O 
and O 
COX-2 O 
expression O 
and O 
PGE2 B-ABBREVIATION 
synthesis O 
remain O 
largely O 
unclear O 
. O 
We O 
showed O 
that O 
pretreatment O 
with O 
the O 
inhibitors O 
of O 
STAT3 O 
( O 
CBE O 
) O 
, O 
NADPH B-ABBREVIATION 
oxidase O 
[ O 
diphenyleneiodonium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
DPI B-ABBREVIATION 
) O 
or O 
apocynin B-TRIVIAL 
( O 
APO B-ABBREVIATION 
) O 
] O 
, O 
ROS O 
[ O 
N-acetyl-l-cysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
] O 
, O 
and O 
PKC O 
( O 
Ro-318220 B-IDENTIFIER 
, O 
Gö6983 B-IDENTIFIER 
, O 
or O 
Rottlerin B-TRIVIAL 
) O 
or O 
transfection O 
with O 
siRNAs O 
of O 
STAT3 O 
and O 
p47(phox) O 
markedly O 
inhibited O 
ATPγS-induced O 
cPLA2 O 
and O 
COX-2 O 
mRNA O 
/ O 
protein O 
expression O 
and O 
promoter O 
activity O 
and O 
PGE2 B-ABBREVIATION 
secretion O 
. O 
ATPγS O 
further O 
stimulated O 
PKC O 
, O 
p47(phox) O 
, O 
and O 
STAT3 O 
translocation O 
. O 
Moreover O 
, O 
ATPγS-induced O 
STAT3 O 
phosphorylation O 
and O 
translocation O 
was O 
inhibited O 
by O 
pretreatment O 
with O 
the O 
inhibitors O 
of O 
PKC O 
, O 
NADPH B-ABBREVIATION 
oxidase O 
, O 
and O 
ROS O 
. O 
ATPγS O 
enhanced O 
NADPH B-ABBREVIATION 
oxidase O 
activity O 
and O 
ROS O 
generation O 
in O 
VSMCs O 
, O 
which O 
were O 
reduced O 
by O 
pretreatment O 
with O 
Ro-318220 B-IDENTIFIER 
, O 
Gö6983 B-IDENTIFIER 
, O 
or O 
Rottlerin B-TRIVIAL 
. O 
Finally O 
, O 
we O 
found O 
that O 
ATPγS O 
significantly O 
induced O 
cyclin O 
D1 O 
expression O 
and O 
VSMCs O 
proliferation O 
, O 
which O 
were O 
inhibited O 
by O 
pretreatment O 
with O 
NAC B-ABBREVIATION 
, O 
APO B-ABBREVIATION 
, O 
DPI B-ABBREVIATION 
, O 
Ro-318220 B-IDENTIFIER 
, O 
Gö6983 B-IDENTIFIER 
, O 
Rottlerin B-TRIVIAL 
, O 
or O 
CBE O 
or O 
transfection O 
with O 
siRNAs O 
of O 
COX-2 O 
and O 
cyclin O 
D1 O 
. O 
We O 
also O 
demonstrated O 
that O 
ATPγS O 
induced O 
cyclin O 
D1 O 
expression O 
via O 
a O 
PGE2 B-ABBREVIATION 
-dependent O 
pathway O 
. O 
These O 
results O 
suggested O 
that O 
ATPγS-induced O 
cPLA2 O 
/ O 
COX-2 O 
expression O 
and O 
PGE2 B-ABBREVIATION 
secretion O 
is O 
mediated O 
through O 
a O 
PKC/ O 
NADPH B-ABBREVIATION 
oxidase O 
/ O 
ROS O 
/ O 
STAT3-dependent O 
pathway O 
in O 
VSMCs O 
. O 

hereditary O 
autosomal O 
recessive O 
disease O 
ataxia O 
telangiectasia O 
( O 
A-T O 
) O 
is O 
caused O 
by O 
mutation O 
in O 
the O 
DNA O 
damage O 
kinase O 
ATM O 
. O 
ATM's O 
main O 
function O 
is O 
to O 
orchestrate O 
DNA O 
repair O 
, O 
thereby O 
maintaining O 
genomic O 
stability O 
. O 
ATM O 
activity O 
is O 
increased O 
in O 
response O 
to O 
several O 
stimuli O 
, O 
including O 
ionising O 
radiation O 
( O 
IR O 
) O 
and O 
hypotonic O 
stress O 
. O 
DNMT1-associated O 
protein O 
1 O 
( O 
DMAP1 O 
) O 
is O 
a O 
member O 
of O 
the O 
TIP60-p400 O 
histone O 
acetyl B-SYSTEMATIC 
transferase O 
( O 
HAT O 
) O 
complex O 
, O 
which O 
acetylates O 
histone O 
H4 O 
at O 
lysine B-TRIVIAL 
16 O 
( O 
H4K16 O 
) O 
to O 
affect O 
chromatin O 
relaxation O 
and O 
modulate O 
ATM O 
activation O 
. O 
Here O 
we O 
demonstrate O 
that O 
DMAP1 O 
is O 
required O 
for O 
both O 
modes O 
of O 
ATM O 
activation O 
. O 
Knockdown O 
of O 
DMAP1 O 
impaired O 
IR-induced O 
ATM O 
activation O 
and O 
consequently O 
resulted O 
in O 
radiosensitivity O 
and O 
impaired O 
the O 
G2 O 
/ O 
M O 
checkpoint O 
. O 
Moreover O 
, O 
DMAP1 O 
was O 
also O 
required O 
for O 
efficient O 
ATM O 
signalling O 
in O 
response O 
to O 
hypotonic O 
stress O 
. O 
Overexpression O 
of O 
DMAP1 O 
increased O 
IR-induced O 
ATM O 
substrate O 
phosphorylation O 
, O 
suggesting O 
that O 
DMAP1 O 
function O 
is O 
rate O 
limiting O 
for O 
ATM O 
signalling O 
. O 
DMAP1 O 
associated O 
with O 
TIP60-dependent O 
HAT O 
activity O 
, O 
and O 
depletion O 
of O 
DMAP1 O 
reduced O 
H4K16 O 
acetylation O 
in O 
response O 
to O 
DNA O 
damage O 
. O 
Treatment O 
with O 
histone O 
deacetylase O 
inhibitors O 
rescued O 
IR-induced O 
ATM O 
signalling O 
in O 
Dmap1-depleted O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
DMAP1 O 
is O 
a O 
critical O 
regulator O 
of O 
ATM O 
activity O 
and O 
function.Oncogene O 
advance O 
online O 
publication O 
, O 
14 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2012.597 O 
. O 

Anemia O 
( O 
FA O 
) O 
is O 
a O 
rare O 
genetic O 
disorder O 
associated O 
with O 
a O 
bone O 
- O 
marrow O 
failure O 
, O 
cancer O 
predisposition O 
and O 
hypersensitivity O 
to O 
DNA O 
crosslinking O 
agents O 
. O 
Majority O 
of O 
the O 
15 O 
FA O 
genes O 
and O 
encoded O 
proteins O 
characterized O 
so O 
far O 
are O 
integrated O 
into O 
DNA O 
repair O 
pathways O 
, O 
however O 
, O 
other O 
important O 
functions O 
cannot O 
be O 
excluded O 
. O 
FA O 
cells O 
are O 
sensitive O 
to O 
oxidants O 
, O 
and O 
accumulation O 
of O 
oxidized O 
proteins O 
has O 
been O 
characterized O 
for O 
several O 
FA O 
subgroups O 
. O 
Clinical O 
phenotypes O 
of O 
both O 
FA O 
and O 
other O 
closely O 
related O 
diseases O 
suggest O 
altered O 
functions O 
of O 
mitochondria O 
, O 
organelles O 
responsible O 
for O 
cellular O 
energetic O 
metabolism O 
, O 
and O 
also O 
serving O 
as O 
an O 
important O 
producer O 
and O 
the O 
most O 
susceptible O 
target O 
from O 
reactive O 
oxidative O 
species O 
( O 
ROS O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
have O 
shown O 
that O 
elevated O 
level O 
of O 
mitochondrial O 
ROS O 
in O 
FA O 
cells O 
is O 
in O 
parallel O 
with O 
the O 
decrease O 
of O 
mitochondrial O 
membrane O 
potential O 
, O 
the O 
decrease O 
of O 
ATP O 
production O 
, O 
impaired O 
oxygen B-SYSTEMATIC 
uptake O 
and O 
pathological O 
changes O 
in O 
the O 
morphology O 
of O 
mitochondria O 
. O 
This O 
is O 
accompanied O 
by O 
inactivation O 
of O 
enzymes O 
that O 
are O 
essential O 
for O 
the O 
energy O 
production O 
( O 
F1F0ATPase O 
and O 
cytochrome O 
C O 
oxidase O 
) O 
and O 
detoxification O 
of O 
ROS O 
( O 
superoxide B-TRIVIAL 
dismutase O 
, O 
SOD1 O 
) O 
. O 
In O 
turn O 
, O 
overexpression O 
of O 
SOD1 O 
could O 
rescue O 
oxygen B-SYSTEMATIC 
consumption O 
rate O 
in O 
FA-deficient O 
cells O 
. O 
Importantly O 
, O 
the O 
depletion O 
of O 
mitochondria O 
improved O 
survival O 
rate O 
of O 
mitomycin O 
C O 
treated O 
FA O 
cells O 
suggesting O 
that O 
hypersensitivity O 
of O 
FA O 
cells O 
to O 
chemotherapeutic O 
drugs O 
could O 
be O 
in O 
part O 
due O 
to O 
the O 
mitochondria O 
- O 
mediated O 
oxidative O 
stress O 
. O 
On O 
the O 
basis O 
of O 
our O 
results O 
, O 
we O 
propose O 
that O 
deficiency O 
in O 
FA O 
genes O 
lead O 
to O 
disabling O 
mitochondrial O 
ROS-scavenging O 
machinery O 
further O 
affecting O 
mitochondrial O 
functions O 
and O 
suppressing O 
cell O 
respiration.Oncogene O 
advance O 
online O 
publication O 
, O 
14 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2012.583 O 
. O 

cancers O 
arising O 
from O 
a O 
thyroglossal O 
duct O 
cyst O 
( O 
TGDC O 
) O 
are O 
rarely O 
reported O 
. O 
No O 
clear O 
consensus O 
exists O 
regarding O 
optimal O 
management O 
. O 
In O 
this O 
light O 
, O 
TGDC O 
carcinomas O 
recently O 
treated O 
at O 
Asan O 
Medical O 
Center O 
, O 
as O 
well O 
as O 
previously O 
reported O 
cases O 
in O 
the O 
literature O 
, O 
were O 
reviewed O 
. O 
There O 
were O 
ten O 
patients O 
who O 
were O 
diagnosed O 
with O 
TGDC O 
carcinoma O 
at O 
our O 
institution O 
. O 
All O 
patients O 
underwent O 
pre O 
- O 
operative O 
fine O 
- O 
needle O 
aspiration O 
biopsy O 
( O 
FNAB O 
) O 
. O 
Nine O 
patients O 
were O 
suspected O 
of O 
having O 
papillary O 
carcinoma O 
following O 
cytology O 
. O 
The O 
Sistrunk O 
operation O 
( O 
SO O 
) O 
was O 
performed O 
in O 
four O 
patients O 
, O 
SO O 
with O 
total O 
thyroidectomy O 
( O 
SO O 
/ O 
TT O 
) O 
was O 
performed O 
in O 
three O 
patients O 
, O 
and O 
SO O 
/ O 
TT O 
with O 
neck O 
dissection O 
was O 
performed O 
in O 
three O 
patients O 
. O 
Six O 
patients O 
who O 
received O 
total O 
thyroidectomy O 
underwent O 
radioactive O 
iodine B-SYSTEMATIC 
( O 
RAI O 
) O 
therapy O 
and O 
T4 O 
suppression O 
. O 
With O 
a O 
median O 
follow O 
- O 
up O 
period O 
of O 
28.5 O 
months O 
, O 
two O 
patients O 
showed O 
recurrence O 
and O 
one O 
of O 
them O 
died O 
of O 
the O 
disease O 
. O 
We O 
analyzed O 
163 O 
cases O 
from O 
1990 O 
to O 
2012 O 
with O 
three O 
or O 
more O 
cases O 
TGDC O 
carcinoma O 
, O 
including O 
the O 
present O 
study O 
. O 
Among O 
48 O 
patients O 
who O 
underwent O 
FNAB O 
, O 
75% O 
had O 
papillary O 
thyroid O 
carcinoma O 
( O 
PTC O 
) O 
. O 
SO O 
, O 
SO O 
/ O 
TT O 
, O 
or O 
SO O 
/ O 
TT O 
with O 
neck O 
dissection O 
was O 
performed O 
in O 
27% O 
, O 
41% O 
, O 
and O 
32% O 
of O 
patients O 
, O 
respectively O 
. O 
Among O 
119 O 
patients O 
who O 
received O 
total O 
thyroidectomy O 
, O 
36% O 
had O 
concomitant O 
PTC O 
in O 
the O 
thyroid O 
. O 
Among O 
52 O 
patients O 
who O 
received O 
neck O 
dissection O 
, O 
69% O 
had O 
cervical O 
nodal O 
involvement O 
. O 
The O 
results O 
of O 
our O 
review O 
suggest O 
that O 
when O 
TGDC O 
carcinoma O 
is O 
suspected O 
, O 
ultrasonography O 
and O 
, O 
if O 
necessary O 
, O 
FNAB O 
should O 
be O 
performed O 
. O 
If O 
these O 
tests O 
reveal O 
a O 
suspected O 
lesion O 
in O 
the O 
thyroid O 
or O 
lymph O 
node O 
, O 
SO O 
/ O 
TT O 
and O 
lymph O 
node O 
dissection O 
should O 
be O 
performed O 
. O 

in O 
vitro O 
and O 
in O 
vivo O 
genotoxicity O 
of O 
isotretinoin B-TRIVIAL 
assessed O 
by O 
cytokinesis O 
blocked O 
micronucleus O 
assay O 
and O 
comet O 
assay O 
. O 

is O 
a O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
frequently O 
used O 
in O 
monotherapy O 
or O 
combined O 
with O 
narrow O 
- O 
band O 
ultraviolet O 
B O 
( O 
NBUVB O 
) O 
irradiation O 
to O 
treat O 
patients O 
with O 
acne O 
and O 
psoriasis O 
vulgaris O 
. O 
As O 
both O 
diseases O 
need O 
frequent O 
and O 
/ O 
or O 
prolonged O 
therapeutic O 
interventions O 
, O 
the O 
study O 
of O 
the O 
genotoxicity O 
of O 
retinoids B-FAMILY 
becomes O 
important O 
. O 
Our O 
aim O 
was O 
to O 
study O 
the O 
genotoxic O 
effects O 
of O 
isotretinoin B-TRIVIAL 
alone O 
or O 
combined O 
with O 
NBUVB O 
. O 
In O 
vitro O 
studies O 
were O 
performed O 
in O 
the O 
absence O 
of O 
S9 O 
metabolic O 
activation O 
using O 
blood O 
from O 
five O 
healthy O 
volunteers O 
, O 
incubated O 
72 O 
h O 
with O 
isotretinoin B-TRIVIAL 
( O 
1.2-20 O 
μM O 
) O 
( O 
i.e O 
. O 
, O 
at O 
concentrations O 
usually O 
achieved O 
in O 
blood O 
with O 
therapeutic O 
doses O 
as O 
well O 
as O 
at O 
higher O 
concentrations O 
) O 
. O 
In O 
vivo O 
studies O 
were O 
also O 
performed O 
using O 
blood O 
from O 
two O 
patients O 
with O 
acne O 
and O 
three O 
patients O 
with O 
psoriasis O 
vulgaris O 
treated O 
with O 
isotretinoin B-TRIVIAL 
in O 
monotherapy O 
( O 
8 O 
or O 
20mg O 
/ O 
day O 
) O 
or O 
combined O 
with O 
NBUVB O 
( O 
20mg O 
isotretinoin B-TRIVIAL 
/ O 
day O 
+ O 
NBUVB O 
) O 
. O 
The O 
genotoxic O 
effect O 
was O 
evaluated O 
by O 
the O 
cytokinesis O 
- O 
blocked O 
micronucleus O 
and O 
the O 
comet O 
assays O 
. O 
Our O 
studies O 
showed O 
that O 
isotretinoin B-TRIVIAL 
alone O 
was O 
not O 
genotoxic O 
when O 
tested O 
in O 
human O 
lymphocytes O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
There O 
was O 
no O 
clear O 
genotoxic O 
effect O 
in O 
psoriatic O 
patients O 
treated O 
with O 
isotretinoin B-TRIVIAL 
and O 
NBUVB O 
. O 
The O 
in O 
vitro O 
studies O 
showed O 
that O 
isotretinoin B-TRIVIAL 
induced O 
apoptosis O 
and O 
necrosis O 
in O 
human O 
lymphocytes O 
at O 
higher O 
doses O 
. O 

folate I-SYSTEMATIC 
nanoparticles O 
toxicity O 
: O 
cancer O 
vs O 
. O 
normal O 
cells O 
. O 

for O 
two O 
decades O 
metallic O 
nanoparticles O 
are O 
successfully O 
used O 
for O 
cancer O 
detection O 
, O 
imaging O 
and O 
treatment O 
. O 
Due O 
to O 
their O 
high O 
electron O 
density O 
they O 
can O 
be O 
easily O 
observed O 
by O 
electron O 
microscopy O 
and O 
used O 
in O 
laser O 
and O 
radiofrequency O 
therapy O 
as O 
energy O 
releasing O 
agents O 
. O 
However O 
, O 
the O 
limitation O 
for O 
this O 
practice O 
is O 
an O 
inability O 
to O 
generate O 
tumor O 
- O 
specific O 
heating O 
in O 
a O 
minimally O 
invasive O 
manner O 
to O 
the O 
healthy O 
tissue O 
. O 
To O 
overcome O 
this O 
restraint O 
we O 
proposed O 
to O 
use O 
folic B-TRIVIAL 
acid I-TRIVIAL 
coated O 
metallic O 
nanoparticles O 
and O 
determine O 
whether O 
they O 
preferentially O 
penetrate O 
cancer O 
cells O 
. O 
We O 
developed O 
technique O 
for O 
synthesizing O 
platinum B-SYSTEMATIC 
nanoparticles O 
using O 
folic B-TRIVIAL 
acid I-TRIVIAL 
as O 
stabilizing O 
agent O 
which O 
produced O 
particles O 
of O 
relatively O 
narrow O 
size O 
distribution O 
, O 
having O 
d=2.3 O 
± O 
0.5 O 
nm O 
. O 
High O 
resolution O 
TEM O 
and O 
zeta O 
potential O 
analysis O 
indicated O 
that O 
the O 
particles O 
produced O 
by O 
this O 
method O 
had O 
a O 
high O 
degree O 
of O 
crystalline O 
order O 
with O 
no O 
amorphous O 
outer O 
shell O 
and O 
a O 
high O 
degree O 
of O 
colloidal O 
stability O 
. O 
The O 
keratinocytes O 
and O 
mammary O 
breast O 
cells O 
( O 
cancer O 
and O 
normal O 
) O 
were O 
incubated O 
with O 
platinum B-SYSTEMATIC 
folate I-SYSTEMATIC 
nanoparticles O 
, O 
and O 
the O 
results O 
showed O 
that O 
the O 
IC50 O 
was O 
significantly O 
higher O 
for O 
the O 
normal O 
cells O 
than O 
the O 
cancer O 
cells O 
in O 
both O 
cases O 
, O 
indicating O 
that O 
these O 
nanoparticles O 
preferentially O 
target O 
the O 
cancer O 
cells O 
. O 
TEM O 
images O 
of O 
thin O 
sections O 
taken O 
from O 
the O 
two O 
types O 
of O 
cells O 
indicated O 
that O 
the O 
number O 
of O 
vacuoles O 
and O 
morphology O 
changes O 
after O 
incubation O 
with O 
nanoparticles O 
was O 
also O 
larger O 
for O 
the O 
cancer O 
cells O 
in O 
both O 
types O 
of O 
tissue O 
studied O 
. O 
No O 
preferential O 
toxicity O 
was O 
observed O 
when O 
folic B-TRIVIAL 
acid I-TRIVIAL 
receptors O 
were O 
saturated O 
with O 
free O 
folic B-TRIVIAL 
acid I-TRIVIAL 
prior O 
to O 
exposure O 
to O 
nanoparticles O 
. O 
These O 
results O 
confirm O 
our O 
hypothesis O 
regarding O 
the O 
preferential O 
penetration O 
of O 
folic B-TRIVIAL 
acid I-TRIVIAL 
coated O 
nanoparticles O 
to O 
cancer O 
cells O 
due O 
to O 
receptor O 
mediated O 
endocytosis O 
. O 

of O 
benzofuran-3-yl(phenyl)methanones B-FAMILY 
as O 
novel O 
SIRT1 O 
inhibitors O 
: O 
binding O 
mode O 
, O 
inhibitory O 
mechanism O 
and O 
biological O 
action O 
. O 

is O 
a O 
NAD(+) B-ABBREVIATION 
-dependent O 
deacetylase O 
. O 
Here O 
we O 
described O 
new O 
SIRT1 O 
inhibitors O 
with O 
the O 
scaffold O 
of O 
benzofuran-3-yl(phenyl)methanone B-SYSTEMATIC 
. O 
The O 
inhibitors O 
were O 
predicted O 
to O 
bind O 
in O 
C-pocket O 
of O 
SIRT1 O 
, O 
forming O 
hydrophobic O 
interactions O 
with O 
Phe B-FORMULA 
273 O 
, O 
Phe B-FORMULA 
312 O 
and O 
Ile B-FORMULA 
347 O 
. O 
Introducing O 
hydroxyl B-SYSTEMATIC 
to O 
meta O 
position O 
of O 
phenyl B-SYSTEMATIC 
may O 
form O 
H B-FORMULA 
-bond O 
with O 
Asn B-FORMULA 
346 O 
. O 
Indeed O 
, O 
(2,5-dihydroxyphenyl)(5-hydroxy-1-benzofuran-3-yl)methanone B-SYSTEMATIC 
( O 
16 O 
) O 
, O 
an O 
analogue O 
with O 
hydroxyls B-FAMILY 
at O 
ortho O 
and O 
meta O 
positions O 
, O 
showed O 
greater O 
inhibition O 
. O 
The O 
binding O 
mode O 
was O 
validated O 
by O 
structural O 
modifications O 
and O 
kinetic O 
studies O 
. O 
Since O 
C-pocket O 
is O 
the O 
site O 
where O 
the O 
nicotinamide B-TRIVIAL 
moiety O 
of O 
NAD(+) B-ABBREVIATION 
binds O 
and O 
the O 
hydrolysis O 
takes O 
place O 
, O 
binding O 
of O 
16 O 
in O 
C-pocket O 
would O 
block O 
the O 
transformation O 
of O 
NAD(+) B-ABBREVIATION 
to O 
productive O 
conformation O 
and O 
hence O 
inhibit O 
the O 
deacetylase O 
activity O 
. O 
Consistently O 
, O 
16 O 
inhibited O 
SIRT1 O 
through O 
up O 
- O 
regulating O 
p53 O 
acetylation O 
on O 
cellular O 
level O 
. O 

binding O 
to O 
thin O 
filaments O 
is O 
a O 
major O 
element O 
controlling O 
active O 
force O 
generation O 
in O 
striated O 
muscles O 
. O 
Recent O 
evidence O 
suggests O 
that O 
processes O 
other O 
than O 
Ca(2+) B-FORMULA 
binding O 
, O 
such O 
as O 
phosphorylation O 
of O 
myosin O 
regulatory O 
light O 
chain O 
( O 
RLC O 
) O 
also O 
controls O 
contraction O 
of O 
vertebrate O 
striated O 
muscle O 
( O 
Cooke O 
, O 
R O 
. O 
( O 
2011 O 
) O 
Biophys O 
. O 
Rev O 
. O 
3 O 
, O 
33-45 O 
) O 
. O 
Electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
studies O 
using O 
nucleotide B-FAMILY 
analog O 
spin O 
label O 
probes O 
showed O 
that O 
dephosphorylated O 
myosin O 
heads O 
are O 
highly O 
ordered O 
in O 
the O 
relaxed O 
fibers O 
and O 
have O 
very O 
low O 
ATPase O 
activity O 
. O 
This O 
ordered O 
structure O 
of O 
myosin O 
cross O 
- O 
bridges O 
disappears O 
with O 
the O 
phosphorylation O 
of O 
RLC O 
( O 
Stewart O 
, O 
M O 
. O 
( O 
2010 O 
) O 
Proc O 
. O 
Natl O 
. O 
Acad O 
. O 
Sci O 
. O 
U.S.A O 
. O 
107 O 
, O 
430-435 O 
) O 
. O 
The O 
slower O 
ATPase O 
activity O 
in O 
the O 
dephosporylated O 
moiety O 
has O 
been O 
defined O 
as O 
a O 
new O 
super O 
- O 
relaxed O 
state O 
( O 
SRX O 
) O 
. O 
It O 
can O 
be O 
observed O 
in O 
both O 
skeletal O 
and O 
cardiac O 
muscle O 
fibers O 
( O 
Hooijman O 
, O 
P O 
. O 
, O 
Stewart O 
, O 
M O 
. O 
A O 
. O 
, O 
and O 
Cooke O 
, O 
R O 
. O 
( O 
2011 O 
) O 
Biophys O 
. O 
J O 
. O 
100 O 
, O 
1969-1976 O 
) O 
. O 
Given O 
the O 
importance O 
of O 
the O 
finding O 
that O 
suggests O 
a O 
novel O 
pathway O 
of O 
regulation O 
of O 
skeletal O 
muscle O 
, O 
we O 
aim O 
to O 
examine O 
the O 
effects O 
of O 
phosphorylation O 
on O 
cross O 
- O 
bridge O 
orientation O 
and O 
rotational O 
motion O 
. O 
We O 
find O 
that O 
: O 
(i) O 
relaxed O 
cross O 
- O 
bridges O 
, O 
but O 
not O 
active O 
ones O 
, O 
are O 
statistically O 
better O 
ordered O 
in O 
muscle O 
where O 
the O 
RLC O 
is O 
dephosporylated O 
compared O 
with O 
phosphorylated O 
RLC O 
; O 
(ii) O 
relaxed O 
phosphorylated O 
and O 
dephosphorylated O 
cross O 
- O 
bridges O 
rotate O 
equally O 
slowly O 
; O 
and O 
(iii) O 
active O 
phosphorylated O 
cross O 
- O 
bridges O 
rotate O 
considerably O 
faster O 
than O 
dephosphorylated O 
ones O 
during O 
isometric O 
contraction O 
but O 
the O 
duty O 
cycle O 
remained O 
the O 
same O 
, O 
suggesting O 
that O 
both O 
phosphorylated O 
and O 
dephosphorylated O 
muscles O 
develop O 
the O 
same O 
isometric O 
tension O 
at O 
full O 
Ca(2+) B-FORMULA 
saturation O 
. O 
A O 
simple O 
theory O 
was O 
developed O 
to O 
account O 
for O 
this O 
fact O 
. O 

of O 
histone O 
H3 O 
on O 
lysine B-TRIVIAL 
4 O 
by O 
the O 
lysine B-TRIVIAL 
methyltransferase O 
SET1 O 
protein O 
is O 
needed O 
for O 
normal O 
clock O 
gene O 
expression O 
. O 

effect O 
of O 
anthocyanidins B-FAMILY 
on O 
hepatic O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
, O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
and O 
carbonyl B-FAMILY 
reductase O 
activities O 
in O 
rat O 
and O 
human O 
. O 

1 O 
. O 
Anthocyanins B-FAMILY 
and O 
their O 
aglycone O 
anthocyanidins B-FAMILY 
represent O 
the O 
most O 
abundant O 
flavonoids B-FAMILY 
in O 
human O 
diet O 
and O 
popular O 
constituents O 
of O 
various O 
dietary O 
supplements O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
inhibitory O 
effect O 
of O 
four O 
anthocyanidins B-FAMILY 
( O 
delphinidin B-TRIVIAL 
, O 
cyanidin B-TRIVIAL 
, O 
malvidin B-TRIVIAL 
and O 
pelargonidin B-TRIVIAL 
) O 
on O 
three O 
families O 
of O 
important O 
drug O 
- O 
metabolizing O 
enzymes O 
: O 
carbonyl B-FAMILY 
reductases O 
( O 
CBRs O 
) O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
( O 
GSTs O 
) O 
and O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
( O 
UGT O 
) O 
. O 
2 O 
. O 
Human O 
or O 
rat O 
hepatic O 
subcellular O 
fractions O 
were O 
incubated O 
with O 
or O 
without O 
pure O 
anthocyanidins B-FAMILY 
( O 
100 O 
µM O 
) O 
and O 
the O 
activities O 
of O 
CBR O 
, O 
GST O 
and O 
UGT O 
were O 
assayed O 
using O 
menadione B-TRIVIAL 
, O 
1-chloro-2,4-dinitrobenzene B-SYSTEMATIC 
and O 
p-nitrophenol B-SYSTEMATIC 
as O 
substrates O 
, O 
respectively O 
. O 
For O 
the O 
most O 
potent O 
inhibitors O 
, O 
half O 
maximal O 
inhibitory O 
concentrations O 
(IC(50)) O 
were O 
determined O 
and O 
the O 
inhibition O 
kinetics O 
study O 
was O 
performed O 
. O 
3 O 
. O 
Anthocyanidins B-FAMILY 
inhibited O 
weakly O 
the O 
activity O 
of O 
GST O 
and O 
moderately O 
the O 
activities O 
of O 
CBR O 
and O 
UGT O 
. O 
Cyanidin B-TRIVIAL 
was O 
the O 
most O 
potent O 
inhibitor O 
of O 
human O 
UGT O 
with O 
IC(50) O 
= O 
69 O 
µM O 
( O 
at O 
200 O 
µM O 
substrate O 
concentration O 
) O 
and O 
competitive O 
type O 
of O 
action O 
. O 
Delphinidin B-TRIVIAL 
acted O 
as O 
significant O 
non-competitive O 
inhibitor O 
of O 
human O 
CBR O 
with O 
IC(50) O 
= O 
16 O 
µM O 
( O 
at O 
substrate O 
concentration O 
500 O 
µM O 
) O 
. O 
The O 
inhibitory O 
potency O 
of O 
anthocyanidins B-FAMILY 
differed O 
in O 
rat O 
and O 
human O 
samples O 
significantly O 
. O 
4 O 
. O 
Anthocyanidins B-FAMILY 
are O 
able O 
to O 
inhibit O 
CBR O 
and O 
UGT O 
in O 
vitro O 
. O 
Possible O 
interference O 
of O 
anthocyanidins B-FAMILY 
( O 
in O 
high O 
- O 
dose O 
dietary O 
supplements O 
) O 
with O 
simultaneously O 
administered O 
drugs O 
, O 
which O 
are O 
UGT O 
or O 
CBR O 
substrates O 
, O 
should O 
be O 
checked O 
. O 

chondroitin O 
sulfate B-SYSTEMATIC 
-bone O 
marrow O 
( O 
CS-BM O 
) O 
adhesive O 
hydrogel O 
was O 
used O 
to O 
localize O 
rhBMP-2 O 
to O 
enhance O 
articular O 
cartilage O 
tissue O 
formation O 
. O 
Chondrocyte O 
pellet O 
culture O 
revealed O 
that O 
0.1 O 
and O 
1 O 
μg O 
/ O 
mL O 
of O 
rhBMP-2 O 
enhanced O 
sulfated-GAG O 
content O 
. O 
rhBMP-2 O 
localization O 
within O 
the O 
hydrogels O 
was O 
investigated O 
, O 
and O 
it O 
was O 
found O 
that O 
BM O 
, O 
CS-NHS O 
, O 
and O 
rhBMP-2 O 
levels O 
and O 
time O 
affected O 
rhBMP-2 O 
retention O 
. O 
Retention O 
was O 
modulated O 
from O 
82 O 
to O 
99% O 
over O 
a O 
3-week O 
period O 
for O 
the O 
material O 
formulations O 
investigated O 
. O 
To O 
evaluate O 
carrier O 
efficacy O 
, O 
rhBMP-2 O 
and O 
bovine O 
articular O 
chondrocytes O 
were O 
encapsulated O 
within O 
CS-BM O 
, O 
and O 
biochemical O 
evaluation O 
revealed O 
significant O 
increases O 
in O 
total O 
collagen O 
production O 
with O 
rhBMP-2 O 
. O 
Histological O 
analysis O 
revealed O 
more O 
robust O 
tissue O 
formation O 
and O 
greater O 
type-II O 
collagen O 
production O 
with O 
encapsulated O 
rhBMP-2 O 
. O 
Subsequently O 
, O 
a O 
subcutaneous O 
culture O 
of O 
hydrogels O 
revealed O 
increased O 
total O 
collagen O 
, O 
type-II O 
to O 
type-I O 
collagen O 
ratio O 
, O 
and O 
sulfated O 
GAG O 
in O 
samples O 
carrying O 
rhBMP-2 O 
. O 
These O 
findings O 
indicate O 
the O 
development O 
of O 
a O 
multifunctional O 
system O 
capable O 
of O 
localizing O 
rhBMP-2 O 
to O 
enhance O 
repair O 
tissue O 
quality O 
. O 

antiviral O 
activity O 
of O 
l-dideoxy B-FAMILY 
bicyclic I-FAMILY 
nucleoside I-FAMILY 
analogues O 
versus O 
vaccinia O 
and O 
measles O 
viruses O 
in O 
vitro O 
. O 

bicyclic I-FAMILY 
pyrimidine I-FAMILY 
nucleoside I-FAMILY 
analogues O 
( O 
ddBCNAs B-ABBREVIATION 
) O 
with O 
d-chirality O 
have O 
previously O 
been O 
described O 
by O 
us O 
to O 
inhibit O 
replication O 
of O 
human O 
cytomegalovirus O 
. O 
We O 
herein O 
report O 
for O 
the O 
first O 
time O 
that O 
activity O 
against O 
vaccinia O 
virus O 
( O 
VACV O 
) O 
was O 
achieved O 
using O 
novel O 
l-analogues O 
. O 
A O 
structure O 
- O 
activity O 
relationship O 
was O 
established O 
: O 
Antiviral O 
activity O 
versus O 
VACV O 
was O 
highest O 
with O 
an O 
ether B-SYSTEMATIC 
side O 
chain O 
with O 
an O 
optimum O 
of O 
n-C(9)H(18)-O-n-C(5)H(11) B-FORMULA 
. O 
This O 
gave O 
an O 
IC(50) O 
of O 
190 O 
nM O 
, O 
a O 
60-fold O 
enhancement O 
over O 
the O 
FDA-approved O 
antiviral O 
cidofovir B-TRIVIAL 
. O 
Interestingly O 
, O 
l- O 
ddBCNAs B-ABBREVIATION 
also O 
inhibit O 
wild O 
type O 
measles O 
virus O 
syncytia O 
formation O 
with O 
a O 
TCID(50) O 
of O 
7.5 O 
μM O 
for O 
the O 
lead O 
compound O 
. O 
We O 
propose O 
that O 
l- O 
ddBCNAs B-ABBREVIATION 
represent O 
significant O 
innovative O 
antiviral O 
candidates O 
versus O 
measles O 
and O 
poxviruses O 
, O 
and O 
we O 
suggest O 
a O 
mechanism O 
of O 
action O 
versus O 
one O 
or O 
more O 
cellular O 
targets O 
that O 
are O 
essential O 
for O 
viral O 
replication O 
. O 

recruitment O 
and O 
emission O 
of O 
DO3A O 
- O 
derived O 
lanthanide B-FAMILY 
complexes O 
at O 
ligating O 
molecular O 
films O 
on O 
gold O 
. O 

recruitment O 
of O 
DO3A O 
- O 
derived O 
lanthanide B-FAMILY 
complexes O 
by O 
ligation O 
to O 
isophthalic B-TRIVIAL 
acid I-TRIVIAL 
and O 
catechol B-TRIVIAL 
-modified O 
gold O 
surfaces O 
, O 
and O 
their O 
resulting O 
sensitization O 
, O 
is O 
reported O 
herein O 
. O 
Predictably O 
pH-dependent O 
surface O 
recruitment O 
is O 
associated O 
with O 
the O 
expected O 
fingerprint O 
europium B-SYSTEMATIC 
and O 
terbium B-SYSTEMATIC 
emission O 
characteristics O 
. O 
The O 
intensity O 
of O 
the O 
lanthanide B-FAMILY 
luminescence O 
scales O 
exponentially O 
with O 
spacer O 
length O 
, O 
indicating O 
a O 
strong O 
quenching O 
interaction O 
between O 
the O 
lanthanide B-FAMILY 
and O 
the O 
gold O 
surface O 
. O 
The O 
switchable O 
catechol B-TRIVIAL 
oxidation O 
state O 
provides O 
a O 
means O 
of O 
electrochemically O 
triggering O 
the O 
release O 
of O 
prior O 
ligated O 
complexes O 
. O 

rotational O 
correlation O 
times O 
of O 
perdeuterated B-TRIVIAL 
tempone I-TRIVIAL 
( O 
PDT B-ABBREVIATION 
) O 
are O 
found O 
in O 
alkane O 
and O 
aromatic O 
liquids O 
by O 
directly O 
using O 
the O 
spectral O 
width O 
of O 
the O 
central O 
electron O 
paramagnetic O 
resonance O 
line O 
. O 
This O 
is O 
done O 
by O 
mathematically O 
eliminating O 
the O 
nonsecular O 
spectral O 
density O 
from O 
the O 
spectral O 
parameter O 
equations O 
, O 
thereby O 
removing O 
the O 
need O 
to O 
assume O 
a O 
particular O 
form O 
for O 
it O 
. O 
This O 
is O 
preferable O 
to O 
fitting O 
a O 
constant O 
correction O 
factor O 
to O 
the O 
spectral O 
density O 
, O 
because O 
such O 
a O 
factor O 
does O 
not O 
fit O 
well O 
in O 
the O 
low O 
picosecond O 
range O 
. O 
The O 
electron O 
- O 
nuclear O 
spin O 
dipolar O 
interaction O 
between O 
the O 
probe O 
and O 
solvent O 
is O 
shown O 
to O 
be O 
negligible O 
for O 
the O 
very O 
rapid O 
rotation O 
of O 
PDT B-ABBREVIATION 
in O 
these O 
liquids O 
at O 
the O 
temperatures O 
of O 
the O 
study O 
. O 
The O 
rotational O 
correlation O 
times O 
obtained O 
with O 
the O 
proposed O 
method O 
generally O 
agree O 
to O 
within O 
experimental O 
uncertainty O 
with O 
those O 
determined O 
by O 
using O 
the O 
traditional O 
parameters O 
. O 
Using O 
the O 
middle O 
line O 
width O 
offers O 
greater O 
precision O 
and O 
smoother O 
trends O 
. O 
Previous O 
work O 
with O 
the O 
central O 
line O 
width O 
is O 
discussed O 
, O 
and O 
past O 
discrepancies O 
are O 
explained O 
as O 
possibly O 
resulting O 
from O 
residual O 
inhomogeneous O 
broadening O 
. O 
The O 
rotational O 
correlation O 
time O 
almost O 
forms O 
a O 
common O 
curve O 
across O 
all O 
of O 
the O 
solvents O 
when O 
plotted O 
with O 
respect O 
to O 
isothermal O 
compressibility O 
, O 
which O 
shows O 
the O 
high O 
dependence O 
of O 
rotation O 
on O 
liquid O 
free O 
volume O 
. O 

evidence O 
for O 
the O 
sleep O 
- O 
promoting O 
effects O 
of O 
5-HT2A O 
receptor O 
antagonists O 
and O 
demonstration O 
of O 
synergistic O 
effects O 
with O 
the O 
hypnotic O 
, O 
zolpidem B-TRIVIAL 
in O 
rats O 
. O 

( O 
5-HT B-SYSTEMATIC 
)2A O 
antagonists O 
are O 
promising O 
therapeutic O 
agents O 
for O 
the O 
treatment O 
of O 
sleep O 
maintenance O 
insomnias O 
, O 
but O 
unlike O 
hypnotics O 
, O 
they O 
have O 
limited O 
effects O 
on O 
sleep O 
initiation O 
. O 
This O 
study O 
evaluated O 
the O 
effects O 
of O 
several O 
5-HT2A O 
antagonists O 
( O 
eplivanserin B-TRIVIAL 
, O 
volinanserin B-TRIVIAL 
and O 
AVE8488 B-NO_CLASS 
) O 
alone O 
and O 
/ O 
or O 
in O 
combination O 
with O 
the O 
short O 
- O 
acting O 
hypnotic O 
, O 
zolpidem B-TRIVIAL 
, O 
on O 
the O 
rat O 
sleep O 
profile O 
. O 
A O 
repeated O 
- O 
measures O 
design O 
was O 
used O 
in O 
which O 
rats O 
were O 
treated O 
with O 
eplivanserin B-TRIVIAL 
( O 
3 O 
and O 
10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
or O 
p.o O 
. O 
) O 
, O 
volinanseri B-TRIVIAL 
n O 
( O 
0.3-3 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
, B-NO_CLASS 
AVE84 I-NO_CLASS 
88 O 
( O 
0.1-3 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
an O 
d B-TRIVIAL 
zolpid I-TRIVIAL 
em O 
( O 
3 O 
and O 
10 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
In O 
addition O 
, O 
animals O 
received O 
a O 
combination O 
o O 
f B-TRIVIAL 
eplivanser I-TRIVIAL 
in O 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
an O 
d B-TRIVIAL 
zolpid I-TRIVIAL 
em O 
( O 
3 O 
mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
Electroencephalogram O 
was O 
analyzed O 
for O 
6 O 
h O 
after O 
administration O 
. O 
Eplivanserin O 
did O 
not O 
modify O 
wakefulness O 
and O 
non-rapid O 
eye O 
movement O 
sleep O 
( O 
NREMS O 
) O 
, O 
whil O 
e B-TRIVIAL 
zolpid I-TRIVIAL 
em O 
( O 
10 O 
mg O 
/ O 
kg O 
po O 
) O 
induced O 
a O 
marked O 
increase O 
in O 
NREMS O 
duration O 
. O 
Volinanserin O 
( O 
1 O 
and O 
3 O 
mg O 
/ O 
kg O 
) O 
an O 
d B-NO_CLASS 
AVE84 I-NO_CLASS 
88 O 
( O 
0.3 O 
mg O 
/ O 
kg O 
) O 
similarly O 
increased O 
NREMS O 
, O 
while O 
reducing O 
wakefulness O 
. O 
Moreover O 
, O 
the O 
5-HT2A O 
antagonists O 
and O 
, O 
to O 
a O 
lesser O 
extent O 
, B-TRIVIAL 
zolpid I-TRIVIAL 
em O 
, O 
increased O 
duration O 
of O 
NREMS O 
episodes O 
, O 
while O 
decreasing O 
their O 
frequency O 
. O 
Whe O 
n B-TRIVIAL 
eplivanser I-TRIVIAL 
in O 
was O 
co O 
- O 
administered O 
wit O 
h B-TRIVIAL 
zolpid I-TRIVIAL 
em O 
, O 
a O 
synergistic O 
effect O 
was O 
observed O 
as O 
the O 
combination O 
produced O 
an O 
increase O 
in O 
NREMS O 
time O 
and O 
bouts O 
duration O 
. O 
These O 
findings O 
confirm O 
further O 
that O 
5-HT2A O 
antagonists O 
promote O 
the O 
maintenance O 
of O 
sleep O 
, O 
and O 
suggest O 
that O 
combining O 
a O 
5-HT2A O 
antagonist O 
with O 
a O 
short O 
- O 
acting O 
hypnotic O 
may O 
be O 
a O 
useful O 
strategy O 
for O 
the O 
treatment O 
of O 
insomnia O 
. O 

of O 
permethylated B-FAMILY 
transition I-FAMILY 
- I-FAMILY 
metal I-FAMILY 
sandwich O 
complexes O 
as O 
internal O 
reference O 
redox O 
systems O 
in O 
ionic O 
liquids O 
. O 

work O 
reports O 
the O 
voltammetric O 
behaviour O 
of O 
decamethylcobaltocenium B-SYSTEMATIC 
, O 
DmCc(+) B-ABBREVIATION 
, O 
in O 
different O 
ionic O 
liquids O 
for O 
the O 
first O 
time O 
. O 
Its O 
redox O 
potential O 
was O 
studied O 
relative O 
to O 
that O 
of O 
decamethylferrocene B-SYSTEMATIC 
, O 
DmFc B-ABBREVIATION 
, O 
and O 
it O 
is O 
shown O 
that O 
the O 
difference O 
in O 
the O 
mid O 
- O 
point O 
potential O 
between O 
these O 
two O 
permethylated B-FAMILY 
transition I-FAMILY 
- I-FAMILY 
metal I-FAMILY 
sandwich O 
complexes O 
is O 
independent O 
of O 
the O 
ionic O 
liquid O 
composition O 
. O 
A O 
variable O 
difference O 
in O 
mid O 
- O 
point O 
potential O 
, O 
in O 
contrast O 
, O 
was O 
observed O 
for O 
ferrocene B-TRIVIAL 
and O 
cobaltocenium B-SYSTEMATIC 
relative O 
to O 
that O 
of O 
DmFc B-ABBREVIATION 
in O 
similar O 
ionic O 
liquids O 
. O 
In O 
addition O 
, O 
different O 
limitations O 
in O 
the O 
application O 
of O 
DmFc(0 B-ABBREVIATION 
/ I-ABBREVIATION 
+ I-ABBREVIATION 
) I-ABBREVIATION 
and O 
DmCc(+ B-ABBREVIATION 
/ I-ABBREVIATION 
0 I-ABBREVIATION 
) I-ABBREVIATION 
couples O 
as O 
internal O 
reference O 
redox O 
systems O 
in O 
ILs O 
are O 
discussed O 
. O 
From O 
these O 
, O 
the O 
observed O 
spontaneous O 
reaction O 
between O 
DmFc B-ABBREVIATION 
and O 
oxygen O 
leads O 
to O 
important O 
implications O 
toward O 
the O 
establishment O 
of O 
particular O 
conditions O 
for O 
DmFc B-ABBREVIATION 
applications O 
. O 

palmitoyltransferase O 
2 O 
and O 
carnitine B-TRIVIAL 
/ O 
acylcarnitine B-SYSTEMATIC 
translocase O 
are O 
involved O 
in O 
the O 
mitochondrial O 
synthesis O 
and O 
export O 
of O 
acylcarnitines B-FAMILY 
. O 

are O 
commonly O 
used O 
in O 
the O 
diagnosis O 
of O 
mitochondrial O 
fatty B-FAMILY 
acid I-FAMILY 
β-oxidation O 
disorders O 
( O 
mFAODs O 
) O 
. O 
It O 
is O 
generally O 
assumed O 
that O 
this O 
plasma O 
acylcarnitine B-SYSTEMATIC 
profile O 
reflects O 
the O 
mitochondrial O 
accumulation O 
of O 
acyl-CoAs B-FAMILY 
. O 
The O 
identity O 
of O 
the O 
enzymes O 
and O 
the O 
mitochondrial O 
and O 
plasmalemmal O 
transporters O 
involved O 
in O 
the O 
synthesis O 
and O 
export O 
of O 
these O 
metabolites O 
have O 
remained O 
undefined O 
. O 
We O 
used O 
lentiviral O 
shRNA O 
to O 
knock O 
down O 
the O 
expression O 
of O 
medium O 
- O 
chain O 
acyl-CoA B-ABBREVIATION 
dehydrogenase O 
( O 
MCAD O 
) O 
in O 
control O 
and O 
carnitine B-TRIVIAL 
palmitoyltransferase O 
2 O 
(CPT2)- O 
, O 
carnitine B-TRIVIAL 
/ O 
acylcarnitine B-SYSTEMATIC 
translocase O 
(CACT)- O 
, O 
and O 
plasmalemmal O 
carnitine B-TRIVIAL 
transporter O 
(OCTN2)-deficient O 
human O 
fibroblasts O 
. O 
These O 
cell O 
lines O 
, O 
including O 
mock O 
- O 
transduced O 
controls O 
, O 
were O 
loaded O 
with O 
decanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
carnitine B-TRIVIAL 
, O 
followed O 
by O 
the O 
measurement O 
of O 
the O 
acylcarnitine B-SYSTEMATIC 
profile O 
in O 
the O 
extracellular O 
medium O 
. O 
In O 
control O 
fibroblasts O 
, O 
MCAD O 
knockdown O 
markedly O 
increased O 
the O 
production O 
of O 
octanoylcarnitine B-SYSTEMATIC 
( O 
3-fold O 
, O 
P O 
< O 
0.01 O 
) O 
. O 
OCTN2-deficient O 
cell O 
lines O 
also O 
showed O 
extracellular O 
accumulation O 
of O 
octanoylcarnitine B-SYSTEMATIC 
( O 
2.8-fold O 
, O 
P O 
< O 
0.01 O 
) O 
, O 
suggesting O 
that O 
the O 
cellular O 
export O 
of O 
acylcarnitines B-FAMILY 
does O 
not O 
depend O 
on O 
OCTN2 O 
. O 
In O 
contrast O 
, O 
in O 
CPT2- O 
and O 
CACT-deficient O 
cells O 
, O 
the O 
accumulation O 
of O 
octanoylcarnitine B-SYSTEMATIC 
in O 
the O 
medium O 
did O 
not O 
significantly O 
increase O 
in O 
the O 
MCAD O 
knockdown O 
. O 
Similar O 
results O 
were O 
obtained O 
using O 
pharmacological O 
inhibition O 
of O 
CPT2 O 
in O 
fibroblasts O 
from O 
MCAD-deficient O 
individuals O 
. O 
This O 
shows O 
that O 
CPT2 O 
and O 
CACT O 
are O 
crucial O 
for O 
mitochondrial O 
acylcarnitine B-SYSTEMATIC 
formation O 
and O 
export O 
to O 
the O 
extracellular O 
fluids O 
in O 
mFAOD.-Violante O 
, O 
S O 
. O 
, O 
IJlst O 
, O 
L O 
. O 
, O 
te O 
Brinke O 
, O 
H O 
. O 
, O 
Tavares O 
de O 
Almeida O 
, O 
I O 
. O 
, O 
Wanders O 
, O 
R O 
. O 
J O 
. O 
A O 
. O 
, O 
Ventura O 
, O 
F O 
. O 
V O 
. O 
, O 
Houten O 
, O 
S O 
. O 
M O 
. O 
Carnitine B-TRIVIAL 
palmitoyltransferase O 
2 O 
and O 
carnitine B-TRIVIAL 
/ O 
acylcarnitine B-SYSTEMATIC 
translocase O 
are O 
involved O 
in O 
the O 
mitochondrial O 
synthesis O 
and O 
export O 
of O 
acylcarnitines B-FAMILY 
. O 

mechanism O 
for O 
biological O 
effect O 
following O 
exposure O 
to O 
combustion O 
- O 
generated O 
particles O 
is O 
incompletely O 
defined O 
. O 
The O 
identification O 
of O 
pathways O 
regulating O 
the O 
acute O 
toxicological O 
effects O 
of O 
these O 
particles O 
provides O 
specific O 
targets O 
for O 
therapeutic O 
manipulation O 
in O 
an O 
attempt O 
to O 
impact O 
disease O 
following O 
exposures O 
. O 
Transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
cation O 
channels O 
were O 
identified O 
as O 
" O 
particle O 
sensors O 
" O 
in O 
that O 
their O 
activation O 
was O 
coupled O 
with O 
the O 
initiation O 
of O 
protective O 
responses O 
limiting O 
airway O 
deposition O 
and O 
inflammatory O 
responses O 
, O 
which O 
promote O 
degradation O 
and O 
clearance O 
of O 
the O 
particles O 
. O 
TRPA1 O 
, O 
V1 O 
, O 
V4 O 
, O 
and O 
M8 O 
have O 
a O 
capacity O 
to O 
mediate O 
adverse O 
effects O 
after O 
exposure O 
to O 
combustion O 
- O 
generated O 
particulate O 
matter O 
( O 
PM O 
) O 
; O 
relative O 
contributions O 
of O 
each O 
depend O 
upon O 
particle O 
composition O 
, O 
dose O 
, O 
and O 
deposition O 
. O 
Exposure O 
of O 
human O 
bronchial O 
epithelial O 
cells O 
to O 
an O 
organic O 
extract O 
of O 
diesel O 
exhaust O 
particle O 
was O 
followed O 
by O 
TRPV4 O 
mediating O 
Ca(++) B-FORMULA 
influx O 
, O 
increased O 
RAS O 
expression O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
signaling O 
, O 
and O 
matrix O 
metalloproteinase-1 O 
activation O 
. O 
These O 
novel O 
pathways O 
of O 
biological O 
effect O 
can O 
be O 
targeted O 
by O 
compounds O 
that O 
specifically O 
inhibit O 
critical O 
signaling O 
reactions O 
. O 
In O 
addition O 
to O 
TRPs O 
and O 
calcium B-SYSTEMATIC 
biochemistry O 
, O 
humic O 
- O 
like O 
substances O 
( O 
HLS O 
) O 
and O 
cell O 
/ O 
tissue O 
iron B-SYSTEMATIC 
equilibrium O 
were O 
identified O 
as O 
potential O 
mechanistic O 
targets O 
in O 
lung O 
injury O 
after O 
particle O 
exposure O 
. O 
In O 
respiratory O 
epithelial O 
cells O 
, O 
iron B-SYSTEMATIC 
sequestration O 
by O 
HLS O 
in O 
wood O 
smoke O 
particle O 
( O 
WSP O 
) O 
was O 
associated O 
with O 
oxidant O 
generation O 
, O 
cell O 
signaling O 
, O 
transcription O 
factor O 
activation O 
, O 
and O 
release O 
of O 
inflammatory O 
mediators O 
. O 
Similar O 
to O 
WSP O 
, O 
cytotoxic O 
insoluble O 
nanosized O 
spherical O 
particles O 
composed O 
of O 
HLS O 
were O 
isolated O 
from O 
cigarette O 
smoke O 
condensate O 
. O 
Therapies O 
that O 
promote O 
bioelimination O 
of O 
HLS O 
and O 
prevent O 
the O 
disruption O 
of O 
iron B-SYSTEMATIC 
homeostasis O 
could O 
function O 
to O 
reduce O 
the O 
harmful O 
effects O 
of O 
combustion O 
- O 
generated O 
PM O 
exposure O 
. O 

tolerance O 
and O 
genetic O 
diversity O 
of O 
Porcellionides O 
sexfasciatus O 
( O 
ISOPODA O 
) O 
in O 
a O 
highly O 
contaminated O 
mine O 
habitat O 
. O 

inhabiting O 
metal O 
- O 
contaminated O 
areas O 
may O 
develop O 
metal O 
tolerance O 
, O 
with O 
either O 
phenotypic O 
adjustments O 
or O 
genetic O 
changes O 
( O 
adaptation O 
) O 
or O 
with O 
both O 
. O 
In O 
the O 
present O 
study O 
, O 
three O 
populations O 
of O 
the O 
terrestrial O 
isopod O 
Porcellionides O 
sexfasciatus O 
, O 
collected O 
at O 
an O 
abandoned O 
mine O 
area O 
, O 
were O 
compared O 
to O 
assess O 
the O 
effects O 
of O 
metal O 
contamination O 
on O 
tolerance O 
to O 
lethal O 
and O 
sublethal O 
levels O 
of O 
copper B-SYSTEMATIC 
, O 
through O 
comparison O 
of O 
survival O 
, O 
avoidance O 
, O 
and O 
feeding O 
. O 
The O 
effects O 
of O 
metal O 
contamination O 
on O 
genetic O 
diversity O 
were O 
considered O 
using O 
random O 
amplified O 
polymorphic O 
DNA O 
( O 
RAPD O 
) O 
markers O 
. O 
No O 
evidence O 
of O 
increased O 
metal O 
tolerance O 
of O 
the O 
population O 
inhabiting O 
the O 
contaminated O 
site O 
was O 
found O 
. O 
There O 
was O 
no O 
correlation O 
between O 
metal O 
exposure O 
and O 
within O 
- O 
population O 
genetic O 
variance O 
, O 
but O 
the O 
three O 
populations O 
were O 
clearly O 
separated O 
from O 
each O 
other O 
. O 
In O 
conclusion O 
, O 
the O 
populations O 
of O 
P O 
. O 
sexfasciatus O 
in O 
the O 
mine O 
landscape O 
live O 
rather O 
isolated O 
from O 
each O 
other O 
and O 
show O 
no O 
differential O 
tolerance O 
to O 
Cu O 
or O 
indications O 
of O 
genetic O 
erosion O 
. O 
Their O 
phenotypic O 
plasticity O 
provides O 
a O 
means O 
to O 
survive O 
despite O 
exposure O 
to O 
extremely O 
high O 
metal O 
concentrations O 
in O 
the O 
soil O 
. O 

monoterpene B-FAMILY 
lactones I-FAMILY 
from O 
Actaea O 
cimicifuga O 
. O 

new O 
monoterpene B-FAMILY 
lactones I-FAMILY 
, O 
cimicifugolides B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
along O 
with O 
a O 
known O 
one O 
( O 
4 O 
) O 
, O 
were O 
identified O 
from O 
the O 
dried O 
rhizome O 
of O 
Actaea O 
cimicifuga O 
L. O 
that O 
was O 
used O 
as O 
traditional O 
Chinese O 
medicine O 
for O 
thousands O 
of O 
years O 
with O 
the O 
Chinese O 
common O 
name O 
of O 
shengma O 
. O 
The O 
structures O 
of O 
the O 
new O 
isolates O 
were O 
established O 
using O 
spectroscopic O 
methods O 
, O 
including O 
NMR O 
, O 
mass O 
, O 
UV O 
, O 
and O 
IR O 
spectra O 
. O 
The O 
inhibition O 
activity O 
of O 
compounds O 
1 O 
, O 
2 O 
, O 
and O 
4 O 
against O 
pancreatic O 
lipase O 
was O 
evaluated O 
. O 

- O 
activity O 
relationships O 
of O 
glucosamine B-TRIVIAL 
-derived O 
glycerolipids O 
: O 
the O 
role O 
of O 
the O 
anomeric O 
linkage O 
, O 
the O 
cationic O 
charge O 
and O 
the O 
glycero B-SYSTEMATIC 
moiety O 
on O 
the O 
antitumor O 
activity O 
. O 

potent O 
antitumor O 
activity O 
of O 
1-O-hexadecyl-2-O-methyl-3-O-(2'-amino-2'-deoxy-β-D-glucopyranosyl)-sn-glycerol B-SYSTEMATIC 
( O 
1 O 
) O 
was O 
previously O 
shown O 
to O 
arise O 
through O 
an O 
apoptosis O 
- O 
independent O 
pathway O 
. O 
Here O 
, O 
a O 
systematic O 
structure O 
- O 
activity O 
study O 
in O 
which O 
the O 
effects O 
of O 
the O 
anomeric O 
linkage O 
, O 
the O 
cationic O 
charge O 
and O 
the O 
glycero O 
moiety O 
on O 
the O 
antitumor O 
activity O 
is O 
described O 
. O 
Eight O 
analogues O 
of O 
1 O 
were O 
synthesized O 
, O 
and O 
their O 
antitumor O 
activity O 
against O 
breast O 
( O 
JIMT1 O 
and O 
BT549 O 
) O 
, O 
pancreas O 
( O 
MiaPaCa2 O 
) O 
and O 
prostate O 
( O 
DU145 O 
, O 
PC3 O 
) O 
cancer O 
was O 
determined O 
. O 
1-O-Hexadecyl-2-O-methyl-3-O-(2'-amino-2'-deoxy-α-D-glucopyranosyl)-sn-glycerol B-SYSTEMATIC 
( O 
2 O 
) O 
consistently O 
displayed O 
the O 
most O 
potent O 
activity O 
against O 
all O 
five O 
cell O 
lines O 
with O 
CC(50) O 
values O 
in O 
the O 
range O 
of O 
6-10 O 
μM O 
. O 
However O 
, O 
replacement O 
of O 
the O 
O B-FORMULA 
-glycosidic O 
linkage O 
by O 
a O 
thioglycosidic B-FAMILY 
linkage O 
or O 
replacement O 
of O 
the O 
amino B-FAMILY 
group O 
by O 
an O 
azide B-SYSTEMATIC 
or O 
guanidino B-SYSTEMATIC 
group O 
leads O 
to O 
a O 
threefold O 
or O 
greater O 
decrease O 
in O 
potency O 
. O 
The O 
glycero B-SYSTEMATIC 
moiety O 
also O 
contributes O 
to O 
the O 
overall O 
activity O 
of O 
1 O 
and O 
2 O 
but O 
its O 
effects O 
are O 
of O 
lesser O 
importance O 
. O 
Investigation O 
into O 
the O 
mode O 
of O 
action O 
of O 
this O 
class O 
of O 
compounds O 
revealed O 
that O 
, O 
in O 
agreement O 
with O 
previous O 
findings O 
, O 
the O 
cytotoxic O 
effects O 
arise O 
through O 
induction O 
of O 
large O 
acid O 
vacuoles O 
. O 

unique O 
palladium B-SYSTEMATIC 
catalyst O 
for O 
efficient O 
and O 
selective O 
alkoxycarbonylation O 
of O 
olefins B-FAMILY 
with O 
formates B-FAMILY 
. O 

about O 
CO B-FORMULA 
! O 
Carbonylations O 
are O 
among O 
the O 
most O 
important O 
homogeneously O 
catalyzed O 
reactions O 
in O 
the O 
chemical O 
industry O 
, O 
but O 
typically O 
require O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
. O 
Instead O 
, O 
straightforward O 
and O 
efficient O 
alkoxycarbonylations O 
of O 
olefins B-FAMILY 
can O 
proceed O 
with O 
alkyl B-FAMILY 
formates I-FAMILY 
in O 
the O 
presence O 
of O 
a O 
specific O 
palladium B-SYSTEMATIC 
catalyst O 
. O 
Aromatic O 
, O 
terminal O 
aliphatic O 
, O 
and O 
internal O 
olefins B-FAMILY 
are O 
carbonylated O 
to O 
give O 
industrially O 
important O 
linear O 
esters B-FAMILY 
at O 
low O 
catalyst O 
loadings O 
. O 

, O 
characterization O 
, O 
and O 
cure O 
chemistry O 
of O 
renewable O 
bis(cyanate) B-FAMILY 
esters I-FAMILY 
derived O 
from O 
2-methoxy-4-methylphenol B-SYSTEMATIC 
. O 

series O 
of O 
renewable O 
bis(cyanate) B-FAMILY 
esters I-FAMILY 
have O 
been O 
prepared O 
from O 
bisphenols B-FAMILY 
synthesized O 
by O 
condensation O 
of O 
2-methoxy-4-methylphenol B-SYSTEMATIC 
( O 
creosol B-TRIVIAL 
) O 
with O 
formaldehyde B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
, O 
and O 
propionaldehyde B-SYSTEMATIC 
. O 
The O 
cyanate B-FAMILY 
esters I-FAMILY 
have O 
been O 
fully O 
characterized O 
by O 
infrared O 
spectroscopy O 
, O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
, O 
and O 
single O 
crystal O 
X-ray O 
diffraction O 
. O 
These O 
compounds O 
melt O 
from O 
88 O 
to O 
143 O 
°C O 
, O 
while O 
cured O 
resins O 
have O 
glass O 
transition O 
temperatures O 
from O 
219 O 
to O 
248 O 
°C O 
, O 
water O 
uptake O 
( O 
96 O 
h O 
, O 
85 O 
°C O 
immersion O 
) O 
in O 
the O 
range O 
of O 
2.05-3.21% O 
, O 
and O 
wet O 
glass O 
transition O 
temperatures O 
from O 
174 O 
to O 
193 O 
°C O 
. O 
These O 
properties O 
suggest O 
that O 
creosol B-TRIVIAL 
-derived O 
cyanate B-FAMILY 
esters I-FAMILY 
may O 
be O 
useful O 
for O 
a O 
wide O 
variety O 
of O 
military O 
and O 
commercial O 
applications O 
. O 
The O 
cure O 
chemistry O 
of O 
the O 
cyanate B-FAMILY 
esters I-FAMILY 
has O 
been O 
studied O 
with O 
FTIR O 
spectroscopy O 
and O 
differential O 
scanning O 
calorimetry O 
. O 
The O 
results O 
show O 
that O 
cyanate B-FAMILY 
esters I-FAMILY 
with O 
more O 
sterically O 
demanding O 
bridging O 
groups O 
cure O 
more O 
slowly O 
, O 
but O 
also O 
more O 
completely O 
than O 
those O 
with O 
a O 
bridging O 
methylene B-SYSTEMATIC 
group O 
. O 
In O 
addition O 
to O 
the O 
structural O 
differences O 
, O 
the O 
purity O 
of O 
the O 
cyanate B-FAMILY 
esters I-FAMILY 
has O 
a O 
significant O 
effect O 
on O 
both O 
the O 
cure O 
chemistry O 
and O 
final O 
Tg O 
of O 
the O 
materials O 
. O 
In O 
some O 
cases O 
, O 
post O 
- O 
cure O 
of O 
the O 
resins O 
at O 
350 O 
°C O 
resulted O 
in O 
significant O 
decomposition O 
and O 
off O 
- O 
gassing O 
, O 
but O 
cure O 
protocols O 
that O 
terminated O 
at O 
250-300 O 
°C O 
generated O 
void O 
- O 
free O 
resin O 
pucks O 
without O 
degradation O 
. O 
Thermogravimetric O 
analysis O 
revealed O 
that O 
cured O 
resins O 
were O 
stable O 
up O 
to O 
400 O 
°C O 
and O 
then O 
rapidly O 
degraded O 
. O 
TGA O 
/ O 
FTIR O 
and O 
mass O 
spectrometry O 
results O 
showed O 
that O 
the O 
resins O 
decomposed O 
to O 
phenols B-FAMILY 
, O 
isocyanic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
secondary O 
decomposition O 
products O 
, O 
including O 
CO2 B-FORMULA 
. O 
Char O 
yields O 
of O 
cured O 
resins O 
under O 
N2 B-FORMULA 
ranged O 
from O 
27 O 
to O 
35% O 
, O 
while O 
char O 
yields O 
in O 
air O 
ranged O 
from O 
8 O 
to O 
11% O 
. O 
These O 
data O 
suggest O 
that O 
resins O 
of O 
this O 
type O 
may O 
potentially O 
be O 
recycled O 
to O 
parent O 
phenols B-FAMILY 
, O 
creosol B-TRIVIAL 
, O 
and O 
other O 
alkylated B-FAMILY 
creosols I-FAMILY 
by O 
pyrolysis O 
in O 
the O 
presence O 
of O 
excess O 
water O 
vapor O 
. O 
The O 
ability O 
to O 
synthesize O 
these O 
high O 
temperature O 
resins O 
from O 
a O 
phenol B-SYSTEMATIC 
( O 
creosol B-TRIVIAL 
) O 
that O 
can O 
be O 
derived O 
from O 
lignin O 
, O 
coupled O 
with O 
the O 
potential O 
to O 
recycle O 
the O 
composites O 
, O 
provides O 
a O 
possible O 
route O 
to O 
the O 
production O 
of O 
sustainable O 
, O 
high O 
- O 
performance O 
, O 
thermosetting O 
resins O 
with O 
reduced O 
environmental O 
impact O 
. O 

situ O 
TEM O 
of O 
two O 
- O 
phase O 
lithiation O 
of O 
amorphous O 
silicon B-SYSTEMATIC 
nanospheres O 
. O 

utilize O 
high O 
- O 
capacity O 
Si B-FORMULA 
anodes O 
in O 
next O 
- O 
generation O 
Li B-FORMULA 
-ion O 
batteries O 
, O 
the O 
physical O 
and O 
chemical O 
transformations O 
during O 
the O 
Li-Si B-FORMULA 
reaction O 
must O 
be O 
better O 
understood O 
. O 
Here O 
, O 
in O 
situ O 
transmission O 
electron O 
microscopy O 
is O 
used O 
to O 
observe O 
the O 
lithiation O 
/ O 
delithiation O 
of O 
amorphous O 
Si B-FORMULA 
nanospheres O 
; O 
amorphous O 
Si B-FORMULA 
is O 
an O 
important O 
anode O 
material O 
that O 
has O 
been O 
less O 
studied O 
than O 
crystalline O 
Si B-FORMULA 
. O 
Unexpectedly O 
, O 
the O 
experiments O 
reveal O 
that O 
the O 
first O 
lithiation O 
occurs O 
via O 
a O 
two O 
- O 
phase O 
mechanism O 
, O 
which O 
is O 
contrary O 
to O 
previous O 
understanding O 
and O 
has O 
important O 
consequences O 
for O 
mechanical O 
stress O 
evolution O 
during O 
lithiation O 
. O 
On O 
the O 
basis O 
of O 
kinetics O 
measurements O 
, O 
this O 
behavior O 
is O 
suggested O 
to O 
be O 
due O 
to O 
the O 
rate O 
- O 
limiting O 
effect O 
of O 
Si-Si B-FORMULA 
bond O 
breaking O 
. O 
In O 
addition O 
, O 
the O 
results O 
show O 
that O 
amorphous O 
Si B-FORMULA 
has O 
more O 
favorable O 
kinetics O 
and O 
fracture O 
behavior O 
when O 
reacting O 
with O 
Li B-FORMULA 
than O 
does O 
crystalline O 
Si B-FORMULA 
, O 
making O 
it O 
advantageous O 
to O 
use O 
in O 
battery O 
electrodes O 
. O 
Amorphous O 
spheres O 
up O 
to O 
870 O 
nm O 
in O 
diameter O 
do O 
not O 
fracture O 
upon O 
lithiation O 
; O 
this O 
is O 
much O 
larger O 
than O 
the O 
150 O 
nm O 
critical O 
fracture O 
diameter O 
previously O 
identified O 
for O 
crystalline O 
Si B-FORMULA 
spheres O 
. O 

carboxylic B-FAMILY 
acids I-FAMILY 
from O 
Lysimachia O 
clethroides O 
. O 

new O 
carboxylic B-FAMILY 
acids I-FAMILY 
( O 
1-6 O 
) O 
, O 
together O 
with O 
11 O 
known O 
ones O 
( O 
7-17 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Lysimachia O 
clethroides O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
analysis O 
and O 
chemical O 
evidence O 
. O 
Five O 
new O 
carboxylic B-FAMILY 
acids I-FAMILY 
( O 
1 O 
and O 
3-6 O 
) O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
inhibitory O 
activity O 
against O 
aldose B-FAMILY 
reductase O 
. O 

new O 
pyrrolo[1,2-α]azepine B-SYSTEMATIC 
-type O 
stemona O 
alkaloids O 
, O 
named O 
as O 
tuberostemonoxirine B-TRIVIAL 
( O 
1 O 
) O 
and O 
9α-epi-tuberospironine B-TRIVIAL 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Stemona O 
tuberosa O 
. O 
The O 
structures O 
and O 
relative O 
configurations O 
of O 
new O 
compounds O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
evidences O 
, O 
especially O 
1D O 
and O 
2D O 
NMR O 
and O 
HR-MS O 
experiments O 
. O 

and O 
application O 
of O 
anthracene B-SYSTEMATIC 
derivative O 
with O 
aggregation O 
- O 
induced O 
emission O 
charateristics O 
for O 
visualization O 
and O 
monitoring O 
of O 
erythropoietin O 
unfolding O 
. O 

( O 
EPO O 
) O 
is O 
an O 
attractive O 
protein O 
- O 
unfolding O 
/ O 
folding O 
model O 
because O 
of O 
its O 
high O 
degree O 
of O 
unfolding O 
and O 
folding O 
reversibility O 
and O 
intermediate O 
size O 
. O 
Due O 
to O 
its O 
function O 
for O 
regulating O 
red O 
blood O 
cell O 
production O 
by O 
stimulating O 
late O 
erythroid O 
precursor O 
cells O 
, O 
EPO O 
presents O 
obvious O 
values O 
to O 
biological O 
research O 
. O 
A O 
nonemissive O 
anthracene B-SYSTEMATIC 
derivative O 
, O 
that O 
is O 
9,10-bis[4-(3-sulfonatopropoxyl)-styryl]anthracene B-SYSTEMATIC 
sodium I-SYSTEMATIC 
salt I-SYSTEMATIC 
( O 
BSPSA B-ABBREVIATION 
) O 
, O 
with O 
aggregation O 
- O 
induced O 
emission O 
( O 
AIE O 
) O 
charateristics O 
shows O 
a O 
novel O 
phenomenon O 
of O 
AIE O 
when O 
EPO O 
is O 
added O 
. O 
The O 
AIE O 
biosensor O 
for O 
EPO O 
shows O 
the O 
limit O 
of O 
detection O 
is O 
1 O 
× O 
10(-9) O 
M O 
. O 
Utilizing O 
the O 
AIE O 
feature O 
of O 
BSPSA B-ABBREVIATION 
, O 
the O 
unfolding O 
process O 
of O 
EPO O 
using O 
guanidine B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
is O 
monitored O 
, O 
which O 
indicates O 
three O 
steps O 
for O 
the O 
folding O 
structures O 
of O 
EPO O 
to O 
transform O 
to O 
random O 
coil O 
. O 
Computational O 
modeling O 
suggests O 
that O 
the O 
BSPSA B-ABBREVIATION 
luminogens O 
prefer O 
docking O 
in O 
the O 
hydrophobic O 
cavity O 
in O 
the O 
EPO O 
folding O 
structures O 
, O 
and O 
the O 
assembly O 
of O 
BSPSA B-ABBREVIATION 
in O 
this O 
cavity O 
makes O 
the O 
AIE O 
available O 
, O 
making O 
the O 
monitoring O 
of O 
unfolding O 
of O 
EPO O 
possible O 
. O 

cationic O 
liposomes O 
modified O 
with O 
3β-{N-[(N',N'-dimethylamino)ethyl]carbamoyl}cholesterol B-SYSTEMATIC 
can O 
induce O 
partial O 
conformational O 
changes O 
in O 
messenger O 
RNA O 
and O 
regulate O 
translation O 
in O 
an O 
Escherichia O 
coli O 
cell O 
- O 
free O 
translation O 
system O 
. O 

effect O 
of O 
cationic O 
liposomes O 
( O 
CLs O 
) O 
on O 
messenger O 
RNA(mRNA) O 
conformation O 
and O 
translation O 
was O 
studied O 
, O 
focusing O 
on O 
membrane O 
heterogeneity O 
. O 
CLs O 
, O 
composed O 
of O 
1,2-dioleoyl-sn-glycerol-3-phosphocholine B-SYSTEMATIC 
/ O 
1,2-dioleoyl-3-timethylammonium B-SYSTEMATIC 
propane I-SYSTEMATIC 
( O 
DOPC B-ABBREVIATION 
/ O 
DOTAP B-ABBREVIATION 
) O 
and O 
DOPC B-ABBREVIATION 
/ O 
3β-{N-[(N',N'-dimethylamino)ethyl]carbamoyl}cholesterol B-SYSTEMATIC 
( O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
) O 
, O 
inhibited O 
mRNA O 
translation O 
in O 
an O 
Escherichia O 
coli O 
cell O 
- O 
free O 
translation O 
system O 
. O 
Analysis O 
of O 
the O 
membrane O 
fluidity O 
and O 
polarity O 
indicated O 
a O 
heterogeneous O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
membrane O 
, O 
while O 
other O 
CLs O 
exhibited O 
homogeneous O 
disordered O 
membranes O 
. O 
mRNA O 
adsorbed O 
onto O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
liposomes O 
showed O 
translational O 
activity O 
, O 
while O 
DOPC B-ABBREVIATION 
/ O 
DOTAP B-ABBREVIATION 
liposomes O 
inhibited O 
mRNA O 
translation O 
in O 
proportion O 
to O 
its O 
adsorption O 
onto O 
membranes O 
. O 
Dehydration O 
of O 
DOPC B-ABBREVIATION 
/ O 
DOTAP B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
and O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
was O 
observed O 
in O 
the O 
presence O 
of O 
mRNA O 
but O 
not O 
in O 
the O 
case O 
of O 
zwitterionic O 
DOPC B-ABBREVIATION 
liposomes O 
, O 
indicating O 
that O 
mRNA O 
binds O 
in O 
regions O 
between O 
the O 
phosphate B-SYSTEMATIC 
[ O 
- O 
PO(2)(-) B-FORMULA 
- O 
] O 
and O 
carbonyl B-FAMILY 
[ O 
- O 
C=O B-FORMULA 
- O 
] O 
moieties O 
of O 
lipids O 
. O 
UV O 
resonance O 
Raman O 
spectroscopy O 
suggests O 
that O 
adenine B-TRIVIAL 
, O 
cytosine B-TRIVIAL 
, O 
and O 
guanine B-TRIVIAL 
interact O 
with O 
DOPC B-ABBREVIATION 
/ O 
DOTAP B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
and O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
but O 
not O 
with O 
DOPC B-ABBREVIATION 
. O 
Circular O 
dichroism O 
indicates O 
that O 
DOPC B-ABBREVIATION 
/ O 
DOTAP B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
extensively O 
denatured O 
the O 
mRNA O 
. O 
In O 
contrast O 
, O 
heterogeneous O 
DOPC B-ABBREVIATION 
/ O 
DC-Ch B-ABBREVIATION 
( O 
70 O 
/ O 
30 O 
) O 
induced O 
partial O 
conformational O 
changes O 
but O 
maintained O 
the O 
translational O 
activity O 
of O 
mRNA O 
. O 

new O 
diterpenoids B-FAMILY 
from O 
Excoecaria O 
acerifolia O 
. O 

new O 
tigliane B-TRIVIAL 
diterpenoid B-FAMILY 
, O 
acerifolin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
and O 
a O 
new O 
isopimarane B-TRIVIAL 
diterpenoid B-FAMILY 
, O 
acerifolin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
together O 
with O 
two O 
known O 
compounds O 
, O 
were O 
isolated O 
from O 
Excoecaria O 
acerifolia O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
their O 
spectroscopic O 
methods O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
techniques O 
. O 
All O 
of O 
the O 
compounds O 
were O 
evaluated O 
for O 
cytotoxicity O 
against O 
five O 
human O 
cancer O 
cell O 
lines O 
with O 
cisplantin B-TRIVIAL 
as O 
a O 
positive O 
control O 
. O 

GOOD O 
IS O 
THE O 
LEVOTHYROXINE B-TRIVIAL 
REPLACEMENT O 
IN O 
PRIMARY O 
HYPOTHYROIDISM O 
PATIENTS O 
IN O 
BRAZIL?- O 
DATA O 
OF O 
A O 
MULTICENTRE O 
STUDY O 
. O 

: O 
Studies O 
done O 
in O 
every O 
continent O 
has O 
shown O 
that O 
only O 
around O 
50% O 
of O 
the O 
patients O 
subjected O 
to O 
thyroid O 
hormone O 
replacement O 
have O 
TSH O 
in O 
the O 
normal O 
range O 
. O 
However O 
, O 
until O 
to O 
date O 
, O 
there O 
are O 
no O 
consistent O 
data O 
about O 
Brazil O 
. O 
Objectives O 
: O 
To O 
evaluate O 
levothyroxine B-TRIVIAL 
( O 
LT4 B-ABBREVIATION 
) O 
replacement O 
treatment O 
in O 
patients O 
with O 
primary O 
hypothyroidism O 
followed O 
in O 
referral O 
centers O 
in O 
Brazil O 
. O 
Methods O 
: O 
Patients O 
with O 
primary O 
hypothyroidism O 
followed O 
in O 
referral O 
centers O 
( O 
University O 
Hospitals O 
from O 
Universidade O 
Federal O 
do O 
Rio O 
de O 
Janeiro O 
-UFRJ O 
, O 
Unicamp O 
, O 
Universidade O 
Federal O 
do O 
Paraná O 
- O 
UFPR O 
and O 
Universidade O 
Federal O 
do O 
Ceará-UFC O 
) O 
answered O 
a O 
questionnairethat O 
inquired O 
about O 
clinical O 
and O 
biochemical O 
conditions O 
, O 
social O 
- O 
economic O 
status O 
, O 
life O 
quality O 
and O 
clinicians O 
' O 
orientations O 
as O 
well O 
as O 
their O 
understanding O 
about O 
the O 
information O 
given O 
. O 
Serum O 
TSH O 
was O 
checked O 
close O 
to O 
the O 
interview O 
. O 
Results O 
: O 
2292 O 
consecutive O 
patients O 
met O 
the O 
inclusion O 
criteria O 
. O 
Mean O 
age O 
51.2 O 
years O 
and O 
TSH O 
values O 
between O 
0.4 O 
and O 
4 O 
mUI O 
/ O 
l O 
were O 
considered O 
to O 
be O 
within O 
the O 
reference O 
range O 
. O 
Among O 
all O 
patients O 
taking O 
thyroid O 
medication O 
, O 
42.7%% O 
had O 
an O 
abnormal O 
serum O 
TSH O 
( O 
28.3% O 
were O 
undertreated O 
and O 
14.4% O 
were O 
over O 
treated O 
) O 
. O 
Approximately O 
all O 
patients O 
( O 
99% O 
) O 
took O 
LT4 B-ABBREVIATION 
in O 
the O 
morning O 
but O 
less O 
than O 
30 O 
minutes O 
before O 
breakfast O 
( O 
85.4% O 
) O 
. O 
Regarding O 
the O 
clinicians´ O 
orientations O 
: O 
97.5% O 
of O 
the O 
patients O 
were O 
instructed O 
to O 
take O 
the O 
medication O 
daily O 
, O 
and O 
92.6% O 
to O 
take O 
30 O 
minutes O 
before O 
breakfast O 
( O 
92.6% O 
) O 
. O 
However O 
, O 
only O 
52.1% O 
were O 
told O 
that O 
not O 
to O 
take O 
LT4 B-ABBREVIATION 
along O 
with O 
other O 
medication O 
. O 
Conclusions O 
: O 
Our O 
study O 
found O 
that O 
there O 
was O 
a O 
significant O 
number O 
of O 
patients O 
taking O 
thyroid O 
hormones O 
were O 
not O 
in O 
the O 
therapeutic O 
range O 
. O 
Clinicians O 
should O 
, O 
therefore O 
, O 
consider O 
monitoring O 
patients O 
on O 
thyroid O 
replacement O 
more O 
frequently O 
and O 
being O 
more O 
precise O 
on O 
giving O 
recommendations O 
about O 
the O 
correct O 
use O 
of O 
LT4 B-ABBREVIATION 
. O 

Postprandial O 
Ghrelin O 
Response O 
by O 
Nateglinide B-TRIVIAL 
or O 
Acarbose B-TRIVIAL 
Therapy O 
Contributes O 
to O 
Glucose B-TRIVIAL 
Stability O 
in O 
Type O 
2 O 
Diabetic O 
Patients O 
. O 

: O 
Recent O 
studies O 
highlight O 
an O 
important O 
role O 
of O 
ghrelin O 
in O 
glucose B-TRIVIAL 
homeostasis O 
, O 
while O 
the O 
association O 
between O 
ghrelin O 
regulation O 
and O 
glucose B-TRIVIAL 
fluctuation O 
is O 
unclear O 
. O 
Aim O 
: O 
We O 
compared O 
the O 
effects O 
of O 
two O 
postprandial O 
hypoglycemic O 
agents O 
on O 
ghrelin O 
response O 
and O 
determined O 
the O 
contribution O 
of O 
ghrelin O 
response O 
to O 
glucose B-TRIVIAL 
stability O 
in O 
type O 
2 O 
diabetic O 
( O 
T2DM O 
) O 
patients O 
. O 
Subjects O 
and O 
Methods O 
: O 
Forty O 
newly O 
- O 
diagnosed O 
T2DM O 
patients O 
were O 
randomly O 
allocated O 
to O 
receive O 
Nateglinide B-TRIVIAL 
or O 
Acarbose B-TRIVIAL 
for O 
4 O 
weeks O 
, O 
with O 
twenty O 
BMI-matched O 
normoglycemic O 
subjects O 
as O 
controls O 
. O 
Mean O 
glucose B-TRIVIAL 
values O 
and O 
daily O 
average O 
glucose B-TRIVIAL 
excursion O 
were O 
assessed O 
using O 
continuous O 
glucose B-TRIVIAL 
monitoring O 
system O 
. O 
Serum O 
ghrelin O 
levels O 
were O 
determined O 
by O 
ELISA O 
. O 
Results O 
: O 
T2DM O 
patients O 
had O 
similar O 
fasting O 
ghrelin O 
levels O 
( O 
P O 
= O 
0.546 O 
) O 
, O 
while O 
their O 
postprandial O 
ghrelin O 
suppressions O 
at O 
30 O 
min O 
and O 
120 O 
min O 
were O 
reduced O 
as O 
compared O 
to O 
BMI-matched O 
normoglycemic O 
controls O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Both O 
Nateglinide B-TRIVIAL 
and O 
Acarbose B-TRIVIAL 
increased O 
postprandial O 
ghrelin O 
suppression O 
at O 
120 O 
min O 
and O 
reduced O 
ghrelin O 
area O 
under O 
the O 
curve O 
( O 
AUCGHRL O 
) O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
while O 
only O 
Nateglinide B-TRIVIAL 
increased O 
postprandial O 
ghrelin O 
suppression O 
at O 
30 O 
min O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
which O 
was O 
positively O 
correlated O 
with O 
the O 
increased O 
early O 
- O 
phase O 
insulin O 
secretion O 
by O 
4 O 
weeks O 
of O 
Nateglinide B-TRIVIAL 
therapy O 
( O 
r O 
= O 
0.48 O 
, O 
P O 
= O 
0.05 O 
) O 
. O 
The O 
decrease O 
in O 
AUCGHRL O 
was O 
positively O 
correlated O 
with O 
the O 
decrease O 
in O 
daily O 
average O 
glucose B-TRIVIAL 
excursion O 
and O 
mean O 
glucose B-TRIVIAL 
values O 
either O 
by O 
4 O 
weeks O 
of O 
Nateglinide B-TRIVIAL 
or O 
Acarbose B-TRIVIAL 
therapy O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Conclusions O 
: O 
Both O 
Natelinide B-TRIVIAL 
and O 
Acarbose B-TRIVIAL 
increase O 
postprandial O 
ghrelin O 
suppression O 
. O 
Improved O 
ghrelin O 
regulation O 
is O 
most O 
likely O 
to O 
play O 
a O 
role O 
in O 
glucose B-TRIVIAL 
stability O 
in O 
T2DM O 
patients O 
with O 
Natelinide B-TRIVIAL 
or O 
Acarbose B-TRIVIAL 
therapy O 
. O 

method O 
for O 
stably O 
purifying O 
a O 
functional O 
dye O 
, O 
phycocyanin O 
from O 
Spirulina O 
platensis O 
was O 
developed O 
by O 
a O 
hexane B-SYSTEMATIC 
extraction O 
process O 
combined O 
with O 
high O 
pressure O 
. O 
This O 
was O 
necessary O 
because O 
this O 
dye O 
is O 
known O 
to O 
be O 
very O 
unstable O 
during O 
normal O 
extraction O 
processes O 
. O 
The O 
purification O 
yield O 
of O 
this O 
method O 
was O 
estimated O 
as O 
10.2% O 
, O 
whose O 
value O 
is O 
3%-5% O 
higher O 
than O 
is O 
the O 
case O 
from O 
another O 
conventional O 
separation O 
method O 
using O 
phosphate O 
buffer O 
. O 
The O 
isolated O 
phycocyanin O 
from O 
this O 
process O 
also O 
showed O 
the O 
highest O 
purity O 
of O 
0.909 O 
based O 
on O 
absorbance O 
of O 
2.104 O 
at O 
280 O 
nm O 
and O 
1.912 O 
at O 
620 O 
nm O 
. O 
Two O 
subunits O 
of O 
phycocyanin O 
namely O 
α-phycocyanin O 
( O 
18.4 O 
kDa O 
) O 
and O 
β-phycocyanin O 
( O 
21.3 O 
kDa O 
) O 
were O 
found O 
to O 
remain O 
from O 
the O 
original O 
mixtures O 
after O 
being O 
extracted O 
, O 
based O 
on O 
SDS-PAGE O 
analysis O 
, O 
clearly O 
demonstrating O 
that O 
this O 
process O 
can O 
stably O 
extract O 
phycocyanin O 
and O 
is O 
not O 
affected O 
by O 
extraction O 
solvent O 
, O 
temperature O 
, O 
etc O 
. O 
The O 
stability O 
of O 
the O 
extracted O 
phycocyanin O 
was O 
also O 
confirmed O 
by O 
comparing O 
its O 
DPPH B-ABBREVIATION 
( O 
α,α-diphenyl-β-picrylhydrazyl B-SYSTEMATIC 
) O 
scavenging O 
activity O 
, O 
showing O 
83% O 
removal O 
of O 
oxygen B-SYSTEMATIC 
free O 
radicals O 
. O 
This O 
activity O 
was O 
about O 
15% O 
higher O 
than O 
that O 
of O 
commercially O 
available O 
standard O 
phycocyanin O 
, O 
which O 
implies O 
that O 
the O 
combined O 
extraction O 
method O 
can O 
yield O 
relatively O 
intact O 
chromoprotein O 
through O 
absence O 
of O 
degradation O 
. O 
The O 
results O 
were O 
achieved O 
because O 
the O 
low O 
temperature O 
and O 
high O 
pressure O 
extraction O 
effectively O 
disrupted O 
the O 
cell O 
membrane O 
of O 
Spirulina O 
platensis O 
and O 
degraded O 
less O 
the O 
polypeptide O 
subunits O 
of O 
phycocyanin O 
( O 
which O 
is O 
a O 
temperature O 
/ O 
pH-sensitive O 
chromoprotein O 
) O 
as O 
well O 
as O 
increasing O 
the O 
extraction O 
yield O 
. O 

of O 
bisindolylmethanes B-FAMILY 
and O 
their O 
cytotoxicity O 
properties O 
. O 

supported O 
dichlorophosphate B-SYSTEMATIC 
( O 
PEG-OPOCl(2) B-FORMULA 
) O 
is O 
an O 
efficient O 
green O 
catalyst O 
for O 
the O 
electrophilic O 
substitution O 
reaction O 
of O 
indole B-SYSTEMATIC 
with O 
aromatic B-FAMILY 
aldehydes I-FAMILY 
, O 
in O 
neat O 
condition O 
, O 
to O 
afford O 
an O 
excellent O 
yield O 
of O 
bis(indolyl) B-FAMILY 
methanes I-FAMILY 
with O 
short O 
reaction O 
time O 
, O 
at O 
room O 
temperature O 
. O 
The O 
synthesized O 
compounds O 
and O 
their O 
anti-cancer O 
activity O 
are O 
evaluated O 
. O 

you O 
enhance O 
executive O 
control O 
without O 
glucose B-TRIVIAL 
? O 
The O 
effects O 
of O 
fructose B-TRIVIAL 
on O 
problem O 
solving O 
. O 

consumption O 
of O 
glucose B-TRIVIAL 
can O 
enhance O 
executive O 
control O 
by O 
increasing O 
blood O 
glucose B-TRIVIAL 
and O 
providing O 
energy O 
for O 
brain O 
processes O 
. O 
However O 
, O 
a O 
glucose B-TRIVIAL 
mouth O 
rinse O 
also O 
positively O 
affects O 
executive O 
control O 
in O 
the O 
absence O 
of O 
an O 
effect O 
on O 
blood O 
glucose B-TRIVIAL 
. O 
This O 
observation O 
suggests O 
that O 
glucose B-TRIVIAL 
can O 
enhance O 
executive O 
control O 
via O 
another O 
mechanism O 
, O 
perhaps O 
by O 
increasing O 
cortical O 
activation O 
in O 
motivational O 
reward O 
pathways O 
. O 
This O 
hypothesis O 
was O 
examined O 
in O 
the O 
current O 
study O 
by O 
having O 
participants O 
consume O 
fructose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
or O 
a O 
placebo O 
10 O 
minutes O 
before O 
solving O 
word O 
anagrams O 
. O 
Fructose B-TRIVIAL 
was O 
used O 
because O 
it O 
does O 
not O 
affect O 
blood O 
glucose B-TRIVIAL 
levels O 
, O 
inhibits O 
cortical O 
responding O 
, O 
and O 
cannot O 
entrain O 
a O 
taste O 
preference O 
post O 
- O 
ingestion O 
. O 
The O 
latter O 
evidences O 
that O 
fructose B-TRIVIAL 
differs O 
from O 
glucose B-TRIVIAL 
in O 
its O 
ability O 
to O 
elicit O 
activation O 
in O 
motivational O 
reward O 
pathways O 
. O 
It O 
was O 
observed O 
that O 
consuming O 
fructose B-TRIVIAL 
and O 
glucose B-TRIVIAL 
resulted O 
in O 
the O 
resolution O 
of O 
more O 
anagrams O 
than O 
the O 
placebo O 
. O 
These O 
results O 
suggest O 
that O 
at O 
least O 
some O 
of O 
the O 
effects O 
of O 
glucose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
on O 
problem O 
solving O 
operate O 
through O 
a O 
common O 
peripheral O 
mechanism O 
that O 
is O 
independent O 
of O 
motivational O 
reward O 
pathways O 
. O 

receptor O 
5 O 
( O 
CCR5 O 
) O 
is O 
an O 
important O 
receptor O 
used O 
by O 
human O 
immunodeficiency O 
virus O 
type O 
1 O 
( O 
HIV-1 O 
) O 
to O 
gain O 
viral O 
entry O 
into O 
host O 
cell O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
combined O 
approach O 
of O 
comparative O 
modeling O 
, O 
molecular O 
docking O 
, O 
and O 
three O 
dimensional O 
quantitative O 
structure O 
activity O 
relationship O 
( O 
3D-QSAR O 
) O 
analyses O 
to O 
elucidate O 
detailed O 
interaction O 
of O 
CCR5 O 
with O 
their O 
inhibitors O 
. O 
Docking O 
study O 
of O 
the O 
most O 
potent O 
inhibitor O 
from O 
a O 
series O 
of O 
compounds O 
was O 
done O 
to O 
derive O 
the O 
bioactive O 
conformation O 
. O 
Parameters O 
such O 
as O 
random O 
selection O 
, O 
rational O 
selection O 
, O 
different O 
charges O 
and O 
grid O 
spacing O 
were O 
utilized O 
in O 
the O 
model O 
development O 
to O 
check O 
their O 
performance O 
on O 
the O 
model O 
predictivity O 
. O 
Final O 
comparative O 
molecular O 
field O 
analysis O 
( O 
CoMFA O 
) O 
and O 
comparative O 
molecular O 
similarity O 
indices O 
analysis O 
( O 
CoMSIA O 
) O 
models O 
were O 
chosen O 
based O 
on O 
the O 
rational O 
selection O 
method O 
, O 
Gasteiger-Hückel O 
charges O 
and O 
a O 
grid O 
spacing O 
of O 
0.5 O 
Å O 
. O 
Rational O 
model O 
for O 
CoMFA O 
( O 
q(2) O 
= O 
0.722 O 
, O 
r(2) O 
= O 
0.884 O 
, O 
Q(2) O 
= O 
0.669 O 
) O 
and O 
CoMSIA O 
( O 
q(2) O 
= O 
0.712 O 
, O 
r(2) O 
= O 
0.825 O 
, O 
Q(2) O 
= O 
0.522 O 
) O 
was O 
obtained O 
with O 
good O 
statistics O 
. O 
Mapping O 
of O 
contour O 
maps O 
onto O 
CCR5 O 
interface O 
led O 
us O 
to O 
better O 
understand O 
of O 
the O 
ligand O 
- O 
protein O 
interaction O 
. O 
Docking O 
analysis O 
revealed O 
that O 
the O 
Glu B-FORMULA 
283 O 
is O 
crucial O 
for O 
interaction O 
. O 
Two O 
new O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
, O 
Tyr B-FORMULA 
89 O 
and O 
Thr B-FORMULA 
167 O 
were O 
identified O 
as O 
important O 
in O 
ligand O 
- O 
protein O 
interaction O 
. O 
No O 
site O 
directed O 
mutagenesis O 
studies O 
on O 
these O 
residues O 
have O 
been O 
reported O 
. O 

and O 
quantification O 
of O 
the O 
sedative O 
and O 
anticonvulsant O 
flavone B-FAMILY 
glycoside I-FAMILY 
from O 
Chrysanthemum O 
boreale O 
. O 

flowers O 
or O 
leaves O 
of O 
Chrysanthemum O 
boreale O 
( O 
Compositae O 
) O 
have O 
been O 
traditionally O 
used O 
as O 
herb O 
tea O 
to O 
reduce O 
anxiety O 
, O 
insomnia O 
, O 
and O 
stress O 
. O 
Sedative O 
and O 
anticonvulsant O 
activities O 
were O 
evaluated O 
in O 
mice O 
using O 
pentobarbital B-TRIVIAL 
-induced O 
sleeping O 
assay O 
and O 
pentylenetetrazole B-SYSTEMATIC 
( O 
PTZ B-ABBREVIATION 
)-induced O 
convulsion O 
assay O 
. O 
The O 
flower O 
extract O 
exhibited O 
more O 
potent O 
activities O 
than O 
the O 
extracts O 
of O 
the O 
leaves O 
and O 
stems O 
, O 
and O 
chromatographic O 
isolation O 
yielded O 
the O 
five O 
compounds O 
acacetin B-TRIVIAL 
, O 
linarin B-TRIVIAL 
, O 
acacetin B-SYSTEMATIC 
7-O-β-D-glucopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)[α-L-rhamnopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
6)]-β-D-glucopyranoside I-SYSTEMATIC 
, O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
3,5-di-O-caffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
These O 
compounds O 
were O 
simultaneously O 
analyzed O 
by O 
HPLC O 
, O 
and O 
the O 
method O 
was O 
validated O 
. O 
The O 
contents O 
of O 
linarin B-TRIVIAL 
, O 
which O 
were O 
shown O 
to O 
be O 
most O 
abundant O 
in O 
C O 
. O 
boreale O 
, O 
were O 
observed O 
in O 
the O 
order O 
of O 
leaf O 
( O 
11.93 O 
mg O 
/ O 
g) O 
> O 
flower O 
( O 
8.5 O 
mg O 
/ O 
g) O 
> O 
stem O 
( O 
5.6 O 
mg O 
/ O 
g O 
) O 
. O 
Linarin B-TRIVIAL 
and O 
its O 
aglycone O 
, O 
acacetin B-TRIVIAL 
, O 
exhibited O 
sedative O 
and O 
anticonvulsant O 
activities O 
in O 
the O 
present O 
in O 
vivo O 
assays O 
. O 
It O 
can O 
be O 
considered O 
that O 
linarin B-TRIVIAL 
is O 
one O 
of O 
the O 
active O 
compounds O 
effective O 
against O 
anxiety O 
, O 
insomnia O 
, O 
and O 
stress O 
, O 
with O 
acacetin B-TRIVIAL 
as O 
its O 
active O 
moiety O 
. O 

of O 
citrate B-FAMILY 
-capped O 
silver B-SYSTEMATIC 
nanoparticles O 
in O 
exposure O 
media O 
and O 
their O 
effects O 
on O 
the O 
development O 
of O 
embryonic O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
. O 

stability O 
of O 
citrate B-FAMILY 
-capped O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
and O 
the O 
embryonic O 
developmental O 
toxicity O 
were O 
evaluated O 
in O 
the O 
fish O 
test O 
water O 
. O 
Serious O 
aggregation O 
of O 
AgNPs O 
was O 
observed O 
in O 
undiluted O 
fish O 
water O 
( O 
DM-100 O 
) O 
in O 
which O 
high O 
concentration O 
of O 
ionic O 
salts O 
exist O 
. O 
However O 
, O 
AgNPs O 
were O 
found O 
to O 
be O 
stable O 
for O 
7 O 
days O 
in O 
DM-10 O 
, O 
prepared O 
by O 
diluting O 
the O 
original O 
fish O 
water O 
( O 
DM-100 O 
) O 
with O 
deionized O 
water O 
to O 
10 O 
% O 
. O 
The O 
normal O 
physiology O 
of O 
zebrafish O 
embryos O 
were O 
evaluated O 
in O 
DM-10 O 
to O 
see O 
if O 
DM-10 O 
can O 
be O 
used O 
as O 
a O 
control O 
vehicle O 
for O 
the O 
embryonic O 
fish O 
toxicity O 
test O 
. O 
As O 
results O 
, O 
DM-10 O 
without O 
AgNPs O 
did O 
not O 
induce O 
any O 
significant O 
adverse O 
effects O 
on O 
embryonic O 
development O 
of O 
zebrafish O 
determined O 
by O 
mortality O 
, O 
hatching O 
, O 
malformations O 
and O 
heart O 
rate O 
. O 
When O 
embryonic O 
toxicity O 
of O 
AgNPs O 
was O 
tested O 
in O 
both O 
DM-10 O 
and O 
in O 
DM-100 O 
, O 
AgNPs O 
showed O 
higher O 
toxicity O 
in O 
DM-10 O 
than O 
in O 
DM-100 O 
. O 
This O 
means O 
that O 
the O 
big O 
- O 
sized O 
aggregates O 
of O 
AgNPs O 
were O 
low O 
toxic O 
compared O 
to O 
the O 
nano O 
- O 
sized O 
AgNPs O 
. O 
AgNPs O 
induced O 
delayed O 
hatching O 
, O 
decreased O 
heart O 
rate O 
, O 
pericardial O 
edema O 
, O 
and O 
embryo O 
death O 
. O 
Accumulation O 
of O 
AgNPs O 
in O 
the O 
embryo O 
bodies O 
was O 
also O 
observed O 
. O 
Based O 
on O 
this O 
study O 
, O 
citrate B-FAMILY 
-capped O 
AgNPs O 
are O 
not O 
aggregated O 
in O 
DM-10 O 
and O 
it O 
can O 
be O 
used O 
as O 
a O 
control O 
vehicle O 
in O 
the O 
toxicity O 
test O 
of O 
fish O 
embryonic O 
development O 
. O 

: O 
New O 
data O 
on O 
chronic O 
toxicity O 
and O 
bioconcentration O 
in O 
fish O 
. O 

( O 
DCF B-ABBREVIATION 
) O 
is O 
a O 
widely O 
used O 
nonsteroidal O 
anti-inflammatory O 
drug O 
that O 
is O 
regularly O 
detected O 
in O 
surface O 
waters O 
. O 
To O 
support O 
a O 
robust O 
aquatic O 
risk O 
assessment O 
, O 
two O 
early O 
life O 
stage O 
( O 
ELS O 
) O 
tests O 
, O 
compliant O 
with O 
the O 
Organisation O 
for O 
Economic O 
Co-operation O 
and O 
Development O 
( O 
OECD O 
) O 
test O 
guideline O 
210 O 
, O 
were O 
conducted O 
in O 
rainbow O 
trout O 
and O 
in O 
zebrafish O 
. O 
Population O 
relevant O 
endpoints O 
, O 
such O 
as O 
hatching O 
, O 
growth O 
, O 
and O 
survival O 
, O 
and O 
in O 
the O 
trout O 
study O 
, O 
histopathological O 
effects O 
in O 
potential O 
target O 
organs O 
, O 
were O 
examined O 
. O 
The O 
bioconcentration O 
of O 
DCF B-ABBREVIATION 
in O 
rainbow O 
trout O 
was O 
measured O 
in O 
a O 
separate O 
study O 
according O 
to O 
OECD O 
test O 
guideline O 
305 O 
. O 
The O 
bioconcentration O 
factor O 
( O 
BCF O 
) O 
in O 
rainbow O 
trout O 
remained O 
below O 
10 O 
, O 
demonstrating O 
no O 
relevant O 
bioconcentration O 
of O 
DCF B-ABBREVIATION 
in O 
fish O 
. O 
In O 
the O 
rainbow O 
trout O 
ELS O 
test O 
, O 
the O 
no O 
observed O 
effect O 
concentration O 
( O 
NOEC O 
) O 
including O 
histopathology O 
was O 
320 O 
µg O 
/ O 
L O 
. O 
The O 
effect O 
of O 
DCF B-ABBREVIATION 
on O 
zebrafish O 
growth O 
was O 
less O 
clear O 
, O 
and O 
the O 
NOEC O 
can O 
be O 
interpreted O 
as O 
10 O 
µg O 
/ O 
L O 
. O 
However O 
, O 
for O 
a O 
number O 
of O 
reasons O 
, O 
the O 
authors O 
consider O 
the O 
moderately O 
reduced O 
growth O 
of O 
zebrafish O 
exposed O 
to O 
concentrations O 
of O 
up O 
to O 
320 O 
µg O 
/ O 
L O 
not O 
a O 
repeatable O 
, O 
treatment O 
- O 
related O 
effect O 
of O 
DCF B-ABBREVIATION 
. O 
This O 
leads O 
us O 
to O 
a O 
conclusion O 
that O 
DCF B-ABBREVIATION 
has O 
, O 
with O 
high O 
probability O 
, O 
no O 
adverse O 
effect O 
on O 
both O 
fish O 
species O 
up O 
to O 
320 O 
µg O 
/ O 
L O 
. O 
This O 
NOEC O 
indicates O 
a O 
sufficient O 
safety O 
margin O 
for O 
fish O 
populations O 
, O 
because O 
concentrations O 
of O 
DCF B-ABBREVIATION 
in O 
European O 
rivers O 
are O 
in O 
the O 
range O 
of O 
ng O 
/ O 
L O 
to O 
low O 
µg O 
/ O 
L O 
. O 

CO(2) B-FORMULA 
for O 
the O 
direct O 
observation O 
of O 
CO(2) B-FORMULA 
-consuming O 
reactions O 
. O 

-consuming O 
reactions O 
, O 
in O 
particular O 
carboxylations O 
, O 
play O 
important O 
roles O 
in O 
technical O 
processes O 
and O 
in O 
nature O 
. O 
Their O 
kinetic O 
behavior O 
and O 
the O 
reaction O 
mechanisms O 
of O 
carboxylating O 
enzymes O 
are O 
difficult O 
to O 
study O 
because O 
CO(2) B-FORMULA 
is O 
inconvenient O 
to O 
handle O 
as O 
a O 
gas O 
, O 
exists O 
in O 
equilibrium O 
with O 
bicarbonate B-SYSTEMATIC 
in O 
aqueous O 
solution O 
, O 
and O 
typically O 
yields O 
products O 
that O 
show O 
no O 
significant O 
spectroscopic O 
differences O 
from O 
the O 
reactants O 
in O 
the O 
UV O 
/ O 
Vis O 
range O 
. O 
Here O 
we O 
demonstrate O 
the O 
utility O 
of O 
3-nitrophenylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
related O 
compounds O 
( O 
caged O 
CO(2) B-FORMULA 
) O 
in O 
conjunction O 
with O 
infrared O 
spectroscopy O 
as O 
widely O 
applicable O 
tools O 
for O 
the O 
investigation O 
of O 
such O 
reactions O 
, O 
permitting O 
convenient O 
measurement O 
of O 
the O 
kinetics O 
of O 
CO(2) B-FORMULA 
consumption O 
. O 
The O 
use O 
of O 
isotopically O 
labeled O 
caged O 
CO(2) B-FORMULA 
provides O 
a O 
tool O 
for O 
the O 
assignment O 
of O 
infrared O 
absorption O 
bands O 
, O 
thus O 
aiding O 
insight O 
into O 
reaction O 
intermediates O 
and O 
mechanisms O 
. O 

from O 
roots O 
of O 
Clausena O 
excavata O 
. O 

new O 
coumarins B-FAMILY 
, O 
clauexcavatins B-MULTIPLE 
A I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
, O 
along O 
with O 
seven O 
known O 
ones O 
( O 
3-9 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Clausena O 
excavata O 
Burm O 
. O 
f O 
. O 
( O 
Rutaceae O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectral O 
data O 
. O 

characterization O 
of O 
phosphopeptide/ O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
interactions O 
employing O 
the O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
technique O 
. O 

rapidly O 
growing O 
field O 
of O 
phosphoproteomics O 
has O 
led O 
to O 
a O 
strong O 
demand O 
for O 
procedures O 
enabling O 
fast O 
and O 
reliable O 
isolation O 
and O 
enrichment O 
of O 
phosphorylated O 
proteins O 
and O 
peptides O 
. O 
During O 
the O 
past O 
decade O 
, O 
several O 
novel O 
phosphopeptide O 
enrichment O 
methods O 
based O 
on O 
the O 
affinity O 
of O 
phosphoryl B-FAMILY 
groups O 
for O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO(2) B-FORMULA 
) O 
have O 
been O 
developed O 
and O 
tested O 
. O 
The O 
ultimate O 
goal O 
of O 
obtaining O 
comprehensive O 
phosphoproteomes O 
has O 
, O 
however O 
, O 
been O 
found O 
difficult O 
to O 
achieve O 
and O 
the O 
obtained O 
results O 
often O 
vary O 
, O 
dependent O 
on O 
the O 
enrichment O 
method O 
and O 
protocol O 
used O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
physical O 
chemistry O 
of O 
the O 
phosphopeptide O 
binding O 
to O 
TiO(2) B-FORMULA 
is O 
investigated O 
by O 
means O 
of O 
measurements O 
using O 
a O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
with O 
dissipation O 
monitoring O 
( O 
QCM-D O 
) O 
. O 
Special O 
emphasis O 
is O 
put O 
on O 
the O 
effect O 
of O 
the O 
degree O 
of O 
phosphorylation O 
of O 
the O 
phosphopeptide O 
, O 
the O 
impact O 
of O 
the O 
primary O 
amino B-FAMILY 
acid I-FAMILY 
structure O 
, O 
and O 
the O 
role O 
of O 
electrostatic O 
interactions O 
. O 
The O 
results O 
show O 
that O 
, O 
in O 
general O 
, O 
adsorption O 
of O 
phosphopeptides O 
follows O 
the O 
Langmuir O 
model O 
and O 
that O 
the O 
affinity O 
for O 
the O 
TiO(2) B-FORMULA 
surface O 
increases O 
in O 
a O 
nonlinear O 
fashion O 
with O 
increasing O 
degree O 
of O 
phosphorylation O 
. O 
An O 
exception O 
was O 
detected O 
, O 
however O 
, O 
where O 
positive O 
cooperativity O 
between O 
the O 
peptides O 
existed O 
and O 
the O 
Langmuir O 
model O 
no O 
longer O 
applied O 
. O 
The O 
source O 
behind O 
the O 
cooperativity O 
could O 
be O 
traced O 
back O 
to O 
the O 
primary O 
amino B-FAMILY 
acid I-FAMILY 
structure O 
and O 
, O 
more O 
specifically O 
, O 
the O 
presence O 
of O 
positively O 
charged O 
amino B-FAMILY 
acids I-FAMILY 
in O 
positions O 
that O 
enable O 
electrostatic O 
interaction O 
with O 
phosphoryl B-FAMILY 
groups O 
on O 
neighboring O 
peptides O 
. O 
Regardless O 
of O 
the O 
net O 
peptide O 
charge O 
, O 
the O 
TiO(2) B-FORMULA 
-phosphopeptide O 
interaction O 
was O 
for O 
all O 
phosphopeptides O 
investigated O 
found O 
to O 
be O 
mainly O 
of O 
electrostatic O 
origin O 
. O 
This O 
study O 
highlights O 
and O 
explains O 
some O 
of O 
the O 
most O 
common O 
problems O 
with O 
the O 
TiO(2) B-FORMULA 
-based O 
enrichment O 
methods O 
used O 
today O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effect O 
of O 
orally O 
administered O 
Uncaria O 
tomentosa O 
aqueous O 
extracts O 
( O 
UTE O 
) O 
( O 
Willd O 
. O 
ex O 
Roem O 
. O 
& O 
Schult O 
. O 
) O 
DC O 
. O 
( O 
Rubiaceae O 
) O 
during O 
7 O 
, O 
15 O 
, O 
30 O 
and O 
90 O 
days O 
of O 
treatment O 
on O 
the O 
expression O 
of O 
anxiety O 
, O 
as O 
expressed O 
in O 
the O 
elevated O 
plus O 
maze O 
test O 
in O 
male O 
Albino O 
Swiss O 
mice O 
. O 
UTE O 
revealed O 
an O 
anxiogenic O 
effect O 
in O 
relation O 
to O 
the O 
control O 
group O 
at O 
15 O 
and O 
30 O 
days O 
, O 
but O 
it O 
was O 
reversed O 
after O 
90 O 
days O 
of O 
administration O 
, O 
without O 
affecting O 
the O 
locomotor O 
activity O 
or O 
any O 
deleterious O 
effects O 
on O 
the O 
overall O 
performance O 
of O 
the O 
animal O 
, O 
either O 
for O 
its O 
ambulation O 
, O 
or O 
clinical O 
status O 
, O 
and O 
body O 
weight O 
and O 
organ O 
weight O 
/ O 
body O 
weight O 
from O 
liver O 
, O 
lung O 
and O 
kidney O 
were O 
unaffected O 
. O 
These O 
biphasic O 
effects O 
are O 
usually O 
indicative O 
of O 
heterogeneity O 
in O 
sites O 
of O 
action O 
due O 
to O 
the O 
presence O 
of O 
many O 
alkaloids O 
( O 
speciophylline B-TRIVIAL 
, O 
uncarine B-TRIVIAL 
F I-TRIVIAL 
and O 
uncarine B-TRIVIAL 
E I-TRIVIAL 
) O 
and O 
flavanols B-FAMILY 
( O 
catechin B-TRIVIAL 
and O 
epigallocatechin B-TRIVIAL 
) O 
identified O 
and O 
isolated O 
from O 
UTE O 
. O 

effects O 
for O 
CYP2E1 O 
differ O 
between O 
styrene B-TRIVIAL 
and O 
its O 
metabolites O 
. O 

1 O 
. O 
Cooperative O 
interactions O 
are O 
frequently O 
observed O 
in O 
the O 
metabolism O 
of O 
drugs O 
and O 
pollutants O 
by O 
cytochrome O 
P450s O 
; O 
nevertheless O 
, O 
the O 
molecular O 
determinants O 
for O 
cooperativity O 
remain O 
elusive O 
. O 
Previously O 
, O 
we O 
demonstrated O 
that O 
steady O 
- O 
state O 
styrene O 
metabolism O 
by O 
CYP2E1 O 
exhibits O 
positive O 
cooperativity O 
. O 
2 O 
. O 
We O 
hypothesized O 
that O 
styrene B-TRIVIAL 
metabolites O 
have O 
lower O 
affinity O 
than O 
styrene B-TRIVIAL 
toward O 
CYP2E1 O 
and O 
limited O 
ability O 
to O 
induce O 
cooperative O 
effects O 
during O 
metabolism O 
. O 
To O 
test O 
the O 
hypothesis O 
, O 
we O 
determined O 
the O 
potency O 
and O 
mechanism O 
of O 
inhibition O 
for O 
styrene B-TRIVIAL 
and O 
its O 
metabolites O 
toward O 
oxidation O 
of O 
4-nitrophenol B-SYSTEMATIC 
using O 
CYP2E1 O 
Supersomes O 
® O 
and O 
human O 
liver O 
microsomes O 
. O 
3 O 
. O 
Styrene B-TRIVIAL 
inhibited O 
the O 
reaction O 
through O 
a O 
mixed O 
cooperative O 
mechanism O 
with O 
high O 
affinity O 
for O 
the O 
catalytic O 
site O 
( O 
67 O 
µM O 
) O 
and O 
lower O 
affinity O 
for O 
the O 
cooperative O 
site O 
( O 
1100 O 
µM O 
) O 
, O 
while O 
increasing O 
substrate O 
turnover O 
at O 
high O 
concentrations O 
. O 
Styrene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
4-vinylphenol B-SYSTEMATIC 
possessed O 
similar O 
affinity O 
for O 
CYP2E1 O 
. O 
Styrene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
behaved O 
cooperatively O 
like O 
styrene B-TRIVIAL 
, O 
but O 
4-vinylphenol B-SYSTEMATIC 
decreased O 
turnover O 
at O 
high O 
concentrations O 
. O 
Styrene B-TRIVIAL 
glycol I-TRIVIAL 
was O 
a O 
very O 
poor O 
competitive O 
inhibitor O 
. O 
Among O 
all O 
compounds O 
, O 
there O 
was O 
a O 
positive O 
correlation O 
with O 
binding O 
and O 
hydrophobicity O 
. O 
4 O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
for O 
CYP2E1 O 
further O 
validate O 
contributions O 
of O 
cooperative O 
mechanisms O 
to O 
metabolic O 
processes O 
, O 
demonstrate O 
the O 
role O 
of O 
molecular O 
structure O 
on O 
those O 
mechanisms O 
and O 
underscore O 
the O 
potential O 
for O 
heterotropic O 
cooperative O 
effects O 
between O 
different O 
compounds O 
. O 

essential O 
oils O 
from O 
three O 
organs O 
( O 
i.e O 
. O 
flowers O 
, O 
leaves O 
and O 
stems O 
) O 
of O 
wild O 
Lindera O 
chunii O 
Merr O 
. O 
in O 
Dinghu O 
Mountain O 
( O 
China O 
) O 
were O 
obtained O 
by O 
microwave O 
- O 
assisted O 
hydrodistillation O 
. O 
The O 
essential O 
oils O 
were O 
analysed O 
by O 
gas O 
chromatography O 
with O 
flame O 
ionisation O 
detection O 
and O 
gas O 
chromatography O 
with O 
mass O 
spectrometry O 
. O 
The O 
yields O 
of O 
essential O 
oil O 
varied O 
from O 
0.06% O 
to O 
0.59% O 
and O 
showed O 
a O 
remarkable O 
variation O 
among O 
the O 
plant O 
organs O 
. O 
A O 
total O 
of O 
43 O 
compounds O 
accounting O 
for O 
95.4-96.3% O 
of O 
the O 
total O 
essential O 
oil O 
were O 
identified O 
, O 
and O 
the O 
major O 
compounds O 
were O 
germacrene B-TRIVIAL 
B I-TRIVIAL 
( O 
0.7-43.2% O 
) O 
, O 
viridiflorene B-TRIVIAL 
( O 
trace O 
to O 
14.6% O 
) O 
, O 
globulol B-TRIVIAL 
( O 
6.3-11.6% O 
) O 
, O 
α-cadinol B-TRIVIAL 
( O 
1.7-8.6% O 
) O 
and O 
τ-cadinol B-TRIVIAL 
( O 
0.5-7.3% O 
) O 
. O 
This O 
study O 
shows O 
that O 
the O 
chemical O 
compositions O 
of O 
the O 
essential O 
oils O 
from O 
the O 
different O 
organs O 
of O 
L O 
. O 
chunii O 
are O 
very O 
variable O 
. O 

between O 
pectic O 
compounds O 
and O 
procyanidins B-FAMILY 
are O 
influenced O 
by O 
methylation O 
degree O 
and O 
chain O 
length O 
. O 

interactions O 
between O 
procyanidins B-FAMILY 
and O 
pectic O 
compounds O 
are O 
of O 
importance O 
in O 
food O 
chemistry O 
. O 
Procyanidins B-FAMILY 
with O 
low O 
( O 
9 O 
) O 
and O 
high O 
( O 
30 O 
) O 
average O 
degrees O 
of O 
polymerization O 
( O 
DP9 O 
and O 
DP30 O 
) O 
were O 
extracted O 
from O 
two O 
cider O 
apple O 
varieties O 
. O 
Commercial O 
apple O 
and O 
citrus O 
pectins O 
, O 
as O 
well O 
as O 
three O 
pectin O 
subfractions O 
( O 
homogalacturonans O 
, O 
partially O 
methylated O 
homogalacturonans O 
with O 
degree O 
of O 
methylation O 
30 O 
and O 
70 O 
) O 
at O 
30 O 
mM O 
galacturonic B-TRIVIAL 
acid I-TRIVIAL 
equivalent O 
, O 
were O 
titrated O 
with O 
the O 
two O 
procyanidin B-FAMILY 
fractions O 
( O 
at O 
30 O 
mM O 
(-)-epicatechin B-SYSTEMATIC 
equivalent O 
) O 
by O 
isothermal O 
titration O 
calorimetry O 
and O 
UV-vis O 
spectrophotometry O 
. O 
Slightly O 
stronger O 
affinities O 
were O 
recorded O 
between O 
commercial O 
apple O 
or O 
citrus O 
pectins O 
and O 
procyanidins B-FAMILY 
of O 
DP30 O 
( O 
Ka O 
= O 
1460 O 
and O 
1225 O 
M(-1) O 
respectively O 
, O 
expressed O 
per O 
monomer O 
units O 
) O 
compared O 
to O 
procyanidins B-FAMILY 
of O 
DP9 O 
( O 
Ka O 
= O 
1240 O 
and O 
1085 O 
M(-1) O 
, O 
respectively O 
) O 
, O 
but O 
stoichiometry O 
and O 
absorbance O 
maxima O 
differed O 
between O 
apple O 
and O 
citrus O 
pectins O 
. O 
It O 
was O 
proposed O 
that O 
methylated O 
homogalacturonans O 
interacted O 
with O 
procyanidins B-FAMILY 
DP30 O 
mainly O 
through O 
hydrophobic O 
interactions O 
. O 
The O 
stronger O 
association O 
was O 
obtained O 
with O 
the O 
longer O 
procyanidin B-FAMILY 
molecules O 
interacting O 
with O 
highly O 
methylated O 
pectins O 
. O 

to O 
the O 
heart O 
can O 
result O 
from O 
both O 
traditional O 
chemotherapeutic O 
agents O 
, O 
such O 
as O 
doxorubicin B-TRIVIAL 
, O 
and O 
newer O 
' O 
targeted O 
' O 
therapies O 
, O 
such O 
as O 
trastuzumab O 
. O 
This O 
chemotherapeutic O 
cardiotoxicity O 
is O 
potentially O 
life O 
- O 
threatening O 
and O 
necessitates O 
limiting O 
or O 
discontinuing O 
an O 
otherwise O 
- O 
effective O 
cancer O 
treatment O 
. O 
Clinical O 
strategies O 
focus O 
on O 
surveillance O 
rather O 
than O 
prevention O 
, O 
although O 
there O 
are O 
no O 
specific O 
therapies O 
for O 
this O 
highly O 
morbid O 
adverse O 
effect O 
. O 
Current O 
models O 
for O 
prospectively O 
predicting O 
risk O 
of O 
chemotherapeutic O 
cardiotoxicity O 
are O 
limited O 
. O 
Cardiotoxicity O 
can O 
occur O 
idiosyncratically O 
in O 
patients O 
without O 
obvious O 
demographic O 
risk O 
factors O 
, O 
suggesting O 
a O 
genetically O 
determined O 
susceptibility O 
, O 
and O 
candidate O 
- O 
gene O 
studies O 
have O 
identified O 
a O 
limited O 
number O 
of O 
variants O 
that O 
increase O 
risk O 
. O 
In O 
this O 
commentary O 
we O 
indicate O 
a O 
need O 
for O 
more O 
powerful O 
means O 
to O 
identify O 
risk O 
prospectively O 
, O 
and O 
suggest O 
that O 
broad O 
pharmacogenomic O 
approaches O 
may O 
be O 
fruitful O 
. O 

abietane B-TRIVIAL 
and O 
ent-kaurane B-TRIVIAL 
diterpenoids B-FAMILY 
from O 
Isodon O 
tenuifolius O 
. O 

new O 
abietane B-TRIVIAL 
diterpenoids B-FAMILY 
, O 
isoabietenins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
and O 
13 O 
new O 
ent-kauranoids B-FAMILY 
, O 
tenuifolins B-MULTIPLE 
A-M I-MULTIPLE 
( O 
4-16 O 
) O 
, O 
along O 
with O 
four O 
known O 
compounds O 
( O 
17-20 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Isodon O 
tenuifolius O 
. O 
The O 
structures O 
of O 
the O 
new O 
metabolites O 
were O 
established O 
on O 
the O 
basis O 
of O 
detailed O 
spectroscopic O 
analysis O 
. O 
The O 
absolute O 
configurations O 
of O 
1 O 
, O 
15 O 
, O 
and O 
16 O 
were O 
confirmed O 
by O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
. O 
Selected O 
compounds O 
were O 
evaluated O 
for O 
their O 
cytotoxicity O 
against O 
a O 
small O 
panel O 
of O 
human O 
tumor O 
cell O 
lines O 
, O 
and O 
some O 
compounds O 
showed O 
inhibitory O 
effects O 
. O 
Furthermore O 
, O 
several O 
isolates O 
exhibited O 
inhibitory O 
activity O 
against O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
LPS-activated O 
RAW264.7 O 
macrophages O 
. O 

paniculata O 
is O 
a O 
large O 
shrub O 
or O 
small O 
tree O 
that O 
grows O 
in O 
several O 
countries O 
in O 
South O 
and O 
Southeast O 
Asia O 
. O 
In O 
the O 
present O 
study O 
, O 
three O 
new O 
piperidine B-FAMILY 
alkaloids I-FAMILY 
, O 
microgrewiapines B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
as O 
well O 
as O 
three O 
known O 
compounds O 
, O 
inclusive O 
of O 
microcosamine B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
, O 
7'-(3',4'-dihydroxyphenyl)-N-[4-methoxyphenyl)ethyl]propenamide B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
and O 
liriodenine B-TRIVIAL 
( O 
6 O 
) O 
, O 
were O 
isolated O 
from O 
cytotoxic O 
fractions O 
of O 
the O 
separate O 
chloroform B-TRIVIAL 
-soluble O 
extracts O 
of O 
the O 
stem O 
bark O 
, O 
branches O 
, O 
and O 
leaves O 
of O 
M O 
. O 
paniculata O 
. O 
Compounds O 
1-6 O 
and O 
1a O 
( O 
microgrewiapine B-SYSTEMATIC 
A I-SYSTEMATIC 
3-acetate I-SYSTEMATIC 
) O 
showed O 
a O 
range O 
of O 
cytotoxicity O 
values O 
against O 
the O 
HT-29 O 
human O 
colon O 
cancer O 
cell O 
line O 
. O 
When O 
evaluated O 
for O 
their O 
effects O 
on O 
human O 
α3β4 O 
or O 
α4β2 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
, O 
several O 
of O 
these O 
compounds O 
were O 
shown O 
to O 
be O 
active O 
as O 
nAChR O 
antagonists O 
. O 
As O 
a O 
result O 
of O 
this O 
study O 
, O 
microgrewiapine B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
was O 
found O 
to O 
be O 
a O 
selective O 
cytotoxic O 
agent O 
for O 
colon O 
cancer O 
cells O 
over O 
normal O 
colon O 
cells O 
and O 
to O 
exhibit O 
nicotinic O 
receptor O 
antagonistic O 
activity O 
for O 
both O 
the O 
hα3β4 O 
and O 
hα4β2 O 
receptor O 
subtypes O 
. O 

- O 
mimetic O 
peptides O 
( O 
TXM O 
) O 
reverse O 
auranofin B-TRIVIAL 
induced O 
apoptosis O 
and O 
restore O 
insulin O 
secretion O 
in O 
insulinoma O 
cells O 
. O 

thioredoxin O 
reductase O 
/ O 
thioredoxin O 
system O 
( O 
TrxR O 
/ O 
Trx1 O 
) O 
plays O 
a O 
major O 
role O 
in O 
protecting O 
cells O 
from O 
oxidative O 
stress O 
. O 
Disruption O 
of O 
the O 
TrxR-Trx1 O 
system O 
keeps O 
Trx1 O 
in O 
the O 
oxidized O 
state O 
leading O 
to O 
cell O 
death O 
through O 
activation O 
of O 
the O 
ASK1-Trx1 O 
apoptotic O 
pathway O 
. O 
The O 
potential O 
mechanism O 
and O 
ability O 
of O 
tri- O 
and O 
tetra O 
- O 
oligopeptides O 
derived O 
from O 
the O 
canonical O 
-CxxC- O 
motif O 
of O 
the O 
Trx1-active O 
site O 
to O 
mimic O 
and O 
enhance O 
Trx1 O 
cellular O 
activity O 
was O 
examined O 
. O 
The O 
Trx O 
mimetics O 
peptides O 
( O 
TXM O 
) O 
protected O 
insulinoma O 
INS O 
832 O 
/ O 
13 O 
cells O 
from O 
oxidative O 
stress O 
induced O 
by O 
selectively O 
inhibiting O 
TrxR O 
with O 
auranofin B-TRIVIAL 
( O 
AuF B-ABBREVIATION 
) O 
. O 
TXM O 
reversed O 
the O 
AuF B-ABBREVIATION 
-effects O 
preventing O 
apoptosis O 
, O 
and O 
increasing O 
cell O 
- O 
viability O 
. O 
The O 
TXM O 
peptides O 
were O 
effective O 
in O 
inhibiting O 
AuF B-ABBREVIATION 
-induced O 
MAPK O 
, O 
JNK O 
and O 
p38(MAPK) O 
phosphorylation O 
, O 
in O 
correlation O 
with O 
preventing O 
caspase-3 O 
cleavage O 
and O 
thereby O 
PARP-1 O 
dissociation O 
. O 
The O 
ability O 
to O 
form O 
a O 
disulfide B-SYSTEMATIC 
-bridge O 
- O 
like O 
conformation O 
was O 
estimated O 
from O 
molecular O 
dynamics O 
simulations O 
. O 
The O 
TXM O 
peptides O 
restored O 
insulin O 
secretion O 
and O 
displayed O 
Trx1 O 
denitrosylase O 
activity O 
. O 
Their O 
potency O 
was O 
10-100-fold O 
higher O 
than O 
redox O 
reagents O 
like O 
NAC B-ABBREVIATION 
, O 
AD4 B-IDENTIFIER 
, O 
or O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Unable O 
to O 
reverse O 
ERK1 O 
/ O 
2 O 
phosphorylation O 
, O 
TXM-CB3 O 
( O 
NAc-Cys-Pro-Cys B-SYSTEMATIC 
amide I-SYSTEMATIC 
) O 
appeared O 
to O 
function O 
in O 
part O 
, O 
through O 
inhibiting O 
ASK1-Trx O 
dissociation O 
. O 
These O 
highly O 
effective O 
anti-apoptotic O 
effects O 
of O 
Trx1 O 
mimetic O 
peptides O 
exhibited O 
in O 
INS O 
832 O 
/ O 
13 O 
cells O 
could O 
become O 
valuable O 
in O 
treating O 
adverse O 
oxidative O 
- O 
stress O 
related O 
disorders O 
such O 
as O 
diabetes O 
. O 

- O 
dependent O 
effects O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
on O 
transdifferentiation O 
of O 
skeletal O 
muscle O 
cells O 
to O 
adipose O 
cells O 
. O 

infiltration O 
within O 
muscle O 
is O 
one O 
of O 
a O 
number O 
of O 
features O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
, O 
which O 
leads O 
to O 
a O 
decline O 
in O 
muscle O 
functionality O 
. O 
The O 
origin O 
of O 
this O 
fat O 
is O 
unclear O 
, O 
but O 
one O 
possibility O 
is O 
that O 
it O 
forms O 
from O 
myogenic O 
precursor O 
cells O 
present O 
in O 
the O 
muscle O 
, O 
which O 
transdifferentiate O 
into O 
mature O 
adipocytes O 
. O 
The O 
current O 
study O 
examined O 
the O 
effect O 
of O 
the O 
active O 
form O 
of O 
vitamin B-TRIVIAL 
D₃ I-TRIVIAL 
, O 
1,25-dihydroxyvitamin B-SYSTEMATIC 
D₃ I-SYSTEMATIC 
( O 
1,25(OH)₂D₃ B-SYSTEMATIC 
) O 
, O 
on O 
the O 
capacity O 
of O 
the O 
C2C12 O 
muscle O 
cell O 
line O 
to O 
differentiate O 
towards O 
the O 
myogenic O 
and O 
adipogenic O 
lineages O 
. O 
Cells O 
were O 
cultured O 
in O 
myogenic O 
or O 
adipogenic O 
differentiation O 
media O 
containing O 
increasing O 
concentrations O 
( O 
0 O 
, O 
10⁻¹³ O 
, O 
10⁻¹¹ O 
, O 
10⁻⁹ O 
, O 
10⁻⁷ O 
or O 
10⁻⁵ O 
M O 
) O 
of O 
1,25(OH)₂D₃ B-SYSTEMATIC 
for O 
up O 
to O 
6 O 
days O 
and O 
markers O 
of O 
muscle O 
and O 
fat O 
development O 
measured O 
. O 
Mature O 
myofibres O 
were O 
formed O 
in O 
both O 
adipogenic O 
and O 
myogenic O 
media O 
, O 
but O 
fat O 
droplets O 
were O 
only O 
observed O 
in O 
adipogenic O 
media O 
. O 
Relative O 
to O 
controls O 
, O 
low O 
physiological O 
concentrations O 
( O 
10⁻¹³ O 
and O 
10⁻¹¹ O 
M O 
) O 
of O 
1,25(OH)₂D3 B-SYSTEMATIC 
increased O 
fat O 
droplet O 
accumulation O 
, O 
whereas O 
high O 
physiological O 
( O 
10⁻⁹ O 
M O 
) O 
and O 
supraphysiological O 
concentrations O 
( O 
≥ O 
10⁻⁷ O 
M O 
) O 
inhibited O 
fat O 
accumulation O 
. O 
This O 
increased O 
accumulation O 
of O 
fat O 
with O 
low O 
physiological O 
concentrations O 
( O 
10⁻¹³ O 
and O 
10⁻¹¹ O 
M O 
) O 
was O 
associated O 
with O 
a O 
sequential O 
up O 
- O 
regulation O 
of O 
PPARγ2 O 
( O 
PPARG O 
) O 
and O 
FABP4 O 
mRNA O 
, O 
indicating O 
formation O 
of O 
adipocytes O 
, O 
whereas O 
higher O 
concentrations O 
( O 
≥ O 
10⁻⁹ O 
M O 
) O 
reduced O 
all O 
these O 
effects O 
, O 
and O 
the O 
highest O 
concentration O 
( O 
10⁻⁵ O 
M O 
) O 
appeared O 
to O 
have O 
toxic O 
effects O 
. O 
This O 
is O 
the O 
first O 
study O 
to O 
demonstrate O 
dose O 
- O 
dependent O 
effects O 
of O 
1,25(OH)₂D₃ B-SYSTEMATIC 
on O 
the O 
transdifferentiation O 
of O 
muscle O 
cells O 
into O 
adipose O 
cells O 
. O 
Low O 
physiological O 
concentrations O 
( O 
possibly O 
mimicking O 
a O 
deficient O 
state O 
) O 
induced O 
adipogenesis O 
, O 
whereas O 
higher O 
( O 
physiological O 
and O 
supraphysiological O 
) O 
concentrations O 
attenuated O 
this O 
effect O 
. O 

Fatty I-FAMILY 
acids I-FAMILY 
reduce O 
adipose O 
tissue O 
macrophages O 
in O 
human O 
subjects O 
with O 
insulin O 
resistance O 
. O 

oils O 
( O 
FOs O 
) O 
have O 
anti-inflammatory O 
effects O 
and O 
lower O 
serum O 
triglycerides O 
. O 
This O 
study O 
examined O 
adipose O 
and O 
muscle O 
inflammatory O 
markers O 
after O 
treatment O 
of O 
humans O 
with O 
FOs O 
and O 
measured O 
the O 
effects O 
of O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
on O 
adipocytes O 
and O 
macrophages O 
in O 
vitro O 
. O 
Insulin O 
- O 
resistant O 
, O 
nondiabetic O 
subjects O 
were O 
treated O 
with O 
Omega-3-Acid B-FAMILY 
Ethyl I-FAMILY 
Esters I-FAMILY 
( O 
4 O 
g O 
/ O 
day O 
) O 
or O 
placebo O 
for O 
12 O 
weeks O 
. O 
Plasma O 
macrophage O 
chemoattractant O 
protein O 
1 O 
( O 
MCP-1 O 
) O 
levels O 
were O 
reduced O 
by O 
FO O 
, O 
but O 
the O 
levels O 
of O 
other O 
cytokines O 
were O 
unchanged O 
. O 
The O 
adipose O 
( O 
but O 
not O 
muscle O 
) O 
of O 
FO O 
- O 
treated O 
subjects O 
demonstrated O 
a O 
decrease O 
in O 
macrophages O 
, O 
a O 
decrease O 
in O 
MCP-1 O 
, O 
and O 
an O 
increase O 
in O 
capillaries O 
, O 
and O 
subjects O 
with O 
the O 
most O 
macrophages O 
demonstrated O 
the O 
greatest O 
response O 
to O 
treatment O 
. O 
Adipose O 
and O 
muscle O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
content O 
increased O 
after O 
treatment O 
; O 
however O 
, O 
there O 
was O 
no O 
change O 
in O 
insulin O 
sensitivity O 
or O 
adiponectin O 
. O 
In O 
vitro O 
, O 
M1-polarized O 
macrophages O 
expressed O 
high O 
levels O 
of O 
MCP-1 O 
. O 
The O 
addition O 
of O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
reduced O 
MCP-1 O 
expression O 
with O 
no O 
effect O 
on O 
TNF-α O 
. O 
In O 
addition O 
, O 
ω-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
suppressed O 
the O 
upregulation O 
of O 
adipocyte O 
MCP-1 O 
that O 
occurred O 
when O 
adipocytes O 
were O 
cocultured O 
with O 
macrophages O 
. O 
Thus O 
, O 
FO O 
reduced O 
adipose O 
macrophages O 
, O 
increased O 
capillaries O 
, O 
and O 
reduced O 
MCP-1 O 
expression O 
in O 
insulin O 
- O 
resistant O 
humans O 
and O 
in O 
macrophages O 
and O 
adipocytes O 
in O 
vitro O 
; O 
however O 
, O 
there O 
was O 
no O 
measureable O 
effect O 
on O 
insulin O 
sensitivity O 
. O 

stimulated O 
the O 
growth O 
of O 
BG-1 O 
ovarian O 
cancer O 
cells O 
by O 
cell O 
cycle O 
regulation O 
via O 
an O 
estrogen B-FAMILY 
receptor O 
alpha O 
- O 
mediated O 
signaling O 
pathway O 
in O 
cellular O 
and O 
xenograft O 
mouse O 
models O 
. O 

( O 
benzophenone-1 B-SYSTEMATIC 
; O 
BP-1 B-ABBREVIATION 
) O 
is O 
an O 
UV O 
stabilizer O 
primarily O 
used O 
to O 
prevent O 
polymer O 
degradation O 
and O 
deterioration O 
in O 
quality O 
due O 
to O 
UV O 
irradiation O 
. O 
Recently O 
, O 
BP-1 B-ABBREVIATION 
has O 
been O 
reported O 
to O 
bioaccumulate O 
in O 
human O 
bodies O 
by O 
absorption O 
through O 
the O 
skin O 
and O 
has O 
the O 
potential O 
to O 
induce O 
health O 
problems O 
including O 
endocrine O 
disruption O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
xenoestrogenic O 
effect O 
of O 
BP-1 B-ABBREVIATION 
on O 
BG-1 O 
human O 
ovarian O 
cancer O 
cells O 
expressing O 
estrogen B-FAMILY 
receptors O 
( O 
ERs O 
) O 
and O 
relevant O 
xenografted O 
animal O 
models O 
in O 
comparison O 
with O 
17-β B-SYSTEMATIC 
estradiol I-SYSTEMATIC 
( O 
E2 O 
) O 
. O 
In O 
in O 
vitro O 
cell O 
viability O 
assay O 
, O 
BP-1 B-ABBREVIATION 
( O 
10(-8)-10(-5)M O 
) O 
significantly O 
increased O 
BG-1 O 
cell O 
growth O 
the O 
way O 
E2 O 
did O 
. O 
The O 
mechanism O 
underlying O 
the O 
BG-1 O 
cell O 
proliferation O 
was O 
proved O 
to O 
be O 
related O 
with O 
the O 
up O 
- O 
regulation O 
of O 
cyclin O 
D1 O 
, O 
a O 
cell O 
cycle O 
progressor O 
, O 
by O 
E2 O 
or O 
BP-1 B-ABBREVIATION 
. O 
Both O 
BP-1 B-ABBREVIATION 
and O 
E2 O 
induced O 
cell O 
growth O 
and O 
up O 
- O 
regulation O 
of O 
cyclin O 
D1 O 
were O 
reversed O 
by O 
co O 
- O 
treatment O 
with O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
, O 
an O 
ER O 
antagonist O 
, O 
suggesting O 
that O 
BP-1 B-ABBREVIATION 
may O 
mediate O 
the O 
cancer O 
cell O 
proliferation O 
via O 
an O 
ER-dependent O 
pathway O 
like O 
E2 O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
expression O 
of O 
p21 O 
, O 
a O 
regulator O 
of O 
cell O 
cycle O 
progression O 
at O 
G1 O 
phase O 
, O 
was O 
not O 
altered O 
by O 
BP-1 B-ABBREVIATION 
though O 
it O 
was O 
down O 
- O 
regulated O 
by O 
E2 O 
. O 
In O 
xenograft O 
mouse O 
models O 
transplanted O 
with O 
BG-1 O 
cells O 
, O 
BP-1 B-ABBREVIATION 
or O 
E2 O 
treatment O 
significantly O 
increased O 
the O 
tumor O 
mass O 
formation O 
compared O 
to O 
a O 
vehicle O 
( O 
corn O 
oil O 
) O 
within O 
8 O 
weeks O 
. O 
In O 
histopathological O 
analysis O 
, O 
the O 
tumor O 
sections O 
of O 
E2 O 
or O 
BP-1 B-ABBREVIATION 
group O 
displayed O 
extensive O 
cell O 
formations O 
with O 
high O 
density O 
and O 
disordered O 
arrangement O 
, O 
which O 
were O 
supported O 
by O 
the O 
increased O 
number O 
of O 
BrdUrd O 
positive O 
nuclei O 
and O 
the O 
over O 
- O 
expression O 
of O 
cyclin O 
D1 O 
protein O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
BP-1 B-ABBREVIATION 
is O 
an O 
endocrine O 
disrupting O 
chemical O 
( O 
EDC O 
) O 
that O 
exerts O 
xenoestrogenic O 
effects O 
by O 
stimulating O 
the O 
proliferation O 
of O 
BG-1 O 
ovarian O 
cancer O 
via O 
ER O 
signaling O 
pathway O 
associated O 
with O 
cell O 
cycle O 
as O 
did O 
E2 O 
. O 

of O 
dopamine B-TRIVIAL 
D2 O 
agonist O 
quinpirole B-TRIVIAL 
on O 
neuronal O 
activity O 
of O 
anterior O 
cingulate O 
cortex O 
and O 
striatum O 
in O 
rats O 
. O 

: O 
The O 
influence O 
of O 
acute O 
D2 O 
agonist O 
quinpirole B-TRIVIAL 
on O 
locomotor O 
activity O 
has O 
been O 
effectively O 
characterized O 
. O 
However O 
, O 
few O 
studies O 
have O 
addressed O 
the O 
dynamic O 
changes O 
in O 
neuronal O 
activity O 
of O 
the O 
anterior O 
cingulate O 
cortex O 
( O 
ACC O 
) O 
and O 
striatum O 
( O 
STR O 
) O 
, O 
two O 
crucial O 
regions O 
for O 
cognitive O 
and O 
motor O 
functions O 
, O 
after O 
quinpirole B-TRIVIAL 
administration O 
. O 
OBJECTIVE O 
: O 
This O 
study O 
was O 
conducted O 
in O 
order O 
to O 
acquire O 
detailed O 
information O 
on O 
the O 
evoked O 
activity O 
of O 
the O 
neurons O 
in O 
the O 
ACC O 
and O 
STR O 
after O 
acute O 
quinpirole B-TRIVIAL 
administration O 
. O 
METHODS O 
: O 
Multichannel O 
electrophysiological O 
recording O 
was O 
used O 
for O 
tracking O 
neuronal O 
activity O 
in O 
the O 
ACC O 
and O 
STR O 
of O 
urethane B-TRIVIAL 
-anesthetized O 
rats O 
after O 
administration O 
of O 
saline O 
or O 
0.05 O 
or O 
0.5 O 
mg O 
/ O 
kg O 
quinpirole B-TRIVIAL 
. O 
RESULTS O 
: O 
In O 
contrast O 
to O 
the O 
responses O 
to O 
saline O 
, O 
quinpirole B-TRIVIAL 
dose O 
- O 
dependently O 
increased O 
the O 
ratio O 
of O 
neurons O 
, O 
the O 
activity O 
of O 
which O 
was O 
inhibited O 
in O 
the O 
ACC O 
and O 
STR O 
. O 
By O 
examining O 
the O 
ensemble O 
neuronal O 
activities O 
of O 
inhibition O 
- O 
responded O 
neurons O 
, O 
there O 
was O 
no O 
significant O 
activity O 
difference O 
among O 
the O 
" O 
treatments O 
" O 
( O 
saline O 
and O 
low- O 
and O 
high O 
- O 
dose O 
quinpirole B-TRIVIAL 
) O 
, O 
the O 
" O 
periods O 
" O 
( O 
the O 
duration O 
of O 
0- O 
15 O 
and O 
16-45 O 
min O 
after O 
i.v O 
. O 
injection O 
) O 
, O 
and O 
the O 
interaction O 
between O 
" O 
treatments O 
" O 
and O 
" O 
periods O 
. O 
" O 
Regarding O 
activation O 
- O 
responded O 
neurons O 
, O 
however O 
, O 
there O 
was O 
a O 
significant O 
" O 
periods O 
" O 
difference O 
in O 
both O 
ACC O 
and O 
STR O 
, O 
and O 
the O 
activity O 
of O 
16-45 O 
min O 
was O 
significantly O 
higher O 
than O 
the O 
activity O 
of O 
0-15 O 
min O 
after O 
high O 
- O 
dose O 
quinpirole B-TRIVIAL 
administration O 
in O 
ACC O 
( O 
p O 
< O 
0.05 O 
) O 
and O 
STR O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
CONCLUSION O 
: O 
Dose O 
- O 
dependent O 
ACC O 
and O 
STR O 
neuronal O 
responses O 
to O 
quinpirole B-TRIVIAL 
may O 
offer O 
a O 
possible O 
mechanism O 
for O 
understanding O 
the O 
locomotor O 
responses O 
to O 
quinpirole B-TRIVIAL 
in O 
behaving O 
rats O 
. O 
The O 
late O 
excitatory O 
effect O 
of O 
high O 
- O 
dose O 
quinpirole B-TRIVIAL 
in O 
the O 
STR O 
further O 
suggests O 
that O 
this O 
region O 
would O 
be O 
critical O 
for O 
the O 
activation O 
of O 
locomotor O 
activity O 
. O 

Bedford O 
Harbor O 
( O 
MA O 
, O 
U.S.A O 
. O 
; O 
NBH O 
) O 
is O 
a O 
Superfund O 
site O 
inhabited O 
by O 
Atlantic O 
killifish O 
( O 
Fundulus O 
heteroclitus O 
) O 
with O 
altered O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
Ahr O 
) O 
signaling O 
, O 
leading O 
to O 
resistance O 
to O 
effects O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
and O 
2,3,7,8-tetrachlorodibenzo-p-dioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
. O 
The O 
Ahr O 
is O 
a O 
transcription O 
factor O 
that O 
regulates O 
gene O 
expression O 
of O 
many O 
Phase O 
I O 
and O 
II O 
detoxifying O 
enzymes O 
and O 
interacts O 
with O 
Nrf2 O 
, O 
a O 
transcription O 
factor O 
that O 
regulates O 
the O 
response O 
to O 
oxidative O 
stress O 
. O 
This O 
study O 
tested O 
the O 
hypothesis O 
that O 
PCB B-ABBREVIATION 
-resistant O 
killifish O 
exhibit O 
altered O 
sensitivity O 
to O 
oxidative O 
stress O 
. O 
Killifish O 
F(1) O 
embryos O 
from O 
NBH O 
and O 
a O 
clean O 
reference O 
site O 
( O 
Scorton O 
Creek O 
, O 
MA O 
, O 
U.S.A O 
. O 
; O 
SC O 
) O 
were O 
exposed O 
to O 
model O 
pro O 
- O 
oxidant O 
and O 
Nrf2-activator O 
, O 
tert-butylhydroquinone B-SYSTEMATIC 
( O 
tBHQ B-ABBREVIATION 
) O 
. O 
Embryos O 
were O 
exposed O 
at O 
specific O 
embryonic O 
developmental O 
stages O 
( O 
5 O 
, O 
7 O 
, O 
and O 
9 O 
days O 
post O 
fertilization O 
) O 
and O 
toxicity O 
was O 
assessed O 
, O 
using O 
a O 
deformity O 
score O 
, O 
survival O 
, O 
heart O 
rate O 
, O 
and O 
gene O 
expression O 
to O 
compare O 
sensitivity O 
between O 
PCB B-ABBREVIATION 
-resistant O 
and O 
-sensitive O 
( O 
reference O 
) O 
populations O 
. O 
Acute O 
exposure O 
to O 
tBHQ B-ABBREVIATION 
resulted O 
in O 
transient O 
reduction O 
in O 
heart O 
rate O 
in O 
NBH O 
and O 
SC O 
F(1) O 
embryos O 
. O 
However O 
, O 
embryos O 
from O 
NBH O 
were O 
more O 
sensitive O 
to O 
tBHQ B-ABBREVIATION 
, O 
with O 
more O 
frequent O 
and O 
severe O 
deformities O 
, O 
including O 
pericardial O 
edema O 
, O 
tail O 
deformities O 
, O 
small O 
body O 
size O 
, O 
and O 
reduced O 
pigment O 
and O 
erythrocytes O 
. O 
NBH O 
embryos O 
had O 
lower O 
basal O 
expression O 
of O 
antioxidant O 
genes O 
catalase O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
alpha O 
( O 
gsta O 
) O 
, O 
and O 
upon O 
exposure O 
to O 
tBHQ B-ABBREVIATION 
, O 
exhibited O 
lower O 
levels O 
of O 
expression O 
of O 
catalase O 
, O 
gsta O 
, O 
and O 
superoxide B-TRIVIAL 
dismutase O 
compared O 
to O 
controls O 
. O 
This O 
result O 
suggests O 
that O 
adaptation O 
to O 
tolerate O 
PCBs B-ABBREVIATION 
has O 
altered O 
the O 
sensitivity O 
of O 
NBH O 
fish O 
to O 
oxidative O 
stress O 
during O 
embryonic O 
development O 
, O 
demonstrating O 
a O 
cost O 
of O 
the O 
PCB B-ABBREVIATION 
resistance O 
adaptation O 
. O 

in O 
REarranged O 
during O 
Transfection O 
( O 
RET O 
) O 
receptor O 
tyrosine B-TRIVIAL 
, O 
followed O 
by O 
the O 
oncogenic O 
activation O 
of O 
RET O 
kinase O 
is O 
responsible O 
for O 
the O 
development O 
of O 
medullary O 
thyroid O 
carcinoma O 
( O 
MTC O 
) O 
that O 
responds O 
poorly O 
to O 
conventional O 
chemotherapy O 
. O 
Targeting O 
RET O 
, O 
therefore O 
, O 
might O 
be O 
useful O 
in O 
tailoring O 
surveillance O 
of O 
MTC O 
patients O 
. O 
Here O 
we O 
showed O 
that O 
theaflavins B-FAMILY 
, O 
the O 
bioactive O 
components O 
of O 
black O 
tea O 
, O 
successfully O 
induced O 
apoptosis O 
in O 
human O 
MTC O 
cell O 
line O 
, O 
TT O 
, O 
by O 
inversely O 
modulating O 
two O 
molecular O 
pathways O 
: O 
(i) O 
stalling O 
PI3K O 
/ O 
Akt O 
/ O 
Bad O 
pathway O 
that O 
resulted O 
in O 
mitochondrial O 
transmembrane O 
potential O 
( O 
MTP O 
) O 
loss O 
, O 
cytochrome-c O 
release O 
and O 
activation O 
of O 
the O 
executioner O 
caspases-9 O 
and O 
-3 O 
, O 
and O 
(ii) O 
upholding O 
p38MAPK O 
/ O 
caspase-8 O 
/ O 
caspase-3 O 
pathway O 
via O 
inhibition O 
of O 
Ras O 
/ O 
Raf O 
/ O 
ERK O 
. O 
Over O 
- O 
expression O 
of O 
either O 
constitutively O 
active O 
myristoylated-Akt-cDNA O 
( O 
Myr-Akt-cDNA O 
) O 
or O 
dominant-negative-caspase-8-cDNA O 
( O 
Dn-caspase-8-cDNA O 
) O 
partially O 
blocked O 
theaflavin O 
- O 
induced O 
apoptosis O 
, O 
while O 
co O 
- O 
transfection O 
of O 
Myr-Akt-cDNA O 
and O 
Dn-caspase-8-cDNA O 
completely O 
eradicated O 
the O 
effect O 
of O 
theaflavins B-FAMILY 
thereby O 
negating O 
the O 
possibility O 
of O 
existence O 
of O 
other O 
pathways O 
. O 
A O 
search O 
for O 
the O 
upstream O 
signaling O 
revealed O 
that O 
theaflavin B-TRIVIAL 
-induced O 
disruption O 
of O 
lipid O 
raft O 
caused O 
interference O 
in O 
anchorage O 
of O 
RET O 
in O 
lipid O 
raft O 
that O 
in O 
turn O 
stalled O 
phosphorylation O 
of O 
Ras O 
and O 
PI3Kinase O 
. O 
In O 
such O 
anti-survival O 
cellular O 
micro O 
- O 
environment O 
, O 
pro O 
- O 
apoptotic O 
signals O 
were O 
triggered O 
to O 
culminate O 
into O 
programmed O 
death O 
of O 
MTC O 
cell O 
. O 
These O 
findings O 
not O 
only O 
unveil O 
a O 
hitherto O 
unexplained O 
mechanism O 
underlying O 
theaflavin B-TRIVIAL 
-induced O 
MTC O 
death O 
, O 
but O 
also O 
validate O 
RET O 
as O 
a O 
promising O 
and O 
potential O 
target O 
for O 
MTC O 
therapy O 
. O 

orphan O 
nuclear O 
receptor O 
( O 
NR O 
) O 
, O 
pregnane B-TRIVIAL 
X O 
receptor O 
( O 
PXR O 
) O 
, O 
plays O 
a O 
central O 
role O 
in O 
the O 
regulation O 
of O 
xeno- O 
and O 
endobiotic O 
metabolism O 
. O 
Since O 
the O 
discovery O 
of O 
the O 
functional O 
role O 
of O 
PXR O 
in O 
1998 O 
, O 
there O 
is O 
evolving O 
evidence O 
for O 
the O 
role O 
of O 
PXR O 
agonists O 
in O 
abrogating O 
metabolic O 
pathophysiology O 
( O 
e.g O 
. O 
, O 
cholestasis O 
, O 
hypercholesterolemia O 
, O 
and O 
inflammation O 
) O 
. O 
However O 
, O 
more O 
recently O 
, O 
it O 
is O 
clear O 
that O 
PXR O 
is O 
also O 
an O 
important O 
mediator O 
of O 
adverse O 
xeno- O 
( O 
e.g O 
. O 
, O 
enhances O 
acetaminophen B-TRIVIAL 
toxicity O 
) O 
and O 
endobiotic O 
( O 
e.g O 
. O 
, O 
hepatic O 
steatosis O 
) O 
metabolic O 
phenotypes O 
. O 
Moreover O 
, O 
in O 
cancer O 
therapeutics O 
, O 
PXR O 
activation O 
can O 
induce O 
drug O 
resistance O 
, O 
and O 
there O 
is O 
growing O 
evidence O 
for O 
tissue O 
- O 
specific O 
enhancement O 
of O 
the O 
malignant O 
phenotype O 
. O 
Thus O 
, O 
in O 
these O 
instances O 
, O 
there O 
may O 
be O 
a O 
role O 
for O 
PXR O 
antagonists O 
. O 
However O 
, O 
as O 
opposed O 
to O 
the O 
discovery O 
efforts O 
for O 
PXR O 
agonists O 
, O 
there O 
are O 
only O 
a O 
few O 
antagonists O 
described O 
. O 
The O 
mode O 
of O 
action O 
of O 
these O 
antagonists O 
( O 
e.g O 
. O 
, O 
sulforaphane B-TRIVIAL 
) O 
remains O 
less O 
clear O 
. O 
Our O 
laboratory O 
efforts O 
have O 
focused O 
on O 
this O 
question O 
. O 
Since O 
the O 
original O 
discovery O 
of O 
azoles B-FAMILY 
analogs O 
as O 
PXR O 
antagonists O 
, O 
we O 
have O 
preliminarily O 
defined O 
an O 
important O 
PXR O 
antagonist O 
pharmacophore O 
and O 
developed O 
less O 
- O 
toxic O 
PXR O 
antagonists O 
. O 
In O 
this O 
review O 
, O 
we O 
describe O 
our O 
published O 
and O 
unpublished O 
findings O 
on O 
recent O 
structure O 
- O 
function O 
studies O 
involving O 
the O 
azole B-FAMILY 
chemical O 
scaffold O 
. O 
Further O 
work O 
in O 
the O 
future O 
is O 
needed O 
to O 
fully O 
define O 
potent O 
, O 
more O 
- O 
selective O 
PXR O 
antagonists O 
that O 
may O 
be O 
useful O 
in O 
clinical O 
application O 
. O 

molecular O 
platinum B-SYSTEMATIC 
cluster O 
junction O 
: O 
a O 
single O 
- O 
molecule O 
switch O 
. O 

present O 
a O 
theoretical O 
study O 
of O 
electron O 
transport O 
through O 
single O 
- O 
molecule O 
junctions O 
incorporating O 
a O 
Pt(6) B-FORMULA 
metal O 
cluster O 
bound O 
within O 
an O 
organic O 
framework O 
. O 
The O 
insertion O 
of O 
this O 
molecule O 
between O 
a O 
pair O 
of O 
electrodes O 
leads O 
to O 
a O 
fully O 
atomically O 
engineered O 
nanometallic O 
device O 
with O 
high O 
conductance O 
at O 
the O 
Fermi O 
level O 
and O 
two O 
sequential O 
high O 
on O 
/ O 
off O 
switching O 
states O 
. O 
The O 
origin O 
of O 
this O 
property O 
can O 
be O 
traced O 
back O 
to O 
the O 
existence O 
of O 
a O 
degenerate O 
HOMO O 
consisting O 
of O 
two O 
asymmetric O 
orbitals O 
with O 
energies O 
close O 
to O 
the O 
Fermi O 
level O 
of O 
the O 
metal O 
leads O 
. O 
The O 
degeneracy O 
is O 
broken O 
when O 
the O 
molecule O 
is O 
contacted O 
to O 
the O 
leads O 
, O 
giving O 
rise O 
to O 
two O 
resonances O 
that O 
become O 
pinned O 
to O 
the O 
Fermi O 
level O 
and O 
display O 
destructive O 
interference O 
. O 

production O 
is O 
downstream O 
and O 
upstream O 
of O 
oncogenic O 
PI3K O 
signalling O 
and O 
contributes O 
to O 
tumour O 
cell O 
growth O 
. O 

( O 
phosphoinositide B-FAMILY 
3-kinase O 
) O 
signalling O 
pathways O 
regulate O 
a O 
large O 
array O 
of O 
cell O 
biological O 
functions O 
in O 
normal O 
and O 
cancer O 
cells O 
. O 
In O 
the O 
present O 
study O 
we O 
investigated O 
the O 
involvement O 
of O 
PI3K O 
in O 
modulating O 
small O 
molecule O 
metabolism O 
. O 
A O 
LC O 
( O 
liquid O 
chromatography)-MS O 
screen O 
in O 
colorectal O 
cancer O 
cell O 
lines O 
isogenic O 
for O 
oncogenic O 
PIK3CA O 
mutations O 
revealed O 
an O 
association O 
between O 
PI3K O 
activation O 
and O 
the O 
levels O 
of O 
polyamine B-FAMILY 
pathway O 
metabolites O 
, O 
including O 
5-methylthioadenosine B-SYSTEMATIC 
, O 
putrescine B-TRIVIAL 
and O 
spermidine B-TRIVIAL 
. O 
Pharmacological O 
inhibition O 
confirmed O 
that O 
the O 
PI3K O 
pathway O 
controls O 
polyamine B-FAMILY 
production O 
. O 
Despite O 
inducing O 
a O 
decrease O 
in O 
PKB O 
( O 
protein O 
kinase O 
B O 
) O 
/ O 
Akt O 
phosphorylation O 
, O 
spermidine B-TRIVIAL 
promoted O 
cell O 
survival O 
and O 
opposed O 
the O 
anti-proliferative O 
effects O 
of O 
PI3K O 
inhibitors O 
. O 
Conversely O 
, O 
polyamine B-FAMILY 
depletion O 
by O 
an O 
ornithine B-TRIVIAL 
decarboxylase O 
inhibitor O 
enhanced O 
PKB O 
/ O 
Akt O 
phosphorylation O 
, O 
but O 
suppressed O 
cell O 
survival O 
. O 
These O 
results O 
suggest O 
that O 
spermidine B-TRIVIAL 
mediates O 
cell O 
proliferation O 
and O 
survival O 
downstream O 
of O 
PI3K O 
/ O 
Akt O 
and O 
indicate O 
that O 
these O 
two O 
biochemical O 
pathways O 
control O 
each O 
other's O 
activities O 
, O 
highlighting O 
a O 
mechanism O 
by O 
which O 
small O 
molecule O 
metabolism O 
feeds O 
back O 
to O 
regulate O 
kinase O 
signalling O 
. O 
Consistent O 
with O 
this O 
feedback O 
loop O 
having O 
a O 
functional O 
role O 
in O 
these O 
cell O 
models O 
, O 
pharmacological O 
inhibitors O 
of O 
PI3K O 
and O 
ornithine B-TRIVIAL 
decarboxylase O 
potentiated O 
each O 
other O 
in O 
inhibiting O 
tumour O 
growth O 
in O 
a O 
xenograft O 
model O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
support O 
the O 
notion O 
that O 
the O 
modulation O 
of O 
spermidine B-TRIVIAL 
concentrations O 
may O 
be O 
a O 
previously O 
unrecognized O 
mechanism O 
by O 
which O 
PI3K O 
sustains O 
chronic O 
proliferation O 
of O 
cancer O 
cells O 
. O 

, O 
proteins O 
, O 
and O 
extracellular O 
matrix O 
act O 
synergistically O 
to O 
influence O 
cellular O 
function O 
at O 
the O 
biotic O 
- O 
synthetic O 
interface O 
. O 
However O 
, O 
identifying O 
the O 
individual O 
and O 
cooperative O 
contributions O 
of O 
the O 
various O 
combinations O 
and O 
concentration O 
regimes O 
is O 
extremely O 
difficult O 
. O 
The O 
confined O 
channel O 
deposition O 
method O 
we O 
describe O 
affords O 
highly O 
tunable O 
orthogonal O 
reactive O 
concentration O 
gradients O 
that O 
greatly O 
expand O 
the O 
dynamic O 
range O 
, O 
spatial O 
control O 
, O 
and O 
chemical O 
versatility O 
of O 
the O 
reactive O 
silanes B-FAMILY 
that O 
can O 
be O 
controllably O 
deposited O 
. O 
Using O 
metal O 
- O 
free O 
" O 
dual O 
click O 
" O 
immobilization O 
chemistries O 
, O 
multiple O 
peptides O 
with O 
a O 
variety O 
of O 
functionality O 
can O 
be O 
immobilized O 
efficiently O 
and O 
reproducibly O 
enabling O 
optimal O 
concentration O 
profiling O 
and O 
the O 
assessment O 
of O 
synergistic O 
interactions O 
. O 

-terminated O 
conjugated O 
polymer O 
nanoparticles O 
have O 
near O 
- O 
unity O 
bright O 
fraction O 
and O 
reveal O 
cholesterol B-TRIVIAL 
-dependence O 
of O 
IGF1R O 
nanodomains O 
. O 

nanoparticles O 
have O 
enabled O 
many O 
discoveries O 
regarding O 
how O 
molecular O 
machines O 
function O 
. O 
Quantum O 
dots O 
have O 
been O 
the O 
dominant O 
class O 
of O 
fluorescent O 
nanoparticles O 
but O 
suffer O 
from O 
blinking O 
and O 
from O 
a O 
substantial O 
dark O 
fraction O 
-- O 
particles O 
where O 
the O 
fluorescence O 
is O 
never O 
seen O 
-- O 
complicating O 
any O 
analysis O 
of O 
biological O 
function O 
. O 
Nanoparticles O 
composed O 
of O 
conjugated O 
fluorescent O 
polymers O 
( O 
Pdots O 
) O 
have O 
recently O 
been O 
shown O 
to O 
have O 
high O 
brightness O 
and O 
no O 
blinking O 
. O 
Here O 
we O 
develop O 
a O 
robust O 
and O 
efficient O 
means O 
to O 
measure O 
the O 
dark O 
fraction O 
of O 
Pdots O 
, O 
conjugating O 
Atto O 
dyes O 
to O 
the O 
nanoparticles O 
and O 
testing O 
fluorescence O 
colocalization O 
of O 
dye O 
and O 
Pdot O 
puncta O 
. O 
This O 
established O 
that O 
the O 
Pdots O 
we O 
generated O 
had O 
minimal O 
dark O 
fraction O 
: O 
∼3% O 
. O 
The O 
application O 
of O 
nanoparticles O 
in O 
biological O 
environments O 
is O 
highly O 
sensitive O 
to O 
surface O 
functionalization O 
. O 
For O 
Pdots O 
we O 
found O 
that O 
passivation O 
with O 
uncharged O 
hydroxy B-SYSTEMATIC 
-terminated O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
caused O 
a O 
dramatic O 
reduction O 
in O 
nonspecific O 
cell O 
binding O 
and O 
aggregation O 
compared O 
to O 
a O 
charged O 
coating O 
. O 
Using O 
carbonyl B-SYSTEMATIC 
di I-SYSTEMATIC 
- I-SYSTEMATIC 
imidazole I-SYSTEMATIC 
the O 
hydroxy B-SYSTEMATIC 
-Pdots O 
were O 
functionalized O 
efficiently O 
with O 
streptavidin O 
for O 
high O 
stability O 
targeting O 
, O 
allowing O 
specific O 
labeling O 
of O 
mammalian O 
cells O 
. O 
Type O 
I O 
insulin O 
- O 
like O 
growth O 
factor O 
receptor O 
( O 
IGF1R O 
) O 
regulates O 
cell O 
survival O 
and O 
development O 
, O 
with O 
roles O 
in O 
aging O 
, O 
heart O 
disease O 
, O 
and O 
cancer O 
. O 
We O 
used O 
hydroxy B-SYSTEMATIC 
-Pdots O 
to O 
track O 
the O 
dynamics O 
of O 
IGF1R O 
on O 
a O 
breast O 
cancer O 
cell O 
- O 
line O 
, O 
determining O 
the O 
diffusion O 
characteristics O 
and O 
showing O 
cholesterol B-TRIVIAL 
-containing O 
membrane O 
nanodomains O 
were O 
important O 
for O 
receptor O 
mobility O 
at O 
the O 
plasma O 
membrane O 
. O 
The O 
near O 
- O 
unity O 
bright O 
fraction O 
and O 
low O 
nonspecific O 
binding O 
of O 
hydroxy B-SYSTEMATIC 
-Pdots O 
, O 
combined O 
with O 
Pdot O 
photostability O 
and O 
lack O 
of O 
blinking O 
, O 
provides O 
many O 
advantages O 
for O 
investigations O 
at O 
the O 
single O 
molecule O 
level O 
. O 

use O 
of O 
immobilized O 
capillary O 
enzyme O 
reactors O 
( O 
ICERs O 
) O 
for O 
online O 
ligand O 
screening O 
has O 
been O 
adopted O 
as O 
a O 
new O 
technique O 
for O 
high O 
- O 
throughput O 
screening O 
( O 
HTS O 
) O 
. O 
In O 
this O 
work O 
, O 
the O 
selected O 
target O 
was O 
the O 
enzyme O 
acetylcholinesterase O 
( O 
AChE O 
) O 
, O 
and O 
the O 
AChE-ICERs O 
produced O 
were O 
used O 
in O 
a O 
liquid O 
chromatograph O 
- O 
tandem O 
ion O 
- O 
trap O 
mass O 
spectrometer O 
. O 
The O 
activity O 
and O 
kinetic O 
parameters O 
were O 
evaluated O 
by O 
monitoring O 
the O 
choline B-FAMILY 
' O 
s O 
precursor O 
ion O 
( O 
M O 
+ O 
H B-FORMULA 
)(+)m O 
/ O 
z O 
104 O 
and O 
its O 
ion O 
fragment O 
( O 
C2H3OH B-FORMULA 
) O 
- O 
( O 
M O 
+ O 
H B-FORMULA 
)(+)m O 
/ O 
z O 
60 O 
. O 
The O 
assay O 
method O 
was O 
validated O 
using O 
the O 
reference O 
AChE O 
inhibitors O 
tacrine B-TRIVIAL 
and O 
galanthamine B-TRIVIAL 
. O 
Two O 
new O 
ligands O 
, O 
out O 
of O 
a O 
library O 
of O 
17 O 
coumarin B-TRIVIAL 
derivatives O 
, O 
were O 
identified O 
, O 
and O 
the O 
half O 
- O 
maximal O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
, O 
inhibition O 
constant O 
(K(i)) O 
, O 
and O 
the O 
inhibition O 
mechanism O 
were O 
determined O 
. O 
A O 
coumarin B-TRIVIAL 
derivative O 
with O 
IC50 O 
similar O 
to O 
tacrine B-TRIVIAL 
was O 
highlighted O 
. O 

- O 
based O 
design O 
and O 
synthesis O 
of O 
C B-FORMULA 
-1- O 
and O 
C B-FORMULA 
-4 O 
- O 
modified O 
analogs O 
of O 
zanamivir B-TRIVIAL 
as O 
neuraminidase O 
inhibitors O 
. O 

order O 
to O 
exploit O 
the O 
430-cavity O 
in O 
the O 
active O 
sites O 
of O 
neuraminidases O 
, O 
22 O 
zanamivir B-TRIVIAL 
analogs O 
with O 
C B-FORMULA 
-1 O 
and O 
C B-FORMULA 
-4 O 
modification O 
were O 
synthesized O 
, O 
and O 
their O 
inhibitory O 
activities O 
against O 
both O 
group-1 O 
( O 
H5N1 O 
, O 
H1N1 O 
) O 
and O 
group-2 O 
neuraminidases O 
( O 
H3N2 O 
) O 
were O 
determined O 
. O 
Compound O 
9f O 
exerts O 
the O 
most O 
potency O 
, O 
with O 
IC(50) O 
value O 
of O 
0.013 O 
, O 
0.001 O 
, O 
and O 
0.09 O 
μM O 
against O 
H3N2 O 
, O 
H5N1 O 
, O 
and O 
H1N1 O 
, O 
which O 
is O 
similar O 
to O 
that O 
of O 
zanamivir B-TRIVIAL 
( O 
H3N2 O 
IC(50) O 
= O 
0.0014 O 
μM O 
, O 
H5N1 O 
IC(50) O 
= O 
0.012 O 
μM O 
, O 
H1N1 O 
IC(50) O 
= O 
0.001 O 
μM O 
) O 
. O 
Pharmacokinetic O 
studies O 
of O 
compound O 
9f O 
in O 
rats O 
showed O 
a O 
much O 
longer O 
plasma O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
than O 
that O 
of O 
zanamivir B-TRIVIAL 
following O 
administration O 
( O 
po O 
dose O 
) O 
. O 
Molecular O 
modeling O 
provided O 
information O 
about O 
the O 
binding O 
model O 
between O 
the O 
new O 
inhibitors O 
and O 
neuraminidase O 
, O 
with O 
the O 
elongated O 
groups O 
at O 
the O 
C-1- O 
position O 
being O 
projected O 
toward O 
the O 
430-loop O 
region O 
. O 
This O 
study O 
may O 
represent O 
a O 
novel O 
starting O 
point O 
for O 
the O 
future O 
development O 
of O 
improved O 
antiflu O 
agents O 
. O 

transparent O 
low O 
resistance O 
ZnO B-FORMULA 
/ O 
Ag B-FORMULA 
nanowire/ O 
ZnO B-FORMULA 
composite O 
electrode O 
for O 
thin O 
film O 
solar O 
cells O 
. O 

present O 
an O 
indium B-SYSTEMATIC 
-free O 
transparent O 
conducting O 
composite O 
electrode O 
composed O 
of O 
silver B-SYSTEMATIC 
nanowires O 
( O 
AgNWs O 
) O 
and O 
ZnO B-FORMULA 
bilayers O 
. O 
The O 
AgNWs O 
form O 
a O 
random O 
percolating O 
network O 
embedded O 
between O 
the O 
ZnO B-FORMULA 
layers O 
. O 
The O 
unique O 
structural O 
features O 
of O 
our O 
ZnO B-FORMULA 
/ O 
AgNW/ O 
ZnO B-FORMULA 
multilayered O 
composite O 
allow O 
for O 
a O 
novel O 
transparent O 
conducting O 
electrode O 
with O 
unprecedented O 
excellent O 
thermal O 
stability O 
( O 
∼375 O 
°C O 
) O 
, O 
adhesiveness O 
, O 
and O 
flexibility O 
as O 
well O 
as O 
high O 
electrical O 
conductivity O 
( O 
∼8.0 O 
Ω O 
/ O 
sq O 
) O 
and O 
good O 
optical O 
transparency O 
( O 
> O 
91% O 
at O 
550 O 
nm O 
) O 
. O 
Cu(In,Ga)(S,Se)₂ B-FORMULA 
( O 
CIGSSe B-ABBREVIATION 
) O 
thin O 
film O 
solar O 
cells O 
incorporating O 
this O 
composite O 
electrode O 
exhibited O 
a O 
20% O 
increase O 
of O 
the O 
power O 
conversion O 
efficiency O 
compared O 
to O 
a O 
conventional O 
sputtered O 
indium O 
tin O 
oxide B-SYSTEMATIC 
-based O 
CIGSSe B-ABBREVIATION 
solar O 
cell O 
. O 
The O 
ZnO B-FORMULA 
/ O 
AgNW/ O 
ZnO B-FORMULA 
composite O 
structure O 
enables O 
effective O 
light O 
transmission O 
and O 
current O 
collection O 
as O 
well O 
as O 
a O 
reduced O 
leakage O 
current O 
, O 
all O 
of O 
which O 
lead O 
to O 
better O 
cell O 
performance O 
. O 

effect O 
of O 
molecular O 
structure O 
on O 
ensemble O 
structure O 
of O 
phospholipid O 
films O 
has O 
been O 
investigated O 
. O 
Bilayers O 
of O 
dimyristoyl B-SYSTEMATIC 
phosphatidylethanolamine I-SYSTEMATIC 
( O 
DMPE B-ABBREVIATION 
) O 
were O 
prepared O 
on O 
Au(111) B-FORMULA 
electrodes O 
using O 
Langmuir-Blodgett O 
and O 
Langmuir-Schaeffer O 
deposition O 
. O 
Capacitance O 
and O 
charge O 
density O 
measurements O 
were O 
used O 
to O 
investigate O 
the O 
adsorption O 
behavior O 
and O 
barrier O 
properties O 
of O 
the O 
lipid O 
bilayers O 
. O 
In O 
situ O 
polarization O 
modulation O 
infrared O 
reflection O 
absorption O 
spectroscopy O 
( O 
PM-IRRAS O 
) O 
was O 
employed O 
to O 
investigate O 
the O 
organization O 
of O 
the O 
molecules O 
within O 
the O 
bilayer O 
. O 
DMPE B-ABBREVIATION 
bilayers O 
exhibit O 
lower O 
capacitance O 
than O 
bilayers O 
formed O 
from O 
the O 
related O 
lipid O 
, O 
dimyristoyl B-SYSTEMATIC 
phosphatidylcholine I-SYSTEMATIC 
( O 
DMPC B-ABBREVIATION 
) O 
. O 
The O 
infrared O 
data O 
show O 
that O 
these O 
results O 
can O 
be O 
explained O 
by O 
structural O 
differences O 
between O 
the O 
bilayers O 
formed O 
from O 
each O 
molecule O 
. O 
DMPE B-ABBREVIATION 
organizes O 
into O 
bilayers O 
with O 
hydrocarbon B-FAMILY 
chains O 
tilted O 
at O 
a O 
smaller O 
angle O 
to O 
the O 
surface O 
normal O 
, O 
which O 
results O 
in O 
a O 
thicker O 
film O 
. O 
The O 
hydrocarbon B-FAMILY 
chains O 
contain O 
few O 
conformational O 
defects O 
. O 
Spectra O 
in O 
the O 
carbonyl B-FAMILY 
and O 
phosphate B-SYSTEMATIC 
stretching O 
mode O 
regions O 
indicate O 
low O 
solvent O 
content O 
of O 
DMPE B-ABBREVIATION 
films O 
. O 
Both O 
of O 
these O 
effects O 
combine O 
to O 
produce O 
films O 
with O 
lower O 
capacitance O 
and O 
enhanced O 
barrier O 
properties O 
. O 
The O 
results O 
are O 
explained O 
in O 
terms O 
of O 
the O 
differences O 
in O 
structure O 
between O 
the O 
constituent O 
molecules O 
. O 

- O 
based O 
design O 
of O 
novel O 
quinazolinon B-FAMILY 
derivatives O 
as O 
human O 
acrosin O 
inhibitors O 
. O 

acrosin O 
is O 
a O 
promising O 
target O 
for O 
the O 
male O 
contraceptives O 
. O 
On O 
the O 
basis O 
of O 
the O 
active O 
site O 
of O 
human O 
acrosin O 
, O 
a O 
series O 
of O 
novel O 
quinazolinon B-FAMILY 
compounds O 
were O 
designed O 
by O 
a O 
fragment O 
docking O 
and O 
growing O 
strategy O 
. O 
In O 
vitro O 
anti-acrosin O 
assay O 
revealed O 
that O 
all O 
the O 
compounds O 
showed O 
potent O 
human O 
acrosin O 
inhibitory O 
activities O 
. O 
In O 
particular O 
, O 
compounds O 
5c O 
and O 
5g O 
are O 
more O 
active O 
than O 
the O 
known O 
inhibitors O 
. O 
Molecular O 
docking O 
studies O 
revealed O 
that O 
the O 
quinazolinon B-FAMILY 
inhibitors O 
interacted O 
with O 
human O 
acrosin O 
mainly O 
through O 
hydrogen B-SYSTEMATIC 
bonding O 
and O 
hydrophobic O 
interactions O 
. O 
The O 
binding O 
mode O 
was O 
also O 
consistent O 
with O 
the O 
structure O 
- O 
activity O 
relationships O 
. O 
The O 
quinazolinon B-FAMILY 
derivatives O 
in O 
this O 
study O 
can O 
serve O 
as O 
new O 
lead O 
structure O 
for O 
the O 
development O 
of O 
novel O 
male O 
contraceptives O 
. O 

-Based O 
Hybrids O 
with O 
Improved O 
In O 
Vitro O 
Antimalarial O 
Activity O 
Against O 
CQ-Sensitive O 
and O 
CQ-Resistant O 
Strains O 
of O 
Plasmodium O 
falciparum O 
. O 

systematic O 
chemical O 
modification O 
in O 
the O 
triazine B-FAMILY 
moiety O 
covalently O 
attached O 
via O 
suitable O 
linkers O 
to O 
4-amino-7-chloroquinolines B-FAMILY 
yielded O 
a O 
series O 
of O 
new O 
7-chloro-4-aminoquinoline- B-FAMILY 
triazine I-FAMILY 
hybrids O 
exhibiting O 
high O 
in O 
vitro O 
activity O 
against O 
W2 O 
( O 
chloroquine B-TRIVIAL 
-resistant O 
) O 
and O 
D6 O 
( O 
chloroquine B-TRIVIAL 
-sensitive O 
) O 
strains O 
of O 
Plasmodium O 
falciparum O 
without O 
any O 
toxicity O 
against O 
mammalian O 
cell O 
lines O 
( O 
Vero O 
, O 
LLC-PK11 O 
, O 
HepG2 O 
) O 
. O 
Many O 
of O 
the O 
compounds O 
( O 
6 O 
, O 
8 O 
, O 
10 O 
, O 
11 O 
, O 
13 O 
, O 
14 O 
, O 
16 O 
, O 
27 O 
, O 
29 O 
and O 
33 O 
) O 
showed O 
excellent O 
potency O 
against O 
chloroquine B-TRIVIAL 
sensitive O 
and O 
resistant O 
strains O 
. O 
In O 
particular O 
, O 
compounds O 
6 O 
, O 
8 O 
, O 
14 O 
, O 
16 O 
and O 
29 O 
were O 
found O 
to O 
be O 
significantly O 
more O 
active O 
than O 
chloroquine B-TRIVIAL 
against O 
the O 
chloroquine B-TRIVIAL 
-resistant O 
strains O 
( O 
W2 O 
clone O 
) O 
of O 
P. O 
falciparum O 
. O 

has O 
reached O 
epidemic O 
proportions O 
and O 
is O 
a O 
significant O 
public O 
health O 
concern O 
. O 
Obesity O 
is O 
associated O 
with O 
increased O 
diabetes O 
, O 
cardiovascular O 
and O 
kidney O 
disease O 
, O 
and O 
associated O 
morbidity O 
and O 
mortality O 
. O 
Despite O 
the O 
increasing O 
public O 
health O 
problem O 
of O 
obesity O 
, O 
there O 
is O 
a O 
dearth O 
of O 
effective O 
treatment O 
options O 
. O 
Following O 
the O 
FDA O 
mandated O 
withdrawal O 
of O 
sibutramine B-TRIVIAL 
, O 
the O 
treatment O 
options O 
for O 
obesity O 
were O 
limited O 
to O 
orlistat B-TRIVIAL 
as O 
the O 
only O 
pharmacological O 
treatment O 
option O 
for O 
long O 
- O 
term O 
management O 
of O 
obesity O 
. O 
Recently O 
two O 
new O 
medications O 
( O 
Belviq B-TRIVIAL 
and O 
Qsymia B-TRIVIAL 
) O 
were O 
approved O 
by O 
FDA O 
for O 
long O 
- O 
term O 
management O 
of O 
obesity O 
. O 
Many O 
other O 
antiobesity O 
drugs O 
are O 
under O 
development O 
. O 
Bariatric O 
surgery O 
has O 
been O 
shown O 
to O 
be O 
effective O 
in O 
the O 
treatment O 
of O 
obesity O 
and O 
its O 
comorbidities O 
. O 
The O 
available O 
data O 
suggest O 
that O 
even O 
modest O 
weight O 
loss O 
improves O 
diabetes O 
and O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
risk O 
factors O 
. O 
We O 
summarize O 
the O 
treatment O 
options O 
for O 
obesity O 
and O 
the O 
efficacy O 
of O 
these O 
options O 
in O 
ameliorating O 
cardiovascular O 
risk O 
factors O 
. O 
We O 
also O 
focus O 
on O 
the O 
recently O 
approved O 
antiobesity O 
drugs O 
. O 

IκB O 
kinase O 
complex O 
( O 
IKK O 
) O 
is O 
a O 
key O 
regulator O 
of O 
immune O 
responses O 
, O 
inflammation O 
, O 
cell O 
survival O 
, O 
and O 
tumorigenesis O 
. O 
The O 
prosurvival O 
function O 
of O 
IKK O 
centers O 
on O 
activation O 
of O 
the O 
transcription O 
factor O 
NF-κB O 
, O 
whose O 
target O 
gene O 
products O 
inhibit O 
caspases O 
and O 
prevent O 
prolonged O 
JNK O 
activation O 
. O 
Here O 
, O 
we O 
report O 
that O 
inactivation O 
of O 
the O 
BH3 O 
- O 
only O 
protein O 
BAD O 
by O 
IKK O 
independently O 
of O 
NF-κB O 
activation O 
suppresses O 
TNFα-induced O 
apoptosis O 
. O 
TNFα O 
- O 
treated O 
Ikkβ(- O 
/ O 
- O 
) O 
mouse O 
embryonic O 
fibroblasts O 
( O 
MEFs O 
) O 
undergo O 
apoptosis O 
significantly O 
faster O 
than O 
MEFs O 
deficient O 
in O 
both O 
RelA O 
and O 
cRel O 
due O 
to O 
lack O 
of O 
inhibition O 
of O 
BAD O 
by O 
IKK O 
. O 
IKK O 
phosphorylates O 
BAD O 
at O 
serine B-TRIVIAL 
-26 O 
( O 
Ser B-FORMULA 
26 O 
) O 
and O 
primes O 
it O 
for O 
inactivation O 
. O 
Elimination O 
of O 
Ser B-FORMULA 
26 O 
phosphorylation O 
promotes O 
BAD O 
proapoptotic O 
activity O 
, O 
thereby O 
accelerating O 
TNFα-induced O 
apoptosis O 
in O 
cultured O 
cells O 
and O 
increasing O 
mortality O 
in O 
animals O 
. O 
Our O 
results O 
reveal O 
that O 
IKK O 
inhibits O 
TNFα-induced O 
apoptosis O 
through O 
two O 
distinct O 
but O 
cooperative O 
mechanisms O 
: O 
activation O 
of O 
the O 
survival O 
factor O 
NF-κB O 
and O 
inactivation O 
of O 
the O 
proapoptotic O 
BH3 O 
- O 
only O 
BAD O 
protein O 
. O 

tea O 
catechin B-TRIVIAL 
leads O 
to O 
global O 
improvement O 
among O 
Alzheimer's O 
disease O 
- O 
related O 
phenotypes O 
in O 
NSE O 
/ O 
hAPP-C105 O 
Tg O 
mice O 
. O 

β O 
( O 
Αβ O 
) O 
has O 
been O 
reported O 
to O 
be O 
responsible O 
for O 
the O 
functional O 
and O 
structural O 
abnormalities O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
through O 
the O 
induction O 
of O 
oxidative O 
stress O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
whether O 
or O 
not O 
treatment O 
of O 
transgenic O 
( O 
Tg O 
) O 
mice O 
with O 
green O 
tea O 
catechin B-TRIVIAL 
( O 
GTC O 
) O 
, O 
a O 
radical O 
scavenger O 
, O 
improves O 
AD O 
phenotypes O 
. O 
To O 
test O 
this O 
, O 
7-month- O 
old O 
Tg O 
mice O 
were O 
treated O 
with O 
a O 
low O 
( O 
1 O 
mg O 
) O 
or O 
high O 
( O 
10 O 
mg O 
) O 
dose O 
of O 
GTC O 
for O 
6 O 
months O 
. O 
Surprisingly O 
, O 
GTC O 
- O 
treated O 
Tg O 
mice O 
exhibited O 
significant O 
decreases O 
in O 
behavioral O 
impairment O 
, O 
Aβ-42 O 
production O 
, O 
APP-C99 O 
/ O 
89 O 
expression O 
, O 
γ-secretase O 
component O 
and O 
Wnt O 
protein O 
levels O 
, O 
γ-secretase O 
activity O 
and O 
MAPK O 
activation O 
. O 
In O 
contrast O 
, O 
the O 
levels O 
of O 
APP-C83 O 
protein O 
and O 
enzyme O 
activities O 
( O 
α-secretase O 
, O 
neprilysin O 
and O 
Pin1 O 
) O 
were O 
elevated O 
in O 
the O 
GTC O 
- O 
treated O 
groups O 
. O 
Moreover O 
, O 
GTC O 
- O 
treated O 
groups O 
showed O 
lower O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
and O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
whereas O 
the O 
level O 
of O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
increased O 
. O 
These O 
results O 
provide O 
the O 
first O 
experimental O 
evidence O 
that O 
GTC O 
improves O 
AD O 
phenotypes O 
, O 
thereby O 
suggesting O 
that O 
GTC O 
can O 
be O 
used O 
in O 
the O 
prevention O 
of O 
AD O 
or O 
treatment O 
of O 
AD O 
patients O 
. O 

mellitus O 
is O 
associated O 
to O 
central O 
nervous O 
system O 
damage O 
, O 
which O 
results O 
in O 
impairment O 
of O 
brain O 
functions O 
and O 
cognitive O 
deficits O 
and O 
decline O 
in O 
memory O 
. O 
However O 
, O 
the O 
mechanisms O 
mediating O 
the O 
actions O 
of O 
glucose B-TRIVIAL 
on O 
the O 
neurons O 
remained O 
elusive O 
. O 
Single O 
- O 
minded O 
2 O 
( O 
Sim2 O 
) O 
, O 
a O 
basic O 
helix O 
- O 
loop O 
- O 
helix O 
(bHLH)-PAS O 
transcriptional O 
repressor O 
, O 
is O 
thought O 
to O 
be O 
involved O 
in O 
some O 
symptoms O 
of O 
Down O 
syndrome O 
. O 
We O 
hypothesized O 
that O 
Sim2 O 
mediated O 
hyperglycaemia O 
- O 
induced O 
neuronal O 
injury O 
and O 
impairment O 
of O 
learning O 
and O 
memory O 
. O 
It O 
was O 
found O 
that O 
expression O 
of O 
Sim2 O 
protein O 
in O 
cortical O 
neurons O 
was O 
increased O 
in O 
streptozotocin B-TRIVIAL 
-induced O 
diabetes O 
mellitus O 
rat O 
model O 
. O 
Drebrin O 
, O 
down O 
- O 
regulated O 
by O 
Sim2 O 
, O 
was O 
subsequently O 
decreased O 
as O 
detected O 
by O 
confocal O 
laser O 
scanning O 
microscopy O 
and O 
Western O 
blot O 
analysis O 
. O 
The O 
expression O 
pattern O 
of O 
Sim2 O 
and O 
Drebrin O 
correspond O 
to O 
50mmol O 
/ O 
L O 
glucose B-TRIVIAL 
( O 
hyperglycaemia O 
) O 
was O 
also O 
found O 
in O 
primary O 
cultured O 
neurons O 
. O 
Curcumin B-TRIVIAL 
, O 
one O 
neuroprotective O 
agent O 
, O 
inhibited O 
hyperglycaemia O 
- O 
induced O 
neurotoxicity O 
. O 
Moreover O 
, O 
curcumin B-TRIVIAL 
alleviated O 
Sim2 O 
expression O 
, O 
and O 
reversely O 
raised O 
Drebrin O 
expression O 
in O 
neurons O 
treated O 
with O 
hyperglycaemia O 
. O 
Finally O 
, O 
we O 
found O 
that O 
silencing O 
Sim2 O 
expression O 
decreased O 
hyperglycaemia O 
- O 
induced O 
neuronal O 
injury O 
. O 
In O 
conclusion O 
, O 
Sim2 O 
may O 
mediate O 
neurotoxicity O 
during O 
hyperglycaemia O 
and O 
thereby O 
play O 
a O 
critical O 
role O 
in O 
the O 
development O 
of O 
hyperglycaemia O 
- O 
induced O 
cognitive O 
deficits O 
. O 

protection O 
against O 
acetaminophen B-TRIVIAL 
-induced O 
liver O 
injury O 
via O 
its O 
potential O 
impact O 
on O 
the O 
activation O 
of O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
and O 
antioxidant O 
enzymes O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
genistein B-TRIVIAL 
' O 
s O 
influence O 
on O 
the O 
relationship O 
between O 
the O 
activation O 
of O 
uridine B-SYSTEMATIC 
diphosphate I-SYSTEMATIC 
glucuronosyltransferase O 
( O 
UGTs O 
) O 
and O 
the O 
protection O 
against O 
acetaminophen B-TRIVIAL 
-induced O 
liver O 
toxicity O 
. O 
Animal O 
experimental O 
results O 
revealed O 
that O 
genistein B-TRIVIAL 
( O 
50 O 
, O 
100 O 
or O 
200mg O 
/ O 
BWkg O 
) O 
significantly O 
ameliorated O 
the O 
biomarkers O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
lactate B-FAMILY 
dehydrogenase O 
and O 
malondialdehyde B-TRIVIAL 
, O 
as O 
indicators O 
of O 
acute O 
liver O 
damage O 
caused O 
by O 
APAP B-ABBREVIATION 
( O 
200mg O 
/ O 
BWkg O 
) O 
. O 
The O 
level O 
of O 
GSH B-ABBREVIATION 
declined O 
sharply O 
after O 
treatment O 
with O 
APAP B-ABBREVIATION 
within O 
1h O 
in O 
both O 
the O 
liver O 
and O 
blood O 
with O 
and O 
without O 
genistein B-TRIVIAL 
. O 
However O 
, O 
after O 
16h O 
, O 
the O 
levels O 
approached O 
or O 
returned O 
to O 
the O 
original O 
level O 
. O 
Genistein B-TRIVIAL 
may O 
accelerate O 
and O 
promote O 
APAP B-ABBREVIATION 
glucuronidation O 
as O 
the O 
results O 
showed O 
that O 
APAP B-ABBREVIATION 
- O 
glucuronide B-TRIVIAL 
increased O 
by O 
18.44% O 
, O 
46.79% O 
, O 
and O 
66.49% O 
for O 
4h O 
of O 
treatment O 
with O 
genistein B-TRIVIAL 
dosages O 
of O 
50 O 
, O 
100 O 
or O 
200mg O 
/ O 
BWkg O 
, O 
respectively O 
, O 
compared O 
with O 
the O 
APAP B-ABBREVIATION 
-only O 
treatment O 
. O 
The O 
activation O 
of O 
UGTs O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
the O 
inhibition O 
of O 
CYP2E1 O 
by O 
genistein B-TRIVIAL 
were O 
observed O 
, O 
and O 
UGTs O 
mRNA O 
expression O 
level O 
with O 
genistein B-TRIVIAL 
was O 
measured O 
. O 
These O 
findings O 
suggest O 
that O 
genistein B-TRIVIAL 
can O 
prevent O 
and O 
protect O 
against O 
APAP B-ABBREVIATION 
-induced O 
liver O 
toxicity O 
due O 
to O 
the O 
inhibition O 
of O 
APAP B-ABBREVIATION 
biotransformation O 
and O 
the O 
resistance O 
to O 
oxidative O 
stress O 
via O 
the O 
modulation O 
of O 
the O 
activities O 
of O 
metabolism O 
and O 
the O 
antioxidant O 
enzyme O 
. O 

exposure O 
to O 
radiofrequency O 
electromagnetic O 
radiation O 
( O 
RF-EMR O 
) O 
emitted O 
from O 
mobile O 
phones O 
can O 
induce O 
DNA O 
damage O 
in O 
male O 
germ O 
cells O 
remains O 
unclear O 
. O 
In O 
this O 
study O 
, O 
we O 
conducted O 
a O 
24h O 
intermittent O 
exposure O 
( O 
5 O 
min O 
on O 
and O 
10 O 
min O 
off O 
) O 
of O 
a O 
mouse O 
spermatocyte O 
- O 
derived O 
GC-2 O 
cell O 
line O 
to O 
1800 O 
MHz O 
Global O 
System O 
for O 
Mobile O 
Communication O 
( O 
GSM O 
) O 
signals O 
in O 
GSM-Talk O 
mode O 
at O 
specific O 
absorption O 
rates O 
( O 
SAR O 
) O 
of O 
1 O 
W O 
/ O 
kg O 
, O 
2 O 
W O 
/ O 
kg O 
or O 
4 O 
W O 
/ O 
kg O 
. O 
Subsequently O 
, O 
through O 
the O 
use O 
of O 
formamidopyrimidine B-SYSTEMATIC 
DNA O 
glycosylase O 
( O 
FPG O 
) O 
in O 
a O 
modified O 
comet O 
assay O 
, O 
we O 
determined O 
that O 
the O 
extent O 
of O 
DNA O 
migration O 
was O 
significantly O 
increased O 
at O 
a O 
SAR O 
of O 
4 O 
W O 
/ O 
kg O 
. O 
Flow O 
cytometry O 
analysis O 
demonstrated O 
that O 
levels O 
of O 
the O 
DNA O 
adduct O 
8-oxoguanine B-SYSTEMATIC 
( O 
8-oxoG B-SYSTEMATIC 
) O 
were O 
also O 
increased O 
at O 
a O 
SAR O 
of O 
4 O 
W O 
/ O 
kg O 
. O 
These O 
increases O 
were O 
concomitant O 
with O 
similar O 
increases O 
in O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
; O 
these O 
phenomena O 
were O 
mitigated O 
by O 
co O 
- O 
treatment O 
with O 
the O 
antioxidant O 
α-tocopherol B-TRIVIAL 
. O 
However O 
, O 
no O 
detectable O 
DNA O 
strand O 
breakage O 
was O 
observed O 
by O 
the O 
alkaline O 
comet O 
assay O 
. O 
Taking O 
together O 
, O 
these O 
findings O 
may O 
imply O 
the O 
novel O 
possibility O 
that O 
RF-EMR O 
with O 
insufficient O 
energy O 
for O 
the O 
direct O 
induction O 
of O 
DNA O 
strand O 
breaks O 
may O 
produce O 
genotoxicity O 
through O 
oxidative O 
DNA O 
base O 
damage O 
in O 
male O 
germ O 
cells O 
. O 

of O 
methoxychlor B-TRIVIAL 
and O 
its O 
metabolite O 
2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane B-SYSTEMATIC 
on O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
activities O 
in O 
vitro O 
. O 

( O 
MXC B-ABBREVIATION 
) O 
is O 
primarily O 
used O 
as O 
a O 
pesticide O 
and O 
widely O 
present O 
in O 
the O 
environment O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
is O 
to O 
investigate O 
the O 
direct O 
effects O 
of O 
MXC B-ABBREVIATION 
and O 
its O 
metabolite O 
2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane B-SYSTEMATIC 
( O 
HPTE B-ABBREVIATION 
) O 
on O 
two O 
isoforms O 
of O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
( O 
11β-HSD1 O 
and O 
11β-HSD2 O 
) O 
in O 
vitro O 
. O 
Human O 
liver O 
microsome O 
, O 
rat O 
testis O 
microsome O 
and O 
adult O 
Leydig O 
cells O 
were O 
used O 
for O 
the O 
measurement O 
of O 
11β-HSD1 O 
activity O 
. O 
Human O 
placental O 
and O 
rat O 
kidney O 
microsomes O 
were O 
used O 
for O 
11β-HSD2 O 
activity O 
. O 
The O 
IC(50) O 
values O 
on O 
human O 
11β-HSD1 O 
by O 
MXC B-ABBREVIATION 
and O 
HPTE B-ABBREVIATION 
were O 
1.91±0.07 O 
and O 
8.88 O 
± O 
0.08 O 
μM O 
, O 
respectively O 
. O 
HPTE B-ABBREVIATION 
inhibited O 
rat O 
11β-HSD1 O 
with O 
IC(50) O 
of O 
9.15±0.05μM O 
, O 
while O 
MXC B-ABBREVIATION 
did O 
not O 
inhibit O 
the O 
enzyme O 
. O 
MXC B-ABBREVIATION 
and O 
HPTE B-ABBREVIATION 
were O 
competitive O 
inhibitors O 
of O 
11β-HSD1 O 
. O 
HPTE B-ABBREVIATION 
also O 
inhibited O 
human O 
and O 
rat O 
11β-HSD2 O 
with O 
IC(50) O 
values O 
of O 
55.57 O 
± O 
0.08 O 
and O 
12.96 O 
± O 
0.11 O 
μM O 
, O 
respectively O 
, O 
while O 
MXC B-ABBREVIATION 
did O 
not O 
inhibit O 
11β-HSD2 O 
. O 
In O 
summary O 
, O 
our O 
results O 
showed O 
that O 
MXC B-ABBREVIATION 
and O 
its O 
metabolite O 
HPTE B-ABBREVIATION 
inhibited O 
both O 
isoforms O 
of O 
11β-HSD O 
in O 
a O 
species- O 
and O 
chemical O 
structure O 
- O 
dependent O 
manner O 
. O 

activity O 
of O 
Veronica O 
montana O 
L O 
. O 
extract O 
and O 
of O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
incorporated O 
in O 
a O 
food O 
system O 
. O 

study O 
was O 
designed O 
to O 
evaluate O 
the O 
antibacterial O 
activity O 
of O 
the O 
Veronica O 
montana O 
L O 
. O 
water O 
extract O 
and O 
its O 
main O 
phenolic B-FAMILY 
compound O 
, O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
antibacterial O 
activity O 
was O 
determined O 
by O 
microdilution O 
assay O 
against O 
six O 
strains O 
of O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
Listeria O 
monocytogenes O 
was O 
the O 
most O 
sensitive O 
of O 
the O 
tested O 
bacterial O 
species O 
. O 
Antibacterial O 
preserving O 
properties O 
of O 
protocatechuic B-TRIVIAL 
acid I-TRIVIAL 
were O 
also O 
evaluated O 
after O 
its O 
incorporation O 
in O 
cream O 
cheese O 
, O 
using O 
L O 
. O 
monocytogenes O 
as O 
commonly O 
cheese O 
contaminant O 
. O 
The O 
compound O 
successfully O 
inhibited O 
L O 
. O 
monocytogenes O 
development O 
in O 
cream O 
cheese O 
, O 
at O 
room O 
temperature O 
and O 
in O 
refrigerator O 
( O 
25°C O 
and O 
4°C O 
, O 
respectively O 
) O 
, O 
after O 
3days O 
of O 
inoculation O 
. O 
Sensory O 
evaluation O 
was O 
carried O 
out O 
in O 
order O 
to O 
validate O 
the O 
mentioned O 
food O 
system O 
. O 
A O 
possible O 
mode O 
of O 
action O 
of O 
the O 
tested O 
compound O 
towards O 
bacterial O 
cells O 
was O 
assessed O 
and O 
appears O 
to O 
be O 
direct O 
lysis O 
of O 
pathogenic O 
cytoplasmic O 
membrane O 
. O 
Prediction O 
of O 
pharmacokinetic O 
properties O 
was O 
also O 
performed O 
using O 
computational O 
analyzes O 
. O 
The O 
obtained O 
results O 
can O 
serve O 
as O 
an O 
important O 
platform O 
for O 
the O 
development O 
of O 
effective O 
natural O 
preservatives O 
. O 

designed O 
from O 
osteoprotegerin O 
( O 
OPG O 
) O 
have O 
previously O 
been O 
shown O 
to O 
inhibit O 
receptor O 
activator O 
of O 
NF-κB O 
ligand O 
( O 
RANKL O 
) O 
and O 
prevent O 
bone O 
loss O 
without O 
significantly O 
inhibiting O 
inflammation O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
develop O 
a O 
novel O 
peptide O 
with O 
dual O 
inhibitory O 
activity O 
against O 
bone O 
loss O 
and O 
inflammation O 
using O 
site O 
- O 
directed O 
mutagenesis O 
. O 
Out O 
of O 
the O 
three O 
putative O 
sites O 
( O 
i.e O 
. O 
, O 
Tyr B-FORMULA 
70- O 
Asp B-FORMULA 
78 O 
, O 
Tyr B-FORMULA 
82- O 
Glu B-FORMULA 
96 O 
, O 
and O 
Leu B-FORMULA 
113- O 
Arg B-FORMULA 
122 O 
) O 
available O 
on O 
OPG O 
for O 
RANKL O 
binding O 
, O 
Leu B-FORMULA 
113- O 
Arg B-FORMULA 
122 O 
was O 
used O 
as O 
a O 
template O 
for O 
peptide O 
synthesis O 
. O 
Peptide O 
mutants O 
of O 
the O 
template O 
sequence O 
( O 
112YLEIEFCLKHR122 O 
) O 
were O 
synthesized O 
and O 
initially O 
screened O 
for O 
their O 
inhibitory O 
effect O 
on O 
RANK-RANKL O 
binding O 
by O 
competitive O 
ELISA O 
. O 
The O 
most O 
active O 
peptide O 
was O 
further O 
evaluated O 
in O 
vitro O 
for O 
RANKL O 
induced O 
osteoclastogenesis O 
in O 
mouse O 
macrophage O 
cells O 
, O 
and O 
in O 
vivo O 
for O 
Freund's O 
complete O 
adjuvant O 
induced O 
arthritis O 
( O 
AIA O 
) O 
in O 
Lewis O 
rats O 
. O 
The O 
efficacy O 
of O 
the O 
candidate O 
peptide O 
was O 
compared O 
with O 
that O 
of O 
the O 
standard O 
drug O 
celecoxib B-TRIVIAL 
. O 
The O 
peptide O 
YR-11 B-IDENTIFIER 
( O 
YLEIEFSLKHR O 
) O 
, O 
obtained O 
by O 
direct O 
substitution O 
of O 
cysteine B-TRIVIAL 
with O 
a O 
serine B-TRIVIAL 
residue O 
in O 
the O 
template O 
sequence O 
, O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
inhibited O 
RANK-RANKL O 
binding O 
, O 
and O 
RANKL O 
induced O 
TRAP O 
activity O 
and O 
formation O 
of O 
multinucleated O 
osteoclasts O 
without O 
any O 
cytotoxicity O 
. O 
Administration O 
of O 
YR-11 B-IDENTIFIER 
peptide O 
at O 
the O 
dose O 
of O 
30mg O 
/ O 
kg O 
( O 
i.p O 
. O 
) O 
ameliorated O 
both O 
bone O 
loss O 
and O 
inflammation O 
in O 
AIA O 
rats O 
. O 
To O 
elucidate O 
the O 
mechanism O 
for O 
inhibition O 
of O 
inflammation O 
in O 
arthritic O 
rats O 
, O 
serum O 
and O 
tissue O 
cytokines O 
( O 
TNF-α O 
, O 
IL-1β O 
, O 
and O 
IL-6 O 
) O 
were O 
analyzed O 
by O 
ELISA O 
and O 
RT-PCR O 
methods O 
. O 
Results O 
confirmed O 
that O 
YR-11 B-IDENTIFIER 
peptide O 
inhibited O 
pro O 
- O 
inflammatory O 
cytokines O 
in O 
the O 
sera O 
and O 
hind O 
paw O 
tissues O 
of O 
AIA O 
rats O 
through O 
its O 
suppressive O 
effect O 
on O 
RANKL O 
induced O 
nuclear O 
translocation O 
of O 
NF-κB O 
. O 
The O 
results O 
obtained O 
in O 
this O 
study O 
substantiate O 
the O 
therapeutic O 
benefit O 
of O 
this O 
novel O 
peptide O 
in O 
the O 
prevention O 
of O 
bone O 
loss O 
and O 
inflammation O 
in O 
rheumatoid O 
arthritis O 
with O 
reduced O 
side O 
effects O 
. O 

functionalization O 
of O 
doxorubicin B-TRIVIAL 
-loaded O 
liposomes O 
with O 
octa B-TRIVIAL 
- I-TRIVIAL 
arginine I-TRIVIAL 
for O 
enhanced O 
anticancer O 
activity O 
. O 

-loaded O 
PEGylated O 
liposomes O 
( O 
commercially O 
available O 
as O 
DOXIL B-TRIVIAL 
® O 
or O 
Lipodox B-TRIVIAL 
® O 
) O 
were O 
surface O 
functionalized O 
with O 
a O 
cell O 
- O 
penetrating O 
peptide O 
, O 
octa B-TRIVIAL 
- I-TRIVIAL 
arginine I-TRIVIAL 
( O 
R8 O 
) O 
. O 
For O 
this O 
purpose O 
, O 
R8 O 
- O 
peptide O 
was O 
conjugated O 
to O 
the O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
- I-SYSTEMATIC 
dioleoyl I-SYSTEMATIC 
phosphatidylethanolamine I-SYSTEMATIC 
( O 
PEG-DOPE B-ABBREVIATION 
) O 
amphiphilic O 
co O 
- O 
polymer O 
. O 
The O 
resultant O 
R8-PEG-PE B-FORMULA 
conjugate O 
was O 
introduced O 
into O 
the O 
lipid O 
bilayer O 
of O 
liposomes O 
at O 
2mol% O 
of O 
total O 
lipid O 
amount O 
via O 
spontaneous O 
micelle O 
- O 
transfer O 
technique O 
. O 
The O 
liposomal O 
modification O 
did O 
not O 
alter O 
the O 
particle O 
size O 
distribution O 
, O 
as O 
measured O 
by O 
Particle O 
Size O 
Analyzer O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
. O 
However O 
, O 
surface O 
- O 
associated O 
cationic O 
peptide O 
increased O 
zeta O 
potential O 
of O 
the O 
modified O 
liposomes O 
. O 
R8-functionalized O 
liposomes O 
( O 
R8- O 
Dox B-ABBREVIATION 
-L O 
) O 
markedly O 
increased O 
the O 
intracellular O 
and O 
intratumoral O 
delivery O 
of O 
doxorubicin B-TRIVIAL 
as O 
measured O 
by O 
flow O 
cytometry O 
and O 
visualizing O 
by O 
confocal O 
laser O 
scanning O 
microscopy O 
( O 
CLSM O 
) O 
compared O 
to O 
unmodified O 
Doxorubicin B-TRIVIAL 
-loaded O 
PEGylated O 
liposomes O 
( O 
Dox B-ABBREVIATION 
-L O 
) O 
. O 
R8- O 
Dox B-ABBREVIATION 
-L O 
delivered O 
loaded O 
Doxorubicin B-TRIVIAL 
to O 
the O 
nucleus O 
, O 
being O 
released O 
from O 
the O 
endosomes O 
at O 
higher O 
efficiency O 
compared O 
to O 
unmodified O 
liposomes O 
, O 
which O 
had O 
marked O 
entrapment O 
in O 
the O 
endosomes O 
at O 
tested O 
time O 
point O 
of O 
1h O 
. O 
The O 
significantly O 
higher O 
accumulation O 
of O 
loaded O 
drug O 
to O 
its O 
site O 
of O 
action O 
for O 
R8- O 
Dox B-ABBREVIATION 
-L O 
resulted O 
in O 
improved O 
cytotoxic O 
activity O 
in O 
vitro O 
( O 
cell O 
viability O 
of O 
58.5±7% O 
for O 
R8- O 
Dox B-ABBREVIATION 
-L O 
compared O 
to O 
90.6±2% O 
for O 
Dox B-ABBREVIATION 
-L O 
at O 
Dox B-ABBREVIATION 
dose O 
of O 
50μg O 
/ O 
mL O 
for O 
4h O 
followed O 
by O 
24h O 
incubation O 
) O 
and O 
enhanced O 
suppression O 
of O 
tumor O 
growth O 
( O 
348±53mm(3) O 
for O 
R8- O 
Dox B-ABBREVIATION 
-L O 
, O 
compared O 
to O 
504±54mm(3) O 
for O 
Dox B-ABBREVIATION 
-L O 
treatment O 
) O 
in O 
vivo O 
compared O 
to O 
Dox B-ABBREVIATION 
-L O 
. O 
R8-modification O 
has O 
the O 
potential O 
for O 
broadening O 
the O 
therapeutic O 
window O 
of O 
pegylated O 
liposomal O 
doxorubicin B-TRIVIAL 
treatment O 
, O 
which O 
could O 
lead O 
to O 
lower O 
non-specific O 
toxicity O 
. O 

of O 
carbamazepine B-TRIVIAL 
- O 
Soluplus B-TRIVIAL 
® O 
solid O 
dispersions O 
by O 
hot O 
- O 
melt O 
extrusion O 
, O 
and O 
prediction O 
of O 
drug O 
- O 
polymer O 
miscibility O 
by O 
thermodynamic O 
model O 
fitting O 
. O 

- O 
melt O 
extrusion O 
( O 
HME O 
) O 
is O 
a O 
dust- O 
and O 
solvent-free O 
continuous O 
process O 
enabling O 
the O 
preparation O 
of O 
a O 
variety O 
of O 
solid O 
dosage O 
forms O 
containing O 
solid O 
dispersions O 
of O 
poorly O 
soluble O 
drugs O 
into O 
thermoplastic O 
polymers O 
. O 
Miscibility O 
of O 
drug O 
and O 
polymer O 
is O 
a O 
prerequisite O 
for O 
stable O 
solid O 
dispersion O 
formation O 
. O 
The O 
present O 
study O 
investigates O 
the O 
feasibility O 
of O 
forming O 
solid O 
dispersions O 
of O 
carbamazepine B-TRIVIAL 
( O 
CBZ B-ABBREVIATION 
) O 
into O 
polyethyleneglycol B-SYSTEMATIC 
- O 
polyvinyl B-SYSTEMATIC 
caprolactam I-SYSTEMATIC 
- O 
polyvinyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
grafted O 
copolymer O 
( O 
Soluplus B-TRIVIAL 
® O 
) O 
by O 
hot O 
- O 
melt O 
extrusion O 
. O 
Physicochemical O 
properties O 
of O 
the O 
raw O 
materials O 
, O 
extrudates O 
, O 
co O 
- O 
melted O 
products O 
, O 
and O 
corresponding O 
physical O 
mixtures O 
were O 
characterized O 
by O 
thermo O 
- O 
gravimetric O 
analysis O 
( O 
TGA O 
) O 
, O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
, O 
attenuated O 
total O 
reflectance O 
infrared O 
( O 
ATR-FTIR O 
) O 
spectroscopy O 
and O 
hot O 
stage O 
microscopy O 
( O 
HSM O 
) O 
, O 
while O 
miscibility O 
of O 
CBZ B-ABBREVIATION 
and O 
Soluplus B-TRIVIAL 
® O 
was O 
estimated O 
on O 
the O 
basis O 
of O 
the O 
Flory-Huggins O 
theory O 
, O 
Hansen O 
solubility O 
parameters O 
, O 
and O 
solid O 
- O 
liquid O 
equilibrium O 
equation O 
. O 
It O 
was O 
found O 
that O 
hot O 
- O 
melt O 
extrusion O 
of O 
carbamazepine B-TRIVIAL 
and O 
Soluplus B-TRIVIAL 
® O 
is O 
feasible O 
on O 
a O 
single O 
- O 
screw O 
hot O 
- O 
melt O 
extruder O 
without O 
the O 
addition O 
of O 
plasticizers O 
. O 
DSC O 
analysis O 
and O 
FTIR O 
spectroscopy O 
revealed O 
that O 
a O 
molecular O 
dispersion O 
is O 
formed O 
when O 
the O 
content O 
of O 
CBZ B-ABBREVIATION 
does O 
not O 
exceed O 
∼5% O 
w O 
/ O 
w O 
while O 
higher O 
CBZ B-ABBREVIATION 
content O 
results O 
in O 
a O 
microcrystalline O 
dispersion O 
of O 
CBZ B-ABBREVIATION 
form O 
III O 
crystals O 
, O 
with O 
the O 
molecularly O 
dispersed O 
percentage O 
increasing O 
with O 
extrusion O 
temperature O 
, O 
at O 
the O 
risk O 
of O 
inducing O 
transformation O 
to O 
the O 
undesirable O 
form O 
I O 
of O 
CBZ B-ABBREVIATION 
. O 
Thermodynamic O 
modeling O 
elucidated O 
potential O 
limitations O 
and O 
temperature O 
dependence O 
of O 
solubility O 
/ O 
dispersibility O 
of O 
carbamazepine B-TRIVIAL 
in O 
Soluplus B-TRIVIAL 
® O 
hot O 
- O 
melt O 
extrudates O 
. O 
The O 
results O 
obtained O 
by O 
thermodynamic O 
models O 
are O 
in O 
agreement O 
with O 
the O 
findings O 
of O 
the O 
HME O 
processing O 
, O 
encouraging O 
therefore O 
their O 
further O 
application O 
in O 
the O 
HME O 
process O 
development O 
. O 

effectiveness O 
of O 
Hibiscus O 
sabdariffa O 
L O 
. O 
( O 
HS O 
) O 
in O 
the O 
treatment O 
of O 
risk O 
factors O 
associated O 
with O 
cardiovascular O 
disease O 
is O 
assessed O 
in O 
this O 
review O 
by O 
taking O 
a O 
comprehensive O 
approach O 
to O 
interpreting O 
the O 
randomized O 
clinical O 
trial O 
( O 
RCT O 
) O 
results O 
in O 
the O 
context O 
of O 
the O 
available O 
ethnomedical O 
, O 
phytochemical O 
, O 
pharmacological O 
, O 
and O 
safety O 
and O 
toxicity O 
information O 
. O 
HS O 
decoctions O 
and O 
infusions O 
of O 
calyxes O 
, O 
and O 
on O 
occasion O 
leaves O 
, O 
are O 
used O 
in O 
at O 
least O 
10 O 
countries O 
worldwide O 
in O 
the O 
treatment O 
of O 
hypertension O 
and O 
hyperlipidemia O 
with O 
no O 
reported O 
adverse O 
events O 
or O 
side O 
effects O 
. O 
HS O 
extracts O 
have O 
a O 
low O 
degree O 
of O 
toxicity O 
with O 
a O 
LD50 O 
ranging O 
from O 
2000 O 
to O 
over O 
5,000mg O 
/ O 
kg O 
/ O 
day O 
. O 
There O 
is O 
no O 
evidence O 
of O 
hepatic O 
or O 
renal O 
toxicity O 
as O 
the O 
result O 
of O 
HS O 
extract O 
consumption O 
, O 
except O 
for O 
possible O 
adverse O 
hepatic O 
effects O 
at O 
high O 
doses O 
. O 
There O 
is O 
evidence O 
that O 
HS O 
acts O 
as O 
a O 
diuretic O 
, O 
however O 
in O 
most O 
cases O 
the O 
extract O 
did O 
not O 
significantly O 
influence O 
electrolyte O 
levels O 
. O 
Animal O 
studies O 
have O 
consistently O 
shown O 
that O 
consumption O 
of O 
HS O 
extract O 
reduces O 
blood O 
pressure O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
In O 
RCTs O 
, O 
the O 
daily O 
consumption O 
of O 
a O 
tea O 
or O 
extract O 
produced O 
from O 
HS O 
calyxes O 
significantly O 
lowered O 
systolic O 
blood O 
pressure O 
( O 
SBP O 
) O 
and O 
diastolic O 
blood O 
pressure O 
( O 
DBP O 
) O 
in O 
adults O 
with O 
pre O 
to O 
moderate O 
essential O 
hypertension O 
and O 
type O 
2 O 
diabetes O 
. O 
In O 
addition O 
, O 
HS O 
tea O 
was O 
as O 
effective O 
at O 
lowering O 
blood O 
pressure O 
as O 
the O 
commonly O 
used O 
blood O 
pressure O 
medication O 
Captropril B-TRIVIAL 
, O 
but O 
less O 
effective O 
than O 
Lisinopril B-TRIVIAL 
. O 
Total O 
cholesterol B-TRIVIAL 
, O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
LDL-C O 
) O 
, O 
and O 
triglycerides B-FAMILY 
were O 
lowered O 
in O 
the O 
majority O 
of O 
normolipidemic O 
, O 
hyperlipidemic O 
, O 
and O 
diabetic O 
animal O 
models O 
, O 
whereas O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
was O 
generally O 
not O 
affected O 
by O 
the O 
consumption O 
of O 
HS O 
extract O 
. O 
Over O 
half O 
of O 
the O 
RCTs O 
showed O 
that O 
daily O 
consumption O 
of O 
HS O 
tea O 
or O 
extracts O 
had O 
favorable O 
influence O 
on O 
lipid O 
profiles O 
including O 
reduced O 
total O 
cholesterol B-TRIVIAL 
, O 
LDL-C O 
, O 
triglycerides B-FAMILY 
, O 
as O 
well O 
as O 
increased O 
HDL-C O 
. O 
Anthocyanins B-FAMILY 
found O 
in O 
abundance O 
in O 
HS O 
calyxes O 
are O 
generally O 
considered O 
the O 
phytochemicals O 
responsible O 
for O 
the O 
antihypertensive O 
and O 
hypocholesterolemic O 
effects O 
, O 
however O 
evidence O 
has O 
also O 
been O 
provided O 
for O 
the O 
role O 
of O 
polyphenols B-FAMILY 
and O 
hibiscus B-TRIVIAL 
acid I-TRIVIAL 
. O 
A O 
number O 
of O 
potential O 
mechanisms O 
have O 
been O 
proposed O 
to O 
explain O 
the O 
hypotensive O 
and O 
anticholesterol O 
effects O 
, O 
but O 
the O 
most O 
common O 
explanation O 
is O 
the O 
antioxidant O 
effects O 
of O 
the O 
anthocyanins B-FAMILY 
inhibition O 
of O 
LDL-C O 
oxidation O 
, O 
which O 
impedes O 
atherosclerosis O 
, O 
an O 
important O 
cardiovascular O 
risk O 
factor O 
. O 
This O 
comprehensive O 
body O 
of O 
evidence O 
suggests O 
that O 
extracts O 
of O 
HS O 
are O 
promising O 
as O 
a O 
treatment O 
of O 
hypertension O 
and O 
hyperlipidemia O 
, O 
however O 
more O 
high O 
quality O 
animal O 
and O 
human O 
studies O 
informed O 
by O 
actual O 
therapeutic O 
practices O 
are O 
needed O 
to O 
provide O 
recommendations O 
for O 
use O 
that O 
have O 
the O 
potential O 
for O 
widespread O 
public O 
health O 
benefit O 
. O 

: O 
Past O 
research O 
on O 
the O 
association O 
of O 
antidepressant O 
medication O 
use O 
with O 
glycemic O 
control O 
abnormalities O 
has O 
produced O 
mixed O 
results O 
. O 
OBJECTIVE O 
: O 
To O 
examine O 
the O 
association O 
of O 
antidepressant O 
use O 
with O 
glycemic O 
control O 
abnormalities O 
and O 
screen O 
- O 
positive O 
diabetes O 
in O 
a O 
representative O 
population O 
sample O 
of O 
US O 
adults O 
without O 
a O 
diagnosis O 
of O 
diabetes O 
. O 
METHODS O 
: O 
Using O 
data O 
from O 
adult O 
participants O 
of O 
the O 
National O 
Health O 
and O 
Nutrition O 
Examination O 
Survey O 
( O 
NHANES O 
, O 
2005-2010 O 
) O 
, O 
the O 
association O 
of O 
antidepressant O 
use O 
with O 
continuous O 
measures O 
of O 
HbA1c O 
, O 
fasting O 
blood O 
sugar B-FAMILY 
, O 
2-h O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
insulin O 
sensitivity O 
and O 
screen O 
- O 
positive O 
diabetes O 
according O 
to O 
HbA1c O 
, O 
fasting O 
blood O 
sugar O 
and O 
2-h O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
were O 
assessed O 
. O 
RESULTS O 
: O 
Antidepressant O 
use O 
was O 
not O 
associated O 
with O 
increased O 
levels O 
of O 
HbA1c O 
, O 
fasting O 
blood O 
sugar B-FAMILY 
, O 
2-h O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
, O 
reduced O 
insulin O 
sensitivity O 
or O 
increased O 
prevalence O 
of O 
screen O 
- O 
positive O 
diabetes O 
. O 
Results O 
were O 
mostly O 
consistent O 
across O 
sociodemographic O 
groups O 
and O 
across O 
different O 
lengths O 
of O 
exposure O 
, O 
different O 
classes O 
of O 
antidepressants O 
and O 
levels O 
of O 
body O 
mass O 
index O 
. O 
CONCLUSIONS O 
: O 
In O 
this O 
representative O 
population O 
sample O 
, O 
antidepressant O 
use O 
was O 
not O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
abnormalities O 
in O 
glycemic O 
control O 
or O 
undetected O 
diabetes O 
. O 
Positive O 
findings O 
from O 
past O 
research O 
may O 
be O 
attributable O 
to O 
detection O 
bias O 
, O 
in O 
that O 
individuals O 
prescribed O 
antidepressants O 
may O 
be O 
more O 
likely O 
to O 
be O 
tested O 
and O 
diagnosed O 
with O 
diabetes O 
. O 

of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
metabolism O 
on O 
oncogenesis O 
, O 
tumor O 
progression O 
and O 
therapeutic O 
responses O 
. O 

( O 
PLP B-ABBREVIATION 
) O 
, O 
the O 
bioactive O 
form O 
of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
, O 
reportedly O 
functions O 
as O 
a O 
prosthetic O 
group O 
for O 
> O 
4% O 
of O 
classified O 
enzymatic O 
activities O 
of O 
the O 
cell O 
. O 
It O 
is O 
therefore O 
not O 
surprising O 
that O 
alterations O 
of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
metabolism O 
have O 
been O 
associated O 
with O 
multiple O 
human O 
diseases O 
. O 
As O 
a O 
striking O 
example O 
, O 
mutations O 
in O 
the O 
gene O 
coding O 
for O 
antiquitin O 
, O 
an O 
evolutionary O 
old O 
aldehyde B-SYSTEMATIC 
dehydrogenase O 
, O 
result O 
in O 
pyridoxine B-TRIVIAL 
-dependent O 
seizures O 
, O 
owing O 
to O 
the O 
accumulation O 
of O 
a O 
metabolic O 
intermediate O 
that O 
inactivates O 
PLP B-ABBREVIATION 
. O 
In O 
addition O 
, O 
PLP B-ABBREVIATION 
is O 
required O 
for O 
the O 
catabolism O 
of O 
homocysteine B-TRIVIAL 
by O 
transsulfuration O 
. O 
Hence O 
, O 
reduced O 
circulating O 
levels O 
of O 
B6 B-TRIVIAL 
vitamers O 
( O 
including O 
PLP B-ABBREVIATION 
as O 
well O 
as O 
its O 
major O 
precursor O 
pyridoxine B-TRIVIAL 
) O 
are O 
frequently O 
paralleled O 
by O 
hyperhomocysteinemia O 
, O 
a O 
condition O 
that O 
has O 
been O 
associated O 
with O 
an O 
increased O 
risk O 
for O 
multiple O 
cardiovascular O 
diseases O 
. O 
During O 
the O 
past O 
30 O 
years O 
, O 
an O 
intense O 
wave O 
of O 
clinical O 
investigation O 
has O 
attempted O 
to O 
dissect O 
the O 
putative O 
links O 
between O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
and O 
cancer O 
. O 
Thus O 
, O 
high O 
circulating O 
levels O 
of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
, O 
as O 
such O 
or O 
as O 
they O 
reflected O 
reduced O 
amounts O 
of O 
circulating O 
homocysteine B-TRIVIAL 
, O 
have O 
been O 
associated O 
with O 
improved O 
disease O 
outcome O 
in O 
patients O 
bearing O 
a O 
wide O 
range O 
of O 
hematological O 
and O 
solid O 
neoplasms O 
. O 
More O 
recently O 
, O 
the O 
proficiency O 
of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
metabolism O 
has O 
been O 
shown O 
to O 
modulate O 
the O 
adaptive O 
response O 
of O 
tumor O 
cells O 
to O 
a O 
plethora O 
of O 
physical O 
and O 
chemical O 
stress O 
conditions O 
. O 
Moreover O 
, O 
elevated O 
levels O 
of O 
pyridoxal B-TRIVIAL 
kinase O 
( O 
PDXK O 
) O 
, O 
the O 
enzyme O 
that O 
converts O 
pyridoxine B-TRIVIAL 
and O 
other O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
precursors O 
into O 
PLP B-ABBREVIATION 
, O 
have O 
been O 
shown O 
to O 
constitute O 
a O 
good O 
, O 
therapy O 
- O 
independent O 
prognostic O 
marker O 
in O 
patients O 
affected O 
by O 
non-small O 
cell O 
lung O 
carcinoma O 
( O 
NSCLC O 
) O 
. O 
Here O 
, O 
we O 
will O 
discuss O 
the O 
clinical O 
relevance O 
of O 
vitamin B-TRIVIAL 
B6 I-TRIVIAL 
metabolism O 
as O 
a O 
prognostic O 
factor O 
in O 
cancer O 
patients.Oncogene O 
advance O 
online O 
publication O 
, O 
21 O 
January O 
2013 O 
; O 
doi O 
: O 
10.1038 O 
/ O 
onc.2012.623 O 
. O 

processes O 
are O 
important O 
for O 
physiologic O 
renewal O 
of O 
an O 
intact O 
epithelial O 
barrier O 
and O 
contribute O 
some O 
antimicrobial O 
resistance O 
for O 
bacteria O 
and O 
viruses O 
, O 
as O 
well O 
as O 
anti-inflammatory O 
effects O 
that O 
benefits O 
the O 
mucosa O 
. O 
The O 
oral O 
cavity O 
presents O 
a O 
model O 
of O 
host O 
- O 
bacterial O 
interactions O 
at O 
mucosal O 
surfaces O 
, O 
in O 
which O 
a O 
panoply O 
of O 
microorganisms O 
colonizes O 
various O 
niches O 
in O 
the O 
oral O 
cavity O 
and O 
creates O 
complex O 
multispecies O 
biofilms O 
that O 
challenge O 
the O 
gingival O 
tissues O 
. O 
This O 
report O 
details O 
gene O 
expression O 
in O 
apoptotic O 
pathways O 
that O 
occur O 
in O 
oral O 
mucosal O 
tissues O 
across O 
the O 
lifespan O 
, O 
using O 
a O 
nonhuman O 
primate O 
model O 
. O 
Macaca O 
mulatta O 
primates O 
from O 
2 O 
to O 
23 O 
years O 
of O 
age O 
( O 
n O 
= O 
23 O 
) O 
were O 
used O 
in O 
a O 
cross O 
- O 
sectional O 
study O 
to O 
obtain O 
clinical O 
healthy O 
gingival O 
tissues O 
specimens O 
. O 
Further O 
, O 
mRNA O 
was O 
prepared O 
and O 
evaluated O 
using O 
the O 
Affymetrix O 
Rhesus O 
GeneChip O 
and O 
88 O 
apoptotic O 
pathway O 
genes O 
were O 
evaluated O 
. O 
The O 
results O 
identified O 
significant O 
positive O 
correlations O 
with O 
age O 
in O 
12 O 
genes O 
and O 
negative O 
correlations O 
with O 
an O 
additional O 
five O 
genes O 
. O 
The O 
gene O 
effects O 
were O 
predicted O 
to O 
alter O 
apoptosis O 
receptor O 
levels O 
, O 
extrinsic O 
apoptotic O 
pathways O 
through O 
caspases O 
, O 
cytokine O 
effects O 
on O 
apoptotic O 
events O 
, O 
Ca(+2) B-FORMULA 
-induced O 
death O 
signaling O 
, O 
cell O 
cycle O 
checkpoints O 
, O 
and O 
potential O 
effects O 
of O 
survival O 
factors O 
. O 
Both O 
the O 
positively O 
and O 
negatively O 
correlated O 
genes O 
within O 
the O 
apoptotic O 
pathways O 
provided O 
evidence O 
that O 
healthy O 
tissues O 
in O 
aging O 
animals O 
exhibit O 
decreased O 
apoptotic O 
potential O 
compared O 
to O 
younger O 
animals O 
. O 
The O 
results O 
suggested O 
that O 
decreased O 
physiologic O 
apoptotic O 
process O 
in O 
the O 
dynamic O 
septic O 
environment O 
of O 
the O 
oral O 
mucosal O 
tissues O 
could O 
increase O 
the O 
risk O 
of O 
aging O 
tissues O 
to O 
undergo O 
destructive O 
disease O 
processes O 
through O 
dysregulated O 
inflammatory O 
responses O 
to O 
the O 
oral O 
microbial O 
burden O 
. O 

of O 
phenanthrene B-SYSTEMATIC 
sorbed O 
on O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

nanotubes O 
have O 
attracted O 
attention O 
around O 
the O 
world O 
because O 
of O 
their O 
high O 
sorption O 
capacity O 
for O 
hydrophobic O 
organic O 
compounds O 
( O 
HOCs O 
) O 
; O 
however O 
, O 
the O 
bioavailability O 
of O 
HOCs O 
sorbed O 
on O 
carbon B-SYSTEMATIC 
nanotubes O 
to O 
bacteria O 
is O 
not O 
well O 
known O 
. O 
In O 
the O 
present O 
study O 
, O 
( B-FORMULA 
14 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
-labeled O 
and O 
unlabeled O 
phenanthrene B-SYSTEMATIC 
was O 
spiked O 
onto O 
four O 
kinds O 
of O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNTs O 
) O 
and O 
aged O 
for O 
60 O 
d O 
, O 
and O 
the O 
mineralization O 
of O 
phenanthrene B-SYSTEMATIC 
sorbed O 
on O 
MWCNTs O 
was O 
studied O 
. O 
The O 
mineralization O 
efficiencies O 
of O 
phenanthrene B-SYSTEMATIC 
sorbed O 
on O 
the O 
four O 
kinds O 
of O 
MWCNTs O 
were O 
2.38 O 
, O 
8.84 O 
, O 
23.88 O 
, O 
and O 
31.47% O 
, O 
respectively O 
, O 
after O 
incubation O 
for O 
35 O 
d O 
, O 
which O 
were O 
positively O 
correlated O 
with O 
the O 
sum O 
of O 
fast O 
and O 
slow O 
desorption O 
fractions O 
of O 
phenanthrene B-SYSTEMATIC 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
authors O 
found O 
that O 
the O 
mineralization O 
efficiencies O 
agreed O 
well O 
with O 
the O 
MWCNT O 
properties O 
; O 
the O 
increasing O 
specific O 
surface O 
area O 
and O 
mesopore O 
and O 
micropore O 
volume O 
of O 
MWCNTs O 
caused O 
a O 
significant O 
decrease O 
in O 
the O 
mineralization O 
efficiency O 
of O 
phenanthrene B-SYSTEMATIC 
( O 
p O 
< O 
0.05 O 
) O 
. O 
After O 
incubation O 
for O 
35 O 
d O 
, O 
the O 
density O 
of O 
bacteria O 
had O 
a O 
significant O 
positive O 
correlation O 
with O 
both O 
the O 
desorption O 
and O 
the O 
mineralization O 
efficiencies O 
. O 
The O 
authors O 
inferred O 
that O 
, O 
although O 
MWCNTs O 
might O 
have O 
toxic O 
effects O 
on O 
the O 
bacteria O 
, O 
the O 
biodegrading O 
ability O 
of O 
bacteria O 
might O 
not O 
decrease O 
significantly O 
under O 
the O 
influence O 
of O 
MWCNTs O 
with O 
low O 
surface O 
area O 
. O 

- O 
catalyzed O 
protein O 
phosphorylation O 
is O 
involved O 
in O 
a O 
wide O 
variety O 
of O 
cellular O 
events O 
. O 
Development O 
of O 
methods O 
to O 
monitor O 
phosphorylation O 
is O 
critical O 
to O 
understand O 
cell O 
biology O 
. O 
Our O 
lab O 
recently O 
discovered O 
kinase O 
- O 
catalyzed O 
biotinylation O 
, O 
where O 
ATP B-ABBREVIATION 
- O 
biotin B-TRIVIAL 
is O 
utilized O 
by O 
kinases O 
to O 
label O 
phosphopeptides O 
or O 
phosphoproteins O 
with O 
a O 
biotin B-TRIVIAL 
tag O 
. O 
To O 
exploit O 
kinase O 
- O 
catalyzed O 
biotinylation O 
for O 
phosphoprotein O 
purification O 
and O 
identification O 
in O 
a O 
cellular O 
context O 
, O 
the O 
susceptibility O 
of O 
the O 
biotin B-TRIVIAL 
tag O 
to O 
phosphatases O 
was O 
characterized O 
. O 
We O 
found O 
that O 
the O 
phosphorylbiotin B-SYSTEMATIC 
group O 
on O 
peptide O 
and O 
protein O 
substrates O 
was O 
relatively O 
insensitive O 
to O 
protein O 
phosphatases O 
. O 
To O 
understand O 
how O 
phosphatase O 
stability O 
would O 
impact O 
phosphoproteomics O 
research O 
applications O 
, O 
kinase O 
- O 
catalyzed O 
biotinylation O 
of O 
cell O 
lysates O 
was O 
performed O 
in O 
the O 
presence O 
of O 
kinase O 
or O 
phosphatase O 
inhibitors O 
. O 
We O 
found O 
that O 
biotinylation O 
with O 
ATP B-ABBREVIATION 
- O 
biotin B-TRIVIAL 
was O 
sensitive O 
to O 
inhibitors O 
, O 
although O 
with O 
variable O 
effects O 
compared O 
to O 
ATP B-ABBREVIATION 
phosphorylation O 
. O 
The O 
results O 
suggest O 
that O 
kinase O 
- O 
catalyzed O 
biotinylation O 
is O 
well O 
suited O 
for O 
phosphoproteomics O 
studies O 
, O 
with O 
particular O 
utility O 
towards O 
monitoring O 
low O 
- O 
abundance O 
phosphoproteins O 
or O 
characterizing O 
the O 
influence O 
of O 
inhibitor O 
drugs O 
on O 
protein O 
phosphorylation O 
. O 

dissection O 
of O 
sesquiterpene B-FAMILY 
biosynthesis O 
by O 
Fusarium O 
fujikuroi O 
. O 

treasure O 
trove O 
of O 
terpenes B-FAMILY 
: O 
The O 
products O 
of O 
two O 
fungal O 
sesquiterpene B-FAMILY 
synthases O 
from O 
the O 
rice O 
pathogen O 
Fusarium O 
fujikuroi O 
were O 
identified O 
by O 
gene O 
- O 
knockout O 
experiments O 
, O 
genetic O 
engineering O 
of O 
the O 
fungus O 
for O 
production O 
optimization O 
, O 
isolation O 
of O 
the O 
sesquiterpenes B-FAMILY 
, O 
and O 
structure O 
elucidation O 
by O 
spectroscopic O 
methods O 
. O 

and O 
characterization O 
of O 
conformationally O 
rigid O 
chiral O 
pyridine B-SYSTEMATIC 
- O 
N-heterocyclic B-FAMILY 
carbene I-FAMILY 
-based O 
palladacycles B-FAMILY 
with O 
an O 
unexpected O 
Pd B-FORMULA 
- O 
N B-FORMULA 
bond O 
cleavage O 
. O 

versatility O 
of O 
a O 
previously O 
developed O 
method O 
for O 
the O 
synthesis O 
of O 
chiral O 
carbene B-FAMILY 
-based O 
palladacycles B-FAMILY 
is O 
demonstrated O 
through O 
the O 
synthesis O 
of O 
two O 
new O 
chiral O 
pyridine B-SYSTEMATIC 
-functionalized O 
N-heterocyclic B-FAMILY 
carbene I-FAMILY 
palladacycles B-FAMILY 
with O 
different O 
wingtip O 
groups O 
. O 
The O 
efficiency O 
in O 
their O 
resolution O 
with O 
different O 
counter O 
anions O 
and O 
different O 
chiral O 
amino B-FAMILY 
acid I-FAMILY 
salt O 
auxiliaries O 
has O 
been O 
studied O 
. O 
The O 
absolute O 
stereochemistries O 
of O 
all O 
the O 
chiral O 
compounds O 
were O 
confirmed O 
by O 
single O 
crystal O 
X-ray O 
crystallography O 
. O 
An O 
unexpected O 
Pd B-FORMULA 
- O 
N B-FORMULA 
bond O 
cleavage O 
that O 
resulted O 
in O 
the O 
racemization O 
of O 
the O 
α-carbon B-SYSTEMATIC 
center O 
in O 
these O 
complexes O 
has O 
also O 
been O 
investigated O 
. O 

nanoparticles O 
( O 
AuNPs O 
) O 
are O 
widely O 
used O 
as O 
carriers O 
or O 
therapeutic O 
agents O 
due O 
to O 
their O 
great O 
biocompatibility O 
and O 
unique O 
physical O 
properties O 
. O 
Transforming O 
growth O 
factor O 
- O 
beta O 
1 O 
( O 
TGF-β1 O 
) O 
, O 
a O 
member O 
of O 
the O 
cysteine B-TRIVIAL 
-knot O 
structural O 
superfamily O 
, O 
plays O 
a O 
pivotal O 
role O 
in O 
many O 
diseases O 
and O 
is O 
known O 
as O 
an O 
immunosuppressive O 
agent O 
that O 
attenuates O 
immune O 
response O 
resulting O 
in O 
tumor O 
growth O 
. O 
The O 
results O 
reported O 
herein O 
reflect O 
strong O 
interactions O 
between O 
TGF-β1 O 
and O 
the O 
surface O 
of O 
AuNPs O 
when O 
incubated O 
with O 
serum O 
- O 
containing O 
medium O 
, O 
and O 
demonstrate O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
pattern O 
. O 
Compared O 
with O 
other O 
serum O 
proteins O 
that O 
can O 
also O 
bind O 
to O 
the O 
AuNP O 
surface O 
, O 
AuNP-TGFβ1 O 
conjugate O 
is O 
a O 
thermodynamically O 
favored O 
compound O 
. O 
Epithelial O 
cells O 
undergo O 
epithelial O 
- O 
mesenchymal O 
transition O 
( O 
EMT O 
) O 
upon O 
treatment O 
with O 
TGF-β1 O 
; O 
however O 
, O 
treatment O 
with O 
AuNPs O 
reverses O 
this O 
effect O 
, O 
as O 
detected O 
by O 
cell O 
morphology O 
and O 
expression O 
levels O 
of O 
EMT O 
markers O 
. O 
TGF-β1 O 
is O 
found O 
to O 
bind O 
to O 
AuNPs O 
through O 
S-Au B-FORMULA 
bonds O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
. O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
is O 
employed O 
to O 
analyze O 
the O 
conformational O 
changes O 
of O 
TGF-β1 O 
on O 
the O 
surface O 
of O 
AuNPs O 
. O 
The O 
results O 
indicate O 
that O 
TGF-β1 O 
undergoes O 
significant O 
conformational O 
changes O 
at O 
both O 
secondary O 
and O 
tertiary O 
structural O 
levels O 
after O 
conjugation O 
to O 
the O 
AuNP O 
surface O 
, O 
which O 
results O 
in O 
the O 
deactivation O 
of O 
TGF-β1 O 
protein O 
. O 
An O 
in O 
vivo O 
experiment O 
also O 
shows O 
that O 
addition O 
of O 
AuNPs O 
attenuates O 
the O 
growth O 
of O 
TGF-β1-secreting O 
murine O 
bladder O 
tumor O 
2 O 
cells O 
in O 
syngeneic O 
C3H O 
/ O 
HeN O 
mice O 
, O 
but O 
not O 
in O 
immunocompromised O 
NOD-SCID O 
mice O 
, O 
and O 
this O 
is O 
associated O 
with O 
an O 
increase O 
in O 
the O 
number O 
of O 
tumor O 
- O 
infiltrating O 
CD4(+) O 
and O 
CD8(+) O 
T O 
lymphocytes O 
and O 
a O 
decrease O 
in O 
the O 
number O 
of O 
intrasplenic O 
Foxp3(+) O 
lymphocytes O 
. O 
The O 
findings O 
demonstrate O 
that O 
AuNPs O 
may O 
be O 
a O 
promising O 
agent O 
for O 
modulating O 
tumor O 
immunity O 
through O 
inhibiting O 
immunosuppressive O 
TGF-β1 O 
signaling O 
. O 

native O 
extracellular O 
matrix O 
with O 
phytic B-TRIVIAL 
Acid I-TRIVIAL 
-crosslinked O 
protein O 
nanofibers O 
for O 
cardiac O 
tissue O 
engineering O 
. O 

functional O 
scaffold O 
fabricated O 
is O 
developed O 
from O 
natural O 
polymers O 
, O 
favoring O 
regeneration O 
of O 
the O 
ischemic O 
myocardium O 
. O 
Hemoglobin O 
/ O 
gelatin O 
/ O 
fibrinogen O 
( O 
Hb O 
/ O 
gel O 
/ O 
fib O 
) O 
nanofibers O 
are O 
fabricated O 
by O 
electrospinning O 
and O 
are O 
characterized O 
for O 
morphology O 
, O 
scaffold O 
composition O 
, O 
functional O 
groups O 
and O 
hydrophilicity O 
. O 
It O 
is O 
hypothesized O 
that O 
ex O 
vivo O 
pretreatment O 
of O 
mesenchymal O 
stem O 
cells O 
( O 
MSCs O 
) O 
using O 
5-azacytidine B-SYSTEMATIC 
and O 
such O 
a O 
functional O 
nanofibrous O 
construct O 
having O 
a O 
high O 
oxygen B-SYSTEMATIC 
-carrying O 
potential O 
could O 
lead O 
to O 
enhanced O 
cardiomyogenic O 
differentiation O 
of O 
MSCs O 
and O 
result O 
in O 
superior O 
biological O 
and O 
functional O 
effects O 
. O 
The O 
combination O 
of O 
a O 
functional O 
nanofibrous O 
scaffold O 
composed O 
of O 
natural O 
polymers O 
and O 
crosslinked O 
with O 
a O 
natural O 
crosslinking O 
agent O 
, O 
phytic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
stem O 
cell O 
biology O 
may O 
prove O 
to O 
be O 
a O 
novel O 
therapeutic O 
device O 
for O 
treatment O 
of O 
myocardial O 
infarction O 
. O 

and O 
receding O 
contact O 
angles O 
of O 
water O 
, O 
formamide B-SYSTEMATIC 
and O 
diiodomethane B-SYSTEMATIC 
were O 
measured O 
on O 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DPPC B-ABBREVIATION 
) O 
layers O 
deposited O 
on O 
three O 
different O 
solid O 
supports O 
- O 
glass O 
, O 
mica O 
and O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 
Up O 
to O 
five O 
statistical O 
monolayers O 
were O 
deposited O 
on O 
the O 
surfaces O 
by O 
spreading O 
DPPC B-ABBREVIATION 
solution O 
. O 
It O 
was O 
found O 
that O 
even O 
on O 
five O 
statistical O 
DPPC B-ABBREVIATION 
monolayers O 
, O 
the O 
hysteresis O 
of O 
a O 
given O 
liquid O 
depends O 
on O 
the O 
kind O 
of O 
solid O 
support O 
. O 
Also O 
on O 
the O 
same O 
solid O 
support O 
the O 
contact O 
angle O 
hysteresis O 
is O 
different O 
for O 
each O 
probe O 
liquid O 
used O 
. O 
The O 
AFM O 
images O 
show O 
that O 
the O 
heights O 
of O 
roughness O 
of O 
the O 
DPPC B-ABBREVIATION 
films O 
cannot O 
be O 
the O 
primary O 
cause O 
of O 
the O 
observed O 
hysteresis O 
because O 
the O 
heights O 
are O 
too O 
small O 
to O 
cause O 
the O 
observed O 
hystereses O 
. O 
It O 
is O 
believed O 
that O 
the O 
hysteresis O 
is O 
due O 
to O 
the O 
liquid O 
film O 
present O 
right O 
behind O 
the O 
three O 
- O 
phase O 
solid O 
surface O 
/ O 
liquid O 
drop O 
/ O 
gas O 
( O 
vapour O 
) O 
contact O 
line O 
and O 
the O 
presence O 
of O 
Derjaguin O 
pressure O 
. O 
The O 
value O 
of O 
contact O 
angle O 
hysteresis O 
depends O 
on O 
both O 
the O 
solid O 
surface O 
and O 
liquid O 
properties O 
as O 
well O 
as O 
on O 
intermolecular O 
interactions O 
between O 
them O 
. O 

macrocyclic O 
diterpenes B-FAMILY 
as O 
multidrug O 
- O 
resistance O 
reversers O 
: O 
structure O 
- O 
activity O 
studies O 
on O 
jolkinol B-TRIVIAL 
D I-TRIVIAL 
derivatives O 
. O 

phytochemical O 
study O 
of O 
Euphorbia O 
piscatoria O 
yielded O 
jolkinol B-TRIVIAL 
D I-TRIVIAL 
( O 
1 O 
) O 
in O 
a O 
large O 
amount O 
, O 
whose O 
derivatization O 
gave O 
rise O 
to O 
12 O 
ester B-FAMILY 
derivatives O 
( O 
2-13 O 
) O 
and O 
hydrolysis O 
to O 
compound O 
14 O 
. O 
The O 
in O 
vitro O 
modulation O 
of O 
P-gp O 
of O 
compounds O 
1-14 O 
was O 
evaluated O 
through O 
a O 
combination O 
of O 
transport O 
and O 
chemosensitivity O 
assays O 
, O 
using O 
the O 
L5178 O 
mouse O 
T O 
lymphoma O 
cell O 
line O 
transfected O 
with O 
the O 
human O 
MDR1 O 
gene O 
. O 
Apart O 
from O 
jolkinol B-TRIVIAL 
D I-TRIVIAL 
, O 
all O 
derivatives O 
( O 
2-14 O 
) O 
showed O 
potential O 
as O 
MDR O 
reversal O 
agents O 
. O 
In O 
this O 
small O 
library O 
of O 
novel O 
bioactive O 
macrocyclic O 
lathyrane B-FAMILY 
diterpene I-FAMILY 
derivatives O 
, O 
designed O 
to O 
evaluate O 
structure O 
- O 
activity O 
relationships O 
essential O 
in O 
overcoming O 
multidrug O 
resistance O 
( O 
MDR O 
) O 
, O 
some O 
correlations O 
between O 
MDR O 
reversal O 
and O 
molecular O 
weight O 
, O 
accessible O 
solvent O 
areas O 
, O 
and O 
octanol B-SYSTEMATIC 
/ O 
water O 
partition O 
coefficient O 
were O 
identified O 
that O 
can O 
contribute O 
to O 
the O 
development O 
of O 
new O 
selective O 
P-gp O 
reversal O 
agents O 
. O 

and O 
structure O 
elucidation O 
of O 
a O 
new O 
homoflavanol B-FAMILY 
derivative O 
from O 
Pteridium O 
aquilinum O 
( O 
L O 
. O 
) O 
Kuhn O 
. O 

novel O 
homoflavanol B-FAMILY 
derivative O 
( O 
1 O 
) O 
with O 
an O 
unprecedented O 
skeleton O 
, O 
as O 
well O 
as O 
two O 
known O 
flavonoids B-FAMILY 
kaempferol B-TRIVIAL 
( O 
2 O 
) O 
and O 
quercetin B-TRIVIAL 
( O 
3 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
plant O 
Pteridium O 
aquilinum O 
( O 
L O 
. O 
) O 
Kuhn O 
, O 
and O 
the O 
structure O 
and O 
relative O 
stereochemistry O 
of O 
the O 
new O 
compound O 
( O 
1 O 
) O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
. O 

polymer O 
brushes O 
containing O 
tethered O 
acetylcholine B-SYSTEMATIC 
analogs O 
for O 
protein O 
and O 
hippocampal O 
neuronal O 
cell O 
patterning O 
. O 

paper O 
describes O 
a O 
method O 
to O 
control O 
neuronal O 
cell O 
adhesion O 
and O 
differentiation O 
with O 
both O 
chemical O 
and O 
topographic O 
cues O 
by O 
using O 
a O 
spatially O 
defined O 
polymer O 
brush O 
pattern O 
. O 
First O 
, O 
biomimetic O 
methacrylate B-TRIVIAL 
polymer O 
brushes O 
containing O 
tethered O 
neurotransmitter O 
acetylcholine B-SYSTEMATIC 
functionalities O 
in O 
the O 
form O 
of O 
dimethylaminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
or O 
free O 
hydroxyl B-SYSTEMATIC 
-terminated O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
units O 
were O 
prepared O 
using O 
the O 
" O 
grown O 
from O 
" O 
method O 
through O 
surface O 
- O 
initiated O 
atom O 
transfer O 
radical O 
polymerization O 
reactions O 
. O 
The O 
surface O 
properties O 
of O 
the O 
resulting O 
brushes O 
were O 
thoroughly O 
characterized O 
with O 
various O 
techniques O 
and O 
hippocampal O 
neuronal O 
cell O 
culture O 
on O 
the O 
brush O 
surfaces O 
exhibit O 
cell O 
viability O 
and O 
differentiation O 
comparable O 
to O 
, O 
or O 
even O 
better O 
than O 
, O 
those O 
on O 
commonly O 
used O 
poly-l-lysine B-SYSTEMATIC 
coated O 
glass O 
coverslips O 
. O 
The O 
polymer O 
brushes O 
were O 
then O 
patterned O 
via O 
UV O 
photolithography O 
techniques O 
to O 
provide O 
specially O 
designed O 
surface O 
features O 
with O 
different O 
sizes O 
( O 
varying O 
from O 
2 O 
to O 
200 O 
μm O 
) O 
and O 
orientations O 
( O 
horizontal O 
and O 
vertical O 
) O 
. O 
Protein O 
absorption O 
experiments O 
and O 
hippocampal O 
neuronal O 
cell O 
culture O 
tests O 
on O 
the O 
brush O 
patterns O 
showed O 
that O 
both O 
protein O 
and O 
neurons O 
can O 
adhere O 
to O 
the O 
patterns O 
and O 
therefore O 
be O 
guided O 
by O 
such O 
patterns O 
. O 
These O 
results O 
also O 
demonstrate O 
that O 
, O 
because O 
of O 
their O 
unique O 
chemical O 
composition O 
and O 
well O 
- O 
defined O 
nature O 
, O 
the O 
developed O 
polymer O 
brushes O 
may O 
find O 
many O 
potential O 
applications O 
in O 
cell O 
- O 
material O 
interactions O 
studies O 
and O 
neural O 
tissue O 
engineering O 
. O 

integration O 
of O 
discrete O 
metal O 
complexes O 
has O 
been O 
attracting O 
significant O 
interest O 
due O 
to O 
the O 
potential O 
of O 
these O 
materials O 
for O 
soft O 
metal O 
- O 
metal O 
interactions O 
and O 
supramolecular O 
assembly O 
. O 
Additionally O 
, O 
block O 
copolypeptide O 
amphiphiles O 
have O 
been O 
investigated O 
concerning O 
their O 
capacity O 
for O 
self O 
- O 
assembly O 
into O 
structures O 
such O 
as O 
nanoparticles O 
, O 
nanosheets O 
and O 
nanofibers O 
. O 
In O 
this O 
study O 
, O 
we O 
combined O 
these O 
two O 
concepts O 
by O 
investigating O 
the O 
self O 
- O 
assembly O 
of O 
discrete O 
metal O 
complexes O 
in O 
aqueous O 
solution O 
using O 
block O 
copolypeptides O 
. O 
Normally O 
, O 
discrete O 
metal O 
complexes O 
such O 
as O 
[Au(CN)(2)]- B-FORMULA 
, O 
when O 
molecularly O 
dispersed O 
in O 
water O 
, O 
cannot O 
interact O 
with O 
one O 
another O 
. O 
Our O 
results O 
demonstrated O 
, O 
however O 
, O 
that O 
the O 
addition O 
of O 
block O 
copolypeptide O 
amphiphiles O 
such O 
as O 
K(183)L(19) O 
to O 
[Au(CN)(2)]- B-FORMULA 
solutions O 
induced O 
one O 
- O 
dimensional O 
integration O 
of O 
the O 
discrete O 
metal O 
complex O 
, O 
resulting O 
in O 
photoluminescence O 
originating O 
from O 
multinuclear O 
complexes O 
with O 
metal O 
- O 
metal O 
interactions O 
. O 
Transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
showed O 
a O 
fibrous O 
nanostructure O 
with O 
lengths O 
and O 
widths O 
of O 
approximately O 
100 O 
and O 
20 O 
nm O 
, O 
respectively O 
, O 
which O 
grew O 
to O 
form O 
advanced O 
nanoarchitectures O 
, O 
including O 
those O 
resembling O 
the O 
weave O 
patterns O 
of O 
Waraji O 
( O 
traditional O 
Japanese O 
straw O 
sandals O 
) O 
. O 
This O 
concept O 
of O 
combining O 
block O 
copolypeptide O 
amphiphiles O 
with O 
discrete O 
coordination O 
compounds O 
allows O 
the O 
design O 
of O 
flexible O 
and O 
functional O 
supramolecular O 
coordination O 
systems O 
in O 
water O 
. O 

cytotoxin O 
NN-32 O 
( O 
6.7 O 
kDa O 
) O 
from O 
Indian O 
cobra O 
( O 
Naja O 
naja O 
) O 
venom O 
inhibited O 
human O 
leukemic O 
U937 O 
cell O 
growth O 
as O 
observed O 
by O 
Trypan B-TRIVIAL 
blue I-TRIVIAL 
dye O 
exclusion O 
method O 
and O 
cytotoxicity O 
was O 
confirmed O 
by O 
MTT B-ABBREVIATION 
assay O 
. O 
NN-32 O 
induced O 
apoptosis O 
of O 
U937 O 
cell O 
and O 
cell O 
cycle O 
arrest O 
of O 
sub-G1 O 
phase O 
were O 
revealed O 
by O 
FACS O 
analysis O 
. O 
Increased O 
Bax O 
/ O 
Bcl-2 O 
ratio O 
, O 
increased O 
caspase O 
3 O 
and O 
9 O 
activities O 
, O 
cleaved O 
PARP O 
, O 
decreased O 
VEGF O 
, O 
MMP-2 O 
and O 
MMP-9 O 
activities O 
were O 
observed O 
after O 
NN-32 O 
treatment O 
of O 
U937 O 
cell O 
. O 
Antileukemic O 
activity O 
of O 
NN-32 O 
on O 
U937 O 
cell O 
may O 
be O 
due O 
to O 
activation O 
of O 
apoptosis O 
, O 
arresting O 
cell O 
cycle O 
and O 
antiangiogenesis O 
activities O 
. O 

, O 
C-3 O 
substituted O 
indoles B-FAMILY 
as O 
5-LOX O 
inhibitors O 
-- O 
in O 
vitro O 
enzyme O 
immunoaasay O 
, O 
mass O 
spectral O 
and O 
molecular O 
docking O 
investigations O 
. O 

upon O 
the O 
structures O 
of O 
some O 
known O 
5-LOX O 
inhibitors O 
, O 
a O 
set O 
of O 
five O 
compounds O 
carrying O 
appropriate O 
substituents O 
at O 
N-1 O 
and O 
C-3 O 
of O 
indole B-SYSTEMATIC 
were O 
synthesized O 
and O 
investigated O 
for O 
5-LOX O 
inhibitory O 
activities O 
. O 
Fifty O 
percent O 
inhibitory O 
concn O 
(IC(50)) O 
of O 
these O 
compounds O 
ranges O 
from O 
0.6 O 
to O 
5 O 
μM O 
and O 
found O 
to O 
be O 
comparable O 
to O 
that O 
of O 
clinically O 
used O 
5-LOX O 
inhibitor O 
, O 
zileuton B-TRIVIAL 
. O 
The O 
compounds O 
under O 
present O 
investigations O 
exhibited O 
appreciable O 
interactions O 
with O 
5-LOX O 
as O 
apparent O 
from O 
their O 
association O 
constants O 
calculated O 
from O 
the O 
mass O 
spectral O 
data O 
. O 
Compound O 
5a O 
with O 
a O 
tosyl B-TRIVIAL 
group O 
at O 
N-1 O 
and O 
pyrolidinyl-1,2-dione B-SYSTEMATIC 
substituent O 
at O 
C-3 O 
of O 
indole B-SYSTEMATIC 
, O 
exhibiting O 
IC(50) O 
0.6 O 
μM O 
and O 
stoichiometry O 
of O 
1 O 
: O 
7 O 
in O 
the O 
enzyme O 
- O 
compound O 
complex O 
was O 
identified O 
as O 
highly O 
potent O 
5-LOX O 
inhibitor O 
and O 
seems O 
to O 
be O 
suitable O 
for O 
further O 
investigations O 
. O 

, O 
a O 
potential O 
tracer O 
for O 
apoptosis O 
detection O 
. O 

was O 
radiolabeled O 
with O 
technetium-99m B-SYSTEMATIC 
in O 
high O 
yield O 
. O 
This O 
tracer O 
was O 
preferentially O 
accumulated O 
in O 
apoptotic O 
cells O 
in O 
the O 
in O 
vitro O 
studies O 
. O 
Tumor O 
uptake O 
occurred O 
in O 
vivo O 
after O 
cisplatin B-TRIVIAL 
injection O 
due O 
to O 
the O 
apoptosis O 
induction O 
, O 
which O 
not O 
observed O 
in O 
the O 
untreated O 
tumors O 
. O 
Therefore O 
, O 
(99m)Tc-(Me)FGCDEVD B-SYSTEMATIC 
is O 
a O 
potential O 
tracer O 
for O 
apoptosis O 
detection O 
. O 

chemical O 
importance O 
of O 
the O 
linear O 
response O 
kernel O 
from O 
conceptual O 
Density O 
Functional O 
Theory O 
( O 
DFT O 
) O 
is O 
investigated O 
for O 
some O 
σ O 
and O 
π O 
aromatic O 
and O 
anti-aromatic O 
systems O 
. O 
The O 
effect O 
of O 
the O 
ring O 
size O 
is O 
studied O 
by O 
looking O 
at O 
some O 
well O 
known O 
aromatic O 
and O 
anti-aromatic O 
molecules O 
of O 
different O 
sizes O 
, O 
showing O 
that O 
the O 
linear O 
response O 
is O 
capable O 
of O 
correctly O 
classifying O 
and O 
quantifying O 
the O 
aromaticity O 
for O 
five- O 
to O 
eight O 
- O 
membered O 
aromatic O 
and O 
anti-aromatic O 
molecules O 
. O 
The O 
splitting O 
of O 
the O 
linear O 
response O 
in O 
σ O 
and O 
π O 
contributions O 
is O 
introduced O 
and O 
its O 
significance O 
is O 
illustrated O 
using O 
some O 
σ-aromatic O 
molecules O 
. O 
The O 
linear O 
response O 
also O 
correctly O 
predicts O 
the O 
aromatic O 
transition O 
states O 
of O 
the O 
Diels-Alder O 
reaction O 
and O 
the O 
acetylene B-SYSTEMATIC 
trimerisation O 
and O 
shows O 
the O 
expected O 
behavior O 
along O 
the O 
reaction O 
coordinate O 
, O 
proving O 
that O 
the O 
method O 
is O 
accurate O 
not O 
only O 
at O 
the O 
minimum O 
of O 
the O 
potential O 
energy O 
surface O 
, O 
but O 
also O 
in O 
non-equilibrium O 
states O 
. O 
Finally O 
, O 
the O 
reason O 
for O 
the O 
close O 
correlation O 
between O 
the O 
linear O 
response O 
and O 
the O 
Para O 
Delocalisation O 
Index O 
( O 
PDI O 
) O 
, O 
found O 
in O 
previous O 
and O 
the O 
present O 
study O 
, O 
is O 
proven O 
mathematically O 
. O 
These O 
results O 
show O 
the O 
linear O 
response O 
to O 
be O 
a O 
reliable O 
DFT-index O 
to O 
probe O 
the O 
σ O 
and O 
π O 
aromaticity O 
or O 
anti-aromaticity O 
of O 
a O 
broad O 
range O 
of O 
molecules O 
. O 

report O 
on O 
singlet O 
- O 
singlet O 
annihilation O 
and O 
exciton O 
diffusion O 
in O 
as-prepared O 
p- O 
type O 
and O 
annealed O 
n O 
- O 
type O 
thin O 
films O 
of O 
the O 
low O 
- O 
bandgap O 
quinoidal B-SYSTEMATIC 
quaterthiophene I-SYSTEMATIC 
[ O 
QQT(CN)4 B-FORMULA 
] O 
using O 
ultrafast O 
transient O 
absorption O 
measurements O 
. O 
The O 
decay O 
dynamics O 
of O 
exciton O 
populations O 
are O 
well O 
described O 
by O 
a O 
one O 
- O 
dimensional O 
diffusion O 
- O 
limited O 
bimolecular O 
recombination O 
, O 
indicating O 
that O 
the O 
singlet O 
excitons O 
migrate O 
preferentially O 
along O 
the O 
stacking O 
direction O 
. O 
Our O 
results O 
show O 
that O 
the O 
exciton O 
diffusion O 
constants O 
in O 
QQT(CN)4 B-FORMULA 
films O 
do O 
not O 
vary O 
significantly O 
upon O 
thermal O 
annealing O 
. O 
Exciton O 
diffusion O 
lengths O 
are O 
measured O 
to O 
be O 
as O 
high O 
as O 
4 O 
and O 
5 O 
nm O 
in O 
as-prepared O 
and O 
annealed O 
QQT(CN)4 B-FORMULA 
films O 
, O 
respectively O 
. O 
We O 
also O 
observe O 
an O 
influence O 
of O 
the O 
excitation O 
densities O 
on O 
the O 
singlet O 
exciton O 
diffusion O 
, O 
which O 
is O 
attributed O 
to O 
phonon O 
scattering O 
. O 
Because O 
of O 
the O 
possibility O 
of O 
patterning O 
p-n O 
regions O 
in O 
QQT(CN)4 B-FORMULA 
films O 
by O 
thermal O 
nanolithography O 
techniques O 
, O 
this O 
study O 
provides O 
important O 
insight O 
not O 
only O 
into O 
the O 
photophysical O 
properties O 
of O 
quinoidal B-TRIVIAL 
oligothiophene I-TRIVIAL 
derivatives O 
but O 
also O 
for O 
their O 
future O 
integration O 
into O 
high O 
- O 
performance O 
p-n O 
nanostructured O 
near O 
infrared O 
light O 
- O 
sensing O 
devices O 
. O 

effective O 
Ir B-FORMULA 
(x) O 
Sn B-FORMULA 
( O 
1-x O 
) O 
O2 B-FORMULA 
electrocatalysts O 
for O 
oxygen B-SYSTEMATIC 
evolution O 
reaction O 
in O 
the O 
solid O 
polymer O 
electrolyte O 
water O 
electrolyser O 
. O 

developed O 
an O 
advanced O 
surfactant O 
- O 
assistant O 
method O 
for O 
the O 
Ir B-FORMULA 
(x) O 
Sn B-FORMULA 
( O 
1-x O 
) O 
O(2) B-FORMULA 
( O 
0 O 
< O 
x O 
≤ O 
1 O 
) O 
nanoparticle O 
( O 
NP O 
) O 
preparation O 
, O 
and O 
examined O 
the O 
OER O 
performances O 
by O 
a O 
series O 
of O 
half O 
- O 
cell O 
and O 
full O 
- O 
cell O 
tests O 
. O 
In O 
contrast O 
to O 
the O 
commercial O 
Ir O 
black O 
, O 
the O 
collective O 
data O 
confirmed O 
the O 
outstanding O 
activity O 
and O 
stability O 
of O 
the O 
fabricated O 
Ir B-FORMULA 
(x) O 
Sn B-FORMULA 
( O 
1-x O 
) O 
O(2) B-FORMULA 
( O 
x O 
= O 
1 O 
, O 
0.67 O 
and O 
0.52 O 
) O 
NPs O 
, O 
which O 
could O 
be O 
ascribed O 
to O 
the O 
amorphous O 
structure O 
, O 
good O 
dispersion O 
, O 
high O 
pore O 
volume O 
, O 
solid O 
- O 
solution O 
state O 
and O 
Ir B-FORMULA 
-rich O 
surface O 
for O 
bi B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
oxides I-FAMILY 
, O 
and O 
relatively O 
large O 
size O 
( O 
10-11 O 
nm O 
) O 
, O 
while O 
Ir B-FORMULA 
( O 
0.31 O 
) O 
Sn B-FORMULA 
( O 
0.69 O 
) O 
exhibited O 
poor O 
electro O 
- O 
catalytic O 
activity O 
because O 
of O 
the O 
separated O 
two O 
phases O 
, O 
a O 
SnO(2) B-FORMULA 
-rich O 
phase O 
and O 
an O 
IrO(2) B-FORMULA 
-rich O 
phase O 
. O 
Furthermore O 
, O 
compared O 
with O 
highly O 
active O 
IrO(2) B-FORMULA 
, O 
the O 
improved O 
durability O 
, O 
precious O 
- O 
metal O 
Ir B-FORMULA 
utilization O 
efficiency O 
and O 
correspondingly O 
reduced O 
Ir B-FORMULA 
loading O 
were O 
realized O 
by O 
the O 
addition O 
of O 
Sn B-FORMULA 
component O 
. O 
When O 
the O 
Ir B-FORMULA 
( O 
0.52 O 
) O 
Sn B-FORMULA 
( O 
0.48 O 
) O 
O(2) B-FORMULA 
cell O 
operated O 
at O 
80 O 
°C O 
using O 
Nafion B-TRIVIAL 
® O 
115 O 
membrane O 
and O 
less O 
than O 
0.8 O 
mg O 
cm(-2) O 
of O 
the O 
noble O 
- O 
metal O 
Ir B-FORMULA 
loading O 
, O 
the O 
cell O 
voltages O 
we O 
achieved O 
were O 
1.631 O 
V O 
at O 
1000 O 
mA O 
cm(-2) O 
, O 
and O 
1.821 O 
V O 
at O 
2000 O 
mA O 
cm(-2) O 
. O 
The O 
IR-free O 
voltage O 
at O 
the O 
studied O 
current O 
density O 
was O 
very O 
close O 
to O 
the O 
onset O 
voltage O 
of O 
oxygen B-SYSTEMATIC 
evolution O 
. O 
The O 
only O 
50 O 
μV O 
h(-1) O 
of O 
voltage O 
increased O 
for O 
the O 
500 O 
h O 
durability O 
test O 
at O 
500 O 
mA O 
cm(-2) O 
. O 
In O 
fact O 
, O 
these O 
results O 
are O 
exceptional O 
compared O 
to O 
the O 
performances O 
for O 
OER O 
in O 
SPEWE O 
cells O 
known O 
so O 
far O 
. O 
This O 
work O 
highlights O 
the O 
potential O 
of O 
using O 
highly O 
active O 
and O 
stable O 
IrO(2) B-FORMULA 
- O 
SnO(2) B-FORMULA 
amorphous O 
NPs O 
to O 
enhance O 
the O 
electrolysis O 
efficiency O 
, O 
reduce O 
the O 
noble O 
- O 
metal O 
Ir B-FORMULA 
loading O 
and O 
thus O 
the O 
cost O 
of O 
hydrogen B-SYSTEMATIC 
production O 
from O 
the O 
solid O 
polymer O 
electrolyte O 
water O 
electrolysis O 
. O 

cefuroxime B-TRIVIAL 
: O 
prophylaxis O 
of O 
postoperative O 
endophthalmitis O 
after O 
cataract O 
surgery O 
. O 

of O 
the O 
landmark O 
European O 
Society O 
of O 
Cataract O 
and O 
Refractive O 
Surgeons O 
trial O 
and O 
additional O 
prospective O 
and O 
retrospective O 
studies O 
support O 
the O 
use O 
of O 
intracameral O 
cefuroxime B-TRIVIAL 
in O 
the O 
prophylaxis O 
of O 
endophthalmitis O 
following O 
cataract O 
surgery O 
. O 
Prophylaxis O 
with O 
intracameral O 
cefuroxime B-TRIVIAL 
at O 
the O 
recommended O 
dose O 
appears O 
to O 
be O 
well O 
tolerated O 
in O 
patients O 
undergoing O 
cataract O 
surgery O 
. O 
However O 
, O 
off O 
- O 
label O 
use O 
of O 
intracameral O 
cefuroxime B-TRIVIAL 
usually O 
requires O 
a O 
two O 
- O 
step O 
dilution O 
process O 
with O 
the O 
potential O 
for O 
dilution O 
errors O 
, O 
and O 
there O 
are O 
also O 
concerns O 
regarding O 
the O 
risk O 
of O 
contamination O 
. O 
Aprokam B-TRIVIAL 
® O 
( O 
intracameral O 
cefuroxime B-TRIVIAL 
) O 
has O 
been O 
approved O 
in O 
the O 
EU O 
for O 
the O 
prophylaxis O 
of O 
postoperative O 
endophthalmitis O 
after O 
cataract O 
surgery O 
. O 
After O 
reconstitution O 
of O 
Aprokam B-TRIVIAL 
® O 
, O 
no O 
further O 
dilution O 
is O 
required O 
and O 
each O 
vial O 
is O 
only O 
indicated O 
for O 
single O 
- O 
patient O 
use O 
; O 
this O 
has O 
the O 
potential O 
to O 
reduce O 
the O 
risk O 
of O 
both O 
dilution O 
errors O 
and O 
contamination O 
. O 

cancer O 
is O 
the O 
most O 
common O 
cancer O 
in O 
women O 
worldwide O 
. O 
There O 
are O 
many O 
endocrine O 
adjuvant O 
therapies O 
for O 
breast O 
cancer O 
patients O 
that O 
are O 
categorized O 
according O 
to O 
their O 
mechanisms O 
. O 
Among O 
them O 
, O 
aromatase O 
inhibitors O 
( O 
AIs O 
) O 
that O 
block O 
the O 
synthesis O 
of O 
estrogens B-FAMILY 
have O 
proven O 
superiority O 
compared O 
with O 
tamoxifen B-TRIVIAL 
and O 
have O 
replaced O 
it O 
as O 
a O 
first O 
- O 
line O 
hormonal O 
therapy O 
. O 
However O 
, O 
AIs O 
also O 
have O 
limitations O 
due O 
to O 
their O 
side O 
effects O 
- O 
increased O 
rate O 
of O 
bone O 
loss O 
and O 
musculoskeletal O 
complaints O 
. O 
We O 
therefore O 
need O 
new O 
candidate O 
AIs O 
with O 
fewer O 
side O 
effects O 
. O 
The O 
extracts O 
of O 
Ginkgo O 
biloba O 
( O 
EGb O 
) O 
, O 
which O 
contain O 
phytochemicals O 
from O 
the O 
tree O 
, O 
had O 
biphasic O 
effects O 
for O 
estrogens B-FAMILY 
and O 
osteoporosis O 
- O 
inhibiting O 
activities O 
in O 
our O 
previous O 
experiments O 
. O 
In O 
this O 
study O 
, O 
we O 
explored O 
the O 
possibility O 
of O 
EGb O 
as O 
an O 
AI O 
and O 
their O 
mechanisms O 
. O 
Aromatase O 
activities O 
were O 
inhibited O 
by O 
EGb O 
both O 
in O 
JEG-3 O 
cells O 
and O 
in O 
recombinant O 
CYP19 O 
microsomes O 
. O 
The O 
results O 
of O 
polymerase O 
chain O 
reaction O 
for O 
aromatase O 
from O 
a O 
coding O 
sequence O 
and O 
specific O 
promoter O 
sequences O 
( O 
exon O 
I.a O 
, O 
exon O 
I.c O 
) O 
in O 
JEG-3 O 
cells O 
as O 
well O 
as O 
the O 
results O 
of O 
reporter O 
gene O 
assays O 
showed O 
that O 
EGb O 
dose O 
- O 
dependently O 
decreased O 
the O 
aromatase O 
gene O 
expression O 
. O 
The O 
decreased O 
protein O 
levels O 
were O 
demonstrated O 
by O 
Western O 
blotting O 
. O 
From O 
these O 
results O 
, O 
we O 
concluded O 
that O 
EGb O 
could O 
act O 
as O 
an O 
AI O 
at O 
both O 
the O 
enzyme O 
and O 
transcriptional O 
levels O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

single O 
- O 
dose O 
pharmacokinetics O 
of O 
rasagiline B-TRIVIAL 
in O 
minipigs O 
after O 
oral O 
dosing O 
or O 
transdermal O 
administration O 
via O 
a O 
newly O 
developed O 
patch O 
. O 

1 O 
. O 
A O 
rasagiline B-TRIVIAL 
transdermal O 
patch O 
was O 
developed O 
for O 
the O 
treatment O 
of O 
early O 
and O 
advanced O 
Parkinson's O 
disease O 
. O 
Relevant O 
pharmacokinetic O 
parameters O 
of O 
rasagiline B-TRIVIAL 
obtained O 
after O 
transdermal O 
administration O 
to O 
minipigs O 
were O 
compared O 
with O 
those O 
of O 
rasagiline B-TRIVIAL 
after O 
oral O 
administration O 
. O 
2 O 
. O 
A O 
total O 
of O 
18 O 
minipigs O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
( O 
six O 
animals O 
for O 
each O 
group O 
) O 
. O 
A O 
single O 
dose O 
of O 
1 O 
mg O 
rasagiline B-TRIVIAL 
tablet O 
was O 
orally O 
administrated O 
to O 
one O 
group O 
. O 
Meanwhile O 
, O 
single O 
dose O 
of O 
1.25 O 
and O 
2.5 O 
mg O 
( O 
2 O 
and O 
4 O 
cm(2) O 
) O 
rasagiline B-TRIVIAL 
patches O 
were O 
given O 
( O 
at O 
the O 
postauricular O 
skin O 
) O 
to O 
the O 
other O 
two O 
groups O 
, O 
respectively O 
. O 
The O 
pharmacokinetic O 
parameters O 
such O 
as O 
plasma O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
, O 
time O 
to O 
peak O 
plasma O 
- O 
concentration O 
(T(max)) O 
, O 
mean O 
residence O 
time O 
( O 
MRT O 
) O 
, O 
area O 
under O 
the O 
curve O 
(AUC((0-)(t)())) O 
were O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
different O 
between O 
transdermal O 
and O 
oral O 
administrations O 
. O 
3 O 
. O 
The O 
plasma O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
of O 
rasagiline B-TRIVIAL 
( O 
1.25 O 
mg O 
patch O 
: O 
11.8 O 
± O 
6.5 O 
h O 
, O 
2.5 O 
mg O 
patch O 
: O 
12.5 O 
± O 
4.7 O 
h O 
) O 
in O 
minipig O 
following O 
transdermal O 
administration O 
was O 
significantly O 
prolonged O 
as O 
compared O 
with O 
that O 
following O 
the O 
oral O 
administration O 
( O 
1 O 
mg O 
tablet O 
: O 
4.7 O 
± O 
2.5 O 
h O 
) O 
. O 
The O 
dose O 
- O 
normalized O 
relative O 
bioavailability O 
of O 
rasagiline B-TRIVIAL 
patch O 
in O 
minipig O 
were O 
178.5% O 
and O 
156.4% O 
, O 
respectively O 
, O 
for O 
1.25 O 
and O 
2.5 O 
mg O 
patches O 
compared O 
with O 
1 O 
mg O 
rasagiline B-TRIVIAL 
tablet O 
. O 
The O 
prolonged O 
t(1 O 
/ O 
2 O 
) O 
and O 
increased O 
bioavailability O 
of O 
rasagiline B-TRIVIAL 
patch O 
suggested O 
a O 
possible O 
longer O 
dosing O 
interval O 
compared O 
with O 
oral O 
tablet O 
. O 

reactivity O 
and O 
biological O 
activity O 
of O 
chalcones B-FAMILY 
and O 
other O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
compounds O 
. O 

1 O 
. O 
Chalcones B-FAMILY 
are O 
structural O 
analogues O 
of O 
benzalacetophenone B-SYSTEMATIC 
( O 
BAP B-ABBREVIATION 
) O 
. O 
Several O 
derivatives O 
have O 
been O 
identified O 
in O 
plants O 
and O 
anticarcinogenic O 
and O 
anti-inflammatory O 
properties O 
were O 
attributed O 
to O 
the O 
compounds O 
, O 
probably O 
related O 
to O 
their O 
direct O 
antioxidant O 
activity O 
or O 
stimulatory O 
effects O 
on O 
the O 
expression O 
of O 
endogenous O 
defence O 
enzymes O 
like O 
hemeoxygenase-1 O 
( O 
HO-1 O 
) O 
. O 
HO-1 O 
expression O 
is O 
triggered O 
by O 
the O 
Nrf2-Keap1 O 
signalling O 
pathway O 
, O 
initiated O 
by O 
the O 
addition O 
of O 
chalcones B-FAMILY 
to O 
thiol B-FAMILY 
groups O 
of O 
Keap1 O 
via O 
Michael O 
- O 
type O 
reaction O 
. O 
2 O 
. O 
The O 
present O 
study O 
used O 
a O 
model O 
system O 
estimating O 
the O 
reactivity O 
of O 
different O 
synthetic O 
chalcones B-FAMILY 
and O 
other O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
compounds O 
with O 
thiols B-FAMILY 
and O 
compared O 
the O 
chemical O 
reactivity O 
with O 
the O 
biological O 
activity O 
, O 
measured O 
by O 
HO-1 O 
expression O 
in O 
human O 
dermal O 
fibroblasts O 
. O 
3 O 
. O 
Chemical O 
reactivity O 
with O 
the O 
thiol B-FAMILY 
group O 
of O 
N-acetylcysteine B-SYSTEMATIC 
was O 
determined O 
with O 
5,5'-dithiobis-(2-nitrobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
followed O 
chemical O 
principles O 
of O 
structure O 
- O 
reactivity O 
relationship O 
. O 
Most O 
reactive O 
were O 
sulforaphane B-TRIVIAL 
, O 
dimethylfumarate B-SYSTEMATIC 
, O 
chalcone B-FAMILY 
3 O 
( O 
(2E)-1-phenyl-3-pyrimidin-2-ylprop-2-en-1-one B-SYSTEMATIC 
) O 
and O 
chalcone B-FAMILY 
7 O 
( O 
1,3-diphenylprop-2-yn-1-one B-SYSTEMATIC 
) O 
. O 
This O 
result O 
demonstrates O 
that O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
carbonyl I-FAMILY 
derivatives O 
react O 
with O 
thiols B-FAMILY 
differently O 
. O 
All O 
compounds O 
were O 
also O 
biologically O 
active O 
; O 
however O 
, O 
expression O 
of O 
HO-1 O 
was O 
not O 
only O 
related O 
to O 
the O 
chemical O 
reactivity O 
but O 
also O 
to O 
the O 
lipophilicity O 
of O 
the O 
molecules O 
which O 
likely O 
affected O 
transmembrane O 
uptake O 
. O 
Most O 
efficient O 
inducers O 
of O 
HO-1 O 
expression O 
were O 
BAP B-ABBREVIATION 
, O 
4-hydroxynonenal B-SYSTEMATIC 
and O 
chalcone B-FAMILY 
1 O 
( O 
4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]benzonitrile B-SYSTEMATIC 
) O 
, O 
chalcone B-FAMILY 
5 O 
( O 
(2E)-1-phenyl-3-[4-(trifluoromethyl)-phenyl]prop-2-en-1-one B-SYSTEMATIC 
) O 
and O 
chalcone B-FAMILY 
7 O 
. O 

- O 
active O 
π-conjugated O 
organometallic B-FAMILY 
monolayers O 
: O 
pronounced O 
Coulomb O 
blockade O 
characteristic O 
at O 
room O 
temperature O 
. O 

report O 
the O 
electrical O 
transport O 
characteristics O 
of O 
a O 
series O 
of O 
molecular O 
wires O 
, O 
fc-C≡C-C6H4-SAc B-FORMULA 
( O 
fc O 
= O 
ferrocenyl B-TRIVIAL 
; O 
Ac O 
= O 
acetyl B-SYSTEMATIC 
) O 
and O 
AcS-C6H4-C≡C-(fc)n-C≡C-C6H4-SAc B-FORMULA 
( O 
n O 
= O 
2 O 
, O 
3 O 
) O 
, O 
consisting O 
of O 
multiple O 
redox O 
- O 
active O 
ferrocenyl B-TRIVIAL 
centers O 
. O 
The O 
self O 
- O 
assembled O 
monolayers O 
of O 
these O 
molecular O 
wires O 
on O 
Au B-FORMULA 
surfaces O 
were O 
comprehensively O 
characterized O 
by O 
electrochemistry O 
and O 
conductive O 
atomic O 
force O 
microscopy O 
techniques O 
. O 
Characterization O 
of O 
the O 
wires O 
revealed O 
that O 
electron O 
transport O 
is O 
made O 
extremely O 
efficient O 
by O 
the O 
organometallic B-FAMILY 
redox O 
states O 
. O 
There O 
is O 
a O 
strong O 
electronic O 
coupling O 
between O 
ferrocenyl B-TRIVIAL 
moieties O 
, O 
and O 
superior O 
electron O 
- O 
transport O 
ability O 
exists O 
through O 
these O 
semirigid O 
molecular O 
wires O 
. O 
Standard O 
rate O 
constants O 
for O 
the O 
electron O 
transfer O 
between O 
the O 
electrode O 
and O 
the O 
ferrocenyl B-TRIVIAL 
moieties O 
were O 
measured O 
for O 
the O 
monolayers O 
by O 
a O 
potential O 
- O 
step O 
chronoamperometry O 
technique O 
. O 
The O 
electron O 
conduction O 
through O 
the O 
molecular O 
wires O 
was O 
estimated O 
using O 
the O 
monolayers O 
as O 
a O 
bridge O 
from O 
the O 
Au(111) B-FORMULA 
metal O 
surface O 
to O 
the O 
gold O 
tip O 
of O 
a O 
conductive O 
atomic O 
force O 
microscope O 
( O 
CAFM O 
) O 
. O 
Using O 
the O 
CAFM O 
, O 
Coulomb O 
blockade O 
behavior O 
arising O 
from O 
the O 
capacitive O 
charging O 
of O 
the O 
multinuclear O 
redox O 
- O 
active O 
molecules O 
was O 
observed O 
at O 
room O 
temperature O 
. O 
The O 
conductance O 
switching O 
was O 
mediated O 
by O 
the O 
presence O 
of O 
various O 
ferrocenyl B-TRIVIAL 
redox O 
states O 
and O 
each O 
current O 
step O 
corresponded O 
to O 
a O 
specific O 
redox O 
state O 
. O 

organization O 
and O 
magnetic O 
properties O 
of O 
mesogen O 
- O 
hybridized O 
mixed O 
- O 
valent O 
manganese B-SYSTEMATIC 
single O 
molecule O 
magnets O 
[ O 
Mn(III)8Mn(IV)4O12(L(x,y,z-CB))16(H2O)4 B-FAMILY 
] O 
. O 

molecule O 
magnets O 
( O 
SMM O 
) O 
may O 
be O 
considered O 
for O 
the O 
construction O 
of O 
future O 
integrated O 
nanodevices O 
, O 
provided O 
however O 
that O 
some O 
degree O 
of O 
ordering O 
is O 
imparted O 
to O 
these O 
molecules O 
( O 
surfaces O 
nanostructuration O 
) O 
. O 
Combining O 
such O 
nanoobjects O 
with O 
liquid O 
- O 
crystalline O 
orderings O 
to O 
control O 
their O 
assembly O 
and O 
to O 
potentially O 
address O 
them O 
individually O 
therefore O 
appears O 
as O 
one O 
promising O 
strategy O 
. O 
Four O 
mesomorphic O 
, O 
mixed O 
- O 
valent O 
[ O 
Mn(III)(8)Mn(IV)(4)O(12)(L(x,y,z-CB))(16)(H(2)O)(4) B-FAMILY 
] O 
SMM O 
, O 
differing O 
in O 
the O 
number O 
of O 
liquid O 
- O 
crystalline O 
promoters O 
, O 
(L(x,y,z-CB)) O 
, O 
were O 
synthesized O 
, O 
and O 
their O 
self O 
- O 
organizing O 
and O 
magnetic O 
properties O 
were O 
investigated O 
. O 
The O 
influence O 
of O 
the O 
peripheral O 
modifications O 
, O 
and O 
precisely O 
how O 
supramolecular O 
ordering O 
and O 
magnetic O 
properties O 
may O 
be O 
affected O 
by O 
the O 
evolution O 
of O 
the O 
proto O 
- O 
mesogenic O 
cyanobiphenyl O 
- O 
based O 
ligands O 
substitution O 
pattern O 
, O 
was O 
explored O 
. O 
Small O 
- O 
angle O 
X-ray O 
scattering O 
studies O 
revealed O 
that O 
all O 
of O 
the O 
hybridized O 
clusters O 
self O 
- O 
organize O 
into O 
room O 
- O 
temperature O 
bilayer O 
smectic O 
phases O 
, O 
mandated O 
by O 
the O 
specific O 
mesogenic O 
functionalization O 
and O 
that O 
the O 
polymetallic O 
cores O 
are O 
further O 
organized O 
according O 
to O 
a O 
short O 
- O 
range O 
pseudo-2D O 
lattice O 
with O 
hexagonal O 
and O 
/ O 
or O 
square O 
symmetry O 
. O 
All O 
mesomorphous O 
hybridized O 
dodecamanganese B-SYSTEMATIC 
complexes O 
still O 
behave O 
as O 
SMM O 
: O 
they O 
exhibit O 
blocking O 
of O 
the O 
magnetization O 
at O 
about O 
2.6 O 
K O 
as O 
evidenced O 
by O 
the O 
occurrence O 
of O 
frequency O 
- O 
dependent O 
out O 
- O 
of O 
- O 
phase O 
ac O 
susceptibility O 
signals O 
as O 
well O 
as O 
an O 
opening O 
of O 
the O 
hysteresis O 
cycle O 
with O 
coercive O 
fields O 
varying O 
between O 
0.13 O 
and O 
0.6 O 
T O 
, O 
depending O 
on O 
the O 
surface O 
ligands O 
topology O 
. O 
Comparison O 
of O 
the O 
magnetic O 
properties O 
within O 
this O 
series O 
reveals O 
intricate O 
correlations O 
between O 
the O 
structural O 
features O 
of O 
the O 
mesomorphous O 
molecule O 
magnet O 
( O 
i.e O 
. O 
, O 
symmetry O 
of O 
the O 
ligands O 
substitution O 
patterns O 
, O 
molecular O 
conformation O 
, O 
average O 
intercluster O 
distances O 
, O 
and O 
respective O 
inclination O 
) O 
with O 
respect O 
to O 
the O 
relative O 
proportion O 
of O 
slow- O 
and O 
fast O 
- O 
relaxing O 
species O 
and O 
the O 
absolute O 
values O 
of O 
the O 
coercive O 
fields O 
. O 

of O 
ketorolac B-TRIVIAL 
administration O 
around O 
ovarian O 
stimulation O 
on O 
in O 
vivo O 
and O 
in O 
vitro O 
fertilization O 
and O 
subsequent O 
embryo O 
development O 
. O 

We O 
performed O 
this O 
study O 
to O 
investigate O 
the O 
effect O 
of O 
ketorolac B-TRIVIAL 
( O 
a O 
non-steroidal O 
anti-inflammatory O 
drug O 
) O 
administration O 
around O 
ovarian O 
stimulation O 
on O 
in O 
vivo O 
and O 
in O 
vitro O 
fertilization O 
process O 
. O 
Sixty O 
- O 
four O 
female O 
mice O 
( O 
ICR O 
) O 
were O 
injected O 
with O 
ketorolac B-TRIVIAL 
( O 
0 O 
, O 
7.5 O 
, O 
15 O 
and O 
30 O 
µg O 
/ O 
d O 
) O 
for O 
3 O 
d O 
starting O 
from O 
the O 
day O 
of O 
eCG O 
treatment O 
. O 
In O 
experiment O 
1 O 
, O 
41 O 
mice O 
were O 
triggered O 
by O 
hCG O 
and O 
then O 
mated O 
; O 
two O 
- O 
cell O 
embryos O 
were O 
obtained O 
and O 
in O 
vitro O 
development O 
up O 
to O 
blastocyst O 
was O 
observed O 
. O 
In O 
experiment O 
2 O 
, O 
23 O 
mice O 
were O 
triggered O 
by O 
hCG O 
and O 
mature O 
oocytes O 
were O 
collected O 
; O 
in O 
vitro O 
fertilization O 
rate O 
and O 
subsequent O 
embryo O 
development O 
up O 
to O 
blastocyst O 
was O 
recorded O 
. O 
In O 
experiment O 
1 O 
, O 
the O 
blastocyst O 
- O 
forming O 
rates O 
per O 
in O 
vivo O 
fertilized O 
two O 
- O 
cell O 
embryo O 
showed O 
an O 
inverse O 
relationship O 
with O 
a O 
dosage O 
of O 
ketorolac B-TRIVIAL 
( O 
97.6% O 
, O 
64.2% O 
, O 
35.4% O 
and O 
25.9% O 
) O 
. O 
In O 
experiment O 
2 O 
, O 
degenerated O 
oocytes O 
were O 
frequently O 
observed O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
( O 
4.3% O 
, O 
22.9% O 
, O 
22.4% O 
and O 
75.0% O 
) O 
. O 
Lower O 
fertilization O 
rates O 
were O 
noted O 
in O 
all O 
the O 
three O 
ketorolac B-TRIVIAL 
-treating O 
groups O 
; O 
blastocyst O 
- O 
forming O 
rate O 
was O 
significantly O 
lower O 
in O 
30-µg-treating O 
group O 
when O 
compared O 
with O 
the O 
control O 
group O 
. O 
Administration O 
of O 
ketorolac B-TRIVIAL 
around O 
ovarian O 
stimulation O 
significantly O 
affects O 
the O 
development O 
of O 
in O 
vivo O 
fertilized O 
embryo O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
High O 
- O 
dose O 
ketorolac B-TRIVIAL 
could O 
result O 
in O 
a O 
poor O 
oocyte O 
quality O 
and O 
decreased O 
embryo O 
developmental O 
competence O 
. O 

neurodegenerative O 
and O 
infectious O 
diseases O 
and O 
tumorigenesis O 
are O 
associated O 
with O 
alterations O 
in O 
ubiquitin O 
pathways O 
. O 
Over O 
10% O 
of O 
the O 
genome O 
encode O 
for O 
genes O 
that O 
either O 
bind O 
or O 
manipulate O 
ubiquitin O 
to O 
affect O 
a O 
large O 
proportion O 
of O 
biological O 
processes O 
. O 
This O 
has O 
been O 
the O 
basis O 
for O 
the O 
development O 
of O 
approaches O 
allowing O 
the O 
enrichment O 
of O 
ubiquitinated O 
proteins O 
for O 
comparisons O 
using O 
proteomics O 
and O 
mass O 
spectrometry O 
. O 
Tools O 
such O 
as O 
tagged O 
tandem O 
ubiquitin O 
binding O 
domains O 
, O 
chemically O 
derivatized O 
ubiquitin O 
or O 
anti- O 
gly B-FORMULA 
- I-FORMULA 
gly I-FORMULA 
- I-FORMULA 
lys I-FORMULA 
antibodies O 
combined O 
with O 
mass O 
spectrometry O 
have O 
contributed O 
to O 
surveys O 
of O 
poly O 
- O 
ubiquitinated O 
proteins O 
, O 
poly O 
- O 
ubiquitin O 
linkage O 
diversity O 
and O 
protein O 
ubiquitination O 
sites O 
and O 
their O 
relation O 
to O 
other O 
posttranslational O 
modifications O 
at O 
a O 
proteome O 
wide O 
level O 
, O 
providing O 
insights O 
in O 
to O 
how O 
dynamic O 
alterations O 
in O 
ubiquitination O 
and O 
deubiquitination O 
steps O 
are O 
associated O 
with O 
normal O 
physiology O 
and O 
pathogenesis O 
. O 

toxicity O 
of O 
many O 
metals O 
is O 
impacted O 
by O 
environmental O 
pH O 
, O 
through O 
both O 
competition O 
and O 
complexation O 
by O 
hydroxide B-SYSTEMATIC 
and O 
carbonate B-FAMILY 
ions O 
. O 
To O 
establish O 
safe O 
environmental O 
regulation O 
it O 
is O 
important O 
to O 
properly O 
define O 
the O 
relationship O 
between O 
pH O 
and O 
metal O 
toxicity O 
, O 
a O 
process O 
that O 
involves O 
manipulating O 
the O 
pH O 
of O 
test O 
water O 
in O 
the O 
lab O 
. O 
The O 
current O 
study O 
compares O 
the O 
effects O 
of O 
the O 
three O 
most O 
common O 
pH O 
manipulation O 
methods O 
( O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
, O 
acid O 
- O 
base O 
addition O 
, O 
and O 
chemical O 
buffers O 
) O 
on O 
acute O 
Pb B-FORMULA 
toxicity O 
of O 
a O 
model O 
fish O 
species O 
, O 
Pimephales O 
promelas O 
. O 
Acidification O 
of O 
test O 
water O 
revealed O 
that O 
the O 
Pb B-FORMULA 
and O 
Pb(2+) B-FORMULA 
LC50 O 
values O 
were O 
impacted O 
by O 
the O 
pH O 
manipulation O 
method O 
, O 
with O 
the O 
following O 
order O 
of O 
effects O 
: O 
HCl B-FORMULA 
< O 
CO2 O 
< O 
MOPS O 
. O 
Conversely O 
no O 
differences O 
in O 
toxicity O 
were O 
observed O 
when O 
test O 
pH O 
was O 
alkalinized O 
using O 
MOPS O 
or O 
NaOH O 
. O 
The O 
different O 
impacts O 
of O 
pH O 
manipulation O 
methods O 
on O 
Pb O 
toxicity O 
are O 
likely O 
due O 
to O 
different O 
physiological O 
stresses O 
resulting O 
from O 
the O 
respective O 
methods O 
; O 
the O 
physiological O 
implications O 
of O 
each O 
method O 
are O 
discussed O 
. O 
The O 
results O 
suggest O 
that O 
when O 
studying O 
the O 
impacts O 
of O 
pH O 
on O 
metal O 
toxicity O 
it O 
is O 
important O 
to O 
properly O 
replicate O 
the O 
ambient O 
conditions O 
of O 
interest O 
as O 
artificial O 
buffering O 
using O 
CO2 O 
environments O 
or O 
organic O 
buffers O 
significantly O 
affects O 
the O 
physiology O 
of O 
the O 
test O 
organisms O 
above O 
and O 
beyond O 
what O 
is O 
expected O 
from O 
pH O 
alone O 
. O 
Thus O 
, O 
using O 
CO2 O 
and O 
organic O 
buffers O 
overestimates O 
the O 
impact O 
of O 
acid O 
pH O 
on O 
Pb O 
toxicity O 
. O 

and O 
combined O 
effects O 
of O 
copper B-SYSTEMATIC 
and O 
parasitism O 
on O 
osmoregulation O 
in O 
the O 
European O 
eel O 
Anguilla O 
anguilla O 
. O 

European O 
eel O 
( O 
Anguilla O 
anguilla O 
) O 
, O 
a O 
catadromous O 
species O 
, O 
breeds O 
in O 
the O 
sea O 
and O 
migrates O 
to O 
estuarine O 
, O 
lagoon O 
or O 
freshwater O 
habitats O 
for O 
growth O 
and O 
development O 
. O 
Yellow O 
eels O 
, O 
exposed O 
to O 
low O 
or O 
fluctuating O 
salinities O 
, O 
are O 
also O 
exposed O 
to O 
multiple O 
other O 
stressors O 
as O 
pollution O 
, O 
over O 
- O 
fishing O 
and O 
parasitism O 
, O 
which O 
contribute O 
to O 
the O 
dramatic O 
decrease O 
of O 
eel O 
populations O 
in O 
several O 
European O 
countries O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
single O 
and O 
combined O 
effects O 
of O 
waterborne O 
copper B-SYSTEMATIC 
and O 
experimental O 
infestation O 
of O 
eels O 
with O 
the O 
nematode O 
Anguillicoloides O 
crassus O 
after O 
a O 
salinity O 
challenge O 
from O 
nearly O 
isotonic O 
( O 
18ppt O 
) O 
to O 
hypo- O 
( O 
5ppt O 
) O 
and O 
hypertonic O 
( O 
29ppt O 
) O 
conditions O 
, O 
in O 
order O 
to O 
investigate O 
the O 
osmoregulatory O 
capacity O 
of O 
eels O 
exposed O 
to O 
these O 
stressors O 
. O 
In O 
a O 
nearly O 
isotonic O 
condition O 
( O 
18ppt O 
) O 
, O 
blood O 
osmolality O 
remained O 
constant O 
over O 
the O 
6 O 
weeks O 
contamination O 
to O 
Cu(2+) B-FORMULA 
and O 
Anguillicoloides O 
crassus O 
. O 
In O 
fish O 
exposed O 
to O 
a O 
salinity O 
challenge O 
of O 
29ppt O 
for O 
2 O 
weeks O 
, O 
no O 
significant O 
effect O 
was O 
recorded O 
in O 
blood O 
osmolality O 
, O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
( O 
NKA O 
) O 
activity O 
, O 
Na(+) B-FORMULA 
and O 
Cl(-) B-FORMULA 
concentrations O 
. O 
After O 
2 O 
weeks O 
at O 
5ppt O 
however O 
, O 
a O 
significant O 
blood O 
osmolality O 
decrease O 
was O 
detected O 
in O 
fish O 
exposed O 
to O 
Anguillicoloides O 
crassus O 
infestation O 
with O 
or O 
without O 
Cu(2+) B-FORMULA 
addition O 
. O 
This O 
decrease O 
may O 
originate O 
from O 
lower O 
Cl(-) B-FORMULA 
levels O 
measured O 
in O 
eels O 
exposed O 
to O 
both O 
stressors O 
. O 
Blood O 
Na(+) B-FORMULA 
levels O 
remained O 
relatively O 
stable O 
in O 
all O 
tested O 
animals O 
, O 
but O 
gill O 
NKA O 
activities O 
were O 
lower O 
in O 
eels O 
exposed O 
to O 
combined O 
stress O 
. O 
No O 
apparent O 
branchial O 
lesions O 
were O 
detected O 
following O 
the O 
different O 
treatments O 
and O 
immunolocalization O 
of O 
NKA O 
revealed O 
well O 
- O 
differentiated O 
ionocytes O 
. O 
Thus O 
, O 
the O 
5ppt O 
challenge O 
in O 
eels O 
exposed O 
to O 
copper B-SYSTEMATIC 
and O 
Anguillicoloides O 
crassus O 
seems O 
to O 
clearly O 
enhance O 
iono O 
/ O 
osmoregulatory O 
disturbances O 
. O 
Funded O 
by O 
ANR O 
CES O 
/ O 
CIEL O 
2008-12 O 
. O 

physiology O 
and O 
reproductive O 
performance O 
of O 
eelpout O 
( O 
Zoarces O 
viviparus O 
) O 
have O 
been O 
monitored O 
along O 
the O 
Swedish O 
coast O 
for O 
more O 
than O 
three O 
decades O 
. O 
In O 
this O 
study O 
, O 
transcriptomic O 
profiling O 
was O 
applied O 
for O 
the O 
first O 
time O 
as O 
an O 
exploratory O 
tool O 
to O 
search O 
for O 
new O 
potential O 
candidate O 
biomarkers O 
and O 
to O 
investigate O 
possible O 
stress O 
responses O 
in O 
fish O 
collected O 
from O 
a O 
chronically O 
polluted O 
area O 
. O 
An O 
oligonucleotide O 
microarray O 
with O 
more O 
than O 
15000 O 
sequences O 
was O 
used O 
to O 
assess O 
differentially O 
expressed O 
hepatic O 
mRNA O 
levels O 
in O 
female O 
eelpout O 
collected O 
from O 
the O 
contaminated O 
area O 
at O 
Göteborg O 
harbor O 
compared O 
to O 
fish O 
from O 
a O 
national O 
reference O 
site O 
, O 
Fjällbacka O 
. O 
Genes O 
involved O 
in O 
apoptosis O 
and O 
DNA O 
damage O 
( O 
e.g O 
. O 
, O 
SMAC O 
/ O 
diablo O 
homolog O 
and O 
DDIT4 O 
/ O 
DNA-damage O 
- O 
inducible O 
protein O 
transcript O 
4 O 
) O 
had O 
higher O 
mRNA O 
expression O 
levels O 
in O 
eelpout O 
from O 
the O 
harbor O 
compared O 
to O 
the O 
reference O 
site O 
, O 
whereas O 
mRNA O 
expression O 
of O 
genes O 
involved O 
in O 
the O 
innate O 
immune O 
system O 
( O 
e.g O 
. O 
, O 
complement O 
components O 
and O 
hepcidin O 
) O 
and O 
protein O 
transport O 
/ O 
folding O 
( O 
e.g O 
. O 
, O 
signal O 
recognition O 
particle O 
and O 
protein O 
disulfide B-SYSTEMATIC 
-isomerase O 
) O 
were O 
expressed O 
at O 
lower O 
levels O 
. O 
Gene O 
Ontology O 
enrichment O 
analysis O 
revealed O 
that O 
genes O 
involved O 
biological O 
processes O 
associated O 
with O 
protein O 
folding O 
, O 
immune O 
responses O 
and O 
complement O 
activation O 
were O 
differentially O 
expressed O 
in O 
the O 
harbor O 
eelpout O 
compared O 
to O 
the O 
reference O 
site O 
. O 
The O 
differential O 
mRNA O 
expression O 
of O 
selected O 
genes O 
involved O 
in O 
apoptosis O 
/ O 
DNA O 
damage O 
and O 
in O 
the O 
innate O 
immune O 
system O 
was O 
verified O 
by O 
quantitative O 
PCR O 
, O 
using O 
the O 
same O 
fish O 
in O 
addition O 
to O 
eelpout O 
captured O 
four O 
years O 
later O 
. O 
Thus O 
, O 
our O 
approach O 
has O 
identified O 
new O 
potential O 
biomarkers O 
of O 
pollutant O 
exposure O 
and O 
has O 
generated O 
hypotheses O 
on O 
disturbed O 
physiological O 
processes O 
in O 
eelpout O 
. O 
Despite O 
a O 
higher O 
mRNA O 
expression O 
of O 
genes O 
related O 
to O 
apoptosis O 
( O 
e.g O 
. O 
, O 
diablo O 
homolog O 
) O 
in O 
eelpout O 
captured O 
in O 
the O 
harbor O 
there O 
were O 
no O 
significant O 
differences O 
in O 
the O 
number O 
of O 
TUNEL-positive O 
apoptotic O 
cells O 
between O 
sites O 
. O 
The O 
mRNA O 
level O 
of O 
genes O 
involved O 
in O 
apoptosis O 
/ O 
DNA O 
damage O 
and O 
the O 
status O 
of O 
the O 
innate O 
immune O 
system O 
in O 
fish O 
species O 
captured O 
in O 
polluted O 
environments O 
should O 
be O 
studied O 
in O 
more O 
detail O 
to O 
lay O 
the O 
groundwork O 
for O 
future O 
biomonitoring O 
studies O 
. O 

protocol O 
was O 
developed O 
for O 
testing O 
the O 
ecotoxicological O 
effects O 
of O 
volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
on O 
groundwater O 
invertebrates O 
. O 
Test O 
substance O 
volatility O 
was O 
addressed O 
in O 
a O 
" O 
closed O 
from O 
start O 
to O 
analysis"-design O 
. O 
Since O 
manifestation O 
of O 
toxic O 
effects O 
may O 
be O 
delayed O 
in O 
' O 
slower O 
metabolizing O 
' O 
organisms O 
such O 
as O 
groundwater O 
fauna O 
, O 
a O 
time O 
- O 
independent O 
( O 
TI- O 
) O 
approach O 
was O 
adopted O 
. O 
Toluene B-TRIVIAL 
was O 
used O 
as O 
a O 
model O 
substance O 
and O 
its O 
toxicity O 
to O 
the O 
groundwater O 
amphipod O 
Niphargus O 
inopinatus O 
was O 
assessed O 
as O 
an O 
example O 
. O 
The O 
method O 
evaluation O 
process O 
considered O 
various O 
methodological O 
issues O 
such O 
as O 
partitioning O 
of O 
the O 
toxicant O 
between O 
the O 
water O 
and O 
the O 
gas O 
phase O 
( O 
Henry O 
equilibrium O 
) O 
, O 
the O 
possible O 
depletion O 
of O 
oxygen B-SYSTEMATIC 
in O 
closed O 
test O 
vials O 
, O 
as O 
well O 
as O 
microbial O 
biodegradation O 
of O 
the O 
test O 
substance O 
. O 
For O 
N O 
. O 
inopinatus O 
, O 
an O 
LC50,14 O 
days O 
of O 
46.6mgL(-1) O 
toluene B-TRIVIAL 
was O 
obtained O 
. O 
The O 
ultimate O 
LC50 O 
value O 
was O 
estimated O 
at O 
23.3mgL(-1) O 
toluene B-TRIVIAL 
. O 
No O 
oxygen B-SYSTEMATIC 
depletion O 
occurred O 
in O 
the O 
test O 
vials O 
and O 
Henry O 
equilibrium O 
was O 
found O 
to O 
be O 
established O 
after O 
6h O 
. O 
The O 
new O 
test O 
system O 
proposed O 
now O 
awaits O 
broad O 
practical O 
application O 
. O 

rationally O 
designed O 
dual O 
role O 
anode O 
material O 
for O 
lithium B-SYSTEMATIC 
-ion O 
and O 
sodium B-SYSTEMATIC 
-ion O 
batteries O 
: O 
case O 
study O 
of O 
eco O 
- O 
friendly O 
Fe3O4 B-FORMULA 
. O 

dual O 
role O 
electrode O 
materials O 
capable O 
of O 
storing O 
both O 
lithium B-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
are O 
thought O 
to O 
be O 
highly O 
relevant O 
, O 
as O 
these O 
materials O 
could O 
find O 
potential O 
applications O 
simultaneously O 
in O 
lithium B-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
ion O 
batteries O 
. O 
In O 
this O 
regard O 
, O 
the O 
concept O 
of O 
dual O 
alkali O 
storage O 
is O 
demonstrated O 
in O 
Fe(3)O(4) B-FORMULA 
anode O 
material O 
undergoing O 
conversion O 
reaction O 
. O 
To O 
enable O 
improved O 
storage O 
, O 
a O 
rational O 
active O 
material O 
and O 
electrode O 
design O 
is O 
proposed O 
. O 
Accordingly O 
, O 
the O 
following O 
features O 
were O 
simultaneously O 
incorporated O 
into O 
the O 
design O 
: O 
(i) O 
an O 
optimal O 
particle O 
size O 
, O 
(ii) O 
a O 
conducting O 
matrix O 
, O 
(iii) O 
adequately O 
large O 
active O 
material O 
surface O 
area O 
and O 
(iv) O 
strong O 
electrode O 
material O 
- O 
current O 
collector O 
integrity O 
. O 
Electrodes O 
incorporating O 
this O 
rational O 
design O 
exhibit O 
excellent O 
high O 
rate O 
performance O 
and O 
impressive O 
cyclability O 
during O 
lithium B-SYSTEMATIC 
storage O 
. O 
For O 
instance O 
, O 
Fe(3)O(4) B-FORMULA 
electrodes O 
deliver O 
a O 
charge O 
capacity O 
of O 
950 O 
mAh O 
g(-1) O 
at O 
1.2 O 
C O 
( O 
~2.6 O 
times O 
higher O 
than O 
graphite B-TRIVIAL 
and O 
5.4 O 
times O 
higher O 
than O 
Li(4)Ti(5)O(12) B-FORMULA 
) O 
. O 
Further O 
, O 
these O 
electrodes O 
show O 
no O 
signs O 
of O 
capacity O 
fade O 
even O 
up O 
to O 
1100 O 
cycles O 
. O 
Impressively O 
, O 
the O 
cells O 
could O 
also O 
be O 
charged O 
- O 
discharged O 
to O 
65% O 
of O 
their O 
theoretical O 
capacity O 
in O 
just O 
5 O 
min O 
or O 
12 O 
C O 
( O 
11.11 O 
A O 
g(-1) O 
) O 
. O 
The O 
rate O 
performance O 
and O 
cyclability O 
of O 
lithium B-SYSTEMATIC 
storage O 
achieved O 
here O 
are O 
amongst O 
the O 
highest O 
reported O 
values O 
in O 
the O 
literature O 
for O 
the O 
conversion O 
reaction O 
in O 
Fe(3)O(4) B-FORMULA 
. O 
Besides O 
lithium B-SYSTEMATIC 
storage O 
, O 
the O 
dual O 
role O 
of O 
this O 
anode O 
is O 
shown O 
by O 
demonstrating O 
its O 
sodium B-SYSTEMATIC 
storage O 
ability O 
by O 
conversion O 
reaction O 
for O 
the O 
first O 
time O 
. O 

broadly O 
tunable O 
GaZnSeAs B-FORMULA 
alloy O 
nanowires O 
. O 

- O 
tunable O 
semiconductor O 
alloy O 
nanowires O 
are O 
emerging O 
as O 
an O 
important O 
class O 
of O 
materials O 
for O 
the O 
realization O 
of O 
high O 
- O 
performance O 
laterally O 
- O 
arranged O 
multiple O 
bandgap O 
( O 
LAMB O 
) O 
solar O 
cells O 
. O 
Here O 
we O 
report O 
the O 
first O 
growth O 
of O 
GaZnSeAs B-FORMULA 
quaternary O 
alloy O 
nanowires O 
with O 
composed O 
elements O 
between O 
two O 
different O 
groups O 
using O 
a O 
temperature O 
/ O 
space O 
- O 
selective O 
CVD O 
route O 
. O 
Under O 
laser O 
excitation O 
, O 
these O 
special O 
quaternary O 
alloy O 
nanowires O 
exhibit O 
composition O 
- O 
related O 
characteristic O 
emissions O 
, O 
with O 
peak O 
wavelengths O 
gradually O 
tunable O 
from O 
470 O 
nm O 
( O 
2.64 O 
eV O 
) O 
to O 
832 O 
nm O 
( O 
1.49 O 
eV O 
) O 
, O 
covering O 
almost O 
the O 
entire O 
visible O 
spectrum O 
. O 
Surface O 
photovoltage O 
measurements O 
further O 
reveal O 
that O 
these O 
alloy O 
nanowires O 
have O 
tunable O 
bandgaps O 
along O 
the O 
length O 
of O 
the O 
substrate O 
, O 
making O 
them O 
promising O 
candidates O 
for O 
developing O 
high O 
- O 
efficiency O 
LAMB O 
solar O 
cells O 
. O 
These O 
quaternary O 
alloy O 
nanowires O 
represent O 
a O 
new O 
advancement O 
in O 
material O 
synthesis O 
and O 
would O 
have O 
potential O 
applications O 
in O 
a O 
variety O 
of O 
function O 
- O 
tunable O 
and O 
broadband O 
- O 
response O 
optoelectronic O 
devices O 
. O 

bottom O 
- O 
up O 
approach O 
is O 
introduced O 
to O 
fabricate O 
two O 
- O 
dimensional O 
self O 
- O 
assembled O 
layers O 
of O 
molecular O 
spin O 
- O 
systems O 
containing O 
Mn B-FORMULA 
and O 
Fe B-FORMULA 
ions O 
arranged O 
in O 
a O 
chessboard O 
lattice O 
. O 
We O 
demonstrate O 
that O 
the O 
Mn B-FORMULA 
and O 
Fe B-FORMULA 
spin O 
states O 
can O 
be O 
reversibly O 
operated O 
by O 
their O 
selective O 
response O 
to O 
coordination O 
/ O 
decoordination O 
of O 
volatile O 
ligands O 
like O 
ammonia B-SYSTEMATIC 
( O 
NH3 B-FORMULA 
) O 
. O 

of O 
acute O 
and O 
sub O 
- O 
chronic O 
nicotine B-TRIVIAL 
on O 
impulsive O 
choice O 
in O 
rats O 
in O 
a O 
probabilistic O 
delay O 
- O 
discounting O 
task O 
. O 

: O 
Cigarette O 
smokers O 
typically O 
display O 
impulsivity O 
by O 
preferring O 
immediate O 
rewards O 
over O 
larger O 
, O 
delayed O 
rewards O 
at O 
shorter O 
delays O 
than O 
do O 
non-smokers O 
. O 
Suggesting O 
causality O 
, O 
nicotine B-TRIVIAL 
injections O 
in O 
rats O 
increase O 
the O 
choice O 
for O 
an O 
immediate O 
reward O 
over O 
a O 
larger O 
, O 
delayed O 
reward O 
. O 
OBJECTIVES O 
: O 
To O 
examine O 
the O 
generality O 
of O 
this O 
latter O 
effect O 
, O 
the O 
present O 
study O 
employed O 
a O 
delay O 
- O 
discounting O 
task O 
to O 
determine O 
if O 
acute O 
and O 
sub O 
- O 
chronic O 
nicotine B-TRIVIAL 
will O 
also O 
increase O 
impulsive O 
choice O 
when O 
subjective O 
reward O 
value O 
is O 
manipulated O 
by O 
changes O 
in O 
the O 
probability O 
, O 
rather O 
than O 
magnitude O 
, O 
of O 
reward O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Rats O 
were O 
presented O 
with O 
two O 
levers O 
, O 
one O 
of O 
which O 
delivered O 
an O 
immediate O 
water O 
reward O 
on O 
half O 
of O 
the O 
trials O 
, O 
while O 
the O 
other O 
lever O 
delivered O 
the O 
same O 
reward O 
on O 
every O 
trial O 
, O 
but O 
only O 
after O 
one O 
of O 
five O 
increasing O 
delays O 
. O 
RESULTS O 
: O 
Acute O 
injections O 
of O 
1.2 O 
mg O 
/ O 
kg O 
, O 
but O 
not O 
0.8 O 
mg O 
/ O 
kg O 
, O 
of O 
nicotine B-TRIVIAL 
increased O 
the O 
preference O 
for O 
the O 
immediate O 
( O 
but O 
less O 
certain O 
) O 
reward O 
lever O 
at O 
intermediate O 
delays O 
. O 
Moreover O 
, O 
twice O 
- O 
daily O 
injections O 
of O 
0.8 O 
mg O 
/ O 
kg O 
of O 
nicotine B-TRIVIAL 
for O 
6 O 
days O 
progressively O 
increased O 
the O 
preference O 
for O 
the O 
immediate O 
reward O 
. O 
Latency O 
to O 
make O 
the O 
first O 
response O 
on O 
each O 
trial O 
was O 
not O 
affected O 
by O 
nicotine B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
The O 
similar O 
increases O 
in O 
impulsive O 
choice O 
produced O 
by O 
both O 
acute O 
and O 
sub O 
- O 
chronic O 
nicotine B-TRIVIAL 
in O 
delay O 
- O 
discounting O 
paradigms O 
whether O 
subjective O 
reward O 
value O 
is O 
manipulated O 
by O 
changes O 
in O 
reward O 
magnitude O 
or O 
probability O 
suggests O 
that O 
nicotine B-TRIVIAL 
may O 
be O 
increasing O 
what O 
is O 
common O 
to O 
these O 
paradigms O 
, O 
namely O 
delay O 
discounting O 
. O 
Whatever O 
the O 
mechanism O 
, O 
these O 
data O 
indicate O 
that O 
both O 
acute O 
and O 
sub O 
- O 
chronic O 
nicotine B-TRIVIAL 
may O 
help O 
develop O 
and O 
maintain O 
an O 
addiction O 
by O 
increasing O 
impulsivity O 
. O 

refined O 
aquatic O 
ecological O 
risk O 
assessment O 
for O 
a O 
pyrethroid B-FAMILY 
insecticide O 
used O 
for O 
adult O 
mosquito O 
management O 
. O 

use O 
of O 
pyrethroid B-FAMILY 
insecticides O 
has O 
increased O 
substantially O 
throughout O 
the O 
world O 
over O 
the O 
past O 
few O 
decades O 
as O 
the O 
use O 
of O 
organophorous B-FAMILY 
, O 
carbamate B-FAMILY 
, O 
and O 
organochlorine B-FAMILY 
insecticides O 
is O 
being O 
phased O 
out O 
. O 
Pyrethroids B-FAMILY 
are O 
the O 
most O 
common O 
class O 
of O 
insecticides O 
for O 
ultralow O 
- O 
volume O 
( O 
ULV O 
) O 
aerosol O 
applications O 
used O 
to O 
manage O 
high O 
densities O 
of O 
adult O 
mosquitoes O 
. O 
Pyrethroids B-FAMILY 
are O 
highly O 
toxic O 
to O 
nontarget O 
organisms O 
such O 
as O 
certain O 
aquatic O 
organisms O 
, O 
and O 
there O 
have O 
been O 
concerns O 
about O 
the O 
effect O 
of O 
applications O 
of O 
ULV O 
insecticides O 
on O 
these O 
organisms O 
. O 
To O 
address O 
the O 
uncertainties O 
associated O 
with O 
the O 
risks O 
of O 
ULV O 
applications O 
and O 
the O 
contradictory O 
findings O 
of O 
other O 
ecological O 
risk O 
assessments O 
, O 
the O 
authors O 
performed O 
a O 
probabilistic O 
aquatic O 
ecological O 
risk O 
assessment O 
for O 
permethrin B-TRIVIAL 
using O 
actual O 
environmental O 
deposition O 
on O 
surfaces O 
to O 
estimate O 
permethrin B-TRIVIAL 
concentrations O 
in O 
water O 
. O 
The O 
present O 
study O 
is O 
the O 
first O 
ecological O 
risk O 
assessment O 
for O 
pyrethroids B-FAMILY 
to O 
quantitatively O 
integrate O 
the O 
reduction O 
in O 
bioavailability O 
resulting O 
from O 
the O 
presence O 
of O 
dissolved O 
organic O 
matter O 
. O 
As O 
part O 
of O 
the O 
risk O 
assessment O 
, O 
the O 
authors O 
incorporated O 
a O 
species O 
sensitivity O 
distribution O 
to O 
take O 
into O 
account O 
the O 
differences O 
in O 
toxicity O 
for O 
different O 
species O 
. O 
The O 
95th O 
percentile O 
estimated O 
concentration O 
would O 
result O 
in O 
less O 
than O 
0.0001% O 
of O 
the O 
potentially O 
affected O 
fraction O 
of O 
species O 
reaching O 
the O 
lethal O 
concentration O 
that O 
kills O 
50% O 
of O 
a O 
population O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
are O 
supported O 
by O 
the O 
weight O 
of O 
evidence O 
that O 
pyrethroids B-FAMILY 
applied O 
by O 
ground O 
- O 
based O 
ULV O 
equipment O 
will O 
not O 
result O 
in O 
deleterious O 
effects O 
on O 
aquatic O 
organisms O 
. O 

nanoparticle O 
toxicity O 
effect O 
on O 
growth O 
and O 
cellular O 
viability O 
of O 
the O 
aquatic O 
plant O 
Lemna O 
gibba O 
. O 

toxicity O 
effect O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
on O 
growth O 
and O 
cellular O 
viability O 
was O 
investigated O 
on O 
the O 
aquatic O 
plant O 
Lemna O 
gibba O 
exposed O 
over O 
7 O 
d O 
to O 
0 O 
, O 
0.01 O 
, O 
0.1 O 
, O 
1 O 
, O 
and O 
10 O 
mg O 
/ O 
L O 
of O 
AgNPs O 
. O 
Growth O 
inhibition O 
was O 
demonstrated O 
by O 
a O 
significant O 
decrease O 
of O 
frond O 
numbers O 
dependent O 
on O 
AgNP O 
concentration O 
. O 
Under O 
these O 
conditions O 
, O 
reduction O 
in O 
plant O 
cellular O 
viability O 
was O 
detected O 
for O 
0.1 O 
, O 
1 O 
, O 
and O 
10 O 
mg O 
/ O 
L O 
of O 
AgNPs O 
within O 
7 O 
d O 
of O 
AgNPs O 
treatment O 
. O 
This O 
effect O 
was O 
highly O 
correlated O 
with O 
the O 
production O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
A O 
significant O 
increase O 
of O 
intracellular O 
ROS O 
formation O 
was O 
triggered O 
by O 
1 O 
and O 
10 O 
mg O 
/ O 
L O 
of O 
AgNP O 
exposure O 
. O 
The O 
induced O 
oxidative O 
stress O 
was O 
related O 
to O 
Ag B-FORMULA 
accumulation O 
within O 
L O 
. O 
gibba O 
plant O 
cells O 
and O 
with O 
the O 
increasing O 
concentration O 
of O 
AgNP O 
exposure O 
in O 
the O 
medium O 
. O 
The O 
authors O 
' O 
results O 
clearly O 
suggested O 
that O 
AgNP O 
suspension O 
represented O 
a O 
potential O 
source O 
of O 
toxicity O 
for O 
L O 
. O 
gibba O 
plant O 
cells O 
. O 
Due O 
to O 
the O 
low O 
release O 
capacity O 
of O 
free O 
soluble O 
Ag B-FORMULA 
from O 
AgNP O 
dissolution O 
in O 
the O 
medium O 
, O 
it O 
is O 
most O 
likely O 
that O 
the O 
intracellular O 
uptake O 
of O 
Ag B-FORMULA 
was O 
directly O 
from O 
AgNPs O 
, O 
triggering O 
cellular O 
oxidative O 
stress O 
that O 
may O 
be O 
due O 
to O 
the O 
release O 
of O 
free O 
Ag B-FORMULA 
inside O 
plant O 
cells O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
demonstrated O 
that O 
AgNP O 
accumulation O 
in O 
an O 
aquatic O 
environment O 
may O 
represent O 
a O 
potential O 
source O 
of O 
toxicity O 
and O 
a O 
risk O 
for O 
the O 
viability O 
of O 
duckweeds O 
. O 

effects O 
of O 
environment-friendly O 
antifoulant O 
nonivamide B-TRIVIAL 
on O 
Phaeodactylum O 
tricornutum O 
. O 

, O 
a O 
synthetic O 
derivate O 
of O 
natural O 
capsaicin B-TRIVIAL 
, O 
has O 
an O 
effective O 
antifouling O 
activity O 
. O 
However O 
, O 
the O 
poor O 
understanding O 
of O 
the O 
toxicity O 
mechanism O 
limits O 
the O 
application O 
of O 
nonivamide B-TRIVIAL 
in O 
antifouling O 
paints O 
. O 
The O 
present O 
study O 
investigated O 
the O 
inhibitory O 
effects O 
and O 
toxicity O 
mechanism O 
of O 
nonivamide B-TRIVIAL 
on O 
Phaeodactylum O 
tricornutum O 
. O 
Under O 
a O 
1.5 O 
× O 
10(5) O 
cells O 
/ O 
ml O 
of O 
initial O 
algal O 
density O 
( O 
IAD O 
) O 
, O 
the O 
effective O 
concentration O 
causing O 
50% O 
inhibition O 
at O 
4- O 
d O 
( O 
4 O 
d-EC50 O 
) O 
value O 
of O 
nonivamide B-TRIVIAL 
was O 
5.1 O 
mg O 
/ O 
L O 
. O 
Reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
level O 
was O 
significantly O 
increased O 
in O 
nonivamide B-TRIVIAL 
-treated O 
algae O 
. O 
Algal O 
antioxidants O 
, O 
including O 
catalases O 
( O 
CAT O 
) O 
, O 
peroxidases O 
( O 
POD O 
) O 
, O 
superoxide B-TRIVIAL 
dismutases O 
( O 
SOD O 
) O 
, O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
were O 
all O 
stimulated O 
by O 
the O 
ROS O 
burst O 
. O 
The O 
excessive O 
ROS O 
substances O 
led O 
to O 
the O 
loss O 
of O 
algal O 
photosynthetic O 
pigments O 
and O 
also O 
damage O 
to O 
the O 
integrity O 
of O 
the O 
lipid O 
membrane O 
. O 
Furthermore O 
, O 
ROS O 
- O 
related O 
genes O 
, O 
including O 
psbA O 
, O 
psbD O 
, O 
psaB O 
, O 
rbcL O 
, O 
nad1 O 
, O 
and O 
cob O 
, O 
were O 
found O 
to O 
be O 
suppressed O 
in O 
the O 
chloroplasts O 
and O 
mitochondria O 
of O 
nonivamide B-TRIVIAL 
-treated O 
algae O 
, O 
and O 
the O 
concentration O 
of O 
cytoplasmic O 
Ca(2+) B-FORMULA 
, O 
an O 
important O 
regulator O 
of O 
chloroplast O 
and O 
mitochondrion O 
, O 
was O 
elevated O 
. O 
The O 
present O 
study O 
demonstrates O 
that O 
nonivamide B-TRIVIAL 
could O 
cause O 
peroxidative O 
damages O 
to O 
P O 
. O 
tricornutum O 
by O 
inducing O 
ROS O 
overproduction O 
, O 
which O 
may O 
be O 
initiated O 
by O 
the O 
suppression O 
of O 
ROS O 
- O 
related O 
genes O 
in O 
algal O 
chloroplasts O 
and O 
mitochondria O 
. O 

for O 
different O 
fluorescence O 
response O 
of O 
a O 
coumarin B-TRIVIAL 
- O 
amide B-FAMILY 
- O 
dipicolylamine B-FAMILY 
linkage O 
to O 
Zn B-FORMULA 
(II) I-FORMULA 
and O 
Cd B-FORMULA 
(II) I-FORMULA 
in O 
water O 
. O 

coumarin B-TRIVIAL 
- O 
amide B-FAMILY 
- O 
dipicolylamine B-FAMILY 
linkage O 
( O 
L O 
) O 
was O 
synthesized O 
and O 
used O 
as O 
a O 
fluorescent O 
receptor O 
for O 
metal O 
cations O 
in O 
water O 
. O 
The O 
receptor O 
dissolved O 
in O 
water O 
with O 
neutral O 
pH O 
shows O 
almost O 
no O 
fluorescence O 
due O 
to O 
the O 
photoinduced O 
electron O 
transfer O 
( O 
PET O 
) O 
from O 
the O 
amide B-MULTIPLE 
and I-MULTIPLE 
amine I-MULTIPLE 
nitrogens I-MULTIPLE 
to O 
the O 
excited O 
state O 
coumarin B-TRIVIAL 
moiety O 
. O 
Coordination O 
of O 
Zn(2+) B-FORMULA 
or O 
Cd(2+) B-FORMULA 
with O 
L O 
creates O 
strong O 
fluorescence O 
at O 
437 O 
or O 
386 O 
nm O 
, O 
respectively O 
, O 
due O 
to O 
the O 
suppression O 
of O 
PET O 
. O 
In O 
contrast O 
, O 
other O 
metal O 
cations O 
scarcely O 
show O 
fluorescence O 
enhancement O 
. O 
IR O 
, O 
NMR O 
, O 
and O 
potentiometric O 
analysis O 
revealed O 
that O 
both O 
Zn(2+) B-FORMULA 
and O 
Cd(2+) B-FORMULA 
are O 
coordinated O 
with O 
two O 
pyridine B-SYSTEMATIC 
N B-FORMULA 
, O 
amine B-SYSTEMATIC 
N B-FORMULA 
, O 
and O 
amide B-FAMILY 
O B-FORMULA 
; O 
however O 
, O 
the O 
Zn(2+) B-FORMULA 
center O 
is O 
also O 
coordinated O 
with O 
a O 
hydroxide B-SYSTEMATIC 
anion O 
( O 
OH(-) B-FORMULA 
) O 
. O 
The O 
structure O 
difference O 
for O 
Zn B-FORMULA 
and O 
Cd B-FORMULA 
complexes O 
results O 
in O 
longer- O 
and O 
shorter O 
- O 
wavelength O 
fluorescence O 
. O 
Ab O 
initio O 
calculations O 
revealed O 
that O 
π O 
electrons O 
on O 
the O 
excited O 
state O 
Cd B-FORMULA 
complex O 
are O 
delocalized O 
over O 
the O 
molecules O 
and O 
the O 
Cd B-FORMULA 
complex O 
shows O 
shorter O 
- O 
wavelength O 
emission O 
. O 
In O 
contrast O 
, O 
π O 
electrons O 
of O 
OH(-) B-FORMULA 
-coordinated O 
Zn B-FORMULA 
complex O 
are O 
localized O 
on O 
the O 
coumarin B-TRIVIAL 
moiety O 
. O 
This O 
increases O 
the O 
electron O 
density O 
of O 
coumarin B-TRIVIAL 
moiety O 
and O 
shows O 
longer O 
- O 
wavelength O 
fluorescence O 
. O 

have O 
been O 
investigating O 
complexes O 
composed O 
of O 
nanolayered O 
materials O 
with O 
anionic O 
charges O 
such O 
as O 
clay O 
nanosheets O 
and O 
dye O 
molecules O 
such O 
as O 
cationic O 
porphyrins B-FAMILY 
. O 
It O 
was O 
found O 
that O 
the O 
structure O 
of O 
dye O 
assembly O 
on O 
the O 
layered O 
materials O 
can O 
be O 
effectively O 
controlled O 
by O 
the O 
use O 
of O 
electrostatic O 
host O 
- O 
guest O 
interaction O 
. O 
The O 
intermolecular O 
distance O 
, O 
the O 
molecular O 
orientation O 
angle O 
, O 
the O 
segregation O 
/ O 
integration O 
behavior O 
, O 
and O 
the O 
immobilization O 
strength O 
of O 
the O 
dyes O 
can O 
be O 
controlled O 
in O 
the O 
clay O 
- O 
dye O 
complexes O 
. O 
The O 
mechanism O 
to O 
control O 
these O 
structural O 
factors O 
has O 
been O 
discussed O 
and O 
was O 
established O 
as O 
a O 
size O 
- O 
matching O 
effect O 
. O 
Unique O 
photochemical O 
reactions O 
such O 
as O 
energy O 
transfer O 
through O 
the O 
use O 
of O 
this O 
methodology O 
have O 
been O 
examined O 
. O 
Almost O 
100% O 
efficiency O 
of O 
the O 
energy O 
- O 
transfer O 
reaction O 
was O 
achieved O 
in O 
the O 
clay- O 
porphyrin B-FAMILY 
complexes O 
as O 
a O 
typical O 
example O 
for O 
an O 
artificial O 
light O 
- O 
harvesting O 
system O 
. O 
Control O 
of O 
the O 
molecular O 
orientation O 
angle O 
is O 
found O 
to O 
be O 
useful O 
in O 
regulating O 
the O 
energy O 
- O 
transfer O 
efficiency O 
and O 
in O 
preparing O 
photofunctional O 
materials O 
exhibiting O 
solvatochromic O 
behavior O 
. O 
Through O 
our O 
study O 
, O 
clay O 
minerals O 
turned O 
out O 
to O 
serve O 
as O 
protein O 
- O 
like O 
media O 
to O 
control O 
the O 
molecular O 
position O 
, O 
modify O 
the O 
properties O 
of O 
the O 
molecule O 
, O 
and O 
provide O 
a O 
unique O 
environment O 
for O 
chemical O 
reactions O 
. O 

directed O 
self O 
- O 
assembly O 
of O 
3-miktoarm O 
star O 
terpolymer O 
chains O 
( O 
polyisoprene B-SYSTEMATIC 
-arm- O 
polystyrene B-SYSTEMATIC 
-arm- O 
polyferrocenylethylmethylsilane B-SYSTEMATIC 
( O 
3 B-ABBREVIATION 
μ-ISF I-ABBREVIATION 
) O 
) O 
into O 
2D O 
Archimedean O 
tilings O 
is O 
described O 
. O 
A O 
morphological O 
change O 
from O 
(4.8(2)) O 
to O 
(6(3)) O 
tiling O 
is O 
reported O 
in O 
the O 
3 B-ABBREVIATION 
μ-ISF I-ABBREVIATION 
thin O 
film O 
blended O 
with O 
PS O 
homopolymer O 
when O 
a O 
greater O 
swelling O 
of O 
PI O 
is O 
achieved O 
during O 
the O 
solvent O 
annealing O 
process O 
. O 
Highly O 
oriented O 
(4.8(2)) O 
tilings O 
were O 
produced O 
by O 
templating O 
the O 
self O 
- O 
assembled O 
three O 
colored O 
structures O 
in O 
blended O 
thin O 
films O 
. O 
The O 
use O 
of O 
(4.8(2)) O 
and O 
(6(3)) O 
tilings O 
as O 
nanolithographic O 
masks O 
to O 
transfer O 
square O 
and O 
triangular O 
hole O 
arrays O 
into O 
the O 
substrate O 
is O 
also O 
demonstrated O 
. O 

optical O 
Faraday O 
rotations O 
of O 
semiconductor O 
EuS B-FORMULA 
nanocrystals O 
with O 
paramagnetic O 
transition B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
ions O 
. O 

EuS B-FORMULA 
nanocrystals O 
containing O 
paramagnetic O 
Mn B-FORMULA 
(II) I-FORMULA 
, O 
Co B-FORMULA 
(II) I-FORMULA 
, O 
or O 
Fe B-FORMULA 
(II) I-FORMULA 
ions O 
have O 
been O 
reported O 
as O 
advanced O 
semiconductor O 
materials O 
with O 
effective O 
optical O 
rotation O 
under O 
a O 
magnetic O 
field O 
, O 
Faraday O 
rotation O 
. O 
EuS B-FORMULA 
nanocrystals O 
with O 
transition O 
- O 
metal O 
ions O 
, O 
EuS B-FORMULA 
:M O 
nanocrystals O 
, O 
were O 
prepared O 
by O 
the O 
reduction O 
of O 
the O 
Eu B-FORMULA 
(III) I-FORMULA 
dithiocarbamate B-SYSTEMATIC 
complex O 
tetraphenylphosphonium B-SYSTEMATIC 
tetrakis(diethyldithiocarbamate)europium I-SYSTEMATIC 
(III) I-SYSTEMATIC 
with O 
transition B-FAMILY 
- I-FAMILY 
metal I-FAMILY 
complexes O 
at O 
300 O 
°C O 
. O 
The O 
EuS B-FORMULA 
:M O 
nanocrystals O 
thus O 
prepared O 
were O 
characterized O 
using O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
, O 
inductively O 
coupled O 
plasma O 
atomic O 
emission O 
spectroanalysis O 
( O 
ICP-AES O 
) O 
, O 
and O 
a O 
superconducting O 
quantum O 
interference O 
device O 
( O 
SQUID O 
) O 
magnetometer O 
. O 
Enhanced O 
Faraday O 
rotations O 
of O 
the O 
EuS B-FORMULA 
:M O 
nanocrystals O 
were O 
observed O 
around O 
550 O 
nm O 
, O 
and O 
their O 
enhanced O 
spin O 
polarization O 
was O 
estimated O 
using O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
measurements O 
. O 
In O 
this O 
report O 
, O 
the O 
magneto O 
- O 
optical O 
relationship O 
between O 
the O 
Faraday O 
rotation O 
efficiency O 
and O 
spin O 
polarization O 
is O 
discussed O 
. O 

monolayers O 
of O 
corannulene B-FAMILY 
penta I-FAMILY 
- I-FAMILY 
thioethers I-FAMILY 
on O 
gold O 
. O 

and O 
penta(4-dimethylaminophenylthio)corannulene B-SYSTEMATIC 
form O 
highly O 
stable O 
monolayers O 
on O 
gold O 
surfaces O 
, O 
as O 
indicated O 
by O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
Formation O 
of O 
these O 
homogeneous O 
monolayers O 
involves O 
multivalent O 
coordination O 
of O 
the O 
five O 
sulfur B-SYSTEMATIC 
atoms O 
to O 
gold O 
with O 
the O 
peripheral O 
alkyl O 
or O 
aryl O 
substituents O 
pointing O 
away O 
from O 
the O 
surface O 
. O 
No O 
dissociation O 
of O 
C-S B-FORMULA 
bonds O 
upon O 
binding O 
could O 
be O 
observed O 
at O 
room O 
temperature O 
. O 
Yet O 
, O 
the O 
XPS O 
experiments O 
reveal O 
strong O 
chemical O 
bonding O 
between O 
the O 
thioether B-SYSTEMATIC 
groups O 
and O 
gold O 
. O 
Temperature O 
- O 
dependent O 
XPS O 
study O 
shows O 
that O 
the O 
thermal O 
stability O 
of O 
the O 
monolayers O 
is O 
higher O 
than O 
the O 
typical O 
stability O 
of O 
self O 
- O 
assembled O 
monolayers O 
( O 
SAMs O 
) O 
of O 
thiolates B-FAMILY 
on O 
gold O 
. O 

aim O 
was O 
to O 
explore O 
weight O 
and O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
changes O 
by O 
baseline O 
BMI O 
in O 
patients O 
completing O 
three O 
years O 
of O 
monotherapy O 
with O 
various O 
first- O 
and O 
second O 
- O 
generation O 
antipsychotics O 
in O 
a O 
large O 
cohort O 
in O 
a O 
post O 
hoc O 
analysis O 
of O 
three O 
- O 
year O 
observational O 
data O 
. O 
Data O 
were O 
analyzed O 
by O 
antipsychotic O 
and O 
three O 
baseline O 
BMI O 
bands O 
: O 
underweight O 
/ O 
normal O 
weight O 
( O 
BMI O 
< O 
25 O 
kg O 
/ O 
m(2) O 
) O 
, O 
overweight O 
( O 
25-30 O 
kg O 
/ O 
m(2) O 
) O 
and O 
obese O 
( O 
> O 
30 O 
kg O 
/ O 
m(2) O 
) O 
. O 
Baseline O 
BMI O 
was O 
associated O 
with O 
subsequent O 
weight O 
change O 
irrespective O 
of O 
the O 
antipsychotic O 
given O 
. O 
Specifically O 
, O 
a O 
smaller O 
proportion O 
of O 
patients O 
gained O 
≥ O 
7% O 
baseline O 
bodyweight O 
, O 
and O 
a O 
greater O 
proportion O 
of O 
patients O 
lost O 
≥ O 
7% O 
baseline O 
bodyweight O 
with O 
increasing O 
baseline O 
BMI O 
. O 
For O 
olanzapine B-TRIVIAL 
( O 
the O 
antipsychotic O 
associated O 
with O 
highest O 
mean O 
weight O 
gain O 
in O 
the O 
total O 
drug O 
cohort O 
) O 
, O 
the O 
percentage O 
of O 
patients O 
gaining O 
≥ O 
7% O 
baseline O 
weight O 
was O 
45% O 
( O 
95% O 
CI O 
: O 
43-48 O 
) O 
in O 
the O 
underweight O 
/ O 
normal O 
weight O 
BMI O 
cohort O 
and O 
20% O 
( O 
95% O 
CI O 
: O 
15-27 O 
) O 
in O 
the O 
obese O 
BMI O 
cohort O 
; O 
7% O 
( O 
95% O 
CI O 
: O 
6-8 O 
) O 
of O 
the O 
underweight O 
/ O 
normal O 
cohort O 
and O 
19% O 
( O 
95% O 
CI O 
: O 
13-27 O 
) O 
of O 
the O 
obese O 
cohort O 
lost O 
≥ O 
7% O 
baseline O 
weight O 
. O 
BMI O 
has O 
an O 
association O 
with O 
the O 
likelihood O 
of O 
weight O 
gain O 
or O 
loss O 
and O 
should O 
be O 
considered O 
in O 
analyses O 
of O 
antipsychotic O 
weight O 
change O 
. O 

catalysis O 
and O 
homogeneous O 
catalysis O 
offer O 
complementary O 
means O 
to O 
address O 
synthetic O 
challenges O 
, O 
both O 
in O 
chemistry O 
and O 
in O 
biology O 
. O 
Despite O 
its O 
attractiveness O 
, O 
the O 
implementation O 
of O 
concurrent O 
cascade O 
reactions O 
that O 
combine O 
an O 
organometallic O 
catalyst O 
with O 
an O 
enzyme O 
has O 
proven O 
challenging O 
because O 
of O 
the O 
mutual O 
inactivation O 
of O 
both O 
catalysts O 
. O 
To O 
address O 
this O 
, O 
we O 
show O 
that O 
incorporation O 
of O 
a O 
d(6)-piano O 
stool O 
complex O 
within O 
a O 
host O 
protein O 
affords O 
an O 
artificial O 
transfer O 
hydrogenase O 
( O 
ATHase O 
) O 
that O 
is O 
fully O 
compatible O 
with O 
and O 
complementary O 
to O 
natural O 
enzymes O 
, O 
thus O 
enabling O 
efficient O 
concurrent O 
tandem O 
catalysis O 
. O 
To O 
illustrate O 
the O 
generality O 
of O 
the O 
approach O 
, O 
the O 
ATHase O 
was O 
combined O 
with O 
various O 
NADH B-ABBREVIATION 
- O 
, O 
FAD B-ABBREVIATION 
- O 
and O 
haem B-TRIVIAL 
-dependent O 
enzymes O 
, O 
resulting O 
in O 
orthogonal O 
redox O 
cascades O 
. O 
Up O 
to O 
three O 
enzymes O 
were O 
integrated O 
in O 
the O 
cascade O 
and O 
combined O 
with O 
the O 
ATHase O 
with O 
a O 
view O 
to O 
achieving O 
(i) O 
a O 
double O 
stereoselective O 
amine B-SYSTEMATIC 
deracemization O 
, O 
(ii) O 
a O 
horseradish O 
peroxidase O 
- O 
coupled O 
readout O 
of O 
the O 
transfer O 
hydrogenase O 
activity O 
towards O 
its O 
genetic O 
optimization O 
, O 
(iii) O 
the O 
formation O 
of O 
L-pipecolic B-TRIVIAL 
acid I-TRIVIAL 
from O 
L-lysine B-TRIVIAL 
and O 
(iv) O 
regeneration O 
of O 
NADH B-ABBREVIATION 
to O 
promote O 
a O 
monooxygenase O 
- O 
catalysed O 
oxyfunctionalization O 
reaction O 
. O 

modulation O 
of O 
cell O 
energy O 
by O 
2-deoxyglucose B-SYSTEMATIC 
and O 
malonate B-TRIVIAL 
in O 
7,12-dimethylbenz(a)anthracene B-SYSTEMATIC 
-induced O 
carcinogenesis O 
in O 
rats O 
. O 

goal O 
of O 
this O 
study O 
was O 
to O 
explore O 
the O 
impact O 
of O 
2-deoxglucose B-SYSTEMATIC 
or O 
malonate B-TRIVIAL 
individually O 
or O 
in O 
combination O 
on O 
the O 
level O 
of O 
cell O 
energy O 
( O 
adenosine-5'-triphosphate B-SYSTEMATIC 
) O 
and O 
oxidative O 
stress O 
in O 
7,12-dimethylbenz(a)anthracene B-SYSTEMATIC 
( O 
DMBA B-ABBREVIATION 
)-induced O 
mammary O 
proliferation O 
in O 
rats O 
. O 
A O 
total O 
of O 
60 O 
adult O 
female O 
Sprague O 
Dawley O 
rats O 
were O 
randomly O 
divided O 
into O 
five O 
groups O 
( O 
12 O 
rats O 
each O 
) O 
: O 
group O 
I O 
serves O 
as O 
the O 
control O 
group O 
. O 
Rats O 
in O 
groups O 
( O 
II-V O 
) O 
were O 
administrated O 
intragastrically O 
a O 
single O 
dose O 
of O 
50 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
of O 
DMBA B-ABBREVIATION 
. O 
A O 
day O 
after O 
DMBA B-ABBREVIATION 
administration O 
, O 
rats O 
in O 
group O 
III O 
were O 
injected O 
intraperitoneally O 
( O 
ip O 
) O 
with O 
100 O 
mg O 
2-deoxyglucose B-SYSTEMATIC 
( O 
2-DG B-ABBREVIATION 
) O 
/ O 
kg O 
bw O 
daily O 
. O 
Rats O 
in O 
group O 
IV O 
were O 
injected O 
ip O 
with O 
10 O 
mg O 
sodium B-SYSTEMATIC 
malonate I-SYSTEMATIC 
/ O 
kg O 
bw O 
daily O 
. O 
Rats O 
in O 
group O 
V O 
were O 
injected O 
ip O 
with O 
100 O 
mg O 
2-DG O 
/ O 
kg O 
bw O 
and O 
10 O 
mg O 
sodium B-SYSTEMATIC 
malonate I-SYSTEMATIC 
/ O 
kg O 
bw O 
( O 
treatment O 
for O 
90 O 
days O 
) O 
. O 
The O 
results O 
obtained O 
showed O 
that O 
DMBA B-ABBREVIATION 
induced O 
oxidative O 
stress O 
by O 
decreasing O 
the O 
activities O 
of O 
glutathione B-TRIVIAL 
reductase O 
( O 
GRase O 
) O 
and O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
and O 
elevating O 
the O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO O 
) O 
in O 
mammary O 
tissues O 
when O 
compared O 
with O 
control O 
. O 
The O 
combined O 
treatment O 
protected O 
against O 
the O 
previous O 
deleterious O 
changes O 
by O 
a O 
significant O 
elevation O 
in O 
the O 
activities O 
of O 
GRase O 
and O 
SOD O 
, O 
GPx O 
and O 
lowering O 
the O 
levels O 
of O 
MDA B-ABBREVIATION 
and O 
NO B-FORMULA 
more O 
potentially O 
when O 
compared O 
with O 
individual O 
treatment O 
. O 
Apoptosis O 
, O 
as O 
indicated O 
by O 
a O 
significant O 
release O 
of O 
cytochrome O 
c O 
from O 
mitochondria O 
into O 
the O 
cytosol O 
, O 
observed O 
in O 
DMBA B-ABBREVIATION 
-injected O 
rats O 
was O 
positively O 
significantly O 
correlated O 
with O 
the O 
elevation O 
of O 
the O 
level O 
of O 
NO B-FORMULA 
. O 
These O 
data O 
explained O 
the O 
possible O 
additive O 
effect O 
of O 
2-DG B-ABBREVIATION 
and O 
malonate B-TRIVIAL 
by O 
depleting O 
the O 
cell O 
energy O 
by O 
their O 
protective O 
effects O 
against O 
the O 
earlier O 
stages O 
of O 
carcinogenesis O 
. O 

work O 
examines O 
the O 
crude O 
methanolic O 
extracts O 
of O 
three O 
medicinally O 
important O 
plants O 
native O 
to O 
Pakistan O 
for O 
potent O 
phytotoxic O 
activities O 
and O 
important O 
phytochemicals O 
. O 
These O 
plants O 
include O 
Euphorbia O 
wallichii O 
, O 
Bergenia O 
ciliata O 
and O 
Phytolacca O 
latbenia O 
. O 
The O 
phytotoxic O 
effects O 
were O 
checked O 
at O 
10000 O 
, O 
1000 O 
, O 
and O 
100 O 
µg O 
/ O 
ml O 
against O 
two O 
economically O 
important O 
standard O 
target O 
species O 
, O 
Triticum O 
aestivum O 
( O 
monocot O 
representative O 
) O 
and O 
Brassica O 
napus O 
( O 
dicot O 
representative O 
) O 
. O 
The O 
phytotoxicity O 
effects O 
on O 
seed O 
germination O 
, O 
seedling O 
growth O 
and O 
seedling O 
weight O 
were O 
checked O 
. O 
A O 
simple O 
, O 
cost O 
- O 
effective O 
in O 
vitro O 
phytotoxicity O 
assay O 
( O 
that O 
uses O 
petri O 
plates O 
) O 
was O 
used O 
to O 
evaluate O 
the O 
allelopathic O 
properties O 
of O 
crude O 
extracts O 
. O 
At O 
highest O 
concentration O 
, O 
extracts O 
from O 
all O 
the O 
three O 
plants O 
showed O 
phytotoxic O 
activities O 
such O 
that O 
P O 
. O 
latbenia O 
> O 
E O 
. O 
wallichii O 
> O 
B O 
. O 
ciliata O 
. O 
In O 
seedling O 
growth O 
, O 
root O 
length O 
was O 
affected O 
more O 
than O 
shoot O 
length O 
, O 
whereas O 
among O 
the O 
target O 
species O 
B O 
. O 
napus O 
was O 
found O 
to O 
be O 
more O 
sensitive O 
towards O 
extracts O 
when O 
compared O 
with O 
T O 
. O 
aestivum O 
. O 
Phytochemical O 
analysis O 
showed O 
that O 
P O 
. O 
latbenia O 
is O 
rich O 
in O 
saponins B-FAMILY 
and O 
terpenoids B-FAMILY 
, O 
while O 
E O 
. O 
wallichii O 
and O 
B O 
. O 
ciliata O 
are O 
rich O 
in O 
tannins B-FAMILY 
, O 
terpenoids B-FAMILY 
and O 
cardiac O 
glycoside O 
. O 
P O 
. O 
latbenia O 
also O 
carries O 
a O 
moderate O 
amount O 
of O 
cardiac O 
glycosides O 
. O 

accumulation O 
of O 
heavy O 
metals O 
such O 
as O 
lead O 
( O 
Pb B-FORMULA 
) O 
, O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
, O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
, O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
, O 
and O 
chromium B-SYSTEMATIC 
( O 
Cr B-FORMULA 
) O 
was O 
examined O 
in O 
crab O 
( O 
Scylla O 
serrata O 
) O 
and O 
shrimps O 
( O 
Penaeus O 
semisulcatus O 
, O 
Penaeus O 
indicus O 
, O 
and O 
Penaeus O 
monodon O 
) O 
collected O 
from O 
Pulicat O 
lake O 
that O 
receives O 
effluents O 
from O 
industries O 
located O 
in O 
north O 
Chennai O 
, O 
southeast O 
coast O 
of O 
India O 
. O 
The O 
results O 
showed O 
limited O 
difference O 
between O 
crab O 
and O 
prawns O 
as O 
well O 
as O 
significant O 
variations O 
between O 
the O 
organs O 
. O 
Pb B-FORMULA 
is O 
the O 
highly O 
accumulated O 
metal O 
in O 
both O 
crab O 
and O 
shrimps O 
, O 
except O 
P O 
. O 
monodon O 
. O 
The O 
highest O 
metal O 
concentration O 
was O 
mostly O 
found O 
in O 
the O 
liver O 
followed O 
by O 
other O 
organs O 
. O 
The O 
concentration O 
of O 
metals O 
in O 
edible O 
parts O 
( O 
muscle O 
) O 
was O 
within O 
the O 
permissible O 
level O 
and O 
safe O 
for O 
consumption O 
. O 
However O 
, O 
the O 
results O 
of O 
the O 
study O 
clearly O 
indicate O 
the O 
biomagnification O 
of O 
metals O 
in O 
Pulicat O 
lake O 
. O 

gene O 
expression O 
and O 
bioinformatics O 
analysis O 
of O 
copper B-SYSTEMATIC 
resistance O 
gene O 
afe_1073 O 
in O 
Acidithiobacillus O 
ferrooxidans O 
. O 

resistance O 
of O 
acidophilic O 
bacteria O 
is O 
very O 
significant O 
in O 
bioleaching O 
of O 
copper B-SYSTEMATIC 
ore O 
since O 
high O 
concentration O 
of O 
copper B-SYSTEMATIC 
are O 
harmful O 
to O 
the O 
growth O 
of O 
organisms O 
. O 
Copper B-SYSTEMATIC 
resistance O 
gene O 
afe_1073 O 
was O 
putatively O 
considered O 
to O 
be O 
involved O 
in O 
copper B-SYSTEMATIC 
homeostasis O 
in O 
Acidithiobacillus O 
ferrooxidans O 
ATCC23270 O 
. O 
In O 
the O 
present O 
study O 
, O 
differential O 
expression O 
of O 
afe_1073 O 
in O 
A O 
. O 
ferrooxidans O 
strain O 
DY26 O 
and O 
DC O 
was O 
assessed O 
with O 
quantitative O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
. O 
The O 
results O 
showed O 
the O 
expression O 
of O 
afe_1073 O 
in O 
two O 
strains O 
increased O 
with O 
the O 
increment O 
of O 
copper B-SYSTEMATIC 
concentrations O 
. O 
The O 
expression O 
of O 
DY26 O 
was O 
lower O 
than O 
that O 
of O 
DC O 
at O 
the O 
same O 
copper B-SYSTEMATIC 
concentration O 
although O 
A O 
. O 
ferrooxidans O 
strain O 
DY26 O 
possessed O 
higher O 
copper B-SYSTEMATIC 
resistance O 
than O 
strain O 
DC O 
. O 
In O 
addition O 
, O 
bioinformatics O 
analysis O 
showed O 
AFE_1073 O 
was O 
a O 
typical O 
transmembrane O 
protein O 
P1b1-ATPase O 
, O 
which O 
could O 
reduce O 
the O 
harm O 
of O 
Cu(+) B-FORMULA 
by O 
pumping O 
it O 
out O 
from O 
the O 
cell O 
. O 
There O 
were O 
two O 
mutation O 
sites O 
in O 
AFE_1073 O 
between O 
DY26 O 
and O 
DC O 
and O 
one O 
may O 
change O 
the O 
hydrophobicity O 
of O 
AFE_1073 O 
, O 
which O 
could O 
enhance O 
the O 
ability O 
of O 
DY26 O 
to O 
pump O 
out O 
Cu(+) B-FORMULA 
. O 
Therefore O 
, O 
DY26 O 
needed O 
less O 
gene O 
expression O 
of O 
afe_1073 O 
for O 
resisting O 
copper B-SYSTEMATIC 
toxicity O 
than O 
that O 
of O 
DC O 
at O 
the O 
same O 
copper B-SYSTEMATIC 
stress O 
. O 
Our O 
study O 
will O 
be O 
beneficial O 
to O 
understanding O 
the O 
copper B-SYSTEMATIC 
resistance O 
mechanism O 
of O 
A O 
. O 
ferrooxidans O 
. O 

synthesis O 
in O 
patients O 
with O 
congenital O 
adrenal O 
hyperplasia O 
due O 
to O 
21-hydroxylase O 
deficiency O 
. O 

hallmark O 
of O 
severe O 
congenital O 
adrenal O 
hyperplasia O 
due O 
to O 
21-hydroxylase O 
deficiency O 
is O 
pre- O 
and O 
postnatal O 
virilization O 
. O 
The O 
most O 
characteristic O 
biochemical O 
abnormality O 
is O 
the O 
elevation O 
of O 
17α-hydroxyprogesterone B-SYSTEMATIC 
, O 
which O 
is O 
metabolized O 
to O 
the O 
most O 
potent O 
androgen B-FAMILY 
receptor O 
agonist O 
dihydrotestosterone B-SYSTEMATIC 
. O 
17α-Hydroxyprogesterone B-SYSTEMATIC 
can O 
be O 
metabolized O 
to O 
dihydrotestosterone B-SYSTEMATIC 
via O 
4-androstenedione B-SYSTEMATIC 
through O 
the O 
classical O 
Δ4-pathway O 
or O 
via O 
17α-hydroxypregnenolone B-SYSTEMATIC 
and O 
dehydroepiandrosterone B-TRIVIAL 
through O 
the O 
classical O 
Δ5-pathway O 
, O 
as O 
well O 
as O 
through O 
an O 
alternative O 
route O 
, O 
called O 
the O 
' O 
backdoor O 
pathway O 
' O 
, O 
that O 
bypasses O 
dehydroepiandrosterone B-TRIVIAL 
, O 
4-androstenedione B-SYSTEMATIC 
, O 
and O 
testosterone B-TRIVIAL 
as O 
intermediates O 
. O 
This O 
review O 
article O 
will O 
summarize O 
recent O 
advances O 
in O 
the O 
understanding O 
of O 
the O 
activities O 
of O 
androgen B-FAMILY 
synthesis O 
pathways O 
in O 
patients O 
with O 
21-hydroxylase O 
deficiency O 
obtained O 
by O 
urinary O 
steroid B-FAMILY 
metabolomics O 
based O 
on O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 
Compared O 
with O 
healthy O 
controls O 
, O 
the O 
relative O 
activities O 
of O 
the O 
backdoor O 
and O 
Δ4-pathways O 
increase O 
in O 
patients O 
with O 
congenital O 
adrenal O 
hyperplasia O 
during O 
neonatal O 
age O 
and O 
infancy O 
, O 
whereas O 
the O 
activity O 
of O 
the O 
Δ5-pathway O 
remains O 
unchanged O 
. O 
Thereafter O 
, O 
the O 
activity O 
of O 
the O 
Δ5-pathway O 
dominates O 
, O 
whereas O 
a O 
decreasing O 
5α-reductase O 
activity O 
leads O 
to O 
a O 
diminished O 
role O 
of O 
the O 
backdoor O 
pathway O 
for O 
androgenic O 
steroid B-FAMILY 
production O 
. O 
Beside O 
the O 
backdoor O 
pathway O 
, O 
the O 
Δ4-pathway O 
seems O 
to O 
be O 
responsible O 
for O 
increased O 
androgen B-FAMILY 
generation O 
in O 
patients O 
with O 
21-hydroxylase O 
deficiency O 
before O 
the O 
onset O 
of O 
adrenarche O 
, O 
whereas O 
the O 
Δ5-pathway O 
might O 
contribute O 
to O 
the O 
increased O 
androgen B-FAMILY 
formation O 
in O 
those O 
patients O 
only O 
after O 
the O 
onset O 
of O 
adrenarche O 
. O 

Ising O 
- O 
type O 
magnetic O 
anisotropy O 
in O 
trigonal B-FAMILY 
bipyramidal I-FAMILY 
Ni I-FAMILY 
(II) I-FAMILY 
complexes O 
: O 
experiment O 
and O 
theory O 
. O 

paper O 
reports O 
the O 
experimental O 
and O 
theoretical O 
investigations O 
of O 
two O 
trigonal B-FAMILY 
bipyramidal I-FAMILY 
Ni I-FAMILY 
(II) I-FAMILY 
complexes O 
, O 
[Ni(Me(6)tren)Cl](ClO(4)) B-FORMULA 
( O 
1 O 
) O 
and O 
[Ni(Me(6)tren)Br](Br) B-FORMULA 
( O 
2 O 
) O 
. O 
High O 
- O 
field O 
, O 
high O 
- O 
frequency O 
electron O 
paramagnetic O 
resonance O 
spectroscopy O 
performed O 
on O 
a O 
single O 
crystal O 
of O 
1 O 
shows O 
a O 
giant O 
uniaxial O 
magnetic O 
anisotropy O 
with O 
an O 
experimental O 
D(expt) O 
value O 
( O 
energy O 
difference O 
between O 
the O 
M(s) O 
= O 
± O 
1 O 
and O 
M(s) O 
= O 
0 O 
components O 
of O 
the O 
ground O 
spin O 
state O 
S O 
= O 
1 O 
) O 
estimated O 
to O 
be O 
between O 
-120 O 
and O 
-180 O 
cm(-1) O 
. O 
The O 
theoretical O 
study O 
shows O 
that O 
, O 
for O 
an O 
ideally O 
trigonal O 
Ni B-FORMULA 
(II) I-FORMULA 
complex O 
, O 
the O 
orbital O 
degeneracy O 
leads O 
to O 
a O 
first O 
- O 
order O 
spin O 
- O 
orbit O 
coupling O 
that O 
results O 
in O 
a O 
splitting O 
of O 
the O 
M(s) O 
= O 
± O 
1 O 
and O 
M(s) O 
= O 
0 O 
components O 
of O 
approximately O 
-600 O 
cm(-1) O 
. O 
Despite O 
the O 
Jahn-Teller O 
distortion O 
that O 
removes O 
the O 
ground O 
term O 
degeneracy O 
and O 
reduces O 
the O 
effects O 
of O 
the O 
first O 
- O 
order O 
spin O 
- O 
orbit O 
interaction O 
, O 
the O 
D O 
value O 
remains O 
very O 
large O 
. O 
A O 
good O 
agreement O 
between O 
theoretical O 
and O 
experimental O 
results O 
( O 
theoretical O 
D(theor) O 
between O 
-100 O 
and O 
-200 O 
cm(-1) O 
) O 
is O 
obtained O 
. O 

- O 
healing O 
hydrogels O 
can O 
be O 
made O 
using O 
either O 
reversible O 
covalent O 
cross O 
- O 
links O 
or O 
coordination O 
chemistry O 
bonds O 
. O 
Here O 
we O 
present O 
a O 
multi-pH-responsive O 
system O 
inspired O 
by O 
the O 
chemistry O 
of O 
blue O 
mussel O 
adhesive O 
proteins O 
. O 
By O 
attaching O 
DOPA B-ABBREVIATION 
to O 
an O 
amine B-SYSTEMATIC 
-functionalized O 
polymer O 
, O 
a O 
multiresponsive O 
system O 
is O 
formed O 
upon O 
reaction O 
with O 
iron B-SYSTEMATIC 
. O 
The O 
degree O 
of O 
polymer O 
cross O 
- O 
linking O 
is O 
pH O 
controlled O 
through O 
the O 
pH-dependent O 
DOPA B-ABBREVIATION 
/ O 
iron B-SYSTEMATIC 
coordination O 
chemistry O 
. O 
This O 
leads O 
to O 
the O 
formation O 
of O 
rapidly O 
self O 
- O 
healing O 
high O 
- O 
strength O 
hydrogels O 
when O 
pH O 
is O 
raised O 
from O 
acidic O 
toward O 
basic O 
values O 
. O 
Close O 
to O 
the O 
pK(a) O 
value O 
, O 
or O 
more O 
precisely O 
the O 
pI O 
value O 
, O 
of O 
the O 
polymer O 
, O 
the O 
gel O 
collapses O 
due O 
to O 
reduced O 
repulsion O 
between O 
polymer O 
chains O 
. O 
Thereby O 
a O 
bistable O 
gel O 
- O 
system O 
is O 
obtained O 
. O 
The O 
present O 
polymer O 
system O 
more O 
closely O 
resembles O 
mussel O 
adhesive O 
proteins O 
than O 
those O 
previously O 
reported O 
and O 
thus O 
also O 
serves O 
as O 
a O 
model O 
system O 
for O 
mussel O 
adhesive O 
chemistry O 
. O 

of O 
hydrogen B-SYSTEMATIC 
bonding O 
on O 
internal O 
conversion O 
of O 
GFP O 
- O 
like O 
chromophores O 
. O 
I O 
. O 
The O 
para-amino B-SYSTEMATIC 
systems O 
. O 

understand O 
the O 
effects O 
of O 
solvent-solute O 
hydrogen B-SYSTEMATIC 
bonding O 
( O 
SSHB O 
) O 
on O 
the O 
excited O 
- O 
state O 
dynamics O 
of O 
two O 
GFP O 
- O 
like O 
chromophores O 
, O 
p-ABDI O 
and O 
p-CFABDI O 
, O 
we O 
have O 
determined O 
the O 
quantum O 
yields O 
for O 
fluorescence O 
( O 
Φf O 
) O 
and O 
the O 
isomerization O 
Z O 
→ O 
E O 
( O 
ΦZE O 
) O 
and O 
the O 
femtosecond O 
fluorescence O 
and O 
transient O 
infrared O 
absorption O 
in O 
selected O 
solvents O 
. O 
The O 
behavior O 
that O 
ΦZE O 
≅ O 
0.5 O 
in O 
aprotic O 
solvents O 
, O 
such O 
as O 
CH3CN B-FORMULA 
, O 
indicates O 
that O 
the O 
E-Z O 
photoisomerization O 
adopts O 
a O 
one O 
- O 
bond O 
- O 
flip O 
mechanism O 
through O 
the O 
torsion O 
of O 
the O 
exocyclic O 
C═C B-FORMULA 
bond O 
( O 
the O 
τ O 
torsion O 
) O 
to O 
form O 
a O 
perpendicular O 
species O 
( O 
τ O 
∼90° O 
) O 
in O 
the O 
singlet O 
excited O 
state O 
followed O 
by O 
internal O 
conversion O 
( O 
IC O 
) O 
to O 
the O 
ground O 
state O 
and O 
partition O 
to O 
form O 
the O 
E O 
and O 
Z O 
isomers O 
with O 
equal O 
probabilities O 
. O 
The O 
observed O 
ΦZE O 
decreased O 
from O 
0.5 O 
to O 
0.15-0.28 O 
when O 
CH3CN B-FORMULA 
was O 
replaced O 
with O 
the O 
protic O 
solvents O 
CH3OH B-FORMULA 
and O 
CF3CH2OH B-FORMULA 
. O 
In O 
conjunction O 
with O 
the O 
solvent O 
- O 
independent O 
rapid O 
( O 
< O 
1 O 
ps O 
) O 
kinetics O 
for O 
the O 
fluorescence O 
decay O 
and O 
the O 
solvent-dependent O 
slow O 
( O 
7-20 O 
ps O 
) O 
kinetics O 
for O 
the O 
ground O 
- O 
state O 
recovery O 
, O 
we O 
conclude O 
that O 
the O 
SSHB O 
modifies O 
the O 
potential O 
energy O 
surface O 
for O 
the O 
τ O 
torsion O 
in O 
a O 
way O 
that O 
the O 
IC O 
occurs O 
also O 
for O 
the O 
twisted O 
intermediates O 
with O 
a O 
τ-torsion O 
angle O 
smaller O 
than O 
90° O 
, O 
which O 
favors O 
the O 
formation O 
of O 
the O 
Z O 
isomers O 
. O 
The O 
possibility O 
of O 
IC O 
induced O 
by O 
torsion O 
of O 
the O 
exocyclic O 
C-C B-FORMULA 
bond O 
( O 
the O 
φ O 
torsion O 
) O 
is O 
also O 
considered O 
but O 
excluded O 
. O 

describe O 
a O 
stable O 
and O 
functional O 
model O 
biological O 
membrane O 
based O 
on O 
a O 
polymerized O 
lipid O 
bilayer O 
with O 
a O 
chemically O 
modified O 
surface O 
. O 
A O 
polymerized O 
lipid O 
bilayer O 
was O 
formed O 
from O 
a O 
mixture O 
of O 
two O 
diacetylene B-SYSTEMATIC 
-containing O 
phospholipids O 
, O 
1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DiynePC B-ABBREVIATION 
) O 
and O 
1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphoethanolamine B-SYSTEMATIC 
( O 
DiynePE B-ABBREVIATION 
) O 
. O 
DiynePC B-ABBREVIATION 
formed O 
a O 
stable O 
bilayer O 
structure O 
, O 
whereas O 
the O 
ethanolamine B-SYSTEMATIC 
headgroup O 
of O 
DiynePE B-ABBREVIATION 
enabled O 
functional O 
molecules O 
to O 
be O 
grafted O 
onto O 
the O 
membrane O 
surface O 
. O 
Copolymerization O 
of O 
DiynePC B-ABBREVIATION 
and O 
DiynePE B-ABBREVIATION 
resulted O 
in O 
a O 
robust O 
bilayer O 
. O 
Functionalization O 
of O 
the O 
polymeric O 
bilayer O 
provided O 
a O 
route O 
to O 
a O 
robust O 
and O 
biomimetic O 
surface O 
that O 
can O 
be O 
linked O 
with O 
biomolecules O 
, O 
cells O 
, O 
and O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
microstructures O 
. O 
Biotin O 
and O 
peptides O 
were O 
grafted O 
onto O 
the O 
polymeric O 
bilayer O 
for O 
attaching O 
streptavidin O 
and O 
cultured O 
mammalian O 
cells O 
by O 
molecular O 
recognition O 
, O 
respectively O 
. O 
Nonspecific O 
adsorption O 
of O 
proteins O 
and O 
cells O 
on O 
polymeric O 
bilayers O 
was O 
minimum O 
. O 
DiynePE B-ABBREVIATION 
was O 
also O 
used O 
to O 
attach O 
a O 
microstructure O 
made O 
of O 
an O 
elastomer O 
( O 
polydimethylsiloxan B-SYSTEMATIC 
: O 
PDMS B-ABBREVIATION 
) O 
onto O 
the O 
membrane O 
, O 
forming O 
a O 
confined O 
aqueous O 
solution O 
between O 
the O 
two O 
surfaces O 
. O 
The O 
microcompartment O 
enabled O 
us O 
to O 
assay O 
the O 
activity O 
of O 
a O 
membrane O 
- O 
bound O 
enzyme O 
( O 
cyochrome O 
P450 O 
) O 
. O 
Natural O 
( O 
fluid O 
) O 
lipid O 
bilayers O 
were O 
incorporated O 
together O 
with O 
membrane O 
- O 
bound O 
proteins O 
by O 
lithographically O 
polymerizing O 
DiynePC B-ABBREVIATION 
/ O 
DiynePE B-ABBREVIATION 
bilayers O 
. O 
The O 
hybrid O 
membrane O 
of O 
functionalized O 
polymeric O 
bilayers O 
and O 
fluid O 
bilayers O 
offers O 
a O 
novel O 
platform O 
for O 
a O 
wide O 
range O 
of O 
biomedical O 
applications O 
including O 
biosensor O 
, O 
bioassay O 
, O 
cell O 
culture O 
, O 
and O 
cell O 
- O 
based O 
assay O 
. O 

-loaded O 
microcapsules O 
ameliorate O 
experimental O 
colitis O 
in O 
mice O 
by O 
anti-inflammatory O 
and O 
antioxidant O 
mechanisms O 
. O 

( O 
1 O 
) O 
is O 
an O 
anti-inflammatory O 
and O 
antioxidant O 
flavonoid B-FAMILY 
. O 
However O 
, O 
the O 
oral O 
administration O 
of O 
1 O 
did O 
not O 
lead O 
to O 
beneficial O 
effects O 
in O 
experimental O 
animal O 
colitis O 
models O 
, O 
which O 
involve O 
cytokines O 
and O 
oxidative O 
stress O 
. O 
A O 
possible O 
explanation O 
is O 
that O 
the O 
absorption O 
profile O 
of O 
1 O 
prevents O 
its O 
activity O 
. O 
Therefore O 
, O 
it O 
was O 
reasoned O 
that O 
the O 
controlled O 
release O 
of O 
1 O 
would O 
improve O 
its O 
therapeutic O 
effect O 
. O 
Thus O 
, O 
the O 
therapeutic O 
effect O 
and O 
mechanisms O 
of O 
1-loaded O 
microcapsules O 
in O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
colitis O 
in O 
mice O 
were O 
evaluated O 
. O 
Microcapsules O 
were O 
prepared O 
using O 
pectin O 
/ O 
casein O 
polymer O 
and O 
1 O 
. O 
The O 
oral O 
administration O 
of O 
1-loaded O 
microcapsules O 
decreased O 
neutrophil O 
recruitment O 
, O 
attenuated O 
histological O 
alterations O 
, O 
and O 
reduced O 
macroscopical O 
damage O 
, O 
edema O 
, O 
and O 
IL-1β O 
and O 
IL-33 O 
production O 
in O 
the O 
colon O 
samples O 
. O 
Microcapsules O 
loaded O 
with O 
1 O 
also O 
prevented O 
the O 
reduction O 
of O 
anti-inflammatory O 
cytokine O 
IL-10 O 
and O 
the O 
antioxidant O 
capacity O 
of O 
the O 
colon O 
. O 
These O 
preclinical O 
data O 
indicate O 
that O 
pectin O 
/ O 
casein O 
polymer O 
microcapsules O 
loaded O 
with O 
1 O 
improved O 
the O 
anti-inflammatory O 
and O 
antioxidant O 
effects O 
of O 
1 O 
compared O 
to O 
the O 
nonencapsulated O 
drug O 
. O 
Therefore O 
, O 
quercetin B-TRIVIAL 
seems O 
to O 
be O 
a O 
promising O 
active O 
molecule O 
in O 
inflammatory O 
bowel O 
disease O 
if O 
provided O 
with O 
adequate O 
controlled O 
release O 
. O 

novel O 
class O 
of O 
3-(phenoxy-phenyl-methyl)-pyrrolidines B-FAMILY 
as O 
potent O 
and O 
balanced O 
norepinephrine B-TRIVIAL 
and O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
: O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationships O 
. O 

series O 
of O 
3-(phenoxy-phenyl-methyl)-pyrrolidine B-SYSTEMATIC 
analogues O 
were O 
discovered O 
to O 
be O 
potent O 
and O 
balanced O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
and O 
serotonin B-TRIVIAL 
( O 
5-hydroxytryptamine B-SYSTEMATIC 
, O 
5-HT B-SYSTEMATIC 
) O 
reuptake O 
inhibitors O 
. O 
Several O 
of O 
these O 
compounds O 
were O 
identified O 
to O 
have O 
suitable O 
in O 
vitro O 
pharmacokinetic O 
properties O 
for O 
an O 
orally O 
dosed O 
and O 
CNS-targeted O 
drug O 
. O 
Compound O 
39b O 
, O 
in O 
particular O 
, O 
was O 
identified O 
as O 
a O 
potent O 
NET O 
and O 
SERT O 
reuptake O 
inhibitor O 
( O 
NSRI O 
) O 
with O 
minimal O 
off O 
- O 
target O 
activity O 
and O 
demonstrated O 
robust O 
efficacy O 
in O 
the O 
spinal O 
nerve O 
ligation O 
model O 
of O 
pain O 
behavior O 
. O 

of O 
2-aminomethyl-4-phenyl-1-azabicyclo[2.2.1]heptanes B-FAMILY 
via O 
LiAlH₄ B-FORMULA 
-induced O 
reductive O 
cyclization O 
of O 
2-(4-chloro-2-cyano-2-phenylbutyl)aziridines B-FAMILY 
and O 
evaluation O 
of O 
their O 
antimalarial O 
activity O 
. O 

were O 
employed O 
for O 
the O 
one O 
- O 
step O 
stereoselective O 
construction O 
of O 
both O 
endo- B-MULTIPLE 
and I-MULTIPLE 
exo-2-aminomethyl-4-phenyl-1-azabicyclo[2.2.1]heptanes I-MULTIPLE 
as O 
new O 
azaheterobicyclic B-FAMILY 
scaffolds O 
via O 
a O 
double O 
LiAlH(4) B-FORMULA 
-induced O 
reductive O 
cyclization O 
protocol O 
. O 
Antiplasmodial O 
assessment O 
of O 
these O 
1-azabicyclo[2.2.1]heptanes B-FAMILY 
revealed O 
moderate O 
to O 
good O 
activities O 
in O 
the O 
micromolar O 
range O 
, O 
with O 
the O 
exo- O 
isomers O 
being O 
the O 
most O 
promising O 
structures O 
. O 
Furthermore O 
, O 
the O 
proposed O 
mode O 
of O 
action O 
was O 
supported O 
by O 
ligand O 
docking O 
studies O 
, O 
pointing O 
to O 
a O 
strong O 
binding O 
interaction O 
with O 
the O 
enzyme O 
plasmepsin O 
II O 
. O 

effects O 
of O 
hexabromocyclododecane B-SYSTEMATIC 
on O 
Leydig O 
cell O 
cyclic O 
nucleotide B-FAMILY 
signaling O 
and O 
steroidogenesis O 
in O 
vitro O 
. O 

( O 
HBCDD B-ABBREVIATION 
) O 
, O 
an O 
additive O 
brominated O 
flame O 
retardant O 
routinely O 
added O 
to O 
various O 
consumer O 
products O 
, O 
was O 
reported O 
to O 
have O 
toxic O 
effects O 
upon O 
biota O 
, O 
including O 
endocrine O 
disruption O 
. O 
In O 
this O 
study O 
, O 
the O 
potential O 
toxicity O 
of O 
HBCDD B-ABBREVIATION 
was O 
tested O 
in O 
peripubertal O 
rat O 
Leydig O 
cells O 
in O 
vitro O 
during O 
6h O 
exposure O 
. O 
HBCDD B-ABBREVIATION 
inhibited O 
human O 
chorionic O 
gonadotropin- O 
and O 
forskolin B-TRIVIAL 
-supported O 
cAMP B-ABBREVIATION 
accumulation O 
and O 
steroidogenesis O 
. O 
It O 
also O 
inhibited O 
basal O 
cAMP B-ABBREVIATION 
production O 
, O 
but O 
elevated O 
basal O 
steroidogenesis O 
. O 
The O 
expression O 
of O 
several O 
cAMP B-ABBREVIATION 
-dependent O 
genes O 
, O 
including O 
steroidogenic O 
acute O 
regulatory O 
protein O 
, O 
cholesterol B-TRIVIAL 
side O 
chain O 
cleavage O 
enzyme O 
, O 
and O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase O 
, O 
was O 
also O 
inhibited O 
by O 
HBCDD B-ABBREVIATION 
treatment O 
. O 
Nevertheless O 
, O 
this O 
was O 
not O 
accompanied O 
by O 
a O 
decrease O 
in O 
steroidogenic O 
acute O 
regulatory O 
protein O 
expression O 
, O 
as O 
documented O 
by O 
western O 
blot O 
analysis O 
, O 
and O 
activity O 
of O 
steroidogenic O 
enzymes O 
, O 
as O 
documented O 
by O 
unaffected O 
steroidogenesis O 
in O 
the O 
presence O 
of O 
permeable O 
22(R)-hydroxycholesterol B-SYSTEMATIC 
. O 
However O 
, O 
HBCDD B-ABBREVIATION 
caused O 
significant O 
decrease O 
in O 
mitochondrial O 
membrane O 
potential O 
in O 
untreated O 
and O 
human O 
chorionic O 
gonadotropin O 
- O 
treated O 
cells O 
. O 
This O 
indicates O 
that O 
HBCDD B-ABBREVIATION 
acute O 
toxicity O 
in O 
Leydig O 
cells O 
reflects O 
changes O 
in O 
mitochondrial O 
membrane O 
potential O 
- O 
dependent O 
cAMP B-ABBREVIATION 
production O 
and O 
basal O 
and O 
cAMP B-ABBREVIATION 
-regulated O 
cholesterol B-TRIVIAL 
transport O 
. O 
This O 
in O 
turn O 
facilitates O 
basal O 
but O 
inhibits O 
cAMP B-ABBREVIATION 
-dependent O 
steroidogenesis O 
. O 
Acute O 
effects O 
of O 
HBCDD B-ABBREVIATION 
treatment O 
on O 
transcription O 
are O 
also O 
indicative O 
of O 
its O 
sustained O 
effects O 
on O 
Leydig O 
cell O 
function O 
. O 

diaryl B-FAMILY 
diselenides I-FAMILY 
as O 
potential O 
atheroprotective O 
compounds O 
: O 
Involvement O 
of O 
TrxR O 
and O 
GPx O 
- O 
like O 
systems O 
. O 

modifications O 
of O 
low O 
- O 
density O 
lipoproteins O 
( O 
LDLs O 
) O 
have O 
a O 
determinant O 
role O 
in O 
atherogenesis O 
and O 
the O 
study O 
of O 
agents O 
that O 
can O 
modulate O 
LDL O 
oxidation O 
is O 
of O 
pharmacological O 
and O 
therapeutic O 
significance O 
. O 
Therefore O 
, O 
the O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
antioxidant O 
effect O 
of O 
the O 
disubstituted O 
diaryl B-FAMILY 
diselenides I-FAMILY 
, O 
p-methoxyl-diphenyl B-SYSTEMATIC 
diselenide I-SYSTEMATIC 
(p-CH(3)O-C(6)H(4)Se)(2) B-FORMULA 
( O 
DM O 
) O 
and O 
p-chloro- B-SYSTEMATIC 
diphenyl I-SYSTEMATIC 
diselenide I-SYSTEMATIC 
(p-Cl-C(6)H(4)Se)(2) B-SYSTEMATIC 
( O 
DC O 
) O 
, O 
on O 
Cu(2+) B-FORMULA 
-induced O 
LDL O 
oxidation O 
. O 
Both O 
compounds O 
caused O 
a O 
dose O 
- O 
dependent O 
inhibition O 
of O 
human O 
serum O 
and O 
isolated O 
LDL O 
oxidation O 
evidenced O 
by O 
the O 
increasing O 
of O 
the O 
lag O 
phase O 
of O 
lipid O 
peroxidation O 
and O 
decreased O 
the O 
lipid O 
oxidation O 
rate O 
(V(max)) O 
. O 
The O 
protein O 
moieties O 
from O 
isolated O 
LDL O 
were O 
also O 
protected O 
from O 
Cu(2+) B-FORMULA 
-induced O 
oxidation O 
. O 
Moreover O 
, O 
the O 
disubstituted O 
diaryl B-FAMILY 
diselenides I-FAMILY 
efficiently O 
decreased O 
the O 
oxidized O 
LDL O 
( O 
ox-LDL O 
) O 
induced O 
foam O 
cell O 
formation O 
in O 
J774A.1 O 
macrophage O 
cells O 
. O 
Mechanistically O 
, O 
we O 
have O 
demonstrated O 
that O 
the O 
antioxidant O 
and O 
antiatherogenic O 
effects O 
of O 
DM O 
and O 
DC O 
are O 
related O 
to O 
formation O 
of O 
their O 
selenol B-FAMILY 
intermediates O 
( O 
RSeH B-FORMULA 
) O 
either O 
by O 
a O 
direct O 
reaction O 
with O 
endogenous O 
thiols B-FAMILY 
( O 
GPx O 
- O 
like O 
activity O 
) O 
or O 
via O 
their O 
reduction O 
by O 
TrxR O 
( O 
using O 
NADPH B-ABBREVIATION 
as O 
electron O 
donor O 
) O 
. O 
Considering O 
the O 
powerful O 
effect O 
of O 
DM O 
and O 
DC O 
against O 
LDL-induced O 
toxicity O 
, O 
they O 
could O 
be O 
considered O 
for O 
developing O 
of O 
new O 
therapeutic O 
approaches O 
to O 
preventing O 
and O 
treating O 
atherosclerosis O 
and O 
cardiovascular O 
diseases O 
. O 

glucagon O 
- O 
like O 
peptide-1 O 
receptor O 
( O 
GLP-1R O 
) O 
is O 
a O 
major O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
due O 
to O 
its O 
role O 
in O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Despite O 
the O 
availability O 
of O 
peptide O 
- O 
based O 
GLP-1R O 
drugs O 
for O 
treatment O 
of O 
this O 
disease O 
, O 
there O 
is O 
great O 
interest O 
in O 
developing O 
small O 
molecules O 
that O 
can O 
be O 
administered O 
orally O 
. O 
The O 
GLP-1R O 
system O 
is O 
complex O 
, O 
with O 
multiple O 
endogenous O 
and O 
clinically O 
used O 
peptide O 
ligands O 
that O 
exhibit O 
different O 
signaling O 
biases O 
at O 
this O 
receptor O 
. O 
This O 
study O 
revealed O 
that O 
small O 
molecule O 
ligands O 
acting O 
at O 
this O 
receptor O 
are O 
differentially O 
biased O 
to O 
peptide O 
ligands O 
and O 
also O 
from O 
each O 
other O 
with O 
respect O 
to O 
the O 
signaling O 
pathways O 
that O 
they O 
activate O 
. O 
Furthermore O 
, O 
allosteric O 
small O 
molecule O 
ligands O 
were O 
also O 
able O 
to O 
induce O 
bias O 
in O 
signaling O 
mediated O 
by O 
orthosteric O 
ligands O 
. O 
This O 
was O 
dependent O 
on O 
both O 
the O 
orthosteric O 
and O 
allosteric O 
ligand O 
as O 
no O 
two O 
allosteric O 
- O 
orthosteric O 
ligand O 
pairs O 
could O 
induce O 
the O 
same O 
signaling O 
profile O 
. O 
We O 
highlight O 
the O 
need O 
to O 
profile O 
compounds O 
across O 
multiple O 
signaling O 
pathways O 
and O 
in O 
combination O 
with O 
multiple O 
orthosteric O 
ligands O 
in O 
systems O 
such O 
as O 
the O 
GLP-1R O 
where O 
more O 
than O 
one O 
endogenous O 
ligand O 
exists O 
. O 
In O 
the O 
context O 
of O 
pleiotropical O 
coupling O 
of O 
receptors O 
and O 
the O 
interplay O 
of O 
multiple O 
pathways O 
leading O 
to O 
physiologic O 
responses O 
, O 
profiling O 
of O 
small O 
molecules O 
in O 
this O 
manner O 
may O 
lead O 
to O 
a O 
better O 
understanding O 
of O 
the O 
physiologic O 
consequences O 
of O 
biased O 
signaling O 
at O 
this O 
receptor O 
. O 
This O 
could O 
enable O 
the O 
design O 
and O 
development O 
of O 
improved O 
therapeutics O 
that O 
have O 
the O 
ability O 
to O 
fine O 
- O 
tune O 
receptor O 
signaling O 
, O 
leading O 
to O 
beneficial O 
therapeutic O 
outcomes O 
while O 
reducing O 
side O 
effect O 
profiles O 
. O 

, O 
reactivity O 
, O 
and O 
antiplatelet O 
activity O 
of O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
of O 
clopidogrel B-TRIVIAL 
. O 

this O 
work O 
, O 
we O 
investigated O 
the O 
formation O 
, O 
reactivity O 
, O 
and O 
antiplatelet O 
activity O 
of O 
various O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
of O 
clopidogrel B-TRIVIAL 
. O 
Our O 
results O 
showed O 
that O 
the O 
production O 
of O 
the O 
active O 
metabolite O 
( O 
AM O 
) O 
from O 
2-oxoclopidogrel B-SYSTEMATIC 
by O 
human O 
liver O 
microsomes O 
( O 
HLMs O 
) O 
is O 
greatly O 
affected O 
by O 
the O 
thiol B-FAMILY 
reductants O 
used O 
. O 
Among O 
the O 
10 O 
thiol B-FAMILY 
compounds O 
tested O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
is O 
most O 
efficient O 
in O 
producing O 
the O 
AM O 
at O 
a O 
rate O 
of O 
167 O 
pmoles O 
AM O 
/ O 
min O 
/ O 
mg O 
HLM O 
. O 
Interestingly O 
, O 
no O 
AM O 
but O 
only O 
the O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
were O 
formed O 
in O 
the O 
presence O 
of O 
6-chloropyridazine-3-thiol B-SYSTEMATIC 
( O 
CPT B-ABBREVIATION 
) O 
, O 
2,5-dimethylfuran-3-thiol B-SYSTEMATIC 
, O 
and O 
3-nitropyridine-2-thiol B-SYSTEMATIC 
( O 
NPT B-ABBREVIATION 
) O 
. O 
The O 
mass O 
spectrometry O 
( O 
MS O 
) O 
and O 
MS(2) O 
spectra O 
of O 
the O 
conjugates O 
of O 
these O 
thiol O 
compounds O 
confirmed O 
the O 
presence O 
of O 
a O 
mixed O 
disulfide B-SYSTEMATIC 
bond O 
linkage O 
between O 
the O 
AM O 
and O 
the O 
thiol B-FAMILY 
reductants O 
. O 
Kinetic O 
studies O 
revealed O 
that O 
the O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
were O 
capable O 
of O 
exchanging O 
thiols B-FAMILY 
with O 
GSH B-ABBREVIATION 
to O 
release O 
the O 
AM O 
with O 
second O 
order O 
rate O 
constants O 
ranging O 
from O 
1.2 O 
to O 
28 O 
M(-1)s(-1) O 
. O 
The O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
of O 
CPT B-ABBREVIATION 
and O 
NPT B-ABBREVIATION 
showed O 
potent O 
inhibition O 
of O 
platelet O 
aggregation O 
after O 
pretreatment O 
with O 
1 O 
mM O 
GSH B-ABBREVIATION 
, O 
confirming O 
that O 
the O 
AM O 
is O 
responsible O 
for O 
the O 
antiplatelet O 
activity O 
of O 
clopidogrel B-TRIVIAL 
. O 
Collectively O 
, O 
our O 
results O 
provide O 
strong O 
support O 
for O 
a O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
- O 
mediated O 
bioactivation O 
mechanism O 
involving O 
the O 
initial O 
formation O 
of O 
a O 
glutathionyl O 
conjugate O 
, O 
followed O 
by O 
thiol B-FAMILY 
- O 
disulfide B-SYSTEMATIC 
exchange O 
with O 
another O 
GSH B-ABBREVIATION 
molecule O 
to O 
release O 
the O 
AM O 
. O 
Furthermore O 
, O 
the O 
stable O 
mixed O 
disulfide B-SYSTEMATIC 
conjugates O 
identified O 
in O 
this O 
study O 
provide O 
a O 
platform O 
to O 
quantitatively O 
generate O 
the O 
therapeutic O 
AM O 
without O 
the O 
need O 
for O 
P450 O 
- O 
mediated O 
bioactivation O 
. O 
This O 
property O 
can O 
be O 
further O 
explored O 
to O 
overcome O 
the O 
interindividual O 
variability O 
in O 
clopidogrel B-TRIVIAL 
therapy O 
. O 

of O 
metformin B-TRIVIAL 
on O 
burn O 
- O 
induced O 
hepatic O 
endoplasmic O 
reticulum O 
stress O 
in O 
male O 
rats O 
. O 

burn O 
injury O 
causes O 
hepatic O 
dysfunction O 
that O 
results O 
in O 
major O 
metabolic O 
derangements O 
including O 
insulin O 
resistance O 
and O 
hyperglycemia O 
and O 
is O 
associated O 
with O 
hepatic O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
. O 
We O 
have O 
recently O 
shown O 
that O 
insulin O 
reduces O 
ER O 
stress O 
and O 
improves O 
liver O 
function O 
and O 
morphology O 
; O 
however O 
, O 
it O 
is O 
not O 
clear O 
whether O 
these O 
changes O 
are O 
directly O 
insulin O 
mediated O 
or O 
are O 
due O 
to O 
glucose B-TRIVIAL 
alterations O 
. O 
Metformin B-TRIVIAL 
is O 
an O 
antidiabetic O 
agent O 
that O 
decreases O 
hyperglycemia O 
by O 
different O 
pathways O 
than O 
insulin O 
; O 
therefore O 
, O 
we O 
asked O 
whether O 
metformin B-TRIVIAL 
affects O 
postburn O 
ER O 
stress O 
and O 
hepatic O 
metabolism O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
is O 
to O 
determine O 
the O 
effects O 
of O 
metformin B-TRIVIAL 
on O 
postburn O 
hepatic O 
ER O 
stress O 
and O 
metabolic O 
markers O 
. O 
Male O 
rats O 
were O 
randomized O 
to O 
sham O 
, O 
burn O 
injury O 
and O 
burn O 
injury O 
plus O 
metformin B-TRIVIAL 
and O 
were O 
sacrificed O 
at O 
various O 
time O 
points O 
. O 
Outcomes O 
measured O 
were O 
hepatic O 
damage O 
, O 
function O 
, O 
metabolism O 
and O 
ER O 
stress O 
. O 
Burn O 
- O 
induced O 
decrease O 
in O 
albumin O 
mRNA O 
and O 
increase O 
in O 
alanine B-TRIVIAL 
transaminase O 
( O 
p O 
< O 
0.01 O 
versus O 
sham O 
) O 
were O 
not O 
normalized O 
by O 
metformin B-TRIVIAL 
treatment O 
. O 
In O 
addition O 
, O 
ER O 
stress O 
markers O 
were O 
similarly O 
increased O 
in O 
burn O 
injury O 
with O 
or O 
without O 
metformin B-TRIVIAL 
compared O 
with O 
sham O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
We O 
also O 
found O 
that O 
gluconeogenesis O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
gene O 
expressions O 
were O 
upregulated O 
with O 
or O 
without O 
metformin B-TRIVIAL 
compared O 
with O 
sham O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Our O 
results O 
indicate O 
that O 
, O 
whereas O 
thermal O 
injury O 
results O 
in O 
hepatic O 
ER O 
stress O 
, O 
metformin B-TRIVIAL 
does O 
not O 
ameliorate O 
postburn O 
stress O 
responses O 
by O 
correcting O 
hepatic O 
ER O 
stress O 
. O 

brief O 
history O 
of O 
oxytocin B-TRIVIAL 
and O 
its O 
role O 
in O 
modulating O 
psychostimulant O 
effects O 
. O 

the O 
past O 
century O 
, O 
the O 
polypeptide O 
oxytocin B-TRIVIAL 
has O 
played O 
an O 
important O 
role O 
in O 
medicine O 
with O 
major O 
highlights O 
including O 
the O 
identification O 
of O 
its O 
involvement O 
in O 
parturition O 
and O 
the O 
milk O 
let O 
- O 
down O 
reflex O 
. O 
Oxytocin B-TRIVIAL 
is O 
now O 
implicated O 
in O 
an O 
extensive O 
range O 
of O 
psychological O 
phenomena O 
including O 
reward O 
and O 
memory O 
processes O 
and O 
has O 
been O 
investigated O 
as O 
a O 
treatment O 
for O 
several O 
psychiatric O 
disorders O 
including O 
addiction O 
, O 
anxiety O 
, O 
autism O 
, O 
and O 
schizophrenia O 
. O 
In O 
this O 
review O 
, O 
we O 
first O 
provide O 
an O 
historical O 
overview O 
of O 
oxytocin B-TRIVIAL 
and O 
describe O 
key O 
aspects O 
of O 
its O 
physiological O 
activity O 
. O 
We O 
then O 
outline O 
some O 
pharmacological O 
limitations O 
in O 
this O 
field O 
of O 
research O 
before O 
highlighting O 
the O 
role O 
of O 
oxytocin B-TRIVIAL 
in O 
a O 
wide O 
range O 
of O 
behavioral O 
and O 
neuronal O 
processes O 
. O 
Finally O 
, O 
we O 
review O 
evidence O 
for O 
a O 
modulatory O 
role O 
of O 
oxytocin B-TRIVIAL 
with O 
regard O 
to O 
psychostimulant O 
effects O 
. O 
Key O 
findings O 
suggest O 
that O 
oxytocin B-TRIVIAL 
attenuates O 
a O 
broad O 
number O 
of O 
cocaine B-TRIVIAL 
and O 
methamphetamine B-TRIVIAL 
induced O 
behaviors O 
and O 
associated O 
neuronal O 
activity O 
in O 
rodents O 
. O 
Evidence O 
also O 
outlines O 
a O 
role O 
for O 
oxytocin B-TRIVIAL 
in O 
the O 
prosocial O 
effects O 
of O 
3,4-methylenedioxymethamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
, O 
Ecstasy B-TRIVIAL 
) O 
in O 
both O 
rodents O 
and O 
humans O 
. O 
Clinical O 
trials O 
should O 
now O 
investigate O 
the O 
effectiveness O 
of O 
oxytocin B-TRIVIAL 
as O 
a O 
novel O 
intervention O 
for O 
psychostimulant O 
addiction O 
and O 
should O 
aim O 
to O 
determine O 
its O 
specific O 
role O 
in O 
the O 
therapeutic O 
properties O 
of O 
MDMA B-ABBREVIATION 
that O 
are O 
currently O 
being O 
investigated O 
. O 

Adipose O 
Tissue O 
Macrophage O 
Content O 
Is O 
Associated O 
With O 
Improved O 
Insulin O 
Sensitivity O 
in O 
Thiazolidinedione B-SYSTEMATIC 
-Treated O 
Diabetic O 
Humans O 
. O 

is O 
associated O 
with O 
increased O 
adipose O 
tissue O 
macrophage O 
( O 
ATM O 
) O 
infiltration O 
, O 
and O 
rodent O 
studies O 
suggest O 
that O 
inflammatory O 
factors O 
produced O 
by O 
ATMs O 
contribute O 
to O 
insulin O 
resistance O 
and O 
type O 
2 O 
diabetes O 
. O 
However O 
, O 
a O 
relationship O 
between O 
ATM O 
content O 
and O 
insulin O 
resistance O 
has O 
not O 
been O 
clearly O 
established O 
in O 
humans O 
. O 
Since O 
thiazolidinediones B-FAMILY 
attenuate O 
adipose O 
tissue O 
inflammation O 
and O 
improve O 
insulin O 
sensitivity O 
, O 
we O 
examined O 
the O 
temporal O 
relationship O 
of O 
the O 
effects O 
of O 
pioglitazone B-TRIVIAL 
on O 
these O 
two O 
parameters O 
. O 
The O 
effect O 
of O 
10 O 
and O 
21 O 
days O 
of O 
pioglitazone B-TRIVIAL 
treatment O 
on O 
insulin O 
sensitivity O 
in O 
26 O 
diabetic O 
subjects O 
was O 
assessed O 
by O 
hyperinsulinemic O 
- O 
euglycemic O 
clamp O 
studies O 
. O 
Because O 
chemoattractant O 
factors O 
, O 
cytokines O 
, O 
and O 
immune O 
cells O 
have O 
been O 
implicated O 
in O 
regulating O 
the O 
recruitment O 
of O 
ATMs O 
, O 
we O 
studied O 
their O 
temporal O 
relationship O 
to O 
changes O 
in O 
ATM O 
content O 
. O 
Improved O 
hepatic O 
and O 
peripheral O 
insulin O 
sensitivity O 
was O 
seen O 
after O 
21 O 
days O 
of O 
pioglitazone B-TRIVIAL 
. O 
We O 
found O 
early O 
reductions O 
in O 
macrophage O 
chemoattractant O 
factors O 
after O 
only O 
10 O 
days O 
of O 
pioglitazone B-TRIVIAL 
, O 
followed O 
by O 
a O 
69% O 
reduction O 
in O 
ATM O 
content O 
at O 
21 O 
days O 
and O 
reduced O 
ATM O 
activation O 
at O 
both O 
time O 
points O 
. O 
Although O 
markers O 
for O 
dendritic O 
cells O 
and O 
neutrophils O 
were O 
reduced O 
at O 
both O 
time O 
points O 
, O 
there O 
were O 
no O 
significant O 
changes O 
in O 
regulatory O 
T O 
cells O 
. O 
These O 
results O 
are O 
consistent O 
with O 
an O 
association O 
between O 
adipose O 
macrophage O 
content O 
and O 
systemic O 
insulin O 
resistance O 
in O 
humans O 
. O 

grade O 
inflammation O 
in O 
obesity O 
is O 
associated O 
with O 
accumulation O 
of O 
the O 
macrophagederived O 
cytokine O 
osteopontin O 
in O 
adipose O 
tissue O 
and O 
induction O 
of O 
local O 
as O 
well O 
as O 
systemic O 
insulin O 
resistance O 
. O 
Since O 
GIP O 
( O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
polypeptide O 
) O 
is O 
a O 
strong O 
stimulator O 
of O 
adipogenesis O 
and O 
may O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
obesity O 
, O 
we O 
explored O 
whether O 
GIP O 
directly O 
would O 
stimulate O 
osteopontin O 
( O 
OPN O 
) O 
expression O 
in O 
adipose O 
tissue O 
and O 
thereby O 
induce O 
insulin O 
resistance O 
. O 
GIP O 
stimulated O 
OPN O 
protein O 
expression O 
in O 
a O 
dose O 
- O 
dependent O 
fashion O 
in O 
rat O 
primary O 
adipocytes O 
. O 
The O 
level O 
of O 
OPN O 
mRNA O 
was O 
higher O 
in O 
adipose O 
tissue O 
of O 
obese O 
individuals O 
(0.13±}0.04 O 
vs O 
0.04±}0.01 O 
, O 
P O 
< O 
0.05 O 
) O 
and O 
correlated O 
inversely O 
with O 
measures O 
of O 
insulin O 
sensitivity O 
( O 
r=-0.24 O 
, O 
P=0.001 O 
) O 
. O 
A O 
common O 
variant O 
of O 
the O 
GIP O 
receptor O 
( O 
GIPR O 
) O 
( O 
rs10423928 O 
) O 
gene O 
was O 
associated O 
with O 
lower O 
amount O 
of O 
the O 
exon O 
9 O 
containing O 
isoform O 
required O 
for O 
transmembrane O 
activity O 
. O 
Carriers O 
of O 
the O 
A-allele O 
with O 
a O 
reduced O 
receptor O 
function O 
showed O 
lower O 
adipose O 
tissue O 
OPN O 
mRNA O 
levels O 
and O 
better O 
insulin O 
sensitivity O 
. O 
Together O 
, O 
these O 
data O 
suggest O 
a O 
role O 
for O 
GIP O 
not O 
only O 
as O 
an O 
incretin O 
hormone O 
, O 
but O 
also O 
as O 
a O 
trigger O 
of O 
inflammation O 
and O 
insulin O 
resistance O 
in O 
adipose O 
tissue O 
. O 
Carriers O 
of O 
GIPR O 
rs10423928 O 
A-allele O 
showed O 
protective O 
properties O 
via O 
reduced O 
GIP O 
effects O 
. O 
Identification O 
of O 
this O 
unprecedented O 
link O 
between O 
GIP O 
and O 
OPN O 
in O 
adipose O 
tissue O 
might O 
open O 
new O 
avenues O 
for O 
therapeutic O 
interventions O 
. O 

Protein O 
Kinase O 
A O 
Activation O 
Enhances O 
the O 
Efficiency O 
of O 
Glucose B-TRIVIAL 
Control O 
by O 
Increasing O 
Acute-Phase O 
Insulin O 
Secretion O 
. O 

insulin O 
secretion O 
determines O 
the O 
efficiency O 
of O 
glucose B-TRIVIAL 
clearance O 
. O 
Moreover O 
, O 
impaired O 
acute O 
insulin O 
release O 
is O 
characteristic O 
of O 
reduced O 
glucose B-TRIVIAL 
control O 
in O 
the O 
prediabetic O 
state O 
. O 
Incretin O 
hormones O 
, O 
which O 
increase O 
β-cell O 
cAMP B-ABBREVIATION 
, O 
restore O 
acute O 
- O 
phase O 
insulin O 
secretion O 
and O 
improve O 
glucose B-TRIVIAL 
control O 
. O 
To O 
determine O 
the O 
physiological O 
role O 
of O 
the O 
cAMP B-ABBREVIATION 
-dependent O 
protein O 
kinase O 
( O 
PKA O 
) O 
, O 
a O 
mouse O 
model O 
was O 
developed O 
to O 
increase O 
PKA O 
activity O 
specifically O 
in O 
the O 
pancreatic O 
β-cells O 
. O 
In O 
response O 
to O 
sustained O 
hyperglycemia O 
, O 
PKA O 
activity O 
potentiated O 
both O 
acute O 
and O 
sustained O 
insulin O 
release O 
. O 
In O 
contrast O 
, O 
a O 
glucose B-TRIVIAL 
bolus O 
enhanced O 
acute O 
- O 
phase O 
insulin O 
secretion O 
alone O 
. O 
Acute O 
- O 
phase O 
insulin O 
secretion O 
was O 
increased O 
3.5-fold O 
, O 
reducing O 
circulating O 
glucose B-TRIVIAL 
to O 
58% O 
of O 
levels O 
in O 
controls O 
. O 
Exendin-4 O 
increased O 
acute O 
- O 
phase O 
insulin O 
release O 
to O 
a O 
similar O 
degree O 
as O 
PKA O 
activation O 
. O 
However O 
, O 
incretins O 
did O 
not O 
augment O 
the O 
effects O 
of O 
PKA O 
on O 
acute O 
- O 
phase O 
insulin O 
secretion O 
, O 
consistent O 
with O 
incretins O 
acting O 
primarily O 
via O 
PKA O 
to O 
potentiate O 
acute O 
- O 
phase O 
insulin O 
secretion O 
. O 
Intracellular O 
calcium B-SYSTEMATIC 
signaling O 
was O 
unaffected O 
by O 
PKA O 
activation O 
, O 
suggesting O 
that O 
the O 
effects O 
of O 
PKA O 
on O 
acute O 
- O 
phase O 
insulin O 
secretion O 
are O 
mediated O 
by O 
the O 
phosphorylation O 
of O 
proteins O 
involved O 
in O 
β-cell O 
exocytosis O 
. O 
Thus O 
, O 
β-cell O 
PKA O 
activity O 
transduces O 
the O 
cAMP O 
signal O 
to O 
dramatically O 
increase O 
acute O 
- O 
phase O 
insulin O 
secretion O 
, O 
thereby O 
enhancing O 
the O 
efficiency O 
of O 
insulin O 
to O 
control O 
circulating O 
glucose B-TRIVIAL 
. O 

local O 
production O 
of O 
pro O 
- O 
resolving O 
lipid O 
mediators O 
in O 
obesity O 
and O 
17-HDHA B-SYSTEMATIC 
as O 
a O 
potential O 
treatment O 
for O 
obesity O 
- O 
associated O 
inflammation O 
. O 

- O 
induced O 
chronic O 
low O 
- O 
grade O 
inflammation O 
originates O 
from O 
adipose O 
tissue O 
and O 
is O 
crucial O 
for O 
obesity O 
- O 
driven O 
metabolic O 
deterioration O 
including O 
insulin O 
resistance O 
and O 
type O 
2 O 
diabetes.Chronic O 
inflammation O 
may O 
be O 
a O 
consequence O 
of O 
a O 
failure O 
to O 
actively O 
resolve O 
inflammation,and O 
could O 
result O 
from O 
a O 
lack O 
of O 
local O 
specialized O 
pro O 
- O 
resolving O 
lipid O 
mediators O 
( O 
SPM O 
) O 
such O 
as O 
resolvins B-FAMILY 
and O 
protectins O 
, O 
which O 
derive O 
from O 
the O 
n-3 O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
. O 
We O 
assessed O 
obesity O 
- O 
induced O 
changes O 
of O 
n-3 O 
- O 
derived O 
SPM O 
in O 
adipose O 
tissue O 
and O 
effects O 
of O 
dietary O 
EPA B-ABBREVIATION 
/ O 
DHA B-ABBREVIATION 
thereon.Moreover O 
, O 
we O 
treated O 
obese O 
mice O 
with O 
SPM O 
precursors O 
and O 
investigated O 
effects O 
on O 
inflammation O 
and O 
metabolic O 
dysregulation O 
. O 
Obesity O 
significantly O 
decreased O 
DHA B-ABBREVIATION 
-derived O 
17-hydroxydocosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
17-HDHA B-SYSTEMATIC 
, O 
resolvin B-TRIVIAL 
D1 I-TRIVIAL 
precursor O 
) O 
and O 
protectin B-TRIVIAL 
D1 I-TRIVIAL 
levels O 
in O 
murine O 
adipose O 
tissue O 
. O 
Dietary O 
EPA B-ABBREVIATION 
/ O 
DHA B-ABBREVIATION 
treatment O 
restored O 
endogenous O 
biosynthesis O 
of O 
n-3 O 
derived O 
lipid O 
mediators O 
in O 
obesity O 
while O 
attenuating O 
adipose O 
tissue O 
inflammation O 
and O 
improving O 
insulin O 
sensitivity O 
. O 
Notably O 
, O 
17-HDHA B-SYSTEMATIC 
treatment O 
reduced O 
adipose O 
tissue O 
expression O 
of O 
inflammatory O 
cytokines O 
, O 
increased O 
adiponectin O 
expression O 
and O 
improved O 
glucose B-TRIVIAL 
tolerance O 
parallel O 
to O 
insulin O 
sensitivity O 
in O 
obese O 
mice O 
. O 
These O 
findings O 
indicate O 
that O 
impaired O 
biosynthesis O 
of O 
certain O 
SPM O 
and O 
SPM O 
precursors O 
including O 
17-HDHA B-SYSTEMATIC 
and O 
protectin B-TRIVIAL 
D1 I-TRIVIAL 
contributes O 
to O 
adipose O 
tissue O 
inflammation O 
in O 
obesity O 
and O 
suggest O 
17-HDHA B-SYSTEMATIC 
as O 
a O 
novel O 
treatment O 
option O 
for O 
obesity O 
- O 
associated O 
complications O 
. O 

and O 
calcium B-SYSTEMATIC 
metabolism O 
disorders O 
during O 
pregnancy O 
. O 

Parathyroid O 
disorders O 
are O 
not O 
common O 
among O 
pregnant O 
women O 
, O 
but O 
harbor O 
a O 
significant O 
morbidity O 
and O 
mortality O 
potential O 
if O 
they O 
remain O 
unrecognized O 
and O 
untreated O 
. O 
The O 
symptoms O 
caused O 
by O 
abnormally O 
low O 
or O 
high O 
blood O 
free O 
calcium B-SYSTEMATIC 
level O 
are O 
mostly O 
non-specific O 
in O 
the O 
initial O 
stages O 
, O 
thus O 
when O 
recognized O 
might O 
pose O 
a O 
real O 
danger O 
. O 
Here O 
we O 
will O 
survey O 
the O 
alterations O 
in O 
calcium B-SYSTEMATIC 
metabolism O 
induced O 
by O 
pregnancy O 
, O 
and O 
describe O 
the O 
clinical O 
manifestations O 
, O 
diagnosis O 
and O 
treatment O 
of O 
parathyroid O 
and O 
other O 
calcium B-SYSTEMATIC 
metabolism O 
disorders O 
during O 
pregnancy O 
. O 
The O 
current O 
literature O 
on O 
the O 
impact O 
of O 
calcium B-SYSTEMATIC 
and O 
vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
during O 
pregnancy O 
will O 
also O 
be O 
reviewed O 
. O 

Hydrazones I-FAMILY 
: O 
A O 
Promising O 
and O 
Potent O 
Class O 
of O 
Antileishmanial O 
Compounds O 
. O 

this O 
work O 
, O 
we O 
report O 
the O 
antileishmanial O 
evaluation O 
of O 
twenty O 
7-chloro-4-quinolinyl B-FAMILY 
hydrazone I-FAMILY 
derivatives O 
( O 
1-20 O 
) O 
. O 
Firstly O 
, O 
the O 
compounds O 
were O 
tested O 
against O 
promastigotes O 
of O 
four O 
different O 
Leishmania O 
species O 
. O 
After O 
that O 
, O 
all O 
derivatives O 
were O 
assayed O 
against O 
L O 
. O 
braziliensis O 
amastigotes O 
and O 
murine O 
macrophages O 
. O 
Furthermore O 
, O 
it O 
was O 
investigated O 
whether O 
the O 
antiamastigote O 
L. O 
braziliensis O 
effect O 
of O 
the O 
compounds O 
could O 
be O 
associated O 
with O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
. O 
Compounds O 
6 O 
and O 
7 O 
showed O 
a O 
strong O 
leishmanicidal O 
activity O 
against O 
intracellular O 
parasite O 
with O 
IC50 O 
in O 
nanogram O 
levels O 
( O 
30 O 
and O 
20 O 
ng O 
/ O 
mL O 
, O 
respectively O 
) O 
. O 
Appreciable O 
activity O 
of O 
three O 
compounds O 
tested O 
can O 
be O 
considered O 
an O 
important O 
finding O 
for O 
the O 
rational O 
design O 
of O 
new O 
leads O 
for O 
antileishmanial O 
compounds O 
. O 

of O 
the O 
interaction O 
of O 
γ- O 
Al2O3 B-FORMULA 
with O 
aqueous O 
solutions O 
of O 
dimethyl B-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
using O 
infrared O 
multiple O 
internal O 
reflection O 
spectroscopy O 
. O 

interaction O 
of O 
dilute O 
solutions O 
of O 
dimethyl B-SYSTEMATIC 
methylphosphonate I-SYSTEMATIC 
( O 
DMMP B-ABBREVIATION 
) O 
in O 
H(2)O B-FORMULA 
with O 
thin O 
porous O 
layers O 
of O 
γ- O 
Al(2)O(3) B-FORMULA 
has O 
been O 
studied O 
under O 
steady O 
- O 
state O 
conditions O 
using O 
infrared O 
multiple O 
- O 
internal O 
- O 
reflection O 
spectroscopy O 
. O 
Upon O 
the O 
initial O 
introduction O 
of O 
the O 
DMMP B-ABBREVIATION 
solution O 
to O 
a O 
previously O 
H(2)O B-FORMULA 
-saturated O 
surface O 
, O 
DMMP B-ABBREVIATION 
diffuses O 
into O 
the O 
porous O 
layer O 
and O 
displaces O 
weakly O 
hydrogen B-SYSTEMATIC 
-bonded O 
H(2)O B-FORMULA 
molecules O 
. O 
This O 
is O 
accompanied O 
by O 
hydrolysis O 
of O 
the O 
γ- O 
Al(2)O(3) B-FORMULA 
to O 
form O 
Al(OH)(3) B-FORMULA 
and O 
/ O 
or O 
AlO(OH) B-FORMULA 
. O 
The O 
P═O B-FORMULA 
group O 
of O 
DMMP B-ABBREVIATION 
interacts O 
predominantly O 
with O 
H(2)O B-FORMULA 
and O 
gives O 
no O 
clear O 
indication O 
of O 
bonding O 
to O 
the O 
oxide B-SYSTEMATIC 
surface O 
itself O 
, O 
from O 
which O 
it O 
is O 
inferred O 
that O 
the O 
displacement O 
of O 
weakly O 
adsorbed O 
H(2)O B-FORMULA 
results O 
from O 
the O 
interaction O 
of O 
acidic O 
Al-OH B-FORMULA 
sites O 
with O 
the O 
methoxy B-SYSTEMATIC 
O B-FORMULA 
atoms O 
of O 
DMMP B-ABBREVIATION 
. O 
No O 
hydrolysis O 
of O 
the O 
DMMP B-ABBREVIATION 
, O 
either O 
in O 
solution O 
or O 
in O 
contact O 
with O 
the O 
oxide B-SYSTEMATIC 
, O 
was O 
detectable O 
under O 
the O 
present O 
conditions O 
. O 
The O 
results O 
have O 
practical O 
implications O 
in O 
the O 
decontamination O 
of O 
materials O 
following O 
exposure O 
to O 
toxic O 
reagents O 
related O 
to O 
DMMP B-ABBREVIATION 
. O 

( O 
Apis O 
mellifera O 
) O 
royal O 
jelly O 
( O 
RJ O 
) O 
has O 
a O 
long O 
history O 
in O 
human O 
medicine O 
because O 
of O 
its O 
health O 
- O 
protecting O 
properties O 
. O 
To O 
develop O 
a O 
fundamental O 
and O 
comprehensive O 
understanding O 
of O 
lipids O 
in O 
RJ O 
, O 
this O 
article O 
reviews O 
the O 
available O 
literature O 
on O 
lipid O 
compounds O 
identified O 
from O 
RJ O 
extracts O 
and O 
in O 
vitro O 
pharmacological O 
effects O 
of O 
10-hydroxy-2-decenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
RJ O 
and O 
other O 
closely O 
related O 
compounds O 
, O 
some O 
of O 
which O 
are O 
also O 
identified O 
as O 
lipid O 
compounds O 
in O 
RJ O 
. O 
Overall O 
, O 
the O 
lipids O 
in O 
RJ O 
are O 
composed O 
of O 
mostly O 
( O 
aliphatic O 
) O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
almost O 
all O 
of O 
which O 
are O 
present O 
as O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
scarcely O 
any O 
as O 
esters B-FAMILY 
. O 
Most O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
RJ O 
are O 
medium B-FAMILY 
- I-FAMILY 
chain I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
whether O 
hydroxylated O 
in O 
terminal O 
and O 
/ O 
or O 
internal O 
positions O 
, O 
terminated O 
with O 
mono- B-MULTIPLE 
or I-MULTIPLE 
dicarboxylic I-MULTIPLE 
acid I-MULTIPLE 
groups O 
, O 
and O 
saturated O 
or O 
monounsaturated O 
at O 
the O 
2- O 
position O 
. O 
Besides O 
these O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
lipids O 
in O 
RJ O 
contain O 
sterols O 
in O 
minor O 
amounts O 
. O 
Lipids O 
in O 
RJ O 
are O 
useful O 
as O 
preventive O 
and O 
supportive O 
medicines O 
with O 
functionalities O 
that O 
include O 
potential O 
inhibitors O 
of O 
cancer O 
growth O 
, O 
immune O 
system O 
modulators O 
, O 
alternative O 
therapies O 
for O 
menopause O 
, O 
skin O 
- O 
aging O 
protectors O 
, O 
neurogenesis O 
inducers O 
, O 
and O 
more O 
. O 
Taken O 
together O 
, O 
the O 
evidence O 
suggests O 
that O 
health O 
- O 
protecting O 
properties O 
of O 
RJ O 
can O 
be O 
, O 
in O 
part O 
, O 
ascribed O 
to O 
actions O 
of O 
lipids O 
in O 
RJ O 
. O 

nanoarchitectures O 
are O 
among O 
the O 
most O 
promising O 
nanotechnology O 
- O 
enabled O 
materials O 
for O 
biomedical O 
applications O 
. O 
Interfacing O 
of O 
nanoparticles O 
with O 
active O 
materials O 
gives O 
rise O 
to O 
the O 
structures O 
with O 
unique O 
multiple O 
functionality O 
. O 
Superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
particles O 
SPION O 
are O 
widely O 
employed O 
in O 
the O 
biology O 
and O 
in O 
developing O 
of O 
advanced O 
medical O 
technologies O 
. O 
Polymeric O 
micelles O 
offer O 
the O 
advantage O 
of O 
multifunctional O 
carriers O 
which O 
can O 
serve O 
as O 
delivery O 
vehicles O 
carrying O 
nanoparticles O 
, O 
hydrophobic O 
chemotherapeutics O 
and O 
other O 
functional O 
materials O 
and O 
molecules O 
. O 
Stimuli O 
- O 
responsive O 
polymers O 
are O 
especially O 
attractive O 
since O 
their O 
properties O 
can O 
be O 
modulated O 
in O 
a O 
controlled O 
manner O 
. O 
Here O 
we O 
report O 
on O 
multifunctional O 
thermo O 
- O 
responsive O 
poly(N-isopropylacrylamide-co-acrylamide)-block-poly(ε-caprolactone) B-SYSTEMATIC 
random O 
block O 
copolymer O 
micelles O 
as O 
magnetic O 
hyperthermia O 
- O 
mediated O 
payload O 
release O 
and O 
imaging O 
agents O 
. O 
The O 
combination O 
of O 
copolymers O 
, O 
nanoparticles O 
and O 
doxorubicin B-TRIVIAL 
drug O 
was O 
tailored O 
the O 
way O 
that O 
the O 
loaded O 
micelles O 
were O 
cable O 
to O 
respond O 
to O 
magnetic O 
heating O 
at O 
physiologically O 
- O 
relevant O 
temperatures O 
. O 
A O 
surface O 
functionalization O 
of O 
the O 
micelles O 
with O 
the O 
integrin O 
β4 O 
antibody O 
and O 
consequent O 
interfacing O 
of O 
the O 
resulting O 
nanobio O 
hybrid O 
with O 
squamous O 
head O 
and O 
neck O 
carcinoma O 
cells O 
which O 
is O 
known O 
to O 
specifically O 
over O 
- O 
express O 
the O 
A9 O 
antigen O 
resulted O 
in O 
concentration O 
of O 
the O 
micelles O 
on O 
the O 
surface O 
of O 
cells O 
. O 
No O 
inherent O 
cytotoxicity O 
was O 
detected O 
for O 
the O 
magnetic O 
micelles O 
without O 
external O 
stimuli O 
application O 
. O 
Furthermore O 
, O 
SPION-loaded O 
micelles O 
demonstrate O 
significant O 
MRI O 
contrast O 
enhancement O 
abilities O 
. O 

- O 
induced O 
nanocarrier O 
assembly O 
as O 
a O 
strategy O 
for O 
the O 
cellular O 
delivery O 
of O 
nucleotides B-FAMILY 
and O 
nucleotide B-FAMILY 
analogues O 
. O 

natural O 
nucleotide O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
ATP B-ABBREVIATION 
) O 
and O 
nucleotide B-FAMILY 
analogues O 
such O 
as O 
azidothymidine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
( O 
AZT-TP B-ABBREVIATION 
) O 
display O 
important O 
pharmacological O 
activities O 
for O 
the O 
treatment O 
of O 
ischemia O 
and O 
HIV O 
infections O 
, O 
respectively O 
. O 
Their O 
clinical O 
use O 
is O 
, O 
however O 
, O 
limited O 
mostly O 
due O 
to O 
their O 
hydrophilicity O 
, O 
which O 
highly O 
restricts O 
their O 
diffusion O 
into O 
the O 
target O 
cells O 
. O 
Few O 
nanocarriers O 
have O 
been O 
proposed O 
to O 
address O 
the O 
challenge O 
of O 
ATP B-ABBREVIATION 
/ O 
AZT-TP B-ABBREVIATION 
cellular O 
delivery O 
, O 
but O 
the O 
loading O 
efficiency O 
, O 
preparation O 
complexity O 
, O 
and O 
efficient O 
cellular O 
delivery O 
remain O 
important O 
barriers O 
to O 
their O 
development O 
. O 
In O 
this O 
study O 
, O 
we O 
propose O 
an O 
original O 
, O 
straightforward O 
and O 
versatile O 
design O 
of O 
nucleotide B-FAMILY 
and O 
nucleotide B-FAMILY 
analogue O 
nanocarriers O 
based O 
on O 
the O 
natural O 
polysaccharide O 
chitosan O 
( O 
CS O 
) O 
. O 
We O 
show O 
that O 
the O 
drugs O 
ATP B-ABBREVIATION 
and O 
AZT-TP B-ABBREVIATION 
can O 
induce O 
ionotropic O 
gelation O 
of O 
CS O 
, O 
leading O 
to O 
CS/ O 
ATP B-ABBREVIATION 
and O 
CS/ O 
AZT-TP B-ABBREVIATION 
nanoparticles O 
with O 
high O 
drug O 
entrapment O 
efficiency O 
and O 
loading O 
rate O 
- O 
up O 
to O 
44% O 
. O 
Such O 
nanocarriers O 
release O 
ATP B-ABBREVIATION 
and O 
AZT-TP B-ABBREVIATION 
in O 
physiological O 
media O 
and O 
allow O 
an O 
efficient O 
in O 
vitro O 
cellular O 
delivery O 
of O 
these O 
molecules O 
down O 
to O 
the O 
cell O 
cytoplasm O 
. O 

effects O 
of O 
curcumin B-TRIVIAL 
on O 
gastric O 
cancer O 
cells O 
: O 
A O 
proteomic O 
study O 
of O 
molecular O 
targets O 
. O 

, O 
a O 
natural O 
anticancer O 
agent O 
, O 
has O 
been O 
shown O 
to O 
inhibit O 
cell O 
growth O 
in O 
a O 
number O 
of O 
tumor O 
cell O 
lines O 
and O 
animal O 
models O 
. O 
We O 
examined O 
the O 
inhibition O 
of O 
curcumin B-TRIVIAL 
on O 
cell O 
viability O 
and O 
its O 
induction O 
of O 
apoptosis O 
using O 
different O 
gastric O 
cancer O 
cell O 
lines O 
( O 
BGC-823 O 
, O 
MKN-45 O 
and O 
SCG-7901 O 
) O 
. O 
3-(4,5-dimethyl-thiazol-2-yl)-2-5-diphenyltetrazolium- B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
showed O 
that O 
curcumin B-TRIVIAL 
inhibited O 
cell O 
growth O 
in O 
a O 
dose- O 
( O 
1 O 
, O 
5 O 
, O 
10 O 
and O 
30μM O 
) O 
and O 
time- O 
( O 
24 O 
, O 
48 O 
, O 
72 O 
and O 
96h O 
) O 
dependent O 
manner O 
; O 
analysis O 
of O 
Annexin O 
V O 
binding O 
showed O 
that O 
curcumin B-TRIVIAL 
induced O 
apoptosis O 
at O 
the O 
dose O 
of O 
10 O 
and O 
30μM O 
when O 
the O 
cells O 
were O 
treated O 
for O 
24 O 
and O 
48h O 
. O 
As O 
cancers O 
are O 
caused O 
by O 
dysregulation O 
of O 
various O 
proteins O 
, O 
we O 
investigated O 
target O 
proteins O 
associated O 
with O 
curcumin B-TRIVIAL 
by O 
two O 
- O 
dimensional O 
gel O 
electrophoresis O 
( O 
2-DE O 
) O 
and O 
MALDI-TOF-TOF O 
mass O 
spectrometer O 
. O 
BGC-823cells O 
were O 
treated O 
with O 
30μM O 
curcumin B-TRIVIAL 
for O 
24h O 
and O 
total O 
protein O 
was O 
extracted O 
for O 
the O 
2-DE O 
. O 
In O 
the O 
first O 
dimension O 
of O 
the O 
2-DE O 
, O 
protein O 
samples O 
( O 
800μg O 
) O 
were O 
applied O 
to O 
immobilized O 
pH O 
gradient O 
( O 
IPG O 
) O 
strips O 
( O 
24cm O 
, O 
pH O 
3-10 O 
, O 
NL O 
) O 
and O 
the O 
isoelectric O 
focusing O 
( O 
IEF O 
) O 
was O 
performed O 
using O 
a O 
step O 
- O 
wise O 
voltage O 
ramp O 
; O 
the O 
second O 
dimension O 
was O 
performed O 
using O 
12.5% O 
SDS B-ABBREVIATION 
-PAGE O 
gel O 
at O 
1W O 
constant O 
power O 
per O 
gel O 
. O 
In O 
total O 
, O 
75 O 
proteins O 
showed O 
significant O 
changes O 
over O 
1.5-fold O 
in O 
curcumin B-TRIVIAL 
-treated O 
cells O 
compared O 
to O 
control O 
cells O 
( O 
Student's O 
t-test O 
, O 
p O 
< O 
0.05 O 
) O 
. O 
Among O 
them O 
, O 
33 O 
proteins O 
were O 
upregulated O 
and O 
42 O 
proteins O 
downregulated O 
by O 
curcumin B-TRIVIAL 
as O 
determined O 
by O 
spot O 
densitometry O 
. O 
52 O 
proteins O 
with O 
significant O 
mascot O 
scores O 
were O 
identified O 
and O 
implicated O 
in O 
cancer O 
development O 
and O 
progression O 
. O 
Their O 
biological O 
function O 
included O 
cell O 
proliferation O 
, O 
cycle O 
and O 
apoptosis O 
( O 
20% O 
) O 
, O 
metabolism O 
( O 
16% O 
) O 
, O 
nucleic O 
acid O 
processing O 
( O 
15% O 
) O 
, O 
cytoskeleton O 
organization O 
and O 
movement O 
( O 
11% O 
) O 
, O 
signal O 
transduction O 
( O 
11% O 
) O 
, O 
protein O 
folding O 
, O 
proteolysis O 
and O 
translation O 
( O 
20% O 
) O 
, O 
and O 
immune O 
response O 
( O 
2% O 
) O 
. O 
Furthermore O 
, O 
protein O 
- O 
protein O 
interacting O 
analysis O 
demonstrated O 
the O 
interaction O 
networks O 
affected O 
by O 
curcumin B-TRIVIAL 
in O 
gastric O 
cancer O 
cells O 
. O 
These O 
data O 
provide O 
some O 
clues O 
for O 
explaining O 
the O 
anticancer O 
mechanisms O 
of O 
curcumin B-TRIVIAL 
and O 
explore O 
more O 
potent O 
molecular O 
targets O 
of O 
the O 
drug O 
expected O 
to O 
be O 
helpful O 
for O 
the O 
development O 
of O 
new O 
drugs O 
. O 

bacterial O 
source O 
for O 
mollusk O 
pyrone B-FAMILY 
polyketides I-FAMILY 
. O 

the O 
oceans O 
, O 
secondary O 
metabolites O 
often O 
protect O 
otherwise O 
poorly O 
defended O 
invertebrates O 
, O 
such O 
as O 
shell O 
- O 
less O 
mollusks O 
, O 
from O 
predation O 
. O 
The O 
origins O 
of O 
these O 
metabolites O 
are O 
largely O 
unknown O 
, O 
but O 
many O 
of O 
them O 
are O 
thought O 
to O 
be O 
made O 
by O 
symbiotic O 
bacteria O 
. O 
In O 
contrast O 
, O 
mollusks O 
with O 
thick O 
shells O 
and O 
toxic O 
venoms O 
are O 
thought O 
to O 
lack O 
these O 
secondary O 
metabolites O 
because O 
of O 
reduced O 
defensive O 
needs O 
. O 
Here O 
, O 
we O 
show O 
that O 
heavily O 
defended O 
cone O 
snails O 
also O 
occasionally O 
contain O 
abundant O 
secondary O 
metabolites O 
, O 
γ-pyrones B-FAMILY 
known O 
as O 
nocapyrones B-FAMILY 
, O 
which O 
are O 
synthesized O 
by O 
symbiotic O 
bacteria O 
. O 
The O 
bacteria O 
, O 
Nocardiopsis O 
alba O 
CR167 O 
, O 
are O 
related O 
to O 
widespread O 
actinomycetes O 
that O 
we O 
propose O 
to O 
be O 
casual O 
symbionts O 
of O 
invertebrates O 
on O 
land O 
and O 
in O 
the O 
sea O 
. O 
The O 
natural O 
roles O 
of O 
nocapyrones B-FAMILY 
are O 
unknown O 
, O 
but O 
they O 
are O 
active O 
in O 
neurological O 
assays O 
, O 
revealing O 
that O 
mollusks O 
with O 
external O 
shells O 
are O 
an O 
overlooked O 
source O 
of O 
secondary O 
metabolite O 
diversity O 
. O 

double O 
- O 
strand O 
breaks O 
( O 
DSBs O 
) O 
in O 
B O 
lymphocytes O 
arise O 
stochastically O 
during O 
replication O 
or O 
as O 
a O 
result O 
of O 
targeted O 
DNA O 
damage O 
by O 
activation O 
- O 
induced O 
cytidine B-TRIVIAL 
deaminase O 
( O 
AID O 
) O 
. O 
Here O 
we O 
identify O 
recurrent O 
, O 
early O 
replicating O 
, O 
and O 
AID O 
- O 
independent O 
DNA O 
lesions O 
, O 
termed O 
early O 
replication O 
fragile O 
sites O 
( O 
ERFSs O 
) O 
, O 
by O 
genome O 
- O 
wide O 
localization O 
of O 
DNA O 
repair O 
proteins O 
in O 
B O 
cells O 
subjected O 
to O 
replication O 
stress O 
. O 
ERFSs O 
colocalize O 
with O 
highly O 
expressed O 
gene O 
clusters O 
and O 
are O 
enriched O 
for O 
repetitive O 
elements O 
and O 
CpG B-ABBREVIATION 
dinucleotides B-FAMILY 
. O 
Although O 
distinct O 
from O 
late O 
- O 
replicating O 
common O 
fragile O 
sites O 
( O 
CFS O 
) O 
, O 
the O 
stability O 
of O 
ERFSs O 
and O 
CFSs O 
is O 
similarly O 
dependent O 
on O 
the O 
replication O 
- O 
stress O 
response O 
kinase O 
ATR O 
. O 
ERFSs O 
break O 
spontaneously O 
during O 
replication O 
, O 
but O 
their O 
fragility O 
is O 
increased O 
by O 
hydroxyurea B-SYSTEMATIC 
, O 
ATR O 
inhibition O 
, O 
or O 
deregulated O 
c-Myc O 
expression O 
. O 
Moreover O 
, O 
greater O 
than O 
50% O 
of O 
recurrent O 
amplifications O 
/ O 
deletions O 
in O 
human O 
diffuse O 
large O 
B O 
cell O 
lymphoma O 
map O 
to O 
ERFSs O 
. O 
In O 
summary O 
, O 
we O 
have O 
identified O 
a O 
source O 
of O 
spontaneous O 
DNA O 
lesions O 
that O 
drives O 
instability O 
at O 
preferred O 
genomic O 
sites O 
. O 

- O 
to O 
- O 
point O 
ligand O 
- O 
receptor O 
interactions O 
across O 
the O 
subunit O 
interface O 
modulate O 
the O 
induction O 
and O 
stabilization O 
of O 
conformational O 
states O 
of O 
alpha7 O 
nAChR O 
by O 
benzylidene B-FAMILY 
anabaseines I-FAMILY 
. O 

homomeric O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
is O 
a O 
well O 
- O 
studied O 
therapeutic O 
target O 
, O 
though O 
its O 
characteristically O 
rapid O 
desensitization O 
complicates O 
the O 
development O 
of O 
drugs O 
with O 
specific O 
agonist O 
effects O 
. O 
Moreover O 
, O 
some O 
experimental O 
compounds O 
such O 
as O 
GTS-21 B-IDENTIFIER 
( O 
2,4diMeOBA B-SYSTEMATIC 
) O 
, O 
a O 
derivative O 
of O 
the O 
α7-selective O 
partial O 
agonist O 
benzylidene B-FAMILY 
anabaseine I-FAMILY 
( O 
BA O 
) O 
, O 
produce O 
a O 
prolonged O 
residual O 
desensitization O 
( O 
RD O 
) O 
in O 
which O 
the O 
receptor O 
remains O 
non-activatable O 
long O 
after O 
the O 
drug O 
has O 
been O 
removed O 
from O 
extracellular O 
solution O 
. O 
In O 
contrast O 
, O 
the O 
desensitization O 
caused O 
by O 
GTS-21 B-IDENTIFIER 
' O 
s O 
dihydroxy B-SYSTEMATIC 
metabolite O 
( O 
2,4diOHBA B-SYSTEMATIC 
) O 
is O 
relatively O 
short O 
- O 
lived O 
. O 
RD O 
is O 
hypothetically O 
due O 
to O 
stable O 
binding O 
of O 
the O 
ligand O 
to O 
the O 
receptor O 
in O 
its O 
desensitized O 
state O 
. O 
We O 
can O 
attribute O 
the O 
reduction O 
in O 
RD O 
to O 
a O 
single O 
BA O 
hydroxyl B-SYSTEMATIC 
group O 
on O 
the O 
4 O 
' O 
benzylidene B-SYSTEMATIC 
position O 
. O 
Computational O 
prediction O 
derived O 
from O 
homology O 
modeling O 
showed O 
the O 
serine B-TRIVIAL 
36 O 
( O 
S36 O 
) O 
residue O 
of O 
α7 O 
as O 
a O 
reasonable O 
candidate O 
for O 
point O 
- O 
to O 
- O 
point O 
interaction O 
between O 
BA O 
compounds O 
and O 
the O 
receptor O 
. O 
Through O 
evaluating O 
the O 
activity O 
of O 
BA O 
and O 
simple O 
derivatives O 
on O 
wild O 
- O 
type O 
and O 
mutant O 
α7 O 
receptors O 
, O 
it O 
was O 
observed O 
that O 
the O 
drug O 
- O 
receptor O 
pairs O 
which O 
were O 
capable O 
of O 
hydrogen B-SYSTEMATIC 
bonding O 
at O 
residue O 
36 O 
exhibited O 
significantly O 
less O 
stable O 
desensitization O 
. O 
Further O 
experiments O 
involving O 
the O 
type O 
II O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
PNU-120596 B-IDENTIFIER 
showed O 
that O 
the O 
various O 
BA O 
compounds O 
' O 
preference O 
to O 
induce O 
either O 
a O 
PAM-sensitive O 
(D(s)) O 
or O 
PAM-insensitive O 
(D(i)) O 
desensitized O 
state O 
is O 
concentration O 
dependent O 
and O 
suggested O 
that O 
both O 
states O 
are O 
destabilized O 
by O 
S36 O 
H B-FORMULA 
-bonding O 
. O 
These O 
results O 
indicate O 
that O 
the O 
fine O 
- O 
tuning O 
of O 
agonists O 
for O 
specific O 
interaction O 
with O 
S36 O 
can O 
facilitate O 
the O 
development O 
of O 
therapeutics O 
with O 
targeted O 
effects O 
on O 
ion O 
channel O 
desensitization O 
properties O 
and O 
conformational O 
state O 
stability O 
. O 

nano O 
- O 
particulate O 
systems O 
hold O 
extraordinary O 
potential O 
for O 
delivery O 
of O 
therapeutics O 
across O 
blood O 
brain O 
barrier O 
( O 
BBB O 
) O 
. O 
In O 
this O 
work O 
, O 
we O 
investigated O 
the O 
potential O 
of O 
novel O 
bi O 
- O 
ligand O 
( O 
transferrin- O 
poly-l-arginine B-SYSTEMATIC 
) O 
liposomal O 
vector O 
for O 
delivery O 
of O 
desired O 
gene O 
to O 
brain O 
, O 
in O 
vivo O 
. O 
The O 
in O 
vivo O 
evaluation O 
of O 
the O 
delivery O 
vectors O 
is O 
essential O 
for O 
clinical O 
translation O 
. O 
We O 
followed O 
an O 
innovative O 
approach O 
of O 
combining O 
transferrin O 
receptor O 
targeting O 
with O 
enhanced O 
cell O 
penetration O 
to O 
design O 
liposomal O 
vectors O 
for O 
improving O 
the O 
transport O 
of O 
molecules O 
into O 
brain O 
. O 
The O 
biodistribution O 
profile O 
of O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine I-SYSTEMATIC 
iodide I-SYSTEMATIC 
( O 
DiR B-ABBREVIATION 
)-labeled O 
liposomes O 
was O 
evaluated O 
in O 
adult O 
rats O 
after O 
single O 
intravenous O 
injection O 
at O 
dose O 
of O 
15.2μmoles O 
of O 
phospholipids O 
/ O 
kg O 
body O 
weight O 
. O 
We O 
demonstrated O 
that O 
bi O 
- O 
ligand O 
liposomes O 
accumulated O 
in O 
rat O 
brain O 
at O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
higher O 
concentrations O 
as O 
compared O 
to O 
the O 
single O 
- O 
ligand O 
( O 
transferrin O 
) O 
or O 
plain O 
liposomes O 
. O 
In O 
addition O 
, O 
the O 
bi O 
- O 
ligand O 
liposomes O 
resulted O 
in O 
increased O 
expression O 
of O 
β-galactosidase(β-gal) O 
plasmid O 
in O 
rat O 
brain O 
tissue O 
in O 
comparison O 
to O 
the O 
single O 
- O 
ligand O 
liposomes O 
. O 
Histological O 
examination O 
of O 
the O 
transfected O 
tissues O 
did O 
not O 
show O 
any O 
signs O 
of O 
tissue O 
necrosis O 
or O 
inflammation O 
. O 
Hemolysis O 
assay O 
further O 
authenticated O 
the O 
biocompatibility O 
of O 
bi O 
- O 
ligand O 
liposomes O 
in O 
blood O 
up O 
to O 
600 O 
nmoles O 
of O 
phospholipids O 
/ O 
1.4×10(7) O 
erythrocytes O 
. O 
The O 
findings O 
of O 
this O 
study O 
provide O 
important O 
and O 
detailed O 
information O 
regarding O 
the O 
distribution O 
of O 
bi O 
- O 
ligand O 
liposomes O 
in O 
vivo O 
and O 
accentuate O 
their O 
ability O 
to O 
demonstrate O 
improved O 
brain O 
penetration O 
and O 
transfection O 
potential O 
over O 
single O 
- O 
ligand O 
liposomes O 
. O 

suffruticosa O 
Mill O 
is O 
used O 
as O 
an O 
herbal O 
medicine O 
for O 
the O 
treatment O 
of O 
inflammation O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
assess O 
the O 
anti-inflammatory O 
potency O 
of O 
I O 
. O 
suffruticosa O 
and O 
its O 
likely O 
molecular O 
mechanisms O 
of O 
action O 
in O 
lipopolysaccharide O 
(LPS)-induced O 
RAW O 
264.7 O 
macrophages O 
. O 
Both O 
water O 
and O 
ethanolic O 
extracts O 
of O 
I O 
. O 
suffruticosa O 
significantly O 
decreased O 
LPS-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
as O 
well O 
as O 
the O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
, O 
and O 
pro-interleukin-1β O 
. O 
Moreover O 
, O 
LPS-induced O 
inhibitory O 
factor-κB-α O 
phosphorylation O 
, O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
nuclear O 
protein-DNA O 
binding O 
affinity O 
, O 
and O 
NF-κB O 
reporter O 
gene O 
activity O 
were O 
dramatically O 
inhibited O 
by O 
I O 
. O 
suffruticosa O 
extracts O 
. O 
Exogenous O 
addition O 
of O 
I O 
. O 
suffruticosa O 
significantly O 
induced O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
expression O 
, O 
and O 
the O 
presence O 
of O 
HO-1 O 
small O 
interfering O 
RNA O 
partly O 
reversed O 
the O 
inhibitory O 
effects O 
of O 
I O 
. O 
suffruticosa O 
on O 
LPS-induced O 
NO B-FORMULA 
production O 
and O 
iNOS O 
expression O 
. O 
Furthermore O 
, O 
I O 
. O 
suffruticosa O 
induced O 
HO-1 O 
expression O 
may O 
be O 
through O 
activation O 
of O 
the O 
ERK O 
/ O 
nuclear O 
factor O 
E2 O 
- O 
related O 
factor O 
2 O 
pathway O 
. O 
Eight O 
phenolic B-FAMILY 
compounds O 
were O 
found O 
in O 
the O 
I O 
. O 
suffruticosa O 
extracts O 
, O 
but O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
was O 
the O 
only O 
one O 
detected O 
in O 
the O 
plasma O 
of O 
mice O 
fed O 
with O 
I O 
. O 
suffruticosa O 
extracts O 
. O 
In O 
summary O 
, O 
I O 
. O 
suffruticosa O 
have O 
a O 
strong O 
anti-inflammatory O 
property O 
that O 
diminishes O 
pro O 
- O 
inflammatory O 
mediator O 
expressions O 
by O 
lessening O 
LPS-induced O 
NF-κB O 
activation O 
and O 
inducing O 
HO-1 O 
expression O 
in O 
macrophages O 
. O 

stress O 
involvement O 
in O 
manganese B-SYSTEMATIC 
-induced O 
alpha-synuclein O 
oligomerization O 
in O 
organotypic O 
brain O 
slice O 
cultures O 
. O 

to O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
has O 
been O 
known O 
to O 
induce O 
neuronal O 
damage O 
. O 
However O 
, O 
little O 
is O 
known O 
of O 
the O 
role O 
that O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
play O 
in O 
protein O 
aggregation O 
resulting O 
from O 
Mn B-FORMULA 
exposure O 
. O 
The O 
current O 
study O 
investigated O 
whether O 
oxidative O 
stress O 
is O 
involved O 
in O 
manganese B-SYSTEMATIC 
-induced O 
alpha-synuclein O 
oligomerization O 
in O 
organotypic O 
brain O 
slices O 
. O 
After O 
application O 
of O 
Mn B-FORMULA 
( O 
0-400μM O 
) O 
for O 
24h O 
, O 
there O 
was O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
average O 
percentage O 
of O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
positive O 
(PI(+)) O 
nuclei O 
in O 
slices O 
and O 
levels O 
of O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
in O 
the O 
culture O 
medium O 
. O 
Moreover O 
, O 
the O 
treatment O 
with O 
Mn B-FORMULA 
resulted O 
in O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
neurocyte O 
apoptosis O 
, O 
ROS O 
level O 
, O 
and O 
decrease O 
in O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activity O 
. O 
Mn B-FORMULA 
also O 
caused O 
oxidative O 
damage O 
in O 
cell O 
lipid O 
and O 
protein O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
exposure O 
of O 
Mn B-FORMULA 
leaded O 
to O 
significantly O 
increase O 
in O 
the O 
expression O 
of O 
alpha-synuclein O 
mRNA O 
and O 
protein O 
. O 
Alpha-synuclein O 
oligomerization O 
occurred O 
in O 
Mn B-FORMULA 
-treated O 
slices O 
, O 
especially O 
on O 
membrane O 
- O 
bound O 
form O 
. O 
It O 
indicated O 
that O 
alpha-synuclein O 
oligomers O 
were O 
more O 
likely O 
to O 
combination O 
cell O 
membranes O 
and O 
resulting O 
in O 
membrane O 
damage O 
. O 
Mn B-FORMULA 
-induced O 
neurocyte O 
damage O 
and O 
alpha-synuclein O 
oligomerization O 
were O 
also O 
partially O 
alleviated O 
by O 
the O 
pretreatment O 
with O 
GSH B-ABBREVIATION 
and O 
aggravated O 
by O 
H2O2 B-FORMULA 
pretreatment O 
. O 
The O 
findings O 
revealed O 
Mn B-FORMULA 
might O 
exert O 
its O 
neurotoxic O 
effects O 
by O 
oxidative O 
stress O 
- O 
mediated O 
alpha-synuclein O 
oligomerization O 
in O 
organotypic O 
brain O 
slices O 
. O 

vitro O 
toxicological O 
characterisation O 
of O 
the O 
S B-FORMULA 
-containing O 
arsenic B-SYSTEMATIC 
metabolites O 
thio B-SYSTEMATIC 
- I-SYSTEMATIC 
dimethylarsinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
dimethylarsinic B-SYSTEMATIC 
glutathione I-SYSTEMATIC 
. O 

arsenic B-SYSTEMATIC 
is O 
a O 
well O 
- O 
documented O 
, O 
exposure O 
relevant O 
human O 
carcinogen O 
. O 
A O 
promising O 
starting O 
point O 
to O 
further O 
understand O 
the O 
mechanisms O 
behind O 
inorganic O 
arsenic B-SYSTEMATIC 
carcinogenicity O 
might O 
be O 
a O 
formation O 
of O 
reactive O 
, O 
highly O 
toxic O 
metabolites O 
during O 
human O 
arsenic B-SYSTEMATIC 
metabolism O 
. O 
This O 
study O 
characterises O 
the O 
toxicity O 
of O 
recently O 
identified O 
S B-FORMULA 
-containing O 
arsenic B-SYSTEMATIC 
metabolites O 
in O 
cultured O 
human O 
A549 O 
lung O 
adenocarcinoma O 
epithelium O 
cells O 
. O 
In O 
direct O 
comparison O 
to O 
arsenite B-SYSTEMATIC 
, O 
thio B-SYSTEMATIC 
- I-SYSTEMATIC 
dimethylarsinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
thio-DMA B-SYSTEMATIC 
( O 
V O 
) O 
) O 
and O 
dimethylarsinic B-SYSTEMATIC 
glutathione I-SYSTEMATIC 
( O 
DMAG B-ABBREVIATION 
) O 
exerted O 
a O 
5- O 
to O 
20-fold O 
stronger O 
cytotoxicity O 
and O 
showed O 
a O 
2- O 
to O 
20-fold O 
higher O 
cellular O 
bioavailability O 
, O 
respectively O 
. O 
All O 
three O 
arsenicals O 
disturbed O 
cell O 
cycle O 
progression O 
at O 
cytotoxic O 
concentrations O 
, O 
but O 
failed O 
to O 
increase O 
the O 
level O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
species O 
( O 
RONS O 
) O 
in O 
healthy O 
A549 O 
cells O 
. O 
However O 
, O 
a O 
strong O 
disturbance O 
of O 
the O 
oxidative O 
defense O 
system O 
was O 
observed O 
after O 
incubation O 
with O 
absolutely O 
sub O 
- O 
cytotoxic O 
, O 
pico- O 
to O 
nanomolar O 
concentrations O 
of O 
arsenite B-SYSTEMATIC 
and O 
thio-DMA B-SYSTEMATIC 
(V) O 
, O 
respectively O 
. O 
Thus O 
, O 
both O 
GSH B-ABBREVIATION 
and O 
GSSG B-ABBREVIATION 
levels O 
were O 
significantly O 
decreased O 
by O 
up O 
to O 
40% O 
. O 
Accordingly O 
, O 
RONS O 
levels O 
of O 
oxidatively O 
( O 
H2O2 B-FORMULA 
) O 
stressed O 
cells O 
were O 
strongly O 
increased O 
by O 
the O 
arsenicals O 
. O 
Since O 
in O 
vivo O 
RONS O 
are O 
permanently O 
endogenously O 
and O 
exogenously O 
produced O 
, O 
this O 
boost O 
of O 
the O 
existing O 
oxidative O 
stress O 
by O 
arsenite B-SYSTEMATIC 
and O 
thio-DMA B-SYSTEMATIC 
(V) O 
might O 
contribute O 
to O 
the O 
process O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
induced O 
carcinogenicity O 
. O 

of O 
copper B-SYSTEMATIC 
acclimation O 
in O 
the O 
least O 
killifish O 
Heterandria O 
formosa O 
, O 
and O 
associated O 
biochemical O 
and O 
physiological O 
mechanisms O 
. O 

investigated O 
the O 
occurrence O 
of O 
copper B-SYSTEMATIC 
acclimation O 
in O 
the O 
least O 
killifish O 
, O 
Heterandria O 
formosa O 
using O 
both O 
lethal O 
and O 
sublethal O 
endpoints O 
. O 
We O 
also O 
investigated O 
potential O 
mechanisms O 
underlying O 
the O 
observed O 
acclimation O 
. O 
To O 
assess O 
the O 
occurrence O 
of O 
acclimation O 
, O 
fish O 
were O 
exposed O 
to O 
either O 
a O 
background O 
Cu B-FORMULA 
level O 
or O 
to O 
15 O 
μg O 
/ O 
L O 
Cu B-FORMULA 
for O 
seven O 
days O 
and O 
subsequently O 
exposed O 
to O 
a O 
lethal O 
Cu B-FORMULA 
level O 
( O 
150 O 
μg O 
/ O 
L O 
Cu B-FORMULA 
) O 
. O 
During O 
the O 
latter O 
exposure O 
, O 
fish O 
were O 
monitored O 
for O 
survival O 
till O 
all O 
fish O 
had O 
died O 
, O 
and O 
( O 
during O 
the O 
first O 
8h O 
of O 
this O 
exposure O 
) O 
for O 
changes O 
in O 
whole O 
- O 
body O 
Na B-FORMULA 
levels O 
and O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
. O 
During O 
the O 
high O 
- O 
level O 
Cu B-FORMULA 
exposure O 
, O 
fish O 
pre O 
- O 
exposed O 
to O 
copper B-SYSTEMATIC 
had O 
a O 
significantly O 
longer O 
time O 
- O 
to O 
- O 
death O 
than O 
did O 
the O 
control O 
fish O 
. O 
Similarly O 
, O 
neither O 
whole O 
- O 
body O 
Na B-FORMULA 
nor O 
LPO O 
changed O 
in O 
the O 
Cu B-FORMULA 
-pre O 
- O 
exposed O 
fish O 
during O 
the O 
8h O 
of O 
the O 
exposure O 
to O 
150 O 
μg O 
/ O 
L O 
Cu B-FORMULA 
- O 
while O 
both O 
decreased O 
significantly O 
in O 
the O 
control O 
fish O 
. O 
Thus O 
, O 
acclimation O 
was O 
evident O 
for O 
both O 
time O 
- O 
to O 
- O 
death O 
and O 
the O 
sublethal O 
endpoints O 
. O 
These O 
results O 
also O 
indicate O 
that O 
Cu B-FORMULA 
toxicity O 
may O 
involve O 
both O 
Na B-FORMULA 
loss O 
and O 
LPO O 
, O 
and O 
that O 
Cu B-FORMULA 
-acclimation O 
may O 
be O 
brought O 
about O 
by O 
prevention O 
of O 
these O 
effects O 
. O 
Our O 
follow O 
- O 
up O 
study O 
on O 
potential O 
mechanisms O 
underlying O 
this O 
copper B-SYSTEMATIC 
acclimation O 
used O 
a O 
similar O 
pre O 
- O 
exposure O 
/ O 
exposure O 
design O 
. O 
Fish O 
were O 
subsampled O 
at O 
the O 
end O 
of O 
the O 
7-day O 
acclimation O 
period O 
- O 
just O 
before O 
the O 
commencement O 
of O 
high O 
- O 
level O 
Cu B-FORMULA 
exposure O 
( O 
T O 
) O 
, O 
after O 
4h O 
of O 
this O 
Cu B-FORMULA 
exposure O 
( O 
T O 
) O 
, O 
and O 
again O 
after O 
8h O 
of O 
this O 
Cu B-FORMULA 
exposure O 
( O 
T O 
) O 
. O 
Whole O 
- O 
body O 
Cu B-FORMULA 
accumulation O 
, O 
Na B-FORMULA 
/ O 
K B-FORMULA 
-ATPase O 
activity O 
, O 
metallothionein O 
levels O 
, O 
and O 
catalase O 
activity O 
were O 
quantified O 
for O 
these O 
time O 
points O 
. O 
While O 
Cu B-FORMULA 
levels O 
were O 
higher O 
in O 
the O 
Cu B-FORMULA 
-pre O 
- O 
exposed O 
fish O 
than O 
in O 
the O 
control O 
fish O 
at O 
T O 
, O 
net O 
Cu B-FORMULA 
accumulation O 
was O 
faster O 
in O 
the O 
control O 
fish O 
than O 
in O 
the O 
Cu B-FORMULA 
-pre O 
- O 
exposed O 
fish O 
during O 
the O 
subsequent O 
high O 
- O 
level O 
Cu B-FORMULA 
exposure O 
. O 
Consequently O 
, O 
changes O 
in O 
Cu B-FORMULA 
accumulation O 
dynamics O 
may O 
play O 
a O 
role O 
in O 
the O 
resistance O 
. O 
Metallothionein O 
induction O 
may O 
also O 
play O 
a O 
role O 
in O 
the O 
observed O 
acclimation O 
, O 
as O 
Cu B-FORMULA 
-acclimated O 
fish O 
had O 
a O 
significantly O 
higher O 
metallothionein O 
concentration O 
compared O 
to O 
the O 
control O 
fish O 
. O 
There O 
was O 
no O 
evidence O 
of O 
involvement O 
of O 
Na B-FORMULA 
/ O 
K B-FORMULA 
-ATPase O 
in O 
the O 
acclimation O 
, O 
as O 
the O 
activity O 
of O 
this O 
enzyme O 
remained O 
lower O 
in O 
the O 
pre O 
- O 
exposed O 
fish O 
than O 
in O 
the O 
control O 
fish O 
throughout O 
both O 
Cu B-FORMULA 
exposure O 
periods O 
. O 
There O 
was O 
limited O 
evidence O 
that O 
a O 
reduced O 
loss O 
of O 
catalase O 
activity O 
plays O 
a O 
role O 
in O 
the O 
acclimation O 
; O 
catalase O 
activity O 
did O 
not O 
differ O 
after O 
the O 
pre O 
- O 
exposure O 
period O 
but O 
was O 
significantly O 
higher O 
in O 
Cu B-FORMULA 
-acclimated O 
fish O 
than O 
in O 
the O 
control O 
fish O 
at O 
T O 
. O 

vitro O 
permeability O 
analysis O 
, O 
pharmacokinetic O 
and O 
brain O 
distribution O 
study O 
in O 
mice O 
of O 
imperatorin B-TRIVIAL 
, O 
isoimperatorin B-TRIVIAL 
and O 
cnidilin B-TRIVIAL 
in O 
Radix O 
Angelicae O 
Dahuricae O 
. O 

are O 
important O 
constituents O 
of O 
Radix O 
Angelicae O 
Dahuricae O 
, O 
a O 
well O 
- O 
known O 
traditional O 
Chinese O 
medicine O 
possess O 
several O 
known O 
bioactivities O 
with O 
potentials O 
in O 
the O 
treatment O 
of O 
central O 
nervous O 
system O 
diseases O 
. O 
By O 
using O 
an O 
HPLC-MS O 
/ O 
MS O 
method O 
, O 
we O 
analyzed O 
the O 
in O 
vivo O 
plasma O 
and O 
brain O 
pharmacokinetics O 
of O 
three O 
ingredients O 
of O 
coumarins B-FAMILY 
, O 
including O 
imperatorin B-TRIVIAL 
, O 
isoimperatorin B-TRIVIAL 
and O 
cnidilin B-TRIVIAL 
in O 
mice O 
after O 
oral O 
administration O 
of O 
Dahuricae O 
extract O 
at O 
doses O 
of O 
800mg O 
/ O 
kg O 
. O 
The O 
biosamples O 
were O 
prepared O 
using O 
acetonitrile B-SYSTEMATIC 
precipitation O 
and O 
the O 
separation O 
was O 
achieved O 
on O 
an O 
XDB-C18 O 
column O 
by O 
gradient O 
elution O 
. O 
The O 
BBB O 
permeability O 
and O 
P-gp O 
- O 
mediated O 
efflux O 
were O 
further O 
examined O 
in O 
Madin O 
Canine O 
kidney O 
cells O 
transfected O 
with O 
full O 
length O 
cDNA O 
for O 
human O 
multidrug O 
resistance O 
gene1 O 
( O 
MDCKII-MDR1 O 
) O 
. O 
Our O 
results O 
demonstrate O 
that O 
the O 
method O 
has O 
excellent O 
and O 
satisfactory O 
selectivity O 
, O 
sensitivity O 
, O 
linearity O 
, O 
precision O 
, O 
and O 
accuracy O 
for O 
simultaneous O 
determination O 
of O 
imperatorin B-TRIVIAL 
, O 
isoimperatorin B-TRIVIAL 
and O 
cnidilin B-TRIVIAL 
. O 
The O 
pharmacokinetics O 
parameters O 
were O 
determined O 
by O 
using O 
noncompartmental O 
analyses O 
, O 
including O 
the O 
AUC(0-t) O 
in O 
plasma O 
( O 
1695.22 O 
, O 
1326.45 O 
and O 
636.98mg*h O 
/ O 
L O 
) O 
, O 
the O 
AUC(0-t) O 
in O 
brain O 
( O 
1812.35 O 
, O 
2125.17 O 
and O 
1145.83ng*h O 
/ O 
g O 
) O 
as O 
well O 
as O 
the O 
T1 O 
/ O 
2 O 
in O 
plasma O 
( O 
0.66 O 
, O 
0.82 O 
, O 
0.97h O 
) O 
and O 
brain O 
( O 
0.96 O 
, O 
1.1 O 
, O 
0.99h O 
) O 
for O 
imperatorin B-TRIVIAL 
, O 
isoimperatorin B-TRIVIAL 
and O 
cnidilin B-TRIVIAL 
, O 
respectively O 
, O 
suggesting O 
that O 
the O 
three O 
coumarins B-FAMILY 
could O 
easily O 
pass O 
through O 
the O 
BBB O 
in O 
vivo O 
. O 
In O 
the O 
in O 
vitro O 
model O 
we O 
observed O 
high O 
permeability O 
of O 
imperatorin B-TRIVIAL 
and O 
isoimperatorin B-TRIVIAL 
with O 
the O 
P-gp O 
- O 
mediated O 
efflux O 
ratios O 
of O 
0.53 O 
and O 
0.06 O 
, O 
as O 
well O 
as O 
medium O 
permeability O 
of O 
cnidilin B-TRIVIAL 
with O 
0.82 O 
. O 
All O 
data O 
suggest O 
that O 
these O 
three O 
coumarins B-FAMILY 
have O 
high O 
BBB O 
permeability O 
and O 
have O 
pharmacokinetic O 
potentials O 
for O 
the O 
treatment O 
of O 
central O 
nervous O 
system O 
diseases O 
. O 

glycosides I-FAMILY 
from O 
Curculigo O 
orchioides O 
Gaertn O 
. O 

new O 
chlorophenolic B-FAMILY 
glucosides I-FAMILY 
, O 
curculigine B-TRIVIAL 
E I-TRIVIAL 
( O 
1 O 
) O 
, O 
curculigine B-TRIVIAL 
F I-TRIVIAL 
( O 
2 O 
) O 
, O 
curculigine B-TRIVIAL 
G I-TRIVIAL 
( O 
3 O 
) O 
, O 
curculigine B-TRIVIAL 
H I-TRIVIAL 
( O 
5 O 
) O 
, O 
curculigine B-TRIVIAL 
I I-TRIVIAL 
( O 
6 O 
) O 
and O 
one O 
new O 
phenolic B-FAMILY 
glycoside I-FAMILY 
, O 
orcinoside B-TRIVIAL 
H I-TRIVIAL 
( O 
4 O 
) O 
, O 
together O 
with O 
eight O 
known O 
phenolic B-FAMILY 
glycosides I-FAMILY 
( O 
7-14 O 
) O 
were O 
isolated O 
from O 
the O 
Curculigo O 
orchioides O 
Gaertn O 
. O 
Their O 
structures O 
were O 
established O 
by O 
spectroscopic O 
techniques O 
( O 
IR O 
, O 
UV O 
, O 
MS O 
, O 
1D O 
and O 
2D O 
NMR O 
) O 
. O 
The O 
isolated O 
phenolic B-FAMILY 
glycosides I-FAMILY 
were O 
evaluated O 
for O 
antiosteoporotic O 
activity O 
against O 
MC3T3-E1 O 
cell O 
line O 
using O 
MTT B-ABBREVIATION 
assays O 
. O 
Compounds O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
and O 
5 O 
showed O 
moderate O 
antiosteoporotic O 
activity O 
with O 
the O 
proliferation O 
rate O 
of O 
10.1-14.1% O 
. O 

resistance O 
in O 
B-cells O 
isolated O 
from O 
chronic O 
lymphocytic O 
leukemia O 
patients O 
and O 
leukemia O 
cell O 
lines O 
is O 
overcome O 
by O 
the O 
pleiotropic O 
kinase O 
inhibitor O 
quercetin B-TRIVIAL 
through O 
Mcl-1 O 
down O 
- O 
regulation O 
. O 

lymphocytic O 
leukemia O 
( O 
CLL O 
) O 
is O 
the O 
most O 
frequent O 
form O 
of O 
leukemia O 
in O 
adult O 
population O 
and O 
despite O 
numerous O 
studies O 
, O 
it O 
is O 
considered O 
an O 
incurable O 
disease O 
. O 
Since O 
CLL O 
is O 
characterized O 
by O 
overexpression O 
of O 
pro O 
- O 
survival O 
Bcl-2 O 
family O 
members O 
, O 
treatments O 
with O 
their O 
antagonists O 
, O 
such O 
as O 
ABT-737 B-IDENTIFIER 
, O 
represent O 
a O 
promising O 
new O 
therapeutic O 
strategy O 
. O 
ABT-737 B-IDENTIFIER 
is O 
a O 
BH3 O 
mimetic O 
agent O 
which O 
binds O 
Bcl-2 O 
, O 
Bcl-XL O 
and O 
Bcl-w O 
with O 
high O 
affinity O 
, O 
while O 
weakly O 
interacts O 
with O 
Mcl-1 O 
and O 
Bfl-1 O 
. O 
Previous O 
studies O 
demonstrated O 
that O 
quercetin B-TRIVIAL 
, O 
a O 
flavonoid B-FAMILY 
naturally O 
present O 
in O 
food O 
and O 
beverages O 
, O 
was O 
able O 
to O 
sensitize O 
B-cells O 
isolated O 
from O 
CLL O 
patients O 
to O 
apoptosis O 
when O 
associated O 
with O 
death O 
ligands O 
or O 
fludarabine O 
, O 
through O 
a O 
mechanism O 
involving O 
Mcl-1 O 
down O 
- O 
regulation O 
. O 
Here O 
, O 
we O 
report O 
that O 
the O 
association O 
between O 
ABT-737 B-IDENTIFIER 
and O 
quercetin B-TRIVIAL 
synergistically O 
induces O 
apoptosis O 
in O 
B-cells O 
and O 
in O 
five O 
leukemic O 
cell O 
lines O 
( O 
Combination O 
Index O 
< O 
1 O 
) O 
. O 
Peripheral O 
blood O 
mononuclear O 
cell O 
from O 
healthy O 
donors O 
were O 
not O 
affected O 
by O 
quercetin B-TRIVIAL 
treatment O 
. O 
The O 
molecular O 
pathways O 
triggered O 
by O 
quercetin B-TRIVIAL 
have O 
been O 
investigated O 
in O 
HPB-ALL O 
cells O 
, O 
characterized O 
by O 
the O 
highest O 
resistance O 
to O 
both O 
ABT-737 B-IDENTIFIER 
and O 
quercetin B-TRIVIAL 
when O 
applied O 
as O 
single O 
molecules O 
, O 
but O 
highly O 
sensitivity O 
to O 
the O 
co O 
- O 
treatment O 
. O 
In O 
this O 
cell O 
line O 
, O 
quercetin B-TRIVIAL 
down O 
- O 
regulated O 
Mcl-1 O 
through O 
the O 
inhibition O 
of O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
, O 
leading O 
to O 
Mcl-1 O 
instability O 
. O 
The O 
same O 
mechanism O 
was O 
confirmed O 
in O 
B-cells O 
. O 
These O 
results O 
may O 
open O 
new O 
clinical O 
perspectives O 
based O 
on O 
a O 
translational O 
approach O 
in O 
CLL O 
therapy O 
. O 

plays O 
a O 
critical O 
mediator O 
in O 
the O 
pathogenesis O 
of O 
chronic O 
heart O 
failure O 
contributing O 
to O 
cardiac O 
remodeling O 
and O 
peripheral O 
vascular O 
disturbances O 
. O 
The O 
implication O 
of O 
TNF-α O 
in O 
inflammatory O 
responses O 
has O 
been O 
shown O 
to O 
be O 
mediated O 
through O 
up O 
- O 
regulation O 
of O 
inflammatory O 
genes O 
, O 
including O 
matrix O 
metalloproteinase-9 O 
( O 
MMP-9 O 
) O 
. O 
However O 
, O 
the O 
detailed O 
mechanisms O 
of O 
TNF-α-induced O 
MMP-9 O 
expression O 
are O 
largely O 
unclear O 
in O 
the O 
heart O 
cells O 
. O 
Here O 
, O 
we O 
demonstrated O 
that O 
in O 
rat O 
embryonic O 
- O 
heart O 
derived O 
H9c2 O 
cells O 
, O 
TNF-α O 
could O 
induce O 
MMP-9 O 
mRNA O 
expression O 
associated O 
with O 
an O 
increase O 
in O 
the O 
secretion O 
of O 
MMP-9 O 
, O 
determined O 
by O 
real O 
- O 
time O 
PCR O 
, O 
zymography O 
, O 
and O 
promoter O 
activity O 
assays O 
. O 
TNF-α O 
- O 
mediated O 
responses O 
were O 
attenuated O 
by O 
pretreatment O 
with O 
the O 
inhibitor O 
of O 
c-Src O 
( O 
PP1 B-IDENTIFIER 
) O 
, O 
EGFR O 
( O 
AG1478 B-IDENTIFIER 
) O 
, O 
PDGFR O 
( O 
AG1296 B-IDENTIFIER 
) O 
, O 
PI3K O 
( O 
LY294002 B-IDENTIFIER 
) O 
, O 
Akt O 
( O 
SH-5 B-IDENTIFIER 
) O 
, O 
MEK1 O 
/ O 
2 O 
( O 
U0126 B-IDENTIFIER 
) O 
, O 
p38 O 
MAPK O 
( O 
SB202190 B-IDENTIFIER 
) O 
, O 
JNK1 O 
/ O 
2 O 
( O 
SP600125 B-IDENTIFIER 
) O 
, O 
or O 
AP-1 O 
( O 
Tanshinone B-TRIVIAL 
IIA I-TRIVIAL 
) O 
and O 
transfection O 
with O 
siRNA O 
of O 
c-Src O 
, O 
EGFR O 
, O 
PDGFR O 
, O 
p110 O 
, O 
Akt O 
, O 
or O 
c-Jun O 
. O 
TNF-α O 
stimulated O 
c-Src O 
, O 
PDGFR O 
, O 
and O 
EGFR O 
phosphorylation O 
, O 
which O 
were O 
reduced O 
by O 
PP1 B-IDENTIFIER 
. O 
In O 
addition O 
, O 
TNF-α-stimulated O 
Akt O 
phosphorylation O 
was O 
inhibited O 
by O 
PP1 B-IDENTIFIER 
, O 
AG1478 B-IDENTIFIER 
, O 
AG1296 B-IDENTIFIER 
, O 
or O 
LY294002 B-IDENTIFIER 
. O 
We O 
further O 
demonstrated O 
that O 
TNF-α O 
markedly O 
stimulated O 
p38 O 
MAPK O 
, O 
p42 O 
/ O 
p44 O 
MAPK O 
, O 
and O 
JNK1 O 
/ O 
2 O 
phosphorylation O 
via O 
a O 
c-Src O 
/ O 
EGFR O 
, O 
PDGFR O 
/ O 
PI3K O 
/ O 
Akt O 
pathway O 
. O 
Finally O 
, O 
we O 
showed O 
that O 
, O 
in O 
H9c2 O 
cells O 
, O 
TNF-α-stimulated O 
AP-1 O 
promoter O 
activity O 
, O 
c-Jun O 
mRNA O 
expression O 
, O 
and O 
c-Jun O 
phosphorylation O 
were O 
attenuated O 
by O 
PP1 B-IDENTIFIER 
, O 
AG1478 B-IDENTIFIER 
, O 
AG1296 B-IDENTIFIER 
, O 
LY294002 B-IDENTIFIER 
, O 
SB202190 B-IDENTIFIER 
, O 
SP600125 B-IDENTIFIER 
, O 
or O 
U0126 B-IDENTIFIER 
. O 
These O 
results O 
suggested O 
that O 
TNF-α-induced O 
MMP-9 O 
expression O 
is O 
mediated O 
through O 
a O 
c-Src O 
/ O 
EGFR O 
, O 
PDGFR O 
/ O 
PI3K O 
/ O 
Akt O 
/ O 
MAPKs O 
/ O 
AP-1 O 
cascade O 
in O 
H9c2 O 
cells O 
. O 
Consequently O 
, O 
MMP-9 O 
induction O 
may O 
contribute O 
to O 
cell O 
migration O 
and O 
cardiovascular O 
inflammation O 
. O 

flexible O 
approach O 
to O 
1,4-di- B-FAMILY 
substituted I-FAMILY 
2-aminoimidazoles I-FAMILY 
that O 
inhibit O 
and O 
disperse O 
biofilms O 
and O 
potentiate O 
the O 
effects O 
of O 
β-lactams B-FAMILY 
against O 
multi O 
- O 
drug O 
resistant O 
bacteria O 
. O 

pyrrole B-FAMILY 
- I-FAMILY 
imidazole I-FAMILY 
alkaloids I-FAMILY 
are O 
a O 
2-aminoimidazoles B-FAMILY 
containing O 
family O 
of O 
natural O 
products O 
that O 
possess O 
anti-biofilm O 
activity O 
. O 
A O 
library O 
of O 
1,4-di- B-FAMILY 
substituted I-FAMILY 
2-aminoimidazole I-FAMILY 
/ O 
triazoles B-FAMILY 
( O 
2-AITs B-FAMILY 
) O 
was O 
synthesized O 
, O 
and O 
its O 
anti-biofilm O 
activity O 
as O 
well O 
as O 
oxacillin O 
resensitization O 
efficacy O 
toward O 
methicillin O 
resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
was O 
investigated O 
. O 
These O 
2-AITs B-FAMILY 
were O 
found O 
to O 
inhibit O 
biofilm O 
formation O 
by O 
MRSA O 
with O 
low O 
micromolar O 
IC50 O 
values O 
. O 
Additionally O 
, O 
the O 
most O 
active O 
compound O 
acted O 
synergistically O 
with O 
oxacillin O 
against O 
MRSA O 
lowering O 
the O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
4-fold O 
. O 

and O 
biological O 
evaluation O 
of O 
some O 
novel O 
resveratrol B-SYSTEMATIC 
amide I-SYSTEMATIC 
derivatives O 
as O 
potential O 
anti-tumor O 
agents O 
. O 

series O 
of O 
novel O 
resveratrol B-SYSTEMATIC 
amide I-SYSTEMATIC 
derivatives O 
( O 
1a-q O 
, O 
2a-h O 
, O 
3a-l O 
) O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
biological O 
activities O 
. O 
All O 
compounds O 
were O 
characterized O 
by O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
MS O 
and O 
elemental O 
analysis O 
. O 
Furthermore O 
, O 
compound O 
3e O 
was O 
also O 
characterized O 
by O 
X-ray O 
crystallography O 
. O 
All O 
the O 
compounds O 
were O 
evaluated O 
for O 
their O 
anti-tumor O 
activity O 
against O 
MCF-7 O 
, O 
A549 O 
and O 
B16-F10 O 
tumor O 
cell O 
lines O 
as O 
well O 
as O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
- O 
derived O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
inhibitory O 
activity O 
of O 
murine O 
macrophage O 
RAW O 
264.7 O 
cell O 
line O 
. O 
Among O 
them O 
, O 
compounds O 
1c O 
, O 
1g O 
and O 
3e O 
displayed O 
the O 
most O 
potent O 
COX-2 O 
inhibitory O 
activity O 
with O 
the O 
IC50 O 
values O 
of O 
1.02 O 
, O 
1.27 O 
and O 
1.98 O 
μM O 
, O 
respectively O 
. O 
Molecular O 
docking O 
studies O 
were O 
performed O 
to O 
position O 
compounds O 
1c O 
and O 
3e O 
into O 
the O 
active O 
site O 
of O 
COX-2 O 
to O 
determine O 
the O 
probable O 
binding O 
modes O 
. O 

and O 
synthesis O 
of O 
novel O 
1,2,3-triazole- B-SYSTEMATIC 
dithiocarbamate I-SYSTEMATIC 
hybrids O 
as O 
potential O 
anticancer O 
agents O 
. O 

series O 
of O 
novel O 
1,2,3-triazole- B-SYSTEMATIC 
dithiocarbamate I-SYSTEMATIC 
hybrids O 
were O 
designed O 
, O 
synthesized O 
and O 
evaluated O 
for O 
anticancer O 
activity O 
against O 
four O 
selected O 
human O 
tumor O 
cell O 
lines O 
( O 
MGC-803 O 
, O 
MCF-7 O 
, O 
PC-3 O 
, O 
EC-109 O 
) O 
. O 
Majority O 
of O 
the O 
synthesized O 
compounds O 
exhibited O 
moderate O 
to O 
potent O 
activity O 
against O 
MGC-803 O 
and O 
MCF-7 O 
. O 
Among O 
them O 
, O 
compounds O 
3a O 
and O 
3c O 
showed O 
excellent O 
broad O 
spectrum O 
anticancer O 
activity O 
with O 
IC50 O 
values O 
ranging O 
from O 
0.73 O 
to O 
11.61 O 
μM O 
and O 
0.49-12.45 O 
μM O 
, O 
respectively O 
. O 
Particularly O 
, O 
compound O 
3a O 
was O 
more O 
potent O 
than O 
5-fluorouracil B-SYSTEMATIC 
against O 
all O 
tested O 
human O 
cancer O 
cell O 
lines O 
. O 
Flow O 
cytometry O 
analysis O 
demonstrated O 
that O 
treatment O 
of O 
MGC-803 O 
with O 
3c O 
led O 
to O 
cell O 
cycle O 
arrest O 
at O 
G2 O 
/ O 
M O 
phase O 
accompanied O 
by O 
an O 
increase O 
in O 
apoptotic O 
cell O 
death O 
after O 
12 O 
h O 
. O 

of O 
the O 
essential O 
metal O 
transporter O 
Zip14 O 
in O 
hepatic O 
Cd B-FORMULA 
accumulation O 
during O 
inflammation O 
. O 

of O 
Zip14 O 
contributes O 
to O 
hepatic O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
and O 
non O 
- O 
transferrin O 
- O 
bound O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
uptake O 
during O 
infection O 
and O 
inflammation O 
. O 
We O 
investigated O 
whether O 
this O 
essential O 
metal O 
transporter O 
is O 
also O 
involved O 
in O 
hepatic O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
uptake O 
under O 
these O 
conditions O 
. O 
An O 
injection O 
of O 
lipopolysaccharide O 
( O 
LPS O 
) O 
, O 
turpentine O 
oil O 
( O 
Tur O 
) O 
and O 
n-hexane B-SYSTEMATIC 
( O 
Hex B-ABBREVIATION 
) O 
resulted O 
in O 
an O 
decrease O 
in O 
plasma O 
Zn B-FORMULA 
and O 
Fe B-FORMULA 
concentrations O 
to O 
25-50% O 
and O 
an O 
increase O 
in O 
hepatic O 
concentrations O 
of O 
both O 
metals O 
to O 
150-200% O 
of O 
control O 
mice O 
. O 
LPS O 
significantly O 
increased O 
plasma O 
interleukin O 
(IL)-6 O 
levels O 
more O 
rapidly O 
than O 
Tur O 
or O 
Hex B-ABBREVIATION 
. O 
Tur O 
or O 
Hex B-ABBREVIATION 
significantly O 
increased O 
hepatic O 
Zip14 O 
mRNA O 
expression O 
and O 
decreased O 
ferroportin O 
1 O 
mRNA O 
expression O 
following O 
continuous O 
increase O 
of O 
IL-6 O 
level O 
. O 
Hepatic O 
Cd B-FORMULA 
and O 
Zn B-FORMULA 
concentrations O 
increased O 
significantly O 
after O 
repeated O 
injections O 
of O 
Cd B-FORMULA 
in O 
Tur- O 
or O 
Hex B-ABBREVIATION 
-treated O 
mice O 
fed O 
a O 
control O 
diet O 
. O 
Treatment O 
with O 
Tur O 
or O 
Hex B-ABBREVIATION 
additionally O 
increased O 
hepatic O 
Cd B-FORMULA 
accumulation O 
in O 
Zn B-FORMULA 
-deficient O 
mice O 
, O 
unlike O 
in O 
Fe B-FORMULA 
-deficient O 
mice O 
. O 
These O 
results O 
suggest O 
that O 
Zn B-FORMULA 
transporters O 
, O 
such O 
as O 
Zip14 O 
, O 
may O 
be O 
involved O 
in O 
hepatic O 
Cd B-FORMULA 
uptake O 
during O 
inflammation O 
. O 

toxicity O 
and O 
gene O 
expression O 
in O 
Caco-2 O 
cells O 
exposed O 
to O 
arsenic B-SYSTEMATIC 
species O 
. O 

arsenic B-SYSTEMATIC 
[ O 
As B-FORMULA 
(V) I-FORMULA 
+ O 
As B-FORMULA 
(III) I-FORMULA 
] O 
and O 
its O 
metabolites O 
, O 
especially O 
the O 
trivalent O 
forms O 
[ O 
monomethylarsonous B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
MMA B-ABBREVIATION 
(III) I-ABBREVIATION 
, O 
and O 
dimethylarsinous B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
DMA B-FORMULA 
(III) I-FORMULA 
] O 
, O 
are O 
considered O 
the O 
forms O 
of O 
arsenic B-SYSTEMATIC 
with O 
the O 
highest O 
degree O 
of O 
toxicity O 
, O 
linked O 
to O 
certain O 
types O 
of O 
cancer O 
and O 
other O 
pathologies O 
. O 
The O 
gastrointestinal O 
mucosa O 
is O 
exposed O 
to O 
these O 
forms O 
of O 
arsenic B-SYSTEMATIC 
, O 
but O 
it O 
is O 
not O 
known O 
what O 
toxic O 
effect O 
these O 
species O 
may O 
have O 
on O 
it O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
was O 
to O 
evaluate O 
the O 
toxicity O 
and O 
some O 
mechanisms O 
of O 
action O 
of O 
inorganic O 
arsenic O 
and O 
its O 
metabolites O 
[ O 
monomethylarsonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
MMA B-ABBREVIATION 
(V) I-ABBREVIATION 
, O 
dimethylarsinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
DMA B-FORMULA 
(V) I-FORMULA 
, O 
MMA B-ABBREVIATION 
(III) I-ABBREVIATION 
and O 
DMA B-FORMULA 
(III) I-FORMULA 
] O 
in O 
intestinal O 
epithelial O 
cells O 
, O 
using O 
the O 
Caco-2 O 
human O 
cell O 
line O 
as O 
a O 
model O 
. O 
The O 
results O 
show O 
that O 
the O 
pentavalent O 
forms O 
do O 
not O 
produce O 
toxic O 
effects O 
on O 
the O 
intestinal O 
monolayer O 
, O 
but O 
the O 
trivalent O 
species O 
have O 
a O 
different O 
degree O 
of O 
toxicity O 
. O 
As B-FORMULA 
(III) I-FORMULA 
induces O 
death O 
mainly O 
by O 
necrosis O 
, O 
whereas O 
only O 
apoptotic O 
cells O 
are O 
detected O 
after O 
exposure O 
to O 
MMA B-ABBREVIATION 
(III) I-ABBREVIATION 
, O 
and O 
for O 
DMA B-FORMULA 
(III) I-FORMULA 
the O 
percentages O 
of O 
apoptosis O 
and O 
necrosis O 
are O 
similar O 
. O 
The O 
three O 
forms O 
produce O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
accompanied O 
by O 
a O 
reduction O 
in O 
intracellular O 
GSH B-ABBREVIATION 
and O 
lipid O 
peroxidation O 
, O 
the O 
latter O 
being O 
especially O 
notable O 
in O 
the O 
dimethylated O 
form O 
. O 
They O 
also O 
alter O 
the O 
enzyme O 
activity O 
of O 
glutathione B-TRIVIAL 
peroxidase O 
and O 
catalase O 
and O 
induce O 
expression O 
of O 
stress O 
proteins O 
and O 
metallothioneins O 
. O 
The O 
results O 
indicate O 
that O 
the O 
trivalent O 
forms O 
of O 
arsenic B-SYSTEMATIC 
can O 
affect O 
cell O 
viability O 
of O 
intestinal O 
cells O 
by O 
mechanisms O 
related O 
to O 
the O 
induction O 
of O 
oxidative O 
stress O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
evaluate O 
how O 
the O 
effects O 
observed O 
in O 
this O 
study O 
affect O 
the O 
structure O 
and O 
functionality O 
of O 
the O 
intestinal O 
epithelium O 
. O 

for O 
a O 
new O 
binding O 
mode O 
to O 
GSK-3 O 
: O 
allosteric O 
regulation O 
by O 
the O 
marine O 
compound O 
palinurin B-TRIVIAL 
. O 

synthase O 
kinase O 
3β O 
( O 
GSK-3β O 
) O 
is O 
widely O 
recognised O 
as O 
a O 
relevant O 
player O 
in O 
the O 
pathogenesis O 
of O 
several O 
highly O 
prevalent O 
disorders O 
such O 
as O 
Alzheimer's O 
disease O 
, O 
mood O 
disorders O 
, O 
diabetes O 
and O 
cancer O 
. O 
Therefore O 
, O 
this O 
enzyme O 
constitutes O 
a O 
highly O 
attractive O 
therapeutic O 
target O 
for O 
the O 
development O 
of O 
selective O 
inhibitors O 
as O 
new O 
promising O 
drugs O 
for O 
the O 
treatment O 
of O 
these O 
pathologies O 
. O 
We O 
describe O 
here O 
the O 
isolation O 
and O 
biochemical O 
characterization O 
of O 
the O 
marine O 
natural O 
sesquiterpene B-FAMILY 
palinurin B-TRIVIAL 
as O 
a O 
GSK-3β O 
inhibitor O 
. O 
Experimental O 
studies O 
performed O 
for O 
characterizing O 
the O 
inhibitory O 
mechanism O 
indicate O 
that O 
GSK-3β O 
inhibition O 
by O 
palinurin B-TRIVIAL 
cannot O 
be O 
competed O 
out O 
by O 
ATP B-ABBREVIATION 
nor O 
peptide O 
substrate O 
. O 
Molecular O 
modelling O 
techniques O 
have O 
enabled O 
us O 
to O 
propose O 
an O 
unconventional O 
binding O 
mode O 
to O 
GSK-3β O 
. O 
Moreover O 
, O 
molecular O 
dynamics O 
simulations O 
have O 
identified O 
an O 
allosteric O 
mechanism O 
by O 
which O 
binding O 
of O 
palinurin B-TRIVIAL 
leads O 
to O 
GSK-3β O 
inhibition O 
. O 
The O 
inhibitory O 
activities O 
determined O 
for O 
a O 
series O 
of O 
structurally O 
related O 
analogues O 
support O 
the O 
proposed O 
binding O 
mode O 
of O 
palinurin B-TRIVIAL 
, O 
which O 
is O 
the O 
first O 
compound O 
described O 
to O 
target O 
this O 
allosteric O 
site O 
. O 
The O 
results O 
offer O 
new O 
opportunities O 
for O 
designing O 
and O 
developing O 
selective O 
inhibitors O 
with O 
novel O 
mechanisms O 
of O 
action O 
. O 

and O 
identification O 
of O 
β-hematin B-TRIVIAL 
inhibitors O 
from O 
Flacourtia O 
indica O 
as O 
promising O 
antiplasmodial O 
agents O 
. O 

ethanolic O 
extract O 
( O 
A001 O 
) O 
of O 
the O 
leaves O 
and O 
twigs O 
of O 
Flacourtia O 
indica O 
( O 
Burm.f O 
. O 
) O 
Merr O 
. O 
, O 
was O 
purified O 
to O 
give O 
a O 
new O 
phenolic B-FAMILY 
glycoside I-FAMILY 
, O 
2-(2-benzoyl-β-D-glucopyranosyloxy)-7-(1α,2α,6α-trihydroxy-3-oxocyclohex-4-enoyl)-5-hydroxybenzyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
1 O 
) O 
together O 
with O 
poliothrysoside B-TRIVIAL 
( O 
2 O 
) O 
, O 
catechin-[5,6-e]-4β-(3,4-dihydroxyphenyl)dihydro-2(3H)-pyranone B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
2-(6-benzoyl-β-D-glucopyranosyloxy)-7-(1α,2α,6α-trihydroxy-3-oxocyclohex-4-enoyl)-5-hydroxybenzyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
chrysoeriol-7-O-β-D-glucopyranoside B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
and O 
mururin B-TRIVIAL 
A I-TRIVIAL 
( O 
6 O 
) O 
. O 
Compound O 
6 O 
significantly O 
inhibited O 
the O 
in O 
vitro O 
growth O 
of O 
both O 
a O 
chloroquine B-TRIVIAL 
-sensitive O 
( O 
3D7 O 
) O 
and O 
a O 
chloroquine B-TRIVIAL 
-resistant O 
( O 
K1 O 
) O 
strain O 
of O 
Plasmodium O 
falciparum O 
. O 
It O 
forms O 
a O 
complex O 
with O 
hematin B-TRIVIAL 
and O 
inhibits O 
β-hematin B-TRIVIAL 
formation O 
, O 
suggesting O 
that O 
this O 
compound O 
act O 
on O 
a O 
heme B-FAMILY 
polymerization O 
target O 
. O 

evaluation O 
of O 
daidzein B-TRIVIAL 
in O 
laying O 
hens O 
: O 
part O 
II O 
. O 
Effects O 
on O 
calcium B-SYSTEMATIC 
-related O 
metabolism O 
. O 

, O 
an O 
estrogen B-FAMILY 
-like O 
product O 
, O 
has O 
become O 
increasingly O 
popular O 
as O 
a O 
dietary O 
supplement O 
, O 
particularly O 
for O 
postpeak O 
- O 
estrus O 
animals O 
seeking O 
a O 
safe O 
natural O 
alternative O 
to O 
play O 
a O 
role O 
of O 
estrogen B-FAMILY 
. O 
However O 
, O 
there O 
is O 
little O 
available O 
safety O 
data O 
of O 
it O 
for O 
raisers O 
and O 
consumers O 
. O 
A O 
subchronic O 
laying O 
hensafety O 
study O 
has O 
been O 
conducted O 
to O 
examine O 
if O 
the O 
high O 
- O 
dose O 
daidzein B-TRIVIAL 
could O 
affect O 
calcium B-SYSTEMATIC 
-related O 
metabolism O 
( O 
eggshell O 
quality O 
and O 
bone O 
mineralization O 
) O 
. O 
Seven O 
hundred O 
and O 
sixty O 
- O 
eight O 
56-week- O 
old O 
Hyline O 
Brown O 
were O 
randomly O 
assigned O 
to O 
4 O 
groups O 
with O 
8 O 
replicates O 
of O 
24 O 
birds O 
each O 
( O 
192 O 
laying O 
hensper O 
group O 
) O 
and O 
3weeks O 
later O 
fed O 
diets O 
supplemented O 
with O 
0(control) O 
, O 
10 O 
, O 
50 O 
and O 
100mg O 
of O 
daidzein B-TRIVIAL 
/ O 
kg O 
for O 
12week O 
. O 
Eggshell O 
thickness O 
, O 
eggshell O 
percentage O 
, O 
eggshell O 
strength O 
, O 
eggshell O 
Ca B-FORMULA 
concentration O 
was O 
increased O 
linearly O 
with O 
increasing O 
dietary O 
daidzein B-TRIVIAL 
supplementation O 
( O 
P=0.001 O 
, O 
P=0.007 O 
, O 
P=0.002 O 
and O 
P=0.000 O 
, O 
respectively O 
) O 
. O 
Serum O 
Ca B-FORMULA 
increased O 
linearly O 
with O 
increasing O 
dietary O 
daidzein B-TRIVIAL 
supplementation O 
( O 
P=0.042 O 
) O 
, O 
and O 
serum O 
P O 
showed O 
a O 
significant O 
quadratic O 
response O 
to O 
dietary O 
daidzein B-TRIVIAL 
supplementation O 
( O 
P=0.036 O 
) O 
. O 
Bone O 
ash O 
and O 
bone O 
Ca B-FORMULA 
were O 
significantly O 
influenced O 
by O 
dietary O 
daidzein B-TRIVIAL 
supplementation O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
These O 
findings O 
indicate O 
that O 
daidzein B-TRIVIAL 
hold O 
no O 
observed O 
adverse O 
effect O 
on O 
calcium B-SYSTEMATIC 
metabolism O 
, O 
but O 
also O 
a O 
safe O 
and O 
effective O 
food O 
additive O 
for O 
calcium B-SYSTEMATIC 
metabolism O 
in O 
animals O 
and O 
humans O 
. O 

osteoporosis O 
in O 
men O 
has O 
been O 
recognized O 
as O 
an O 
important O 
clinical O 
problem O 
, O 
new O 
information O 
is O 
being O 
accumulated O 
on O 
its O 
scope O 
, O 
pathophysiology O 
, O 
evaluation O 
, O 
and O 
treatment O 
. O 
Fracture O 
risk O 
calculators O 
, O 
such O 
as O 
FRAX O 
, O 
identify O 
a O 
large O 
proportion O 
of O 
the O 
older O 
male O 
population O 
to O 
be O 
at O 
heightened O 
risk O 
for O 
fracture O 
. O 
The O 
classification O 
of O 
osteoporosis O 
into O 
primary O 
and O 
secondary O 
forms O 
, O 
while O 
still O 
useful O 
, O 
is O 
affected O 
by O 
the O 
fact O 
that O 
many O 
men O 
have O 
multiple O 
contributing O 
factors O 
to O 
their O 
fracture O 
risk O 
. O 
The O 
role O 
of O 
sex O 
steroids B-FAMILY 
is O 
being O 
better O 
defined O 
as O 
other O 
risk O 
factors O 
for O 
fracture O 
are O 
delineated O 
. O 
As O 
longevity O 
continues O 
to O 
increase O 
in O 
men O 
and O 
until O 
osteoporotic O 
fracture O 
is O 
truly O 
recognized O 
as O 
a O 
potentially O 
fatal O 
disorder O 
, O 
many O 
men O 
will O 
be O 
undiagnosed O 
and O 
untreated O 
. O 
Two O 
recent O 
studies O 
provide O 
more O 
evidence O 
that O 
treatments O 
which O 
decrease O 
fracture O 
risk O 
in O 
women O 
do O 
the O 
same O 
in O 
men O 
. O 
With O 
the O 
publication O 
of O 
guidelines O 
and O 
increasing O 
strength O 
of O 
evidence O 
for O 
treatment O 
efficacy O 
, O 
it O 
is O 
hoped O 
that O 
more O 
men O 
will O 
be O 
evaluated O 
and O 
treated O 
for O 
this O 
often O 
neglected O 
disorder O 
. O 

assessment O 
of O 
dredging O 
to O 
remove O 
coal B-TRIVIAL 
fly O 
ash O 
at O 
the O 
Tennessee O 
Valley O 
Authority O 
Kingston O 
Fossil O 
plant O 
using O 
fathead O 
minnow O 
elutriate O 
exposures O 
. O 

December O 
22 O 
, O 
2008 O 
, O 
failure O 
of O 
an O 
earthen O 
containment O 
structure O 
resulted O 
in O 
the O 
release O 
of O 
approximately O 
4.1 O 
million O 
m(3) O 
of O 
coal B-TRIVIAL 
fly O 
ash O 
into O 
the O 
Emory O 
River O 
and O 
the O 
surrounding O 
area O 
from O 
the O 
Tennessee O 
Valley O 
Authority O 
Kingston O 
Fossil O 
Plant O 
near O 
Kingston O 
, O 
Tennessee O 
, O 
USA O 
. O 
The O 
purpose O 
of O 
the O 
present O 
study O 
was O 
to O 
assess O 
the O 
potential O 
of O 
dredging O 
activities O 
performed O 
to O 
remove O 
the O 
fly O 
ash O 
from O 
the O 
river O 
to O 
result O 
in O 
increased O 
risk O 
to O 
pelagic O 
fish O 
, O 
with O 
special O 
consideration O 
of O 
mobilization O 
of O 
metals O 
. O 
Elutriates O 
were O 
created O 
using O 
two O 
sources O 
of O 
fly O 
ash O 
by O 
bubbling O 
with O 
air O 
over O 
10 O 
d O 
. O 
This O 
elutriate O 
preparation O 
method O 
was O 
designed O 
to O 
represent O 
worst O 
- O 
case O 
conditions O 
for O 
oxidation O 
, O 
metal O 
release O 
, O 
and O 
dissolution O 
. O 
Larval O 
and O 
juvenile O 
Pimephales O 
promelas O 
underwent O 
10-d O 
exposures O 
to O 
these O 
elutriates O 
. O 
Larval O 
end O 
points O 
included O 
survival O 
and O 
biomass O 
, O 
and O 
juvenile O 
end O 
points O 
included O 
survival O 
, O 
length O 
, O 
biomass O 
, O 
liver O 
somatic O 
index O 
, O 
and O 
bioaccumulation O 
. O 
No O 
significant O 
toxicity O 
was O 
observed O 
. O 
Bioaccumulation O 
of O 
metals O 
in O 
juveniles O 
was O 
found O 
to O 
be O 
primarily O 
attributable O 
to O 
metals O 
associated O 
with O 
particles O 
in O 
the O 
gut O 
. O 
Results O 
suggest O 
little O 
potential O 
for O 
toxicity O 
to O 
related O 
fish O 
species O 
due O 
to O 
fly O 
ash O 
removal O 
dredging O 
activities O 
given O 
the O 
extreme O 
conditions O 
represented O 
by O 
the O 
elutriates O 
in O 
the O 
present O 
study O 
. O 

TiO2 B-FORMULA 
nanorods O 
with O 
carbon B-SYSTEMATIC 
nanotubes O 
for O 
efficient O 
electron O 
collection O 
in O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

high O 
power O 
conversion O 
efficiency O 
of O 
10.24% O 
can O 
be O 
obtained O 
in O 
a O 
dye O 
- O 
sensitized O 
solar O 
cell O 
by O 
incorporating O 
multiwall O 
carbon B-SYSTEMATIC 
nanotubes O 
inside O 
a O 
TiO2 B-FORMULA 
nanorod O 
photoanode O 
. O 
The O 
multiwall O 
carbon O 
nanotubes O 
in O 
the O 
nanorod O 
can O 
effectively O 
collect O 
and O 
transport O 
photogenerated O 
electrons O 
reducing O 
the O 
recombination O 
as O 
well O 
as O 
improving O 
efficiency O 
of O 
the O 
device O 
. O 

Drosophila O 
fat O 
body O 
is O 
a O 
liver- O 
and O 
adipose O 
- O 
like O 
tissue O 
that O 
stores O 
fat O 
and O 
serves O 
as O 
a O 
detoxifying O 
and O 
immune O 
responsive O 
organ O 
. O 
We O 
have O 
previously O 
shown O 
that O 
a O 
high O 
sugar B-FAMILY 
diet O 
leads O 
to O 
elevated O 
hemolymph O 
glucose B-TRIVIAL 
and O 
systemic O 
insulin O 
resistance O 
in O 
developing O 
larvae O 
and O 
adults O 
. O 
Here O 
, O 
we O 
used O 
stable O 
isotope O 
tracer O 
feeding O 
to O 
demonstrate O 
that O 
rearing O 
larvae O 
on O 
high O 
sugar B-FAMILY 
diets O 
impaired O 
the O 
synthesis O 
of O 
esterified O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
dietary O 
glucose B-TRIVIAL 
. O 
Fat O 
body O 
lipid O 
profiling O 
revealed O 
changes O 
in O 
both O 
carbon B-SYSTEMATIC 
chain O 
length O 
and O 
degree O 
of O 
unsaturation O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
substituents O 
, O 
particularly O 
in O 
stored O 
triglycerides B-FAMILY 
. O 
We O 
tested O 
the O 
role O 
of O 
the O 
fat O 
body O 
in O 
larval O 
tolerance O 
of O 
caloric O 
excess O 
. O 
Our O 
experiments O 
demonstrated O 
that O 
lipogenesis O 
was O 
necessary O 
for O 
animals O 
to O 
tolerate O 
high O 
sugar B-FAMILY 
feeding O 
as O 
tissue O 
- O 
specific O 
loss O 
of O 
orthologs O 
of O 
carbohydrate B-FAMILY 
response O 
element O 
- O 
binding O 
protein O 
or O 
stearoyl-CoA B-TRIVIAL 
desaturase O 
1 O 
resulted O 
in O 
lethality O 
on O 
high O 
sugar B-FAMILY 
diets O 
. O 
By O 
contrast O 
, O 
increasing O 
the O 
fat O 
content O 
of O 
the O 
fat O 
body O 
by O 
knockdown O 
of O 
king O 
- O 
tubby O 
was O 
associated O 
with O 
reduced O 
hyperglycemia O 
and O 
improved O 
growth O 
and O 
tolerance O 
of O 
high O 
sugar B-FAMILY 
diets O 
. O 
Our O 
work O 
supports O 
a O 
critical O 
role O 
for O 
the O 
fat O 
body O 
and O 
the O 
Drosophila O 
carbohydrate B-FAMILY 
response O 
element O 
- O 
binding O 
protein O 
ortholog O 
in O 
metabolic O 
homeostasis O 
in O 
Drosophila O 
. O 

to O 
their O 
excellent O 
binding O 
properties O 
, O 
high O 
stability O 
, O 
and O 
low O 
off O 
- O 
target O 
toxicity O 
, O 
polycyclic O 
peptides O 
are O 
an O 
attractive O 
molecule O 
format O 
for O 
the O 
development O 
of O 
therapeutics O 
. O 
Currently O 
, O 
only O 
a O 
handful O 
of O 
polycyclic O 
peptides O 
are O 
used O 
in O 
the O 
clinic O 
; O 
examples O 
include O 
the O 
antibiotic O 
vancomycin B-TRIVIAL 
, O 
the O 
anticancer O 
drugs O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
and O 
romidepsin B-TRIVIAL 
, O 
and O 
the O 
analgesic O 
agent O 
ziconotide O 
. O 
All O 
clinically O 
used O 
polycyclic O 
peptide O 
drugs O 
are O 
derived O 
from O 
natural O 
sources O 
, O 
such O 
as O 
soil O 
bacteria O 
in O 
the O 
case O 
of O 
vancomycin B-TRIVIAL 
, O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
and O 
romidepsin B-TRIVIAL 
, O 
or O 
the O 
venom O 
of O 
a O 
fish O 
- O 
hunting O 
coil O 
snail O 
in O 
the O 
case O 
of O 
ziconotide O 
. O 
Unfortunately O 
, O 
nature O 
provides O 
peptide O 
macrocyclic O 
ligands O 
for O 
only O 
a O 
small O 
fraction O 
of O 
therapeutic O 
targets O 
. O 
For O 
the O 
generation O 
of O 
ligands O 
of O 
targets O 
of O 
choice O 
, O 
researchers O 
have O 
inserted O 
artificial O 
binding O 
sites O 
into O 
natural O 
polycyclic O 
peptide O 
scaffolds O 
, O 
such O 
as O 
cystine B-TRIVIAL 
knot O 
proteins O 
, O 
using O 
rational O 
design O 
or O 
directed O 
evolution O 
approaches O 
. O 
More O 
recently O 
, O 
large O 
combinatorial O 
libraries O 
of O 
genetically O 
encoded O 
bicyclic O 
peptides O 
have O 
been O 
generated O 
de O 
novo O 
and O 
screened O 
by O 
phage O 
display O 
. O 
In O 
this O 
Minireview O 
, O 
the O 
properties O 
of O 
existing O 
polycyclic O 
peptide O 
drugs O 
are O 
discussed O 
and O 
related O 
to O 
their O 
interesting O 
molecular O 
architectures O 
. O 
Furthermore O 
, O 
technologies O 
that O 
allow O 
the O 
development O 
of O 
unnatural O 
polycyclic O 
peptide O 
ligands O 
are O 
discussed O 
. O 
Recent O 
application O 
of O 
these O 
technologies O 
has O 
generated O 
promising O 
results O 
, O 
suggesting O 
that O 
polycyclic O 
peptide O 
therapeutics O 
could O 
potentially O 
be O 
developed O 
for O 
a O 
broad O 
range O 
of O 
diseases O 
. O 

telangiectasia O 
mutated O 
( O 
ATM O 
) O 
is O 
activated O 
upon O 
DNA O 
double O 
strand O 
breaks O 
( O 
DSBs O 
) O 
and O 
phosphorylates O 
numerous O 
DSB O 
response O 
proteins O 
, O 
including O 
histone O 
H2AX O 
on O 
serine B-TRIVIAL 
139 O 
( O 
Ser B-FORMULA 
-139 O 
) O 
to O 
form O 
γ-H2AX O 
. O 
Through O 
interaction O 
with O 
MDC1 O 
, O 
γ-H2AX O 
promotes O 
DSB O 
repair O 
by O 
homologous O 
recombination O 
( O 
HR O 
) O 
. O 
H2AX O 
Ser B-FORMULA 
-139 O 
can O 
also O 
be O 
phosphorylated O 
by O 
DNA-dependent O 
protein O 
kinase O 
catalytic O 
subunit O 
and O 
ataxia O 
telangiectasia- O 
and O 
Rad3 O 
- O 
related O 
kinase O 
. O 
Thus O 
, O 
we O 
tested O 
whether O 
ATM O 
functions O 
in O 
HR O 
, O 
particularly O 
that O 
controlled O 
by O 
γ-H2AX O 
, O 
by O 
comparing O 
HR O 
occurring O 
at O 
the O 
euchromatic O 
ROSA26 O 
locus O 
between O 
mouse O 
embryonic O 
stem O 
cells O 
lacking O 
either O 
ATM O 
, O 
H2AX O 
, O 
or O 
both O 
. O 
We O 
show O 
here O 
that O 
loss O 
of O 
ATM O 
does O 
not O 
impair O 
HR O 
, O 
including O 
H2AX-dependent O 
HR O 
, O 
but O 
confers O 
sensitivity O 
to O 
inhibition O 
of O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerases O 
. O 
Loss O 
of O 
ATM O 
or O 
H2AX O 
has O 
independent O 
contributions O 
to O 
cellular O 
sensitivity O 
to O 
ionizing O 
radiation O 
. O 
The O 
ATM O 
- O 
independent O 
HR O 
function O 
of O 
H2AX O 
requires O 
both O 
Ser B-FORMULA 
-139 O 
phosphorylation O 
and O 
γ-H2AX O 
/ O 
MDC1 O 
interaction O 
. O 
Our O 
data O 
suggest O 
that O 
ATM O 
is O 
dispensable O 
for O 
HR O 
, O 
including O 
that O 
controlled O 
by O 
H2AX O 
, O 
in O 
the O 
context O 
of O 
euchromatin O 
, O 
excluding O 
the O 
implication O 
of O 
such O 
an O 
HR O 
function O 
in O 
genomic O 
instability O 
, O 
hypersensitivity O 
to O 
DNA O 
damage O 
, O 
and O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
inhibition O 
associated O 
with O 
ATM O 
deficiency O 
. O 

of O 
DNA O 
at O 
CpG B-ABBREVIATION 
dinucleotides B-FAMILY 
represents O 
one O 
of O 
the O 
most O 
important O 
epigenetic O 
mechanisms O 
involved O 
in O 
the O 
control O 
of O 
gene O 
expression O 
in O 
vertebrate O 
cells O 
. O 
In O 
this O 
report O 
, O 
we O 
conducted O 
nucleosome O 
reconstitution O 
experiments O 
in O 
conjunction O 
with O 
high O 
- O 
throughput O 
sequencing O 
on O 
572 O 
KB O 
of O 
human O 
DNA O 
and O 
668 O 
KB O 
of O 
mouse O 
DNA O 
that O 
was O 
unmethylated O 
or O 
methylated O 
in O 
order O 
to O 
investigate O 
the O 
effects O 
of O 
this O 
epigenetic O 
modification O 
on O 
the O 
positioning O 
and O 
stability O 
of O 
nucleosomes O 
. O 
The O 
results O 
demonstrated O 
that O 
a O 
subset O 
of O 
nucleosomes O 
positioned O 
by O 
nucleotide B-FAMILY 
sequence O 
was O 
sensitive O 
to O 
methylation O 
where O 
the O 
modification O 
increased O 
the O 
affinity O 
of O 
these O 
sequences O 
for O 
the O 
histone O 
octamer O 
. O 
The O 
features O 
that O 
distinguished O 
these O 
nucleosomes O 
from O 
the O 
bulk O 
of O 
the O 
methylation O 
- O 
insensitive O 
nucleosomes O 
were O 
an O 
increase O 
in O 
the O 
frequency O 
of O 
CpG B-ABBREVIATION 
dinucleotides B-FAMILY 
and O 
a O 
unique O 
rotational O 
orientation O 
of O 
CpGs B-ABBREVIATION 
such O 
that O 
their O 
minor O 
grooves O 
tended O 
to O 
face O 
toward O 
the O 
histones O 
in O 
the O 
nucleosome O 
rather O 
than O 
away O 
. O 
These O 
methylation O 
- O 
sensitive O 
nucleosomes O 
were O 
preferentially O 
associated O 
with O 
exons O 
as O 
compared O 
to O 
introns O 
while O 
unmethylated O 
CpG B-ABBREVIATION 
islands O 
near O 
transcription O 
start O 
sites O 
became O 
enriched O 
in O 
nucleosomes O 
upon O 
methylation O 
. O 
The O 
results O 
of O 
this O 
study O 
suggest O 
that O 
the O 
effects O 
of O 
DNA O 
methylation O 
on O 
nucleosome O 
stability O 
in O 
vitro O 
can O 
recapitulate O 
what O 
has O 
been O 
observed O 
in O 
the O 
cell O 
and O 
provide O 
a O 
direct O 
link O 
between O 
DNA O 
methylation O 
and O 
the O 
structure O 
and O 
function O 
of O 
chromatin O 
. O 

purity O 
- O 
activity O 
relationships O 
of O 
natural O 
products O 
: O 
the O 
case O 
of O 
anti-tuberculosis O 
active O 
triterpenes B-FAMILY 
from O 
Oplopanax O 
horridus O 
. O 

present O 
study O 
provides O 
an O 
extension O 
of O 
the O 
previously O 
developed O 
concept O 
of O 
purity O 
- O 
activity O 
relationships O 
( O 
PARs O 
) O 
and O 
enables O 
the O 
quantitative O 
evaluation O 
of O 
the O 
effects O 
of O 
multiple O 
minor O 
components O 
on O 
the O 
bioactivity O 
of O 
residually O 
complex O 
natural O 
products O 
. O 
The O 
anti-tuberculosis O 
active O 
triterpenes O 
from O 
the O 
Alaskan O 
ethnobotanical O 
Oplopanax O 
horridus O 
were O 
selected O 
as O 
a O 
case O 
for O 
the O 
development O 
of O 
the O 
quantitative O 
PAR O 
( O 
QPAR O 
) O 
concept O 
. O 
The O 
residual O 
complexity O 
of O 
the O 
purified O 
triterpenes B-FAMILY 
was O 
initially O 
evaluated O 
by O 
1D- O 
and O 
2D-NMR O 
and O 
identified O 
as O 
a O 
combination O 
of O 
structurally O 
related O 
and O 
unrelated O 
impurities O 
. O 
Using O 
a O 
biochemometric O 
approach O 
, O 
the O 
qHNMR O 
purity O 
and O 
anti-TB O 
activity O 
of O 
successive O 
chromatographic O 
fractions O 
of O 
O O 
. O 
horridus O 
triterpenes B-FAMILY 
were O 
correlated O 
by O 
linear O 
regression O 
analysis O 
to O 
generate O 
a O 
mathematical O 
QPAR O 
model O 
. O 
The O 
results O 
demonstrate O 
that O 
impurities O 
, O 
such O 
as O 
widely O 
occurring O 
monoglycerides B-FAMILY 
, O 
can O 
have O 
a O 
profound O 
impact O 
on O 
the O 
observed O 
antimycobacterial O 
activity O 
of O 
triterpene B-FAMILY 
-enriched O 
fractions O 
. O 
The O 
QPAR O 
concept O 
is O 
shown O 
to O 
be O 
capable O 
of O 
providing O 
a O 
quantitative O 
assessment O 
in O 
situations O 
where O 
residually O 
complex O 
constitution O 
contributes O 
toward O 
the O 
biological O 
activity O 
of O 
natural O 
products O 
. O 

comparison O 
of O 
the O 
signalling O 
properties O 
of O 
two O 
tyramine B-TRIVIAL 
receptors O 
from O 
Drosophila O 
. O 

invertebrates O 
, O 
the O 
phenolamines B-FAMILY 
, O 
tyramine B-TRIVIAL 
and O 
octopamine B-TRIVIAL 
, O 
mediate O 
many O 
functional O 
roles O 
usually O 
associated O 
with O 
the O 
catecholamines B-FAMILY 
, O 
noradrenaline B-TRIVIAL 
and O 
adrenaline B-TRIVIAL 
, O 
in O 
vertebrates O 
. O 
The O 
α- O 
and O 
β-adrenergic O 
classes O 
of O 
insect O 
octopamine B-TRIVIAL 
receptor O 
are O 
better O 
activated O 
by O 
octopamine B-TRIVIAL 
than O 
tyramine B-TRIVIAL 
. O 
Similarly O 
, O 
the O 
Tyramine B-TRIVIAL 
1 O 
subgroup O 
of O 
receptors O 
( O 
or O 
Octopamine B-TRIVIAL 
/ O 
Tyramine B-TRIVIAL 
receptors O 
) O 
are O 
better O 
activated O 
by O 
tyramine B-TRIVIAL 
than O 
octopamine B-TRIVIAL 
. O 
However O 
, O 
recently O 
, O 
a O 
new O 
Tyramine B-TRIVIAL 
2 O 
subgroup O 
of O 
receptors O 
was O 
identified O 
, O 
which O 
appears O 
to O 
be O 
activated O 
highly O 
preferentially O 
by O 
tyramine B-TRIVIAL 
. O 
We O 
examined O 
immunocytochemically O 
the O 
ability O 
of O 
CG7431 O 
, O 
the O 
founding O 
member O 
of O 
this O 
subgroup O 
from O 
Drosophila O 
melanogaster O 
, O 
to O 
be O 
internalized O 
in O 
transfected O 
Chinese O 
hamster O 
ovary O 
( O 
CHO O 
) O 
cells O 
by O 
different O 
agonists O 
. O 
It O 
was O 
only O 
internalized O 
after O 
activation O 
by O 
tyramine B-TRIVIAL 
. O 
Conversely O 
, O 
the O 
structurally O 
related O 
receptor O 
, O 
CG16766 O 
, O 
was O 
internalized O 
by O 
a O 
number O 
of O 
biogenic O 
amines B-FAMILY 
, O 
including O 
octopamine B-TRIVIAL 
, O 
dopamine B-TRIVIAL 
, O 
noradrenaline B-TRIVIAL 
, O 
adrenaline B-TRIVIAL 
, O 
which O 
also O 
were O 
able O 
to O 
elevate O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
levels O 
. O 
Studies O 
with O 
synthetic O 
agonists O 
and O 
antagonists O 
confirm O 
that O 
CG16766 O 
has O 
a O 
different O 
pharmacological O 
profile O 
to O 
that O 
of O 
CG7431 O 
. O 
Species O 
orthologues O 
of O 
CG16766 O 
were O 
only O 
found O 
in O 
Drosophila O 
species O 
, O 
whereas O 
orthologues O 
of O 
CG7431 O 
could O 
be O 
identified O 
in O 
the O 
genomes O 
of O 
a O 
number O 
of O 
insect O 
species O 
. O 
We O 
propose O 
that O 
CG16766 O 
represents O 
a O 
new O 
group O 
of O 
tyramine B-TRIVIAL 
receptors O 
, O 
which O 
we O 
have O 
designated O 
the O 
Tyramine B-TRIVIAL 
3 O 
receptors O 
. O 

metabolism O 
and O 
formaldehyde B-SYSTEMATIC 
-induced O 
stimulation O 
of O 
lactate B-FAMILY 
production O 
and O 
glutathione B-TRIVIAL 
export O 
in O 
cultured O 
neurons O 
. O 

is O 
endogenously O 
produced O 
in O 
the O 
human O 
body O 
and O 
brain O 
levels O 
of O 
this O 
compound O 
are O 
elevated O 
in O 
neurodegenerative O 
conditions O 
. O 
Although O 
the O 
toxic O 
potential O 
of O 
an O 
excess O 
of O 
formaldehyde B-SYSTEMATIC 
has O 
been O 
studied O 
, O 
little O 
is O 
known O 
on O 
the O 
molecular O 
mechanisms O 
underlying O 
its O 
neurotoxicity O 
as O 
well O 
as O 
on O 
the O 
ability O 
of O 
neurons O 
to O 
metabolize O 
formaldehyde B-SYSTEMATIC 
. O 
To O 
address O 
these O 
topics O 
, O 
we O 
have O 
used O 
cerebellar O 
granule O 
neuron O 
cultures O 
as O 
model O 
system O 
. O 
These O 
cultures O 
express O 
mRNAs O 
of O 
various O 
enzymes O 
that O 
are O 
involved O 
in O 
formaldehyde B-SYSTEMATIC 
metabolism O 
and O 
were O 
remarkably O 
resistant O 
toward O 
acute O 
formaldehyde B-SYSTEMATIC 
toxicity O 
. O 
Cerebellar O 
granule O 
neurons O 
metabolized O 
formaldehyde B-SYSTEMATIC 
with O 
a O 
rate O 
of O 
around O 
200 O 
nmol O 
/ O 
( O 
h O 
× O 
mg O 
) O 
which O 
was O 
accompanied O 
by O 
significant O 
increases O 
in O 
the O 
cellular O 
and O 
extracellular O 
concentrations O 
of O 
formate B-SYSTEMATIC 
. O 
In O 
addition O 
, O 
formaldehyde B-SYSTEMATIC 
application O 
significantly O 
increased O 
glucose B-TRIVIAL 
consumption O 
, O 
almost O 
doubled O 
the O 
rate O 
of O 
lactate B-FAMILY 
release O 
from O 
viable O 
neurons O 
and O 
strongly O 
accelerated O 
the O 
export O 
of O 
the O 
antioxidant O 
glutathione B-TRIVIAL 
. O 
The O 
latter O 
process O 
was O 
completely O 
prevented O 
by O 
inhibition O 
of O 
the O 
known O 
glutathione B-TRIVIAL 
exporter O 
multidrug O 
resistance O 
protein O 
1 O 
. O 
These O 
data O 
indicate O 
that O 
cerebellar O 
granule O 
neurons O 
are O 
capable O 
of O 
metabolizing O 
formaldehyde B-SYSTEMATIC 
and O 
that O 
the O 
neuronal O 
glycolysis O 
and O 
glutathione B-TRIVIAL 
export O 
are O 
severely O 
affected O 
by O 
the O 
presence O 
of O 
formaldehyde B-SYSTEMATIC 
. O 

Objective O 
: O 
This O 
study O 
engaged O 
in O 
investigation O 
of O 
optimal O 
formulation O 
, O 
characteristics O 
analysis O 
of O 
Brucea O 
javanica O 
oil O 
microemulsion O 
( O 
BJOM O 
) O 
in O 
order O 
to O 
address O 
safety O 
concerns O 
and O 
make O 
recommendations O 
for O 
improvements O 
in O 
BJOM O 
safety O 
during O 
clinical O 
use O 
in O 
vivo O 
. O 
Methods O 
: O 
Pseudo O 
- O 
ternary O 
phase O 
diagram O 
techniques O 
were O 
used O 
to O 
determine O 
the O 
appropriate O 
ratio O 
of O 
surfactant O 
, O 
cosurfactant O 
and O 
oil O 
phases O 
. O 
Subsequent O 
stability O 
testing O 
of O 
BJOM O 
was O 
performed O 
by O 
dilution O 
, O 
centrifugation O 
and O 
accelerated O 
stability O 
testing O 
. O 
The O 
results O 
were O 
expounded O 
through O 
additional O 
assessment O 
utilizing O 
the O 
classical O 
thermostat O 
method O 
to O 
establish O 
the O 
shelf O 
life O 
of O 
the O 
material O 
. O 
These O 
results O 
were O 
utilized O 
to O 
evaluate O 
the O 
safety O 
of O 
BJOM O 
by O 
haemolytic O 
, O 
irritative O 
and O 
allergic O 
testing O 
in O 
vitro O 
. O 
In O 
addition O 
, O 
the O 
cytotoxicity O 
of O 
BJOM O 
was O 
examined O 
using O 
the O 
tetrazolium B-SYSTEMATIC 
salt O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
, O 
with O 
particular O 
emphasis O 
given O 
to O 
potential O 
uses O 
in O 
cancer O 
treatment O 
. O 
Results O 
: O 
The O 
most O 
suitable O 
method O 
of O 
preparation O 
for O 
BJOM O 
was O 
found O 
to O 
be O 
a O 
one O 
to O 
one O 
ratio O 
( O 
K(m) O 
1 O 
: O 
1 O 
) O 
of O 
Solutol O 
HS15 O 
surfactant O 
matched O 
with O 
sorbitol O 
cosurfactant O 
in O 
the O 
ratio O 
. O 
The O 
microemulsion O 
droplets O 
of O 
BJOM O 
possessed O 
a O 
spherical O 
shape O 
, O 
uniform O 
size O 
and O 
average O 
diameter O 
of O 
23.8 O 
nm O 
. O 
The O 
expiration O 
date O 
of O 
BJOM O 
was O 
found O 
to O 
be O 
568 O 
d O 
. O 
The O 
safety O 
study O 
demonstrated O 
no O 
hemolysis O 
activity O 
at O 
the O 
experimental O 
BJOM O 
concentrations O 
; O 
however O 
, O 
mild O 
hemolysis O 
was O 
observed O 
at O 
higher O 
concentrations O 
of O 
Brucea O 
javanica O 
oil O 
emulsion O 
( O 
BJOE O 
) O 
, O 
a O 
common O 
commercially O 
available O 
product O 
. O 
Irritation O 
observed O 
upon O 
BJOM O 
treatment O 
can O 
be O 
primarily O 
attributed O 
to O 
Brucea O 
javanica O 
oil O 
( O 
BJO O 
) O 
with O 
little O 
influence O 
of O 
BJOM O 
excipients O 
. O 
In O 
addition O 
, O 
BJOM O 
caused O 
no O 
observed O 
hypersensitivity O 
or O 
other O 
visible O 
allergic O 
reactions O 
in O 
guinea O 
pigs O 
. O 
The O 
anticancer O 
activity O 
curves O 
of O 
BJOM O 
and O 
BJOE O 
demonstrate O 
that O 
both O 
BJOM O 
and O 
BJOE O 
inhibit O 
Hela O 
cells O 
, O 
with O 
BJOM O 
demonstrating O 
significantly O 
more O 
dramatic O 
anticancer O 
activity O 
. O 
Conclusion O 
: O 
An O 
optimal O 
formulation O 
of O 
BJOM O 
superior O 
to O 
commercially O 
available O 
products O 
and O 
safe O 
for O 
medical O 
application O 
such O 
as O 
intravenous O 
injection O 
has O 
been O 
outlined O 
along O 
with O 
its O 
anticancer O 
activity O 
rating O 
. O 

structure O 
, O 
dynamics O 
and O 
binding O 
studies O 
of O 
a O 
family O 
11 O 
carbohydrate B-FAMILY 
-binding O 
module O 
from O 
Clostridium O 
thermocellum O 
( O 
CtCBM11 O 
) O 
. O 

cellulosomal O 
CBMs O 
( O 
carbohydrate B-FAMILY 
-binding O 
modules O 
) O 
are O 
responsible O 
for O 
increasing O 
the O 
catalytic O 
efficiency O 
of O 
cellulosic O 
enzymes O 
by O 
selectively O 
putting O 
the O 
substrate O 
( O 
a O 
wide O 
range O 
of O 
poly- O 
and O 
oligo O 
- O 
saccharides O 
) O 
and O 
enzyme O 
into O 
close O 
contact O 
. O 
In O 
the O 
present O 
study O 
we O 
carried O 
out O 
an O 
atomistic O 
rationalization O 
of O 
the O 
molecular O 
determinants O 
of O 
ligand O 
specificity O 
for O 
a O 
family O 
11 O 
CBM O 
from O 
thermophilic O 
Clostridium O 
thermocellum O 
[ O 
CtCBM11 O 
( O 
C O 
. O 
thermocellum O 
CBM11 O 
) O 
] O 
, O 
based O 
on O 
a O 
NMR O 
and O 
molecular O 
modelling O 
approach O 
. O 
We O 
have O 
determined O 
the O 
NMR O 
solution O 
structure O 
of O 
CtCBM11 O 
at O 
25°C O 
and O 
50°C O 
and O 
derived O 
information O 
on O 
the O 
residues O 
of O 
the O 
protein O 
that O 
are O 
involved O 
in O 
ligand O 
recognition O 
and O 
on O 
the O 
influence O 
of O 
the O 
length O 
of O 
the O 
saccharide B-FAMILY 
chain O 
on O 
binding O 
. O 
We O 
obtained O 
models O 
of O 
the O 
CtCBM11- O 
cellohexaose B-TRIVIAL 
and O 
CtCBM11- O 
cellotetraose B-TRIVIAL 
complexes O 
by O 
docking O 
in O 
accordance O 
with O 
the O 
NMR O 
experimental O 
data O 
. O 
Specific O 
ligand O 
- O 
protein O 
CH-π O 
and O 
Van O 
der O 
Waals O 
interactions O 
were O 
found O 
to O 
be O 
determinant O 
for O 
the O 
stability O 
of O 
the O 
complexes O 
and O 
for O 
defining O 
specificity O 
. O 
Using O 
the O 
order O 
parameters O 
derived O 
from O 
backbone O 
dynamics O 
analysis O 
in O 
the O 
presence O 
and O 
absence O 
of O 
ligand O 
and O 
at O 
25°C O 
and O 
50°C O 
, O 
we O 
determined O 
that O 
the O 
protein's O 
backbone O 
conformational O 
entropy O 
is O 
slightly O 
positive O 
. O 
This O 
data O 
in O 
combination O 
with O 
the O 
negative O 
binding O 
entropy O 
calculated O 
from O 
ITC O 
( O 
isothermal O 
titration O 
calorimetry O 
) O 
studies O 
supports O 
a O 
selection O 
mechanism O 
where O 
a O 
rigid O 
protein O 
selects O 
a O 
defined O 
oligosaccharide O 
conformation O 
. O 

-Peptide O 
Conjugates O 
: O 
Receptor-Targeting O 
Bifunctional O 
Agents O 
for O 
Imaging O 
and O 
Photodynamic O 
Therapy O 
. O 

synthesis O 
of O 
a O 
series O 
of O 
new O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
-peptide O 
conjugates O 
targeting O 
the O 
gastrin O 
- O 
releasing O 
peptide O 
( O 
GRP O 
) O 
and O 
integrin O 
receptors O 
is O 
reported O 
. O 
Two O 
alternative O 
synthetic O 
methods O 
based O 
on O 
Sonogashira O 
cross O 
- O 
coupling O 
of O 
an O 
iodinated O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
with O 
acetylenic B-SYSTEMATIC 
bombesin I-SYSTEMATIC 
or O 
arginine B-TRIVIAL 
- O 
glycine B-TRIVIAL 
- O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RGD O 
) O 
derivatives O 
, O 
either O 
in O 
solution O 
or O 
on O 
solid O 
phase O 
, O 
are O 
presented O 
. O 
The O 
water O 
- O 
soluble O 
conjugates O 
were O 
screened O 
for O 
their O 
photodynamic O 
efficacy O 
against O 
several O 
cancer O 
cell O 
lines O 
expressing O 
different O 
levels O 
of O 
GRP O 
and O 
integrin O 
receptors O 
, O 
and O 
their O 
intracellular O 
localization O 
was O 
evaluated O 
via O 
confocal O 
fluorescence O 
microscopy O 
. O 
Variations O 
in O 
photocytotoxicity O 
between O 
the O 
conjugates O 
correlate O 
to O 
differences O 
in O 
hydrophobicity O 
as O 
well O 
as O 
receptor O 
- O 
mediated O 
cell O 
uptake O 
. O 
In O 
the O 
case O 
of O 
the O 
phthalocyanine B-TRIVIAL 
- O 
bombesin B-TRIVIAL 
conjugate O 
, O 
competition O 
experiments O 
confirm O 
the O 
involvement O 
of O 
the O 
GRP O 
receptor O 
in O 
both O 
the O 
phototherapeutic O 
activity O 
as O 
well O 
as O 
intracellular O 
localization O 
. O 
These O 
findings O 
warrant O 
further O 
in O 
vivo O 
studies O 
to O 
evaluate O 
the O 
potential O 
of O 
this O 
conjugate O 
as O 
photosensitizer O 
for O 
photodynamic O 
therapy O 
( O 
PDT O 
) O 
of O 
cancers O 
overexpressing O 
the O 
GRP O 
receptor O 
. O 

synthesis O 
and O 
characterization O 
of O 
epicatechin B-MULTIPLE 
glucuronides I-MULTIPLE 
and I-MULTIPLE 
sulfates I-MULTIPLE 
: O 
bioanalytical O 
standards O 
for O 
epicatechin O 
metabolite O 
identification O 
. O 

monoglucuronides B-FAMILY 
and O 
sulfates B-FAMILY 
of O 
epicatechin O 
, O 
3'-O-methylepicatechin B-SYSTEMATIC 
, O 
and O 
4'-O-methylepicatechin B-SYSTEMATIC 
, O 
respectively O 
, O 
were O 
synthesized O 
as O 
authentic O 
bioanalytical O 
standards O 
. O 
Reversed O 
- O 
phase O 
HPLC O 
methods O 
capable O 
of O 
baseline O 
separation O 
of O 
the O 
glucuronides B-FAMILY 
and O 
sulfates B-FAMILY 
have O 
been O 
developed O 
. O 
Both O 
the O 
epicatechin B-MULTIPLE 
glucuronides I-MULTIPLE 
and I-MULTIPLE 
sulfates I-MULTIPLE 
were O 
stable O 
in O 
the O 
solid O 
state O 
when O 
stored O 
under O 
ambient O 
conditions O 
and O 
in O 
aqueous O 
solution O 
when O 
stored O 
refrigerated O 
. O 
These O 
results O 
should O 
prove O 
invaluable O 
to O 
the O 
research O 
community O 
as O 
analytical O 
standards O 
as O 
well O 
as O 
in O 
future O 
studies O 
of O 
the O 
biological O 
and O 
pharmacological O 
effects O 
of O 
epicatechin B-TRIVIAL 
in O 
humans O 
. O 

tetraglycosides I-FAMILY 
and O 
benzyl B-FAMILY 
alcohol I-FAMILY 
glycosides I-FAMILY 
from O 
the O 
Mongolian O 
medicinal O 
plant O 
Dracocephalum O 
ruyschiana O 
. O 

an O 
extract O 
of O 
the O 
aerial O 
parts O 
of O 
Dracocephalum O 
ruyschiana O 
, O 
five O 
new O 
f O 
lavone B-FAMILY 
tetraglycosides I-FAMILY 
, O 
five O 
new O 
benzyl B-FAMILY 
alcohol I-FAMILY 
glycosides I-FAMILY 
, O 
and O 
19 O 
known O 
compounds O 
were O 
isolated O 
. O 
The O 
tetraglycosides O 
contain O 
a O 
7-O-β-d-glucopyranosyl-(1→2)-β-d-glucopyranosyl-(1→2)-[α-l-rhamnopyranosyl-(1→6)]-β-d-glucopyranosyl B-SYSTEMATIC 
moiety O 
. O 
The O 
benzyl B-FAMILY 
alcohol I-FAMILY 
glycosides I-FAMILY 
had O 
acyl B-FAMILY 
groups O 
on O 
their O 
glycosyl B-SYSTEMATIC 
or O 
aglycone O 
moieties O 
. O 
The O 
compounds O 
were O 
tested O 
for O 
antioxidant O 
activity O 
using O 
DPPH B-ABBREVIATION 
. O 
Although O 
the O 
new O 
compounds O 
were O 
not O 
active O 
, O 
phenylpropanoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivatives O 
were O 
revealed O 
as O 
radical O 
scavengers O 
in O 
D O 
. O 
ruyschiana O 
. O 

of O 
some O 
new O 
2-(3-pyridyl)-4,5- B-FAMILY 
disubstituted I-FAMILY 
thiazoles I-FAMILY 
as O 
potent O 
antimicrobial O 
agents O 
. O 

a O 
part O 
of O 
ongoing O 
studies O 
in O 
developing O 
new O 
potent O 
antimicrobial O 
agents O 
, O 
a O 
series O 
of O 
novel O 
2-(3-pyridyl)-4,5- B-FAMILY 
disubstituted I-FAMILY 
thiazoles I-FAMILY 
was O 
efficiently O 
synthesized O 
and O 
characterized O 
by O 
spectral O 
and O 
elemental O 
analyses O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
antimicrobial O 
activity O 
against O 
ten O 
bacterial O 
and O 
five O 
fungal O 
human O 
pathogenic O 
strains O 
using O 
the O 
disc O 
diffusion O 
assay O 
. O 
Among O 
the O 
synthesized O 
compounds O 
, O 
5-acetyl-4-methyl-2-(3-pyridyl)thiazole B-SYSTEMATIC 
( O 
5 O 
) O 
exhibited O 
twofold O 
antibacterial O 
activity O 
of O 
ampicillin B-TRIVIAL 
in O 
inhibiting O 
the O 
growth O 
of O 
Staphylococcus O 
epidermidis O 
( O 
MIC O 
0.24 O 
μg O 
/ O 
mL O 
) O 
and O 
also O 
showed O 
equipotent O 
antifungal O 
activity O 
with O 
amphotricin B-TRIVIAL 
B I-TRIVIAL 
against O 
Geotricum O 
candidum O 
( O 
MIC O 
0.48 O 
μg O 
/ O 
mL O 
) O 
. O 
From O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
point O 
of O 
view O 
, O 
increasing O 
the O 
size O 
of O 
the O 
substitutions O 
either O 
at O 
position O 
4 O 
or O 
5 O 
on O 
the O 
thiazole B-SYSTEMATIC 
nucleus O 
decreased O 
the O 
antimicrobial O 
activity O 
. O 

suppresses O 
oxidized O 
low O 
- O 
density O 
lipoprotein O 
induced O 
endothelial O 
cell O 
apoptosis O 
via O 
activation O 
of O 
LOX-1 O 
/ O 
p38MAPK O 
/ O 
NF-κB O 
pathway O 
. O 

is O 
an O 
active O 
compound O 
isolated O 
from O 
traditional O 
Chinese O 
medicine O 
, O 
and O 
has O 
been O 
shown O 
to O 
have O 
anti-atherosclerosis O 
, O 
anti-inflammatory O 
, O 
antioxidant O 
effects O 
. O 
The O 
present O 
investigation O 
was O 
undertaken O 
to O 
determine O 
the O 
suppression O 
effects O 
of O 
paeonol B-TRIVIAL 
on O 
oxidized O 
low O 
- O 
density O 
lipoprotein O 
( O 
ox-LDL O 
) O 
induced O 
endothelial O 
cell O 
line O 
HUVEC O 
apoptosis O 
and O 
to O 
uncover O 
some O 
of O 
the O 
underlying O 
mechanisms O 
of O 
these O 
effects O 
. O 
Cell O 
viability O 
and O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
were O 
measured O 
to O 
evaluate O 
the O 
cell O 
injuries O 
. O 
Apoptosis O 
was O 
evaluated O 
by O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
staining O 
and O 
flow O 
cytometry O 
. O 
Intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
generation O 
was O 
detected O 
by O 
2',7'-dichlorofluorescein B-SYSTEMATIC 
diacetate I-SYSTEMATIC 
( O 
DCFH-DA B-ABBREVIATION 
) O 
. O 
Real O 
- O 
time O 
PCR O 
was O 
used O 
to O 
confirm O 
the O 
expression O 
of O 
LOX-1 O 
mRNA O 
. O 
Western O 
blotting O 
was O 
used O 
to O 
evaluate O 
the O 
protein O 
expression O 
of O 
LOX-1 O 
and O 
Bcl-2 O 
, O 
as O 
well O 
as O 
caspase-3 O 
cleavage O 
, O 
p38-mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p38MAPK O 
) O 
phosphorylation O 
. O 
NF-κB O 
nuclear O 
translocation O 
was O 
detected O 
by O 
Western O 
blotting O 
and O 
immunofluorescence O 
. O 
Caspase-3 O 
activity O 
was O 
measured O 
using O 
a O 
colorimetric O 
protease O 
assay O 
kit O 
. O 
The O 
results O 
showed O 
that O 
ox-LDL O 
significantly O 
decreased O 
cell O 
viability O 
and O 
increased O 
the O 
LDH O 
release O 
, O 
as O 
well O 
as O 
the O 
apoptotic O 
rate O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
Pre O 
- O 
treatment O 
of O 
paeonol B-TRIVIAL 
resulted O 
in O 
remarkable O 
increase O 
of O 
cell O 
viability O 
, O 
decrease O 
of O 
LDH O 
release O 
and O 
cell O 
apoptosis O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
Besides O 
, O 
ox-LDL O 
caused O 
the O 
up O 
- O 
regulation O 
of O 
LOX-1 O 
, O 
the O 
down O 
- O 
regulation O 
of O 
Bcl-2 O 
, O 
the O 
phosphorylation O 
of O 
p38MAPK O 
, O 
the O 
translocation O 
of O 
NF-κB O 
and O 
the O 
activation O 
of O 
caspase-3 O 
. O 
Paeonol B-TRIVIAL 
pre O 
- O 
treatment O 
reversed O 
these O 
effects O 
introduced O 
by O 
ox-LDL O 
. O 
Moreover O 
, O 
paeonol B-TRIVIAL 
also O 
showed O 
its O 
inhibition O 
effects O 
on O 
ox-LDL O 
induced O 
ROS O 
overproduction O 
. O 
These O 
results O 
indicate O 
the O 
preventive O 
effects O 
of O 
paeonol B-TRIVIAL 
on O 
ox-LDL O 
induced O 
endothelial O 
cell O 
apoptosis O 
. O 
The O 
effects O 
might O 
, O 
at O 
least O 
partly O 
, O 
be O 
obtained O 
via O 
inhibition O 
of O 
LOX-1-ROS- O 
p38MAPK-NF-κB O 
signaling O 
pathway O 
. O 

of O 
Perilla O 
frutescens O 
extract O 
and O 
Vicenin B-TRIVIAL 
2 I-TRIVIAL 
for O 
their O 
antispasmodic O 
effect O 
. O 

discomfort O 
is O 
frequently O 
observed O 
. O 
The O 
effects O 
of O 
Perilla O 
frutescens O 
extract O 
and O 
Vicenin B-TRIVIAL 
2 I-TRIVIAL 
( O 
a O 
compound O 
in O 
this O 
extract O 
) O 
were O 
assayed O 
in O 
rat O 
ileum O 
with O 
or O 
without O 
stimulation O 
with O 
acetylcholine B-SYSTEMATIC 
or O 
Ba(2+) B-FORMULA 
. O 
Both O 
had O 
no O 
direct O 
spasmolytic O 
effect O 
, O 
but O 
both O 
decreased O 
acetylcholine B-SYSTEMATIC 
- O 
or O 
Ba(2+) B-FORMULA 
-induced O 
contraction O 
of O 
rat O 
ileum O 
indicating O 
an O 
antispasmodic O 
effect O 
. O 
This O 
is O 
valuable O 
because O 
effects O 
were O 
only O 
observed O 
when O 
spasms O 
were O 
induced O 
and O 
may O 
disturb O 
the O 
patient O 
. O 
The O 
extract O 
and O 
the O 
compound O 
may O 
be O 
used O 
to O 
maintain O 
and O 
improve O 
gut O 
health O 
. O 

effect O 
of O 
silymarin B-FAMILY 
against O 
ethanol B-SYSTEMATIC 
-induced O 
gastritis O 
in O 
rats O 
: O 
role O 
of O 
sulfhydryls B-FAMILY 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
gastric O 
sensory O 
afferents O 
. O 

has O 
been O 
known O 
to O 
exert O 
antioxidant O 
, O 
anti-carcinogenic O 
and O 
anti-inflammatory O 
effects O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
effect O 
of O 
silymarin B-FAMILY 
on O 
gastritis O 
in O 
rats O 
. O 
Oral O 
administration O 
of O 
silymarin B-FAMILY 
dose O 
- O 
dependently O 
decreased O 
gastric O 
lesions O 
in O 
ethanol B-SYSTEMATIC 
-induced O 
gastritis O 
model O 
. O 
Silymarin B-FAMILY 
also O 
significantly O 
suppressed O 
the O 
development O 
of O 
gastric O 
lesions O 
in O 
aspirin B-TRIVIAL 
- O 
or O 
water O 
immersion O 
- O 
restraint O 
stress O 
- O 
induced O 
gastritis O 
models O 
. O 
Further O 
study O 
demonstrated O 
that O 
the O 
gastroprotective O 
effect O 
of O 
silymarin B-FAMILY 
was O 
blocked O 
by O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
synthase O 
inhibitor O 
l-NAME B-ABBREVIATION 
, O 
SH B-FORMULA 
blocker O 
N-ethylmaleimide B-SYSTEMATIC 
or O 
TRPV1 O 
antagonist O 
capsazepine B-TRIVIAL 
in O 
ethanol B-SYSTEMATIC 
-induced O 
gastritis O 
model O 
. O 
In O 
addition O 
, O 
ex O 
vivo O 
analysis O 
revealed O 
that O 
ethanol B-SYSTEMATIC 
-induced O 
decrease O 
in O 
gastric O 
mucus O 
and O 
non O 
- O 
protein O 
sulfhydryl B-FAMILY 
( O 
NPSH O 
) O 
groups O 
was O 
significantly O 
reversed O 
by O 
silymarin B-FAMILY 
treatment O 
and O 
lipid O 
peroxidation O 
was O 
also O 
suppressed O 
by O 
silymarin B-FAMILY 
in O 
ethanol B-SYSTEMATIC 
-induced O 
gastritis O 
model O 
. O 
Taken O 
together O 
, O 
these O 
results O 
suggest O 
that O 
silymarin B-FAMILY 
exerts O 
gastroprotective O 
effects O 
and O 
the O 
gastroprotective O 
effects O 
of O 
silymarin B-FAMILY 
might O 
be O 
related O 
to O 
the O 
protection O 
of O 
gastric O 
mucosal O 
NO B-FORMULA 
and O 
NP- O 
SH B-FORMULA 
and O 
the O 
modulation O 
of O 
capsaicin B-TRIVIAL 
-sensitive O 
gastric O 
sensory O 
afferents O 
. O 

- O 
inducing O 
activity O 
of O 
the O 
actin O 
- O 
depolymerizing O 
agent O 
aplyronine B-TRIVIAL 
A I-TRIVIAL 
and O 
its O 
side-chain O 
derivatives O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
and O 
mycalolide B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
, O 
which O 
are O 
cytotoxic O 
actin O 
- O 
depolymerizing O 
marine O 
macrolides O 
, O 
were O 
revealed O 
to O 
induce O 
apoptosis O 
in O 
human O 
leukemia O 
HL60 O 
cells O 
and O 
human O 
epithelial O 
carcinoma O 
HeLa O 
S(3) O 
cells O 
. O 
Based O 
on O 
these O 
results O 
, O 
actin O 
- O 
depolymerizing O 
compounds O 
were O 
expected O 
to O 
exhibit O 
apoptosis O 
- O 
inducing O 
activity O 
in O 
cancer O 
cells O 
. O 
Compounds O 
3-6 O 
, O 
which O 
were O 
synthesized O 
based O 
on O 
the O 
side-chain O 
structure O 
of O 
aplyronine B-TRIVIAL 
A I-TRIVIAL 
, O 
were O 
evaluated O 
for O 
their O 
actin O 
- O 
depolymerizing O 
activities O 
in O 
vitro O 
and O 
cytotoxicities O 
against O 
HL60 O 
cells O 
. O 
The O 
growth O 
- O 
inhibitory O 
activities O 
of O 
3-6 O 
were O 
well O 
correlated O 
with O 
their O 
actin O 
- O 
depolymerizing O 
activities O 
, O 
and O 
derivative O 
6 O 
was O 
shown O 
to O 
induce O 
the O 
disruption O 
of O 
actin O 
filaments O 
and O 
apoptosis O 
in O 
HL60 O 
cells O 
. O 
These O 
results O 
suggested O 
that O 
actin O 
- O 
depolymerizing O 
agents O 
1 O 
, O 
2 O 
, O 
and O 
6-induced O 
apoptosis O 
in O 
HL60 O 
cells O 
may O 
have O 
been O 
due O 
to O 
their O 
actin O 
- O 
depolymerizing O 
activity O 
. O 

analogues O 
of O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
as O 
irreversible O 
inhibitors O 
of O 
Staphylococcus O 
aureus O 
endoproteinase O 
GluC O 
: O 
an O 
efficient O 
synthesis O 
and O 
inhibition O 
of O 
the O 
human O 
IgG O 
degradation O 
. O 

GluC O 
( O 
V8 O 
protease O 
) O 
is O 
one O 
of O 
many O 
virulence O 
factors O 
released O 
by O 
the O 
Staphylococcus O 
aureus O 
species O 
in O 
vivo O 
. O 
The O 
V8 O 
protease O 
is O 
able O 
to O 
hydrolyze O 
some O 
serpins O 
and O 
all O 
classes O 
of O 
mammalian O 
immunoglobulins O 
. O 
The O 
application O 
of O 
specific O 
and O 
potent O 
inhibitors O 
of O 
V8 O 
protease O 
may O 
lead O 
to O 
the O 
development O 
of O 
new O 
antibacterial O 
agents O 
. O 
Herein O 
, O 
we O 
present O 
the O 
synthesis O 
and O 
the O 
inhibitory O 
properties O 
of O 
novel O 
peptidyl O 
derivatives O 
of O 
a O 
phosphonic B-SYSTEMATIC 
glutamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
analogue O 
. O 
One O 
of O 
the O 
compounds O 
Boc-Phe-Leu-Glu(P)(OC(6)H(4))(2) B-FORMULA 
displayed O 
an O 
apparent O 
second O 
- O 
order O 
inhibition O 
rate O 
value O 
of O 
8540 O 
M(-1)s(-1) O 
. O 
The O 
Boc-Phe-Leu-Glu(P)(OC(6)H(4))(2) B-FORMULA 
compound O 
with O 
the O 
highest O 
inhibitory O 
potency O 
showed O 
the O 
ability O 
to O 
prevent O 
V8 O 
- O 
mediated O 
human O 
IgG O 
proteolysis O 
in O 
vitro O 
. O 

and O 
synthesis O 
of O 
dimethylaminomethyl B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
curcumin I-FAMILY 
derivatives O 
/ O 
analogues O 
: O 
potent O 
antitumor O 
and O 
antioxidant O 
activity O 
, O 
improved O 
stability O 
and O 
aqueous O 
solubility O 
compared O 
with O 
curcumin B-TRIVIAL 
. O 

series O 
of O 
dimethylaminomethyl B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
curcumin I-FAMILY 
derivatives O 
/ O 
analogues O 
were O 
designed O 
and O 
synthesized O 
. O 
All O 
compounds O 
effectively O 
inhibited O 
HepG2 O 
, O 
SGC-7901 O 
, O 
A549 O 
and O 
HCT-116 O 
tumor O 
cell O 
lines O 
proliferation O 
in O 
MTT B-ABBREVIATION 
assay O 
. O 
Particularly O 
, O 
compounds O 
2a O 
and O 
3d O 
showed O 
much O 
better O 
activity O 
than O 
curcumin B-TRIVIAL 
against O 
all O 
of O 
the O 
four O 
tumor O 
cell O 
lines O 
. O 
Antioxidant O 
test O 
revealed O 
that O 
these O 
compounds O 
had O 
higher O 
free O 
radical O 
scavenging O 
activity O 
than O 
curcumin O 
towards O 
both O 
DPPH B-ABBREVIATION 
and O 
galvinoxyl B-TRIVIAL 
radicals O 
. O 
Furthermore O 
, O 
the O 
aqueous O 
solubility O 
and O 
stability O 
of O 
the O 
target O 
compounds O 
were O 
also O 
significantly O 
improved O 
compared O 
with O 
curcumin B-TRIVIAL 
. O 

, O 
synthesis O 
, O 
characterization O 
and O 
anti-inflammatory O 
evaluation O 
of O 
novel O 
pyrazole B-SYSTEMATIC 
amalgamated O 
flavones B-FAMILY 
. O 

series O 
of O 
novel O 
pyrazole B-SYSTEMATIC 
amalgamated O 
flavones B-FAMILY 
has O 
been O 
designed O 
and O 
synthesized O 
from O 
1-methyl-5-(2,4,6-trimethoxy-phenyl)-1H-pyrazole B-SYSTEMATIC 
6 O 
. O 
The O 
structures O 
of O 
regioisomers O 
6 O 
and O 
7 O 
were O 
resolved O 
by O 
2D O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
(1)H B-FORMULA 
- O 
(13)C B-FORMULA 
HSQC O 
and O 
(1)H B-FORMULA 
- O 
(13)C B-FORMULA 
HMBC O 
experiments O 
. O 
The O 
newly O 
synthesized O 
compounds O 
were O 
tested O 
for O 
their O 
in O 
vitro O 
COX O 
inhibition O 
and O 
in O 
vivo O 
carrageenan O 
induced O 
hind O 
paw O 
edema O 
in O 
rats O 
and O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
induced O 
vascular O 
permeability O 
in O 
mice O 
. O 
Although O 
the O 
compounds O 
have O 
inhibitory O 
profile O 
against O 
both O 
COX-1 O 
and O 
COX-2 O 
, O 
some O 
of O 
the O 
compounds O 
are O 
found O 
to O 
be O 
selective O 
against O 
COX-2 O 
, O 
supported O 
by O 
inhibition O 
of O 
paw O 
edema O 
and O 
vascular O 
permeability O 
. O 
Docking O 
studies O 
were O 
also O 
carried O 
out O 
to O 
determine O 
the O 
structural O 
features O 
which O 
sway O 
the O 
anti-inflammatory O 
activity O 
of O 
the O 
tested O 
compounds O 
. O 
The O 
keto B-SYSTEMATIC 
and O 
phenolic B-FAMILY 
- O 
OH B-FORMULA 
are O 
major O 
factors O 
that O 
are O 
prominently O 
involved O 
in O 
interaction O 
with O 
COX-2 O 
active O 
site O 
. O 

activity O 
evaluation O 
, O 
time O 
- O 
kill O 
kinetic O 
and O 
3D-QSAR O 
study O 
of O 
C-(3-aminomethyl-cyclohexyl)-methylamine B-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
C-(3-aminomethyl-cyclohexyl)-methylamine B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antitubercular O 
activity O 
. O 
Some O 
of O 
the O 
compounds O 
exhibited O 
potent O 
activity O 
against O 
Mycobacterium O 
tuberculosis O 
H37Rv O 
. O 
One O 
of O 
the O 
compound O 
having O 
t-butyl B-SYSTEMATIC 
at O 
para O 
position O 
of O 
the O 
benzene B-SYSTEMATIC 
ring O 
showed O 
excellent O 
activity O 
even O 
better O 
than O 
the O 
standard O 
drug O 
ethambutol B-TRIVIAL 
with O 
MIC O 
value O 
1.1 O 
± O 
0.2 O 
μM O 
. O 
The O 
time O 
- O 
kill O 
kinetics O 
study O 
of O 
two O 
most O 
active O 
compounds O 
showed O 
rapid O 
killing O 
of O 
the O 
M O 
. O 
tuberculosis O 
within O 
4 O 
days O 
. O 
Additionally O 
atom O 
- O 
based O 
quantitative O 
structure O 
- O 
activity O 
relationship O 
( O 
QSAR O 
) O 
model O 
was O 
developed O 
that O 
gave O 
a O 
statistically O 
satisfying O 
result O 
(R(2))=0.92 O 
, O 
Q(2)=0.75 O 
, O 
Pearson-R=0.96 O 
and O 
effectively O 
predicts O 
the O 
anti-tuberculosis O 
activity O 
of O 
training O 
and O 
test O 
set O 
compounds O 
. O 

HSD11B2 O 
CA-repeat O 
in O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
and O 
type O 
2 O 
diabetes O 
. O 

2 O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
encoded O 
by O 
the O 
HSD11B2 O 
gene O 
converts O 
cortisol B-TRIVIAL 
to O 
inactive O 
cortisone B-TRIVIAL 
, O 
and O 
alteration O 
in O 
this O 
enzymatic O 
activity O 
might O 
affect O 
glucose B-TRIVIAL 
homeostasis O 
by O 
affecting O 
circulating O 
levels O 
or O 
tissue O 
availability O 
of O 
glucocorticoids O 
. O 
We O 
investigated O 
the O 
association O 
of O 
HSD11B2 O 
variant O 
with O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Subjects O 
with O 
normal O 
glucose B-TRIVIAL 
tolerance O 
( O 
n=585 O 
) O 
, O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
( O 
n=202 O 
) O 
and O 
type O 
2 O 
diabetes O 
( O 
n=355 O 
) O 
were O 
genotyped O 
for O 
a O 
highly O 
polymorphic O 
CA-repeat O 
polymorphism O 
in O 
the O 
first O 
intron O 
of O 
HSD11B2 O 
. O 
Allele O 
and O 
genotype O 
frequencies O 
differed O 
between O 
normal O 
and O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
( O 
P O 
= O 
0.0014 O 
and O 
0.0407 O 
, O 
respectively O 
; O 
4DF O 
) O 
or O 
type O 
2 O 
diabetes O 
( O 
P O 
= O 
0.0053 O 
and O 
0.0078 O 
) O 
, O 
with O 
significant O 
linear O 
trends O 
between O 
the O 
repeat O 
length O 
and O 
the O 
phenotype O 
fraction O 
. O 
In O 
normal O 
subjects O 
, O 
total O 
CA-repeat O 
length O 
was O 
negatively O 
correlated O 
with O 
fasting O 
insulin O 
and O 
HOMA-β O 
. O 
Thus O 
, O 
subjects O 
having O 
more O 
CA O 
repeats O 
are O 
susceptible O 
to O 
developing O 
abnormal O 
glucose B-TRIVIAL 
tolerance O 
, O 
whereas O 
normal O 
subjects O 
carrying O 
more O 
CA O 
repeats O 
appeared O 
to O 
have O 
frugal O 
characteristics O 
in O 
insulin O 
secretion O 
. O 

with O 
a O 
triscarbazole B-SYSTEMATIC 
hole O 
- O 
transport O 
group O 
and O 
an O 
oxetane B-SYSTEMATIC 
or O 
benzocyclobutene B-SYSTEMATIC 
crosslinkable O 
group O 
can O 
be O 
readily O 
thermally O 
crosslinked O 
on O 
timescales O 
of O 
30 O 
min O 
or O 
less O 
, O 
with O 
rapid O 
thermal O 
processing O 
( O 
RTP O 
) O 
being O 
highly O 
effective O 
for O 
this O 
purpose O 
. O 
Devices O 
with O 
RTP-crosslinked O 
hole O 
- O 
transport O 
layers O 
and O 
spin O 
- O 
coated O 
emissive O 
layers O 
exhibit O 
high O 
external O 
quantum O 
efficiencies O 
of O 
up O 
to O 
15% O 
. O 

open O 
, O 
controlled O 
study O 
evaluated O 
the O 
effects O 
of O 
6 O 
month O 
supplementation O 
with O 
Pycnogenol O 
® O 
maritime O 
pine O 
bark O 
extract O 
on O 
health O 
risk O 
factors O 
in O 
subjects O 
with O 
metabolic O 
syndrome O 
. O 
Pycnogenol O 
® O 
was O 
used O 
with O 
the O 
aim O 
of O 
improving O 
risk O 
factors O 
associated O 
with O 
metabolic O 
syndrome O 
, O 
central O 
obesity O 
, O 
elevated O 
triglycerides B-FAMILY 
( O 
TG O 
) O 
, O 
low O 
HDL O 
cholesterol B-TRIVIAL 
, O 
high O 
blood O 
pressure O 
and O 
fasting O 
blood O 
glucose B-TRIVIAL 
. O 
Sixty O 
- O 
four O 
subjects O 
( O 
range O 
45-55 O 
years O 
) O 
presenting O 
with O 
all O 
five O 
risk O 
factors O 
of O 
metabolic O 
syndrome O 
were O 
included O 
, O 
and O 
Pycnogenol O 
® O 
was O 
administered O 
for O 
6 O 
months O 
. O 
A O 
group O 
of O 
66 O 
equivalent O 
subjects O 
were O 
followed O 
up O 
as O 
controls O 
. O 
In O 
the O 
6-month O 
study O 
Pycnogenol O 
® O 
supplementation O 
150 O 
mg O 
/ O 
day O 
decreased O 
waist O 
circumference O 
, O 
TG O 
levels O 
, O 
blood O 
pressure O 
and O 
increased O 
the O 
HDL O 
cholesterol B-TRIVIAL 
levels O 
in O 
subjects O 
. O 
Pycnogenol O 
lowered O 
fasting O 
glucose B-TRIVIAL 
from O 
baseline O 
123 O 
± O 
8.6 O 
mg O 
/ O 
dl O 
to O 
106.4 O 
± O 
5.3 O 
after O 
3 O 
months O 
and O 
to O 
105.3 O 
± O 
2.5 O 
at O 
the O 
end O 
of O 
the O 
study O 
( O 
p O 
< O 
0.05 O 
vs O 
controls O 
) O 
. O 
Men's O 
waist O 
circumference O 
decreased O 
with O 
Pycnogenol O 
from O 
106.2 O 
± O 
2.2 O 
cm O 
to O 
98.8 O 
± O 
2.3 O 
cm O 
and O 
to O 
98.3 O 
± O 
2.1 O 
after O 
3 O 
and O 
6 O 
months O 
. O 
Women's O 
waist O 
decreased O 
from O 
90.9 O 
± O 
1.6 O 
cm O 
to O 
84.6 O 
± O 
2.1 O 
cm O 
and O 
to O 
83.6 O 
± O 
2.2 O 
cm O 
after O 
3 O 
and O 
6 O 
months O 
. O 
Both O 
genders O 
waist O 
circumference O 
reduction O 
was O 
significant O 
as O 
compared O 
to O 
controls O 
at O 
both O 
time O 
points O 
. O 
In O 
addition O 
, O 
plasma O 
free O 
radicals O 
decrease O 
in O 
the O 
Pycnogenol O 
group O 
was O 
more O 
effective O 
than O 
in O 
the O 
control O 
group O 
( O 
-34.6% O 
; O 
p O 
< O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
indicates O 
a O 
role O 
for O 
Pycnogenol O 
® O 
for O 
improving O 
health O 
risk O 
factors O 
in O 
subjects O 
with O 
metabolic O 
syndrome O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

for O 
the O 
continuous O 
monitoring O 
and O 
removal O 
of O 
ultra O 
- O 
trace O 
levels O 
of O 
toxic O 
inorganic O 
species O 
( O 
e.g O 
. O 
, O 
mercury B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
and O 
cadmium B-SYSTEMATIC 
ions O 
) O 
from O 
aqueous O 
media O 
such O 
as O 
drinking O 
water O 
and O 
biological O 
fluids O 
are O 
essential O 
. O 
In O 
this O 
paper O 
, O 
the O 
design O 
and O 
engineering O 
of O 
a O 
simple O 
, O 
pH-dependent O 
, O 
micro O 
- O 
object O 
optical O 
sensor O 
is O 
described O 
based O 
on O 
mesoporous O 
aluminosilica B-TRIVIAL 
pellets O 
with O 
an O 
adsorbed O 
dressing O 
receptor O 
( O 
a O 
porphyrinic O 
chelating O 
ligand O 
) O 
. O 
This O 
tailor O 
- O 
made O 
optical O 
sensor O 
permits O 
ultra O 
- O 
fast O 
( O 
≤ O 
60 O 
s O 
) O 
, O 
specific O 
, O 
pH-dependent O 
visualization O 
and O 
removal O 
of O 
Cu(2+) B-FORMULA 
, O 
Cd(2+) B-FORMULA 
, O 
and O 
Hg(2+) B-FORMULA 
at O 
sub O 
- O 
picomolar O 
concentrations O 
( O 
∼10(-11) O 
mol O 
dm(-3) O 
) O 
from O 
aqueous O 
media O 
, O 
including O 
drinking O 
water O 
and O 
a O 
suspension O 
of O 
red O 
blood O 
cells O 
. O 
The O 
acidic O 
active O 
acid O 
sites O 
of O 
the O 
pellets O 
consist O 
of O 
heteroatoms O 
arranged O 
around O 
uniformly O 
shaped O 
pores O 
in O 
3D O 
nanoscale O 
gyroidal O 
mesostructures O 
densely O 
coated O 
with O 
the O 
chelating O 
ligand O 
. O 
The O 
sensor O 
can O 
be O 
used O 
in O 
batch O 
mode O 
, O 
as O 
well O 
as O 
in O 
a O 
flow O 
- O 
through O 
system O 
in O 
which O 
sampling O 
, O 
target O 
ion O 
recognition O 
and O 
removal O 
, O 
and O 
analysis O 
are O 
integrated O 
in O 
a O 
highly O 
automated O 
and O 
efficient O 
manner O 
. O 
Because O 
the O 
pellets O 
exhibit O 
long O 
- O 
term O 
stability O 
, O 
reproducibility O 
, O 
and O 
versatility O 
over O 
a O 
number O 
of O 
analysis O 
/ O 
regeneration O 
cycles O 
, O 
they O 
can O 
be O 
expected O 
to O 
be O 
useful O 
for O 
the O 
fabrication O 
of O 
inexpensive O 
sensor O 
devices O 
for O 
naked O 
- O 
eye O 
detection O 
of O 
toxic O 
pollutants O 
. O 

Synthesis O 
of O 
Transparent O 
, O 
Amorphous O 
, O 
C(60) B-TRIVIAL 
-Rich O 
, O 
Photoactive O 
, O 
and O 
Low-Doped O 
Film O 
with O 
an O 
Interconnected O 
Structure O 
. O 

electrochemical O 
synthesis O 
is O 
developed O 
through O 
quantitative O 
electrochemical O 
reaction O 
of O 
N-alkylcarbazole B-FAMILY 
leading O 
to O 
a O 
novel O 
class O 
of O 
structurally O 
interconnected O 
high- O 
C(60) B-TRIVIAL 
content O 
( O 
60 O 
wt% O 
) O 
polymer O 
films O 
with O 
negligible O 
doping O 
and O 
intrinsic O 
physicochemical O 
properties O 
of O 
pure O 
C(60) B-TRIVIAL 
. O 
This O 
strategy O 
allows O 
preparation O 
of O 
previously O 
unavailable O 
low O 
- O 
doped O 
fullerene B-TRIVIAL 
-containing O 
non-conjugated O 
polymers O 
and O 
broadens O 
the O 
potential O 
applications O 
of O 
electrochemical O 
synthesis O 
for O 
controlled O 
polymer O 
film O 
structures O 
. O 

6mer O 
+ O 
BSP O 
protein O 
, O 
combining O 
six O 
repeats O 
of O 
the O 
consensus O 
sequence O 
for O 
Nephila O 
clavipes O 
dragline O 
( O 
6mer O 
) O 
and O 
bone O 
sialoprotein O 
sequence O 
( O 
BSP O 
) O 
, O 
shows O 
good O 
support O 
for O 
cell O 
viability O 
and O 
induces O 
the O 
nucleation O 
of O 
hydroxyapatite B-TRIVIAL 
and O 
tricalcium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
during O 
osteoblast O 
in O 
vitro O 
culture O 
. O 
The O 
present O 
study O 
is O 
conducted O 
to O 
characterize O 
this O 
bioengineered O 
protein O 
- O 
based O 
biomaterial O 
further O 
for O 
in O 
vivo O 
behavior O 
related O 
to O 
biocompatibility O 
. O 
6mer O 
+ O 
BSP O 
protein O 
films O 
are O 
implanted O 
in O 
subcutaneous O 
pouches O 
in O 
the O 
back O 
of O 
mice O 
and O 
responses O 
are O 
evaluated O 
by O 
flow O 
cytometry O 
and O 
histology O 
. O 
The O 
results O 
show O 
no O 
major O 
differences O 
between O 
the O 
inflammatory O 
responses O 
induced O 
by O 
6mer O 
+ O 
BSP O 
films O 
and O 
the O 
responses O 
observed O 
for O 
the O 
controls O 
. O 
Thus O 
, O 
this O 
new O 
chimeric O 
protein O 
could O 
represent O 
an O 
alternative O 
for O 
bone O 
regeneration O 
applications O 
. O 

and O 
CO B-FORMULA 
-releasing O 
molecules O 
in O 
medicinal O 
chemistry O 
. O 

the O 
discovery O 
that O 
CO B-FORMULA 
acts O 
as O 
a O 
cytoprotective O 
and O 
homeostatic O 
molecule O 
, O 
increasing O 
research O 
efforts O 
have O 
been O 
devoted O 
to O 
the O 
exploitation O 
of O 
its O 
therapeutic O 
effects O 
. O 
Both O 
endogenous O 
and O 
exogenous O 
CO B-FORMULA 
improves O 
experimental O 
lung O 
, O 
vascular O 
and O 
cardiac O 
injuries O 
and O 
protects O 
against O 
several O 
inflammatory O 
states O 
. O 
The O 
technology O 
is O 
now O 
in O 
place O 
to O 
bring O 
CO B-FORMULA 
to O 
clinical O 
applications O 
, O 
but O 
the O 
use O 
of O 
the O 
gaseous O 
molecule O 
poses O 
several O 
problems O 
. O 
The O 
challenges O 
associated O 
with O 
the O 
clinical O 
implementation O 
of O 
the O 
gas O 
have O 
in O 
part O 
been O 
answered O 
by O 
the O 
development O 
of O 
CO B-FORMULA 
-releasing O 
molecules O 
( O 
CO B-FORMULA 
-RMs O 
) O 
. O 
As O 
stable O 
solid O 
forms O 
of O 
CO B-FORMULA 
, O 
these O 
molecules O 
represent O 
an O 
alternative O 
to O 
the O 
administration O 
of O 
carbon B-SYSTEMATIC 
monoxide I-SYSTEMATIC 
( O 
orally O 
or O 
by O 
injection O 
) O 
. O 
In O 
this O 
article O 
, O 
we O 
present O 
insights O 
into O 
the O 
biochemical O 
action O 
of O 
CO B-FORMULA 
and O 
discuss O 
the O 
efficacy O 
of O 
CO B-FORMULA 
and O 
CO B-FORMULA 
-RMs O 
in O 
preclinical O 
disease O 
models O 
. O 
Recent O 
advances O 
in O 
the O 
CO B-FORMULA 
-RMs O 
field O 
are O 
critically O 
addressed O 
. O 

effects O 
of O 
Ag B-FORMULA 
nanoparticles O 
and O 
oxygen B-SYSTEMATIC 
plasma O 
treatment O 
on O 
PLGA O 
morphological O 
, O 
chemical O 
, O 
and O 
antibacterial O 
properties O 
. O 

purpose O 
of O 
this O 
study O 
is O 
to O 
investigate O 
the O 
combined O 
effects O 
of O 
oxygen B-SYSTEMATIC 
plasma O 
treatments O 
and O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
Ag B-FORMULA 
) O 
on O 
PLGA B-ABBREVIATION 
in O 
order O 
to O 
modulate O 
the O 
surface O 
antimicrobial O 
properties O 
through O 
tunable O 
bacteria O 
adhesion O 
mechanisms O 
. O 
PLGA B-ABBREVIATION 
nanocomposite O 
films O 
, O 
produced O 
by O 
solvent O 
casting O 
with O 
1 O 
wt O 
% O 
and O 
7 O 
wt O 
% O 
of O 
Ag B-FORMULA 
nanoparticles O 
were O 
investigated O 
. O 
The O 
PLGA B-ABBREVIATION 
and O 
PLGA B-ABBREVIATION 
/ O 
Ag B-FORMULA 
nanocomposite O 
surfaces O 
were O 
treated O 
with O 
oxygen B-SYSTEMATIC 
plasma O 
. O 
Surface O 
properties O 
of O 
PLGA B-ABBREVIATION 
were O 
investigated O 
by O 
field O 
emission O 
scanning O 
electron O 
microscopy O 
( O 
FESEM O 
) O 
, O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
, O 
static O 
contact O 
angle O 
( O 
CA O 
) O 
, O 
and O 
high O 
resolution O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
Antibacterial O 
tests O 
were O 
performed O 
using O 
an O 
Escherichia O 
coli O 
RB O 
( O 
a O 
Gram O 
negative O 
) O 
and O 
Staphylococcus O 
aureus O 
8325-4 O 
( O 
a O 
Gram O 
positive O 
) O 
. O 
The O 
PLGA B-ABBREVIATION 
surface O 
becomes O 
hydrophilic O 
after O 
the O 
oxygen B-SYSTEMATIC 
treatment O 
and O 
its O 
roughness O 
increases O 
with O 
the O 
treatment O 
time O 
. O 
The O 
surface O 
treatment O 
and O 
the O 
Ag B-FORMULA 
nanoparticle O 
introduction O 
have O 
a O 
dominant O 
influence O 
on O 
the O 
bacteria O 
adhesion O 
and O 
growth O 
. O 
Oxygen B-SYSTEMATIC 
-treated O 
PLGA B-ABBREVIATION 
/ O 
Ag B-FORMULA 
systems O 
promote O 
higher O 
reduction O 
of O 
the O 
bacteria O 
viability O 
in O 
comparison O 
to O 
the O 
untreated O 
samples O 
and O 
neat O 
PLGA B-ABBREVIATION 
. O 
The O 
combination O 
of O 
Ag B-FORMULA 
nanoparticles O 
with O 
the O 
oxygen B-SYSTEMATIC 
plasma O 
treatment O 
opens O 
new O 
perspectives O 
for O 
the O 
studied O 
biodegradable O 
systems O 
in O 
biomedical O 
applications O 
. O 

- O 
enhanced O 
Raman O 
scattering O 
dye O 
- O 
labeled O 
Au B-FORMULA 
nanoparticles O 
for O 
triplexed O 
detection O 
of O 
leukemia O 
and O 
lymphoma O 
cells O 
and O 
SERS O 
flow O 
cytometry O 
. O 

labeling O 
of O 
cell O 
surface O 
receptors O 
by O 
fluorescent O 
markers O 
is O 
an O 
established O 
method O 
for O 
the O 
identification O 
of O 
cell O 
phenotype O 
in O 
both O 
research O 
and O 
clinical O 
settings O 
. O 
Fluorescence O 
dye O 
labeling O 
has O 
inherent O 
constraints O 
, O 
most O 
notably O 
the O 
upper O 
limit O 
of O 
labels O 
per O 
cell O 
that O 
may O 
be O 
probed O 
using O 
a O 
single O 
excitation O 
source O 
, O 
in O 
addition O 
to O 
a O 
physical O 
limit O 
to O 
the O 
number O 
of O 
broad O 
emission O 
spectra O 
that O 
can O 
be O 
distinctly O 
collected O 
within O 
the O 
visible O 
wavelength O 
region O 
. O 
SERS O 
labeling O 
has O 
the O 
potential O 
to O 
mitigate O 
these O 
shortfalls O 
. O 
Herein O 
, O 
antibody O 
- O 
targeted O 
, O 
PEG B-ABBREVIATION 
-coated O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
Au B-FORMULA 
nanoparticles O 
are O 
used O 
simultaneously O 
to O 
label O 
three O 
cell O 
surface O 
markers O 
of O 
interest O 
on O 
malignant O 
B O 
cells O 
from O 
the O 
LY10 O 
lymphoma O 
cell O 
line O 
. O 
The O 
SERS O 
probes O 
were O 
characterized O 
by O 
multiple O 
methods O 
to O 
confirm O 
their O 
monodispersity O 
and O 
functionalization O 
with O 
both O 
PEG B-ABBREVIATION 
and O 
monoclonal O 
antibodies O 
. O 
The O 
specificity O 
of O 
the O 
particles O 
' O 
cell O 
labeling O 
was O 
demonstrated O 
on O 
both O 
primary O 
chronic O 
lymphocytic O 
leukemia O 
and O 
LY10 O 
cells O 
using O 
SERS O 
from O 
cell O 
suspensions O 
and O 
confocal O 
Raman O 
mapping O 
, O 
respectively O 
. O 
Fluorescence O 
flow O 
cytometry O 
was O 
employed O 
to O 
confirm O 
the O 
binding O 
of O 
SERS O 
probes O 
to O 
LY10 O 
over O 
large O 
cell O 
populations O 
, O 
and O 
the O 
particles O 
' O 
SERS O 
was O 
collected O 
directly O 
from O 
labeled O 
cells O 
using O 
a O 
commercial O 
flow O 
cytometer O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
demonstration O 
of O 
SERS O 
flow O 
cytometry O 
from O 
cells O 
tagged O 
with O 
targeted O 
SERS O 
probes O 
. O 

characterized O 
in O 
this O 
study O 
the O 
pharmacokinetics O 
and O 
antitumor O 
efficacy O 
of O 
histidine B-TRIVIAL 
- O 
lysine B-TRIVIAL 
( O 
HK O 
) O 
: O 
siRNA O 
nanoplexes O 
modified O 
with O 
PEG B-ABBREVIATION 
and O 
a O 
cyclic O 
RGD O 
( O 
cRGD O 
) O 
ligand O 
targeting O 
αvβ3 O 
and O 
αvβ5 O 
integrins O 
. O 
With O 
noninvasive O 
imaging O 
, O 
systemically O 
administered O 
surface O 
- O 
modified O 
HK O 
: O 
siRNA O 
nanoplexes O 
showed O 
nearly O 
4-fold O 
greater O 
blood O 
levels O 
, O 
40% O 
higher O 
accumulation O 
in O 
tumor O 
tissue O 
, O 
and O 
60% O 
lower O 
luciferase O 
activity O 
than O 
unmodified O 
HK O 
: O 
siRNA O 
nanoplexes O 
. O 
We O 
then O 
determined O 
whether O 
the O 
surface O 
- O 
modified O 
HK O 
: O 
siRNA O 
nanoplex O 
carrier O 
was O 
more O 
effective O 
in O 
reducing O 
MDA-MB-435 O 
tumor O 
growth O 
with O 
an O 
siRNA O 
targeting O 
Raf-1 O 
. O 
Repeated O 
systemic O 
administration O 
of O 
the O 
selected O 
surface O 
modified O 
HK O 
: O 
siRNA O 
nanoplexes O 
targeting O 
Raf-1 O 
showed O 
35% O 
greater O 
inhibition O 
of O 
tumor O 
growth O 
than O 
unmodified O 
HK O 
: O 
siRNA O 
nanoplexes O 
and O 
60% O 
greater O 
inhibition O 
of O 
tumor O 
growth O 
than O 
untreated O 
mice O 
. O 
The O 
improved O 
blood O 
pharmacokinetic O 
results O 
and O 
tumor O 
localization O 
observed O 
with O 
the O 
integrin O 
- O 
targeting O 
surface O 
modification O 
of O 
HK O 
: O 
siRNA O 
nanoplexes O 
correlated O 
with O 
greater O 
tumor O 
growth O 
inhibition O 
. O 
This O 
investigation O 
reveals O 
that O 
through O 
control O 
of O 
targeting O 
ligand O 
surface O 
display O 
in O 
association O 
with O 
a O 
steric O 
PEG B-ABBREVIATION 
layer O 
, O 
modified O 
HK O 
: O 
siRNA O 
nanoplexes O 
show O 
promise O 
to O 
advance O 
RNAi O 
therapeutics O 
in O 
oncology O 
and O 
potentially O 
other O 
critical O 
diseases O 
. O 

composed O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
and O 
N-[3-(dimethylamino)propyl]-octadecanamide B-SYSTEMATIC 
: O 
effect O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
chain O 
length O 
on O 
physicochemical O 
properties O 
of O 
vesicles O 
. O 

Background O 
and O 
objectives O 
: O 
Vesicles O 
, O 
recently O 
claimed O 
as O 
drug O 
delivery O 
carriers O 
, O 
were O 
prepared O 
by O 
taking O 
advantage O 
of O 
an O 
electrostatic O 
interaction O 
between O 
the O 
carboxylic B-SYSTEMATIC 
groups O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FAs O 
) O 
and O 
the O 
amino B-FAMILY 
groups O 
of O 
N-[3-(Dimethylamino)propyl]-Octadecanamide B-SYSTEMATIC 
( O 
DMAPODA B-ABBREVIATION 
) O 
. O 
The O 
study O 
is O 
to O 
find O 
out O 
the O 
effect O 
of O 
FAs O 
' O 
chain O 
length O 
on O 
physicochemical O 
properties O 
of O 
vesicles O 
. O 
Methods O 
: O 
Decanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DA O 
) O 
, O 
myristic B-TRIVIAL 
acid I-TRIVIAL 
( O 
MA O 
) O 
, O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
( O 
SA O 
) O 
and O 
behenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
BA O 
) O 
were O 
used O 
as O 
FAs O 
. O 
Vesicles O 
composed O 
of O 
them O 
and O 
DMAPODA B-ABBREVIATION 
were O 
studied O 
about O 
formation O 
on O 
microscope O 
, O 
calorimetric O 
analysis O 
, O 
size O 
and O 
zeta O 
potential O 
. O 
Results O 
: O 
On O 
microphotographs O 
, O 
all O 
of O 
FAs O 
could O 
form O 
vesicles O 
when O 
mixed O 
with O 
DMAPODA B-ABBREVIATION 
in O 
an O 
equi O 
- O 
molar O 
ratio O 
. O 
However O 
, O 
DA/ O 
DMAPODA B-ABBREVIATION 
vesicles O 
were O 
disintegrated O 
during O 
the O 
homogenization O 
. O 
Due O 
to O 
the O 
asymmetry O 
of O 
DA/ O 
DMAPODA B-ABBREVIATION 
associate O 
, O 
it O 
seems O 
to O 
hardly O 
form O 
a O 
stable O 
and O 
well O 
- O 
packed O 
bilayer O 
. O 
On O 
thermograms O 
, O 
the O 
vesicles O 
exhibited O 
one O 
strong O 
peak O 
, O 
indicating O 
that O 
FAs O 
can O 
be O 
homogeneously O 
mixed O 
with O 
the O 
cationic O 
amphiphile O 
. O 
The O 
sizes O 
of O 
the O 
four O 
kinds O 
of O 
vesicles O 
suspended O 
in O 
an O 
aqueous O 
solution O 
( O 
final O 
pH O 
7.5 O 
) O 
were O 
in O 
the O 
same O 
order O 
( O 
hundreds O 
of O 
nanometer O 
) O 
on O 
microphotographs O 
. O 
But O 
, O 
on O 
a O 
light O 
scattering O 
machine O 
, O 
the O 
mean O 
size O 
of O 
MA/ O 
DMAPODA B-ABBREVIATION 
vesicle O 
was O 
measured O 
to O 
be O 
much O 
greater O 
than O 
those O 
of O 
the O 
other O 
vesicles O 
, O 
possibly O 
because O 
of O 
the O 
low O 
absolute O 
value O 
of O 
the O 
zeta O 
potential O 
. O 
In O 
addition O 
, O 
the O 
medium O 
pH O 
value O 
had O 
a O 
significant O 
effect O 
on O 
the O 
size O 
of O 
BA/ O 
DMAPODA B-ABBREVIATION 
vesicle O 
possibly O 
because O 
the O 
zeta O 
potential O 
was O 
strongly O 
dependent O 
on O 
the O 
pH O 
value O 
. O 
Conclusion O 
: O 
FAs O 
' O 
chain O 
length O 
would O 
affect O 
the O 
physicochemical O 
properties O 
of O 
vesicles O 
composed O 
of O 
them O 
and O 
DMAPODA B-ABBREVIATION 
. O 

of O 
the O 
Molecular O 
Interaction O 
between O 
Cisplatin B-TRIVIAL 
and O 
Flavonol B-FAMILY 
( O 
s O 
) O 
and O 
their O 
Effect O 
on O 
DNA O 
Binding O 
. O 

therapy O 
of O 
cisplatin B-TRIVIAL 
with O 
flavonols B-FAMILY 
is O 
a O 
promising O 
treatment O 
for O 
increasing O 
the O 
efficacy O 
of O 
cisplatin B-TRIVIAL 
when O 
combating O 
cancer O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
the O 
molecular O 
interactions O 
between O 
cisplatin B-TRIVIAL 
and O 
flavonols B-FAMILY 
. O 
The O 
data O 
herein O 
helps O 
to O 
elucidate O 
this O 
interaction O 
. O 
Spectrophotometric O 
data O 
in O 
the O 
UV-visible O 
range O 
indicates O 
that O 
hydroxyl B-SYSTEMATIC 
groups O 
on O 
the O 
B-ring O 
of O 
flavonols B-FAMILY 
are O 
essential O 
for O 
reactivity O 
with O 
cisplatin B-TRIVIAL 
. O 
The O 
use O 
of O 
a O 
quartz B-TRIVIAL 
crystal O 
microbalance O 
with O 
dissipation O 
monitoring O 
approach O 
clearly O 
supports O 
the O 
critical O 
role O 
played O 
by O 
B-ring O 
hydroxyls B-FAMILY 
in O 
their O 
interactions O 
with O 
a O 
cisplatin B-TRIVIAL 
-bound O 
double O 
- O 
stranded O 
DNA O 
surface O 
; O 
an O 
increase O 
in O 
the O 
number O 
of O 
hydroxyl B-SYSTEMATIC 
groups O 
on O 
the O 
B-ring O 
of O 
flavonols B-FAMILY 
parallels O 
the O 
increase O 
in O 
their O 
reaction O 
rates O 
with O 
cisplatin B-TRIVIAL 
and O 
correlates O 
well O 
with O 
their O 
reported O 
effects O 
on O 
leukemia O 
cell O 
apoptosis O 
efficacy O 
. O 
This O 
study O 
underscores O 
the O 
importance O 
of O 
B-ring O 
hydroxyls B-FAMILY 
in O 
cisplatin B-TRIVIAL 
' O 
s O 
toxicity O 
and O 
may O 
be O 
used O 
to O 
better O 
understand O 
and O 
improve O 
combination O 
therapies O 
of O 
flavonols B-FAMILY 
with O 
cisplatin B-TRIVIAL 
. O 

of O 
the O 
nasal O 
toxicant O 
2,6-dichlorobenzonitrile B-SYSTEMATIC 
: O 
an O 
assessment O 
of O 
metabolic O 
activity O 
in O 
human O 
nasal O 
mucosa O 
and O 
identification O 
of O 
indicators O 
of O 
exposure O 
and O 
potential O 
toxicity O 
. O 

herbicide O 
2,6-dichlorobenzonitrile B-SYSTEMATIC 
( O 
DCBN B-ABBREVIATION 
) O 
is O 
a O 
potent O 
nasal O 
toxicant O 
in O 
rodents O 
; O 
however O 
, O 
it O 
is O 
not O 
known O 
whether O 
DCBN B-ABBREVIATION 
causes O 
similar O 
nasal O 
toxicity O 
in O 
humans O 
. O 
The O 
tissue O 
- O 
selective O 
toxicity O 
of O 
DCBN B-ABBREVIATION 
in O 
mouse O 
nasal O 
mucosa O 
is O 
largely O 
dependent O 
on O 
target O 
tissue O 
bioactivation O 
by O 
CYP2A5 O 
. O 
The O 
human O 
orthologues O 
of O 
CYP2A5 O 
, O 
CYP2A6 O 
and O 
CYP2A13 O 
, O 
are O 
both O 
expressed O 
in O 
nasal O 
mucosa O 
and O 
are O 
capable O 
of O 
activating O 
DCBN B-ABBREVIATION 
. O 
In O 
this O 
study O 
, O 
we O 
directly O 
determined O 
the O 
ability O 
of O 
human O 
nasal O 
mucosa O 
to O 
bioactivate O 
DCBN B-ABBREVIATION 
. O 
We O 
also O 
tested O 
the O 
suitability O 
of O 
a O 
glutathione B-TRIVIAL 
conjugate O 
of O 
DCBN B-ABBREVIATION 
( O 
GS- O 
DCBN B-ABBREVIATION 
) O 
or O 
its O 
derivatives O 
as O 
biomarkers O 
of O 
DCBN B-ABBREVIATION 
exposure O 
and O 
nasal O 
toxicity O 
in O 
mouse O 
models O 
. O 
We O 
found O 
that O 
human O 
fetal O 
nasal O 
mucosa O 
microsomes O 
catalyze O 
the O 
formation O 
of O 
GS- O 
DCBN B-ABBREVIATION 
, O 
with O 
a O 
Km O 
value O 
comparable O 
to O 
that O 
of O 
adult O 
mouse O 
nasal O 
mucosa O 
microsomes O 
. O 
The O 
activity O 
of O 
the O 
human O 
nasal O 
mucosa O 
microsomes O 
was O 
inhibited O 
by O 
8-methoxypsoralen B-SYSTEMATIC 
, O 
a O 
known O 
CYP2A O 
inhibitor O 
. O 
GS- O 
DCBN B-ABBREVIATION 
and O 
its O 
metabolites O 
were O 
detected O 
in O 
the O 
nasal O 
mucosa O 
and O 
nasal O 
- O 
wash O 
fluid O 
obtained O 
from O 
DCBN B-ABBREVIATION 
-treated O 
mice O 
, O 
in O 
amounts O 
that O 
increased O 
with O 
escalations O 
in O 
DCBN B-ABBREVIATION 
dose O 
, O 
and O 
they O 
were O 
all O 
still O 
detectable O 
at O 
24 O 
h O 
after O 
a O 
DCBN B-ABBREVIATION 
treatment O 
( O 
at O 
10 O 
mg O 
/ O 
kg O 
) O 
. O 
Further O 
studies O 
in O 
Cyp2a5-null O 
mice O 
indicated O 
that O 
GS- O 
DCBN B-ABBREVIATION 
and O 
its O 
metabolites O 
in O 
nasal O 
- O 
wash O 
fluid O 
were O 
generated O 
in O 
the O 
nasal O 
mucosa O 
, O 
rather O 
than O 
in O 
other O 
organs O 
. O 
Thus O 
, O 
our O 
data O 
indicate O 
for O 
the O 
first O 
time O 
that O 
the O 
human O 
nasal O 
mucosa O 
is O 
capable O 
of O 
bioactivating O 
DCBN B-ABBREVIATION 
and O 
that O 
GS- O 
DCBN B-ABBREVIATION 
and O 
its O 
metabolites O 
in O 
nasal O 
- O 
wash O 
fluid O 
may O 
collectively O 
serve O 
as O 
indicators O 
of O 
DCBN B-ABBREVIATION 
exposure O 
and O 
potential O 
nasal O 
toxicity O 
in O 
humans O 
. O 

splicing O 
( O 
AS O 
) O 
is O 
one O 
of O 
the O 
most O 
significant O 
components O 
of O 
the O 
functional O 
complexity O 
of O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
enzymes O 
( O 
UGTs O 
) O 
, O 
particularly O 
for O 
the O 
UGT1A O 
gene O 
, O 
which O 
represents O 
one O 
of O 
the O 
best O 
examples O 
of O 
a O 
drug O 
- O 
metabolizing O 
gene O 
regulated O 
by O 
AS O 
. O 
Shorter O 
UGT1A O 
isoforms O 
[ O 
isoform O 
2 O 
( O 
i2 O 
) O 
] O 
are O 
deficient O 
in O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
transferase O 
activity O 
but O 
function O 
as O 
negative O 
regulators O 
of O 
enzyme O 
activity O 
through O 
protein O 
- O 
protein O 
interaction O 
. O 
Their O 
abundance O 
, O 
relative O 
to O 
active O 
UGT1A O 
enzymes O 
, O 
is O 
expected O 
to O 
be O 
a O 
determinant O 
of O 
the O 
global O 
transferase O 
activity O 
of O 
cells O 
and O 
tissues O 
. O 
Here O 
we O 
tested O 
whether O 
i2 O 
- O 
mediated O 
inhibition O 
increases O 
with O 
greater O 
abundance O 
of O 
the O 
i2 O 
protein O 
relative O 
to O 
the O 
isoform O 
1 O 
( O 
i1 O 
) O 
enzyme O 
, O 
using O 
the O 
extrahepatic O 
UGT1A7 O 
as O 
a O 
model O 
and O 
a O 
series O 
of O 
23 O 
human O 
embryonic O 
kidney O 
293 O 
clonal O 
cell O 
lines O 
expressing O 
variable O 
contents O 
of O 
i1 O 
and O 
i2 O 
proteins O 
. O 
Upon O 
normalization O 
for O 
i1 O 
, O 
a O 
significant O 
reduction O 
of O 
7-ethyl-10-hydroxycamptothecin B-SYSTEMATIC 
glucuronide I-SYSTEMATIC 
formation O 
was O 
observed O 
for O 
i1 O 
+ O 
i2 O 
clones O 
( O 
mean O 
of O 
53% O 
) O 
compared O 
with O 
the O 
reference O 
i1 O 
cell O 
line O 
. O 
In O 
these O 
clones O 
, O 
the O 
i2 O 
protein O 
content O 
varied O 
greatly O 
( O 
38-263% O 
relative O 
to O 
i1 O 
) O 
and O 
revealed O 
two O 
groups O 
: O 
17 O 
clones O 
with O 
i2 O 
< O 
i1 O 
( O 
60% O 
± O 
3% O 
) O 
and O 
6 O 
clones O 
with O 
i2 O 
≥ O 
i1 O 
( O 
153% O 
± O 
24% O 
) O 
. O 
The O 
inhibition O 
induced O 
by O 
i2 O 
was O 
more O 
substantial O 
for O 
clones O 
displaying O 
i2 O 
≥ O 
i1 O 
( O 
74.5% O 
; O 
P O 
= O 
0.001 O 
) O 
compared O 
with O 
those O 
with O 
i2 O 
< O 
i1 O 
( O 
45.5% O 
) O 
. O 
Coimmunoprecipitation O 
supports O 
a O 
more O 
substantial O 
i1-i2 O 
complex O 
formation O 
when O 
i2 O 
exceeds O 
i1 O 
. O 
We O 
conclude O 
that O 
the O 
relative O 
abundance O 
of O 
regulatory O 
i2 O 
proteins O 
has O 
the O 
potential O 
to O 
drastically O 
alter O 
the O 
local O 
drug O 
metabolism O 
in O 
the O 
cells O 
, O 
particularly O 
when O 
i2 O 
surpasses O 
the O 
protein O 
content O 
of O 
i1 O 
. O 

popular O 
ephedra O 
- O 
free O 
dietary O 
supplements O 
were O 
evaluated O 
for O 
their O 
effects O 
on O 
heart O 
rate O 
( O 
HR O 
) O 
, O 
blood O 
pressure O 
( O 
BP O 
) O 
, O 
and O 
electrocardiographic O 
( O 
ECG O 
) O 
parameters O 
. O 
Twelve O 
healthy O 
men O 
participated O 
in O 
a O 
study O 
randomized O 
for O 
product O 
sequence O 
, O 
with O 
a O 
21-day O 
washout O 
period O 
between O 
supplement-administration O 
phases O 
. O 
Throughout O 
the O 
study O 
, O 
Holter O 
monitors O 
were O 
used O 
to O 
assess O 
ECG O 
and O 
HR O 
activity O 
. O 
BP O 
was O 
assessed O 
automatically O 
on O 
multiple O 
occasions O 
. O 
The O 
supplements O 
were O 
ingested O 
three O 
times O 
daily O 
for O 
3 O 
days O 
. O 
Caffeine B-TRIVIAL 
content O 
, O 
microbial O 
load O 
, O 
and O 
serum O 
caffeine B-TRIVIAL 
concentrations O 
were O 
determined O 
. O 
Mean O 
systolic O 
( O 
SBP O 
) O 
and O 
diastolic O 
BP O 
( O 
DBP O 
) O 
readings O 
showed O 
significant O 
increases O 
relative O 
to O 
baseline O 
( O 
10.8 O 
± O 
2.5 O 
and O 
5.3 O 
± O 
3.1 O 
mm O 
Hg O 
, O 
respectively O 
; O 
P O 
< O 
0.05 O 
) O 
. O 
All O 
supplements O 
significantly O 
increased O 
HR O 
and O 
decreased O 
bradycardia O 
runs O 
; O 
abnormal O 
atrial O 
/ O 
ventricular O 
events O 
were O 
frequently O 
noted O 
. O 
Gastrointestinal O 
and O 
sympathomimetic O 
symptoms O 
were O 
also O 
common O 
. O 
Two O 
supplements O 
were O 
heavily O 
contaminated O 
with O 
Bacillus O 
species O 
. O 
In O 
light O 
of O 
these O 
findings O 
, O 
the O 
use O 
of O 
ephedra O 
- O 
free O 
dietary O 
supplements O 
should O 
be O 
discouraged O 
in O 
individuals O 
with O 
hypertension O 
, O 
diabetes O 
, O 
or O 
other O 
cardiovascular O 
diseases O 
. O 

of O 
diuretics O 
and O 
lipid O 
formulations O 
in O 
the O 
prevention O 
of O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
-induced O 
nephrotoxicity O 
. O 

: O 
To O 
collect O 
available O 
clinical O 
data O 
to O 
define O 
the O 
role O 
of O 
diuretics O 
and O 
lipid O 
formulations O 
in O 
the O 
prevention O 
of O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
( O 
AmB B-ABBREVIATION 
)-induced O 
nephrotoxicity O 
( O 
AIN O 
) O 
in O 
human O 
populations O 
. O 
METHOD O 
: O 
A O 
literature O 
search O 
was O 
performed O 
in O 
the O 
following O 
databases O 
: O 
Scopus O 
, O 
Medline O 
, O 
Embase O 
, O 
Cochrane O 
Central O 
Register O 
of O 
Controlled O 
Trials O 
, O 
and O 
Cochrane O 
Database O 
of O 
Systematic O 
Reviews O 
. O 
RESULTS O 
AND O 
CONCLUSION O 
: O 
Co-administration O 
of O 
mannitol B-TRIVIAL 
failed O 
to O 
show O 
any O 
clinically O 
significant O 
benefit O 
in O 
preventing O 
AIN O 
. O 
Potassium B-SYSTEMATIC 
-sparing O 
diuretics O 
, O 
such O 
as O 
amiloride B-TRIVIAL 
and O 
spironolactone B-TRIVIAL 
, O 
have O 
been O 
shown O 
to O 
have O 
beneficial O 
effects O 
as O 
an O 
alternative O 
or O 
adjunct O 
to O 
oral O 
/ O 
parenteral O 
potassium B-SYSTEMATIC 
supplements O 
in O 
preventing O 
hypokalemia O 
due O 
to O 
AmB B-ABBREVIATION 
. O 
Lipid O 
- O 
based O 
formulations O 
of O 
AmB B-ABBREVIATION 
are O 
clinically O 
effective O 
and O 
safe O 
in O 
preventing O 
AIN O 
. O 
However O 
, O 
due O 
to O 
their O 
high O 
cost O 
and O 
limited O 
accessibility O 
, O 
these O 
formulations O 
are O 
generally O 
used O 
as O 
second O 
- O 
line O 
antifungal O 
therapy O 
in O 
cases O 
of O 
conventional O 
AmB B-ABBREVIATION 
refractoriness O 
and O 
/ O 
or O 
intolerance O 
or O 
pre O 
- O 
existing O 
renal O 
dysfunction O 
. O 
The O 
potential O 
effects O 
of O 
other O 
nephroprotective O 
agents O 
, O 
such O 
as O 
N-acetylcysteine B-SYSTEMATIC 
, O 
AIN O 
merit O 
further O 
considerations O 
and O 
investigations O 
. O 

and O 
up O 
- O 
conversion O 
properties O 
of O 
Er3+ B-FORMULA 
and O 
Yb3+ B-FORMULA 
co O 
- O 
doped O 
Y2Ti2O7 B-FORMULA 
phosphors O 
. O 

( O 
YTO B-FORMULA 
) O 
and O 
Er(3+) B-FORMULA 
/ O 
Yb(3+) B-FORMULA 
co O 
- O 
doped O 
Y(2)Ti(2)O(7) B-FORMULA 
( O 
EYYTO B-FORMULA 
) O 
phosphors O 
have O 
been O 
prepared O 
by O 
solid O 
- O 
state O 
reaction O 
method O 
. O 
Structures O 
of O 
YTO B-FORMULA 
and O 
EYYTO B-FORMULA 
phosphors O 
are O 
identified O 
as O 
face O 
centered O 
cubic O 
pyrochlores O 
. O 
Up-conversion O 
emission O 
spectra O 
of O 
EYYTO B-FORMULA 
under O 
976 O 
nm O 
excitation O 
is O 
studied O 
, O 
which O 
revealed O 
three O 
prominent O 
emission O 
lines O 
at O 
~524 O 
, O 
548 O 
and O 
661 O 
nm O 
originating O 
from O 
( O 
2)H(11 O 
/ O 
2)→(4)I(15 O 
/ O 
2 O 
) O 
, O 
( O 
4)S(3 O 
/ O 
2)→(4)I(15 O 
/ O 
2 O 
) O 
and O 
( O 
4)F(9 O 
/ O 
2)→(4)I(15 O 
/ O 
2 O 
) O 
electronic O 
transitions O 
of O 
Er(3+) B-FORMULA 
ion O 
, O 
respectively O 
in O 
green O 
and O 
red O 
regions O 
. O 
The O 
power O 
dependence O 
study O 
suggests O 
that O 
these O 
bands O 
arise O 
due O 
to O 
two O 
photon O 
absorption O 
. O 
The O 
monodispersed O 
laser O 
ablated O 
colloidal O 
solution O 
of O 
EYYTO B-FORMULA 
shows O 
strong O 
red O 
and O 
green O 
emissions O 
on O 
excitation O 
with O 
976 O 
nm O 
laser O 
. O 
The O 
variation O 
of O 
luminescence O 
intensity O 
at O 
different O 
laser O 
excitation O 
powers O 
is O 
observed O 
and O 
thus O 
a O 
color O 
can O 
be O 
tuned O 
. O 
The O 
photoluminescence O 
lifetime O 
of O 
green O 
band O 
at O 
548 O 
nm O 
( O 
( O 
4)S(3 O 
/ O 
2 O 
) O 
level O 
) O 
has O 
been O 
found O 
to O 
be O 
~446 O 
μs O 
. O 

restriction O 
prolongs O 
the O 
lifespan O 
of O 
many O 
species O 
. O 
Therefore O 
, O 
investigators O 
have O 
researched O 
the O 
usefulness O 
of O 
caloric O 
restriction O 
for O 
healthy O 
lifespan O 
extension O 
. O 
Sirt1 O 
, O 
an O 
NAD(+) B-ABBREVIATION 
-dependent O 
deacetylase O 
, O 
was O 
identified O 
as O 
a O 
molecule O 
necessary O 
for O 
caloric O 
restriction O 
- O 
related O 
anti-aging O 
strategies O 
. O 
Sirt1 O 
functions O 
as O 
an O 
intracellular O 
energy O 
sensor O 
to O 
detect O 
the O 
concentration O 
of O 
NAD(+) B-ABBREVIATION 
, O 
and O 
controls O 
in O 
vivo O 
metabolic O 
changes O 
under O 
caloric O 
restriction O 
and O 
starvation O 
through O 
its O 
deacetylase O 
activity O 
to O 
many O 
targets O 
including O 
histones O 
, O 
nuclear O 
transcriptional O 
factors O 
, O 
and O 
enzymes O 
. O 
During O 
the O 
past O 
decade O 
, O 
investigators O 
have O 
reported O 
the O 
relationship O 
between O 
disturbance O 
of O 
Sirt1 O 
activation O 
and O 
the O 
onset O 
of O 
aging- O 
and O 
obesity O 
- O 
associated O 
diseases O 
such O 
as O 
diabetes O 
, O 
cardiovascular O 
disease O 
and O 
neurodegenerative O 
disorders O 
. O 
Consequently O 
, O 
a O 
calorie O 
restriction O 
- O 
mimetic O 
action O 
of O 
Sirt1 O 
is O 
now O 
expected O 
as O 
a O 
new O 
therapy O 
for O 
these O 
diseases O 
. O 
In O 
addition O 
, O 
recent O 
studies O 
have O 
gradually O 
clarified O 
the O 
role O 
of O 
Sirt1 O 
in O 
the O 
onset O 
of O 
kidney O 
disease O 
. O 
Its O 
activation O 
may O 
also O 
become O 
a O 
new O 
target O 
of O 
treatment O 
in O 
the O 
patients O 
with O 
chronic O 
kidney O 
disease O 
including O 
diabetic O 
nephropathy O 
. O 
In O 
this O 
article O 
, O 
we O 
would O 
like O 
to O 
review O 
the O 
role O 
of O 
Sirt1 O 
in O 
the O 
onset O 
of O 
kidney O 
disease O 
based O 
on O 
previous O 
studies O 
, O 
and O 
discuss O 
its O 
possibility O 
as O 
the O 
target O 
of O 
treatment O 
in O 
diabetic O 
nephropathy O 
. O 

: O 
a O 
selective O 
nonpeptide O 
radioligand O 
and O 
insurmountable O 
antagonist O 
for O 
the O 
neuropeptide O 
Y O 
Y(2) O 
receptor O 
. O 

in O 
on O 
NPY O 
: O 
Attachment O 
of O 
a O 
[2,3-(3)H]propionyl B-SYSTEMATIC 
group O 
through O 
an O 
appropriate O 
linker O 
to O 
the O 
guanidine B-TRIVIAL 
group O 
of O 
an O 
(S)-argininamide B-TRIVIAL 
-type O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
Y(2) O 
receptor O 
antagonist O 
resulted O 
in O 
a O 
subtype O 
- O 
selective O 
radioligand O 
. O 

oligomerization O 
domain O 
- O 
containing O 
protein O 
2 O 
( O 
Nod2 O 
) O 
, O 
an O 
innate O 
immune O 
receptor O 
, O 
recognizes O 
bacterial O 
cell O 
- O 
wall O 
peptidoglycan O 
( O 
PGN O 
) O 
, O 
the O 
minimum O 
ligand O 
of O 
which O 
is O 
muramyl B-TRIVIAL 
dipeptide I-TRIVIAL 
( O 
MDP B-ABBREVIATION 
) O 
. O 
Enzymatic O 
digestion O 
of O 
PGN O 
appears O 
to O 
be O 
important O 
for O 
Nod2 O 
recognition O 
. O 
PGN O 
is O 
degraded O 
by O 
muramidase O 
or O 
glucosamidase O 
through O 
a O 
process O 
that O 
produces O 
two O 
types O 
of O 
glycan O 
sequence O 
; O 
glycans O 
containing O 
GlcNAcβ(1→4)MurNAc B-ABBREVIATION 
or O 
MurNAcβ(1→4)GlcNAc B-ABBREVIATION 
. O 
In O 
this O 
report O 
, O 
a O 
range O 
of O 
disaccharide B-FAMILY 
or O 
tetrasaccharide B-FAMILY 
fragments O 
of O 
each O 
sequence O 
were O 
chemically O 
synthesized O 
, O 
and O 
their O 
activities O 
in O 
stimulating O 
human O 
Nod2 O 
( O 
hNod2 O 
) O 
were O 
investigated O 
. O 
The O 
results O 
reveal O 
that O 
hNod2 O 
recognitions O 
is O 
dependent O 
on O 
the O 
glycan O 
sequence O 
, O 
as O 
demonstrated O 
by O 
comparing O 
the O 
activities O 
of O 
glycans O 
with O 
the O 
same O 
peptide O 
moieties O 
. O 
( O 
MurNAcβ(1→4)GlcNAc B-ABBREVIATION 
)(2 O 
) O 
-containing O 
structures O 
exhibited O 
stronger O 
activity O 
than O 
those O 
containing O 
( O 
GlcNAcβ(1→4)MurNAc B-ABBREVIATION 
)(2 O 
) O 
. O 
The O 
results O 
suggest O 
that O 
differences O 
in O 
the O 
enzymatic O 
degradation O 
process O 
affect O 
the O 
host's O 
immunomodulation O 
process O 
. O 

-dependent O 
phosphorylation O 
of O 
Ca²⁺ B-FORMULA 
cycling O 
proteins O 
generates O 
robust O 
rhythmic O 
local O 
Ca²⁺ B-FORMULA 
releases O 
in O 
cardiac O 
pacemaker O 
cells O 
. O 

spontaneous O 
beating O 
of O 
the O 
heart O 
is O 
governed O 
by O 
spontaneous O 
firing O 
of O 
sinoatrial O 
node O 
cells O 
, O 
which O 
generate O 
action O 
potentials O 
due O 
to O 
spontaneous O 
depolarization O 
of O 
the O 
membrane O 
potential O 
, O 
or O 
diastolic O 
depolarization O 
. O 
The O 
spontaneous O 
diastolic O 
depolarization O 
rate O 
is O 
determined O 
by O 
spontaneous O 
local O 
submembrane O 
Ca²⁺ B-FORMULA 
releases O 
through O 
ryanodine B-TRIVIAL 
receptors O 
( O 
RyRs O 
) O 
. O 
We O 
sought O 
to O 
identify O 
specific O 
mechanisms O 
of O 
intrinsic O 
Ca²⁺ B-FORMULA 
cycling O 
by O 
which O 
sinoatrial O 
node O 
cells O 
, O 
but O 
not O 
ventricular O 
myocytes O 
, O 
generate O 
robust O 
, O 
rhythmic O 
local O 
Ca²⁺ B-FORMULA 
releases O 
. O 
At O 
similar O 
physiological O 
intracellular O 
Ca²⁺ B-FORMULA 
concentrations O 
, O 
local O 
Ca²⁺ B-FORMULA 
releases O 
were O 
large O 
and O 
rhythmic O 
in O 
permeabilized O 
sinoatrial O 
node O 
cells O 
but O 
small O 
and O 
random O 
in O 
permeabilized O 
ventricular O 
myocytes O 
. O 
Furthermore O 
, O 
sinoatrial O 
node O 
cells O 
spontaneously O 
released O 
more O 
Ca²⁺ B-FORMULA 
from O 
the O 
sarcoplasmic O 
reticulum O 
than O 
did O 
ventricular O 
myocytes O 
, O 
despite O 
comparable O 
sarcoplasmic O 
reticulum O 
Ca²⁺ B-FORMULA 
content O 
in O 
both O 
cell O 
types O 
. O 
This O 
ability O 
of O 
sinoatrial O 
node O 
cells O 
to O 
generate O 
larger O 
and O 
rhythmic O 
local O 
Ca²⁺ B-FORMULA 
releases O 
was O 
associated O 
with O 
increased O 
abundance O 
of O 
sarcoplasmic O 
reticulum O 
Ca²⁺ B-FORMULA 
-ATPase O 
( O 
SERCA O 
) O 
, O 
reduced O 
abundance O 
of O 
the O 
SERCA O 
inhibitor O 
phospholamban O 
, O 
and O 
increased O 
Ca²⁺ B-FORMULA 
-dependent O 
phosphorylation O 
of O 
phospholamban O 
and O 
RyR O 
. O 
The O 
increased O 
phosphorylation O 
of O 
RyR O 
in O 
sinoatrial O 
node O 
cells O 
may O 
facilitate O 
Ca²⁺ B-FORMULA 
release O 
from O 
the O 
sarcoplasmic O 
reticulum O 
, O 
whereas O 
Ca²⁺ B-FORMULA 
-dependent O 
increase O 
in O 
phosphorylation O 
of O 
phospholamban O 
relieves O 
its O 
inhibition O 
of O 
SERCA O 
, O 
augmenting O 
the O 
pumping O 
rate O 
of O 
Ca²⁺ B-FORMULA 
required O 
to O 
support O 
robust O 
, O 
rhythmic O 
local O 
Ca²⁺ B-FORMULA 
releases O 
. O 
The O 
differences O 
in O 
Ca²⁺ B-FORMULA 
cycling O 
between O 
sinoatrial O 
node O 
cells O 
and O 
ventricular O 
myocytes O 
provide O 
insights O 
into O 
the O 
regulation O 
of O 
intracellular O 
Ca²⁺ B-FORMULA 
cycling O 
that O 
drives O 
the O 
automaticity O 
of O 
sinoatrial O 
node O 
cells O 
. O 

of O 
isoDGR O 
Peptides O 
for O 
Fibronectin O 
Binding O 
Integrin O 
Subtypes O 
α5β1 O 
and O 
αvβ6 O 
: O 
Conformational O 
Control O 
through O 
Flanking O 
Amino B-FAMILY 
Acids I-FAMILY 
. O 

are O 
the O 
major O 
class O 
of O 
cell O 
adhesion O 
proteins O 
. O 
Their O 
interaction O 
with O 
different O 
ligands O 
of O 
the O 
extracellular O 
matrix O 
is O 
diverse O 
. O 
To O 
get O 
more O 
insight O 
into O 
these O 
interactions O 
, O 
artificial O 
ligands O 
endowed O 
with O 
a O 
well O 
- O 
defined O 
activity O 
/ O 
selectivity O 
profile O 
are O 
necessary O 
. O 
Herein O 
, O 
we O 
present O 
a O 
library O 
of O 
cyclic B-FAMILY 
pentapeptides I-FAMILY 
, O 
based O 
on O 
our O 
previously O 
reported O 
peptide O 
motif O 
c(-phg-isoDGR-X-) O 
, O 
in O 
which O 
high O 
activity O 
toward O 
fibronectin O 
binding O 
integrins O 
α5β1 O 
and O 
αvβ6 O 
and O 
not O 
on O 
vitronectin O 
binding O 
integrins O 
αvβ3 O 
and O 
αvβ5 O 
has O 
been O 
achieved O 
by O 
changing O 
the O 
flanking O 
amino B-FAMILY 
acids I-FAMILY 
. O 
The O 
structure O 
of O 
the O 
most O 
promising O 
candidates O 
has O 
been O 
determined O 
using O 
a O 
combined O 
approach O 
of O 
NMR O 
, O 
distance O 
geometry O 
, O 
and O 
molecular O 
dynamics O 
simulations O 
, O 
and O 
docking O 
studies O 
have O 
been O 
further O 
used O 
to O 
elucidate O 
the O 
peptide-integrin O 
interactions O 
at O 
the O 
molecular O 
level O 
. O 
The O 
peptides O 
' O 
binding O 
affinity O 
has O 
been O 
characterized O 
by O 
enzyme O 
linked O 
immunosorbent O 
assay O 
experiments O 
, O 
and O 
the O 
results O 
have O 
been O 
verified O 
by O 
cell O 
adhesion O 
experiments O 
on O 
specifically O 
functionalized O 
surfaces O 
. O 

selective O 
transmembrane O 
transport O 
of O 
amino B-FAMILY 
acids I-FAMILY 
through O 
artificial O 
channels O 
. O 

pillar[n]arene B-SYSTEMATIC 
( I-SYSTEMATIC 
n I-SYSTEMATIC 
= I-SYSTEMATIC 
5 I-SYSTEMATIC 
, I-SYSTEMATIC 
6 I-SYSTEMATIC 
) I-SYSTEMATIC 
derivatives O 
have O 
been O 
synthesized O 
. O 
(1)H B-FORMULA 
NMR O 
and O 
IR O 
studies O 
revealed O 
that O 
the O 
molecules O 
adopt O 
a O 
tubular O 
conformation O 
in O 
solution O 
and O 
lipid O 
bilayer O 
membranes O 
. O 
Kinetic O 
measurements O 
using O 
the O 
fluorescent O 
labeling O 
method O 
with O 
lipid O 
vesicles O 
revealed O 
that O 
these O 
molecules O 
can O 
efficiently O 
mediate O 
the O 
transport O 
of O 
amino B-FAMILY 
acids I-FAMILY 
across O 
lipid O 
membranes O 
at O 
a O 
very O 
low O 
channel O 
- O 
to O 
- O 
lipid O 
ratio O 
( O 
EC(50) O 
= O 
0.002 O 
mol O 
% O 
) O 
. O 
In O 
several O 
cases O 
, O 
chiral O 
selectivity O 
for O 
amino B-FAMILY 
acid I-FAMILY 
enantiomers O 
was O 
achieved O 
, O 
which O 
is O 
one O 
of O 
the O 
key O 
functions O 
of O 
natural O 
amino B-FAMILY 
acid I-FAMILY 
channels O 
. O 

are O 
promising O 
nanostructures O 
composed O 
of O 
various O 
materials O 
that O 
bring O 
new O 
functionalities O 
for O 
applications O 
ranging O 
from O 
photovoltaics O 
to O 
analytics O 
. O 
We O 
developed O 
DNA O 
nanopillars O 
with O 
a O 
height O 
of O 
220 O 
nm O 
and O 
a O 
diameter O 
of O 
~14 O 
nm O 
using O 
the O 
DNA O 
origami O 
technique O 
. O 
Modifying O 
the O 
base O 
of O 
the O 
nanopillars O 
with O 
biotins B-FAMILY 
allowed O 
selective O 
, O 
upright O 
, O 
and O 
rigid O 
immobilization O 
on O 
solid O 
substrates O 
. O 
With O 
the O 
help O 
of O 
site O 
- O 
selective O 
dye O 
labels O 
, O 
we O 
visualized O 
the O 
structure O 
and O 
determined O 
the O 
orientation O 
of O 
the O 
nanopillars O 
by O 
three O 
- O 
dimensional O 
fluorescence O 
superresolution O 
microscopy O 
. O 
Because O 
of O 
their O 
rigidity O 
and O 
nanometer O 
- O 
precise O 
addressability O 
, O 
DNA O 
origami O 
nanopillars O 
qualify O 
as O 
scaffold O 
for O 
the O 
assembly O 
of O 
plasmonic O 
devices O 
as O 
well O 
as O 
for O 
three O 
- O 
dimensional O 
superresolution O 
standards O 
. O 

dihydrogen B-SYSTEMATIC 
bonding O 
in O 
alkali B-FAMILY 
metal I-FAMILY 
amidoboranes I-FAMILY 
: O 
crystal O 
engineering O 
of O 
low O 
- O 
dimensional O 
molecular O 
materials O 
. O 

bonding O 
is O 
a O 
predominant O 
interaction O 
in O 
supramolecular O 
chemistry O 
. O 
The O 
absence O 
of O 
a O 
conventional O 
hydrogen B-SYSTEMATIC 
bond O 
donor O 
in O 
LiNMe(2)BH(3) B-FORMULA 
and O 
KNMe(2)BH(3) B-FORMULA 
results O 
in O 
the O 
formation O 
of O 
elaborate O 
M··· O 
H-B B-FORMULA 
polymeric O 
arrays O 
supported O 
by O 
heteropolar O 
and O 
homopolar O 
H B-FORMULA 
··· O 
H B-FORMULA 
bonding O 
, O 
in O 
a O 
unique O 
synergistic O 
combination O 
of O 
unconventional O 
intermolecular O 
interactions O 
. O 

- O 
flipping O 
propensities O 
of O 
unmethylated O 
, O 
hemimethylated O 
, O 
and O 
fully O 
methylated O 
CpG B-ABBREVIATION 
sites O 
. O 

of O 
C5 O 
of O 
cytosines B-FAMILY 
at O 
CpG B-FAMILY 
dinucleotide I-FAMILY 
sites O 
of O 
the O 
DNA O 
is O 
one O 
of O 
the O 
most O 
important O 
factors O 
regulating O 
the O 
expression O 
of O 
genes O 
. O 
The O 
interactions O 
of O 
these O 
CpG B-ABBREVIATION 
sites O 
with O 
proteins O 
are O 
essential O 
for O 
recognition O 
and O 
catalysis O 
and O 
in O 
many O 
cases O 
are O 
characterized O 
by O 
the O 
flipping O 
of O 
either O 
of O 
the O 
cytosine B-TRIVIAL 
bases O 
out O 
of O 
the O 
DNA O 
helix O 
. O 
In O 
this O 
paper O 
, O 
we O 
present O 
results O 
from O 
molecular O 
dynamics O 
simulations O 
indicating O 
that O 
methylation O 
of O 
CpG B-ABBREVIATION 
sites O 
suppresses O 
spontaneous O 
extra O 
- O 
helical O 
conformations O 
of O 
either O 
of O 
the O 
two O 
cytosines B-FAMILY 
. O 
Thus O 
, O 
cytosines B-FAMILY 
in O 
unmethylated O 
sites O 
flip O 
out O 
easier O 
than O 
in O 
hemimethylated O 
sites O 
and O 
the O 
latter O 
flip O 
out O 
easier O 
than O 
in O 
fully O 
methylated O 
sites O 
. O 
The O 
different O 
propensities O 
for O 
base O 
flipping O 
is O 
observed O 
not O 
only O 
between O 
the O 
cytosines B-FAMILY 
that O 
differ O 
in O 
their O 
methylation O 
states O 
but O 
also O 
between O 
the O 
cytosines B-FAMILY 
on O 
the O 
complementary O 
strand O 
. O 
From O 
alchemical O 
mutation O 
calculations O 
, O 
we O 
find O 
that O 
methylation O 
of O 
one O 
of O 
the O 
cytosines B-FAMILY 
increases O 
the O 
free O 
energy O 
of O 
the O 
extra O 
- O 
helical O 
conformation O 
by O 
10.3-16.5 O 
kJ O 
/ O 
mol O 
and O 
this O 
increase O 
is O 
additive O 
with O 
respect O 
to O 
the O 
second O 
methylation O 
. O 
Potential O 
of O 
mean O 
force O 
calculations O 
confirm O 
these O 
results O 
and O 
reveal O 
that O 
cytosines B-FAMILY 
in O 
unmethylated O 
sites O 
favor O 
flipping O 
via O 
the O 
major O 
- O 
groove O 
pathway O 
. O 
We O 
perform O 
several O 
analyses O 
to O 
correlate O 
this O 
behavior O 
with O 
structural O 
changes O 
induced O 
by O 
the O 
different O 
methylation O 
states O 
of O 
the O 
CpG B-ABBREVIATION 
site O 
. O 
However O 
, O 
we O 
demonstrate O 
that O 
the O 
driving O 
force O 
for O 
these O 
propensities O 
is O 
the O 
change O 
in O 
the O 
electronic O 
distribution O 
around O 
the O 
pyrimidine B-SYSTEMATIC 
ring O 
upon O 
methylation O 
. O 
In O 
particular O 
, O 
unmethylated O 
cytosine B-TRIVIAL 
interacts O 
more O 
favorably O 
( O 
primarily O 
via O 
electrostatic O 
forces O 
) O 
with O 
solvent O 
water O 
molecules O 
than O 
methylated O 
cytosine B-TRIVIAL 
. O 
This O 
is O 
observed O 
for O 
, O 
both O 
, O 
extra O 
- O 
helical O 
cytosines B-FAMILY 
and O 
intra O 
- O 
helical O 
cytosines B-FAMILY 
in O 
which O 
the O 
cytosine B-TRIVIAL 
on O 
the O 
complementary O 
strand O 
flips O 
out O 
and O 
water O 
molecules O 
enter O 
the O 
DNA O 
double O 
- O 
helix O 
and O 
substitute O 
the O 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
the O 
orphan O 
guanine B-TRIVIAL 
. O 
On O 
the O 
basis O 
of O 
these O 
results O 
of O 
spontaneous O 
base O 
flipping O 
, O 
we O 
conjecture O 
that O 
the O 
mechanism O 
for O 
base O 
flipping O 
observed O 
in O 
complexes O 
between O 
hemimethylated O 
DNAs O 
and O 
proteins O 
is O 
not O 
likely O 
to O 
be O 
passive O 
. O 

luminescent O 
and O 
photostable O 
quantum O 
dot- O 
silica B-TRIVIAL 
monolith O 
and O 
its O 
application O 
to O 
light O 
- O 
emitting O 
diodes O 
. O 

highly O 
luminescent O 
and O 
photostable O 
quantum O 
dot O 
- O 
silica O 
monolith O 
( O 
QD-SM O 
) O 
substance O 
was O 
prepared O 
by O 
preliminary O 
surface O 
exchange O 
of O 
the O 
QDs O 
and O 
base O 
- O 
catalyzed O 
sol O 
- O 
gel O 
condensation O 
of O 
silica B-TRIVIAL 
. O 
The O 
SM O 
was O 
heavily O 
doped O 
with O 
6-mercaptohexanol B-SYSTEMATIC 
exchanged O 
QDs O 
up O 
to O 
12 O 
vol O 
% O 
( O 
26 O 
wt O 
% O 
) O 
without O 
particle O 
aggregation O 
. O 
Propylamine O 
catalyst O 
was O 
important O 
in O 
maintaining O 
the O 
original O 
luminescence O 
of O 
the O 
QDs O 
in O 
the O 
SM O 
during O 
sol O 
- O 
gel O 
condensation O 
. O 
The O 
silica B-TRIVIAL 
layer O 
was O 
a O 
good O 
barrier O 
against O 
oxygen B-SYSTEMATIC 
and O 
moisture O 
, O 
so O 
that O 
the O 
QD-SM O 
maintained O 
its O 
initial O 
luminescence O 
after O 
high O 
- O 
power O 
UV O 
radiation O 
( O 
∼1 O 
W O 
) O 
for O 
200 O 
h O 
and O 
through O 
the O 
150 O 
°C O 
LED O 
encapsulant O 
curing O 
process O 
. O 
Green O 
and O 
red O 
light O 
- O 
emitting O 
QD-SMs O 
were O 
applied O 
as O 
color O 
- O 
converting O 
layers O 
on O 
blue O 
LEDs O 
, O 
and O 
the O 
external O 
quantum O 
efficiency O 
reached O 
up O 
to O 
89% O 
for O 
the O 
green O 
QD-SM O 
and O 
63% O 
for O 
the O 
red O 
one O 
. O 
A O 
white O 
LED O 
made O 
with O 
a O 
mixture O 
of O 
green O 
and O 
red O 
QDs O 
in O 
the O 
SM O 
, O 
in O 
which O 
the O 
color O 
coordinate O 
was O 
adjusted O 
at O 
( O 
0.23 O 
, O 
0.21 O 
) O 
in O 
CIE1931 O 
color O 
space O 
for O 
a O 
backlight O 
application O 
, O 
showed O 
an O 
efficacy O 
of O 
47 O 
lm O 
/ O 
W O 
, O 
the O 
highest O 
value O 
yet O 
reported O 
. O 

precipitation O 
by O 
synthetic O 
minicollagens O 
. O 

Pro-Hyp-Gly B-FORMULA 
- O 
( O 
POG- O 
) O 
peptides O 
, O 
wherein O 
the O 
collagenous O 
triple O 
helix O 
is O 
supported O 
by O 
C B-FORMULA 
-terminal O 
capping O 
, O 
exhibit O 
silica B-TRIVIAL 
precipitation O 
properties O 
( O 
O O 
, O 
Hyp B-ABBREVIATION 
= O 
(2S,4R)hydroxyproline B-SYSTEMATIC 
) O 
. O 
As O 
quantified O 
by O 
a O 
molybdate O 
assay O 
, O 
the O 
length O 
of O 
the O 
covalently O 
tethered O 
triple O 
helix O 
( O 
number O 
of O 
POG O 
units O 
) O 
determines O 
the O 
amount O 
of O 
amorphous O 
silica B-TRIVIAL 
obtained O 
from O 
silicic B-TRIVIAL 
acid I-TRIVIAL 
solution O 
. O 
Although O 
lacking O 
charged O 
side O 
chains O 
, O 
the O 
synthetic O 
collagens O 
precipitate O 
large O 
quantities O 
of O 
silicic B-TRIVIAL 
acid I-TRIVIAL 
resulting O 
in O 
micrometer O 
- O 
sized O 
spheres O 
of O 
varying O 
surface O 
morphologies O 
as O 
analyzed O 
by O 
scanning O 
electron O 
microscopy O 
. O 
Similar O 
precipitation O 
efficiencies O 
on O 
a O 
fast O 
time O 
scale O 
of O 
less O 
than O 
10 O 
min O 
were O 
previously O 
described O 
only O 
for O 
biogenic O 
diatom O 
proteins O 
and O 
sponge O 
collagen O 
, O 
respectively O 
, O 
which O 
have O 
a O 
considerably O 
higher O 
structural O 
complexity O 
and O 
limited O 
accessibility O 
. O 
The O 
minicollagens O 
described O 
here O 
provide O 
an O 
unexpected O 
alternative O 
to O 
the O 
widely O 
used O 
precipitation O 
conditions O 
, O 
which O 
generally O 
depend O 
on O 
(poly-)amines B-FAMILY 
in O 
phosphate B-SYSTEMATIC 
buffer O 
. O 
Collagen O 
can O 
form O 
intimate O 
connections O 
with O 
inorganic O 
matter O 
. O 
Hence O 
, O 
silica B-TRIVIAL 
-enclosed O 
collagens O 
have O 
promising O 
perspectives O 
as O 
composite O 
materials O 
. O 

and O 
characterization O 
of O 
glucose B-SYSTEMATIC 
6-phosphate I-SYSTEMATIC 
dehydrogenase O 
enzyme O 
from O 
rainbow O 
trout O 
( O 
Oncorhynchus O 
mykiss O 
) O 
liver O 
and O 
investigation O 
of O 
the O 
effects O 
of O 
some O 
metal O 
ions O 
on O 
enzyme O 
activity O 
. O 

6-phosphate I-SYSTEMATIC 
dehydrogenase O 
( O 
< B-SYSTEMATIC 
sc I-SYSTEMATIC 
> I-SYSTEMATIC 
d I-SYSTEMATIC 
< I-SYSTEMATIC 
/ I-SYSTEMATIC 
sc I-SYSTEMATIC 
> I-SYSTEMATIC 
-glucose I-SYSTEMATIC 
6-phosphate I-SYSTEMATIC 
: O 
NADP(+) B-ABBREVIATION 
oxidoreductase O 
, O 
EC O 
1.1.1.49 O 
; O 
G6PD O 
) O 
is O 
a O 
key O 
enzyme O 
that O 
is O 
localized O 
in O 
all O 
mammal O 
tissues O 
, O 
especially O 
in O 
cytoplasmic O 
sections O 
and O 
that O 
catalyzes O 
the O 
first O 
step O 
of O 
pentose B-FAMILY 
phosphate I-FAMILY 
metabolic O 
pathway O 
. O 
In O 
this O 
study O 
, O 
G6PD O 
enzyme O 
was O 
purified O 
1444-fold O 
with O 
a O 
yield O 
of O 
77% O 
from O 
rainbow O 
trout O 
liver O 
using O 
2',5'-ADP-sepharose-4B B-SYSTEMATIC 
affinity O 
chromatography O 
. O 
Moreover O 
, O 
a O 
purity O 
check O 
of O 
the O 
enzyme O 
was O 
performed O 
with O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulfate I-SYSTEMATIC 
- O 
polyacrylamide B-SYSTEMATIC 
gel O 
electrophoresis O 
. O 
Some O 
characteristic O 
features O 
like O 
optimal O 
pH O 
, O 
stable O 
pH O 
, O 
optimal O 
temperature O 
and O 
optimal O 
ionic O 
strength O 
were O 
determined O 
for O 
the O 
purified O 
enzyme O 
. O 
In O 
addition O 
to O 
this O 
, O 
in O 
vitro O 
effects O 
of O 
ions O 
like O 
silver B-SYSTEMATIC 
nitrate I-SYSTEMATIC 
( O 
Ag(+) B-FORMULA 
) O 
, O 
thallium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
TI(+) B-FORMULA 
) O 
, O 
cobalt B-SYSTEMATIC 
(II) I-SYSTEMATIC 
nitrate I-SYSTEMATIC 
( O 
Co(2+) B-FORMULA 
) O 
and O 
arsenic B-SYSTEMATIC 
(V) I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
As(5+) B-FORMULA 
) O 
on O 
enzyme O 
activity O 
were O 
researched O 
. O 
Half O 
- O 
maximal O 
inhibitory O 
concentration O 
(IC(50)) O 
values O 
of O 
Ag(+) B-FORMULA 
, O 
Co(2+) B-FORMULA 
and O 
As(5+) B-FORMULA 
metal O 
ions O 
, O 
which O 
showed O 
an O 
inhibitory O 
effect O 
, O 
were O 
found O 
to O 
be O 
0.0044 O 
, O 
0.084 O 
and O 
4.058 O 
mM O 
, O 
respectively O 
; O 
and O 
their O 
inhibition O 
constants O 
(K(i)) O 
were O 
found O 
to O 
be O 
0.0052 O 
± O 
0.00042 O 
, O 
0.087 O 
± O 
0.0157 O 
and O 
4.833 O 
± O 
1.753207 O 
mM O 
, O 
respectively O 
. O 
Tl(+) B-FORMULA 
not O 
exhibited O 
inhibitory O 
effect O 
on O 
the O 
enzyme O 
activity O 
. O 

effect O 
of O 
carob O 
against O 
acute O 
ethanol B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
in O 
rat O 
. O 

present O 
study O 
was O 
undertaken O 
to O 
determine O 
whether O 
subacute O 
treatment O 
with O 
aqueous O 
extract O 
of O 
carob O 
( O 
Ceratonia O 
siliqua O 
L O 
. O 
) O 
pods O 
( O 
AECPs O 
) O 
protects O 
against O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
)-induced O 
oxidative O 
stress O 
in O 
rat O 
liver O 
. O 
Animals O 
were O 
divided O 
into O 
four O 
groups O 
: O 
control O 
, O 
carob O 
, O 
EtOH B-FORMULA 
and O 
EtOH B-FORMULA 
+ O 
carob O 
. O 
Wistar O 
rats O 
were O 
intraperitoneally O 
pretreated O 
with O 
AECP O 
( O 
600 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
bw O 
) O 
) O 
during O 
7 O 
days O 
and O 
intoxicated O 
for O 
6 O 
h O 
by O 
acute O 
oral O 
administration O 
of O 
EtOH B-FORMULA 
( O 
6 O 
g O 
/ O 
kg O 
bw O 
) O 
24 O 
h O 
after O 
the O 
last O 
injection O 
. O 
We O 
found O 
that O 
acute O 
administration O 
of O 
EtOH B-FORMULA 
leads O 
to O 
hepatotoxicity O 
as O 
monitored O 
by O 
the O 
increase O 
in O 
the O 
levels O 
of O 
hepatic O 
marker O 
aspartate B-TRIVIAL 
aminotransferase O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
as O 
well O 
as O 
hepatic O 
tissue O 
injury O 
. O 
EtOH B-FORMULA 
also O 
increased O 
the O 
formation O 
of O 
malondialdehyde B-TRIVIAL 
in O 
the O 
liver O 
, O 
indicating O 
an O 
increase O 
in O 
lipid O 
peroxidation O 
and O 
depletion O 
of O 
antioxidant O 
enzyme O 
activities O 
as O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
. O 
Subacute O 
carob O 
pretreatment O 
prevented O 
all O 
the O 
alterations O 
induced O 
by O 
EtOH B-FORMULA 
and O 
returned O 
their O 
levels O 
to O 
near O 
normal O 
. O 
Importantly O 
, O 
we O 
showed O 
that O 
acute O 
alcohol O 
increased O 
hepatic O 
and O 
plasmatic O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
free O 
iron O 
levels O 
. O 
The O 
carob O 
pretreatment O 
reversed O 
EtOH B-FORMULA 
effects O 
to O 
near O 
control O 
levels O 
. O 
These O 
data O 
suggest O 
that O 
carob O 
could O 
have O 
a O 
beneficial O 
effect O 
in O 
inhibiting O 
the O 
oxidative O 
damage O 
induced O 
by O 
acute O 
EtOH B-FORMULA 
administration O 
and O 
that O 
its O 
mode O 
of O 
action O 
may O 
involve O 
an O 
opposite O 
effect O 
on O 
plasma O 
and O 
tissue O 
- O 
free O 
iron O 
accumulation O 
. O 
Indeed O 
, O 
carob O 
can O 
be O 
offered O 
as O 
a O 
food O 
additive O 
to O 
protect O 
against O 
EtOH B-FORMULA 
-induced O 
oxidative O 
damage O 
. O 

present O 
study O 
was O 
investigated O 
to O 
evaluate O 
the O 
uptake O 
and O 
accumulation O 
of O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
by O 
the O 
stem O 
cuttings O 
of O 
Portulaca O 
oleracea O 
L O 
. O 
grown O 
in O 
alfisol O 
amended O 
with O 
various O 
concentrations O 
of O 
Se O 
. O 
P O 
. O 
oleracea O 
accumulated O 
a O 
maximum O 
of O 
63.4 O 
µg O 
g(-1) O 
dry O 
weight O 
in O 
a O 
short O 
growth O 
period O 
of O 
42 O 
days O 
. O 
The O 
order O 
of O 
accumulation O 
of O 
Se B-FORMULA 
among O 
the O 
plant O 
parts O 
was O 
leaves O 
( O 
31.5 O 
μg O 
g(-1) O 
) O 
> O 
stems O 
( O 
16.4 O 
μg O 
g(-1) O 
) O 
> O 
roots O 
( O 
15.5 O 
μg O 
g(-1) O 
) O 
. O 
The O 
accumulation O 
potential O 
was O 
fourfold O 
higher O 
than O 
the O 
plant O 
available O 
concentration O 
of O 
15.2 O 
μg O 
g(-1) O 
of O 
Se B-FORMULA 
g(-1) O 
of O 
soil O 
( O 
diethylenetriaminepentaacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
extracted O 
) O 
. O 
Although O 
the O 
plant O 
was O 
able O 
to O 
accumulate O 
Se B-FORMULA 
in O 
their O 
tissues O 
, O 
increase O 
in O 
Se B-FORMULA 
concentrations O 
in O 
soil O 
caused O 
a O 
concentration O 
- O 
dependent O 
decrease O 
in O 
the O 
growth O 
rate O 
of O 
plants O 
( O 
regeneration O 
of O 
leaves O 
, O 
number O 
of O 
leaves O 
, O 
number O 
of O 
roots O 
, O 
root O 
length O 
, O 
stem O 
length O 
and O 
biomass O 
) O 
. O 

approach&#8212;multicomponent O 
production O 
of O 
boron B-SYSTEMATIC 
&#8212;containing O 
hantzsch O 
and O 
biginelli O 
esters O 
. O 

reactions O 
are O 
excellent O 
methods O 
that O 
meet O 
the O 
requirements O 
of O 
green O 
chemistry O 
, O 
by O 
reducing O 
the O 
number O 
of O 
steps O 
, O 
and O 
consequently O 
reducing O 
purification O 
requirements O 
. O 
Accordingly O 
, O 
in O 
this O 
work O 
, O 
11 O 
novel O 
hybrid- O 
boron B-SYSTEMATIC 
-containing O 
molecules O 
, O 
namely O 
eight O 
1,4-dihydropyridines B-FAMILY 
and O 
three O 
3,4-dihydropyrimidinones B-FAMILY 
, O 
derived O 
from O 
formylphenylboronic B-FAMILY 
acids I-FAMILY 
( O 
ortho O 
, O 
meta O 
and O 
para O 
) O 
, O 
were O 
obtained O 
using O 
a O 
green O 
approach O 
, O 
involving O 
H-4CR O 
and O 
B-3CR O 
practices O 
, O 
in O 
the O 
presence O 
of O 
ethanol B-SYSTEMATIC 
, O 
which O 
is O 
a O 
green O 
solvent O 
, O 
and O 
using O 
three O 
comparatively O 
different O 
modes O 
of O 
activation O 
( O 
mantle O 
heating O 
, O 
yield O 
3%-7% O 
in O 
24 O 
h O 
, O 
Infrared O 
Radiation O 
( O 
IR O 
) O 
irradiation O 
, O 
yield O 
12%-17% O 
in O 
12 O 
h O 
, O 
and O 
microwave O 
irradiation O 
, O 
yield O 
18%-80% O 
, O 
requiring O 
very O 
low O 
reaction O 
times O 
of O 
0.25-0.33 O 
h O 
) O 
. O 
In O 
addition O 
, O 
as O 
a O 
green O 
- O 
approach O 
is O 
offered O 
, O 
a O 
convenient O 
analysis O 
, O 
of O 
the O 
12 O 
green O 
chemistry O 
principles O 
for O 
the O 
overall O 
procedure O 
was O 
performed O 
. O 
Finally O 
, O 
since O 
all O 
the O 
products O 
are O 
new O 
, O 
characterizations O 
were O 
carried O 
out O 
using O 
common O 
analytic O 
procedures O 
( O 
1H B-FORMULA 
, O 
11B B-FORMULA 
, O 
and O 
13C B-FORMULA 
NMR O 
, O 
FAB O 
+ O 
MS O 
, O 
HRMS O 
, O 
and O 
IR O 
) O 
. O 
The O 
accurate O 
mass O 
data O 
of O 
unexpected O 
ions O 
related O 
to O 
interactions O 
between O 
thioglycerol B-SYSTEMATIC 
and O 
the O 
expected O 
products O 
, O 
in O 
the O 
FAB O 
+ O 
-mode O 
, O 
enabled O 
unequivocal O 
characterization O 
of O 
the O 
target O 
molecules O 
. O 

and O 
Self-Assembly O 
of O 
Large O 
Polycyclic O 
Molecules O 
on O 
the O 
Surfaces O 
of O 
TiO2 B-FORMULA 
Single O 
Crystals O 
. O 

dioxide I-SYSTEMATIC 
is O 
one O 
of O 
the O 
most O 
frequently O 
studied O 
metal B-FAMILY 
oxides I-FAMILY 
, O 
and O 
its O 
( O 
110 O 
) O 
rutile O 
surface O 
serves O 
as O 
a O 
prototypical O 
model O 
for O 
the O 
surface O 
science O 
of O 
such O 
materials O 
. O 
Recent O 
studies O 
have O 
also O 
shown O 
that O 
the O 
( O 
11 O 
) O 
surface O 
is O 
relatively O 
easy O 
for O 
preparation O 
in O 
ultra O 
- O 
high O 
vacuum O 
( O 
UHV O 
) O 
and O 
that O 
both O 
the O 
( O 
110 O 
) O 
and O 
( O 
11 O 
) O 
surfaces O 
could O 
be O 
precisely O 
characterized O 
using O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
. O 
The O 
supramolecular O 
self O 
- O 
assembly O 
of O 
organic O 
molecules O 
on O 
the O 
surfaces O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
plays O 
an O 
important O 
role O 
in O 
nanofabrication O 
, O 
and O 
it O 
can O 
control O 
the O 
formation O 
and O 
properties O 
of O 
nanostructures O 
, O 
leading O 
to O 
wide O 
range O 
of O 
applications O 
covering O 
the O 
fields O 
of O 
catalysis O 
, O 
coatings O 
and O 
fabrication O 
of O 
sensors O 
and O 
extends O 
to O 
the O 
optoelectronic O 
industry O 
and O 
medical O 
usage O 
. O 
Although O 
the O 
majority O 
of O 
experiments O 
and O 
theoretical O 
calculations O 
are O 
focused O 
on O 
the O 
adsorption O 
of O 
relatively O 
small O 
organic O 
species O 
, O 
in O 
recent O 
years O 
, O 
there O 
has O 
been O 
increasing O 
interest O 
in O 
the O 
properties O 
of O 
larger O 
molecules O 
that O 
have O 
several O 
aromatic O 
rings O 
in O 
which O 
functional O 
units O 
could O 
also O 
be O 
observed O 
. O 
The O 
purpose O 
of O 
this O 
review O 
is O 
to O 
summarize O 
the O 
achievements O 
in O 
the O 
study O 
of O 
single O 
polycyclic O 
molecules O 
and O 
thin O 
layers O 
adsorbed O 
onto O 
the O 
surfaces O 
of O 
single O 
crystalline O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
over O 
the O 
past O 
decade O 
. O 

plant O 
proteases O 
( O 
e O 
. O 
g O 
. O 
, O 
papain O 
, O 
bromelain O 
, O 
ficin O 
) O 
have O 
been O 
used O 
as O 
anti-inflammatory O 
agents O 
for O 
some O 
years O 
, O 
and O 
especially O 
bromelain O 
is O 
still O 
being O 
used O 
as O 
alternative O 
and O 
/ O 
or O 
complementary O 
therapy O 
to O 
glucocorticoids O 
, O 
nonsteroidal O 
antirheumatics O 
, O 
and O 
immunomodulators O 
. O 
Bromelain O 
is O 
an O 
extract O 
rich O 
in O 
cysteine B-TRIVIAL 
endopeptidases O 
obtained O 
from O 
Ananas O 
comosus O 
. O 
In O 
this O 
study O 
the O 
anti-inflammatory O 
action O 
of O 
a O 
partially O 
purified O 
extract O 
of O 
Bromelia O 
hieronymi O 
fruits O 
, O 
whose O 
main O 
components O 
are O 
cysteine B-TRIVIAL 
endopeptidases O 
, O 
is O 
presented O 
. O 
Different O 
doses O 
of O 
a O 
partially O 
purified O 
extract O 
of O 
B O 
. O 
hieronymi O 
were O 
assayed O 
on O 
carrageenan O 
- O 
induced O 
and O 
serotonine B-TRIVIAL 
-induced O 
rat O 
paw O 
edema O 
, O 
as O 
well O 
as O 
in O 
cotton O 
pellet O 
granuloma O 
model O 
. O 
Doses O 
with O 
equal O 
proteolytic O 
activity O 
of O 
the O 
partially O 
purified O 
extract O 
and O 
bromelain O 
showed O 
significantly O 
similar O 
anti-inflammatory O 
responses O 
. O 
Treatment O 
of O 
the O 
partially O 
purified O 
extract O 
and O 
bromelain O 
with O 
E-64 B-TRIVIAL 
provoked O 
loss O 
of O 
anti-inflammatory O 
activity O 
on O 
carrageenan O 
- O 
induced O 
paw O 
edema O 
, O 
a O 
fact O 
which O 
is O 
consistent O 
with O 
the O 
hypothesis O 
that O 
the O 
proteolytic O 
activity O 
would O 
be O 
responsible O 
for O 
the O 
anti-inflammatory O 
action O 
. O 

characteristics O 
of O 
lixisenatide O 
once O 
daily O 
versus O 
liraglutide O 
once O 
daily O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
insufficiently O 
controlled O 
on O 
metformin B-TRIVIAL 
. O 

: O 
Assess O 
the O 
pharmacodynamics O 
of O 
lixisenatide O 
once O 
daily O 
( O 
QD O 
) O 
versus O 
liraglutide O 
QD O 
in O 
type O 
2 O 
diabetes O 
insufficiently O 
controlled O 
on O 
metformin B-TRIVIAL 
. O 
METHODS O 
: O 
In O 
this O 
28-day O 
, O 
randomized O 
, O 
open O 
- O 
label O 
, O 
parallel O 
- O 
group O 
, O 
multicentre O 
study O 
( O 
NCT01175473 O 
) O 
, O 
patients O 
( O 
mean O 
HbA1c O 
7.3% O 
) O 
received O 
subcutaneous O 
lixisenatide O 
QD O 
( O 
10 O 
µg O 
weeks O 
1-2 O 
, O 
then O 
20 O 
µg O 
; O 
n O 
= O 
77 O 
) O 
or O 
liraglutide O 
QD O 
( O 
0.6 O 
mg O 
week O 
1 O 
, O 
1.2 O 
mg O 
week O 
2 O 
, O 
then O 
1.8 O 
mg O 
; O 
n O 
= O 
71 O 
) O 
30 O 
min O 
before O 
breakfast O 
. O 
Primary O 
endpoint O 
was O 
change O 
in O 
postprandial O 
plasma O 
glucose B-TRIVIAL 
( O 
PPG O 
) O 
exposure O 
from O 
baseline O 
to O 
day O 
28 O 
during O 
a O 
breakfast O 
test O 
meal O 
. O 
RESULTS O 
: O 
Lixisenatide O 
reduced O 
PPG O 
significantly O 
more O 
than O 
liraglutide O 
[ O 
mean O 
change O 
in O 
AUC(0) O 
( O 
: O 
30-4 O 
: O 
30h O 
) O 
: O 
-12.6 O 
vs O 
. O 
-4 O 
h O 
/ O 
mmol O 
/ O 
l O 
, O 
respectively O 
; O 
p O 
< O 
0.0001 O 
( O 
0 O 
: O 
30 O 
h O 
= O 
start O 
of O 
meal O 
) O 
] O 
. O 
Change O 
in O 
maximum O 
PPG O 
excursion O 
was O 
-3.9 O 
mmol O 
/ O 
l O 
vs O 
. O 
-1.4 O 
mmol O 
/ O 
l O 
, O 
respectively O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
More O 
lixisenatide O 
- O 
treated O 
patients O 
achieved O 
2-h O 
PPG O 
< O 
7.8 O 
mmol O 
/ O 
l O 
( O 
69% O 
vs O 
. O 
29% O 
) O 
. O 
Changes O 
in O 
fasting O 
plasma O 
glucose O 
were O 
greater O 
with O 
liraglutide O 
( O 
-0.3 O 
vs O 
. O 
-1.3 O 
mmol O 
/ O 
l O 
, O 
p O 
< O 
0.0001 O 
) O 
. O 
Lixisenatide O 
provided O 
greater O 
decreases O 
in O 
postprandial O 
glucagon O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
insulin O 
( O 
p O 
< O 
0.0001 O 
) O 
and O 
C- O 
peptide O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
Mean O 
HbA1c O 
decreased O 
in O 
both O 
treatment O 
groups O 
( O 
from O 
7.2% O 
to O 
6.9% O 
with O 
lixisenatide O 
vs O 
. O 
7.4% O 
to O 
6.9% O 
with O 
liraglutide O 
) O 
as O 
did O 
body O 
weight O 
( O 
-1.6 O 
kg O 
vs O 
. O 
-2.4 O 
kg O 
, O 
respectively O 
) O 
. O 
Overall O 
incidence O 
of O 
adverse O 
events O 
was O 
lower O 
with O 
lixisenatide O 
( O 
55% O 
) O 
versus O 
liraglutide O 
( O 
65% O 
) O 
, O 
with O 
no O 
serious O 
events O 
or O 
hypoglycaemia O 
reported O 
. O 
CONCLUSIONS O 
: O 
Once O 
daily O 
prebreakfast O 
lixisenatide O 
provided O 
a O 
significantly O 
greater O 
reduction O 
in O 
PPG O 
( O 
AUC O 
) O 
during O 
a O 
morning O 
test O 
meal O 
versus O 
prebreakfast O 
liraglutide O 
. O 
Lixisenatide O 
provided O 
significant O 
decreases O 
in O 
postprandial O 
insulin O 
, O 
C- O 
peptide O 
( O 
vs O 
. O 
an O 
increase O 
with O 
liraglutide O 
) O 
and O 
glucagon O 
, O 
and O 
better O 
gastrointestinal O 
tolerability O 
than O 
liraglutide O 
. O 

protein O 
known O 
as O 
eIF5A O 
( O 
eukaryotic O 
initiation O 
factor O 
5A O 
) O 
has O 
an O 
elusive O 
role O 
in O 
translation O 
. O 
It O 
has O 
a O 
unique O 
and O 
essential O 
hypusine O 
modification O 
at O 
a O 
conserved O 
lysine B-TRIVIAL 
residue O 
in O 
most O 
eukaryotes O 
. O 
In O 
addition O 
, O 
this O 
protein O 
is O 
modified O 
by O 
phosphorylation O 
with O 
unknown O 
functions O 
. O 
In O 
the O 
present O 
study O 
we O 
show O 
that O 
a O 
phosphorylated O 
state O 
of O 
eIF5A O 
predominates O 
in O 
exponentially O 
growing O 
Trypanosoma O 
cruzi O 
cells O 
, O 
and O 
extensive O 
dephosphorylation O 
occurs O 
in O 
cells O 
in O 
stationary O 
phase O 
. O 
Phosphorylation O 
occurs O 
mainly O 
at O 
Ser B-FORMULA 
( O 
2 O 
) O 
, O 
as O 
shown O 
in O 
yeast O 
eIF5A O 
. O 
In O 
addition O 
, O 
a O 
novel O 
phosphorylation O 
site O 
was O 
identified O 
at O 
Tyr B-FORMULA 
( O 
21 O 
) O 
. O 
In O 
exponential O 
cells O 
, O 
T O 
. O 
cruzi O 
eIF5A O 
is O 
partially O 
associated O 
with O 
polysomes O 
, O 
compatible O 
with O 
a O 
proposed O 
function O 
as O 
an O 
elongation O 
factor O 
, O 
and O 
becomes O 
relatively O 
enriched O 
in O 
polysomal O 
fractions O 
in O 
stationary O 
phase O 
. O 
Overexpression O 
of O 
the O 
wild O 
- O 
type O 
eIF5A O 
, O 
or O 
eIF5A O 
with O 
Ser B-FORMULA 
( O 
2 O 
) O 
replaced O 
by O 
an O 
aspartate B-TRIVIAL 
residue O 
, O 
but O 
not O 
by O 
alanine B-TRIVIAL 
, O 
increases O 
the O 
rate O 
of O 
cell O 
proliferation O 
and O 
protein O 
synthesis O 
. O 
However O 
, O 
the O 
presence O 
of O 
an O 
aspartate B-TRIVIAL 
residue O 
instead O 
of O 
Ser B-FORMULA 
( O 
2 O 
) O 
is O 
toxic O 
for O 
cells O 
reaching O 
the O 
stationary O 
phase O 
, O 
which O 
show O 
a O 
less O 
- O 
pronounced O 
protein O 
synthesis O 
arrest O 
and O 
a O 
decreased O 
amount O 
of O 
eIF5A O 
in O 
dense O 
fractions O 
of O 
sucrose B-TRIVIAL 
gradients O 
. O 
We O 
conclude O 
that O 
eIF5A O 
phosphorylation O 
and O 
dephosphorylation O 
cycles O 
regulate O 
translation O 
according O 
to O 
the O 
growth O 
conditions O 
. O 

acids I-FAMILY 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
evaluated O 
for O 
their O 
ability O 
to O 
selectively O 
inhibit O 
human O 
histone O 
deacetylase O 
6 O 
( O 
HDAC6 O 
) O 
. O 
Several O 
inhibitors O 
, O 
including O 
compound O 
14 O 
( O 
BRD9757 B-IDENTIFIER 
) O 
, O 
exhibited O 
excellent O 
potency O 
and O 
selectivity O 
despite O 
the O 
absence O 
of O 
a O 
surface O 
- O 
binding O 
motif O 
. O 
The O 
binding O 
of O 
these O 
highly O 
efficient O 
ligands O 
for O 
HDAC6 O 
is O 
rationalized O 
via O 
structure O 
- O 
activity O 
relationships O 
. O 
These O 
results O 
demonstrate O 
that O 
high O 
selectivity O 
and O 
potent O 
inhibition O 
of O 
HDAC6 O 
can O 
be O 
achieved O 
through O 
careful O 
choice O 
of O 
linker O 
element O 
only O 
. O 

, O 
right O 
, O 
or O 
both O 
? O 
On O 
the O 
configuration O 
of O 
the O 
phenanthroindolizidine B-FAMILY 
alkaloid I-FAMILY 
tylophorine O 
from O 
Tylophora O 
indica O 
. O 

alkaloid O 
(-)-tylophorine B-TRIVIAL 
was O 
isolated O 
from O 
a O 
sample O 
of O 
Tylophora O 
indica O 
, O 
and O 
the O 
crude O 
extract O 
was O 
analyzed O 
by O 
HPLC O 
/ O 
MS(n) O 
and O 
chiral O 
HPLC O 
/ O 
MS O 
. O 
While O 
the O 
literature O 
states O 
that O 
the O 
naturally O 
occurring O 
form O 
of O 
this O 
alkaloid O 
is O 
the O 
R-enantiomer O 
and O 
that O 
its O 
S-antipode O 
is O 
usually O 
not O 
found O 
in O 
nature O 
, O 
we O 
confirmed O 
the O 
hypothesis O 
of O 
Govindachari O 
and O 
Nagarajan O 
that O 
natural O 
levorotatory B-TRIVIAL 
tylophorine I-TRIVIAL 
is O 
indeed O 
a O 
nearly O 
racemic O 
mixture O 
with O 
a O 
slight O 
excess O 
of O 
the O 
R-enantiomer O 
. O 

of O 
in O 
vivo O 
anti-hyperglycemic O 
and O 
antioxidant O 
potentials O 
of O 
α-santalol B-TRIVIAL 
and O 
sandalwood O 
oil O 
. O 

finds O 
numerous O 
mentions O 
across O 
diverse O 
traditional O 
medicinal O 
systems O 
in O 
use O 
worldwide O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
in O 
vivo O 
anti-hyperglycemic O 
and O 
antioxidant O 
potential O 
of O 
sandalwood O 
oil O 
and O 
its O 
major O 
constituent O 
α-santalol B-TRIVIAL 
. O 
The O 
in O 
vivo O 
anti-hyperglycemic O 
experiment O 
was O 
conducted O 
in O 
alloxan B-TRIVIAL 
-induced O 
diabetic O 
male O 
Swiss O 
albino O 
mice O 
models O 
. O 
The O 
in O 
vivo O 
antioxidant O 
experiment O 
was O 
performed O 
in O 
d-galactose B-TRIVIAL 
mediated O 
oxidative O 
stress O 
induced O 
male O 
Swiss O 
albino O 
mice O 
models O 
. O 
Intraperitoneal O 
administration O 
of O 
α-santalol B-TRIVIAL 
( O 
100mg O 
/ O 
kg O 
BW O 
) O 
and O 
sandalwood O 
oil O 
( O 
1g O 
/ O 
kg O 
BW O 
) O 
for O 
an O 
week O 
modulated O 
parameters O 
such O 
as O 
body O 
weight O 
, O 
blood O 
glucose B-TRIVIAL 
, O 
serum O 
bilirubin B-TRIVIAL 
, O 
liver O 
glycogen O 
, O 
and O 
lipid O 
peroxides B-FAMILY 
contents O 
to O 
normoglycemic O 
levels O 
in O 
the O 
alloxan B-TRIVIAL 
-induced O 
diabetic O 
mice O 
. O 
Similarly O 
, O 
intraperitoneal O 
administration O 
of O 
α-santalol B-TRIVIAL 
( O 
100mg O 
/ O 
kg O 
BW O 
) O 
and O 
sandalwood O 
oil O 
( O 
1g O 
/ O 
kg O 
BW O 
) O 
for O 
two O 
weeks O 
modulated O 
parameters O 
such O 
as O 
serum O 
aminotransferases O 
, O 
alkaline O 
phosphatase O 
, O 
bilirubin B-TRIVIAL 
, O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
free O 
sulfhydryl B-FAMILY 
, O 
protein O 
carbonyl B-FAMILY 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
liver O 
lipid O 
peroxide B-SYSTEMATIC 
contents O 
, O 
and O 
antioxidant O 
capacity O 
in O 
d-galactose B-TRIVIAL 
mediated O 
oxidative O 
stress O 
induced O 
mice O 
. O 
Besides O 
, O 
it O 
was O 
observed O 
that O 
the O 
beneficial O 
effects O 
of O 
α-santalol B-TRIVIAL 
were O 
well O 
complimented O 
, O 
differentially O 
by O 
other O 
constituents O 
present O 
in O 
sandalwood O 
oil O 
, O 
thus O 
indicating O 
synergism O 
in O 
biological O 
activity O 
of O 
this O 
traditionally O 
used O 
bioresource O 
. O 

Alpiniae O 
Zerumbet O 
( O 
FAZ O 
) O 
is O 
an O 
herb O 
widely O 
used O 
to O 
treat O 
vascular O 
disorders O 
in O 
Guizhou O 
province O 
, O 
China O 
, O 
the O 
essential O 
oil O 
has O 
been O 
identified O 
as O 
one O 
of O 
it O 
vasodilation O 
effect O 
active O 
components O 
, O 
and O 
especial O 
, O 
the O 
composition O 
was O 
significantly O 
difference O 
from O 
the O 
leaves O 
. O 
Vasodilation O 
effects O 
and O 
mechanism O 
of O 
essential O 
oil O 
from O 
FAZ O 
( O 
EOFAZ O 
) O 
were O 
investigated O 
. O 
The O 
EOFAZ O 
showed O 
significant O 
vasodilation O 
effect O 
on O 
endothelium O 
- O 
with O 
rat O 
thoracic O 
aortic O 
rings O 
preincubated O 
with O 
norepinephrine O 
( O 
NE O 
, O 
1.0μM O 
) O 
or O 
KCl O 
( O 
60mM O 
) O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
1.14-72.96μg O 
/ O 
ml O 
) O 
. O 
The O 
non-selective O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
l-NAME B-ABBREVIATION 
, O 
as O 
well O 
as O 
the O 
soluble O 
guanylate B-TRIVIAL 
cyclase O 
inhibitor O 
MB O 
, O 
attenuated O 
the O 
relaxation O 
of O 
EOFAZ O 
in O 
endothelium O 
- O 
intact O 
rat O 
thoracic O 
aortic O 
rings O 
. O 
However O 
, O 
there O 
were O 
not O 
significantly O 
affected O 
the O 
vasodilation O 
effects O 
pretreated O 
with O 
cyclooxygenase O 
inhibition O 
by O 
indomethacin B-TRIVIAL 
( O 
Indo B-ABBREVIATION 
) O 
or O 
β-noradrenergic O 
inhibition O 
by O 
propranolol B-TRIVIAL 
( O 
Prop B-ABBREVIATION 
) O 
. O 
The O 
present O 
results O 
first O 
demonstrated O 
that O 
vasodilation O 
effect O 
of O 
EOFAZ O 
depending O 
upon O 
the O 
endothelium O 
and O 
concentration O 
, O 
and O 
the O 
mechanism O 
involvement O 
of O 
NOS- O 
cGMP B-ABBREVIATION 
system O 
. O 
In O 
contrast O 
, O 
prostacyclin B-TRIVIAL 
and O 
β-adrenoceptor O 
may O 
not O 
be O 
associated O 
with O 
EOFAZ-induced O 
vasorelaxation O 
. O 

of O 
lipophilic O 
chalcones B-FAMILY 
and O 
their O 
conformationally O 
restricted O 
analogues O 
as O 
antitubercular O 
agents O 
. O 

periodic O 
occurrence O 
of O 
Paralytic O 
Shellfish O 
Poisoning O 
( O 
PSP O 
) O 
toxins O 
in O 
UK O 
surf O 
clams O 
and O 
the O 
recent O 
move O 
away O 
from O 
biological O 
assays O 
for O 
PSP O 
testing O 
resulted O 
in O 
the O 
need O 
to O 
determine O 
method O 
performance O 
characteristics O 
for O 
the O 
replacement O 
analytical O 
method O 
in O 
this O 
species O 
. O 
With O 
the O 
requirement O 
for O 
laboratory O 
reference O 
materials O 
to O 
aid O 
this O 
validation O 
together O 
with O 
known O 
issues O 
relating O 
to O 
toxin O 
transformation O 
in O 
live O 
clams O 
and O 
homogenised O 
tissue O 
, O 
there O 
was O 
the O 
need O 
to O 
assess O 
the O 
toxin O 
transformation O 
characteristics O 
of O 
PSP O 
toxins O 
in O 
surf O 
clam O 
tissue O 
. O 
Initial O 
work O 
examined O 
the O 
rates O 
of O 
toxin O 
transformation O 
in O 
UK O 
surf O 
clam O 
tissue O 
incubated O 
with O 
toxin O 
standards O 
, O 
showing O 
rapid O 
transformation O 
of O 
N-sulfocarbamoyl B-SYSTEMATIC 
toxins O 
with O 
slower O 
transformation O 
of O 
carbamate B-FAMILY 
toxins O 
. O 
Full O 
transformational O 
pathways O 
were O 
determined O 
using O 
a O 
combination O 
of O 
three O 
different O 
analytical O 
methods O 
and O 
confirmed O 
the O 
major O 
expected O 
transformations O 
involving O 
decarbamoylation O 
, O 
with O 
some O 
evidence O 
for O 
additional O 
reaction O 
pathways O 
. O 
Results O 
obtained O 
from O 
the O 
analysis O 
of O 
surf O 
clam O 
and O 
oyster O 
tissues O 
incubated O 
with O 
varying O 
concentrations O 
of O 
toxic O 
Alexandrium O 
algae O 
highlighted O 
expected O 
transformation O 
reactions O 
, O 
although O 
significant O 
differences O 
were O 
observed O 
in O 
the O 
extent O 
of O 
the O 
transformations O 
amongst O 
the O 
range O 
of O 
toxins O 
studied O 
, O 
with O 
less O 
efficient O 
transformation O 
of O 
N B-FORMULA 
-hydroxylated O 
toxins O 
as O 
compared O 
with O 
other O 
carbamate B-MULTIPLE 
and I-MULTIPLE 
N-sulfocarbamoyl I-MULTIPLE 
toxins O 
. O 
Analysis O 
of O 
PSP-toxic O 
incurred O 
oyster O 
, O 
scallop O 
and O 
mussel O 
tissues O 
incubated O 
with O 
variable O 
proportions O 
of O 
surf O 
clam O 
tissue O 
showed O 
large O 
differences O 
in O 
the O 
extent O 
of O 
the O 
transformations O 
. O 
Total O 
conversion O 
of O 
N B-FORMULA 
-sulfocarbamoyl O 
toxins O 
was O 
confirmed O 
at O 
low O 
relative O 
proportions O 
of O 
surf O 
clam O 
tissue O 
in O 
all O 
three O 
species O 
, O 
whereas O 
transformation O 
of O 
carbamate B-FAMILY 
toxins O 
was O 
found O 
to O 
occur O 
only O 
in O 
the O 
presence O 
of O 
higher O 
proportions O 
of O 
surf O 
clam O 
tissue O 
in O 
oysters O 
and O 
mussels O 
in O 
comparison O 
with O 
scallops O 
. O 
Results O 
enabled O 
the O 
production O 
of O 
three O 
laboratory O 
reference O 
materials O 
prepared O 
following O 
incubation O 
of O 
incurred O 
homogenates O 
with O 
optimum O 
proportions O 
of O 
surf O 
clam O 
tissue O 
, O 
resulting O 
in O 
materials O 
containing O 
a O 
large O 
number O 
of O 
PSP O 
toxins O 
. O 
Stability O 
experiments O 
provided O 
good O 
preliminary O 
evidence O 
for O 
the O 
stability O 
of O 
these O 
targeted O 
materials O 
under O 
storage O 
conditions O 
. O 
The O 
work O 
therefore O 
provides O 
both O 
additional O 
information O 
relating O 
to O 
the O 
transformational O 
activity O 
in O 
UK O 
surf O 
clams O 
and O 
highlights O 
a O 
good O 
potential O 
method O 
for O 
the O 
targeted O 
production O 
of O 
reference O 
materials O 
which O 
include O 
a O 
wider O 
range O 
of O 
toxins O 
than O 
normally O 
present O 
in O 
naturally O 
incurred O 
shellfish O 
. O 

chloride I-SYSTEMATIC 
-induced O 
testicular O 
toxicity O 
in O 
rats O 
and O 
the O 
protective O 
role O 
of O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
vitamin B-FAMILY 
E I-FAMILY 
. O 

has O 
been O 
recognized O 
as O 
an O 
environmental O 
pollutant O 
that O 
adversely O 
affects O 
male O 
reproductive O 
systems O 
of O 
animals O 
. O 
This O 
study O 
examined O 
the O 
effects O 
of O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
on O 
the O 
antioxidant O 
system O 
and O 
histopathological O 
changes O 
and O 
also O 
evaluated O 
the O 
ameliorating O 
effects O 
of O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
/ O 
or O 
vitamin B-FAMILY 
E I-FAMILY 
in O 
the O 
rat O 
testis O 
tissues O 
. O 
Sexually O 
mature O 
male O 
Wistar O 
rats O 
( O 
weighing O 
300-320g O 
and O 
each O 
group O 
six O 
animals O 
) O 
were O 
given O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
1mg O 
/ O 
kg O 
bw O 
) O 
and O 
/ O 
or O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
( O 
0.25mg O 
/ O 
kg O 
bw)+ O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
100mg O 
/ O 
kg O 
) O 
daily O 
via O 
gavage O 
for O 
4weeks O 
. O 
In O 
the O 
present O 
study O 
, O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
exposure O 
resulted O 
in O 
an O 
increase O 
in O 
the O 
TBARS O 
level O 
and O 
a O 
decrease O 
in O 
the O 
SOD O 
, O 
CAT O 
, O 
GPx O 
activities O 
, O 
with O 
respect O 
to O 
the O 
control O 
. O 
Further O 
, O 
light O 
microscopic O 
investigation O 
revealed O 
that O 
mercury B-SYSTEMATIC 
exposure O 
induced O 
histopathological O 
alterations O 
in O 
the O 
testis O 
tissues O 
. O 
Supplementation O 
of O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
/ O 
or O 
vitamin B-FAMILY 
E I-FAMILY 
to O 
mercury B-SYSTEMATIC 
-induced O 
groups O 
declined O 
lipid O 
peroxidation O 
, O 
increased O 
SOD O 
, O 
CAT O 
, O 
GPx O 
activities O 
. O 
While O 
some O 
histopathological O 
changes O 
were O 
detected O 
in O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
treated O 
group O 
, O 
milder O 
histopathological O 
changes O 
were O 
observed O 
in O 
animal O 
co O 
- O 
treated O 
with O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
/ O 
or O 
vitamin B-FAMILY 
E I-FAMILY 
supplementation O 
to O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
-treated O 
rats O 
. O 
As O 
a O 
result O 
, O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
induced O 
testicular O 
toxicity O 
is O 
reduced O 
by O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
and O 
/ O 
or O 
vitamin B-FAMILY 
E I-FAMILY 
, O 
but O 
not O 
ameliorate O 
completely O 
. O 

a O 
human O 
population O 
inhabiting O 
nearby O 
a O 
deactivated O 
uranium B-SYSTEMATIC 
mine O 
. O 

exposure O 
to O 
uranium B-SYSTEMATIC 
and O 
its O 
daughter O 
radionuclides O 
, O 
has O 
been O 
linked O 
to O 
several O 
negative O 
effects O 
such O 
as O 
those O 
related O 
with O 
important O 
physiological O 
processes O 
, O 
like O 
hematopoiesis O 
, O 
and O 
may O 
also O 
be O 
associated O 
with O 
genotoxicity O 
effects O 
. O 
Herein O 
, O 
genotoxic O 
effects O 
, O 
immunotoxicity O 
, O 
trace O 
elements O 
and O 
C O 
reactive O 
protein O 
( O 
CRP O 
) O 
analyses O 
, O 
were O 
performed O 
in O 
peripheral O 
blood O 
samples O 
collected O 
from O 
individuals O 
of O 
a O 
population O 
living O 
near O 
a O 
deactivated O 
uranium B-SYSTEMATIC 
mine O 
. O 
C O 
reactive O 
protein O 
analysis O 
was O 
performed O 
to O 
exclude O 
candidates O 
with O 
active O 
inflammatory O 
processes O 
from O 
further O 
evaluations O 
. O 
DNA O 
damage O 
and O 
immunotoxicity O 
( O 
immunophenotyping O 
and O 
immune O 
cell O 
counts O 
) O 
were O 
evaluated O 
by O 
comet O 
assay O 
and O 
flow O 
cytometry O 
, O 
respectively O 
. O 
Significant O 
DNA O 
damage O 
was O 
observed O 
in O 
the O 
peripheral O 
blood O 
samples O 
from O 
volunteers O 
living O 
in O 
the O 
Cunha O 
Baixa O 
village O 
. O 
A O 
significant O 
decrease O 
of O 
NK O 
and O 
T O 
lymphocytes O 
counts O 
were O 
observed O 
in O 
the O 
individuals O 
from O 
the O 
Cunha O 
Baixa O 
village O 
, O 
when O 
compared O 
with O 
individuals O 
from O 
the O 
reference O 
site O 
. O 
Uranium B-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
levels O 
were O 
significantly O 
higher O 
in O 
the O 
Cunha O 
Baixa O 
village O 
inhabitants O 
. O 
On O 
the O 
other O 
hand O 
, O 
zinc B-SYSTEMATIC 
levels O 
were O 
significantly O 
lower O 
in O 
those O 
individuals O 
when O 
compared O 
with O 
the O 
volunteers O 
from O 
the O 
control O 
village O 
. O 
Results O 
suggest O 
that O 
inhabitants O 
from O 
Cunha O 
Baixa O 
have O 
a O 
higher O 
risk O 
of O 
suffering O 
from O 
serious O 
diseases O 
such O 
as O 
cancer O 
, O 
since O 
high O 
DNA O 
damages O 
were O 
observed O 
in O 
peripheral O 
blood O 
leukocytes O 
and O 
also O 
decreased O 
levels O 
of O 
NK O 
and O 
T O 
cells O 
, O 
which O 
play O 
an O 
essential O 
role O 
in O 
the O 
defense O 
against O 
tumor O 
growth O 
. O 

close O 
genomic O 
and O 
phenotypic O 
similarity O 
to O 
humans O 
, O 
nonhuman O 
primate O 
models O 
provide O 
comprehensive O 
epigenetic O 
mimics O 
of O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
, O 
suggesting O 
early O 
life O 
targeting O 
for O 
prevention O 
. O 
Fetal O 
exposure O 
to O 
testosterone B-TRIVIAL 
( O 
T O 
) O 
, O 
of O 
all O 
nonhuman O 
primate O 
emulations O 
, O 
provides O 
the O 
closest O 
PCOS O 
- O 
like O 
phenotypes O 
, O 
with O 
early O 
- O 
to O 
- O 
mid O 
gestation O 
T-exposed O 
female O 
rhesus O 
monkeys O 
exhibiting O 
adult O 
reproductive O 
, O 
endocrinological O 
and O 
metabolic O 
dysfunctional O 
traits O 
that O 
are O 
co O 
- O 
pathologies O 
of O 
PCOS O 
. O 
Late O 
gestational O 
T O 
exposure O 
, O 
while O 
inducing O 
adult O 
ovarian O 
hyperandrogenism O 
and O 
menstrual O 
abnormalities O 
, O 
has O 
less O 
dysfunctional O 
metabolic O 
accompaniment O 
. O 
Fetal O 
exposures O 
to O 
dihydrotestosterone B-SYSTEMATIC 
( O 
DHT B-ABBREVIATION 
) O 
or O 
diethylstilbestrol B-SYSTEMATIC 
( O 
DES B-ABBREVIATION 
) O 
suggest O 
androgenic O 
and O 
estrogenic O 
aspects O 
of O 
fetal O 
programming O 
. O 
Neonatal O 
exposure O 
to O 
T O 
produces O 
no O 
PCOS O 
- O 
like O 
outcome O 
, O 
while O 
continuous O 
T O 
treatment O 
of O 
juvenile O 
females O 
causes O 
precocious O 
weight O 
gain O 
and O 
early O 
menarche O 
( O 
high O 
T O 
) O 
, O 
or O 
high O 
LH O 
and O 
weight O 
gain O 
( O 
moderate O 
T O 
) O 
. O 
Acute O 
T O 
exposure O 
of O 
adult O 
females O 
generates O 
polyfollicular O 
ovaries O 
, O 
while O 
chronic O 
T O 
exposure O 
induces O 
subtle O 
menstrual O 
irregularities O 
without O 
metabolic O 
dysfunction O 
. O 

New O 
Diterpenoids B-FAMILY 
and O 
Two O 
New O 
Nor-Diterpenoids B-FAMILY 
from O 
the O 
Stems O 
of O 
Croton O 
cascarilloides O 
. O 

the O 
stems O 
of O 
Croton O 
cascarilloides O 
, O 
eight O 
new O 
diterpenoids B-FAMILY 
, O 
named O 
crotocascarins B-MULTIPLE 
A-H I-MULTIPLE 
( O 
1-8 O 
) O 
, O 
having O 
a O 
crotofolane B-TRIVIAL 
skeleton O 
were O 
isolated O 
along O 
with O 
two O 
new O 
nor-diterpenoids B-FAMILY 
( O 
9 O 
and O 
10 O 
) O 
, O 
named O 
crotocascarins O 
α O 
and O 
β O 
, O 
derived O 
through O 
rearrangement O 
of O 
the O 
crotofolane B-TRIVIAL 
skeleton O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
elucidated O 
by O 
means O 
of O 
extensive O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
spectroscopic O 
analyses O 
. O 
The O 
absolute O 
structures O 
of O 
the O 
diterpene B-FAMILY 
moiety O 
were O 
determined O 
by O 
application O 
of O 
the O 
circular O 
dichroism O 
( O 
CD O 
) O 
rule O 
for O 
the O 
γ-lactone B-SYSTEMATIC 
ring O 
. O 
The O 
relative O 
structures O 
of O 
the O 
two O 
crotofolanes B-FAMILY 
( O 
1 O 
and O 
2 O 
) O 
and O 
one O 
rearranged O 
compound O 
( O 
9 O 
) O 
were O 
confirmed O 
by O 
X-ray O 
crystallographic O 
analyses O 
. O 
Compounds O 
1 O 
, O 
2 O 
and O 
9 O 
possessed O 
2-methylbutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
their O 
molecules O 
, O 
the O 
absolute O 
configuration O 
of O 
which O 
was O 
found O 
to O 
be O 
2S O 
by O 
comparison O 
of O 
its O 
HPLC O 
behavior O 
with O 
that O 
of O 
an O 
authentic O 
sample O 
. O 
Therefore O 
, O 
the O 
absolute O 
structures O 
of O 
these O 
crotocascarins B-FAMILY 
( O 
1 O 
, O 
2 O 
and O 
9 O 
) O 
were O 
unambiguously O 
determined O 
. O 
The O 
absolute O 
structures O 
of O 
crotofolanes B-FAMILY 
are O 
reported O 
for O 
the O 
first O 
time O 
in O 
this O 
paper O 
. O 

buprenorphine B-TRIVIAL 
phMRI O 
responses O 
in O 
conscious O 
rodents O 
and O 
healthy O 
human O 
subjects O 
. O 

magnetic O 
resonance O 
imaging O 
( O 
phMRI O 
) O 
is O 
one O 
method O 
by O 
which O 
a O 
drug's O 
pharmacodynamic O 
effects O 
in O 
the O 
brain O 
can O 
be O 
assessed O 
. O 
Although O 
phMRI O 
has O 
been O 
frequently O 
used O 
in O 
preclinical O 
and O 
clinical O 
settings O 
, O 
the O 
extent O 
to O 
which O 
a O 
phMRI O 
signature O 
for O 
a O 
compound O 
translates O 
between O 
rodents O 
and O 
humans O 
has O 
not O 
been O 
systematically O 
examined O 
. O 
In O 
the O 
current O 
investigation O 
, O 
we O 
aimed O 
to O 
build O 
on O 
recent O 
clinical O 
work O 
in O 
which O 
the O 
functional O 
response O 
to O 
0.1 O 
and O 
0.2 O 
mg O 
/ O 
70 O 
kg O 
i.v O 
. O 
buprenorphine B-TRIVIAL 
( O 
partial O 
µ-opioid O 
receptor O 
agonist O 
) O 
was O 
measured O 
in O 
healthy O 
humans O 
. O 
Here O 
, O 
we O 
measured O 
the O 
phMRI O 
response O 
to O 
0.04 O 
and O 
0.1 O 
mg O 
/ O 
kg O 
i.v O 
. O 
buprenorphine B-TRIVIAL 
in O 
conscious O 
, O 
naive O 
rats O 
to O 
establish O 
the O 
parallelism O 
of O 
the O 
phMRI O 
signature O 
of O 
buprenorphine B-TRIVIAL 
across O 
species O 
. O 
PhMRI O 
of O 
0.04 O 
and O 
0.1 O 
mg O 
/ O 
kg O 
i.v O 
. O 
buprenorphine B-TRIVIAL 
yielded O 
dose O 
- O 
dependent O 
activation O 
in O 
a O 
brain O 
network O 
composed O 
of O 
the O 
somatosensory O 
cortex O 
, O 
cingulate O 
, O 
insula O 
, O 
striatum O 
, O 
thalamus O 
, O 
periaqueductal O 
gray O 
, O 
and O 
cerebellum O 
. O 
Similar O 
dose O 
- O 
dependent O 
phMRI O 
activation O 
was O 
observed O 
in O 
the O 
human O 
phMRI O 
studies O 
. O 
These O 
observations O 
indicate O 
an O 
overall O 
preservation O 
of O 
pharmacodynamic O 
responses O 
to O 
buprenorphine B-TRIVIAL 
between O 
conscious O 
, O 
naive O 
rodents O 
and O 
healthy O 
human O 
subjects O 
, O 
particularly O 
in O 
brain O 
regions O 
implicated O 
in O 
pain O 
and O 
analgesia O 
. O 
This O 
investigation O 
further O 
demonstrates O 
the O 
usefulness O 
of O 
phMRI O 
as O 
a O 
translational O 
tool O 
in O 
neuroscience O 
research O 
that O 
can O 
provide O 
mechanistic O 
insight O 
and O 
guide O 
dose O 
selection O 
in O 
drug O 
development O 
. O 

house O 
fly O 
, O 
Musca O 
domestica O 
L O 
. O 
, O 
is O 
an O 
important O 
hygienic O 
pest O 
of O 
humans O 
and O 
dairy O 
animals O 
with O 
the O 
potential O 
to O 
develop O 
resistance O 
to O 
most O 
chemical O 
classes O 
of O 
insecticides O 
. O 
Six O 
adult O 
house O 
fly O 
strains O 
from O 
dairy O 
farms O 
in O 
Punjab O 
, O 
Pakistan O 
were O 
evaluated O 
for O 
resistance O 
to O 
selected O 
insecticides O 
from O 
organochlorine B-FAMILY 
, O 
organophosphate B-FAMILY 
, O 
carbamate B-FAMILY 
and O 
pyrethroid B-FAMILY 
classes O 
. O 
For O 
a O 
chlorocyclodiene B-FAMILY 
and O 
two O 
organophosphates B-FAMILY 
tested O 
, O 
the O 
resistance O 
ratios O 
( O 
RR O 
) O 
at O 
LC50 O 
were O 
in O 
the O 
range O 
of O 
5.60-22.02 O 
fold O 
for O 
endosulfan B-TRIVIAL 
, O 
7.66-23.24 O 
fold O 
for O 
profenofos O 
and O 
2.47-7.44 O 
fold O 
for O 
chlorpyrifos B-TRIVIAL 
. O 
For O 
two O 
pyrethroids B-FAMILY 
and O 
one O 
carbamate B-FAMILY 
, O 
the O 
RR O 
values O 
at O 
LC50 O 
were O 
30.22-70.02 O 
for O 
cypermethrin B-TRIVIAL 
, O 
5.73-18.31 O 
for O 
deltamethrin B-TRIVIAL 
, O 
and O 
4.39-15.50 O 
for O 
methomyl B-TRIVIAL 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
resistance O 
to O 
different O 
classes O 
of O 
insecticides O 
in O 
Pakistani O 
dairy O 
populations O 
of O 
house O 
flies O 
. O 
Regular O 
insecticide O 
resistance O 
monitoring O 
programs O 
on O 
dairy O 
farms O 
are O 
needed O 
to O 
prevent O 
field O 
control O 
failures O 
. O 
Moreover O 
, O 
integrated O 
approaches O 
including O 
the O 
judicious O 
use O 
of O 
insecticides O 
are O 
needed O 
to O 
delay O 
the O 
development O 
of O 
insecticide O 
resistance O 
in O 
house O 
flies O 
. O 

- O 
avibactam B-TRIVIAL 
: O 
a O 
novel O 
cephalosporin B-FAMILY 
/ O 
β-lactamase O 
inhibitor O 
combination O 
. O 

( O 
formerly O 
NXL104 B-IDENTIFIER 
, O 
AVE1330A B-IDENTIFIER 
) O 
is O 
a O 
synthetic O 
non- O 
β-lactam B-TRIVIAL 
, O 
β-lactamase O 
inhibitor O 
that O 
inhibits O 
the O 
activities O 
of O 
Ambler O 
class O 
A O 
and O 
C O 
β-lactamases O 
and O 
some O 
Ambler O 
class O 
D O 
enzymes O 
. O 
This O 
review O 
summarizes O 
the O 
existing O 
data O 
published O 
for O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
, O 
including O 
relevant O 
chemistry O 
, O 
mechanisms O 
of O 
action O 
and O 
resistance O 
, O 
microbiology O 
, O 
pharmacokinetics O 
, O 
pharmacodynamics O 
, O 
and O 
efficacy O 
and O 
safety O 
data O 
from O 
animal O 
and O 
human O 
trials O 
. O 
Although O 
not O 
a O 
β-lactam B-TRIVIAL 
, O 
the O 
chemical O 
structure O 
of O 
avibactam B-TRIVIAL 
closely O 
resembles O 
portions O 
of O 
the O 
cephem B-TRIVIAL 
bicyclic O 
ring O 
system O 
, O 
and O 
avibactam B-TRIVIAL 
has O 
been O 
shown O 
to O 
bond O 
covalently O 
to O 
β-lactamases O 
. O 
Very O 
little O 
is O 
known O 
about O 
the O 
potential O 
for O 
avibactam B-TRIVIAL 
to O 
select O 
for O 
resistance O 
. O 
The O 
addition O 
of O 
avibactam B-TRIVIAL 
greatly O 
( O 
4-1024-fold O 
minimum O 
inhibitory O 
concentration O 
[ O 
MIC O 
] O 
reduction O 
) O 
improves O 
the O 
activity O 
of O 
ceftazidime B-TRIVIAL 
versus O 
most O 
species O 
of O 
Enterobacteriaceae O 
depending O 
on O 
the O 
presence O 
or O 
absence O 
of O 
β-lactamase O 
enzyme(s) O 
. O 
Against O 
Pseudomonas O 
aeruginosa O 
, O 
the O 
addition O 
of O 
avibactam B-TRIVIAL 
also O 
improves O 
the O 
activity O 
of O 
ceftazidime B-TRIVIAL 
( O 
~fourfold O 
MIC O 
reduction O 
) O 
. O 
Limited O 
data O 
suggest O 
that O 
the O 
addition O 
of O 
avibactam B-TRIVIAL 
does O 
not O 
improve O 
the O 
activity O 
of O 
ceftazidime B-TRIVIAL 
versus O 
Acinetobacter O 
species O 
or O 
most O 
anaerobic O 
bacteria O 
( O 
exceptions O 
: O 
Bacteroides O 
fragilis O 
, O 
Clostridium O 
perfringens O 
, O 
Prevotella O 
spp O 
. O 
and O 
Porphyromonas O 
spp O 
. O 
) O 
. O 
The O 
pharmacokinetics O 
of O 
avibactam B-TRIVIAL 
follow O 
a O 
two O 
- O 
compartment O 
model O 
and O 
do O 
not O 
appear O 
to O 
be O 
altered O 
by O 
the O 
co O 
- O 
administration O 
of O 
ceftazidime B-TRIVIAL 
. O 
The O 
maximum O 
plasma O 
drug O 
concentration O 
(C(max)) O 
and O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
of O 
avibactam B-TRIVIAL 
increase O 
linearly O 
with O 
doses O 
ranging O 
from O 
50 O 
mg O 
to O 
2000 O 
mg O 
. O 
The O 
mean O 
volume O 
of O 
distribution O 
and O 
half O 
- O 
life O 
of O 
22 O 
L O 
( O 
~0.3 O 
L O 
/ O 
kg O 
) O 
and O 
~2 O 
hours O 
, O 
respectively O 
, O 
are O 
similar O 
to O 
ceftazidime B-TRIVIAL 
. O 
Like O 
ceftazidime B-TRIVIAL 
, O 
avibactam B-TRIVIAL 
is O 
primarily O 
renally O 
excreted O 
, O 
and O 
clearance O 
correlates O 
with O 
creatinine B-TRIVIAL 
clearance O 
. O 
Pharmacodynamic O 
data O 
suggest O 
that O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
is O 
rapidly O 
bactericidal O 
versus O 
β-lactamase- O 
producing O 
Gram O 
- O 
negative O 
bacilli O 
that O 
are O 
not O 
inhibited O 
by O 
ceftazidime B-TRIVIAL 
alone.Clinical O 
trials O 
to O 
date O 
have O 
reported O 
that O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
is O 
as O 
effective O 
as O 
standard O 
carbapenem B-FAMILY 
therapy O 
in O 
complicated O 
intra O 
- O 
abdominal O 
infection O 
and O 
complicated O 
urinary O 
tract O 
infection O 
, O 
including O 
infection O 
caused O 
by O 
cephalosporin B-FAMILY 
-resistant O 
Gram O 
- O 
negative O 
isolates O 
. O 
The O 
safety O 
and O 
tolerability O 
of O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
has O 
been O 
reported O 
in O 
three O 
phase O 
I O 
pharmacokinetic O 
studies O 
and O 
two O 
phase O 
II O 
clinical O 
studies O 
. O 
Ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
appears O 
to O 
be O 
well O 
tolerated O 
in O 
healthy O 
subjects O 
and O 
hospitalized O 
patients O 
, O 
with O 
few O 
serious O 
drug O 
- O 
related O 
treatment-emergent O 
adverse O 
events O 
reported O 
to O 
date.In O 
conclusion O 
, O 
avibactam B-TRIVIAL 
serves O 
to O 
broaden O 
the O 
spectrum O 
of O 
ceftazidime B-TRIVIAL 
versus O 
ß-lactamase O 
- O 
producing O 
Gram O 
- O 
negative O 
bacilli O 
. O 
The O 
exact O 
roles O 
for O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
will O 
be O 
defined O 
by O 
efficacy O 
and O 
safety O 
data O 
from O 
further O 
clinical O 
trials O 
. O 
Potential O 
future O 
roles O 
for O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
include O 
the O 
treatment O 
of O 
suspected O 
or O 
documented O 
infections O 
caused O 
by O 
resistant O 
Gram O 
- O 
negative O 
- O 
bacilli O 
producing O 
extended O 
- O 
spectrum O 
ß-lactamase O 
( O 
ESBL O 
) O 
, O 
Klebsiella O 
pneumoniae O 
carbapenemases O 
( O 
KPCs O 
) O 
and O 
/ O 
or O 
AmpC O 
ß-lactamases O 
. O 
In O 
addition O 
, O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
may O 
be O 
used O 
in O 
combination O 
( O 
with O 
metronidazole B-TRIVIAL 
) O 
for O 
suspected O 
polymicrobial O 
infections O 
. O 
Finally O 
, O 
the O 
increased O 
activity O 
of O 
ceftazidime B-TRIVIAL 
- O 
avibactam B-TRIVIAL 
versus O 
P O 
. O 
aeruginosa O 
may O 
be O 
of O 
clinical O 
benefit O 
in O 
patients O 
with O 
suspected O 
or O 
documented O 
P O 
. O 
aeruginosa O 
infections O 
. O 

human O 
dermal O 
microvascular O 
endothelial O 
cell O 
survival O 
induced O 
by O 
cysteamine B-TRIVIAL 
. O 

: O 
Cystinosis O 
is O 
an O 
autosomal O 
recessive O 
disease O 
caused O 
by O 
intralysosomal O 
cystine O 
accumulation O 
, O 
treated O 
with O 
cysteamine B-TRIVIAL 
. O 
Recently O 
, O 
new O 
adverse O 
effects O 
of O 
cysteamine B-TRIVIAL 
were O 
reported O 
. O 
Skin O 
biopsies O 
showed O 
microvascular O 
proliferation O 
( O 
angioendotheliomatosis O 
) O 
. O 
To O 
examine O 
the O 
mechanism O 
of O 
angioendotheliomatosis O 
associated O 
with O 
cysteamine B-TRIVIAL 
toxicity O 
, O 
we O 
examined O 
the O 
effect O 
of O 
cysteamine B-TRIVIAL 
on O 
human O 
dermal O 
microvascular O 
endothelial O 
cells O 
( O 
HDMVEC O 
) O 
. O 
METHODS O 
: O 
After O 
cysteamine B-TRIVIAL 
exposure O 
( O 
range O 
0-3.0 O 
mM O 
) O 
during O 
24 O 
h O 
, O 
cell O 
viability O 
was O 
measured O 
using O 
water O 
soluble O 
tetrazolium B-FAMILY 
salt-1 I-FAMILY 
( O 
WST-1 O 
) O 
in O 
both O 
control O 
HDMVEC O 
and O 
fibroblasts O 
. O 
Cell O 
proliferation O 
and O 
apoptosis O 
rate O 
were O 
measured O 
in O 
HDMVEC O 
by O 
bromodeoxyuridine B-TRIVIAL 
( O 
BrdU B-ABBREVIATION 
) O 
incorporation O 
and O 
caspase O 
3 O 
and O 
caspase O 
7 O 
activity O 
, O 
respectively O 
. O 
Intracellular O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
was O 
measured O 
in O 
HDMVEC O 
after O 
cysteamine B-TRIVIAL 
exposure O 
of O 
0 O 
, O 
0.1 O 
or O 
1 O 
mM O 
. O 
Medium O 
and O 
cysteamine B-TRIVIAL 
were O 
refreshed O 
every O 
6 O 
h O 
to O 
mimic O 
the O 
in O 
vivo O 
situation O 
. O 
Next O 
, O 
cell O 
viability O 
in O 
HDMVEC O 
was O 
measured O 
after O 
24 O 
h O 
of O 
GSH B-ABBREVIATION 
exposure O 
( O 
range O 
0-10.0 O 
mM O 
) O 
. O 
RESULTS O 
: O 
HDMVEC O 
viability O 
and O 
proliferation O 
increased O 
after O 
cysteamine B-TRIVIAL 
exposure O 
0.03-3.0 O 
mM O 
( O 
p O 
< O 
0.01 O 
) O 
and O 
0.03-1.0 O 
mM O 
( O 
p O 
= O 
0.01 O 
) O 
respectively O 
; O 
cell O 
viability O 
in O 
fibroblasts O 
was O 
not O 
affected O 
by O 
incubation O 
with O 
cysteamine B-TRIVIAL 
. O 
Apoptosis O 
remained O 
unaffected O 
by O 
incubation O 
with O 
0-1.0 O 
mM O 
cysteamine B-TRIVIAL 
, O 
3 O 
mM O 
caused O 
increased O 
apoptosis O 
. O 
Intracellular O 
GSH B-ABBREVIATION 
was O 
significantly O 
increased O 
after O 
incubation O 
with O 
cysteamine B-TRIVIAL 
0.1 O 
mM O 
( O 
p O 
= O 
0.02 O 
) O 
and O 
1 O 
mM O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
HDMVEC O 
viability O 
increased O 
after O 
exposure O 
to O 
GSH B-ABBREVIATION 
1.0-5.0 O 
mM O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
CONCLUSION O 
: O 
Cysteamine B-TRIVIAL 
concentrations O 
, O 
similar O 
to O 
those O 
described O 
in O 
plasma O 
of O 
cystinosis O 
patients O 
, O 
stimulate O 
HDMVEC O 
viability O 
and O 
proliferation O 
and O 
increase O 
intracellular O 
GSH B-ABBREVIATION 
content O 
. O 
We O 
postulate O 
that O 
this O 
mechanism O 
might O 
underlie O 
angioendotheliomatosis O 
induced O 
by O 
cysteamine B-TRIVIAL 
. O 

of O 
wheel O 
- O 
running O 
during O 
abstinence O 
on O 
subsequent O 
nicotine B-TRIVIAL 
-seeking O 
in O 
rats O 
. O 

: O 
Exercise O 
appears O 
to O 
be O 
a O 
promising O 
non-pharmacological O 
treatment O 
for O 
nicotine B-TRIVIAL 
addiction O 
that O 
may O 
be O 
useful O 
for O 
the O 
vulnerable O 
adolescent O 
population O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
determine O 
if O 
wheel O 
- O 
running O 
, O 
an O 
animal O 
model O 
of O 
aerobic O 
exercise O 
, O 
during O 
an O 
abstinence O 
period O 
would O 
decrease O 
subsequent O 
nicotine O 
- O 
seeking O 
in O 
rats O 
that O 
had O 
extended O 
access O 
to O 
nicotine B-TRIVIAL 
self O 
- O 
administration O 
during O 
adolescence O 
. O 
METHODS O 
: O 
Male O 
adolescent O 
rats O 
( O 
n O 
= O 
55 O 
) O 
were O 
trained O 
to O 
self O 
- O 
administer O 
saline O 
or O 
nicotine B-TRIVIAL 
infusions O 
( O 
5 O 
or O 
10 O 
μg O 
/ O 
kg O 
) O 
under O 
a O 
fixed O 
ratio O 
1 O 
schedule O 
with O 
a O 
maximum O 
of O 
20 O 
infusions O 
/ O 
day O 
beginning O 
on O 
postnatal O 
day O 
30 O 
. O 
After O 
5 O 
days O 
, O 
access O 
was O 
extended O 
to O 
23 O 
h O 
/ O 
day O 
with O 
unlimited O 
infusions O 
for O 
a O 
total O 
of O 
10 O 
days O 
. O 
After O 
the O 
last O 
self O 
- O 
administration O 
session O 
, O 
rats O 
were O 
moved O 
to O 
polycarbonate B-FAMILY 
cages O 
for O 
a O 
10-day O 
abstinence O 
period O 
where O 
they O 
either O 
had O 
access O 
to O 
a O 
locked O 
or O 
unlocked O 
running O 
wheel O 
for O 
2 O 
h O 
/ O 
day O 
. O 
Nicotine B-TRIVIAL 
-seeking O 
was O 
examined O 
following O 
the O 
10th O 
day O 
of O 
abstinence O 
under O 
a O 
within O 
- O 
session O 
extinction O 
/ O 
cue O 
- O 
induced O 
reinstatement O 
paradigm O 
. O 
RESULTS O 
: O 
Intake O 
was O 
higher O 
at O 
the O 
10 O 
μg O 
/ O 
kg O 
dose O 
as O 
compared O 
to O 
the O 
5 O 
μg O 
/ O 
kg O 
dose O 
; O 
however O 
, O 
intake O 
did O 
not O 
differ O 
within O 
doses O 
prior O 
to O 
wheel O 
assignment O 
. O 
Compared O 
to O 
saline O 
controls O 
, O 
rats O 
that O 
self O 
- O 
administered O 
nicotine B-TRIVIAL 
at O 
either O 
dose O 
showed O 
a O 
significant O 
increase O 
in O 
drug O 
- O 
seeking O 
during O 
extinction O 
, O 
and O 
consistent O 
with O 
our O 
hypothesis O 
, O 
exercise O 
during O 
abstinence O 
attenuated O 
this O 
effect O 
. O 
Nicotine B-TRIVIAL 
led O 
to O 
modest O 
but O 
significant O 
levels O 
of O 
cue O 
- O 
induced O 
reinstatement O 
; O 
however O 
, O 
in O 
this O 
adolescent-onset O 
model O 
, O 
levels O 
were O 
variable O 
and O 
not O 
affected O 
by O 
exercise O 
. O 
CONCLUSIONS O 
: O 
Exercise O 
may O 
effectively O 
reduce O 
relapse O 
vulnerability O 
for O 
adolescent-onset O 
nicotine B-TRIVIAL 
addiction O 
. O 

and O 
methylenedioxypyrovalerone B-SYSTEMATIC 
( O 
MDPV B-ABBREVIATION 
) O 
, O 
major O 
constituents O 
of O 
" O 
bath O 
salts O 
, O 
" O 
produce O 
opposite O 
effects O 
at O 
the O 
human O 
dopamine B-TRIVIAL 
transporter O 
. O 

: O 
Psychoactive O 
" O 
bath O 
salts O 
" O 
represent O 
a O 
relatively O 
new O 
drug O 
of O 
abuse O 
combination O 
that O 
was O 
placed O 
in O 
Schedule O 
I O 
in O 
October O 
2011 O 
. O 
Two O 
common O 
ingredients O 
of O 
bath O 
salts O 
include O 
the O 
cathinone B-TRIVIAL 
analogs O 
: O 
mephedrone B-TRIVIAL 
and O 
methylenedioxypyrovalerone B-SYSTEMATIC 
( O 
MDPV B-ABBREVIATION 
) O 
. O 
The O 
mechanism O 
of O 
action O 
of O 
these O 
synthetic O 
cathinone B-TRIVIAL 
analogs O 
has O 
not O 
been O 
well O 
investigated O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Because O 
cathinone B-TRIVIAL 
and O 
methcathinone B-TRIVIAL 
are O 
known O 
to O 
act O 
as O 
releasing O 
agents O 
at O 
the O 
human O 
dopamine B-TRIVIAL 
transporter O 
( O 
hDAT O 
) O 
, O 
mephedrone B-TRIVIAL 
and O 
MDPV B-ABBREVIATION 
were O 
investigated O 
at O 
hDAT O 
expressed O 
in O 
Xenopus O 
oocytes O 
. O 
RESULTS O 
: O 
Whereas O 
mephedrone B-TRIVIAL 
was O 
found O 
to O 
have O 
the O 
signature O 
of O 
a O 
dopamine B-TRIVIAL 
-releasing O 
agent O 
similar O 
to O 
methamphetamine B-TRIVIAL 
or O 
methcathinone B-TRIVIAL 
, O 
MDPV B-ABBREVIATION 
behaved O 
as O 
a O 
cocaine B-TRIVIAL 
-like O 
reuptake O 
inhibitor O 
of O 
dopamine B-TRIVIAL 
. O 
CONCLUSIONS O 
: O 
Mephedrone B-TRIVIAL 
and O 
MDPV B-ABBREVIATION 
produce O 
opposite O 
electrophysiological O 
signatures O 
through O 
hDAT O 
expressed O 
in O 
oocytes O 
. O 
Implications O 
are O 
that O 
the O 
combination O 
( O 
as O 
found O 
in O 
bath O 
salts O 
) O 
might O 
produce O 
effects O 
similar O 
to O 
a O 
combination O 
of O 
methamphetamine B-TRIVIAL 
and O 
cocaine B-TRIVIAL 
. O 

acid I-FAMILY 
conversion O 
with O 
CYP105A1 O 
: O 
an O 
enzyme O 
with O 
potential O 
for O 
the O 
production O 
of O 
pharmaceutically O 
relevant O 
diterpenoids B-FAMILY 
. O 

P450s O 
are O 
very O 
versatile O 
enzymes O 
with O 
great O 
potential O 
for O 
biotechnological O 
applications O 
because O 
of O 
their O 
ability O 
to O 
oxidize O 
unactivated O 
CH B-FORMULA 
bonds O 
. O 
CYP105A1 O 
from O 
Streptomyces O 
griseolus O 
was O 
first O 
described O 
as O 
a O 
herbicide-inducible O 
sulfonylurea B-FAMILY 
hydroxylase O 
, O 
but O 
it O 
is O 
also O 
able O 
to O 
convert O 
other O 
substrates O 
such O 
as O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
. O 
To O 
extend O 
the O 
substrate O 
pool O 
of O 
this O 
interesting O 
enzyme O 
further O 
, O 
we O 
screened O 
a O 
small O 
diterpenoid B-FAMILY 
compound O 
library O 
and O 
were O 
able O 
to O 
show O 
the O 
conversion O 
of O 
several O 
resin B-FAMILY 
acids I-FAMILY 
. O 
Binding O 
of O 
abietic B-TRIVIAL 
acid I-TRIVIAL 
, O 
dehydroabietic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
isopimaric B-TRIVIAL 
acid I-TRIVIAL 
to O 
the O 
active O 
site O 
was O 
assayed O 
, O 
and O 
V(max) O 
and O 
K(m) O 
values O 
were O 
calculated O 
. O 
The O 
products O 
were O 
analyzed O 
by O 
NMR O 
spectroscopy O 
and O 
identified O 
as O 
15-hydroxyabietic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
15-hydroxydehydroabietic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
15,16-epoxyisopimaric B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
As O 
the O 
observed O 
products O 
are O 
difficult O 
to O 
obtain O 
by O 
chemical O 
synthesis O 
, O 
CYP105A1 O 
has O 
proved O 
to O 
be O 
a O 
promising O 
candidate O 
for O 
biotechnological O 
applications O 
that O 
combine O 
bioconversion O 
and O 
chemical O 
synthesis O 
to O 
obtain O 
functionalized O 
resin B-FAMILY 
acids I-FAMILY 
. O 

Luminescent O 
Hydrogels O 
Containing O 
Magnetically-Aligned O 
MWCNTs- O 
Eu B-FORMULA 
(III) I-FORMULA 
Hybrids O 
. O 

anisotropic O 
emission O 
properties O 
of O 
an O 
Eu B-FORMULA 
(III) I-FORMULA 
-MWCNTs O 
- O 
based O 
nanocomposite O 
PNIPAAm O 
hydrogel O 
is O 
induced O 
upon O 
application O 
of O 
a O 
10 O 
T O 
magnetic O 
field O 
, O 
the O 
latter O 
dictating O 
the O 
alignment O 
of O 
the O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 
This O 
structuration O 
creates O 
directional O 
highways O 
for O 
light O 
to O 
be O 
preferentially O 
absorbed O 
, O 
giving O 
rise O 
to O 
orientation O 
- O 
dependent O 
light O 
emission O 
intensity O 
. O 
Thermal O 
control O 
of O 
the O 
transparency O 
of O 
the O 
aqueous O 
matrix O 
also O 
allowed O 
a O 
stimulus O 
- O 
induced O 
switching O 
of O 
the O 
materials O 
' O 
emission O 
properties O 
. O 

inactivation O 
of O 
human O 
CYP2E1 O 
by O 
phenethyl B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
, O 
a O 
naturally O 
occurring O 
chemopreventive O 
agent O 
, O 
and O 
its O 
oxidative O 
bioactivation O 
. O 

( O 
PEITC B-ABBREVIATION 
) O 
, O 
a O 
naturally O 
occurring O 
isothiocyanate B-FAMILY 
and O 
potent O 
cancer O 
chemopreventive O 
agent O 
, O 
works O 
by O 
multiple O 
mechanisms O 
, O 
including O 
the O 
inhibition O 
of O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzymes O 
, O 
such O 
as O 
CYP2E1 O 
, O 
that O 
are O 
involved O 
in O 
the O 
bioactivation O 
of O 
carcinogens O 
. O 
PEITC B-ABBREVIATION 
has O 
been O 
reported O 
to O 
be O 
a O 
mechanism O 
- O 
based O 
inactivator O 
of O 
some O 
P450s O 
. O 
We O 
describe O 
here O 
the O 
possible O 
mechanism O 
for O 
the O 
inactivation O 
of O 
human O 
CYP2E1 O 
by O 
PEITC B-ABBREVIATION 
, O 
as O 
well O 
as O 
the O 
putative O 
intermediate O 
that O 
might O 
be O 
involved O 
in O 
the O 
bioactivation O 
of O 
PEITC B-ABBREVIATION 
. O 
PEITC B-ABBREVIATION 
inactivated O 
recombinant O 
CYP2E1 O 
with O 
a O 
partition O 
ratio O 
of O 
12 O 
, O 
and O 
the O 
inactivation O 
was O 
not O 
inhibited O 
in O 
the O 
presence O 
of O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
not O 
fully O 
recovered O 
by O 
dialysis O 
. O 
The O 
inactivation O 
of O 
CYP2E1 O 
by O 
PEITC B-ABBREVIATION 
is O 
due O 
to O 
both O 
heme O 
destruction O 
and O 
protein O 
modification O 
, O 
with O 
the O 
latter O 
being O 
the O 
major O 
pathway O 
for O 
inactivation O 
. O 
GSH B-ABBREVIATION 
-adducts O 
of O 
phenethyl B-SYSTEMATIC 
isocyanate I-SYSTEMATIC 
( O 
PIC B-ABBREVIATION 
) O 
and O 
phenethylamine B-SYSTEMATIC 
were O 
detected O 
during O 
the O 
metabolism O 
by O 
CYP2E1 O 
, O 
indicating O 
formation O 
of O 
PIC B-ABBREVIATION 
as O 
a O 
reactive O 
intermediate O 
following O 
P450 O 
- O 
catalyzed O 
desulfurization O 
of O 
PEITC B-ABBREVIATION 
. O 
Surprisingly O 
, O 
PIC B-ABBREVIATION 
bound O 
covalently O 
to O 
CYP2E1 O 
to O 
form O 
protein O 
adducts O 
but O 
did O 
not O 
inactivate O 
the O 
enzyme O 
. O 
Liquid O 
chromatography O 
mass O 
spectroscopy O 
analysis O 
of O 
the O 
inactivated O 
CYP2E1 O 
apo O 
- O 
protein O 
suggests O 
that O 
a O 
reactive O 
sulfur B-SYSTEMATIC 
atom O 
generated O 
during O 
desulfurization O 
of O 
PEITC B-ABBREVIATION 
is O 
involved O 
in O 
the O 
inactivation O 
of O 
CYP2E1 O 
. O 
Our O 
data O 
suggest O 
that O 
the O 
metabolism O 
of O 
PEITC B-ABBREVIATION 
by O 
CYP2E1 O 
that O 
results O 
in O 
the O 
inactivation O 
of O 
CYP2E1 O 
may O 
occur O 
by O 
a O 
mechanism O 
similar O 
to O 
that O 
observed O 
with O 
other O 
sulfur B-SYSTEMATIC 
-containing O 
compounds O 
, O 
such O 
as O 
parathion B-TRIVIAL 
. O 
Digestion O 
of O 
the O 
inactivated O 
enzyme O 
and O 
analysis O 
by O 
SEQUEST O 
showed O 
that O 
Cys B-FORMULA 
268 O 
may O 
be O 
the O 
residue O 
modified O 
by O 
PIC B-ABBREVIATION 
. O 

- O 
enzyme O 
frameworks O 
: O 
role O 
of O 
metal O 
ions O 
in O 
promoting O 
enzyme O 
self O 
- O 
assembly O 
on O 
α-zirconium B-SYSTEMATIC 
(IV) I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
nanoplates O 
. O 

, O 
an O 
ion O 
- O 
coupled O 
protein O 
binding O 
( O 
ICPB O 
) O 
model O 
was O 
proposed O 
to O 
explain O 
the O 
thermodynamics O 
of O 
protein O 
binding O 
to O 
negatively O 
charged O 
α-Zr B-SYSTEMATIC 
(IV) I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
α-ZrP B-SYSTEMATIC 
) O 
. O 
This O 
model O 
is O 
tested O 
here O 
using O 
glucose B-TRIVIAL 
oxidase O 
( O 
GO O 
) O 
and O 
met O 
- O 
hemoglobin O 
( O 
Hb O 
) O 
and O 
several O 
cations O 
( O 
Zr B-FORMULA 
(IV) I-FORMULA 
, O 
Cr B-FORMULA 
(III) I-FORMULA 
, O 
Au B-FORMULA 
(III) I-FORMULA 
, O 
Al B-FORMULA 
(III) I-FORMULA 
, O 
Ca B-FORMULA 
(II) I-FORMULA 
, O 
Mg B-FORMULA 
(II) I-FORMULA 
, O 
Zn B-FORMULA 
(II) I-FORMULA 
, O 
Ni B-FORMULA 
(II) I-FORMULA 
, O 
Na B-FORMULA 
(I) I-FORMULA 
, O 
and O 
H B-FORMULA 
(I) I-FORMULA 
) O 
. O 
The O 
binding O 
constant O 
of O 
GO O 
with O 
α-ZrP B-SYSTEMATIC 
was O 
increased O 
∼380-fold O 
by O 
the O 
addition O 
of O 
either O 
1 O 
mM O 
Zr B-FORMULA 
(IV) I-FORMULA 
or O 
1 O 
mM O 
Ca B-FORMULA 
(II) I-FORMULA 
, O 
and O 
affinities O 
followed O 
the O 
trend O 
Zr B-FORMULA 
(IV) I-FORMULA 
≃ O 
Ca B-FORMULA 
(II) I-FORMULA 
> O 
Cr B-FORMULA 
(III) I-FORMULA 
> O 
Mg B-FORMULA 
(II) I-FORMULA 
≫ O 
H B-FORMULA 
(I) I-FORMULA 
> O 
Na B-FORMULA 
(I) I-FORMULA 
. O 
Binding O 
studies O 
could O 
not O 
be O 
conducted O 
with O 
Au B-FORMULA 
(III) I-FORMULA 
, O 
Al B-FORMULA 
(III) I-FORMULA 
, O 
Zn B-FORMULA 
(II) I-FORMULA 
, O 
Cu B-FORMULA 
(II) I-FORMULA 
, O 
and O 
Ni B-FORMULA 
(II) I-FORMULA 
, O 
as O 
these O 
precipitated O 
both O 
proteins O 
. O 
Zr B-FORMULA 
(IV) I-FORMULA 
increased O 
Hb O 
binding O 
constant O 
to O 
α-ZrP B-SYSTEMATIC 
by O 
43-fold O 
, O 
and O 
affinity O 
enhancements O 
followed O 
the O 
trend O 
Zr B-FORMULA 
(IV) I-FORMULA 
> O 
H B-FORMULA 
(I) I-FORMULA 
> O 
Mg B-FORMULA 
(II) I-FORMULA 
> O 
Na B-FORMULA 
(I) I-FORMULA 
> O 
Ca B-FORMULA 
(II) I-FORMULA 
> O 
Cr B-FORMULA 
(III) I-FORMULA 
. O 
Zeta O 
potential O 
studies O 
clearly O 
showed O 
metal O 
ion O 
binding O 
to O 
α-ZrP B-SYSTEMATIC 
and O 
affinities O 
followed O 
the O 
trend O 
, O 
Zr B-FORMULA 
(IV) I-FORMULA 
≫ O 
Cr B-FORMULA 
(III) I-FORMULA 
> O 
Zn B-FORMULA 
(II) I-FORMULA 
> O 
Ni B-FORMULA 
(II) I-FORMULA 
> O 
Mg B-FORMULA 
(II) I-FORMULA 
> O 
Ca B-FORMULA 
(II) I-FORMULA 
> O 
Au B-FORMULA 
(III) I-FORMULA 
> O 
Na B-FORMULA 
(I) I-FORMULA 
> O 
H B-FORMULA 
(I) I-FORMULA 
. O 
Electron O 
microscopy O 
showed O 
highly O 
ordered O 
structures O 
of O 
protein O 
/ O 
metal/ O 
α-ZrP B-SYSTEMATIC 
intercalates O 
on O 
micrometer O 
length O 
scales O 
, O 
and O 
protein O 
intercalation O 
was O 
also O 
confirmed O 
by O 
powder O 
X-ray O 
diffraction O 
. O 
Specific O 
activities O 
of O 
GO/ O 
Zr B-FORMULA 
(IV) I-FORMULA 
/ O 
α-ZrP B-SYSTEMATIC 
and O 
Hb/ O 
Zr B-FORMULA 
(IV) I-FORMULA 
/ O 
α-ZrP B-SYSTEMATIC 
ternary O 
complexes O 
were O 
2 O 
× O 
10(-3) O 
and O 
6.5 O 
× O 
10(-4) O 
M(-1) O 
s(-1) O 
, O 
respectively O 
. O 
While O 
activities O 
of O 
all O 
GO O 
/ O 
cation/ O 
α-ZrP B-SYSTEMATIC 
samples O 
were O 
comparable O 
, O 
those O 
of O 
Hb O 
/ O 
cation/ O 
α-ZrP B-SYSTEMATIC 
followed O 
the O 
trend O 
Mg B-FORMULA 
(II) I-FORMULA 
> O 
Na B-FORMULA 
(I) I-FORMULA 
> O 
H B-FORMULA 
(I) I-FORMULA 
> O 
Cr B-FORMULA 
(III) I-FORMULA 
> O 
Ca B-FORMULA 
(II) I-FORMULA 
≃ O 
Zr B-FORMULA 
(IV) I-FORMULA 
. O 
Metal O 
ions O 
enhanced O 
protein O 
binding O 
by O 
orders O 
of O 
magnitude O 
, O 
as O 
predicted O 
by O 
the O 
ICPB O 
model O 
, O 
and O 
binding O 
enhancements O 
depended O 
on O 
charge O 
as O 
well O 
as O 
the O 
phosphophilicity O 
/ O 
oxophilicity O 
of O 
the O 
cation O 
. O 

- O 
diffusion O 
framework O 
: O 
the O 
mechanism O 
of O 
the O 
polymorphic O 
transition O 
of O 
α- B-MULTIPLE 
to I-MULTIPLE 
β-cobalt I-MULTIPLE 
hydroxide I-MULTIPLE 
. O 

new O 
and O 
simple O 
method O 
is O 
proposed O 
to O 
explore O 
the O 
mechanism O 
of O 
the O 
intercalation O 
/ O 
deintercalation O 
of O 
a O 
variety O 
of O 
anions O 
throughout O 
the O 
formation O 
of O 
α-Co(OH)2 B-FORMULA 
crystals O 
and O 
their O 
polymorphic O 
conversion O 
to O 
β-Co(OH)2 B-FORMULA 
. O 
This O 
method O 
is O 
based O 
on O 
the O 
reaction O 
- O 
diffusion O 
of O 
hydroxide B-SYSTEMATIC 
ions O 
in O 
a O 
gel O 
matrix O 
containing O 
the O 
cobalt B-SYSTEMATIC 
salt O 
. O 
The O 
spatiotemporal O 
evolution O 
of O 
each O 
polymorph O 
and O 
their O 
interaction O 
is O 
revealed O 
by O 
tracking O 
the O 
location O 
of O 
the O 
two O 
sharp O 
interfaces O 
between O 
the O 
two O 
polymorphs O 
( O 
conversion O 
zone O 
) O 
and O 
between O 
the O 
gel O 
and O 
α-Co(OH)2 B-FORMULA 
( O 
formation O 
zone O 
) O 
and O 
by O 
measuring O 
the O 
weight O 
composition O 
of O 
each O 
zone O 
. O 
We O 
thereby O 
find O 
that O 
the O 
dynamics O 
of O 
the O 
transformation O 
reaction O 
are O 
correctly O 
described O 
by O 
the O 
two O 
- O 
dimensional O 
Avrami-Erofe'ev O 
equation O 
at O 
different O 
temperatures O 
. O 
The O 
data O 
suggest O 
that O 
the O 
structural O 
redistribution O 
of O 
the O 
atoms O 
inside O 
the O 
α-Co(OH)2 B-FORMULA 
particles O 
plays O 
the O 
fundamental O 
role O 
in O 
establishing O 
the O 
overall O 
rate O 
of O 
the O 
reaction O 
. O 
On O 
the O 
other O 
hand O 
, O 
we O 
notice O 
that O 
other O 
factors O 
such O 
as O 
the O 
nature O 
of O 
the O 
intercalated O 
anions O 
and O 
the O 
concentration O 
of O 
the O 
polymer O 
matrix O 
alter O 
considerably O 
the O 
final O 
rate O 
of O 
the O 
transition O 
reaction O 
through O 
increasing O 
the O 
stability O 
of O 
the O 
α O 
phase O 
. O 

Infrared O 
Reflection O 
Absorption O 
Spectroscopy O 
( O 
PM-IRRAS O 
) O 
was O 
employed O 
to O 
observe O 
the O 
changes O 
in O 
the O 
molecular O 
conformation O 
of O 
poly(2-phenyl-1,4-xylylene) B-SYSTEMATIC 
( O 
PPPX B-ABBREVIATION 
) O 
films O 
that O 
occurred O 
after O 
exposure O 
to O 
organic O 
solvent O 
vapors O 
. O 
The O 
PPPX B-ABBREVIATION 
films O 
were O 
supported O 
on O 
solid O 
matrixes O 
by O 
casting O 
, O 
spin O 
- O 
coating O 
, O 
and O 
Langmuir-Blodgett O 
( O 
LB O 
) O 
techniques O 
. O 
The O 
results O 
show O 
that O 
the O 
polymer O 
is O 
sensitive O 
to O 
the O 
solvent O 
vapors O 
, O 
which O 
affect O 
some O 
of O 
the O 
vibration O 
dipole O 
moments O 
, O 
as O 
detected O 
by O 
PM-IRRAS O 
. O 
The O 
sensitivity O 
depends O 
on O 
the O 
method O 
employed O 
to O 
immobilize O 
the O 
polymer O 
, O 
with O 
more O 
significant O 
changes O 
in O 
films O 
formed O 
using O 
techniques O 
that O 
result O 
in O 
a O 
less O 
systematically O 
organized O 
conformation O 
. O 
This O 
feature O 
enables O 
the O 
use O 
of O 
surface O 
vibration O 
spectroscopy O 
to O 
detect O 
organic O 
solvent O 
vapors O 
and O 
may O 
be O 
applied O 
in O 
an O 
artificial O 
nose O 
. O 

lignans B-FAMILY 
-loaded O 
enteric O 
nanoparticles O 
: O 
preparation O 
, O 
characterization O 
, O 
and O 
in O 
vitro O 
- O 
in O 
vivo O 
evaluation O 
. O 

lignans B-FAMILY 
( O 
SL O 
) O 
have O 
been O 
well O 
proven O 
to O 
possess O 
hepatoprotective O 
effect O 
against O 
the O 
hepatic O 
dysfunction O 
induced O 
by O 
various O 
chemical O 
hepatotoxins O 
. O 
Deoxyschisandrin B-TRIVIAL 
( O 
DA O 
) O 
and O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
( O 
SA O 
) O 
are O 
both O 
considered O 
as O 
the O 
major O 
active O 
components O 
in O 
SL O 
. O 
The O 
objective O 
of O 
the O 
study O 
was O 
to O 
prepare O 
and O 
evaluate O 
Schisandra O 
lignans B-FAMILY 
( O 
composed O 
of O 
DA O 
and O 
SA)-loaded O 
enteric O 
nanoparticles O 
produced O 
by O 
a O 
novel O 
toxic O 
solvent-free O 
modified O 
spontaneous O 
emulsification O 
solvent O 
diffusion O 
( O 
SESD O 
) O 
method O 
. O 
An O 
organic O 
Schisandra O 
lignans B-FAMILY 
/ O 
Eudragit B-TRIVIAL 
( O 
® O 
) O 
S100 O 
solution O 
was O 
injected O 
into O 
an O 
aqueous O 
poloxamer B-TRIVIAL 
188 I-TRIVIAL 
solution O 
under O 
a O 
agitation O 
. O 
The O 
nanoparticles O 
were O 
characterized O 
with O 
respect O 
to O 
particle O 
size O 
distribution O 
, O 
morphology O 
, O 
encapsulation O 
efficiency O 
( O 
EE O 
) O 
and O 
physical O 
stability O 
of O 
the O 
drug O 
, O 
wettability O 
, O 
in O 
vitro O 
release O 
and O 
in O 
vivo O 
bioavailability O 
. O 
Nanoparticles O 
with O 
a O 
smooth O 
surface O 
and O 
dense O 
structure O 
were O 
obtained O 
with O 
high O 
EE O 
( O 
EE(DA) O 
> O 
90% O 
; O 
EE(SA) O 
> O 
85% O 
) O 
. O 
The O 
drug O 
was O 
in O 
a O 
noncrystalline O 
state O 
in O 
the O 
matrix O 
and O 
physically O 
stable O 
for O 
120 O 
days O 
at O 
room O 
temperature O 
. O 
In O 
vitro O 
drug O 
release O 
study O 
, O 
the O 
drug O 
dissolution O 
rate O 
from O 
the O 
nanoparticles O 
was O 
significantly O 
enhanced O 
compared O 
to O 
the O 
physical O 
mixture O 
and O 
to O 
the O 
pure O 
drug O 
; O 
the O 
release O 
profile O 
of O 
the O 
nanoparticles O 
was O 
stable O 
after O 
120 O 
days O 
. O 
The O 
appropriate O 
size O 
of O 
nanoparticles O 
( O 
~93 O 
nm O 
) O 
, O 
the O 
solubilization O 
of O 
the O 
surfactant O 
, O 
the O 
noncrystalline O 
state O 
of O 
the O 
drug O 
in O 
the O 
matrix O 
and O 
the O 
fast O 
dissolution O 
rate O 
contributed O 
to O 
a O 
significantly O 
enhanced O 
oral O 
bioavailability O 
from O 
the O 
nanoparticles O 
when O 
compared O 
to O 
pure O 
drug O 
suspension O 
. O 

of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
in O 
high O 
sodium B-SYSTEMATIC 
and O 
calcium B-SYSTEMATIC 
brine O 
at O 
high O 
temperatures O 
with O 
adsorbed O 
sulfonated O 
copolymers O 
. O 

series O 
of O 
sulfonated O 
random O 
and O 
block O 
copolymers O 
were O 
adsorbed O 
on O 
the O 
surface O 
of O 
~100 O 
nm O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
IO O 
) O 
nanoparticles O 
( O 
NPs O 
) O 
to O 
provide O 
colloidal O 
stability O 
in O 
extremely O 
concentrated O 
brine O 
composed O 
of O 
8% O 
wt O 
NaCl B-FORMULA 
+ O 
2% O 
wt O 
CaCl2 B-FORMULA 
( O 
API O 
brine O 
; O 
1.4 O 
M O 
NaCl B-FORMULA 
+ O 
0.2 O 
M O 
CaCl2 B-FORMULA 
) O 
at O 
90 O 
°C O 
. O 
A O 
combinatorial O 
materials O 
chemistry O 
approach O 
, O 
which O 
employed O 
Ca(2+) B-FORMULA 
-mediated O 
adsorption O 
of O 
anionic O 
acrylic B-TRIVIAL 
acid I-TRIVIAL 
-containing O 
sulfonated O 
polymers O 
to O 
preformed O 
citrate B-FAMILY 
-stabilized O 
IO O 
nanoclusters O 
, O 
enabled O 
the O 
investigation O 
of O 
a O 
large O 
number O 
of O 
polymer O 
coatings O 
. O 
Initially O 
a O 
series O 
of O 
poly(2-methyl-2-acrylamidopropanesulfonate B-SYSTEMATIC 
- I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
acrylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
poly(AMPS-co-AA) B-SYSTEMATIC 
) O 
( O 
1 O 
: O 
8 O 
to O 
1 O 
: O 
1 O 
mol O 
: O 
mol O 
) O 
, O 
poly(styrenesulfonate B-SYSTEMATIC 
- I-SYSTEMATIC 
block I-SYSTEMATIC 
- I-SYSTEMATIC 
acrylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
2.4 O 
: O 
1 O 
mol O 
: O 
mol O 
) O 
, O 
and O 
poly(styrenesulfonate B-SYSTEMATIC 
- I-SYSTEMATIC 
alt I-SYSTEMATIC 
- I-SYSTEMATIC 
maleic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
3 O 
: O 
1 O 
mol O 
: O 
mol O 
) O 
copolymers O 
were O 
screened O 
for O 
solubility O 
in O 
API O 
brine O 
at O 
90 O 
°C O 
. O 
The O 
ratio O 
of O 
AMPS B-ABBREVIATION 
to O 
AA O 
groups O 
was O 
varied O 
to O 
balance O 
the O 
requirement O 
of O 
colloid O 
dispersibility O 
at O 
high O 
salinity O 
( O 
provided O 
by O 
AMPS B-ABBREVIATION 
) O 
against O 
the O 
need O 
for O 
anchoring O 
of O 
the O 
polymers O 
to O 
the O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
surface O 
( O 
via O 
the O 
AA O 
) O 
. O 
Steric O 
stabilization O 
of O 
IO O 
NPs O 
coated O 
with O 
poly(AMPS-co-AA) B-SYSTEMATIC 
( O 
1 O 
: O 
1 O 
mol O 
: O 
mol O 
) O 
provided O 
colloidal O 
stability O 
in O 
API O 
brine O 
at O 
room O 
temperature O 
and O 
90 O 
°C O 
for O 
up O 
to O 
1 O 
month O 
. O 
The O 
particles O 
were O 
characterized O 
before O 
and O 
after O 
coating O 
at O 
ambient O 
and O 
elevated O 
temperatures O 
by O 
a O 
variety O 
of O 
techniques O 
including O 
colloidal O 
stability O 
experiments O 
, O 
dynamic O 
light O 
scattering O 
, O 
zeta O 
potential O 
, O 
and O 
thermogravimetric O 
analysis O 
. O 

magnetic O 
field O 
improves O 
the O 
transport O 
of O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
through O 
cell O 
barriers O 
. O 

advancements O 
in O 
small O 
molecule O 
inhibitors O 
of O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
receptor O 
( O 
IGF-1R O 
) O 
tyrosine B-TRIVIAL 
kinase O 
as O 
anticancer O 
agents O 
. O 

in O 
understanding O 
of O 
the O 
genetics O 
, O 
genomics O 
, O 
biochemistry O 
and O 
the O 
pharmacology O 
of O 
cancer O 
inhuman O 
, O 
have O 
driven O 
the O 
current O 
cancer O 
chemotherapy O 
to O 
intently O 
focus O 
on O 
development O 
of O 
target O 
- O 
based O 
approaches O 
rather O 
than O 
conventional O 
approaches O 
. O 
From O 
among O 
the O 
various O 
targets O 
identified O 
, O 
validated O 
and O 
inhibited O 
at O 
different O 
hallmarks O 
of O 
cancer O 
, O 
protein O 
tyrosine B-TRIVIAL 
kinases O 
( O 
PTKs O 
) O 
have O 
been O 
exploited O 
the O 
most O 
. O 
Insulin O 
receptors O 
( O 
IRs O 
) O 
, O 
insulin O 
like O 
growth O 
factor O 
receptors O 
( O 
IGF-1R O 
) O 
and O 
their O 
hybrid O 
receptors O 
belong O 
to O 
tyrosine B-TRIVIAL 
kinase O 
receptor O 
( O 
TKR O 
) O 
family O 
, O 
constitute O 
a O 
structural O 
homology O 
among O 
them O 
and O 
generate O 
a O 
growth O 
promoting O 
IGF O 
system O 
on O 
binding O 
with O 
either O 
insulin O 
, O 
IGF-1 O 
or O 
IGF-2 O 
. O 
The O 
system O 
induces O 
the O 
mitogenic O 
effects O 
through O 
a O 
torrent O 
of O 
cell O 
signals O 
produced O 
as O 
a O 
result O 
of O 
cross O 
talk O 
with O 
other O 
growth O 
promoting O 
peptides O 
and O 
steroidal B-FAMILY 
hormones I-FAMILY 
, O 
ultimately O 
resulting O 
in O 
hijacking O 
apoptosis O 
and O 
increasing O 
cell O 
proliferation O 
and O 
cell O 
survival O 
in O 
cancer O 
cells O 
. O 
Various O 
strategies O 
such O 
as O 
anti-IGF-1R O 
antibodies O 
, O 
IGF-1 O 
mimetic O 
peptides O 
, O 
antisense O 
strategies O 
, O 
IGF-1R O 
specific O 
peptide O 
aptamers O 
, O 
targeted O 
degradation O 
of O 
IGF-1R O 
and O 
expression O 
of O 
dominant O 
negative O 
IGF-1R O 
mutants O 
have O 
been O 
explored O 
to O 
inhibit O 
the O 
IGF-1R O 
signaling O 
. O 
However O 
, O 
targeting O 
IGF-1R O 
with O 
small O 
molecules O 
has O 
gained O 
considerable O 
attention O 
in O 
last O 
few O 
years O 
due O 
to O 
their O 
ease O 
of O 
synthesis O 
, O 
ease O 
of O 
optimization O 
of O 
absorption,distribution O 
, O 
metabolism O 
, O 
excretion O 
and O 
toxicity O 
( O 
ADMET O 
) O 
parameters O 
, O 
oral O 
route O 
of O 
administration O 
, O 
lesser O 
side O 
effects O 
and O 
cost O 
effectiveness O 
. O 
The O 
present O 
review O 
provides O 
a O 
broad O 
overview O 
and O 
discusses O 
the O 
highlights O 
on O 
discoveries O 
, O 
SAR O 
studies O 
and O 
binding O 
interactions O 
of O 
small O 
molecules O 
with O 
either O 
IGF-1R O 
active O 
or O 
allosteric O 
sites O 
reported O 
till O 
date O 
. O 

the O 
efficacy O 
of O 
Ara-C B-ABBREVIATION 
through O 
conjugation O 
with O 
PAMAM B-ABBREVIATION 
dendrimer O 
and O 
linear O 
PEG B-ABBREVIATION 
: O 
a O 
comparative O 
study O 
. O 

( O 
Cytarabine B-TRIVIAL 
, O 
Ara-C B-ABBREVIATION 
) O 
is O 
a O 
key O 
drug O 
in O 
the O 
treatment O 
of O 
acute O 
myeloid O 
leukemia O 
. O 
Ara-C B-ABBREVIATION 
has O 
a O 
number O 
of O 
limitations O 
such O 
as O 
a O 
rapid O 
deactivation O 
by O 
cytidine B-TRIVIAL 
deaminase O 
leading O 
to O 
the O 
formation O 
of O 
a O 
biologically O 
inactive O 
metabolite O 
, O 
Ara-U B-ABBREVIATION 
( O 
1β-d-arabinofuranosyluracil B-SYSTEMATIC 
) O 
, O 
a O 
low O 
lipophilicity O 
, O 
and O 
fast O 
clearance O 
from O 
the O 
body O 
. O 
To O 
address O 
these O 
problems O 
, O 
we O 
developed O 
a O 
conjugate O 
in O 
which O 
hydroxyl B-SYSTEMATIC 
-terminated O 
PAMAM B-ABBREVIATION 
dendrimer O 
, O 
G4- O 
OH B-FORMULA 
[ O 
" O 
D O 
" O 
] O 
and O 
PEG B-ABBREVIATION 
were O 
used O 
as O 
carriers O 
for O 
the O 
drug O 
( O 
Ara-C B-ABBREVIATION 
) O 
. O 
The O 
conjugates O 
were O 
synthesized O 
using O 
an O 
efficient O 
multistep O 
protection O 
/ O 
deprotection O 
method O 
resulting O 
in O 
the O 
formation O 
of O 
a O 
covalent O 
bond O 
between O 
the O 
primary O 
hydroxyl B-SYSTEMATIC 
group O 
of O 
Ara-C B-ABBREVIATION 
and O 
dendrimer/ O 
PEG B-ABBREVIATION 
. O 
The O 
structure O 
, O 
physicochemical O 
properties O 
, O 
and O 
drug O 
release O 
kinetics O 
were O 
characterized O 
extensively O 
. O 
(1)H B-FORMULA 
NMR O 
and O 
MALDI-TOF O 
mass O 
spectrometry O 
suggested O 
covalent O 
attachment O 
of O 
10 O 
Ara-C B-ABBREVIATION 
molecules O 
to O 
the O 
dendrimer O 
. O 
The O 
release O 
profile O 
of O 
Ara-C B-ABBREVIATION 
in O 
human O 
plasma O 
and O 
in O 
PBS O 
buffer O 
( O 
pH O 
7.4 O 
) O 
showed O 
that O 
the O 
conjugates O 
released O 
the O 
drug O 
over O 
14 O 
days O 
in O 
PBS O 
, O 
with O 
the O 
release O 
sped O 
up O 
in O 
plasma O 
. O 
In O 
PBS O 
, O 
while O 
most O 
of O 
the O 
drug O 
is O 
released O 
from O 
PEG B-ABBREVIATION 
- O 
Ara-C B-ABBREVIATION 
, O 
the O 
dendrimer O 
continues O 
to O 
release O 
the O 
drug O 
in O 
a O 
sustained O 
fashion O 
. O 
The O 
results O 
also O 
suggested O 
that O 
the O 
formation O 
of O 
the O 
inactive O 
form O 
of O 
Ara-C B-ABBREVIATION 
( O 
Ara-U B-ABBREVIATION 
) O 
was O 
delayed O 
upon O 
conjugation O 
of O 
Ara-C B-ABBREVIATION 
to O 
the O 
polymers O 
. O 
The O 
inhibition O 
of O 
cancer O 
growth O 
by O 
the O 
dendrimer- O 
Ara-C B-ABBREVIATION 
and O 
PEG B-ABBREVIATION 
- O 
Ara-C B-ABBREVIATION 
conjugates O 
was O 
evaluated O 
in O 
A549 O 
human O 
adenocarcinoma O 
epithelial O 
cells O 
. O 
Both O 
dendrimer- O 
and O 
PEG B-ABBREVIATION 
- O 
Ara-C B-ABBREVIATION 
conjugates O 
were O 
4-fold O 
more O 
effective O 
in O 
inhibition O 
of O 
A549 O 
cells O 
compared O 
to O 
free O 
Ara-C B-ABBREVIATION 
after O 
72 O 
h O 
of O 
treatment O 
. O 

hydrotrifluoromethylation O 
of O 
unactivated O 
alkenes B-FAMILY 
. O 

visible O 
- O 
light O 
- O 
mediated O 
hydrotrifluoromethylation O 
of O 
unactivated O 
alkenes B-FAMILY 
that O 
uses O 
the O 
Umemoto O 
reagent O 
as O 
the O 
CF(3) B-FORMULA 
source O 
and O 
MeOH B-FORMULA 
as O 
the O 
reductant O 
is O 
disclosed O 
. O 
This O 
effective O 
transformation O 
operates O 
at O 
room O 
temperature O 
in O 
the O 
presence O 
of O 
5 O 
mol O 
% O 
Ru(bpy)(3)Cl(2) B-FORMULA 
; O 
the O 
process O 
is O 
characterized O 
by O 
its O 
operational O 
simplicity O 
and O 
functional O 
group O 
tolerance O 
. O 

of O 
a O 
potential O 
anti-inflammatory O 
agent O 
: O 
3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile B-SYSTEMATIC 
. O 

novel O 
derivatives O 
of O 
glycyrrhetinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
) O 
were O 
synthesized O 
and O 
evaluated O 
for O 
anti-inflammatory O 
activities O 
. O 
It O 
was O 
found O 
that O 
the O 
introduction O 
of O 
1-en-3-one B-SYSTEMATIC 
and O 
9(11),12-diene B-SYSTEMATIC 
and O 
2,20-dinitrile B-SYSTEMATIC 
functionalities O 
into O 
the O 
scaffold O 
of O 
GA O 
led O 
to O 
the O 
discovery O 
of O 
potent O 
compound O 
19 O 
for O 
inhibition O 
of O 
LPS-induced O 
NO B-FORMULA 
production O 
. O 
Furthermore O 
, O 
19 O 
effectively O 
inhibited O 
the O 
protein O 
and O 
mRNA O 
expression O 
of O 
inducible O 
NO B-FORMULA 
synthase O 
( O 
iNOS O 
) O 
and O 
the O 
mRNA O 
expression O 
of O 
TNF-α O 
, O 
IL-6 O 
, O 
and O 
IL-1β O 
in O 
LPS-stimulated O 
RAW O 
264.7 O 
macrophages O 
. O 
Mechanistically O 
, O 
19 O 
exerted O 
inhibitory O 
effects O 
on O 
the O 
activation O 
of O 
the O 
three O 
main O 
MAPKs O 
and O 
phosphorylation O 
and O 
degradation O 
of O 
IκB-α O 
, O 
as O 
well O 
as O 
the O 
ratio O 
of O 
nuclear O 
/ O 
cytosolic O 
content O 
of O 
p65 O 
. O 
Importantly O 
, O 
19 O 
significantly O 
decreased O 
the O 
mortality O 
rate O 
in O 
the O 
mouse O 
model O 
of O 
LPS-induced O 
sepsis O 
shock O 
. O 
It O 
is O 
noteworthy O 
that O 
inhibitory O 
effect O 
of O 
19 O 
on O 
NO B-FORMULA 
production O 
was O 
not O 
blocked O 
by O 
the O 
glucocorticoid O 
receptor O 
antagonist O 
mifepristone O 
, O 
indicating O 
that O 
it O 
does O 
not O 
act O 
through O 
the O 
glucocorticoid O 
receptor O 
. O 

and O 
micellar O 
mimic O 
properties O 
of O 
bile B-FAMILY 
acid I-FAMILY 
trimers O 
. O 

fan O 
- O 
shaped O 
bile B-FAMILY 
acid I-FAMILY 
trimers O 
have O 
been O 
synthesized O 
via O 
Cu B-FORMULA 
(I) I-FORMULA 
-catalyzed O 
azide-alkyne B-FAMILY 
cycloaddition O 
( O 
CuAAC O 
) O 
' O 
click O 
chemistry O 
' O 
, O 
and O 
their O 
extraction O 
experiments O 
of O 
cresol B-TRIVIAL 
red I-TRIVIAL 
sodium I-TRIVIAL 
( O 
CR O 
) O 
and O 
pyrene B-SYSTEMATIC 
were O 
investigated O 
in O 
the O 
polar O 
and O 
non-polar O 
solvents O 
, O 
respectively O 
. O 
The O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
results O 
showed O 
that O 
the O 
homogenous O 
hollow O 
capsules O 
formed O 
with O 
the O 
diameter O 
size O 
range O 
of O 
40-70 O 
nm O 
in O 
a O 
solution O 
of O 
water O 
and O 
acetone B-SYSTEMATIC 
. O 
Thus O 
the O 
amphiphilicity O 
of O 
fan O 
- O 
shaped O 
bile B-FAMILY 
acid I-FAMILY 
trimers O 
might O 
be O 
used O 
as O 
the O 
promising O 
candidate O 
in O 
biological O 
and O 
drug O 
delivery O 
applications O 
. O 

as O 
novel O 
CCR1 O 
antagonists O 
. O 

novel O 
series O 
of O 
CCR1 O 
antagonists O 
based O 
on O 
the O 
1-(4-phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanone B-SYSTEMATIC 
scaffold O 
was O 
identified O 
by O 
screening O 
a O 
compound O 
library O 
utilizing O 
CCR1-expressing O 
human O 
THP-1 O 
cells O 
. O 
SAR O 
studies O 
led O 
to O 
the O 
discovery O 
of O 
the O 
highly O 
potent O 
and O 
selective O 
CCR1 O 
antagonist O 
14 O 
( O 
CCR1 O 
binding O 
IC(50)=4 O 
nM O 
using O 
[(125)I]-CCL3 B-SYSTEMATIC 
as O 
the O 
chemokine O 
ligand O 
) O 
. O 
Compound O 
14 O 
displayed O 
promising O 
pharmacokinetic O 
and O 
toxicological O 
profiles O 
in O 
preclinical O 
species O 
. O 

of O 
monoamine B-FAMILY 
oxidase O 
by O 
phthalide B-TRIVIAL 
analogues O 
. O 

on O 
recent O 
reports O 
that O 
the O 
small O 
molecules O 
, O 
isatin B-TRIVIAL 
and O 
phthalimide B-TRIVIAL 
, O 
are O 
suitable O 
scaffolds O 
for O 
the O 
design O 
of O 
high O 
potency O 
monoamine B-FAMILY 
oxidase O 
( O 
MAO O 
) O 
inhibitors O 
, O 
the O 
present O 
study O 
examines O 
the O 
MAO O 
inhibitory O 
properties O 
of O 
a O 
series O 
of O 
phthalide B-TRIVIAL 
[ O 
2-benzofuran-1(3H)-one B-SYSTEMATIC 
] O 
analogues O 
. O 
Phthalide B-TRIVIAL 
is O 
structurally O 
related O 
to O 
isatin B-TRIVIAL 
and O 
phthalimide B-TRIVIAL 
and O 
it O 
is O 
demonstrated O 
here O 
that O 
substitution O 
at O 
C6 O 
of O 
the O 
phthalide B-TRIVIAL 
moiety O 
yields O 
compounds O 
endowed O 
with O 
high O 
binding O 
affinities O 
to O 
both O 
human O 
MAO O 
isoforms O 
. O 
Among O 
the O 
nineteen O 
homologues O 
evaluated O 
, O 
the O 
lowest O 
IC(50) O 
values O 
recorded O 
for O 
the O 
inhibition O 
of O 
MAO-A O 
and O 
-B O 
were O 
0.096 O 
and O 
0.0014 O 
μM O 
, O 
respectively O 
. O 
In O 
most O 
instances O 
, O 
C6- O 
substituted O 
phthalides B-FAMILY 
exhibit O 
MAO-B O 
specific O 
inhibition O 
. O 
Among O 
a O 
series O 
of O 
6-benzyloxyphthalides B-FAMILY 
bearing O 
substituents O 
on O 
the O 
para O 
position O 
of O 
the O 
phenyl B-SYSTEMATIC 
ring O 
the O 
general O 
order O 
of O 
potency O 
was O 
CF(3) B-FORMULA 
> O 
I B-FORMULA 
> O 
Br B-FORMULA 
> O 
Cl B-FORMULA 
> O 
F B-FORMULA 
> O 
CH(3) B-FORMULA 
> O 
H B-FORMULA 
. O 
The O 
results O 
also O 
show O 
that O 
the O 
binding O 
modes O 
of O 
representative O 
phthalides B-FAMILY 
are O 
reversible O 
and O 
competitive O 
at O 
both O 
MAO O 
isoforms O 
. O 
Based O 
on O 
these O 
data O 
, O 
C B-FORMULA 
6- O 
substituted O 
phthalides B-FAMILY 
may O 
serve O 
as O 
leads O 
for O 
the O 
development O 
of O 
therapies O 
for O 
neurodegenerative O 
disorders O 
such O 
as O 
Parkinson's O 
disease O 
. O 

, O 
crystal O 
structure O 
and O 
antibacterial O 
activity O 
of O 
new O 
highly O 
functionalized O 
ionic O 
compounds O 
based O 
on O 
the O 
imidazole B-SYSTEMATIC 
nucleus O 
. O 

new O 
highly O 
functionalized O 
imidazolium B-SYSTEMATIC 
derivatives O 
were O 
synthesized O 
, O 
via O 
appropriate O 
synthetic O 
routes O 
, O 
using O 
imidazole B-SYSTEMATIC 
, O 
1-methylimidazole B-SYSTEMATIC 
and O 
2-phenyl-1-methylimidazole B-SYSTEMATIC 
as O 
key O 
intermediates O 
. O 
The O 
antibacterial O 
activity O 
of O 
the O 
prepared O 
compounds O 
was O 
evaluated O 
against O 
: O 
Escherichia O 
coli O 
, O 
Staphylococcus O 
aureus O 
, O 
Pseudomonas O 
aeruginosa O 
and O 
Salmonella O 
thipymurium O 
using O 
disk O 
- O 
diffusion O 
and O 
MIC O 
methods O 
. O 
Crystal O 
X-ray O 
structures O 
are O 
reported O 
for O 
six O 
compounds O 
. O 

and O 
selective O 
tariquidar B-TRIVIAL 
bioisosters O 
as O 
potential O 
PET O 
radiotracers O 
for O 
imaging O 
P-gp O 
. O 

8a-d O 
have O 
been O 
designed O 
as O 
bioisosters O 
of O 
tariquidar B-TRIVIAL 
for O 
imaging O 
P-gp O 
expression O 
and O 
density O 
by O 
PET O 
. O 
The O 
results O 
displayed O 
that O 
compounds O 
8b O 
and O 
8d O 
could O 
be O 
considered O 
potential O 
P-gp O 
/ O 
BCRP O 
ligands O 
suitable O 
as O 
(11)C B-FORMULA 
and O 
(18)F B-FORMULA 
radiotracers O 
, O 
respectively O 
. O 

basis O 
for O 
autoinhibition O 
of O 
the O 
guanine B-TRIVIAL 
nucleotide I-TRIVIAL 
exchange O 
factor O 
FARP2 O 
. O 

is O 
a O 
Dbl O 
- O 
family O 
guanine B-TRIVIAL 
nucleotide I-TRIVIAL 
exchange O 
factor O 
( O 
GEF O 
) O 
that O 
contains O 
a O 
4.1 O 
, O 
ezrin O 
, O 
radixin O 
and O 
moesin O 
( O 
FERM O 
) O 
domain O 
, O 
a O 
Dbl O 
- O 
homology O 
( O 
DH O 
) O 
domain O 
and O 
two O 
pleckstrin O 
homology O 
( O 
PH O 
) O 
domains O 
. O 
FARP2 O 
activates O 
Rac1 O 
or O 
Cdc42 O 
in O 
response O 
to O 
upstream O 
signals O 
, O 
thereby O 
regulating O 
processes O 
such O 
as O 
neuronal O 
axon O 
guidance O 
and O 
bone O 
homeostasis O 
. O 
How O 
the O 
GEF O 
activity O 
of O 
FARP2 O 
is O 
regulated O 
remained O 
poorly O 
understood O 
. O 
We O 
have O 
determined O 
the O 
crystal O 
structures O 
of O 
the O 
catalytic O 
DH O 
domain O 
and O 
the O 
DH-PH-PH O 
domains O 
of O 
FARP2 O 
. O 
The O 
structures O 
reveal O 
an O 
auto O 
- O 
inhibited O 
conformation O 
in O 
which O 
the O 
GEF O 
substrate O 
- O 
binding O 
site O 
is O 
blocked O 
collectively O 
by O 
the O 
last O 
helix O 
in O 
the O 
DH O 
domain O 
and O 
the O 
two O 
PH O 
domains O 
. O 
This O 
conformation O 
is O 
stabilized O 
by O 
multiple O 
interactions O 
among O 
the O 
domains O 
and O 
two O 
well O 
- O 
structured O 
inter O 
- O 
domain O 
linkers O 
. O 
Our O 
cell O 
- O 
based O 
activity O 
assays O 
confirm O 
the O 
suppression O 
of O 
the O 
FARP2 O 
GEF O 
activity O 
by O 
these O 
auto O 
- O 
inhibitory O 
elements O 
. O 

are O 
found O 
in O 
both O 
receiving O 
and O 
drinking O 
water O 
due O 
to O 
their O 
persistent O 
release O 
in O 
waste O 
- O 
water O 
effluents O 
, O 
raising O 
concerns O 
for O 
environmental O 
and O 
human O 
health O 
. O 
Chronic O 
, O 
aqueous O 
exposure O 
of O 
zebrafish O 
( O 
Danio O 
rerio O 
) O 
to O 
environmentally O 
relevant O 
concentrations O 
of O 
acetaminophen B-TRIVIAL 
( O 
ACE B-ABBREVIATION 
) O 
, O 
venlafaxaine B-TRIVIAL 
( O 
VEN B-ABBREVIATION 
) O 
(10μgL(-1)) O 
, O 
carbamazepine B-TRIVIAL 
( O 
CBZ B-ABBREVIATION 
) O 
and O 
gemfibrozil B-TRIVIAL 
( O 
GEM B-ABBREVIATION 
) O 
( O 
0.5 O 
and O 
10μgL(-1) O 
) O 
decreased O 
reproductive O 
output O 
. O 
Atretic O 
oocytes O 
and O 
altered O 
ovarian O 
histology O 
were O 
seen O 
in O 
female O 
zebrafish O 
exposed O 
to O 
CBZ B-ABBREVIATION 
and O 
GEM B-ABBREVIATION 
, O 
suggesting O 
a O 
direct O 
effect O 
on O 
oocyte O 
development O 
that O 
may O 
account O 
for O 
the O 
reduced O 
fecundity O 
. O 
Apoptosis O 
within O 
the O 
theca O 
and O 
granulosa O 
cells O 
was O 
identified O 
in O 
exposed O 
female O 
zebrafish O 
with O 
atretic O 
oocytes O 
by O 
TUNEL O 
positive O 
staining O 
. O 
The O 
incidence O 
of O 
follicular O 
apoptosis O 
was O 
nearly O 
2-fold O 
higher O 
in O 
exposed O 
females O 
than O 
the O 
controls O 
. O 
All O 
compounds O 
significantly O 
altered O 
kidney O 
proximal O 
tubule O 
morphology O 
but O 
there O 
was O 
no O 
difference O 
in O 
the O 
incidence O 
of O 
apoptotic O 
cells O 
within O 
the O 
kidney O 
between O 
control O 
and O 
exposed O 
in O 
either O 
males O 
or O 
females O 
. O 
Liver O 
histology O 
was O 
altered O 
by O 
ACE B-ABBREVIATION 
and O 
GEM B-ABBREVIATION 
exposure O 
. O 
Parental O 
exposure O 
to O 
pharmaceuticals O 
did O 
not O 
increase O 
developmental O 
abnormalities O 
, O 
hatching O 
success O 
, O 
or O 
mortality O 
in O 
embryos O 
. O 
Yet O 
, O 
direct O 
exposure O 
of O 
embryos O 
to O 
ACE B-ABBREVIATION 
increased O 
developmental O 
abnormalities O 
and O 
mortality O 
; O 
exposure O 
to O 
0.5μgL(-1) O 
of O 
all O 
pharmaceuticals O 
increased O 
mortality O 
. O 
CBZ B-ABBREVIATION 
decreased O 
plasma O 
11-ketotestosterone B-SYSTEMATIC 
concentrations O 
in O 
males O 
and O 
females O 
. O 
Overall O 
, O 
these O 
data O 
suggest O 
that O 
low O 
concentration O 
, O 
chronic O 
exposure O 
of O 
fish O 
to O 
pharmaceuticals O 
impacts O 
fish O 
development O 
as O 
well O 
as O 
multiple O 
organ O 
systems O 
in O 
adult O 
fish O 
, O 
leading O 
to O 
effects O 
on O 
reproduction O 
and O 
histology O 
of O 
liver O 
and O 
kidney O 
. O 
These O 
results O 
are O 
significant O 
in O 
understanding O 
the O 
consequences O 
of O 
chronic O 
, O 
low O 
concentration O 
pharmaceutical O 
exposure O 
to O 
fish O 
and O 
suggest O 
that O 
exposed O 
populations O 
are O 
at O 
risk O 
of O 
negative O 
impacts O 
to O 
reproduction O 
and O 
health O 
. O 

to O 
an O 
organochlorine B-FAMILY 
pesticide O 
( O 
chlordecone B-TRIVIAL 
) O 
and O 
development O 
of O 
18-month- O 
old O 
infants O 
. O 

is O 
a O 
persistent O 
organochlorine B-FAMILY 
pesticide O 
that O 
was O 
used O 
in O 
the O 
French O 
West O 
Indies O 
until O 
the O 
early O 
1990s O 
for O 
banana O 
weevil O 
borer O 
control O 
. O 
Human O 
exposure O 
to O 
this O 
chemical O 
in O 
this O 
area O 
still O 
occurs O 
nowadays O 
due O 
to O 
consumption O 
of O 
contaminated O 
food O 
. O 
Although O 
adverse O 
effects O 
on O 
neurodevelopment O 
, O 
including O 
tremors O 
and O 
memory O 
deficits O 
, O 
have O 
been O 
documented O 
in O 
experimental O 
studies O 
conducted O 
with O 
rodents O 
exposed O 
during O 
the O 
gestational O 
and O 
neonatal O 
periods O 
, O 
no O 
study O 
has O 
been O 
conducted O 
yet O 
to O 
determine O 
if O 
chlordecone B-TRIVIAL 
alters O 
child O 
development O 
. O 
This O 
study O 
examines O 
the O 
relation O 
of O 
gestational O 
and O 
postnatal O 
exposure O 
to O 
chlordecone B-TRIVIAL 
to O 
infant O 
development O 
at O 
18 O 
months O 
of O 
age O 
in O 
a O 
birth O 
- O 
cohort O 
of O 
Guadeloupean O 
children O 
. O 
In O 
a O 
prospective O 
longitudinal O 
study O 
conducted O 
in O 
Guadeloupe O 
( O 
Timoun O 
mother O 
- O 
child O 
cohort O 
study O 
) O 
, O 
exposure O 
to O 
chlordecone B-TRIVIAL 
was O 
measured O 
at O 
birth O 
from O 
an O 
umbilical O 
cord O 
blood O 
sample O 
( O 
n=141 O 
) O 
and O 
from O 
a O 
breast O 
milk O 
sample O 
collected O 
at O 
3 O 
months O 
postpartum O 
( O 
n=75 O 
) O 
. O 
Toddlers O 
were O 
assessed O 
using O 
an O 
adapted O 
version O 
of O 
the O 
Ages O 
and O 
Stages O 
Questionnaire O 
. O 
Higher O 
chlordecone B-TRIVIAL 
concentrations O 
in O 
cord O 
blood O 
were O 
associated O 
with O 
poorer O 
fine O 
motor O 
scores O 
. O 
When O 
analyses O 
were O 
conducted O 
separately O 
for O 
boys O 
and O 
girls O 
, O 
this O 
effect O 
was O 
only O 
observed O 
among O 
boys O 
. O 
These O 
results O 
suggest O 
that O 
prenatal O 
exposure O 
to O 
chlordecone B-TRIVIAL 
is O 
associated O 
with O 
specific O 
impairments O 
in O 
fine O 
motor O 
function O 
in O 
boys O 
, O 
and O 
add O 
to O 
the O 
growing O 
evidence O 
that O 
exposure O 
to O 
organochlorine B-FAMILY 
pesticides O 
early O 
in O 
life O 
impairs O 
child O 
development O 
. O 

of O 
novel O 
16-spiro B-FAMILY 
steroids I-FAMILY 
: O 
Spiro-7'-(aryl)tetrahydro-1H-pyrrolo[1,2-c][1,3]thiazolo-trans-androsterone B-FAMILY 
hybrid O 
heterocycles O 
. O 

1,3-dipolar O 
cycloaddition O 
of O 
azomethine B-SYSTEMATIC 
ylide O 
derived O 
in O 
situ O 
from O 
the O 
reaction O 
of O 
acenaphthylene-1,2-dione B-SYSTEMATIC 
and O 
1,3-thiazolane-4-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
to O 
various O 
exocyclic O 
dipolarophiles O 
synthesized O 
from O 
trans-androsterone B-SYSTEMATIC 
and O 
trans-dehydroandrosterone B-SYSTEMATIC 
afforded O 
a O 
library O 
of O 
novel O 
spiro[5'.2″]acenaphthylene-1″-one-spiro[16.6']-(7'-aryl)-tetrahydro-1H-pyrrolo B-FAMILY 
[1,2-c][1,3]thiazolo-trans-androsterone I-FAMILY 
/ O 
dehydroandrosterone B-SYSTEMATIC 
hybrid O 
heterocycles O 
respectively O 
. O 
These O 
reactions O 
proceeded O 
stereo O 
- O 
specifically O 
affording O 
a O 
single O 
isomer O 
of O 
the O 
16-spiro B-FAMILY 
steroids I-FAMILY 
in O 
excellent O 
yields O 
. O 

involvement O 
in O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
1 O 
signaling O 
of O 
topoisomerase O 
I-dependent O 
DNA O 
damage O 
in O 
carcinoma O 
cells O 
. O 

polymerase O 
1 O 
( O 
PARP-1 O 
) O 
inhibitors O 
are O 
thought O 
as O 
breakthrough O 
for O 
cancer O 
treatment O 
in O 
solid O 
tumors O 
such O 
as O 
breast O 
cancer O 
through O 
their O 
effects O 
on O 
PARP's O 
enzymatic O 
activity O 
. O 
Our O 
previous O 
findings O 
showed O 
that O 
the O 
hydrophilic O 
PARP O 
inhibitor O 
PJ34 O 
enhances O 
the O 
sensitivity O 
of O 
p53 O 
proficient O 
MCF7 O 
breast O 
carcinoma O 
cells O 
to O 
topotecan O 
, O 
a O 
DNA O 
Topoisomerase O 
I O 
( O 
TOP O 
1 O 
) O 
inhibitor O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
combine O 
the O 
classical O 
TOP O 
1 O 
poison O 
camptothecin B-TRIVIAL 
or O 
its O 
water O 
- O 
soluble O 
derivative O 
topotecan B-TRIVIAL 
with O 
PJ34 B-IDENTIFIER 
to O 
investigate O 
the O 
potentiation O 
of O 
chemotherapeutic O 
efficiency O 
in O 
MCF7 O 
(p53(WT)) O 
, O 
MDA-MB231 O 
(p53(mut)) O 
breast O 
carcinoma O 
cells O 
and O 
SCC022 O 
(p53(null)) O 
squamous O 
carcinoma O 
cells O 
. O 
We O 
show O 
that O 
, O 
following O 
TPT B-ABBREVIATION 
- O 
PJ34 B-IDENTIFIER 
combined O 
treatment O 
, O 
MCF7 O 
cells O 
exhibit O 
apoptotic O 
death O 
while O 
MDA-MB231 O 
and O 
SCC022 O 
cells O 
are O 
more O 
resistant O 
to O 
these O 
agents O 
. O 
Specifically O 
, O 
in O 
MCF7 O 
, O 
(i) O 
PJ34 B-IDENTIFIER 
in O 
combination O 
with O 
TPT B-ABBREVIATION 
causes O 
a O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
followed O 
by O 
massive O 
apoptosis O 
; O 
(ii) O 
PJ34 B-IDENTIFIER 
addition O 
reverts O 
TPT B-ABBREVIATION 
-dependent O 
PARP-1 O 
automodification O 
and O 
triggers O 
caspase O 
- O 
dependent O 
PARP-1 O 
proteolysis O 
; O 
(iii) O 
TPT B-ABBREVIATION 
, O 
used O 
as O 
a O 
single O 
agent O 
, O 
stimulates O 
p53 O 
expression O 
while O 
in O 
combination O 
with O 
PJ34 B-IDENTIFIER 
increases O 
p53 O 
, O 
TAp63α O 
and O 
TAp63γ O 
protein O 
levels O 
with O 
a O 
concomitant O 
reduction O 
of O 
MDM2 O 
protein O 
. O 
The O 
identification O 
of O 
p63 O 
proteins O 
as O 
new O 
players O 
involved O 
in O 
the O 
cancer O 
cell O 
response O 
to O 
TPT B-ABBREVIATION 
- O 
PJ34 B-IDENTIFIER 
is O 
relevant O 
for O 
a O 
better O 
understanding O 
of O 
the O 
PARP1-dependent O 
signaling O 
of O 
DNA O 
damage O 
. O 
Furthermore O 
, O 
our O 
data O 
indicate O 
that O 
, O 
in O 
response O 
to O 
TPT B-ABBREVIATION 
- O 
PJ34 B-IDENTIFIER 
combined O 
chemotherapy O 
, O 
a O 
functional O 
cooperation O 
between O 
p53 O 
and O 
TAp63 O 
proteins O 
may O 
occur O 
and O 
be O 
essential O 
to O 
trigger O 
apoptotic O 
cell O 
death O 
. O 

from O 
the O 
rhizomes O 
of O 
Alpinia O 
japonica O 
and O 
their O 
inhibitory O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
. O 

novel O 
norsesquiterpene O 
( O 
1 O 
) O 
, O 
three O 
new O 
bisabolenes B-FAMILY 
sesquiterpenes B-FAMILY 
( O 
2-4 O 
) O 
, O 
along O 
with O 
7 O 
known O 
compounds O 
( O 
5-11 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
rhizomes O 
of O 
Alpinia O 
japonica O 
. O 
The O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
by O 
analysis O 
of O 
spectroscopic O 
data O 
. O 
The O 
absolute O 
configuration O 
of O 
C-1 O 
in O 
3 O 
was O 
deduced O 
via O 
the O 
circular O 
dichroism O 
data O 
of O 
the O 
in O 
situ O 
formed O 
[ B-FORMULA 
Rh2(OCOCF3)4 I-FORMULA 
] I-FORMULA 
complexes O 
. O 
Inhibitory O 
effects O 
of O 
the O 
isolates O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
lipopolysaccaride-activated O 
RAW264.7 O 
macrophages O 
were O 
evaluated O 
. O 
Compound O 
6 O 
showed O 
significant O 
inhibitory O 
activity O 
with O 
IC50 O 
value O 
of O 
5.3μΜ O 
, O 
and O 
compounds O 
1 O 
, O 
3 O 
, O 
5 O 
and O 
7-10 O 
exhibited O 
moderate O 
inhibitory O 
activities O 
with O 
IC50 O 
values O 
between O 
24.5 O 
and O 
46.3μM O 
. O 

modified O 
with O 
P-aminophenyl-α-d-mannopyranoside B-SYSTEMATIC 
: O 
A O 
carrier O 
for O 
targeting O 
cerebral O 
functional O 
regions O 
in O 
mice O 
. O 

of O 
intracerebral O 
functional O 
regions O 
has O 
been O 
limited O 
by O 
the O 
inability O 
to O 
transport O 
drugs O 
across O 
the O 
blood O 
- O 
brain O 
barrier O 
( O 
BBB O 
) O 
and O 
by O 
poor O 
accumulation O 
in O 
these O 
regions O 
. O 
To O 
overcome O 
these O 
hurdles O 
, O 
liposomes O 
modified O 
with O 
P-aminophenyl-α-d-mannopyranoside B-SYSTEMATIC 
( O 
MAN B-ABBREVIATION 
) O 
were O 
used O 
as O 
a O 
fluorescent O 
dye O 
carrier O 
through O 
the O 
BBB O 
and O 
used O 
the O 
specific O 
distribution O 
of O 
liposomes O 
( O 
LIP O 
) O 
modified O 
with O 
MAN B-ABBREVIATION 
( O 
MAN B-ABBREVIATION 
-LIP O 
) O 
to O 
target O 
various O 
functional O 
regions O 
of O 
the O 
brain O 
. O 
An O 
in O 
vitro O 
BBB O 
model O 
was O 
established O 
to O 
evaluate O 
the O 
transendothelial O 
ability O 
of O 
MAN B-ABBREVIATION 
-LIP O 
, O 
and O 
liposomes O 
uptake O 
by O 
C6 O 
glioma O 
cells O 
was O 
analyzed O 
by O 
flow O 
cytometry O 
and O 
live O 
cell O 
imaging O 
. O 
Liposome O 
targeting O 
was O 
evaluated O 
using O 
in O 
vivo O 
and O 
ex O 
vivo O 
imaging O 
. O 
After O 
MAN B-ABBREVIATION 
-LIP O 
administration O 
, O 
the O 
transendothelial O 
ability O 
and O 
the O 
delivery O 
of O 
fluorescent O 
dye O 
to O 
the O 
brain O 
significantly O 
increased O 
. O 
MAN B-ABBREVIATION 
-LIP O 
concentrated O 
in O 
the O 
cortex O 
at O 
4h O 
, O 
shifting O 
distribution O 
to O 
the O 
cerebellum O 
and O 
brainstem O 
at O 
12h O 
. O 
The O 
fluorescence O 
intensity O 
in O 
the O 
hippocampus O 
and O 
pontine O 
nuclei O 
remained O 
high O 
and O 
stable O 
over O 
a O 
period O 
of O 
12h O 
. O 
The O 
results O 
demonstrate O 
that O 
MAN B-ABBREVIATION 
-LIP O 
is O 
able O 
to O 
enhance O 
cellular O 
uptake O 
in O 
vitro O 
and O 
also O 
promotes O 
penetration O 
through O 
the O 
BBB O 
and O 
accumulation O 
in O 
the O 
brain O 
with O 
a O 
distinct O 
spatio O 
- O 
temporal O 
pattern O 
. O 

of O 
protein O 
tyrosine B-TRIVIAL 
phosphatases O 
in O 
spinal O 
dorsal O 
horn O 
attenuated O 
inflammatory O 
pain O 
by O 
repressing O 
Src O 
signaling O 
. O 

phosphorylation O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
subtype O 
glutamate B-TRIVIAL 
receptors O 
by O 
Src O 
- O 
family O 
protein O 
tyrosine B-TRIVIAL 
kinases O 
( O 
SFKs O 
) O 
plays O 
a O 
critical O 
role O 
in O 
spinal O 
sensitization O 
. O 
Besides O 
SFKs O 
, O 
the O 
tyrosine B-TRIVIAL 
phosphorylation O 
levels O 
of O 
proteins O 
are O 
also O 
determined O 
by O 
protein O 
tyrosine B-TRIVIAL 
phosphatases O 
( O 
PTPs O 
) O 
. O 
However O 
, O 
whether O 
PTPs O 
are O 
involved O 
in O 
spinal O 
nociceptive O 
processing O 
is O 
largely O 
unknown O 
. O 
The O 
present O 
study O 
found O 
that O 
intrathecal O 
application O 
of O 
broad O 
- O 
spectrum O 
PTPs O 
inhibitors O 
orthovanadate B-SYSTEMATIC 
or O 
Bpv B-ABBREVIATION 
( I-ABBREVIATION 
phen I-ABBREVIATION 
) I-ABBREVIATION 
generated O 
little O 
effects O 
on O 
the O 
paw O 
withdrawal O 
thresholds O 
of O 
intact O 
rats O 
to O 
Von O 
Frey O 
filament O 
stimuli O 
. O 
Although O 
the O 
basal O 
nociceptive O 
responses O 
didn't O 
require O 
the O 
involvement O 
of O 
PTPs O 
, O 
the O 
mechanical O 
allodynia O 
evoked O 
by O 
intrathecal O 
injection O 
of O 
NMDA B-ABBREVIATION 
was O 
greatly O 
attenuated O 
by O 
orthovanadate B-SYSTEMATIC 
and O 
Bpv B-ABBREVIATION 
( I-ABBREVIATION 
phen I-ABBREVIATION 
) I-ABBREVIATION 
, O 
suggesting O 
that O 
PTPs O 
activity O 
, O 
once O 
stimulated O 
by O 
NMDA B-ABBREVIATION 
receptors O 
, O 
became O 
essential O 
for O 
spinal O 
sensitization O 
. O 
Biochemical O 
analysis O 
demonstrated O 
that O 
PTPs O 
functioned O 
to O 
activate O 
SFKs O 
member O 
Src O 
and O 
promote O 
Src O 
interaction O 
with O 
NR2B O 
subunit O 
- O 
containing O 
NMDA B-ABBREVIATION 
receptors O 
( O 
NR2B O 
receptors O 
) O 
. O 
As O 
a O 
result O 
, O 
PTPs O 
inhibition O 
largely O 
suppressed O 
Src O 
- O 
mediated O 
NR2B O 
phosphorylation O 
at O 
Tyr B-FORMULA 
1472 O 
and O 
reduced O 
the O 
synaptic O 
concentration O 
of O 
NR2B O 
receptors O 
in O 
spinal O 
dorsal O 
horn O 
of O 
NMDA B-ABBREVIATION 
-treated O 
rats O 
. O 
Importantly O 
, O 
intraplantar O 
injection O 
of O 
Complete O 
Freund's O 
Adjuvant O 
( O 
CFA O 
) O 
naturally O 
activated O 
spinal O 
PTPs O 
to O 
initiate O 
Src O 
signaling O 
, O 
because O 
PTPs O 
inhibition O 
significantly O 
repressed O 
Src O 
activity O 
, O 
reduced O 
Src O 
phosphorylation O 
of O 
NR2B O 
, O 
decreased O 
NR2B O 
synaptic O 
accumulation O 
and O 
eventually O 
ameliorated O 
inflammatory O 
pain O 
. O 
These O 
data O 
indicated O 
an O 
important O 
role O 
played O 
by O 
spinal O 
PTPs O 
in O 
inducing O 
Src O 
- O 
dependent O 
NR2B O 
receptor O 
hyperfunction O 
and O 
suggested O 
that O 
PTPs O 
inhibition O 
might O 
represent O 
an O 
effective O 
strategy O 
for O 
the O 
treatment O 
of O 
inflammatory O 
pain O 
. O 

and O 
biological O 
evaluation O 
of O 
1,3,4-thiadiazole B-SYSTEMATIC 
analogues O 
as O 
novel O 
AChE O 
and O 
BuChE O 
inhibitors O 
. O 

this O 
paper O 
a O 
series O 
of O 
new O 
1,3,4-thiadiazole B-SYSTEMATIC 
derivatives O 
has O 
been O 
designed O 
, O 
synthesized O 
and O 
evaluated O 
as O 
the O 
acetyl B-SYSTEMATIC 
- O 
and O 
butyrylcholinesterase O 
inhibitors O 
. O 
Some O 
analogues O 
showed O 
promising O 
inhibition O 
of O 
both O 
enzymes O 
in O 
vitro O 
in O 
the O 
nM O 
range O 
. O 
Generally O 
, O 
inhibitory O 
potency O 
of O 
compounds O 
was O 
stronger O 
against O 
AChE O 
than O 
BuChE O 
, O 
and O 
one O 
of O 
them O 
was O 
1154-fold O 
more O 
active O 
inhibiting O 
AChE O 
( O 
IC50 O 
= O 
0.17 O 
μM O 
) O 
than O 
BuChE O 
. O 
The O 
kinetic O 
studies O 
showed O 
that O 
one O 
of O 
the O 
most O 
active O 
analogues O 
8 O 
( O 
IC50 O 
= O 
0.09 O 
μM O 
, O 
AChE O 
) O 
acted O 
as O 
a O 
non-competitive O 
AChE O 
inhibitor O 
and O 
was O 
characterized O 
by O 
the O 
high O 
selectivity O 
index O 
( O 
300 O 
) O 
. O 
The O 
other O 
derivative O 
( O 
1 O 
) O 
exhibited O 
a O 
mixed O 
- O 
type O 
of O 
AChE O 
inhibition O 
. O 
Docking O 
simulations O 
enabled O 
the O 
detection O 
of O 
key O 
binding O 
interactions O 
of O 
the O 
compounds O 
with O 
AChE O 
and O 
revealed O 
that O 
they O 
occupied O 
mainly O 
the O 
catalytic O 
active O 
site O 
. O 
The O 
scoring O 
function O 
for O 
the O 
novel O 
compounds O 
was O 
similar O 
or O 
higher O 
than O 
for O 
the O 
reference O 
inhibitor O 
. O 
Additionally O 
, O 
based O 
on O 
Lipinski O 
and O 
other O 
filters O 
, O 
the O 
drug O 
- O 
likeness O 
of O 
compounds O 
was O 
assessed O 
. O 
They O 
revealed O 
that O 
the O 
compounds O 
possess O 
properties O 
which O 
can O 
suggest O 
the O 
favourable O 
pharmacokinetics O 
in O 
the O 
human O 
body O 
after O 
oral O 
admission O 
. O 

this O 
paper O 
we O 
give O 
a O 
method O 
of O 
integrated O 
treatment O 
for O 
cancer O 
and O 
drug O 
- O 
induced O 
complications O 
in O 
the O 
process O 
of O 
cancer O 
therapy O 
through O 
dual O 
- O 
drug O 
delivery O 
system O 
( O 
DDDS O 
) O 
. O 
Two O 
hydrophilic O 
drugs O 
, O 
doxorubicin B-TRIVIAL 
( O 
an O 
antitumor O 
drug O 
) O 
and O 
verapamil B-TRIVIAL 
( O 
an O 
antiangiocardiopathy O 
drug O 
) O 
combined O 
preliminarily O 
with O 
chitosan O 
shell O 
coated O 
on O 
magnetic O 
nanoparticles O 
( O 
MNPs O 
) O 
, O 
followed O 
by O 
entrapping O 
into O 
the O 
PLGA B-ABBREVIATION 
nanoparticles O 
. O 
Further O 
modification O 
was O 
conducted O 
by O 
conjugating O 
tumor O 
- O 
targeting O 
ligand O 
, O 
cyclo(Arg-Gly-Asp-D-Phe-Lys) B-SYSTEMATIC 
(c(RGDfK)) O 
peptide O 
, O 
onto O 
the O 
end O 
carboxyl B-SYSTEMATIC 
groups O 
on O 
the O 
PLGA B-ABBREVIATION 
-NPs O 
. O 
The O 
size O 
of O 
the O 
resulting O 
cRGD- O 
DOX B-ABBREVIATION 
/ O 
VER B-ABBREVIATION 
-MNP- O 
PLGA B-ABBREVIATION 
NPs O 
was O 
approximately O 
144nm O 
under O 
simulate O 
physiological O 
environment O 
. O 
Under O 
present O 
experiment O 
condition O 
, O 
the O 
entrapment O 
efficiencies O 
of O 
DOX B-ABBREVIATION 
and O 
VER B-ABBREVIATION 
were O 
approximately O 
74.8 O 
and O 
53.2wt% O 
for O 
cRGD- O 
DOX B-ABBREVIATION 
/ O 
VER B-ABBREVIATION 
-MNP- O 
PLGA B-ABBREVIATION 
NPs O 
. O 
This O 
paper O 
contains O 
interesting O 
pilot O 
data O 
such O 
as O 
NIR-triggered O 
drug O 
release O 
, O 
in O 
vivo O 
drug O 
distribution O 
studies O 
and O 
whole O 
- O 
mouse O 
optical O 
imaging O 
. O 
Histopathological O 
examinations O 
and O 
electrocardiogram O 
comparison O 
demonstrated O 
that O 
the O 
intelligent O 
DDDS O 
could O 
markedly O 
inhibit O 
the O 
growth O 
of O 
tumor O 
and O 
potentially O 
offer O 
an O 
approach O 
for O 
safe O 
cancer O 
therapy O 
. O 

channels O 
are O 
multimeric O 
, O 
transmembrane O 
proteins O 
that O 
selectively O 
mediate O 
ion O 
flux O 
across O 
the O 
plasma O 
membrane O 
in O 
a O 
variety O 
of O 
cells O 
including O 
vascular O 
smooth O 
muscle O 
cells O 
( O 
VSMCs O 
) O 
. O 
The O 
dynamic O 
interplay O 
of O 
Ca(2+) B-FORMULA 
and O 
K(+) B-FORMULA 
channels O 
on O 
the O 
plasma O 
membrane O 
of O 
VSMCs O 
plays O 
a O 
pivotal O 
role O 
in O 
modulating O 
the O 
vascular O 
tone O 
of O 
small O 
arteries O 
and O 
arterioles O 
. O 
The O 
abnormally O 
- O 
elevated O 
arterial O 
tone O 
observed O 
in O 
hypertension O 
thus O 
points O 
to O 
an O 
aberrant O 
expression O 
and O 
function O 
of O 
Ca(2+) B-FORMULA 
and O 
K(+) B-FORMULA 
channels O 
in O 
the O 
VSMCs O 
. O 
In O 
this O 
short O 
review O 
, O 
we O 
focus O 
on O 
the O 
three O 
well O 
- O 
studied O 
ion O 
channels O 
in O 
VSMCs O 
, O 
namely O 
the O 
L- O 
type O 
Ca(2+) B-FORMULA 
( O 
CaV1.2 O 
) O 
channels O 
, O 
the O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
( O 
KV O 
) O 
channels O 
, O 
and O 
the O 
large O 
- O 
conductance O 
Ca(2+) B-FORMULA 
-activated O 
K(+) B-FORMULA 
( O 
BK O 
) O 
channels O 
. O 
First O 
, O 
we O 
provide O 
a O 
brief O 
overview O 
on O 
the O 
physiological O 
role O 
of O 
vascular O 
CaV1.2 O 
, O 
KV O 
and O 
BK O 
channels O 
in O 
regulating O 
arterial O 
tone O 
. O 
Second O 
, O 
we O 
discuss O 
the O 
current O 
understanding O 
of O 
the O 
expression O 
changes O 
and O 
regulation O 
of O 
CaV1.2 O 
, O 
KV O 
and O 
BK O 
channels O 
in O 
the O 
vasculature O 
during O 
hypertension O 
. O 
Third O 
, O 
based O 
on O 
available O 
proof O 
- O 
of O 
- O 
concept O 
studies O 
, O 
we O 
describe O 
the O 
potential O 
therapeutic O 
approaches O 
targeting O 
these O 
vascular O 
ion O 
channels O 
in O 
order O 
to O 
restore O 
blood O 
pressure O 
to O 
normotensive O 
levels O 
. O 

review O 
on O 
indole B-FAMILY 
alkaloids I-FAMILY 
isolated O 
from O 
Uncaria O 
rhynchophylla O 
and O 
their O 
pharmacological O 
studies O 
. O 

rhynchophylla O 
( O 
Miq O 
. O 
) O 
Jacks O 
, O 
Rubiaceae O 
, O 
is O 
one O 
of O 
the O 
original O 
plants O 
of O 
the O 
important O 
Chinese O 
crude O 
drug O 
, O 
Gou O 
- O 
teng O 
, O 
mainly O 
used O 
for O 
the O 
treatment O 
of O 
convulsion O 
, O 
hypertension O 
, O 
epilepsy O 
, O 
eclampsia O 
, O 
and O 
cerebral O 
diseases O 
. O 
The O 
pharmacological O 
activities O 
of O 
this O 
plant O 
are O 
related O 
to O 
the O 
presence O 
of O 
active O 
compounds O 
predominantly O 
indole B-FAMILY 
alkaloids I-FAMILY 
. O 
In O 
this O 
article O 
, O 
we O 
have O 
reviewed O 
some O 
reports O 
about O 
the O 
pharmacological O 
activities O 
of O 
the O 
main O 
indole B-FAMILY 
alkaloids I-FAMILY 
isolated O 
from O 
U O 
. O 
rhynchophylla O 
. O 
This O 
review O 
paper O 
will O 
contribute O 
to O 
the O 
studies O 
on O 
the O 
chemistry O 
, O 
safety O 
and O 
quality O 
control O 
of O 
medicinal O 
preparations O 
containing O 
Uncaria O 
species O 
. O 

vitro O 
biokinetics O 
of O 
chlorpromazine B-TRIVIAL 
and O 
the O 
influence O 
of O 
different O 
dose O 
metrics O 
on O 
effect O 
concentrations O 
for O 
cytotoxicity O 
in O 
Balb O 
/ O 
c O 
3T3 O 
, O 
Caco-2 O 
and O 
HepaRG O 
cell O 
cultures O 
. O 

extrapolation O 
of O 
in O 
vitro O 
to O 
in O 
vivo O 
toxicity O 
data O 
is O 
a O 
challenge O 
. O 
Differences O 
in O 
sensitivity O 
between O 
cell O 
systems O 
may O 
be O 
due O 
to O 
intrinsic O 
properties O 
of O 
the O 
cell O 
but O 
also O 
because O 
of O 
differences O 
in O 
exposure O 
. O 
In O 
this O 
study O 
, O 
the O 
cytotoxicity O 
and O 
biokinetics O 
of O 
the O 
antipsychotic O 
chlorpromazine B-TRIVIAL 
( O 
CPZ B-ABBREVIATION 
) O 
were O 
studied O 
in O 
in O 
vitro O 
assays O 
using O 
different O 
cell O 
types O 
and O 
exposure O 
conditions O 
. O 
Different O 
dose O 
metrics O 
were O 
assessed O 
to O 
express O 
the O 
sensitivity O 
to O 
CPZ B-ABBREVIATION 
. O 
The O 
biokinetics O 
of O 
CPZ B-ABBREVIATION 
were O 
measured O 
in O 
cell O 
cultures O 
of O 
Balb O 
/ O 
c O 
3T3 O 
, O 
Caco-2 O 
and O 
HepaRG O 
cells O 
. O 
Cytotoxicity O 
was O 
measured O 
by O 
Alamar O 
Blue O 
and O 
expressed O 
using O 
different O 
dose O 
metrics O 
, O 
including O 
the O 
nominal O 
, O 
measured O 
total O 
and O 
measured O 
free O 
CPZ B-ABBREVIATION 
medium O 
concentrations O 
. O 
CPZ B-ABBREVIATION 
was O 
taken O 
up O 
by O 
the O 
cells O 
; O 
the O 
highest O 
amounts O 
in O 
the O 
cell O 
compartments O 
were O 
found O 
in O 
the O 
Caco-2 O 
and O 
HepaRG O 
cells O 
. O 
CPZ B-ABBREVIATION 
was O 
highly O 
protein O 
- O 
bound O 
in O 
the O 
Caco-2 O 
cell O 
medium O 
containing O 
10% O 
fetal O 
bovine O 
serum O 
, O 
resulting O 
in O 
lower O 
bioavailable O 
exposure O 
concentrations O 
. O 
Moreover O 
, O 
also O 
uptake O 
into O 
the O 
cells O 
strongly O 
influenced O 
the O 
concentration O 
in O 
the O 
medium O 
. O 
The O 
Balb O 
/ O 
c O 
3T3 O 
cells O 
were O 
the O 
most O 
sensitive O 
to O 
the O 
toxic O 
effect O 
of O 
CPZ B-ABBREVIATION 
. O 
The O 
use O 
of O 
different O 
dose O 
metrics O 
influenced O 
the O 
cytotoxicity O 
results O 
found O 
in O 
the O 
three O 
cell O 
types O 
. O 
The O 
data O 
show O 
that O 
in O 
comparing O 
the O 
sensitivity O 
of O 
the O 
tested O 
cell O 
systems O 
, O 
the O 
freely O 
dissolved O 
concentration O 
is O 
a O 
more O 
appropriate O 
dose O 
metric O 
than O 
total O 
concentration O 
in O 
the O 
medium O 
. O 
The O 
ranking O 
in O 
sensitivity O 
of O 
the O 
three O 
cell O 
types O 
for O 
CPZ B-ABBREVIATION 
was O 
dependent O 
on O 
the O 
dose O 
metric O 
used O 
. O 

toxicology O 
of O 
hydrocarbons B-FAMILY 
and O 
lamp O 
oils O 
studied O 
by O 
in O 
vitro O 
technology O 
. O 

literature O 
regularly O 
reports O 
on O 
accidental O 
poisoning O 
in O 
children O 
after O 
aspiration O 
of O 
combustibles O 
such O 
as O 
lamp O 
oils O 
which O 
usually O 
contain O 
hydrocarbons B-FAMILY 
or O 
rape O 
methyl B-FAMILY 
esters I-FAMILY 
( O 
RMEs O 
) O 
. O 
We O 
aimed O 
to O 
analyze O 
the O 
toxic O 
potential O 
of O 
alkanes B-FAMILY 
and O 
different O 
combustible O 
classes O 
in O 
vitro O 
with O 
regard O 
to O 
biologic O 
responses O 
and O 
mechanisms O 
mediating O 
toxicity O 
. O 
Two O 
different O 
in O 
vitro O 
models O 
were O 
used O 
, O 
i.e O 
. O 
(i) O 
a O 
captive O 
bubble O 
surfactometer O 
( O 
CBS O 
) O 
to O 
assess O 
direct O 
influence O 
of O 
combustibles O 
on O 
biophysical O 
properties O 
of O 
surfactant O 
film O 
and O 
(ii) O 
cell O 
cultures O 
( O 
BEAS-2B O 
and O 
R3 O 
/ O 
1 O 
cells O 
, O 
primary O 
macrophages O 
, O 
re O 
- O 
differentiated O 
epithelia O 
) O 
closely O 
mimicking O 
the O 
inner O 
lung O 
surface O 
. O 
Biological O 
endpoints O 
included O 
cell O 
viability O 
, O 
cytotoxicity O 
and O 
inflammatory O 
mediator O 
release O 
. O 
CBS O 
measurements O 
demonstrate O 
that O 
combustibles O 
affect O 
film O 
dynamics O 
, O 
i.e O 
. O 
the O 
surface O 
tension O 
/ O 
area O 
characteristics O 
during O 
compression O 
and O 
expansion O 
, O 
in O 
a O 
dose O 
and O 
molecular O 
chain O 
length O 
dependent O 
manner O 
. O 
Cell O 
culture O 
results O 
confirm O 
the O 
dose O 
dependent O 
toxicity O 
. O 
Generally O 
, O 
cytotoxicity O 
and O 
cytokine O 
release O 
are O 
higher O 
in O 
short O 
- O 
chained O 
alkanes B-FAMILY 
and O 
hydrocarbon B-FAMILY 
-based O 
combustibles O 
than O 
in O 
long O 
- O 
chained O 
substances O 
, O 
e.g O 
. O 
highest O 
inducible O 
cytotoxicity O 
in O 
BEAS-2B O 
was O 
for O 
hexane B-SYSTEMATIC 
84.6% O 
, O 
decane B-SYSTEMATIC 
74% O 
and O 
hexadecane B-SYSTEMATIC 
30.8% O 
. O 
Effects O 
of O 
RME O 
- O 
based O 
combustibles O 
differed O 
between O 
the O 
cell O 
models O 
. O 
Our O 
results O 
confirm O 
data O 
from O 
animal O 
experiments O 
and O 
give O 
new O 
insights O 
into O 
the O 
mechanisms O 
underlying O 
the O 
adverse O 
health O 
effects O 
observed O 
. O 

, O 
an O 
environmental O 
estrogen B-FAMILY 
, O 
affects O 
voltage O 
- O 
gated O 
K⁺ B-FORMULA 
currents O 
and O 
L- O 
type O 
Ca²⁺ B-FORMULA 
currents O 
in O 
a O 
non-monotonic O 
manner O 
in O 
GH₃ O 
pituitary O 
cells O 
. O 

have O 
investigated O 
the O 
characteristics O 
of O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
channels O 
and O 
L- O 
type O 
Ca(2+) B-FORMULA 
channels O 
in O 
GH3 O 
rat O 
pituitary O 
cells O 
and O 
the O 
effects O 
of O 
the O 
xenoestrogen B-FAMILY 
( O 
XEs O 
) O 
nonylphenol B-SYSTEMATIC 
( O 
NP O 
) O 
on O 
these O 
ion O 
channel O 
currents O 
. O 
Our O 
results O 
have O 
shown O 
that O 
the O 
lower O 
concentrations O 
( O 
10(-15)-10(-14)M O 
) O 
of O 
NP O 
decreased O 
the O 
amplitudes O 
of O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
currents O 
( O 
IKv O 
) O 
and O 
activated O 
L- O 
type O 
Ca(2+) B-FORMULA 
currents O 
( O 
ICa-L O 
) O 
by O 
reducing O 
half O 
- O 
activation O 
membrane O 
potentials O 
of O 
activation O 
kinetics O 
curves O 
. O 
However O 
, O 
the O 
higher O 
concentrations O 
( O 
10(-10)-10(-9)M O 
) O 
of O 
NP O 
increased O 
the O 
amplitudes O 
of O 
IKv O 
and O 
inhibited O 
ICa-L O 
by O 
reducing O 
the O 
peak O 
values O 
of O 
ICa-L O 
. O 
Thus O 
, O 
NP O 
affects O 
IKv O 
and O 
ICa-L O 
in O 
an O 
opposite O 
and O 
non-monotonic O 
manner O 
. O 

induces O 
c-Myc O 
- O 
mediated O 
apoptosis O 
in O 
FRO O 
anaplastic O 
thyroid O 
carcinoma O 
cells O 
. O 

promotes O 
apoptosis O 
in O 
cancer O 
cells O 
. O 
We O 
studied O 
the O 
effect O 
of O 
apigenin B-TRIVIAL 
on O 
cell O 
survival O 
and O 
c-Myc O 
expression O 
in O 
FRO O 
anaplastic O 
thyroid O 
carcinoma O 
( O 
ATC O 
) O 
cells O 
. O 
Apigenin B-TRIVIAL 
caused O 
apoptosis O 
via O 
the O 
elevation O 
of O 
c-Myc O 
levels O 
in O 
conjunction O 
with O 
the O 
phosphorylation O 
of O 
p38 O 
and O 
p53 O 
. O 
In O 
the O 
c-Myc O 
siRNA-transfected O 
and O 
apigenin B-TRIVIAL 
-treated O 
cells O 
, O 
compared O 
with O 
the O 
apigenin B-TRIVIAL 
-treated O 
control O 
cells O 
, O 
apoptosis O 
and O 
phosphorylation O 
of O 
p38 O 
and O 
p53 O 
were O 
ameliorated O 
. O 
In O 
the O 
presence O 
of O 
apigenin B-TRIVIAL 
, O 
diminution O 
of O 
p38 O 
and O 
p53 O 
did O 
not O 
affect O 
cell O 
survival O 
although O 
apigenin B-TRIVIAL 
activated O 
the O 
phosphorylation O 
of O 
p38 O 
and O 
p53 O 
via O 
increased O 
c-Myc O 
levels O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
indicate O 
that O 
apigenin B-TRIVIAL 
induces O 
apoptosis O 
mediated O 
via O 
c-Myc O 
with O 
concomitant O 
phosphorylation O 
of O 
p53 O 
and O 
p38 O 
in O 
FRO O 
ATC O 
cells O 
. O 
These O 
findings O 
suggest O 
that O 
augmented O 
c-Myc O 
acts O 
as O 
a O 
core O 
regulator O 
and O 
is O 
necessary O 
for O 
apigenin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
FRO O 
ATC O 
cells O 
. O 

distributions O 
of O 
fluoride B-SYSTEMATIC 
and O 
its O 
toxicity O 
in O 
the O 
gills O 
of O 
a O 
freshwater O 
teleost O 
, O 
Cyprinus O 
carpio O 
. O 

take O 
up O 
fluoride O 
directly O 
from O 
water O 
and O 
are O 
susceptible O 
to O 
fluoride B-SYSTEMATIC 
contamination O 
of O 
their O 
environment O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
tissue O 
distributions O 
of O 
fluoride B-SYSTEMATIC 
and O 
its O 
toxicity O 
in O 
the O 
gills O 
of O 
the O 
common O 
carp O 
( O 
Cyprinus O 
carpio O 
) O 
chronically O 
exposed O 
to O 
fluoride B-SYSTEMATIC 
. O 
Carp O 
were O 
exposed O 
to O 
a O 
range O 
of O 
aqueous O 
fluoride B-SYSTEMATIC 
( O 
35-124 O 
mg O 
/ O 
L O 
) O 
and O 
sampled O 
at O 
30 O 
, O 
60 O 
and O 
90 O 
days O 
. O 
The O 
accumulation O 
of O 
fluoride B-SYSTEMATIC 
in O 
the O 
tissues O 
increased O 
with O 
the O 
level O 
and O 
duration O 
of O 
exposure O 
. O 
Steady O 
state O 
was O 
not O 
achieved O 
under O 
the O 
experimental O 
conditions O 
. O 
The O 
gills O 
accumulated O 
the O 
highest O 
levels O 
of O 
fluoride B-SYSTEMATIC 
followed O 
by O 
the O 
liver O 
> O 
brain O 
> O 
kidney O 
> O 
muscle O 
> O 
intestine O 
. O 
A O 
dose O 
- O 
dependent O 
inhibition O 
was O 
observed O 
for O 
the O 
enzyme O 
activities O 
of O 
Na(+) B-FORMULA 
- O 
K(+) B-FORMULA 
-ATPase O 
and O 
Ca(2+) B-FORMULA 
-ATPase O 
in O 
the O 
gills O 
after O 
the O 
fish O 
were O 
exposed O 
for O 
90 O 
days O 
. O 
Also O 
, O 
accumulation O 
of O 
fluoride B-SYSTEMATIC 
was O 
associated O 
with O 
the O 
inhibition O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
activities O 
and O 
a O 
dose O 
- O 
dependent O 
stimulation O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
levels O 
in O 
the O 
gill O 
tissues O 
, O 
suggesting O 
that O 
fluoride B-SYSTEMATIC 
promoted O 
oxidative O 
stress O 
in O 
the O 
fish O 
. O 
Microscopic O 
examinations O 
revealed O 
injuries O 
to O 
gill O 
tissues O 
and O 
chloride B-SYSTEMATIC 
cells O 
, O 
with O 
the O 
severity O 
of O 
injury O 
increasing O 
with O 
exposure O 
concentration O 
. O 
These O 
results O 
suggest O 
that O 
chronic O 
exposure O 
to O 
elevated O 
concentrations O 
of O 
fluoride B-SYSTEMATIC 
may O 
induce O 
toxicity O 
in O 
the O 
common O 
carp O 
. O 

objective O 
of O 
this O 
study O 
is O 
to O 
examine O 
the O 
toxicity O 
of O 
engineered O 
nanoparticles O 
( O 
NPs O 
) O 
that O 
are O 
dispersed O 
in O 
sea O 
water O 
by O 
using O 
an O 
in O 
vivo O 
model O 
. O 
Because O 
many O 
products O 
of O 
nanotechnology O 
contain O 
NPs O 
and O 
are O 
commonly O 
used O 
and O 
well O 
- O 
established O 
in O 
the O 
market O 
, O 
the O 
accidental O 
release O 
of O 
NPs O 
into O 
the O 
air O 
and O 
water O 
is O 
quite O 
possible O 
. O 
Indeed O 
, O 
at O 
the O 
end O 
of O 
their O 
life O 
cycle O 
, O 
some O 
NPs O 
are O 
inevitably O 
released O 
into O 
waste O 
water O 
and O 
can O 
reach O 
marine O 
ecosystem O 
and O 
affect O 
the O 
organisms O 
there O 
. O 
Although O 
there O 
are O 
few O 
data O 
on O 
the O 
presence O 
of O 
NPs O 
in O 
the O 
marine O 
environment O 
, O 
our O 
awareness O 
of O 
their O 
potential O 
impact O 
on O 
environmental O 
and O 
organismal O 
health O 
is O 
growing O 
. O 
Shallow O 
- O 
water O 
benthonic O 
organisms O 
such O 
as O 
sea O 
urchins O 
provide O 
planktonic O 
larvae O 
as O 
a O 
trophic O 
base O 
for O 
finfish O 
juveniles O 
and O 
are O 
exposed O 
to O 
water O 
from O 
estuaries O 
and O 
precipitation O 
. O 
Such O 
organisms O 
can O 
therefore O 
be O 
directly O 
affected O 
by O 
NPs O 
that O 
are O 
dispersed O 
into O 
those O 
media O 
. O 
We O 
evaluated O 
the O 
effects O 
of O 
exposure O 
to O 
different O 
concentrations O 
of O 
nanosilver O 
, O 
titanium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
cobalt B-SYSTEMATIC 
NPs O 
on O 
the O 
sperm O 
of O 
the O 
sea O 
urchin O 
Paracentrotus O 
lividus O 
by O 
analyzing O 
the O 
functionality O 
and O 
the O 
morphology O 
and O 
biochemistry O 
of O 
the O 
first O 
developmental O 
stages O 
of O 
the O 
sea O 
urchin O 
. O 
Sperm O 
were O 
exposed O 
to O 
sea O 
water O 
containing O 
suspensions O 
of O 
NPs O 
ranging O 
from O 
0.0001 O 
mg O 
/ O 
L O 
to O 
1 O 
mg O 
/ O 
L O 
. O 
Fertilization O 
ability O 
was O 
not O 
affected O 
, O 
but O 
developmental O 
anomalies O 
were O 
identified O 
in O 
embryos O 
from O 
the O 
gastrula O 
to O 
pluteus O 
stages O 
, O 
including O 
morphological O 
alterations O 
of O 
the O 
skeletal O 
rods O 
. O 
In O 
addition O 
, O 
the O 
enzymatic O 
activity O 
( O 
cholinesterase O 
, O 
ChE O 
) O 
of O 
the O 
larvae O 
was O 
measured O 
. O 
Acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
propionylcholinesterase O 
activity O 
( O 
PrChE O 
) O 
was O 
affected O 
in O 
all O 
of O 
the O 
exposed O 
samples O 
. O 
The O 
results O 
did O 
not O 
vary O 
consistently O 
with O 
the O 
concentration O 
of O 
NP O 
, O 
but O 
controls O 
were O 
significantly O 
different O 
from O 
exposed O 
samples O 
. O 
Exposure O 
of O 
sea O 
urchin O 
to O 
these O 
NPs O 
may O 
cause O 
neurotoxic O 
damage O 
, O 
and O 
the O 
altered O 
ChE O 
activity O 
may O 
be O 
involved O 
in O 
skeletogenic O 
aberrations O 
. O 
In O 
conclusion O 
, O 
the O 
sea O 
urchin O 
represents O 
a O 
suitable O 
and O 
sensitive O 
model O 
for O 
testing O 
the O 
toxicity O 
and O 
effects O 
of O 
engineered O 
NPs O 
that O 
are O 
dispersed O 
in O 
sea O 
water O 
. O 

of O 
the O 
effects O 
of O 
the O 
GABAB O 
receptor O 
positive O 
modulator O 
BHF177 B-IDENTIFIER 
and O 
the O 
GABAB O 
receptor O 
agonist O 
baclofen B-TRIVIAL 
on O 
anxiety O 
- O 
like O 
behavior O 
, O 
learning O 
, O 
and O 
memory O 
in O 
mice O 
. O 

acid I-SYSTEMATIC 
B O 
( O 
GABAB O 
) O 
receptor O 
activation O 
is O 
a O 
potential O 
therapeutic O 
approach O 
for O 
the O 
treatment O 
of O 
drug O 
addiction O 
, O 
pain O 
, O 
anxiety O 
, O 
and O 
depression O 
. O 
However O 
, O 
full O 
agonists O 
of O 
this O 
receptor O 
induce O 
side-effects O 
, O 
such O 
as O 
sedation O 
, O 
muscle O 
relaxation O 
, O 
tolerance O 
, O 
and O 
cognitive O 
disruption O 
. O 
Positive O 
allosteric O 
modulators O 
( O 
PAMs O 
) O 
of O 
the O 
GABAB O 
receptor O 
may O 
have O 
similar O 
therapeutic O 
effects O 
as O 
agonists O 
with O 
superior O 
side-effect O 
profiles O 
. O 
The O 
present O 
study O 
behaviorally O 
characterized O 
N-([1R,2R,4S]-bicyclo[2.2.1]hept-2-yl)-2-methyl-5-(4-[trifluoromethyl]phenyl)-4-pyrimidinamine B-SYSTEMATIC 
( O 
BHF177 B-IDENTIFIER 
) O 
, O 
a O 
GABAB O 
receptor O 
PAM O 
, O 
in O 
mouse O 
models O 
of O 
anxiety O 
- O 
like O 
behavior O 
, O 
learning O 
and O 
memory O 
. O 
In O 
addition O 
, O 
the O 
effects O 
of O 
BHF177 B-IDENTIFIER 
were O 
compared O 
with O 
the O 
agonist O 
baclofen B-TRIVIAL 
. O 
Unlike O 
the O 
anxiolytic O 
chlordiazepoxide B-TRIVIAL 
, O 
baclofen B-TRIVIAL 
( O 
0.5 O 
, O 
1.5 O 
, O 
and O 
2.5 O 
mg O 
/ O 
kg O 
, O 
intraperitoneally O 
) O 
and O 
BHF177 B-IDENTIFIER 
( O 
10 O 
, O 
20 O 
, O 
and O 
40 O 
mg O 
/ O 
kg O 
, O 
orally O 
) O 
had O 
no O 
effect O 
on O 
anxiety O 
- O 
like O 
behavior O 
in O 
the O 
elevated O 
plus O 
maze O 
, O 
light O 
/ O 
dark O 
box O 
, O 
or O 
Vogel O 
conflict O 
test O 
. O 
Baclofen B-TRIVIAL 
increased O 
punished O 
drinking O 
in O 
the O 
Vogel O 
conflict O 
test O 
, O 
but O 
this O 
effect O 
may O 
be O 
attributable O 
to O 
the O 
analgesic O 
actions O 
of O 
baclofen B-TRIVIAL 
. O 
At O 
the O 
highest O 
dose O 
tested O 
( O 
2.5 O 
mg O 
/ O 
kg O 
) O 
, O 
baclofen B-TRIVIAL 
-treated O 
mice O 
exhibited O 
sedation O 
- O 
like O 
effects O 
( O 
i.e O 
. O 
, O 
reduced O 
locomotor O 
activity O 
) O 
across O 
many O 
of O 
the O 
tests O 
, O 
whereas O 
BHF177 B-IDENTIFIER 
-treated O 
mice O 
exhibited O 
no O 
sedation O 
- O 
like O 
effects O 
. O 
BHF177 B-IDENTIFIER 
exhibited O 
pro O 
- O 
convulsion O 
properties O 
only O 
in O 
mice O 
, O 
but O 
not O 
in O 
rats O 
, O 
indicating O 
that O 
this O 
effect O 
may O 
be O 
species O 
- O 
specific O 
. O 
At O 
doses O 
that O 
were O 
not O 
sedative O 
or O 
pro O 
- O 
convulsant O 
, O 
baclofen B-TRIVIAL 
and O 
BHF177 B-IDENTIFIER 
had O 
no O 
selective O 
effects O 
on O 
fear O 
memory O 
retrieval O 
in O 
contextual O 
and O 
cued O 
fear O 
conditioning O 
or O 
spatial O 
learning O 
and O 
memory O 
in O 
the O 
Barnes O 
maze O 
. O 
These O 
data O 
suggest O 
that O 
BHF177 B-IDENTIFIER 
has O 
little O 
sedative O 
activity O 
, O 
no O 
anxiolytic O 
- O 
like O 
profile O 
, O 
and O 
minimal O 
impairment O 
of O 
learning O 
and O 
memory O 
in O 
mice O 
. O 

study O 
presents O 
a O 
consumer O 
and O 
farmer O 
safety O 
evaluation O 
on O 
the O 
use O 
of O 
four O 
botanical O 
pesticides O 
in O 
pepper O 
berry O 
crop O 
protection O 
. O 
The O 
pesticides O 
evaluated O 
include O 
preparations O 
from O 
clove O 
, O 
tuba O 
root O 
, O 
sweet O 
flag O 
and O 
pyrethrum O 
. O 
Their O 
safety O 
evaluation O 
was O 
based O 
on O 
their O 
active O 
ingredients O 
being O 
eugenol B-TRIVIAL 
, O 
rotenone B-TRIVIAL 
, O 
β-asarone B-TRIVIAL 
and O 
pyrethrins B-FAMILY 
, O 
respectively O 
. O 
Botanical O 
pesticides O 
from O 
Acorus O 
calamus O 
are O 
of O 
possible O 
concern O 
because O 
of O 
the O 
genotoxic O 
and O 
carcinogenic O 
ingredient O 
β-asarone B-TRIVIAL 
although O 
estimated O 
margins O 
of O 
exposure O 
( O 
MOE O 
) O 
for O 
consumers O 
indicate O 
a O 
low O 
priority O 
for O 
risk O 
management O 
. O 
For O 
the O 
other O 
three O 
botanical O 
pesticides O 
the O 
margin O 
of O 
safety O 
( O 
MOS O 
) O 
between O 
established O 
acute O 
reference O 
doses O 
and O 
/ O 
or O 
acceptable O 
daily O 
intake O 
values O 
and O 
intake O 
estimates O 
for O 
the O 
consumer O 
, O 
resulting O 
from O 
their O 
use O 
as O 
a O 
botanical O 
pesticide O 
are O 
not O 
of O 
safety O 
concern O 
, O 
with O 
the O 
exception O 
for O 
levels O 
of O 
rotenone B-TRIVIAL 
upon O 
use O 
of O 
tuba O 
root O 
extracts O 
on O 
stored O 
berries O 
. O 
Used O 
levels O 
of O 
clove O 
and O 
pyrethrum O 
as O 
botanical O 
pesticides O 
in O 
pepper O 
berry O 
crop O 
production O 
is O 
not O 
of O 
safety O 
concern O 
for O 
consumers O 
or O 
farmers O 
, O 
whereas O 
for O 
use O 
of O 
tuba O 
root O 
and O 
sweet O 
flag O 
some O 
risk O 
factors O 
were O 
defined O 
requiring O 
further O 
evaluation O 
and O 
/ O 
or O 
risk O 
management O 
. O 
It O 
seems O 
prudent O 
to O 
look O 
for O 
alternatives O 
for O 
use O 
of O 
sweet O 
flag O 
extracts O 
containing O 
β-asarone B-TRIVIAL 
. O 

of O 
dietary O 
treatment O 
with O 
dimethylarsinous B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DMA B-FORMULA 
(III) I-FORMULA 
) O 
on O 
the O 
urinary O 
bladder O 
epithelium O 
of O 
arsenic B-SYSTEMATIC 
( O 
3 O 
oxidation O 
state O 
) O 
methyltransferase O 
( O 
As3mt O 
) O 
knockout O 
and O 
C57BL O 
/ O 
6 O 
wild O 
type O 
female O 
mice O 
. O 

exposure O 
to O 
inorganic O 
arsenic B-SYSTEMATIC 
( O 
iAs O 
) O 
is O 
carcinogenic O 
to O 
the O 
human O 
urinary O 
bladder O 
. O 
It O 
produces O 
urothelial O 
cytotoxicity O 
and O 
proliferation O 
in O 
rats O 
and O 
mice O 
. O 
DMA B-FORMULA 
(V) I-FORMULA 
, O 
a O 
major O 
methylated O 
urinary O 
metabolite O 
of O 
iAs O 
, O 
is O 
a O 
rat O 
bladder O 
carcinogen O 
, O 
but O 
without O 
effects O 
on O 
the O 
mouse O 
urothelium O 
. O 
DMA B-FORMULA 
(III) I-FORMULA 
was O 
shown O 
to O 
be O 
the O 
likely O 
urinary O 
metabolite O 
of O 
DMA B-FORMULA 
(V) I-FORMULA 
inducing O 
urothelial O 
changes O 
and O 
is O 
also O 
postulated O 
to O 
be O 
one O 
of O 
the O 
active O 
metabolites O 
of O 
iAs O 
. O 
To O 
evaluate O 
potential O 
DMA B-FORMULA 
(III) I-FORMULA 
-induced O 
urothelial O 
effects O 
, O 
it O 
was O 
administered O 
to O 
As3mt O 
knockout O 
mice O 
which O 
cannot O 
methylate B-FAMILY 
arsenicals I-FAMILY 
. O 
Female O 
C57BL O 
/ O 
6 O 
wild O 
type O 
and O 
As3mt O 
knockout O 
mice O 
( O 
10 O 
/ O 
group O 
) O 
were O 
administered O 
DMA B-FORMULA 
(III) I-FORMULA 
, O 
77.3ppm O 
in O 
water O 
for O 
four O 
weeks O 
. O 
Urothelial O 
effects O 
were O 
evaluated O 
by O 
light O 
and O 
scanning O 
electron O 
microscopy O 
( O 
EM O 
) O 
and O 
immunohistochemical O 
detection O 
of O 
bromodeoxyuridine B-TRIVIAL 
( O 
BrdU B-ABBREVIATION 
) O 
incorporation O 
. O 
EM O 
findings O 
were O 
rated O 
1-5 O 
, O 
with O 
higher O 
rating O 
indicating O 
greater O 
extent O 
of O 
cytotoxicity O 
visualized O 
. O 
DMA B-FORMULA 
(III) I-FORMULA 
significantly O 
increased O 
the O 
BrdU B-ABBREVIATION 
labeling O 
index O 
, O 
a O 
ratio O 
of O 
BrdU B-ABBREVIATION 
labeled O 
cells O 
to O 
non-labeled O 
cells O 
, O 
in O 
the O 
treated O 
knockout O 
group O 
compared O 
to O 
control O 
and O 
wild O 
type O 
treated O 
groups O 
. O 
DMA B-FORMULA 
(III) I-FORMULA 
induced O 
simple O 
hyperplasia O 
in O 
more O 
knockout O 
mice O 
( O 
4 O 
/ O 
10 O 
) O 
compared O 
to O 
wild O 
type O 
mice O 
( O 
2 O 
/ O 
10 O 
) O 
. O 
All O 
treated O 
knockout O 
mice O 
had O 
more O 
and O 
larger O 
intracytoplasmic O 
granules O 
compared O 
to O 
the O 
treated O 
wild O 
type O 
mice O 
. O 
Changes O 
in O 
EM O 
classification O 
were O 
not O 
significant O 
. O 
In O 
conclusion O 
, O 
DMA B-FORMULA 
(III) I-FORMULA 
induces O 
urothelial O 
toxicity O 
and O 
regenerative O 
hyperplasia O 
in O 
mice O 
and O 
most O 
likely O 
plays O 
a O 
role O 
in O 
inorganic O 
arsenic B-SYSTEMATIC 
-induced O 
urothelial O 
changes O 
. O 
However O 
, O 
DMA B-FORMULA 
(V) I-FORMULA 
does O 
not O 
induce O 
hyperplasia O 
in O 
mice O 
, O 
suggesting O 
that O 
urinary O 
concentrations O 
of O 
DMA B-FORMULA 
(III) I-FORMULA 
do O 
not O 
reach O 
cytotoxic O 
levels O 
in O 
DMA B-FORMULA 
(V) I-FORMULA 
-treated O 
mice O 
. O 

inhibitors O 
of O 
aggrecanases O 
as O 
potential O 
therapeutic O 
agents O 
for O 
osteoarthritis O 
: O 
Synthesis O 
and O 
biological O 
evaluation O 
. O 

, O 
in O 
particular O 
aggrecanase-2 O 
( O 
ADAMTS-5 O 
) O 
, O 
are O 
considered O 
the O 
principal O 
proteases O 
responsible O 
for O 
aggrecan O 
degradation O 
in O 
osteoarthritis O 
. O 
For O 
this O 
reason O 
, O 
considerable O 
effort O 
has O 
been O 
put O 
on O 
the O 
discovery O 
and O 
development O 
of O 
aggrecanase O 
inhibitors O 
able O 
to O 
slow O 
down O 
or O 
halt O 
the O 
progression O 
of O 
osteoarthritis O 
. O 
We O 
report O 
herein O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
a O 
series O 
of O 
arylsulfonamido B-FAMILY 
-based O 
hydroxamates B-FAMILY 
as O 
aggrecanase O 
inhibitors O 
. O 
Compound O 
18 O 
was O 
found O 
to O 
have O 
a O 
nanomolar O 
activity O 
for O 
ADAMTS-5 O 
, O 
ADAMTS-4 O 
and O 
MMP-13 O 
and O 
high O 
selectivity O 
over O 
MMP-1 O 
and O 
MMP-14 O 
. O 
Furthermore O 
, O 
this O 
compound O 
proved O 
to O 
be O 
effective O 
in O 
blocking O 
ex O 
vivo O 
cartilage O 
degradation O 
without O 
having O 
effect O 
on O 
cell O 
cytotoxicity O 
. O 

differentiating O 
ascorbate B-TRIVIAL 
-mediated O 
dissolution O 
of O 
quantum O 
dots O 
in O 
cell O 
culture O 
media O 
. O 

investigate O 
the O 
dynamic O 
dissolution O 
of O 
quantum O 
dots O 
( O 
QDs O 
) O 
in O 
cell O 
culture O 
media O 
, O 
in O 
this O 
study O 
we O 
constructed O 
an O 
online O 
automatic O 
analytical O 
system O 
comprising O 
a O 
sequential O 
in O 
- O 
tube O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
device O 
and O 
an O 
inductively O 
coupled O 
plasma O 
( O 
ICP O 
) O 
mass O 
spectrometer O 
. O 
By O 
means O 
of O 
selectively O 
extracting O 
QDs O 
and O 
cadmium B-SYSTEMATIC 
ions O 
( O 
Cd(2+) B-FORMULA 
) O 
onto O 
the O 
interior O 
surface O 
of O 
the O 
polytetrafluoroethylene B-TRIVIAL 
( O 
PTFE B-ABBREVIATION 
) O 
tube O 
, O 
this O 
novel O 
SPE O 
device O 
could O 
be O 
used O 
to O 
determine O 
the O 
degree O 
of O 
QD O 
dissolution O 
through O 
a O 
simple O 
adjustment O 
of O 
sample O 
acidity O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
study O 
is O 
the O 
first O 
to O 
exploit O 
PTFE B-ABBREVIATION 
tubing O 
as O 
a O 
selective O 
SPE O 
adsorbent O 
for O 
the O 
online O 
chemical O 
differentiation O 
of O 
QDs O 
and O 
Cd(2+) B-FORMULA 
ions O 
with O 
the O 
goal O 
of O 
monitoring O 
the O 
phenomenon O 
of O 
QD O 
dissolution O 
in O 
complicated O 
biological O 
matrices O 
. O 
We O 
confirmed O 
the O 
analytical O 
reliability O 
of O 
this O 
system O 
through O 
comparison O 
of O 
the O 
measured O 
Cd B-FORMULA 
-to-QD O 
ratios O 
to O 
the O 
expected O 
values O 
. O 
When O 
analyzing O 
QDs O 
and O 
Cd(2+) B-FORMULA 
ions O 
at O 
picomolar O 
levels O 
, O 
a O 
temporal O 
resolution O 
of O 
8 O 
min O 
was O 
required O 
to O 
load O 
sufficient O 
amounts O 
of O 
the O 
analytes O 
to O 
meet O 
the O 
sensitivity O 
requirements O 
of O 
the O 
ICP O 
mass O 
spectrometer O 
. O 
To O 
demonstrate O 
the O 
practicability O 
of O 
this O 
developed O 
method O 
, O 
we O 
measured O 
the O 
dynamic O 
variations O 
in O 
the O 
Cd B-FORMULA 
-to-QD705 O 
ratio O 
in O 
the O 
presence O 
of O 
ascorbate B-TRIVIAL 
as O 
a O 
physiological O 
stimulant O 
to O 
generate O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
cell O 
culture O 
media O 
and O 
trigger O 
the O 
dissolution O 
of O 
QDs O 
; O 
our O 
results O 
suggest O 
that O 
the O 
ascorbate B-TRIVIAL 
-induced O 
QD O 
dissolution O 
was O 
dependent O 
on O 
the O 
time O 
, O 
treatment O 
concentration O 
, O 
and O 
nature O 
of O 
the O 
biomolecule O 
. O 

of O 
genotoxic O 
effects O 
of O 
five O 
flavour O 
enhancers O 
( O 
glutamates B-FAMILY 
) O 
on O 
the O 
root O 
meristem O 
cells O 
of O 
Allium O 
cepa O 
. O 

effects O 
of O 
different O 
treatments O 
with O 
flavour O 
enhancers O 
monosodium B-SYSTEMATIC 
glutamate I-SYSTEMATIC 
, O 
monopotassium B-SYSTEMATIC 
glutamate I-SYSTEMATIC 
, O 
calcium B-SYSTEMATIC 
diglutamate I-SYSTEMATIC 
, O 
monoammonium B-SYSTEMATIC 
glutamate I-SYSTEMATIC 
, O 
and O 
magnesium B-SYSTEMATIC 
diglutamate I-SYSTEMATIC 
on O 
the O 
cytology O 
, O 
DNA O 
content O 
, O 
and O 
interphase O 
nuclear O 
volume O 
( O 
INV O 
) O 
of O 
A O 
. O 
cepa O 
were O 
investigated O 
. O 
Three O 
concentrations O 
of O 
these O 
additives O 
- O 
20 O 
, O 
40 O 
, O 
and O 
60 O 
ppm O 
- O 
were O 
applied O 
for O 
6 O 
, O 
12 O 
, O 
and O 
24 O 
h O 
. O 
All O 
the O 
concentrations O 
of O 
these O 
chemicals O 
showed O 
an O 
inhibitory O 
effect O 
on O 
cell O 
division O 
in O 
root O 
tips O 
of O 
A O 
. O 
cepa O 
and O 
caused O 
a O 
decrease O 
in O 
mitotic O 
index O 
values O 
. O 
Additionally O 
, O 
all O 
the O 
treatments O 
changed O 
the O 
frequency O 
of O 
mitotic O 
phases O 
when O 
compared O 
with O 
the O 
control O 
groups O 
. O 
These O 
compounds O 
increased O 
chromosome O 
abnormalities O 
, O 
among O 
them O 
are O 
micronuclei O 
, O 
c-mitosis O 
, O 
anaphase O 
bridges O 
, O 
stickiness O 
, O 
binucleus O 
, O 
laggards O 
, O 
and O 
breaks O 
. O 
The O 
nuclear O 
DNA O 
content O 
and O 
INV O 
decreased O 
when O 
compared O 
with O 
control O 
groups O 
. O 

of O 
novel O 
monoclonal O 
antibodies O 
against O 
chelated O 
cadmium B-SYSTEMATIC 
ions O 
. O 

detection O 
of O 
cadmium B-SYSTEMATIC 
ions O 
using O 
enzyme O 
- O 
linked O 
immunosorbent O 
assays O 
( O 
ELISA O 
) O 
has O 
been O 
reported O 
by O 
several O 
research O 
groups O 
. O 
Because O 
cadmium B-SYSTEMATIC 
ions O 
are O 
too O 
small O 
to O 
stimulate O 
the O 
immune O 
system O 
, O 
high O 
molecular O 
weight O 
immunogens O 
of O 
cadmium B-SYSTEMATIC 
are O 
constructed O 
using O 
bifunctional O 
chelators O 
. O 
At O 
present O 
, O 
the O 
most O 
commonly O 
used O 
bifunctional O 
chelator O 
for O 
the O 
preparation O 
of O 
antigens O 
for O 
heavy O 
metal O 
ions O 
is O 
1-(4-isothiocyanobenzyl) B-SYSTEMATIC 
ethylenediamine I-SYSTEMATIC 
N,N,N',N'-tetraacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
ITCBE B-ABBREVIATION 
) O 
. O 
However O 
, O 
the O 
price O 
of O 
ITCBE B-ABBREVIATION 
is O 
high O 
. O 
So O 
we O 
are O 
interested O 
in O 
a O 
cheaper O 
bifunctional O 
chelator O 
, O 
1-(4-aminobenzyl) B-SYSTEMATIC 
ethylenediamine I-SYSTEMATIC 
N,N,N',N'-tetraacetic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
aminobenzyl-EDTA B-SYSTEMATIC 
) O 
. O 
Here O 
, O 
cadmium B-SYSTEMATIC 
ions O 
were O 
conjugated O 
to O 
carrier O 
proteins O 
using O 
aminobenzyl-EDTA B-SYSTEMATIC 
to O 
make O 
artificial O 
antigens O 
. O 
Then O 
, O 
several O 
mice O 
were O 
immunized O 
with O 
the O 
antigen O 
. O 
And O 
monoclonal O 
antibodies O 
( O 
MAbs O 
) O 
against O 
cadmium B-SYSTEMATIC 
were O 
produced O 
. O 
Spleen O 
cells O 
of O 
immunized O 
mice O 
were O 
fused O 
with O 
myeloma O 
cells O 
. O 
The O 
resulting O 
hybridomas O 
were O 
screened O 
using O 
protein O 
conjugates O 
which O 
were O 
covalently O 
bound O 
to O 
metal O 
- O 
free O 
EDTA B-ABBREVIATION 
or O 
cadmium B-SYSTEMATIC 
. O 
Three O 
hybridoma O 
cell O 
lines O 
( O 
A3 O 
, O 
E4 O 
and O 
B5 O 
) O 
that O 
produced O 
MAbs O 
with O 
high O 
selectivity O 
and O 
sensitivity O 
were O 
expanded O 
for O 
further O 
study O 
. O 
Cross O 
- O 
reactivities O 
with O 
other O 
metals O 
were O 
below O 
1 O 
% O 
. O 
These O 
antibodies O 
were O 
used O 
to O 
construct O 
competitive O 
ELISAs O 
. O 
The O 
IC50 O 
for O 
A3 O 
was O 
8.4 O 
μg O 
/ O 
l O 
. O 
The O 
detection O 
range O 
and O 
the O 
lowest O 
detection O 
limit O 
using O 
the O 
antibody O 
A3 O 
was O 
0.394-64.39 O 
and O 
0.051 O 
μg O 
/ O 
l O 
, O 
respectively O 
. O 
Spike O 
- O 
recovery O 
studies O 
in O 
tap O 
water O 
showed O 
that O 
the O 
antibody O 
A3 O 
could O 
be O 
used O 
for O 
cadmium B-SYSTEMATIC 
detection O 
in O 
drinking O 
water O 
. O 

zinc B-SYSTEMATIC 
availability O 
affects O 
glutathione B-TRIVIAL 
metabolism O 
in O 
neuronal O 
cells O 
and O 
in O 
the O 
developing O 
brain O 
. O 

deficit O 
in O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
availability O 
can O 
increase O 
cell O 
oxidant O 
production O 
, O 
affect O 
the O 
antioxidant O 
defense O 
system O 
, O 
and O 
trigger O 
oxidant O 
- O 
sensitive O 
signals O 
in O 
neuronal O 
cells O 
. O 
This O 
work O 
tested O 
the O 
hypothesis O 
that O 
a O 
decreased O 
Zn B-FORMULA 
availability O 
can O 
affect O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
metabolism O 
in O 
the O 
developing O 
rat O 
brain O 
and O 
in O 
neuronal O 
cells O 
in O 
culture O 
, O 
as O 
well O 
as O 
the O 
capacity O 
of O 
human O 
neuroblastoma O 
IMR-32 O 
cells O 
to O 
upregulate O 
GSH B-ABBREVIATION 
when O 
challenged O 
with O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
. O 
GSH B-ABBREVIATION 
levels O 
were O 
low O 
in O 
the O 
brain O 
of O 
gestation O 
day O 
19 O 
( O 
GD19 O 
) O 
fetuses O 
from O 
dams O 
fed O 
marginal O 
Zn B-FORMULA 
diets O 
throughout O 
gestation O 
and O 
in O 
Zn B-FORMULA 
-deficient O 
IMR-32 O 
cells O 
. O 
γ-Glutamylcysteine B-SYSTEMATIC 
synthetase O 
( O 
GCL O 
) O 
, O 
the O 
first O 
enzyme O 
in O 
the O 
GSH B-ABBREVIATION 
synthetic O 
pathway O 
, O 
was O 
altered O 
by O 
Zn B-FORMULA 
deficiency O 
( O 
ZD O 
) O 
. O 
The O 
protein O 
and O 
mRNA O 
levels O 
of O 
the O 
GCL O 
modifier O 
( O 
GCLM O 
) O 
and O 
catalytic O 
( O 
GCLC O 
) O 
subunits O 
were O 
lower O 
in O 
the O 
Zn B-FORMULA 
-deficient O 
GD19 O 
fetal O 
brain O 
and O 
in O 
IMR-32 O 
cells O 
compared O 
with O 
controls O 
. O 
The O 
nuclear O 
translocation O 
of O 
transcription O 
factor O 
nuclear O 
factor O 
( O 
erythroid O 
- O 
derived O 
2 O 
) O 
- O 
like O 
2 O 
, O 
which O 
controls O 
GCL O 
transcription O 
, O 
was O 
impaired O 
by O 
ZD O 
. O 
Posttranslationally O 
, O 
the O 
caspase-3-dependent O 
GCLC O 
cleavage O 
was O 
high O 
in O 
Zn B-FORMULA 
-deficient O 
IMR-32 O 
cells O 
. O 
Cells O 
challenged O 
with O 
DA O 
showed O 
an O 
increase O 
in O 
GCLM O 
and O 
GCLC O 
protein O 
and O 
mRNA O 
levels O 
and O 
a O 
consequent O 
increase O 
in O 
GSH B-ABBREVIATION 
concentration O 
. O 
Although O 
Zn B-FORMULA 
-deficient O 
cells O 
partially O 
upregulated O 
GCL O 
subunits O 
after O 
exposure O 
to O 
DA O 
, O 
GSH B-ABBREVIATION 
content O 
remained O 
low O 
. O 
In O 
summary O 
, O 
results O 
show O 
that O 
a O 
low O 
Zn B-FORMULA 
availability O 
affects O 
the O 
GSH B-ABBREVIATION 
synthetic O 
pathway O 
in O 
neuronal O 
cells O 
and O 
fetal O 
brain O 
both O 
at O 
transcriptional O 
and O 
posttranslational O 
levels O 
. O 
This O 
can O 
in O 
part O 
underlie O 
the O 
GSH B-ABBREVIATION 
depletion O 
associated O 
with O 
ZD O 
and O 
the O 
high O 
sensitivity O 
of O 
Zn B-FORMULA 
-deficient O 
neurons O 
to O 
pro O 
- O 
oxidative O 
stressors O 
. O 

of O 
baicalin B-TRIVIAL 
on O 
airway O 
remodeling O 
in O 
asthmatic O 
mice O 
. O 

remodeling O 
is O 
an O 
important O 
characteristic O 
of O 
asthma O 
, O 
linking O 
inflammation O 
with O 
airway O 
hyperresponsiveness O 
. O 
Baicalin B-TRIVIAL 
, O 
a O 
major O 
active O 
component O 
, O 
was O 
isolated O 
from O 
Radix O 
Scutellariae O 
. O 
Many O 
studies O 
show O 
that O 
baicalin B-TRIVIAL 
has O 
anti-inflammatory O 
, O 
anti-bacterial O 
, O 
and O 
anti-allergic O 
effects O 
. O 
Here O 
we O 
investigate O 
the O 
influence O 
of O 
baicalin B-TRIVIAL 
on O 
asthmatic O 
airway O 
remodeling O 
and O 
the O 
mechanism O 
underlining O 
the O 
anti-remodeling O 
effect O 
in O 
vivo.Asthmatic O 
airway O 
remodeling O 
mice O 
model O 
was O 
established O 
by O 
ovalbumin O 
exposure O 
. O 
Seventy O 
female O 
BALB O 
/ O 
c O 
mice O 
were O 
randomly O 
assigned O 
to O 
seven O 
experimental O 
groups O 
: O 
blank O 
, O 
ovalbumin O 
, O 
hexadecadrol O 
, O 
control O 
, O 
and O 
baicalin B-TRIVIAL 
( O 
25 O 
mg O 
/ O 
kg O 
, O 
50 O 
mg O 
/ O 
kg O 
, O 
100 O 
mg O 
/ O 
kg O 
) O 
groups O 
. O 
Pulmonary O 
function O 
was O 
measured O 
using O 
a O 
whole O 
- O 
body O 
plethysmograph O 
in O 
conscious O 
and O 
unrestrained O 
mice O 
. O 
The O 
lung O 
pathology O 
was O 
observed O 
and O 
measured O 
. O 
The O 
production O 
of O 
cytokines O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
and O 
serum O 
was O 
measured O 
using O 
enzyme O 
- O 
labeled O 
immunosorbent O 
assay O 
kits O 
, O 
and O 
the O 
expression O 
levels O 
of O 
transforming O 
growth O 
factor-β1 O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
were O 
detected O 
by O 
immunohistochemistry O 
. O 
The O 
protein O 
expression O 
levels O 
of O 
transforming O 
growth O 
factor-β1 O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
, O 
and O 
p21ras O 
were O 
measured O 
using O 
Western O 
blot O 
. O 
The O 
results O 
show O 
that O 
ovalbumin O 
exposure O 
significantly O 
increased O 
the O 
expression O 
of O 
interleukin-13 O 
in O 
BALF O 
and O 
serum O 
, O 
and O 
transforming O 
growth O 
factor-β1 O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
and O 
p21ras O 
expressions O 
in O 
the O 
lungs O 
. O 
Baicalin B-TRIVIAL 
attenuated O 
the O 
effects O 
of O 
ovalbumin O 
significantly.It O 
can O 
be O 
concluded O 
that O 
baicalin B-TRIVIAL 
has O 
significant O 
anti-remodeling O 
effect O 
on O 
ovalbumin O 
- O 
induced O 
asthmatic O 
airway O 
remodeling O 
mice O 
model O 
by O 
decreasing O 
expression O 
of O 
transforming O 
growth O 
factor-β1 O 
, O 
interleukin-13 O 
, O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
and O 
inhibiting O 
the O 
activation O 
of O 
the O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
pathway O 
. O 

is O 
tightly O 
associated O 
with O 
the O 
outgrowth O 
of O 
adipose O 
tissue O 
, O 
leading O 
to O 
obesity O 
, O 
which O 
is O 
a O 
risk O 
factor O 
for O 
type O 
2 O 
diabetes O 
and O 
hypertension O 
, O 
mainly O 
because O 
expanding O 
adipose O 
tissue O 
requires O 
an O 
increased O 
nutrient O 
supply O 
from O 
blood O 
vessels O 
. O 
Therefore O 
, O 
induction O 
of O 
vessel O 
abnormality O 
by O 
adipokines O 
has O 
been O 
well O 
studied O 
, O 
whereas O 
how O 
altered O 
vascular O 
function O 
promotes O 
obesity O 
is O 
relatively O 
unexplored O 
. O 
Also O 
, O 
surviving O 
Prox1 O 
heterozygous O 
mice O 
showed O 
abnormal O 
lymphatic O 
patterning O 
and O 
adult O 
- O 
onset O 
obesity O 
, O 
indicating O 
that O 
accumulation O 
of O 
adipocytes O 
could O 
be O 
closely O 
linked O 
with O 
lymphatic O 
function O 
. O 
Here O 
we O 
propose O 
a O 
new O 
anti-obesity O 
strategy O 
based O 
on O 
enhancement O 
of O 
lymphatic O 
and O 
blood O 
vessel O 
integrity O 
with O 
apelin O 
. O 
Apelin O 
- O 
knockout O 
mice O 
given O 
a O 
high O 
- O 
fat O 
diet O 
showed O 
an O 
obese O 
phenotype O 
associated O 
with O 
abnormal O 
lymphatic O 
and O 
blood O 
vessel O 
enlargement O 
. O 
Fatty B-FAMILY 
acids I-FAMILY 
present O 
in O 
the O 
high O 
- O 
fat O 
diet O 
induced O 
hyperpermeability O 
of O 
endothelial O 
cells O 
, O 
causing O 
adipocyte O 
differentiation O 
, O 
whereas O 
apelin O 
promoted O 
vascular O 
stabilization O 
. O 
Moreover O 
, O 
treatment O 
of O 
high O 
- O 
fat O 
- O 
diet O 
- O 
fed O 
apelin O 
- O 
knockout O 
mice O 
with O 
a O 
selective O 
cyclooxygenase-2 O 
inhibitor O 
, O 
celecoxib B-TRIVIAL 
, O 
improved O 
vascular O 
function O 
, O 
and O 
also O 
attenuated O 
obesity O 
. O 
Finally O 
, O 
apelin O 
transgenic O 
mice O 
showed O 
decreased O 
subcutaneous O 
adipose O 
tissue O 
owing O 
to O 
inhibition O 
of O 
high O 
- O 
fat O 
- O 
diet O 
- O 
induced O 
hyperpermeability O 
of O 
vessels O 
. O 
These O 
results O 
indicate O 
that O 
apelin O 
inhibits O 
high O 
- O 
fat O 
- O 
diet O 
- O 
induced O 
obesity O 
by O 
enhancing O 
vessel O 
integrity O 
. O 
Apelin O 
could O 
serve O 
as O 
a O 
therapeutic O 
target O 
for O 
treating O 
obesity O 
and O 
related O 
diseases O 
. O 

, O 
elimination O 
, O 
and O 
metabolism O 
of O 
CS-1036 B-IDENTIFIER 
, O 
a O 
novel O 
α-amylase O 
inhibitor O 
in O 
rats O 
and O 
monkeys O 
, O 
and O 
the O 
relationship O 
between O 
gastrointestinal O 
distribution O 
and O 
suppression O 
of O 
glucose B-TRIVIAL 
absorption O 
. O 

absorption O 
, O 
metabolism O 
, O 
and O 
excretion O 
of O 
(2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl B-SYSTEMATIC 
4-O-(6-deoxy-β-d-glucopyranosyl)-α-d-glucopyranoside I-SYSTEMATIC 
( O 
CS-1036 B-IDENTIFIER 
) O 
, O 
a O 
novel O 
and O 
potent O 
pancreatic O 
and O 
salivary O 
α-amylase O 
inhibitor O 
, O 
were O 
evaluated O 
in O 
F344 O 
/ O 
DuCrlCrlj O 
rats O 
and O 
cynomolgus O 
monkeys O 
. O 
The O 
total O 
body O 
clearance O 
and O 
volume O 
of O 
distribution O 
of O 
CS-1036 B-IDENTIFIER 
were O 
low O 
( O 
2.67-3.44 O 
ml O 
/ O 
min O 
/ O 
kg O 
and O 
0.218-0.237 O 
l O 
/ O 
kg O 
for O 
rats O 
and O 
2.25-2.84 O 
ml O 
/ O 
min O 
/ O 
kg O 
and O 
0.217-0.271 O 
l O 
/ O 
kg O 
for O 
monkeys O 
) O 
. O 
After O 
intravenous O 
administration O 
of O 
[(14)C]CS-1036 B-IDENTIFIER 
to O 
rats O 
and O 
monkeys O 
, O 
radioactivity O 
was O 
mainly O 
excreted O 
into O 
urine O 
( O 
77.2% O 
for O 
rats O 
and O 
81.1% O 
for O 
monkeys O 
) O 
. O 
After O 
oral O 
administration O 
, O 
most O 
of O 
the O 
radioactivity O 
was O 
recovered O 
from O 
feces O 
( O 
80.28% O 
for O 
rats O 
and O 
88.13% O 
for O 
monkeys O 
) O 
with O 
a O 
low O 
oral O 
bioavailability O 
( O 
1.73-2.44% O 
for O 
rats O 
and O 
0.983-1.20% O 
for O 
monkeys O 
) O 
. O 
In O 
rats O 
, O 
intestinal O 
secretion O 
is O 
suggested O 
to O 
be O 
involved O 
in O 
the O 
fecal O 
excretion O 
as O 
a O 
minor O 
component O 
because O 
fecal O 
excretion O 
after O 
intravenous O 
administration O 
was O 
observed O 
( O 
15.66% O 
) O 
and O 
biliary O 
excretion O 
was O 
almost O 
negligible O 
. O 
Although O 
intestinal O 
flora O 
was O 
involved O 
in O 
CS-1036 B-IDENTIFIER 
metabolism O 
, O 
CS-1036 B-IDENTIFIER 
was O 
the O 
main O 
component O 
in O 
feces O 
( O 
70.3% O 
for O 
rats O 
and O 
48.7% O 
for O 
monkeys O 
) O 
and O 
in O 
the O 
intestinal O 
contents O 
( O 
33-68% O 
for O 
rats O 
up O 
to O 
2 O 
hours O 
after O 
the O 
dose O 
) O 
after O 
oral O 
administration O 
. O 
In O 
Zucker O 
diabetic O 
fatty O 
rats O 
, O 
CS-1036 B-IDENTIFIER 
showed O 
a O 
suppressive O 
effect O 
on O 
plasma O 
glucose B-TRIVIAL 
elevation O 
after O 
starch O 
loading O 
with O 
a O 
50% O 
effective O 
dose O 
at O 
0.015 O 
mg O 
/ O 
kg O 
. O 
In O 
summary O 
, O 
CS-1036 B-IDENTIFIER 
showed O 
optimal O 
pharmacokinetic O 
profiles O 
: O 
low O 
oral O 
absorption O 
and O 
favorable O 
stability O 
in O 
gastrointestinal O 
lumen O 
, O 
resulting O 
in O 
suppression O 
of O 
postprandial O 
hyperglycemia O 
by O 
α-amylase O 
inhibition O 
. O 

and O 
characterization O 
of O 
novel O 
alternative O 
splice O 
variants O 
of O 
human O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
in O 
liver O 
samples O 
of O 
Koreans O 
and O 
Caucasians O 
. O 

constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
hCAR O 
, O 
NR1I3 O 
) O 
is O 
a O 
member O 
of O 
the O 
orphan O 
nuclear O 
receptor O 
family O 
and O 
regulates O 
the O 
transcription O 
of O 
many O 
drug O 
- O 
metabolizing O 
enzymes O 
and O 
drug O 
transporters O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
the O 
hCAR O 
gene O 
produces O 
a O 
number O 
of O 
different O 
kinds O 
of O 
mRNA O 
splicing O 
variants O 
( O 
SVs O 
) O 
in O 
non-Asian O 
ethnicities O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
identified O 
18 O 
hCAR O 
SVs O 
( O 
SV1-SV18 O 
) O 
, O 
including O 
four O 
novel O 
SVs O 
in O 
Korean O 
human O 
livers O 
. O 
Among O 
the O 
four O 
novel O 
SVs O 
, O 
SV2 O 
showed O 
enhanced O 
transactivation O 
activity O 
when O 
cotransfected O 
with O 
CYP2B6 O 
reporter O 
gene O 
, O 
whereas O 
other O 
SVs O 
were O 
nonfunctional O 
. O 
When O 
profiles O 
of O 
major O 
hCAR O 
SVs O 
were O 
compared O 
among O 
30 O 
livers O 
from O 
Korean O 
patients O 
and O 
20 O 
livers O 
from O 
Caucasian O 
patients O 
, O 
the O 
relative O 
composition O 
of O 
each O 
SV O 
showed O 
interethnic O 
variation O 
as O 
well O 
as O 
interindividual O 
variation O 
. O 
The O 
most O 
predominant O 
form O 
of O 
hCAR O 
SV O 
was O 
not O 
wild O 
type O 
, O 
but O 
either O 
SV4 O 
or O 
SV7 O 
. O 
The O 
summed O 
relative O 
amounts O 
of O 
SV4 O 
and O 
SV7 O 
ranged O 
from O 
34.5 O 
to O 
57.6% O 
in O 
the O 
30 O 
Korean O 
livers O 
and O 
from O 
47.2 O 
to O 
82.6% O 
in O 
the O 
20 O 
Caucasian O 
livers O 
, O 
suggesting O 
large O 
interindividual O 
variation O 
. O 
The O 
mean O 
relative O 
amount O 
of O 
nonfunctional O 
SV9 O 
was O 
significantly O 
higher O 
in O 
Koreans O 
( O 
29.8% O 
) O 
than O 
in O 
Caucasians O 
( O 
12.8% O 
) O 
. O 
The O 
mean O 
relative O 
amount O 
of O 
novel O 
SV2 O 
was O 
9.7% O 
in O 
Korean O 
livers O 
and O 
3.5% O 
in O 
Caucasian O 
livers O 
. O 
Expression O 
profiling O 
of O 
hCAR O 
proteins O 
in O 
human O 
livers O 
also O 
supported O 
large O 
interindividual O 
variation O 
in O 
the O 
expressional O 
ratio O 
of O 
wild O 
- O 
type O 
and O 
SVs O 
. O 
Our O 
results O 
describe O 
for O 
the O 
first O 
time O 
the O 
direct O 
comparison O 
of O 
hCAR O 
SV O 
profiles O 
between O 
Koreans O 
and O 
Caucasians O 
. O 
The O 
functional O 
relevance O 
of O 
these O 
interindividual O 
and O 
interethnic O 
variations O 
of O 
hCAR O 
mRNA O 
expression O 
needs O 
to O 
be O 
further O 
characterized O 
. O 

Removal O 
Of O 
Selenate B-SYSTEMATIC 
From O 
Aqueous O 
Solutions O 
. O 

of O 
selenate B-SYSTEMATIC 
from O 
solution O 
is O 
investigated O 
in O 
batch O 
electrochemical O 
systems O 
using O 
reactive O 
iron B-SYSTEMATIC 
anodes O 
and O 
copper O 
plate O 
cathode O 
in O 
a O 
bicarbonate B-SYSTEMATIC 
medium O 
. O 
Iron B-SYSTEMATIC 
anodes O 
produce O 
ferrous B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
, O 
which O 
is O 
a O 
major O 
factor O 
in O 
the O 
removal O 
of O 
selenate B-SYSTEMATIC 
from O 
solution O 
. O 
Iron B-SYSTEMATIC 
anodes O 
also O 
generate O 
a O 
significant O 
decrease O 
in O 
the O 
oxidation O 
- O 
reduction O 
potential O 
( O 
ORP O 
) O 
of O 
the O 
solution O 
because O 
it O 
prevents O 
generation O 
of O 
oxygen B-SYSTEMATIC 
gas O 
at O 
the O 
anode O 
by O 
electrolysis O 
. O 
The O 
removal O 
rates O 
varied O 
from O 
45.1 O 
to O 
97.4% O 
, O 
depending O 
on O 
current O 
density O 
and O 
selenate B-SYSTEMATIC 
concentration O 
. O 
The O 
transformation O 
of O 
selenate B-SYSTEMATIC 
by O 
the O 
process O 
is O 
modeled O 
based O 
on O 
a O 
heterogeneous O 
reaction O 
coupled O 
with O 
electrochemical O 
generation O 
of O 
ferrous B-SYSTEMATIC 
and O 
hydroxide B-SYSTEMATIC 
. O 
The O 
rates O 
are O 
optimized O 
at O 
lower O 
initial O 
concentrations O 
, O 
higher O 
electrical O 
currents O 
, O 
and O 
the O 
presence O 
of O 
anions O 
. O 
Presence O 
of O 
dissolved O 
oxygen B-SYSTEMATIC 
does O 
not O 
cause O 
any O 
significant O 
effects O 
the O 
removal O 
of O 
selenate B-SYSTEMATIC 
. O 

, O 
a O 
new O 
polyacetylene B-SYSTEMATIC 
from O 
the O 
marine O 
sponge O 
Petrosia O 
solida O 
that O 
inhibits O 
blastulation O 
of O 
starfish O 
embryos O 
. O 

new O 
C(30) O 
linear O 
polyacetylene B-SYSTEMATIC 
compound O 
designated O 
petroacetylene B-TRIVIAL 
( O 
1 O 
) O 
has O 
been O 
isolated O 
from O 
the O 
marine O 
sponge O 
Petrosia O 
solida O 
Hoshino O 
1981 O 
, O 
collected O 
off O 
the O 
coast O 
of O 
Amami-Oshima O 
, O 
Kagoshima O 
Prefecture O 
, O 
Japan O 
. O 
The O 
structure O 
was O 
elucidated O 
on O 
the O 
basis O 
of O 
spectroscopic O 
data O 
and O 
chemical O 
means O 
. O 
Petroacetylene B-TRIVIAL 
( O 
1 O 
) O 
inhibited O 
blastulation O 
of O 
starfish O 
embryos O 
at O 
a O 
concentration O 
of O 
3.1 O 
μg O 
mL(- O 
1) O 
or O 
greater O 
. O 

, O 
microwave O 
spectrum O 
, O 
and O 
conformational O 
properties O 
of O 
2-fluoroethyl B-SYSTEMATIC 
azide I-SYSTEMATIC 
( O 
FCH2CH2N3 B-FORMULA 
) O 
. O 

novel O 
synthesis O 
producing O 
neat O 
2-fluoroethyl B-SYSTEMATIC 
azide I-SYSTEMATIC 
( O 
FCH2CH2N3 B-FORMULA 
) O 
is O 
described O 
. O 
A O 
conformational O 
analysis O 
using O 
microwave O 
spectroscopy O 
augmented O 
by O 
quantum O 
chemical O 
calculations O 
at O 
the O 
CCSD(T) O 
/ O 
cc-pVTZ O 
, O 
B3LYP O 
/ O 
aug-cc-pVTZ O 
, O 
and O 
B3LYP O 
/ O 
cc-pVTZ O 
levels O 
of O 
theory O 
has O 
been O 
performed O 
for O 
this O 
compound O 
. O 
The O 
spectra O 
of O 
the O 
ground O 
vibrational O 
state O 
and O 
two O 
vibrationally O 
excited O 
states O 
of O 
one O 
rotameric O 
form O 
were O 
assigned O 
. O 
A O 
large O 
number O 
of O 
transitions O 
was O 
assigned O 
, O 
and O 
very O 
accurate O 
values O 
were O 
obtained O 
for O 
the O 
rotational O 
and O 
quartic O 
centrifugal O 
distortion O 
constants O 
. O 
The O 
identified O 
conformer O 
has O 
synclinal O 
orientations O 
for O 
the O 
F-C-C-N B-FORMULA 
and O 
C-C-N-N B-FORMULA 
chains O 
of O 
atoms O 
bringing O 
the O 
fluorine B-SYSTEMATIC 
atom O 
and O 
the O 
azido B-SYSTEMATIC 
group O 
into O 
close O 
proximity O 
. O 
It O 
is O 
concluded O 
from O 
consideration O 
of O 
absolute O 
intensities O 
that O 
this O 
conformer O 
is O 
indeed O 
the O 
preferred O 
form O 
of O 
the O 
molecule O 
in O 
accord O 
with O 
the O 
theoretical O 
calculations O 
. O 
The O 
experimental O 
and O 
CCSD(T) O 
rotational O 
constants O 
are O 
in O 
very O 
good O 
agreement O 
, O 
whereas O 
much O 
larger O 
discrepancies O 
were O 
seen O 
for O 
the O 
experimental O 
and O 
B3LYP O 
quartic O 
centrifugal O 
distortion O 
constants O 
. O 

- O 
aggregation O 
properties O 
of O 
ionic O 
liquid O 
1,3-didecyl-2-methylimidazolium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
in O 
aqueous O 
solution O 
: O 
from O 
spheres O 
to O 
cylinders O 
to O 
bilayers O 
. O 

self O 
- O 
aggregation O 
behavior O 
of O 
the O 
double O 
- O 
chained O 
ionic O 
liquid O 
( O 
IL O 
) O 
1,3-didecyl-2-methylimidazolium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
[C10C10mim]Cl B-FORMULA 
) O 
in O 
aqueous O 
solution O 
has O 
been O 
investigated O 
with O 
a O 
number O 
of O 
different O 
experimental O 
techniques O 
. O 
Two O 
cmc O 
values O 
( O 
cmc1 O 
and O 
cmc2 O 
) O 
are O 
obtained O 
from O 
conductivity O 
measurements O 
. O 
The O 
fraction O 
of O 
neutralized O 
charge O 
on O 
the O 
micellar O 
surface O 
suggests O 
that O 
cmc1 O 
corresponds O 
to O 
the O 
formation O 
of O 
spherical O 
micelles O 
and O 
cmc2 O 
to O 
the O 
transition O 
from O 
spherical O 
to O 
cylindrical O 
micelles O 
. O 
Data O 
obtained O 
from O 
fluorescence O 
spectroscopy O 
( O 
using O 
pyrene B-SYSTEMATIC 
and O 
Nile B-TRIVIAL 
red I-TRIVIAL 
as O 
chemical O 
probes O 
) O 
, O 
fluorescence O 
anisotropy O 
( O 
using O 
rhodamine B-TRIVIAL 
B I-TRIVIAL 
as O 
probe O 
) O 
, O 
and O 
chemical O 
shift O 
(1)H B-FORMULA 
NMR O 
( O 
in O 
D2O B-FORMULA 
) O 
provide O 
a O 
picture O 
that O 
is O 
also O 
consistent O 
with O 
a O 
sphere O 
- O 
to O 
- O 
cylinder O 
transition O 
. O 
This O 
structural O 
change O 
is O 
further O 
confirmed O 
by O 
diffusion O 
- O 
ordered O 
NMR O 
spectroscopy O 
( O 
DOSY O 
) O 
, O 
from O 
the O 
self O 
- O 
diffusion O 
coefficients O 
for O 
surfactant O 
unimer O 
and O 
aggregates O 
. O 
Furthermore O 
, O 
a O 
third O 
evolution O 
from O 
cylindrical O 
micelles O 
to O 
bilayer O 
aggregates O 
is O 
proposed O 
from O 
the O 
analysis O 
of O 
diffusion O 
coefficients O 
at O 
high O 
surfactant O 
concentration O 
( O 
[ O 
IL O 
] O 
> O 
0.2 O 
M O 
) O 
. O 
Phase O 
scanning O 
experiments O 
performed O 
with O 
polarized O 
light O 
microscopy O 
clearly O 
demonstrate O 
the O 
presence O 
of O 
a O 
lamellar O 
liquid O 
crystalline O 
phase O 
at O 
very O 
high O 
IL O 
concentration O 
, O 
thus O 
confirming O 
the O 
coexistence O 
of O 
bilayer O 
structures O 
with O 
elongated O 
micelles O 
, O 
found O 
at O 
lower O 
concentration O 
. O 
Additionally O 
, O 
[C10C10mim]Cl B-FORMULA 
micelles O 
are O 
proposed O 
as O 
novel O 
reaction O 
media O 
, O 
as O 
evidenced O 
by O 
the O 
solvolysis O 
reaction O 
of O 
4-methoxybenzenesulfonyl B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
MBSC B-ABBREVIATION 
) O 
. O 

polymeric O 
microcapillary O 
coatings O 
for O 
photodetection O 
of O 
solvent O 
polarity O 
. O 

silica B-TRIVIAL 
microcapillaries O 
were O 
functionalized O 
with O 
spiropyran B-FAMILY 
-polymer O 
brushes O 
using O 
surface O 
- O 
initiated O 
ring O 
- O 
opening O 
metathesis O 
polymerization O 
. O 
Based O 
on O 
the O 
inherited O 
spiropyran B-FAMILY 
properties O 
, O 
the O 
functionalized O 
capillaries O 
were O 
successfully O 
used O 
to O 
photoidentify O 
solvents O 
of O 
different O 
polarity O 
when O 
passing O 
through O 
the O 
microcapillary O 
in O 
continuous O 
flow O 
. O 
In O 
the O 
present O 
study O 
, O 
six O 
different O 
solvents O 
( O 
toluene B-TRIVIAL 
, O 
tetrahydrofuran B-SYSTEMATIC 
, O 
acetone B-SYSTEMATIC 
, O 
acetonitrile B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
, O 
and O 
methanol B-SYSTEMATIC 
) O 
can O 
be O 
easily O 
detected O 
while O 
passing O 
through O 
the O 
modified O 
microcapillary O 
by O 
simply O 
irradiating O 
a O 
portion O 
of O 
it O 
with O 
UV O 
light O 
( O 
365 O 
nm O 
) O 
. O 
This O 
converts O 
the O 
closed O 
spiropyran B-FAMILY 
moiety O 
to O 
the O 
open O 
merocyanine B-FAMILY 
form O 
, O 
and O 
as O 
a O 
consequence O 
, O 
the O 
microcapillary O 
gains O 
a O 
distinct O 
color O 
and O 
spectral O 
response O 
depending O 
on O 
the O 
polarity O 
of O 
the O 
solvent O 
. O 
The O 
rate O 
of O 
ring O 
- O 
opening O 
of O 
the O 
spiropyran B-FAMILY 
-polymer O 
brushes O 
coatings O 
has O 
been O 
determined O 
in O 
situ O 
in O 
the O 
presence O 
of O 
different O 
solvents O 
, O 
showing O 
that O 
the O 
coloration O 
rate O 
is O 
also O 
influenced O 
by O 
the O 
solvent O 
polarity O 
and O 
therefore O 
can O 
be O 
used O 
as O 
an O 
additional O 
parameter O 
for O 
solvent O 
sensing O 
. O 

Quasi- O 
) O 
2D O 
aggregation O 
of O 
polystyrene B-SYSTEMATIC 
-b-dextran O 
at O 
the O 
air O 
- O 
water O 
interface O 
. O 

-b-dextran O 
( O 
PS-b-Dextran O 
) O 
copolymers O 
can O 
be O 
used O 
to O 
prepare O 
dextran O 
brushes O 
at O 
solid O 
surfaces O 
, O 
applying O 
Langmuir-Blodgett O 
deposition O 
. O 
When O 
recording O 
the O 
interfacial O 
pressure O 
versus O 
area O 
isotherms O 
of O 
a O 
PS-b-Dextran O 
monolayer O 
, O 
time O 
- O 
dependent O 
hysteresis O 
was O 
observed O 
upon O 
compression O 
and O 
expansion O 
. O 
We O 
argue O 
that O 
this O 
is O 
due O 
to O 
( O 
quasi- O 
) O 
2D O 
aggregation O 
of O 
the O 
copolymer O 
at O 
the O 
air O 
- O 
water O 
surface O 
, O 
with O 
three O 
contributions O 
. O 
First O 
, O 
at O 
large O 
area O 
per O 
molecule O 
, O 
a O 
zero O 
surface O 
pressure O 
is O 
measured O 
; O 
we O 
ascribe O 
this O 
to O 
self O 
- O 
assembly O 
of O 
block O 
copolymers O 
into O 
surface O 
micelles O 
. O 
At O 
intermediate O 
area O 
we O 
identify O 
a O 
second O 
regime O 
( O 
" O 
desorption O 
regime O 
" O 
) O 
where O 
aggregation O 
into O 
large O 
patches O 
occurs O 
due O 
to O 
van O 
der O 
Waals O 
attraction O 
between O 
PS O 
blocks O 
. O 
At O 
high O 
surface O 
pressure O 
( O 
" O 
brush O 
regime O 
" O 
) O 
we O 
observe O 
hysteretic O 
behavior O 
attributed O 
to O 
H B-FORMULA 
-bonding O 
between O 
dextran O 
chains O 
. O 
When O 
compared O 
to O 
hysteresis O 
of O 
other O 
amphiphilic O 
diblock O 
copolymers O 
( O 
also O 
containing O 
PS O 
, O 
e.g O 
. O 
, O 
polystyrene B-SYSTEMATIC 
-b- O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
) O 
a O 
general O 
criterion O 
can O 
be O 
formulated O 
concerning O 
the O 
extent O 
of O 
hysteresis O 
: O 
when O 
the O 
hydrophobic O 
( O 
PS O 
) O 
block O 
is O 
of O 
equal O 
size O 
as O 
( O 
or O 
bigger O 
than O 
) O 
the O 
hydrophilic O 
block O 
, O 
the O 
hysteresis O 
is O 
maximal O 
. O 
The O 
( O 
quasi- O 
) O 
2D O 
aggregation O 
of O 
PS-b-Dextran O 
has O 
significant O 
implications O 
for O 
the O 
preparation O 
of O 
dextran O 
brushes O 
at O 
solid O 
surfaces O 
using O 
Langmuir-Blodgett O 
deposition O 
. O 
For O 
each O 
grafting O 
density O 
the O 
monolayer O 
needs O 
to O 
relax O 
, O 
up O 
to O 
several O 
hours O 
, O 
prior O 
to O 
transfer O 
. O 

- O 
yield O 
dispersions O 
of O 
large O 
- O 
diameter O 
semiconducting O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
with O 
tunable O 
narrow O 
chirality O 
distributions O 
. O 

, O 
we O 
report O 
a O 
thorough O 
study O 
on O 
the O 
ability O 
of O 
fluorene B-SYSTEMATIC 
-based O 
semiconducting O 
polymers O 
to O 
disperse O 
large O 
- O 
diameter O 
( O 
average O 
diameter O 
⟨d⟩ O 
≈ O 
1.3 O 
nm O 
) O 
laser O 
vaporization O 
( O 
LV O 
) O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
. O 
We O 
demonstrate O 
the O 
ability O 
to O 
select O 
purely O 
semiconducting O 
species O 
using O 
poly[(9,9-dioctylfluorenyl-2,7-diyl)-alt-co-(6,6'-{2,2'-bipyridine})] B-SYSTEMATIC 
( O 
PFO-BPy B-ABBREVIATION 
) O 
and O 
poly[(9,9-dihexylfluorenyl-2,7-diyl)-co-(9,10-anthracene)] B-SYSTEMATIC 
( O 
PFH-A B-ABBREVIATION 
) O 
, O 
producing O 
samples O 
with O 
narrow O 
and O 
bright O 
excitonic O 
emission O 
relative O 
to O 
comparable O 
aqueous O 
dispersions O 
. O 
Rapid O 
processing O 
and O 
high O 
yields O 
offer O 
the O 
ability O 
to O 
easily O 
incorporate O 
these O 
semiconducting O 
SWCNTs O 
into O 
commercially O 
scalable O 
applications O 
, O 
as O 
demonstrated O 
by O 
large O 
- O 
area O 
thin O 
films O 
prepared O 
by O 
ultrasonic O 
spraying O 
. O 
By O 
modifying O 
the O 
growth O 
temperature O 
of O 
the O 
LV O 
synthesis O 
, O 
we O 
demonstrate O 
the O 
ability O 
to O 
tune O 
the O 
range O 
of O 
diameters O 
and O 
chiralities O 
within O 
dispersions O 
by O 
exerting O 
synthetic O 
control O 
over O 
the O 
composition O 
of O 
the O 
starting O 
material O 
. O 
This O 
synthetic O 
control O 
allows O 
us O 
to O 
show O 
that O 
PFH-A B-ABBREVIATION 
preferentially O 
disperses O 
near O 
- O 
armchair O 
semiconducting O 
SWCNTs O 
over O 
a O 
large O 
range O 
of O 
diameters O 
( O 
0.8 O 
nm O 
< O 
d O 
< O 
1.4 O 
nm O 
) O 
and O 
induces O 
unique O 
solvatochromic O 
shifts O 
for O 
the O 
excitonic O 
transitions O 
of O 
nanotubes O 
with O 
particular O 
chiral O 
indices O 
. O 

of O 
the O 
Combination O 
Index O 
to O 
determine O 
interactions O 
between O 
plant O 
- O 
derived O 
phenolic B-FAMILY 
acids I-FAMILY 
on O 
hepatotoxicity O 
endpoints O 
in O 
human O 
and O 
rat O 
hepatoma O 
cells O 
. O 

beneficial O 
or O 
adverse O 
effects O 
of O 
isolated O 
phytochemicals O 
are O 
not O 
always O 
concordant O 
with O 
effects O 
of O 
the O 
botanical O 
dietary O 
supplements O 
from O 
which O 
they O 
were O 
derived O 
. O 
This O 
disparity O 
could O 
be O 
due O 
to O 
interactions O 
between O 
the O 
various O 
phytochemicals O 
present O 
in O 
the O 
whole O 
plant O 
. O 
The O 
phenolic B-FAMILY 
acids I-FAMILY 
, O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CA O 
) O 
and O 
ferulic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
are O 
widely O 
present O 
in O 
foods O 
and O 
dietary O 
supplements O 
, O 
and O 
they O 
are O 
assumed O 
to O 
exert O 
various O 
beneficial O 
biological O 
effects O 
. O 
However O 
, O 
there O 
is O 
little O 
data O 
on O 
the O 
potential O 
biological O 
interactions O 
of O 
these O 
three O 
phenolic B-FAMILY 
acids I-FAMILY 
which O 
commonly O 
occur O 
together O 
and O 
are O 
linked O 
metabolically O 
. O 
In O 
the O 
present O 
study O 
, O 
liver O 
toxicity O 
of O 
the O 
three O 
phenolic B-FAMILY 
acids I-FAMILY 
was O 
assessed O 
on O 
the O 
three O 
compounds O 
singly O 
and O 
in O 
various O 
binary O 
and O 
one O 
ternary O 
combinations O 
. O 
A O 
series O 
of O 
in O 
vitro O 
endpoints O 
relevant O 
to O 
liver O 
toxicity O 
were O 
evaluated O 
in O 
both O 
a O 
human O 
( O 
HepG2 O 
/ O 
C3A O 
) O 
and O 
rat O 
( O 
MH1C1 O 
) O 
hepatocyte O 
cell O 
line O 
. O 
The O 
Combination O 
Index O 
( O 
CI O 
) O 
was O 
calculated O 
for O 
each O 
endpoint O 
from O 
both O 
the O 
concentration O 
responses O 
of O 
the O 
single O 
compounds O 
and O 
the O 
responses O 
of O 
the O 
various O 
binary O 
and O 
ternary O 
mixtures O 
. O 
Both O 
synergistic O 
and O 
antagonistic O 
interactions O 
were O 
observed O 
for O 
some O 
endpoints O 
and O 
some O 
combinations O 
of O 
test O 
agents O 
. O 
Interactions O 
were O 
most O 
prevalent O 
in O 
measures O 
of O 
oxidative O 
stress O 
and O 
cytochrome O 
P450 O 
activities O 
in O 
both O 
cell O 
types O 
. O 
There O 
was O 
only O 
a O 
53% O 
concordance O 
between O 
the O 
rat O 
and O 
human O 
cells O 
which O 
may O 
be O 
suggestive O 
of O 
species O 
differences O 
. O 
The O 
data O 
suggest O 
an O 
approach O 
for O 
better O 
characterizing O 
the O 
beneficial O 
or O 
adverse O 
effects O 
of O 
complex O 
botanical O 
products O 
through O 
evaluation O 
of O 
interactions O 
between O 
individual O 
phytochemical O 
components O 
. O 

, O 
a O 
wide O 
class O 
of O 
environmental O 
contaminants O 
, O 
may O 
cause O 
both O 
acute O 
and O 
delayed O 
health O 
effects O 
in O 
exposed O 
subjects O 
. O 
These O 
effects O 
can O 
range O 
from O 
simple O 
irritation O 
of O 
the O 
skin O 
and O 
eyes O 
to O 
more O 
severe O 
effects O 
such O 
as O 
affecting O 
the O 
nervous O 
system O 
, O 
the O 
reproductive O 
system O 
and O 
cancer O 
. O 
The O 
molecular O 
mechanisms O 
underlying O 
such O 
effects O 
are O 
still O 
under O 
investigation O 
. O 
Epigenetics O 
is O 
the O 
study O 
of O 
heritable O 
changes O 
in O 
gene O 
expression O 
that O 
occur O 
without O 
a O 
change O 
in O 
the O 
DNA O 
sequence O 
. O 
Several O 
epigenetic O 
mechanisms O 
, O 
including O 
DNA O 
methylation O 
, O 
histone O 
modifications O 
and O 
microRNA O 
expression O 
, O 
can O 
be O 
triggered O 
by O 
environmental O 
factors O 
. O 
We O 
review O 
current O 
evidences O 
indicating O 
that O 
epigenetic O 
modifications O 
may O 
mediate O 
pesticide O 
effects O 
on O 
human O 
health O 
. O 
In O 
vitro O 
, O 
animal O 
, O 
and O 
human O 
investigations O 
have O 
identified O 
several O 
classes O 
of O 
pesticides O 
that O 
modify O 
epigenetic O 
marks O 
, O 
including O 
endocrine O 
disruptors O 
, O 
persistent O 
organic O 
pollutants O 
, O 
arsenic B-SYSTEMATIC 
, O 
several O 
herbicides O 
and O 
insecticides O 
. O 
Several O 
investigations O 
have O 
examined O 
the O 
effects O 
of O 
environmental O 
exposures O 
and O 
epigenetic O 
markers O 
, O 
and O 
identified O 
toxicants O 
that O 
modify O 
epigenetic O 
states O 
. O 
These O 
modifications O 
are O 
similar O 
to O 
the O 
ones O 
found O 
in O 
pathological O 
tissue O 
samples O 
. O 
In O 
spite O 
of O 
the O 
current O 
limitations O 
, O 
available O 
evidence O 
supports O 
the O 
concept O 
that O 
epigenetics O 
holds O 
substantial O 
potential O 
for O 
furthering O 
our O 
understanding O 
of O 
the O 
molecular O 
mechanisms O 
of O 
pesticides O 
health O 
effects O 
, O 
as O 
well O 
as O 
for O 
predicting O 
health O 
- O 
related O 
risks O 
due O 
to O 
conditions O 
of O 
environmental O 
exposure O 
and O 
individual O 
susceptibility O 
. O 

brain O 
region O 
activation O 
by O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonist O 
/ O 
inverse O 
agonist O 
ABT-239 B-IDENTIFIER 
enhances O 
acetylcholine B-SYSTEMATIC 
and O 
histamine B-TRIVIAL 
release O 
and O 
increases O 
c-Fos O 
expression O 
. O 

axons O 
originate O 
solely O 
from O 
the O 
tuberomamillary O 
nucleus O 
( O 
TMN O 
) O 
to O 
innervate O 
almost O 
all O 
brain O 
regions O 
. O 
This O 
feature O 
is O 
consistent O 
with O 
a O 
function O 
for O 
histamine B-TRIVIAL 
over O 
a O 
host O 
of O 
physiological O 
processes O 
, O 
including O 
regulation O 
of O 
appetite O 
, O 
body O 
temperature O 
, O 
cognitive O 
processes O 
, O 
pain O 
perception O 
and O 
sleep O 
- O 
wake O 
cycle O 
. O 
An O 
important O 
question O 
is O 
whether O 
these O 
diverse O 
physiological O 
roles O 
are O 
served O 
by O 
different O 
histamine O 
neuronal O 
subpopulations O 
. O 
Here O 
we O 
report O 
that O 
systemic O 
administration O 
of O 
the O 
non-imidazole O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonist O 
4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile B-SYSTEMATIC 
( O 
ABT-239 B-IDENTIFIER 
, O 
3 O 
mg O 
/ O 
kg O 
) O 
increased O 
c-Fos O 
expression O 
dose O 
- O 
dependently O 
in O 
rat O 
cortex O 
and O 
nucleus O 
basalis O 
magnocellularis O 
( O 
NBM O 
) O 
but O 
not O 
in O 
the O 
nucleus O 
accumbens O 
( O 
NAcc O 
) O 
nor O 
striatum O 
, O 
and O 
augmented O 
acetylcholine B-SYSTEMATIC 
and O 
histamine B-TRIVIAL 
release O 
from O 
rat O 
prefrontal O 
cortex O 
. O 
To O 
further O 
understand O 
functional O 
histaminergic O 
pathways O 
in O 
the O 
brain O 
, O 
dual O 
- O 
probe O 
microdialysis O 
was O 
used O 
to O 
pharmacologically O 
block O 
H3 O 
receptors O 
in O 
the O 
TMN O 
. O 
Perfusion O 
of O 
the O 
TMN O 
with O 
ABT-239 B-IDENTIFIER 
( O 
10 O 
μM O 
) O 
increased O 
histamine B-TRIVIAL 
release O 
from O 
the O 
TMN O 
, O 
NBM O 
, O 
and O 
cortex O 
, O 
but O 
not O 
from O 
the O 
striatum O 
or O 
NAcc O 
. O 
When O 
administered O 
locally O 
, O 
ABT-239 B-IDENTIFIER 
increased O 
histamine B-TRIVIAL 
release O 
from O 
the O 
NBM O 
, O 
but O 
not O 
from O 
the O 
NAcc O 
. O 
Systemic O 
as O 
well O 
as O 
intra-TMN O 
administration O 
of O 
ABT-239 B-IDENTIFIER 
increased O 
c-Fos O 
expression O 
in O 
the O 
NBM O 
, O 
and O 
cortex O 
, O 
but O 
not O 
in O 
the O 
striatum O 
or O 
NAcc O 
. O 
Thus O 
, O 
as O 
defined O 
by O 
their O 
sensitivity O 
to O 
ABT-239 B-IDENTIFIER 
, O 
histaminergic O 
neurons O 
establish O 
distinct O 
pathways O 
according O 
to O 
their O 
terminal O 
projections O 
, O 
and O 
can O 
differentially O 
modulate O 
neurotransmitter O 
release O 
in O 
a O 
brain O 
region O 
- O 
specific O 
manner O 
. O 
This O 
implies O 
independent O 
functions O 
of O 
subsets O 
of O 
histamine B-TRIVIAL 
neurons O 
according O 
to O 
their O 
terminal O 
projections O 
, O 
with O 
relevant O 
consequences O 
for O 
the O 
development O 
of O 
specific O 
compounds O 
that O 
affect O 
only O 
subsets O 
of O 
histamine B-TRIVIAL 
neurones O 
, O 
thus O 
increasing O 
target O 
specificity O 
. O 

takes O 
place O 
in O 
mutated O 
p53 O 
neuroblastoma O 
cells O 
in O 
response O 
to O 
hypoxia O 
mimetic O 
CoCl(2) B-FORMULA 
. O 

tumors O 
like O 
neuroblastoma O 
exhibit O 
hypoxic O 
areas O 
, O 
which O 
can O 
lead O 
both O 
to O 
cell O 
death O 
or O 
aggressiveness O 
increase O 
. O 
Hypoxia O 
is O 
a O 
known O 
stress O 
able O 
to O 
induce O 
stabilization O 
of O 
p53 O 
, O 
implicated O 
in O 
cell O 
fate O 
regulation O 
. O 
Recently O 
, O 
p53 O 
appeared O 
to O 
be O 
involved O 
in O 
autophagy O 
in O 
an O 
opposite O 
manner O 
, O 
depending O 
on O 
its O 
location O 
: O 
when O 
nuclear O 
, O 
it O 
enhanced O 
transcription O 
of O 
pro O 
- O 
autophagic O 
genes O 
whereas O 
when O 
cytoplasmic O 
, O 
it O 
inhibited O 
the O 
autophagic O 
process O 
. O 
Today O 
, O 
we O 
used O 
cobalt B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
a O 
hypoxia O 
mimetic O 
that O 
inhibits O 
proteasomal O 
HIF-1 O 
degradation O 
and O 
generates O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
We O 
focused O 
on O 
CoCl2 B-FORMULA 
-induced O 
cell O 
death O 
in O 
a O 
DNA O 
- O 
binding O 
mutated O 
p53 O 
neuroblastoma O 
cell O 
line O 
(SKNBE(2c)) O 
. O 
An O 
autophagic O 
signaling O 
was O 
evidenced O 
by O 
an O 
increase O 
of O 
Beclin-1 O 
, O 
ATG O 
5-12 O 
, O 
and O 
LC3-II O 
expression O 
whereas O 
the O 
p53(mut) O 
presence O 
decreased O 
with O 
CoCl2 B-FORMULA 
time O 
exposure O 
. O 
Activation O 
of O 
the O 
pathway O 
seemed O 
to O 
protect O 
cells O 
from O 
ROS O 
production O 
and O 
, O 
at O 
least O 
in O 
part O 
, O 
from O 
death O 
. O 
The O 
autophagic O 
inhibitors O 
activated O 
the O 
apoptotic O 
signaling O 
and O 
the O 
death O 
was O 
enhanced O 
. O 
To O 
delineate O 
the O 
eventual O 
implication O 
of O 
the O 
p53(mut) O 
in O 
the O 
autophagic O 
process O 
in O 
response O 
to O 
hypoxia O 
, O 
we O 
monitored O 
signaling O 
in O 
p53(WT)SHSY5Y O 
cells O 
, O 
after O 
either O 
shRNA-p53 O 
down O 
- O 
regulation O 
or O 
transcriptional O 
activity O 
inhibition O 
by O 
pifithrin O 
alpha O 
. O 
We O 
did O 
not O 
detect O 
autophagy O 
neither O 
with O 
p53(wt) O 
nor O 
when O 
p53 O 
was O 
lacking O 
whereas O 
such O 
a O 
response O 
was O 
effective O 
with O 
a O 
mutated O 
or O 
inactivated O 
p53 O 
. O 
To O 
conclude O 
, O 
mutated O 
p53 O 
in O 
neuroblastoma O 
cells O 
could O 
be O 
linked O 
with O 
the O 
switch O 
between O 
apoptotic O 
response O 
and O 
cell O 
death O 
by O 
autophagy O 
in O 
response O 
to O 
hypoxic O 
mimetic O 
stress O 
. O 

phencyclidine B-TRIVIAL 
administration O 
decreases O 
the O 
density O 
of O 
cortical O 
interneurons O 
and O 
increases O 
the O 
expression O 
of O 
neuregulin-1 O 
. O 

: O 
Perinatal O 
phencyclidine B-TRIVIAL 
( O 
PCP B-ABBREVIATION 
) O 
administration O 
in O 
rat O 
blocks O 
the O 
N-methyl B-SYSTEMATIC 
D-aspartate I-SYSTEMATIC 
receptor O 
( O 
NMDAR O 
) O 
and O 
causes O 
symptoms O 
reminiscent O 
of O 
schizophrenia O 
in O 
human O 
. O 
A O 
growing O 
body O 
of O 
evidence O 
suggests O 
that O 
alterations O 
in O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
interneuron O 
neurotransmission O 
may O 
be O 
associated O 
with O 
schizophrenia O 
. O 
Neuregulin-1 O 
( O 
NRG-1 O 
) O 
is O 
a O 
trophic O 
factor O 
important O 
for O 
neurodevelopment O 
, O 
synaptic O 
plasticity O 
, O 
and O 
wiring O 
of O 
GABA B-ABBREVIATION 
circuits O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
long O 
- O 
term O 
effects O 
of O 
perinatal O 
PCP B-ABBREVIATION 
administration O 
on O 
the O 
projection O 
and O 
local O 
circuit O 
neurons O 
and O 
NRG-1 O 
expression O 
in O 
the O 
cortex O 
and O 
hippocampus O 
. O 
METHODS O 
: O 
Rats O 
were O 
treated O 
on O 
postnatal O 
day O 
2 O 
( O 
P2 O 
) O 
, O 
P6 O 
, O 
P9 O 
, O 
and O 
P12 O 
with O 
either O 
PCP B-ABBREVIATION 
( O 
10 O 
mg O 
/ O 
kg O 
) O 
or O 
saline O 
. O 
Morphological O 
studies O 
and O 
determination O 
of O 
NRG-1 O 
expression O 
were O 
performed O 
at O 
P70 O 
. O 
RESULTS O 
: O 
We O 
demonstrate O 
reduced O 
densities O 
of O 
principal O 
neurons O 
in O 
the O 
CA3 O 
and O 
dentate O 
gyrus O 
( O 
DG O 
) O 
subregions O 
of O 
the O 
hippocampus O 
and O 
a O 
reduction O 
of O 
major O 
interneuronal O 
populations O 
in O 
all O 
cortical O 
and O 
hippocampal O 
regions O 
studied O 
in O 
PCP B-ABBREVIATION 
-treated O 
rats O 
compared O 
with O 
controls O 
. O 
For O 
the O 
first O 
time O 
, O 
we O 
show O 
the O 
reduced O 
density O 
of O 
reelin- O 
and O 
somatostatin O 
- O 
positive O 
cells O 
in O 
the O 
cortex O 
and O 
hippocampus O 
of O 
animals O 
perinatally O 
treated O 
with O 
PCP B-ABBREVIATION 
. O 
Furthermore O 
, O 
an O 
increase O 
in O 
the O 
numbers O 
of O 
perisomatic O 
inhibitory O 
terminals O 
around O 
the O 
principal O 
cells O 
was O 
observed O 
in O 
the O 
motor O 
cortex O 
and O 
DG O 
. O 
We O 
also O 
show O 
that O 
perinatal O 
PCP B-ABBREVIATION 
administration O 
leads O 
to O 
an O 
increased O 
NRG-1 O 
expression O 
in O 
the O 
cortex O 
and O 
hippocampus O 
. O 
CONCLUSION O 
: O 
Taken O 
together O 
, O 
our O 
findings O 
demonstrate O 
that O 
perinatal O 
PCP B-ABBREVIATION 
administration O 
increases O 
NRG-1 O 
expression O 
and O 
reduces O 
the O 
number O 
of O 
projecting O 
and O 
local O 
circuit O 
neurons O 
, O 
revealing O 
complex O 
consequences O 
of O 
NMDAR O 
blockade O 
. O 

of O 
supplementary O 
selenium B-SYSTEMATIC 
source O 
on O 
the O 
blood O 
parameters O 
in O 
beef O 
cows O 
and O 
their O 
nursing O 
calves O 
. O 

2 O 
years O 
, O 
32 O 
beef O 
cows O 
nursing O 
calves O 
in O 
southwest O 
Arkansas O 
were O 
randomly O 
selected O 
from O 
a O 
herd O 
of O 
120 O 
that O 
were O 
managed O 
in O 
six O 
groups O 
and O 
were O 
assigned O 
to O 
six O 
5.1-ha O 
bermudagrass O 
( O 
Cynodon O 
dactylon O 
[ O 
L O 
. O 
] O 
Pers O 
. O 
) O 
pastures O 
. O 
Treatments O 
were O 
assigned O 
to O 
pastures O 
( O 
two O 
pastures O 
/ O 
treatment O 
) O 
and O 
cows O 
had O 
ad O 
libitum O 
access O 
to O 
one O 
of O 
three O 
free O 
- O 
choice O 
minerals O 
: O 
( O 
1 O 
) O 
no O 
supplemental O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
) O 
, O 
( O 
2 O 
) O 
26 O 
mg O 
of O 
supplemental O 
Se B-FORMULA 
from O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
per O 
kilogram O 
, O 
and O 
( O 
3 O 
) O 
26 O 
mg O 
of O 
supplemental O 
Se B-FORMULA 
from O 
seleno B-SYSTEMATIC 
-yeast O 
per O 
kilogram O 
( O 
designed O 
mineral O 
intake O 
= O 
113 O 
g O 
/ O 
cow O 
daily O 
) O 
. O 
Data O 
were O 
analyzed O 
using O 
a O 
mixed O 
model O 
; O 
year O 
and O 
pasture O 
were O 
the O 
random O 
effects O 
and O 
treatment O 
was O 
the O 
fixed O 
effect O 
. O 
At O 
the O 
beginning O 
of O 
the O 
calving O 
and O 
breeding O 
seasons O 
, O 
cows O 
supplemented O 
with O 
Se B-FORMULA 
had O 
greater O 
( O 
P O 
< O 
0.01 O 
) O 
whole O 
blood O 
Se B-FORMULA 
concentration O 
( O 
WBSe O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
activities O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
than O 
cows O 
receiving O 
no O 
supplemental O 
Se B-FORMULA 
; O 
cows O 
fed O 
seleno B-SYSTEMATIC 
-yeast O 
had O 
greater O 
( O 
P O 
≤ O 
0.05 O 
) O 
WBSe O 
than O 
cows O 
fed O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
, O 
but O 
GSH B-ABBREVIATION 
-Px O 
did O 
not O 
differ O 
( O 
P O 
≥ O 
0.25 O 
) O 
between O 
the O 
two O 
sources O 
. O 
At O 
birth O 
and O 
near O 
peak O 
lactation O 
( O 
late O 
May O 
) O 
, O 
calves O 
from O 
cows O 
supplemented O 
with O 
Se B-FORMULA 
had O 
greater O 
( O 
P O 
< O 
0.01 O 
) O 
WBSe O 
than O 
calves O 
from O 
cows O 
fed O 
no O 
Se B-FORMULA 
and O 
calves O 
from O 
cows O 
fed O 
seleno B-SYSTEMATIC 
-yeast O 
had O 
greater O 
( O 
P O 
≤ O 
0.01 O 
) O 
WBSe O 
and O 
GSH B-ABBREVIATION 
-Px O 
than O 
calves O 
from O 
cows O 
fed O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
. O 
Thyroxine B-TRIVIAL 
( O 
T4 O 
) O 
, O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
, O 
and O 
the O 
T4 O 
: O 
T3 O 
ratio O 
in O 
calves O 
did O 
not O 
differ O 
among O 
treatments O 
( O 
P O 
≥ O 
0.35 O 
) O 
. O 
At O 
birth O 
, O 
insulin O 
- O 
like O 
growth O 
factor O 
1 O 
( O 
IGF-1 O 
) O 
was O 
greater O 
( O 
P O 
= O 
0.02 O 
) O 
in O 
calves O 
nursing O 
cows O 
with O 
no O 
supplemental O 
Se B-FORMULA 
than O 
in O 
ones O 
with O 
supplemental O 
Se B-FORMULA 
; O 
in O 
calves O 
nursing O 
cows O 
with O 
supplemental O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
, O 
IGF-1 O 
did O 
not O 
differ O 
( O 
P O 
= O 
0.96 O 
) O 
from O 
ones O 
offered O 
supplemental O 
seleno B-SYSTEMATIC 
-yeast O 
. O 
Selenium B-SYSTEMATIC 
supplementation O 
of O 
gestating O 
beef O 
cows O 
benefited O 
cows O 
and O 
calves O 
by O 
increasing O 
WBSe O 
and O 
GSH B-ABBREVIATION 
-Px O 
. O 
The O 
use O 
of O 
seleno B-SYSTEMATIC 
-yeast O 
as O 
a O 
Se B-FORMULA 
supplement O 
compared O 
to O 
sodium B-SYSTEMATIC 
selenite I-SYSTEMATIC 
increased O 
the O 
WBSe O 
of O 
both O 
cows O 
and O 
their O 
calves O 
without O 
affecting O 
the O 
T4 O 
to O 
T3 O 
conversion O 
or O 
IGF-1 O 
concentrations O 
. O 

of O 
Pharmacokinetic O 
Enhancement O 
Between O 
Ritonavir B-TRIVIAL 
and O 
Saquinavir B-TRIVIAL 
; O 
Micro O 
/ O 
Small O 
Dosing O 
Tests O 
Using O 
Midazolam B-TRIVIAL 
( O 
CYP3A4 O 
) O 
, O 
Fexofenadine B-TRIVIAL 
( O 
p-Glycoprotein O 
) O 
, O 
and O 
Pravastatin B-TRIVIAL 
( O 
OATP1B1 O 
) O 
as O 
Probe O 
Drugs O 
. O 

investigated O 
the O 
mechanisms O 
of O 
ritonavir B-TRIVIAL 
-mediated O 
enhancement O 
effect O 
on O 
the O 
pharmacokinetics O 
of O 
saquinavir B-TRIVIAL 
using O 
in O 
vivo O 
probes O 
for O 
CYP3A4 O 
( O 
midazolam B-TRIVIAL 
) O 
, O 
p-glycoprotein O 
( O 
fexofenadine B-TRIVIAL 
) O 
, O 
and O 
OATP1B1 O 
( O 
pravastatin B-TRIVIAL 
) O 
following O 
oral O 
micro O 
/ O 
small O 
dosing O 
. O 
A O 
cocktail O 
of O 
the O 
drugs O 
( O 
2 O 
mg O 
of O 
saquinavir B-TRIVIAL 
, O 
100 O 
µg O 
of O 
each O 
probe O 
) O 
was O 
administered O 
to O 
eight O 
healthy O 
volunteers O 
( O 
phase O 
1 O 
) O 
, O 
and O 
then O 
coadministered O 
with O 
20 O 
mg O 
( O 
phase O 
2 O 
) O 
and O 
100 O 
mg O 
( O 
phase O 
3 O 
) O 
of O 
ritonavir B-TRIVIAL 
. O 
Plasma O 
concentrations O 
of O 
the O 
drugs O 
were O 
measured O 
by O 
validated O 
LC-MS O 
/ O 
MS O 
methods O 
. O 
The O 
mean O 
plasma O 
AUC(0-24) O 
( O 
pg O 
hour O 
/ O 
mL O 
) O 
of O 
saquinavir B-TRIVIAL 
at O 
phases O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
was O 
101 O 
, O 
2 O 
540 O 
, O 
and O 
23 O 
900 O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
respectively O 
. O 
The O 
relative O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
(AUC)(0-24) O 
ratios O 
of O 
midazolam B-TRIVIAL 
and O 
fexofenadine B-TRIVIAL 
at O 
phases O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
were O 
1 O 
: O 
5.9 O 
: O 
14.7 O 
( O 
P O 
< O 
0.01 O 
) O 
, O 
and O 
1 O 
: O 
1.4 O 
: O 
2.2 O 
( O 
P O 
< O 
.01-.05 O 
) O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
there O 
was O 
no O 
difference O 
in O 
the O 
pharmacokinetics O 
of O 
pravastatin B-TRIVIAL 
. O 
Inhibition O 
of O 
intestinal O 
and O 
hepatic O 
CYP3A O 
- O 
mediated O 
metabolism O 
, O 
and O 
intestinal O 
p-glycoprotein- O 
mediated O 
efflux O 
of O 
saquinavir B-TRIVIAL 
, O 
but O 
not O 
OATP1B1 O 
, O 
is O 
involved O 
in O 
the O 
enhancement O 
mechanism O 
. O 
Micro O 
/ O 
small O 
dosing O 
is O 
useful O 
for O 
examining O 
the O 
mechanism O 
of O 
drug O 
interactions O 
without O 
safety O 
concern O 
. O 

of O 
Allopurinol B-TRIVIAL 
-Making O 
an O 
Old O 
Drug O 
Safer O 
. O 

is O 
a O 
drug O 
that O 
has O 
been O 
used O 
for O 
decades O 
to O 
lower O 
serum O 
urate O 
levels O 
in O 
patients O 
with O 
gout O 
or O 
chronic O 
renal O 
failure O 
and O 
in O 
cancer O 
patients O 
undergoing O 
chemotherapy O 
at O 
risk O 
of O 
tumor O 
lysis O 
syndrome O 
. O 
Patients O 
may O 
develop O 
cutaneous O 
hypersensitivity O 
reactions O 
, O 
ranging O 
from O 
mild O 
rashes O 
to O 
potentially O 
fatal O 
severe O 
cutaneous O 
adverse O 
reactions O 
( O 
SCARs O 
) O 
namely O 
drug O 
hypersensitivity O 
syndrome O 
, O 
Stevens-Johnson O 
syndrome O 
( O 
SJS O 
) O 
, O 
and O 
toxic O 
epidermal O 
necrolysis O 
( O 
TEN O 
) O 
. O 
Recent O 
studies O 
have O 
demonstrated O 
the O 
association O 
between O 
human O 
leukocyte O 
antigen O 
( O 
HLA O 
) O 
B*58 O 
: O 
1 O 
allele O 
and O 
allopurinol B-TRIVIAL 
-induced O 
SCARs O 
, O 
which O 
might O 
explain O 
ethnic O 
differences O 
in O 
their O 
incidences O 
. O 
Genotyping O 
is O 
now O 
required O 
before O 
starting O 
abacavir B-TRIVIAL 
and O 
carbamazepine B-TRIVIAL 
so O 
as O 
to O 
identify O 
individuals O 
susceptible O 
to O 
SJS O 
. O 
However O 
, O 
no O 
genetic O 
screening O 
is O 
advocated O 
before O 
commencement O 
of O 
allopurinol B-TRIVIAL 
. O 
The O 
lack O 
of O 
availability O 
of O 
a O 
rapid O 
and O 
inexpensive O 
screening O 
test O 
for O 
the O 
HLA-B*58 O 
: O 
1 O 
allele O 
is O 
one O 
of O 
the O 
obstacles O 
to O 
such O 
screening O 
. O 
Development O 
of O 
a O 
test O 
that O 
is O 
quick O 
, O 
accurate O 
, O 
and O 
cost O 
- O 
effective O 
is O 
warranted O 
. O 

present O 
study O 
presents O 
a O 
data O 
- O 
oriented O 
, O 
tiered O 
approach O 
to O 
assessing O 
the O 
bioaccumulation O 
potential O 
of O 
chemicals O 
according O 
to O 
the O 
European O 
chemicals O 
regulation O 
on O 
Registration O 
, O 
Evaluation O 
, O 
Authorisation O 
and O 
Restriction O 
of O 
Chemicals O 
( O 
REACH O 
) O 
. O 
The O 
authors O 
compiled O 
data O 
for O 
eight O 
physicochemical O 
descriptors O 
( O 
partition O 
coefficients O 
, O 
degradation O 
half O 
- O 
lives O 
, O 
polarity O 
, O 
and O 
so O 
forth O 
) O 
for O 
a O 
set O 
of O 
713 O 
organic O 
chemicals O 
for O 
which O 
experimental O 
values O 
of O 
the O 
bioconcentration O 
factor O 
( O 
BCF O 
) O 
are O 
available O 
. O 
The O 
authors O 
employed O 
supervised O 
machine O 
learning O 
methods O 
( O 
conditional O 
inference O 
trees O 
and O 
random O 
forests O 
) O 
to O 
derive O 
relationships O 
between O 
the O 
physicochemical O 
descriptors O 
and O 
the O 
BCF O 
values O 
. O 
In O 
a O 
first O 
tier O 
, O 
the O 
authors O 
established O 
rules O 
for O 
classifying O 
a O 
chemical O 
as O 
bioaccumulative O 
( O 
B O 
) O 
or O 
nonbioaccumulative O 
( O 
non-B O 
) O 
. O 
In O 
a O 
second O 
tier O 
, O 
the O 
authors O 
developed O 
a O 
new O 
tool O 
for O 
estimating O 
numerical O 
BCF O 
values O 
. O 
For O 
both O 
cases O 
the O 
optimal O 
set O 
of O 
relevant O 
descriptors O 
was O 
determined O 
; O 
these O 
are O 
biotransformation O 
half O 
- O 
life O 
and O 
octanol B-SYSTEMATIC 
-water O 
distribution O 
coefficient O 
( O 
log O 
D O 
) O 
for O 
the O 
classification O 
rules O 
and O 
log O 
D O 
, O 
biotransformation O 
half O 
- O 
life O 
, O 
and O 
topological O 
polar O 
surface O 
area O 
for O 
the O 
BCF O 
estimation O 
tool O 
. O 
The O 
uncertainty O 
of O 
the O 
BCF O 
estimates O 
obtained O 
with O 
the O 
new O 
estimation O 
tool O 
was O 
quantified O 
by O 
comparing O 
the O 
estimated O 
and O 
experimental O 
BCF O 
values O 
of O 
the O 
713 O 
chemicals O 
. O 
Comparison O 
with O 
existing O 
BCF O 
estimation O 
methods O 
indicates O 
that O 
the O 
performance O 
of O 
this O 
new O 
BCF O 
estimation O 
tool O 
is O 
at O 
least O 
as O 
high O 
as O 
that O 
of O 
existing O 
methods O 
. O 
The O 
authors O 
recommend O 
the O 
present O 
study's O 
classification O 
rules O 
and O 
BCF O 
estimation O 
tool O 
for O 
a O 
consensus O 
application O 
in O 
combination O 
with O 
existing O 
BCF O 
estimation O 
methods O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1187-1195 O 
. O 
© O 
2013 O 
SETAC O 
. O 

pharmacokinetics O 
and O 
dose O 
optimization O 
of O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
HCT O 
recipients O 
receiving O 
oral O 
mycophenolate B-TRIVIAL 
mofetil I-TRIVIAL 
. O 

sought O 
to O 
create O 
a O 
population O 
pharmacokinetic O 
model O 
for O 
total O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
MPA B-ABBREVIATION 
) O 
, O 
to O 
study O 
the O 
effects O 
of O 
different O 
covariates O 
on O 
MPA B-ABBREVIATION 
pharmacokinetics O 
, O 
to O 
create O 
a O 
limited O 
sampling O 
schedule O 
( O 
LSS O 
) O 
to O 
characterize O 
MPA B-ABBREVIATION 
exposure O 
( O 
i.e O 
. O 
, O 
area O 
under O 
the O 
curve O 
or O 
AUC O 
) O 
with O 
maximum O 
a O 
posteriori O 
Bayesian O 
estimation O 
, O 
and O 
to O 
simulate O 
an O 
optimized O 
dosing O 
scheme O 
for O 
allogeneic O 
hematopoietic O 
cell O 
transplantation O 
( O 
HCT O 
) O 
recipients O 
. O 
Four O 
thousand O 
four O 
hundred O 
ninety O 
- O 
six O 
MPA B-ABBREVIATION 
concentration O 
- O 
time O 
points O 
from O 
408 O 
HCT O 
recipients O 
were O 
analyzed O 
retrospectively O 
using O 
a O 
nonlinear O 
mixed O 
effects O 
modeling O 
approach O 
. O 
MPA B-ABBREVIATION 
pharmacokinetics O 
was O 
characterized O 
with O 
a O 
two O 
- O 
compartment O 
model O 
with O 
first O 
- O 
order O 
elimination O 
and O 
a O 
time O 
- O 
lagged O 
first O 
- O 
order O 
absorption O 
process O 
. O 
Concomitant O 
cyclosporine B-TRIVIAL 
and O 
serum O 
albumin O 
were O 
significant O 
covariates O 
. O 
The O 
median O 
MPA B-ABBREVIATION 
clearance O 
( O 
CL O 
) O 
and O 
volume O 
of O 
the O 
central O 
compartment O 
were O 
24.2 O 
L O 
/ O 
hour O 
and O 
36.4 O 
L O 
, O 
respectively O 
, O 
for O 
a O 
70 O 
kg O 
patient O 
receiving O 
tacrolimus B-TRIVIAL 
with O 
a O 
serum O 
albumin O 
of O 
3.4 O 
g O 
/ O 
dL O 
. O 
Dosing O 
simulations O 
indicated O 
that O 
higher O 
oral O 
MMF B-ABBREVIATION 
doses O 
are O 
needed O 
with O 
concomitant O 
cyclosporine B-TRIVIAL 
, O 
which O 
increases O 
MPA B-ABBREVIATION 
CL O 
by O 
33.8% O 
. O 
The O 
optimal O 
LSS O 
was O 
immediately O 
before O 
and O 
at O 
0.25 O 
hours O 
, O 
1.25 O 
hours O 
, O 
2 O 
hours O 
, O 
and O 
4 O 
hours O 
after O 
oral O 
mycophenolate B-TRIVIAL 
mofetil I-TRIVIAL 
administration O 
. O 
MPA B-ABBREVIATION 
AUC O 
in O 
an O 
individual O 
HCT O 
recipient O 
can O 
be O 
accurately O 
estimated O 
using O 
a O 
five O 
- O 
sample O 
LSS O 
and O 
maximum O 
a O 
posteriori O 
Bayesian O 
estimation O 
. O 

receptors O 
( O 
AMPARs O 
) O 
are O 
glutamate B-TRIVIAL 
-gated O 
ion O 
channels O 
ubiquitous O 
in O 
the O 
vertebrate O 
central O 
nervous O 
system O 
, O 
where O 
they O 
mediate O 
fast O 
excitatory O 
neurotransmission O 
and O 
act O 
as O 
molecular O 
determinants O 
of O 
memory O 
formation O 
and O 
learning O 
. O 
Together O 
with O 
detailed O 
analyses O 
of O 
individual O 
AMPAR O 
domains O 
, O 
structural O 
studies O 
of O 
full O 
- O 
length O 
AMPARs O 
by O 
electron O 
microscopy O 
and O 
x-ray O 
crystallography O 
have O 
provided O 
important O 
insights O 
into O 
channel O 
assembly O 
and O 
function O 
. O 
However O 
, O 
the O 
correlation O 
between O 
the O 
structure O 
and O 
functional O 
states O 
of O 
the O 
channel O 
remains O 
ambiguous O 
particularly O 
because O 
these O 
functional O 
states O 
can O 
be O 
assessed O 
only O 
with O 
the O 
receptor O 
bound O 
within O 
an O 
intact O 
lipid O 
bilayer O 
. O 
To O 
provide O 
a O 
basis O 
for O 
investigating O 
AMPAR O 
structure O 
in O 
a O 
membrane O 
environment O 
, O 
we O 
developed O 
an O 
optimized O 
reconstitution O 
protocol O 
using O 
a O 
receptor O 
whose O 
structure O 
has O 
previously O 
been O 
characterized O 
by O 
electron O 
microscopy O 
. O 
Single O 
- O 
channel O 
recordings O 
of O 
reconstituted O 
homomeric O 
GluA2(flop) O 
receptors O 
recapitulate O 
key O 
electrophysiological O 
parameters O 
of O 
the O 
channels O 
expressed O 
in O 
native O 
cellular O 
membranes O 
. O 
Atomic O 
force O 
microscopy O 
studies O 
of O 
the O 
reconstituted O 
samples O 
provide O 
high O 
- O 
resolution O 
images O 
of O 
membrane O 
- O 
embedded O 
full O 
- O 
length O 
AMPARs O 
at O 
densities O 
comparable O 
to O 
those O 
in O 
postsynaptic O 
membranes O 
. O 
The O 
data O 
demonstrate O 
the O 
effect O 
of O 
protein O 
density O 
on O 
conformational O 
flexibility O 
and O 
dimensions O 
of O 
the O 
receptors O 
and O 
provide O 
the O 
first O 
structural O 
characterization O 
of O 
functional O 
membrane O 
- O 
embedded O 
AMPARs O 
, O 
thus O 
laying O 
the O 
foundation O 
for O 
correlated O 
structure O 
- O 
function O 
analyses O 
of O 
the O 
predominant O 
mediators O 
of O 
excitatory O 
synaptic O 
signals O 
in O 
the O 
brain O 
. O 

activation O 
of O 
the O 
complement O 
cascade O 
, O 
a O 
cornerstone O 
of O 
the O 
innate O 
immune O 
response O 
, O 
produces O 
a O 
number O 
of O 
small O 
( O 
74-77 O 
amino B-FAMILY 
acid I-FAMILY 
) O 
fragments O 
, O 
originally O 
termed O 
anaphylatoxins O 
, O 
that O 
are O 
potent O 
chemoattractants O 
and O 
secretagogues O 
that O 
act O 
on O 
a O 
wide O 
variety O 
of O 
cell O 
types O 
. O 
These O 
fragments O 
, O 
C5a O 
, O 
C4a O 
, O 
and O 
C3a O 
, O 
participate O 
at O 
all O 
levels O 
of O 
the O 
immune O 
response O 
and O 
are O 
also O 
involved O 
in O 
other O 
processes O 
such O 
as O 
neural O 
development O 
and O 
organ O 
regeneration O 
. O 
Their O 
primary O 
function O 
, O 
however O 
, O 
is O 
in O 
inflammation O 
, O 
so O 
they O 
are O 
important O 
targets O 
for O 
the O 
development O 
of O 
antiinflammatory O 
therapies O 
. O 
Only O 
three O 
receptors O 
for O 
complement O 
peptides O 
have O 
been O 
found O 
, O 
but O 
there O 
are O 
no O 
satisfactory O 
antagonists O 
as O 
yet O 
, O 
despite O 
intensive O 
investigation O 
. O 
In O 
humans O 
, O 
there O 
is O 
a O 
single O 
receptor O 
for O 
C3a O 
( O 
C3a O 
receptor O 
) O 
, O 
no O 
known O 
receptor O 
for O 
C4a O 
, O 
and O 
two O 
receptors O 
for O 
C5a O 
( O 
C5a₁ O 
receptor O 
and O 
C5a₂ O 
receptor O 
) O 
. O 
The O 
most O 
recently O 
characterized O 
receptor O 
, O 
the O 
C5a₂ O 
receptor O 
( O 
previously O 
known O 
as O 
C5L2 O 
or O 
GPR77 O 
) O 
, O 
has O 
been O 
regarded O 
as O 
a O 
passive O 
binding O 
protein O 
, O 
but O 
signaling O 
activities O 
are O 
now O 
ascribed O 
to O 
it O 
, O 
so O 
we O 
propose O 
that O 
it O 
be O 
formally O 
identified O 
as O 
a O 
receptor O 
and O 
be O 
given O 
a O 
name O 
to O 
reflect O 
this O 
. O 
Here O 
, O 
we O 
describe O 
the O 
complex O 
biology O 
of O 
the O 
complement O 
peptides O 
, O 
introduce O 
a O 
new O 
suggested O 
nomenclature O 
, O 
and O 
review O 
our O 
current O 
knowledge O 
of O 
receptor O 
pharmacology O 
. O 

adsorbent O 
performance O 
indicator O 
( O 
API O 
) O 
is O 
proposed O 
in O 
an O 
effort O 
to O 
initially O 
highlight O 
porous O 
materials O 
of O 
potential O 
interest O 
for O 
PSA O 
separation O 
processes O 
. O 
This O 
expression O 
takes O 
into O 
account O 
working O 
capacities O 
, O 
selectivities O 
, O 
and O 
adsorption O 
energies O 
and O 
additionally O 
uses O 
weighting O 
factors O 
to O 
reflect O 
the O 
specific O 
requirements O 
of O 
a O 
given O 
process O 
. O 
To O 
demonstrate O 
the O 
applicability O 
of O 
the O 
API O 
, O 
we O 
have O 
performed O 
the O 
adsorption O 
of O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
and O 
methane B-SYSTEMATIC 
at O 
room O 
temperature O 
on O 
a O 
number O 
of O 
metal O 
- O 
organic O 
frameworks O 
, O 
a O 
zeolite B-TRIVIAL 
and O 
a O 
molecular O 
sieve O 
carbon B-SYSTEMATIC 
. O 
The O 
API O 
is O 
calculated O 
for O 
two O 
different O 
CO2 B-FORMULA 
/ O 
CH4 B-FORMULA 
separation O 
case O 
scenarios O 
: O 
" O 
bulk O 
separation O 
" O 
and O 
" O 
natural O 
gas O 
purification O 
" O 
. O 
This O 
comparison O 
highlights O 
how O 
the O 
API O 
can O 
be O 
more O 
versatile O 
than O 
previously O 
proposed O 
comparison O 
factors O 
for O 
an O 
initial O 
indication O 
of O 
potential O 
adsorbent O 
performance O 
. O 

, O 
we O 
developed O 
a O 
new O 
gene O 
delivery O 
vector O 
by O 
grafting O 
a O 
betaine O 
monomer O 
( O 
N,N-dimethyl(acrylamidopropyl)ammonium B-SYSTEMATIC 
propane I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
, O 
DMAAPS B-ABBREVIATION 
) O 
onto O 
25 O 
KDa O 
polyethylenimine B-SYSTEMATIC 
( O 
PEI B-ABBREVIATION 
25K O 
) O 
via O 
the O 
Michael O 
addition O 
reaction O 
. O 
The O 
graft O 
ratio O 
for O 
betaine O 
on O 
PEI O 
polymer O 
could O 
be O 
readily O 
controlled O 
, O 
and O 
in O 
this O 
study O 
three O 
PEI B-ABBREVIATION 
-betaine O 
conjugates O 
PEI B-ABBREVIATION 
- O 
DMAAPS B-ABBREVIATION 
23% O 
, O 
PEI B-ABBREVIATION 
- O 
DMAAPS B-ABBREVIATION 
55% O 
, O 
and O 
PEI B-ABBREVIATION 
- O 
DMAAPS B-ABBREVIATION 
95% O 
were O 
prepared O 
with O 
their O 
graft O 
ratios O 
of O 
23 O 
, O 
55 O 
, O 
and O 
95% O 
, O 
respectively O 
. O 
The O 
PEI B-ABBREVIATION 
-betaine O 
conjugates O 
exhibited O 
much O 
lower O 
protein O 
adsorption O 
and O 
cytotoxicities O 
compared O 
with O 
PEI B-ABBREVIATION 
25K O 
, O 
and O 
they O 
also O 
showed O 
little O 
or O 
no O 
hemolytic O 
effect O 
. O 
Moreover O 
, O 
the O 
PEI B-ABBREVIATION 
-betaine O 
conjugates O 
display O 
satisfactory O 
DNA O 
condensation O 
capability O 
; O 
and O 
in O 
the O 
absence O 
and O 
presence O 
of O 
serum O 
, O 
PEI B-ABBREVIATION 
- O 
DMAAPS B-ABBREVIATION 
23% O 
/ O 
pEGFP O 
and O 
PEI B-ABBREVIATION 
- O 
DMAAPS B-ABBREVIATION 
55% O 
/ O 
pEGFP O 
complexes O 
exhibited O 
remarkable O 
gene O 
transfection O 
efficiencies O 
determined O 
by O 
flow O 
cytometry O 
, O 
which O 
are O 
in O 
general O 
several O 
times O 
higher O 
than O 
that O 
of O 
PEI B-ABBREVIATION 
25K O 
. O 
With O 
these O 
favorable O 
properties O 
, O 
the O 
PEI B-ABBREVIATION 
-betaine O 
conjugates O 
hold O 
great O 
potential O 
for O 
use O 
as O 
efficient O 
gene O 
delivery O 
vectors O 
. O 
This O 
study O 
suggests O 
that O 
the O 
betaine O 
monomer O 
may O 
serve O 
as O 
a O 
biocompatible O 
modifying O 
agent O 
and O 
this O 
facile O 
strategy O 
may O 
provide O 
a O 
facile O 
and O 
effective O 
way O 
for O 
constructing O 
some O 
other O 
biocompatible O 
materials O 
. O 

between O 
Pluronics B-MULTIPLE 
( I-MULTIPLE 
F127 I-MULTIPLE 
and I-MULTIPLE 
F68 I-MULTIPLE 
) I-MULTIPLE 
and O 
bile B-FAMILY 
salts I-FAMILY 
( O 
NaTDC B-ABBREVIATION 
) O 
in O 
the O 
aqueous O 
phase O 
and O 
the O 
interface O 
of O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
. O 

are O 
being O 
introduced O 
in O 
food O 
research O 
in O 
order O 
to O 
delay O 
lipid O 
digestion O 
, O 
with O 
the O 
length O 
of O 
hydrophilic O 
and O 
hydrophobic O 
chains O 
playing O 
an O 
important O 
role O 
in O 
the O 
rate O 
of O 
such O 
a O 
process O 
. O 
Since O 
bile B-FAMILY 
salts I-FAMILY 
play O 
a O 
crucial O 
role O 
in O 
the O 
lipid O 
digestion O 
process O 
, O 
the O 
aim O 
of O 
this O 
work O 
is O 
to O 
analyze O 
the O 
interactions O 
between O 
Pluronic B-MULTIPLE 
F127 I-MULTIPLE 
or I-MULTIPLE 
F68 I-MULTIPLE 
and O 
the O 
bile B-FAMILY 
salt I-FAMILY 
NaTDC B-ABBREVIATION 
when O 
the O 
latter O 
is O 
added O 
at O 
physiological O 
concentrations O 
. O 
These O 
interactions O 
are O 
studied O 
at O 
the O 
Pluronic B-FAMILY 
-covered O 
oil O 
- O 
water O 
interface O 
and O 
in O 
the O 
aqueous O 
phase O 
of O 
Pluronic B-FAMILY 
-stabilized O 
emulsions O 
. O 
This O 
work O 
has O 
been O 
carried O 
out O 
with O 
techniques O 
such O 
as O 
differential O 
scanning O 
calorimetry O 
, O 
interfacial O 
tension O 
, O 
dilatational O 
rheology O 
, O 
and O 
scanning O 
electron O 
microscopy O 
. O 
As O 
a O 
result O 
, O 
Pluronic B-TRIVIAL 
F127 I-TRIVIAL 
was O 
shown O 
to O 
be O 
more O 
resistant O 
to O 
displacement O 
by O 
bile B-FAMILY 
salt I-FAMILY 
than O 
F68 B-IDENTIFIER 
at O 
the O 
oil O 
- O 
water O 
interface O 
due O 
to O 
the O 
larger O 
steric O 
hindrance O 
and O 
interfacial O 
coverage O 
provided O 
. O 
In O 
addition O 
, O 
Pluronics B-FAMILY 
have O 
the O 
ability O 
to O 
compete O 
for O 
the O 
oil O 
- O 
water O 
interface O 
and O 
interact O 
in O 
the O 
bulk O 
with O 
the O 
bile B-FAMILY 
salt I-FAMILY 
. O 
Concretely O 
, O 
Pluronic B-TRIVIAL 
F127 I-TRIVIAL 
seems O 
to O 
interact O 
with O 
more O 
molecules O 
of O 
bile B-FAMILY 
salt I-FAMILY 
in O 
the O 
bulk O 
, O 
thus O 
hindering O 
their O 
adsorption O 
onto O 
the O 
oil O 
- O 
water O 
interface O 
. O 
As O 
a O 
conclusion O 
, O 
Pluronic B-TRIVIAL 
F127 I-TRIVIAL 
affects O 
to O 
a O 
larger O 
extent O 
the O 
ability O 
of O 
bile B-FAMILY 
salt I-FAMILY 
to O 
promote O 
the O 
further O 
cascade O 
of O 
lipolysis O 
in O 
the O 
presence O 
of O 
lipase O 
owing O 
to O 
a O 
combination O 
of O 
interfacial O 
and O 
bulk O 
events O 
. O 

( O 
fluidity O 
/ O 
hydration O 
) O 
and O 
calorimetric O 
studies O 
of O 
interactions O 
of O 
bile B-FAMILY 
acid I-FAMILY 
-drug O 
conjugates O 
with O 
model O 
membranes O 
. O 

have O 
studied O 
the O 
interactions O 
of O 
three O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
, O 
lithocholic B-TRIVIAL 
acid I-TRIVIAL 
- O 
tamoxifen B-TRIVIAL 
( O 
LA-Tam B-ABBREVIATION 
(1)-Am O 
) O 
, O 
deoxycholic B-TRIVIAL 
acid I-TRIVIAL 
- O 
tamoxifen B-TRIVIAL 
( O 
DCA-Tam B-ABBREVIATION 
(2)-Am O 
) O 
, O 
and O 
cholic B-TRIVIAL 
acid I-TRIVIAL 
- O 
tamoxifen B-TRIVIAL 
( O 
CA-Tam B-ABBREVIATION 
(3)-Am O 
) O 
, O 
possessing O 
1-3 O 
tamoxifen B-TRIVIAL 
molecules O 
having O 
an O 
amine B-SYSTEMATIC 
headgroup O 
with O 
model O 
DPPC B-ABBREVIATION 
membranes O 
and O 
compared O 
with O 
N-desmethylated B-TRIVIAL 
tamoxifen I-TRIVIAL 
( O 
TamNHMe B-FORMULA 
) O 
using O 
DPH B-ABBREVIATION 
based O 
fluorescence O 
anisotropy O 
, O 
Prodan B-ABBREVIATION 
based O 
hydration O 
, O 
and O 
differential O 
scanning O 
calorimetry O 
studies O 
. O 
DPH B-ABBREVIATION 
based O 
anisotropy O 
studies O 
showed O 
that O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
increase O 
membrane O 
fluidity O 
, O 
which O 
strongly O 
depends O 
on O 
the O 
number O 
of O 
tamoxifen B-TRIVIAL 
molecules O 
conjugated O 
to O 
bile B-FAMILY 
acid I-FAMILY 
and O 
the O 
percentage O 
of O 
doping O 
of O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
in O 
the O 
DPPC B-ABBREVIATION 
membranes O 
. O 
The O 
order O 
of O 
membrane O 
fluidity O 
of O 
the O 
coliposomes O 
from O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
and O 
DPPC B-ABBREVIATION 
lipids O 
in O 
gel O 
phase O 
was O 
found O 
to O 
be O 
CA-Tam B-ABBREVIATION 
(3)-Am O 
> O 
DCA-Tam B-ABBREVIATION 
(2)-Am O 
> O 
LA-Tam B-ABBREVIATION 
(1)-Am O 
> O 
TamNHMe B-FORMULA 
. O 
Incorporation O 
of O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
showed O 
an O 
unusual O 
complex O 
behavior O 
of O 
membrane O 
hydration O 
, O 
as O 
evident O 
from O 
Prodan B-ABBREVIATION 
based O 
hydration O 
studies O 
. O 
Temperature O 
dependent O 
study O 
showed O 
incorporation O 
of O 
LA-Tam B-ABBREVIATION 
(1)-Am O 
and O 
DCA-Tam B-ABBREVIATION 
(2)-Am O 
conjugates O 
decreases O 
membrane O 
hydration O 
with O 
an O 
increase O 
in O 
temperature O 
up O 
to O 
the O 
phase O 
transition O 
temperature O 
(T(m)) O 
. O 
Differential O 
scanning O 
calorimetry O 
studies O 
showed O 
a O 
decrease O 
in O 
phase O 
transition O 
temperature O 
(T(m)) O 
upon O 
an O 
increase O 
in O 
the O 
percentage O 
of O 
doping O 
of O 
TamNHMe B-FORMULA 
and O 
CA-Tam B-ABBREVIATION 
(3)-Am O 
, O 
whereas O 
LA-Tam B-ABBREVIATION 
(1)-Am O 
and O 
DCA-Tam B-ABBREVIATION 
(2)-Am O 
do O 
not O 
cause O 
a O 
major O 
change O 
in O 
the O 
phase O 
transition O 
temperature O 
(T(m)) O 
of O 
DPPC B-ABBREVIATION 
liposomes O 
. O 
These O 
studies O 
showed O 
the O 
differential O 
behavior O 
of O 
bile B-FAMILY 
acid I-FAMILY 
- O 
tamoxifen B-TRIVIAL 
conjugates O 
regulating O 
the O 
membrane O 
fluidity O 
, O 
hydration O 
, O 
and O 
phase O 
transition O 
of O 
model O 
membranes O 
depending O 
upon O 
the O 
percentage O 
of O 
doping O 
and O 
tamoxifen B-TRIVIAL 
conjugation O 
to O 
bile B-FAMILY 
acids I-FAMILY 
. O 

and O 
Controlling O 
Morphology O 
Formation O 
in O 
Langmuir-Blodgett O 
Block O 
Copolymer O 
Films O 
Using O 
PS-P4VP B-ABBREVIATION 
and O 
PS-P4VP B-ABBREVIATION 
/ O 
PDP B-ABBREVIATION 
. O 

contribution O 
offers O 
a O 
comprehensive O 
understanding O 
of O 
the O 
factors O 
that O 
govern O 
the O 
morphologies O 
of O 
Langmuir-Blodgett O 
( O 
LB O 
) O 
monolayers O 
of O 
amphiphilic O 
diblock O 
copolymers O 
( O 
BCs O 
) O 
. O 
This O 
is O 
achieved O 
by O 
a O 
detailed O 
investigation O 
of O 
a O 
wide O 
range O 
of O 
polystyrene-poly(4-vinyl B-SYSTEMATIC 
pyridine I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PS-P4VP B-ABBREVIATION 
) O 
block O 
copolymers O 
, O 
in O 
contrast O 
to O 
much O 
more O 
limited O 
ranges O 
in O 
previous O 
studies O 
. O 
Parameters O 
that O 
are O 
varied O 
include O 
the O 
block O 
ratios O 
( O 
mainly O 
for O 
similar O 
total O 
molecular O 
weights O 
, O 
occasionally O 
other O 
total O 
molecular O 
weights O 
) O 
, O 
the O 
presence O 
or O 
not O 
of O 
3-n-pentadecylphenol B-SYSTEMATIC 
( O 
PDP B-ABBREVIATION 
, O 
usually O 
equimolar O 
with O 
VP O 
, O 
with O 
which O 
it O 
hydrogen B-SYSTEMATIC 
bonds O 
) O 
, O 
the O 
spreading O 
solution O 
concentration O 
( O 
" O 
low O 
" O 
and O 
" O 
high O 
" O 
) O 
, O 
and O 
the O 
LB O 
technique O 
( O 
standard O 
vs O 
" O 
solvent O 
- O 
assisted O 
" O 
) O 
. O 
Our O 
observations O 
are O 
compared O 
with O 
previously O 
published O 
results O 
on O 
other O 
amphiphilic O 
diblock O 
copolymers O 
, O 
which O 
had O 
given O 
rise O 
to O 
contradictory O 
interpretations O 
of O 
morphology O 
formation O 
. O 
Based O 
on O 
the O 
accumulated O 
results O 
, O 
we O 
re O 
- O 
establish O 
early O 
literature O 
conclusions O 
that O 
three O 
main O 
categories O 
of O 
LB O 
block O 
copolymer O 
morphologies O 
are O 
obtained O 
depending O 
on O 
the O 
block O 
ratio O 
, O 
termed O 
planar O 
, O 
strand O 
, O 
and O 
dot O 
regimes O 
. O 
The O 
block O 
composition O 
boundaries O 
in O 
terms O 
of O 
mol O 
% O 
block O 
content O 
are O 
shown O 
to O 
be O 
similar O 
for O 
all O 
BCs O 
having O 
alkyl O 
chain O 
substituents O 
on O 
the O 
hydrophilic O 
block O 
( O 
such O 
as O 
PS-P4VP B-ABBREVIATION 
/ O 
PDP B-ABBREVIATION 
) O 
and O 
are O 
shifted O 
to O 
higher O 
values O 
for O 
BCs O 
with O 
no O 
alkyl O 
chain O 
substituents O 
( O 
such O 
as O 
PS-P4VP B-ABBREVIATION 
) O 
. O 
This O 
is O 
attributed O 
to O 
the O 
higher O 
surface O 
area O 
per O 
repeat O 
unit O 
of O 
the O 
hydrophilic O 
block O 
monolayer O 
on O 
the O 
water O 
surface O 
for O 
the O 
former O 
, O 
as O 
supported O 
by O 
the O 
onset O 
and O 
limiting O 
areas O 
of O 
the O 
Langmuir O 
isotherms O 
for O 
the O 
BCs O 
in O 
the O 
dot O 
regime O 
. O 
2D O 
phase O 
diagrams O 
are O 
discussed O 
in O 
terms O 
of O 
relative O 
effective O 
surface O 
areas O 
of O 
the O 
two O 
blocks O 
. O 
We O 
identify O 
and O 
discuss O 
how O 
kinetic O 
effects O 
on O 
morphology O 
formation O 
, O 
which O 
have O 
been O 
highlighted O 
in O 
more O 
recent O 
literature O 
, O 
are O 
superposed O 
on O 
the O 
compositional O 
effects O 
. O 
The O 
kinetic O 
effects O 
are O 
shown O 
to O 
depend O 
on O 
the O 
morphology O 
regime O 
, O 
most O 
strongly O 
influencing O 
the O 
strand O 
and O 
, O 
especially O 
, O 
planar O 
regimes O 
, O 
where O 
they O 
give O 
rise O 
to O 
a O 
diversity O 
of O 
specific O 
structures O 
. O 
Besides O 
film O 
dewetting O 
mechanisms O 
, O 
which O 
are O 
different O 
when O 
occurring O 
in O 
structured O 
versus O 
unstructured O 
films O 
( O 
the O 
latter O 
previously O 
discussed O 
in O 
the O 
literature O 
) O 
, O 
kinetic O 
influences O 
are O 
discussed O 
in O 
terms O 
of O 
chain O 
association O 
dynamics O 
leading O 
to O 
depletion O 
effects O 
that O 
impact O 
on O 
growing O 
aggregates O 
. O 
These O 
depletion O 
effects O 
particularly O 
manifest O 
themselves O 
in O 
more O 
dilute O 
spreading O 
solutions O 
, O 
with O 
higher O 
molecular O 
weight O 
polymers O 
, O 
and O 
in O 
composition O 
regimes O 
characterized O 
by O 
equilibrium O 
degrees O 
of O 
aggregation O 
that O 
are O 
effectively O 
infinite O 
. O 
It O 
is O 
by O 
understanding O 
these O 
various O 
kinetic O 
influences O 
that O 
the O 
diversity O 
of O 
structures O 
can O 
be O 
classified O 
by O 
the O 
three O 
main O 
composition O 
- O 
dependent O 
regimes O 
. O 

chemicals O 
for O 
their O 
endocrine O 
- O 
disrupting O 
potential O 
, O 
including O 
interference O 
with O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
signaling O 
, O 
is O 
an O 
important O 
aspect O 
of O 
chemical O 
safety O 
testing O 
. O 
Because O 
of O 
the O 
practical O 
drawbacks O 
of O 
animal O 
testing O 
, O 
the O 
development O 
of O 
in O 
vitro O 
alternatives O 
for O 
the O 
uterotrophic O 
assay O 
and O 
other O 
in O 
vivo O 
(anti)estrogenicity O 
tests O 
has O 
high O 
priority O 
. O 
It O 
was O 
previously O 
demonstrated O 
that O 
an O 
in O 
vitro O 
assay O 
that O 
profiles O 
ligand O 
- O 
induced O 
binding O 
of O 
ERα O 
to O 
a O 
microarray O 
of O 
coregulator O 
- O 
derived O 
peptides O 
might O 
be O 
a O 
valuable O 
candidate O 
for O 
a O 
panel O 
of O 
in O 
vitro O 
assays O 
aiming O 
at O 
an O 
ultimate O 
replacement O 
of O 
the O 
uterotrophic O 
assay O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
reproducibility O 
and O 
robustness O 
of O 
this O 
coregulator O 
binding O 
assay O 
was O 
determined O 
by O 
measuring O 
the O 
binding O 
profiles O 
of O 
14 O 
model O 
compounds O 
that O 
are O 
recommended O 
by O 
the O 
Office O 
of O 
Prevention O 
, O 
Pesticides O 
and O 
Toxic O 
Substances O 
for O 
testing O 
laboratory O 
proficiency O 
in O 
estrogen B-FAMILY 
receptor O 
transactivation O 
assays O 
. O 
With O 
a O 
median O 
coefficient O 
of O 
variation O 
of O 
5.0% O 
and O 
excellent O 
correlation O 
( O 
R(2) O 
= O 
0.993 O 
) O 
between O 
duplicate O 
measurements O 
, O 
the O 
reproducibility O 
of O 
the O 
ERα-coregulator O 
binding O 
assay O 
was O 
better O 
than O 
the O 
reproducibility O 
of O 
other O 
commonly O 
used O 
in O 
vitro O 
ER O 
functional O 
assays O 
. O 
In O 
addition O 
, O 
the O 
coregulator O 
binding O 
assay O 
is O 
correctly O 
predicting O 
the O 
estrogenicity O 
for O 
13 O 
out O 
of O 
14 O 
compounds O 
tested O 
. O 
When O 
the O 
potency O 
of O 
the O 
ER-agonists O 
to O 
induce O 
ERα-coregulator O 
binding O 
was O 
compared O 
to O 
their O 
ER O 
binding O 
affinity O 
, O 
their O 
ranking O 
was O 
similar O 
, O 
and O 
the O 
correlation O 
between O 
the O 
EC50 O 
values O 
was O 
excellent O 
( O 
R(2) O 
= O 
0.96 O 
) O 
, O 
as O 
was O 
the O 
correlation O 
with O 
their O 
potency O 
in O 
a O 
transactivation O 
assay O 
( O 
R(2) O 
= O 
0.94 O 
) O 
. O 
Moreover O 
, O 
when O 
the O 
ERα-coregulator O 
binding O 
profiles O 
were O 
hierarchically O 
clustered O 
using O 
Euclidian O 
cluster O 
distance O 
, O 
the O 
structurally O 
related O 
compounds O 
were O 
found O 
to O 
cluster O 
together O 
, O 
whereas O 
the O 
steroid B-FAMILY 
test O 
compounds O 
having O 
an O 
aromatic O 
A-ring O 
were O 
separated O 
from O 
those O 
with O 
a O 
cyclohexene B-SYSTEMATIC 
A-ring O 
. O 
We O 
concluded O 
that O 
this O 
assay O 
is O 
capable O 
of O 
distinguishing O 
ERα O 
agonists O 
and O 
antagonists O 
and O 
that O 
it O 
even O 
reflects O 
the O 
structural O 
similarity O 
of O 
ERα O 
agonists O 
, O 
indicating O 
a O 
potential O 
to O 
achieve O 
identification O 
and O 
classification O 
of O 
ERα O 
endocrine O 
disruptors O 
with O 
high O 
fidelity O 
. O 

- O 
photon O 
circular O 
- O 
linear O 
dichroism O 
of O 
perylene B-SYSTEMATIC 
in O 
solution O 
: O 
a O 
theoretical O 
- O 
experimental O 
study O 
. O 

, O 
we O 
report O 
on O 
the O 
theoretical O 
- O 
experimental O 
analysis O 
of O 
the O 
two O 
- O 
photon O 
absorption O 
( O 
TPA O 
) O 
and O 
two O 
- O 
photon O 
circular O 
- O 
linear O 
dichroism O 
( O 
TPCLD O 
) O 
spectra O 
of O 
a O 
highly O 
conjugated O 
, O 
rigid O 
, O 
and O 
centrosymmetric O 
molecule O 
in O 
solution O 
, O 
that O 
is O 
, O 
perylene B-SYSTEMATIC 
/ O 
CH2Cl2 B-FORMULA 
. O 
We O 
show O 
how O 
a O 
three O 
- O 
energy O 
- O 
level O 
diagram O 
, O 
under O 
the O 
sum O 
- O 
over O 
- O 
essential O 
states O 
approach O 
, O 
assists O 
in O 
the O 
determination O 
of O 
the O 
magnitude O 
of O 
transition O 
electric O 
dipole O 
moments O 
and O 
the O 
angle O 
between O 
them O 
for O 
the O 
main O 
TPA O 
transitions O 
. O 
We O 
demonstrate O 
the O 
potential O 
of O 
TPCLD O 
to O 
reveal O 
the O 
symmetry O 
of O 
excited O 
states O 
and O 
the O 
angles O 
between O 
their O 
transition O 
electric O 
dipole O 
moments O 
and O 
that O 
of O 
the O 
ground O 
state O 
. O 
By O 
means O 
of O 
TPCLD O 
, O 
we O 
explain O 
how O 
the O 
overwhelming O 
contribution O 
of O 
certain O 
TPA O 
transitions O 
can O 
mask O 
important O 
spectral O 
features O 
in O 
regions O 
where O 
the O 
transition O 
electric O 
dipole O 
moments O 
are O 
perpendicular O 
. O 
TPCLD O 
is O 
expected O 
to O 
enhance O 
the O 
understanding O 
of O 
the O 
photophysical O 
properties O 
of O 
materials O 
that O 
are O 
not O 
accessible O 
using O 
conventional O 
linear O 
and O 
two O 
- O 
photon O 
spectroscopy O 
. O 
TPA O 
and O 
TPCLD O 
measurements O 
were O 
performed O 
employing O 
the O 
open O 
- O 
aperture O 
Z-scan O 
technique O 
using O 
an O 
amplified O 
femtosecond O 
system O 
. O 
Time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TD-DFT O 
) O 
calculations O 
were O 
carried O 
out O 
using O 
response O 
theory O 
at O 
the O 
B3LYP O 
level O 
with O 
the O 
aug-cc-pVDZ O 
basis O 
set O 
. O 
Solvent O 
effects O 
were O 
included O 
through O 
the O 
polarizable O 
continuum O 
model O 
( O 
PCM O 
) O 
. O 

imaging O 
by O 
optically O 
detected O 
electron O 
spin O 
resonance O 
of O 
nitrogen B-SYSTEMATIC 
-vacancies O 
in O 
nanodiamonds O 
. O 

propose O 
a O 
novel O 
biomedical O 
imaging O 
technique O 
, O 
called O 
nanodiamond O 
imaging O 
, O 
that O 
noninvasively O 
records O 
the O 
three O 
- O 
dimensional O 
distribution O 
of O 
biologically O 
tagged O 
nanodiamonds O 
in O 
vivo O 
. O 
Our O 
technique O 
performs O 
optically O 
detected O 
electron O 
spin O 
resonance O 
of O 
nitrogen B-SYSTEMATIC 
-vacancy O 
centers O 
in O 
nanodiamonds O 
, O 
a O 
nontoxic O 
nanomaterial O 
that O 
is O 
easily O 
biologically O 
functionalized O 
. O 
We O 
demonstrate O 
the O 
feasibility O 
of O 
the O 
technique O 
by O 
imaging O 
multiple O 
nanodiamond O 
targets O 
within O 
pieces O 
of O 
chicken O 
breast O 
; O 
it O 
is O 
the O 
first O 
demonstration O 
of O 
imaging O 
within O 
scattering O 
tissue O 
by O 
optically O 
detected O 
magnetic O 
resonance O 
. O 
We O 
achieve O 
a O 
sensitivity O 
equivalent O 
to O 
740 O 
pg O 
of O 
nanodiamond O 
in O 
100 O 
s O 
of O 
measurement O 
time O 
and O 
a O 
spatial O 
resolution O 
of O 
800 O 
μm O 
over O 
a O 
1 O 
cm(2) O 
field O 
of O 
view O 
, O 
and O 
we O 
show O 
how O 
the O 
technique O 
has O 
the O 
potential O 
to O 
yield O 
images O 
with O 
combined O 
high O 
sensitivity O 
( O 
∼100 O 
fg O 
nanodiamond O 
) O 
AND O 
high O 
spatial O 
resolution O 
( O 
∼100 O 
μm O 
) O 
over O 
organism O 
- O 
scale O 
fields O 
of O 
view O 
, O 
features O 
which O 
are O 
mutually O 
exclusive O 
in O 
existing O 
imaging O 
modalities O 
except O 
at O 
the O 
shallowest O 
imaging O 
depths O 
. O 

acylethanolamide B-FAMILY 
derivatives O 
that O 
modulate O 
body O 
weight O 
through O 
enhancement O 
of O 
hypothalamic O 
pro O 
- O 
opiomelanocortin O 
( O 
POMC O 
) O 
and O 
/ O 
or O 
decreased O 
neuropeptide O 
Y O 
( O 
NPY O 
) O 
. O 

synthesized O 
acylethanolamide B-FAMILY 
derivatives O 
oleoyl-L-valinolamide B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
oleoyl-D-valinolamide B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
elaidoyl-L-valinolamide B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
elaidoyl-D-valinolamide B-SYSTEMATIC 
( O 
4 O 
) O 
stearoyl-L-valinolamide B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
and O 
palmitoyl-L-valinolamide B-SYSTEMATIC 
( O 
6 O 
) O 
were O 
investigated O 
in O 
mice O 
as O 
antiobesity O 
compounds O 
. O 
Compounds O 
1 O 
, O 
2 O 
, O 
5 O 
, O 
6 O 
significantly O 
decreased O 
body O 
weight O 
by O 
6.57% O 
following O 
eight O 
injections O 
of O 
1 O 
mg O 
/ O 
kg O 
i.p O 
. O 
during O 
39 O 
days O 
, O 
while O 
3 O 
and O 
4 O 
showed O 
no O 
such O 
activity O 
. O 
Receptor O 
binding O 
indicated O 
that O 
no O 
compound O 
activated O 
CB1 O 
, O 
CB2 O 
, O 
PPARα O 
, O 
or O 
TRPV1 O 
receptors O 
. O 
Hypothalamic O 
RT-PCR O 
showed O 
that O 
mRNA O 
expression O 
of O 
the O 
anorexigenic O 
genes O 
POMC O 
and O 
CART O 
was O 
up O 
- O 
regulated O 
by O 
1 O 
, O 
2 O 
, O 
5 O 
and O 
1 O 
, O 
2 O 
, O 
respectively O 
, O 
while O 
that O 
of O 
the O 
orexigenic O 
genes O 
NPY O 
and O 
CaMKK2 O 
was O 
down O 
- O 
regulated O 
by O 
the O 
respective O 
compounds O 
1 O 
, O 
5 O 
, O 
6 O 
and O 
1 O 
, O 
2 O 
, O 
5 O 
. O 
Oleoyl-L-valinolamide B-SYSTEMATIC 
enhances O 
anorectic O 
pathways O 
and O 
lead O 
to O 
decreased O 
glucose B-TRIVIAL 
levels O 
, O 
enhanced O 
locomotor O 
activity O 
, O 
and O 
improved O 
cognition O 
. O 
Effects O 
of O 
oleoyl-L-valinolamide B-SYSTEMATIC 
on O 
weight O 
were O 
dose O 
- O 
dependent O 
, O 
and O 
it O 
could O 
be O 
given O 
orally O 
. O 
1 O 
, O 
2 O 
, O 
4 O 
, O 
5 O 
down O 
- O 
regulated O 
FAAH O 
mRNA O 
expression O 
. O 

effect O 
of O 
inorganic O 
arsenic B-SYSTEMATIC 
on O 
endothelium O 
- O 
dependent O 
relaxation O 
: O 
Role O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 

arsenic B-SYSTEMATIC 
ingestion O 
predisposes O 
to O 
vascular O 
disease O 
, O 
but O 
underlying O 
mechanisms O 
are O 
poorly O 
understood O 
. O 
In O 
the O 
present O 
study O 
we O 
have O 
analyzed O 
the O 
effects O 
of O 
short O 
- O 
term O 
arsenite B-SYSTEMATIC 
exposure O 
on O 
vascular O 
function O 
and O 
endothelium O 
- O 
dependent O 
relaxation O 
. O 
Endothelium O 
- O 
dependent O 
relaxations O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
endothelium O 
derived O 
hyperpolarizing O 
factor O 
( O 
EDHF O 
) O 
- O 
type O 
, O 
were O 
studied O 
in O 
rabbit O 
iliac O 
artery O 
and O 
aortic O 
rings O 
using O 
the O 
G O 
protein O 
- O 
coupled O 
receptor O 
agonist O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
and O 
by O 
cyclopiazonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CPA B-ABBREVIATION 
) O 
, O 
which O 
promotes O 
store O 
- O 
operated O 
Ca(2+) B-FORMULA 
entry O 
by O 
inhibiting O 
the O 
endothelial O 
SERCA O 
pump O 
. O 
Production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
in O 
the O 
endothelium O 
of O 
rabbit O 
aortic O 
valve O 
leaflets O 
and O 
endothelium O 
- O 
denuded O 
RIA O 
and O 
aortic O 
rings O 
was O 
assessed O 
by O 
imaging O 
of O 
dihydroethidium B-SYSTEMATIC 
. O 
In O 
the O 
iliac O 
artery O 
, O 
exposure O 
to O 
100μM O 
arsenite B-SYSTEMATIC 
for O 
30min O 
potentiated O 
EDHF O 
- O 
type O 
relaxations O 
evoked O 
by O 
both O 
CPA B-ABBREVIATION 
and O 
ACh B-ABBREVIATION 
. O 
Potentiation O 
was O 
prevented O 
by O 
catalase O 
, O 
the O 
catalase/ O 
superoxide B-TRIVIAL 
dismutase O 
mimetic O 
manganese B-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
and O 
the O 
NADPH B-ABBREVIATION 
oxidase O 
inhibitor O 
apocynin B-TRIVIAL 
. O 
By O 
contrast O 
in O 
aortic O 
rings O 
, O 
that O 
exhibited O 
negligible O 
EDHF O 
- O 
type O 
responses O 
, O 
endothelium O 
- O 
dependent O 
NO B-FORMULA 
-mediated O 
relaxations O 
evoked O 
by O 
CPA B-ABBREVIATION 
and O 
ACh B-ABBREVIATION 
were O 
unaffected O 
by O 
arsenite B-SYSTEMATIC 
. O 
Arsenite B-SYSTEMATIC 
induced O 
apocynin B-TRIVIAL 
-sensitive O 
increases O 
in O 
ROS O 
production O 
in O 
the O 
aortic O 
valve O 
endothelium O 
, O 
but O 
not O 
in O 
the O 
media O 
and O 
adventitia O 
of O 
the O 
iliac O 
artery O 
and O 
aorta O 
. O 
Our O 
results O 
suggest O 
that O 
arsenite B-SYSTEMATIC 
can O 
potentiate O 
EDHF O 
- O 
type O 
relaxations O 
via O 
a O 
mechanism O 
that O 
is O 
dependent O 
on O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
, O 
thus O 
demonstrating O 
that O 
dismutation O 
of O 
the O 
superoxide B-TRIVIAL 
anion O 
generated O 
by O 
NADPH B-ABBREVIATION 
oxidase O 
can O 
potentially O 
offset O 
loss O 
of O 
NO B-FORMULA 
bioavailability O 
under O 
conditions O 
of O 
reduced O 
eNOS O 
activity O 
. O 
By O 
contrast O 
, O 
selective O 
increases O 
in O 
endothelial O 
ROS O 
production O 
following O 
exposure O 
to O 
arsenite B-SYSTEMATIC 
failed O 
to O 
modify O 
relaxations O 
mediated O 
by O 
endogenous O 
NO B-FORMULA 
. O 

analysis O 
of O 
human O 
CYP3A4 O 
and O 
rat O 
CYP3A1 O 
induction O 
and O 
relevant O 
gene O 
expression O 
by O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
diethylstilbestrol B-SYSTEMATIC 
: O 
implications O 
for O 
toxicity O 
testing O 
paradigms O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
and O 
diethylstilbestrol B-SYSTEMATIC 
( O 
DES B-ABBREVIATION 
) O 
are O 
endocrine O 
- O 
disrupting O 
chemicals O 
that O 
interact O 
with O 
the O 
human O 
pregnane O 
X O 
receptor O 
( O 
PXR O 
) O 
. O 
CYP3A4 O 
enzyme O 
is O 
essential O 
in O 
the O 
hydroxylation O 
of O 
steroid B-FAMILY 
hormones O 
and O 
is O 
regulated O 
by O 
PXR O 
. O 
In O 
the O 
present O 
study O 
, O 
human O 
and O 
rat O 
hepatoma O 
cell O 
lines O 
were O 
exposed O 
to O 
BPA O 
and O 
DES O 
. O 
Both O 
BPA B-ABBREVIATION 
and O 
DES B-ABBREVIATION 
( O 
10-50μM O 
) O 
caused O 
a O 
significant O 
activation O 
of O 
the O 
CYP3A4 O 
promoter O 
via O 
the O 
PXR O 
in O 
the O 
DPX2 O 
human O 
hepatoma O 
cell O 
line O 
. O 
No O 
activation O 
of O 
rat O 
PXR O 
was O 
seen O 
. O 
BPA B-ABBREVIATION 
and O 
DES B-ABBREVIATION 
treated O 
DPX2 O 
cells O 
demonstrated O 
increased O 
expression O 
of O 
CYP3A4 O 
mRNA O 
, O 
and O 
increased O 
enzyme O 
activity O 
. O 
In O 
summary O 
, O 
BPA B-ABBREVIATION 
, O 
in O 
concentrations O 
relevant O 
to O 
current O 
safety O 
levels O 
of O 
human O 
exposure O 
, O 
activates O 
the O 
human O 
PXR O 
and O 
demonstrates O 
an O 
increase O 
in O 
CYP3A4 O 
mRNA O 
expression O 
and O 
enzyme O 
activity O 
. O 
BPA B-ABBREVIATION 
actions O 
in O 
this O 
model O 
system O 
occur O 
to O 
a O 
greater O 
extent O 
than O 
DES B-ABBREVIATION 
. O 
This O 
study O 
raises O 
concerns O 
regarding O 
our O 
current O 
toxicity O 
testing O 
paradigms O 
and O 
species O 
utilization O 
. O 

of O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
as O 
a O 
defensive O 
strategy O 
in O 
the O 
brain O 
of O 
three O 
freshwater O 
teleosts O 
in O 
response O 
to O 
high O 
environmental O 
ammonia B-SYSTEMATIC 
exposure O 
. O 

teleosts O 
have O 
evolved O 
mechanisms O 
to O 
cope O 
with O 
ammonia B-SYSTEMATIC 
toxicity O 
in O 
the O 
brain O 
when O 
confronted O 
with O 
high O 
environmental O 
ammonia B-SYSTEMATIC 
( O 
HEA O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
possible O 
role O 
of O 
conversion O 
of O 
accumulated O 
ammonia B-SYSTEMATIC 
to O 
glutamine B-TRIVIAL 
and O 
other O 
free O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
brain O 
of O 
three O 
freshwater O 
teleosts O 
differing O 
in O 
their O 
sensitivities O 
to O 
ammonia B-SYSTEMATIC 
was O 
investigated O 
. O 
The O 
detoxification O 
mode O 
of O 
ammonia B-SYSTEMATIC 
in O 
brain O 
is O 
suggested O 
to O 
be O 
through O 
amination O 
of O 
glutamate B-TRIVIAL 
to O 
glutamine B-TRIVIAL 
by O 
the O 
coupled O 
activities O 
of O 
glutamate B-TRIVIAL 
dehydrogenase O 
( O 
GDH O 
) O 
, O 
transaminase O 
( O 
aspartate B-TRIVIAL 
aminotransaminase O 
' O 
AST O 
' O 
and O 
alanine B-TRIVIAL 
aminotransaminase O 
' O 
ALT O 
' O 
) O 
and O 
glutamine B-TRIVIAL 
synthetase O 
( O 
GSase O 
) O 
. O 
We O 
investigated O 
the O 
metabolic O 
response O 
of O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
brain O 
of O 
highly O 
sensitive O 
salmonid O 
Oncorhynchus O 
mykiss O 
( O 
rainbow O 
trout O 
) O 
, O 
the O 
less O 
sensitive O 
cyprinid O 
Cyprinus O 
carpio O 
( O 
common O 
carp O 
) O 
and O 
the O 
highly O 
resistant O 
cyprinid O 
Carassius O 
auratus O 
( O 
goldfish O 
) O 
when O 
exposed O 
to O 
1mM O 
ammonia B-SYSTEMATIC 
( O 
as O 
NH4HCO3 B-FORMULA 
; O 
pH O 
7.9 O 
) O 
for O 
0 O 
h O 
( O 
control O 
) O 
, O 
3 O 
h O 
, O 
12 O 
h O 
, O 
24 O 
h O 
, O 
48 O 
h O 
, O 
84 O 
h O 
and O 
180 O 
h O 
. O 
Results O 
show O 
that O 
HEA O 
exposure O 
increased O 
ammonia B-SYSTEMATIC 
accumulation O 
significantly O 
in O 
the O 
brain O 
of O 
all O 
the O 
three O 
species O 
from O 
12h O 
onwards O 
. O 
Unlike O 
in O 
trout O 
, O 
ammonia B-SYSTEMATIC 
accumulation O 
in O 
carp O 
and O 
goldfish O 
was O 
restored O 
to O 
control O 
levels O 
( O 
48-84h O 
) O 
; O 
which O 
was O 
accompanied O 
with O 
a O 
significant O 
increase O 
in O 
glutamine B-TRIVIAL 
content O 
as O 
well O 
as O 
GSase O 
activity O 
. O 
In O 
trout O 
, O 
glutamine B-TRIVIAL 
levels O 
also O 
increased O 
( O 
84-180 O 
h O 
) O 
but O 
GSase O 
was O 
not O 
activated O 
. O 
The O 
elevated O 
glutamine B-TRIVIAL 
level O 
in O 
trout O 
was O 
accompanied O 
by O 
a O 
significant O 
depletion O 
of O 
the O 
glutamate B-TRIVIAL 
pool O 
in O 
contrast O 
to O 
the O 
stable O 
glutamate B-TRIVIAL 
levels O 
seen O 
in O 
carp O 
and O 
goldfish O 
. O 
This O 
suggests O 
a O 
simultaneous O 
increase O 
in O 
the O 
rate O 
of O 
glutamate B-TRIVIAL 
formation O 
to O 
match O 
with O 
the O 
demand O 
of O 
glutamine B-TRIVIAL 
formation O 
in O 
cyprinids O 
. O 
The O 
activity O 
of O 
GDH O 
was O 
elevated O 
significantly O 
in O 
carp O 
and O 
goldfish O 
but O 
remained O 
unaltered O 
in O 
trout O 
. O 
Also O 
, O 
the O 
transaminase O 
enzymes O 
( O 
AST O 
and O 
ALT O 
) O 
were O 
elevated O 
significantly O 
in O 
exposed O 
carp O 
and O 
goldfish O 
while O 
only O 
ALT O 
was O 
up O 
- O 
regulated O 
in O 
trout O 
. O 
Consequently O 
, O 
in O 
carp O 
and O 
goldfish O 
both O 
aspartate B-TRIVIAL 
and O 
alanine B-TRIVIAL 
were O 
utilized O 
under O 
HEA O 
, O 
whereas O 
only O 
alanine B-TRIVIAL 
was O 
consumed O 
in O 
trout O 
. O 
With O 
ammonia B-SYSTEMATIC 
treatment O 
, O 
significant O 
changes O 
in O 
concentrations O 
of O 
other O 
amino B-FAMILY 
acids I-FAMILY 
also O 
occurred O 
. O 
None O 
of O 
the O 
species O 
could O 
detoxify O 
brain O 
ammonia B-SYSTEMATIC 
into O 
urea O 
. O 
This O 
study O 
suggests O 
that O 
protective O 
strategies O 
to O 
combat O 
ammonia B-SYSTEMATIC 
toxicity O 
in O 
brain O 
are O 
more O 
pronounced O 
in O 
carp O 
and O 
goldfish O 
than O 
in O 
trout O 
. O 

N B-FORMULA 
-interlinked O 
imipramines B-FAMILY 
show O 
apoptotic O 
activity O 
against O 
malignant O 
cells O 
including O 
Burkitt's O 
lymphoma O 
. O 

here O 
report O 
the O 
synthesis O 
of O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
N B-FORMULA 
-interlinked O 
imipramine B-TRIVIAL 
dimers O 
of O 
various O 
lengths O 
from O 
the O 
tricyclic O 
antidepressant O 
desipramine B-TRIVIAL 
via O 
an O 
amide O 
coupling O 
reaction O 
followed O 
by O 
reduction O 
with O 
lithium B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
hydride I-SYSTEMATIC 
. O 
The O 
target O 
molecules O 
were O 
found O 
to O 
be O 
potent O 
inhibitors O 
of O 
cellular O 
viability O 
while O 
inducing O 
cell O 
type O 
specific O 
death O 
mechanisms O 
in O 
three O 
cancer O 
cell O 
lines O 
including O 
a O 
highly O 
chemoresistant O 
Burkitt's O 
lymphoma O 
cell O 
line O 
. O 
Basic O 
amine B-SYSTEMATIC 
analogues O 
were O 
found O 
to O 
be O 
important O 
for O 
increased O 
potency O 
. O 
Imipramine B-TRIVIAL 
and O 
desipramine B-TRIVIAL 
were O 
also O 
tested O 
for O 
apoptotic O 
activity O 
and O 
were O 
found O 
to O 
be O 
much O 
less O 
active O 
than O 
the O 
novel O 
dimeric O 
compounds O 
. O 
Imipramine B-TRIVIAL 
dimers O 
were O 
only O 
found O 
to O 
be O 
moderate O 
inhibitors O 
of O 
the O 
human O 
serotonin B-TRIVIAL 
transporter O 
( O 
hSERT O 
) O 
having O 
IC(50) O 
values O 
in O 
the O 
micromolar O 
region O 
whilst O 
the O 
induction O 
of O 
cell O 
death O 
occurred O 
independently O 
of O 
hSERT O 
expression O 
. O 
These O 
results O 
demonstrate O 
the O 
potential O 
of O 
newly O 
designed O 
and O 
synthesised O 
imipramines B-FAMILY 
derivatives O 
for O 
use O 
against O 
malignant O 
cells O 
, O 
including O 
those O 
resistant O 
to O 
standard O 
chemotherapy O 
. O 

- O 
infrared O 
spectra O 
have O 
been O 
measured O 
for O 
cubic O 
ice O 
(I(c)) O 
nanoparticles O 
( O 
3-150 O 
nm O 
diameter O 
) O 
formed O 
by O 
rapid O 
collisional O 
cooling O 
over O 
a O 
wide O 
range O 
of O 
temperatures O 
( O 
5-209 O 
K O 
) O 
. O 
Spectral O 
diagnostics O 
, O 
such O 
as O 
the O 
ratio O 
of O 
surface O 
related O 
dangling O 
OH B-FORMULA 
to O 
interior O 
H B-FORMULA 
-bonded O 
OH B-FORMULA 
stretch O 
bands O 
, O 
reveal O 
the O 
manner O 
in O 
which O 
particle O 
size O 
depends O 
on O 
bath O 
gas O 
temperature O 
and O 
density O 
, O 
and O 
on O 
water O 
molecule O 
concentration O 
. O 
For O 
particles O 
smaller O 
than O 
5 O 
nm O 
strained O 
intermolecular O 
bonds O 
on O 
the O 
surface O 
and O 
subsurface O 
cause O 
the O 
predominant O 
OH B-FORMULA 
stretch O 
peak O 
position O 
to O 
be O 
dramatically O 
blue O 
shifted O 
by O 
up O 
to O 
40 O 
cm(-1) O 
. O 
In O 
the O 
size O 
regime O 
of O 
8-200 O 
nm O 
the O 
position O 
of O 
the O 
OH B-FORMULA 
stretch O 
absorption O 
band O 
maximum O 
is O 
relatively O 
unaffected O 
by O 
particle O 
size O 
and O 
it O 
is O 
possible O 
to O 
measure O 
the O 
temperature O 
dependence O 
of O 
the O 
peak O 
location O 
without O 
influences O 
from O 
the O 
surface O 
or O 
scattering O 
. O 
The O 
band O 
maximum O 
shifts O 
in O 
a O 
linear O 
fashion O 
from O 
3218 O 
cm(-1) O 
at O 
30 O 
K O 
to O 
3253 O 
cm(-1) O 
at O 
209 O 
K O 
, O 
which O 
may O 
assist O 
with O 
temperature O 
profiling O 
of O 
ice O 
particles O 
in O 
atmospheric O 
clouds O 
and O 
extraterrestrial O 
systems O 
. O 
Over O 
the O 
same O 
temperature O 
range O 
the O 
librational O 
mode O 
band O 
shifts O 
very O 
little O 
, O 
from O 
870 O 
to O 
860 O 
cm(-1) O 
. O 
In O 
the O 
water O 
stretching O 
and O 
bending O 
regions O 
discrete O 
spectral O 
features O 
associated O 
with O 
the O 
surface O 
or O 
sub O 
- O 
surface O 
layers O 
have O 
been O 
detected O 
in O 
particles O 
as O 
large O 
as O 
80 O 
nm O 
. O 

injury O 
induces O 
long O 
- O 
term O 
changes O 
in O 
gene O 
expression O 
in O 
the O 
nociceptive O 
circuitry O 
and O 
can O 
lead O 
to O 
chronic O 
neuropathic O 
pain O 
. O 
However O 
, O 
the O 
transcriptional O 
mechanism O 
involved O 
in O 
neuropathic O 
pain O 
is O 
poorly O 
understood O 
. O 
Nuclear O 
factor O 
of O 
activated O 
T-cells O 
( O 
NFATc O 
) O 
is O 
a O 
transcriptional O 
factor O 
regulated O 
by O 
the O 
Ca(2+) B-FORMULA 
-dependent O 
protein O 
phosphatase O 
calcineurin O 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
nerve O 
injury O 
- O 
induced O 
changes O 
in O 
the O 
expression O 
of O 
NFATc1-c4 O 
in O 
the O 
dorsal O 
root O 
ganglia O 
( O 
DRG O 
) O 
and O 
spinal O 
cords O 
and O 
their O 
role O 
in O 
the O 
development O 
of O 
neuropathic O 
pain O 
. O 
The O 
mRNA O 
of O 
NFATc1-c4 O 
was O 
detected O 
in O 
the O 
rat O 
DRG O 
and O 
dorsal O 
spinal O 
cord O 
. O 
Nerve O 
injury O 
transiently O 
elevated O 
NFATc1-c3 O 
mRNA O 
levels O 
and O 
persistently O 
increased O 
NFATc4 O 
and O 
C-C O 
chemokine O 
receptor O 
type O 
2 O 
( O 
CCR2 O 
) O 
mRNA O 
levels O 
in O 
the O 
DRG O 
. O 
However O 
, O 
NFATc1-c4 O 
mRNA O 
levels O 
in O 
the O 
spinal O 
cord O 
were O 
not O 
altered O 
significantly O 
by O 
nerve O 
injury O 
. O 
Nerve O 
injury O 
also O 
significantly O 
increased O 
the O 
protein O 
level O 
of O 
dephosphorylated O 
NFATc4 O 
in O 
the O 
DRG O 
. O 
Intrathecal O 
injection O 
of O 
the O 
specific O 
NFATc O 
inhibitor O 
11R-VIVIT O 
or O 
the O 
calcineurin O 
inhibitor O 
FK-506 B-IDENTIFIER 
( O 
tacrolimus B-TRIVIAL 
) O 
early O 
after O 
nerve O 
injury O 
significantly O 
attenuated O 
the O 
development O 
of O 
tactile O 
allodynia O 
. O 
In O 
addition O 
, O 
treatment O 
with O 
FK-506 B-IDENTIFIER 
or O 
11R-VIVIT O 
significantly O 
reduced O 
the O 
mRNA O 
levels O 
of O 
NFATc4 O 
and O 
CCR2 O 
but O 
not O 
large O 
- O 
conductance O 
Ca(2+) B-FORMULA 
-activated O 
K(+) B-FORMULA 
channels O 
, O 
in O 
the O 
DRG O 
after O 
nerve O 
injury O 
. O 
Our O 
findings O 
suggest O 
that O 
peripheral O 
nerve O 
injury O 
causes O 
a O 
time O 
- O 
dependent O 
change O 
in O 
NFATc1-c4 O 
expression O 
in O 
the O 
DRG O 
. O 
Calcineurin-NFATc O 
- O 
mediated O 
expression O 
of O 
pronociceptive O 
cytokines O 
contributes O 
to O 
the O 
transition O 
from O 
acute O 
to O 
chronic O 
pain O 
after O 
nerve O 
injury O 
. O 

and O 
biological O 
evaluation O 
of O 
purine B-SYSTEMATIC 
2'-fluoro-2'-deoxyriboside I-SYSTEMATIC 
ProTides O 
as O 
anti-influenza O 
virus O 
agents O 
. O 

has O 
been O 
reported O 
to O 
have O 
potent O 
anti-influenza O 
virus O 
activity O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Herein O 
we O 
describe O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
6- O 
modified O 
2'-fluoro-2'-deoxyguanosine B-SYSTEMATIC 
analogues O 
and O 
their O 
corresponding O 
phosphoramidate B-SYSTEMATIC 
ProTides O 
as O 
potential O 
anti-influenza O 
virus O 
agents O 
. O 
Whereas O 
the O 
parent O 
nucleosides B-FAMILY 
were O 
devoid O 
of O 
antiviral O 
activity O 
in O 
two O 
different O 
cellular O 
assays O 
, O 
the O 
5'-O-naphthyl(methoxy-L-alaninyl) B-SYSTEMATIC 
ProTide O 
derivatives O 
of O 
6-O-methyl-2'-fluoro-2'-deoxyguanosine B-SYSTEMATIC 
, O 
6-O-ethyl-2'-fluoro-2'-deoxyguanosine B-SYSTEMATIC 
, O 
and O 
2'-deoxy-2'-fluoro-6-chloroguanosine B-SYSTEMATIC 
, O 
and O 
the O 
5'-O-naphthyl(ethoxy-L-alaninyl) B-SYSTEMATIC 
ProTide O 
of O 
6-O-ethyl-2'-fluoro-2'-deoxyguanosine B-SYSTEMATIC 
displayed O 
antiviral O 
EC(99) O 
values O 
of O 
~12 O 
μM O 
. O 
The O 
antiviral O 
results O 
are O 
supported O 
by O 
metabolism O 
studies O 
. O 
Rapid O 
conversion O 
into O 
the O 
L-alaninyl B-TRIVIAL 
metabolite O 
and O 
then O 
6- O 
modified O 
2'-fluoro-2'-deoxyguanosine B-SYSTEMATIC 
5'-monophosphate I-SYSTEMATIC 
was O 
observed O 
in O 
enzymatic O 
assays O 
with O 
yeast O 
carboxypeptidase O 
Y O 
or O 
crude O 
cell O 
lysate O 
. O 
Evidence O 
for O 
efficient O 
removal O 
of O 
the O 
6- O 
substituent O 
on O 
the O 
guanine B-TRIVIAL 
part O 
was O 
provided O 
by O 
enzymatic O 
studies O 
with O 
adenosine B-TRIVIAL 
deaminase O 
, O 
and O 
by O 
molecular O 
modeling O 
of O 
the O 
nucleoside B-FAMILY 
5'-monophosphates I-FAMILY 
in O 
the O 
catalytic O 
site O 
of O 
a O 
model O 
of O 
ADAL1 O 
, O 
thus O 
indicating O 
the O 
utility O 
of O 
the O 
double O 
prodrug O 
concept O 
. O 

: O 
a O 
novel O 
antiepileptic O 
for O 
adjunctive O 
treatment O 
of O 
partial O 
- O 
onset O 
seizures O 
. O 

is O 
defined O 
as O 
a O 
tendency O 
toward O 
recurrent O 
seizures O 
unprovoked O 
by O 
any O 
systemic O 
or O 
acute O 
neurologic O 
insults O 
. O 
It O 
is O 
a O 
disruption O 
of O 
the O 
electrical O 
conductivity O 
or O 
activity O 
in O 
the O 
brain O 
, O 
resulting O 
in O 
a O 
seizure O 
. O 
In O 
the O 
United O 
States O 
, O 
approximately O 
120 O 
of O 
every O 
100000 O 
people O 
seek O 
medical O 
attention O 
due O 
to O 
new O 
seizure O 
activity O 
. O 
Ezogabine B-TRIVIAL 
, O 
known O 
as O 
retigabine B-TRIVIAL 
in O 
Europe O 
, O 
is O 
an O 
ethyl B-SYSTEMATIC 
N-(2-amino-4-[{fluorophenyl}methlamino]phenylcarbamate) I-SYSTEMATIC 
. O 
The O 
drug O 
has O 
been O 
approved O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
( O 
FDA O 
) O 
and O 
European O 
Medicines O 
Agency O 
for O 
adjunctive O 
treatment O 
of O 
partial O 
- O 
onset O 
seizures O 
in O 
adults O 
. O 
Ezogabine B-TRIVIAL 
exerts O 
its O 
therapeutic O 
effect O 
by O 
enhancing O 
transmembrane O 
potassium B-SYSTEMATIC 
channels O 
( O 
KCNQ O 
ion O 
channels O 
) O 
, O 
which O 
is O 
a O 
novel O 
mechanism O 
in O 
comparison O 
with O 
other O 
antiepileptics O 
. O 
There O 
are O 
no O 
specific O 
documented O 
contraindications O 
to O 
ezogabine B-TRIVIAL 
. O 
Warnings O 
target O 
patients O 
that O 
have O 
benign O 
prostatic O 
hyperplasia O 
or O 
are O 
receiving O 
concomitant O 
anticholinergic O 
drugs O 
due O 
to O 
a O 
risk O 
of O 
urinary O 
retention O 
( O 
2% O 
) O 
. O 
The O 
FDA O 
has O 
required O 
that O 
ezogabine B-TRIVIAL 
be O 
part O 
of O 
a O 
risk O 
evaluation O 
and O 
mitigation O 
strategy O 
program O 
in O 
order O 
to O 
inform O 
health O 
care O 
professionals O 
of O 
the O 
risk O 
of O 
urinary O 
retention O 
. O 
Prescribers O 
should O 
inform O 
patients O 
that O 
ezogabine B-TRIVIAL 
can O 
cause O 
urinary O 
retention O 
, O 
including O 
urinary O 
hesitation O 
, O 
and O 
instruct O 
them O 
to O 
seek O 
immediate O 
medical O 
attention O 
if O 
these O 
symptoms O 
occur O 
. O 
A O 
medication O 
guide O 
has O 
been O 
developed O 
for O 
distribution O 
to O 
patients O 
. O 

are O 
a O 
multigene O 
family O 
of O 
mammalian O 
enzymes O 
widely O 
distributed O 
throughout O 
the O 
body O 
that O 
catalyze O 
the O 
hydrolysis O 
of O 
esters B-FAMILY 
, O 
amides B-FAMILY 
, O 
thioesters B-FAMILY 
, O 
and O 
carbamates B-FAMILY 
. O 
In O 
humans O 
, O 
two O 
carboxylesterases O 
, O 
hCE1 O 
and O 
hCE2 O 
, O 
are O 
important O 
mediators O 
of O 
drug O 
metabolism O 
. O 
Both O 
are O 
expressed O 
in O 
the O 
liver O 
, O 
but O 
hCE1 O 
greatly O 
exceeds O 
hCE2 O 
. O 
In O 
the O 
intestine O 
, O 
only O 
hCE2 O 
is O 
present O 
and O 
highly O 
expressed O 
. O 
The O 
most O 
common O 
drug O 
substrates O 
of O 
these O 
enzymes O 
are O 
ester B-FAMILY 
prodrugs O 
specifically O 
designed O 
to O 
enhance O 
oral O 
bioavailability O 
by O 
hydrolysis O 
to O 
the O 
active O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
after O 
absorption O 
from O 
the O 
gastrointestinal O 
tract O 
. O 
Carboxylesterases O 
also O 
play O 
an O 
important O 
role O 
in O 
the O 
hydrolysis O 
of O 
some O 
drugs O 
to O 
inactive O 
metabolites O 
. O 
It O 
has O 
been O 
widely O 
believed O 
that O 
drugs O 
undergoing O 
hydrolysis O 
by O 
hCE1 O 
and O 
hCE2 O 
are O 
not O 
subject O 
to O 
clinically O 
significant O 
alterations O 
in O 
their O 
disposition O 
, O 
but O 
evidence O 
exists O 
that O 
genetic O 
polymorphisms O 
, O 
drug O 
- O 
drug O 
interactions O 
, O 
drug O 
- O 
disease O 
interactions O 
and O 
other O 
factors O 
are O 
important O 
determinants O 
of O 
the O 
variability O 
in O 
the O 
therapeutic O 
response O 
to O 
carboxylesterase O 
- O 
substrate O 
drugs O 
. O 
The O 
implications O 
for O 
drug O 
therapy O 
are O 
far O 
- O 
reaching O 
, O 
as O 
substrate O 
drugs O 
include O 
numerous O 
examples O 
from O 
widely O 
prescribed O 
therapeutic O 
classes O 
. O 
Representative O 
drugs O 
include O 
angiotensin O 
- O 
converting O 
enzyme O 
inhibitors O 
, O 
angiotensin O 
receptor O 
blockers O 
, O 
antiplatelet O 
drugs O 
, O 
statins B-FAMILY 
, O 
antivirals O 
, O 
and O 
central O 
nervous O 
system O 
agents O 
. O 
As O 
research O 
interest O 
increases O 
in O 
the O 
carboxylesterases O 
, O 
evidence O 
is O 
accumulating O 
of O 
their O 
important O 
role O 
in O 
drug O 
metabolism O 
and O 
, O 
therefore O 
, O 
the O 
outcomes O 
of O 
pharmacotherapy O 
. O 

- O 
like O 
receptor O 
2 O 
mediates O 
peripheral O 
nerve O 
injury O 
- O 
induced O 
NADPH B-ABBREVIATION 
oxidase O 
2 O 
expression O 
in O 
spinal O 
cord O 
microglia O 
. O 

have O 
previously O 
reported O 
that O 
NADPH B-ABBREVIATION 
oxidase O 
2 O 
( O 
Nox2 O 
) O 
is O 
up O 
- O 
regulated O 
in O 
spinal O 
cord O 
microglia O 
after O 
spinal O 
nerve O 
injury O 
, O 
demonstrating O 
that O 
it O 
is O 
critical O 
for O 
microglia O 
activation O 
and O 
subsequent O 
pain O 
hypersensitivity O 
. O 
However O 
, O 
the O 
mechanisms O 
and O 
molecules O 
involved O 
in O 
Nox2 O 
induction O 
have O 
not O 
been O 
elucidated O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
Toll O 
- O 
like O 
receptors O 
( O 
TLRs O 
) O 
are O 
involved O 
in O 
nerve O 
injury O 
- O 
induced O 
spinal O 
cord O 
microglia O 
activation O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
role O 
of O 
TLR O 
in O 
Nox2 O 
expression O 
in O 
spinal O 
cord O 
microglia O 
after O 
peripheral O 
nerve O 
injury O 
. O 
Studies O 
using O 
TLR O 
knock O 
- O 
out O 
mice O 
have O 
shown O 
that O 
nerve O 
injury O 
- O 
induced O 
microglial O 
Nox2 O 
up O 
- O 
regulation O 
is O 
abrogated O 
in O 
TLR2 O 
but O 
not O 
in O 
TLR3 O 
or O 
-4 O 
knock O 
- O 
out O 
mice O 
. O 
Intrathecal O 
injection O 
of O 
lipoteichoic O 
acid O 
, O 
a O 
TLR2 O 
agonist O 
, O 
induced O 
Nox2 O 
expression O 
in O 
spinal O 
cord O 
microglia O 
both O 
at O 
the O 
mRNA O 
and O 
protein O 
levels O 
. O 
Similarly O 
, O 
lipoteichoic O 
acid O 
stimulation O 
induced O 
Nox2 O 
expression O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
in O 
primary O 
spinal O 
cord O 
glial O 
cells O 
in O 
vitro O 
. O 
Studies O 
on O 
intracellular O 
signaling O 
pathways O 
indicate O 
that O 
NF-κB O 
and O 
p38 O 
MAP O 
kinase O 
activation O 
is O 
required O 
for O 
TLR2-induced O 
Nox2 O 
expression O 
in O 
glial O 
cells O 
. O 
Conclusively O 
, O 
our O 
data O 
show O 
that O 
TLR2 O 
mediates O 
nerve O 
injury O 
- O 
induced O 
Nox2 O 
gene O 
expression O 
in O 
spinal O 
cord O 
microglia O 
via O 
NF-κB O 
and O 
p38 O 
activation O 
and O 
thereby O 
may O 
contribute O 
to O 
spinal O 
cord O 
microglia O 
activation O 
. O 

levels O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
and O 
the O 
CYP3A O 
biomarker O 
4β-hydroxycholesterol B-SYSTEMATIC 
in O 
a O 
high O 
- O 
dose O 
vitamin B-FAMILY 
D I-FAMILY 
supplementation O 
study O 
. O 

primary O 
aim O 
was O 
to O 
study O 
the O 
relationship O 
between O 
individual O 
serum O 
levels O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
and O 
4β-hydroxycholesterol B-SYSTEMATIC 
, O 
which O 
is O 
an O 
endogenous O 
biomarker O 
of O 
the O 
drug O 
- O 
metabolizing O 
CYP3A O 
enzymes O 
. O 
In O 
addition O 
, O 
the O 
relationship O 
between O 
this O 
biomarker O 
and O 
inflammation O 
, O 
measured O 
as O 
C-reactive O 
protein O 
( O 
CRP O 
) O 
, O 
was O 
investigated O 
. O 
Serum O 
samples O 
were O 
used O 
from O 
a O 
recently O 
performed O 
clinical O 
trial O 
in O 
patients O 
with O 
antibody O 
deficiency O 
or O 
increased O 
susceptibility O 
to O 
respiratory O 
tract O 
infections O 
that O 
were O 
randomized O 
to O 
either O 
placebo O 
or O 
high O 
- O 
dose O 
( O 
4000 O 
IU O 
/ O 
day O 
) O 
vitamin B-FAMILY 
D I-FAMILY 
for O 
12 O 
months O 
. O 
One O 
hundred O 
sixteen O 
patients O 
were O 
included O 
in O 
the O 
final O 
analyses O 
, O 
and O 
serum O 
samples O 
collected O 
6 O 
months O 
after O 
study O 
start O 
were O 
analyzed O 
. O 
At O 
this O 
time O 
point O 
, O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
levels O 
were O 
found O 
to O 
range O 
between O 
10 O 
and O 
284 O 
nM O 
. O 
Individual O 
levels O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
as O 
well O 
as O 
CRP O 
were O 
compared O 
with O 
4β-hydroxycholesterol B-SYSTEMATIC 
levels O 
. O 
In O 
addition O 
, O 
all O 
participants O 
were O 
genotyped O 
for O 
two O 
polymorphisms O 
( O 
Taq1 O 
and O 
Foq1 O 
) O 
in O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
gene O 
. O 
There O 
was O 
no O 
significant O 
correlation O 
between O 
individual O 
serum O 
levels O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
and O 
4β-hydroxycholesterol B-SYSTEMATIC 
. O 
However O 
, O 
a O 
moderate O 
, O 
but O 
statistically O 
significant O 
, O 
negative O 
correlation O 
between O 
CRP O 
and O 
4β-hydroxycholesterol B-SYSTEMATIC 
levels O 
was O 
observed O 
. O 
This O 
study O 
in O 
patients O 
with O 
highly O 
variable O 
serum O 
levels O 
of O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
could O 
not O 
reveal O 
any O 
relationship O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
and O 
4β-hydroxycholesterol B-SYSTEMATIC 
, O 
an O 
endogenous O 
biomarker O 
of O 
CYP3A O 
activity O 
. O 
However O 
, O 
the O 
negative O 
correlation O 
between O 
CRP O 
and O 
4β-hydroxycholesterol B-SYSTEMATIC 
supports O 
earlier O 
experimental O 
results O 
that O 
inflammation O 
may O 
suppress O 
hepatic O 
CYP3A O 
activity O 
, O 
a O 
finding O 
of O 
potentially O 
high O 
clinical O 
relevance O 
that O 
warrants O 
further O 
exploration O 
. O 

cell O 
death O 
in O 
rat O 
epididymis O 
following O 
epichlorohydrin B-TRIVIAL 
treatment O 
. O 

( O 
ECH B-ABBREVIATION 
) O 
is O 
an O 
antifertility O 
agent O 
that O 
acts O 
both O 
as O 
an O 
epididymal O 
toxicant O 
and O 
an O 
agent O 
capable O 
of O 
directly O 
affecting O 
sperm O 
motility O 
. O 
This O 
study O 
identified O 
the O 
time O 
course O 
of O 
apoptotic O 
cell O 
death O 
in O 
rat O 
epididymides O 
after O 
ECH O 
treatment O 
. O 
Rats O 
were O 
administrated O 
with O 
a O 
single O 
oral O 
dose O 
of O 
ECH B-ABBREVIATION 
( O 
50 O 
mg O 
/ O 
kg O 
) O 
. O 
ECH B-ABBREVIATION 
-induced O 
apoptotic O 
changes O 
were O 
evaluated O 
by O 
terminal O 
deoxynucleotidyl O 
transferase O 
dUTP B-ABBREVIATION 
nick O 
end O 
labeling O 
( O 
TUNEL O 
) O 
assay O 
and O 
its O 
related O 
mechanism O 
was O 
confirmed O 
by O 
Western O 
blot O 
analysis O 
and O 
colorimetric O 
assay O 
. O 
The O 
TUNEL O 
assay O 
showed O 
that O 
the O 
number O 
of O 
apoptotic O 
cells O 
increased O 
at O 
8 O 
h O 
, O 
reached O 
a O 
maximum O 
level O 
at O 
12 O 
h O 
, O 
and O 
then O 
decreased O 
progressively O 
. O 
The O 
Western O 
blot O 
analysis O 
demonstrated O 
no O 
significant O 
changes O 
in O 
proapoptotic O 
Bcl-2-associated O 
X O 
( O 
Bax O 
) O 
and O 
anti-apoptotic O 
Bcl-2 O 
expression O 
during O 
the O 
time O 
course O 
of O 
the O 
study O 
. O 
However O 
, O 
phospho-p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
p-p38 O 
MAPK O 
) O 
and O 
phospho-c-Jun O 
amino B-FAMILY 
-terminal O 
kinase O 
( O 
p-JNK O 
) O 
expression O 
increased O 
at O 
8-24 O 
h O 
. O 
Caspase-3 O 
and O 
caspase-8 O 
activities O 
also O 
increased O 
at O 
8-48 O 
h O 
and O 
12-48 O 
h O 
, O 
respectively O 
, O 
in O 
the O 
same O 
manner O 
as O 
p-p38 O 
MAPK O 
and O 
p-JNK O 
expression O 
. O 
These O 
results O 
indicate O 
that O 
ECH O 
induced O 
apoptotic O 
changes O 
in O 
rat O 
epididymides O 
and O 
that O 
the O 
apoptotic O 
cell O 
death O 
may O 
be O 
related O 
more O 
to O 
the O 
MAPK O 
pathway O 
than O 
to O 
the O 
mitochondrial O 
pathway O 
. O 

and O 
characterization O 
of O 
unusual O 
hydrazides B-FAMILY 
from O 
Streptomyces O 
sp O 
. O 
impact O 
of O 
the O 
cultivation O 
support O 
and O 
extraction O 
procedure O 
. O 

novel O 
hydrazides B-FAMILY 
, O 
geralcins B-MULTIPLE 
C-E I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
were O 
isolated O 
from O 
Streptomyces O 
sp O 
. O 
LMA-545 O 
, O 
together O 
with O 
MH-031 O 
and O 
geralcins B-MULTIPLE 
A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
. O 
This O 
unusual O 
family O 
of O 
compounds O 
was O 
isolated O 
from O 
liquid O 
- O 
state O 
and O 
agar O 
- O 
supported O 
fermentation O 
using O 
Amberlite B-TRIVIAL 
XAD-16 I-TRIVIAL 
solid O 
- O 
phase O 
extraction O 
during O 
the O 
cultivation O 
step O 
. O 
The O 
use O 
of O 
such O 
neutral O 
resin O 
during O 
the O 
cultivation O 
step O 
allowed O 
the O 
specific O 
adsorption O 
of O 
microbial O 
secondary O 
metabolites O 
, O 
avoiding O 
any O 
contamination O 
of O 
the O 
crude O 
extracts O 
by O 
the O 
constituents O 
of O 
the O 
culture O 
medium O 
. O 
The O 
trapped O 
compounds O 
were O 
eluted O 
from O 
the O 
resin O 
with O 
methanol B-SYSTEMATIC 
, O 
and O 
their O 
structures O 
elucidated O 
using O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
, O 
and O 
(15)N B-FORMULA 
NMR O 
spectroscopic O 
analysis O 
and O 
high O 
- O 
resolution O 
mass O 
spectrometry O 
. O 
Molecular O 
modeling O 
calculations O 
were O 
applied O 
in O 
order O 
to O 
support O 
structural O 
attributions O 
. O 
No O 
antimicrobial O 
, O 
cytotoxic O 
, O 
or O 
DnaG-inhibition O 
activities O 
were O 
detected O 
for O 
geralcins B-MULTIPLE 
D I-MULTIPLE 
and I-MULTIPLE 
E I-MULTIPLE 
. O 
Geralcin B-TRIVIAL 
C I-TRIVIAL 
has O 
no O 
antimicrobial O 
activity O 
but O 
exhibited O 
an O 
IC(50) O 
of O 
0.8 O 
μM O 
against O 
KB O 
and O 
HCT116 O 
cancer O 
cell O 
lines O 
. O 
Furthermore O 
, O 
geralcin B-TRIVIAL 
C I-TRIVIAL 
inhibited O 
the O 
E O 
. O 
coli O 
DnaG O 
primase O 
, O 
a O 
Gram O 
- O 
negative O 
antimicrobial O 
target O 
, O 
with O 
an O 
IC(50) O 
of O 
0.7 O 
mM O 
. O 

: O 
Sigma O 
receptors O 
are O 
involved O 
in O 
several O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
disorders O 
, O 
including O 
mood O 
disorders O 
( O 
depression O 
and O 
anxiety O 
) O 
, O 
psychosis O 
, O 
schizophrenia O 
, O 
movement O 
disorders O 
( O 
i.e O 
. O 
, O 
Parkinson's O 
disease O 
) O 
and O 
memory O 
deficits O 
( O 
i.e O 
. O 
, O 
Alzheimer's O 
disease O 
) O 
. O 
Recently O 
, O 
the O 
involvement O 
of O 
sigma O 
receptors O 
in O 
neuropathic O 
pain O 
and O 
cancer O 
has O 
also O 
been O 
observed O 
. O 
Areas O 
covered O 
: O 
This O 
review O 
aims O 
at O 
highlighting O 
the O 
research O 
advancements O 
published O 
in O 
the O 
patent O 
literature O 
between O 
1986 O 
and O 
2012 O 
, O 
dividing O 
patents O 
according O 
to O 
both O 
their O 
time O 
frame O 
and O 
applicants O 
. O 
The O 
review O 
especially O 
focuses O 
on O 
the O 
development O 
of O 
sigma O 
receptor O 
modulators O 
and O 
their O 
application O 
over O 
the O 
years O 
with O 
respect O 
to O 
CNS O 
diseases O 
, O 
neuropathic O 
pain O 
and O 
neurodegenerative O 
pathologies O 
. O 
The O 
literature O 
was O 
sought O 
through O 
Espacenet O 
, O 
Orbit O 
, O 
ISI O 
Web O 
and O 
PubMed O 
databases O 
. O 
Expert O 
opinion O 
: O 
In O 
recent O 
years O 
, O 
considerable O 
progress O 
in O 
the O 
knowledge O 
of O 
the O 
biology O 
and O 
pharmacology O 
of O 
sigma O 
receptors O 
has O 
encouraged O 
research O 
on O 
the O 
potential O 
benefits O 
of O 
sigma O 
modulators O 
in O 
a O 
wide O 
range O 
of O 
pathologies O 
. O 
So O 
far O 
, O 
only O 
few O 
potent O 
agonists O 
and O 
antagonists O 
of O 
sigma O 
receptors O 
are O 
in O 
clinical O 
trial O 
for O 
acute O 
and O 
chronic O 
neurodegenerative O 
diseases O 
( O 
SA4503 B-IDENTIFIER 
and O 
ANAVEX B-IDENTIFIER 
2-73 I-IDENTIFIER 
) O 
or O 
neuropathic O 
pain O 
( O 
E-52862 B-IDENTIFIER 
) O 
. O 

solution O 
structure O 
study O 
of O 
the O 
representative O 
component O 
hydroxysafflor B-SYSTEMATIC 
yellow I-SYSTEMATIC 
A I-SYSTEMATIC 
and O 
other O 
quinochalcone B-FAMILY 
C-glycosides I-FAMILY 
from O 
Carthamus O 
tinctorius O 
. O 

yellow I-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
HSYA B-ABBREVIATION 
) O 
, O 
a O 
representative O 
component O 
of O 
Carthamus O 
tinctorius O 
, O 
has O 
attracted O 
much O 
attention O 
because O 
of O 
its O 
remarkable O 
cardiovascular O 
activities O 
. O 
Its O 
structure O 
was O 
originally O 
reported O 
in O 
1993 O 
and O 
has O 
been O 
widely O 
cited O 
to O 
date O 
. O 
In O 
our O 
experiments O 
, O 
its O 
solution O 
structure O 
was O 
studied O 
using O 
NMR O 
techniques O 
in O 
different O 
solvents O 
, O 
including O 
DMSO-d(6) B-ABBREVIATION 
, O 
pyridine-d(5) B-SYSTEMATIC 
, O 
and O 
CD(3)OH B-FORMULA 
. O 
The O 
results O 
indicate O 
that O 
the O 
structure O 
of O 
HSYA B-ABBREVIATION 
is O 
different O 
than O 
the O 
previously O 
described O 
1b O 
, O 
with O 
3-enol-1,7-diketo B-SYSTEMATIC 
form O 
. O 
The O 
structure O 
has O 
two O 
keto-enol B-SYSTEMATIC 
tautomers O 
( O 
2a O 
and O 
2b O 
) O 
, O 
and O 
2a O 
, O 
with O 
the O 
1-enol-3,7-diketo B-SYSTEMATIC 
form O 
, O 
is O 
the O 
preferred O 
tautomer O 
. O 
On O 
the O 
basis O 
of O 
this O 
finding O 
, O 
other O 
published O 
quinochalcone B-FAMILY 
C-glycoside I-FAMILY 
structures O 
were O 
revised O 
. O 
Furthermore O 
, O 
a O 
trend O 
in O 
the O 
(13)C B-FORMULA 
NMR O 
data O 
of O 
the O 
(E)-olefinic B-FAMILY 
carbons I-FAMILY 
of O 
quinochalcone B-FAMILY 
C-glycosides I-FAMILY 
is O 
summarized O 
, O 
and O 
a O 
hypothesis O 
is O 
proposed O 
for O 
the O 
relationship O 
between O 
the O 
features O 
of O 
the O 
molecular O 
structure O 
and O 
the O 
preferred O 
keto-enol B-SYSTEMATIC 
tautomer O 
. O 

modification O 
enzymes O 
regulate O 
gene O 
expression O 
by O 
altering O 
the O 
accessibility O 
of O 
promoters O 
to O 
transcription O 
factors O 
. O 
We O 
sought O 
to O 
determine O 
whether O 
the O 
genes O 
encoding O 
histone O 
modification O 
enzymes O 
are O 
dysregulated O 
in O 
pediatric O 
acute O 
lymphoblastic O 
leukemia O 
( O 
ALL O 
) O 
. O 
A O 
real O 
- O 
time O 
PCR O 
array O 
was O 
designed O 
, O 
tested O 
and O 
used O 
to O 
profile O 
the O 
expression O 
of O 
85 O 
genes O 
encoding O 
histone O 
modification O 
enzymes O 
in O 
bone O 
marrow O 
mononuclear O 
cells O 
from O 
30 O 
pediatric O 
ALL O 
patients O 
and O 
20 O 
normal O 
controls O 
. O 
The O 
expression O 
profile O 
of O 
histone O 
- O 
modifying O 
genes O 
was O 
significantly O 
different O 
between O 
normal O 
karyotype O 
B O 
cell O 
pediatric O 
ALL O 
and O 
normal O 
controls O 
. O 
Eleven O 
genes O 
were O 
upregulated O 
in O 
pediatric O 
ALL O 
, O 
including O 
the O 
histone O 
deacetylases O 
HDAC2 O 
and O 
PAK1 O 
, O 
and O 
seven O 
genes O 
were O 
downregulated O 
, O 
including O 
PRMT2 O 
and O 
the O 
putative O 
tumor O 
suppressor O 
EP300 O 
. O 
Future O 
studies O 
will O 
seek O 
to O 
determine O 
whether O 
these O 
genes O 
serve O 
as O 
biomarkers O 
of O 
pediatric O 
ALL O 
. O 
Ingenuity O 
Pathway O 
Analysis O 
revealed O 
that O 
Gene O 
Expression O 
and O 
Organ O 
Morphology O 
was O 
the O 
highest O 
rated O 
network O 
, O 
with O 
13 O 
focus O 
molecules O 
( O 
significance O 
score O 
= O 
35 O 
) O 
. O 
Ingenuity O 
Pathway O 
Analysis O 
also O 
indicated O 
that O 
curcumin B-TRIVIAL 
and O 
miR-34 O 
are O 
upstream O 
regulators O 
of O 
histone O 
- O 
modifying O 
enzymes O 
; O 
future O 
studies O 
will O 
seek O 
to O 
validate O 
these O 
results O 
and O 
examine O 
the O 
role O 
of O 
curcumin B-TRIVIAL 
and O 
miR-34 O 
in O 
leukemia O 
. O 
This O 
study O 
provides O 
new O 
clues O 
into O 
the O 
molecular O 
mechanisms O 
of O 
pediatric O 
ALL O 
. O 

- O 
assembly O 
of O 
pyridine B-SYSTEMATIC 
-modified O 
lipoic B-TRIVIAL 
Acid I-TRIVIAL 
derivatives O 
on O 
gold O 
and O 
their O 
interaction O 
with O 
thyroxine B-TRIVIAL 
( I-TRIVIAL 
t4 I-TRIVIAL 
) I-TRIVIAL 
. O 

derivatives O 
of O 
lipoic O 
acid O 
were O 
prepared O 
as O 
ligands O 
for O 
the O 
study O 
of O 
the O 
interaction O 
with O 
thyroxine B-TRIVIAL 
( I-TRIVIAL 
T4 I-TRIVIAL 
) I-TRIVIAL 
. O 
Thin O 
self O 
- O 
assembled O 
films O 
of O 
the O 
ligands O 
were O 
prepared O 
in O 
70% O 
ethanol B-SYSTEMATIC 
on O 
gold O 
and O 
their O 
interaction O 
with O 
T4 O 
was O 
studied O 
by O 
titration O 
experiments O 
in O 
an O 
aqueous O 
buffer O 
solution O 
using O 
Surface O 
Plasmon O 
Resonance O 
( O 
SPR O 
) O 
. O 
The O 
thickness O 
and O 
refractive O 
index O 
of O 
the O 
ligand O 
layers O 
were O 
calculated O 
from O 
SPR O 
spectra O 
recorded O 
in O 
two O 
media O 
, O 
also O 
allowing O 
for O 
surface O 
coverage O 
and O 
the O 
density O 
of O 
the O 
layers O 
to O 
be O 
estimated O 
. O 
Two O 
ligands O 
, O 
a O 
4-pyridyl B-SYSTEMATIC 
and O 
a O 
bis(2-hydroxyethyl) B-SYSTEMATIC 
derivative O 
of O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
were O 
selected O 
to O 
investigate O 
the O 
feasibility O 
for O 
producing O 
molecularly O 
imprinted O 
self O 
- O 
assembled O 
layers O 
on O 
gold O 
for O 
T4 O 
. O 
The O 
methodology O 
was O 
to O 
co O 
- O 
assemble O 
T4 O 
and O 
the O 
ligand O 
onto O 
the O 
gold O 
surface O 
, O 
elute O 
the O 
T4 O 
from O 
the O 
layer O 
under O 
alkaline O 
conditions O 
, O 
and O 
study O 
the O 
rebinding O 
of O 
T4 O 
to O 
the O 
layer O 
. O 
Multiple O 
elution O 
/ O 
rebinding O 
cycles O 
were O 
conducted O 
in O 
different O 
buffer O 
solutions O 
, O 
and O 
rebinding O 
of O 
T4 O 
could O 
be O 
observed O 
, O 
with O 
a O 
moderate O 
binding O 
affinity O 
that O 
depended O 
greatly O 
on O 
the O 
solvent O 
used O 
. O 
More O 
optimal O 
binding O 
was O 
observed O 
in O 
HBS O 
buffer O 
, O 
and O 
the O 
affinity O 
of O 
the O 
interaction O 
could O 
be O 
slightly O 
increased O 
when O 
the O 
4-pyridyl B-SYSTEMATIC 
and O 
bis(2-hydroxy-ethyl) B-SYSTEMATIC 
derivatives O 
of O 
lipoic B-TRIVIAL 
acid I-TRIVIAL 
were O 
combined O 
in O 
the O 
imprinted O 
layer O 
. O 

-coated O 
LiFePO4 B-FORMULA 
-porous O 
carbon B-SYSTEMATIC 
composites O 
as O 
cathode O 
materials O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

work O 
introduces O 
a O 
facile O 
strategy O 
for O 
the O 
synthesis O 
of O 
carbon B-SYSTEMATIC 
-coated O 
LiFePO(4) B-FORMULA 
-porous O 
carbon B-SYSTEMATIC 
( O 
C B-FORMULA 
- O 
LiFePO(4) B-FORMULA 
-PC O 
) O 
composites O 
as O 
a O 
cathode O 
material O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 
The O 
LiFePO(4) B-FORMULA 
particles O 
obtained O 
are O 
about O 
200 O 
nm O 
in O 
size O 
and O 
homogeneously O 
dispersed O 
in O 
porous O 
carbon B-SYSTEMATIC 
matrix O 
. O 
These O 
particles O 
are O 
further O 
coated O 
with O 
the O 
carbon B-SYSTEMATIC 
layers O 
pyrolyzed O 
from O 
sucrose B-TRIVIAL 
. O 
The O 
C B-FORMULA 
- O 
LiFePO(4) B-FORMULA 
-PC O 
composites O 
display O 
a O 
high O 
initial O 
discharge O 
capacity O 
of O 
152.3 O 
mA O 
h O 
g(-1) O 
at O 
0.1 O 
C O 
, O 
good O 
cycling O 
stability O 
, O 
as O 
well O 
as O 
excellent O 
rate O 
capability O 
( O 
112 O 
mA O 
h O 
g(-1) O 
at O 
5 O 
C O 
) O 
. O 
The O 
likely O 
contributing O 
factors O 
to O 
the O 
excellent O 
electrochemical O 
performance O 
of O 
the O 
C B-FORMULA 
- O 
LiFePO(4) B-FORMULA 
-PC O 
composites O 
could O 
be O 
related O 
to O 
the O 
combined O 
effects O 
of O 
enhancement O 
of O 
conductivity O 
by O 
the O 
porous O 
carbon B-SYSTEMATIC 
matrix O 
and O 
the O 
carbon B-SYSTEMATIC 
coating O 
layers O 
. O 
It O 
is O 
believed O 
that O 
further O 
carbon B-SYSTEMATIC 
coating O 
is O 
a O 
facile O 
and O 
effective O 
way O 
to O 
improve O 
the O 
electrochemical O 
performance O 
of O 
LiFePO(4) B-FORMULA 
-PC O 
. O 

of O 
ethyl B-SYSTEMATIC 
tertiary I-SYSTEMATIC 
- I-SYSTEMATIC 
butyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
with O 
2-year O 
inhalation O 
exposure O 
in O 
F344 O 
rats O 
. O 

of O 
ethyl B-SYSTEMATIC 
tertiary I-SYSTEMATIC 
- I-SYSTEMATIC 
butyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
ETBE B-ABBREVIATION 
) O 
was O 
examined O 
with O 
inhalation O 
exposure O 
using O 
F344 O 
/ O 
DuCrlCrlj O 
rats O 
. O 
Groups O 
of O 
50 O 
male O 
and O 
50 O 
female O 
rats O 
, O 
6 O 
week O 
old O 
at O 
commencement O 
, O 
were O 
exposed O 
to O 
ETBE B-ABBREVIATION 
at O 
0 O 
, O 
500 O 
, O 
1500 O 
or O 
5000 O 
ppm O 
( O 
v O 
/ O 
v O 
) O 
in O 
whole O 
- O 
body O 
inhalation O 
chambers O 
for O 
6 O 
h O 
/ O 
day O 
, O 
5 O 
days O 
/ O 
week O 
for O 
104 O 
weeks O 
. O 
A O 
significant O 
increase O 
in O 
the O 
incidence O 
of O 
hepatocellular O 
adenomas O 
was O 
indicated O 
in O 
males O 
exposed O 
at O 
5000 O 
ppm O 
, O 
but O 
not O 
in O 
females O 
at O 
any O 
concentration O 
. O 
In O 
addition O 
, O 
significantly O 
increased O 
incidences O 
of O 
eosinophilic O 
and O 
basophilic O 
cell O 
foci O 
were O 
observed O 
in O 
male O 
rats O 
at O 
5000 O 
ppm O 
. O 
Regarding O 
non-neoplastic O 
lesions O 
, O 
rat O 
- O 
specific O 
changes O 
were O 
observed O 
in O 
kidney O 
, O 
with O 
an O 
increase O 
in O 
the O 
severity O 
of O 
chronic O 
progressive O 
nephropathy O 
in O 
both O 
sexes O 
at O 
5000 O 
ppm O 
. O 
Increased O 
incidences O 
of O 
urothelial O 
hyperplasia O 
of O 
the O 
pelvis O 
were O 
observed O 
at O 
1500 O 
ppm O 
and O 
above O 
, O 
and O 
mineral O 
deposition O 
was O 
apparent O 
in O 
the O 
renal O 
papilla O 
at O 
5000 O 
ppm O 
in O 
males O 
. O 
There O 
were O 
no O 
treatment O 
- O 
related O 
histopathological O 
changes O 
observed O 
in O 
any O 
other O 
organs O 
or O 
tissues O 
in O 
either O 
sex O 
. O 
The O 
present O 
2-year O 
inhalation O 
study O 
demonstrated O 
hepatotumorigenicity O 
of O 
ETBE B-ABBREVIATION 
in O 
male O 
, O 
but O 
not O 
in O 
female O 
rats O 
. O 

late O 
- O 
gestation O 
surge O 
in O 
fetal O 
plasma O 
cortisol B-TRIVIAL 
is O 
critical O 
for O 
maturation O 
of O 
fetal O 
organ O 
systems O 
. O 
As O 
a O 
result O 
, O 
synthetic O 
glucocorticoids O 
( O 
sGCs O 
) O 
are O 
administered O 
to O 
pregnant O 
women O 
at O 
risk O 
of O 
delivering O 
preterm O 
. O 
However O 
, O 
animal O 
studies O 
have O 
shown O 
that O 
fetal O 
exposure O 
to O 
sGC B-ABBREVIATION 
results O 
in O 
increased O 
risk O 
of O 
behavioral O 
, O 
endocrine O 
, O 
and O 
metabolic O 
abnormalities O 
in O 
offspring O 
. O 
Here O 
, O 
we O 
test O 
the O 
hypothesis O 
that O 
prenatal O 
GC O 
exposure O 
resulting O 
from O 
the O 
fetal O 
cortisol B-TRIVIAL 
surge O 
or O 
after O 
sGC O 
exposure O 
results O 
in O 
promoter O 
- O 
specific O 
epigenetic O 
changes O 
in O 
the O 
hippocampus O 
. O 
Fetal O 
guinea O 
pig O 
hippocampi O 
were O 
collected O 
before O 
( O 
gestational O 
day O 
[ O 
GD52 O 
] O 
) O 
and O 
after O 
( O 
GD65 O 
) O 
the O 
fetal O 
plasma O 
cortisol B-TRIVIAL 
surge O 
( O 
Term∼GD67 O 
) O 
and O 
24 O 
hours O 
after O 
( O 
GD52 O 
) O 
and O 
14 O 
days O 
after O 
( O 
GD65 O 
) O 
two O 
repeat O 
courses O 
of O 
maternal O 
sGC O 
( O 
betamethasone B-TRIVIAL 
) O 
treatment O 
( O 
n O 
= O 
3-4 O 
/ O 
gp O 
) O 
. O 
We O 
identified O 
extensive O 
genome O 
- O 
wide O 
alterations O 
in O 
promoter O 
methylation O 
in O 
late O 
fetal O 
development O 
( O 
coincident O 
with O 
the O 
fetal O 
cortisol B-TRIVIAL 
surge O 
) O 
, O 
whereby O 
the O 
majority O 
of O 
the O 
affected O 
promoters O 
exhibited O 
hypomethylation O 
. O 
Fetuses O 
exposed O 
to O 
sGC O 
in O 
late O 
gestation O 
exhibited O 
substantial O 
differences O 
in O 
DNA O 
methylation O 
and O 
histone O 
h3 O 
lysine O 
9 O 
( O 
H3K9 O 
) O 
acetylation O 
in O 
specific O 
gene O 
promoters O 
; O 
24 O 
hours O 
after O 
the O 
sGC O 
treatment O 
, O 
the O 
majority O 
of O 
genes O 
affected O 
were O 
hypomethylated O 
or O 
hyperacetylated O 
. O 
However O 
, O 
14 O 
days O 
after O 
sGC O 
exposure O 
these O 
differences O 
did O 
not O 
persist O 
, O 
whereas O 
other O 
promoters O 
became O 
hypermethylated O 
or O 
hyperacetylated O 
. O 
These O 
data O 
support O 
the O 
hypothesis O 
that O 
the O 
fetal O 
GC O 
surge O 
is O 
responsible O 
, O 
in O 
part O 
, O 
for O 
significant O 
variations O 
in O 
genome O 
- O 
wide O 
promoter O 
methylation O 
and O 
that O 
prenatal O 
sGC O 
treatment O 
profoundly O 
changes O 
the O 
epigenetic O 
landscape O 
, O 
affecting O 
both O 
DNA O 
methylation O 
and O 
H3K9 O 
acetylation O 
. O 
This O 
is O 
important O 
given O 
the O 
widespread O 
use O 
of O 
sGC O 
in O 
the O 
management O 
of O 
women O 
in O 
preterm O 
labor O 
. O 

-conjugated O 
PAMAM B-ABBREVIATION 
dendrimers O 
adversely O 
affect O 
microtubule O 
structure O 
through O 
two O 
independent O 
modes O 
of O 
action O 
. O 

( O 
Taxol B-TRIVIAL 
) O 
is O 
an O 
anticancer O 
drug O 
that O 
induces O 
mitotic O 
arrest O 
via O 
microtubule O 
hyperstabilization O 
but O 
causes O 
side O 
effects O 
due O 
to O 
its O 
hydrophobicity O 
and O 
cellular O 
promiscuity O 
. O 
The O 
targeted O 
cytotoxicity O 
of O 
hydrophilic O 
paclitaxel B-TRIVIAL 
-conjugated O 
polyamidoamine B-FAMILY 
( O 
PAMAM B-ABBREVIATION 
) O 
dendrimers O 
has O 
been O 
demonstrated O 
in O 
cultured O 
cancer O 
cells O 
. O 
Mechanisms O 
of O 
action O 
responsible O 
for O 
this O 
cytotoxicity O 
are O 
unknown O 
, O 
that O 
is O 
, O 
whether O 
the O 
cytotoxicity O 
is O 
due O 
to O 
paclitaxel B-TRIVIAL 
stabilization O 
of O 
microtubules O 
, O 
as O 
is O 
whether O 
paclitaxel B-TRIVIAL 
is O 
released O 
intracellularly O 
from O 
the O 
dendrimer O 
. O 
To O 
determine O 
whether O 
the O 
conjugated O 
paclitaxel B-TRIVIAL 
can O 
bind O 
microtubules O 
, O 
we O 
used O 
a O 
combination O 
of O 
ensemble O 
and O 
single O 
microtubule O 
imaging O 
techniques O 
in O 
vitro O 
. O 
We O 
demonstrate O 
that O 
these O 
conjugates O 
adversely O 
affect O 
microtubules O 
by O 
( O 
1 O 
) O 
promoting O 
the O 
polymerization O 
and O 
stabilization O 
of O 
microtubules O 
in O 
a O 
paclitaxel B-TRIVIAL 
-dependent O 
manner O 
, O 
and O 
( O 
2 O 
) O 
bundling O 
preformed O 
microtubules O 
in O 
a O 
paclitaxel B-TRIVIAL 
-independent O 
manner O 
, O 
potentially O 
due O 
to O 
protonation O 
of O 
tertiary B-FAMILY 
amines I-FAMILY 
in O 
the O 
dendrimer O 
interior O 
. O 
Our O 
results O 
provide O 
mechanistic O 
insights O 
into O 
the O 
cytotoxicity O 
of O 
paclitaxel B-TRIVIAL 
-conjugated O 
PAMAM B-ABBREVIATION 
dendrimers O 
and O 
uncover O 
unexpected O 
risks O 
of O 
using O 
such O 
conjugates O 
therapeutically O 
. O 

is O 
commonly O 
believed O 
to O 
be O 
inactive O 
to O 
organic O 
substances O 
; O 
this O 
inertness O 
is O 
an O 
essential O 
requirement O 
for O 
raw O 
materials O 
in O 
industrial O 
products O 
. O 
Here O 
we O 
demonstrate O 
the O 
contradictory O 
but O 
promising O 
properties O 
, O 
which O 
are O 
the O 
hydrolytic O 
activities O 
of O 
crystalline O 
cellulose O 
nanofibers O 
for O 
the O 
ester B-FAMILY 
, O 
monophosphate B-SYSTEMATIC 
, O 
and O 
even O 
amide B-FAMILY 
bonds O 
of O 
small O 
organic O 
substrates O 
under O 
extremely O 
mild O 
conditions O 
( O 
neutral O 
pH O 
, O 
moderate O 
temperature O 
, O 
and O 
atmospheric O 
pressure O 
) O 
. O 
The O 
hydrolytic O 
activities O 
were O 
significantly O 
extended O 
to O 
decompose O 
the O 
coat O 
proteins O 
of O 
model O 
viruses O 
, O 
followed O 
by O 
a O 
drastic O 
decrease O 
in O 
their O 
infection O 
capabilities O 
to O 
the O 
host O 
cells O 
. O 

Relationships O 
of O 
Serum O 
Albumin O 
Targeted O 
MRI O 
Probes O 
Based O 
on O 
a O 
Single O 
Amino B-FAMILY 
Acid I-FAMILY 
Gd B-FORMULA 
Complex O 
. O 

Gd B-FORMULA 
(III) I-FORMULA 
complex O 
of O 
DO3A-N-α-aminopropionate B-SYSTEMATIC 
, O 
Gd(DOTAla) B-FORMULA 
, O 
was O 
used O 
to O 
generate O 
a O 
small O 
library O 
of O 
putative O 
MRI O 
probes O 
targeted O 
to O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
. O 
Ten O 
compounds O 
were O 
synthesized O 
via O 
multistep O 
organic O 
synthesis O 
, O 
and O 
the O 
corresponding O 
Gd B-FORMULA 
complexes O 
were O 
investigated O 
for O 
their O 
affinity O 
to O 
HSA O 
, O 
lipophilicity O 
, O 
and O 
relaxivity O 
in O 
the O 
absence O 
and O 
presence O 
of O 
HSA O 
. O 
Negative O 
charge O 
and O 
moderate O 
lipophilicity O 
correlate O 
with O 
increased O 
HSA O 
affinity O 
and O 
relaxivity O 
. O 

interconnected O 
lipid O 
nanotube O 
networks O 
were O 
fabricated O 
on O 
the O 
millimeter O 
scale O 
based O 
on O 
the O 
simple O 
, O 
cooperative O 
interaction O 
between O 
phospholipid O 
vesicles O 
and O 
kinesin O 
- O 
microtubule O 
( O 
MT O 
) O 
transport O 
systems O 
. O 
More O 
specifically O 
, O 
taxol B-TRIVIAL 
-stabilized O 
MTs O 
, O 
in O 
constant O 
2D O 
motion O 
via O 
surface O 
absorbed O 
kinesin O 
, O 
extracted O 
and O 
extended O 
lipid O 
nanotube O 
networks O 
from O 
large O 
Lα O 
phase O 
multilamellar O 
liposomes O 
( O 
5-25 O 
μm O 
) O 
. O 
Based O 
on O 
the O 
properties O 
of O 
the O 
inverted O 
motility O 
geometry O 
, O 
the O 
total O 
size O 
of O 
these O 
nanofluidic O 
networks O 
was O 
limited O 
by O 
MT O 
surface O 
density O 
, O 
molecular O 
motor O 
energy O 
source O 
( O 
ATP B-ABBREVIATION 
) O 
, O 
and O 
total O 
amount O 
and O 
physical O 
properties O 
of O 
lipid O 
source O 
material O 
. O 
Interactions O 
between O 
MTs O 
and O 
extended O 
lipid O 
nanotubes O 
resulted O 
in O 
bifurcation O 
of O 
the O 
nanotubes O 
and O 
ultimately O 
the O 
generation O 
of O 
highly O 
branched O 
networks O 
of O 
fluidically O 
connected O 
nanotubes O 
. O 
The O 
network O 
bifurcation O 
was O 
easily O 
tuned O 
by O 
changing O 
the O 
density O 
of O 
microtubules O 
on O 
the O 
surface O 
to O 
increase O 
or O 
decrease O 
the O 
frequency O 
of O 
branching O 
. O 
The O 
ability O 
of O 
these O 
networks O 
to O 
capture O 
nanomaterials O 
at O 
the O 
membrane O 
surface O 
with O 
high O 
fidelity O 
was O 
subsequently O 
demonstrated O 
using O 
quantum O 
dots O 
as O 
a O 
model O 
system O 
. O 
The O 
diffusive O 
transport O 
of O 
quantum O 
dots O 
was O 
also O 
characterized O 
with O 
respect O 
to O 
using O 
these O 
nanotube O 
networks O 
for O 
mass O 
transport O 
applications O 
. O 

round O 
window O 
membrane O 
( O 
RWM O 
) O 
acts O 
as O 
a O 
barrier O 
between O 
the O 
middle O 
ear O 
and O 
cochlea O 
and O 
can O 
serve O 
as O 
a O 
crucial O 
route O 
for O 
therapeutic O 
medications O 
entering O 
the O 
inner O 
ear O 
via O 
middle O 
ear O 
applications O 
. O 
In O 
this O 
study O 
, O 
we O 
targeted O 
the O 
practical O 
application O 
of O 
microbubbles O 
( O 
MBs O 
) O 
ultrasound O 
on O 
increasing O 
the O 
RWM O 
permeability O 
for O 
facilitating O 
drug O 
or O 
medication O 
delivery O 
to O 
the O 
inner O 
ear O 
. O 
Using O 
biotin B-FAMILY 
- I-FAMILY 
fluorescein I-FAMILY 
isothiocyanate I-FAMILY 
conjugates O 
( O 
biotin B-TRIVIAL 
- O 
FITC B-ABBREVIATION 
) O 
as O 
delivery O 
agents O 
and O 
guinea O 
pig O 
animal O 
models O 
, O 
we O 
showed O 
that O 
MB O 
ultrasound O 
exposure O 
can O 
improve O 
the O 
inner O 
ear O 
system O 
use O 
of O 
biotin B-TRIVIAL 
- O 
FITC B-ABBREVIATION 
delivery O 
via O 
the O 
RWM O 
by O 
approximately O 
3.5 O 
to O 
38 O 
times O 
that O 
of O 
solely O 
soaking O 
biotin B-TRIVIAL 
- O 
FITC B-ABBREVIATION 
around O 
the O 
RWM O 
for O 
spontaneous O 
diffusion O 
. O 
We O 
also O 
showed O 
that O 
there O 
was O 
significant O 
enhancement O 
of O 
hair O 
cell O 
uptake O 
of O 
gentamicin B-FAMILY 
in O 
animals O 
whose O 
tympanic O 
bullas O 
were O 
soaked O 
with O 
MB-mixed O 
gentamicin B-FAMILY 
- O 
Texas B-TRIVIAL 
Red I-TRIVIAL 
or O 
gentamicin B-FAMILY 
and O 
exposed O 
to O 
ultrasound O 
. O 
Furthermore O 
, O 
increased O 
permeability O 
of O 
the O 
RWM O 
from O 
acoustic O 
cavitation O 
of O 
MBs O 
could O 
also O 
be O 
visualized O 
immediately O 
following O 
ultrasound O 
exposure O 
by O 
using O 
Alexa B-TRIVIAL 
Fluor I-TRIVIAL 
488 I-TRIVIAL 
-conjugated O 
phalloidin B-TRIVIAL 
as O 
a O 
tracer O 
. O 
Most O 
importantly O 
, O 
such O 
applications O 
had O 
no O 
resulting O 
damage O 
to O 
the O 
integrity O 
of O 
the O 
RWM O 
or O 
deterioration O 
of O 
the O 
hearing O 
thresholds O 
assessed O 
by O 
auditory O 
brainstem O 
responses O 
. O 
We O 
herein O 
provide O 
a O 
basis O 
for O 
MB O 
ultrasound O 
- O 
mediated O 
techniques O 
with O 
therapeutic O 
medication O 
delivery O 
to O 
the O 
inner O 
ear O 
for O 
future O 
application O 
in O 
humans O 
. O 

heart O 
diseases O 
caused O 
by O 
insufficient O 
oxygen B-SYSTEMATIC 
supply O 
to O 
the O 
cardiac O 
muscle O 
require O 
pharmaceutical O 
agents O 
for O 
the O 
prevention O 
of O 
the O 
progress O 
and O 
recurrence O 
. O 
Metallothionein O 
( O 
MT O 
) O 
has O 
a O 
potential O 
as O 
a O 
protein O 
therapeutic O 
for O 
the O 
treatment O 
of O 
this O 
disease O 
due O 
to O 
its O 
anti-oxidative O 
effects O 
under O 
stressful O 
conditions O 
. O 
In O 
spite O 
of O 
its O 
therapeutic O 
potential O 
, O 
efficient O 
delivery O 
systems O 
need O 
to O 
be O 
developed O 
to O 
overcome O 
limitations O 
such O 
as O 
low O 
transduction O 
efficiency O 
, O 
instability O 
and O 
short O 
half O 
- O 
life O 
in O 
the O 
body O 
. O 
To O 
enhance O 
intra O 
- O 
cellular O 
transduction O 
efficiency O 
, O 
Tat O 
sequence O 
as O 
a O 
protein O 
transduction O 
domain O 
( O 
PTD O 
) O 
was O 
fused O 
with O 
MT O 
in O 
a O 
recombinant O 
method O 
. O 
Anti-apoptotic O 
and O 
anti-oxidative O 
effects O 
of O 
Tat-MT O 
fusion O 
protein O 
were O 
evaluated O 
under O 
hyperglycemia O 
and O 
hypoxia O 
stress O 
conditions O 
in O 
cultured O 
H9c2 O 
cells O 
. O 
Recovery O 
of O 
cardiac O 
functions O 
by O 
anti-apoptotic O 
and O 
anti-fibrotic O 
effects O 
of O 
Tat-MT O 
was O 
confirmed O 
in O 
an O 
ischemia O 
/ O 
reperfusion O 
( O 
I O 
/ O 
R O 
) O 
rat O 
myocardial O 
infarction O 
model O 
. O 
Tat-MT O 
fusion O 
protein O 
effectively O 
protected O 
H9c2 O 
cells O 
under O 
stressful O 
conditions O 
by O 
reducing O 
intracellular O 
ROS O 
production O 
and O 
inhibiting O 
caspase-3 O 
activation O 
. O 
Tat-MT O 
fusion O 
protein O 
inhibited O 
apoptosis O 
, O 
reduced O 
fibrosis O 
area O 
and O 
enhanced O 
cardiac O 
functions O 
in O 
I O 
/ O 
R O 
. O 
Tat-MT O 
fusion O 
protein O 
could O 
be O 
a O 
promising O 
therapeutic O 
for O 
the O 
treatment O 
of O 
ischemic O 
heart O 
diseases O 
. O 

inappropriate O 
inflammatory O 
responses O 
contribute O 
to O 
the O 
pathogenesis O 
of O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
and O 
to O 
aspects O 
of O 
osteoarthritis O 
( O 
OA O 
) O 
. O 
The O 
orphan O 
nuclear O 
receptor O 
, O 
NR4A2 O 
, O 
is O 
a O 
key O 
regulator O 
and O 
potential O 
biomarker O 
for O 
inflammation O 
and O 
represents O 
a O 
potentially O 
valuable O 
therapeutic O 
target O 
. O 
Both O 
salmon O 
calcitonin O 
( O 
sCT O 
) O 
and O 
hyaluronic O 
acid O 
( O 
HA O 
) O 
attenuated O 
activated O 
mRNA O 
expression O 
of O 
NR4A1 O 
, O 
NR4A2 O 
, O 
NR4A3 O 
, O 
and O 
matrix O 
metalloproteinases O 
( O 
MMPs O 
) O 
1 O 
, O 
3 O 
and O 
13 O 
in O 
three O 
human O 
cell O 
lines O 
: O 
SW1353 O 
chondrocytes O 
, O 
U937 O 
and O 
THP-1 O 
monocytes O 
. O 
Ad-mixtures O 
of O 
sCT O 
and O 
HA O 
further O 
down O 
- O 
regulated O 
expression O 
of O 
NR4A2 O 
compared O 
to O 
either O 
agent O 
alone O 
at O 
specific O 
concentrations O 
, O 
hence O 
the O 
rationale O 
for O 
their O 
formulation O 
in O 
nanocomplexes O 
( O 
NPs O 
) O 
using O 
chitosan O 
. O 
The O 
sCT O 
released O 
from O 
NP O 
stimulated O 
cAMP B-ABBREVIATION 
production O 
in O 
human O 
T47D O 
breast O 
cancer O 
cells O 
expressing O 
sCT O 
receptors O 
. O 
When O 
NP O 
were O 
injected O 
by O 
the O 
intra O 
- O 
articular O 
( O 
I.A O 
. O 
) O 
route O 
to O 
the O 
mouse O 
knee O 
during O 
on O 
- O 
going O 
inflammatory O 
arthritis O 
of O 
the O 
K O 
/ O 
BxN O 
serum O 
transfer O 
model O 
, O 
joint O 
inflammation O 
was O 
reduced O 
together O 
with O 
NR4A2 O 
expression O 
, O 
and O 
local O 
bone O 
architecture O 
was O 
preserved O 
. O 
These O 
data O 
highlight O 
remarkable O 
anti-inflammatory O 
effects O 
of O 
sCT O 
and O 
HA O 
at O 
the O 
level O 
of O 
reducing O 
NR4A2 O 
mRNA O 
expression O 
in O 
vitro O 
. O 
Combining O 
them O 
in O 
NP O 
elicits O 
anti-arthritic O 
effects O 
in O 
vivo O 
following O 
I.A O 
. O 
delivery O 
. O 

vitro O 
toxicological O 
characterization O 
of O 
perfluorinated B-FAMILY 
carboxylic I-FAMILY 
acids I-FAMILY 
with O 
different O 
carbon B-SYSTEMATIC 
chain O 
lengths O 
. O 

acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
is O 
in O 
use O 
for O 
the O 
production O 
of O 
fluoropolymers B-FAMILY 
( O 
PFT B-ABBREVIATION 
) O 
. O 
Due O 
to O 
its O 
toxic O 
properties O 
it O 
was O 
proposed O 
to O 
replace O 
the O 
substance O 
in O 
its O 
industrial O 
applications O 
by O 
homologous O 
compounds O 
with O 
shorter O 
carbon B-SYSTEMATIC 
chain O 
length O 
that O 
were O 
supposed O 
to O 
be O 
less O 
toxic O 
compared O 
to O 
PFOA B-ABBREVIATION 
, O 
however O 
, O 
the O 
smaller O 
PFOA B-ABBREVIATION 
homologs O 
are O 
poorly O 
characterized O 
so O 
far O 
. O 
In O 
this O 
study O 
we O 
have O 
conducted O 
a O 
comparative O 
analysis O 
of O 
the O 
toxicity O 
of O 
perfluorinated B-FAMILY 
carboxylic I-FAMILY 
acids I-FAMILY 
( O 
PFCA B-ABBREVIATION 
) O 
with O 
a O 
carbon B-SYSTEMATIC 
chain O 
length O 
ranging O 
from O 
four O 
to O 
twelve O 
carbon B-SYSTEMATIC 
atoms O 
. O 
By O 
using O 
the O 
human O 
hepatocarcinoma O 
cell O 
line O 
HepG2 O 
as O 
an O 
in O 
vitro O 
model O 
for O 
human O 
hepatocytes O 
we O 
could O 
show O 
a O 
positive O 
correlation O 
between O 
the O 
carbon B-SYSTEMATIC 
chain O 
length O 
of O 
the O 
respective O 
PFCA B-ABBREVIATION 
and O 
its O 
cytotoxicity O 
. O 
There O 
was O 
, O 
however O 
, O 
no O 
indication O 
of O 
an O 
apoptotic O 
mechanism O 
for O 
cytotoxicity O 
. O 
All O 
PFCA B-ABBREVIATION 
under O 
investigation O 
were O 
negative O 
in O 
two O 
independent O 
genotoxicity O 
assays O 
. O 
As O 
PFOA B-ABBREVIATION 
, O 
being O 
a O 
well O 
- O 
known O 
peroxisome O 
proliferator O 
, O 
the O 
other O 
PFCA B-ABBREVIATION 
tested O 
in O 
this O 
study O 
were O 
also O 
shown O 
to O 
activate O 
human O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
( O 
PPARα O 
) O 
with O 
PFOA B-ABBREVIATION 
having O 
the O 
highest O 
potential O 
of O 
PPARα O 
activation O 
. O 
Moreover O 
, O 
the O 
compounds O 
showed O 
weak O 
potential O 
to O 
activate O 
PPARγ O 
and O 
hardly O 
activated O 
PPARδ O 
. O 
Taken O 
together O 
, O 
the O 
in O 
vitro O 
study O 
revealed O 
that O 
PFCA B-ABBREVIATION 
with O 
a O 
shorter O 
carbon B-SYSTEMATIC 
chain O 
length O 
seem O 
to O 
be O 
less O 
toxic O 
than O 
PFOA B-ABBREVIATION 
. O 

of O 
low O 
dose O 
Bisphenol B-TRIVIAL 
A I-TRIVIAL 
on O 
the O 
early O 
differentiation O 
of O 
human O 
embryonic O 
stem O 
cells O 
into O 
mammary O 
epithelial O 
cells O 
. O 

has O 
been O 
previously O 
reported O 
that O 
Bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
can O 
disturb O 
the O 
development O 
of O 
mammary O 
structure O 
and O 
increase O 
the O 
risk O 
of O 
breast O 
cancer O 
in O 
experimental O 
animals O 
. O 
In O 
this O 
study O 
, O 
an O 
in O 
vitro O 
model O 
of O 
human O 
embryonic O 
stem O 
cell O 
( O 
hESC O 
) O 
differentiation O 
into O 
mammary O 
epithelial O 
cells O 
was O 
applied O 
to O 
investigate O 
the O 
effect O 
of O 
low O 
dose O 
BPA B-ABBREVIATION 
on O 
the O 
early O 
stages O 
of O 
mammogenesis O 
. O 
A O 
newly O 
established O 
hESC O 
line O 
was O 
directionally O 
differentiated O 
into O 
mammary O 
epithelial O 
cells O 
by O 
a O 
well O 
- O 
established O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
culture O 
system O 
. O 
The O 
differentiated O 
mammary O 
epithelial O 
cells O 
were O 
characterized O 
by O 
immunofluorescence O 
and O 
western O 
blotting O 
assay O 
, O 
and O 
were O 
called O 
induced O 
differentiated O 
mammary O 
epithelial O 
cells O 
( O 
iDMECs O 
) O 
based O 
on O 
these O 
data O 
. O 
The O 
hESCs O 
were O 
treated O 
with O 
low O 
doses O 
of O 
BPA B-ABBREVIATION 
range O 
10(-9)-10(-6)M O 
during O 
the O 
differentiation O 
process O 
, O 
with O 
DMSO B-ABBREVIATION 
as O 
the O 
solvent O 
control O 
and O 
17-β-estrodiol B-SYSTEMATIC 
( O 
E2 O 
) O 
as O 
the O 
estrogen O 
- O 
positive O 
control O 
. O 
Our O 
results O 
showed O 
that O 
low O 
dose O 
BPA B-ABBREVIATION 
and O 
E2 O 
could O 
influence O 
the O 
mammosphere O 
area O 
of O 
iDMECs O 
and O 
upregulate O 
the O 
expression O 
level O 
of O 
Oct4 O 
and O 
Nanog O 
proteins O 
, O 
while O 
only O 
BPA B-ABBREVIATION 
could O 
downregulate O 
the O 
expression O 
of O 
E-cadherin O 
protein O 
. O 
Taken O 
together O 
, O 
this O 
study O 
provides O 
some O 
insights O 
into O 
the O 
effects O 
of O 
low O 
dose O 
BPA B-ABBREVIATION 
on O 
the O 
early O 
differentiation O 
stage O 
of O 
mammary O 
epithelial O 
cells O 
and O 
suggests O 
an O 
easier O 
canceration O 
status O 
of O 
iDMECs O 
under O 
the O 
effect O 
of O 
low O 
dose O 
BPA B-ABBREVIATION 
during O 
its O 
early O 
differentiation O 
stage O 
. O 

composition O 
and O 
husbandry O 
practices O 
largely O 
determine O 
essential O 
trace O 
element O 
status O 
and O 
toxic O 
element O 
exposure O 
of O 
livestock O 
, O 
and O 
consequently O 
their O 
concentrations O 
in O 
animal O 
products O 
. O 
This O 
study O 
evaluates O 
the O 
main O 
essential O 
trace O 
( O 
Co B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Fe B-FORMULA 
, O 
I B-FORMULA 
, O 
Mn B-FORMULA 
, O 
Mo B-FORMULA 
, O 
Ni B-FORMULA 
, O 
Se B-FORMULA 
and O 
Zn B-FORMULA 
) O 
and O 
toxic O 
( O 
As B-FORMULA 
, O 
Cd B-FORMULA 
, O 
Hg B-FORMULA 
and O 
Pb B-FORMULA 
) O 
element O 
concentrations O 
in O 
milk O 
from O 
organic O 
and O 
conventional O 
farms O 
in O 
NW O 
Spain O 
( O 
n=50 O 
) O 
. O 
Milk O 
samples O 
were O 
acid O 
digested O 
and O 
analyzed O 
by O 
ICP-MS O 
. O 
Essential O 
trace O 
element O 
concentrations O 
in O 
organic O 
milk O 
were O 
significantly O 
lower O 
compared O 
to O 
conventional O 
milk O 
, O 
this O 
was O 
especially O 
evident O 
for O 
elements O 
that O 
are O 
routinely O 
supplemented O 
at O 
high O 
concentrations O 
in O 
the O 
conventional O 
concentrate O 
feed O 
: O 
Cu B-FORMULA 
( O 
41 O 
and O 
68.9μg O 
/ O 
L O 
in O 
organic O 
and O 
conventional O 
milk O 
, O 
respectively O 
) O 
, O 
Zn B-FORMULA 
( O 
3326 O 
and O 
3933μg O 
/ O 
L O 
) O 
, O 
I B-FORMULA 
( O 
78 O 
and O 
265μg O 
/ O 
L O 
) O 
and O 
Se B-FORMULA 
( O 
9.4 O 
and O 
19.2μg O 
/ O 
L O 
) O 
. O 
Toxic O 
metal O 
concentrations O 
in O 
milk O 
were O 
in O 
general O 
very O 
low O 
and O 
no O 
statistically O 
significant O 
differences O 
were O 
observed O 
between O 
organic O 
and O 
conventional O 
milk O 
. O 
In O 
addition O 
, O 
the O 
mineral O 
content O 
of O 
organic O 
milk O 
showed O 
a O 
seasonal O 
pattern O 
, O 
the O 
significantly O 
higher O 
As B-FORMULA 
( O 
65% O 
) O 
and O 
Fe B-FORMULA 
( O 
13% O 
) O 
concentrations O 
found O 
in O 
the O 
winter O 
sampling O 
possibly O 
being O 
related O 
to O 
a O 
higher O 
consumption O 
of O 
concentration O 
feed O 
and O 
soil O 
ingestion O 
when O 
grazing O 
. O 

role O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
signaling O 
pathway O 
in O 
cardiotoxicity O 
of O 
acute O 
lead O 
intoxication O 
in O 
vivo O 
and O 
in O 
vitro O 
rat O 
model O 
. O 

( O 
Pb(2+) B-FORMULA 
) O 
is O 
a O 
naturally O 
occurring O 
systemic O 
toxicant O 
heavy O 
metal O 
that O 
affects O 
several O 
organs O 
in O 
the O 
body O 
including O 
the O 
kidneys O 
, O 
liver O 
, O 
and O 
central O 
nervous O 
system O 
. O 
However O 
, O 
Pb(2+) B-FORMULA 
-induced O 
cardiotoxicity O 
has O 
never O 
been O 
investigated O 
yet O 
and O 
the O 
exact O 
mechanism O 
of O 
Pb(2+) B-FORMULA 
associated O 
cardiotoxicity O 
has O 
not O 
been O 
studied O 
. O 
The O 
current O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
potential O 
effect O 
of O 
Pb(2+) B-FORMULA 
to O 
induce O 
cardiotoxicity O 
in O 
vivo O 
and O 
in O 
vitro O 
rat O 
model O 
and O 
to O 
explore O 
the O 
molecular O 
mechanisms O 
and O 
the O 
role O 
of O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
and O 
regulated O 
gene O 
, O 
cytochrome O 
P4501A1 O 
( O 
CYP1A1 O 
) O 
, O 
in O 
Pb(2+) B-FORMULA 
-mediated O 
cardiotoxicity O 
. O 
For O 
these O 
purposes O 
, O 
Wistar O 
albino O 
rats O 
were O 
treated O 
with O 
Pb(2+) B-FORMULA 
( O 
25 O 
, O 
50 O 
and O 
100mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
for O 
three O 
days O 
and O 
the O 
effects O 
on O 
physiological O 
and O 
histopathological O 
parameters O 
of O 
cardiotoxicity O 
were O 
determined O 
. O 
At O 
the O 
in O 
vitro O 
level O 
, O 
rat O 
cardiomyocyte O 
H9c2 O 
cell O 
lines O 
were O 
incubated O 
with O 
increasing O 
concentration O 
of O 
Pb(2+) B-FORMULA 
( O 
25 O 
, O 
50 O 
, O 
and O 
100μM O 
) O 
and O 
the O 
expression O 
of O 
hypertrophic O 
genes O 
, O 
α- O 
and O 
β-myosin O 
heavy O 
chain O 
( O 
α-MHC O 
and O 
β-MHC O 
) O 
, O 
brain O 
Natriuretic O 
Peptide O 
( O 
BNP O 
) O 
, O 
and O 
CYP1A1 O 
were O 
determined O 
at O 
the O 
mRNA O 
and O 
protein O 
levels O 
using O 
real O 
- O 
time O 
PCR O 
and O 
Western O 
blot O 
analysis O 
, O 
respectively O 
. O 
The O 
results O 
showed O 
that O 
Pb(2+) B-FORMULA 
significantly O 
induced O 
cardiotoxicity O 
and O 
heart O 
failure O 
as O 
evidenced O 
by O 
increase O 
cardiac O 
enzymes O 
, O 
lactate B-FAMILY 
dehydrogenase O 
and O 
creatine B-TRIVIAL 
kinase O 
and O 
changes O 
in O 
histopathology O 
in O 
vivo O 
. O 
In O 
addition O 
, O 
Pb(2+) B-FORMULA 
treatment O 
induced O 
β-MHC O 
and O 
BNP O 
whereas O 
inhibited O 
α-MHC O 
mRNA O 
and O 
protein O 
levels O 
in O 
vivo O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
contrast O 
, O 
at O 
the O 
in O 
vitro O 
level O 
, O 
Pb(2+) B-FORMULA 
treatment O 
induced O 
both O 
β-MHC O 
and O 
α-MHC O 
mRNA O 
levels O 
in O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
Importantly O 
, O 
these O 
changes O 
were O 
accompanied O 
with O 
a O 
proportional O 
increase O 
in O 
the O 
expression O 
of O 
CYP1A1 O 
mRNA O 
and O 
protein O 
expression O 
levels O 
, O 
suggesting O 
a O 
role O 
for O 
the O 
CYP1A1 O 
in O 
cardiotoxicity O 
. O 
The O 
direct O 
evidence O 
for O 
the O 
involvement O 
of O 
CYP1A1 O 
in O 
the O 
induction O 
of O 
cardiotoxicity O 
by O 
Pb(2+) B-FORMULA 
was O 
evidenced O 
by O 
the O 
ability O 
of O 
AhR O 
antagonist O 
, O 
resveratrol B-TRIVIAL 
, O 
to O 
significantly O 
inhibit O 
the O 
Pb(2+) B-FORMULA 
-modulated O 
effect O 
on O 
β-MHC O 
and O 
α-MHC O 
mRNAs O 
. O 
It O 
was O 
concluded O 
that O 
acute O 
lead O 
exposure O 
induced O 
cardiotoxicity O 
through O 
AhR O 
/ O 
CYP1A1 O 
- O 
mediated O 
mechanism O 
. O 

increased O 
number O 
of O 
Leydig O 
cells O 
by O 
di(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
comes O 
from O 
the O 
differentiation O 
of O 
stem O 
cells O 
into O 
Leydig O 
cell O 
lineage O 
in O 
the O 
adult O 
rat O 
testis O 
. O 

objective O 
of O 
the O 
present O 
study O 
is O 
to O 
determine O 
whether O 
di(2-ethylhexyl) B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
( O 
DEHP B-ABBREVIATION 
) O 
exposure O 
at O 
adulthood O 
increases O 
rat O 
Leydig O 
cell O 
number O 
and O 
to O 
investigate O 
the O 
possible O 
mechanism O 
. O 
90-day- O 
old O 
Long-Evans O 
rats O 
were O 
randomly O 
divided O 
into O 
3 O 
groups O 
, O 
and O 
were O 
gavaged O 
with O 
the O 
corn O 
oil O 
( O 
control O 
) O 
or O 
10 O 
or O 
750mg O 
/ O 
kg O 
DEHP B-ABBREVIATION 
daily O 
for O 
7 O 
days O 
, O 
and O 
then O 
received O 
an O 
intraperitoneal O 
injection O 
of O 
75mg O 
/ O 
kg O 
ethane B-SYSTEMATIC 
dimethanesulfonate I-SYSTEMATIC 
( O 
EDS B-ABBREVIATION 
) O 
to O 
eliminate O 
Leydig O 
cells O 
. O 
Serum O 
testosterone B-TRIVIAL 
concentrations O 
were O 
assessed O 
by O 
RIA O 
, O 
and O 
the O 
mRNA O 
levels O 
of O 
Leydig O 
cell O 
genes O 
were O 
measured O 
by O 
qPCR O 
. O 
EDS B-ABBREVIATION 
eliminated O 
all O 
Leydig O 
cells O 
in O 
the O 
control O 
testis O 
on O 
day O 
4 O 
post- O 
EDS B-ABBREVIATION 
, O 
as O 
judged O 
by O 
undetectable O 
serum O 
testosterone B-TRIVIAL 
level O 
and O 
no O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase O 
positive O 
(3β-HSD(pos)) O 
cells O 
in O 
the O 
interstitium O 
. O 
However O 
, O 
in O 
DEHP B-ABBREVIATION 
-treated O 
groups O 
, O 
there O 
were O 
detectable O 
serum O 
testosterone B-TRIVIAL 
concentrations O 
and O 
some O 
oval O 
- O 
shaped O 
3β-HSD(pos) O 
cells O 
in O 
the O 
interstitium O 
. O 
These O 
3β-HSD(pos) O 
cells O 
were O 
not O 
stained O 
by O 
the O 
antibody O 
against O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
1 O 
( O 
11β-HSD1 O 
) O 
, O 
a O 
marker O 
for O 
Leydig O 
cells O 
at O 
a O 
more O 
advanced O 
stage O 
. O 
The O 
disappearance O 
of O 
mRNAs O 
of O 
Leydig O 
cell O 
biomarkers O 
including O 
Lhcgr O 
, O 
Cyp11a1 O 
, O 
Cyp17a1 O 
, O 
Insl3 O 
and O 
Hsd11b1 O 
in O 
the O 
control O 
testis O 
was O 
observed O 
on O 
day O 
4 O 
post- O 
EDS B-ABBREVIATION 
. O 
However O 
, O 
there O 
were O 
detectable O 
concentrations O 
of O 
Lhcgr O 
, O 
Cyp11a1 O 
and O 
Cyp17a1 O 
mRNAs O 
but O 
undetectable O 
concentrations O 
of O 
Insl3 O 
, O 
Hsd17b3 O 
and O 
Hsd11b1 O 
in O 
the O 
DEHP B-ABBREVIATION 
-treated O 
testes O 
, O 
indicating O 
that O 
these O 
3β-HSD(pos) O 
cells O 
were O 
newly O 
formed O 
progenitor O 
Leydig O 
cells O 
. O 
The O 
mRNA O 
level O 
for O 
nestin O 
( O 
Nes O 
, O 
biomarker O 
for O 
stem O 
Leydig O 
cells O 
) O 
was O 
significantly O 
increased O 
in O 
the O 
control O 
testis O 
on O 
day O 
4 O 
post- O 
EDS B-ABBREVIATION 
, O 
but O 
not O 
in O 
the O 
DEHP B-ABBREVIATION 
treated O 
testes O 
, O 
suggesting O 
that O 
these O 
nestin O 
positive O 
stem O 
cells O 
were O 
differentiated O 
into O 
progenitor O 
Leydig O 
cells O 
in O 
the O 
DEHP B-ABBREVIATION 
-treated O 
testes O 
. O 
The O 
present O 
study O 
suggests O 
that O 
DEHP B-ABBREVIATION 
increases O 
the O 
differentiation O 
of O 
stem O 
cells O 
into O 
progenitor O 
Leydig O 
cells O 
. O 

sulfurous O 
is O 
a O 
venomous O 
spider O 
distributed O 
in O 
the O 
south O 
of O 
China O 
and O 
characterized O 
with O 
feeding O 
on O 
fish O 
. O 
The O 
venom O 
exhibits O 
great O 
diversity O 
and O 
contains O 
hundreds O 
of O 
peptides O 
as O 
revealed O 
by O 
off O 
- O 
line O 
RP-HPLC O 
/ O 
MALDI-TOF-MS O 
analysis O 
. O 
The O 
venom O 
peptides O 
followed O 
a O 
triple O 
- O 
modal O 
distribution O 
, O 
with O 
40.7% O 
of O 
peptides O 
falling O 
in O 
the O 
mass O 
range O 
of O 
1000-3000 O 
Da O 
, O 
25.6% O 
peptides O 
in O 
the O 
7000-9000 O 
Da O 
range O 
and O 
23.5% O 
peptides O 
in O 
the O 
3000-5000 O 
Da O 
range O 
. O 
This O 
distribution O 
modal O 
is O 
rather O 
different O 
from O 
these O 
of O 
peptides O 
from O 
other O 
spider O 
venoms O 
analyzed O 
. O 
The O 
venom O 
could O 
inhibit O 
voltage O 
- O 
activated O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
and O 
Ca(2+) B-FORMULA 
channels O 
in O 
rat O 
DRG O 
neurons O 
as O 
revealed O 
by O 
voltage O 
- O 
clamp O 
analysis O 
. O 
Significantly O 
, O 
the O 
venom O 
exhibited O 
inhibitory O 
effects O 
on O 
TTX-R O 
Na(+) B-FORMULA 
and O 
T O 
- O 
type O 
Ca(2+) B-FORMULA 
currents O 
, O 
suggesting O 
that O 
there O 
exist O 
both O 
channel O 
antagonists O 
which O 
might O 
be O 
valuable O 
tools O 
for O 
investigation O 
of O 
both O 
channels O 
and O 
drug O 
development O 
. O 
Additionally O 
, O 
intrathoracically O 
injection O 
of O 
venom O 
could O 
cause O 
serve O 
neurotoxic O 
effects O 
on O 
zebrafish O 
and O 
death O 
at O 
higher O 
concentrations O 
. O 
The O 
LD50 O 
value O 
was O 
calculated O 
to O 
be O 
28.8 O 
μg O 
/ O 
g O 
body O 
weight O 
. O 
Our O 
results O 
indicated O 
that O 
the O 
venom O 
of O 
D O 
. O 
sulfurous O 
contain O 
diverse O 
neurotoxins O 
which O 
serve O 
to O 
capture O 
prey O 
. O 
Intensive O 
studies O 
will O 
be O 
necessary O 
to O 
investigate O 
the O 
structures O 
and O 
functions O 
of O 
specific O 
peptides O 
of O 
the O 
venom O 
in O 
the O 
future O 
. O 

exposure O 
to O 
mercury B-SYSTEMATIC 
chloride I-SYSTEMATIC 
during O 
pregnancy O 
and O 
lactation O 
affects O 
the O 
immunity O 
and O 
social O 
behavior O 
of O 
offspring O 
. O 

HgCl2 B-FORMULA 
exposures O 
of O 
F1 O 
offspring O 
( O 
H-2(q O 
/ O 
s O 
) O 
) O 
from O 
unsociable O 
SJL O 
/ O 
J O 
(H-2(s)) O 
dams O 
with O 
high O 
susceptibility O 
to O 
Hg B-FORMULA 
-induced O 
autoimmunity O 
( O 
SFvF1 O 
) O 
and O 
from O 
highly O 
sociable O 
FVB O 
/ O 
NJ O 
( O 
FVB O 
; O 
H-2(q) O 
) O 
dams O 
with O 
lower O 
susceptibility O 
to O 
Hg B-FORMULA 
-induced O 
autoimmunity O 
( O 
FvSF1 O 
) O 
were O 
investigated O 
. O 
Hg B-FORMULA 
exposure O 
increased O 
the O 
serum O 
IgG O 
levels O 
of O 
all O 
offspring O 
at O 
postnatal O 
day O 
21 O 
( O 
pnd21 O 
) O 
and O 
of O 
SJL O 
/ O 
J O 
dams O 
but O 
not O 
of O 
FVB O 
dams O 
. O 
Serum O 
IgG O 
anti-brain O 
antibody O 
( O 
Ab O 
) O 
levels O 
of O 
pnd21 O 
SFvF1 O 
offspring O 
and O 
SJL O 
dams O 
were O 
higher O 
than O 
those O 
of O 
the O 
FvSF1 O 
offspring O 
and O 
FVB O 
dams O 
, O 
but O 
Hg B-FORMULA 
only O 
increased O 
the O 
titers O 
of O 
the O 
FVB O 
dams O 
and O 
their O 
offspring O 
. O 
Hg B-FORMULA 
significantly O 
elevated O 
the O 
presence O 
of O 
IgG O 
in O 
all O 
brain O 
regions O 
of O 
the O 
pnd21 O 
SFvF1 O 
offspring O 
, O 
and O 
the O 
SFvF1 O 
offspring O 
had O 
greater O 
amounts O 
of O 
IgG O 
in O 
the O 
brain O 
than O 
the O 
FvSF1 O 
offspring O 
, O 
which O 
had O 
Hg B-FORMULA 
-induced O 
increases O 
in O 
only O 
two O 
brain O 
regions O 
. O 
Cytokine O 
levels O 
were O 
elevated O 
in O 
the O 
brain O 
regions O 
of O 
Hg B-FORMULA 
-treated O 
pnd21 O 
SFvF1 O 
but O 
not O 
of O 
FvSF1 O 
offspring O 
, O 
and O 
SFvF1 O 
females O 
had O 
more O 
brain O 
regions O 
expressing O 
cytokines O 
than O 
the O 
males O 
. O 
At O 
pnd70 O 
, O 
the O 
serum O 
IgG O 
, O 
serum O 
antibrain O 
Abs O 
, O 
amounts O 
of O 
brain O 
IgG O 
, O 
and O 
brain O 
cytokine O 
levels O 
of O 
all O 
of O 
the O 
Hg B-FORMULA 
-treated O 
offspring O 
were O 
equivalent O 
to O 
those O 
of O 
their O 
appropriate O 
controls O 
, O 
suggesting O 
that O 
developmental O 
Hg B-FORMULA 
exposure O 
did O 
not O 
induce O 
chronic O 
immunological O 
effects O 
. O 
However O 
, O 
the O 
social O 
behaviors O 
of O 
Hg B-FORMULA 
-exposed O 
SFvF1 O 
offspring O 
at O 
pnd70 O 
were O 
significantly O 
impaired O 
, O 
and O 
SFvF1 O 
females O 
displayed O 
greater O 
decline O 
in O 
social O 
behaviors O 
than O 
males O 
, O 
suggesting O 
that O 
the O 
higher O 
neuroinflammation O 
of O 
SFvF1 O 
females O 
earlier O 
in O 
life O 
is O 
associated O 
with O 
the O 
altered O 
behavior O 
. O 
Thus O 
, O 
developmental O 
Hg B-FORMULA 
exposure O 
induces O 
long O 
- O 
lasting O 
effects O 
on O 
social O 
behavior O 
of O 
offspring O 
, O 
which O 
is O 
dependent O 
on O 
sex O 
and O 
genetics O 
and O 
the O 
induction O 
of O 
neuroinflammation O 
. O 

fibrous O 
tissue O 
scaffolds O 
with O 
controlled O 
fiber O 
nanoscale O 
surface O 
roughness O 
are O 
fabricated O 
with O 
a O 
novel O 
centrifugal O 
jet O 
spinning O 
process O 
. O 
The O 
centrifugal O 
jet O 
spinning O 
technique O 
is O 
a O 
highly O 
efficient O 
synthesis O 
method O 
for O 
micron- O 
to O 
nano O 
- O 
sized O 
fibers O 
with O 
a O 
production O 
rate O 
up O 
to O 
0.5 O 
g O 
min(-1) O 
. O 
During O 
the O 
centrifugal O 
jet O 
spinning O 
process O 
, O 
a O 
polymer O 
solution O 
jet O 
is O 
stretched O 
by O 
the O 
centrifugal O 
force O 
of O 
a O 
rotating O 
chamber O 
. O 
By O 
engineering O 
the O 
rheological O 
properties O 
of O 
the O 
polymer O 
solution O 
, O 
solvent O 
evaporation O 
rate O 
and O 
centrifugal O 
force O 
that O 
are O 
applied O 
on O 
the O 
solution O 
jet O 
, O 
polyvinylpyrrolidone B-SYSTEMATIC 
( O 
PVP B-ABBREVIATION 
) O 
and O 
poly(l-lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PLLA B-ABBREVIATION 
) O 
composite O 
fibers O 
with O 
various O 
diameters O 
are O 
fabricated O 
. O 
Viscosity O 
measurements O 
of O 
polymer O 
solutions O 
allowed O 
us O 
to O 
determine O 
critical O 
polymer O 
chain O 
entanglement O 
limits O 
that O 
allow O 
the O 
generation O 
of O 
continuous O 
fiber O 
as O 
opposed O 
to O 
beads O 
or O 
beaded O 
fibers O 
. O 
Above O 
a O 
critical O 
concentration O 
at O 
which O 
polymer O 
chains O 
are O 
partially O 
or O 
fully O 
entangled O 
, O 
lower O 
polymer O 
concentrations O 
and O 
higher O 
centrifugal O 
forces O 
resulted O 
in O 
thinner O 
fibers O 
. O 
Etching O 
of O 
PVP B-ABBREVIATION 
from O 
the O 
PLLA B-ABBREVIATION 
- O 
PVP B-ABBREVIATION 
composite O 
fibers O 
doped O 
with O 
increasing O 
PVP B-ABBREVIATION 
concentrations O 
yielded O 
PLLA B-ABBREVIATION 
fibers O 
with O 
increasing O 
nano O 
- O 
scale O 
surface O 
roughness O 
and O 
porosity O 
, O 
which O 
increased O 
the O 
fiber O 
hydrophilicity O 
dramatically O 
. O 
Scanning O 
electron O 
micrographs O 
of O 
the O 
etched O 
composite O 
fibers O 
suggest O 
that O 
PVP B-ABBREVIATION 
and O 
PLLA B-ABBREVIATION 
were O 
co O 
- O 
contiguously O 
phase O 
separated O 
within O 
the O 
composite O 
fibers O 
during O 
spinning O 
and O 
nano O 
- O 
scale O 
roughness O 
features O 
were O 
created O 
after O 
the O 
partial O 
etching O 
of O 
PVP B-ABBREVIATION 
. O 
To O 
study O 
the O 
tissue O 
regeneration O 
efficacy O 
of O 
the O 
engineered O 
PLLA B-ABBREVIATION 
fiber O 
matrix O 
, O 
human O 
dermal O 
fibroblasts O 
are O 
used O 
to O 
simulate O 
partial O 
skin O 
graft O 
. O 
Fibers O 
with O 
increased O 
PLLA B-ABBREVIATION 
surface O 
roughness O 
and O 
porosity O 
demonstrated O 
a O 
trend O 
towards O 
higher O 
cell O 
attachment O 
and O 
proliferation O 
. O 

Suppresses O 
TNFα O 
mRNA O 
Expression O 
by O 
Inhibiting O 
Valosin O 
- O 
Containing O 
Protein O 
. O 

is O 
a O 
synthetic O 
quinolinone B-SYSTEMATIC 
derivative O 
used O 
in O 
the O 
treatment O 
of O 
cardiac O 
failure O 
and O 
cancer O 
. O 
It O 
is O 
also O 
known O 
to O 
cause O 
agranulocytosis O 
as O 
a O 
side O 
effect O 
, O 
which O 
restricts O 
its O 
use O 
, O 
although O 
the O 
mechanism O 
underlying O 
agranulocytosis O 
is O 
not O 
well O 
understood O 
. O 
Here O 
, O 
we O 
show O 
that O 
vesnarinone B-TRIVIAL 
binds O 
to O 
valosin O 
- O 
containing O 
protein O 
( O 
VCP O 
) O 
, O 
which O 
interacts O 
with O 
polyubiquitinated O 
proteins O 
and O 
is O 
essential O 
for O 
the O 
degradation O 
of O 
IκBα O 
to O 
activate O 
nuclear O 
factor O 
(NF)κB O 
. O 
We O 
show O 
that O 
vesnarinone B-TRIVIAL 
impairs O 
the O 
degradation O 
of O 
IκBα O 
, O 
and O 
that O 
the O 
impairment O 
of O 
the O 
degradation O 
of O 
IκBα O 
is O 
the O 
result O 
of O 
the O 
inhibition O 
of O 
the O 
interaction O 
between O 
VCP O 
and O 
the O 
26S O 
proteasome O 
by O 
vesnarinone B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
vesnarinone B-TRIVIAL 
suppresses O 
NFκB O 
activation O 
by O 
inhibiting O 
the O 
VCP-dependent O 
degradation O 
of O 
polyubiquitinated O 
IκBα O 
, O 
resulting O 
in O 
the O 
suppression O 
of O 
tumor O 
necrosis O 
factor-α O 
mRNA O 
expression O 
. O 

of O 
Maternal O 
Triglycerides B-FAMILY 
in O 
Women O 
With O 
Gestational O 
Diabetes O 
Mellitus O 
in O 
the O 
Metformin B-TRIVIAL 
in O 
Gestational O 
Diabetes O 
( O 
MiG O 
) O 
Study O 
. O 

associated O 
with O 
increasing O 
maternal O 
triglyceride B-FAMILY 
concentrations O 
in O 
late O 
pregnancy O 
include O 
gestational O 
age O 
, O 
obesity O 
, O 
preeclampsia O 
, O 
and O 
altered O 
glucose B-TRIVIAL 
metabolism O 
. O 
In O 
a O 
subgroup O 
of O 
women O 
in O 
the O 
Metformin B-TRIVIAL 
in O 
Gestational O 
Diabetes O 
( O 
MiG O 
) O 
trial O 
, O 
maternal O 
plasma O 
triglycerides B-FAMILY 
increased O 
more O 
between O 
enrollment O 
( O 
30 O 
weeks O 
) O 
and O 
36 O 
weeks O 
in O 
those O 
treated O 
with O 
metformin B-TRIVIAL 
compared O 
with O 
insulin O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
explain O 
this O 
finding O 
by O 
examining O 
factors O 
potentially O 
related O 
to O 
triglycerides B-FAMILY 
in O 
these O 
women.RESEARCH O 
DESIGN O 
AND O 
METHODSOf O 
the O 
733 O 
women O 
randomized O 
to O 
metformin B-TRIVIAL 
or O 
insulin O 
in O 
the O 
MiG O 
trial O 
, O 
432 O 
( O 
219 O 
metformin B-TRIVIAL 
and O 
213 O 
insulin O 
) O 
had O 
fasting O 
plasma O 
triglycerides B-FAMILY 
measured O 
at O 
enrollment O 
and O 
at O 
36 O 
weeks O 
. O 
Factors O 
associated O 
with O 
maternal O 
triglycerides B-FAMILY 
were O 
assessed O 
using O 
general O 
linear O 
modeling.RESULTSMean O 
plasma O 
triglyceride B-FAMILY 
concentrations O 
were O 
2.43 O 
( O 
95% O 
CI O 
2.35-2.51 O 
) O 
mmol O 
/ O 
L O 
at O 
enrollment O 
. O 
Triglycerides B-FAMILY 
were O 
higher O 
at O 
36 O 
weeks O 
in O 
women O 
randomized O 
to O 
metformin B-TRIVIAL 
( O 
2.94 O 
[ O 
2.80-3.08 O 
] O 
mmol O 
/ O 
L O 
; O 
+ O 
23.13% O 
[ O 
18.72-27.53% O 
] O 
) O 
than O 
insulin O 
( O 
2.65 O 
[ O 
2.54-2.77 O 
] O 
mmol O 
/ O 
L O 
, O 
P O 
= O 
0.002 O 
; O 
+ O 
14.36% O 
[ O 
10.91-17.82% O 
] O 
, O 
P O 
= O 
0.002 O 
) O 
. O 
At O 
36 O 
weeks O 
, O 
triglycerides B-FAMILY 
were O 
associated O 
with O 
HbA1c O 
( O 
P O 
= O 
0.03 O 
) O 
, O 
ethnicity O 
( O 
P O 
= O 
0.001 O 
) O 
, O 
and O 
treatment O 
allocation O 
( O 
P O 
= O 
0.005 O 
) O 
. O 
In O 
insulin O 
- O 
treated O 
women O 
, O 
36-week O 
triglycerides B-FAMILY 
were O 
associated O 
with O 
36-week O 
HbA1c O 
( O 
P O 
= O 
0.02 O 
) O 
, O 
and O 
in O 
metformin B-TRIVIAL 
-treated O 
women O 
, O 
they O 
were O 
related O 
to O 
ethnicity.CONCLUSIONSAt O 
36 O 
weeks O 
, O 
maternal O 
triglycerides B-FAMILY 
were O 
related O 
to O 
glucose B-TRIVIAL 
control O 
in O 
women O 
treated O 
with O 
insulin O 
and O 
ethnicity O 
in O 
women O 
treated O 
with O 
metformin B-TRIVIAL 
. O 
Whether O 
there O 
are O 
ethnicity O 
- O 
related O 
dietary O 
changes O 
or O 
differences O 
in O 
metformin B-TRIVIAL 
response O 
that O 
alter O 
the O 
relationship O 
between O 
glucose B-TRIVIAL 
control O 
and O 
triglycerides B-FAMILY 
requires O 
further O 
study O 
. O 

serum O 
concentrations O 
of O 
25-hydroxycholecalciferol B-SYSTEMATIC 
are O 
associated O 
with O 
increased O 
risk O 
of O 
progression O 
to O 
impaired O 
fasting O 
glucose B-TRIVIAL 
and O 
diabetes O 
. O 

To O 
study O 
the O 
association O 
between O 
vitamin B-FAMILY 
D I-FAMILY 
status O 
and O 
the O 
risk O 
of O 
incident O 
impaired O 
fasting O 
glucose B-TRIVIAL 
( O 
IFG O 
) O 
and O 
diabetes O 
in O 
a O 
population O 
- O 
based O 
cohort O 
of O 
diabetes O 
- O 
free O 
subjects O 
. O 
RESEARCH O 
DESIGN O 
AND O 
METHODS O 
In O 
a O 
historical O 
prospective O 
cohort O 
study O 
of O 
subjects O 
from O 
the O 
Clalit O 
Health O 
Services O 
database O 
, O 
which O 
includes O 
information O 
on O 
nearly O 
4 O 
million O 
people O 
, O 
diabetes O 
- O 
free O 
subjects O 
aged O 
40-70 O 
years O 
with O 
serum O 
25-hydroxycholecalciferol B-SYSTEMATIC 
( O 
25-OHD B-SYSTEMATIC 
) O 
measurements O 
available O 
were O 
followed O 
for O 
2 O 
years O 
to O 
assess O 
the O 
development O 
of O 
IFG O 
and O 
diabetes O 
in O 
five O 
25-OHD B-SYSTEMATIC 
subgroups O 
: O 
≥ O 
25 O 
, O 
25.1-37.5 O 
, O 
37.6-50 O 
, O 
50.1-75 O 
, O 
and O 
> O 
75 O 
nmol O 
/ O 
L O 
. O 
RESULTS O 
The O 
baseline O 
cohort O 
included O 
117960 O 
adults O 
: O 
83526 O 
normoglycemic O 
subjects O 
and O 
34434 O 
subjects O 
with O 
IFG O 
. O 
During O 
follow O 
- O 
up O 
, O 
8629 O 
subjects O 
( O 
10.3% O 
of O 
the O 
normoglycemic O 
group O 
) O 
developed O 
IFG O 
, O 
and O 
2162 O 
subjects O 
( O 
1.8% O 
of O 
the O 
total O 
cohort O 
) O 
progressed O 
to O 
diabetes O 
. O 
A O 
multivariable O 
model O 
adjusted O 
for O 
age O 
, O 
sex O 
, O 
population O 
group O 
, O 
immigrant O 
status O 
, O 
BMI O 
, O 
season O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
measurement O 
, O 
LDL O 
and O 
HDL O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
estimated O 
glomerular O 
filtration O 
rate O 
, O 
history O 
of O 
hypertension O 
or O 
cardiovascular O 
disease O 
, O 
Charlson O 
comorbidity O 
index O 
, O 
smoking O 
, O 
and O 
socioeconomic O 
status O 
revealed O 
an O 
inverse O 
association O 
between O 
25-OHD B-SYSTEMATIC 
and O 
the O 
risk O 
of O 
progression O 
to O 
IFG O 
and O 
diabetes O 
. O 
The O 
odds O 
of O 
transitioning O 
from O 
normoglycemia O 
to O 
IFG O 
, O 
from O 
normoglycemia O 
to O 
diabetes O 
, O 
and O 
from O 
IFG O 
to O 
diabetes O 
in O 
subjects O 
with O 
a O 
25-OHD B-SYSTEMATIC 
level O 
≤ O 
25 O 
nmol O 
/ O 
L O 
were O 
greater O 
than O 
those O 
of O 
subjects O 
with O 
a O 
25-OHD B-SYSTEMATIC 
level O 
> O 
75 O 
nmol O 
/ O 
L O 
[ O 
odds O 
ratio O 
1.13 O 
( O 
95% O 
CI O 
1.03-1.24 O 
) O 
, O 
1.77 O 
( O 
1.11-2.83 O 
) O 
, O 
and O 
1.43 O 
( O 
1.16-1.76 O 
) O 
, O 
respectively O 
] O 
. O 
CONCLUSIONS O 
Vitamin B-FAMILY 
D I-FAMILY 
deficiency O 
appears O 
to O 
be O 
an O 
independent O 
risk O 
factor O 
for O 
the O 
development O 
of O 
IFG O 
and O 
diabetes O 
. O 

Prediction O 
of O 
Repaglinide B-TRIVIAL 
- O 
Rifampicin B-TRIVIAL 
Complex O 
Drug O 
Interactions O 
Using O 
Dynamic O 
and O 
Static O 
Mechanistic O 
Models O 
: O 
Delineating O 
Differential O 
CYP3A4 O 
Induction O 
and O 
OATP1B1 O 
Inhibition O 
Potential O 
of O 
Rifampicin B-TRIVIAL 
. O 

is O 
mainly O 
metabolized O 
by O 
cytochrome O 
P450 O 
enzymes O 
CYP2C8 O 
and O 
CYP3A4 O 
, O 
and O 
it O 
is O 
also O 
a O 
substrate O 
to O 
a O 
hepatic O 
uptake O 
transporter O 
, O 
organic O 
anion O 
transporting O 
polypeptide O 
(OATP)1B1 O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
predict O 
the O 
dosing O 
time O 
- O 
dependent O 
pharmacokinetic O 
interactions O 
of O 
repaglinide B-TRIVIAL 
with O 
rifampicin B-TRIVIAL 
, O 
using O 
mechanistic O 
models O 
. O 
In O 
vitro O 
hepatic O 
transport O 
of O 
repaglinide B-TRIVIAL 
, O 
characterized O 
using O 
sandwich O 
- O 
cultured O 
human O 
hepatocytes O 
, O 
and O 
intrinsic O 
metabolic O 
parameters O 
were O 
used O 
to O 
build O 
a O 
dynamic O 
whole O 
- O 
body O 
physiologically O 
- O 
based O 
pharmacokinetic O 
( O 
PBPK O 
) O 
model O 
. O 
The O 
PBPK O 
model O 
adequately O 
described O 
repaglinide B-TRIVIAL 
plasma O 
concentration O 
- O 
time O 
profiles O 
and O 
successfully O 
predicted O 
area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
ratios O 
of O 
repaglinide B-TRIVIAL 
( O 
within O 
± O 
25% O 
error O 
) O 
, O 
dosed O 
( O 
staggered O 
0-24 O 
hours O 
) O 
after O 
rifampicin B-TRIVIAL 
treatment O 
when O 
primarily O 
considering O 
induction O 
of O 
CYP3A4 O 
and O 
reversible O 
inhibition O 
of O 
OATP1B1 O 
by O 
rifampicin B-TRIVIAL 
. O 
Further O 
, O 
a O 
static O 
mechanistic O 
" O 
extended O 
net O 
- O 
effect O 
" O 
model O 
incorporating O 
transport O 
and O 
metabolic O 
disposition O 
parameters O 
of O 
repaglinide B-TRIVIAL 
and O 
interaction O 
potency O 
of O 
rifampicin B-TRIVIAL 
was O 
devised O 
. O 
Predictions O 
based O 
on O 
the O 
static O 
model O 
are O 
similar O 
to O 
those O 
observed O 
in O 
the O 
clinic O 
( O 
average O 
error O 
∼19% O 
) O 
and O 
to O 
those O 
based O 
on O 
the O 
PBPK O 
model O 
. O 
Both O 
the O 
models O 
suggested O 
that O 
the O 
combined O 
effect O 
of O 
increased O 
gut O 
extraction O 
and O 
decreased O 
hepatic O 
uptake O 
caused O 
minimal O 
repaglinide B-TRIVIAL 
systemic O 
exposure O 
change O 
when O 
repaglinide B-TRIVIAL 
is O 
dosed O 
simultaneously O 
or O 
1 O 
hour O 
after O 
the O 
rifampicin B-TRIVIAL 
dose O 
. O 
On O 
the O 
other O 
hand O 
, O 
isolated O 
induction O 
effect O 
as O 
a O 
result O 
of O 
temporal O 
separation O 
of O 
the O 
two O 
drugs O 
translated O 
to O 
an O 
approximate O 
5-fold O 
reduction O 
in O 
repaglinide B-TRIVIAL 
systemic O 
exposure O 
. O 
In O 
conclusion O 
, O 
both O 
dynamic O 
and O 
static O 
mechanistic O 
models O 
are O 
instrumental O 
in O 
delineating O 
the O 
quantitative O 
contribution O 
of O 
transport O 
and O 
metabolism O 
in O 
the O 
dosing O 
time O 
- O 
dependent O 
repaglinide B-TRIVIAL 
- O 
rifampicin B-TRIVIAL 
interactions O 
. O 

of O 
4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide B-SYSTEMATIC 
( O 
AZD5363 B-IDENTIFIER 
) O 
, O 
an O 
orally O 
bioavailable O 
, O 
potent O 
inhibitor O 
of O 
Akt O 
kinases O 
. O 

exploration O 
of O 
analogues O 
of O 
an O 
ATP-competitive O 
pyrrolopyrimidine O 
inhibitor O 
of O 
Akt O 
led O 
to O 
the O 
discovery O 
of O 
clinical O 
candidate O 
AZD5363 B-IDENTIFIER 
, O 
which O 
showed O 
increased O 
potency O 
, O 
reduced O 
hERG O 
affinity O 
, O 
and O 
higher O 
selectivity O 
against O 
the O 
closely O 
related O 
AGC O 
kinase O 
ROCK O 
. O 
This O 
compound O 
demonstrated O 
good O 
preclinical O 
drug O 
metabolism O 
and O 
pharmacokinetics O 
( O 
DMPK O 
) O 
properties O 
and O 
, O 
after O 
oral O 
dosing O 
, O 
showed O 
pharmacodynamic O 
knockdown O 
of O 
phosphorylation O 
of O 
Akt O 
and O 
downstream O 
biomarkers O 
in O 
vivo O 
, O 
and O 
inhibition O 
of O 
tumor O 
growth O 
in O 
a O 
breast O 
cancer O 
xenograft O 
model O 
. O 

of O 
Reactive O 
Force O 
Field O 
: O 
Dynamics O 
of O 
the O 
[Nb6O19Hx]((8-x)-) B-FAMILY 
Lindqvist O 
Polyoxoanion O 
in O 
Bulk O 
Water O 
. O 

present O 
results O 
on O 
parameterization O 
of O 
reactive O 
force O 
field O 
[ O 
van O 
Duin O 
, O 
A O 
. O 
C O 
. O 
T O 
. O 
; O 
Dasgupta O 
, O 
S O 
. O 
; O 
Lorant O 
, O 
F O 
. O 
; O 
Goddard O 
, O 
W O 
. O 
A O 
. O 
ReaxFF O 
: O 
A O 
Reactive O 
Force O 
Field O 
for O 
Hydrocarbons B-FAMILY 
. O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
A2001 O 
, O 
105 O 
, O 
9396-9409 O 
] O 
for O 
investigating O 
the O 
properties O 
of O 
the O 
[Nb6O19Hx]((8-x)-) B-FAMILY 
Lindqvist O 
polyoxoanion O 
, O 
x O 
= O 
0-8 O 
, O 
in O 
water O 
. O 
Force O 
- O 
field O 
parameters O 
were O 
fitted O 
to O 
an O 
extensive O 
data O 
set O 
consisting O 
of O 
structures O 
and O 
energetics O 
obtained O 
at O 
the O 
Perdew-Burke-Ernzerhof O 
density O 
functional O 
level O 
of O 
theory O 
. O 
These O 
parameters O 
can O 
reasonably O 
describe O 
pure O 
water O 
structure O 
as O 
well O 
as O 
water O 
with O 
an O 
excess O 
of O 
H(+) B-FORMULA 
and O 
OH(-) B-FORMULA 
ions O 
. O 
Molecular O 
dynamics O 
simulations O 
were O 
performed O 
on O 
[Nb6O19Hx]((8-x)-) B-FAMILY 
, O 
x O 
= O 
0-8 O 
, O 
submerged O 
in O 
bulk O 
water O 
at O 
298 O 
K O 
. O 
Analysis O 
of O 
the O 
MD O 
trajectories O 
showed O 
facile O 
H B-FORMULA 
atom O 
transfer O 
between O 
the O 
protonated O 
polyoxoanion O 
core O 
and O 
bulk O 
water O 
. O 
The O 
number O 
of O 
oxygen B-SYSTEMATIC 
sites O 
labeled O 
with O 
an O 
H B-FORMULA 
atom O 
was O 
found O 
to O 
vary O 
depending O 
on O 
the O 
pH O 
of O 
the O 
solution O 
. O 
Detailed O 
analysis O 
shows O 
that O 
the O 
total O 
number O 
of O 
protons O 
at O 
bridging O 
( O 
terminal O 
) O 
, O 
η- O 
O B-FORMULA 
( O 
μ2- O 
O B-FORMULA 
) O 
, O 
sites O 
ranges O 
from O 
3(1) O 
at O 
pH O 
7 O 
, O 
to O 
2(0) O 
at O 
pH O 
11 O 
, O 
to O 
1(0) O 
at O 
pH O 
15 O 
. O 
These O 
findings O 
closely O 
reflect O 
available O 
experimental O 
measurements O 
. O 

abietane B-TRIVIAL 
diterpenoids B-FAMILY 
from O 
Chinese O 
eaglewood O 
. O 

new O 
abietane B-TRIVIAL 
diterpenoids B-FAMILY 
, O 
aquilarabietic B-MULTIPLE 
acids I-MULTIPLE 
A-J I-MULTIPLE 
( O 
1-10 O 
) O 
, O 
and O 
a O 
new O 
podocarpane B-TRIVIAL 
diterpenoid B-FAMILY 
, O 
aquilarabietic B-TRIVIAL 
acid I-TRIVIAL 
K I-TRIVIAL 
( O 
11 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
and O 
ethanol B-SYSTEMATIC 
extracts O 
of O 
Chinese O 
eaglewood O 
. O 
Among O 
them O 
, O 
3 O 
, O 
9 O 
, O 
and O 
10 O 
are O 
artifacts O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
data O 
from O 
extensive O 
spectroscopic O 
and O 
X-ray O 
diffraction O 
analyses O 
. O 
Bioassay O 
results O 
indicated O 
that O 
1 O 
at O 
10 O 
μM O 
demonstrated O 
remarkable O 
antidepressant O 
activity O 
in O 
vitro O 
by O 
inhibiting O 
norepinephrine B-TRIVIAL 
reuptake O 
in O 
rat O 
brain O 
synaptosomes O 
by O 
81.4% O 
and O 
with O 
an O 
IC(50) O 
value O 
of O 
9.1 O 
× O 
10(-7) O 
M O 
. O 

the O 
optical O 
gain O 
and O 
mode-selection O 
mechanisms O 
in O 
semiconductor O 
nanowire O 
( O 
NW O 
) O 
lasers O 
is O 
key O 
to O 
the O 
development O 
of O 
high O 
- O 
performance O 
nanoscale O 
oscillators O 
, O 
amplified O 
semiconductor O 
/ O 
plasmon O 
lasers O 
and O 
single O 
photon O 
emitters O 
, O 
and O 
so O 
forth O 
. O 
Modification O 
of O 
semiconductor O 
band O 
structure O 
/ O 
bandgap O 
through O 
electric O 
field O 
modulation O 
, O 
elemental O 
doping O 
, O 
or O 
alloying O 
semiconductors O 
has O 
so O 
far O 
gained O 
limited O 
success O 
in O 
achieving O 
output O 
mode O 
tunability O 
of O 
the O 
NW O 
laser O 
. O 
One O 
stifling O 
issue O 
is O 
the O 
considerable O 
optical O 
losses O 
induced O 
in O 
the O 
NW O 
cavities O 
by O 
these O 
extrinsic O 
methods O 
that O 
limit O 
their O 
applicability O 
. O 
Herein O 
we O 
demonstrate O 
a O 
new O 
optical O 
self O 
- O 
feedback O 
mechanism O 
based O 
on O 
the O 
intrinsic O 
self O 
- O 
absorption O 
of O 
the O 
gain O 
media O 
to O 
achieve O 
low O 
- O 
loss O 
, O 
room O 
- O 
temperature O 
NW O 
lasing O 
with O 
a O 
high O 
degree O 
of O 
mode O 
selectivity O 
( O 
over O 
30 O 
nm O 
) O 
. O 
The O 
cadmium B-SYSTEMATIC 
sulfide I-SYSTEMATIC 
( O 
CdS B-FORMULA 
) O 
NW O 
lasing O 
wavelength O 
is O 
continuously O 
tunable O 
from O 
489 O 
to O 
520 O 
nm O 
as O 
the O 
length O 
of O 
the O 
NWs O 
increases O 
from O 
4 O 
to O 
25 O 
μm O 
. O 
Our O 
straightforward O 
approach O 
is O 
widely O 
applicable O 
in O 
most O 
semiconductor O 
or O 
semiconductor O 
/ O 
plasmonic O 
NW O 
cavities O 
. O 

adsorption O 
is O 
of O 
wide O 
interest O 
including O 
in O 
many O 
technological O 
applications O 
such O 
as O 
tissue O 
engineering O 
, O 
nanotechnology O 
, O 
biosensors O 
, O 
drug O 
delivery O 
, O 
and O 
vaccine O 
production O 
among O 
others O 
. O 
Understanding O 
the O 
fundamentals O 
of O 
such O 
technologies O 
and O 
their O 
design O 
would O 
be O 
greatly O 
aided O 
by O 
an O 
ability O 
to O 
efficiently O 
predict O 
the O 
conformation O 
of O 
an O 
adsorbed O 
protein O 
and O 
its O 
free O 
energy O 
of O 
adsorption O 
. O 
In O 
the O 
study O 
reported O 
here O 
, O 
we O 
show O 
that O 
this O 
is O 
possible O 
when O 
data O 
obtained O 
from O 
nonequilibrium O 
thermodynamic O 
integration O 
( O 
NETI O 
) O 
combined O 
with O 
steered O 
molecular O 
dynamics O 
( O 
SMD O 
) O 
is O 
subject O 
to O 
bootstrapping O 
. O 
For O 
the O 
met B-TRIVIAL 
- I-TRIVIAL 
enkephalin I-TRIVIAL 
pentapeptide B-FAMILY 
at O 
a O 
water- O 
graphite B-TRIVIAL 
interface O 
, O 
we O 
were O 
able O 
to O 
obtain O 
accurate O 
predictions O 
for O 
the O 
location O 
of O 
the O 
adsorbed O 
peptide O 
and O 
its O 
free O 
energy O 
of O 
adsorption O 
from O 
around O 
50 O 
and O 
80 O 
SMD O 
simulations O 
, O 
respectively O 
. O 
It O 
was O 
also O 
shown O 
that O 
adsorption O 
in O 
this O 
system O 
is O 
both O 
energetically O 
and O 
entropically O 
driven O 
. O 
The O 
free O 
energy O 
of O 
adsorption O 
was O 
also O 
decomposed O 
into O 
that O 
associated O 
with O 
formation O 
of O 
the O 
cavity O 
in O 
the O 
water O 
near O 
the O 
graphite B-TRIVIAL 
surface O 
sufficient O 
to O 
accommodate O 
the O 
adsorbed O 
peptide O 
and O 
that O 
associated O 
with O 
insertion O 
of O 
the O 
peptide O 
into O 
this O 
cavity O 
. O 
This O 
decomposition O 
reveals O 
that O 
the O 
former O 
is O 
modestly O 
energetically O 
and O 
entropically O 
unfavorable O 
, O 
whereas O 
the O 
latter O 
is O 
the O 
opposite O 
in O 
both O 
regards O 
to O 
a O 
much O 
greater O 
extent O 
. O 

- O 
modulated O 
thermoelectric O 
power O 
factor O 
of O 
hole O 
gas O 
in O 
Ge B-FORMULA 
- O 
Si B-FORMULA 
core O 
- O 
shell O 
nanowires O 
. O 

experimentally O 
studied O 
the O 
thermoelectric O 
power O 
factor O 
of O 
hole O 
gas O 
in O 
individual O 
Ge B-FORMULA 
- O 
Si B-FORMULA 
core O 
- O 
shell O 
nanowires O 
with O 
Ge B-FORMULA 
core O 
diameters O 
ranging O 
from O 
11 O 
to O 
25 O 
nm O 
. O 
The O 
Ge B-FORMULA 
cores O 
are O 
dopant O 
- O 
free O 
, O 
but O 
the O 
Fermi O 
level O 
in O 
the O 
cores O 
is O 
pinned O 
by O 
surface O 
and O 
defect O 
states O 
in O 
the O 
epitaxial O 
Si B-FORMULA 
shell O 
thereby O 
doping O 
the O 
cores O 
into O 
the O 
degenerate O 
regime O 
. O 
This O 
doping O 
mechanism O 
avoids O 
the O 
high O 
concentration O 
of O 
dopants O 
usually O 
encountered O 
in O 
bulk O 
thermoelectric O 
materials O 
and O 
provides O 
a O 
unique O 
opportunity O 
to O 
enhance O 
the O 
carrier O 
mobility O 
with O 
suppressed O 
ionized O 
impurity O 
scattering O 
. O 
Moreover O 
, O 
the O 
carrier O 
concentration O 
in O 
small O 
diameter O 
nanowires O 
has O 
also O 
been O 
effectively O 
modulated O 
by O 
field O 
effect O 
, O 
allowing O 
one O 
to O 
probe O 
the O 
electrical O 
conductivity O 
and O 
thermopower O 
within O 
a O 
wide O 
range O 
of O 
carrier O 
concentrations O 
, O 
which O 
is O 
crucial O 
to O 
understand O 
the O 
thermoelectric O 
transport O 
behavior O 
. O 
We O 
found O 
that O 
the O 
thermopower O 
of O 
nanowires O 
with O 
Ge B-FORMULA 
core O 
diameters O 
down O 
to O 
11 O 
nm O 
still O 
follows O 
the O 
behavior O 
of O 
bulk O 
Ge B-FORMULA 
. O 
As O 
a O 
result O 
, O 
the O 
power O 
factor O 
is O 
found O 
to O 
be O 
closely O 
correlated O 
with O 
the O 
carrier O 
mobility O 
, O 
which O 
is O 
higher O 
than O 
that O 
of O 
bulk O 
Ge B-FORMULA 
in O 
one O 
of O 
the O 
core O 
- O 
shell O 
nanowires O 
studied O 
here O 
. O 

quantum O 
dots O 
and O 
graphitic O 
surfaces O 
with O 
chlorine B-SYSTEMATIC 
atomic O 
ligands O 
. O 

performance O 
of O 
devices O 
based O 
on O 
semiconductor O 
nanocrystals O 
( O 
NCs O 
) O 
improves O 
both O 
with O 
stronger O 
interface O 
interactions O 
among O 
NCs O 
and O 
between O 
NCs O 
and O 
solid O 
electrode O 
surfaces O 
. O 
The O 
combination O 
of O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
and O 
solid O 
(31)P B-FORMULA 
CP O 
/ O 
MAS O 
NMR O 
( O 
cross O 
- O 
polarization O 
/ O 
magic O 
angle O 
spinning O 
nuclear O 
magnetic O 
resonance O 
) O 
shows O 
that O 
the O 
selective O 
substitution O 
of O 
long O 
organic O 
chains O 
by O 
chlorine B-SYSTEMATIC 
atomic O 
ligands O 
during O 
the O 
colloidal O 
synthesis O 
by O 
the O 
hot O 
injection O 
method O 
promotes O 
the O 
adsorption O 
of O 
CdSe B-FORMULA 
NCs O 
to O 
carbon B-SYSTEMATIC 
sp(2) O 
surfaces O 
, O 
leading O 
to O 
the O 
formation O 
of O 
well O 
- O 
ordered O 
NC O 
monolayers O 
on O 
graphitic O 
materials O 
. O 

Hunger O 
Games O 
: O 
p53 O 
regulates O 
metabolism O 
upon O 
serine B-TRIVIAL 
starvation O 
. O 

cells O 
reprogram O 
their O 
metabolism O 
to O 
support O 
a O 
high O 
proliferative O 
rate O 
. O 
A O 
new O 
study O 
shows O 
that O 
, O 
upon O 
serine B-TRIVIAL 
starvation O 
, O 
the O 
tumor O 
suppressor O 
p53 O 
activates O 
p21 O 
to O 
shift O 
metabolic O 
flux O 
from O 
purine B-TRIVIAL 
biosynthesis O 
to O 
glutathione B-TRIVIAL 
production O 
, O 
which O 
enhances O 
cellular O 
proliferation O 
and O 
viability O 
by O 
combating O 
ROS O 
( O 
Maddocks O 
et O 
al O 
. O 
, O 
2013 O 
) O 
. O 

analogs O 
of O 
huperzine B-TRIVIAL 
A I-TRIVIAL 
improve O 
survival O 
in O 
guinea O 
pigs O 
exposed O 
to O 
soman O 
. O 

warfare O 
nerve O 
agents O 
such O 
as O 
soman O 
exert O 
their O 
toxic O 
effects O 
through O 
an O 
irreversible O 
inhibition O 
of O 
acetylcholinesterase O 
( O 
AChE O 
) O 
and O 
subsequently O 
glutamatergic O 
function O 
, O 
leading O 
to O 
uncontrolled O 
seizures O 
. O 
The O 
natural O 
alkaloid O 
(-)-huperzine B-TRIVIAL 
A I-TRIVIAL 
is O 
a O 
potent O 
inhibitor O 
of O 
AChE O 
and O 
has O 
been O 
demonstrated O 
to O 
exert O 
neuroprotection O 
at O 
an O 
appropriate O 
dose O 
. O 
It O 
is O 
hypothesized O 
that O 
analogs O 
of O 
both O 
(+)- B-MULTIPLE 
and I-MULTIPLE 
(-)-huperzine I-MULTIPLE 
A I-MULTIPLE 
with O 
an O 
improved O 
ability O 
to O 
interact O 
with O 
NMDA B-ABBREVIATION 
receptors O 
together O 
with O 
reduced O 
AChE O 
inhibition O 
will O 
exhibit O 
more O 
effective O 
neuroprotection O 
against O 
nerve O 
agents O 
. O 
In O 
this O 
manuscript O 
, O 
the O 
tested O 
huperzine B-TRIVIAL 
A I-TRIVIAL 
analogs O 
2 O 
and O 
3 O 
were O 
demonstrated O 
to O 
improve O 
survival O 
of O 
guinea O 
pigs O 
exposed O 
to O 
soman O 
at O 
either O 
1.2 O 
or O 
2×LD(50) O 
. O 

and O 
biological O 
evaluation O 
of O 
new O 
cytotoxic O 
indazolo[4,3-gh]isoquinolinone B-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
indazolo[4,3-gh]isoquinolinones B-FAMILY 
derivatives O 
have O 
been O 
synthesized O 
to O 
decrease O 
cardiotoxic O 
side O 
effects O 
in O 
comparison O 
to O 
Mitoxantrone B-TRIVIAL 
. O 
The O 
antiproliferative O 
effects O 
of O 
different O 
side O 
chains O 
were O 
investigated O 
and O 
tested O 
on O 
at O 
least O 
four O 
different O 
cell O 
lines O 
of O 
cervix O 
, O 
ovarian O 
, O 
CNS O 
, O 
NSCLC O 
( O 
non-small O 
- O 
cell O 
lung O 
cancer O 
) O 
and O 
colon O 
carcinoma O 
. O 
In O 
addition O 
to O 
antiproliferative O 
activities O 
, O 
influence O 
on O 
cell O 
cycle O 
and O 
intercalation O 
behavior O 
have O 
been O 
tested O 
. O 

substituted O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
: O 
a O 
near O 
infrared O 
fluorescence O 
imaging O 
probe O 
for O 
liver O 
cancer O 
targeting O 
. O 

near O 
infrared O 
fluorescence O 
probe O 
, O 
lactose B-TRIVIAL 
substituted O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
, O 
[ B-SYSTEMATIC 
2,9(10),16(17),23(24)-tetrakis((1-(β-d-lactose-2-yl)-1H-1,2,3-triazol-4-yl)methoxyl)phthalocyaninato I-SYSTEMATIC 
] I-SYSTEMATIC 
zinc I-SYSTEMATIC 
(II) I-SYSTEMATIC 
, O 
was O 
synthesized O 
via O 
click O 
reaction O 
. O 
Structural O 
characterization O 
and O 
optical O 
experiment O 
demonstrated O 
its O 
excellent O 
biocompatibility O 
and O 
fluorescence O 
imaging O 
ability O 
. O 
Near O 
infrared O 
fluorescence O 
imaging O 
in O 
vivo O 
for O 
liver O 
cancer O 
, O 
lung O 
cancer O 
and O 
melanoma O 
cancer O 
with O 
tumor O 
bearing O 
nude O 
mice O 
as O 
models O 
demonstrated O 
that O 
lactose B-TRIVIAL 
substituted O 
zinc B-SYSTEMATIC 
phthalocyanine I-SYSTEMATIC 
has O 
specifically O 
targeting O 
ability O 
to O 
liver O 
cancer O 
while O 
no O 
targeting O 
to O 
lung O 
cancer O 
or O 
melanoma O 
, O 
which O 
implied O 
its O 
potential O 
in O 
liver O 
cancer O 
diagnosis O 
as O 
a O 
near O 
infrared O 
optical O 
probe O 
. O 

one O 
- O 
pot O 
synthesis O 
of O 
novel O 
dispirooxindole B-SYSTEMATIC 
- I-SYSTEMATIC 
pyrrolidine I-SYSTEMATIC 
derivatives O 
and O 
their O 
antimicrobial O 
and O 
anticancer O 
activity O 
against O 
A549 O 
human O 
lung O 
adenocarcinoma O 
cancer O 
cell O 
line O 
. O 

dispirooxindole B-SYSTEMATIC 
- I-SYSTEMATIC 
pyrrolidine I-SYSTEMATIC 
derivatives O 
have O 
been O 
synthesized O 
through O 
1,3-dipolar O 
cycloaddition O 
of O 
an O 
azomethine B-SYSTEMATIC 
ylide O 
generated O 
from O 
isatin B-TRIVIAL 
and O 
sarcosine B-TRIVIAL 
with O 
the O 
dipolarophile O 
3-(1H-indol-3-yl)-3-oxo-2-(2-oxoindolin-3-ylidene)propanenitrile B-SYSTEMATIC 
, O 
and O 
also O 
spiro O 
compound O 
of O 
acenaphthenequinone B-SYSTEMATIC 
obtained O 
by O 
the O 
same O 
optimized O 
reaction O 
condition O 
. O 
Synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
antimicrobial O 
activity O 
and O 
all O 
the O 
compounds O 
shown O 
significant O 
activity O 
. O 
Anticancer O 
activity O 
was O 
evaluated O 
against O 
A549 O 
human O 
lung O 
adenocarcinoma O 
cancer O 
cell O 
lines O 
. O 
Compounds O 
7b O 
, O 
7g O 
, O 
7i O 
and O 
7r O 
exhibit O 
very O 
good O 
anticancer O 
activity O 
62.96% O 
, O 
62.03% O 
, O 
67.67% O 
and O 
60.22% O 
, O 
respectively O 
, O 
at O 
the O 
dose O 
of O 
200μg O 
/ O 
mL O 
and O 
compound O 
7i O 
shows O 
IC50 O 
value O 
in O 
50μg O 
/ O 
mL O 
. O 

-loaded O 
lipid O 
- O 
micellar O 
theranostics O 
for O 
simultaneous O 
drug O 
and O 
gene O 
delivery O 
to O 
lungs O 
. O 

( O 
Gd B-FORMULA 
) O 
contrast O 
agents O 
are O 
predominantly O 
used O 
for O 
T(1) O 
MR O 
imaging O 
. O 
However O 
, O 
the O 
high O 
toxicity O 
of O 
Gd(3+) B-FORMULA 
and O 
potential O 
side O 
effects O 
including O 
nephrogenic O 
systemic O 
fibrosis O 
have O 
led O 
to O 
the O 
search O 
for O 
alternative O 
T(1) O 
contrast O 
agents O 
. O 
Since O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
has O 
paramagnetic O 
properties O 
with O 
five O 
unpaired O 
electrons O 
that O 
permit O 
high O 
spin O 
number O 
, O 
long O 
electronic O 
relaxation O 
times O 
, O 
and O 
labile O 
water O 
exchange O 
, O 
we O 
evaluated O 
Mn B-FORMULA 
as O 
a O 
T(1) O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
contrast O 
agent O 
for O 
lung O 
imaging O 
. O 
Here O 
we O 
report O 
on O 
the O 
design O 
and O 
synthesis O 
of O 
multifunctional O 
lipid O 
- O 
micellar O 
nanoparticles O 
( O 
LMNs O 
) O 
containing O 
Mn B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
M-LMNs O 
) O 
for O 
MRI O 
that O 
can O 
also O 
be O 
used O 
for O 
DNA O 
and O 
drug O 
delivery O 
. O 
Oleic B-TRIVIAL 
acid I-TRIVIAL 
-coated O 
MnO B-FORMULA 
nanoparticles O 
were O 
encapsulated O 
in O 
micelles O 
composed O 
of O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG-2000 B-ABBREVIATION 
) O 
, O 
phosphatidylethanolamine B-SYSTEMATIC 
( O 
PE O 
) O 
, O 
DC- O 
cholesterol B-TRIVIAL 
, O 
and O 
dioleoyl-phosphatidylethanolamine B-SYSTEMATIC 
( O 
DOPE B-ABBREVIATION 
) O 
. O 
The O 
particles O 
are O 
taken O 
up O 
in O 
vitro O 
by O 
human O 
embryonic O 
kidney O 
( O 
HEK293 O 
) O 
, O 
Lewis O 
lung O 
carcinoma O 
( O 
LLC1 O 
) O 
, O 
and O 
A549 O 
cells O 
and O 
are O 
devoid O 
of O 
cytotoxicity O 
. O 
When O 
administered O 
to O 
mice O 
intranasally O 
, O 
they O 
preferentially O 
accumulate O 
in O 
the O 
lungs O 
. O 
In O 
vitro O 
phantom O 
and O 
ex O 
vivo O 
lung O 
MRI O 
results O 
confirmed O 
that O 
M-LMNs O 
are O 
able O 
to O 
enhance O 
T(1) O 
MRI O 
contrast O 
. O 
M-LMNs O 
loaded O 
with O 
plasmid O 
DNA O 
and O 
/ O 
or O 
doxorubicin B-TRIVIAL 
are O 
efficiently O 
taken O 
up O 
by O 
HEK293 O 
cells O 
in O 
vitro O 
and O 
by O 
target O 
cells O 
in O 
vivo O 
. O 
Taken O 
together O 
, O 
these O 
results O 
demonstrate O 
that O 
M-LMNs O 
are O 
capable O 
of O 
simultaneously O 
providing O 
MRI O 
contrast O 
and O 
DNA O 
and O 
/ O 
or O 
drug O 
delivery O 
to O 
target O 
cells O 
in O 
the O 
lung O 
and O 
therefore O 
may O 
prove O 
useful O 
as O 
a O 
lung O 
theranostic O 
, O 
especially O 
for O 
lung O 
cancers O 
. O 

C I-TRIVIAL 
induces O 
monocytic O 
differentiation O 
of O 
HL60 O 
cells O 
through O 
activation O 
of O 
the O 
ERK O 
pathway O 
. O 

C I-TRIVIAL 
( O 
XC O 
) O 
, O 
which O 
is O 
a O 
group O 
of O 
macrocyclic O 
bis-1-oxaquinolizidines B-FAMILY 
, O 
is O 
a O 
potent O 
inhibitor O 
of O 
sarcoendoplasmic O 
reticulum O 
calcium O 
transport O 
ATPase O 
and O 
IP3 O 
receptor O 
. O 
Nevertheless O 
, O 
very O 
less O 
information O 
is O 
available O 
regarding O 
whether O 
XC O 
induces O 
AML O 
differentiation O 
. O 
We O 
investigated O 
the O 
potential O 
role O 
of O 
XC O 
in O 
the O 
differentiation O 
of O 
human O 
leukemia O 
HL60 O 
cells O 
and O 
mechanisms O 
underlying O 
XC O 
actin O 
. O 
XC O 
treatment O 
inhibited O 
proliferation O 
by O 
inducing O 
G1-phase O 
cell O 
cycle O 
arrest O 
in O 
the O 
HL60 O 
cells O 
. O 
In O 
addition O 
, O 
XC O 
induced O 
differentiation O 
of O 
HL60 O 
cells O 
into O 
the O 
CD14(+) O 
monocytic O 
lineage O 
, O 
which O 
was O 
indicated O 
by O 
morphological O 
changes O 
, O 
nitroblue B-TRIVIAL 
tetrazolium I-TRIVIAL 
reduction O 
assay O 
, O 
and O 
expressions O 
of O 
CD11b O 
and O 
CD14 O 
surface O 
antigens O 
. O 
Our O 
results O 
also O 
showed O 
that O 
XC O 
promotes O 
phagocytic O 
activity O 
and O 
granularity O 
in O 
HL60 O 
cells O 
, O 
suggesting O 
that O 
the O 
cells O 
are O 
functionally O 
activated O 
. O 
Furthermore O 
, O 
XC O 
enhanced O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
- O 
mediated O 
cytotoxic O 
effect O 
by O 
increasing O 
the O 
numbers O 
of O 
TNF O 
receptors O 
. O 
Moreover O 
, O 
we O 
showed O 
that O 
XC O 
activates O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
pathway O 
in O 
the O 
differentiation O 
stages O 
. O 
Inhibition O 
of O 
ERK O 
activation O 
using O 
PD98059 B-IDENTIFIER 
significantly O 
decreased O 
NBT O 
+ O 
HL60 O 
cells O 
induced O 
by O 
XC O 
treatment O 
. O 
Taken O 
together O 
, O 
the O 
results O 
show O 
that O 
XC O 
promotes O 
monocytic O 
differentiation O 
of O 
HL60 O 
cells O 
via O 
ERK O 
pathway O 
activation O 
, O 
suggesting O 
that O 
XC O 
could O 
be O 
a O 
candidate O 
for O 
use O 
as O 
a O 
differentiation O 
- O 
inducing O 
agent O 
for O 
AML O 
treatment O 
. O 

of O 
polyphenols B-FAMILY 
and O 
their O 
metabolites O 
in O 
human O 
urine O 
after O 
cranberry O 
- O 
syrup O 
consumption O 
. O 

the O 
beneficial O 
effects O 
of O 
American O 
cranberry O 
( O 
Vaccinium O 
macrocarpon O 
) O 
can O 
be O 
partly O 
attributed O 
to O 
its O 
phenolic B-FAMILY 
composition O 
, O 
the O 
evaluation O 
of O 
the O 
physiological O 
behaviour O 
of O 
this O 
fraction O 
is O 
crucial O 
. O 
A O 
rapid O 
and O 
sensitive O 
method O 
by O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
quadrupole O 
- O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
UPLC-Q-TOF-MS O 
) O 
has O 
been O 
used O 
to O 
identify O 
phenolic B-FAMILY 
metabolites O 
in O 
human O 
urine O 
after O 
a O 
single O 
dose O 
of O 
cranberry O 
syrup O 
. O 
Prior O 
to O 
the O 
analysis O 
, O 
metabolites O 
were O 
extracted O 
using O 
an O 
optimised O 
solid O 
- O 
phase O 
extraction O 
procedure O 
. O 
All O 
possible O 
metabolites O 
were O 
investigated O 
based O 
on O 
retention O 
time O 
, O 
accurate O 
mass O 
data O 
and O 
isotope O 
and O 
fragmentation O 
patterns O 
. O 
Free O 
coumaroyl B-FAMILY 
hexose I-FAMILY 
( O 
isomer O 
1 O 
and O 
2 O 
) O 
, O 
dihydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
caffeoyl B-TRIVIAL 
glucose I-TRIVIAL 
, O 
dihydroferulic B-SYSTEMATIC 
acid I-SYSTEMATIC 
4-O-β-d-glucuronide I-SYSTEMATIC 
, O 
methoxyquercetin B-SYSTEMATIC 
3-O-galactoside I-SYSTEMATIC 
, O 
scopoletin B-TRIVIAL 
, O 
myricetin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
, O 
together O 
with O 
other O 
23 O 
phase-I O 
and O 
phase-II O 
metabolites O 
, O 
including O 
various O 
isomers O 
, O 
could O 
be O 
tentatively O 
identified O 
in O 
the O 
urine O 
. O 
Afterwards O 
, O 
the O 
metabolites O 
were O 
simultaneously O 
screened O 
in O 
the O 
urine O 
of O 
different O 
subjects O 
at O 
0 O 
, O 
2 O 
, O 
4 O 
, O 
and O 
6h O 
after O 
the O 
ingestion O 
of O 
cranberry O 
syrup O 
by O 
Target O 
Analysis O 
( O 
TM O 
) O 
software O 
. O 

protects O 
against O 
acute O 
cadmium B-SYSTEMATIC 
-induced O 
oxidative O 
damage O 
in O 
mice O 
testes O 
. O 

is O 
a O 
non-essential O 
heavy O 
metal O 
that O 
is O 
present O 
at O 
low O 
levels O 
mainly O 
in O 
food O 
and O 
water O 
and O 
also O 
in O 
cigar O 
smoke O 
. O 
The O 
present O 
study O 
evaluated O 
the O 
testicular O 
damage O 
caused O 
by O 
acute O 
cadmium B-SYSTEMATIC 
exposure O 
and O 
verified O 
the O 
protective O 
role O 
of O 
γ-oryzanol B-TRIVIAL 
( O 
ORY B-ABBREVIATION 
) O 
. O 
Mice O 
were O 
administrated O 
with O 
a O 
single O 
dose O 
of O 
2.5mg O 
/ O 
kg O 
of O 
CdCl2 B-FORMULA 
, O 
and O 
then O 
treated O 
with O 
ORY B-ABBREVIATION 
( O 
50mM O 
in O 
canola O 
oil O 
, O 
5mL O 
/ O 
kg O 
) O 
. O 
Testes O 
were O 
removed O 
after O 
24h O 
and O 
tested O 
for O 
lipid O 
peroxidation O 
( O 
TBARS O 
) O 
, O 
protein O 
carbonylation O 
, O 
DNA O 
breakage O 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
cadmium B-SYSTEMATIC 
and O 
non-proteic O 
thiols B-FAMILY 
contents O 
, O 
and O 
for O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
, O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
and O 
δ-aminolevulic B-SYSTEMATIC 
acid I-SYSTEMATIC 
dehydratase O 
( O 
δ-ALA B-SYSTEMATIC 
-D O 
) O 
. O 
Cadmium B-SYSTEMATIC 
presented O 
a O 
significant O 
alteration O 
in O 
all O 
parameters O 
, O 
except O 
GPx O 
and O 
CAT O 
activities O 
. O 
Therapy O 
reduced O 
in O 
a O 
slight O 
degree O 
cadmium B-SYSTEMATIC 
concentration O 
in O 
testes O 
( O 
around O 
23% O 
) O 
. O 
ORY B-ABBREVIATION 
restored O 
SOD O 
and O 
GST O 
activities O 
as O 
well O 
as O 
TBARS O 
production O 
to O 
the O 
control O 
levels O 
. O 
Furthermore O 
, O 
ORY B-ABBREVIATION 
partially O 
recovered O 
δ-ALA B-SYSTEMATIC 
-D O 
activity O 
inhibited O 
by O 
cadmium B-SYSTEMATIC 
. O 
This O 
study O 
provides O 
the O 
first O 
evidence O 
on O 
the O 
therapeutic O 
properties O 
of O 
ORY B-ABBREVIATION 
in O 
protecting O 
against O 
cadmium B-SYSTEMATIC 
-induced O 
testicular O 
toxicity O 
. O 

dependent O 
intestinal O 
absorption O 
of O 
darunavir B-TRIVIAL 
and O 
its O 
interaction O 
with O 
ketoconazole B-TRIVIAL 
. O 

expression O 
of O 
P-gp O 
increases O 
from O 
proximal O 
to O 
distal O 
parts O 
of O 
the O 
small O 
intestine O 
, O 
whereas O 
for O 
P450 O 
enzymes O 
the O 
expression O 
is O 
reported O 
to O 
be O 
highest O 
in O 
duodenum O 
and O 
jejunum O 
, O 
decreasing O 
to O 
more O 
distal O 
sites O 
. O 
To O 
evaluate O 
to O 
what O 
extent O 
the O 
regional O 
differences O 
in O 
expression O 
of O 
P-gp O 
and O 
P450 O 
enzymes O 
affect O 
the O 
absorption O 
of O 
a O 
dual O 
substrate O 
, O 
we O 
investigated O 
the O 
transport O 
of O 
darunavir B-TRIVIAL 
across O 
different O 
small O 
intestinal O 
segments O 
( O 
duodenum O 
, O 
proximal O 
jejunum O 
and O 
ileum O 
) O 
. O 
Moreover O 
, O 
the O 
effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
the O 
intestinal O 
absorption O 
of O 
darunavir B-TRIVIAL 
was O 
explored O 
, O 
since O 
these O 
drugs O 
are O 
commonly O 
co O 
- O 
administered O 
. O 
Performing O 
the O 
rat O 
in O 
situ O 
intestinal O 
perfusion O 
technique O 
with O 
mesenteric O 
blood O 
sampling O 
, O 
we O 
found O 
no O 
significant O 
differences O 
in O 
the O 
transport O 
of O 
darunavir B-TRIVIAL 
at O 
the O 
different O 
intestinal O 
segments O 
. O 
The O 
involvement O 
of O 
P-gp O 
in O 
the O 
absorption O 
of O 
darunavir B-TRIVIAL 
was O 
clearly O 
shown O 
by O 
coperfusion O 
of O 
darunavir B-TRIVIAL 
with O 
the O 
P-gp O 
inhibitor O 
zosuquidar B-TRIVIAL 
. O 
In O 
presence O 
of O 
zosuquidar B-TRIVIAL 
, O 
a O 
2.2- O 
, O 
4.2- O 
and O 
5.7-fold O 
increase O 
in O 
Papp O 
values O 
were O 
measured O 
for O 
duodenum O 
, O 
proximal O 
jejunum O 
and O 
ileum O 
, O 
respectively O 
. O 
Involvement O 
of O 
P450 O 
mediated O 
metabolism O 
in O 
the O 
absorption O 
of O 
darunavir B-TRIVIAL 
could O 
not O 
be O 
demonstrated O 
in O 
this O 
rat O 
model O 
. O 
Upon O 
studying O 
the O 
drug O 
- O 
drug O 
interaction O 
of O 
darunavir B-TRIVIAL 
with O 
ketoconazole B-TRIVIAL 
, O 
data O 
were O 
indicative O 
for O 
an O 
inhibitory O 
effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
P-gp O 
as O 
the O 
main O 
mechanism O 
for O 
the O 
increased O 
transport O 
of O 
darunavir B-TRIVIAL 
across O 
the O 
small O 
intestine O 
. O 

azaspiracids B-FAMILY 
are O 
absorbed O 
and O 
metabolized O 
by O 
blue O 
mussels O 
( O 
Mytilus O 
edulis O 
) O 
. O 

relationship O 
between O 
azaspiracid B-TRIVIAL 
shellfish O 
poisoning O 
and O 
a O 
small O 
dinoflagellate O 
, O 
Azadinium O 
spinosum O 
, O 
has O 
been O 
shown O 
recently O 
. O 
The O 
organism O 
produces O 
AZA1 B-MULTIPLE 
and I-MULTIPLE 
-2 I-MULTIPLE 
, O 
while O 
AZA3 B-ABBREVIATION 
and O 
other O 
analogues O 
are O 
metabolic O 
products O 
formed O 
in O 
shellfish O 
. O 
We O 
evaluated O 
whether O 
mussels O 
were O 
capable O 
of O 
accumulating O 
dissolved O 
AZA1 B-MULTIPLE 
and I-MULTIPLE 
-2 I-MULTIPLE 
, O 
and O 
compared O 
the O 
toxin O 
profiles O 
of O 
these O 
mussels O 
at O 
24 O 
h O 
with O 
profiles O 
of O 
those O 
exposed O 
to O 
live O 
or O 
lysed O 
A O 
. O 
spinosum O 
. O 
We O 
also O 
assessed O 
the O 
possibility O 
of O 
preparative O 
production O 
of O 
AZA B-ABBREVIATION 
metabolites O 
by O 
exposing O 
mussels O 
to O 
semi-purified O 
AZA1 B-ABBREVIATION 
. O 
We O 
exposed O 
mussels O 
to O 
similar O 
concentration O 
of O 
AZAs B-ABBREVIATION 
: O 
dissolved O 
AZA1 B-MULTIPLE 
+ I-MULTIPLE 
2 I-MULTIPLE 
( O 
crude O 
extract O 
) O 
at O 
7.5 O 
and O 
0.75 O 
μg O 
L(-1) O 
, O 
dissolved O 
AZA1 B-MULTIPLE 
+ I-MULTIPLE 
2 I-MULTIPLE 
( O 
7.5 O 
μg O 
L(-1) O 
) O 
in O 
combination O 
with O 
Isochrysis O 
affinis O 
galbana O 
, O 
and O 
lysed O 
and O 
live O 
A O 
. O 
spinosum O 
cells O 
at O 
1 O 
× O 
10(5) O 
and O 
1 O 
× O 
10(4) O 
cell O 
mL(-1) O 
( O 
containing O 
equivalent O 
amounts O 
of O 
AZA1 B-MULTIPLE 
+ I-MULTIPLE 
2 I-MULTIPLE 
) O 
. O 
Subsequently O 
, O 
we O 
dissected O 
and O 
analysed O 
digestive O 
glands O 
, O 
gills O 
and O 
remaining O 
flesh O 
. O 
Mussels O 
( O 
whole O 
flesh O 
) O 
accumulated O 
AZAs B-ABBREVIATION 
to O 
levels O 
above O 
the O 
regulatory O 
limit O 
, O 
except O 
at O 
the O 
lower O 
levels O 
of O 
dissolved O 
AZAs B-ABBREVIATION 
. O 
The O 
toxin O 
profile O 
of O 
the O 
mussels O 
varied O 
significantly O 
with O 
treatment O 
. O 
The O 
gills O 
contained O 
42-46% O 
and O 
the O 
digestive O 
glands O 
23-24% O 
of O 
the O 
total O 
toxin O 
load O 
using O 
dissolved O 
AZAs B-ABBREVIATION 
, O 
compared O 
to O 
3-12% O 
and O 
75-90% O 
, O 
respectively O 
, O 
in O 
mussels O 
exposed O 
to O 
live O 
A O 
. O 
spinosum O 
. O 
Exposure O 
of O 
mussels O 
to O 
semi-purified O 
AZA1 B-ABBREVIATION 
produced O 
the O 
metabolites O 
AZA17 B-ABBREVIATION 
( O 
16.5% O 
) O 
and O 
AZA3 B-ABBREVIATION 
( O 
1.7% O 
) O 
after O 
4 O 
days O 
of O 
exposure O 
, O 
but O 
the O 
conversion O 
efficiency O 
was O 
too O 
low O 
to O 
justify O 
using O 
this O 
procedure O 
for O 
preparative O 
isolation O 
. O 

in O 
the O 
transfer O 
profile O 
of O 
orally O 
administered O 
tetrodotoxin B-TRIVIAL 
to O 
non-toxic O 
cultured O 
pufferfish O 
Takifugu O 
rubripes O 
depending O 
of O 
its O 
development O 
stage O 
. O 

investigate O 
the O 
effects O 
of O 
growth O 
( O 
organ O 
development O 
) O 
on O 
tetrodotoxin B-TRIVIAL 
( O 
TTX B-ABBREVIATION 
) O 
dynamics O 
in O 
the O 
pufferfish O 
body O 
, O 
TTX B-ABBREVIATION 
-containing O 
feed O 
homogenate O 
was O 
administered O 
to O 
6- O 
and O 
15-month O 
old O 
non-toxic O 
cultured O 
specimens O 
of O 
the O 
pufferfish O 
Takifugu O 
rubripes O 
at O 
a O 
dose O 
of O 
40 O 
mouse O 
units O 
( O 
MU O 
) O 
( O 
8.8 O 
μg O 
) O 
/ O 
20 O 
g O 
body O 
weight O 
by O 
oral O 
gavage O 
. O 
After O 
24 O 
h O 
, O 
the O 
specimens O 
were O 
killed O 
and O 
the O 
skin O 
tissues O 
( O 
dorsal O 
and O 
ventral O 
) O 
, O 
muscle O 
, O 
liver O 
, O 
digestive O 
tract O 
, O 
and O 
gonads O 
were O 
separated O 
. O 
TTX B-ABBREVIATION 
content O 
( O 
μg O 
/ O 
g O 
) O 
in O 
each O 
tissue O 
, O 
determined O 
by O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
, O 
revealed O 
that O 
the O 
TTX B-ABBREVIATION 
distribution O 
profile O 
, O 
particularly O 
the O 
TTX B-ABBREVIATION 
content O 
of O 
the O 
liver O 
, O 
greatly O 
differed O 
between O 
the O 
two O 
ages O 
; O 
the O 
TTX B-ABBREVIATION 
score O 
of O 
15-month O 
old O 
fish O 
( O 
3.3 O 
μg O 
/ O 
g O 
) O 
was O 
nearly O 
5-fold O 
that O 
of O 
6-month O 
old O 
fish O 
( O 
0.68 O 
μg O 
/ O 
g O 
) O 
. O 
The O 
total O 
remaining O 
TTX B-ABBREVIATION 
amount O 
per O 
individual O 
( O 
relative O 
amount O 
to O 
the O 
given O 
dose O 
) O 
was O 
31% O 
in O 
6-month O 
old O 
fish O 
, O 
of O 
which O 
71% O 
was O 
in O 
the O 
skin O 
, O 
and O 
84% O 
in O 
15-month O 
old O 
fish O 
, O 
of O 
which O 
83% O 
was O 
in O 
the O 
liver O 
. O 
The O 
gonadosomatic O 
index O 
( O 
GSI O 
) O 
and O 
hepatosomatic O 
index O 
( O 
HSI O 
) O 
scores O 
, O 
and O 
histologic O 
observations O 
of O 
the O 
gonads O 
and O 
liver O 
suggest O 
that O 
although O 
there O 
is O 
little O 
difference O 
in O 
maturation O 
stage O 
between O 
these O 
two O 
ages O 
, O 
there O 
are O 
clear O 
distinctions O 
in O 
the O 
developmental O 
stage O 
of O 
the O 
liver O 
. O 
The O 
results O 
suggest O 
that O 
the O 
TTX B-ABBREVIATION 
dynamics O 
in O 
T O 
. O 
rubripes O 
are O 
linked O 
to O 
the O 
development O 
of O 
the O 
liver O 
, O 
i.e O 
. O 
, O 
the O 
TTX B-ABBREVIATION 
taken O 
up O 
into O 
the O 
pufferfish O 
body O 
via O 
food O 
organisms O 
is O 
eliminated O 
or O 
transferred O 
mainly O 
to O 
the O 
skin O 
in O 
young O 
fish O 
with O 
an O 
undeveloped O 
liver O 
, O 
but O 
as O 
the O 
fish O 
grow O 
and O 
the O 
liver O 
continues O 
to O 
develop O 
, O 
most O 
of O 
the O 
TTX B-ABBREVIATION 
is O 
transferred O 
to O 
and O 
accumulated O 
in O 
the O 
liver O 
. O 

domain O 
- O 
associated O 
protein O 
( O 
Daxx O 
) O 
cooperates O 
with O 
X O 
- O 
linked O 
α-thalassaemia O 
retardation O 
syndrome O 
protein O 
( O 
ATRX O 
) O 
, O 
a O 
putative O 
member O 
of O 
the O 
sucrose B-TRIVIAL 
non-fermentable O 
2 O 
family O 
of O 
ATP B-ABBREVIATION 
-dependent O 
chromatin O 
- O 
remodelling O 
proteins O 
, O 
acting O 
as O 
the O 
core O 
ATPase O 
subunit O 
in O 
this O 
complex O 
, O 
whereas O 
Daxx O 
is O 
the O 
targeting O 
factor O 
, O 
leading O 
to O 
histone O 
deacetylase O 
recruitment O 
, O 
H3.3 O 
deposition O 
and O 
transcriptional O 
repression O 
of O 
cellular O 
promoters O 
. O 
Despite O 
recent O 
findings O 
on O 
the O 
fundamental O 
importance O 
of O 
chromatin O 
modification O 
in O 
host O 
- O 
cell O 
gene O 
regulation O 
, O 
it O 
remains O 
unclear O 
whether O 
adenovirus O 
type O 
5 O 
( O 
Ad5 O 
) O 
transcription O 
is O 
regulated O 
by O 
cellular O 
chromatin O 
remodelling O 
to O 
allow O 
efficient O 
virus O 
gene O 
expression O 
. O 
Here O 
, O 
we O 
focus O 
on O 
the O 
repressive O 
role O 
of O 
the O 
Daxx O 
/ O 
ATRX O 
complex O 
during O 
Ad5 O 
replication O 
, O 
which O 
depends O 
on O 
intact O 
protein O 
- O 
protein O 
interaction O 
, O 
as O 
negative O 
regulation O 
could O 
be O 
relieved O 
with O 
a O 
Daxx O 
mutant O 
that O 
is O 
unable O 
to O 
interact O 
with O 
ATRX O 
. O 
To O 
ensure O 
efficient O 
viral O 
replication O 
, O 
Ad5 O 
E1B-55K O 
protein O 
inhibits O 
Daxx O 
and O 
targets O 
ATRX O 
for O 
proteasomal O 
degradation O 
in O 
cooperation O 
with O 
early O 
region O 
4 O 
open O 
reading O 
frame O 
protein O 
6 O 
and O 
cellular O 
components O 
of O 
a O 
cullin O 
- O 
dependent O 
E3-ubiquitin O 
ligase O 
. O 
Our O 
studies O 
illustrate O 
the O 
importance O 
and O 
diversity O 
of O 
viral O 
factors O 
antagonizing O 
Daxx O 
/ O 
ATRX O 
- O 
mediated O 
repression O 
of O 
viral O 
gene O 
expression O 
and O 
shed O 
new O 
light O 
on O 
the O 
modulation O 
of O 
cellular O 
chromatin O 
remodelling O 
factors O 
by O 
Ad5 O 
. O 
We O 
show O 
for O 
the O 
first O 
time O 
that O 
cellular O 
Daxx O 
/ O 
ATRX O 
chromatin O 
remodelling O 
complexes O 
play O 
essential O 
roles O 
in O 
Ad O 
gene O 
expression O 
and O 
illustrate O 
the O 
importance O 
of O 
early O 
viral O 
proteins O 
to O 
counteract O 
cellular O 
chromatin O 
remodelling O 
. O 

experiments O 
provided O 
controversial O 
observations O 
that O 
either O 
parallel O 
or O 
non-parallel O 
G-quadruplex O 
exists O 
in O 
molecularly O 
crowded O 
buffers O 
that O 
mimic O 
cellular O 
environment O 
. O 
Here O 
, O 
we O 
used O 
laser O 
tweezers O 
to O 
mechanically O 
unfold O 
structures O 
in O 
a O 
human O 
telomeric O 
DNA O 
fragment O 
, O 
5'-(TTAGGG)4TTA O 
, O 
along O 
three O 
different O 
trajectories O 
. O 
After O 
the O 
end O 
- O 
to O 
- O 
end O 
distance O 
of O 
each O 
unfolding O 
geometry O 
was O 
measured O 
, O 
it O 
was O 
compared O 
with O 
PDB O 
structures O 
to O 
identify O 
the O 
best O 
- O 
matching O 
G-quadruplex O 
conformation O 
. O 
This O 
method O 
is O 
well O 
- O 
suited O 
to O 
identify O 
biomolecular O 
structures O 
in O 
complex O 
settings O 
not O 
amenable O 
to O 
conventional O 
approaches O 
, O 
such O 
as O 
in O 
a O 
solution O 
with O 
mixed O 
species O 
or O 
at O 
physiologically O 
significant O 
concentrations O 
. O 
With O 
this O 
approach O 
, O 
we O 
found O 
that O 
parallel O 
G-quadruplex O 
coexists O 
with O 
non-parallel O 
species O 
( O 
1 O 
: O 
1 O 
ratio O 
) O 
in O 
crowded O 
buffers O 
with O 
dehydrating O 
cosolutes O 
[ O 
40% O 
w O 
/ O 
v O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
or O 
acetonitrile B-SYSTEMATIC 
( O 
ACN B-ABBREVIATION 
) O 
] O 
. O 
In O 
crowded O 
solutions O 
with O 
steric O 
cosolutes O 
[ O 
40% O 
w O 
/ O 
v O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
] O 
, O 
the O 
parallel O 
G-quadruplex O 
constitutes O 
only O 
10% O 
of O 
the O 
population O 
. O 
This O 
difference O 
unequivocally O 
supports O 
the O 
notion O 
that O 
dehydration O 
promotes O 
the O 
formation O 
of O 
parallel O 
G-quadruplexes O 
. O 
Compared O 
with O 
DNA O 
hairpins O 
that O 
have O 
decreased O 
unfolding O 
forces O 
in O 
crowded O 
( O 
9 O 
pN O 
) O 
versus O 
diluted O 
( O 
15 O 
pN O 
) O 
buffers O 
, O 
those O 
of O 
G-quadruplexes O 
remain O 
the O 
same O 
( O 
20 O 
pN O 
) O 
. O 
Such O 
a O 
result O 
implies O 
that O 
in O 
a O 
cellular O 
environment O 
, O 
DNA O 
G-quadruplexes O 
, O 
instead O 
of O 
hairpins O 
, O 
can O 
stop O 
DNA O 
/ O 
RNA O 
polymerases O 
with O 
stall O 
forces O 
often O 
< O 
20 O 
pN O 
. O 

( O 
GC O 
) O 
excess O 
causes O 
a O 
rapid O 
loss O 
of O 
bone O 
with O 
a O 
reduction O 
in O 
bone O 
formation O 
. O 
Intermittent O 
PTH O 
( O 
1-34 O 
) O 
administration O 
stimulates O 
bone O 
formation O 
and O 
counteracts O 
the O 
inhibition O 
of O 
bone O 
formation O 
by O 
GC O 
excess O 
. O 
We O 
have O 
previously O 
demonstrated O 
that O 
mechanical O 
strain O 
enhances O 
interleukin O 
(IL)-11 O 
gene O 
transcription O 
by O 
a O 
rapid O 
induction O 
of O 
ΔFosB O 
expression O 
and O 
protein O 
kinase O 
C O 
(PKC)-δ O 
- O 
mediated O 
phosphorylation O 
of O 
phosphorylated O 
mothers O 
against O 
decapentaplegic O 
(Smad)-1 O 
. O 
Because O 
IL-11 O 
suppresses O 
the O 
expression O 
of O 
dickkopf-1 O 
and O 
-2 O 
and O 
stimulates O 
Wnt O 
signaling O 
, O 
IL-11 O 
appears O 
to O 
mediate O 
at O 
least O 
a O 
part O 
of O 
the O 
effect O 
of O 
mechanical O 
strain O 
on O 
osteoblast O 
differentiation O 
and O 
bone O 
formation O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
examine O 
the O 
effect O 
of O 
PTH(1-34) O 
and O 
GCs O 
on O 
IL-11 O 
expression O 
in O 
murine O 
primary O 
osteoblasts O 
( O 
mPOBs O 
) O 
. O 
PTH(1-34) O 
treatment O 
of O 
mPOBs O 
enhanced O 
IL-11 O 
expression O 
in O 
a O 
time- O 
and O 
dose O 
- O 
dependent O 
manner O 
. O 
PTH(1-34) O 
also O 
stimulated O 
ΔFosB O 
expression O 
and O 
Smad1 O 
phosphorylation O 
, O 
which O 
cooperatively O 
stimulated O 
IL-11 O 
gene O 
transcription O 
. O 
PTH(1-34)-induced O 
Smad1 O 
phosphorylation O 
was O 
mediated O 
via O 
PKCδ O 
and O 
was O 
abrogated O 
in O 
mPOBs O 
from O 
PKCδ O 
knockout O 
mice O 
. O 
Dexamethasone B-TRIVIAL 
suppressed O 
IL-11 O 
gene O 
transcription O 
enhanced O 
by O 
PTH(1-34) O 
without O 
affecting O 
ΔFosB O 
expression O 
or O 
Smad1 O 
phosphorylation O 
, O 
and O 
dexamethasone B-TRIVIAL 
-GC O 
receptor O 
complex O 
was O 
bound O 
to O 
JunD O 
, O 
which O 
forms O 
heterodimers O 
with O 
ΔFosB O 
. O 
High O 
doses O 
of O 
PTH(1-34) O 
counteracted O 
the O 
effect O 
of O 
dexamethasone B-TRIVIAL 
on O 
apoptosis O 
of O 
mPOBs O 
, O 
which O 
was O 
blunted O 
by O 
neutralizing O 
anti-IL-11 O 
antibody O 
or O 
IL-11 O 
small O 
interfering O 
RNA O 
. O 
These O 
results O 
demonstrate O 
that O 
PTH(1-34) O 
and O 
GCs O 
interact O 
to O 
regulate O 
IL-11 O 
expression O 
in O 
parallel O 
with O 
osteoblast O 
differentiation O 
and O 
apoptosis O 
and O 
suggest O 
that O 
PTH(1-34) O 
and O 
dexamethasone B-TRIVIAL 
may O 
regulate O 
osteoblast O 
differentiation O 
and O 
apoptosis O 
via O 
their O 
effect O 
on O 
IL-11 O 
expression O 
. O 

prospective O 
open O 
- O 
label O 
trial O 
of O 
paliperidone B-TRIVIAL 
monotherapy O 
for O 
the O 
treatment O 
of O 
bipolar O 
spectrum O 
disorders O 
in O 
children O 
and O 
adolescents O 
. O 

: O 
Treatment O 
studies O 
for O 
the O 
management O 
of O 
pediatric O 
bipolar O 
disorder O 
are O 
limited O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
evaluates O 
the O 
safety O 
and O 
efficacy O 
of O 
paliperidone B-TRIVIAL 
monotherapy O 
as O 
an O 
acute O 
treatment O 
of O 
mania O 
and O 
related O 
symptoms O 
in O 
youth O 
with O 
bipolar O 
spectrum O 
disorders O 
. O 
METHODS O 
: O 
An O 
8-week O 
, O 
prospective O 
, O 
open O 
- O 
label O 
paliperidone B-TRIVIAL 
monotherapy O 
trial O 
to O 
assess O 
effectiveness O 
and O 
tolerability O 
in O 
treating O 
pediatric O 
bipolar O 
spectrum O 
and O 
related O 
disorders O 
( O 
depression O 
, O 
psychosis O 
, O 
attention O 
- O 
deficit O 
/ O 
hyperactivity O 
disorder O 
[ O 
ADHD O 
] O 
) O 
. O 
Assessments O 
included O 
the O 
Young O 
Mania O 
Rating O 
Scale O 
( O 
YMRS O 
) O 
, O 
Clinical O 
Global O 
Impression O 
scale O 
( O 
CGI O 
) O 
, O 
Children's O 
Depression O 
Rating O 
Scale-Revised O 
( O 
CDRS-R O 
) O 
, O 
and O 
Brief O 
Psychiatric O 
Rating O 
Scale O 
( O 
BPRS O 
) O 
. O 
Adverse O 
events O 
were O 
assessed O 
through O 
spontaneous O 
self O 
- O 
reports O 
, O 
vital O 
signs O 
, O 
weight O 
monitoring O 
, O 
and O 
laboratory O 
analysis O 
. O 
RESULTS O 
: O 
Fifteen O 
youth O 
with O 
bipolar O 
spectrum O 
disorders O 
( O 
YMRS O 
at O 
entry O 
: O 
32.8 O 
± O 
6.1 O 
) O 
were O 
enrolled O 
in O 
the O 
study O 
and O 
11 O 
( O 
73 O 
% O 
) O 
completed O 
the O 
8-week O 
trial O 
. O 
The O 
total O 
daily O 
dose O 
of O 
paliperidone B-TRIVIAL 
at O 
study O 
endpoint O 
was O 
3 O 
mg O 
in O 
12 O 
subjects O 
and O 
6 O 
mg O 
in O 
three O 
subjects O 
. O 
Treatment O 
with O 
paliperidone B-TRIVIAL 
was O 
associated O 
with O 
statistically O 
significant O 
levels O 
of O 
improvement O 
in O 
mean O 
YMRS O 
scores O 
( O 
-18.7 O 
± O 
13.9 O 
, O 
p O 
< O 
0.001 O 
) O 
at O 
endpoint O 
. O 
Paliperidone B-TRIVIAL 
treatment O 
also O 
resulted O 
in O 
significant O 
improvement O 
in O 
the O 
severity O 
of O 
ADHD O 
and O 
psychotic O 
symptoms O 
. O 
Although O 
treatment O 
with O 
paliperidone B-TRIVIAL 
was O 
generally O 
well O 
tolerated O 
and O 
was O 
not O 
associated O 
with O 
clinically O 
significant O 
change O 
in O 
cardiovascular O 
or O 
metabolic O 
parameters O 
, O 
increases O 
in O 
body O 
weight O 
( O 
4.1 O 
± O 
5.5 O 
lb O 
) O 
were O 
substantial O 
. O 
CONCLUSIONS O 
: O 
Open O 
- O 
label O 
paliperidone B-TRIVIAL 
treatment O 
appears O 
to O 
be O 
beneficial O 
in O 
the O 
treatment O 
of O 
bipolar O 
spectrum O 
disorders O 
and O 
associated O 
conditions O 
in O 
youth O 
. O 
Future O 
placebo O 
- O 
controlled O 
studies O 
are O 
warranted O 
to O 
confirm O 
these O 
findings O 
. O 

and O 
glucocorticoids O 
target O 
common O 
genes O 
in O 
hippocampal O 
HT22 O 
cells O 
. O 

A I-FAMILY 
metabolite O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
plays O 
a O 
major O 
role O 
in O 
the O 
aging O 
adult O 
brain O 
plasticity O 
. O 
Conversely O 
, O 
chronic O 
excess O 
of O 
glucocorticoids O 
( O 
GC O 
) O 
elicits O 
some O 
deleterious O 
effects O 
in O 
the O 
hippocampus O 
. O 
We O 
questioned O 
here O 
the O 
involvement O 
of O 
RA O 
and O 
GC O 
in O 
the O 
expression O 
of O 
target O 
proteins O 
in O 
hippocampal O 
neurons O 
. O 
We O 
investigated O 
proteins O 
involved O 
either O 
in O 
the O 
signaling O 
pathways O 
[ O 
RA O 
receptor O 
β O 
( O 
RARβ O 
) O 
and O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
] O 
or O 
in O 
neuron O 
differentiation O 
and O 
plasticity O 
[ O 
tissue O 
transglutaminase O 
2 O 
( O 
tTG O 
) O 
and O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
] O 
in O 
a O 
hippocampal O 
cell O 
line O 
, O 
HT22 O 
. O 
We O 
applied O 
RA O 
and O 
/ O 
or O 
dexamethasone B-TRIVIAL 
( O 
Dex B-ABBREVIATION 
) O 
as O 
activators O 
of O 
the O 
pathways O 
and O 
investigated O 
mRNA O 
and O 
protein O 
expression O 
of O 
their O 
receptors O 
and O 
of O 
tTG O 
and O 
BDNF O 
as O 
well O 
as O 
tTG O 
activity O 
and O 
BDNF O 
secretion O 
. O 
Our O 
results O 
confirm O 
the O 
involvement O 
of O 
RA- O 
and O 
GC-dependent O 
pathways O 
and O 
their O 
interaction O 
in O 
our O 
neuronal O 
cell O 
model O 
. O 
First O 
, O 
both O 
pathways O 
regulate O 
the O 
transcription O 
and O 
expression O 
of O 
own O 
and O 
reciprocal O 
receptors O 
: O 
RA O 
and O 
Dex O 
increased O 
RARβ O 
and O 
decreased O 
GR O 
expressions O 
. O 
Second O 
, O 
Dex B-ABBREVIATION 
reduces O 
the O 
expression O 
of O 
tTG O 
when O 
associated O 
with O 
RA O 
despite O 
stimulating O 
its O 
expression O 
when O 
used O 
alone O 
. O 
Importantly O 
, O 
when O 
they O 
are O 
combined O 
, O 
RA O 
counteracts O 
the O 
deleterious O 
effect O 
of O 
glucocorticoids O 
on O 
BDNF O 
regulation O 
and O 
thus O 
may O 
improve O 
neuronal O 
plasticity O 
under O 
stress O 
conditions O 
. O 
In O 
conclusion O 
, O 
GC O 
and O 
RA O 
both O 
interact O 
through O 
regulations O 
of O 
the O 
two O 
receptors O 
, O 
RARβ O 
and O 
GR O 
. O 
Furthermore O 
, O 
they O 
both O 
act O 
, O 
synergistically O 
or O 
oppositely O 
, O 
on O 
other O 
target O 
proteins O 
critical O 
for O 
neuronal O 
plasticity O 
, O 
tTG O 
and O 
BDNF O 
. O 

of O 
ghrelin O 
O B-FORMULA 
-acyltransferase O 
attenuates O 
food O 
deprivation O 
- O 
induced O 
increases O 
in O 
ingestive O 
behavior O 
. O 

is O 
an O 
orexigenic O 
hormone O 
produced O 
by O 
the O 
stomach O 
in O 
direct O 
proportion O 
to O 
the O 
time O 
since O 
the O 
last O 
meal O 
and O 
has O 
therefore O 
been O 
called O 
a O 
' O 
hunger O 
signal O 
' O 
. O 
The O 
octanoylation O 
of O 
ghrelin O 
is O 
critical O 
for O 
its O 
orexigenic O 
functions O 
and O 
is O 
dependent O 
upon O 
ghrelin O 
O B-FORMULA 
-acyltransferase O 
( O 
GOAT O 
) O 
catalyzation O 
. O 
The O 
GOAT O 
inhibitor O 
, O 
GO-CoA-Tat O 
, O 
decreases O 
the O 
circulating O 
concentrations O 
of O 
octanoylated O 
ghrelin O 
and O 
attenuates O 
weight O 
gain O 
on O 
a O 
high O 
fat O 
diet O 
in O 
mice O 
. O 
Unlike O 
rats O 
and O 
mice O 
, O 
Siberian O 
hamsters O 
and O 
humans O 
do O 
not O 
increase O 
food O 
intake O 
after O 
food O 
deprivation O 
, O 
but O 
increase O 
food O 
hoarding O 
after O 
food O 
deprivation O 
. O 
In O 
Siberian O 
hamsters O 
, O 
exogenous O 
ghrelin O 
increases O 
ingestive O 
behaviors O 
similarly O 
to O 
48-56h O 
food O 
deprivation O 
. O 
Therefore O 
, O 
we O 
tested O 
the O 
necessity O 
of O 
increased O 
ghrelin O 
in O 
food O 
- O 
deprived O 
Siberian O 
hamsters O 
to O 
stimulate O 
ingestive O 
behaviors O 
. O 
To O 
do O 
so O 
we O 
used O 
our O 
simulated O 
natural O 
housing O 
system O 
that O 
allows O 
hamsters O 
to O 
forage O 
for O 
and O 
hoard O 
food O 
. O 
Animals O 
were O 
given O 
an O 
injection O 
of O 
GO-CoA-Tat O 
( O 
i.p O 
. O 
, O 
11μmol O 
/ O 
kg O 
) O 
every O 
6h O 
because O 
that O 
is O 
the O 
duration O 
of O 
its O 
effective O 
inhibition O 
of O 
octanoylated O 
ghrelin O 
concentrations O 
during O 
a O 
48h O 
food O 
deprivation O 
. O 
We O 
found O 
that O 
GO-CoA-Tat O 
attenuated O 
food O 
foraging O 
( O 
0-1h O 
) O 
, O 
food O 
intake O 
( O 
0-1 O 
and O 
2-4h O 
) O 
, O 
and O 
food O 
hoarding O 
( O 
0-1h O 
and O 
2 O 
and O 
3days O 
) O 
post O 
- O 
refeeding O 
compared O 
with O 
saline O 
treated O 
animals O 
. O 
This O 
suggests O 
that O 
increased O 
octanoylated O 
ghrelin O 
concentrations O 
play O 
a O 
role O 
in O 
the O 
food O 
deprivation O 
- O 
induced O 
increases O 
in O 
ingestive O 
behavior O 
. O 
Therefore O 
, O 
ghrelin O 
is O 
a O 
critical O 
aspect O 
of O 
the O 
multi O 
- O 
faceted O 
mechanisms O 
that O 
stimulate O 
ingestive O 
behaviors O 
, O 
and O 
might O 
be O 
a O 
critical O 
point O 
for O 
a O 
successful O 
clinical O 
intervention O 
scheme O 
in O 
humans O 
. O 

stabilizers O 
are O 
some O 
of O 
the O 
most O 
successful O 
drugs O 
used O 
in O 
the O 
treatment O 
of O 
adult O 
solid O 
tumors O 
and O 
yet O 
the O 
molecular O 
events O 
responsible O 
for O 
their O 
antimitotic O 
actions O 
are O 
not O 
well O 
defined O 
. O 
The O 
mitotic O 
events O 
initiated O 
by O 
three O 
structurally O 
and O 
biologically O 
diverse O 
microtubule O 
stabilizers O 
; O 
taccalonolide B-TRIVIAL 
AJ I-TRIVIAL 
, O 
laulimalide B-TRIVIAL 
/ O 
fijianolide B-TRIVIAL 
B I-TRIVIAL 
and O 
paclitaxel B-TRIVIAL 
were O 
studied O 
. O 
These O 
microtubule O 
stabilizers O 
cause O 
the O 
formation O 
of O 
aberrant O 
, O 
but O 
structurally O 
distinct O 
mitotic O 
spindles O 
leading O 
to O 
the O 
hypothesis O 
that O 
they O 
differentially O 
affect O 
mitotic O 
signaling O 
. O 
Each O 
microtubule O 
stabilizer O 
initiated O 
different O 
patterns O 
of O 
expression O 
of O 
key O 
mitotic O 
signaling O 
proteins O 
. O 
Taccalonolide B-TRIVIAL 
AJ I-TRIVIAL 
causes O 
centrosome O 
separation O 
and O 
disjunction O 
failure O 
to O 
a O 
much O 
greater O 
extent O 
than O 
paclitaxel B-TRIVIAL 
or O 
laulimalide B-TRIVIAL 
, O 
which O 
is O 
consistent O 
with O 
the O 
distinct O 
defects O 
in O 
expression O 
and O 
activation O 
of O 
Plk1 O 
and O 
Eg5 O 
caused O 
by O 
each O 
stabilizer O 
. O 
Localization O 
studies O 
revealed O 
that O 
TPX2 O 
and O 
Aurora O 
A O 
are O 
associated O 
with O 
each O 
spindle O 
aster O 
formed O 
by O 
each O 
stabilizer O 
. O 
This O 
suggests O 
a O 
common O 
mechanism O 
of O 
aster O 
formation O 
. O 
However O 
, O 
taccalonolide B-TRIVIAL 
AJ I-TRIVIAL 
also O 
causes O 
pericentrin O 
accumulation O 
on O 
every O 
spindle O 
aster O 
. O 
The O 
presence O 
of O 
pericentrin O 
at O 
every O 
spindle O 
aster O 
initiated O 
by O 
taccalonolide B-TRIVIAL 
AJ I-TRIVIAL 
might O 
facilitate O 
the O 
maintenance O 
and O 
stability O 
of O 
the O 
highly O 
focused O 
asters O 
formed O 
by O 
this O 
stabilizer O 
. O 
Laulimalide B-TRIVIAL 
and O 
paclitaxel B-TRIVIAL 
cause O 
completely O 
different O 
patterns O 
of O 
expression O 
and O 
activation O 
of O 
these O 
proteins O 
, O 
as O 
well O 
as O 
phenotypically O 
different O 
spindle O 
phenotypes O 
. O 
Delineating O 
how O 
diverse O 
microtubule O 
stabilizers O 
affect O 
mitotic O 
signaling O 
pathways O 
could O 
identify O 
key O 
proteins O 
involved O 
in O 
modulating O 
sensitivity O 
and O 
resistance O 
to O 
the O 
antimitotic O 
actions O 
of O 
these O 
compounds O 
. O 

and O 
screening O 
of O 
a O 
multi O 
- O 
family O 
bacterial O 
oxidoreductase O 
library O 
to O 
discover O 
novel O 
nitroreductases O 
that O 
efficiently O 
activate O 
the O 
bioreductive O 
prodrugs O 
CB1954 B-IDENTIFIER 
and O 
PR-104A B-IDENTIFIER 
. O 

potentially O 
complementary O 
approaches O 
to O 
improve O 
the O 
anti-cancer O 
strategy O 
gene O 
- O 
directed O 
enzyme O 
prodrug O 
therapy O 
( O 
GDEPT O 
) O 
are O 
discovery O 
of O 
more O 
efficient O 
prodrug O 
- O 
activating O 
enzymes O 
, O 
and O 
development O 
of O 
more O 
effective O 
prodrugs O 
. O 
Here O 
we O 
demonstrate O 
the O 
utility O 
of O 
a O 
flexible O 
screening O 
system O 
based O 
on O 
the O 
Escherichia O 
coli O 
SOS O 
response O 
to O 
evaluate O 
novel O 
nitroreductase O 
enzymes O 
and O 
prodrugs O 
in O 
concert O 
. O 
To O 
achieve O 
this O 
, O 
a O 
library O 
of O 
47 O 
candidate O 
genes O 
representing O 
11 O 
different O 
oxidoreductase O 
families O 
was O 
created O 
and O 
screened O 
to O 
identify O 
the O 
most O 
efficient O 
activators O 
of O 
two O 
different O 
nitroaromatic O 
prodrugs O 
, O 
CB1954 B-IDENTIFIER 
and O 
PR-104A B-IDENTIFIER 
. O 
The O 
most O 
catalytically O 
efficient O 
nitroreductases O 
were O 
found O 
in O 
the O 
NfsA O 
and O 
NfsB O 
enzyme O 
families O 
, O 
with O 
NfsA O 
homologues O 
generally O 
more O 
active O 
than O 
NfsB O 
. O 
Some O 
members O 
of O 
the O 
AzoR O 
, O 
NemA O 
and O 
MdaB O 
families O 
also O 
exhibited O 
low O 
- O 
level O 
activity O 
with O 
one O 
or O 
both O 
prodrugs O 
. O 
The O 
results O 
of O 
SOS O 
screening O 
in O 
our O 
optimised O 
E O 
. O 
coli O 
reporter O 
strain O 
SOS-R2 O 
were O 
generally O 
predictive O 
of O 
the O 
ability O 
of O 
nitroreductase O 
candidates O 
to O 
sensitise O 
E O 
. O 
coli O 
to O 
CB1954 B-IDENTIFIER 
, O 
and O 
of O 
the O 
kcat O 
/ O 
Km O 
for O 
each O 
prodrug O 
substrate O 
at O 
a O 
purified O 
protein O 
level O 
. O 
However O 
, O 
we O 
also O 
found O 
that O 
not O 
all O 
nitroreductases O 
express O 
stably O 
in O 
human O 
( O 
HCT-116 O 
colon O 
carcinoma O 
) O 
cells O 
, O 
and O 
that O 
activity O 
at O 
a O 
purified O 
protein O 
level O 
did O 
not O 
necessarily O 
predict O 
activity O 
in O 
stably O 
transfected O 
HCT-116 O 
. O 
These O 
results O 
highlight O 
a O 
need O 
for O 
all O 
enzyme O 
- O 
prodrug O 
partners O 
for O 
GDEPT O 
to O 
be O 
assessed O 
in O 
the O 
specific O 
context O 
of O 
the O 
vector O 
and O 
cell O 
line O 
that O 
they O 
are O 
intended O 
to O 
target O 
. O 
Nonetheless O 
, O 
our O 
oxidoreductase O 
library O 
and O 
optimised O 
screens O 
provide O 
valuable O 
tools O 
to O 
identify O 
preferred O 
nitroreductase O 
- O 
prodrug O 
combinations O 
to O 
advance O 
to O 
preclinical O 
evaluation O 
. O 

importance O 
of O 
the O 
TiO2 B-FORMULA 
/ O 
quantum O 
dots O 
interface O 
in O 
the O 
recombination O 
processes O 
of O 
quantum O 
dot O 
sensitized O 
solar O 
cells O 
. O 

dot O 
sensitized O 
solar O 
cells O 
( O 
QDSSCs O 
) O 
present O 
a O 
promising O 
technology O 
for O 
next O 
generation O 
photovoltaic O 
cells O 
, O 
having O 
exhibited O 
a O 
considerable O 
leap O 
in O 
performance O 
over O 
the O 
last O 
few O 
years O 
. O 
However O 
, O 
recombination O 
processes O 
occurring O 
in O 
parallel O 
at O 
the O 
TiO(2) B-FORMULA 
-QDs-electrolyte O 
triple O 
junction O 
constitute O 
one O 
of O 
the O 
major O 
limitations O 
for O 
further O 
improvement O 
of O 
QDSSCs O 
. O 
Reaching O 
higher O 
conversion O 
efficiencies O 
necessitates O 
gaining O 
a O 
better O 
understanding O 
of O 
the O 
mechanisms O 
of O 
charge O 
recombination O 
in O 
these O 
kinds O 
of O 
cells O 
; O 
this O 
will O 
essentially O 
lead O 
to O 
the O 
development O 
of O 
new O 
solutions O 
for O 
inhibiting O 
the O 
described O 
losses O 
. O 
In O 
this O 
study O 
we O 
have O 
systematically O 
examined O 
the O 
contribution O 
of O 
each O 
interface O 
formed O 
at O 
the O 
triple O 
junction O 
to O 
the O 
recombination O 
of O 
the O 
solar O 
cell O 
. O 
We O 
show O 
that O 
the O 
recombination O 
of O 
electrons O 
at O 
the O 
TiO(2) B-FORMULA 
/ O 
QDs O 
interface O 
is O 
as O 
important O 
as O 
the O 
recombination O 
from O 
TiO(2) B-FORMULA 
and O 
QDs O 
to O 
the O 
electrolyte O 
. O 
By O 
applying O 
conformal O 
MgO B-FORMULA 
coating O 
both O 
above O 
and O 
below O 
the O 
QD O 
surface O 
, O 
recombination O 
rates O 
were O 
significantly O 
reduced O 
, O 
and O 
an O 
improvement O 
of O 
more O 
than O 
20% O 
in O 
cell O 
efficiency O 
was O 
recorded O 
. O 

- O 
templating O 
synthesis O 
of O 
hollow O 
mesoporous O 
silica B-TRIVIAL 
and O 
their O 
applications O 
in O 
catalysis O 
and O 
drug O 
delivery O 
. O 

mesoporous O 
silica B-TRIVIAL 
materials O 
have O 
been O 
intensively O 
pursued O 
because O 
of O 
their O 
unique O 
properties O 
for O 
various O 
applications O 
. O 
Yolk O 
/ O 
shell O 
structured O 
hollow O 
mesoporous O 
silica B-TRIVIAL 
with O 
functional O 
cores O 
inside O 
their O 
hollow O 
interior O 
can O 
further O 
broaden O 
the O 
applications O 
of O 
hollow O 
mesoporous O 
silica B-TRIVIAL 
. O 
The O 
self O 
- O 
templating O 
strategy O 
has O 
been O 
developed O 
as O 
one O 
of O 
the O 
most O 
important O 
strategies O 
to O 
effectively O 
fabricate O 
hollow O 
mesoporous O 
silicas O 
and O 
their O 
yolk O 
/ O 
shell O 
counterparts O 
. O 
In O 
this O 
feature O 
article O 
, O 
we O 
provide O 
an O 
overview O 
of O 
advances O 
in O 
the O 
self O 
- O 
templating O 
synthesis O 
of O 
hollow O 
mesoporous O 
silica B-TRIVIAL 
based O 
on O 
the O 
following O 
three O 
strategies O 
: O 
surface O 
- O 
protected O 
etching O 
, O 
structural O 
difference O 
- O 
based O 
selective O 
etching O 
, O 
and O 
cationic O 
surfactant O 
assisted O 
self O 
- O 
templating O 
. O 
We O 
then O 
discuss O 
some O 
important O 
applications O 
of O 
these O 
self O 
- O 
templating O 
strategy O 
- O 
derived O 
hollow O 
mesoporous O 
silicas B-TRIVIAL 
, O 
such O 
as O 
nanoreactors O 
for O 
confined O 
catalysis O 
and O 
multifunctional O 
platforms O 
for O 
combined O 
therapy O 
. O 
Finally O 
, O 
some O 
perspectives O 
for O 
the O 
future O 
development O 
of O 
this O 
active O 
research O 
field O 
are O 
provided O 
. O 

of O 
Escherichia O 
coli O 
: O 
the O 
ε- O 
inhibited O 
state O 
forms O 
after O 
ATP B-ABBREVIATION 
hydrolysis O 
, O 
is O 
distinct O 
from O 
the O 
ADP B-ABBREVIATION 
-inhibited O 
state O 
, O 
and O 
responds O 
dynamically O 
to O 
catalytic O 
site O 
ligands O 
. O 

is O 
the O 
catalytic O 
complex O 
of O 
rotary O 
nanomotor O 
ATP B-ABBREVIATION 
synthases O 
. O 
Bacterial O 
ATP B-ABBREVIATION 
synthases O 
can O 
be O 
autoinhibited O 
by O 
the O 
C B-FORMULA 
-terminal O 
domain O 
of O 
subunit O 
ε O 
, O 
which O 
partially O 
inserts O 
into O 
the O 
enzyme's O 
central O 
rotor O 
cavity O 
to O 
block O 
functional O 
subunit O 
rotation O 
. O 
Using O 
a O 
kinetic O 
, O 
optical O 
assay O 
of O 
F1·ε O 
binding O 
and O 
dissociation O 
, O 
we O 
show O 
that O 
formation O 
of O 
the O 
extended O 
, O 
inhibitory O 
conformation O 
of O 
ε O 
( O 
εX O 
) O 
initiates O 
after O 
ATP B-ABBREVIATION 
hydrolysis O 
at O 
the O 
catalytic O 
dwell O 
step O 
. O 
Prehydrolysis O 
conditions O 
prevent O 
formation O 
of O 
the O 
εX O 
state O 
, O 
and O 
post O 
- O 
hydrolysis O 
conditions O 
stabilize O 
it O 
. O 
We O 
also O 
show O 
that O 
ε O 
inhibition O 
and O 
ADP B-ABBREVIATION 
inhibition O 
are O 
distinct O 
, O 
competing O 
processes O 
that O 
can O 
follow O 
the O 
catalytic O 
dwell O 
. O 
We O 
show O 
that O 
the O 
N B-FORMULA 
-terminal O 
domain O 
of O 
ε O 
is O 
responsible O 
for O 
initial O 
binding O 
to O 
F1 O 
and O 
provides O 
most O 
of O 
the O 
binding O 
energy O 
. O 
Without O 
the O 
C B-FORMULA 
-terminal O 
domain O 
, O 
partial O 
inhibition O 
by O 
the O 
ε O 
N B-FORMULA 
-terminal O 
domain O 
is O 
due O 
to O 
enhanced O 
ADP B-ABBREVIATION 
inhibition O 
. O 
The O 
rapid O 
effects O 
of O 
catalytic O 
site O 
ligands O 
on O 
conformational O 
changes O 
of O 
F1 O 
- O 
bound O 
ε O 
suggest O 
dynamic O 
conformational O 
and O 
rotational O 
mobility O 
in O 
F1 O 
that O 
is O 
paused O 
near O 
the O 
catalytic O 
dwell O 
position O 
. O 

relevant O 
concentrations O 
of O 
organotin B-FAMILY 
compounds O 
( O 
OTs O 
) O 
may O 
trigger O 
sex O 
changes O 
in O 
marine O 
invertebrates O 
and O 
pose O 
a O 
threat O 
to O 
the O 
marine O 
ecosystem O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
organotin B-FAMILY 
levels O 
and O 
the O 
biological O 
responses O 
of O 
wild O 
veined O 
rapa O 
whelk O 
( O 
Rapana O 
venosa O 
) O 
from O 
Lüjuhe O 
district O 
( O 
LJH O 
) O 
, O 
Dashentang O 
district O 
( O 
DST O 
) O 
, O 
and O 
Nanpaihe O 
district O 
( O 
NPH O 
) O 
in O 
Bohai O 
Bay O 
, O 
China O 
. O 
We O 
found O 
that O 
11.11 O 
and O 
22.95 O 
% O 
of O 
the O 
veined O 
rapa O 
whelks O 
from O 
DST O 
and O 
NPH O 
exhibited O 
imposex O 
characteristics O 
with O 
a O 
relative O 
penis O 
size O 
index O 
( O 
RPSI O 
) O 
of O 
12.5 O 
and O 
12.31 O 
, O 
respectively O 
. O 
The O 
RNA O 
/ O 
DNA O 
ratio O 
was O 
significantly O 
lower O 
in O 
females O 
from O 
DST O 
than O 
those O 
from O 
LJH O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
and O 
a O 
slight O 
increase O 
in O 
DNA O 
damage O 
was O 
observed O 
in O 
females O 
and O 
imposex O 
individuals O 
compared O 
to O 
males O 
. O 
Moreover O 
, O 
less O 
genetic O 
distance O 
occurred O 
between O 
LJH O 
and O 
NPH O 
( O 
0.016 O 
) O 
than O 
between O 
LJH O 
and O 
DST O 
( O 
0.028 O 
) O 
, O 
although O 
they O 
belonged O 
to O 
the O 
same O 
regional O 
population O 
. O 
OTs O 
analysis O 
showed O 
that O 
triphenyltin B-SYSTEMATIC 
chloride I-SYSTEMATIC 
concentrations O 
( O 
41.45 O 
ng O 
/ O 
g O 
dried O 
weight O 
) O 
were O 
significantly O 
higher O 
than O 
tributyltin B-SYSTEMATIC 
concentrations O 
( O 
9.51 O 
ng O 
/ O 
g O 
dried O 
weight O 
) O 
in O 
tissues O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
but O 
no O 
significant O 
differences O 
were O 
observed O 
in O 
sediments O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
the O 
occurrence O 
of O 
imposex O 
individuals O 
and O 
biological O 
responses O 
of O 
the O 
wild O 
veined O 
rapa O 
whelk O 
from O 
Bohai O 
Bay O 
suggest O 
that O 
the O 
marine O 
ecosystem O 
might O 
be O 
at O 
risk O 
. O 

accumulation O 
of O 
metal O 
( O 
Co B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Mn B-FORMULA 
and O 
Zn B-FORMULA 
) O 
in O 
freshwater O 
Ulva O 
( O 
Chlorophyta O 
) O 
and O 
its O 
habitat O 
. O 

possibility O 
of O 
using O 
freshwater O 
Ulva O 
( O 
Chlorophyta O 
) O 
as O 
a O 
bioaccumulator O 
of O 
metals O 
( O 
Co B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Mn B-FORMULA 
and O 
Zn B-FORMULA 
) O 
in O 
lake O 
and O 
river O 
water O 
was O 
examined O 
weekly O 
in O 
the O 
summer O 
of O 
2010 O 
in O 
three O 
types O 
of O 
samples O 
: O 
the O 
water O 
, O 
the O 
sediment O 
and O 
the O 
thalli O 
of O 
Ulva O 
. O 
Samples O 
of O 
freshwater O 
Ulva O 
were O 
collected O 
from O 
two O 
aqueous O 
ecosystems O 
lie O 
250 O 
km O 
away O 
from O 
the O 
basin O 
of O 
the O 
Baltic O 
Sea O 
and O 
53 O 
km O 
from O 
each O 
other O 
. O 
A O 
flow O 
lake O 
located O 
in O 
the O 
centre O 
of O 
the O 
big O 
city O 
was O 
the O 
first O 
water O 
reservoir O 
( O 
ten O 
sites O 
) O 
and O 
second O 
, O 
the O 
suburban O 
river O 
( O 
six O 
sites O 
) O 
. O 
The O 
mean O 
metal O 
concentrations O 
in O 
the O 
Ulva O 
tissue O 
from O 
the O 
river O 
and O 
the O 
lake O 
decreased O 
in O 
the O 
following O 
order O 
: O 
Mn B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Cr B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Co B-FORMULA 
and O 
Mn B-FORMULA 
> O 
Cr B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Co B-FORMULA 
, O 
respectively O 
. O 
Moreover O 
, O 
a O 
negative O 
and O 
statistically O 
significant O 
correlation O 
between O 
Mn B-FORMULA 
concentrations O 
in O 
the O 
Ulva O 
thalli O 
and O 
the O 
river O 
water O 
was O 
observed O 
. O 
Additionally O 
, O 
numerous O 
correlations O 
were O 
noted O 
between O 
the O 
different O 
concentrations O 
of O 
metals O 
within O 
the O 
Ulva O 
thalli O 
, O 
in O 
the O 
water O 
and O 
in O 
the O 
sediment O 
. O 
The O 
great O 
concentrations O 
of O 
Mn B-FORMULA 
and O 
Zn B-FORMULA 
and O 
the O 
smallest O 
of O 
Co B-FORMULA 
were O 
found O 
in O 
thalli O 
of O 
Ulva O 
, O 
irrespective O 
of O 
the O 
type O 
of O 
the O 
ecosystem O 
from O 
which O 
samples O 
of O 
algal O 
thalli O 
originated O 
. O 
Freshwater O 
Ulva O 
populations O 
examined O 
in O 
this O 
study O 
were O 
clearly O 
characterized O 
a O 
dozen O 
or O 
so O 
times O 
by O 
the O 
higher O 
Mn B-FORMULA 
and O 
Cr B-FORMULA 
accumulation O 
than O 
taxa O 
from O 
that O 
genera O 
coming O 
from O 
sea O 
ecosystems O 
. O 
The O 
calculated O 
bioconcentration O 
factor O 
confirm O 
the O 
high O 
potential O 
for O 
freshwater O 
Ulva O 
to O 
be O 
a O 
bioaccumulator O 
of O 
trace O 
metals O 
in O 
freshwater O 
ecosystems O 
. O 

neurotoxin O 
( O 
BoNT O 
) O 
is O 
an O 
acetylcholine B-SYSTEMATIC 
release O 
inhibitor O 
and O 
a O 
neuromuscular O 
- O 
blocking O 
agent O 
used O 
for O 
the O 
treatment O 
of O 
a O 
variety O 
of O 
medical O 
and O 
cosmetic O 
indications O 
. O 
Currently O 
, O 
in O 
the O 
United O 
States O 
, O 
there O 
are O 
four O 
BoNT O 
formulations O 
licensed O 
for O 
use O 
: O 
abobotulinumtoxinA O 
, O 
incobotulinumtoxinA O 
, O 
onabotulinumtoxinA O 
, O 
and O 
rimabotulinumtoxinB O 
. O 
These O 
revised O 
name O 
designations O 
were O 
established O 
to O 
reinforce O 
the O 
understanding O 
that O 
each O 
BoNT O 
product O 
has O 
an O 
individual O 
potency O 
and O 
is O 
not O 
interchangeable O 
with O 
any O 
other O 
BoNT O 
product O 
. O 
The O 
therapeutic O 
use O 
of O 
BoNTs O 
is O 
expanding O 
and O 
new O 
formulations O 
are O 
on O 
the O 
horizon O 
. O 
This O 
article O 
is O 
a O 
primer O 
that O 
describes O 
distinctions O 
among O 
currently O 
available O 
, O 
licensed O 
BoNT O 
formulations O 
. O 
Toxin O 
pharmacology O 
, O 
product O 
characteristics O 
, O 
storage O 
, O 
handling O 
, O 
preparation O 
, O 
and O 
dosages O 
will O 
be O 
reviewed O 
. O 
In O 
addition O 
, O 
issues O 
related O 
to O 
dose O 
equivalency O 
ratios O 
, O 
immunogenicity O 
, O 
potency O 
, O 
and O 
toxin O 
spread O 
will O 
be O 
discussed O 
. O 
Therapeutic O 
indications O 
and O 
safety O 
are O 
discussed O 
briefly O 
. O 
Knowledge O 
of O 
the O 
available O 
and O 
licensed O 
BoNT O 
formulations O 
and O 
the O 
ability O 
to O 
make O 
distinctions O 
in O 
toxin O 
pharmacology O 
, O 
product O 
characteristics O 
, O 
and O 
indications O 
are O 
vital O 
for O 
product O 
selection O 
, O 
preparation O 
, O 
drug O 
information O 
, O 
avoidance O 
of O 
drug O 
errors O 
, O 
quality O 
assurance O 
, O 
and O 
patient O 
safety O 
. O 

and O 
biomagnification O 
of O 
mercury B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
in O 
the O 
sarasota O 
bay O 
ecosystem O 
. O 

bioaccumulation O 
and O 
biomagnification O 
of O 
Hg B-FORMULA 
and O 
Se B-FORMULA 
were O 
investigated O 
in O 
Sarasota O 
Bay O 
, O 
Florida O 
, O 
USA O 
, O 
to O 
characterize O 
the O 
Hg B-FORMULA 
exposure O 
risks O 
to O 
wild O 
bottlenose O 
dolphins O 
in O 
the O 
bay O 
. O 
Concentrations O 
of O 
total O 
mercury B-SYSTEMATIC 
( O 
THg O 
) O 
, O 
monomethylmercury B-SYSTEMATIC 
( O 
MMHg B-FORMULA 
) O 
, O 
and O 
total O 
selenium B-SYSTEMATIC 
( O 
TSe O 
) O 
were O 
monitored O 
in O 
the O 
bay O 
, O 
the O 
latter O 
of O 
which O 
might O 
reduce O 
Hg B-FORMULA 
toxicity O 
. O 
The O 
food O 
web O 
structure O 
and O 
dolphins O 
' O 
trophic O 
level O 
- O 
specific O 
consumption O 
rates O 
were O 
evaluated O 
using O 
stable O 
isotope O 
ratios O 
of O 
carbon B-SYSTEMATIC 
( O 
δ O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
) O 
and O 
nitrogen B-SYSTEMATIC 
( O 
δ O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
) O 
. O 
Regressions O 
developed O 
for O 
Hg B-FORMULA 
biomagnification O 
in O 
the O 
food O 
chain O 
were O 
log10 O 
CTHg O 
( O 
nanograms O 
per O 
gram) O 
= O 
0.27 O 
× O 
δ O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
( O 
‰ O 
) O 
- O 
0.42 O 
, O 
R(2) O 
= O 
0.87 O 
, O 
for O 
THg O 
and O 
log10 O 
CMMHg O 
= O 
0.33 O 
× O 
δ O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
( O 
‰ O 
) O 
- O 
1 O 
, O 
R(2) O 
= O 
0.93 O 
, O 
for O 
MMHg B-FORMULA 
. O 
Unlike O 
Hg B-FORMULA 
, O 
nearly O 
constant O 
TSe O 
concentrations O 
were O 
observed O 
at O 
248 O 
± O 
179 O 
ng O 
g(-1) O 
in O 
the O 
food O 
web O 
, O 
and O 
the O 
TSe-to-THg O 
molar O 
ratio O 
was O 
predicted O 
by O 
log10 O 
( O 
CTSe O 
/ O 
CTHg O 
) O 
= O 
-0.1 O 
× O 
δ O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
(‰) O 
+ O 
2.8 O 
, O 
R(2) O 
= O 
0.6 O 
. O 
The O 
THg-uptake O 
rates O 
of O 
Sarasota O 
bottlenose O 
dolphins O 
are O 
estimated O 
to O 
vary O 
between O 
2.1 O 
and O 
4.9 O 
µg O 
kg(-1) O 
d(-1) O 
; O 
however O 
, O 
the O 
estimated O 
TSe-uptake O 
rates O 
( O 
15.1 O 
µg O 
kg(-1) O 
d(-1) O 
) O 
were O 
higher O 
than O 
those O 
for O 
THg O 
, O 
and O 
the O 
Hg B-FORMULA 
-exposure O 
risks O 
of O 
the O 
Sarasota O 
Bay O 
resident O 
bottlenose O 
dolphins O 
are O 
considered O 
to O 
be O 
low O 
. O 
Approaches O 
employed O 
in O 
the O 
present O 
study O 
can O 
be O 
extended O 
to O 
other O 
environments O 
to O 
characterize O 
Hg B-FORMULA 
contamination O 
in O 
aquatic O 
systems O 
and O 
Hg B-FORMULA 
exposure O 
risks O 
in O 
top O 
predators O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1143-1152 O 
. O 
© O 
2013 O 
SETAC O 
. O 

are O 
a O 
frequent O 
complication O 
associated O 
with O 
several O 
neurogenetic O 
disorders O 
. O 
Antiepileptic O 
medications O 
remain O 
the O 
mainstay O 
of O 
treatment O 
in O 
these O 
patients O 
. O 
We O 
summarized O 
the O 
available O 
data O 
associated O 
with O 
various O 
antiepileptic O 
therapies O 
used O 
to O 
treat O 
patients O 
with O 
neurogenetic O 
disorders O 
who O 
experienced O 
recurrent O 
seizures O 
. O 
A O 
MEDLINE O 
search O 
was O 
conducted O 
to O 
identify O 
articles O 
and O 
abstracts O 
describing O 
the O 
use O 
of O 
antiepileptic O 
therapy O 
for O 
the O 
treatment O 
of O 
various O 
neurogenetic O 
syndromes O 
. O 
Of O 
all O 
the O 
neurogenetic O 
syndromes O 
, O 
only O 
autism O 
spectrum O 
disorders O 
, O 
Angelman O 
syndrome O 
, O 
Rett O 
syndrome O 
, O 
Dravet O 
syndrome O 
, O 
and O 
tuberous O 
sclerosis O 
complex O 
were O 
identified O 
as O 
having O 
sufficient O 
published O 
information O 
to O 
evaluate O 
therapy O 
. O 
Some O 
efficacy O 
trends O 
were O 
identified O 
, O 
including O 
frequent O 
successes O 
with O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
with O 
clonazepam B-TRIVIAL 
for O 
epilepsy O 
with O 
Angelman O 
syndrome O 
; O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
stiripentol B-TRIVIAL 
, O 
and O 
clobazam B-TRIVIAL 
( O 
triple O 
combination O 
therapy O 
) O 
for O 
epilepsy O 
with O 
Dravet O 
syndrome O 
; O 
and O 
vigabatrin B-TRIVIAL 
for O 
infantile O 
spasms O 
associated O 
with O 
tuberous O 
sclerosis O 
complex O 
. O 
Due O 
to O 
a O 
paucity O 
of O 
information O 
regarding O 
the O 
mechanisms O 
by O 
which O 
seizures O 
are O 
generated O 
in O 
the O 
various O 
disorders O 
, O 
approach O 
to O 
seizure O 
control O 
is O 
primarily O 
based O 
on O 
clinical O 
experience O 
and O 
a O 
limited O 
amount O 
of O 
study O 
data O 
exploring O 
patient O 
outcomes O 
. O 
Although O 
exposure O 
of O 
the O 
developing O 
brain O 
to O 
antiepileptic O 
medications O 
is O 
of O 
some O 
concern O 
, O 
the O 
control O 
of O 
epileptic O 
activity O 
is O 
an O 
important O 
undertaking O 
in O 
these O 
individuals O 
, O 
as O 
the O 
severity O 
of O 
eventual O 
developmental O 
delay O 
often O 
appears O 
to O 
correlate O 
with O 
the O 
severity O 
of O 
seizures O 
. O 
As O 
such O 
, O 
early O 
aggressive O 
therapy O 
is O 
warranted O 
. O 

and O 
toxicokinetics O 
of O 
binary O 
combinations O 
of O 
petroleum B-FAMILY 
hydrocarbon I-FAMILY 
distillates O 
with O 
the O 
earthworm O 
Eisenia O 
andrei O 
. O 

hydrocarbons I-FAMILY 
( O 
PHCs B-ABBREVIATION 
) O 
act O 
via O 
narcosis O 
and O 
are O 
expected O 
to O 
have O 
additive O 
toxicity O 
. O 
However O 
, O 
previous O 
work O 
has O 
demonstrated O 
less O 
- O 
than O 
- O 
additive O 
toxicity O 
with O 
PHC B-ABBREVIATION 
distillates O 
and O 
earthworms O 
. O 
A O 
study O 
was O 
initiated O 
to O 
investigate O 
this O 
through O 
toxicity O 
and O 
toxicokinetic O 
studies O 
with O 
the O 
earthworm O 
Eisenia O 
andrei O 
. O 
Three O 
petroleum O 
distillate O 
fractions O 
, O 
F2 O 
( O 
> O 
C10-C16 B-MULTIPLE 
) O 
, O 
F3a O 
( O 
> O 
C16-C23 B-MULTIPLE 
) O 
, O 
and O 
F3b O 
( O 
> O 
C23-C34 B-MULTIPLE 
) O 
, O 
were O 
used O 
in O 
two O 
binary O 
combinations O 
, O 
F2F3a O 
and O 
F3aF3b O 
. O 
In O 
the O 
toxicity O 
study O 
, O 
clean O 
soil O 
was O 
spiked O 
with O 
equitoxic O 
combinations O 
of O 
the O 
two O 
distillates O 
ranging O 
from O 
0.5 O 
to O 
2.5 O 
toxic O 
units O 
. O 
In O 
the O 
toxicokinetic O 
study O 
, O 
a O 
binary O 
combination O 
consisting O 
of O 
one O 
concentration O 
of O 
each O 
distillate O 
was O 
used O 
. O 
On O 
a O 
soil O 
concentration O 
basis O 
, O 
the O 
toxicity O 
of O 
the O 
binary O 
combinations O 
of O 
distillates O 
was O 
less O 
than O 
additive O 
. O 
Accumulation O 
of O 
the O 
individual O 
distillates O 
, O 
however O 
, O 
was O 
generally O 
reduced O 
when O 
a O 
second O 
distillate O 
was O 
present O 
, O 
resulting O 
in O 
lower O 
body O 
burden O 
. O 
This O 
is O 
thought O 
to O 
be O 
due O 
to O 
the O 
presence O 
of O 
a O 
nonaqueous O 
- O 
phase O 
liquid O 
at O 
the O 
soil O 
concentrations O 
used O 
. O 
On O 
a O 
tissue O 
concentration O 
basis O 
, O 
toxicity O 
was O 
closer O 
to O 
additive O 
. O 
The O 
results O 
demonstrate O 
that O 
tissue O 
concentrations O 
are O 
the O 
preferred O 
metric O 
for O 
toxicity O 
for O 
earthworms O 
. O 
They O 
also O 
demonstrate O 
that O 
the O 
Canada O 
- O 
wide O 
soil O 
standards O 
based O 
on O 
individual O 
distillates O 
are O 
likely O 
protective O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1016-1026 O 
. O 
© O 
2013 O 
SETAC O 
. O 

and O 
intraspecific O 
variation O 
in O 
mercury B-SYSTEMATIC 
bioaccumulation O 
by O 
snakes O 
inhabiting O 
a O 
contaminated O 
river O 
floodplain O 
. O 

mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
is O 
a O 
well O 
- O 
studied O 
contaminant O 
, O 
knowledge O 
about O 
Hg B-FORMULA 
accumulation O 
in O 
snakes O 
is O 
limited O 
. O 
The O 
authors O 
evaluated O 
Hg B-FORMULA 
bioaccumulation O 
within O 
and O 
among O 
four O 
snake O 
species O 
( O 
northern O 
watersnakes O 
, O 
Nerodia O 
sipedon O 
; O 
queen O 
snakes O 
, O 
Regina O 
septemvittata O 
; O 
common O 
garter O 
snakes O 
, O 
Thamnophis O 
sirtalis O 
; O 
and O 
rat O 
snakes O 
, O 
Elaphe O 
obsoleta O 
[ O 
Pantherophis O 
alleghaniensis O 
] O 
) O 
from O 
a O 
contaminated O 
site O 
on O 
the O 
South O 
River O 
( O 
Waynesboro O 
, O 
VA O 
, O 
USA O 
) O 
and O 
two O 
nearby O 
reference O 
sites O 
. O 
Total O 
Hg B-FORMULA 
( O 
THg O 
) O 
concentrations O 
in O 
northern O 
watersnake O 
tail O 
tissue O 
at O 
the O 
contaminated O 
site O 
ranged O 
from O 
2.25 O 
to O 
13.84 O 
mg O 
/ O 
kg O 
dry O 
weight O 
( O 
mean O 
: O 
4.85 O 
± O 
0.29 O 
) O 
, O 
or O 
11 O 
to O 
19 O 
times O 
higher O 
than O 
reference O 
sites O 
. O 
Blood O 
THg O 
concentrations O 
( O 
0.03-7.04 O 
mg O 
/ O 
kg O 
wet O 
wt O 
; O 
mean O 
: O 
2.24 O 
± O 
0.42 O 
) O 
were O 
strongly O 
correlated O 
with O 
tail O 
concentrations O 
and O 
were O 
the O 
highest O 
yet O 
reported O 
in O 
a O 
snake O 
species O 
. O 
Within O 
watersnakes O 
, O 
nitrogen B-SYSTEMATIC 
stable O 
isotope O 
values O 
indicated O 
ontogenetic O 
trophic O 
shifts O 
that O 
correlated O 
with O 
THg O 
bioaccumulation O 
, O 
suggesting O 
that O 
diet O 
plays O 
a O 
substantial O 
role O 
in O 
Hg B-FORMULA 
exposure O 
. O 
Female O 
watersnakes O 
had O 
higher O 
mean O 
THg O 
concentrations O 
( O 
5.67 O 
± O 
0.46 O 
mg O 
/ O 
kg O 
) O 
than O 
males O 
( O 
4.93 O 
± O 
0.49 O 
mg O 
/ O 
kg O 
) O 
, O 
but O 
no O 
significant O 
differences O 
between O 
sexes O 
were O 
observed O 
after O 
correcting O 
for O 
body O 
size O 
. O 
Interspecific O 
comparisons O 
identified O 
differences O 
in O 
THg O 
concentrations O 
among O 
snake O 
species O 
, O 
with O 
more O 
aquatic O 
species O 
( O 
watersnakes O 
and O 
queen O 
snakes O 
) O 
accumulating O 
higher O 
mean O 
concentrations O 
( O 
5.6 O 
± O 
0.4 O 
and O 
4.59 O 
± O 
0.38 O 
mg O 
/ O 
kg O 
in O 
tail O 
tissue O 
, O 
respectively O 
) O 
than O 
the O 
more O 
terrestrial O 
species O 
, O 
garter O 
snakes O 
and O 
rat O 
snakes O 
( O 
1.28 O 
± O 
0.32 O 
and O 
0.26 O 
± O 
0.09 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
warrant O 
further O 
investigation O 
of O 
potential O 
adverse O 
effects O 
and O 
will O 
aid O 
in O 
prioritizing O 
conservation O 
efforts O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1178-1186 O 
. O 
© O 
2013 O 
SETAC O 
. O 

consist O 
of O 
three O 
dimensionally O 
cross O 
- O 
linked O 
hydrophilic O 
polymer O 
chains O 
and O 
can O 
thus O 
be O 
easily O 
modified O 
through O 
functionalization O 
of O 
the O 
polymeric O 
building O 
blocks O 
, O 
for O 
example O 
to O 
yield O 
stimuli O 
- O 
sensitive O 
materials O 
. O 
For O 
drug O 
transport O 
and O 
intracellular O 
release O 
, O 
redox O 
- O 
sensitive O 
systems O 
are O 
especially O 
of O 
interest O 
, O 
as O 
the O 
intracellular O 
space O 
is O 
reductive O 
. O 
In O 
this O 
study O 
, O 
parameters O 
that O 
allow O 
preparation O 
of O 
nanogels O 
with O 
tunable O 
size O 
between O 
150 O 
and O 
350 O 
nm O 
are O 
systematically O 
evaluated O 
and O 
identified O 
. O 
Most O 
importantly O 
, O 
a O 
new O 
and O 
mild O 
oxidation O 
catalyst O 
, O 
alloxan B-TRIVIAL 
, O 
is O 
introduced O 
for O 
the O 
preparation O 
of O 
the O 
nanogels O 
. O 
This O 
broadens O 
the O 
range O 
of O 
possible O 
payloads O 
to O 
more O 
- O 
sensitive O 
molecules O 
. O 
Particle O 
stability O 
, O 
degradation O 
in O 
cytosolic O 
conditions O 
, O 
and O 
cytocompatibility O 
in O 
concentrations O 
up O 
to O 
10 O 
mg O 
· O 
mL(-1) O 
are O 
demonstrated O 
. O 

OF O 
C60 B-TRIVIAL 
FULLERENES B-FAMILY 
ON O 
THE O 
ACCUMULATION O 
OF O 
WEATHERED O 
p,p'-DDE B-SYSTEMATIC 
BY O 
PLANT O 
AND O 
EARTHWORM O 
SPECIES O 
UNDER O 
SINGLE O 
AND O 
MULTISPECIES O 
CONDITIONS O 
. O 

use O 
of O 
engineered O 
nanomaterials O 
has O 
increased O 
dramatically O 
in O 
recent O 
years O 
, O 
but O 
an O 
understanding O 
of O 
nanomaterial O 
fate O 
and O 
effects O 
in O 
the O 
environment O 
is O 
lacking O 
. O 
In O 
particular O 
, O 
the O 
interaction O 
of O 
nanomaterials O 
with O 
coexisting O 
organic O 
contaminants O 
and O 
the O 
subsequent O 
implications O 
for O 
sensitive O 
biota O 
is O 
almost O 
completely O 
unknown O 
. O 
Here O 
, O 
the O 
effect O 
of O 
C60 B-TRIVIAL 
fullerenes B-FAMILY 
on O 
the O 
accumulation O 
of O 
weathered O 
dichlorodiphenyldichloroethylene B-SYSTEMATIC 
( O 
p,p'-DDE B-SYSTEMATIC 
; O 
DDT B-ABBREVIATION 
metabolite O 
) O 
by O 
Cucurbita O 
pepo O 
( O 
pumpkin O 
) O 
and O 
Eisenia O 
fetida O 
( O 
earthworm O 
) O 
was O 
determined O 
under O 
single O 
and O 
multispecies O 
conditions O 
. O 
The O 
plants O 
, O 
in O 
the O 
presence O 
or O 
absence O 
of O 
earthworms O 
, O 
were O 
grown O 
in O 
soil O 
containing O 
weathered O 
DDE B-ABBREVIATION 
( O 
200 O 
ng O 
/ O 
g O 
) O 
and O 
0 O 
or O 
1670 O 
mg O 
/ O 
kg O 
C60 B-TRIVIAL 
fullerenes B-FAMILY 
. O 
Plants O 
and O 
earthworms O 
were O 
added O 
either O 
simultaneously O 
or O 
sequentially O 
( O 
earthworms O 
after O 
plants O 
) O 
. O 
Neither O 
DDE B-ABBREVIATION 
nor O 
C60 B-TRIVIAL 
had O 
an O 
impact O 
on O 
survival O 
or O 
biomass O 
of O 
plants O 
and O 
earthworms O 
, O 
although O 
fullerenes B-FAMILY 
significantly O 
decreased O 
( O 
29.6-39.0% O 
) O 
the O 
relative O 
root O 
mass O 
. O 
Under O 
single O 
or O 
multispecies O 
conditions O 
, O 
C60 B-TRIVIAL 
had O 
little O 
impact O 
on O 
DDE B-ABBREVIATION 
bioaccumulation O 
by O 
either O 
species O 
. O 
The O 
DDE B-ABBREVIATION 
concentrations O 
in O 
non- O 
fullerene B-TRIVIAL 
-exposed O 
shoots O 
, O 
roots O 
, O 
and O 
earthworms O 
were O 
181 O 
, O 
7400 O 
, O 
and O 
8230 O 
ng O 
/ O 
g O 
, O 
respectively O 
. O 
On O 
fullerene B-TRIVIAL 
exposure O 
, O 
the O 
DDE B-ABBREVIATION 
content O 
was O 
nonsignificantly O 
lower O 
at O 
163 O 
, O 
7280 O 
, O 
and O 
7540 O 
ng O 
/ O 
g O 
, O 
respectively O 
. O 
In O 
the O 
presence O 
of O 
the O 
earthworms O 
, O 
C60 B-TRIVIAL 
significantly O 
decreased O 
the O 
shoot O 
DDE B-ABBREVIATION 
content O 
( O 
28.6% O 
) O 
, O 
but O 
no O 
impact O 
on O 
root O 
concentrations O 
was O 
observed O 
. O 
Root O 
DDE B-ABBREVIATION 
content O 
was O 
unaffected O 
by O 
the O 
presence O 
of O 
fullerenes B-FAMILY 
and O 
decreased O 
by O 
21.6 O 
to O 
37.5% O 
during O 
coexposure O 
with O 
earthworms O 
. O 
Earthworm O 
DDE B-ABBREVIATION 
content O 
was O 
decreased O 
by O 
plant O 
presence O 
. O 
Earthworms O 
added O 
to O 
soils O 
after O 
plant O 
harvest O 
accumulated O 
more O 
DDE B-ABBREVIATION 
but O 
were O 
unaffected O 
by O 
the O 
C60 B-TRIVIAL 
exposure O 
. O 
Additional O 
work O 
is O 
necessary O 
, O 
but O 
these O 
findings O 
suggest O 
that O 
fullerenes O 
may O 
have O 
minimal O 
impact O 
on O 
the O 
bioaccumulation O 
of O 
weathered O 
cocontaminants O 
in O 
soil O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1117-1123 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
Lepidium O 
sativum O 
, O 
Nigella O 
sativa O 
and O 
Trigonella O 
foenum O 
- O 
graceum O 
on O 
Phenytoin B-TRIVIAL 
Pharmacokinetics O 
in O 
Beagle O 
Dogs O 
. O 

present O 
work O 
was O 
designed O 
to O 
evaluate O 
the O 
effect O 
of O 
some O 
commonly O 
used O 
herbs O 
viz O 
. O 
garden O 
cress O 
( O 
Lepidium O 
sativum O 
) O 
, O 
black O 
seed O 
( O 
Nigella O 
sativa O 
) O 
and O 
fenugreek O 
( O 
Trigonella O 
foenum O 
- O 
graceum O 
) O 
on O 
the O 
disposition O 
of O 
phenytoin B-TRIVIAL 
after O 
oral O 
administration O 
in O 
a O 
dog O 
model O 
. O 
Phenytoin B-TRIVIAL 
was O 
given O 
orally O 
at O 
a O 
dose O 
of O 
50 O 
mg O 
, O 
and O 
blood O 
samples O 
were O 
obtained O 
for O 
the O 
determination O 
of O 
drug's O 
pharmacokinetic O 
parameters O 
. O 
After O 
a O 
suitable O 
washout O 
period O 
, O 
animals O 
were O 
commenced O 
on O 
a O 
specific O 
herb O 
treatment O 
for O 
one O 
week O 
. O 
Garden O 
cress O 
treatment O 
caused O 
a O 
modest O 
increase O 
in O 
maximum O 
observed O 
concentration O 
( O 
C(max) O 
) O 
and O 
terminal O 
half O 
- O 
life O 
( O 
T(1 O 
/ O 
2λ O 
) O 
) O 
of O 
phenytoin B-TRIVIAL 
with O 
a O 
reduction O 
in O 
clearance O 
by O 
33% O 
. O 
The O 
effect O 
of O 
black O 
seed O 
therapy O 
was O 
more O 
drastic O 
on O 
drug O 
elimination O 
and O 
to O 
a O 
lesser O 
extent O 
on O 
its O 
volume O 
of O 
distribution O 
at O 
steady O 
state O 
( O 
V(ss) O 
) O 
with O 
a O 
consequent O 
reduction O 
in O 
systemic O 
exposure O 
measured O 
by O 
area O 
under O 
the O 
curve O 
( O 
AUC(0-∞) O 
) O 
by O 
about O 
87% O 
. O 
The O 
effect O 
of O 
fenugreek O 
therapy O 
resembled O 
, O 
albeit O 
to O 
a O 
lesser O 
extent O 
, O 
that O 
of O 
black O 
seed O 
with O 
a O 
significant O 
reduction O 
in O 
AUC(0-∞) O 
by O 
~72% O 
. O 
In O 
addition O 
, O 
there O 
was O 
a O 
73% O 
increase O 
in O 
V(ss) O 
. O 
Our O 
findings O 
suggest O 
that O 
the O 
phenytoin B-TRIVIAL 
disposition O 
can O 
be O 
significantly O 
altered O 
by O 
the O 
concurrent O 
consumption O 
of O 
tested O 
herbal O 
products O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

potential O 
impact O 
of O 
diverse O 
inputs O 
of O 
organic O 
matter O 
( O 
hay O 
, O 
maize O 
straw O 
, O 
and O 
peat O 
) O 
on O 
the O 
mobility O 
and O 
bioavailability O 
of O 
Cd B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Pb B-FORMULA 
, O 
and O 
Zn B-FORMULA 
was O 
examined O 
at O 
laboratory O 
scale O 
for O 
three O 
soils O 
with O 
contrasting O 
properties O 
and O 
for O 
two O 
moisture O 
regimes O 
: O 
field O 
capacity O 
and O 
saturated O 
conditions O 
. O 
Soil O 
solution O 
was O 
characterized O 
for O 
total O 
soluble O 
metals O 
, O 
dissolved O 
soil O 
organic O 
carbon B-SYSTEMATIC 
, O 
and O 
ultraviolet O 
absorbance O 
at O 
254 O 
nm O 
. O 
Speciation O 
analyses O 
were O 
performed O 
with O 
WHAM O 
VI O 
. O 
For O 
field O 
capacity O 
conditions O 
, O 
metal O 
mobility O 
increased O 
( O 
Pb B-FORMULA 
> O 
Cu B-FORMULA 
> O 
Zn B-FORMULA 
> O 
Cd B-FORMULA 
) O 
for O 
all O 
soils O 
and O 
treatments O 
compared O 
with O 
controls O 
and O 
was O 
significantly O 
correlated O 
( O 
p O 
< O 
0.05 O 
) O 
with O 
dissolved O 
organic O 
matter O 
( O 
r O 
= O 
0.54 O 
) O 
. O 
Solubilization O 
of O 
organic O 
matter O 
was O 
mostly O 
driven O 
by O 
Al B-FORMULA 
mobilization O 
( O 
r O 
= O 
0.58 O 
, O 
p O 
< O 
0.05 O 
) O 
and O 
variations O 
in O 
solution O 
pH O 
. O 
The O 
bioavailable O 
pool O 
of O 
metals O 
, O 
estimated O 
as O 
free O 
ion O 
activities O 
, O 
decreased O 
with O 
the O 
increasing O 
occurrence O 
of O 
metal O 
- O 
organic O 
matter O 
complexes O 
, O 
which O 
was O 
accompanied O 
by O 
an O 
increase O 
in O 
solution O 
of O 
highly O 
aromatic O 
organic O 
matter O 
. O 
Soil O 
saturation O 
generally O 
decreased O 
metal O 
mobility O 
and O 
the O 
ratio O 
of O 
metal O 
- O 
organo O 
matter O 
complexes O 
in O 
solution O 
. O 
Consistently O 
, O 
such O 
effects O 
were O 
accompanied O 
by O 
a O 
decrease O 
in O 
the O 
solubilization O 
of O 
organic O 
matter O 
and O 
lower O 
mobilization O 
of O 
Al B-FORMULA 
, O 
Fe B-FORMULA 
, O 
and O 
Mn B-FORMULA 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1027-1032 O 
. O 
© O 
2013 O 
SETAC O 
. O 

Schiff B-FAMILY 
- I-FAMILY 
base I-FAMILY 
-derived O 
FabH O 
inhibitors O 
with O 
dioxygenated O 
rings O 
as O 
antibiotic O 
agents O 
. O 

acid I-FAMILY 
biosynthesis O 
plays O 
a O 
vital O 
role O 
in O 
bacterial O 
survival O 
and O 
several O 
key O 
enzymes O 
involved O 
in O 
this O 
biosynthetic O 
pathway O 
have O 
been O 
identified O 
as O 
attractive O 
targets O 
for O 
the O 
development O 
of O 
new O 
antibacterial O 
agents O 
. O 
Of O 
these O 
promising O 
targets O 
, O 
β-ketoacyl B-SYSTEMATIC 
- O 
acyl B-FAMILY 
carrier O 
protein O 
( O 
ACP O 
) O 
synthase O 
III O 
( O 
FabH O 
) O 
is O 
the O 
most O 
attractive O 
target O 
that O 
could O 
trigger O 
the O 
initiation O 
of O 
fatty B-FAMILY 
acid I-FAMILY 
biosynthesis O 
and O 
is O 
highly O 
conserved O 
among O 
Gram O 
- O 
positive O 
and O 
-negative O 
bacteria O 
. O 
Designing O 
small O 
molecules O 
with O 
FabH O 
inhibitory O 
activity O 
displays O 
great O 
significance O 
for O 
developing O 
antibiotic O 
agents O 
, O 
which O 
should O 
be O 
highly O 
selective O 
, O 
nontoxic O 
and O 
broad O 
- O 
spectrum O 
. O 
In O 
this O 
manuscript O 
, O 
a O 
series O 
of O 
novel O 
Schiff B-FAMILY 
base I-FAMILY 
compounds O 
were O 
designed O 
and O 
synthesized O 
, O 
and O 
their O 
biological O 
activities O 
were O 
evaluated O 
as O 
potential O 
inhibitors O 
. O 
Among O 
these O 
21 O 
new O 
compounds O 
, O 
(E)-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methylene)hexadecan-1-amine B-SYSTEMATIC 
( O 
10 O 
) O 
showed O 
the O 
most O 
potent O 
antibacterial O 
activity O 
with O 
a O 
MIC O 
value O 
of O 
3.89-7.81 O 
μM(-1) O 
against O 
the O 
tested O 
bacterial O 
strains O 
and O 
exhibited O 
the O 
most O 
potent O 
E O 
. O 
coli O 
FabH O 
inhibitory O 
activity O 
with O 
an O 
IC(50) O 
value O 
of O 
1.6 O 
μM O 
. O 
Docking O 
simulation O 
was O 
performed O 
to O 
position O 
compound O 
10 O 
into O 
the O 
E O 
. O 
coli O 
FabH O 
active O 
site O 
to O 
determine O 
the O 
probable O 
binding O 
conformation O 
. O 

sorption O 
behavior O 
of O 
pyrethroids B-FAMILY 
between O 
formulated O 
and O 
natural O 
sediments O 
. O 

sediments O 
are O 
recommended O 
for O 
use O 
in O 
toxicity O 
tests O 
to O 
achieve O 
standardized O 
evaluations O 
. O 
However O 
, O 
the O 
organic O 
matter O 
used O 
in O 
formulated O 
sediments O 
may O 
differ O 
qualitatively O 
from O 
that O 
in O 
natural O 
sediments O 
, O 
which O 
may O 
lead O 
to O 
different O 
chemical O 
partition O 
patterns O 
and O 
, O 
hence O 
, O 
different O 
toxicity O 
effects O 
. O 
By O 
deriving O 
partition O 
coefficients O 
for O 
organic O 
carbon B-SYSTEMATIC 
and O 
dissolved O 
organic O 
carbon B-SYSTEMATIC 
( O 
KOC O 
and O 
KDOC O 
, O 
respectively O 
) O 
for O 
eight O 
pyrethroid B-FAMILY 
insecticides O 
from O 
three O 
formulated O 
and O 
five O 
natural O 
sediments O 
, O 
the O 
authors O 
characterized O 
the O 
differences O 
between O 
formulated O 
and O 
natural O 
sediments O 
in O 
pesticide O 
sorption O 
. O 
For O 
all O 
pyrethroids B-FAMILY 
, O 
the O 
mean O 
values O 
of O 
KOC O 
and O 
KDOC O 
of O 
formulated O 
sediments O 
were O 
two O 
to O 
three O 
, O 
and O 
three O 
to O 
10 O 
times O 
smaller O 
than O 
those O 
of O 
natural O 
sediments O 
, O 
respectively O 
. O 
The O 
two O 
formulated O 
sediments O 
containing O 
α-cellulose O 
or O 
Manitoba O 
peat O 
showed O 
significantly O 
( O 
p O 
< O 
0.0001 O 
) O 
smaller O 
KOC O 
and O 
KDOC O 
values O 
than O 
natural O 
sediments O 
based O 
on O 
statistical O 
analyses O 
, O 
while O 
the O 
difference O 
was O 
not O 
significant O 
for O 
the O 
formulated O 
sediment O 
containing O 
New O 
Brunswick O 
peat O 
. O 
The O 
KOC O 
values O 
were O 
closely O 
correlated O 
( O 
p O 
< O 
0.001 O 
) O 
with O 
soot O 
carbon B-SYSTEMATIC 
content O 
, O 
while O 
the O 
amount O 
of O 
carboxylic B-SYSTEMATIC 
or O 
phenolic B-FAMILY 
functional O 
groups O 
may O 
have O 
affected O 
KDOC O 
. O 
Therefore O 
, O 
the O 
source O 
and O 
quality O 
of O 
organic O 
matter O 
are O 
likely O 
the O 
most O 
important O 
factors O 
in O 
formulated O 
sediments O 
and O 
must O 
be O 
standardized O 
to O 
provide O 
consistency O 
in O 
sediment O 
toxicity O 
tests O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
1033-1039 O 
. O 
© O 
2013 O 
SETAC O 
. O 

maltose B-SYSTEMATIC 
- I-SYSTEMATIC 
neopentyl I-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
HF- O 
MNG B-ABBREVIATION 
) O 
amphiphiles O 
for O 
membrane O 
protein O 
stabilisation O 
. O 

OPERA O 
: O 
Fluorinated O 
amphiphile O 
F4-MNG O 
confers O 
greater O 
stability O 
on O 
Rhodobacter O 
capsulatus O 
superassembly O 
relative O 
to O 
conventional O 
detergents O 
and O 
nonfluorinated O 
MNG B-ABBREVIATION 
s O 
. O 
Such O 
amphiphiles O 
are O 
attractive O 
as O 
tools O 
for O 
membrane O 
science O 
because O 
of O 
their O 
ease O 
of O 
preparation O 
and O 
structure O 
variation O 
. O 

consumption O 
by O 
grizzly O 
bears O 
reduces O 
biomagnification O 
of O 
salmon O 
- O 
derived O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
, O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
, O 
and O 
organochlorine B-FAMILY 
pesticides O 
. O 

present O 
study O 
characterizes O 
the O 
uptake O 
and O 
loss O 
of O 
persistent O 
organic O 
pollutants O 
( O 
POPs O 
) O 
in O 
grizzly O 
bears O 
( O 
Ursus O 
arctos O 
horribilis O 
) O 
by O 
sampling O 
and O 
analyzing O 
their O 
terrestrial O 
and O 
marine O 
foods O 
and O 
fecal O 
material O 
from O 
a O 
remote O 
coastal O 
watershed O 
in O 
British O 
Columbia O 
, O 
Canada O 
. O 
The O 
authors O 
estimate O 
that O 
grizzly O 
bears O 
consume O 
341 O 
to O 
1120 O 
µg O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
and O 
3.9 O 
to O 
33 O 
µg O 
of O 
polybrominated B-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
daily O 
in O 
the O 
fall O 
when O 
they O 
have O 
access O 
to O 
an O 
abundant O 
supply O 
of O 
returning O 
salmon O 
. O 
The O 
authors O 
also O 
estimate O 
that O 
POP O 
elimination O 
by O 
grizzly O 
bears O 
through O 
defecation O 
is O 
very O 
low O 
following O 
salmon O 
consumption O 
( O 
typically O 
< O 
2% O 
of O 
intake O 
) O 
but O 
surprisingly O 
high O 
following O 
plant O 
consumption O 
( O 
> O 
100% O 
for O 
PCBs B-ABBREVIATION 
and O 
organochlorine B-FAMILY 
pesticides O 
) O 
. O 
Excretion O 
of O 
individual O 
POPs O 
is O 
largely O 
driven O 
by O 
a O 
combination O 
of O 
fugacity O 
( O 
differences O 
between O 
bear O 
and O 
food O 
concentrations O 
) O 
and O 
the O 
digestibility O 
of O 
the O 
food O 
. O 
The O 
results O 
of O 
the O 
present O 
study O 
are O 
substantiated O 
by O 
a O 
principal O 
components O 
analysis O 
, O 
which O 
also O 
demonstrates O 
a O 
strong O 
role O 
for O 
log O 
KOW O 
in O 
governing O 
the O 
excretion O 
of O 
different O 
POPs O 
in O 
grizzly O 
bears O 
. O 
Collectively O 
, O 
the O 
present O 
study's O 
results O 
reveal O 
that O 
grizzly O 
bears O 
experience O 
a O 
vegetation O 
- O 
associated O 
drawdown O 
of O 
POPs O 
previously O 
acquired O 
through O 
the O 
consumption O 
of O 
salmon O 
, O 
to O 
such O 
an O 
extent O 
that O 
net O 
biomagnification O 
is O 
reduced O 
. O 
Environ O 
. O 
Toxicol O 
. O 
Chem O 
. O 
2013;32 O 
: O 
995-1005 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
nanostructured O 
MnO B-FORMULA 
/ O 
Co B-FORMULA 
/ O 
solid O 
- O 
electrolyte O 
interphase O 
ternary O 
composites O 
as O 
a O 
durable O 
anode O 
material O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

MnO B-FORMULA 
frameworks O 
with O 
highly O 
dispersed O 
Co B-FORMULA 
nanoparticles O 
were O 
produced O 
from O 
MnCO3 B-FORMULA 
precursors O 
prepared O 
in O 
a O 
gel O 
matrix O 
. O 
The O 
MnO B-FORMULA 
frameworks O 
that O 
contain O 
20 O 
mol% O 
Co B-FORMULA 
exhibited O 
excellent O 
cycle O 
performance O 
as O 
an O 
anode O 
material O 
for O 
Li B-FORMULA 
-ion O 
batteries O 
. O 
The O 
solid O 
- O 
electrolyte O 
interphase O 
( O 
SEI O 
) O 
formed O 
in O 
the O 
frameworks O 
through O 
the O 
electrochemical O 
reaction O 
mediates O 
the O 
active O 
materials O 
, O 
such O 
as O 
MnO B-FORMULA 
, O 
Mn B-FORMULA 
, O 
and O 
Li2O B-FORMULA 
, O 
during O 
the O 
conversion O 
reaction O 
in O 
the O 
charge O 
- O 
discharge O 
cycle O 
. O 
The O 
Co B-FORMULA 
nanoparticles O 
and O 
SEI O 
provide O 
the O 
electron O 
and O 
Li B-FORMULA 
-ion O 
conductive O 
networks O 
, O 
respectively O 
. O 
The O 
ternary O 
nanocomposites O 
of O 
the O 
MnO B-FORMULA 
framework O 
, O 
metallic O 
Co B-FORMULA 
nanoparticles O 
, O 
and O 
embedded O 
SEI O 
are O 
categorized O 
as O 
durable O 
anode O 
materials O 
for O 
Li B-FORMULA 
-ion O 
batteries O 
. O 

that O 
recognize O 
PTMs O 
of O 
histones O 
play O 
a O 
central O 
role O 
in O 
epigenetic O 
proteomic O 
research O 
. O 
Modification O 
- O 
specific O 
antibodies O 
are O 
employed O 
in O 
chromatin O 
immunoprecipitation O 
, O 
for O 
Western O 
blotting O 
and O 
during O 
the O 
immunoprecipitation O 
steps O 
for O 
MS O 
- O 
based O 
global O 
proteomic O 
analyses O 
. O 
Knowledge O 
about O 
the O 
antibodies O 
' O 
off O 
- O 
target O 
binding O 
is O 
essential O 
for O 
the O 
interpretation O 
of O 
experimental O 
data O 
. O 
To O 
address O 
this O 
challenge O 
we O 
developed O 
a O 
fast O 
and O 
cost O 
efficient O 
system O 
for O 
generating O 
peptide O 
bead O 
arrays O 
. O 
We O 
employed O 
this O 
method O 
to O 
establish O 
a O 
bead O 
- O 
based O 
peptide O 
array O 
containing O 
384 O 
peptides O 
displaying O 
phosphorylated O 
, O 
acetylated O 
, O 
methylated O 
, O 
and O 
citrullinated O 
N B-FORMULA 
-terminal O 
regions O 
of O 
histones O 
H2A O 
, O 
H2B O 
, O 
H3 O 
and O 
H4 O 
and O 
controls O 
. O 
We O 
profiled O 
the O 
binding O 
of O 
40 O 
PTM-specific O 
antibodies O 
important O 
for O 
epigenetic O 
proteomic O 
research O 
. O 

UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
1A1 O 
catalyzes O 
the O 
metabolism O 
of O 
numerous O 
clinically O 
and O 
pharmacologically O 
important O 
compounds O 
such O 
as O 
bilirubin B-TRIVIAL 
and O 
SN-38 B-IDENTIFIER 
. O 
UGT1A1 O 
is O 
predominantly O 
expressed O 
in O 
the O 
liver O 
and O 
intestine O 
, O 
but O 
not O 
in O 
the O 
kidney O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
uncover O 
the O 
mechanism O 
of O 
the O 
tissue O 
- O 
specific O 
expression O 
of O 
UGT1A1 O 
, O 
focusing O 
on O 
its O 
epigenetic O 
regulation O 
. O 
Bisulfite B-SYSTEMATIC 
sequence O 
analysis O 
revealed O 
that O 
the O 
CpG B-ABBREVIATION 
-rich O 
region O 
near O 
the O 
UGT1A1 O 
promoter O 
( O 
-85 O 
to O 
+ O 
40 O 
) O 
was O 
hypermethylated O 
( O 
83% O 
) O 
in O 
the O 
kidney O 
, O 
whereas O 
it O 
was O 
hypomethylated O 
( O 
37% O 
) O 
in O 
the O 
liver O 
. O 
A O 
chromatin O 
immunoprecipitation O 
assay O 
demonstrated O 
that O 
histone O 
H3 O 
near O 
the O 
promoter O 
was O 
hypoacetylated O 
in O 
the O 
kidney O 
but O 
was O 
hyperacetylated O 
in O 
the O 
liver O 
; O 
this O 
hyperacetylation O 
was O 
accompanied O 
by O 
the O 
recruitment O 
of O 
HNF1α O 
to O 
the O 
promoter O 
. O 
The O 
UGT1A1 O 
promoter O 
in O 
human O 
kidney O 
- O 
derived O 
HK-2 O 
cells O 
that O 
do O 
not O 
express O 
UGT1A1 O 
was O 
fully O 
methylated O 
, O 
but O 
was O 
relatively O 
unmethylated O 
in O 
human O 
liver O 
- O 
derived O 
HuH-7 O 
cells O 
that O 
express O 
UGT1A1 O 
. O 
Treatment O 
with O 
5-aza-2'-deoxycytidine B-SYSTEMATIC 
( O 
5-Aza-dC B-SYSTEMATIC 
) O 
, O 
an O 
inhibitor O 
of O 
DNA O 
methylation O 
, O 
resulted O 
in O 
an O 
increase O 
of O 
UGT1A1 O 
mRNA O 
expression O 
in O 
both O 
cell O 
types O 
, O 
but O 
the O 
increase O 
was O 
much O 
larger O 
in O 
HK-2 O 
cells O 
than O 
in O 
HuH-7 O 
cells O 
. O 
The O 
transfection O 
of O 
an O 
HNF1α O 
expression O 
plasmid O 
into O 
the O 
HK-2 O 
cells O 
resulted O 
in O 
an O 
increase O 
of O 
UGT1A1 O 
mRNA O 
only O 
in O 
the O 
presence O 
of O 
5-Aza-dC B-SYSTEMATIC 
. O 
In O 
summary O 
, O 
we O 
found O 
that O 
DNA O 
hypermethylation O 
along O 
with O 
histone O 
hypoacetylation O 
interferes O 
with O 
the O 
binding O 
of O 
HNF1α O 
, O 
resulting O 
in O 
the O 
defective O 
expression O 
of O 
UGT1A1 O 
in O 
the O 
human O 
kidney O 
. O 
Thus O 
, O 
epigenetic O 
regulation O 
is O 
a O 
crucial O 
determinant O 
of O 
tissue O 
- O 
specific O 
expression O 
of O 
UGT1A1 O 
. O 

linoleic B-TRIVIAL 
acid I-TRIVIAL 
reduces O 
adiposity O 
and O 
increases O 
markers O 
of O 
browning O 
and O 
inflammation O 
in O 
white O 
adipose O 
tissue O 
of O 
mice O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
mechanism O 
by O 
which O 
conjugated O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CLA O 
) O 
reduces O 
body O 
fat O 
. O 
Young O 
male O 
mice O 
were O 
fed O 
three O 
combinations O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
at O 
three O 
doses O 
( O 
0.06% O 
, O 
0.2% O 
, O 
and O 
0.6% O 
, O 
w O 
/ O 
w O 
) O 
incorporated O 
into O 
AIN76 O 
diets O 
for O 
7 O 
weeks O 
. O 
The O 
types O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
were O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
control O 
) O 
, O 
an O 
equal O 
mixture O 
of O 
trans-10 O 
, O 
cis-12 O 
( O 
10,12 O 
) O 
CLA O 
plus O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
an O 
equal O 
isomer O 
mixture O 
of O 
10,12 O 
plus O 
cis-9 O 
, O 
trans-11 O 
( O 
9,11 O 
) O 
CLA O 
. O 
Mice O 
receiving O 
the O 
0.2% O 
and O 
0.6% O 
dose O 
of O 
10,12 O 
CLA O 
plus O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
or O 
the O 
CLA O 
isomer O 
mixture O 
had O 
decreased O 
white O 
adipose O 
tissue O 
( O 
WAT O 
) O 
and O 
brown O 
adipose O 
tissue O 
( O 
BAT O 
) O 
mass O 
and O 
increased O 
incorporation O 
of O 
CLA O 
isomers O 
in O 
epididymal O 
WAT O 
and O 
liver O 
. O 
Notably O 
, O 
in O 
mice O 
receiving O 
0.2% O 
of O 
both O 
CLA O 
treatments O 
, O 
the O 
mRNA O 
levels O 
of O 
genes O 
associated O 
with O 
browning O 
, O 
including O 
uncoupling O 
protein O 
1 O 
( O 
UCP1 O 
) O 
, O 
UCP1 O 
protein O 
levels O 
, O 
and O 
cytochrome O 
c O 
oxidase O 
activity O 
, O 
were O 
increased O 
in O 
epididymal O 
WAT O 
. O 
CLA-induced O 
browning O 
in O 
WAT O 
was O 
accompanied O 
by O 
increases O 
in O 
mRNA O 
levels O 
of O 
markers O 
of O 
inflammation O 
. O 
Muscle O 
cytochrome O 
c O 
oxidase O 
activity O 
and O 
BAT O 
UCP1 O 
protein O 
levels O 
were O 
not O 
affected O 
by O 
CLA O 
treatment O 
. O 
These O 
data O 
suggest O 
a O 
linkage O 
between O 
decreased O 
adiposity O 
, O 
browning O 
in O 
WAT O 
, O 
and O 
low O 
- O 
grade O 
inflammation O 
due O 
to O 
consumption O 
of O 
10,12 O 
CLA O 
. O 

spherical O 
polyelectrolyte O 
brushes O 
( O 
SPBs O 
) O 
were O 
synthesized O 
by O 
photoemulsion O 
polymerization O 
, O 
consisting O 
of O 
a O 
polystyrene B-SYSTEMATIC 
core O 
with O 
a O 
diameter O 
around O 
80 O 
nm O 
and O 
a O 
poly(2-aminoethylmethacrylate B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAEMH B-ABBREVIATION 
) O 
shell O 
with O 
a O 
thickness O 
from O 
10 O 
to O 
50 O 
nm O 
densely O 
grafted O 
on O 
the O 
core O 
surface O 
. O 
The O 
binding O 
of O 
various O 
proteins O 
onto O 
SPBs O 
was O 
observed O 
by O 
turbidimetric O 
titration O 
, O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
, O 
zeta O 
potential O 
, O 
and O 
isothermal O 
titration O 
calorimetry O 
( O 
ITC O 
) O 
. O 
The O 
binding O 
, O 
aggregation O 
, O 
and O 
releasing O 
of O 
proteins O 
by O 
SPB O 
can O 
be O 
tuned O 
by O 
modulating O 
pH O 
. O 
The O 
pH O 
regions O 
of O 
binding O 
for O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
, O 
β-lactoglobulin O 
( O 
BLG O 
) O 
, O 
and O 
papain O 
onto O 
SPBs O 
are O 
markedly O 
different O 
and O 
tunable O 
by O 
ionic O 
strength O 
and O 
stoichiometry O 
between O 
protein O 
and O 
SPB O 
. O 
Binding O 
energetics O 
, O 
affinity O 
, O 
and O 
amount O 
of O 
various O 
proteins O 
onto O 
cationic O 
SPBs O 
were O 
determined O 
by O 
ITC O 
. O 
These O 
findings O 
lay O 
the O 
foundation O 
for O 
SPB O 
applications O 
in O 
the O 
protein O 
purification O 
and O 
selective O 
immobilization O 
of O 
different O 
proteins O 
, O 
enzymes O 
, O 
and O 
antibodies O 
. O 

of O 
the O 
acyl B-FAMILY 
- O 
adenylate B-TRIVIAL 
linked O 
metabolite O 
of O 
mefenamic B-TRIVIAL 
Acid I-TRIVIAL 
. O 

acid I-TRIVIAL 
, O 
( O 
MFA B-ABBREVIATION 
) O 
, O 
a O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-containing O 
nonsteroidal O 
anti-inflammatory O 
drug O 
( O 
NSAID O 
) O 
, O 
is O 
metabolized O 
into O 
the O 
chemically O 
reactive O 
conjugates O 
MFA-1-O-acyl-glucuronide B-FAMILY 
( O 
MFA-1-O-G B-SYSTEMATIC 
) O 
and O 
MFA-S-acyl-CoA B-FAMILY 
( O 
MFA-CoA B-ABBREVIATION 
) O 
, O 
which O 
are O 
both O 
implicated O 
in O 
the O 
formation O 
of O 
MFA-S-acyl-glutathione B-FAMILY 
( O 
MFA-GSH B-ABBREVIATION 
) O 
conjugates O 
, O 
protein O 
- O 
adduct O 
formation O 
, O 
and O 
thus O 
the O 
potential O 
toxicity O 
of O 
the O 
drug O 
. O 
However O 
, O 
current O 
studies O 
suggest O 
that O 
an O 
additional O 
acyl B-FAMILY 
-linked O 
metabolite O 
may O 
be O 
implicated O 
in O 
the O 
formation O 
of O 
MFA-GSH B-ABBREVIATION 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
ability O 
of O 
MFA B-ABBREVIATION 
to O 
become O 
bioactivated O 
into O 
the O 
acyl B-FAMILY 
-linked O 
metabolite O 
, O 
mefenamyl B-TRIVIAL 
- O 
adenylate B-TRIVIAL 
( O 
MFA-AMP B-ABBREVIATION 
) O 
. O 
In O 
vitro O 
incubations O 
in O 
rat O 
hepatocytes O 
with O 
MFA B-ABBREVIATION 
( O 
100 O 
μM O 
) O 
, O 
followed O 
by O 
LC-MS O 
/ O 
MS O 
analyses O 
of O 
extracts O 
, O 
led O 
to O 
the O 
detection O 
of O 
MFA-AMP B-ABBREVIATION 
. O 
In O 
these O 
incubations O 
, O 
the O 
initial O 
rate O 
of O 
MFA-AMP B-ABBREVIATION 
formation O 
was O 
rapid O 
, O 
leveling O 
off O 
at O 
a O 
maximum O 
concentration O 
of O 
90.1 O 
nM O 
( O 
20 O 
s O 
) O 
, O 
while O 
MFA-GSH B-ABBREVIATION 
formation O 
increased O 
linearly O 
, O 
reaching O 
a O 
concentration O 
of O 
1.7 O 
μM O 
after O 
60 O 
min O 
of O 
incubation O 
. O 
In O 
comparison O 
, O 
MFA-CoA B-ABBREVIATION 
was O 
undetectable O 
in O 
incubation O 
extracts O 
until O 
the O 
4 O 
min O 
time O 
point O 
, O 
achieving O 
a O 
concentration O 
of O 
45.6 O 
nM O 
at O 
the O 
60 O 
min O 
time O 
point O 
, O 
and O 
MFA-1-O-G B-SYSTEMATIC 
formation O 
was O 
linear O 
, O 
attaining O 
a O 
concentration O 
of O 
42.2 O 
μM O 
after O 
60 O 
min O 
of O 
incubation O 
. O 
In O 
vitro O 
incubation O 
in O 
buffer O 
with O 
the O 
model O 
nucleophile O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
under O 
physiological O 
conditions O 
showed O 
MFA-AMP B-ABBREVIATION 
to O 
be O 
reactive O 
toward O 
GSH B-ABBREVIATION 
, O 
but O 
11-fold O 
less O 
reactive O 
than O 
MFA-CoA B-ABBREVIATION 
, O 
while O 
MFA-1-O-G B-SYSTEMATIC 
exhibited O 
little O 
reactivity O 
. O 
However O 
, O 
in O 
the O 
presence O 
of O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
, O 
MFA-AMP B-ABBREVIATION 
mediated O 
formation O 
of O 
MFA-GSH B-ABBREVIATION 
increased O 
6-fold O 
, O 
while O 
MFA-CoA B-ABBREVIATION 
mediated O 
formation O 
of O 
MFA-GSH B-ABBREVIATION 
only O 
increased O 
1.4-fold O 
. O 
Collectively O 
, O 
in O 
addition O 
to O 
the O 
MFA-1-O-G B-SYSTEMATIC 
, O 
these O 
results O 
demonstrate O 
that O 
mefenamic B-TRIVIAL 
acid I-TRIVIAL 
does O 
become O 
bioactivated O 
by O 
acyl-CoA B-ABBREVIATION 
synthetase O 
enzyme(s) O 
in O 
vitro O 
in O 
rat O 
hepatocytes O 
into O 
the O 
reactive O 
transacylating O 
derivatives O 
MFA-AMP B-ABBREVIATION 
and O 
MFA-CoA B-ABBREVIATION 
, O 
both O 
of O 
which O 
contribute O 
to O 
the O 
transacylation O 
of O 
GSH B-ABBREVIATION 
and O 
may O 
be O 
involved O 
in O 
the O 
formation O 
of O 
protein O 
adducts O 
and O 
potentially O 
elicit O 
an O 
idiosyncratic O 
toxicity O 
. O 

of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
in O 
the O 
chemistry O 
and O 
anticancer O 
activity O 
of O 
etoposide B-TRIVIAL 
( O 
VP-16,213 B-IDENTIFIER 
) O 
. O 

identified O 
as O 
an O 
innate O 
cytotoxin O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
(·)NO B-FORMULA 
) O 
formation O 
in O 
tumors O 
can O 
influence O 
chemotherapy O 
and O 
exacerbate O 
cancer O 
progression O 
. O 
Here O 
, O 
we O 
examined O 
the O 
hypothesis O 
that O 
(·)NO B-FORMULA 
generation O 
contributes O 
to O 
cancer O 
cell O 
drug O 
resistance O 
toward O 
the O 
widely O 
used O 
anticancer O 
drug O 
Etoposide B-TRIVIAL 
( O 
VP-16 B-IDENTIFIER 
) O 
. O 
The O 
UV-vis O 
spectrum O 
of O 
VP-16 B-IDENTIFIER 
was O 
not O 
changed O 
by O 
exposure O 
of O 
VP-16 B-IDENTIFIER 
to O 
(·)NO B-FORMULA 
in O 
aqueous O 
buffer O 
. O 
In O 
contrast O 
, O 
reddish O 
- O 
orange O 
compound(s) O 
characteristic O 
of O 
o-quinone- B-MULTIPLE 
and I-MULTIPLE 
nitroso-VP-16 I-MULTIPLE 
were O 
readily O 
generated O 
in O 
a O 
hydrophobic O 
medium O 
( O 
chloroform B-TRIVIAL 
) O 
in O 
an O 
oxygen B-SYSTEMATIC 
-dependent O 
manner O 
. O 
Similar O 
products O 
were O 
also O 
formed O 
when O 
the O 
VP-16 B-IDENTIFIER 
radical O 
, O 
generated O 
from O 
VP-16 B-IDENTIFIER 
and O 
horseradish O 
peroxidase/ O 
H2O2 B-FORMULA 
, O 
was O 
exposed O 
directly O 
to O 
(·)NO B-FORMULA 
in O 
chloroform B-TRIVIAL 
in O 
the O 
presence O 
of O 
oxygen B-SYSTEMATIC 
. O 
Separation O 
and O 
spectral O 
analysis O 
of O 
VP-16 B-IDENTIFIER 
reaction O 
extracts O 
by O 
electron O 
spin O 
resonance O 
and O 
UV-vis O 
indicated O 
the O 
generation O 
of O 
the O 
phenoxy B-SYSTEMATIC 
radical O 
and O 
the O 
o-quinone B-SYSTEMATIC 
of O 
VP-16 B-IDENTIFIER 
, O 
as O 
well O 
as O 
putative O 
nitroxide B-SYSTEMATIC 
, O 
iminoxyl B-SYSTEMATIC 
, O 
and O 
other O 
nitrogen B-SYSTEMATIC 
oxide I-SYSTEMATIC 
intermediates O 
. O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
products O 
of O 
VP-16 B-IDENTIFIER 
displayed O 
significantly O 
diminished O 
topoisomerase O 
II-dependent O 
cleavage O 
of O 
DNA O 
and O 
cytotoxicity O 
to O 
human O 
HL-60 O 
leukemia O 
cells O 
. O 
LPS O 
- O 
mediated O 
induction O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
in O 
murine O 
macrophages O 
resulted O 
in O 
VP-16 B-IDENTIFIER 
resistance O 
compared O 
to O 
Raw O 
cells O 
. O 
Furthermore O 
, O 
(·)NO B-FORMULA 
products O 
derived O 
from O 
iNOS O 
rapidly O 
reacted O 
with O 
VP-16 B-IDENTIFIER 
leading O 
to O 
decreased O 
DNA O 
damage O 
and O 
cytotoxicity O 
. O 
Together O 
, O 
these O 
observations O 
suggest O 
that O 
the O 
formation O 
of O 
(·)NO B-FORMULA 
in O 
tumors O 
( O 
associated O 
macrophages O 
) O 
can O 
contribute O 
to O 
VP-16 B-IDENTIFIER 
resistance O 
via O 
the O 
detoxification O 
of O 
VP-16 B-IDENTIFIER 
. O 

report O 
a O 
ligand O 
decoration O 
strategy O 
to O 
enlarge O 
the O 
lattice O 
dilation O 
of O 
quantum O 
dots O 
( O 
QDs O 
) O 
, O 
which O 
greatly O 
enhances O 
the O 
characteristic O 
sensitivity O 
of O 
a O 
QD O 
- O 
based O 
thermometer O 
. O 
Upon O 
a O 
multiple O 
covalent O 
linkage O 
of O 
macrocyclic O 
compounds O 
with O 
QDs O 
, O 
for O 
example O 
, O 
thiolated O 
cyclodextrin O 
( O 
CD O 
) O 
and O 
CdTe B-FORMULA 
, O 
the O 
conformation O 
- O 
related O 
torsional O 
force O 
of O 
CD O 
is O 
conducted O 
to O 
the O 
inner O 
lattice O 
of O 
CdTe B-FORMULA 
under O 
altered O 
temperature O 
. O 
The O 
combination O 
of O 
the O 
lattice O 
expansion O 
/ O 
contraction O 
of O 
CdTe B-FORMULA 
and O 
the O 
stress O 
from O 
CD O 
conformation O 
change O 
greatly O 
enhances O 
the O 
shifts O 
of O 
both O 
UV-vis O 
absorption O 
and O 
photoluminescence O 
( O 
PL O 
) O 
spectra O 
, O 
thus O 
improving O 
the O 
temperature O 
sensitivity O 
. O 
As O 
an O 
example O 
, O 
β-CD-decorated O 
CdTe B-FORMULA 
QDs O 
exhibit O 
the O 
0.28 O 
nm O 
shift O 
of O 
the O 
spectra O 
per O 
degree O 
centigrade O 
( O 
0.28 O 
nm O 
/ O 
°C O 
) O 
, O 
2.4-fold O 
higher O 
than O 
those O 
of O 
monothiol B-FAMILY 
-ligand O 
- O 
decorated O 
QDs O 
. O 

- O 
green O 
algae O 
( O 
BGA O 
) O 
are O 
among O 
the O 
most O 
primitive O 
life O 
forms O 
on O 
earth O 
and O 
have O 
been O 
consumed O 
as O 
food O 
or O 
medicine O 
by O 
humans O 
for O 
centuries O 
. O 
BGA O 
contain O 
various O 
bioactive O 
components O 
, O 
such O 
as O 
phycocyanin O 
, O 
carotenoids O 
, O 
γ-linolenic B-TRIVIAL 
acid I-TRIVIAL 
, O 
fibers O 
, O 
and O 
plant O 
sterols B-FAMILY 
, O 
which O 
can O 
promote O 
optimal O 
health O 
in O 
humans O 
. O 
Studies O 
have O 
demonstrated O 
that O 
several O 
BGA O 
species O 
or O 
their O 
active O 
components O 
have O 
plasma O 
total O 
cholesterol B-TRIVIAL 
and O 
triglyceride B-FAMILY 
-lowering O 
properties O 
due O 
to O 
their O 
modulation O 
of O 
intestinal O 
cholesterol B-TRIVIAL 
absorption O 
and O 
hepatic O 
lipogenic O 
gene O 
expression O 
. O 
BGA O 
can O 
also O 
reduce O 
inflammation O 
by O 
inhibiting O 
the O 
nuclear O 
factor O 
κ O 
B O 
activity O 
, O 
consequently O 
reducing O 
the O 
production O 
of O 
proinflammatory O 
cytokines O 
. O 
Furthermore O 
, O 
BGA O 
inhibit O 
lipid O 
peroxidation O 
and O 
have O 
free O 
radical O 
scavenging O 
activity O 
, O 
which O 
can O 
be O 
beneficial O 
for O 
the O 
protection O 
against O 
oxidative O 
stress O 
. O 
The O 
aforementioned O 
effects O 
of O 
BGA O 
can O 
contribute O 
to O 
the O 
prevention O 
of O 
metabolic O 
and O 
inflammatory O 
diseases O 
. O 
This O 
review O 
provides O 
an O 
overview O 
of O 
the O 
current O 
knowledge O 
of O 
the O 
health O 
- O 
promoting O 
functions O 
of O 
BGA O 
against O 
cardiovascular O 
disease O 
and O 
nonalcoholic O 
fatty O 
liver O 
disease O 
, O 
which O 
are O 
major O 
health O 
threats O 
in O 
the O 
developed O 
countries O 
. O 

(II) I-SYSTEMATIC 
-catalyzed O 
intramolecular O 
aminohydroxylation O 
of O 
olefins B-FAMILY 
with O 
functionalized O 
hydroxylamines B-FAMILY 
. O 

diastereoselective O 
aminohydroxylation O 
of O 
olefins B-FAMILY 
with O 
a O 
functionalized O 
hydroxylamine B-SYSTEMATIC 
is O 
catalyzed O 
by O 
new O 
iron B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
. O 
This O 
efficient O 
intramolecular O 
process O 
readily O 
affords O 
synthetically O 
useful O 
amino B-FAMILY 
alcohols I-FAMILY 
with O 
excellent O 
selectivity O 
( O 
dr O 
up O 
to O 
> O 
20 O 
: O 
1 O 
) O 
. O 
Asymmetric O 
catalysis O 
with O 
chiral O 
iron B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
and O 
preliminary O 
mechanistic O 
studies O 
reveal O 
an O 
iron B-FAMILY 
nitrenoid I-FAMILY 
is O 
a O 
possible O 
intermediate O 
that O 
can O 
undergo O 
either O 
aminohydroxylation O 
or O 
aziridination O 
, O 
and O 
the O 
selectivity O 
can O 
be O 
controlled O 
by O 
careful O 
selection O 
of O 
counteranion O 
/ O 
ligand O 
combinations O 
. O 

liquid O 
mediated O 
synthesis O 
and O 
surface O 
modification O 
of O 
multifunctional O 
mesoporous O 
Eu B-FORMULA 
: O 
GdF3 B-FORMULA 
nanoparticles O 
for O 
biomedical O 
applications O 
. O 

procedure O 
for O 
the O 
synthesis O 
of O 
multifunctional O 
europium B-SYSTEMATIC 
(III) I-SYSTEMATIC 
-doped O 
gadolinium B-SYSTEMATIC 
(III) I-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
Eu B-FORMULA 
: O 
GdF3 B-FORMULA 
) O 
nanoparticles O 
( O 
~85 O 
nm O 
) O 
with O 
quasispherical O 
shape O 
by O 
precipitation O 
at O 
120 O 
°C O 
from O 
diethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
solutions O 
containing O 
lanthanide B-FAMILY 
chlorides I-FAMILY 
and O 
an O 
ionic O 
liquid O 
( O 
1-Butyl B-SYSTEMATIC 
, O 
2-methylimidazolium B-SYSTEMATIC 
tetrafluoroborate I-SYSTEMATIC 
) O 
as O 
fluoride B-SYSTEMATIC 
source O 
has O 
been O 
developed O 
. O 
These O 
nanoparticles O 
were O 
polycrystalline O 
and O 
crystallized O 
into O 
a O 
hexagonal O 
structure O 
, O 
which O 
is O 
unusual O 
for O 
GdF3 B-FORMULA 
. O 
They O 
were O 
also O 
mesoporous O 
( O 
pore O 
size O 
= O 
3.5 O 
Å O 
) O 
, O 
having O 
a O 
rather O 
high O 
BET O 
surface O 
area O 
( O 
75 O 
m(2) O 
g(-1) O 
) O 
. O 
The O 
luminescent O 
and O 
magnetic O 
( O 
relaxivity O 
) O 
properties O 
of O 
the O 
Eu B-FORMULA 
: O 
GdF3 B-FORMULA 
nanoparticles O 
have O 
been O 
also O 
evaluated O 
in O 
order O 
to O 
assess O 
their O 
potentiality O 
as O 
" O 
in O 
vitro O 
" O 
optical O 
biolabels O 
and O 
contrast O 
agent O 
for O 
magnetic O 
resonance O 
imaging O 
. O 
Finally O 
, O 
a O 
procedure O 
for O 
their O 
functionalization O 
with O 
aspartic O 
- O 
dextran O 
polymers O 
is O 
also O 
reported O 
. O 
The O 
functionalized O 
Eu B-FORMULA 
: O 
GdF3 B-FORMULA 
nanoparticles O 
presented O 
negligible O 
toxicity O 
for O 
Vero O 
cells O 
, O 
which O 
make O 
them O 
suitable O 
for O 
biotecnological O 
applications O 
. O 

activity O 
of O 
edible O 
brown O 
alga O 
Saccharina O 
japonica O 
and O 
its O 
constituents O 
pheophorbide B-TRIVIAL 
a I-TRIVIAL 
and O 
pheophytin B-TRIVIAL 
a I-TRIVIAL 
in O 
LPS-stimulated O 
RAW O 
264.7 O 
macrophage O 
cells O 
. O 

activity O 
of O 
Saccharina O 
japonica O 
and O 
its O 
active O 
components O 
was O 
evaluated O 
via O 
in O 
vitro O 
inhibitory O 
activities O 
against O 
lipopolysaccharide O 
(LPS)-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
production O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
expression O 
in O 
RAW O 
264.7 O 
murine O 
macrophage O 
cells O 
. O 
Since O 
the O 
methanolic O 
extract O 
of O 
S O 
. O 
japonica O 
showed O 
strong O 
anti-inflammatory O 
activity O 
, O 
it O 
was O 
fractionated O 
with O 
several O 
solvents O 
. O 
Among O 
the O 
fractions O 
, O 
the O 
ethyl O 
acetate O 
fraction O 
demonstrated O 
the O 
highest O 
inhibition O 
of O 
LPS-induced O 
NO B-FORMULA 
production O 
( O 
IC50=25.32μg O 
/ O 
mL O 
) O 
, O 
followed O 
by O 
the O 
CH2Cl2 B-FORMULA 
fraction O 
( O 
IC50=75.86μg O 
/ O 
mL O 
) O 
. O 
Considering O 
the O 
yield O 
and O 
anti-inflammatory O 
potential O 
together O 
, O 
the O 
CH2Cl2 B-FORMULA 
fraction O 
was O 
selected O 
for O 
chromatographic O 
separation O 
to O 
yield O 
two O 
active O 
porphyrin B-FAMILY 
derivatives O 
, O 
pheophorbide B-TRIVIAL 
a I-TRIVIAL 
and O 
pheophytin B-TRIVIAL 
a I-TRIVIAL 
, O 
together O 
with O 
an O 
inactive O 
fucoxanthin B-TRIVIAL 
. O 
In O 
contrast O 
to O 
fucoxanthin B-TRIVIAL 
, O 
pheophorbide B-TRIVIAL 
a I-TRIVIAL 
and O 
pheophytin B-TRIVIAL 
a I-TRIVIAL 
showed O 
dose O 
- O 
dependent O 
inhibition O 
against O 
LPS-induced O 
NO B-FORMULA 
production O 
at O 
nontoxic O 
concentrations O 
in O 
RAW O 
264.7 O 
cells O 
. O 
Both O 
compounds O 
also O 
suppressed O 
the O 
expression O 
of O 
iNOS O 
proteins O 
, O 
while O 
they O 
did O 
not O 
inhibit O 
the O 
COX-2 O 
expression O 
in O 
LPS-stimulated O 
macrophages O 
. O 
These O 
results O 
indicate O 
that O 
pheophorbide B-TRIVIAL 
a I-TRIVIAL 
and O 
pheophytin B-TRIVIAL 
a I-TRIVIAL 
are O 
two O 
important O 
candidates O 
of O 
S O 
. O 
japonica O 
as O 
anti-inflammatory O 
agents O 
which O 
can O 
inhibit O 
the O 
production O 
of O 
NO B-FORMULA 
via O 
inhibition O 
of O 
iNOS O 
protein O 
expression O 
. O 
Thus O 
, O 
these O 
compounds O 
hold O 
great O 
promise O 
for O 
use O 
in O 
the O 
treatment O 
of O 
various O 
inflammatory O 
diseases O 
. O 

induced O 
hepatotoxic O 
and O 
hematologic O 
changes O 
in O 
rats O 
: O 
the O 
role O 
of O 
quercetin B-TRIVIAL 
and O 
catechin B-TRIVIAL 
. O 

is O 
an O 
organophosphorus B-FAMILY 
insecticide O 
which O 
is O 
widely O 
used O 
throughout O 
in O 
the O 
world O 
and O 
it O 
caused O 
toxic O 
effects O 
on O 
nontarget O 
organisms O 
especially O 
mammalian O 
. O 
In O 
the O 
present O 
study O 
, O 
catechin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
chlorpyrifos B-TRIVIAL 
, O 
catechin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
were O 
given O 
to O 
male O 
rats O 
through O 
gavage O 
for O 
4weeks O 
. O 
Serum O 
total O 
protein O 
, O 
albumin O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
alkaline O 
phosphatase O 
, O 
lactate B-FAMILY 
dehydrogenase O 
, O 
trigliceride B-FAMILY 
, O 
total O 
cholesterol B-TRIVIAL 
levels O 
, O 
hematological O 
changes O 
, O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
, O 
glutathione B-TRIVIAL 
-S-transferase O 
activities O 
and O 
malondialdehyde B-TRIVIAL 
content O 
in O 
liver O 
tissues O 
and O 
also O 
histopathological O 
changes O 
of O 
liver O 
were O 
investigated O 
in O 
the O 
rats O 
compared O 
to O 
control O 
group O 
. O 
No O 
significant O 
differences O 
in O 
all O 
investigated O 
parameters O 
were O 
observed O 
between O 
control O 
, O 
catechin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
groups O 
. O 
There O 
were O 
statistically O 
significantly O 
changes O 
in O 
liver O 
function O 
tests O 
, O 
some O 
hematological O 
parameters O 
, O 
antioxidant O 
enzyme O 
activities O 
and O 
malondialdehyde B-TRIVIAL 
levels O 
in O 
chlorpyrifos B-TRIVIAL 
treated O 
group O 
compared O 
to O 
control O 
group O 
. O 
In O 
catechin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
treated O 
group O 
and O 
quercetin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
treated O 
group O 
we O 
observed O 
the O 
protective O 
effects O 
of O 
catechin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
on O 
examining O 
parameters O 
but O 
not O 
completely O 
. O 
While O 
some O 
histopathological O 
changes O 
detected O 
in O 
liver O 
tissues O 
in O 
chlorpyrifos B-TRIVIAL 
treated O 
group O 
, O 
less O 
histopathological O 
changes O 
were O 
observed O 
in O 
catechin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
+ O 
chlorpyrifos B-TRIVIAL 
treated O 
groups O 
at O 
the O 
end O 
of O 
the O 
4thweek O 
. O 
As O 
a O 
result O 
, O 
catechin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
significantly O 
reduce O 
chlorpyrifos B-TRIVIAL 
induced O 
hepatotoxicity O 
in O 
rats O 
. O 

comparative O 
study O 
of O 
the O 
modulatory O 
effects O 
of O 
(-)-cubebin B-TRIVIAL 
on O 
the O 
mutagenicity O 
/ O 
recombinogenicity O 
induced O 
by O 
different O 
chemical O 
agents O 
. O 

( O 
CUB B-ABBREVIATION 
) O 
is O 
a O 
lignan B-FAMILY 
isolated O 
from O 
dry O 
seeds O 
of O 
Piper O 
cubeba O 
. O 
We O 
aimed O 
to O 
assess O 
its O 
genotoxic O 
potential O 
and O 
influence O 
on O 
chromosomal O 
damage O 
( O 
frequency O 
of O 
micronuclei O 
- O 
MN O 
) O 
induced O 
by O 
doxorubicin B-TRIVIAL 
( O 
DXR B-ABBREVIATION 
) O 
in O 
V79 O 
cells O 
and O 
by O 
urethane B-TRIVIAL 
( O 
URE B-ABBREVIATION 
) O 
in O 
somatic O 
Drosophila O 
melanogaster O 
cells O 
. O 
Our O 
findings O 
indicate O 
an O 
absence O 
of O 
a O 
CUB B-ABBREVIATION 
-mediated O 
genotoxic O 
effect O 
at O 
the O 
concentrations O 
tested O 
. O 
The O 
results O 
also O 
revealed O 
that O 
CUB B-ABBREVIATION 
significantly O 
reduced O 
the O 
frequency O 
of O 
MN O 
induced O 
by O 
DXR B-ABBREVIATION 
, O 
with O 
a O 
mean O 
reduction O 
of O 
63.88% O 
. O 
In O 
a O 
previous O 
study O 
, O 
our O 
research O 
group O 
demonstrated O 
an O 
absence O 
of O 
CUB B-ABBREVIATION 
-mediated O 
mutagenic O 
effects O 
through O 
the O 
wing O 
Somatic O 
Mutation O 
and O 
Recombination O 
Test O 
( O 
SMART O 
) O 
in O 
Drosophila O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
used O 
the O 
standard O 
and O 
high O 
bioactivation O 
versions O 
of O 
the O 
SMART O 
to O 
estimate O 
the O 
antigenotoxic O 
effects O 
of O 
CUB B-ABBREVIATION 
associated O 
with O 
URE B-ABBREVIATION 
. O 
At O 
lower O 
concentrations O 
, O 
the O 
recombination O 
level O 
decreased O 
, O 
but O 
at O 
the O 
highest O 
concentration O 
, O 
the O 
recombination O 
level O 
increased O 
. O 
Our O 
data O 
and O 
previous O 
studies O 
suggest O 
that O 
CUB B-ABBREVIATION 
may O 
act O 
as O 
a O 
free O 
radical O 
scavenger O 
at O 
low O 
concentrations O 
, O 
a O 
pro O 
- O 
oxidant O 
at O 
higher O 
concentrations O 
when O 
it O 
interacts O 
with O 
the O 
enzymatic O 
system O 
that O 
catalyzes O 
the O 
metabolic O 
detoxification O 
of O 
DXR B-ABBREVIATION 
or O 
URE B-ABBREVIATION 
, O 
and O 
/ O 
or O 
an O 
inducer O 
of O 
recombinational O 
DNA O 
repair O 
. O 

and O 
toxicokinetics O 
of O 
the O 
insect O 
repellent O 
IR3535 B-IDENTIFIER 
® O 
in O 
male O 
and O 
female O 
human O 
subjects O 
after O 
dermal O 
exposure O 
. O 

absorption O 
and O 
excretion O 
of O 
the O 
insect O 
repellent O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
was O 
studied O 
in O 
human O 
subjects O 
( O 
five O 
males O 
and O 
five O 
females O 
) O 
after O 
dermal O 
application O 
of O 
approx O 
. O 
3g O 
of O 
a O 
formulation O 
containing O 
20% O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
, O 
i.e O 
. O 
the O 
amounts O 
of O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
applied O 
were O 
between O 
1.94 O 
and O 
3.4 O 
mmol O 
/ O 
person O 
( O 
418-731 O 
mg O 
/ O 
person O 
) O 
. O 
Blood O 
and O 
urinary O 
concentrations O 
of O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
and O 
its O 
only O 
metabolite O 
, O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
, O 
were O 
determined O 
over O 
time O 
. O 
In O 
plasma O 
, O 
concentrations O 
of O 
the O 
parent O 
compound O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
were O 
at O 
or O 
below O 
the O 
limit O 
of O 
quantification O 
( O 
0.037 O 
μmol O 
/ O 
L O 
) O 
. O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
peaked O 
in O 
plasma O 
samples O 
2-6h O 
after O 
dermal O 
application O 
. O 
Cmax O 
mean O 
values O 
were O 
5.7 O 
μmol O 
/ O 
L O 
in O 
males O 
, O 
3 O 
μmol O 
/ O 
L O 
in O 
females O 
and O 
4.2 O 
μmol O 
/ O 
L O 
in O 
all O 
volunteers O 
. O 
Mean O 
AUC O 
values O 
were O 
41.6 O 
, O 
24.5 O 
and O 
33.9 O 
μmolL(-1)h O 
in O 
males O 
, O 
females O 
and O 
all O 
subjects O 
, O 
respectively O 
. O 
In O 
urine O 
samples O 
from O 
all O 
human O 
subjects O 
, O 
both O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
and O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
were O 
detectable O 
, O 
however O 
, O 
only O 
very O 
small O 
amounts O 
of O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
were O 
found O 
. O 
Concentrations O 
of O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
were O 
several O 
thousand O 
- O 
fold O 
higher O 
than O 
the O 
parent O 
compound O 
and O 
peaked O 
at O 
the O 
first O 
two O 
sampling O 
points O 
( O 
4h O 
and O 
8h O 
after O 
dermal O 
application O 
) O 
. O 
Overall O 
, O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
and O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
excreted O 
with O 
urine O 
over O 
48 O 
h O 
representing O 
13.3 O 
± O 
3.05% O 
of O 
the O 
dose O 
applied O 
. O 
Since O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
is O 
rapidly O 
and O 
extensively O 
metabolized O 
, O 
and O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
has O 
a O 
low O 
molecular O 
weight O 
and O 
high O 
water O 
solubility O 
, O 
it O 
is O 
expected O 
that O 
urinary O 
excretion O 
of O 
IR3535 B-IDENTIFIER 
(®)-free O 
acid O 
and O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
represents O 
the O 
total O 
extent O 
of O 
absorption O 
of O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
in O 
humans O 
. O 
Based O 
on O 
the O 
results O 
of O 
this O 
study O 
, O 
the O 
skin O 
penetration O 
rate O 
of O 
IR3535 B-IDENTIFIER 
( O 
® O 
) O 
is O 
13.3% O 
in O 
humans O 
after O 
dermal O 
application O 
. O 

TLC O 
data O 
in O 
correlation O 
studies O 
with O 
in O 
silico O 
pharmacokinetic O 
properties O 
of O 
benzimidazole B-SYSTEMATIC 
and O 
benztriazole B-SYSTEMATIC 
derivatives O 
. O 

- O 
phase O 
thin O 
- O 
layer O 
chromatographic O 
( O 
RP O 
TLC O 
) O 
retention O 
constants O 
for O 
a O 
newly O 
designed O 
series O 
benzimidazole B-SYSTEMATIC 
/ O 
benztriazole B-SYSTEMATIC 
with O 
expected O 
biological O 
activity O 
were O 
determined O 
as O 
parameters O 
of O 
their O 
lipophilicity O 
and O 
this O 
series O 
was O 
recognized O 
as O 
congeneric O 
. O 
Pharmacokinetic O 
descriptors O 
of O 
the O 
compounds O 
investigated O 
were O 
calculated O 
in O 
silico O 
with O 
the O 
use O 
of O 
the O 
established O 
drug O 
design O 
software O 
. O 
The O 
bioactivity O 
descriptors O 
, O 
which O 
are O 
assumed O 
to O 
predicted O 
drug O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
, O 
elimination O 
and O 
toxicity O 
( O 
ADMETox O 
) O 
in O 
humans O 
, O 
were O 
correlated O 
with O 
retention O 
constants O 
and O 
good O 
statistical O 
parameters O 
were O 
obtained O 
. O 
Multiple O 
regression O 
analysis O 
which O 
was O 
introduced O 
suggested O 
that O 
the O 
absorption O 
through O 
different O 
epithelial O 
membranes O 
( O 
intestinal O 
, O 
blood O 
- O 
brain O 
or O 
erythrocyte O 
membrane O 
) O 
and O 
distribution O 
process O 
depend O 
on O 
retention O 
constants O 
( O 
as O 
measure O 
of O 
lipophilicty O 
) O 
and O 
total O 
polar O 
surface O 
area O 
and O 
molar O 
weight O 
/ O 
volume O 
of O 
the O 
analyte O 
. O 
Finally O 
, O 
the O 
compounds O 
with O 
halogen O 
substituent O 
( O 
compounds O 
A4 O 
/ O 
A7 O 
and O 
A5 O 
/ O 
A8 O 
in O 
Table O 
1 O 
) O 
, O 
were O 
suggested O 
as O 
the O 
best O 
drug O 
candidates O 
, O 
because O 
of O 
their O 
predicted O 
proper O 
pharmacokinetics O 
and O 
have O 
been O 
proposed O 
for O 
further O 
biological O 
tests O 
. O 

food O 
effects O 
on O 
indinavir B-TRIVIAL 
absorption O 
with O 
human O 
intestinal O 
fluids O 
in O 
the O 
mouse O 
intestine O 
. O 

can O 
have O 
a O 
significant O 
impact O 
on O 
the O 
pharmacokinetics O 
of O 
orally O 
administered O 
drugs O 
, O 
as O 
it O 
may O 
affect O 
drug O 
solubility O 
as O 
well O 
as O 
permeability O 
. O 
Since O 
fed O 
state O 
conditions O 
cannot O 
easily O 
be O 
implemented O 
in O 
the O 
presently O 
available O 
permeability O 
tools O 
, O 
including O 
the O 
frequently O 
used O 
Caco-2 O 
system O 
, O 
exploring O 
food O 
effects O 
during O 
drug O 
development O 
can O 
be O 
quite O 
challenging O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effect O 
of O 
fasted O 
and O 
fed O 
state O 
conditions O 
on O 
the O 
intestinal O 
absorption O 
of O 
the O 
HIV O 
protease O 
inhibitor O 
indinavir B-TRIVIAL 
using O 
simulated O 
and O 
human O 
intestinal O 
fluids O 
in O 
the O 
in O 
situ O 
intestinal O 
perfusion O 
technique O 
in O 
mice O 
. O 
Although O 
the O 
solubility O 
of O 
indinavir B-TRIVIAL 
was O 
6-fold O 
higher O 
in O 
fed O 
state O 
human O 
intestinal O 
fluids O 
( O 
FeHIF O 
) O 
as O 
compared O 
to O 
fasted O 
state O 
HIF O 
( O 
FaHIF O 
) O 
, O 
the O 
intestinal O 
permeation O 
of O 
indinavir B-TRIVIAL 
was O 
22-fold O 
lower O 
in O 
FeHIF O 
as O 
compared O 
to O 
FaHIF O 
. O 
Dialysis O 
experiments O 
showed O 
that O 
only O 
a O 
small O 
fraction O 
of O 
indinavir B-TRIVIAL 
is O 
accessible O 
for O 
absorption O 
in O 
FeHIF O 
due O 
to O 
micellar O 
entrapment O 
, O 
possibly O 
explaining O 
its O 
low O 
intestinal O 
permeation O 
. O 
The O 
presence O 
of O 
ritonavir B-TRIVIAL 
, O 
a O 
known O 
P-gp O 
inhibitor O 
, O 
increased O 
the O 
intestinal O 
permeation O 
of O 
indinavir B-TRIVIAL 
by O 
2-fold O 
in O 
FaHIF O 
, O 
while O 
there O 
was O 
no O 
increase O 
when O 
using O 
FeHIF O 
. O 
These O 
data O 
confirm O 
that O 
drug O 
- O 
food O 
interactions O 
form O 
a O 
complex O 
interplay O 
between O 
solubility O 
and O 
permeability O 
effects O 
. O 
The O 
use O 
of O 
HIF O 
in O 
in O 
situ O 
intestinal O 
perfusions O 
holds O 
great O 
promise O 
for O 
biorelevant O 
absorption O 
evaluation O 
as O 
it O 
allows O 
to O 
directly O 
explore O 
this O 
complex O 
solubility O 
/ O 
permeability O 
interplay O 
on O 
drug O 
absorption O 
. O 

and O 
anti-Candida O 
activity O 
of O 
novel O 
2-hydrazino-1,3-thiazole B-SYSTEMATIC 
derivatives O 
. O 

new O 
hydrazino-1,3-thiazole B-SYSTEMATIC 
derivatives O 
were O 
evaluated O 
against O 
8 O 
strains O 
of O 
multi O 
- O 
resistant O 
Candida O 
spp O 
. O 
Introduction O 
of O 
an O 
indolyl B-SYSTEMATIC 
moiety O 
linked O 
to O 
the O 
hydrazone B-FAMILY 
function O 
enhanced O 
the O 
in O 
vitro O 
anti-Candida O 
activity O 
, O 
with O 
an O 
activity O 
spectrum O 
towards O 
Candida O 
albicans O 
strains O 
. O 
Introduction O 
of O 
a O 
(S)-2-aminoethyl B-SYSTEMATIC 
chain O 
on O 
the O 
thiazole B-SYSTEMATIC 
nucleus O 
largely O 
enhanced O 
the O 
in O 
vitro O 
antifungal O 
activity O 
, O 
with O 
a O 
selectivity O 
oriented O 
towards O 
non-C O 
. O 
albicans O 
species O 
. O 

co O 
- O 
delivery O 
of O 
docetaxel B-TRIVIAL 
, O 
cisplatin B-TRIVIAL 
and O 
herceptin O 
by O 
vitamin B-FAMILY 
E I-FAMILY 
TPGS B-ABBREVIATION 
- O 
cisplatin B-TRIVIAL 
prodrug O 
nanoparticles O 
for O 
multimodality O 
treatment O 
of O 
cancer O 
. O 

developed O 
a O 
nanocarrier O 
system O 
of O 
herceptin O 
- O 
conjugated O 
nanoparticles O 
of O 
d-alpha-tocopheryl-co-poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
1000 I-SYSTEMATIC 
succinate I-SYSTEMATIC 
( O 
TPGS B-ABBREVIATION 
)- O 
cisplatin B-TRIVIAL 
prodrug O 
( O 
HTCP O 
NPs O 
) O 
for O 
targeted O 
co O 
- O 
delivery O 
of O 
cisplatin B-TRIVIAL 
, O 
docetaxel B-TRIVIAL 
and O 
herceptin O 
for O 
multimodality O 
treatment O 
of O 
breast O 
cancer O 
of O 
high O 
human O 
epidermal O 
growth O 
factor O 
receptor O 
2 O 
( O 
HER2 O 
) O 
overexpression O 
. O 
Co-polymers O 
poly(lactic B-SYSTEMATIC 
acid)-TPGS I-SYSTEMATIC 
( O 
PLA-TPGS B-ABBREVIATION 
) O 
and O 
carboxyl B-SYSTEMATIC 
group O 
- O 
terminated O 
TPGS B-ABBREVIATION 
( O 
TPGS B-ABBREVIATION 
- O 
COOH B-FORMULA 
) O 
were O 
also O 
added O 
in O 
the O 
polymeric O 
matrix O 
to O 
stabilize O 
the O 
prodrug O 
nanoparticles O 
and O 
to O 
facilitate O 
herceptin O 
conjugation O 
. O 
The O 
HTCP O 
NPs O 
of O 
high O 
, O 
moderate O 
and O 
low O 
docetaxel B-TRIVIAL 
versus O 
cisplatin B-TRIVIAL 
ratio O 
were O 
prepared O 
by O 
the O 
nanoprecipitation O 
method O 
, O 
which O 
showed O 
a O 
pH-sensitive O 
release O 
for O 
both O 
anticancer O 
drugs O 
. O 
The O 
therapeutic O 
effects O 
of O 
HTCP O 
NPs O 
were O 
evaluated O 
in O 
vitro O 
and O 
compared O 
with O 
Taxotere B-TRIVIAL 
® O 
and O 
cisplatin B-TRIVIAL 
. O 
The O 
HTCP O 
NPs O 
of O 
high O 
docetaxel B-TRIVIAL 
versus O 
cisplatin B-TRIVIAL 
ratio O 
were O 
found O 
to O 
have O 
better O 
efficacy O 
than O 
those O 
of O 
moderate O 
and O 
low O 
docetaxel B-TRIVIAL 
versus O 
cisplatin B-TRIVIAL 
ratio O 
. O 
The O 
targeting O 
effects O 
of O 
the O 
HTCP O 
NPs O 
were O 
demonstrated O 
by O 
a O 
much O 
lower O 
IC50 O 
value O 
of O 
0.0201 O 
+ O 
0.0078 O 
+ O 
0.1629μg O 
/ O 
mL O 
of O 
docetaxel B-TRIVIAL 
+ O 
cisplatin B-TRIVIAL 
+ O 
herceptin O 
for O 
SK-BR-3 O 
cells O 
, O 
which O 
are O 
of O 
high O 
HER2 O 
overexpression O 
, O 
than O 
that O 
of O 
0.225 O 
+ O 
0.0875 O 
+ O 
1.827μg O 
/ O 
mL O 
for O 
NIH3T3 O 
cells O 
, O 
which O 
are O 
of O 
low O 
HER2 O 
overexpression O 
, O 
after O 
24h O 
incubation O 
. O 
The O 
same O 
design O 
of O 
TPGS O 
prodrug O 
nanoparticles O 
can O 
also O 
be O 
applied O 
for O 
targeted O 
co O 
- O 
delivery O 
of O 
other O 
hydrophilic O 
and O 
hydrophobic O 
drugs O 
. O 

quantum O 
chemical O 
energies O 
for O 
tetrapeptide B-FAMILY 
conformations O 
: O 
why O 
MP2 O 
data O 
with O 
an O 
insufficient O 
basis O 
set O 
should O 
be O 
handled O 
with O 
caution O 
. O 

- O 
level O 
quantum O 
chemical O 
calculations O 
have O 
been O 
carried O 
out O 
for O 
biologically O 
- O 
relevant O 
conformers O 
of O 
tetrapeptides B-FAMILY 
. O 
Our O 
results O 
indicate O 
potential O 
problems O 
if O 
the O 
widely O 
- O 
applied O 
MP2 O 
approach O 
is O 
used O 
in O 
such O 
situations O 
with O 
basis O 
sets O 
of O 
insufficient O 
size O 
. O 
Efficient O 
alternatives O 
are O 
discussed O 
. O 

effects O 
between O 
CA1 O 
mu O 
opioid O 
and O 
dopamine B-TRIVIAL 
D1 O 
- O 
like O 
receptors O 
in O 
impaired O 
passive O 
avoidance O 
performance O 
induced O 
by O 
hepatic O 
encephalopathy O 
in O 
mice O 
. O 

AND O 
AIM O 
: O 
Numerous O 
investigations O 
have O 
indicated O 
that O 
hepatic O 
encephalopathy O 
( O 
HE O 
) O 
alters O 
the O 
levels O 
of O 
various O 
neurotransmitters O 
. O 
However O 
, O 
comprehensive O 
data O 
regarding O 
the O 
effects O 
of O 
CA1 O 
opioidergic O 
and O 
dopaminergic O 
( O 
DAergic O 
) O 
systems O 
on O 
HE-induced O 
amnesia O 
are O 
still O 
lacking O 
. O 
METHODS O 
: O 
Following O 
intra O 
- O 
dorsal O 
hippocampal O 
( O 
CA1 O 
) O 
injection O 
of O 
mu O 
opioid O 
and O 
dopamine B-TRIVIAL 
D1- O 
and O 
D2 O 
- O 
like O 
receptors O 
antagonists O 
in O 
male O 
mice O 
, O 
one O 
- O 
trial O 
step O 
- O 
down O 
and O 
hole O 
- O 
board O 
paradigms O 
were O 
used O 
to O 
assess O 
memory O 
and O 
exploratory O 
behaviors O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Our O 
data O 
demonstrated O 
that O 
HE O 
impairs O 
memory O 
24 O 
days O 
after O 
bile O 
duct O 
ligation O 
( O 
BDL O 
) O 
. O 
Furthermore O 
, O 
while O 
the O 
higher O 
dose O 
of O 
DA O 
D1 O 
- O 
like O 
receptor O 
antagonist O 
( O 
SCH23390 B-IDENTIFIER 
, O 
0.5 O 
μg O 
/ O 
mouse O 
) O 
induced O 
amnesia O 
and O 
anxiogenic O 
- O 
like O 
behaviors O 
, O 
mu O 
receptor O 
antagonist O 
( O 
naloxone B-TRIVIAL 
: O 
0.0125 O 
, O 
0.025 O 
and O 
0.05 O 
μg O 
/ O 
mouse O 
) O 
and O 
DA O 
D2 O 
- O 
like O 
receptor O 
antagonist O 
( O 
sulpiride B-TRIVIAL 
: O 
0.0625 O 
, O 
0.125 O 
and O 
0.25 O 
μg O 
/ O 
mouse O 
) O 
by O 
themselves O 
, O 
could O 
not O 
exert O 
an O 
effect O 
on O 
memory O 
performance O 
in O 
passive O 
avoidance O 
task O 
. O 
On O 
the O 
other O 
hand O 
, O 
pre O 
- O 
test O 
injection O 
of O 
all O 
drugs O 
reversed O 
the O 
HE-induced O 
amnesia O 
24 O 
days O 
after O 
BDL O 
, O 
while O 
having O 
no O 
effect O 
on O 
exploratory O 
behaviors O 
. O 
Pre O 
- O 
test O 
co O 
- O 
administration O 
of O 
the O 
subthreshold O 
dose O 
SCH23390 B-IDENTIFIER 
( O 
0.25 O 
μg O 
/ O 
mouse O 
) O 
and O 
sulpiride B-TRIVIAL 
( O 
0.0625 O 
μg O 
/ O 
mouse O 
) O 
or O 
naloxone B-TRIVIAL 
( O 
0.0125 O 
μg O 
/ O 
mouse O 
) O 
could O 
likewise O 
reverse O 
the O 
BDL-induced O 
amnesia O 
. O 
However O 
, O 
when O 
the O 
subthreshold O 
sulpiride B-TRIVIAL 
plus O 
naloxone B-TRIVIAL 
were O 
co O 
- O 
administered O 
, O 
BDL-induced O 
amnesia O 
was O 
not O 
blocked O 
. O 
CONCLUSIONS O 
: O 
Memory O 
performance O 
is O 
impaired O 
24 O 
days O 
post O 
BDL O 
and O 
CA1 O 
mu O 
opioid O 
and O 
DA O 
D1 O 
- O 
like O 
receptors O 
antagonist O 
synergistic O 
effects O 
are O 
likely O 
involved O 
in O 
this O 
phenomenon O 
. O 

/ O 
HYPOTHESIS O 
: O 
We O 
examined O 
the O 
effects O 
of O 
serum O 
insulin O 
levels O 
on O 
vagal O 
control O 
over O 
the O 
heart O 
and O 
tested O 
the O 
hypothesis O 
that O 
higher O 
fasting O 
insulin O 
levels O 
are O 
associated O 
with O 
lower O 
vagal O 
control O 
. O 
We O 
also O 
examined O 
whether O 
experimentally O 
induced O 
increases O 
in O 
insulin O 
by O 
beta O 
cell O 
secretagogues O 
, O 
including O 
glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
, O 
will O 
decrease O 
vagal O 
control O 
. O 
METHODS O 
: O 
Respiration O 
and O 
ECGs O 
were O 
recorded O 
for O 
130 O 
healthy O 
participants O 
undergoing O 
clamps O 
. O 
Three O 
variables O 
of O 
cardiac O 
vagal O 
effects O 
( O 
the O 
root O 
mean O 
square O 
of O 
successive O 
differences O 
[ O 
rMSSD O 
] O 
in O 
the O 
interbeat O 
interval O 
of O 
the O 
heart O 
rate O 
[ O 
IBI O 
] O 
, O 
heart O 
- O 
rate O 
variability O 
[ O 
HRV O 
] O 
caused O 
by O 
peak O 
- O 
valley O 
respiratory O 
sinus O 
arrhythmia O 
[ O 
pvRSA O 
] O 
, O 
and O 
high O 
- O 
frequency O 
power O 
[ O 
HF O 
] O 
) O 
and O 
heart O 
rate O 
( O 
HR O 
) O 
were O 
obtained O 
at O 
seven O 
time O 
points O 
during O 
the O 
clamps O 
, O 
characterised O 
by O 
increasing O 
levels O 
of O 
insulin O 
( O 
achieved O 
by O 
administering O 
insulin O 
plus O 
glucose B-TRIVIAL 
, O 
glucose B-TRIVIAL 
only O 
, O 
glucose B-TRIVIAL 
and O 
GLP-1 O 
, O 
and O 
glucose B-TRIVIAL 
and O 
GLP-1 O 
combined O 
with O 
arginine B-TRIVIAL 
) O 
. O 
RESULTS O 
: O 
Serum O 
insulin O 
level O 
was O 
positively O 
associated O 
with O 
HR O 
at O 
all O 
time O 
points O 
during O 
the O 
clamps O 
except O 
the O 
first O 
- O 
phase O 
hyperglycaemic O 
clamp O 
. O 
Insulin O 
levels O 
were O 
negatively O 
correlated O 
with O 
variables O 
of O 
vagal O 
control O 
, O 
reaching O 
significance O 
for O 
rMSSD O 
and O 
log(10)HF O 
, O 
but O 
not O 
for O 
pvRSA O 
, O 
during O 
the O 
last O 
four O 
phases O 
of O 
the O 
hyperglycaemic O 
clamp O 
( O 
hyperglycaemic O 
second O 
phase O 
, O 
GLP-1 O 
first O 
and O 
second O 
phases O 
, O 
and O 
arginine B-TRIVIAL 
) O 
. O 
These O 
associations O 
disappeared O 
when O 
adjusted O 
for O 
age O 
, O 
BMI O 
and O 
insulin O 
sensitivity O 
. O 
Administration O 
of O 
the O 
beta O 
cell O 
secretagogues O 
GLP-1 O 
and O 
arginine B-TRIVIAL 
led O 
to O 
a O 
significant O 
increase O 
in O 
HR O 
, O 
but O 
this O 
was O 
not O 
paired O 
with O 
a O 
significant O 
reduction O 
in O 
HRV O 
measures O 
. O 
CONCLUSION O 
/ O 
INTERPRETATION O 
: O 
Experimentally O 
induced O 
hyperinsulinaemia O 
is O 
not O 
correlated O 
with O 
cardiac O 
vagal O 
control O 
or O 
HR O 
when O 
adjusting O 
for O 
age O 
, O 
BMI O 
and O 
insulin O 
sensitivity O 
index O 
. O 
Our O 
findings O 
suggest O 
that O 
exposure O 
to O 
a O 
GLP-1 O 
during O 
hyperglycaemia O 
leads O 
to O 
a O 
small O 
acute O 
increase O 
in O 
HR O 
but O 
not O 
to O 
an O 
acute O 
decrease O 
in O 
cardiac O 
vagal O 
control O 
. O 

elements O 
( O 
TEs O 
) O 
may O 
contribute O 
to O 
the O 
formation O 
of O 
calculi O 
or O 
stones O 
or O 
be O 
involved O 
in O 
the O 
aetiopathogenesis O 
of O 
stone O 
diseases O 
. O 
The O 
compositions O 
and O 
spatial O 
distribution O 
of O 
elements O 
from O 
the O 
inner O 
nucleus O 
to O 
outer O 
crust O 
of O 
the O 
cardiac O 
calculus O 
were O 
investigated O 
by O 
energy O 
- O 
dispersive O 
X-ray O 
fluorescence O 
( O 
EDXRF O 
) O 
spectrometer O 
. O 
The O 
surface O 
topograph O 
, O 
distribution O 
map O 
of O 
elements O 
, O 
elemental O 
and O 
chemical O 
compositions O 
were O 
also O 
determined O 
by O 
environmental O 
scanning O 
electron O 
microscope O 
(ESEM)-energy O 
- O 
dispersive O 
X-ray O 
( O 
EDX O 
) O 
analysis O 
. O 
Twenty O 
- O 
five O 
elements O 
were O 
identifiable O 
from O 
18 O 
positions O 
on O 
the O 
cardiac O 
calculus O 
by O 
EDXRF O 
spectrometer O 
, O 
in O 
which O 
the O 
highest O 
concentrations O 
of O 
toxic O 
TEs O 
( O 
Ni B-FORMULA 
, O 
Pt B-FORMULA 
, O 
Hg B-FORMULA 
, O 
Sn B-FORMULA 
, O 
Pb B-FORMULA 
, O 
W B-FORMULA 
, O 
Au B-FORMULA 
, O 
Al B-FORMULA 
, O 
Si B-FORMULA 
) O 
and O 
higher O 
levels O 
of O 
essential O 
TEs O 
( O 
Ca B-FORMULA 
, O 
Sr B-FORMULA 
, O 
Cr B-FORMULA 
, O 
P B-FORMULA 
) O 
were O 
detected O 
. O 
A O 
moderate O 
positive O 
Pearson's O 
correlation O 
between O 
TEs O 
concentrations O 
of O 
Mg B-FORMULA 
, O 
Ca B-FORMULA 
or O 
P B-FORMULA 
and O 
location O 
differences O 
from O 
centre O 
to O 
periphery O 
in O 
the O 
cardiac O 
calculus O 
was O 
observed O 
. O 
A O 
positive O 
correlation O 
was O 
also O 
found O 
for O 
Ca B-FORMULA 
/ O 
Zn B-FORMULA 
and O 
Ca B-FORMULA 
/ O 
Cu B-FORMULA 
, O 
indicating O 
the O 
gradual O 
increase O 
of O 
calcium B-SYSTEMATIC 
concentration O 
from O 
inner O 
nucleus O 
to O 
outer O 
crust O 
of O 
cardiac O 
calculus O 
. O 
The O 
drop O 
- O 
like O 
nodules O 
/ O 
crystals O 
on O 
the O 
surface O 
of O 
petrous O 
part O 
of O 
cardiac O 
calculus O 
were O 
observed O 
from O 
ESEM O 
analysis O 
. O 
ESEM-EDX O 
analysis O 
determined O 
the O 
calculus O 
to O 
be O 
predominantly O 
composed O 
of O 
calcium B-SYSTEMATIC 
hydroxyapatite I-SYSTEMATIC 
and O 
cholesterol B-TRIVIAL 
, O 
as O 
indicated O 
by O 
the O 
petrous O 
surface O 
and O 
drop O 
- O 
like O 
nodules O 
/ O 
crystals O 
, O 
respectively O 
. O 
This O 
composition O 
was O 
confirmed O 
using O 
a O 
portable O 
Raman O 
analyser O 
. O 
The O 
spatial O 
distribution O 
analysis O 
indicated O 
a O 
gradual O 
increase O 
in O 
Mg B-FORMULA 
, O 
P B-FORMULA 
and O 
Ca B-FORMULA 
concentrations O 
from O 
the O 
inner O 
nucleus O 
to O 
the O 
outer O 
crust O 
of O 
the O 
cardiac O 
calculus O 
. O 
The O 
major O 
chemical O 
compositions O 
of O 
calcium B-SYSTEMATIC 
hydroxyapatite I-SYSTEMATIC 
and O 
cholesterol B-TRIVIAL 
were O 
detected O 
on O 
this O 
cardiac O 
calculus O 
. O 

of O 
marine O 
triterpene B-FAMILY 
sipholenols B-FAMILY 
as O 
inhibitors O 
of O 
breast O 
cancer O 
migration O 
and O 
invasion O 
. O 

A I-TRIVIAL 
, O 
a O 
sipholane B-FAMILY 
triterpene I-FAMILY 
isolated O 
from O 
the O 
Red O 
Sea O 
sponge O 
Callyspongia O 
siphonella O 
, O 
has O 
the O 
ability O 
to O 
reverse O 
multidrug O 
resistance O 
in O 
cancer O 
cells O 
that O 
overexpress O 
P-glycoprotein O 
( O 
P-gp O 
) O 
. O 
Here O 
, O 
the O 
antimigratory O 
activity O 
of O 
sipholenol B-TRIVIAL 
A I-TRIVIAL 
and O 
analogues O 
are O 
reported O 
against O 
the O 
highly O 
metastatic O 
human O 
breast O 
cancer O 
cell O 
line O 
MDA-MB-231 O 
in O 
a O 
wound O 
- O 
healing O 
assay O 
. O 
Sipholenol B-TRIVIAL 
A I-TRIVIAL 
and O 
sipholenone B-TRIVIAL 
A I-TRIVIAL 
were O 
semisynthetically O 
optimized O 
using O 
ligand O 
- O 
based O 
strategies O 
to O 
generate O 
structurally O 
diverse O 
analogues O 
in O 
an O 
attempt O 
to O 
maximize O 
their O 
antimigratory O 
activity O 
. O 
A O 
total O 
of O 
22 O 
semisynthetic O 
ester B-FAMILY 
, O 
ether B-SYSTEMATIC 
, O 
oxime B-SYSTEMATIC 
, O 
and O 
carbamate B-FAMILY 
analogues O 
were O 
generated O 
and O 
identified O 
by O 
extensive O 
one- O 
and O 
two O 
- O 
dimensional O 
NMR O 
spectroscopy O 
and O 
high O 
- O 
resolution O 
mass O 
spectrometry O 
analyses O 
. O 
Sipholenol B-SYSTEMATIC 
A I-SYSTEMATIC 
4β-4-chlorobenzoate I-SYSTEMATIC 
and O 
19,20-anhydrosipholenol B-SYSTEMATIC 
A I-SYSTEMATIC 
4β-4-chlorobenzoate I-SYSTEMATIC 
esters B-FAMILY 
were O 
the O 
most O 
potent O 
of O 
all O 
tested O 
analogues O 
in O 
the O 
wound O 
- O 
healing O 
assay O 
, O 
with O 
IC(50) O 
values O 
of O 
5.3 O 
and O 
5.9 O 
μM O 
, O 
respectively O 
. O 
Generally O 
, O 
ester O 
derivatives O 
showed O 
better O 
antimigratory O 
activities O 
than O 
the O 
carbamate B-FAMILY 
analogues O 
. O 
A O 
KINOMEscan O 
of O 
19,20-anhydrosipholenol B-SYSTEMATIC 
A I-SYSTEMATIC 
4β-benzoate I-SYSTEMATIC 
ester I-SYSTEMATIC 
against O 
451 O 
human O 
protein O 
kinases O 
identified O 
protein O 
tyrosine B-TRIVIAL 
kinase O 
6 O 
( O 
PTK6 O 
) O 
as O 
a O 
potential O 
target O 
. O 
In O 
breast O 
tumor O 
cells O 
, O 
PTK6 O 
promotes O 
growth O 
factor O 
signaling O 
and O 
migration O 
, O 
and O 
as O 
such O 
the O 
semisynthetic O 
sipholanes B-FAMILY 
were O 
evaluated O 
for O 
their O 
ability O 
to O 
inhibit O 
PTK6 O 
phosphorylation O 
in O 
vitro O 
. O 
The O 
two O 
analogues O 
with O 
the O 
highest O 
antimigratory O 
activities O 
, O 
sipholenol B-SYSTEMATIC 
A I-SYSTEMATIC 
4β-4-chlorobenzoate I-SYSTEMATIC 
and O 
19,20-anhydrosipholenol B-SYSTEMATIC 
A I-SYSTEMATIC 
4β-4-chlorobenzoate I-SYSTEMATIC 
esters B-FAMILY 
, O 
also O 
exhibited O 
the O 
most O 
potent O 
inhibition O 
of O 
PTK6 O 
phosphorylation O 
inhibition O 
. O 
None O 
of O 
the O 
compounds O 
exhibited O 
cytotoxicity O 
in O 
a O 
normal O 
epithelial O 
breast O 
cell O 
line O 
. O 
These O 
derivatives O 
were O 
evaluated O 
in O 
an O 
in O 
vitro O 
invasion O 
assay O 
, O 
where O 
sipholenol B-TRIVIAL 
A I-TRIVIAL 
succinate I-TRIVIAL 
potently O 
inhibited O 
MDA-MB-231 O 
cell O 
invasion O 
at O 
10 O 
μM O 
. O 
These O 
results O 
highlight O 
sipholane B-FAMILY 
triterpenoids I-FAMILY 
as O 
novel O 
antimigratory O 
marine O 
natural O 
products O 
with O 
potential O 
for O 
further O 
development O 
as O 
agents O 
for O 
the O 
control O 
of O 
metastatic O 
breast O 
malignancies O 
. O 

studies O 
identifying O 
entry O 
inhibitor O 
scaffolds O 
targeting O 
the O 
Phe B-FORMULA 
43 O 
cavity O 
of O 
HIV-1 O 
gp120 O 
. O 

protein O 
- O 
protein O 
interactions O 
, O 
such O 
as O 
the O 
HIV-1 O 
gp120-CD4 O 
interface O 
, O 
has O 
become O 
a O 
cutting O 
- O 
edge O 
approach O 
in O 
the O 
current O 
drug O 
discovery O 
scenario O 
. O 
Many O 
small O 
molecules O 
have O 
been O 
developed O 
so O 
far O 
as O 
inhibitors O 
of O 
the O 
interaction O 
between O 
CD4 O 
and O 
HIV-1 O 
gp120 O 
. O 
However O 
, O 
due O 
to O 
a O 
variety O 
of O 
reasons O 
such O 
as O 
solubility O 
, O 
drug O 
toxicity O 
and O 
drug O 
resistance O 
, O 
these O 
inhibitors O 
have O 
failed O 
to O 
prove O 
clinically O 
useful O 
. O 
As O 
such O 
, O 
the O 
identification O 
of O 
novel O 
compounds O 
that O 
bind O 
to O 
protein O 
- O 
protein O 
interactions O 
is O 
still O 
a O 
research O 
area O 
of O 
considerable O 
interest O 
. O 
Here O 
, O 
a O 
structure O 
- O 
based O 
virtual O 
screening O 
approach O 
was O 
successfully O 
applied O 
with O 
the O 
aim O 
of O 
identifying O 
novel O 
HIV-1 O 
entry O 
inhibitors O 
targeting O 
the O 
Phe43 O 
pocket O 
of O 
HIV-1 O 
gp120 O 
. O 
Several O 
compounds O 
able O 
to O 
inhibit O 
viral O 
replication O 
in O 
cell O 
culture O 
were O 
identified O 
, O 
with O 
the O 
best O 
agent O 
endowed O 
with O 
an O 
EC(50) O 
value O 
of O 
0.9 O 
μM O 
. O 
Inactivity O 
of O 
all O 
the O 
identified O 
hits O 
toward O 
a O 
mutant O 
( O 
Met475Ile O 
) O 
strain O 
strongly O 
suggests O 
that O 
they O 
interact O 
in O 
the O 
Phe B-FORMULA 
43 O 
cavity O 
of O 
gp120 O 
, O 
as O 
intended O 
. O 
Remarkably O 
, O 
all O 
of O 
these O 
small O 
molecules O 
have O 
a O 
chemical O 
scaffold O 
unrelated O 
to O 
any O 
known O 
class O 
of O 
entry O 
inhibitors O 
reported O 
thus O 
far O 
. O 
Overall O 
, O 
our O 
strategy O 
led O 
to O 
the O 
identification O 
of O 
four O 
novel O 
chemical O 
scaffolds O 
that O 
inhibit O 
HIV-1 O 
replication O 
through O 
the O 
destabilization O 
of O 
the O 
HIV-1 O 
gp120-CD4 O 
interface O 
. O 

and O 
evaluation O 
of O 
4-aminophenol B-SYSTEMATIC 
and O 
salicylate B-SYSTEMATIC 
derivatives O 
as O 
free O 
- O 
radical O 
scavenger O 
. O 

theoretical O 
and O 
experimental O 
study O 
describes O 
the O 
design O 
and O 
evaluation O 
of O 
the O 
free O 
- O 
radical O 
scavenging O 
effect O 
for O 
the O 
molecular O 
association O 
of O 
4-aminophenol B-SYSTEMATIC 
and O 
salicylate B-SYSTEMATIC 
derivatives O 
. O 
For O 
this O 
purpose O 
, O 
we O 
employed O 
theoretical O 
methods O 
for O 
the O 
selection O 
of O 
antioxidant O 
drugs O 
and O 
the O 
rapid O 
methods O 
of O 
evaluation O 
: O 
the O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
radical O 
and O 
the O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
in O 
the O 
lipid O 
peroxidation O 
initiated O 
by O 
Fe(2+) B-FORMULA 
and O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
in O 
human O 
erythrocytes O 
. O 
The O 
associate O 
derivatives O 
exhibited O 
a O 
more O 
potent O 
inhibition O 
than O 
the O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
, O 
while O 
the O 
benzoyl B-SYSTEMATIC 
compound O 
exhibited O 
a O 
more O 
potent O 
inhibition O 
than O 
paracetamol B-TRIVIAL 
. O 
The O 
molecular O 
parameters O 
related O 
to O 
the O 
electron O 
distribution O 
and O 
structure O 
( O 
ionization O 
potential O 
and O 
energy O 
of O 
the O 
highest O 
occupied O 
molecular O 
orbital O 
) O 
correlated O 
very O 
well O 
with O 
the O 
antioxidant O 
action O 
of O 
the O 
compounds O 
studied O 
here O 
in O 
different O 
tests O 
. O 

new O 
O-prenylated B-FAMILY 
flavonol I-FAMILY 
from O 
the O 
roots O 
of O 
Sophora O 
interrupta O 
. O 

new O 
O-prenylated B-FAMILY 
flavonol I-FAMILY 
, O 
3',4'-dimethoxy-7-(γ,γ-dimethylallyloxy)flavonol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
three O 
known O 
compounds O 
, O 
2'-hydroxy-3,4-dimethoxychalcone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
biochanin B-TRIVIAL 
A I-TRIVIAL 
( O 
3 O 
) O 
and O 
kaempferol-3-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Sophora O 
interrupta O 
Bedd O 
. O 
The O 
structure O 
of O 
compound O 
1 O 
was O 
elucidated O 
by O 
extensive O 
1D O 
and O 
2D O 
NMR O 
spectral O 
studies O 
. O 

of O 
binuclear O 
ruthenium B-SYSTEMATIC 
(II) I-SYSTEMATIC 
complexes O 
with O 
oligonucleotides O 
in O 
hydrogel O 
matrix O 
: O 
enantioselective O 
threading O 
intercalation O 
into O 
GC O 
context O 
. O 

stretched O 
poly(vinyl B-SYSTEMATIC 
alcohol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVA B-ABBREVIATION 
) O 
film O 
provides O 
a O 
unique O 
matrix O 
that O 
enables O 
also O 
short O 
DNA O 
oligonucleotide O 
duplex O 
to O 
be O 
oriented O 
and O 
studied O 
by O 
linear O 
dichroism O 
( O 
LD O 
) O 
. O 
This O 
matrix O 
further O 
allows O 
controlling O 
DNA O 
secondary O 
structure O 
by O 
proper O 
hydration O 
( O 
A O 
or O 
B O 
form O 
) O 
, O 
and O 
such O 
humid O 
films O 
could O 
potentially O 
also O 
mimic O 
the O 
molecular O 
crowding O 
in O 
cellular O 
contexts O 
. O 
However O 
, O 
early O 
attempts O 
to O 
study O 
intercalators O 
and O 
groove O 
binders O 
for O 
probing O 
DNA O 
in O 
PVA B-ABBREVIATION 
failed O 
due O 
to O 
competitive O 
matrix O 
binding O 
. O 
Here O 
we O 
report O 
the O 
successful O 
orientation O 
in O 
PVA B-ABBREVIATION 
of O 
DNA O 
oligonucleotide O 
duplex O 
hairpins O 
with O 
thread O 
- O 
intercalated O 
binuclear O 
complex O 
[μ-(11,11'-bidppz)(phen)4Ru2](4+) B-FORMULA 
, O 
and O 
how O 
LD O 
depends O 
on O 
oligonucleotide O 
sequence O 
and O 
metal O 
center O 
chirality O 
. O 
Opposite O 
enantiomers O 
of O 
the O 
ruthenium B-SYSTEMATIC 
complex O 
, O 
ΔΔ O 
and O 
ΛΛ O 
, O 
were O 
investigated O 
with O 
respect O 
to O 
enantioselectivity O 
toward O 
GC O 
stretches O 
as O 
long O 
as O 
22 O 
bp O 
. O 
LD O 
, O 
supported O 
by O 
emission O 
kinetics O 
, O 
reveals O 
that O 
threading O 
intercalation O 
occurs O 
only O 
with O 
ΔΔ O 
whereas O 
ΛΛ O 
remains O 
externally O 
bound O 
, O 
probably O 
in O 
either O 
or O 
both O 
of O 
the O 
grooves O 
of O 
the O 
GC-DNA O 
. O 
Enantioselective O 
binding O 
properties O 
of O 
sterically O 
rigid O 
DNA O 
probes O 
such O 
as O 
the O 
ruthenium B-SYSTEMATIC 
complexes O 
could O 
find O 
applications O 
for O 
targeting O 
nucleic O 
acids O 
, O 
e.g O 
. O 
, O 
to O 
inhibit O 
transcription O 
in O 
therapeutic O 
context O 
such O 
as O 
treatment O 
of O 
malaria O 
or O 
cancer O 
. O 

study O 
of O 
chain O 
transfer O 
to O 
monomer O 
reactions O 
in O 
high O 
- O 
temperature O 
polymerization O 
of O 
alkyl B-FAMILY 
acrylates I-FAMILY 
. O 

article O 
presents O 
a O 
computational O 
study O 
of O 
chain O 
transfer O 
to O 
monomer O 
( O 
CTM O 
) O 
reactions O 
in O 
self O 
- O 
initiated O 
high O 
- O 
temperature O 
homopolymerization O 
of O 
alkyl B-FAMILY 
acrylates I-FAMILY 
( O 
methyl B-MULTIPLE 
, I-MULTIPLE 
ethyl I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
n-butyl I-MULTIPLE 
acrylate I-MULTIPLE 
) O 
. O 
Several O 
mechanisms O 
of O 
CTM O 
are O 
studied O 
. O 
The O 
effects O 
of O 
the O 
length O 
of O 
live O 
polymer O 
chains O 
and O 
the O 
type O 
of O 
monoradical O 
that O 
initiated O 
the O 
live O 
polymer O 
chains O 
on O 
the O 
energy O 
barriers O 
and O 
rate O 
constants O 
of O 
the O 
involved O 
reaction O 
steps O 
are O 
investigated O 
theoretically O 
. O 
All O 
calculations O 
are O 
carried O 
out O 
using O 
density O 
functional O 
theory O 
. O 
Three O 
types O 
of O 
hybrid O 
functionals O 
( O 
B3LYP O 
, O 
X3LYP O 
, O 
and O 
M06-2X O 
) O 
and O 
four O 
basis O 
sets O 
( O 
6-31G(d) O 
, O 
6-31G(d,p) O 
, O 
6-311G(d) O 
, O 
and O 
6-311G(d,p) O 
) O 
are O 
applied O 
to O 
predict O 
the O 
molecular O 
geometries O 
of O 
the O 
reactants O 
, O 
products O 
and O 
transition O 
sates O 
, O 
and O 
energy O 
barriers O 
. O 
Transition O 
state O 
theory O 
is O 
used O 
to O 
estimate O 
rate O 
constants O 
. O 
The O 
results O 
indicate O 
that O 
abstraction O 
of O 
a O 
hydrogen B-SYSTEMATIC 
atom O 
( O 
by O 
live O 
polymer O 
chains O 
) O 
from O 
the O 
methyl B-SYSTEMATIC 
group O 
in O 
methyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
, O 
the O 
methylene B-SYSTEMATIC 
group O 
in O 
ethyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
, O 
and O 
methylene B-SYSTEMATIC 
groups O 
in O 
n-butyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
are O 
the O 
most O 
likely O 
mechanisms O 
of O 
CTM O 
. O 
Also O 
, O 
the O 
rate O 
constants O 
of O 
CTM O 
reactions O 
calculated O 
using O 
M06-2X O 
are O 
in O 
good O 
agreement O 
with O 
those O 
estimated O 
from O 
polymer O 
sample O 
measurements O 
using O 
macroscopic O 
mechanistic O 
models O 
. O 
The O 
rate O 
constant O 
values O 
do O 
not O 
change O 
significantly O 
with O 
the O 
length O 
of O 
live O 
polymer O 
chains O 
. O 
Abstraction O 
of O 
a O 
hydrogen B-SYSTEMATIC 
atom O 
by O 
a O 
tertiary O 
radical O 
has O 
a O 
higher O 
energy O 
barrier O 
than O 
abstraction O 
by O 
a O 
secondary O 
radical O 
, O 
which O 
agrees O 
with O 
experimental O 
findings O 
. O 
The O 
calculated O 
and O 
experimental O 
NMR O 
spectra O 
of O 
dead O 
polymer O 
chains O 
produced O 
by O 
CTM O 
reactions O 
are O 
comparable O 
. O 
This O 
theoretical O 
/ O 
computational O 
study O 
reveals O 
that O 
CTM O 
occurs O 
most O 
likely O 
via O 
hydrogen B-SYSTEMATIC 
abstraction O 
by O 
live O 
polymer O 
chains O 
from O 
the O 
methyl B-SYSTEMATIC 
group O 
of O 
methyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
and O 
methylene B-SYSTEMATIC 
group(s) O 
of O 
ethyl B-SYSTEMATIC 
( I-SYSTEMATIC 
n-butyl I-SYSTEMATIC 
) I-SYSTEMATIC 
acrylate I-SYSTEMATIC 
. O 

triaryl B-FAMILY 
sulfonamide I-FAMILY 
derivatives O 
as O 
selective O 
cannabinoid O 
receptor O 
2 O 
inverse O 
agonists O 
and O 
osteoclast O 
inhibitors O 
: O 
discovery O 
, O 
optimization O 
, O 
and O 
biological O 
evaluation O 
. O 

receptors O 
have O 
gained O 
increasing O 
attention O 
as O 
drug O 
targets O 
for O 
developing O 
potential O 
therapeutic O 
ligands O 
. O 
Here O 
, O 
we O 
report O 
the O 
discovery O 
and O 
optimization O 
of O 
triaryl B-FAMILY 
sulfonamides I-FAMILY 
as O 
a O 
novel O 
series O 
possessing O 
significant O 
CB2 O 
receptor O 
affinity O 
and O 
selectivity O 
. O 
Four O 
sets O 
of O 
triaryl B-FAMILY 
ligands O 
were O 
designed O 
and O 
synthesized O 
for O 
further O 
structural O 
modifications O 
and O 
led O 
to O 
the O 
identification O 
of O 
eight O 
compounds O 
as O 
potent O 
and O 
selective O 
CB2 O 
inverse O 
agonists O 
with O 
high O 
binding O 
affinity O 
( O 
CB2K O 
(i) O 
< O 
10 O 
nM O 
) O 
. O 
Especially O 
, O 
compound O 
57 O 
exhibited O 
the O 
strongest O 
binding O 
affinity O 
on O 
the O 
CB2 O 
receptor O 
( O 
CB2K O 
(i) O 
of O 
0.5 O 
nM O 
) O 
and O 
the O 
best O 
selectivity O 
over O 
the O 
CB1 O 
receptor O 
( O 
selectivity O 
index O 
of O 
2594 O 
) O 
. O 
Importantly O 
, O 
57 O 
also O 
showed O 
potent O 
inhibitory O 
activity O 
on O 
osteoclast O 
formation O 
, O 
and O 
it O 
was O 
confirmed O 
by O 
a O 
cell O 
viability O 
assay O 
that O 
the O 
inhibition O 
effects O 
were O 
not O 
derived O 
from O 
the O 
cytotoxicity O 
. O 
Finally O 
, O 
3D O 
QSAR O 
studies O 
confirmed O 
our O 
SAR O 
findings O 
that O 
three O 
bulky O 
groups O 
play O 
an O 
important O 
role O 
for O 
CB2 O 
receptor O 
binding O 
affinity O 
. O 

type O 
determines O 
the O 
light O 
- O 
induced O 
endosomal O 
escape O 
kinetics O 
of O 
multifunctional O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
. O 

investigated O 
uptake O 
and O 
individual O 
endosome O 
lysis O 
events O 
in O 
fibroblast O 
, O 
normal O 
, O 
and O 
carcinoma O 
cell O 
lines O 
using O 
a O 
colloidal O 
mesoporous O 
silica B-TRIVIAL 
( O 
CMS O 
) O 
nanoparticle O 
( O 
NP O 
) O 
- O 
based O 
reporter O 
system O 
with O 
a O 
covalently O 
attached O 
photosensitizer O 
. O 
Endosome O 
lysis O 
was O 
induced O 
through O 
the O 
activation O 
of O 
protoporphyrin B-TRIVIAL 
IX I-TRIVIAL 
( O 
PpIX B-ABBREVIATION 
) O 
. O 
Surprisingly O 
, O 
this O 
release O 
- O 
on O 
- O 
demand O 
system O 
resulted O 
in O 
more O 
broadly O 
distributed O 
lysis O 
times O 
than O 
expected O 
, O 
particularly O 
for O 
Renca O 
, O 
a O 
renal O 
carcinoma O 
cell O 
line O 
. O 
An O 
analysis O 
of O 
the O 
NP O 
load O 
per O 
endosome O 
, O 
endosome O 
size O 
, O 
and O 
uptake O 
characteristics O 
indicate O 
that O 
Renca O 
cells O 
not O 
only O 
take O 
up O 
a O 
lower O 
amount O 
of O 
NPs O 
in O 
comparison O 
with O 
the O 
fibroblast O 
cells O 
but O 
also O 
have O 
larger O 
endosomes O 
and O 
a O 
lower O 
NP O 
load O 
per O 
endosome O 
. O 
We O 
then O 
created O 
a O 
stochastic O 
model O 
detailing O 
steps O 
downstream O 
of O 
uptake O 
to O 
understand O 
how O 
much O 
factors O 
that O 
cannot O 
be O 
directly O 
measured O 
, O 
such O 
as O 
variations O 
in O 
the O 
PpIX B-ABBREVIATION 
load O 
per O 
NP O 
, O 
affect O 
the O 
lysis O 
time O 
distributions O 
. O 
Model O 
results O 
indicate O 
that O 
the O 
distributions O 
are O 
primarily O 
determined O 
by O 
the O 
endosome O 
properties O 
, O 
rather O 
than O 
variations O 
across O 
NPs O 
. O 

-like O 
nanotubes O 
: O 
structure O 
, O 
stability O 
, O 
electronic O 
and O 
mechanical O 
properties O 
of O 
the O 
phosphorous B-SYSTEMATIC 
and O 
arsenic B-SYSTEMATIC 
derivatives O 
. O 

is O 
a O 
single O 
- O 
walled O 
aluminosilicate B-TRIVIAL 
nanotube O 
( O 
NT O 
) O 
found O 
in O 
nature O 
that O 
can O 
be O 
easily O 
synthesized O 
, O 
as O 
well O 
as O 
its O 
analogue O 
aluminogermanate B-TRIVIAL 
NT O 
. O 
Based O 
on O 
geometrical O 
assumptions O 
and O 
pKa O 
values O 
, O 
species O 
such O 
as O 
H3PO4 B-FORMULA 
, O 
H3PO3 B-FORMULA 
, O 
H3AsO3 B-FORMULA 
, O 
H3AsO4 B-FORMULA 
could O 
also O 
be O 
candidates O 
to O 
form O 
imogolite B-TRIVIAL 
-like O 
structures O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
provide O 
insights O 
about O 
the O 
stability O 
, O 
electronic O 
, O 
structural O 
and O 
mechanical O 
properties O 
of O 
possible O 
imogolite B-TRIVIAL 
like O 
NTs O 
by O 
means O 
of O 
self O 
- O 
consistent O 
charge O 
density O 
- O 
functional O 
tight O 
- O 
binding O 
method O 
( O 
SCC-DFTB O 
) O 
. O 
Similarly O 
to O 
aluminogermanate B-TRIVIAL 
, O 
where O 
the O 
tetrahedral O 
silicate B-FAMILY 
groups O 
are O 
replaced O 
by O 
germanate B-SYSTEMATIC 
, O 
in O 
this O 
work O 
tetrahedral O 
silicate B-FAMILY 
groups O 
are O 
substituted O 
by O 
phosphate B-SYSTEMATIC 
, O 
phosphite B-SYSTEMATIC 
, O 
arsenate B-SYSTEMATIC 
and O 
arsenite B-SYSTEMATIC 
units O 
in O 
the O 
imogolite B-TRIVIAL 
structure O 
. O 
Detailed O 
analysis O 
is O 
focused O 
on O 
structural O 
properties O 
, O 
strain O 
energy O 
, O 
band O 
gap O 
and O 
Mulliken O 
charges O 
distribution O 
. O 
The O 
calculated O 
strain O 
energy O 
curves O 
for O 
all O 
studied O 
zigzag O 
imogolite B-TRIVIAL 
-like O 
NTs O 
present O 
well O 
- O 
defined O 
minima O 
, O 
which O 
change O 
as O 
a O 
consequence O 
of O 
composition O 
variation O 
. O 
Moreover O 
, O 
the O 
strain O 
energy O 
curves O 
of O 
armchair O 
imogolite B-TRIVIAL 
-like O 
NTs O 
also O 
present O 
minima O 
, O 
although O 
in O 
all O 
cases O 
less O 
stable O 
than O 
zigzags O 
by O 
at O 
least O 
2.2 O 
meV O 
per O 
atom O 
. O 
The O 
insulating O 
NT O 
behaviour O 
changes O 
after O 
internal O 
modification O 
from O 
silicate B-FAMILY 
to O 
phosphate B-SYSTEMATIC 
, O 
phosphite B-SYSTEMATIC 
, O 
arsenate B-SYSTEMATIC 
and O 
arsenite B-SYSTEMATIC 
, O 
as O 
well O 
as O 
the O 
charge O 
distribution O 
inside O 
and O 
outside O 
the O 
nanotubes O 
. O 

UDP B-ABBREVIATION 
-Glucuronosyltransferase O 
( O 
UGT O 
) O 
1A O 
Polymorphism O 
c.2042C O 
> O 
G O 
( O 
rs8330 O 
) O 
Is O 
Associated O 
with O 
Increased O 
Human O 
Liver O 
Acetaminophen B-TRIVIAL 
Glucuronidation O 
, O 
Increased O 
UGT1A O 
Exon O 
5a O 
/ O 
5b O 
Splice O 
Variant O 
mRNA O 
Ratio O 
, O 
and O 
Decreased O 
Risk O 
of O 
Unintentional O 
Acetaminophen B-TRIVIAL 
-Induced O 
Acute O 
Liver O 
Failure O 
. O 

is O 
cleared O 
primarily O 
by O 
hepatic O 
glucuronidation O 
. O 
Polymorphisms O 
in O 
genes O 
encoding O 
the O 
acetaminophen B-TRIVIAL 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
enzymes O 
could O 
explain O 
interindividual O 
variability O 
in O 
acetaminophen B-TRIVIAL 
glucuronidation O 
and O 
variable O 
risk O 
for O 
liver O 
injury O 
after O 
acetaminophen B-TRIVIAL 
overdose O 
. O 
In O 
this O 
study O 
, O 
human O 
liver O 
bank O 
samples O 
were O 
phenotyped O 
for O 
acetaminophen B-TRIVIAL 
glucuronidation O 
activity O 
and O 
genotyped O 
for O 
the O 
major O 
acetaminophen B-TRIVIAL 
-glucuronidating O 
enzymes O 
( O 
UGTs O 
1A1 O 
, O 
1A6 O 
, O 
1A9 O 
, O 
and O 
2B15 O 
) O 
. O 
Of O 
these O 
, O 
only O 
three O 
linked O 
single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
located O 
in O 
the O 
shared O 
UGT1A-3'UTR O 
region O 
( O 
rs10929303 O 
, O 
rs1042640 O 
, O 
rs8330 O 
) O 
were O 
associated O 
with O 
acetaminophen B-TRIVIAL 
glucuronidation O 
activity O 
, O 
with O 
rs8330 O 
consistently O 
showing O 
higher O 
acetaminophen B-TRIVIAL 
glucuronidation O 
at O 
all O 
the O 
tested O 
concentrations O 
of O 
acetaminophen B-TRIVIAL 
. O 
Mechanistic O 
studies O 
using O 
luciferase-UGT1A-3'UTR O 
reporters O 
indicated O 
that O 
these O 
SNPs O 
do O 
not O 
alter O 
mRNA O 
stability O 
or O 
translation O 
efficiency O 
. O 
However O 
, O 
there O 
was O 
evidence O 
for O 
allelic O 
imbalance O 
and O 
a O 
gene O 
- O 
dose O 
proportional O 
increase O 
in O 
the O 
amount O 
of O 
exon O 
5a O 
versus O 
exon O 
5b O 
containing O 
UGT1A O 
mRNA O 
spliced O 
transcripts O 
in O 
livers O 
with O 
the O 
rs8330 O 
variant O 
allele O 
. O 
Cotransfection O 
studies O 
demonstrated O 
an O 
inhibitory O 
effect O 
of O 
exon O 
5b O 
containing O 
cDNAs O 
on O 
acetaminophen B-TRIVIAL 
glucuronidation O 
by O 
UGT1A1 O 
and O 
UGT1A6 O 
cDNAs O 
containing O 
exon O 
5a O 
. O 
In O 
silico O 
analysis O 
predicted O 
that O 
rs8330 O 
creates O 
an O 
exon O 
splice O 
enhancer O 
site O 
that O 
could O 
favor O 
exon O 
5a O 
( O 
over O 
exon O 
5b O 
) O 
utilization O 
during O 
splicing O 
. O 
Finally O 
, O 
the O 
prevalence O 
of O 
rs8330 O 
was O 
significantly O 
lower O 
( O 
P O 
= O 
0.027 O 
, O 
χ(2) O 
test O 
) O 
in O 
patients O 
who O 
had O 
acute O 
liver O 
failure O 
from O 
unintentional O 
acetaminophen B-TRIVIAL 
overdose O 
compared O 
with O 
patients O 
with O 
acute O 
liver O 
failure O 
from O 
other O 
causes O 
or O 
a O 
race- O 
or O 
ethnicity O 
- O 
matched O 
population O 
. O 
Together O 
, O 
these O 
findings O 
suggest O 
that O 
rs8330 O 
is O 
an O 
important O 
determinant O 
of O 
acetaminophen B-TRIVIAL 
glucuronidation O 
and O 
could O 
affect O 
an O 
individual's O 
risk O 
for O 
acetaminophen B-TRIVIAL 
-induced O 
liver O 
injury O 
. O 

activity O 
of O 
the O 
natural O 
compound O 
(+)-limonene B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
against O 
Schistosoma O 
mansoni O 
. O 

fluke O 
of O 
the O 
genus O 
Schistosoma O 
are O 
the O 
etiological O 
agents O 
of O 
human O 
schistosomiasis O 
, O 
an O 
important O 
neglected O 
tropical O 
disease O 
that O 
afflicts O 
over O 
200 O 
million O 
people O 
worldwide O 
. O 
The O 
treatment O 
for O 
this O 
disease O 
relies O 
heavily O 
on O 
a O 
single O 
drug O 
, O 
praziquantel B-TRIVIAL 
. O 
Recent O 
reports O 
of O 
praziquantel B-TRIVIAL 
resistance O 
raise O 
concerns O 
about O 
future O 
control O 
of O 
the O 
disease O 
and O 
show O 
the O 
importance O 
of O 
developing O 
new O 
antischistosomal O 
drugs O 
. O 
Currently O 
, O 
natural O 
products O 
have O 
been O 
a O 
good O 
source O 
for O 
drug O 
development O 
. O 
(+)-Limonene B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
is O 
a O 
mixture O 
of O 
cis O 
and O 
trans O 
isomers O 
found O 
in O 
many O 
plants O 
. O 
Here O 
, O 
we O 
report O 
the O 
in O 
vitro O 
effect O 
of O 
this O 
natural O 
compound O 
on O 
the O 
survival O 
time O 
of O 
Schistosoma O 
mansoni O 
adult O 
worms O 
. O 
In O 
addition O 
, O 
we O 
examined O 
alterations O 
on O 
the O 
tegumental O 
surface O 
of O 
adult O 
schistosomes O 
by O 
means O 
of O 
confocal O 
laser O 
scanning O 
microscopy O 
. O 
The O 
effects O 
of O 
(+)-limonene B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
at O 
25 O 
µg O 
/ O 
mL O 
on O 
S O 
. O 
mansoni O 
adult O 
worms O 
were O 
similar O 
to O 
those O 
of O 
the O 
positive O 
control O 
( O 
praziquantel B-TRIVIAL 
) O 
, O 
with O 
reduction O 
in O 
motility O 
and O 
death O 
of O 
all O 
worms O 
after O 
120 O 
h O 
. O 
Confocal O 
laser O 
scanning O 
microscopy O 
revealed O 
that O 
(+)-limonene B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
-mediated O 
worm O 
killing O 
was O 
associated O 
with O 
tegumental O 
destruction O 
. O 
Our O 
results O 
, O 
along O 
with O 
the O 
low O 
toxicity O 
of O 
the O 
(+)-limonene B-SYSTEMATIC 
epoxide I-SYSTEMATIC 
, O 
suggest O 
that O 
this O 
natural O 
compound O 
might O 
be O 
promising O 
for O 
the O 
development O 
of O 
new O 
schistosomicidal O 
agents O 
. O 

- O 
mediated O 
aberrant O 
calcium B-SYSTEMATIC 
signaling O 
and O 
endoplasmic O 
reticulum O 
stress O 
underlie O 
neuropathology O 
in O 
Lafora O 
disease O 
. O 

disease O 
( O 
LD O 
) O 
is O 
a O 
teenage O 
- O 
onset O 
inherited O 
progressive O 
myoclonus O 
epilepsy O 
characterized O 
by O 
the O 
accumulations O 
of O 
intracellular O 
inclusions O 
called O 
Lafora O 
bodies O 
and O 
caused O 
by O 
mutations O 
in O 
protein O 
phosphatase O 
laforin O 
or O 
ubiquitin O 
ligase O 
malin O 
. O 
But O 
how O 
the O 
loss O 
of O 
function O 
of O 
either O 
laforin O 
or O 
malin O 
causes O 
disease O 
pathogenesis O 
is O 
poorly O 
understood O 
. O 
Recently O 
, O 
neuronatin O 
was O 
identified O 
as O 
a O 
novel O 
substrate O 
of O 
malin O 
that O 
regulates O 
glycogen O 
synthesis O 
. O 
Here O 
we O 
demonstrate O 
that O 
the O 
level O 
of O 
neuronatin O 
is O 
significantly O 
up O 
- O 
regulated O 
in O 
the O 
skin O 
biopsy O 
sample O 
of O 
LD O 
patients O 
having O 
mutations O 
in O 
both O 
malin O 
and O 
laforin O 
. O 
Neuronatin O 
is O 
highly O 
expressed O 
in O 
human O 
fetal O 
brain O 
with O 
gradual O 
decrease O 
in O 
expression O 
in O 
developing O 
and O 
adult O 
brain O 
. O 
However O 
, O 
in O 
adult O 
brain O 
, O 
neuronatin O 
is O 
predominantly O 
expressed O 
in O 
parvalbumin O 
- O 
positive O 
GABAergic O 
interneurons O 
and O 
localized O 
in O 
their O 
processes O 
. O 
The O 
level O 
of O 
neuronatin O 
is O 
increased O 
and O 
accumulated O 
as O 
insoluble O 
aggregates O 
in O 
the O 
cortical O 
area O 
of O 
LD O 
brain O 
biopsy O 
samples O 
, O 
and O 
there O 
is O 
also O 
a O 
dramatic O 
loss O 
of O 
parvalbumin O 
- O 
positive O 
GABAergic O 
interneurons O 
. O 
Ectopic O 
expression O 
of O 
neuronatin O 
in O 
cultured O 
neuronal O 
cells O 
results O 
in O 
increased O 
intracellular O 
Ca(2+) B-FORMULA 
, O 
endoplasmic O 
reticulum O 
stress O 
, O 
proteasomal O 
dysfunction O 
, O 
and O 
cell O 
death O 
that O 
can O 
be O 
partially O 
rescued O 
by O 
malin O 
. O 
These O 
findings O 
suggest O 
that O 
the O 
neuronatin O 
- O 
induced O 
aberrant O 
Ca(2+) B-FORMULA 
signaling O 
and O 
endoplasmic O 
reticulum O 
stress O 
might O 
underlie O 
LD O 
pathogenesis O 
. O 

activator O 
- O 
like O 
effectors O 
( O 
TALEs O 
) O 
have O 
revolutionized O 
the O 
field O 
of O 
genome O 
engineering O 
. O 
We O 
present O 
here O 
a O 
systematic O 
assessment O 
of O 
TALE O 
DNA O 
recognition O 
, O 
using O 
quantitative O 
electrophoretic O 
mobility O 
shift O 
assays O 
and O 
reporter O 
gene O 
activation O 
assays O 
. O 
Within O 
TALE O 
proteins O 
, O 
tandem O 
34- O 
amino B-FAMILY 
acid I-FAMILY 
repeats O 
recognize O 
one O 
base O 
pair O 
each O 
and O 
direct O 
sequence O 
- O 
specific O 
DNA O 
binding O 
through O 
repeat O 
variable O 
di O 
- O 
residues O 
( O 
RVDs O 
) O 
. O 
We O 
found O 
that O 
RVD O 
choice O 
can O 
affect O 
affinity O 
by O 
four O 
orders O 
of O 
magnitude O 
, O 
with O 
the O 
relative O 
RVD O 
contribution O 
in O 
the O 
order O 
NG O 
> O 
HD O 
∼ O 
NN O 
≫ O 
NI O 
> O 
NK O 
. O 
The O 
NN O 
repeat O 
preferred O 
the O 
base O 
G O 
over O 
A O 
, O 
whereas O 
the O 
NK O 
repeat O 
bound O 
G O 
with O 
10(3)-fold O 
lower O 
affinity O 
. O 
We O 
compared O 
AvrBs3 O 
, O 
a O 
naturally O 
occurring O 
TALE O 
that O 
recognizes O 
its O 
target O 
using O 
some O 
atypical O 
RVD-base O 
combinations O 
, O 
with O 
a O 
designed O 
TALE O 
that O 
precisely O 
matches O 
' O 
standard O 
' O 
RVDs O 
with O 
the O 
target O 
bases O 
. O 
This O 
comparison O 
revealed O 
unexpected O 
differences O 
in O 
sensitivity O 
to O 
substitutions O 
of O 
the O 
invariant O 
5'-T O 
. O 
Another O 
surprising O 
observation O 
was O 
that O 
base O 
mismatches O 
at O 
the O 
5 O 
' O 
end O 
of O 
the O 
target O 
site O 
had O 
more O 
disruptive O 
effects O 
on O 
affinity O 
than O 
those O 
at O 
the O 
3 O 
' O 
end O 
, O 
particularly O 
in O 
designed O 
TALEs O 
. O 
These O 
results O 
provide O 
evidence O 
that O 
TALE-DNA O 
recognition O 
exhibits O 
a O 
hitherto O 
un O 
- O 
described O 
polarity O 
effect O 
, O 
in O 
which O 
the O 
N B-FORMULA 
-terminal O 
repeats O 
contribute O 
more O 
to O 
affinity O 
than O 
C B-FORMULA 
-terminal O 
ones O 
. O 

mammals O 
several O 
members O 
of O 
the O 
Transient O 
Receptor O 
Potential O 
channel O 
family O 
( O 
TRPs O 
) O 
, O 
expressed O 
mainly O 
in O 
the O 
sensory O 
neurons O 
and O 
skin O 
keratinocytes O 
, O 
are O 
implicated O 
in O 
relevant O 
physiological O 
functions O 
, O 
including O 
thermosensation,nociception O 
and O 
vision O 
. O 
Since O 
the O 
TRPV1-4 O 
, O 
TRPA1 O 
and O 
TRPM8 O 
channels O 
from O 
this O 
family O 
play O 
a O 
pivotal O 
role O 
in O 
both O 
the O 
detection O 
and O 
possibly O 
modulation O 
of O 
painful O 
stimuli O 
, O 
they O 
are O 
regarded O 
as O 
a O 
very O 
promising O 
target O 
of O 
novel O 
analgesic O 
drugs O 
. O 
A O 
few O 
agents O 
acting O 
at O 
TRPs O 
, O 
such O 
as O 
capsaicin B-TRIVIAL 
or O 
menthol B-TRIVIAL 
, O 
have O 
a O 
long O 
history O 
of O 
their O 
application O 
as O 
analgesics,whereas O 
others O 
( O 
e.g O 
. O 
SB705498 B-IDENTIFIER 
, O 
JTS653 B-IDENTIFIER 
, O 
JNJ17203212 B-IDENTIFIER 
, O 
AP18 B-IDENTIFIER 
, O 
A967079 B-IDENTIFIER 
, O 
Chembridge-5861528 B-IDENTIFIER 
or O 
PBMC O 
) O 
are O 
currently O 
being O 
evaluated O 
both O 
in O 
animals O 
and O 
in O 
humans O 
. O 
In O 
this O 
review O 
we O 
discuss O 
pain O 
physiology O 
, O 
as O 
well O 
as O 
the O 
pharmacological O 
properties O 
of O 
the O 
TRPs O 
involved O 
in O 
pain O 
detection O 
as O 
potential O 
critical O 
peripheral O 
analgesic O 
targets O 
. O 
We O 
present O 
one O 
of O 
the O 
most O 
relevant O 
strategies O 
in O 
the O 
search O 
for O 
novel O 
analgesic O 
drugs O 
, O 
namely O 
the O 
TRP O 
channels O 
and O 
their O 
ligands O 
, O 
both O 
agonists O 
and O 
antagonists O 
as O 
potential O 
novel O 
therapeutics O 
for O 
inflammatory O 
and O 
neuropathic O 
pain O 
syndromes O 
. O 
The O 
safety O 
profile O 
of O 
these O 
agents O 
, O 
in O 
particular O 
their O 
impact O 
on O 
thermosensation O 
, O 
is O 
also O 
discussed O 
below O 
. O 

analogs O 
of O 
farnesyl B-SYSTEMATIC 
diphosphate I-SYSTEMATIC 
and O 
related O 
isoprenoids B-FAMILY 
: O 
design O 
and O 
applications O 
in O 
studies O 
of O 
medicinally O 
important O 
isoprenoid B-FAMILY 
- O 
utilizing O 
enzymes O 
. O 

diphosphate I-SYSTEMATIC 
( O 
FPP B-ABBREVIATION 
) O 
is O 
an O 
important O 
metabolic O 
intermediate O 
in O 
the O 
biosynthesis O 
of O 
a O 
variety O 
of O 
molecules O 
including O 
sesquiterpenes B-FAMILY 
and O 
the O 
side O 
chains O 
of O 
a O 
number O 
of O 
cofactors O 
. O 
FPP B-ABBREVIATION 
is O 
also O 
the O 
source O 
of O 
isoprenoid B-FAMILY 
side O 
chains O 
found O 
attached O 
to O 
proteins O 
. O 
Enzymes O 
that O 
employ O 
FPP B-ABBREVIATION 
as O 
a O 
substrate O 
are O 
of O 
interest O 
because O 
they O 
are O 
involved O 
in O 
the O 
semisynthesis O 
of O 
drugs O 
as O 
well O 
as O 
targets O 
for O 
drug O 
design O 
. O 
Photoactive O 
analogs O 
of O 
FPP B-ABBREVIATION 
have O 
been O 
useful O 
for O 
identifying O 
enzymes O 
that O 
use O 
this O 
molecule O 
as O 
a O 
substrate O 
. O 
A O 
variety O 
of O 
photocrosslinking O 
groups O 
have O 
been O 
employed O 
to O 
prepare O 
FPP B-ABBREVIATION 
analogs O 
for O 
use O 
in O 
such O 
experiments O 
including O 
aryl B-FAMILY 
azides I-FAMILY 
, O 
diazotrifluoropropionates B-FAMILY 
and O 
benzophenones B-FAMILY 
. O 
In O 
this O 
review O 
, O 
the O 
design O 
of O 
these O 
probes O 
is O 
described O 
along O 
with O 
an O 
examination O 
of O 
how O 
they O 
have O 
been O 
used O 
in O 
crosslinking O 
experiments O 
. O 

morpheein O 
model O 
of O 
allosteric O 
regulation O 
draws O 
attention O 
to O 
proteins O 
that O 
can O 
exist O 
as O 
an O 
equilibrium O 
of O 
functionally O 
distinct O 
assemblies O 
where O 
: O 
one O 
subunit O 
conformation O 
assembles O 
into O 
one O 
multimer O 
; O 
a O 
different O 
subunit O 
conformation O 
assembles O 
into O 
a O 
different O 
multimer O 
; O 
and O 
the O 
various O 
multimers O 
are O 
in O 
a O 
dynamic O 
equilibrium O 
whose O 
position O 
can O 
be O 
modulated O 
by O 
ligands O 
that O 
bind O 
to O 
a O 
multimer O 
- O 
specific O 
ligand O 
binding O 
site O 
. O 
The O 
case O 
study O 
of O 
porphobilinogen B-TRIVIAL 
synthase O 
( O 
PBGS O 
) O 
illustrates O 
how O 
such O 
an O 
equilibrium O 
holds O 
lessons O 
for O 
disease O 
mechanisms O 
, O 
drug O 
discovery O 
, O 
understanding O 
drug O 
side O 
effects O 
, O 
and O 
identifying O 
proteins O 
wherein O 
drug O 
discovery O 
efforts O 
might O 
focus O 
on O 
quaternary O 
structure O 
dynamics O 
. O 
The O 
morpheein O 
model O 
of O 
allostery O 
has O 
been O 
proposed O 
as O 
applicable O 
for O 
a O 
wide O 
assortment O 
of O 
disease O 
- O 
associated O 
proteins O 
( O 
Selwood O 
, O 
T O 
. O 
, O 
Jaffe O 
, O 
E O 
. O 
, O 
( O 
2012 O 
) O 
Arch O 
. O 
Bioch O 
. O 
Biophys O 
, O 
519 O 
: O 
131-143 O 
) O 
. O 
Herein O 
we O 
discuss O 
quaternary O 
structure O 
dynamics O 
aspects O 
to O 
drug O 
discovery O 
for O 
the O 
disease O 
- O 
associated O 
putative O 
morpheeins O 
phenylalanine B-TRIVIAL 
hydroxylase O 
, O 
HIV O 
integrase O 
, O 
pyruvate B-TRIVIAL 
kinase O 
, O 
and O 
tumor O 
necrosis O 
factor O 
α O 
. O 
Also O 
highlighted O 
is O 
the O 
quaternary O 
structure O 
equilibrium O 
of O 
transthyretin O 
and O 
successful O 
drug O 
discovery O 
efforts O 
focused O 
on O 
controlling O 
its O 
quaternary O 
structure O 
dynamics O 
. O 

plays O 
a O 
major O 
structural O 
and O 
functional O 
role O 
around O 
proteins O 
. O 
In O 
an O 
attempt O 
to O 
explore O 
this O 
mechanistic O 
structural O 
aspect O 
of O 
proteins O 
, O 
we O 
present O 
site O 
- O 
specific O 
interaction O 
of O 
hydration O 
water O 
with O 
the O 
major O 
coat O 
protein O 
subunit O 
of O 
filamentous O 
virus O 
Pf1 O 
by O 
magic O 
angle O 
spinning O 
( O 
MAS O 
) O 
solid O 
- O 
state O 
NMR O 
. O 
The O 
interaction O 
of O 
surrounding O 
water O 
with O 
36 O 
MDa O 
Pf1 O 
virion O 
is O 
investigated O 
in O 
uniformly O 
(13)C B-FORMULA 
, O 
(15)N B-FORMULA 
isotopically O 
labeled O 
; O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
precipitated O 
fully O 
hydrated O 
samples O 
by O 
solid O 
- O 
state O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
. O 
Dipolar O 
edited O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
(1)H B-FORMULA 
- O 
(15)N B-FORMULA 
heteronuclear O 
correlation O 
( O 
HETCOR O 
) O 
experiments O 
lead O 
to O 
unambiguous O 
assignments O 
of O 
cross O 
- O 
peaks O 
originating O 
exclusively O 
from O 
(1)H B-FORMULA 
resonances O 
of O 
water O 
molecules O 
correlating O 
to O 
the O 
protein O 
amide B-SYSTEMATIC 
nitrogen I-SYSTEMATIC 
. O 
An O 
enhanced O 
resolved O 
(1)H B-FORMULA 
chemical O 
shift O 
dimension O 
in O 
these O 
experiments O 
also O 
precludes O 
the O 
need O 
of O 
perdeuteration O 
. O 
We O 
report O 
seven O 
residues O 
spanning O 
the O 
40-residue O 
continuous O 
α-helical O 
conformation O 
assembly O 
of O 
Pf1 O 
interacting O 
with O 
surrounding O 
water O 
. O 
It O 
shows O 
a O 
highly O 
hydrated O 
inner O 
core O 
inside O 
this O 
viral O 
filamentous O 
assembly O 
. O 
The O 
results O 
obtained O 
also O 
suggest O 
the O 
first O 
evidence O 
of O 
a O 
water O 
- O 
mediated O 
interface O 
cluster O 
formed O 
at O 
the O 
site O 
of O 
Arg B-FORMULA 
44 O 
with O 
the O 
single O 
- O 
stranded O 
DNA O 
genome O 
of O 
the O 
filamentous O 
phage O 
supramolecular O 
assembly O 
. O 

carboxymethyl B-SYSTEMATIC 
cellulose O 
- O 
based O 
magnetic O 
nanovector O 
as O 
a O 
theragnostic O 
system O 
for O 
folate B-TRIVIAL 
receptor O 
targeted O 
chemotherapy O 
, O 
imaging O 
, O 
and O 
hyperthermia O 
against O 
cancer O 
. O 

multifunctional O 
biocompatible O 
nanovector O 
based O 
on O 
magnetic O 
nanoparticle O 
and O 
carboxymethyl B-SYSTEMATIC 
cellulose O 
( O 
CMC O 
) O 
was O 
developed O 
. O 
The O 
nanoparticles O 
have O 
been O 
characterized O 
using O 
TEM O 
, O 
SEM O 
, O 
DLS O 
, O 
FT-IR O 
spectra O 
, O 
VSM O 
, O 
and O 
TGA O 
studies O 
. O 
We O 
found O 
that O 
the O 
synthesized O 
carboxymethyl B-SYSTEMATIC 
cellulose O 
magnetic O 
nanoparticles O 
( O 
CMC O 
MNPs O 
) O 
were O 
spherical O 
in O 
shape O 
with O 
an O 
average O 
size O 
of O 
150 O 
nm O 
having O 
low O 
aggregation O 
and O 
superparamagnetic O 
properties O 
. O 
We O 
found O 
that O 
the O 
folate B-TRIVIAL 
-tagged O 
CMC O 
MNPs O 
were O 
delivered O 
to O 
cancer O 
cells O 
by O 
a O 
folate B-TRIVIAL 
-receptor O 
- O 
mediated O 
endocytosis O 
mechanism O 
. O 
5-FU B-SYSTEMATIC 
was O 
encapsulated O 
as O 
a O 
model O 
drug O 
for O 
delivering O 
cytotoxicity O 
, O 
and O 
we O 
could O 
demonstrate O 
the O 
sustained O 
release O 
of O 
5-FU B-SYSTEMATIC 
. O 
It O 
was O 
also O 
observed O 
that O 
the O 
FITC B-ABBREVIATION 
-labeled O 
CMC O 
MNPs O 
could O 
effectively O 
enter O 
cells O 
, O 
and O 
the O 
fate O 
of O 
nanoparticles O 
was O 
tracked O 
with O 
Lysotracker O 
. O 
The O 
CMC O 
MNPs O 
could O 
induce O 
significant O 
cell O 
death O 
when O 
an O 
alternating O 
magnetic O 
field O 
was O 
applied O 
. O 
These O 
results O 
indicate O 
that O 
the O 
multifunctional O 
CMC O 
MNPs O 
possess O 
a O 
high O 
drug O 
loading O 
efficiency O 
and O 
high O 
biocompatibility O 
and O 
with O 
low O 
cell O 
cytotoxicity O 
and O 
can O 
be O 
considered O 
to O 
be O 
promising O 
candidates O 
for O 
CMC O 
- O 
based O 
targeted O 
drug O 
delivery O 
, O 
cellular O 
imaging O 
, O 
and O 
magnetic O 
hyperthermia O 
( O 
MHT O 
) O 
. O 

dynamics O 
of O 
metal B-FAMILY 
azide I-FAMILY 
ion O 
pairs O 
in O 
dimethylsulfoxide B-SYSTEMATIC 
solutions O 
. O 

ion O 
is O 
an O 
excellent O 
vibrational O 
probe O 
for O 
studying O 
ion O 
- O 
ion O 
and O 
ion O 
- O 
dipole O 
interactions O 
in O 
solutions O 
because O 
its O 
frequency O 
is O 
sensitively O 
dependent O 
on O 
its O 
local O 
environments O 
. O 
When O 
azide B-SYSTEMATIC 
ion O 
forms O 
contact O 
ion O 
pairs O 
with O 
cations O 
in O 
dimethylsulfoxide B-SYSTEMATIC 
( O 
DMSO B-ABBREVIATION 
) O 
, O 
free O 
azide B-SYSTEMATIC 
ion O 
and O 
contact O 
ion O 
pairs O 
are O 
spectrally O 
well O 
distinguished O 
in O 
FTIR O 
spectra O 
. O 
Here O 
, O 
we O 
investigated O 
vibrational O 
population O 
relaxation O 
, O 
P(t) O 
, O 
and O 
orientational O 
relaxation O 
dynamics O 
, O 
r(t) O 
, O 
of O 
free O 
azide B-SYSTEMATIC 
ion O 
and O 
contact O 
ion O 
pairs O 
( O 
LiN3 B-FORMULA 
, O 
NaN3 B-FORMULA 
, O 
NH4N3 B-FORMULA 
, O 
MgN3(+) B-FORMULA 
, O 
and O 
CaN3(+) B-FORMULA 
) O 
in O 
DMSO B-ABBREVIATION 
by O 
IR O 
pump O 
- O 
probe O 
spectroscopy O 
. O 
For O 
metal B-FAMILY 
azide I-FAMILY 
ion O 
pairs O 
, O 
the O 
metal O 
ion O 
slowed O 
down O 
the O 
vibrational O 
relaxation O 
of O 
azide B-SYSTEMATIC 
ion O 
by O 
acting O 
like O 
a O 
thermal O 
insulator O 
. O 
Biexponential O 
behavior O 
of O 
r(t) O 
was O 
analyzed O 
in O 
the O 
wobbling-in-a-cone O 
model O 
. O 
The O 
long O 
time O 
component O 
of O 
r(t) O 
of O 
free O 
azide B-SYSTEMATIC 
ion O 
was O 
found O 
to O 
be O 
viscosity O 
- O 
dependent O 
. O 
The O 
wobbling O 
motion O 
of O 
azide B-SYSTEMATIC 
ion O 
within O 
the O 
frame O 
of O 
metal B-FAMILY 
azide I-FAMILY 
ion O 
pairs O 
was O 
weakly O 
dependent O 
on O 
the O 
countercation O 
. O 
When O 
the O 
overall O 
orientational O 
relaxation O 
of O 
metal B-FAMILY 
azide I-FAMILY 
ion O 
pairs O 
was O 
analyzed O 
by O 
the O 
extended O 
Debye-Stokes-Einstein O 
equation O 
, O 
it O 
was O 
well O 
described O 
under O 
stick O 
or O 
superstick O 
boundary O 
conditions O 
due O 
to O 
a O 
strong O 
interaction O 
between O 
the O 
metal O 
ion O 
and O 
DMSO B-ABBREVIATION 
molecules O 
. O 
Our O 
experimental O 
results O 
provide O 
important O 
insight O 
in O 
understanding O 
the O 
rotational O 
dynamics O 
of O 
small O 
ionic O 
species O 
in O 
polar O 
solvents O 
when O 
the O 
size O 
of O 
the O 
ionic O 
species O 
is O 
smaller O 
than O 
or O 
comparable O 
to O 
that O 
of O 
the O 
solvent O 
molecule O 
. O 

and O 
structures O 
of O 
axistatins B-MULTIPLE 
1-3 I-MULTIPLE 
from O 
the O 
Republic O 
of O 
Palau O 
marine O 
sponge O 
Agelas O 
axifera O 
Hentschel O 
. O 

investigation O 
begun O 
in O 
1979 O 
directed O 
at O 
the O 
Republic O 
of O 
Palau O 
marine O 
sponge O 
Agelas O 
axifera O 
Hentschel O 
for O 
cancer O 
cell O 
growth O 
inhibitory O 
constituents O 
subsequently O 
led O 
to O 
the O 
isolation O 
of O 
three O 
new O 
pyrimidine B-SYSTEMATIC 
diterpenes B-FAMILY 
designated O 
axistatins B-MULTIPLE 
1 I-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
2 I-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
3 I-MULTIPLE 
( I-MULTIPLE 
3 I-MULTIPLE 
) I-MULTIPLE 
, O 
together O 
with O 
the O 
previously O 
reported O 
formamides B-FAMILY 
4 O 
, O 
5 O 
, O 
and O 
agelasine B-TRIVIAL 
F I-TRIVIAL 
( O 
6 O 
) O 
. O 
The O 
structures O 
were O 
elucidated O 
by O 
analysis O 
of O 
2D-NMR O 
spectra O 
and O 
by O 
HRMS O 
. O 
All O 
of O 
the O 
isolated O 
compounds O 
were O 
found O 
to O 
be O 
moderate O 
inhibitors O 
of O 
cancer O 
cell O 
growth O 
. O 
Axistatins B-MULTIPLE 
1-3 I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
formamide B-SYSTEMATIC 
4 O 
, O 
and O 
agelasine B-TRIVIAL 
F I-TRIVIAL 
( O 
6 O 
) O 
also O 
exhibited O 
antimicrobial O 
activity O 
. O 

the O 
subsequent O 
steps O 
leading O 
from O 
impact O 
to O 
explosive O 
decomposition O 
in O 
nitro B-SYSTEMATIC 
compounds O 
, O 
the O 
ability O 
of O 
early O 
exothermic O 
reactions O 
to O 
trigger O 
the O 
decomposition O 
of O 
neighboring O 
molecules O 
before O 
the O 
released O 
energy O 
has O 
dissipated O 
away O 
is O 
assumed O 
to O 
be O 
critical O 
. O 
The O 
rate O 
of O 
this O 
process O 
is O 
roughly O 
estimated O 
using O 
as O 
inputs O 
the O 
energy O 
content O 
and O 
the O 
dissociation O 
energy O 
of O 
the O 
weakest O 
X-NO2 B-FAMILY 
bonds O 
. O 
While O 
the O 
sensitivity O 
index O 
thus O 
obtained O 
was O 
previously O 
shown O 
to O 
exhibit O 
striking O 
correlations O 
with O 
gap O 
test O 
pressures O 
, O 
its O 
correlation O 
with O 
drop O 
weight O 
impact O 
test O 
data O 
is O 
poorer O 
. O 
Nevertheless O 
, O 
considering O 
four O 
different O 
subsets O 
of O 
molecules O 
depending O 
on O 
the O 
environment O 
of O 
the O 
most O 
labile O 
nitro B-SYSTEMATIC 
groups O 
, O 
straightforward O 
regressions O 
against O 
this O 
sensitivity O 
index O 
yield O 
a O 
practical O 
method O 
to O 
estimate O 
impact O 
sensitivity O 
, O 
whose O 
combination O 
of O 
fair O 
performance O 
and O 
generality O 
is O 
provided O 
by O 
no O 
alternative O 
approach O 
, O 
except O 
purely O 
empirical O 
models O 
based O 
on O 
extensive O 
parametrization O 
. O 

modulation O 
of O 
multiple O 
targets O 
is O 
an O 
attractive O 
therapeutic O 
strategy O 
in O 
treating O 
complex O 
diseases O 
including O 
cancer O 
. O 
Comparing O 
with O 
drugs O 
combination O 
, O 
single O 
molecule O 
modulating O 
desirable O 
multiple O 
targets O 
has O 
advantages O 
in O 
pharmacokinetic O 
and O 
pharmacodynamics O 
. O 
Different O 
from O 
previous O 
reviews O 
, O 
we O 
provided O 
an O 
overview O 
of O 
reported O 
multitarget O 
antitumor O 
agents O 
from O 
the O 
viewpoint O 
of O 
pharmacophores O 
. O 
These O 
multitarget O 
antitumor O 
agents O 
were O 
designed O 
by O 
combination O 
of O 
pharmacophores O 
or O 
by O 
high O 
- O 
throughput O 
screening O 
plus O 
structural O 
modification O 
, O 
which O 
were O 
exemplified O 
by O 
the O 
privileged O 
pharmacophore O 
quinazoline O 
and O 
several O 
other O 
popular O 
pharmacophores O 
, O 
including O 
phenylaminopyrimidine B-SYSTEMATIC 
, O 
anthracycline B-FAMILY 
and O 
naphthalimide B-FAMILY 
. O 
Previous O 
research O 
demonstrated O 
the O 
importance O 
of O 
in O 
- O 
depth O 
validation O 
against O 
multiple O 
targets O 
not O 
only O 
in O 
cell O 
- O 
free O 
system O 
, O 
but O 
also O 
in O 
cancer O 
cells O 
. O 
Furthermore O 
, O 
the O 
multitarget O 
compounds O 
were O 
also O 
effective O 
for O 
resistance O 
cell O 
lines O 
which O 
highlighted O 
their O 
antitumor O 
potency O 
in O 
the O 
era O 
of O 
increasing O 
drug O 
resistance O 
in O 
cancer O 
patients O 
. O 

acid I-TRIVIAL 
( O 
ARA B-ABBREVIATION 
) O 
undergoes O 
enzyme O 
- O 
mediated O 
oxidative O 
metabolism O 
, O 
resulting O 
in O 
the O 
formation O 
of O 
a O 
number O 
of O 
biologically O 
active O 
metabolites O 
. O 
For O 
over O 
a O 
century O 
, O 
these O 
biochemical O 
transformations O 
have O 
been O 
the O 
target O 
of O 
numerous O 
pharmacological O 
drugs O 
for O 
inflammation O 
and O 
pain O 
. O 
In O 
particular O 
, O 
non-steroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
and O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
selective O 
inhibitors O 
( O 
coxibs O 
) O 
are O 
widely O 
used O 
in O 
the O 
treatment O 
of O 
inflammation O 
and O 
pain O 
. O 
However O 
, O 
gastrointestinal O 
( O 
GI O 
) O 
and O 
cardiovascular O 
adverse O 
effects O 
of O 
NSAIDs O 
and O 
coxibs O 
, O 
and O 
recent O 
findings O 
demonstrating O 
that O 
there O 
are O 
significant O 
risks O 
from O 
the O 
disruption O 
of O 
oxylipin B-FAMILY 
levels O 
when O 
pharmacologically O 
inhibiting O 
a O 
single O 
ARA B-ABBREVIATION 
cascade O 
metabolic O 
pathway O 
, O 
have O 
led O 
to O 
studies O 
involving O 
the O 
simultaneous O 
inhibition O 
of O 
multiple O 
pathways O 
in O 
ARA B-ABBREVIATION 
cascade O 
. O 
These O 
studies O 
suggest O 
that O 
multitarget O 
inhibition O 
represents O 
a O 
new O 
and O 
valuable O 
option O 
to O 
enhance O 
efficacy O 
or O 
reduce O 
side-effects O 
in O 
the O 
treatment O 
of O 
inflammation O 
and O 
pain O 
. O 
This O 
review O 
focuses O 
on O 
the O 
crosstalk O 
within O 
the O 
three O 
pathways O 
of O 
the O 
ARA B-ABBREVIATION 
cascade O 
( O 
cyclooxygenase O 
( O 
COX O 
) O 
, O 
lipoxygenase O 
( O 
LOX O 
) O 
, O 
and O 
cytochrome O 
P450 O 
( O 
CYP450 O 
) O 
) O 
, O 
and O 
summarizes O 
the O 
current O 
and O 
future O 
approaches O 
of O 
multitarget O 
inhibitors O 
for O 
the O 
treatment O 
of O 
eicosanoid B-FAMILY 
driven O 
inflammation O 
and O 
pain O 
. O 

stress O 
plays O 
an O 
important O 
role O 
in O 
chemically O 
induced O 
liver O 
injury O 
, O 
however O 
, O 
our O 
insight O 
into O 
molecular O 
responses O 
to O 
different O 
oxygen B-SYSTEMATIC 
radicals O 
is O 
fragmentary O 
. O 
Since O 
these O 
cellular O 
responses O 
will O 
differ O 
over O 
time O 
, O 
examining O 
time O 
- O 
dependent O 
changes O 
in O 
gene O 
expression O 
, O 
and O 
correlating O 
these O 
with O 
markers O 
for O 
oxidative O 
stress O 
, O 
may O 
provide O 
new O 
insights O 
into O 
responses O 
to O 
oxidants O 
. O 
We O 
used O 
the O 
human O 
hepatoma O 
cell O 
line O 
HepG2 O 
to O 
investigate O 
the O 
effects O 
of O 
oxidative O 
stress O 
on O 
the O 
transcriptome O 
level O 
by O 
micro O 
- O 
arrays O 
at O 
seven O 
time O 
points O 
( O 
0.5 O 
, O 
1 O 
, O 
2 O 
, O 
4 O 
, O 
6 O 
, O 
8 O 
and O 
24h O 
) O 
following O 
exposure O 
to O 
the O 
oxidants O 
menadione B-TRIVIAL 
, O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
tert-butyl B-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
including O 
the O 
effects O 
on O 
cell O 
cycle O 
and O 
apoptosis O 
by O 
flow O 
cytometry O 
, O 
protein O 
carbonyl B-FAMILY 
formation O 
by O 
spectrophotometry O 
and O 
oxidative O 
DNA O 
damage O 
by O 
FPG-comet O 
. O 
In O 
total O 
, O 
3429 O 
genes O 
were O 
differentially O 
expressed O 
, O 
including O 
136 O 
genes O 
that O 
were O 
significantly O 
modified O 
by O 
all O 
oxidants O 
. O 
Time O 
- O 
dependent O 
biological O 
pathway O 
analysis O 
showed O 
that O 
these O 
genes O 
were O 
particularly O 
involved O 
in O 
inflammatory O 
responses O 
, O 
cell O 
cycle O 
processes O 
and O 
glutathione B-TRIVIAL 
signaling O 
. O 
These O 
responses O 
were O 
confirmed O 
and O 
supported O 
by O 
phenotypic O 
anchoring O 
to O 
the O 
different O 
cellular O 
endpoints O 
. O 
In O 
addition O 
, O 
using O 
an O 
innovative O 
temporal O 
analysis O 
we O 
established O 
an O 
oxidative O 
stress O 
- O 
related O 
gene O 
expression O 
time O 
cluster O 
. O 
Altogether O 
, O 
this O 
study O 
provides O 
new O 
insights O 
in O 
temporal O 
oxidative O 
stress O 
mechanisms O 
and O 
demonstrates O 
sequential O 
cellular O 
responses O 
that O 
may O 
contribute O 
to O 
a O 
better O 
hazard O 
identification O 
and O 
the O 
mechanisms O 
of O 
toxicological O 
responses O 
in O 
the O 
liver O 
induced O 
by O 
oxidative O 
stress O 
. O 

: O 
Both O 
metabolic O 
syndrome O 
( O 
MetS O 
) O 
and O 
nephrolithiasis O 
( O 
NL O 
) O 
are O 
common O 
and O 
clinically O 
important O 
disorders O 
. O 
Therefore O 
, O 
we O 
conducted O 
this O 
study O 
to O 
assess O 
the O 
association O 
of O 
MetS O 
and O 
NL O 
. O 
MATERIALS O 
/ O 
METHODS O 
: O 
Data O 
were O 
obtained O 
from O 
116536 O 
individuals O 
who O 
underwent O 
health O 
screening O 
tests O 
between O 
January O 
2010 O 
and O 
December O 
2010 O 
at O 
a O 
health O 
promotion O 
center O 
in O 
Seoul O 
, O 
Korea O 
. O 
All O 
subjects O 
were O 
asked O 
to O 
respond O 
to O 
a O 
questionnaire O 
including O 
medical O 
history O 
of O 
each O 
subject O 
. O 
Anthropometric O 
and O 
biochemical O 
measurements O 
were O 
applied O 
to O 
each O 
subject O 
. O 
Presence O 
of O 
NL O 
was O 
evaluated O 
by O 
an O 
abdominal O 
ultrasonography O 
. O 
The O 
subjects O 
were O 
classified O 
into O 
MetS O 
and O 
non-MetS O 
group O 
according O 
to O 
the O 
criteria O 
for O 
MetS O 
( O 
National O 
Cholesterol B-TRIVIAL 
Education O 
Program O 
Adult O 
Treatment O 
Panel O 
III O 
) O 
. O 
Compared O 
to O 
the O 
non-MetS O 
group O 
, O 
we O 
estimated O 
the O 
Odds O 
Ratios O 
( O 
ORs O 
) O 
and O 
95% O 
Confidence O 
Intervals O 
( O 
CIs O 
) O 
of O 
the O 
presence O 
of O 
NL O 
in O 
the O 
MetS O 
group O 
adjusting O 
for O 
age O 
, O 
serum O 
levels O 
of O 
creatinine B-TRIVIAL 
and O 
uric B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
past O 
medical O 
history O 
of O 
NL O 
based O 
on O 
the O 
multivariate O 
logistic O 
regression O 
analysis O 
. O 
RESULTS O 
: O 
The O 
prevalence O 
of O 
MetS O 
was O 
15.9% O 
( O 
N=1129 O 
/ O 
7107 O 
) O 
in O 
the O 
NL O 
group O 
, O 
and O 
11.2% O 
( O 
N=12,287 O 
/ O 
109429 O 
) O 
in O 
the O 
non-NL O 
group O 
, O 
respectively O 
. O 
After O 
adjusting O 
for O 
the O 
potential O 
confounding O 
factors O 
, O 
male O 
MetS O 
patients O 
had O 
a O 
higher O 
presence O 
of O 
NL O 
than O 
non-MetS O 
subjects O 
( O 
OR O 
1.11 O 
; O 
95% O 
CI O 
1.02-1.20 O 
; O 
p=0.01 O 
) O 
. O 
Of O 
MetS O 
components O 
, O 
only O 
high O 
blood O 
pressure O 
( O 
BP O 
) O 
was O 
a O 
significantly O 
related O 
factor O 
to O 
the O 
presence O 
of O 
NL O 
( O 
male O 
; O 
OR O 
1.08 O 
; O 
95% O 
CI O 
1.01-1.15 O 
; O 
p=0.043 O 
, O 
female O 
; O 
OR O 
1.24 O 
; O 
95% O 
CI O 
1.08-1.42 O 
; O 
p=0.002 O 
) O 
. O 
As O 
the O 
number O 
MetS O 
components O 
increased O 
, O 
the O 
presence O 
of O 
NL O 
was O 
significantly O 
higher O 
in O 
male O 
subjects O 
( O 
P O 
for O 
trend O 
< O 
0.001 O 
) O 
, O 
but O 
not O 
in O 
female O 
subjects O 
( O 
P O 
for O 
trend=0.961 O 
) O 
. O 
CONCLUSIONS O 
: O 
We O 
found O 
that O 
NL O 
was O 
associated O 
with O 
MetS O 
and O 
high O 
BP O 
. O 

derivatives O 
as O 
potent O 
transient O 
receptor O 
potential O 
melastatin O 
8 O 
( O 
TRPM8 O 
) O 
antagonists O 
. O 

series O 
of O 
arylglycine B-FAMILY 
-based O 
analogs O 
was O 
synthesized O 
and O 
tested O 
for O 
TRPM8 O 
antagonism O 
in O 
a O 
cell O 
- O 
based O 
functional O 
assay O 
. O 
Following O 
structure O 
- O 
activity O 
relationship O 
studies O 
in O 
vitro O 
, O 
a O 
number O 
of O 
compounds O 
were O 
identified O 
as O 
potent O 
TRPM8 O 
antagonists O 
and O 
were O 
subsequently O 
evaluated O 
in O 
an O 
in O 
vivo O 
pharmacodynamic O 
assay O 
of O 
icilin B-TRIVIAL 
-induced O 
' O 
wet O 
- O 
dog O 
' O 
shaking O 
in O 
which O 
compound O 
12 O 
was O 
fully O 
effective O 
. O 
TRPM8 O 
antagonists O 
of O 
the O 
type O 
described O 
here O 
may O 
be O 
useful O 
in O 
treating O 
pain O 
conditions O 
wherein O 
cold O 
hypersensitivity O 
is O 
a O 
dominant O 
feature O 
. O 

, O 
synthesis O 
and O 
structure O 
- O 
activity O 
relationship O 
of O 
rhenium B-FAMILY 
2-arylbenzothiazoles I-FAMILY 
as O 
β-amyloid O 
plaque O 
binding O 
agents O 
. O 

continue O 
our O 
efforts O 
toward O 
the O 
development O 
of O 
(99m)Tc B-FORMULA 
PiB O 
analogs O 
, O 
we O 
have O 
synthesized O 
24 O 
neutral O 
and O 
lipophilic O 
Re B-FORMULA 
( O 
as O 
a O 
surrogate O 
of O 
(99m)Tc B-FORMULA 
) O 
2-arylbenzothiazoles B-FAMILY 
, O 
and O 
explored O 
their O 
structure O 
- O 
activity O 
relationship O 
for O 
binding O 
to O 
Aβ1-40 O 
fibrils O 
. O 
These O 
Re B-FORMULA 
complexes O 
were O 
designed O 
and O 
synthesized O 
via O 
the O 
integrated O 
approach O 
, O 
so O 
their O 
(99m)Tc B-FORMULA 
analogs O 
would O 
have O 
a O 
greater O 
chance O 
of O 
crossing O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
While O 
the O 
lipophilicities O 
( O 
logPC18=1.59-3.53 O 
) O 
of O 
these O 
Re B-FAMILY 
2-arylbenzothiazoles I-FAMILY 
were O 
all O 
within O 
suitable O 
range O 
, O 
their O 
binding O 
affinities O 
( O 
Ki=30-617nM O 
) O 
to O 
Aβ1-40 O 
fibrils O 
varied O 
widely O 
depending O 
on O 
the O 
selection O 
and O 
integration O 
of O 
the O 
tetradentate O 
chelator O 
into O 
the O 
2-phenylbenzothiazole B-FAMILY 
pharmacophore O 
. O 
For O 
potential O 
clinical O 
applications O 
, O 
further O 
refinement O 
to O 
obtain O 
Re B-FAMILY 
2-arylbenzothiazoles I-FAMILY 
with O 
better O 
binding O 
affinities O 
( O 
< O 
10nM O 
) O 
will O 
likely O 
be O 
needed O 
. O 
The O 
integrated O 
approach O 
reported O 
here O 
to O 
generate O 
compact O 
, O 
neutral O 
and O 
lipophilic O 
Re B-FAMILY 
2-arylbenzothiazoles I-FAMILY 
could O 
be O 
applied O 
to O 
other O 
potent O 
pharmacophores O 
as O 
well O 
to O 
convert O 
other O 
current O 
Aβ O 
PET O 
tracers O 
to O 
their O 
(99m)Tc B-FORMULA 
analogs O 
for O 
more O 
widespread O 
application O 
via O 
the O 
use O 
of O 
SPECT O 
scanners O 
. O 

constituents O 
from O 
the O 
leaves O 
of O 
Hosta O 
longipes O 
and O 
their O 
inhibitory O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
. O 

longipes O 
( O 
FR O 
. O 
et O 
SAV O 
. O 
) O 
MATSUMURA O 
( O 
Liliaceae O 
) O 
is O 
an O 
edible O 
vegetable O 
in O 
Korea O 
. O 
This O 
study O 
was O 
conducted O 
with O 
the O 
aim O 
of O 
evaluating O 
the O 
potential O 
of O 
H O 
. O 
longipes O 
as O 
a O 
functional O 
food O 
for O 
the O 
treatment O 
of O 
neurodegenerative O 
diseases O 
such O 
as O 
Alzheimer's O 
disease O 
and O 
Parkinson's O 
disease O 
. O 
In O 
this O 
respect O 
, O 
the O 
study O 
resulted O 
in O 
the O 
identification O 
of O 
three O 
new O 
steroidal B-FAMILY 
compounds O 
, O 
longipenane B-TRIVIAL 
( O 
1 O 
) O 
, O 
longipenane B-SYSTEMATIC 
26-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
neogitogenin B-SYSTEMATIC 
3-O-α-l-rhamnopyranosyl-(1→2)-O-[β-d-glucopyranosyl-(1→4)]-β-d-galactopyranoside I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
along O 
with O 
two O 
known O 
steroidal B-FAMILY 
saponins I-FAMILY 
( O 
4 O 
and O 
5 O 
) O 
. O 
The O 
identification O 
and O 
structural O 
elucidation O 
of O 
these O 
compounds O 
were O 
based O 
on O 
1D O 
and O 
2D O 
NMR O 
measurements O 
, O 
high O 
- O 
resolution O 
FAB O 
mass O 
spectroscopy O 
( O 
HR-FAB-MS O 
) O 
, O 
and O 
chemical O 
methods O 
. O 
A O 
proinflammatory O 
mediator O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
, O 
in O 
murine O 
microglial O 
BV-2 O 
cells O 
was O 
used O 
to O 
assess O 
the O 
anti-neuroinflammatory O 
effect O 
of O 
the O 
isolated O 
compounds O 
from O 
H O 
. O 
longipes O 
. O 
Among O 
them O 
, O 
compounds O 
4 O 
and O 
5 O 
showed O 
strong O 
inhibitory O 
effects O 
on O 
NO B-FORMULA 
production O 
without O 
high O 
cell O 
toxicity O 
in O 
lipopolysaccharide-activated O 
BV-2 O 
cells O 
( O 
IC50=17.66 O 
and O 
13.16μM O 
, O 
respectively O 
) O 
. O 

of O 
Hypocrellin B-TRIVIAL 
A I-TRIVIAL 
with O 
Al3+ B-FORMULA 
in O 
water O 
solution O 
and O 
the O 
photodynamic O 
therapy O 
study O 
. O 

complex O 
of O 
Hypocrellin B-TRIVIAL 
A I-TRIVIAL 
with O 
Al(3+) B-FORMULA 
is O 
prepared O 
in O 
water O 
solution O 
by O 
a O 
facile O 
method O 
. O 
The O 
water O 
- O 
solubility O 
and O 
stability O 
of O 
complexes O 
are O 
improved O 
. O 
Irradiation O 
of O 
Al(3+) B-FORMULA 
-HA O 
complex O 
results O 
in O 
higher O 
efficient O 
generation O 
of O 
singlet O 
oxygen B-SYSTEMATIC 
( O 
(1)O2 B-FORMULA 
) O 
and O 
photocleavage O 
ability O 
to O 
CT O 
DNA O 
than O 
HA O 
. O 
In O 
vitro O 
studies O 
have O 
illustrated O 
that O 
the O 
Al(3+) B-FORMULA 
-HA O 
complex O 
has O 
anti-cancer O 
activity O 
. O 

of O 
the O 
simple O 
and O 
sensitive O 
method O 
for O 
lipoxygenase O 
assay O 
in O 
AOT B-ABBREVIATION 
/ O 
isooctane B-SYSTEMATIC 
reversed O 
micelles O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
possibility O 
of O 
reversed O 
micelles O 
, O 
widely O 
used O 
as O 
an O 
enzyme O 
reactor O 
for O 
lipases O 
, O 
for O 
the O 
determination O 
of O 
lipoxygenase O 
activity O 
. O 
Although O 
it O 
is O 
rapid O 
and O 
simple O 
, O 
reversed O 
micelles O 
have O 
some O 
limitations O 
, O 
such O 
as O 
interference O 
by O 
UV-absorbing O 
materials O 
and O 
surfactant O 
. O 
Lipoxygenase O 
activity O 
in O 
the O 
reversed O 
micelles O 
was O 
determined O 
by O 
reading O 
the O 
absorbance O 
of O 
the O 
lipid O 
hydroperoxidation O 
product O 
( O 
conjugated O 
diene B-SYSTEMATIC 
) O 
at O 
234 O 
nm O 
. O 
Among O 
surfactants O 
and O 
organic O 
media O 
, O 
AOT B-ABBREVIATION 
and O 
isooctane B-SYSTEMATIC 
were O 
most O 
effective O 
for O 
the O 
dioxygenation O 
of O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
in O 
reversed O 
micelles O 
. O 
The O 
strong O 
absorbance O 
of O 
AOT B-ABBREVIATION 
in O 
the O 
UV O 
region O 
is O 
a O 
major O 
obstacle O 
for O 
the O 
direct O 
application O 
of O 
the O 
AOT B-ABBREVIATION 
/ O 
isooctane B-SYSTEMATIC 
reversed O 
micelles O 
to O 
lipoxygenase O 
activity O 
determination O 
. O 
To O 
prevent O 
interference O 
by O 
AOT B-ABBREVIATION 
, O 
we O 
added O 
an O 
AOT B-ABBREVIATION 
removal O 
step O 
in O 
the O 
procedure O 
for O 
lipoxygenase O 
activity O 
determination O 
in O 
reversed O 
micelles O 
. O 
The O 
lipoxygenase O 
activity O 
was O 
dependent O 
on O 
water O 
content O 
, O 
and O 
maximum O 
activity O 
was O 
obtained O 
at O 
an O 
R-value O 
of O 
10 O 
. O 

and O 
processed O 
( O 
soaked O 
, O 
soaked O 
/ O 
boiled O 
, O 
roasted O 
) O 
wattle O 
, O 
Acacia O 
saligna O 
subspecies O 
( O 
subsp O 
. O 
) O 
saligna O 
, O 
pruinescens O 
, O 
stolonifera O 
and O 
lindleyi O 
, O 
seeds O 
were O 
analysed O 
for O 
nutritional O 
and O 
antinutritional O 
qualities O 
. O 
Whole O 
wattle O 
seeds O 
mainly O 
comprised O 
proteins O 
( O 
27.6-32.6% O 
) O 
and O 
carbohydrates B-FAMILY 
( O 
30.2-36.4% O 
) O 
, O 
which O 
had O 
approximately O 
12.0-14.0% O 
fat O 
and O 
13.0-15.0% O 
crude O 
fibre O 
. O 
Palmitic B-TRIVIAL 
( O 
9.6% O 
) O 
, O 
stearic B-TRIVIAL 
( O 
2.0% O 
) O 
, O 
oleic B-TRIVIAL 
( O 
20.0% O 
) O 
and O 
linoleic B-TRIVIAL 
( O 
64.3% O 
) O 
acids O 
were O 
identified O 
by O 
gas O 
chromatography O 
( O 
GC O 
) O 
analysis O 
. O 
Phenolic O 
( O 
∼0.2% O 
) O 
, O 
oxalate B-SYSTEMATIC 
( O 
2.2-3.4% O 
) O 
and O 
saponin B-FAMILY 
( O 
2.6-3.0% O 
) O 
contents O 
were O 
fairly O 
high O 
; O 
phytate B-TRIVIAL 
content O 
was O 
low O 
. O 
All O 
untreated O 
samples O 
contained O 
a O 
high O 
level O 
of O 
trypsin O 
inhibitor O 
( O 
2474.3-3271.4 O 
trypsin O 
inhibitor O 
units O 
per O 
gramme O 
( O 
TIU O 
/ O 
g O 
) O 
of O 
flour O 
) O 
and O 
low O 
level O 
of O 
α-chymotrypsin O 
inhibitor O 
( O 
120.4-150.6 O 
CIU O 
/ O 
g O 
) O 
. O 
Soaking O 
overnight O 
following O 
with O 
2-min O 
boiling O 
led O 
to O 
a O 
significant O 
reduction O 
of O 
protease O 
inhibitor O 
activity O 
. O 
Roasting O 
at O 
2 O 
min O 
or O 
longer O 
was O 
sufficient O 
to O 
reduce O 
both O 
trypsin O 
and O 
α-chymotrypsin O 
inhibitors O 
to O 
negligible O 
values O 
, O 
also O 
to O 
reduce O 
phytate B-TRIVIAL 
, O 
oxalate B-SYSTEMATIC 
and O 
saponin B-FAMILY 
contents O 
, O 
simultaneously O 
enhanced O 
the O 
nutritional O 
values O 
of O 
wattle O 
seeds O 
. O 

and O 
digestibility O 
of O 
phaseolin/ O 
polyphenol B-FAMILY 
in O 
the O 
common O 
bean O 
. O 

polyphenols B-FAMILY 
and O 
phaseolin O 
interaction O 
in O 
common O 
bean O 
varieties O 
was O 
studied O 
. O 
Raw O 
beans O 
of O 
three O 
different O 
colours O 
were O 
analysed O 
: O 
black O 
( O 
BRS O 
Supremo O 
) O 
, O 
brown O 
( O 
BRS O 
Pontal O 
) O 
and O 
white O 
( O 
WAF-75 O 
) O 
. O 
Based O 
on O 
the O 
phaseolin O 
digestibility O 
in O 
vitro O 
and O 
phaseolin- O 
polyphenol B-FAMILY 
complexation O 
obtained O 
by O 
SDS-PAGE O 
on O 
a O 
10% O 
polyacrylamide B-SYSTEMATIC 
gel O 
, O 
it O 
was O 
observed O 
that O 
the O 
polyphenols B-FAMILY 
interfere O 
with O 
the O 
digestibility O 
of O 
beans O 
by O 
decreasing O 
the O 
hydrolysis O 
of O 
phaseolin O 
, O 
especially O 
in O 
the O 
darker O 
ones O 
. O 
Furthermore O 
it O 
was O 
possible O 
to O 
verify O 
a O 
difference O 
in O 
the O 
electrophoretic O 
pattern O 
of O 
phaseolin O 
, O 
indicating O 
an O 
interaction O 
between O 
phaseolin O 
and O 
polyphenols B-FAMILY 
. O 

paper O 
aimed O 
to O 
evaluate O 
the O 
influence O 
of O 
seasonality O 
on O 
the O 
chemical O 
composition O 
of O 
oysters O 
( O 
Crassostrea O 
rhizophorae O 
) O 
. O 
Samples O 
were O 
collected O 
during O 
summer O 
and O 
winter O 
from O 
the O 
estuary O 
and O 
lagoon O 
complex O 
of O 
the O 
municipality O 
of O 
Barra O 
de O 
São O 
Miguel O 
, O 
Alagoas O 
, O 
Brazil O 
. O 
Statistical O 
differences O 
( O 
p O 
< O 
0.05 O 
) O 
between O 
summer O 
and O 
winter O 
were O 
observed O 
in O 
relation O 
to O 
chemical O 
composition O 
. O 
The O 
oysters O 
cultivated O 
in O 
the O 
winter O 
presented O 
some O 
nutritional O 
advantages O 
because O 
of O 
the O 
higher O 
levels O 
of O 
proteins O 
and O 
functional O 
nutrients O 
, O 
such O 
as O 
the O 
eicosapentaenoic B-MULTIPLE 
- I-MULTIPLE 
docosahexaenoic I-MULTIPLE 
acid I-MULTIPLE 
combination O 
and O 
percentages O 
of O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
n-3 O 
and O 
n-6 O 
) O 
, O 
and O 
the O 
lower O 
levels O 
of O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
. O 
Therefore O 
, O 
the O 
animals O 
in O 
winter O 
presented O 
a O 
higher O 
content O 
of O 
cholesterol B-FAMILY 
oxides I-FAMILY 
. O 
The O 
levels O 
of O 
cholesterol B-FAMILY 
oxides I-FAMILY 
found O 
in O 
these O 
products O 
during O 
winter O 
may O 
encourage O 
researchers O 
to O 
investigate O 
the O 
composition O 
of O 
oysters O 
cultivated O 
in O 
different O 
climates O 
all O 
over O 
the O 
world O 
. O 

determination O 
of O 
2-naphthol B-SYSTEMATIC 
and O 
1-hydroxypyrene B-SYSTEMATIC 
in O 
fish O 
and O 
shellfish O 
contaminated O 
with O 
crude O 
oil O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
. O 

paper O 
describes O 
a O 
gas O 
chromatography O 
- O 
mass O 
spectrometric O 
method O 
of O 
l-hydroxypyrene B-SYSTEMATIC 
( O 
1-HOP B-SYSTEMATIC 
) O 
and O 
2-naphthol B-SYSTEMATIC 
( O 
2-NAP B-SYSTEMATIC 
) O 
in O 
fish O 
and O 
shellfish O 
. O 
Alkali O 
hydrolysis O 
method O 
in O 
this O 
study O 
was O 
chosen O 
and O 
optimized O 
to O 
the O 
reaction O 
condition O 
for O 
90 O 
min O 
at O 
90°C O 
in O 
a O 
2.0M O 
KOH B-FORMULA 
solution O 
. O 
For O 
five O 
independent O 
determinations O 
at O 
0.2 O 
and O 
1 O 
μg O 
/ O 
kg O 
, O 
the O 
coefficient O 
of O 
variation O 
was O 
less O 
than O 
5.1% O 
. O 
This O 
method O 
was O 
used O 
to O 
assess O 
the O 
long O 
- O 
term O 
influence O 
of O 
spilled O 
crude O 
oil O 
on O 
marine O 
ecosystems O 
and O 
analyze O 
fifty O 
- O 
two O 
shellfish O 
samples O 
taken O 
in O 
the O 
near O 
of O 
the O 
accident O 
region O 
of O 
the O 
Hebei O 
Spirit O 
oil O 
spill O 
. O 
2-NAP B-SYSTEMATIC 
and O 
1-HOP B-SYSTEMATIC 
were O 
detected O 
in O 
the O 
mean O 
concentration O 
range O 
of O 
0.09-12.42 O 
and O 
0.03-0.06 O 
μg O 
/ O 
kg O 
, O 
respectively O 
. O 
2-NAP B-SYSTEMATIC 
was O 
detected O 
in O 
a O 
high O 
concentration O 
range O 
in O 
shellfishes O 
gathered O 
in O 
2 O 
months O 
after O 
the O 
accident O 
and O 
it O 
decreased O 
rapidly O 
to O 
6 O 
months O 
after O 
that O 
. O 
The O 
results O 
showed O 
that O 
2-NAP B-SYSTEMATIC 
might O 
be O 
an O 
important O 
biomarker O 
in O 
biota O 
contaminated O 
with O 
crude O 
oil O 
. O 

vitro O 
biological O 
activity O 
of O 
essential O 
oils O 
and O 
isolated O 
furanosesquiterpenes B-FAMILY 
from O 
the O 
neglected O 
vegetable O 
Smyrnium O 
olusatrum O 
L O 
. O 
( O 
Apiaceae O 
) O 
. O 

olusatrum O 
, O 
better O 
known O 
as O 
Alexanders O 
or O 
wild O 
celery O 
, O 
is O 
a O 
biennal O 
herb O 
used O 
in O 
cuisine O 
for O 
many O 
centuries O 
by O 
Romans O 
in O 
many O 
dishes O 
, O 
where O 
it O 
has O 
now O 
been O 
replaced O 
by O 
celery O 
. O 
In O 
order O 
to O 
provide O 
additional O 
evidences O 
so O 
that O 
this O 
forgotten O 
vegetable O 
can O 
be O 
reconsidered O 
in O 
the O 
human O 
diet O 
, O 
as O 
well O 
as O 
in O 
pharmaceutics O 
, O 
the O 
essential O 
oils O 
obtained O 
from O 
different O 
parts O 
and O 
its O 
main O 
isolated O 
furanosesquiterpenes B-FAMILY 
were O 
in O 
vitro O 
biologically O 
assayed O 
for O 
antiproliferative O 
activity O 
on O 
human O 
tumor O 
cell O 
lines O 
by O 
MTT B-ABBREVIATION 
assay O 
, O 
for O 
antioxidant O 
potential O 
by O 
DPPH B-ABBREVIATION 
, O 
ABTS B-ABBREVIATION 
and O 
FRAP O 
assays O 
, O 
and O 
for O 
antimicrobial O 
activity O 
by O 
the O 
agar O 
disc O 
diffusion O 
method O 
. O 
The O 
essential O 
oils O 
showed O 
cytotoxic O 
effects O 
on O 
tested O 
human O 
tumor O 
cell O 
lines O 
, O 
related O 
to O 
the O 
furanosesquiterpenoid O 
content O 
; O 
the O 
IC(50) O 
values O 
on O 
colon O 
carcinoma O 
, O 
glioblastoma O 
, O 
and O 
breast O 
adenocarcinoma O 
cells O 
were O 
8.51 O 
, O 
13.35 O 
, O 
and O 
14.81 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Isofuranodiene B-SYSTEMATIC 
and O 
1β-acetoxyfuranoeudesm-4(15)-ene B-SYSTEMATIC 
resulted O 
the O 
most O 
active O 
constituents O 
. O 
The O 
essential O 
oils O 
possessed O 
also O 
radical O 
scavenging O 
activity O 
. O 

, O 
electronic O 
tongues O 
( O 
ET O 
) O 
have O 
appeared O 
as O 
an O 
excellent O 
alternative O 
to O 
traditional O 
techniques O 
for O 
the O 
evaluation O 
of O 
food O 
quality O 
and O 
processes O 
. O 
ET O 
systems O 
are O 
based O 
on O 
arrays O 
of O 
low O 
selectivity O 
sensors O 
that O 
are O 
simultaneously O 
sensitive O 
to O 
several O 
components O 
in O 
a O 
measured O 
sample O 
( O 
cross O 
- O 
sensitivity O 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
ability O 
of O 
an O 
ET O 
based O 
on O 
pulse O 
voltammetry O 
to O 
quantify O 
organic O 
acids O 
( O 
ascorbic B-MULTIPLE 
, I-MULTIPLE 
citric I-MULTIPLE 
and I-MULTIPLE 
malic I-MULTIPLE 
acids I-MULTIPLE 
) O 
in O 
simple O 
( O 
SS O 
) O 
and O 
binary O 
solutions O 
( O 
BS O 
) O 
using O 
different O 
electrodes O 
. O 
The O 
most O 
significant O 
electrodes O 
for O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
prediction O 
were O 
Ni B-FORMULA 
and O 
Ag B-FORMULA 
for O 
SS O 
, O 
and O 
Ag B-FORMULA 
and O 
Ir B-FORMULA 
for O 
BS O 
where O 
positive O 
pulses O 
were O 
more O 
suitable O 
than O 
negative O 
ones O 
. O 
The O 
prediction O 
of O 
citric B-MULTIPLE 
and I-MULTIPLE 
malic I-MULTIPLE 
acids I-MULTIPLE 
in O 
SS O 
and O 
BS O 
were O 
suitable O 
using O 
Ir B-FORMULA 
, O 
Rh B-FORMULA 
, O 
Pt B-FORMULA 
, O 
Ag B-FORMULA 
and O 
Cu B-FORMULA 
electrodes O 
, O 
using O 
both O 
positive O 
and O 
negative O 
pulses O 
. O 

present O 
work O 
was O 
undertaken O 
to O 
examine O 
the O 
influence O 
of O 
grape O 
seed O 
extract O 
( O 
GS O 
) O 
and O 
tea O 
polyphenols B-FAMILY 
( O 
TP O 
) O 
, O 
as O 
natural O 
preservatives O 
, O 
combined O 
with O 
chitosan O 
( O 
Ch O 
) O 
, O 
on O 
the O 
quality O 
of O 
red O 
drum O 
( O 
Sciaenops O 
ocellatus O 
) O 
fillets O 
during O 
refrigerated O 
storage O 
. O 
Two O 
different O 
treatments O 
( O 
Ch O 
+ O 
GS O 
and O 
Ch O 
+ O 
TP O 
) O 
and O 
a O 
control O 
were O 
prepared O 
. O 
The O 
samples O 
were O 
stored O 
( O 
4 O 
± O 
1°C O 
) O 
for O 
20 O 
days O 
and O 
the O 
sampling O 
was O 
done O 
at O 
0 O 
, O 
4 O 
, O 
8 O 
, O 
12 O 
, O 
16 O 
, O 
20 O 
days O 
. O 
Microbiological O 
, O 
physicochemical O 
and O 
sensory O 
attributes O 
were O 
periodically O 
assessed O 
. O 
The O 
results O 
indicated O 
that O 
the O 
two O 
pretreatments O 
could O 
more O 
effectively O 
maintain O 
quality O 
and O 
could O 
extend O 
the O 
shelf O 
life O 
by O 
6-8 O 
days O 
compared O 
with O 
the O 
control O 
group O 
during O 
refrigerated O 
storage O 
. O 

rapid O 
, O 
simple O 
and O 
generic O 
analytical O 
method O 
which O 
was O 
able O 
to O 
simultaneously O 
determine O 
220 O 
undesirable O 
chemical O 
residues O 
in O 
infant O 
formula O 
had O 
been O 
developed O 
. O 
The O 
method O 
comprised O 
of O 
extraction O 
with O 
acetonitrile B-SYSTEMATIC 
, O 
clean O 
- O 
up O 
by O 
low O 
temperature O 
and O 
water O 
precipitation O 
, O 
and O 
analysis O 
by O 
ultra O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
electrospray O 
ionization O 
tandem O 
mass O 
spectrometry O 
( O 
UPLC-ESI-MS-MS O 
) O 
using O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
mode O 
. O 
Most O 
fat O 
materials O 
in O 
acetonitrile B-SYSTEMATIC 
extract O 
were O 
eliminated O 
by O 
low O 
temperature O 
clean O 
- O 
up O 
. O 
The O 
water O 
precipitation O 
, O 
providing O 
a O 
necessary O 
and O 
supplementary O 
cleanup O 
, O 
could O 
avoid O 
losses O 
of O 
hydrophobic O 
analytes O 
( O 
avermectins B-FAMILY 
, O 
ionophores O 
) O 
. O 
Average O 
recoveries O 
for O 
spiked O 
infant O 
formula O 
were O 
in O 
the O 
range O 
from O 
57% O 
to O 
147% O 
with O 
associated O 
RSD O 
values O 
between O 
1% O 
and O 
28% O 
. O 
For O 
over O 
80% O 
of O 
the O 
analytes O 
, O 
the O 
recoveries O 
were O 
between O 
70% O 
and O 
120% O 
with O 
RSD O 
values O 
in O 
the O 
range O 
of O 
1-15% O 
. O 
The O 
limits O 
of O 
quantification O 
( O 
LOQs O 
) O 
were O 
from O 
0.01 O 
to O 
5 O 
μg O 
/ O 
kg O 
, O 
which O 
were O 
usually O 
sufficient O 
to O 
verify O 
the O 
compliance O 
of O 
products O 
with O 
legal O 
tolerances O 
. O 
Application O 
of O 
this O 
method O 
in O 
routine O 
monitoring O 
programs O 
would O 
imply O 
a O 
drastic O 
reduction O 
of O 
both O 
effort O 
and O 
time O 
. O 

analysis O 
of O 
nutritional O 
compositions O 
of O 
transgenic O 
high O 
iron B-SYSTEMATIC 
rice O 
with O 
its O 
non-transgenic O 
counterpart O 
. O 

is O 
an O 
essential O 
micronutrient O 
for O 
human O 
nutrition O 
and O 
polished O 
rice O 
contains O 
very O 
low O 
amount O 
of O 
iron B-SYSTEMATIC 
. O 
Rice O 
with O 
high O 
iron B-SYSTEMATIC 
content O 
in O 
seed O 
endosperm O 
has O 
been O 
developed O 
by O 
insertion O 
of O 
soybean O 
ferritin O 
gene O 
under O 
the O 
control O 
of O 
the O 
endosperm O 
specific O 
glutelin O 
promoter O 
into O 
the O 
genome O 
of O 
indica O 
rice O 
line O 
IR68144 O 
. O 
The O 
nutritional O 
composition O 
of O 
the O 
brown O 
and O 
milled O 
rice O 
grain O 
has O 
been O 
compared O 
with O 
that O 
of O 
the O 
non-transgenic O 
rice O 
of O 
the O 
same O 
variety O 
. O 
In O 
this O 
study O 
, O 
the O 
nutritional O 
components O 
, O 
as O 
well O 
as O 
the O 
anti-nutrient O 
levels O 
, O 
were O 
measured O 
. O 
Our O 
studies O 
established O 
that O 
apart O 
from O 
the O 
increased O 
level O 
of O 
iron B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
in O 
transgenic O 
seeds O 
, O 
the O 
nutritional O 
quality O 
of O 
both O 
the O 
brown O 
and O 
milled O 
rice O 
grains O 
from O 
the O 
transgenic O 
line O 
was O 
substantially O 
equivalent O 
to O 
that O 
of O 
the O 
non-transgenic O 
rice O 
plants O 
. O 
The O 
result O 
clearly O 
shows O 
that O 
the O 
measured O 
amounts O 
of O 
the O 
nutritional O 
components O 
are O 
well O 
within O 
the O 
range O 
of O 
values O 
reported O 
for O 
other O 
commercial O 
lines O 
. O 

of O 
ethylenediaminetetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
foods O 
by O 
reversed O 
- O 
phase O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 

convenient O 
HPLC O 
method O 
for O 
the O 
quantitative O 
determination O 
of O 
EDTA B-ABBREVIATION 
in O 
foods O 
was O 
developed O 
. O 
EDTA B-ABBREVIATION 
in O 
food O 
samples O 
was O 
easily O 
extracted O 
with O 
water O 
by O 
ultrasonication O 
. O 
After O 
converting O 
to O 
Fe B-FORMULA 
(III) I-FORMULA 
complex O 
in O 
the O 
presence O 
of O 
Fe B-FORMULA 
(III) I-FORMULA 
ions O 
, O 
EDTA B-ABBREVIATION 
was O 
separated O 
on O 
a O 
reversed O 
- O 
phase O 
C30 O 
column O 
and O 
detected O 
with O 
ultraviolet O 
detection O 
( O 
260 O 
nm O 
) O 
. O 
Citrate B-TRIVIAL 
and O 
malate B-TRIVIAL 
, O 
which O 
are O 
present O 
in O 
many O 
foods O 
, O 
also O 
formed O 
Fe B-FORMULA 
(III) I-FORMULA 
complexes O 
but O 
they O 
did O 
not O 
interfere O 
the O 
chromatographic O 
detection O 
of O 
EDTA B-ABBREVIATION 
. O 
The O 
method O 
allowed O 
determination O 
of O 
EDTA B-ABBREVIATION 
in O 
foods O 
at O 
concentrations O 
as O 
low O 
as O 
0.01 O 
mmol O 
/ O 
kg O 
. O 
Good O 
recoveries O 
( O 
95.2-101% O 
) O 
were O 
obtained O 
by O 
the O 
standard O 
addition O 
method O 
on O 
four O 
samples O 
with O 
high O 
repeatability O 
( O 
RSD O 
, O 
0.8-3.4% O 
) O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
to O 
the O 
analysis O 
of O 
EDTA B-ABBREVIATION 
in O 
carbonated O 
drinks O 
, O 
jellies O 
, O 
canned O 
beans O 
, O 
canned O 
corn O 
and O 
food O 
supplements O 
. O 

in O 
antioxidant O 
and O 
anticancer O 
effects O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
- O 
lysine B-TRIVIAL 
mixture O 
by O 
Maillard O 
reaction O 
. O 

are O 
the O 
main O 
active O 
components O 
of O 
Panax O 
ginseng O 
. O 
Structural O 
changes O 
in O 
diol B-SYSTEMATIC 
type O 
ginsenosides B-FAMILY 
along O 
with O 
generation O 
of O 
Maillard O 
reaction O 
products O 
( O 
MRPs O 
) O 
are O 
strongly O 
associated O 
with O 
increased O 
free O 
radical O 
- O 
scavenging O 
activities O 
. O 
Ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
, O 
one O 
of O 
the O 
major O 
triol B-SYSTEMATIC 
type O 
ginsenosides B-FAMILY 
of O 
P O 
. O 
ginseng O 
, O 
possesses O 
a O 
hydrophobic O 
four O 
- O 
ring O 
steroid O 
- O 
like O 
structure O 
with O 
hydrophilic O 
sugar B-FAMILY 
moieties O 
at O 
carbons B-FAMILY 
-3 O 
and O 
-20 O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
identify O 
changes O 
in O 
the O 
structure O 
, O 
antioxidant O 
and O 
anticancer O 
effects O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
upon O 
Maillard O 
reaction O 
. O 
Ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
was O 
transformed O 
into O 
less O 
- O 
polar O 
ginsenosides B-MULTIPLE 
, I-MULTIPLE 
namely I-MULTIPLE 
Rg(2) I-MULTIPLE 
, I-MULTIPLE 
Rg(6) I-MULTIPLE 
and I-MULTIPLE 
F(4) I-MULTIPLE 
by O 
heat O 
- O 
processing O 
. O 
Free O 
radical O 
- O 
scavenging O 
activity O 
of O 
the O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
- O 
lysine B-TRIVIAL 
mixture O 
increased O 
upon O 
heat O 
processing O 
. O 
This O 
improved O 
free O 
radical O 
- O 
scavenging O 
activity O 
mediated O 
by O 
antioxidant O 
MRPs O 
, O 
which O 
were O 
generated O 
through O 
Maillard O 
reaction O 
of O 
a O 
glucosyl B-TRIVIAL 
moiety O 
separated O 
from O 
carbon B-SYSTEMATIC 
-20 O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
and O 
lysine B-TRIVIAL 
. O 
The O 
increased O 
anticancer O 
effect O 
of O 
ginsenoside B-TRIVIAL 
Re I-TRIVIAL 
- O 
lysine B-TRIVIAL 
mixture O 
upon O 
heat O 
processing O 
was O 
mainly O 
derived O 
from O 
the O 
generation O 
of O 
less O 
- O 
polar O 
ginsenosides B-FAMILY 
through O 
the O 
regulation O 
of O 
Bcl-2 O 
and O 
Bax O 
, O 
as O 
well O 
as O 
caspase O 
- O 
dependent O 
apoptotic O 
pathway O 
. O 
These O 
results O 
reported O 
here O 
have O 
shed O 
significant O 
new O 
lights O 
on O 
the O 
mechanism O 
of O 
increased O 
antioxidant O 
and O 
anticancer O 
effects O 
of O 
P O 
. O 
ginseng O 
upon O 
heat O 
processing O 
. O 

formulation O 
of O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
a O 
food O 
constituent O 
demonstrating O 
potential O 
anticaries O 
and O 
antigingivitis O 
properties O 
, O 
was O 
investigated O 
in O 
an O 
adhesive O 
microparticulate O 
delivery O 
system O 
with O 
the O 
goal O 
of O 
improving O 
its O 
effect O 
by O 
prolonging O 
its O 
residence O 
time O 
at O 
the O 
site O 
of O 
action O 
. O 
Alginate O 
and O 
chitosan O 
were O 
selected O 
as O 
mucoadhesive O 
polymers O 
. O 
The O 
microspheres O 
were O 
prepared O 
by O 
coacervation O 
. O 
Different O 
types O 
of O 
alginates O 
, O 
polymers O 
blends O 
and O 
crosslinking O 
agent O 
concentrations O 
were O 
considered O 
and O 
evaluated O 
. O 
The O 
best O 
results O 
in O 
terms O 
of O 
encapsulation O 
efficiency O 
, O 
in O 
vitro O 
active O 
agent O 
release O 
profile O 
and O 
in O 
vitro O 
adhesive O 
properties O 
, O 
both O 
to O 
oral O 
mucosa O 
and O 
to O 
teeth O 
surface O 
, O 
were O 
obtained O 
with O 
a O 
blend O 
of O 
Alginate O 
Protanal O 
LF200S O 
: O 
Alginate O 
Protanal O 
LF120LS O 
1 O 
: O 
1.5 O 
w O 
/ O 
w O 
, O 
0.1M O 
CaCl(2) O 
, O 
and O 
chitosan O 
coating O 
, O 
prepared O 
by O 
a O 
one O 
- O 
step O 
complex O 
coacervation O 
method O 
. O 
This O 
microparticulate O 
delivery O 
system O 
showed O 
prolonged O 
release O 
of O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
could O 
be O 
used O 
as O 
an O 
active O 
component O 
in O 
chewing O 
gums O 
or O 
mouthwashes O 
for O 
both O 
caries O 
and O 
gingivitis O 
prevention O 
. O 

study O 
aimed O 
to O 
determine O 
whether O 
compositional O 
or O 
processing O 
parameters O 
have O 
an O 
influence O 
on O 
the O 
odour O 
quality O 
of O 
egg O 
powders O 
. O 
The O 
parameters O 
tested O 
were O 
: O 
whole O 
egg O 
vs O 
. O 
egg O 
yolk O 
, O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
( O 
PUFA B-ABBREVIATION 
) O 
enrichment O 
, O 
spray O 
- O 
drying O 
temperature O 
( O 
160°C O 
vs O 
. O 
180°C O 
) O 
, O 
production O 
scale O 
( O 
industrial O 
vs O 
. O 
pilot O 
plant O 
) O 
, O 
storage O 
temperature O 
( O 
15°C O 
vs O 
. O 
30°C O 
) O 
and O 
time O 
( O 
1 O 
, O 
2 O 
, O 
4 O 
and O 
8 O 
months O 
) O 
. O 
The O 
quality O 
of O 
egg O 
powders O 
was O 
evaluated O 
by O 
sensory O 
analysis O 
using O 
free O 
sorting O 
, O 
and O 
by O 
gas O 
chromatography O 
coupled O 
to O 
mass O 
spectrometry O 
and O 
olfactometry O 
. O 
PUFA B-ABBREVIATION 
enrichment O 
and O 
spray O 
- O 
drying O 
temperature O 
do O 
not O 
affect O 
the O 
odour O 
of O 
egg O 
yolk O 
powders O 
. O 
There O 
are O 
significant O 
differences O 
between O 
the O 
odour O 
of O 
whole O 
- O 
egg O 
and O 
egg O 
- O 
yolk O 
powders O 
as O 
well O 
as O 
between O 
powders O 
produced O 
on O 
an O 
industrial O 
scale O 
or O 
in O 
a O 
pilot O 
plant O 
. O 
An O 
increase O 
in O 
the O 
odour O 
intensity O 
of O 
egg O 
powders O 
was O 
observed O 
during O 
storage O 
, O 
while O 
unpleasant O 
odours O 
were O 
perceived O 
when O 
the O 
egg O 
powders O 
were O 
stored O 
at O 
30°C O 
. O 

by O 
UHPLC O 
of O 
total O 
individual O 
polyphenols B-FAMILY 
in O 
fruit O 
juices O 
. O 

present O 
work O 
proposes O 
a O 
new O 
UHPLC-PDA-fluorescence O 
method O 
able O 
to O 
identify O 
and O 
quantify O 
the O 
main O 
polyphenols B-FAMILY 
present O 
in O 
commercial O 
fruit O 
juices O 
in O 
a O 
28-min O 
chromatogram O 
. O 
The O 
proposed O 
method O 
improve O 
the O 
IFU O 
method O 
No O 
. O 
71 O 
used O 
to O 
evaluate O 
anthocyanins B-FAMILY 
profiles O 
of O 
fruit O 
juices O 
. O 
Fruit O 
juices O 
of O 
strawberry O 
, O 
American O 
cranberry O 
, O 
bilberry O 
, O 
sour O 
cherry O 
, O 
black O 
grape O 
, O 
orange O 
, O 
and O 
apple O 
, O 
were O 
analysed O 
identifying O 
70 O 
of O 
their O 
main O 
polyphenols B-FAMILY 
( O 
23 O 
anthocyanins B-FAMILY 
, O 
15 O 
flavonols B-FAMILY 
, O 
6 O 
hydroxybenzoic B-FAMILY 
acids I-FAMILY 
, O 
14 O 
hydroxycinnamic B-FAMILY 
acids I-FAMILY 
, O 
4 O 
flavanones B-FAMILY 
, O 
2 O 
dihydrochalcones B-FAMILY 
, O 
4 O 
flavan-3-ols B-FAMILY 
and O 
2 O 
stilbenes B-FAMILY 
) O 
. O 
One O 
standard O 
polyphenol B-FAMILY 
of O 
each O 
group O 
was O 
used O 
to O 
calculate O 
individual O 
polyphenol B-FAMILY 
concentration O 
presents O 
in O 
a O 
juice O 
. O 
Total O 
amount O 
of O 
polyphenols B-FAMILY 
in O 
a O 
fruit O 
juice O 
was O 
estimated O 
as O 
total O 
individual O 
polyphenols B-FAMILY 
( O 
TIP O 
) O 
. O 
A O 
good O 
correlation O 
( O 
r(2)=0.966 O 
) O 
was O 
observed O 
between O 
calculated O 
TIP O 
, O 
and O 
total O 
polyphenols B-FAMILY 
( O 
TP O 
) O 
determined O 
by O 
the O 
well O 
- O 
known O 
colorimetric O 
Folin-Ciocalteu O 
method O 
. O 
In O 
this O 
work O 
, O 
the O 
higher O 
TIP O 
value O 
corresponded O 
to O 
bilberry O 
juice O 
( O 
607.324 O 
mg O 
/ O 
100mL O 
fruit O 
juice O 
) O 
and O 
the O 
lower O 
to O 
orange O 
juice O 
( O 
32.638 O 
mg O 
/ O 
100mL O 
fruit O 
juice O 
) O 
. O 
This O 
method O 
is O 
useful O 
for O 
authentication O 
analyses O 
and O 
for O 
labelling O 
total O 
polyphenols B-FAMILY 
contents O 
of O 
commercial O 
fruit O 
juices O 
. O 

potential O 
of O 
Raman O 
chemical O 
imaging O 
for O 
simultaneously O 
detecting O 
multiple O 
adulterants O 
in O 
milk O 
powder O 
was O 
investigated O 
. O 
Potential O 
chemical O 
adulterants O 
, O 
including O 
ammonium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
, O 
dicyandiamide B-SYSTEMATIC 
, O 
melamine B-TRIVIAL 
, O 
and O 
urea B-TRIVIAL 
, O 
were O 
mixed O 
together O 
into O 
skim O 
dry O 
milk O 
in O 
the O 
concentration O 
range O 
of O 
0.1-5.0% O 
for O 
each O 
adulterant O 
. O 
Using O 
a O 
785-nm O 
laser O 
, O 
a O 
Raman O 
imaging O 
system O 
acquired O 
hyperspectral O 
images O 
in O 
the O 
wavenumber O 
range O 
of O 
102-2538 O 
cm(-1) O 
for O 
a O 
25 O 
× O 
25 O 
mm(2) O 
area O 
of O 
each O 
mixture O 
sample O 
, O 
with O 
a O 
spatial O 
resolution O 
of O 
0.25 O 
mm O 
. O 
Self O 
- O 
modelling O 
mixture O 
analysis O 
( O 
SMA O 
) O 
was O 
used O 
to O 
extract O 
pure O 
component O 
spectra O 
, O 
by O 
which O 
the O 
four O 
types O 
of O 
the O 
adulterants O 
were O 
identified O 
at O 
all O 
concentration O 
levels O 
based O 
on O 
their O 
spectral O 
information O 
divergence O 
values O 
to O 
the O 
reference O 
spectra O 
. O 
Raman O 
chemical O 
images O 
were O 
created O 
using O 
the O 
contribution O 
images O 
from O 
SMA O 
, O 
and O 
their O 
use O 
to O 
effectively O 
visualise O 
identification O 
and O 
spatial O 
distribution O 
of O 
the O 
multiple O 
adulterant O 
particles O 
in O 
the O 
dry O 
milk O 
was O 
demonstrated O 
. O 

of O 
α-tocopherol B-TRIVIAL 
-associated O 
protein O 
( O 
TAP O 
) O 
expression O 
in O 
human O 
breast O 
epithelial O 
cells O 
during O 
breast O 
cancer O 
development O 
. O 

cancer O 
is O 
the O 
most O 
common O 
malignancy O 
among O 
women O 
and O 
has O 
an O 
age O 
- O 
specific O 
incidence O 
profile O 
. O 
Over O 
the O 
last O 
decade O 
, O 
many O 
studies O 
have O 
demonstrated O 
the O 
anticancer O 
activity O 
of O 
α-tocopherol B-TRIVIAL 
, O 
the O 
main O 
and O 
most O 
active O 
form O 
of O 
natural O 
vitamin B-FAMILY 
E I-FAMILY 
. O 
α-Tocopherol B-TRIVIAL 
-associated O 
protein O 
( O 
TAP O 
) O 
was O 
found O 
to O 
be O 
one O 
of O 
the O 
major O 
α-tocopherol B-TRIVIAL 
binding O 
proteins O 
in O 
human O 
serum O 
and O 
in O 
liver O 
, O 
brain O 
, O 
and O 
prostate O 
tissues O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
reduced O 
TAP O 
expression O 
was O 
significantly O 
correlated O 
with O 
Her2 O 
/ O 
neu O 
receptor O 
expression O 
, O 
breast O 
cancer O 
stage O 
and O 
nodal O 
stage O 
in O 
paired O 
normal O 
and O 
cancerous O 
breast O 
tissue O 
samples O 
from O 
93 O 
patients O 
using O 
real O 
- O 
time O 
PCR O 
analysis O 
. O 
A O 
cell O 
viability O 
assay O 
showed O 
that O 
α-tocopheryl B-SYSTEMATIC 
succinate I-SYSTEMATIC 
( O 
α-TOS B-ABBREVIATION 
) O 
, O 
a O 
synthetic O 
derivative O 
of O 
α-tocopherol B-TRIVIAL 
, O 
enhanced O 
the O 
cells O 
' O 
sensitivity O 
to O 
doxorubicin B-TRIVIAL 
and O 
resulted O 
in O 
a O 
reduction O 
in O 
cell O 
viability O 
in O 
breast O 
cancers O 
. O 
Taken O 
together O 
, O 
these O 
data O 
suggest O 
that O 
the O 
use O 
of O 
vitamin B-FAMILY 
E I-FAMILY 
or O 
its O 
analogue O 
as O 
a O 
dietary O 
supplement O 
may O 
be O 
beneficial O 
for O 
the O 
treatment O 
of O 
cancer O 
. O 

effects O 
of O 
oral O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
against O 
oxidative O 
stress O 
induced O 
by O 
6-hydroxydopamine B-SYSTEMATIC 
in O 
rats O 
. O 

radical O 
- O 
induced O 
neural O 
damage O 
is O 
implicated O 
in O 
neurodegenerative O 
diseases O 
and O 
antioxidants O 
have O 
protective O 
activity O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
examined O 
the O 
effect O 
of O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
; O 
50 O 
, O 
100 O 
and O 
200mg O 
/ O 
kg O 
, O 
p.o O 
. O 
for O 
10 O 
days O 
) O 
on O 
memory O 
deficit O 
and O 
cerebral O 
oxidative O 
stress O 
induced O 
by O 
6-hydroxydopamine B-SYSTEMATIC 
( O 
6-OHDA B-SYSTEMATIC 
; O 
8 O 
μg O 
/ O 
2 O 
μL O 
) O 
injected O 
into O 
the O 
medial O 
forebrain O 
bundle O 
( O 
MFB O 
, O 
full O 
nigral O 
lesion O 
) O 
as O 
an O 
animal O 
model O 
of O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
The O 
results O 
showed O 
that O 
6-OHDA B-SYSTEMATIC 
significantly O 
reduced O 
the O 
passive O 
avoidance O 
memory O 
performance O 
, O 
non-enzymatic O 
( O 
total O 
thiol B-FAMILY 
) O 
and O 
enzymatic O 
[ O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
] O 
antioxidant O 
contents O 
and O 
increased O 
the O 
level O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
in O 
the O 
hippocampus O 
and O 
striatum O 
of O 
vehicle O 
- O 
treated O 
group O 
as O 
compared O 
to O 
sham O 
- O 
operated O 
rats O 
. O 
Furthermore O 
, O 
oral O 
administration O 
of O 
GA O 
significantly O 
increased O 
the O 
passive O 
avoidance O 
memory O 
, O 
total O 
thiol B-FAMILY 
and O 
GPx O 
contents O 
and O 
also O 
decreased O 
MDA B-ABBREVIATION 
levels O 
in O 
the O 
above O 
tissues O 
. O 
The O 
results O 
suggest O 
that O 
GA O 
has O 
neuroprotective O 
activity O 
against O 
6-OHDA B-SYSTEMATIC 
-induced O 
oxidative O 
stress O 
via O 
enhancement O 
of O 
cerebral O 
antioxidant O 
defence O 
. O 

B I-TRIVIAL 
induces O 
autophagic O 
cell O 
death O 
by O 
inhibiting O 
the O 
AKT O 
/ O 
mTOR O 
pathway O 
and O 
S O 
phase O 
cell O 
cycle O 
arrest O 
in O 
HepG2 O 
cells O 
. O 

study O 
investigates O 
the O 
anticancer O 
properties O 
of O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
, O 
purified O 
from O 
hempseed O 
hull O 
, O 
in O 
HepG2 O 
human O 
hepatoblastoma O 
cells O 
. O 
The O 
results O 
indicate O 
that O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
significantly O 
inhibited O 
cell O 
proliferation O 
by O 
inducing O 
autophagic O 
cell O 
death O 
rather O 
than O 
typical O 
apoptosis O 
. O 
Cell O 
viability O 
transiently O 
increased O 
upon O 
the O 
addition O 
of O 
a O 
low O 
concentration O 
of O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
but O 
decreased O 
upon O 
the O 
addition O 
of O 
high O 
concentrations O 
. O 
Cannabisin B-TRIVIAL 
B I-TRIVIAL 
-induced O 
changes O 
in O 
cell O 
viability O 
were O 
completely O 
inhibited O 
by O 
pre O 
- O 
treatment O 
with O 
3-methyladenine B-SYSTEMATIC 
( O 
3-MA B-SYSTEMATIC 
) O 
, O 
indicating O 
that O 
the O 
induction O 
of O 
autophagy O 
by O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
caused O 
cell O 
death O 
. O 
Additionally O 
, O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
induced O 
S O 
phase O 
cell O 
cycle O 
arrest O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Moreover O 
, O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
was O 
found O 
to O 
inhibit O 
survival O 
signaling O 
by O 
blocking O 
the O 
activation O 
of O 
AKT O 
and O 
down O 
- O 
stream O 
targets O 
of O 
the O 
mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
cannabisin B-TRIVIAL 
B I-TRIVIAL 
possesses O 
considerable O 
antiproliferative O 
activity O 
and O 
that O 
it O 
may O 
be O 
utilised O 
as O 
a O 
promising O 
chemopreventive O 
agent O 
against O 
hepatoblastoma O 
disease O 
. O 

D I-FAMILY 
and O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
determination O 
in O 
meats O 
by O 
LC-IT-MS O 
. O 

paper O 
reports O 
a O 
method O 
for O 
the O 
rapid O 
, O 
sensitive O 
and O 
simultaneous O 
analysis O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
( O 
Vit B-ABBREVIATION 
D I-ABBREVIATION 
) O 
and O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
25OH-Vit B-SYSTEMATIC 
D I-SYSTEMATIC 
) O 
in O 
meats O 
. O 
Samples O 
were O 
saponified O 
and O 
underwent O 
solid O 
phase O 
extraction O 
with O 
analysis O 
by O 
normal O 
phase O 
liquid O 
chromatography O 
( O 
LC O 
) O 
with O 
ion O 
trap O 
mass O 
spectroscopy O 
( O 
IT-MS O 
) O 
, O 
using O 
positive O 
polarity O 
atmospheric O 
pressure O 
chemical O 
ionisation O 
( O 
APCI O 
) O 
. O 
Limits O 
of O 
detection O 
( O 
LOD O 
) O 
and O 
quantification O 
( O 
LOQ O 
) O 
for O 
Vit B-ABBREVIATION 
D I-ABBREVIATION 
and O 
25OH-Vit B-SYSTEMATIC 
D I-SYSTEMATIC 
were O 
0.03 O 
and O 
0.05 O 
μg O 
/ O 
100g O 
respectively O 
. O 
Deuterium B-SYSTEMATIC 
labelled O 
Vit B-ABBREVIATION 
D I-ABBREVIATION 
and O 
25OH-Vit B-SYSTEMATIC 
D I-SYSTEMATIC 
internal O 
standards O 
were O 
added O 
as O 
surrogates O 
prior O 
to O 
saponification O 
, O 
correcting O 
for O 
extraction O 
inefficiencies O 
and O 
potential O 
MS O 
matrix O 
enhancement O 
or O 
suppression O 
effects O 
. O 
Recoveries O 
using O 
internal O 
/ O 
surrogate O 
standard O 
correction O 
ranged O 
from O 
80% O 
to O 
100% O 
for O 
all O 
vitamers O 
. O 
Measurement O 
uncertainty O 
ranged O 
from O 
6% O 
to O 
15% O 
for O 
all O 
vitamers O 
in O 
this O 
method O 
. O 
This O 
process O 
required O 
only O 
7.5 O 
g O 
of O 
sample O 
per O 
extraction O 
and O 
a O 
batch O 
of O 
28 O 
extractions O 
could O 
be O 
completed O 
in O 
six O 
hours O 
. O 

determination O 
of O 
aflatoxin B-TRIVIAL 
B(1) I-TRIVIAL 
and O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
in O 
licorice O 
roots O 
and O 
fritillary O 
bulbs O 
by O 
solid O 
- O 
phase O 
extraction O 
coupled O 
with O 
high O 
- O 
performance O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
. O 

effective O 
method O 
was O 
developed O 
for O 
screening O 
licorice O 
roots O 
and O 
fritillary O 
bulbs O 
for O 
contamination O 
by O 
aflatoxin B-TRIVIAL 
B(1) I-TRIVIAL 
and O 
ochratoxin B-TRIVIAL 
A I-TRIVIAL 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
connected O 
to O 
tandem O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
/ O 
MS O 
) O 
. O 
The O 
samples O 
were O 
pre O 
- O 
concentrated O 
and O 
purified O 
using O 
solid O 
- O 
phase O 
extraction O 
, O 
which O 
provided O 
satisfactory O 
results O 
. O 
The O 
separation O 
was O 
performed O 
on O 
a O 
Waters O 
Xbridge O 
( O 
TM O 
) O 
C18 O 
column O 
with O 
a O 
linear O 
gradient O 
of O 
acetonitrile B-SYSTEMATIC 
- O 
water O 
containing O 
5mM O 
ammonium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
The O 
MS O 
spectrum O 
was O 
acquired O 
in O 
positive O 
mode O 
with O 
both O 
single O 
quadrupole O 
( O 
Q1 O 
) O 
and O 
multiple O 
reaction O 
monitoring O 
( O 
MRM O 
) O 
. O 
The O 
optimised O 
method O 
offered O 
a O 
good O 
linear O 
correlation O 
( O 
r(2) O 
> O 
0.9967 O 
) O 
, O 
excellent O 
precision O 
( O 
RSD O 
< O 
2.83% O 
) O 
and O 
acceptable O 
recovery O 
( O 
from O 
92.78 O 
to O 
105.37% O 
) O 
. O 
The O 
limits O 
of O 
detection O 
( O 
LOD O 
) O 
and O 
the O 
limits O 
of O 
quantification O 
( O 
LOQ O 
) O 
were O 
less O 
than O 
0.024 O 
μg O 
/ O 
kg O 
and O 
0.095 O 
μg O 
/ O 
kg O 
, O 
respectively O 
. O 
The O 
validated O 
method O 
was O 
successfully O 
applied O 
to O 
the O 
rapid O 
screening O 
for O 
AFB(1) O 
and O 
OTA O 
in O 
licorice O 
roots O 
and O 
fritillary O 
bulbs O 
. O 

intestinal O 
immune O 
system O 
modulating O 
polysaccharide O 
( O 
CUI-3IIb-3-2 O 
, O 
18kDa O 
) O 
was O 
purified O 
from O 
Citrus O 
unshiu O 
peel O 
. O 
CUI-3IIb-3-2 O 
mainly O 
comprised O 
GalA B-ABBREVIATION 
, O 
GlcA B-ABBREVIATION 
, O 
Ara B-ABBREVIATION 
, O 
Gal B-ABBREVIATION 
and O 
Rha B-ABBREVIATION 
, O 
and O 
it O 
consisted O 
of O 
4- O 
linked O 
GalA B-ABBREVIATION 
, O 
terminal O 
Araf B-ABBREVIATION 
, O 
4- O 
or O 
5- O 
linked O 
/ O 
3,4- O 
or O 
3,5-branched O 
Ara B-ABBREVIATION 
, O 
terminal O 
Gal B-ABBREVIATION 
, O 
and O 
2- O 
linked O 
/ O 
2,4-branched O 
Rha B-ABBREVIATION 
. O 
After O 
CUI-3IIb-3-2 O 
digestion O 
by O 
endo-α-d-(1→4)-polygalacturonase O 
, O 
its O 
hydrolysate O 
was O 
fractionated O 
into O 
PG-1 O 
and O 
PG-2 O 
. O 
Methylation O 
analyses O 
of O 
PG-1 O 
and O 
PG-2 O 
using O 
base O 
- O 
catalysed O 
β-elimination O 
suggested O 
that O 
CUI-3IIb-3-2 O 
be O 
assumed O 
as O 
pectic O 
- O 
type O 
polysaccharide O 
. O 
Since O 
the O 
activities O 
of O 
PG-1 O 
and O 
PG-2 O 
were O 
potently O 
decreased O 
, O 
the O 
whole O 
polysaccharide O 
structure O 
of O 
CUI-3IIb-3-2 O 
would O 
be O 
essential O 
to O 
maintain O 
the O 
activity O 
. O 
Meanwhile O 
, O 
when O 
CUI-3IIb O 
was O 
orally O 
administered O 
in O 
mice O 
, O 
bone O 
marrow O 
cell O 
proliferation O 
and O 
GM-CSF O 
/ O 
IL-6 O 
production O 
from O 
Peyer's O 
patch O 
cell O 
were O 
significantly O 
higher O 
( O 
1.76- O 
and O 
2.03 O 
/ O 
2.51-fold O 
, O 
respectively O 
) O 
than O 
a O 
saline O 
. O 
Therefore O 
, O 
a O 
pectic O 
- O 
type O 
polysaccharide O 
from O 
citrus O 
peel O 
could O 
stimulate O 
Peyer's O 
patches O 
and O 
produce O 
hematopoietic O 
growth O 
factors O 
resulted O 
in O 
bone O 
marrow O 
cell O 
proliferation O 
. O 

electrospray O 
ionisation O 
- O 
mass O 
spectrometry O 
screening O 
of O 
triacylglycerols B-FAMILY 
in O 
developing O 
cultivated O 
and O 
wild O 
peanut O 
kernels O 
( O 
Arachis O 
hypogaea O 
L O 
. O 
) O 
. O 

accumulation O 
of O 
triacylglycerols B-FAMILY 
during O 
the O 
development O 
of O 
three O 
varieties O 
of O 
peanuts O 
was O 
monitored O 
in O 
two O 
Tunisian O 
cultivated O 
peanut O 
( O 
Trabelsia O 
( O 
AraT O 
) O 
and O 
Chounfakhi O 
( O 
AraC O 
) O 
) O 
and O 
one O 
wild O 
Tunisian O 
peanut O 
( O 
Arbi O 
( O 
AraA O 
) O 
) O 
. O 
The O 
presence O 
of O 
TAGs O 
composed O 
of O 
rare O 
fatty B-FAMILY 
acid I-FAMILY 
residues O 
such O 
as O 
hexacosanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
(C(23:0)) O 
and O 
heneicosanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
(C(21:0)) O 
among O 
the O 
triacylglycerols B-FAMILY 
C(23:0) O 
LL O 
, O 
C(23:0) O 
OO O 
and O 
C(21:0) O 
LL O 
was O 
noted O 
. O 
The O 
major O 
molecular O 
species O 
of O 
triacylglycerol B-FAMILY 
detected O 
in O 
the O 
three O 
peanut O 
varieties O 
were O 
dioleoyl B-TRIVIAL 
linoleoyl I-TRIVIAL 
( O 
OOL B-ABBREVIATION 
) O 
, O 
1,2,3-trioleyl B-SYSTEMATIC 
( O 
OOO B-ABBREVIATION 
) O 
, O 
1,2-dioleyl-3-palmitoyl B-SYSTEMATIC 
( O 
POO B-ABBREVIATION 
) O 
, O 
1,2-dilinoleoyl-3-oleyl B-SYSTEMATIC 
( O 
OLL B-ABBREVIATION 
) O 
and O 
1-oleoyl-2-linoleoyl-3-linolenoyl B-SYSTEMATIC 
( O 
OLLn B-ABBREVIATION 
) O 
. O 
The O 
TAG O 
composition O 
and O 
content O 
were O 
significantly O 
different O 
among O 
the O 
three O 
peanut O 
varieties O 
. O 
The O 
three O 
major O 
TAGs O 
were O 
OOL O 
( O 
20.6% O 
) O 
, O 
OOO B-ABBREVIATION 
( O 
15.6% O 
) O 
and O 
OLLn O 
( O 
13.2% O 
) O 
in O 
AraA O 
; O 
OOL B-ABBREVIATION 
( O 
21.4% O 
) O 
, O 
OOO B-ABBREVIATION 
( O 
20.1% O 
) O 
and O 
POO B-ABBREVIATION 
( O 
17.5% O 
) O 
in O 
AraC O 
and O 
finally O 
OLL B-ABBREVIATION 
( O 
20.7% O 
) O 
, O 
OOO B-ABBREVIATION 
( O 
19.8% O 
) O 
and O 
OLL B-ABBREVIATION 
( O 
17.7% O 
) O 
in O 
AraT O 
. O 

forming O 
ability O 
of O 
gelatins O 
from O 
splendid O 
squid O 
( O 
Loligo O 
formosana O 
) O 
skin O 
bleached O 
with O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 

of O 
gelatin O 
films O 
from O 
splendid O 
squid O 
( O 
Loligo O 
formosana O 
) O 
skin O 
bleached O 
with O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H(2)O(2) B-FORMULA 
) O 
at O 
various O 
concentrations O 
( O 
0-8% O 
w O 
/ O 
v O 
) O 
were O 
investigated O 
. O 
Tensile O 
strength O 
( O 
TS O 
) O 
and O 
water O 
vapour O 
permeability O 
( O 
WVP O 
) O 
of O 
films O 
decreased O 
, O 
but O 
elongation O 
at O 
break O 
( O 
EAB O 
) O 
increased O 
( O 
p O 
< O 
0.05 O 
) O 
as O 
the O 
concentration O 
of O 
H(2)O(2) B-FORMULA 
increased O 
. O 
Among O 
all O 
films O 
, O 
that O 
prepared O 
from O 
gelatin O 
with O 
2% O 
H(2)O(2) B-FORMULA 
bleaching O 
showed O 
the O 
lowest O 
ΔE(∗)-value O 
( O 
total O 
colour O 
difference O 
) O 
, O 
which O 
was O 
concomitant O 
with O 
the O 
highest O 
L(∗)-value O 
( O 
lightness O 
) O 
. O 
Generally O 
, O 
higher O 
concentration O 
of O 
H(2)O(2) B-FORMULA 
resulted O 
in O 
increased O 
b(∗)-value O 
( O 
yellowness O 
) O 
of O 
resulting O 
films O 
. O 
Electrophoretic O 
study O 
revealed O 
that O 
α- O 
chains O 
of O 
gelatin O 
in O 
films O 
became O 
lowered O 
with O 
increasing O 
H(2)O(2) B-FORMULA 
concentrations O 
used O 
for O 
bleaching O 
. O 
Thermogravimetric O 
analysis O 
indicated O 
that O 
heat O 
susceptibility O 
and O 
weight O 
loss O 
of O 
different O 
films O 
varied O 
with O 
H(2)O(2) B-FORMULA 
concentrations O 
. O 
Rougher O 
surface O 
was O 
obtained O 
in O 
gelatin O 
films O 
prepared O 
from O 
skin O 
bleached O 
with O 
H(2)O(2) B-FORMULA 
concentrations O 
above O 
4% O 
. O 
Thus O 
, O 
the O 
concentrations O 
of O 
H(2)O(2) B-FORMULA 
used O 
for O 
bleaching O 
of O 
squid O 
skin O 
prior O 
to O 
gelatin O 
extraction O 
directly O 
affected O 
the O 
properties O 
of O 
corresponding O 
gelatin O 
films O 
. O 

elemental O 
analysis O 
, O 
besides O 
its O 
ability O 
to O 
determine O 
stable O 
isotopes O 
ratios O 
, O 
represents O 
a O 
possible O 
complementary O 
tool O 
useful O 
to O 
differentiate O 
wines O 
based O 
on O 
their O 
regional O 
origins O 
. O 
Wines O 
and O 
their O 
provenance O 
soils O 
from O 
two O 
major O 
wine O 
producing O 
areas O 
in O 
Southeast O 
Romania O 
( O 
' O 
Valea O 
Calugareasca O 
' O 
and O 
' O 
Murfatlar O 
' O 
) O 
, O 
and O 
also O 
wine O 
from O 
the O 
region O 
of O 
Moldova O 
( O 
Eastern O 
Romania O 
) O 
were O 
analyzed O 
by O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
( O 
ICP-MS O 
) O 
, O 
and O 
statistical O 
data O 
of O 
elemental O 
composition O 
was O 
used O 
to O 
differentiate O 
these O 
wines O 
according O 
to O 
grape O 
type O 
and O 
geographical O 
origin O 
. O 
Moreover O 
, O 
this O 
study O 
gathers O 
relevant O 
elemental O 
trace O 
composition O 
of O 
wines O 
produced O 
in O 
most O 
important O 
Romanian O 
vineyards O 
, O 
thus O 
offering O 
a O 
useful O 
wine O 
differentiation O 
tool O 
by O 
their O 
production O 
district O 
. O 
The O 
results O 
show O 
that O 
the O 
differentiation O 
of O 
Romanian O 
wines O 
according O 
to O 
their O 
provenance O 
is O 
based O 
on O 
the O 
following O 
main O 
elements O 
: O 
Ni B-FORMULA 
, O 
Ag B-FORMULA 
, O 
Cr B-FORMULA 
, O 
Sr B-FORMULA 
, O 
Zn B-FORMULA 
, O 
and O 
Cu B-FORMULA 
for O 
Valea O 
Calugareasca O 
, O 
Rb B-FORMULA 
, O 
Zn B-FORMULA 
, O 
and O 
Mn B-FORMULA 
for O 
Murfatlar O 
, O 
and O 
Pb B-FORMULA 
, O 
Co B-FORMULA 
, O 
and O 
V B-FORMULA 
for O 
Moldova O 
. O 

of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
its O 
hydroxylated O 
metabolites O 
in O 
waxy O 
leaf O 
nightshade O 
( O 
Solanum O 
glaucophyllum O 
Desf O 
. O 
) O 
, O 
tomato O 
( O 
Solanum O 
lycopersicum O 
L O 
. O 
) O 
and O 
bell O 
pepper O 
( O 
Capsicum O 
annuum O 
L O 
. O 
) O 
. O 

in O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
and O 
its O 
metabolites O 
were O 
investigated O 
following O 
UVB- O 
and O 
heat O 
- O 
treatment O 
in O 
the O 
leaves O 
of O 
Solanum O 
glaucophyllum O 
Desf O 
. O 
, O 
Solanum O 
lycopersicum O 
L O 
. O 
and O 
Capsicum O 
annuum O 
L O 
. O 
The O 
analytical O 
method O 
used O 
was O 
a O 
sensitive O 
and O 
selective O 
liquid O 
chromatography O 
electrospray O 
ionisation O 
tandem O 
mass O 
spectrometry O 
( O 
LC-ESI-MS O 
/ O 
MS O 
) O 
method O 
including O 
Diels-Alder O 
derivatisation O 
. O 
Vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
and O 
25-hydroxy B-SYSTEMATIC 
vitamin I-SYSTEMATIC 
D(3) I-SYSTEMATIC 
were O 
found O 
in O 
the O 
leaves O 
of O 
all O 
plants O 
after O 
UVB O 
- O 
treatment O 
. O 
S O 
. O 
glaucophyllum O 
had O 
the O 
highest O 
content O 
, O 
200 O 
ng O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
/g O 
dry O 
weight O 
and O 
31 O 
ng O 
25-hydroxy B-SYSTEMATIC 
vitamin I-SYSTEMATIC 
D(3) I-SYSTEMATIC 
/g O 
dry O 
weight O 
, O 
and O 
was O 
the O 
only O 
plant O 
that O 
also O 
contained O 
1,25 B-SYSTEMATIC 
dihydroxy I-SYSTEMATIC 
vitamin I-SYSTEMATIC 
D(3) I-SYSTEMATIC 
in O 
both O 
free O 
( O 
32 O 
ng O 
/ O 
g O 
dry O 
weight O 
) O 
and O 
glycosylated O 
form O 
( O 
17 O 
ng O 
/ O 
g O 
dry O 
weight O 
) O 
. O 

novel O 
chitinase O 
from O 
the O 
persimmon O 
fruit O 
was O 
isolated O 
, O 
purified O 
and O 
characterised O 
in O 
this O 
report O 
. O 
The O 
Diospyros O 
kaki O 
chitinase O 
( O 
DKC O 
) O 
was O 
found O 
to O 
be O 
a O 
monomer O 
with O 
a O 
molecular O 
mass O 
of O 
29 O 
kDa O 
. O 
It O 
exhibited O 
optimal O 
activity O 
at O 
pH O 
4.5 O 
with O 
broad O 
pH O 
stability O 
from O 
pH O 
4.0-9.0 O 
. O 
It O 
has O 
an O 
optimal O 
temperature O 
of O 
60°C O 
and O 
thermostable O 
up O 
to O 
60°C O 
when O 
incubated O 
for O 
30 O 
min O 
. O 
The O 
internal O 
peptide O 
sequences O 
of O 
DKC O 
showed O 
similarity O 
with O 
other O 
reported O 
plant O 
chitinases O 
. O 
It O 
has O 
the O 
ability O 
to O 
hydrolyse O 
colloidal O 
chitin O 
into O 
chito O 
- O 
oligomers O 
such O 
as O 
chitotriose B-TRIVIAL 
, O 
chitobiose B-TRIVIAL 
and O 
into O 
its O 
monomer O 
N-acetylglucosamine B-SYSTEMATIC 
. O 
It O 
can O 
be O 
used O 
to O 
degrade O 
chitin O 
waste O 
into O 
useful O 
products O 
such O 
as O 
chito O 
- O 
oligosacchaarides O 
. O 
DKC O 
exhibited O 
antifungal O 
activity O 
towards O 
pathogenic O 
fungus O 
Trichoderma O 
viride O 
. O 
Chitinases O 
with O 
antifungal O 
property O 
can O 
be O 
used O 
as O 
biocontrol O 
agents O 
replacing O 
chemical O 
fungicides O 
. O 

of O 
apple O 
certified O 
reference O 
material O 
for O 
quantification O 
of O 
organophosphorus B-FAMILY 
and O 
pyrethroid B-FAMILY 
pesticides O 
. O 

apple O 
certified O 
reference O 
material O 
for O 
the O 
analysis O 
of O 
pesticide O 
residues O 
was O 
issued O 
by O 
the O 
National O 
Metrology O 
Institute O 
of O 
Japan O 
. O 
Organophosphorus B-FAMILY 
and O 
pyrethroid B-FAMILY 
pesticides O 
were O 
sprayed O 
on O 
apples O 
, O 
and O 
these O 
were O 
used O 
as O 
raw O 
materials O 
of O 
certified O 
reference O 
material O 
. O 
The O 
harvested O 
apples O 
were O 
cut O 
into O 
small O 
pieces O 
, O 
freeze O 
- O 
dried O 
, O 
pulverized O 
, O 
sieved O 
, O 
placed O 
into O 
200 O 
brown O 
glass O 
bottles O 
( O 
3g O 
each O 
) O 
, O 
and O 
sterilized O 
by O 
γ-irradiation O 
. O 
Stability O 
and O 
homogeneity O 
assessment O 
was O 
performed O 
, O 
and O 
the O 
relative O 
uncertainties O 
due O 
to O 
instability O 
( O 
for O 
an O 
expiry O 
date O 
of O 
32 O 
months O 
) O 
and O 
inhomogeneity O 
were O 
10.3-25.0% O 
and O 
4.0-6.8% O 
, O 
respectively O 
. O 
The O 
characterization O 
was O 
carried O 
out O 
using O 
multiple O 
analytical O 
methods O 
to O 
ensure O 
the O 
reliability O 
of O 
analytical O 
results O 
; O 
the O 
values O 
of O 
target O 
pesticides O 
were O 
obtained O 
by O 
isotope O 
dilution O 
mass O 
spectrometry O 
. O 
Certified O 
values O 
were O 
2.28 O 
± O 
0.82 O 
mg O 
/ O 
kg O 
for O 
diazinon B-TRIVIAL 
, O 
3.14 O 
± O 
0.79 O 
mg O 
/ O 
kg O 
for O 
fenitrothion B-TRIVIAL 
, O 
1.55 O 
± O 
0.81 O 
mg O 
/ O 
kg O 
for O 
cypermethrin B-TRIVIAL 
, O 
and O 
2.81 O 
± O 
0.7 O 
mg O 
/ O 
kg O 
for O 
permethrin B-TRIVIAL 
. O 

and O 
antimicrobial O 
activity O 
of O 
xylan-chitooligomer- O 
zinc B-SYSTEMATIC 
complex O 
. O 

this O 
study O 
, O 
a O 
ternary O 
complex O 
based O 
on O 
natural O 
polysaccharides O 
was O 
explored O 
as O 
a O 
novel O 
food O 
preservative O 
. O 
Chitooligomer O 
was O 
obtained O 
by O 
enzyme O 
hydrolysis O 
of O 
chitosan O 
with O 
immobilised O 
neutral O 
protease O 
, O 
and O 
the O 
degree O 
of O 
polymerisation O 
( O 
DP O 
) O 
was O 
mainly O 
from O 
2 O 
to O 
5 O 
. O 
Chitooligomer- O 
zinc B-SYSTEMATIC 
complex O 
( O 
CGZC O 
) O 
was O 
first O 
produced O 
and O 
then O 
co O 
- O 
heated O 
with O 
xylan O 
to O 
prepare O 
xylan-chitooligomer- O 
zinc B-SYSTEMATIC 
complex O 
( O 
XCGZC O 
) O 
. O 
XCGZC O 
showed O 
higher O 
antioxidant O 
and O 
antibacterial O 
activity O 
than O 
chitooligomer O 
, O 
chitooligomer- O 
zinc B-SYSTEMATIC 
and O 
xylan O 
- O 
chitooligomer O 
. O 
The O 
IC(50) O 
of O 
XCGZC O 
was O 
5.37 O 
mg O 
/ O 
mL O 
, O 
which O 
was O 
equal O 
to O 
the O 
antioxidant O 
ability O 
of O 
3.28 O 
mg O 
/ O 
mL O 
BHT O 
. O 
The O 
diameter O 
of O 
the O 
inhibition O 
zone O 
for O 
XCGZC O 
against O 
Escherichia O 
coli O 
and O 
Staphylococcus O 
aureus O 
was O 
17.2 O 
± O 
0.4 O 
and O 
30.3 O 
± O 
0.6mm O 
vs O 
. O 
control O 
of O 
6.0mm O 
. O 
Besides O 
, O 
XCGZC O 
had O 
excellent O 
antibacterial O 
activity O 
against O 
Bacillus O 
subtilis O 
, O 
Salmonella O 
typhimurium O 
, O 
Bacillus O 
megaterium O 
. O 
Therefore O 
, O 
XCGZC O 
can O 
be O 
used O 
as O 
a O 
novel O 
promising O 
preservative O 
with O 
antibacterial O 
and O 
antioxidant O 
properties O 
in O 
the O 
food O 
industry O 
. O 

critical O 
study O 
of O 
use O 
of O 
the O 
Fe B-FORMULA 
(II) I-FORMULA 
/ O 
3-hydroxy-4-nitroso-2,7-naphthalenedisulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
complexes O 
in O 
the O 
quantification O 
of O 
polyphenols B-FAMILY 
in O 
medicinal O 
plants O 
. O 

critical O 
study O 
of O 
the O 
use O 
of O 
the O 
Fe B-FORMULA 
(III) I-FORMULA 
/ O 
3-hydroxy-4-nitroso-2,7-naphthalenedisulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
NRS B-ABBREVIATION 
) O 
complexes O 
on O 
the O 
quantification O 
of O 
the O 
polyphenols B-FAMILY 
content O 
in O 
aqueous O 
extracts O 
of O 
plants O 
, O 
expressed O 
as O 
pyrogallic B-TRIVIAL 
acid I-TRIVIAL 
, O 
[ O 
PA O 
] O 
, O 
is O 
presented O 
. O 
The O 
reaction O 
used O 
is O 
based O 
on O 
the O 
reduction O 
of O 
Fe B-FORMULA 
(III) I-FORMULA 
to O 
Fe B-FORMULA 
(II) I-FORMULA 
by O 
[ O 
PA O 
] O 
in O 
the O 
presence O 
of O 
NRS B-ABBREVIATION 
in O 
a O 
buffered O 
medium O 
( O 
Tris O 
; O 
pH O 
8 O 
) O 
with O 
formation O 
of O 
Fe B-FORMULA 
(II) I-FORMULA 
/ O 
NRS B-ABBREVIATION 
complexes O 
. O 
A O 
calibration O 
curve O 
of O 
absorbance O 
( O 
at O 
730 O 
nm O 
) O 
vs O 
. O 
[ O 
PA O 
] O 
is O 
linear O 
( O 
r=0.998 O 
; O 
n=7 O 
) O 
from O 
1 O 
to O 
7 O 
μmolL(-1) O 
[ O 
PA O 
] O 
. O 
LD O 
and O 
RSD O 
were O 
0.5 O 
μmolL(-1) O 
and O 
2.5% O 
( O 
6 O 
μmolL(-1) O 
[ O 
PA O 
] O 
, O 
n=10 O 
) O 
, O 
respectively O 
. O 
The O 
influence O 
of O 
pH O 
, O 
type O 
of O 
buffer O 
solution O 
and O 
interfering O 
species O 
possibly O 
present O 
in O 
the O 
samples O 
were O 
evaluated O 
. O 
Aqueous O 
extracts O 
of O 
twelve O 
medicinal O 
plants O 
used O 
in O 
the O 
Brazilian O 
folk O 
medicine O 
were O 
analysed O 
by O 
using O 
both O 
Fe B-FORMULA 
(III) I-FORMULA 
/ O 
NRS B-ABBREVIATION 
complexes O 
and O 
the O 
Folin-Ciocalteu O 
reagent O 
. O 

isomers O 
of O 
carotenoids O 
behave O 
differently O 
in O 
aspects O 
like O 
stability O 
towards O 
oxidants O 
, O 
bioavailability O 
, O 
vitamin B-FAMILY 
A I-FAMILY 
activity O 
and O 
specificity O 
for O 
enzymes O 
. O 
The O 
availability O 
of O 
HPLC O 
methods O 
for O 
their O 
detailed O 
profiling O 
is O 
therefore O 
advisable O 
to O 
expand O 
our O 
knowledge O 
on O 
their O 
metabolism O 
and O 
biological O 
role O 
. O 
In O 
this O 
paper O 
the O 
development O 
of O 
a O 
methodology O 
to O 
determine O 
the O 
highest O 
number O 
of O 
geometrical O 
isomers O 
of O 
major O 
carotenoids O 
in O 
humans O 
( O 
phytoene B-TRIVIAL 
, O 
phytofluene B-TRIVIAL 
, O 
lutein B-TRIVIAL 
, O 
zeaxanthin B-TRIVIAL 
, O 
β-cryptoxanthin B-TRIVIAL 
, O 
α-carotene B-TRIVIAL 
, O 
β-carotene B-TRIVIAL 
and O 
lycopene B-TRIVIAL 
) O 
is O 
described O 
. O 
To O 
assess O 
its O 
usefulness O 
with O 
biological O 
samples O 
both O 
postprandial O 
human O 
plasma O 
and O 
lung O 
samples O 
from O 
ferrets O 
were O 
analysed O 
. O 
Up O 
to O 
48 O 
isomers O 
of O 
the O 
main O 
human O 
carotenoids O 
were O 
separated O 
in O 
62 O 
min O 
. O 
This O 
is O 
to O 
the O 
best O 
of O 
our O 
knowledge O 
the O 
report O 
of O 
the O 
highest O 
number O 
of O 
carotenoid O 
geometrical O 
isomers O 
separated O 
with O 
a O 
HPLC O 
method O 
. O 
Twenty O 
- O 
six O 
different O 
carotenoid O 
isomers O 
were O 
readily O 
detected O 
in O 
the O 
biological O 
samples O 
. O 

the O 
degradation O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
in O 
relation O 
to O 
the O 
levels O 
of O 
oxidative O 
stress O 
biomarkers O 
in O 
broccoli O 
( O 
Brassica O 
oleracea O 
L O 
. O 
italica O 
cv O 
. O 
Bellstar O 
) O 
during O 
storage O 
and O 
mechanical O 
processing O 
. O 

purpose O 
of O 
this O 
research O 
was O 
to O 
understand O 
the O 
degradation O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
content O 
in O 
broccoli O 
florets O 
( O 
Brassica O 
oleracea O 
L O 
. O 
italica O 
cv O 
. O 
Bellstar O 
) O 
during O 
prolonged O 
storage O 
and O 
subsequent O 
mechanical O 
processing O 
. O 
The O 
initial O 
content O 
of O 
total O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
in O 
broccoli O 
florets O 
averaged O 
at O 
5.18 O 
± O 
0.23 O 
and O 
0.7 O 
± O 
0.03 O 
μmol O 
/ O 
g O 
fresh O 
weight O 
, O 
respectively O 
. O 
Results O 
showed O 
that O 
the O 
content O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
in O 
broccoli O 
degraded O 
during O 
storage O 
at O 
23°C O 
, O 
for O 
at O 
least O 
4.5-fold O 
after O 
6 O 
days O 
of O 
storage O 
. O 
On O 
each O 
day O 
of O 
storage O 
, O 
broccoli O 
florets O 
were O 
mechanically O 
processed O 
, O 
but O 
the O 
content O 
of O 
total O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
was O 
not O 
significantly O 
affected O 
. O 
When O 
the O 
mechanically O 
processed O 
broccoli O 
florets O 
were O 
further O 
incubated O 
for O 
up O 
to O 
6h O 
, O 
the O 
amount O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
was O 
greatly O 
reduced O 
as O 
compared O 
to O 
glutathione B-TRIVIAL 
. O 
To O 
obtain O 
an O 
in O 
- O 
depth O 
understanding O 
on O 
the O 
degradation O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
, O 
the O 
activity O 
of O 
enzymes O 
involved O 
in O 
plant O 
antioxidative O 
system O 
via O 
ascorbate B-TRIVIAL 
- O 
glutathione B-TRIVIAL 
cycle O 
, O 
as O 
a O 
response O 
towards O 
oxidative O 
stress O 
that O 
took O 
place O 
during O 
storage O 
was O 
determined O 
in O 
this O 
study O 
. O 
The O 
content O 
of O 
total O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
in O 
broccoli O 
florets O 
before O 
and O 
after O 
mechanical O 
processing O 
were O 
found O 
to O 
decrease O 
concurrently O 
with O 
the O 
activity O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
peroxidase O 
and O 
glutathione B-TRIVIAL 
reductase O 
over O 
the O 
experimental O 
storage O 
duration O 
. O 
Meanwhile O 
, O 
the O 
effect O 
of O 
oxidative O 
stress O 
on O 
the O 
content O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
was O 
apparent O 
during O 
the O 
6h O 
of O 
incubation O 
after O 
mechanical O 
processing O 
. O 
This O 
phenomenon O 
was O 
demonstrated O 
by O 
the O 
level O 
of O 
oxidative O 
stress O 
biomarkers O 
examined O 
, O 
in O 
which O 
the O 
formation O 
of O 
lipid O 
peroxides B-FAMILY 
, O 
protein O 
carbonyls B-FAMILY 
and O 
DNA O 
oxidised O 
products O 
was O 
positively O 
associated O 
with O 
the O 
degradation O 
of O 
total O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
glutathione B-TRIVIAL 
. O 

sinapates I-FAMILY 
and O 
vanillates B-FAMILY 
: O 
chemoenzymatic O 
synthesis O 
and O 
antioxidant O 
capacity O 
assessment O 
. O 

and O 
their O 
derivatives O 
have O 
attracted O 
much O 
attention O 
because O 
of O 
their O 
health O 
benefits O 
to O 
humans O 
and O 
are O 
widely O 
used O 
in O 
food O 
, O 
pharmaceuticals O 
, O 
and O 
cosmetics O 
in O 
the O 
past O 
decades O 
. O 
While O 
most O 
of O 
the O 
research O 
has O 
focused O 
on O 
free O 
phytosterols B-FAMILY 
and O 
phytosteryl B-FAMILY 
esters I-FAMILY 
of I-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
, O 
few O 
researches O 
reported O 
on O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
, O 
the O 
esters O 
of O 
phytosterols B-FAMILY 
with O 
phenolic B-FAMILY 
acids I-FAMILY 
. O 
Two O 
novel O 
group O 
phytosteryl B-FAMILY 
phenolates I-FAMILY 
, O 
namely O 
phytosteryl B-FAMILY 
sinapates I-FAMILY 
and O 
vanillates B-FAMILY 
, O 
were O 
successfully O 
chemoenzymatically O 
synthesised O 
in O 
this O 
work O 
and O 
their O 
structures O 
confirmed O 
. O 
Fourier O 
transform O 
infrared O 
( O 
FTIR O 
) O 
and O 
high O 
performance O 
chromatography O 
- O 
mass O 
spectrometry O 
/ O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
/ O 
MS O 
) O 
using O 
atmospheric O 
pressure O 
chemical O 
ionisation O 
( O 
APCI O 
) O 
under O 
both O 
positive O 
and O 
negative O 
ion O 
modes O 
were O 
employed O 
for O 
this O 
purpose O 
. O 
High O 
antioxidant O 
capacity O 
of O 
phytosteryl B-FAMILY 
sinapates I-FAMILY 
was O 
observed O 
using O 
both O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
assay O 
and O 
cooked O 
ground O 
meat O 
model O 
system O 
. O 
Although O 
phytosteryl B-FAMILY 
vanillates I-FAMILY 
showed O 
lower O 
antioxidant O 
capacity O 
than O 
phytosteryl B-FAMILY 
sinapates I-FAMILY 
, O 
they O 
were O 
stronger O 
antioxidants O 
than O 
vanillic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
vinyl B-SYSTEMATIC 
vanillate I-SYSTEMATIC 
in O 
both O 
assays O 
employed O 
. O 
Conjugation O 
of O 
phytosterols B-FAMILY 
with O 
sinapic B-MULTIPLE 
or I-MULTIPLE 
vanillic I-MULTIPLE 
acid I-MULTIPLE 
rendered O 
higher O 
antioxidant O 
capacity O 
. O 
Further O 
studies O 
on O 
health O 
benefits O 
of O 
phytosteryl B-FAMILY 
sinapates I-FAMILY 
and O 
vanillates B-FAMILY 
are O 
necessary O 
. O 

of O 
oils O 
and O 
fats O 
by O 
1H B-FORMULA 
NMR O 
and O 
GC O 
/ O 
MS O 
fingerprinting O 
: O 
classification O 
, O 
prediction O 
and O 
detection O 
of O 
adulteration O 
. O 

correct O 
identification O 
of O 
oils O 
and O 
fats O 
is O 
important O 
to O 
consumers O 
from O 
both O 
commercial O 
and O 
health O 
perspectives O 
. O 
Proton O 
nuclear O 
magnetic O 
resonance O 
( O 
(1)H B-FORMULA 
NMR O 
) O 
spectroscopy O 
, O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC O 
/ O 
MS O 
) O 
fingerprinting O 
and O 
chemometrics O 
were O 
employed O 
successfully O 
for O 
the O 
quality O 
control O 
of O 
oils O 
and O 
fats O 
. O 
Principal O 
component O 
analysis O 
( O 
PCA O 
) O 
of O 
both O 
techniques O 
showed O 
group O 
clustering O 
of O 
14 O 
types O 
of O 
oils O 
and O 
fats O 
. O 
Partial O 
least O 
squares O 
discriminant O 
analysis O 
( O 
PLS-DA O 
) O 
and O 
orthogonal O 
projections O 
to O 
latent O 
structures O 
discriminant O 
analysis O 
( O 
OPLS-DA O 
) O 
using O 
GC O 
/ O 
MS O 
data O 
had O 
excellent O 
classification O 
sensitivity O 
and O 
specificity O 
compared O 
to O 
models O 
using O 
NMR O 
data O 
. O 
Depending O 
on O 
the O 
availability O 
of O 
the O 
instruments O 
, O 
data O 
from O 
either O 
technique O 
can O 
effectively O 
be O 
applied O 
for O 
the O 
establishment O 
of O 
an O 
oils O 
and O 
fats O 
database O 
to O 
identify O 
unknown O 
samples O 
. O 
Partial O 
least O 
squares O 
( O 
PLS O 
) O 
models O 
were O 
successfully O 
established O 
for O 
the O 
detection O 
of O 
as O 
low O 
as O 
5% O 
of O 
lard O 
and O 
beef O 
tallow O 
spiked O 
into O 
canola O 
oil O 
, O 
thus O 
illustrating O 
possible O 
applications O 
in O 
Islamic O 
and O 
Jewish O 
countries O 
. O 

evidence O 
for O 
the O 
synergistic O 
effect O 
of O 
a O 
cysteinyl B-SYSTEMATIC 
thiol I-SYSTEMATIC 
on O 
the O 
antioxidant O 
activity O 
of O 
caffeic B-MULTIPLE 
and I-MULTIPLE 
dihydrocaffeic I-MULTIPLE 
esters I-MULTIPLE 
. O 

activity O 
of O 
methyl B-SYSTEMATIC 
caffeate I-SYSTEMATIC 
and O 
methyl B-SYSTEMATIC 
dihydrocaffeate I-SYSTEMATIC 
in O 
the O 
presence O 
of O 
a O 
cysteinyl B-SYSTEMATIC 
thiol I-SYSTEMATIC 
was O 
measured O 
in O 
an O 
azo B-SYSTEMATIC 
-initiator O 
- O 
induced O 
lipid O 
oxidation O 
system O 
. O 
The O 
coexistence O 
of O 
the O 
thiol B-FAMILY 
was O 
observed O 
to O 
display O 
a O 
synergistic O 
effect O 
on O 
the O 
antioxidant O 
activity O 
of O 
both O 
caffeates B-FAMILY 
. O 
The O 
synergism O 
was O 
observed O 
mainly O 
with O 
respect O 
to O 
the O 
elongation O 
of O 
the O 
induction O 
period O 
, O 
rather O 
than O 
the O 
inhibition O 
rate O 
for O 
lipid O 
oxidation O 
. O 
For O 
methyl B-SYSTEMATIC 
caffeate I-SYSTEMATIC 
, O 
the O 
maximum O 
elongation O 
of O 
the O 
induction O 
period O 
was O 
observed O 
in O 
the O 
presence O 
of O 
more O 
than O 
two O 
equivalents O 
of O 
the O 
thiol B-FAMILY 
, O 
whereas O 
the O 
maximum O 
effect O 
on O 
the O 
activity O 
of O 
methyl B-SYSTEMATIC 
dihydrocaffeate I-SYSTEMATIC 
was O 
observed O 
in O 
the O 
presence O 
of O 
more O 
than O 
three O 
equivalents O 
of O 
the O 
thiol B-FAMILY 
. O 
These O 
synergistic O 
effects O 
were O 
analysed O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
and O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
analyses O 
of O 
the O 
intermediates O 
produced O 
during O 
the O 
antioxidation O 
period O 
. O 
The O 
analytical O 
results O 
clarified O 
that O 
the O 
mono- O 
thiol B-FAMILY 
adduct O 
of O 
methyl B-SYSTEMATIC 
caffeate I-SYSTEMATIC 
and O 
the O 
mono- O 
and O 
di- O 
thiol B-FAMILY 
adducts O 
of O 
methyl B-SYSTEMATIC 
dihydrocaffeate I-SYSTEMATIC 
contributed O 
to O 
the O 
synergism O 
in O 
the O 
antioxidant O 
activity O 
of O 
both O 
caffeates B-FAMILY 
. O 

procyanidins B-FAMILY 
of O 
lotus O 
seedpod O 
inhibits O 
the O 
formation O 
of O 
advanced O 
glycation O 
end O 
- O 
products O 
by O 
scavenging O 
reactive O 
carbonyls B-FAMILY 
. O 

has O 
been O 
reported O 
that O 
oligomeric O 
procyanidins B-FAMILY 
of O 
lotus O 
seedpod O 
( O 
LSOPC O 
) O 
is O 
effective O 
in O 
the O 
alleviation O 
of O 
Alzheimer's O 
disease O 
and O 
diabetes O 
through O 
its O 
antioxidant O 
and O 
insulin O 
- O 
potentiating O 
activities O 
. O 
This O 
study O 
investigated O 
the O 
anti-glycative O 
activity O 
of O 
LSOPC O 
in O 
a O 
bovine O 
serum O 
albumin O 
(BSA)- O 
glucose B-TRIVIAL 
model O 
. O 
The O 
level O 
of O 
glycation O 
and O 
conformational O 
alterations O 
were O 
assessed O 
by O 
specific O 
fluorescence O 
, O 
Congo O 
red O 
binding O 
assay O 
and O 
circular O 
dichroism O 
. O 
The O 
results O 
show O 
that O 
LSOPC O 
has O 
a O 
significant O 
anti-glycative O 
activity O 
in O 
vitro O 
and O 
it O 
can O 
also O 
effectively O 
protect O 
the O 
secondary O 
structure O 
of O 
BSA O 
during O 
glycation O 
. O 
LSOPC O 
or O 
catechin B-TRIVIAL 
( O 
a O 
major O 
constituent O 
unit O 
of O 
LSOPC O 
) O 
, O 
were O 
used O 
to O 
react O 
with O 
methylglyoxal B-SYSTEMATIC 
. O 
The O 
structures O 
of O 
their O 
carbonyl B-FAMILY 
adducts O 
were O 
tentatively O 
identified O 
using O 
HPLC-MS(2) O 
. O 
Their O 
capacity O 
to O 
scavenge O 
methylglyoxal B-SYSTEMATIC 
suggested O 
carbonyl B-FAMILY 
scavenging O 
as O 
a O 
major O 
mechanism O 
of O 
antiglycation O 
. O 
Therefore O 
, O 
LSOPC O 
could O 
be O 
helpful O 
to O 
prevent O 
AGEs-associated O 
diseases O 
, O 
and O 
with O 
the O 
potential O 
to O 
be O 
used O 
as O 
functional O 
food O 
ingredients O 
. O 

related O 
compounds O 
in O 
traditional O 
antidiabetic O 
functional O 
foods O 
. O 

such O 
as O 
metformin B-TRIVIAL 
are O 
widely O 
used O 
worldwide O 
for O 
the O 
treatment O 
of O 
type-2 O 
diabetes O 
. O 
The O 
identification O 
of O 
guanidine B-TRIVIAL 
and O 
related O 
compounds O 
in O 
French O 
lilac O 
plant O 
( O 
Galega O 
officinalis O 
L O 
. O 
) O 
led O 
to O 
the O 
development O 
of O 
biguanides B-FAMILY 
. O 
Despite O 
of O 
their O 
plant O 
origin O 
, O 
biguanides B-FAMILY 
have O 
not O 
been O 
reported O 
in O 
plants O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
quantify O 
biguanide B-TRIVIAL 
related O 
compounds O 
( O 
BRCs O 
) O 
in O 
experimentally O 
or O 
clinically O 
substantiated O 
antidiabetic O 
functional O 
plant O 
foods O 
and O 
potatoes O 
. O 
The O 
corrected O 
results O 
of O 
the O 
Voges-Proskauer O 
( O 
V-P O 
) O 
assay O 
suggest O 
that O 
the O 
highest O 
amounts O 
of O 
BRCs O 
are O 
present O 
in O 
green O 
curry O 
leaves O 
( O 
Murraya O 
koenigii O 
( O 
L O 
. O 
) O 
Sprengel O 
) O 
followed O 
by O 
fenugreek O 
seeds O 
( O 
Trigonella O 
foenum O 
- O 
graecum O 
L O 
. O 
) O 
, O 
green O 
bitter O 
gourd O 
( O 
Momordica O 
charantia O 
Descourt O 
. O 
) O 
, O 
and O 
potato O 
( O 
Solanum O 
tuberosum O 
L O 
. O 
) O 
. O 
Whereas O 
, O 
garlic O 
( O 
Allium O 
sativum O 
L O 
. O 
) O 
, O 
and O 
sweet O 
potato O 
( O 
Ipomea O 
batatas O 
( O 
L O 
. O 
) O 
Lam O 
. O 
) O 
contain O 
negligible O 
amounts O 
of O 
BRCs O 
. O 
In O 
addition O 
, O 
the O 
possible O 
biosynthetic O 
routes O 
of O 
biguanid B-TRIVIAL 
e O 
in O 
these O 
plant O 
foods O 
are O 
discussed O 
. O 

protection O 
of O 
β-carotene B-TRIVIAL 
in O 
re O 
- O 
assembled O 
casein O 
micelles O 
during O 
different O 
processing O 
technologies O 
applied O 
in O 
food O 
industry O 
. O 

is O 
a O 
carotenoid O 
usually O 
applied O 
in O 
the O 
food O 
industry O 
as O 
a O 
precursor O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
or O 
as O 
a O 
colourant O 
. O 
β-Carotene B-TRIVIAL 
is O 
a O 
labile O 
compound O 
easily O 
degraded O 
by O 
light O 
, O 
heat O 
and O 
oxygen B-SYSTEMATIC 
. O 
Casein O 
micelles O 
were O 
used O 
as O 
nanostructures O 
to O 
encapsulate O 
, O 
stabilise O 
and O 
protect O 
β-carotene B-TRIVIAL 
from O 
degradation O 
during O 
processing O 
in O 
the O 
food O 
industry O 
. O 
Self O 
- O 
assembly O 
method O 
was O 
applied O 
to O 
re O 
- O 
assemble O 
nanomicelles O 
containing O 
β-carotene B-TRIVIAL 
. O 
The O 
protective O 
effect O 
of O 
the O 
nanostructures O 
against O 
degradation O 
during O 
the O 
most O 
common O 
industrial O 
treatments O 
( O 
sterilisation O 
, O 
pasteurisation O 
, O 
high O 
hydrostatic O 
pressure O 
and O 
baking O 
) O 
was O 
proven O 
. O 
Casein O 
micelles O 
protected O 
β-carotene B-TRIVIAL 
from O 
degradation O 
during O 
heat O 
stabilisation O 
, O 
high O 
pressure O 
processing O 
and O 
the O 
processes O 
most O 
commonly O 
used O 
in O 
the O 
food O 
industry O 
including O 
baking O 
. O 
This O 
opens O 
new O 
possibilities O 
for O 
introducing O 
thermolabile O 
ingredients O 
in O 
bakery O 
products O 
. O 

efficient O 
method O 
was O 
developed O 
for O 
the O 
simultaneous O 
determination O 
of O 
seven O 
commonly O 
used O 
synthetic O 
sulfonate B-SYSTEMATIC 
dyes O 
( O 
Ponceau B-TRIVIAL 
4RC I-TRIVIAL 
, O 
Sunset B-TRIVIAL 
yellow I-TRIVIAL 
, O 
Allura B-TRIVIAL 
red I-TRIVIAL 
, O 
Azophloxine B-TRIVIAL 
, O 
Ponceau B-TRIVIAL 
xylidine I-TRIVIAL 
, O 
Erythrosine B-TRIVIAL 
and O 
Orange B-TRIVIAL 
II I-TRIVIAL 
) O 
in O 
animal O 
feed O 
and O 
meat O 
using O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC-DAD O 
) O 
and O 
tandem O 
mass O 
spectrometry O 
( O 
HPLC-MS O 
/ O 
MS O 
) O 
. O 
Ethanol B-SYSTEMATIC 
- O 
ammonia B-SYSTEMATIC 
-water O 
( O 
80 O 
: O 
1 O 
: O 
19 O 
, O 
V O 
/ O 
V O 
/ O 
V O 
) O 
solution O 
was O 
used O 
as O 
extract O 
solution O 
, O 
which O 
can O 
extract O 
target O 
species O 
while O 
reducing O 
interference O 
from O 
the O 
sample O 
matrices O 
. O 
The O 
recoveries O 
of O 
these O 
7 O 
dyes O 
in O 
animal O 
feed O 
and O 
chicken O 
meat O 
were O 
between O 
71% O 
and O 
97% O 
with O 
relative O 
standard O 
deviations O 
less O 
than O 
14.8% O 
. O 
HPLC-MS O 
/ O 
MS O 
was O 
employed O 
as O 
a O 
further O 
means O 
of O 
confirmation O 
to O 
assure O 
accuracy O 
of O 
the O 
results O 
. O 
Limits O 
of O 
detection O 
for O 
these O 
dyes O 
were O 
in O 
the O 
range O 
of O 
0.02-21.83 O 
ng O 
mL(-1) O 
. O 
The O 
proposed O 
method O 
can O 
be O 
applied O 
to O 
confirmative O 
screening O 
of O 
seven O 
commonly O 
used O 
food O 
colorants O 
in O 
feed O 
and O 
meat O 
samples O 
. O 

acid I-FAMILY 
composition O 
of O 
cooked O 
chicken O 
meat O 
and O 
chicken O 
meat O 
products O 
as O 
influenced O 
by O 
price O 
range O 
at O 
retail O 
. O 

primary O 
objective O 
was O 
to O 
determine O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
of O 
skinless O 
chicken O 
breast O 
and O 
leg O 
meat O 
portions O 
and O 
chicken O 
burgers O 
and O 
nuggets O 
from O 
the O 
economy O 
price O 
range O 
, O 
standard O 
price O 
range O 
( O 
both O 
conventional O 
intensive O 
rearing O 
) O 
and O 
the O 
organic O 
range O 
from O 
four O 
leading O 
supermarkets O 
. O 
Few O 
significant O 
differences O 
in O 
the O 
SFA B-ABBREVIATION 
, O 
MUFA B-ABBREVIATION 
and O 
PUFA B-ABBREVIATION 
composition O 
of O 
breast O 
and O 
leg O 
meat O 
portions O 
were O 
found O 
among O 
price O 
ranges O 
, O 
and O 
supermarket O 
had O 
no O 
effect O 
. O 
No O 
significant O 
differences O 
in O 
fatty B-FAMILY 
acid I-FAMILY 
concentrations O 
of O 
economy O 
and O 
standard O 
chicken O 
burgers O 
were O 
found O 
, O 
whereas O 
economy O 
chicken O 
nuggets O 
had O 
higher O 
C16 O 
: O 
1 O 
, O 
C18 O 
: O 
1 O 
cis O 
, O 
C18 O 
: O 
1 O 
trans O 
and O 
C18 O 
: O 
3 O 
n-3 O 
concentrations O 
than O 
had O 
standard O 
ones O 
. O 
Overall O 
, O 
processed O 
chicken O 
products O 
had O 
much O 
higher O 
fat O 
contents O 
and O 
SFA O 
than O 
had O 
whole O 
meat O 
. O 
Long O 
chain O 
n-3 O 
fatty B-FAMILY 
acids I-FAMILY 
had O 
considerably O 
lower O 
concentrations O 
in O 
processed O 
products O 
than O 
in O 
whole O 
meat O 
. O 
Overall O 
there O 
was O 
no O 
evidence O 
that O 
organic O 
chicken O 
breast O 
or O 
leg O 
meat O 
had O 
a O 
more O 
favourable O 
fatty B-FAMILY 
acid I-FAMILY 
composition O 
than O 
had O 
meat O 
from O 
conventionally O 
reared O 
birds O 
. O 

of O 
the O 
degree O 
of O 
oxidation O 
in O 
highly O 
- O 
oxidised O 
lipids O 
using O 
profile O 
changes O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
. O 

degree O 
of O 
highly O 
oxidised O 
lipids O 
was O 
determined O 
by O 
a O 
modified O 
method O 
using O 
profile O 
changes O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
lard O 
and O 
soybean O 
oil O 
heated O 
at O 
180°C O 
. O 
The O 
usefulness O 
of O 
the O 
modified O 
method O 
was O 
compared O 
through O 
conjugated O 
dienoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CDA O 
) O 
and O 
/ O 
or O 
p-anisidine B-SYSTEMATIC 
value O 
( O 
p-AV O 
) O 
methods O 
. O 
Absolute O 
values O 
, O 
which O 
were O 
expressed O 
as O 
equivalent O 
to O 
an O 
internal O 
standard O 
( O 
C11 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
, O 
of O 
both O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
UFAs B-ABBREVIATION 
) O 
and O 
saturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
SFAs B-ABBREVIATION 
) O 
decreased O 
significantly O 
during O 
thermal O 
oxidation O 
( O 
p O 
< O 
0.05 O 
) O 
while O 
relative O 
percentage O 
of O 
SFA B-ABBREVIATION 
increased O 
and O 
those O 
of O 
UFA B-ABBREVIATION 
decreased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
content O 
of O 
caprylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
C8 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
increased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
as O 
thermal O 
oxidation O 
time O 
increased O 
. O 
The O 
ratio O 
of O 
total O 
saturated O 
over O 
total O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
SFAs B-ABBREVIATION 
/ O 
UFAs B-ABBREVIATION 
) O 
or O 
caprylic B-TRIVIAL 
acid I-TRIVIAL 
( O 
C8 B-FORMULA 
: I-FORMULA 
0 I-FORMULA 
) O 
over O 
UFAs B-ABBREVIATION 
could O 
be O 
useful O 
markers O 
to O 
determine O 
the O 
degree O 
of O 
oxidation O 
. O 
Antioxidant O 
capacity O 
of O 
sesamol B-TRIVIAL 
, O 
a O 
free O 
radical O 
scavenger O 
, O 
was O 
determined O 
using O 
the O 
ratio O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
. O 
The O 
modified O 
method O 
can O 
be O 
applied O 
to O 
determine O 
the O 
quality O 
control O 
of O 
fried O 
foods O 
containing O 
highly O 
oxidised O 
and O 
abused O 
oils O 
, O 
which O 
may O 
not O 
be O 
measured O 
correctly O 
using O 
CDA O 
and O 
p-AV O 
. O 

stability O 
of O 
anthocyanins B-FAMILY 
and O 
colourless O 
phenolics O 
in O 
pomegranate O 
( O 
Punica O 
granatum O 
L O 
. O 
) O 
juices O 
and O 
model O 
solutions O 
. O 

present O 
study O 
aimed O 
at O 
a O 
systematic O 
assessment O 
of O 
the O 
factors O 
influencing O 
the O 
anthocyanin B-FAMILY 
( O 
AC O 
) O 
stability O 
and O 
colour O 
retention O 
of O 
pomegranate O 
juices O 
and O 
less O 
complex O 
model O 
solutions O 
with O 
particular O 
focus O 
on O 
the O 
effects O 
of O 
colourless O 
phenolic O 
copigments O 
( O 
CP O 
) O 
. O 
The O 
thermal O 
stability O 
of O 
ACs B-ABBREVIATION 
in O 
three O 
pomegranate O 
juices O 
obtained O 
from O 
isolated O 
arils O 
and O 
the O 
entire O 
fruit O 
with O 
and O 
without O 
previous O 
steaming O 
, O 
in O 
model O 
solutions O 
with O 
AC O 
: O 
CP O 
ratios O 
ranging O 
from O 
1 O 
: O 
0 O 
to O 
1 O 
: O 
4 O 
( O 
m O 
/ O 
m O 
) O 
, O 
and O 
in O 
two O 
purified O 
extracts O 
from O 
pomegranate O 
juices O 
characterised O 
by O 
different O 
phenolic O 
profiles O 
, O 
respectively O 
, O 
was O 
investigated O 
upon O 
heating O 
at O 
60 O 
, O 
70 O 
, O 
80 O 
and O 
90°C O 
for O 
15 O 
min O 
to O 
5h O 
. O 
The O 
thermal O 
impact O 
on O 
the O 
AC O 
and O 
CP O 
contents O 
, O 
and O 
the O 
formation O 
of O 
5-hydroxymethylfurfural B-SYSTEMATIC 
( O 
HMF B-ABBREVIATION 
) O 
and O 
AC O 
degradation O 
products O 
were O 
monitored O 
using O 
HPLC-DAD-MS(n) O 
. O 
Total O 
phenolic O 
contents O 
, O 
antioxidant O 
capacity O 
and O 
colour O 
properties O 
were O 
determined O 
spectrophotometrically O 
. O 
Heating O 
at O 
90°C O 
for O 
5h O 
resulted O 
in O 
total O 
AC O 
losses O 
ranging O 
from O 
76% O 
to O 
87% O 
of O 
the O 
initial O 
AC O 
levels O 
in O 
the O 
juices O 
, O 
78% O 
in O 
both O 
extracts O 
as O 
well O 
as O 
57% O 
and O 
∼78% O 
in O 
the O 
model O 
solutions O 
, O 
showing O 
the O 
best O 
stability O 
at O 
an O 
AC O 
: O 
CP O 
ratio O 
of O 
1 O 
: O 
2 O 
and O 
in O 
juices O 
having O 
the O 
highest O 
initial O 
AC O 
contents O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
the O 
AC O 
stability O 
was O 
independent O 
of O 
total O 
phenolic O 
contents O 
, O 
and O 
low O 
and O 
high O 
molecular O 
pomegranate O 
matrix O 
components O 
( O 
such O 
as O 
organic O 
acids O 
and O 
sugars B-FAMILY 
) O 
. O 
Good O 
correlation O 
of O 
the O 
AC O 
contents O 
with O 
red O 
colour O 
(a(∗)) O 
was O 
observed O 
for O 
all O 
samples O 
at O 
elevated O 
temperatures O 
( O 
70-90°C O 
) O 
. O 
The O 
stability O 
of O 
putative O 
health O 
- O 
promoting O 
polyphenols B-FAMILY 
of O 
pomegranate O 
juices O 
was O 
not O 
markedly O 
affected O 
by O 
the O 
thermal O 
treatment O 
. O 
Unexpectedly O 
, O 
the O 
HMF B-ABBREVIATION 
contents O 
only O 
slightly O 
increased O 
upon O 
forced O 
heating O 
. O 
Therefore O 
, O 
the O 
visual O 
appearance O 
does O 
not O 
adequately O 
reflect O 
the O 
quality O 
and O 
storage O 
stability O 
of O 
pomegranate O 
juices O 
. O 

compounds O 
present O 
in O 
ethanolic O 
extracts O 
from O 
18 O 
macroalgae O 
of O 
the O 
Portuguese O 
coast O 
were O 
analysed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
, O 
leading O 
to O 
the O 
characterization O 
of O 
14 O 
compounds O 
: O 
proline B-TRIVIAL 
, O 
phloroglucinol B-TRIVIAL 
, O 
mannitol B-TRIVIAL 
, O 
8 O 
fatty B-FAMILY 
acids I-FAMILY 
and O 
3 O 
sterols B-FAMILY 
. O 
A O 
dose O 
- O 
dependent O 
response O 
against O 
enzymes O 
with O 
biological O 
significance O 
( O 
α-glucosidase O 
, O 
acetylcholinesterase O 
and O 
butyrylcholinesterase O 
) O 
and O 
free O 
radicals O 
( O 
DPPH B-ABBREVIATION 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
superoxide B-TRIVIAL 
and O 
hydroxyl B-SYSTEMATIC 
) O 
was O 
found O 
, O 
Phaeophyta O 
being O 
the O 
most O 
promising O 
group O 
. O 
A O 
PCA O 
analysis O 
was O 
performed O 
and O 
allowed O 
the O 
establishment O 
of O 
a O 
correlation O 
between O 
the O 
algae O 
chemical O 
composition O 
and O 
the O 
biological O 
activity O 
. O 
Cystoseira O 
tamariscifolia O 
( O 
Hudson O 
) O 
Papenfuss O 
, O 
Cystoseira O 
nodicaulis O 
( O 
Withering O 
) O 
M O 
. O 
Roberts O 
, O 
Cystoseira O 
usneoides O 
( O 
Linnaeus O 
) O 
M O 
. O 
Roberts O 
and O 
Fucus O 
spiralis O 
Linnaeus O 
are O 
among O 
the O 
most O 
active O 
species O 
, O 
which O 
is O 
in O 
accordance O 
with O 
their O 
higher O 
contents O 
in O 
phloroglucinol B-TRIVIAL 
, O 
mannitol B-TRIVIAL 
, O 
oleic B-MULTIPLE 
, I-MULTIPLE 
arachidonic I-MULTIPLE 
and I-MULTIPLE 
eicosapentaenoic I-MULTIPLE 
acids I-MULTIPLE 
, O 
and O 
fucosterol B-TRIVIAL 
. O 
The O 
results O 
point O 
to O 
the O 
potential O 
interest O 
of O 
the O 
use O 
of O 
Phaeophyta O 
species O 
as O 
food O 
additives O 
, O 
due O 
to O 
their O 
potent O 
antiradical O 
activities O 
, O 
and O 
especially O 
highlights O 
the O 
importance O 
of O 
F O 
. O 
spiralis O 
in O 
the O 
food O 
chain O 
of O 
Mediterranean O 
countries O 
. O 
Moreover O 
, O 
the O 
incorporation O 
of O 
the O 
extracts O 
of O 
these O 
species O 
in O 
food O 
products O 
, O 
nutraceutical O 
and O 
pharmaceutical O 
preparations O 
for O 
human O 
health O 
should O 
also O 
be O 
instigated O 
, O 
since O 
they O 
can O 
suppress O 
hyperglycemia O 
and O 
inhibit O 
cholinesterases O 
. O 

properties O 
of O 
catechins B-FAMILY 
and O 
enriched O 
green O 
tea O 
extracts O 
effectively O 
preserve O 
L-5-methyltetrahydrofolate B-SYSTEMATIC 
: O 
assessment O 
using O 
cyclic O 
voltammetry O 
analysis O 
. O 

cyclic O 
voltammetry O 
( O 
CV O 
) O 
study O 
was O 
performed O 
in O 
pH O 
5.5 O 
Britton-Robinson O 
buffer O 
at O 
room O 
temperature O 
to O 
study O 
the O 
stability O 
of O 
1mM O 
l-5-methyltetrahydrofolate B-SYSTEMATIC 
( O 
l-5-MTHF B-SYSTEMATIC 
) O 
in O 
combination O 
with O 
epigallocatechin B-TRIVIAL 
- I-TRIVIAL 
gallate I-TRIVIAL 
-enriched O 
extract O 
( O 
EGCGe O 
) O 
and O 
epigallocatechin O 
- O 
enriched O 
extract O 
( O 
EGCe O 
) O 
. O 
The O 
combination O 
of O 
l-5-MTHF B-SYSTEMATIC 
with O 
enriched O 
catechin B-TRIVIAL 
extracts O 
provided O 
enhanced O 
stability O 
of O 
l-5-MTHF B-SYSTEMATIC 
over O 
a O 
period O 
of O 
12h O 
under O 
ambient O 
air O 
conditions O 
at O 
pH O 
5.5 O 
. O 
CV O 
experiments O 
showed O 
that O 
increasing O 
the O 
concentrations O 
of O 
EGCGe O 
or O 
EGCe O 
extracts O 
from O 
80 O 
to O 
400mg O 
/ O 
L O 
produced O 
a O 
decrease O 
in O 
the O 
second O 
oxidation O 
peak O 
of O 
l-5-MTHF B-SYSTEMATIC 
. O 
Thus O 
, O 
we O 
calculated O 
that O 
l-5-MTHF B-SYSTEMATIC 
remained O 
at O 
nearly O 
90% O 
when O 
in O 
the O 
presence O 
of O 
enriched O 
tea O 
extracts O 
, O 
compared O 
to O 
74% O 
without O 
the O 
tea O 
antioxidants O 
. O 
The O 
catechins B-FAMILY 
responsible O 
for O 
this O 
preservation O 
were O 
EGCG B-ABBREVIATION 
and O 
C O 
, O 
confirmed O 
by O 
LC-MS O 
. O 
Compared O 
to O 
covalent O 
link O 
only O 
low O 
interaction O 
( O 
hydrogen B-SYSTEMATIC 
bonds O 
) O 
between O 
the O 
different O 
catechins B-FAMILY 
present O 
in O 
the O 
tea O 
extract O 
would O 
stabilise O 
l-5-MTHF B-SYSTEMATIC 
. O 
Rather O 
, O 
it O 
was O 
hypothesised O 
that O 
EGCGe O 
and O 
EGCe O 
were O 
effective O 
agents O 
to O 
preserve O 
l-5-MTHF B-SYSTEMATIC 
, O 
through O 
a O 
mechanism O 
that O 
also O 
involved O 
the O 
redox O 
potential O 
of O 
catechins O 
to O 
maintain O 
l-5-MTHF B-SYSTEMATIC 
in O 
its O 
reduced O 
form O 
. O 

responses O 
and O 
microbial O 
characteristics O 
of O 
shiitake O 
mushroom O 
( O 
Lentinus O 
edodes O 
) O 
to O 
gum O 
arabic O 
coating O 
enriched O 
with O 
natamycin B-TRIVIAL 
during O 
storage O 
. O 

responses O 
and O 
microbial O 
characteristics O 
of O 
shiitake O 
mushroom O 
( O 
Lentinus O 
edodes O 
) O 
to O 
gum O 
arabic O 
( O 
GA O 
) O 
coating O 
incorporating O 
natamycin B-TRIVIAL 
( O 
nan O 
) O 
during O 
storage O 
were O 
investigated O 
. O 
Mushroom O 
weight O 
loss O 
, O 
firmness O 
, O 
total O 
soluble O 
solids O 
, O 
total O 
sugar B-FAMILY 
, O 
reducing O 
sugar B-FAMILY 
, O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
microbial O 
and O 
sensory O 
quality O 
were O 
measured O 
. O 
Mushroom O 
coated O 
with O 
gum O 
arabic+ O 
natamycin B-TRIVIAL 
( O 
GANA O 
) O 
maintained O 
tissue O 
firmness O 
and O 
showed O 
reduction O 
in O 
microbial O 
counts O 
from O 
yeasts O 
and O 
moulds O 
compared O 
with O 
the O 
control O 
. O 
In O 
addition O 
, O 
GANA O 
coating O 
also O 
delayed O 
changes O 
in O 
the O 
soluble O 
solids O 
concentration O 
, O 
total O 
sugar B-FAMILY 
and O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Sensory O 
evaluation O 
proved O 
the O 
efficacy O 
of O 
GANA O 
coating O 
by O 
maintaining O 
the O 
overall O 
quality O 
of O 
shiitake O 
mushroom O 
during O 
the O 
storage O 
period O 
. O 
The O 
efficiency O 
was O 
better O 
than O 
that O 
of O 
GA O 
or O 
nan O 
treatment O 
alone O 
. O 
Our O 
study O 
suggests O 
that O 
GANA O 
has O 
the O 
potential O 
to O 
improve O 
the O 
quality O 
of O 
shiitake O 
mushroom O 
and O 
extend O 
its O 
shelf O 
- O 
life O 
up O 
to O 
16d O 
. O 

spectrophotometric O 
method O 
involving O 
electrolytically O 
generated O 
manganese B-SYSTEMATIC 
(III) I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
with O 
diphenylamine B-SYSTEMATIC 
for O 
the O 
determination O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
present O 
in O 
the O 
samples O 
of O 
various O 
fruits O 
, O 
commercial O 
juices O 
and O 
sprouted O 
food O 
grains O 
. O 

spectrophotometric O 
method O 
was O 
developed O 
for O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
present O 
in O 
various O 
fruits O 
, O 
commercial O 
fruit O 
juices O 
and O 
sprouted O 
food O 
grains O 
. O 
The O 
method O 
involves O 
the O 
oxidation O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
with O 
excess O 
manganese B-SYSTEMATIC 
(III) I-SYSTEMATIC 
following O 
reduction O 
of O 
unreacted O 
manganese B-SYSTEMATIC 
(III) I-SYSTEMATIC 
with O 
diphenylamine B-SYSTEMATIC 
or O 
barium B-SYSTEMATIC 
diphenylamine I-SYSTEMATIC 
sulphonate I-SYSTEMATIC 
forming O 
a O 
product O 
λ(max) O 
570 O 
nm O 
the O 
system O 
1 O 
or O 
540 O 
nm O 
the O 
system O 
2 O 
and O 
decrease O 
in O 
the O 
colour O 
intensity O 
is O 
proportional O 
to O 
the O 
concentration O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
with O 
quantification O 
range O 
0.3-3.0 O 
μg O 
ml(-1) O 
. O 
The O 
molar O 
absorptivity O 
and O 
Sandell's O 
sensitivity O 
values O 
of O 
the O 
system O 
1 O 
and O 
the O 
system O 
2 O 
were O 
1.829 O 
× O 
10(4) O 
and O 
1.813 O 
× O 
10(4)mol(-1)cm(-1) O 
and O 
0.0096 O 
and O 
0.0097 O 
μg O 
cm(-2) O 
respectively O 
. O 
The O 
stoichiometry O 
was O 
4 O 
: O 
1 O 
between O 
manganese B-SYSTEMATIC 
(III) I-SYSTEMATIC 
and O 
diphenylamine B-SYSTEMATIC 
. O 
The O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
contents O 
of O 
the O 
same O 
samples O 
were O 
determined O 
separately O 
following O 
the O 
procedures O 
of O 
the O 
developed O 
method O 
as O 
well O 
as O 
the O 
reference O 
method O 
and O 
the O 
results O 
were O 
comparable O 
. O 

paper O 
describes O 
the O 
preparation O 
of O 
new O 
Pb B-FORMULA 
(II) I-FORMULA 
-imprinted O 
polymeric O 
particles O 
using O 
2-vinylpyridine B-SYSTEMATIC 
as O 
a O 
functional O 
monomer O 
, O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
dimethacrylate I-SYSTEMATIC 
as O 
the O 
cross O 
- O 
linker O 
, O 
2,2'- B-SYSTEMATIC 
azobisisobutyronitrile I-SYSTEMATIC 
as O 
the O 
initiator O 
, O 
diphenylcarbazone B-SYSTEMATIC 
as O 
the O 
ligand O 
, O 
acetonitril B-SYSTEMATIC 
as O 
the O 
solvent O 
, O 
and O 
Pb(NO(3))(2) B-FORMULA 
as O 
the O 
template O 
ion O 
, O 
through O 
bulk O 
polymerisation O 
technique O 
. O 
The O 
imprinted O 
lead O 
ions O 
were O 
removed O 
from O 
the O 
polymeric O 
matrix O 
using O 
5 O 
mL O 
of O 
HCl B-FORMULA 
( O 
2 O 
mol.L(-1) O 
) O 
as O 
the O 
eluting O 
solvent O 
. O 
The O 
lead O 
ion O 
concentration O 
was O 
determined O 
by O 
flame O 
atomic O 
absorption O 
spectrometry O 
. O 
Optimum O 
pH O 
for O 
maximum O 
sorption O 
was O 
obtained O 
at O 
6 O 
. O 
Sorption O 
and O 
desorption O 
of O 
Pb B-FORMULA 
(II) I-FORMULA 
ions O 
on O 
the O 
IIP O 
particles O 
were O 
quite O 
fast O 
and O 
achieved O 
fully O 
over O 
5 O 
min O 
. O 
In O 
the O 
proposed O 
method O 
, O 
the O 
maximum O 
sorbent O 
capacity O 
of O 
the O 
ion O 
- O 
imprinted O 
polymer O 
was O 
calculated O 
to O 
be O 
75.4 O 
mg O 
g(-1) O 
. O 
The O 
preconcentration O 
factor O 
, O 
relative O 
standard O 
deviation O 
, O 
and O 
limit O 
of O 
detection O 
of O 
the O 
method O 
were O 
found O 
to O 
be O 
245 O 
, O 
2.1% O 
, O 
and O 
0.42 O 
ng O 
mL(-1) O 
, O 
respectively O 
. O 
The O 
prepared O 
ion O 
- O 
imprinted O 
polymer O 
particles O 
have O 
an O 
increased O 
selectivity O 
toward O 
Pb B-FORMULA 
(II) I-FORMULA 
ions O 
over O 
a O 
range O 
of O 
competing O 
metal O 
ions O 
with O 
the O 
same O 
charge O 
and O 
similar O 
ionic O 
radius O 
. O 
This O 
ion O 
- O 
imprinted O 
polymer O 
is O 
an O 
efficient O 
solid O 
phase O 
for O 
extraction O 
and O 
preconcentration O 
of O 
lead O 
ions O 
in O 
complex O 
matrixes O 
. O 
For O 
proving O 
that O 
the O 
proposed O 
method O 
is O 
reliable O 
, O 
a O 
wide O 
range O 
of O 
food O 
samples O 
with O 
different O 
and O 
complex O 
matrixes O 
was O 
used O 
. O 

effects O 
of O 
a O 
bacterial O 
parasite O 
and O 
the O 
insecticide O 
carbaryl B-TRIVIAL 
to O 
life O 
- O 
history O 
and O 
physiology O 
of O 
two O 
Daphnia O 
magna O 
clones O 
differing O 
in O 
carbaryl B-TRIVIAL 
sensitivity O 
. O 

and O 
chemical O 
stressors O 
occur O 
simultaneously O 
in O 
the O 
aquatic O 
environment O 
. O 
Their O 
combined O 
effects O 
on O 
biota O 
are O 
usually O 
difficult O 
to O 
predict O 
from O 
their O 
individual O 
effects O 
due O 
to O 
interactions O 
between O 
the O 
different O 
stressors O 
. O 
Several O 
recent O 
studies O 
have O 
suggested O 
that O 
synergistic O 
effects O 
of O 
multiple O 
stressors O 
on O 
organisms O 
may O 
be O 
more O 
common O 
at O 
high O 
compared O 
to O 
low O 
overall O 
levels O 
of O 
stress O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
a O 
three O 
- O 
way O 
full O 
factorial O 
design O 
to O 
investigate O 
whether O 
interactive O 
effects O 
between O 
a O 
natural O 
stressor O 
, O 
the O 
bacterial O 
parasite O 
Pasteuria O 
ramosa O 
, O 
and O 
a O 
chemical O 
stressor O 
, O 
the O 
insecticide O 
carbaryl B-TRIVIAL 
, O 
were O 
different O 
between O 
two O 
genetically O 
distinct O 
clones O 
of O 
Daphnia O 
magna O 
that O 
strongly O 
differ O 
in O 
their O 
sensitivity O 
to O 
carbaryl B-TRIVIAL 
. O 
Interactive O 
effects O 
on O 
various O 
life O 
- O 
history O 
and O 
physiological O 
endpoints O 
were O 
assessed O 
as O 
significant O 
deviations O 
from O 
the O 
reference O 
Independent O 
Action O 
( O 
IA O 
) O 
model O 
, O 
which O 
was O 
implemented O 
by O 
testing O 
the O 
significance O 
of O 
the O 
two O 
- O 
way O 
carbaryl B-TRIVIAL 
×parasite O 
interaction O 
term O 
in O 
two O 
- O 
way O 
ANOVA's O 
on O 
log O 
- O 
transformed O 
observational O 
data O 
for O 
each O 
clone O 
separately O 
. O 
Interactive O 
effects O 
( O 
and O 
thus O 
significant O 
deviations O 
from O 
IA O 
) O 
were O 
detected O 
in O 
both O 
the O 
carbaryl B-TRIVIAL 
-sensitive O 
clone O 
( O 
on O 
survival O 
, O 
early O 
reproduction O 
and O 
growth O 
) O 
and O 
in O 
the O 
non-sensitive O 
clone O 
( O 
on O 
growth O 
, O 
electron O 
transport O 
activity O 
and O 
prophenoloxidase O 
activity O 
) O 
. O 
No O 
interactions O 
were O 
found O 
for O 
maturation O 
rate O 
, O 
filtration O 
rate O 
, O 
and O 
energy O 
reserve O 
fractions O 
( O 
carbohydrate B-FAMILY 
, O 
protein O 
, O 
lipid O 
) O 
. O 
Furthermore O 
, O 
only O 
antagonistic O 
interactions O 
were O 
detected O 
in O 
the O 
non-sensitive O 
clone O 
, O 
while O 
only O 
synergistic O 
interactions O 
were O 
observed O 
in O 
the O 
carbaryl B-TRIVIAL 
sensitive O 
clone O 
. O 
Our O 
data O 
clearly O 
show O 
that O 
there O 
are O 
genetically O 
determined O 
differences O 
in O 
the O 
interactive O 
effects O 
following O 
combined O 
exposure O 
to O 
carbaryl B-TRIVIAL 
and O 
Pasteuria O 
in O 
D O 
. O 
magna O 
. O 

Lowers O 
Postprandial O 
Glucose B-TRIVIAL 
and O 
Insulin O 
by O 
Delaying O 
Intestinal O 
Glucose B-TRIVIAL 
Absorption O 
in O 
Addition O 
to O 
Increasing O 
Urinary O 
Glucose B-TRIVIAL 
Excretion O 
: O 
Results O 
of O 
a O 
randomized O 
, O 
placebo O 
- O 
controlled O 
study O 
. O 

Canagliflozin B-TRIVIAL 
, O 
a O 
sodium B-SYSTEMATIC 
glucose B-TRIVIAL 
cotransporter O 
2 O 
( O 
SGLT2 O 
) O 
inhibitor O 
, O 
is O 
also O 
a O 
low O 
- O 
potency O 
SGLT1 O 
inhibitor O 
. O 
This O 
study O 
tested O 
the O 
hypothesis O 
that O 
intestinal O 
canagliflozin B-TRIVIAL 
levels O 
postdose O 
are O 
sufficiently O 
high O 
to O 
transiently O 
inhibit O 
intestinal O 
SGLT1 O 
, O 
thereby O 
delaying O 
intestinal O 
glucose B-TRIVIAL 
absorption.RESEARCH O 
DESIGN O 
AND O 
METHODSThis O 
two O 
- O 
period O 
, O 
crossover O 
study O 
evaluated O 
effects O 
of O 
canagliflozin B-TRIVIAL 
on O 
intestinal O 
glucose B-TRIVIAL 
absorption O 
in O 
20 O 
healthy O 
subjects O 
using O 
a O 
dual O 
- O 
tracer O 
method O 
. O 
Placebo O 
or O 
canagliflozin B-TRIVIAL 
300 O 
mg O 
was O 
given O 
20 O 
min O 
before O 
a O 
600-kcal O 
mixed O 
- O 
meal O 
tolerance O 
test O 
. O 
Plasma O 
glucose B-TRIVIAL 
, O 
(3)H-glucose B-SYSTEMATIC 
, O 
(14)C-glucose B-SYSTEMATIC 
, O 
and O 
insulin O 
were O 
measured O 
frequently O 
for O 
6 O 
h O 
to O 
calculate O 
rates O 
of O 
appearance O 
of O 
oral O 
glucose B-TRIVIAL 
( O 
R(a)O O 
) O 
in O 
plasma O 
, O 
endogenous O 
glucose B-TRIVIAL 
production O 
, O 
and O 
glucose B-TRIVIAL 
disposal.RESULTSCompared O 
with O 
placebo O 
, O 
canagliflozin B-TRIVIAL 
treatment O 
reduced O 
postprandial O 
plasma O 
glucose B-TRIVIAL 
and O 
insulin O 
excursions O 
( O 
incremental O 
0- O 
to O 
2-h O 
area O 
under O 
the O 
curve O 
[AUC(0-2h)] O 
reductions O 
of O 
35% O 
and O 
43% O 
, O 
respectively O 
; O 
P O 
< O 
0.001 O 
for O 
both O 
) O 
, O 
increased O 
0- O 
to O 
6-h O 
urinary O 
glucose B-TRIVIAL 
excretion O 
( O 
UGE(0-6h) O 
, O 
18.2 O 
± O 
5.6 O 
vs O 
< O 
0.2 O 
g O 
; O 
P O 
< O 
0.001 O 
) O 
, O 
and O 
delayed O 
R(a)O O 
. O 
Canagliflozin B-TRIVIAL 
reduced O 
AUC O 
R(a)O O 
by O 
31% O 
over O 
0 O 
to O 
1 O 
h O 
( O 
geometric O 
means O 
, O 
264 O 
vs O 
. O 
381 O 
mg O 
/ O 
kg O 
; O 
P O 
< O 
0.001 O 
) O 
and O 
by O 
20% O 
over O 
0 O 
to O 
2 O 
h O 
( O 
576 O 
vs O 
. O 
723 O 
mg O 
/ O 
kg O 
; O 
P O 
= O 
0.002 O 
) O 
. O 
Over O 
2 O 
to O 
6 O 
h O 
, O 
canagliflozin B-TRIVIAL 
increased O 
R(a)O O 
such O 
that O 
total O 
AUC O 
R(a)O O 
over O 
0 O 
to O 
6 O 
h O 
was O 
< O 
6% O 
lower O 
versus O 
placebo O 
( O 
960 O 
vs O 
. O 
1018 O 
mg O 
/ O 
kg O 
; O 
P O 
= O 
0.003 O 
) O 
. O 
A O 
modest O 
( O 
∼10% O 
) O 
reduction O 
in O 
acetaminophen B-TRIVIAL 
absorption O 
was O 
observed O 
over O 
the O 
first O 
2 O 
h O 
, O 
but O 
this O 
difference O 
was O 
not O 
sufficient O 
to O 
explain O 
the O 
reduction O 
in O 
R(a)O O 
. O 
Total O 
glucose B-TRIVIAL 
disposal O 
over O 
0 O 
to O 
6 O 
h O 
was O 
similar O 
across O 
groups.CONCLUSIONS O 
Canagliflozin B-TRIVIAL 
reduces O 
postprandial O 
plasma O 
glucose B-TRIVIAL 
and O 
insulin O 
by O 
increasing O 
UGE O 
( O 
via O 
renal O 
SGLT2 O 
inhibition O 
) O 
and O 
delaying O 
R(a)O O 
, O 
likely O 
due O 
to O 
intestinal O 
SGLT1 O 
inhibition O 
. O 

Low O 
Dose O 
Administration O 
of O 
the O 
Monoacylglycerol B-SYSTEMATIC 
Lipase O 
Inhibitor O 
JZL184 B-IDENTIFIER 
Retains O 
CB1 O 
Receptor O 
Mediated O 
Antinociceptive O 
and O 
Gastroprotective O 
Effects O 
. O 

monoacylglycerol B-SYSTEMATIC 
lipase O 
( O 
MAGL O 
) O 
inhibitor O 
JZL184 B-IDENTIFIER 
produces O 
antinociceptive O 
and O 
anti-inflammatory O 
effects O 
. O 
However O 
, O 
repeated O 
administration O 
of O 
high O 
dose O 
JZL184 B-IDENTIFIER 
( O 
40 O 
mg O 
/ O 
kg O 
) O 
causes O 
dependence O 
, O 
antinociceptive O 
tolerance O 
, O 
cross O 
- O 
tolerance O 
to O 
the O 
pharmacological O 
effects O 
of O 
cannabinoid O 
receptor O 
agonists O 
, O 
and O 
CB(1) O 
receptor O 
downregulation O 
and O 
desensitization O 
. O 
This O 
functional O 
CB(1) O 
receptor O 
tolerance O 
poses O 
a O 
hurdle O 
in O 
the O 
development O 
of O 
MAGL O 
inhibitors O 
for O 
therapeutic O 
use O 
. O 
Consequently O 
, O 
the O 
present O 
study O 
tested O 
whether O 
repeated O 
administration O 
of O 
low O 
dose O 
JZL184 B-IDENTIFIER 
maintains O 
its O 
antinociceptive O 
actions O 
in O 
the O 
chronic O 
constrictive O 
injury O 
( O 
CCI O 
) O 
of O 
the O 
sciatic O 
nerve O 
neuropathic O 
pain O 
model O 
and O 
protective O 
effects O 
in O 
a O 
model O 
of O 
NSAlD-induced O 
gastric O 
hemorrhages O 
. O 
Mice O 
given O 
daily O 
injections O 
of O 
high O 
dose O 
JZL184 B-IDENTIFIER 
( O 
≥ O 
16 O 
mg O 
/ O 
kg O 
) O 
for O 
six O 
days O 
displayed O 
decreased O 
CB(1) O 
receptor O 
density O 
and O 
function O 
in O 
brain O 
, O 
as O 
assessed O 
in O 
[(3)H]SR141716A B-SYSTEMATIC 
binding O 
and O 
CP55,940 B-IDENTIFIER 
-stimulated O 
[ O 
(35)S B-FORMULA 
]GTPγS O 
binding O 
assays O 
, O 
respectively O 
. O 
In O 
contrast O 
, O 
normal O 
CB(1) O 
receptor O 
expression O 
and O 
function O 
were O 
maintained O 
following O 
repeated O 
administration O 
of O 
low O 
dose O 
JZL184 B-IDENTIFIER 
( O 
≤ O 
8 O 
mg O 
/ O 
kg O 
) O 
. O 
Likewise O 
, O 
the O 
antinociceptive O 
and O 
gastroprotective O 
effects O 
of O 
high O 
dose O 
JZL184 B-IDENTIFIER 
underwent O 
tolerance O 
following O 
repeated O 
administration O 
, O 
but O 
these O 
effects O 
were O 
maintained O 
following O 
repeated O 
low O 
dose O 
JZL184 B-IDENTIFIER 
treatment O 
. O 
Consistent O 
with O 
these O 
observations O 
, O 
repeated O 
high O 
dose O 
JZL184 B-IDENTIFIER 
, O 
but O 
not O 
repeated O 
low O 
dose O 
JZL184 B-IDENTIFIER 
, O 
elicited O 
cross O 
- O 
tolerance O 
to O 
the O 
common O 
pharmacological O 
effects O 
of O 
Δ(9)-tetrahydrocannabinol B-SYSTEMATIC 
( O 
THC B-ABBREVIATION 
) O 
. O 
This O 
same O 
pattern O 
of O 
effects O 
was O 
found O 
in O 
a O 
rimonabant B-TRIVIAL 
-precipitated O 
withdrawal O 
model O 
of O 
cannabinoid O 
dependence O 
. O 
Taken O 
together O 
, O 
these O 
results O 
indicate O 
that O 
prolonged O 
, O 
partial O 
MAGL O 
inhibition O 
maintains O 
potentially O 
beneficial O 
antinociceptive O 
and O 
anti-inflammatory O 
effects O 
, O 
without O 
producing O 
functional O 
CB(1) O 
receptor O 
tachyphylaxsis O 
/ O 
tolerance O 
or O 
cannabinoid O 
dependence O 
. O 

steroids O 
- O 
mediated O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
targeting O 
could O 
circumvent O 
various O 
chemoresistance O 
pathways O 
. O 

cancer O 
patients O 
fail O 
to O 
respond O 
to O 
chemotherapy O 
because O 
of O 
the O 
intrinsic O 
resistance O 
of O 
their O 
cancer O 
to O 
pro O 
- O 
apoptotic O 
stimuli O 
or O 
the O 
acquisition O 
of O 
the O 
multidrug O 
resistant O 
phenotype O 
during O 
chronic O 
treatment O 
. O 
Previous O 
data O 
from O 
our O 
groups O 
and O 
from O 
others O 
point O 
to O 
the O 
sodium B-SYSTEMATIC 
/ O 
potassium B-SYSTEMATIC 
pump O 
( O 
the O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
, O 
i.e O 
. O 
, O 
NaK B-FORMULA 
) O 
with O 
its O 
highly O 
specific O 
ligands O 
( O 
i.e O 
. O 
, O 
cardiotonic O 
steroids B-FAMILY 
) O 
as O 
a O 
new O 
target O 
for O 
combating O 
cancers O 
associated O 
with O 
dismal O 
prognoses O 
, O 
including O 
gliomas O 
, O 
melanomas O 
, O 
non-small O 
cell O 
lung O 
cancers O 
, O 
renal O 
cell O 
carcinomas O 
, O 
and O 
colon O 
cancers O 
. O 
Cardiotonic O 
steroid O 
- O 
mediated O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
targeting O 
could O 
circumvent O 
various O 
resistance O 
pathways O 
. O 
The O 
most O 
probable O 
pathways O 
include O 
the O 
involvement O 
of O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
β O 
subunits O 
in O 
invasion O 
features O 
and O 
Na+ B-FORMULA 
/ O 
K+ B-FORMULA 
-ATPase O 
α O 
subunits O 
in O 
chemosensitisation O 
by O 
specific O 
cardiotonic O 
steroid B-FAMILY 
-mediated O 
apoptosis O 
and O 
anoïkis O 
- O 
sensitisation O 
; O 
the O 
regulation O 
of O 
the O 
expression O 
of O 
multidrug O 
resistant O 
- O 
related O 
genes O 
; O 
post O 
- O 
translational O 
regulation O 
, O 
including O 
glycosylation O 
and O 
ubiquitinylation O 
of O 
multidrug O 
resistant O 
- O 
related O 
proteins O 
; O 
c-Myc O 
downregulation O 
; O 
hypoxia O 
- O 
inducible O 
factor O 
downregulation O 
; O 
NF-κB O 
downregulation O 
and O 
deactivation O 
; O 
the O 
inhibition O 
of O 
the O 
glycolytic O 
pathway O 
with O 
a O 
reduction O 
of O 
intra O 
- O 
cellular O 
ATP B-ABBREVIATION 
levels O 
and O 
an O 
induction O 
of O 
non-apoptotic O 
cell O 
death O 
. O 
The O 
aims O 
of O 
this O 
review O 
are O 
to O 
examine O 
the O 
various O 
molecular O 
pathways O 
by O 
which O 
the O 
NaK B-FORMULA 
targeting O 
can O 
be O 
more O 
deleterious O 
to O 
biologically O 
aggressive O 
cancer O 
cells O 
than O 
to O 
normal O 
cells O 
. O 

- O 
tuning O 
of O 
Voltage O 
Sensitivity O 
of O 
the O 
Kv1.2 O 
Potassium B-SYSTEMATIC 
Channel O 
by O 
Interhelix O 
Loop O 
Dynamics O 
. O 

proteins O 
function O 
by O 
changing O 
conformation O 
in O 
response O 
to O 
ligand O 
binding O 
or O 
changes O 
in O 
other O 
factors O 
in O 
their O 
environment O 
. O 
Any O 
change O 
in O 
the O 
sequence O 
of O 
a O 
protein O 
, O 
for O 
example O 
during O 
evolution O 
, O 
which O 
alters O 
the O 
relative O 
free O 
energies O 
of O 
the O 
different O 
functional O 
conformations O 
changes O 
the O 
conditions O 
under O 
which O 
the O 
protein O 
will O 
function O 
. O 
Voltage O 
- O 
gated O 
ion O 
channels O 
are O 
membrane O 
proteins O 
that O 
open O 
and O 
close O 
an O 
ion O 
- O 
selective O 
pore O 
in O 
response O 
to O 
changes O 
in O 
transmembrane O 
voltage O 
. O 
The O 
charged O 
S4 O 
transmembrane O 
helix O 
transduces O 
changes O 
in O 
transmembrane O 
voltage O 
into O 
a O 
change O 
in O 
protein O 
internal O 
energy O 
by O 
interacting O 
with O 
the O 
rest O 
of O 
the O 
channel O 
protein O 
through O 
a O 
combination O 
of O 
non-covalent O 
interactions O 
between O 
adjacent O 
helices O 
and O 
covalent O 
interactions O 
along O 
the O 
peptide O 
backbone O 
. O 
However O 
, O 
the O 
structural O 
basis O 
for O 
the O 
wide O 
variation O 
in O 
the O 
V50 O 
value O 
between O 
different O 
voltage O 
- O 
gated O 
potassium B-SYSTEMATIC 
channels O 
is O 
not O 
well O 
defined O 
. O 
To O 
test O 
the O 
role O 
of O 
the O 
loop O 
linking O 
the O 
S3 O 
helix O 
and O 
the O 
S4 O 
helix O 
in O 
voltage O 
sensitivity O 
, O 
we O 
have O 
constructed O 
a O 
set O 
of O 
mutants O 
of O 
the O 
rat O 
Kv1.2 O 
channel O 
that O 
vary O 
solely O 
in O 
the O 
length O 
and O 
composition O 
of O 
the O 
extracellular O 
loop O 
that O 
connects O 
S4 O 
to O 
S3 O 
. O 
We O 
evaluated O 
the O 
effect O 
of O 
these O 
different O 
loop O 
substitutions O 
on O 
the O 
voltage O 
sensitivity O 
of O 
the O 
channel O 
and O 
compared O 
these O 
experimental O 
results O 
with O 
molecular O 
dynamics O 
simulations O 
of O 
the O 
loop O 
structures O 
. O 
Here O 
, O 
we O 
show O 
that O 
this O 
loop O 
has O 
a O 
significant O 
role O 
in O 
setting O 
the O 
precise O 
V50 O 
of O 
activation O 
in O 
Kv1 O 
family O 
channels O 
. O 

, O 
a O 
recombinant O 
humanized O 
monoclonal O 
antibody O 
, O 
is O 
the O 
first O 
approved O 
anti-immunoglobulin O 
E O 
( O 
IgE O 
) O 
agent O 
for O 
the O 
treatment O 
of O 
subjects O 
with O 
moderate O 
to O 
severe O 
persistent O 
allergic O 
asthma O 
that O 
are O 
inadequately O 
controlled O 
by O 
the O 
standard O 
of O 
care O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
quantitatively O 
characterize O 
relationships O 
between O 
serum O 
free O 
IgE O 
and O 
pulmonary O 
function O 
( O 
as O 
measured O 
by O 
forced O 
expiratory O 
volume O 
in O 
1 O 
s O 
[ O 
FEV1 O 
] O 
) O 
as O 
well O 
as O 
serum O 
free O 
IgE O 
and O 
airway O 
inflammation O 
( O 
as O 
measured O 
by O 
fractional O 
exhaled O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
[ O 
FeNO O 
] O 
) O 
using O 
population O 
- O 
based O 
efficacy O 
models O 
. O 
Data O 
were O 
collected O 
from O 
patients O 
in O 
the O 
EXTRA O 
trial O 
who O 
received O 
omalizumab O 
or O 
placebo O 
150 O 
to O 
375 O 
mg O 
subcutaneously O 
every O 
2 O 
or O 
4 O 
weeks O 
from O 
week O 
0 O 
to O 
48 O 
with O 
constant O 
standard O 
of O 
care O 
as O 
background O 
therapy O 
. O 
None O 
of O 
the O 
covariates O 
evaluated O 
, O 
including O 
demographics O 
, O 
disease O 
status O 
, O 
and O 
baseline O 
pharmacodynamic O 
biomarkers O 
, O 
were O 
significant O 
in O 
explaining O 
the O 
variability O 
in O 
the O 
FEV1 O 
or O 
FeNO O 
response O 
to O 
omalizumab O 
. O 
Results O 
from O 
the O 
efficacy O 
models O 
further O 
confirmed O 
the O 
current O 
omalizumab O 
dosing O 
rationale O 
based O 
on O 
the O 
mean O 
target O 
free O 
IgE O 
level O 
of O 
25 O 
ng O 
/ O 
ml O 
and O 
quantified O 
the O 
variability O 
for O 
the O 
target O 
. O 
In O 
addition O 
, O 
the O 
resulting O 
population O 
models O 
could O 
be O 
used O 
to O 
predict O 
population O 
FEV1 O 
or O 
FeNO O 
response O 
for O 
omalizumab O 
and O 
/ O 
or O 
other O 
anti-IgE O 
therapeutics O 
for O 
which O 
PK-IgE O 
models O 
are O 
constructed O 
. O 

dynamics O 
simulations O 
and O 
elastic O 
neutron O 
scattering O 
experiments O 
have O 
been O 
used O 
to O 
highlight O 
how O 
the O 
structural O 
organization O 
of O 
hydration O 
water O 
is O 
able O 
in O 
some O 
cases O 
to O 
locally O 
constrain O 
atomic O 
movements O 
at O 
biologic O 
interfaces O 
. O 
Using O 
fully O 
hydrated O 
small O 
peptides O 
as O 
models O 
of O 
protein O 
interfaces O 
, O 
we O 
show O 
that O 
the O 
length O 
of O 
the O 
side O 
chains O 
and O 
the O 
hydrophilic O 
backbone O 
have O 
specific O 
signatures O 
. O 
The O 
dynamics O 
of O 
the O 
side O 
chain O 
, O 
which O 
is O 
part O 
of O 
biomolecules O 
, O 
have O 
not O 
only O 
a O 
crucial O 
role O 
in O 
the O 
whole O 
flexibility O 
as O 
compared O 
to O 
the O 
backbone O 
, O 
but O 
also O 
modify O 
the O 
values O 
of O 
transition O 
temperatures O 
. O 
The O 
analysis O 
of O 
the O 
activation O 
energies O 
of O 
methyl B-SYSTEMATIC 
group O 
dynamics O 
suggests O 
that O 
the O 
interaction O 
between O 
hydrophobic O 
side O 
chain O 
and O 
surrounding O 
water O 
plays O 
an O 
important O 
role O 
in O 
the O 
whole O 
flexibility O 
as O 
well O 
. O 
We O 
suggest O 
that O 
the O 
progressive O 
water O 
cluster O 
organization O 
, O 
around O 
hydrophobic O 
interfaces O 
increases O 
the O 
activation O 
energy O 
and O 
that O 
a O 
plateau O 
regime O 
is O 
reached O 
only O 
when O 
an O 
extended O 
hydrogen B-SYSTEMATIC 
-bond O 
network O 
is O 
established O 
. O 
The O 
cluster O 
size O 
corresponds O 
to O 
a O 
single O 
layer O 
of O 
water O 
molecules O 
. O 

reactivity O 
in O 
resistance O 
to O 
methamphetamine B-TRIVIAL 
-induced O 
neurotoxicity O 
. O 

regimens O 
of O 
methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
) O 
result O 
in O 
reactive O 
microglia O 
and O 
astrocytes O 
in O 
striatum O 
. O 
Prior O 
data O 
indicate O 
that O 
rats O 
with O 
partial O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
loss O 
resulting O 
from O 
prior O 
exposure O 
to O 
METH B-ABBREVIATION 
are O 
resistant O 
to O 
further O 
decreases O 
in O 
striatal O 
DA O 
when O 
re O 
- O 
exposed O 
to O 
METH B-ABBREVIATION 
30 O 
days O 
later O 
. O 
Such O 
resistant O 
animals O 
also O 
do O 
not O 
show O 
an O 
activated O 
microglia O 
phenotype O 
, O 
suggesting O 
a O 
relation O 
between O 
microglial O 
activation O 
and O 
METH B-ABBREVIATION 
-induced O 
neurotoxicity O 
. O 
To O 
date O 
, O 
the O 
astrocyte O 
response O 
in O 
such O 
resistance O 
has O 
not O 
been O 
examined O 
. O 
Thus O 
, O 
this O 
study O 
examined O 
glial O 
- O 
fibrillary O 
acidic O 
protein O 
( O 
GFAP O 
) O 
and O 
CD11b O 
protein O 
expression O 
in O 
striata O 
of O 
animals O 
administered O 
saline O 
or O 
a O 
neurotoxic O 
regimen O 
of O 
METH B-ABBREVIATION 
on O 
post O 
- O 
natal O 
days O 
60 O 
and O 
/ O 
or O 
90 O 
( O 
Saline O 
: O 
Saline O 
, O 
Saline O 
: O 
METH B-ABBREVIATION 
, O 
METH B-ABBREVIATION 
: O 
Saline O 
, O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
) O 
. O 
Consistent O 
with O 
previous O 
work O 
, O 
animals O 
experiencing O 
acute O 
toxicity O 
( O 
Saline O 
: O 
METH B-ABBREVIATION 
) O 
showed O 
both O 
activated O 
microglia O 
and O 
astocytes O 
, O 
whereas O 
those O 
resistant O 
to O 
the O 
acute O 
toxicity O 
( O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
) O 
did O 
not O 
show O 
activated O 
microglia O 
. O 
Interestingly O 
, O 
GFAP O 
expression O 
remained O 
elevated O 
in O 
rats O 
exposed O 
to O 
METH O 
at O 
PND60 O 
( O 
METH O 
: O 
Saline O 
) O 
, O 
and O 
was O 
not O 
elevated O 
further O 
in O 
resistant O 
rats O 
treated O 
for O 
the O 
second O 
time O 
with O 
METH B-ABBREVIATION 
( O 
METH B-ABBREVIATION 
: O 
METH B-ABBREVIATION 
) O 
. O 
These O 
data O 
suggest O 
that O 
astrocytes O 
remain O 
reactive O 
up O 
to O 
30 O 
days O 
post- O 
METH B-ABBREVIATION 
exposure O 
. O 
In O 
addition O 
, O 
these O 
data O 
indicate O 
that O 
astrocyte O 
reactivity O 
does O 
not O 
reflect O 
acute O 
, O 
METH B-ABBREVIATION 
-induced O 
DA O 
terminal O 
toxicity O 
, O 
whereas O 
microglial O 
reactivity O 
does O 
. O 

of O 
novel O 
2-hydroxydiarylamide B-FAMILY 
derivatives O 
as O 
TMPRSS4 O 
inhibitors O 
. O 

is O 
a O 
novel O 
type O 
II O 
transmembrane O 
serine O 
protease O 
that O 
has O 
been O 
implicated O 
in O 
the O 
invasion O 
and O 
metastasis O 
of O 
colon O 
cancer O 
cells O 
. O 
In O 
this O 
study O 
, O 
a O 
novel O 
series O 
of O 
2-hydroxydiarylamide B-FAMILY 
derivatives O 
were O 
synthesized O 
and O 
evaluated O 
for O 
inhibiting O 
TMPRSS4 O 
serine B-TRIVIAL 
protease O 
activity O 
and O 
suppressing O 
cancer O 
cell O 
invasion O 
. O 
These O 
derivatives O 
demonstrated O 
good O 
inhibitory O 
activity O 
against O 
TMPRSS4 O 
serine B-TRIVIAL 
protease O 
, O 
which O 
correlated O 
with O 
the O 
promising O 
anti-invasive O 
activity O 
of O 
colon O 
cancer O 
cells O 
overexpressing O 
TMPRSS4 O 
. O 

novel O 
concept O 
of O 
radiosynthesis O 
of O 
a O 
(99m)Tc B-FORMULA 
-labeled O 
dimeric O 
RGD O 
peptide O 
as O 
a O 
potential O 
radiotracer O 
for O 
tumor O 
imaging O 
. O 

Arg-Gly-Asp B-FORMULA 
( O 
RGD O 
) O 
peptides O 
are O 
promising O 
agents O 
for O 
non O 
invasive O 
imaging O 
of O 
αvβ3 O 
expression O 
in O 
malignant O 
tumors O 
. O 
The O 
integrin O 
αvβ3 O 
binding O 
affinity O 
and O 
consequent O 
tumor O 
uptake O 
could O 
be O 
improved O 
when O 
a O 
dimeric O 
RGD O 
peptide O 
is O 
used O 
as O 
the O 
targeting O 
moiety O 
instead O 
of O 
a O 
monomer O 
. O 
Towards O 
this O 
, O 
a O 
novel O 
approach O 
was O 
envisaged O 
to O 
synthesize O 
a O 
(99m)Tc B-FORMULA 
labeled O 
dimeric O 
RGD O 
derivative O 
using O 
a O 
RGD O 
monomer O 
and O 
[(99m)TcN](+2) B-FORMULA 
intermediate O 
. O 
The O 
dithiocarbamate B-SYSTEMATIC 
derivative O 
of O 
cyclic O 
RGD O 
peptide O 
G3-c(RGDfK) B-FORMULA 
( O 
G3=Gly-Gly-Gly B-FORMULA 
, O 
f=Phe B-FORMULA 
, O 
K=Lys B-FORMULA 
) O 
was O 
synthesized O 
and O 
radiolabeled O 
with O 
[(99m)TcN](+2) B-FORMULA 
intermediate O 
to O 
form O 
the O 
(99m)TcN-[G3-c(RGDfK)]2 B-FORMULA 
complex O 
in O 
high O 
yield O 
( O 
∼98% O 
) O 
. O 
Biodistribution O 
studies O 
carried O 
out O 
in O 
C57 O 
/ O 
BL6 O 
mice O 
bearing O 
melanoma O 
tumors O 
showed O 
good O 
tumor O 
uptake O 
[ O 
4.61±0.04% O 
IA O 
/ O 
g O 
at O 
30min O 
post O 
- O 
injection O 
] O 
with O 
fast O 
clearance O 
of O 
the O 
activity O 
from O 
non-target O 
organs O 
/ O 
tissue O 
. O 
Scintigraphic O 
imaging O 
studies O 
showed O 
visible O 
accumulation O 
of O 
activity O 
in O 
the O 
tumor O 
with O 
appreciable O 
target O 
to O 
background O 
ratio O 
. O 

/ O 
androgen B-FAMILY 
receptor O 
pathway O 
regulates O 
expression O 
of O 
the O 
genes O 
for O 
cyclooxygenase-2 O 
and O 
amphiregulin O 
in O 
periovulatory O 
granulosa O 
cells O 
. O 

is O 
well O 
known O 
that O 
the O 
androgen B-FAMILY 
/ O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
pathway O 
is O 
involved O 
in O 
both O 
male O 
and O 
female O 
fertility O 
in O 
mammals O 
. O 
AR O 
knockout O 
female O 
mice O 
are O 
reported O 
to O 
exhibit O 
various O 
abnormalities O 
in O 
follicle O 
development O 
, O 
and O 
a O 
subfertile O 
phenotype O 
. O 
In O 
exogenous O 
gonadotropin O 
- O 
induced O 
superovulation O 
, O 
serum O 
androgen B-FAMILY 
levels O 
were O 
robustly O 
elevated O 
in O 
female O 
mice O 
at O 
the O 
periovulatory O 
stage O 
after O 
human O 
chorionic O 
gonadotropin O 
( O 
hCG O 
) O 
treatment O 
. O 
At O 
this O 
stage O 
, O 
ovarian O 
AR O 
proteins O 
were O 
strongly O 
expressed O 
in O 
cumulus O 
cells O 
. O 
Because O 
these O 
results O 
suggested O 
that O 
the O 
androgen B-FAMILY 
/ O 
AR O 
pathway O 
is O 
involved O 
in O 
ovulation O 
, O 
we O 
investigated O 
the O 
expression O 
of O 
ovulation O 
- O 
related O 
genes O 
in O 
the O 
mouse O 
ovary O 
treated O 
with O 
the O 
nonaromatizable O 
androgen B-FAMILY 
, O 
5α-dihydrotestosterone B-SYSTEMATIC 
( O 
DHT B-ABBREVIATION 
) O 
. O 
DHT B-ABBREVIATION 
treatment O 
induced O 
the O 
expression O 
of O 
the O 
genes O 
for O 
cyclooxyganase-2 O 
( O 
Cox-2 O 
or O 
prostaglandin B-FAMILY 
endoperoxidase O 
synthase O 
2 O 
) O 
and O 
the O 
epidermal O 
growth O 
factor O 
- O 
like O 
factor O 
, O 
amphiregulin O 
( O 
Areg O 
) O 
, O 
in O 
the O 
ovary O 
, O 
whereas O 
their O 
hCG-induced O 
expression O 
was O 
suppressed O 
by O 
the O 
AR O 
antagonist O 
flutamide B-TRIVIAL 
. O 
These O 
genes O 
were O 
also O 
induced O 
by O 
DHT B-ABBREVIATION 
in O 
AR-expressing O 
primary O 
granulosa O 
and O 
granulosa O 
tumor O 
- O 
derived O 
cells O 
. O 
Reporter O 
assays O 
, O 
electrophoretic O 
shift O 
mobility O 
assays O 
and O 
chromatin O 
immunoprecipitation O 
assays O 
demonstrated O 
that O 
androgen B-FAMILY 
response O 
sequence(s) O 
existing O 
upstream O 
of O 
each O 
gene O 
were O 
responsible O 
for O 
androgen B-FAMILY 
responsiveness O 
and O 
were O 
occupied O 
by O 
the O 
AR O 
in O 
periovulatory O 
granulosa O 
cells O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
androgen B-FAMILY 
/ O 
AR O 
pathway O 
is O 
involved O 
in O 
the O 
ovulatory O 
process O 
via O 
expression O 
of O 
the O 
Cox-2 O 
and O 
Areg O 
genes O 
in O 
periovulatory O 
granulosa O 
cells O 
. O 

drug O 
delivery O 
to O 
renal O 
proximal O 
tubule O 
epithelial O 
cells O 
mediated O 
by O 
2-glucosamine B-SYSTEMATIC 
. O 

order O 
to O 
develop O 
a O 
novel O 
kidney O 
- O 
targeted O 
drug O 
delivery O 
system O 
, O 
we O 
synthesized O 
prednisolone B-SYSTEMATIC 
carbamate I-SYSTEMATIC 
- O 
glucosamine B-TRIVIAL 
conjugate O 
( O 
PCG O 
) O 
using O 
2-glucosamine B-SYSTEMATIC 
as O 
a O 
ligand O 
, O 
and O 
investigated O 
its O 
potential O 
targeting O 
efficacy O 
. O 
In O 
vitro O 
studies O 
demonstrated O 
that O 
PCG O 
could O 
remarkably O 
improve O 
the O 
uptake O 
of O 
drug O 
by O 
kidney O 
cells O 
. O 
And O 
the O 
specific O 
uptake O 
of O 
PCG O 
could O 
be O 
largely O 
reduced O 
by O 
the O 
inhibitors O 
of O 
megalin O 
receptor O 
. O 
More O 
importantly O 
, O 
PCG O 
showed O 
an O 
excellent O 
kidney O 
targeting O 
property O 
in O 
vivo O 
, O 
and O 
the O 
concentration O 
of O 
the O 
conjugate O 
in O 
the O 
kidney O 
was O 
8.1-fold O 
higher O 
than O 
that O 
of O 
prednisolone O 
group O 
at O 
60 O 
min O 
after O 
intravenous O 
injection O 
. O 
Besides O 
, O 
PCG O 
could O 
significantly O 
reverse O 
the O 
disease O 
progression O 
in O 
renal O 
ischemia O 
- O 
reperfusion O 
( O 
I O 
/ O 
R O 
) O 
injury O 
animal O 
models O 
. O 
Furthermore O 
, O 
PCG O 
presented O 
no O 
adverse O 
effect O 
on O 
bone O 
density O 
while O 
prednisolone B-TRIVIAL 
resulted O 
in O 
severe O 
osteoporosis O 
. O 
Thus O 
, O 
it O 
indicated O 
that O 
2-glucosamine B-SYSTEMATIC 
could O 
be O 
a O 
potential O 
ligand O 
for O 
kidney O 
- O 
targeted O 
delivery O 
of O 
prednisolone B-TRIVIAL 
. O 

replacements O 
for O 
the O 
isatin B-TRIVIAL 
in O 
the O 
highly O 
selective O 
, O 
muscarinic O 
M1 O 
PAM O 
ML137 O 
: O 
the O 
continued O 
optimization O 
of O 
an O 
MLPCN O 
probe O 
molecule O 
. O 

Letter O 
describes O 
the O 
further O 
optimization O 
of O 
an O 
MLPCN O 
probe O 
molecule O 
( O 
ML137 O 
) O 
through O 
the O 
introduction O 
of O 
5- O 
and O 
6-membered O 
spirocycles B-FAMILY 
in O 
place O 
of O 
the O 
isatin B-TRIVIAL 
ketone B-SYSTEMATIC 
. O 
Interestingly O 
divergent O 
structure O 
- O 
activity O 
relationships O 
, O 
when O 
compared O 
to O 
earlier O 
M1 O 
PAMs O 
, O 
are O 
presented O 
. O 
These O 
novel O 
spirocycles O 
possess O 
improved O 
efficacy O 
relative O 
to O 
ML137 O 
, O 
while O 
also O 
maintaining O 
high O 
selectivity O 
for O 
the O 
human O 
and O 
rat O 
muscarinic O 
M1 O 
receptor O 
subtype O 
. O 

nitropheny B-SYSTEMATIC 
l O 
- O 
based O 
prodrug O 
type O 
for O 
colorectal O 
targeting O 
of O 
prednisolone B-TRIVIAL 
, O 
budesonide B-TRIVIAL 
and O 
celecoxib B-TRIVIAL 
. O 

is O 
a O 
COX-2 O 
inhibitor O 
drug O 
that O 
can O 
be O 
used O 
to O 
reduce O 
the O 
risk O 
of O 
colorectal O 
adenocarcinoma O 
. O 
Glucocorticoids O 
are O 
used O 
in O 
the O 
treatment O 
of O 
inflammatory O 
bowel O 
disease O 
. O 
A O 
limitation O 
to O 
the O 
use O 
of O 
both O 
drug O 
types O 
is O 
that O 
they O 
undergo O 
absorption O 
from O 
the O 
intestinal O 
tract O 
with O 
serious O 
side O 
effects O 
. O 
The O 
prodrug O 
systems O 
introduced O 
here O 
involve O 
forming O 
a O 
nitro B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
acylsulfonamide I-FAMILY 
group O 
in O 
the O 
case O 
of O 
celecoxib B-TRIVIAL 
and O 
a O 
nitro B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
21-ester I-FAMILY 
for O 
the O 
glucocorticoids O 
. O 
Drug O 
release O 
is O 
triggered O 
by O 
the O 
nitro B-SYSTEMATIC 
reductase O 
action O 
of O 
the O 
colonic O 
microflora O 
, O 
liberating O 
a O 
cyclization O 
competent O 
species O 
. O 
The O 
release O 
of O 
the O 
active O 
parent O 
drugs O 
was O 
evaluated O 
in O 
vitro O 
using O 
Clostridium O 
perfringens O 
and O 
epithelial O 
transport O 
through O 
Caco-2 O 
monolayer O 
evaluation O 
was O 
carried O 
out O 
to O 
estimate O 
the O 
absorption O 
properties O 
of O 
the O 
prodrugs O 
compared O 
to O 
the O 
parental O 
drugs O 
. O 

levels O 
of O 
insulin O 
and O 
glucagon O 
reflect O 
the O 
nutritional O 
state O 
of O 
animals O 
and O 
elicit O 
regulatory O 
responses O 
in O 
the O 
liver O 
that O 
maintain O 
glucose B-TRIVIAL 
and O 
lipid O 
homeostasis O 
. O 
The O 
transcription O 
factor O 
Foxa2 O 
activates O 
lipid O 
metabolism O 
and O 
ketogenesis O 
during O 
fasting O 
and O 
is O 
inhibited O 
via O 
insulin-PI3K-Akt O 
signaling O 
- O 
mediated O 
phosphorylation O 
at O 
Thr156 O 
and O 
nuclear O 
exclusion O 
. O 
Here O 
we O 
show O 
that O 
, O 
in O 
addition O 
, O 
Foxa2 O 
is O 
acetylated O 
at O 
the O 
conserved O 
residue O 
Lys259 O 
following O 
inhibition O 
of O 
histone O 
deacetylases O 
( O 
HDACs O 
) O 
class O 
I-III O 
and O 
the O 
cofactors O 
p300 O 
and O 
SirT1 O 
are O 
involved O 
in O 
Foxa2 O 
acetylation O 
and O 
deacetylation O 
, O 
respectively O 
. O 
Physiologically O 
, O 
fasting O 
states O 
and O 
glucagon O 
stimulation O 
are O 
sufficient O 
to O 
induce O 
Foxa2 O 
acetylation O 
. O 
Introduction O 
of O 
the O 
acetylation O 
- O 
mimicking O 
( O 
K259Q O 
) O 
or O 
-deficient O 
( O 
K259R O 
) O 
mutations O 
promotes O 
or O 
inhibits O 
Foxa2 O 
activity O 
, O 
respectively O 
, O 
and O 
adenoviral O 
expression O 
of O 
Foxa2-K259Q O 
augments O 
expression O 
of O 
genes O 
involved O 
in O 
fatty B-FAMILY 
acid I-FAMILY 
oxidation O 
and O 
ketogenesis O 
. O 
Our O 
study O 
reveals O 
a O 
molecular O 
mechanism O 
by O 
which O 
glucagon O 
signaling O 
activates O 
a O 
fasting O 
response O 
through O 
acetylation O 
of O 
Foxa2 O 
. O 

and O 
anti-lipidemic O 
effects O 
of O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
are O 
mediated O 
by O 
ampk O 
activation O 
. O 

acid I-TRIVIAL 
( O 
CGA B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
stimulate O 
glucose B-TRIVIAL 
uptake O 
in O 
skeletal O 
muscle O 
through O 
the O 
activation O 
of O 
AMPK O 
. O 
However O 
, O 
its O 
effect O 
on O 
other O 
metabolic O 
pathways O 
and O 
likewise O 
its O 
effects O 
after O 
long O 
- O 
term O 
consumption O 
have O 
yet O 
to O 
be O 
understood O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
CGA B-ABBREVIATION 
on O 
glucose B-TRIVIAL 
tolerance O 
, O 
insulin O 
sensitivity O 
, O 
hepatic O 
gluconeogenesis O 
, O 
lipid O 
metabolism O 
and O 
skeletal O 
muscle O 
glucose B-TRIVIAL 
uptake O 
in O 
Lepr(db O 
/ O 
db O 
) O 
mice O 
. O 
Hepatoma O 
HepG2 O 
was O 
used O 
to O 
investigate O 
CGA B-ABBREVIATION 
' O 
s O 
effect O 
on O 
hepatic O 
glucose B-TRIVIAL 
production O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
. O 
Subsequently O 
, O 
we O 
attempted O 
to O 
evaluate O 
whether O 
these O 
effects O 
of O 
CGA B-ABBREVIATION 
are O 
associated O 
with O 
the O 
activation O 
of O 
AMPK O 
. O 
In O 
Lepr(db O 
/ O 
db O 
) O 
mice O 
, O 
acute O 
treatment O 
with O 
CGA B-ABBREVIATION 
lowered O 
AUC O 
glucose B-TRIVIAL 
in O 
an O 
OGTT O 
. O 
Chronic O 
administration O 
of O 
CGA B-ABBREVIATION 
inhibited O 
hepatic O 
G6Pase O 
expression O 
and O 
activity O 
, O 
attenuated O 
hepatic O 
steatosis O 
, O 
improved O 
lipid O 
profiles O 
and O 
skeletal O 
muscle O 
glucose B-TRIVIAL 
uptake O 
, O 
which O 
in O 
turn O 
improved O 
fasting O 
glucose B-TRIVIAL 
level O 
, O 
glucose B-TRIVIAL 
tolerance O 
, O 
insulin O 
sensitivity O 
and O 
dyslipidemia O 
in O 
Lepr(db O 
/ O 
db O 
) O 
mice O 
. O 
CGA B-ABBREVIATION 
activated O 
AMPK O 
, O 
leading O 
to O 
subsequent O 
beneficial O 
metabolic O 
outcomes O 
, O 
such O 
as O 
suppression O 
of O 
hepatic O 
glucose B-TRIVIAL 
production O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
. O 
Inhibition O 
and O 
knockdown O 
of O 
AMPK O 
abrogated O 
these O 
metabolic O 
alterations O 
. O 
In O 
conclusion O 
, O 
CGA B-ABBREVIATION 
improved O 
glucose B-TRIVIAL 
and O 
lipid O 
metabolism O 
, O 
via O 
the O 
activation O 
of O 
AMPK O 
. O 

- O 
based O 
drug O 
design O 
and O 
identification O 
of O 
HJC0123 B-IDENTIFIER 
, O 
a O 
novel O 
orally O 
bioavailable O 
STAT3 O 
inhibitor O 
for O 
cancer O 
therapy O 
. O 

- O 
based O 
drug O 
design O 
( O 
FBDD O 
) O 
is O 
a O 
promising O 
approach O 
for O 
the O 
generation O 
of O 
lead O 
molecules O 
with O 
enhanced O 
activity O 
and O 
especially O 
drug O 
- O 
like O 
properties O 
against O 
therapeutic O 
targets O 
. O 
Herein O 
, O 
we O 
report O 
the O 
fragment O 
- O 
based O 
drug O 
design O 
, O 
systematic O 
chemical O 
synthesis O 
and O 
pharmacological O 
evaluation O 
of O 
novel O 
scaffolds O 
as O 
potent O 
anticancer O 
agents O 
by O 
utilizing O 
six O 
privileged O 
fragments O 
from O 
known O 
STAT3 O 
inhibitors O 
. O 
Several O 
new O 
molecules O 
such O 
as O 
compounds O 
5 O 
, O 
12 O 
, O 
and O 
19 O 
that O 
may O 
act O 
as O 
advanced O 
chemical O 
leads O 
have O 
been O 
identified O 
. O 
The O 
most O 
potent O 
compound O 
5 O 
( O 
HJC0123 B-IDENTIFIER 
) O 
has O 
demonstrated O 
to O 
inhibit O 
STAT3 O 
promoter O 
activity O 
, O 
downregulate O 
phosphorylation O 
of O 
STAT3 O 
, O 
increase O 
the O 
expression O 
of O 
cleaved O 
caspase-3 O 
, O 
inhibit O 
cell O 
cycle O 
progression O 
and O 
promote O 
apoptosis O 
in O 
breast O 
and O 
pancreatic O 
cancer O 
cells O 
with O 
low O 
micromolar O 
to O 
nanomolar O 
IC50 O 
values O 
. O 
Furthermore O 
, O 
compound O 
5 O 
significantly O 
suppressed O 
estrogen B-FAMILY 
receptor O 
(ER)-negative O 
breast O 
cancer O 
MDA-MB-231 O 
xenograft O 
tumor O 
growth O 
in O 
vivo O 
( O 
p.o O 
. O 
) O 
, O 
indicating O 
its O 
great O 
potential O 
as O 
an O 
efficacious O 
and O 
orally O 
bioavailable O 
drug O 
candidate O 
for O 
human O 
cancer O 
therapy O 
. O 

and O 
pharmacological O 
evaluation O 
of O 
some O 
novel O 
2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles B-FAMILY 
. O 

series O 
of O 
novel O 
2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles B-FAMILY 
( O 
6 O 
) O 
were O 
synthesized O 
by O 
condensing O 
3-(2-bromoacetyl)coumarins B-FAMILY 
( O 
4 O 
) O 
with O 
various O 
5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-thiocarboxamides B-FAMILY 
( O 
5 O 
) O 
, O 
obtained O 
by O 
the O 
reaction O 
of O 
thiosemicarbazide B-SYSTEMATIC 
with O 
trifluoromethyl-β-diketones B-FAMILY 
. O 
All O 
the O 
tested O 
compounds O 
displayed O 
significant O 
to O 
moderate O 
in O 
vivo O 
anti-inflammatory O 
activity O 
when O 
compared O 
to O 
the O 
standard O 
drug O 
indomethacin B-TRIVIAL 
, O 
and O 
good O 
broad O 
spectrum O 
in O 
vitro O 
antibacterial O 
activity O 
against O 
three O 
Gram O 
- O 
positive O 
and O 
four O 
Gram O 
- O 
negative O 
bacteria O 
when O 
compared O 
with O 
cefixime B-TRIVIAL 
. O 

have O 
been O 
isolated O 
from O 
hydrophid O 
, O 
elapid O 
and O 
, O 
more O 
recently O 
, O 
colubrid O 
snake O 
venoms O 
. O 
Also O 
referred O 
to O 
as O 
postsynaptic O 
neurotoxins O 
or O 
' O 
curare O 
mimetic O 
' O 
neurotoxins O 
, O 
they O 
play O 
an O 
important O 
role O 
in O 
the O 
capture O 
and O 
/ O 
or O 
killing O 
of O 
prey O 
by O 
binding O 
to O 
the O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
on O 
the O 
skeletal O 
muscle O 
disrupting O 
neurotransmission O 
. O 
They O 
are O 
also O 
thought O 
to O 
cause O 
respiratory O 
paralysis O 
in O 
envenomed O 
humans O 
. O 
This O 
review O 
will O 
discuss O 
the O 
historical O 
background O 
into O 
the O 
discovery O 
, O 
isolation O 
, O 
structure O 
and O 
mechanism O 
of O 
action O 
of O 
the O 
α-neurotoxins O 
, O 
including O 
targets O 
and O 
cellular O 
outcomes O 
, O 
and O 
then O 
will O 
examine O 
the O 
potential O 
uses O 
of O 
α-neurotoxins O 
as O 
pharmacological O 
tools O 
and O 
/ O 
or O 
as O 
drug O 
leads O 
. O 

- O 
induced O 
toxicity O 
is O 
of O 
considerable O 
concern O 
in O 
drug O 
discovery O 
and O 
development O 
, O 
placing O 
emphasis O 
on O 
the O 
need O 
for O 
predictive O 
in O 
vitro O 
technologies O 
that O 
identify O 
potential O 
cytotoxic O 
side O 
effects O 
of O 
drugs O 
. O 
A O 
label O 
- O 
free O 
, O 
real O 
- O 
time O 
, O 
multiparametric O 
cytosensor O 
system O 
has O 
therefore O 
been O 
established O 
for O 
in O 
vitro O 
assessment O 
of O 
drug O 
- O 
induced O 
toxicity O 
. O 
The O 
system O 
is O 
based O 
on O 
monitoring O 
cellular O 
oxygen B-SYSTEMATIC 
consumption O 
, O 
acidification O 
and O 
impedance O 
of O 
human O 
hepatocarcinoma O 
- O 
derived O 
HepG2 O 
cells O 
. O 
The O 
read O 
- O 
out O 
derived O 
from O 
the O 
multiparametric O 
cytosensor O 
system O 
has O 
been O 
optimised O 
and O 
permits O 
sensitive O 
, O 
reliable O 
, O 
and O 
simultaneous O 
recording O 
of O 
cell O 
physiological O 
signals O 
, O 
such O 
as O 
metabolic O 
activity O 
, O 
cellular O 
respiration O 
and O 
morphological O 
changes O 
and O 
cell O 
adhesion O 
upon O 
exposure O 
to O 
a O 
drug O 
. O 
Analysis O 
of O 
eight O 
prototypic O 
reference O 
drugs O 
revealed O 
distinct O 
patterns O 
of O 
drug O 
- O 
induced O 
physiological O 
signals O 
. O 
Effects O 
proved O 
to O 
be O 
rigidly O 
concentration O 
- O 
dependent O 
. O 
Based O 
on O 
signal O 
patterns O 
and O 
reversibility O 
of O 
the O 
observed O 
effects O 
, O 
compounds O 
could O 
be O 
classified O 
based O 
as O 
triggering O 
mechanisms O 
of O 
respiratory O 
or O 
metabolic O 
stress O 
or O 
conditions O 
leading O 
to O 
cell O 
death O 
( O 
necrosis O 
- O 
like O 
and O 
apoptosis O 
- O 
like O 
) O 
. O 
A O 
test O 
- O 
flag O 
- O 
risk O 
mitigation O 
strategy O 
is O 
proposed O 
to O 
address O 
potential O 
risks O 
for O 
drug O 
- O 
induced O 
cytotoxicity O 
. O 

vitro O 
effects O 
of O 
aldehydes B-FAMILY 
present O 
in O 
tobacco O 
smoke O 
on O 
gene O 
expression O 
in O 
human O 
lung O 
alveolar O 
epithelial O 
cells O 
. O 

smoke O 
consists O 
of O 
thousands O 
of O 
harmful O 
components O 
. O 
A O 
major O 
class O 
of O 
chemicals O 
found O 
in O 
tobacco O 
smoke O 
is O 
formed O 
by O 
aldehydes B-FAMILY 
, O 
in O 
particular O 
formaldehyde B-SYSTEMATIC 
, O 
acetaldehyde B-SYSTEMATIC 
and O 
acrolein B-TRIVIAL 
. O 
The O 
present O 
study O 
investigates O 
the O 
gene O 
expression O 
changes O 
in O 
human O 
lung O 
alveolar O 
epithelial O 
cells O 
upon O 
exposure O 
to O 
formaldehyde B-SYSTEMATIC 
, O 
acrolein B-TRIVIAL 
and O 
acetaldehyde B-SYSTEMATIC 
at O 
sub O 
- O 
cytotoxic O 
levels O 
. O 
We O 
exposed O 
A549 O 
cells O 
in O 
vitro O 
to O 
aldehydes B-FAMILY 
and O 
non- O 
aldehyde B-SYSTEMATIC 
chemicals O 
( O 
nicotine B-TRIVIAL 
, O 
hydroquinone B-SYSTEMATIC 
and O 
2,5-dimethylfuran B-SYSTEMATIC 
) O 
present O 
in O 
tobacco O 
smoke O 
and O 
used O 
microarrays O 
to O 
obtain O 
a O 
global O 
view O 
of O 
the O 
transcriptomic O 
responses O 
. O 
We O 
compared O 
responses O 
of O 
the O 
individual O 
aldehydes B-FAMILY 
with O 
that O 
of O 
the O 
non- O 
aldehydes B-FAMILY 
. O 
We O 
also O 
studied O 
the O 
response O 
of O 
the O 
aldehydes B-FAMILY 
when O 
present O 
in O 
a O 
mixture O 
at O 
relative O 
concentrations O 
as O 
present O 
in O 
cigarette O 
smoke O 
. O 
Formaldehyde B-SYSTEMATIC 
gave O 
the O 
strongest O 
response O 
; O 
a O 
total O 
of O 
66 O 
genes O 
were O 
more O 
than O 
1.5-fold O 
differentially O 
expressed O 
mostly O 
involved O 
in O 
apoptosis O 
and O 
DNA O 
damage O 
related O 
processes O 
, O 
followed O 
by O 
acetaldehyde B-SYSTEMATIC 
( O 
57 O 
genes O 
) O 
, O 
hydroquinone B-SYSTEMATIC 
( O 
55 O 
genes O 
) O 
and O 
nicotine B-TRIVIAL 
( O 
8 O 
genes O 
) O 
. O 
For O 
acrolein B-TRIVIAL 
and O 
the O 
mixture O 
only O 
one O 
gene O 
was O 
upregulated O 
involved O 
in O 
oxidative O 
stress O 
. O 
No O 
gene O 
expression O 
effect O 
was O 
found O 
for O 
exposure O 
to O 
2,5-dimethylfuran B-SYSTEMATIC 
. O 
Overall O 
, O 
aldehyde B-SYSTEMATIC 
responses O 
are O 
primarily O 
indicative O 
for O 
genotoxicity O 
and O 
oxidative O 
stress O 
. O 
These O 
two O 
toxicity O 
mechanisms O 
are O 
linked O 
to O 
respiratory O 
diseases O 
such O 
as O 
cancer O 
and O 
COPD O 
, O 
respectively O 
. O 
The O 
present O 
findings O 
could O 
be O 
important O 
in O 
providing O 
further O 
understanding O 
of O 
the O 
role O 
of O 
aldehydes B-FAMILY 
emitted O 
from O 
cigarette O 
smoke O 
in O 
the O 
onset O 
of O 
pulmonary O 
diseases O 
. O 

of O 
PAH B-ABBREVIATION 
-DNA O 
adducts O 
in O 
placental O 
tissue O 
and O 
the O 
risk O 
of O 
fetal O 
neural O 
tube O 
defects O 
in O 
a O 
Chinese O 
population O 
. O 

examined O 
the O 
relationship O 
between O 
PAH B-ABBREVIATION 
-DNA O 
adduct O 
levels O 
in O 
the O 
placental O 
tissue O 
, O 
measured O 
by O 
a O 
highly O 
sensitive O 
(32)P B-FORMULA 
-postlabeling O 
assay O 
, O 
and O 
the O 
risk O 
of O 
fetal O 
neural O 
tube O 
defects O 
( O 
NTDs O 
) O 
. O 
We O 
further O 
explored O 
the O 
interaction O 
between O 
PAH B-ABBREVIATION 
-DNA O 
adducts O 
and O 
placental O 
PAHs B-ABBREVIATION 
with O 
respect O 
to O 
NTD O 
risk O 
. O 
Placental O 
tissues O 
from O 
80 O 
NTD-affected O 
pregnancies O 
and O 
50 O 
uncomplicated O 
normal O 
pregnancies O 
were O 
included O 
in O 
this O 
case O 
- O 
control O 
study O 
. O 
Levels O 
of O 
PAH B-ABBREVIATION 
-DNA O 
adducts O 
were O 
lower O 
in O 
the O 
NTD O 
group O 
( O 
8.12 O 
per O 
10(8) O 
nucleotides B-FAMILY 
) O 
compared O 
to O 
controls O 
( O 
9.92 O 
per O 
10(8) O 
nucleotides B-FAMILY 
) O 
. O 
PAH B-ABBREVIATION 
-DNA O 
adduct O 
concentrations O 
below O 
the O 
median O 
was O 
associated O 
with O 
a O 
3-fold O 
increased O 
NTD O 
risk O 
. O 
Women O 
with O 
a O 
low O 
PAH B-ABBREVIATION 
-DNA O 
adduct O 
level O 
in O 
concert O 
with O 
a O 
high O 
placental O 
PAH B-ABBREVIATION 
level O 
resulted O 
in O 
a O 
10-fold O 
elevated O 
risk O 
of O 
having O 
an O 
NTD-complicated O 
pregnancy O 
. O 
A O 
low O 
level O 
of O 
placental O 
PAH B-ABBREVIATION 
-DNA O 
adducts O 
was O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
NTDs O 
; O 
this O 
risk O 
increased O 
dramatically O 
when O 
a O 
low O 
adduct O 
level O 
was O 
coupled O 
with O 
a O 
high O 
placental O 
PAH B-ABBREVIATION 
concentration O 
. O 

proteomic O 
analysis O 
reveals O 
the O 
mode-of O 
- O 
action O 
for O 
chronic O 
mercury B-SYSTEMATIC 
hepatotoxicity O 
to O 
marine O 
medaka O 
( O 
Oryzias O 
melastigma O 
) O 
. O 

( O 
Hg B-FORMULA 
) O 
is O 
a O 
widespread O 
persistent O 
pollutant O 
in O 
aquatic O 
ecosystems O 
. O 
We O 
investigated O 
the O 
protein O 
profiles O 
of O 
medaka O 
( O 
Oryzias O 
melastigma O 
) O 
liver O 
chronically O 
exposed O 
to O 
different O 
mercuric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
HgCl2 B-FORMULA 
) O 
concentrations O 
( O 
1 O 
or O 
10 O 
μg O 
/ O 
L O 
) O 
for O 
60 O 
d O 
using O 
two O 
- O 
dimensional O 
difference O 
gel O 
electrophoresis O 
( O 
2D-DIGE O 
) O 
, O 
as O 
well O 
as O 
cell O 
ultrastructure O 
and O 
Hg B-FORMULA 
content O 
analysis O 
of O 
the O 
hepatic O 
tissue O 
. O 
The O 
results O 
showed O 
that O 
Hg B-FORMULA 
exposure O 
significantly O 
increased O 
metal O 
accumulation O 
in O 
the O 
liver O 
, O 
and O 
subsequently O 
damaged O 
liver O 
ultrastructure O 
. O 
Comparison O 
of O 
the O 
2D-DIGE O 
protein O 
profiles O 
of O 
the O 
exposed O 
and O 
control O 
groups O 
revealed O 
that O 
the O 
abundance O 
of O 
45 O 
protein O 
spots O 
was O 
remarkably O 
altered O 
in O 
response O 
to O 
Hg B-FORMULA 
treatment O 
. O 
The O 
altered O 
spots O 
were O 
subjected O 
to O 
matrix O 
- O 
assisted O 
laser O 
desorption O 
/ O 
ionization O 
tandem O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
analysis O 
, O 
with O 
the O 
resultant O 
identification O 
of O 
33 O 
spots O 
. O 
These O 
proteins O 
were O 
mainly O 
involved O 
in O 
cytoskeleton O 
assembly O 
, O 
oxidative O 
stress O 
, O 
and O 
energy O 
production O 
. O 
Among O 
them O 
, O 
several O 
proteins O 
related O 
to O 
mitochondrial O 
function O 
( O 
e.g O 
. O 
respiratory O 
metabolism O 
) O 
were O 
significantly O 
altered O 
in O 
the O 
treated O 
hepatocytes O 
, O 
implying O 
that O 
this O 
organelle O 
might O 
be O 
the O 
primary O 
target O 
for O 
Hg B-FORMULA 
attack O 
in O 
the O 
cells O 
. O 
This O 
study O 
provided O 
new O 
insights O 
into O 
the O 
molecular O 
mechanisms O 
and O 
/ O 
or O 
toxic O 
pathways O 
by O 
which O 
chronic O 
Hg B-FORMULA 
hepatotoxicity O 
affects O 
aquatic O 
organisms O 
, O 
and O 
also O 
provided O 
basic O 
information O 
for O 
screening O 
potential O 
biomarkers O 
for O 
aquatic O 
Hg B-FORMULA 
monitoring O 
. O 

Rhus O 
verniciflua O 
stem O 
bark O 
( O 
FRVSB O 
) O 
extract O 
, O 
an O 
urushiol B-TRIVIAL 
-free O 
extract O 
of O 
Rhus O 
verniciflua O 
Stokes O 
( O 
RVS O 
) O 
fermented O 
with O 
Fomitella O 
fraxinea O 
, O 
has O 
various O 
biological O 
activities O 
. O 
The O 
present O 
study O 
was O 
carried O 
out O 
to O 
investigate O 
the O 
potential O 
toxicity O 
of O 
the O 
FRVSB O 
extract O 
following O 
single O 
and O 
repeated O 
oral O 
administration O 
to O 
Sprague-Dawley O 
rats O 
. O 
In O 
the O 
single O 
dose O 
toxicity O 
study O 
, O 
the O 
FRVSB O 
extract O 
was O 
administered O 
orally O 
to O 
male O 
and O 
female O 
rats O 
at O 
single O 
doses O 
of O 
0 O 
, O 
2500 O 
, O 
5000 O 
, O 
and O 
10,000mg O 
/ O 
kg O 
. O 
No O 
animals O 
died O 
and O 
no O 
toxic O 
changes O 
were O 
observed O 
in O 
clinical O 
signs O 
, O 
body O 
weight O 
, O 
and O 
necropsy O 
findings O 
during O 
the O 
15-day O 
period O 
following O 
administration O 
. O 
In O 
the O 
repeated O 
dose O 
toxicity O 
study O 
, O 
the O 
FRVSB O 
extract O 
was O 
administered O 
orally O 
to O 
male O 
and O 
female O 
rats O 
for O 
90days O 
at O 
doses O 
of O 
0 O 
, O 
556 O 
, O 
1667 O 
, O 
and O 
5000mg O 
/ O 
kg O 
/ O 
day O 
. O 
There O 
were O 
no O 
treatment O 
- O 
related O 
adverse O 
effects O 
in O 
clinical O 
signs O 
, O 
body O 
weight O 
, O 
food O 
and O 
water O 
consumption O 
, O 
ophthalmic O 
examination O 
, O 
urinalysis O 
, O 
hematology O 
, O 
serum O 
biochemistry O 
, O 
necropsy O 
findings O 
, O 
organ O 
weight O 
, O 
and O 
histopathology O 
at O 
any O 
dose O 
tested O 
. O 
The O 
approximate O 
lethal O 
dose O 
of O 
the O 
FRVSB O 
extract O 
was O 
> O 
10,000mg O 
/ O 
kg O 
in O 
both O 
genders O 
, O 
the O 
oral O 
no O 
- O 
observed O 
- O 
adverse O 
- O 
effect O 
level O 
of O 
the O 
FRVSB O 
extract O 
was O 
> O 
5000mg O 
/ O 
kg O 
/ O 
day O 
in O 
both O 
genders O 
, O 
and O 
no O 
target O 
organs O 
were O 
identified O 
. O 

is O 
a O 
cell O 
self O 
- O 
digestion O 
process O 
via O 
lysosomes O 
that O 
clears O 
" O 
cellular O 
waste O 
" O 
, O 
including O 
aberrantly O 
modified O 
proteins O 
or O 
protein O 
aggregates O 
and O 
damaged O 
organelles O 
. O 
Therefore O 
, O 
autophagy O 
is O 
considered O 
a O 
protein O 
and O 
organelle O 
quality O 
control O 
mechanism O 
that O 
maintains O 
normal O 
cellular O 
homeostasis O 
. O 
Dysfunctional O 
autophagy O 
has O 
been O 
observed O 
in O 
ageing O 
tissues O 
and O 
several O 
ageing O 
- O 
associated O 
diseases O 
. O 
Lifespan O 
of O 
model O 
organisms O 
such O 
as O 
yeast O 
, O 
worms O 
, O 
flies O 
, O 
and O 
mice O 
can O 
be O 
extended O 
through O 
promoting O 
autophagy O 
, O 
either O 
by O 
genetic O 
manipulations O 
such O 
as O 
over O 
- O 
expression O 
of O 
Sirtuin O 
1 O 
, O 
or O 
by O 
administrations O 
of O 
rapamycin B-TRIVIAL 
, O 
resveratrol B-TRIVIAL 
or O 
spermidine B-TRIVIAL 
. O 
The O 
evidence O 
supports O 
that O 
autophagy O 
may O 
play O 
an O 
important O 
role O 
in O 
delaying O 
ageing O 
or O 
extending O 
lifespan O 
. O 
In O 
this O 
review O 
, O 
we O 
summarize O 
the O 
current O 
knowledge O 
about O 
autophagy O 
and O 
its O 
regulation O 
, O 
outline O 
recent O 
developments O 
ie O 
the O 
genetic O 
and O 
pharmacological O 
manipulations O 
of O 
autophagy O 
that O 
affects O 
the O 
lifespan O 
, O 
and O 
discuss O 
the O 
role O 
of O 
autophagy O 
in O 
the O 
ageing O 
- O 
related O 
diseases O 
. O 

androgen B-FAMILY 
during O 
puberty O 
disrupts O 
circadian O 
organization O 
in O 
female O 
rats O 
. O 

clocks O 
have O 
been O 
described O 
in O 
each O 
tissue O 
of O 
the O 
hypothalamo O 
- O 
pituitary O 
- O 
ovarian O 
axis O 
. O 
Although O 
a O 
role O 
for O 
the O 
clock O 
in O 
the O 
timing O 
of O 
ovulation O 
is O 
indicated O 
, O 
the O 
impact O 
of O 
diseases O 
that O 
disrupt O 
fertility O 
on O 
clock O 
function O 
or O 
the O 
clocks O 
' O 
role O 
in O 
the O 
etiology O 
of O 
these O 
pathologies O 
has O 
yet O 
to O 
be O 
fully O 
appreciated O 
. O 
Polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
is O 
a O 
particularly O 
devastating O 
endocrinopathy O 
, O 
affecting O 
approximately O 
10% O 
of O 
women O 
at O 
childbearing O 
age O 
. O 
Common O 
features O 
of O 
PCOS O 
are O 
a O 
polycystic O 
ovary O 
, O 
amenorrhea O 
, O 
and O 
excess O 
serum O 
androgen B-FAMILY 
. O 
Approximately O 
40% O 
of O 
these O 
women O 
have O 
metabolic O 
syndrome O 
, O 
including O 
hyperinsulinemia O 
, O 
dyslipidemia O 
, O 
and O 
hyperleptinemia O 
. O 
It O 
has O 
been O 
suggested O 
that O 
excess O 
androgen B-FAMILY 
is O 
a O 
critical O 
factor O 
in O 
the O 
etiology O 
of O 
PCOS O 
. O 
We O 
have O 
examined O 
the O 
effects O 
of O 
androgen B-FAMILY 
excess O 
during O 
puberty O 
on O 
the O 
phase O 
of O 
circadian O 
clocks O 
in O 
tissues O 
of O 
the O 
metabolic O 
and O 
hypothalamo O 
- O 
pituitary O 
- O 
ovarian O 
axes O 
. O 
Female O 
period1-luciferase O 
( O 
per1-luc O 
) O 
rats O 
were O 
exposed O 
to O 
androgen B-FAMILY 
( O 
5α-dihydrotestosterone B-SYSTEMATIC 
[ O 
DHT B-ABBREVIATION 
] O 
) O 
or O 
placebo O 
for O 
4-6 O 
weeks O 
( O 
short O 
term O 
) O 
or O 
9- O 
15 O 
weeks O 
( O 
long O 
term O 
) O 
. O 
As O 
expected O 
, O 
DHT B-ABBREVIATION 
-treated O 
animals O 
gained O 
more O 
weight O 
than O 
controls O 
and O 
had O 
disrupted O 
estrous O 
cycles O 
. O 
At O 
the O 
end O 
of O 
treatment O 
, O 
tissues O 
, O 
including O 
the O 
liver O 
, O 
lung O 
, O 
kidney O 
, O 
white O 
adipose O 
, O 
cornea O 
, O 
pituitary O 
, O 
oviduct O 
, O 
and O 
ovarian O 
follicles O 
, O 
were O 
cultured O 
, O 
and O 
per1-luc O 
expression O 
in O 
each O 
was O 
recorded O 
. O 
Analysis O 
of O 
per1-luc O 
expression O 
revealed O 
that O 
DHT B-ABBREVIATION 
exposure O 
increased O 
phase O 
distribution O 
of O 
multiple O 
oscillators O 
, O 
including O 
ovarian O 
follicles O 
, O 
liver O 
, O 
and O 
adipose O 
, O 
and O 
altered O 
phase O 
synchrony O 
between O 
animals O 
. O 
These O 
data O 
suggest O 
that O 
excess O 
androgen B-FAMILY 
during O 
puberty O 
, O 
a O 
common O 
feature O 
of O 
PCOS O 
, O 
negatively O 
affects O 
internal O 
circadian O 
organization O 
in O 
both O 
the O 
reproductive O 
and O 
metabolic O 
axes O 
. O 

population O 
- O 
level O 
HC5 O 
for O 
copper B-SYSTEMATIC 
using O 
a O 
species O 
sensitivity O 
distribution O 
approach O 
. O 

of O 
population O 
- O 
level O 
benchmark O 
concentrations O 
for O 
protecting O 
aquatic O 
organisms O 
from O 
chemicals O 
is O 
important O 
for O 
value O 
- O 
relevant O 
ecological O 
risk O 
assessments O 
. O 
By O 
employing O 
a O 
species O 
sensitivity O 
distribution O 
( O 
SSD O 
) O 
approach O 
, O 
the O 
authors O 
aimed O 
to O 
derive O 
the O 
population O 
- O 
level O 
hazardous O 
concentration O 
for O 
5% O 
of O 
species O 
( O 
PHC5 O 
) O 
for O 
copper B-SYSTEMATIC 
. O 
Based O 
on O 
available O 
information O 
on O 
copper B-SYSTEMATIC 
toxicity O 
and O 
population O 
models O 
, O 
the O 
authors O 
estimated O 
population O 
threshold O 
concentrations O 
at O 
which O 
the O 
population O 
size O 
is O 
stable O 
( O 
that O 
is O 
, O 
0 O 
net O 
population O 
growth O 
) O 
for O 
13 O 
freshwater O 
species O 
( O 
3 O 
algal O 
, O 
6 O 
invertebrate O 
, O 
and O 
4 O 
fish O 
species O 
) O 
. O 
The O 
PHC5 O 
for O 
copper B-SYSTEMATIC 
was O 
then O 
estimated O 
( O 
6.8 O 
µg O 
/ O 
L O 
; O 
95% O 
confidence O 
interval O 
[ O 
CI O 
] O 
, O 
1.8-13.6 O 
µg O 
/ O 
L O 
) O 
, O 
by O 
fitting O 
a O 
log O 
- O 
normal O 
distribution O 
to O 
the O 
population O 
threshold O 
concentrations O 
obtained O 
. O 
The O 
close O 
overlap O 
between O 
the O 
present O 
study's O 
estimate O 
of O 
the O 
PHC5 O 
and O 
a O 
field O 
- O 
derived O 
threshold O 
concentration O 
suggests O 
that O 
the O 
population O 
- O 
level O 
SSD O 
approach O 
provides O 
a O 
reasonable O 
level O 
of O 
protection O 
for O 
species O 
richness O 
in O 
the O 
natural O 
environment O 
. O 
By O 
contrast O 
, O 
and O 
counterintuitively O 
, O 
the O 
authors O 
' O 
estimate O 
was O 
comparable O 
with O 
the O 
individual O 
- O 
level O 
HC5 O 
reported O 
in O 
the O 
European O 
Union O 
risk O 
assessment O 
. O 
Although O 
the O 
present O 
study O 
cannot O 
determine O 
the O 
underlying O 
reasons O 
for O 
the O 
similar O 
figures O 
, O 
the O 
result O 
provides O 
an O 
indication O 
that O 
the O 
margin O 
between O 
individual O 
- O 
level O 
and O 
population O 
- O 
level O 
benchmarks O 
derived O 
from O 
SSD O 
approaches O 
can O 
be O 
very O 
small O 
. O 
The O 
results O 
therefore O 
suggest O 
that O 
attention O 
is O 
needed O 
to O 
achieve O 
population O 
- O 
level O 
protection O 
using O 
an O 
individual O 
- O 
level O 
SSD O 
approach O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1396-1402 O 
. O 
© O 
2013 O 
SETAC O 
. O 

of O 
mercury B-SYSTEMATIC 
speciation O 
in O 
fish O 
tissue O 
with O 
a O 
direct O 
mercury B-SYSTEMATIC 
analyzer O 
. O 

of O 
Hg B-FORMULA 
speciation O 
in O 
tissue O 
is O 
valuable O 
for O 
assessing O 
potential O 
toxicological O 
effects O 
in O 
fish O 
. O 
Direct O 
Hg B-FORMULA 
analyzers O 
, O 
which O 
use O 
thermal O 
decomposition O 
and O 
atomic O 
absorption O 
spectrometry O 
, O 
have O 
recently O 
gained O 
popularity O 
for O 
determining O 
organic O 
Hg B-FORMULA 
after O 
procedural O 
solvent O 
extraction O 
from O 
some O 
environmental O 
media O 
, O 
although O 
quantitative O 
recovery O 
from O 
lipid O 
- O 
rich O 
materials O 
, O 
such O 
as O 
fish O 
liver O 
, O 
has O 
been O 
problematic O 
. O 
The O 
authors O 
developed O 
a O 
new O 
method O 
by O 
which O 
organic O 
Hg B-FORMULA 
in O 
fish O 
liver O 
and O 
muscle O 
is O 
estimated O 
by O 
the O 
difference O 
between O 
direct O 
measurements O 
of O 
inorganic O 
Hg B-FORMULA 
in O 
an O 
acid O 
extract O 
and O 
total O 
Hg B-FORMULA 
in O 
whole O 
tissue O 
. O 
The O 
method O 
was O 
validated O 
by O 
analysis O 
of O 
a O 
certified O 
reference O 
material O 
( O 
DOLT-4 O 
dogfish O 
liver O 
) O 
and O 
naturally O 
contaminated O 
fish O 
tissues O 
with O 
comparison O 
to O 
an O 
established O 
Hg B-FORMULA 
speciation O 
method O 
( O 
gas O 
chromatography O 
cold O 
vapor O 
atomic O 
fluorescence O 
spectrometry O 
) O 
. O 
Recovery O 
of O 
organic O 
Hg B-FORMULA 
from O 
DOLT-4 O 
, O 
estimated O 
by O 
difference O 
, O 
averaged O 
99 O 
± O 
5% O 
of O 
the O 
mean O 
certified O 
value O 
for O 
methylmercury B-SYSTEMATIC 
. O 
In O 
most O 
liver O 
samples O 
and O 
all O 
muscle O 
samples O 
, O 
estimates O 
of O 
organic O 
Hg B-FORMULA 
from O 
the O 
proposed O 
method O 
were O 
indiscernible O 
from O 
direct O 
speciation O 
measurements O 
of O 
methylmercury B-SYSTEMATIC 
( O 
99% O 
± O 
6% O 
) O 
. O 
Estimation O 
of O 
organic O 
Hg B-FORMULA 
by O 
the O 
difference O 
between O 
total O 
Hg B-FORMULA 
and O 
inorganic O 
Hg B-FORMULA 
was O 
less O 
accurate O 
in O 
liver O 
samples O 
with O 
a O 
high O 
percentage O 
of O 
inorganic O 
Hg B-FORMULA 
( O 
90% O 
) O 
. O 
This O 
was O 
because O 
of O 
the O 
increased O 
uncertainty O 
that O 
results O 
from O 
estimating O 
a O 
third O 
value O 
( O 
i.e O 
. O 
, O 
organic O 
Hg B-FORMULA 
) O 
by O 
using O 
the O 
difference O 
between O 
two O 
large O 
concentrations O 
( O 
inorganic O 
and O 
total O 
Hg B-FORMULA 
) O 
. O 
The O 
proposed O 
method O 
is O 
a O 
useful O 
tool O 
for O 
examining O 
the O 
speciation O 
of O 
Hg B-FORMULA 
in O 
fish O 
muscle O 
and O 
liver O 
, O 
and O 
by O 
extension O 
, O 
potentially O 
other O 
tissues O 
and O 
environmental O 
media O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1237-1241 O 
. O 
© O 
2013 O 
SETAC O 
. O 

Nanostructured O 
Materials O 
via O 
Direct O 
Reaction O 
of O 
Functionalized O 
Catechols B-FAMILY 
. O 

facile O 
one O 
- O 
step O 
polymerization O 
strategy O 
is O 
explored O 
to O 
achieve O 
novel O 
catechol B-TRIVIAL 
-based O 
materials O 
. O 
Depending O 
on O 
the O 
functionality O 
of O 
the O 
catechol B-TRIVIAL 
, O 
the O 
as-prepared O 
product O 
can O 
be O 
used O 
to O 
modify O 
at O 
will O 
the O 
surface O 
tension O 
of O 
nano O 
and O 
bulk O 
structures O 
, O 
from O 
oleo- O 
/ O 
hydrophobic O 
to O 
highly O 
hydrophilic O 
. O 
A O 
hydrophobic O 
catechol B-TRIVIAL 
prepared O 
thus O 
polymerized O 
shows O 
the O 
ability O 
to O 
self O 
- O 
assemble O 
as O 
solid O 
nanoparticles O 
with O 
sticky O 
properties O 
in O 
polar O 
solvent O 
media O 
. O 
Such O 
a O 
versatile O 
concept O 
is O 
ideal O 
for O 
the O 
development O 
of O 
catechol B-TRIVIAL 
-based O 
multifunctional O 
materials O 
. O 

insights O 
into O 
the O 
recovery O 
of O 
aldolase O 
activity O 
in O 
N-acetylneuraminic B-SYSTEMATIC 
acid I-SYSTEMATIC 
lyase O 
by O 
replacement O 
of O 
the O 
catalytically O 
active O 
lysine B-TRIVIAL 
with O 
γ-thialysine B-SYSTEMATIC 
by O 
using O 
a O 
chemical O 
mutagenesis O 
strategy O 
. O 

modification O 
has O 
been O 
used O 
to O 
introduce O 
the O 
unnatural O 
amino B-FAMILY 
acid I-FAMILY 
γ-thialysine B-SYSTEMATIC 
in O 
place O 
of O 
the O 
catalytically O 
important O 
Lys B-FORMULA 
165 O 
in O 
the O 
enzyme O 
N-acetylneuraminic B-SYSTEMATIC 
acid I-SYSTEMATIC 
lyase O 
( O 
NAL O 
) O 
. O 
The O 
Staphylococcus O 
aureus O 
nanA O 
gene O 
, O 
encoding O 
NAL O 
, O 
was O 
cloned O 
and O 
expressed O 
in O 
E O 
. O 
coli O 
. O 
The O 
protein O 
, O 
purified O 
in O 
high O 
yield O 
, O 
has O 
all O 
the O 
properties O 
expected O 
of O 
a O 
class O 
I O 
NAL O 
. O 
The O 
S O 
. O 
aureus O 
NAL O 
which O 
contains O 
no O 
natural O 
cysteine B-TRIVIAL 
residues O 
was O 
subjected O 
to O 
site O 
- O 
directed O 
mutagenesis O 
to O 
introduce O 
a O 
cysteine B-TRIVIAL 
in O 
place O 
of O 
Lys B-FORMULA 
165 O 
in O 
the O 
enzyme O 
active O 
site O 
. O 
Subsequently O 
chemical O 
mutagenesis O 
completely O 
converted O 
the O 
cysteine B-TRIVIAL 
into O 
γ-thialysine B-SYSTEMATIC 
through O 
dehydroalanine B-SYSTEMATIC 
( O 
Dha B-ABBREVIATION 
) O 
as O 
demonstrated O 
by O 
ESI-MS O 
. O 
Initial O 
kinetic O 
characterisation O 
showed O 
that O 
the O 
protein O 
containing O 
γ-thialysine B-SYSTEMATIC 
regained O 
17 O 
% O 
of O 
the O 
wild O 
- O 
type O 
activity O 
. O 
To O 
understand O 
the O 
reason O 
for O 
this O 
lower O 
activity O 
, O 
we O 
solved O 
X-ray O 
crystal O 
structures O 
of O 
the O 
wild O 
- O 
type O 
S O 
. O 
aureus O 
NAL O 
, O 
both O 
in O 
the O 
absence O 
of O 
, O 
and O 
in O 
complex O 
with O 
, O 
pyruvate B-TRIVIAL 
. O 
We O 
also O 
report O 
the O 
structures O 
of O 
the O 
K165C O 
variant O 
, O 
and O 
the O 
K165- O 
γ-thialysine B-SYSTEMATIC 
enzyme O 
in O 
the O 
presence O 
, O 
or O 
absence O 
, O 
of O 
pyruvate B-TRIVIAL 
. O 
These O 
structures O 
reveal O 
that O 
γ-thialysine B-SYSTEMATIC 
in O 
NAL O 
is O 
an O 
excellent O 
structural O 
mimic O 
of O 
lysine B-TRIVIAL 
. O 
Measurement O 
of O 
the O 
pH-activity O 
profile O 
of O 
the O 
thialysine B-SYSTEMATIC 
modified O 
enzyme O 
revealed O 
that O 
its O 
pH O 
optimum O 
is O 
shifted O 
from O 
7.4 O 
to O 
6.8 O 
. O 
At O 
its O 
optimum O 
pH O 
, O 
the O 
thialysine B-SYSTEMATIC 
-containing O 
enzyme O 
showed O 
almost O 
30 O 
% O 
of O 
the O 
activity O 
of O 
the O 
wild O 
- O 
type O 
enzyme O 
at O 
its O 
pH O 
optimum O 
. O 
The O 
lowered O 
activity O 
and O 
altered O 
pH O 
profile O 
of O 
the O 
unnatural O 
amino B-FAMILY 
acid I-FAMILY 
-containing O 
enzyme O 
can O 
be O 
rationalised O 
by O 
imbalances O 
of O 
the O 
ionisation O 
states O 
of O 
residues O 
within O 
the O 
active O 
site O 
when O 
the O 
pK(a) O 
of O 
the O 
residue O 
at O 
position O 
165 O 
is O 
perturbed O 
by O 
replacement O 
with O 
γ-thialysine B-SYSTEMATIC 
. O 
The O 
results O 
reveal O 
the O 
utility O 
of O 
chemical O 
mutagenesis O 
for O 
the O 
modification O 
of O 
enzyme O 
active O 
sites O 
and O 
the O 
exquisite O 
sensitivity O 
of O 
catalysis O 
to O 
the O 
local O 
structural O 
and O 
electrostatic O 
environment O 
in O 
NAL O 
. O 

and O 
bird O 
eggs O 
are O 
priority O 
samples O 
for O 
specimen O 
banking O 
programs O 
that O 
assess O 
spatial O 
and O 
temporal O 
trends O 
of O 
environmental O 
contaminants O 
. O 
From O 
endangered O 
species O 
, O 
such O 
as O 
sea O 
turtles O 
, O 
nonlethal O 
sampling O 
is O 
required O 
( O 
e.g O 
. O 
, O 
unhatched O 
eggs O 
collected O 
postemergence O 
) O 
. O 
Previous O 
contaminant O 
monitoring O 
studies O 
have O 
used O 
unhatched O 
sea O 
turtle O 
eggs O 
, O 
but O 
no O 
study O 
has O 
tested O 
whether O 
their O 
concentrations O 
represent O 
levels O 
found O 
in O 
fresh O 
eggs O 
( O 
e.g O 
. O 
, O 
eggs O 
collected O 
within O 
24 O 
h O 
of O 
oviposition O 
) O 
. O 
The O 
author O 
analyzed O 
three O 
fresh O 
eggs O 
from O 
different O 
nest O 
depths O 
and O 
up O 
to O 
three O 
unhatched O 
eggs O 
from O 
10 O 
loggerhead O 
sea O 
turtle O 
( O 
Caretta O 
caretta O 
) O 
nests O 
in O 
South O 
Carolina O 
, O 
USA O 
, O 
for O 
a O 
suite O 
of O 
persistent O 
organic O 
pollutants O 
( O 
POPs O 
) O 
. O 
Lipid O 
- O 
normalized O 
POP O 
concentrations O 
were O 
not O 
significantly O 
different O 
( O 
p O 
> O 
0.05 O 
) O 
between O 
fresh O 
and O 
unhatched O 
eggs O 
or O 
among O 
different O 
depths O 
from O 
the O 
same O 
nest O 
. O 
The O 
POP O 
concentrations O 
in O 
loggerhead O 
eggs O 
from O 
South O 
Carolina O 
were O 
higher O 
than O 
previously O 
measured O 
concentrations O 
in O 
eggs O 
from O 
Florida O 
and O 
slightly O 
lower O 
than O 
concentrations O 
in O 
eggs O 
from O 
North O 
Carolina O 
. O 
This O 
pattern O 
agrees O 
with O 
previously O 
observed O 
trends O 
of O 
increasing O 
POP O 
concentrations O 
in O 
loggerhead O 
turtles O 
inhabiting O 
northern O 
latitudes O 
along O 
the O 
U.S O 
. O 
East O 
Coast O 
. O 
Contaminant O 
profiles O 
are O 
discussed O 
, O 
including O 
a O 
higher O 
chlorinated O 
pattern O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
possibly O 
associated O 
with O 
a O 
Superfund O 
site O 
in O 
nearby O 
Brunswick O 
, O 
Georgia O 
, O 
USA O 
, O 
and O 
unusual O 
polybrominated B-FAMILY 
diphenylether I-FAMILY 
patterns O 
seen O 
in O 
this O 
and O 
previous O 
sea O 
turtle O 
studies O 
. O 
Concentrations O 
correlated O 
with O 
one O 
of O 
eight O 
measurements O 
of O 
reproductive O 
success O 
; O 
levels O 
were O 
negatively O 
correlated O 
with O 
egg O 
mass O 
( O 
p O 
< O 
0.05 O 
) O 
, O 
which O 
may O 
have O 
implications O 
for O 
hatchling O 
fitness O 
. O 
The O 
present O 
study O 
suggests O 
that O 
unhatched O 
eggs O 
can O 
be O 
used O 
for O 
POP-monitoring O 
projects O 
. O 

exposure O 
to O 
bisphenol B-TRIVIAL 
a I-TRIVIAL 
alters O 
cardiac O 
structure O 
/ O 
function O 
, O 
protein O 
expression O 
, O 
and O 
DNA O 
methylation O 
in O 
adult O 
mice O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
an O 
estrogenizing O 
endocrine O 
disruptor O 
compound O 
of O 
concern O 
. O 
Our O 
objective O 
was O 
to O 
test O 
whether O 
lifelong O 
BPA B-ABBREVIATION 
would O 
impact O 
cardiac O 
structure O 
/ O 
function O 
, O 
calcium B-SYSTEMATIC 
homeostasis O 
protein O 
expression O 
, O 
and O 
the O 
DNA O 
methylation O 
of O 
cardiac O 
genes O 
. O 
We O 
delivered O 
0.5 O 
and O 
5 O 
µg O 
/ O 
kg O 
/ O 
day O 
BPA B-ABBREVIATION 
lifelong O 
from O 
gestation O 
day O 
11 O 
or O 
200 O 
µg O 
/ O 
kg O 
/ O 
day O 
from O 
gestation O 
day O 
11 O 
to O 
postnatal O 
day O 
21 O 
via O 
the O 
drinking O 
water O 
to O 
C57bl O 
/ O 
6n O 
mice O 
. O 
BPA B-ABBREVIATION 
5 O 
males O 
and O 
females O 
had O 
increased O 
body O 
weight O 
, O 
body O 
mass O 
index O 
, O 
body O 
surface O 
area O 
, O 
and O 
adiposity O 
. O 
Echocardiography O 
identified O 
concentric O 
remodeling O 
in O 
all O 
BPA B-ABBREVIATION 
-treated O 
males O 
. O 
Systolic O 
and O 
diastolic O 
cardiac O 
functions O 
were O 
essentially O 
similar O 
, O 
but O 
lifelong O 
BPA B-ABBREVIATION 
enhanced O 
male O 
and O 
reduced O 
female O 
sex O 
- O 
specific O 
differences O 
in O 
velocity O 
of O 
circumferential O 
shortening O 
and O 
ascending O 
aorta O 
velocity O 
time O 
integral O 
. O 
Diastolic O 
blood O 
pressure O 
was O 
increased O 
in O 
all O 
BPA B-ABBREVIATION 
females O 
. O 
The O 
calcium B-SYSTEMATIC 
homeostasis O 
proteins O 
sarcoendoplasmic O 
reticulum O 
ATPase O 
2a O 
( O 
SERCA2a O 
) O 
, O 
sodium B-SYSTEMATIC 
calcium B-SYSTEMATIC 
exchanger-1 O 
, O 
phospholamban O 
( O 
PLB O 
) O 
, O 
phospho B-SYSTEMATIC 
-PLB O 
, O 
and O 
calsequestrin O 
2 O 
are O 
important O 
for O 
contraction O 
and O 
relaxation O 
. O 
Changes O 
in O 
their O 
expression O 
suggest O 
increased O 
calcium B-SYSTEMATIC 
mobility O 
in O 
males O 
and O 
reduced O 
calcium B-SYSTEMATIC 
mobility O 
in O 
females O 
supporting O 
the O 
cardiac O 
function O 
changes O 
. O 
DNA O 
methyltransferase O 
3a O 
expression O 
was O 
increased O 
in O 
all O 
BPA B-ABBREVIATION 
males O 
and O 
BPA B-ABBREVIATION 
0.5 O 
females O 
and O 
reduced O 
in O 
BPA B-ABBREVIATION 
200 O 
females O 
. O 
Global O 
DNA O 
methylation O 
was O 
increased O 
in O 
BPA B-ABBREVIATION 
0.5 O 
males O 
and O 
reduced O 
in O 
BPA B-ABBREVIATION 
0.5 O 
females O 
. O 
BPA B-ABBREVIATION 
induced O 
sex O 
- O 
specific O 
altered O 
DNA O 
methylation O 
in O 
specific O 
CpG B-ABBREVIATION 
pairs O 
in O 
the O 
calsequestrin O 
2 O 
CpG O 
island O 
. O 
These O 
results O 
suggest O 
that O 
continual O 
exposure O 
to O 
BPA B-ABBREVIATION 
impacts O 
cardiac O 
structure O 
/ O 
function O 
, O 
protein O 
expression O 
, O 
and O 
epigenetic O 
DNA O 
methylation O 
marks O 
in O 
males O 
and O 
females O 
. O 

date O 
, O 
peroxisome O 
proliferator O 
- O 
activated O 
receptors O 
( O 
PPARs O 
) O 
are O 
becoming O 
the O 
new O 
therapeutic O 
targets O 
for O 
the O 
treatment O 
of O 
metabolic O 
diseases O 
, O 
such O 
as O 
Type O 
2 O 
diabetes O 
, O 
obesity O 
, O 
and O 
cardiovascular O 
disease O 
. O 
In O 
this O 
study O 
, O 
a O 
cell O 
- O 
based O 
high O 
- O 
throughput O 
PPARs O 
( O 
PPARα O 
/ O 
β O 
/ O 
γ O 
) O 
model O 
was O 
developed O 
for O 
the O 
screening O 
of O 
PPARs O 
agonists O 
. O 
The O 
screening O 
conditions O 
were O 
evaluated O 
through O 
analyzing O 
the O 
expression O 
value O 
of O 
luciferase O 
. O 
Finally O 
, O 
24 O 
h O 
of O 
drug O 
acting O 
time O 
, O 
5 O 
times O 
of O 
the O 
dilution O 
factor O 
of O 
luciferase O 
zymolyte O 
, O 
and O 
about O 
2 O 
× O 
10(4) O 
cells/ O 
well O 
on O 
HeLa O 
cells O 
in O 
96-well O 
plates O 
were O 
used O 
, O 
respectively O 
. O 
Furthermore O 
, O 
the O 
quality O 
of O 
high O 
- O 
throughput O 
screening O 
( O 
HTS O 
) O 
in O 
stability O 
and O 
reliability O 
was O 
evaluated O 
by O 
the O 
Z'-factor O 
. O 
Additionally O 
, O 
different O 
extracts O 
of O 
Rhizoma O 
Coptis O 
and O 
berberine B-TRIVIAL 
were O 
tested O 
by O 
the O 
developed O 
method O 
. O 
The O 
results O 
suggested O 
that O 
both O 
the O 
EtOAc B-FORMULA 
extract O 
and O 
berberine B-TRIVIAL 
were O 
able O 
to O 
activate O 
PPARα O 
/ O 
β O 
/ O 
γ O 
, O 
and O 
Rhizoma O 
Coptis O 
contains O 
potential O 
natural O 
agonists O 
of O 
PPARs O 
besides O 
berberine B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
the O 
developed O 
HTS O 
assay O 
is O 
a O 
simple O 
, O 
rapid O 
, O 
stable O 
, O 
and O 
specific O 
method O 
for O 
the O 
screening O 
of O 
PPARs O 
natural O 
agonists O 
. O 

attenuates O 
myocardial O 
ischemia O 
- O 
reperfusion O 
injury O 
via O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
. O 

investigate O 
the O 
cardioprotective O 
effects O 
of O 
salidroside B-TRIVIAL 
on O 
myocardial O 
ischemia O 
- O 
reperfusion O 
injury O 
( O 
IRI O 
) O 
in O 
rabbits O 
and O 
the O 
underlying O 
action O 
mechanisms O 
in O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
, O 
a O 
rabbit O 
ischemia O 
/ O 
reperfusion O 
model O 
was O 
created O 
by O 
ligating O 
the O 
left O 
anterior O 
descending O 
coronary O 
arterial O 
branch O 
for O 
30 O 
min O 
and O 
by O 
releasing O 
the O 
ligature O 
to O 
allow O 
reperfusion O 
for O 
120 O 
min O 
. O 
Salidroside B-TRIVIAL 
or O 
salidroside B-TRIVIAL 
+ O 
PI3K O 
inhibitor O 
( O 
LY294002 B-IDENTIFIER 
) O 
was O 
administered O 
via O 
intracoronary O 
injections O 
at O 
the O 
onset O 
of O 
reperfusion O 
. O 
Apoptosis O 
of O 
cardiomyocytes O 
was O 
assessed O 
by O 
terminal O 
dUTP B-ABBREVIATION 
nick O 
- O 
end O 
labeling O 
assay O 
, O 
and O 
the O 
expression O 
of O 
apoptosis O 
- O 
related O 
proteins O 
was O 
observed O 
by O 
immunohistochemistry O 
. O 
The O 
expressions O 
of O 
total O 
Akt O 
and O 
phosphorylated O 
Akt O 
( O 
p-Akt O 
) O 
were O 
detected O 
by O 
western O 
blot O 
analysis O 
. O 
The O 
results O 
showed O 
that O 
intracoronary O 
injection O 
of O 
salidroside B-TRIVIAL 
at O 
the O 
onset O 
of O 
reperfusion O 
markedly O 
reduced O 
the O 
apoptosis O 
of O 
cardiomyocytes O 
, O 
significantly O 
increasing O 
Bcl-2 O 
and O 
p-Akt O 
proteins O 
expressions O 
and O 
decreasing O 
Bax O 
and O 
caspase-3 O 
expressions O 
in O 
the O 
hearts O 
subjected O 
to O 
ischemia O 
followed O 
by O 
120-min O 
reperfusion O 
. O 
However O 
, O 
the O 
anti-apoptotic O 
effect O 
induced O 
by O 
salidroside B-TRIVIAL 
was O 
inhibited O 
by O 
LY294002 B-IDENTIFIER 
, O 
which O 
blocked O 
the O 
activation O 
of O 
Akt O 
. O 
These O 
results O 
suggested O 
that O 
intracoronary O 
administration O 
of O 
salidroside B-TRIVIAL 
at O 
the O 
onset O 
of O 
reperfusion O 
could O 
significantly O 
reduce O 
the O 
IRI-induced O 
apoptosis O 
of O 
cardiomyocytes O 
, O 
and O 
this O 
protective O 
mechanism O 
seemed O 
to O 
be O 
mediated O 
by O 
the O 
PI3K-Akt O 
signaling O 
pathway O 
. O 

new O 
antibacterial O 
denitroaristolochic B-TRIVIAL 
acid I-TRIVIAL 
from O 
the O 
tubers O 
of O 
Stephania O 
succifera O 
. O 

new O 
denitroaristolochic B-TRIVIAL 
acid I-TRIVIAL 
, O 
demethylaristofolin B-SYSTEMATIC 
C I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
together O 
with O 
six O 
known O 
alkaloids O 
, O 
crebanine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
(-)-sukhodianine-β-N-oxide B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
palmatine B-TRIVIAL 
( O 
4 O 
) O 
, O 
corydalmine B-TRIVIAL 
( O 
5 O 
) O 
, O 
dehydrocorydalmine B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
and O 
corynoxidine B-TRIVIAL 
( O 
7 O 
) O 
, O 
was O 
isolated O 
from O 
the O 
tubers O 
of O 
Stephania O 
succifera O 
. O 
The O 
structure O 
of O 
demethylaristofolin B-SYSTEMATIC 
C I-SYSTEMATIC 
was O 
elucidated O 
by O 
spectroscopic O 
techniques O 
( O 
UV O 
, O 
IR O 
, O 
1D O 
, O 
and O 
2D O 
NMR O 
) O 
and O 
HR-ESI-MS O 
analyses O 
. O 
These O 
compounds O 
exhibited O 
antibacterial O 
activities O 
against O 
Staphylococcus O 
aureus O 
and O 
methicillin B-TRIVIAL 
-resistant O 
S O 
. O 
aureus O 
strains O 
in O 
different O 
degrees O 
. O 

and O 
characterization O 
of O 
progesterone B-TRIVIAL 
dispersions O 
using O 
supercritical O 
carbon B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
. O 

Context O 
: O 
Supercritical O 
fluid O 
methods O 
offer O 
an O 
alternative O 
to O 
conventional O 
mixing O 
methods O 
, O 
particularly O 
for O 
heat O 
sensitive O 
drugs O 
and O 
where O 
an O 
organic O 
solvent O 
is O 
undesirable O 
. O 
Objective O 
: O 
To O 
design O 
, O 
develop O 
and O 
construct O 
a O 
unit O 
for O 
the O 
particles O 
from O 
a O 
gas O 
- O 
saturated O 
suspension O 
/ O 
solution O 
( O 
PGSS O 
) O 
method O 
and O 
form O 
endogenous O 
progesterone B-TRIVIAL 
( O 
PGN B-ABBREVIATION 
) O 
dispersion O 
systems O 
using O 
SC- O 
CO(2) B-FORMULA 
. O 
Materials O 
and O 
methods O 
: O 
The O 
PGN B-ABBREVIATION 
dispersions O 
were O 
manufactured O 
using O 
three O 
selected O 
excipients O 
: O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
400 O 
/ O 
4000 O 
( O 
50 O 
: O 
50 O 
) O 
, O 
Gelucire B-TRIVIAL 
44 O 
/ O 
14 O 
and O 
D-α-tocopheryl B-SYSTEMATIC 
PEG I-SYSTEMATIC 
1000 I-SYSTEMATIC 
succinate I-SYSTEMATIC 
( O 
TPGS B-ABBREVIATION 
) O 
. O 
Semisolid O 
dispersions O 
of O 
PGN B-ABBREVIATION 
prepared O 
by O 
PGSS O 
method O 
were O 
compared O 
to O 
the O 
conventional O 
methods O 
; O 
comelting O 
( O 
CM O 
) O 
, O 
cosolvent O 
( O 
CS O 
) O 
and O 
physical O 
mixing O 
( O 
PM O 
) O 
. O 
The O 
dispersion O 
systems O 
made O 
were O 
characterized O 
by O 
Raman O 
and O 
Fourier O 
transform O 
infrared O 
( O 
FTIR O 
) O 
spectroscopies O 
, O 
X-ray O 
powder O 
diffraction O 
( O 
XRPD O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
PGN B-ABBREVIATION 
recovery O 
, O 
uniformity O 
and O 
in O 
vitro O 
dissolution O 
, O 
analyzed O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
. O 
Results O 
: O 
Raman O 
spectra O 
revealed O 
no O 
changes O 
in O 
the O 
crystalline O 
structure O 
of O 
PGN B-ABBREVIATION 
treated O 
with O 
SC- O 
CO(2) B-FORMULA 
compared O 
to O 
that O 
of O 
untreated O 
PGN B-ABBREVIATION 
. O 
XRPD O 
and O 
FTIR O 
showed O 
the O 
presence O 
of O 
peaks O 
and O 
bands O 
for O 
PGN B-ABBREVIATION 
confirming O 
that O 
PGN B-ABBREVIATION 
has O 
been O 
incorporated O 
well O 
with O 
each O 
individual O 
excipient O 
. O 
All O 
PGN B-ABBREVIATION 
dispersions O 
prepared O 
by O 
the O 
PGSS O 
method O 
resulted O 
in O 
the O 
improvement O 
of O 
PGN B-ABBREVIATION 
dissolution O 
rates O 
compared O 
to O 
that O 
prepared O 
by O 
the O 
conventional O 
methods O 
and O 
untreated O 
PGN B-ABBREVIATION 
after O 
60 O 
min O 
( O 
p O 
value O 
< O 
0.05 O 
) O 
. O 
Conclusion O 
: O 
The O 
novel O 
PGN B-ABBREVIATION 
dispersions O 
prepared O 
by O 
the O 
PGSS O 
method O 
offer O 
the O 
great O 
potential O 
to O 
enhance O 
PGN B-ABBREVIATION 
dissolution O 
rate O 
, O 
reduce O 
preparation O 
time O 
and O 
form O 
stable O 
crystalline O 
dispersion O 
systems O 
over O 
those O 
prepared O 
by O 
conventional O 
methods O 
. O 

- O 
based O 
drug O 
discovery O 
( O 
FBDD O 
) O 
has O 
enjoyed O 
increasing O 
popularity O 
in O 
recent O 
years O 
. O 
We O 
introduce O 
SITE O 
( O 
single O 
- O 
injection O 
thermal O 
extinction O 
) O 
, O 
a O 
novel O 
thermodynamic O 
methodology O 
that O 
selects O 
high O 
- O 
quality O 
hits O 
early O 
in O 
FBDD O 
. O 
SITE O 
is O 
a O 
fast O 
calorimetric O 
competitive O 
assay O 
suitable O 
for O 
automation O 
that O 
captures O 
the O 
essence O 
of O 
isothermal O 
titration O 
calorimetry O 
but O 
using O 
significantly O 
fewer O 
resources O 
. O 
We O 
describe O 
the O 
principles O 
of O 
SITE O 
and O 
identify O 
a O 
novel O 
family O 
of O 
fragment O 
inhibitors O 
of O 
the O 
enzyme O 
ketosteroid B-FAMILY 
isomerase O 
displaying O 
high O 
values O 
of O 
enthalpic O 
efficiency O 
. O 

vivo O 
drug O 
interactions O 
of O 
the O 
teratogen O 
thalidomide B-TRIVIAL 
with O 
midazolam B-TRIVIAL 
: O 
heterotropic O 
cooperativity O 
of O 
human O 
cytochrome O 
P450 O 
in O 
humanized O 
TK-NOG O 
mice O 
. O 

vivo O 
drug O 
interactions O 
of O 
the O 
teratogen O 
thalidomide B-TRIVIAL 
with O 
the O 
model O 
cytochrome O 
P450 O 
( O 
P450 O 
) O 
3A O 
substrate O 
midazolam B-TRIVIAL 
were O 
investigated O 
in O 
mice O 
with O 
humanized O 
livers O 
. O 
The O 
clearance O 
of O 
midazolam B-TRIVIAL 
( O 
administered O 
intravenously O 
, O 
10 O 
mg O 
kg(-1) O 
) O 
in O 
chimeric O 
mice O 
was O 
enhanced O 
by O 
orally O 
co O 
- O 
administered O 
thalidomide B-TRIVIAL 
( O 
100 O 
mg O 
kg(-1) O 
) O 
. O 
A O 
larger O 
area O 
under O 
the O 
curve O 
of O 
the O 
major O 
metabolite O 
1'-hydroxymidazolam B-SYSTEMATIC 
( O 
1.7-fold O 
) O 
was O 
obtained O 
with O 
thalidomide B-TRIVIAL 
because O 
of O 
the O 
heterotropic O 
cooperativity O 
of O 
human O 
P450 O 
3A O 
enzymes O 
. O 
A O 
larger O 
area O 
under O 
the O 
curve O 
of O 
the O 
minor O 
metabolite O 
4-hydroxymidazolam B-SYSTEMATIC 
( O 
3.5-fold O 
) O 
was O 
seen O 
with O 
daily O 
pretreatment O 
with O 
thalidomide B-TRIVIAL 
for O 
3 O 
days O 
, O 
presumably O 
because O 
of O 
human O 
P450 O 
3A O 
induction O 
. O 
These O 
results O 
demonstrate O 
that O 
livers O 
of O 
humanized O 
mice O 
mediate O 
drug O 
interactions O 
of O 
thalidomide B-TRIVIAL 
and O 
suggest O 
interactions O 
of O 
therapeutic O 
agents O 
during O 
therapies O 
with O 
thalidomide B-TRIVIAL 
. O 

conductive O 
gold- O 
and O 
copper B-SYSTEMATIC 
-metallized O 
DNA O 
origami O 
nanostructures O 
. O 

work O 
demonstrates O 
the O 
use O 
of O 
a O 
circuit O 
- O 
like O 
DNA O 
origami O 
structure O 
as O 
a O 
template O 
to O 
fabricate O 
conductive O 
gold O 
and O 
copper B-SYSTEMATIC 
nanostructures O 
on O 
Si B-FORMULA 
surfaces O 
. O 
We O 
improved O 
over O 
previous O 
results O 
by O 
using O 
multiple O 
Pd B-FORMULA 
seeding O 
steps O 
to O 
increase O 
seed O 
uniformity O 
and O 
density O 
. O 
Our O 
process O 
has O 
also O 
been O 
characterized O 
through O 
atomic O 
force O 
microscopy O 
, O 
particle O 
size O 
distribution O 
analysis O 
, O 
and O 
scanning O 
electron O 
microscopy O 
. O 
We O 
found O 
that O 
four O 
successive O 
Pd B-FORMULA 
seeding O 
steps O 
yielded O 
the O 
best O 
results O 
for O 
electroless O 
metal O 
plating O 
on O 
DNA O 
origami O 
. O 
Electrical O 
resistance O 
measurements O 
were O 
done O 
on O 
both O 
Au B-FORMULA 
- O 
and O 
Cu B-FORMULA 
-metallized O 
nanostructures O 
, O 
with O 
each O 
showing O 
ohmic O 
behavior O 
. O 
Gold O 
- O 
plated O 
DNA O 
origami O 
structures O 
made O 
under O 
optimal O 
conditions O 
had O 
an O 
average O 
resistivity O 
of O 
7 O 
× O 
10(-5) O 
Ω·m O 
, O 
whereas O 
copper B-SYSTEMATIC 
-metallized O 
structures O 
had O 
a O 
resistivity O 
as O 
low O 
as O 
3.6 O 
× O 
10(-4) O 
Ω·m O 
. O 
Importantly O 
, O 
this O 
is O 
the O 
first O 
demonstration O 
of O 
electrically O 
conductive O 
Cu B-FORMULA 
nanostructures O 
fabricated O 
on O 
either O 
DNA O 
or O 
DNA O 
origami O 
templates O 
. O 
Although O 
resistivities O 
for O 
both O 
gold O 
and O 
copper B-SYSTEMATIC 
samples O 
were O 
larger O 
than O 
those O 
of O 
the O 
bulk O 
metal O 
, O 
these O 
metal O 
nanostructures O 
have O 
the O 
potential O 
for O 
use O 
in O 
electrically O 
connecting O 
small O 
structures O 
. O 
In O 
addition O 
, O 
these O 
metallized O 
objects O 
might O 
find O 
use O 
in O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
experiments O 
. O 

astrocyte O 
markers O 
, O 
the O 
glial O 
water O 
channel O 
aquaporin-4 O 
( O 
AQP4 O 
) O 
and O 
the O 
glial O 
fibrillary O 
acidic O 
protein O 
( O 
GFAP O 
) O 
, O 
have O 
been O 
implicated O 
in O 
several O 
physiological O 
and O 
pathological O 
conditions O 
in O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
as O 
well O 
as O 
in O 
blood O 
- O 
brain O 
barrier O 
breakdown O 
( O 
BBBb O 
) O 
. O 
By O 
color O 
segmentation O 
the O 
immunoreactivity O 
of O 
both O 
proteins O 
, O 
we O 
demonstrate O 
that O 
the O 
expression O 
of O 
AQP4 O 
and O 
GFAP O 
was O 
increased O 
in O 
the O 
cerebellum O 
of O 
neonate O 
( O 
14-day- O 
old O 
, O 
P14 O 
) O 
and O 
adult O 
( O 
8-week- O 
old O 
) O 
rats O 
administered O 
Phoneutria O 
nigriventer O 
spider O 
venom O 
( O 
PNV O 
) O 
known O 
to O 
cause O 
perivascular O 
edema O 
, O 
BBBb O 
and O 
convulsion O 
. O 
In O 
the O 
cerebellum's O 
gray O 
matter O 
, O 
PNV O 
produced O 
a O 
major O 
response O 
, O 
especially O 
in O 
the O 
granular O 
layer O 
. O 
Parallel O 
increases O 
in O 
AQP4 O 
and O 
GFAP O 
expression O 
occurred O 
24 O 
h O 
after O 
envenomation O 
in O 
the O 
white O 
matter O 
of O 
P14 O 
and O 
in O 
the O 
molecular O 
layer O 
of O 
adults O 
, O 
as O 
well O 
as O 
in O 
the O 
granular O 
layer O 
2 O 
h O 
after O 
envenomation O 
. O 
In O 
the O 
Purkinje O 
layer O 
there O 
was O 
a O 
tendency O 
of O 
increased O 
AQP4 O 
, O 
for O 
both O 
, O 
neonates O 
( O 
5 O 
h O 
) O 
, O 
and O 
adults O 
( O 
2 O 
and O 
24 O 
h O 
) O 
. O 
Moreover O 
, O 
PNV O 
also O 
provoked O 
nonparallel O 
upregulation O 
of O 
both O 
markers O 
with O 
prevalence O 
of O 
upregulation O 
of O 
AQP O 
4 O 
for O 
P14 O 
rats O 
, O 
and O 
GFAP O 
for O 
adults O 
. O 
The O 
major O 
expression O 
of O 
both O 
proteins O 
was O 
in O 
the O 
gray O 
matter O 
. O 
The O 
data O 
indicates O 
a O 
venom O 
effect O 
in O 
water O 
/ O 
electrolyte O 
balance O 
in O 
the O 
cerebellum O 
and O 
the O 
participation O 
of O 
AQP4 O 
in O 
these O 
effects O 
. O 
Age O 
- O 
related O 
and O 
time O 
- O 
related O 
regional O 
differences O 
probably O 
reflect O 
specificity O 
in O 
AQP4 O 
distribution O 
in O 
different O 
astrocytic O 
membrane O 
domains O 
as O 
well O 
as O 
its O 
participation O 
in O 
K(+) B-FORMULA 
buffering O 
and O 
neural O 
activity O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
associate O 
astrocytic O 
AQP4 O 
expression O 
and O 
reactive O 
gliosis O 
in O 
a O 
model O 
of O 
BBB O 
permeability O 
promoted O 
by O 
P O 
. O 
nigriventer O 
venom O 
. O 
Our O 
data O 
provide O 
compelling O 
evidence O 
that O 
AQP4 O 
expression O 
was O 
increased O 
in O 
the O 
cerebellum O 
of O 
rats O 
administered O 
PNV O 
. O 

activates O 
the O 
AhR O 
and O 
induces O 
CYP1A1 O 
in O 
primary O 
human O 
hepatocytes O 
and O 
human O 
cancer O 
cell O 
lines O 
HepG2 O 
and O 
LS174T O 
. O 

examined O 
the O 
effects O 
of O 
anthocyanidins B-FAMILY 
( O 
cyanidin B-TRIVIAL 
, O 
delphinidin B-TRIVIAL 
, O 
malvidin B-TRIVIAL 
, O 
peonidin B-TRIVIAL 
, O 
petunidin B-TRIVIAL 
, O 
pelargonidin B-TRIVIAL 
) O 
on O 
the O 
aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
(AhR)-CYP1A1 O 
signaling O 
pathway O 
in O 
human O 
hepatocytes O 
, O 
hepatic O 
HepG2 O 
and O 
intestinal O 
LS174T O 
cancer O 
cells O 
. O 
AhR-dependent O 
reporter O 
gene O 
expression O 
in O 
transfected O 
HepG2 O 
cells O 
was O 
increased O 
by O 
pelargonidin B-TRIVIAL 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
at O 
24h O 
. O 
Similarly O 
, O 
pelargonidin B-TRIVIAL 
induced O 
the O 
expression O 
of O 
CYP1A1 O 
mRNA O 
up O 
to O 
5-fold O 
in O 
HepG2 O 
and O 
LS174T O 
cells O 
relative O 
to O 
the O 
induction O 
by O 
5 O 
nM O 
2,3,7,8-tetrachlorodibenzodioxin B-SYSTEMATIC 
( O 
TCDD B-ABBREVIATION 
) O 
, O 
the O 
most O 
potent O 
activator O 
of O 
AhR O 
. O 
CYP1A1 O 
and O 
CYP1A2 O 
mRNAs O 
were O 
also O 
increased O 
by O 
pelargonidin B-TRIVIAL 
in O 
three O 
primary O 
human O 
hepatocytes O 
cultures O 
( O 
approximately O 
5% O 
of O 
TCDD B-ABBREVIATION 
potency O 
) O 
and O 
the O 
increase O 
in O 
CYP1A1 O 
protein O 
in O 
HepG2 O 
and O 
LS174T O 
cells O 
was O 
comparable O 
to O 
the O 
increase O 
in O 
catalytic O 
activity O 
of O 
CYP1A1 O 
enzyme O 
. O 
Ligand O 
binding O 
analysis O 
demonstrated O 
that O 
pelargonidin B-TRIVIAL 
was O 
a O 
weak O 
ligand O 
of O 
AhR O 
. O 
Enzyme O 
kinetic O 
analyses O 
using O 
human O 
liver O 
microsomes O 
revealed O 
inhibition O 
of O 
CYP1A1 O 
activity O 
by O 
delphinidin B-TRIVIAL 
( O 
IC50 O 
78 O 
μM O 
) O 
and O 
pelargonidin B-TRIVIAL 
( O 
IC50 O 
33 O 
μM O 
) O 
. O 
Overall O 
, O 
although O 
most O 
anthocyanidins B-FAMILY 
had O 
no O 
effects O 
on O 
AhR-CYP1A1 O 
signaling O 
, O 
pelargonidin B-TRIVIAL 
can O 
bind O 
to O 
and O 
activate O 
the O 
AhR O 
and O 
AhR-dependent O 
gene O 
expression O 
, O 
and O 
pelargonidin B-TRIVIAL 
and O 
delphinidin B-TRIVIAL 
inhibit O 
the O 
CYP1A1 O 
catalytic O 
activity O 
. O 

and O 
Sulfonylureas B-FAMILY 
in O 
Relation O 
to O 
Cancer O 
Risk O 
in O 
Type O 
II O 
Diabetes O 
Patients O 
: O 
A O 
Meta-analysis O 
using O 
primary O 
data O 
of O 
published O 
studies O 
. O 

: O 
Accumulating O 
evidence O 
suggests O 
that O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
and O 
hyperinsulinemia O 
are O 
at O 
increased O 
risk O 
for O 
developing O 
malignancies O 
. O 
It O 
remains O 
to O 
be O 
fully O 
elucidated O 
whether O 
use O 
of O 
metformin B-TRIVIAL 
, O 
an O 
insulin O 
sensitizer O 
, O 
and O 
/ O 
or O 
sulfonylureas B-FAMILY 
, O 
insulin O 
secretagogues O 
, O 
affect O 
cancer O 
incidence O 
in O 
subjects O 
with O 
T2DM O 
. O 
MATERIAL O 
& O 
METHODS O 
: O 
We O 
performed O 
a O 
meta-analysis O 
using O 
PubMed O 
, O 
of O 
randomized O 
control O 
trials O 
( O 
RCTs O 
) O 
, O 
cohorts O 
, O 
and O 
case O 
- O 
control O 
studies O 
published O 
through O 
July O 
2012 O 
that O 
assess O 
effects O 
of O 
metformin B-TRIVIAL 
and O 
/ O 
or O 
sulfonylurea B-FAMILY 
sulfonylureas B-FAMILY 
on O 
cancer O 
risk O 
at O 
any O 
site O 
, O 
in O 
subjects O 
with O 
T2DM O 
. O 
Fixed O 
and O 
random O 
effects O 
meta-analysis O 
models O 
were O 
used O 
, O 
and O 
the O 
effect O 
size O 
was O 
summarized O 
as O 
relative O 
risk O 
( O 
RR O 
) O 
for O 
RCTs O 
/ O 
cohorts O 
and O 
as O 
odds O 
ratio O 
( O 
OR O 
) O 
for O 
the O 
case O 
- O 
control O 
studies O 
. O 
RESULTS O 
: O 
Analysis O 
of O 
24 O 
metformin B-TRIVIAL 
studies O 
in O 
subjects O 
with O 
T2DM O 
showed O 
that O 
metformin B-TRIVIAL 
use O 
is O 
associated O 
with O 
reduced O 
risk O 
for O 
the O 
development O 
of O 
cancer O 
, O 
in O 
both O 
cohort O 
( O 
RR=0.70 O 
[ O 
95% O 
CI=0.67-0.73 O 
] O 
) O 
and O 
case O 
- O 
control O 
studies O 
( O 
OR=0.90 O 
[ O 
95% O 
CI=0.84-0.98 O 
] O 
) O 
, O 
but O 
this O 
finding O 
was O 
not O 
supported O 
by O 
RCTs O 
( O 
RR=1.01[95% O 
CI=0.81-1.26 O 
] O 
) O 
. O 
Data O 
from O 
18 O 
sulfonylurea B-FAMILY 
studies O 
in O 
subjects O 
with O 
T2DM O 
showed O 
that O 
sulfonylurea B-FAMILY 
use O 
is O 
associated O 
with O 
an O 
increase O 
in O 
all O 
- O 
cancer O 
risk O 
, O 
in O 
cohort O 
studies O 
( O 
RR=1.55 O 
[ O 
95% O 
CI=1.48 O 
-1.63 O 
] O 
) O 
, O 
though O 
data O 
from O 
RCTs O 
( O 
RR=1.17 O 
[ O 
95% O 
CI=0.95-1.45 O 
] O 
) O 
and O 
case O 
- O 
control O 
studies O 
( O 
OR=1.02 O 
[ O 
95% O 
CI=0.93-1.13 O 
] O 
) O 
failed O 
to O 
demonstrate O 
a O 
statistically O 
significant O 
effect O 
. O 
CONCLUSIONS O 
: O 
This O 
analysis O 
using O 
pooled O 
primary O 
data O 
demonstrates O 
that O 
metformin B-TRIVIAL 
use O 
reduces O 
, O 
while O 
sulfonylurea B-FAMILY 
use O 
may O 
be O 
associated O 
with O 
an O 
increased O 
cancer O 
risk O 
in O 
subjects O 
with O 
T2DM O 
. O 
These O 
findings O 
need O 
to O 
be O 
confirmed O 
in O 
large O 
- O 
scale O 
RCTs O 
before O 
they O 
are O 
translated O 
into O 
clinical O 
practice O 
. O 

glycol I-SYSTEMATIC 
monosubstituted O 
with O 
a O 
polymerizable O 
acrylic B-SYSTEMATIC 
moiety O 
was O 
linked O 
to O 
6-carboxy B-SYSTEMATIC 
free O 
position O 
on O 
dextran O 
side O 
chains O 
and O 
then O 
subjected O 
to O 
radical O 
polymerization O 
with O 
a O 
comonomer O 
in O 
order O 
to O 
obtain O 
microspheres O 
for O 
the O 
oral O 
controlled O 
release O 
of O 
ketoconazole B-TRIVIAL 
, O 
a O 
hydrophobic O 
model O 
drug O 
. O 
Microparticles O 
were O 
submitted O 
to O 
studies O 
on O 
their O 
ability O 
to O 
absorb O 
and O 
retain O 
water O 
. O 
Cell O 
uptake O 
studies O 
, O 
in O 
the O 
presence O 
and O 
absence O 
of O 
mucus O 
, O 
across O 
two O 
different O 
monolayers O 
, O 
respectively O 
, O 
HT29-MTX-E12 O 
and O 
Caco-2 O 
, O 
were O 
done O 
. O 
Cytotoxicity O 
studies O 
were O 
carried O 
out O 
to O 
calculate O 
the O 
IC50 O 
value O 
. O 
The O 
ability O 
of O 
microspheres O 
to O 
open O 
monolayers O 
tight O 
junctions O 
was O 
tested O 
by O 
measuring O 
their O 
TEER O 
values O 
. O 
Images O 
of O 
cell O 
uptake O 
were O 
visualized O 
by O 
CLSM O 
. O 
In O 
HT29-MTX-E12 O 
cells O 
, O 
more O 
mucoadhesion O 
and O 
drug O 
internalization O 
is O 
seen O 
thanks O 
to O 
the O 
presence O 
of O 
PEG B-ABBREVIATION 
and O 
dextran O 
chains O 
. O 

transdermal O 
delivery O 
of O 
fentanyl B-TRIVIAL 
. O 

fentanyl B-TRIVIAL 
patch O 
is O 
one O 
of O 
the O 
great O 
commercial O 
successes O 
in O 
transdermal O 
drug O 
delivery O 
. O 
The O 
suitability O 
of O 
this O 
molecule O 
for O 
delivery O 
through O 
skin O 
had O 
been O 
identified O 
in O 
the O 
1970s O 
, O 
and O 
subsequently O 
, O 
a O 
number O 
of O 
transdermal O 
formulations O 
became O 
available O 
on O 
the O 
market O 
. O 
This O 
article O 
reviews O 
the O 
development O 
of O 
fentanyl B-TRIVIAL 
patch O 
technology O 
with O 
particular O 
emphasis O 
on O 
the O 
pharmacokinetics O 
and O 
disposition O 
of O 
the O 
drug O 
when O 
delivered O 
through O 
the O 
skin O 
. O 
The O 
various O 
patch O 
designs O 
are O 
considered O 
as O 
well O 
as O 
the O 
bioequivalence O 
of O 
the O 
different O 
designs O 
. O 
The O 
influence O 
of O 
heat O 
on O 
fentanyl B-TRIVIAL 
permeation O 
is O 
highlighted O 
. O 
Post O 
- O 
mortem O 
redistribution O 
of O 
fentanyl B-TRIVIAL 
is O 
discussed O 
in O 
light O 
of O 
the O 
reported O 
discrepancies O 
in O 
serum O 
levels O 
reported O 
in O 
patients O 
after O 
death O 
compared O 
with O 
therapeutic O 
levels O 
in O 
living O 
subjects O 
. O 
Finally O 
, O 
alternatives O 
to O 
patch O 
technology O 
are O 
considered O 
, O 
and O 
recent O 
novel O 
transdermal O 
formulations O 
are O 
highlighted O 
. O 

of O 
tuberculosis O 
is O 
impaired O 
by O 
poor O 
drug O 
bioavailability O 
, O 
systemic O 
side O 
effects O 
, O 
patient O 
non-compliance O 
, O 
and O 
pathogen O 
resistance O 
to O 
existing O 
therapies O 
. O 
The O 
mannose B-TRIVIAL 
receptor O 
( O 
MR O 
) O 
is O 
known O 
to O 
be O 
involved O 
in O 
the O 
recognition O 
and O 
internalization O 
of O 
Mycobacterium O 
tuberculosis O 
. O 
We O 
present O 
a O 
new O 
assembly O 
process O 
to O 
produce O 
nanocarriers O 
with O 
variable O 
surface O 
densities O 
of O 
mannose B-TRIVIAL 
targeting O 
ligands O 
in O 
a O 
single O 
step O 
, O 
using O 
kinetically O 
- O 
controlled O 
, O 
block O 
copolymer O 
- O 
directed O 
assembly O 
. O 
Nanocarrier O 
association O 
with O 
murine O 
macrophage O 
J774 O 
cells O 
expressing O 
the O 
MR O 
is O 
examined O 
as O 
a O 
function O 
of O 
incubation O 
time O 
and O 
temperature O 
, O 
nanocarrier O 
size O 
, O 
dose O 
, O 
and O 
PEG B-ABBREVIATION 
corona O 
properties O 
. O 
Amphiphilic O 
diblock O 
copolymers O 
are O 
prepared O 
with O 
terminal O 
hydroxyl B-SYSTEMATIC 
, O 
methoxy B-SYSTEMATIC 
, O 
or O 
mannoside B-FAMILY 
functionality O 
and O 
incorporated O 
into O 
nanocarrier O 
formulations O 
at O 
specific O 
ratios O 
by O 
Flash O 
NanoPrecipitation O 
. O 
Association O 
of O 
nanocarriers O 
protected O 
by O 
a O 
hydroxyl B-SYSTEMATIC 
-terminated O 
PEG B-ABBREVIATION 
corona O 
with O 
J774 O 
cells O 
is O 
size O 
dependent O 
, O 
while O 
nanocarriers O 
with O 
methoxy B-SYSTEMATIC 
-terminated O 
PEG B-ABBREVIATION 
coronas O 
do O 
not O 
associate O 
with O 
cells O 
, O 
regardless O 
of O 
size O 
. O 
Specific O 
targeting O 
of O 
the O 
MR O 
is O 
investigated O 
using O 
nanocarriers O 
having O 
0-75% O 
mannoside B-FAMILY 
-terminated O 
PEG B-ABBREVIATION 
chains O 
in O 
the O 
PEG B-ABBREVIATION 
corona O 
. O 
This O 
is O 
a O 
wider O 
range O 
of O 
mannose B-TRIVIAL 
densities O 
than O 
has O 
been O 
previously O 
studied O 
. O 
Maximum O 
nanocarrier O 
association O 
is O 
attained O 
with O 
9% O 
mannoside B-FAMILY 
-terminated O 
PEG B-ABBREVIATION 
chains O 
, O 
increasing O 
uptake O 
more O 
than O 
3-fold O 
compared O 
to O 
non-targeted O 
nanocarriers O 
with O 
a O 
5kgmol(-1) O 
methoxy B-SYSTEMATIC 
-terminated O 
PEG B-ABBREVIATION 
corona O 
. O 
While O 
a O 
5kgmol(-1) O 
methoxy B-SYSTEMATIC 
-terminated O 
PEG B-ABBREVIATION 
corona O 
prevents O 
non-specific O 
uptake O 
, O 
a O 
1.8kgmol(-1) O 
methoxy B-SYSTEMATIC 
-terminated O 
PEG B-ABBREVIATION 
corona O 
does O 
not O 
sufficiently O 
protect O 
the O 
nanocarriers O 
from O 
nonspecific O 
association O 
. O 
There O 
is O 
continuous O 
uptake O 
of O 
MR-targeted O 
nanocarriers O 
at O 
37°C O 
, O 
but O 
a O 
saturation O 
of O 
association O 
at O 
4°C O 
. O 
The O 
majority O 
of O 
targeted O 
nanocarriers O 
associated O 
with O 
J774E O 
cells O 
are O 
internalized O 
at O 
37°C O 
and O 
uptake O 
is O 
receptor O 
- O 
dependent O 
, O 
diminishing O 
with O 
competitive O 
inhibition O 
by O 
dextran O 
. O 
This O 
characterization O 
of O 
nanocarrier O 
uptake O 
and O 
targeting O 
provides O 
promise O 
for O 
optimizing O 
drug O 
delivery O 
to O 
macrophages O 
for O 
TB O 
treatment O 
and O 
establishes O 
a O 
general O 
route O 
for O 
optimizing O 
targeted O 
formulations O 
of O 
nanocarriers O 
for O 
specific O 
delivery O 
at O 
targeted O 
sites O 
. O 

of O 
theobromine B-TRIVIAL 
in O 
healthy O 
volunteers O 
. O 

: O 
Theobromine B-TRIVIAL 
, O 
a O 
methylxanthine B-SYSTEMATIC 
related O 
to O 
caffeine B-TRIVIAL 
and O 
present O 
in O 
high O 
levels O 
in O 
cocoa O 
, O 
may O 
contribute O 
to O 
the O 
appeal O 
of O 
chocolate O 
. O 
However O 
, O 
current O 
evidence O 
for O 
this O 
is O 
limited O 
. O 
OBJECTIVES O 
: O 
We O 
conducted O 
a O 
within O 
- O 
subjects O 
placebo O 
- O 
controlled O 
study O 
of O 
a O 
wide O 
range O 
of O 
oral O 
theobromine B-TRIVIAL 
doses O 
( O 
250 O 
, O 
500 O 
, O 
and O 
1000 O 
mg O 
) O 
using O 
an O 
active O 
control O 
dose O 
of O 
caffeine B-TRIVIAL 
( O 
200 O 
mg O 
) O 
in O 
80 O 
healthy O 
participants O 
. O 
RESULTS O 
: O 
Caffeine B-TRIVIAL 
had O 
the O 
expected O 
effects O 
on O 
mood O 
including O 
feelings O 
of O 
alertness O 
and O 
cardiovascular O 
parameters O 
. O 
Theobromine B-TRIVIAL 
responses O 
differed O 
according O 
to O 
dose O 
; O 
it O 
showed O 
limited O 
subjective O 
effects O 
at O 
250 O 
mg O 
and O 
negative O 
mood O 
effects O 
at O 
higher O 
doses O 
. O 
It O 
also O 
dose O 
- O 
dependently O 
increased O 
heart O 
rate O 
. O 
In O 
secondary O 
analyses O 
, O 
we O 
also O 
examined O 
individual O 
differences O 
in O 
the O 
drug's O 
effects O 
in O 
relation O 
to O 
genes O 
related O 
to O 
their O 
target O 
receptors O 
, O 
but O 
few O 
associations O 
were O 
detected O 
. O 
CONCLUSIONS O 
: O 
This O 
study O 
represents O 
the O 
highest O 
dose O 
of O 
theobromine B-TRIVIAL 
studied O 
in O 
humans O 
. O 
We O 
conclude O 
that O 
theobromine B-TRIVIAL 
at O 
normal O 
intake O 
ranges O 
may O 
contribute O 
to O 
the O 
positive O 
effects O 
of O 
chocolate O 
, O 
but O 
at O 
higher O 
intakes O 
, O 
effects O 
become O 
negative O 
. O 

studies O 
on O 
the O 
thermodynamic O 
properties O 
, O 
densities O 
, O 
detonation O 
properties O 
, O 
and O 
pyrolysis O 
mechanisms O 
of O 
trinitromethyl B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
aminotetrazole I-FAMILY 
compounds O 
. O 

- I-FAMILY 
substituted I-FAMILY 
aminotetrazoles I-FAMILY 
with O 
- O 
NH(2) B-FORMULA 
, O 
- O 
NO(2) B-FORMULA 
, O 
- O 
N(3) B-FORMULA 
, O 
and O 
- O 
NHC(NO(2))(3) B-FORMULA 
groups O 
were O 
investigated O 
at O 
the O 
B3LYP O 
/ O 
6-31G(d) O 
level O 
of O 
density O 
functional O 
theory O 
. O 
Their O 
sublimation O 
enthalpies O 
, O 
thermodynamic O 
properties O 
, O 
and O 
heats O 
of O 
formation O 
were O 
calculated O 
. O 
The O 
thermodynamic O 
properties O 
of O 
these O 
compounds O 
increase O 
with O 
temperature O 
as O 
well O 
as O 
with O 
the O 
number O 
of O 
nitro B-SYSTEMATIC 
groups O 
attached O 
to O 
the O 
tetrazole B-FAMILY 
ring O 
. O 
In O 
addition O 
, O 
the O 
detonation O 
velocities O 
and O 
detonation O 
pressures O 
of O 
these O 
compounds O 
were O 
successfully O 
predicted O 
using O 
the O 
Kamlet-Jacobs O 
equations O 
. O 
It O 
was O 
found O 
that O 
these O 
compounds O 
exhibit O 
good O 
detonation O 
properties O 
, O 
and O 
that O 
compound O 
G O 
( O 
D O 
= O 
9.2 O 
km O 
/ O 
s O 
, O 
P O 
= O 
38.8 O 
GPa O 
) O 
has O 
the O 
most O 
powerful O 
detonation O 
properties O 
, O 
which O 
are O 
similar O 
to O 
those O 
of O 
the O 
well O 
- O 
known O 
explosive O 
HMX B-ABBREVIATION 
( O 
1,3,5,7-tetranitro-1,3,5,7-tetrazocine B-SYSTEMATIC 
) O 
. O 
Finally O 
, O 
the O 
electronic O 
structures O 
and O 
bond O 
dissociation O 
energies O 
of O 
these O 
compounds O 
were O 
calculated O 
. O 
The O 
BDEs O 
of O 
their O 
C-NO(2) B-FORMULA 
bonds O 
were O 
found O 
to O 
range O 
from O 
101.9 O 
to O 
125.8 O 
kJ O 
/ O 
mol(-1) O 
. O 
All O 
of O 
these O 
results O 
should O 
provide O 
useful O 
fundamental O 
information O 
for O 
the O 
design O 
of O 
novel O 
HEDMs O 
. O 

nanowire O 
electron O 
transport O 
pathways O 
inside O 
organic O 
photovoltaics O 
. O 

transport O 
is O 
one O 
of O 
the O 
five O 
main O 
steps O 
in O 
the O 
operation O 
of O 
organic O 
photovoltaics O 
, O 
but O 
achieving O 
balanced O 
hole O 
and O 
electron O 
transport O 
with O 
high O 
mobility O 
has O 
been O 
challenging O 
in O 
devices O 
. O 
Here O 
, O 
we O 
report O 
improved O 
charge O 
transport O 
in O 
organic O 
photovoltaics O 
via O 
incorporation O 
of O 
nanostructured O 
inorganic O 
electron O 
transport O 
materials O 
into O 
the O 
active O 
layers O 
of O 
devices O 
. O 
Co-depositing O 
TiO2 B-FORMULA 
nanowires O 
with O 
the O 
organic O 
active O 
layer O 
solution O 
embeds O 
the O 
nanowires O 
directly O 
within O 
active O 
layers O 
of O 
the O 
solar O 
cell O 
. O 
The O 
ability O 
of O 
these O 
nanowires O 
to O 
transport O 
electrons O 
is O 
compared O 
with O 
neat O 
P3HT B-ABBREVIATION 
: O 
PCBM B-ABBREVIATION 
active O 
layers O 
and O 
also O 
devices O 
containing O 
TiO2 B-FORMULA 
nanotube O 
aggregates O 
. O 
Incorporation O 
of O 
TiO2 B-FORMULA 
nanowires O 
yields O 
a O 
six O 
- O 
fold O 
increase O 
in O 
the O 
electron O 
mobility O 
relative O 
to O 
unmodified O 
devices O 
, O 
leading O 
to O 
a O 
19% O 
improvement O 
in O 
the O 
power O 
conversion O 
efficiency O 
. O 
Lower O 
energetic O 
disorder O 
of O 
the O 
film O 
and O 
more O 
balanced O 
charge O 
transport O 
are O 
also O 
observed O 
upon O 
incorporating O 
TiO2 B-FORMULA 
nanowires O 
. O 
These O 
advantageous O 
effects O 
correlate O 
with O 
the O 
TiO2 B-FORMULA 
nanowire O 
length O 
. O 

- O 
daily O 
initiation O 
of O 
basal O 
insulin O 
as O 
add O 
- O 
on O 
to O 
metformin B-TRIVIAL 
: O 
a O 
26-week O 
, O 
randomized O 
, O 
treat O 
- O 
to O 
- O 
target O 
trial O 
comparing O 
insulin O 
detemir O 
with O 
insulin O 
glargine O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 

: O 
This O 
study O 
assessed O 
the O 
efficacy O 
and O 
safety O 
of O 
once O 
- O 
daily O 
insulin O 
initiation O 
using O 
insulin O 
detemir O 
( O 
detemir O 
) O 
or O 
insulin O 
glargine O 
( O 
glargine O 
) O 
added O 
to O 
existing O 
metformin B-TRIVIAL 
in O 
type O 
2 O 
diabetes O 
( O 
T2D O 
) O 
. O 
METHODS O 
: O 
This O 
26-week O 
, O 
multinational O 
, O 
randomized O 
, O 
treat O 
- O 
to O 
- O 
target O 
trial O 
involved O 
457 O 
insulin-naïve O 
adults O 
with O 
T2D O 
( O 
HbA1c O 
7-9% O 
) O 
. O 
Detemir O 
or O 
glargine O 
was O 
added O 
to O 
current O 
metformin B-TRIVIAL 
therapy O 
[ O 
any O 
second O 
oral O 
antidiabetic O 
drug O 
( O 
OAD O 
) O 
discontinued O 
] O 
and O 
titrated O 
to O 
a O 
target O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
≤ O 
90 O 
mg O 
/ O 
dl O 
( O 
≤ O 
5 O 
mmol O 
/ O 
l O 
) O 
. O 
Primary O 
efficacy O 
endpoint O 
was O 
change O 
in O 
HbA1c O 
. O 
RESULTS O 
: O 
Mean O 
( O 
s.d O 
. O 
) O 
HbA1c O 
decreased O 
with O 
detemir O 
and O 
glargine O 
by O 
0.48 O 
and O 
0.74%-points O 
, O 
respectively O 
, O 
to O 
7.48% O 
( O 
0.91% O 
) O 
and O 
7.13% O 
( O 
0.72% O 
) O 
[ O 
estimated O 
between O 
- O 
treatment O 
difference O 
, O 
0.3 O 
( O 
95% O 
CI O 
: O 
0.14-0.46 O 
) O 
] O 
. O 
Non-inferiority O 
for O 
detemir O 
at O 
the O 
a O 
priori O 
level O 
of O 
0.4%-points O 
was O 
not O 
established O 
. O 
The O 
proportions O 
of O 
patients O 
reaching O 
HbA1c O 
≤ O 
7% O 
at O 
26 O 
weeks O 
were O 
38% O 
and O 
53% O 
( O 
p O 
= O 
0.026 O 
) O 
with O 
detemir O 
and O 
glargine O 
, O 
respectively O 
. O 
FPG O 
decreased O 
∼43.2 O 
mg O 
/ O 
dl O 
( O 
∼2.4 O 
mmol O 
/ O 
l O 
) O 
in O 
both O 
groups O 
[ O 
non-significant O 
( O 
NS O 
) O 
] O 
. O 
Treatment O 
satisfaction O 
was O 
good O 
for O 
both O 
insulins O 
. O 
Hypoglycaemia O 
, O 
which O 
occurred O 
infrequently O 
, O 
was O 
observed O 
less O 
with O 
detemir O 
than O 
glargine O 
[ O 
rate O 
ratio O 
0.73 O 
( O 
95% O 
CI O 
0.54-0.98 O 
) O 
] O 
. O 
The O 
proportions O 
of O 
patients O 
reaching O 
HbA1c O 
≤ O 
7% O 
without O 
hypoglycaemia O 
in O 
the O 
detemir O 
and O 
glargine O 
groups O 
were O 
32% O 
and O 
38% O 
( O 
NS O 
) O 
, O 
respectively O 
. O 
Weight O 
decreased O 
with O 
detemir O 
[ O 
-0.49 O 
( O 
3.3 O 
) O 
kg O 
] O 
and O 
increased O 
with O 
glargine O 
[ O 
+ O 
1 O 
( O 
3.1 O 
) O 
kg O 
] O 
( O 
95% O 
CI O 
for O 
difference O 
: O 
-2.17 O 
to O 
-0.89 O 
kg O 
) O 
. O 
CONCLUSION O 
: O 
While O 
both O 
detemir O 
and O 
glargine O 
, O 
when O 
added O 
to O 
metformin B-TRIVIAL 
therapy O 
, O 
improved O 
glycaemic O 
control O 
, O 
glargine O 
resulted O 
in O 
greater O 
reductions O 
in O 
HbA1c O 
, O 
while O 
detemir O 
demonstrated O 
less O 
weight O 
gain O 
and O 
hypoglycaemia O 
. O 

of O 
model O 
perfume O 
molecules O 
on O 
the O 
self O 
- O 
assembly O 
of O 
anionic O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
6-benzene I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
. O 

impact O 
of O 
two O 
model O 
perfumes O 
with O 
differing O 
degrees O 
of O 
hydrophobicity O 
/ O 
hydrophilicity O 
, O 
linalool B-TRIVIAL 
( O 
LL O 
) O 
and O 
phenylethanol B-SYSTEMATIC 
( O 
PE O 
) O 
, O 
on O 
the O 
solution O 
structure O 
of O 
anionic O 
surfactant O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
6-benzene I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
, O 
LAS-6 B-ABBREVIATION 
, O 
has O 
been O 
studied O 
by O 
small O 
angle O 
neutron O 
scattering O 
, O 
SANS O 
. O 
For O 
both O 
types O 
of O 
perfume O 
molecules O 
, O 
complex O 
phase O 
behavior O 
is O 
observed O 
. O 
The O 
phase O 
behavior O 
depends O 
upon O 
the O 
concentration O 
, O 
surfactant O 
/ O 
perfume O 
composition O 
, O 
and O 
type O 
of O 
perfume O 
. O 
The O 
more O 
hydrophilic O 
perfume O 
PE O 
promotes O 
the O 
formation O 
of O 
more O 
highly O 
curved O 
structures O 
. O 
At O 
relatively O 
low O 
surfactant O 
concentrations O 
, O 
small O 
globular O 
micelles O 
, O 
L1 O 
, O 
are O 
formed O 
. O 
These O 
become O 
perfume O 
droplets O 
, O 
L(sm) O 
, O 
stabilized O 
by O 
the O 
surfactant O 
at O 
much O 
higher O 
perfume O 
solution O 
compositions O 
. O 
At O 
higher O 
surfactant O 
concentrations O 
, O 
the O 
tendency O 
of O 
LAS-6 B-ABBREVIATION 
to O 
form O 
more O 
planar O 
structures O 
is O 
evident O 
. O 
The O 
more O 
hydrophobic O 
linalool B-TRIVIAL 
promotes O 
the O 
formation O 
of O 
more O 
planar O 
structures O 
. O 
Combined O 
with O 
the O 
greater O 
tendency O 
of O 
LAS-6 B-ABBREVIATION 
to O 
form O 
planar O 
structures O 
, O 
this O 
results O 
in O 
the O 
planar O 
structures O 
dominating O 
the O 
phase O 
behavior O 
for O 
the O 
LAS-6 B-ABBREVIATION 
/ O 
linalool B-TRIVIAL 
mixtures O 
. O 
For O 
the O 
LAS-6 B-ABBREVIATION 
/ O 
linalool B-TRIVIAL 
mixture O 
, O 
the O 
self O 
- O 
assembly O 
is O 
in O 
the O 
form O 
of O 
micelles O 
only O 
at O 
the O 
lowest O 
surfactant O 
and O 
perfume O 
concentrations O 
. O 
Over O 
most O 
of O 
the O 
concentration O 
- O 
composition O 
space O 
explored O 
, O 
the O 
structures O 
are O 
predominantly O 
lamellar O 
, O 
L(α) O 
, O 
or O 
vesicle O 
, O 
L O 
(v) O 
, O 
or O 
in O 
the O 
form O 
of O 
a O 
lamellar O 
/ O 
micellar O 
coexistence O 
. O 
At O 
low O 
and O 
intermediate O 
amounts O 
of O 
LL O 
, O 
a O 
significantly O 
different O 
structure O 
is O 
observed O 
, O 
and O 
the O 
aggregates O 
are O 
in O 
the O 
form O 
of O 
small O 
, O 
relatively O 
monodisperse O 
vesicles O 
( O 
i.e O 
. O 
, O 
nanovesicles O 
) O 
, O 
L(sv) O 
. O 

and I-MULTIPLE 
(P)-Bicelaphanol I-MULTIPLE 
A I-MULTIPLE 
, O 
Dimeric O 
Trinorditerpenes B-FAMILY 
with O 
Promising O 
Neuroprotective O 
Activity O 
from O 
Celastrus O 
orbiculatus O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
and O 
(P)-bicelaphanol B-TRIVIAL 
A I-TRIVIAL 
( O 
2 O 
) O 
, O 
two O 
unprecedented O 
dimeric O 
trinorditerpenes O 
existing O 
as O 
atropisomers O 
, O 
together O 
with O 
their O 
monomer O 
celaphanol B-TRIVIAL 
A I-TRIVIAL 
( O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
root O 
bark O 
of O 
Celastrus O 
orbiculatus O 
. O 
The O 
structures O 
and O 
absolute O 
configurations O 
of O 
1 O 
and O 
2 O 
were O 
determined O 
by O 
spectroscopic O 
and O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
analyses O 
. O 
Compound O 
1 O 
exhibited O 
a O 
significant O 
in O 
vitro O 
neuroprotective O 
effect O 
against O 
a O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
-induced O 
cell O 
viability O 
decrease O 
in O 
PC12 O 
cells O 
at O 
1 O 
μM O 
, O 
while O 
compounds O 
2 O 
and O 
3 O 
showed O 
such O 
effects O 
at O 
10 O 
μM O 
. O 

microbial O 
transformation O 
of O 
desacetylcinobufagin B-TRIVIAL 
by O 
Fusarium O 
avenaceum O 
AS O 
3.4594 O 
. O 

this O 
paper O 
, O 
the O 
microbial O 
transformation O 
of O 
desacetylcinobufagin B-TRIVIAL 
( O 
1 O 
) O 
by O 
Fusarium O 
avenaceum O 
AS O 
3.4594 O 
was O 
investigated O 
, O 
and O 
four O 
metabolites O 
were O 
isolated O 
and O 
characterized O 
as O 
3-keton- B-SYSTEMATIC 
desacetylcinobufagin I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
3-epi-desacetylcinobufagin B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
bufadienolide B-TRIVIAL 
A I-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
15β,16α-dihydroxyl-17βH-bufalin B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
respectively O 
. O 
Among O 
them O 
, O 
4 O 
and O 
5 O 
are O 
new O 
compounds O 
. O 
The O 
cytotoxicities O 
of O 
transformed O 
products O 
( O 
2-5 O 
) O 
against O 
Hela O 
cells O 
were O 
also O 
investigated O 
. O 

' O 
s O 
, O 
Glycerolipids O 
Carrying O 
a O 
Dehydrophenylalanine B-SYSTEMATIC 
Ester B-SYSTEMATIC 
Moiety O 
from O 
the O 
Seed-Eating O 
Larvae O 
of O 
the O 
Bruchid O 
Beetle O 
Bruchidius O 
dorsalis O 
. O 

a O 
TLC O 
autographic O 
assay O 
for O 
radical O 
- O 
scavenging O 
activity O 
with O 
the O 
ABTS B-ABBREVIATION 
radical O 
, O 
the O 
presence O 
of O 
lipophilic O 
antioxidants O 
in O 
the O 
larvae O 
of O 
the O 
wild O 
bruchid O 
seed O 
beetle O 
Bruchidius O 
dorsalis O 
was O 
detected O 
. O 
Assay O 
- O 
guided O 
fractionation O 
of O 
the O 
CHCl(3) B-FORMULA 
-soluble O 
fraction O 
of O 
the O 
larvae O 
resulted O 
in O 
the O 
isolation O 
of O 
new O 
glycerolipids O 
, O 
designated O 
dorsamin-A763 B-MULTIPLE 
, I-MULTIPLE 
-A737 I-MULTIPLE 
, I-MULTIPLE 
-A765 I-MULTIPLE 
, I-MULTIPLE 
-A739 I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
-A767 I-MULTIPLE 
, O 
comprising O 
1,2-diacyl-sn-glycero-3-dehydrophenylalanine B-SYSTEMATIC 
ester I-SYSTEMATIC 
structural O 
units O 
. O 
The O 
ABTS B-ABBREVIATION 
radical O 
scavenging O 
activity O 
of O 
the O 
dorsamin-A B-FAMILY 
' O 
s O 
was O 
comparable O 
with O 
or O 
stronger O 
than O 
that O 
of O 
Trolox B-TRIVIAL 
. O 

new O 
eudesmane B-TRIVIAL 
-type O 
sesquiterpenoid B-FAMILY 
lactones I-FAMILY 
from O 
atractylenolide B-TRIVIAL 
II I-TRIVIAL 
by O 
biotransformation O 
of O 
rat O 
hepatic O 
microsomes O 
. O 

biotransformation O 
of O 
atractylenolide B-TRIVIAL 
II I-TRIVIAL 
, O 
a O 
major O 
bioactive O 
principle O 
of O 
the O 
rhizomes O 
of O 
Atractylodes O 
macrocephala O 
Koidz O 
. O 
, O 
was O 
investigated O 
in O 
vitro O 
by O 
incubation O 
with O 
rat O 
hepatic O 
microsomes O 
pretreated O 
with O 
sodium B-SYSTEMATIC 
phenobarbital I-SYSTEMATIC 
. O 
The O 
biotransformation O 
products O 
were O 
extracted O 
and O 
purified O 
by O 
chromatographic O 
methods O 
. O 
Seven O 
biotransformation O 
products O 
( O 
BP1-BP7 O 
) O 
were O 
obtained O 
and O 
their O 
structures O 
were O 
elucidated O 
by O 
NMR O 
and O 
MS O 
data O 
analyses O 
and O 
by O 
comparison O 
with O 
the O 
previously O 
reported O 
values O 
, O 
including O 
four O 
new O 
compounds O 
, O 
namely O 
4(R),15-epoxy-atractylenolide B-SYSTEMATIC 
II I-SYSTEMATIC 
( O 
BP1 O 
) O 
, O 
4(R),15-epoxy-13-hydroxyatractylenolide B-SYSTEMATIC 
II I-SYSTEMATIC 
( O 
BP5 O 
) O 
, O 
4(R),15-epoxy-1β-hydroxyatractylenolide B-SYSTEMATIC 
II I-SYSTEMATIC 
( O 
BP6 O 
) O 
, O 
and O 
4(R),15-dihydroxyatractylenolide B-SYSTEMATIC 
II I-SYSTEMATIC 
( O 
BP7 O 
) O 
. O 
The O 
biotransformation O 
pathway O 
of O 
atractylenolide B-TRIVIAL 
II I-TRIVIAL 
by O 
hepatic O 
microsomes O 
was O 
deducted O 
based O 
on O 
the O 
structure O 
resolution O 
of O 
the O 
products O 
. O 

enhances O 
exercise O 
training O 
responses O 
in O 
rats O 
selectively O 
bred O 
for O 
high O 
running O 
performance O 
. O 

Capacity O 
Runner O 
( O 
HCR O 
) O 
rats O 
have O 
been O 
developed O 
by O 
divergent O 
artificial O 
selection O 
for O 
treadmill O 
endurance O 
running O 
capacity O 
to O 
explore O 
an O 
aerobic O 
biology O 
- O 
disease O 
connection O 
. O 
The O 
beneficial O 
effects O 
of O 
resveratrol B-TRIVIAL 
supplementation O 
have O 
been O 
demonstrated O 
in O 
endurance O 
running O 
and O 
the O 
antioxidant O 
capacity O 
of O 
resveratrol B-TRIVIAL 
is O 
also O 
demonstrated O 
. O 
In O 
this O 
study O 
we O 
examine O 
whether O 
12weeks O 
of O 
treadmill O 
exercise O 
training O 
and O 
/ O 
or O 
resveratrol B-TRIVIAL 
can O 
enhance O 
performance O 
in O 
HCR O 
. O 
Indeed O 
, O 
resveratrol B-TRIVIAL 
increased O 
aerobic O 
performance O 
and O 
strength O 
of O 
upper O 
limbs O 
of O 
these O 
rats O 
. O 
Moreover O 
, O 
we O 
have O 
found O 
that O 
resveratrol B-TRIVIAL 
activated O 
the O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
, O 
SIRT1 O 
, O 
and O 
mitochondrial O 
transcription O 
factor O 
A O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
changes O 
in O 
mitochondrial O 
fission O 
/ O 
fusion O 
and O 
Lon O 
protease O 
/ O 
HSP78 O 
levels O 
suggest O 
that O 
exercise O 
training O 
does O 
not O 
significantly O 
induce O 
damage O 
of O 
proteins O 
. O 
Moreover O 
, O 
neither O 
exercise O 
training O 
nor O 
resveratrol B-TRIVIAL 
supplementation O 
altered O 
the O 
content O 
of O 
protein O 
carbonyls O 
. O 
Changes O 
in O 
the O 
levels O 
of O 
forkhead O 
transcription O 
factor O 
1 O 
and O 
SIRT4 O 
could O 
suggest O 
increased O 
fat O 
utilization O 
and O 
improved O 
insulin O 
sensitivity O 
. O 
These O 
data O 
indicate O 
, O 
that O 
resveratrol B-TRIVIAL 
supplementation O 
enhances O 
aerobic O 
performance O 
due O 
to O 
the O 
activation O 
of O 
the O 
AMPK-SIRT1-PGC-1α O 
pathway O 
. O 

Água O 
- O 
mel O 
" O 
is O 
a O 
honey O 
- O 
based O 
product O 
produced O 
in O 
Portugal O 
for O 
ancient O 
times O 
. O 
Several O 
attributes O 
have O 
been O 
reported O 
to O 
" O 
água O 
- O 
mel O 
" O 
particularly O 
in O 
the O 
alleviation O 
of O 
simple O 
symptoms O 
of O 
upper O 
respiratory O 
tract O 
. O 
Samples O 
of O 
" O 
água O 
- O 
mel O 
" O 
from O 
diverse O 
beekeepers O 
from O 
different O 
regions O 
of O 
Portugal O 
were O 
studied O 
in O 
what O 
concerns O 
antimicrobial O 
, O 
antioxidant O 
and O 
antiviral O 
properties O 
. O 
The O 
amounts O 
of O 
phenol B-SYSTEMATIC 
and O 
brown O 
pigment O 
were O 
also O 
evaluated O 
and O 
correlated O 
with O 
the O 
antioxidant O 
activities O 
. O 
A O 
great O 
variability O 
on O 
the O 
levels O 
of O 
these O 
compounds O 
was O 
found O 
among O 
samples O 
which O 
were O 
responsible O 
for O 
the O 
variability O 
detected O 
also O 
on O 
the O 
antioxidant O 
activities O 
, O 
independent O 
on O 
the O 
method O 
used O 
. O 
Generally O 
, O 
antioxidant O 
activity O 
correlated O 
better O 
with O 
brown O 
pigments O 
' O 
amount O 
than O 
with O 
phenols B-FAMILY 
' O 
content O 
. O 
The O 
antimicrobial O 
activity O 
found O 
for O 
" O 
água O 
- O 
mel O 
" O 
samples O 
confirm O 
the O 
virtues O 
reported O 
by O 
popular O 
findings O 
. O 
In O 
addition O 
, O 
this O 
work O 
also O 
reveals O 
the O 
antiviral O 
properties O 
of O 
" O 
água O 
- O 
mel O 
" O 
evidenced O 
by O 
a O 
decrease O 
on O 
the O 
infectivity O 
of O 
the O 
Qβ O 
bacteriophage O 
. O 

-type O 
triterpenoid B-FAMILY 
and O 
steroid B-FAMILY 
from O 
the O 
stem O 
bark O 
of O 
Klainedoxa O 
gabonensis O 
. O 

new O 
lanostane B-FAMILY 
triterpenoid I-FAMILY 
, O 
2-hydroxy-24-methylenelanostan-1,8-dien-3-one B-SYSTEMATIC 
named O 
klainedoxalanostenone B-TRIVIAL 
( O 
1 O 
) O 
with O 
one O 
new O 
steroid B-FAMILY 
, O 
6-O-acyl-β-d-glucosyl-β-sitosterol B-SYSTEMATIC 
named O 
klainedoxasterol B-TRIVIAL 
( O 
2 O 
) O 
together O 
with O 
ten O 
known O 
compounds O 
including O 
six O 
triterpenoids B-FAMILY 
( O 
3-8 O 
) O 
, O 
two O 
steroids B-FAMILY 
( O 
9 O 
, O 
10 O 
) O 
and O 
two O 
tanins B-FAMILY 
( O 
11 O 
, O 
12 O 
) O 
were O 
isolated O 
from O 
the O 
stem O 
bark O 
of O 
Klainedoxa O 
gabonensis O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
lanostane B-TRIVIAL 
-type O 
triterpenoids B-FAMILY 
from O 
this O 
genus O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
extensive O 
analysis O 
of O 
spectroscopic O 
data O 
( O 
1D O 
and O 
2D O 
NMR O 
, O 
MS O 
) O 
and O 
by O 
comparison O 
with O 
literature O 
data O 
. O 
The O 
xanthine B-TRIVIAL 
oxidase O 
inhibitory O 
activity O 
of O 
nine O 
compounds O 
( O 
1-6 O 
, O 
8 O 
, O 
10 O 
and O 
11 O 
) O 
were O 
evaluated O 
. O 
Compound O 
5 O 
showed O 
a O 
good O 
xanthine B-TRIVIAL 
oxidase O 
inhibitory O 
activity O 
; O 
the O 
other O 
tested O 
compounds O 
were O 
moderately O 
active O 
. O 

sesquiterpenes B-FAMILY 
from O 
Hedychium O 
spicatum O 
: O 
Isolation O 
, O 
structure O 
elucidation O 
and O 
structure O 
- O 
activity O 
relationship O 
studies O 
. O 

investigation O 
of O 
chloroform B-TRIVIAL 
extract O 
from O 
rhizomes O 
of O 
Hedychium O 
spicatum O 
resulted O 
in O 
the O 
isolation O 
of O 
six O 
new O 
sesquiterpenes B-FAMILY 
( O 
1-6 O 
) O 
along O 
with O 
fifteen O 
known O 
compounds O 
( O 
7-21 O 
) O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
the O 
extensive O 
spectroscopic O 
analyses O 
( O 
IR O 
, O 
Mass O 
and O 
NMR O 
) O 
and O 
by O 
comparison O 
of O 
the O 
data O 
with O 
those O 
reported O 
in O 
the O 
literature O 
. O 
Further O 
, O 
cytotoxic O 
activities O 
of O 
all O 
the O 
isolates O 
were O 
evaluated O 
by O 
determining O 
their O 
inhibitory O 
effects O 
against O 
A-549 O 
, O 
B-16 O 
, O 
Hela O 
, O 
HT-29 O 
, O 
NCI-H460 O 
, O 
PC-3 O 
, O 
IEC-6 O 
and O 
L-6 O 
cancer O 
cell O 
lines O 
. O 
Results O 
indicated O 
that O 
compounds O 
1 O 
and O 
3 O 
may O 
serve O 
as O 
an O 
important O 
natural O 
lead O 
compounds O 
for O 
future O 
development O 
as O 
they O 
showed O 
potent O 
cytotoxic O 
activity O 
against O 
Hela O 
cell O 
lines O 
with O 
an O 
IC50 O 
value O 
of O 
0.3μg O 
/ O 
mL O 
and O 
1.80μg O 
/ O 
mL O 
, O 
respectively O 
. O 

of O 
the O 
cumulative O 
body O 
burden O 
of O 
estrogen-3,4-quinone B-FAMILY 
in O 
breast O 
cancer O 
patients O 
and O 
controls O 
using O 
albumin O 
adducts O 
as O 
biomarkers O 
. O 

17β-estradiol-2,3-quinone B-SYSTEMATIC 
( O 
E2-2,3-Q B-SYSTEMATIC 
) O 
and O 
17β-estradiol-3,4-quinone B-SYSTEMATIC 
( O 
E2-3,4-Q B-SYSTEMATIC 
) O 
are O 
reactive O 
metabolites O 
of O 
estrogen B-FAMILY 
. O 
Elevation O 
of O 
E2-3,4-Q B-SYSTEMATIC 
to O 
E2-2,3-Q B-SYSTEMATIC 
ratio O 
is O 
thought O 
to O 
be O 
an O 
important O 
indicator O 
of O 
estrogen B-FAMILY 
-induced O 
carcinogenesis O 
. O 
Our O 
current O 
study O 
compared O 
the O 
cumulative O 
body O 
burden O 
of O 
these O 
estrogen B-FAMILY 
quinones I-FAMILY 
in O 
serum O 
samples O 
taken O 
from O 
Taiwanese O 
women O 
with O 
breast O 
cancer O 
( O 
n=152 O 
) O 
vs O 
healthy O 
controls O 
( O 
n=75 O 
) O 
by O 
using O 
albumin O 
( O 
Alb O 
) O 
adducts O 
as O 
biomarkers O 
. O 
Results O 
clearly O 
demonstrated O 
the O 
presence O 
of O 
cysteinyl B-TRIVIAL 
adducts O 
of O 
E2-2,3-Q B-SYSTEMATIC 
-4-S-Alb O 
and O 
E2-3,4-Q B-SYSTEMATIC 
-2-S-Alb O 
in O 
all O 
study O 
population O 
at O 
levels O 
ranging O 
from O 
61.7-1330 O 
to O 
66.6-1,590 O 
pmol O 
/ O 
g O 
, O 
respectively O 
. O 
Correlation O 
coefficient O 
between O 
E2-2,3-Q B-SYSTEMATIC 
-4-S-Alb O 
and O 
E2-3,4-Q B-SYSTEMATIC 
-2-S-Alb O 
was O 
0.61 O 
for O 
controls O 
and O 
0.767 O 
for O 
breast O 
cancer O 
patients O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
We O 
also O 
noticed O 
that O 
in O 
premenopausal O 
subjects O 
with O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
less O 
than O 
27 O 
, O 
background O 
levels O 
of O 
E2-3,4-Q B-SYSTEMATIC 
-2-S-Alb O 
was O 
inversely O 
proportional O 
to O 
BMI O 
with O 
about O 
25% O 
increase O 
in O 
E2-3,4-Q B-SYSTEMATIC 
-2-S-Alb O 
per O 
5 O 
kg O 
/ O 
m(2) O 
decrease O 
in O 
BMI O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
In O 
addition O 
, O 
we O 
confirmed O 
that O 
mean O 
levels O 
of O 
E2-3,4-Q B-SYSTEMATIC 
-2-S-Alb O 
in O 
breast O 
cancer O 
patients O 
were O 
∼5-fold O 
greater O 
than O 
in O 
those O 
of O 
controls O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Overall O 
, O 
this O 
evidence O 
suggests O 
that O 
disparity O 
in O 
estrogen B-FAMILY 
disposition O 
and O 
the O 
subsequent O 
elevation O 
of O 
cumulative O 
body O 
burden O 
of O 
E2-3,4-Q B-SYSTEMATIC 
may O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
breast O 
cancer O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
develop O 
by O 
means O 
of O 
co O 
- O 
extrusion O 
a O 
multilayered O 
dosage O 
form O 
characterized O 
by O 
a O 
dual O 
release O 
profile O 
of O 
the O 
same O 
drug O 
. O 
Co-extrudates O 
consisted O 
of O 
two O 
concentric O 
polymer O 
matrices O 
: O 
a O 
core O 
having O 
a O 
lipophilic O 
character O 
and O 
a O 
coat O 
with O 
a O 
hydrophilic O 
character O 
. O 
Diclofenac B-SYSTEMATIC 
sodium I-SYSTEMATIC 
( O 
DS O 
) O 
was O 
incorporated O 
as O 
model O 
drug O 
in O 
both O 
layers O 
. O 
Several O 
polymers O 
were O 
screened O 
on O 
the O 
basis O 
of O 
their O 
processability O 
via O 
hot O 
melt O 
extrusion O 
( O 
HME O 
) O 
and O 
in O 
vitro O 
drug O 
release O 
. O 
Polymer O 
combinations O 
with O 
suitable O 
properties O 
( O 
i.e O 
. O 
, O 
similar O 
extrusion O 
temperature O 
, O 
appropriate O 
drug O 
release O 
profile O 
) O 
were O 
processed O 
via O 
co O 
- O 
extrusion O 
. O 
( O 
Co- O 
) O 
extruded O 
samples O 
were O 
characterized O 
in O 
terms O 
of O 
solid O 
state O 
( O 
XRD O 
, O 
SEM O 
) O 
, O 
in O 
vitro O 
drug O 
release O 
, O 
core O 
/ O 
coat O 
adhesion O 
, O 
and O 
bioavailability O 
. O 
Based O 
on O 
the O 
polymer O 
screening O 
, O 
two O 
polymer O 
combinations O 
were O 
selected O 
for O 
co O 
- O 
extrusion O 
: O 
ethylcellulose O 
( O 
core O 
) O 
combined O 
with O 
Soluplus B-TRIVIAL 
® O 
( O 
coat O 
) O 
and O 
polycaprolactone B-SYSTEMATIC 
( O 
core O 
) O 
with O 
PEO B-ABBREVIATION 
( O 
coat O 
) O 
. O 
These O 
combinations O 
were O 
successfully O 
co O 
- O 
extruded O 
. O 
XRD O 
revealed O 
that O 
DS O 
remained O 
crystalline O 
during O 
extrusion O 
in O 
ethylcellulose O 
, O 
Soluplus B-TRIVIAL 
® O 
, O 
polycaprolactone B-SYSTEMATIC 
, O 
and O 
PEO B-ABBREVIATION 
. O 
The O 
polycaprolactone B-SYSTEMATIC 
/ O 
PEO B-ABBREVIATION 
combination O 
could O 
be O 
processed O 
at O 
a O 
lower O 
temperature O 
( O 
70°C O 
) O 
, O 
vs O 
. O 
140°C O 
for O 
ethylcellulose/ O 
Soluplus B-TRIVIAL 
® O 
. O 
The O 
maximum O 
drug O 
load O 
in O 
core O 
and O 
coat O 
depended O 
on O 
the O 
extrusion O 
temperature O 
and O 
the O 
die O 
dimensions O 
, O 
while O 
adhesion O 
between O 
core O 
and O 
coat O 
was O 
mainly O 
determined O 
by O 
the O 
drug O 
load O 
and O 
by O 
the O 
extrusion O 
temperature O 
. O 
In O 
vitro O 
drug O 
release O 
from O 
the O 
co O 
- O 
extruded O 
formulations O 
was O 
reflected O 
in O 
the O 
in O 
vivo O 
behavior O 
: O 
formulations O 
with O 
a O 
higher O 
DS O 
content O 
in O 
the O 
coat O 
( O 
i.e O 
. O 
, O 
faster O 
drug O 
release O 
) O 
resulted O 
in O 
higher O 
Cmax O 
and O 
higher O 
AUC O 
values O 
. O 
Co-extrusion O 
is O 
a O 
viable O 
method O 
to O 
produce O 
in O 
a O 
single O 
step O 
a O 
multilayer O 
dosage O 
form O 
with O 
dual O 
drug O 
release O 
. O 

societal O 
needs O 
and O 
regulatory O 
certainty O 
: O 
the O 
case O 
study O 
of O 
peramivir B-TRIVIAL 
in O 
Japan O 
. O 

must O 
balance O 
societal O 
and O 
medical O 
requirements O 
against O 
the O 
need O 
for O 
certainty O 
about O 
benefit O 
and O 
risk O 
for O 
new O 
medicines O 
. O 
This O 
is O 
described O 
in O 
a O 
case O 
study O 
of O 
the O 
expedited O 
review O 
and O 
approval O 
of O 
peramivir B-TRIVIAL 
, O 
a O 
novel O 
neuraminidase O 
inhibitor O 
, O 
in O 
Japan O 
in O 
the O 
context O 
of O 
the O 
emergence O 
of O 
new O 
strain O 
of O 
influenza O 
in O 
2009 O 
. O 
The O 
case O 
illustrates O 
the O 
importance O 
of O 
regulatory O 
science O 
and O 
transparency O 
in O 
supporting O 
such O 
decision O 
making O 
. O 

of O 
non- O 
warfarin B-TRIVIAL 
-associated O 
bleeding O 
events O 
reported O 
to O 
the O 
Norwegian O 
spontaneous O 
reporting O 
system O 
. O 

: O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
analyse O 
non- O 
warfarin B-TRIVIAL 
-associated O 
bleeding O 
adverse O 
drug O 
events O 
reported O 
to O 
the O 
Norwegian O 
spontaneous O 
reporting O 
system O 
, O 
with O 
characterisation O 
of O 
the O 
bleeding O 
locations O 
, O 
outcome O 
and O 
drug O 
interactions O 
. O 
In O 
addition O 
, O 
concordance O 
in O 
assessments O 
between O 
reporters O 
and O 
evaluators O 
, O 
trend O 
shifts O 
in O 
reporting O 
, O 
and O 
detection O 
of O 
potentially O 
new O 
adverse O 
drug O 
interaction O 
signals O 
were O 
studied O 
. O 
METHODS O 
: O 
Data O 
on O 
bleeding O 
events O 
reported O 
between O 
1 O 
January O 
2003 O 
and O 
31 O 
December O 
2005 O 
were O 
retrieved O 
from O 
the O 
Norwegian O 
spontaneous O 
reporting O 
system O 
database O 
. O 
RESULTS O 
: O 
Of O 
327 O 
case O 
reports O 
of O 
non- O 
warfarin B-TRIVIAL 
-associated O 
bleeding O 
events O 
, O 
270 O 
reports O 
( O 
82.6 O 
% O 
) O 
were O 
characterised O 
as O 
serious O 
and O 
69 O 
( O 
21.1 O 
% O 
) O 
had O 
a O 
fatal O 
outcome O 
. O 
One O 
hundred O 
and O 
eighty O 
- O 
seven O 
bleeds O 
( O 
57.5 O 
% O 
) O 
were O 
gastrointestinal O 
, O 
57 O 
( O 
17.4 O 
% O 
) O 
were O 
cerebral O 
, O 
and O 
81 O 
( O 
24.8 O 
% O 
) O 
were O 
from O 
other O 
bleeding O 
sites O 
. O 
The O 
bleeding O 
sites O 
differed O 
with O 
respect O 
to O 
the O 
patient's O 
age O 
, O 
drug O 
use O 
, O 
diagnoses O 
and O 
outcomes O 
. O 
Of O 
drugs O 
associated O 
with O 
bleeding O 
, O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
/ O 
COX-2 O 
inhibitors O 
( O 
145 O 
reports O 
) O 
and O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
128 O 
reports O 
) O 
were O 
most O 
frequently O 
used O 
. O 
Only O 
fibrinolytics O 
were O 
associated O 
with O 
increased O 
mortality O 
. O 
There O 
was O 
a O 
67.4 O 
% O 
correlation O 
between O 
reporters O 
and O 
evaluators O 
in O 
assessment O 
of O 
drugs O 
associated O 
with O 
bleeding O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
with O 
considerable O 
variation O 
in O 
concordance O 
between O 
drug O 
groups O 
. O 
CONCLUSION O 
: O 
Non- O 
warfarin B-TRIVIAL 
-associated O 
bleeding O 
events O 
are O 
associated O 
with O 
substantial O 
mortality O 
. O 
Old O 
age O 
, O 
cerebral O 
bleeds O 
, O 
number O 
of O 
drugs O 
used O 
, O 
and O 
use O 
of O 
fibrinolytics O 
are O 
all O 
independently O 
associated O 
with O 
increased O 
mortality O 
. O 
The O 
recognition O 
of O 
the O 
bleeding O 
risk O 
of O 
commonly O 
used O 
drugs O 
such O 
as O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
heparins O 
may O 
be O 
insufficient O 
among O 
prescribers O 
. O 

to O 
drugs O 
targeting O 
human O 
thymidylate O 
synthase O 
( O 
TS O 
) O 
poses O 
a O 
major O 
challenge O 
in O 
the O 
field O 
of O 
anti-cancer O 
therapeutics O 
. O 
Overexpression O 
of O 
the O 
TS O 
protein O 
has O 
been O 
implicated O 
as O 
one O 
of O 
the O 
factors O 
leading O 
to O 
the O 
development O 
of O 
resistance O 
. O 
Therefore O 
, O 
repressing O 
translation O 
by O 
targeting O 
the O 
TS O 
mRNA O 
could O 
help O 
to O 
overcome O 
this O 
problem O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
that O 
the O 
compound O 
Hoechst B-TRIVIAL 
33258 I-TRIVIAL 
( O 
HT O 
) O 
can O 
reduce O 
cellular O 
TS O 
protein O 
levels O 
without O 
altering O 
TS O 
mRNA O 
levels O 
, O 
suggesting O 
that O 
it O 
modulates O 
TS O 
expression O 
at O 
the O 
translation O 
level O 
. O 
We O 
have O 
combined O 
nuclear O 
magnetic O 
resonance O 
, O 
UV-visible O 
and O 
fluorescence O 
spectroscopy O 
methods O 
with O 
docking O 
and O 
molecular O 
dynamics O 
simulations O 
to O 
study O 
the O 
interaction O 
of O 
HT O 
with O 
a O 
region O 
in O 
the O 
TS O 
mRNA O 
. O 
The O 
interaction O 
predominantly O 
involves O 
intercalation O 
of O 
HT O 
at O 
a O 
CC O 
mismatch O 
in O 
the O 
region O 
near O 
the O 
translational O 
initiation O 
site O 
. O 
Our O 
results O 
support O 
the O 
use O 
of O 
HT O 
- O 
like O 
compounds O 
to O 
guide O 
the O 
design O 
of O 
therapeutic O 
agents O 
targeting O 
TS O 
mRNA O 
. O 

investigation O 
of O 
the O 
photophysical O 
properties O 
of O 
minor O 
groove O 
bound O 
and O 
intercalated O 
DAPI B-ABBREVIATION 
through O 
quantum O 
- O 
mechanical O 
and O 
spectroscopic O 
tools O 
. O 

fluorescent O 
probe O 
4',6-diamidino-2-phenylindole B-SYSTEMATIC 
( O 
DAPI B-ABBREVIATION 
) O 
is O 
a O 
dye O 
known O 
to O 
interact O 
with O 
polynucleotides O 
in O 
a O 
non-univocal O 
manner O 
, O 
both O 
intercalation O 
and O 
minor O 
groove O 
binding O 
modes O 
being O 
possible O 
, O 
and O 
to O 
specifically O 
change O 
its O 
photophysical O 
properties O 
according O 
to O 
the O 
different O 
environments O 
. O 
To O 
investigate O 
this O 
behavior O 
, O 
quantum O 
- O 
mechanical O 
calculations O 
using O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TDDFT O 
) O 
, O 
coupled O 
with O 
polarizable O 
continuum O 
and O 
/ O 
or O 
atomistic O 
models O 
, O 
were O 
performed O 
in O 
combination O 
with O 
spectroscopic O 
measurements O 
of O 
the O 
probe O 
in O 
the O 
different O 
environments O 
, O 
ranging O 
from O 
a O 
homogeneous O 
solution O 
to O 
the O 
minor O 
groove O 
or O 
intercalation O 
pockets O 
of O 
double O 
stranded O 
nucleic O 
acids O 
. O 
According O 
to O 
our O 
simulation O 
, O 
the O 
electronic O 
transition O 
involves O 
a O 
displacement O 
of O 
the O 
electron O 
charge O 
towards O 
the O 
external O 
amidine B-SYSTEMATIC 
groups O 
and O 
this O 
feature O 
makes O 
the O 
absorption O 
energies O 
very O 
environment-sensitive O 
while O 
a O 
much O 
smaller O 
sensitivity O 
is O 
seen O 
in O 
the O 
fluorescence O 
energies O 
. O 
Moreover O 
, O 
the O 
calculations O 
show O 
that O 
the O 
DAPI B-ABBREVIATION 
molecule O 
, O 
when O 
minor O 
groove O 
bound O 
to O 
the O 
nucleic O 
acid O 
, O 
presents O 
both O 
a O 
reduced O 
geometrical O 
flexibility O 
because O 
of O 
the O 
rigid O 
DNA O 
pocket O 
and O 
a O 
reduced O 
polarization O 
due O 
to O 
the O 
very O 
" O 
apolar O 
" O 
microenvironment O 
. O 
All O 
these O 
effects O 
can O 
be O 
used O 
to O 
better O 
understand O 
the O 
observed O 
enhancement O 
of O 
the O 
fluorescence O 
, O 
which O 
makes O 
it O 
an O 
excellent O 
marker O 
for O 
DNA O 
. O 

are O 
categorized O 
by O 
the O 
extent O 
of O 
fat O 
loss O 
( O 
generalized O 
vs O 
. O 
partial O 
) O 
and O 
by O 
inheritance O 
( O 
congenital O 
vs O 
. O 
acquired O 
) O 
. O 
We O 
examined O 
whether O 
a O 
group O 
of O 
patients O 
with O 
partial O 
lipodystrophy O 
of O 
the O 
limbs O 
( O 
PLL O 
) O 
, O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
and O 
an O 
absence O 
of O 
a O 
family O 
history O 
of O 
lipodystrophy O 
constitute O 
a O 
new O 
clinical O 
subtype.RESEARCH O 
AND O 
DESIGN O 
METHODSTen O 
women O 
with O 
T2DM O 
and O 
PLL O 
were O 
identified O 
in O 
academic O 
diabetes O 
clinics O 
and O 
were O 
matched O 
by O 
age O 
, O 
sex O 
, O 
BMI O 
, O 
ethnicity O 
, O 
and O 
diabetes O 
status O 
with O 
10 O 
women O 
with O 
control O 
T2DM O 
without O 
lipodystrophy O 
. O 
All O 
patients O 
were O 
characterized O 
by O 
clinical O 
evaluation O 
and O 
hyperinsulinemic O 
clamp.RESULTSPatients O 
with O 
T2DM O 
and O 
PLL O 
exhibited O 
symmetrical O 
loss O 
of O 
subcutaneous O 
fat O 
in O 
forearms O 
, O 
or O 
forearms O 
plus O 
calves O 
, O 
and O 
acanthosis O 
nigricans O 
. O 
Maximally O 
stimulated O 
glucose B-TRIVIAL 
disposal O 
rates O 
were O 
markedly O 
reduced O 
by O 
56% O 
in O 
the O 
T2DM O 
with O 
PLL O 
group O 
compared O 
with O 
the O 
control O 
T2DM O 
patients O 
, O 
whether O 
normalized O 
by O 
body O 
weight O 
or O 
surface O 
area O 
. O 
Most O 
PLL O 
patients O 
exhibited O 
little O 
or O 
no O 
insulin O 
- O 
mediated O 
glucose B-TRIVIAL 
uptake O 
after O 
subtraction O 
of O 
non-insulin O 
- O 
mediated O 
glucose B-TRIVIAL 
uptake O 
. O 
The O 
T2DM O 
with O 
PLL O 
group O 
also O 
had O 
greater O 
elevations O 
in O 
hepatic O 
transaminases O 
and O 
triglycerides B-FAMILY 
and O 
earlier O 
onset O 
of O 
diabetes O 
compared O 
with O 
control O 
T2DM.CONCLUSIONST2DM O 
with O 
PLL O 
represents O 
a O 
previously O 
unrecognized O 
phenotype O 
of O 
lipodystrophy O 
and O 
of O 
T2DM O 
. O 
These O 
T2DM O 
patients O 
exhibit O 
symmetrical O 
lipodystrophy O 
of O 
the O 
distal O 
limbs O 
, O 
acanthosis O 
nigricans O 
, O 
marked O 
insulin O 
resistance O 
with O 
little O 
insulin O 
- O 
mediated O 
glucose B-TRIVIAL 
uptake O 
, O 
hypertriglyceridemia O 
, O 
and O 
hepatic O 
transaminase O 
elevations O 
, O 
which O 
are O 
greater O 
in O 
severity O 
than O 
observed O 
in O 
patients O 
with O 
common O 
T2DM O 
. O 

inhibited O 
PDGF-induced O 
rat O 
airway O 
smooth O 
muscle O 
cell O 
phenotypic O 
switching O 
. O 

smooth O 
muscle O 
( O 
ASM O 
) O 
cell O 
phenotypic O 
switching O 
played O 
an O 
important O 
role O 
in O 
airway O 
remodeling O 
in O 
asthma O 
. O 
In O 
vitro O 
platelet O 
- O 
derived O 
growth O 
factor O 
( O 
PDGF O 
) O 
induced O 
ASM O 
cell O 
phenotypic O 
switching O 
from O 
a O 
mature O 
to O 
pro O 
- O 
remodeling O 
phenotype O 
, O 
but O 
the O 
mechanism O 
remained O 
incompletely O 
understood O 
. O 
This O 
study O 
was O 
to O 
explore O 
the O 
effect O 
of O 
DNA O 
methyltransferase O 
inhibitor O 
5-Aza-2'-deoxycytidine B-SYSTEMATIC 
( O 
Aza-CdR B-SYSTEMATIC 
) O 
on O 
PDGF-induced O 
rat O 
ASM O 
cell O 
phenotypic O 
switching O 
and O 
biological O 
behaviors O 
. O 
Rat O 
airway O 
smooth O 
muscle O 
( O 
RASM O 
) O 
cells O 
were O 
obtained O 
by O 
primary O 
explant O 
techniques O 
. O 
Western O 
blot O 
, O 
3-dimensional O 
gel O 
contraction O 
, O 
transwell O 
and O 
wound O 
healing O 
assay O 
, O 
and O 
MTT B-ABBREVIATION 
were O 
applied O 
to O 
detect O 
cell O 
phenotypic O 
switching O 
, O 
contractility O 
, O 
migration O 
and O 
proliferation O 
, O 
respectively O 
. O 
Cytoskeleton O 
rearrangement O 
was O 
observed O 
by O 
immunofluorescence O 
. O 
Results O 
showed O 
Aza-CdR B-SYSTEMATIC 
inhibited O 
PDGF-induced O 
down O 
- O 
regulation O 
of O 
contractile O 
markers O 
in O 
RASM O 
cells O 
and O 
increased O 
cell O 
contractility O 
. O 
Aza-CdR B-SYSTEMATIC 
inhibited O 
PDGF-induced O 
RASM O 
cell O 
migration O 
by O 
abrogating O 
cell O 
morphology O 
change O 
and O 
cytoskeletal O 
reorganization O 
and O 
attenuated O 
the O 
effect O 
of O 
PDGF O 
on O 
proliferating O 
cell O 
nuclear O 
antigen O 
expression O 
and O 
cell O 
cycle O 
progression O 
, O 
ultimately O 
cell O 
proliferation O 
. O 
PDGF-induced O 
DNA O 
methyltransferase O 
1 O 
( O 
DNMT1 O 
) O 
expression O 
was O 
mediated O 
by O 
activation O 
of O 
PI3K O 
/ O 
Akt O 
and O 
ERK O 
signaling O 
in O 
RASM O 
cells O 
. O 
Selective O 
depletion O 
of O 
DNMT1 O 
protein O 
by O 
Aza-CdR B-SYSTEMATIC 
inhibited O 
PDGF-induced O 
RASM O 
cell O 
phenotypic O 
switching O 
, O 
revealing O 
DNMT1 O 
- O 
mediated O 
DNA O 
methylation O 
was O 
implicated O 
in O 
asthmatic O 
ASM O 
remodeling O 
. O 
We O 
proposed O 
for O 
the O 
first O 
time O 
that O 
DNMT1 O 
played O 
a O 
key O 
role O 
in O 
PDGF-induced O 
RASM O 
cell O 
phenotypic O 
switching O 
and O 
Aza-CdR B-SYSTEMATIC 
is O 
promising O 
in O 
intervening O 
ASM O 
remodeling O 
in O 
asthma O 
. O 
Although O 
study O 
of O 
abnormal O 
DNA O 
methylation O 
in O 
PDGF-stimulated O 
ASM O 
cells O 
is O 
in O 
its O 
infancy O 
, O 
this O 
work O 
contributes O 
to O 
providing O 
new O 
insights O 
into O 
the O 
mechanism O 
of O 
ASM O 
remodeling O 
and O 
may O 
be O 
helpful O 
for O 
developing O 
effective O 
treatments O 
for O 
airway O 
remodeling O 
in O 
asthma O 
. O 

of O 
gene O 
expression O 
data O 
to O 
determine O 
effects O 
on O 
gonad O 
phenotype O 
in O 
japanese O 
medaka O 
after O 
exposure O 
to O 
trenbolone B-TRIVIAL 
or O 
estradiol B-TRIVIAL 
. O 

aquatic O 
bioassays O 
using O 
one O 
of O 
several O 
fish O 
species O 
have O 
been O 
developed O 
or O 
are O 
in O 
the O 
process O 
of O 
being O 
developed O 
by O 
organizations O 
like O 
the O 
US O 
Environmental O 
Protection O 
Agency O 
and O 
the O 
Office O 
of O 
Economic O 
Cooperation O 
and O 
Development O 
for O 
testing O 
potential O 
endocrine O 
- O 
disrupting O 
chemicals O 
( O 
EDCs O 
) O 
. O 
Often O 
, O 
these O 
involve O 
assessment O 
of O 
the O 
gonad O 
phenotype O 
of O 
individuals O 
as O 
a O 
key O 
endpoint O 
that O 
is O 
inputted O 
into O 
a O 
risk O 
or O 
hazard O 
assessment O 
. O 
Typically O 
, O 
gonad O 
phenotype O 
is O 
determined O 
histologically O 
, O 
which O 
involves O 
specialized O 
and O 
time O 
- O 
consuming O 
techniques O 
. O 
The O 
methods O 
detailed O 
here O 
utilize O 
an O 
entirely O 
different O 
methodology O 
, O 
reverse O 
- O 
transcription O 
quantitative O 
polymerase O 
chain O 
reaction O 
, O 
to O 
determine O 
the O 
relative O 
expression O 
levels O 
of O 
4 O 
genes O 
after O 
exposure O 
to O 
either O 
17β-estradiol B-SYSTEMATIC 
or O 
17β-trenbolone B-SYSTEMATIC 
and O 
, O 
by O 
extension O 
, O 
the O 
effects O 
of O 
EDCs O 
on O 
the O 
phenotypic O 
status O 
of O 
the O 
gonad O 
. O 
The O 
4 O 
genes O 
quantified O 
, O 
Sox9b O 
, O 
protamine O 
, O 
Fig1α O 
, O 
and O 
ZPC1 O 
, O 
are O 
all O 
involved O 
in O 
gonad O 
development O 
and O 
maintenance O 
in O 
Japanese O 
medaka O 
( O 
Oryzias O 
latipes O 
) O 
; O 
these O 
data O 
were O 
then O 
inputted O 
into O 
a O 
permutational O 
multivariate O 
analysis O 
of O 
variance O 
to O 
determine O 
whether O 
significant O 
differences O 
exist O 
between O 
treatment O 
groups O 
. O 
This O 
information O 
in O 
conjunction O 
with O 
the O 
sexual O 
genotype O 
, O 
which O 
can O 
be O 
determined O 
in O 
medaka O 
, O 
can O 
be O 
used O 
to O 
determine O 
adverse O 
effects O 
of O 
exposure O 
to O 
EDCs O 
in O 
a O 
similar O 
fashion O 
to O 
the O 
histologically O 
determined O 
gonad O 
phenotype O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1344-1353 O 
. O 
© O 
2013 O 
SETAC O 
. O 

, O 
distribution O 
, O 
and O 
biotransformation O 
of O 
hexahydro-1,3,5-trinitro-1,3,5-triazine B-SYSTEMATIC 
in O 
B6C3F1 O 
mice O 
( O 
Mus O 
musculus O 
) O 
. O 

, O 
distribution O 
, O 
and O 
biotransformation O 
are O 
3 O 
critical O 
aspects O 
affecting O 
toxicant O 
action O 
in O 
animals O 
. O 
In O 
the O 
present O 
study O 
, O 
B6C3F1 O 
mice O 
( O 
Mus O 
musculus O 
) O 
were O 
exposed O 
for O 
28 O 
d O 
to O 
contaminated O 
feed O 
that O 
contained O 
1 O 
of O 
5 O 
different O 
hexahydro-1,3,5-trinitro-1,3,5-triazine B-SYSTEMATIC 
( O 
RDX O 
) O 
concentrations O 
: O 
0 O 
mg O 
/ O 
kg O 
, O 
0.5 O 
mg O 
/ O 
kg O 
, O 
5 O 
mg O 
/ O 
kg O 
, O 
50 O 
mg O 
/ O 
kg O 
, O 
and O 
500 O 
mg O 
/ O 
kg O 
. O 
The O 
authors O 
quantified O 
RDX O 
and O 
its O 
reductive O 
transformation O 
products O 
hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine B-SYSTEMATIC 
( O 
MNX O 
) O 
, O 
hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine B-SYSTEMATIC 
( O 
DNX O 
) O 
, O 
and O 
hexahydro-1,3,5-trinitroso-1,3,5-triazine B-SYSTEMATIC 
( O 
TNX O 
) O 
in O 
the O 
stomach O 
, O 
intestine O 
, O 
plasma O 
, O 
liver O 
, O 
and O 
brain O 
of O 
these O 
mice O 
. O 
Average O 
RDX O 
concentrations O 
followed O 
a O 
dose O 
- O 
dependent O 
pattern O 
for O 
all O 
matrices O 
tested O 
. O 
No O 
controls O 
had O 
concentrations O 
above O 
limits O 
of O 
detection O 
. O 
Average O 
RDX O 
concentrations O 
in O 
tissues O 
of O 
exposed O 
mice O 
ranged O 
from O 
11.1 O 
ng O 
/ O 
mL O 
to O 
182 O 
ng O 
/ O 
mL O 
, O 
25.6 O 
ng O 
/ O 
g O 
to O 
3319 O 
ng O 
/ O 
g O 
, O 
123 O 
ng O 
/ O 
g O 
to O 
233 O 
ng O 
/ O 
g O 
, O 
144 O 
ng O 
/ O 
g O 
to O 
35 O 
900 O 
ng O 
/ O 
g O 
, O 
and O 
51.1 O 
ng O 
/ O 
g O 
to O 
2697 O 
ng O 
/ O 
g O 
in O 
the O 
plasma O 
, O 
brain O 
, O 
liver O 
, O 
stomach O 
, O 
and O 
intestine O 
, O 
respectively O 
. O 
A O 
considerable O 
amount O 
of O 
RDX O 
was O 
present O 
in O 
the O 
brain O 
, O 
especially O 
in O 
the O 
highest O 
- O 
exposure O 
group O 
. O 
This O 
is O 
consistent O 
with O 
the O 
widely O 
observed O 
central O 
nervous O 
system O 
effects O 
caused O 
by O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
inhibition O 
associated O 
with O 
RDX O 
exposure O 
. O 
N-nitroso B-SYSTEMATIC 
metabolites O 
of O 
RDX O 
were O 
also O 
present O 
in O 
tested O 
tissues O 
in O 
a O 
dose O 
- O 
dependent O 
pattern O 
. O 
Average O 
MNX O 
concentrations O 
in O 
the O 
stomachs O 
of O 
mice O 
exposed O 
to O 
RDX O 
ranged O 
from O 
nondetectable O 
in O 
control O 
exposures O 
to O 
490 O 
ng O 
/ O 
g O 
in O 
the O 
highest O 
- O 
exposure O 
groups O 
. O 
In O 
the O 
brain O 
, O 
MNX O 
accumulated O 
at O 
a O 
maximum O 
average O 
concentration O 
of O 
165.1 O 
ng O 
/ O 
g O 
, O 
suggesting O 
the O 
potential O 
formation O 
of O 
MNX O 
from O 
RDX O 
within O 
the O 
brain O 
. O 
At O 
higher O 
exposures O 
, O 
DNX O 
and O 
TNX O 
were O 
present O 
in O 
the O 
stomach O 
, O 
plasma O 
, O 
and O 
brain O 
of O 
mice O 
. O 
The O 
presence O 
of O 
RDX O 
metabolites O 
at O 
notable O 
amounts O 
in O 
different O 
tissues O 
suggests O 
that O 
RDX O 
can O 
transform O 
into O 
its O 
N-nitroso B-SYSTEMATIC 
metabolites O 
in O 
vivo O 
by O 
an O 
undefined O 
mechanism O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1295-1303 O 
. O 
© O 
2013 O 
SETAC O 
. O 

triterpenoid B-FAMILY 
saponins I-FAMILY 
from O 
the O 
stems O 
of O 
Gordonia O 
longicarpa O 
. O 

new O 
triterpenoid B-FAMILY 
saponins I-FAMILY 
named O 
longicarposides B-MULTIPLE 
A-I I-MULTIPLE 
( O 
1-9 O 
) O 
, O 
together O 
with O 
three O 
known O 
saponins B-FAMILY 
( O 
10-12 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
stems O 
of O 
Gordonia O 
longicarpa O 
. O 
The O 
structures O 
of O 
the O 
saponins B-FAMILY 
were O 
elucidated O 
by O 
a O 
combination O 
of O 
1D O 
and O 
2D O 
NMR O 
techniques O 
, O 
mass O 
spectrometry O 
, O 
and O 
chemical O 
methods O 
. O 
They O 
were O 
characterized O 
to O 
be O 
oleanane B-TRIVIAL 
-type O 
saponins B-FAMILY 
with O 
sugar B-FAMILY 
moieties O 
linked O 
to O 
C-3 O 
of O 
the O 
aglycone O 
. O 
Cytotoxic O 
activities O 
of O 
these O 
saponins B-FAMILY 
were O 
evaluated O 
against O 
five O 
human O 
tumor O 
cell O 
lines O 
( O 
HCT-8 O 
, O 
Bel-7402 O 
, O 
BGC-823 O 
, O 
A549 O 
, O 
and O 
A2780 O 
) O 
by O 
using O 
the O 
MTT B-ABBREVIATION 
in O 
vitro O 
assay O 
. O 
Compounds O 
5 O 
, O 
7 O 
, O 
8 O 
, O 
10 O 
, O 
and O 
11 O 
exhibited O 
potent O 
cytotoxic O 
activity O 
with O 
IC50 O 
values O 
of O 
1.42-8.42 O 
µM O 
, O 
while O 
6 O 
, O 
9 O 
, O 
and O 
12 O 
showed O 
selective O 
cytotoxic O 
activity O 
toward O 
the O 
tested O 
cell O 
lines O 
. O 

- O 
based O 
chronic O 
toxicity O 
measurements O 
of O 
permethrin B-TRIVIAL 
to O 
Chironomus O 
dilutus O 
. O 

with O 
acute O 
toxicity O 
, O 
chronic O 
exposures O 
to O 
low O 
levels O 
of O 
contaminants O 
are O 
more O 
environmentally O 
relevant O 
, O 
but O 
fewer O 
data O 
are O 
available O 
. O 
In O 
the O 
present O 
study O 
, O 
sediment O 
toxicity O 
of O 
the O 
pyrethoid B-TRIVIAL 
permethrin I-TRIVIAL 
to O 
Chironomus O 
dilutus O 
was O 
determined O 
. O 
The O 
whole O 
- O 
life O 
- O 
cycle O 
toxicity O 
testing O 
was O 
conducted O 
with O 
the O 
endpoints O 
covering O 
survival O 
, O 
growth O 
, O 
emergence O 
, O 
and O 
reproduction O 
. O 
Permethrin B-TRIVIAL 
caused O 
50% O 
lethality O 
in O 
C O 
. O 
dilutus O 
at O 
1.83 O 
± O 
1.13 O 
µg O 
/ O 
g O 
organic O 
carbon B-SYSTEMATIC 
( O 
OC O 
) O 
and O 
1.2 O 
± O 
0.55 O 
µg O 
/ O 
g O 
OC O 
after O 
exposures O 
of O 
20 O 
d O 
( O 
before O 
pupation O 
) O 
and O 
58 O 
d O 
( O 
the O 
end O 
of O 
the O 
testing O 
) O 
, O 
respectively O 
. O 
The O 
5% O 
and O 
median O 
effect O 
concentrations O 
( O 
EC5 O 
and O 
EC50 O 
) O 
represented O 
the O 
marginal O 
and O 
toxic O 
levels O 
of O 
the O 
sublethal O 
effects O 
, O 
respectively O 
, O 
and O 
effect O 
data O 
were O 
all O 
normalized O 
to O 
the O 
controls O 
before O 
Probit O 
analysis O 
. O 
The O 
EC5s O 
for O 
growth O 
, O 
emergence O 
, O 
and O 
reproduction O 
were O 
0.034 O 
± O 
0.006 O 
µg O 
/ O 
g O 
OC O 
, O 
0.016 O 
± O 
0.008 O 
µg O 
/ O 
g O 
OC O 
, O 
and O 
0.009 O 
± O 
0.008 O 
µg O 
/ O 
g O 
OC O 
, O 
respectively O 
; O 
the O 
respective O 
EC50s O 
were O 
1.09 O 
± O 
0.56 O 
µg O 
/ O 
g O 
OC O 
, O 
0.838 O 
± O 
0.077 O 
µg O 
/ O 
g O 
OC O 
, O 
and O 
0.039 O 
± O 
0.105 O 
µg O 
/ O 
g O 
OC O 
. O 
In O 
addition O 
, O 
a O 
24-h O 
Tenax O 
extraction O 
was O 
employed O 
to O 
better O 
assess O 
permethrin B-TRIVIAL 
bioavailability O 
. O 
Ultimately O 
, O 
response O 
spectra O 
with O 
a O 
series O 
of O 
endpoints O 
were O 
developed O 
for O 
permethrin B-TRIVIAL 
using O 
either O 
OC-normalized O 
bulk O 
sediment O 
concentrations O 
or O 
bioavailability O 
- O 
based O 
Tenax O 
extractable O 
concentrations O 
as O 
the O 
dose O 
metric O 
. O 
The O 
development O 
of O 
bioavailability O 
- O 
based O 
chronic O 
toxicity O 
endpoints O 
for O 
sediment-associated O 
permethrin O 
would O 
provide O 
valuable O 
benchmarks O 
for O 
evaluating O 
ecological O 
risk O 
of O 
this O 
contaminant O 
and O 
contributing O 
to O 
improve O 
sediment O 
management O 
policies O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1403-1411 O 
. O 
© O 
2013 O 
SETAC O 
. O 

- O 
and O 
Selenium B-SYSTEMATIC 
-attenuated O 
cadmium B-SYSTEMATIC 
-induced O 
testicular O 
pathophysiology O 
in O 
rats O 
. O 

( O 
Cd B-FORMULA 
) O 
is O 
known O 
to O 
cause O 
oxidative O 
damage O 
in O 
the O 
testes O 
of O 
rats O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
protective O 
role O 
of O 
rutin B-TRIVIAL 
( O 
RUT B-ABBREVIATION 
, O 
30 O 
mg O 
/ O 
kg O 
) O 
and O 
selenium B-SYSTEMATIC 
( O 
Se B-FORMULA 
, O 
0.15 O 
ppm O 
) O 
alone O 
or O 
in O 
combination O 
against O 
Cd B-FORMULA 
( O 
200 O 
ppm)-induced O 
lipid O 
peroxidation O 
, O 
steroidogenesis O 
and O 
changes O 
in O 
antioxidant O 
defence O 
system O 
in O 
the O 
rat O 
testes O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
Cd B-FORMULA 
increased O 
lipid O 
peroxidation O 
and O 
abnormal O 
sperm O 
count O 
and O 
decreased O 
plasma O 
testosterone B-TRIVIAL 
, O 
lactate B-FAMILY 
dehydrogenase O 
, O 
acid O 
phosphatase O 
, O 
alkaline O 
phosphatase O 
and O 
testicular O 
steroidogenic O 
enzymes O 
: O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase O 
( O 
HSD O 
) O 
, O 
17β-HSD O 
activities O 
as O 
well O 
as O 
epididymal O 
sperm O 
counts O 
and O 
motility O 
, O 
while O 
RUT B-ABBREVIATION 
and O 
Se B-FORMULA 
treatment O 
reversed O 
this O 
change O 
to O 
control O 
values O 
. O 
Acute O 
intoxication O 
with O 
Cd B-FORMULA 
was O 
also O 
followed O 
by O 
significantly O 
decreased O 
activity O 
of O 
the O 
antioxidant O 
defence O 
system O 
( O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
, O 
catalase O 
( O 
CAT O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GSH B-ABBREVIATION 
-Px O 
) O 
, O 
glutathione B-TRIVIAL 
reductase O 
( O 
GR O 
) O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
and O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
) O 
. O 
Treatment O 
with O 
RUT B-ABBREVIATION 
and O 
Se B-FORMULA 
reversed O 
Cd B-FORMULA 
-induced O 
alterations O 
of O 
antioxidant O 
defence O 
system O 
and O 
significantly O 
prevented O 
Cd B-FORMULA 
-induced O 
testes O 
damage O 
and O 
depletion O 
of O 
plasma O 
and O 
testicular O 
Se B-FORMULA 
levels O 
. O 
RUT B-ABBREVIATION 
and O 
Se B-FORMULA 
appear O 
not O 
to O 
have O 
more O 
profound O 
effects O 
than O 
their O 
separate O 
effects O 
against O 
Cd B-FORMULA 
-induced O 
testicular O 
toxicity O 
, O 
although O 
Se B-FORMULA 
was O 
more O 
potent O 
than O 
RUT B-ABBREVIATION 
in O 
the O 
recovery O 
of O 
testosterone B-TRIVIAL 
levels O 
. O 
These O 
results O 
suggest O 
that O 
both O 
RUT B-ABBREVIATION 
and O 
Se B-FORMULA 
do O 
not O 
have O 
synergistic O 
role O 
against O 
Cd B-FORMULA 
-induced O 
testicular O 
injury O 
. O 

and O 
the O 
cholesterol B-TRIVIAL 
synthesis O 
inhibitors O 
simvastatin B-TRIVIAL 
and O 
triparanol B-TRIVIAL 
regulate O 
Iks O 
channel O 
function O 
differently O 
. O 

responsible O 
for O 
slowly O 
activating O 
delayed O 
- O 
rectifier O 
potassium B-SYSTEMATIC 
current O 
(I(Ks)) O 
are O 
composed O 
of O 
KCNQ1 O 
and O 
KCNE1 O 
subunits O 
, O 
and O 
these O 
channels O 
play O 
a O 
role O 
in O 
the O 
repolarization O 
of O 
cardiac O 
action O 
potentials O 
. O 
Recently O 
, O 
we O 
showed O 
that O 
the O 
antihyperlipidemic O 
drug O 
probucol B-TRIVIAL 
, O 
which O 
induces O 
QT O 
prolongation O 
, O 
decreases O 
the O 
I(Ks) O 
after O 
24-h O 
treatment O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
three O 
cholesterol B-TRIVIAL 
-lowering O 
agents O 
( O 
probucol B-TRIVIAL 
, O 
an O 
enhancer O 
of O 
cholesterol B-TRIVIAL 
efflux O 
; O 
simvastatin B-TRIVIAL 
, O 
a O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
coenzyme O 
A O 
reductase O 
inhibitor O 
; O 
and O 
triparanol B-TRIVIAL 
, O 
a O 
3β-hydroxysterol B-FAMILY 
-▵24-reductase O 
inhibitor O 
) O 
on O 
cholesterol B-TRIVIAL 
synthesis O 
, O 
the O 
KCNQ1 O 
current O 
(I(KCNQ1)) O 
, O 
and O 
the O 
I(Ks) O 
to O 
clarify O 
the O 
differences O 
in O 
the O 
modes O 
of O 
action O 
of O 
these O 
agents O 
on O 
the O 
I(Ks) O 
. O 
Probucol B-TRIVIAL 
did O 
not O 
inhibit O 
cholesterol B-TRIVIAL 
synthesis O 
and O 
had O 
no O 
effect O 
on O 
I(KCNQ1) O 
, O 
while O 
I(Ks) O 
decreased O 
after O 
24-h O 
treatment O 
. O 
Simvastatin B-TRIVIAL 
inhibited O 
cholesterol B-TRIVIAL 
synthesis O 
and O 
decreased O 
I(KCNQ1) O 
and O 
I(Ks) O 
. O 
Additionally O 
, O 
the O 
activation O 
kinetics O 
of O 
I(Ks) O 
became O 
faster O 
, O 
compared O 
with O 
that O 
of O 
control O 
I(Ks) O 
. O 
Triparanol B-TRIVIAL 
inhibited O 
cholesterol B-TRIVIAL 
synthesis O 
but O 
did O 
not O 
reduce O 
I(KCNQ1) O 
and O 
I(Ks) O 
. O 
However O 
, O 
the O 
activation O 
kinetics O 
of O 
I(Ks) O 
became O 
faster O 
. O 
Our O 
data O 
indicated O 
that O 
the O 
mechanism O 
by O 
which O 
probucol B-TRIVIAL 
inhibits O 
I(Ks) O 
was O 
not O 
mediated O 
by O 
the O 
inhibition O 
of O 
cholesterol B-TRIVIAL 
synthesis O 
but O 
depended O 
on O 
an O 
interaction O 
with O 
the O 
KCNQ1 O 
/ O 
KCNE1 O 
complex O 
. O 
Meanwhile O 
, O 
the O 
reduction O 
in O 
cholesterol B-TRIVIAL 
induced O 
by O 
simvastatin B-TRIVIAL 
and O 
triparanol B-TRIVIAL 
is O 
one O 
of O 
the O 
mechanisms O 
that O 
affects O 
the O 
kinetics O 
of O 
I(ks) O 
. O 

ameliorates O 
methotrexate B-TRIVIAL 
-induced O 
hepatotoxicity O 
in O 
rats O 
via O 
inhibition O 
of O 
lipid O 
peroxidation O 
. O 

is O 
one O 
of O 
the O 
major O 
complications O 
of O 
methotrexate B-TRIVIAL 
( O 
MTX B-ABBREVIATION 
) O 
therapy O 
. O 
This O 
study O 
was O 
carried O 
out O 
to O 
evaluate O 
the O 
possible O 
protective O 
effect O 
of O 
resveratrol B-TRIVIAL 
( O 
trans-3,5,4'-trihydroxystilbene B-SYSTEMATIC 
, O 
RVT B-ABBREVIATION 
) O 
against O 
MTX B-ABBREVIATION 
-induced O 
hepatotoxicity O 
. O 
Rats O 
were O 
randomly O 
divided O 
into O 
four O 
groups O 
as O 
control O 
, O 
MTX B-ABBREVIATION 
treated O 
( O 
7 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
intraperitoneally O 
( O 
i.p O 
. O 
) O 
, O 
once O 
daily O 
for O 
3 O 
consecutive O 
days O 
) O 
, O 
MT B-ABBREVIATION 
X O 
+ O 
RV B-ABBREVIATION 
T O 
treated O 
( O 
20 O 
mg O 
/ O 
kg O 
/ O 
day O 
, O 
i.p O 
. O 
) O 
, O 
an O 
d B-ABBREVIATION 
R I-ABBREVIATION 
VT O 
treated O 
. O 
First O 
dose O 
o O 
f B-ABBREVIATION 
R I-ABBREVIATION 
VT O 
was O 
administrated O 
3 O 
days O 
before O 
th O 
e B-ABBREVIATION 
M I-ABBREVIATION 
TX O 
injection O 
and O 
continued O 
for O 
3 O 
days O 
. O 
Histopathology O 
of O 
liver O 
was O 
evaluated O 
by O 
light O 
microscopy O 
. O 
Aspartate O 
aminotransferase O 
( O 
AST O 
) O 
, B-TRIVIAL 
alani I-TRIVIAL 
ne O 
aminotransferase O 
( O 
ALT O 
) O 
, O 
and O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
were O 
used O 
as O 
biochemical O 
markers O 
o O 
f B-ABBREVIATION 
M I-ABBREVIATION 
TX-induced O 
hepatic O 
injury O 
. O 
The O 
levels O 
o O 
f B-SYSTEMATIC 
thiobarbituric I-SYSTEMATIC 
ac I-SYSTEMATIC 
id O 
reactive O 
substances O 
( O 
TBARS O 
, O 
a O 
marker O 
of O 
lipid O 
peroxidation O 
) O 
and O 
activities O 
of O 
hepatic O 
antioxidant O 
enzymes O 
such O 
as O 
catalase O 
( O 
CAT O 
) O 
an O 
d B-TRIVIAL 
glutathio I-TRIVIAL 
n O 
e B-FORMULA 
-S-transferase O 
( O 
GST O 
) O 
were O 
used O 
to O 
analyze O 
the O 
oxidative O 
stress O 
- O 
mediated O 
lipid O 
peroxidation O 
in O 
liver O 
sections O 
. O 
Our O 
results O 
showed O 
tha O 
t B-ABBREVIATION 
M I-ABBREVIATION 
TX O 
administration O 
significantly O 
increased O 
ALT O 
, O 
ASP O 
, O 
and O 
ALP O 
levels O 
. O 
TBARS O 
, O 
CAT O 
, O 
and O 
GST O 
levels O 
were O 
also O 
markedly O 
increased O 
in O 
liver O 
afte O 
r B-ABBREVIATION 
M I-ABBREVIATION 
TX O 
administration O 
. O 
RVT O 
treatment O 
significantly O 
prevente O 
d B-ABBREVIATION 
M I-ABBREVIATION 
TX-induced O 
hepatotoxicity O 
, O 
as O 
indicated O 
by O 
AST O 
, O 
ALT O 
, O 
and O 
ALP O 
levels O 
and O 
liver O 
histopathology O 
. O 
Moreover O 
, O 
administration O 
o O 
f B-ABBREVIATION 
R I-ABBREVIATION 
VT O 
significantly O 
decreased O 
the O 
elevated O 
levels O 
of O 
TBARS O 
and O 
activities O 
of O 
CAT O 
and O 
GST O 
in O 
the O 
liver O 
compared O 
t O 
o B-ABBREVIATION 
M I-ABBREVIATION 
TX O 
- O 
treated O 
group O 
. O 
These O 
results O 
revealed O 
tha O 
t B-ABBREVIATION 
R I-ABBREVIATION 
VT O 
may O 
have O 
a O 
protective O 
effect O 
agains O 
t B-ABBREVIATION 
M I-ABBREVIATION 
TX-induced O 
hepatotoxicity O 
by O 
inhibiting O 
oxidative O 
stress O 
- O 
mediated O 
lipid O 
peroxidation O 
. O 
Consequently O 
, B-ABBREVIATION 
R I-ABBREVIATION 
VT O 
treatment O 
might O 
be O 
a O 
promising O 
strategy O 
agains O 
t B-ABBREVIATION 
M I-ABBREVIATION 
TX-induced O 
hepatotoxicity O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
protective O 
effect O 
of O 
aqueous O 
extract O 
from O 
Platycodon O 
grandiflorum O 
( O 
BC703 O 
) O 
on O 
bile O 
duct O 
ligation O 
(BDL)-induced O 
hepatic O 
fibrosis O 
in O 
rats O 
. O 
BDL O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
, O 
which O 
orally O 
received O 
distilled O 
water O 
or O 
BC703 O 
( O 
10 O 
or O 
50 O 
mg O 
/ O 
kg O 
/ O 
day O 
) O 
for O 
consecutive O 
28 O 
days O 
. O 
Antifibrotic O 
effects O 
of O 
BC703 O 
on O 
BDL-induced O 
hepatic O 
fibrosis O 
in O 
rats O 
were O 
estimated O 
by O 
assessing O 
serum O 
levels O 
of O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
, O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
, O 
total O 
bilirubin B-TRIVIAL 
( O 
TBIL O 
) O 
, O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
, O 
transforming O 
growth O 
factor O 
- O 
beta O 
1 O 
( O 
TGF-β1 O 
) O 
and O 
hepatic O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
, O 
total O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
. O 
The O 
biochemical O 
observations O 
were O 
supplemented O 
by O 
histopathological O 
examination O 
of O 
liver O 
samples O 
stained O 
with O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
and O 
Masson's O 
trichrome O 
stain O 
. O 
ALT O 
, O 
AST O 
, O 
TBIL O 
and O 
BUN O 
were O 
elevated O 
in O 
the O 
group O 
treated O 
with O 
BDL O 
alone O 
than O 
in O 
the O 
sham O 
- O 
operated O 
group O 
. O 
These O 
elevations O 
were O 
significantly O 
decreased O 
by O 
BC703 O 
treatment O 
. O 
Hepatic O 
GSH B-ABBREVIATION 
and O 
SOD O 
levels O 
, O 
depressed O 
by O 
BDL O 
, O 
were O 
also O 
increased O 
in O 
the O 
BC703 O 
group O 
. O 
In O 
addition O 
, O 
increases O 
in O 
hepatic O 
MDA B-ABBREVIATION 
and O 
NO B-FORMULA 
levels O 
in O 
the O 
BDL-induced O 
cholestasis O 
were O 
attenuated O 
by O 
BC703 O 
treatment O 
. O 
Furthermore O 
, O 
BC703 O 
treatment O 
significantly O 
reduced O 
the O 
serum O 
level O 
of O 
fibrogenic O 
cytokine O 
, O 
TGF-β1 O 
. O 
Histopathological O 
studies O 
further O 
substantiated O 
the O 
protective O 
effect O 
of O 
BC703 O 
on O 
BDL-induced O 
hepatic O 
fibrosis O 
in O 
rat O 
. O 
BC703 O 
may O 
have O 
beneficial O 
effects O 
not O 
only O 
on O 
hepatic O 
fibrosis O 
by O 
cholestasis O 
but O 
also O 
on O 
hepatic O 
fibrosis O 
development O 
in O 
patients O 
with O 
chronic O 
hepatic O 
disease O 
. O 

of O 
iron B-SYSTEMATIC 
ions O 
in O 
some O 
acetone B-SYSTEMATIC 
based O 
electrolytes O 
. O 

absorption O 
, O 
Mössbauer O 
, O 
and O 
Raman O 
spectroscopy O 
were O 
combined O 
to O 
determine O 
the O 
local O 
environment O 
of O 
iron B-SYSTEMATIC 
ions O 
in O 
acetone B-SYSTEMATIC 
based O 
solutions O 
of O 
FeCl2 B-FORMULA 
. O 
It O 
is O 
shown O 
that O 
part O 
of O 
the O 
Fe B-FORMULA 
(II) I-FORMULA 
ions O 
change O 
their O 
oxidation O 
state O 
, O 
accompanied O 
by O 
symmetry O 
change O 
from O 
octahedral O 
Fe(H2O)6(2+) B-FORMULA 
to O 
tetrahedral O 
[FeCl4](-) B-FORMULA 
at O 
large O 
acetone B-SYSTEMATIC 
concentrations O 
. O 
The O 
ratio O 
of O 
Fe B-FORMULA 
(II) I-FORMULA 
/ O 
Fe B-FORMULA 
(III) I-FORMULA 
determined O 
by O 
Mössbauer O 
spectroscopy O 
agrees O 
well O 
with O 
that O 
determined O 
by O 
the O 
X-ray O 
absorption O 
studies O 
. O 
Raman O 
measurements O 
confirm O 
quantitative O 
estimations O 
of O 
[FeCl4](-) B-FORMULA 
species O 
in O 
acetone B-SYSTEMATIC 
rich O 
solutions O 
. O 

of O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
by O 
Syncephalastrum O 
racemosum O 
CGMCC O 
3.25 O 
and O 
anti-HCV O 
activity O 
. O 

transformation O 
of O 
ursolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
UA O 
, O 
3β-hydroxy-urs-12-en-28-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
1 O 
) O 
by O 
filamentous O 
fungus O 
Syncephalastrum O 
racemosum O 
CGMCC O 
3.25 O 
was O 
conducted O 
. O 
Five O 
metabolites O 
3β B-SYSTEMATIC 
, I-SYSTEMATIC 
7β I-SYSTEMATIC 
, I-SYSTEMATIC 
21β-trihydroxy-urs-12-en-28-oic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
; O 
3β B-SYSTEMATIC 
, I-SYSTEMATIC 
21β-dihydroxy-urs-11-en-28-oic I-SYSTEMATIC 
acid-13-lactone I-SYSTEMATIC 
( O 
3 O 
) O 
; O 
1β B-SYSTEMATIC 
, I-SYSTEMATIC 
3β I-SYSTEMATIC 
, I-SYSTEMATIC 
21β-trihydroxy-urs-12-en-28-oic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
; O 
3β B-SYSTEMATIC 
, I-SYSTEMATIC 
7β I-SYSTEMATIC 
, I-SYSTEMATIC 
21β-trihydroxy-urs-1-en-28-oic I-SYSTEMATIC 
acid-13-lactone I-SYSTEMATIC 
( O 
5 O 
) O 
; O 
and O 
21-oxo-1β B-SYSTEMATIC 
, I-SYSTEMATIC 
3β-dihydroxy-urs-12-en-28-oic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
6 O 
) O 
were O 
afforded O 
. O 
Elucidation O 
of O 
the O 
structures O 
of O 
these O 
metabolites O 
was O 
primarily O 
based O 
on O 
1D O 
and O 
2D O 
NMR O 
and O 
HR-MS O 
data O 
. O 
Metabolite O 
2 O 
was O 
a O 
new O 
compound O 
. O 
In O 
addition O 
, O 
the O 
anti-HCV O 
activity O 
of O 
compounds O 
1-6 O 
was O 
evaluated O 
. O 

of O 
Exposure O 
and O 
Effect O 
in O 
Human O 
Lymphoblastoid O 
TK6 O 
Cells O 
Following O 
[13C2]-Acetaldehyde B-SYSTEMATIC 
Exposure O 
. O 

dose O 
- O 
response O 
relationship O 
for O 
biomarkers O 
of O 
exposure O 
( O 
N(2)-ethylidene-dG B-SYSTEMATIC 
adducts O 
) O 
and O 
effect O 
( O 
cell O 
survival O 
and O 
micronucleus O 
formation O 
) O 
was O 
determined O 
across O 
4.5 O 
orders O 
of O 
magnitude O 
( O 
50nM-2mM O 
) O 
using O 
[(13)C2]-acetaldehyde B-SYSTEMATIC 
exposures O 
to O 
human O 
lymphoblastoid O 
TK6 O 
cells O 
for O 
12h O 
. O 
There O 
was O 
a O 
clear O 
increase O 
in O 
exogenous O 
N B-SYSTEMATIC 
(2)-ethylidene-dG I-SYSTEMATIC 
formation O 
at O 
exposure O 
concentrations O 
≥ O 
1µM O 
, O 
whereas O 
the O 
endogenous O 
adducts O 
remained O 
nearly O 
constant O 
across O 
all O 
exposure O 
concentrations O 
, O 
with O 
an O 
average O 
of O 
3 O 
adducts O 
/ O 
10(7) O 
dG O 
. O 
Exogenous O 
adducts O 
were O 
lower O 
than O 
endogenous O 
adducts O 
at O 
concentrations O 
≤ O 
10µM O 
and O 
were O 
greater O 
than O 
endogenous O 
adducts O 
at O 
concentrations O 
≥ O 
250µM O 
. O 
When O 
the O 
endogenous O 
and O 
exogenous O 
adducts O 
were O 
summed O 
together O 
, O 
statistically O 
significant O 
increases O 
in O 
total O 
adduct O 
formation O 
over O 
the O 
endogenous O 
background O 
occurred O 
at O 
50µM O 
. O 
Cell O 
survival O 
and O 
micronucleus O 
formation O 
were O 
monitored O 
across O 
the O 
exposure O 
range O 
and O 
statistically O 
significant O 
decreases O 
in O 
cell O 
survival O 
and O 
increases O 
in O 
micronucleus O 
formation O 
occurred O 
at O 
≥ O 
1000µM O 
. O 
This O 
research O 
supports O 
the O 
hypothesis O 
that O 
endogenously O 
produced O 
reactive O 
species O 
, O 
including O 
acetaldehyde B-SYSTEMATIC 
, O 
are O 
always O 
present O 
and O 
constitute O 
the O 
majority O 
of O 
the O 
observed O 
biological O 
effects O 
following O 
very O 
low O 
exposures O 
to O 
exogenous O 
acetaldehyde B-SYSTEMATIC 
. O 
These O 
data O 
can O 
replace O 
default O 
assumptions O 
of O 
linear O 
extrapolation O 
to O 
very O 
low O 
doses O 
of O 
exogenous O 
acetaldehyde B-SYSTEMATIC 
for O 
risk O 
prediction O 
. O 

role O 
of O 
de O 
novo O 
catecholamine B-TRIVIAL 
synthesis O 
in O 
mediating O 
methylmercury B-SYSTEMATIC 
-induced O 
vesicular O 
dopamine B-TRIVIAL 
release O 
from O 
rat O 
pheochromocytoma O 
( O 
PC12 O 
) O 
cells O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
characterize O 
methylmercury B-SYSTEMATIC 
( O 
MeHg B-FORMULA 
)-induced O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
release O 
from O 
undifferentiated O 
pheochromocytoma O 
( O 
PC12 O 
) O 
cells O 
and O 
to O 
examine O 
the O 
potential O 
role O 
for O 
DA O 
synthesis O 
in O 
this O 
process O 
. O 
MeHg B-FORMULA 
caused O 
a O 
significant O 
increase O 
in O 
DA O 
release O 
that O 
was O 
both O 
concentration- O 
and O 
time O 
- O 
dependent O 
. O 
DA O 
release O 
was O 
significantly O 
increased O 
by O 
2µM O 
MeHg B-FORMULA 
at O 
60min O 
and O 
by O 
5µM O 
MeHg B-FORMULA 
at O 
30min O 
; O 
1µM O 
MeHg B-FORMULA 
was O 
without O 
effect O 
. O 
Because O 
DA O 
release O 
induced O 
by O 
5µM O 
MeHg B-FORMULA 
was O 
associated O 
with O 
a O 
significant O 
percentage O 
of O 
cell O 
death O 
at O 
60 O 
and O 
120min O 
, O 
2µM O 
MeHg B-FORMULA 
was O 
chosen O 
for O 
further O 
characterization O 
of O 
release O 
mechanisms O 
. O 
MeHg B-FORMULA 
-induced O 
DA O 
release O 
was O 
attenuated O 
but O 
not O 
abolished O 
in O 
the O 
absence O 
of O 
extracellular O 
calcium B-SYSTEMATIC 
, O 
whereas O 
the O 
vesicular O 
content O 
depleting O 
drug O 
reserpine O 
( O 
50nM O 
) O 
abolished O 
release O 
. O 
Thus O 
, O 
MeHg B-FORMULA 
-induced O 
DA O 
release O 
requires O 
vesicular O 
exocytosis O 
but O 
not O 
extracellular O 
calcium B-SYSTEMATIC 
. O 
MeHg B-FORMULA 
also O 
increased O 
intracellular O 
DA O 
and O 
the O 
rate O 
of O 
DA O 
storage O 
utilization O 
, O 
suggesting O 
a O 
role O 
for O 
DA O 
synthesis O 
in O 
MeHg B-FORMULA 
-induced O 
DA O 
release O 
. O 
The O 
tyrosine B-TRIVIAL 
hydroxylase O 
inhibitor O 
α-methyltyrosine B-SYSTEMATIC 
( O 
300µM O 
, O 
24h O 
) O 
completely O 
abolished O 
MeHg B-FORMULA 
-induced O 
DA O 
release O 
. O 
MeHg B-FORMULA 
significantly O 
increased O 
DA O 
precursor O 
accumulation O 
in O 
cells O 
treated O 
with O 
3-hydroxybenzylhydrazine B-SYSTEMATIC 
( O 
10µM O 
) O 
, O 
revealing O 
that O 
MeHg B-FORMULA 
increases O 
tyrosine B-TRIVIAL 
hydroxylase O 
activity O 
. O 
Overall O 
, O 
these O 
data O 
demonstrate O 
that O 
MeHg B-FORMULA 
facilitates O 
DA O 
synthesis O 
, O 
increases O 
intracellular O 
DA O 
, O 
and O 
augments O 
vesicular O 
exocytosis O 
. O 

assessing O 
the O 
impact O 
of O 
epilepsy O 
and O 
its O 
medication O 
on O 
the O 
risk O 
of O 
road O 
traffic O 
crashes O 
have O 
shown O 
inconsistent O 
results O 
. O 
The O 
aim O 
in O 
this O 
study O 
was O 
to O 
assess O 
this O 
risk O 
using O 
French O 
databases O 
. O 
Data O 
from O 
three O 
French O 
national O 
databases O 
were O 
extracted O 
and O 
matched O 
: O 
the O 
national O 
health O 
care O 
insurance O 
database O 
, O 
police O 
reports O 
, O 
and O 
the O 
national O 
police O 
database O 
of O 
injurious O 
crashes O 
. O 
Only O 
antiepileptics O 
prescribed O 
predominantly O 
in O 
epilepsy O 
were O 
studied O 
( O 
phenobarbital B-TRIVIAL 
, O 
phenytoin B-TRIVIAL 
, O 
ethosuximide B-TRIVIAL 
, O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
, O 
vigabatrin B-TRIVIAL 
, O 
tiagabin B-TRIVIAL 
, O 
levitiracetam B-TRIVIAL 
, O 
zonisamide B-TRIVIAL 
, O 
and O 
lacosamide B-TRIVIAL 
) O 
. O 
A O 
case O 
- O 
control O 
analysis O 
comparing O 
responsible O 
and O 
non-responsible O 
drivers O 
and O 
a O 
case O 
- O 
crossover O 
analysis O 
were O 
performed O 
. O 
Drivers O 
( O 
72 O 
685 O 
) O 
involved O 
in O 
an O 
injurious O 
crash O 
in O 
France O 
between O 
July O 
2005 O 
and O 
May O 
2008 O 
, O 
were O 
included O 
. O 
Drivers O 
exposed O 
to O 
prescribed O 
antiepileptic O 
medicines O 
( O 
n O 
= O 
251 O 
) O 
had O 
an O 
increased O 
risk O 
of O 
being O 
responsible O 
for O 
a O 
crash O 
( O 
OR O 
1.74 O 
[ O 
1.29-2.34 O 
] O 
) O 
. O 
The O 
association O 
was O 
also O 
significant O 
for O 
the O 
most O 
severe O 
epileptic O 
patients O 
( O 
n O 
= O 
99 O 
; O 
OR O 
= O 
2.2 O 
[ O 
1.31-3.69 O 
] O 
) O 
. O 
Case O 
- O 
crossover O 
analysis O 
found O 
no O 
association O 
between O 
crash O 
risk O 
and O 
treatment O 
prescription O 
. O 
Patients O 
with O 
prescription O 
of O 
antiepileptic O 
drugs O 
should O 
be O 
cautioned O 
about O 
their O 
potential O 
risk O 
of O 
road O 
traffic O 
crash O 
. O 
This O 
risk O 
is O 
however O 
more O 
likely O 
to O 
be O 
related O 
to O 
seizures O 
than O 
to O 
the O 
effect O 
of O 
antiepileptic O 
medicines O 
. O 

profile O 
of O 
paricalcitol B-TRIVIAL 
in O 
hemodialysis O 
patients O 
: O 
a O 
prospective O 
, O 
open O 
- O 
label O 
, O 
pilot O 
study O 
. O 

is O 
a O 
strong O 
predictor O 
of O 
increased O 
morbidity O 
and O 
mortality O 
in O 
hemodialysis O 
( O 
HD O 
) O 
patients O 
. O 
Paricalcitol B-TRIVIAL 
, O 
a O 
selective O 
vitamin B-FAMILY 
D I-FAMILY 
receptor O 
activator O 
used O 
for O 
prevention O 
and O 
treatment O 
of O 
secondary O 
hyperparathyroidism O 
, O 
has O 
shown O 
anti-inflammatory O 
properties O 
in O 
experimental O 
studies O 
, O 
although O 
clinical O 
data O 
are O 
scarce O 
. O 
In O 
an O 
open O 
- O 
label O 
, O 
prospective O 
, O 
single O 
center O 
, O 
pilot O 
study O 
, O 
25 O 
stable O 
HD O 
patients O 
, O 
previously O 
receiving O 
calcitriol B-TRIVIAL 
, O 
completed O 
12 O 
weeks O 
of O 
therapy O 
with O 
oral O 
paricalcitol B-TRIVIAL 
. O 
Serum O 
and O 
peripheral O 
blood O 
mononuclear O 
cell O 
( O 
PBMC O 
) O 
expression O 
profiles O 
of O 
inflammatory O 
cytokines O 
were O 
analyzed O 
. O 
Serum O 
interleukin O 
(IL)-1 O 
, O 
IL-10 O 
, O 
and O 
IL-18 O 
did O 
not O 
change O 
, O 
unlike O 
high O 
- O 
sensitivity O 
C-reactive O 
protein O 
( O 
hs-CRP O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
and O 
IL-6 O 
, O 
which O 
experienced O 
a O 
significant O 
mean O 
percent O 
decrease O 
of O 
14.3% O 
, O 
4.7% O 
, O 
and O 
5% O 
, O 
respectively O 
. O 
There O 
was O 
a O 
significant O 
reduction O 
in O 
the O 
TNF-α O 
/ O 
IL-10 O 
and O 
the O 
IL-6 O 
/ O 
IL-10 O 
ratios O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Serum O 
intact O 
parathyroid O 
hormone O 
concentration O 
experienced O 
a O 
mild O 
but O 
significant O 
reduction O 
. O 
In O 
addition O 
, O 
expression O 
levels O 
of O 
TNF-α O 
and O 
IL-6 O 
decreased O 
by O 
19.1% O 
( O 
P O 
< O 
0.01 O 
) O 
and O 
17.5% O 
( O 
P O 
< O 
0.001 O 
) O 
, O 
respectively O 
, O 
whereas O 
expression O 
of O 
IL-10 O 
increased O 
by O 
17.7% O 
( O 
P O 
< O 
0.01 O 
) O 
after O 
treatment O 
. O 
In O 
conclusion O 
, O 
paricalcitol B-TRIVIAL 
administration O 
to O 
HD O 
patients O 
is O 
associated O 
with O 
a O 
beneficial O 
effect O 
on O 
the O 
inflammatory O 
cytokine O 
serum O 
and O 
gene O 
expression O 
profile O 
of O 
PBMC O 
. O 
This O 
effect O 
may O 
contribute O 
to O 
the O 
survival O 
benefits O 
of O 
paricalcitol B-TRIVIAL 
observed O 
in O 
clinical O 
studies O 
. O 

of O 
the O 
cannabinoid O 
CB1 O 
receptor O 
( O 
CB1 O 
) O 
is O 
modulated O 
by O 
aspartate B-TRIVIAL 
residue O 
D2.63(176) O 
in O 
transmembrane O 
helix O 
( O 
TMH O 
) O 
2 O 
. O 
Interestingly O 
, O 
D2.63 O 
does O 
not O 
affect O 
the O 
affinity O 
for O 
ligand O 
binding O 
at O 
the O 
CB1 O 
receptor O 
. O 
Studies O 
in O 
class O 
A O 
G O 
protein O 
- O 
coupled O 
receptors O 
have O 
suggested O 
an O 
ionic O 
interaction O 
between O 
residues O 
of O 
TMH2 O 
and O 
7 O 
. O 
In O 
this O 
report O 
, O 
modeling O 
studies O 
identified O 
residue O 
K373 O 
in O 
the O 
extracellular-3 O 
( O 
EC-3 O 
) O 
loop O 
in O 
charged O 
interactions O 
with O 
D2.63 O 
. O 
We O 
investigated O 
this O 
possibility O 
by O 
performing O 
reciprocal O 
mutations O 
and O 
biochemical O 
studies O 
. O 
D2.63(176)A O 
, O 
K373A O 
, O 
D2.63(176)A-K373A O 
, O 
and O 
the O 
reciprocal O 
mutant O 
with O 
the O 
interacting O 
residues O 
juxtaposed O 
D2.63(176)K-K373D O 
were O 
characterized O 
using O 
radioligand O 
binding O 
and O 
guanosine B-TRIVIAL 
5'-3-O-(thio)triphosphate I-TRIVIAL 
functional O 
assays O 
. O 
None O 
of O 
the O 
mutations O 
resulted O 
in O 
a O 
significant O 
change O 
in O 
the O 
binding O 
affinity O 
of O 
N-(piperidiny-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxamide B-SYSTEMATIC 
hydrochloride I-SYSTEMATIC 
( O 
SR141716A B-IDENTIFIER 
) O 
or O 
(-)-3cis B-SYSTEMATIC 
-[2-hydroxyl-4-(1,1-dimethyl-heptyl)phenyl]-trans-4-[3-hydroxyl-propyl] I-SYSTEMATIC 
cyclohexan-1-ol I-SYSTEMATIC 
( O 
CP55,940 B-IDENTIFIER 
) O 
. O 
Modeling O 
studies O 
indicated O 
that O 
binding O 
- O 
site O 
interactions O 
and O 
energies O 
of O 
interaction O 
for O 
CP55,940 B-IDENTIFIER 
were O 
similar O 
between O 
wild O 
- O 
type O 
and O 
mutant O 
receptors O 
. O 
However O 
, O 
the O 
signaling O 
of O 
CP55,940 B-IDENTIFIER 
, O 
and O 
(R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)-methanone B-SYSTEMATIC 
mesylate I-SYSTEMATIC 
( O 
WIN55,212-2 B-IDENTIFIER 
) O 
was O 
impaired O 
at O 
the O 
D2.63(176)A-K373A O 
and O 
the O 
single- O 
alanine B-TRIVIAL 
mutants O 
. O 
In O 
contrast O 
, O 
the O 
reciprocal O 
D2.63(176)K-K373D O 
mutant O 
regained O 
function O 
for O 
both O 
CP55,940 B-IDENTIFIER 
and O 
WIN55,212-2 B-IDENTIFIER 
. O 
Computational O 
results O 
indicate O 
that O 
the O 
D2.63(176)-K373 O 
ionic O 
interaction O 
strongly O 
influences O 
the O 
conformation(s) O 
of O 
the O 
EC-3 O 
loop O 
, O 
providing O 
a O 
structure O 
- O 
based O 
rationale O 
for O 
the O 
importance O 
of O 
the O 
EC-3 O 
loop O 
to O 
signal O 
transduction O 
in O 
CB1 O 
. O 
The O 
putative O 
ionic O 
interaction O 
results O 
in O 
the O 
EC-3 O 
loop O 
pulling O 
over O 
the O 
top O 
( O 
extracellular O 
side O 
) O 
of O 
the O 
receptor O 
; O 
this O 
EC-3 O 
loop O 
conformation O 
may O 
serve O 
protective O 
and O 
mechanistic O 
roles O 
. O 
These O 
results O 
suggest O 
that O 
the O 
ionic O 
interaction O 
between O 
D2.63(176) O 
and O 
K373 O 
is O 
important O 
for O 
CB1 O 
signal O 
transduction O 
. O 

Study O 
on O 
the O 
Photodegradation O 
Mechanism O 
of O 
Nona-BDEs B-ABBREVIATION 
in O 
Methanol B-SYSTEMATIC 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
have O 
received O 
special O 
environmental O 
concern O 
due O 
to O 
their O 
potential O 
toxicity O 
to O 
humans O 
and O 
wildlife O 
worldwide O 
, O 
however O 
, O 
it O 
is O 
difficult O 
to O 
reveal O 
their O 
dominant O 
photochemical O 
degradation O 
pathways O 
by O 
experiment O 
. O 
We O 
explored O 
the O 
reaction O 
mechanisms O 
of O 
photochemical O 
degradation O 
- O 
debromination O 
of O 
three O 
nona-BDEs B-ABBREVIATION 
in O 
methanol B-SYSTEMATIC 
using O 
theoretical O 
calculations O 
, O 
in O 
which O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TDDFT O 
) O 
combined O 
with O 
the O 
polarizable O 
continuum O 
( O 
PCM O 
) O 
model O 
is O 
applied O 
. O 
The O 
selectivity O 
of O 
debromination O 
was O 
studied O 
, O 
and O 
the O 
major O 
octa-BDE B-ABBREVIATION 
products O 
photochemically O 
debrominated O 
from O 
nona-BDEs B-ABBREVIATION 
were O 
identified O 
. O 
We O 
find O 
that O 
the O 
debromination O 
reaction O 
results O 
from O 
the O 
electronic O 
transitions O 
from O 
π O 
to O 
σ* O 
orbitals O 
when O 
nona-BDEs B-ABBREVIATION 
are O 
exposed O 
to O 
UV-light O 
in O 
the O 
sunlight O 
region O 
, O 
at O 
which O 
point O 
the O 
two O 
low O 
- O 
lying O 
excited O 
states O 
for O 
each O 
nona-BDE B-ABBREVIATION 
are O 
πσ*(5 O 
Br B-FORMULA 
) O 
and O 
πσ*(4 O 
Br B-FORMULA 
) O 
, O 
which O 
correlate O 
to O 
the O 
σ* O 
orbitals O 
located O 
on O 
the O 
penta-Br B-FORMULA 
and O 
tetra-Br B-FORMULA 
substituted O 
phenyls B-FAMILY 
, O 
respectively O 
. O 
Our O 
calculations O 
indicate O 
that O 
each O 
nona-BDE B-ABBREVIATION 
may O 
degrade O 
to O 
form O 
three O 
kinds O 
of O 
octa-BDE B-ABBREVIATION 
products O 
via O 
the O 
πσ*(5 O 
Br B-FORMULA 
) O 
state O 
, O 
whereas O 
only O 
one O 
kind O 
of O 
octa-BDEs B-ABBREVIATION 
can O 
be O 
formed O 
via O 
the O 
πσ*(4 O 
Br B-FORMULA 
) O 
state O 
. O 
Our O 
calculations O 
can O 
interpret O 
the O 
recent O 
experiments O 
successfully O 
. O 

conditions O 
affect O 
the O 
absorption O 
of O 
supplemental O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
but O 
not O 
the O 
plasma O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
response O 
to O 
supplementation O 
. O 

is O 
sometimes O 
assumed O 
that O 
dietary O 
fat O 
is O 
required O 
for O 
vitamin B-FAMILY 
D I-FAMILY 
absorption O 
, O 
although O 
the O 
impact O 
of O 
different O 
amounts O 
of O 
dietary O 
fat O 
on O 
vitamin B-FAMILY 
D I-FAMILY 
absorption O 
is O 
not O 
established O 
. O 
This O 
study O 
was O 
conducted O 
to O 
determine O 
whether O 
the O 
presence O 
of O 
a O 
meal O 
and O 
the O 
fat O 
content O 
of O 
the O 
meal O 
influences O 
vitamin B-FAMILY 
D I-FAMILY 
absorption O 
or O 
the O 
25-hydroxyvitamin B-SYSTEMATIC 
D I-SYSTEMATIC 
( O 
25OHD B-SYSTEMATIC 
) O 
response O 
to O 
supplemental O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
. O 
Based O 
on O 
earlier O 
studies O 
in O 
rats O 
we O 
postulated O 
that O 
absorption O 
would O 
be O 
greatest O 
in O 
the O 
low O 
- O 
fat O 
meal O 
group O 
. O 
Sixty O 
two O 
healthy O 
older O 
men O 
and O 
women O 
were O 
randomly O 
assigned O 
to O 
one O 
of O 
three O 
meal O 
groups O 
: O 
no O 
meal O 
, O 
high O 
- O 
fat O 
meal O 
or O 
low O 
- O 
fat O 
meal O 
; O 
each O 
was O 
given O 
a O 
monthly O 
50000 O 
IU O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
supplement O 
with O 
the O 
test O 
breakfast O 
meal O 
( O 
or O 
after O 
a O 
fast O 
for O 
the O 
no O 
- O 
meal O 
group O 
) O 
and O 
followed O 
for O 
90 O 
days O 
. O 
Plasma O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
was O 
measured O 
by O 
LC O 
/ O 
MS O 
before O 
and O 
12 O 
hrs O 
after O 
the O 
first O 
dose O 
; O 
plasma O 
25OHD B-SYSTEMATIC 
was O 
measured O 
by O 
radioimmunoassay O 
at O 
baseline O 
and O 
after O 
30 O 
and O 
90 O 
days O 
. O 
The O 
mean O 
12-hr O 
increments O 
in O 
vitamin B-TRIVIAL 
D(3) I-TRIVIAL 
, O 
after O 
adjusting O 
for O 
age O 
and O 
sex O 
, O 
were O 
200.9 O 
nmol O 
/ O 
L O 
in O 
the O 
no O 
- O 
meal O 
group O 
, O 
207.4 O 
nmol O 
/ O 
L O 
in O 
the O 
high O 
- O 
fat O 
meal O 
group O 
, O 
and O 
241.1 O 
nmol O 
/ O 
L O 
in O 
the O 
low O 
- O 
fat O 
meal O 
group O 
( O 
P O 
= O 
0.038 O 
) O 
, O 
with O 
the O 
increase O 
in O 
the O 
low O 
- O 
fat O 
group O 
being O 
significantly O 
greater O 
than O 
the O 
increases O 
in O 
the O 
other O 
two O 
groups O 
. O 
However O 
, O 
increments O 
in O 
25OHD B-SYSTEMATIC 
levels O 
at O 
30 O 
and O 
90 O 
days O 
didn't O 
differ O 
significantly O 
in O 
the O 
three O 
groups O 
. O 
We O 
conclude O 
that O 
absorption O 
was O 
increased O 
when O 
a O 
50000 O 
IU O 
dose O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
was O 
taken O 
with O 
a O 
low O 
- O 
fat O 
meal O 
, O 
compared O 
with O 
a O 
high O 
- O 
fat O 
meal O 
and O 
no O 
meal O 
, O 
but O 
that O 
the O 
greater O 
absorption O 
didn't O 
result O 
in O 
higher O 
plasma O 
25OHD B-SYSTEMATIC 
levels O 
in O 
the O 
low O 
- O 
fat O 
meal O 
group O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

mainly O 
affects O 
postmenopausal O 
women O 
and O 
older O 
men O 
. O 
Gastrointestinal O 
hormones O 
released O 
after O 
meal O 
ingestion O 
, O 
such O 
as O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
peptide O 
( O 
GIP O 
) O 
and O 
glucagon O 
- O 
like O 
peptide O 
(GLP)-2 O 
, O 
have O 
been O 
shown O 
to O 
regulate O 
bone O 
turnover O 
. O 
However O 
, O 
whether O 
GLP-1 O 
, O 
another O 
important O 
gastrointestinal O 
hormone O 
, O 
and O 
its O 
analogues O 
also O 
have O 
anti-osteoporotic O 
effects O 
, O 
especially O 
in O 
aged O 
postmenopausal O 
situation O 
, O 
is O 
not O 
confirmed O 
yet O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
effects O 
of O 
the O 
GLP-1 O 
receptor O 
agonist O 
exendin-4 O 
on O 
ovariectomy O 
( O 
OVX O 
) O 
induced O 
osteoporosis O 
in O 
old O 
rats O 
. O 
Twelve O 
- O 
month O 
- O 
old O 
female O 
Sprague-Dawley O 
rats O 
were O 
subjected O 
to O 
OVX O 
, O 
and O 
exendin-4 O 
were O 
administrated O 
4 O 
weeks O 
after O 
the O 
surgery O 
and O 
lasted O 
for O 
16 O 
weeks O 
. O 
Bone O 
characters O 
and O 
related O 
serum O 
and O 
gene O 
biomarkers O 
were O 
analyzed O 
. O 
Sixteen O 
weeks O 
treatment O 
of O 
exendin-4 O 
slowed O 
down O 
the O 
body O 
weight O 
gain O 
by O 
decreasing O 
fat O 
mass O 
and O 
prevented O 
the O 
loss O 
of O 
bone O 
mass O 
in O 
old O 
OVX O 
rats O 
. O 
Exendin-4 O 
also O 
enhanced O 
the O 
bone O 
strength O 
and O 
prevented O 
the O 
deterioration O 
of O 
trabecular O 
microarchitecture O 
. O 
Moreover O 
, O 
exendin-4 O 
decreased O 
urinary O 
DPD/ O 
creatinine B-TRIVIAL 
ratio O 
and O 
serum O 
CTX-I O 
and O 
increased O 
serum O 
ALP O 
, O 
OC O 
and O 
P1NP O 
levels O 
, O 
key O 
biochemical O 
markers O 
of O 
bone O 
turnover O 
. O 
Interestingly O 
, O 
gene O 
expression O 
results O 
further O 
showed O 
that O 
exendin-4 O 
not O 
only O 
inhibited O 
bone O 
resorption O 
by O 
increasing O 
OPG O 
/ O 
RANKL O 
ratio O 
, O 
but O 
also O 
promoted O 
bone O 
formation O 
by O 
increasing O 
the O 
expressions O 
of O 
OC O 
, O 
Col1 O 
, O 
Runx2 O 
, O 
and O 
ALP O 
, O 
which O 
exhibited O 
dual O 
regulatory O 
effects O 
on O 
bone O 
turnover O 
as O 
compared O 
with O 
previous O 
anti-osteoporotic O 
agents O 
. O 
In O 
conclusion O 
, O 
these O 
findings O 
demonstrated O 
for O 
the O 
first O 
time O 
the O 
anti-osteoporotic O 
effects O 
of O 
exendin-4 O 
in O 
old O 
OVX O 
rats O 
and O 
that O 
it O 
might O 
be O 
a O 
potential O 
candidate O 
for O 
treatment O 
of O 
aged O 
postmenopausal O 
osteoporosis O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

of O 
second O 
harmonic O 
generation O 
( O 
SHG O 
) O 
are O 
produced O 
from O 
nanopatterned O 
sub O 
- O 
micrometer O 
areas O 
of O 
nonlinear O 
polymer O 
media O 
. O 
Information O 
is O 
written O 
by O 
using O 
a O 
biased-AFM O 
tip O 
, O 
a O 
highly O 
nonlinear O 
polymer O 
( O 
poly(methyl B-SYSTEMATIC 
metha I-SYSTEMATIC 
- I-SYSTEMATIC 
acrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
-co- O 
Disperse B-TRIVIAL 
Red I-TRIVIAL 
1 I-TRIVIAL 
) O 
, O 
and O 
a O 
novel O 
" O 
floating O 
- O 
tip O 
nanolithography O 
" O 
( O 
FTN O 
) O 
technique O 
. O 
Dipoles O 
are O 
oriented O 
and O 
aligned O 
at O 
the O 
nanoscale O 
under O 
the O 
biased-AFM O 
tip O 
, O 
resulting O 
in O 
SHG O 
production O 
. O 
The O 
information O 
is O 
storable O 
over O 
weeks O 
. O 

effects O 
of O 
contaminants O 
and O 
climate O 
- O 
related O 
stressors O 
: O 
High O 
temperature O 
increases O 
sensitivity O 
to O 
cadmium B-SYSTEMATIC 
. O 

emerging O 
issue O 
in O 
environmental O 
toxicology O 
is O 
in O 
understanding O 
how O 
climate O 
change O 
will O 
alter O 
responses O 
of O 
organisms O 
to O 
chemical O 
contaminants O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
characterize O 
the O 
interactive O 
effects O 
of O 
cadmium B-SYSTEMATIC 
and O 
elevated O 
temperature O 
on O 
life O 
- O 
stage O 
- O 
specific O 
responses O 
in O 
the O 
freshwater O 
snail O 
Physa O 
pomilia O 
. O 
We O 
exposed O 
developing O 
eggs O 
, O 
juveniles O 
, O 
and O 
adults O 
to O 
Cd B-FORMULA 
( O 
5 O 
µg O 
/ O 
L O 
, O 
15 O 
µg O 
/ O 
L O 
, O 
and O 
25 O 
µg O 
/ O 
L O 
for O 
eggs O 
, O 
and O 
250 O 
µg O 
/ O 
L O 
for O 
juveniles O 
and O 
adults O 
) O 
and O 
2 O 
temperatures O 
of O 
25 O 
°C O 
( O 
control O 
) O 
and O 
35 O 
°C O 
( O 
upper O 
range O 
of O 
tolerance O 
) O 
. O 
In O 
the O 
absence O 
of O 
Cd B-FORMULA 
, O 
time O 
to O 
hatch O 
was O 
shorter O 
at O 
35 O 
°C O 
compared O 
with O 
25 O 
°C O 
, O 
demonstrating O 
a O 
stimulatory O 
effect O 
of O 
the O 
higher O 
temperature O 
. O 
However O 
, O 
when O 
egg O 
masses O 
were O 
reared O 
at O 
35 O 
°C O 
and O 
exposed O 
to O 
Cd B-FORMULA 
, O 
hatching O 
success O 
was O 
significantly O 
lower O 
, O 
and O 
time O 
- O 
to O 
- O 
hatching O 
was O 
significantly O 
longer O 
. O 
The O 
effects O 
of O 
the O 
higher O 
temperature O 
and O 
Cd B-FORMULA 
on O 
newly O 
hatched O 
neonate O 
survival O 
were O 
additive O 
, O 
except O 
at O 
the O 
highest O 
Cd B-FORMULA 
concentration O 
, O 
at O 
which O 
effects O 
of O 
the O 
2 O 
stressors O 
were O 
greater O 
than O 
additive O 
. O 
Overall O 
, O 
within O 
the O 
combined O 
stressor O 
treatments O 
, O 
adult O 
snails O 
generally O 
survived O 
significantly O 
longer O 
than O 
did O 
juvenile O 
snails O 
, O 
and O 
both O 
were O 
more O 
tolerant O 
than O 
developing O 
snails O 
. O 
Many O 
climate O 
projection O 
models O 
predict O 
future O 
increases O 
in O 
global O 
temperatures O 
. O 
The O 
present O 
study O 
shows O 
that O 
combined O 
stressors O 
may O 
produce O 
greater O 
- O 
than O 
- O 
additive O 
effects O 
, O 
challenging O 
predictive O 
power O 
. O 
More O 
studies O 
are O 
needed O 
to O 
better O 
characterize O 
the O 
interactive O 
effects O 
of O 
chemical O 
contaminants O 
and O 
stressors O 
related O 
to O 
climate O 
change O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1337-1343 O 
. O 
© O 
2013 O 
SETAC O 
. O 

plus I-TRIVIAL 
monoadducts O 
in O 
a O 
lake O 
ontario O 
( O 
Canada O 
) O 
food O 
web O 
and O 
biotransformation O 
by O 
lake O 
trout O 
( O 
Salvelinus O 
namaycush O 
) O 
liver O 
microsomes O 
. O 

related O 
to O 
the O 
high O 
- O 
production O 
- O 
volume O 
flame O 
retardant O 
Dechlorane B-TRIVIAL 
Plus I-TRIVIAL 
( O 
DP O 
) O 
were O 
measured O 
in O 
a O 
Lake O 
Ontario O 
food O 
web O 
located O 
downstream O 
of O 
a O 
DP O 
manufacturing O 
plant O 
. O 
These O 
compounds O 
, O 
1,3- B-MULTIPLE 
and I-MULTIPLE 
1,5-DP I-MULTIPLE 
-monoadducts O 
( O 
DPMA O 
) O 
, O 
are O 
positional O 
isomers O 
and O 
are O 
thought O 
to O 
arise O 
from O 
the O 
incomplete O 
reaction O 
of O 
DP O 
or O 
impurities O 
in O 
the O 
DP O 
starting O 
material O 
during O 
its O 
manufacture O 
. O 
The O 
1,3-DPMA O 
isomer O 
was O 
measured O 
( O 
0.12-199 O 
ng O 
g(-1) O 
lipid O 
wt O 
) O 
in O 
all O 
trophic O 
levels O 
, O 
whereas O 
1,5-DPMA O 
was O 
measured O 
only O 
sporadically O 
in O 
the O 
food O 
web O 
and O 
was O 
not O 
detectable O 
in O 
the O 
apex O 
predator O 
, O 
lake O 
trout O 
( O 
Salvelinus O 
namaycush O 
) O 
. O 
Concentrations O 
of O 
DPMA O 
isomers O 
when O 
detected O 
in O 
Lake O 
Ontario O 
biota O 
were O 
greater O 
than O 
that O 
of O 
total O 
DP O 
for O 
all O 
trophic O 
levels O 
. O 
The O 
prevalence O 
of O 
1,3-DPMA O 
in O 
the O 
food O 
web O 
, O 
and O 
especially O 
in O 
lake O 
trout O 
, O 
may O 
be O 
due O 
to O 
obstruction O 
of O 
the O 
existing O 
carbon B-SYSTEMATIC 
double O 
bond O 
to O 
enzyme O 
attack O 
, O 
rendering O 
it O 
less O 
readily O 
metabolized O 
. O 
To O 
examine O 
this O 
hypothesis O 
, O 
biotransformation O 
kinetic O 
experiments O 
using O 
in O 
vitro O 
lake O 
trout O 
liver O 
microsomal O 
exposures O 
were O 
performed O 
. O 
Zero O 
- O 
order O 
depletion O 
rate O 
constants O 
for O 
1,3- O 
and O 
1,5-DPMA O 
were O 
92.2 O 
and O 
134.6 O 
pmole O 
h(-1) O 
, O 
respectively O 
, O 
with O 
corresponding O 
half O 
- O 
lives O 
of O 
2.03 O 
± O 
0.14 O 
h O 
( O 
1,3-DPMA O 
) O 
and O 
1.39 O 
± O 
0.09 O 
h O 
( O 
1,5-DPMA O 
) O 
. O 
Furthermore O 
, O 
the O 
1,5- O 
isomer O 
was O 
depleted O 
to O 
a O 
greater O 
extent O 
than O 
1,3-DPMA O 
. O 
Specific O 
biotransformation O 
products O 
were O 
not O 
identified O 
. O 
These O 
data O 
support O 
the O 
hypothesis O 
that O 
1,5-DPMA O 
is O 
more O 
readily O 
metabolized O 
than O 
1,3-DPMA O 
by O 
lake O 
trout O 
. O 
The O 
present O 
study O 
also O 
shows O 
that O 
the O 
concentrations O 
of O 
these O 
isomers O 
, O 
which O 
the O 
authors O 
speculate O 
might O 
be O 
unintended O 
impurities O 
or O 
byproducts O 
in O 
some O 
technical O 
DP O 
formulations O 
, O 
exceed O 
that O 
of O 
the O 
intended O 
product O 
in O 
biota O 
. O 
Environ O 
Toxicol O 
Chem O 
2013;32 O 
: O 
1376-1381 O 
. O 
© O 
2013 O 
SETAC O 
. O 

anisotropic O 
wetting O 
of O 
functional O 
organic O 
molecules O 
on O 
a O 
patterned O 
surface O 
and O 
the O 
development O 
of O 
a O 
photolithography O 
- O 
compatible O 
method O 
to O 
fabricate O 
addressable O 
organic O 
structures O 
is O 
reported O 
. O 
For O 
example O 
, O 
DtCDQA O 
is O 
grown O 
on O 
a O 
SiO2 B-FORMULA 
surface O 
with O 
a O 
Au B-FORMULA 
prepattern O 
, O 
achieving O 
a O 
high O 
resolution O 
cross O 
- O 
over O 
organic O 
structure O 
. O 

ablation O 
of O 
tissue O 
- O 
nonspecific O 
alkaline O 
phosphatase O 
( O 
TNAP O 
) O 
( O 
Alpl(- O 
/ O 
- O 
) O 
mice O 
) O 
leads O 
to O 
hypophosphatasia O 
, O 
characterized O 
by O 
rickets O 
/ O 
osteomalacia O 
attributable O 
to O 
elevated O 
levels O 
of O 
extracellular O 
inorganic O 
pyrophosphate B-SYSTEMATIC 
, O 
a O 
potent O 
mineralization O 
inhibitor O 
. O 
Osteopontin O 
( O 
OPN O 
) O 
is O 
also O 
elevated O 
in O 
the O 
plasma O 
and O 
skeleton O 
of O 
Alpl(- O 
/ O 
- O 
) O 
mice O 
. O 
Phosphorylated O 
OPN O 
is O 
known O 
to O 
inhibit O 
mineralization O 
, O 
however O 
, O 
the O 
phosphorylation O 
status O 
of O 
the O 
increased O 
OPN O 
found O 
in O 
Alpl(- O 
/ O 
- O 
) O 
mice O 
is O 
unknown O 
. O 
Here O 
, O 
we O 
generated O 
a O 
transgenic O 
mouse O 
line O 
expressing O 
human O 
TNAP O 
under O 
control O 
of O 
an O 
osteoblast O 
- O 
specific O 
Col1a1 O 
promoter O 
( O 
Col1a1-Tnap O 
) O 
. O 
The O 
transgene O 
is O 
expressed O 
in O 
osteoblasts O 
, O 
periosteum O 
, O 
and O 
cortical O 
bones O 
, O 
and O 
plasma O 
levels O 
of O 
TNAP O 
in O 
mice O 
expressing O 
Col1a1-Tnap O 
are O 
10-20 O 
times O 
higher O 
than O 
those O 
of O 
wild O 
- O 
type O 
mice O 
. O 
The O 
Col1a1-Tnap O 
animals O 
are O 
healthy O 
and O 
exhibit O 
increased O 
bone O 
mineralization O 
by O 
microCT O 
analysis O 
. O 
Crossbreeding O 
of O 
Col1a1-Tnap O 
transgenic O 
mice O 
to O 
Alpl(- O 
/ O 
- O 
) O 
mice O 
rescues O 
the O 
lethal O 
hypophosphatasia O 
phenotype O 
characteristic O 
of O 
this O 
disease O 
model O 
. O 
Osteoblasts O 
from O 
[ O 
Col1a1-Tnap O 
] O 
mice O 
mineralize O 
better O 
than O 
non-transgenic O 
controls O 
and O 
osteoblasts O 
from O 
[ O 
Col1a1-Tnap(+ O 
/ O 
- O 
) O 
; O 
Alpl(- O 
/ O 
- O 
) O 
] O 
mice O 
are O 
able O 
to O 
mineralize O 
to O 
the O 
level O 
of O 
Alpl(+ O 
/ O 
- O 
) O 
heterozygous O 
osteoblasts O 
, O 
while O 
Alpl(- O 
/ O 
- O 
) O 
osteoblasts O 
show O 
no O 
mineralization O 
. O 
We O 
found O 
that O 
the O 
increased O 
levels O 
of O 
OPN O 
in O 
bone O 
tissue O 
of O 
Alpl(- O 
/ O 
- O 
) O 
mice O 
are O 
comprised O 
of O 
phosphorylated O 
forms O 
of O 
OPN O 
while O 
WT O 
and O 
[ O 
Col1a1-Tnap(+ O 
/ O 
- O 
) O 
; O 
Alpl(- O 
/ O 
- O 
) O 
] O 
mice O 
had O 
both O 
phosphorylated O 
and O 
dephosphorylated O 
forms O 
of O 
OPN O 
. O 
OPN O 
from O 
[ O 
Col1a1-Tnap O 
] O 
osteoblasts O 
were O 
more O 
phosphorylated O 
than O 
non-transgenic O 
control O 
cells O 
. O 
Titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
-liquid O 
chromatography O 
and O 
tandem O 
mass O 
spectrometry O 
analysis O 
revealed O 
that O 
OPN O 
peptides O 
derived O 
from O 
Alpl(- O 
/ O 
- O 
) O 
bone O 
and O 
osteoblasts O 
yielded O 
a O 
higher O 
proportion O 
of O 
phosphorylated O 
peptides O 
than O 
samples O 
from O 
WT O 
mice O 
, O 
and O 
at O 
least O 
two O 
phosphopeptides O 
, O 
p(S(174) O 
FQVS(178) O 
DEQY(182) O 
PDAT(186) O 
DEDLT(191) O 
)SHMK O 
and O 
FRIp(S(299) O 
HELES(304) O 
S(305) O 
S(306) O 
S(307) O 
)EVN O 
, O 
with O 
one O 
non-localized O 
site O 
each O 
, O 
appear O 
to O 
be O 
preferred O 
sites O 
of O 
TNAP O 
action O 
on O 
OPN O 
. O 
Our O 
data O 
suggest O 
that O 
the O 
pro O 
- O 
mineralization O 
role O 
of O 
TNAP O 
may O 
be O 
related O 
not O 
only O 
to O 
its O 
accepted O 
pyrophosphatase O 
activity O 
but O 
also O 
to O 
its O 
ability O 
to O 
modify O 
the O 
phosphorylation O 
status O 
of O 
OPN O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

new O 
liquid O 
crystalline O 
( O 
LC O 
) O 
phase O 
with O 
uniform O 
tilt O 
, O 
local O 
polar O 
order O 
and O 
capability O 
of O 
symmetry O 
breaking O 
is O 
found O 
for O 
a O 
bent-core O 
mesogen O 
combining O 
a O 
4-cyanoresorcinol B-SYSTEMATIC 
unit O 
with O 
two O 
azobenzene B-SYSTEMATIC 
wings O 
. O 
The O 
combination O 
of O 
local O 
polar O 
order O 
and O 
long O 
range O 
synclinic O 
tilt O 
in O 
this O 
SmCs O 
PR O 
phase O 
leads O 
, O 
under O 
special O 
conditions O 
, O 
to O 
macroscopic O 
domains O 
with O 
opposite O 
chirality O 
, O 
though O 
the O 
molecules O 
themselves O 
are O 
achiral O 
. O 

we O 
demonstrate O 
the O 
generation O 
of O 
polymer O 
monolithic O 
surfaces O 
possessing O 
a O 
gradient O 
of O 
pore O 
and O 
polymer O 
globule O 
sizes O 
from O 
~0.1 O 
to O 
~0.5 O 
μm O 
defined O 
by O 
the O 
composition O 
of O 
two O 
polymerization O 
mixtures O 
injected O 
into O 
a O 
microfluidic O 
chip O 
. O 
To O 
generate O 
the O 
gradient O 
, O 
we O 
used O 
a O 
PDMS B-ABBREVIATION 
microfluidic O 
chip O 
with O 
a O 
cascade O 
micromixer O 
with O 
a O 
subsequent O 
reaction O 
chamber O 
for O 
the O 
formation O 
of O 
a O 
continuous O 
gradient O 
film O 
. O 
The O 
micromixer O 
has O 
zigzag O 
channels O 
of O 
400 O 
× O 
680 O 
μm(2) O 
cross O 
section O 
and O 
six O 
cascades O 
. O 
The O 
chip O 
was O 
used O 
with O 
a O 
reversible O 
bonding O 
connection O 
, O 
realized O 
by O 
curing O 
agent O 
coating O 
. O 
After O 
polymerization O 
in O 
the O 
microfluidic O 
chip O 
the O 
reversible O 
bond O 
was O 
opened O 
, O 
resulting O 
in O 
a O 
450 O 
μm O 
thick O 
polymer O 
film O 
possessing O 
the O 
pore O 
size O 
gradient O 
. O 
The O 
gradient O 
formation O 
in O 
the O 
microfluidic O 
reaction O 
chamber O 
was O 
studied O 
using O 
microscopic O 
laser O 
- O 
induced O 
fluorescence O 
( O 
μLIF O 
) O 
and O 
different O 
model O 
fluids O 
. O 
Formation O 
of O 
linear O 
gradients O 
was O 
shown O 
using O 
the O 
fluids O 
of O 
the O 
same O 
density O 
by O 
both O 
diffusive O 
mixing O 
at O 
flow O 
rates O 
of O 
0.001 O 
mL O 
/ O 
min O 
and O 
in O 
a O 
convective O 
mixing O 
regime O 
at O 
flow O 
rates O 
of O 
20 O 
mL O 
/ O 
min O 
. O 
By O 
using O 
different O 
density O 
fluids O 
, O 
formation O 
of O 
a O 
two O 
- O 
dimensional O 
wedge O 
- O 
like O 
gradient O 
controlled O 
by O 
the O 
density O 
difference O 
and O 
orientation O 
of O 
the O 
microfluidic O 
chip O 
was O 
observed O 
. O 

- O 
driven O 
optimization O 
of O 
( B-FAMILY 
pyridin-3-yl I-FAMILY 
) I-FAMILY 
benzoxazinyl-oxazolidinones I-FAMILY 
leading O 
to O 
a O 
promising O 
antibacterial O 
agent O 
. O 

solubility O 
- O 
driven O 
structural O 
modification O 
of O 
( B-FAMILY 
pyridin-3-yl I-FAMILY 
) I-FAMILY 
benzoxazinyl-oxazolidinones I-FAMILY 
is O 
described O 
, O 
which O 
resulted O 
in O 
the O 
development O 
of O 
a O 
new O 
series O 
of O 
benzoxazinyl-oxazolidinone B-SYSTEMATIC 
analogues O 
with O 
high O 
antibacterial O 
activity O 
against O 
Gram O 
- O 
positive O 
pathogens O 
, O 
including O 
that O 
against O 
linezolid B-TRIVIAL 
-resistant O 
strains O 
and O 
low O 
hERG O 
inhibition O 
. O 
With O 
regard O 
to O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
trends O 
among O 
the O 
various O 
substituents O 
on O 
the O 
pyridyl B-SYSTEMATIC 
ring O 
, O 
relatively O 
small O 
and O 
nonbasic O 
substituents O 
were O 
preferable O 
to O 
sterically O 
demanding O 
or O 
basic O 
substituents O 
. O 
Oxazolidinone B-SYSTEMATIC 
ring O 
substitution O 
on O 
the O 
pyridyl B-SYSTEMATIC 
ring O 
generated O 
analogues O 
with O 
antibacterial O 
activity O 
superior O 
to O 
imidazolidinone B-SYSTEMATIC 
ring O 
. O 
Solubility O 
was O 
enhanced O 
by O 
the O 
incorporation O 
of O 
polar O 
groups O 
, O 
especially O 
when O 
compounds O 
were O 
converted O 
to O 
their O 
prodrugs O 
. O 
Among O 
the O 
prodrugs O 
, O 
compound O 
85 O 
exhibited O 
excellent O 
solubility O 
and O 
a O 
good O 
pharmacokinetic O 
profile O 
. O 
In O 
a O 
MRSA O 
systemic O 
infection O 
model O 
, O 
compound O 
85 O 
displayed O 
an O 
ED50 O 
= O 
5 O 
mg O 
/ O 
kg O 
, O 
a O 
potency O 
that O 
is O 
2-fold O 
better O 
than O 
that O 
of O 
linezolid B-TRIVIAL 
. O 

, O 
Conductive O 
, O 
and O 
Printable O 
Composites O 
Consisting O 
of O 
TEMPO B-ABBREVIATION 
-Oxidized O 
Nanocellulose O 
and O 
Carbon B-SYSTEMATIC 
Nanotube O 
. O 

, O 
transparent O 
, O 
conductive O 
and O 
printable O 
nanocomposites O 
were O 
successfully O 
prepared O 
by O 
mixing O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
with O 
2,2,6,6-tetramethylpiperidine-1-oxyl B-SYSTEMATIC 
( O 
TEMPO B-ABBREVIATION 
)-oxidized O 
cellulose O 
nanofibrils O 
( O 
TOCNs O 
) O 
with O 
abundant O 
sodium B-SYSTEMATIC 
carboxyl I-SYSTEMATIC 
groups O 
on O 
the O 
crystalline O 
nanocellulose O 
surfaces O 
. O 
The O 
surface O 
- O 
anionic O 
cellulose O 
nanofibrils O 
had O 
reinforcing O 
and O 
nanodispersing O 
effects O 
on O 
the O 
CNTs O 
both O 
in O 
water O 
used O 
as O 
the O 
dispersed O 
medium O 
and O 
in O 
the O 
dried O 
composite O 
film O 
, O 
providing O 
highly O 
conductive O 
and O 
printable O 
nanocomposites O 
with O 
a O 
small O 
amount O 
of O 
CNTs O 
. O 
TOCNs O 
are O 
therefore O 
expected O 
as O 
an O 
effective O 
flexible O 
matrix O 
that O 
can O 
be O 
used O 
as O 
an O 
alternative O 
to O 
conventional O 
polymers O 
for O 
various O 
electrical O 
materials O 
, O 
when O 
nanocomposited O 
with O 
CNTs O 
and O 
also O 
graphene B-TRIVIAL 
. O 
Our O 
findings O 
provide O 
a O 
promising O 
route O 
to O 
realize O 
green O 
and O 
flexible O 
electronics O 
. O 

development O 
: O 
brassinosteroids B-FAMILY 
go O 
out O 
of O 
bounds O 
. O 

in O 
plants O 
requires O 
defining O 
boundary O 
domains O 
that O 
separate O 
and O 
organize O 
the O 
development O 
of O 
the O 
neighboring O 
organs O 
. O 
Two O 
papers O 
now O 
show O 
how O 
the O 
interplay O 
between O 
brassinosteroid B-FAMILY 
phytohormones O 
and O 
frontier O 
genes O 
contributes O 
to O 
boundary O 
formation O 
in O 
plants O 
. O 

enhances O 
antigen O 
- O 
specific O 
cytotoxic O 
T O 
cell O 
responses O 
against O 
immune O 
- O 
resistant O 
cancer O 
cells O 
generated O 
by O 
STAT3-ablated O 
dendritic O 
cells O 
. O 

cell O 
( O 
DC O 
) O 
- O 
based O 
vaccines O 
have O 
received O 
attention O 
as O 
a O 
new O 
therapeutic O 
modality O 
against O 
cancer O 
. O 
However O 
, O 
increased O 
STAT3 O 
activity O 
in O 
the O 
tumor O 
microenvironment O 
makes O 
DCs O 
tolerogenic O 
and O 
suppresses O 
their O 
antitumor O 
activity O 
. O 
In O 
this O 
study O 
, O 
we O 
explored O 
the O 
effects O 
of O 
a O 
combination O 
treatment O 
consisting O 
of O 
a O 
proteasome O 
inhibitor O 
, O 
bortezomib B-TRIVIAL 
, O 
and O 
an O 
antigen O 
specific O 
STAT3-ablated O 
( O 
STAT3(- O 
/ O 
- O 
) O 
) O 
DC O 
- O 
based O 
vaccine O 
on O 
the O 
control O 
of O 
TC-1(P3) O 
tumors O 
, O 
a O 
p53-degraded O 
immune O 
resistant O 
cancer O 
cells O 
. O 
We O 
found O 
that O 
E7-antigen O 
expressing O 
STAT3(- O 
/ O 
- O 
) O 
DC O 
( O 
E7-DC-1STAT3(- O 
/ O 
- O 
) O 
) O 
vaccination O 
enhanced O 
generation O 
of O 
E7-specific O 
CD8(+) O 
T O 
cells O 
, O 
but O 
was O 
not O 
enough O 
to O 
control O 
TC-1(P3) O 
cancer O 
cells O 
. O 
Therefore O 
, O 
we O 
investigated O 
whether O 
bortezomib B-TRIVIAL 
could O 
create O 
a O 
synergistic O 
effect O 
with O 
E7-DC-1STAT3(- O 
/ O 
- O 
) O 
vaccination O 
. O 
We O 
found O 
that O 
apoptosis O 
via O 
down O 
- O 
regulation O 
of O 
STAT3 O 
and O 
NF-κB O 
and O 
up O 
- O 
regulation O 
of O 
Fas O 
and O 
death O 
receptor O 
5 O 
( O 
DR5 O 
) O 
expression O 
in O 
TC-1(P3) O 
induced O 
by O 
bortezomib B-TRIVIAL 
was O 
independent O 
of O 
p53 O 
status O 
. O 
We O 
also O 
observed O 
that O 
TC-1(P3) O 
cells O 
pretreated O 
with O 
bortezomib B-TRIVIAL 
had O 
markedly O 
enhanced O 
anti-tumor O 
effects O 
on O 
E7-specific O 
CD8(+) O 
T O 
cells O 
through O 
a O 
Fas O 
/ O 
DR5 O 
- O 
mediated O 
mechanism O 
. O 
In O 
addition O 
, O 
TC-1(P3) O 
tumor O 
- O 
bearing O 
mice O 
treated O 
with O 
bortezomib B-TRIVIAL 
prior O 
to O 
vaccination O 
with O 
E7-DC-1STAT3(- O 
/ O 
- O 
) O 
demonstrated O 
enhanced O 
generation O 
of O 
E7-specific O 
CD8(+) O 
T O 
cells O 
and O 
prolonged O 
survival O 
compared O 
to O 
those O 
treated O 
with O 
monotherapy O 
. O 
These O 
results O 
suggest O 
that O 
the O 
anti-tumor O 
effects O 
against O 
a O 
p53-degraded O 
immune O 
resistant O 
variant O 
generated O 
by O 
antigen O 
- O 
expressing O 
STAT3-ablated O 
mature O 
DCs O 
may O 
be O 
enhanced O 
by O 
bortezomib B-TRIVIAL 
via O 
death O 
receptor O 
- O 
mediated O 
apoptosis O 
. O 

/ O 
chitosan O 
controlled O 
release O 
nanopreparations O 
of O 
tamoxifen B-SYSTEMATIC 
citrate I-SYSTEMATIC 
: O 
Loading O 
, O 
enzyme O 
- O 
trigger O 
release O 
and O 
cell O 
uptake O 
. O 

citrate I-SYSTEMATIC 
( O 
TAM B-ABBREVIATION 
) O 
, O 
an O 
anticancer O 
drug O 
with O 
amphiphilic O 
properties O 
, O 
was O 
loaded O 
in O 
lecithin B-FAMILY 
/ O 
chitosan O 
nanoparticles O 
( O 
LCN O 
) O 
with O 
a O 
view O 
to O 
oral O 
administration O 
. O 
The O 
influence O 
of O 
tamoxifen B-TRIVIAL 
loading O 
on O 
the O 
physico O 
- O 
chemical O 
properties O 
of O 
nanoparticles O 
was O 
studied O 
. O 
Size O 
, O 
surface O 
charge O 
and O 
morphological O 
properties O 
of O 
tamoxifen B-TRIVIAL 
-loaded O 
nanoparticles O 
( O 
LCN- O 
TAM B-ABBREVIATION 
) O 
were O 
assessed O 
. O 
The O 
increase O 
in O 
the O 
tamoxifen B-TRIVIAL 
amount O 
in O 
the O 
LCN- O 
TAM B-ABBREVIATION 
preparation O 
up O 
to O 
60mg O 
/ O 
100ml O 
maintained O 
the O 
positive O 
zeta O 
potential O 
value O 
of O 
about O 
+ O 
45mV O 
. O 
A O 
statistically O 
significant O 
decrease O 
in O 
particle O 
size O 
was O 
observed O 
for O 
TAM B-ABBREVIATION 
amounts O 
between O 
5 O 
and O 
20mg O 
. O 
A O 
strong O 
influence O 
of O 
loaded O 
tamoxifen B-TRIVIAL 
on O 
the O 
structure O 
of O 
lecithin B-FAMILY 
/ O 
chitosan O 
nanoparticles O 
was O 
observed O 
, O 
supported O 
by O 
the O 
quantification O 
of O 
free O 
chitosan O 
and O 
morphological O 
analysis O 
. O 
A O 
loading O 
of O 
tamoxifen B-TRIVIAL 
in O 
nanoparticles O 
of O 
around O 
19% O 
was O 
obtained O 
. O 
The O 
release O 
of O 
the O 
drug O 
from O 
the O 
LCN- O 
TAM B-ABBREVIATION 
colloidal O 
dispersion O 
was O 
measured O 
, O 
showing O 
that O 
tamoxifen B-SYSTEMATIC 
citrate I-SYSTEMATIC 
was O 
released O 
very O 
slowly O 
in O 
simulated O 
gastro O 
- O 
intestinal O 
fluids O 
without O 
enzymes O 
. O 
When O 
enzymes O 
able O 
to O 
dismantle O 
the O 
nanoparticle O 
structure O 
were O 
added O 
to O 
the O 
dissolution O 
medium O 
, O 
drug O 
release O 
was O 
triggered O 
and O 
continued O 
in O 
a O 
prolonged O 
manner O 
. O 
Tamoxifen B-TRIVIAL 
-loaded O 
nanoparticles O 
showed O 
cytotoxicity O 
towards O 
MCF-7 O 
cells O 
comparable O 
to O 
that O 
obtained O 
with O 
tamoxifen B-SYSTEMATIC 
citrate I-SYSTEMATIC 
solution O 
, O 
but O 
the O 
rate O 
of O 
this O 
toxic O 
effect O 
was O 
dependent O 
on O 
drug O 
release O 
. O 
Caco-2 O 
cells O 
, O 
used O 
as O 
a O 
model O 
of O 
the O 
intestinal O 
epithelium O 
, O 
were O 
shown O 
to O 
take O 
up O 
the O 
TAM B-ABBREVIATION 
loaded O 
nanoparticles O 
extensively O 
. O 

of O 
the O 
safe O 
use O 
concentrations O 
of O 
the O 
preservative O 
1,2-benzisothiazolin-3-one B-SYSTEMATIC 
( O 
BIT B-ABBREVIATION 
) O 
in O 
consumer O 
cleaning O 
products O 
and O 
sunscreens O 
. O 

( O 
BIT B-ABBREVIATION 
; O 
CAS O 
# O 
2634-33-5 B-IDENTIFIER 
) O 
is O 
a O 
preservative O 
used O 
in O 
consumer O 
products O 
. O 
Dermal O 
exposure O 
to O 
BIT B-ABBREVIATION 
at O 
sufficient O 
dose O 
and O 
duration O 
can O 
produce O 
skin O 
sensitization O 
and O 
allergic O 
contact O 
dermatitis O 
in O 
animals O 
and O 
susceptible O 
humans.The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
derive O 
a O 
maximal O 
concentration O 
of O 
BIT B-ABBREVIATION 
in O 
various O 
consumer O 
products O 
that O 
would O 
result O 
in O 
exposures O 
below O 
the O 
No O 
Expected O 
Sensitization O 
Induction O 
Level O 
( O 
NESIL O 
) O 
, O 
a O 
dose O 
below O 
which O 
skin O 
sensitization O 
should O 
not O 
occur O 
. O 
A O 
screening O 
level O 
exposure O 
estimate O 
was O 
performed O 
for O 
several O 
product O 
use O 
scenarios O 
with O 
sunscreen O 
, O 
laundry O 
detergent O 
, O 
dish O 
soap O 
, O 
and O 
spray O 
cleaner O 
. O 
We O 
calculated O 
that O 
BIT B-ABBREVIATION 
concentrations O 
below O 
the O 
following O 
concentrations O 
of O 
0.0075% O 
, O 
0.035% O 
, O 
0.035% O 
, O 
0.021% O 
in O 
sunscreen O 
, O 
laundry O 
detergent O 
, O 
dish O 
soap O 
, O 
and O 
spray O 
cleaner O 
, O 
respectively O 
, O 
are O 
unlikely O 
to O 
induce O 
skin O 
sensitization O 
. O 
We O 
completed O 
a O 
pilot O 
study O 
consisting O 
of O 
bulk O 
sample O 
analysis O 
of O 
one O 
representative O 
product O 
from O 
each O 
category O 
labelled O 
as O 
containing O 
BIT B-ABBREVIATION 
, O 
and O 
found O 
BIT B-ABBREVIATION 
concentrations O 
of O 
0.0009% O 
and O 
0.0027% O 
for O 
sunscreen O 
and O 
dish O 
soap O 
, O 
respectively O 
. O 
BIT B-ABBREVIATION 
was O 
not O 
detected O 
in O 
the O 
laundry O 
detergent O 
and O 
spray O 
cleaner O 
products O 
above O 
the O 
limit O 
of O 
detection O 
of O 
0.0006% O 
. O 
Based O 
on O 
publically O 
available O 
data O 
for O 
product O 
formulations O 
and O 
our O 
results O 
, O 
we O 
were O 
able O 
to O 
establish O 
that O 
cleaning O 
products O 
and O 
sunscreens O 
likely O 
contain O 
BIT B-ABBREVIATION 
at O 
concentrations O 
similar O 
to O 
or O 
less O 
than O 
our O 
calculated O 
maximal O 
safe O 
concentrations O 
and O 
that O 
exposures O 
are O 
unlikely O 
to O 
induce O 
skin O 
sensitization O 
in O 
most O 
users O 
. O 

number O 
of O 
snake O 
venom O 
thrombin O 
- O 
like O 
enzymes O 
( O 
TLEs O 
) O 
have O 
already O 
been O 
characterized O 
. O 
Some O 
TLEs O 
play O 
significant O 
roles O 
in O 
vessel O 
injury O 
hemostasis O 
. O 
A O 
novel O 
TLE O 
( O 
Agacutase O 
) O 
was O 
purified O 
from O 
Deinagkistrodon O 
acutus O 
snake O 
venom O 
by O 
the O 
means O 
of O 
Sephadex O 
G-75 O 
, O 
DEAE-Sepharose O 
FF O 
, O 
and O 
Sephadex O 
G-25 O 
column O 
chromatography O 
. O 
Structural O 
analysis O 
indicated O 
that O 
Agacutase O 
is O 
a O 
single O 
- O 
chain O 
glycoprotein O 
with O 
a O 
molecular O 
mass O 
of O 
31,084Da O 
, O 
isoelectric O 
point O 
of O 
4.38 O 
, O 
optimal O 
activity O 
at O 
37°C O 
and O 
pH O 
6.6 O 
, O 
sugar O 
content O 
of O 
7.6% O 
. O 
Its O 
N B-FORMULA 
-terminal O 
44 O 
amino O 
acid O 
sequence O 
was O 
determined O 
to O 
be O 
VIGGNECDTNEHRFLAAFFTSRPWIFQCAGTLIHEEWVLAAAHC O 
, O 
showing O 
maximum O 
identity O 
of O 
80% O 
with O 
that O 
of O 
Dav-X O 
protease O 
. O 
The O 
Agacutase O 
- O 
induced O 
clotting O 
activity O 
was O 
not O 
influenced O 
by O 
heparin O 
, O 
hirudin O 
, O 
or O 
Dextran O 
40 O 
, O 
but O 
activated O 
by O 
Ca(2+) B-FORMULA 
and O 
inhibited O 
by O 
PMSF B-ABBREVIATION 
or O 
lactose B-TRIVIAL 
, O 
which O 
suggests O 
that O 
Agacutase O 
is O 
a O 
serine B-TRIVIAL 
protease O 
and O 
the O 
coagulation O 
activity O 
is O 
independent O 
of O 
Thrombin O 
. O 
Agacutase O 
with O 
arginine O 
esterase O 
activity O 
specifically O 
cleaves O 
the O 
α-chain O 
of O 
fibrinogen O 
. O 
Agacutase O 
iv O 
( O 
0.03-0.12U O 
/ O 
kg O 
) O 
shortened O 
16-68% O 
of O 
the O 
rabbit O 
blood O 
clotting O 
time O 
. O 
No O 
significant O 
influence O 
was O 
indicated O 
on O 
platelet O 
, O 
Factor O 
II O 
and O 
XIII O 
, O 
or O 
fibrinolytic O 
system O 
. O 
It O 
converts O 
fibrinogen O 
into O 
the O 
soluble O 
fibrin O 
that O 
accelerates O 
hemostasis O 
at O 
wound O 
. O 
Pharmacological O 
comparison O 
showed O 
the O 
hemostatic O 
effect O 
of O 
Agacutase O 
lasted O 
24h O 
while O 
Reptilase O 
did O 
8h O 
. O 
Its O 
maximum O 
tolerated O 
, O 
abnormal O 
toxicity O 
, O 
allergic O 
, O 
and O 
hemorrhagin O 
doses O 
were O 
80U O 
/ O 
kg O 
, O 
1U O 
, O 
2U O 
, O 
and O 
50U O 
, O 
respectively O 
, O 
whereas O 
those O 
of O 
Reptilase O 
or O 
Agacutin O 
were O 
35U O 
/ O 
kg O 
, O 
0.25U O 
, O 
0.25U O 
, O 
and O 
0.2U O 
, O 
respectively O 
. O 
The O 
results O 
indicated O 
that O 
Agacutase O 
may O 
be O 
a O 
predominant O 
coagulant O 
. O 

cells O 
lining O 
the O 
lumen O 
of O 
blood O 
vessels O 
serve O 
as O 
a O 
physiological O 
barrier O 
controlling O 
nanoparticle O 
movement O 
from O 
the O 
vasculature O 
into O 
the O 
tissue O 
. O 
For O 
exploring O 
the O 
effect O 
of O 
polymer O 
hydrophilicity O 
on O 
nanoparticle O 
interactions O 
with O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
in O 
vitro O 
, O 
a O 
series O 
of O 
monomodal O 
poly[acrylonitrile-co-(N-vinylpyrrolidone)] B-SYSTEMATIC 
model O 
nanoparticles O 
with O 
increasing O 
hydrophilicity O 
as O 
related O 
to O 
their O 
increasing O 
content O 
( O 
0-30mol.% O 
) O 
of O 
N-vinylpyrrolidone B-SYSTEMATIC 
( O 
NVP B-ABBREVIATION 
) O 
were O 
synthesized O 
by O 
miniemulsion O 
polymerization O 
. O 
Nanoparticles O 
with O 
a O 
low O 
NVP B-ABBREVIATION 
content O 
were O 
rapidly O 
endocytized O 
into O 
all O 
cells O 
independent O 
from O 
the O 
particle O 
dose O 
with O 
toxic O 
effects O 
only O 
observed O 
at O 
high O 
particle O 
concentrations O 
, O 
while O 
only O 
10-30% O 
of O 
the O 
cells O 
incorporated O 
particles O 
with O 
⩾20mol.% O 
NVP B-ABBREVIATION 
. O 
Since O 
pathologies O 
are O 
often O 
related O 
to O 
inflammation O 
, O 
an O 
inflammatory O 
HUVEC O 
culture O 
condition O 
with O 
IL-1β O 
stimulation O 
has O 
been O 
introduced O 
and O 
suggested O 
to O 
be O 
widely O 
applied O 
for O 
studying O 
nanocarriers O 
, O 
since O 
cellular O 
uptake O 
in O 
this O 
assay O 
was O 
clearly O 
increased O 
for O 
NVP B-ABBREVIATION 
contents O 
⩾20mol.% O 
. O 
Importantly O 
, O 
the O 
secretion O 
of O 
functional O 
biological O 
mediators O 
by O 
HUVEC O 
was O 
not O 
relevantly O 
influenced O 
by O 
the O 
nanoparticles O 
for O 
both O 
homeostatic O 
and O 
inflammatory O 
conditions O 
. O 
These O 
findings O 
may O 
motivate O 
concepts O 
for O 
nanocarriers O 
specifically O 
targeted O 
to O 
pathologic O 
regions O 
. O 
Additionally O 
, O 
rapidly O 
endocytized O 
RhodaminB B-TRIVIAL 
loaded O 
particles O 
with O 
low O 
NVP B-ABBREVIATION 
content O 
may O 
be O 
explored O 
for O 
cell O 
labeling O 
and O 
tracking O 
. O 

studies O 
report O 
temporal O 
, O 
geographical O 
, O 
and O 
intra O 
- O 
individual O 
variation O 
in O 
sponge O 
metabolite O 
yields O 
. O 
However O 
, O 
the O 
internal O 
and O 
/ O 
or O 
external O 
factors O 
that O 
regulate O 
the O 
metabolite O 
production O 
remain O 
poorly O 
understood O 
. O 
Dysidea O 
avara O 
is O 
a O 
demosponge O 
that O 
produces O 
sesquiterpenoids B-FAMILY 
( O 
avarol B-TRIVIAL 
and O 
derivatives O 
) O 
with O 
interesting O 
medical O 
properties O 
, O 
which O 
has O 
prompted O 
addressed O 
studies O 
to O 
obtain O 
enough O 
amounts O 
of O 
these O 
metabolites O 
for O 
research O 
on O 
drug O 
discovery O 
. O 
Within O 
this O 
framework O 
, O 
specimens O 
of O 
Dysidea O 
avara O 
from O 
a O 
population O 
of O 
the O 
Northwest O 
Mediterranean O 
were O 
sampled O 
and O 
their O 
secondary O 
metabolites O 
quantified O 
to O 
assess O 
their O 
variability O 
and O 
the O 
possible O 
relationship O 
with O 
external O 
( O 
seasonality O 
, O 
interactions O 
with O 
neighbors O 
) O 
and O 
internal O 
( O 
reproductive O 
stages O 
) O 
factors O 
. O 
The O 
results O 
show O 
a O 
variation O 
of O 
the O 
amount O 
of O 
both O 
avarol B-MULTIPLE 
and I-MULTIPLE 
its I-MULTIPLE 
monoacetate I-MULTIPLE 
derivative O 
with O 
time O 
, O 
with O 
no O 
clear O 
relationship O 
with O 
seawater O 
temperature O 
. O 
A O 
trade-off O 
with O 
sponge O 
reproduction O 
was O 
not O 
found O 
either O 
. O 
However O 
, O 
our O 
results O 
showed O 
for O 
the O 
first O 
time O 
that O 
sponges O 
are O 
able O 
to O 
increase O 
production O 
or O 
accumulation O 
of O 
secondary O 
metabolites O 
in O 
their O 
peripheral O 
zone O 
depending O 
on O 
the O 
nature O 
of O 
their O 
neighbors O 
. O 
This O 
finding O 
could O 
explain O 
part O 
of O 
the O 
high O 
variability O 
in O 
the O 
amount O 
of O 
secondary O 
metabolites O 
usually O 
found O 
in O 
chemical O 
ecology O 
studies O 
on O 
sponges O 
and O 
opens O 
new O 
biotechnological O 
approaches O 
to O 
enhance O 
the O 
metabolite O 
yield O 
in O 
sponge O 
cultures O 
. O 

oatp1a O 
/ O 
1b O 
uptake O 
transporters O 
control O 
rosuvastatin B-TRIVIAL 
systemic O 
exposure O 
without O 
affecting O 
its O 
apparent O 
liver O 
exposure O 
. O 

anion O 
- O 
transporting O 
polypeptides O 
( O 
OATPs O 
) O 
mediate O 
the O 
liver O 
uptake O 
and O 
hence O 
plasma O 
clearance O 
of O 
a O 
broad O 
range O 
of O 
drugs O 
. O 
For O 
rosuvastatin B-TRIVIAL 
, O 
a O 
cholesterol B-TRIVIAL 
-lowering O 
drug O 
and O 
OATP1A O 
/ O 
1B O 
substrate O 
, O 
the O 
liver O 
represents O 
both O 
its O 
main O 
therapeutic O 
target O 
and O 
its O 
primary O 
clearance O 
organ O 
. O 
Here O 
we O 
studied O 
the O 
impact O 
of O 
Oatp1a O 
/ O 
1b O 
uptake O 
transporters O 
on O 
the O 
pharmacokinetics O 
of O 
rosuvastatin B-TRIVIAL 
using O 
wild O 
- O 
type O 
and O 
Oatp1a O 
/ O 
1b-null O 
mice O 
. O 
After O 
oral O 
administration O 
( O 
15 O 
mg O 
/ O 
kg O 
) O 
, O 
intestinal O 
absorption O 
of O 
rosuvastatin B-TRIVIAL 
was O 
not O 
impaired O 
in O 
Oatp1a O 
/ O 
1b-null O 
mice O 
, O 
but O 
systemic O 
exposure O 
( O 
area O 
under O 
the O 
curve O 
) O 
was O 
8-fold O 
higher O 
in O 
these O 
mice O 
compared O 
with O 
wild O 
- O 
type O 
. O 
Although O 
liver O 
exposure O 
was O 
comparable O 
between O 
the O 
two O 
mouse O 
strains O 
( O 
despite O 
the O 
increased O 
blood O 
exposure O 
) O 
, O 
the O 
liver O 
- O 
to O 
- O 
blood O 
ratios O 
were O 
markedly O 
decreased O 
( O 
> O 
10-fold O 
) O 
in O 
the O 
absence O 
of O 
Oatp1a O 
/ O 
1b O 
transporters O 
. O 
After O 
intravenous O 
administration O 
( O 
5 O 
mg O 
/ O 
kg O 
) O 
, O 
systemic O 
exposure O 
was O 
3-fold O 
higher O 
in O 
Oatp1a O 
/ O 
1b-null O 
mice O 
than O 
in O 
the O 
wild O 
- O 
type O 
mice O 
. O 
Liver O 
, O 
small O 
intestinal O 
, O 
and O 
kidney O 
exposure O 
were O 
slightly O 
, O 
but O 
not O 
significantly O 
, O 
increased O 
in O 
Oatp1a O 
/ O 
1b-null O 
mice O 
. O 
The O 
biliary O 
excretion O 
of O 
rosuvastatin B-TRIVIAL 
was O 
very O 
fast O 
, O 
with O 
60% O 
of O 
the O 
dose O 
eliminated O 
within O 
15 O 
minutes O 
after O 
intravenous O 
administration O 
, O 
and O 
also O 
not O 
significantly O 
altered O 
in O 
Oatp1a O 
/ O 
1b-null O 
mice O 
. O 
Rosuvastatin B-TRIVIAL 
renal O 
clearance O 
, O 
although O 
still O 
minor O 
, O 
was O 
increased O 
∼15-fold O 
in O 
Oatp1a O 
/ O 
1b-null O 
males O 
, O 
suggesting O 
a O 
role O 
of O 
Oatp1a1 O 
in O 
the O 
renal O 
reabsorption O 
of O 
rosuvastatin B-TRIVIAL 
. O 
Absence O 
of O 
Oatp1a O 
/ O 
1b O 
uptake O 
transporters O 
increases O 
the O 
systemic O 
exposure O 
of O 
rosuvastatin B-TRIVIAL 
by O 
reducing O 
its O 
hepatic O 
extraction O 
ratio O 
. O 
However O 
, O 
liver O 
concentrations O 
are O 
not O 
significantly O 
affected O 
, O 
most O 
likely O 
due O 
to O 
the O 
compensatory O 
activity O 
of O 
high O 
- O 
capacity O 
, O 
low O 
- O 
affinity O 
alternative O 
uptake O 
transporters O 
at O 
higher O 
systemic O 
rosuvastatin B-TRIVIAL 
levels O 
and O 
the O 
absence O 
of O 
efficient O 
alternative O 
rosuvastatin B-TRIVIAL 
clearance O 
mechanisms O 
. O 

mechanism O 
regulating O 
24-hour O 
rhythm O 
of O 
dopamine B-TRIVIAL 
d3 O 
receptor O 
expression O 
in O 
mouse O 
ventral O 
striatum O 
. O 

dopamine B-TRIVIAL 
D3 O 
receptor O 
( O 
DRD3 O 
) O 
in O 
the O 
ventral O 
striatum O 
is O 
thought O 
to O 
influence O 
motivation O 
and O 
motor O 
functions O 
. O 
Although O 
the O 
expression O 
of O 
DRD3 O 
in O 
the O 
ventral O 
striatum O 
has O 
been O 
shown O 
to O 
exhibit O 
24-hour O 
variations O 
, O 
the O 
mechanisms O 
underlying O 
the O 
variation O 
remain O 
obscure O 
. O 
Here O 
, O 
we O 
demonstrated O 
that O 
molecular O 
components O 
of O 
the O 
circadian O 
clock O 
act O 
as O 
regulators O 
that O 
control O 
the O 
24-hour O 
variation O 
in O 
the O 
expression O 
of O 
DRD3 O 
. O 
The O 
transcription O 
of O 
DRD3 O 
was O 
enhanced O 
by O 
the O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
-related O 
orphan O 
receptor O 
α O 
( O 
RORα O 
) O 
, O 
and O 
its O 
activation O 
was O 
inhibited O 
by O 
the O 
orphan O 
receptor O 
REV-ERBα O 
, O 
an O 
endogenous O 
antagonist O 
of O 
RORα O 
. O 
The O 
serum O 
or O 
dexamethasone B-TRIVIAL 
-induced O 
oscillation O 
in O 
the O 
expression O 
of O 
DRD3 O 
in O 
cells O 
was O 
abrogated O 
by O 
the O 
downregulation O 
or O 
overexpression O 
of O 
REV-ERBα O 
, O 
suggesting O 
that O 
REV-ERBα O 
functions O 
as O 
a O 
regulator O 
of O 
DRD3 O 
oscillations O 
in O 
the O 
cellular O 
autonomous O 
clock O 
. O 
Chromatin O 
immunoprecipitation O 
assays O 
of O 
the O 
DRD3 O 
promoter O 
indicated O 
that O 
the O 
binding O 
of O 
the O 
REV-ERBα O 
protein O 
to O 
the O 
DRD3 O 
promoter O 
increased O 
in O 
the O 
early O 
dark O 
phase O 
. O 
DRD3 O 
protein O 
expression O 
varied O 
with O 
higher O 
levels O 
during O 
the O 
dark O 
phase O 
. O 
Moreover O 
, O 
the O 
effects O 
of O 
the O 
DRD3 O 
agonist O 
7-hydroxy-N,N-dipropyl-2-aminotetralin B-SYSTEMATIC 
( O 
7-OH-DPAT B-SYSTEMATIC 
)-induced O 
locomotor O 
hypoactivity O 
were O 
significantly O 
increased O 
when O 
DRD3 O 
proteins O 
were O 
abundant O 
. O 
These O 
results O 
suggest O 
that O 
RORα O 
and O 
REV-ERBα O 
consist O 
of O 
a O 
reciprocating O 
mechanism O 
wherein O 
RORα O 
upregulates O 
the O 
expression O 
of O 
DRD3 O 
, O 
whereas O 
REV-ERBα O 
periodically O 
suppresses O 
the O 
expression O 
at O 
the O 
time O 
of O 
day O 
when O 
REV-ERBα O 
is O 
abundant O 
. O 
Our O 
present O 
findings O 
revealed O 
that O 
a O 
molecular O 
link O 
between O 
the O 
circadian O 
clock O 
and O 
the O 
function O 
of O 
DRD3 O 
in O 
the O 
ventral O 
striatum O 
acts O 
as O 
a O 
modulator O 
of O 
the O 
pharmacological O 
actions O 
of O 
DRD3 O 
agonists O 
/ O 
antagonists O 
. O 

toxicokinetic O 
model O 
for O 
thiamethoxam B-TRIVIAL 
in O 
rats O 
: O 
implications O 
for O 
higher O 
- O 
tier O 
risk O 
assessment O 
. O 

assessment O 
for O 
mammals O 
is O 
currently O 
based O 
on O 
external O 
exposure O 
measurements O 
, O 
but O 
effects O 
of O 
toxicants O 
are O 
better O 
correlated O 
with O 
the O 
systemically O 
available O 
dose O 
than O 
with O 
the O 
external O 
administered O 
dose O 
. O 
So O 
for O 
risk O 
assessment O 
of O 
pesticides O 
, O 
toxicokinetics O 
should O 
be O 
interpreted O 
in O 
the O 
context O 
of O 
potential O 
exposure O 
in O 
the O 
field O 
taking O 
account O 
of O 
the O 
timescale O 
of O 
exposure O 
and O 
individual O 
patterns O 
of O 
feeding O 
. O 
Internal O 
concentration O 
is O 
the O 
net O 
result O 
of O 
absorption O 
, O 
distribution O 
, O 
metabolism O 
and O 
excretion O 
( O 
ADME O 
) O 
. O 
We O 
present O 
a O 
case O 
study O 
for O 
thiamethoxam B-TRIVIAL 
to O 
show O 
how O 
data O 
from O 
ADME O 
study O 
on O 
rats O 
can O 
be O 
used O 
to O 
parameterize O 
a O 
body O 
burden O 
model O 
which O 
predicts O 
body O 
residue O 
levels O 
after O 
exposures O 
to O 
LD50 O 
dose O 
either O 
as O 
a O 
bolus O 
or O 
eaten O 
at O 
different O 
feeding O 
rates O 
. O 
Kinetic O 
parameters O 
were O 
determined O 
in O 
male O 
and O 
female O 
rats O 
after O 
an O 
intravenous O 
and O 
oral O 
administration O 
of O 
(14)C B-FORMULA 
labelled O 
by O 
fitting O 
one O 
- O 
compartment O 
models O 
to O 
measured O 
pesticide O 
concentrations O 
in O 
blood O 
for O 
each O 
individual O 
separately O 
. O 
The O 
concentration O 
of O 
thiamethoxam B-TRIVIAL 
in O 
blood O 
over O 
time O 
correlated O 
closely O 
with O 
concentrations O 
in O 
other O 
tissues O 
and O 
so O 
was O 
considered O 
representative O 
of O 
pesticide O 
concentration O 
in O 
the O 
whole O 
body O 
. O 
Body O 
burden O 
model O 
simulations O 
showed O 
that O 
maximum O 
body O 
weight O 
- O 
normalized O 
doses O 
of O 
thiamethoxam B-TRIVIAL 
were O 
lower O 
if O 
the O 
same O 
external O 
dose O 
was O 
ingested O 
normally O 
than O 
if O 
it O 
was O 
force O 
fed O 
in O 
a O 
single O 
bolus O 
dose O 
. O 
This O 
indicates O 
lower O 
risk O 
to O 
rats O 
through O 
dietary O 
exposure O 
than O 
would O 
be O 
estimated O 
from O 
the O 
bolus O 
LD50 O 
. O 
The O 
importance O 
of O 
key O 
questions O 
that O 
should O 
be O 
answered O 
before O 
using O 
the O 
body O 
burden O 
approach O 
in O 
risk O 
assessment O 
, O 
data O 
requirements O 
and O 
assumptions O 
made O 
in O 
this O 
study O 
are O 
discussed O 
in O 
detail O 
. O 

and O 
evaluation O 
of O 
ondansetron B-TRIVIAL 
liquid O 
suppository O 
for O 
the O 
treatment O 
of O 
emesis O 
. O 

thermosensitive O 
- O 
mucoadhesive O 
ondansetron B-TRIVIAL 
liquid O 
suppository O 
( O 
tmOLS O 
) O 
was O 
developed O 
to O 
enhance O 
patient O 
compliance O 
and O 
bioavailability O 
in O 
high O 
- O 
risk O 
patients O 
receiving O 
highly O 
emetogenic O 
therapy O 
and O 
having O 
difficulty O 
in O 
swallowing O 
, O 
The O 
thermosensitive O 
- O 
mucoadhesive O 
liquid O 
suppository O 
bases O 
were O 
formulated O 
using O 
poloxamers B-FAMILY 
( O 
P407 B-IDENTIFIER 
and O 
P188 B-IDENTIFIER 
) O 
and O 
hydroxypropylmethyl B-SYSTEMATIC 
cellulose O 
( O 
HPMC O 
) O 
. O 
The O 
physicochemical O 
properties O 
of O 
the O 
liquid O 
suppository O 
bases O 
were O 
characterized O 
by O 
their O 
gelation O 
temperature O 
, O 
mucoadhesive O 
force O 
, O 
rheological O 
properties O 
, O 
and O 
in O 
vitro O 
release O 
. O 
Rectal O 
mucosal O 
damage O 
following O 
rectal O 
administration O 
of O 
tmOLS O 
in O 
rats O 
was O 
assessed O 
using O 
microscopy O 
. O 
Pharmacokinetic O 
analyses O 
were O 
performed O 
to O 
compare O 
tmOLS O 
administered O 
via O 
the O 
rectal O 
route O 
to O 
ondansetron B-TRIVIAL 
solution O 
administered O 
orally O 
. O 
The O 
liquid O 
suppository O 
base O 
of O 
tmOLS O 
contained O 
P407 B-IDENTIFIER 
, O 
P188 B-IDENTIFIER 
, O 
and O 
HPMC O 
in O 
the O 
ratio O 
18 O 
: O 
20 O 
: O 
0.8 O 
, O 
was O 
in O 
the O 
liquid O 
state O 
at O 
room O 
temperature O 
, O 
underwent O 
gelation O 
at O 
body O 
temperature O 
. O 
Area O 
under O 
the O 
curve O 
and O 
half O 
- O 
life O 
( O 
t(1 O 
/ O 
2 O 
) O 
) O 
of O 
ondansetron B-TRIVIAL 
were O 
significantly O 
higher O 
in O 
the O 
tmOLS O 
- O 
treated O 
group O 
, O 
indicating O 
that O 
the O 
formulation O 
bypassed O 
the O 
first O 
- O 
pass O 
metabolism O 
and O 
that O 
it O 
was O 
released O 
slowly O 
from O 
the O 
tmOLS O 
because O 
of O 
the O 
formation O 
of O 
mucoadhesive O 
gel O 
state O 
. O 
Furthermore O 
, O 
the O 
t(1 O 
/ O 
2 O 
) O 
of O 
tmOLS O 
was O 
two O 
- O 
fold O 
that O 
of O 
the O 
oral O 
solution O 
. O 
Thus O 
, O 
tmOLS O 
could O 
be O 
administered O 
to O 
patients O 
who O 
have O 
difficulty O 
in O 
swallowing O 
; O 
however O 
, O 
adjustments O 
in O 
dosing O 
interval O 
may O 
be O 
needed O 
. O 

-based O 
Macromolecules O 
and O 
Nanoparticles O 
as O 
Magnetic O 
Resonance O 
Contrast O 
Agents O 
for O 
Molecular O 
Imaging O 
. O 

we O 
move O 
towards O 
an O 
era O 
of O 
personalized O 
medicine O 
, O 
molecular O 
imaging O 
contrast O 
agents O 
are O 
likely O 
to O 
see O 
an O 
increasing O 
presence O 
in O 
routine O 
clinical O 
practice O 
. O 
Magnetic O 
resonance O 
( O 
MR O 
) O 
imaging O 
has O 
garnered O 
particular O 
interest O 
as O 
a O 
platform O 
for O 
molecular O 
imaging O 
applications O 
due O 
its O 
ability O 
to O 
monitor O 
anatomical O 
changes O 
concomitant O 
with O 
physiologic O 
and O 
molecular O 
changes O 
. O 
One O 
promising O 
new O 
direction O 
in O 
the O 
development O 
of O 
MR O 
contrast O 
agents O 
involves O 
the O 
labeling O 
and O 
/ O 
or O 
loading O 
of O 
nanoparticles O 
with O 
gadolinium B-SYSTEMATIC 
( O 
Gd B-FORMULA 
) O 
. O 
These O 
nanoplatforms O 
are O 
capable O 
of O 
carrying O 
large O 
payloads O 
of O 
Gd B-FORMULA 
, O 
thus O 
providing O 
the O 
requisite O 
sensitivity O 
to O 
detect O 
molecular O 
signatures O 
within O 
disease O 
pathologies O 
. O 
In O 
this O 
review O 
, O 
we O 
discuss O 
some O 
of O 
the O 
progress O 
that O 
has O 
recently O 
been O 
made O 
in O 
the O 
development O 
of O 
Gd B-FORMULA 
-based O 
macromolecules O 
and O 
nanoparticles O 
and O 
outline O 
some O 
of O 
the O 
physical O 
and O 
chemical O 
properties O 
that O 
will O 
be O 
important O 
to O 
incorporate O 
into O 
the O 
next O 
generation O 
of O 
contrast O 
agents O 
, O 
including O 
high O 
Gd B-FORMULA 
chelate O 
stability O 
, O 
high O 
" O 
relaxivity O 
per O 
particle O 
" O 
and O 
" O 
relaxivity O 
density O 
" O 
, O 
and O 
biodegradability O 
. O 

-PET O 
Radiochemistry O 
in O 
the O 
Development O 
and O 
Application O 
of O 
Therapeutic O 
Monoclonal O 
Antibodies O 
and O 
Other O 
Biologicals O 
. O 

emission O 
tomography O 
with O 
(89)Zr B-FORMULA 
can O 
be O 
used O 
to O 
follow O 
the O 
behaviour O 
of O 
therapeutic O 
monoclonal O 
antibodies O 
( O 
mAbs O 
) O 
and O 
other O 
biologicals O 
in O 
vivo O 
. O 
The O 
favourable O 
radiophysical O 
characteristics O 
of O 
(89)Zr B-FORMULA 
allow O 
multiple O 
days O 
PET O 
scanning O 
after O 
injection O 
. O 
For O 
the O 
coupling O 
of O 
(89)Zr B-FORMULA 
to O 
proteins O 
six O 
desferrioxamine B-TRIVIAL 
( O 
DFO B-ABBREVIATION 
) O 
- O 
based O 
bifunctional O 
chelators O 
have O 
been O 
described O 
, O 
five O 
of O 
which O 
forming O 
stable O 
complexes O 
in O 
vivo O 
. O 
Of O 
the O 
methods O 
that O 
give O 
stable O 
complexes O 
three O 
are O 
based O 
on O 
random O 
lysine B-TRIVIAL 
modification O 
of O 
mAbs O 
and O 
two O 
on O 
site O 
- O 
specific O 
engineering O 
. O 
Up O 
to O 
now O 
only O 
two O 
methods O 
, O 
random O 
lysine B-TRIVIAL 
modification O 
with O 
N-suc-DFO B-FORMULA 
or O 
DFO-Bz-NCS B-FORMULA 
, O 
have O 
been O 
used O 
in O 
clinical O 
studies O 
. O 
In O 
this O 
review O 
firstly O 
aspects O 
of O 
the O 
physicochemical O 
properties O 
and O 
production O 
of O 
(89)Zr B-FORMULA 
are O 
emphasized O 
as O 
well O 
as O 
important O 
items O 
that O 
have O 
to O 
be O 
taken O 
into O 
account O 
for O 
current O 
good O 
manufacturing O 
practice O 
( O 
cGMP O 
) O 
compliant O 
production O 
of O 
(89)Zr B-FORMULA 
-labeled O 
proteins O 
. O 
Next O 
, O 
the O 
different O 
DFO O 
- O 
based O 
conjugation O 
strategies O 
will O 
be O 
discussed O 
with O 
respect O 
to O 
synthesis O 
, O 
and O 
their O 
(pre)clinical O 
evaluation O 
particularly O 
in O 
the O 
field O 
of O 
oncology O 
. O 

the O 
past O 
20 O 
years O 
, O 
studies O 
of O 
transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
channels O 
have O 
significantly O 
extended O 
our O 
knowledge O 
regarding O 
the O 
molecular O 
basis O 
of O 
Ca2+ B-FORMULA 
signals O 
in O 
cardiac O 
myocytes O 
. O 
The O 
functional O 
significance O 
of O 
cardiac O 
TRP O 
channels O 
is O 
likely O 
connected O 
to O 
the O 
alteration O 
of O 
membrane O 
potential O 
or O 
Ca2+ B-FORMULA 
entry O 
into O 
a O 
noncontractile O 
compartment O 
, O 
where O 
gene O 
expression O 
responsible O 
for O 
various O 
cardiac O 
diseases O 
is O 
induced O 
. O 
This O 
review O 
highlights O 
some O 
aspects O 
of O 
TRP O 
channels O 
with O 
anticipated O 
roles O 
in O 
cardiac O 
disease O 
. O 
Evidence O 
suggests O 
that O 
( O 
a O 
) O 
increased O 
activities O 
of O 
TRPC1 O 
, O 
TRPC3 O 
, O 
or O 
TRPC6 O 
are O 
involved O 
in O 
the O 
development O 
of O 
cardiac O 
hypertrophy O 
, O 
where O 
these O 
TRPC O 
channels O 
act O 
as O 
unique O 
sensors O 
for O 
a O 
wide O 
range O 
of O 
hypertrophic O 
stimuli O 
, O 
and O 
( O 
b O 
) O 
mutations O 
in O 
TRPM4 O 
are O 
now O 
recognized O 
as O 
causes O 
of O 
human O 
cardiac O 
conduction O 
disorders O 
. O 
Ultimately O 
, O 
TRP O 
channels O 
may O 
become O 
novel O 
pharmacological O 
targets O 
in O 
the O 
treatment O 
of O 
human O 
cardiac O 
disease O 
. O 

of O 
potent O 
and O 
selective O 
indomethacin B-TRIVIAL 
analogues O 
for O 
the O 
inhibition O 
of O 
AKR1C3 O 
( O 
Type O 
5 O 
17β-hydroxysteroid B-SYSTEMATIC 
dehydrogenase O 
/ O 
prostaglandin O 
F O 
synthase O 
) O 
in O 
castrate O 
- O 
resistant O 
prostate O 
cancer O 
. O 

- O 
resistant O 
prostate O 
cancer O 
( O 
CRPC O 
) O 
is O 
a O 
fatal O 
, O 
metastatic O 
form O 
of O 
prostate O 
cancer O 
. O 
CRPC O 
is O 
characterized O 
by O 
reactivation O 
of O 
the O 
androgen B-FAMILY 
axis O 
due O 
to O 
changes O 
in O 
androgen B-FAMILY 
receptor O 
signaling O 
and O 
/ O 
or O 
adaptive O 
intratumoral O 
androgen B-FAMILY 
biosynthesis O 
. O 
AKR1C3 O 
is O 
upregulated O 
in O 
CRPC O 
where O 
it O 
catalyzes O 
the O 
formation O 
of O 
potent O 
androgens B-FAMILY 
. O 
This O 
makes O 
AKR1C3 O 
a O 
target O 
for O 
the O 
treatment O 
of O 
CRPC O 
. O 
AKR1C3 O 
inhibitors O 
should O 
not O 
inhibit O 
AKR1C1 O 
/ O 
AKR1C2 O 
, O 
which O 
inactivate O 
5α-dihydrotestosterone B-SYSTEMATIC 
. O 
Indomethacin B-TRIVIAL 
, O 
used O 
to O 
inhibit O 
cyclooxygenase O 
, O 
also O 
inhibits O 
AKR1C3 O 
and O 
displays O 
selectivity O 
over O 
AKR1C1 O 
/ O 
AKR1C2 O 
. O 
Parallel O 
synthetic O 
strategies O 
were O 
used O 
to O 
generate O 
libraries O 
of O 
indomethacin B-TRIVIAL 
analogues O 
, O 
which O 
exhibit O 
reduced O 
cyclooxygenase O 
inhibitory O 
activity O 
but O 
retain O 
AKR1C3 O 
inhibitory O 
potency O 
and O 
selectivity O 
. O 
The O 
lead O 
compounds O 
inhibited O 
AKR1C3 O 
with O 
nanomolar O 
potency O 
, O 
displayed O 
> O 
100-fold O 
selectivity O 
over O 
AKR1C1 O 
/ O 
AKR1C2 O 
, O 
and O 
blocked O 
testosterone B-TRIVIAL 
formation O 
in O 
LNCaP-AKR1C3 O 
cells O 
. O 
The O 
AKR1C3· O 
NADP(+) B-ABBREVIATION 
· O 
2'-des-methyl-indomethacin B-SYSTEMATIC 
crystal O 
structure O 
was O 
determined O 
, O 
and O 
it O 
revealed O 
a O 
unique O 
inhibitor O 
binding O 
mode O 
. O 
The O 
compounds O 
reported O 
are O 
promising O 
agents O 
for O 
the O 
development O 
of O 
therapeutics O 
for O 
CRPC O 
. O 

grains O 
of O 
Hordeum O 
vulgare O 
and O 
Sorghum O 
bicolor O 
were O 
individually O 
fermented O 
with O 
Monascus O 
purpureus O 
MTCC O 
369 O 
under O 
solid O 
state O 
fermentation O 
. O 
The O 
aqueous O 
extract O 
of O 
Monascus O 
which O 
fermented O 
H O 
. O 
vulgare O 
and O 
S O 
. O 
bicolor O 
was O 
found O 
to O 
contain O 
five O 
different O 
new O 
metabolites O 
. O 
Silica B-TRIVIAL 
gel I-TRIVIAL 
column O 
chromatography O 
of O 
the O 
aqueous O 
extract O 
with O 
a O 
linear O 
gradient O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
acetonitrile B-SYSTEMATIC 
and O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
v O 
/ O 
v O 
) O 
yielded O 
five O 
new O 
metabolites O 
named O 
benzopranyl B-TRIVIAL 
capriate I-TRIVIAL 
( O 
9H-1-isoprenyl-benzopyran-5-isopropanoic B-SYSTEMATIC 
acid-6-ol-6-n-decanoate I-SYSTEMATIC 
) O 
, O 
shorghumoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
n-octadec-8,11-dien-7α-ol-1-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
and O 
sorghumflavin B-TRIVIAL 
A I-TRIVIAL 
( O 
2-n-butyloxo-6-β-hydroxy-7-β-isoprenyl B-SYSTEMATIC 
ankaflavin I-SYSTEMATIC 
) O 
from O 
Monascus O 
- O 
fermented O 
S O 
. O 
bicolor O 
, O 
while O 
hordeumflavin B-TRIVIAL 
B I-TRIVIAL 
( O 
2-n-undecanyloxo-7-β-isoprenyl B-SYSTEMATIC 
ankaflavin I-SYSTEMATIC 
) O 
and O 
vulgaredilone B-TRIVIAL 
( O 
2-dodecanyl-7-β B-SYSTEMATIC 
isopranyl I-SYSTEMATIC 
monoscodilone I-SYSTEMATIC 
) O 
from O 
Monascus O 
- O 
fermented O 
H O 
. O 
vulgare O 
. O 

the O 
N-end O 
rule O 
pathway O 
, O 
a O 
set O 
of O 
N B-FORMULA 
-terminal O 
amino B-FAMILY 
acids I-FAMILY 
, O 
called O 
N-degrons O 
, O 
are O 
recognized O 
and O 
ubiquitinated O 
by O 
the O 
UBR O 
proteins O 
. O 
Here O 
we O 
examined O 
various O 
N-end O 
rule O 
inhibitors O 
to O 
identify O 
essential O 
structural O 
components O 
of O 
the O 
system O 
. O 
Our O 
study O 
using O 
in O 
vitro O 
biochemical O 
assay O 
indicated O 
that O 
the O 
l-conformation O 
and O 
protonated O 
α-amino B-SYSTEMATIC 
group O 
of O 
the O 
first O 
residue O 
were O 
critical O 
for O 
N-degrons O 
to O 
properly O 
interact O 
with O 
the O 
UBR O 
proteins O 
. O 
The O 
monomeric O 
molecules O 
with O 
minimum O 
interacting O 
motifs O 
showed O 
endopeptidase O 
resistance O 
and O 
better O 
inhibitory O 
activities O 
than O 
traditional O 
dipeptide O 
inhibitors O 
. O 
Collectively O 
, O 
our O 
study O 
identifies O 
a O 
pharmacophore O 
of O 
N-end O 
rule O 
inhibitors O 
, O 
which O 
provides O 
a O 
structural O 
platform O 
to O 
improve O 
the O 
efficiency O 
and O 
druggable O 
properties O 
of O 
inhibitors O 
. O 
Considering O 
that O 
the O 
N-end O 
rule O 
has O 
been O 
implicated O 
in O 
many O 
pathophysiological O 
processes O 
in O 
cells O 
, O 
inhibitors O 
of O 
this O 
pathway O 
, O 
such O 
as O 
p-chloroamphetamine B-SYSTEMATIC 
, O 
are O 
potentially O 
of O 
clinical O 
interest O 
in O 
a O 
novel O 
aspect O 
of O 
action O 
mechanisms O 
. O 

acid I-TRIVIAL 
D I-TRIVIAL 
, O 
a O 
new O 
polyacetylene B-FAMILY 
carboxylic I-FAMILY 
acid I-FAMILY 
from O 
scleractinian O 
coral O 
Montipora O 
digitata O 
. O 

new O 
polyacetylene B-FAMILY 
carboxylic I-FAMILY 
acid I-FAMILY 
named O 
montiporic B-TRIVIAL 
acid I-TRIVIAL 
D I-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
along O 
with O 
a O 
known O 
polyacetylene B-FAMILY 
alcohol I-FAMILY 
, O 
(Z)-13,15-hexadecadien-2,4-diyn-1-ol B-SYSTEMATIC 
( O 
2 O 
) O 
from O 
scleractinian O 
coral O 
Montipora O 
digitata O 
. O 
The O 
structures O 
of O 
compounds O 
were O 
determined O 
by O 
analyses O 
of O 
NMR O 
and O 
MS O 
spectra O 
. O 

Cause O 
G2 O 
/ O 
M O 
Arrest O 
Associated O 
with O 
the O 
Modulation O 
of O 
CDK1 O 
and O 
Chk2 O 
in O 
Human O 
Breast O 
Cancer O 
MCF-7 O 
Cells O 
. O 

derivatives O 
( O 
BSC B-ABBREVIATION 
) O 
are O 
potent O 
anticancer O 
agents O 
with O 
a O 
strong O 
cytotoxic O 
activity O 
against O 
different O 
types O 
of O 
tumour O 
cells O 
. O 
Based O 
in O 
phosphatidylserine B-FAMILY 
exposure O 
on O 
the O 
cell O 
membranes O 
we O 
show O 
that O 
BSC B-ABBREVIATION 
treatment O 
resulted O 
in O 
enhanced O 
cell O 
death O 
in O 
leukaemia O 
CCRF-CEM O 
cells O 
. O 
DNA O 
fragmentation O 
detection O 
in O 
breast O 
adenocarcinoma O 
MCF-7 O 
cells O 
showed O 
that O 
BSC B-ABBREVIATION 
triggered O 
cell O 
death O 
is O 
concentration O 
and O 
time O 
dependent O 
. O 
We O 
also O 
show O 
that O 
two O 
of O 
these O 
compounds O 
, O 
BSC B-ABBREVIATION 
3g O 
and O 
3n O 
, O 
cause O 
cell O 
- O 
cycle O 
arrest O 
in O 
the O 
late O 
G2 O 
/ O 
M O 
in O 
MCF-7 O 
cells O 
. O 
Consistent O 
with O 
this O 
, O 
a O 
reduction O 
in O 
CDK1 O 
and O 
CDK2 O 
expression O 
with O 
no O 
change O 
in O 
cyclin O 
A O 
an O 
B1 O 
was O 
observed O 
in O 
this O 
cell O 
line O 
. O 
Activation O 
of O 
caspase-2 O 
was O 
also O 
detected O 
. O 
However O 
, O 
the O 
involvement O 
of O 
the O 
caspase O 
- O 
dependent O 
pathway O 
in O 
the O 
process O 
of O 
cell O 
death O 
induced O 
by O 
either O 
BSC B-ABBREVIATION 
3g O 
or O 
3n O 
is O 
discarded O 
since O 
cell O 
death O 
could O 
not O 
be O 
prevented O 
by O 
pretreatment O 
with O 
the O 
pancaspase O 
inhibitor O 
z-VAD-fmk B-ABBREVIATION 
. O 
Moreover O 
, O 
since O 
reduced O 
levels O 
of O 
p21CIP1 O 
and O 
Chk2 O 
proteins O 
but O 
no O 
change O 
in O 
p53 O 
levels O 
could O 
be O 
detected O 
in O 
MCF-7 O 
cells O 
after O 
BSC B-ABBREVIATION 
3g O 
or O 
3n O 
treatment O 
our O 
results O 
suggest O 
that O 
BSC B-ABBREVIATION 
treated O 
cells O 
die O 
from O 
lethal O 
mitosis O 
. O 

hyperaggregability O 
might O 
contribute O 
to O 
vascular O 
complications O 
associated O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
(DM2).Experimental O 
evidence O 
supports O 
a O 
direct O 
link O 
between O 
altered O 
Ca2+ B-FORMULA 
entry O 
and O 
hyperaggregability O 
in O 
DM2 O 
patients O 
. O 
Objectives O 
: O 
We O 
aimed O 
to O 
investigate O 
whether O 
altered O 
immunophilin O 
expression O 
and O 
function O 
are O 
involved O 
in O 
the O 
abnormal O 
Ca2+ B-FORMULA 
entry O 
observed O 
in O 
platelets O 
from O 
DM2 O 
patients O 
. O 
Results O 
: O 
Inhibition O 
of O 
immunophilins O 
by O 
tacrolimus B-TRIVIAL 
( O 
FK506 B-IDENTIFIER 
) O 
and O 
sirolimus B-TRIVIAL 
( O 
rapamycin B-TRIVIAL 
) O 
reduced O 
Ca2+ B-FORMULA 
entry O 
in O 
platelets O 
from O 
healthy O 
donors O 
and O 
DM2 O 
patients O 
. O 
Similarly O 
, O 
immunophilin O 
inhibitors O 
reduced O 
platelet O 
degranulation O 
in O 
both O 
healthy O 
and O 
DM2 O 
subjects O 
. O 
Nevertheless O 
, O 
α-granule O 
secretion O 
reduction O 
was O 
greater O 
than O 
that O 
observed O 
for O 
dense O 
granules O 
in O 
platelets O 
from O 
DM2 O 
patients O 
. O 
However O 
, O 
no O 
difference O 
was O 
observed O 
in O 
the O 
inhibition O 
of O 
secretion O 
in O 
platelets O 
from O 
healthy O 
subjects O 
. O 
Additionally O 
, O 
altered O 
expression O 
of O 
FK506 B-IDENTIFIER 
binding O 
protein-52 O 
( O 
FKBP52 O 
) O 
and O 
coupling O 
to O 
Ca(2+) B-FORMULA 
channels O 
were O 
found O 
in O 
platelets O 
from O 
DM2 O 
patients O 
compared O 
to O 
healthy O 
subjects O 
. O 
Finally O 
, O 
reduction O 
in O 
platelet O 
function O 
from O 
healthy O 
subjects O 
and O 
DM2 O 
patients O 
in O 
the O 
presence O 
of O 
immunophilin O 
antagonists O 
was O 
observed O 
, O 
being O 
this O 
dysfunction O 
more O 
evident O 
in O 
platelets O 
from O 
DM2 O 
patients O 
. O 
Conclusions O 
: O 
We O 
suggest O 
that O 
, O 
among O 
others O 
, O 
FKBP52 O 
expression O 
and O 
function O 
are O 
altered O 
in O 
platelets O 
from O 
DM2 O 
patients O 
, O 
contributing O 
to O 
the O 
altered O 
Ca(2+) B-FORMULA 
entry O 
and O 
hyperaggregability O 
in O 
these O 
cells O 
. O 

metal O 
complexes O 
of O 
biomedical O 
potential O 
. O 

and O 
their O 
complexes O 
with O 
organic O 
ligands O 
have O 
an O 
important O 
role O 
in O 
biochemical O 
systems O 
such O 
as O 
enzymatic O 
catalysis O 
, O 
metal O 
ion O 
transfer O 
across O 
the O 
cell O 
membranes O 
, O 
treatment O 
of O 
malignancy O 
, O 
rheumatoid O 
arthritis O 
, O 
ulcer O 
and O 
other O 
types O 
of O 
diseases O 
. O 
Special O 
attention O 
is O 
directed O 
to O 
metal O 
complexes O 
with O 
ligands O 
which O 
are O 
important O 
in O 
biological O 
systems O 
, O 
as O 
their O 
incorporation O 
into O 
metallo-organic O 
compounds O 
offers O 
much O 
scope O 
for O 
design O 
of O 
potential O 
metal O 
- O 
based O 
agents O 
that O 
provide O 
new O 
opportunities O 
in O 
the O 
medicinal O 
chemistry O 
. O 
In O 
view O 
of O 
this O 
, O 
derivatives O 
of O 
aminophosphonic B-FAMILY 
acids I-FAMILY 
, O 
owing O 
to O 
their O 
broad O 
spectrum O 
of O 
biological O 
activities O 
and O 
wide O 
range O 
of O 
applications O 
in O 
the O 
medicinal O 
and O 
agrochemical O 
fields O 
, O 
are O 
very O 
attractive O 
metal O 
- O 
ligand O 
agents O 
that O 
might O 
form O 
biomedical O 
important O 
metal O 
complexes O 
. O 
Thus O 
, O 
a O 
number O 
of O 
aminophosphonate B-SYSTEMATIC 
complexes O 
of O 
platinum B-SYSTEMATIC 
group O 
metals O 
have O 
been O 
found O 
to O 
possess O 
remarkable O 
antitumor O 
activity O 
while O 
complexes O 
of O 
some O 
other O 
transition O 
and O 
rare O 
- O 
earth O 
metals O 
like O 
technetium B-SYSTEMATIC 
, O 
rhenium B-SYSTEMATIC 
, O 
samarium B-SYSTEMATIC 
and O 
gadolinium B-SYSTEMATIC 
have O 
been O 
used O 
either O 
as O 
therapeutic O 
and O 
diagnostic O 
radiopharmaceuticals O 
or O 
as O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
contrast O 
agents O 
. O 
In O 
addition O 
, O 
the O 
high O 
phosphonate B-SYSTEMATIC 
affinity O 
towards O 
bone O 
and O 
other O 
calcified O 
tissues O 
may O 
be O 
utilized O 
for O 
the O 
drug O 
targeting O 
based O 
on O 
synthesis O 
of O 
metal O 
complexes O 
linked O 
to O 
bioactive O 
carrier O 
systems O 
, O 
affording O 
better O 
modalities O 
of O 
attack O 
to O 
the O 
site O 
of O 
pathology O 
. O 
In O 
this O 
review O 
article O 
, O 
aminophosphonate B-SYSTEMATIC 
metal O 
- O 
based O 
compounds O 
with O 
potential O 
biomedical O 
applications O 
are O 
described O 
. O 

monosulfide I-SYSTEMATIC 
( O 
CS B-FORMULA 
) O 
, O 
which O 
plays O 
an O 
important O 
role O 
in O 
a O 
variety O 
of O 
research O 
fields O 
, O 
has O 
long O 
received O 
considerable O 
interest O 
. O 
Due O 
to O 
its O 
transient O 
nature O 
and O 
large O 
state O 
density O 
, O 
the O 
electronic O 
states O 
of O 
CS B-FORMULA 
have O 
not O 
been O 
well O 
understood O 
, O 
especially O 
the O 
interactions O 
between O 
different O 
states O 
. O 
In O 
this O 
paper O 
, O 
we O 
performed O 
a O 
detail O 
ab O 
initio O 
study O 
on O 
the O 
low O 
- O 
lying O 
electronic O 
states O 
of O 
CS B-FORMULA 
by O 
means O 
of O 
the O 
internally O 
contracted O 
multireference O 
configuration O 
interaction O 
method O 
( O 
including O 
Davidson O 
correction O 
) O 
with O 
scalar O 
relativistic O 
correction O 
using O 
the O 
Douglas-Kroll-Hess O 
Hamiltonian O 
. O 
We O 
focused O 
on O 
the O 
spin O 
- O 
orbit O 
coupling O 
of O 
the O 
states O 
via O 
the O 
state O 
interaction O 
method O 
with O 
the O 
full O 
Breit-Pauli O 
Hamiltonian O 
. O 
The O 
potential O 
energy O 
curves O 
( O 
PECs O 
) O 
of O 
18 O 
Λ-S O 
states O 
correlated O 
with O 
the O 
lowest O 
dissociation O 
limit O 
of O 
the O 
CS B-FORMULA 
molecule O 
were O 
calculated O 
, O 
as O 
well O 
as O 
those O 
of O 
50 O 
Ω O 
states O 
generated O 
from O 
the O 
Λ-S O 
states O 
. O 
The O 
spectroscopic O 
constants O 
of O 
the O 
bound O 
states O 
were O 
obtained O 
, O 
which O 
are O 
in O 
good O 
agreement O 
with O 
previous O 
available O 
experimental O 
and O 
theoretical O 
results O 
. O 
The O 
state O 
perturbations O 
of O 
the O 
a(3)Π O 
and O 
A(1)Π O 
states O 
with O 
other O 
low O 
- O 
lying O 
electronic O 
states O 
are O 
discussed O 
in O 
detail O 
, O 
based O 
on O 
the O 
calculated O 
spin O 
- O 
orbit O 
matrix O 
as O 
well O 
as O 
the O 
PECs O 
of O 
the O 
Ω O 
states O 
. O 
Avoided O 
crossing O 
in O 
the O 
states O 
of O 
CS B-FORMULA 
was O 
indicated O 
when O 
spin O 
- O 
orbit O 
coupling O 
was O 
taken O 
into O 
account O 
. O 
Finally O 
, O 
the O 
allowed O 
transition O 
dipole O 
moments O 
as O 
well O 
as O 
the O 
lifetimes O 
of O 
the O 
five O 
lowest O 
vibrational O 
states O 
of O 
the O 
A(1)Π1 O 
, O 
A'(1)Σ(+)0(+) O 
and O 
a(3)Πi O 
states O 
were O 
obtained O 
. O 

of O 
dNTP B-ABBREVIATION 
levels O 
enhances O 
DNA O 
replication O 
fidelity O 
in O 
vivo O 
. O 

is O 
the O 
most O 
important O 
energy O 
source O 
for O 
the O 
maintenance O 
and O 
growth O 
of O 
living O 
cells O 
. O 
Here O 
we O 
report O 
that O 
the O 
impairment O 
of O 
the O 
aerobic O 
respiratory O 
chain O 
by O 
inactivation O 
of O 
the O 
ndh O 
gene O 
, O 
or O 
the O 
inhibition O 
of O 
glycolysis O 
with O 
arsenate B-SYSTEMATIC 
, O 
both O 
of O 
which O 
reduce O 
intracellular O 
ATP B-ABBREVIATION 
, O 
result O 
in O 
a O 
significant O 
decrease O 
in O 
spontaneous O 
mutagenesis O 
in O 
Escherichia O 
coli O 
. O 
The O 
genetic O 
analyses O 
and O 
mutation O 
spectra O 
in O 
the O 
ndh O 
strain O 
revealed O 
that O 
the O 
decrease O 
in O 
spontaneous O 
mutagenesis O 
resulted O 
from O 
an O 
enhanced O 
accuracy O 
of O 
the O 
replicative O 
DNA O 
polymerase O 
. O 
Quantification O 
of O 
the O 
dNTP B-ABBREVIATION 
content O 
in O 
the O 
ndh O 
mutant O 
cells O 
and O 
in O 
the O 
arsenate B-SYSTEMATIC 
-treated O 
cells O 
showed O 
reduction O 
of O 
the O 
dNTP B-ABBREVIATION 
pool O 
, O 
which O 
could O 
explain O 
the O 
observed O 
broad O 
antimutator O 
effects O 
. O 
In O 
conclusion O 
, O 
our O 
work O 
indicates O 
that O 
the O 
cellular O 
energy O 
supply O 
could O 
affect O 
spontaneous O 
mutation O 
rates O 
and O 
that O 
a O 
reduction O 
of O 
the O 
dNTP B-ABBREVIATION 
levels O 
can O 
be O 
antimutagenic O 
. O 

of O 
the O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
3 O 
( O 
STAT3 O 
) O 
signaling O 
pathway O 
has O 
been O 
considered O 
a O 
novel O 
therapeutic O 
strategy O 
to O 
treat O 
human O 
cancers O 
that O 
harbor O 
aberrantly O 
- O 
active O 
STAT3 O 
. O 
In O 
this O 
study O 
, O 
a O 
series O 
of O 
small O 
molecules O 
were O 
identified O 
as O 
novel O 
inhibitors O 
of O 
STAT3 O 
signaling O 
pathway O 
through O 
virtual O 
screening O 
. O 
A O 
tricyclic O 
scaffold O 
containing O 
compound O 
, O 
6 O 
, O 
was O 
identified O 
as O 
an O 
inhibitor O 
of O 
IL-6 O 
/ O 
STAT3 O 
signaling O 
with O 
an O 
IC50 O 
of O 
26.68 O 
μM O 
. O 
In O 
addition O 
, O 
this O 
compound O 
inhibited O 
Tyr B-FORMULA 
705 O 
phosphorylation O 
of O 
STAT3 O 
and O 
had O 
no O 
obvious O 
effect O 
on O 
upstream O 
tyrosine B-TRIVIAL 
kinases O 
. O 
Thus O 
, O 
compound O 
6 O 
is O 
a O 
potential O 
lead O 
structure O 
and O 
valuable O 
for O 
further O 
drug O 
development O 
. O 

and O 
photochemical O 
behavior O 
of O 
coumarin B-TRIVIAL 
-caged O 
cholesterol B-TRIVIAL 
. O 

syntheses O 
of O 
three O 
coumarin B-TRIVIAL 
-caged O 
cholesterols B-FAMILY 
are O 
reported O 
that O 
contain O 
the O 
6-diethylaminocoumarin B-SYSTEMATIC 
( O 
DEACM B-ABBREVIATION 
) O 
, O 
6-bromo-7-hydroxycoumarin B-SYSTEMATIC 
( O 
BHC B-ABBREVIATION 
) O 
and O 
6-bromo-7-methoxycoumarin B-SYSTEMATIC 
( O 
BMCM B-ABBREVIATION 
) O 
photocleavable O 
groups O 
. O 
Upon O 
photolysis O 
, O 
the O 
best O 
caged O 
derivative O 
was O 
found O 
to O 
be O 
BHC B-ABBREVIATION 
- O 
cholesterol B-TRIVIAL 
whose O 
quantum O 
yield O 
was O 
determined O 
to O 
be O 
0.032 O 
at O 
350 O 
nm O 
. O 

readers O 
for O 
5-(hydroxy)methylcytosine B-SYSTEMATIC 
and O 
its O 
oxidized O 
derivatives O 
. O 

proteins O 
oxidize O 
5-methylcytosine B-SYSTEMATIC 
( O 
mC O 
) O 
to O 
generate O 
5-hydroxymethyl B-SYSTEMATIC 
( O 
hmC B-ABBREVIATION 
) O 
, O 
5- B-SYSTEMATIC 
formyl I-SYSTEMATIC 
( O 
fC O 
) O 
, O 
and O 
5-carboxylcytosine B-SYSTEMATIC 
( O 
caC B-ABBREVIATION 
) O 
. O 
The O 
exact O 
function O 
of O 
these O 
oxidative O 
cytosine B-TRIVIAL 
bases O 
remains O 
elusive O 
. O 
We O 
applied O 
quantitative O 
mass O 
- O 
spectrometry O 
- O 
based O 
proteomics O 
to O 
identify O 
readers O 
for O 
mC O 
and O 
hmC B-ABBREVIATION 
in O 
mouse O 
embryonic O 
stem O 
cells O 
( O 
mESC O 
) O 
, O 
neuronal O 
progenitor O 
cells O 
( O 
NPC O 
) O 
, O 
and O 
adult O 
mouse O 
brain O 
tissue O 
. O 
Readers O 
for O 
these O 
modifications O 
are O 
only O 
partially O 
overlapping O 
, O 
and O 
some O 
readers O 
, O 
such O 
as O 
Rfx O 
proteins O 
, O 
display O 
strong O 
specificity O 
. O 
Interactions O 
are O 
dynamic O 
during O 
differentiation O 
, O 
as O 
for O 
example O 
evidenced O 
by O 
the O 
mESC-specific O 
binding O 
of O 
Klf4 O 
to O 
mC O 
and O 
the O 
NPC-specific O 
binding O 
of O 
Uhrf2 O 
to O 
hmC B-ABBREVIATION 
, O 
suggesting O 
specific O 
biological O 
roles O 
for O 
mC O 
and O 
hmC B-ABBREVIATION 
. O 
Oxidized O 
derivatives O 
of O 
mC O 
recruit O 
distinct O 
transcription O 
regulators O 
as O 
well O 
as O 
a O 
large O 
number O 
of O 
DNA O 
repair O 
proteins O 
in O 
mouse O 
ES O 
cells O 
, O 
implicating O 
the O 
DNA O 
damage O 
response O 
as O 
a O 
major O 
player O 
in O 
active O 
DNA O 
demethylation O 
. O 

A-C I-MULTIPLE 
, O 
three O 
new O 
unique O 
sesquiterpenes B-FAMILY 
from O 
a O 
marine O 
sponge O 
Euryspongia O 
sp O 
. O 

new O 
unique O 
sesquiterpenes B-FAMILY 
, O 
euryspongins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
were O 
isolated O 
from O 
a O 
marine O 
sponge O 
Euryspongia O 
sp O 
. O 
collected O 
at O 
Iriomote O 
Island O 
, O 
Okinawa O 
, O 
Japan O 
. O 
Compound O 
1 O 
possessed O 
a O 
bicyclic B-SYSTEMATIC 
furanosesquiterpene I-SYSTEMATIC 
structure O 
with O 
six- O 
and O 
eight O 
- O 
membered O 
rings O 
, O 
whereas O 
compounds O 
2 O 
and O 
3 O 
had O 
an O 
α,β- B-SYSTEMATIC 
unsaturated-γ-lactone I-SYSTEMATIC 
ring O 
instead O 
of O 
the O 
furan B-SYSTEMATIC 
ring O 
in O 
1 O 
. O 
Only O 
five O 
natural O 
products O 
in O 
this O 
class O 
have O 
been O 
reported O 
, O 
and O 
compounds O 
1-3 O 
are O 
the O 
sixth O 
- O 
eighth O 
examples O 
of O 
natural O 
products O 
. O 
Compounds O 
1-3 O 
had O 
no O 
inhibition O 
effect O 
against O 
PTP1B O 
, O 
an O 
important O 
target O 
enzyme O 
for O 
the O 
treatment O 
of O 
diabetes O 
, O 
while O 
the O 
dehydro O 
derivative O 
of O 
1 O 
[ O 
dehydroeuryspongin B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
4 O 
) O 
] O 
exhibited O 
inhibitory O 
activity O 
( O 
IC(50)=3.6 O 
μM O 
) O 
. O 

of O 
17β-estradiol B-SYSTEMATIC 
and O 
ketoconazole B-TRIVIAL 
on O 
endocrine O 
function O 
in O 
goldfish O 
( O 
Carassius O 
auratus O 
) O 
. O 

understanding O 
of O 
the O 
effects O 
of O 
toxic O 
mixtures O 
of O 
endocrine O 
disrupting O 
chemicals O 
( O 
EDCs O 
) O 
on O 
aquatic O 
organisms O 
is O 
challenging O 
as O 
these O 
organisms O 
are O 
exposed O 
to O 
multiple O 
classes O 
of O 
contaminants O 
in O 
their O 
natural O 
habitat O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
interactions O 
of O 
two O 
classes O 
of O 
EDCs O 
, O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 B-FORMULA 
) O 
and O 
ketoconazole B-TRIVIAL 
( O 
KTC B-ABBREVIATION 
) O 
, O 
on O 
endocrine O 
function O 
in O 
male O 
goldfish O 
( O 
Carassius O 
auratus O 
) O 
, O 
including O 
vitellogenesis O 
, O 
metabolic O 
capability O 
and O 
serum O 
steroid O 
synthesis O 
. O 
Changes O 
in O 
vitellogenin O 
( O 
VTG O 
) O 
concentration O 
, O 
liver O 
7-ethoxyresorufin B-SYSTEMATIC 
- O 
O B-FORMULA 
-deethylase O 
( O 
EROD O 
) O 
activity O 
and O 
circulating O 
serum O 
E2 B-FORMULA 
level O 
were O 
examined O 
. O 
The O 
expression O 
of O 
related O 
genes O 
was O 
also O 
determined O 
using O 
quantitative O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
. O 
Exposure O 
to O 
E2 B-FORMULA 
caused O 
a O 
significant O 
increase O 
in O 
VTG O 
concentrations O 
which O 
corresponded O 
with O 
the O 
gene O 
expression O 
of O 
VTG O 
and O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
in O 
males O 
, O 
which O 
were O 
further O 
elevated O 
after O 
combined O 
exposure O 
to O 
E2 B-FORMULA 
and O 
KTC B-ABBREVIATION 
, O 
indicative O 
of O 
a O 
synergetic O 
relationship O 
. O 
Exposure O 
to O 
E2 B-FORMULA 
also O 
resulted O 
in O 
a O 
distinct O 
increase O 
in O 
serum O 
steroid B-FAMILY 
biosynthesis O 
and O 
associated O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
aromatase O 
expression O 
after O 
10 O 
days O 
. O 
However O 
, O 
these O 
changes O 
were O 
inhibited O 
by O 
the O 
presence O 
of O 
KTC B-ABBREVIATION 
, O 
which O 
acted O 
as O 
a O 
steroidogenic O 
inhibitor O 
in O 
fish O 
. O 
Moreover O 
, O 
KTC B-ABBREVIATION 
significantly O 
decreased O 
liver O 
EROD O 
activity O 
and O 
increased O 
the O 
related O 
gene O 
expression O 
of O 
CYP1A O 
. O 
However O 
, O 
these O 
KTC B-ABBREVIATION 
-mediated O 
metabolic O 
reactions O 
in O 
goldfish O 
were O 
up O 
- O 
regulated O 
following O 
exposure O 
to O 
KTC B-ABBREVIATION 
in O 
combination O 
with O 
E2 B-FORMULA 
. O 
These O 
findings O 
reveal O 
complex O 
interactions O 
on O 
endocrine O 
functions O 
in O 
male O 
goldfish O 
when O 
exposed O 
to O 
multiple O 
contaminations O 
and O 
may O 
provide O 
a O 
better O 
understanding O 
of O 
the O 
effects O 
of O 
toxic O 
mixtures O 
. O 

2-benzylsulfanyl-nicotinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
based O 
1,3,4-oxadiazoles B-FAMILY 
: O 
Their O 
synthesis O 
and O 
biological O 
evaluation O 
. O 

novel O 
series O 
of O 
5-(2-benzylsulfanyl-pyridin-3-yl)-2-(substituted)-sulfanyl-1,3,4-oxadiazoles B-FAMILY 
6a-j O 
were O 
synthesized O 
from O 
key O 
intermediate O 
5-(2-benzylsulfanyl-pyridin-3-yl)-3H-[1,3,4]oxadiazole-2-thione B-SYSTEMATIC 
5 O 
. O 
Nucleophilic O 
substitution O 
reactions O 
with O 
different O 
electrophiles O 
( O 
E+ O 
) O 
, O 
such O 
as O 
haloacetate B-FAMILY 
and O 
haloalkyl B-FAMILY 
groups O 
, O 
were O 
performed O 
to O 
get O 
target O 
compounds O 
6a-j O 
. O 
Compounds O 
were O 
characterized O 
by O 
NMR O 
, O 
mass O 
, O 
IR O 
spectra O 
and O 
C B-FORMULA 
, O 
H B-FORMULA 
, O 
N B-FORMULA 
analyses O 
. O 
All O 
compounds O 
were O 
evaluated O 
for O 
their O 
antimicrobial O 
and O 
antimycobacterial O 
activities O 
; O 
selected O 
analogs O 
were O 
screened O 
for O 
their O 
anticancer O 
activity O 
on O 
60 O 
tumor O 
cell O 
lines O 
at O 
single O 
dose O 
1.00(-5) O 
M O 
. O 
Unfortunately O 
, O 
none O 
of O 
the O 
compounds O 
showed O 
a O 
significant O 
antitumor O 
activity O 
on O 
60 O 
human O 
tumor O 
cell O 
lines O 
. O 
However O 
, O 
compounds O 
6g O 
and O 
6f O 
with O 
benzothiazole B-SYSTEMATIC 
moiety O 
( O 
12.5 O 
and O 
25 O 
μg O 
/ O 
ml O 
) O 
showed O 
promising O 
activity O 
against O 
Escherichia O 
coli O 
compared O 
to O 
ampicillin B-TRIVIAL 
; O 
compounds O 
6d O 
, O 
6j O 
bearing O 
triazole B-FAMILY 
and O 
morpholine B-SYSTEMATIC 
, O 
respectively O 
, O 
showed O 
promising O 
antitubercular O 
activity O 
( O 
25 O 
μg O 
/ O 
ml O 
) O 
compared O 
to O 
rifampicin B-TRIVIAL 
. O 

protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
structures O 
are O 
of O 
interest O 
as O 
a O 
means O 
to O 
understand O 
biological O 
signal O 
transduction O 
and O 
as O 
tools O 
for O 
therapeutic O 
discovery O 
. O 
The O 
growing O 
number O 
of O 
GPCR O 
crystal O 
structures O 
demonstrates O 
that O 
the O 
extracellular O 
loops O 
( O 
EL O 
) O 
connecting O 
the O 
membrane O 
- O 
spanning O 
helices O 
show O 
tremendous O 
structural O 
variability O 
relative O 
to O 
the O 
more O 
structurally O 
- O 
conserved O 
seven O 
transmembrane O 
α-helical O 
domains O 
. O 
The O 
EL O 
of O 
the O 
LPA B-ABBREVIATION 
( O 
1 O 
) O 
receptor O 
have O 
not O 
yet O 
been O 
conclusively O 
resolved O 
, O 
and O 
bear O 
limited O 
sequence O 
identity O 
to O 
known O 
structures O 
. O 
This O 
study O 
involved O 
development O 
of O 
a O 
peptide O 
to O 
characterize O 
the O 
intrinsic O 
structure O 
of O 
the O 
LPA B-ABBREVIATION 
( O 
1 O 
) O 
GPCR O 
second O 
EL O 
. O 
The O 
loop O 
was O 
embedded O 
between O 
two O 
helices O 
that O 
assemble O 
into O 
a O 
coiled O 
- O 
coil O 
, O 
which O 
served O 
as O 
a O 
receptor O 
- O 
mimetic O 
folding O 
constraint O 
( O 
LPA B-ABBREVIATION 
(1)-CC-EL2 O 
peptide O 
) O 
. O 
The O 
ensemble O 
of O 
structures O 
from O 
multi O 
- O 
dimensional O 
NMR O 
experiments O 
demonstrated O 
that O 
a O 
robust O 
coiled O 
- O 
coil O 
formed O 
without O 
noticeable O 
deformation O 
due O 
to O 
the O 
EL2 O 
sequence O 
. O 
In O 
contrast O 
, O 
the O 
EL2 O 
sequence O 
showed O 
well O 
- O 
defined O 
structure O 
only O 
near O 
its O 
C B-FORMULA 
-terminal O 
residues O 
. O 
The O 
NMR O 
ensemble O 
was O 
combined O 
with O 
a O 
computational O 
model O 
of O 
the O 
LPA B-ABBREVIATION 
( O 
1 O 
) O 
receptor O 
that O 
had O 
previously O 
been O 
validated O 
. O 
The O 
resulting O 
hybrid O 
models O 
were O 
evaluated O 
using O 
docking O 
. O 
Nine O 
different O 
hybrid O 
models O 
interacted O 
with O 
LPA B-ABBREVIATION 
18 O 
: O 
1 O 
as O 
expected O 
, O 
based O 
on O 
prior O 
mutagenesis O 
studies O 
, O 
and O 
one O 
was O 
additionally O 
consistent O 
with O 
antagonist O 
affinity O 
trends O 
. O 

Inhibitors O 
and O 
microRNAs O 
( O 
miRNA O 
) O 
Targeting O 
the O 
Mammalian O 
Target O 
of O 
Rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
Pathway O 
: O 
Potential O 
for O 
Novel O 
Anticancer O 
Therapeutics O 
. O 

mammalian O 
target O 
of O 
rapamycin B-TRIVIAL 
( O 
mTOR O 
) O 
is O 
a O 
critical O 
regulator O 
of O 
many O 
fundamental O 
features O 
in O 
response O 
to O 
upstream O 
cellular O 
signals O 
, O 
such O 
as O 
growth O 
factors O 
, O 
energy O 
, O 
stress O 
and O 
nutrients O 
, O 
controlling O 
cell O 
growth O 
, O 
proliferation O 
and O 
metabolism O 
through O 
two O 
complexes O 
, O 
mTORC1 O 
and O 
mTORC2 O 
. O 
Dysregulation O 
of O 
mTOR O 
signalling O 
often O 
occurs O 
in O 
a O 
variety O 
of O 
human O 
malignant O 
diseases O 
making O 
it O 
a O 
crucial O 
and O 
validated O 
target O 
in O 
the O 
treatment O 
of O 
cancer O 
. O 
Tumour O 
cells O 
have O 
shown O 
high O 
susceptibility O 
to O 
mTOR O 
inhibitors O 
. O 
Rapamycin B-TRIVIAL 
and O 
its O 
derivatives O 
( O 
rapalogs O 
) O 
have O 
been O 
tested O 
in O 
clinical O 
trials O 
in O 
several O 
tumour O 
types O 
and O 
found O 
to O 
be O 
effective O 
as O 
anticancer O 
agents O 
in O 
patients O 
with O 
advanced O 
cancers O 
. O 
To O 
block O 
mTOR O 
function O 
, O 
they O 
form O 
a O 
complex O 
with O 
FKBP12 O 
and O 
then O 
bind O 
the O 
FRB O 
domain O 
of O 
mTOR O 
. O 
Furthermore O 
, O 
a O 
new O 
generation O 
of O 
mTOR O 
inhibitors O 
targeting O 
ATP B-ABBREVIATION 
-binding O 
in O 
the O 
catalytic O 
site O 
of O 
mTOR O 
showed O 
potent O 
and O 
more O 
selective O 
inhibition O 
. O 
More O 
recently O 
, O 
microRNAs O 
( O 
miRNA O 
) O 
have O 
emerged O 
as O 
modulators O 
of O 
biological O 
pathways O 
that O 
are O 
essential O 
in O 
cancer O 
initiation O 
, O 
development O 
and O 
progression O 
. O 
Evidence O 
collected O 
to O 
date O 
shows O 
that O 
miRNAs O 
may O 
function O 
as O 
tumour O 
suppressors O 
or O 
oncogenes O 
in O 
several O 
human O 
neoplasms O 
. O 
The O 
mTOR O 
pathway O 
is O 
a O 
promising O 
target O 
by O 
miRNAs O 
for O 
anticancer O 
therapy O 
. O 
Extensive O 
studies O 
have O 
indicated O 
that O 
regulation O 
of O 
the O 
mTOR O 
pathway O 
by O 
miRNAs O 
plays O 
a O 
major O 
role O 
in O 
cancer O 
progression O 
, O 
indicating O 
a O 
novel O 
way O 
to O 
investigate O 
the O 
tumorigenesis O 
and O 
therapy O 
of O 
cancer O 
. O 
Here O 
, O 
we O 
summarize O 
current O 
findings O 
of O 
the O 
role O 
of O 
mTOR O 
inhibitors O 
and O 
miRNAs O 
in O 
carcinogenesis O 
through O 
targeting O 
mTOR O 
signalling O 
pathways O 
and O 
determine O 
their O 
potential O 
as O 
novel O 
anti-cancer O 
therapeutics O 
. O 

of O 
Hypoglycemia O 
via O 
Somatostatin B-TRIVIAL 
Receptor O 
Type O 
2 O 
Antagonism O 
in O 
Recurrently O 
Hypoglycemic O 
Diabetic O 
Rats O 
. O 

antagonism O 
of O 
somatostatin B-TRIVIAL 
receptor O 
type O 
2 O 
( O 
SSTR2- O 
) O 
normalizes O 
glucagon O 
and O 
corticosterone B-TRIVIAL 
responses O 
to O 
hypoglycemic O 
clamp O 
in O 
diabetic O 
rats O 
. O 
The O 
purpose O 
of O 
this O 
study O 
is O 
to O 
determine O 
if O 
SSTR2 O 
antagonism O 
( O 
SSTR2a O 
) O 
ameliorates O 
hypoglycemia O 
in O 
response O 
to O 
overinsulinization O 
in O 
diabetic O 
rats O 
previously O 
exposed O 
to O 
recurrent O 
hypoglycemia O 
. O 
Streptozotocin B-TRIVIAL 
-diabetic O 
rats O 
( O 
n= O 
19 O 
) O 
, O 
previously O 
subjected O 
to O 
5 O 
hypoglycemia O 
events O 
over O 
3 O 
days O 
, O 
received O 
an O 
i.v O 
. O 
insulin O 
bolus O 
( O 
10 O 
U O 
/ O 
kg O 
) O 
+ O 
insulin O 
infusion O 
( O 
50 O 
mU O 
/ O 
kg O 
/ O 
min O 
) O 
until O 
hypoglycemia O 
ensued O 
( O 
≤ O 
3.9 O 
mM O 
) O 
( O 
Expt-D1 O 
) O 
. O 
The O 
next O 
day O 
( O 
Expt-D2 O 
) O 
, O 
rats O 
were O 
allocated O 
to O 
receive O 
either O 
placebo O 
treatment O 
( O 
n=7 O 
) O 
or O 
SSTR2a O 
infusion O 
( O 
3000 O 
nmol O 
/ O 
kg O 
/ O 
min O 
, O 
n=12 O 
) O 
60-min O 
prior O 
to O 
same O 
insulin O 
regimen O 
. O 
On O 
Expt-D1 O 
, O 
all O 
rats O 
developed O 
hypoglycemia O 
by O 
∼90 O 
minutes O 
, O 
while O 
on O 
Expt-D2 O 
hypoglycemia O 
was O 
attenuated O 
with O 
SSTR2a O 
treatment O 
( O 
nadir O 
= O 
3.7 O 
± O 
0.3 O 
mM O 
vs O 
. O 
2.7±0.3 O 
mM O 
in O 
SSTR2a O 
and O 
controls O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
Glucagon O 
response O 
to O 
hypoglycemia O 
on O 
Expt-D2 O 
deteriorated O 
by O 
20-fold O 
in O 
the O 
placebo O 
group O 
( O 
P O 
< O 
0.001 O 
) O 
but O 
improved O 
in O 
the O 
SSTR2a O 
group O 
( O 
3-fold O 
increase O 
in O 
AUC O 
, O 
P O 
< O 
0.001 O 
) O 
. O 
Corticosterone B-TRIVIAL 
response O 
deteriorated O 
in O 
the O 
placebo O 
treated O 
rats O 
on O 
Expt-D2 O 
but O 
increased O 
2-fold O 
in O 
the O 
SSTR2a O 
group O 
. O 
Catecholamine B-FAMILY 
responses O 
were O 
not O 
affected O 
by O 
antagonism O 
. O 
Thus O 
, O 
SSTR2 O 
antagonism O 
following O 
recurrent O 
hypoglycemia O 
improves O 
the O 
glucagon O 
and O 
corticosterone B-TRIVIAL 
responses O 
and O 
largely O 
ameliorates O 
insulin O 
- O 
induced O 
hypoglycemia O 
in O 
diabetic O 
rats O 
. O 

diabetic O 
retinopathy O 
( O 
PDR O 
) O 
is O 
the O 
most O 
severe O 
vision O 
- O 
threatening O 
complication O 
of O 
diabetes O 
. O 
To O 
investigated O 
genetic O 
association O 
between O 
TCF7L2 O 
and O 
PDR O 
in O 
Caucasian O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
and O 
its O 
functional O 
consequences O 
, O 
383 O 
T2DM O 
patients O 
with O 
PDR O 
( O 
T2DM-PDR O 
) O 
and O 
756 O 
T2DM O 
patients O 
without O 
diabetic O 
retinopathy O 
( O 
T2DM-no O 
DR O 
) O 
were O 
genotyped O 
with O 
rs7903146 O 
in O 
TCF7L2 O 
. O 
We O 
found O 
that O 
risk O 
allele O 
( O 
T O 
) O 
frequency O 
of O 
rs7903146 O 
was O 
significantly O 
higher O 
in O 
T2DM-PDR O 
patients O 
( O 
allelic O 
P O 
= O 
0.000252 O 
) O 
. O 
In O 
lymphoblastoid O 
cells O 
induced O 
to O 
undergo O 
endoplasmic O 
reticulum O 
( O 
ER O 
) O 
stress O 
by O 
treatment O 
of O 
tunicamycin B-TRIVIAL 
, O 
higher O 
fold O 
change O 
of O 
TCF7L2 O 
and O 
VEGFA O 
mRNA O 
levels O 
were O 
observed O 
in O 
rs7903146-TT O 
cells O 
than O 
that O 
in O 
rs7903146-CC O 
cells O 
( O 
P O 
= O 
0.02 O 
for O 
TCF7L2 O 
; O 
P O 
= O 
0.004 O 
for O 
VEGFA O 
) O 
, O 
suggesting O 
ER O 
stress O 
plays O 
a O 
role O 
in O 
PDR O 
pathogenesis O 
. O 
Silencing O 
TCF7L2 O 
resulted O 
in O 
decreased O 
mRNA O 
levels O 
of O 
both O 
TCF7L2 O 
and O 
VEGFA O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Retinas O 
of O 
oxygen B-SYSTEMATIC 
-induced O 
retinopathy O 
( O 
OIR O 
) O 
mice O 
( O 
a O 
model O 
for O 
PDR O 
) O 
had O 
higher O 
TCF7L2 O 
and O 
VEGFA O 
mRNA O 
levels O 
than O 
controls O 
( O 
P O 
= O 
0.00029 O 
for O 
TCF7L2 O 
; O 
P O 
= O 
1.9E-07 O 
for O 
VEGFA O 
) O 
. O 
Together O 
, O 
our O 
study O 
showed O 
that O 
TCF7L2-rs7903146 O 
is O 
associated O 
with O 
PDR O 
in O 
Caucasian O 
T2DM O 
and O 
suggested O 
TCF7L2 O 
promoted O 
pathological O 
retinal O 
neovascularization O 
via O 
ER O 
stress O 
- O 
dependent O 
upregulation O 
of O 
VEGFA O 
. O 

wide O 
association O 
studies O 
( O 
GWAS O 
) O 
have O 
proven O 
to O 
be O 
highly O 
effective O 
at O 
defining O 
causal O 
relationships O 
between O 
single O 
nucleotide B-FAMILY 
polymorphisms O 
( O 
SNP O 
) O 
and O 
clinical O 
phenotypes O 
in O 
complex O 
diseases O 
. O 
Establishing O 
a O 
mechanistic O 
link O 
between O 
a O 
non-coding O 
SNP O 
and O 
the O 
clinical O 
outcome O 
is O 
a O 
significant O 
hurdle O 
in O 
translating O 
associations O 
into O 
biological O 
insight O 
. O 
We O 
demonstrate O 
an O 
approach O 
to O 
assess O 
the O 
functional O 
context O 
of O 
a O 
diabetic O 
nephropathy O 
( O 
DN O 
) O 
associated O 
SNP O 
located O 
in O 
the O 
promoter O 
region O 
of O 
the O 
gene O 
FRMD3 O 
. O 
The O 
approach O 
integrates O 
pathway O 
analyses O 
with O 
transcriptional O 
regulatory O 
pattern O 
based O 
promoter O 
modeling O 
and O 
allows O 
the O 
identification O 
of O 
a O 
transcriptional O 
framework O 
impacted O 
by O 
the O 
DN-associated O 
SNP O 
in O 
the O 
FRMD3 O 
promoter O 
. O 
This O 
framework O 
provides O 
a O 
testable O 
hypothesis O 
for O 
mechanisms O 
of O 
genomic O 
variation O 
and O 
transcriptional O 
regulation O 
in O 
the O 
context O 
of O 
DN O 
. O 
Our O 
model O 
proposes O 
a O 
possible O 
transcriptional O 
link O 
through O 
which O 
the O 
polymorphism O 
in O 
the O 
FRMD3 O 
promoter O 
could O 
influence O 
transcriptional O 
regulation O 
within O 
the O 
bone O 
morphogenetic O 
protein O 
( O 
BMP O 
) O 
signaling O 
pathway O 
. O 
These O 
findings O 
provide O 
the O 
rationale O 
to O 
interrogate O 
the O 
biological O 
link O 
between O 
FRMD3 O 
and O 
the O 
BMP O 
pathway O 
, O 
and O 
serve O 
as O 
an O 
example O 
of O 
functional O 
genomics O 
- O 
based O 
hypothesis O 
generation O 
. O 

toxin O 
( O 
BoNT O 
) O 
is O 
a O 
potent O 
neurotoxin O 
that O 
is O 
produced O 
by O 
the O 
gram O 
- O 
positive O 
, O 
spore O 
- O 
forming O 
, O 
anaerobic O 
bacterium O 
, O 
Clostridum O 
botulinum O 
. O 
There O 
are O 
7 O 
known O 
immunologically O 
distinct O 
serotypes O 
of O 
BoNT O 
: O 
types O 
A O 
, O 
B O 
, O 
C1 O 
, O 
D O 
, O 
E O 
, O 
F O 
, O 
and O 
G O 
. O 
Clostridum O 
neurotoxins O 
are O 
produced O 
as O 
a O 
single O 
inactive O 
polypeptide O 
chain O 
of O 
150kDa O 
, O 
which O 
is O 
cleaved O 
by O 
tissue O 
proteinases O 
into O 
an O 
active O 
di O 
- O 
chain O 
molecule O 
: O 
a O 
heavy O 
chain O 
( O 
H O 
) O 
of O 
∼100kDa O 
and O 
a O 
light O 
chain O 
( O 
L O 
) O 
of O 
∼50kDa O 
held O 
together O 
by O 
a O 
single O 
disulfide B-SYSTEMATIC 
bond O 
. O 
Each O 
serotype O 
demonstrates O 
its O 
own O 
varied O 
mechanisms O 
of O 
action O 
and O 
duration O 
of O 
effect O 
. O 
The O 
heavy O 
chain O 
of O 
each O 
BoNT O 
serotype O 
binds O 
to O 
its O 
specific O 
neuronal O 
ecto O 
- O 
acceptor O 
, O 
whereby O 
, O 
membrane O 
translocation O 
and O 
endocytosis O 
by O 
intracellular O 
synaptic O 
vesicles O 
occurs O 
. O 
The O 
light O 
chain O 
acts O 
to O 
cleave O 
SNAP-25 O 
, O 
which O 
inhibits O 
synaptic O 
exocytosis O 
, O 
and O 
therefore O 
, O 
disables O 
neural O 
transmission O 
. O 
The O 
action O 
of O 
BoNT O 
to O 
block O 
the O 
release O 
of O 
acetylcholine B-SYSTEMATIC 
botulinum O 
toxin O 
at O 
the O 
neuromuscular O 
junction O 
is O 
best O 
understood O 
, O 
however O 
, O 
most O 
experts O 
acknowledge O 
that O 
this O 
effect O 
alone O 
appears O 
inadequate O 
to O 
explain O 
the O 
entirety O 
of O 
the O 
neurotoxin's O 
apparent O 
analgesic O 
activity O 
. O 
Consequently O 
, O 
scientific O 
and O 
clinical O 
evidence O 
has O 
emerged O 
that O 
suggests O 
multiple O 
antinociceptive O 
mechanisms O 
for O 
botulinum O 
toxins O 
in O 
a O 
variety O 
of O 
painful O 
disorders O 
, O 
including O 
: O 
chronic O 
musculoskeletal O 
, O 
neurological O 
, O 
pelvic O 
, O 
perineal O 
, O 
osteoarticular O 
, O 
and O 
some O 
headache O 
conditions O 
. O 

hydroxylase-2 O 
: O 
An O 
emerging O 
therapeutic O 
target O 
for O 
stress O 
disorders O 
. O 

( O 
5-HT B-SYSTEMATIC 
) O 
has O 
been O 
long O 
recognized O 
to O 
modulate O 
the O 
stress O 
response O 
, O 
and O 
dysfunction O 
of O 
5-HT B-SYSTEMATIC 
has O 
been O 
implicated O 
in O 
numerous O 
stress O 
disorders O 
. O 
Accordingly O 
, O 
the O 
5-HT B-SYSTEMATIC 
system O 
has O 
been O 
targeted O 
for O 
the O 
treatment O 
of O 
stress O 
disorders O 
. O 
Tryptophan B-TRIVIAL 
hydroxylase O 
( O 
TPH O 
) O 
is O 
the O 
rate O 
- O 
limiting O 
enzyme O 
in O 
5-HT B-SYSTEMATIC 
synthesis O 
, O 
and O 
the O 
recent O 
identification O 
of O 
a O 
second O 
, O 
neuron O 
- O 
specific O 
TPH O 
isoform O 
( O 
TPH2 O 
) O 
opened O 
up O 
a O 
new O 
area O 
of O 
research O 
. O 
With O 
a O 
decade O 
of O 
extensive O 
investigation O 
, O 
it O 
is O 
now O 
recognized O 
that O 
: O 
( O 
1 O 
) O 
TPH2 O 
exhibits O 
a O 
highly O 
flexible O 
gene O 
expression O 
that O 
is O 
modulated O 
by O 
an O 
increasing O 
number O 
of O 
internal O 
and O 
external O 
environmental O 
factors O 
including O 
the O 
biological O 
clock O 
, O 
stressors O 
, O 
endogenous O 
hormones O 
, O 
and O 
antidepressant O 
therapies O 
; O 
and O 
( O 
2 O 
) O 
genetically O 
determined O 
TPH2 O 
activity O 
is O 
linked O 
to O 
a O 
growing O 
body O 
of O 
stress O 
- O 
related O 
neuronal O 
correlates O 
and O 
behavioral O 
traits O 
. O 
These O 
findings O 
reveal O 
an O 
active O 
role O 
of O 
TPH2 O 
in O 
the O 
stress O 
response O 
and O 
provide O 
new O 
insights O 
into O 
the O 
long O 
recognized O 
but O 
not O 
yet O 
fully O 
understood O 
5-HT B-SYSTEMATIC 
-stress O 
interaction O 
. O 
As O 
a O 
major O 
modulator O 
of O 
5-HT B-SYSTEMATIC 
neurotransmission O 
and O 
the O 
stress O 
response O 
, O 
TPH2 O 
is O 
of O 
both O 
pathophysiological O 
and O 
pharmacological O 
significance O 
, O 
and O 
is O 
emerging O 
as O 
a O 
new O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
stress O 
disorders O 
. O 
Given O 
that O 
numerous O 
antidepressant O 
therapies O 
influence O 
TPH2 O 
gene O 
expression O 
, O 
TPH2 O 
is O 
already O 
inadvertently O 
targeted O 
for O 
the O 
treatment O 
of O 
stress O 
disorders O 
. O 
With O 
increased O 
understanding O 
of O 
the O 
regulation O 
of O 
TPH2 O 
activity O 
we O 
can O 
now O 
purposely O 
utilize O 
TPH2 O 
as O 
a O 
target O 
to O 
develop O 
new O 
or O 
optimize O 
current O 
therapies O 
, O 
which O 
are O 
expected O 
to O 
greatly O 
improve O 
the O 
prevention O 
and O 
treatment O 
of O 
a O 
wide O 
variety O 
of O 
stress O 
disorders O 
. O 

(R)-omeprazole B-TRIVIAL 
hydroxylation O 
index O 
reflects O 
CYP2C19 O 
activity O 
in O 
healthy O 
Japanese O 
volunteers O 
. O 

: O 
Omeprazole B-TRIVIAL 
has O 
(R)- O 
and O 
(S)-enantiomers O 
, O 
which O 
exhibit O 
different O 
pharmacokinetics O 
( O 
PK O 
) O 
among O 
patients O 
with O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
2C19 O 
genotype O 
groups O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
the O 
1-point O 
, O 
4-h O 
postdose O 
(R)-omeprazole B-TRIVIAL 
hydroxylation O 
index O 
( O 
HI O 
) O 
of O 
racemic B-SYSTEMATIC 
omeprazole I-SYSTEMATIC 
reflects O 
the O 
three O 
CYP2C19 O 
genotype O 
groups O 
in O 
Japanese O 
individuals O 
. O 
METHODS O 
: O 
Ninety O 
healthy O 
Japanese O 
individuals O 
were O 
enrolled O 
and O 
classified O 
into O 
the O 
three O 
different O 
CYP2C19 O 
genotype O 
groups O 
: O 
homozygous O 
extensive O 
metabolizers O 
( O 
hmEMs O 
; O 
n O 
= O 
34 O 
) O 
, O 
heterozygous O 
EMs O 
( O 
htEMs O 
; O 
n O 
= O 
44 O 
) O 
, O 
and O 
poor O 
metabolizers O 
( O 
PMs O 
; O 
n O 
= O 
12 O 
) O 
. O 
Blood O 
samples O 
were O 
drawn O 
4 O 
h O 
after O 
the O 
intake O 
of O 
an O 
oral O 
dose O 
of O 
omeprazole B-TRIVIAL 
40 O 
mg O 
, O 
and O 
plasma O 
levels O 
of O 
omeprazole B-TRIVIAL 
and O 
its O 
metabolites O 
were O 
analyzed O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
using O 
a O 
chiral O 
column O 
. O 
RESULTS O 
: O 
Mean O 
plasma O 
concentrations O 
of O 
(R)- B-MULTIPLE 
and I-MULTIPLE 
(S)-omeprazole I-MULTIPLE 
in O 
PMs O 
were O 
significantly O 
higher O 
than O 
those O 
in O 
hmEMs O 
and O 
htEMs O 
, O 
and O 
similar O 
results O 
were O 
obtained O 
in O 
the O 
case O 
of O 
omeprazole B-TRIVIAL 
sulfone I-TRIVIAL 
. O 
Additionally O 
, O 
there O 
was O 
a O 
significant O 
difference O 
in O 
plasma O 
concentrations O 
of O 
(R)-5-hydroxyomeprazole B-SYSTEMATIC 
among O 
CYP2C19 O 
genotype O 
groups O 
, O 
whereas O 
no O 
significant O 
differences O 
were O 
observed O 
in O 
that O 
of O 
(S)-5-hydroxyomeprazole B-SYSTEMATIC 
. O 
Similarly O 
, O 
(R)-omeprazole B-TRIVIAL 
HI O 
in O 
hmEMs O 
, O 
htEMs O 
, O 
and O 
PMs O 
were O 
5.6 O 
, O 
3.1 O 
, O 
and O 
0.3 O 
, O 
respectively O 
, O 
which O 
were O 
significantly O 
different O 
, O 
but O 
no O 
significant O 
difference O 
was O 
present O 
in O 
the O 
(S)-omeprazole B-TRIVIAL 
HI O 
. O 
CONCLUSION O 
: O 
Our O 
findings O 
demonstrate O 
that O 
(R)-omeprazole B-TRIVIAL 
HI O 
correlated O 
better O 
with O 
CYP2C19 O 
genotype O 
groups O 
than O 
racemic B-SYSTEMATIC 
- I-SYSTEMATIC 
omeprazole I-SYSTEMATIC 
HI O 
, O 
and O 
these O 
results O 
may O 
be O 
useful O 
for O 
classification O 
among O 
patients O 
in O 
CYP2C19 O 
genotype O 
groups O 
prior O 
to O 
omeprazole O 
treatment O 
. O 

of O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
against O 
dimethylnitrosamine B-SYSTEMATIC 
-induced O 
hepatic O 
fibrosis O 
in O 
rats O 
. O 

acid I-TRIVIAL 
is O 
a O 
member O 
of O 
the O 
phenylpropanoid B-SYSTEMATIC 
family O 
and O 
is O 
abundant O 
in O 
cereals O 
, O 
nuts O 
, O 
oil O 
seeds O 
, O 
and O 
berries O 
. O 
It O 
exhibits O 
a O 
wide O 
range O 
of O 
pharmacological O 
properties O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
hepatoprotective O 
and O 
antifibrotic O 
effects O 
of O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
on O 
dimethylnitrosamine B-SYSTEMATIC 
( O 
DMN B-ABBREVIATION 
)-induced O 
chronic O 
liver O 
injury O 
in O 
rats O 
. O 
Sinapic B-TRIVIAL 
acid I-TRIVIAL 
remarkably O 
prevented O 
DMN B-ABBREVIATION 
-induced O 
loss O 
of O 
body O 
weight O 
. O 
This O 
was O 
accompanied O 
by O 
a O 
significant O 
increase O 
in O 
levels O 
of O 
serum O 
alanine B-TRIVIAL 
transaminase O 
, O 
aspartate B-TRIVIAL 
transaminase O 
, O 
and O 
liver O 
malondialdehyde B-TRIVIAL 
content O 
. O 
Furthermore O 
, O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
reduced O 
hepatic O 
hydroxyproline B-SYSTEMATIC 
content O 
, O 
which O 
correlated O 
with O 
a O 
reduction O 
in O 
the O 
expression O 
of O 
type O 
I O 
collagen O 
mRNA O 
and O 
histological O 
analysis O 
of O 
collagen O 
in O 
liver O 
tissue O 
. O 
Additionally O 
, O 
the O 
expression O 
of O 
hepatic O 
fibrosis O 
- O 
related O 
factors O 
such O 
as O 
α-smooth O 
muscle O 
actin O 
and O 
transforming O 
growth O 
factor-β1 O 
( O 
TGF-β1 O 
) O 
, O 
were O 
reduced O 
in O 
rats O 
treated O 
with O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Sinapic B-TRIVIAL 
acid I-TRIVIAL 
exhibited O 
strong O 
scavenging O 
activity O 
. O 
In O 
conclusion O 
, O 
we O 
find O 
that O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
exhibits O 
hepatoprotective O 
and O 
antifibrotic O 
effects O 
against O 
DMN B-ABBREVIATION 
-induced O 
liver O 
injury O 
, O 
most O 
likely O 
due O 
to O 
its O 
antioxidant O 
activities O 
of O 
scavenging O 
radicals O 
, O 
its O 
capacity O 
to O 
suppress O 
TGF-β1 O 
and O 
its O 
ability O 
to O 
attenuate O 
activation O 
of O 
hepatic O 
stellate O 
cells O 
. O 
This O 
suggests O 
that O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
is O 
a O 
potentially O 
useful O 
agent O 
for O 
the O 
protection O 
against O 
liver O 
fibrosis O 
and O 
cirrhosis O 
. O 

and O 
sensitive O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
methods O 
for O 
quantification O 
of O 
tadalafil B-TRIVIAL 
in O 
rat O 
plasma O 
: O 
application O 
to O 
pharmacokinetic O 
study O 
in O 
rats O 
. O 

simple O 
and O 
sensitive O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
method O 
was O 
developed O 
and O 
validated O 
in O 
rat O 
plasma O 
for O 
quantification O 
of O 
tadalafil B-TRIVIAL 
, O 
a O 
novel O 
therapeutic O 
agent O 
for O 
erectile O 
dysfunction O 
. O 
Tadalafil B-TRIVIAL 
and O 
acebutolol B-TRIVIAL 
( O 
internal O 
standard O 
) O 
were O 
extracted O 
by O 
liquid O 
- O 
liquid O 
extraction O 
with O 
tert-butyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
. O 
The O 
chromatographic O 
separation O 
was O 
performed O 
on O 
a O 
reverse O 
phase O 
C18 O 
column O 
with O 
a O 
mobile O 
phase O 
consisting O 
of O 
0.1 O 
% O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
acetonitrile B-SYSTEMATIC 
( O 
45 O 
: O 
55 O 
, O 
v O 
/ O 
v O 
) O 
at O 
a O 
flow O 
rate O 
of O 
0.3 O 
mL O 
/ O 
min O 
. O 
The O 
protonated O 
analyte O 
was O 
quantitated O 
by O 
multiple O 
reaction O 
monitoring O 
with O 
a O 
Waters O 
Quattro O 
micro O 
™ O 
API O 
mass O 
spectrometer O 
. O 
The O 
calibration O 
curve O 
was O 
linear O 
over O 
a O 
concentration O 
range O 
of O 
2-2000 O 
ng O 
/ O 
mL O 
, O 
and O 
the O 
lower O 
limit O 
of O 
quantification O 
was O 
2 O 
ng O 
/ O 
mL O 
with O 
a O 
precision O 
( O 
CV O 
% O 
) O 
of O 
10.9 O 
% O 
. O 
Acceptable O 
intra O 
- O 
day O 
and O 
inter O 
- O 
day O 
precision O 
and O 
accuracy O 
were O 
obtained O 
at O 
3 O 
concentration O 
levels O 
( O 
3 O 
, O 
200 O 
, O 
and O 
1500 O 
ng O 
/ O 
mL O 
) O 
. O 
Tadalafil B-TRIVIAL 
was O 
found O 
to O 
be O 
stable O 
in O 
a O 
battery O 
of O 
studies O 
, O 
including O 
bench O 
top O 
, O 
freeze O 
- O 
thaw O 
, O 
and O 
autosampler O 
conditions O 
. O 
The O 
validated O 
method O 
was O 
successfully O 
used O 
to O 
determine O 
tadalafil B-TRIVIAL 
concentration O 
in O 
rat O 
plasma O 
samples O 
after O 
oral O 
administration O 
at O 
a O 
dose O 
of O 
1 O 
mg O 
/ O 
kg O 
. O 

effect O 
of O 
pristimerin B-TRIVIAL 
on O 
lipopolysaccharide-induced O 
inflammatory O 
responses O 
in O 
murine O 
macrophages O 
. O 

, O 
a O 
quinonemethide B-FAMILY 
triterpenoid I-FAMILY 
derived O 
from O 
Celastraceae O 
and O 
Hippocrateaceae O 
, O 
has O 
recently O 
been O 
found O 
to O 
suppress O 
tumor O 
promotion O 
, O 
metastasis O 
and O 
angiogenesis O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
evaluated O 
the O 
anti-inflammatory O 
potentials O 
of O 
pristimerin B-TRIVIAL 
in O 
a O 
cell O 
culture O 
system O 
. O 
Pristimerin B-TRIVIAL 
suppressed O 
not O 
only O 
the O 
generation O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
, O 
but O 
also O 
the O 
expression O 
of O 
inducible O 
NO B-FORMULA 
synthase O 
and O 
cyclooxygenase-2 O 
induced O 
by O 
lipopolysacharide O 
( O 
LPS O 
) O 
in O 
murine O 
macrophage O 
RAW264.7 O 
cells O 
. O 
Similarly O 
, O 
pristimerin B-TRIVIAL 
inhibited O 
the O 
release O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
, O 
namely O 
, O 
tumor O 
necrosis O 
factor-α O 
and O 
interleukin-6 O 
, O 
induced O 
by O 
LPS O 
. O 
The O 
underlying O 
mechanism O 
of O 
the O 
anti-inflammatory O 
action O 
of O 
pristimerin B-TRIVIAL 
was O 
correlated O 
with O 
down O 
- O 
regulation O 
of O 
nuclear O 
factor-κB O 
and O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
signal O 
pathway O 
. O 

disease O 
( O 
AD O 
) O 
, O 
a O 
progressive O 
neurodegenerative O 
disorder O 
, O 
is O 
characterized O 
by O 
the O 
deficits O 
in O 
the O 
cholinergic O 
system O 
and O 
deposition O 
of O 
beta O 
amyloid O 
( O 
Aβ O 
) O 
in O 
the O 
form O 
of O 
neurofibrillary O 
tangles O 
and O 
amyloid O 
plaques O 
. O 
Since O 
the O 
cholinergic O 
system O 
plays O 
an O 
important O 
role O 
in O 
the O 
regulation O 
of O 
learning O 
and O 
memory O 
processes O 
, O 
it O 
has O 
been O 
targetted O 
for O 
the O 
design O 
of O 
anti-Alzheimer's O 
drugs O 
. O 
Cholinesterase O 
inhibitors O 
enhance O 
cholinergic O 
transmission O 
directly O 
by O 
inhibiting O 
the O 
enzyme O 
acetylcholinesterase O 
( O 
AChE O 
) O 
which O 
hydrolyses O 
acetylcholine B-SYSTEMATIC 
. O 
Furthermore O 
, O 
it O 
has O 
been O 
also O 
demonstrated O 
that O 
both O 
acetylcholinesterase O 
and O 
butrylcholinesterase O 
( O 
BuChE O 
) O 
play O 
an O 
important O 
role O 
in O 
Aβ-aggregation O 
during O 
the O 
early O 
stages O 
of O 
senile O 
plaque O 
formation O 
. O 
Therefore O 
, O 
AChE O 
and O 
BuChE O 
inhibition O 
have O 
been O 
documented O 
as O 
critical O 
targets O 
for O 
the O 
effective O 
management O 
of O 
AD O 
by O 
an O 
increase O 
in O 
the O 
availability O 
of O 
acetylcholine B-SYSTEMATIC 
in O 
the O 
brain O 
regions O 
and O 
decrease O 
in O 
the O 
Aβ O 
deposition O 
. O 
This O 
review O 
discusses O 
the O 
different O 
classes O 
of O 
cholinesterase O 
inhibitors O 
including O 
tacrine B-TRIVIAL 
, O 
donepezil B-TRIVIAL 
, O 
rivastigmine B-TRIVIAL 
, O 
galantamine B-TRIVIAL 
, O 
xanthostigmine B-TRIVIAL 
, O 
para-aminobenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
coumarin B-TRIVIAL 
, O 
flavonoid B-FAMILY 
, O 
and O 
pyrrolo B-SYSTEMATIC 
- I-SYSTEMATIC 
isoxazole I-SYSTEMATIC 
analogues O 
developed O 
for O 
the O 
treatment O 
of O 
AD O 
. O 

α-glucosidase O 
and O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
inhibitors O 
from O 
Artemisia O 
capillaris O 
. O 

a O 
part O 
of O 
our O 
ongoing O 
effort O 
to O 
identify O 
anti-diabetic O 
constituents O 
from O 
natural O 
sources O 
, O 
we O 
examined O 
the O 
inhibitory O 
activity O 
of O 
the O 
methanol B-SYSTEMATIC 
extracts O 
of O 
12 O 
species O 
of O 
the O 
genus O 
Artemisia O 
, O 
against O 
α-glucosidase O 
and O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP1B O 
) O 
. O 
The O 
methanol B-SYSTEMATIC 
extracts O 
of O 
different O 
species O 
exhibited O 
promising O 
α-glucosidase O 
and O 
PTP1B O 
inhibitory O 
activities O 
. O 
Since O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Artemisia O 
capillaris O 
exhibited O 
the O 
highest O 
α-glucosidase O 
inhibitory O 
activity O 
together O 
with O 
significant O 
PTP1B O 
inhibitory O 
activity O 
, O 
it O 
was O 
selected O 
for O 
further O 
investigation O 
. O 
Repeated O 
column O 
chromatography O 
based O 
on O 
bioactivity O 
guided O 
fractionation O 
yielded O 
10 O 
coumarins B-FAMILY 
( O 
esculetin B-TRIVIAL 
, O 
esculin B-TRIVIAL 
, O 
scopolin B-TRIVIAL 
, O 
isoscopolin B-TRIVIAL 
, O 
daphnetin B-TRIVIAL 
, O 
umbelliferone B-TRIVIAL 
, O 
7-methoxy B-SYSTEMATIC 
coumarin I-SYSTEMATIC 
, O 
scoparone B-TRIVIAL 
, O 
scopoletin B-TRIVIAL 
, O 
6-methoxy B-SYSTEMATIC 
artemicapin I-SYSTEMATIC 
C I-SYSTEMATIC 
) O 
, O 
8 O 
flavonoids B-FAMILY 
( O 
hyperoside B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
isorhamnetin B-TRIVIAL 
, O 
cirsilineol B-TRIVIAL 
, O 
arcapillin B-TRIVIAL 
, O 
isorhamnetin B-SYSTEMATIC 
3-robinobioside I-SYSTEMATIC 
, O 
linarin B-TRIVIAL 
, O 
isorhamnetin B-SYSTEMATIC 
3-glucoiside I-SYSTEMATIC 
) O 
, O 
6 O 
phenolic B-FAMILY 
compounds O 
( O 
1,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3,4-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
4,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3-caffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
, O 
and O 
one O 
chromone B-TRIVIAL 
( O 
capillarisin B-TRIVIAL 
) O 
. O 
Among O 
these O 
compounds O 
, O 
esculetin B-TRIVIAL 
, O 
scopoletin B-TRIVIAL 
, O 
quercetin B-TRIVIAL 
, O 
hyperoside B-TRIVIAL 
, O 
isorhamnetin B-TRIVIAL 
, O 
3,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
3,4-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
1,5-dicaffeoylquinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
exhibited O 
potent O 
α-glucosidase O 
inhibitory O 
activity O 
when O 
compared O 
to O 
the O 
positive O 
control O 
acarbose B-TRIVIAL 
. O 
In O 
addition O 
, O 
esculetin B-TRIVIAL 
and O 
6-methoxy B-SYSTEMATIC 
artemicapin I-SYSTEMATIC 
C I-SYSTEMATIC 
displayed O 
PTP1B O 
inhibitory O 
activity O 
. O 
Interestingly O 
, O 
all O 
isolated O 
dicaffeoylquinic B-FAMILY 
acids I-FAMILY 
showed O 
significant O 
PTP1B O 
inhibitory O 
activity O 
. O 
Therefore O 
, O 
the O 
results O 
of O 
the O 
present O 
study O 
clearly O 
demonstrate O 
the O 
potential O 
of O 
the O 
A O 
. O 
capillaris O 
extract O 
to O 
inhibit O 
α-glucosidase O 
and O 
PTP1B O 
. O 
These O 
inhibitory O 
properties O 
can O 
be O 
largely O 
attributed O 
to O 
a O 
combination O 
of O 
different O 
chemical O 
structures O 
, O 
including O 
coumarins B-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
and O 
dicaffeoylquinic B-FAMILY 
acids I-FAMILY 
, O 
which O 
could O 
be O 
further O 
explored O 
to O 
develop O 
therapeutic O 
or O 
preventive O 
agents O 
for O 
the O 
treatment O 
of O 
diabetes O 
. O 

of O 
acamprosate B-TRIVIAL 
on O 
behavior O 
and O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
: O 
an O 
open O 
- O 
label O 
study O 
in O 
youth O 
with O 
fragile O 
X O 
syndrome O 
. O 

: O 
Fragile O 
X O 
syndrome O 
( O 
FXS O 
) O 
is O 
an O 
inherited O 
form O 
of O 
developmental O 
disability O 
and O 
a O 
single O 
gene O 
cause O 
of O 
autism O 
. O 
As O 
a O 
disorder O 
with O 
increasingly O 
understood O 
pathophysiology O 
, O 
FXS O 
is O 
a O 
model O 
form O 
of O 
developmental O 
disability O 
for O 
targeted O 
drug O 
development O 
efforts O 
. O 
Preclinical O 
animal O 
model O 
findings O 
have O 
focused O 
targeted O 
drug O 
treatment O 
development O 
in O 
FXS O 
on O 
an O 
imbalance O 
between O 
excessive O 
glutamate B-TRIVIAL 
and O 
deficient O 
gamma-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
) O 
neurotransmission O 
. O 
METHODS O 
: O 
We O 
conducted O 
a O 
prospective O 
open O 
- O 
label O 
10-week O 
trial O 
of O 
acamprosate B-TRIVIAL 
in O 
12 O 
youth O 
aged O 
6-17 O 
years O 
( O 
mean O 
age O 
: O 
11.9 O 
years O 
) O 
with O 
FXS O 
. O 
RESULTS O 
: O 
Acamprosate B-TRIVIAL 
use O 
( O 
mean O 
dose O 
: O 
1054 O 
± O 
422 O 
mg O 
/ O 
day O 
) O 
was O 
associated O 
with O 
treatment O 
response O 
( O 
defined O 
by O 
a O 
Clinical O 
Global O 
Impressions O 
Improvement O 
( O 
CGI-I O 
) O 
scale O 
score O 
of O 
" O 
very O 
much O 
improved O 
" O 
or O 
" O 
much O 
improved O 
" O 
) O 
in O 
nine O 
of O 
12 O 
( O 
75 O 
% O 
) O 
subjects O 
. O 
Improvement O 
was O 
noted O 
in O 
social O 
behavior O 
and O 
inattention O 
/ O 
hyperactivity O 
using O 
multiple O 
standard O 
behavioral O 
outcome O 
measures O 
. O 
No O 
significant O 
adverse O 
effects O 
or O 
changes O 
in O 
vital O 
signs O 
, O 
including O 
weight O 
or O 
laboratory O 
measures O 
, O 
occurred O 
during O 
treatment O 
with O 
acamprosate B-TRIVIAL 
. O 
Additionally O 
, O 
pre- O 
and O 
post O 
- O 
treatment O 
blood O 
biomarker O 
analyses O 
looking O 
at O 
brain O 
- O 
derived O 
neurotrophic O 
factor O 
( O 
BDNF O 
) O 
levels O 
found O 
a O 
significant O 
increase O 
in O 
BDNF O 
with O 
treatment O 
. O 
In O 
our O 
pilot O 
sample O 
, O 
treatment O 
response O 
did O 
not O 
correlate O 
with O 
change O 
in O 
BDNF O 
with O 
treatment O 
. O 
CONCLUSIONS O 
: O 
Acamprosate B-TRIVIAL 
was O 
generally O 
safe O 
and O 
well O 
tolerated O 
and O 
was O 
associated O 
with O 
a O 
significant O 
improvement O 
in O 
social O 
behavior O 
and O 
a O 
reduction O 
in O 
inattention O 
/ O 
hyperactivity O 
. O 
The O 
increase O 
in O 
BDNF O 
that O 
occurred O 
with O 
treatment O 
may O 
be O 
a O 
useful O 
pharmacodynamic O 
marker O 
in O 
future O 
acamprosate B-TRIVIAL 
studies O 
. O 
Given O 
these O 
findings O 
, O 
a O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
study O 
of O 
acamprosate B-TRIVIAL 
in O 
youth O 
with O 
FXS O 
is O 
warranted O 
. O 

risk O 
factors O 
for O 
adverse O 
events O 
in O 
allopurinol B-TRIVIAL 
users O 
. O 

, O 
one O 
of O 
the O 
most O 
commonly O 
used O 
uric B-TRIVIAL 
acid I-TRIVIAL 
-lowering O 
agents O 
, O 
can O 
cause O 
serious O 
adverse O 
events O 
. O 
To O 
investigate O 
the O 
risk O 
factors O 
for O 
allopurinol B-TRIVIAL 
-induced O 
adverse O 
events O 
, O 
the O 
authors O 
enrolled O 
94 O 
patients O 
who O 
developed O 
allopurinol B-TRIVIAL 
-induced O 
adverse O 
events O 
and O 
378 O 
controls O 
who O 
were O 
randomly O 
chosen O 
from O 
1934 O 
patients O 
who O 
used O 
allopurinol B-TRIVIAL 
but O 
did O 
not O 
develop O 
any O 
adverse O 
events O 
in O 
this O 
retrospective O 
case O 
control O 
study O 
. O 
Univariate O 
analysis O 
showed O 
that O 
patients O 
who O 
developed O 
allopurinol B-TRIVIAL 
-induced O 
adverse O 
events O 
had O 
more O 
chronic O 
kidney O 
disease O 
( O 
46% O 
vs O 
30% O 
, O 
P O 
= O 
0.005 O 
) O 
, O 
more O 
hypertension O 
( O 
42% O 
vs O 
30% O 
, O 
P O 
= O 
0.036 O 
) O 
, O 
less O 
tumor O 
lysis O 
syndrome O 
( O 
P O 
= O 
0.03 O 
) O 
, O 
higher O 
cholesterol B-TRIVIAL 
( O 
P O 
= O 
0.013 O 
) O 
, O 
and O 
lower O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
P O 
= O 
0.002 O 
) O 
and O 
alanine B-TRIVIAL 
aminotransferase O 
levels O 
( O 
P O 
= O 
0.033 O 
) O 
and O 
more O 
commonly O 
used O 
angiotensin O 
receptor O 
blockers O 
( O 
27% O 
vs O 
15% O 
, O 
P O 
= O 
0.007 O 
) O 
, O 
colchicines B-FAMILY 
( O 
16% O 
vs O 
5% O 
, O 
P O 
= O 
0.01 O 
) O 
, O 
or O 
statins B-FAMILY 
( O 
19% O 
vs O 
8% O 
, O 
P O 
= O 
0.002 O 
) O 
than O 
those O 
who O 
did O 
not O 
. O 
In O 
multiple O 
logistic O 
regression O 
analysis O 
, O 
the O 
use O 
of O 
colchicines B-FAMILY 
( O 
odds O 
ratio O 
, O 
3.11 O 
; O 
95% O 
confidence O 
interval O 
, O 
1.28-7.58 O 
; O 
P O 
= O 
0.012 O 
) O 
and O 
statins B-FAMILY 
( O 
2.1 O 
; O 
1.03-4.25 O 
; O 
P O 
= O 
0.041 O 
) O 
was O 
an O 
independent O 
risk O 
factor O 
predicting O 
adverse O 
events O 
in O 
allopurinol B-TRIVIAL 
users O 
. O 
In O 
conclusion O 
, O 
patients O 
who O 
use O 
colchicine B-TRIVIAL 
or O 
statins B-FAMILY 
are O 
at O 
significant O 
risk O 
for O 
developing O 
allopurinol B-TRIVIAL 
-induced O 
adverse O 
events O 
. O 

-associated O 
pancreatitis O 
: O 
case O 
report O 
. O 

is O 
a O 
novel O 
BRAF O 
kinase O 
inhibitor O 
indicated O 
in O 
metastatic O 
melanoma O 
patients O 
with O 
V600E O 
mutation O 
. O 
We O 
report O 
the O 
first O 
case O 
of O 
vemurafenib B-TRIVIAL 
-associated O 
pancreatitis O 
. O 
Two O 
weeks O 
after O 
initiation O 
of O 
vemurafenib B-TRIVIAL 
, O 
a O 
patient O 
presented O 
to O 
the O 
emergency O 
department O 
with O 
severe O 
epigastric O 
pain O 
and O 
a O 
serum O 
lipase O 
of O 
1544 O 
units O 
/ O 
L O 
. O 
Drug O 
- O 
induced O 
pancreatitis O 
was O 
diagnosed O 
on O 
exclusion O 
of O 
all O 
other O 
potential O 
causes O 
. O 
Vemurafenib B-TRIVIAL 
was O 
rechallenged O 
at O 
half O 
the O 
daily O 
dose O 
and O 
the O 
patient O 
subsequently O 
developed O 
exacerbated O 
symptoms O 
of O 
pancreatitis O 
after O 
two O 
doses O 
. O 
The O 
strong O 
temporal O 
relationship O 
between O 
drug O 
exposure O 
and O 
toxicity O 
, O 
along O 
with O 
the O 
positive O 
results O 
from O 
a O 
rechallenge O 
study O 
, O 
strongly O 
support O 
a O 
conclusion O 
of O 
causality O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
of O 
vemurafenib B-TRIVIAL 
-induced O 
pancreatitis O 
. O 

combination O 
strategy O 
to O 
inhibit O 
Pim-1 O 
: O 
synergism O 
between O 
noncompetitive O 
and O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
. O 

is O 
a O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
critically O 
involved O 
in O 
the O 
initiation O 
and O 
progression O 
of O 
various O 
types O 
of O 
cancer O 
, O 
especially O 
leukemia O 
, O 
lymphomas O 
and O 
solid O 
tumors O 
such O 
as O 
prostate O 
, O 
pancreas O 
and O 
colon O 
, O 
and O 
is O 
considered O 
a O 
potential O 
drug O 
target O 
against O 
these O 
malignancies O 
. O 
In O 
an O 
effort O 
to O 
discover O 
new O 
potent O 
Pim-1 O 
inhibitors O 
, O 
a O 
previously O 
identified O 
ATP B-ABBREVIATION 
-competitive O 
indolyl-pyrrolone B-SYSTEMATIC 
scaffold O 
was O 
expanded O 
to O 
derive O 
structure O 
- O 
activity O 
relationship O 
data O 
. O 
A O 
virtual O 
screening O 
campaign O 
was O 
also O 
performed O 
, O 
which O 
led O 
to O 
the O 
discovery O 
of O 
additional O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
as O 
well O 
as O 
a O 
series O 
of O 
2-aminothiazole B-SYSTEMATIC 
derivatives O 
, O 
which O 
are O 
noncompetitive O 
with O 
respect O 
to O 
both O 
ATP B-ABBREVIATION 
and O 
peptide O 
substrate O 
. O 
This O 
mechanism O 
of O 
action O 
, O 
which O 
resembles O 
allosteric O 
inhibition O 
, O 
has O 
not O 
previously O 
been O 
characterized O 
for O 
Pim-1 O 
. O 
Notably O 
, O 
further O 
evaluation O 
of O 
the O 
2-aminothiazoles B-FAMILY 
indicated O 
a O 
synergistic O 
inhibitory O 
effect O 
in O 
enzymatic O 
assays O 
when O 
tested O 
in O 
combination O 
with O 
ATP B-ABBREVIATION 
-competitive O 
inhibitors O 
. O 
A O 
synergistic O 
effect O 
in O 
the O 
inhibition O 
of O 
cell O 
proliferation O 
by O 
ATP B-ABBREVIATION 
-competitive O 
and O 
ATP B-ABBREVIATION 
-noncompetitive O 
compounds O 
was O 
also O 
observed O 
in O 
prostate O 
cancer O 
cell O 
lines O 
( O 
PC3 O 
) O 
, O 
where O 
all O 
Pim-1 O 
inhibitors O 
tested O 
in O 
showed O 
synergism O 
with O 
the O 
known O 
anticancer O 
agent O 
, O 
paclitaxel B-TRIVIAL 
. O 
These O 
results O 
further O 
establish O 
Pim-1 O 
as O 
a O 
target O 
in O 
cancer O 
therapy O 
, O 
and O 
highlight O 
the O 
potential O 
of O 
these O 
agents O 
for O 
use O 
as O 
adjuvant O 
agents O 
in O 
the O 
treatment O 
of O 
cancer O 
diseases O 
in O 
which O 
Pim-1 O 
is O 
associated O 
with O 
chemotherapeutic O 
resistance O 
. O 

drugs O 
, O 
amantadine B-TRIVIAL 
and O 
rimantadine B-TRIVIAL 
, O 
targeting O 
the O 
M2 O 
channel O 
from O 
influenza O 
A O 
virus O 
are O 
no O 
longer O 
effective O 
because O 
of O 
widespread O 
drug O 
resistance O 
. O 
S31N O 
is O 
the O 
predominant O 
and O 
amantadine B-TRIVIAL 
-resistant O 
M2 O 
mutant O 
, O 
present O 
in O 
almost O 
all O 
of O 
the O 
circulating O 
influenza O 
A O 
strains O 
as O 
well O 
as O 
in O 
the O 
pandemic O 
2009 O 
H1N1 O 
and O 
the O 
highly O 
pathogenic O 
H5N1 O 
flu O 
strains O 
. O 
Thus O 
, O 
there O 
is O 
an O 
urgent O 
need O 
to O 
develop O 
second O 
- O 
generation O 
M2 O 
inhibitors O 
targeting O 
the O 
S31N O 
mutant O 
. O 
However O 
, O 
the O 
S31N O 
mutant O 
presents O 
a O 
huge O 
challenge O 
to O 
drug O 
discovery O 
, O 
and O 
it O 
has O 
been O 
considered O 
undruggable O 
for O 
several O 
decades O 
. O 
Using O 
structural O 
information O 
, O 
classical O 
medicinal O 
chemistry O 
approaches O 
, O 
and O 
M2-specific O 
biological O 
testing O 
, O 
we O 
discovered O 
benzyl B-SYSTEMATIC 
-substituted O 
amantadine B-TRIVIAL 
derivatives O 
with O 
activity O 
against O 
both O 
S31N O 
and O 
WT O 
, O 
among O 
which O 
4-(adamantan-1-ylaminomethyl)-benzene-1,3-diol B-SYSTEMATIC 
( O 
44 O 
) O 
is O 
the O 
most O 
potent O 
dual O 
inhibitor O 
. O 
These O 
inhibitors O 
demonstrate O 
that O 
S31N O 
is O 
a O 
druggable O 
target O 
and O 
provide O 
a O 
new O 
starting O 
point O 
to O 
design O 
novel O 
M2 O 
inhibitors O 
that O 
address O 
the O 
problem O 
of O 
drug O 
- O 
resistant O 
influenza O 
A O 
infections O 
. O 

for O 
the O 
Involvement O 
of O 
Descending O 
Pain-Inhibitory O 
Mechanisms O 
in O 
the O 
Antinociceptive O 
Effect O 
of O 
Hecogenin B-SYSTEMATIC 
Acetate I-SYSTEMATIC 
. O 

is O 
a O 
sapogenin O 
present O 
in O 
the O 
leaves O 
of O 
species O 
from O 
the O 
Agave O 
genus O 
, O 
with O 
a O 
wide O 
spectrum O 
of O 
reported O 
pharmacological O 
activities O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
evaluate O 
whether O 
hecogenin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
( O 
1 O 
) O 
has O 
antinociceptive O 
properties O 
and O 
to O 
determine O 
its O 
mechanism O 
of O 
action O 
. O 
The O 
nociceptive O 
threshold O 
was O 
evaluated O 
using O 
the O 
tail O 
flick O 
test O 
in O 
mice O 
. O 
Mice O 
motor O 
performance O 
was O 
evaluated O 
in O 
a O 
Rotarod O 
test O 
. O 
By O 
using O 
Fos O 
expression O 
as O 
a O 
marker O 
of O 
neural O 
activation O 
, O 
the O 
involvement O 
of O 
the O 
periaqueductal O 
gray O 
in O 
1-induced O 
antinociception O 
was O 
evaluated O 
. O 
Intraperitoneal O 
administration O 
of O 
1 O 
( O 
5-40 O 
mg O 
/ O 
kg O 
) O 
produced O 
a O 
dose O 
- O 
dependent O 
increase O 
in O 
the O 
tail O 
flick O 
latency O 
time O 
compared O 
to O 
vehicle O 
- O 
treated O 
group O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Mice O 
treated O 
with O 
1 O 
( O 
40 O 
mg O 
/ O 
kg O 
) O 
did O 
not O 
show O 
motor O 
performance O 
alterations O 
. O 
The O 
antinociception O 
of O 
1 O 
( O 
40 O 
mg O 
/ O 
kg O 
) O 
was O 
prevented O 
by O 
naloxone B-TRIVIAL 
( O 
nonselective O 
opioid O 
receptor O 
antagonist O 
; O 
5 O 
mg O 
/ O 
kg O 
) O 
, O 
CTOP B-ABBREVIATION 
( O 
μ-opioid O 
receptor O 
antagonist O 
; O 
1 O 
mg O 
/ O 
kg O 
) O 
, O 
nor-BNI B-ABBREVIATION 
( O 
κ-opioid O 
receptor O 
antagonist O 
; O 
0.5 O 
mg O 
/ O 
kg O 
) O 
, O 
naltrindole B-TRIVIAL 
( O 
δ-opioid O 
receptor O 
antagonist O 
; O 
3 O 
mg O 
/ O 
kg O 
) O 
, O 
or O 
glibenclamide B-TRIVIAL 
( O 
ATP B-ABBREVIATION 
-sensitive O 
K(+) B-FORMULA 
channel O 
blocker O 
; O 
2 O 
mg O 
/ O 
kg O 
) O 
. O 
Systemic O 
administration O 
of O 
1 O 
( O 
5-40 O 
mg O 
/ O 
kg O 
) O 
increased O 
the O 
number O 
of O 
Fos O 
positive O 
cells O 
in O 
the O 
periaqueductal O 
gray O 
. O 
The O 
present O 
study O 
has O 
demonstrated O 
for O 
the O 
first O 
time O 
that O 
1 O 
produces O 
consistent O 
antinociception O 
mediated O 
by O 
opioid O 
receptors O 
and O 
endogenous O 
analgesic O 
mechanisms O 
. O 

analysis O 
of O 
the O 
coverage O 
density O 
of O 
Br- B-FORMULA 
ions O 
on O 
Pd B-FORMULA 
{ O 
100 O 
} O 
facets O 
and O 
its O 
role O 
in O 
controlling O 
the O 
shape O 
of O 
Pd B-FORMULA 
nanocrystals O 
. O 

report O 
an O 
approach O 
based O 
on O 
a O 
combination O 
of O 
inductively O 
coupled O 
plasma O 
mass O 
spectrometry O 
and O 
X-ray O 
photoelectron O 
spectroscopy O 
for O 
quantitative O 
analysis O 
of O 
the O 
role O 
played O 
by O 
Br(-) B-FORMULA 
ions O 
in O 
the O 
synthesis O 
of O 
Pd B-FORMULA 
nanocrystals O 
. O 
The O 
Br(-) B-FORMULA 
ions O 
were O 
found O 
to O 
adsorb O 
onto O 
Pd B-FORMULA 
{ O 
100 O 
} O 
facets O 
selectively O 
with O 
a O 
coverage O 
density O 
of O 
ca O 
. O 
0.8 O 
ion O 
per O 
surface O 
Pd B-FORMULA 
atom O 
. O 
The O 
chemisorbed O 
Br(-) B-FORMULA 
ions O 
could O 
be O 
removed O 
via O 
desorption O 
at O 
an O 
elevated O 
temperature O 
under O 
reductive O 
conditions O 
. O 
They O 
could O 
also O 
be O 
gradually O 
released O 
from O 
the O 
surface O 
when O 
Pd B-FORMULA 
cubic O 
seeds O 
grew O 
into O 
cuboctahedrons O 
and O 
then O 
octahedrons O 
. O 
On O 
the O 
basis O 
of O 
the O 
coverage O 
density O 
information O 
, O 
we O 
were O 
able O 
to O 
estimate O 
the O 
minimum O 
concentration O 
of O 
Br(-) B-FORMULA 
ions O 
needed O 
for O 
the O 
formation O 
of O 
Pd B-FORMULA 
nanocubes O 
with O 
a O 
specific O 
size O 
. O 
If O 
the O 
concentration O 
of O 
Br(-) B-FORMULA 
ions O 
was O 
below O 
this O 
minimum O 
value O 
, O 
not O 
all O 
of O 
the O 
{ O 
100 O 
} O 
facets O 
could O 
be O 
stabilized O 
by O 
the O 
capping O 
agent O 
, O 
leading O 
to O 
the O 
formation O 
of O 
nanocubes O 
with O 
truncated O 
corners O 
. O 
The O 
quantitative O 
analysis O 
developed O 
in O 
this O 
study O 
is O 
potentially O 
extendable O 
to O 
other O 
systems O 
involving O 
chemisorbed O 
capping O 
agents O 
. O 

review O 
of O 
atomoxetine B-TRIVIAL 
data O 
in O 
childhood O 
and O 
adolescent O 
attention O 
- O 
deficit O 
hyperactivity O 
disorder O 
2009-2011 O 
: O 
Focus O 
on O 
clinical O 
efficacy O 
and O 
safety O 
. O 

: O 
Clinicians O 
obtain O 
critical O 
prescribing O 
knowledge O 
from O 
clinical O 
papers O 
and O 
review O 
articles O 
. O 
This O 
is O 
the O 
first O 
published O 
systematic O 
review O 
of O 
clinical O 
atomoxetine B-TRIVIAL 
data O 
covering O 
2009-2011.Objective O 
: O 
We O 
aim O 
to O 
update O 
clinicians O 
on O 
current O 
clinical O 
atomoxetine B-TRIVIAL 
data O 
with O 
specific O 
reference O 
to O 
time O 
of O 
onset O 
of O 
efficacy O 
and O 
maximal O 
efficacy O 
. O 
These O 
data O 
may O 
allow O 
critical O 
analysis O 
of O 
comparative O 
efficacy O 
between O 
atomoxetine B-TRIVIAL 
and O 
stimulant O 
medications.Methods O 
: O 
A O 
formal O 
systematic O 
review O 
of O 
atomoxetine B-TRIVIAL 
data O 
from O 
January O 
2009-June O 
2011 O 
was O 
conducted O 
. O 
The O 
search O 
term O 
used O 
was O 
" O 
atomoxetine B-TRIVIAL 
" O 
in O 
the O 
English O 
language O 
. O 
The O 
search O 
yielded O 
747 O 
citations O 
from O 
which O 
106 O 
are O 
clinical O 
data O 
. O 
This O 
paper O 
includes O 
clinical O 
efficacy O 
and O 
safety O 
data O 
and O 
excludes O 
quality O 
- O 
of O 
- O 
life O 
and O 
review O 
papers.Results O 
: O 
Atomoxetine B-TRIVIAL 
has O 
an O 
onset O 
of O 
action O 
within O 
4 O 
weeks O 
( O 
possibly O 
within O 
1 O 
week O 
in O 
subsequent O 
responders O 
) O 
but O 
requires O 
at O 
least O 
12 O 
weeks O 
for O 
full O 
response O 
to O 
be O 
demonstrated O 
. O 
Treatment-naïve O 
cohorts O 
( O 
6-12 O 
weeks O 
) O 
report O 
effect O 
sizes O 
of O 
0.6-1.3 O 
. O 
Using O 
minimum O 
6-week O 
clinical O 
trial O 
criteria O 
, O 
atomoxetine B-TRIVIAL 
may O 
demonstrate O 
similar O 
efficacy O 
to O 
methylphenidate B-SYSTEMATIC 
comparing O 
reduction O 
in O 
core O 
ADHD O 
symptoms O 
in O 
meta-analysis O 
, O 
although O 
the O 
diversity O 
of O 
the O 
data O 
makes O 
interpretation O 
complex O 
. O 
From O 
epidemiological O 
databases O 
, O 
cardiovascular O 
and O 
suicide O 
- O 
related O 
events O 
were O 
similar O 
to O 
those O 
seen O 
in O 
patients O 
taking O 
methylphenidate B-SYSTEMATIC 
.Conclusions O 
: O 
Incremental O 
response O 
time O 
to O 
atomoxetine B-TRIVIAL 
should O 
be O 
considered O 
in O 
the O 
design O 
of O 
future O 
comparative O 
efficacy O 
trials O 
. O 

ability O 
to O 
spatially O 
deposit O 
multiple O 
biomolecules O 
onto O 
a O 
single O 
surface O 
with O 
high O 
- O 
resolution O 
while O 
retaining O 
biomolecule O 
stability O 
and O 
integrity O 
is O 
critical O 
to O 
the O 
development O 
of O 
micro- O 
and O 
nanoscale O 
biodevices O 
. O 
While O 
conventional O 
lithographic O 
patterning O 
methods O 
are O 
attractive O 
for O 
this O 
application O 
, O 
they O 
typically O 
require O 
the O 
use O 
of O 
UV O 
exposure O 
and O 
/ O 
or O 
harsh O 
solvents O 
and O 
imaging O 
materials O 
, O 
which O 
may O 
be O 
damaging O 
to O 
fragile O 
biomolecules O 
. O 
Here O 
, O 
we O 
report O 
the O 
development O 
of O 
a O 
new O 
patterning O 
process O 
based O 
on O 
a O 
fluorinated O 
patterning O 
material O 
that O 
is O 
soluble O 
in O 
hydrofluoroether B-SYSTEMATIC 
solvents O 
, O 
which O 
we O 
show O 
to O 
be O 
benign O 
to O 
biomolecules O 
, O 
including O 
proteins O 
and O 
DNA O 
. O 
We O 
demonstrate O 
the O 
implementation O 
of O 
these O 
materials O 
into O 
an O 
orthogonal O 
processing O 
system O 
for O 
patterning O 
multibiomolecule O 
arrays O 
by O 
imprint O 
lithography O 
at O 
room O 
temperature O 
. O 
We O 
further O 
showcase O 
this O 
method's O 
capacity O 
for O 
fabricating O 
patterns O 
of O 
receptor O 
- O 
specific O 
ligands O 
for O 
fundamental O 
cell O 
studies O 
. O 

microfluidic O 
technology O 
is O 
applied O 
for O 
the O 
high O 
- O 
throughput O 
synthesis O 
via O 
Michael O 
- O 
type O 
addition O 
of O 
reactive O 
, O 
micrometer O 
- O 
sized O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
hydrogels O 
( O 
" O 
microgels O 
" O 
) O 
with O 
precisely O 
controlled O 
dimension O 
and O 
physicochemical O 
properties O 
. O 
A O 
versatile O 
chemical O 
scheme O 
is O 
used O 
to O 
modify O 
the O 
reactive O 
PEG B-ABBREVIATION 
microgels O 
with O 
tethered O 
biomolecules O 
to O 
tune O 
their O 
bioactive O 
properties O 
for O 
the O 
bioreactor O 
culture O 
and O 
manipulation O 
of O 
various O 
( O 
stem O 
) O 
cell O 
types O 
. O 

- O 
partum O 
variation O 
in O 
the O 
expression O 
of O 
paternal O 
care O 
is O 
unrelated O 
to O 
urinary O 
steroid B-FAMILY 
metabolites O 
in O 
marmoset O 
fathers O 
. O 

organization O 
and O 
activation O 
of O 
maternal O 
care O 
are O 
known O 
to O 
be O 
highly O 
regulated O 
by O 
hormones O 
and O 
there O 
is O 
growing O 
evidence O 
that O 
expression O 
of O 
paternal O 
care O 
is O 
also O 
related O 
to O 
endocrine O 
substrates O 
. O 
We O 
examined O 
the O 
relationship O 
between O 
paternal O 
behavior O 
and O 
steroid B-FAMILY 
hormones O 
in O 
marmoset O 
fathers O 
( O 
Callithrix O 
geoffroyi O 
) O 
and O 
evaluated O 
whether O 
hormone O 
- O 
paternal O 
behavior O 
relationships O 
were O 
altered O 
by O 
previous O 
offspring O 
- O 
care O 
experience O 
in O 
males O 
. O 
Based O 
on O 
previous O 
findings O 
, O 
we O 
predicted O 
that O 
testosterone B-TRIVIAL 
, O 
estradiol B-TRIVIAL 
, O 
and O 
cortisol B-TRIVIAL 
would O 
decrease O 
following O 
the O 
birth O 
of O 
offspring O 
and O 
would O 
be O 
lowest O 
during O 
the O 
period O 
of O 
maximal O 
infant O 
carrying O 
. O 
Furthermore O 
, O 
we O 
predicted O 
that O 
post O 
- O 
partum O 
changes O 
in O 
carrying O 
effort O 
and O 
hormone O 
levels O 
would O 
be O 
influenced O 
by O 
the O 
level O 
of O 
offspring O 
- O 
care O 
experience O 
. O 
Carrying O 
effort O 
and O 
other O 
paternal O 
care O 
behaviors O 
underwent O 
temporal O 
changes O 
over O 
the O 
post O 
- O 
partum O 
period O 
, O 
but O 
these O 
patterns O 
were O 
not O 
related O 
to O 
variation O 
in O 
hormone O 
concentrations O 
over O 
the O 
same O 
period O 
. O 
There O 
was O 
a O 
limited O 
effect O 
of O 
offspring O 
- O 
care O 
experience O 
on O 
hormone O 
concentrations O 
, O 
but O 
experience O 
was O 
found O 
to O 
play O 
a O 
role O 
in O 
the O 
expression O 
of O 
paternal O 
care O 
, O 
with O 
experienced O 
fathers O 
engaging O 
in O 
significantly O 
more O 
infant O 
allogrooming O 
than O 
inexperienced O 
fathers O 
. O 
Furthermore O 
, O 
inexperienced O 
fathers O 
increased O 
the O 
frequency O 
of O 
food O 
sharing O 
in O 
response O 
to O 
infant O 
begging O 
across O 
the O 
post O 
- O 
partum O 
period O 
, O 
while O 
experienced O 
fathers O 
displayed O 
consistently O 
low O 
levels O 
. O 
We O 
posit O 
that O 
a O 
combination O 
of O 
experiential O 
factors O 
and O 
an O 
increased O 
role O 
for O 
alloparents O 
in O 
offspring O 
- O 
care O 
led O 
to O 
these O 
changes O 
. O 
However O 
, O 
it O 
appears O 
that O 
hormonal O 
changes O 
may O 
not O 
influence O 
paternal O 
responsiveness O 
in O 
white O 
- O 
faced O 
marmoset O 
fathers O 
and O 
that O 
hormone O 
- O 
paternal O 
behavior O 
relationships O 
are O 
not O 
critically O 
dependent O 
on O 
a O 
male's O 
previous O 
offspring O 
- O 
care O 
experience O 
. O 

the O 
present O 
study O 
we O 
validated O 
a O 
widely O 
used O 
, O 
high O 
- O 
throughput O 
in O 
vitro O 
permeability O 
model O 
( O 
PAMPA O 
) O 
to O 
be O 
used O 
at O 
the O 
early O 
stage O 
of O 
drug O 
discovery O 
for O 
the O 
phospholipidosis O 
( O 
PLD O 
) O 
prediction O 
of O 
drug O 
- O 
like O 
compounds O 
. O 
Regarding O 
the O 
mechanism O 
of O 
action O 
of O 
PLD O 
, O 
our O 
pH-gradient O 
PAMPA O 
system O 
is O 
the O 
first O 
noncell O 
based O 
model O 
to O 
mimic O 
one O 
- O 
way O 
transport O 
of O 
cationic O 
amphiphilic O 
drugs O 
( O 
CADs O 
) O 
from O 
cytosol O 
to O 
the O 
lysosome O 
. O 
Moreover O 
, O 
due O 
to O 
the O 
fact O 
that O 
PLD O 
can O 
mainly O 
occur O 
in O 
lung O 
, O 
liver O 
, O 
brain O 
, O 
kidney O 
and O 
heart O 
, O 
we O 
have O 
used O 
similar O 
commercially O 
available O 
original O 
tissue O 
- O 
derived O 
lipid O 
fractions O 
( O 
heart O 
, O 
liver O 
, O 
brain O 
) O 
, O 
and O 
in O 
the O 
case O 
mimicking O 
membrane O 
of O 
kidney O 
and O 
lung O 
tissue O 
we O 
prepared O 
tissue O 
- O 
mimetic O 
artificial O 
lipid O 
mixtures O 
in O 
house O 
. O 
Metabolism O 
of O 
a O 
drug O 
can O 
change O 
the O 
degree O 
of O 
PLD O 
depending O 
on O 
the O 
physicochemical O 
properties O 
of O 
metabolites O 
and O 
the O 
rate O 
of O 
metabolism O 
. O 
Our O 
data O 
from O 
57 O 
drugs O 
and O 
4 O 
metabolites O 
of O 
earlier O 
and O 
2 O 
metabolites O 
of O 
newly O 
recognized O 
outliers O 
( O 
phenacetin B-TRIVIAL 
and O 
bupropion B-TRIVIAL 
) O 
using O 
our O 
pH-gradient O 
PAMPA O 
system O 
show O 
a O 
good O 
correlation O 
with O 
in O 
vivo O 
PLD O 
data O 
. O 
Moreover O 
, O 
predictive O 
ability O 
of O 
our O 
best O 
system O 
, O 
the O 
lung O 
specific O 
pH-gradient O 
PAMPA O 
model O 
was O 
significantly O 
better O 
than O 
widely O 
used O 
in O 
silico O 
models O 
and O 
it O 
was O 
also O 
slightly O 
better O 
than O 
that O 
of O 
the O 
known O 
noncell O 
based O 
models O 
on O 
our O 
selection O 
of O 
compounds O 
. O 
Our O 
pH-gradient O 
PAMPA O 
systems O 
therefore O 
offer O 
mechanistically O 
alternative O 
, O 
accurate O 
and O 
cost O 
- O 
effective O 
screening O 
tools O 
for O 
the O 
early O 
prediction O 
of O 
PLD O 
potential O 
of O 
drug O 
- O 
like O 
compounds O 
. O 

Oxidase O 
NOX5-S O 
and O 
Nuclear O 
Factor O 
κB1 O 
Mediate O 
Acid-Induced O 
Microsomal O 
Prostaglandin B-FAMILY 
E I-FAMILY 
Synthase-1 O 
Expression O 
in O 
Barrett's O 
Esophageal O 
Adenocarcinoma O 
Cells O 
. O 

mechanisms O 
of O 
progression O 
from O 
Barrett's O 
esophagus O 
( O 
BE O 
) O 
to O 
esophageal O 
adenocarcinoma O 
( O 
EA O 
) O 
are O 
not O 
known O 
. O 
Cycloxygenase-2 O 
( O 
COX-2 O 
) O 
- O 
derived O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
has O 
been O 
shown O 
to O 
be O 
important O 
in O 
esophageal O 
tumorigenesis O 
. O 
We O 
have O 
shown O 
that O 
COX-2 O 
mediates O 
acid O 
- O 
induced O 
PGE2 B-ABBREVIATION 
production O 
. O 
The O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase O 
( O 
PGES O 
) O 
responsible O 
for O 
acid O 
- O 
induced O 
PGE2 B-ABBREVIATION 
production O 
in O 
BE O 
, O 
however O 
, O 
is O 
not O 
known O 
. O 
We O 
found O 
that O 
microsomal O 
PGES1 O 
( O 
mPGES1 O 
) O 
, O 
mPGES2 O 
, O 
and O 
cytosolic O 
PGES O 
( O 
cPGES O 
) O 
were O 
present O 
in O 
FLO O 
EA O 
cells O 
. O 
Pulsed O 
acid O 
treatment O 
significantly O 
increased O 
mPGES1 O 
mRNA O 
and O 
protein O 
levels O 
but O 
had O 
little O 
or O 
no O 
effect O 
on O 
mPGES2 O 
or O 
cPGES O 
mRNA O 
. O 
Knockdown O 
of O 
mPGES1 O 
by O 
mPGES1 O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
blocked O 
acid O 
- O 
induced O 
increase O 
in O 
PGE2 B-ABBREVIATION 
production O 
and O 
thymidine B-TRIVIAL 
incorporation O 
. O 
Knockdown O 
of O 
NADPH B-ABBREVIATION 
oxidase O 
, O 
NOX5-S O 
, O 
a O 
variant O 
lacking O 
calcium B-SYSTEMATIC 
-binding O 
domains O 
, O 
by O 
NOX5 O 
siRNA O 
significantly O 
inhibited O 
acid O 
- O 
induced O 
increase O 
in O 
mPGES1 O 
expression O 
, O 
thymidine B-TRIVIAL 
incorporation O 
, O 
and O 
PGE2 B-ABBREVIATION 
production O 
. O 
Overexpression O 
of O 
NOX5-S O 
significantly O 
increased O 
the O 
luciferase O 
activity O 
in O 
FLO O 
cells O 
transfected O 
with O 
a O 
nuclear O 
factor O 
κB O 
( O 
NF-κB O 
) O 
in O 
vivo O 
activation O 
reporter O 
plasmid O 
pNF-κB-Luc O 
. O 
Knockdown O 
of O 
NF-κB1 O 
p50 O 
by O 
p50 O 
siRNA O 
significantly O 
decreased O 
acid O 
- O 
induced O 
increase O 
in O 
mPGES1 O 
expression O 
, O 
thymidine B-TRIVIAL 
incorporation O 
, O 
and O 
PGE2 B-ABBREVIATION 
production O 
. O 
Two O 
novel O 
NF-κB O 
binding O 
elements O 
, O 
GGAGTCTCCC O 
and O 
CGGGACACCC O 
, O 
were O 
identified O 
in O 
the O 
mPGES1 O 
gene O 
promoter O 
. O 
We O 
conclude O 
that O 
mPGES1 O 
mediates O 
acid O 
- O 
induced O 
increase O 
in O 
PGE2 B-ABBREVIATION 
production O 
and O 
cell O 
proliferation O 
. O 
Acid O 
- O 
induced O 
mPGES1 O 
expression O 
depends O 
on O 
activation O 
of O 
NOX5-S O 
and O 
NF-κB1 O 
p50 O 
. O 
Microsomal O 
PGES1 O 
may O 
be O 
a O 
potential O 
target O 
to O 
prevent O 
or O 
treat O 
EA O 
. O 

exploiting O 
(125)I B-FORMULA 
-polyubiquitin O 
chain O 
formation O 
as O 
a O 
functional O 
readout O 
of O 
enzyme O 
activity O 
, O 
we O 
have O 
quantitatively O 
examined O 
the O 
mechanism O 
of O 
human O 
E6AP O 
/ O 
UBE3A O 
for O 
the O 
first O 
time O 
. O 
Initial O 
rate O 
studies O 
identify O 
UbcH7 O 
as O 
the O 
cognate O 
E2 O 
carrier O 
protein O 
for O 
E6AP O 
, O 
although O 
related O 
Ubc5 O 
isoforms O 
and O 
the O 
ISG15-specific O 
UbcH8 O 
paralog O 
also O 
support O 
E6AP O 
with O 
reduced O 
efficacy O 
due O 
to O 
impaired O 
binding O 
and O 
catalytic O 
competence O 
. O 
Initial O 
rates O 
of O 
polyubiquitin O 
chain O 
formation O 
displayed O 
hyperbolic O 
kinetics O 
with O 
respect O 
to O 
UbcH7 O 
concentration O 
( O 
Km O 
= O 
57.6 O 
± O 
5.7 O 
nm O 
and O 
kcat O 
= O 
0.032 O 
± O 
0.001 O 
s(-1) O 
) O 
and O 
substrate O 
inhibition O 
above O 
2 O 
μm O 
. O 
Competitive O 
inhibition O 
by O 
an O 
isosteric O 
UbcH7C86S-ubiquitin O 
oxyester B-SYSTEMATIC 
substrate O 
analog O 
( O 
Ki O 
= O 
64 O 
± O 
18 O 
nm O 
) O 
demonstrates O 
that O 
Km O 
reflects O 
intrinsic O 
substrate O 
affinity O 
. O 
In O 
contrast O 
, O 
noncompetitive O 
inhibition O 
by O 
a O 
UbcH7C86A O 
product O 
analog O 
( O 
Ki O 
= O 
7 O 
± O 
0.7 O 
μm O 
) O 
and O 
substrate O 
inhibition O 
at O 
high O 
concentrations O 
require O 
two O 
functionally O 
distinct O 
E2∼ubiquitin O 
substrate O 
binding O 
sites O 
. O 
The O 
kinetics O 
of O 
polyubiquitin O 
chain O 
formation O 
reflect O 
binding O 
at O 
a O 
cryptic O 
Site O 
1 O 
not O 
previously O 
recognized O 
that O 
catalyzes O 
E6AP∼ubiquitin O 
thioester B-SYSTEMATIC 
formation O 
. O 
Subsequent O 
binding O 
of O 
E2∼ubiquitin O 
at O 
the O 
canonical O 
Site O 
2 O 
present O 
in O 
the O 
extant O 
crystal O 
structure O 
is O 
responsible O 
for O 
polyubiquitin O 
chain O 
elongation O 
. O 
Other O 
rate O 
studies O 
show O 
that O 
the O 
conserved O 
-4 O 
Phe B-FORMULA 
( O 
849 O 
) O 
residue O 
is O 
required O 
for O 
polyubiquitin O 
chain O 
formation O 
rather O 
than O 
target O 
protein O 
conjugation O 
as O 
originally O 
suggested O 
. O 
The O 
present O 
studies O 
unambiguously O 
preclude O 
earlier O 
models O 
for O 
the O 
mechanism O 
of O 
Hect O 
domain O 
- O 
catalyzed O 
conjugation O 
through O 
the O 
canonical O 
binding O 
site O 
suggested O 
by O 
the O 
crystal O 
structure O 
and O 
define O 
a O 
novel O 
two O 
- O 
step O 
mechanism O 
for O 
formation O 
of O 
the O 
polyubiquitin O 
degradation O 
signal O 
. O 

of O 
xenobiotic O 
receptors O 
, O 
transporters O 
, O 
and O 
drug O 
metabolizing O 
enzymes O 
by O 
oxycodone B-TRIVIAL 
. O 

of O 
the O 
expression O 
of O 
transporters O 
and O 
drug O 
- O 
metabolizing O 
enzymes O 
( O 
DMEs O 
) O 
by O 
opioids O 
can O 
be O 
the O 
locus O 
of O 
deleterious O 
drug O 
- O 
drug O 
interactions O 
( O 
DDIs O 
) O 
. O 
Many O 
transporters O 
and O 
DMEs O 
are O 
regulated O 
by O 
xenobiotic O 
receptors O 
[ O 
XRs O 
; O 
e.g O 
. O 
, O 
pregnane O 
X O 
receptor O 
( O 
PXR O 
) O 
, O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
, O 
and O 
Aryl B-FAMILY 
hydrocarbon I-FAMILY 
receptor O 
( O 
AhR O 
) O 
] O 
; O 
however O 
, O 
there O 
is O 
a O 
paucity O 
of O 
information O 
regarding O 
the O 
influence O 
of O 
opioids O 
on O 
XRs O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
influence O 
of O 
oxycodone B-TRIVIAL 
administration O 
( O 
15 O 
mg O 
/ O 
kg O 
intraperitoneally O 
twice O 
daily O 
for O 
8 O 
days O 
) O 
on O 
liver O 
expression O 
of O 
XRs O 
, O 
transporters O 
, O 
and O 
DMEs O 
in O 
rats O 
. O 
Microarray O 
, O 
quantitative O 
real O 
- O 
time O 
polymerase O 
chain O 
reaction O 
and O 
immunoblotting O 
analyses O 
were O 
used O 
to O 
identify O 
significantly O 
regulated O 
genes O 
. O 
Three O 
XRs O 
( O 
e.g O 
. O 
, O 
PXR O 
, O 
CAR O 
, O 
and O 
AhR O 
) O 
, O 
27 O 
transporters O 
( O 
e.g O 
. O 
, O 
ABCB1 O 
and O 
SLC22A8 O 
) O 
, O 
and O 
19 O 
DMEs O 
( O 
e.g O 
. O 
, O 
CYP2B2 O 
and O 
CYP3A1 O 
) O 
were O 
regulated O 
( O 
P O 
< O 
0.05 O 
) O 
with O 
fold O 
changes O 
ranging O 
from O 
-46.3 O 
to O 
17.1 O 
. O 
Using O 
MetaCore O 
( O 
computational O 
platform O 
) O 
, O 
we O 
identified O 
a O 
unique O 
gene O 
- O 
network O 
of O 
transporters O 
and O 
DMEs O 
assembled O 
around O 
PXR O 
, O 
CAR O 
, O 
and O 
AhR O 
. O 
Therefore O 
, O 
a O 
series O 
of O 
transactivation O 
/ O 
translocation O 
assays O 
were O 
conducted O 
to O 
determine O 
whether O 
the O 
observed O 
changes O 
of O 
transporters O 
/ O 
DMEs O 
are O 
mediated O 
by O 
direct O 
activation O 
of O 
PXR O 
, O 
CAR O 
, O 
or O 
AhR O 
by O 
oxycodone B-TRIVIAL 
or O 
its O 
major O 
metabolites O 
( O 
noroxycodone B-TRIVIAL 
and O 
oxymorphone B-TRIVIAL 
) O 
. O 
Neither O 
oxycodone B-TRIVIAL 
nor O 
its O 
metabolites O 
activated O 
PXR O 
, O 
CAR O 
, O 
or O 
AhR O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
identify O 
a O 
signature O 
hepatic O 
gene O 
- O 
network O 
associated O 
with O 
repeated O 
oxycodone B-TRIVIAL 
administration O 
in O 
rats O 
and O 
demonstrate O 
that O 
oxycodone B-TRIVIAL 
alters O 
the O 
expression O 
of O 
many O 
transporters O 
and O 
DMEs O 
( O 
without O 
direct O 
activation O 
of O 
PXR O 
, O 
CAR O 
, O 
and O 
AhR O 
) O 
, O 
which O 
could O 
lead O 
to O 
undesirable O 
DDIs O 
after O 
coadministration O 
of O 
substrates O 
of O 
these O 
transporters O 
/ O 
DMEs O 
with O 
oxycodone B-TRIVIAL 
. O 

initio O 
molecular O 
dynamics O 
simulations O 
have O 
been O 
performed O 
of O 
a O 
gold-1,4-benzenedithiol B-SYSTEMATIC 
( O 
BDT B-ABBREVIATION 
)-gold O 
nanojunction O 
under O 
mechanical O 
stress O 
. O 
For O 
three O 
different O 
pulling O 
rates O 
between O 
10 O 
and O 
40 O 
m O 
s(-1) O 
, O 
it O 
is O 
found O 
that O 
the O 
nanowire O 
always O 
ruptures O 
between O 
the O 
second O 
and O 
third O 
Au B-FORMULA 
atom O 
from O 
the O 
thiol B-SYSTEMATIC 
sulfur I-SYSTEMATIC 
. O 
Larger O 
rupture O 
forces O 
and O 
longer O 
extensions O 
are O 
required O 
at O 
higher O 
pulling O 
rates O 
and O 
vice O 
versa O 
. O 
The O 
electrical O 
conductance O 
was O 
calculated O 
along O 
a O 
pulling O 
trajectory O 
using O 
the O 
DFT-NEGF O 
method O 
to O 
study O 
the O 
effect O 
of O 
thermal O 
and O 
stress O 
- O 
induced O 
structural O 
changes O 
on O 
the O 
electrical O 
transport O 
properties O 
. O 
While O 
the O 
mechanically O 
induced O 
stretching O 
of O 
the O 
junction O 
is O 
seen O 
to O 
lower O 
the O 
time O 
- O 
averaged O 
conductance O 
, O 
thermal O 
conformational O 
changes O 
are O 
capable O 
of O 
altering O 
the O 
conductance O 
by O 
one O 
order O 
of O 
magnitude O 
. O 
No O 
single O 
geometric O 
quantity O 
could O 
be O 
identified O 
as O 
the O 
main O 
contributor O 
to O 
the O 
conductance O 
fluctuations O 
. O 
Small O 
modulations O 
, O 
however O 
, O 
can O 
be O 
explained O 
in O 
terms O 
of O 
C=C B-FORMULA 
double O 
bond O 
vibrations O 
in O 
the O 
BDT B-ABBREVIATION 
molecule O 
. O 
The O 
dependence O 
of O 
the O 
conductance O 
on O 
different O 
geometric O 
variables O 
has O 
further O 
been O 
investigated O 
systematically O 
by O 
performing O 
constrained O 
geometry O 
optimizations O 
along O 
a O 
number O 
of O 
angle O 
and O 
dihedral O 
coordinates O 
. O 
The O 
largest O 
changes O 
in O 
the O 
conductance O 
are O 
observed O 
when O 
the O 
Au-S-C B-FORMULA 
angle O 
and O 
the O 
Au-S-C-C B-FORMULA 
dihedral O 
are O 
simultaneously O 
constrained O 
. O 

practical O 
and O 
scalable O 
manufacturing O 
process O 
for O 
an O 
anti-fungal O 
agent O 
, O 
Nikkomycin B-TRIVIAL 
Z I-TRIVIAL 
. O 

scalable O 
and O 
reliable O 
manufacturing O 
process O 
for O 
Nikkomycin B-TRIVIAL 
Z I-TRIVIAL 
HCl B-FORMULA 
on O 
a O 
170 O 
g O 
scale O 
has O 
been O 
developed O 
and O 
optimized O 
. O 
The O 
process O 
is O 
characterized O 
by O 
a O 
2.3 O 
g O 
/ O 
L O 
fermentation O 
yield O 
, O 
79% O 
purification O 
yield O 
, O 
and O 
> O 
98% O 
relative O 
purity O 
of O 
the O 
final O 
product O 
. O 
This O 
method O 
is O 
suitable O 
for O 
further O 
scale O 
up O 
and O 
cGMP B-ABBREVIATION 
production O 
. O 
The O 
Streptomyces O 
tendae O 
ΔNikQ O 
strain O 
developed O 
during O 
the O 
course O 
of O 
this O 
study O 
is O 
superior O 
to O 
any O 
previously O 
reported O 
strain O 
in O 
terms O 
of O 
higher O 
yield O 
and O 
purity O 
of O 
Nikkomycin B-TRIVIAL 
Z I-TRIVIAL 
. O 

-Bonded O 
and O 
-Encapsulated O 
Si B-FORMULA 
Nanoparticles O 
for O 
Lithium B-SYSTEMATIC 
Ion O 
Battery O 
Anodes O 
. O 

( O 
Si B-FORMULA 
) O 
has O 
been O 
considered O 
a O 
very O 
promising O 
anode O 
material O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
due O 
to O 
its O 
high O 
theoretical O 
capacity O 
. O 
However O 
, O 
high O 
- O 
capacity O 
Si B-FORMULA 
nanoparticles O 
usually O 
suffer O 
from O 
low O 
electronic O 
conductivity O 
, O 
large O 
volume O 
change O 
, O 
and O 
severe O 
aggregation O 
problems O 
during O 
lithiation O 
and O 
delithiation O 
. O 
In O 
this O 
paper O 
, O 
a O 
unique O 
nanostructured O 
anode O 
with O 
Si B-FORMULA 
nanoparticles O 
bonded O 
and O 
wrapped O 
by O 
graphene B-TRIVIAL 
is O 
synthesized O 
by O 
a O 
one O 
- O 
step O 
aerosol O 
spraying O 
of O 
surface O 
- O 
modified O 
Si B-FORMULA 
nanoparticles O 
and O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
suspension O 
. O 
The O 
functional O 
groups O 
on O 
the O 
surface O 
of O 
Si B-FORMULA 
nanoparticles O 
( O 
50-100 O 
nm O 
) O 
not O 
only O 
react O 
with O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
bind O 
Si B-FORMULA 
nanoparticles O 
to O 
the O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
shell O 
, O 
but O 
also O 
prevent O 
Si B-FORMULA 
nanoparticles O 
from O 
aggregation O 
, O 
thus O 
contributing O 
to O 
a O 
uniform O 
Si B-FORMULA 
suspension O 
. O 
A O 
homogeneous O 
graphene B-TRIVIAL 
-encapsulated O 
Si B-FORMULA 
nanoparticle O 
morphology O 
forms O 
during O 
the O 
aerosol O 
spraying O 
process O 
. O 
The O 
open O 
- O 
ended O 
graphene B-TRIVIAL 
shell O 
with O 
defects O 
allows O 
fast O 
electrochemical O 
lithiation O 
/ O 
delithiation O 
, O 
and O 
the O 
void O 
space O 
inside O 
the O 
graphene B-TRIVIAL 
shell O 
accompanied O 
by O 
its O 
strong O 
mechanical O 
strength O 
can O 
effectively O 
accommodate O 
the O 
volume O 
expansion O 
of O 
Si B-FORMULA 
upon O 
lithiation O 
. O 
The O 
graphene B-TRIVIAL 
shell O 
provides O 
good O 
electronic O 
conductivity O 
for O 
Si B-FORMULA 
nanoparticles O 
and O 
prevents O 
them O 
from O 
aggregating O 
during O 
charge O 
/ O 
discharge O 
cycles O 
. O 
The O 
functionalized O 
Si B-FORMULA 
encapsulated O 
by O 
graphene B-TRIVIAL 
sample O 
exhibits O 
a O 
capacity O 
of O 
2250 O 
mAh O 
g(-1) O 
( O 
based O 
on O 
the O 
total O 
mass O 
of O 
graphene B-TRIVIAL 
and O 
Si B-FORMULA 
) O 
at O 
0.1C O 
and O 
1000 O 
mAh O 
g(-1) O 
at O 
10C O 
, O 
and O 
retains O 
85% O 
of O 
its O 
initial O 
capacity O 
even O 
after O 
120 O 
charge O 
/ O 
discharge O 
cycles O 
. O 
The O 
exceptional O 
performance O 
of O 
graphene B-TRIVIAL 
-encapsulated O 
Si B-FORMULA 
anodes O 
combined O 
with O 
the O 
scalable O 
and O 
one O 
- O 
step O 
aerosol O 
synthesis O 
technique O 
makes O 
this O 
material O 
very O 
promising O 
for O 
lithium B-SYSTEMATIC 
ion O 
batteries O 
. O 

and O 
distribution O 
of O 
a O 
model O 
small O 
molecule O 
drug O 
in O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
brushes O 
: O 
a O 
neutron O 
reflectometry O 
and O 
AFM O 
study O 
. O 

structure O 
of O 
a O 
hydrated B-SYSTEMATIC 
poly(N-isopropylacrylamide) I-SYSTEMATIC 
brush O 
loaded O 
with O 
5 O 
vol O 
% O 
Isoniazid B-TRIVIAL 
is O 
studied O 
as O 
a O 
function O 
of O 
temperature O 
using O 
neutron O 
reflectometry O 
( O 
NR O 
) O 
and O 
atomic O 
force O 
microscopy O 
( O 
AFM O 
) O 
. O 
NR O 
measurements O 
show O 
that O 
Isoniazid B-TRIVIAL 
increases O 
the O 
thickness O 
of O 
the O 
brush O 
before O 
, O 
during O 
and O 
after O 
the O 
polymer O 
collapse O 
, O 
and O 
it O 
is O 
retained O 
inside O 
the O 
brush O 
at O 
all O 
measured O 
temperatures O 
. O 
The O 
Isoniazid B-TRIVIAL 
concentration O 
in O 
the O 
expanded O 
brush O 
is O 
~14% O 
higher O 
than O 
in O 
the O 
bulk O 
solution O 
, O 
and O 
the O 
concentration O 
nearly O 
doubles O 
in O 
the O 
collapsed O 
polymer O 
, O 
suggesting O 
stronger O 
binding O 
between O 
Isoniazid B-TRIVIAL 
and O 
the O 
polymer O 
compared O 
to O 
water O 
, O 
even O 
at O 
temperatures O 
below O 
the O 
lower O 
critical O 
solution O 
temperature O 
( O 
LCST O 
) O 
where O 
the O 
polymer O 
is O 
hydrophilic O 
. O 
Typically O 
, O 
additives O 
that O 
bind O 
strongly O 
to O 
the O 
polymer O 
backbone O 
and O 
increase O 
the O 
hydrophilicity O 
of O 
the O 
polymer O 
will O 
delay O 
the O 
onset O 
of O 
the O 
LCST O 
, O 
which O 
is O 
suggested O 
by O 
AFM O 
and O 
NR O 
measurements O 
. O 
The O 
extent O 
of O 
small O 
- O 
molecule O 
loading O 
and O 
distribution O 
throughout O 
a O 
thermo O 
- O 
responsive O 
polymer O 
brush O 
, O 
such O 
as O 
pNIPAAm B-ABBREVIATION 
, O 
will O 
have O 
important O 
consequences O 
for O 
applications O 
such O 
as O 
drug O 
delivery O 
and O 
gating O 
. O 

-calmodulin O 
interacts O 
with O 
DdCAD-1 O 
and O 
promotes O 
DdCAD-1 O 
transport O 
by O 
contractile O 
vacuoles O 
in O 
Dictyostelium O 
cells O 
. O 

Ca(2+) B-FORMULA 
-dependent O 
cell O 
- O 
cell O 
adhesion O 
molecule O 
DdCAD-1 O 
, O 
encoded O 
by O 
the O 
cadA O 
gene O 
of O 
Dictyostelium O 
discoideum O 
, O 
is O 
synthesized O 
at O 
the O 
onset O 
of O 
development O 
as O 
a O 
soluble O 
protein O 
and O 
then O 
transported O 
to O 
the O 
plasma O 
membrane O 
by O 
contractile O 
vacuoles O 
. O 
Calmodulin O 
associates O 
with O 
contractile O 
vacuoles O 
in O 
a O 
Ca(2+) B-FORMULA 
-dependent O 
manner O 
, O 
and O 
co O 
- O 
localizes O 
with O 
DdCAD-1 O 
on O 
the O 
surface O 
of O 
contractile O 
vacuoles O 
. O 
Bioinformatics O 
analysis O 
revealed O 
multiple O 
calmodulin O 
- O 
binding O 
motifs O 
in O 
DdCAD-1 O 
. O 
Co-immunoprecipitation O 
and O 
pull O 
- O 
down O 
studies O 
showed O 
that O 
only O 
Ca(2+) B-FORMULA 
-bound O 
calmodulin O 
was O 
able O 
to O 
bind O 
DdCAD-1 O 
. O 
Structural O 
integrity O 
of O 
DdCAD-1 O 
, O 
but O 
not O 
the O 
native O 
conformation O 
, O 
was O 
required O 
for O 
its O 
interaction O 
with O 
calmodulin O 
. O 
To O 
investigate O 
the O 
role O 
of O 
calmodulin O 
in O 
the O 
import O 
of O 
DdCAD-1 O 
into O 
contractile O 
vacuoles O 
, O 
an O 
in O 
vitro O 
import O 
assay O 
consisting O 
of O 
contractile O 
vacuoles O 
derived O 
from O 
cadA(-) O 
cells O 
and O 
recombinant O 
proteins O 
was O 
employed O 
. O 
Prior O 
stripping O 
of O 
the O 
bound O 
calmodulin O 
from O 
contractile O 
vacuoles O 
by O 
EGTA O 
impaired O 
import O 
of O 
DdCAD-1 O 
, O 
which O 
was O 
restored O 
by O 
addition O 
of O 
exogenous O 
calmodulin O 
. O 
The O 
calmodulin O 
antagonists O 
W-7 O 
and O 
compound O 
48 O 
/ O 
80 O 
blocked O 
the O 
binding O 
of O 
calmodulin O 
onto O 
stripped O 
contractile O 
vacuoles O 
, O 
and O 
inhibited O 
the O 
import O 
of O 
DdCAD-1 O 
. O 
Together O 
, O 
the O 
data O 
show O 
that O 
calmodulin O 
forms O 
a O 
complex O 
with O 
DdCAD-1 O 
and O 
promotes O 
the O 
docking O 
and O 
import O 
of O 
DdCAD-1 O 
into O 
contractile O 
vacuoles O 
. O 
STRUCTURED O 
DIGITAL O 
ABSTRACT O 
: O 
CaM O 
physically O 
interacts O 
with O 
DdCAD-1 O 
by O 
pull O 
down O 
( O 
View O 
Interaction O 
: O 
1 O 
, O 
2 O 
) O 
DdCAD-1 O 
binds O 
to O 
CaM O 
by O 
far O 
western O 
blotting O 
( O 
View O 
interaction O 
) O 
DdCAD-1 O 
physically O 
interacts O 
with O 
CaM O 
by O 
anti O 
bait O 
coimmunoprecipitation O 
( O 
View O 
interaction O 
) O 
. O 

C-H B-FORMULA 
bond O 
activation O 
of O 
hydrocarbons B-FAMILY 
by O 
a O 
gas O 
phase O 
neutral O 
oxide B-SYSTEMATIC 
cluster O 
: O 
the O 
importance O 
of O 
spin O 
state O 
. O 

neutral O 
cluster O 
V2O5 B-FORMULA 
is O 
generated O 
and O 
detected O 
in O 
the O 
gas O 
phase O 
. O 
Its O 
reactivity O 
toward O 
butane O 
is O 
studied O 
both O 
experimentally O 
and O 
theoretically O 
. O 
Experimental O 
results O 
show O 
clearly O 
that O 
neutral O 
V2O5 B-FORMULA 
can O 
react O 
with O 
n-butane B-SYSTEMATIC 
( O 
C4H10 B-FORMULA 
) O 
to O 
generate O 
V2O5H2 B-FORMULA 
, O 
indicating O 
double O 
hydrogen B-SYSTEMATIC 
atom O 
transfer O 
from O 
C4H10 B-FORMULA 
to O 
V2O5 B-FORMULA 
to O 
produce O 
C4H8 B-FORMULA 
. O 
Further O 
experimental O 
evidence O 
indicates O 
that O 
V2O5 B-FORMULA 
is O 
only O 
partially O 
reacted O 
even O 
at O 
very O 
high O 
concentrations O 
of O 
C4H10 B-FORMULA 
. O 
Density O 
functional O 
theory O 
( O 
DFT O 
) O 
studies O 
show O 
that O 
the O 
lowest O 
energy O 
triplet O 
state O 
of O 
V2O5 B-FORMULA 
is O 
reactive O 
toward O 
C4H10 B-FORMULA 
, O 
whereas O 
the O 
ground O 
state O 
singlet O 
V2O5 B-FORMULA 
is O 
inert O 
. O 
Calculated O 
results O 
are O 
in O 
agreement O 
with O 
experimental O 
findings O 
, O 
and O 
a O 
detailed O 
reaction O 
mechanism O 
is O 
provided O 
. O 
Reactions O 
of O 
V2O5H2 B-FORMULA 
with O 
several O 
oxidants O 
are O 
also O 
studied O 
theoretically O 
to O 
find O 
a O 
path O 
to O 
regenerate O 
V2O5 B-FORMULA 
. O 
Neutral O 
( O 
3 O 
) O 
V2O5 B-FORMULA 
can O 
also O 
react O 
with O 
C2H6 B-FORMULA 
to O 
form O 
V2O5H2 B-FORMULA 
and O 
C2H4 B-FORMULA 
, O 
but O 
only O 
as O 
a O 
minor O 
reaction O 
channel O 
; O 
the O 
major O 
product O 
is O 
the O 
adsorption O 
product O 
V2O5 B-FORMULA 
( O 
C2H6 B-FORMULA 
) O 
. O 

reactivation O 
of O 
Nrf2 O 
in O 
murine O 
prostate O 
cancer O 
TRAMP O 
C1 O 
cells O 
by O 
natural O 
phytochemicals O 
Z-ligustilide B-SYSTEMATIC 
and O 
Radix O 
angelica O 
sinensis O 
via O 
promoter O 
CpG O 
demethylation O 
. O 

development O 
has O 
been O 
linked O 
to O 
epigenetic O 
modifications O 
of O 
cancer O 
oncogenes O 
and O 
tumor O 
suppressor O 
genes O 
; O 
in O 
advanced O 
metastatic O 
cancers O 
, O 
severe O 
epigenetic O 
modifications O 
are O 
present O 
. O 
We O 
previously O 
demonstrated O 
that O 
the O 
progression O 
of O 
prostate O 
tumors O 
in O 
TRAMP O 
mice O 
is O 
associated O 
with O 
methylation O 
silencing O 
of O 
the O 
Nrf2 O 
promoter O 
and O 
a O 
reduced O 
level O 
of O 
transcription O 
of O 
Nrf2 O 
and O 
Nrf2 O 
target O 
genes O 
. O 
Radix O 
Angelicae O 
Sinensis O 
( O 
RAS O 
; O 
Danggui O 
) O 
is O 
a O 
medicinal O 
herb O 
and O 
health O 
food O 
supplement O 
that O 
has O 
been O 
widely O 
used O 
in O 
Asia O 
for O 
centuries O 
. O 
Z-Ligustilide B-SYSTEMATIC 
( O 
Lig B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
bioactive O 
components O 
of O 
RAS O 
. O 
We O 
investigated O 
the O 
potential O 
of O 
Lig B-ABBREVIATION 
and O 
RAS O 
to O 
restore O 
Nrf2 O 
gene O 
expression O 
through O 
epigenetic O 
modification O 
in O 
TRAMP O 
C1 O 
cells O 
. O 
Lig B-ABBREVIATION 
and O 
RAS O 
induced O 
the O 
mRNA O 
and O 
protein O 
expression O 
of O 
endogenous O 
Nrf2 O 
and O 
Nrf2 O 
downstream O 
target O 
genes O 
, O 
such O 
as O 
HO-1 O 
, O 
NQO1 O 
, O 
and O 
UGT1A1 O 
. O 
Bisulfite B-SYSTEMATIC 
genomic O 
sequencing O 
revealed O 
that O 
Lig B-ABBREVIATION 
and O 
RAS O 
treatment O 
decreased O 
the O 
level O 
of O 
methylation O 
of O 
the O 
first O 
five O 
CpGs O 
of O 
the O 
Nrf2 O 
promoter O 
. O 
A O 
methylation O 
DNA O 
immunoprecipitation O 
assay O 
demonstrated O 
that O 
Lig B-ABBREVIATION 
and O 
RAS O 
significantly O 
decreased O 
the O 
relative O 
amount O 
of O 
methylated O 
DNA O 
in O 
the O 
Nrf2 O 
gene O 
promoter O 
region O 
. O 
Lig B-ABBREVIATION 
and O 
RAS O 
also O 
inhibited O 
DNA O 
methyltransferase O 
activity O 
in O 
vitro O 
. O 
Collectively O 
, O 
these O 
results O 
suggest O 
that O 
Lig B-ABBREVIATION 
and O 
RAS O 
are O 
able O 
to O 
demethylate O 
the O 
Nrf2 O 
promoter O 
CpGs O 
, O 
resulting O 
in O 
the O 
re O 
- O 
expression O 
of O 
Nrf2 O 
and O 
Nrf2 O 
target O 
genes O 
. O 
Epigenetic O 
modifications O 
of O 
genes O 
, O 
including O 
Nrf2 O 
, O 
may O 
therefore O 
contribute O 
to O 
the O 
overall O 
health O 
benefits O 
of O 
RAS O 
, O 
including O 
the O 
anticancer O 
effect O 
of O 
RAS O 
and O 
its O 
bioactive O 
component O 
, O 
Lig B-ABBREVIATION 
. O 

the O 
Photoisomerization O 
of O 
CHBr3 B-FORMULA 
and O 
CHI3 B-FORMULA 
in O 
Solution O 
with O 
Transient O 
Vibrational O 
and O 
Electronic O 
Spectroscopy O 
. O 

infrared O 
absorption O 
spectroscopy O 
monitors O 
condensed O 
- O 
phase O 
photodissociation O 
dynamics O 
of O 
30 O 
mM O 
CHBr3 B-FORMULA 
and O 
50 O 
mM O 
CHI3 B-FORMULA 
in O 
liquid O 
CCl4 B-FORMULA 
. O 
The O 
experiments O 
have O 
picosecond O 
time O 
resolution O 
and O 
monitor O 
the O 
C B-FORMULA 
- O 
H B-FORMULA 
stretch O 
region O 
of O 
both O 
the O 
parent O 
polyhalomethanes B-FAMILY 
and O 
their O 
photolytically O 
generated O 
isomers O 
. O 
The O 
C B-FORMULA 
- O 
H B-FORMULA 
stretching O 
transitions O 
of O 
these O 
isomers O 
, O 
in O 
which O 
the O 
emergent O 
halogen B-FAMILY 
atom O 
returns O 
to O 
form O 
a O 
C B-FORMULA 
-X-X O 
bonding O 
motif O 
, O 
appear O 
about O 
9 O 
ps O 
after O 
photolysis O 
for O 
iso- O 
CHBr2 B-FORMULA 
- O 
Br B-FORMULA 
and O 
in O 
about O 
46 O 
ps O 
for O 
iso- O 
CHI2 B-FORMULA 
- O 
I B-FORMULA 
. O 
These O 
time O 
scales O 
are O 
consistent O 
with O 
, O 
but O 
differ O 
from O 
, O 
the O 
time O 
evolution O 
of O 
the O 
transient O 
electronic O 
absorption O 
spectra O 
of O 
the O 
same O 
samples O 
, O 
highlighting O 
the O 
subtle O 
differences O 
between O 
monitoring O 
the O 
vibrational O 
and O 
electronic O 
chromophores O 
. O 
The O 
specificity O 
of O 
using O 
vibrational O 
transitions O 
to O 
track O 
condensed O 
- O 
phase O 
reaction O 
dynamics O 
permits O 
reassessment O 
of O 
the O 
transient O 
electronic O 
spectrum O 
of O 
photolysis O 
in O 
neat O 
CHBr3 B-FORMULA 
, O 
which O 
has O 
an O 
additional O 
prompt O 
feature O 
near O 
400 O 
nm O 
. O 
Calculations O 
show O 
that O 
this O 
feature O 
, O 
which O 
arises O 
from O 
a O 
precursor O 
to O 
the O 
isomer O 
, O 
is O 
a O 
charge O 
- O 
transfer O 
transition O 
of O 
a O 
contact O 
pair O 
between O 
the O 
nascent O 
Br B-FORMULA 
fragment O 
and O 
a O 
nearby O 
CHBr3 B-FORMULA 
molecule O 
. O 
Dilution O 
and O 
solvent O 
studies O 
show O 
that O 
transition O 
is O 
independent O 
of O 
the O 
solvent O 
. O 
The O 
iso- O 
CHBr2 B-FORMULA 
- O 
Br B-FORMULA 
transition O 
wavelength O 
, O 
however O 
, O 
shifts O 
over O 
the O 
range O 
of O 
400 O 
to O 
510 O 
nm O 
depending O 
on O 
the O 
solvent O 
. O 
Time O 
- O 
dependent O 
density O 
functional O 
calculations O 
faithfully O 
reproduce O 
these O 
trends O 
. O 

Functional O 
Study O 
of O 
Organocatalytic O 
Cross-Aldol O 
Reactions O 
between O 
Two O 
Aliphatic B-FAMILY 
Aldehydes I-FAMILY 
: O 
Insight O 
into O 
Their O 
Functional O 
Differentiation O 
and O 
Origins O 
of O 
Chemo- O 
and O 
Stereoselectivities O 
. O 

chemo- O 
, O 
diastereo- O 
, O 
and O 
enantioselectivities O 
in O 
proline B-TRIVIAL 
and O 
axially O 
chiral O 
amino B-SYSTEMATIC 
sulfonamide I-SYSTEMATIC 
-catalyzed O 
direct O 
aldol O 
reactions O 
between O 
two O 
enolizable O 
aldehydes B-FAMILY 
with O 
different O 
electronic O 
nature O 
have O 
been O 
studied O 
with O 
the O 
aid O 
of O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
method O 
. O 
The O 
potential O 
energy O 
profiles O 
for O 
the O 
enamine B-SYSTEMATIC 
formation O 
between O 
each O 
aliphatic B-FAMILY 
aldehyde I-FAMILY 
and O 
the O 
catalyst O 
confirm O 
that O 
two O 
subject O 
catalysts O 
can O 
successfully O 
differentiate O 
between O 
3-methylbutanal B-SYSTEMATIC 
as O 
an O 
enamine B-SYSTEMATIC 
component O 
and O 
α-chloroaldehydes B-FAMILY 
as O 
a O 
carbonyl B-FAMILY 
component O 
. O 
Transition O 
states O 
associated O 
with O 
the O 
stereochemistry O 
- O 
determining O 
C B-FORMULA 
- O 
C B-FORMULA 
bond O 
- O 
forming O 
step O 
with O 
the O 
enamine B-SYSTEMATIC 
intermediate O 
addition O 
to O 
the O 
aldehyde B-SYSTEMATIC 
acceptor O 
for O 
proline B-TRIVIAL 
and O 
chiral O 
amino B-SYSTEMATIC 
sulfonamide I-SYSTEMATIC 
-promoted O 
aldol O 
reactions O 
are O 
reported O 
. O 
DFT O 
calculations O 
not O 
only O 
provide O 
a O 
good O 
explanation O 
for O 
the O 
formation O 
of O 
the O 
sole O 
cross O 
- O 
aldol O 
product O 
between O 
two O 
aliphatic B-FAMILY 
aldehydes I-FAMILY 
both O 
bearing O 
α-methylene B-SYSTEMATIC 
protons O 
but O 
also O 
well O 
reproduce O 
the O 
opposite O 
syn O 
vs O 
anti O 
diastereoselectivities O 
in O 
the O 
chiral O 
amino B-SYSTEMATIC 
sulfonamide I-SYSTEMATIC 
and O 
proline B-TRIVIAL 
-catalyzed O 
aldol O 
reactions O 
. O 

formation O 
of O 
the O 
hydrated O 
electron O 
through O 
the O 
secondary O 
reaction O 
, O 
H B-FORMULA 
+ O 
OH(–) B-FORMULA 
→ O 
H(2)O B-FORMULA 
+ O 
e(aq) O 
, O 
has O 
been O 
examined O 
in O 
the O 
sonolysis O 
of O 
argon B-SYSTEMATIC 
-saturated O 
aqueous O 
solutions O 
at O 
an O 
ultrasound O 
frequency O 
of O 
355 O 
kHz O 
. O 
The O 
detection O 
of O 
the O 
hydrated O 
electron O 
was O 
achieved O 
by O 
measuring O 
its O 
reaction O 
with O 
the O 
one O 
- O 
electron O 
acceptors O 
Fe(CN)(6)(3–) B-FORMULA 
and O 
methyl B-SYSTEMATIC 
viologen O 
. O 
The O 
results O 
obtained O 
indicate O 
that O 
hydrated O 
electrons O 
are O 
produced O 
predominately O 
at O 
the O 
bubble O 
/ O 
aqueous O 
solution O 
interface O 
at O 
comparatively O 
high O 
local O 
concentrations O 
, O 
estimated O 
to O 
be O 
> O 
1.5 O 
× O 
10(–3) O 
M O 
. O 
The O 
half O 
life O 
of O 
the O 
hydrated O 
electron O 
under O 
such O 
conditions O 
is O 
estimated O 
to O 
be O 
< O 
60 O 
ns O 
. O 

formation O 
in O 
gamma O 
radiolysis O 
of O 
aqueous O 
benzene B-SYSTEMATIC 
solution O 
with O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
. O 

formation O 
by O 
gamma O 
radiolysis O 
of O 
an O 
aqueous O 
benzene B-SYSTEMATIC 
solution O 
containing O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
is O 
reported O 
. O 
The O 
phenol O 
formation O 
in O 
a O 
benzene B-SYSTEMATIC 
solution O 
containing O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
irradiated O 
with O 
(60)Co O 
γ-rays O 
is O 
about O 
six O 
times O 
higher O 
than O 
that O 
without O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
. O 
Ten O 
micromolar O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
enhanced O 
the O 
formation O 
of O 
phenol B-SYSTEMATIC 
up O 
to O 
a O 
total O 
dose O 
of O 
6 O 
Gy O 
. O 
Above O 
6 O 
Gy O 
in O 
solutions O 
containing O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
, O 
the O 
rate O 
of O 
phenol B-SYSTEMATIC 
yield O 
sharply O 
decreased O 
and O 
was O 
essentially O 
the O 
same O 
as O 
that O 
without O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
. O 
The O 
yield O 
of O 
phenol B-SYSTEMATIC 
with O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
is O 
0.89 O 
μmol O 
J(-1) O 
and O 
is O 
larger O 
than O 
the O 
sum O 
of O 
yield O 
for O 
the O 
radicals O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
by O 
water O 
radiolysis O 
such O 
as O 
•OH B-FORMULA 
, O 
e(-) O 
, O 
H B-FORMULA 
, O 
H2 B-FORMULA 
, O 
and O 
H2O2 B-FORMULA 
. O 
The O 
formation O 
of O 
phenol B-SYSTEMATIC 
with O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
was O 
reduced O 
by O 
NaCl B-FORMULA 
. O 
Results O 
suggest O 
that O 
the O 
radiolytic O 
formation O 
of O 
phenol B-SYSTEMATIC 
in O 
a O 
benzene B-SYSTEMATIC 
solution O 
with O 
sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
relates O 
to O 
the O 
reaction O 
process O 
involving O 
chlorine B-SYSTEMATIC 
atoms O 
. O 
Sodium B-SYSTEMATIC 
hypochlorite I-SYSTEMATIC 
can O 
be O 
applied O 
as O 
a O 
sensitizer O 
for O 
a O 
benzene B-SYSTEMATIC 
chemical O 
dosimetry O 
system O 
. O 
The O 
lower O 
limit O 
of O 
dose O 
detection O 
calculated O 
from O 
the O 
detection O 
limit O 
of O 
phenol B-SYSTEMATIC 
and O 
the O 
G O 
value O 
of O 
phenol B-SYSTEMATIC 
was O 
estimated O 
to O 
be O 
1 O 
× O 
10(-3) O 
Gy O 
. O 

and O 
refactoring O 
of O 
the O 
A-74528 B-IDENTIFIER 
biosynthetic O 
pathway O 
. O 

is O 
a O 
C30 B-FAMILY 
polyketide I-FAMILY 
natural O 
product O 
that O 
functions O 
as O 
an O 
inhibitor O 
of O 
2',5'-oligoadenylate O 
phosphodiesterase O 
( O 
2'-PDE O 
) O 
, O 
a O 
key O 
regulatory O 
enzyme O 
of O 
the O 
interferon O 
pathway O 
. O 
Modulation O 
of O 
2'-PDE O 
represents O 
a O 
unique O 
therapeutic O 
approach O 
for O 
regulating O 
viral O 
infections O 
. O 
The O 
gene O 
cluster O 
responsible O 
for O 
biosynthesis O 
of O 
A-74528 B-IDENTIFIER 
yields O 
minute O 
amounts O 
of O 
this O 
natural O 
product O 
together O 
with O 
considerably O 
larger O 
quantities O 
of O 
a O 
structurally O 
dissimilar O 
C30 O 
cytotoxic O 
agent O 
, O 
fredericamycin B-TRIVIAL 
. O 
Through O 
construction O 
and O 
analysis O 
of O 
a O 
series O 
of O 
knockout O 
mutants O 
, O 
we O 
identified O 
the O 
genes O 
necessary O 
for O 
A-74528 B-IDENTIFIER 
biosynthesis O 
. O 
Remarkably O 
, O 
the O 
formation O 
of O 
six O 
stereocenters O 
and O 
the O 
regiospecific O 
formation O 
of O 
six O 
rings O 
in O 
A-74528 B-IDENTIFIER 
appear O 
to O 
be O 
catalyzed O 
by O 
only O 
two O 
tailoring O 
enzymes O 
, O 
a O 
cyclase O 
and O 
an O 
oxygenase O 
, O 
in O 
addition O 
to O 
the O 
core O 
polyketide O 
synthase O 
. O 
The O 
inferred O 
pathway O 
was O 
genetically O 
refactored O 
in O 
a O 
heterologous O 
host O 
, O 
Streptomyces O 
coelicolor O 
CH999 O 
, O 
to O 
produce O 
3 O 
mg O 
/ O 
L O 
A-74528 B-IDENTIFIER 
in O 
the O 
absence O 
of O 
fredericamycin B-TRIVIAL 
. O 

temperature O 
solution O 
- O 
processed O 
high O 
performance O 
photodiode O 
based O 
on O 
Si B-FORMULA 
- O 
ZnO B-FORMULA 
core O 
- O 
shell O 
structure O 
. O 

heterojunction O 
photodiodes O 
based O 
on O 
a O 
silicon B-SYSTEMATIC 
nanowire O 
arrays O 
(SiNWs)- O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ZnO B-FORMULA 
) O 
core O 
- O 
shell O 
structure O 
is O 
demonstrated O 
in O 
this O 
report O 
. O 
The O 
heterojunction O 
can O 
be O 
constructed O 
by O 
spin O 
- O 
coating O 
ZnO B-FORMULA 
nanoparticles O 
onto O 
SiNWs O 
and O 
a O 
low O 
temperature O 
post O 
- O 
annealing O 
process O 
( O 
< O 
270 O 
°C O 
) O 
. O 
The O 
photodiode O 
displays O 
typical O 
diode O 
rectifying O 
characteristics O 
with O 
an O 
ideality O 
factor O 
of O 
as O 
low O 
as O 
1.28 O 
, O 
and O 
shows O 
an O 
excellent O 
photoresponse O 
in O 
both O 
visible O 
and O 
near O 
infrared O 
regions O 
in O 
which O 
a O 
peak O 
value O 
of O 
0.54 O 
A O 
/ O 
W O 
at O 
zero O 
bias O 
was O 
attained O 
. O 
The O 
sensitivity O 
is O 
superior O 
to O 
that O 
of O 
previously O 
reported O 
devices O 
fabricated O 
with O 
vacuum O 
- O 
deposition O 
methods O 
. O 
In O 
contrast O 
, O 
the O 
planar O 
silicon B-SYSTEMATIC 
- O 
ZnO B-FORMULA 
junction O 
only O 
displays O 
the O 
peak O 
photoresponsivity O 
of O 
0.34 O 
A O 
/ O 
W O 
. O 
The O 
superior O 
performance O 
of O 
radial O 
junction O 
is O 
ascribed O 
to O 
the O 
highlight O 
- O 
harvesting O 
capability O 
, O 
large O 
interfacial O 
area O 
and O 
efficient O 
charge O 
carrier O 
collection O 
arising O 
from O 
the O 
core O 
(SiNWs)-shell O 
( O 
ZnO B-FORMULA 
) O 
structure O 
. O 
Here O 
, O 
high O 
temperature O 
processes O 
are O 
dispensable O 
by O 
using O 
facile O 
solution O 
- O 
processed O 
techniques O 
, O 
which O 
avoid O 
thermal O 
minority O 
lifetime O 
degradation O 
of O 
silicon B-SYSTEMATIC 
and O 
simplify O 
the O 
fabrication O 
process O 
of O 
the O 
photodiodes O 
. O 

vivo O 
evaluation O 
of O 
the O 
interaction O 
between O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticle O 
and O 
rat O 
liver O 
DNA O 
. O 

dioxide I-SYSTEMATIC 
nanoparticles O 
( O 
TiO2 B-FORMULA 
NPs O 
) O 
are O 
massively O 
produced O 
and O 
widely O 
used O 
in O 
daily O 
life O 
, O 
which O 
may O 
pose O 
potential O 
risk O 
to O 
human O 
health O 
via O 
uncharacterized O 
interaction O 
between O 
DNAs O 
. O 
This O 
research O 
aims O 
to O 
examine O 
the O 
interaction O 
between O 
DNA O 
and O 
three O 
types O 
of O 
TiO2 B-FORMULA 
NPs O 
of O 
different O 
sizes O 
and O 
crystallines O 
. O 
The O 
interaction O 
between O 
TiO2 B-FORMULA 
NPs O 
and O 
liver O 
DNA O 
molecules O 
obtained O 
from O 
Sprague-Dawley O 
rats O 
was O 
systematically O 
evaluated O 
in O 
vivo O 
using O 
atomic O 
force O 
microscopy O 
, O 
transmission O 
electron O 
microscopy O 
, O 
various O 
spectroscopic O 
techniques O 
and O 
gel O 
electrophoresis O 
. O 
We O 
found O 
that O 
TiO2 B-FORMULA 
NPs O 
( O 
diameter O 
< O 
25 O 
nm O 
and O 
< O 
100 O 
nm O 
) O 
in O 
anatase O 
crystalline O 
can O 
covalently O 
interact O 
with O 
liver O 
DNA O 
by O 
either O 
inserting O 
itself O 
in O 
between O 
DNA O 
base O 
pairs O 
or O 
binding O 
to O 
DNA O 
nucleotide B-FAMILY 
via O 
P- O 
O-Ti-O B-FORMULA 
bond O 
. O 
Such O 
interaction O 
may O 
not O 
be O 
NP O 
size O 
- O 
dependent O 
but O 
may O 
be O 
crystalline O 
phase O 
- O 
dependent O 
, O 
because O 
such O 
interaction O 
did O 
not O 
occur O 
in O 
rutile O 
crystal O 
phase O 
, O 
in O 
which O 
the O 
DNA O 
damage O 
was O 
potentially O 
caused O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 

: O 
Cholinesterase O 
inhibitors O 
and O 
memantine B-TRIVIAL 
are O 
the O 
mainstay O 
of O 
pharmacological O 
intervention O 
for O 
the O 
cognitive O 
symptoms O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
. O 
This O 
study O 
assessed O 
the O 
adequacy O 
of O 
dosing O 
and O 
persistence O 
with O 
AD O 
medications O 
and O 
the O 
predictors O 
of O 
these O 
variables O 
in O 
the O 
' O 
real O 
world O 
' O 
( O 
outside O 
the O 
clinical O 
trial O 
setting O 
) O 
. O 
METHODS O 
: O 
The O 
Health O 
Service O 
Executive-Primary O 
Care O 
Reimbursement O 
Services O 
prescription O 
claims O 
database O 
in O 
the O 
Republic O 
of O 
Ireland O 
contains O 
prescription O 
information O 
for O 
1.6 O 
million O 
people O 
. O 
Patients O 
aged O 
> O 
70 O 
years O 
who O 
received O 
at O 
least O 
two O 
prescriptions O 
for O 
donepezil B-TRIVIAL 
, O 
rivastigmine B-TRIVIAL 
, O 
galantamine B-TRIVIAL 
and O 
memantine B-TRIVIAL 
between O 
January O 
2006 O 
and O 
December O 
2010 O 
were O 
included O 
in O 
the O 
study O 
. O 
Rates O 
of O 
dose O 
- O 
maximisation O 
were O 
recorded O 
by O 
examining O 
the O 
initiation O 
dose O 
of O 
each O 
AD O 
drug O 
commenced O 
during O 
the O 
study O 
period O 
and O 
any O 
subsequent O 
dose O 
titrations O 
. O 
Non-persistence O 
was O 
defined O 
by O 
a O 
gap O 
in O 
prescribing O 
of O 
more O 
than O 
63 O 
consecutive O 
days O 
. O 
Predictors O 
of O 
dose O 
- O 
maximisation O 
and O 
non-persistence O 
were O 
also O 
analysed O 
. O 
RESULTS O 
: O 
Between O 
January O 
2006 O 
and O 
December O 
2010 O 
, O 
20729 O 
patients O 
aged O 
> O 
70 O 
years O 
received O 
a O 
prescription O 
for O 
an O 
AD O 
medication O 
. O 
Despite O 
most O 
patients O 
on O 
donepezil B-TRIVIAL 
and O 
memantine B-TRIVIAL 
receiving O 
a O 
prescription O 
for O 
the O 
maximum O 
drug O 
dose O 
, O 
this O 
dose O 
was O 
maintained O 
for O 
2 O 
consecutive O 
months O 
in O 
only O 
two O 
- O 
thirds O 
of O 
patients O 
. O 
Patients O 
were O 
significantly O 
more O 
likely O 
to O 
have O 
their O 
doses O 
of O 
donepezil B-TRIVIAL 
and O 
memantine B-TRIVIAL 
maximised O 
if O 
prescribed O 
in O 
more O 
recent O 
years O 
( O 
2010 O 
vs O 
. O 
2007 O 
) O 
. O 
Rates O 
of O 
non-persistence O 
were O 
30.1 O 
% O 
at O 
6 O 
months O 
and O 
43.8 O 
% O 
at O 
12 O 
months O 
. O 
Older O 
age O 
[ O 
75+ O 
vs O 
. O 
< O 
75 O 
years O 
; O 
hazards O 
ratio O 
(HR) O 
1.16 O 
, O 
95 O 
% O 
confidence O 
interval O 
( O 
CI O 
) O 
1.06-1.27 O 
] O 
and O 
drug O 
type O 
( O 
rivastigmine B-TRIVIAL 
vs O 
. O 
donepezil B-TRIVIAL 
; O 
HR O 
1.15 O 
, O 
95 O 
% O 
CI O 
1.03-1.27 O 
) O 
increased O 
the O 
risk O 
of O 
non-persistence O 
. O 
Non-persistence O 
was O 
lower O 
for O 
those O 
commencing O 
therapy O 
in O 
more O 
recent O 
years O 
( O 
2010 O 
vs O 
. O 
2007 O 
; O 
HR O 
0.81 O 
, O 
95 O 
% O 
CI O 
0.73-0.89 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
for O 
those O 
on O 
multiple O 
anti-dementia O 
medications O 
( O 
HR O 
0.59 O 
, O 
95 O 
% O 
CI O 
0.54-0.65 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Persistence O 
was O 
significantly O 
higher O 
when O 
memantine B-TRIVIAL 
was O 
co O 
- O 
prescribed O 
with O 
donepezil B-TRIVIAL 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
CONCLUSION O 
: O 
Future O 
studies O 
should O 
explore O 
the O 
reasons O 
underlying O 
non-persistence O 
and O 
failure O 
to O 
maintain O 
dose O 
- O 
maximisation O 
in O 
patients O 
on O 
AD O 
medications O 
. O 
There O 
may O 
be O 
scope O 
to O 
improve O 
the O 
dosing O 
and O 
persistence O 
with O 
these O 
medications O 
in O 
the O 
community O 
. O 

oxygen B-SYSTEMATIC 
imaging O 
using O 
integrated O 
optical O 
sensor O 
layers O 
and O 
a O 
color O 
camera O 
. O 

this O 
work O 
we O 
present O 
a O 
high O 
resolution O 
oxygen B-SYSTEMATIC 
imaging O 
approach O 
, O 
which O 
can O 
be O 
used O 
to O 
study O 
2D O 
oxygen B-SYSTEMATIC 
distribution O 
inside O 
microfluidic O 
environments O 
. O 
The O 
presented O 
setup O 
comprises O 
a O 
fabrication O 
process O 
of O 
microfluidic O 
chips O 
with O 
integrated O 
luminescent O 
sensing O 
films O 
combined O 
with O 
referenced O 
oxygen B-SYSTEMATIC 
imaging O 
applying O 
a O 
color O 
CCD-camera O 
. O 
Enhancement O 
of O 
the O 
sensor O 
performance O 
was O 
achieved O 
by O 
applying O 
the O 
principle O 
of O 
light O 
harvesting O 
. O 
This O 
principle O 
enabled O 
ratiometric O 
imaging O 
employing O 
the O 
red O 
and O 
the O 
green O 
channel O 
of O 
a O 
color O 
CCD-camera O 
. O 
The O 
oxygen B-SYSTEMATIC 
sensitive O 
emission O 
of O 
platinum(ii)-5,10,15,20-tetrakis-(2,3,4,5,6-pentafluorphenyl)-porphyrin B-SYSTEMATIC 
( O 
PtTFPP B-ABBREVIATION 
) O 
was O 
detected O 
by O 
the O 
red O 
channel O 
, O 
while O 
the O 
emission O 
of O 
a O 
reference O 
dye O 
was O 
detected O 
by O 
the O 
green O 
channel O 
. O 
This O 
measurement O 
setup O 
allowed O 
for O 
accurate O 
real O 
- O 
time O 
2D O 
oxygen B-SYSTEMATIC 
imaging O 
with O 
superior O 
quality O 
compared O 
to O 
intensity O 
imaging O 
. O 
The O 
sensor O 
films O 
were O 
subsequently O 
used O 
to O 
measure O 
the O 
respiratory O 
activity O 
of O 
human O 
cell O 
cultures O 
( O 
HeLa O 
carcinoma O 
cells O 
and O 
normal O 
human O 
dermal O 
fibroblasts O 
) O 
in O 
a O 
microfluidic O 
system O 
. O 
The O 
sensor O 
setup O 
is O 
well O 
suited O 
for O 
different O 
applications O 
from O 
spatially O 
and O 
temporally O 
resolving O 
oxygen B-SYSTEMATIC 
concentration O 
inside O 
microfluidic O 
channels O 
to O 
parallelization O 
of O 
oxygen B-SYSTEMATIC 
measurements O 
and O 
paves O 
the O 
way O 
to O 
novel O 
cell O 
based O 
assays O 
, O 
e.g O 
. O 
in O 
tissue O 
engineering O 
, O 
tumor O 
biology O 
and O 
hypoxia O 
reperfusion O 
phenomena O 
. O 

/ O 
tenofovir B-TRIVIAL 
disoproxil I-TRIVIAL 
fumarate I-TRIVIAL 
: O 
a O 
review O 
of O 
its O 
use O 
in O 
HIV-1 O 
pre O 
- O 
exposure O 
prophylaxis O 
. O 

fixed O 
- O 
dose O 
combination O 
of O 
emtricitabine B-TRIVIAL 
( O 
FTC B-ABBREVIATION 
) O 
200 O 
mg O 
and O 
tenofovir B-TRIVIAL 
disoproxil I-TRIVIAL 
fumarate I-TRIVIAL 
( O 
TDF B-ABBREVIATION 
) O 
300 O 
mg O 
( O 
Truvada B-TRIVIAL 
( O 
® O 
) O 
) O 
, O 
administered O 
orally O 
once O 
daily O 
, O 
is O 
widely O 
used O 
as O 
part O 
of O 
first O 
- O 
line O 
regimens O 
for O 
the O 
treatment O 
of O 
HIV-1 O 
infection O 
. O 
Recently O 
, O 
once O 
- O 
daily O 
administration O 
of O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
was O 
approved O 
in O 
the O 
USA O 
for O 
pre O 
- O 
exposure O 
prophylaxis O 
in O 
conjunction O 
with O 
safer O 
sex O 
practices O 
to O 
reduce O 
the O 
risk O 
of O 
sexually O 
acquired O 
HIV-1 O 
in O 
high O 
- O 
risk O 
adults O 
who O 
are O 
not O 
infected O 
. O 
To O 
date O 
, O 
results O 
of O 
four O 
large O 
, O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
, O 
multicentre O 
trials O 
with O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
as O 
pre O 
- O 
exposure O 
prophylaxis O 
have O 
been O 
published O 
. O 
Three O 
studies O 
showed O 
statistically O 
significant O 
reductions O 
in O 
the O 
number O 
of O 
individuals O 
with O 
emergent O 
HIV-1 O 
infection O 
when O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
was O 
compared O 
with O 
placebo O 
over O 
the O 
≈1- O 
to O 
2-year O 
study O 
periods O 
. O 
Efficacy O 
( O 
i.e O 
. O 
risk O 
reduction O 
relative O 
to O 
placebo O 
) O 
was O 
44 O 
% O 
in O 
the O 
iPrEx O 
trial O 
in O 
men O 
who O 
have O 
sex O 
with O 
men O 
, O 
75 O 
% O 
in O 
the O 
Partners O 
PrEP O 
study O 
in O 
heterosexual O 
HIV-1-serodiscordant O 
couples O 
and O 
62 O 
% O 
in O 
the O 
TDF2 O 
trial O 
in O 
heterosexual O 
men O 
and O 
women O 
. O 
The O 
fourth O 
study O 
( O 
FEM-PrEP O 
) O 
in O 
heterosexual O 
women O 
did O 
not O 
show O 
a O 
statistically O 
significant O 
difference O 
between O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
and O 
placebo O 
, O 
although O 
low O 
adherence O 
rates O 
reported O 
in O 
this O 
trial O 
may O 
have O 
been O 
a O 
factor O 
. O 
No O 
unexpected O 
adverse O 
events O 
were O 
reported O 
in O 
the O 
trials O 
. O 
However O 
, O 
since O 
pre O 
- O 
exposure O 
prophylaxis O 
involves O 
long O 
- O 
term O 
administration O 
of O 
drugs O 
to O 
healthy O 
individuals O 
, O 
it O 
is O 
important O 
to O 
monitor O 
the O 
long O 
- O 
term O 
safety O 
of O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
( O 
e.g O 
. O 
renal O 
function O 
, O 
bone O 
mineral O 
density O 
) O 
in O 
this O 
setting O 
. O 
Other O 
notable O 
considerations O 
include O 
adherence O 
, O 
cost O 
and O 
the O 
potential O 
for O 
development O 
of O 
drug O 
resistance O 
. O 
Interim O 
guidelines O 
are O 
available O 
for O 
prescribing O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
as O 
pre O 
- O 
exposure O 
prophylaxis O 
. O 
If O 
used O 
appropriately O 
in O 
selected O 
high O 
- O 
risk O 
individuals O 
, O 
pre O 
- O 
exposure O 
prophylaxis O 
with O 
FTC B-ABBREVIATION 
/ O 
TDF B-ABBREVIATION 
represents O 
an O 
important O 
additional O 
strategy O 
to O 
reduce O 
the O 
spread O 
of O 
HIV-1 O 
infection O 
, O 
which O 
continues O 
to O 
be O 
a O 
significant O 
global O 
concern O 
. O 

pharmacokinetic O 
analysis O 
of O 
a O 
nevirapine B-TRIVIAL 
-based O 
HIV-1 O 
prevention O 
of O 
mother O 
- O 
to O 
- O 
child O 
transmission O 
program O 
in O 
Uganda O 
to O 
assess O 
the O 
impact O 
of O 
different O 
dosing O 
regimens O 
for O 
newborns O 
. O 

- O 
dose O 
nevirapine B-TRIVIAL 
for O 
mothers O 
and O 
newborns O 
at O 
delivery O 
is O 
the O 
simplest O 
prevention O 
strategy O 
for O 
vertical O 
HIV-1 O 
transmission O 
and O 
hence O 
widely O 
used O 
in O 
resource O 
- O 
constrained O 
settings O 
. O 
HIV-1-positive O 
mothers O 
and O 
newborns O 
received O 
single O 
- O 
dose O 
nevirapine B-TRIVIAL 
in O 
a O 
prevention O 
of O 
mother O 
- O 
to O 
- O 
child O 
HIV-1 O 
transmission O 
( O 
PMTCT O 
) O 
program O 
in O 
Uganda O 
. O 
In O 
a O 
pharmacokinetic O 
investigation O 
, O 
breast O 
milk O 
and O 
plasma O 
samples O 
of O 
mothers O 
and O 
newborns O 
were O 
collected O 
. O 
The O 
nonlinear O 
mixed O 
- O 
effects O 
modeling O 
approach O 
was O 
suitable O 
for O 
analysis O 
( O 
average O 
: O 
1.8 O 
samples O 
/ O 
matrix O 
/ O 
individual O 
) O 
. O 
For O 
describing O 
the O 
nevirapine B-TRIVIAL 
pharmacokinetics O 
in O 
mothers O 
and O 
newborns O 
, O 
a O 
1-compartment O 
model O 
was O 
demonstrated O 
to O 
be O 
sufficient O 
. O 
The O 
plasma O 
- O 
placenta O 
transfer O 
could O 
be O 
quantified O 
, O 
revealing O 
a O 
transfer O 
fraction O 
of O 
11% O 
to O 
25% O 
( O 
with O 
a O 
significant O 
influence O 
of O 
time O 
span O 
between O 
maternal O 
nevirapine B-TRIVIAL 
intake O 
and O 
birth O 
) O 
and O 
a O 
high O 
transfer O 
rate O 
constant O 
from O 
maternal O 
drug O 
administration O 
. O 
Interindividual O 
variability O 
was O 
moderate O 
between O 
mothers O 
and O 
high O 
between O 
newborns O 
. O 
Simulations O 
revealed O 
that O 
newborns O 
born O 
early O 
( O 
< O 
1 O 
hour O 
) O 
after O 
maternal O 
nevirapine B-TRIVIAL 
intake O 
would O 
benefit O 
from O 
a O 
3-fold O 
higher O 
nevirapine B-TRIVIAL 
dosage O 
( O 
6 O 
mg O 
/ O 
kg O 
) O 
after O 
birth O 
for O 
analogous O 
protective O 
plasma O 
concentrations O 
over O 
the O 
first O 
2 O 
weeks O 
. O 
In O 
contrast O 
, O 
postnatal O 
nevirapine B-TRIVIAL 
dosage O 
seemed O 
to O 
be O 
dispensable O 
for O 
newborns O 
born O 
late O 
( O 
> O 
24 O 
hours O 
) O 
after O 
maternal O 
nevirapine B-TRIVIAL 
intake O 
. O 
These O 
dosing O 
recommendations O 
should O 
be O 
evaluated O 
in O 
prospective O 
studies O 
, O 
including O 
additional O 
antiretroviral O 
drugs O 
in O 
accordance O 
with O 
current O 
PMTCT O 
guidelines O 
. O 

study O 
on O 
the O 
effects O 
of O 
pica O 
and O 
iron B-SYSTEMATIC 
-deficiency O 
anemia O 
on O 
oxidative O 
stress O 
, O 
antioxidant O 
capacity O 
and O 
trace O 
elements O 
. O 

is O 
defined O 
as O 
developmentally O 
inappropriate O 
consumption O 
of O 
nonnutritive O 
substances O 
for O 
at O 
least O 
1 O 
month O 
. O 
There O 
are O 
a O 
few O 
studies O 
on O 
serum O 
trace O 
element O 
levels O 
of O 
patients O 
with O 
pica O 
. O 
The O 
literature O 
contains O 
contracting O 
data O 
on O 
the O 
levels O 
of O 
oxidative O 
stress O 
and O 
antioxidant O 
levels O 
in O 
patients O 
with O 
iron B-SYSTEMATIC 
-deficiency O 
anemia O 
( O 
IDA O 
) O 
. O 
The O 
effect O 
of O 
pica O 
on O 
oxidative O 
stress O 
and O 
antioxidant O 
capacity O 
has O 
not O 
been O 
investigated O 
yet O 
. O 
The O 
present O 
study O 
evaluated O 
the O 
effects O 
of O 
pica O 
and O 
IDA O 
on O 
oxidative O 
stress O 
and O 
antioxidant O 
capacity O 
as O 
well O 
as O 
on O 
the O 
levels O 
of O 
trace O 
elements O 
including O 
serum O 
zinc B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
in O 
47 O 
children O 
with O 
IDA O 
plus O 
pica O 
, O 
22 O 
children O 
with O 
IDA O 
only O 
and O 
21 O 
nonanemic O 
children O 
as O 
controls O 
. O 
The O 
results O 
demonstrated O 
significantly O 
lower O 
levels O 
of O 
serum O 
selenium B-SYSTEMATIC 
and O 
zinc B-SYSTEMATIC 
in O 
pica O 
and O 
IDA O 
groups O 
compared O 
to O 
the O 
control O 
group O 
. O 
Total O 
oxidant O 
levels O 
were O 
highest O 
in O 
the O 
pica O 
group O 
and O 
consistently O 
, O 
the O 
lowest O 
total O 
antioxidant O 
capacity O 
was O 
observed O 
again O 
in O 
the O 
pica O 
group O 
. O 
Comparison O 
of O 
pica O 
and O 
IDA O 
groups O 
yielded O 
significantly O 
lower O 
levels O 
of O 
total O 
antioxidant O 
levels O 
and O 
significantly O 
higher O 
oxidative O 
stress O 
index O 
in O 
the O 
pica O 
group O 
. O 
Consequently O 
, O 
it O 
is O 
thought O 
that O 
the O 
detrimental O 
effects O 
of O 
pica O 
within O 
the O 
organism O 
were O 
mediated O 
by O 
adverse O 
impacts O 
on O 
antioxidant O 
capacity O 
and O 
oxidative O 
stress O 
. O 
These O 
effects O 
should O 
be O 
kept O 
in O 
mind O 
while O 
managing O 
patients O 
with O 
pica O 
. O 

number O 
of O 
new O 
drug O 
candidates O 
that O 
are O 
cleared O 
via O 
non-cytochrome O 
P450 O 
( O 
P450 O 
) O 
enzymes O 
has O 
increased O 
. O 
However O 
, O 
unlike O 
oxidation O 
by O 
P450 O 
, O 
the O 
roles O 
of O 
reductive O 
enzymes O 
are O 
less O 
understood O 
. O 
The O 
metabolism O 
in O 
intestine O 
is O 
especially O 
not O 
well O 
known O 
. O 
The O 
purposes O 
of O 
this O 
study O 
were O 
to O 
investigate O 
the O 
significance O 
of O 
reductive O 
metabolism O 
in O 
human O 
intestine O 
, O 
and O 
to O 
establish O 
a O 
quantitative O 
prediction O 
method O 
of O 
intestinal O 
first O 
- O 
pass O 
metabolism O 
by O 
cytosolic O 
reductive O 
enzymes O 
, O 
using O 
haloperidol B-TRIVIAL 
, O 
mebendazole B-TRIVIAL 
, O 
and O 
ziprasidone B-TRIVIAL 
. O 
First O 
, O 
we O 
estimated O 
the O 
metabolic O 
activities O 
for O 
these O 
compounds O 
in O 
intestine O 
and O 
liver O 
using O 
subcellular O 
fractions O 
. O 
Metabolic O 
activities O 
were O 
detected O 
in O 
human O 
intestinal O 
cytosol O 
( O 
HIC O 
) O 
for O 
all O 
three O 
compounds O 
, O 
and O 
the O 
intrinsic O 
clearance O 
values O 
were O 
higher O 
than O 
those O 
in O 
human O 
liver O 
cytosol O 
for O 
haloperidol B-TRIVIAL 
and O 
mebendazole B-TRIVIAL 
. O 
These O 
metabolic O 
activities O 
in O 
HIC O 
were O 
NADPH B-ABBREVIATION 
- O 
and O 
/ O 
or O 
NADH B-ABBREVIATION 
-dependent O 
. O 
Furthermore O 
, O 
the O 
metabolic O 
activities O 
for O 
all O 
three O 
compounds O 
in O 
HIC O 
were O 
largely O 
inhibited O 
by O 
menadione B-TRIVIAL 
, O 
which O 
has O 
been O 
used O 
as O 
a O 
carbonyl B-FAMILY 
reductase O 
(CBR)-selective O 
chemical O 
inhibitor O 
. O 
Therefore O 
, O 
considering O 
subcellular O 
location O 
, O 
cofactor O 
requirement O 
, O 
and O 
chemical O 
inhibition O 
, O 
these O 
compounds O 
might O 
be O 
metabolized O 
by O 
CBRs O 
in O 
human O 
intestine O 
. O 
Subsequently O 
, O 
we O 
tried O 
to O 
quantitatively O 
predict O 
intestinal O 
availability O 
( O 
Fg O 
) O 
for O 
these O 
compounds O 
using O 
human O 
intestinal O 
S9 O 
( O 
HIS9 O 
) O 
. O 
Our O 
prediction O 
model O 
using O 
apparent O 
permeability O 
of O 
parallel O 
artificial O 
membrane O 
permeability O 
assay O 
and O 
metabolic O 
activities O 
in O 
HIS9 O 
could O 
predict O 
Fg O 
in O 
humans O 
for O 
the O 
three O 
compounds O 
well O 
. O 
In O 
conclusion O 
, O 
CBRs O 
might O 
have O 
higher O 
metabolic O 
activities O 
in O 
human O 
intestine O 
than O 
in O 
human O 
liver O 
. O 
Furthermore O 
, O 
our O 
prediction O 
method O 
of O 
human O 
Fg O 
using O 
HIS9 O 
is O 
applicable O 
to O 
substrates O 
of O 
cytosolic O 
reductive O 
enzymes O 
. O 

glucagon O 
- O 
like O 
peptide-1 O 
secretion O 
may O 
be O 
involved O 
in O 
antidiabetic O 
effects O 
of O 
ginsenosides B-FAMILY 
. O 

ginseng O 
is O 
one O 
of O 
the O 
most O 
popular O 
herbal O 
remedies O 
. O 
Ginsenosides B-FAMILY 
, O 
major O 
bioactive O 
constituents O 
in O 
P O 
. O 
ginseng O 
, O 
have O 
shown O 
good O 
antidiabetic O 
action O 
, O 
but O 
the O 
precise O 
mechanism O 
was O 
not O 
fully O 
understood O 
. O 
Glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP1 O 
) O 
is O 
considered O 
to O 
be O 
an O 
important O 
incretin O 
that O 
can O 
regulate O 
glucose B-TRIVIAL 
homeostasis O 
in O 
the O 
gastrointestinal O 
tract O 
after O 
meals O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
ginseng O 
total O 
saponins B-FAMILY 
( O 
GTS O 
) O 
exerts O 
its O 
antidiabetic O 
effects O 
via O 
modulating O 
GLP1 O 
release O 
. O 
Ginsenoside B-TRIVIAL 
Rb1 I-TRIVIAL 
( O 
Rb1 B-ABBREVIATION 
) O 
, O 
the O 
most O 
abundant O 
constituent O 
in O 
GTS O 
, O 
was O 
selected O 
to O 
further O 
explore O 
the O 
underlying O 
mechanisms O 
in O 
cultured O 
NCI-H716 O 
cells O 
. O 
Diabetic O 
rats O 
were O 
developed O 
by O 
a O 
combination O 
of O 
high O 
- O 
fat O 
diet O 
and O 
low O 
- O 
dose O 
streptozotocin B-TRIVIAL 
injection O 
. O 
The O 
diabetic O 
rats O 
orally O 
received O 
GTS O 
( O 
150 O 
or O 
300 O 
mg O 
/ O 
kg O 
) O 
daily O 
for O 
4 O 
weeks O 
. O 
It O 
was O 
found O 
that O 
GTS O 
treatment O 
significantly O 
ameliorated O 
hyperglycemia O 
and O 
dyslipidemia O 
, O 
accompanied O 
by O 
a O 
significant O 
increase O 
in O 
glucose B-TRIVIAL 
-induced O 
GLP1 O 
secretion O 
and O 
upregulation O 
of O 
proglucagon O 
gene O 
expression O 
. O 
Data O 
from O 
NCI-H716 O 
cells O 
showed O 
that O 
both O 
GTS O 
and O 
Rb1 B-ABBREVIATION 
promoted O 
GLP1 O 
secretion O 
. O 
It O 
was O 
observed O 
that O 
Rb1 B-ABBREVIATION 
increased O 
the O 
ratio O 
of O 
intracellular O 
ATP B-ABBREVIATION 
to O 
ADP B-ABBREVIATION 
concentration O 
and O 
intracellular O 
Ca(2)(+) B-FORMULA 
concentration O 
. O 
The O 
metabolic O 
inhibitor O 
azide B-SYSTEMATIC 
( O 
3 O 
mM O 
) O 
, O 
the O 
KATP O 
channel O 
opener O 
diazoxide B-SYSTEMATIC 
( O 
340 O 
μM O 
) O 
, O 
and O 
the O 
Ca(2)(+) B-FORMULA 
channel O 
blocker O 
nifedipine B-TRIVIAL 
( O 
20 O 
μM O 
) O 
significantly O 
reversed O 
Rb1 B-ABBREVIATION 
-mediated O 
GLP1 O 
secretion O 
. O 
All O 
these O 
results O 
drew O 
a O 
conclusion O 
that O 
ginsenosides B-FAMILY 
stimulated O 
GLP1 O 
secretion O 
both O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
The O 
antidiabetic O 
effects O 
of O 
ginsenosides B-FAMILY 
may O 
be O 
a O 
result O 
of O 
enhanced O 
GLP1 O 
secretion O 
. O 

B O 
virus O 
( O 
HBV O 
) O 
is O 
implicated O 
in O 
liver O 
cancer O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
find O 
out O 
whether O 
HBV O 
or O 
its O 
components O 
[ O 
HBV O 
surface O 
antigen O 
( O 
HBsAg O 
) O 
, O 
HBV O 
core O 
protein O 
( O 
HBc O 
) O 
, O 
and O 
HBV O 
X O 
protein O 
( O 
HBx O 
) O 
] O 
could O 
interfere O 
with O 
the O 
host O 
DNA O 
damage O 
response O 
and O 
repair O 
pathway O 
. O 
The O 
full O 
HBV O 
genome O 
or O 
individual O 
HBV O 
open O 
- O 
reading O 
frame O 
( O 
ORF O 
) O 
was O 
introduced O 
into O 
HepG2 O 
cells O 
to O 
examine O 
the O 
effect O 
on O 
host O 
genomic O 
stability O 
, O 
DNA O 
repair O 
efficacy O 
in O 
response O 
to O 
double O 
- O 
strand O 
DNA O 
damage O 
, O 
and O 
DNA O 
damage O 
- O 
induced O 
cell O 
death O 
. O 
Responses O 
to O 
apoptosis O 
induction O 
in O 
the O 
HBV O 
ORF-transfected O 
HepG2 O 
cells O 
were O 
also O 
compared O 
with O 
those O 
in O 
HBV-positive O 
and O 
HBV-negative O 
human O 
hepatocellular O 
carcinoma O 
( O 
HCC O 
) O 
cells O 
. O 
In O 
the O 
absence O 
of O 
HBV O 
replication O 
, O 
accumulation O 
of O 
HBsAg O 
in O 
liver O 
cells O 
without O 
other O 
HBV O 
proteins O 
enhanced O 
DNA O 
repair O 
protein O 
and O 
tumor O 
suppressor O 
promyelocytic O 
leukemia O 
( O 
PML O 
) O 
degradation O 
, O 
which O 
resulted O 
in O 
resistance O 
to O 
apoptosis O 
induction O 
and O 
deficient O 
double O 
- O 
strand O 
DNA O 
repair O 
. O 
However O 
, O 
HBsAg-positive O 
cells O 
exhibited O 
increased O 
cell O 
death O 
with O 
exposure O 
to O 
the O 
poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
inhibitor O 
that O 
blocks O 
single O 
- O 
strand O 
DNA O 
repair O 
. O 
These O 
results O 
indicate O 
that O 
suppression O 
of O 
PML O 
by O 
HBsAg O 
disrupts O 
cellular O 
mechanisms O 
that O 
respond O 
to O 
double O 
- O 
strand O 
DNA O 
damage O 
for O 
DNA O 
repair O 
or O 
apoptosis O 
induction O 
, O 
which O 
may O 
facilitate O 
hepatocarcinogenesis O 
and O 
open O 
up O 
a O 
synthetic O 
lethality O 
strategy O 
for O 
HBsAg-positive O 
HCC O 
treatment.-Chung O 
, O 
Y.-L O 
. O 
Defective O 
DNA O 
damage O 
response O 
and O 
repair O 
in O 
liver O 
cells O 
expressing O 
hepatitis O 
B O 
virus O 
surface O 
antigen O 
. O 

study O 
of O 
rare O 
genetic O 
diseases O 
usually O 
inspires O 
the O 
research O 
of O 
cancer O 
biology O 
. O 
Fanconi O 
anemia O 
( O 
FA O 
) O 
, O 
is O 
a O 
rare O 
cancer O 
susceptibility O 
syndrome O 
with O 
an O 
incidence O 
of O 
only O 
1 O 
per O 
350000 O 
births O 
. O 
FA O 
is O 
an O 
autosomal O 
recessive O 
disease O 
with O 
three O 
main O 
features O 
: O 
chromosome O 
instability O 
, O 
hypersensitivity O 
to O 
DNA O 
cross O 
- O 
linking O 
agents O 
such O 
as O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
( O 
MMC B-ABBREVIATION 
) O 
, O 
cisplatin B-TRIVIAL 
and O 
so O 
on O 
, O 
and O 
susceptible O 
to O 
a O 
number O 
of O 
cancer O 
types O 
, O 
mainly O 
leukemia O 
and O 
squamous O 
cell O 
carcinomas O 
of O 
the O 
head O 
and O 
neck O 
or O 
gynecologic O 
system O 
. O 
DNA O 
crosslinking O 
agents O 
may O 
led O 
to O 
DNA O 
cross O 
- O 
linking O 
lesion O 
, O 
and O 
Fanconi O 
anemia O 
pathway O 
plays O 
a O 
key O 
role O 
in O 
repairing O 
its O 
cross O 
- O 
linking O 
. O 
However O 
, O 
FA O 
pathway O 
is O 
closely O 
linked O 
with O 
carcinogenesis O 
and O 
tumor O 
drug O 
resistance O 
. O 
This O 
paper O 
mainly O 
focuses O 
on O 
the O 
FA O 
pathway O 
and O 
its O 
progress O 
in O 
cancer O 
research O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
examine O 
the O 
effects O 
of O 
a O 
new O 
sustained O 
- O 
release O 
( O 
SR O 
) O 
microsphere O 
formulation O 
of O 
exenatide O 
, O 
DA-3091 O 
, O 
on O 
body O 
weight O 
gain O 
and O 
hepatic O 
injury O 
in O 
high O 
fat O 
diet O 
(HFD)-induced O 
obese O 
mice O 
and O 
high O 
sucrose O 
diet O 
(HSD)-induced O 
non-alcoholic O 
fatty O 
liver O 
disease O 
( O 
NAFLD O 
) O 
mice O 
. O 
Then O 
, O 
we O 
determined O 
whether O 
DA-3091 O 
has O 
the O 
potency O 
as O 
a O 
drug O 
for O 
the O 
treatment O 
of O 
metabolic O 
disease O 
. O 
In O 
obese O 
mice O 
, O 
after O 
8-week O 
treatment O 
, O 
the O 
body O 
weight O 
gain O 
was O 
significantly O 
more O 
suppressed O 
by O 
both O 
1 O 
mg O 
/ O 
kg O 
and O 
2 O 
mg O 
/ O 
kg O 
of O 
DA-3091 O 
, O 
monthly O 
subcutaneous O 
administered O 
, O 
than O 
by O 
10 O 
mg O 
/ O 
kg O 
/ O 
day O 
of O 
sibutramin B-TRIVIAL 
, O 
a O 
drug O 
against O 
obesity O 
. O 
In O 
NAFLD O 
mice O 
, O 
a O 
significant O 
reduction O 
in O 
serum O 
alanine B-TRIVIAL 
aminotransferase O 
( O 
ALT O 
) O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
( O 
AST O 
) O 
levels O 
, O 
representative O 
markers O 
of O 
hepatic O 
injury O 
, O 
was O 
observed O 
after O 
biweekly O 
subcutaneous O 
administration O 
of O 
1 O 
mg O 
/ O 
kg O 
and O 
2 O 
mg O 
/ O 
kg O 
of O 
DA-3091 O 
for O 
8 O 
weeks O 
. O 
A O 
significant O 
reduction O 
in O 
hepatic O 
lipid O 
accumulation O 
was O 
observed O 
in O 
DA-3091 O 
treated O 
groups O 
as O 
well O 
. O 
Based O 
on O 
these O 
results O 
, O 
it O 
is O 
demonstrated O 
that O 
DA-3091 O 
has O 
the O 
potency O 
as O 
a O 
drug O 
for O 
the O 
treatment O 
of O 
metabolic O 
disease O 
. O 

of O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
on O 
neurochemical O 
phenotypes O 
of O 
cultured O 
dorsal O 
root O 
ganglion O 
neurons O 
with O 
excitotoxicity O 
induced O 
by O 
glutamate B-TRIVIAL 
. O 

- O 
like O 
growth O 
factor-1 O 
( O 
IGF-1 O 
) O 
is O 
a O 
neurotrophic O 
factor O 
and O 
plays O 
an O 
important O 
role O 
in O 
promoting O 
axonal O 
growth O 
from O 
dorsal O 
root O 
ganglion O 
( O 
DRG O 
) O 
neurons O 
. O 
The O 
neuropeptide- O 
and O 
neurofilament O 
(NF)-immunoreactive O 
( O 
IR O 
) O 
neurons O 
are O 
two O 
major O 
phenotypical O 
classes O 
in O 
DRG O 
. O 
Whether O 
IGF-1 O 
affects O 
neurochemical O 
phenotypes O 
of O 
DRG O 
neurons O 
remains O 
unknown O 
. O 
In O 
the O 
present O 
study O 
, O 
primary O 
cultured O 
DRG O 
neurons O 
were O 
used O 
to O 
determine O 
the O 
effects O 
of O 
IGF-1 O 
on O 
neurochemical O 
phenotypes O 
of O 
the O 
neurons O 
with O 
excitotoxicity O 
induced O 
by O 
glutamate B-TRIVIAL 
( O 
Glu B-FORMULA 
) O 
. O 
DRG O 
neurons O 
were O 
dissociated O 
and O 
cultured O 
for O 
48 O 
hours O 
and O 
then O 
exposed O 
to O 
IGF-1 O 
( O 
20 O 
nmol O 
/ O 
L O 
) O 
, O 
Glu B-FORMULA 
( O 
0.2 O 
mmol O 
/ O 
L O 
) O 
, O 
Glu B-FORMULA 
( O 
0.2 O 
mmol O 
/ O 
L O 
) O 
plus O 
IGF-1 O 
( O 
20 O 
nmol O 
/ O 
L O 
) O 
for O 
additional O 
24 O 
hours O 
. O 
The O 
DRG O 
neurons O 
were O 
continuously O 
exposed O 
to O 
culture O 
media O 
as O 
control O 
. O 
After O 
that O 
, O 
all O 
above O 
cultured O 
DRG O 
neurons O 
were O 
processed O 
for O 
detecting O 
mRNA O 
levels O 
of O 
calcitonin O 
gene O 
- O 
related O 
peptide O 
( O 
CGRP O 
) O 
and O 
neurofilament-200 O 
( O 
NF-200 O 
) O 
by O 
real O 
time-PCR O 
analysis O 
. O 
CGRP O 
and O 
NF-200 O 
expression O 
in O 
situ O 
was O 
determined O 
by O 
fluorescent O 
labeling O 
technique O 
. O 
The O 
results O 
showed O 
that O 
CGRP O 
mRNA O 
, O 
but O 
not O 
NF-200 O 
mRNA O 
, O 
increased O 
after O 
IGF-1 O 
administration O 
in O 
the O 
absence O 
or O 
presence O 
of O 
Glu B-FORMULA 
. O 
IGF-1 O 
could O 
increase O 
the O 
percentage O 
of O 
CGRP-expressing O 
neurons O 
, O 
but O 
not O 
NF-200-expressing O 
neurons O 
, O 
in O 
the O 
absence O 
or O 
presence O 
of O 
Glu B-FORMULA 
. O 
The O 
ability O 
of O 
IGF-1 O 
on O 
CGRP O 
expression O 
may O 
play O 
a O 
role O 
in O 
neurogenic O 
inflammation O 
or O 
nociception O 
. O 

present O 
study O 
was O 
designed O 
to O 
identify O 
and O 
compare O 
the O 
in O 
vivo O 
wound O 
healing O 
capacity O 
of O 
a O 
bark O 
extract O 
from O 
Pinus O 
brutia O 
and O 
Pycnogenol O 
in O 
an O 
incision O 
wound O 
model O 
in O 
rats O 
. O 
O O 
/ O 
W O 
cream O 
formulations O 
were O 
prepared O 
incorporating O 
2% O 
Pycnogenol O 
and O 
P O 
. O 
brutia O 
bark O 
extract O 
. O 
The O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
( O 
n O 
= O 
8 O 
) O 
. O 
Subsequently O 
placebo O 
and O 
test O 
formulations O 
were O 
applied O 
to O 
animals O 
once O 
a O 
day O 
from O 
day O 
" O 
0 O 
" O 
until O 
the O 
9th O 
day O 
. O 
Malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
were O 
studied O 
in O 
addition O 
to O 
histopathological O 
examinations O 
. O 
Treatment O 
with O 
F O 
. O 
brutia O 
extract O 
containing O 
cream O 
inhibited O 
lipid O 
peroxidation O 
by O 
a O 
35% O 
decrease O 
in O 
MDA B-ABBREVIATION 
and O 
46.8% O 
increase O 
in O 
SOD O 
activity O 
, O 
whereas O 
19.3% O 
decrease O 
in O 
MDA B-ABBREVIATION 
and O 
34.7% O 
increase O 
in O 
SOD O 
activity O 
were O 
attained O 
with O 
Pynogenol O 
compared O 
to O 
control O 
. O 
The O 
histological O 
data O 
revealed O 
a O 
better O 
performance O 
of O 
P O 
. O 
brutia O 
extract O 
enriched O 
formulation O 
in O 
terms O 
of O 
degeneration O 
of O 
hair O 
roots O 
, O 
increased O 
vascularization O 
and O 
a O 
decrease O 
in O 
necrotic O 
area O 
. O 
Consequently O 
, O 
a O 
high O 
wound O 
healing O 
activity O 
was O 
observed O 
in O 
animals O 
treated O 
with O 
P O 
. O 
brutia O 
extract O 
significantly O 
accelerating O 
the O 
wound O 
healing O 
process O 
. O 

, O 
Structure O 
Elucidation O 
, O 
and O 
Iron B-SYSTEMATIC 
-Binding O 
Properties O 
of O 
Lystabactins B-FAMILY 
, O 
Siderophores O 
Isolated O 
from O 
a O 
Marine O 
Pseudoalteromonas O 
sp O 
. O 

marine O 
bacterium O 
Pseudoalteromonas O 
sp O 
. O 
S2B O 
, O 
isolated O 
from O 
the O 
Gulf O 
of O 
Mexico O 
after O 
the O 
Deepwater O 
Horizon O 
oil O 
spill O 
, O 
was O 
found O 
to O 
produce O 
lystabactins B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
three O 
new O 
siderophores O 
. O 
The O 
structures O 
were O 
elucidated O 
through O 
mass O 
spectrometry O 
, O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
, O 
and O 
NMR O 
. O 
The O 
lystabactins B-FAMILY 
are O 
composed O 
of O 
serine B-TRIVIAL 
( O 
Ser B-FORMULA 
) O 
, O 
asparagine B-TRIVIAL 
( O 
Asn B-FORMULA 
) O 
, O 
two O 
formylated B-MULTIPLE 
/ I-MULTIPLE 
hydroxylated I-MULTIPLE 
ornithines I-MULTIPLE 
( O 
FOHOrn B-ABBREVIATION 
) O 
, O 
dihydroxy B-SYSTEMATIC 
benzoic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
Dhb B-ABBREVIATION 
) O 
, O 
and O 
a O 
very O 
unusual O 
nonproteinogenic B-NO_CLASS 
amino I-NO_CLASS 
acid I-NO_CLASS 
, O 
4,8-diamino-3-hydroxyoctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
LySta B-ABBREVIATION 
) O 
. O 
The O 
iron O 
- O 
binding O 
properties O 
of O 
the O 
compounds O 
were O 
investigated O 
through O 
a O 
spectrophotometric O 
competition O 
. O 

this O 
paper O 
, O 
we O 
present O 
different O 
strategies O 
to O 
vectorize O 
HldE O 
kinase O 
inhibitors O 
with O 
the O 
goal O 
to O 
improve O 
their O 
gram O 
- O 
negative O 
intracellular O 
concentration O 
. O 
Syntheses O 
and O 
biological O 
effects O 
of O 
siderophoric O 
, O 
aminoglycosidic O 
, O 
amphoteric O 
, O 
and O 
polycationic O 
vectors O 
are O 
discussed O 
. O 
While O 
siderophoric O 
and O 
amphoteric O 
vectorization O 
efforts O 
proved O 
to O 
be O 
disappointing O 
in O 
this O 
series O 
, O 
aminoglycosidic O 
and O 
polycationic O 
vectors O 
were O 
able O 
for O 
the O 
first O 
time O 
to O 
achieve O 
synergistic O 
effects O 
of O 
our O 
inhibitors O 
with O 
erythromycin B-TRIVIAL 
. O 
Although O 
these O 
effects O 
proved O 
to O 
be O 
nonspecific O 
, O 
this O 
study O 
provides O 
information O 
about O 
the O 
required O 
stereoelectronic O 
arrangement O 
of O 
the O 
polycationic O 
amines B-FAMILY 
and O 
their O 
basicity O 
requirements O 
to O 
fulfill O 
outer O 
membrane O 
destabilization O 
resulting O 
in O 
better O 
erythromycin B-TRIVIAL 
synergies O 
. O 

derivatives O 
as O 
inhibitors O 
of O 
mutant O 
superoxide B-TRIVIAL 
dismutase O 
1 O 
dependent O 
protein O 
aggregation O 
for O 
the O 
treatment O 
of O 
amyotrophic O 
lateral O 
sclerosis O 
. O 

arylsulfanylpyrazolone B-FAMILY 
and O 
aryloxanylpyrazolone B-FAMILY 
scaffolds O 
previously O 
were O 
reported O 
to O 
inhibit O 
Cu B-FORMULA 
/ O 
Zn B-FORMULA 
superoxide B-TRIVIAL 
dismutase O 
1 O 
dependent O 
protein O 
aggregation O 
and O 
to O 
extend O 
survival O 
in O 
the O 
ALS O 
mouse O 
model O 
. O 
However O 
, O 
further O 
evaluation O 
of O 
these O 
compounds O 
indicated O 
weak O 
pharmacokinetic O 
properties O 
and O 
a O 
relatively O 
low O 
maximum O 
tolerated O 
dose O 
. O 
On O 
the O 
basis O 
of O 
an O 
ADME O 
analysis O 
, O 
a O 
new O 
series O 
of O 
compounds O 
, O 
the O 
arylazanylpyrazolones B-FAMILY 
, O 
has O 
been O 
synthesized O 
, O 
and O 
structure O 
- O 
activity O 
relationships O 
were O 
determined O 
. O 
The O 
SAR O 
results O 
showed O 
that O 
the O 
pyrazolone B-SYSTEMATIC 
ring O 
is O 
critical O 
to O 
cellular O 
protection O 
. O 
The O 
NMR O 
, O 
IR O 
, O 
and O 
computational O 
analyses O 
suggest O 
that O 
phenol B-SYSTEMATIC 
-type O 
tautomers O 
of O 
the O 
pyrazolone B-SYSTEMATIC 
ring O 
are O 
the O 
active O 
pharmacophore O 
with O 
the O 
arylazanylpyrazolone B-FAMILY 
analogues O 
. O 
A O 
comparison O 
of O 
experimental O 
and O 
calculated O 
IR O 
spectra O 
is O 
shown O 
to O 
be O 
a O 
valuable O 
method O 
to O 
identify O 
the O 
predominant O 
tautomer O 
. O 

- O 
initiated O 
ring O 
- O 
opening O 
polymerization O 
of O 
O-carboxyanhydrides B-FAMILY 
for O 
the O 
preparation O 
of O 
anticancer O 
drug- O 
poly(O-carboxyanhydride) B-FAMILY 
nanoconjugates O 
. O 

report O 
a O 
novel O 
synthetic O 
strategy O 
of O 
polymer O 
- O 
drug O 
conjugates O 
for O 
nanoparticulate O 
drug O 
delivery O 
: O 
hydroxyl B-SYSTEMATIC 
-containing O 
drug O 
( O 
e.g O 
. O 
, O 
camptothecin B-TRIVIAL 
, O 
paclitaxel B-TRIVIAL 
, O 
doxorubicin B-TRIVIAL 
and O 
docetaxel B-TRIVIAL 
) O 
can O 
initiate O 
controlled O 
polymerization O 
of O 
phenyl B-SYSTEMATIC 
O-carboxyanhydride I-SYSTEMATIC 
( O 
Phe-OCA B-ABBREVIATION 
) O 
to O 
afford O 
drug-poly( O 
Phe-OCA B-ABBREVIATION 
) O 
conjugated O 
nanoparticles O 
, O 
termed O 
drug- O 
PheLA B-ABBREVIATION 
nanoconjugates O 
( O 
NCs O 
) O 
. O 
Our O 
new O 
NCs O 
have O 
well O 
- O 
controlled O 
physicochemical O 
properties O 
, O 
including O 
high O 
drug O 
loading O 
, O 
quantitative O 
drug O 
loading O 
efficiency O 
, O 
controlled O 
particle O 
size O 
with O 
narrow O 
particle O 
size O 
distribution O 
, O 
and O 
sustained O 
drug O 
release O 
profile O 
over O 
days O 
without O 
" O 
burst O 
" O 
release O 
effect O 
as O 
observed O 
in O 
conventional O 
polymer O 
/ O 
drug O 
encapsulates O 
. O 
Compared O 
with O 
polylactide B-FAMILY 
NCs O 
, O 
the O 
PheLA B-ABBREVIATION 
NCs O 
have O 
increased O 
noncovalent O 
hydrophobic O 
interchain O 
interactions O 
and O 
thereby O 
result O 
in O 
remarkable O 
stability O 
in O 
human O 
serum O 
with O 
negligible O 
particle O 
aggregation O 
. O 
Such O 
distinctive O 
properties O 
can O 
reduce O 
the O 
premature O 
disassembly O 
of O 
NCs O 
upon O 
dilution O 
in O 
the O 
bloodstream O 
and O 
prolong O 
NCs O 
' O 
in O 
vivo O 
circulation O 
with O 
the O 
enhancement O 
of O 
intratumoral O 
accumulation O 
of O 
NCs O 
, O 
which O 
has O 
a O 
bearing O 
on O 
therapeutic O 
effectiveness O 
. O 

overexpression O 
increases O 
EETs B-ABBREVIATION 
and O 
protects O 
against O 
angiotensin O 
II-induced O 
abdominal O 
aortic O 
aneurysm O 
in O 
mice O 
. O 

P450 O 
epoxygenase O 
2J2 O 
( O 
CYP2J2 O 
) O 
metabolizes O 
arachidonic B-FAMILY 
acids I-FAMILY 
to O 
form O 
epoxyeicosatrienoic B-FAMILY 
acids I-FAMILY 
( O 
EETs B-ABBREVIATION 
) O 
, O 
which O 
possess O 
various O 
beneficial O 
effects O 
on O 
the O 
cardiovascular O 
system O 
. O 
However O 
, O 
whether O 
increasing O 
EETs B-ABBREVIATION 
production O 
by O 
CYP2J2 O 
overexpression O 
in O 
vivo O 
could O 
prevent O 
abdominal O 
aortic O 
aneurysm O 
( O 
AAA O 
) O 
remains O 
unknown O 
. O 
Here O 
we O 
investigated O 
the O 
effects O 
of O 
recombinant O 
adeno O 
- O 
associated O 
virus O 
( O 
rAAV O 
) O 
- O 
mediated O 
CYP2J2 O 
overexpression O 
on O 
angiotensin O 
( O 
Ang O 
) O 
II-induced O 
AAA O 
in O 
apoE-deficient O 
mice O 
. O 
rAAV-CYP2J2 O 
delivery O 
led O 
to O 
an O 
abundant O 
aortic O 
CYP2J2 O 
expression O 
and O 
increased O 
EETs B-ABBREVIATION 
generation O 
. O 
It O 
was O 
shown O 
that O 
CYP2J2 O 
overexpression O 
attenuated O 
matrix O 
metalloproteinase O 
expression O 
and O 
activity O 
, O 
elastin O 
degradation O 
, O 
and O 
AAA O 
formation O 
, O 
which O 
was O 
associated O 
with O 
reduced O 
aortic O 
inflammation O 
and O 
macrophage O 
infiltration O 
. O 
In O 
cultured O 
vascular O 
smooth O 
muscle O 
cells O 
( O 
VSMCs O 
) O 
, O 
rAAV O 
- O 
mediated O 
CYP2J2 O 
overexpression O 
and O 
EETs B-ABBREVIATION 
markedly O 
suppressed O 
Ang O 
II-induced O 
inflammatory O 
cytokine O 
expression O 
. O 
Moreover O 
, O 
overexpressed O 
CYP2J2 O 
and O 
EETs B-ABBREVIATION 
inhibited O 
Ang O 
II-induced O 
macrophage O 
migration O 
in O 
a O 
VSMC-macrophage O 
coculture O 
system O 
. O 
We O 
further O 
indicated O 
that O 
these O 
protective O 
effects O 
were O 
mediated O 
by O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
(PPAR)γ O 
activation O 
. O 
Taken O 
together O 
, O 
these O 
results O 
provide O 
evidence O 
that O 
rAAV O 
- O 
mediated O 
CYP2J2 O 
overexpression O 
prevents O 
AAA O 
development O 
which O 
is O 
likely O 
via O 
PPARγ O 
activation O 
and O 
anti-inflammatory O 
action O 
, O 
suggesting O 
that O 
increasing O 
EETs B-ABBREVIATION 
levels O 
could O 
be O 
considered O 
as O 
a O 
potential O 
strategy O 
to O 
prevent O 
and O 
treat O 
AAA O 
. O 

date O 
, O 
single O 
- O 
molecule O 
RNA O 
science O 
has O 
been O 
developed O 
almost O 
exclusively O 
around O 
the O 
effect O 
of O 
metal O 
ions O 
as O 
folding O 
promoters O 
and O 
stabilizers O 
of O 
the O 
RNA O 
structure O 
. O 
Here O 
, O 
we O 
introduce O 
a O 
novel O 
strategy O 
that O 
combines O 
single O 
- O 
molecule O 
Förster O 
resonance O 
energy O 
transfer O 
( O 
FRET O 
) O 
and O 
chemical O 
denaturation O 
to O 
observe O 
and O 
manipulate O 
RNA O 
dynamics O 
. O 
We O 
demonstrate O 
that O 
the O 
competing O 
interplay O 
between O 
metal O 
ions O 
and O 
denaturant O 
agents O 
provides O 
a O 
platform O 
to O 
extract O 
information O 
that O 
otherwise O 
will O 
remain O 
hidden O 
with O 
current O 
methods O 
. O 
Using O 
the O 
adenine B-TRIVIAL 
-sensing O 
riboswitch O 
aptamer O 
as O 
a O 
model O 
, O 
we O 
provide O 
strong O 
evidence O 
for O 
a O 
rate O 
- O 
limiting O 
folding O 
step O 
of O 
the O 
aptamer O 
domain O 
being O 
modulated O 
through O 
ligand O 
binding O 
, O 
a O 
feature O 
that O 
is O 
important O 
for O 
regulation O 
of O 
the O 
controlled O 
gene O 
. O 
In O 
the O 
absence O 
of O 
ligand O 
, O 
the O 
rate O 
- O 
determining O 
step O 
is O 
dominated O 
by O 
the O 
formation O 
of O 
long O 
- O 
range O 
key O 
tertiary O 
contacts O 
between O 
peripheral O 
stem O 
- O 
loop O 
elements O 
. O 
In O 
contrast O 
, O 
when O 
the O 
adenine B-TRIVIAL 
ligand O 
interacts O 
with O 
partially O 
folded O 
messenger O 
RNAs O 
, O 
the O 
aptamer O 
requires O 
specifically O 
bound O 
Mg(2+) B-FORMULA 
ions O 
, O 
as O 
those O 
observed O 
in O 
the O 
crystal O 
structure O 
, O 
to O 
progress O 
further O 
towards O 
the O 
native O 
form O 
. O 
Moreover O 
, O 
despite O 
that O 
the O 
ligand O 
- O 
free O 
and O 
ligand O 
- O 
bound O 
states O 
are O 
indistinguishable O 
by O 
FRET O 
, O 
their O 
different O 
stability O 
against O 
urea B-TRIVIAL 
-induced O 
denaturation O 
allowed O 
us O 
to O 
discriminate O 
them O 
, O 
even O 
when O 
they O 
coexist O 
within O 
a O 
single O 
FRET O 
trajectory O 
; O 
a O 
feature O 
not O 
accessible O 
by O 
existing O 
methods O 
. O 

protein O 
directly O 
activated O 
by O 
cAMP B-ABBREVIATION 
( O 
epac O 
) O 
: O 
a O 
multidomain O 
cAMP B-ABBREVIATION 
mediator O 
in O 
the O 
regulation O 
of O 
diverse O 
biological O 
functions O 
. O 

the O 
discovery O 
nearly O 
60 O 
years O 
ago O 
, O 
cAMP B-ABBREVIATION 
is O 
envisioned O 
as O 
one O 
of O 
the O 
most O 
universal O 
and O 
versatile O 
second O 
messengers O 
. O 
The O 
tremendous O 
feature O 
of O 
cAMP B-ABBREVIATION 
to O 
tightly O 
control O 
highly O 
diverse O 
physiologic O 
processes O 
, O 
including O 
calcium B-SYSTEMATIC 
homeostasis O 
, O 
metabolism O 
, O 
secretion O 
, O 
muscle O 
contraction O 
, O 
cell O 
fate O 
, O 
and O 
gene O 
transcription O 
, O 
is O 
reflected O 
by O 
the O 
award O 
of O 
five O 
Nobel O 
prizes O 
. O 
The O 
discovery O 
of O 
Epac O 
( O 
exchange O 
protein O 
directly O 
activated O 
by O 
cAMP B-ABBREVIATION 
) O 
has O 
ignited O 
a O 
new O 
surge O 
of O 
cAMP B-ABBREVIATION 
-related O 
research O 
and O 
has O 
depicted O 
novel O 
cAMP B-ABBREVIATION 
properties O 
independent O 
of O 
protein O 
kinase O 
A O 
and O 
cyclic O 
nucleotide B-FAMILY 
-gated O 
channels O 
. O 
The O 
multidomain O 
architecture O 
of O 
Epac O 
determines O 
its O 
activity O 
state O 
and O 
allows O 
cell O 
- O 
type O 
specific O 
protein O 
- O 
protein O 
and O 
protein O 
- O 
lipid O 
interactions O 
that O 
control O 
fine O 
- O 
tuning O 
of O 
pivotal O 
biologic O 
responses O 
through O 
the O 
" O 
old O 
" O 
second O 
messenger O 
cAMP B-ABBREVIATION 
. O 
Compartmentalization O 
of O 
cAMP B-ABBREVIATION 
in O 
space O 
and O 
time O 
, O 
maintained O 
by O 
A-kinase O 
anchoring O 
proteins O 
, O 
phosphodiesterases O 
, O 
and O 
β-arrestins O 
, O 
contributes O 
to O 
the O 
Epac O 
signalosome O 
of O 
small O 
GTPases O 
, O 
phospholipases O 
, O 
mitogen- O 
and O 
lipid O 
- O 
activated O 
kinases O 
, O 
and O 
transcription O 
factors O 
. O 
These O 
novel O 
cAMP B-ABBREVIATION 
sensors O 
seem O 
to O 
implement O 
certain O 
unexpected O 
signaling O 
properties O 
of O 
cAMP B-ABBREVIATION 
and O 
thereby O 
to O 
permit O 
delicate O 
adaptations O 
of O 
biologic O 
responses O 
. O 
Agonists O 
and O 
antagonists O 
selective O 
for O 
Epac O 
are O 
developed O 
and O 
will O 
support O 
further O 
studies O 
on O 
the O 
biologic O 
net O 
outcome O 
of O 
the O 
activation O 
of O 
Epac O 
. O 
This O 
will O 
increase O 
our O 
current O 
knowledge O 
on O 
the O 
pathophysiology O 
of O 
devastating O 
diseases O 
, O 
such O 
as O 
diabetes O 
, O 
cognitive O 
impairment O 
, O 
renal O 
and O 
heart O 
failure O 
, O 
( O 
pulmonary O 
) O 
hypertension O 
, O 
asthma O 
, O 
and O 
chronic O 
obstructive O 
pulmonary O 
disease O 
. O 
Further O 
insights O 
into O 
the O 
cAMP B-ABBREVIATION 
dynamics O 
executed O 
by O 
the O 
Epac O 
signalosome O 
will O 
help O 
to O 
optimize O 
the O 
pharmacological O 
treatment O 
of O 
these O 
diseases O 
. O 

- O 
induced O 
synthesis O 
of O 
uniform O 
single O 
- O 
crystalline O 
sulphide B-SYSTEMATIC 
-based O 
quaternary O 
- O 
alloy O 
hexagonal O 
nanorings O 
for O 
highly O 
efficient O 
photocatalytic O 
hydrogen B-SYSTEMATIC 
evolution O 
. O 

single O 
- O 
crystalline O 
quaternary O 
sulphide B-SYSTEMATIC 
nanoring O 
photocatalysts O 
are O 
synthesized O 
via O 
the O 
copper B-SYSTEMATIC 
-ion O 
- O 
induced O 
Kirkendall O 
effect O 
and O 
is O 
followed O 
by O 
a O 
cation O 
exchange O 
reaction O 
. O 
The O 
obtained O 
Cu(2+) B-FORMULA 
-doped O 
ZnIn2 B-FORMULA 
S4 I-FORMULA 
nanorings O 
show O 
highly O 
preserved O 
morphology O 
, O 
and O 
demonstrate O 
high O 
visible O 
- O 
light O 
- O 
driven O 
photocatalytic O 
activity O 
for O 
H2 B-FORMULA 
evolution O 
in O 
water O 
splitting O 
. O 

tail O 
loss O 
is O 
an O 
evolutionary O 
mechanism O 
for O 
liberating O 
marapsins O 
and O 
other O 
type O 
I O 
serine B-TRIVIAL 
proteases O 
from O 
transmembrane O 
anchors O 
. O 

and O 
mouse O 
marapsins O 
( O 
Prss27 O 
) O 
are O 
serine B-TRIVIAL 
proteases O 
preferentially O 
expressed O 
by O 
stratified O 
squamous O 
epithelia O 
. O 
However O 
, O 
mouse O 
marapsin O 
contains O 
a O 
transmembrane O 
anchor O 
absent O 
from O 
the O 
human O 
enzyme O 
. O 
To O 
gain O 
insights O 
into O 
physical O 
forms O 
, O 
activities O 
, O 
inhibition O 
, O 
and O 
roles O 
in O 
epithelial O 
differentiation O 
, O 
we O 
traced O 
tail O 
loss O 
in O 
human O 
marapsin O 
to O 
a O 
nonsense O 
mutation O 
in O 
an O 
ancestral O 
ape O 
, O 
compared O 
substrate O 
preferences O 
of O 
mouse O 
and O 
human O 
marapsins O 
with O 
those O 
of O 
the O 
epithelial O 
peptidase O 
prostasin O 
, O 
designed O 
a O 
selective O 
substrate O 
and O 
inhibitor O 
, O 
and O 
generated O 
Prss27-null O 
mice O 
. O 
Phylogenetic O 
analysis O 
predicts O 
that O 
most O 
marapsins O 
are O 
transmembrane O 
proteins O 
. O 
However O 
, O 
nonsense O 
mutations O 
caused O 
membrane O 
anchor O 
loss O 
in O 
three O 
clades O 
: O 
human O 
/ O 
bonobo O 
/ O 
chimpanzee O 
, O 
guinea O 
pig O 
/ O 
degu O 
/ O 
tuco O 
- O 
tuco O 
/ O 
mole O 
rat O 
, O 
and O 
cattle O 
/ O 
yak O 
. O 
Most O 
marapsin O 
- O 
related O 
proteases O 
, O 
including O 
prostasins O 
, O 
are O 
type O 
I O 
transmembrane O 
proteins O 
, O 
but O 
the O 
closest O 
relatives O 
( O 
prosemins O 
) O 
are O 
not O 
. O 
Soluble O 
mouse O 
and O 
human O 
marapsins O 
are O 
tryptic O 
with O 
subsite O 
preferences O 
distinct O 
from O 
those O 
of O 
prostasin O 
, O 
lack O 
general O 
proteinase O 
activity O 
, O 
and O 
unlike O 
prostasins O 
resist O 
antiproteases O 
, O 
including O 
leupeptin O 
, O 
aprotinin O 
, O 
serpins O 
, O 
and O 
α2-macroglobulin O 
, O 
suggesting O 
the O 
presence O 
of O 
non-canonical O 
active O 
sites O 
. O 
Prss27-null O 
mice O 
develop O 
normally O 
in O 
barrier O 
conditions O 
and O 
are O 
fertile O 
without O 
overt O 
epithelial O 
defects O 
, O 
indicating O 
that O 
marapsin O 
does O 
not O 
play O 
critical O 
, O 
non-redundant O 
roles O 
in O 
development O 
, O 
reproduction O 
, O 
or O 
epithelial O 
differentiation O 
. O 
In O 
conclusion O 
, O 
marapsins O 
are O 
conserved O 
, O 
inhibitor O 
- O 
resistant O 
, O 
tryptic B-FAMILY 
peptidases O 
. O 
Although O 
marapsins O 
are O 
type O 
I O 
transmembrane O 
proteins O 
in O 
their O 
typical O 
form O 
, O 
they O 
mutated O 
independently O 
into O 
anchorless O 
forms O 
in O 
several O 
mammalian O 
clades O 
, O 
including O 
one O 
involving O 
humans O 
. O 
Similar O 
pathways O 
appear O 
to O 
have O 
been O 
traversed O 
by O 
prosemins O 
and O 
tryptases O 
, O 
suggesting O 
that O 
mutational O 
tail O 
loss O 
is O 
an O 
important O 
means O 
of O 
evolving O 
new O 
functions O 
of O 
tryptic O 
serine B-TRIVIAL 
proteases O 
from O 
transmembrane O 
ancestors O 
. O 

replacement O 
therapy O 
corrects O 
a O 
core O 
defect O 
of O 
diabetes O 
pathophysiology O 
. O 
Since O 
its O 
introduction O 
as O 
a O 
therapeutic O 
modality O 
almost O 
100 O 
years O 
ago O 
, O 
insulin O 
therapy O 
has O 
undergone O 
remarkable O 
changes O 
in O 
purity O 
and O 
ability O 
to O 
provide O 
more O 
physiologic O 
control O 
of O 
blood O 
glucose B-TRIVIAL 
levels O 
. O 
With O 
glucose B-TRIVIAL 
-lowering O 
potential O 
limited O 
only O 
by O 
risks O 
of O 
hypoglycaemia O 
, O 
which O 
remains O 
the O 
major O 
limitation O 
in O 
our O 
ability O 
to O 
achieve O 
glycaemic O 
goals O 
, O 
insulin O 
replacement O 
therapy O 
remains O 
a O 
cornerstone O 
of O 
therapy O 
. O 
Major O 
progress O 
in O 
reducing O 
the O 
risks O 
of O 
hypoglycemia O 
has O 
occurred O 
with O 
the O 
development O 
of O 
insulin O 
analogs O 
. O 
This O 
review O 
article O 
briefly O 
chronicles O 
the O 
evolution O 
of O 
insulin O 
replacement O 
strategies O 
, O 
highlighting O 
both O 
challenges O 
in O 
pharmaceutical O 
development O 
and O 
patient O 
acceptance O 
, O 
underscoring O 
achievements O 
, O 
as O 
well O 
as O 
denoting O 
what O 
improvements O 
are O 
still O 
needed O 
. O 

enhancement O 
of O 
nonlinear O 
optical O 
response O 
in O 
a O 
hybrid O 
nanobiomaterial O 
consisting O 
of O 
bacteriorhodopsin O 
and O 
cadmium B-SYSTEMATIC 
telluride I-SYSTEMATIC 
quantum O 
dots O 
. O 

- O 
temperature O 
and O 
pressure O 
- O 
induced O 
ferroelectricity O 
in O 
hydrogen B-SYSTEMATIC 
-bonded O 
supramolecular O 
crystals O 
of O 
anilic B-FAMILY 
acids I-FAMILY 
and O 
2,3-di(2-pyridinyl)pyrazine B-SYSTEMATIC 
. O 

of O 
anilic B-FAMILY 
acids I-FAMILY 
( O 
H2xa B-ABBREVIATION 
) O 
and O 
2,3-di(2-pyridinyl)pyrazine B-SYSTEMATIC 
( O 
dppz B-ABBREVIATION 
) O 
affords O 
a O 
variety O 
of O 
molecular O 
geometries O 
, O 
including O 
hydrogen B-SYSTEMATIC 
-bonding O 
and O 
supramolecular O 
structures O 
. O 
Proton O 
- O 
transferred O 
1 O 
: O 
1 O 
salts O 
of O 
[H-dppz][Hca] B-ABBREVIATION 
and O 
[H-dppz][Hba] B-ABBREVIATION 
( O 
H2ca B-ABBREVIATION 
= O 
chloranilic B-TRIVIAL 
acid I-TRIVIAL 
, O 
H2ba B-ABBREVIATION 
= O 
bromanilic B-TRIVIAL 
acid I-TRIVIAL 
) O 
were O 
found O 
to O 
host O 
room O 
- O 
temperature O 
ferroelectricity O 
with O 
a O 
spontaneous O 
polarization O 
of O 
3-4 O 
μC O 
/ O 
cm(2) O 
along O 
the O 
hydrogen B-SYSTEMATIC 
-bonded O 
chains O 
. O 
Compared O 
with O 
the O 
Curie O 
points O 
of O 
other O 
supramolecular O 
ferroelectrics O 
, O 
those O 
of O 
the O 
salts O 
are O 
relatively O 
high O 
( O 
402 O 
K O 
and O 
> O 
420 O 
K O 
, O 
respectively O 
) O 
because O 
of O 
the O 
elongated O 
hydrogen B-SYSTEMATIC 
bonds O 
, O 
which O 
stabilize O 
the O 
proton O 
- O 
ordered O 
state O 
against O 
thermal O 
agitation O 
. O 
In O 
addition O 
to O 
the O 
ferroelectric O 
black O 
( O 
α O 
) O 
form O 
, O 
dppz B-ABBREVIATION 
and O 
H2ba B-ABBREVIATION 
gave O 
two O 
different O 
crystal O 
forms O 
with O 
a O 
2 O 
: O 
3 O 
ratio O 
: O 
the O 
brown O 
β O 
form O 
of O 
[H(1.5)-dppz]2[Hba]3 B-FORMULA 
and O 
the O 
brownish O 
- O 
red O 
γ O 
form O 
of O 
[H-dppz]2[Hba]2[H2ba] B-FORMULA 
. O 
Mixed O 
solutions O 
of O 
dppz B-ABBREVIATION 
with O 
the O 
less O 
acidic O 
fluoranilic B-TRIVIAL 
acid I-TRIVIAL 
( O 
H2fa B-ABBREVIATION 
) O 
exhibit O 
valence O 
instability O 
; O 
the O 
H2fa B-ABBREVIATION 
molecules O 
remain O 
mostly O 
neutral O 
in O 
absolute O 
ethanol B-SYSTEMATIC 
, O 
whereas O 
methanol B-SYSTEMATIC 
( O 
MeOH B-FORMULA 
) O 
solution O 
apparently O 
increases O 
the O 
deprotonated O 
Hfa(-) B-ABBREVIATION 
content O 
. O 
Crystallizations O 
of O 
these O 
solutions O 
gave O 
a O 
neutral O 
[dppz][H2fa] B-ABBREVIATION 
cocrystal O 
and O 
ionic O 
[H-dppz(+)][Hfa(-)]·MeOH B-FORMULA 
salt O 
, O 
respectively O 
. O 
The O 
ferroelectricity O 
induced O 
by O 
a O 
modest O 
hydrostatic O 
pressure O 
corroborates O 
the O 
conclusion O 
that O 
the O 
ionic O 
state O 
with O 
a O 
dipolar O 
[H-dppz(+)][Hfa(-)] B-FORMULA 
chain O 
is O 
energetically O 
close O 
to O 
the O 
nonpolar O 
neutral O 
ground O 
state O 
of O 
the O 
[dppz][H2fa] B-ABBREVIATION 
crystal O 
. O 

multiple O 
targeted O 
drug O 
carrying O 
bilayer O 
membrane O 
for O 
preventing O 
an O 
abdominal O 
adhesion O 
is O 
prepared O 
by O 
electrospinning O 
. O 
Two O 
bioactive O 
drugs O 
were O 
successfully O 
incorporated O 
into O 
this O 
bilayer O 
membrane O 
and O 
can O 
be O 
independently O 
released O 
from O 
nanofibrous O 
scaffolds O 
without O 
losing O 
structural O 
integrity O 
and O 
functionality O 
of O 
the O 
anti-adhesion O 
membrane O 
. O 
Besides O 
, O 
the O 
drug O 
release O 
profile O 
could O 
be O 
easily O 
adjusted O 
by O 
optimizing O 
the O 
swelling O 
behavior O 
of O 
the O 
fibrous O 
scaffold O 
. O 
The O 
inner O 
layer O 
of O 
the O 
bilayered O 
fibrous O 
membranes O 
loaded O 
with O 
carbazochrome B-SYSTEMATIC 
sodium I-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
CA O 
) O 
showed O 
an O 
excellent O 
vascular O 
hemostatic O 
efficacy O 
and O 
formed O 
little O 
clot O 
during O 
in O 
vivo O 
experiment O 
. O 
The O 
outer O 
layer O 
loaded O 
with O 
tinidazole B-TRIVIAL 
( O 
TI O 
) O 
had O 
outstanding O 
antibacterial O 
effect O 
against O 
the O 
anaerobe O 
. O 
We O 
believe O 
this O 
approach O 
could O 
serve O 
as O 
a O 
model O 
technique O 
to O 
guide O 
the O 
design O 
of O 
implants O 
with O 
drug O 
delivery O 
functions O 
. O 

tractable O 
click O 
hydrogels O 
for O 
three O 
- O 
dimensional O 
cell O 
culture O 
formed O 
using O 
tetrazine B-FAMILY 
- O 
norbornene B-TRIVIAL 
chemistry O 
. O 

implementation O 
of O 
bio O 
- O 
orthogonal O 
click O 
chemistries O 
is O 
a O 
topic O 
of O 
growing O 
importance O 
in O 
the O 
field O 
of O 
biomaterials O 
, O 
as O 
it O 
is O 
enabling O 
the O 
development O 
of O 
increasingly O 
complex O 
hydrogel O 
materials O 
capable O 
of O 
providing O 
dynamic O 
, O 
cell O 
- O 
instructive O 
microenvironments O 
. O 
Here O 
, O 
we O 
introduce O 
the O 
tetrazine B-FAMILY 
- O 
norbornene B-TRIVIAL 
inverse O 
electron O 
demand O 
Diels-Alder O 
reaction O 
as O 
a O 
new O 
cross O 
- O 
linking O 
chemistry O 
for O 
the O 
formation O 
of O 
cell O 
laden O 
hydrogels O 
. O 
The O 
fast O 
reaction O 
rate O 
and O 
irreversible O 
nature O 
of O 
this O 
click O 
reaction O 
allowed O 
for O 
hydrogel O 
formation O 
within O 
minutes O 
when O 
a O 
multifunctional O 
PEG B-ABBREVIATION 
- O 
tetrazine B-FAMILY 
macromer O 
was O 
reacted O 
with O 
a O 
dinorbornene B-TRIVIAL 
peptide O 
. O 
In O 
addition O 
, O 
the O 
cytocompatibility O 
of O 
the O 
polymerization O 
led O 
to O 
high O 
postencapsulation O 
viability O 
of O 
human O 
mesenchymal O 
stem O 
cells O 
, O 
and O 
the O 
specificity O 
of O 
the O 
tetrazine B-FAMILY 
- O 
norbornene B-TRIVIAL 
reaction O 
was O 
exploited O 
for O 
sequential O 
modification O 
of O 
the O 
network O 
via O 
thiol B-FAMILY 
- O 
ene B-SYSTEMATIC 
photochemistry O 
. O 
These O 
advantages O 
, O 
combined O 
with O 
the O 
synthetic O 
accessibility O 
of O 
the O 
tetrazine B-FAMILY 
molecule O 
compared O 
to O 
other O 
bio O 
- O 
orthogonal O 
click O 
reagents O 
, O 
make O 
this O 
cross O 
- O 
linking O 
chemistry O 
an O 
interesting O 
and O 
powerful O 
new O 
tool O 
for O 
the O 
development O 
of O 
cell O 
- O 
instructive O 
hydrogels O 
for O 
tissue O 
engineering O 
applications O 
. O 

low O 
- O 
frequency O 
magnetic O 
field O 
induces O 
manganese B-SYSTEMATIC 
accumulation O 
in O 
brain O 
, O 
kidney O 
and O 
liver O 
of O 
rats O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
the O 
effects O 
of O 
extremely O 
low O 
- O 
frequency O 
magnetic O 
field O 
( O 
ELF-MF O 
) O 
on O 
accumulation O 
of O 
manganese B-SYSTEMATIC 
( O 
Mn B-FORMULA 
) O 
in O 
the O 
kidney O 
, O 
liver O 
and O 
brain O 
of O 
rats O 
. O 
A O 
total O 
of O 
40 O 
rats O 
were O 
randomly O 
divided O 
into O 
eight O 
groups O 
. O 
Four O 
control O 
groups O 
received O 
0 O 
, O 
3.75 O 
, O 
15 O 
and O 
60 O 
mg O 
Mn B-FORMULA 
per O 
kg O 
body O 
weight O 
orally O 
every O 
2 O 
days O 
for O 
45 O 
days O 
, O 
respectively O 
. O 
The O 
remaining O 
four O 
groups O 
received O 
same O 
concentrations O 
of O 
Mn B-FORMULA 
and O 
were O 
also O 
exposed O 
to O 
ELF-MF O 
( O 
1.5 O 
mT O 
; O 
50 O 
Hz O 
) O 
for O 
4 O 
h O 
for O 
5 O 
days O 
a O 
week O 
during O 
45 O 
days O 
. O 
Following O 
the O 
last O 
exposure O 
, O 
kidney O 
, O 
liver O 
and O 
brain O 
were O 
taken O 
from O 
all O 
rats O 
and O 
they O 
were O 
analyzed O 
for O 
Mn B-FORMULA 
accumulation O 
levels O 
using O 
an O 
inductively O 
coupled O 
plasma O 
- O 
optical O 
emission O 
spectrometer O 
. O 
In O 
result O 
of O 
the O 
current O 
study O 
, O 
we O 
observed O 
that O 
Mn B-FORMULA 
levels O 
in O 
brain O 
, O 
kidney O 
and O 
liver O 
were O 
higher O 
in O 
Mn B-FORMULA 
groups O 
than O 
in O 
control O 
groups O 
. O 
Mn B-FORMULA 
levels O 
in O 
brain O 
, O 
kidney O 
and O 
liver O 
were O 
also O 
higher O 
in O 
Mn B-FORMULA 
plus O 
ELF-MF O 
groups O 
than O 
in O 
Mn B-FORMULA 
groups O 
. O 
In O 
conclusion O 
, O 
result O 
of O 
the O 
current O 
study O 
showed O 
that O 
the O 
ELF-MF O 
induced O 
manganese B-SYSTEMATIC 
accumulation O 
in O 
kidney O 
, O 
liver O 
and O 
brain O 
of O 
rats O 
. O 

respiratory O 
distress O 
syndrome O 
due O 
to O 
exposure O 
to O 
high O 
- O 
concentration O 
mixture O 
of O 
ethenone B-SYSTEMATIC 
and O 
crotonaldehyde B-TRIVIAL 
. O 

: O 
Acute O 
inhalational O 
exposure O 
leads O 
to O 
rapidly O 
progressive O 
acute O 
respiratory O 
distress O 
syndrome O 
( O 
ARDS O 
) O 
. O 
This O 
report O 
is O 
the O 
first O 
one O 
to O 
present O 
a O 
patient O 
with O 
ARDS O 
in O 
relation O 
to O 
long O 
- O 
standing O 
exposure O 
to O 
a O 
high O 
- O 
concentration O 
mixture O 
of O 
ethenone B-SYSTEMATIC 
and O 
crotonaldehyde B-TRIVIAL 
. O 
Case O 
report O 
: O 
A O 
male O 
worker O 
in O 
a O 
chemical O 
plant O 
was O 
accidentally O 
exposed O 
to O 
the O 
mixture O 
of O 
high O 
- O 
concentrated O 
ethenone B-SYSTEMATIC 
and O 
crotonaldehyde B-TRIVIAL 
for O 
5 O 
min O 
in O 
an O 
open O 
space O 
and O 
worked O 
continuously O 
in O 
the O 
polluted O 
area O 
for O 
approximately O 
12 O 
h O 
. O 
On O 
admission O 
, O 
he O 
was O 
conscious O 
with O 
the O 
following O 
vital O 
parameters O 
: O 
blood O 
pressure O 
, O 
151 O 
/ O 
91 O 
mmHg O 
; O 
pulse O 
rate O 
, O 
107 O 
beats O 
/ O 
min O 
; O 
respiratory O 
rate O 
, O 
30 O 
breaths O 
/ O 
min O 
; O 
temperature O 
, O 
37.6°C O 
; O 
oxygen B-SYSTEMATIC 
saturation O 
, O 
92% O 
supported O 
by O 
mask O 
saturation O 
10 O 
L O 
/ O 
min O 
; O 
arterial O 
blood O 
gases O 
showed O 
P O 
/ O 
F O 
oxygen B-SYSTEMATIC 
ratio O 
of O 
less O 
than O 
200 O 
. O 
Physical O 
examination O 
disclosed O 
decreased O 
bilateral O 
vesicular O 
sounds O 
. O 
A O 
chest O 
computed O 
tomography O 
revealed O 
bilateral O 
nonsegmental O 
ground O 
- O 
glass O 
opacities O 
. O 
The O 
patient O 
was O 
mechanically O 
ventilated O 
and O 
treated O 
with O 
corticosteroid O 
. O 
The O 
patient O 
was O 
discharged O 
without O 
any O 
symptoms O 
. O 
CONCLUSION O 
: O 
Exposure O 
to O 
mixtures O 
of O 
ethenone B-SYSTEMATIC 
and O 
crotonaldehyde B-TRIVIAL 
can O 
cause O 
severe O 
pulmonary O 
injury O 
leading O 
to O 
delayed O 
ARDS O 
. O 

, O 
we O 
statistically O 
identified O 
the O 
critical O 
factor O 
of O 
the O 
granulation O 
rate O 
during O 
the O 
fluidized O 
bed O 
granulation O 
process O 
. O 
Lactose B-TRIVIAL 
was O 
selected O 
as O 
the O 
excipient O 
and O 
was O 
granulated O 
with O 
several O 
binders O 
, O 
including O 
hydroxypropyl B-SYSTEMATIC 
cellulose O 
, O 
hydroxypropyl B-SYSTEMATIC 
methyl I-SYSTEMATIC 
cellulose O 
, O 
and O 
polyvinylpyrrolidone B-SYSTEMATIC 
. O 
The O 
viscosity O 
, O 
density O 
, O 
and O 
surface O 
tension O 
of O 
the O 
binder O 
solution O 
, O 
contact O 
angle O 
, O 
and O 
the O 
work O 
done O 
during O 
adhesion O 
and O 
cohesion O 
between O 
the O 
binder O 
and O 
lactose B-TRIVIAL 
, O 
mist O 
diameter O 
, O 
Stokes O 
number O 
, O 
and O 
the O 
dimension O 
of O 
the O 
droplet O 
were O 
considered O 
. O 
The O 
Stokes O 
number O 
was O 
defined O 
as O 
the O 
ratio O 
of O 
the O 
inertial O 
force O 
to O 
the O 
viscous O 
- O 
damping O 
force O 
of O 
a O 
particle O 
. O 
We O 
confirmed O 
that O 
droplet O 
diameter O 
after O 
adhesion O 
had O 
the O 
highest O 
correlation O 
coefficient O 
with O 
the O 
granulation O 
rate O 
constant O 
in O 
our O 
investigated O 
parameters O 
. O 
Partial O 
least O 
squares O 
regression O 
revealed O 
two O 
critical O 
principal O 
components O 
of O 
the O 
granulation O 
rate O 
: O 
one O 
relating O 
to O 
the O 
droplet O 
dimension O 
, O 
which O 
is O 
composed O 
of O 
mist O 
diameter O 
and O 
diameter O 
and O 
thickness O 
of O 
the O 
droplet O 
after O 
adhesion O 
of O 
the O 
binder O 
to O 
the O 
lactose B-TRIVIAL 
surface O 
; O 
and O 
the O 
other O 
relating O 
to O 
wettability O 
, O 
which O 
involves O 
the O 
work O 
done O 
during O 
adhesion O 
and O 
cohesion O 
, O 
surface O 
tension O 
, O 
and O 
the O 
thickness O 
of O 
the O 
droplet O 
after O 
adhesion O 
of O 
the O 
binder O 
to O 
the O 
lactose B-TRIVIAL 
surface O 
. O 

analogues O 
from O 
the O 
endophytic O 
fungus O 
Sarocladium O 
kiliense O 
. O 

new O 
12-membered O 
ring O 
lactone B-FAMILY 
, O 
(3S),(6R)-6-hydroxylasiodiplodin B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
with O 
two O 
known O 
analogues O 
, O 
(3R)-lasiodiplodin B-TRIVIAL 
( O 
2 O 
) O 
, O 
and O 
(3R),(5S)-5-hydroxylasiodiplodin B-SYSTEMATIC 
( O 
3 O 
) O 
were O 
isolated O 
from O 
the O 
EtOH B-FORMULA 
extracts O 
of O 
normal O 
Apriona O 
germari O 
(Hope)-associated O 
fungus O 
Sarocladium O 
kiliense O 
grown O 
in O 
rice O 
medium O 
. O 
The O 
structures O 
of O 
compounds O 
1-3 O 
were O 
elucidated O 
by O 
a O 
combination O 
of O 
spectroscopic O 
data O 
interpretation O 
, O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
analysis O 
, O 
and O 
modified O 
Mosher's O 
method O 
. O 

of O 
modified O 
siRNA O 
molecules O 
incorporating O 
5-fluoro-2'-deoxyuridine B-SYSTEMATIC 
residues O 
to O 
enhance O 
cytotoxicity O 
. O 

small O 
interfering O 
RNAs O 
( O 
siRNAs O 
) O 
are O 
composed O 
of O 
chemically O 
modified O 
nucleotides O 
, O 
which O 
enhance O 
RNA O 
stability O 
and O 
increase O 
affinity O 
in O 
Watson-Crick O 
base O 
pairing O 
. O 
However O 
, O 
the O 
precise O 
fate O 
of O 
such O 
modified O 
nucleotides O 
once O 
the O 
siRNA O 
is O 
degraded O 
within O 
the O 
cell O 
is O 
unknown O 
. O 
Previously O 
, O 
we O 
demonstrated O 
that O 
deoxythymidine B-SYSTEMATIC 
release O 
from O 
degraded O 
siRNAs O 
reversed O 
the O 
cytotoxicity O 
of O 
thymidylate O 
synthase O 
(TS)-targeted O 
siRNAs O 
and O 
other O 
TS O 
inhibitor O 
compounds O 
. O 
We O 
hypothesized O 
that O 
siRNAs O 
could O 
be O 
designed O 
with O 
specific O 
nucleoside O 
analogues O 
that O 
, O 
once O 
released O 
, O 
would O 
enhance O 
siRNA O 
cytotoxicity O 
. O 
TS-targeted O 
siRNAs O 
were O 
designed O 
that O 
contained O 
5-fluoro-2'-deoxyuridine B-SYSTEMATIC 
( O 
FdU B-ABBREVIATION 
) O 
moieties O 
at O 
various O 
locations O 
within O 
the O 
siRNA O 
. O 
After O 
transfection O 
, O 
these O 
siRNAs O 
suppressed O 
TS O 
protein O 
and O 
messenger O 
RNA O 
expression O 
with O 
different O 
efficiencies O 
depending O 
on O 
the O 
location O 
of O 
the O 
FdU B-ABBREVIATION 
modification O 
. O 
FdU B-ABBREVIATION 
was O 
rapidly O 
released O 
from O 
the O 
siRNA O 
as O 
evidenced O 
by O 
formation O 
of O 
the O 
covalent O 
inhibitory O 
ternary O 
complex O 
formed O 
between O 
TS O 
protein O 
and O 
the O 
FdU B-ABBREVIATION 
metabolite O 
, O 
FdUMP B-ABBREVIATION 
. O 
These O 
modified O 
siRNAs O 
exhibited O 
10-100-fold O 
greater O 
cytotoxicity O 
and O 
induced O 
multiple O 
DNA O 
damage O 
repair O 
and O 
apoptotic O 
pathways O 
when O 
compared O 
with O 
control O 
siRNAs O 
. O 
The O 
strategy O 
of O 
designing O 
siRNA O 
molecules O 
that O 
incorporate O 
cytotoxic O 
nucleosides O 
represents O 
a O 
potentially O 
novel O 
drug O 
development O 
approach O 
for O 
the O 
treatment O 
of O 
cancer O 
and O 
other O 
human O 
diseases O 
. O 

luminescent O 
water O 
- O 
soluble O 
quaternary O 
Zn B-FORMULA 
- O 
Ag B-FORMULA 
- O 
In B-FORMULA 
- O 
S B-FORMULA 
quantum O 
dots O 
for O 
tumor O 
cell O 
- O 
targeted O 
imaging O 
. O 

the O 
synthesis O 
and O 
biomedical O 
applications O 
of O 
biocompatible O 
quantum O 
dots O 
( O 
QDs O 
) O 
is O 
currently O 
one O 
of O 
the O 
fastest O 
growing O 
fields O 
of O 
nanotechnology O 
. O 
Hence O 
, O 
in O 
this O 
work O 
, O 
we O 
present O 
a O 
facile O 
approach O 
to O 
produce O 
water O 
- O 
soluble O 
( O 
cadmium B-SYSTEMATIC 
-free O 
) O 
quaternary O 
Zn B-FORMULA 
- O 
Ag B-FORMULA 
- O 
In B-FORMULA 
- O 
S B-FORMULA 
( O 
ZAIS B-ABBREVIATION 
) O 
QDs O 
. O 
Their O 
efficient O 
photoluminescence O 
( O 
PL O 
) O 
emissions O 
can O 
be O 
tuned O 
widely O 
in O 
the O 
range O 
of O 
525-625 O 
nm O 
by O 
controlling O 
the O 
size O 
and O 
composition O 
of O 
the O 
QDs O 
with O 
the O 
PL O 
quantum O 
yields O 
( O 
QYs O 
) O 
of O 
15-30% O 
. O 
These O 
highly O 
luminescent O 
ZAIS B-ABBREVIATION 
QDs O 
are O 
less O 
toxic O 
due O 
to O 
the O 
absence O 
of O 
highly O 
toxic O 
cadmium B-SYSTEMATIC 
, O 
and O 
can O 
be O 
versatilely O 
modified O 
by O 
a O 
DHLA-PEG B-ABBREVIATION 
-based O 
ligand O 
. O 
Importantly O 
, O 
after O 
being O 
modified O 
by O 
tumor O 
cell O 
- O 
specific O 
targeting O 
ligands O 
( O 
e.g O 
. O 
, O 
folate B-TRIVIAL 
and O 
RGD O 
peptide O 
) O 
, O 
the O 
PEGylated O 
quaternary O 
QDs O 
show O 
potential O 
applications O 
in O 
tumor O 
cell O 
imaging O 
as O 
a O 
promising O 
alternative O 
for O 
Cd B-FORMULA 
-based O 
QDs O 
. O 

separation O 
of O 
racemic O 
4-aryl-1,4-dihydropyridines B-FAMILY 
and O 
4-aryl-1,2,3,4-tetrahydropyrimidines B-FAMILY 
on O 
a O 
chiral O 
tetraproline B-FAMILY 
stationary O 
phase O 
. O 

chromatographic O 
chiral O 
resolution O 
of O 
4-aryl-1,4-dihydropyridines B-FAMILY 
( O 
1-32 O 
) O 
, O 
4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
33-38 O 
) O 
, O 
and O 
4-aryl-2-oxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
39-41 O 
) O 
was O 
studied O 
on O 
a O 
tetraproline B-FAMILY 
-immobilized O 
chiral O 
column O 
synthesized O 
in O 
our O 
lab O 
. O 
This O 
tetraproline B-FAMILY 
chiral O 
stationary O 
phase O 
can O 
resolve O 
most O 
of O 
these O 
compounds O 
. O 
The O 
4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
33-38 O 
) O 
and O 
4-aryl-2-oxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
39-41 O 
) O 
were O 
more O 
efficiently O 
resolved O 
than O 
the O 
racemic B-FAMILY 
4-aryl-1,4-dihydropyridines I-FAMILY 
on O 
the O 
tetraproline B-FAMILY 
chiralstationary O 
phase O 
. O 
Analytes O 
with O 
5,5-dimethyl B-SYSTEMATIC 
groups O 
( O 
39-41 O 
) O 
were O 
less O 
efficiently O 
resolved O 
than O 
analytes O 
without O 
5,5-dimethyl B-SYSTEMATIC 
substituents O 
( O 
1-16 O 
) O 
. O 
The O 
4-aryl-2-oxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
39-41 O 
) O 
without O 
a O 
sulfur B-SYSTEMATIC 
atom O 
were O 
much O 
more O 
efficiently O 
resolved O 
than O 
4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidines B-FAMILY 
( O 
33-38 O 
) O 
. O 
No O 
obvious O 
electronic O 
effects O 
on O 
the O 
resolution O 
of O 
any O 
of O 
these O 
analytes O 
( O 
1-41 O 
) O 
were O 
observed O 
on O 
the O 
tetraproline B-FAMILY 
chiral O 
stationary O 
phase O 
. O 
The O 
tetraproline B-FAMILY 
chiral O 
stationary O 
phase O 
separated O 
enantiomers O 
mainly O 
via O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
. O 

graphitic B-SYSTEMATIC 
carbon I-SYSTEMATIC 
nitride I-SYSTEMATIC 
nanosheets O 
as O 
efficient O 
catalysts O 
for O 
hydrogen B-SYSTEMATIC 
evolution O 
under O 
visible O 
light O 
. O 

carbon I-SYSTEMATIC 
nitride I-SYSTEMATIC 
nanosheets O 
are O 
extracted O 
, O 
produced O 
via O 
simple O 
liquid O 
- O 
phase O 
exfoliation O 
of O 
a O 
layered O 
bulk O 
material O 
, O 
g- O 
C3 B-FORMULA 
N4 I-FORMULA 
. O 
The O 
resulting O 
nanosheets O 
, O 
having O 
≈2 O 
nm O 
thickness O 
and O 
N B-FORMULA 
/ O 
C B-FORMULA 
atomic O 
ratio O 
of O 
1.31 O 
, O 
show O 
an O 
optical O 
bandgap O 
of O 
2.65 O 
eV O 
. O 
The O 
carbon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
nanosheets O 
are O 
demonstrated O 
to O 
exhibit O 
excellent O 
photocatalytic O 
activity O 
for O 
hydrogen B-SYSTEMATIC 
evolution O 
under O 
visible O 
light O 
. O 

TiO2 B-FORMULA 
nanotube O 
arrays O 
grown O 
on O 
Ti B-FORMULA 
foil O 
are O 
yielded O 
by O 
subjecting O 
electrochemically O 
anodized O 
, O 
vertically O 
oriented O 
TiO2 B-FORMULA 
nanotube O 
arrays O 
to O 
hydrothermal O 
processing O 
. O 
The O 
resulting O 
DSSCs O 
exhibit O 
a O 
significantly O 
enhanced O 
power O 
conversion O 
efficiency O 
of O 
7.24% O 
, O 
which O 
is O 
a O 
direct O 
consequence O 
of O 
the O 
synergy O 
of O 
higher O 
dye O 
loading O 
, O 
superior O 
light O 
- O 
scattering O 
ability O 
, O 
and O 
fast O 
electron O 
transport O 
. O 

discover O 
promising O 
sulfated O 
allosteric O 
modulators O 
( O 
SAMs O 
) O 
of O 
glycosaminoglycan O 
- O 
binding O 
proteins O 
( O 
GBPs O 
) O 
, O 
such O 
as O 
human O 
factor O 
XIa O 
( O 
FXIa O 
) O 
, O 
we O 
screened O 
a O 
library O 
of O 
26 O 
synthetic O 
, O 
sulfated B-FAMILY 
quinazolin-4(3H)-ones I-FAMILY 
( O 
QAOs B-ABBREVIATION 
) O 
resulting O 
in O 
the O 
identification O 
of O 
six O 
molecules O 
that O 
reduced O 
the O 
Vmax O 
of O 
substrate O 
hydrolysis O 
without O 
influencing O 
the O 
KM O 
. O 
Mutagenesis O 
of O 
residues O 
of O 
the O 
heparin O 
- O 
binding O 
site O 
( O 
HBS O 
) O 
of O 
FXIa O 
introduced O 
a O 
nearly O 
5-fold O 
loss O 
in O 
inhibition O 
potency O 
supporting O 
recognition O 
of O 
an O 
allosteric O 
site O 
. O 
Fluorescence O 
studies O 
showed O 
a O 
sigmoidal O 
binding O 
profile O 
indicating O 
highly O 
cooperative O 
binding O 
. O 
Competition O 
with O 
a O 
positively O 
charged O 
, O 
heparin O 
- O 
binding O 
polymer O 
did O 
not O 
fully O 
nullify O 
inhibition O 
suggesting O 
importance O 
of O 
hydrophobic O 
forces O 
to O 
binding O 
. O 
This O 
discovery O 
suggests O 
the O 
operation O 
of O 
a O 
dual O 
- O 
element O 
recognition O 
process O 
, O 
which O 
relies O 
on O 
an O 
initial O 
Coulombic O 
attraction O 
of O 
anionic O 
SAMs O 
to O 
the O 
cationic O 
HBS O 
of O 
FXIa O 
that O 
forms O 
a O 
locked O 
complex O 
through O 
tight O 
interaction O 
with O 
an O 
adjacent O 
hydrophobic O 
patch O 
. O 
The O 
dual O 
- O 
element O 
strategy O 
may O 
be O 
widely O 
applicable O 
for O 
discovering O 
SAMs O 
of O 
other O 
GBPs O 
. O 

amino B-FAMILY 
acid I-FAMILY 
histidine B-TRIVIAL 
( O 
His B-FORMULA 
) O 
has O 
a O 
number O 
of O 
unique O 
roles O 
that O 
can O 
dictate O 
function O 
in O 
proteins O 
, O 
and O 
these O 
roles O 
are O 
typically O 
conferred O 
through O 
noncovalent O 
interactions O 
that O 
depend O 
on O 
the O 
protonation O 
state O 
of O 
His B-FORMULA 
' O 
s O 
4- B-FAMILY 
substituted I-FAMILY 
imidazole I-FAMILY 
ring O 
. O 
His B-FORMULA 
' O 
s O 
protonation O 
state O 
can O 
vary O 
near O 
physiological O 
pH O 
, O 
and O 
a O 
probe O 
of O 
His B-FORMULA 
' O 
s O 
variable O 
protonation O 
state O 
and O 
its O 
resulting O 
noncovalent O 
interactions O 
that O 
has O 
both O 
high O 
time O 
resolution O 
and O 
no O 
sample O 
limitations O 
could O 
find O 
wide O 
use O 
in O 
determining O 
the O 
role O 
of O 
particular O 
His B-FORMULA 
residues O 
in O 
proteins O 
. O 
Here O 
we O 
use O 
a O 
classic O 
deuterium B-SYSTEMATIC 
exchange O 
reaction O 
to O 
replace O 
the O 
C2-H B-FORMULA 
hydrogen B-SYSTEMATIC 
atom O 
of O 
the O 
His B-FORMULA 
imidazole B-SYSTEMATIC 
ring O 
with O 
deuterium B-SYSTEMATIC 
, O 
leading O 
to O 
a O 
unique O 
aromatic O 
C2-D B-FORMULA 
stretching O 
vibration O 
whose O 
frequency O 
is O 
sensitive O 
to O 
environmental O 
changes O 
across O 
the O 
entire O 
imidazole B-SYSTEMATIC 
ring O 
. O 
Using O 
nonresonant O 
Raman O 
spectroscopy O 
, O 
we O 
demonstrate O 
using O 
model O 
compounds O 
that O 
the O 
frequency O 
of O 
this O 
C2-D B-FORMULA 
vibration O 
shifts O 
by O 
35 O 
cm(-1) O 
upon O 
changes O 
in O 
the O 
His B-FORMULA 
protonation O 
state O 
. O 
The O 
C2-D B-FORMULA 
band O 
is O 
a O 
very O 
weak O 
infrared O 
absorber O 
, O 
so O 
this O 
vibration O 
is O 
not O 
expected O 
to O 
be O 
useful O 
in O 
infrared O 
transmission O 
experiments O 
for O 
proteins O 
. O 
Solvent-dependent O 
Raman O 
experiments O 
indicate O 
that O 
the O 
C2-D B-FORMULA 
band O 
of O 
the O 
neutral O 
imidazole B-SYSTEMATIC 
ring O 
is O 
sensitive O 
to O 
H B-FORMULA 
-bonding O 
interaction O 
with O 
donors O 
and O 
acceptors O 
of O 
varying O 
strengths O 
, O 
suggesting O 
that O 
the O 
C2-D B-FORMULA 
frequency O 
can O 
be O 
used O 
to O 
identify O 
H B-FORMULA 
-bonding O 
partners O 
of O 
specific O 
His B-FORMULA 
residues O 
. O 
Raman O 
spectra O 
at O 
varying O 
concentrations O 
of O 
Cu(2+) B-FORMULA 
also O 
show O 
the O 
C2-D B-FORMULA 
band's O 
sensitivity O 
to O 
metal O 
coordination O 
, O 
with O 
differences O 
due O 
to O 
changes O 
in O 
the O 
coordination O 
environment O 
. O 
The O 
strong O 
Raman O 
signal O 
of O 
this O 
band O 
and O 
the O 
sampling O 
flexibility O 
of O 
Raman O 
spectroscopy O 
suggest O 
that O 
this O 
vibration O 
could O 
be O 
very O 
useful O 
in O 
documenting O 
the O 
local O 
role O 
of O 
His B-FORMULA 
residues O 
in O 
many O 
His B-FORMULA 
-containing O 
proteins O 
and O 
protein O 
assemblies O 
. O 

Investigation O 
and O 
Biological O 
Activity O 
of O 
Sesquiterpene B-FAMILY 
Lactones I-FAMILY 
from O 
the O 
Traditional O 
Chinese O 
Herb O 
Inula O 
racemosa O 
. O 

new O 
sesquiterpene B-FAMILY 
lactones I-FAMILY 
, O 
racemosalactones B-MULTIPLE 
A-E I-MULTIPLE 
( O 
1-5 O 
) O 
, O 
along O 
with O 
19 O 
known O 
sesquiterpene B-FAMILY 
latones I-FAMILY 
( O 
6-24 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
roots O 
of O 
Inula O 
racemosa O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
analysis O 
, O 
and O 
the O 
absolute O 
configuration O 
of O 
2 O 
was O 
deduced O 
from O 
X-ray O 
diffraction O 
analysis O 
. O 
Compounds O 
1 O 
, O 
6 O 
, O 
8 O 
, O 
10 O 
, O 
12 O 
, O 
14 O 
, O 
and O 
17 O 
exhibited O 
antiproliferative O 
activities O 
with O 
IC50 O 
values O 
ranging O 
from O 
0.38 O 
to O 
4.19 O 
μg O 
/ O 
mL O 
against O 
human O 
non-small O 
- O 
cell O 
lung O 
cancer O 
A549 O 
, O 
hepatocellular O 
carcinoma O 
HepG2 O 
, O 
and O 
human O 
fibrosarcoma O 
HT1080 O 
cells O 
. O 
Compounds O 
6 O 
and O 
8 O 
exhibited O 
antiproliferative O 
activities O 
against O 
endothelial O 
cells O 
with O 
IC50 O 
values O 
of O 
2.4 O 
and O 
2.5 O 
μg O 
/ O 
mL O 
, O 
respectively O 
. O 
Furthermore O 
, O 
compounds O 
6 O 
and O 
8 O 
both O 
inhibited O 
endothelial O 
cell O 
tube O 
formation O 
at O 
1 O 
μg O 
/ O 
mL O 
. O 
A O 
method O 
for O 
the O 
rapid O 
and O 
straightforward O 
preparative O 
- O 
scale O 
isolation O 
of O 
compound O 
6 O 
from O 
alantolides B-FAMILY 
is O 
described O 
. O 

- O 
ordered O 
metal O 
- O 
organic O 
nanostructures O 
of O 
Fe-PTCDA B-FORMULA 
( O 
perylene-3,4,9,10-tetracarboxylic-3,4,9,10-dianhydride B-SYSTEMATIC 
) O 
chains O 
and O 
networks O 
are O 
grown O 
on O 
a O 
Au B-FORMULA 
( O 
111 O 
) O 
surface O 
. O 
These O 
structures O 
are O 
investigated O 
by O 
high O 
- O 
resolution O 
scanning O 
tunneling O 
microscopy O 
. O 
Digitized O 
frontier O 
orbital O 
shifts O 
are O 
followed O 
in O 
scanning O 
tunneling O 
spectroscopy O 
. O 
By O 
comparing O 
the O 
frontier O 
energies O 
with O 
the O 
molecular O 
coordination O 
environments O 
, O 
we O 
conclude O 
that O 
the O 
specific O 
coordination O 
affects O 
the O 
magnitude O 
of O 
charge O 
transfer O 
onto O 
each O 
PTCDA B-ABBREVIATION 
in O 
the O 
Fe-PTCDA B-FORMULA 
hybridization O 
system O 
. O 
A O 
basic O 
model O 
is O 
derived O 
, O 
which O 
captures O 
the O 
essential O 
underlying O 
physics O 
and O 
correlates O 
the O 
observed O 
energetic O 
shift O 
of O 
the O 
frontier O 
orbital O 
with O 
the O 
charge O 
transfer O 
. O 

-Type O 
Carotenoids O 
from O 
Red O 
Mamey O 
, O 
Pouteria O 
sapota O 
. O 

carotenoids O 
, O 
cryptocapsin-5,6-epoxide B-SYSTEMATIC 
, O 
3'-deoxycapsanthin-5,6-epoxide B-SYSTEMATIC 
, O 
and O 
cryptocapsin-5,8-epoxides B-FAMILY 
, O 
have O 
been O 
isolated O 
from O 
the O 
ripe O 
fruits O 
of O 
red O 
mamey O 
( O 
Pouteria O 
sapota O 
) O 
. O 
Cryptocapsin-5,6-epoxide B-SYSTEMATIC 
was O 
prepared O 
by O 
partial O 
synthesis O 
via O 
epoxidation O 
of O 
cryptocapsin B-TRIVIAL 
, O 
and O 
the O 
(5R,6S)- O 
and O 
(5S,6R)-stereoisomers O 
were O 
identified O 
by O 
HPLC-ECD O 
analysis O 
. O 
Spectroscopic O 
data O 
of O 
the O 
natural O 
( O 
anti O 
) O 
and O 
semisynthetic O 
( O 
syn O 
) O 
derivatives O 
obtained O 
by O 
acid O 
- O 
catalyzed O 
rearrangement O 
of O 
cryptocapsin-5,8-epoxide B-SYSTEMATIC 
stereoisomers O 
were O 
compared O 
for O 
structural O 
elucidation O 
. O 
Chiral O 
HPLC O 
separation O 
of O 
natural O 
and O 
semisynthetic O 
samples O 
of O 
cryptocapsin-5,8-epoxides B-FAMILY 
was O 
performed O 
, O 
and O 
HPLC-ECD O 
analysis O 
allowed O 
configurational O 
assignment O 
of O 
the O 
separated O 
stereoisomers O 
. O 

, O 
we O 
report O 
the O 
use O 
of O 
biodegradable O 
nanoparticles O 
( O 
NPs O 
) O 
containing O 
perfluoro-1,5-crown B-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
PFCE B-ABBREVIATION 
) O 
, O 
a O 
fluorine B-SYSTEMATIC 
-based O 
compound O 
( O 
NP170- O 
PFCE B-ABBREVIATION 
) O 
with O 
the O 
capacity O 
to O 
track O 
cells O 
in O 
vivo O 
by O 
magnetic O 
ressonance O 
imaging O 
( O 
MRI O 
) O 
and O 
efficiently O 
release O 
miRNA O 
. O 
NP170- O 
PFCE B-ABBREVIATION 
complexed O 
with O 
miRNAs O 
accumulate O 
whitin O 
the O 
cell's O 
endolysosomal O 
compartment O 
and O 
interact O 
with O 
higher O 
frequency O 
with O 
argonaute2 O 
( O 
Ago2 O 
) O 
and O 
GW182 O 
proteins O 
, O 
which O 
are O 
involved O 
in O 
the O 
biological O 
action O 
of O 
miRNAs O 
, O 
than O 
commercial O 
complexes O 
formed O 
by O 
commercial O 
reagents O 
and O 
miRNA O 
, O 
which O 
in O 
turn O 
accumulate O 
in O 
the O 
cell O 
cytoplasm O 
. O 
The O 
release O 
of O 
miRNA132 O 
( O 
miR132 O 
) O 
from O 
the O 
NPs O 
increased O 
3-fold O 
the O 
survival O 
of O 
endothelial O 
cells O 
( O 
ECs O 
) O 
transplanted O 
in O 
vivo O 
and O 
3.5-fold O 
the O 
blood O 
perfusion O 
in O 
ischemic O 
limbs O 
relatively O 
to O 
control O 
. O 

acetylated O 
lysine B-TRIVIAL 
residues O 
play O 
important O 
roles O 
in O 
the O 
enzymatic O 
activity O 
of O 
Escherichia O 
coli O 
N-hydroxyarylamine B-FAMILY 
O B-FORMULA 
-acetyltransferase O 
. O 

is O 
a O 
bacterial O 
NAD(+) B-ABBREVIATION 
-dependent O 
protein O 
deacetylase O 
. O 
Although O 
progress O 
has O 
been O 
made O 
in O 
functional O 
studies O 
of O 
this O 
protein O 
in O 
recent O 
years O 
, O 
its O 
substrates O 
and O 
biological O 
functions O 
are O 
still O 
largely O 
unclear O 
. O 
Using O 
proteome O 
microarray O 
technology O 
, O 
potential O 
substrates O 
of O 
Escherichia O 
coli O 
CobB O 
were O 
screened O 
and O 
nine O 
proteins O 
were O 
identified O 
, O 
including O 
N-hydroxyarylamine B-FAMILY 
O B-FORMULA 
-acetyltransferase O 
( O 
NhoA O 
) O 
. O 
In O 
vitro O 
acetylation O 
/ O 
deacetylation O 
of O 
NhoA O 
was O 
verified O 
by O 
western O 
blotting O 
and O 
mass O 
spectrometry O 
, O 
and O 
two O 
acetylated O 
lysine B-TRIVIAL 
residues O 
were O 
identified O 
. O 
Site O 
- O 
specific O 
mutagenesis O 
experiments O 
showed O 
that O 
mutation O 
of O 
each O 
acetylated O 
lysine B-TRIVIAL 
decreased O 
the O 
acetylation O 
level O 
of O 
NhoA O 
in O 
vitro O 
. O 
Further O 
analysis O 
showed O 
that O 
variant O 
NhoA O 
proteins O 
carrying O 
substitutions O 
at O 
the O 
two O 
acetylated O 
lysine B-TRIVIAL 
residues O 
are O 
involved O 
in O 
both O 
the O 
O B-FORMULA 
-acetyltransferase O 
and O 
N B-FORMULA 
-acetyltransferase O 
activity O 
of O 
NhoA O 
. O 
Structural O 
analyses O 
were O 
also O 
performed O 
to O 
explore O 
the O 
effects O 
of O 
the O 
acetylated O 
lysine B-TRIVIAL 
residues O 
on O 
the O 
activity O 
of O 
NhoA O 
. O 
These O 
results O 
suggest O 
that O 
reversible O 
acetylation O 
may O 
play O 
a O 
role O 
in O 
the O 
activity O 
of O 
Escherichia O 
coli O 
NhoA O 
. O 

many O 
other O 
RNA O 
viruses O 
, O 
severe O 
acute O 
respiratory O 
syndrome O 
coronavirus O 
( O 
SARS-CoV O 
) O 
produces O 
polyproteins O 
containing O 
several O 
non-structural O 
proteins O 
, O 
which O 
are O 
then O 
processed O 
by O 
the O 
viral O 
proteases O 
. O 
These O 
proteases O 
often O 
exist O 
within O 
the O 
polyproteins O 
, O 
and O 
are O 
excised O 
by O 
their O 
own O 
proteolytic O 
activity O 
( O 
' O 
autoprocessing O 
' O 
) O 
. O 
It O 
is O 
important O 
to O 
investigate O 
the O 
autoprocessing O 
mechanism O 
of O 
these O 
proteases O 
from O 
the O 
point O 
of O 
view O 
of O 
anti-SARS-CoV O 
drug O 
design O 
. O 
In O 
this O 
paper O 
, O 
we O 
describe O 
a O 
new O 
method O 
for O 
investigating O 
the O 
autoprocessing O 
mechanism O 
of O 
the O 
main O 
protease O 
( O 
M(pro) O 
) O 
, O 
which O 
is O 
also O 
called O 
the O 
3C O 
- O 
like O 
protease O 
( O 
3CL(pro) O 
) O 
. O 
Using O 
our O 
method O 
, O 
we O 
measured O 
the O 
activities O 
, O 
under O 
the O 
same O 
conditions O 
, O 
of O 
the O 
mature O 
form O 
and O 
pro O 
- O 
forms O 
with O 
the O 
N B-FORMULA 
-terminal O 
pro O 
- O 
sequence O 
, O 
the O 
C B-FORMULA 
-terminal O 
pro O 
- O 
sequence O 
or O 
both O 
pro O 
- O 
sequences O 
, O 
toward O 
the O 
pro O 
- O 
form O 
with O 
both O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
pro O 
- O 
sequences O 
. O 
The O 
data O 
indicate O 
that O 
the O 
pro O 
- O 
forms O 
of O 
the O 
enzyme O 
have O 
proteolytic O 
activity O 
, O 
and O 
are O 
stimulated O 
by O 
the O 
same O 
proteolytic O 
activity O 
. O 
The O 
stimulation O 
occurs O 
in O 
two O 
steps O 
, O 
with O 
approximately O 
eightfold O 
stimulation O 
by O 
N B-FORMULA 
-terminal O 
cleavage O 
, O 
approximately O 
fourfold O 
stimulation O 
by O 
C B-FORMULA 
-terminal O 
cleavage O 
, O 
and O 
23-fold O 
stimulation O 
by O 
the O 
cleavage O 
of O 
both O 
termini O 
, O 
compared O 
to O 
the O 
pro O 
- O 
form O 
with O 
both O 
the O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-terminal O 
pro O 
- O 
sequences O 
. O 
Such O 
cleavage O 
mainly O 
occurs O 
in O 
a O 
trans O 
manner O 
; O 
i.e O 
. O 
the O 
pro O 
- O 
form O 
dimer O 
cleaves O 
the O 
monomeric O 
form O 
. O 
The O 
stimulation O 
by O 
N B-FORMULA 
-terminal O 
pro O 
- O 
sequence O 
removal O 
is O 
due O 
to O 
the O 
cis O 
( O 
intra O 
- O 
dimer O 
and O 
inter O 
- O 
protomer O 
) O 
effect O 
of O 
formation O 
of O 
the O 
new O 
N-terminus O 
, O 
whereas O 
that O 
by O 
C B-FORMULA 
-terminal O 
cleavage O 
is O 
due O 
to O 
removal O 
of O 
its O 
trans O 
( O 
inter O 
- O 
dimer O 
) O 
inhibitory O 
effect O 
. O 
A O 
numerical O 
simulation O 
of O 
the O 
maturation O 
pathway O 
is O 
presented O 
. O 

I O 
describe O 
accurate O 
and O 
time O 
- O 
efficient O 
computational O 
methods O 
for O 
designing O 
small O 
molecule O 
- O 
sensing O 
allosteric O 
ribozymes O 
that O 
serve O 
as O 
logic O 
gates O 
with O 
NOT O 
or O 
YES O 
Boolean O 
logic O 
functions O 
. O 
Theophylline B-TRIVIAL 
-sensing O 
ribozymes O 
are O 
engineered O 
to O 
have O 
a O 
high O 
cleavage O 
rate O 
of O 
1.3 O 
min(-1) O 
under O 
physiologically O 
relevant O 
conditions O 
. O 
They O 
are O 
highly O 
specific O 
to O 
theophylline B-TRIVIAL 
and O 
do O 
not O 
respond O 
to O 
caffeine B-TRIVIAL 
, O 
which O 
differs O 
in O 
a O 
single O 
methyl B-SYSTEMATIC 
group O 
. O 
These O 
ribozymes O 
are O 
designed O 
by O 
fusing O 
a O 
theophylline B-TRIVIAL 
aptamer O 
with O 
an O 
extended O 
version O 
of O 
the O 
hammerhead O 
ribozyme O 
by O 
modeling O 
secondary O 
structures O 
. O 
Purine B-TRIVIAL 
-sensing O 
ribozymes O 
are O 
designed O 
by O 
fusing O 
the O 
minimal O 
version O 
of O 
the O 
hammerhead O 
ribozyme O 
with O 
bacterial O 
guanine B-TRIVIAL 
or O 
adenine B-TRIVIAL 
aptamers O 
by O 
modeling O 
3D O 
interactions O 
. O 
I O 
have O 
developed O 
high O 
- O 
throughput O 
compatible O 
arrays O 
based O 
on O 
purine B-TRIVIAL 
RNA O 
sensors O 
that O 
can O 
be O 
used O 
for O 
antibacterial O 
drug O 
discovery O 
. O 
The O 
ribozymes O 
can O 
be O 
employed O 
as O 
molecular O 
sensors O 
in O 
various O 
applications O 
, O 
including O 
exogenous O 
control O 
of O 
gene O 
expression O 
, O 
high O 
- O 
throughput O 
screening O 
arrays O 
, O 
and O 
molecular O 
computing O 
. O 

electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
and O 
UV-visible O 
absorption O 
( O 
UV-vis O 
) O 
spectra O 
of O 
Strandberg O 
- O 
type O 
polyoxometalates B-FAMILY 
( O 
POMs B-ABBREVIATION 
) O 
( B-FAMILY 
R I-FAMILY 
, I-FAMILY 
R)-[(R*PO3)2M5O15](2- I-FAMILY 
) I-FAMILY 
( O 
R* O 
= O 
CH3CH(NH3) B-FORMULA 
, O 
( O 
M O 
= O 
Mo B-FORMULA 
, O 
W B-FORMULA 
) O 
) O 
have O 
been O 
explored O 
using O 
the O 
time O 
- O 
dependent O 
density O 
functional O 
theory O 
( O 
TDDFT O 
) O 
method O 
. O 
It O 
demonstrates O 
that O 
the O 
absolute O 
configurations O 
of O 
chiral O 
systems O 
can O 
be O 
determined O 
by O 
chiroptical O 
spectroscopic O 
methods O 
combined O 
with O 
DFT O 
calculations O 
. O 
The O 
calculated O 
ECD O 
spectra O 
of O 
the O 
Strandberg O 
- O 
type O 
molybdate O 
were O 
produced O 
over O 
the O 
range O 
of O 
3.3-6.5 O 
eV O 
, O 
which O 
are O 
generally O 
in O 
agreement O 
with O 
the O 
experimental O 
spectra O 
. O 
In O 
addition O 
, O 
the O 
ECD O 
spectra O 
of O 
( B-FAMILY 
R I-FAMILY 
, I-FAMILY 
R)-[(R*PO3)2W5O15](2- I-FAMILY 
) I-FAMILY 
( O 
R* O 
= O 
CH3CH(NH3) B-FORMULA 
) O 
were O 
produced O 
over O 
the O 
range O 
of O 
4.5-8.5 O 
eV O 
. O 
The O 
Becke's O 
half O 
- O 
and O 
- O 
half O 
hybrid O 
exchange O 
- O 
correlation O 
functional O 
( O 
BHandHLYP O 
) O 
with O 
the O 
HF O 
exchange O 
fraction O 
to O 
55% O 
hybrid O 
functional O 
was O 
found O 
to O 
well O 
predict O 
the O 
excitation O 
energies O 
of O 
studied O 
systems O 
. O 
The O 
origins O 
of O 
the O 
ECD O 
bands O 
of O 
two O 
systems O 
are O 
mainly O 
ascribed O 
to O 
charge O 
- O 
transfer O 
( O 
CT O 
) O 
transitions O 
from O 
oxygen B-SYSTEMATIC 
atoms O 
to O 
metal O 
atoms O 
in O 
polyanion O 
. O 
The O 
results O 
suggest O 
that O 
the O 
polyanion O 
are O 
chiroptical O 
chromophores O 
. O 
The O 
polyanion O 
plays O 
a O 
role O 
as O 
an O 
optically O 
active O 
chromophore O 
and O 
contribute O 
to O 
the O 
absorptions O 
of O 
ECD O 
spectra O 
. O 
The O 
difference O 
of O 
the O 
UV-vis O 
/ O 
ECD O 
spectra O 
between O 
two O 
systems O 
shows O 
that O 
the O 
transition B-FAMILY 
metal I-FAMILY 
atom O 
significantly O 
influences O 
on O 
the O 
chiroptical O 
properties O 
of O 
the O 
studied O 
Strandberg O 
- O 
type O 
POMs B-ABBREVIATION 
. O 

determination O 
in O 
the O 
mammalian O 
circadian O 
clock O 
involves O 
the O 
turnover O 
rate O 
of O 
the O 
repressors O 
CRY O 
and O 
PER O 
. O 
We O 
show O 
that O 
CRY O 
ubiquitination O 
engages O 
two O 
competing O 
E3 O 
ligase O 
complexes O 
that O 
either O 
lengthen O 
or O 
shorten O 
circadian O 
period O 
in O 
mice O 
. O 
Cloning O 
of O 
a O 
short O 
- O 
period O 
circadian O 
mutant O 
, O 
Past O 
- O 
time O 
, O 
revealed O 
a O 
glycine B-TRIVIAL 
to O 
glutamate B-TRIVIAL 
missense O 
mutation O 
in O 
Fbxl21 O 
, O 
an O 
F-box O 
protein O 
gene O 
that O 
is O 
a O 
paralog O 
of O 
Fbxl3 O 
that O 
targets O 
the O 
CRY O 
proteins O 
for O 
degradation O 
. O 
While O 
loss O 
of O 
function O 
of O 
FBXL3 O 
leads O 
to O 
period O 
lengthening O 
, O 
mutation O 
of O 
Fbxl21 O 
causes O 
period O 
shortening O 
. O 
FBXL21 O 
forms O 
an O 
SCF O 
E3 O 
ligase O 
complex O 
that O 
slowly O 
degrades O 
CRY O 
in O 
the O 
cytoplasm O 
but O 
antagonizes O 
the O 
stronger O 
E3 O 
ligase O 
activity O 
of O 
FBXL3 O 
in O 
the O 
nucleus O 
. O 
FBXL21 O 
plays O 
a O 
dual O 
role O 
: O 
protecting O 
CRY O 
from O 
FBXL3 O 
degradation O 
in O 
the O 
nucleus O 
and O 
promoting O 
CRY O 
degradation O 
within O 
the O 
cytoplasm O 
. O 
Thus O 
, O 
the O 
balance O 
and O 
cellular O 
compartmentalization O 
of O 
competing O 
E3 O 
ligases O 
for O 
CRY O 
determine O 
circadian O 
period O 
of O 
the O 
clock O 
in O 
mammals O 
. O 

and O 
transducing O 
the O 
synaptic O 
or O 
extrasynaptic O 
origin O 
of O 
NMDA B-ABBREVIATION 
receptor O 
signals O 
to O 
the O 
nucleus O 
. O 

activation O 
of O 
N-methyl-D-aspartate B-SYSTEMATIC 
-receptors O 
( O 
NMDARs O 
) O 
in O 
synapses O 
provides O 
plasticity O 
and O 
cell O 
survival O 
signals O 
, O 
whereas O 
NMDARs O 
residing O 
in O 
the O 
neuronal O 
membrane O 
outside O 
synapses O 
trigger O 
neurodegeneration O 
. O 
At O 
present O 
, O 
it O 
is O 
unclear O 
how O 
these O 
opposing O 
signals O 
are O 
transduced O 
to O 
and O 
discriminated O 
by O 
the O 
nucleus O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrate O 
that O 
Jacob O 
is O 
a O 
protein O 
messenger O 
that O 
encodes O 
the O 
origin O 
of O 
synaptic O 
versus O 
extrasynaptic O 
NMDAR O 
signals O 
and O 
delivers O 
them O 
to O 
the O 
nucleus O 
. O 
Exclusively O 
synaptic O 
, O 
but O 
not O 
extrasynaptic O 
, O 
NMDAR O 
activation O 
induces O 
phosphorylation O 
of O 
Jacob O 
at O 
serine B-TRIVIAL 
-180 O 
by O 
ERK1 O 
/ O 
2 O 
. O 
Long O 
- O 
distance O 
trafficking O 
of O 
Jacob O 
from O 
synaptic O 
, O 
but O 
not O 
extrasynaptic O 
, O 
sites O 
depends O 
on O 
ERK O 
activity O 
, O 
and O 
association O 
with O 
fragments O 
of O 
the O 
intermediate O 
filament O 
α-internexin O 
hinders O 
dephosphorylation O 
of O 
the O 
Jacob O 
/ O 
ERK O 
complex O 
during O 
nuclear O 
transit O 
. O 
In O 
the O 
nucleus O 
, O 
the O 
phosphorylation O 
state O 
of O 
Jacob O 
determines O 
whether O 
it O 
induces O 
cell O 
death O 
or O 
promotes O 
cell O 
survival O 
and O 
enhances O 
synaptic O 
plasticity O 
. O 

( O 
RGN O 
/ O 
SMP30 O 
) O 
was O 
originally O 
discovered O 
in O 
1978 O 
as O 
a O 
unique O 
calcium B-SYSTEMATIC 
-binding O 
protein O 
that O 
does O 
not O 
contain O 
the O 
EF-hand O 
motif O 
of O 
calcium B-SYSTEMATIC 
-binding O 
domain O 
. O 
The O 
regucalcin O 
gene O 
( O 
rgn O 
) O 
is O 
localized O 
on O 
the O 
X O 
chromosome O 
and O 
is O 
identified O 
in O 
over O 
15 O 
species O 
consisting O 
the O 
regucalcin O 
family O 
. O 
Regucalcin O 
has O 
been O 
shown O 
to O 
play O 
a O 
multifunctional O 
role O 
in O 
cell O 
regulation O 
; O 
maintaining O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
homeostasis O 
and O 
suppressing O 
of O 
signal O 
transduction O 
, O 
translational O 
protein O 
synthesis O 
, O 
nuclear O 
deoxyribonucleic O 
acid O 
( O 
DNA O 
) O 
and O 
ribonucleic O 
acid O 
( O 
RNA O 
) O 
synthesis O 
, O 
proliferation O 
, O 
and O 
apoptosis O 
in O 
many O 
cell O 
types O 
. O 
Moreover O 
, O 
regucalcin O 
may O 
play O 
a O 
pathophysiological O 
role O 
in O 
metabolic O 
disorder O 
. O 
The O 
expression O 
of O 
regucalcin O 
is O 
stimulated O 
through O 
the O 
action O 
of O 
insulin O 
in O 
liver O 
cells O 
in O 
vitro O 
and O 
in O 
vivo O 
and O 
it O 
is O 
decreased O 
in O 
the O 
liver O 
of O 
rats O 
with O 
type O 
I O 
diabetes O 
induced O 
by O 
streptozotocin B-TRIVIAL 
administration O 
in O 
vivo O 
. O 
Overexpression O 
of O 
endogenous O 
regucalcin O 
stimulates O 
glucose B-TRIVIAL 
utilization O 
and O 
lipid O 
production O 
in O 
liver O 
cells O 
with O 
glucose B-TRIVIAL 
supplementation O 
in O 
vitro O 
. O 
Regucalcin O 
reveals O 
insulin O 
resistance O 
in O 
liver O 
cells O 
. O 
Deficiency O 
of O 
regucalcin O 
induces O 
an O 
impairment O 
of O 
glucose B-TRIVIAL 
tolerance O 
and O 
lipid O 
accumulation O 
in O 
the O 
liver O 
of O 
mice O 
in O 
vivo O 
. O 
Overexpression O 
of O 
endogenous O 
regucalcin O 
has O 
been O 
shown O 
to O 
decrease O 
triglyceride B-FAMILY 
, O 
total O 
cholesterol B-TRIVIAL 
and O 
glycogen O 
contents O 
in O 
the O 
liver O 
of O 
rats O 
, O 
inducing O 
hyperlipidemia O 
. O 
Leptin O 
and O 
adiponectin O 
mRNA O 
expressions O 
in O 
the O 
liver O 
tissues O 
are O 
decreased O 
in O 
regucalcin O 
transgenic O 
rats O 
. O 
Decrease O 
in O 
hepatic O 
regucalcin O 
is O 
associated O 
with O 
the O 
development O 
and O 
progression O 
of O 
nonalcoholic O 
fatty O 
liver O 
disease O 
and O 
fibrosis O 
in O 
human O 
patients O 
. O 
Regucalcin O 
may O 
be O 
a O 
key O 
molecule O 
in O 
lipid O 
metabolic O 
disorder O 
and O 
diabetes O 
. O 

and O 
evaluation O 
against O 
hepatitis O 
C O 
virus O 
of O 
7-deaza O 
analogues O 
of O 
2'-C-methyl-6-O-methyl B-FAMILY 
guanosine I-FAMILY 
nucleoside I-FAMILY 
and O 
L-Alanine B-FAMILY 
ester I-FAMILY 
phosphoramidates I-FAMILY 
. O 

are O 
known O 
to O 
possess O 
broad O 
antiviral O 
activity O 
, O 
however O 
the O 
2'-C-methylguanosine B-FAMILY 
analogue O 
displays O 
poor O 
cell O 
permeation O 
and O 
limited O 
phosphorylation O 
, O 
thus O 
is O 
not O 
an O 
efficient O 
inhibitor O 
of O 
hepatitis O 
C O 
virus O 
( O 
HCV O 
) O 
replication O 
. O 
We O 
previously O 
reported O 
the O 
6-O-methyl B-SYSTEMATIC 
entity O 
as O 
a O 
prodrug O 
moiety O 
to O 
increase O 
liphophilicity O 
of O 
guanine B-FAMILY 
nucleosides I-FAMILY 
and O 
the O 
ProTide O 
approach O 
applied O 
to O 
2'-C-methyl-6-O-methylguanosine B-SYSTEMATIC 
has O 
lead O 
to O 
potent O 
HCV O 
inhibitors O 
now O 
in O 
clinical O 
trials O 
. O 
In O 
this O 
Letter O 
, O 
we O 
report O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
2'-C-methyl-6-O-methyl- B-SYSTEMATIC 
7-deaza O 
guanosine B-TRIVIAL 
and O 
ProTide O 
derivatives O 
. O 
In O 
contrast O 
to O 
prior O 
studies O 
, O 
removal O 
of O 
the O 
N B-FORMULA 
-7 O 
of O 
the O 
nucleobase B-FAMILY 
entirely O 
negates O 
anti-HCV O 
activity O 
compared O 
to O 
the O 
2'-C-methyl-6-O-methylguanosine B-SYSTEMATIC 
analogues O 
. O 
To O 
understand O 
better O 
this O 
significant O 
loss O 
of O 
activity O 
, O 
enzymatic O 
assays O 
and O 
molecular O 
modeling O 
were O 
carried O 
out O 
and O 
suggested O 
2'-C-methyl-6-O-methyl- B-SYSTEMATIC 
7-deaza O 
guanosine B-TRIVIAL 
and O 
related O 
ProTides O 
do O 
not O 
act O 
as O 
efficient O 
prodrugs O 
of O 
the O 
free O 
nucleotide B-FAMILY 
, O 
in O 
marked O 
contrast O 
to O 
the O 
case O 
of O 
the O 
parent O 
guanine B-TRIVIAL 
analogue O 
. O 

of O 
4-alkylamino-7-aryl-3-cyanoquinoline B-FAMILY 
LRRK2 O 
kinase O 
inhibitors O 
. O 

in O 
leucine B-TRIVIAL 
-rich O 
repeat O 
kinase O 
2 O 
( O 
LRRK2 O 
) O 
are O 
associated O 
with O 
familial O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
The O 
kinase O 
activity O 
of O 
this O 
complex O 
protein O 
is O 
increased O 
by O 
pathogenic O 
mutations O 
. O 
Inhibition O 
of O 
LRRK2 O 
kinase O 
activity O 
has O 
therefore O 
emerged O 
as O 
a O 
promising O 
approach O 
for O 
the O 
treatment O 
of O 
PD O 
. O 
Herein O 
we O 
report O 
our O 
findings O 
on O 
a O 
series O 
of O 
4-alkylamino-7-aryl-3-cyanoquinolines B-FAMILY 
that O 
exhibit O 
kinase O 
inhibitory O 
activity O 
against O 
both O 
wild O 
type O 
and O 
G2019S O 
mutant O 
LRRK2 O 
. O 
Activity O 
was O 
determined O 
in O 
both O 
biochemical O 
and O 
cellular O 
assays O 
. O 
Compound O 
14 O 
was O 
further O 
evaluated O 
in O 
an O 
in O 
vivo O 
pharmacodynamic O 
study O 
and O 
found O 
to O 
significantly O 
inhibit O 
Ser B-FORMULA 
935 O 
phosphorylation O 
after O 
oral O 
dosing O 
. O 

recent O 
years O 
, O 
propolis O 
has O 
been O 
the O 
object O 
of O 
extensive O 
research O 
for O 
its O 
antibacterial O 
, O 
antioxidant O 
, O 
anti-inflammatory O 
, O 
and O 
antitumoral O 
activities O 
. O 
This O 
study O 
aims O 
to O 
determine O 
the O 
hepatoprotective O 
efficiency O 
of O 
propolis O 
on O 
experimental O 
endotoxemia O 
in O 
rats O 
. O 
In O 
the O 
current O 
study O 
, O 
fifty O 
adult O 
Sprague O 
Dawley O 
rats O 
( O 
weighing O 
200-300g O 
) O 
were O 
randomly O 
divided O 
into O 
five O 
groups O 
of O 
ten O 
rats O 
each O 
. O 
Normal O 
saline O 
solution O 
was O 
administered O 
to O 
the O 
rats O 
in O 
the O 
control O 
group O 
, O 
while O 
in O 
the O 
second O 
group O 
LPS O 
( O 
30mg O 
/ O 
kg O 
) O 
, O 
in O 
the O 
third O 
group O 
propolis O 
( O 
250mg O 
/ O 
kg O 
) O 
, O 
in O 
the O 
fourth O 
group O 
first O 
propolis O 
and O 
then O 
LPS O 
( O 
30mg O 
/ O 
kg O 
) O 
, O 
and O 
in O 
the O 
fifth O 
group O 
, O 
first O 
LPS O 
( O 
30mg O 
/ O 
kg O 
) O 
and O 
then O 
propolis O 
were O 
given O 
. O 
Six O 
hours O 
after O 
the O 
application O 
, O 
biochemical O 
( O 
MDA B-ABBREVIATION 
levels O 
) O 
and O 
histopathological O 
changes O 
as O 
well O 
as O 
global O 
DNA O 
methylation O 
analysis O 
in O 
the O 
liver O 
tissue O 
samples O 
were O 
determined O 
, O 
while O 
in O 
the O 
blood O 
tissue O 
samples O 
Genomic O 
Template O 
Stability O 
( O 
GTS O 
, O 
% O 
) O 
was O 
evaluated O 
using O 
RAPD-PCR O 
profiles O 
. O 
The O 
results O 
demonstrated O 
that O 
the O 
administration O 
of O 
propolis O 
could O 
have O 
a O 
protective O 
effect O 
against O 
changes O 
of O 
both O 
genomic O 
stability O 
values O 
and O 
methylation O 
profiles O 
, O 
and O 
it O 
minimized O 
the O 
increase O 
in O 
MDA B-ABBREVIATION 
and O 
tissue O 
damage O 
caused O 
by O 
LPS O 
. O 
In O 
conclusion O 
, O 
the O 
application O 
of O 
propolis O 
prior O 
to O 
LPS-induced O 
endotoxemia O 
has O 
shown O 
to O 
reduce O 
hepatic O 
damage O 
. O 

objective O 
of O 
the O 
current O 
study O 
was O 
to O 
evaluate O 
the O 
methanolic O 
root O 
extract O 
of O 
Gentiana O 
kurroo O 
for O 
antioxidant O 
and O 
antiproliferative O 
activities O 
as O 
well O 
as O 
to O 
study O 
the O 
effect O 
of O 
the O 
extract O 
on O 
the O 
induction O 
of O 
apoptosis O 
in O 
human O 
pancreatic O 
cancer O 
cell O 
line O 
( O 
Miapaca-2 O 
) O 
. O 
The O 
extract O 
exerted O 
significant O 
antioxidant O 
activity O 
as O 
verified O 
by O 
DPPH B-ABBREVIATION 
, O 
hydroxyl B-SYSTEMATIC 
radical O 
, O 
lipid O 
peroxidation O 
and O 
protective O 
oxidative O 
DNA O 
damage O 
assays O 
. O 
The O 
results O 
were O 
comparable O 
to O 
standard O 
antioxidants O 
like O 
α-tocopherol B-TRIVIAL 
, O 
catechin B-TRIVIAL 
and O 
BHT B-ABBREVIATION 
used O 
in O 
such O 
experiments O 
. O 
Antioxidant O 
potential O 
of O 
G O 
. O 
kurroo O 
may O 
be O 
attributed O 
to O 
the O 
presence O 
of O 
high O 
phenolic O 
and O 
flavonoid B-FAMILY 
content O 
( O 
73±1.02 O 
and O 
46±2.05mg O 
/ O 
g O 
extract O 
respectively O 
) O 
. O 
The O 
anti-proliferative O 
property O 
of O 
Gentiana O 
kurroo O 
root O 
extract O 
was O 
determined O 
by O 
sulphorhodamine B-TRIVIAL 
B I-TRIVIAL 
( O 
SRB B-ABBREVIATION 
) O 
assay O 
against O 
Human O 
colon O 
cancer O 
cell O 
line O 
( O 
HCT-116 O 
) O 
, O 
Lung O 
carcinoma O 
cell O 
line O 
( O 
A-549 O 
) O 
, O 
Pancreatic O 
cancer O 
cell O 
line O 
( O 
Miapaca-2 O 
) O 
, O 
Lung O 
cancer O 
cell O 
line O 
( O 
HOP-62 O 
) O 
and O 
acute O 
monocytic O 
leukaemia O 
cell O 
line O 
( O 
THP-1 O 
) O 
. O 
G O 
. O 
kurroo O 
root O 
extract O 
inhibited O 
cancer O 
cell O 
growth O 
depending O 
upon O 
the O 
cell O 
line O 
used O 
and O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
The O 
extract O 
induced O 
cell O 
cycle O 
arrest O 
in O 
Miapaca-2 O 
cells O 
at O 
G0 O 
/ O 
G1 O 
phase O 
of O 
the O 
cell O 
cycle O 
. O 
The O 
population O 
of O 
apoptotic O 
cells O 
increased O 
from O 
11.4% O 
in O 
case O 
of O 
control O 
to O 
49.6% O 
at O 
100μg O 
/ O 
ml O 
of O 
G O 
. O 
kurroo O 
root O 
extract O 
. O 
The O 
extract O 
also O 
induced O 
a O 
remarkable O 
decrease O 
in O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨm O 
) O 
leading O 
to O 
apoptosis O 
of O 
cancer O 
cells O 
used O 
. O 
The O 
main O 
chemical O 
constituents O 
identified O 
by O 
the O 
liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
LC-ESI-MSMS O 
) O 
were O 
found O 
to O 
be O 
iridoid B-FAMILY 
glucosides I-FAMILY 
( O 
iridoids B-FAMILY 
and O 
secoiridoids B-FAMILY 
) O 
, O 
xanthones B-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
Iridoid B-FAMILY 
glucosides I-FAMILY 
are O 
the O 
bitter O 
principles O 
of O 
Gentiana O 
species O 
. O 
Loganic B-TRIVIAL 
acid I-TRIVIAL 
, O 
Sweroside B-TRIVIAL 
, O 
Swertiamarin B-TRIVIAL 
, O 
Gentiopicroside B-TRIVIAL 
, O 
Gentisin B-TRIVIAL 
, O 
Isogentisin B-TRIVIAL 
, O 
Gentioside B-TRIVIAL 
, O 
Norswertianolin B-TRIVIAL 
, O 
Swertianolin B-TRIVIAL 
, O 
4″-O-β-d-glucosyl-6'-O-(4-O-β-d-glucosylcaffeoyl)-linearoside B-SYSTEMATIC 
and O 
Swertisin B-TRIVIAL 
were O 
the O 
principal O 
compounds O 
present O 
in O 
the O 
methanol B-SYSTEMATIC 
root O 
extract O 
of O 
G O 
. O 
kurroo O 
. O 

of O 
co O 
- O 
administration O 
of O 
protonated O 
nanostructured O 
aluminum B-TRIVIAL 
silicate I-TRIVIAL 
( O 
cholesterol B-TRIVIAL 
absorption O 
inhibitor O 
) O 
on O 
the O 
absorption O 
of O 
lipid O 
soluble O 
vitamins B-MULTIPLE 
D3 I-MULTIPLE 
and I-MULTIPLE 
K1 I-MULTIPLE 
: O 
An O 
assessment O 
of O 
pharmacokinetic O 
and O 
in O 
vitro O 
intraluminal O 
processing O 
. O 

nanostructured O 
aluminum B-TRIVIAL 
silicate I-TRIVIAL 
( O 
NSAS O 
) O 
is O 
a O 
protonated O 
montmorillonite B-TRIVIAL 
clay O 
that O 
was O 
shown O 
to O 
be O 
effective O 
as O 
an O 
inhibitor O 
of O 
intestinal O 
cholesterol B-TRIVIAL 
absorption O 
. O 
The O 
effect O 
of O 
NSAS O 
on O 
the O 
intestinal O 
absorption O 
of O 
nutrients O 
is O 
unknown O 
. O 
An O 
in O 
vitro O 
lipolysis O 
model O 
was O 
adapted O 
to O 
test O 
the O 
intraluminal O 
processing O 
of O 
vitamin B-MULTIPLE 
D3 I-MULTIPLE 
and I-MULTIPLE 
K1 I-MULTIPLE 
in O 
the O 
presence O 
of O 
various O 
amounts O 
of O 
NSAS O 
. O 
Additionally O 
, O 
vitamin O 
absorption O 
was O 
assessed O 
in O 
male O 
Sprague-Dawley O 
rats O 
randomized O 
in O 
the O 
following O 
treatment O 
groups O 
: O 
IV O 
administration O 
of O 
0.1mg O 
/ O 
kg O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
1mg O 
/ O 
kg O 
vitamin B-TRIVIAL 
K1 I-TRIVIAL 
, O 
and O 
a O 
single O 
- O 
dose O 
gavage O 
of O 
1mg O 
/ O 
kg O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
5mg O 
/ O 
kg O 
of O 
vitamin B-TRIVIAL 
K1 I-TRIVIAL 
in O 
peanut O 
oil O 
with O 
various O 
doses O 
of O 
NSAS O 
slurry O 
, O 
2% O 
NSAS-fortified O 
diet O 
, O 
or O 
50mg O 
/ O 
kg O 
stigmastanol B-TRIVIAL 
. O 
The O 
solubilized O 
fraction O 
of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
in O 
the O 
lipolysis O 
medium O 
was O 
reduced O 
from O 
70% O 
to O 
46% O 
upon O 
the O 
addition O 
of O 
120mg O 
NSAS O 
. O 
In O 
contrast O 
, O 
the O 
solubilized O 
fractions O 
of O 
vitamin B-TRIVIAL 
K1 I-TRIVIAL 
were O 
not O 
significantly O 
affected O 
. O 
Although O 
the O 
NSAS-fortified O 
diet O 
did O 
not O 
significantly O 
affect O 
the O 
absorbed O 
fraction O 
of O 
both O 
vitamins B-FAMILY 
, O 
NSAS O 
slurry O 
decreased O 
the O 
absorption O 
of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
as O 
compared O 
to O 
the O 
control O 
. O 
These O 
results O 
indicate O 
that O 
NSAS O 
may O 
be O 
incorporated O 
in O 
diet O 
to O 
treat O 
hypercholesterolemia O 
; O 
however O 
, O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
monitoring O 
may O 
be O 
required O 
. O 

effect O 
of O 
formulation O 
on O 
the O 
penetration O 
of O 
coated O 
and O 
uncoated O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
into O 
the O 
viable O 
epidermis O 
of O 
human O 
skin O 
in O 
vivo O 
. O 

use O 
of O 
nanoparticulate O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ZnO B-FORMULA 
-NP O 
) O 
in O 
sunscreens O 
and O 
other O 
cosmetic O 
products O 
has O 
raised O 
public O 
health O 
concerns O 
. O 
The O 
two O 
key O 
issues O 
are O 
the O 
extent O 
of O 
exposure O 
to O 
ZnO B-FORMULA 
-NP O 
and O 
the O 
likely O 
hazard O 
after O 
the O 
application O 
of O 
ZnO B-FORMULA 
-NP O 
in O 
sunscreen O 
and O 
cosmetic O 
products O 
to O 
humans O 
in O 
vivo O 
. O 
Our O 
aims O 
were O 
to O 
assess O 
exposure O 
by O 
the O 
extent O 
of O 
ZnO B-FORMULA 
-NP O 
penetration O 
into O 
the O 
viable O 
epidermis O 
and O 
hazard O 
by O 
changes O 
in O 
the O 
viable O 
epidermal O 
redox O 
state O 
for O 
a O 
number O 
of O 
topical O 
products O 
. O 
Of O 
particular O 
interest O 
is O 
the O 
role O 
of O 
the O 
particle O 
coating O 
, O 
formulation O 
used O 
, O 
and O 
the O 
presence O 
of O 
any O 
enhancers O 
. O 
Multiphoton O 
tomography O 
with O 
fluorescence O 
lifetime O 
imaging O 
microscopy O 
( O 
MPT-FLIM O 
) O 
was O 
used O 
to O 
simultaneously O 
observe O 
ZnO B-FORMULA 
-NP O 
penetration O 
and O 
potential O 
metabolic O 
changes O 
within O 
the O 
viable O 
epidermis O 
of O 
human O 
volunteers O 
after O 
topical O 
application O 
of O 
various O 
ZnO B-FORMULA 
-NP O 
products O 
. O 
Coated O 
and O 
uncoated O 
ZnO B-FORMULA 
-NP O 
remained O 
in O 
the O 
superficial O 
layers O 
of O 
the O 
SC O 
and O 
in O 
the O 
skin O 
furrows O 
. O 
We O 
observed O 
limited O 
penetration O 
of O 
coated O 
ZnO B-FORMULA 
-NP O 
dispersed O 
in O 
a O 
water O 
- O 
in O 
- O 
oil O 
emulsion O 
formulation O 
, O 
which O 
was O 
predominantly O 
localized O 
adjacent O 
to O 
the O 
skin O 
furrow O 
. O 
However O 
, O 
the O 
presence O 
of O 
ZnO B-FORMULA 
-NP O 
in O 
the O 
viable O 
epidermis O 
did O 
not O 
alter O 
the O 
metabolic O 
state O 
or O 
morphology O 
of O 
the O 
cells O 
. O 
In O 
summary O 
, O 
our O 
data O 
suggest O 
that O 
some O 
limited O 
penetration O 
of O 
coated O 
and O 
uncoated O 
ZnO B-FORMULA 
-NP O 
may O 
occur O 
into O 
viable O 
stratum O 
granulosum O 
epidermis O 
adjacent O 
to O 
furrows O 
, O 
but O 
that O 
the O 
extent O 
is O 
not O 
sufficient O 
to O 
affect O 
the O 
redox O 
state O 
of O 
those O 
viable O 
cells O 
. O 

of O 
indomethacin B-TRIVIAL 
- O 
saccharin B-TRIVIAL 
( O 
IMC B-ABBREVIATION 
- O 
SAC B-ABBREVIATION 
) O 
co O 
- O 
crystals O 
prepared O 
by O 
an O 
anti-solvent O 
crystallization O 
process O 
. O 

creation O 
of O 
co O 
- O 
crystals O 
of O 
various O 
insoluble O 
drug O 
substances O 
has O 
been O 
extensively O 
investigated O 
as O 
a O 
promising O 
approach O 
to O 
improve O 
their O 
pharmaceutical O 
performance O 
. O 
In O 
this O 
study O 
, O 
co O 
- O 
crystal O 
powders O 
of O 
indomethacin B-TRIVIAL 
and O 
saccharin B-TRIVIAL 
( O 
IMC B-ABBREVIATION 
- O 
SAC B-ABBREVIATION 
) O 
were O 
prepared O 
by O 
an O 
anti-solvent O 
( O 
water O 
) O 
addition O 
and O 
compared O 
with O 
co O 
- O 
crystals O 
by O 
evaporation O 
method O 
. O 
No O 
successful O 
synthesis O 
of O 
a O 
pharmaceutical O 
co O 
- O 
crystal O 
powder O 
via O 
an O 
anti-solvent O 
approach O 
has O 
been O 
reported O 
. O 
Among O 
solvents O 
examined O 
, O 
methanol B-SYSTEMATIC 
was O 
practically O 
the O 
only O 
one O 
that O 
resulted O 
in O 
the O 
formation O 
of O 
highly O 
pure O 
IMC B-ABBREVIATION 
- O 
SAC B-ABBREVIATION 
co O 
- O 
crystal O 
powders O 
by O 
anti-solvent O 
approach O 
. O 
The O 
mechanism O 
of O 
a O 
preferential O 
formation O 
of O 
IMC B-ABBREVIATION 
- O 
SAC B-ABBREVIATION 
co O 
- O 
crystal O 
to O 
IMC B-ABBREVIATION 
was O 
explained O 
with O 
two O 
aspects O 
: O 
phase O 
solubility O 
diagram O 
and O 
solution O 
complexation O 
concept O 
. O 
Accordingly O 
, O 
the O 
anti-solvent O 
approach O 
can O 
be O 
considered O 
as O 
a O 
competitive O 
route O 
for O 
producing O 
pharmaceutical O 
co O 
- O 
crystal O 
powders O 
with O 
acceptable O 
properties O 
. O 

of O 
drugs O 
directed O 
at O 
commonly O 
associated O 
diseases O 
provides O 
a O 
convenient O 
means O 
for O 
administration O 
, O 
especially O 
if O 
transdermally O 
delivered O 
. O 
In O 
this O 
work O 
, O 
a O 
comprehensive O 
study O 
for O 
the O 
co O 
- O 
encapsulation O 
of O 
drugs O 
with O 
a O 
differential O 
lipophilicity O 
, O 
olanzapine B-TRIVIAL 
and O 
simvastatin B-TRIVIAL 
, O 
and O 
their O 
transdermal O 
delivery O 
in O 
a O 
formulation O 
containing O 
nanostructured O 
lipid O 
carriers O 
( O 
NLC O 
) O 
is O 
presented O 
. O 
Focus O 
is O 
given O 
to O 
the O 
evaluation O 
of O 
a O 
strategy O 
in O 
which O 
NLC O 
and O 
chemical O 
permeation O 
enhancers O 
are O 
combined O 
. O 
It O 
comprises O 
in O 
vitro O 
, O 
in O 
silico O 
and O 
cellular O 
viability O 
approaches O 
. O 
The O 
optimization O 
and O 
rationalization O 
of O 
the O 
systems O 
are O 
carried O 
out O 
using O 
a O 
two O 
- O 
step O 
factorial O 
design O 
. O 
It O 
is O 
shown O 
that O 
the O 
external O 
medium O 
in O 
the O 
NLC O 
dispersion O 
strongly O 
influences O 
permeation O 
. O 
It O 
is O 
also O 
seen O 
that O 
the O 
use O 
of O 
NLC O 
determines O 
a O 
synergistic O 
effect O 
with O 
selected O 
permeation O 
enhancers O 
, O 
thus O 
promoting O 
marked O 
flux O 
enhancement O 
ratios O 
( O 
48 O 
and O 
21 O 
, O 
respectively O 
for O 
olanzapine B-TRIVIAL 
and O 
simvastatin B-TRIVIAL 
) O 
relative O 
to O 
the O 
drugs O 
in O 
solution O 
. O 
The O 
developed O 
formulations O 
can O 
be O 
considered O 
non-irritant O 
. O 
A O 
correlation O 
between O 
enhancer O 
positioning O 
in O 
a O 
lipid O 
bilayer O 
, O 
partially O 
governed O 
by O 
a O 
H B-FORMULA 
-bonding O 
phenomenon O 
, O 
and O 
enhancement O 
effect O 
is O 
suggested O 
from O 
molecular O 
dynamics O 
studies O 
and O 
experimental O 
observations O 
. O 

of O 
protein O 
malnutrition O 
on O 
the O 
metabolism O 
and O 
toxicity O 
of O 
cisplatin B-TRIVIAL 
, O 
5-fluorouracil B-SYSTEMATIC 
and O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
in O 
rat O 
stomach O 
. O 

study O 
investigated O 
the O 
effect O 
of O 
protein O 
malnutrition O 
on O 
metabolism O 
and O 
toxicity O 
of O 
cisplatin B-TRIVIAL 
( O 
CP O 
) O 
, O 
5-fluorouracil B-SYSTEMATIC 
( O 
FU O 
) O 
and O 
mitomycin B-TRIVIAL 
C I-TRIVIAL 
( O 
MMC B-ABBREVIATION 
) O 
in O 
rat O 
stomach O 
. O 
Weanling O 
male O 
Wistar O 
rats O 
received O 
a O 
normal O 
( O 
24% O 
) O 
or O 
low O 
( O 
2.5% O 
) O 
protein O 
diet O 
for O 
28days O 
and O 
were O 
allocated O 
into O 
: O 
normally O 
- O 
fed O 
control O 
, O 
protein O 
- O 
malnourished O 
control O 
( O 
PM O 
) O 
, O 
3 O 
normally O 
- O 
fed O 
drug O 
- O 
treated O 
groups O 
and O 
3 O 
protein O 
- O 
malnourished O 
drug O 
- O 
treated O 
groups O 
( O 
PM-CP O 
, O 
PM-FU O 
and O 
PM- O 
MMC B-ABBREVIATION 
) O 
. O 
Cisplatin B-TRIVIAL 
and O 
MMC B-ABBREVIATION 
were O 
injected O 
intraperitoneally O 
( O 
8mg O 
/ O 
kg O 
on O 
day O 
26 O 
and O 
1mg O 
/ O 
kg O 
/ O 
day O 
for O 
7days O 
, O 
respectively O 
) O 
. O 
5-Fluorouracil B-SYSTEMATIC 
was O 
given O 
orally O 
( O 
50mg O 
/ O 
kg O 
/ O 
day O 
for O 
5days O 
) O 
. O 
Compared O 
with O 
normally O 
- O 
fed O 
counterparts O 
, O 
PM-CP O 
rats O 
exhibited O 
higher O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferase O 
, O 
aminopeptidase O 
N B-FORMULA 
and O 
cysteine B-TRIVIAL 
S B-FORMULA 
-conjugate O 
beta-lyase O 
( O 
CCBL O 
) O 
and O 
lower O 
gamma-glutamyltransferase O 
activities O 
, O 
PM-FU O 
rats O 
exhibited O 
decreased O 
dihydropyrimidine B-SYSTEMATIC 
dehydrogenase O 
and O 
cytochrome O 
P450 O 
1A1 O 
/ O 
2 O 
activities O 
and O 
PM- O 
MMC B-ABBREVIATION 
rats O 
showed O 
higher O 
quinone B-FAMILY 
reductase O 
and O 
depleted O 
xanthine B-TRIVIAL 
oxidase O 
activities O 
. O 
Protein O 
- O 
malnourished O 
drug O 
- O 
treated O 
groups O 
exhibited O 
exacerbated O 
gastrotoxicity O 
, O 
relative O 
to O 
normally O 
- O 
fed O 
counterparts O 
, O 
manifested O 
by O 
lower O 
mucus O 
levels O 
, O 
higher O 
permeability O 
and O 
histopathological O 
deterioration O 
, O 
along O 
with O 
increased O 
oxidative O 
stress O 
in O 
PM-CP O 
rats O 
and O 
exaggerated O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
production O 
in O 
PM- O 
MMC B-ABBREVIATION 
rats O 
. O 
Conclusively O 
, O 
protein O 
malnutrition O 
alters O 
CP O 
, O 
FU O 
and O 
MMC B-ABBREVIATION 
metabolism O 
in O 
rat O 
stomach O 
by O 
enhancing O 
CCBL O 
pathway O 
for O 
CP O 
activation O 
, O 
delaying O 
FU O 
elimination O 
and O 
activating O 
two O 
- O 
electron O 
reduction O 
of O 
MMC B-ABBREVIATION 
, O 
potentiating O 
their O 
gastrotoxicity O 
. O 

of O 
endoplasmic O 
reticulum O 
stress O 
- O 
mediated O 
apoptosis O 
and O 
non-canonical O 
autophagy O 
by O 
luteolin B-TRIVIAL 
in O 
NCI-H460 O 
lung O 
carcinoma O 
cells O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
anti-cancer O 
effects O 
of O 
luteolin B-TRIVIAL 
, O 
a O 
member O 
of O 
the O 
flavonoid B-FAMILY 
family O 
, O 
in O 
NCI-H460 O 
human O 
lung O 
carcinoma O 
cells O 
. O 
It O 
was O 
shown O 
that O 
luteolin B-TRIVIAL 
induces O 
apoptotic O 
cell O 
death O 
through O 
modulating O 
both O 
the O 
extrinsic O 
pathway O 
and O 
intrinsic O 
pathways O 
, O 
which O 
are O 
suppressed O 
by O 
z-VAD-fmk O 
, O 
indicating O 
that O 
luteolin B-TRIVIAL 
triggers O 
caspase O 
- O 
dependant O 
apoptosis O 
. O 
Furthermore O 
, O 
we O 
found O 
that O 
the O 
α O 
subunit O 
of O 
the O 
eukaryotic O 
initiation O 
factor O 
2 O 
( O 
eIF2α O 
/ O 
C O 
/ O 
EBP O 
homologous O 
protein O 
pathway O 
, O 
but O 
not O 
the O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
pathway O 
, O 
played O 
a O 
critical O 
role O 
in O 
induction O 
of O 
apoptosis O 
by O 
luteolin B-TRIVIAL 
. O 
The O 
data O 
indicated O 
that O 
luteolin B-TRIVIAL 
also O 
induces O 
autophagy O 
; O 
evidence O 
for O 
this O 
is O 
the O 
accumulation O 
of O 
microtubule O 
- O 
associated O 
protein O 
light O 
chain-3 O 
( O 
LC3 O 
) O 
II O 
protein O 
, O 
the O 
increase O 
of O 
LC3 O 
puncta O 
as O 
well O 
as O 
an O 
enhanced O 
autophagy O 
flux O 
. O 
In O 
addition O 
, O 
inhibiting O 
autophagy O 
by O 
bafilomycin B-TRIVIAL 
A1 I-TRIVIAL 
reduced O 
apoptotic O 
cell O 
death O 
, O 
suggesting O 
that O 
luteolin B-TRIVIAL 
-induced O 
autophagy O 
functions O 
as O 
a O 
cell O 
death O 
mechanism O 
. O 
Notably O 
, O 
the O 
activated O 
caspases O 
that O 
appeared O 
with O 
luteolin B-TRIVIAL 
treatment O 
cleaved O 
Beclin-1 O 
, O 
and O 
the O 
expression O 
of O 
LC3II O 
remained O 
the O 
same O 
even O 
after O 
cells O 
were O 
challenged O 
with O 
Beclin-1 O 
siRNA O 
, O 
demonstrating O 
that O 
luteolin B-TRIVIAL 
induces O 
Beclin-1 O 
- O 
independent O 
autophagy O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
showed O 
that O 
luteolin B-TRIVIAL 
triggers O 
both O 
endoplasmic O 
reticulum O 
stress O 
- O 
related O 
apoptosis O 
and O 
non-canonical O 
autophagy O 
, O 
which O 
function O 
as O 
a O 
cell O 
death O 
mechanism O 
in O 
NCI-H460 O 
human O 
lung O 
cancer O 
cells O 
. O 

acid I-TRIVIAL 
treatment O 
alters O 
the O 
extracellular O 
adenine B-TRIVIAL 
nucleotide I-TRIVIAL 
hydrolysis O 
in O 
platelets O 
and O 
lymphocytes O 
of O 
adult O 
rats O 
. O 

study O 
evaluated O 
the O 
effects O 
of O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
on O 
ectonucleotidase O 
activities O 
such O 
as O 
NTPDase O 
( O 
nucleoside B-FAMILY 
triphosphate I-FAMILY 
diphosphohydrolase O 
) O 
, O 
Ecto-NPP O 
( O 
nucleotide B-FAMILY 
pyrophosphatase O 
/ O 
phosphodiesterase O 
) O 
, O 
5'-nucleotidase O 
and O 
adenosine B-TRIVIAL 
deaminase O 
( O 
ADA O 
) O 
in O 
platelets O 
and O 
lymphocytes O 
of O 
rats O 
, O 
as O 
well O 
as O 
in O 
the O 
profile O 
of O 
platelet O 
aggregation O 
. O 
Animals O 
were O 
divided O 
into O 
five O 
groups O 
: O 
I O 
( O 
control O 
) O 
; O 
II O 
( O 
oil O 
) O 
; O 
III O 
( O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
10mg O 
/ O 
kg O 
) O 
; O 
IV O 
( O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
50mg O 
/ O 
kg O 
) O 
; O 
and O 
V O 
( O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
100mg O 
/ O 
kg O 
) O 
. O 
Animals O 
were O 
treated O 
with O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
diluted O 
in O 
oil O 
for O 
30days O 
. O 
In O 
platelets O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
decreased O 
the O 
ATP B-ABBREVIATION 
hydrolysis O 
and O 
increased O 
ADP B-ABBREVIATION 
hydrolysis O 
in O 
groups O 
III O 
, O 
IV O 
and O 
V O 
when O 
compared O 
to O 
control O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
5'-nucleotidase O 
activity O 
was O 
decreased O 
, O 
while O 
E-NPP O 
and O 
ADA O 
activities O 
were O 
increased O 
in O 
platelets O 
of O 
rats O 
of O 
groups O 
III O 
, O 
IV O 
and O 
V O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Caffeic B-TRIVIAL 
acid I-TRIVIAL 
reduced O 
significantly O 
the O 
platelet O 
aggregation O 
in O 
the O 
animals O 
of O 
groups O 
III O 
, O 
IV O 
and O 
V O 
in O 
relation O 
to O 
group O 
I O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
In O 
lymphocytes O 
, O 
the O 
NTPDase O 
and O 
ADA O 
activities O 
were O 
increased O 
in O 
all O 
groups O 
treated O 
with O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
when O 
compared O 
to O 
control O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
These O 
findings O 
demonstrated O 
that O 
the O 
enzymes O 
were O 
altered O 
in O 
tissues O 
by O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
and O 
this O 
compound O 
decreased O 
the O 
platelet O 
aggregation O 
suggesting O 
that O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
should O 
be O 
considered O 
a O 
potentially O 
therapeutic O 
agent O 
in O 
disorders O 
related O 
to O 
the O 
purinergic O 
system O 
. O 

of O 
aluminium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
towards O 
fresh O 
water O 
algal O 
isolate O 
at O 
low O 
exposure O 
concentrations O 
. O 

growing O 
commercial O 
applications O 
had O 
brought O 
aluminium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
under O 
toxicologists O 
' O 
purview O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
cytotoxicity O 
of O 
two O 
different O 
sized O 
aluminium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
ANP(1) O 
, O 
mean O 
hydrodynamic O 
diameter O 
82.6±22nm O 
and O 
ANP(2) O 
, O 
mean O 
hydrodynamic O 
diameter O 
246.9±39nm O 
) O 
towards O 
freshwater O 
algal O 
isolate O 
Chlorella O 
ellipsoids O 
at O 
low O 
exposure O 
levels O 
( O 
≤ O 
1μg O 
/ O 
mL O 
) O 
using O 
sterile O 
lake O 
water O 
as O 
the O 
test O 
medium O 
was O 
assessed O 
. O 
The O 
dissolution O 
of O 
alumina B-TRIVIAL 
nanoparticles O 
and O 
consequent O 
contribution O 
towards O 
toxicity O 
remained O 
largely O 
unexplored O 
owing O 
to O 
its O 
presumed O 
insoluble O 
nature O 
. O 
Herein O 
, O 
the O 
leached O 
Al(3+) B-FORMULA 
ion O 
mediated O 
toxicity O 
has O 
been O 
studied O 
along O 
with O 
direct O 
particulate O 
toxicity O 
to O 
bring O 
out O 
the O 
dynamics O 
of O 
toxicity O 
through O 
colloidal O 
stability O 
, O 
biochemical O 
, O 
spectroscopic O 
and O 
microscopic O 
analyses O 
. O 
The O 
mean O 
hydrodynamic O 
diameter O 
increased O 
with O 
time O 
both O 
for O 
ANP(1) O 
[ O 
82.6±22nm O 
( O 
0h O 
) O 
to O 
246.3±59nm O 
( O 
24h O 
) O 
, O 
to O 
1204±140nm O 
( O 
72h O 
) O 
] O 
and O 
ANP(2) O 
[ O 
246.9±39nm O 
( O 
0h O 
) O 
to O 
368.28±48nm O 
( O 
24h O 
) O 
, O 
to O 
1225.96±186nm O 
( O 
72h O 
) O 
] O 
signifying O 
decreased O 
relative O 
abundance O 
of O 
submicron O 
sized O 
particles O 
( O 
< O 
1000nm O 
) O 
. O 
The O 
detailed O 
cytotoxicity O 
assays O 
showed O 
a O 
significant O 
reduction O 
in O 
the O 
viability O 
dependent O 
on O 
dose O 
and O 
exposure O 
. O 
A O 
significant O 
increase O 
in O 
ROS O 
and O 
LDH O 
levels O 
were O 
noted O 
for O 
both O 
ANPs O 
at O 
1μg O 
/ O 
mL O 
concentration O 
. O 
The O 
zeta O 
potential O 
and O 
FT-IR O 
analyses O 
suggested O 
surface O 
chemical O 
interaction O 
between O 
nanoparticles O 
and O 
algal O 
cells O 
. O 
The O 
substantial O 
morphological O 
changes O 
and O 
cell O 
wall O 
damage O 
were O 
confirmed O 
through O 
microscopic O 
analyses O 
( O 
SEM O 
, O 
TEM O 
, O 
and O 
CLSM O 
) O 
. O 
At O 
72h O 
, O 
significant O 
Al(3+) B-FORMULA 
ion O 
release O 
in O 
the O 
test O 
medium O 
[ O 
0.092μg O 
/ O 
mL O 
for O 
ANP(1) O 
, O 
and O 
0.19μg O 
/ O 
mL O 
for O 
ANP(2) O 
] O 
was O 
noted O 
, O 
and O 
the O 
resulting O 
suspension O 
containing O 
leached O 
ions O 
caused O 
significant O 
cytotoxicity O 
, O 
revealing O 
a O 
substantial O 
ionic O 
contribution O 
. O 
This O 
study O 
indicates O 
that O 
both O 
the O 
nano O 
- O 
size O 
and O 
ionic O 
dissolution O 
play O 
a O 
significant O 
role O 
in O 
the O 
cytotoxicity O 
of O 
ANPs O 
towards O 
freshwater O 
algae O 
, O 
and O 
the O 
exposure O 
period O 
largely O 
determines O 
the O 
prevalent O 
mode O 
of O 
nano O 
- O 
toxicity O 
. O 

web O 
analysis O 
reveals O 
effects O 
of O 
pH O 
on O 
mercury B-SYSTEMATIC 
bioaccumulation O 
at O 
multiple O 
trophic O 
levels O 
in O 
streams O 
. O 

processes O 
and O 
the O 
factors O 
that O 
govern O 
them O 
, O 
including O 
those O 
for O 
mercury B-SYSTEMATIC 
( O 
Hg B-FORMULA 
) O 
, O 
are O 
poorly O 
understood O 
in O 
streams O 
. O 
Total O 
and O 
methyl B-SYSTEMATIC 
Hg B-FORMULA 
concentrations O 
and O 
relative O 
trophic O 
position O 
( O 
using O 
δ O 
(15)N B-FORMULA 
) O 
were O 
analyzed O 
in O 
biofilm O 
and O 
invertebrates O 
from O 
21 O 
streams O 
in O 
New O 
Brunswick O 
, O 
Canada O 
to O 
assess O 
food O 
web O 
biomagnification O 
leading O 
to O 
the O 
common O 
minnow O 
blacknose O 
dace O 
( O 
Rhinichthys O 
atratulus O 
) O 
, O 
a O 
species O 
known O 
to O 
have O 
Hg B-FORMULA 
concentrations O 
that O 
are O 
higher O 
in O 
low O 
pH O 
waters O 
. O 
Biomagnification O 
slopes O 
within O 
stream O 
food O 
webs O 
measured O 
using O 
Hg B-FORMULA 
vs O 
. O 
δ O 
(15)N B-FORMULA 
or O 
corresponding O 
trophic O 
levels O 
( O 
TL O 
) O 
differed O 
depending O 
on O 
the O 
chemical O 
species O 
analyzed O 
, O 
with O 
total O 
Hg B-FORMULA 
exhibiting O 
increases O 
of O 
1.3-2.5 O 
per O 
TL O 
( O 
mean O 
slope O 
of O 
total O 
Hg B-FORMULA 
vs O 
. O 
δ O 
(15)N B-FORMULA 
= O 
0.14±0.06 O 
S.D O 
. O 
, O 
range=0.06-0.20 O 
) O 
and O 
methyl B-SYSTEMATIC 
Hg B-FORMULA 
showing O 
a O 
more O 
pronounced O 
increase O 
of O 
2.8 O 
to O 
6 O 
per O 
TL O 
( O 
mean O 
slope O 
of O 
methyl B-SYSTEMATIC 
Hg B-FORMULA 
vs O 
. O 
δ O 
(15)N B-FORMULA 
= O 
0.30±0.08 O 
S.D O 
. O 
, O 
range=0.22-0.39 O 
) O 
. O 
While O 
Hg B-FORMULA 
biomagnification O 
slopes O 
through O 
the O 
entire O 
food O 
web O 
( O 
Trophic O 
Magnification O 
Factors O 
, O 
TMFs O 
) O 
were O 
not O 
influenced O 
by O 
water O 
chemistry O 
( O 
pH O 
) O 
, O 
dietary O 
concentrations O 
of O 
methyl B-SYSTEMATIC 
Hg B-FORMULA 
strongly O 
influenced O 
biomagnification O 
factors O 
( O 
BMFs O 
) O 
for O 
consumer O 
- O 
diet O 
pairs O 
within O 
the O 
food O 
web O 
at O 
lower O 
trophic O 
levels O 
, O 
and O 
BMFs O 
between O 
dace O 
and O 
predatory O 
invertebrates O 
were O 
significantly O 
higher O 
in O 
low O 
pH O 
waters O 
. O 
These O 
analyses O 
, O 
coupled O 
with O 
observations O 
of O 
higher O 
Hg B-FORMULA 
in O 
primary O 
producers O 
in O 
streams O 
with O 
low O 
pH O 
, O 
suggest O 
that O 
pH O 
influences O 
both O 
baseline O 
concentrations O 
and O 
biomagnification O 
of O 
Hg B-FORMULA 
in O 
these O 
systems O 
. O 
Because O 
higher O 
Hg B-FORMULA 
concentrations O 
in O 
the O 
diets O 
of O 
primary O 
consumers O 
and O 
predatory O 
insects O 
in O 
lower O 
pH O 
waters O 
led O 
to O 
lower O 
BMFs O 
, O 
these O 
feeding O 
groups O 
showed O 
insignificant O 
relationships O 
between O 
Hg B-FORMULA 
and O 
pH O 
; O 
thus O 
, O 
altered O 
BMFs O 
associated O 
with O 
dietary O 
concentrations O 
can O 
dampen O 
the O 
effects O 
of O 
environmental O 
conditions O 
on O 
Hg B-FORMULA 
concentrations O 
. O 

induced O 
toxicity O 
reduction O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
to O 
Tetrahymena O 
Pyriformis O 
: O 
Effect O 
of O 
particle O 
size O 
. O 

a O 
result O 
of O 
the O 
extensive O 
application O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
, O 
their O 
potential O 
hazards O 
, O 
once O 
they O 
are O 
released O 
into O 
the O 
natural O 
environment O 
, O 
are O 
of O 
great O 
concern O 
to O 
people O 
. O 
Since O 
silver B-SYSTEMATIC 
is O 
very O 
sensitive O 
to O 
light O 
, O 
the O 
toxicity O 
of O 
AgNPs O 
released O 
into O 
the O 
natural O 
environment O 
will O 
be O 
inevitably O 
affected O 
by O 
light O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
relationship O 
between O 
light O 
, O 
toxicity O 
, O 
and O 
particle O 
size O 
of O 
AgNPs O 
and O 
deduce O 
the O 
possible O 
mechanism O 
of O 
any O 
interaction O 
. O 
Our O 
study O 
revealed O 
that O 
there O 
was O 
negative O 
correlation O 
between O 
the O 
particle O 
size O 
and O 
the O 
toxicity O 
: O 
small O 
AgNPs O 
( O 
5-10nm O 
) O 
had O 
higher O 
toxicity O 
than O 
large O 
AgNPs O 
( O 
15-25nm O 
) O 
to O 
Tetrahymena O 
pyriformis O 
( O 
T O 
. O 
pyriformis O 
) O 
under O 
dark O 
condition O 
. O 
Comparing O 
the O 
size O 
dependent O 
AgNPs O 
toxicity O 
under O 
dark O 
and O 
light O 
conditions O 
, O 
the O 
effect O 
of O 
light O 
to O 
size O 
dependent O 
AgNPs O 
toxicity O 
was O 
ascertained O 
. O 
The O 
results O 
indicated O 
that O 
AgNPs O 
toxicity O 
was O 
decreased O 
by O 
light O 
and O 
the O 
most O 
important O 
discovery O 
was O 
that O 
the O 
change O 
of O 
size O 
dependent O 
AgNPs O 
toxicity O 
had O 
significant O 
difference O 
under O 
light O 
irradiation O 
. O 
The O 
decrease O 
of O 
small O 
AgNPs O 
toxicity O 
induced O 
by O 
light O 
was O 
more O 
notable O 
than O 
large O 
AgNPs O 
. O 
The O 
decreased O 
level O 
of O 
cell O 
toxicity O 
for O 
small O 
AgNPs O 
was O 
32±0.7% O 
, O 
whereas O 
it O 
was O 
only O 
10.6±5.2% O 
for O 
large O 
AgNPs O 
kept O 
24h O 
under O 
light O 
irradiation O 
. O 
The O 
further O 
investigation O 
indicated O 
that O 
the O 
above O 
changes O 
induced O 
by O 
light O 
can O 
be O 
attributed O 
to O 
the O 
decrease O 
of O 
released O 
silver B-SYSTEMATIC 
ions O 
, O 
particle O 
growth O 
and O 
aggregation O 
of O 
AgNPs O 
under O 
light O 
irradiation O 
. O 
The O 
obtained O 
results O 
showed O 
that O 
the O 
light O 
irradiation O 
can O 
promote O 
the O 
rapid O 
growth O 
of O 
small O 
AgNPs O 
and O 
result O 
in O 
the O 
obvious O 
increase O 
of O 
particle O 
size O 
and O 
serious O 
aggregation O 
. O 
These O 
phenomena O 
would O 
induce O 
the O 
decrease O 
of O 
silver B-SYSTEMATIC 
ions O 
released O 
from O 
small O 
AgNPs O 
, O 
which O 
is O 
responsible O 
for O 
the O 
remarkable O 
decrease O 
of O 
toxicity O 
for O 
small O 
AgNPs O 
. O 

quinazoline B-SYSTEMATIC 
derivatives O 
for O 
telomeric O 
G-quadruplex O 
DNA O 
: O 
Effects O 
of O 
an O 
added O 
phenyl B-SYSTEMATIC 
group O 
on O 
quadruplex O 
binding O 
ability O 
. O 

improve O 
the O 
selectivity O 
of O 
indoloquinoline B-SYSTEMATIC 
or O 
benzofuroquinoline B-SYSTEMATIC 
derivatives O 
, O 
we O 
previously O 
reported O 
several O 
quinazoline B-SYSTEMATIC 
derivatives O 
[ O 
17 O 
] O 
. O 
These O 
compounds O 
could O 
mimic O 
a O 
tetracyclic O 
aromatic O 
system O 
through O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bond O 
. O 
Studies O 
showed O 
that O 
these O 
quinazoline B-SYSTEMATIC 
derivatives O 
were O 
effective O 
and O 
selective O 
telomeric O 
G-quadruplex O 
ligands O 
. O 
With O 
this O 
encouragement O 
, O 
here O 
we O 
synthesized O 
a O 
series O 
of O 
N-(2-(quinazolin-2-yl)phenyl)benzamide B-SYSTEMATIC 
( O 
QPB B-ABBREVIATION 
) O 
compounds O 
as O 
modified O 
quinazoline B-SYSTEMATIC 
derivatives O 
. O 
In O 
this O 
modification O 
, O 
a O 
phenyl B-SYSTEMATIC 
group O 
was O 
introduced O 
to O 
the O 
aromatic O 
core O 
. O 
The O 
evaluation O 
results O 
showed O 
that O 
part O 
of O 
QPB B-ABBREVIATION 
derivatives O 
had O 
stronger O 
binding O 
ability O 
and O 
better O 
selectivity O 
for O 
telomeric O 
G-quadruplex O 
DNA O 
than O 
LZ-11 B-IDENTIFIER 
, O 
the O 
most O 
potential O 
compound O 
of O 
reported O 
quinazoline B-SYSTEMATIC 
derivatives O 
. O 
Furthermore O 
, O 
telomerase O 
inhibition O 
of O 
QPB B-ABBREVIATION 
derivatives O 
and O 
their O 
cellular O 
effects O 
were O 
studied O 
. O 

of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
genotoxicity O 
effect O 
to O 
exposure O 
of O 
nanosized O 
polyamidoamine B-FAMILY 
( O 
PAMAM B-ABBREVIATION 
) O 
dendrimers O 
in O 
PLHC-1 O 
cells O 
in O 
vitro O 
. O 

( O 
PAMAM B-ABBREVIATION 
) O 
dendrimers O 
have O 
previously O 
been O 
demonstrated O 
to O 
elicit O 
systematically O 
variable O 
cyto- O 
and O 
eco O 
- O 
toxic O 
responses O 
, O 
promising O 
as O 
the O 
basis O 
for O 
structure O 
- O 
activity O 
relationships O 
governing O 
nanotoxicological O 
responses O 
. O 
In O 
this O 
study O 
, O 
increased O 
production O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
genotoxicity O 
and O 
apoptosis O 
due O 
to O 
in O 
vitro O 
exposure O 
of O 
fish O 
hepatocellular O 
carcinoma O 
cells O 
to O 
dendrimer O 
generations O 
G4 O 
, O 
G5 O 
and O 
G6 O 
is O 
demonstrated O 
. O 
A O 
PAMAM B-ABBREVIATION 
dendrimer O 
generation O 
dependent O 
increase O 
in O 
ROS O 
and O 
genotoxicity O 
was O 
observed O 
, O 
consistent O 
with O 
our O 
previous O 
studies O 
. O 
The O 
toxicological O 
responses O 
correlate O 
well O 
with O 
the O 
nanoparticle O 
surface O 
chemistry O 
, O 
specifically O 
, O 
the O 
number O 
of O 
surface O 
amino B-FAMILY 
groups O 
per O 
generation O 
. O 
Although O 
ROS O 
production O 
initially O 
increases O 
approximately O 
linearly O 
, O 
it O 
saturates O 
at O 
higher O 
doses O 
. O 
Notably O 
, O 
normalized O 
to O 
the O 
molar O 
dose O 
of O 
surface O 
amino B-FAMILY 
groups O 
, O 
the O 
dose O 
- O 
dependent O 
ROS O 
production O 
for O 
different O 
generations O 
overlap O 
exactly O 
, O 
indicating O 
that O 
the O 
response O 
is O 
due O 
to O 
these O 
functional O 
units O 
. O 
The O 
genotoxicity O 
response O 
is O 
also O 
well O 
correlated O 
to O 
the O 
number O 
of O 
surface O 
amino B-FAMILY 
groups O 
and O 
therefore O 
generation O 
of O 
PAMAM B-ABBREVIATION 
dendrimers O 
. O 
The O 
observed O 
genotoxicity O 
, O 
related O 
to O 
DNA O 
damage O 
, O 
is O 
related O 
to O 
the O 
generation O 
and O 
dose O 
dependent O 
production O 
of O 
intracellular O 
ROS O 
, O 
at O 
low O 
levels O 
. O 
At O 
the O 
higher O 
ROS O 
levels O 
, O 
increased O 
DNA O 
damage O 
is O 
associated O 
with O 
the O 
onset O 
of O 
necrosis O 
. O 

Distribution O 
and O 
Identification O 
of O 
Radioactivity O 
Components O 
at O 
Elimination O 
Phase O 
after O 
Oral O 
Administration O 
of O 
[14C]CS-1036 B-IDENTIFIER 
, O 
an O 
α-Amylase O 
Inhibitor O 
, O 
to O 
Rats O 
. O 

4-O-(6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside I-SYSTEMATIC 
( O 
CS-1036 B-IDENTIFIER 
) O 
is O 
a O 
potent O 
inhibitor O 
of O 
pancreatic O 
and O 
salivary O 
α-amylase O 
. O 
After O 
oral O 
administration O 
of O 
[(14)C]CS-1036 B-IDENTIFIER 
to O 
rats O 
, O 
the O 
radioactivity O 
was O 
still O 
detectable O 
up O 
to O 
7-14 O 
days O 
after O 
administration O 
in O 
various O 
tissues O 
, O 
and O 
its O 
terminal O 
phase O 
in O 
plasma O 
could O 
be O 
explained O 
neither O 
by O 
the O 
exposure O 
of O 
CS-1036 B-IDENTIFIER 
nor O 
its O 
major O 
metabolite O 
M1 O 
. O 
The O 
slow O 
elimination O 
of O 
radioactivity O 
in O 
various O 
tissues O 
was O 
hypothesized O 
to O 
be O 
caused O 
by O 
covalent O 
binding O 
to O 
macromolecules O 
or O 
use O 
for O 
biogenic O 
components O 
. O 
To O 
assess O 
the O 
use O 
for O 
biogenic O 
components O 
, O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
of O 
plasma O 
proteins O 
and O 
lipid O 
analysis O 
of O 
adipose O 
tissue O 
were O 
conducted O 
after O 
repeated O 
oral O 
administration O 
of O 
[(14)C]CS-1036 B-IDENTIFIER 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
and O 
accelerated O 
mass O 
spectrometry O 
and O 
by O 
thin O 
layer O 
chromatography O 
and O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
, O 
respectively O 
. O 
In O 
amino B-FAMILY 
acid I-FAMILY 
analysis O 
, O 
glutamic B-TRIVIAL 
acid I-TRIVIAL 
, O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
, O 
alanine B-TRIVIAL 
, O 
and O 
proline B-TRIVIAL 
were O 
identified O 
as O 
major O 
radioactive O 
amino B-FAMILY 
acids I-FAMILY 
, O 
and O 
radioactive O 
nonessential O 
amino B-FAMILY 
acids I-FAMILY 
occupied O 
76.0% O 
of O 
the O 
radioactivity O 
. O 
In O 
lipid O 
analysis O 
, O 
a O 
part O 
of O 
the O 
radioactive O 
lipids O 
were O 
identified O 
as O 
the O 
fatty B-FAMILY 
acids I-FAMILY 
constituting O 
the O 
neutral O 
lipids O 
by O 
lipase O 
- O 
hydrolysis O 
. O 
The O 
radioactive O 
fatty B-FAMILY 
acids I-FAMILY 
from O 
neutral O 
lipids O 
were O 
identified O 
as O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
, O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
8,11,14-eicosatrienoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 
Intestinal O 
flora O 
were O 
involved O 
in O 
CS-1036 B-IDENTIFIER 
metabolism O 
and O 
are O 
indicated O 
to O 
be O 
involved O 
in O 
the O 
production O 
of O 
small O 
molecule O 
metabolites O 
, O 
which O 
are O 
the O 
sources O 
for O 
amino B-FAMILY 
acids I-FAMILY 
and O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
from O 
[(14)C]CS-1036 B-IDENTIFIER 
. O 
In O 
conclusion O 
, O 
radioactivity O 
derived O 
from O 
[(14)C]CS-1036 B-IDENTIFIER 
was O 
incorporated O 
as O 
the O 
constituents O 
of O 
amino B-FAMILY 
acids I-FAMILY 
of O 
plasma O 
proteins O 
and O 
fatty B-FAMILY 
acids I-FAMILY 
of O 
neutral O 
lipids O 
. O 

oleanolic B-FAMILY 
vinyl I-FAMILY 
boronates I-FAMILY 
: O 
Synthesis O 
and O 
antitumor O 
activity O 
. O 

series O 
of O 
novel O 
oleanane B-TRIVIAL 
-type O 
pentacyclic O 
triterpenoids B-FAMILY 
bearing O 
a O 
boronate B-FAMILY 
ester I-FAMILY 
moiety O 
at O 
C3 O 
have O 
been O 
synthesized O 
by O 
palladium B-SYSTEMATIC 
-catalyzed O 
cross O 
- O 
coupling O 
of O 
bis(pinacolato)diboron B-SYSTEMATIC 
with O 
vinyl B-FAMILY 
triflates I-FAMILY 
, O 
in O 
the O 
presence O 
of O 
base O 
, O 
and O 
these O 
compounds O 
were O 
fully O 
characterized O 
by O 
1D O 
and O 
2D O 
NMR O 
techniques O 
. O 
Evaluation O 
of O 
their O 
antiproliferative O 
effects O 
on O 
a O 
panel O 
of O 
hematological O 
- O 
based O 
and O 
solid O 
tumor O 
cell O 
lines O 
identified O 
three O 
active O 
oleanolic B-FAMILY 
vinyl I-FAMILY 
boronates I-FAMILY 
that O 
inhibited O 
the O 
growth O 
of O 
leukemia O 
( O 
Jurkat O 
, O 
K562 O 
) O 
, O 
Burkitt's O 
lymphoma O 
( O 
Jijoye O 
) O 
, O 
cervix O 
( O 
Hela O 
) O 
, O 
colon O 
( O 
SW480 O 
) O 
, O 
and O 
ovary O 
( O 
SKOV-3 O 
) O 
cancer O 
cells O 
without O 
concomitant O 
inhibition O 
of O 
non-tumoral O 
human O 
fibroblasts O 
. O 
Their O 
mechanisms O 
of O 
action O 
were O 
investigated O 
on O 
the O 
leukemia O 
Jurkat O 
cell O 
line O 
. O 
The O 
results O 
show O 
that O 
the O 
incorporation O 
of O 
boron B-SYSTEMATIC 
in O 
the O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
core O 
combined O 
with O 
the O 
presence O 
of O 
amide B-FAMILY 
bonds O 
afforded O 
compounds O 
with O 
desirable O 
biological O 
effects O 
such O 
as O 
apoptosis O 
induction O 
and O 
inhibition O 
of O 
proteasomal O 
activity O 
on O 
tumor O 
cells O 
, O 
which O 
makes O 
them O 
potential O 
templates O 
for O 
further O 
development O 
in O 
the O 
anticancer O 
drug O 
setting O 
. O 

- O 
assisted O 
synthesis O 
of O 
arene B-FAMILY 
ruthenium I-FAMILY 
(II) I-FAMILY 
complexes O 
that O 
induce O 
S-phase O 
arrest O 
in O 
cancer O 
cells O 
by O 
DNA O 
damage O 
- O 
mediated O 
p53 O 
phosphorylation O 
. O 

series O 
of O 
arene B-FAMILY 
ruthenium I-FAMILY 
(II) I-FAMILY 
complexes O 
coordinated O 
by O 
phenanthroimidazole B-FAMILY 
derivates O 
, O 
[(C6H6)Ru(L)Cl]Cl·2H2O B-FORMULA 
( O 
1b O 
L O 
= O 
IP O 
, O 
2b O 
L O 
= O 
p-NMe2PIP B-FORMULA 
, O 
3b O 
L O 
= O 
p-MeOPIP B-FORMULA 
, O 
4b O 
L O 
= O 
p-HOPIP B-FORMULA 
, O 
5b O 
L O 
= O 
p-COOHPIP B-FORMULA 
, O 
6b O 
L O 
= O 
p-CF3PIP B-FORMULA 
, O 
7b O 
L O 
= O 
p-BrPIP B-FORMULA 
) O 
have O 
been O 
synthesized O 
in O 
yields O 
of O 
89-92% O 
under O 
microwave O 
irradiation O 
in O 
30 O 
min O 
, O 
and O 
the O 
crystal O 
structure O 
of O 
1b O 
by O 
XRD O 
gives O 
a O 
typical O 
" O 
piano O 
stool O 
" O 
conformation O 
. O 
The O 
antitumor O 
activity O 
of O 
these O 
complexes O 
against O 
various O 
tumor O 
cells O 
have O 
been O 
evaluated O 
by O 
MTT B-ABBREVIATION 
assay O 
, O 
and O 
the O 
results O 
show O 
that O 
this O 
type O 
of O 
arene B-FAMILY 
Ru B-FORMULA 
(II) I-FORMULA 
complexes O 
exhibit O 
acceptable O 
inhibitory O 
effect O 
against O 
all O 
of O 
these O 
tumor O 
cells O 
, O 
especially O 
osteosarcoma O 
MG-63 O 
cells O 
, O 
but O 
with O 
low O 
toxicity O 
toward O 
HK-2 O 
human O 
normal O 
cells O 
. O 
Studies O 
on O 
the O 
mechanism O 
revealed O 
that O 
cell O 
cycle O 
arrest O 
at O 
S-phase O 
in O 
MG-63 O 
cells O 
induced O 
by O 
the O 
arene B-FAMILY 
Ru B-FORMULA 
(II) I-FORMULA 
complex O 
2b O 
, O 
which O 
was O 
confirmed O 
by O 
the O 
increase O 
in O 
the O 
percentage O 
of O 
cells O 
at O 
S-phase O 
and O 
down O 
- O 
regulator O 
of O 
cyclin O 
A O 
. O 
The O 
further O 
studies O 
by O 
Comet O 
assay O 
at O 
single O 
cell O 
level O 
indicated O 
that O 
DNA O 
damage O 
in O 
MG-63 O 
cells O 
was O 
triggered O 
by O 
2b O 
, O 
following O 
with O 
the O 
up O 
- O 
regulation O 
of O 
phosphorylated O 
p53 O 
and O 
histone O 
. O 
The O 
studies O 
by O 
spectroscopy O 
in O 
vitro O 
also O 
indicate O 
that O 
2b O 
bind O 
to O 
DNA O 
molecule O 
by O 
intercalative O 
mode O 
to O 
disturb O 
the O 
bio O 
- O 
function O 
of O 
tumor O 
cells O 
. O 
In O 
conclusion O 
, O 
the O 
synthetic O 
arene B-FAMILY 
Ru B-FORMULA 
(II) I-FORMULA 
complexes O 
could O 
serve O 
as O 
novel O 
p53 O 
activator O 
with O 
potential O 
application O 
in O 
cancer O 
chemotherapy O 
. O 

report O 
a O 
new O 
capping-agent-free O 
strategy O 
for O 
the O 
synthesis O 
of O 
substrate O 
- O 
supported O 
porous O 
icosahedral O 
Au B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
with O 
rough O 
naked O 
surfaces O 
, O 
based O 
on O 
the O 
crystallization O 
from O 
substrate O 
- O 
supported O 
thin O 
solution O 
layers O 
followed O 
by O 
solid O 
- O 
phase O 
thermolysis O 
. O 
The O 
plasmonic O 
properties O 
of O 
icosahedral O 
Au B-FORMULA 
NPs O 
have O 
been O 
studied O 
using O 
single O 
particle O 
dark O 
- O 
field O 
scattering O 
microscopy O 
and O 
spectroscopy O 
. O 
The O 
two O 
distinct O 
localized O 
surface O 
plasmon O 
resonance O 
( O 
LSPR O 
) O 
bands O 
observed O 
in O 
the O 
single O 
particle O 
dark O 
- O 
field O 
spectra O 
can O 
be O 
ascribed O 
to O 
the O 
quadrupole O 
resonance O 
at O 
ca O 
. O 
425 O 
nm O 
and O 
the O 
size O 
- O 
dependent O 
dipole O 
resonance O 
in O 
the O 
red O 
region O 
( O 
645-708 O 
nm O 
) O 
. O 
The O 
unique O 
rough O 
naked O 
surface O 
, O 
the O 
facile O 
synthesis O 
, O 
together O 
with O 
the O 
ability O 
to O 
control O 
the O 
nanoparticle O 
size O 
and O 
to O 
vary O 
the O 
LSPR O 
frequency O 
in O 
the O 
red O 
region O 
, O 
would O 
make O 
the O 
substrate O 
- O 
supported O 
porous O 
icosahedral O 
Au B-FORMULA 
NPs O 
promising O 
on O 
multiple O 
levels O 
in O 
the O 
applications O 
of O 
catalysis O 
, O 
ultrasensitive O 
biosensors O 
, O 
and O 
in O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
. O 

Dilation O 
via O 
Selective O 
Targeting O 
of O 
the O 
Cholane B-TRIVIAL 
Steroid B-FAMILY 
-Recognition O 
Site O 
in O 
the O 
BK O 
Channel O 
β1-Subunit O 
by O 
a O 
Novel O 
Nonsteroidal O 
Agent O 
. O 

Ca(2+ B-FORMULA 
) O 
/ O 
voltage O 
- O 
gated O 
K(+) B-FORMULA 
large O 
conductance O 
( O 
BK O 
) O 
channel O 
β1 O 
subunit O 
is O 
particularly O 
abundant O 
in O 
vascular O 
smooth O 
muscle O 
. O 
By O 
determining O 
their O 
phenotype O 
, O 
BK O 
β1 O 
allows O 
the O 
BK O 
channels O 
to O 
reduce O 
myogenic O 
tone O 
, O 
facilitating O 
vasodilation O 
. O 
The O 
endogenous O 
steroid B-FAMILY 
lithocholic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LCA B-ABBREVIATION 
) O 
dilates O 
cerebral O 
arteries O 
via O 
BK O 
channel O 
activation O 
, O 
which O 
requires O 
recognition O 
by O 
a O 
BK O 
β1 O 
site O 
that O 
includes O 
Thr B-FORMULA 
169 O 
. O 
Whether O 
exogenous O 
nonsteroidal O 
agents O 
can O 
access O 
this O 
site O 
to O 
selectively O 
activate O 
β1 O 
- O 
containing O 
BK O 
channels O 
and O 
evoke O 
vasodilation O 
remain O 
unknown O 
. O 
We O 
performed O 
a O 
chemical O 
structure O 
database O 
similarity O 
search O 
using O 
LCA B-ABBREVIATION 
as O 
a O 
template O 
, O 
along O 
with O 
a O 
two O 
- O 
step O 
reaction O 
to O 
generate O 
sodium B-SYSTEMATIC 
3-hydroxyolean-12-en-30-oate I-SYSTEMATIC 
( O 
HENA B-ABBREVIATION 
) O 
. O 
HENA B-ABBREVIATION 
activated O 
the O 
BK O 
( O 
cbv1 O 
+ O 
β1 O 
) O 
channels O 
cloned O 
from O 
rat O 
cerebral O 
artery O 
myocytes O 
with O 
a O 
potency O 
( O 
EC50 O 
= O 
53 O 
μM O 
) O 
similar O 
to O 
and O 
an O 
efficacy O 
( O 
×2.5 O 
potentiation O 
) O 
significantly O 
greater O 
than O 
that O 
of O 
LCA B-ABBREVIATION 
. O 
This O 
HENA B-ABBREVIATION 
action O 
was O 
replicated O 
on O 
native O 
channels O 
in O 
rat O 
cerebral O 
artery O 
myocytes O 
. O 
HENA B-ABBREVIATION 
failed O 
to O 
activate O 
the O 
channels O 
made O 
of O 
cbv1 O 
+ O 
β2 O 
, O 
β3 O 
, O 
β4 O 
, O 
or O 
β1T169A O 
, O 
indicating O 
that O 
this O 
drug O 
selectively O 
targets O 
β1 O 
- O 
containing O 
BK O 
channels O 
via O 
the O 
BK O 
β1 O 
steroid B-FAMILY 
-sensing O 
site O 
. O 
HENA B-ABBREVIATION 
( O 
3-45 O 
μM O 
) O 
dilated O 
the O 
rat O 
and O 
C57BL O 
/ O 
6 O 
mouse O 
pressurized O 
cerebral O 
arteries O 
. O 
Consistent O 
with O 
the O 
electrophysiologic O 
results O 
, O 
this O 
effect O 
was O 
larger O 
than O 
that O 
of O 
LCA B-ABBREVIATION 
. O 
HENA B-ABBREVIATION 
failed O 
to O 
dilate O 
the O 
arteries O 
from O 
the O 
KCNMB1 O 
knockout O 
mouse O 
, O 
underscoring O 
BK O 
β1's O 
role O 
in O 
HENA B-ABBREVIATION 
action O 
. O 
Finally O 
, O 
carotid O 
artery O 
- O 
infusion O 
of O 
HENA B-ABBREVIATION 
( O 
45 O 
μM O 
) O 
dilated O 
the O 
pial O 
cerebral O 
arterioles O 
via O 
selective O 
BK-channel O 
targeting O 
. O 
In O 
conclusion O 
, O 
we O 
have O 
identified O 
for O 
the O 
first O 
time O 
a O 
nonsteroidal O 
agent O 
that O 
selectively O 
activates O 
β1 O 
- O 
containing O 
BK O 
channels O 
by O 
targeting O 
the O 
steroid B-FAMILY 
-sensing O 
site O 
in O 
BK O 
β1 O 
, O 
rendering O 
vasodilation O 
. O 

of O 
the O 
m1 O 
transmembrane O 
helix O 
and O 
pre-m1 O 
region O 
to O 
positive O 
allosteric O 
modulation O 
and O 
gating O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
receptors O 
. O 

( O 
NMDA B-ABBREVIATION 
) O 
receptors O 
are O 
glutamate O 
- O 
gated O 
ion O 
channels O 
whose O 
function O 
is O 
critical O 
for O 
normal O 
excitatory O 
synaptic O 
transmission O 
in O 
the O 
brain O 
and O 
whose O 
dysfunction O 
has O 
been O 
implicated O 
in O 
several O 
neurologic O 
conditions O 
. O 
NMDA B-ABBREVIATION 
receptor O 
function O 
is O 
subject O 
to O 
extensive O 
allosteric O 
regulation O 
both O 
by O 
endogenous O 
compounds O 
and O 
by O 
exogenous O 
small O 
molecules O 
. O 
Elucidating O 
the O 
structural O 
determinants O 
and O 
mechanism O 
of O 
action O 
by O 
which O 
allosteric O 
regulators O 
control O 
gating O 
will O 
enhance O 
our O 
understanding O 
of O 
NMDA B-ABBREVIATION 
receptor O 
activation O 
and O 
facilitate O 
the O 
development O 
of O 
novel O 
therapeutics O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
structural O 
determinants O 
for O 
(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone B-SYSTEMATIC 
( O 
CIQ B-ABBREVIATION 
) O 
, O 
a O 
GluN2C O 
/ O 
2D-selective O 
positive O 
allosteric O 
modulator O 
. O 
We O 
show O 
that O 
CIQ B-ABBREVIATION 
does O 
not O 
bind O 
to O 
the O 
amino B-FAMILY 
-terminal O 
domain O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
and O 
does O 
not O 
share O 
structural O 
determinants O 
with O 
modulators O 
acting O 
at O 
the O 
agonist O 
- O 
binding O 
domain O 
dimer O 
interface O 
or O 
ion O 
channel O 
pore O 
. O 
Rather O 
, O 
we O 
identified O 
critical O 
determinants O 
of O 
CIQ B-ABBREVIATION 
modulation O 
in O 
the O 
region O 
near O 
the O 
first O 
transmembrane O 
helix O 
of O 
GluN2D O 
, O 
including O 
in O 
a O 
putative O 
pre-M1 O 
cuff O 
helix O 
that O 
may O 
influence O 
channel O 
gating O 
. O 
We O 
also O 
show O 
that O 
mutations O 
within O 
the O 
GluN2D O 
pre-M1 O 
region O 
alter O 
open O 
probability O 
of O 
the O 
NMDA B-ABBREVIATION 
receptor O 
. O 
These O 
results O 
suggest O 
a O 
novel O 
site O 
of O 
action O 
for O 
potentiation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
by O 
small O 
molecules O 
and O 
implicate O 
the O 
pre-M1 O 
region O 
in O 
NMDA B-ABBREVIATION 
receptor O 
gating O 
. O 

and O 
self O 
- O 
assembled O 
packing O 
morphology O 
of O 
long O 
alkyl-chained O 
substituted O 
polyhedral B-FAMILY 
oligomeric I-FAMILY 
silsesquioxanes I-FAMILY 
( O 
POSS B-ABBREVIATION 
) O 
cages O 
. O 

oligomeric I-FAMILY 
silsesquioxane I-FAMILY 
( O 
POSS B-ABBREVIATION 
) O 
cubic O 
cage O 
systems O 
( O 
octa-n-octadecyloctasilsesquioxane B-SYSTEMATIC 
, O 
( O 
T8C18 B-FORMULA 
) O 
and O 
octakis(n-octadecyldimethylsiloxy)octasilsesquioxane B-SYSTEMATIC 
, O 
( O 
Q8C18 B-FORMULA 
) O 
) O 
were O 
synthesised O 
with O 
eight O 
long O 
n-alkyl O 
chain O 
( O 
R O 
= O 
C18H37 B-FORMULA 
) O 
substituent O 
arms O 
, O 
as O 
model O 
nano O 
- O 
functionalized O 
compounds O 
. O 
The O 
crystalline O 
packing O 
morphology O 
of O 
the O 
cages O 
was O 
studied O 
using O 
time O 
- O 
resolved O 
Small- O 
and O 
Wide-angle O 
X-ray O 
scattering O 
( O 
SAXS O 
/ O 
WAXS O 
) O 
, O 
thermal O 
and O 
optical O 
techniques O 
. O 
From O 
thermal O 
analysis O 
the O 
melting O 
and O 
crystallization O 
temperatures O 
of O 
the O 
Q8 O 
cage O 
were O 
significantly O 
less O 
than O 
those O 
for O 
the O 
T8 O 
cage O 
. O 
X-ray O 
scattering O 
showed O 
that O 
both O 
cage O 
systems O 
have O 
long O 
- O 
range O 
crystalline O 
ordering O 
where O 
the O 
alkyl O 
chains O 
align O 
in O 
a O 
parallel O 
axial O 
disposition O 
from O 
the O 
POSS O 
core O 
giving O 
a O 
' O 
rod O 
- O 
like O 
' O 
self O 
- O 
assembled O 
packing O 
morphology O 
. O 
The O 
packing O 
length O 
- O 
scale O 
can O 
be O 
directly O 
related O 
to O 
the O 
overall O 
dimensions O 
of O 
the O 
POSS O 
molecules O 
. O 
Compared O 
to O 
the O 
T8 O 
cages O 
, O 
the O 
Q8 O 
cages O 
pack O 
more O 
efficiently O 
allowing O 
the O 
interdigitation O 
of O 
the O 
alkyl O 
chain O 
arms O 
. O 
Different O 
packing O 
modes O 
and O 
thermal O 
behaviour O 
observed O 
for O 
the O 
T8 O 
and O 
Q8 O 
cages O 
is O 
directly O 
attributed O 
to O 
their O 
structural O 
chemistry O 
. O 
For O 
the O 
Q8 O 
cage O 
, O 
the O 
presence O 
of O 
the O 
OSiMe2 B-FORMULA 
spacer O 
groups O 
which O 
tether O 
the O 
alkyl O 
chain O 
arms O 
to O 
the O 
cage O 
( O 
absent O 
in O 
the O 
T8 O 
cages O 
) O 
allows O 
greater O 
flexibility O 
of O 
the O 
arms O 
letting O 
them O 
interdigitate O 
with O 
each O 
other O 
when O 
packing O 
which O 
is O 
not O 
observed O 
for O 
the O 
analogous O 
T8 O 
cages O 
. O 

are O 
small O 
peptides O 
present O 
in O 
the O 
venom O 
of O 
cone O 
snails O 
. O 
The O 
snail O 
uses O 
this O 
venom O 
to O 
paralyze O 
and O 
capture O 
prey O 
. O 
The O 
constituent O 
conopeptides O 
display O 
a O 
high O 
level O 
of O 
chemical O 
diversity O 
and O 
are O 
of O 
particular O 
interest O 
for O 
scientists O 
as O 
tools O 
employed O 
in O 
neurological O 
studies O 
and O 
for O 
drug O 
development O 
, O 
because O 
they O 
target O 
with O 
exquisite O 
specificity O 
membrane O 
receptors O 
, O 
transporters O 
, O 
and O 
various O 
ion O 
channels O 
in O 
the O 
nervous O 
system O 
. O 
However O 
, O 
these O 
peptides O 
are O 
known O 
to O 
contain O 
a O 
high O 
frequency O 
and O 
variability O 
of O 
post O 
- O 
translational O 
modifications O 
- O 
including O 
sometimes O 
O B-FORMULA 
-glycosylation O 
- O 
which O 
are O 
of O 
importance O 
for O 
biological O 
activity O 
. O 
The O 
potential O 
application O 
of O 
specific O 
conotoxins O 
as O 
neuropharmalogical O 
agents O 
and O 
chemical O 
probes O 
requires O 
a O 
full O 
characterization O 
of O 
the O 
relevant O 
peptides O 
, O 
including O 
the O 
structure O 
of O 
the O 
carbohydrate B-FAMILY 
part O 
. O 
In O 
this O 
review O 
, O 
the O 
currently O 
existing O 
knowledge O 
of O 
O B-FORMULA 
-glycosylation O 
of O 
conotoxins O 
is O 
described O 
. O 

of O 
spinosad B-FAMILY 
and O 
λ-cyhalothrin B-FAMILY 
on O 
spider O 
communities O 
in O 
cabbage O 
fields O 
in O 
south O 
Texas O 
. O 

are O 
a O 
principal O 
arthropod O 
group O 
that O 
preys O 
on O 
numerous O 
pests O 
of O 
vegetables O 
and O 
other O 
crops O 
. O 
In O 
this O 
study O 
, O 
we O 
determined O 
the O 
effects O 
of O 
the O 
two O 
most O 
commonly O 
used O 
insecticides O 
, O 
spinosad B-FAMILY 
and O 
λ-cyhalothrin B-FAMILY 
, O 
on O 
diversity O 
of O 
spiders O 
on O 
cabbage O 
in O 
south O 
Texas O 
. O 
In O 
two O 
seasons O 
( O 
fall O 
2008 O 
and O 
spring O 
2009 O 
) O 
, O 
we O 
collected O 
a O 
total O 
of O 
588 O 
spiders O 
belonging O 
to O 
53 O 
species O 
in O 
11 O 
families O 
from O 
spinosad B-FAMILY 
and O 
λ-cyhalothrin B-FAMILY 
-treated O 
cabbages O 
and O 
the O 
untreated O 
control O 
plants O 
. O 
A O 
great O 
majority O 
of O 
spiders O 
were O 
collected O 
from O 
the O 
pitfall O 
traps O 
( O 
554 O 
) O 
where O 
only O 
a O 
few O 
( O 
34 O 
) O 
were O 
collected O 
from O 
the O 
blower O 
/ O 
vacuum O 
sampling O 
. O 
In O 
the O 
insecticide O 
- O 
treated O 
plots O 
, O 
there O 
were O 
significantly O 
fewer O 
spider O 
individuals O 
, O 
species O 
and O 
families O 
than O 
in O 
untreated O 
fields O 
. O 
Spinosad B-FAMILY 
had O 
significantly O 
less O 
effect O 
on O 
spiders O 
in O 
total O 
individuals O 
, O 
number O 
of O 
species O 
and O 
families O 
than O 
λ-cyhalothrin B-FAMILY 
. O 
The O 
effects O 
of O 
the O 
two O 
insecticides O 
were O 
further O 
demonstrated O 
by O 
the O 
Shannon-Weiner O 
index O 
( O 
H O 
' O 
) O 
and O 
the O 
hierarchical O 
richness O 
index O 
( O 
HRI O 
) O 
. O 
Spider O 
diversity O 
in O 
the O 
spinosad B-FAMILY 
-treated O 
plots O 
were O 
not O 
significantly O 
different O 
from O 
that O 
in O 
the O 
untreated O 
fields O 
but O 
were O 
greater O 
than O 
those O 
in O 
λ-cyhalothrin B-FAMILY 
-treated O 
plots O 
in O 
both O 
seasons O 
when O 
measured O 
by O 
H O 
' O 
values O 
. O 
In O 
contrast O 
, O 
the O 
H O 
' O 
values O 
of O 
spider's O 
diversity O 
in O 
the O 
λ-cyhalothrin B-FAMILY 
-treated O 
plots O 
were O 
significantly O 
lower O 
than O 
spinosad B-FAMILY 
-treated O 
and O 
untreated O 
plots O 
. O 
High O 
values O 
of O 
HRI O 
for O 
spider O 
richness O 
in O 
the O 
spinosad B-FAMILY 
-treated O 
plots O 
suggested O 
that O 
spinosad B-FAMILY 
had O 
less O 
effect O 
on O 
spiders O 
than O 
λ-cyhalothrin B-FAMILY 
. O 
We O 
concluded O 
that O 
spinosad B-FAMILY 
was O 
more O 
compatible O 
with O 
spiders O 
on O 
cabbage O 
compared O 
to O 
λ-cyhalothrin B-FAMILY 
and O 
that O 
this O 
information O 
should O 
be O 
used O 
when O 
developing O 
insecticide O 
resistance O 
management O 
strategies O 
. O 

Pin1 O 
protein O 
plays O 
a O 
critical O 
role O 
in O 
the O 
functional O 
regulation O 
of O 
the O 
hyperphosphorylated O 
neuronal O 
Tau O 
protein O 
in O 
Alzheimer's O 
disease O 
and O 
is O 
by O 
itself O 
regulated O 
by O 
phosphorylation O 
. O 
We O 
have O 
used O 
Nuclear O 
Magnetic O 
Resonance O 
( O 
NMR O 
) O 
spectroscopy O 
to O 
both O 
identify O 
the O 
PKA O 
phosphorylation O 
site O 
in O 
the O 
Pin1 O 
WW O 
domain O 
and O 
investigate O 
the O 
functional O 
consequences O 
of O 
this O 
phosphorylation O 
. O 
Detection O 
and O 
identification O 
of O 
phosphorylation O 
on O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
residues O 
in O 
a O 
globular O 
protein O 
, O 
while O 
mostly O 
occurring O 
in O 
solvent-exposed O 
flexible O 
loops O 
, O 
does O 
not O 
lead O 
to O 
chemical O 
shift O 
changes O 
as O 
obvious O 
as O 
in O 
disordered O 
proteins O 
and O 
hence O 
does O 
not O 
necessarily O 
shift O 
the O 
resonances O 
outside O 
the O 
spectrum O 
of O 
the O 
folded O 
protein O 
. O 
Other O 
complications O 
were O 
encountered O 
to O 
characterize O 
the O 
extent O 
of O 
the O 
phosphorylation O 
, O 
as O 
part O 
of O 
the O 
(1)H B-FORMULA 
, O 
(15)N B-FORMULA 
amide B-FAMILY 
resonances O 
around O 
the O 
phosphorylation O 
site O 
are O 
specifically O 
broadened O 
in O 
the O 
unphosphorylated O 
state O 
. O 
Despite O 
these O 
obstacles O 
, O 
NMR O 
spectroscopy O 
was O 
an O 
efficient O 
tool O 
to O 
confirm O 
phosphorylation O 
on O 
S16 O 
of O 
the O 
WW O 
domain O 
and O 
to O 
quantify O 
the O 
level O 
of O 
phosphorylation O 
. O 
Based O 
on O 
this O 
analytical O 
characterization O 
, O 
we O 
show O 
that O 
WW O 
phosphorylation O 
on O 
S16 O 
abolishes O 
its O 
binding O 
capacity O 
to O 
a O 
phosphorylated O 
Tau O 
peptide O 
. O 
A O 
reduced O 
conformational O 
heterogeneity O 
and O 
flexibility O 
of O 
the O 
phospho B-SYSTEMATIC 
-binding O 
loop O 
upon O 
S16 O 
phosphorylation O 
could O 
account O 
for O 
part O 
of O 
the O 
decreased O 
affinity O 
for O 
its O 
phosphorylated O 
partner O 
. O 
Additionally O 
, O 
a O 
structural O 
model O 
of O 
the O 
phospho B-SYSTEMATIC 
-WW O 
obtained O 
by O 
molecular O 
dynamics O 
simulation O 
and O 
energy O 
minimization O 
suggests O 
that O 
the O 
phosphate B-SYSTEMATIC 
moiety O 
of O 
phospho B-SYSTEMATIC 
-S16 O 
could O 
compete O 
with O 
the O 
phospho B-SYSTEMATIC 
-substrate O 
. O 

processes O 
in O 
the O 
regulation O 
of O 
gene O 
expression O 
and O 
signaling O 
involve O 
the O 
formation O 
of O 
protein O 
complexes O 
involving O 
multi O 
- O 
domain O 
proteins O 
. O 
Individual O 
domains O 
that O 
mediate O 
protein O 
- O 
protein O 
and O 
protein O 
- O 
nucleic O 
acid O 
interactions O 
are O 
typically O 
connected O 
by O 
flexible O 
linkers O 
, O 
which O 
contribute O 
to O 
conformational O 
dynamics O 
and O 
enable O 
the O 
formation O 
of O 
complexes O 
with O 
distinct O 
binding O 
partners O 
. O 
Solution O 
techniques O 
are O 
therefore O 
required O 
for O 
structural O 
analysis O 
and O 
to O 
characterize O 
potential O 
conformational O 
dynamics O 
. O 
Nuclear O 
magnetic O 
resonance O 
spectroscopy O 
( O 
NMR O 
) O 
provides O 
such O 
information O 
but O 
often O 
only O 
sparse O 
data O 
are O 
obtained O 
with O 
increasing O 
molecular O 
weight O 
of O 
the O 
complexes O 
. O 
It O 
is O 
therefore O 
beneficial O 
to O 
combine O 
NMR O 
data O 
with O 
additional O 
structural O 
restraints O 
from O 
complementary O 
solution O 
techniques O 
. O 
Small O 
angle O 
X-ray O 
/ O 
neutron O 
scattering O 
( O 
SAXS O 
/ O 
SANS O 
) O 
data O 
can O 
be O 
efficiently O 
combined O 
with O 
NMR O 
- O 
derived O 
information O 
, O 
either O 
for O 
validation O 
or O 
by O 
providing O 
additional O 
restraints O 
for O 
structural O 
analysis O 
. O 
Here O 
, O 
we O 
show O 
that O 
the O 
combination O 
of O 
SAXS O 
and O 
SANS O 
data O 
can O 
help O 
to O 
refine O 
structural O 
models O 
obtained O 
from O 
data O 
- O 
driven O 
docking O 
using O 
HADDOCK O 
based O 
on O 
sparse O 
NMR O 
data O 
. O 
The O 
approach O 
is O 
demonstrated O 
with O 
the O 
ternary O 
protein O 
- O 
protein-RNA O 
complex O 
involving O 
two O 
RNA O 
recognition O 
motif O 
( O 
RRM O 
) O 
domains O 
of O 
Sex O 
- O 
lethal O 
, O 
the O 
N B-FORMULA 
-terminal O 
cold O 
shock O 
domain O 
of O 
Upstream-to-N-Ras O 
, O 
and O 
msl-2 O 
mRNA O 
. O 
Based O 
on O 
chemical O 
shift O 
perturbations O 
we O 
have O 
mapped O 
protein O 
- O 
protein O 
and O 
protein-RNA O 
interfaces O 
and O 
complemented O 
this O 
NMR O 
- O 
derived O 
information O 
with O 
SAXS O 
data O 
, O 
as O 
well O 
as O 
SANS O 
measurements O 
on O 
subunit O 
- O 
selectively O 
deuterated O 
samples O 
of O 
the O 
ternary O 
complex O 
. O 
Our O 
results O 
show O 
that O 
, O 
while O 
the O 
use O 
of O 
SAXS O 
data O 
is O 
beneficial O 
, O 
the O 
additional O 
combination O 
with O 
contrast O 
variation O 
in O 
SANS O 
data O 
resolves O 
remaining O 
ambiguities O 
and O 
improves O 
the O 
docking O 
based O 
on O 
chemical O 
shift O 
perturbations O 
of O 
the O 
ternary O 
protein-RNA O 
complex O 
. O 

is O 
cultivated O 
in O 
water O 
- O 
logged O 
paddy O 
lands O 
. O 
Thus O 
, O 
rice O 
root O 
hairs O 
on O 
the O 
epidermal O 
layers O 
are O 
exposed O 
to O 
a O 
different O 
redox O 
status O 
of O 
nitrogen B-SYSTEMATIC 
species O 
, O 
organic O 
acids O 
, O 
and O 
metal O 
ions O 
than O 
root O 
hairs O 
growing O 
in O 
drained O 
soil O 
. O 
To O 
identify O 
genes O 
that O 
play O 
an O 
important O 
role O 
in O 
root O 
hair O 
growth O 
, O 
a O 
forward O 
genetics O 
approach O 
was O 
used O 
to O 
screen O 
for O 
short O 
- O 
root O 
- O 
hair O 
mutants O 
. O 
A O 
short O 
- O 
root O 
- O 
hair O 
mutant O 
was O 
identified O 
and O 
isolated O 
by O 
using O 
map O 
- O 
based O 
cloning O 
and O 
sequencing O 
. O 
The O 
mutation O 
arose O 
from O 
a O 
single O 
amino B-FAMILY 
acid I-FAMILY 
substitution O 
of O 
OsSNDP1 O 
( O 
Oryza O 
sativa O 
Sec14-nodulin O 
domain O 
protein O 
) O 
, O 
which O 
shows O 
high O 
sequence O 
homology O 
with O 
Arabidopsis O 
COW1 O 
/ O 
AtSFH1 O 
and O 
encodes O 
a O 
phosphatidylinositol B-TRIVIAL 
transfer O 
protein O 
( O 
PITP O 
) O 
. O 
By O 
performing O 
complementation O 
assays O 
with O 
Atsfh1 O 
mutants O 
, O 
we O 
demonstrated O 
that O 
OsSNDP1 O 
is O 
involved O 
in O 
growth O 
of O 
root O 
hairs O 
. O 
Cryo O 
- O 
scanning O 
electron O 
microscopy O 
was O 
utilized O 
to O 
further O 
characterize O 
the O 
effect O 
of O 
the O 
Ossndp1 O 
mutation O 
on O 
root O 
hair O 
morphology O 
. O 
Aberrant O 
morphogenesis O 
was O 
detected O 
in O 
root O 
hair O 
elongation O 
and O 
maturation O 
zones O 
. O 
Many O 
root O 
hairs O 
were O 
branched O 
and O 
showed O 
irregular O 
shapes O 
due O 
to O 
bulged O 
nodes O 
. O 
Many O 
epidermal O 
cells O 
also O 
produced O 
dome O 
- O 
shaped O 
root O 
hairs O 
, O 
which O 
indicated O 
that O 
root O 
hair O 
elongation O 
ceased O 
at O 
an O 
early O 
stage O 
. O 
These O 
studies O 
showed O 
that O 
PITP O 
- O 
mediated O 
phospholipid O 
signaling O 
and O 
metabolism O 
is O 
critical O 
for O 
root O 
hair O 
elongation O 
in O 
rice O 
. O 

are O 
reports O 
of O 
insulin O 
overdose O 
by O 
injection O 
, O 
yet O 
little O 
is O 
known O 
regarding O 
the O 
potential O 
harms O 
of O 
intentional O 
oral O 
ingestion O 
of O 
insulin O 
. O 
In O 
this O 
report O 
, O 
we O 
describe O 
a O 
case O 
of O 
massive O 
insulin O 
ingestion O 
and O 
ensuing O 
hypoglycemia O 
. O 
To O 
our O 
knowledge O 
, O 
there O 
are O 
no O 
previously O 
published O 
cases O 
of O 
hypoglycemia O 
caused O 
by O 
intentional O 
insulin O 
ingestion O 
. O 
A O 
51-year- O 
old O 
man O 
intentionally O 
ingested O 
three O 
10-ml O 
vials O 
( O 
total O 
of O 
3000 O 
units O 
) O 
of O 
various O 
insulins O 
: O 
one O 
vial O 
each O 
of O 
insulin O 
aspart O 
, O 
lispro O 
, O 
and O 
glargine O 
. O 
Four O 
symptomatic O 
hypoglycemic O 
episodes O 
, O 
with O 
blood O 
glucose B-TRIVIAL 
levels O 
of O 
48 O 
, O 
25 O 
, O 
34 O 
, O 
and O 
40 O 
mg O 
/ O 
dl O 
, O 
occurred O 
approximately O 
1 O 
, O 
3 O 
, O 
4 O 
, O 
and O 
5 O 
hours O 
, O 
respectively O 
, O 
after O 
ingestion O 
. O 
The O 
hypoglycemia O 
could O 
not O 
be O 
explained O 
other O 
than O 
the O 
ingestion O 
of O 
the O 
insulins O 
. O 
The O 
patient O 
was O 
admitted O 
for O 
observation O 
, O 
and O 
euglycemia O 
occurred O 
within O 
24 O 
hours O 
without O 
any O 
additional O 
hypoglycemic O 
episodes O 
. O 
Hypoglycemia O 
treatment O 
is O 
reviewed O 
in O 
this O 
case O 
report O 
, O 
and O 
factors O 
that O 
may O 
affect O 
systemic O 
response O 
of O 
orally O 
ingested O 
insulin O 
, O 
including O 
gastrointestinal O 
absorption O 
and O 
insulin O 
sensitivity O 
, O 
are O 
discussed O 
. O 
In O 
addition O 
, O 
the O 
findings O 
of O 
our O 
case O 
report O 
may O 
provide O 
useful O 
insight O 
into O 
the O 
development O 
of O 
novel O 
oral O 
insulin O 
products O 
that O 
are O 
currently O 
in O 
research O 
. O 
Despite O 
poor O 
bioavailability O 
( O 
1% O 
) O 
when O 
taken O 
orally O 
, O 
insulin O 
may O 
produce O 
symptomatic O 
hypoglycemia O 
with O 
a O 
massive O 
ingestion O 
. O 
Vigilant O 
blood O 
glucose B-TRIVIAL 
monitoring O 
, O 
supportive O 
care O 
with O 
glucose B-TRIVIAL 
replacement O 
therapy O 
, O 
and O 
admission O 
to O 
the O 
hospital O 
for O 
observation O 
may O 
be O 
required O 
. O 

present O 
study O 
was O 
performed O 
to O 
investigate O 
the O 
effect O 
of O 
Urtica O 
dioica O 
( O 
UD O 
) O 
on O 
liver O 
regeneration O 
after O 
partial O 
hepatectomy O 
( O 
PH O 
) O 
in O 
rats O 
. O 
A O 
total O 
of O 
24 O 
male O 
Sprague O 
Dawley O 
rats O 
were O 
divided O 
into O 
three O 
groups O 
: O 
sham O 
- O 
operated O 
, O 
PH O 
and O 
PH O 
+ O 
UD O 
; O 
each O 
group O 
contains O 
eight O 
animals O 
. O 
The O 
rats O 
in O 
UD O 
- O 
treated O 
groups O 
were O 
given O 
UD O 
oils O 
( O 
2 O 
ml O 
/ O 
kg O 
/ O 
day O 
) O 
once O 
a O 
day O 
orally O 
for O 
7 O 
days O 
starting O 
3 O 
days O 
prior O 
to O 
hepatectomy O 
operation O 
. O 
At O 
day O 
7 O 
after O 
resection O 
, O 
liver O 
samples O 
were O 
collected O 
. O 
The O 
levels O 
of O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
, O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
were O 
estimated O 
in O 
liver O 
homogenates O 
. O 
Moreover O 
, O 
histopathological O 
examination O 
, O 
mitotic O 
index O 
( O 
MI O 
) O 
, O 
proliferating O 
cell O 
nuclear O 
antigen O 
labeling O 
, O 
proliferation O 
index O 
( O 
PI O 
) O 
, O 
transferase O 
- O 
mediated O 
deoxyuridine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
nick O 
end O 
- O 
labeling O 
assay O 
, O 
apoptotic O 
index O 
( O 
AI O 
) O 
were O 
evaluated O 
at O 
day O 
7 O 
after O 
hepatectomy O 
. O 
As O 
a O 
result O 
, O 
UD O 
significantly O 
increased O 
MI O 
and O 
PI O 
, O 
significantly O 
decreased O 
AI O 
and O 
also O 
attenuated O 
hepatic O 
vacuolar O 
degeneration O 
and O 
sinusoidal O 
congestion O 
in O 
PH O 
rats O 
. O 
UD O 
treatment O 
significantly O 
decreased O 
the O 
elevated O 
tissue O 
MDA B-ABBREVIATION 
level O 
and O 
increased O 
the O 
reduced O 
SOD O 
activity O 
and O 
GSH B-ABBREVIATION 
level O 
in O 
the O 
tissues O 
. O 
These O 
results O 
suggest O 
that O 
UD O 
pretreatment O 
was O 
beneficial O 
for O 
rat O 
liver O 
regeneration O 
after O 
partial O 
hepatectomy O 
. O 

: O 
Corrosive O 
esophageal O 
injury O 
causes O 
serious O 
clinical O 
problems O 
. O 
We O 
aimed O 
to O 
create O 
a O 
new O 
experimental O 
esophageal O 
burn O 
model O 
using O 
a O 
single O 
catheter O 
without O 
a O 
surgical O 
procedure O 
. O 
Materials O 
and O 
methods O 
: O 
We O 
conducted O 
the O 
study O 
with O 
two O 
groups O 
of O 
12 O 
male O 
rats O 
that O 
fasted O 
for O 
12 O 
h O 
before O 
application O 
. O 
A O 
modified O 
Foley O 
balloon O 
catheter O 
was O 
inserted O 
into O 
the O 
esophageal O 
lumen O 
. O 
The O 
control O 
group O 
was O 
given O 
0.9% O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
while O 
the O 
experimental O 
group O 
was O 
given O 
37.5% O 
sodium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
with O 
the O 
other O 
part O 
of O 
the O 
catheter O 
. O 
After O 
60s O 
, O 
esophagus O 
was O 
washed O 
with O 
distilled O 
water O 
. O 
The O 
killed O 
rats O 
were O 
examined O 
using O 
histopathological O 
methods O 
after O 
28 O 
days O 
. O 
RESULTS O 
: O 
In O 
comparison O 
with O 
the O 
histopathological O 
changes O 
experienced O 
by O 
the O 
study O 
groups O 
, O 
the O 
control O 
groups O 
were O 
observed O 
to O 
have O 
no O 
pathological O 
changes O 
. O 
Basal O 
cell O 
degeneration O 
, O 
dermal O 
edema O 
, O 
and O 
a O 
slight O 
increase O 
in O 
the O 
keratin O 
layer O 
and O 
collagen O 
density O 
of O 
submucosa O 
due O 
to O 
stenosis O 
were O 
all O 
observed O 
in O 
the O 
group O 
subjected O 
to O 
esophageal O 
corrosion O 
. O 
CONCLUSION O 
: O 
A O 
new O 
burn O 
model O 
can O 
thus O 
, O 
we O 
believe O 
, O 
be O 
created O 
without O 
the O 
involvement O 
of O 
invasive O 
laparoscopic O 
surgery O 
and O 
general O 
anesthesia O 
. O 
The O 
burn O 
in O 
our O 
experiment O 
was O 
formed O 
in O 
both O 
the O 
distal O 
and O 
proximal O 
esophagus O 
, O 
as O 
in O 
other O 
models O 
; O 
it O 
can O 
also O 
be O 
formed O 
optionally O 
in O 
the O 
entire O 
esophagus O 
. O 

effect O 
of O 
rosiglitazone B-TRIVIAL 
on O 
bone O 
mass O 
and O 
fragility O 
is O 
reversible O 
and O 
can O 
be O 
attenuated O 
with O 
alendronate B-TRIVIAL 
. O 

( O 
RSG B-ABBREVIATION 
) O 
is O 
an O 
anti-diabetic O 
drug O 
that O 
has O 
been O 
associated O 
with O 
increased O 
peripheral O 
fractures O 
primarily O 
in O 
postmenopausal O 
women O 
. O 
In O 
this O 
report O 
, O 
we O 
investigated O 
the O 
underlying O 
mechanisms O 
of O 
RSG B-ABBREVIATION 
-associated O 
bone O 
loss O 
in O 
ovariectomized O 
( O 
OVX O 
) O 
rats O 
and O 
determine O 
whether O 
changes O 
in O 
bone O 
parameters O 
associated O 
with O 
RSG B-ABBREVIATION 
administration O 
are O 
reversible O 
on O 
treatment O 
cessation O 
or O 
preventable O 
by O 
co O 
- O 
administration O 
with O 
an O 
antiresorptive O 
agent O 
. O 
Nine O 
- O 
month O 
- O 
old O 
Sprague-Dawley O 
rats O 
underwent O 
OVX O 
or O 
sham O 
operation O 
. O 
Sham O 
- O 
operated O 
rats O 
received O 
oral O 
vehicle O 
only O 
; O 
OVX O 
animals O 
were O 
randomized O 
to O 
receive O 
vehicle O 
, O 
RSG B-ABBREVIATION 
, O 
alendronate B-TRIVIAL 
( O 
ALN B-ABBREVIATION 
) O 
or O 
RSG B-ABBREVIATION 
plus O 
ALN B-ABBREVIATION 
for O 
12 O 
weeks O 
. O 
All O 
treatment O 
started O 
the O 
day O 
after O 
ovariectomy O 
. O 
After O 
the O 
12 O 
week O 
treatment O 
period O 
, O 
the O 
OVX O 
and O 
RSG B-ABBREVIATION 
groups O 
also O 
underwent O 
an O 
8-week O 
treatment-free O 
recovery O 
period O 
. O 
Bone O 
densitometry O 
measurements O 
, O 
bone O 
turnover O 
markers O 
, O 
biomechanical O 
testing O 
and O 
histomorphometric O 
analysis O 
were O 
conducted O 
. O 
Micro O 
- O 
computed O 
tomography O 
was O 
also O 
used O 
to O 
investigate O 
changes O 
in O 
microarchitecture O 
. O 
RSG B-ABBREVIATION 
significantly O 
increased O 
deoxypyridinoline B-SYSTEMATIC 
levels O 
compared O 
with O 
OVX O 
. O 
Significant O 
exacerbation O 
of O 
OVX-induced O 
loss O 
of O 
bone O 
mass O 
, O 
strength O 
and O 
microarchitectural O 
deteriorations O 
was O 
observed O 
in O 
RSG B-ABBREVIATION 
-treated O 
OVX O 
animals O 
compared O 
with O 
OVX O 
controls O 
. O 
These O 
effects O 
were O 
observed O 
predominantly O 
at O 
sites O 
rich O 
in O 
trabecular O 
bone O 
with O 
less O 
pronounced O 
effects O 
in O 
cortical O 
bone O 
. O 
Co-administration O 
of O 
RSG B-ABBREVIATION 
and O 
ALN B-ABBREVIATION 
prevented O 
the O 
bone O 
loss O 
associated O 
with O 
RSG B-ABBREVIATION 
treatment O 
. O 
Following O 
cessation O 
of O 
RSG B-ABBREVIATION 
treatment O 
, O 
effects O 
on O 
bone O 
mass O 
and O 
strength O 
showed O 
evidence O 
of O 
reversal O 
. O 
Thus O 
, O 
treatment O 
of O 
OVX O 
rats O 
with O 
RSG B-ABBREVIATION 
results O 
in O 
loss O 
of O 
bone O 
mass O 
and O 
strength O 
, O 
primarily O 
at O 
sites O 
rich O 
in O 
trabecular O 
bone O 
mainly O 
due O 
to O 
increased O 
bone O 
resorption O 
. O 
These O 
effects O 
can O 
be O 
prevented O 
by O 
concomitant O 
treatment O 
with O 
ALN B-ABBREVIATION 
and O 
may O 
be O 
reversed O 
following O 
discontinuation O 
of O 
RSG B-ABBREVIATION 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

-PET O 
as O 
an O 
Imaging O 
Biomarker O 
to O 
NMDA B-ABBREVIATION 
Receptor O 
Antagonist-Induced O 
Neurotoxicity O 
. O 

emission O 
tomography O 
( O 
PET O 
) O 
is O 
an O 
effective O 
tool O 
for O 
noninvasive O 
examination O 
of O 
the O 
body O 
and O 
provides O 
a O 
range O 
of O 
functional O 
information O 
. O 
PET O 
imaging O 
with O 
[(18)F]fluoro-2-deoxy-d-glucose B-SYSTEMATIC 
( O 
[(18)F]FDG B-SYSTEMATIC 
) O 
has O 
been O 
used O 
to O 
image O 
alterations O 
in O 
glucose B-TRIVIAL 
metabolism O 
in O 
brain O 
or O 
cancer O 
tissue O 
in O 
the O 
field O 
of O 
clinical O 
diagnosis O 
but O 
not O 
in O 
the O 
field O 
of O 
toxicology O 
. O 
A O 
single O 
dose O 
of O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
receptor O 
antagonist O 
induces O 
neuronal O 
cell O 
degeneration O 
/ O 
death O 
in O 
the O 
rat O 
retrosplenial O 
/ O 
posterior O 
cingulate O 
( O 
RS O 
/ O 
PC O 
) O 
cortex O 
region O 
. O 
These O 
antagonists O 
also O 
increase O 
local O 
cerebral O 
glucose B-TRIVIAL 
utilization O 
. O 
Here O 
, O 
we O 
examined O 
the O 
potential O 
of O 
[(18)F]FDG B-SYSTEMATIC 
-PET O 
as O 
an O 
imaging O 
biomarker O 
of O 
neurotoxicity O 
induced O 
by O 
an O 
NMDA B-ABBREVIATION 
receptor O 
antagonist O 
, O 
MK-801 B-IDENTIFIER 
. O 
Using O 
[(18)F]FDG B-SYSTEMATIC 
-PET O 
, O 
we O 
determined O 
that O 
increased O 
glucose B-TRIVIAL 
utilization O 
involved O 
the O 
neurotoxicity O 
induced O 
by O 
MK-801 B-IDENTIFIER 
. O 
The O 
accumulation O 
of O 
[(18)F]FDG B-SYSTEMATIC 
was O 
increased O 
in O 
the O 
rat O 
RS O 
/ O 
PC O 
cortex O 
region O 
showing O 
neuronal O 
cell O 
degeneration O 
/ O 
death O 
and O 
detected O 
before O 
the O 
onset O 
of O 
neuronal O 
cell O 
death O 
. O 
This O 
effect O 
increased O 
at O 
a O 
dose O 
level O 
at O 
which O 
neuronal O 
cell O 
degeneration O 
recovered O 
24h O 
after O 
MK-801 B-IDENTIFIER 
administration O 
. O 
Scopolamine B-TRIVIAL 
prevented O 
the O 
neurotoxicity O 
and O 
[(18)F]FDG B-SYSTEMATIC 
accumulation O 
induced O 
by O 
MK-801 B-IDENTIFIER 
. O 
Furthermore O 
, O 
in O 
cynomolgus O 
monkeys O 
that O 
showed O 
no O 
neuronal O 
cell O 
degeneration O 
/ O 
death O 
when O 
treated O 
with O 
MK-801 B-IDENTIFIER 
, O 
we O 
noted O 
no O 
differences O 
in O 
[(18)F]FDG B-SYSTEMATIC 
accumulation O 
between O 
test O 
and O 
control O 
subjects O 
in O 
any O 
region O 
of O 
the O 
brain O 
. O 
These O 
findings O 
suggest O 
that O 
[(18)F]FDG B-SYSTEMATIC 
-PET O 
, O 
which O 
is O 
available O 
for O 
clinical O 
trials O 
, O 
may O 
be O 
useful O 
in O 
generating O 
a O 
predictive O 
imaging O 
biomarker O 
for O 
detecting O 
neurotoxicity O 
against O 
NMDA B-ABBREVIATION 
receptor O 
antagonists O 
with O 
the O 
same O 
pharmacological O 
activity O 
as O 
MK-801 B-IDENTIFIER 
. O 

ionic O 
properties O 
of O 
a O 
metal O 
- O 
coated O 
silicon B-SYSTEMATIC 
nanopore O 
were O 
examined O 
in O 
a O 
nanofluidic O 
system O 
. O 
We O 
observed O 
a O 
strong O 
increase O 
of O 
the O 
ionic O 
noise O 
upon O 
laser O 
light O 
illumination O 
. O 
The O 
effect O 
appeared O 
to O 
be O 
strongly O 
mediated O 
by O 
the O 
resonant O 
excitation O 
of O 
surface O 
plasmons O 
in O 
the O 
nanopore O 
as O 
was O 
demonstrated O 
by O 
means O 
of O 
ionic O 
mapping O 
of O 
the O 
plasmonic O 
electromagnetic O 
field O 
. O 
Evidence O 
from O 
both O 
simulations O 
and O 
experiments O 
ruled O 
out O 
plasmonic O 
heating O 
as O 
the O 
main O 
source O 
of O 
the O 
noise O 
, O 
and O 
point O 
toward O 
photoinduced O 
electrochemical O 
catalysis O 
at O 
the O 
semiconductor O 
- O 
electrolyte O 
interface O 
. O 
This O 
ionic O 
mapping O 
technique O 
described O 
is O 
opening O 
up O 
new O 
opportunities O 
on O 
noninvasive O 
applications O 
ranging O 
from O 
biosensing O 
to O 
energy O 
conversion O 
. O 

electropherogram O 
of O 
native O 
heparin O 
shows O 
a O 
broad O 
distribution O 
of O 
mobilities O 
μ O 
, O 
which O 
truncates O 
abruptly O 
at O 
a O 
notably O 
high O 
μ O 
= O 
4.7 O 
× O 
10(-4) O 
cm(2) O 
V(-1) O 
s(-1) O 
. O 
This O 
highly O 
skewed O 
mobility O 
distribution O 
is O 
also O 
found O 
for O 
the O 
20- O 
saccharide B-FAMILY 
chain O 
, O 
which O 
shows O 
from O 
mass O 
spectrometry O 
a O 
more O 
uniform O 
( O 
symmetrical O 
) O 
with O 
respect O 
to O 
sulfation O 
level O 
. O 
Since O 
a O 
partially O 
degraded O 
heparin O 
exhibits O 
oligomer O 
peaks O 
with O 
μ> O 
5 O 
× O 
10(-4) O 
cm(2) O 
V(-1) O 
s(-1) O 
( O 
appearing O 
to O 
escape O 
the O 
limitation O 
of O 
the O 
mobility O 
value O 
for O 
native O 
heparin O 
) O 
, O 
we O 
examined O 
the O 
electrophoretic O 
behavior O 
of O 
chain O 
- O 
length O 
monodisperse O 
heparin O 
oligomers O 
. O 
Their O 
mobilities O 
varied O 
inversely O 
with O 
the O 
logarithm O 
of O 
the O 
contour O 
length O 
, O 
L O 
, O 
for O 
L O 
from O 
3 O 
to O 
10 O 
nm O 
and O 
reached O 
an O 
asymptotic O 
limit O 
for O 
L O 
> O 
20 O 
nm O 
. O 
The O 
generality O 
of O 
this O 
effect O 
was O 
indicated O 
by O 
similar O 
behavior O 
for O 
oligomers O 
of O 
poly(styrene B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
) I-SYSTEMATIC 
. O 
A O 
recent O 
theory O 
of O 
polyelectrolyte O 
end O 
effects O 
( O 
Manning O 
, O 
G O 
. O 
S O 
. O 
Macromolecules2008 O 
, O 
41 O 
, O 
6217-6227 O 
) O 
, O 
in O 
which O 
chain O 
termini O 
exhibit O 
reduced O 
counterion O 
condensation O 
was O 
found O 
to O 
quantitatively O 
account O 
for O 
these O 
results O 
. O 
A O 
qualitative O 
explanation O 
for O 
the O 
anomalously O 
high O 
value O 
of O 
μ O 
of O 
native O 
heparin O 
, O 
10-20% O 
higher O 
than O 
those O 
seen O 
for O 
synthetic O 
polyelectrolytes O 
of O 
higher O 
linear O 
charge O 
density O 
, O 
is O 
suggested O 
on O 
the O 
basis O 
of O 
similar O 
junction O 
effects O 
( O 
Manning O 
, O 
G O 
. O 
S O 
. O 
Macromolecules2008 O 
, O 
41 O 
, O 
6217-6227 O 
) O 
, O 
which O 
reduce O 
counterion O 
condensation O 
at O 
the O 
interfaces O 
of O 
regions O 
of O 
high O 
and O 
low O 
sulfation O 
. O 
We O 
suggest O 
that O 
these O 
effects O 
should O 
be O 
considered O 
in O 
models O 
for O 
the O 
biofunctionality O 
of O 
the O 
regulated O 
high O 
and O 
low O 
sulfation O 
( O 
NS O 
/ O 
nan O 
) O 
domains O 
of O 
heparan O 
sulfate O 
. O 

Bacterial O 
Cellulose O 
Whisker/ O 
Poly(NIPAM-co-BMA) B-SYSTEMATIC 
Nanogel O 
Complexes O 
: O 
Synthesis O 
, O 
Characterization O 
, O 
and O 
Biological O 
Evaluation O 
. O 

of O 
poly(N-isopropylacrylamide-co B-SYSTEMATIC 
- I-SYSTEMATIC 
butyl I-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PNB B-ABBREVIATION 
) O 
nanogels O 
are O 
known O 
to O 
exhibit O 
reversible O 
thermosensitive O 
sol O 
- O 
gel O 
phase O 
behavior O 
and O 
can O 
consequently O 
be O 
used O 
in O 
a O 
wide O 
range O 
of O 
biomedical O 
applications O 
. O 
However O 
, O 
some O 
dissatisfactory O 
mechanical O 
properties O 
of O 
PNB B-ABBREVIATION 
nanogels O 
can O 
limit O 
their O 
applications O 
. O 
In O 
this O 
paper O 
, O 
bacterial O 
cellulose O 
( O 
BC O 
) O 
whiskers O 
were O 
first O 
prepared O 
by O 
sulfuric B-SYSTEMATIC 
acid I-SYSTEMATIC 
hydrolysis O 
and O 
then O 
nanosized O 
by O 
high O 
- O 
pressure O 
homogenization O 
for O 
subsequent O 
use O 
in O 
the O 
preparation O 
of O 
BC O 
whisker/ O 
PNB B-ABBREVIATION 
nanogel O 
complexes O 
( O 
designated O 
as O 
BC/ O 
PNB B-ABBREVIATION 
) O 
. O 
The O 
mechanical O 
properties O 
of O 
PNB B-ABBREVIATION 
was O 
successfully O 
enhanced O 
, O 
resulting O 
in O 
good O 
biosafety O 
. O 
The O 
BC/ O 
PNB B-ABBREVIATION 
nanogel O 
dispersions O 
exhibited O 
phase O 
transitions O 
from O 
swollen O 
gel O 
to O 
shrunken O 
gel O 
with O 
increasing O 
temperature O 
. O 
In O 
addition O 
, O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
data O 
showed O 
that O 
the O 
thermosensitivity O 
of O 
PNB B-ABBREVIATION 
nanogels O 
was O 
retained O 
. O 
Rheological O 
tests O 
also O 
indicated O 
that O 
BC/ O 
PNB B-ABBREVIATION 
nanogel O 
complexes O 
had O 
stronger O 
gel O 
strengths O 
when O 
compared O 
with O 
PNB B-ABBREVIATION 
nanogels O 
. O 
The O 
concentrated O 
dispersions O 
showed O 
shear O 
thinning O 
behavior O 
and O 
improved O 
toughness O 
, O 
both O 
of O 
which O 
can O 
play O 
a O 
key O 
role O 
in O 
the O 
medical O 
applications O 
of O 
nanogel O 
complexes O 
. O 
Furthermore O 
, O 
the O 
BC/ O 
PNB B-ABBREVIATION 
nanogel O 
complexes O 
were O 
noncytotoxic O 
according O 
to O 
cytotoxicity O 
and O 
hemolysis O 
tests O 
. O 
Concentrated O 
BC/ O 
PNB B-ABBREVIATION 
nanogel O 
dispersion O 
displayed O 
gel O 
a O 
forming O 
capacity O 
in O 
situ O 
by O 
catheter O 
injection O 
, O 
which O 
indicates O 
potential O 
for O 
a O 
wide O 
range O 
of O 
medical O 
applications O 
. O 

studies O 
in O 
nonhuman O 
primate O 
models O 
of O 
cocaine B-TRIVIAL 
abuse O 
: O 
Translational O 
research O 
related O 
to O 
vulnerability O 
and O 
neuroadaptations O 
. O 

current O 
review O 
highlights O 
the O 
utility O 
of O 
positron O 
emission O 
tomography O 
( O 
PET O 
) O 
imaging O 
to O 
study O 
the O 
neurobiological O 
substrates O 
underlying O 
vulnerability O 
to O 
cocaine B-TRIVIAL 
addiction O 
and O 
subsequent O 
adaptations O 
following O 
chronic O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
in O 
nonhuman O 
primate O 
models O 
of O 
cocaine B-TRIVIAL 
abuse O 
. O 
Environmental O 
( O 
e.g O 
. O 
, O 
social O 
rank O 
) O 
and O 
sex O 
- O 
specific O 
influences O 
on O 
dopaminergic O 
function O 
and O 
sensitivity O 
to O 
the O 
reinforcing O 
effects O 
of O 
cocaine B-TRIVIAL 
are O 
discussed O 
. O 
Cocaine B-TRIVIAL 
-related O 
cognitive O 
deficits O 
have O 
been O 
hypothesized O 
to O 
contribute O 
to O 
high O 
rates O 
of O 
relapse O 
and O 
are O 
described O 
in O 
nonhuman O 
primate O 
models O 
. O 
Lastly O 
, O 
the O 
long O 
- O 
term O 
consequences O 
of O 
cocaine B-TRIVIAL 
on O 
neurobiology O 
are O 
discussed O 
. O 
PET O 
imaging O 
and O 
longitudinal O 
, O 
within O 
- O 
subject O 
behavioral O 
studies O 
in O 
nonhuman O 
primates O 
have O 
provided O 
a O 
strong O 
framework O 
for O 
designing O 
pharmacological O 
and O 
behavioral O 
treatment O 
strategies O 
to O 
aid O 
drug O 
- O 
dependent O 
treatment O 
seekers O 
. O 
Non-invasive O 
PET O 
imaging O 
will O 
allow O 
for O 
individualized O 
treatment O 
strategies O 
. O 
Recent O 
advances O 
in O 
radiochemistry O 
of O 
novel O 
PET O 
ligands O 
and O 
other O 
imaging O 
modalities O 
can O 
further O 
advance O 
our O 
understanding O 
of O 
stimulant O 
use O 
on O 
the O 
brain O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
Neuroimaging O 
' O 
. O 

critical O 
role O 
of O 
mitochondria O 
in O 
cardiomyocyte O 
survival O 
and O 
death O 
has O 
become O 
an O 
exciting O 
field O 
of O 
research O 
in O 
cardiac O 
biology O 
. O 
Indeed O 
, O 
it O 
is O 
accepted O 
that O 
mitochondrial O 
dysfunction O 
plays O 
a O 
crucial O 
role O 
in O 
the O 
pathogenesis O 
of O 
multiple O 
cardiac O 
diseases O 
. O 
Besides O 
the O 
obvious O 
relevance O 
of O 
mitochondria O 
in O 
energy O 
production O 
, O 
calcium O 
homeostasis O 
, O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
, O 
new O 
processes O 
like O 
mitochondrial O 
fusion O 
/ O 
fission O 
, O 
phosphorylation O 
and O 
nitrosylation O 
modifications O 
in O 
mitochondrial O 
proteins O 
have O 
been O 
suggested O 
to O 
form O 
part O 
of O 
a O 
cast O 
of O 
key O 
players O 
in O 
cardiac O 
disease O 
. O 
This O 
review O 
describes O 
currently O 
studied O 
drugs O 
and O 
compounds O 
that O 
target O 
mitochondria O 
in O 
the O 
scenario O 
of O 
cardiovascular O 
diseases O 
. O 

the O 
discovery O 
of O 
p53 O 
as O 
" O 
guardian O 
of O 
the O 
genome O 
" O 
, O 
a O 
large O 
number O 
of O 
efforts O 
have O 
been O 
put O 
in O 
place O 
in O 
order O 
to O 
find O 
molecular O 
strategies O 
aiming O 
to O 
restore O 
p53 O 
wild O 
- O 
type O 
functions O 
, O 
particularly O 
in O 
the O 
light O 
of O 
the O 
fact O 
that O 
its O 
pathway O 
results O 
ineffective O 
in O 
most O 
tumors O 
even O 
though O 
they O 
have O 
non-mutated O 
p53 O 
. O 
In O 
this O 
context O 
, O 
pediatric O 
cancers O 
, O 
that O 
are O 
mostly O 
p53 O 
wild O 
- O 
type O 
at O 
the O 
time O 
of O 
diagnosis O 
, O 
represent O 
an O 
ideal O 
target O 
for O 
such O 
therapeutic O 
approach O 
. O 
Within O 
the O 
several O 
mechanisms O 
and O 
proteins O 
ruling O 
p53 O 
activity O 
, O 
the O 
murine O 
double O 
minute O 
2 O 
( O 
MDM2 O 
) O 
is O 
its O 
crucial O 
negative O 
regulator O 
, O 
frequently O 
found O 
overexpressed O 
in O 
p53-wild O 
- O 
type O 
tumors O 
. O 
The O 
development O 
of O 
new O 
technologies O 
such O 
as O 
nuclear O 
magnetic O 
resonance O 
structure O 
analyses O 
, O 
computational O 
structure O 
- O 
based O 
design O 
studies O 
, O 
and O 
library O 
peptides O 
screening O 
have O 
recently O 
led O 
to O 
the O 
discovery O 
and O 
characterization O 
of O 
a O 
large O 
number O 
of O 
compounds O 
belonging O 
to O 
different O 
chemical O 
families O 
that O 
are O 
able O 
to O 
target O 
the O 
interaction O 
p53-MDM2 O 
, O 
rescuing O 
the O 
p53 O 
wild O 
- O 
type O 
pathway O 
with O 
an O 
overall O 
pro O 
- O 
apoptotic O 
and O 
anticancer O 
activity O 
. O 
Within O 
the O 
preclinical O 
assessment O 
of O 
these O 
molecules O 
, O 
the O 
cis-imidazoline B-SYSTEMATIC 
analogue O 
Nutlin-3 B-TRIVIAL 
has O 
definitely O 
attracted O 
great O 
interest O 
for O 
its O 
in O 
vitro O 
and O 
in O 
vivo O 
antitumor O 
activity O 
in O 
several O 
pediatric O 
cancer O 
models O 
, O 
either O 
as O 
single O 
agent O 
on O 
in O 
combination O 
with O 
standard O 
chemotherapy O 
. O 
In O 
this O 
light O 
, O 
the O 
aim O 
of O 
this O 
review O 
is O 
to O 
summarize O 
the O 
main O 
preclinical O 
evidences O 
of O 
the O 
potential O 
of O 
MDM2 O 
inhibitors O 
for O 
the O 
treatment O 
of O 
childhood O 
cancers O 
and O 
the O 
key O 
suggestions O 
coming O 
from O 
their O 
assessment O 
in O 
the O 
treatment O 
of O 
adult O 
cancers O 
as O 
proof O 
of O 
concept O 
for O 
future O 
pediatric O 
clinical O 
studies O 
. O 

silica B-TRIVIAL 
nanoparticles O 
for O 
cancer O 
diagnosis O 
. O 

imaging O 
techniques O 
are O 
becoming O 
essential O 
for O 
preclinical O 
investigations O 
, O 
necessitating O 
the O 
development O 
of O 
suitable O 
tools O 
for O 
in O 
vivo O 
measurements O 
. O 
Nanotechnology O 
entered O 
this O 
field O 
to O 
help O 
overcome O 
many O 
of O 
the O 
current O 
technical O 
limitations O 
, O 
and O 
luminescent O 
nanoparticles O 
( O 
NPs O 
) O 
are O 
one O 
of O 
the O 
most O 
promising O 
materials O 
proposed O 
for O 
future O 
diagnostic O 
implementation O 
. O 
NPs O 
also O 
constitute O 
a O 
versatile O 
platform O 
that O 
can O 
allow O 
facile O 
multi O 
- O 
functionalization O 
to O 
perform O 
multimodal O 
imaging O 
or O 
theranostics O 
( O 
simultaneous O 
diagnosis O 
and O 
therapy O 
) O 
. O 
In O 
this O 
contribution O 
we O 
have O 
mainly O 
focused O 
on O 
dye O 
doped O 
silica B-TRIVIAL 
or O 
silica B-TRIVIAL 
-based O 
NPs O 
conjugated O 
with O 
targeting O 
moieties O 
to O 
enable O 
imaging O 
of O 
specific O 
cancer O 
cells O 
. O 
We O 
also O 
cite O 
and O 
briefly O 
discuss O 
a O 
few O 
non-targeted O 
systems O 
for O 
completeness O 
. O 
We O 
summarize O 
common O 
synthetic O 
approaches O 
to O 
these O 
materials O 
, O 
and O 
then O 
survey O 
the O 
most O 
recent O 
imaging O 
applications O 
of O 
silica B-TRIVIAL 
-based O 
nanoparticles O 
in O 
cancer O 
. O 
The O 
field O 
of O 
theranostics O 
is O 
particularly O 
important O 
and O 
stimulating O 
, O 
so O 
, O 
even O 
though O 
it O 
is O 
not O 
the O 
central O 
topic O 
of O 
this O 
paper O 
, O 
we O 
have O 
included O 
some O 
significant O 
examples O 
. O 
We O 
conclude O 
with O 
a O 
short O 
section O 
on O 
NP O 
- O 
based O 
systems O 
already O 
in O 
clinical O 
trials O 
and O 
examples O 
of O 
specific O 
applications O 
in O 
childhood O 
tumors O 
. O 
This O 
review O 
aims O 
to O 
describe O 
and O 
discuss O 
, O 
through O 
focused O 
examples O 
, O 
the O 
great O 
potential O 
of O 
these O 
materials O 
in O 
the O 
medical O 
field O 
, O 
with O 
the O 
aim O 
to O 
encourage O 
further O 
research O 
to O 
implement O 
applications O 
, O 
which O 
today O 
are O 
still O 
rare O 
. O 

small O 
molecule O 
fusion O 
inhibitors O 
N-(4-carboxy-3-hydroxyphenyl)-2,5-dimethylpyrrole B-SYSTEMATIC 
( O 
NB-2 B-ABBREVIATION 
) O 
and O 
N-(3-carboxy-4-hydroxyphenyl)-2,5-dimethylpyrrole B-SYSTEMATIC 
( O 
A12 B-ABBREVIATION 
) O 
target O 
a O 
hydrophobic O 
pocket O 
of O 
HIV-1 O 
gp41 O 
and O 
have O 
moderate O 
anti-HIV-1 O 
activity O 
. O 
In O 
this O 
paper O 
, O 
we O 
report O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
structure O 
- O 
activity O 
relationship O 
of O 
a O 
group O 
of O 
hybrid O 
molecules O 
in O 
which O 
the O 
pocket O 
- O 
binding O 
domain O 
segment O 
of O 
the O 
C34 O 
peptide O 
was O 
replaced O 
with O 
NB-2 B-ABBREVIATION 
and O 
A12 B-ABBREVIATION 
derivatives O 
. O 
In O 
addition O 
, O 
the O 
synergistic O 
effect O 
between O 
the O 
small O 
molecule O 
and O 
peptide O 
moieties O 
was O 
analyzed O 
, O 
and O 
lead O 
compounds O 
with O 
a O 
novel O 
scaffold O 
were O 
discovered O 
. O 
We O 
found O 
that O 
either O 
the O 
nonpeptide O 
or O 
peptide O 
part O 
alone O 
showed O 
weak O 
activity O 
against O 
HIV-1 O 
- O 
mediated O 
cell O 
- O 
cell O 
fusion O 
, O 
but O 
the O 
conjugates O 
properly O 
generated O 
a O 
strong O 
synergistic O 
effect O 
. O 
Among O 
them O 
, O 
conjugates O 
Aoc-βAla-P26 O 
and O 
Noc-βAla-P26 O 
exhibited O 
a O 
low O 
nanomolar O 
IC50 O 
in O 
the O 
cell O 
- O 
cell O 
fusion O 
assay O 
and O 
effectively O 
inhibited O 
T20-sensitive O 
and O 
-resistant O 
HIV-1 O 
strains O 
. O 
Furthermore O 
, O 
the O 
new O 
molecules O 
exhibited O 
better O 
stability O 
against O 
proteinase O 
K O 
digestion O 
than O 
T20 O 
and O 
C34 O 
. O 

- O 
dependent O 
inhibitory O 
effects O 
of O 
baicalin B-TRIVIAL 
on O 
the O 
metabolism O 
of O 
dextromethorphan B-TRIVIAL 
, O 
a O 
dual O 
probe O 
of O 
CYP2D O 
and O 
CYP3A O 
, O 
in O 
rats O 
. O 

has O 
been O 
shown O 
to O 
possess O 
many O 
pharmacological O 
effects O 
, O 
including O 
antiviral O 
, O 
antioxidant O 
, O 
anti-cancer O 
and O 
anti-inflammatory O 
properties O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
reveal O 
the O 
inhibitory O 
effects O 
of O 
baicalin B-TRIVIAL 
on O 
the O 
metabolism O 
of O 
dextromethorphan B-TRIVIAL 
( O 
DXM B-ABBREVIATION 
) O 
, O 
a O 
dual O 
probe O 
substrate O 
of O 
CYP2D O 
and O 
CYP3A O 
, O 
in O 
rats O 
. O 
Lineweaver-Burk O 
plots O 
demonstrated O 
that O 
baicalin B-TRIVIAL 
inhibited O 
the O 
activities O 
of O 
CYP2D O 
and O 
CYP3A O 
in O 
a O 
non-competitive O 
manner O 
in O 
rat O 
liver O 
microsomes O 
( O 
RLMs O 
) O 
. O 
Concomitant O 
administration O 
of O 
baicalin B-TRIVIAL 
( O 
0.90g O 
/ O 
kg O 
, O 
i.v O 
. O 
) O 
and O 
DXM B-ABBREVIATION 
( O 
10mg O 
/ O 
kg O 
, O 
i.v O 
. O 
) O 
increased O 
the O 
maximum O 
drug O 
concentration O 
( O 
Cmax O 
) O 
( O 
37% O 
) O 
and O 
the O 
area O 
under O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
( O 
42% O 
) O 
and O 
decreased O 
the O 
clearance O 
( O 
CL O 
) O 
( O 
27% O 
) O 
of O 
DXM B-ABBREVIATION 
in O 
a O 
randomised O 
, O 
crossover O 
study O 
in O 
rats O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
The O 
change O 
in O 
the O 
AUC O 
of O 
DXM B-ABBREVIATION 
was O 
significantly O 
correlated O 
with O 
the O 
Cmax O 
and O 
AUC O 
of O 
baicalin B-TRIVIAL 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
inhibitory O 
effects O 
of O 
multiple O 
doses O 
of O 
baicalin B-TRIVIAL 
( O 
0.90g O 
/ O 
kg O 
, O 
i.v O 
. O 
, O 
12days O 
) O 
on O 
the O 
metabolism O 
of O 
DXM B-ABBREVIATION 
were O 
similar O 
to O 
those O 
observed O 
following O 
a O 
single O 
dose O 
in O 
rats O 
. O 
The O 
activity O 
of O 
CYP3A O 
in O 
excised O 
liver O 
samples O 
from O 
rats O 
following O 
multiple O 
baicalin B-TRIVIAL 
treatment O 
was O 
significantly O 
decreased O 
compared O 
to O 
that O 
of O 
the O 
control O 
group O 
( O 
P O 
< O 
0.05 O 
) O 
, O 
whereas O 
multiple O 
doses O 
of O 
baicalin B-TRIVIAL 
had O 
no O 
obvious O 
effect O 
on O 
the O 
activity O 
of O 
CYP2D O 
. O 
Taken O 
together O 
, O 
these O 
data O 
demonstrate O 
that O 
baicalin B-TRIVIAL 
inhibits O 
the O 
metabolism O 
of O 
DXM B-ABBREVIATION 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
in O 
rats O 
, O 
possibly O 
through O 
inhibiting O 
hepatic O 
CYP2D O 
and O 
CYP3A O 
activities O 
. O 

vulnerability O 
to O 
β-cell O 
destruction O 
and O 
diabetes O 
in O 
mice O 
lacking O 
NAD(P)H B-ABBREVIATION 
: O 
quinone B-FAMILY 
oxidoreductase O 
1 O 
. O 

: O 
quinone B-FAMILY 
oxidoreductase O 
1 O 
( O 
NQO1 O 
) O 
has O 
been O 
known O 
to O 
protect O 
cells O 
against O 
stressors O 
, O 
including O 
the O 
diabetogenic O 
reagent O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
. O 
The O 
present O 
study O 
demonstrated O 
that O 
NQO1 O 
deficiency O 
resulted O 
in O 
increased O 
pancreatic O 
β-cell O 
death O 
induced O 
by O 
multiple O 
low O 
dose O 
of O 
STZ B-ABBREVIATION 
( O 
MLDS O 
) O 
injections O 
. O 
NQO1 O 
knockout O 
( O 
KO O 
) O 
mice O 
showed O 
hyperglycemia O 
, O 
body O 
weight O 
loss O 
, O 
impaired O 
glucose B-TRIVIAL 
clearance O 
rate O 
and O 
a O 
lower O 
plasma O 
insulin O 
level O 
after O 
MLDS O 
treatment O 
. O 
Moreover O 
, O 
β-cell O 
mass O 
and O 
pancreatic O 
insulin O 
content O 
were O 
significantly O 
lower O 
in O 
KO O 
mice O 
than O 
in O 
wild O 
- O 
type O 
( O 
WT O 
) O 
mice O 
after O 
MLDS O 
treatment O 
. O 
Five O 
days O 
after O 
the O 
first O 
STZ B-ABBREVIATION 
treatment O 
, O 
the O 
islets O 
of O 
KO O 
mice O 
had O 
substantially O 
more O 
TUNEL-positive O 
β-cells O 
than O 
those O 
of O 
WT O 
mice O 
, O 
but O 
there O 
was O 
no O 
difference O 
in O 
the O 
regeneration O 
of O 
β-cells O 
between O 
KO O 
mice O 
and O 
WT O 
mice O 
. O 
At O 
the O 
same O 
time O 
, O 
MLDS O 
- O 
treated O 
KO O 
mice O 
showed O 
significantly O 
increased O 
apoptotic O 
markers O 
in O 
β-cells O 
, O 
including O 
cleaved O 
caspase O 
3 O 
, O 
Smac O 
/ O 
DIABLO O 
and O 
AIF O 
( O 
apoptosis O 
inducing O 
factor O 
) O 
in O 
the O 
cytoplasm O 
. O 
These O 
results O 
suggest O 
that O 
mice O 
deficient O 
in O 
NQO1 O 
are O 
vulnerable O 
to O 
MLDS-induced O 
β-cell O 
destruction O 
and O 
diabetes O 
, O 
caused O 
by O 
increase O 
of O 
β-cell O 
apoptosis O 
in O 
pancreas O 
. O 

of O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
on O 
reproductive O 
function O 
in O 
female O 
rats O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
sodium B-SYSTEMATIC 
fluoride I-SYSTEMATIC 
( O 
NaF B-FORMULA 
) O 
on O 
female O 
reproductive O 
function O 
and O 
examine O 
the O 
morphology O 
of O 
the O 
ovaries O 
and O 
uteri O 
of O 
rats O 
exposed O 
to O 
NaF B-FORMULA 
. O 
Eighty O 
female O 
Sprague-Dawley O 
( O 
SD O 
) O 
rats O 
were O 
divided O 
randomly O 
into O 
four O 
groups O 
of O 
20 O 
: O 
one O 
control O 
group O 
and O 
three O 
NaF B-FORMULA 
treated O 
groups O 
. O 
The O 
three O 
NaF B-FORMULA 
treated O 
groups O 
received O 
100 O 
, O 
150 O 
, O 
and O 
200ppm O 
, O 
respectively O 
, O 
of O 
NaF B-FORMULA 
for O 
6months O 
via O 
their O 
drinking O 
water O 
, O 
while O 
the O 
control O 
group O 
( O 
GC O 
) O 
received O 
distilled O 
water O 
. O 
The O 
levels O 
of O 
follicle O 
- O 
stimulating O 
hormone O 
( O 
FSH O 
) O 
, O 
luteinizing O 
hormone O 
( O 
LH O 
) O 
, O 
testosterone B-TRIVIAL 
( O 
T O 
) O 
, O 
progesterone B-TRIVIAL 
( O 
P O 
) O 
and O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
were O 
measured O 
using O 
an O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
. O 
Pathomorphological O 
evaluation O 
of O 
the O 
uteri O 
and O 
ovaries O 
was O 
conducted O 
after O 
staining O 
with O 
hematoxylin B-TRIVIAL 
- O 
eosin B-FAMILY 
and O 
immunohistochemistry O 
. O 
The O 
rate O 
of O 
successful O 
pregnancy O 
in O 
the O 
NaF B-FORMULA 
-treated O 
groups O 
declined O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
The O 
concentration O 
of O 
reproductive O 
hormones O 
was O 
significantly O 
lower O 
in O 
the O 
three O 
NaF B-FORMULA 
-treated O 
groups O 
, O 
and O 
the O 
endometrium O 
was O 
damaged O 
. O 
The O 
maturation O 
of O 
follicles O 
was O 
inhibited O 
. O 
In O 
addition O 
, O 
the O 
total O 
number O 
of O 
follicles O 
of O 
all O 
types O 
was O 
significantly O 
lower O 
in O 
the O 
NaF B-FORMULA 
-treated O 
groups O 
. O 
These O 
results O 
suggest O 
that O 
female O 
reproductive O 
function O 
is O 
inhibited O 
by O 
NaF B-FORMULA 
and O 
that O 
exposure O 
to O 
NaF B-FORMULA 
causes O 
ovarian O 
and O 
uterine O 
structural O 
damage O 
. O 
NaF B-FORMULA 
may O 
thus O 
significantly O 
reduce O 
the O 
fertility O 
of O 
female O 
rats O 
. O 

Analysis O 
of O 
the O 
Symbiotic O 
Efficiency O 
of O 
Medicago O 
truncatula O 
and O 
Medicago O 
sativa O 
under O 
Phosphorus B-SYSTEMATIC 
Deficiency O 
. O 

( O 
P B-FORMULA 
)-deficiency O 
is O 
a O 
major O 
abiotic O 
stress O 
that O 
limits O 
legume O 
growth O 
in O 
many O 
types O 
of O 
soils O 
. O 
The O 
relationship O 
between O 
Medicago O 
and O 
Sinorhizobium O 
, O 
is O 
known O 
to O 
be O 
affected O 
by O 
different O 
environmental O 
conditions O 
. O 
Recent O 
reports O 
have O 
shown O 
that O 
, O 
in O 
combination O 
with O 
S O 
. O 
meliloti O 
2011 O 
, O 
Medicago O 
truncatula O 
had O 
a O 
lower O 
symbiotic O 
efficiency O 
than O 
Medicago O 
sativa O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
how O 
Medicago-Sinorhizobium O 
is O 
affected O 
by O 
P B-FORMULA 
-deficiency O 
at O 
the O 
whole O 
- O 
plant O 
level O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
compare O 
and O 
characterize O 
the O 
symbiotic O 
efficiency O 
of O 
N2 B-FORMULA 
fixation O 
of O 
M O 
. O 
truncatula O 
and O 
M O 
. O 
sativa O 
grown O 
in O 
sand O 
under O 
P B-FORMULA 
-limitation O 
. O 
Under O 
this O 
condition O 
, O 
M O 
. O 
truncatula O 
exhibited O 
a O 
significantly O 
higher O 
rate O 
of O 
N2 B-FORMULA 
fixation O 
. O 
The O 
specific O 
activity O 
of O 
the O 
nodules O 
was O 
much O 
higher O 
in O 
M O 
. O 
truncatula O 
in O 
comparison O 
to O 
M O 
. O 
sativa O 
, O 
partially O 
as O 
a O 
result O 
of O 
an O 
increase O 
in O 
electron O 
allocation O 
to O 
N2 B-FORMULA 
versus O 
H+ B-FORMULA 
. O 
Although O 
the O 
main O 
organic O 
acid O 
, O 
succinate B-TRIVIAL 
, O 
exhibited O 
a O 
strong O 
tendency O 
to O 
decrease O 
under O 
P B-FORMULA 
-deficiency O 
, O 
the O 
more O 
efficient O 
symbiotic O 
ability O 
observed O 
in O 
M O 
. O 
truncatula O 
coincided O 
with O 
an O 
apparent O 
increase O 
in O 
the O 
content O 
of O 
malate O 
in O 
its O 
nodules O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
higher O 
efficiency O 
of O 
the O 
M O 
. O 
truncatula O 
symbiotic O 
system O 
is O 
related O 
to O 
the O 
ability O 
to O 
increase O 
malate O 
content O 
under O 
limited O 
P B-FORMULA 
-conditions O 
. O 

Cell O 
Cultures O 
Using O 
PEG-DMA B-ABBREVIATION 
Micromolding O 
in O 
Standard O 
Culture O 
Dishes O 
. O 

robust O 
and O 
effortless O 
procedure O 
is O 
presented O 
, O 
which O 
allows O 
for O 
the O 
microstructuring O 
of O 
standard O 
cell O 
culture O 
dishes O 
. O 
Cell O 
adhesion O 
and O 
proliferation O 
are O 
controlled O 
by O 
three O 
- O 
dimensional O 
poly(ethylene B-SYSTEMATIC 
glycol)-dimethacrylate I-SYSTEMATIC 
( O 
PEG-DMA B-ABBREVIATION 
) O 
microstructures O 
. O 
The O 
spacing O 
between O 
microwells O 
can O 
be O 
extended O 
to O 
millimeter O 
size O 
in O 
order O 
to O 
enable O 
the O 
combination O 
with O 
robotic O 
workstations O 
. O 
Cell O 
arrays O 
of O 
microcolonies O 
can O 
be O 
studied O 
under O 
boundary O 
- O 
free O 
growth O 
conditions O 
by O 
lift O 
- O 
off O 
of O 
the O 
PEG-DMA B-ABBREVIATION 
layer O 
in O 
which O 
the O 
growth O 
rate O 
is O 
accessible O 
via O 
the O 
evolution O 
of O 
patch O 
areas O 
. O 
Alternatively O 
, O 
PEG-DMA B-ABBREVIATION 
stencils O 
can O 
be O 
used O 
as O 
templates O 
for O 
plasma O 
- O 
induced O 
patterning O 
. O 

Polyurethanes B-FAMILY 
From O 
Undecylenic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
-Based O 
Soft O 
Segments O 
: O 
Structural O 
Features O 
and O 
Release O 
Properties O 
. O 

set O 
of O 
thermoplastic O 
polyurethanes B-FAMILY 
is O 
synthesized O 
, O 
combining O 
undecylenic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-derived O 
telechelic B-FAMILY 
diols I-FAMILY 
as O 
soft O 
segments O 
and O 
1,4-butanediol B-SYSTEMATIC 
/ O 
4,4'-methylenebis(phenylisocyanate) B-SYSTEMATIC 
as O 
a O 
hard O 
segment O 
( O 
HS O 
) O 
. O 
These O 
polymers O 
are O 
fully O 
chemically O 
and O 
physically O 
characterized O 
by O 
means O 
of O 
NMR O 
and O 
Fourier O 
transform O 
IR O 
( O 
FTIR O 
) O 
spectroscopy O 
, O 
size O 
- O 
exclusion O 
chromatography O 
( O 
SEC O 
) O 
, O 
DSC O 
, O 
thermogravimetric O 
analysis O 
( O 
TGA O 
) O 
, O 
tensile O 
testing O 
, O 
and O 
contact O 
angle O 
measurements O 
. O 
The O 
obtained O 
results O 
reveal O 
that O 
both O 
the O 
molecular O 
weight O 
of O 
the O 
diol B-SYSTEMATIC 
and O 
the O 
HS O 
content O 
greatly O 
influence O 
the O 
physical O 
and O 
mechanical O 
properties O 
of O 
these O 
polymers O 
. O 
In O 
addition O 
, O 
given O 
the O 
potential O 
use O 
of O 
these O 
materials O 
for O 
biomedical O 
applications O 
, O 
hydrolytic O 
degradation O 
, O 
their O 
biocompatibility O 
using O 
a O 
human O 
fibroblast O 
cell O 
line O 
, O 
and O 
performance O 
as O 
drug O 
delivery O 
carriers O 
are O 
evaluated O 
. O 

Underlying O 
the O 
Varied O 
Mammary O 
Carcinogenicity O 
of O 
the O 
Environmental O 
Pollutant O 
6-Nitrochrysene B-SYSTEMATIC 
and O 
Its O 
Metabolites O 
(-)-[R,R]- B-MULTIPLE 
and I-MULTIPLE 
(+)-[S,S]-1,2-Dihydroxy-1,2-dihydro-6-nitrochrysene I-MULTIPLE 
in O 
the O 
Rat O 
. O 

mechanisms O 
that O 
can O 
account O 
for O 
the O 
remarkable O 
mammary O 
carcinogenicity O 
of O 
the O 
environmental O 
pollutant O 
6-nitrochrysene B-SYSTEMATIC 
( O 
6-NC B-SYSTEMATIC 
) O 
in O 
the O 
rat O 
remain O 
elusive O 
. O 
In O 
our O 
previous O 
studies O 
, O 
we O 
identified O 
several O 
6-NC B-SYSTEMATIC 
-derived O 
DNA O 
adducts O 
in O 
the O 
rat O 
mammary O 
gland O 
; O 
one O 
major O 
adduct O 
was O 
derived O 
from O 
(±)-trans-1,2-dihydroxy-1,2-dihydro-6-nitrochrysene B-SYSTEMATIC 
( O 
1,2-DHD-6-NC B-SYSTEMATIC 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
resolved O 
the O 
racemic O 
(±)-1,2-DHD-6-NC B-SYSTEMATIC 
into O 
(-)-[R,R]- B-MULTIPLE 
and I-MULTIPLE 
(+)-[S,S]-1,2-DHD-6-NC I-MULTIPLE 
and O 
compared O 
their O 
in O 
vivo O 
mutagenicity O 
and O 
carcinogenicity O 
in O 
the O 
mammary O 
glands O 
of O 
female O 
transgenic O 
( O 
BigBlue O 
F344 O 
× O 
Sprague-Dawley)F1 O 
rats O 
harboring O 
lacI O 
/ O 
cII O 
and O 
Sprague-Dawley O 
rats O 
, O 
respectively O 
. O 
Both O 
[R,R]- O 
and O 
[ O 
S,S O 
] O 
- O 
isomers O 
exerted O 
similar O 
mutagenicity O 
and O 
carcinogenicity O 
but O 
were O 
less O 
potent O 
than O 
6-NC B-SYSTEMATIC 
. O 
Additional O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
were O 
then O 
performed O 
to O 
explore O 
possible O 
mechanisms O 
that O 
can O 
explain O 
the O 
higher O 
potency O 
of O 
6-NC B-SYSTEMATIC 
than O 
1,2-DHD-6-NC B-SYSTEMATIC 
. O 
Using O 
ELISA O 
, O 
we O 
found O 
that O 
neither O 
6-NC B-SYSTEMATIC 
nor O 
1,2-DHD-6-NC B-SYSTEMATIC 
increased O 
the O 
levels O 
of O 
several O 
inflammatory O 
cytokines O 
in O 
plasma O 
obtained O 
from O 
rats O 
24 O 
h O 
after O 
treatment O 
. O 
In O 
MCF-7 O 
cells O 
, O 
as O 
determined O 
by O 
immunoblotting O 
, O 
the O 
effects O 
of O 
6-NC B-SYSTEMATIC 
and O 
1,2-DHD-6-NC B-SYSTEMATIC 
on O 
protein O 
expression O 
( O 
p53 O 
, O 
Akt O 
, O 
p38 O 
, O 
JNK O 
, O 
c-myc O 
, O 
bcl-2 O 
, O 
PCNA O 
, O 
and O 
ERβ O 
) O 
were O 
comparable O 
; O 
however O 
, O 
the O 
expressions O 
of O 
AhR O 
and O 
ERα O 
proteins O 
were O 
decreased O 
by O 
6-NC B-SYSTEMATIC 
but O 
not O 
1,2-DHD-6-NC B-SYSTEMATIC 
. O 
The O 
expression O 
of O 
both O 
receptors O 
was O 
decreased O 
in O 
mammary O 
tissues O 
of O 
rats O 
treated O 
with O 
6-NC B-SYSTEMATIC 
. O 
Our O 
findings O 
suggest O 
that O 
the O 
differential O 
effects O 
of O 
6-NC B-SYSTEMATIC 
and O 
1,2-DHD-6-NC B-SYSTEMATIC 
on O 
AhR O 
and O 
ERα O 
could O 
potentially O 
account O 
for O 
the O 
higher O 
carcinogenicity O 
of O 
6-NC B-SYSTEMATIC 
in O 
the O 
rat O 
mammary O 
gland O 
. O 

J-aggregates O 
of O 
cyanine B-TRIVIAL 
dyes O 
, O 
closely O 
packed O 
molecules O 
form O 
mesoscopic O 
tubes O 
with O 
nanometer O 
- O 
diameter O 
and O 
micrometer O 
- O 
length O 
. O 
Their O 
efficient O 
energy O 
transfer O 
pathways O 
make O 
them O 
suitable O 
candidates O 
for O 
artificial O 
light O 
harvesting O 
systems O 
. O 
This O 
great O 
potential O 
calls O 
for O 
an O 
in O 
- O 
depth O 
spectroscopic O 
analysis O 
of O 
the O 
underlying O 
energy O 
deactivation O 
network O 
and O 
coherence O 
dynamics O 
. O 
We O 
use O 
two O 
- O 
dimensional O 
electronic O 
spectroscopy O 
with O 
sub-10 O 
fs O 
laser O 
pulses O 
in O 
combination O 
with O 
two O 
- O 
dimensional O 
decay O 
- O 
associated O 
spectra O 
analysis O 
to O 
describe O 
the O 
population O 
flow O 
within O 
the O 
aggregate O 
. O 
Based O 
on O 
the O 
analysis O 
of O 
Fourier O 
- O 
transform O 
amplitude O 
maps O 
, O 
we O 
distinguish O 
between O 
vibrational O 
or O 
vibronic O 
coherence O 
dynamics O 
as O 
the O 
origin O 
of O 
pronounced O 
oscillations O 
in O 
our O 
two O 
- O 
dimensional O 
electronic O 
spectra O 
. O 

Germanium B-SYSTEMATIC 
Nanoparticles O 
under O 
Electrochemical O 
Cycling O 
. O 

degradation O 
of O 
the O 
electrode O 
materials O 
during O 
electrochemical O 
cycling O 
remains O 
a O 
serious O 
issue O 
that O 
critically O 
limits O 
the O 
capacity O 
retention O 
and O 
cyclability O 
of O 
rechargeable O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 
Here O 
we O 
report O 
the O 
highly O 
reversible O 
expansion O 
and O 
contraction O 
of O 
germanium B-SYSTEMATIC 
nanoparticles O 
under O 
lithiation O 
- O 
delithiation O 
cycling O 
with O 
in O 
situ O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
. O 
During O 
multiple O 
cycles O 
to O 
the O 
full O 
capacity O 
, O 
the O 
germanium B-SYSTEMATIC 
nanoparticles O 
remained O 
robust O 
without O 
any O 
visible O 
cracking O 
despite O 
∼260% O 
volume O 
changes O 
, O 
in O 
contrast O 
to O 
the O 
size O 
- O 
dependent O 
fracture O 
of O 
silicon B-SYSTEMATIC 
nanoparticles O 
upon O 
the O 
first O 
lithiation O 
. O 
The O 
comparative O 
in O 
situ O 
TEM O 
study O 
of O 
fragile O 
silicon B-SYSTEMATIC 
nanoparticles O 
suggests O 
that O 
the O 
tough O 
behavior O 
of O 
germanium B-SYSTEMATIC 
nanoparticles O 
can O 
be O 
attributed O 
to O 
the O 
weak O 
anisotropy O 
of O 
the O 
lithiation O 
strain O 
at O 
the O 
reaction O 
front O 
. O 
The O 
tough O 
germanium B-SYSTEMATIC 
nanoparticles O 
offer O 
substantial O 
potential O 
for O 
the O 
development O 
of O 
durable O 
, O 
high O 
- O 
capacity O 
, O 
and O 
high O 
- O 
rate O 
anodes O 
for O 
advanced O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

synthesis O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
stabilized O 
by O 
cationic O 
polynorbornenes B-FAMILY 
and O 
their O 
catalytic O 
activity O 
in O 
4-nitrophenol B-SYSTEMATIC 
reduction O 
. O 

report O 
the O 
facile O 
one O 
- O 
pot O 
single O 
- O 
phase O 
syntheses O 
of O 
silver B-SYSTEMATIC 
nanoparticles O 
stabilized O 
by O 
norbornene B-TRIVIAL 
type O 
cationic O 
polymers O 
. O 
Silver B-SYSTEMATIC 
nanoparticles O 
( O 
AgNPs O 
) O 
stabilized O 
by O 
polyguanidino B-FAMILY 
oxanorbornenes I-FAMILY 
( O 
PG O 
) O 
at O 
5 O 
and O 
25 O 
kDa O 
and O 
polyamino B-FAMILY 
oxanorbornenes I-FAMILY 
( O 
PA O 
) O 
at O 
3 O 
and O 
15 O 
kDa O 
have O 
been O 
synthesized O 
by O 
the O 
reduction O 
of O 
silver B-SYSTEMATIC 
ions O 
with O 
NaBH4 B-FORMULA 
in O 
aqueous O 
solutions O 
at O 
ambient O 
temperature O 
. O 
The O 
four O 
different O 
silver B-SYSTEMATIC 
nanoparticles O 
have O 
been O 
characterized O 
by O 
UV-vis O 
spectroscopy O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
, O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
, O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
for O 
their O 
particle O 
size O 
distributions O 
. O 
Interestingly O 
, O 
PG O 
stabilizes O 
the O 
silver B-SYSTEMATIC 
nanoparticles O 
better O 
than O 
PA O 
as O 
evident O 
from O 
our O 
spectroscopic O 
data O 
. O 
Furthermore O 
, O 
the O 
AgNP-PG-5K O 
( O 
5K O 
= O 
5 O 
kDa O 
) O 
was O 
found O 
to O 
serve O 
as O 
an O 
effective O 
catalyst O 
for O 
the O 
reduction O 
of O 
4-nitrophenol B-SYSTEMATIC 
to O 
4-aminophenol B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
NaBH4 B-FORMULA 
. O 
The O 
reduction O 
has O 
a O 
pseudo O 
- O 
first O 
- O 
order O 
rate O 
constant O 
of O 
5.5 O 
× O 
10(-3) O 
s(-1) O 
and O 
an O 
activity O 
parameter O 
of O 
1375 O 
s(-1) O 
g(-1) O 
, O 
which O 
is O 
significantly O 
higher O 
than O 
other O 
systems O 
reported O 
in O 
the O 
literature O 
. O 

free O 
fatty B-FAMILY 
acid I-FAMILY 
levels O 
in O 
PCOS O 
patients O 
treated O 
with O 
glucophage O 
, O 
magnesium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
spironolactone B-TRIVIAL 
. O 

To O 
assess O 
the O 
effect O 
of O 
glucophage O 
, O 
magnesium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
spironolactone B-TRIVIAL 
in O 
altering O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FFAs O 
) O 
, O 
36 O 
PCOS O 
women O 
were O 
randomly O 
divided O 
into O 
three O 
groups O 
. O 
Group O 
1 O 
( O 
n O 
= O 
14 O 
) O 
was O 
treated O 
with O 
500 O 
mg O 
glucophage O 
po O 
bid O 
, O 
group O 
2 O 
( O 
n O 
= O 
10 O 
) O 
was O 
treated O 
with O 
400 O 
mg O 
magnesium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
po O 
bid O 
and O 
group O 
3 O 
( O 
n O 
= O 
12 O 
) O 
was O 
treated O 
with O 
50 O 
mg O 
spironolactone B-TRIVIAL 
po O 
bid O 
for O 
12 O 
weeks O 
. O 
A O 
glucose B-TRIVIAL 
tolerance O 
test O 
with O 
75 O 
g O 
glucose B-TRIVIAL 
load O 
was O 
performed O 
before O 
and O 
after O 
treatment O 
, O 
collecting O 
blood O 
at O 
0 O 
, O 
1 O 
and O 
2 O 
h O 
for O 
insulin O 
, O 
glucose B-TRIVIAL 
, O 
FFA O 
and O 
aldosterone B-TRIVIAL 
. O 
Amount O 
of O 
FFA O 
before O 
and O 
after O 
treatment O 
were O 
compared O 
by O 
repeated O 
measure O 
ANOVA O 
and O 
represented O 
as O 
area O 
under O 
the O 
curve O 
. O 
FFA O 
levels O 
before O 
treatment O 
were O 
0.83 O 
± O 
0.23 O 
, O 
0.77 O 
± O 
0.15 O 
and O 
0.85 O 
± O 
0.28 O 
and O 
after O 
treatment O 
were O 
0.77 O 
± O 
0.48 O 
, O 
0.71 O 
± O 
0.18 O 
and O 
0.66 O 
± O 
0.25 O 
for O 
glucophage O 
, O 
magnesium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
spironolactone B-TRIVIAL 
-treated O 
patients O 
, O 
respectively O 
. O 
The O 
FFA O 
levels O 
were O 
unchanged O 
in O 
the O 
groups O 
treated O 
with O 
glucophage O 
and O 
magnesium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
but O 
were O 
significantly O 
( O 
p O 
< O 
0.03 O 
) O 
decreased O 
in O 
the O 
group O 
treated O 
with O 
spironolactone B-TRIVIAL 
. O 
Since O 
FFAs O 
are O 
known O 
to O 
be O 
involved O 
in O 
the O 
development O 
of O 
insulin O 
resistance O 
, O 
these O 
results O 
suggest O 
that O 
spironolactone B-TRIVIAL 
may O 
be O 
useful O 
for O 
lowering O 
insulin O 
resistance O 
in O 
PCOS O 
patients O 
. O 

this O 
study O 
, O 
we O 
report O 
on O 
modeling O 
of O 
galanin O 
receptor O 
type O 
3 O 
and O 
its O 
interaction O 
with O 
agonist O 
and O 
antagonists O 
using O 
in O 
silico O 
methodologies O 
. O 
Comparative O 
structural O 
modeling O 
of O 
galanin O 
receptor O 
type O 
3 O 
was O 
based O 
on O 
multiple O 
templates O 
. O 
With O 
the O 
availability O 
of O 
reported O 
selective O 
galanin O 
receptor O 
type O 
3 O 
antagonists O 
, O 
docking O 
was O 
carried O 
out O 
into O 
the O 
predicted O 
binding O 
site O 
. O 
Similarly O 
, O 
galanin O 
, O 
a O 
reported O 
agonist O 
, O 
was O 
also O 
modeled O 
and O 
then O 
docked O 
into O 
the O 
receptor's O 
active O 
site O 
. O 
CoMFA O 
models O 
were O 
developed O 
using O 
ligand O 
- O 
based O 
( O 
q(2) O 
= O 
0.537 O 
, O 
r(2) O 
= O 
0.961 O 
, O 
noc O 
= O 
5 O 
) O 
, O 
and O 
receptor O 
- O 
guided O 
( O 
docked O 
mode O 
1 O 
: O 
q(2) O 
= O 
0.574 O 
, O 
r(2) O 
= O 
0.946 O 
, O 
noc O 
= O 
5 O 
) O 
, O 
( O 
docked O 
mode O 
2 O 
: O 
q(2) O 
= O 
0.499 O 
, O 
r(2) O 
= O 
0.954 O 
, O 
noc O 
= O 
5 O 
) O 
alignment O 
schemes O 
. O 
CoMFA O 
contour O 
analysis O 
revealed O 
that O 
bulky O 
substitution O 
around O 
the O 
meta O 
position O 
of O 
the O 
phenyl B-SYSTEMATIC 
ring O 
, O 
as O 
well O 
as O 
optimal O 
substitution O 
( O 
para O 
) O 
of O 
the O 
phenyl B-SYSTEMATIC 
ring O 
, O 
could O 
produce O 
molecules O 
with O 
improved O 
activity O 
. O 
We O 
also O 
found O 
that O 
Gln B-FORMULA 
79 O 
, O 
Ile B-FORMULA 
82 O 
, O 
Asp B-FORMULA 
86 O 
, O 
Trp B-FORMULA 
88 O 
, O 
His B-FORMULA 
99 O 
, O 
Ile B-FORMULA 
102 O 
, O 
Tyr B-FORMULA 
103 O 
, O 
Glu B-FORMULA 
170 O 
, O 
Pro B-FORMULA 
174 O 
, O 
Ala B-FORMULA 
175 O 
, O 
Asp B-FORMULA 
185 O 
, O 
Arg B-FORMULA 
273 O 
, O 
His B-FORMULA 
277 O 
, O 
and O 
Tyr B-FORMULA 
281 O 
are O 
crucial O 
, O 
and O 
mutational O 
studies O 
on O 
these O 
residues O 
could O 
be O 
helpful O 
. O 
The O 
results O 
obtained O 
from O 
this O 
study O 
can O 
further O 
be O 
exploited O 
for O 
structure O 
- O 
based O 
drug O 
design O 
and O 
also O 
help O 
the O 
researchers O 
to O 
identify O 
novel O 
antagonists O 
targeting O 
galanin O 
receptor O 
type O 
3 O 
. O 

of O 
seaweed O 
- O 
restructured O 
pork O 
diets O 
enriched O 
or O 
not O 
with O 
cholesterol B-TRIVIAL 
on O 
rat O 
cholesterolaemia O 
and O 
liver O 
damage O 
. O 

enriched O 
- O 
restructured O 
pork O 
( O 
RP O 
) O 
is O 
a O 
potential O 
functional O 
food O 
. O 
However O 
, O 
indications O 
of O 
adverse O 
effects O 
associated O 
with O 
herbal O 
medications O 
, O 
which O 
include O 
among O 
others O 
liver O 
failure O 
, O 
toxic O 
hepatitis O 
, O 
and O 
death O 
have O 
been O 
reported O 
. O 
Cholesterol B-TRIVIAL 
feeding O 
produces O 
hepatomegalia O 
and O 
fat O 
liver O 
infiltration O 
. O 
The O 
effect O 
of O 
seaweed-RP O 
diet O 
, O 
cholesterol B-TRIVIAL 
-enriched O 
or O 
not O 
, O 
on O 
plasma O 
cholesterol B-TRIVIAL 
, O 
liver O 
damage O 
markers O 
, O 
structure O 
, O 
and O 
cytochrome O 
CYP4A-1 O 
were O 
evaluated O 
after O 
5wk O 
. O 
Eight O 
rat O 
groups O 
were O 
fed O 
a O 
mix O 
of O 
85% O 
AIN-93M O 
rodent-diet O 
plus O 
15% O 
RP O 
. O 
The O 
Cholesterol B-TRIVIAL 
-control O 
( O 
CC O 
) O 
, O 
Cholesterol B-TRIVIAL 
-Wakame O 
( O 
CW O 
) O 
, O 
Cholesterol B-TRIVIAL 
-Nori O 
( O 
CN O 
) O 
and O 
Cholesterol B-TRIVIAL 
-Sea O 
Spaghetti O 
( O 
CS O 
) O 
groups O 
respectively O 
consumed O 
similar O 
diets O 
to O 
control O 
( O 
C O 
) O 
, O 
Wakame O 
( O 
W O 
) O 
, O 
Nori O 
( O 
N O 
) O 
, O 
and O 
Sea O 
Spaghetti O 
( O 
S O 
) O 
but O 
as O 
part O 
of O 
hypercholesterolaemic O 
diets O 
. O 
CN O 
and O 
CS O 
significantly O 
blocked O 
the O 
hypercholesterolaemic O 
effect O 
observed O 
in O 
CC O 
group O 
. O 
After O 
5-wk O 
, O 
N O 
and O 
S O 
diets O 
increased O 
the O 
CYP4A-1 O 
expression O 
. O 
However O 
, O 
seaweed-RPs O 
were O 
unable O 
to O 
reduce O 
the O 
histological O 
liver O 
alterations O 
observed O 
in O 
CC O 
group O 
. O 
Larger O 
and O 
more O 
abundant O 
hepatocellular O 
alterations O 
were O 
found O 
in O 
CS O 
and O 
CN O 
rats O 
suggesting O 
that O 
the O 
hypocholesterolaemic O 
effects O 
of O 
these O 
seaweed-RPs O 
seem O 
to O 
be O 
a O 
two O 
- O 
edged O 
sword O 
as O 
they O 
increased O 
liver O 
damage O 
. O 
Future O 
studies O 
are O 
needed O 
to O 
understand O 
the O 
involved O 
mechanisms O 
. O 

transporter O 
GLUT4 O 
protein O 
, O 
codified O 
by O 
Slc2a4 O 
gene O 
plays O 
a O 
key O 
role O 
in O 
glycemic O 
homeostasis O 
. O 
Insulin O 
resistance O 
, O 
as O 
in O 
obesity O 
, O 
has O 
been O 
associated O 
to O 
inflammatory O 
state O 
, O 
in O 
which O 
decreased O 
GLUT4 O 
is O 
a O 
feature O 
. O 
Inflammatory O 
NF-κB O 
transcriptional O 
factor O 
has O 
been O 
proposed O 
as O 
a O 
repressor O 
of O 
Slc2a4 O 
; O 
although O 
, O 
the O 
binding O 
site(s) O 
in O 
Slc2a4 O 
promoter O 
and O 
the O 
direct O 
repressor O 
effect O 
have O 
never O 
been O 
reported O 
yet O 
. O 
A O 
motif O 
- O 
based O 
sequence O 
analysis O 
of O 
mouse O 
Slc2a4 O 
promoter O 
revealed O 
two O 
putative O 
κB O 
sites O 
located O 
inside O 
-83 O 
/ O 
-62 O 
and O 
-134 O 
/ O 
-113bp O 
. O 
Eletrophoretic O 
mobility O 
assay O 
showed O 
that O 
p50 O 
and O 
p65 O 
NF-κB O 
subunits O 
bind O 
to O 
both O 
putative O 
κB O 
sites O 
. O 
Chromatin O 
immunoprecipitation O 
assay O 
using O 
genomic O 
DNA O 
from O 
adipocytes O 
confirmed O 
p50- O 
and O 
p65 O 
- O 
binding O 
to O 
Slc2a4 O 
promoter O 
. O 
Moreover O 
, O 
transfection O 
experiments O 
revealed O 
that O 
NF-κB O 
binds O 
to O 
the O 
-134 O 
/ O 
-113bp O 
region O 
of O 
the O 
mouse O 
Slc2a4 O 
gene O 
promoter O 
, O 
inhibiting O 
the O 
Slc2a4 O 
gene O 
transcription O 
. O 
The O 
current O 
findings O 
demonstrate O 
the O 
existence O 
of O 
two O 
κB O 
sites O 
in O 
Slc2a4 O 
gene O 
promote O 
, O 
and O 
that O 
NF-κB O 
has O 
a O 
direct O 
repressor O 
effect O 
upon O 
the O 
Slc2a4 O 
gene O 
, O 
providing O 
an O 
important O 
link O 
between O 
insulin O 
resistance O 
and O 
inflammation O 
. O 

vitro O 
evaluation O 
of O 
the O 
therapeutic O 
potential O 
of O 
nevirapine B-TRIVIAL 
in O 
treatment O 
of O 
human O 
thyroid O 
anaplastic O 
carcinoma O 
. O 

thyroid O 
carcinoma O 
( O 
ATC O 
) O 
is O 
a O 
severe O 
thyroid O 
malignancy O 
with O 
poor O 
prognosis O 
, O 
due O 
to O 
its O 
early O 
metastasis O 
and O 
unresponsiveness O 
to O 
both O 
radiation O 
and O 
chemotherapy O 
. O 
Nevirapine B-TRIVIAL 
, O 
a O 
non-nucleoside O 
reverse O 
transcriptase O 
inhibitor O 
, O 
has O 
been O 
used O 
as O 
a O 
re O 
- O 
differentiation O 
agent O 
to O 
treat O 
cancers O 
in O 
several O 
human O 
cancer O 
models O 
. O 
So O 
far O 
, O 
the O 
effects O 
of O 
nevirapine B-TRIVIAL 
on O 
human O 
thyroid O 
anaplastic O 
carcinoma O 
cells O 
have O 
not O 
been O 
documented O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
therapeutic O 
potential O 
of O 
nevirapine B-TRIVIAL 
in O 
treatment O 
of O 
human O 
thyroid O 
anaplastic O 
carcinoma O 
. O 
Cell O 
proliferation O 
was O 
determined O 
by O 
methly B-SYSTEMATIC 
thiazolyl I-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
. O 
Cell O 
apoptosis O 
was O 
analyzed O 
by O 
Hoechst B-TRIVIAL 
33258 I-TRIVIAL 
staining O 
. O 
The O 
mRNA O 
expression O 
of O 
NIS O 
and O 
TSHR O 
was O 
determined O 
by O 
real O 
- O 
time O 
quantitative O 
reverse O 
transcription O 
- O 
polymerase O 
chain O 
reaction O 
( O 
real O 
time O 
RT-PCR O 
) O 
. O 
Iodine B-SYSTEMATIC 
uptake O 
was O 
determined O 
by O 
(125)I B-FORMULA 
radioactivity O 
assay O 
. O 
At O 
all O 
doses O 
( O 
100 O 
, O 
200 O 
, O 
350 O 
, O 
500μmol O 
/ O 
L O 
) O 
tested O 
, O 
nevirapine B-TRIVIAL 
significantly O 
inhibited O 
cell O 
proliferation O 
after O 
48h O 
treatment O 
. O 
At O 
high O 
dose O 
( O 
500μmol O 
/ O 
L O 
) O 
, O 
nevirapine B-TRIVIAL 
significantly O 
increased O 
the O 
percentage O 
of O 
apoptotic O 
cells O 
compared O 
with O 
control O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
At O 
lower O 
doses O 
( O 
200μmol O 
/ O 
L O 
and O 
350μmol O 
/ O 
L O 
) O 
, O 
nevirapine B-TRIVIAL 
did O 
not O 
induce O 
cell O 
apoptosis O 
, O 
but O 
up O 
- O 
regulated O 
NIS O 
and O 
THSR O 
mRNA O 
expression O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
FRO O 
cells O 
pre O 
- O 
treated O 
with O 
nevirapine B-TRIVIAL 
, O 
the O 
increase O 
in O 
NIS O 
expression O 
had O 
no O 
obvious O 
effect O 
on O 
iodine B-SYSTEMATIC 
uptake O 
. O 
These O 
findings O 
indicate O 
that O 
nevirapine B-TRIVIAL 
has O 
an O 
anti-proliferative O 
effect O 
on O 
FRO O 
cells O 
, O 
which O 
correlates O 
with O 
an O 
induction O 
of O 
cell O 
differentiation O 
. O 

and O 
cyto O 
- O 
protective O 
effects O 
of O 
chebulinic B-TRIVIAL 
acid I-TRIVIAL 
isolated O 
from O 
the O 
fruits O 
of O 
Terminalia O 
chebula O 
on O 
gastric O 
ulcers O 
. O 

continuation O 
of O 
our O 
drug O 
discovery O 
program O 
on O 
Indian O 
medicinal O 
plants O 
, O 
the O 
gastro O 
protective O 
mechanism O 
of O 
chebulinic B-TRIVIAL 
acid I-TRIVIAL 
isolated O 
from O 
Terminalia O 
chebula O 
fruit O 
was O 
investigated O 
. O 
Chebulinic B-TRIVIAL 
acid I-TRIVIAL 
was O 
evaluated O 
against O 
cold O 
restraint O 
( O 
CRU O 
) O 
, O 
aspirin B-TRIVIAL 
( O 
AS O 
) O 
, O 
alcohol B-FAMILY 
( O 
AL O 
) O 
and O 
pyloric O 
ligation O 
( O 
PL O 
) O 
induced O 
gastric O 
ulcer O 
models O 
in O 
rats O 
. O 
Potential O 
anti-ulcer O 
activity O 
of O 
chebulinic B-TRIVIAL 
acid I-TRIVIAL 
was O 
observed O 
against O 
CRU O 
( O 
62.9% O 
) O 
, O 
AS O 
( O 
55.3% O 
) O 
, O 
AL O 
( O 
80.67% O 
) O 
and O 
PL O 
( O 
66.63% O 
) O 
induced O 
ulcer O 
models O 
. O 
The O 
reference O 
drug O 
omeprazole B-TRIVIAL 
( O 
10mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
showed O 
77.73% O 
protection O 
against O 
CRU O 
, O 
58.30% O 
against O 
AS O 
and O 
70.80% O 
against O 
PL O 
model O 
. O 
Sucralfate B-TRIVIAL 
, O 
another O 
reference O 
drug O 
( O 
500mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
showed O 
65.67% O 
protection O 
in O 
AL O 
induced O 
ulcer O 
model O 
. O 
Chebulinic B-TRIVIAL 
acid I-TRIVIAL 
significantly O 
reduced O 
free O 
acidity O 
( O 
48.82% O 
) O 
, O 
total O 
acidity O 
( O 
38.29% O 
) O 
and O 
upregulated O 
mucin O 
secretion O 
by O 
59.75% O 
respectively O 
. O 
Further O 
, O 
chebulinic B-TRIVIAL 
acid I-TRIVIAL 
significantly O 
inhibited O 
H(+) B-FORMULA 
K(+) B-FORMULA 
-ATPase O 
activity O 
in O 
vitro O 
with O 
IC50 O 
of O 
65.01μg O 
/ O 
ml O 
as O 
compared O 
to O 
the O 
IC50 O 
value O 
of O 
omeprazole B-TRIVIAL 
( O 
30.24μg O 
/ O 
ml O 
) O 
confirming O 
its O 
anti-secretory O 
activity O 
. O 

Chinese O 
herb O 
formula O 
decreases O 
the O 
monocarboxylate B-SYSTEMATIC 
transporter O 
- O 
mediated O 
absorption O 
of O 
valproic B-TRIVIAL 
acid I-TRIVIAL 
in O 
rats O 
. O 

( O 
HQT O 
) O 
, O 
a O 
Chinese O 
medicine O 
prescription O 
containing O 
Scutellariae O 
Radix O 
( O 
SR O 
) O 
, O 
Paeoniae O 
Radix O 
( O 
PR O 
) O 
, O 
Glycyrrhizae O 
Radix O 
( O 
GR O 
) O 
and O 
JuJubae O 
Fructus O 
( O 
JF O 
) O 
, O 
was O 
used O 
for O 
the O 
treatments O 
of O 
cold O 
with O 
symptoms O 
of O 
abdominalgia O 
and O 
diarrhea O 
. O 
Valproic B-TRIVIAL 
acid I-TRIVIAL 
( O 
VPA B-ABBREVIATION 
) O 
is O 
an O 
antiepileptic O 
drug O 
with O 
narrow O 
therapeutic O 
window O 
. O 
This O 
study O 
investigated O 
the O 
effect O 
of O 
coadministration O 
of O 
HQT O 
on O 
the O 
pharmacokinetics O 
of O 
VPA B-ABBREVIATION 
, O 
a O 
probe O 
drug O 
for O 
monocarboxylate B-SYSTEMATIC 
transporter O 
( O 
MCT O 
) O 
. O 
Rats O 
were O 
administered O 
VPA B-ABBREVIATION 
alone O 
( O 
200.0mg O 
/ O 
kg O 
) O 
and O 
coadministered O 
HQT O 
( O 
8.0g O 
/ O 
kg O 
) O 
at O 
0.5h O 
before O 
VPA B-ABBREVIATION 
and O 
1.5h O 
after O 
VPA B-ABBREVIATION 
in O 
crossover O 
designs O 
. O 
In O 
addition O 
, O 
the O 
chronic O 
effect O 
of O 
HQT O 
was O 
also O 
evaluated O 
by O 
coadministration O 
of O 
the O 
7th O 
dose O 
at O 
0.5h O 
before O 
VPA B-ABBREVIATION 
. O 
The O 
serum O 
concentration O 
of O 
VPA B-ABBREVIATION 
was O 
determined O 
by O 
a O 
fluorescence O 
polarization O 
immunoassay O 
. O 
The O 
results O 
showed O 
that O 
coadministration O 
of O 
HQT O 
at O 
0.5h O 
before O 
VPA B-ABBREVIATION 
significantly O 
decreased O 
the O 
AUC0-t O 
and O 
Cmax O 
by O 
62% O 
and O 
77% O 
, O 
respectively O 
, O 
whereas O 
coadministration O 
of O 
HQT O 
at O 
1.5h O 
after O 
VPA B-ABBREVIATION 
exerted O 
no O 
significant O 
influence O 
. O 
When O 
the O 
7th O 
dose O 
of O 
HQT O 
was O 
given O 
at O 
0.5h O 
before O 
VPA B-ABBREVIATION 
, O 
the O 
AUC0-t O 
and O 
Cmax O 
of O 
VPA B-ABBREVIATION 
were O 
markedly O 
decreased O 
by O 
65% O 
and O 
82% O 
, O 
respectively O 
. O 
Mechanism O 
study O 
revealed O 
that O 
the O 
MCT O 
- O 
mediated O 
uptake O 
of O 
fluorescein B-TRIVIAL 
was O 
inhibited O 
by O 
HQT O 
and O 
each O 
component O 
herbs O 
. O 
In O 
conclusion O 
, O 
the O 
MCT O 
- O 
mediated O 
absorption O 
of O 
VPA B-ABBREVIATION 
was O 
significantly O 
decreased O 
by O 
concomitant O 
administration O 
of O 
HQT O 
. O 

Beneficial O 
Role O 
of O 
Thiamine B-TRIVIAL 
in O 
Parkinson O 
Disease O 
. O 

disease O 
( O 
PD O 
) O 
is O 
the O 
second O 
most O 
common O 
form O 
of O 
neurodegeneration O 
among O 
elderly O 
individuals O 
. O 
PD O 
is O 
clinically O 
characterized O 
by O 
tremors O 
, O 
rigidity O 
, O 
slowness O 
of O 
movement O 
, O 
and O 
postural O 
imbalance O 
. O 
In O 
this O 
paper O 
, O 
we O 
review O 
the O 
evidence O 
for O 
an O 
association O 
between O 
PD O 
and O 
thiamine B-TRIVIAL 
. O 
Interestingly O 
, O 
a O 
significant O 
association O 
has O 
been O 
demonstrated O 
between O 
PD O 
and O 
low O 
levels O 
of O 
serum O 
thiamine B-TRIVIAL 
, O 
and O 
thiamine B-TRIVIAL 
supplements O 
appear O 
to O 
have O 
beneficial O 
clinical O 
effects O 
against O 
PD O 
. O 
Multiple O 
studies O 
have O 
evaluated O 
the O 
connection O 
between O 
thiamine B-TRIVIAL 
and O 
PD O 
pathology O 
, O 
and O 
candidate O 
pathways O 
involve O 
the O 
transcription O 
factor O 
Sp1 O 
, O 
p53 O 
, O 
Bcl-2 O 
, O 
caspase-3 O 
, O 
tyrosine B-TRIVIAL 
hydroxylase O 
, O 
glycogen O 
synthase O 
kinase-3β O 
, O 
vascular O 
endothelial O 
growth O 
factor O 
, O 
advanced O 
glycation O 
end O 
products O 
, O 
nuclear O 
factor O 
kappa O 
B O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
, O 
and O 
the O 
reduced O 
form O 
of O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
. O 
Thus O 
, O 
a O 
review O 
of O 
the O 
literature O 
suggests O 
that O 
thiamine B-TRIVIAL 
plays O 
a O 
role O 
in O 
PD O 
, O 
although O 
further O 
investigation O 
into O 
the O 
effects O 
of O 
thiamine B-TRIVIAL 
in O 
PD O 
is O 
needed O 
. O 

- O 
inactivating O 
proteins O 
( O 
RIPs O 
) O 
either O 
single O 
- O 
chain O 
( O 
type O 
1 O 
) O 
or O 
two O 
- O 
chain O 
( O 
type O 
2 O 
) O 
are O 
frequent O 
in O 
plants O 
, O 
often O 
in O 
multiple O 
forms O 
. O 
They O 
are O 
RNA O 
N B-FORMULA 
-glycosidases O 
, O 
have O 
antiviral O 
, O 
antifungal O 
and O 
insecticidal O 
activity O 
. O 
Their O 
expression O 
in O 
plants O 
is O 
increased O 
under O 
stressful O 
conditions O 
. O 
They O 
are O 
investigated O 
for O 
practical O 
applications O 
in O 
medicine O 
and O 
in O 
agriculture O 
. O 
In O 
medicine O 
, O 
RIPs O 
have O 
been O 
linked O 
to O 
, O 
or O 
fused O 
with O 
, O 
appropriate O 
antibodies O 
or O 
other O 
carriers O 
to O 
form O 
" O 
immunotoxins O 
" O 
or O 
other O 
conjugates O 
specifically O 
toxic O 
to O 
the O 
cells O 
target O 
of O 
the O 
carrier O 
, O 
with O 
the O 
aim O 
of O 
eliminating O 
malignant O 
or O 
other O 
undesired O 
cells O 
. O 
In O 
agriculture O 
, O 
it O 
has O 
been O 
observed O 
that O 
an O 
enhanced O 
expression O 
of O 
RIPs O 
confers O 
to O 
plants O 
an O 
increased O 
resistance O 
to O 
viruses O 
, O 
fungi O 
, O 
insects O 
, O 
and O 
also O 
to O 
drought O 
and O 
salinity O 
. O 

- O 
fanged O 
colubroid O 
snakes O 
( O 
NFFC O 
; O 
formerly O 
and O 
artificially O 
taxonomically O 
assembled O 
as O 
" O 
colubrids O 
" O 
) O 
comprise O 
about O 
70% O 
of O 
extant O 
snake O 
species O 
and O 
include O 
several O 
taxa O 
now O 
known O 
to O 
cause O 
lethal O 
or O 
life O 
threatening O 
envenoming O 
in O 
humans O 
. O 
Although O 
the O 
medical O 
risks O 
of O 
bites O 
by O 
only O 
a O 
handful O 
of O 
species O 
have O 
been O 
documented O 
, O 
a O 
growing O 
number O 
of O 
NFFC O 
are O 
implicated O 
in O 
medically O 
significant O 
bites O 
. O 
The O 
majority O 
of O 
these O 
snakes O 
have O 
oral O 
products O 
( O 
Duvernoy's O 
secretions O 
, O 
or O 
venoms O 
) O 
with O 
unknown O 
biomedical O 
properties O 
and O 
their O 
potential O 
for O 
causing O 
harm O 
in O 
humans O 
is O 
unknown O 
. O 
Increasingly O 
, O 
multiple O 
NFFC O 
species O 
are O 
entering O 
the O 
commercial O 
snake O 
trade O 
posing O 
an O 
uncertain O 
risk O 
. O 
Published O 
case O 
reports O 
describing O 
NFFC O 
bites O 
were O 
assessed O 
for O 
evidence O 
- O 
based O 
value O 
, O 
clinical O 
detail O 
and O 
verified O 
species O 
identification O 
. O 
These O 
data O 
were O 
subjected O 
to O 
meta-analysis O 
and O 
a O 
hazard O 
index O 
was O 
generated O 
for O 
select O 
taxa O 
. O 
Cases O 
on O 
which O 
we O 
consulted O 
or O 
personally O 
treated O 
were O 
included O 
and O 
subjected O 
to O 
the O 
same O 
assessment O 
criteria O 
. O 
Cases O 
involving O 
approximately O 
120 O 
species O 
met O 
the O 
selection O 
criteria O 
, O 
and O 
a O 
small O 
subset O 
designated O 
Hazard O 
Level O 
1 O 
( O 
most O 
hazardous O 
) O 
, O 
contained O 
5 O 
species O 
with O 
lethal O 
potential O 
. O 
Recommended O 
management O 
of O 
these O 
cases O 
included O 
antivenom O 
for O 
3 O 
species O 
, O 
Dispholidus O 
typus O 
, O 
Rhabdophis O 
tiginis O 
, O 
Rhabdophis O 
subminiatus O 
, O 
whereas O 
others O 
in O 
this O 
subset O 
without O 
commercially O 
available O 
antivenoms O 
( O 
Thelotornis O 
spp O 
. O 
) O 
were O 
treated O 
with O 
plasma O 
/ O 
erythrocyte O 
replacement O 
therapy O 
and O 
supportive O 
care O 
. O 
Heparin O 
, O 
antifibrinolytics O 
and O 
/ O 
or O 
plasmapheresis O 
/ O 
exchange O 
transfusion O 
have O 
been O 
used O 
in O 
the O 
management O 
of O 
some O 
Hazard O 
Level O 
1 O 
envenomings O 
, O 
but O 
evidence O 
- O 
based O 
analysis O 
positively O 
contraindicates O 
the O 
use O 
of O 
any O 
of O 
these O 
interventions O 
. O 
Hazard O 
Level O 
2 O 
/ O 
3 O 
species O 
were O 
involved O 
in O 
cases O 
containing O 
mixed O 
quality O 
data O 
that O 
implicated O 
these O 
taxa O 
( O 
e.g O 
. O 
Boiga O 
irregularis O 
, O 
Philodryas O 
olfersii O 
, O 
Malpolon O 
monspessulanus O 
) O 
with O 
bites O 
that O 
caused O 
rare O 
systemic O 
effects O 
. O 
Recommended O 
management O 
may O 
include O 
use O 
of O 
acetylcholinesterase O 
inhibitors O 
( O 
e.g O 
. O 
neostigmine B-TRIVIAL 
) O 
and O 
wound O 
care O 
on O 
a O 
case O 
- O 
by O 
- O 
case O 
basis O 
. O 
Hazard O 
level O 
3 O 
species O 
comprised O 
a O 
larger O 
group O 
capable O 
of O 
producing O 
significant O 
local O 
effects O 
only O 
, O 
often O 
associated O 
with O 
a O 
protracted O 
bite O 
( O 
eg O 
Heterodon O 
nasicus O 
, O 
Borikenophis O 
( O 
Alsophis O 
) O 
portoricensis O 
, O 
Platyceps O 
( O 
Coluber O 
) O 
rhodorachis O 
) O 
. O 
Management O 
is O 
restricted O 
to O 
wound O 
care O 
. O 
Bites O 
by O 
Hazard O 
level O 
4 O 
species O 
comprised O 
the O 
majority O 
of O 
surveyed O 
taxa O 
and O 
these O 
showed O 
only O 
minor O 
effects O 
of O 
no O 
clinical O 
importance O 
. O 
This O 
study O 
has O 
produced O 
a O 
comprehensive O 
evidence O 
- O 
based O 
listing O 
of O 
NFFC O 
snakes O 
tabulated O 
against O 
medical O 
significance O 
of O 
bites O 
, O 
together O 
with O 
best O 
- O 
practice O 
management O 
recommendations O 
. O 
This O 
analysis O 
assumes O 
increasing O 
importance O 
, O 
as O 
there O 
is O 
growing O 
exposure O 
to O 
lesser O 
- O 
known O 
NFFC O 
snakes O 
, O 
particularly O 
in O 
captive O 
collections O 
that O 
may O 
uncover O 
further O 
species O 
of O 
significance O 
in O 
the O 
future O 
. O 
Careful O 
and O 
accurate O 
documentation O 
of O 
bites O 
by O 
verified O 
species O 
of O 
NFFC O 
snakes O 
is O 
required O 
to O 
increase O 
the O 
evidence O 
base O 
and O 
establish O 
the O 
best O 
medical O 
management O 
approach O 
for O 
each O 
species O 
. O 

activation O 
of O 
gene O 
expression O 
by O 
agonists O 
and O 
antagonists O 
mediated O 
by O 
estrogen B-FAMILY 
receptor O 
heteroligand O 
dimer O 
complexes O 
. O 

receptor O 
( O 
ER O 
) O 
antagonists O 
are O 
generally O 
thought O 
to O 
inhibit O 
estrogen B-FAMILY 
action O 
through O 
competitive O 
inhibition O 
, O 
resulting O 
in O 
receptor O 
binding O 
to O 
antagonist O 
rather O 
than O 
agonist O 
. O 
However O 
, O 
microarray O 
analyses O 
reveal O 
a O 
group O 
of O 
genes O 
for O 
which O 
ER O 
agonist O 
and O 
antagonist O 
cooperatively O 
regulate O 
expression O 
, O 
suggesting O 
additional O 
models O 
of O 
combined O 
agonist O 
/ O 
antagonist O 
action O 
must O 
exist O 
. O 
In O 
conjunction O 
with O 
a O 
chimeric O 
reporter O 
gene O 
and O 
two O 
modified O 
ERs O 
, O 
one O 
[ERα(GSCKV)] O 
with O 
a O 
mutation O 
in O 
the O 
DNA O 
- O 
binding O 
domain O 
and O 
the O 
other O 
( O 
ERα-G521R O 
) O 
with O 
a O 
ligand O 
- O 
binding O 
specificity O 
mutation O 
, O 
we O 
herein O 
demonstrate O 
that O 
ER O 
agonist O 
and O 
antagonist O 
cooperatively O 
activate O 
gene O 
expression O 
through O 
an O 
ER O 
heteroligand O 
dimer O 
complex O 
( O 
ER-HLD O 
) O 
consisting O 
of O 
one O 
subunit O 
of O 
the O 
receptor O 
dimer O 
bound O 
to O 
agonist O 
and O 
another O 
occupied O 
by O 
antagonist O 
. O 
Coimmunoprecipitation O 
experiments O 
confirmed O 
interaction O 
between O 
the O 
agonist O 
- O 
bound O 
and O 
antagonist O 
- O 
bound O 
receptors O 
. O 
This O 
cooperative O 
activation O 
of O 
gene O 
expression O 
was O 
enhanced O 
by O 
steroid O 
receptor O 
coactivator O 
3 O 
coactivator O 
, O 
and O 
required O 
each O 
ligand O 
- O 
bound O 
subunit O 
of O 
the O 
dimer O 
to O 
bind O 
to O 
DNA O 
, O 
as O 
well O 
as O 
both O 
activation O 
function O 
1 O 
domains O 
for O 
maximal O 
transcriptional O 
activity O 
. O 
Ligand O 
combinations O 
able O 
to O 
induce O 
ER-HLD O 
transcriptional O 
activity O 
include O 
the O 
agonists O 
17β-estradiol B-SYSTEMATIC 
or O 
conjugated O 
estrogens O 
with O 
the O 
antagonists O 
tamoxifen B-TRIVIAL 
, O 
raloxifene B-TRIVIAL 
, O 
bazedoxifene B-TRIVIAL 
, O 
or O 
fulvestrant B-TRIVIAL 
. O 
Moreover O 
, O 
ER-HLD O 
can O 
activate O 
transcription O 
in O 
the O 
context O 
of O 
a O 
natural O 
promoter O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
broaden O 
our O 
understanding O 
of O 
the O 
complex O 
relationship O 
between O 
ER O 
agonist O 
and O 
antagonist O 
, O 
and O 
suggest O 
a O 
novel O 
model O 
by O 
which O 
cell O 
and O 
tissue O 
selective O 
effects O 
of O 
antiestrogens O 
may O 
be O 
achieved O 
. O 

To O 
evaluate O 
coronary O 
artery O 
stenosis O 
in O 
early O 
diabetes O 
or O 
prediabetes O 
asymptomatic O 
of O 
myocardial O 
ischemia O 
in O 
community O 
- O 
dwelling O 
Chinese O 
adults.RESEARCH O 
DESIGN O 
AND O 
METHODS O 
Age- O 
and O 
sex O 
- O 
matched O 
participants O 
with O 
normal O 
glucose B-TRIVIAL 
regulation O 
( O 
NGR O 
) O 
, O 
prediabetes O 
, O 
or O 
diabetes O 
diagnosed O 
within O 
5 O 
years O 
, O 
asymptomatic O 
of O 
coronary O 
artery O 
disease O 
( O 
CAD O 
) O 
, O 
were O 
randomly O 
selected O 
from O 
a O 
community O 
- O 
dwelling O 
Chinese O 
population O 
aged O 
40-60 O 
years O 
. O 
Dual O 
- O 
source O 
computed O 
tomography O 
coronary O 
angiography O 
was O 
used O 
to O 
evaluate O 
the O 
existence O 
and O 
extent O 
of O 
coronary O 
stenosis O 
, O 
which O 
was O 
considered O 
significant O 
if O 
> O 
50% O 
narrowing O 
of O 
vessel O 
lumen O 
was O 
detected.RESULTS O 
After O 
excluding O 
uninterpretable O 
segments O 
attributable O 
to O 
motion O 
artifacts O 
, O 
a O 
total O 
of O 
135 O 
participants O 
with O 
NGR O 
, O 
132 O 
with O 
prediabetes O 
, O 
and O 
134 O 
with O 
diabetes O 
participated O 
in O 
data O 
analysis O 
. O 
Significant O 
coronary O 
stenosis O 
was O 
detected O 
in O 
10 O 
( O 
7.4% O 
) O 
, O 
10 O 
( O 
7.6% O 
) O 
, O 
and O 
22 O 
( O 
16.4% O 
) O 
individuals O 
with O 
NGR O 
, O 
prediabetes O 
, O 
and O 
diabetes O 
, O 
respectively O 
( O 
P O 
for O 
trend O 
= O 
0.029 O 
) O 
. O 
Diabetes O 
, O 
rather O 
than O 
prediabetes O 
, O 
was O 
associated O 
with O 
a O 
significant O 
2.34-fold O 
elevated O 
risk O 
[ O 
odds O 
ratio O 
( O 
OR O 
) O 
2.34 O 
( O 
95% O 
CI O 
1.01-5.43 O 
) O 
; O 
P O 
= O 
0.047 O 
] O 
of O 
significant O 
coronary O 
stenosis O 
as O 
compared O 
with O 
that O 
associated O 
with O 
NGR O 
. O 
Levels O 
of O 
glucose B-TRIVIAL 
evaluation O 
were O 
independently O 
and O 
significantly O 
associated O 
with O 
risks O 
of O 
significant O 
coronary O 
stenosis O 
in O 
diabetes O 
. O 
Each O 
1-SD O 
increase O 
in O 
fasting O 
plasma O 
glucose B-TRIVIAL 
, O 
2-h O 
postload O 
plasma O 
glucose B-TRIVIAL 
, O 
and O 
HbA1c O 
conveyed O 
2.11-fold O 
, O 
1.73-fold O 
, O 
and O 
1.81-fold O 
higher O 
risks O 
of O 
significant O 
coronary O 
stenosis O 
, O 
respectively O 
, O 
after O 
adjustment O 
for O 
other O 
conventional O 
cardiovascular O 
risk O 
factors.CONCLUSIONSUsing O 
a O 
noninvasive O 
CAD O 
diagnostic O 
modality O 
such O 
as O 
dual O 
- O 
source O 
computed O 
tomography O 
coronary O 
angiography O 
, O 
we O 
detected O 
a O 
markedly O 
elevated O 
risk O 
of O 
significant O 
coronary O 
stenosis O 
with O 
early O 
diabetes O 
in O 
asymptomatic O 
Chinese O 
adults O 
. O 

of O 
robenidine B-TRIVIAL 
residues O 
in O 
chicken O 
muscle O 
by O 
high O 
performance O 
liquid O 
chromatography O 
with O 
ultraviolet O 
detection O 
. O 

simple O 
, O 
robust O 
and O 
reliable O 
method O 
for O 
the O 
determination O 
of O 
residual O 
robenidine B-TRIVIAL 
in O 
chicken O 
muscle O 
using O 
high O 
performance O 
liquid O 
chromatography O 
with O 
ultraviolet O 
( O 
UV O 
) O 
detection O 
was O 
developed O 
and O 
validated O 
according O 
to O 
the O 
Codex O 
Alimentarius O 
Commission O 
guidelines O 
. O 
Chicken O 
muscle O 
was O 
extracted O 
by O 
acetonitrile B-SYSTEMATIC 
/ O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
98 O 
: O 
2 O 
, O 
v O 
/ O 
v O 
) O 
and O 
defatted O 
with O 
hexane B-SYSTEMATIC 
. O 
Analytes O 
were O 
isocratically O 
separated O 
on O 
a O 
Luna O 
C18 O 
column O 
( O 
4.6 O 
× O 
150 O 
mm O 
, O 
5 O 
μm O 
) O 
using O 
70 O 
% O 
methanol B-SYSTEMATIC 
in O 
water O 
containing O 
0.1 O 
% O 
trifluoroacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
at O 
a O 
flow O 
rate O 
of O 
1 O 
mL O 
/ O 
min O 
at O 
30 O 
°C O 
. O 
UV O 
detection O 
was O 
performed O 
at O 
312 O 
nm O 
. O 
The O 
method O 
was O 
validated O 
by O 
assessing O 
performance O 
parameters O 
including O 
selectivity O 
, O 
linearity O 
, O 
limit O 
of O 
quantification O 
( O 
LOQ O 
) O 
, O 
precision O 
, O 
accuracy O 
, O 
recovery O 
, O 
stability O 
and O 
robustness O 
. O 
A O 
calibration O 
curve O 
that O 
was O 
constructed O 
over O 
0.05-0.5 O 
μg O 
/ O 
g O 
showed O 
correlation O 
coefficients O 
of O 
more O 
than O 
0.999 O 
. O 
The O 
intra- O 
and O 
inter O 
- O 
day O 
precisions O 
( O 
as O 
coefficient O 
of O 
variation O 
) O 
were O 
1.45-3.32 O 
and O 
2.63-4.99 O 
% O 
, O 
respectively O 
. O 
The O 
intra- O 
and O 
inter O 
- O 
day O 
accuracies O 
were O 
99.4-105.3 O 
and O 
98.3-101.6 O 
% O 
, O 
respectively O 
. O 
The O 
recoveries O 
were O 
in O 
the O 
range O 
of O 
76.6-81.8 O 
% O 
and O 
the O 
LOQ O 
was O 
0.05 O 
μg O 
/ O 
g O 
. O 
The O 
developed O 
method O 
showed O 
suitable O 
performance O 
for O 
the O 
determination O 
of O 
robenidine B-TRIVIAL 
residues O 
in O 
chicken O 
muscle O 
. O 

and O 
pharmacokinetic O 
evaluation O 
of O 
once O 
- O 
daily O 
sustained O 
- O 
released O 
system O 
of O 
nifedipine B-TRIVIAL 
with O 
solid O 
dispersion O 
and O 
coating O 
techniques O 
. O 

novel O 
sustained O 
- O 
release O 
system O 
was O 
developed O 
for O 
poorly O 
water O 
- O 
soluble O 
drugs O 
by O 
applying O 
solid O 
dispersion O 
( O 
SD O 
) O 
technique O 
to O 
improve O 
the O 
solubility O 
. O 
The O 
SD O 
systems O 
composed O 
of O 
polyvinyl B-SYSTEMATIC 
pyrrolidone I-SYSTEMATIC 
and O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
could O 
not O 
control O 
the O 
release O 
of O 
nifedipine B-TRIVIAL 
. O 
When O 
the O 
above O 
SD O 
granules O 
were O 
coated O 
with O 
ethylcellolulose O 
( O 
EC10 O 
, O 
45 O 
and O 
100cp O 
) O 
, O 
the O 
dissolution O 
rate O 
extended O 
from O 
16 O 
to O 
20 O 
h O 
. O 
When O 
the O 
concentration O 
of O 
EC100cp O 
was O 
increased O 
to O 
4-6 O 
% O 
, O 
the O 
sustained O 
- O 
release O 
formulation O 
F7 O 
and O 
F8 O 
prepared O 
with O 
4 O 
% O 
EC100cp O 
and O 
6 O 
% O 
EC100cp O 
, O 
respectively O 
, O 
could O 
control O 
the O 
drug O 
release O 
in O 
a O 
better O 
manner O 
, O 
namely O 
, O 
they O 
could O 
control O 
drug O 
release O 
in O 
the O 
initial O 
hours O 
with O 
a O 
high O 
cumulative O 
amount O 
of O 
drug O 
at O 
24 O 
h O 
. O 
The O 
mechanism O 
of O 
drug O 
release O 
from O 
F7 O 
and O 
F8 O 
was O 
diffusion O 
coupled O 
with O 
erosion O 
. O 
When O 
immediate O 
- O 
release O 
capsules O 
was O 
orally O 
administered O 
to O 
rabbits O 
, O 
its O 
absorption O 
was O 
very O 
rapid O 
with O 
a O 
short O 
elimination O 
half O 
- O 
life O 
, O 
while O 
a O 
prolonged O 
maintenance O 
of O 
the O 
plasma O 
drug O 
level O 
up O 
to O 
24 O 
h O 
was O 
obtained O 
for O 
F7 O 
and O 
F8 O 
. O 
Furthermore O 
, O 
the O 
oral O 
bioavailability O 
of O 
F7 O 
and O 
F8 O 
was O 
significantly O 
improved O 
. O 
The O 
results O 
suggested O 
that O 
this O 
novel O 
sustained O 
- O 
release O 
system O 
would O 
be O 
a O 
promising O 
system O 
to O 
improve O 
the O 
solubility O 
and O 
sustain O 
the O 
absorption O 
of O 
poorly O 
water O 
- O 
soluble O 
drugs O 
. O 

extracts O 
of O 
the O 
dried O 
mature O 
( O 
ANP-W O 
) O 
and O 
immature O 
Citrus O 
unshiu O 
peels O 
( O 
CUP-W O 
) O 
have O 
been O 
used O 
as O 
a O 
traditional O 
folk O 
medicine O 
for O 
the O 
treatment O 
of O 
gastrointestinal O 
( O 
GI O 
) O 
motility O 
disorders O 
in O 
Korea O 
. O 
In O 
the O 
present O 
study O 
, O 
neither O 
ANP-W O 
nor O 
CUP-W O 
exhibited O 
significant O 
toxicity O 
even O 
at O 
an O 
oral O 
dose O 
of O 
5 O 
g O 
/ O 
kg O 
to O 
mice O 
. O 
The O 
effects O 
of O 
ANP-W O 
and O 
CUP-W O 
on O 
GI O 
motor O 
function O 
were O 
investigated O 
by O 
measuring O 
the O 
intestinal O 
transit O 
rate O 
( O 
ITR O 
) O 
of O 
Evans O 
blue O 
in O 
normal O 
mice O 
and O 
rats O 
with O 
experimental O 
GI O 
motility O 
dysfunctions O 
( O 
GMDs O 
) O 
. O 
In O 
normal O 
mice O 
, O 
the O 
ITR O 
was O 
significantly O 
increased O 
by O 
ANP-W O 
( O 
0.1-1 O 
g O 
/ O 
kg O 
) O 
in O 
a O 
dose O 
dependent O 
manner O 
, O 
whereas O 
CUP-W O 
elicited O 
no O 
significant O 
change O 
. O 
GMD O 
was O 
induced O 
by O 
appropriate O 
surgery O 
or O 
an O 
intraperitoneal O 
injection O 
of O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
to O 
the O 
rats O 
. O 
The O 
ITR O 
in O 
the O 
GMD O 
rats O 
was O 
significantly O 
retarded O 
compared O 
to O 
that O 
in O 
normal O 
rats O 
. O 
However O 
, O 
the O 
retardation O 
was O 
significantly O 
inhibited O 
by O 
ANP-W O 
( O 
0.1-1 O 
g O 
/ O 
kg O 
) O 
in O 
a O 
dose O 
dependent O 
manner O 
. O 
The O 
above O 
results O 
suggest O 
that O 
ANP-W O 
has O 
the O 
potential O 
for O 
development O 
as O 
a O 
prokinetic O 
agent O 
that O 
may O 
prevent O 
or O 
alleviate O 
GMD O 
in O 
human O 
patients O 
. O 

stretchable O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
- O 
polymer O 
composite O 
films O 
with O 
near O 
- O 
infrared O 
fluorescence O 
. O 

report O 
transparent O 
stretchable O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
- O 
polymer O 
composite O 
films O 
that O 
emit O 
pronounced O 
Raman O 
and O 
near O 
- O 
infrared O 
fluorescence O 
with O 
a O 
fine O 
spatial O 
resolution O 
. O 
The O 
independent O 
modulation O 
in O 
Raman O 
and O 
fluorescence O 
spectra O 
is O 
demonstrated O 
in O 
response O 
to O 
touch O 
and O 
temperature O 
. O 
The O 
optical O 
signal O 
transduction O 
of O 
transparent O 
stretchable O 
optoelectronic O 
films O 
may O 
enable O 
a O 
paradigm O 
shift O 
in O 
touch O 
- O 
sensing O 
devices O 
eliminating O 
electrical O 
interconnects O 
. O 

graphene B-TRIVIAL 
core O 
- O 
sheath O 
microfibers O 
for O 
all O 
- O 
solid O 
- O 
state O 
, O 
stretchable O 
fibriform O 
supercapacitors O 
and O 
wearable O 
electronic O 
textiles O 
. O 

all- O 
graphene B-TRIVIAL 
core O 
- O 
sheath O 
fibers O 
composed O 
of O 
a O 
graphene B-TRIVIAL 
fiber O 
core O 
with O 
a O 
sheath O 
of O 
3D O 
graphene B-TRIVIAL 
network O 
have O 
been O 
developed O 
. O 
Used O 
as O 
flexible O 
electrodes O 
, O 
all O 
- O 
solid O 
- O 
state O 
fiber O 
supercapacitors O 
have O 
been O 
fabricated O 
, O 
which O 
can O 
be O 
managed O 
to O 
highly O 
compressible O 
and O 
stretchable O 
spring O 
supercapacitors O 
and O 
can O 
also O 
be O 
woven O 
into O 
a O 
textile O 
for O 
wearable O 
electronics O 
. O 

polymers O 
( O 
CPs O 
) O 
are O 
promising O 
materials O 
for O 
fluorescence O 
imaging O 
application O 
. O 
However O 
, O 
a O 
significant O 
problem O 
in O 
this O 
field O 
is O 
the O 
unexplained O 
abnormally O 
low O 
fluorescence O 
brightness O 
( O 
or O 
number O 
of O 
fluorescence O 
photons O 
detected O 
per O 
one O 
excitation O 
photon O 
) O 
exhibited O 
by O 
most O 
of O 
CP O 
single O 
chains O 
in O 
solid O 
polymer O 
hosts O 
. O 
Here O 
it O 
is O 
shown O 
that O 
this O 
detrimental O 
effect O 
can O 
be O 
fully O 
avoided O 
for O 
short O 
chains O 
of O 
polyfluorene-bis-vinylphenylene B-SYSTEMATIC 
( O 
PFBV B-ABBREVIATION 
) O 
embedded O 
in O 
a O 
host O 
polymer O 
matrix O 
of O 
PMMA B-ABBREVIATION 
, O 
if O 
the O 
conjugated O 
backbone O 
is O 
insulated O 
by O 
cyclodextrin O 
rings O 
to O 
form O 
a O 
polyrotaxane O 
( O 
PFBV B-ABBREVIATION 
-Rtx O 
) O 
. O 
Fluorescence O 
kinetics O 
and O 
quantum O 
yields O 
are O 
measured O 
for O 
the O 
polymers O 
in O 
liquid O 
solutions O 
, O 
pristine O 
films O 
, O 
and O 
solid O 
PMMA B-ABBREVIATION 
blends O 
. O 
The O 
fluorescence O 
brightness O 
of O 
PFBV B-ABBREVIATION 
-Rtx O 
single O 
chains O 
dispersed O 
in O 
a O 
solid O 
PMMA B-ABBREVIATION 
is O 
very O 
close O 
to O 
that O 
expected O 
for O 
a O 
chain O 
with O 
100% O 
fluorescence O 
quantum O 
yield O 
, O 
while O 
the O 
unprotected O 
PFBV B-ABBREVIATION 
chains O 
of O 
the O 
same O 
length O 
possess O 
4 O 
times O 
lower O 
brightness O 
. O 
Despite O 
this O 
, O 
the O 
fluorescence O 
decay O 
kinetics O 
are O 
the O 
same O 
for O 
both O 
polymers O 
, O 
suggesting O 
the O 
presence O 
of O 
static O 
or O 
ultrafast O 
fluorescence O 
quenching O 
in O 
the O 
unprotected O 
polymer O 
. O 
About O 
80% O 
of O 
an O 
unprotected O 
PFBV B-ABBREVIATION 
chain O 
is O 
estimated O 
to O 
be O 
completely O 
quenched O 
. O 
The O 
hypothesis O 
is O 
that O 
the O 
cyclodextrin O 
rings O 
prevent O 
the O 
quenching O 
by O 
working O 
as O 
' O 
bumpers O 
' O 
reducing O 
the O 
mechanical O 
forces O 
applied O 
by O 
the O 
host O 
polymer O 
to O 
the O 
conjugated O 
backbone O 
and O 
help O 
retaining O 
its O 
conformational O 
freedom O 
. O 
While O 
providing O 
a O 
recipe O 
for O 
making O 
CP O 
fluorescence O 
bright O 
at O 
the O 
single O 
- O 
molecule O 
level O 
, O 
these O 
results O 
identify O 
a O 
lack O 
of O 
fundamental O 
understanding O 
in O 
the O 
community O 
of O 
the O 
influence O 
of O 
the O 
environment O 
on O 
excited O 
states O 
in O 
conjugated O 
materials O 
. O 

of O 
complementary O 
nucleic O 
acid O 
strands O 
is O 
fundamental O 
to O 
nearly O 
all O 
molecular O 
bioanalytical O 
methods O 
ranging O 
from O 
polymerase O 
chain O 
reaction O 
and O 
DNA O 
biosensors O 
to O 
next O 
generation O 
sequencing O 
. O 
For O 
nucleic O 
acid O 
amplification O 
methods O 
, O 
controlled O 
DNA O 
denaturation O 
and O 
renaturation O 
is O 
particularly O 
essential O 
and O 
achieved O 
by O 
cycling O 
elevated O 
temperatures O 
. O 
Although O 
this O 
is O 
by O 
far O 
the O 
most O 
used O 
technique O 
, O 
the O 
management O 
of O 
rapid O 
temperature O 
changes O 
requires O 
bulky O 
instrumentation O 
and O 
intense O 
power O 
supply O 
. O 
These O 
factors O 
so O 
far O 
precluded O 
the O 
development O 
of O 
true O 
point O 
- O 
of O 
- O 
care O 
tests O 
for O 
molecular O 
diagnostics O 
. O 
To O 
overcome O 
this O 
limitation O 
we O 
explored O 
the O 
possibility O 
of O 
using O 
electrochemical O 
means O 
to O 
control O 
reversible O 
DNA O 
hybridization O 
by O 
using O 
the O 
electroactive O 
intercalator O 
daunomycin B-TRIVIAL 
( O 
DM O 
) O 
. O 
We O 
show O 
that O 
redox O 
- O 
state O 
switching O 
of O 
DM O 
altered O 
its O 
properties O 
from O 
DNA O 
binding O 
to O 
nonbinding O 
, O 
under O 
otherwise O 
constant O 
conditions O 
, O 
and O 
thus O 
altered O 
the O 
thermodynamic O 
stability O 
of O 
duplex O 
DNA O 
. O 
The O 
operational O 
principle O 
was O 
demonstrated O 
using O 
complementary O 
synthetic O 
20mer O 
and O 
40mer O 
DNA O 
oligonucleotides O 
. O 
Absorbance O 
- O 
based O 
melting O 
curve O 
analysis O 
revealed O 
significantly O 
higher O 
melting O 
temperatures O 
for O 
DNA O 
in O 
the O 
presence O 
of O 
oxidized O 
compared O 
to O 
chemically O 
reduced O 
DM O 
. O 
This O 
difference O 
was O 
exploited O 
to O 
drive O 
cyclic O 
electrochemically O 
controlled O 
denaturation O 
and O 
renaturation O 
. O 
Analysis O 
with O 
in O 
situ O 
UV-vis O 
and O 
circular O 
dichroism O 
spectroelectrochemistry O 
, O 
as O 
two O 
independent O 
techniques O 
, O 
indicated O 
that O 
up O 
to O 
80% O 
of O 
the O 
DNA O 
was O 
reversibly O 
hybridized O 
. O 
This O 
remarkable O 
demonstration O 
of O 
electrochemical O 
control O 
of O 
five O 
cycles O 
of O 
DNA O 
denaturation O 
and O 
renaturation O 
, O 
under O 
otherwise O 
constant O 
conditions O 
, O 
could O 
have O 
wide-ranging O 
implications O 
for O 
the O 
future O 
development O 
of O 
miniaturized O 
analytical O 
systems O 
for O 
molecular O 
diagnostics O 
and O 
beyond O 
. O 

dynamics O 
of O 
coupled O 
semiconducting O 
carbon B-SYSTEMATIC 
nanotube O 
thin O 
films O 
. O 

nanotubes O 
are O 
a O 
promising O 
means O 
of O 
capturing O 
photons O 
for O 
use O 
in O 
solar O 
cell O 
devices O 
. O 
We O 
time O 
- O 
resolved O 
the O 
photoexcitation O 
dynamics O 
of O 
coupled O 
, O 
bandgap O 
- O 
selected O 
, O 
semiconducting O 
carbon B-SYSTEMATIC 
nanotubes O 
in O 
thin O 
films O 
tailored O 
for O 
photovoltaics O 
. O 
Using O 
transient O 
absorption O 
spectroscopy O 
and O 
anisotropy O 
measurements O 
, O 
we O 
found O 
that O 
the O 
photoexcitation O 
evolves O 
by O 
two O 
mechanisms O 
with O 
a O 
fast O 
and O 
long O 
- O 
range O 
component O 
followed O 
by O 
a O 
slow O 
and O 
short O 
- O 
range O 
component O 
. O 
Within O 
300 O 
fs O 
of O 
optical O 
excitation O 
, O 
20% O 
of O 
nanotubes O 
transfer O 
their O 
photoexcitation O 
over O 
5-10 O 
nm O 
into O 
nearby O 
nanotube O 
fibers O 
. O 
After O 
3 O 
ps O 
, O 
70% O 
of O 
the O 
photoexcitation O 
resides O 
on O 
the O 
smallest O 
bandgap O 
nanotubes O 
. O 
After O 
this O 
ultrafast O 
process O 
, O 
the O 
photoexcitation O 
continues O 
to O 
transfer O 
on O 
a O 
∼10 O 
ps O 
time O 
scale O 
but O 
to O 
predominantly O 
aligned O 
tubes O 
. O 
Ultimately O 
the O 
photoexcitation O 
hops O 
twice O 
on O 
average O 
between O 
fibers O 
. O 
These O 
results O 
are O 
important O 
for O 
understanding O 
the O 
flow O 
of O 
energy O 
and O 
charge O 
in O 
coupled O 
nanotube O 
materials O 
and O 
light O 
- O 
harvesting O 
devices O 
. O 

prevents O 
Staphylococcus O 
aureus O 
- O 
mediated O 
lung O 
cell O 
injury O 
via O 
inhibiting O 
the O 
production O 
of O 
α-hemolysin O 
. O 

aureus O 
is O 
a O 
significant O 
Gram O 
- O 
positive O 
bacterium O 
that O 
is O 
associated O 
with O 
a O 
broad O 
spectrum O 
of O 
diseases O 
ranging O 
from O 
minor O 
skin O 
infections O 
to O 
lethal O 
pneumonia O 
, O 
endocarditis O 
, O 
and O 
toxinoses O 
. O 
α-Hemolysin O 
is O 
one O 
of O 
the O 
most O 
important O 
exotoxins O 
that O 
contribute O 
to O 
the O 
pathogenesis O 
of O 
S O 
. O 
aureus O 
infections O 
. O 
Liquiritigenin B-TRIVIAL 
is O 
one O 
of O 
the O 
most O 
significant O 
active O 
components O 
in O 
licorice O 
. O 
In O 
this O 
study O 
, O 
hemolysis O 
, O 
western O 
blot O 
, O 
and O 
real O 
- O 
time O 
reverse O 
transcription-PCR O 
assays O 
were O 
performed O 
to O 
investigate O 
the O 
impact O 
of O 
liquiritigenin B-TRIVIAL 
on O 
the O 
production O 
of O 
S O 
. O 
aureus O 
α-hemolysin O 
. O 
The O 
results O 
showed O 
that O 
low O 
concentrations O 
of O 
liquiritigenin B-TRIVIAL 
remarkably O 
decreased O 
S O 
. O 
aureus O 
α-hemolysin O 
production O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Using O 
live O 
/ O 
dead O 
cell O 
staining O 
and O 
lactate B-FAMILY 
dehydrogenase O 
assays O 
, O 
we O 
found O 
that O 
liquiritigenin B-TRIVIAL 
could O 
protect O 
human O 
lung O 
cells O 
( O 
A549 O 
) O 
from O 
α-hemolysin- O 
mediated O 
injury O 
. O 
The O 
data O 
indicated O 
that O 
this O 
compound O 
could O 
potentially O 
be O 
useful O 
in O 
developing O 
drugs O 
aiming O 
at O 
staphylococcal O 
α-hemolysin O 
. O 

Reduction O 
of O 
PHA B-ABBREVIATION 
Biopolyesters O 
and O 
Their O 
Synthetic O 
Analogues O 
to O 
Corresponding O 
PHA B-ABBREVIATION 
Oligodiols O 
Proved O 
by O 
Structural O 
Studies O 
. O 

highly O 
selective O 
method O 
is O 
described O 
for O 
controlling O 
the O 
degradation O 
of O 
polyhydroxyalkanoates B-FAMILY 
, O 
PHA B-ABBREVIATION 
, O 
via O 
a O 
reduction O 
reaction O 
that O 
uses O 
lithium B-SYSTEMATIC 
borohydride I-SYSTEMATIC 
. O 
Using O 
this O 
method O 
, O 
oligo(hydroxyalkanoate)diols B-FAMILY 
derived O 
from O 
a O 
poly(3-hydroxybutyrate-co-4-hydroxybutyrate) B-SYSTEMATIC 
biopolyester O 
[ O 
poly(3HB-co-4HB) B-SYSTEMATIC 
] O 
and O 
from O 
synthetic O 
atactic O 
poly[(R,S)-3-hydroxybutyrate] B-SYSTEMATIC 
( O 
a- O 
PHB B-ABBREVIATION 
) O 
were O 
obtained O 
. O 
The O 
structural O 
characterization O 
of O 
the O 
oligo(hydroxyalkanoate)diols B-FAMILY 
was O 
conducted O 
using O 
NMR O 
and O 
ESI-mass O 
spectrometry O 
analyses O 
, O 
which O 
confirmed O 
that O 
oligomers O 
that O 
were O 
terminated O 
by O 
two O 
hydroxyl B-SYSTEMATIC 
end O 
groups O 
were O 
formed O 
. O 
The O 
reduction O 
of O 
the O 
ester B-FAMILY 
groups O 
occurred O 
in O 
a O 
statistical O 
way O 
regardless O 
of O 
the O 
chemical O 
structure O 
of O 
the O 
comonomer O 
units O 
or O 
of O 
the O 
microstructure O 
of O 
the O 
polyester B-FAMILY 
chain O 
. O 
The O 
presented O 
method O 
can O 
be O 
used O 
to O 
synthesize O 
various O 
PHA B-ABBREVIATION 
oligodiols O 
that O 
are O 
potentially O 
useful O 
in O 
the O 
further O 
synthesis O 
of O 
tailor O 
- O 
made O 
biodegradable O 
materials O 
. O 

have O 
attracted O 
a O 
great O 
deal O 
of O 
attention O 
because O 
of O 
their O 
potential O 
usefulness O 
for O 
high O 
density O 
applications O 
. O 
More O 
importantly O 
, O 
they O 
offer O 
excellent O 
avenues O 
for O 
improved O 
scaling O 
beyond O 
conventional O 
approaches O 
. O 
Less O 
attention O 
has O 
been O 
paid O 
to O 
their O 
intrinsic O 
potential O 
for O 
distinct O 
circuit O 
applications O 
. O 
Here O 
we O 
discuss O 
how O 
a O 
combination O 
of O 
1-D O 
transport O 
, O 
operation O 
in O 
the O 
quantum O 
capacitance O 
limit O 
, O 
and O 
ballistic O 
transport O 
can O 
be O 
utilized O 
for O 
certain O 
RF O 
applications O 
. O 
In O 
particular O 
this O 
work O 
explores O 
how O 
the O 
above O 
transport O 
properties O 
can O 
provide O 
a O 
high O 
degree O 
of O 
transconductance O 
linearity O 
at O 
the O 
device O 
level O 
. O 
The O 
article O 
also O 
discusses O 
how O 
device O 
characteristics O 
can O 
be O 
interpreted O 
and O 
analyzed O 
in O 
terms O 
of O 
device O 
linearity O 
if O 
the O 
above O 
conditions O 
are O 
not O 
ideally O 
fulfilled O 
. O 
Using O 
aggressively O 
scaled O 
silicon B-SYSTEMATIC 
nanowire O 
field O 
- O 
effect O 
transistors O 
as O 
an O 
example O 
device O 
in O 
this O 
work O 
provides O 
new O 
insights O 
toward O 
the O 
proper O 
choice O 
of O 
channel O 
material O 
to O 
improve O 
linearity O 
through O 
the O 
above O 
- O 
mentioned O 
transport O 
conditions O 
. O 
According O 
to O 
this O 
study O 
, O 
a O 
high O 
degree O 
of O 
linearity O 
occurs O 
feasible O 
while O 
operating O 
at O 
low O 
supply O 
voltages O 
making O 
low O 
- O 
dimensional O 
systems O 
, O 
and O 
here O 
in O 
particular O 
nanowires O 
, O 
an O 
interesting O 
candidate O 
for O 
portable O 
RF O 
applications O 
. O 

general O 
strategy O 
for O 
constructing O 
high O 
- O 
effective O 
upconversion O 
nanocapsules O 
based O 
on O 
triplet O 
- O 
triplet O 
annihilation O 
( O 
TTA O 
) O 
was O 
developed O 
by O 
loading O 
both O 
sensitizer O 
and O 
annihilator O 
into O 
BSA-dextran O 
stabilized O 
oil O 
droplets O 
. O 
This O 
strategy O 
can O 
maintain O 
high O 
translational O 
mobility O 
of O 
the O 
chromophores O 
, O 
avoid O 
luminescence O 
quenching O 
of O 
chromophore O 
by O 
aggregation O 
, O 
and O 
decrease O 
the O 
O2 B-FORMULA 
-induced O 
quenching O 
of O 
TTA O 
- O 
based O 
upconversion O 
emission O 
. O 
Pt B-FORMULA 
(II) I-FORMULA 
- O 
tetraphenyl B-SYSTEMATIC 
- O 
tetrabenzoporphyrin B-SYSTEMATIC 
( O 
PtTPBP B-ABBREVIATION 
) O 
and O 
BODIPY B-ABBREVIATION 
dyes O 
( O 
BDP-G B-NO_CLASS 
and O 
BDP-Y B-NO_CLASS 
with O 
the O 
maximal O 
fluorescence O 
emission O 
at O 
528 O 
and O 
546 O 
nm O 
, O 
respectively O 
) O 
were O 
chosen O 
as O 
sensitizer O 
/ O 
annihilator O 
couples O 
to O 
fabricate O 
green O 
and O 
yellow O 
upconversion O 
luminescent O 
emissive O 
nanocapsules O 
, O 
named O 
UCNC-G O 
and O 
UCNC-Y O 
, O 
respectively O 
. O 
In O 
water O 
under O 
the O 
atmospheric O 
environment O 
, O 
interestingly O 
, O 
UCNC-G O 
and O 
UCNC-Y O 
exhibit O 
intense O 
upconversion O 
luminescence O 
( O 
UCL O 
) O 
emission O 
( O 
λex O 
= O 
635 O 
nm O 
) O 
with O 
the O 
quantum O 
efficiencies O 
( O 
ΦUCL O 
) O 
of O 
1.7% O 
and O 
4.8% O 
, O 
respectively O 
, O 
whereas O 
very O 
weak O 
UCL O 
emission O 
( O 
ΦUCL O 
< O 
0.1% O 
) O 
was O 
observed O 
for O 
the O 
corresponding O 
previous O 
reported O 
SiO2 B-FORMULA 
-coating O 
nanosystems O 
because O 
of O 
aggregation O 
- O 
induced O 
fluorescence O 
quenching O 
of O 
annihilators O 
. O 
Furthermore O 
, O 
application O 
of O 
theses O 
upconversion O 
nanocapsules O 
for O 
high O 
- O 
contrast O 
UCL O 
bioimaging O 
in O 
vivo O 
of O 
living O 
mice O 
without O 
removing O 
the O 
skin O 
was O 
demonstrated O 
under O 
635-nm O 
excitation O 
with O 
low O 
power O 
density O 
of O 
12.5 O 
mW O 
cm(-2) O 
. O 

Responsive O 
Ultrathin O 
GaS B-FORMULA 
Nanosheet O 
Photodetectors O 
on O 
Rigid O 
and O 
Flexible O 
Substrates O 
. O 

first O 
GaS B-FORMULA 
nanosheet O 
- O 
based O 
photodetectors O 
are O 
demonstrated O 
on O 
both O 
mechanically O 
rigid O 
and O 
flexible O 
substrates O 
. O 
Highly O 
crystalline O 
, O 
exfoliated O 
GaS B-FORMULA 
nanosheets O 
are O 
promising O 
for O 
optoelectronics O 
due O 
to O 
strong O 
absorption O 
in O 
the O 
UV-visible O 
wavelength O 
region O 
. O 
Photocurrent O 
measurements O 
of O 
GaS B-FORMULA 
nanosheet O 
photodetectors O 
made O 
on O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
substrates O 
and O 
flexible O 
polyethylene B-SYSTEMATIC 
terephthalate I-SYSTEMATIC 
( O 
PET B-ABBREVIATION 
) O 
substrates O 
exhibit O 
a O 
photoresponsivity O 
at O 
254 O 
nm O 
up O 
to O 
4.2 O 
AW(-1) O 
and O 
19.2 O 
AW(-1) O 
, O 
respectively O 
, O 
which O 
exceeds O 
that O 
of O 
graphene B-TRIVIAL 
, O 
MoS2 B-FORMULA 
, O 
or O 
other O 
2D O 
material O 
- O 
based O 
devices O 
. O 
Additionally O 
, O 
the O 
linear O 
dynamic O 
range O 
of O 
the O 
devices O 
on O 
SiO2 B-FORMULA 
/ O 
Si B-FORMULA 
and O 
PET B-ABBREVIATION 
substrates O 
are O 
97.7 O 
dB O 
and O 
78.73 O 
dB O 
, O 
respectively O 
. O 
Both O 
surpass O 
that O 
of O 
currently O 
exploited O 
InGaAs O 
photodetectors O 
( O 
66 O 
dB O 
) O 
. O 
Theoretical O 
modeling O 
of O 
the O 
electronic O 
structures O 
indicates O 
that O 
the O 
reduction O 
of O 
the O 
effective O 
mass O 
at O 
the O 
valence O 
band O 
maximum O 
( O 
VBM O 
) O 
with O 
decreasing O 
sheet O 
thickness O 
enhances O 
the O 
carrier O 
mobility O 
of O 
the O 
GaS B-FORMULA 
nanosheets O 
, O 
contributing O 
to O 
the O 
high O 
photocurrents O 
. O 
Double O 
- O 
peak O 
VBMs O 
are O 
theoretically O 
predicted O 
for O 
ultrathin O 
GaS B-FORMULA 
nanosheets O 
( O 
thickness O 
less O 
than O 
five O 
monolayers O 
) O 
, O 
which O 
is O 
found O 
to O 
promote O 
photon O 
absorption O 
. O 
These O 
theoretical O 
and O 
experimental O 
results O 
show O 
that O 
GaS B-FORMULA 
nanosheets O 
are O 
promising O 
materials O 
for O 
high O 
- O 
performance O 
photodetectors O 
on O 
both O 
conventional O 
silicon B-SYSTEMATIC 
and O 
flexible O 
substrates O 
. O 

GABA B-ABBREVIATION 
/ O 
Glutamate B-TRIVIAL 
Receptor O 
Target O 
for O 
[(3)H]Isoxazoline B-SYSTEMATIC 
Insecticide O 
. O 

highly O 
effective O 
and O 
selective O 
isoxazoline B-SYSTEMATIC 
insecticide O 
A1443 B-IDENTIFIER 
is O 
known O 
to O 
potently O 
displace O 
[(3)H]ethynylbicycloorthobenzoate B-SYSTEMATIC 
( O 
[(3)H]EBOB B-SYSTEMATIC 
) O 
binding O 
to O 
house O 
fly O 
head O 
membranes O 
with O 
an O 
IC50 O 
of O 
0.2 O 
nM O 
in O 
a O 
manner O 
characteristic O 
of O 
GABA B-ABBREVIATION 
-gated O 
chloride B-SYSTEMATIC 
channel O 
antagonists O 
. O 
To O 
further O 
define O 
its O 
mode O 
of O 
action O 
, O 
we O 
prepared O 
phenyl B-SYSTEMATIC 
-labeled O 
[(3)H]A1443 B-SYSTEMATIC 
as O 
described O 
with O 
a O 
specific O 
activity O 
of O 
14 O 
Ci O 
/ O 
mmol O 
. O 
This O 
new O 
radioligand O 
with O 
an O 
apparent O 
IC50 O 
of O 
about O 
0.4 O 
nM O 
is O 
poorly O 
displaced O 
by O 
most O 
insecticides O 
acting O 
at O 
the O 
[(3)H]EBOB B-SYSTEMATIC 
site O 
. O 
Interestingly O 
, O 
the O 
isoxazoline B-SYSTEMATIC 
binding O 
site O 
is O 
directly O 
coupled O 
to O 
the O 
avermectin B-FAMILY 
GABA B-ABBREVIATION 
/ O 
glutamate B-TRIVIAL 
chloride B-SYSTEMATIC 
channel O 
activator O 
site O 
. O 
These O 
findings O 
revive O 
interest O 
in O 
the O 
insect O 
GABA B-ABBREVIATION 
/ O 
glutamate B-TRIVIAL 
receptor O 
as O 
an O 
insecticide O 
target O 
. O 

dietary O 
fat O 
contributes O 
to O 
dysregulation O 
of O 
the O 
LKB1 O 
/ O 
AMPK O 
pathway O 
and O 
increased O 
damage O 
in O 
a O 
mouse O 
model O 
of O 
early O 
- O 
stage O 
ethanol B-SYSTEMATIC 
-mediated O 
steatosis O 
. O 

: O 
The O 
objective O 
of O 
the O 
study O 
was O 
to O 
examine O 
the O 
interaction O 
of O 
moderate O 
and O 
high O 
dietary O 
fat O 
and O 
ethanol B-SYSTEMATIC 
with O 
respect O 
to O 
formation O 
of O 
steatosis O 
and O 
regulation O 
of O 
the O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
pathway O 
in O 
a O 
mouse O 
model O 
of O 
chronic O 
ethanol B-SYSTEMATIC 
consumption O 
. O 
METHODS O 
: O 
Male O 
C57BL O 
/ O 
6J O 
mice O 
were O 
pair O 
- O 
fed O 
a O 
modified O 
Lieber-DeCarli O 
diet O 
composed O 
of O 
either O 
moderate O 
fat O 
[ O 
30% O 
fat O 
- O 
derived O 
calories O 
( O 
MF O 
) O 
] O 
or O 
high O 
fat O 
[ O 
45% O 
fat O 
- O 
derived O 
calories O 
( O 
HF O 
) O 
] O 
combined O 
with O 
increasing O 
concentrations O 
of O 
ethanol B-SYSTEMATIC 
( O 
2%-6% O 
) O 
for O 
6 O 
weeks O 
. O 
RESULTS O 
: O 
Chronic O 
ethanol B-SYSTEMATIC 
consumption O 
resulted O 
in O 
significant O 
increases O 
in O 
plasma O 
alanine B-TRIVIAL 
aminotransferase O 
in O 
MF O 
( O 
1.84-fold O 
) O 
and O 
HF O 
mice O 
( O 
2.33-fold O 
) O 
, O 
yet O 
liver O 
triglycerides B-FAMILY 
only O 
increased O 
significantly O 
in O 
the O 
HF O 
model O 
( O 
1.62-fold O 
) O 
. O 
Ethanol B-SYSTEMATIC 
addition O 
significantly O 
increased O 
plasma O 
adiponectin O 
under O 
conditions O 
of O 
MF O 
but O 
not O 
HF O 
. O 
In O 
combination O 
with O 
MF O 
, O 
the O 
addition O 
of O 
ethanol B-SYSTEMATIC 
significantly O 
decreased O 
total O 
and O 
hepatic O 
p O 
Thr B-FORMULA 
(172)AMPKα O 
and O 
acetyl B-SYSTEMATIC 
CoA I-SYSTEMATIC 
Carboxylase O 
( O 
ACC O 
) O 
. O 
HF O 
plus O 
ethanol B-SYSTEMATIC 
decreased O 
p O 
Ser B-FORMULA 
(108)AMPKβ O 
, O 
yet O 
a O 
marked O 
1.5-fold O 
increase O 
in O 
p O 
Thr B-FORMULA 
(172)AMPKα O 
occurred O 
. O 
No O 
change O 
was O 
evident O 
in O 
p O 
Ser B-FORMULA 
(79)ACC O 
under O 
conditions O 
of O 
ethanol B-SYSTEMATIC 
and O 
HF O 
ingestion O 
. O 
In O 
both O 
models O 
, O 
nuclear O 
levels O 
of O 
sterol B-FAMILY 
response O 
element O 
binding O 
protein O 
1c O 
and O 
carbohydrate B-FAMILY 
response O 
element O 
binding O 
protein O 
were O 
decreased O 
. O 
Surprisingly O 
, O 
MF O 
plus O 
ethanol B-SYSTEMATIC 
significantly O 
elevated O 
protein O 
expression O 
of O 
medium O 
- O 
chain O 
acyl-CoA B-ABBREVIATION 
dehydrogenase O 
( O 
MCAD O 
) O 
, O 
long O 
- O 
chain O 
acyl-CoA B-ABBREVIATION 
dehydrogenase O 
( O 
LCAD O 
) O 
and O 
very O 
long O 
chain O 
acyl-CoA B-ABBREVIATION 
dehydrogenase O 
but O 
did O 
not O 
significantly O 
affect O 
mRNA O 
expression O 
of O 
other O 
proteins O 
involved O 
in O 
β-oxidation O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
synthesis O 
. O 
HF O 
plus O 
ethanol B-SYSTEMATIC 
significantly O 
reduced O 
mRNA O 
expression O 
of O 
both O 
stearoyl B-TRIVIAL 
CoA I-TRIVIAL 
desaturase O 
1 O 
and O 
fatty B-FAMILY 
acid I-FAMILY 
elongase O 
5 O 
, O 
but O 
did O 
not O 
have O 
an O 
effect O 
on O 
MCAD O 
or O 
LCAD O 
. O 
CONCLUSION O 
: O 
These O 
data O 
suggest O 
that O 
, O 
when O 
co O 
- O 
ingested O 
with O 
ethanol B-SYSTEMATIC 
, O 
dietary O 
fat O 
differentially O 
contributes O 
to O 
dysregulation O 
of O 
adiponectin O 
- O 
dependent O 
activation O 
of O 
the O 
AMPK O 
pathway O 
in O 
the O 
liver O 
of O 
mice O 
. O 

- O 
based O 
design O 
of O 
novel O 
dihydroisoquinoline B-SYSTEMATIC 
BACE-1 O 
inhibitors O 
that O 
do O 
not O 
engage O 
the O 
catalytic O 
aspartates B-FAMILY 
. O 

structure O 
- O 
activity O 
relationship O 
of O 
a O 
series O 
of O 
dihydroisoquinoline B-SYSTEMATIC 
BACE-1 O 
inhibitors O 
is O 
described O 
. O 
Application O 
of O 
structure O 
- O 
based O 
design O 
to O 
screening O 
hit O 
1 O 
yielded O 
sub O 
- O 
micromolar O 
inhibitors O 
. O 
Replacement O 
of O 
the O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
of O 
1 O 
was O 
guided O 
by O 
X-ray O 
crystallography O 
, O 
which O 
allowed O 
the O 
replacement O 
of O 
a O 
key O 
water O 
- O 
mediated O 
hydrogen B-SYSTEMATIC 
bond O 
. O 
This O 
work O 
culminated O 
in O 
compounds O 
such O 
as O 
31 O 
, O 
which O 
possess O 
good O 
BACE-1 O 
potency O 
, O 
excellent O 
permeability O 
and O 
a O 
low O 
P-gp O 
efflux O 
ratio O 
. O 

, O 
radiosynthesis O 
and O 
lipophilicity O 
of O 
a O 
new O 
potential O 
PET O 
5-HT2 O 
and O 
D2 O 
receptor O 
radioligand O 
. O 

and O 
its O 
precursor O 
desmethyl-Olanzapine O 
were O 
synthesized O 
from O 
malononitrile B-TRIVIAL 
, O 
propionaldehyde B-SYSTEMATIC 
, O 
1-fluoro-2-nitrobenzene B-SYSTEMATIC 
, O 
and O 
substituted O 
piperazine B-SYSTEMATIC 
in O 
4 O 
, O 
4 O 
, O 
5 O 
, O 
and O 
5 O 
steps O 
with O 
35% O 
, O 
32% O 
, O 
26% O 
, O 
and O 
32% O 
overall O 
chemical O 
yield O 
, O 
respectively O 
. O 
[(11)C]Olanzapine B-SYSTEMATIC 
was O 
prepared O 
from O 
desmethyl-Olanzapine O 
with O 
[(11)C]CH3OTf B-SYSTEMATIC 
through O 
N B-FORMULA 
-[ O 
(11)C B-FORMULA 
]methylation O 
and O 
isolated O 
by O 
HPLC O 
combined O 
with O 
solid O 
- O 
phase O 
extraction O 
( O 
SPE O 
) O 
in O 
40-50% O 
radiochemical O 
yield O 
based O 
on O 
[(11)C]CO2 B-SYSTEMATIC 
and O 
decay O 
corrected O 
to O 
end O 
of O 
bombardment O 
( O 
EOB O 
) O 
, O 
with O 
370-740 O 
GBq O 
/ O 
μmol O 
specific O 
activity O 
at O 
EOB O 
. O 
The O 
calculated O 
LogP O 
( O 
CLogP O 
) O 
value O 
of O 
[(11)C]Olanzapine B-SYSTEMATIC 
is O 
3.39 O 
. O 

amides I-FAMILY 
affecting O 
sterol B-FAMILY 
and O 
triglyceride B-FAMILY 
biosynthesis O 
in O 
Hep O 
G2 O 
cells O 
. O 

of O 
series O 
[17(20)Z]- B-MULTIPLE 
and I-MULTIPLE 
[17(20)E]-pregna-5,17(20)-dien-21-oyl I-MULTIPLE 
amides I-MULTIPLE 
, O 
containing O 
polar O 
substituents O 
in O 
amide O 
moiety O 
, O 
based O 
on O 
rearrangement O 
of O 
17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one B-SYSTEMATIC 
caused O 
by O 
amines O 
, O 
is O 
presented O 
. O 
The O 
titled O 
compounds O 
were O 
evaluated O 
for O 
their O 
potency O 
to O 
regulate O 
sterol B-FAMILY 
and O 
triglyceride B-FAMILY 
biosynthesis O 
in O 
human O 
hepatoma O 
Hep O 
G2 O 
cells O 
in O 
comparison O 
with O 
25-hydroxycholesterol B-SYSTEMATIC 
. O 
Three O 
[17(20)E]-pregna-5,17(20)-dien-21-oyl B-FAMILY 
amides I-FAMILY 
at O 
a O 
concentrations O 
of O 
5 O 
μM O 
inhibited O 
sterol O 
biosynthesis O 
and O 
stimulated O 
triglyceride B-FAMILY 
biosynthesis O 
; O 
their O 
regulatory O 
potency O 
was O 
dependent O 
on O 
the O 
structure O 
of O 
amide B-FAMILY 
moiety O 
; O 
the O 
isomeric O 
[17(20)Z]-pregna-5,17(20)-dien-21-oyl B-FAMILY 
amides I-FAMILY 
were O 
inactive O 
. O 

II O 
( O 
PM O 
II O 
) O 
is O 
an O 
attractive O 
target O 
for O 
anti-malaria O 
drug O 
discovery O 
, O 
which O 
involves O 
in O 
host O 
hemoglobin O 
degradation O 
in O 
the O 
acidic O 
food O 
vacuole O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrated O 
the O 
successful O 
use O 
of O 
structure O 
- O 
based O 
virtual O 
screening O 
to O 
identify O 
inhibitors O 
of O 
PM O 
II O 
from O 
two O 
chemical O 
database O 
. O 
Five O 
novel O 
non O 
- O 
peptide O 
inhibitors O 
were O 
identified O 
and O 
revealed O 
moderate O 
inhibitory O 
potencies O 
with O 
IC50 O 
ranged O 
from O 
4.62 O 
± O 
0.39 O 
to O 
9.47 O 
± O 
0.71 O 
μM O 
. O 
The O 
detailed O 
analysis O 
of O 
binding O 
modes O 
using O 
docking O 
simulations O 
for O 
five O 
inhibitors O 
showed O 
that O 
the O 
inhibitors O 
could O 
be O 
stabilized O 
by O 
forming O 
multiple O 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
catalytic O 
residues O 
( O 
Asp B-FORMULA 
34 O 
and O 
Asp B-FORMULA 
214 O 
) O 
and O 
also O 
with O 
other O 
key O 
residues O 
. O 

gastric O 
pathogen O 
Helicobacter O 
pylori O 
produces O 
large O 
amounts O 
of O 
urease O 
, O 
whose O 
enzyme O 
activity O 
enables O 
the O 
bacterium O 
to O 
survive O 
in O 
the O 
stomach O 
. O 
We O 
have O 
previously O 
shown O 
that O 
ureases O 
display O 
enzyme O 
- O 
independent O 
effects O 
in O 
mammalian O 
models O 
, O 
most O 
through O 
lipoxygenases O 
- O 
mediated O 
pathways O 
. O 
Here O 
, O 
we O 
evaluated O 
potential O 
pro O 
- O 
inflammatory O 
properties O 
of O 
H O 
. O 
pylori O 
urease O 
( O 
HPU O 
) O 
. O 
Mouse O 
paw O 
edema O 
and O 
activation O 
of O 
human O 
neutrophils O 
were O 
tested O 
using O 
a O 
purified O 
, O 
cell O 
- O 
free O 
, O 
recombinant O 
HPU O 
. O 
rHPU O 
induced O 
paw O 
edema O 
with O 
intense O 
neutrophil O 
infiltration O 
. O 
In O 
vitro O 
100 O 
nM O 
rHPU O 
was O 
chemotactic O 
to O 
human O 
neutrophils O 
, O 
inducing O 
production O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
rHPU-activated O 
neutrophils O 
showed O 
increased O 
lifespan O 
, O 
with O 
inhibition O 
of O 
apoptosis O 
accompanied O 
by O 
alterations O 
of O 
Bcl-XL O 
and O 
Bad O 
contents O 
. O 
These O 
effects O 
of O 
rHPU O 
persisted O 
in O 
the O 
absence O 
of O 
enzyme O 
activity O 
. O 
rHPU-induced O 
paw O 
edema O 
, O 
neutrophil O 
chemotaxis O 
and O 
apoptosis O 
inhibition O 
reverted O 
in O 
the O 
presence O 
of O 
the O 
lipoxygenase O 
inhibitors O 
esculetin O 
or O 
AA861 O 
. O 
Neutrophils O 
exposed O 
to O 
rHPU O 
showed O 
increased O 
content O 
of O 
lipoxygenase(s) O 
and O 
no O 
alteration O 
of O 
cyclooxygenase(s) O 
. O 
Altogether O 
, O 
our O 
data O 
indicate O 
that O 
HPU O 
, O 
besides O 
allowing O 
the O 
bacterial O 
survival O 
in O 
the O 
stomach O 
, O 
could O 
play O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
the O 
gastrointestinal O 
inflammatory O 
disease O 
caused O 
by O 
H O 
. O 
pylori O 
. O 

Chlorella O 
protects O 
against O 
heterocyclic B-FAMILY 
amine I-FAMILY 
-induced O 
aberrant O 
gene O 
expression O 
in O 
the O 
rat O 
colon O 
by O 
increasing O 
fecal O 
excretion O 
of O 
unmetabolized O 
PhIP B-ABBREVIATION 
. O 

food O 
mutagen O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
( O 
PhIP B-ABBREVIATION 
) O 
is O 
one O 
of O 
the O 
most O 
abundant O 
heterocyclic B-FAMILY 
amines I-FAMILY 
formed O 
by O 
cooking O 
meat O 
and O 
fish O 
at O 
high O 
temperature O 
. O 
PhIP B-ABBREVIATION 
induces O 
colorectal O 
adenoma O 
risk O 
in O 
male O 
rats O 
when O 
administered O 
orally O 
. O 
This O 
study O 
used O 
male O 
Fisher O 
344 O 
rats O 
to O 
investigate O 
the O 
impact O 
of O 
dietary O 
Chlorella O 
on O 
PhIP B-ABBREVIATION 
metabolism O 
and O 
aberrant O 
colonic O 
gene O 
expression O 
following O 
short O 
- O 
term O 
PhIP B-ABBREVIATION 
treatment O 
. O 
High O 
- O 
performance O 
liquid O 
chromatography O 
analysis O 
revealed O 
that O 
fecal O 
excretion O 
of O 
unmetabolized O 
PhIP B-ABBREVIATION 
was O 
significantly O 
increased O 
in O 
rats O 
whose O 
diets O 
were O 
supplemented O 
with O 
Chlorella O 
compared O 
to O 
rats O 
in O 
a O 
PhIP B-ABBREVIATION 
-only O 
group O 
( O 
P O 
< O 
0.001 O 
) O 
. O 
Quantitative O 
realtime O 
PCR O 
confirmed O 
that O 
the O 
increase O 
in O 
beta-catenin O 
and O 
cyclin O 
D1 O 
mRNA O 
in O 
the O 
colon O 
induced O 
by O 
PhIP B-ABBREVIATION 
was O 
ameliorated O 
in O 
rats O 
pre O 
- O 
fed O 
with O 
Chlorella O 
( O 
P=0.052 O 
for O 
beta-catenin O 
; O 
P=0.005 O 
for O 
cyclin O 
D1 O 
) O 
. O 
The O 
increase O 
in O 
DNA O 
shearing O 
that O 
is O 
a O 
hallmark O 
of O 
caspase-8 O 
- O 
mediated O 
apoptosis O 
by O 
PhIP B-ABBREVIATION 
was O 
also O 
significantly O 
diminished O 
in O 
the O 
colons O 
of O 
rats O 
pre O 
- O 
fed O 
Chlorella O 
( O 
P=0.012 O 
) O 
. O 
These O 
results O 
suggested O 
that O 
administering O 
dietary O 
Chlorella O 
with O 
a O 
Western O 
- O 
style O 
diet O 
concomitantly O 
or O 
immediately O 
before O 
mutagen O 
exposure O 
might O 
be O 
beneficial O 
in O 
blocking O 
the O 
absorption O 
of O 
food O 
mutagens O 
such O 
as O 
PhIP B-ABBREVIATION 
. O 

of O 
fumonisins B-FAMILY 
in O 
organic O 
and O 
conventional O 
cereal O 
- O 
based O 
products O 
commercialized O 
in O 
France O 
, O 
Germany O 
and O 
Spain O 
. O 

fast O 
and O 
effective O 
method O 
for O 
quantitative O 
determination O 
of O 
fumonisins B-MULTIPLE 
B1 I-MULTIPLE 
and I-MULTIPLE 
B2 I-MULTIPLE 
( O 
FB1 B-ABBREVIATION 
and O 
FB2 B-ABBREVIATION 
) O 
in O 
different O 
cereal O 
- O 
based O 
products O 
was O 
developed O 
. O 
Fumonisins B-FAMILY 
were O 
extracted O 
combining O 
a O 
solid O 
liquid O 
extraction O 
( O 
SLE O 
) O 
pre O 
- O 
treatment O 
and O 
immunoaffinity O 
columns O 
( O 
IACs O 
) O 
, O 
which O 
were O 
applied O 
for O 
an O 
effective O 
clean O 
- O 
up O 
. O 
Consecutively O 
, O 
high O 
pressure O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
coupled O 
to O 
hybrid O 
triple O 
quadrupole O 
- O 
linear O 
ion O 
trap O 
mass O 
spectrometer O 
( O 
QTrap O 
® O 
) O 
was O 
used O 
for O 
the O 
separation O 
, O 
detection O 
and O 
quantification O 
of O 
targeted O 
mycotoxins O 
. O 
The O 
analytical O 
method O 
showed O 
acceptable O 
recoveries O 
ranged O 
from O 
89.7% O 
to O 
99.1% O 
, O 
as O 
well O 
as O 
a O 
relative O 
standard O 
deviation O 
( O 
% O 
, O 
RSD O 
) O 
lower O 
than O 
12% O 
. O 
A O 
total O 
of O 
1250 O 
samples O 
from O 
France O 
, O 
Germany O 
and O 
Spain O 
were O 
analysed O 
. O 
The O 
incidence O 
of O 
fumonisin B-MULTIPLE 
B1 I-MULTIPLE 
and I-MULTIPLE 
B2 I-MULTIPLE 
in O 
organic O 
samples O 
were O 
11.4% O 
and O 
11.3% O 
, O 
respectively O 
. O 
By O 
contrast O 
, O 
the O 
occurrence O 
of O 
conventional O 
samples O 
was O 
3.6% O 
of O 
FB1 B-ABBREVIATION 
and O 
3.5% O 
of O 
FB2 B-ABBREVIATION 
. O 
The O 
highest O 
values O 
were O 
obtained O 
in O 
Spanish O 
samples O 
of O 
flour O 
, O 
as O 
an O 
example O 
toasted O 
corn O 
, O 
called O 
gofio O 
that O 
was O 
contaminated O 
with O 
1201.7 O 
and O 
1010.5μgkg(-1) O 
of O 
FB1 B-ABBREVIATION 
and O 
FB2 B-ABBREVIATION 
, O 
respectively O 
. O 

l-glutamine B-TRIVIAL 
increases O 
active O 
GLP-1 O 
( O 
7-36 O 
) O 
amide B-FAMILY 
secretion O 
and O 
improves O 
glycemic O 
control O 
in O 
stretpozotocin B-TRIVIAL 
- O 
nicotinamide B-TRIVIAL 
induced O 
diabetic O 
rats O 
. O 

is O 
a O 
non-essential O 
amino B-FAMILY 
acid I-FAMILY 
. O 
It O 
decreased O 
blood O 
sugar B-FAMILY 
, O 
stimulated O 
insulin O 
secretion O 
in O 
type O 
2 O 
diabetic O 
patients O 
. O 
The O 
objective O 
of O 
the O 
present O 
investigation O 
was O 
to O 
evaluate O 
l-glutamine B-TRIVIAL 
increases O 
glucagon O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
( O 
7-36 O 
) O 
amide B-FAMILY 
secretion O 
in O 
streptozotocin B-TRIVIAL 
- O 
nicotinamide B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
- O 
NTM B-ABBREVIATION 
) O 
induced O 
diabetic O 
Sprague O 
Dawley O 
rats O 
. O 
Molecular O 
docking O 
study O 
was O 
performed O 
to O 
elucidate O 
the O 
molecular O 
basis O 
for O 
GLP-1 O 
receptor O 
agonistic O 
activity O 
. O 
Type O 
2 O 
diabetes O 
was O 
induced O 
in O 
overnight O 
fasted O 
Sprague O 
Dawley O 
rats O 
pre O 
- O 
treated O 
with O 
nicotinamide B-TRIVIAL 
( O 
100mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
followed O 
by O 
20min O 
after O 
administration O 
of O 
streptozotocin B-TRIVIAL 
( O 
55mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
. O 
The O 
rats O 
were O 
divided O 
into O 
; O 
I O 
- O 
nondiabetic O 
, O 
II O 
- O 
diabetic O 
control O 
, O 
III O 
- O 
sitagliptin B-TRIVIAL 
( O 
5mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
IV O 
-l-glutamin B-TRIVIAL 
e O 
( O 
250mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
V O 
-l-glutami B-TRIVIAL 
ne O 
( O 
500mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
and O 
VI O 
-l-glutami B-TRIVIAL 
ne O 
( O 
1000mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
Th O 
e B-TRIVIAL 
l-glutami I-TRIVIAL 
ne O 
an O 
d B-TRIVIAL 
sitaglipt I-TRIVIAL 
in O 
treatment O 
was O 
8week O 
. O 
Plasm O 
a B-TRIVIAL 
gluco I-TRIVIAL 
se O 
was O 
estimated O 
every O 
week O 
. O 
Body O 
weight O 
, O 
food O 
and O 
water O 
intake O 
were O 
recorded O 
daily O 
. O 
Glycosylated O 
haemoglobin O 
, O 
lipid O 
profile O 
, O 
plasma O 
and O 
colonic O 
active O 
( O 
GLP-1 O 
) O 
( O 
7-36 O 
) B-FAMILY 
ami I-FAMILY 
de O 
, O 
mRNA O 
expression O 
of O 
proglucagon O 
GLP-1 O 
, O 
plasma O 
and O 
pancreatic O 
insulin O 
, O 
histology O 
of O 
pancreata O 
and O 
biomarkers O 
of O 
oxidative O 
stress O 
( O 
superoxidase O 
dismutase O 
, O 
reduce O 
d B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
, B-TRIVIAL 
malondialdehy I-TRIVIAL 
de O 
, B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
peroxidase O 
, B-TRIVIAL 
glutathio I-TRIVIAL 
ne O 
S O 
transferase O 
) O 
were O 
measured O 
after O 
8week O 
. O 
In O 
acute O 
study O 
, O 
the O 
rats O 
were O 
divided O 
into O 
I O 
- B-TRIVIAL 
gluco I-TRIVIAL 
se O 
( O 
2.5g O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
II O 
- B-TRIVIAL 
sitaglip I-TRIVIAL 
tin O 
( O 
5mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
I O 
II B-TRIVIAL 
-l-gluta I-TRIVIAL 
mine O 
( O 
250mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
, O 
IV B-TRIVIAL 
-l-glut I-TRIVIAL 
amine O 
( O 
500mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
an O 
d B-TRIVIAL 
V I-TRIVIAL 
-l-glut I-TRIVIAL 
amine O 
( O 
1000mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
Pl O 
asma B-TRIVIAL 
gl I-TRIVIAL 
ucose O 
, O 
active O 
GLP-1 O 
( O 
7 O 
-36 B-FAMILY 
) I-FAMILY 
amide O 
concentration O 
and O 
insulin O 
levels O 
were O 
measured O 
a O 
fter B-TRIVIAL 
gl I-TRIVIAL 
ucose O 
loading O 
. O 
The O 
docking O 
data O 
indicated O 
that B-TRIVIAL 
l-glut I-TRIVIAL 
amine O 
bind O 
to O 
the O 
GLP-1 O 
receptor O 
. O 
l-glutamine O 
decreased O 
pl O 
asma B-TRIVIAL 
gl I-TRIVIAL 
ucose O 
, O 
increased O 
plasma O 
and O 
pancreatic O 
insulin O 
, O 
increased O 
plasma O 
and O 
colonic O 
active O 
GLP-1 O 
( O 
7 O 
-36 B-FAMILY 
) I-FAMILY 
amide O 
secretion O 
as O 
well O 
as O 
decreased O 
oxidative O 
stres O 
s B-TRIVIAL 
in I-TRIVIAL 
streptozo I-TRIVIAL 
t O 
ocin B-TRIVIAL 
- I-TRIVIAL 
nicotin I-TRIVIAL 
amide O 
induced O 
diabetic O 
rats O 
. O 

effects O 
of O 
brown O 
algae O 
derived O 
phlorotannins B-FAMILY 
, O 
marine O 
polyphenols B-FAMILY 
through O 
diverse O 
mechanisms O 
. O 

algae O 
are O 
popular O 
and O 
abundant O 
food O 
ingredients O 
mainly O 
in O 
Asian O 
countries O 
, O 
and O 
also O 
well O 
known O 
for O 
their O 
health O 
beneficial O 
effects O 
due O 
to O 
the O 
presence O 
of O 
biologically O 
active O 
components O 
. O 
The O 
marine O 
algae O 
have O 
been O 
studied O 
for O 
biologically O 
active O 
components O 
and O 
phlorotannins B-FAMILY 
, O 
marine O 
polyphenols B-FAMILY 
are O 
among O 
them O 
. O 
Among O 
marine O 
algae O 
, O 
brown O 
algae O 
have O 
extensively O 
studied O 
for O 
their O 
potential O 
anti-diabetic O 
activities O 
. O 
Majority O 
of O 
the O 
investigations O 
on O 
phlorotannins B-FAMILY 
derived O 
from O 
brown O 
algae O 
have O 
exhibited O 
their O 
various O 
anti-diabetic O 
mechanisms O 
such O 
as O 
α-glucosidase O 
and O 
α-amylase O 
inhibitory O 
effect O 
, O 
glucose B-TRIVIAL 
uptake O 
effect O 
in O 
skeletal O 
muscle O 
, O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP O 
1B O 
) O 
enzyme O 
inhibition O 
, O 
improvement O 
of O 
insulin O 
sensitivity O 
in O 
type O 
2 O 
diabetic O 
db O 
/ O 
db O 
mice O 
, O 
and O 
protective O 
effect O 
against O 
diabetes O 
complication O 
. O 
In O 
this O 
review O 
, O 
we O 
have O 
made O 
an O 
attempt O 
to O 
discuss O 
the O 
various O 
anti-diabetic O 
mechanisms O 
associated O 
with O 
phlorotannins B-FAMILY 
from O 
brown O 
algae O 
that O 
are O 
confined O 
to O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

of O 
chronic O 
social O 
defeat O 
stress O 
on O 
behavior O 
and O 
choline B-FAMILY 
acetyltransferase O 
, O 
78-kDa O 
glucose B-TRIVIAL 
-regulated O 
protein O 
, O 
and O 
CCAAT O 
/ O 
enhancer O 
- O 
binding O 
protein O 
( O 
C O 
/ O 
EBP O 
) O 
homologous O 
protein O 
in O 
adult O 
mice O 
. O 

from O 
Alkanna O 
orientalis O 
is O 
an O 
antimicrobial O 
agent O 
and O 
efflux O 
pump O 
inhibitor O 
. O 

Alkanna O 
orientalis O 
leaf O 
and O 
flower O 
extract O 
inhibited O 
the O 
growth O 
of O 
Staphylococcus O 
aureus O 
, O 
a O 
pathogen O 
that O 
causes O 
an O 
estimated O 
478 O 
0 O 
hospitalizations O 
in O 
the O 
US O 
annually O 
. O 
Bioassay O 
- O 
guided O 
fractionation O 
of O 
A O 
. O 
orientalis O 
resulted O 
in O 
isolation O 
of O 
the O 
flavonoid B-FAMILY 
sarothrin B-TRIVIAL 
( O 
5,7,4'-trihydroxy-3,6,8-trimethoxyflavone B-SYSTEMATIC 
) O 
, O 
which O 
inhibited O 
the O 
growth O 
of O 
Mycobacterium O 
smegmatis O 
( O 
MIC O 
75 O 
µM O 
) O 
and O 
S O 
. O 
aureus O 
( O 
MIC O 
> O 
800 O 
µM O 
) O 
, O 
and O 
possessed O 
efflux O 
pump O 
inhibitory O 
activity O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
antimicrobial O 
or O 
efflux O 
pump O 
inhibitory O 
activity O 
of O 
sarothrin B-TRIVIAL 
, O 
and O 
of O 
its O 
presence O 
in O 
A O 
. O 
orientalis O 
. O 
Our O 
findings O 
suggest O 
that O 
the O 
effectiveness O 
of O 
A O 
. O 
orientalis O 
extracts O 
is O 
due O 
to O 
a O 
combination O 
of O 
multiple O 
constituents O 
, O 
including O 
sarothrin B-TRIVIAL 
. O 

interaction O 
of O 
isopenicillin B-TRIVIAL 
N I-TRIVIAL 
synthase O 
with O 
homologated O 
substrate O 
analogues O 
δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa B-FAMILY 
characterised O 
by O 
protein O 
crystallography O 
. O 

N I-TRIVIAL 
synthase O 
( O 
IPNS O 
) O 
converts O 
the O 
linear O 
tripeptide O 
δ-(L-α-aminoadipoyl)-L-cysteinyl-D-valine B-SYSTEMATIC 
( O 
ACV B-ABBREVIATION 
) O 
into O 
bicyclic O 
isopenicillin B-TRIVIAL 
N I-TRIVIAL 
( O 
IPN B-ABBREVIATION 
) O 
in O 
the O 
central O 
step O 
in O 
the O 
biosynthesis O 
of O 
penicillin B-FAMILY 
and O 
cephalosporin B-FAMILY 
antibiotics O 
. O 
Solution O 
- O 
phase O 
incubation O 
experiments O 
have O 
shown O 
that O 
IPNS O 
turns O 
over O 
analogues O 
with O 
a O 
diverse O 
range O 
of O 
side O 
chains O 
in O 
the O 
third O 
( O 
valinyl B-TRIVIAL 
) O 
position O 
of O 
the O 
substrate O 
, O 
but O 
copes O 
less O 
well O 
with O 
changes O 
in O 
the O 
second O 
( O 
cysteinyl B-TRIVIAL 
) O 
residue O 
. O 
IPNS O 
thus O 
converts O 
the O 
homologated O 
tripeptides O 
δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-valine B-SYSTEMATIC 
( O 
AhCV B-ABBREVIATION 
) O 
and O 
δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-allylglycine B-SYSTEMATIC 
( O 
AhCaG B-ABBREVIATION 
) O 
into O 
monocyclic B-SYSTEMATIC 
hydroxy-lactam I-SYSTEMATIC 
products O 
; O 
this O 
suggests O 
that O 
the O 
additional O 
methylene B-SYSTEMATIC 
unit O 
in O 
these O 
substrates O 
induces O 
conformational O 
changes O 
that O 
preclude O 
second O 
ring O 
closure O 
after O 
initial O 
lactam B-SYSTEMATIC 
formation O 
. O 
To O 
investigate O 
this O 
and O 
solution O 
- O 
phase O 
results O 
with O 
other O 
tripeptides O 
δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-Xaa B-FAMILY 
, O 
we O 
have O 
crystallised O 
AhCV B-ABBREVIATION 
and O 
δ-(L-α-aminoadipoyl)-L-homocysteinyl-D-S-methylcysteine B-SYSTEMATIC 
( O 
AhCmC B-ABBREVIATION 
) O 
with O 
IPNS O 
and O 
solved O 
crystal O 
structures O 
for O 
the O 
resulting O 
complexes O 
. O 
The O 
IPNS O 
: O 
Fe B-FORMULA 
(II) I-FORMULA 
: O 
AhCV B-ABBREVIATION 
complex O 
shows O 
diffuse O 
electron O 
density O 
for O 
several O 
regions O 
of O 
the O 
substrate O 
, O 
revealing O 
considerable O 
conformational O 
freedom O 
within O 
the O 
active O 
site O 
. O 
The O 
substrate O 
is O 
more O 
clearly O 
resolved O 
in O 
the O 
IPNS O 
: O 
Fe B-FORMULA 
(II) I-FORMULA 
: O 
AhCmC B-ABBREVIATION 
complex O 
, O 
by O 
virtue O 
of O 
thioether B-SYSTEMATIC 
coordination O 
to O 
iron B-SYSTEMATIC 
. O 
AhCmC B-ABBREVIATION 
occupies O 
two O 
distinct O 
conformations O 
, O 
both O 
distorted O 
relative O 
to O 
the O 
natural O 
substrate O 
ACV B-ABBREVIATION 
, O 
in O 
order O 
to O 
accommodate O 
the O 
extra O 
methylene B-SYSTEMATIC 
group O 
in O 
the O 
second O 
residue O 
. O 
Attempts O 
to O 
turn O 
these O 
substrates O 
over O 
within O 
crystalline O 
IPNS O 
using O 
hyperbaric O 
oxygenation O 
give O 
rise O 
to O 
product O 
mixtures O 
. O 

inhibits O 
tumour O 
progression O 
through O 
targeting O 
phosphoinositide-3-kinase O 
/ O 
Akt O 
pathway O 
. O 

examined O 
whether O 
8-(tosylamino)quinoline B-SYSTEMATIC 
( O 
8-TQ B-SYSTEMATIC 
) O 
, O 
a O 
structural O 
analogue O 
of O 
BAY B-IDENTIFIER 
11-7082 I-IDENTIFIER 
, O 
is O 
able O 
to O 
modulate O 
various O 
tumourigenic O 
responses O 
using O 
various O 
in O 
vitro O 
and O 
in O 
vivo O 
experimental O 
conditions O 
. O 
8-TQ B-SYSTEMATIC 
exhibited O 
the O 
strongest O 
suppressive O 
activity O 
on O 
the O 
proliferation O 
of O 
C6 O 
, O 
A431 O 
, O 
HeLa O 
and O 
MDA-MB-231 O 
cells O 
with O 
IC550 O 
values O 
ranging O 
from O 
10 O 
to O 
30 O 
microM O 
. O 
According O 
to O 
the O 
analysis O 
of O 
level O 
of O 
active O 
caspase-3 O 
, O 
and O 
morphologies O 
of O 
C6 O 
, O 
HeLa O 
and O 
MDA-MB-231 O 
cells O 
, O 
it O 
was O 
revealed O 
that O 
8-TQ B-SYSTEMATIC 
is O 
able O 
to O 
induce O 
apoptosis O 
. O 
Furthermore O 
, O 
this O 
compound O 
strongly O 
diminished O 
the O 
invasion O 
of O 
MDA-MB-231 O 
cells O 
, O 
the O 
migration O 
of O 
HeLa O 
cells O 
, O 
and O 
the O 
new O 
generation O 
of O 
blood O 
vessels O 
under O 
non-toxic O 
conditions O 
. O 
Reduction O 
of O 
the O 
phospho O 
- O 
form O 
levels O 
of O 
intracellular O 
signalling O 
enzymes O 
by O 
8-TQ B-SYSTEMATIC 
strongly O 
indicated O 
that O 
molecular O 
signalling O 
machineries O 
composed O 
of O 
phosphoinositide O 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
phosphoinositide-dependent O 
kinase-1 O 
( O 
PDK1 O 
) O 
/ O 
Akt O 
and O 
extracellular O 
- O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
could O 
be O 
targeted O 
by O 
8-TQ B-SYSTEMATIC 
treatment O 
. O 
Indeed O 
, O 
the O 
specific O 
inhibitors O 
( O 
LY294002 B-IDENTIFIER 
and O 
U0126 B-IDENTIFIER 
) O 
of O 
PI3K O 
/ O 
PDK1 O 
/ O 
Akt O 
and O 
ERK O 
showed O 
similar O 
anti-cancer O 
properties O 
to O 
8-TQ B-SYSTEMATIC 
. O 
Finally O 
, O 
8-TQ B-SYSTEMATIC 
intraperitoneally O 
injected O 
suppressed O 
the O 
increase O 
of O 
tumour O 
volume O 
up O 
to O 
40% O 
compared O 
to O 
vehicle O 
- O 
treated O 
control O 
. O 
Taken O 
together O 
, O 
our O 
results O 
clearly O 
suggest O 
that O 
8-TQ B-SYSTEMATIC 
might O 
have O 
applications O 
as O 
a O 
novel O 
anti-cancer O 
drug O 
or O 
may O 
be O 
served O 
as O 
a O 
lead O 
compound O 
to O 
be O 
further O 
optimized O 
. O 

as O 
chemotherapeutic O 
agents O 
for O 
leishmaniasis O 
. O 

development O 
of O 
leishmanicidal O 
quinolines B-FAMILY 
and O 
their O 
in O 
vitro O 
( O 
promastigote O 
and O 
amastigote O 
) O 
and O 
, O 
where O 
applicable O 
, O 
in O 
vivo O 
activities O 
are O 
reviewed O 
. O 
This O 
survey O 
provides O 
a O 
direct O 
comparison O 
of O 
bioactivity O 
across O 
different O 
species(e.g O 
. O 
L O 
. O 
donovani O 
, O 
L O 
. O 
amazonensis O 
, O 
L O 
. O 
chagasi O 
, O 
L O 
infantum O 
) O 
, O 
and O 
in O 
different O 
animal O 
models O 
( O 
e.g O 
. O 
L O 
. O 
donovani O 
Balb O 
/ O 
c O 
mice O 
and O 
L O 
. O 
donovani O 
infected O 
hamsters O 
) O 
. O 
The O 
progress O 
of O 
selected O 
quinolines B-FAMILY 
through O 
pre O 
- O 
clinical O 
development O 
and O 
phase O 
I O 
/ O 
II O 
trials O 
, O 
and O 
the O 
lead O 
quinoline B-SYSTEMATIC 
drugs O 
sitamaquinine B-TRIVIAL 
and O 
Imiquimod B-TRIVIAL 
, O 
are O 
discussed O 
in O 
conjunction O 
with O 
delivery O 
systems O 
and O 
combination O 
therapies O 
. O 

of O 
a O 
RhoA- O 
and O 
SRF-Dependent O 
Mechanism O 
of O 
Androgen B-FAMILY 
Action O 
that O 
is O 
Associated O 
with O 
Prostate O 
Cancer O 
Progression O 
. O 

receptor O 
( O 
AR O 
) O 
action O 
is O 
critical O 
for O 
prostate O 
cancer O 
( O 
CaP O 
) O 
progression O 
, O 
but O 
is O 
not O 
inhibited O 
fully O 
by O 
available O 
androgen B-FAMILY 
deprivation O 
therapy O 
( O 
ADT O 
) O 
. O 
One O 
of O 
the O 
limitations O 
to O 
current O 
ADT O 
is O 
that O 
it O 
targets O 
all O 
androgen O 
action O 
in O 
CaP O 
, O 
and O 
other O 
, O 
cells O 
irrespective O 
of O 
clinical O 
relevance O 
. O 
The O 
resulting O 
off O 
- O 
target O 
effects O 
are O 
responsible O 
for O 
ADT O 
associated O 
side O 
effects O 
that O 
affect O 
negatively O 
a O 
patient's O 
quality O 
of O 
life O 
. O 
Isolation O 
of O 
the O 
AR-dependent O 
events O 
that O 
drive O 
CaP O 
progression O 
may O 
lead O 
to O 
novel O 
forms O 
of O 
ADT O 
that O 
are O 
at O 
least O 
as O 
effective O 
but O 
more O 
selective O 
. O 
Here O 
, O 
an O 
approach O 
is O 
described O 
that O 
starts O 
from O 
insights O 
in O 
the O 
basic O 
mechanism(s) O 
by O 
which O 
AR O 
regulates O 
target O 
gene O 
expression O 
to O 
identify O 
novel O 
drugable O 
targets O 
downstream O 
of O 
AR O 
. O 
Exploration O 
of O 
the O 
molecular O 
events O 
that O 
underlie O 
androgen B-FAMILY 
regulation O 
of O 
the O 
ARassociated O 
coregulator O 
FHL2 O 
led O 
to O 
the O 
isolation O 
of O 
a O 
novel O 
indirect O 
mechanism O 
of O 
androgen B-FAMILY 
action O 
that O 
is O 
mediated O 
by O 
the O 
secondary O 
transcription O 
factor O 
Serum O 
Response O 
Factor O 
( O 
SRF O 
) O 
. O 
Using O 
a O 
combination O 
of O 
oligoarray O 
and O 
in O 
silico O 
analyses O 
, O 
an O 
SRF-dependent O 
fraction O 
of O 
AR O 
action O 
was O 
identified O 
that O 
is O 
enriched O 
in O 
CaP O 
tissues O 
, O 
is O 
able O 
to O 
discriminate O 
between O 
benign O 
and O 
malignant O 
prostate O 
, O 
and O 
correlates O 
with O 
aggressive O 
disease O 
and O 
biochemical O 
failure O 
. O 
The O 
RhoA O 
signaling O 
axis O 
, O 
a O 
well O 
known O 
upstream O 
stimulator O 
of O 
SRF O 
action O 
that O 
harbors O 
drugable O 
targets O 
, O 
conveyed O 
androgen B-FAMILY 
-responsiveness O 
to O 
SRF O 
, O 
and O 
was O 
activated O 
in O 
CaP O 
where O 
it O 
correlates O 
with O 
increased O 
CaP O 
aggressiveness O 
and O 
poor O 
outcome O 
after O 
surgery O 
. O 

new O 
tetracyclic B-FAMILY 
triterpenoid I-FAMILY 
compound O 
from O 
Mastich O 
. O 

new O 
tetracyclic B-FAMILY 
triterpenoid I-FAMILY 
compound O 
named O 
as O 
mastichinoic B-TRIVIAL 
acid I-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
from O 
Mastich O 
. O 
The O 
structure O 
was O 
established O 
as O 
3,7-dioxo-11β-hydroxy-5α-tirucalla-8,24(Z)-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
by O 
various O 
spectroscopic O 
techniques O 
including O 
MS O 
, O 
1D O 
, O 
and O 
2D O 
NMR O 
and O 
HRTOFMS O 
. O 

C O 
( O 
cys-C O 
) O 
is O 
a O 
small O 
protein O 
molecule O 
( O 
120 O 
amino B-FAMILY 
acid I-FAMILY 
peptide O 
chain O 
, O 
approximately O 
13kDa O 
) O 
produced O 
by O 
virtually O 
all O 
nucleated O 
cells O 
in O 
the O 
human O 
body O 
. O 
It O 
belongs O 
to O 
the O 
family O 
of O 
papain O 
- O 
like O 
cysteine B-TRIVIAL 
proteases O 
and O 
its O 
main O 
biological O 
role O 
is O 
the O 
extracellular O 
inhibition O 
of O 
cathepsins O 
. O 
It's O 
near O 
constant O 
production O 
rate O 
, O 
the O 
fact O 
that O 
it O 
is O 
freely O 
filtered O 
from O 
the O 
glomerular O 
membrane O 
and O 
then O 
completely O 
reabsorbed O 
without O 
being O 
secreted O 
from O 
the O 
proximal O 
tubular O 
cells O 
, O 
made O 
it O 
an O 
almost O 
perfect O 
candidate O 
for O 
estimating O 
renal O 
function O 
. O 
The O 
strong O 
correlation O 
between O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
and O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
along O 
with O 
the O 
growing O 
understanding O 
of O 
the O 
role O 
of O 
cysteinyl B-TRIVIAL 
cathepsins O 
in O 
the O 
pathophysiology O 
of O 
CVD O 
inspired O 
researchers O 
to O 
explore O 
the O 
potential O 
association O 
of O 
cys-C O 
with O 
CVD O 
. O 
Throughout O 
the O 
spectrum O 
of O 
CVD O 
( O 
peripheral O 
arterial O 
disease O 
, O 
stroke O 
, O 
abdominal O 
aortic O 
aneurysm O 
, O 
heart O 
failure O 
, O 
coronary O 
artery O 
disease O 
) O 
adverse O 
outcomes O 
and O 
risk O 
stratification O 
have O 
been O 
associated O 
with O 
high O 
plasma O 
levels O 
of O 
cys-C O 
. O 
The O 
exact O 
mechanisms O 
behind O 
the O 
observed O 
correlations O 
have O 
not O 
been O 
comprehensively O 
clarified O 
. O 
Plausible O 
links O 
between O 
high O 
cys-C O 
levels O 
and O 
poor O 
cardiovascular O 
outcome O 
could O 
be O 
impaired O 
renal O 
function O 
, O 
atherogenesis O 
and O 
inflammatory O 
mediators O 
, O 
remodeling O 
of O 
myocardial O 
tissue O 
and O 
others O 
( O 
genetic O 
factors O 
, O 
aging O 
and O 
social O 
habits O 
) O 
. O 
The O 
scope O 
of O 
the O 
present O 
article O 
is O 
to O 
systematically O 
review O 
the O 
current O 
knowledge O 
about O 
cys-C O 
biochemistry O 
, O 
metabolism O 
, O 
methods O 
of O 
detection O 
and O 
quantification O 
and O 
pathophysiological O 
associations O 
with O 
different O 
aspects O 
of O 
CVD O 
. O 

introduction O 
of O 
biochemical O 
biomarkers O 
in O 
the O 
evaluation O 
of O 
patients O 
with O 
cardiovascular O 
disease O 
has O 
led O 
to O 
practice O 
- O 
changing O 
advancements O 
in O 
the O 
way O 
these O 
patients O 
are O 
diagnosed O 
and O 
managed O 
. O 
Measurements O 
of O 
cardiac O 
troponins O 
or O 
brain O 
- O 
type O 
natriuretic O 
peptide O 
( O 
BNP O 
) O 
and O 
its O 
precursor O 
, O 
N B-FORMULA 
-terminal O 
brain O 
- O 
type O 
natriuretic O 
peptide O 
( O 
NT-proBNP O 
) O 
, O 
have O 
become O 
indispensable O 
in O 
the O 
evaluation O 
of O 
patients O 
with O 
acute O 
coronary O 
syndromes O 
and O 
heart O 
failure O 
, O 
respectively O 
, O 
constituting O 
an O 
integral O 
part O 
of O 
the O 
diagnostic O 
algorithm O 
and O 
risk O 
stratification O 
of O 
these O 
conditions O 
. O 
Copeptin O 
, O 
a O 
glycopeptide O 
, O 
part O 
of O 
the O 
prehormone O 
molecule O 
of O 
the O 
antidiuretic O 
hormone O 
- O 
or O 
arginine B-TRIVIAL 
-vasopressin O 
- O 
has O 
shown O 
considerable O 
promise O 
in O 
this O 
field O 
. O 
There O 
is O 
evidence O 
that O 
copeptin O 
might O 
be O 
useful O 
as O 
a O 
diagnostic O 
or O 
prognostic O 
biomarker O 
and O 
risk O 
- O 
stratifier O 
in O 
a O 
range O 
of O 
cardiovascular O 
disease O 
conditions O 
. O 
The O 
main O 
clinical O 
scenarios O 
where O 
copeptin O 
has O 
been O 
studied O 
as O 
a O 
biomarker O 
are O 
: O 
early O 
rule O 
- O 
out O 
of O 
myocardial O 
infarction O 
in O 
patients O 
with O 
acute O 
chest O 
pain O 
, O 
diagnosis O 
of O 
heart O 
failure O 
in O 
patients O 
with O 
acute O 
dyspnea O 
and O 
determining O 
the O 
prognosis O 
of O 
destabilized O 
or O 
chronic O 
stable O 
heart O 
failure O 
. O 
The O 
present O 
review O 
is O 
aimed O 
at O 
providing O 
concise O 
information O 
about O 
the O 
molecular O 
structure O 
and O 
biosynthesis O 
of O 
copeptin O 
, O 
the O 
available O 
medical O 
chemistry O 
methods O 
of O 
quantification O 
, O 
and O 
the O 
potential O 
clinical O 
uses O 
of O 
this O 
molecule O 
in O 
patients O 
with O 
heart O 
disease O 
. O 

Direct-Absorption O 
Spectroscopy O 
of O 
Hydroxymethyl B-SYSTEMATIC 
Radical O 
in O 
the O 
CH B-FORMULA 
Symmetric O 
Stretching O 
Region O 
. O 

- O 
resolution O 
, O 
fully O 
rotationally O 
resolved O 
direct O 
absorption O 
spectra O 
of O 
hydroxymethyl B-SYSTEMATIC 
radical O 
, O 
CH2OH B-FORMULA 
, O 
are O 
presented O 
in O 
the O 
infrared O 
CH B-FORMULA 
stretching O 
region O 
. O 
As O 
a O 
result O 
of O 
low O 
rotational O 
temperatures O 
and O 
sub-Doppler O 
linewidths O 
obtained O 
in O 
the O 
slit O 
supersonic O 
expansion O 
, O 
the O 
Ka O 
= O 
0 O 
← O 
0 O 
band O 
of O 
the O 
symmetric O 
CH B-FORMULA 
stretch O 
for O 
CH2OH B-FORMULA 
has O 
been O 
unambiguously O 
identified O 
and O 
analyzed O 
. O 
By O 
way O 
of O 
chemical O 
confirmation O 
, O 
hydroxymethyl B-SYSTEMATIC 
radical O 
is O 
generated O 
via O 
two O 
different O 
slit O 
jet O 
discharge O 
syntheses O 
: O 
(i) O 
direct O 
dissociation O 
of O 
CH3OH B-FORMULA 
to O 
form O 
CH2OH B-FORMULA 
and O 
(ii) O 
dissociation O 
of O 
Cl2 B-FORMULA 
followed O 
by O 
the O 
radical O 
H B-FORMULA 
atom O 
extraction O 
reaction O 
Cl B-FORMULA 
+ O 
CH3OH B-FORMULA 
→ O 
HCl B-FORMULA 
+ O 
CH2OH B-FORMULA 
. O 
The O 
identified O 
transitions O 
are O 
fit O 
to O 
a O 
Watson O 
A-reduced O 
symmetric O 
top O 
Hamiltonian O 
to O 
yield O 
first O 
precision O 
experimental O 
values O 
for O 
the O 
ground O 
state O 
rotational O 
constants O 
as O 
well O 
as O 
improved O 
values O 
for O 
the O 
symmetric O 
stretch O 
rotational O 
constants O 
and O 
vibrational O 
band O 
origin O 
. O 
The O 
results O 
both O 
complement O 
and O 
substantially O 
improve O 
upon O 
spectral O 
efforts O 
via O 
previous O 
double O 
resonance O 
ionization O 
detected O 
infrared O 
methods O 
by O 
Feng O 
et O 
al O 
. O 
[ O 
J O 
. O 
Phys O 
. O 
Chem O 
. O 
A O 
, O 
2004 O 
, O 
108 O 
, O 
7093 O 
] O 
, O 
as O 
well O 
as O 
offer O 
high O 
- O 
resolution O 
predictions O 
for O 
laboratory O 
and O 
astronomical O 
detection O 
of O 
hydroxymethyl B-SYSTEMATIC 
radical O 
in O 
the O 
millimeter O 
- O 
wave O 
region O 
. O 

has O 
become O 
known O 
, O 
most O 
materials O 
, O 
such O 
as O 
proteins O 
and O 
DNA O 
, O 
show O 
orientation O 
under O 
strong O 
magnetic O 
fields O 
. O 
However O 
, O 
the O 
critical O 
threshold O 
for O 
the O 
magnetic O 
field O 
of O 
the O 
magnetomechanical O 
phenomena O 
is O 
still O 
unknown O 
. O 
We O 
demonstrate O 
that O 
a O 
thin O 
micro O 
- O 
mirror O 
from O 
a O 
fish O 
scale O 
with O 
high O 
reflectivity O 
exhibits O 
a O 
distinct O 
magnetic O 
response O 
at O 
100 O 
mT O 
. O 
A O 
dramatic O 
event O 
under O 
a O 
magnetic O 
field O 
is O 
the O 
decrease O 
of O 
light O 
scattering O 
from O 
guanine B-TRIVIAL 
crystals O 
as O 
well O 
as O 
rapid O 
rotation O 
against O 
the O 
applied O 
magnetic O 
field O 
. O 
Enhancement O 
of O 
light O 
scattering O 
intensity O 
is O 
also O 
observed O 
when O 
the O 
three O 
vectors O 
of O 
light O 
incidence O 
, O 
magnetic O 
field O 
, O 
and O 
observation O 
are O 
orthogonally O 
directed O 
. O 
The O 
results O 
indicate O 
that O 
biogenic O 
guanine B-TRIVIAL 
crystals O 
have O 
a O 
large O 
diamagnetic O 
anisotropy O 
along O 
the O 
surface O 
parallel O 
and O 
normal O 
directions O 
. O 
The O 
micrometer O 
to O 
submicrometer O 
scale O 
of O 
thin O 
biogenic O 
plates O 
can O 
act O 
as O 
a O 
noninvasively O 
, O 
magnetically O 
controlled O 
micro O 
- O 
mirror O 
for O 
light O 
irradiation O 
control O 
in O 
the O 
micrometer O 
- O 
scale O 
region O 
. O 

redox O 
behavior O 
of O 
the O 
high O 
- O 
density O 
self O 
- O 
assembled O 
monolayer O 
of O 
a O 
molecular O 
tripod O 
on O 
a O 
au(111) B-FORMULA 
surface O 
with O 
a O 
terminal O 
ferrocene B-TRIVIAL 
group O 
. O 

dyad O 
consisting O 
of O 
a O 
tripod O 
- O 
shaped O 
trithiol B-FAMILY 
with O 
an O 
adamantane B-TRIVIAL 
core O 
and O 
a O 
terminal O 
ferrocenyl B-TRIVIAL 
group O 
linked O 
through O 
ap- O 
phenyleneethynylene B-SYSTEMATIC 
bridge O 
was O 
synthesized O 
. O 
The O 
trithiol B-FAMILY 
formed O 
a O 
stable O 
self O 
- O 
assembled O 
monolayer O 
( O 
SAM O 
) O 
on O 
Au(111) B-FORMULA 
, O 
wherein O 
each O 
molecule O 
is O 
bound O 
to O 
the O 
surface O 
by O 
three O 
- O 
point O 
adsorption O 
using O 
all O 
sulfur B-SYSTEMATIC 
atoms O 
, O 
with O 
confirmation O 
by O 
PM-IRRAS O 
and O 
XPS O 
analyses O 
. O 
Cyclic O 
voltammetry O 
of O 
the O 
SAM O 
showed O 
a O 
line O 
shape O 
typical O 
of O 
an O 
ideal O 
adsorbed O 
system O 
, O 
that O 
is O 
, O 
a O 
monolayer O 
with O 
negligible O 
electrostatic O 
interaction O 
among O 
the O 
terminal O 
ferrocenyl B-TRIVIAL 
groups O 
. O 
Thus O 
, O 
a O 
rare O 
SAM O 
was O 
achieved O 
, O 
in O 
which O 
the O 
component O 
molecules O 
were O 
isolated O 
from O 
adjacent O 
molecules O 
without O 
the O 
coadsorption O 
of O 
nonelectroactive O 
molecules O 
. O 

releasing O 
factor O 
and O 
catecholamines B-FAMILY 
enhance O 
glutamatergic O 
neurotransmission O 
in O 
the O 
lateral O 
subdivision O 
of O 
the O 
central O 
amygdala O 
. O 

neurotransmission O 
in O 
the O 
central O 
nucleus O 
of O 
the O 
amygdala O 
( O 
CeA O 
) O 
plays O 
an O 
important O 
role O 
in O 
many O 
behaviors O 
including O 
anxiety O 
, O 
memory O 
consolidation O 
and O 
cardiovascular O 
responses O 
. O 
While O 
these O 
behaviors O 
can O 
be O 
modulated O 
by O 
corticotropin O 
releasing O 
factor O 
( O 
CRF O 
) O 
and O 
catecholamine B-TRIVIAL 
signaling O 
, O 
the O 
mechanism(s) O 
by O 
which O 
these O 
signals O 
modify O 
CeA O 
glutamatergic O 
neurotransmission O 
remains O 
unclear O 
. O 
Utilizing O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
electrophysiology O 
recordings O 
from O 
neurons O 
in O 
the O 
lateral O 
subdivision O 
of O 
the O 
CeA O 
( O 
CeAL O 
) O 
, O 
we O 
show O 
that O 
CRF O 
, O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
and O 
the O 
β-adrenergic O 
receptor O 
agonist O 
isoproterenol B-TRIVIAL 
( O 
ISO B-ABBREVIATION 
) O 
all O 
enhance O 
the O 
frequency O 
of O 
spontaneous O 
excitatory O 
postsynaptic O 
currents O 
( O 
sEPSC O 
) O 
without O 
altering O 
sEPSC O 
kinetics O 
, O 
suggesting O 
they O 
increase O 
presynaptic O 
glutamate B-TRIVIAL 
release O 
. O 
The O 
effect O 
of O 
CRF O 
on O 
sEPSCs O 
was O 
mediated O 
by O 
a O 
combination O 
of O 
CRFR1 O 
and O 
CRFR2 O 
receptors O 
. O 
While O 
previous O 
work O 
from O 
our O 
lab O 
suggests O 
that O 
CRFRs O 
mediate O 
the O 
effect O 
of O 
catecholamines B-FAMILY 
on O 
excitatory O 
transmission O 
in O 
other O 
subregions O 
of O 
the O 
extended O 
amygdala O 
, O 
blockade O 
of O 
CRFRs O 
in O 
the O 
CeAL O 
failed O 
to O 
significantly O 
alter O 
effects O 
of O 
DA O 
and O 
ISO B-ABBREVIATION 
on O 
glutamatergic O 
transmission O 
. O 
These O 
findings O 
suggest O 
that O 
catecholamine B-TRIVIAL 
and O 
CRF O 
enhancement O 
of O 
glutamatergic O 
transmission O 
onto O 
CeAL O 
neurons O 
occurs O 
via O 
distinct O 
mechanisms O 
. O 
While O 
CRF O 
increased O 
spontaneous O 
glutamate B-TRIVIAL 
release O 
in O 
the O 
CeAL O 
, O 
CRF O 
caused O 
no O 
significant O 
changes O 
to O 
optogenetically O 
evoked O 
glutamate B-TRIVIAL 
release O 
in O 
this O 
region O 
. O 
The O 
dissociable O 
effects O 
of O 
CRF O 
on O 
different O 
types O 
of O 
glutamatergic O 
neurotransmission O 
suggest O 
that O 
CRF O 
may O 
specifically O 
regulate O 
spontaneous O 
excitatory O 
transmission O 
. O 

for O 
departures O 
from O 
additivity O 
in O 
mixtures O 
of O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
( O 
PFAAs B-ABBREVIATION 
) O 
. O 

study O 
is O 
a O 
follow O 
- O 
up O 
to O 
a O 
paper O 
by O 
Carr O 
et O 
al O 
. O 
that O 
determined O 
a O 
design O 
structure O 
to O 
optimally O 
test O 
for O 
departures O 
from O 
additivity O 
in O 
a O 
fixed O 
ratio O 
mixture O 
of O 
four O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
( O 
PFAAs B-ABBREVIATION 
) O 
using O 
an O 
in O 
vitro O 
transiently O 
- O 
transfected O 
COS-1 O 
PPARα O 
reporter O 
model O 
with O 
a O 
mixing O 
ratio O 
that O 
is O 
based O 
on O 
average O 
serum O 
levels O 
in O 
NHANES O 
subjects O 
. O 
Availability O 
of O 
information O 
regarding O 
potential O 
for O 
additivity O 
of O 
PFAAs B-ABBREVIATION 
in O 
mixtures O 
is O 
critically O 
important O 
for O 
risk O 
assessors O 
who O 
are O 
concerned O 
with O 
the O 
ability O 
of O 
the O 
compounds O 
to O 
affect O 
human O 
health O 
and O 
impact O 
ecological O 
systems O 
. O 
It O 
is O 
clear O 
that O 
exposures O 
are O 
not O 
to O 
single O 
compounds O 
, O 
but O 
to O 
mixtures O 
of O 
the O 
PFAAs B-ABBREVIATION 
. O 
This O 
paper O 
presents O 
the O 
results O 
from O 
the O 
data O 
collected O 
using O 
the O 
design O 
from O 
Carr O 
et O 
al O 
. O 
along O 
with O 
subsequent O 
analyses O 
that O 
were O 
performed O 
to O 
classify O 
the O 
relationships O 
among O 
mixtures O 
of O 
PFAAs B-ABBREVIATION 
. O 
A O 
non-linear O 
logistic O 
additivity O 
model O 
was O 
employed O 
to O 
predict O 
relative O 
luciferase O 
units O 
( O 
RLU O 
) O 
, O 
an O 
indicator O 
of O 
PPARα O 
activation O 
. O 
The O 
results O 
indicated O 
a O 
less O 
than O 
additive O 
relationship O 
among O 
the O 
four O 
PFAAs B-ABBREVIATION 
. O 
To O 
determine O 
if O 
the O 
possible O 
" O 
antagonism O 
" O 
is O 
from O 
the O 
competition O 
among O 
or O 
between O 
carboxylates B-FAMILY 
and O 
sulfonates B-FAMILY 
, O 
four O 
different O 
binary O 
mixtures O 
were O 
also O 
studied O 
. O 
There O 
was O 
a O 
less O 
than O 
additive O 
relationship O 
in O 
all O 
four O 
binary O 
mixtures O 
. O 
These O 
findings O 
are O 
generally O 
similar O 
to O 
two O 
other O 
reports O 
of O 
interfering O 
interactions O 
between O 
PFAAs B-ABBREVIATION 
in O 
mixtures O 
. O 
The O 
most O 
conservative O 
interpretation O 
for O 
our O 
data O 
would O 
be O 
an O 
assumption O 
of O 
additivity O 
( O 
and O 
lack O 
of O 
a O 
greater O 
than O 
additive O 
interaction O 
) O 
, O 
with O 
a O 
potential O 
for O 
antagonistic O 
interactions O 
. O 

of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
its O 
analogs O 
( O 
BPF B-ABBREVIATION 
, O 
BPAF B-ABBREVIATION 
, O 
BPZ B-ABBREVIATION 
and O 
DMBPA B-ABBREVIATION 
) O 
in O 
human O 
liver O 
microsomes O 
. O 

A I-TRIVIAL 
analogs O 
are O 
a O 
class O 
of O 
chemicals O 
known O 
as O 
diphenylmethanes B-FAMILY 
, O 
which O 
contain O 
two O 
benzene B-SYSTEMATIC 
rings O 
separated O 
by O 
one O 
central O 
carbon O 
atom O 
, O 
usually O 
with O 
a O 
para-hydroxy B-SYSTEMATIC 
group O 
on O 
both O 
benzene B-SYSTEMATIC 
rings O 
. O 
Bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
can O 
induce O 
an O 
uterotrophic O 
response O 
in O 
immature O 
CD-1 O 
mice O 
and O 
elicits O 
estrogenic O 
responses O 
in O 
many O 
other O 
experimental O 
systems O 
. O 
Besides O 
highlighting O 
endocrine O 
effects O 
, O 
a O 
number O 
of O 
metabolic O 
studies O 
provide O 
strong O 
support O 
for O 
the O 
idea O 
that O 
reactive O 
species O 
of O 
BPA B-ABBREVIATION 
are O 
formed O 
in O 
vitro O 
and O 
in O 
vivo O 
that O 
can O 
form O 
covalent O 
adducts O 
with O 
nucleophilic O 
macromolecules O 
and O 
/ O 
or O 
produce O 
oxidative O 
stress O 
. O 
We O 
used O 
a O 
liquid O 
chromatography O 
with O 
a O 
triple O 
quadrupole O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
for O 
the O 
detection O 
of O 
metabolites O 
and O 
glutathione B-TRIVIAL 
conjugates O 
of O 
BPA B-ABBREVIATION 
and O 
its O 
analogs O 
( O 
BPF B-ABBREVIATION 
, O 
BPAF B-ABBREVIATION 
, O 
BPZ B-ABBREVIATION 
and O 
DMBPA B-ABBREVIATION 
) O 
in O 
human O 
liver O 
microsomes O 
( O 
HLM O 
) O 
or O 
with O 
recombinant O 
CYP O 
isozymes O 
in O 
the O 
presence O 
of O 
NADPH B-ABBREVIATION 
and O 
GSH B-ABBREVIATION 
as O 
a O 
trapping O 
agent O 
. O 
We O 
have O 
confirmed O 
that O 
BPA B-ABBREVIATION 
and O 
its O 
structural O 
analogs O 
form O 
hydroxylated O 
metabolites O 
and O 
electrophilic O 
species O 
during O 
bioactivation O 
in O 
HLM O 
and O 
CYP O 
isozymes O 
. O 
These O 
results O 
provided O 
important O 
mechanistic O 
insight O 
into O 
the O 
metabolic O 
fate O 
of O 
BPA B-ABBREVIATION 
structural O 
analogs O 
in O 
vitro O 
. O 

work O 
studies O 
the O 
effects O 
of O 
water O 
deficit O 
and O 
heat O 
, O 
as O 
well O 
as O 
the O 
involvement O 
of O 
chlororespiration O 
and O 
the O 
ferredoxin O 
- O 
mediated O 
cyclic O 
pathway O 
, O 
on O 
the O 
tolerance O 
of O 
photosynthesis O 
to O 
high O 
light O 
intensity O 
in O 
Hibiscus O 
rosa O 
- O 
sinensis O 
plants O 
. O 
Drought O 
and O 
heat O 
resulted O 
in O 
the O 
down O 
- O 
regulation O 
of O 
photosynthetic O 
linear O 
electron O 
transport O 
in O 
the O 
leaves O 
, O 
although O 
only O 
a O 
slight O 
decrease O 
in O 
variable O 
fluorescence O 
( O 
Fv O 
) O 
/ O 
maximal O 
fluorescence O 
( O 
Fm O 
) O 
was O 
observed O 
, O 
indicating O 
that O 
the O 
chloroplast O 
was O 
protected O 
by O 
mechanisms O 
that O 
dissipate O 
excess O 
excitation O 
energy O 
to O 
prevent O 
damage O 
to O 
the O 
photosynthetic O 
apparatus O 
. O 
The O 
incubation O 
of O 
leaves O 
from O 
unstressed O 
plants O 
under O 
high O 
light O 
intensity O 
resulted O 
in O 
an O 
increase O 
of O 
the O 
activity O 
of O 
electron O 
donation O 
by O 
nicotinamide B-SYSTEMATIC 
adenine I-SYSTEMATIC 
dinucleotide I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
NADPH B-ABBREVIATION 
) O 
and O 
ferredoxin O 
to O 
plastoquinone B-TRIVIAL 
, O 
but O 
no O 
increase O 
was O 
observed O 
in O 
plants O 
exposed O 
to O 
water O 
deficit O 
, O 
suggesting O 
that O 
cyclic O 
electron O 
transport O 
was O 
stimulated O 
by O 
high O 
light O 
only O 
in O 
control O 
plants O 
. O 
In O 
contrast O 
, O 
the O 
activities O 
of O 
the O 
chlororespiration O 
enzymes O 
( O 
NADH B-ABBREVIATION 
dehydrogenase O 
( O 
NDH O 
) O 
complex O 
and O 
plastid O 
terminal O 
oxidase O 
( O 
PTOX O 
) O 
) O 
increased O 
after O 
incubation O 
under O 
high O 
light O 
intensity O 
in O 
leaves O 
of O 
the O 
water O 
deficit O 
plants O 
, O 
but O 
not O 
in O 
control O 
plants O 
, O 
suggesting O 
that O 
chlororespiration O 
was O 
stimulated O 
in O 
stressed O 
plants O 
. O 
The O 
results O 
indicate O 
that O 
the O 
relative O 
importance O 
of O 
chlororespiration O 
and O 
the O 
cyclic O 
electron O 
pathway O 
in O 
the O 
tolerance O 
of O 
photosynthesis O 
to O 
high O 
illumination O 
differs O 
under O 
stress O 
conditions O 
. O 
When O 
plants O 
were O 
not O 
subjected O 
to O 
stress O 
, O 
the O 
contribution O 
of O 
chlororespiration O 
to O 
photosynthetic O 
electron O 
flow O 
regulation O 
was O 
not O 
relevant O 
, O 
and O 
another O 
pathway O 
, O 
such O 
as O 
the O 
ferredoxin O 
- O 
mediated O 
cyclic O 
pathway O 
, O 
was O 
more O 
important O 
. O 
However O 
, O 
when O 
plants O 
were O 
subjected O 
to O 
water O 
deficit O 
and O 
heat O 
, O 
chlororespiration O 
was O 
probably O 
essential O 
. O 

formation O 
of O 
mono- B-FAMILY 
and I-FAMILY 
dihydroxy-resolvins I-FAMILY 
from O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
using O 
soybean O 
15-lipoxygenase O 
. O 

and O 
protectins O 
are O 
important O 
anti-inflammatory O 
and O 
pro O 
- O 
resolution O 
compounds O 
derived O 
from O 
the O 
enzymatic O 
oxidation O 
of O 
omega-3 B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
all-cis-5,8,11,14,17-eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
and O 
all-cis-4,7,10,13,16,19-docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
. O 
We O 
have O 
developed O 
a O 
simple O 
, O 
controlled O 
method O 
to O 
synthesize O 
an O 
array O 
of O 
resolvin B-FAMILY 
and O 
protectin O 
analogs O 
from O 
fatty B-FAMILY 
acid I-FAMILY 
starting O 
materials O 
using O 
soybean O 
15-lipoxygenase O 
. O 
The O 
conditions O 
were O 
optimized O 
for O 
the O 
production O 
of O 
both O 
mono- B-MULTIPLE 
and I-MULTIPLE 
dihydroxy I-MULTIPLE 
derivatives O 
, O 
with O 
enzyme O 
concentration O 
and O 
pH O 
found O 
to O 
have O 
a O 
significant O 
effect O 
on O 
the O 
reaction O 
products O 
. O 
The O 
methods O 
were O 
applied O 
to O 
five O 
biologically O 
important O 
omega-3 B-MULTIPLE 
and I-MULTIPLE 
omega-6 I-MULTIPLE 
fatty I-MULTIPLE 
acid I-MULTIPLE 
substrates O 
. O 
Mono- B-MULTIPLE 
and I-MULTIPLE 
dihydroxy I-MULTIPLE 
compounds O 
were O 
successfully O 
synthesized O 
from O 
all O 
substrates O 
and O 
the O 
products O 
were O 
characterized O 
by O 
normal O 
phase O 
( O 
NP O 
) O 
HPLC O 
, O 
GC-MS O 
, O 
TOF-MS O 
, O 
UV-visible O 
( O 
UV-vis O 
) O 
spectroscopy O 
, O 
and O 
NMR O 
spectroscopy O 
. O 
The O 
methods O 
could O 
be O 
further O 
applied O 
to O 
any O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
containing O 
the O 
cis-1,4,7,10-undecatetraene B-SYSTEMATIC 
moiety O 
to O 
produce O 
a O 
range O 
of O 
novel O 
compounds O 
with O 
potential O 
biological O 
activity O 
. O 

metal B-FAMILY 
oxides I-FAMILY 
for O 
the O 
extraction O 
of O 
nanoparticles O 
from O 
water O 
. O 

of O 
nanomaterials O 
in O 
the O 
environment O 
will O 
pose O 
significant O 
health O 
risks O 
in O 
the O 
future O 
. O 
A O 
viable O 
purification O 
method O 
is O 
necessary O 
to O 
address O 
this O 
problem O 
. O 
Here O 
we O 
report O 
the O 
synthesis O 
and O 
application O 
of O 
a O 
series O 
of O 
metal B-FAMILY 
oxides I-FAMILY 
prepared O 
using O 
a O 
biological O 
template O 
for O 
the O 
removal O 
of O 
nanoparticles O 
from O 
the O 
aqueous O 
environment O 
. O 
A O 
simple O 
synthesis O 
of O 
metal B-FAMILY 
oxides I-FAMILY 
such O 
as O 
ZnO B-FORMULA 
, O 
NiO B-FORMULA 
, O 
CuO B-FORMULA 
, O 
Co3O4 B-FORMULA 
and O 
CeO2 B-FORMULA 
employing O 
eggshell O 
membrane O 
( O 
ESM O 
) O 
as O 
a O 
biotemplate O 
is O 
reported O 
. O 
The O 
morphology O 
of O 
the O 
metal B-FAMILY 
oxide I-FAMILY 
powders O 
was O 
characterized O 
using O 
electron O 
microscopes O 
and O 
the O 
lattice O 
structure O 
was O 
established O 
using O 
X-ray O 
diffraction O 
methods O 
. O 
Extraction O 
of O 
nanoparticles O 
from O 
water O 
was O 
carried O 
out O 
to O 
compare O 
the O 
efficiency O 
of O 
metal B-FAMILY 
oxides I-FAMILY 
. O 
NiO B-FORMULA 
showed O 
good O 
extraction O 
efficiency O 
in O 
removing O 
gold O 
and O 
silver B-SYSTEMATIC 
nanoparticles O 
from O 
spiked O 
water O 
samples O 
within O 
an O 
hour O 
. O 
Easy O 
access O 
and O 
enhanced O 
stability O 
of O 
metal B-FAMILY 
oxides I-FAMILY 
makes O 
them O 
interesting O 
candidates O 
for O 
applications O 
in O 
industrial O 
effluent O 
treatments O 
and O 
water O 
purifications O 
. O 

stress O 
produced O 
during O 
pancreatic O 
islet O 
isolation O 
leads O 
to O 
significant O 
β-cell O 
damage O 
. O 
Homeostatic O 
cytokines O 
secreted O 
subsequently O 
to O 
islet O 
transplantation O 
damage O 
β-cells O 
by O 
generating O 
oxygen B-SYSTEMATIC 
free O 
radicals O 
. O 
In O 
this O 
study O 
, O 
exendin-4 O 
, O 
a O 
glucagon O 
- O 
like O 
peptide-1 O 
analog O 
improved O 
islet O 
transplantation O 
outcome O 
by O 
increasing O 
the O 
survival O 
of O 
diabetic O 
recipient O 
mice O 
from O 
58% O 
to O 
100% O 
. O 
We O 
hypothesized O 
that O 
this O 
beneficial O 
effect O 
was O 
due O 
to O 
the O 
ability O 
of O 
exendin-4 O 
to O 
reduce O 
oxidative O 
stress O 
. O 
Further O 
experiments O 
showed O 
that O 
it O 
significantly O 
reduced O 
the O 
apoptotic O 
rate O 
of O 
cultured O 
β-cells O 
subjected O 
to O 
hypoxia O 
or O 
to O 
IL-1β O 
. O 
Reduction O 
of O 
apoptotic O 
events O 
was O 
confirmed O 
in O 
pancreatic O 
islet O 
grafts O 
of O 
exendin-4 O 
- O 
treated O 
mice O 
. O 
Exendin-4 O 
enhanced O 
Akt O 
phosphorylation O 
of O 
β-cells O 
and O 
insulin O 
released O 
from O 
them O 
. O 
It O 
even O 
augmented O 
insulin O 
secretion O 
from O 
islets O 
cultivated O 
at O 
hypoxic O 
conditions O 
. O 
Exposure O 
to O 
hypoxia O 
led O 
to O 
a O 
decrease O 
in O 
the O 
activation O 
of O 
Akt O 
, O 
which O 
was O 
reversed O 
when O 
β-cells O 
were O 
pretreated O 
with O 
exendin-4 O 
. O 
Moreover O 
, O 
exendin-4 O 
increased O 
the O 
activity O 
of O 
redox O 
enzymes O 
in O 
a O 
hypoxia O 
- O 
treated O 
β-cell O 
line O 
and O 
reduced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
in O 
isolated O 
pancreatic O 
islets O 
. O 
Recovery O 
from O 
diabetes O 
in O 
mice O 
transplanted O 
with O 
hypoxic O 
islets O 
was O 
more O 
efficient O 
when O 
they O 
received O 
exendin-4 O 
. O 
In O 
conclusion O 
, O 
exendin-4 O 
rescued O 
islets O 
from O 
oxidative O 
stress O 
caused O 
by O 
hypoxia O 
or O 
due O 
to O 
cytokine O 
exposure O 
. O 
It O 
improved O 
the O 
outcome O 
of O 
syngenic O 
and O 
xenogenic O 
islet O 
transplantation O 
. O 

to O 
phototoxic O 
NSAIDs O 
and O 
quinolones B-FAMILY 
is O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
melanoma O 
. O 

: O 
Ultraviolet O 
radiation O 
exposure O 
is O 
the O 
most O 
important O 
exogenous O 
risk O 
factor O 
for O 
cutaneous O 
malignancies O 
. O 
It O 
is O 
possible O 
that O 
phototoxic O 
drugs O 
promote O 
the O 
development O 
of O 
cutaneous O 
melanoma O 
( O 
CM O 
) O 
by O 
intensifying O 
the O 
effect O 
of O 
ultraviolet O 
light O 
on O 
the O 
skin O 
. O 
We O 
investigated O 
the O 
association O 
between O 
the O 
use O 
of O 
common O 
systemic O 
phototoxic O 
drugs O 
and O 
development O 
of O 
CM O 
. O 
METHODS O 
: O 
This O 
study O 
was O 
a O 
case O 
- O 
control O 
study O 
in O 
a O 
Dutch O 
population O 
- O 
based O 
cohort O 
. O 
The O 
drug O 
dispensing O 
data O 
was O 
obtained O 
from O 
PHARMO O 
, O 
a O 
Dutch O 
drug O 
dispensing O 
and O 
hospital O 
admissions O 
registry O 
, O 
and O 
linked O 
to O 
PALGA O 
, O 
the O 
nationwide O 
pathology O 
network O 
of O 
the O 
Netherlands O 
. O 
The O 
cases O 
were O 
patients O 
diagnosed O 
with O 
pathologically O 
confirmed O 
primary O 
CM O 
between O 
1991 O 
and O 
2004 O 
. O 
Controls O 
were O 
sampled O 
from O 
the O 
PHARMO O 
population O 
. O 
Exposure O 
to O 
systemic O 
phototoxic O 
drugs O 
was O 
measured O 
and O 
included O 
antimicrobial O 
agents O 
, O 
diuretics O 
, O 
antipsychotic O 
drugs O 
, O 
antidiabetic O 
drugs O 
, O 
cardiac O 
drugs O 
, O 
antimalarials O 
and O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAIDs O 
) O 
. O 
A O 
multivariate O 
conditional O 
logistic O 
regression O 
analysis O 
was O 
performed O 
to O 
study O 
the O 
association O 
between O 
exposure O 
to O 
phototoxic O 
drugs O 
and O 
CM O 
. O 
RESULTS O 
: O 
The O 
study O 
population O 
included O 
1318 O 
cases O 
and O 
6786 O 
controls O 
. O 
Any O 
phototoxic O 
drug O 
during O 
the O 
study O 
period O 
was O 
dispensed O 
for O 
46 O 
% O 
of O 
the O 
cases O 
and O 
43 O 
% O 
of O 
the O 
controls O 
( O 
p O 
= O 
0.012 O 
) O 
. O 
The O 
use O 
of O 
quinolones B-FAMILY 
[ O 
odds O 
ratio O 
( O 
OR O 
) O 
1.33 O 
, O 
95 O 
% O 
confidence O 
interval O 
( O 
CI O 
) O 
1.01-1.76 O 
] O 
and O 
propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivative O 
NSAIDs O 
( O 
OR O 
1.33 O 
, O 
95 O 
% O 
CI O 
1.14-1.54 O 
) O 
had O 
a O 
positive O 
association O 
with O 
CM O 
. O 
CONCLUSIONS O 
: O 
Our O 
study O 
shows O 
that O 
the O 
use O 
of O 
phototoxic O 
drugs O 
is O 
associated O 
with O 
an O 
increased O 
risk O 
of O 
developing O 
CM O 
. O 
Even O 
a O 
short O 
- O 
term O 
use O 
of O 
phototoxic O 
quinolones B-FAMILY 
and O 
propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
derivative O 
NSAIDs O 
may O 
increase O 
the O 
risk O 
for O 
CM O 
. O 
Patient O 
education O 
to O 
promote O 
sun O 
- O 
protective O 
behaviour O 
is O 
essential O 
to O 
avoid O 
immediate O 
adverse O 
effects O 
and O 
possible O 
long O 
- O 
term O 
effects O 
of O 
phototoxic O 
drugs O 
. O 

/ O 
HYPOTHESES O 
: O 
Glucagon O 
- O 
like O 
peptide-1 O 
( O 
GLP-1 O 
) O 
, O 
an O 
important O 
mediator O 
of O 
postprandial O 
glycaemia O 
, O 
could O 
potentially O 
be O 
stimulated O 
by O 
delivering O 
small O 
quantities O 
of O 
nutrient O 
to O 
a O 
long O 
length O 
of O 
distal O 
gut O 
. O 
We O 
aimed O 
to O 
determine O 
whether O 
enteric O 
- O 
coated O 
pellets O 
, O 
releasing O 
small O 
amounts O 
of O 
lauric B-TRIVIAL 
acid I-TRIVIAL 
throughout O 
the O 
ileum O 
and O 
colon O 
, O 
could O 
reduce O 
glycaemic O 
responses O 
to O 
meals O 
in O 
type O 
2 O 
diabetes O 
, O 
associated O 
with O 
stimulation O 
of O 
GLP-1 O 
. O 
METHODS O 
: O 
Eligible O 
patients O 
, O 
who O 
had O 
type O 
2 O 
diabetes O 
controlled O 
by O 
diet O 
or O 
metformin B-TRIVIAL 
, O 
were O 
each O 
studied O 
on O 
two O 
occasions O 
in O 
a O 
hospital O 
setting O 
. O 
After O 
an O 
overnight O 
fast O 
, O 
patients O 
consumed O 
5 O 
g O 
active O 
pellets O 
( O 
47% O 
lauric O 
acid O 
by O 
weight O 
) O 
or O 
placebo O 
with O 
breakfast O 
( O 
T O 
= O 
0 O 
min O 
) O 
and O 
lunch O 
( O 
T O 
= O 
240 O 
min O 
) O 
, O 
in O 
a O 
crossover O 
design O 
with O 
order O 
randomised O 
by O 
the O 
hospital O 
pharmacy O 
and O 
allocation O 
concealed O 
by O 
numbered O 
containers O 
. O 
Patients O 
and O 
investigators O 
making O 
measurements O 
were O 
blinded O 
to O 
the O 
intervention O 
. O 
Blood O 
was O 
sampled O 
frequently O 
for O 
blood O 
glucose B-TRIVIAL 
( O 
the O 
primary O 
outcome O 
) O 
and O 
hormone O 
assays O 
. O 
RESULTS O 
: O 
Eight O 
patients O 
were O 
randomised O 
( O 
four O 
to O 
receive O 
either O 
intervention O 
first O 
) O 
, O 
and O 
all O 
completed O 
the O 
study O 
without O 
adverse O 
effects O 
. O 
Blood O 
glucose B-TRIVIAL 
was O 
lower O 
after O 
breakfast O 
( O 
T O 
= O 
0-240 O 
min O 
, O 
area O 
under O 
the O 
curve O 
( O 
AUC O 
) O 
2075 O 
± O 
368 O 
vs O 
2216 O 
± O 
163 O 
mmol O 
/ O 
l O 
× O 
min O 
) O 
and O 
lunch O 
( O 
T O 
= O 
240-480 O 
min O 
, O 
AUC O 
1916 O 
± O 
115 O 
vs O 
2088 O 
± O 
151 O 
mmol O 
/ O 
l O 
× O 
min O 
) O 
( O 
p O 
= O 
0.02 O 
for O 
each O 
) O 
after O 
active O 
pellets O 
than O 
after O 
placebo O 
. O 
Plasma O 
GLP-1 O 
concentrations O 
were O 
higher O 
after O 
breakfast O 
( O 
p O 
= O 
0.08 O 
) O 
and O 
lunch O 
( O 
p O 
= O 
0.04 O 
) O 
for O 
active O 
pellets O 
. O 
While O 
there O 
were O 
no O 
differences O 
in O 
insulin O 
or O 
glucose B-TRIVIAL 
-dependent O 
insulinotropic O 
polypeptide O 
concentrations O 
, O 
glucagon O 
concentrations O 
were O 
higher O 
after O 
breakfast O 
and O 
lunch O 
( O 
p O 
= O 
0.002 O 
for O 
each O 
) O 
for O 
active O 
pellets O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
Delivering O 
small O 
amounts O 
of O 
nutrient O 
to O 
the O 
ileum O 
and O 
colon O 
can O 
stimulate O 
substantial O 
endogenous O 
GLP-1 O 
release O 
and O 
attenuate O 
postprandial O 
glycaemia O 
. O 
This O 
novel O 
approach O 
has O 
therapeutic O 
potential O 
in O 
type O 
2 O 
diabetes O 
. O 
TRIAL O 
REGISTRATION O 
: O 
Australian O 
New O 
Zealand O 
Clinical O 
Trials O 
Registry O 
ACTRN12612000600842 O 
. O 
FUNDING O 
: O 
The O 
study O 
was O 
funded O 
by O 
Meyer O 
Nutriceuticals O 
. O 

variability O 
of O 
carboxymethylenebutenolidase O 
homolog O 
, O 
a O 
novel O 
olmesartan B-TRIVIAL 
medoxomil I-TRIVIAL 
hydrolase O 
, O 
in O 
the O 
human O 
liver O 
and O 
intestine O 
. O 

medoxomil I-TRIVIAL 
( O 
OM O 
) O 
is O 
a O 
prodrug O 
- O 
type O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
antagonist O 
. O 
OM O 
is O 
rapidly O 
converted O 
into O 
its O 
active O 
metabolite O 
olmesartan B-TRIVIAL 
by O 
multiple O 
hydrolases O 
in O 
humans O 
, O 
and O 
we O 
recently O 
identified O 
carboxymethylenebutenolidase O 
homolog O 
( O 
CMBL O 
) O 
as O 
one O 
of O 
the O 
OM O 
bioactivating O 
hydrolases O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
further O 
investigated O 
the O 
interindividual O 
variability O 
of O 
mRNA O 
and O 
protein O 
expression O 
of O 
CMBL O 
and O 
OM-hydrolase O 
activity O 
using O 
40 O 
individual O 
human O 
liver O 
and O 
30 O 
intestinal O 
specimens O 
. O 
In O 
the O 
intestinal O 
samples O 
, O 
OM-hydrolase O 
activity O 
strongly O 
correlated O 
with O 
the O 
CMBL O 
protein O 
expression O 
, O 
clearly O 
indicating O 
that O 
CMBL O 
is O 
a O 
major O 
contributor O 
to O 
the O 
prodrug O 
bioactivation O 
in O 
human O 
intestine O 
. O 
The O 
protein O 
and O 
activity O 
were O 
highly O 
distributed O 
in O 
the O 
proximal O 
region O 
( O 
duodenum O 
and O 
jejunum O 
) O 
and O 
decreased O 
to O 
the O 
distal O 
region O 
of O 
the O 
intestine O 
. O 
Although O 
there O 
was O 
high O 
interindividual O 
variability O 
( O 
16-fold O 
) O 
in O 
both O 
the O 
protein O 
and O 
activity O 
in O 
the O 
intestinal O 
segments O 
from O 
the O 
duodenum O 
to O 
colon O 
, O 
the O 
interindividual O 
variability O 
in O 
the O 
duodenum O 
and O 
jejunum O 
was O 
relatively O 
small O 
( O 
3.0- O 
and O 
2.4-fold O 
, O 
respectively O 
) O 
. O 
In O 
the O 
liver O 
samples O 
, O 
the O 
interindividual O 
variability O 
in O 
the O 
protein O 
and O 
activity O 
was O 
4.1- O 
and O 
6.8-fold O 
, O 
respectively O 
. O 
No O 
sex O 
differences O 
in O 
the O 
protein O 
and O 
activity O 
were O 
shown O 
in O 
the O 
human O 
liver O 
or O 
intestine O 
. O 
A O 
genetically O 
engineered O 
Y155C O 
mutant O 
of O 
CMBL O 
, O 
which O 
was O 
caused O 
by O 
a O 
single O 
nucleotide O 
polymorphism O 
rs35489000 O 
, O 
showed O 
significantly O 
lower O 
OM-hydrolase O 
activity O 
than O 
the O 
wild O 
- O 
type O 
protein O 
although O 
no O 
minor O 
allele O 
was O 
genotyped O 
in O 
the O 
40 O 
individual O 
liver O 
specimens O 
. O 

protein O 
- O 
coupled O 
receptors O 
( O 
GPCRs O 
) O 
are O 
the O 
largest O 
and O 
most O 
diverse O 
superfamily O 
of O 
membrane O 
proteins O 
and O 
mediate O 
most O 
cellular O 
responses O 
to O 
hormones O 
and O 
neurotransmitters O 
. O 
Posttranslational O 
modifications O 
are O 
considered O 
the O 
main O 
regulators O 
of O 
all O 
GPCRs O 
. O 
In O 
addition O 
to O 
phosphorylation O 
, O 
glycosylation O 
, O 
and O 
palmitoylation O 
, O 
increasing O 
evidence O 
as O 
reviewed O 
here O 
reveals O 
that O 
ubiquitination O 
also O 
regulates O 
the O 
magnitude O 
and O 
temporospatial O 
aspects O 
of O 
GPCR O 
signaling O 
. O 
Posttranslational O 
protein O 
modification O 
by O 
ubiquitin O 
is O 
a O 
key O 
molecular O 
mechanism O 
governing O 
proteins O 
degradation O 
. O 
Ubiquitination O 
mediates O 
the O 
covalent O 
conjugation O 
of O 
ubiquitin O 
, O 
a O 
highly O 
conserved O 
polypeptide O 
of O 
76 O 
amino B-FAMILY 
acids I-FAMILY 
, O 
to O 
protein O 
substrates O 
. O 
This O 
process O 
is O 
catalyzed O 
by O 
3 O 
enzymes O 
acting O 
in O 
tandem O 
: O 
an O 
E1 O 
, O 
ubiquitin O 
- O 
activating O 
enzyme O 
; O 
an O 
E2 O 
, O 
ubiquitin O 
- O 
carrying O 
enzyme O 
; O 
and O 
an O 
E3 O 
, O 
ubiquitin O 
ligase O 
. O 
Ubiquitination O 
is O 
counteracted O 
by O 
deubiquitinating O 
enzymes O 
that O 
deconjugate O 
ubiquitin O 
- O 
modified O 
proteins O 
and O 
rescue O 
the O 
substrate O 
from O 
proteasomal O 
degradation O 
. O 
Although O 
ubiquitination O 
is O 
known O 
to O 
target O 
many O 
GPCRs O 
for O 
lysosomal O 
or O 
proteasomal O 
degradation O 
, O 
emerging O 
findings O 
define O 
novel O 
roles O 
for O 
the O 
basal O 
status O 
of O 
ubiquitination O 
and O 
for O 
rapid O 
deubiquitination O 
and O 
transubiquitination O 
controlling O 
cell O 
surface O 
expression O 
and O 
cellular O 
responsiveness O 
of O 
some O 
GPCRs O 
. O 
In O 
this O 
review O 
, O 
we O 
highlight O 
the O 
classical O 
and O 
novel O 
roles O 
of O 
ubiquitin O 
in O 
the O 
regulation O 
of O 
GPCR O 
function O 
, O 
signaling O 
, O 
and O 
trafficking O 
. O 

of O 
novel O 
bis-anthraquinone B-SYSTEMATIC 
derivatives O 
and O 
their O 
biological O 
evaluation O 
as O 
antitumor O 
agents O 
. O 

has O 
become O 
a O 
major O 
worldwide O 
problem O 
and O 
drug O 
resistance O 
now O 
is O 
one O 
of O 
the O 
most O 
important O 
problems O 
in O 
treatment O 
of O 
cancer O 
. O 
Anthraquinone B-SYSTEMATIC 
derivatives O 
represent O 
one O 
of O 
the O 
most O 
important O 
drugs O 
that O 
can O 
be O 
used O 
in O 
treatment O 
of O 
many O 
types O 
of O 
cancer O 
. O 
In O 
this O 
study O 
two O 
series O 
of O 
novel O 
bis-anthraquinone B-SYSTEMATIC 
derivatives O 
have O 
been O 
synthesized O 
. O 
Five O 
of O 
these O 
compounds O 
were O 
chosen O 
to O 
be O 
evaluated O 
for O 
their O 
antitumor O 
activity O 
against O 
human O 
cancer O 
cell O 
lines O 
by O 
the O 
National O 
Cancer O 
Institute O 
( O 
NCI O 
, O 
USA O 
) O 
. O 
Marked O 
activity O 
was O 
shown O 
for O 
the O 
tested O 
compounds(2-6) O 
. O 
The O 
most O 
active O 
one O 
was O 
compound O 
6 O 
with O 
mean O 
value O 
-67 O 
against O 
all O 
cell O 
lines O 
. O 
Compounds O 
7 O 
and O 
8 O 
were O 
found O 
inactive O 
. O 

drugs O 
commonly O 
used O 
in O 
triple O 
- O 
drug O 
therapy O 
for O 
treatment O 
of O 
a O 
Helicobacter O 
pylori O 
infection O 
, O 
clarithromycin B-TRIVIAL 
and O 
omeprazole B-TRIVIAL 
, O 
have O 
rarely O 
been O 
associated O 
with O 
hypoglycemia O 
when O 
given O 
alone O 
. O 
No O 
documented O 
interactions O 
between O 
H. O 
pylori O 
treatment O 
with O 
clarithromycin B-TRIVIAL 
, O 
amoxicillin B-TRIVIAL 
, O 
and O 
omeprazole B-TRIVIAL 
and O 
insulin O 
detemir O 
have O 
been O 
previously O 
reported O 
. O 
This O 
case O 
report O 
describes O 
an O 
82-year- O 
old O 
man O 
with O 
drug O 
- O 
controlled O 
type O 
2 O 
diabetes O 
who O 
experienced O 
severe O 
hypoglycemia O 
during O 
treatment O 
for O 
a O 
H. O 
pylori O 
infection O 
in O 
an O 
outpatient O 
setting O 
. O 
His O 
diabetes O 
treatment O 
included O 
32 O 
units O 
of O 
insulin O 
detemir O 
once O 
/ O 
day O 
at O 
bedtime O 
and O 
insulin O 
aspart O 
, O 
determined O 
by O 
carbohydrate B-FAMILY 
intake O 
, O 
3 O 
times O 
/ O 
day O 
with O 
meals O 
. O 
After O 
5 O 
days O 
of O 
clarithromycin B-TRIVIAL 
500 O 
mg O 
twice O 
/ O 
day O 
, O 
amoxicillin B-TRIVIAL 
500 O 
mg O 
twice O 
/ O 
day O 
, O 
and O 
omeprazole B-TRIVIAL 
20 O 
mg O 
twice O 
/ O 
day O 
for O 
treatment O 
of O 
the O 
H. O 
pylori O 
infection O 
, O 
the O 
patient O 
experienced O 
hypoglycemia O 
and O 
self O 
- O 
discontinued O 
clarithromycin B-TRIVIAL 
. O 
Insulin O 
detemir O 
was O 
decreased O 
to O 
15 O 
units O 
and O 
hypoglycemia O 
reoccurred O 
. O 
Insulin O 
detemir O 
was O 
further O 
decreased O 
to O 
10 O 
units O 
without O 
further O 
symptoms O 
of O 
hypoglycemia O 
for O 
the O 
remainder O 
of O 
the O 
H. O 
pylori O 
treatment O 
. O 
Once O 
treatment O 
was O 
completed O 
, O 
the O 
patient O 
was O 
instructed O 
to O 
resume O 
taking O 
32 O 
units O 
of O 
insulin O 
detemir O 
once O 
/ O 
day O 
. O 
His O 
blood O 
glucose B-TRIVIAL 
concentration O 
returned O 
to O 
a O 
baseline O 
value O 
, O 
and O 
he O 
denied O 
experiencing O 
further O 
hypoglycemic O 
episodes O 
. O 
Health O 
care O 
practitioners O 
should O 
be O 
aware O 
of O 
this O 
possible O 
drug O 
interaction O 
and O 
anticipate O 
that O 
insulin O 
detemir O 
dosage O 
adjustments O 
may O 
be O 
required O 
during O 
treatment O 
of O 
H. O 
pylori O 
infection O 
to O 
avoid O 
significant O 
adverse O 
events O 
. O 

of O 
nerve O 
growth O 
factor O 
( O 
NGF O 
) O 
signaling O 
by O 
the O 
p75 O 
neurotrophin O 
receptor O 
(p75(NTR)) O 
is O 
critical O 
for O 
neuronal O 
survival O 
and O 
differentiation O 
. O 
However O 
, O 
the O 
interaction O 
between O 
p75(NTR) O 
and O 
TrkA O 
receptors O 
required O 
for O 
this O 
activity O 
is O 
not O 
understood O 
. O 
Here O 
, O 
we O 
report O 
that O 
a O 
specific O 
29- O 
amino B-FAMILY 
acid I-FAMILY 
peptide O 
derived O 
from O 
the O 
intracellular O 
domain O 
fragment O 
of O 
p75(NTR) O 
interacts O 
with O 
and O 
potentiates O 
binding O 
of O 
NGF O 
to O 
TrkA-expressing O 
cells O 
, O 
leading O 
to O 
increased O 
neurite O 
outgrowth O 
in O 
sympathetic O 
neurons O 
as O 
a O 
result O 
of O 
enhanced O 
Erk1 O 
/ O 
2 O 
and O 
Akt O 
signaling O 
. O 
An O 
endogenous O 
intracellular O 
domain O 
fragment O 
of O 
p75(NTR) O 
(p75(ICD)) O 
containing O 
these O 
29 O 
amino B-FAMILY 
acids I-FAMILY 
is O 
produced O 
by O 
regulated O 
proteolysis O 
of O 
the O 
full O 
- O 
length O 
receptor O 
. O 
We O 
demonstrate O 
that O 
generation O 
of O 
this O 
fragment O 
is O 
a O 
requirement O 
for O 
p75(NTR) O 
to O 
facilitate O 
TrkA O 
signaling O 
in O 
neurons O 
and O 
propose O 
that O 
the O 
juxtamembrane O 
region O 
of O 
p75(ICD) O 
acts O 
to O 
cause O 
a O 
conformational O 
change O 
within O 
the O 
extracellular O 
domain O 
of O 
TrkA O 
. O 
This O 
finding O 
provides O 
new O 
insight O 
into O 
the O 
mechanism O 
by O 
which O 
p75(NTR) O 
and O 
TrkA O 
interact O 
to O 
enhance O 
neurotrophic O 
signaling O 
. O 

and O 
Si-H B-FORMULA 
Bond O 
Addition O 
to O 
Fe≡NNR2 B-FAMILY 
Intermediates O 
Derived O 
from O 
N2 B-FORMULA 
. O 

synthesis O 
and O 
characterization O 
of O 
Fe-diphosphineborane B-SYSTEMATIC 
complexes O 
are O 
described O 
in O 
the O 
context O 
of O 
N2 B-FORMULA 
functionalization O 
chemistry O 
. O 
Iron B-FAMILY 
aminoimides I-FAMILY 
can O 
be O 
generated O 
at O 
room O 
temperature O 
under O 
1 O 
atm O 
N2 B-FORMULA 
and O 
are O 
shown O 
to O 
react O 
with O 
E-H B-FAMILY 
bonds O 
from O 
PhSiH3 B-FORMULA 
and O 
H2 B-FORMULA 
. O 
The O 
resulting O 
products O 
derive O 
from O 
delivery O 
of O 
the O 
E O 
fragment O 
to O 
Nα O 
and O 
the O 
H B-FORMULA 
atom O 
to O 
B B-FORMULA 
. O 
The O 
flexibility O 
and O 
lability O 
of O 
the O 
Fe-BPh B-FORMULA 
interactions O 
in O 
these O 
complexes O 
engender O 
this O 
reactivity O 
. O 

curing O 
( O 
photopolymerization O 
) O 
is O 
ubiquitous O 
in O 
many O 
facets O 
of O 
industry O 
ranging O 
from O 
the O 
application O 
of O 
paints O 
, O 
pigments O 
, O 
and O 
barrier O 
coatings O 
all O 
the O 
way O 
to O 
fiber O 
optic O 
cable O 
production O 
. O 
To O 
date O 
no O 
reports O 
have O 
focused O 
on O 
polymerizable O 
phosphonium O 
salts O 
under O 
UV O 
irradiation O 
, O 
and O 
despite O 
this O 
dearth O 
of O 
examples O 
, O 
they O 
potentially O 
offer O 
numerous O 
substantial O 
advantages O 
to O 
traditional O 
UV O 
formulation O 
components O 
. O 
We O 
have O 
generated O 
a O 
highly O 
novel O 
coating O 
based O 
on O 
UV-curable O 
trialkylacryloylphosphonium B-FAMILY 
salts I-FAMILY 
that O 
allow O 
for O 
the O 
fast O 
( O 
seconds O 
) O 
and O 
straightforward O 
preparation O 
of O 
ion O 
- O 
exchange O 
surfaces O 
amenable O 
to O 
a O 
roll O 
- O 
to O 
- O 
roll O 
process O 
. O 
We O 
have O 
quantified O 
the O 
surface O 
charges O 
and O 
exploited O 
their O 
accessibility O 
by O 
employing O 
these O 
surfaces O 
in O 
an O 
anion O 
exchange O 
experiment O 
by O 
which O 
[Au25L18](-) B-FORMULA 
( O 
L O 
= O 
SCH2CH2Ph B-FORMULA 
) O 
nanocrystals O 
can O 
be O 
assembled O 
into O 
the O 
solid O 
state O 
. O 
This O 
unprecedented O 
application O 
of O 
such O 
surfaces O 
offers O 
a O 
paradigm O 
shift O 
in O 
the O 
emerging O 
chemistry O 
of O 
Au25 B-FORMULA 
research O 
where O 
the O 
nanocrystals O 
remain O 
single O 
and O 
intact O 
and O 
where O 
the O 
integrity O 
of O 
the O 
cluster O 
and O 
its O 
solution O 
photophysical O 
properties O 
are O 
resilient O 
in O 
the O 
solid O 
state O 
. O 
The O 
specific O 
loading O 
of O 
[Au25L18](-) B-FORMULA 
on O 
the O 
substrates O 
has O 
been O 
determined O 
and O 
the O 
completely O 
reversible O 
loading O 
and O 
unloading O 
of O 
intact O 
nanocrystals O 
to O 
and O 
from O 
the O 
surface O 
has O 
been O 
established O 
. O 
In O 
the O 
solid O 
state O 
, O 
the O 
assembly O 
has O 
an O 
incredible O 
mechanical O 
resiliency O 
, O 
where O 
the O 
surface O 
remains O 
undamaged O 
even O 
when O 
subjected O 
to O 
repeated O 
Scotch O 
tests O 
. O 

The O 
antioxidant O 
and O 
cytotoxic O 
activities O 
and O 
the O 
polyphenolic B-FAMILY 
and O 
anthocyanin B-FAMILY 
contents O 
of O 
tomato O 
hybrid O 
powders O 
were O 
studied O 
. O 
Tomato O 
powders O 
were O 
obtained O 
, O 
starting O 
from O 
the O 
fresh O 
fruits O 
that O 
had O 
undergone O 
an O 
industrial O 
process O 
of O 
drying O 
and O 
pulverization O 
at O 
two O 
different O 
temperatures O 
. O 
Antioxidant O 
activities O 
were O 
evaluated O 
in O 
different O 
extracts O 
by O 
using O 
spectrophotometric O 
assays O 
: O 
2,2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
N,N-dimethyl-p-phenylenediamine B-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
cation O 
radical O 
inhibition O 
for O 
lipophilic O 
and O 
hydrophilic O 
extracts O 
, O 
respectively O 
, O 
and O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
radical O 
scavenging O 
assay O 
for O 
polyphenolic B-FAMILY 
extracts O 
. O 
Moreover O 
, O 
polyphenolic B-FAMILY 
and O 
anthocyanin B-FAMILY 
contents O 
were O 
also O 
carried O 
out O 
to O 
detect O 
the O 
presence O 
of O 
these O 
bioactive O 
compounds O 
. O 
The O 
effect O 
of O 
cytotoxic O 
activity O 
in O 
vitro O 
of O 
tomato O 
hybrid O 
powder O 
extracts O 
on O 
T47D O 
( O 
human O 
breast O 
carcinoma O 
) O 
cells O 
was O 
also O 
evaluated O 
. O 
Results O 
showed O 
good O 
antioxidant O 
activities O 
in O 
lipophilic O 
, O 
polyphenolic B-FAMILY 
, O 
and O 
hydrophilic O 
extracts O 
of O 
samples O 
that O 
were O 
obtained O 
at O 
a O 
lower O 
temperature O 
. O 
Extracts O 
of O 
the O 
sample O 
obtained O 
at O 
a O 
higher O 
temperature O 
presented O 
moderate O 
antioxidant O 
activity O 
, O 
lower O 
than O 
the O 
extracts O 
of O 
other O 
samples O 
, O 
which O 
was O 
probably O 
due O 
to O 
the O 
loss O 
of O 
labile O 
antioxidant O 
compounds O 
during O 
the O 
industrial O 
process O 
. O 
Very O 
interesting O 
was O 
the O 
presence O 
of O 
anthocyanins B-FAMILY 
in O 
both O 
samples O 
, O 
even O 
if O 
in O 
traces O 
, O 
and O 
also O 
a O 
moderate O 
cytotoxicity O 
of O 
a O 
lipophilic O 
extract O 
on O 
T47D O 
cells O 
. O 
Therefore O 
, O 
tomato O 
hybrid O 
powders O 
, O 
on O 
the O 
basis O 
of O 
their O 
multifunctional O 
properties O 
, O 
could O 
have O 
a O 
biotechnological O 
application O 
in O 
agri O 
- O 
food O 
or O 
cosmetic O 
industries O 
as O 
an O 
additive O 
for O 
improving O 
nutritional O 
and O 
/ O 
or O 
bioactive O 
qualities O 
of O 
commercial O 
products O 
used O 
in O 
daily O 
nutrition O 
and O 
cosmetics O 
. O 

cluster O 
formation O 
of O 
au B-FORMULA 
nanoparticles O 
from O 
colloidal O 
solution O 
. O 

clusters O 
of O 
closely O 
spaced O 
Au B-FORMULA 
nanoparticles O 
can O 
be O 
utilized O 
in O 
devices O 
from O 
photovoltaics O 
to O 
molecular O 
sensors O 
because O 
of O 
the O 
formation O 
of O 
strong O 
local O 
electromagnetic O 
field O 
enhancements O 
when O 
illuminated O 
near O 
their O 
plasmon O 
resonance O 
. O 
In O 
this O 
study O 
, O 
scalable O 
, O 
chemical O 
self O 
- O 
organization O 
methods O 
are O 
shown O 
to O 
produce O 
Au B-FORMULA 
nanoparticle O 
clusters O 
with O 
uniform O 
nanometer O 
interparticle O 
spacing O 
. O 
The O 
performance O 
of O 
two O 
different O 
methods O 
, O 
namely O 
electrophoresis O 
and O 
diffusion O 
, O 
for O 
driving O 
the O 
attachment O 
of O 
Au B-FORMULA 
nanoparticles O 
using O 
a O 
chemical O 
cross O 
- O 
linker O 
on O 
chemically O 
patterned O 
domains O 
of O 
polystyrene B-SYSTEMATIC 
-block- O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PS-b- O 
PMMA B-ABBREVIATION 
) O 
thin O 
films O 
are O 
evaluated O 
. O 
Significantly O 
, O 
electrophoresis O 
is O 
found O 
to O 
produce O 
similar O 
surface O 
coverage O 
as O 
diffusion O 
in O 
1 O 
/ O 
6th O 
of O 
the O 
processing O 
time O 
with O 
an O 
∼2-fold O 
increase O 
in O 
the O 
number O 
of O 
Au B-FORMULA 
nanoparticles O 
forming O 
clusters O 
. O 
Furthermore O 
, O 
average O 
interparticle O 
spacing O 
within O 
Au B-FORMULA 
nanoparticle O 
clusters O 
was O 
found O 
to O 
decrease O 
from O 
2-7 O 
nm O 
for O 
diffusion O 
deposition O 
to O 
approximately O 
1-2 O 
nm O 
for O 
electrophoresis O 
deposition O 
, O 
and O 
the O 
latter O 
method O 
exhibited O 
better O 
uniformity O 
with O 
most O 
clusters O 
appearing O 
to O 
have O 
about O 
1 O 
nm O 
spacing O 
between O 
nanoparticles O 
. O 
The O 
advantage O 
of O 
such O 
fabrication O 
capability O 
is O 
supported O 
by O 
calculations O 
of O 
local O 
electric O 
field O 
enhancements O 
using O 
electromagnetic O 
full O 
- O 
wave O 
simulations O 
from O 
which O 
we O 
can O 
estimate O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
enhancements O 
. O 
In O 
particular O 
, O 
full O 
- O 
wave O 
results O 
show O 
that O 
the O 
maximum O 
SERS O 
enhancement O 
, O 
as O 
estimated O 
here O 
as O 
the O 
fourth O 
power O 
of O 
the O 
local O 
electric O 
field O 
, O 
increases O 
by O 
a O 
factor O 
of O 
100 O 
when O 
the O 
gap O 
goes O 
from O 
2 O 
to O 
1 O 
nm O 
, O 
reaching O 
values O 
as O 
large O 
as O 
10(10) O 
, O 
strengthening O 
the O 
usage O 
of O 
electrophoresis O 
versus O 
diffusion O 
for O 
the O 
development O 
of O 
molecular O 
sensors O 
. O 

of O 
Hydrophobic O 
Drugs O 
in O 
Pluronic B-TRIVIAL 
F127 I-TRIVIAL 
Micelles O 
: O 
Effects O 
of O 
Drug O 
Hydrophobicity O 
, O 
Solution O 
Temperature O 
, O 
and O 
pH O 
. O 

drugs O 
, O 
ibuprofen B-TRIVIAL 
, O 
aspirin B-TRIVIAL 
, O 
and O 
erythromycin B-TRIVIAL 
, O 
are O 
encapsulated O 
in O 
spherical O 
Pluronic B-TRIVIAL 
F127 I-TRIVIAL 
micelles O 
. O 
The O 
shapes O 
and O 
the O 
size O 
distributions O 
of O 
the O 
micelles O 
in O 
dilute O 
, O 
aqueous O 
solutions O 
, O 
with O 
and O 
without O 
drugs O 
, O 
are O 
ascertained O 
using O 
cryo O 
- O 
scanning O 
electron O 
microscopy O 
and O 
dynamic O 
light O 
scattering O 
( O 
DLS O 
) O 
experiments O 
, O 
respectively O 
. O 
Uptake O 
of O 
drugs O 
above O 
a O 
threshold O 
concentration O 
is O 
seen O 
to O 
reduce O 
the O 
critical O 
micellization O 
temperature O 
of O 
the O 
solution O 
. O 
The O 
mean O 
hydrodynamic O 
radii O 
and O 
polydispersities O 
of O 
the O 
micelles O 
are O 
found O 
to O 
increase O 
with O 
decrease O 
in O 
temperature O 
and O 
in O 
the O 
presence O 
of O 
drug O 
molecules O 
. O 
The O 
hydration O 
of O 
the O 
micellar O 
core O 
at O 
lower O 
temperatures O 
is O 
verified O 
using O 
fluorescence O 
measurements O 
. O 
Increasing O 
solution O 
pH O 
leads O 
to O 
the O 
ionization O 
of O 
the O 
drugs O 
incorporated O 
in O 
the O 
micellar O 
cores O 
. O 
This O 
causes O 
rupture O 
of O 
the O 
micelles O 
and O 
release O 
of O 
the O 
drugs O 
into O 
the O 
solution O 
at O 
the O 
highest O 
solution O 
pH O 
value O 
of O 
11.36 O 
investigated O 
here O 
and O 
is O 
studied O 
using O 
DLS O 
and O 
fluorescence O 
spectrocopy O 
. O 

, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
indenoisoquinoline B-FAMILY 
rexinoids I-FAMILY 
with O 
chemopreventive O 
potential O 
. O 

receptors O 
, O 
such O 
as O 
the O 
retinoid O 
X O 
receptor O 
( O 
RXR O 
) O 
, O 
are O 
proteins O 
that O 
regulate O 
a O 
myriad O 
of O 
cellular O 
processes O 
. O 
Molecules O 
that O 
function O 
as O 
RXR O 
agonists O 
are O 
of O 
special O 
interest O 
for O 
the O 
prevention O 
and O 
control O 
of O 
carcinogenesis O 
. O 
The O 
majority O 
of O 
these O 
ligands O 
possess O 
an O 
acidic O 
moiety O 
that O 
is O 
believed O 
to O 
be O 
key O 
for O 
RXR O 
activation O 
. O 
This O 
communication O 
presents O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
both O 
acidic O 
and O 
nonacidic O 
indenoisoquinolines B-FAMILY 
as O 
new O 
RXR O 
ligands O 
. O 
In O 
addition O 
, O 
a O 
comprehensive O 
structure O 
- O 
activity O 
relationship O 
study O 
is O 
presented O 
that O 
identifies O 
the O 
important O 
features O 
of O 
the O 
indenoisoquinoline B-FAMILY 
rexinoids I-FAMILY 
. O 
The O 
ease O 
of O 
modification O 
of O 
the O 
indenoisoquinoline B-SYSTEMATIC 
core O 
and O 
the O 
lack O 
of O 
the O 
necessity O 
of O 
a O 
carboxyl B-SYSTEMATIC 
group O 
for O 
activity O 
make O 
them O 
an O 
attractive O 
and O 
unusual O 
family O 
of O 
RXR O 
agonists O 
. O 
This O 
work O 
establishes O 
a O 
structural O 
foundation O 
for O 
the O 
design O 
of O 
new O 
and O 
novel O 
rexinoid O 
cancer O 
chemopreventive O 
agents O 
. O 

film O 
assemblies O 
as O 
platforms O 
for O 
electrochemical O 
biosensing O 
- O 
factors O 
affecting O 
the O 
amperometric O 
signal O 
enhancement O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
. O 

affecting O 
the O 
enhanced O 
amperometric O 
signal O 
observed O 
at O 
electrodes O 
modified O 
with O 
polyelectrolyte O 
- O 
gold O 
nanoparticle O 
( O 
Au B-FORMULA 
-NP O 
) O 
composite O 
films O 
, O 
which O 
are O 
potential O 
interfaces O 
for O 
first O 
- O 
generation O 
biosensors O 
, O 
were O 
systematically O 
investigated O 
and O 
optimized O 
for O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
detection O 
. O 
Polyelectrolyte O 
multilayer O 
films O 
embedded O 
with O 
citrate B-FAMILY 
-stabilized O 
gold O 
nanoparticles O 
exhibited O 
high O 
sensitivity O 
toward O 
the O 
oxidation O 
of O 
H2O2 B-FORMULA 
. O 
From O 
this O 
Au B-FORMULA 
-NP O 
film O 
assembly O 
, O 
the O 
importance O 
of O 
Au B-FORMULA 
-NP O 
ligand O 
protection O 
, O 
film O 
permeability O 
, O 
the O 
density O 
of O 
Au B-FORMULA 
-NPs O 
within O 
the O 
film O 
, O 
and O 
electronic O 
coupling O 
between O 
Au B-FORMULA 
-NPs O 
( O 
interparticle O 
) O 
and O 
between O 
the O 
film O 
and O 
the O 
electrode O 
( O 
interfacial O 
) O 
were O 
evaluated O 
. O 
Using O 
alternative O 
Au B-FORMULA 
-NPs O 
, O 
including O 
those O 
stabilized O 
with O 
thiols B-FAMILY 
, O 
polymers O 
, O 
and O 
bulky O 
ligands O 
, O 
suggests O 
that O 
the O 
amperometric O 
enhancement O 
of O 
H2O2 B-FORMULA 
is O 
optimized O 
at O 
poly-l-lysine B-SYSTEMATIC 
-linked O 
film O 
assemblies O 
embedded O 
with O 
Au B-FORMULA 
-NPs O 
possessing O 
small O 
, O 
charged O 
, O 
and O 
conductive O 
( O 
conjugated O 
) O 
peripheral O 
ligands O 
. O 
As O 
a O 
potential O 
application O 
of O 
these O 
Au B-FORMULA 
-NP O 
film O 
assemblies O 
, O 
an O 
enhanced O 
amperometric O 
signal O 
for O 
H2O2 B-FORMULA 
oxidation O 
was O 
shown O 
for O 
modified O 
" O 
needle O 
" O 
electrodes O 
. O 
The O 
overall O 
aim O 
of O 
this O 
research O 
is O 
to O 
gain O 
a O 
greater O 
understanding O 
of O 
designing O 
electrochemical O 
sensing O 
strategies O 
that O 
incorporate O 
Au B-FORMULA 
-NPs O 
and O 
target O 
specific O 
analytes O 
. O 

and O 
diabetes O 
risk O 
. O 

overload O 
is O 
a O 
risk O 
factor O 
for O 
diabetes O 
. O 
The O 
link O 
between O 
iron B-SYSTEMATIC 
and O 
diabetes O 
was O 
first O 
recognized O 
in O 
pathologic O 
conditions O 
- O 
hereditary O 
hemochromatosis O 
and O 
thalassemia O 
- O 
but O 
high O 
levels O 
of O 
dietary O 
iron B-SYSTEMATIC 
also O 
impart O 
diabetes O 
risk O 
. O 
Iron B-SYSTEMATIC 
plays O 
a O 
direct O 
and O 
causal O 
role O 
in O 
diabetes O 
pathogenesis O 
mediated O 
both O 
by O 
β O 
cell O 
failure O 
and O 
insulin O 
resistance O 
. O 
Iron B-SYSTEMATIC 
also O 
regulates O 
metabolism O 
in O 
most O 
tissues O 
involved O 
in O 
fuel O 
homeostasis O 
, O 
with O 
the O 
adipocyte O 
in O 
particular O 
serving O 
an O 
iron B-SYSTEMATIC 
-sensing O 
role O 
. O 
The O 
underlying O 
molecular O 
mechanisms O 
mediating O 
these O 
effects O 
are O 
numerous O 
and O 
incompletely O 
understood O 
but O 
include O 
oxidant O 
stress O 
and O 
modulation O 
of O 
adipokines O 
and O 
intracellular O 
signal O 
transduction O 
pathways O 
. O 

1 O 
diabetes O 
is O 
caused O 
by O 
autoimmune O 
- O 
mediated O 
β O 
cell O 
destruction O 
leading O 
to O 
insulin O 
deficiency O 
. O 
The O 
histone O 
deacetylase O 
SIRT1 O 
plays O 
an O 
essential O 
role O 
in O 
modulating O 
several O 
age O 
- O 
related O 
diseases O 
. O 
Here O 
we O 
describe O 
a O 
family O 
carrying O 
a O 
mutation O 
in O 
the O 
SIRT1 O 
gene O 
, O 
in O 
which O 
all O 
five O 
affected O 
members O 
developed O 
an O 
autoimmune O 
disorder O 
: O 
four O 
developed O 
type O 
1 O 
diabetes O 
, O 
and O 
one O 
developed O 
ulcerative O 
colitis O 
. O 
Initially O 
, O 
a O 
26-year- O 
old O 
man O 
was O 
diagnosed O 
with O 
the O 
typical O 
features O 
of O 
type O 
1 O 
diabetes O 
, O 
including O 
lean O 
body O 
mass O 
, O 
autoantibodies O 
, O 
T O 
cell O 
reactivity O 
to O 
β O 
cell O 
antigens O 
, O 
and O 
a O 
rapid O 
dependence O 
on O 
insulin O 
. O 
Direct O 
and O 
exome O 
sequencing O 
identified O 
the O 
presence O 
of O 
a O 
T-to-C O 
exchange O 
in O 
exon O 
1 O 
of O 
SIRT1 O 
, O 
corresponding O 
to O 
a O 
leucine B-TRIVIAL 
-to- O 
proline B-TRIVIAL 
mutation O 
at O 
residue O 
107 O 
. O 
Expression O 
of O 
SIRT1-L107P O 
in O 
insulin O 
- O 
producing O 
cells O 
resulted O 
in O 
overproduction O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
cytokines O 
, O 
and O 
chemokines O 
. O 
These O 
observations O 
identify O 
a O 
role O 
for O 
SIRT1 O 
in O 
human O 
autoimmunity O 
and O 
unveil O 
a O 
monogenic O 
form O 
of O 
type O 
1 O 
diabetes O 
. O 

iron B-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
-based O 
nanoparticles O 
as O 
enhanced O 
t1 O 
contrast O 
agents O 
for O 
efficient O 
tumor O 
imaging O 
. O 

report O 
the O 
design O 
and O 
synthesis O 
of O 
small O 
- O 
sized O 
zwitterion O 
- O 
coated O 
gadolinium B-SYSTEMATIC 
-embedded O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
GdIO B-FORMULA 
) O 
nanoparticles O 
, O 
which O 
exhibit O 
a O 
strong O 
T1 O 
contrast O 
effect O 
for O 
tumor O 
imaging O 
through O 
enhanced O 
permeation O 
and O 
retention O 
effect O 
and O 
the O 
ability O 
to O 
clear O 
out O 
of O 
the O 
body O 
in O 
living O 
subjects O 
. O 
The O 
combination O 
of O 
spin O 
- O 
canting O 
effects O 
and O 
the O 
collection O 
of O 
gadolinium B-SYSTEMATIC 
species O 
within O 
small O 
- O 
sized O 
GdIO B-FORMULA 
nanoparticles O 
led O 
to O 
a O 
significantly O 
enhanced O 
T1 O 
contrast O 
effect O 
. O 
For O 
example O 
, O 
GdIO B-FORMULA 
nanoparticles O 
with O 
a O 
diameter O 
of O 
∼4.8 O 
nm O 
exhibited O 
a O 
high O 
r1 O 
relaxivity O 
of O 
7.85 O 
mM(-1)·S(-1) O 
and O 
a O 
low O 
r2 O 
/ O 
r1 O 
ratio O 
of O 
5.24 O 
. O 
After O 
being O 
coated O 
with O 
zwitterionic O 
dopamine B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
molecules O 
, O 
the O 
4.8 O 
nm O 
GdIO B-FORMULA 
nanoparticles O 
showed O 
a O 
steady O 
hydrodynamic O 
diameter O 
( O 
∼5.2 O 
nm O 
) O 
in O 
both O 
PBS O 
buffer O 
and O 
fetal O 
bovine O 
serum O 
solution O 
, O 
indicating O 
a O 
low O 
nonspecific O 
protein O 
absorption O 
. O 
This O 
study O 
provides O 
a O 
valuable O 
strategy O 
for O 
the O 
design O 
of O 
highly O 
sensitive O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
-based O 
T1 O 
contrast O 
agents O 
with O 
relatively O 
long O 
circulation O 
half O 
- O 
lives O 
( O 
∼50 O 
min O 
) O 
, O 
efficient O 
tumor O 
passive O 
targeting O 
( O 
SKOV3 O 
, O 
human O 
ovarian O 
cancer O 
xenograft O 
tumor O 
as O 
a O 
model O 
) O 
, O 
and O 
the O 
possibility O 
of O 
rapid O 
renal O 
clearance O 
after O 
tumor O 
imaging O 
. O 

on O 
glutamate B-TRIVIAL 
binding O 
in O 
channel O 
- O 
gated O 
receptors O 
. O 

this O 
issue O 
of O 
Structure O 
, O 
Lomash O 
and O 
colleagues O 
report O 
on O 
the O 
crystal O 
structure O 
and O 
ligand O 
binding O 
properties O 
of O 
a O 
primitive O 
eukaryote O 
glutamate B-TRIVIAL 
-gated O 
ion O 
channel O 
: O 
AvGluR1 O 
. O 

of O 
MAC13243 B-IDENTIFIER 
and O 
studies O 
of O 
the O 
interaction O 
of O 
resulting O 
thiourea B-SYSTEMATIC 
compounds O 
with O 
the O 
lipoprotein O 
targeting O 
chaperone O 
LolA O 
. O 

discovery O 
of O 
novel O 
small O 
molecules O 
that O 
function O 
as O 
antibacterial O 
agents O 
or O 
cellular O 
probes O 
of O 
biology O 
is O 
hindered O 
by O 
our O 
limited O 
understanding O 
of O 
bacterial O 
physiology O 
and O 
our O 
ability O 
to O 
assign O 
mechanism O 
of O 
action O 
. O 
We O 
previously O 
employed O 
a O 
chemical O 
genomic O 
strategy O 
to O 
identify O 
a O 
novel O 
small O 
molecule O 
, O 
MAC13243 B-IDENTIFIER 
, O 
as O 
a O 
likely O 
inhibitor O 
of O 
the O 
bacterial O 
lipoprotein O 
targeting O 
chaperone O 
, O 
LolA O 
. O 
Here O 
, O 
we O 
report O 
on O 
the O 
degradation O 
of O 
MAC13243 B-IDENTIFIER 
into O 
the O 
active O 
species O 
, O 
S-(4-chlorobenzyl)isothiourea B-SYSTEMATIC 
. O 
Analogs O 
of O 
this O 
compound O 
( O 
e.g O 
. O 
, O 
A22 O 
) O 
have O 
previously O 
been O 
characterized O 
as O 
inhibitors O 
of O 
the O 
bacterial O 
actin O 
- O 
like O 
protein O 
, O 
MreB O 
. O 
Herein O 
, O 
we O 
demonstrate O 
that O 
the O 
antibacterial O 
activity O 
of O 
MAC13243 B-IDENTIFIER 
and O 
the O 
thiourea B-SYSTEMATIC 
compounds O 
are O 
similar O 
; O 
these O 
activities O 
are O 
suppressed O 
or O 
sensitized O 
in O 
response O 
to O 
increases O 
or O 
decreases O 
of O 
LolA O 
copy O 
number O 
, O 
respectively O 
. O 
We O 
provide O 
STD O 
NMR O 
data O 
which O 
confirms O 
a O 
physical O 
interaction O 
between O 
LolA O 
and O 
the O 
thiourea B-SYSTEMATIC 
degradation O 
product O 
of O 
MAC13243 B-IDENTIFIER 
, O 
with O 
a O 
Kd O 
of O 
~150 O 
μM O 
. O 
Taken O 
together O 
, O 
we O 
conclude O 
that O 
the O 
thiourea B-SYSTEMATIC 
series O 
of O 
compounds O 
share O 
a O 
similar O 
cellular O 
mechanism O 
that O 
includes O 
interaction O 
with O 
LolA O 
in O 
addition O 
to O 
the O 
well O 
- O 
characterized O 
target O 
MreB O 
. O 

inhibits O 
platelet O 
activation O 
ex O 
vivo O 
and O 
thrombus O 
formation O 
in O 
vivo O 
. O 

is O 
a O 
tropolone O 
- O 
related O 
bioactive O 
compound O 
that O 
has O 
been O 
used O 
in O 
hair O 
tonics O 
, O 
cosmetics O 
, O 
and O 
food O 
as O 
an O 
antimicrobial O 
agent O 
. O 
Recently O 
, O 
hinokitiol B-TRIVIAL 
has O 
attracted O 
considerable O 
interest O 
because O 
of O 
its O 
anticancer O 
activities O 
. O 
Platelet O 
activation O 
plays O 
a O 
crucial O 
role O 
in O 
atherothrombotic O 
processes O 
. O 
We O 
examined O 
the O 
effects O 
of O 
hinokitiol B-TRIVIAL 
treatment O 
on O 
platelet O 
activation O 
using O 
human O 
platelets O 
. O 
In O 
the O 
present O 
study O 
, O 
hinokitiol B-TRIVIAL 
( O 
1 O 
and O 
2μM O 
) O 
inhibited O 
the O 
collagen O 
- O 
induced O 
aggregation O 
of O 
human O 
platelets O 
, O 
but O 
did O 
not O 
inhibit O 
the O 
activation O 
of O 
platelets O 
by O 
other O 
agonists O 
, O 
including O 
thrombin O 
, O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
, O 
and O 
ADP B-ABBREVIATION 
. O 
Hinokitiol B-TRIVIAL 
inhibited O 
the O 
phosphorylation O 
of O 
phospholipase O 
C O 
(PLC)γ2 O 
, O 
protein O 
kinase O 
C O 
( O 
PKC O 
) O 
, O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
, O 
and O 
Akt O 
in O 
collagen O 
- O 
activated O 
human O 
platelets O 
, O 
and O 
significantly O 
reduced O 
intracellular O 
calcium B-SYSTEMATIC 
mobilization O 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
( O 
OH B-FORMULA 
) O 
formation O 
. O 
Hinokitiol B-TRIVIAL 
also O 
reduced O 
the O 
PKC O 
activation O 
and O 
platelet O 
aggregation O 
stimulated O 
by O 
PDBu O 
. O 
In O 
addition O 
, O 
hinokitiol B-TRIVIAL 
significantly O 
prolonged O 
thrombogenesis O 
in O 
mice O 
. O 
Hinokitiol B-TRIVIAL 
did O 
not O 
influence O 
the O 
binding O 
of O 
a O 
fluorescent O 
triflavin O 
probe O 
to O 
the O 
αIIbβ3 O 
integrin O 
on O 
platelet O 
membrane O 
, O 
and O 
neither O 
ODQ B-ABBREVIATION 
nor O 
SQ22536 B-IDENTIFIER 
significantly O 
reversed O 
the O 
hinokitiol B-TRIVIAL 
-mediated O 
inhibition O 
of O 
platelet O 
aggregation O 
. O 
In O 
conclusion O 
, O 
hinokitiol B-TRIVIAL 
may O 
inhibit O 
platelet O 
activation O 
by O 
inhibiting O 
the O 
PLCγ2-PKC O 
cascade O 
and O 
hydroxyl B-SYSTEMATIC 
radical O 
formation O 
, O 
followed O 
by O 
suppressing O 
the O 
activation O 
of O 
MAPKs O 
and O 
Akt O 
. O 
Our O 
study O 
suggests O 
that O 
hinokitiol B-TRIVIAL 
may O 
represent O 
a O 
potential O 
therapeutic O 
agent O 
for O 
the O 
prevention O 
or O 
treatment O 
of O 
thromboembolic O 
disorders O 
. O 

of O 
the O 
most O 
potent O 
insecticidal O 
venom O 
peptides O 
described O 
to O 
date O 
is O 
Aps O 
III O 
from O 
the O 
venom O 
of O 
the O 
trapdoor O 
spider O 
Apomastus O 
schlingeri O 
. O 
Aps O 
III O 
is O 
highly O 
neurotoxic O 
to O 
lepidopteran O 
crop O 
pests O 
, O 
making O 
it O 
a O 
promising O 
candidate O 
for O 
bioinsecticide O 
development O 
. O 
However O 
, O 
its O 
disulfide B-SYSTEMATIC 
-connectivity O 
, O 
three O 
- O 
dimensional O 
structure O 
, O 
and O 
mode O 
of O 
action O 
have O 
not O 
been O 
determined O 
. O 
Here O 
we O 
show O 
that O 
recombinant O 
Aps O 
III O 
( O 
rAps O 
III O 
) O 
is O 
an O 
atypical O 
knottin O 
peptide O 
; O 
three O 
of O 
the O 
disulfide B-SYSTEMATIC 
bridges O 
form O 
a O 
classical O 
inhibitor O 
cystine B-TRIVIAL 
knot O 
motif O 
while O 
the O 
fourth O 
disulfide B-SYSTEMATIC 
acts O 
as O 
a O 
molecular O 
staple O 
that O 
restricts O 
the O 
flexibility O 
of O 
an O 
unusually O 
large O 
β O 
hairpin O 
loop O 
that O 
often O 
houses O 
the O 
pharmacophore O 
in O 
this O 
class O 
of O 
toxins O 
. O 
We O 
demonstrate O 
that O 
the O 
irreversible O 
paralysis O 
induced O 
in O 
insects O 
by O 
rAps O 
III O 
results O 
from O 
a O 
potent O 
block O 
of O 
insect O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
channels O 
. O 
Channel O 
block O 
by O 
rAps O 
III O 
is O 
voltage O 
- O 
independent O 
insofar O 
as O 
it O 
occurs O 
without O 
significant O 
alteration O 
in O 
the O 
voltage O 
- O 
dependence O 
of O 
channel O 
activation O 
or O 
steady O 
- O 
state O 
inactivation O 
. O 
Thus O 
, O 
rAps O 
III O 
appears O 
to O 
be O 
a O 
pore O 
blocker O 
that O 
plugs O 
the O 
outer O 
vestibule O 
of O 
insect O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
channels O 
. O 
This O 
mechanism O 
of O 
action O 
contrasts O 
strikingly O 
with O 
virtually O 
all O 
other O 
sodium B-SYSTEMATIC 
channel O 
modulators O 
isolated O 
from O 
spider O 
venoms O 
that O 
act O 
as O 
gating O 
modifiers O 
by O 
interacting O 
with O 
one O 
or O 
more O 
of O 
the O 
four O 
voltage O 
- O 
sensing O 
domains O 
of O 
the O 
channel O 
. O 

of O 
correlation O 
between O 
oxysterol B-FAMILY 
accumulation O 
in O 
lipid O 
raft O 
microdomains O 
, O 
calcium B-SYSTEMATIC 
increase O 
, O 
and O 
apoptosis O 
induction O 
on O 
158N O 
murine O 
oligodendrocytes O 
. O 

is O 
some O 
evidence O 
that O 
oxidized O 
derivatives O 
of O 
cholesterol B-TRIVIAL 
, O 
7-ketocholesterol B-SYSTEMATIC 
( O 
7KC B-SYSTEMATIC 
) O 
and O 
7β-hydroxycholesterol B-SYSTEMATIC 
( O 
7βOHC B-SYSTEMATIC 
) O 
, O 
are O 
increased O 
in O 
the O 
plasma O 
of O 
patients O 
with O 
neurodegenerative O 
diseases O 
associated O 
with O 
demyelinization O 
of O 
the O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
. O 
It O 
was O 
therefore O 
of O 
interest O 
to O 
investigate O 
the O 
effects O 
of O 
these O 
oxysterols B-FAMILY 
on O 
oligodendrocytes O 
, O 
the O 
myelin O 
- O 
forming O 
cells O 
in O 
the O 
CNS O 
. O 
To O 
this O 
end O 
, O 
158N O 
murine O 
oligodendrocytes O 
were O 
treated O 
with O 
7KC B-SYSTEMATIC 
or O 
7βOHC B-SYSTEMATIC 
inducing O 
an O 
apoptotic O 
mode O 
of O 
cell O 
death O 
characterized O 
by O 
condensation O 
/ O 
fragmentation O 
of O 
the O 
nuclei O 
, O 
dephosphorylation O 
of O 
Akt O 
and O 
GSK3 O 
, O 
mitochondrial O 
depolarization O 
involving O 
Mcl-1 O 
, O 
and O 
caspase-3 O 
activation O 
. O 
In O 
contrast O 
, O 
under O 
treatment O 
with O 
27-hydroxycholesterol B-SYSTEMATIC 
( O 
27OHC O 
) O 
, O 
no O 
cell O 
death O 
was O 
observed O 
. O 
When O 
the O 
cells O 
were O 
stained O 
with O 
Fura-2 B-TRIVIAL 
, O 
no O 
significant O 
Ca(2+) B-FORMULA 
rise O 
was O 
found O 
with O 
the O 
different O 
oxysterols B-FAMILY 
, O 
whereas O 
strong O 
signals O 
were O 
detected O 
with O 
ionomycin B-TRIVIAL 
used O 
as O 
positive O 
control O 
. O 
At O 
concentrations O 
which O 
induced O 
apoptosis O 
, O 
7KC B-SYSTEMATIC 
but O 
not O 
7βOHC B-SYSTEMATIC 
accumulated O 
in O 
lipid O 
rafts O 
. O 
Although O 
not O 
cytotoxic O 
, O 
27OHC B-SYSTEMATIC 
was O 
mainly O 
detected O 
in O 
lipid O 
rafts O 
. O 
It O 
is O 
noteworthy O 
that O 
α-tocopherol B-TRIVIAL 
( O 
but O 
not O 
ellagic B-TRIVIAL 
acid I-TRIVIAL 
and O 
resveratrol B-TRIVIAL 
) O 
was O 
able O 
to O 
counteract O 
7KC B-SYSTEMATIC 
- O 
and O 
7βOHC B-SYSTEMATIC 
-induced O 
apoptosis O 
and O 
to O 
decrease O 
the O 
accumulation O 
of O 
7KC B-SYSTEMATIC 
and O 
27OHC B-SYSTEMATIC 
in O 
lipid O 
rafts O 
. O 
Thus O 
, O 
in O 
158N O 
cells O 
, O 
the O 
ability O 
of O 
oxysterols B-FAMILY 
to O 
trigger O 
a O 
mode O 
of O 
cell O 
death O 
by O 
apoptosis O 
involving O 
GSK-3 O 
and O 
caspase-3 O 
activation O 
is O 
independent O 
of O 
the O 
increase O 
in O 
the O 
Ca(2+) B-FORMULA 
level O 
and O 
of O 
their O 
accumulation O 
in O 
lipid O 
raft O 
microdomains O 
. O 

inhibitory O 
control O 
processes O 
in O 
abstinent O 
drug O 
abusers O 
(I) O 
: O 
A O 
functional O 
neuroimaging O 
study O 
in O 
former O 
cocaine B-TRIVIAL 
addicts O 
. O 

studies O 
in O 
current O 
cocaine B-TRIVIAL 
dependent O 
( O 
CD O 
) O 
individuals O 
consistently O 
reveal O 
cortical O 
hypoactivity O 
across O 
regions O 
of O 
the O 
response O 
inhibition O 
circuit O 
( O 
RIC O 
) O 
. O 
Dysregulation O 
of O 
this O 
critical O 
executive O 
network O 
is O 
hypothesized O 
to O 
account O 
for O 
the O 
lack O 
of O 
inhibitory O 
control O 
that O 
is O 
a O 
hallmark O 
of O 
the O 
addictive O 
phenotype O 
, O 
and O 
chronic O 
abuse O 
is O 
believed O 
to O 
compound O 
the O 
issue O 
. O 
A O 
crucial O 
question O 
is O 
whether O 
deficits O 
in O 
this O 
circuit O 
persist O 
after O 
drug O 
cessation O 
, O 
and O 
whether O 
recovery O 
of O 
this O 
system O 
will O 
be O 
seen O 
after O 
extended O 
periods O 
of O 
abstinence O 
, O 
a O 
question O 
with O 
implications O 
for O 
treatment O 
course O 
and O 
outcome O 
. O 
Utilizing O 
functional O 
magnetic O 
resonance O 
imaging O 
( O 
fMRI O 
) O 
, O 
we O 
examined O 
activation O 
in O 
nodes O 
of O 
the O 
RIC O 
in O 
abstinent O 
CD O 
individuals O 
( O 
n O 
= O 
27 O 
) O 
and O 
non-using O 
controls O 
( O 
n O 
= O 
45 O 
) O 
while O 
they O 
performed O 
a O 
motor O 
response O 
inhibition O 
task O 
. O 
In O 
contrast O 
to O 
current O 
users O 
, O 
these O 
abstinent O 
individuals O 
, O 
despite O 
extended O 
histories O 
of O 
chronic O 
cocaine B-TRIVIAL 
-abuse O 
( O 
average O 
duration O 
of O 
use O 
= O 
8.2 O 
years O 
) O 
, O 
performed O 
the O 
task O 
just O 
as O 
efficiently O 
as O 
non-users O 
. O 
In O 
line O 
with O 
these O 
behavioral O 
findings O 
, O 
no O 
evidence O 
for O 
between O 
- O 
group O 
differences O 
in O 
activation O 
of O 
the O 
RIC O 
was O 
found O 
and O 
instead O 
, O 
robust O 
activations O 
were O 
apparent O 
in O 
both O 
groups O 
within O 
the O 
well O 
- O 
characterized O 
nodes O 
of O 
the O 
RIC O 
. O 
Similarly O 
, O 
our O 
complementary O 
Electroencephalography O 
( O 
EEG O 
) O 
investigation O 
also O 
showed O 
an O 
absence O 
of O 
behavioral O 
and O 
electrophysiological O 
deficits O 
in O 
abstinent O 
drug O 
abusers O 
. O 
These O 
results O 
are O 
consistent O 
with O 
an O 
amelioration O 
of O 
neurobiological O 
deficits O 
in O 
inhibitory O 
circuitry O 
following O 
drug O 
cessation O 
, O 
and O 
could O 
help O 
explain O 
how O 
long O 
- O 
term O 
abstinence O 
is O 
maintained O 
. O 
Finally O 
, O 
regression O 
analyses O 
revealed O 
a O 
significant O 
association O 
between O 
level O 
of O 
activation O 
in O 
the O 
right O 
insula O 
with O 
inhibition O 
success O 
and O 
increased O 
abstinence O 
duration O 
in O 
the O 
CD O 
cohort O 
suggesting O 
that O 
this O 
region O 
may O 
be O 
integral O 
to O 
successful O 
recovery O 
from O 
cocaine B-TRIVIAL 
addiction O 
. O 

plant O 
sources O 
of O 
the O 
anti-cancer O 
alkaloid O 
, O 
camptothecine B-TRIVIAL 
from O 
the O 
Icacinaceae O 
taxa O 
, O 
India O 
. O 

this O 
study O 
, O 
the O 
production O 
of O 
camptothecine B-TRIVIAL 
and O 
its O 
derivatives O 
, O 
in O 
thirteen O 
species O 
of O 
the O 
family O 
Icacinaceae O 
, O 
namely O 
, O 
Apodytes O 
dimidiata O 
, O 
Codiocarpus O 
andamanicus O 
, O 
Gomphandra O 
comosa O 
, O 
Gomphandra O 
coriacea O 
, O 
Gomphandra O 
polymorpha O 
, O 
Gomphandra O 
tetrandra O 
, O 
Iodes O 
cirrhosa O 
, O 
Iodes O 
hookeriana O 
, O 
Miquelia O 
dentata O 
, O 
Miquelia O 
kleinii O 
, O 
Natsiatum O 
herpeticum O 
, O 
Pyrenacantha O 
volubilis O 
and O 
Sarcostigma O 
kleinii O 
is O 
reported O 
. O 
Seeds O 
of O 
M O 
. O 
dentata O 
were O 
found O 
to O 
produce O 
the O 
highest O 
content O 
of O 
camptothecine B-TRIVIAL 
( O 
1.0-1.4% O 
by O 
dry O 
weight O 
of O 
seeds O 
) O 
. O 
Full O 
scan O 
LC-MS O 
and O 
ESI-MS O 
/ O 
MS O 
analysis O 
of O 
M O 
. O 
dentata O 
revealed O 
, O 
besides O 
camptothecine B-TRIVIAL 
, O 
a O 
number O 
of O 
other O 
derivatives O 
, O 
namely O 
, O 
10-hydroxycamptothecine B-SYSTEMATIC 
, O 
9-methoxycamptothecine B-SYSTEMATIC 
, O 
20-deoxycamptothecine B-SYSTEMATIC 
. O 
Crude O 
extract O 
preparations O 
of O 
the O 
seeds O 
of O 
M O 
. O 
dentata O 
were O 
effective O 
against O 
a O 
breast O 
cancer O 
cell O 
line O 
( O 
IC50=3.82μg O 
/ O 
ml O 
for O 
MDA O 
MB273 O 
cell O 
lines O 
) O 
and O 
two O 
ovarian O 
cancer O 
cell O 
lines O 
( O 
IC50=2.8μg O 
/ O 
ml O 
for O 
NCI O 
/ O 
ADR-RES O 
and O 
4.5μg O 
/ O 
ml O 
for O 
SKOV O 
) O 
. O 
These O 
results O 
are O 
the O 
first O 
reports O 
of O 
camptothecine B-TRIVIAL 
and O 
its O 
derivatives O 
in O 
these O 
species O 
and O 
offer O 
rich O 
alternative O 
plant O 
sources O 
for O 
the O 
anticancer O 
compound O 
, O 
camptothecine B-TRIVIAL 
. O 

vitro O 
interceptive O 
and O 
reparative O 
effects O 
of O 
myo-inositol B-TRIVIAL 
against O 
copper B-SYSTEMATIC 
-induced O 
oxidative O 
damage O 
and O 
antioxidant O 
system O 
disturbance O 
in O 
primary O 
cultured O 
fish O 
enterocytes O 
. O 

( O 
Cu B-FORMULA 
) O 
is O 
essential O 
for O 
normal O 
cellular O 
processes O 
in O 
most O 
eukaryotic O 
organisms O 
but O 
is O 
toxic O 
in O 
excess O 
. O 
Our O 
previous O 
study O 
reported O 
that O 
a O 
nutrient O 
antioxidant O 
, O 
myo-inositol B-TRIVIAL 
( O 
MI O 
) O 
, O 
can O 
protect O 
fish O 
from O 
Cu B-FORMULA 
-induced O 
oxidative O 
injury O 
; O 
however O 
, O 
the O 
mechanisms O 
involved O 
are O 
not O 
fully O 
understood O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
aimed O 
to O 
analyze O 
potential O 
pathways O 
. O 
First O 
, O 
to O 
investigate O 
the O 
hypothesis O 
that O 
MI O 
protects O 
enterocytes O 
against O 
Cu B-FORMULA 
toxicity O 
via O 
the O 
intercept O 
pathway O 
, O 
enterocytes O 
were O 
treated O 
with O 
different O 
concentrations O 
of O 
MI O 
( O 
0-75mg O 
/ O 
L O 
medium O 
) O 
in O 
the O 
presence O 
of O 
6mg O 
/ O 
L O 
of O 
Cu B-FORMULA 
for O 
24h O 
( O 
Experiment O 
1 O 
) O 
. O 
Next O 
, O 
we O 
investigated O 
the O 
potential O 
reparative O 
role O 
of O 
MI O 
after O 
a O 
Cu B-FORMULA 
challenge O 
( O 
Experiment O 
2 O 
) O 
. O 
The O 
results O 
of O 
Experiment O 
1 O 
indicated O 
that O 
cells O 
exposed O 
to O 
Cu B-FORMULA 
alone O 
for O 
24h O 
exhibited O 
increases O 
in O 
lactate B-FAMILY 
dehydrogenase O 
release O 
( O 
LDH O 
) O 
, O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
formation O 
and O 
protein O 
oxidation O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Notably O 
, O 
a O 
dose O 
- O 
dependent O 
inhibitory O 
effect O 
on O 
LDH O 
release O 
was O 
observed O 
with O 
all O 
doses O 
of O 
MI O 
. O 
Moreover O 
, O 
co O 
- O 
treatment O 
with O 
MI O 
completely O 
inhibited O 
Cu B-FORMULA 
-induced O 
protein O 
carbonyl B-FAMILY 
( O 
PC O 
) O 
formation O 
. O 
However O 
, O 
Cu B-FORMULA 
-induced O 
lipid O 
peroxidation O 
was O 
not O 
altered O 
by O 
MI O 
co O 
- O 
treatment O 
. O 
Additionally O 
, O 
Cu B-FORMULA 
exposure O 
suppressed O 
total- O 
superoxide B-TRIVIAL 
dismutase O 
( O 
T-SOD O 
) O 
, O 
CuZnSOD O 
and O 
catalase O 
( O 
CAT O 
) O 
activities O 
, O 
and O 
these O 
changes O 
were O 
completely O 
blocked O 
by O 
co O 
- O 
treatment O 
with O 
sufficient O 
MI O 
concentrations O 
. O 
In O 
contrast O 
, O 
cells O 
exposed O 
to O 
Cu B-FORMULA 
exhibited O 
adaptive O 
increases O 
in O 
reduced B-TRIVIAL 
glutathione I-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
content O 
and O 
the O 
activities O 
of O 
anti-hydroxyl O 
radical O 
( O 
AHR O 
) O 
, O 
glutathione B-TRIVIAL 
peroxidase O 
( O 
GPx O 
) O 
, O 
glutathione B-TRIVIAL 
- O 
S B-FORMULA 
-transferase O 
( O 
GST O 
) O 
and O 
glutathione B-TRIVIAL 
reductase O 
( O 
GR O 
) O 
. O 
Interestingly O 
, O 
the O 
Cu B-FORMULA 
-stimulated O 
increases O 
in O 
these O 
antioxidants O 
were O 
blocked O 
by O 
co O 
- O 
treatment O 
with O 
sufficient O 
MI O 
concentrations O 
. O 
The O 
results O 
of O 
Experiment O 
2 O 
indicated O 
that O 
cell O 
injury O 
( O 
LDH O 
release O 
) O 
, O 
lipid O 
peroxidation O 
( O 
MDA B-ABBREVIATION 
formation O 
) O 
and O 
protein O 
oxidation O 
induced O 
by O 
Cu B-FORMULA 
were O 
reversed O 
by O 
subsequent O 
MI O 
treatment O 
. O 
Meanwhile O 
, O 
Cu B-FORMULA 
-induced O 
decreases O 
in O 
alkaline O 
phosphatase O 
( O 
AKP O 
) O 
, O 
anti- O 
superoxide B-TRIVIAL 
anion O 
( O 
ASA O 
) O 
, O 
T-SOD O 
and O 
CuZnSOD O 
activities O 
were O 
completely O 
restored O 
by O 
subsequent O 
MI O 
treatment O 
, O 
while O 
the O 
reduced O 
CAT O 
activity O 
was O 
partially O 
restored O 
. O 
However O 
, O 
MI O 
rescues O 
partially O 
restored O 
the O 
adaptive O 
increase O 
in O 
GPx O 
activity O 
induced O 
by O 
Cu B-FORMULA 
, O 
whereas O 
the O 
adaptive O 
increase O 
in O 
reduced B-ABBREVIATION 
GSH I-ABBREVIATION 
content O 
was O 
completely O 
reversed O 
by O 
75mg O 
/ O 
L O 
of O 
MI O 
. O 
However O 
, O 
subsequent O 
MI O 
treatments O 
did O 
not O 
alter O 
the O 
induction O 
of O 
GST O 
activity O 
by O 
Cu B-FORMULA 
. O 
In O 
conclusion O 
, O 
we O 
demonstrated O 
for O 
the O 
first O 
time O 
that O 
MI O 
not O 
only O 
protected O 
enterocytes O 
from O 
Cu B-FORMULA 
-induced O 
oxidative O 
damage O 
but O 
also O 
increased O 
the O 
repair O 
activity O 
in O 
primary O 
enterocytes O 
after O 
challenge O 
with O 
Cu B-FORMULA 
. O 
Moreover O 
, O 
MI O 
- O 
mediated O 
increases O 
in O 
antioxidant O 
enzyme O 
activities O 
contributed O 
to O 
lipid O 
and O 
protein O 
oxidant O 
repair O 
. O 

snails O 
are O 
important O 
opportunistic O 
scavengers O 
widely O 
found O 
in O 
marine O 
intertidal O 
shores O 
and O 
trophic O 
transfer O 
is O 
a O 
predominant O 
source O 
of O 
metal O 
accumulation O 
in O 
these O 
species O 
, O 
thus O 
there O 
is O 
a O 
significant O 
need O 
to O 
understand O 
the O 
controls O 
of O 
metal O 
trophic O 
transfer O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
took O 
advantage O 
of O 
a O 
severely O 
contaminated O 
estuary O 
and O 
collected O 
two O 
prey O 
organisms O 
( O 
oysters O 
Crassostrea O 
angulata O 
and O 
barnacles O 
Fistulobalanus O 
albicostatus O 
) O 
with O 
different O 
contamination O 
histories O 
. O 
These O 
naturally O 
contaminated O 
prey O 
were O 
fed O 
to O 
a O 
marine O 
neogastropod O 
Nassarius O 
siquijorensis O 
for O 
a O 
period O 
of O 
up O 
to O 
7 O 
weeks O 
. O 
We O 
then O 
investigated O 
the O 
influences O 
of O 
prey O 
type O 
, O 
metal O 
burden O 
, O 
and O 
subcellular O 
distribution O 
in O 
the O 
prey O 
on O 
the O 
metal O 
accumulation O 
, O 
trophic O 
transfer O 
, O 
and O 
potential O 
toxicity O 
on O 
N O 
. O 
siquijorensis O 
. O 
We O 
demonstrated O 
an O 
obvious O 
negative O 
relationship O 
between O 
the O 
trophic O 
transfer O 
and O 
the O 
metal O 
concentration O 
in O 
prey O 
or O 
the O 
metal O 
dosage O 
. O 
N O 
. O 
siquijorensis O 
exhibited O 
food O 
avoidance O 
behavior O 
to O 
the O 
Cu B-FORMULA 
contaminated O 
food O 
, O 
which O 
effectively O 
reduced O 
the O 
metal O 
ingestion O 
and O 
resulted O 
in O 
a O 
decrease O 
of O 
trophic O 
transfer O 
, O 
as O 
well O 
as O 
a O 
potential O 
toxic O 
effect O 
from O 
dietary O 
exposure O 
. O 
On O 
the O 
other O 
hand O 
, O 
our O 
results O 
also O 
implied O 
the O 
metal O 
- O 
specific O 
impact O 
of O 
subcellular O 
metal O 
distribution O 
in O 
prey O 
on O 
the O 
trophic O 
transfer O 
to O 
N O 
. O 
siquijorensis O 
. O 
Our O 
study O 
suggested O 
that O 
metal O 
burden O 
and O 
feeding O 
avoidance O 
should O 
be O 
considered O 
in O 
studying O 
the O 
trophic O 
transfer O 
of O 
metals O 
in O 
marine O 
benthic O 
food O 
chain O 
. O 

of O 
salinity O 
stress O 
on O 
Bufo O 
balearicus O 
and O 
Bufo O 
bufo O 
tadpoles O 
: O 
Tolerance O 
, O 
morphological O 
gill O 
alterations O 
and O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
localization O 
. O 

habitats O 
are O 
globally O 
threatened O 
by O 
human O 
- O 
induced O 
secondary O 
salinization O 
. O 
Amphibians O 
are O 
generally O 
poorly O 
adapted O 
to O 
survive O 
in O 
saline O 
environments O 
. O 
We O 
experimentally O 
investigated O 
the O 
effects O 
of O 
chronic O 
exposure O 
to O 
various O 
salinities O 
( O 
5% O 
, O 
10% O 
, O 
15% O 
, O 
20% O 
, O 
25% O 
, O 
30% O 
and O 
35% O 
seawater O 
, O 
SW O 
) O 
on O 
survival O 
, O 
larval O 
growth O 
and O 
metamorphosis O 
of O 
tadpoles O 
from O 
two O 
amphibian O 
populations O 
belonging O 
to O 
two O 
species O 
: O 
the O 
green O 
toad O 
Bufo O 
balearicus O 
and O 
the O 
common O 
toad O 
Bufo O 
bufo O 
. O 
In O 
addition O 
, O 
gill O 
morphology O 
of O 
tadpoles O 
of O 
both O 
species O 
after O 
acute O 
exposure O 
to O 
hypertonic O 
conditions O 
( O 
20% O 
, O 
25% O 
, O 
and O 
30% O 
SW O 
) O 
was O 
examined O 
by O 
light O 
and O 
electron O 
microscopy O 
. O 
Tadpoles O 
experienced O 
100% O 
mortality O 
above O 
20% O 
SW O 
in O 
B O 
. O 
balearicus O 
while O 
above O 
15% O 
SW O 
in O 
B O 
. O 
bufo O 
. O 
We O 
detected O 
also O 
sublethal O 
effects O 
of O 
salinity O 
stress O 
on O 
growth O 
and O 
metamorphosis O 
. O 
B O 
. O 
bufo O 
cannot O 
withstand O 
chronic O 
exposure O 
to O 
salinity O 
above O 
5% O 
SW O 
, O 
tadpoles O 
grew O 
slower O 
and O 
were O 
significantly O 
smaller O 
than O 
those O 
in O 
control O 
at O 
metamorphosis O 
. O 
B O 
. O 
balearicus O 
tolerated O 
salinity O 
up O 
to O 
20% O 
SW O 
without O 
apparent O 
effects O 
during O 
larval O 
development O 
, O 
but O 
starting O 
from O 
15% O 
SW O 
tadpoles O 
metamorphosed O 
later O 
and O 
at O 
a O 
smaller O 
size O 
compared O 
with O 
control O 
. O 
We O 
also O 
revealed O 
a O 
negative O 
relation O 
between O 
increasing O 
salt O 
concentration O 
and O 
gill O 
integrity O 
. O 
The O 
main O 
modifications O 
were O 
increased O 
mucous O 
secretion O 
, O 
detachment O 
of O 
external O 
layer O 
, O 
alteration O 
of O 
epithelial O 
surface O 
, O 
degeneration O 
phenomena O 
, O 
appearance O 
of O 
residual O 
bodies O 
, O 
and O 
macrophage O 
immigration O 
. O 
These O 
morphological O 
alterations O 
of O 
gill O 
epithelium O 
can O 
interfere O 
with O 
respiratory O 
function O 
and O 
both O 
osmotic O 
and O 
acid O 
- O 
base O 
regulation O 
. O 
Significant O 
variations O 
in O 
branchial O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
activity O 
were O 
also O 
observed O 
between O 
two O 
species O 
; O 
moreover O 
an O 
increase O 
in O 
enzyme O 
activity O 
was O 
evident O 
in O 
response O 
to O 
SW O 
exposure O 
. O 
Epithelial O 
responses O 
to O 
increasing O 
salt O 
concentration O 
were O 
different O 
in O 
the O 
populations O 
belonging O 
to O 
two O 
species O 
: O 
the O 
intensity O 
of O 
histological O 
and O 
ultrastructural O 
pathology O 
in O 
B O 
. O 
bufo O 
was O 
greater O 
and O 
we O 
noticed O 
the O 
appearance O 
in O 
exposed O 
samples O 
of O 
the O 
tubular O 
vesicle O 
cells O 
( O 
TVCs O 
) O 
. O 
Taken O 
together O 
, O 
our O 
results O 
demonstrated O 
that O 
increased O 
salinity O 
of O 
freshwater O 
may O 
give O 
cause O 
for O 
concern O 
and O 
must O 
be O 
considered O 
a O 
stressor O 
for O 
amphibians O 
as O 
well O 
as O 
other O 
pollutants O 
. O 

comparative O 
study O 
reports O 
the O 
nutritional O 
and O 
toxicological O 
characteristics O 
of O 
Mucuna O 
pruriens O 
flour O 
and O 
a O 
protein O 
- O 
rich O 
product O 
developed O 
from O 
it O 
. O 
The O 
protein O 
- O 
rich O 
mucuna O 
product O 
( O 
PRMP O 
) O 
was O 
obtained O 
by O 
the O 
three O 
steps O 
procedure O 
: O 
protein O 
solubilization O 
, O 
heat O 
- O 
coagulation O 
and O 
sieving O 
. O 
Three O 
weeks O 
rats O 
( O 
n=6 O 
per O 
group O 
) O 
were O 
fed O 
for O 
28days O 
on O 
standard O 
protein O 
- O 
substituted O 
rat O 
feed O 
with O 
mucuna O 
flour O 
or O 
PRMP O 
. O 
The O 
experimental O 
design O 
was O 
a O 
factorial O 
design O 
with O 
three O 
mucuna O 
accessions O 
( O 
Velvet O 
, O 
Black O 
and O 
White O 
) O 
and O 
two O 
treatments O 
( O 
flour O 
and O 
PRMP O 
) O 
. O 
The O 
protein O 
content O 
ranged O 
27.2-31.5g O 
/ O 
100g O 
for O 
flour O 
and O 
58.8-61.1% O 
for O 
PRMP O 
. O 
Processing O 
flour O 
into O 
PRMP O 
led O 
to O 
a O 
significant O 
( O 
p O 
< O 
0.05 O 
) O 
reduction O 
of O 
tannins B-FAMILY 
( O 
50% O 
) O 
, O 
total O 
polyphenols B-FAMILY 
( O 
50% O 
) O 
and O 
trypsin O 
inhibitors O 
( O 
94% O 
) O 
. O 
The O 
rats O 
fed O 
PMRP O 
diets O 
witnessed O 
weight O 
gain O 
similar O 
to O 
casein O 
, O 
while O 
those O 
fed O 
mucuna O 
flour O 
lost O 
weight O 
. O 
The O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
, O 
HDL- O 
cholesterol B-TRIVIAL 
and O 
LDL- O 
cholesterol B-TRIVIAL 
observed O 
in O 
animals O 
groups O 
fed O 
mucuna O 
flour O 
and O 
PRMP O 
were O 
significantly O 
lower O 
( O 
p O 
< O 
0.05 O 
) O 
than O 
the O 
control O 
group O 
. O 
In O 
addition O 
lymphocytes O 
, O 
granulocytes O 
, O 
red O 
blood O 
cells O 
, O 
hemoglobin O 
and O 
hematocrit O 
of O 
rats O 
fed O 
mucuna O 
flour O 
were O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
lower O 
than O 
values O 
in O 
other O 
rats O 
groups O 
. O 
Kidneys O 
glomerular O 
sclerosis O 
and O 
high O 
creatinine B-TRIVIAL 
levels O 
were O 
observed O 
in O 
group O 
fed O 
mucuna O 
flour O 
. O 
PRMP O 
then O 
represents O 
a O 
good O 
alternative O 
of O 
using O 
mucuna O 
proteins O 
for O 
human O 
nutrition O 
. O 

- O 
property O 
relationship O 
for O 
cellular O 
accumulation O 
of O 
macrolones B-FAMILY 
in O 
human O 
polymorphonuclear O 
leukocytes O 
( O 
PMNs O 
) O 
. O 

are O 
a O 
new O 
class O 
of O 
antimicrobial O 
compounds O 
consisting O 
of O 
a O 
macrolide B-FAMILY 
scaffold O 
linked O 
to O 
a O 
4-quinolone-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
moiety O 
via O 
C B-FORMULA 
( O 
4″ O 
) O 
position O 
of O 
a O 
macrolide B-FAMILY 
. O 
As O 
macrolides B-FAMILY 
are O 
known O 
to O 
possess O 
favorable O 
pharmacokinetic O 
properties O 
by O 
accumulating O 
in O 
inflammatory O 
cells O 
, O 
in O 
this O 
study O 
we O 
determined O 
the O 
intensity O 
of O 
accumulation O 
in O 
human O 
polymorphonuclear O 
leukocytes O 
( O 
PMNs O 
) O 
of O 
57 O 
compounds O 
of O 
the O 
macrolone B-FAMILY 
class O 
and O 
analyzed O 
the O 
relationship O 
between O 
the O 
molecular O 
structure O 
and O 
this O 
cellular O 
pharmacokinetic O 
property O 
. O 
Accumulation O 
of O 
macrolones B-FAMILY 
ranged O 
from O 
0 O 
to O 
5.5-fold O 
higher O 
than O 
the O 
standard O 
macrolide B-FAMILY 
azithromycin B-TRIVIAL 
. O 
Distinct O 
structural O 
features O 
in O 
all O 
three O 
considered O 
molecule O 
parts O 
: O 
the O 
macrolide B-FAMILY 
scaffold O 
, O 
quinolone B-FAMILY 
moiety O 
and O 
the O 
linker O 
, O 
affect O 
cellular O 
accumulation O 
. O 
Interestingly O 
, O 
while O 
the O 
parent O 
macrolide B-FAMILY 
, O 
azithromycin B-TRIVIAL 
, O 
accumulates O 
approximately O 
3-fold O 
more O 
than O 
clarithromycin B-TRIVIAL 
, O 
among O 
macrolones B-FAMILY 
all O 
clarithromycin B-TRIVIAL 
derivatives O 
accumulated O 
in O 
PMNs O 
significantly O 
more O 
than O 
their O 
azithromycin B-TRIVIAL 
counterparts O 
. O 
Modeling O 
cellular O 
accumulation O 
of O 
macrolones B-FAMILY 
with O 
simple O 
molecular O 
descriptors O 
, O 
as O 
well O 
as O 
with O 
the O 
measured O 
octanol B-SYSTEMATIC 
-water O 
distribution O 
coefficient O 
, O 
revealed O 
that O 
the O 
number O 
of O 
hydrogen B-SYSTEMATIC 
bond O 
donors O 
and O 
secondary B-FAMILY 
amide I-FAMILY 
groups O 
negatively O 
contribute O 
to O 
macrolone B-FAMILY 
accumulation O 
, O 
while O 
lipophilicity O 
makes O 
a O 
positive O 
contribution O 
. O 

vast O 
number O 
of O 
variations O 
in O 
drug O 
/ O 
vehicle O 
combinations O 
may O 
come O 
into O 
contact O 
with O 
skin O 
. O 
Evaluating O 
the O 
effect O 
of O 
potential O 
drug O 
, O 
vehicle O 
and O 
skin O 
interactions O 
for O 
all O 
possible O 
combinations O 
is O 
a O 
daunting O 
task O 
. O 
A O 
practical O 
solution O 
is O 
a O 
rapid O 
screening O 
technique O 
amenable O 
to O 
high O 
throughput O 
approaches O 
( O 
e.g O 
. O 
96-well O 
plates O 
) O 
. O 
In O 
this O 
study O 
, O 
three O 
artificial O 
membranes O 
( O 
isopropyl B-SYSTEMATIC 
myristate I-SYSTEMATIC 
( O 
IPM B-ABBREVIATION 
) O 
, O 
certramides B-FAMILY 
and O 
Strat-M O 
™ O 
) O 
were O 
evaluated O 
for O 
their O 
ability O 
to O 
predict O 
the O 
skin O 
permeability O 
of O 
caffeine B-TRIVIAL 
, O 
cortisone B-TRIVIAL 
, O 
diclofenac B-SYSTEMATIC 
sodium I-SYSTEMATIC 
, O 
mannitol B-TRIVIAL 
, O 
salicylic B-TRIVIAL 
acid I-TRIVIAL 
and O 
testosterone B-TRIVIAL 
applied O 
in O 
propylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
, O 
water O 
and O 
ethanol B-SYSTEMATIC 
as O 
unsaturated O 
and O 
saturated O 
concentrations O 
. O 
Resultant O 
absorption O 
data O 
was O 
compared O 
to O 
porcine O 
skin O 
diffusion O 
cell O 
data O 
. O 
The O 
correlations O 
(r(2)) O 
between O 
membrane O 
and O 
diffusion O 
cell O 
data O 
from O 
saturated O 
and O 
unsaturated O 
concentrations O 
were O 
0.38 O 
, O 
0.47 O 
and O 
0.56 O 
for O 
the O 
Strat-M O 
™ O 
, O 
certramide B-FAMILY 
and O 
IPM B-ABBREVIATION 
membranes O 
, O 
respectively O 
. O 
This O 
relationship O 
improved O 
when O 
only O 
saturated O 
concentrations O 
were O 
evaluated O 
( O 
r(2)=0.60 O 
, O 
0.63 O 
and O 
0.66 O 
for O 
the O 
Strat-M O 
™ O 
, O 
certramide B-FAMILY 
and O 
IPM B-ABBREVIATION 
membranes O 
, O 
respectively O 
) O 
. O 
A O 
correlation O 
between O 
membrane O 
retention O 
and O 
the O 
amount O 
remaining O 
in O 
skin O 
had O 
r(2) O 
values O 
of O 
0.73 O 
( O 
Strat-M O 
™ O 
) O 
, O 
0.67 O 
( O 
certramides B-FAMILY 
) O 
, O 
and O 
0.67 O 
( O 
IPM B-ABBREVIATION 
) O 
. O 
Quantitative O 
structure O 
- O 
permeability O 
relationship O 
models O 
for O 
each O 
membrane O 
identified O 
different O 
physicochemical O 
factors O 
influencing O 
the O 
absorption O 
process O 
. O 
Although O 
further O 
investigations O 
exploring O 
complex O 
topical O 
formulations O 
are O 
required O 
, O 
these O 
results O 
suggest O 
potential O 
use O 
as O 
an O 
initial O 
screening O 
approach O 
to O 
assist O 
in O 
narrowing O 
the O 
selection O 
of O 
formulations O 
to O 
be O 
evaluated O 
with O 
a O 
more O 
biologically O 
intact O 
model O 
, O 
thereby O 
assisting O 
in O 
the O 
development O 
of O 
new O 
topical O 
formulations O 
. O 

dosing O 
of O 
simvastatin B-TRIVIAL 
inhibits O 
airway O 
mucus O 
production O 
of O 
epithelial O 
cells O 
: O 
Implications O 
in O 
the O 
treatment O 
of O 
chronic O 
obstructive O 
airway O 
pathologies O 
. O 

: O 
Chronic O 
obstructive O 
pulmonary O 
disease O 
( O 
COPD O 
) O 
is O 
characterised O 
by O 
mucus O 
hyper O 
- O 
production O 
. O 
This O 
pathology O 
, O 
together O 
with O 
other O 
inflammatory O 
contributions O 
, O 
leads O 
to O 
airway O 
obstruction O 
and O 
breathing O 
complications O 
. O 
Newer O 
therapeutic O 
approaches O 
are O 
of O 
increased O 
interest O 
, O 
including O 
the O 
use O 
of O 
HMG-CoA B-ABBREVIATION 
reductase O 
inhibitors O 
. O 
Retrospective O 
studies O 
have O 
shown O 
that O 
statins B-FAMILY 
are O 
effective O 
in O 
reducing O 
patient O 
mortality O 
and O 
blood O 
cytokines O 
levels O 
. O 
These O 
findings O 
suggest O 
statins B-FAMILY 
may O 
also O 
provide O 
a O 
new O 
therapeutic O 
approach O 
in O 
COPD O 
treatment O 
. O 
PURPOSE O 
: O 
The O 
aim O 
of O 
the O 
present O 
work O 
was O 
to O 
study O 
the O 
transport O 
of O 
SV O 
across O 
Calu-3 O 
epithelial O 
cells O 
and O 
to O 
investigate O 
its O 
pharmacological O 
action O 
with O 
respect O 
to O 
reduction O 
in O 
mucus O 
production O 
. O 
METHODS O 
: O 
Calu-3 O 
cells O 
were O 
grown O 
under O 
liquid O 
covered O 
culture O 
( O 
LCC O 
) O 
conditions O 
for O 
transport O 
studies O 
in O 
order O 
to O 
demonstrate O 
the O 
ability O 
of O 
SV O 
to O 
transport O 
across O 
the O 
monolayer O 
. O 
For O 
mucus O 
detection O 
, O 
cells O 
were O 
grown O 
under O 
air O 
interface O 
culture O 
( O 
AIC O 
) O 
conditions O 
. O 
Samples O 
collected O 
for O 
microscope O 
analysis O 
were O 
stained O 
with O 
alcian B-TRIVIAL 
blue I-TRIVIAL 
; O 
images O 
of O 
the O 
stained O 
cell O 
surface O 
were O 
acquired O 
and O 
the O 
mucus O 
was O 
quantified O 
as O 
the O 
RGBB O 
ratio O 
. O 
RESULTS O 
: O 
SV O 
was O 
transported O 
through O 
the O 
cell O 
monolayer O 
and O 
' O 
retained O 
' O 
inside O 
the O 
Calu-3 O 
cells O 
. O 
Colour O 
analysis O 
of O 
stained O 
Calu-3 O 
monolayers O 
microscope O 
- O 
images O 
showed O 
that O 
chronic O 
administration O 
of O 
SV O 
for O 
14days O 
caused O 
a O 
significant O 
inhibition O 
in O 
mucus O 
production O 
. O 
CONCLUSION O 
: O 
These O 
findings O 
suggest O 
that O 
local O 
delivery O 
of O 
SV O 
directly O 
to O 
the O 
lungs O 
may O 
provide O 
a O 
promising O 
treatment O 
and O 
potential O 
disease O 
management O 
approach O 
of O 
COPD O 
, O 
with O 
significant O 
effects O 
on O 
mucus O 
reduction O 
. O 

5-(benzyloxy)pyridin-2(1H)-one B-SYSTEMATIC 
derivatives O 
as O 
potent O 
c-Met O 
inhibitors O 
. O 

series O 
of O 
novel O 
5-(benzyloxy)pyridin-2(1H)-ones B-SYSTEMATIC 
were O 
designed O 
, O 
synthesized O 
and O 
biologically O 
evaluated O 
for O 
c-Met O 
inhibition O 
. O 
Various O 
amides B-FAMILY 
and O 
benzoimidazoles B-FAMILY 
at O 
C-3 O 
position O 
were O 
investigated O 
. O 
A O 
potent O 
compound O 
12b O 
with O 
a O 
c-Met O 
IC50 O 
of O 
12nM O 
was O 
identified O 
. O 
This O 
compound O 
exhibited O 
potent O 
inhibition O 
of O 
EBC-1 O 
cell O 
associated O 
with O 
c-Met O 
constitutive O 
activation O 
and O 
showed O 
high O 
selectivity O 
for O 
c-Met O 
than O 
other O 
tested O 
11 O 
kinases O 
. O 
The O 
binding O 
model O 
12b O 
with O 
c-Met O 
was O 
disclosed O 
by O 
docking O 
analysis O 
. O 

( O 
miRNAs O 
) O 
have O 
been O 
indicated O 
to O 
play O 
key O 
roles O 
in O 
ovarian O 
follicular O 
development O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
how O 
the O 
miRNA O 
gene O 
expression O 
itself O 
is O 
regulated O 
in O 
the O 
mammalian O 
ovary O 
. O 
We O 
previously O 
reported O 
that O 
miR-224 O 
is O 
involved O 
in O 
TGF-β1 O 
- O 
mediated O 
follicular O 
granulosa O 
cell O 
( O 
GC O 
) O 
growth O 
and O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
production O 
by O 
targeting O 
Smad4 O 
. O 
Here O 
, O 
the O 
transcriptional O 
regulation O 
of O 
miR-224 O 
expression O 
in O 
GCs O 
was O 
further O 
investigated O 
. O 
Our O 
results O 
showed O 
that O 
both O 
the O 
tumor O 
suppressor O 
gene O 
p53 O 
and O 
NF-κB O 
p65 O 
subunit O 
suppressed O 
the O 
TGF-β1-induced O 
increase O 
in O 
pri-miR-224 O 
expression O 
in O 
GCs O 
. O 
ChIP O 
assays O 
demonstrated O 
that O 
TGF-β1 O 
enhanced O 
the O 
binding O 
of O 
p53 O 
and O 
p65 O 
to O 
the O 
proximal O 
promoter O 
region O 
of O 
GABAA O 
receptor O 
ε O 
subunit O 
( O 
miR-224 O 
host O 
gene O 
) O 
. O 
p53 O 
and O 
p65 O 
transcriptionally O 
cooperated O 
to O 
inactivate O 
the O 
GABAA O 
receptor O 
ε O 
subunit O 
promoter O 
. O 
In O 
addition O 
, O 
p53 O 
/ O 
p65 O 
could O 
up O 
- O 
regulate O 
Smad4 O 
expression O 
by O 
inhibiting O 
its O 
target O 
miR-224 O 
in O 
GCs O 
which O 
contributed O 
, O 
at O 
least O 
partially O 
, O 
to O 
the O 
effects O 
of O 
miR-224 O 
and O 
Smad4 O 
on O 
GC O 
proliferation O 
and O 
E2 O 
release O 
. O 
Our O 
results O 
provide O 
new O 
data O 
about O 
the O 
interplay O 
between O 
transcription O 
factors O 
involved O 
in O 
GC O 
proliferation O 
and O 
function O 
by O 
cooperatively O 
regulating O 
miRNA O 
expression O 
. O 

CdSe B-FORMULA 
/ O 
CdS B-FORMULA 
/ O 
ZnS B-FORMULA 
quantum O 
dot O 
light O 
emitting O 
devices O 
with O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
as O 
an O 
electron O 
- O 
injection O 
contact O 
. O 

demonstrated O 
the O 
fabrication O 
of O 
inverted O 
CdSe B-FORMULA 
/ O 
CdS B-FORMULA 
/ O 
ZnS B-FORMULA 
quantum O 
dot O 
light O 
emitting O 
devices O 
( O 
QD-LEDs O 
) O 
using O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
( O 
TiO2 B-FORMULA 
) O 
as O 
an O 
electron O 
- O 
injection O 
layer O 
and O 
investigated O 
the O 
operating O 
mechanism O 
by O 
utilizing O 
different O 
hole O 
- O 
transport O 
materials O 
, O 
4,4-N,N-dicarbazole- B-SYSTEMATIC 
biphenyl I-SYSTEMATIC 
( O 
CBP B-ABBREVIATION 
) O 
and O 
4,4',4''-tris(carbazol-9-yl)-triphenylamine B-SYSTEMATIC 
( O 
TCTA B-ABBREVIATION 
) O 
. O 
A O 
more O 
efficient O 
device O 
with O 
CBP O 
as O 
the O 
hole O 
- O 
transport O 
layer O 
( O 
HTL O 
) O 
was O 
obtained O 
compared O 
with O 
the O 
TCTA B-ABBREVIATION 
based O 
device O 
. O 
The O 
peak O 
efficiency O 
of O 
6.7 O 
cd O 
A(-1) O 
for O 
the O 
CBP O 
based O 
device O 
was O 
found O 
to O 
be O 
about O 
74.5% O 
higher O 
than O 
the O 
TCTA B-ABBREVIATION 
based O 
device O 
( O 
3.84 O 
cd O 
A(-1) O 
) O 
. O 
The O 
studies O 
on O 
the O 
time O 
- O 
resolved O 
photoluminescence O 
spectra O 
of O 
the O 
QD-HTL O 
composite O 
structures O 
showed O 
that O 
the O 
energy O 
transfer O 
( O 
ET O 
) O 
efficiencies O 
from O 
the O 
two O 
HTLs O 
to O 
the O 
QD O 
layer O 
were O 
similar O 
and O 
the O 
charge O 
separation O 
between O 
QDs O 
and O 
HTLs O 
could O 
be O 
neglected O 
. O 
The O 
enhancement O 
in O 
the O 
performance O 
of O 
the O 
CBP O 
based O 
device O 
was O 
attributed O 
to O 
the O 
more O 
efficient O 
hole O 
- O 
injection O 
from O 
CBP O 
to O 
QDs O 
. O 

doped O 
holey O 
graphene B-TRIVIAL 
as O 
an O 
efficient O 
metal O 
- O 
free O 
multifunctional O 
electrochemical O 
catalyst O 
for O 
hydrazine B-SYSTEMATIC 
oxidation O 
and O 
oxygen B-SYSTEMATIC 
reduction O 
. O 

for O 
anode O 
or O 
cathode O 
reactions O 
are O 
at O 
the O 
heart O 
of O 
electrochemical O 
energy O 
conversion O 
and O 
storage O 
devices O 
. O 
Molecular O 
design O 
of O 
carbon B-SYSTEMATIC 
based O 
nanomaterials O 
may O 
create O 
the O 
next O 
generation O 
electrochemical O 
catalysts O 
for O 
broad O 
applications O 
. O 
Herein O 
, O 
we O 
present O 
the O 
synthesis O 
of O 
a O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
nanostructure O 
with O 
a O 
large O 
surface O 
area O 
( O 
784 O 
m(2) O 
g(-1) O 
) O 
composed O 
of O 
nitrogen B-SYSTEMATIC 
doped O 
( O 
up O 
to O 
8.6 O 
at.% O 
) O 
holey O 
graphene B-TRIVIAL 
. O 
The O 
holey O 
structure O 
of O 
graphene B-TRIVIAL 
sheets O 
( O 
~25% O 
of O 
surface O 
area O 
is O 
attributed O 
to O 
pores O 
) O 
engenders O 
more O 
exposed O 
catalytic O 
active O 
edge O 
sites O 
. O 
Nitrogen B-SYSTEMATIC 
doping O 
further O 
improves O 
catalytic O 
activity O 
, O 
while O 
the O 
formation O 
of O 
the O 
3D O 
porous O 
nanostructure O 
significantly O 
reduces O 
graphene B-TRIVIAL 
nanosheet O 
stacking O 
and O 
facilitates O 
the O 
diffusion O 
of O 
reactants O 
/ O 
electrolytes O 
. O 
The O 
three O 
factors O 
work O 
together O 
, O 
leading O 
to O 
superb O 
electrochemical O 
catalytic O 
activities O 
for O 
both O 
hydrazine B-SYSTEMATIC 
oxidation O 
( O 
its O 
current O 
generation O 
ability O 
is O 
comparable O 
to O 
that O 
of O 
10 O 
wt% O 
Pt B-FORMULA 
- O 
C B-FORMULA 
catalyst O 
) O 
and O 
oxygen B-SYSTEMATIC 
reduction O 
( O 
its O 
limiting O 
current O 
is O 
comparable O 
to O 
that O 
of O 
20 O 
wt% O 
Pt B-FORMULA 
- O 
C B-FORMULA 
catalyst O 
) O 
with O 
four O 
- O 
electron O 
transfer O 
processes O 
and O 
excellent O 
durability O 
. O 

, O 
in O 
vitro O 
antitumor O 
evaluation O 
and O 
DNA O 
- O 
binding O 
study O 
of O 
novel O 
tetrahydroquinolines B-FAMILY 
and O 
some O 
derived O 
tricyclic O 
and O 
tetracyclic O 
ring O 
systems O 
. O 

synthesis O 
of O 
some O 
new O 
tetrahydroquinolines B-FAMILY 
, O 
tetrahydropyrimido[4,5-b]quinolines B-FAMILY 
, O 
and O 
tetrahydropentaazacyclopenta[a]anthracenes B-FAMILY 
structurally O 
related O 
to O 
some O 
DNA O 
intercalators O 
is O 
described O 
. O 
Fifteen O 
compounds O 
were O 
evaluated O 
for O 
their O 
antitumor O 
activity O 
by O 
the O 
National O 
Cancer O 
Institute O 
( O 
NCI O 
) O 
, O 
in O 
vitro O 
disease O 
oriented O 
antitumor O 
screening O 
. O 
The O 
most O 
active O 
tricyclic B-FAMILY 
pyrimido[4,5-b]quinolines I-FAMILY 
3b O 
, O 
6b O 
, O 
7b O 
and O 
8b O 
were O 
further O 
subjected O 
to O 
DNA O 
- O 
binding O 
investigation O 
in O 
an O 
attempt O 
to O 
rationalize O 
their O 
activity O 
. O 
Compound O 
8b O 
proved O 
to O 
be O 
the O 
most O 
active O 
member O 
in O 
this O 
study O 
as O 
evidenced O 
from O 
its O 
remarkable O 
growth O 
inhibitory O 
potential O 
against O 
some O 
individual O 
cell O 
lines O 
, O 
and O 
its O 
broad O 
spectrum O 
of O 
antitumor O 
activity O 
( O 
GI50 O 
, O 
TGI O 
and O 
LC50 O 
values O 
46.9 O 
, O 
85.3 O 
and O 
97.4 O 
, O 
respectively O 
) O 
, O 
together O 
with O 
a O 
good O 
DNA O 
- O 
binding O 
affinity O 
. O 

contribution O 
to O 
hydration O 
shells O 
in O 
one O 
- O 
dimensional O 
aqueous O 
electrolyte O 
solution O 
by O 
anomalous O 
hydrogen B-SYSTEMATIC 
bonds O 
. O 

hydration O 
structure O 
of O 
NaCl B-FORMULA 
aqueous O 
solution O 
was O 
elucidated O 
in O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
on O 
the O 
basis O 
of O 
canonical O 
ensemble O 
Monte O 
Carlo O 
simulations O 
. O 
Hydration O 
shells O 
were O 
preferentially O 
formed O 
even O 
in O 
narrow O 
CNTs O 
to O 
gain O 
stabilization O 
energy O 
, O 
whereas O 
hydrogen B-SYSTEMATIC 
bonding O 
between O 
water O 
molecules O 
in O 
such O 
CNTs O 
was O 
sacrificed O 
. O 
Nanoscale O 
- O 
confined O 
aqueous O 
electrolyte O 
solutions O 
therefore O 
prioritize O 
hydration O 
shell O 
formation O 
between O 
ions O 
and O 
water O 
rather O 
than O 
hydrogen B-SYSTEMATIC 
-bond O 
formation O 
between O 
water O 
molecules O 
. O 

entry O 
into O 
T O 
cells O 
following O 
antigen O 
stimulation O 
is O 
crucial O 
for O 
nuclear O 
factor O 
of O 
activated O 
T O 
cells O 
( O 
NFAT O 
) O 
- O 
mediated O 
T O 
cell O 
activation O 
. O 
The O 
movement O 
of O 
calcium B-SYSTEMATIC 
is O 
mediated O 
by O 
calcium B-SYSTEMATIC 
release O 
- O 
activated O 
calcium B-SYSTEMATIC 
( O 
CRAC O 
) O 
channels O 
. O 
There O 
are O 
two O 
key O 
components O 
of O 
this O 
channel O 
: O 
Orai1 O 
is O 
the O 
pore O 
- O 
forming O 
subunit O 
located O 
in O 
the O 
plasma O 
membrane O 
, O 
and O 
stromal O 
interaction O 
molecule O 
1 O 
( O 
STIM1 O 
) O 
functions O 
as O 
a O 
Ca(2+) B-FORMULA 
sensor O 
in O 
the O 
endoplasmic O 
reticulum O 
. O 
A O 
subset O 
of O 
human O 
patients O 
carry O 
mutations O 
in O 
either O 
STIM1 O 
or O 
Orai1 O 
that O 
affect O 
protein O 
function O 
or O 
expression O 
, O 
resulting O 
in O 
defective O 
store O 
- O 
operated O 
Ca(2+) B-FORMULA 
influx O 
and O 
CRAC O 
channel O 
function O 
, O 
and O 
impaired O 
T O 
cell O 
activation O 
. O 
These O 
patients O 
suffer O 
from O 
a O 
hereditary O 
form O 
of O 
severe O 
combined O 
immune O 
deficiency O 
syndrome O 
, O 
highlighting O 
the O 
importance O 
of O 
the O 
CRAC O 
channel O 
for O 
T O 
lymphocyte O 
function O 
in O 
humans O 
. O 
Since O 
autoreactive O 
T O 
cells O 
play O 
an O 
important O 
role O 
in O 
the O 
development O 
of O 
autoimmune O 
diseases O 
such O 
as O 
rheumatoid O 
arthritis O 
, O 
multiple O 
sclerosis O 
, O 
and O 
organ O 
transplantation O 
, O 
Orai1 O 
becomes O 
an O 
attractive O 
therapeutic O 
target O 
for O 
ameliorating O 
autoimmune O 
disease O 
. O 
We O 
developed O 
a O 
novel O 
approach O 
to O 
inhibiting O 
CRAC O 
function O 
by O 
generating O 
high O 
- O 
affinity O 
fully O 
human O 
monoclonal O 
antibodies O 
to O 
human O 
Orai1 O 
. O 
These O 
antibodies O 
inhibited O 
ICRAC O 
current O 
, O 
store O 
- O 
operated O 
Ca(2+) B-FORMULA 
influx O 
, O 
NFAT O 
transcription O 
, O 
and O 
cytokine O 
release O 
. O 
These O 
fully O 
human O 
antibodies O 
to O 
human O 
Orai1 O 
may O 
represent O 
a O 
novel O 
therapeutic O 
approach O 
for O 
the O 
treatment O 
of O 
autoimmunity O 
. O 

Preference O 
of O 
Carbon B-SYSTEMATIC 
Nanotube O 
Over O 
Proline B-TRIVIAL 
-Rich O 
Motif O 
Ligand O 
on O 
SH3-Domain O 
: O 
A O 
Comparison O 
with O 
Different O 
Force O 
Fields O 
. O 

the O 
widespread O 
applications O 
of O 
nanomaterials O 
such O 
as O 
carbon B-SYSTEMATIC 
nanotubes O 
, O 
there O 
is O 
a O 
growing O 
concern O 
on O 
the O 
biosafety O 
of O 
these O 
engineered O 
nanoparticles O 
, O 
in O 
particular O 
their O 
interactions O 
with O 
proteins O 
. O 
In O 
molecular O 
simulations O 
of O 
nanoparticle O 
- O 
protein O 
interactions O 
, O 
the O 
choice O 
of O 
empirical O 
parameters O 
( O 
force O 
fields O 
) O 
plays O 
a O 
decisive O 
role O 
, O 
and O 
thus O 
is O 
of O 
great O 
importance O 
and O 
should O 
be O 
examined O 
carefully O 
before O 
wider O 
applications O 
. O 
Here O 
we O 
compare O 
three O 
commonly O 
used O 
force O 
fields O 
, O 
CHARMM O 
, O 
OPLSAA O 
, O 
and O 
AMBER O 
in O 
study O 
of O 
the O 
competitive O 
binding O 
of O 
a O 
single O 
wall O 
carbon O 
nanotube O 
( O 
SWCNT O 
) O 
with O 
a O 
native O 
proline B-TRIVIAL 
-rich O 
motif O 
( O 
PRM O 
) O 
ligand O 
on O 
its O 
target O 
protein O 
SH3 O 
domain O 
, O 
a O 
ubiquitous O 
protein O 
- O 
protein O 
interaction O 
mediator O 
involved O 
in O 
signaling O 
and O 
regulatory O 
pathways O 
. O 
We O 
find O 
that O 
the O 
SWCNT O 
displays O 
a O 
general O 
preference O 
over O 
the O 
PRM O 
in O 
binding O 
with O 
SH3 O 
domain O 
in O 
all O 
the O 
three O 
force O 
fields O 
examined O 
, O 
although O 
the O 
degree O 
of O 
preference O 
can O 
be O 
somewhat O 
different O 
, O 
with O 
the O 
AMBER O 
force O 
field O 
showing O 
the O 
highest O 
preference O 
. O 
The O 
SWCNT O 
prevents O 
the O 
ligand O 
from O 
reaching O 
its O 
native O 
binding O 
pocket O 
by O 
(i) O 
occupying O 
the O 
binding O 
pocket O 
directly O 
, O 
and O 
(ii) O 
binding O 
with O 
the O 
ligand O 
itself O 
and O 
then O 
being O 
trapped O 
together O 
onto O 
some O 
off O 
- O 
sites O 
. O 
The O 
π-π O 
stacking O 
interactions O 
between O 
the O 
SWCNT O 
and O 
aromatic O 
residues O 
are O 
found O 
to O 
play O 
a O 
significant O 
role O 
in O 
its O 
binding O 
to O 
the O 
SH3 O 
domain O 
in O 
all O 
the O 
three O 
force O 
fields O 
. O 
Further O 
analyses O 
show O 
that O 
even O 
the O 
SWCNT O 
- O 
ligand O 
binding O 
can O 
also O 
be O 
relatively O 
more O 
stable O 
than O 
the O 
native O 
ligand O 
- O 
protein O 
binding O 
, O 
indicating O 
a O 
serious O 
potential O 
disruption O 
to O 
the O 
protein O 
SH3 O 
function O 
. O 

, O 
Synthesis O 
, O 
and O 
Pharmacological O 
Characterization O 
of O 
Novel O 
Endomorphin-1 B-TRIVIAL 
Analogues O 
as O 
Extremely O 
Potent O 
μ-Opioid O 
Agonists O 
. O 

we O 
reported O 
the O 
synthesis O 
and O 
structure O 
- O 
activity O 
study O 
of O 
endomorphin-1 B-TRIVIAL 
( O 
EM-1 B-ABBREVIATION 
) O 
analogues O 
containing O 
novel O 
, O 
unnatural O 
α-methylene-β-aminopropanoic B-FAMILY 
acids I-FAMILY 
( O 
Map B-ABBREVIATION 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
describe O 
new O 
EM-1 B-ABBREVIATION 
analogues O 
containing O 
Dmt B-ABBREVIATION 
( O 
1 O 
) O 
, O 
( B-ABBREVIATION 
R I-ABBREVIATION 
/ I-ABBREVIATION 
S)-βPro I-ABBREVIATION 
( O 
2 O 
) O 
, O 
and O 
(ph)Map B-ABBREVIATION 
(4)/ O 
(2-furyl)Map B-SYSTEMATIC 
( O 
4 O 
) O 
. O 
All O 
of O 
the O 
analogues O 
showed O 
a O 
high O 
affinity O 
for O 
the O 
μ-opioid O 
receptor O 
( O 
MOR O 
) O 
and O 
increased O 
stability O 
in O 
mouse O 
brain O 
homogenates O 
. O 
Of O 
the O 
new O 
compounds O 
, O 
Dmt B-ABBREVIATION 
(1)- O 
(R)-βPro B-ABBREVIATION 
(2)- O 
Trp B-FORMULA 
(3)- O 
(2-furyl)Map B-SYSTEMATIC 
( O 
4 O 
) O 
( O 
analogue O 
12 O 
) O 
displayed O 
the O 
highest O 
affinity O 
toward O 
MOR O 
, O 
in O 
the O 
picomolar O 
range O 
( O 
Ki(μ) O 
= O 
3.72 O 
pM O 
) O 
. O 
Forskolin B-TRIVIAL 
-induced O 
cAMP B-ABBREVIATION 
accumulation O 
assays O 
indicated O 
that O 
this O 
analogue O 
displayed O 
an O 
extremely O 
high O 
agonistic O 
potency O 
, O 
in O 
the O 
subpicomolar O 
range O 
( O 
EC50 O 
= O 
0.0421 O 
pM O 
, O 
Emax O 
= O 
99.5% O 
) O 
. O 
This O 
compound O 
also O 
displayed O 
stronger O 
in O 
vivo O 
antinociceptive O 
activity O 
after O 
iv O 
administration O 
when O 
compared O 
to O 
morphine B-TRIVIAL 
in O 
the O 
tail O 
- O 
flick O 
test O 
, O 
which O 
indicates O 
that O 
this O 
analogue O 
was O 
able O 
to O 
cross O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 

Derivatives O 
and O 
Benzofurans B-FAMILY 
from O 
a O 
Sponge O 
- O 
Derived O 
Penicillium O 
sp O 
. O 
Fungus O 
. O 

new O 
fungal O 
metabolites O 
, O 
including O 
three O 
hydroisocoumarins B-FAMILY 
, O 
penicimarins B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
three O 
isocoumarins B-FAMILY 
, O 
penicimarins B-MULTIPLE 
D-F I-MULTIPLE 
( O 
6-8 O 
) O 
, O 
and O 
four O 
benzofurans B-FAMILY 
, O 
penicifurans B-MULTIPLE 
A-D I-MULTIPLE 
( O 
11-14 O 
) O 
, O 
together O 
with O 
four O 
known O 
isocoumarin B-TRIVIAL 
derivatives O 
( O 
4 O 
, O 
5 O 
, O 
9 O 
, O 
10 O 
) O 
, O 
were O 
obtained O 
from O 
the O 
sponge O 
- O 
derived O 
fungus O 
Penicillium O 
sp O 
. O 
MWZ14-4 O 
, O 
collected O 
from O 
the O 
South O 
China O 
Sea O 
. O 
Their O 
planar O 
structures O 
and O 
relative O 
configurations O 
were O 
elucidated O 
by O 
detailed O 
analysis O 
of O 
spectroscopic O 
data O 
and O 
by O 
comparison O 
with O 
related O 
known O 
compounds O 
. O 
The O 
absolute O 
configurations O 
of O 
1-4 O 
were O 
assigned O 
by O 
the O 
modified O 
Mosher's O 
method O 
and O 
TDDFT O 
ECD O 
calculations O 
together O 
with O 
comparison O 
of O 
their O 
CD O 
spectra O 
. O 
Compound O 
1 O 
represents O 
a O 
rare O 
naturally O 
occurring O 
isocoumarin B-TRIVIAL 
derivative O 
with O 
4-substitution O 
, O 
but O 
no O 
substituent O 
at O 
the O 
3- O 
position O 
. O 
These O 
compounds O 
were O 
evaluated O 
for O 
antibacterial O 
activities O 
and O 
cytotoxic O 
activities O 
in O 
vitro O 
. O 
Among O 
them O 
, O 
penicifuran B-TRIVIAL 
A I-TRIVIAL 
( O 
11 O 
) O 
exhibited O 
inhibitory O 
activity O 
against O 
Staphylococcus O 
albus O 
with O 
an O 
MIC O 
value O 
of O 
3.13 O 
μM O 
. O 

of O 
the O 
inhibitory O 
effect O 
against O 
copper B-SYSTEMATIC 
ion O 
- O 
induced O 
oxidation O 
in O 
rat O 
plasma O 
after O 
oral O 
administration O 
of O 
salvianolic B-TRIVIAL 
acid I-TRIVIAL 
B I-TRIVIAL 
and O 
its O 
decocted O 
solutions O 
. O 

effects O 
of O 
salvianolic B-TRIVIAL 
acid I-TRIVIAL 
B I-TRIVIAL 
( O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
) O 
decoction O 
on O 
antioxidative O 
activities O 
were O 
evaluated O 
. O 
The O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
( O 
DPPH B-ABBREVIATION 
) O 
radical O 
- O 
scavenging O 
activity O 
, O 
Fe(2+) B-FORMULA 
-chelating O 
activity O 
, O 
reducing O 
power O 
, O 
and O 
total O 
phenolic B-FAMILY 
content O 
of O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
-decocted O 
solutions O 
did O 
not O 
change O 
significantly O 
after O 
decoction O 
in O 
an O 
aqueous O 
solution O 
. O 
However O 
, O 
the O 
formation O 
of O 
cholesteryl B-SYSTEMATIC 
ester I-SYSTEMATIC 
hydroperoxide I-SYSTEMATIC 
( O 
CE-OOH B-FORMULA 
) O 
in O 
rat O 
blood O 
plasma O 
containing O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
-decocted O 
solutions O 
was O 
more O 
effectively O 
inhibited O 
than O 
that O 
of O 
plasma O 
containing O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
solution O 
, O 
regardless O 
of O 
the O 
decoction O 
time O 
. O 
In O 
addition O 
, O 
the O 
accumulation O 
of O 
CE-OOH B-FORMULA 
in O 
rat O 
plasma O 
after O 
oral O 
administration O 
of O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
-decocted O 
solutions O 
was O 
more O 
effectively O 
suppressed O 
than O 
when O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
solution O 
was O 
administered O 
, O 
considering O 
the O 
lag O 
time O 
. O 
It O 
is O 
likely O 
that O 
the O 
decoction O 
was O 
partly O 
responsible O 
for O 
the O 
increased O 
antioxidant O 
activity O 
in O 
blood O 
plasma O 
. O 
Therefore O 
, O 
the O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
-decocted O 
solution O 
may O 
contribute O 
more O 
to O 
antioxidant O 
defense O 
in O 
blood O 
than O 
a O 
Sal B-ABBREVIATION 
B I-ABBREVIATION 
solution O 
that O 
is O 
not O 
decocted O 
. O 

I I-TRIVIAL 
inhibits O 
rac1 O 
activation O 
in O 
breast O 
cancer O 
cells O 
by O 
a O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
- O 
mediated O 
mechanism O 
and O 
independently O 
of O 
janus O 
tyrosine B-TRIVIAL 
kinase O 
2 O 
and O 
p-rex1 O 
. O 

small O 
GTPase O 
Rac1 O 
has O 
been O 
widely O 
implicated O 
in O 
mammary O 
tumorigenesis O 
and O 
metastasis O 
. O 
Previous O 
studies O 
established O 
that O 
stimulation O 
of O 
ErbB O 
receptors O 
in O 
breast O 
cancer O 
cells O 
activates O 
Rac1 O 
and O 
enhances O 
motility O 
via O 
the O 
Rac- O 
guanine B-TRIVIAL 
nucleotide I-TRIVIAL 
exchange O 
factor O 
P-Rex1 O 
. O 
As O 
the O 
Janus O 
tyrosine B-TRIVIAL 
kinase O 
2 O 
( O 
Jak2 O 
) O 
/ O 
signal O 
transducer O 
and O 
activator O 
of O 
transcription O 
3 O 
( O 
Stat3 O 
) O 
pathway O 
has O 
been O 
shown O 
to O 
be O 
functionally O 
associated O 
with O 
ErbB O 
receptors O 
, O 
we O 
asked O 
if O 
this O 
pathway O 
could O 
mediate O 
P-Rex1 O 
/ O 
Rac1 O 
activation O 
in O 
response O 
to O 
ErbB O 
ligands O 
. O 
Here O 
we O 
found O 
that O 
the O 
anticancer O 
agent O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
, O 
a O 
Jak2 O 
inhibitor O 
, O 
reduced O 
the O 
activation O 
of O 
Rac1 O 
and O 
motility O 
in O 
response O 
to O 
the O 
ErbB3 O 
ligand O 
heregulin O 
in O 
breast O 
cancer O 
cells O 
. O 
However O 
, O 
Rac1 O 
activation O 
was O 
not O 
affected O 
by O 
Jak2 O 
or O 
Stat3 O 
RNA O 
interference O 
, O 
suggesting O 
that O 
the O 
effect O 
of O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
occurs O 
through O 
a O 
Jak2 O 
- O 
independent O 
mechanism O 
. O 
Cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
also O 
failed O 
to O 
affect O 
the O 
activation O 
of O 
P-Rex1 O 
by O 
heregulin O 
. O 
Subsequent O 
analysis O 
revealed O 
that O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
strongly O 
activates O 
RhoA O 
and O 
the O 
Rho O 
effector O 
Rho O 
kinase O 
( O 
ROCK O 
) O 
in O 
breast O 
cancer O 
cells O 
and O 
induces O 
the O 
formation O 
of O 
stress O 
fibers O 
. O 
Interestingly O 
, O 
disruption O 
of O 
the O 
RhoA-ROCK O 
pathway O 
prevented O 
the O 
inhibitory O 
effect O 
of O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
on O 
Rac1 O 
activation O 
by O 
heregulin O 
. O 
Lastly O 
, O 
we O 
found O 
that O 
RhoA O 
activation O 
by O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
is O 
mediated O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
The O 
ROS O 
scavenger O 
N-acetyl B-SYSTEMATIC 
l-cysteine I-SYSTEMATIC 
and O 
the O 
mitochondrial O 
antioxidant O 
Mito-TEMPO O 
rescued O 
the O 
inhibitory O 
effect O 
of O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
on O 
Rac1 O 
activation O 
. O 
In O 
conclusion O 
, O 
these O 
results O 
indicate O 
that O 
ErbB-driven O 
Rac1 O 
activation O 
in O 
breast O 
cancer O 
cells O 
proceeds O 
independently O 
of O 
the O 
Jak2 O 
pathway O 
. O 
Moreover O 
, O 
they O 
established O 
that O 
the O 
inhibitory O 
effect O 
of O 
cucurbitacin B-TRIVIAL 
I I-TRIVIAL 
on O 
Rac1 O 
activity O 
involves O 
the O 
alteration O 
of O 
the O 
balance O 
between O 
Rho O 
and O 
Rac O 
. O 

and O 
in O 
- O 
silico O 
studies O 
of O 
some O 
diaryltriazole B-FAMILY 
derivatives O 
as O 
potential O 
cyclooxygenase O 
inhibitors O 
. O 

synthesis O 
of O 
several O 
4-phenyl-5-pyridin-4-yl-2,3-dihydro-3H-1,2,4-triazole-3-thiones B-FAMILY 
possessing O 
N-2 O 
Mannich B-FAMILY 
bases I-FAMILY 
or O 
S-alkyl B-FAMILY 
substituents O 
, O 
is O 
reported O 
. O 
Several O 
of O 
them O 
exhibited O 
a O 
low O 
nanomolar O 
COX O 
enzyme O 
inhibition O 
activity O 
. O 
Most O 
of O 
the O 
compounds O 
showed O 
inhibition O 
of O 
edema O 
was O 
similar O 
to O 
that O 
evoked O 
by O 
celocoxib B-TRIVIAL 
in O 
animal O 
model O 
. O 
Molecular O 
docking O 
studies O 
of O 
the O 
compounds O 
into O 
the O 
binding O 
sites O 
of O 
COX-1 O 
and O 
COX-2 O 
allowed O 
us O 
to O 
shed O 
light O 
on O 
the O 
binding O 
mode O 
of O 
these O 
novel O 
COX O 
inhibitors O 
. O 

myriophylla O 
has O 
been O 
used O 
for O 
long O 
by O 
Thai O 
traditional O 
healers O 
as O 
an O 
important O 
ingredient O 
herb O 
in O 
Thai O 
herbal O 
formulas O 
for O 
caries O 
. O 
In O 
this O 
study O 
, O 
three O 
flavonoids O 
lupinifolin B-TRIVIAL 
( O 
6 O 
) O 
, O 
8-methoxy-7,3',4'-trihydroxyflavone B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
and O 
7,8,3',4'-tetrahydroxyflavone B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
a O 
triterpenoid B-FAMILY 
lupeol B-TRIVIAL 
( O 
3 O 
) O 
as O 
well O 
as O 
four O 
sterols B-FAMILY 
β-sitosterone B-TRIVIAL 
( O 
1 O 
) O 
, O 
stigmasta-5,22-dien-3-one B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
β-sitosterol B-TRIVIAL 
( O 
4 O 
) O 
, O 
and O 
stigmasterol B-TRIVIAL 
( O 
5 O 
) O 
were O 
isolated O 
from O 
A O 
. O 
myriophylla O 
wood O 
. O 
The O 
antibacterial O 
activity O 
of O 
these O 
compounds O 
against O 
Streptococcus O 
mutans O 
ATCC O 
25175 O 
was O 
performed O 
using O 
broth O 
microdilution O 
method O 
. O 
All O 
compounds O 
exhibited O 
antibacterial O 
activity O 
against O 
S O 
. O 
mutans O 
with O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
and O 
minimum O 
bactericidal O 
concentration O 
( O 
MBC O 
) O 
ranging O 
from O 
1-256 O 
and O 
2-256 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Among O 
the O 
isolated O 
compounds O 
, O 
lupinifolin B-TRIVIAL 
( O 
6 O 
) O 
was O 
found O 
to O 
be O 
the O 
most O 
potent O 
with O 
MIC O 
and O 
MBC O 
of O 
1 O 
and O 
2 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
Lupinifolin B-TRIVIAL 
( O 
6 O 
) O 
also O 
showed O 
a O 
strong O 
activity O 
against O 
ten O 
clinical O 
isolates O 
of O 
S O 
. O 
mutans O 
with O 
MIC O 
and O 
MBC O 
ranging O 
from O 
0.25-2 O 
and O 
0.5-8 O 
μg O 
/ O 
ml O 
, O 
respectively O 
. O 
These O 
results O 
reported O 
the O 
bioactive O 
ingredients O 
of O 
A O 
. O 
myriophylla O 
which O 
support O 
its O 
ethnomedical O 
claims O 
as O 
well O 
. O 
Lupinifolin B-TRIVIAL 
( O 
6 O 
) O 
may O 
have O 
a O 
potential O 
to O 
be O 
a O 
natural O 
anticariogenic O 
agent O 
. O 

of O 
cadmium B-SYSTEMATIC 
and O 
lead O 
with O 
antioxidant O 
status O 
and O 
incidence O 
of O 
benign O 
prostatic O 
hyperplasia O 
in O 
patients O 
of O 
Western O 
India O 
. O 

association O 
of O 
cadmium B-SYSTEMATIC 
( O 
Cd B-FORMULA 
) O 
and O 
lead O 
( O 
Pb B-FORMULA 
) O 
in O 
the O 
pathophysiology O 
and O 
progression O 
of O 
benign O 
prostate O 
hyperplasia O 
( O 
BPH O 
) O 
has O 
been O 
evaluated O 
in O 
an O 
epidemiological O 
study O 
with O 
116 O 
BPH O 
patients O 
of O 
the O 
western O 
part O 
of O 
India O 
. O 
The O 
prostatic O 
acid O 
phosphatase O 
activity O 
, O 
prostate O 
- O 
specific O 
antigen O 
, O 
maximum O 
urinary O 
flow O 
rate O 
( O 
Q O 
max O 
) O 
, O 
and O 
redox O 
status O 
of O 
BPH O 
patients O 
were O 
correlated O 
with O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
contents O 
. O 
Additionally O 
, O 
patients O 
were O 
also O 
separated O 
on O 
the O 
basis O 
of O 
their O 
age O 
, O 
genetic O 
lineage O 
, O 
and O 
additive O 
habits O 
and O 
correlated O 
with O 
the O 
Cd B-FORMULA 
, O 
Pb B-FORMULA 
, O 
and O 
Q O 
max O 
levels O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
accumulation O 
of O 
toxic O 
metals O 
in O 
prostate O 
tissue O 
has O 
a O 
significant O 
positive O 
correlation O 
with O 
the O 
pathogenesis O 
of O 
BPH O 
. O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
exert O 
their O 
effects O 
through O 
altered O 
antioxidant O 
defense O 
mechanisms O 
, O 
ultimately O 
leading O 
to O 
increased O 
BPH O 
severity O 
. O 
Progression O 
of O 
the O 
pathogenesis O 
also O 
depends O 
on O 
other O 
factors O 
such O 
as O 
additive O 
habits O 
, O 
genetic O 
lineage O 
, O 
and O 
age O 
of O 
the O 
patients O 
. O 

: O 
a O 
novel O 
AT₁ O 
antagonist O 
for O 
the O 
treatment O 
of O 
cardiovascular O 
disease O 
. O 

the O 
prevalence O 
of O 
cardiovascular O 
disease O 
in O 
public O 
health O 
and O 
the O 
limited O 
validated O 
therapeutic O 
options O 
, O 
this O 
study O 
aimed O 
to O 
find O 
novel O 
compounds O 
targeting O 
the O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
, O 
accepted O 
as O 
a O 
therapeutic O 
target O 
in O 
cardiovascular O 
disease O 
. O 
A O 
small O 
library O 
consisting O 
of O 
89 O 
compounds O 
from O 
39 O 
Chinese O 
herbs O 
was O 
profiled O 
using O 
a O 
cell O 
- O 
based O 
calcium O 
mobilization O 
assay O 
which O 
was O 
developed O 
and O 
characterized O 
for O 
high O 
- O 
throughput O 
screening O 
. O 
[6]-Gingerol B-TRIVIAL 
derived O 
from O 
Zingiber O 
officinale O 
Roscoe O 
( O 
ginger O 
) O 
was O 
identified O 
as O 
a O 
novel O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
antagonist O 
, O 
with O 
an O 
IC50 O 
value O 
of O 
8.173 O 
µM O 
. O 
The O 
hit O 
was O 
further O 
tested O 
by O 
a O 
specificity O 
assay O 
indicating O 
that O 
it O 
had O 
no O 
antagonistic O 
effects O 
on O 
other O 
evaluated O 
GPCRs O 
, O 
such O 
as O 
endothelin O 
receptors O 
. O 
The O 
major O 
ingredient O 
of O 
ginger O 
, O 
[6]-gingerol B-TRIVIAL 
, O 
could O 
inhibit O 
angiotensin O 
II O 
type O 
1 O 
receptor O 
activation O 
, O 
which O 
partially O 
clarified O 
the O 
mechanism O 
of O 
ginger O 
regulating O 
blood O 
pressure O 
and O 
strengthening O 
heart O 
in O 
the O 
cardiovascular O 
system O 
. O 

and O 
2-Phenoxychromones B-FAMILY 
from O 
Peltophorum O 
pterocarpum O 
and O 
Evaluation O 
of O 
Their O 
Estrogenic O 
Activity O 
. O 

investigation O 
of O 
the O 
dichloromethane B-SYSTEMATIC 
extract O 
of O 
the O 
leaves O 
of O 
Peltophorum O 
pterocarpum O 
, O 
a O 
tropical O 
ornamental O 
tree O 
, O 
led O 
to O 
the O 
isolation O 
of O 
twelve O 
compounds O 
( O 
1-12 O 
) O 
. O 
One O 
new O 
derivative O 
of O 
peltogynoid O 
ophioglonin B-TRIVIAL 
( O 
1 O 
) O 
and O 
a O 
new O 
2-phenoxychromone B-SYSTEMATIC 
( O 
2 O 
) O 
with O 
its O 
3'-O-β-D-glucoside B-SYSTEMATIC 
derivative O 
( O 
3 O 
) O 
are O 
described O 
here O 
for O 
the O 
first O 
time O 
. O 
In O 
addition O 
, O 
nine O 
flavonoid O 
derivatives O 
, O 
including O 
peltogynoid O 
ophioglonin B-TRIVIAL 
( O 
4 O 
) O 
, O 
were O 
isolated O 
for O 
the O 
first O 
time O 
from O 
this O 
plant O 
. O 
The O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
and O 
chemical O 
methods O 
. O 
Evaluation O 
of O 
the O 
estrogenic O 
activities O 
of O 
1 O 
, O 
2 O 
, O 
and O 
4 O 
using O 
different O 
model O 
cell O 
systems O 
revealed O 
that O 
4 O 
was O 
estrogenic O 
and O 
that O 
2 O 
was O 
largely O 
inactive O 
. O 
Interestingly O 
, O 
1 O 
was O 
unable O 
to O 
stimulate O 
the O 
proliferation O 
of O 
breast O 
and O 
endometrial O 
cancer O 
cells O 
but O 
exhibited O 
substantial O 
estrogen B-FAMILY 
receptor O 
α- O 
mediated O 
activation O 
of O 
gene O 
expression O 
. O 
This O 
observation O 
indicates O 
that O 
1 O 
can O 
be O 
further O 
evaluated O 
for O 
its O 
cancer O 
chemopreventive O 
potential O 
. O 

and O 
erlotinib B-TRIVIAL 
are O 
small O 
- O 
molecule O 
reversible O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
( O 
TKIs O 
) O 
of O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
. O 
Objective O 
responses O 
have O 
been O 
observed O 
frequently O 
in O 
patients O 
with O 
non-small O 
cell O 
lung O 
cancer O 
( O 
NSCLC O 
) O 
harbouring O 
activating O 
EGFR O 
mutations O 
, O 
the O 
most O 
common O 
being O 
deletions O 
in O 
exon O 
19 O 
and O 
the O 
exon O 
21 O 
L858R O 
mutation O 
. O 
EGFR O 
mutations O 
are O 
prevalent O 
in O 
female O 
patients O 
, O 
those O 
who O 
have O 
never O 
smoked O 
, O 
those O 
of O 
Asian O 
ethnicity O 
and O 
those O 
who O 
have O 
adenocarcinoma O 
histology O 
. O 
Given O 
the O 
efficacy O 
of O 
EGFR O 
TKIs O 
in O 
advanced O 
NSCLC O 
in O 
the O 
salvage O 
setting O 
, O 
and O 
their O 
favourable O 
toxicity O 
profile O 
compared O 
with O 
conventional O 
chemotherapy O 
, O 
there O 
is O 
considerable O 
interest O 
in O 
evaluating O 
their O 
efficacy O 
in O 
the O 
first O 
- O 
line O 
treatment O 
of O 
advanced O 
NSCLC O 
. O 
To O 
date O 
, O 
there O 
have O 
been O 
several O 
phase O 
II O 
and O 
phase O 
III O 
studies O 
that O 
have O 
examined O 
the O 
efficacy O 
of O 
first O 
- O 
line O 
single O 
- O 
agent O 
EGFR O 
TKIs O 
in O 
unselected O 
, O 
clinically O 
selected O 
or O 
molecularly O 
selected O 
populations O 
. O 
Here O 
we O 
review O 
and O 
compare O 
the O 
differences O 
in O 
these O 
phase O 
III O 
trials O 
. O 
Most O 
phase O 
III O 
trials O 
chose O 
progression O 
- O 
free O 
survival O 
( O 
PFS O 
) O 
rather O 
than O 
overall O 
survival O 
( O 
OS O 
) O 
as O 
their O 
primary O 
endpoint O 
. O 
PFS O 
was O 
prolonged O 
but O 
OS O 
was O 
not O 
. O 
The O 
recent O 
development O 
of O 
novel O 
irreversible O 
EGFR O 
TKIs O 
, O 
such O 
as O 
afatinib B-TRIVIAL 
and O 
dacomitinib B-TRIVIAL 
, O 
is O 
also O 
reviewed O 
. O 

5-hydroxytryptamine B-SYSTEMATIC 
( O 
serotonin B-TRIVIAL 
) O 
receptor O 
6 O 
agonist O 
EMD B-IDENTIFIER 
386088 I-IDENTIFIER 
ameliorates O 
ketamine B-TRIVIAL 
-induced O 
deficits O 
in O 
attentional O 
set O 
shifting O 
and O 
novel O 
object O 
recognition O 
, O 
but O 
not O 
in O 
the O 
prepulse O 
inhibition O 
in O 
rats O 
. O 

data O 
suggest O 
that O 
the O 
5-hydroxytryptamine B-SYSTEMATIC 
( O 
serotonin B-TRIVIAL 
) O 
6 O 
( O 
5-HT6 O 
) O 
receptor O 
may O 
be O 
a O 
potential O 
target O 
for O 
the O 
development O 
of O 
new O 
therapies O 
for O 
treating O 
cognitive O 
dysfunctions O 
in O 
schizophrenia O 
and O 
other O 
central O 
nervous O 
system O 
disorders O 
. O 
Recent O 
evidence O 
indicates O 
that O 
not O 
only O 
blockade O 
but O 
also O 
activation O 
of O 
5-HT6 O 
receptors O 
exerts O 
procognitive O 
effects O 
. O 
Nevertheless O 
, O 
little O 
is O 
known O 
about O 
the O 
potential O 
efficacy O 
of O 
5-HT6 O 
receptor O 
agonists O 
in O 
models O 
of O 
schizophrenia O 
- O 
like O 
cognitive O 
deficits O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
the O 
5-HT6 O 
receptor O 
agonist O 
, O 
EMD B-IDENTIFIER 
386088 I-IDENTIFIER 
, O 
on O 
the O 
ketamine B-TRIVIAL 
-induced O 
deficits O 
in O 
the O 
attentional O 
set O 
- O 
shifting O 
task O 
( O 
ASST O 
) O 
, O 
novel O 
object O 
recognition O 
( O 
NOR O 
) O 
task O 
and O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
task O 
in O 
rats O 
. O 
Acute O 
administration O 
of O 
EMD B-IDENTIFIER 
386088 I-IDENTIFIER 
( O 
2.5 O 
and O 
5 O 
mg O 
/ O 
kg O 
, O 
intraperitoneally O 
) O 
to O 
Sprague-Dawley O 
rats O 
reversed O 
the O 
deficit O 
in O 
the O 
ASST O 
induced O 
by O 
repeated O 
ketamine B-TRIVIAL 
administration O 
. O 
Moreover O 
, O 
the O 
ketamine B-TRIVIAL 
-induced O 
deficit O 
in O 
the O 
NOR O 
task O 
was O 
ameliorated O 
by O 
EMD B-IDENTIFIER 
386088 I-IDENTIFIER 
at O 
a O 
dose O 
of O 
5 O 
mg O 
/ O 
kg O 
. O 
However O 
, O 
in O 
contrast O 
to O 
the O 
antipsychotic O 
drug O 
clozapine B-TRIVIAL 
, O 
the O 
5-HT6 O 
agonist O 
did O 
not O 
affect O 
PPI O 
disrupted O 
by O 
ketamine B-TRIVIAL 
. O 
The O 
present O 
study O 
demonstrated O 
the O 
beneficial O 
effects O 
of O 
the O 
5-HT6 O 
agonist O 
in O 
ameliorating O 
some O 
of O 
the O 
ketamine B-TRIVIAL 
-induced O 
deficits O 
relevant O 
to O 
schizophrenia O 
. O 
It O 
thus O 
seems O 
likely O 
that O 
the O 
5-HT6 O 
receptor O 
activation O 
may O 
represent O 
a O 
useful O 
pharmacological O 
approach O 
to O 
the O 
treatment O 
of O 
cognitive O 
disturbances O 
observed O 
in O 
this O 
disorder O 
. O 

regulation O 
of O 
2- O 
cys B-FORMULA 
peroxiredoxin O 
reaction O 
cycle O 
by O 
s-nitrosylation O 
. O 

( O 
SNOs B-FAMILY 
) O 
, O 
formed O 
by O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
- O 
mediated O 
S B-FORMULA 
-nitrosylation O 
, O 
and O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
, O 
a O 
prominent O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
are O 
implicated O 
in O 
diverse O 
physiological O 
and O 
pathological O 
processes O 
. O 
Recent O 
research O 
has O 
shown O 
that O 
the O 
cellular O 
action O 
and O 
metabolism O 
of O 
SNOs B-FAMILY 
and O 
H2O2 B-FORMULA 
involve O 
overlapping O 
, O 
thiol B-FAMILY 
-based O 
mechanisms O 
, O 
but O 
how O 
these O 
reactive O 
species O 
may O 
affect O 
each O 
other's O 
fate O 
and O 
function O 
is O 
not O 
well O 
understood O 
. O 
In O 
this O 
study O 
we O 
investigated O 
how O 
NO B-FORMULA 
/ O 
SNO B-FORMULA 
may O 
affect O 
the O 
redox O 
cycle O 
of O 
mammalian O 
peroxiredoxin-1 O 
( O 
Prx1 O 
) O 
, O 
a O 
representative O 
of O 
the O 
2- O 
Cys B-FORMULA 
Prxs O 
, O 
a O 
group O 
of O 
thioredoxin O 
(Trx)-dependent O 
peroxidases O 
. O 
We O 
found O 
that O 
, O 
both O 
in O 
a O 
cell O 
- O 
free O 
system O 
and O 
in O 
cells O 
, O 
NO B-FORMULA 
/ O 
SNO B-FORMULA 
donors O 
such O 
as O 
S-nitrosocysteine B-SYSTEMATIC 
and O 
S-nitrosoglutathione B-SYSTEMATIC 
readily O 
induced O 
the O 
S B-FORMULA 
-nitrosylation O 
of O 
Prx1 O 
, O 
causing O 
structural O 
and O 
functional O 
alterations O 
. O 
In O 
particular O 
, O 
nitrosylation O 
promoted O 
disulfide B-SYSTEMATIC 
formation O 
involving O 
the O 
pair O 
of O 
catalytic O 
cysteines B-FAMILY 
( O 
Cys B-FORMULA 
-52 O 
and O 
Cys B-FORMULA 
-173 O 
) O 
and O 
disrupted O 
the O 
oligomeric O 
structure O 
of O 
Prx1 O 
, O 
leading O 
to O 
loss O 
of O 
peroxidase O 
activity O 
. O 
A O 
highly O 
potent O 
inhibition O 
of O 
the O 
peroxidase O 
catalytic O 
reaction O 
by O 
NO B-FORMULA 
/ O 
SNO B-FORMULA 
was O 
seen O 
in O 
assays O 
employing O 
the O 
coupled O 
Prx-Trx O 
system O 
. O 
In O 
this O 
setting O 
, O 
S-nitrosocysteine B-SYSTEMATIC 
( O 
10 O 
μm O 
) O 
effectively O 
blocked O 
the O 
Trx O 
- O 
mediated O 
regeneration O 
of O 
oxidized O 
Prx1 O 
. O 
This O 
effect O 
appeared O 
to O 
be O 
due O 
to O 
both O 
competition O 
between O 
S-nitrosocysteine B-SYSTEMATIC 
and O 
Prx1 O 
for O 
the O 
Trx O 
system O 
and O 
direct O 
modulation O 
by O 
S-nitrosocysteine B-SYSTEMATIC 
of O 
Trx O 
reductase O 
activity O 
. O 
Our O 
findings O 
that O 
NO B-FORMULA 
/ O 
SNO B-FORMULA 
target O 
both O 
Prx O 
and O 
Trx O 
reductase O 
may O 
have O 
implications O 
for O 
understanding O 
the O 
impact O 
of O 
nitrosylation O 
on O 
cellular O 
redox O 
homeostasis O 
. O 

and O 
sidewall O 
functionalization O 
of O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
and O 
resulting O 
bioactivity O 
in O 
two O 
macrophage O 
models O 
. O 

study O 
examined O 
the O 
consequences O 
of O 
surface O 
carboxylation O 
of O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNT O 
) O 
on O 
bioactivity O 
. O 
Since O 
commercial O 
raw O 
MWCNT O 
contain O 
impurities O 
that O 
may O 
affect O 
their O 
bioactivity O 
, O 
HCl B-FORMULA 
refluxing O 
was O 
exploited O 
to O 
purify O 
raw O 
" O 
as-received O 
" O 
MWCNT O 
by O 
removing O 
the O 
amorphous O 
carbon B-SYSTEMATIC 
layer O 
on O 
the O 
MWCNT O 
surface O 
and O 
reducing O 
the O 
metal O 
impurities O 
( O 
e.g O 
. O 
Ni B-FORMULA 
) O 
. O 
The O 
removal O 
of O 
amorphous O 
carbon B-SYSTEMATIC 
layer O 
was O 
confirmed O 
by O 
Raman O 
spectroscopy O 
and O 
thermogravimetric O 
analysis O 
. O 
Furthermore O 
, O 
the O 
HCl B-FORMULA 
-purified O 
MWCNT O 
provided O 
more O 
available O 
reaction O 
sites O 
, O 
leading O 
to O 
enhanced O 
sidewall O 
functionalization O 
. O 
The O 
sidewall O 
of O 
HCl B-FORMULA 
-purified O 
MWCNT O 
was O 
further O 
functionalized O 
with O 
the O 
- O 
COOH B-FORMULA 
moiety O 
by O 
HNO(3) B-FORMULA 
oxidation O 
. O 
This O 
process O 
resulted O 
in O 
four O 
distinct O 
MWCNT O 
: O 
raw O 
, O 
purified O 
, O 
- O 
COOH B-FORMULA 
-terminated O 
raw O 
MWCNT O 
, O 
and O 
- O 
COOH B-FORMULA 
-terminated O 
purified O 
MWCNT O 
. O 
Freshly O 
isolated O 
alveolar O 
macrophages O 
from O 
C57Bl O 
/ O 
6 O 
mice O 
were O 
exposed O 
to O 
these O 
nanomaterials O 
to O 
determine O 
the O 
effects O 
of O 
the O 
surface O 
chemistry O 
on O 
the O 
bioactivity O 
in O 
terms O 
of O 
cell O 
viability O 
and O 
inflammasome O 
activation O 
. O 
Inflammasome O 
activation O 
was O 
confirmed O 
using O 
inhibitors O 
of O 
cathepsin O 
B O 
and O 
Caspase-1 O 
. O 
Purification O 
reduced O 
the O 
cell O 
toxicity O 
and O 
inflammasome O 
activation O 
slightly O 
compared O 
to O 
raw O 
MWCNT O 
. O 
In O 
contrast O 
, O 
functionalization O 
of O 
MWCNT O 
with O 
the O 
- O 
COOH B-FORMULA 
group O 
dramatically O 
reduced O 
the O 
cytotoxicity O 
and O 
inflammasome O 
activation O 
. O 
Similar O 
results O 
were O 
seen O 
using O 
THP-1 O 
cells O 
supporting O 
their O 
potential O 
use O 
for O 
high O 
- O 
throughput O 
screening O 
. O 
This O 
study O 
demonstrated O 
that O 
the O 
toxicity O 
and O 
bioactivity O 
of O 
MWCNT O 
were O 
diminished O 
by O 
removal O 
of O 
the O 
Ni B-FORMULA 
contamination O 
and O 
/ O 
or O 
addition O 
of O 
- O 
COOH B-FORMULA 
groups O 
to O 
the O 
sidewalls O 
. O 

and O 
computational O 
study O 
of O 
the O 
interaction O 
of O 
novel O 
colchicinoids B-FAMILY 
with O 
a O 
recombinant O 
human O 
αI O 
/ O 
βI-tubulin O 
heterodimer O 
. O 

binding O 
free O 
energies O 
on O 
human O 
tubulin O 
of O 
selected O 
colchicine B-TRIVIAL 
and O 
thiocolchicine B-SYSTEMATIC 
compounds O 
were O 
determined O 
. O 
Two O 
methods O 
were O 
used O 
for O 
the O 
determination O 
of O 
binding O 
free O 
energies O 
. O 
One O 
is O 
based O 
on O 
theoretical O 
prediction O 
simulating O 
the O 
dissociation O 
of O 
the O 
compound O 
from O 
tubulin O 
using O 
a O 
series O 
of O 
molecular O 
dynamics O 
simulations O 
. O 
The O 
other O 
method O 
involved O 
a O 
series O 
of O 
experiments O 
that O 
measured O 
the O 
affinity O 
of O 
the O 
compound O 
on O 
a O 
synthetically O 
expressed O 
and O 
purified O 
tubulin O 
protein O 
using O 
a O 
spectrofluorometric O 
technique O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

functionalized O 
palladium B-SYSTEMATIC 
icosahedra I-SYSTEMATIC 
: O 
one O 
- O 
pot O 
water O 
- O 
based O 
synthesis O 
and O 
their O 
superior O 
electrocatalytic O 
activity O 
and O 
ethanol B-SYSTEMATIC 
tolerant O 
ability O 
in O 
alkaline O 
media O 
. O 

( O 
PAH B-ABBREVIATION 
) O 
functionalized O 
Pd B-FORMULA 
icosahedra I-FORMULA 
are O 
synthesized O 
through O 
a O 
simple O 
, O 
one O 
- O 
pot O 
, O 
seedless O 
and O 
hydrothermal O 
growth O 
method O 
. O 
Herein O 
, O 
PAH B-ABBREVIATION 
is O 
used O 
efficiently O 
as O 
a O 
complex O 
- O 
forming O 
agent O 
, O 
capping O 
agent O 
, O 
and O 
facet O 
- O 
selective O 
agent O 
. O 
The O 
strong O 
interaction O 
between O 
PAH B-ABBREVIATION 
and O 
Pd B-FORMULA 
atom O 
sharply O 
changes O 
the O 
electronic O 
structure O 
of O 
Pd B-FORMULA 
atom O 
in O 
the O 
Pd B-FORMULA 
icosahedra I-FORMULA 
. O 
The O 
protective O 
function O 
of O 
PAH B-ABBREVIATION 
layers O 
and O 
enhanced O 
antietching O 
capability O 
of O 
Pd B-FORMULA 
atom O 
are O 
responsible O 
for O 
the O 
formation O 
of O 
the O 
Pd B-FORMULA 
icosahedra I-FORMULA 
. O 
Very O 
importantly O 
, O 
the O 
as-prepared O 
PAH B-ABBREVIATION 
functionalized O 
Pd B-FORMULA 
icosahedra I-FORMULA 
exhibit O 
superior O 
electrocatalytic O 
activity O 
and O 
ethanol B-SYSTEMATIC 
tolerant O 
ability O 
toward O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
compared O 
to O 
the O 
commercially O 
available O 
Pt B-FORMULA 
black I-FORMULA 
in O 
alkaline O 
media O 
. O 
At O 
0.95 O 
V O 
( O 
vs O 
RHE O 
) O 
, O 
the O 
ORR O 
specific O 
kinetic O 
current O 
density O 
at O 
the O 
Pd B-FORMULA 
icosahedra I-FORMULA 
is O 
4.48 O 
times O 
higher O 
than O 
that O 
at O 
commercial O 
Pt B-FORMULA 
black I-FORMULA 
. O 
The O 
fact O 
demonstrates O 
the O 
appropriate O 
surface O 
modification O 
of O 
the O 
Pd B-FORMULA 
nanoparticles O 
by O 
nonmetallic O 
molecules O 
can O 
be O 
regarded O 
as O 
an O 
effective O 
way O 
to O 
enhance O 
the O 
electrocatalytic O 
activity O 
toward O 
the O 
ORR O 
. O 

- O 
assembling O 
multidomain O 
peptides O 
have O 
been O 
shown O 
to O 
have O 
desirable O 
properties O 
, O 
such O 
as O 
the O 
ability O 
to O 
form O 
hydrogels O 
that O 
rapidly O 
recover O 
following O 
shear O 
- O 
thinning O 
and O 
the O 
potential O 
to O 
be O 
tailored O 
by O 
amino B-FAMILY 
acid I-FAMILY 
selection O 
to O 
vary O 
their O 
elasticity O 
and O 
encapsulate O 
and O 
deliver O 
proteins O 
and O 
cells O 
. O 
Here O 
we O 
describe O 
the O 
effects O 
of O 
substitution O 
of O 
aliphatic O 
hydrophobic O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
central O 
domain O 
of O 
the O 
peptide O 
for O 
the O 
aromatic B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
phenylalanine B-TRIVIAL 
, O 
tyrosine B-TRIVIAL 
, O 
and O 
tryptophan B-TRIVIAL 
. O 
While O 
the O 
basic O 
nanofibrous O 
morphology O 
is O 
retained O 
in O 
all O 
cases O 
, O 
selection O 
of O 
the O 
particular O 
core O 
residues O 
results O 
in O 
switching O 
from O 
antiparallel O 
hydrogen B-SYSTEMATIC 
bonding O 
to O 
parallel O 
hydrogen B-SYSTEMATIC 
bonding O 
in O 
addition O 
to O 
changes O 
in O 
nanofiber O 
morphology O 
and O 
in O 
hydrogel O 
rheological O 
properties O 
. O 
Peptide O 
nanofiber O 
assemblies O 
are O 
investigated O 
by O 
circular O 
dichroism O 
polarimetry O 
, O 
infrared O 
spectroscopy O 
, O 
atomic O 
force O 
microscopy O 
, O 
transmission O 
and O 
scanning O 
electron O 
microscopy O 
, O 
oscillatory O 
rheology O 
, O 
and O 
molecular O 
dynamics O 
simulations O 
. O 
Results O 
from O 
this O 
study O 
will O 
aid O 
in O 
designing O 
next O 
generation O 
cell O 
scaffolding O 
materials O 
. O 

Purpose O 
: O 
The O 
study O 
looked O 
into O 
the O 
feasibility O 
of O 
producing O 
pellet O 
using O 
Avicel O 
CL611 O 
as O 
spheronization O 
aid O 
by O 
the O 
extrusion O 
/ O 
spheronization O 
technique O 
. O 
Methods O 
: O 
Pellets O 
were O 
formulated O 
to O 
contain O 
either O 
20% O 
or O 
40% O 
Avicel O 
CL611 O 
and O 
lactose B-TRIVIAL 
monohydrate I-TRIVIAL 
as O 
the O 
other O 
sole O 
ingredient O 
. O 
Water O 
is O 
used O 
as O 
liquid O 
binder O 
. O 
Quality O 
of O 
pellets O 
and O 
extrudates O 
were O 
analyzed O 
for O 
size O 
distribution O 
, O 
shape O 
, O 
surface O 
tensile O 
strength O 
and O 
disintegration O 
profile O 
. O 
Results O 
: O 
More O 
water O 
was O 
needed O 
when O 
higher O 
Avicel O 
CL611 O 
fraction O 
was O 
used O 
during O 
the O 
production O 
of O 
pellets O 
. O 
The O 
pellets O 
of O 
larger O 
size O 
were O 
obtained O 
by O 
increasing O 
the O 
water O 
content O 
. O 
Pellets O 
with O 
aspect O 
ratios O 
of O 
∼1.1 O 
were O 
produced O 
with O 
high O 
spheronization O 
speed O 
at O 
short O 
residence O 
time O 
. O 
Higher O 
tensile O 
strength O 
was O 
achieved O 
when O 
increasing O 
the O 
water O 
content O 
and O 
the O 
fraction O 
of O 
Avicel O 
CL611 O 
during O 
pellet O 
production O 
. O 
These O 
pellets O 
also O 
took O 
longer O 
time O 
to O 
disintegrate O 
, O 
nonetheless O 
all O 
the O 
pellets O 
disintegrated O 
within O 
15 O 
min O 
. O 
A O 
positive O 
linear O 
relationship O 
was O 
obtained O 
between O 
the O 
tensile O 
strength O 
and O 
time O 
for O 
pellets O 
to O 
disintegrate O 
. O 
Conclusion O 
: O 
Strong O 
but O 
round O 
pellets O 
that O 
disintegrate O 
rapidly O 
could O 
be O 
produced O 
with O 
Avicel O 
CL611 O 
as O 
spheronization O 
aid O 
using O 
moderately O 
soluble O 
compounds O 
such O 
as O 
lactose B-TRIVIAL 
. O 

dystrophy O 
type O 
1 O 
( O 
DM1 O 
) O 
is O 
caused O 
by O 
an O 
expanded O 
CUG O 
repeat O 
(CUG(exp)) O 
that O 
sequesters O 
muscleblind O 
- O 
like O 
1 O 
protein O 
( O 
MBNL1 O 
) O 
, O 
a O 
protein O 
that O 
regulates O 
alternative O 
splicing O 
. O 
CUG(exp) O 
RNA O 
is O 
a O 
validated O 
drug O 
target O 
for O 
this O 
currently O 
untreatable O 
disease O 
. O 
Herein O 
, O 
we O 
develop O 
a O 
bioactive O 
small O 
molecule O 
( O 
1 O 
) O 
that O 
targets O 
CUG(exp) O 
RNA O 
and O 
is O 
able O 
to O 
inhibit O 
the O 
CUG(exp)·MBNL1 O 
interaction O 
in O 
cells O 
that O 
model O 
DM1 O 
. O 
The O 
core O 
of O 
this O 
small O 
molecule O 
is O 
based O 
on O 
ligand O 
2 O 
, O 
which O 
was O 
previously O 
reported O 
to O 
be O 
active O 
in O 
an O 
in O 
vitro O 
assay O 
. O 
A O 
polyamine B-FAMILY 
-derivative O 
side O 
chain O 
was O 
conjugated O 
to O 
this O 
core O 
to O 
make O 
it O 
aqueous O 
- O 
soluble O 
and O 
cell O 
- O 
penetrable O 
. O 
In O 
a O 
DM1 O 
cell O 
model O 
this O 
conjugate O 
was O 
found O 
to O 
disperse O 
CUG(exp) O 
ribonuclear O 
foci O 
, O 
release O 
MBNL1 O 
, O 
and O 
partially O 
reverse O 
the O 
mis O 
- O 
splicing O 
of O 
the O 
insulin O 
receptor O 
pre-mRNA O 
. O 
Direct O 
evidence O 
for O 
ribonuclear O 
foci O 
dispersion O 
by O 
this O 
ligand O 
was O 
obtained O 
in O 
a O 
live O 
DM1 O 
cell O 
model O 
using O 
time O 
- O 
lapse O 
confocal O 
microscopy O 
. O 

the O 
intramolecular O 
o-h B-FORMULA 
··· O 
f B-FORMULA 
and O 
o-h B-FORMULA 
··· O 
cl B-FORMULA 
hydrogen B-SYSTEMATIC 
bonds O 
maintained O 
in O 
solution O 
? O 
A O 
theoretical O 
study O 
. O 

present O 
case O 
study O 
aims O 
at O 
calculating O 
the O 
equilibrium O 
conformer O 
compositions O 
for O 
2X- O 
ethanol B-SYSTEMATIC 
and O 
2X- O 
phenol B-SYSTEMATIC 
( O 
X O 
= O 
F B-FORMULA 
, O 
Cl B-FORMULA 
) O 
in O 
solution O 
, O 
and O 
exploring O 
the O 
effect O 
of O 
the O 
applied O 
theoretical O 
method O 
and O 
basis O 
set O 
on O 
the O 
obtained O 
results O 
, O 
as O 
well O 
as O 
considering O 
the O 
usefulness O 
of O 
the O 
continuum O 
solvent O 
approach O 
in O 
comparison O 
with O 
the O 
explicit O 
solvent O 
Monte O 
Carlo O 
model O 
utilizing O 
the O 
free O 
energy O 
perturbation O 
method O 
. O 
Gas-phase O 
optimizations O 
at O 
the O 
DFT O 
/ O 
B97D O 
/ O 
aug O 
- O 
cc O 
- O 
pvtz O 
and O 
ab O 
initio O 
MP2 O 
/ O 
aug O 
- O 
cc O 
- O 
pvtz O 
levels O 
predicted O 
structures O 
in O 
good O 
agreement O 
with O 
the O 
available O 
experimental O 
data O 
for O 
three O 
test O 
molecules O 
. O 
Because O 
in O 
- O 
solution O 
geometries O 
change O 
only O 
slightly O 
according O 
to O 
the O 
IEF-PCM O 
continuum O 
solvent O 
calculations O 
in O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
and O 
water O 
, O 
the O 
two O 
theoretical O 
levels O 
were O 
applied O 
further O 
on O 
, O 
and O 
complete O 
basis O 
set O 
( O 
CBS O 
) O 
relative O 
internal O 
free O 
energies O 
were O 
estimated O 
for O 
the O 
conformers O 
under O 
study O 
. O 
The O 
predicted O 
OCCF B-FORMULA 
gauche O 
/ O 
trans O 
ratio O 
for O 
2F-ethanol B-SYSTEMATIC 
was O 
well O 
reproduced O 
in O 
comparison O 
with O 
available O 
experimental O 
compositions O 
. O 
The O 
predominant O 
gauche O 
structure O 
maintains O 
an O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bond O 
in O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
HB O 
structure O 
) O 
, O 
whereas O 
HB O 
and O 
NoHB O 
gauche O 
conformers O 
appear O 
in O 
nearly O 
the O 
same O 
fraction O 
in O 
aqueous O 
solution O 
. O 
The O 
internally O 
hydrogen B-SYSTEMATIC 
-bonded O 
conformer O 
is O 
predominant O 
also O 
for O 
2X- O 
phenol B-SYSTEMATIC 
species O 
, O 
as O 
calculated O 
on O 
the O 
basis O 
of O 
relative O 
CBS O 
internal O 
free O 
energies O 
and O 
IEF-PCM O 
and O 
FEP O 
/ O 
MC O 
solvation O 
free O 
energies O 
. O 
Use O 
of O 
a O 
trihydrate B-SYSTEMATIC 
supermolecule O 
model O 
for O 
2F-ethanol B-SYSTEMATIC 
conformers O 
leads O 
to O 
the O 
prediction O 
of O 
the O 
aqueous O 
- O 
solution O 
composition O 
in O 
contrast O 
to O 
the O 
experiment O 
. O 
Solution O 
structure O 
modeling O 
predicts O 
weak O 
hydrogen B-SYSTEMATIC 
-bond O 
formation O 
capacity O 
for O 
both O 
the O 
covalently O 
bound O 
F B-FORMULA 
and O 
Cl B-FORMULA 
atoms O 
, O 
even O 
in O 
conformations O 
where O 
they O 
are O 
fully O 
exposed O 
to O 
hydration O 
. O 

of O 
Solvent O 
Polarity O 
on O 
the O 
Vibrational O 
Dephasing O 
Dynamics O 
of O 
the O 
Nitrosyl B-SYSTEMATIC 
Stretch O 
in O 
an O 
Fe B-FORMULA 
(II) I-FORMULA 
Complex O 
Revealed O 
by O 
2D O 
IR O 
Spectroscopy O 
. O 

vibrational O 
dephasing O 
dynamics O 
of O 
the O 
nitrosyl B-SYSTEMATIC 
stretching O 
vibration O 
( O 
ν O 
NO B-FORMULA 
) O 
in O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
( O 
SNP B-ABBREVIATION 
, O 
Na2[Fe(CN)5NO]·2H2O B-FORMULA 
) O 
are O 
investigated O 
using O 
two O 
- O 
dimensional O 
infrared O 
( O 
2D O 
IR O 
) O 
spectroscopy O 
. O 
The O 
ν O 
NO B-FORMULA 
in O 
SNP B-ABBREVIATION 
acts O 
as O 
a O 
model O 
system O 
for O 
the O 
nitrosyl B-SYSTEMATIC 
ligand O 
found O 
in O 
metalloproteins O 
which O 
play O 
an O 
important O 
role O 
in O 
the O 
transportation O 
and O 
detection O 
of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
in O 
biological O 
systems O 
. O 
We O 
perform O 
a O 
2D O 
IR O 
line O 
shape O 
study O 
of O 
the O 
ν O 
NO B-FORMULA 
in O 
the O 
following O 
solvents O 
: O 
water O 
, O 
deuterium B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
methanol B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
, O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
, O 
formamide B-SYSTEMATIC 
, O 
and O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
. O 
The O 
frequency O 
of O 
the O 
ν O 
NO B-FORMULA 
exhibits O 
a O 
large O 
vibrational O 
solvatochromic O 
shift O 
of O 
52 O 
cm(-1) O 
, O 
ranging O 
from O 
1884 O 
cm(-1) O 
in O 
dimethyl B-SYSTEMATIC 
sulfoxide I-SYSTEMATIC 
to O 
1936 O 
cm(-1) O 
in O 
water O 
. O 
The O 
vibrational O 
anharmonicity O 
of O 
the O 
ν O 
NO B-FORMULA 
varies O 
from O 
21 O 
to O 
28 O 
cm(-1) O 
in O 
the O 
solvents O 
used O 
in O 
this O 
study O 
. O 
The O 
frequency O 
- O 
frequency O 
correlation O 
functions O 
( O 
FFCFs O 
) O 
of O 
the O 
ν O 
NO B-FORMULA 
in O 
SNP B-ABBREVIATION 
in O 
each O 
of O 
the O 
seven O 
solvents O 
are O 
obtained O 
by O 
fitting O 
the O 
experimentally O 
obtained O 
2D B-FORMULA 
IR O 
spectra O 
using O 
nonlinear O 
response O 
theory O 
. O 
The O 
fits O 
to O 
the O 
2D O 
IR O 
line O 
shape O 
reveal O 
that O 
the O 
spectral O 
diffusion O 
time O 
scale O 
of O 
the O 
ν O 
NO B-FORMULA 
in O 
SNP B-ABBREVIATION 
varies O 
from O 
0.8 O 
to O 
4 O 
ps O 
and O 
is O 
negatively O 
correlated O 
with O 
the O 
empirical O 
solvent O 
polarity O 
scales O 
. O 
We O 
compare O 
our O 
results O 
with O 
the O 
experimentally O 
determined O 
FFCFs O 
of O 
other O 
charged O 
vibrational O 
probes O 
in O 
polar O 
solvents O 
and O 
in O 
the O 
active O 
sites O 
of O 
heme B-FAMILY 
proteins O 
. O 
Our O 
results O 
suggest O 
that O 
the O 
vibrational O 
dephasing O 
dynamics O 
of O 
the O 
ν O 
NO B-FORMULA 
in O 
SNP B-ABBREVIATION 
reflect O 
the O 
fluctuations O 
of O 
the O 
nonhomogeneous O 
electric O 
field O 
created O 
by O 
the O 
polar O 
solvents O 
around O 
the O 
nitrosyl B-SYSTEMATIC 
and O 
cyanide B-SYSTEMATIC 
ligands O 
. O 
The O 
solute O 
solvent O 
interactions O 
occurring O 
at O 
the O 
trans-CN B-SYSTEMATIC 
ligand O 
are O 
sensed O 
through O 
the O 
π-back- O 
bonding O 
network O 
along O 
the O 
Fe-NO B-FORMULA 
bond O 
in O 
SNP B-ABBREVIATION 
. O 

acid I-TRIVIAL 
conjugates O 
of O 
nonsteroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAID's O 
) O 
and O 
their O 
anti-inflammatory O 
properties O 
. O 

series O 
of O 
nicotinic B-TRIVIAL 
acid I-TRIVIAL 
conjugates O 
with O 
non-steroidal O 
anti-inflammatory O 
drugs O 
( O 
NSAID's O 
) O 
have O 
been O 
effectively O 
synthesized O 
using O 
TBTU B-ABBREVIATION 
in O 
high O 
yield O 
and O 
purity O 
. O 
All O 
the O 
synthesized O 
conjugates O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
anti-inflammatory O 
activity O 
. O 

glucose B-TRIVIAL 
regulation O 
is O 
achieved O 
by O 
having O 
adequate O 
insulin O 
secretion O 
and O 
effective O 
glucose B-TRIVIAL 
uptake O 
/ O 
disposal O 
. O 
Excess O 
lipids O 
in O 
peripheral O 
tissues O 
- O 
skeletal O 
muscle O 
, O 
liver O 
and O 
adipose O 
tissue O 
- O 
may O 
attenuate O 
insulin O 
signaling O 
through O 
the O 
protein O 
kinase O 
B O 
( O 
AKt O 
) O 
pathway O 
and O 
up O 
- O 
regulate O 
protein O 
tyrosine B-TRIVIAL 
phosphatase O 
1B O 
( O 
PTP1B O 
) O 
, O 
a O 
negative O 
regulator O 
of O 
insulin O 
signaling O 
. O 
We O 
studied O 
accumulation O 
of O 
lipid O 
metabolites O 
[ O 
triglycerides B-FAMILY 
( O 
TAGs B-ABBREVIATION 
) O 
, O 
diglycerides B-FAMILY 
( O 
DAGs B-ABBREVIATION 
) O 
] O 
and O 
ceramides B-FAMILY 
in O 
relation O 
to O 
insulin O 
signaling O 
and O 
expression O 
and O 
phosphorylation O 
of O 
PTP1B O 
by O 
preincubating O 
rat O 
skeletal O 
muscle O 
cells O 
( O 
L6 O 
myotubes O 
) O 
with O 
three O 
saturated O 
and O 
three O 
unsaturated O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FFAs O 
) O 
( O 
200 O 
μM O 
) O 
. O 
Cells O 
were O 
also O 
evaluated O 
in O 
the O 
presence O 
of O 
wortmannin B-TRIVIAL 
, O 
an O 
inhibitor O 
of O 
phosphatidylinositol B-TRIVIAL 
3-kinases O 
and O 
thus O 
AKt O 
( O 
0-100 O 
nM O 
) O 
. O 
Unsaturated O 
FFAs O 
increased O 
DAGs B-ABBREVIATION 
, O 
TAGs B-ABBREVIATION 
and O 
PTP1B O 
expression O 
significantly O 
, O 
but O 
cells O 
remained O 
insulin O 
sensitive O 
as O 
assessed O 
by O 
robust O 
AKt O 
and O 
PTP1B O 
phosphorylation O 
at O 
serine B-TRIVIAL 
( O 
Ser B-FORMULA 
) O 
50 O 
, O 
Ser B-FORMULA 
398 O 
and O 
tyrosine B-TRIVIAL 
152 O 
. O 
Saturated O 
palmitic B-MULTIPLE 
and I-MULTIPLE 
stearic I-MULTIPLE 
acids I-MULTIPLE 
increased O 
ceramides B-FAMILY 
, O 
up O 
- O 
regulated O 
PTP1B O 
, O 
and O 
had O 
AKt O 
and O 
PTP1B O 
phosphorylation O 
at O 
Ser B-FORMULA 
50 O 
impaired O 
. O 
We O 
show O 
a O 
significant O 
correlation O 
between O 
phosphorylation O 
levels O 
of O 
AKt O 
and O 
of O 
PTP1B O 
at O 
Ser O 
50 O 
( O 
R(2)=0.84 O 
, O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
same O 
was O 
observed O 
with O 
increasing O 
wortmannin B-TRIVIAL 
dose O 
( O 
R(2)=0.73 O 
, O 
P O 
< O 
0.05 O 
) O 
. O 
Only O 
FFAs O 
that O 
increased O 
ceramides B-FAMILY 
caused O 
impairment O 
of O 
AKt O 
and O 
PTP1B O 
phosphorylation O 
at O 
Ser B-FORMULA 
50 O 
. O 
PTP1B O 
overexpression O 
in O 
the O 
presence O 
of O 
excess O 
lipids O 
may O 
not O 
directly O 
cause O 
insulin O 
resistance O 
unless O 
it O 
is O 
accompanied O 
by O 
decreased O 
PTP1B O 
phosphorylation O 
. O 
A O 
clear O 
relationship O 
between O 
PTP1B O 
phosphorylation O 
levels O 
at O 
Ser B-FORMULA 
50 O 
and O 
its O 
negative O 
effect O 
on O 
insulin O 
signaling O 
is O 
shown O 
. O 

A I-TRIVIAL 
, O 
a O 
new O 
triterpenoid B-FAMILY 
with O 
a O 
unique O 
carbon B-SYSTEMATIC 
skeleton O 
from O 
Aphanamixis O 
grandifolia O 
. O 

A I-TRIVIAL 
( O 
1 O 
) O 
, O 
a O 
novel O 
triterpenoid B-FAMILY 
with O 
a O 
bicyclo[3,2,1]octane B-SYSTEMATIC 
ring O 
skeleton O 
produced O 
by O 
2,3-ring O 
opening O 
and O 
2,6-ring O 
closure O 
, O 
was O 
isolated O 
from O 
the O 
stems O 
of O 
Aphanamixis O 
grandifolia O 
. O 
The O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
methods O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
techniques O 
, O 
and O 
determined O 
unambiguously O 
by O 
X-ray O 
crystal O 
diffraction O 
. O 
Aphanamgrandiol B-TRIVIAL 
A I-TRIVIAL 
showed O 
moderate O 
cytotoxicities O 
against O 
MCG-803 O 
, O 
SKOV-3 O 
, O 
HCT116 O 
and O 
HepG2 O 
cell O 
lines O 
. O 

substituted I-FAMILY 
azaindoles I-FAMILY 
as O 
potent O 
inhibitors O 
of O 
Cdc7 O 
kinase O 
. O 

kinase O 
is O 
responsible O 
for O 
the O 
initiation O 
and O 
regulation O 
of O 
DNA O 
replication O 
and O 
has O 
been O 
proposed O 
as O 
a O 
target O 
for O 
cancer O 
therapy O 
. O 
We O 
have O 
identified O 
a O 
class O 
of O 
Cdc7 O 
inhibitors O 
based O 
on O 
a O 
substituted O 
indole B-SYSTEMATIC 
core O 
. O 
Synthesis O 
of O 
focused O 
indole B-SYSTEMATIC 
and O 
azaindole B-FAMILY 
analogs O 
yielded O 
potent O 
and O 
selective O 
5-azaindole B-SYSTEMATIC 
Cdc7 O 
inhibitors O 
with O 
improved O 
intrinsic O 
metabolic O 
stability O 
( O 
ie O 
36 O 
) O 
. O 
In O 
parallel O 
, O 
quantum O 
mechanical O 
conformational O 
analysis O 
helped O 
to O 
rationalize O 
SAR O 
observations O 
, O 
led O 
to O 
a O 
proposal O 
of O 
the O 
preferred O 
binding O 
conformation O 
in O 
the O 
absence O 
of O 
co O 
- O 
crystallography O 
data O 
, O 
and O 
allowed O 
the O 
design O 
of O 
7-azaindole B-SYSTEMATIC 
37 O 
as O 
a O 
second O 
lead O 
in O 
this O 
series O 
. O 

E I-TRIVIAL 
, O 
Isochromophilone B-TRIVIAL 
X I-TRIVIAL 
and O 
Isochromophilone B-TRIVIAL 
XI I-TRIVIAL 
: O 
New O 
Chloroazaphilones B-FAMILY 
Produced O 
by O 
the O 
Fungus O 
Bartalinia O 
robillardoides O 
Strain O 
LF550 O 
. O 

studies O 
of O 
the O 
Mediterranean O 
sponge O 
Tethya O 
aurantium O 
led O 
to O 
the O 
isolation O 
of O 
the O 
fungus O 
Bartalinia O 
robillardoides O 
strain O 
LF550 O 
. O 
The O 
strain O 
produced O 
a O 
number O 
of O 
secondary O 
metabolites O 
belonging O 
to O 
the O 
chloroazaphilones B-FAMILY 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
the O 
isolation O 
of O 
chloroazaphilones B-FAMILY 
of O 
a O 
fungal O 
strain O 
belonging O 
to O 
the O 
genus O 
Bartalinia O 
. O 
Besides O 
some O 
known O 
compounds O 
( O 
helicusin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
and O 
deacetylsclerotiorin B-TRIVIAL 
( O 
2 O 
) O 
) O 
, O 
three O 
new O 
chloroazaphilones B-FAMILY 
( O 
helicusin B-TRIVIAL 
E I-TRIVIAL 
( O 
3 O 
) O 
; O 
isochromophilone B-TRIVIAL 
X I-TRIVIAL 
( O 
4 O 
) O 
and O 
isochromophilone B-TRIVIAL 
XI I-TRIVIAL 
( O 
5 O 
) O 
) O 
and O 
one O 
new O 
pentaketide B-FAMILY 
( O 
bartanolide B-TRIVIAL 
( O 
6 O 
) O 
) O 
were O 
isolated O 
. O 
The O 
structure O 
elucidations O 
were O 
based O 
on O 
spectroscopic O 
analyses O 
. O 
All O 
isolated O 
compounds O 
revealed O 
different O 
biological O 
activity O 
spectra O 
against O 
a O 
test O 
panel O 
of O 
four O 
bacteria O 
: O 
three O 
fungi O 
; O 
two O 
tumor O 
cell O 
lines O 
and O 
two O 
enzymes O 
. O 

responses O 
indicate O 
attenuated O 
oxidative O 
stress O 
in O 
the O 
springtail O 
Folsomia O 
candida O 
exposed O 
to O 
mixtures O 
of O 
cadmium B-SYSTEMATIC 
and O 
phenanthrene B-SYSTEMATIC 
. O 

the O 
' O 
omics O 
revolution O 
' O 
, O 
the O 
assessment O 
of O 
toxic O 
chemical O 
mixtures O 
has O 
incorporated O 
approaches O 
where O 
phenotypic O 
endpoints O 
are O 
connected O 
to O 
a O 
mechanistic O 
understanding O 
of O 
toxicity O 
. O 
In O 
this O 
study O 
we O 
determined O 
the O 
effect O 
of O 
binary O 
mixtures O 
of O 
cadmium B-SYSTEMATIC 
and O 
phenanthrene B-SYSTEMATIC 
on O 
the O 
reproduction O 
of O 
Folsomia O 
candida O 
and O 
investigated O 
the O 
cellular O 
mechanisms O 
underlying O 
this O 
response O 
. O 
Mixture O 
toxicity O 
modeling O 
showed O 
an O 
antagonistic O 
deviation O 
from O 
concentration O 
addition O 
for O 
reproduction O 
effects O 
of O 
the O 
mixtures O 
. O 
Subsequent O 
transcriptional O 
response O 
analysis O 
was O 
done O 
using O 
five O 
mixtures O 
at O 
the O 
modeled O 
50 O 
% O 
effect O 
level O 
for O 
reproduction O 
. O 
The O 
transcription O 
profiles O 
of O 
86 O 
high O 
throughput O 
RT-qPCR O 
assays O 
were O 
studied O 
by O 
means O 
of O 
partial O 
least O 
squares O 
regression O 
analysis O 
. O 
The O 
first O 
and O 
second O 
principal O 
components O 
( O 
PCs O 
) O 
were O 
correlated O 
with O 
global O 
responses O 
to O 
cadmium B-SYSTEMATIC 
and O 
phenanthrene B-SYSTEMATIC 
, O 
while O 
correlations O 
with O 
the O 
mixture O 
treatments O 
were O 
found O 
in O 
the O 
higher O 
PCs O 
. O 
Specifically O 
associated O 
with O 
the O 
mixture O 
treatments O 
were O 
a O 
biotransformation O 
phase O 
II O 
gene O 
, O 
four O 
mitochondrial O 
related O 
genes O 
and O 
a O 
gene O 
involved O 
in O 
the O 
biosynthesis O 
of O 
antioxidant O 
selenoproteins O 
. O 
Membrane O 
integrity O 
related O 
gene O 
inductions O 
were O 
correlated O 
with O 
the O 
single O 
phenanthrene B-SYSTEMATIC 
treatment O 
but O 
not O 
with O 
the O 
mixtures O 
. O 
Immune O 
and O 
inflammatory O 
response O 
assays O 
did O 
not O 
correlate O 
with O 
any O 
of O 
the O 
mixtures O 
. O 
These O 
results O 
suggest O 
moderated O 
oxidative O 
stress O 
, O 
a O 
higher O 
mitochondrial O 
maintenance O 
and O 
less O 
compromised O 
membrane O 
function O 
in O 
the O 
mixture O 
exposed O 
samples O 
compared O 
to O 
the O 
separate O 
cadmium B-SYSTEMATIC 
or O 
phenanthrene B-SYSTEMATIC 
exposures O 
. O 
The O 
antagonism O 
found O 
for O 
inhibition O 
of O 
reproduction O 
may O 
partially O 
originate O 
from O 
these O 
differences O 
. O 
Mechanistic O 
studies O 
on O 
mixture O 
toxicity O 
can O 
ultimately O 
aid O 
risk O 
assessment O 
by O 
defining O 
relevant O 
toxicity O 
pathways O 
in O 
organisms O 
exposed O 
to O 
real O 
- O 
world O 
mixture O 
exposures O 
present O 
in O 
the O 
field O 
. O 

Purity O 
Isolation O 
and O 
Quantification O 
of O 
Semiconducting O 
Carbon B-SYSTEMATIC 
Nanotubes O 
via O 
Column O 
Chromatography O 
. O 

isolation O 
of O 
semiconducting O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
CNTs O 
) O 
to O 
ultrahigh O 
( O 
ppb O 
) O 
purity O 
is O 
a O 
prerequisite O 
for O 
their O 
integration O 
into O 
high O 
- O 
performance O 
electronic O 
devices O 
. O 
Here O 
, O 
a O 
method O 
employing O 
column O 
chromatography O 
is O 
used O 
to O 
isolate O 
semiconducting O 
nanotubes O 
to O 
99.9% O 
purity O 
. O 
The O 
study O 
finds O 
that O 
by O 
modifying O 
the O 
solution O 
preparation O 
step O 
, O 
both O 
the O 
metallic O 
and O 
semiconducting O 
fraction O 
are O 
resolved O 
and O 
elute O 
using O 
a O 
single O 
surfactant O 
system O 
, O 
allowing O 
for O 
multiple O 
iterations O 
. O 
Iterative O 
processing O 
enables O 
a O 
far O 
more O 
rapid O 
path O 
to O 
achieving O 
the O 
level O 
of O 
purities O 
needed O 
for O 
high O 
performance O 
computing O 
. O 
After O 
a O 
single O 
iteration O 
, O 
the O 
metallic O 
peak O 
in O 
the O 
absorption O 
spectra O 
is O 
completely O 
attenuated O 
. O 
Although O 
absorption O 
spectroscopy O 
is O 
typically O 
used O 
to O 
characterize O 
CNT O 
purity O 
, O 
it O 
is O 
found O 
to O 
be O 
insufficient O 
in O 
quantifying O 
solutions O 
of O 
high O 
purity O 
( O 
> O 
98 O 
to O 
99% O 
) O 
due O 
to O 
low O 
signal O 
- O 
to O 
- O 
noise O 
in O 
the O 
metallic O 
region O 
of O 
ultrahigh O 
purity O 
solutions O 
. O 
Therefore O 
, O 
a O 
high O 
throughput O 
electrical O 
testing O 
method O 
was O 
developed O 
to O 
quantify O 
the O 
degree O 
of O 
separation O 
by O 
characterizing O 
∼4000 O 
field O 
- O 
effect O 
transistors O 
fabricated O 
from O 
the O 
separated O 
nanotubes O 
after O 
multiple O 
iterations O 
of O 
the O 
process O 
. O 
The O 
separation O 
and O 
characterization O 
methods O 
described O 
here O 
provide O 
a O 
path O 
to O 
produce O 
the O 
ultrahigh O 
purity O 
semiconducting O 
CNT O 
solutions O 
needed O 
for O 
high O 
performance O 
electronics O 
. O 

of O 
gas O 
phase O 
equilibria O 
on O 
the O 
chemical O 
vapor O 
deposition O 
of O 
graphene B-TRIVIAL 
. O 

have O 
investigated O 
the O 
influence O 
of O 
gas O 
phase O 
chemistry O 
on O 
the O 
chemical O 
vapor O 
deposition O 
of O 
graphene B-TRIVIAL 
in O 
a O 
hot O 
wall O 
reactor O 
. O 
A O 
new O 
extended O 
parameter O 
space O 
for O 
graphene B-TRIVIAL 
growth O 
was O 
defined O 
through O 
literature O 
review O 
and O 
experimentation O 
at O 
low O 
pressures O 
( O 
≥ O 
0.001 O 
mbar O 
) O 
. O 
The O 
deposited O 
films O 
were O 
characterized O 
by O 
scanning O 
electron O 
microscopy O 
, O 
Raman O 
spectroscopy O 
, O 
and O 
dark O 
field O 
optical O 
microscopy O 
, O 
with O 
the O 
latter O 
showing O 
promise O 
as O 
a O 
rapid O 
and O 
nondestructive O 
characterization O 
technique O 
for O 
graphene B-TRIVIAL 
films O 
. O 
The O 
equilibrium O 
gas O 
compositions O 
have O 
been O 
calculated O 
across O 
this O 
parameter O 
space O 
. O 
Correlations O 
between O 
the O 
graphene B-TRIVIAL 
films O 
grown O 
and O 
prevalent O 
species O 
in O 
the O 
equilibrium O 
gas O 
phase O 
revealed O 
that O 
deposition O 
conditions O 
associated O 
with O 
a O 
high O 
acetylene B-SYSTEMATIC 
equilibrium O 
concentration O 
lead O 
to O 
good O 
quality O 
graphene B-TRIVIAL 
deposition O 
, O 
and O 
conditions O 
that O 
stabilize O 
large O 
hydrocarbon B-FAMILY 
molecules O 
in O 
the O 
gas O 
phase O 
result O 
in O 
films O 
with O 
multiple O 
defects O 
. O 
The O 
transition O 
between O 
lobed O 
and O 
hexagonal O 
graphene B-TRIVIAL 
islands O 
was O 
found O 
to O 
be O 
linked O 
to O 
the O 
concentration O 
of O 
the O 
monatomic O 
hydrogen B-SYSTEMATIC 
radical O 
, O 
with O 
low O 
concentrations O 
associated O 
with O 
hexagonal O 
islands O 
. O 

Radiation O 
Induced O 
Ultrafast O 
Electron O 
Transfer O 
from O 
a O 
Food O 
Carcinogen O 
Benzo[a]pyrene B-SYSTEMATIC 
to O 
Organic O 
Molecules O 
, O 
Biological O 
Macromolecules O 
, O 
and O 
Inorganic O 
Nano O 
Structures O 
. O 

involving O 
electron O 
transfer O 
( O 
ET O 
) O 
and O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
play O 
a O 
pivotal O 
role O 
in O 
carcinogenesis O 
and O 
cancer O 
biochemistry O 
. O 
Our O 
present O 
study O 
emphasizes O 
UVA O 
radiation O 
induced O 
ET O 
reaction O 
as O 
one O 
of O 
the O 
key O 
aspects O 
of O 
a O 
potential O 
carcinogen O 
, O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
BP O 
) O 
, O 
in O 
the O 
presence O 
of O 
a O 
wide O 
variety O 
of O 
molecules O 
covering O 
organic O 
p-benzoquinone B-SYSTEMATIC 
( O 
BQ O 
) O 
, O 
biological O 
macromolecules O 
like O 
calf O 
- O 
thymus O 
DNA O 
( O 
CT-DNA O 
) O 
, O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
protein O 
, O 
and O 
inorganic O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ZnO B-FORMULA 
) O 
nanorods O 
( O 
NRs O 
) O 
. O 
Steady O 
- O 
state O 
and O 
picosecond O 
- O 
resolved O 
fluorescence O 
spectroscopy O 
have O 
been O 
used O 
to O 
monitor O 
such O 
ET O 
reactions O 
. O 
Physical O 
consequences O 
of O 
BP O 
association O 
with O 
CT-DNA O 
have O 
been O 
investigated O 
through O 
temperature O 
- O 
dependent O 
circular O 
dichroism O 
( O 
CD O 
) O 
spectroscopy O 
. O 
The O 
temperature O 
- O 
dependent O 
steady O 
- O 
state O 
, O 
picosecond O 
- O 
resolved O 
fluorescence O 
lifetime O 
and O 
anisotropy O 
studies O 
reveal O 
the O 
effect O 
of O 
temperature O 
on O 
the O 
perturbation O 
of O 
such O 
ET O 
reactions O 
from O 
BP O 
to O 
biological O 
macromolecules O 
, O 
highlighting O 
their O 
temperature O 
- O 
dependent O 
association O 
. O 
Furthermore O 
, O 
the O 
electron O 
- O 
donating O 
property O 
of O 
BP O 
has O 
been O 
corroborated O 
by O 
measuring O 
wavelength O 
- O 
dependent O 
photocurrent O 
in O 
a O 
BP-anchored O 
ZnO B-FORMULA 
NR O 
- O 
based O 
photodevice O 
, O 
offering O 
new O 
physical O 
insights O 
for O 
the O 
carcinogenic O 
study O 
of O 
BP O 
. O 

behavior O 
of O 
five O 
polypeptides O 
made O 
of O 
hydrophilic O 
and O 
pH-responsive O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
Asp B-FORMULA 
) O 
and O 
hydrophobic O 
phenylalanine B-TRIVIAL 
( O 
Phe B-FORMULA 
) O 
, O 
which O 
had O 
been O 
prepared O 
by O 
stitching O 
together O 
short O 
well O 
- O 
defined O 
sequences O 
of O 
Asp B-FORMULA 
and O 
Phe B-FORMULA 
, O 
was O 
studied O 
as O 
a O 
function O 
of O 
pH O 
. O 
The O 
effect O 
of O 
pH O 
on O 
these O 
polypeptides O 
referred O 
to O 
as O 
(Asp3Phe1)n O 
, O 
(Asp2Phe1)n O 
, O 
(Asp1Phe1)n O 
, O 
(Asp1Phe2)n O 
, O 
and O 
(Asp1Phe3)n O 
varied O 
dramatically O 
depending O 
on O 
their O 
constituting O 
sequence O 
. O 
The O 
more O 
hydrophobic O 
polypeptides O 
(Asp1Phe2)n O 
and O 
(Asp1Phe3)n O 
behaved O 
as O 
if O 
the O 
Asp B-FORMULA 
' O 
s O 
were O 
isolated O 
from O 
each O 
other O 
and O 
showed O 
an O 
apparent O 
pKa O 
(pKa(app)) O 
that O 
remained O 
constant O 
with O 
level O 
of O 
ionization O 
( O 
α O 
= O 
[ O 
Asp B-FORMULA 
( O 
- O 
) O 
] O 
/ O 
[ O 
Asp B-FORMULA 
]total O 
) O 
and O 
equaled O 
5.4 O 
and O 
6.4 O 
, O 
respectively O 
. O 
The O 
more O 
hydrophilic O 
polypeptides O 
(Asp3Phe1)n O 
and O 
(Asp2Phe1)n O 
behaved O 
like O 
weak O 
polyacids O 
showing O 
a O 
linear O 
increase O 
in O 
pKa(app) O 
with O 
increasing O 
α O 
. O 
The O 
pKa(app) O 
of O 
(Asp1Phe1)n O 
showed O 
a O 
trend O 
as O 
a O 
function O 
of O 
α O 
intermediate O 
between O 
the O 
Asp B-FORMULA 
-rich O 
and O 
Phe B-FORMULA 
-rich O 
polypeptides O 
, O 
behaving O 
as O 
if O 
the O 
Asp B-FORMULA 
' O 
s O 
were O 
isolated O 
at O 
low O 
α O 
values O 
( O 
< O 
0.35 O 
) O 
but O 
acting O 
as O 
a O 
weak O 
polyacid O 
for O 
large O 
α O 
values O 
( O 
> O 
0.35 O 
) O 
. O 
The O 
effect O 
that O 
α O 
, O 
and O 
thus O 
the O 
charge O 
density O 
of O 
the O 
polypeptides O 
, O 
had O 
on O 
the O 
collapse O 
and O 
aggregation O 
of O 
the O 
polypeptides O 
was O 
characterized O 
by O 
conducting O 
static O 
light O 
scattering O 
and O 
fluorescence O 
measurements O 
. O 
Static O 
light O 
scattering O 
measurements O 
demonstrated O 
that O 
all O 
polypeptides O 
precipitated O 
and O 
aggregated O 
in O 
solution O 
at O 
a O 
critical O 
charge O 
density O 
of O 
0.2 O 
. O 
Fluorescence O 
measurements O 
with O 
pyrene B-SYSTEMATIC 
indicated O 
that O 
this O 
behavior O 
was O 
due O 
to O 
the O 
formation O 
of O 
Phe B-FORMULA 
aggregates O 
in O 
water O 
. O 
Together O 
, O 
these O 
experiments O 
provide O 
a O 
complete O 
description O 
of O 
how O 
pH O 
affects O 
the O 
behavior O 
of O 
a O 
series O 
of O 
unique O 
amphiphilic O 
polypeptides O 
designed O 
with O 
a O 
well O 
- O 
defined O 
sequence O 
. O 

the O 
enzymatic O 
hydrolysis O 
of O 
cellulose O 
and O 
the O 
influence O 
of O 
lignin O 
in O 
the O 
process O 
are O 
critical O 
for O 
viable O 
production O 
of O 
fuels O 
and O 
chemicals O 
from O 
lignocellulosic O 
biomass O 
. O 
The O 
interactions O 
of O 
monocomponent O 
cellulases O 
with O 
cellulose O 
and O 
lignin O 
substrates O 
were O 
investigated O 
by O 
using O 
thin O 
films O 
supported O 
on O 
quartz B-TRIVIAL 
crystal O 
microgravimetry O 
( O 
QCM O 
) O 
resonators O 
. O 
Trichoderma O 
reesei O 
exoglucanase O 
( O 
CBH-I O 
) O 
and O 
endoglucanase O 
( O 
EG-I O 
) O 
bound O 
strongly O 
to O 
both O 
cellulose O 
and O 
lignin O 
but O 
EG-I O 
exhibited O 
a O 
distinctive O 
higher O 
affinity O 
with O 
lignin O 
, O 
causing O 
a O 
more O 
extensive O 
inhibition O 
of O 
the O 
cellulolytic O 
reactions O 
. O 
CBH-I O 
was O 
found O 
to O 
penetrate O 
into O 
the O 
bulk O 
of O 
the O 
cellulose O 
substrate O 
increasing O 
the O 
extent O 
of O 
hydrolysis O 
and O 
film O 
deconstruction O 
. O 
In O 
the O 
absence O 
of O 
a O 
cellulose O 
binding O 
domain O 
( O 
CBD O 
) O 
and O 
a O 
linker O 
, O 
the O 
CBH-I O 
core O 
adsorbed O 
slowly O 
and O 
was O 
not O 
able O 
to O 
penetrate O 
into O 
the O 
film O 
. O 
Conversely O 
to O 
CBH-I O 
, O 
EG-I O 
exhibited O 
activity O 
only O 
on O 
the O 
surface O 
of O 
the O 
lignocellulose O 
substrate O 
even O 
when O 
containing O 
a O 
CBD O 
and O 
a O 
linker O 
. O 
Interestingly O 
, O 
EG-I O 
displayed O 
a O 
clearly O 
different O 
interaction O 
profile O 
as O 
a O 
function O 
of O 
contact O 
time O 
registered O 
by O 
QCM O 
. O 

prospective O 
, O 
large O 
library O 
virtual O 
screen O 
against O 
an O 
activated O 
β2-adrenergic O 
receptor O 
( O 
β2AR O 
) O 
structure O 
returned O 
potent O 
agonists O 
to O 
the O 
exclusion O 
of O 
inverse O 
- O 
agonists O 
, O 
providing O 
the O 
first O 
complement O 
to O 
the O 
previous O 
virtual O 
screening O 
campaigns O 
against O 
inverse O 
- O 
agonist O 
- O 
bound O 
G O 
protein O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
structures O 
, O 
which O 
predicted O 
only O 
inverse O 
- O 
agonists O 
. O 
In O 
addition O 
, O 
two O 
hits O 
recapitulated O 
the O 
signaling O 
profile O 
of O 
the O 
co O 
- O 
crystal O 
ligand O 
with O 
respect O 
to O 
the O 
G O 
protein O 
and O 
arrestin O 
mediated O 
signaling O 
. O 
This O 
functional O 
fidelity O 
has O 
important O 
implications O 
in O 
drug O 
design O 
, O 
as O 
the O 
ability O 
to O 
predict O 
ligands O 
with O 
predefined O 
signaling O 
properties O 
is O 
highly O 
desirable O 
. O 
However O 
, O 
the O 
agonist O 
- O 
bound O 
state O 
provides O 
an O 
uncertain O 
template O 
for O 
modeling O 
the O 
activated O 
conformation O 
of O 
other O 
GPCRs O 
, O 
as O 
a O 
dopamine B-TRIVIAL 
D2 O 
receptor O 
( O 
DRD2 O 
) O 
activated O 
model O 
templated O 
on O 
the O 
activated O 
β2AR O 
structure O 
returned O 
few O 
hits O 
of O 
only O 
marginal O 
potency O 
. O 

modification O 
of O 
a O 
porous O 
coordination O 
polymer O 
by O 
LiCl B-FORMULA 
To O 
enhance O 
H+ B-FORMULA 
transport O 
. O 

Ca(2+) B-FORMULA 
porous O 
coordination O 
polymer O 
with O 
1D O 
channels O 
was O 
functionalized O 
by O 
the O 
postsynthesis O 
addition O 
of O 
LiCl B-FORMULA 
to O 
enhance O 
the O 
H(+) B-FORMULA 
conductivity O 
. O 
The O 
compound O 
showed O 
over O 
10(-2) O 
S O 
cm(-1) O 
at O 
25 O 
°C O 
and O 
20% O 
relative O 
humidity O 
. O 
Pulse O 
- O 
field O 
gradient O 
NMR O 
elucidated O 
that O 
the O 
fast O 
H(+) B-FORMULA 
conductivity O 
was O 
achieved O 
by O 
the O 
support O 
of O 
Li(+) B-FORMULA 
ion O 
movements O 
in O 
the O 
channel O 
. O 

- O 
based O 
assay O 
for O 
human O 
mono- O 
ADP B-ABBREVIATION 
-ribosyltransferases O 
ARTD7 O 
/ O 
PARP15 O 
and O 
ARTD10 O 
/ O 
PARP10 O 
aimed O 
at O 
screening O 
and O 
profiling O 
inhibitors O 
. O 

polymerases O 
( O 
PARPs O 
) O 
or O 
diphtheria O 
toxin O 
like O 
ADP B-ABBREVIATION 
- O 
ribosyl B-TRIVIAL 
transferases O 
( O 
ARTDs O 
) O 
are O 
enzymes O 
that O 
catalyze O 
the O 
covalent O 
modification O 
of O 
proteins O 
by O 
attachment O 
of O 
ADP B-ABBREVIATION 
- O 
ribose B-TRIVIAL 
units O 
to O 
the O 
target O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
or O 
to O 
the O 
growing O 
chain O 
of O 
ADP B-ABBREVIATION 
- O 
ribose B-TRIVIAL 
. O 
A O 
subclass O 
of O 
the O 
ARTD O 
superfamily O 
consists O 
of O 
mono- O 
ADP B-ABBREVIATION 
- O 
ribosyl B-TRIVIAL 
transferases O 
that O 
are O 
thought O 
to O 
modify O 
themselves O 
and O 
other O 
substrate O 
proteins O 
by O 
covalently O 
adding O 
only O 
a O 
single O 
ADP B-ABBREVIATION 
- O 
ribose B-TRIVIAL 
moiety O 
to O 
the O 
target O 
. O 
Many O 
of O 
the O 
ARTD O 
enzymes O 
are O 
either O 
established O 
or O 
potential O 
drug O 
targets O 
and O 
a O 
functional O 
activity O 
assay O 
for O 
them O 
will O 
be O 
a O 
valuable O 
tool O 
to O 
identify O 
selective O 
inhibitors O 
for O 
each O 
enzyme O 
. O 
Existing O 
assays O 
are O 
not O 
directly O 
applicable O 
for O 
screening O 
of O 
inhibitors O 
due O 
to O 
the O 
different O 
nature O 
of O 
the O 
reaction O 
and O 
different O 
target O 
molecules O 
. O 
We O 
modified O 
and O 
applied O 
a O 
fluorescence O 
- O 
based O 
assay O 
previously O 
described O 
for O 
PARP1 O 
/ O 
ARTD1 O 
and O 
tankyrase O 
/ O 
ARTD5 O 
for O 
screening O 
of O 
PARP10 O 
/ O 
ARTD10 O 
and O 
PARP15 O 
/ O 
ARTD7 O 
inhibitors O 
. O 
The O 
assay O 
measures O 
the O 
amount O 
of O 
NAD(+) B-ABBREVIATION 
present O 
after O 
chemically O 
converting O 
it O 
to O 
a O 
fluorescent O 
analog O 
. O 
We O 
demonstrate O 
that O 
by O 
using O 
an O 
excess O 
of O 
a O 
recombinant O 
acceptor O 
protein O 
the O 
performance O 
of O 
the O 
activity O 
- O 
based O 
assay O 
is O 
excellent O 
for O 
screening O 
of O 
compound O 
libraries O 
. O 
The O 
assay O 
is O 
homogenous O 
and O 
cost O 
effective O 
, O 
making O 
it O 
possible O 
to O 
test O 
relatively O 
large O 
compound O 
libraries O 
. O 
This O 
method O 
can O 
be O 
used O 
to O 
screen O 
inhibitors O 
of O 
mono-ARTDs O 
and O 
profile O 
inhibitors O 
of O 
the O 
enzyme O 
class O 
. O 
The O 
assay O 
was O 
optimized O 
for O 
ARTD10 O 
and O 
ARTD7 O 
, O 
but O 
it O 
can O 
be O 
directly O 
applied O 
to O 
other O 
mono-ARTDs O 
of O 
the O 
ARTD O 
superfamily O 
. O 
Profiling O 
of O 
known O 
ARTD O 
inhibitors O 
against O 
ARTD10 O 
and O 
ARTD7 O 
in O 
a O 
validatory O 
screening O 
identified O 
the O 
best O 
inhibitors O 
with O 
submicromolar O 
potencies O 
. O 
Only O 
few O 
of O 
the O 
tested O 
ARTD O 
inhibitors O 
were O 
potent O 
, O 
implicating O 
that O 
there O 
is O 
a O 
need O 
to O 
screen O 
new O 
compound O 
scaffolds O 
. O 
This O 
is O 
needed O 
to O 
create O 
small O 
molecules O 
that O 
could O 
serve O 
as O 
biological O 
probes O 
and O 
potential O 
starting O 
points O 
for O 
drug O 
discovery O 
projects O 
against O 
mono-ARTDs O 
. O 

pH-sensitive O 
superparamagnetic O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanocomposites O 
for O 
targeted O 
drug O 
delivery O 
and O 
MR O 
imaging O 
. O 

multifunctional O 
pH-sensitive O 
superparamagnetic O 
iron B-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
SPIO O 
) O 
nanocomposite O 
system O 
was O 
developed O 
for O 
simultaneous O 
tumor O 
magnetic O 
resonance O 
imaging O 
( O 
MRI O 
) O 
and O 
therapy O 
. O 
Small O 
- O 
size O 
SPIO O 
nanoparticles O 
were O 
chemically O 
bonded O 
with O 
antitumor O 
drug O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
and O 
biocompatible O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
through O 
pH-sensitive O 
acylhydrazone B-SYSTEMATIC 
linkages O 
, O 
resulting O 
in O 
the O 
formation O 
of O 
SPIO O 
nanocomposites O 
with O 
magnetic O 
targeting O 
and O 
pH-sensitive O 
properties O 
. O 
These O 
DOX B-ABBREVIATION 
-conjugated O 
SPIO O 
nanocomposites O 
exhibited O 
not O 
only O 
good O 
stability O 
in O 
aqueous O 
solution O 
but O 
also O 
high O 
saturation O 
magnetizations O 
. O 
Under O 
an O 
acidic O 
environment O 
, O 
the O 
DOX B-ABBREVIATION 
was O 
quickly O 
released O 
from O 
the O 
SPIO O 
nanocomposites O 
due O 
to O 
the O 
cleavage O 
of O 
pH-sensitive O 
acylhydrazone O 
linkages O 
. O 
With O 
the O 
help O 
of O 
magnetic O 
field O 
, O 
the O 
DOX B-ABBREVIATION 
-conjugated O 
SPIO O 
nanocomposites O 
showed O 
high O 
cellular O 
uptake O 
, O 
indicating O 
their O 
magnetic O 
targeting O 
property O 
. O 
Comparing O 
to O 
free O 
DOX B-ABBREVIATION 
, O 
the O 
DOX B-ABBREVIATION 
-conjugated O 
SPIO O 
nanocomposites O 
showed O 
better O 
antitumor O 
effect O 
under O 
magnetic O 
field O 
. O 
At O 
the O 
same O 
time O 
, O 
the O 
relaxivity O 
value O 
of O 
these O 
SPIO O 
nanocomposites O 
was O 
higher O 
than O 
146s(-1)mM(-1) O 
Fe B-FORMULA 
, O 
leading O 
to O 
~4 O 
times O 
enhancement O 
compared O 
to O 
that O 
of O 
free O 
SPIO O 
nanoparticles O 
. O 
As O 
a O 
negative O 
contrast O 
agent O 
, O 
these O 
SPIO O 
nanocomposites O 
illustrated O 
high O 
resolution O 
in O 
MRI O 
diagnosis O 
of O 
tumor O 
- O 
bearing O 
mice O 
. O 
All O 
of O 
these O 
results O 
confirm O 
that O 
these O 
pH-sensitive O 
SPIO O 
nanocomposites O 
are O 
promising O 
hybrid O 
materials O 
for O 
synergistic O 
MRI O 
diagnosis O 
and O 
tumor O 
therapy O 
. O 

of O 
albumin O 
- O 
conjugated O 
gossypol B-TRIVIAL 
as O 
an O 
immunogen O 
to O 
prevent O 
gossypol B-TRIVIAL 
-associated O 
acute O 
hepatotoxicity O 
in O 
rats O 
. O 

is O 
a O 
highly O 
reactive O 
compound O 
present O 
in O 
cotton O 
( O 
Gossypium O 
spp O 
. O 
) O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
determine O 
whether O 
the O 
administration O 
of O 
gossypol B-TRIVIAL 
conjugated O 
to O 
albumin O 
can O 
immunize O 
rats O 
and O 
thereby O 
prevent O 
the O 
acute O 
hepatotoxicity O 
associated O 
with O 
gossypol B-TRIVIAL 
. O 
The O 
first O 
experiment O 
consisted O 
of O 
administering O 
the O 
immunogen O 
gossypol B-TRIVIAL 
-BSA O 
, O 
with O 
or O 
without O 
the O 
Freund's O 
incomplete O 
adjuvant O 
, O 
to O 
rats O 
. O 
The O 
production O 
of O 
antibodies O 
against O 
gossypol B-TRIVIAL 
was O 
subsequently O 
verified O 
. O 
The O 
second O 
experiment O 
comprised O 
three O 
groups O 
of O 
Wistar O 
rats O 
: O 
VG O 
, O 
CG O 
and O 
CO O 
. O 
The O 
rats O 
from O 
the O 
VG O 
cohort O 
were O 
injected O 
with O 
gossypol B-TRIVIAL 
-BSA O 
associated O 
with O 
Freund's O 
incomplete O 
adjuvant O 
, O 
and O 
the O 
animals O 
from O 
the O 
CG O 
and O 
CO O 
groups O 
were O 
injected O 
with O 
saline O 
solution O 
. O 
After O 
21days O 
, O 
the O 
rats O 
from O 
the O 
VG O 
and O 
CG O 
cohorts O 
were O 
treated O 
with O 
30mg O 
/ O 
kg O 
of O 
gossypol B-TRIVIAL 
by O 
intraperitoneal O 
injection O 
, O 
whereas O 
the O 
rats O 
from O 
the O 
CO O 
group O 
received O 
corn O 
oil O 
. O 
After O 
24h O 
, O 
the O 
rats O 
were O 
evaluated O 
for O 
clinical O 
signs O 
of O 
pathology O 
, O 
and O 
their O 
serum O 
was O 
biochemically O 
analyzed O 
. O 
It O 
was O 
found O 
that O 
gossypol B-TRIVIAL 
promoted O 
hepatotoxic O 
effects O 
that O 
were O 
not O 
prevented O 
by O 
the O 
administration O 
of O 
gossypol B-TRIVIAL 
-BSA O 
. O 
In O 
conclusion O 
, O 
the O 
administration O 
of O 
gossypol B-TRIVIAL 
-BSA O 
associated O 
with O 
Freund's O 
incomplete O 
adjuvant O 
may O 
be O 
lightly O 
to O 
prevent O 
the O 
acute O 
hepatotoxicity O 
associated O 
with O 
gossypol B-TRIVIAL 
. O 

putative O 
thylakoid O 
lumen O 
immunophilin O 
, O 
FKBP16-3 O 
, O 
has O 
not O 
yet O 
been O 
characterized O 
, O 
although O 
this O 
protein O 
is O 
known O 
to O 
be O 
regulated O 
by O 
thioredoxin O 
and O 
possesses O 
a O 
well O 
- O 
conserved O 
CxxxC O 
motif O 
in O 
photosynthetic O 
organisms O 
. O 
Here O 
, O 
we O 
characterized O 
rice O 
OsFKBP16-3 O 
and O 
examined O 
the O 
role O 
of O 
this O 
gene O 
in O 
the O 
regulation O 
of O 
abiotic O 
stress O 
in O 
plants O 
. O 
FKBP16-3s O 
are O 
well O 
conserved O 
in O 
eukaryotic O 
photosynthetic O 
organisms O 
, O 
including O 
the O 
presence O 
of O 
a O 
unique O 
disulfide B-SYSTEMATIC 
-forming O 
CxxxC O 
motif O 
in O 
their O 
N B-FORMULA 
-terminal O 
regions O 
. O 
OsFKBP16-3 O 
was O 
mainly O 
expressed O 
in O 
rice O 
leaf O 
tissues O 
and O 
was O 
upregulated O 
by O 
various O 
abiotic O 
stresses O 
, O 
including O 
salt O 
, O 
drought O 
, O 
high O 
light O 
, O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
, O 
heat O 
and O 
methyl B-SYSTEMATIC 
viologen I-SYSTEMATIC 
. O 
The O 
chloroplast O 
localization O 
of O 
OsFKBP16-3-GFP O 
was O 
confirmed O 
through O 
the O 
transient O 
expression O 
of O 
OsFKBP16-3 O 
in O 
Nicotiana O 
benthamiana O 
leaves O 
. O 
Transgenic O 
Arabidopsis O 
and O 
transgenic O 
rice O 
plants O 
that O 
constitutively O 
expressed O 
OsFKBP16-3 O 
exhibited O 
increased O 
tolerance O 
to O 
salinity O 
, O 
drought O 
and O 
oxidative O 
stresses O 
, O 
but O 
showed O 
no O 
change O 
in O 
growth O 
or O 
phenotype O 
, O 
compared O 
with O 
vector O 
control O 
plants O 
, O 
when O 
grown O 
under O 
non-stressed O 
conditions O 
. O 
This O 
is O 
the O 
first O 
report O 
to O 
demonstrate O 
the O 
potential O 
role O 
of O 
FKBP16-3 O 
in O 
the O 
environmental O 
stress O 
response O 
, O 
which O 
may O 
be O 
regulated O 
by O 
a O 
redox O 
relay O 
process O 
in O 
the O 
thylakoid O 
lumen O 
, O 
suggesting O 
that O 
artificial O 
regulation O 
of O 
FKBP16-3 O 
expression O 
is O 
a O 
candidate O 
for O 
stress O 
- O 
tolerant O 
crop O 
breeding O 
. O 

is O 
the O 
most O 
common O 
primary O 
cancer O 
of O 
bone O 
and O 
one O 
that O 
predominantly O 
affects O 
children O 
and O 
adolescents O 
. O 
Osteoblastic O 
osteosarcoma O 
represents O 
the O 
major O 
subtype O 
of O 
this O 
tumor O 
, O 
with O 
approximately O 
equal O 
representation O 
of O 
fibroblastic O 
and O 
chondroblastic O 
subtypes O 
. O 
We O 
and O 
others O 
have O 
previously O 
described O 
murine O 
models O 
of O 
osteosarcoma O 
based O 
on O 
osteoblast O 
- O 
restricted O 
Cre O 
: O 
lox O 
deletion O 
of O 
Trp B-FORMULA 
53 O 
( O 
p53 O 
) O 
and O 
Rb1 O 
( O 
Rb O 
) O 
, O 
resulting O 
in O 
a O 
phenotype O 
most O 
similar O 
to O 
fibroblastic O 
osteosarcoma O 
in O 
humans O 
. O 
We O 
now O 
report O 
a O 
model O 
of O 
the O 
most O 
prevalent O 
form O 
of O 
human O 
osteosarcoma O 
, O 
the O 
osteoblastic O 
subtype O 
. O 
In O 
contrast O 
to O 
other O 
osteosarcoma O 
models O 
that O 
have O 
used O 
Cre O 
: O 
lox O 
mediated O 
gene O 
deletion O 
, O 
this O 
model O 
was O 
generated O 
through O 
shRNA O 
- O 
based O 
knockdown O 
of O 
p53 O 
. O 
As O 
is O 
the O 
case O 
with O 
the O 
human O 
disease O 
the O 
shRNA O 
tumors O 
most O 
frequently O 
present O 
in O 
the O 
long O 
bones O 
and O 
preferentially O 
disseminate O 
to O 
the O 
lungs O 
; O 
feature O 
less O 
consistently O 
modeled O 
using O 
Cre O 
: O 
lox O 
approaches O 
. O 
Our O 
approach O 
allowed O 
direct O 
comparison O 
of O 
the O 
in O 
vivo O 
consequences O 
of O 
targeting O 
the O 
same O 
genetic O 
drivers O 
using O 
two O 
different O 
technologies O 
, O 
Cre O 
: O 
lox O 
and O 
shRNA O 
. O 
This O 
demonstrated O 
that O 
the O 
effects O 
of O 
Cre O 
: O 
lox O 
and O 
shRNA O 
mediated O 
knock O 
- O 
down O 
are O 
qualitatively O 
different O 
, O 
at O 
least O 
in O 
the O 
context O 
of O 
osteosarcoma O 
, O 
and O 
yielded O 
distinct O 
subtypes O 
of O 
osteosarcoma O 
. O 
Through O 
the O 
use O 
of O 
complementary O 
genetic O 
modification O 
strategies O 
we O 
have O 
established O 
a O 
model O 
of O 
the O 
most O 
common O 
clinical O 
subtype O 
of O 
osteosarcoma O 
that O 
was O 
not O 
previously O 
represented O 
and O 
more O 
fully O 
recapitulated O 
the O 
clinical O 
spectrum O 
of O 
this O 
cancer O 
. O 

of O 
progesterone B-TRIVIAL 
and O 
medroxyprogesterone B-TRIVIAL 
on O 
actin O 
remodeling O 
and O 
neuronal O 
spine O 
formation O 
. O 

steroids B-FAMILY 
are O 
important O 
regulators O 
of O 
neuronal O 
cell O 
morphology O 
, O 
and O 
this O 
is O 
critical O 
for O 
gender O 
differences O 
in O 
brain O 
function O 
and O 
dysfunction O 
. O 
Neuronal O 
morphology O 
is O 
controlled O 
by O 
multiprotein O 
complexes O 
including O 
moesin O 
( O 
a O 
member O 
of O 
the O 
ezrin O 
/ O 
radixin O 
/ O 
moesin O 
family O 
) O 
, O 
focal O 
adhesion O 
kinase O 
( O 
FAK O 
) O 
, O 
or O 
the O 
Wiskott-Aldrich O 
syndrome O 
protein O 
- O 
family O 
verprolin O 
homologous O 
( O 
WAVE1 O 
) O 
protein O 
, O 
controlling O 
dynamic O 
remodeling O 
of O 
the O 
cytoskeleton O 
and O 
cell O 
membrane O 
. O 
We O 
investigated O 
the O 
actions O 
of O 
natural O 
progesterone B-TRIVIAL 
( O 
P O 
) O 
and O 
of O 
the O 
synthetic O 
progestin B-FAMILY 
medroxyprogesterone B-TRIVIAL 
acetate I-TRIVIAL 
( O 
MPA B-ABBREVIATION 
) O 
on O 
actin O 
remodeling O 
, O 
focal O 
adhesion O 
complex O 
formation O 
, O 
and O 
actin O 
branching O 
in O 
rat O 
cortical O 
neurons O 
. O 
Treatment O 
with O 
P O 
and O 
, O 
to O 
a O 
lesser O 
extent O 
, O 
MPA B-ABBREVIATION 
, O 
increases O 
the O 
number O 
and O 
density O 
of O 
dendritic O 
spines O 
. O 
P O 
increases O 
the O 
phosphorylation O 
of O 
moesin O 
, O 
FAK O 
, O 
and O 
WAVE1 O 
, O 
and O 
their O 
redistribution O 
toward O 
cell O 
membrane O 
sites O 
where O 
spines O 
are O 
formed O 
. O 
Signaling O 
to O 
moesin O 
is O 
achieved O 
by O 
PR O 
via O 
a O 
Gα O 
/ O 
Gβ-dependent O 
signaling O 
to O 
the O 
small O 
GTPase O 
Ras O 
homolog O 
gene O 
family O 
, O 
member O 
A O 
and O 
its O 
related O 
kinase O 
, O 
Rho-associated O 
kinase-2 O 
. O 
In O 
parallel O 
, O 
WAVE1 O 
recruitment O 
is O 
triggered O 
by O 
a O 
Gαi O 
/ O 
Gβ-dependent O 
signaling O 
of O 
PR O 
to O 
c-Src O 
, O 
FAK O 
, O 
and O 
Rac1 O 
GTPase O 
. O 
Rac1 O 
recruits O 
cyclin O 
- O 
dependent O 
kinase-5 O 
, O 
which O 
phosphorylates O 
WAVE1 O 
. O 
Silencing O 
of O 
moesin O 
, O 
FAK O 
, O 
or O 
WAVE1 O 
abrogates O 
the O 
increase O 
in O 
dendritic O 
spines O 
induced O 
by O 
progesterone B-TRIVIAL 
. O 
In O 
all O 
applications O 
, O 
MPA B-ABBREVIATION 
is O 
found O 
to O 
act O 
similar O 
to O 
P O 
, O 
albeit O 
with O 
a O 
lower O 
efficacy O 
. O 
In O 
conclusion O 
, O 
our O 
findings O 
indicate O 
that O 
the O 
control O 
of O 
actin O 
polymerization O 
and O 
branching O 
and O 
focal O 
adhesion O 
complex O 
formation O 
via O 
moesin O 
, O 
FAK O 
, O 
and O 
WAVE1 O 
is O 
a O 
key O 
function O 
of O 
progesterone B-TRIVIAL 
receptor O 
in O 
neurons O 
, O 
which O 
may O 
be O 
relevant O 
for O 
the O 
regulation O 
of O 
dendritic O 
spine O 
turnover O 
and O 
neuronal O 
plasticity O 
. O 

nanoparticles O 
on O 
oxide B-SYSTEMATIC 
-free O 
silicon B-SYSTEMATIC 
-molecule O 
interface O 
for O 
single O 
electron O 
transport O 
. O 

different O 
organic O 
monolayers O 
were O 
prepared O 
on O 
silicon B-SYSTEMATIC 
Si(111) B-FORMULA 
and O 
modified O 
for O 
attaching O 
gold O 
nanoparticles O 
. O 
The O 
molecules O 
are O 
covalently O 
bound O 
to O 
silicon B-SYSTEMATIC 
and O 
form O 
very O 
ordered O 
monolayers O 
sometimes O 
improperly O 
called O 
self O 
- O 
assembled O 
monolayers O 
( O 
SAM O 
) O 
. O 
They O 
are O 
designed O 
to O 
be O 
electrically O 
insulating O 
and O 
to O 
have O 
very O 
few O 
electrical O 
interface O 
states O 
. O 
By O 
positioning O 
the O 
tip O 
of O 
an O 
STM O 
above O 
a O 
nanoparticle O 
, O 
a O 
double O 
barrier O 
tunnel O 
junction O 
( O 
DBTJ O 
) O 
is O 
created O 
, O 
and O 
Coulomb O 
blockade O 
is O 
demonstrated O 
at O 
40 O 
K O 
. O 
This O 
is O 
the O 
first O 
time O 
Coulomb O 
blockade O 
is O 
observed O 
with O 
an O 
organic O 
monolayer O 
on O 
oxide-free O 
silicon B-SYSTEMATIC 
. O 
This O 
work O 
focuses O 
on O 
the O 
fabrication O 
and O 
initial O 
electrical O 
characterization O 
of O 
this O 
double O 
barrier O 
tunnel O 
junction O 
. O 
The O 
organic O 
layers O 
were O 
prepared O 
by O 
thermal O 
hydrosilylation O 
of O 
two O 
different O 
alkene O 
molecules O 
with O 
either O 
a O 
long O 
carbon B-SYSTEMATIC 
chain O 
( O 
C11 O 
) O 
or O 
a O 
shorter O 
one O 
( O 
C7 O 
) O 
, O 
and O 
both O 
were O 
modified O 
to O 
be O 
amine B-SYSTEMATIC 
-terminated O 
. O 
FTIR O 
and O 
XPS O 
measurements O 
confirm O 
that O 
the O 
Si(111) B-FORMULA 
substrate O 
remains O 
unoxidized O 
during O 
the O 
whole O 
chemical O 
process O 
. O 
Colloidal O 
gold O 
nanoparticles O 
were O 
prepared O 
using O 
two O 
methods O 
: O 
either O 
with O 
citrate B-FAMILY 
molecules O 
( O 
Turkevich O 
method O 
) O 
or O 
with O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
as O 
the O 
surfactant O 
. O 
In O 
both O 
cases O 
AFM O 
and O 
STM O 
images O 
show O 
a O 
well O 
- O 
controlled O 
deposition O 
on O 
the O 
grafted O 
organic O 
monolayer O 
. O 
I-V O 
curves O 
obtained O 
by O 
scanning O 
tunneling O 
spectroscopy O 
( O 
STS O 
) O 
are O 
presented O 
on O 
8 O 
nm O 
diameter O 
nanoparticles O 
and O 
exhibit O 
the O 
well O 
- O 
known O 
Coulomb O 
staircases O 
at O 
low O 
temperature O 
. O 
The O 
curves O 
are O 
discussed O 
as O 
a O 
function O 
of O 
the O 
organic O 
layer O 
thickness O 
and O 
silicon O 
substrate O 
doping O 
. O 

of O 
oxidized O 
ultradispersed O 
diamond B-TRIVIAL 
( O 
UDD O 
) O 
in O 
dimethylsulfoxide B-SYSTEMATIC 
followed O 
by O 
reaction O 
with O 
glycidol B-TRIVIAL 
monomer O 
, O 
purification O 
via O 
aqueous O 
dialysis O 
, O 
and O 
dispersion O 
in O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
EG O 
) O 
base O 
fluid O 
affords O 
nanodiamond O 
(ND)- O 
poly(glycidol) B-SYSTEMATIC 
polymer O 
brush O 
: O 
EG O 
nanofluids O 
exhibiting O 
12% O 
thermal O 
conductivity O 
enhancement O 
at O 
a O 
ND O 
loading O 
of O 
0.9 O 
vol O 
% O 
. O 
Deaggregation O 
of O 
UDD O 
in O 
the O 
presence O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
/ O 
octane B-SYSTEMATIC 
followed O 
by O 
dispersion O 
in O 
light O 
mineral O 
oil O 
and O 
evaporative O 
removal O 
of O 
octane B-SYSTEMATIC 
gives O 
ND· O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
: O 
mineral O 
oil O 
dispersions O 
exhibiting O 
11% O 
thermal O 
conductivity O 
enhancement O 
at O 
a O 
ND O 
loading O 
of O 
1.9 O 
vol O 
% O 
. O 
Average O 
particle O 
sizes O 
of O 
ND O 
additives O 
, O 
determined O 
by O 
dynamic O 
light O 
scattering O 
, O 
are O 
, O 
respectively O 
, O 
ca O 
. O 
11 O 
nm O 
( O 
in O 
H2O B-FORMULA 
) O 
and O 
18 O 
nm O 
( O 
in O 
toluene B-TRIVIAL 
) O 
. O 
Observed O 
thermal O 
conductivity O 
enhancements O 
outperform O 
enhancement O 
effects O 
calculated O 
using O 
Maxwell's O 
effective O 
medium O 
approximation O 
by O 
2- O 
to O 
4-fold O 
. O 
Covalent O 
ND O 
surface O 
modification O 
gives O 
2-fold O 
greater O 
thermal O 
conductivity O 
enhancement O 
than O 
ND O 
surface O 
modification O 
via O 
hydrogen B-SYSTEMATIC 
-bonding O 
interactions O 
at O 
similar O 
concentrations O 
. O 
Stable O 
, O 
static O 
ND O 
: O 
mineral O 
oil O 
dispersions O 
are O 
reported O 
for O 
the O 
first O 
time O 
. O 

dynamics O 
( O 
MD O 
) O 
simulations O 
are O 
performed O 
for O 
the O 
spreading O 
of O 
a O 
nanosized O 
water O 
droplet O 
on O 
a O 
solid O 
substrate O 
subject O 
to O 
a O 
parallel O 
electric O 
field O 
. O 
A O 
combined O 
electrostatic O 
and O 
Lennard-Jones O 
potential O 
is O 
employed O 
to O 
represent O 
the O 
intermolecular O 
interactions O 
. O 
Results O 
show O 
that O 
in O 
response O 
to O 
the O 
applied O 
field O 
, O 
polar O 
water O 
molecules O 
realign O 
themselves O 
and O 
this O 
microscopic O 
reorientation O 
of O 
molecular O 
dipoles O 
combines O 
with O 
the O 
intermolecular O 
forces O 
to O 
produce O 
a O 
macroscopic O 
deformation O 
of O 
a O 
free O 
spherical O 
water O 
droplet O 
into O 
an O 
ellipsoid O 
. O 
The O 
applied O 
field O 
has O 
a O 
strong O 
effect O 
on O 
the O 
spreading O 
of O 
the O 
water O 
droplet O 
on O 
a O 
solid O 
substrate O 
. O 
For O 
a O 
weaker O 
parallel O 
field O 
, O 
the O 
droplet O 
spreading O 
is O 
asymmetric O 
with O 
the O 
leading O 
contact O 
angle O 
being O 
greater O 
than O 
the O 
trailing O 
contact O 
angle O 
. O 
With O 
an O 
increase O 
in O 
field O 
strength O 
, O 
this O 
asymmetry O 
continues O 
to O 
increase O 
, O 
culminates O 
, O 
and O 
then O 
decreases O 
until O 
it O 
disappears O 
. O 
The O 
symmetric O 
spreading O 
remains O 
with O 
a O 
further O 
increase O 
in O 
the O 
field O 
strength O 
until O 
the O 
saturation O 
point O 
is O 
reached O 
. O 
This O 
transition O 
from O 
the O 
asymmetric O 
to O 
symmetric O 
spreading O 
is O 
a O 
manifestation O 
of O 
the O 
interaction O 
of O 
the O 
electric O 
field O 
with O 
polar O 
water O 
molecules O 
and O 
the O 
intermolecular O 
forces O 
within O 
the O 
droplet O 
and O 
between O 
the O 
water O 
and O 
solid O 
; O 
the O 
interaction O 
also O 
leads O 
to O 
a O 
change O 
in O 
hydrogen B-SYSTEMATIC 
bonds O 
along O 
the O 
droplet O 
surface O 
. O 
The O 
dynamics O 
of O 
the O 
droplet O 
spreading O 
is O 
entailed O 
by O 
the O 
electrically O 
induced O 
motion O 
of O 
molecules O 
along O 
the O 
liquid O 
surface O 
toward O 
the O 
solid O 
substrate O 
and O 
is O 
controlled O 
by O 
a O 
competing O 
mechanism O 
among O 
the O 
electric O 
, O 
water O 
- O 
water O 
, O 
and O 
water O 
- O 
solid O 
intermolecular O 
forces O 
. O 

Conversion O 
of O 
6-Nitroquinoline B-SYSTEMATIC 
to O 
the O 
Fluorophore O 
6-Aminoquinoline B-SYSTEMATIC 
Selectively O 
under O 
Hypoxic O 
Conditions O 
. O 

is O 
substantial O 
interest O 
in O 
small O 
molecules O 
that O 
can O 
be O 
used O 
to O 
detect O 
or O 
kill O 
the O 
hypoxic O 
( O 
low O 
oxygen B-SYSTEMATIC 
) O 
cells O 
found O 
in O 
solid O 
tumors O 
. O 
Nitroaryl B-FAMILY 
moieties O 
are O 
useful O 
components O 
in O 
the O 
design O 
of O 
hypoxia O 
- O 
selective O 
imaging O 
agents O 
and O 
prodrugs O 
because O 
one O 
- O 
electron O 
reductases O 
can O 
convert O 
the O 
nitroaryl B-FAMILY 
group O 
to O 
nitroso B-SYSTEMATIC 
, O 
hydroxylamino B-SYSTEMATIC 
, O 
and O 
amino B-FAMILY 
metabolites O 
selectively O 
under O 
low O 
oxygen B-SYSTEMATIC 
conditions O 
. O 
Here O 
, O 
we O 
describe O 
the O 
in O 
vitro O 
, O 
cell O 
free O 
metabolism O 
of O 
a O 
pro O 
- O 
fluorescent O 
substrate O 
, O 
6-nitroquinoline B-SYSTEMATIC 
( O 
1 O 
) O 
under O 
both O 
aerobic O 
and O 
hypoxic O 
conditions O 
. O 
Both O 
LC-MS O 
and O 
fluorescence O 
spectroscopic O 
analyses O 
provided O 
evidence O 
that O 
the O 
one O 
- O 
electron O 
reducing O 
enzyme O 
system O 
, O 
xanthine B-TRIVIAL 
/ O 
xanthine B-TRIVIAL 
oxidase O 
, O 
converted O 
the O 
nonfluorescent O 
parent O 
compound O 
1 O 
to O 
the O 
known O 
fluorophore O 
6-aminoquinoline B-SYSTEMATIC 
( O 
2 O 
) O 
selectively O 
under O 
hypoxic O 
conditions O 
. O 
The O 
presumed O 
intermediate O 
in O 
this O 
reduction O 
process O 
, O 
6-hydroxylaminoquinoline B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
is O 
fluorescent O 
and O 
can O 
be O 
efficiently O 
converted O 
by O 
xanthine B-TRIVIAL 
/ O 
xanthine B-TRIVIAL 
oxidase O 
to O 
2 O 
only O 
under O 
hypoxic O 
conditions O 
. O 
This O 
finding O 
provides O 
evidence O 
for O 
multiple O 
oxygen B-SYSTEMATIC 
-sensitive O 
steps O 
in O 
the O 
enzymatic O 
conversion O 
of O 
nitroaryl B-FAMILY 
compounds O 
to O 
the O 
corresponding O 
amino B-FAMILY 
derivatives O 
. O 
In O 
a O 
side O 
reaction O 
that O 
is O 
separate O 
from O 
the O 
bioreductive O 
metabolism O 
of O 
1 O 
, O 
xanthine B-TRIVIAL 
oxidase O 
converted O 
1 O 
to O 
6-nitroquinolin-2(1H)-one B-SYSTEMATIC 
( O 
5 O 
) O 
. O 
These O 
studies O 
may O 
enable O 
the O 
use O 
of O 
1 O 
as O 
a O 
fluorescent O 
substrate O 
for O 
the O 
detection O 
and O 
profiling O 
of O 
one O 
- O 
electron O 
reductases O 
in O 
cell O 
culture O 
or O 
biopsy O 
samples O 
. O 
In O 
addition O 
, O 
the O 
compound O 
may O 
find O 
use O 
as O 
a O 
fluorogenic O 
probe O 
for O 
the O 
detection O 
of O 
hypoxia O 
in O 
tumor O 
models O 
. O 
The O 
occurrence O 
of O 
side O 
products O 
such O 
as O 
5 O 
in O 
the O 
enzymatic O 
bioreduction O 
of O 
1 O 
underscores O 
the O 
importance O 
of O 
metabolite O 
identification O 
in O 
the O 
characterization O 
of O 
hypoxia O 
- O 
selective O 
probes O 
and O 
drugs O 
that O 
employ O 
nitroaryl B-FAMILY 
units O 
as O 
oxygen B-SYSTEMATIC 
sensors O 
. O 

antimalarial O 
activities O 
and O 
ADME O 
profiles O 
of O 
ozonides B-FAMILY 
( O 
1,2,4-trioxolanes B-FAMILY 
) O 
OZ277 B-IDENTIFIER 
, O 
OZ439 B-IDENTIFIER 
, O 
and O 
their O 
1,2-dioxolane B-SYSTEMATIC 
, O 
1,2,4-trioxane B-SYSTEMATIC 
, O 
and O 
1,2,4,5-tetraoxane B-SYSTEMATIC 
isosteres O 
. O 

ascertain O 
the O 
structure O 
- O 
activity O 
relationship O 
of O 
the O 
core O 
1,2,4-trioxolane B-SYSTEMATIC 
substructure O 
of O 
dispiro B-FAMILY 
ozonides I-FAMILY 
OZ277 B-IDENTIFIER 
and O 
OZ439 B-IDENTIFIER 
, O 
we O 
compared O 
the O 
antimalarial O 
activities O 
and O 
ADME O 
profiles O 
of O 
the O 
1,2-dioxolane B-SYSTEMATIC 
, O 
1,2,4-trioxane B-SYSTEMATIC 
, O 
and O 
1,2,4,5-tetraoxane B-SYSTEMATIC 
isosteres O 
. O 
Consistent O 
with O 
previous O 
data O 
, O 
both O 
dioxolanes B-FAMILY 
had O 
very O 
weak O 
antimalarial O 
properties O 
. O 
For O 
the O 
OZ277 B-IDENTIFIER 
series O 
, O 
the O 
trioxane B-FAMILY 
isostere O 
had O 
the O 
best O 
ADME O 
profile O 
, O 
but O 
its O 
overall O 
antimalarial O 
efficacy O 
was O 
not O 
superior O 
to O 
that O 
of O 
the O 
trioxolane B-FAMILY 
or O 
tetraoxane B-FAMILY 
isosteres O 
. O 
For O 
the O 
OZ439 B-IDENTIFIER 
series O 
, O 
there O 
was O 
a O 
good O 
correlation O 
between O 
the O 
antimalarial O 
efficacy O 
and O 
ADME O 
profiles O 
in O 
the O 
rank O 
order O 
trioxolane B-FAMILY 
> O 
trioxane B-FAMILY 
> O 
tetraoxane B-FAMILY 
. O 
As O 
we O 
have O 
previously O 
observed O 
for O 
OZ439 B-IDENTIFIER 
versus O 
OZ277 B-IDENTIFIER 
, O 
the O 
OZ439 B-IDENTIFIER 
series O 
peroxides B-FAMILY 
had O 
superior O 
exposure O 
and O 
efficacy O 
in O 
mice O 
compared O 
to O 
the O 
corresponding O 
OZ277 B-IDENTIFIER 
series O 
peroxides B-FAMILY 
. O 

safety O 
of O 
the O 
dipetidyl O 
peptidase-4 O 
inhibitor O 
alogliptin B-TRIVIAL 
in O 
type O 
2 O 
diabetes O 
mellitus(†) O 

: O 
As O 
there O 
have O 
been O 
concerns O 
that O 
some O 
classes O 
or O 
agents O 
for O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
may O 
increase O 
CV O 
risk O 
, O 
we O 
evaluated O 
the O 
cardiovascular O 
profile O 
of O 
the O 
dipeptidyl O 
peptidase-4 O 
inhibitor O 
alogliptin B-TRIVIAL 
. O 
METHODS O 
: O 
We O 
evaluated O 
the O 
incidence O 
of O 
CV O 
events O 
in O 
patients O 
treated O 
with O 
alogliptin B-TRIVIAL 
, O 
placebo O 
or O 
comparator O 
antihyperglycaemic O 
drugs O 
in O 
the O 
clinical O 
trial O 
database O 
for O 
alogliptin B-TRIVIAL 
using O 
the O 
composite O 
major O 
adverse O 
cardiovascular O 
event O 
( O 
MACE O 
) O 
endpoints O 
of O 
CV O 
death O 
, O 
non-fatal O 
myocardial O 
infarction O 
and O 
non-fatal O 
stroke O 
. O 
RESULTS O 
: O 
The O 
pooled O 
analysis O 
included O 
4168 O 
patients O 
exposed O 
to O 
alogliptin B-TRIVIAL 
12.5 O 
and O 
25 O 
mg O 
daily O 
for O 
2023 O 
patient-years O 
compared O 
to O 
691 O 
patients O 
treated O 
with O 
placebo O 
for O 
263 O 
patient-years O 
and O 
1169 O 
patients O 
treated O 
with O 
other O 
antidiabetic O 
agents O 
( O 
metformin B-TRIVIAL 
, O 
sulfonylureas B-FAMILY 
and O 
thiazolidinediones B-FAMILY 
) O 
for O 
703 O 
patient-years O 
. O 
CV O 
events O 
were O 
adjudicated O 
by O 
an O 
expert O 
endpoint O 
committee O 
blinded O 
to O 
treatment O 
allocation O 
. O 
The O 
incidence O 
rates O 
of O 
the O 
combined O 
MACE O 
were O 
not O 
significantly O 
different O 
between O 
patients O 
treated O 
with O 
alogliptin B-TRIVIAL 
and O 
comparator O 
therapies O 
( O 
hazard O 
ratio=0.635 O 
, O 
95% O 
confidence O 
interval O 
, O 
0 O 
, O 
1.41 O 
) O 
. O 
Additionally O 
, O 
other O 
types O 
of O 
serious O 
CV O 
events O 
were O 
not O 
significantly O 
different O 
between O 
patients O 
treated O 
with O 
alogliptin B-TRIVIAL 
and O 
comparator O 
therapies O 
. O 
CONCLUSION O 
: O 
These O 
analyses O 
have O 
not O 
shown O 
a O 
signal O 
of O 
increased O 
CV O 
risk O 
with O 
alogliptin B-TRIVIAL 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 
Future O 
results O 
from O 
the O 
adequately O 
powered O 
EXAMINE O 
trial O 
will O 
definitively O 
assess O 
the O 
CV O 
safety O 
profile O 
of O 
aloglipin B-TRIVIAL 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
. O 

of O 
(R)-norbgugaine B-TRIVIAL 
and O 
its O 
potential O 
as O 
quorum O 
sensing O 
inhibitor O 
against O 
Pseudomonas O 
aeruginosa O 
. O 

is O 
a O 
natural O 
pyrrolidine B-FAMILY 
alkaloid I-FAMILY 
from O 
Arisarum O 
vulgare O 
, O 
which O 
shows O 
antifungal O 
and O 
antibacterial O 
activity O 
. O 
In O 
this O 
Letter O 
, O 
we O 
have O 
accomplished O 
the O 
simple O 
synthesis O 
of O 
norbgugaine B-TRIVIAL 
( O 
demethylated O 
form O 
of O 
natural O 
bgugaine B-TRIVIAL 
) O 
employing O 
Wittig O 
olefination O 
and O 
cat O 
. O 
hydrogenation O 
as O 
the O 
key O 
steps O 
and O 
its O 
biological O 
studies O 
are O 
reported O 
for O 
the O 
first O 
time O 
. O 
The O 
synthesized O 
norbgugaine B-TRIVIAL 
was O 
evaluated O 
for O 
inhibition O 
of O 
quorum O 
sensing O 
mediated O 
virulence O 
factors O 
( O 
motility O 
, O 
biofilm O 
formation O 
, O 
pyocyanin B-TRIVIAL 
pigmentation O 
, O 
rhamnolipid O 
production O 
and O 
LasA O 
protease O 
) O 
in O 
Pseudomonas O 
aeruginosa O 
wherein O 
swarming O 
motility O 
is O 
reduced O 
by O 
95% O 
, O 
and O 
biofilm O 
formation O 
by O 
83% O 
. O 

apoptosis O 
is O 
a O 
promising O 
therapeutic O 
approach O 
to O 
overcome O 
cancer O 
. O 
In O 
this O 
study O 
, O 
30 O 
compounds O 
were O 
synthesized O 
and O 
evaluated O 
for O 
their O 
antiproliferative O 
activity O 
against O 
three O 
tumor O 
cell O 
lines O 
in O 
vitro O 
: O 
A875 O 
, O 
H460 O 
and O 
Hela O 
cancer O 
cells O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
. O 
The O 
most O 
potent O 
analogue O 
7a O 
, O 
a O 
novel O 
compound O 
was O 
first O 
reported O 
by O 
our O 
group O 
, O 
inhibited O 
the O 
proliferation O 
of O 
A875 O 
cells O 
with O 
an O 
IC50 O 
value O 
of O 
98 O 
nM O 
. O 
Flow O 
cytometry O 
analysis O 
and O 
morphological O 
analysis O 
suggested O 
that O 
compound O 
7a O 
had O 
potential O 
anticancer O 
efficacy O 
via O 
G2 O 
/ O 
M O 
cell O 
cycle O 
arrest O 
, O 
which O 
could O 
be O 
attributed O 
to O 
its O 
proliferation O 
and O 
apoptosis O 
, O 
and O 
also O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
. O 
The O 
SAR O 
analysis O 
indicated O 
that O 
the O 
substituents O 
R(2) O 
played O 
a O 
crucial O 
role O 
in O 
the O 
antiproliferation O 
activity O 
. O 

arylsulfonamide I-FAMILY 
inhibitors O 
of O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
: O 
strategies O 
to O 
eliminate O 
reactive O 
metabolites O 
. O 

arylsulfonamides I-FAMILY 
1 O 
and O 
2 O 
( O 
PF-915275 B-IDENTIFIER 
) O 
were O 
identified O 
as O 
potent O 
inhibitors O 
of O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
. O 
A O 
screen O 
for O 
bioactivation O 
revealed O 
that O 
these O 
compounds O 
formed O 
glutathione B-TRIVIAL 
conjugates O 
. O 
This O 
communication O 
presents O 
the O 
results O 
of O 
a O 
risk O 
benefit O 
analysis O 
carried O 
out O 
to O 
progress O 
2 O 
( O 
PF-915275 B-IDENTIFIER 
) O 
to O 
a O 
clinical O 
study O 
and O 
the O 
strategies O 
used O 
to O 
eliminate O 
reactive O 
metabolites O 
in O 
this O 
series O 
of O 
inhibitors O 
. O 
Based O 
on O 
the O 
proposed O 
mechanism O 
of O 
bioactivation O 
and O 
structure O 
- O 
activity O 
relationships O 
, O 
design O 
efforts O 
led O 
to O 
N-(pyridin-2-yl) B-FAMILY 
arylsulfonamides I-FAMILY 
such O 
as O 
18 O 
and O 
20 O 
that O 
maintained O 
potent O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
activity O 
, O 
showed O 
exquisite O 
pharmacokinetic O 
profiles O 
, O 
and O 
were O 
negative O 
in O 
the O 
reactive O 
metabolite O 
assay O 
. O 

at O 
Night O 
Alters O 
Daily O 
Patterns O 
of O 
Cortisol B-TRIVIAL 
and O 
Clock O 
Proteins O 
in O 
Female O 
Siberian O 
Hamsters O 
. O 

and O 
other O 
organisms O 
have O 
adapted O 
to O 
a O 
24-h O 
solar O 
cycle O 
in O 
response O 
to O 
life O 
on O 
Earth O 
. O 
The O 
rotation O 
of O 
the O 
planet O 
on O 
its O 
axis O 
and O 
its O 
revolution O 
around O 
the O 
sun O 
cause O 
predictable O 
daily O 
and O 
seasonal O 
patterns O 
in O 
day O 
length O 
. O 
In O 
order O 
to O 
successfully O 
anticipate O 
and O 
adapt O 
to O 
these O 
patterns O 
in O 
the O 
environment O 
, O 
a O 
variety O 
of O 
biological O 
processes O 
oscillate O 
with O 
a O 
daily O 
rhythm O 
approximately O 
24 O 
h O 
in O 
length O 
. O 
These O 
rhythms O 
arise O 
from O 
hierarchally O 
- O 
coupled O 
cellular O 
clocks O 
generated O 
by O 
positive O 
and O 
negative O 
transcription O 
factors O 
of O 
core O 
circadian O 
clock O 
gene O 
expression O 
. O 
From O 
these O 
endogenous O 
cellular O 
clocks O 
, O 
overt O 
rhythms O 
in O 
activity O 
and O 
patterns O 
in O 
hormone O 
secretion O 
and O 
other O 
homeostatic O 
processes O 
emerge O 
. O 
These O 
circadian O 
rhythms O 
in O 
physiology O 
and O 
behavior O 
can O 
be O 
organized O 
by O 
a O 
variety O 
of O 
cues O 
, O 
but O 
they O 
are O 
most O 
potently O 
entrained O 
by O 
light O 
. O 
In O 
recent O 
history O 
, O 
there O 
has O 
been O 
a O 
major O 
change O 
from O 
naturally O 
occurring O 
light O 
cycles O 
set O 
by O 
the O 
sun O 
, O 
to O 
artificial O 
and O 
sometimes O 
erratic O 
light O 
cycles O 
determined O 
by O 
the O 
use O 
of O 
electric O 
lighting O 
. O 
Virtually O 
every O 
individual O 
living O 
in O 
an O 
industrialized O 
country O 
experiences O 
light O 
at O 
night O 
( O 
LAN O 
) O 
, O 
but O 
despite O 
its O 
prevalence O 
, O 
the O 
biological O 
effects O 
of O 
such O 
unnatural O 
lighting O 
have O 
not O 
been O 
fully O 
considered O 
. O 
Using O 
female O 
Siberian O 
hamsters O 
( O 
Phodopus O 
sungorus O 
) O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
chronic O 
nightly O 
exposure O 
to O 
dim O 
light O 
on O 
daily O 
rhythms O 
in O 
locomotor O 
activity O 
, O 
serum O 
cortisol B-TRIVIAL 
concentrations O 
, O 
and O 
brain O 
expression O 
of O 
circadian O 
clock O 
proteins O 
( O 
i.e O 
. O 
, O 
PER1 O 
, O 
PER2 O 
, O 
BMAL1 O 
) O 
. O 
Although O 
locomotor O 
activity O 
remained O 
entrained O 
to O 
the O 
light O 
cycle O 
, O 
the O 
diurnal O 
fluctuation O 
of O 
cortisol B-TRIVIAL 
concentrations O 
was O 
blunted O 
and O 
the O 
expression O 
patterns O 
of O 
clock O 
proteins O 
in O 
the O 
SCN O 
and O 
hippocampus O 
were O 
altered O 
. O 
These O 
results O 
demonstrate O 
that O 
chronic O 
exposure O 
to O 
dim O 
LAN O 
can O 
dramatically O 
affect O 
fundamental O 
cellular O 
function O 
and O 
emergent O 
physiology O 
. O 
© O 
2013 O 
British O 
Society O 
for O 
Neuroendocrinology O 
. O 

effect O 
of O 
a O 
unique O 
halide B-FAMILY 
-stabilizing O 
residue O 
on O 
the O 
catalytic O 
properties O 
of O 
haloalkane B-FAMILY 
dehalogenase O 
DatA O 
from O 
Agrobacterium O 
tumefaciens O 
C58 O 
. O 

dehalogenases O 
catalyze O 
the O 
hydrolysis O 
of O 
carbon B-SYSTEMATIC 
- O 
halogen B-FAMILY 
bonds O 
in O 
various O 
chlorinated O 
, O 
brominated O 
and O 
iodinated O 
compounds O 
. O 
These O 
enzymes O 
have O 
a O 
conserved O 
pair O 
of O 
halide B-FAMILY 
-stabilizing O 
residues O 
that O 
are O 
important O 
in O 
substrate O 
binding O 
and O 
stabilization O 
of O 
the O 
transition O 
state O 
and O 
the O 
halide B-FAMILY 
ion O 
product O 
via O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 
In O 
all O 
previously O 
known O 
haloalkane B-FAMILY 
dehalogenases O 
, O 
these O 
residues O 
are O 
either O 
a O 
pair O 
of O 
tryptophans B-FAMILY 
or O 
a O 
tryptophan B-TRIVIAL 
- O 
asparagine B-TRIVIAL 
pair O 
. O 
The O 
newly O 
- O 
isolated O 
haloalkane B-FAMILY 
dehalogenase O 
DatA O 
from O 
Agrobacterium O 
tumefaciens O 
C58 O 
( O 
EC O 
3.8.1.5 O 
) O 
possesses O 
a O 
unique O 
halide B-FAMILY 
-stabilizing O 
tyrosine B-TRIVIAL 
residue O 
, O 
Y109 O 
, O 
in O 
place O 
of O 
the O 
conventional O 
tryptophan B-TRIVIAL 
. O 
A O 
variant O 
of O 
DatA O 
with O 
the O 
Y109W O 
mutation O 
was O 
created O 
and O 
the O 
effects O 
of O 
this O 
mutation O 
on O 
the O 
structure O 
and O 
catalytic O 
properties O 
of O 
the O 
enzyme O 
were O 
studied O 
using O 
spectroscopy O 
and O 
pre O 
- O 
steady O 
- O 
state O 
kinetic O 
experiments O 
. O 
Quantum O 
mechanical O 
and O 
molecular O 
dynamics O 
calculations O 
were O 
used O 
to O 
obtain O 
a O 
detailed O 
analysis O 
of O 
the O 
hydrogen B-SYSTEMATIC 
-bonding O 
patterns O 
within O 
the O 
active O 
sites O 
of O 
the O 
wild O 
- O 
type O 
and O 
the O 
mutant O 
, O 
as O 
well O 
as O 
of O 
the O 
stabilization O 
of O 
the O 
ligands O 
as O 
the O 
reaction O 
proceeds O 
. O 
Fluorescence O 
quenching O 
experiments O 
suggested O 
that O 
replacing O 
the O 
tyrosine B-TRIVIAL 
with O 
tryptophan B-TRIVIAL 
improves O 
halide B-FAMILY 
binding O 
by O 
3.7-fold O 
, O 
presumably O 
as O 
a O 
result O 
of O 
the O 
introduction O 
of O 
an O 
additional O 
hydrogen B-SYSTEMATIC 
bond O 
. O 
Kinetic O 
analysis O 
revealed O 
that O 
the O 
mutation O 
affected O 
the O 
substrate O 
specificity O 
of O 
the O 
enzyme O 
and O 
reduced O 
its O 
K0.5 O 
for O 
selected O 
halogenated O 
substrates O 
by O 
a O 
factor O 
of O 
2-4 O 
, O 
without O 
impacting O 
the O 
rate O 
- O 
determining O 
hydrolytic O 
step O 
. O 
We O 
conclude O 
that O 
DatA O 
is O 
the O 
first O 
natural O 
haloalkane B-FAMILY 
dehalogenase O 
that O 
stabilizes O 
its O 
substrate O 
in O 
the O 
active O 
site O 
using O 
only O 
a O 
single O 
hydrogen B-SYSTEMATIC 
bond O 
, O 
which O 
is O 
a O 
new O 
paradigm O 
in O 
catalysis O 
by O 
this O 
enzyme O 
family O 
. O 

most O 
important O 
system O 
for O 
correcting O 
replication O 
errors O 
that O 
survive O 
the O 
built O 
in O 
editing O 
system O 
of O 
DNA O 
polymerase O 
is O 
the O 
mismatch O 
repair O 
( O 
MMR O 
) O 
system O 
. O 
We O 
have O 
identified O 
a O 
novel O 
mutator O 
strain O 
yycJ O 
in O 
Bacillus O 
anthracis O 
. O 
Mutations O 
in O 
the O 
yycJ O 
gene O 
result O 
in O 
a O 
spontaneous O 
mutator O 
phenotype O 
with O 
a O 
mutational O 
frequency O 
and O 
specificity O 
comparable O 
to O 
that O 
of O 
MMR-deficient O 
strains O 
such O 
as O 
those O 
with O 
mutations O 
in O 
mutL O 
or O 
mutS O 
. O 
YycJ O 
was O 
annotated O 
as O 
a O 
metallo-β-lactamase O 
( O 
MβL O 
) O 
super O 
family O 
member O 
with O 
unknown O 
activity O 
. O 
In O 
this O 
study O 
we O 
carried O 
out O 
a O 
biochemical O 
characterization O 
of O 
YycJ O 
and O 
demonstrated O 
that O 
a O 
recombinant O 
YycJ O 
protein O 
possesses O 
a O 
5'-3 O 
' O 
exonuclease O 
activity O 
at O 
the O 
5 O 
' O 
termini O 
and O 
at O 
nicks O 
of O 
double O 
- O 
stranded O 
DNA O 
. O 
This O 
activity O 
requires O 
a O 
divalent O 
metal O 
cofactor O 
Mn(2+) B-FORMULA 
and O 
is O 
stimulated O 
by O 
5'-phosphate B-SYSTEMATIC 
ends O 
of O 
duplex O 
DNA O 
. O 
The O 
mutagenesis O 
of O 
conserved O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
revealed O 
that O 
in O 
addition O 
to O 
the O 
five O 
MβL O 
family O 
conserved O 
motifs O 
, O 
YycJ O 
appears O 
to O 
have O 
its O 
specific O 
motifs O 
that O 
can O 
be O 
used O 
to O 
distinguish O 
YycJ O 
from O 
other O 
closely O 
related O 
MβL O 
family O 
members O 
. O 
A O 
phylogenetic O 
survey O 
showed O 
that O 
putative O 
YycJ O 
homologs O 
are O 
present O 
in O 
several O 
bacterial O 
phyla O 
as O 
well O 
as O 
in O 
members O 
of O 
the O 
Methanomicrobiales O 
and O 
Thermoplasmales O 
from O 
Archaea O 
. O 
We O 
propose O 
that O 
YycJ O 
represents O 
a O 
new O 
group O 
of O 
MβL O 
fold O 
exonucleases O 
, O 
which O 
is O 
likely O 
to O 
act O 
in O 
the O 
recognition O 
of O 
MMR O 
entry O 
point O 
and O 
subsequent O 
removal O 
of O 
the O 
mismatched O 
base O 
in O 
certain O 
MutH-less O 
bacterial O 
species O 
. O 

or O 
compensatory O 
responses O 
to O 
chemical O 
exposure O 
can O 
significantly O 
influence O 
in O 
vivo O 
concentration O 
- O 
duration O 
- O 
response O 
relationships O 
. O 
This O 
study O 
provided O 
data O 
to O 
support O 
development O 
of O 
a O 
computational O 
dynamic O 
model O 
of O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
gonadal O 
axis O 
of O 
a O 
model O 
vertebrate O 
and O 
its O 
response O 
to O 
aromatase O 
inhibitors O 
as O 
a O 
class O 
of O 
endocrine O 
active O 
chemicals O 
. O 
Fathead O 
minnows O 
( O 
Pimephales O 
promelas O 
) O 
were O 
either O 
exposed O 
to O 
the O 
aromatase O 
inhibitor O 
fadrozole B-TRIVIAL 
( O 
0.5 O 
or O 
30 O 
μg O 
/ O 
l O 
) O 
continuously O 
for O 
1 O 
, O 
8 O 
, O 
12 O 
, O 
16 O 
, O 
20 O 
, O 
24 O 
, O 
or O 
28 O 
days O 
or O 
exposed O 
for O 
8 O 
days O 
and O 
then O 
held O 
in O 
control O 
water O 
( O 
no O 
fadrozole B-TRIVIAL 
) O 
for O 
an O 
additional O 
4 O 
, O 
8 O 
, O 
12 O 
, O 
16 O 
, O 
or O 
20 O 
days O 
. O 
The O 
time O 
course O 
of O 
effects O 
on O 
ovarian O 
steroid O 
production O 
, O 
circulating O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
and O 
vitellogenin B-TRIVIAL 
( O 
VTG B-ABBREVIATION 
) O 
concentrations O 
, O 
and O 
expression O 
of O 
steroidogenesis O 
- O 
related O 
genes O 
in O 
the O 
ovary O 
was O 
measured O 
. O 
Exposure O 
to O 
30 O 
μg O 
fadrozole B-TRIVIAL 
/l O 
significantly O 
reduced O 
plasma O 
E2 O 
and O 
VTG B-ABBREVIATION 
concentrations O 
after O 
just O 
1 O 
day O 
and O 
those O 
effects O 
persisted O 
throughout O 
28 O 
days O 
of O 
exposure O 
. O 
In O 
contrast O 
, O 
ex O 
vivo O 
E2 O 
production O 
was O 
similar O 
to O 
that O 
of O 
controls O 
on O 
day O 
8-28 O 
of O 
exposure O 
, O 
whereas O 
transcripts O 
coding O 
for O 
aromatase O 
and O 
follicle O 
- O 
stimulating O 
hormone O 
receptor O 
were O 
elevated O 
, O 
suggesting O 
a O 
compensatory O 
response O 
. O 
Following O 
cessation O 
of O 
fadrozole B-TRIVIAL 
exposure O 
, O 
ex O 
vivo O 
E2 O 
and O 
plasma O 
E2 O 
concentrations O 
exceeded O 
and O 
then O 
recovered O 
to O 
control O 
levels O 
, O 
but O 
plasma O 
VTG B-ABBREVIATION 
concentrations O 
did O 
not O 
, O 
even O 
after O 
20 O 
days O 
of O 
depuration O 
. O 
Collectively O 
these O 
data O 
provide O 
several O 
new O 
insights O 
into O 
the O 
nature O 
and O 
time O 
course O 
of O 
adaptive O 
responses O 
to O 
an O 
aromatase O 
inhibitor O 
that O 
support O 
development O 
of O 
a O 
computational O 
model O 
( O 
see O 
companion O 
article O 
) O 
. O 

adipose O 
tissue O 
( O 
BAT O 
) O 
is O 
a O 
highly O 
thermogenic O 
organ O 
that O 
converts O 
lipids O 
and O 
glucose B-TRIVIAL 
into O 
heat O 
. O 
Many O 
of O 
the O 
metabolic O 
and O 
gene O 
transcriptional O 
hallmarks O 
of O 
BAT O 
activation O 
, O 
namely O 
increased O 
lipolysis O 
, O 
uncoupling O 
protein-1 O 
( O 
UCP1 O 
) O 
mRNA O 
, O 
and O 
glucose B-TRIVIAL 
uptake O 
are O 
regulated O 
by O 
the O 
adrenergic O 
second O 
messenger O 
, O 
adenosine-3',5'-cyclic B-SYSTEMATIC 
monophosphate I-SYSTEMATIC 
( O 
cAMP B-ABBREVIATION 
) O 
. O 
Cyclic O 
nucleotide B-FAMILY 
phosphodiesterases O 
( O 
PDEs O 
) O 
catalyze O 
the O 
breakdown O 
of O 
cAMP B-ABBREVIATION 
, O 
thereby O 
regulating O 
the O 
magnitude O 
and O 
duration O 
of O 
this O 
signaling O 
molecule O 
. O 
In O 
the O 
absence O 
of O 
adrenergic O 
stimulus O 
, O 
we O 
found O 
that O 
it O 
required O 
a O 
combination O 
of O 
a O 
PDE3 O 
and O 
a O 
PDE4 O 
inhibitor O 
to O 
fully O 
induce O 
UCP1 O 
mRNA O 
and O 
lipolysis O 
in O 
brown O 
adipocytes O 
, O 
whereas O 
neither O 
PDE O 
inhibitor O 
alone O 
had O 
any O 
substantial O 
effect O 
under O 
basal O 
conditions O 
. O 
Under O 
submaximal O 
β-adrenoceptor O 
stimulation O 
of O 
brown O 
adipocytes O 
, O 
a O 
PDE3 O 
inhibitor O 
alone O 
could O 
potentiate O 
induction O 
of O 
UCP1 O 
mRNA O 
, O 
while O 
a O 
PDE4 O 
inhibitor O 
alone O 
could O 
augment O 
lipolysis O 
, O 
indicating O 
differential O 
roles O 
for O 
each O 
of O 
these O 
two O 
PDEs O 
. O 
Neither O 
induction O 
of O 
UCP1 O 
nor O 
lipolysis O 
was O 
altered O 
by O 
inhibition O 
of O 
PDE1 O 
, O 
PDE2 O 
or O 
PDE8A O 
. O 
Finally O 
, O 
when O 
injected O 
into O 
mice O 
, O 
the O 
combination O 
of O 
PDE3 O 
and O 
PDE4 O 
inhibitors O 
stimulated O 
glucose B-TRIVIAL 
uptake O 
in O 
BAT O 
under O 
thermoneutral O 
and O 
fasted O 
conditions O 
, O 
a O 
response O 
that O 
was O 
further O 
potentiated O 
by O 
the O 
global O 
ablation O 
of O 
PDE8A O 
. O 
Taken O 
together O 
, O 
these O 
data O 
illustrate O 
that O 
multiple O 
PDEs O 
work O 
in O 
concert O 
to O 
regulate O 
three O 
of O 
the O 
important O 
pathways O 
leading O 
to O 
BAT O 
activation O 
, O 
a O 
finding O 
that O 
may O 
provide O 
an O 
improved O 
conceptual O 
basis O 
for O 
the O 
development O 
of O 
therapies O 
for O 
obesity O 
- O 
related O 
diseases O 
. O 

(m)CpG B-ABBREVIATION 
complex O 
transactivates O 
postnatal O 
murine O 
neuronal O 
glucose B-TRIVIAL 
transporter O 
isoform O 
3 O 
expression O 
. O 

murine O 
neuronal O 
facilitative O 
glucose B-TRIVIAL 
transporter O 
isoform O 
3 O 
( O 
Glut3 O 
) O 
is O 
developmentally O 
regulated O 
, O 
peaking O 
in O 
expression O 
at O 
postnatal O 
day O 
(PN)14 O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
characterized O 
a O 
canonical O 
CpG B-ABBREVIATION 
island O 
spanning O 
the O 
5'-flanking O 
region O 
of O 
the O 
glut3 O 
gene O 
. O 
Methylation O 
- O 
specific O 
PCR O 
and O 
bisulfite B-SYSTEMATIC 
sequencing O 
identified O 
methylation O 
of O 
this O 
CpG B-ABBREVIATION 
( O 
(m)CpG B-ABBREVIATION 
) O 
island O 
of O 
the O 
glut3 O 
gene O 
, O 
frequency O 
of O 
methylation O 
increasing O 
2.5-fold O 
with O 
a O 
1.6-fold O 
increase O 
in O 
DNA O 
methyl O 
transferase O 
3a O 
concentrations O 
noted O 
with O 
advancing O 
postnatal O 
age O 
( O 
PN14 O 
vs O 
PN3 O 
) O 
. O 
5'-flanking O 
region O 
of O 
glut3-luciferase O 
reporter O 
transient O 
transfection O 
in O 
HT22 O 
hippocampal O 
neurons O 
demonstrated O 
that O 
(m)CpGs B-ABBREVIATION 
inhibit O 
glut3 O 
transcription O 
. O 
Contrary O 
to O 
this O 
biological O 
function O 
, O 
glut3 O 
expression O 
rises O 
synchronously O 
with O 
(m)CpGs B-ABBREVIATION 
in O 
PN14 O 
vs O 
PN3 O 
neurons O 
. O 
Chromatin O 
immunoprecipitation O 
( O 
IP O 
) O 
revealed O 
that O 
methyl B-SYSTEMATIC 
-CpG O 
binding O 
protein O 
2 O 
( O 
Mecp2 O 
) O 
bound O 
the O 
glut3- O 
(m)CpGs B-ABBREVIATION 
. O 
Depending O 
on O 
association O 
with O 
specific O 
coregulators O 
, O 
Mecp2 O 
, O 
a O 
dual O 
regulator O 
of O 
gene O 
transcription O 
, O 
may O 
repress O 
or O 
activate O 
a O 
downstream O 
gene O 
. O 
Sequential O 
chromatin O 
IP O 
uncovered O 
the O 
glut3- O 
(m)CpGs B-ABBREVIATION 
to O 
bind O 
Mecp2 O 
exponentially O 
upon O 
recruitment O 
of O 
Creb1 O 
rather O 
than O 
histone O 
deacetylase O 
1 O 
. O 
Co-IP O 
and O 
coimmunolocalization O 
confirmed O 
that O 
Creb1 O 
associated O 
with O 
Mecp2 O 
and O 
cotransfection O 
with O 
glut3- O 
(m)CpG B-ABBREVIATION 
in O 
HT22 O 
cells O 
enhanced O 
glut3 O 
transcription O 
. O 
Separate O 
5-aza-2'-deoxycytidine B-SYSTEMATIC 
pretreatment O 
or O 
in O 
combination O 
with O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
reduced O 
(m)CpG B-ABBREVIATION 
and O 
specific O 
small O 
interference O 
RNAs O 
targeting O 
Mecp2 O 
and O 
Creb1 O 
separately O 
or O 
together O 
depleting O 
Mecp2 O 
and O 
/ O 
or O 
Creb1 O 
binding O 
of O 
glut3- O 
(m)CpGs B-ABBREVIATION 
reduced O 
glut3 O 
expression O 
in O 
HT22 O 
cells O 
. O 
We O 
conclude O 
that O 
Glut3 O 
is O 
a O 
methylation O 
- O 
sensitive O 
neuronal O 
gene O 
that O 
recruits O 
Mecp2 O 
. O 
Recruitment O 
of O 
Creb1-Mecp2 O 
by O 
glut3- O 
(m)CpG B-ABBREVIATION 
contributes O 
towards O 
transactivation O 
, O 
formulating O 
an O 
escape O 
from O 
(m)CpG B-ABBREVIATION 
-induced O 
gene O 
suppression O 
, O 
and O 
thereby O 
promoting O 
developmental O 
neuronal O 
glut3 O 
gene O 
transcription O 
and O 
expression O 
. O 

of O 
N-Hydroxycinnamamide B-SYSTEMATIC 
-Based O 
Histone O 
Deacetylase O 
Inhibitors O 
with O 
Indole B-SYSTEMATIC 
-Containing O 
Cap O 
Group O 
. O 

novel O 
series O 
of O 
histone O 
deacetylase O 
inhibitors O 
combining O 
N-hydroxycinnamamide B-SYSTEMATIC 
bioactive O 
fragment O 
and O 
indole B-SYSTEMATIC 
bioactive O 
fragment O 
was O 
designed O 
and O 
synthesized O 
. O 
Several O 
compounds O 
( O 
17c O 
, O 
17g O 
, O 
17h O 
, O 
17j O 
and O 
17k O 
) O 
exhibited O 
comparable O 
even O 
superior O 
total O 
HDACs O 
inhibitory O 
activity O 
and O 
in O 
vitro O 
antiproliferative O 
activities O 
relative O 
to O 
the O 
approved O 
drug O 
SAHA B-ABBREVIATION 
. O 
A O 
representative O 
compound O 
17a O 
with O 
moderate O 
HDACs O 
inhibition O 
was O 
progressed O 
to O 
isoform O 
selectivity O 
profile O 
, O 
western O 
blot O 
analysis O 
and O 
in O 
vivo O 
antitumor O 
assay O 
. O 
Although O 
HDACs O 
isoform O 
selectivity O 
of O 
17a O 
was O 
similar O 
to O 
that O 
of O 
SAHA B-ABBREVIATION 
, O 
our O 
western O 
blot O 
results O 
indicated O 
that O 
intracellular O 
effects O 
of O 
17a O 
at O 
1 O 
μM O 
were O 
class O 
I O 
selective O 
. O 
It O 
was O 
noteworthy O 
that O 
the O 
effect O 
on O 
histone O 
H4 O 
acetylation O 
of O 
SAHA B-ABBREVIATION 
decreased O 
with O 
time O 
while O 
the O 
effect O 
on O 
histone O 
H4 O 
acetylation O 
of O 
17a O 
maintained O 
even O 
increased O 
. O 
Most O 
importantly O 
, O 
compound O 
17a O 
exhibited O 
promising O 
in O 
vivo O 
antitumor O 
activity O 
in O 
a O 
U937 O 
xenograft O 
model O 
. O 

profiles O 
of O 
selected O 
synthetic O 
cannabinoids B-FAMILY 
showing O 
high O 
binding O 
affinities O 
to O 
the O 
cannabinoid B-FAMILY 
receptor O 
subtype O 
CB1 O 
. O 

containing O 
synthetic O 
cannabinoids B-FAMILY 
are O 
consumed O 
as O 
a O 
surrogate O 
for O 
marihuana O 
due O 
to O 
their O 
non-detectability O 
with O 
commonly O 
used O 
drug O 
tests O 
and O 
their O 
strong O 
cannabimimetic O 
effects O 
. O 
Because O 
data O 
concerning O 
their O 
toxicological O 
properties O 
are O 
scarce O 
, O 
the O 
cytotoxic O 
, O 
genotoxic O 
, O 
immunomodulatory O 
, O 
and O 
hormonal O 
activities O 
of O 
four O 
naphthoylindole B-FAMILY 
compounds O 
( O 
JWH-018 B-IDENTIFIER 
, O 
JWH-073 B-IDENTIFIER 
, O 
JWH-122 B-IDENTIFIER 
and O 
JWH-210 B-IDENTIFIER 
) O 
and O 
of O 
one O 
benzoylindole B-FAMILY 
( O 
AM-694 B-IDENTIFIER 
) O 
were O 
studied O 
in O 
human O 
cell O 
lines O 
and O 
primary O 
cells O 
; O 
tetrahydrocannabinol B-SYSTEMATIC 
was O 
included O 
as O 
the O 
classical O 
non-endogenous O 
cannabinoid O 
receptor O 
ligand O 
. O 
All O 
compounds O 
induced O 
damage O 
to O 
the O 
cell O 
membranes O 
of O 
buccal O 
( O 
TR146 O 
) O 
and O 
breast O 
( O 
MCF-7 O 
) O 
derived O 
cells O 
at O 
concentrations O 
of O 
≥ O 
75-100 O 
μM O 
. O 
No O 
cytotoxic O 
responses O 
were O 
seen O 
in O 
other O 
assays O 
which O 
reflect O 
mitochondrial O 
damage O 
, O 
protein O 
synthesis O 
, O 
and O 
lysosomal O 
activities O 
. O 
JWH-073 B-IDENTIFIER 
and O 
JWH-122 B-IDENTIFIER 
induced O 
DNA O 
migration O 
in O 
buccal O 
and O 
liver O 
cells O 
( O 
HepG2 O 
) O 
in O 
single O 
cell O 
gel O 
electrophoresis O 
assays O 
, O 
while O 
JWH-210 B-IDENTIFIER 
was O 
only O 
in O 
the O 
latter O 
cell O 
line O 
active O 
. O 
No O 
estrogenic O 
activities O 
were O 
detected O 
in O 
bone O 
marrow O 
cells O 
( O 
U2-OS O 
) O 
, O 
but O 
all O 
compounds O 
caused O 
anti-estrogenic O 
effects O 
at O 
levels O 
between O 
2.1 O 
and O 
23 O 
μM O 
. O 
Furthermore O 
, O 
no O 
impact O 
on O 
cytokine O 
release O 
( O 
i.e O 
. O 
, O 
on O 
IL-10 O 
, O 
IL-6 O 
, O 
IL-12 O 
/ O 
23p40 O 
and O 
TNFα O 
levels O 
) O 
was O 
seen O 
in O 
LPS-stimulated O 
human O 
PBMCs O 
, O 
except O 
with O 
JWH-210 B-IDENTIFIER 
and O 
JWH-122 B-IDENTIFIER 
which O 
caused O 
a O 
decrease O 
of O 
TNFα O 
and O 
IL-12 O 
/ O 
23p40 O 
. O 
All O 
toxic O 
effects O 
were O 
observed O 
with O 
concentrations O 
higher O 
than O 
those O 
expected O 
in O 
body O 
fluids O 
of O 
users O 
. O 
Since O 
genotoxic O 
effects O 
are O 
in O 
general O 
linear O 
over O 
a O 
wide O 
concentration O 
range O 
and O 
the O 
exposure O 
levels O 
may O 
be O 
higher O 
in O 
epithelial O 
cells O 
or O 
in O 
serum O 
, O 
further O 
experimental O 
work O 
is O 
required O 
to O 
find O 
out O 
if O 
DNA O 
damage O 
takes O 
place O 
in O 
drug O 
users O 
. O 

ketamine B-TRIVIAL 
induces O 
hippocampal O 
synaptic O 
depression O 
and O 
spatial O 
memory O 
impairment O 
through O 
dopamine B-TRIVIAL 
D1 O 
/ O 
D5 O 
receptors O 
. O 

: O 
Subanesthetic O 
doses O 
of O 
ketamine B-TRIVIAL 
have O 
been O 
reported O 
to O 
induce O 
psychotic O 
states O 
that O 
may O 
mimic O 
positive O 
and O 
negative O 
symptoms O 
as O 
well O 
as O 
cognitive O 
and O 
memory O 
deficits O 
similar O 
to O 
those O 
observed O 
in O 
schizophrenia O 
. O 
The O 
cognitive O 
and O 
memory O 
deficits O 
are O 
persistent O 
, O 
and O 
their O 
underlying O 
cellular O 
mechanisms O 
remain O 
unclear O 
. O 
OBJECTIVES O 
: O 
We O 
sought O 
to O 
investigate O 
the O 
roles O 
of O 
dopamine B-TRIVIAL 
D1 O 
/ O 
D5 O 
receptors O 
and O 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
AMPA B-ABBREVIATION 
) O 
receptors O 
in O 
hippocampal O 
synaptic O 
transmission O 
and O 
spatial O 
memory O 
impairment O 
induced O 
by O 
ketamine B-TRIVIAL 
. O 
METHODS O 
: O 
We O 
examined O 
the O 
effects O 
of O 
subanesthetic O 
ketamine B-TRIVIAL 
on O 
hippocampal O 
synaptic O 
transmission O 
in O 
freely O 
moving O 
rats O 
. O 
Spatial O 
memory O 
was O 
tested O 
with O 
the O 
Morris O 
water O 
maze O 
. O 
Pretreatment O 
with O 
the O 
D1 O 
/ O 
D5 O 
receptors O 
antagonist O 
SCH23390 B-IDENTIFIER 
or O 
the O 
AMPA B-ABBREVIATION 
receptors O 
endocytosis O 
interfering O 
peptide O 
Tat-GluR23Y O 
was O 
conducted O 
to O 
examine O 
their O 
capacities O 
to O 
reverse O 
ketamine B-TRIVIAL 
-induced O 
electrophysiological O 
and O 
behavioral O 
alterations O 
. O 
A O 
series O 
of O 
behavioral O 
observations O 
, O 
including O 
locomotion O 
, O 
prepulse O 
inhibition O 
, O 
and O 
social O 
interaction O 
, O 
were O 
also O 
conducted O 
after O 
ketamine B-TRIVIAL 
treatment O 
. O 
RESULTS O 
: O 
Ketamine B-TRIVIAL 
induced O 
synaptic O 
depression O 
lasting O 
at O 
least O 
4 O 
h O 
at O 
hippocampal O 
Schaffer O 
collateral-CA1 O 
synapses O 
in O 
freely O 
moving O 
rats O 
and O 
long O 
- O 
term O 
spatial O 
memory O 
impairment O 
. O 
Both O 
the O 
effects O 
were O 
blocked O 
by O 
either O 
SCH23390 B-IDENTIFIER 
or O 
Tat-GluR23Y O 
. O 
Ketamine B-TRIVIAL 
also O 
elicited O 
transient O 
behavioral O 
changes O 
lasting O 
less O 
than O 
90 O 
min O 
, O 
such O 
as O 
hyperlocomotion O 
and O 
prepulse O 
inhibition O 
deficits O 
. O 
These O 
changes O 
were O 
ameliorated O 
by O 
SCH23390 B-IDENTIFIER 
but O 
not O 
by O 
Tat-GluR23Y O 
. O 
Rats O 
treated O 
with O 
ketamine B-TRIVIAL 
showed O 
social O 
withdrawal O 
that O 
was O 
also O 
attenuated O 
by O 
either O 
SCH23390 B-IDENTIFIER 
or O 
Tat-GluR23Y O 
. O 
CONCLUSIONS O 
: O 
Our O 
results O 
indicate O 
that O 
hippocampal O 
synaptic O 
depression O 
is O 
involved O 
in O 
ketamine B-TRIVIAL 
-induced O 
memory O 
impairment O 
, O 
and O 
this O 
is O 
modulated O 
by O 
D1 O 
/ O 
D5 O 
receptors O 
activation O 
and O 
AMPA B-ABBREVIATION 
receptors O 
endocytosis O 
. O 

of O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibition O 
in O 
the O 
dorsolateral O 
periaqueductal O 
gray O 
matter O 
on O 
ethanol B-SYSTEMATIC 
withdrawal O 
- O 
induced O 
anxiety O 
- O 
like O 
behavior O 
in O 
rats O 
. O 

: O 
Nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
- O 
mediated O 
transmission O 
in O 
the O 
dorsolateral O 
periaqueductal O 
gray O 
matter O 
( O 
dlPAG O 
) O 
has O 
been O 
involved O 
in O 
the O 
expression O 
of O 
anxiety O 
- O 
like O 
behaviors O 
. O 
Ethanol B-SYSTEMATIC 
withdrawal O 
sensitizes O 
the O 
dlPAG O 
and O 
results O 
in O 
increased O 
anxiety O 
- O 
like O 
responses O 
. O 
OBJECTIVES O 
: O 
The O 
objective O 
of O 
the O 
study O 
was O 
to O 
test O 
the O 
hypothesis O 
that O 
NO B-FORMULA 
in O 
the O 
dlPAG O 
is O 
involved O 
in O 
the O 
expression O 
of O 
ethanol B-SYSTEMATIC 
withdrawal O 
- O 
induced O 
anxiety O 
. O 
METHODS O 
: O 
Male O 
Wistar O 
rats O 
were O 
implanted O 
with O 
guide O 
cannulae O 
aimed O 
at O 
the O 
dlPAG O 
. O 
The O 
animals O 
were O 
forced O 
to O 
consume O 
a O 
liquid O 
diet O 
containing O 
ethanol B-SYSTEMATIC 
6-8 O 
% O 
( O 
v O 
/ O 
v O 
) O 
for O 
15 O 
days O 
as O 
their O 
only O 
source O 
of O 
diet O 
. O 
Six O 
days O 
after O 
surgery O 
and O 
24 O 
h O 
after O 
ethanol B-SYSTEMATIC 
discontinuation O 
, O 
the O 
animals O 
received O 
microinjections O 
of O 
the O 
NO B-FORMULA 
scavenger O 
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide B-SYSTEMATIC 
( O 
carboxy-PTIO B-SYSTEMATIC 
) O 
, O 
nonselective O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
N B-SYSTEMATIC 
(G)-nitro-L-arginine I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
L-NAME B-ABBREVIATION 
) O 
, O 
selective O 
neuronal O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
inhibitor O 
1-(2-[trifluoromethyl]phenyl) B-SYSTEMATIC 
imidazole I-SYSTEMATIC 
( O 
TRIM B-ABBREVIATION 
) O 
, O 
or O 
selective O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
inhibitor O 
N-([3-(aminomethyl)phenyl]methyl) B-SYSTEMATIC 
ethanimidamide I-SYSTEMATIC 
dihydrochloride I-SYSTEMATIC 
( O 
1400W B-IDENTIFIER 
) O 
into O 
the O 
dlPAG O 
. O 
Ten O 
minutes O 
later O 
, O 
the O 
animals O 
were O 
tested O 
in O 
the O 
light O 
/ O 
dark O 
box O 
. O 
RESULTS O 
: O 
Carboxy-PTIO B-SYSTEMATIC 
( O 
1 O 
nmol O 
) O 
, O 
L-NAME B-ABBREVIATION 
( O 
200 O 
nmol O 
) O 
, O 
TRIM B-ABBREVIATION 
( O 
20 O 
nmol O 
) O 
, O 
and O 
1400W B-IDENTIFIER 
( O 
0.3 O 
and O 
1 O 
nmol O 
) O 
decreased O 
the O 
anxiogenic O 
- O 
like O 
effects O 
of O 
ethanol B-SYSTEMATIC 
withdrawal O 
in O 
rats O 
in O 
the O 
light O 
/ O 
dark O 
box O 
test O 
. O 
The O 
NO B-FORMULA 
precursor O 
L-arginine B-TRIVIAL 
reversed O 
the O 
effects O 
of O 
L-NAME B-ABBREVIATION 
. O 
CONCLUSIONS O 
: O 
NO B-FORMULA 
production O 
in O 
the O 
dlPAG O 
may O 
play O 
a O 
role O 
in O 
the O 
modulation O 
of O 
ethanol B-SYSTEMATIC 
withdrawal O 
- O 
induced O 
anxiety O 
- O 
like O 
behavior O 
in O 
rats O 
. O 
Furthermore O 
, O 
iNOS O 
- O 
mediated O 
NO B-FORMULA 
synthesis O 
in O 
the O 
dlPAG O 
is O 
predominantly O 
involved O 
in O 
the O 
behavioral O 
expression O 
of O 
anxiety O 
- O 
like O 
behavior O 
during O 
ethanol B-SYSTEMATIC 
withdrawal O 
. O 

Induces O 
Dermal O 
Papilla O 
Cell O 
Proliferation O 
in O 
Vitro O 
, O 
but O 
Fails O 
to O 
Modulate O 
Chemotherapy-Induced O 
Alopecia O 
in O 
Vivo O 
. O 

( O 
ABG B-ABBREVIATION 
) O 
is O 
the O 
predominant O 
indole B-SYSTEMATIC 
-derived O 
compound O 
from O 
Brassica O 
vegetables O 
. O 
In O 
this O 
study O 
, O 
we O 
attempted O 
to O 
evaluate O 
the O 
effects O 
of O 
ABG B-ABBREVIATION 
on O 
hair O 
growth O 
. O 
To O 
this O 
end O 
, O 
we O 
examined O 
the O 
proliferation O 
of O 
isolated O 
human O 
dermal O 
papilla O 
( O 
DP O 
) O 
cells O 
and O 
keratinocytes O 
after O 
incubation O 
in O 
various O 
concentrations O 
( O 
0-1.25 O 
mM O 
) O 
of O 
ABG B-ABBREVIATION 
. O 
Furthermore O 
, O 
hair O 
shaft O 
regrowth O 
was O 
monitored O 
in O 
a O 
mouse O 
model O 
of O 
chemotherapy O 
- O 
induced O 
alopecia O 
( O 
CIA O 
) O 
, O 
and O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
staining O 
was O 
performed O 
for O 
histological O 
analyses O 
. O 
We O 
found O 
that O 
1.25 O 
mM O 
ABG B-ABBREVIATION 
induced O 
a O 
1.2-fold O 
increase O 
in O 
the O 
growth O 
of O 
DP O 
cells O 
, O 
but O 
not O 
keratinocytes O 
. O 
However O 
, O 
ABG B-ABBREVIATION 
did O 
not O 
exert O 
significant O 
protective O 
effects O 
against O 
CIA O 
in O 
the O 
mouse O 
model O 
. O 
These O 
findings O 
suggest O 
that O 
ABG B-ABBREVIATION 
may O 
not O 
be O 
able O 
to O 
counteract O 
CIA O 
and O 
that O 
further O 
investigation O 
of O 
the O 
therapeutic O 
potential O 
of O 
ABG B-ABBREVIATION 
in O 
disease O 
models O 
is O 
required O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
Cytotoxic O 
Properties O 
of O 
Safranal B-TRIVIAL 
and O 
Nanoliposomal O 
Safranal B-TRIVIAL 
in O 
Various O 
Cancer O 
Cell O 
Lines O 
. O 

( O 
Crocus O 
sativus O 
) O 
is O 
a O 
widely O 
used O 
food O 
additive O 
used O 
for O 
its O 
color O 
and O 
taste O 
. O 
It O 
has O 
been O 
reported O 
that O 
saffron O 
possesses O 
significant O 
in O 
vivo O 
and O 
in O 
vitro O 
anti-tumor O 
activity O 
. O 
In O 
the O 
present O 
study O 
, O 
anti-tumor O 
effects O 
of O 
safranal B-TRIVIAL 
, O 
the O 
major O 
aromatic O 
compound O 
in O 
saffron O 
, O 
and O 
its O 
liposomal O 
form O 
were O 
investigated O 
. O 
The O 
role O 
of O 
apoptosis O 
has O 
also O 
been O 
explored O 
in O 
this O 
toxicity O 
. O 
HeLa O 
, O 
MCF7 O 
and O 
L929 O 
cell O 
lines O 
were O 
cultured O 
and O 
exposed O 
to O 
safranal B-TRIVIAL 
( O 
0.01-3 O 
mM O 
) O 
or O 
liposomal O 
safranal B-TRIVIAL 
( O 
0.04-0.32 O 
mM O 
) O 
. O 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl B-SYSTEMATIC 
tetrazolium I-SYSTEMATIC 
( O 
MTT B-ABBREVIATION 
) O 
assay O 
was O 
performed O 
to O 
assess O 
cytotoxicity O 
. O 
Apoptosis O 
was O 
evaluated O 
by O 
staining O 
cells O 
with O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
and O 
quantifying O 
sub-Gl O 
peak O 
by O 
flow O 
cytometry O 
. O 
MTT B-ABBREVIATION 
assay O 
revealed O 
a O 
significant O 
and O 
concentration O 
- O 
dependent O 
cytotoxic O 
effect O 
of O 
safranal O 
on O 
HeLa O 
and O 
MCF7 O 
cell O 
lines O 
. O 
Liposomal O 
safranal O 
showed O 
enhanced O 
effect O 
compared O 
to O 
the O 
safranal B-TRIVIAL 
solution O 
, O 
as O 
compared O 
by O 
their O 
IC50 O 
concentrations O 
. O 
Flow O 
cytometry O 
results O 
revealed O 
induction O 
of O 
apoptosis O 
by O 
safranal B-TRIVIAL 
. O 
It O 
might O 
be O 
concluded O 
that O 
safranal B-TRIVIAL 
could O 
be O 
involved O 
in O 
saffron O 
- O 
induced O 
cell O 
death O 
in O 
HeLa O 
and O 
MCF7 O 
cells O 
. O 
Liposome O 
encapsulation O 
improved O 
anti-tumor O 
effect O 
of O 
safranal B-TRIVIAL 
. O 
Safranal B-TRIVIAL 
and O 
particularly O 
its O 
liposomal O 
form O 
could O 
be O 
investigated O 
as O 
promising O 
chemotherapeutic O 
agents O 
in O 
cancer O 
treatment O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Modulate O 
Pro-Oxidant-Antioxidant O 
Balance O 
but O 
not O 
the O 
Immune O 
Response O 
to O 
Heat O 
Shock O 
Protein O 
27 O 
and O 
Oxidized O 
LDL O 
in O 
Obese O 
Individuals O 
. O 

have O 
potentially O 
important O 
functional O 
qualities O 
including O 
anti-inflammatory O 
and O 
antioxidant O 
properties O 
. O 
In O 
this O 
randomized O 
double O 
- O 
blind O 
placebo O 
- O 
controlled O 
cross O 
- O 
over O 
trial O 
, O 
the O 
effects O 
of O 
a O 
curcuminoid B-FAMILY 
supplement O 
on O 
serum O 
pro O 
- O 
oxidant O 
- O 
antioxidant O 
balance O 
( O 
PAB O 
) O 
and O 
antibody O 
titres O 
to O 
Hsp27 O 
( O 
anti-Hsp27 O 
) O 
and O 
oxLDL O 
( O 
anti-oxLDL O 
) O 
were O 
investigated O 
. O 
Thirty O 
obese O 
individuals O 
were O 
randomized O 
to O 
receive O 
either O 
curcuminoids B-FAMILY 
( O 
1 O 
g O 
/ O 
day O 
) O 
or O 
placebo O 
for O 
a O 
period O 
of O 
30 O 
days O 
. O 
After O 
a O 
wash O 
- O 
out O 
period O 
of O 
2 O 
weeks O 
, O 
subjects O 
were O 
crossed O 
over O 
to O 
the O 
alternate O 
regimen O 
for O 
another O 
30 O 
days O 
. O 
Serum O 
PAB O 
along O 
with O 
anti-Hsp27 O 
and O 
anti-oxLDL O 
titres O 
was O 
measured O 
at O 
the O 
beginning O 
and O 
at O 
the O 
end O 
of O 
each O 
study O 
period O 
. O 
There O 
was O 
no O 
significant O 
carry O 
- O 
over O 
effect O 
for O 
any O 
of O 
the O 
assessed O 
parameters O 
. O 
Curcuminoid B-FAMILY 
supplementation O 
was O 
associated O 
with O 
a O 
significant O 
decrease O 
in O 
PAB O 
( O 
p O 
= O 
0.044 O 
) O 
. O 
However O 
, O 
no O 
significant O 
change O 
was O 
observed O 
in O 
serum O 
concentrations O 
of O 
anti-Hsp27 O 
or O 
anti-oxLDL O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
oral O 
curcuminoids B-FAMILY 
supplementation O 
( O 
1g O 
/ O 
day O 
) O 
is O 
effective O 
in O 
reducing O 
oxidative O 
stress O 
burden O 
, O 
though O 
this O 
needs O 
to O 
be O 
validated O 
in O 
larger O 
study O 
populations O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

Studies O 
on O 
Nicotine B-TRIVIAL 
and O 
Nornicotine B-TRIVIAL 
in O 
the O 
UV O 
Region O 
. O 

UV O 
absorption O 
and O 
electronic O 
circular O 
dichroism O 
( O 
ECD O 
) O 
spectra O 
of O 
(R)- B-MULTIPLE 
and I-MULTIPLE 
(S)-nicotine I-MULTIPLE 
and O 
(S)-nornicotine B-TRIVIAL 
in O 
aqueous O 
solution O 
were O 
measured O 
to O 
a O 
significantly O 
lower O 
wavelength O 
range O 
than O 
previously O 
reported O 
, O 
allowing O 
the O 
identification O 
of O 
four O 
previously O 
unobserved O 
electronic O 
transitions O 
. O 
The O 
ECD O 
spectra O 
of O 
the O 
two O 
enantiomers O 
of O 
nicotine B-TRIVIAL 
were O 
equal O 
in O 
magnitude O 
and O 
opposite O 
in O 
sign O 
, O 
while O 
the O 
UV O 
absorption O 
spectra O 
were O 
coincidental O 
. O 
In O 
line O 
with O 
previous O 
observations O 
, O 
(S)-nicotine B-TRIVIAL 
exhibited O 
a O 
negative O 
cotton O 
effect O 
centered O 
on O 
263 O 
nm O 
with O 
vibronic O 
structure O 
( O 
π-π1 O 
* O 
transition O 
) O 
and O 
a O 
broad O 
, O 
positive O 
ECD O 
signal O 
at O 
around O 
240 O 
nm O 
associated O 
with O 
the O 
n-π1 O 
* O 
transition O 
. O 
As O 
expected O 
this O 
band O 
disappeared O 
when O 
the O 
pyridyl B-SYSTEMATIC 
aromatic O 
moiety O 
was O 
protonated O 
. O 
Four O 
further O 
electronic O 
transitions O 
are O 
reported O 
between O 
215 O 
and O 
180 O 
nm O 
; O 
it O 
is O 
proposed O 
the O 
negative O 
maxima O 
around O 
206 O 
nm O 
is O 
either O 
an O 
n-σ* O 
transition O 
or O 
a O 
charge O 
transfer O 
band O 
resulting O 
from O 
the O 
movement O 
of O 
charge O 
from O 
the O 
pyrrolidyl B-SYSTEMATIC 
N B-FORMULA 
lone O 
pair O 
to O 
the O 
pyridyl B-SYSTEMATIC 
π* O 
orbital O 
. O 
The O 
pyridyl B-SYSTEMATIC 
π-π2 O 
* O 
transition O 
may O 
be O 
contained O 
within O 
the O 
negative O 
ECD O 
signal O 
envelope O 
at O 
around O 
200 O 
nm O 
. O 
Another O 
negative O 
maximum O 
at O 
188 O 
nm O 
is O 
thought O 
to O 
be O 
the O 
pyridyl B-SYSTEMATIC 
π-π3 O 
* O 
transition O 
, O 
while O 
the O 
lowest O 
wavelength O 
end O 
- O 
absorption O 
and O 
positive O 
ECD O 
may O 
be O 
associated O 
with O 
the O 
π-π4 O 
* O 
transition O 
. O 
The O 
UV O 
absorption O 
spectra O 
of O 
(S)-nornicotine B-TRIVIAL 
was O 
similar O 
to O 
that O 
of O 
(S)-nicotine B-TRIVIAL 
in O 
the O 
range O 
280-220 O 
nm O 
and O 
acidification O 
of O 
the O 
aqueous O 
solution O 
enhanced O 
the O 
absorption O 
. O 
The O 
ECD O 
signals O 
of O 
(S)-nornicotine B-TRIVIAL 
were O 
considerably O 
less O 
intense O 
compared O 
to O 
(S)-nicotine B-TRIVIAL 
and O 
declined O 
further O 
on O 
acidification O 
; O 
in O 
the O 
far O 
UV O 
region O 
the O 
ECD O 
spectra O 
diverge O 
considerably O 
. O 
Chirality O 
25 O 
: O 
288-293 O 
, O 
2013 O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

Activation O 
of O 
Apo-obelin- O 
Coelenterazine B-TRIVIAL 
Complex O 
. O 

-regulated O 
photoproteins O 
use O 
a O 
noncovalently O 
bound O 
2-hydroperoxycoelenterazine B-SYSTEMATIC 
ligand O 
to O 
emit O 
light O 
in O 
response O 
to O 
Ca(2+) B-FORMULA 
binding O 
. O 
To O 
better O 
understand O 
the O 
mechanism O 
of O 
formation O 
of O 
active O 
photoprotein O 
from O 
apoprotein O 
, O 
coelenterazine B-TRIVIAL 
and O 
molecular O 
oxygen B-SYSTEMATIC 
, O 
we O 
investigated O 
the O 
spectral O 
properties O 
of O 
the O 
anaerobic O 
apo-obelin- O 
coelenterazine B-TRIVIAL 
complex O 
and O 
the O 
kinetics O 
of O 
its O 
conversion O 
into O 
active O 
photoprotein O 
after O 
exposure O 
to O 
air O 
. O 
Our O 
studies O 
suggest O 
that O 
coelenterazine B-TRIVIAL 
bound O 
within O 
the O 
anaerobic O 
complex O 
might O 
be O 
a O 
mixture O 
of O 
N7 B-FORMULA 
-protonated O 
and O 
C2(-) B-FORMULA 
anionic O 
forms O 
, O 
and O 
that O 
oxygen B-SYSTEMATIC 
shifts O 
the O 
equilibrium O 
in O 
favor O 
of O 
the O 
C2(-) B-FORMULA 
anion O 
as O 
a O 
result O 
of O 
peroxy B-SYSTEMATIC 
anion O 
formation O 
. O 
Proton O 
removal O 
from O 
N7 B-FORMULA 
and O 
further O 
protonation O 
of O 
peroxy B-SYSTEMATIC 
anion O 
and O 
the O 
resulting O 
formation O 
of O 
2-hydroperoxycoelenterazine B-SYSTEMATIC 
in O 
obelin O 
might O 
occur O 
with O 
the O 
assistance O 
of O 
His B-FORMULA 
175 O 
. O 
It O 
is O 
proposed O 
that O 
this O 
conserved O 
His B-FORMULA 
residue O 
might O 
play O 
a O 
key O 
role O 
both O 
in O 
formation O 
of O 
active O 
photoprotein O 
and O 
in O 
Ca(2+) B-FORMULA 
-triggering O 
of O 
the O 
bioluminescence O 
reaction O 
. O 

and O 
challenges O 
of O 
graphene B-TRIVIAL 
in O 
biomedical O 
applications O 
. O 

materials O 
have O 
entered O 
a O 
phase O 
of O 
maturity O 
in O 
their O 
development O 
that O 
is O 
characterized O 
by O 
their O 
explorative O 
utilization O 
in O 
various O 
types O 
of O 
applications O 
and O 
fields O 
from O 
electronics O 
to O 
biomedicine O 
. O 
Herein O 
, O 
we O 
describe O 
the O 
recent O 
advances O 
made O 
with O 
graphene B-TRIVIAL 
-related O 
materials O 
in O 
the O 
biomedical O 
field O 
and O 
the O 
challenges O 
facing O 
these O 
exciting O 
new O 
tools O 
both O 
in O 
terms O 
of O 
biological O 
activity O 
and O 
toxicological O 
profiling O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Graphene B-TRIVIAL 
materials O 
today O 
have O 
mainly O 
been O 
explored O 
as O 
components O 
of O 
biosensors O 
and O 
for O 
construction O 
of O 
matrices O 
in O 
tissue O 
engineering O 
. O 
Their O 
antimicrobial O 
activity O 
and O 
their O 
capacity O 
to O 
act O 
as O 
drug O 
delivery O 
platforms O 
have O 
also O 
been O 
reported O 
, O 
however O 
, O 
not O 
as O 
coherently O 
. O 
This O 
report O 
will O 
attempt O 
to O 
offer O 
some O 
perspective O 
as O 
to O 
which O 
areas O 
of O 
biomedical O 
applications O 
can O 
expect O 
graphene B-TRIVIAL 
-related O 
materials O 
to O 
constitute O 
a O 
tool O 
offering O 
improved O 
functionality O 
and O 
previously O 
unavailable O 
options O 
. O 

sativus O 
L O 
. O 
var O 
niger O 
as O 
a O 
source O 
of O 
Phytochemicals O 
for O 
the O 
Prevention O 
of O 
Cholesterol B-TRIVIAL 
Gallstones O 
. O 

sativus O 
L O 
. O 
var O 
niger O 
( O 
black O 
radish O 
) O 
is O 
a O 
plant O 
of O 
the O 
cruciferous O 
family O 
with O 
important O 
ethnobotanical O 
uses O 
for O 
the O 
treatment O 
of O 
gallstones O 
in O 
Mexican O 
traditional O 
medicine O 
. O 
It O 
has O 
been O 
established O 
that O 
the O 
juice O 
of O 
black O 
radish O 
decreases O 
cholesterol B-TRIVIAL 
levels O 
in O 
plasma O 
and O 
dissolves O 
gallstones O 
in O 
mice O 
. O 
Glucosinolates B-FAMILY 
, O 
the O 
main O 
secondary O 
metabolites O 
of O 
black O 
radish O 
, O 
can O 
hydrolyze O 
into O 
its O 
respective O 
isothiocyanates B-FAMILY 
and O 
have O 
already O 
demonstrated O 
antioxidant O 
properties O 
as O 
well O 
as O 
their O 
ability O 
to O 
diminish O 
hepatic O 
cholesterol B-TRIVIAL 
levels O 
; O 
such O 
therapeutic O 
effects O 
can O 
prevent O 
the O 
formation O 
of O 
cholesterol B-TRIVIAL 
gallstones O 
. O 
This O 
disease O 
is O 
considered O 
a O 
current O 
problem O 
of O 
public O 
health O 
. O 
In O 
the O 
present O 
review O 
, O 
we O 
analyze O 
and O 
discuss O 
the O 
therapeutic O 
effects O 
of O 
the O 
main O 
glucosinolates B-FAMILY 
of O 
black O 
radish O 
, O 
as O 
well O 
as O 
the O 
effects O 
that O 
this O 
plant O 
has O 
on O 
cholesterol B-TRIVIAL 
gallstones O 
disease O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

hopping O 
is O 
the O 
process O 
where O 
a O 
H B-FORMULA 
-atom O 
on O 
a O 
hydronium B-SYSTEMATIC 
ion O 
forms O 
a O 
H B-FORMULA 
-bond O 
with O 
the O 
O B-FORMULA 
-atom O 
of O 
a O 
neighboring O 
H(2)O B-FORMULA 
molecule O 
. O 
There O 
is O 
then O 
an O 
exchange O 
of O 
bonding O 
forces O 
when O 
that O 
covalent O 
bond O 
of O 
the O 
H B-FORMULA 
-atom O 
in O 
the O 
hydronium B-SYSTEMATIC 
ion O 
changes O 
to O 
a O 
H B-FORMULA 
-bond O 
, O 
and O 
the O 
previous O 
H B-FORMULA 
-bond O 
changes O 
to O 
a O 
covalent O 
bond O 
with O 
the O 
neighboring O 
O B-FORMULA 
-atom O 
. O 
The O 
neighboring O 
molecule O 
now O 
becomes O 
a O 
hydronium B-SYSTEMATIC 
( O 
H(3)O(+) B-FORMULA 
) O 
ion O 
. O 
This O 
process O 
repeats O 
itself O 
very O 
rapidly O 
among O 
neighboring O 
hydronium B-SYSTEMATIC 
and O 
H(2)O B-FORMULA 
molecules O 
. O 
There O 
is O 
a O 
flow O 
of O 
protonic O 
character O 
through O 
bulk O 
H(2)O B-FORMULA 
, O 
referred O 
to O 
as O 
proton O 
hopping O 
. O 
This O 
process O 
carries O 
information O 
through O 
living O 
systems O 
where O 
H(2)O B-FORMULA 
is O 
present O 
. O 
A O 
cellular O 
automata O 
model O 
of O 
proton O 
hopping O 
down O 
a O 
channel O 
has O 
been O 
created O 
and O 
studied O 
. O 
Variations O 
in O 
the O 
rate O 
of O 
proton O 
entry O 
into O 
the O 
channel O 
and O 
the O 
effects O 
of O 
the O 
polar O 
character O 
of O 
the O 
channel O 
walls O 
was O 
studied O 
using O 
the O 
model O 
. O 
The O 
behavior O 
of O 
the O 
models O 
corresponds O 
to O 
experimental O 
results O 
. O 

novel O 
potent O 
α-amylase O 
inhibitors O 
from O 
the O 
family O 
of O 
acarviostatins B-FAMILY 
isolated O 
from O 
the O 
culture O 
of O 
Streptomyces O 
coelicoflavus O 
ZG0656 O 
. O 

novel O 
aminooligosaccharides O 
were O 
separated O 
from O 
the O 
culture O 
filtrate O 
of O 
Streptomyces O 
coelicoflavus O 
ZG0656 O 
. O 
Their O 
chemical O 
structures O 
were O 
determined O 
by O 
acidic O 
hydrolysis O 
, O 
electrospray O 
- O 
ionization O 
tandem O 
mass O 
spectrometry O 
( O 
ESI-MS O 
/ O 
MS O 
) O 
, O 
and O 
NMR O 
spectroscopy O 
. O 
The O 
compounds O 
were O 
named O 
acarviostatins B-MULTIPLE 
III0(-1) I-MULTIPLE 
and I-MULTIPLE 
III23 I-MULTIPLE 
according O 
to O 
the O 
nomenclature O 
of O 
this O 
group O 
of O 
metabolites O 
. O 
The O 
two O 
novel O 
acarviostatins B-FAMILY 
were O 
both O 
mixed O 
noncompetitive O 
inhibitors O 
of O 
porcine O 
pancreatic O 
α-amylase O 
( O 
PPA O 
) O 
. O 
The O 
inhibition O 
constants O 
(K(i)) O 
for O 
acarviostatins B-MULTIPLE 
III0(-1) I-MULTIPLE 
and I-MULTIPLE 
III23 I-MULTIPLE 
were O 
0.009 O 
and O 
0.026 O 
μM O 
, O 
respectively O 
, O 
151 O 
and O 
52 O 
times O 
more O 
potent O 
than O 
acarbose O 
. O 

of O 
n-alkanes B-FAMILY 
and O 
nonacosan-10-ol B-SYSTEMATIC 
in O 
natural O 
populations O 
of O 
Picea O 
omorika O 
. O 

is O 
the O 
first O 
report O 
of O 
population O 
variability O 
of O 
the O 
contents O 
of O 
n-alkanes B-FAMILY 
and O 
nonacosan-10-ol B-SYSTEMATIC 
in O 
the O 
needle O 
epicuticular O 
waxes O 
of O 
Serbian O 
spruce O 
( O 
Picea O 
omorika O 
) O 
. O 
The O 
hexane B-SYSTEMATIC 
extracts O 
of O 
needle O 
samples O 
originated O 
from O 
three O 
natural O 
populations O 
in O 
Serbia O 
( O 
Vranjak O 
, O 
Zmajevački O 
potok O 
, O 
and O 
Mileševka O 
Canyon O 
) O 
were O 
investigated O 
by O 
GC O 
and O 
GC O 
/ O 
MS O 
analyses O 
. O 
The O 
amount O 
of O 
nonacosan-10-ol B-SYSTEMATIC 
varied O 
individually O 
from O 
50.05 O 
to O 
74.42% O 
( O 
65.74% O 
in O 
average O 
) O 
, O 
but O 
the O 
differences O 
between O 
the O 
three O 
investigated O 
populations O 
were O 
not O 
statistically O 
confirmed O 
. O 
The O 
results O 
exhibited O 
variability O 
of O 
the O 
composition O 
of O 
n-alkanes B-FAMILY 
in O 
the O 
epicuticular O 
waxes O 
with O 
their O 
size O 
ranging O 
from O 
C B-FORMULA 
( O 
18 O 
) O 
to O 
C B-FORMULA 
( O 
35 O 
) O 
. O 
The O 
most O 
abundant O 
n-alkanes B-FAMILY 
were O 
C B-FORMULA 
( O 
29 O 
) O 
, O 
C B-FORMULA 
( O 
31 O 
) O 
, O 
and O 
C B-FORMULA 
( O 
27 O 
) O 
( O 
35.22 O 
, O 
13.77 O 
, O 
and O 
12.28% O 
in O 
average O 
, O 
resp O 
. O 
) O 
. O 
The O 
carbon B-SYSTEMATIC 
preference O 
index O 
of O 
all O 
the O 
n-alkanes B-FAMILY 
(CPI(total)) O 
of O 
the O 
P O 
. O 
omorika O 
populations O 
( O 
average O 
of O 
populations O 
I-III O 
) O 
ranged O 
from O 
3.3 O 
to O 
11.5 O 
( O 
mean O 
of O 
5.9 O 
) O 
, O 
while O 
the O 
average O 
chain O 
length O 
( O 
ACL O 
) O 
ranged O 
from O 
26.6 O 
to O 
29.2 O 
. O 
The O 
principal O 
component O 
and O 
cluster O 
analyses O 
of O 
the O 
contents O 
of O 
nine O 
n-alkanes B-FAMILY 
showed O 
the O 
greatest O 
difference O 
for O 
the O 
population O 
growing O 
in O 
the O 
Mileševka O 
Canyon O 
. O 
The O 
obtained O 
results O 
were O 
compared O 
with O 
previous O 
literature O 
data O 
given O 
for O 
other O 
Picea O 
species O 
, O 
and O 
this O 
comparison O 
was O 
briefly O 
discussed O 
. O 

- O 
polypyrrole B-FAMILY 
conjugates O 
: O 
synthesis O 
, O 
DNA O 
binding O 
studies O 
and O 
preliminary O 
antiproliferative O 
evaluation O 
. O 

than O 
the O 
sum O 
of O 
its O 
parts O 
: O 
Artemisinins B-FAMILY 
are O 
currently O 
in O 
phase O 
I-II O 
clinical O 
trials O 
against O 
breast O 
, O 
colorectal O 
and O 
non-small O 
- O 
cell O 
lung O 
cancers O 
. O 
In O 
an O 
attempt O 
to O 
offer O 
increased O 
specificity O 
, O 
a O 
series O 
of O 
hybrid O 
artemisinin B-TRIVIAL 
- O 
polypyrrole B-FAMILY 
minor O 
groove O 
binder O 
conjugates O 
are O 
described O 
. O 
DNA O 
binding O 
/ O 
modelling O 
studies O 
and O 
preliminary O 
biological O 
evaluation O 
give O 
insights O 
into O 
their O 
mechanism O 
of O 
action O 
and O 
the O 
potential O 
of O 
this O 
strategy O 
. O 

have O 
constructed O 
and O 
applied O 
an O 
algorithm O 
to O 
simulate O 
the O 
behavior O 
of O 
zeolite O 
frameworks O 
during O 
liquid O 
adsorption O 
. O 
We O 
applied O 
this O 
approach O 
to O 
compute O 
the O 
adsorption O 
isotherms O 
of O 
furfural B-TRIVIAL 
-water O 
and O 
hydroxymethyl B-SYSTEMATIC 
furfural I-SYSTEMATIC 
( O 
HMF B-ABBREVIATION 
)-water O 
mixtures O 
adsorbing O 
in O 
silicalite O 
zeolite O 
at O 
300 O 
K O 
for O 
comparison O 
with O 
experimental O 
data O 
. O 
We O 
modeled O 
these O 
adsorption O 
processes O 
under O 
two O 
different O 
statistical O 
mechanical O 
ensembles O 
: O 
the O 
grand O 
canonical O 
( O 
V-Nz-μg-T O 
or O 
GC O 
) O 
ensemble O 
keeping O 
volume O 
fixed O 
, O 
and O 
the O 
P-Nz-μg-T O 
( O 
osmotic O 
) O 
ensemble O 
allowing O 
volume O 
to O 
fluctuate O 
. O 
To O 
optimize O 
accuracy O 
and O 
efficiency O 
, O 
we O 
compared O 
pure O 
Monte O 
Carlo O 
( O 
MC O 
) O 
sampling O 
to O 
hybrid O 
MC-molecular O 
dynamics O 
( O 
MD O 
) O 
simulations O 
. O 
For O 
the O 
external O 
furfural O 
- O 
water O 
and O 
HMF B-ABBREVIATION 
-water O 
phases O 
, O 
we O 
assumed O 
the O 
ideal O 
solution O 
approximation O 
and O 
employed O 
a O 
combination O 
of O 
tabulated O 
data O 
and O 
extended O 
ensemble O 
simulations O 
for O 
computing O 
solvation O 
free O 
energies O 
. O 
We O 
found O 
that O 
MC O 
sampling O 
in O 
the O 
V-Nz-μg-T O 
ensemble O 
( O 
i.e O 
. O 
, O 
standard O 
GCMC O 
) O 
does O 
a O 
poor O 
job O 
of O 
reproducing O 
both O 
the O 
Henry's O 
law O 
regime O 
and O 
the O 
saturation O 
loadings O 
of O 
these O 
systems O 
. O 
Hybrid O 
MC-MD O 
sampling O 
of O 
the O 
V-Nz-μg-T O 
ensemble O 
, O 
which O 
includes O 
framework O 
vibrations O 
at O 
fixed O 
total O 
volume O 
, O 
provides O 
better O 
results O 
in O 
the O 
Henry's O 
law O 
region O 
, O 
but O 
this O 
approach O 
still O 
does O 
not O 
reproduce O 
experimental O 
saturation O 
loadings O 
. O 
Pure O 
MC O 
sampling O 
of O 
the O 
osmotic O 
ensemble O 
was O 
found O 
to O 
approach O 
experimental O 
saturation O 
loadings O 
more O 
closely O 
, O 
whereas O 
hybrid O 
MC-MD O 
sampling O 
of O 
the O 
osmotic O 
ensemble O 
quantitatively O 
reproduces O 
such O 
loadings O 
because O 
the O 
MC-MD O 
approach O 
naturally O 
allows O 
for O 
locally O 
anisotropic O 
volume O 
changes O 
wherein O 
some O 
pores O 
expand O 
whereas O 
others O 
contract O 
. O 

excitation O 
in O 
metals O 
has O 
received O 
great O 
attention O 
for O 
light O 
localization O 
and O 
control O 
of O 
light O 
- O 
matter O 
interactions O 
at O 
the O 
nanoscale O 
with O 
a O 
plethora O 
of O 
applications O 
in O 
absorption O 
enhancement O 
, O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
, O 
or O 
biosensing O 
. O 
Electrically O 
active O 
plasmonic O 
devices O 
, O 
which O 
had O 
remained O 
underexplored O 
, O 
have O 
recently O 
become O 
a O 
growing O 
field O 
of O 
interest O 
. O 
In O 
this O 
report O 
we O 
introduce O 
a O 
metal O 
- O 
insulator O 
- O 
semiconductor O 
heterostructure O 
for O 
plasmo O 
- O 
electric O 
energy O 
conversion O 
, O 
a O 
novel O 
architecture O 
to O 
harvest O 
hot O 
- O 
electrons O 
derived O 
from O 
plasmonic O 
excitations O 
. O 
We O 
demonstrate O 
external O 
quantum O 
efficiency O 
( O 
EQE O 
) O 
of O 
4% O 
at O 
460 O 
nm O 
using O 
a O 
Ag B-FORMULA 
nanostructured O 
electrode O 
and O 
EQE O 
of O 
1.3% O 
at O 
550 O 
nm O 
employing O 
a O 
Au B-FORMULA 
nanostructured O 
electrode O 
. O 
The O 
insulator O 
interfacial O 
layer O 
has O 
been O 
found O 
to O 
play O 
a O 
crucial O 
role O 
in O 
interface O 
passivation O 
, O 
a O 
requisite O 
in O 
photovoltaic O 
applications O 
to O 
achieving O 
both O 
high O 
open O 
- O 
circuit O 
voltages O 
( O 
0.5 O 
V O 
) O 
and O 
fill O 
- O 
factors O 
( O 
0.5 O 
) O 
, O 
but O 
its O 
introduction O 
simultaneously O 
modifies O 
hot O 
- O 
electron O 
injection O 
and O 
transport O 
. O 
We O 
investigate O 
the O 
influence O 
passivation O 
has O 
on O 
these O 
processes O 
for O 
different O 
material O 
configurations O 
, O 
and O 
characterize O 
different O 
types O 
of O 
transport O 
depending O 
on O 
the O 
initial O 
plasmon O 
energy O 
band O 
, O 
reporting O 
power O 
conversion O 
efficiencies O 
of O 
0.03% O 
for O 
nanopatterned O 
silver B-SYSTEMATIC 
electrodes O 
. O 

supplementation O 
in O 
overweight O 
and O 
obesity O 
: O 
a O 
systematic O 
review O 
and O 
meta-analysis O 
of O 
randomized O 
clinical O 
trials O 
. O 

increased O 
prevalence O 
of O 
obesity O 
has O 
made O 
the O 
use O 
of O 
dietary O 
supplements O 
as O 
weight O 
reducing O 
agents O 
highly O 
popular O 
, O 
but O 
their O 
efficacy O 
has O 
not O 
been O 
proven O 
. O 
One O 
such O 
supplement O 
is O 
chromium B-SYSTEMATIC 
. O 
The O 
purpose O 
of O 
this O 
review O 
was O 
to O 
evaluate O 
the O 
evidence O 
for O 
or O 
against O 
the O 
efficacy O 
of O 
chromium B-SYSTEMATIC 
supplementation O 
in O 
overweight O 
and O 
obese O 
individuals O 
. O 
Electronic O 
searches O 
were O 
conducted O 
in O 
Medline O 
, O 
Embase O 
, O 
Amed O 
and O 
The O 
Cochrane O 
Library O 
. O 
The O 
bibliographies O 
of O 
located O 
articles O 
were O 
also O 
searched O 
. O 
No O 
age O 
, O 
gender O 
or O 
language O 
restrictions O 
were O 
imposed O 
. O 
The O 
reporting O 
quality O 
of O 
identified O 
randomized O 
clinical O 
trials O 
( O 
RCTs O 
) O 
was O 
assessed O 
using O 
a O 
methodological O 
checklist O 
adapted O 
from O 
the O 
Consolidated O 
Standard O 
of O 
Reporting O 
Trials O 
Statement O 
and O 
Preferred O 
Reporting O 
Items O 
for O 
Systematic O 
Reviews O 
and O 
Meta-Analyses O 
guidelines O 
. O 
Thirty O 
- O 
nine O 
trials O 
were O 
identified O 
and O 
20 O 
were O 
included O 
. O 
There O 
were O 
variations O 
in O 
reporting O 
quality O 
of O 
included O 
studies O 
. O 
A O 
meta-analysis O 
of O 
11 O 
studies O 
showed O 
a O 
statistically O 
significant O 
difference O 
in O 
weight O 
loss O 
favouring O 
chromium B-SYSTEMATIC 
over O 
placebo O 
( O 
mean O 
difference O 
( O 
MD O 
) O 
: O 
-0.5 O 
kg O 
; O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
: O 
-0.97 O 
, O 
-0.03 O 
) O 
. O 
There O 
was O 
a O 
high O 
statistical O 
heterogeneity O 
. O 
Adverse O 
events O 
included O 
watery O 
stools O 
, O 
vertigo O 
, O 
headaches O 
and O 
urticaria O 
. O 
The O 
evidence O 
from O 
available O 
RCTs O 
shows O 
that O 
chromium B-SYSTEMATIC 
supplementation O 
generates O 
statistically O 
significant O 
reductions O 
in O 
body O 
weight O 
. O 
The O 
magnitude O 
of O 
the O 
effect O 
is O 
small O 
, O 
and O 
the O 
clinical O 
relevance O 
is O 
uncertain O 
. O 
Future O 
trials O 
should O 
last O 
at O 
least O 
16 O 
weeks O 
and O 
greater O 
uniformity O 
in O 
the O 
measuring O 
and O 
assessment O 
tools O 
for O 
body O 
composition O 
is O 
recommended O 
. O 

hindered O 
diffusion O 
in O 
silica O 
colloidal O 
crystals O 
was O 
studied O 
experimentally O 
, O 
both O 
by O 
fluorescence O 
recovery O 
after O 
photobleaching O 
and O 
by O 
measurement O 
of O 
ionic O 
conductivity O 
. O 
Particle O 
size O 
was O 
varied O 
to O 
include O 
120 O 
, O 
220 O 
, O 
470 O 
, O 
and O 
1300 O 
nm O 
, O 
and O 
the O 
porosities O 
were O 
determined O 
by O 
flow O 
measurements O 
. O 
For O 
fluorescein B-TRIVIAL 
, O 
the O 
results O 
showed O 
that O 
the O 
obstruction O 
factor O 
, O 
which O 
is O 
the O 
ratio O 
of O 
the O 
diffusion O 
coefficients O 
inside O 
the O 
media O 
and O 
in O 
open O 
solution O 
, O 
is O 
equal O 
to O 
the O 
porosity O 
within O 
experimental O 
error O 
. O 
For O 
proteins O 
, O 
the O 
same O 
conclusion O 
is O 
made O 
after O 
correction O 
for O 
size O 
exclusion O 
of O 
the O 
pores O 
. O 
The O 
obstruction O 
factors O 
for O 
these O 
media O 
are O 
2-fold O 
lower O 
than O 
those O 
measured O 
for O 
chromatographic O 
media O 
, O 
60% O 
higher O 
than O 
theoretical O 
predictions O 
, O 
and O 
equal O 
to O 
what O 
is O 
assumed O 
for O 
electrophoretic O 
sieving O 
in O 
random O 
fibers O 
. O 

the O 
Electronic O 
Properties O 
of O 
W3Ox(- B-FAMILY 
/ I-FAMILY 
0 I-FAMILY 
) I-FAMILY 
( O 
x O 
= O 
0-2 O 
) O 
and O 
W3(2-) B-FORMULA 
Clusters O 
: O 
The O 
Aromaticity O 
of O 
W3 B-FORMULA 
and O 
W3(2-) B-FORMULA 
. O 

functional O 
theory O 
( O 
DFT O 
) O 
calculations O 
are O 
employed O 
to O 
investigate O 
the O 
structural O 
and O 
electronic O 
properties O 
of O 
bare O 
tritungsten B-SYSTEMATIC 
clusters O 
( O 
W3 B-FORMULA 
, O 
W3(-) B-FORMULA 
, O 
W3(2-) B-FORMULA 
) O 
and O 
tritungsten B-SYSTEMATIC 
oxide I-SYSTEMATIC 
clusters O 
W3Ox(- B-FAMILY 
/ I-FAMILY 
0 I-FAMILY 
) I-FAMILY 
( O 
x O 
= O 
1 O 
, O 
2 O 
) O 
. O 
Generalized O 
Koopmans' O 
theorem O 
is O 
applied O 
to O 
predict O 
the O 
vertical O 
detachment O 
energies O 
and O 
simulate O 
the O 
photoelectron O 
spectra O 
( O 
PES O 
) O 
for O 
W3Ox(-) B-FAMILY 
( O 
x O 
= O 
0-2 O 
) O 
clusters O 
. O 
Extensive O 
DFT O 
calculations O 
are O 
performed O 
in O 
search O 
of O 
the O 
lowest O 
energy O 
structures O 
for O 
both O 
the O 
anions O 
and O 
the O 
neutrals O 
. O 
The O 
bare O 
tritungsten B-SYSTEMATIC 
clusters O 
are O 
predicted O 
to O 
be O 
triangular O 
structures O 
with O 
D3h O 
( O 
(3)A1 O 
' O 
) O 
, O 
C2v O 
( O 
(2)A1 O 
) O 
and O 
D3h O 
( O 
(1)A1 O 
' O 
) O 
symmetry O 
for O 
W3 B-FORMULA 
, O 
W3(-) B-FORMULA 
and O 
W3(2-) B-FORMULA 
, O 
respectively O 
. O 
For O 
W3O(-) B-FORMULA 
and O 
W3O B-FORMULA 
clusters O 
, O 
the O 
oxygen B-SYSTEMATIC 
atom O 
occupies O 
the O 
terminal O 
site O 
, O 
while O 
the O 
next O 
added O 
oxygen B-SYSTEMATIC 
atom O 
is O 
found O 
to O 
be O 
a O 
bridging O 
one O 
in O 
both O 
W3O2(-) B-FORMULA 
and O 
W3O2 B-FORMULA 
clusters O 
. O 
Molecular O 
orbital O 
analyses O 
are O 
carried O 
out O 
to O 
elucidate O 
the O 
chemical O 
bonding O 
of O 
these O 
clusters O 
and O 
provide O 
insights O 
into O 
the O 
sequential O 
oxidation O 
from O 
W3(-) B-FORMULA 
to O 
W3O2(-) B-FORMULA 
. O 
Partial O 
σ- O 
and O 
δ-aromaticity O 
are O 
revealed O 
in O 
the O 
neutral O 
W3 B-FORMULA 
( O 
D3h O 
, O 
(3)A1 O 
' O 
) O 
, O 
while O 
the O 
anion O 
W3(2-) B-FORMULA 
( O 
D3h O 
, O 
(1)A1 O 
' O 
) O 
possesses O 
only O 
δ-aromaticity O 
. O 

of O 
Aragonitic O 
Layered O 
Structures O 
from O 
Kaolinite B-TRIVIAL 
and O 
Amorphous O 
Calcium B-SYSTEMATIC 
Carbonate I-SYSTEMATIC 
Precursors O 
. O 

materials O 
have O 
been O 
an O 
ever O 
- O 
present O 
accoutrement O 
of O 
modern O 
civilization O 
; O 
improvements O 
to O 
process O 
these O 
materials O 
have O 
quickened O 
their O 
utilization O 
for O 
use O 
in O 
complex O 
multiaxial O 
load O 
- O 
bearing O 
structures O 
. O 
Specifically O 
, O 
with O 
better O 
methods O 
to O 
organize O 
the O 
constituent O 
metal B-FAMILY 
oxide I-FAMILY 
components O 
in O 
clay O 
, O 
the O 
distribution O 
of O 
characteristic O 
nematic O 
and O 
smectic O 
phases O 
can O 
be O 
controlled O 
. O 
In O 
this O 
work O 
, O 
we O 
utilize O 
the O 
interactions O 
of O 
an O 
amorphous O 
calcium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
phase O 
with O 
kaolinite B-TRIVIAL 
to O 
form O 
a O 
complex O 
composite O 
that O 
can O 
be O 
organized O 
into O 
distinct O 
hierarchical O 
structures O 
. O 
We O 
demonstrate O 
that O 
these O 
ACC- O 
kaolinite B-TRIVIAL 
composites O 
can O 
maintain O 
characteristic O 
long O 
- O 
range O 
- O 
ordered O 
layer O 
- O 
by O 
- O 
layer O 
structures O 
across O 
many O 
length O 
scales O 
, O 
from O 
nano- O 
to O 
millimeter O 
, O 
through O 
convenient O 
and O 
economical O 
processing O 
at O 
room O 
temperature O 
. O 

and O 
in O 
vitro O 
evaluation O 
of O 
N-Aryl B-FAMILY 
pyrido I-FAMILY 
- I-FAMILY 
quinazolines I-FAMILY 
derivatives O 
as O 
potent O 
EGFR O 
inhibitors O 
. O 

series O 
of O 
pyrido B-FAMILY 
- I-FAMILY 
quinazolines I-FAMILY 
have O 
been O 
synthesised O 
, O 
characterised O 
and O 
tested O 
for O 
their O 
in O 
vitro O 
EGFR O 
tyrosine B-TRIVIAL 
kinase O 
inhibitory O 
activity O 
. O 
The O 
compounds O 
were O 
prepared O 
from O 
Alkylideno B-MULTIPLE 
/ I-MULTIPLE 
arylideno-bis-ureas I-MULTIPLE 
. O 
Their O 
final O 
structure O 
of O 
the O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
spectral O 
studies O 
( O 
IR O 
. O 
, O 
1H B-FORMULA 
NMR O 
, O 
FT-IR O 
and O 
EI-MS O 
) O 
. O 
The O 
cellular O 
EGFR O 
internalization O 
response O 
of O 
selected O 
compounds O 
was O 
evaluated O 
using O 
HeLa O 
cells O 
. O 
Most O 
of O 
the O 
synthesized O 
compounds O 
displayed O 
potent O 
EGFR-TK O 
inhibitory O 
activity O 
and O 
structurally O 
halogenated O 
derivatives O 
had O 
a O 
pronounced O 
effect O 
in O 
inhibiting O 
EGFR O 
internalization O 
. O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
A O 
/ O 
S O 
. O 

are O 
good O 
crops O 
to O 
produce O 
natural O 
pigments O 
because O 
of O 
their O 
high O 
growth O 
rates O 
. O 
Tropical O 
zones O 
are O 
better O 
locations O 
than O 
temperate O 
areas O 
for O 
microalgal O 
cultivation O 
because O 
they O 
have O 
longer O 
duration O 
of O 
daylight O 
and O 
more O 
stable O 
temperatures O 
throughout O 
the O 
year O 
, O 
but O 
the O 
high O 
temperatures O 
pose O 
a O 
challenge O 
to O 
microalgal O 
cultivation O 
. O 
A O 
newly O 
isolated O 
thermotolerant O 
microalga O 
produces O 
reddish O 
pigments O 
under O 
environmental O 
stress O 
. O 
Morphological O 
and O 
molecular O 
evidence O 
including O 
meridional O 
ribs O 
on O 
the O 
cell O 
wall O 
, O 
pigment O 
production O 
, O 
and O 
its O 
18S O 
rDNA O 
sequence O 
suggests O 
that O 
this O 
microalga O 
belongs O 
to O 
the O 
genus O 
Coelastrella O 
. O 
Salt O 
stress O 
and O 
high O 
light O 
intensity O 
accelerated O 
biosynthesis O 
of O 
the O 
pigments O 
, O 
and O 
significant O 
quantities O 
of O 
oil O 
accumulated O 
as O 
the O 
cells O 
experienced O 
stress O 
due O 
to O 
nutrient O 
deficiency O 
. O 
This O 
microalga O 
could O 
withstand O 
temperature O 
of O 
50°C O 
for O 
more O 
than O 
8h O 
, O 
which O 
is O 
a O 
necessary O 
trait O 
for O 
outdoor O 
cultivation O 
in O 
tropical O 
areas O 
. O 
The O 
pigments O 
contain O 
astaxanthin B-TRIVIAL 
, O 
lutein B-TRIVIAL 
, O 
canthaxanthin B-TRIVIAL 
, O 
and O 
β-carotene B-TRIVIAL 
as O 
analysed O 
by O 
using O 
HPLC O 
. O 

of O 
chemical O 
variability O 
of O 
phenolic B-MULTIPLE 
and I-MULTIPLE 
monoterpene I-MULTIPLE 
glycosides I-MULTIPLE 
in O 
the O 
seeds O 
of O 
Paeonia O 
species O 
using O 
HPLC O 
and O 
profiling O 
analysis O 
. O 

rapid O 
, O 
sensitive O 
, O 
and O 
accurate O 
HPLC-DAD O 
method O 
was O 
developed O 
and O 
validated O 
for O 
simultaneous O 
determination O 
of O 
one O 
phenolic B-FAMILY 
glycoside I-FAMILY 
and O 
seven O 
monoterpene B-FAMILY 
glycosides I-FAMILY 
, O 
including O 
1-O-β-d-(4-hydroxybenzoyl)glucose B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
pyridylpaeoniflorin B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
(8R)-piperitone-4-en-9-O-β-d-glucopyranoside B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
oxypaeoniflorin B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
6'-O-β-glucopyranosylalbiflorin B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
albiflorin B-TRIVIAL 
( O 
6 O 
) O 
, O 
β-gentiobiosylpaeoniflorin B-TRIVIAL 
( O 
7 O 
) O 
, O 
and O 
paeoniflorin B-TRIVIAL 
( O 
8 O 
) O 
, O 
in O 
44 O 
batches O 
of O 
peony O 
seeds O 
from O 
nine O 
Paeonia O 
species O 
collected O 
from O 
different O 
areas O 
. O 
Using O 
the O 
optimised O 
method O 
, O 
separations O 
were O 
conducted O 
with O 
a O 
YMC-pack O 
ODS-A O 
column O 
with O 
water/ O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
as O 
the O 
mobile O 
phase O 
. O 
All O 
eight O 
analytes O 
demonstrated O 
good O 
linearity O 
( O 
r(2) O 
> O 
0.9993 O 
) O 
. O 
The O 
recoveries O 
, O 
measured O 
at O 
three O 
concentration O 
levels O 
, O 
varied O 
from O 
98.20% O 
to O 
103.81% O 
. O 
Six O 
compounds O 
including O 
1 O 
and O 
4-8 O 
occur O 
ubiquitously O 
in O 
all O 
the O 
seeds O 
of O 
nine O 
Paeonia O 
species O 
, O 
and O 
compounds O 
2 O 
and O 
3 O 
showed O 
undetectable O 
levels O 
or O 
very O 
low O 
content O 
in O 
several O 
samples O 
. O 
The O 
seed O 
samples O 
were O 
classified O 
into O 
several O 
groups O 
, O 
which O 
coincide O 
with O 
the O 
taxonomy O 
of O 
Paeonia O 
at O 
the O 
section O 
level O 
. O 
Peony O 
seed O 
might O 
be O 
a O 
useful O 
resource O 
in O 
developing O 
new O 
herbal O 
or O 
food O 
products O 
. O 

of O 
response O 
surface O 
methodology O 
to O 
optimise O 
extraction O 
of O 
flavonoids B-FAMILY 
from O 
fructus O 
sophorae O 
. O 

surface O 
methodology O 
( O 
RSM O 
) O 
based O 
on O 
a O 
central O 
composite O 
design O 
( O 
CCD O 
) O 
was O 
applied O 
to O 
optimise O 
the O 
extraction O 
conditions O 
for O 
flavonoids B-FAMILY 
from O 
fructus O 
sophorae O 
with O 
advantages O 
in O 
terms O 
of O 
resisting O 
flavonoids B-FAMILY 
during O 
the O 
whole O 
process O 
and O 
maximising O 
of O 
extraction O 
yield O 
. O 
Three O 
aglycon O 
forms O 
of O 
the O 
flavonoids B-FAMILY 
, O 
namely O 
, O 
quercetin B-TRIVIAL 
, O 
kaempferol B-TRIVIAL 
and O 
isorhamnetin B-TRIVIAL 
were O 
quantified O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
with O 
ultraviolet O 
detection O 
( O 
HPLC-UV O 
) O 
to O 
estimate O 
extraction O 
yield O 
. O 
The O 
combined O 
effects O 
of O 
independent O 
variables O 
were O 
studied O 
and O 
the O 
optimal O 
extraction O 
conditions O 
were O 
obtained O 
as O 
ethanol B-SYSTEMATIC 
concentration O 
, O 
74.47% O 
; O 
solid O 
- O 
liquid O 
ratio O 
, O 
17.99 O 
ml O 
/ O 
g O 
; O 
temperature O 
, O 
89.13°C O 
; O 
and O 
extraction O 
time O 
, O 
2.10h O 
. O 
The O 
reliability O 
of O 
the O 
method O 
was O 
confirmed O 
by O 
recovery O 
experiments O 
, O 
performed O 
under O 
optimal O 
conditions O 
. O 
Recoveries O 
indicated O 
that O 
flavonoids B-FAMILY 
resisted O 
the O 
extraction O 
conditions O 
. O 
The O 
experimental O 
extraction O 
yield O 
under O 
optimal O 
conditions O 
was O 
found O 
to O 
be O 
10.459% O 
, O 
which O 
was O 
well O 
matched O 
with O 
the O 
predicted O 
values O 
of O 
10.461% O 
. O 

study O 
describes O 
molecular O 
mechanisms O 
for O 
inhibiting O 
tumour O 
cell O 
proliferation O 
using O 
polysaccharides O 
from O 
medicinal O 
mushrooms O 
in O 
human O 
hepatoma O 
cells O 
. O 
The O 
results O 
show O 
that O 
regarding O 
cell O 
cycle O 
- O 
related O 
proteins O 
, O 
three O 
types O 
of O 
polysaccharides O 
significantly O 
enhance O 
the O 
expression O 
of O 
p27(Kip) O 
in O 
HepG2 O 
and O 
Bel-7404 O 
cells O 
, O 
while O 
suppressing O 
the O 
activity O 
of O 
cyclin O 
D1 O 
/ O 
CDK4 O 
and O 
/ O 
or O 
cyclin O 
E O 
/ O 
CDK2 O 
. O 
Considering O 
apoptosis O 
- O 
related O 
factors O 
, O 
the O 
polysaccharides O 
suppressed O 
AKT O 
activity O 
through O 
the O 
inhibition O 
of O 
AKT O 
phosphorylation O 
at O 
Thr B-FORMULA 
( O 
308 O 
) O 
and O 
/ O 
or O 
Ser B-FORMULA 
( O 
473 O 
) O 
. O 
The O 
growth O 
of O 
HepG2 O 
and O 
Bel-7404 O 
cells O 
was O 
suppressed O 
by O 
the O 
up O 
- O 
regulation O 
of O 
a O 
subunit O 
of O 
PI3K O 
and O 
phospho-PTEN O 
, O 
which O 
are O 
modulators O 
of O 
AKT O 
activity O 
. O 
The O 
polysaccharides O 
also O 
activated O 
the O 
mitochondria O 
- O 
mediated O 
apoptosis O 
pathway O 
by O 
stimulating O 
the O 
activation O 
of O 
Bcl-2 O 
family O 
proteins O 
to O 
release O 
cytochrome O 
c O 
and O 
Smac O 
and O 
cleave O 
caspase-9 O 
and O 
caspase-3 O 
in O 
HepG2 O 
and O 
Bel-7404 O 
cells O 
. O 
These O 
factors O 
have O 
a O 
potent O 
effect O 
on O 
cell O 
cycle O 
arrest O 
in O 
G(1) O 
and O 
/ O 
or O 
S O 
phase O 
and O 
induce O 
apoptosis O 
in O 
HepG2 O 
and O 
Bel-7404 O 
cells O 
. O 

Fe B-FORMULA 
-deficiency O 
improves O 
biomass O 
production O 
and O 
quality O 
of O 
hydroponic O 
- O 
cultivated O 
spinach O 
plants O 
( O 
Spinacia O 
oleracea O 
L O 
. O 
) O 
. O 

is O 
of O 
great O 
practical O 
importance O 
to O 
improve O 
yield O 
and O 
quality O 
of O 
vegetables O 
in O 
soilless O 
cultures O 
. O 
This O 
study O 
investigated O 
the O 
effects O 
of O 
iron B-SYSTEMATIC 
-nutrition O 
management O 
on O 
yield O 
and O 
quality O 
of O 
hydroponic O 
- O 
cultivated O 
spinach O 
( O 
Spinacia O 
oleracea O 
L O 
. O 
) O 
. O 
The O 
results O 
showed O 
that O 
mild O 
Fe B-FORMULA 
-deficient O 
treatment O 
( O 
1 O 
μM O 
FeEDTA B-FORMULA 
) O 
yielded O 
a O 
greater O 
biomass O 
of O 
edible O 
parts O 
than O 
Fe B-FORMULA 
-omitted O 
treatment O 
( O 
0 O 
μM O 
FeEDTA B-FORMULA 
) O 
or O 
Fe B-FORMULA 
-sufficient O 
treatments O 
( O 
10 O 
and O 
50 O 
μM O 
FeEDTA B-FORMULA 
) O 
. O 
Conversely O 
, O 
mild O 
Fe B-FORMULA 
-deficient O 
treatment O 
had O 
the O 
lowest O 
nitrate B-SYSTEMATIC 
concentration O 
in O 
the O 
edible O 
parts O 
out O 
of O 
all O 
the O 
Fe B-FORMULA 
treatments O 
. O 
Interestingly O 
, O 
all O 
the O 
concentrations O 
of O 
soluble O 
sugar O 
, O 
soluble O 
protein O 
and O 
ascorbate B-TRIVIAL 
in O 
mild O 
Fe B-FORMULA 
-deficient O 
treatments O 
were O 
higher O 
than O 
Fe B-FORMULA 
-sufficient O 
treatments O 
. O 
In O 
addition O 
, O 
both O 
phenolic O 
concentration O 
and O 
DPPH B-ABBREVIATION 
scavenging O 
activity O 
in O 
mild O 
Fe B-FORMULA 
-deficient O 
treatments O 
were O 
comparable O 
with O 
those O 
in O 
Fe B-FORMULA 
-sufficient O 
treatments O 
, O 
but O 
were O 
higher O 
than O 
those O 
in O 
Fe B-FORMULA 
-omitted O 
treatments O 
. O 
Therefore O 
, O 
we O 
concluded O 
that O 
using O 
a O 
mild O 
Fe B-FORMULA 
-deficient O 
nutrition O 
solution O 
to O 
cultivate O 
spinach O 
not O 
only O 
would O 
increase O 
yield O 
, O 
but O 
also O 
would O 
improve O 
quality O 
. O 

of O 
reduced O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
carbon B-SYSTEMATIC 
nanotube O 
modified O 
electrodes O 
for O 
measuring O 
the O 
enzymatic O 
activity O 
of O 
alcohol B-FAMILY 
dehydrogenase O 
. O 

electrochemical O 
method O 
was O 
developed O 
to O 
measure O 
the O 
enzymatic O 
activity O 
of O 
alcohol B-FAMILY 
dehydrogenase O 
( O 
ADH O 
) O 
by O 
monitoring O 
the O 
amount O 
of O 
reduced B-TRIVIAL 
nicotinamide I-TRIVIAL 
adenine I-TRIVIAL 
dinucleotide I-TRIVIAL 
( O 
NADH B-ABBREVIATION 
) O 
generated O 
in O 
the O 
catalysed O 
oxidation O 
of O 
ethanol B-SYSTEMATIC 
by O 
ADH O 
. O 
The O 
concentration O 
of O 
NADH B-ABBREVIATION 
was O 
determined O 
by O 
amperometric O 
measurements O 
, O 
which O 
recorded O 
the O 
oxidation O 
current O 
of O 
NADH B-ABBREVIATION 
versus O 
time O 
on O 
reduced O 
graphene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
functionalised O 
multi O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotube O 
modified O 
electrodes O 
. O 
The O 
initial O 
reaction O 
rates O 
and O 
the O 
apparent O 
Michaelis O 
constants O 
of O 
the O 
enzymatic O 
reaction O 
were O 
obtained O 
in O 
the O 
absence O 
and O 
presence O 
of O 
Al(3+) B-FORMULA 
and O 
nanometre O 
- O 
sized O 
tridecameric B-SYSTEMATIC 
aluminium I-SYSTEMATIC 
polycationic O 
( O 
nano- O 
Al(13) B-FORMULA 
) O 
species O 
. O 
The O 
results O 
showed O 
that O 
Al(3+) B-FORMULA 
and O 
nano- O 
Al(13) B-FORMULA 
exhibited O 
inhibitory O 
effect O 
on O 
the O 
enzymatic O 
activity O 
of O 
ADH O 
. O 
Fluorescence O 
and O 
circular O 
dichroism O 
spectra O 
indicated O 
the O 
inhibitory O 
effect O 
was O 
likely O 
caused O 
by O 
the O 
conformational O 
changes O 
of O 
ADH O 
and O 
/ O 
or O 
NADH B-ABBREVIATION 
induced O 
by O 
Al(3+) B-FORMULA 
and O 
nano- O 
Al(13) B-FORMULA 
. O 

study O 
investigated O 
the O 
influence O 
of O 
Goishi O 
- O 
tea O 
on O 
visceral O 
fat O 
weight O 
in O 
induced O 
obese O 
mice O 
. O 
Mice O 
were O 
divided O 
into O 
two O 
main O 
groups O 
, O 
normal O 
and O 
obesity O 
. O 
In O 
obesity O 
group O 
, O 
mice O 
were O 
fed O 
with O 
high O 
- O 
fat O 
diet O 
. O 
Goishi O 
- O 
tea O 
including O 
its O 
fractions O 
( O 
ethyl-acetate B-SYSTEMATIC 
layer O 
and O 
water O 
layer O 
) O 
was O 
administrated O 
in O 
normal O 
and O 
obesity O 
three O 
sub O 
- O 
groups O 
. O 
Results O 
showed O 
no O 
influence O 
of O 
Goishi O 
- O 
tea O 
in O 
normal O 
group O 
. O 
However O 
, O 
visceral O 
fat O 
weight O 
, O 
size O 
of O 
adipose O 
cell O 
and O 
cholesterol B-TRIVIAL 
level O 
were O 
significantly O 
decreased O 
in O 
obesity O 
group O 
fed O 
Goishi O 
- O 
tea O 
compared O 
to O 
control O 
group O 
. O 
Moreover O 
, O 
adiponectin O 
levels O 
tended O 
to O 
increase O 
and O 
adipocytokines O 
has O 
significant O 
values O 
lower O 
in O 
obesity O 
group O 
fed O 
Goishi O 
- O 
tea O 
compared O 
to O 
control O 
group O 
. O 
Interestingly O 
, O 
Goishi O 
tea O 
involved O 
in O 
the O 
high O 
- O 
fat O 
diet O 
induced O 
- O 
obese O 
mice O 
can O 
inhibit O 
fat O 
accumulation O 
and O 
maintain O 
adiponectins O 
without O 
increasing O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
and O 
interleukin-6 O 
. O 
It O 
would O 
be O 
beneficial O 
for O 
the O 
prevention O 
of O 
metabolic O 
syndrome O 
and O 
obesity O 
- O 
related O 
disorder O 
. O 

characterisation O 
of O 
dietary O 
fibre O 
components O 
and O 
their O 
ability O 
to O 
bind O 
some O 
process O 
- O 
induced O 
mutagenic O 
heterocyclic O 
amines O 
, O 
Trp-P-1 B-ABBREVIATION 
, O 
Trp-P-2 B-ABBREVIATION 
, O 
AαC B-ABBREVIATION 
and O 
MeAαC B-ABBREVIATION 
. O 

physicochemical O 
properties O 
of O 
potato O 
fibre O 
, O 
wheat O 
bran O 
and O 
oat O 
samples O 
were O 
investigated O 
, O 
along O 
with O 
their O 
binding O 
capability O 
to O 
heterocyclic O 
amines O 
( O 
HCAs O 
) O 
. O 
Potato O 
fibre O 
displayed O 
highest O 
total O 
dietary O 
fibre O 
content O 
( O 
71.8 O 
/ O 
100g O 
dry O 
weight O 
basis O 
, O 
dwb O 
) O 
, O 
followed O 
by O 
wheat O 
bran O 
( O 
57.2 O 
/ O 
100 O 
g O 
dwb O 
) O 
and O 
oat O 
sample O 
2 O 
( O 
53 O 
/ O 
100 O 
g O 
dwb O 
) O 
. O 
Oat O 
samples O 
1 O 
, O 
3 O 
and O 
4 O 
displayed O 
considerably O 
lower O 
dietary O 
fibre O 
content O 
( O 
20.5-28.8 O 
/ O 
100g O 
, O 
dwb O 
) O 
. O 
Oat O 
samples O 
3 O 
and O 
4 O 
displayed O 
highest O 
soluble O 
fibre O 
content O 
( O 
70-83% O 
) O 
, O 
and O 
oat O 
sample O 
3 O 
also O 
displayed O 
highest O 
swelling O 
and O 
water O 
retention O 
capacity O 
( O 
WRC O 
) O 
. O 
Dietary O 
fibre O 
samples O 
, O 
except O 
samples O 
3 O 
and O 
4 O 
, O 
displayed O 
improved O 
binding O 
to O 
HCAs O 
as O 
sample O 
weight O 
increased O 
. O 
The O 
behaviour O 
of O 
wheat O 
bran O 
and O 
potato O 
fibre O 
was O 
similar O 
to O 
oat O 
samples O 
1 O 
and O 
2 O 
. O 
Binding O 
of O 
MeAαC B-ABBREVIATION 
was O 
comparatively O 
greater O 
than O 
that O 
of O 
other O 
HCAs O 
. O 
Dietary O 
fibre O 
fractions O 
with O 
high O 
insoluble O 
fibre O 
and O 
functional O 
groups O 
of O 
HCAs B-ABBREVIATION 
may O 
significantly O 
contribute O 
to O 
the O 
binding O 
capacity O 
. O 

current O 
study O 
was O 
carried O 
out O 
to O 
elucidate O 
the O 
effect O 
of O 
sequential O 
inoculation O 
of O 
Saccharomyces O 
cerevisiae O 
( O 
RC212 O 
, O 
D254 O 
) O 
and O 
Oenococcus O 
oeni O 
( O 
SG26 O 
, O 
Lalvin O 
31 O 
and O 
Uvaferm O 
Alpha O 
) O 
on O 
the O 
production O 
of O 
cherry O 
wines O 
, O 
especially O 
on O 
the O 
chemical O 
and O 
aromatic O 
characteristics O 
. O 
SI-D O 
culture O 
required O 
the O 
shortest O 
period O 
( O 
23 O 
d O 
) O 
to O 
complete O 
the O 
fermentation O 
, O 
while O 
other O 
inoculations O 
needed O 
longer O 
time O 
. O 
Analysis O 
from O 
chemical O 
composition O 
showed O 
that O 
titratable O 
acidity O 
and O 
content O 
of O 
l-malic B-SYSTEMATIC 
acid I-SYSTEMATIC 
exhibited O 
evident O 
differences O 
among O 
the O 
samples O 
after O 
MLF O 
. O 
For O 
volatile O 
compounds O 
, O 
49 O 
major O 
components O 
were O 
identified O 
, O 
mostly O 
comprising O 
of O 
alcohols B-FAMILY 
, O 
acids O 
and O 
esters B-FAMILY 
. O 
Cherry O 
wines O 
obtained O 
from O 
SI-B O 
and O 
SI-C O 
showed O 
higher O 
contents O 
of O 
total O 
volatile O 
alcohols B-FAMILY 
, O 
and O 
SI-D O 
wines O 
produced O 
the O 
greatest O 
amount O 
of O 
volatile O 
acids O 
. O 
According O 
to O 
the O 
odour O 
active O 
value O 
( O 
OAV O 
) O 
, O 
9 O 
out O 
of O 
49 O 
studied O 
volatile O 
components O 
had O 
OAV O 
> O 
1 O 
in O 
all O 
the O 
analyzed O 
wines O 
, O 
while O 
six O 
volatile O 
components O 
showed O 
OAV O 
> O 
1 O 
only O 
for O 
some O 
of O 
them O 
. O 
Furthermore O 
, O 
a O 
sensory O 
analysis O 
was O 
performed O 
to O 
compare O 
the O 
sensory O 
profile O 
of O 
these O 
cherry O 
wines O 
, O 
and O 
results O 
evidenced O 
that O 
wines O 
resulting O 
from O 
different O 
inoculations O 
presented O 
diverse O 
sensory O 
profiles O 
. O 
These O 
findings O 
suggest O 
that O 
sequential O 
inoculations O 
posed O 
a O 
great O 
potential O 
in O 
affecting O 
and O 
modulating O 
the O 
aromatic O 
profile O 
of O 
cherry O 
wines O 
. O 

this O 
study O 
, O 
polysaccharides O 
from O 
Tricholoma O 
matsutake O 
( O 
TM-P O 
) O 
were O 
purified O 
using O 
a O 
DEAE B-ABBREVIATION 
-Sepharose O 
fast O 
flow O 
column O 
and O 
three O 
polysaccharide O 
fractions O 
( O 
TM-P1 O 
, O 
TM-P2 O 
and O 
TM-P3 O 
) O 
were O 
obtained O 
. O 
The O 
chemical O 
composition O 
and O 
structural O 
characteristics O 
of O 
TM-P2 O 
were O 
quite O 
different O 
from O 
those O 
of O 
TM-P1 O 
and O 
TM-P3 O 
. O 
TM-P2 O 
consisted O 
of O 
glucose B-TRIVIAL 
, O 
galactose B-TRIVIAL 
and O 
mannose B-TRIVIAL 
with O 
a O 
molar O 
ratio O 
of O 
5.9 O 
: O 
1.1 O 
: O 
1 O 
. O 
The O 
glycosidic O 
linkages O 
were O 
mainly O 
composed O 
of O 
1,6- O 
and O 
1- O 
linked O 
glucose B-TRIVIAL 
. O 
Furthermore O 
, O 
TM-P2 O 
showed O 
the O 
strongest O 
in O 
vitro O 
antioxidant O 
and O 
antitumour O 
activities O 
. O 
The O 
oxygen B-SYSTEMATIC 
radical O 
absorbance O 
capacity O 
( O 
ORAC O 
) O 
of O 
TM-P2 O 
was O 
2100.44 O 
μmol O 
Trolox B-TRIVIAL 
/g O 
. O 
The O 
antiproliferative O 
activities O 
of O 
TM-P2 O 
( O 
4.0mg O 
/ O 
ml O 
) O 
on O 
the O 
growth O 
of O 
HepG2 O 
and O 
A549 O 
cells O 
were O 
67.98% O 
and O 
59.04% O 
, O 
respectively O 
. O 

of O 
protein O 
physicochemical O 
changes O 
induced O 
by O 
heating O 
in O 
meat O 
using O 
mimetic O 
models O 
: O 
( O 
2 O 
) O 
effects O 
of O 
fibre O 
type O 
, O 
peroxides B-FAMILY 
and O 
antioxidants O 
. O 

- O 
induced O 
changes O 
in O 
meat O 
proteins O 
were O 
investigated O 
using O 
models O 
made O 
of O 
aqueous O 
suspensions O 
of O 
myofibrils O 
according O 
to O 
muscle O 
fibre O 
types O 
and O 
cellular O 
compounds O 
( O 
oxidants O 
and O 
antioxidants O 
) O 
. O 
These O 
changes O 
were O 
evaluated O 
by O 
measurements O 
of O 
carbonyl B-FAMILY 
groups O 
and O 
protein O 
surface O 
hydrophobicity O 
. O 
Model O 
results O 
were O 
compared O 
to O 
trial O 
results O 
obtained O 
on O 
pork O 
meat O 
( O 
M O 
. O 
Longissimus O 
dorsi O 
) O 
heated O 
under O 
the O 
same O 
conditions O 
( O 
45 O 
and O 
75°C O 
, O 
from O 
5 O 
to O 
120 O 
min O 
) O 
. O 
Myofibrillar O 
proteins O 
from O 
α-white O 
fibres O 
were O 
more O 
sensitive O 
to O 
oxidation O 
and O 
thermal O 
denaturation O 
than O 
those O 
from O 
β-red O 
fibres O 
. O 
At O 
45°C O 
, O 
there O 
were O 
negligible O 
differences O 
due O 
to O 
peroxide B-SYSTEMATIC 
or O 
antioxidant O 
types O 
. O 
At O 
75°C O 
, O 
organic B-FAMILY 
peroxides I-FAMILY 
( O 
ROOH B-FAMILY 
) O 
were O 
less O 
oxidative O 
than O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
, O 
and O 
antioxidant O 
enzymes O 
were O 
less O 
efficient O 
than O 
vitamin B-FAMILY 
E I-FAMILY 
and O 
carnosine B-TRIVIAL 
at O 
protecting O 
proteins O 
against O 
oxidation O 
. O 
Protein O 
oxidation O 
observed O 
in O 
meat O 
is O 
lower O 
than O 
in O 
the O 
mimetic O 
models O 
and O 
the O 
increase O 
in O 
hydrophobicity O 
remained O 
limited O 
in O 
meat O 
. O 

pressure O 
homogenization O 
increases O 
antioxidant O 
capacity O 
and O 
short B-FAMILY 
- I-FAMILY 
chain I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
yield O 
of O 
polysaccharide O 
from O 
seeds O 
of O 
Plantago O 
asiatica O 
L O 
. O 

properties O 
of O 
homogenized O 
and O 
non-homogenized O 
polysaccharide O 
from O 
the O 
seeds O 
of O 
Plantago O 
asiatica O 
L O 
. O 
, O 
including O 
antioxidant O 
capacity O 
and O 
short B-FAMILY 
- I-FAMILY 
chain I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
( O 
SCFA B-ABBREVIATION 
) O 
production O 
, O 
were O 
compared O 
in O 
this O 
study O 
. O 
High O 
pressure O 
homogenization O 
decreased O 
particle O 
size O 
of O 
the O 
polysaccharide O 
, O 
and O 
changed O 
the O 
surface O 
topography O 
from O 
large O 
flake O 
- O 
like O 
structure O 
to O 
smaller O 
porous O 
chips O 
. O 
FT-IR O 
showed O 
that O 
high O 
pressure O 
homogenization O 
did O 
not O 
alter O 
the O 
primary O 
structure O 
of O 
the O 
polysaccharide O 
. O 
However O 
, O 
high O 
pressure O 
homogenization O 
increased O 
antioxidant O 
capacity O 
of O 
the O 
polysaccharide O 
, O 
evaluated O 
by O 
4 O 
antioxidant O 
capacity O 
assays O 
( O 
hydroxyl B-SYSTEMATIC 
radical O 
- O 
scavenging O 
, O 
superoxide B-TRIVIAL 
radical O 
- O 
scavenging O 
, O 
1,1-diphenyl-2-picryl-hydrazyl B-SYSTEMATIC 
radical O 
(DPPH)-scavenging O 
and O 
lipid O 
peroxidation O 
inhibition O 
) O 
. O 
Additionally O 
, O 
the O 
production O 
of O 
total O 
SCFA B-ABBREVIATION 
, O 
propionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
n-butyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
ceca O 
and O 
colons O 
of O 
mice O 
significantly O 
increased O 
after O 
dieting O 
supplementation O 
with O 
homogenized O 
polysaccharide O 
. O 
These O 
results O 
showed O 
that O 
high O 
pressure O 
homogenization O 
treatment O 
could O 
be O 
a O 
promising O 
approach O 
for O 
the O 
production O 
of O 
value O 
- O 
added O 
polysaccharides O 
in O 
the O 
food O 
industry O 
. O 

of O 
citral B-TRIVIAL 
degradation O 
in O 
an O 
acidic O 
aqueous O 
environment O 
by O 
polyoxyethylene B-FAMILY 
alkylether I-FAMILY 
surfactants O 
. O 

is O 
a O 
flavour O 
component O 
widely O 
used O 
in O 
food O 
and O 
cosmetic O 
industries O 
, O 
but O 
is O 
chemically O 
unstable O 
and O 
degrades O 
over O 
time O 
in O 
aqueous O 
solutions O 
due O 
to O 
acid O 
- O 
catalysed O 
and O 
oxidative O 
reactions O 
leading O 
to O 
loss O 
of O 
desirable O 
flavour O 
. O 
The O 
present O 
study O 
reveals O 
the O 
effect O 
of O 
non-ionic O 
micellar O 
solutions O 
of O 
Brij30 O 
and O 
Brij35 O 
on O 
the O 
extent O 
of O 
solubilisation O 
and O 
stabilisation O 
of O 
citral B-TRIVIAL 
. O 
The O 
rate O 
of O 
chemical O 
degradation O 
of O 
citral B-TRIVIAL 
in O 
acidic O 
aqueous O 
solutions O 
was O 
found O 
to O 
be O 
highest O 
, O 
which O 
was O 
subsequently O 
reduced O 
significantly O 
within O 
these O 
studied O 
surfactant O 
systems O 
, O 
suggesting O 
protection O 
of O 
citral B-TRIVIAL 
from O 
an O 
acidic O 
environment O 
once O 
it O 
is O 
incorporated O 
into O 
the O 
micelles O 
. O 
The O 
work O 
concludes O 
that O 
polyoxyethylene B-FAMILY 
alkylether I-FAMILY 
surfactants O 
with O 
lower O 
HLB O 
value O 
, O 
less O 
dense O 
hydrophilic O 
corona O 
and O 
more O 
hydrophobic O 
core O 
volume O 
are O 
efficient O 
in O 
solubilising O 
and O 
stabilising O 
citral B-TRIVIAL 
against O 
an O 
acidic O 
environment O 
. O 

order O 
for O 
a O 
protein O 
to O 
elicit O 
a O 
systemic O 
allergic O 
response O 
it O 
must O 
reach O 
the O 
circulatory O 
system O 
through O 
the O 
intestinal O 
mucosa O 
as O 
a O 
sufficiently O 
large O 
fragment O 
with O 
adequate O 
structural O 
integrity O 
. O 
Sunflower O 
LTP O 
and O 
2S O 
albumins O 
( O 
SFA8 O 
and O 
three O 
mixed O 
fractions O 
of O 
Alb1 O 
and O 
Alb2 O 
) O 
were O 
digested O 
in O 
simulated O 
gastric O 
fluid O 
( O 
SGF O 
) O 
for O 
2h O 
and O 
the O 
conditions O 
were O 
then O 
changed O 
to O 
mimic O 
the O 
intestinal O 
environment O 
for O 
a O 
further O 
2h O 
digestion O 
. O 
The O 
effects O 
of O 
phosphatidylcholine B-FAMILY 
( O 
PC O 
) O 
and O 
emulsification O 
on O 
the O 
digestibility O 
of O 
the O 
proteins O 
were O 
investigated O 
. O 
PC O 
protected O 
all O 
of O 
the O 
proteins O 
studied O 
against O 
both O 
gastric O 
and O 
intestinal O 
digestive O 
enzymes O 
but O 
to O 
different O 
extents O 
. O 
Emulsification O 
of O 
SFA8 O 
resulted O 
in O 
strong O 
protection O 
against O 
digestion O 
, O 
which O 
was O 
further O 
enhanced O 
by O 
the O 
presence O 
of O 
PC O 
in O 
the O 
SGF O 
. O 
These O 
results O 
highlight O 
the O 
importance O 
of O 
considering O 
real O 
food O 
structures O 
such O 
as O 
emulsified O 
systems O 
and O 
also O 
the O 
gastrointestinal O 
environment O 
that O 
proteins O 
are O 
exposed O 
to O 
once O 
consumed O 
when O 
assessing O 
allergenicity O 
. O 

of O 
a O 
Chardonnay O 
wine O 
to O 
light O 
from O 
a O 
mercury B-SYSTEMATIC 
vapour O 
lamp O 
under O 
controlled O 
temperature O 
conditions O 
showed O 
that O 
colour O 
enhancement O 
was O 
dependent O 
on O 
bottle O 
colour O 
. O 
The O 
increase O 
in O 
colouration O 
was O 
Antique O 
Green O 
< O 
French O 
Green O 
< O 
Arctic O 
Blue O 
< O 
Flint O 
, O 
in O 
agreement O 
with O 
the O 
transmission O 
characteristics O 
of O 
each O 
bottle O 
type O 
. O 
Xanthylium O 
pigments O 
were O 
identified O 
as O 
one O 
component O 
contributing O 
to O 
the O 
observed O 
enhancement O 
of O 
colour O 
. O 
The O 
presence O 
of O 
oxygen O 
was O 
shown O 
to O 
be O 
a O 
critical O 
factor O 
to O 
initiate O 
the O 
formation O 
of O 
these O 
xanthylium O 
pigments O 
during O 
light O 
exposure O 
. O 
Without O 
temperature O 
control O 
, O 
wine O 
colour O 
development O 
was O 
highest O 
in O 
Antique O 
Green O 
and O 
lowest O 
in O 
Flint O 
. O 
This O 
alternate O 
order O 
reflects O 
the O 
ability O 
of O 
the O 
darker O 
bottles O 
to O 
retain O 
heat O 
longer O 
than O 
lighter O 
coloured O 
ones O 
as O 
confirmed O 
by O 
surface O 
temperature O 
decay O 
rates O 
. O 
Specific O 
pigments O 
contributing O 
to O 
the O 
wine O 
colour O 
enhancement O 
in O 
uncontrolled O 
temperature O 
/ O 
light O 
exposure O 
experiments O 
could O 
not O 
be O 
identified O 
, O 
although O 
tentative O 
evidence O 
was O 
obtained O 
for O 
the O 
presence O 
of O 
flavan-3-ol O 
based O 
compounds O 
. O 
The O 
different O 
bottle O 
glass O 
surfaces O 
did O 
not O 
influence O 
the O 
rate O 
of O 
loss O 
of O 
dissolved O 
oxygen O 
or O 
oxidation O 
of O 
ascorbic O 
acid O 
. O 
The O 
potential O 
to O 
develop O 
the O 
results O 
obtained O 
in O 
this O 
study O 
to O 
identify O 
markers O 
for O 
light O 
and O 
/ O 
or O 
temperature O 
exposure O 
of O 
white O 
wines O 
is O 
discussed O 
. O 

of O 
new O 
potential O 
hits O 
of O 
Plasmodium O 
falciparum O 
enoyl B-FAMILY 
-ACP O 
reductase O 
through O 
ligand- O 
and O 
structure O 
- O 
based O 
drug O 
design O 
approaches O 
. O 

here O 
report O 
the O 
discovery O 
of O 
novel O 
Plasmodium O 
falciparum O 
enoyl B-FAMILY 
-ACP O 
reductase O 
( O 
PfENR O 
) O 
inhibitors O 
as O 
new O 
antimalarial O 
hits O 
through O 
ligand- O 
and O 
structure O 
- O 
based O 
drug O 
design O 
approaches O 
. O 
We O 
performed O 
2D O 
and O 
3D O 
QSAR O 
studies O 
on O 
a O 
set O 
of O 
rhodanine B-FAMILY 
analogues O 
using O 
hologram O 
QSAR O 
( O 
HQSAR O 
) O 
, O 
comparative O 
molecular O 
field O 
analysis O 
( O 
CoMFA O 
) O 
and O 
comparative O 
molecular O 
similarity O 
indices O 
analysis O 
( O 
CoMSIA O 
) O 
techniques O 
. O 
Statistical O 
and O 
satisfactory O 
results O 
were O 
obtained O 
for O 
the O 
best O 
HQSAR O 
( O 
r(2) O 
of O 
0.968 O 
and O 
qLOO(2) O 
of O 
0.751 O 
) O 
, O 
CoMFA O 
( O 
r(2) O 
of O 
0.955 O 
and O 
qLOO(2) O 
of O 
0.806 O 
) O 
and O 
CoMSIA O 
( O 
r(2) O 
of O 
0.965 O 
and O 
qLOO(2) O 
of O 
0.659 O 
) O 
models O 
. O 
The O 
information O 
gathered O 
from O 
the O 
QSAR O 
models O 
guided O 
us O 
to O 
design O 
new O 
PfENR O 
inhibitors O 
. O 
Three O 
new O 
hits O 
were O 
predicted O 
with O 
potency O 
in O 
the O 
submicromolar O 
range O 
and O 
presented O 
drug O 
- O 
like O 
properties O 
. O 

the O 
UDP B-ABBREVIATION 
pocket O 
of O 
LpxC O 
through O 
amino B-FAMILY 
acid I-FAMILY 
analogs O 
. O 

( O 
LPS O 
) O 
biosynthesis O 
is O 
an O 
attractive O 
antibacterial O 
target O 
as O 
it O 
is O 
both O 
conserved O 
and O 
essential O 
for O 
the O 
survival O 
of O 
key O 
pathogenic O 
bacteria O 
. O 
Lipid O 
A O 
is O 
the O 
hydrophobic O 
anchor O 
for O 
LPS O 
and O 
a O 
key O 
structural O 
component O 
of O 
the O 
outer O 
membrane O 
of O 
Gram O 
- O 
negative O 
bacteria O 
. O 
Lipid O 
A O 
biosynthesis O 
is O 
performed O 
in O 
part O 
by O 
a O 
unique O 
zinc B-SYSTEMATIC 
dependent O 
metalloamidase O 
, O 
LpxC O 
( O 
UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine B-SYSTEMATIC 
deacetylase O 
) O 
, O 
which O 
catalyzes O 
the O 
first O 
non-reversible O 
step O 
in O 
lipid O 
A O 
biosynthesis O 
. O 
The O 
UDP B-ABBREVIATION 
portion O 
of O 
the O 
LpxC O 
substrate O 
- O 
binding O 
pocket O 
has O 
been O 
relatively O 
unexplored O 
. O 
We O 
have O 
designed O 
and O 
evaluated O 
a O 
series O 
of O 
hydroxamate B-SYSTEMATIC 
based O 
inhibitors O 
which O 
explore O 
the O 
SAR O 
of O 
substitutions O 
directed O 
into O 
the O 
UDP B-ABBREVIATION 
pocket O 
with O 
a O 
range O 
of O 
substituted O 
α-amino B-FAMILY 
acid I-FAMILY 
based O 
linkers O 
. O 
We O 
also O 
provide O 
the O 
first O 
wild O 
type O 
structure O 
of O 
Pseudomonas O 
aeruginosa O 
LpxC O 
which O 
was O 
utilized O 
in O 
the O 
design O 
of O 
many O 
of O 
these O 
analogs O 
. O 

( O 
F2695 B-IDENTIFIER 
) O 
, O 
a O 
norepinephrine B-TRIVIAL 
-preferring O 
SNRI O 
: O 
Profile O 
in O 
vitro O 
and O 
in O 
models O 
of O 
depression O 
and O 
anxiety O 
. O 

( O 
LVM B-ABBREVIATION 
; O 
F2695 B-IDENTIFIER 
) O 
is O 
the O 
more O 
active O 
enantiomer O 
of O 
the O 
serotonin B-TRIVIAL 
/ O 
norepinephrine B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
/ O 
NE O 
) O 
reuptake O 
inhibitor O 
( O 
SNRI O 
) O 
milnacipran B-TRIVIAL 
and O 
is O 
currently O 
under O 
development O 
for O 
the O 
treatment O 
of O 
major O 
depressive O 
disorder O 
. O 
LVM B-ABBREVIATION 
was O 
benchmarked O 
against O 
two O 
other O 
SNRIs O 
, O 
duloxetine B-TRIVIAL 
and O 
venlafaxine B-TRIVIAL 
, O 
in O 
biochemical O 
, O 
neurochemical O 
and O 
pharmacological O 
assays O 
. O 
LVM B-ABBREVIATION 
exhibited O 
high O 
affinity O 
for O 
human O 
NE O 
( O 
Ki O 
= O 
92.2 O 
nM O 
) O 
and O 
5-HT B-SYSTEMATIC 
( O 
11.2 O 
nM O 
) O 
transporters O 
, O 
and O 
potently O 
inhibited O 
NE O 
( O 
IC50 O 
= O 
10.5 O 
nM O 
) O 
and O 
5-HT B-SYSTEMATIC 
( O 
19 O 
nM O 
) O 
reuptake O 
( O 
human O 
transporter O 
) O 
in O 
vitro O 
. O 
LVM B-ABBREVIATION 
had O 
2-fold O 
greater O 
potency O 
for O 
norepinephrine B-TRIVIAL 
relative O 
to O 
serotonin B-TRIVIAL 
reuptake O 
inhibition O 
( O 
i.e O 
. O 
NE/ O 
5-HT B-SYSTEMATIC 
potency O 
ratio O 
: O 
0.6 O 
) O 
and O 
17 O 
and O 
27 O 
times O 
higher O 
selectivity O 
for O 
NE O 
reuptake O 
inhibition O 
compared O 
with O 
venlafaxine B-TRIVIAL 
and O 
duloxetine B-TRIVIAL 
, O 
respectively O 
. O 
LVM B-ABBREVIATION 
did O 
not O 
exhibit O 
affinity O 
for O 
23 O 
off O 
- O 
target O 
receptors O 
. O 
LVM B-ABBREVIATION 
( O 
i.p O 
. O 
) O 
increased O 
cortical O 
extracellular O 
levels O 
of O 
5-HT B-SYSTEMATIC 
, O 
and O 
NE O 
( O 
minimal O 
effective O 
doses O 
: O 
MEDs O 
= O 
20 O 
and O 
10 O 
mg O 
/ O 
kg O 
, O 
respectively O 
) O 
. O 
In O 
anti-depressive O 
/ O 
anti-stress O 
models O 
, O 
i.p O 
. O 
LVM B-ABBREVIATION 
diminished O 
immobility O 
time O 
in O 
the O 
mouse O 
forced O 
swim O 
( O 
MED O 
= O 
20 O 
mg O 
/ O 
kg O 
) O 
and O 
tail O 
suspension O 
( O 
MED O 
= O 
2.5 O 
mg O 
/ O 
kg O 
) O 
tests O 
, O 
and O 
reduced O 
shock O 
- O 
induced O 
ultrasonic O 
vocalizations O 
in O 
rats O 
( O 
MED O 
= O 
5 O 
mg O 
/ O 
kg O 
) O 
. O 
Duloxetine B-TRIVIAL 
and O 
venlafaxine B-TRIVIAL 
were O 
less O 
potent O 
( O 
MEDs O 
≥ O 
10 O 
mg O 
/ O 
kg O 
) O 
. O 
At O 
doses O 
active O 
in O 
these O 
three O 
therapeutically O 
- O 
relevant O 
models O 
, O 
LVM B-ABBREVIATION 
( O 
i.p O 
. O 
) O 
did O 
not O 
significantly O 
affect O 
spontaneous O 
locomotor O 
activity O 
. O 
In O 
summary O 
, O 
LVM B-ABBREVIATION 
is O 
a O 
potent O 
, O 
selective O 
inhibitor O 
of O 
NE O 
and O 
5-HT B-SYSTEMATIC 
transporters O 
with O 
preferential O 
activity O 
at O 
the O 
former O 
. O 
It O 
is O 
efficacious O 
in O 
models O 
of O 
anti-depressive O 
/ O 
anti-stress O 
activity O 
, O 
with O 
minimal O 
potential O 
for O 
locomotor O 
side O 
effects O 
. O 

of O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
1A8 O 
polymorphism O 
on O 
raloxifene B-TRIVIAL 
glucuronidation O 
. O 

is O 
an O 
antiestrogen O 
marketed O 
for O 
the O 
treatment O 
of O 
osteoporosis O 
. O 
The O 
major O 
metabolic O 
pathway O 
of O 
raloxifene B-TRIVIAL 
is O 
glucuronidation O 
at O 
6- O 
and O 
/ O 
or O 
4'- O 
positions O 
, O 
which O 
is O 
mainly O 
catalyzed O 
by O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
1A8 O 
( O 
UGT1A8 O 
) O 
expressed O 
in O 
extrahepatic O 
tissues O 
such O 
as O 
the O 
small O 
intestine O 
and O 
colon O 
. O 
Two O 
non-synonymous O 
allelic O 
variants O 
, O 
termed O 
UGT1A8*2 O 
( O 
518C O 
> O 
G O 
, O 
A173G O 
) O 
and O 
UGT1A8*3 O 
( O 
830G O 
> O 
A O 
, O 
C277Y O 
) O 
, O 
have O 
been O 
found O 
in O 
Caucasian O 
, O 
African-American O 
and O 
Asian O 
populations O 
. O 
In O 
this O 
study O 
, O 
the O 
effect O 
of O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
in O 
UGT1A8 O 
on O 
raloxifene B-TRIVIAL 
glucuronidation O 
was O 
studied O 
using O 
recombinant O 
UGT1A8 O 
enzymes O 
of O 
wild O 
- O 
type O 
( O 
UGT1A8.1 O 
) O 
and O 
variant O 
UGT1A8 O 
( O 
UGT1A8.2 O 
and O 
UGT1A8.3 O 
) O 
expressed O 
in O 
Sf9 O 
cells O 
. O 
Raloxifene B-TRIVIAL 
6- O 
and O 
4'-glucuronidation O 
by O 
UGT1A8.1 O 
exhibited O 
negative O 
allosteric O 
kinetics O 
. O 
The O 
Km O 
and O 
Vmax O 
values O 
of O 
UGT1A8.1 O 
were O 
15.0μM O 
and O 
111pmol O 
/ O 
min O 
/ O 
mg O 
protein O 
for O 
6-glucuronidation O 
, O 
and O 
9.35μM O 
and O 
232pmol O 
/ O 
min O 
/ O 
mg O 
protein O 
for O 
4'-glucuronidation O 
, O 
respectively O 
. O 
The O 
kinetics O 
of O 
raloxifene B-TRIVIAL 
6-glucuronidation O 
by O 
UGT1A8.2 O 
was O 
positive O 
allosteric O 
, O 
whereas O 
the O 
kinetics O 
of O 
raloxifene B-TRIVIAL 
4'-glucuronidation O 
was O 
negative O 
allosteric O 
. O 
The O 
S50 O 
value O 
of O 
raloxifene B-TRIVIAL 
6-glucuronidation O 
was O 
markedly O 
low O 
( O 
1.2% O 
) O 
compared O 
with O 
the O 
Km O 
value O 
of O 
UGT1A8.1 O 
, O 
and O 
the O 
Km O 
value O 
for O 
raloxifene B-TRIVIAL 
4'-glucuronidation O 
was O 
29% O 
that O 
of O 
UGT1A8.1 O 
. O 
The O 
Vmax O 
value O 
for O 
raloxifene B-TRIVIAL 
6-glucuronidation O 
by O 
UGT1A8.2 O 
was O 
comparable O 
to O 
that O 
of O 
UGT1A8.1 O 
, O 
whereas O 
the O 
Vmax O 
value O 
for O 
raloxifene B-TRIVIAL 
4'-glucuronidation O 
was O 
significantly O 
lower O 
( O 
54% O 
) O 
than O 
that O 
of O 
UGT1A8.1 O 
. O 
The O 
activities O 
of O 
raloxifene B-TRIVIAL 
6- O 
and O 
4'-glucuronidation O 
in O 
UGT1A8.3 O 
were O 
markedly O 
lower O 
than O 
those O 
of O 
UGT1A8.1 O 
. O 
In O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
glucuronidation O 
, O 
the O 
kinetics O 
by O 
wild O 
- O 
type O 
and O 
variant O 
UGT1A8s O 
fitted O 
the O 
Michaelis-Menten O 
model O 
. O 
The O 
Km O 
and O 
Vmax O 
values O 
of O 
UGT1A8.1 O 
were O 
123μM O 
and O 
4820pmol O 
/ O 
min O 
/ O 
mg O 
protein O 
, O 
respectively O 
. O 
The O 
Km O 
and O 
Vmax O 
values O 
of O 
UGT1A8.2 O 
were O 
comparable O 
to O 
those O 
of O 
UGT1A8.1 O 
. O 
The O 
Km O 
value O 
of O 
UGT1A8.3 O 
was O 
similar O 
to O 
that O 
of O 
UGT1A8.1 O 
, O 
whereas O 
the O 
Vmax O 
value O 
was O 
reduced O 
to O 
2.4% O 
of O 
UGT1A8.1 O 
. O 
These O 
findings O 
suggest O 
that O 
A173G O 
and O 
C277Y O 
substitutions O 
of O 
UGT1A8 O 
change O 
the O 
metabolic O 
ability O 
toward O 
raloxifene B-TRIVIAL 
, O 
and O 
that O 
the O 
polymorphic O 
alleles O 
of O 
UGT1A8 O 
may O 
influence O 
the O 
clinical O 
response O 
and O 
bioavailability O 
of O 
medicines O 
metabolized O 
mainly O 
by O 
UGT1A8 O 
. O 

and O 
molecular O 
modeling O 
of O 
(4'R)- B-MULTIPLE 
and I-MULTIPLE 
(4'S)- I-MULTIPLE 
4'- I-MULTIPLE 
substituted I-MULTIPLE 
2'-{[(E)-androst-5-en-17-ylidene]-methyl}oxazolines I-MULTIPLE 
. O 

of O 
four O 
novel O 
(4'R)- B-MULTIPLE 
and I-MULTIPLE 
(4'S)- I-MULTIPLE 
2'-{[(E)-3β-hydroxyandrost-5-en-17-ylidene]-methyl} I-MULTIPLE 
oxazolines I-MULTIPLE 
, O 
comprising O 
4'-hydroxymethyl B-SYSTEMATIC 
( O 
1 O 
and O 
2 O 
) O 
and O 
4'-methoxycarbonyl B-SYSTEMATIC 
( O 
3 O 
and O 
4 O 
) O 
substituents O 
is O 
presented O 
. O 
Reaction O 
of O 
17α-bromo-21-iodo-3β-acetoxypregn-5-en-20-one B-SYSTEMATIC 
with O 
either O 
(L)-serine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
or O 
(D)-serine B-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
resulted O 
in O 
methyl B-SYSTEMATIC 
N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(L)-serinate I-SYSTEMATIC 
and O 
methyl B-SYSTEMATIC 
N-[3β-acetoxy-21-oxopregna-5,17(20)-dien-21-yl]-(D)-serinate I-SYSTEMATIC 
( O 
as O 
mixtures O 
of O 
related O 
[17(20)E]- O 
and O 
[ O 
17(20)Z O 
] O 
- O 
isomers O 
) O 
. O 
Cyclization O 
of O 
obtained O 
amides B-FAMILY 
led O 
to O 
methyl B-SYSTEMATIC 
2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'S)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate I-SYSTEMATIC 
and O 
methyl B-SYSTEMATIC 
2'-{[(E)-3β-acetoxyandrost-5-en-17-ylidene]methyl}-(4'R)-4',5'-dihydro-1',3'-oxazole-4'-carboxylate I-SYSTEMATIC 
which O 
were O 
transformed O 
to O 
titled O 
compounds O 
1-4 O 
. O 
The O 
molecular O 
docking O 
of O 
compounds O 
1-4 O 
to O 
ligand O 
binding O 
site O 
of O 
nuclear O 
receptor O 
LXRβ O 
revealed O 
significant O 
differences O 
due O 
to O 
stereochemical O 
configuration O 
of O 
4 O 
' O 
atom O 
and O 
structure O 
of O 
4'- O 
substituent O 
. O 

sting O 
may O 
cause O 
myocardial O 
injury O 
and O 
heart O 
failure O 
( O 
HF O 
) O 
. O 
Clinical O 
signs O 
of O 
failure O 
may O 
develop O 
several O 
hours O 
or O 
even O 
days O 
after O 
the O 
sting O 
, O 
while O 
electrocardiography O 
( O 
ECG O 
) O 
and O 
blood O 
examination O 
soon O 
after O 
the O 
sting O 
may O 
be O 
normal O 
. O 
We O 
sought O 
to O 
examine O 
whether O 
normal O 
echocardiographic O 
( O 
echo O 
) O 
examination O 
performed O 
shortly O 
after O 
hospital O 
arrival O 
would O 
exclude O 
subsequent O 
HF O 
. O 
We O 
also O 
sought O 
to O 
check O 
if O 
blood O 
troponin O 
and O 
natriuretic O 
peptide O 
values O 
measured O 
shortly O 
after O 
arrival O 
may O 
predict O 
or O 
exclude O 
subsequent O 
HF O 
. O 
Natriuretic O 
peptide O 
activities O 
have O 
not O 
been O 
measured O 
in O 
scorpion O 
sting O 
victims O 
. O 
We O 
also O 
wanted O 
to O 
check O 
if O 
HF O 
occurs O 
in O 
envenomated O 
young O 
infants O 
. O 
In O 
a O 
3-year O 
prospective O 
study O 
we O 
looked O 
at O 
the O 
demographic O 
, O 
clinical O 
, O 
laboratory O 
, O 
ECG O 
, O 
and O 
echo O 
data O 
of O 
all O 
patients O 
with O 
general O 
envenomation O 
who O 
arrived O 
at O 
the O 
emergency O 
department O 
( O 
ED O 
) O 
after O 
scorpion O 
sting O 
. O 
Clinical O 
, O 
laboratory O 
, O 
ECG O 
, O 
and O 
echo O 
results O 
on O 
arrival O 
and O 
24 O 
h O 
after O 
arrival O 
were O 
checked O 
and O 
compared O 
between O 
groups O 
of O 
patients O 
with O 
normal O 
and O 
abnormal O 
echo O 
on O 
arrival O 
. O 
We O 
then O 
looked O 
for O 
differences O 
in O 
clinical O 
course O 
, O 
therapy O 
, O 
and O 
outcome O 
between O 
groups O 
. O 
The O 
study O 
included O 
98 O 
children O 
aged O 
80 O 
days O 
to O 
19 O 
years O 
( O 
median O 
53.1 O 
months O 
) O 
, O 
25 O 
were O 
below O 
the O 
age O 
of O 
2 O 
years O 
. O 
Envenomation O 
by O 
the O 
" O 
yellow O 
scorpion"Leiurus O 
quinquestriatus O 
was O 
suspected O 
in O 
74 O 
cases O 
. O 
Median O 
time O 
between O 
sting O 
and O 
ED O 
arrival O 
was O 
80 O 
min O 
. O 
Echo O 
was O 
performed O 
on O 
arrival O 
in O 
93 O 
of O 
the O 
98 O 
patients O 
, O 
( O 
in O 
5 O 
occasions O 
it O 
was O 
not O 
performed O 
or O 
not O 
recorded O 
) O 
74 O 
were O 
normal O 
and O 
19 O 
were O 
abnormal O 
. O 
Abnormal O 
echo O 
included O 
hypokinesia O 
and O 
low O 
fractional O 
shortening O 
and O 
ejection O 
fraction O 
of O 
the O 
left O 
ventricle O 
. O 
Clinical O 
signs O 
, O 
abnormal O 
ECG O 
, O 
and O 
laboratory O 
results O 
were O 
not O 
discriminative O 
between O 
groups O 
on O 
arrival O 
. O 
Mean O 
troponin O 
T O 
was O 
higher O 
in O 
patients O 
with O 
abnormal O 
echo O 
, O 
but O 
within O 
normal O 
range O 
in O 
13 O 
of O 
the O 
19 O 
patients O 
with O 
abnormal O 
echo O 
and O 
above O 
normal O 
in O 
2 O 
of O 
the O 
74 O 
patients O 
with O 
normal O 
echo O 
- O 
missing O 
sensitivity O 
and O 
specificity O 
. O 
Mean O 
N B-FORMULA 
-terminal O 
pro O 
B O 
- O 
type O 
natriuretic O 
peptide O 
was O 
above O 
normal O 
in O 
both O 
groups O 
but O 
within O 
normal O 
range O 
in O 
5 O 
patients O 
with O 
abnormal O 
echo O 
and O 
above O 
normal O 
range O 
in O 
24 O 
patients O 
with O 
normal O 
echo O 
- O 
missing O 
sensitivity O 
and O 
specificity O 
. O 
None O 
of O 
the O 
patients O 
with O 
normal O 
echo O 
had O 
subsequent O 
HF O 
and O 
none O 
of O 
the O 
children O 
younger O 
than O 
2 O 
years O 
of O 
age O 
had O 
HF O 
. O 
All O 
patients O 
survived O 
the O 
intoxication O 
and O 
were O 
discharged O 
home O 
without O 
sequel O 
. O 
We O 
conclude O 
that O 
early O 
echo O 
examination O 
is O 
an O 
important O 
procedure O 
. O 
In O 
our O 
study O 
, O 
normal O 
examination O 
excluded O 
subsequent O 
HF O 
. O 
Abnormal O 
examination O 
accelerated O 
cardiac O 
therapy O 
which O 
might O 
have O 
contributed O 
to O 
our O 
favorable O 
outcome O 
. O 
HF O 
did O 
not O 
occur O 
in O 
infants O 
younger O 
than O 
two O 
years O 
of O 
age O 
. O 

cardioprotective O 
effects O 
of O 
SHP-1 O 
gene O 
silencing O 
against O 
ischemia O 
- O 
reperfusion O 
injury O 
: O 
Use O 
of O 
deoxycholic B-TRIVIAL 
acid I-TRIVIAL 
-modified O 
low O 
molecular O 
weight O 
polyethyleneimine B-SYSTEMATIC 
as O 
a O 
cardiac O 
siRNA-carrier O 
. O 

cardiomyocyte O 
apoptosis O 
plays O 
a O 
critical O 
role O 
in O 
the O 
development O 
of O 
myocardial O 
injury O 
after O 
ischemia O 
and O 
reperfusion O 
. O 
Thus O 
, O 
alteration O 
of O 
the O 
major O 
apoptosis O 
- O 
regulatory O 
factors O 
during O 
myocardial O 
ischemia O 
- O 
reperfusion O 
is O 
expected O 
to O 
have O 
favorable O 
cardioprotective O 
effects O 
. O 
Herein O 
, O 
we O 
report O 
ischemic O 
- O 
reperfused O 
myocardial O 
infarction O 
( O 
MI O 
) O 
repair O 
with O 
siRNA O 
against O 
Src O 
homology O 
region O 
2 O 
domain O 
- O 
containing O 
tyrosine B-TRIVIAL 
phosphatase-1 O 
( O 
SHP-1 O 
) O 
, O 
which O 
is O 
known O 
as O 
a O 
key O 
factor O 
involved O 
in O 
regulating O 
the O 
progress O 
of O 
apoptosis O 
in O 
many O 
cell O 
types O 
. O 
A O 
low O 
molecular O 
weight O 
polyethyleneimine B-SYSTEMATIC 
modified O 
with O 
deoxycholic B-TRIVIAL 
acid I-TRIVIAL 
( O 
PEI1.8-DA O 
) O 
- O 
based O 
delivery O 
strategy O 
was O 
suggested O 
for O 
the O 
cardiac O 
application O 
of O 
SHP-1 O 
siRNA O 
to O 
overcome O 
the O 
poor O 
gene O 
delivery O 
efficiency O 
to O 
myocardium O 
due O 
to O 
the O 
highly O 
charged O 
structures O 
of O 
the O 
compact O 
cardiac O 
muscles O 
. O 
The O 
PEI1.8-DA O 
conjugates O 
formed O 
stable O 
nanocomplexes O 
with O 
SHP-1 O 
siRNA O 
via O 
electrostatic O 
and O 
hydrophobic O 
interactions O 
. O 
The O 
PEI1.8-DA O 
/ O 
SHP-1 O 
siRNA O 
polyplexes O 
effectively O 
silenced O 
SHP-1 O 
gene O 
expression O 
in O 
cardiomyocytes O 
, O 
leading O 
to O 
a O 
significant O 
inhibition O 
of O 
cardiomyocyte O 
apoptosis O 
under O 
hypoxia O 
. O 
In O 
comparison O 
to O 
conventional O 
gene O 
carriers O 
, O 
relatively O 
large O 
amounts O 
of O 
siRNA O 
molecules O 
remained O 
after O 
treatment O 
with O 
the O 
PEI1.8-DA O 
/ O 
SHP-1 O 
siRNA O 
polyplexes O 
. O 
Cardiac O 
administration O 
of O 
the O 
PEI1.8-DA O 
/ O 
SHP-1 O 
siRNA O 
polyplexes O 
resulted O 
in O 
substantial O 
improvement O 
in O 
SHP-1 O 
gene O 
silencing O 
, O 
which O 
can O 
be O 
explained O 
by O 
the O 
enhancement O 
of O 
cardiac O 
delivery O 
efficiency O 
of O 
the O 
PEI1.8-DA O 
conjugates O 
. O 
In O 
addition O 
, O 
in O 
vivo O 
treatment O 
with O 
the O 
PEI1.8-DA O 
/ O 
SHP-1 O 
siRNA O 
polyplexes O 
induced O 
a O 
highly O 
significant O 
reduction O 
in O 
myocardial O 
apoptosis O 
and O 
infarct O 
size O 
in O 
rat O 
MI O 
models O 
. O 
These O 
results O 
demonstrate O 
that O 
the O 
PEI1.8-DA O 
/ O 
SHP-1 O 
siRNA O 
polyplex O 
formulation O 
is O 
a O 
useful O 
system O 
for O 
efficient O 
gene O 
delivery O 
into O 
the O 
compact O 
myocardium O 
that O 
provides O 
a O 
fundamental O 
advantage O 
in O 
treating O 
ischemic O 
- O 
reperfused O 
MI O 
. O 

interaction O 
of O 
a O 
polymeric O 
persimmon O 
proanthocyanidin B-FAMILY 
fraction O 
with O 
Chinese O 
cobra O 
PLA2 O 
and O 
BSA O 
. O 

elucidate O 
the O 
anti-venom O 
mechanism O 
of O 
persimmon O 
tannin O 
, O 
the O 
interaction O 
between O 
a O 
polymeric O 
persimmon O 
proanthocyanidin B-FAMILY 
fraction O 
( O 
PT40 O 
) O 
and O 
phospholipase O 
A2 O 
( O 
PLA2 O 
) O 
or O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
were O 
studied O 
using O 
a O 
competitive O 
binding O 
assay O 
and O 
spectroscopic O 
methods O 
including O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
, O 
circular O 
dichroism O 
( O 
CD O 
) O 
, O 
and O 
resonance O 
light O 
scattering O 
( O 
RLS O 
) O 
spectroscopy O 
. O 
The O 
results O 
revealed O 
that O 
PT40 O 
has O 
a O 
higher O 
affinity O 
for O 
PLA2 O 
than O 
for O 
BSA O 
at O 
physiological O 
pH O 
and O 
induced O 
greater O 
conformational O 
changes O 
in O 
PLA2 O 
than O 
in O 
BSA O 
. O 
PT40 O 
covalently O 
bound O 
to O 
PLA2 O 
in O 
a O 
reaction O 
probably O 
involving O 
Lys B-FORMULA 
residues O 
. O 
We O 
propose O 
that O 
the O 
high O 
affinity O 
of O 
PT40 O 
for O 
PLA2 O 
and O 
the O 
covalent O 
modification O 
of O 
PLA2 O 
by O 
PT40 O 
may O 
be O 
responsible O 
for O 
the O 
ability O 
of O 
the O 
tannin O 
to O 
irreversibly O 
inhibit O 
PLA2 O 
catalytic O 
activity O 
, O 
to O 
prevent O 
edema O 
, O 
and O 
to O 
neutralize O 
the O 
lethality O 
of O 
Chinese O 
cobra O 
PLA2in O 
vivo O 
. O 

and O 
skin O 
permeation O 
of O 
ketoprofen B-TRIVIAL 
loaded O 
vesicular O 
systems O 
. O 

: O 
To O 
determine O 
the O 
effect O 
of O 
elasticity O 
on O 
the O 
skin O 
permeation O 
of O 
ketoprofen B-TRIVIAL 
from O 
surfactant O 
- O 
based O 
vesicular O 
formulations O 
and O 
elastic O 
liposomes O 
. O 
METHODS O 
: O 
Ketoprofen B-TRIVIAL 
loaded O 
surfactant O 
- O 
based O 
vesicles O 
and O 
elastic O 
liposomes O 
were O 
prepared O 
by O 
sonication O 
. O 
Citric O 
buffer O 
( O 
at O 
pH O 
3 O 
) O 
was O 
used O 
as O 
rehydration O 
buffer O 
. O 
Characterization O 
studies O 
of O 
the O 
prepared O 
liposomal O 
formulations O 
were O 
performed O 
by O 
dynamic O 
light O 
scattering O 
, O 
extrusion O 
, O 
and O 
(1)H B-FORMULA 
and O 
(31)P B-FORMULA 
-nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
. O 
Ketoprofen B-TRIVIAL 
transport O 
studies O 
across O 
human O 
skin O 
were O 
performed O 
for O 
all O 
formulations O 
. O 
RESULTS O 
: O 
Stable O 
ketoprofen B-TRIVIAL 
loaded O 
formulations O 
were O 
prepared O 
. O 
Addition O 
of O 
an O 
edge O 
activator O 
, O 
in O 
the O 
absence O 
of O 
the O 
drug O 
, O 
increased O 
the O 
elasticity O 
of O 
the O 
vesicles O 
and O 
liposomes O 
. O 
Ketoprofen B-TRIVIAL 
loading O 
reduced O 
the O 
elasticity O 
of O 
the O 
liposomes O 
and O 
surfactant O 
- O 
based O 
- O 
vesicles O 
. O 
However O 
, O 
at O 
saturation O 
the O 
elasticity O 
was O 
still O 
higher O 
than O 
that O 
in O 
the O 
absence O 
of O 
the O 
edge O 
activator O 
and O 
ketoprofen B-TRIVIAL 
, O 
except O 
for O 
ketoprofen B-TRIVIAL 
loaded O 
liposomes O 
with O 
Span O 
80 O 
. O 
NMR O 
studies O 
revealed O 
that O 
the O 
ketoprofen B-TRIVIAL 
molecules O 
were O 
entrapped O 
in O 
a O 
vesicle O 
bilayer O 
in O 
all O 
vesicular O 
formulations O 
, O 
and O 
that O 
the O 
ketoprofen B-TRIVIAL 
molecules O 
affected O 
the O 
phosphate B-SYSTEMATIC 
mobility O 
in O 
the O 
liposomal O 
formulations O 
. O 
Ketoprofen B-TRIVIAL 
transport O 
studies O 
across O 
human O 
skin O 
clearly O 
showed O 
that O 
the O 
surfactant O 
- O 
based O 
vesicular O 
formulations O 
were O 
superior O 
to O 
the O 
elastic O 
liposomal O 
formulations O 
. O 
CONCLUSION O 
: O 
Surfactant O 
- O 
based O 
vesicles O 
enhance O 
ketoprofen B-TRIVIAL 
transport O 
across O 
human O 
skin O 
, O 
while O 
no O 
enhancement O 
of O 
ketoprofen B-TRIVIAL 
was O 
observed O 
when O 
loaded O 
in O 
elastic O 
liposomes O 
. O 

specific O 
impact O 
of O 
perinatal O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
exposure O 
over O 
a O 
range O 
of O 
orally O 
administered O 
doses O 
on O 
rat O 
hypothalamic O 
sexual O 
differentiation O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
a O 
high O 
volume O 
production O 
chemical O 
used O 
in O 
polycarbonate B-FAMILY 
plastics O 
, O 
epoxy B-SYSTEMATIC 
resins O 
, O 
thermal O 
paper O 
receipts O 
, O 
and O 
other O 
household O 
products O 
. O 
The O 
neural O 
effects O 
of O 
early O 
life O 
BPA B-ABBREVIATION 
exposure O 
, O 
particularly O 
to O 
low O 
doses O 
administered O 
orally O 
, O 
remain O 
unclear O 
. O 
Thus O 
, O 
to O 
better O 
characterize O 
the O 
dose O 
range O 
over O 
which O 
BPA B-ABBREVIATION 
alters O 
sex O 
specific O 
neuroanatomy O 
, O 
we O 
examined O 
the O 
impact O 
of O 
perinatal O 
BPA B-ABBREVIATION 
exposure O 
on O 
two O 
sexually O 
dimorphic O 
regions O 
in O 
the O 
anterior O 
hypothalamus O 
, O 
the O 
sexually O 
dimorphic O 
nucleus O 
of O 
the O 
preoptic O 
area O 
( O 
SDN-POA O 
) O 
and O 
the O 
anterioventral O 
periventricular O 
( O 
AVPV O 
) O 
nucleus O 
. O 
Both O 
are O 
sexually O 
differentiated O 
by O 
estradiol B-TRIVIAL 
and O 
play O 
a O 
role O 
in O 
sex O 
specific O 
reproductive O 
physiology O 
and O 
behavior O 
. O 
Long O 
Evans O 
rats O 
were O 
prenatally O 
exposed O 
to O 
10 O 
, O 
100 O 
, O 
1000 O 
, O 
10,000μg O 
/ O 
kg O 
bw O 
/ O 
day O 
BPA B-ABBREVIATION 
through O 
daily O 
, O 
non-invasive O 
oral O 
administration O 
of O 
dosed O 
- O 
cookies O 
to O 
the O 
dams O 
. O 
Offspring O 
were O 
reared O 
to O 
adulthood O 
. O 
Their O 
brains O 
were O 
collected O 
and O 
immunolabeled O 
for O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
in O 
the O 
AVPV O 
and O 
calbindin O 
( O 
CALB O 
) O 
in O 
the O 
SDN-POA O 
. O 
We O 
observed O 
decreased O 
TH-ir O 
cell O 
numbers O 
in O 
the O 
female O 
AVPV O 
across O 
all O 
exposure O 
groups O 
, O 
an O 
effect O 
indicative O 
of O 
masculinization O 
. O 
In O 
males O 
, O 
AVPV O 
TH-ir O 
cell O 
numbers O 
were O 
significantly O 
reduced O 
in O 
only O 
the O 
BPA B-ABBREVIATION 
10 O 
and O 
BPA B-ABBREVIATION 
10000 O 
groups O 
. O 
SDN-POA O 
endpoints O 
were O 
unaltered O 
in O 
females O 
but O 
in O 
males O 
SDN-POA O 
volume O 
was O 
significantly O 
lower O 
in O 
all O 
BPA B-ABBREVIATION 
exposure O 
groups O 
. O 
CALB-ir O 
was O 
significantly O 
lower O 
in O 
all O 
but O 
the O 
BPA B-ABBREVIATION 
1000 O 
group O 
. O 
These O 
effects O 
are O 
consistent O 
with O 
demasculinization O 
. O 
Collectively O 
these O 
data O 
demonstrate O 
that O 
early O 
life O 
oral O 
exposure O 
to O 
BPA B-ABBREVIATION 
at O 
levels O 
well O 
below O 
the O 
current O 
No O 
Observed O 
Adverse O 
Effect O 
Level O 
( O 
NOAEL O 
) O 
of O 
50mg O 
/ O 
kg O 
/ O 
day O 
can O 
alter O 
sex O 
specific O 
hypothalamic O 
morphology O 
in O 
the O 
rat O 
. O 

of O 
C17- O 
OH B-FORMULA 
-north O 
unit O 
of O 
ritterazine B-TRIVIAL 
G I-TRIVIAL 
via O 
" O 
Red-Ox O 
" O 
modifications O 
of O 
hecogenin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 

C17- O 
OH B-FORMULA 
-north O 
unit O 
of O 
ritterazine B-TRIVIAL 
G I-TRIVIAL 
was O 
prepared O 
in O 
13 O 
steps O 
from O 
hecogenin B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
This O 
synthesis O 
features O 
a O 
highly O 
efficient O 
and O 
stereoselective O 
introduction O 
of O 
the O 
C17- O 
OH B-FORMULA 
via O 
E-ring O 
cleavage O 
/ O 
F-ring O 
formation O 
, O 
D-ring O 
oxidation O 
, O 
and O 
F-ring O 
cleavage O 
/ O 
E-ring O 
formation O 
. O 

formation O 
in O 
humans O 
: O 
Identification O 
of O 
high O 
vs O 
. O 
low O 
oxidizers O 
. O 

studies O 
suggest O 
that O 
oxyphytosterols B-FAMILY 
are O 
atherogenic O 
. O 
However O 
, O 
we O 
have O 
previously O 
shown O 
that O 
plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
did O 
not O 
increase O 
after O 
consuming O 
a O 
diet O 
enriched O 
in O 
plant O 
sterol B-FAMILY 
esters I-FAMILY 
( O 
3g O 
/ O 
day O 
) O 
, O 
while O 
minor O 
reductions O 
were O 
seen O 
after O 
consuming O 
a O 
plant O 
stanol B-FAMILY 
ester I-FAMILY 
-enriched O 
diet O 
. O 
Large O 
variations O 
in O 
oxyphytosterol B-FAMILY 
concentrations O 
between O 
individuals O 
however O 
existed O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
identify O 
factors O 
that O 
may O 
explain O 
inter O 
- O 
individual O 
differences O 
in O 
plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
. O 
For O 
this O 
, O 
43 O 
subjects O 
consumed O 
for O 
4 O 
weeks O 
in O 
random O 
order O 
a O 
plant O 
sterol B-FAMILY 
, O 
stanol B-FAMILY 
and O 
control O 
margarine O 
. O 
Plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
were O 
determined O 
in O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
- O 
enriched O 
EDTA B-ABBREVIATION 
plasma O 
via O 
GC-MS O 
and O 
serum O 
oxidized O 
low O 
- O 
density O 
lipoprotein O 
( O 
oxLDL O 
) O 
concentrations O 
were O 
analyzed O 
via O 
ELISA O 
. O 
Trolox B-TRIVIAL 
equivalent O 
antioxidant O 
capacity O 
( O 
TEAC O 
) O 
values O 
, O 
α-tocopherol B-TRIVIAL 
concentrations O 
and O 
iron B-SYSTEMATIC 
/ O 
copper B-SYSTEMATIC 
status O 
were O 
determined O 
to O 
assess O 
plasma O 
oxidative O 
and O 
anti-oxidative O 
capacity O 
. O 
Serum O 
( O 
non-oxidized O 
) O 
sitosterol B-TRIVIAL 
and O 
campesterol B-TRIVIAL 
concentrations O 
did O 
not O 
correlate O 
with O 
plasma O 
oxysitosterol B-FAMILY 
and O 
oxycampesterol B-FAMILY 
concentrations O 
during O 
any O 
of O 
the O 
three O 
dietary O 
interventions O 
. O 
Moreover O 
, O 
plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
remained O 
relatively O 
stable O 
over O 
time O 
. O 
Six O 
subjects O 
could O 
be O 
arbitrarily O 
classified O 
as O 
having O 
consistent O 
low O 
or O 
high O 
plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
, O 
which O 
was O 
also O 
reflected O 
in O 
oxLDL O 
concentrations O 
. O 
However O 
, O 
oxidative O 
and O 
anti-oxidative O 
capacity O 
markers O 
, O 
such O 
as O 
iron B-SYSTEMATIC 
/ O 
copper B-SYSTEMATIC 
status O 
, O 
α-tocopherol B-TRIVIAL 
concentrations O 
and O 
TEAC O 
values O 
, O 
could O 
not O 
explain O 
these O 
differences O 
. O 
In O 
conclusion O 
, O 
subjects O 
seem O 
to O 
have O 
consistent O 
plasma O 
oxyphytosterol B-FAMILY 
concentrations O 
, O 
which O 
resulted O 
in O 
the O 
identification O 
of O 
' O 
low O 
and O 
high O 
oxidizers O 
' O 
. O 
Differences O 
, O 
however O 
, O 
could O 
not O 
be O 
attributed O 
to O 
the O 
oxidative O 
and O 
anti-oxidative O 
capacity O 
markers O 
analyzed O 
. O 

all O 
existing O 
pharmaceuticals O 
aiming O 
at O 
effectively O 
reducing O 
LDL O 
cholesterol B-TRIVIAL 
, O 
the O 
steadily O 
increasing O 
prevalence O 
of O 
coronary O 
heart O 
disease O 
( O 
CHD O 
) O 
worldwide O 
shifted O 
focus O 
on O 
HDL O 
as O 
an O 
alternative O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
CHD O 
. O 
Indeed O 
, O 
based O 
on O 
the O 
results O 
from O 
epidemiological O 
studies O 
, O 
high O 
HDL O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
levels O 
have O 
been O 
traditionally O 
associated O 
to O 
atheroprotection O 
. O 
Therefore O 
, O 
current O 
drug O 
design O 
considers O 
plasma O 
HDL-C O 
levels O 
as O 
a O 
primary O 
pharmacological O 
target O 
for O 
combating O 
CHD O 
. O 
However O 
, O 
this O 
approach O 
does O 
not O 
take O 
into O 
consideration O 
the O 
fact O 
that O 
HDL O 
is O 
a O 
rather O 
heterogeneous O 
mixture O 
of O 
lipoprotein O 
particles O 
with O 
distinct O 
apolipoprotein O 
and O 
lipid O 
composition O 
that O 
dictate O 
their O 
atheroprotective O 
or O 
proatherogenic O 
function O 
. O 
This O 
may O 
explain O 
why O 
simply O 
raising O 
HDL-C O 
levels O 
by O 
pharmacological O 
means O 
has O 
yet O 
to O 
yield O 
the O 
expected O 
atheroprotection O 
in O 
recent O 
clinical O 
trials O 
. O 
In O 
this O 
review O 
we O 
argue O 
that O 
HDL O 
particle O 
functionality O 
rather O 
than O 
HDL-C O 
levels O 
should O 
be O 
the O 
primary O 
target O 
in O 
the O 
rational O 
design O 
of O 
new O 
HDL O 
- O 
based O 
pharmaceuticals O 
aiming O 
at O 
successfully O 
treating O 
CHD O 
. O 

is O 
characterized O 
by O 
low O 
bone O 
mineral O 
density O 
and O 
/ O 
or O 
poor O 
bone O 
microarchitecture O 
leading O 
to O 
an O 
increased O 
risk O 
of O 
fractures O 
. O 
The O 
skeletal O 
alterations O 
in O 
osteoporosis O 
are O 
a O 
consequence O 
of O 
a O 
relative O 
deficit O 
of O 
bone O 
formation O 
compared O 
to O 
bone O 
resorption O 
. O 
Osteoporosis O 
therapies O 
have O 
mostly O 
relied O 
on O 
antiresorptive O 
drugs O 
. O 
An O 
alternative O 
therapeutic O 
approach O 
for O 
osteoporosis O 
is O 
currently O 
available O 
, O 
based O 
on O 
the O 
intermittent O 
administration O 
of O 
parathyroid O 
hormone O 
( O 
PTH O 
) O 
. O 
Bone O 
anabolism O 
caused O 
by O 
PTH O 
therapy O 
is O 
mainly O 
accounted O 
for O 
by O 
the O 
ability O 
of O 
PTH O 
to O 
increase O 
osteoblastogenesis O 
and O 
osteoblast O 
survival O 
. O 
PTH O 
and O 
PTH O 
- O 
related O 
protein O 
(PTHrP)-an O 
abundant O 
local O 
factor O 
in O 
bone- O 
interact O 
with O 
the O 
common O 
PTH O 
type O 
1 O 
receptor O 
with O 
similar O 
affinities O 
in O 
osteoblasts O 
. O 
Studies O 
mainly O 
in O 
osteoporosis O 
rodent O 
models O 
and O 
limited O 
data O 
in O 
postmenopausal O 
women O 
suggest O 
that O 
N B-FORMULA 
-terminal O 
PTHrP O 
peptides O 
might O 
be O 
considered O 
a O 
promising O 
bone O 
anabolic O 
therapy O 
. O 
In O 
addition O 
, O 
putative O 
osteogenic O 
actions O 
of O 
PTHrP O 
might O 
be O 
ascribed O 
not O 
only O 
to O 
its O 
N B-FORMULA 
-terminal O 
domain O 
but O 
also O 
to O 
its O 
PTH O 
- O 
unrelated O 
C B-FORMULA 
-terminal O 
region O 
. O 
In O 
this O 
review O 
, O 
we O 
discuss O 
the O 
underlying O 
cellular O 
and O 
molecular O 
mechanisms O 
of O 
the O 
anabolic O 
actions O 
of O 
PTH O 
and O 
the O 
similar O 
potential O 
of O 
PTH O 
- O 
related O 
protein O 
( O 
PTHrP O 
) O 
to O 
increase O 
bone O 
mass O 
and O 
improve O 
bone O 
regeneration O 
. O 

ameliorates O 
lung O 
fibrosis O 
in O 
vivo O 
and O 
in O 
vitro O 
by O 
preventing O 
transdifferentiation O 
, O 
inhibiting O 
proliferation O 
, O 
and O 
promoting O 
apoptosis O 
of O 
activated O 
cells O 
. O 

, O 
a O 
member O 
of O 
the O 
carotenoid O 
family O 
, O 
is O 
the O 
only O 
known O 
ketocarotenoid O 
transported O 
into O 
the O 
brain O 
by O 
transcytosis O 
through O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
However O 
, O 
whether O 
astaxanthin B-TRIVIAL 
has O 
antifibrotic O 
functions O 
is O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
astaxanthin B-TRIVIAL 
on O 
transforming O 
growth O 
factor O 
β1 O 
- O 
mediated O 
and O 
bleomycin B-FAMILY 
-induced O 
pulmonary O 
fibrosis O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
The O 
results O 
showed O 
that O 
astaxanthin B-TRIVIAL 
significantly O 
improved O 
the O 
structure O 
of O 
the O 
alveoli O 
and O 
alleviated O 
collagen O 
deposition O 
in O 
vivo O 
. O 
Compared O 
with O 
the O 
control O 
group O 
, O 
the O 
astaxanthin B-TRIVIAL 
-treated O 
groups O 
exhibited O 
downregulated O 
protein O 
expressions O 
of O 
α-smooth O 
muscle O 
actin O 
, O 
vimentin O 
, O 
hydroxyproline B-SYSTEMATIC 
, O 
and O 
B O 
cell O 
lymphoma O 
/ O 
leukemia-2 O 
as O 
well O 
as O 
upregulated O 
protein O 
expressions O 
of O 
E-cadherin O 
and O 
p53 O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
Astaxanthin B-TRIVIAL 
also O 
inhibited O 
the O 
proliferation O 
of O 
activated O 
A549 O 
and O 
MRC-5 O 
cells O 
at O 
median O 
inhibitory O 
concentrations O 
of O 
40 O 
and O 
30μM O 
, O 
respectively O 
. O 
In O 
conclusion O 
, O 
astaxanthin B-TRIVIAL 
could O 
relieve O 
the O 
symptoms O 
and O 
halt O 
the O 
progression O 
of O 
pulmonary O 
fibrosis O 
, O 
partly O 
by O 
preventing O 
transdifferentiation O 
, O 
inhibiting O 
proliferation O 
, O 
and O 
promoting O 
apoptosis O 
of O 
activated O 
cells O 
. O 

between O 
the O 
Fusarium O 
toxin O 
deoxynivalenol B-TRIVIAL 
and O 
lipopolysaccharides O 
on O 
the O 
in O 
vivo O 
protein O 
synthesis O 
of O 
acute O 
phase O 
proteins O 
, O 
cytokines O 
and O 
metabolic O 
activity O 
of O 
peripheral O 
blood O 
mononuclear O 
cells O 
in O 
pigs O 
. O 

in O 
vivo O 
effects O 
of O 
the O 
Fusarium O 
toxin O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
on O 
albumin O 
and O 
fibrinogen O 
synthesis O 
in O 
pigs O 
and O 
metabolic O 
activity O 
of O 
porcine O 
peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMCs O 
) O 
were O 
studied O 
alone O 
or O 
in O 
combination O 
with O 
lipopolysaccharides O 
( O 
LPSs O 
) O 
in O 
order O 
to O 
examine O 
proposed O 
synergistic O 
effects O 
of O 
both O 
substances O 
. O 
A O 
total O 
of O 
36 O 
male O 
castrated O 
pigs O 
( O 
initial O 
weight O 
of O 
26kg O 
) O 
were O 
used O 
. O 
Uncontaminated O 
( O 
Control O 
) O 
and O 
naturally O 
DON B-ABBREVIATION 
-contaminated O 
( O 
chronic O 
oral O 
DON B-ABBREVIATION 
, O 
3.1mg O 
/ O 
kg O 
diet O 
) O 
wheat O 
was O 
fed O 
for O 
37days O 
. O 
On O 
the O 
day O 
of O 
protein O 
synthesis O 
measurement O 
, O 
pigs O 
recruited O 
from O 
the O 
Control O 
group O 
were O 
treated O 
once O 
intravenously O 
with O 
(iv) O 
DON B-ABBREVIATION 
( O 
100μg O 
/ O 
kg O 
live O 
weight O 
( O 
LW O 
) O 
/ O 
h O 
) O 
, O 
iv O 
LPS O 
( O 
7.5μg O 
/ O 
kgLW O 
/ O 
h O 
) O 
or O 
a O 
combination O 
of O 
both O 
substances O 
, O 
and O 
six O 
pigs O 
from O 
the O 
chronic O 
oral O 
group O 
were O 
treated O 
once O 
with O 
iv O 
LPS O 
. O 
A O 
treatment O 
with O 
DON B-ABBREVIATION 
alone O 
exhibited O 
no O 
alterations O 
of O 
acute O 
phase O 
protein O 
synthesis O 
and O 
metabolic O 
activity O 
of O 
PBMC O 
. O 
There O 
was O 
no O 
evidence O 
that O 
the O 
chosen O 
dosing O 
regimen O 
of O 
DON B-ABBREVIATION 
had O 
influences O 
on O 
the O 
induced O 
sub O 
- O 
acute O 
stage O 
of O 
sepsis O 
, O 
as O 
the O 
LPS O 
challenge O 
, O 
irrespective O 
of O 
DON B-ABBREVIATION 
co O 
- O 
exposure O 
, O 
mediated O 
an O 
acute O 
phase O 
reaction O 
with O 
a O 
typical O 
decrease O 
of O 
albumin O 
synthesis O 
, O 
as O 
well O 
as O 
changes O 
in O 
cytokine O 
concentration O 
and O 
a O 
loss O 
of O 
metabolic O 
activity O 
in O 
PBMC O 
. O 

of O 
ALDH2 O 
with O 
ethanol B-SYSTEMATIC 
attenuates O 
diabetes O 
induced O 
myocardial O 
injury O 
in O 
rats O 
. O 

study O 
assessed O 
changes O 
in O 
myocardial O 
ALDH2 O 
expression O 
in O 
the O 
diabetic O 
rat O 
, O 
in O 
particular O 
the O 
diabetic O 
rat O 
pretreated O 
with O 
ALDH2 O 
activator O 
ethanol B-SYSTEMATIC 
( O 
EtOH B-FORMULA 
) O 
. O 
The O 
rats O 
were O 
divided O 
into O 
six O 
groups O 
: O 
control O 
, O 
EtOH B-FORMULA 
control O 
, O 
diabetic O 
rat O 
at O 
4th O 
week O 
( O 
DM4W O 
) O 
, O 
8th O 
week O 
( O 
DM8W O 
) O 
, O 
12th O 
week O 
( O 
DM12W O 
) O 
and O 
EtOH B-FORMULA 
+ O 
DM8W O 
groups O 
. O 
Compared O 
with O 
control O 
group O 
, O 
fasting O 
blood O 
glucose B-TRIVIAL 
( O 
FBG O 
) O 
and O 
glycosylated O 
hemoglobin O 
( O 
HbA1c O 
) O 
levels O 
were O 
increased O 
in O 
DM O 
groups O 
. O 
HbA1c O 
level O 
in O 
DM12W O 
group O 
was O 
higher O 
than O 
in O 
DM4W O 
group O 
, O 
HbA1c O 
level O 
in O 
EtOH B-FORMULA 
+ O 
DM8W O 
group O 
was O 
lower O 
than O 
in O 
DM8W O 
group O 
. O 
Compared O 
with O 
control O 
group O 
, O 
there O 
were O 
no O 
changes O 
of O 
LVDP O 
, O 
HR O 
and O 
±dp O 
/ O 
dtmax O 
in O 
DM4W O 
group O 
, O 
but O 
there O 
were O 
decreased O 
in O 
DM8W O 
and O 
DM12W O 
groups O 
, O 
and O 
increased O 
in O 
the O 
EtOH B-FORMULA 
+ O 
DM8W O 
group O 
. O 
In O 
DM O 
groups O 
, O 
SOD O 
activity O 
, O 
ALDH2 O 
mRNA O 
and O 
protein O 
levels O 
were O 
reduced O 
, O 
MDA B-ABBREVIATION 
content O 
was O 
increased O 
compared O 
with O 
control O 
group O 
; O 
which O 
decreased O 
further O 
as O 
diabetes O 
progressed O 
. O 
Compared O 
with O 
DM8W O 
group O 
, O 
SOD O 
and O 
ALDH2 O 
in O 
EtOH B-FORMULA 
+ O 
DM8W O 
group O 
was O 
increased O 
, O 
MDA B-ABBREVIATION 
was O 
decreased O 
. O 
Our O 
results O 
indicated O 
with O 
the O 
development O 
of O 
diabetes O 
, O 
myocardial O 
ALDH2 O 
expression O 
was O 
further O 
decreased O 
accompanying O 
decreased O 
ventricular O 
function O 
. O 
However O 
, O 
activation O 
of O 
ALDH2 O 
can O 
decrease O 
diabetes O 
induced O 
myocardial O 
injury O 
. O 
ALDH2 O 
may O 
be O 
one O 
key O 
endogenous O 
cardiac O 
protective O 
factor O 
in O 
diabetic O 
individuals O 
. O 

, O 
we O 
investigated O 
whether O 
hirsutenone B-TRIVIAL 
, O 
a O 
compound O 
isolated O 
from O 
Alnus O 
japonica O 
, O 
was O 
able O 
to O 
attenuate O 
oxidative O 
stress O 
- O 
induced O 
death O 
in O 
transformed O 
retinal O 
ganglion O 
( O 
RGC-5 O 
) O 
cells O 
. O 
Hirsutenone O 
effectively O 
protected O 
RGC-5 O 
cells O 
from O 
oxidative O 
insult O 
induced O 
by O 
, O 
l-buthionine-(S,R)-sulfoximine B-SYSTEMATIC 
( O 
BSO B-ABBREVIATION 
) O 
plus O 
glutamate B-TRIVIAL 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
as O 
demonstrated O 
by O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
/ O 
Hoechst O 
33342 O 
double O 
staining O 
, O 
flow O 
cytometry O 
, O 
and O 
MTT B-ABBREVIATION 
assays O 
. O 
Moreover O 
, O 
hirsutenone B-TRIVIAL 
inhibited O 
the O 
increase O 
in O 
apoptotic O 
protein O 
expression O 
resulting O 
from O 
BSO B-ABBREVIATION 
plus O 
glutamate O 
. O 
Hirsutenone B-TRIVIAL 
also O 
effectively O 
inhibited O 
sodium B-SYSTEMATIC 
nitroprusside I-SYSTEMATIC 
( O 
SNP B-ABBREVIATION 
)-induced O 
lipid O 
peroxidation O 
in O 
rat O 
brain O 
homogenates O 
. O 
To O 
investigate O 
the O 
effects O 
of O 
hirsutenone B-TRIVIAL 
in O 
vivo O 
, O 
we O 
used O 
N-methyl-d-aspartate B-SYSTEMATIC 
( O 
NMDA B-ABBREVIATION 
) O 
as O 
a O 
negative O 
insult O 
on O 
the O 
retinas O 
of O 
rats O 
. O 
NMDA B-ABBREVIATION 
affects O 
the O 
thinning O 
of O 
the O 
inner O 
plexiform O 
layer O 
( O 
IPL O 
) O 
and O 
causes O 
an O 
increase O 
in O 
the O 
number O 
of O 
terminal O 
deoxynucleotidyl O 
transferase O 
- O 
mediated O 
dUTP B-ABBREVIATION 
nick O 
- O 
end O 
labeling O 
(TUNEL)-positive O 
ganglion O 
cells O 
in O 
the O 
ganglion O 
cell O 
layer O 
( O 
GCL O 
) O 
. O 
Hirsutenone B-TRIVIAL 
treatment O 
led O 
to O 
a O 
reduction O 
in O 
NMDA B-ABBREVIATION 
-induced O 
IPL O 
and O 
TUNEL O 
staining O 
of O 
the O 
GCL O 
. O 
In O 
conclusion O 
, O 
hirsutenone B-TRIVIAL 
isolated O 
from O 
A O 
. O 
japonica O 
may O 
act O 
as O 
neuroprotective O 
agent O 
for O 
conditions O 
such O 
as O 
glaucoma O 
. O 

and O 
anticancer O 
activity O 
of O 
novel O 
2-pyridyl B-SYSTEMATIC 
hexahyrocyclooctathieno[2,3-d]pyrimidine I-SYSTEMATIC 
derivatives O 
. O 

series O 
of O 
new O 
2-pyridyl B-FAMILY 
hexahydrocycloocta I-FAMILY 
[4,5]thieno[2,3-d]pyrimidines I-FAMILY 
with O 
different O 
substituents O 
as O 
C-4 O 
position O 
was O 
synthesized O 
. O 
The O 
anticancer O 
activity O 
of O 
the O 
newly O 
synthesized O 
compounds O 
was O 
tested O 
in O 
vitro O 
using O 
a O 
two O 
- O 
stage O 
process O 
utilizing O 
60 O 
different O 
human O 
tumor O 
cell O 
lines O 
representing O 
leukemia O 
, O 
melanoma O 
and O 
cancers O 
of O 
lung O 
, O 
colon O 
, O 
central O 
nervous O 
system O 
, O 
ovary O 
, O 
kidney O 
, O 
prostate O 
as O 
well O 
as O 
breast O 
. O 
Compounds O 
4a O 
, O 
6a O 
, O 
7a O 
, O 
7d O 
and O 
7g O 
showed O 
potent O 
anticancer O 
activity O 
at O 
low O 
concentrations O 
against O 
most O 
of O 
the O 
used O 
human O 
tumor O 
cell O 
lines O 
comparable O 
with O 
doxorubicin B-TRIVIAL 
as O 
standard O 
potent O 
anticancer O 
drug O 
( O 
average O 
log10 O 
GI50 O 
over O 
all O 
cell O 
lines O 
= O 
-6.85 O 
) O 
. O 
Also O 
, O 
compound O 
4b O 
was O 
selective O 
against O 
SNB-75 O 
( O 
CNS O 
cancer O 
) O 
log10 O 
GI50 O 
= O 
-5.57 O 
. O 
Interestingly O 
, O 
compound O 
7e O 
exhibited O 
promising O 
selectivity O 
against O 
13 O 
tumor O 
cell O 
lines O 
showing O 
growth O 
inhibition O 
percentages O 
between O 
54.05 O 
and O 
89.23 O 
. O 

and O 
antibacterial O 
evaluation O 
of O 
novel O 
pleuromutilin B-TRIVIAL 
derivatives O 
. O 

series O 
of O 
novel O 
pleuromutilin B-TRIVIAL 
derivatives O 
possessing O 
thioether O 
moiety O 
has O 
been O 
synthesized O 
via O 
acylation O 
reaction O 
under O 
mild O 
conditions O 
. O 
Their O 
in O 
vitro O 
antibacterial O 
activity O 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
, O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
epidermidis O 
, O 
Escherichia O 
coli O 
, O 
and O 
Streptococcus O 
agalactiae O 
were O 
tested O 
by O 
agar O 
dilution O 
method O 
and O 
Oxford O 
cup O 
assay O 
. O 
Among O 
the O 
17 O 
compounds O 
screened O 
, O 
14-O-[(4-methoxybenzamide-2- B-SYSTEMATIC 
methylpropane-2-yl I-SYSTEMATIC 
) I-SYSTEMATIC 
thioacetate I-SYSTEMATIC 
] I-SYSTEMATIC 
mutilin I-SYSTEMATIC 
4i O 
, O 
14-O-[(2-aminobenzamide-2-methylpropane-2-yl) B-SYSTEMATIC 
thioacetate I-SYSTEMATIC 
] I-SYSTEMATIC 
mutilin I-SYSTEMATIC 
5a O 
and O 
14-O-[(4-aminobenzamide-2-methylpropane-2-yl) B-SYSTEMATIC 
thioacetate I-SYSTEMATIC 
] I-SYSTEMATIC 
mutilin I-SYSTEMATIC 
5c O 
were O 
resulted O 
as O 
most O 
active O 
antibacterial O 
agents O 
. O 

of O 
ABCB1 O 
, O 
NFKB1 O 
, O 
CYP3A O 
, O 
and O 
NR1I2 O 
polymorphisms O 
with O 
cyclosporine B-TRIVIAL 
trough O 
concentrations O 
in O 
Chinese O 
renal O 
transplant O 
recipients O 
. O 

: O 
Cyclosporine B-TRIVIAL 
requires O 
close O 
therapeutic O 
drug O 
monitoring O 
because O 
of O 
its O 
narrow O 
therapeutic O 
index O 
and O 
marked O 
inter O 
- O 
individual O 
pharmacokinetic O 
variation O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
associations O 
of O 
CYP3A4 O 
, O 
CYP3A5 O 
, O 
ABCB1 O 
, O 
NFKB1 O 
, O 
and O 
NR1I2 O 
polymorphisms O 
with O 
cyclosporine B-TRIVIAL 
concentrations O 
in O 
Chinese O 
renal O 
transplant O 
recipients O 
in O 
the O 
early O 
period O 
after O 
renal O 
transplantation.Methods O 
: O 
A O 
total O 
of O 
101 O 
renal O 
transplant O 
recipients O 
receiving O 
cyclosporine B-TRIVIAL 
were O 
genotyped O 
for O 
CYP3A4(*)1G O 
, O 
CYP3A5(*)3 O 
, O 
ABCB1 O 
C1236T O 
, O 
G2677T O 
/ O 
A O 
, O 
C3435T O 
, O 
NFKB1 O 
-94 O 
ins O 
/ O 
del O 
ATTG O 
, O 
and O 
NR1I2 O 
polymorphisms O 
. O 
Cyclosporine B-TRIVIAL 
whole O 
blood O 
levels O 
were O 
measured O 
by O 
a O 
fluorescence O 
polarization O 
immunoassay O 
. O 
Trough O 
concentrations O 
of O 
cyclosporine B-TRIVIAL 
were O 
determined O 
for O 
days O 
7-18 O 
following O 
transplantation.Results O 
: O 
The O 
dose O 
- O 
adjusted O 
trough O 
concentration O 
( O 
C0 O 
) O 
of O 
cyclosporine B-TRIVIAL 
in O 
ABCB1 O 
2677 O 
TT O 
carriers O 
was O 
significantly O 
higher O 
than O 
that O 
in O 
GG O 
carriers O 
together O 
with O 
GT O 
carriers O 
[ O 
90.4±24.5 O 
vs O 
67.8±26.8 O 
( O 
ng O 
/ O 
mL O 
) O 
/ O 
( O 
mg O 
/ O 
kg O 
) O 
, O 
P=0.001 O 
] O 
. O 
ABCB1 O 
3435 O 
TT O 
carriers O 
had O 
a O 
significantly O 
higher O 
dose O 
- O 
adjusted O 
C0 O 
of O 
cyclosporine B-TRIVIAL 
than O 
CC O 
carriers O 
together O 
with O 
CT O 
carriers O 
[ O 
92.0±24.0 O 
vs O 
68.4±26.5 O 
( O 
ng O 
/ O 
mL O 
) O 
/ O 
( O 
mg O 
/ O 
kg O 
) O 
, O 
P=0.002 O 
] O 
. O 
Carriers O 
of O 
the O 
ABCB1 O 
1236TT-2677TT-3435TT O 
haplotype O 
had O 
a O 
considerably O 
higher O 
CsA O 
C0 O 
/ O 
D O 
than O 
carriers O 
of O 
other O 
genotypes O 
[ O 
97.2±21.8 O 
vs O 
68.7±26.9 O 
( O 
ng O 
/ O 
mL O 
) O 
/ O 
( O 
mg O 
/ O 
kg O 
) O 
, O 
P=0.001 O 
] O 
. O 
Among O 
non-carriers O 
of O 
the O 
ABCB1 O 
2677 O 
TT O 
and O 
3435 O 
TT O 
genotypes O 
, O 
patients O 
with O 
the O 
NFKB1 O 
-94 O 
ATTG O 
ins O 
/ O 
ins O 
genotype O 
had O 
a O 
significantly O 
higher O 
dose O 
- O 
adjusted O 
C0 O 
than O 
those O 
with O 
the O 
-94 O 
ATTG O 
del O 
/ O 
del O 
genotype O 
[ O 
75.9±32.9 O 
vs O 
55.1±15.1 O 
( O 
ng O 
/ O 
mL O 
) O 
/ O 
( O 
mg O 
/ O 
kg O 
) O 
, O 
P=0.026].Conclusion:These O 
results O 
illustrate O 
that O 
the O 
ABCB1 O 
and O 
NFKB1 O 
genotypes O 
are O 
closely O 
correlated O 
with O 
cyclosporine B-TRIVIAL 
trough O 
concentrations O 
, O 
suggesting O 
that O 
these O 
SNPs O 
are O 
useful O 
for O 
determining O 
the O 
appropriate O 
dose O 
of O 
cyclosporine B-TRIVIAL 
. O 

administration O 
has O 
the O 
potential O 
to O 
improve O 
therapeutics O 
delivery O 
, O 
providing O 
an O 
approach O 
that O 
is O 
safer O 
and O 
more O 
convenient O 
than O 
traditional O 
alternatives O 
, O 
while O 
offering O 
the O 
opportunity O 
for O 
improved O 
therapeutic O 
efficacy O 
through O 
sustained O 
/ O 
controlled O 
drug O 
release O 
. O 
To O 
this O 
end O 
, O 
we O 
demonstrate O 
a O 
microneedle O 
materials O 
platform O 
for O 
rapid O 
implantation O 
of O 
controlled O 
- O 
release O 
polymer O 
depots O 
into O 
the O 
cutaneous O 
tissue O 
. O 
Arrays O 
of O 
microneedles O 
comprised O 
of O 
drug O 
- O 
loaded O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
microparticles O 
or O 
solid O 
PLGA B-ABBREVIATION 
tips O 
were O 
prepared O 
with O 
a O 
supporting O 
and O 
rapidly O 
water O 
- O 
soluble O 
poly(acrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PAA B-ABBREVIATION 
) O 
matrix O 
. O 
Upon O 
application O 
of O 
microneedle O 
patches O 
to O 
the O 
skin O 
of O 
mice O 
, O 
the O 
microneedles O 
perforated O 
the O 
stratum O 
corneum O 
and O 
epidermis O 
. O 
Penetration O 
of O 
the O 
outer O 
skin O 
layers O 
was O 
followed O 
by O 
rapid O 
dissolution O 
of O 
the O 
PAA B-ABBREVIATION 
binder O 
on O 
contact O 
with O 
the O 
interstitial O 
fluid O 
of O 
the O 
epidermis O 
, O 
implanting O 
the O 
microparticles O 
or O 
solid O 
polymer O 
microneedles O 
in O 
the O 
tissue O 
, O 
which O 
were O 
retained O 
following O 
patch O 
removal O 
. O 
These O 
polymer O 
depots O 
remained O 
in O 
the O 
skin O 
for O 
weeks O 
following O 
application O 
and O 
sustained O 
the O 
release O 
of O 
encapsulated O 
cargos O 
for O 
systemic O 
delivery O 
. O 
To O 
show O 
the O 
utility O 
of O 
this O 
approach O 
we O 
demonstrated O 
the O 
ability O 
of O 
these O 
composite O 
microneedle O 
arrays O 
to O 
deliver O 
a O 
subunit O 
vaccine O 
formulation O 
. O 
In O 
comparison O 
to O 
traditional O 
needle O 
- O 
based O 
vaccination O 
, O 
microneedle O 
delivery O 
gave O 
improved O 
cellular O 
immunity O 
and O 
equivalent O 
generation O 
of O 
serum O 
antibodies O 
, O 
suggesting O 
the O 
potential O 
of O 
this O 
approach O 
for O 
vaccine O 
delivery O 
. O 
However O 
, O 
the O 
flexibility O 
of O 
this O 
system O 
should O 
allow O 
for O 
improved O 
therapeutic O 
delivery O 
in O 
a O 
variety O 
of O 
diverse O 
contexts O 
. O 

- O 
charged O 
complexes O 
of O 
(8S,9R)-tert-butylcarbamoylquinine B-SYSTEMATIC 
( O 
tBuCQN B-ABBREVIATION 
) O 
, O 
N-3,5-dinitrobenzoyl-(S,R)-leucine B-SYSTEMATIC 
( O 
DNB B-ABBREVIATION 
- O 
S B-TRIVIAL 
/ I-TRIVIAL 
R-leucine I-TRIVIAL 
) O 
, O 
and O 
alkali O 
metal O 
counter O 
ions O 
( O 
Li(+) B-FORMULA 
, O 
Na(+) B-FORMULA 
, O 
K(+) B-FORMULA 
) O 
were O 
investigated O 
by O 
density O 
- O 
functional O 
theory O 
. O 
It O 
is O 
shown O 
that O 
the O 
cations O 
prefer O 
formation O 
of O 
an O 
ionic O 
pair O 
with O 
the O 
carboxylate B-SYSTEMATIC 
group O 
of O 
DNB B-ABBREVIATION 
- O 
Leu B-FORMULA 
over O 
the O 
formation O 
of O 
a O 
cation-π O 
interaction O 
. O 
The O 
[ B-FORMULA 
tBuCQN·DNB-S I-FORMULA 
/ I-FORMULA 
R-Leu·Na](+ I-FORMULA 
) I-FORMULA 
complex O 
is O 
bound O 
by O 
a O 
coulombic O 
attraction O 
, O 
a O 
hydrogen O 
bond O 
, O 
a O 
π-π O 
interaction O 
and O 
van O 
der O 
Waals O 
forces O 
. O 
The O 
tBuCQN B-ABBREVIATION 
chiral O 
selector O 
preferentially O 
complexes O 
with O 
the O 
DNB B-ABBREVIATION 
- O 
S-Leu B-FORMULA 
enantiomer O 
, O 
because O 
the O 
favourable O 
stereochemistry O 
allows O 
the O 
stabilization O 
of O 
the O 
complex O 
by O 
at O 
least O 
one O 
binding O 
mode O 
more O 
compared O 
to O 
the O 
complex O 
containing O 
the O 
DNB B-ABBREVIATION 
- O 
R-Leu B-FORMULA 
molecule O 
. O 
Weakening O 
of O 
the O 
binding O 
modes O 
is O 
observed O 
using O 
the O 
lithium B-SYSTEMATIC 
counter O 
ion O 
compared O 
to O 
the O 
sodium B-SYSTEMATIC 
one O 
. O 
The O 
weakening O 
is O 
more O 
pronounced O 
in O 
[tBuCQN·DNB-R-Leu·Li](+) B-FORMULA 
than O 
in O 
[tBuCQN·DNB-S-Leu·Li](+) B-FORMULA 
. O 
The O 
exact O 
opposite O 
effect O 
is O 
observed O 
using O 
the O 
potassium B-SYSTEMATIC 
counter O 
ion O 
. O 
Hence O 
, O 
the O 
lithium B-SYSTEMATIC 
counter O 
ion O 
enhances O 
the O 
enantioselectivity O 
of O 
tBuCQN B-ABBREVIATION 
while O 
the O 
potassium B-SYSTEMATIC 
counter O 
ion O 
reduces O 
the O 
enantioselectivity O 
of O 
tBuCQN B-ABBREVIATION 
. O 

of O 
new O 
1,3,4-benzotriazepin-5-one B-SYSTEMATIC 
derivatives O 
and O 
their O 
biological O 
evaluation O 
as O 
antitumor O 
agents O 
. O 

derivatives O 
of O 
1,3,4-benzotriazepin-5-one B-SYSTEMATIC 
were O 
designed O 
and O 
synthesized O 
as O 
structural O 
analogues O 
to O 
the O 
antitumor O 
agents O 
devazepide B-TRIVIAL 
and O 
asperlicin B-TRIVIAL 
. O 
An O 
efficient O 
and O 
novel O 
approach O 
to O 
the O 
synthesis O 
of O 
2-amino-1,3,4-benzotriazepin-5-one B-SYSTEMATIC 
2 O 
was O 
developed O 
and O 
its O 
structure O 
was O 
confirmed O 
. O 
The O 
newly O 
synthesized O 
derivatives O 
were O 
evaluated O 
for O 
their O 
in O 
vitro O 
antitumor O 
activity O 
on O 
60 O 
different O 
cell O 
lines O 
. O 
Compounds O 
8 O 
and O 
9 O 
displayed O 
the O 
most O 
potent O 
antitumor O 
activity O 
against O 
several O 
cell O 
lines O 
specifically O 
ovarian O 
cancer O 
, O 
renal O 
cancer O 
and O 
prostate O 
cancer O 
, O 
while O 
compounds O 
5 O 
, O 
10 O 
and O 
12 O 
showed O 
significant O 
activities O 
against O 
UO-31 O 
renal O 
cancer O 
cell O 
line O 
. O 

current O 
review O 
covers O 
extant O 
literature O 
on O 
pharmacotherapy O 
for O 
core O 
symptoms O 
of O 
autism O 
. O 
The O 
core O 
symptoms O 
of O 
autism O 
include O 
impairments O 
in O 
social O 
interaction O 
and O 
communication O 
, O 
as O 
well O 
as O 
the O 
presence O 
of O 
restricted O 
and O 
repetitive O 
behaviors O 
. O 
There O 
are O 
no O 
known O 
efficacious O 
treatments O 
for O 
the O 
core O 
social O 
symptoms O 
, O 
although O 
effects O 
on O 
repetitive O 
behaviors O 
are O 
indicated O 
with O 
some O 
data O 
. O 
While O 
studies O 
of O 
fenfluramine B-TRIVIAL 
, O 
secretin O 
, O 
opiates O 
, O 
and O 
mood O 
stabilizers O 
generally O 
find O 
no O 
effect O 
, O 
mixed O 
results O 
suggest O 
more O 
research O 
is O 
needed O 
on O 
antidepressants O 
and O 
atypical O 
antipsychotics O 
. O 
Newer O 
lines O 
of O 
research O 
, O 
including O 
cholinergic O 
and O 
glutamatergic O 
agents O 
and O 
oxytocin B-TRIVIAL 
, O 
will O 
be O 
of O 
considerable O 
interest O 
in O 
the O 
future O 
. O 
However O 
, O 
research O 
on O 
the O 
treatment O 
of O 
core O 
symptoms O 
is O 
plagued O 
by O 
limitations O 
in O 
study O 
design O 
, O 
statistical O 
power O 
, O 
and O 
other O 
issues O 
inherent O 
to O 
the O 
study O 
of O 
treatments O 
for O 
autism O 
( O 
e.g O 
. O 
, O 
heterogeneity O 
of O 
the O 
disorder O 
) O 
that O 
continue O 
to O 
prevent O 
the O 
elucidation O 
of O 
efficacious O 
treatments O 
. O 

photoinduced O 
solid O 
- O 
state O 
SO2 B-FORMULA 
isomerism O 
drives O 
a O 
larger O 
mechanical O 
change O 
( O 
benzene B-SYSTEMATIC 
-ring O 
rotation O 
) O 
in O 
a O 
neighbouring O 
ion O 
( O 
i.e O 
. O 
, O 
the O 
system O 
acts O 
as O 
a O 
solar O 
- O 
powered O 
molecular O 
transducer O 
) O 
. O 
The O 
ring O 
rotation O 
and O 
SO2 B-FORMULA 
photoisomerisation O 
are O 
observed O 
using O 
in O 
situ O 
X-ray O 
crystallography O 
and O 
are O 
controllable O 
, O 
reproducible O 
, O 
and O 
metastable O 
at O 
low O 
temperatures O 
. O 
This O 
discovery O 
presents O 
a O 
new O 
range O 
of O 
materials O 
for O 
solar O 
- O 
energy O 
- O 
based O 
molecular O 
transduction O 
. O 

Effect O 
of O 
Ketoconazole B-TRIVIAL 
on O 
the O 
Pharmacokinetics O 
of O 
a O 
Multireceptor O 
Tyrosine B-TRIVIAL 
Kinase O 
Inhibitor O 
BMS-690514 B-IDENTIFIER 
in O 
Healthy O 
Participants O 
: O 
Assessing O 
the O 
Mechanism O 
of O 
the O 
Interaction O 
With O 
Physiologically O 
- O 
Based O 
Pharmacokinetic O 
Simulations O 
. O 

, O 
a O 
selective O 
inhibitor O 
of O 
the O 
ErbB O 
and O 
vascular O 
endothelial O 
growth O 
factor O 
receptors O 
, O 
has O 
shown O 
antitumor O 
activity O 
in O 
early O 
clinical O 
development O 
. O 
The O 
compound O 
is O 
metabolized O 
by O 
multiple O 
enzymes O 
, O 
with O 
CYP3A4 O 
responsible O 
for O 
the O 
largest O 
fraction O 
( O 
34% O 
) O 
of O 
metabolism O 
. O 
It O 
is O 
also O 
a O 
substrate O 
of O 
P-glycoprotein O 
( O 
P-gp O 
) O 
in O 
vitro O 
. O 
To O 
assess O 
the O 
effect O 
of O 
ketoconazole B-TRIVIAL 
on O 
BMS-690514 B-IDENTIFIER 
pharmacokinetics O 
, O 
17 O 
healthy O 
volunteers O 
received O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
followed O 
by O 
100 O 
mg O 
BMS-690514 B-IDENTIFIER 
with O 
ketoconazole B-TRIVIAL 
( O 
400 O 
mg O 
once O 
daily O 
for O 
4 O 
days O 
) O 
. O 
The O 
AUC∞ O 
of O 
100 O 
mg O 
BMS-690514 B-IDENTIFIER 
concomitantly O 
administered O 
with O 
ketoconazole B-TRIVIAL 
was O 
similar O 
to O 
that O 
of O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
. O 
The O 
dose O 
- O 
normalized O 
Cmax O 
and O 
AUC∞ O 
of O 
BMS-690514 B-IDENTIFIER 
from O 
the O 
100-mg O 
BMS-690514 B-IDENTIFIER 
/ O 
400-mg O 
ketoconazole B-TRIVIAL 
treatment O 
increased O 
by O 
55% O 
and O 
127% O 
, O 
respectively O 
, O 
relative O 
to O 
those O 
from O 
200 O 
mg O 
BMS-690514 B-IDENTIFIER 
alone O 
. O 
Prediction O 
of O 
the O 
drug O 
- O 
drug O 
interaction O 
( O 
DDI O 
) O 
using O 
a O 
population O 
- O 
based O 
simulator O 
( O 
Simcyp O 
) O 
indicated O 
that O 
, O 
in O 
addition O 
to O 
CYP3A4 O 
inhibition O 
, O 
the O 
inhibition O 
of O 
P-gp O 
by O 
ketoconazole B-TRIVIAL 
in O 
the O 
intestine O 
, O 
liver O 
, O 
and O 
kidneys O 
must O 
be O 
invoked O 
to O 
fully O 
account O 
for O 
the O 
DDI O 
observed O 
. O 
This O 
finding O 
suggests O 
that O 
the O 
inhibition O 
of O 
P-gp O 
by O 
ketoconazole B-TRIVIAL 
, O 
along O 
with O 
its O 
effect O 
on O 
CYP3A4 O 
, O 
needs O 
to O 
be O 
considered O 
when O 
designing O 
a O 
DDI O 
study O 
of O 
ketoconazole B-TRIVIAL 
with O 
a O 
victim O 
drug O 
that O 
is O 
a O 
dual O 
substrate O 
. O 

( O 
UV O 
) O 
irradiation O 
induces O 
photo O 
- O 
damage O 
of O 
the O 
skin O 
, O 
which O 
in O 
turn O 
causes O 
depletion O 
of O 
the O 
dermal O 
extracellular O 
matrix O 
and O 
chronic O 
alterations O 
in O 
skin O 
structure O 
. O 
Skin O 
wrinkle O 
formations O 
are O 
associated O 
with O 
collagen O 
synthesis O 
and O 
matrix O 
metalloproteinase O 
( O 
MMP O 
) O 
expression O 
. O 
The O 
production O 
of O 
type O 
I O 
procollagen O 
is O 
regulated O 
by O 
transforming O 
growth O 
factor-β1 O 
( O 
TGF-β1 O 
) O 
expression O 
; O 
the O 
activation O 
of O 
MMP O 
is O 
also O 
correlated O 
with O 
an O 
increase O 
of O 
interleukin-6 O 
( O 
IL-6 O 
) O 
. O 
Aloe O 
barbadensis O 
M O 
. O 
( O 
Aloe O 
vera O 
) O 
is O 
widely O 
used O 
in O 
cosmetic O 
and O 
pharmaceutical O 
products O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
whether O 
baby O 
aloe O 
shoot O 
extract O 
( O 
BAE O 
, O 
immature O 
aloe O 
extract O 
) O 
, O 
which O 
is O 
from O 
the O 
one O 
- O 
month O 
- O 
old O 
shoots O 
of O 
Aloe O 
vera O 
, O 
and O 
adult O 
aloe O 
shoot O 
extract O 
( O 
AE O 
) O 
, O 
which O 
is O 
from O 
the O 
four O 
- O 
month O 
- O 
old O 
shoots O 
of O 
Aloe O 
vera O 
, O 
have O 
a O 
protective O 
effect O 
on O 
UVB-induced O 
skin O 
photoaging O 
in O 
normal O 
human O 
dermal O 
fibroblasts O 
( O 
NHDFs O 
) O 
. O 
The O 
effects O 
of O 
BAE O 
and O 
AE O 
on O 
UVB-induced O 
photoaging O 
were O 
tested O 
by O 
measuring O 
the O 
levels O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
, O 
MMP-1 O 
, O 
MMP-3 O 
, O 
IL-6 O 
, O 
type O 
I O 
procollagen O 
, O 
and O 
TGF-β1 O 
after O 
UVB O 
irradiation O 
. O 
We O 
found O 
that O 
NHDF O 
cells O 
treated O 
with O 
BAE O 
after O 
UVB-irradiation O 
suppressed O 
MMP-1 O 
, O 
MMP-3 O 
, O 
and O 
IL-6 O 
levels O 
compared O 
to O 
the O 
AE O 
- O 
treated O 
cells O 
. O 
Furthermore O 
, O 
BAE O 
treatment O 
elevated O 
type O 
I O 
procollagen O 
and O 
TGF-β1 O 
levels O 
. O 
Our O 
results O 
suggest O 
that O 
BAE O 
may O 
potentially O 
protect O 
the O 
skin O 
from O 
UVB-induced O 
damage O 
more O 
than O 
AE O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

with O 
in O 
vitro O 
conditions O 
, O 
the O 
intracellular O 
environment O 
is O 
highly O 
crowded O 
with O 
biomolecules O 
; O 
this O 
has O 
numerous O 
effects O 
on O 
protein O 
functions O 
, O 
including O 
enzymatic O 
activity O 
. O 
We O 
examined O 
the O 
effects O 
of O 
macromolecular O 
crowding O 
on O 
glycan O 
processing O 
of O 
N B-FORMULA 
-glycoprotein O 
in O 
the O 
endoplasmic O 
reticulum O 
as O 
a O 
model O 
sequential O 
metabolic O 
pathway O 
. O 
Experiments O 
with O 
synthetic O 
substrates O 
of O 
physiological O 
glycan O 
structure O 
clearly O 
showed O 
that O 
the O 
first O 
half O 
of O 
the O 
pathway O 
( O 
glucose B-TRIVIAL 
trimming O 
) O 
was O 
accelerated O 
, O 
whereas O 
the O 
second O 
( O 
mannose B-TRIVIAL 
trimming O 
) O 
was O 
decelerated O 
under O 
molecular O 
crowding O 
conditions O 
. O 
Furthermore O 
, O 
calreticulin O 
, O 
a O 
lectin O 
- O 
like O 
molecular O 
chaperone O 
, O 
bound O 
more O 
strongly O 
to O 
a O 
glycan O 
- O 
processing O 
intermediate O 
under O 
these O 
conditions O 
. O 
This O 
study O 
demonstrates O 
the O 
diverse O 
effects O 
of O 
molecular O 
crowding O 
on O 
sequential O 
enzymatic O 
processing O 
, O 
and O 
the O 
importance O 
of O 
the O 
effects O 
of O 
macromolecular O 
crowding O 
on O 
in O 
vitro O 
assays O 
for O 
understanding O 
sequential O 
metabolic O 
pathways O 
. O 

computational O 
study O 
of O 
water O 
and O 
CO B-FORMULA 
migration O 
sites O 
and O 
channels O 
inside O 
myoglobin O 
. O 

are O 
computed O 
for O 
transport O 
of O 
H2O B-FORMULA 
and O 
CO B-FORMULA 
in O 
myoglobin O 
( O 
Mb O 
) O 
, O 
using O 
the O 
single O 
sweep O 
and O 
zero O 
- O 
temperature O 
string O 
methods O 
in O 
a O 
fully O 
atomistic O 
, O 
explicitly O 
solvated O 
model O 
system O 
. O 
Our O 
predictions O 
of O 
sites O 
and O 
barriers O 
in O 
the O 
pathways O 
for O 
CO B-FORMULA 
transport O 
agree O 
with O 
previous O 
studies O 
. O 
For O 
H2O B-FORMULA 
, O 
we O 
predict O 
a O 
binding O 
site O 
in O 
the O 
distal O 
pocket O 
( O 
DP O 
) O 
, O 
in O 
agreement O 
with O 
crystallographic O 
observations O 
, O 
and O 
another O 
one O 
close O 
to O 
Leu B-FORMULA 
29 O 
which O 
explains O 
the O 
importance O 
of O 
this O 
residue O 
in O 
controlling O 
the O 
pocket's O 
hydrophobicity O 
, O 
as O 
well O 
as O 
disordered O 
minima O 
in O 
the O 
largely O 
apolar O 
xenon B-SYSTEMATIC 
cavities O 
. O 
In O 
particular O 
, O 
H2O B-FORMULA 
can O 
occupy O 
and O 
transition O 
among O 
the O 
xenon B-SYSTEMATIC 
cavities O 
, O 
Xe4 B-FORMULA 
, O 
Xe2 B-FORMULA 
, O 
and O 
Xe3 B-FORMULA 
. O 
Our O 
results O 
support O 
the O 
hypothesis O 
that O 
the O 
thermodynamically O 
most O 
favorable O 
entry O 
/ O 
exit O 
portal O 
for O 
H2O B-FORMULA 
is O 
the O 
so O 
- O 
called O 
histidine B-TRIVIAL 
gate O 
( O 
HG O 
) O 
, O 
the O 
same O 
as O 
for O 
CO B-FORMULA 
. O 
This O 
result O 
, O 
along O 
with O 
the O 
observation O 
of O 
water O 
occupation O 
of O 
both O 
DP O 
and O 
apolar O 
Xe B-FORMULA 
cavities O 
, O 
suggest O 
that O 
water O 
and O 
small O 
gas O 
molecules O 
like O 
CO B-FORMULA 
compete O 
for O 
access O 
to O 
the O 
protein O 
interior O 
, O 
and O 
therefore O 
models O 
of O 
gas O 
molecule O 
transport O 
within O 
proteins O 
should O 
also O 
explicitly O 
consider O 
water O 
transport O 
. O 

of O 
Nanosized O 
Ordered O 
Domains O 
in O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
and O 
DOPC B-ABBREVIATION 
/ O 
Ch O 
Binary O 
Lipid O 
Mixture O 
Systems O 
of O 
Large O 
Unilamellar O 
Vesicles O 
Using O 
a O 
TEMPO O 
Quenching O 
Method O 
. O 

ordered O 
domains O 
formed O 
in O 
1,2-dioleoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
/ O 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
) O 
and O 
DOPC B-ABBREVIATION 
/ O 
cholesterol B-TRIVIAL 
( O 
Ch O 
) O 
liposomes O 
were O 
characterized O 
using O 
a O 
newly O 
developed O 
(2,2,6,6-tetramethylpiperidin-1-yl)oxyl B-SYSTEMATIC 
( O 
TEMPO B-ABBREVIATION 
) O 
quenching O 
method O 
. O 
The O 
membrane O 
fluidity O 
of O 
the O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
liposomes O 
, O 
evaluated O 
by O 
the O 
use O 
of O 
1,6-diphenyl-1,3,5-hexatriene B-SYSTEMATIC 
( O 
DPH B-ABBREVIATION 
) O 
, O 
increased O 
significantly O 
above O 
their O 
phase O 
- O 
transition O 
temperature O 
. O 
The O 
fluorescence O 
spectra O 
of O 
6-lauroyl-2-dimethylamino B-SYSTEMATIC 
naphthalene I-SYSTEMATIC 
( O 
Laurdan B-ABBREVIATION 
) O 
indicated O 
the O 
formation O 
of O 
an O 
immiscible O 
ordered O 
phase O 
in O 
the O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
( O 
50 O 
/ O 
50 O 
) O 
liposomal O 
membrane O 
at O 
30 O 
°C O 
. O 
The O 
analysis O 
of O 
the O 
membrane O 
polarity O 
indicated O 
that O 
the O 
surface O 
of O 
the O 
liquid O 
- O 
disordered O 
phase O 
was O 
hydrated O 
whereas O 
that O 
of O 
the O 
ordered O 
phase O 
was O 
dehydrated O 
. O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
and O 
DOPC B-ABBREVIATION 
/ O 
Ch O 
( O 
70 O 
/ O 
30 O 
) O 
liposomes O 
exhibited O 
heterogeneous O 
membranes O 
, O 
indicating O 
that O 
nanosized O 
ordered O 
domains O 
formed O 
on O 
the O 
surface O 
of O 
the O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
liposomes O 
. O 
The O 
size O 
of O 
these O 
nanosized O 
ordered O 
domains O 
was O 
estimated O 
using O 
the O 
TEMPO B-ABBREVIATION 
quenching O 
method O 
. O 
Because O 
TEMPO B-ABBREVIATION 
can O 
quench O 
DPH B-ABBREVIATION 
distributed O 
in O 
the O 
disordered O 
phases O 
, O 
the O 
remaining O 
fluorescence O 
from O 
DPH B-ABBREVIATION 
is O 
proportional O 
to O 
the O 
size O 
of O 
the O 
ordered O 
domain O 
. O 
The O 
domain O 
sizes O 
calculated O 
for O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
( O 
50 O 
/ O 
50 O 
) O 
, O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
( O 
25 O 
/ O 
75 O 
) O 
, O 
DOPC B-ABBREVIATION 
/ O 
Ch O 
( O 
70 O 
/ O 
30 O 
) O 
, O 
and O 
DOPC B-ABBREVIATION 
/ O 
DPPC B-ABBREVIATION 
/ O 
Ch O 
( O 
40 O 
/ O 
40 O 
/ O 
20 O 
) O 
were O 
13.9 O 
, O 
36.2 O 
, O 
13.2 O 
, O 
and O 
35.5 O 
Å O 
, O 
respectively O 
. O 

compounds O 
such O 
as O 
glyoxals B-FAMILY 
, O 
which O 
are O 
toxic O 
due O 
to O 
their O 
reactive O 
carbonyl B-FAMILY 
group O 
, O 
are O 
generated O 
in O 
vivo O 
through O 
various O 
pathways O 
. O 
In O 
this O 
study O 
, O 
we O 
obtained O 
evidence O 
indicating O 
that O 
the O 
nemRA O 
operon O 
, O 
previously O 
reported O 
to O 
encode O 
a O 
repressor O 
and O 
the O 
N-ethylmaleimide B-SYSTEMATIC 
reductase O 
, O 
respectively O 
, O 
is O 
co O 
- O 
transcribed O 
with O 
the O 
3'-proximal O 
gloA O 
gene O 
encoding O 
glyoxalase O 
I O 
. O 
The O 
operon O 
is O 
not O 
only O 
involved O 
in O 
cytosolic O 
detoxification O 
but O 
is O 
also O 
regulated O 
by O 
electrophiles O 
such O 
as O 
quinones B-FAMILY 
and O 
glyoxals B-FAMILY 
. O 
A O 
gel O 
mobility O 
shift O 
assay O 
revealed O 
that O 
purified O 
NemR O 
repressor O 
bound O 
to O 
DNA O 
was O 
dissociated O 
upon O 
interaction O 
with O 
quinones B-FAMILY 
and O 
glyoxals B-FAMILY 
, O 
while O 
their O 
reduced O 
forms O 
were O 
ineffective O 
. O 
The O 
cysteines O 
of O 
NemR O 
at O 
21 O 
and O 
116 O 
were O 
essential O 
in O 
sensing O 
electrophiles O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 
Reversible O 
intermolecular O 
disulphide B-SYSTEMATIC 
bonds O 
were O 
observed O 
with O 
a O 
reducing O 
agent O 
as O 
well O 
as O 
with O 
electrophiles O 
. O 
DNA O 
binding O 
affinity O 
reduced O 
by O 
glyoxal B-TRIVIAL 
was O 
also O 
increased O 
with O 
a O 
reducing O 
agent O 
. O 
The O 
NemA O 
reductase O 
, O 
an O 
FMN B-ABBREVIATION 
-containing O 
enzyme O 
, O 
exhibited O 
catalytic O 
activity O 
toward O 
various O 
electrophiles O 
including O 
quinones B-FAMILY 
, O 
while O 
GloA O 
played O 
a O 
major O 
role O 
in O 
glyoxal B-TRIVIAL 
detoxification O 
. O 
Therefore O 
, O 
we O 
propose O 
that O 
cells O 
have O 
a O 
cytosolic O 
system O 
consisting O 
of O 
the O 
nemRA-gloA O 
operon O 
for O 
the O 
reduction O 
of O 
electrophiles O 
, O 
especially O 
quinones B-FAMILY 
and O 
glyoxals B-FAMILY 
, O 
to O 
maintain O 
an O 
appropriate O 
intracellular O 
redox O 
balance O 
. O 

shock O 
is O 
characterized O 
by O 
circulatory O 
compromise O 
, O 
microcirculatory O 
alterations O 
and O 
mitochondrial O 
damage O 
, O 
which O 
all O 
reduce O 
cellular O 
energy O 
production O 
. O 
In O 
order O 
to O 
reduce O 
the O 
risk O 
of O 
major O 
cell O 
death O 
and O 
a O 
diminished O 
likelihood O 
of O 
recovery O 
, O 
adaptive O 
changes O 
appear O 
to O 
be O 
activated O 
. O 
As O 
a O 
result O 
, O 
cells O 
and O 
organs O 
may O 
survive O 
in O 
a O 
non-functioning O 
hibernation O 
- O 
like O 
condition O 
. O 
Sepsis O 
- O 
induced O 
cardiac O 
dysfunction O 
may O 
represent O 
an O 
example O 
of O 
such O 
functional O 
shutdown O 
. O 
Sepsis O 
- O 
induced O 
myocardial O 
dysfunction O 
is O 
common O 
, O 
corresponds O 
to O 
the O 
severity O 
of O 
sepsis O 
, O 
and O 
is O 
reversible O 
in O 
survivors O 
. O 
Its O 
mechanisms O 
include O 
the O 
attenuation O 
of O 
the O 
adrenergic O 
response O 
at O 
the O 
cardiomyocyte O 
level O 
, O 
alterations O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
trafficking O 
and O 
blunted O 
calcium B-SYSTEMATIC 
sensitivity O 
of O 
contractile O 
proteins O 
. O 
All O 
these O 
changes O 
are O 
mediated O 
by O 
cytokines O 
. O 
Treatment O 
includes O 
preload O 
optimization O 
with O 
sufficient O 
fluids O 
. O 
However O 
, O 
excessive O 
volume O 
loading O 
is O 
harmful O 
. O 
The O 
first O 
line O 
vasopressor O 
recommended O 
at O 
present O 
is O 
norepinephrine B-TRIVIAL 
, O 
while O 
vasopressin O 
can O 
be O 
started O 
as O 
a O 
salvage O 
therapy O 
for O 
those O 
not O 
responding O 
to O 
catecholamines B-FAMILY 
. O 
During O 
early O 
sepsis O 
, O 
cardiac O 
output O 
can O 
be O 
increased O 
by O 
dobutamine B-TRIVIAL 
. O 
While O 
early O 
administration O 
of O 
catecholamines B-FAMILY 
might O 
be O 
necessary O 
to O 
restore O 
adequate O 
organ O 
perfusion O 
, O 
prolonged O 
administration O 
might O 
be O 
harmful O 
. O 
Novel O 
therapies O 
for O 
sepsis O 
- O 
induced O 
cardiac O 
dysfunction O 
are O 
discussed O 
in O 
this O 
article O 
. O 
Cardiac O 
inotropy O 
can O 
be O 
increased O 
by O 
levosimendan B-TRIVIAL 
, O 
istaroxime B-TRIVIAL 
or O 
omecamtiv B-TRIVIAL 
mecarbil I-TRIVIAL 
without O 
greatly O 
increasing O 
cellular O 
oxygen B-SYSTEMATIC 
demands O 
. O 
Heart O 
rate O 
reduction O 
with O 
ivabradine B-TRIVIAL 
reduces O 
myocardial O 
oxygen B-SYSTEMATIC 
expenditure O 
and O 
ameliorates O 
diastolic O 
filling O 
. O 
Beta-blockers O 
additionally O 
reduce O 
local O 
and O 
systemic O 
inflammation O 
. O 
Advances O 
may O 
also O 
come O 
from O 
metabolic O 
interventions O 
such O 
as O 
pyruvate B-TRIVIAL 
, O 
succinate B-TRIVIAL 
or O 
high O 
dose O 
insulin O 
substitutions O 
. O 
All O 
these O 
potentially O 
advantageous O 
concepts O 
require O 
rigorous O 
testing O 
before O 
implementation O 
in O 
routine O 
clinical O 
practice O 
. O 

novel O 
benzo[d]imidazole B-SYSTEMATIC 
derivate O 
prevents O 
the O 
development O 
of O 
dextran O 
sulfate O 
sodium B-SYSTEMATIC 
-induced O 
murine O 
experimental O 
colitis O 
via O 
inhibition O 
of O 
NLRP3 O 
inflammasome O 
. O 

inflammasome O 
has O 
been O 
reported O 
to O 
be O 
associated O 
with O 
various O 
kinds O 
of O 
immunological O 
diseases O 
including O 
colitis O 
. O 
However O 
, O 
there O 
are O 
few O 
drug O 
candidates O 
targeting O 
inflammasomes O 
for O 
the O 
treatment O 
of O 
colitis O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
aimed O 
at O 
examining O 
the O 
effect O 
of O 
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole B-SYSTEMATIC 
, O 
a O 
synthetic O 
small O 
molecular O 
compound O 
also O 
named O 
Fc11a-2 B-FORMULA 
, O 
for O 
the O 
treatment O 
of O 
dextran O 
sulfate B-SYSTEMATIC 
sodium B-SYSTEMATIC 
(DSS)-induced O 
experimental O 
colitis O 
in O 
mice O 
via O 
targeting O 
NLRP3 O 
inflammasome O 
. O 
Treatment O 
with O 
Fc11a-2 O 
dose O 
- O 
dependently O 
attenuated O 
the O 
loss O 
of O 
body O 
weight O 
and O 
shortening O 
of O 
colon O 
length O 
induced O 
by O 
DSS O 
. O 
In O 
addition O 
, O 
the O 
disease O 
activity O 
index O 
, O 
histopathologic O 
scores O 
and O 
myeloperoxidase O 
activity O 
were O 
also O 
significantly O 
reduced O 
by O 
Fc11a-2 B-FORMULA 
treatment O 
. O 
Moreover O 
, O 
protein O 
and O 
mRNA O 
levels O 
of O 
DSS-induced O 
proinflammatory O 
cytokines O 
in O 
colon O 
, O 
including O 
TNF-α O 
, O 
IL-1β O 
, O 
IL-18 O 
, O 
IL-17A O 
and O 
IFN-γ O 
, O 
were O 
markedly O 
suppressed O 
by O 
Fc11a-2 B-FORMULA 
. O 
Furthermore O 
, O 
a O 
decreased O 
CD11c(+) O 
macrophage O 
infiltration O 
in O 
colons O 
and O 
inactivation O 
of O 
caspase-1 O 
in O 
peritoneal O 
macrophages O 
were O 
detected O 
in O 
Fc11a B-FORMULA 
-2 O 
- O 
treated O 
mice O 
. O 
The O 
mechanism O 
of O 
action O 
of O 
Fc11a-2 B-FORMULA 
was O 
related O 
to O 
the O 
inhibition O 
of O 
the O 
cleavage O 
of O 
pro-caspase-1 O 
, O 
pro-IL-1β O 
and O 
pro-IL-18 O 
which O 
in O 
turn O 
suppressed O 
the O 
activation O 
of O 
NLRP3 O 
inflammasome O 
. O 
Taken O 
together O 
, O 
our O 
results O 
demonstrate O 
the O 
ability O 
of O 
Fc11a-2 B-FORMULA 
to O 
inhibit O 
NLRP3 O 
inflammasome O 
activation O 
and O 
its O 
potential O 
use O 
in O 
the O 
treatment O 
of O 
inflammatory O 
bowel O 
diseases O 
. O 

inhibitory O 
control O 
processes O 
in O 
abstinent O 
drug O 
abusers O 
(II) O 
: O 
A O 
high O 
- O 
density O 
electrical O 
mapping O 
study O 
in O 
former O 
cocaine B-TRIVIAL 
and O 
heroin B-TRIVIAL 
addicts O 
. O 

specificity O 
of O 
the O 
insulin O 
receptor O 
( O 
InsR O 
) O 
and O 
insulin O 
- O 
like O 
growth O 
factor-1 O 
receptor O 
( O 
IGF1R O 
) O 
signaling O 
pathways O 
has O 
been O 
the O 
focus O 
of O 
significant O 
debate O 
over O 
the O 
past O 
few O 
years O 
. O 
Recent O 
evidence O 
showing O 
nuclear O 
import O 
and O 
a O 
direct O 
transcriptional O 
role O 
for O 
both O 
InsR O 
and O 
IGF1R O 
adds O 
a O 
new O 
layer O 
of O 
complexity O 
to O 
this O 
dialog O 
. O 
Hence O 
, O 
in O 
addition O 
to O 
the O 
classical O 
roles O 
associated O 
with O 
cell O 
- O 
surface O 
receptors O 
( O 
eg O 
, O 
ligand O 
binding O 
, O 
autophosphorylation O 
of O 
the O 
tyrosine B-TRIVIAL 
kinase O 
domain O 
, O 
activation O 
of O 
insulin O 
receptor O 
substrate O 
1 O 
( O 
IRS-1 O 
) O 
and O 
additional O 
substrates O 
, O 
protein O 
- O 
protein O 
interactions O 
with O 
membrane O 
and O 
cytoplasm O 
components O 
) O 
, O 
new O 
data O 
are O 
consistent O 
with O 
nuclear O 
( O 
genomic O 
) O 
role(s) O 
for O 
both O 
InsR O 
and O 
IGF1R O 
. O 
The O 
present O 
review O 
provides O 
a O 
brief O 
overview O 
of O 
the O 
physical O 
and O 
functional O 
similarities O 
and O 
differences O 
between O 
InsR O 
and O 
IGF1R O 
and O 
describes O 
data O 
from O 
a O 
number O 
of O 
laboratories O 
providing O 
evidence O 
for O 
a O 
new O 
layer O 
of O 
signaling O 
regulation O 
( O 
ie O 
, O 
the O 
ability O 
of O 
InsR O 
and O 
IGF1R O 
to O 
translocate O 
to O 
the O 
cell O 
nucleus O 
and O 
to O 
elicit O 
genomic O 
activities O 
usually O 
associated O 
with O 
transcription O 
factors O 
) O 
. O 
The O 
ability O 
of O 
InsR O 
and O 
IGF1R O 
to O 
function O 
as O 
transcription O 
factors O 
, O 
although O 
poorly O 
understood O 
, O 
constitutes O 
a O 
new O 
paradigm O 
in O 
signal O 
transduction O 
. O 
Although O 
research O 
on O 
the O 
role O 
of O 
nuclear O 
InsR O 
/ O 
IGF1R O 
is O 
still O 
in O 
its O 
infancy O 
, O 
we O 
believe O 
that O 
this O 
rapidly O 
developing O 
area O 
may O 
have O 
a O 
major O 
basic O 
and O 
translational O 
impact O 
on O 
the O 
fields O 
of O 
metabolism O 
, O 
diabetes O 
, O 
and O 
cancer O 
. O 

functional O 
polymorphisms O 
in O 
the O 
G6PC2 O 
gene O 
contribute O 
to O 
the O 
association O 
with O 
higher O 
fasting O 
plasma O 
glucose B-TRIVIAL 
levels O 
. O 

/ O 
HYPOTHESIS O 
: O 
We O 
previously O 
identified O 
the O 
G6PC2 O 
locus O 
as O 
a O 
strong O 
determinant O 
of O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
and O 
showed O 
that O 
a O 
common O 
G6PC2 O 
intronic O 
single O 
nucleotide O 
polymorphism O 
( O 
SNP O 
) O 
( O 
rs560887 O 
) O 
and O 
two O 
common O 
G6PC2 O 
promoter O 
SNPs O 
( O 
rs573225 O 
and O 
rs13431652 O 
) O 
are O 
highly O 
associated O 
with O 
FPG O 
. O 
However O 
, O 
these O 
promoter O 
SNPs O 
have O 
complex O 
effects O 
on O 
G6PC2 O 
fusion O 
gene O 
expression O 
, O 
and O 
our O 
data O 
suggested O 
that O 
only O 
rs13431652 O 
is O 
a O 
potentially O 
causative O 
SNP O 
. O 
Here O 
we O 
examine O 
the O 
effect O 
of O 
rs560887 O 
on O 
G6PC2 O 
pre-mRNA O 
splicing O 
and O 
the O 
contribution O 
of O 
an O 
additional O 
common O 
G6PC2 O 
promoter O 
SNP O 
, O 
rs2232316 O 
, O 
to O 
the O 
association O 
signal O 
. O 
METHODS O 
: O 
Minigene O 
analyses O 
were O 
used O 
to O 
characterise O 
the O 
effect O 
of O 
rs560887 O 
on O 
G6PC2 O 
pre-mRNA O 
splicing O 
. O 
Fusion O 
gene O 
and O 
gel O 
retardation O 
analyses O 
characterised O 
the O 
effect O 
of O 
rs2232316 O 
on O 
G6PC2 O 
promoter O 
activity O 
and O 
transcription O 
factor O 
binding O 
. O 
The O 
genetic O 
association O 
of O 
rs2232316 O 
with O 
FPG O 
variation O 
was O 
assessed O 
using O 
regression O 
adjusted O 
for O 
age O 
, O 
sex O 
and O 
BMI O 
in O 
4220 O 
Europeans O 
with O 
normal O 
FPG O 
. O 
RESULTS O 
: O 
The O 
rs560887-G O 
allele O 
was O 
shown O 
to O 
enhance O 
G6PC2 O 
pre-mRNA O 
splicing O 
, O 
whereas O 
the O 
rs2232316-A O 
allele O 
enhanced O 
G6PC2 O 
transcription O 
by O 
promoting O 
Foxa2 O 
binding O 
. O 
Genetic O 
analyses O 
provide O 
evidence O 
for O 
association O 
of O 
the O 
rs2232316-A O 
allele O 
with O 
increased O 
FPG O 
( O 
β O 
= O 
0.04 O 
mmol O 
/ O 
l O 
; O 
p O 
= O 
4.3 O 
× O 
10(-3) O 
) O 
as O 
part O 
of O 
the O 
same O 
signal O 
as O 
rs560887 O 
, O 
rs573225 O 
and O 
rs13431652 O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
As O 
with O 
rs13431652 O 
, O 
the O 
in O 
situ O 
functional O 
data O 
with O 
rs560887 O 
and O 
rs2232316 O 
are O 
in O 
accord O 
with O 
the O 
putative O 
function O 
of O 
G6PC2 O 
in O 
pancreatic O 
islets O 
, O 
and O 
suggest O 
that O 
all O 
three O 
are O 
potentially O 
causative O 
SNPs O 
that O 
contribute O 
to O 
the O 
association O 
between O 
G6PC2 O 
and O 
FPG O 
. O 

methylation O 
is O 
a O 
significant O 
regulator O 
of O 
gene O 
expression O 
, O 
and O 
its O 
role O 
in O 
carcinogenesis O 
recently O 
has O 
been O 
a O 
subject O 
of O 
remarkable O 
interest O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
analyze O 
the O 
mechanism O 
and O 
cell O 
regulatory O 
effects O 
of O 
both O 
hypo- O 
and O 
hyper-DNA O 
methylation O 
on O 
cancer O 
. O 
In O 
this O 
review O 
, O 
we O 
report O 
new O 
developments O 
and O 
their O 
implications O 
regarding O 
the O 
effects O 
of O 
DNA O 
methylation O 
on O 
cancer O 
development O 
. O 
Indeed O 
, O 
alteration O 
of O 
the O 
pattern O 
of O 
DNA O 
methylation O 
has O 
been O 
a O 
constant O 
finding O 
in O 
cancer O 
cells O 
of O 
the O 
same O 
type O 
and O 
differences O 
in O 
the O 
pattern O 
of O 
DNA O 
methylation O 
not O 
only O 
occur O 
in O 
a O 
variety O 
of O 
tumor O 
types O 
, O 
but O 
also O 
in O 
developmental O 
processes O 
Furthermore O 
, O 
the O 
pattern O 
of O 
histone O 
modification O 
appears O 
to O 
be O 
a O 
predicator O 
of O 
the O 
risk O 
of O 
recurrence O 
of O 
human O 
cancers O 
. O 
It O 
is O 
well O 
known O 
that O 
hypermethylation O 
represses O 
transcription O 
of O 
the O 
promoter O 
sections O 
of O 
tumor O 
- O 
suppressor O 
genes O 
leading O 
to O 
gene O 
silencing O 
. O 
However O 
, O 
hypomethylation O 
also O 
has O 
been O 
identified O 
as O 
a O 
cause O 
of O 
oncogenesis O 
. O 
Furthermore O 
, O 
experiments O 
concerning O 
the O 
mechanism O 
of O 
methylation O 
and O 
its O 
control O 
have O 
led O 
to O 
the O 
discovery O 
of O 
many O 
regulatory O 
enzymes O 
and O 
proteins O 
. O 
This O 
review O 
reports O 
on O 
methods O 
developed O 
for O 
the O 
detection O 
of O 
5-hydroxymethylcytosine B-SYSTEMATIC 
methylation O 
at O 
the O 
5-methylcytosine B-SYSTEMATIC 
of O 
protein O 
domains O 
in O 
the O 
CpG O 
context O 
compared O 
to O 
non-methylated O 
DNA O 
, O 
histone O 
modification O 
, O 
and O 
microRNA O 
change O 
. O 

kinase O 
C O 
( O 
PKC O 
) O 
isozymes O 
undergo O 
down O 
- O 
regulation O 
upon O 
sustained O 
stimulation O 
. O 
Previous O 
studies O 
have O 
pointed O 
to O 
the O 
existence O 
of O 
both O 
proteasome O 
- O 
dependent O 
and O 
-independent O 
pathways O 
of O 
PKCα O 
processing O 
. O 
Here O 
we O 
demonstrate O 
that O 
these O 
down O 
- O 
regulation O 
pathways O 
are O 
engaged O 
in O 
different O 
subcellular O 
compartments O 
; O 
proteasomal O 
degradation O 
occurs O 
mainly O 
at O 
the O 
plasma O 
membrane O 
, O 
whereas O 
non-proteasomal O 
processing O 
occurs O 
in O 
the O 
perinuclear O 
region O 
. O 
Using O 
cholesterol B-TRIVIAL 
depletion O 
, O 
pharmacological O 
inhibitors O 
, O 
RNA O 
interference O 
, O 
and O 
dominant O 
- O 
negative O 
mutants O 
, O 
we O 
define O 
the O 
mechanisms O 
involved O 
in O 
perinuclear O 
accumulation O 
of O 
PKCα O 
and O 
identify O 
the O 
non-proteasomal O 
mechanism O 
mediating O 
its O 
degradation O 
. O 
We O 
show O 
that O 
intracellular O 
accumulation O 
of O 
PKCα O 
involves O 
at O 
least O 
two O 
clathrin O 
- O 
independent O 
, O 
cholesterol B-TRIVIAL 
/ O 
lipid O 
raft O 
- O 
mediated O 
pathways O 
that O 
do O 
not O 
require O 
ubiquitination O 
of O 
the O 
protein O 
; O 
one O 
is O 
dynamin O 
- O 
dependent O 
and O 
likely O 
involves O 
caveolae O 
, O 
whereas O 
the O 
other O 
is O 
dynamin- O 
and O 
small O 
GTPase O 
- O 
independent O 
. O 
Internalized O 
PKCα O 
traffics O 
through O 
endosomes O 
and O 
is O 
delivered O 
to O 
the O 
lysosome O 
for O 
degradation O 
. O 
Supportive O 
evidence O 
includes O 
( O 
a O 
) O 
detection O 
of O 
the O 
enzyme O 
in O 
EEA1-positive O 
early O 
endosomes O 
, O 
Rab7-positive O 
late O 
endosomes O 
/ O 
multivesicular O 
bodies O 
, O 
and O 
LAMP1-positive O 
lysosomes O 
and O 
( O 
b O 
) O 
inhibition O 
of O 
its O 
down O 
- O 
regulation O 
by O 
lysosome O 
- O 
disrupting O 
agents O 
and O 
leupeptin B-TRIVIAL 
. O 
Only O 
limited O 
dephosphorylation O 
of O 
PKCα O 
occurs O 
during O 
trafficking O 
, O 
with O 
fully O 
mature O 
enzyme O 
being O 
the O 
main O 
target O 
for O 
lysosomal O 
degradation O 
. O 
These O 
studies O 
define O 
a O 
novel O 
and O 
widespread O 
mechanism O 
of O 
desensitization O 
of O 
PKCα O 
signaling O 
that O 
involves O 
endocytic O 
trafficking O 
and O 
lysosome O 
- O 
mediated O 
degradation O 
of O 
the O 
mature O 
, O 
fully O 
phosphorylated O 
protein O 
. O 

with O 
improved O 
pharmacotherapeutic O 
properties O 
for O 
treatment O 
of O 
prion O 
disease O 
. O 

, O 
we O 
described O 
the O 
aminothiazole B-SYSTEMATIC 
lead O 
(4-biphenyl-4-ylthiazol-2-yl)-(6-methylpyridin-2-yl)-amine B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
which O 
exhibits O 
many O 
desirable O 
properties O 
, O 
including O 
excellent O 
stability O 
in O 
liver O 
microsomes O 
, O 
oral O 
bioavailability O 
of O 
∼40 O 
% O 
, O 
and O 
high O 
exposure O 
in O 
the O 
brains O 
of O 
mice O 
. O 
Despite O 
its O 
good O 
pharmacokinetic O 
properties O 
, O 
compound O 
1 O 
exhibited O 
only O 
modest O 
potency O 
in O 
mouse O 
neuroblastoma O 
cells O 
overexpressing O 
the O 
disease O 
- O 
causing O 
prion O 
protein O 
PrP(Sc) O 
. O 
Accordingly O 
, O 
we O 
sought O 
to O 
identify O 
analogues O 
of O 
1 O 
with O 
improved O 
antiprion O 
potency O 
in O 
ScN2a-cl3 O 
cells O 
while O 
retaining O 
similar O 
or O 
superior O 
properties O 
. O 
Herein O 
we O 
report O 
the O 
discovery O 
of O 
improved O 
lead O 
compounds O 
such O 
as O 
(6-methylpyridin-2-yl)-[4-(4-pyridin-3-yl-phenyl)thiazol-2-yl]amine B-SYSTEMATIC 
and O 
cyclopropanecarboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
(4-biphenylthiazol-2-yl)amide I-SYSTEMATIC 
, O 
which O 
exhibit O 
brain O 
exposure O 
/ O 
EC50 O 
ratios O 
at O 
least O 
tenfold O 
greater O 
than O 
that O 
of O 
compound O 
1 O 
. O 

Catalytic O 
Four-Electron O 
Dioxygen B-SYSTEMATIC 
( O 
O2 B-FORMULA 
) O 
and O 
Two-Electron O 
Hydrogen B-SYSTEMATIC 
Peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
Reduction O 
with O 
a O 
Copper B-SYSTEMATIC 
(II) I-SYSTEMATIC 
Complex O 
Possessing O 
a O 
Pendant O 
Ligand O 
Pivalamido O 
Group O 
. O 

copper B-SYSTEMATIC 
complex O 
, O 
[(PV-tmpa)Cu(II)](ClO4)2 B-FORMULA 
( O 
1 O 
) O 
[ O 
PV-tmpa B-ABBREVIATION 
= O 
bis(pyrid-2-ylmethyl){[6-(pivalamido)pyrid-2-yl]methyl}amine B-SYSTEMATIC 
] O 
, O 
acts O 
as O 
a O 
more O 
efficient O 
catalyst O 
for O 
the O 
four O 
- O 
electron O 
reduction O 
of O 
O2 B-FORMULA 
by O 
decamethylferrocene B-SYSTEMATIC 
( O 
Fc* O 
) O 
in O 
the O 
presence O 
of O 
trifluoroacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
CF3COOH B-FORMULA 
) O 
in O 
acetone B-SYSTEMATIC 
as O 
compared O 
with O 
the O 
corresponding O 
copper B-SYSTEMATIC 
complex O 
without O 
a O 
pivalamido B-SYSTEMATIC 
group O 
, O 
[(tmpa)Cu(II)](ClO4)2 B-FORMULA 
( O 
2 O 
) O 
( O 
tmpa B-ABBREVIATION 
= O 
tris(2-pyridylmethyl)amine B-SYSTEMATIC 
) O 
. O 
The O 
rate O 
constant O 
( O 
kobs O 
) O 
of O 
formation O 
of O 
decamethylferrocenium B-SYSTEMATIC 
ion O 
(Fc*(+)) O 
in O 
the O 
catalytic O 
four O 
- O 
electron O 
reduction O 
of O 
O2 B-FORMULA 
by O 
Fc* O 
in O 
the O 
presence O 
of O 
a O 
large O 
excess O 
CF3COOH B-FORMULA 
and O 
O2 B-FORMULA 
obeyed O 
first O 
- O 
order O 
kinetics O 
. O 
The O 
kobs O 
value O 
was O 
proportional O 
to O 
the O 
concentration O 
of O 
catalyst O 
1 O 
or O 
2 O 
, O 
whereas O 
the O 
kobs O 
value O 
remained O 
constant O 
irrespective O 
of O 
the O 
concentration O 
of O 
CF3COOH B-FORMULA 
or O 
O2 B-FORMULA 
. O 
This O 
indicates O 
that O 
electron O 
transfer O 
from O 
Fc* O 
to O 
1 O 
or O 
2 O 
is O 
the O 
rate O 
- O 
determining O 
step O 
in O 
the O 
catalytic O 
cycle O 
of O 
the O 
four O 
- O 
electron O 
reduction O 
of O 
O2 B-FORMULA 
by O 
Fc* O 
in O 
the O 
presence O 
of O 
CF3COOH B-FORMULA 
. O 
The O 
second O 
- O 
order O 
catalytic O 
rate O 
constant O 
( O 
kcat O 
) O 
for O 
1 O 
is O 
4 O 
times O 
larger O 
than O 
the O 
corresponding O 
value O 
determined O 
for O 
2 O 
. O 
With O 
the O 
pivalamido B-SYSTEMATIC 
group O 
in O 
1 O 
compared O 
to O 
2 O 
, O 
the O 
Cu B-FORMULA 
(II) I-FORMULA 
/ O 
Cu B-FORMULA 
(I) I-FORMULA 
potentials O 
are O 
-0.23 O 
and O 
-0.05 O 
V O 
vs O 
SCE O 
, O 
respectively O 
. O 
However O 
, O 
during O 
catalytic O 
turnover O 
, O 
the O 
CF3COO(-) B-FORMULA 
anion O 
present O 
readily O 
binds O 
to O 
2 O 
shifting O 
the O 
resulting O 
complex's O 
redox O 
potential O 
to O 
-0.35 O 
V O 
. O 
The O 
pivalamido B-SYSTEMATIC 
group O 
in O 
1 O 
is O 
found O 
to O 
inhibit O 
anion O 
binding O 
. O 
The O 
overall O 
effect O 
is O 
to O 
make O 
1 O 
easier O 
to O 
reduce O 
( O 
relative O 
to O 
2 O 
) O 
during O 
catalysis O 
, O 
accounting O 
for O 
the O 
relative O 
kcat O 
values O 
observed O 
. O 
1 O 
is O 
also O 
an O 
excellent O 
catalyst O 
for O 
the O 
two O 
- O 
electron O 
two O 
- O 
proton O 
reduction O 
of O 
H2O2 B-FORMULA 
to O 
water O 
and O 
is O 
also O 
more O 
efficient O 
than O 
is O 
2 O 
. O 
For O 
both O 
complexes O 
, O 
reaction O 
rates O 
are O 
greater O 
than O 
for O 
the O 
overall O 
four O 
- O 
electron O 
O2 B-FORMULA 
-reduction O 
to O 
water O 
, O 
an O 
important O 
asset O 
in O 
the O 
design O 
of O 
catalysts O 
for O 
the O 
latter O 
. O 

amyloid O 
hypothesis O 
asserts O 
that O 
excess O 
production O 
or O 
reduced O 
clearance O 
of O 
the O 
amyloid-β O 
( O 
Aβ O 
) O 
peptides O 
in O 
the O 
brain O 
initiates O 
a O 
sequence O 
of O 
events O 
that O 
ultimately O 
lead O 
to O 
Alzheimer's O 
disease O 
and O 
dementia O 
. O 
The O 
Aβ O 
hypothesis O 
has O 
identified O 
BACE1 O 
as O 
a O 
therapeutic O 
target O 
to O 
treat O 
Alzheimer's O 
and O 
led O 
to O 
medicinal O 
chemistry O 
efforts O 
to O 
design O 
its O 
inhibitors O 
both O 
in O 
the O 
pharmaceutical O 
industry O 
and O 
in O 
academia O 
. O 
This O 
review O 
summarizes O 
two O 
distinct O 
categories O 
of O 
inhibitors O 
designed O 
based O 
on O 
conformational O 
states O 
of O 
" O 
closed O 
" O 
and O 
" O 
open O 
" O 
forms O 
of O 
the O 
enzyme O 
. O 
In O 
each O 
category O 
the O 
inhibitors O 
are O 
classified O 
based O 
on O 
the O 
core O 
catalytic O 
interaction O 
group O 
or O 
the O 
aspartyl B-TRIVIAL 
binding O 
motif O 
( O 
ABM O 
) O 
. O 
This O 
review O 
covers O 
the O 
description O 
of O 
inhibitors O 
in O 
each O 
ABM O 
class O 
with O 
X-ray O 
crystal O 
structures O 
of O 
key O 
compounds O 
, O 
their O 
binding O 
modes O 
, O 
related O 
structure O 
- O 
activity O 
data O 
highlighting O 
potency O 
advances O 
, O 
and O 
additional O 
properties O 
such O 
as O 
selectivity O 
profile O 
, O 
P-gp O 
efflux O 
, O 
pharmacokinetic O 
, O 
and O 
pharmacodynamic O 
data O 
. O 

importance O 
of O 
nanomotors O 
in O 
nanotechnology O 
is O 
akin O 
to O 
that O 
of O 
mechanical O 
engines O 
to O 
daily O 
life O 
. O 
The O 
AAA+ O 
superfamily O 
is O 
a O 
class O 
of O 
nanomotors O 
performing O 
various O 
functions O 
. O 
Their O 
hexagonal O 
arrangement O 
facilitates O 
bottom O 
- O 
up O 
assembly O 
for O 
stable O 
structures O 
. O 
The O 
bacteriophage O 
phi29 O 
DNA O 
translocation O 
motor O 
contains O 
three O 
coaxial O 
rings O 
: O 
a O 
dodecamer O 
channel O 
, O 
a O 
hexameric O 
ATPase O 
ring O 
, O 
and O 
a O 
hexameric O 
pRNA O 
ring O 
. O 
The O 
viral O 
DNA O 
packaging O 
motor O 
has O 
been O 
believed O 
to O 
be O 
a O 
rotational O 
machine O 
. O 
However O 
, O 
we O 
discovered O 
a O 
revolution O 
mechanism O 
without O 
rotation O 
. O 
By O 
analogy O 
, O 
the O 
earth O 
revolves O 
around O 
the O 
sun O 
while O 
rotating O 
on O 
its O 
own O 
axis O 
. O 
One O 
- O 
way O 
traffic O 
of O 
dsDNA O 
translocation O 
is O 
facilitated O 
by O 
five O 
factors O 
: O 
( O 
1 O 
) O 
ATPase O 
changes O 
its O 
conformation O 
to O 
revolve O 
dsDNA O 
within O 
a O 
hexameric O 
channel O 
in O 
one O 
direction O 
; O 
( O 
2 O 
) O 
the O 
30° O 
tilt O 
of O 
the O 
channel O 
subunits O 
causes O 
an O 
antiparallel O 
arrangement O 
between O 
two O 
helices O 
of O 
dsDNA O 
and O 
channel O 
wall O 
to O 
advance O 
one O 
- O 
way O 
translocation O 
; O 
( O 
3 O 
) O 
unidirectional O 
flow O 
property O 
of O 
the O 
internal O 
channel O 
loops O 
serves O 
as O 
a O 
ratchet O 
valve O 
to O 
prevent O 
reversal O 
; O 
( O 
4 O 
) O 
5'-3 O 
' O 
single O 
- O 
direction O 
movement O 
of O 
one O 
DNA O 
strand O 
along O 
the O 
channel O 
wall O 
ensures O 
single O 
direction O 
; O 
and O 
( O 
5 O 
) O 
four O 
electropositive O 
layers O 
interact O 
with O 
one O 
strand O 
of O 
the O 
electronegative O 
dsDNA O 
phosphate B-SYSTEMATIC 
backbone O 
, O 
resulting O 
in O 
four O 
relaying O 
transitional O 
pauses O 
during O 
translocation O 
. O 
The O 
discovery O 
of O 
a O 
riding O 
system O 
along O 
one O 
strand O 
provides O 
a O 
motion O 
nanosystem O 
for O 
cargo O 
transportation O 
and O 
a O 
tool O 
for O 
studying O 
force O 
generation O 
without O 
coiling O 
, O 
friction O 
, O 
and O 
torque O 
. O 
The O 
revolution O 
of O 
dsDNA O 
among O 
12 O 
subunits O 
offers O 
a O 
series O 
of O 
recognition O 
sites O 
on O 
the O 
DNA O 
backbone O 
to O 
provide O 
additional O 
spatial O 
variables O 
for O 
nucleotide B-FAMILY 
discrimination O 
for O 
sensing O 
applications O 
. O 

this O 
report O 
, O 
we O 
show O 
the O 
preparation O 
of O 
honeycomb O 
scaffolds O 
for O 
cell O 
culturing O 
by O 
using O 
" O 
breath O 
figure O 
" O 
method O 
, O 
and O 
we O 
found O 
that O 
their O 
mechanical O 
and O 
topographical O 
properties O 
strongly O 
affect O 
the O 
adhesion O 
of O 
fibroblasts O 
. O 
By O 
photo O 
- O 
cross O 
- O 
linking O 
of O 
the O 
poly(1,2-butadiene) B-SYSTEMATIC 
, O 
the O 
hardness O 
of O 
the O 
honeycomb O 
scaffold O 
can O 
be O 
successfully O 
controlled O 
without O 
any O 
surface O 
chemical O 
changes O 
, O 
and O 
detail O 
modulus O 
values O 
of O 
scaffolds O 
were O 
measured O 
by O 
atomic O 
force O 
microscopy O 
. O 
We O 
found O 
that O 
only O 
small O 
numbers O 
of O 
the O 
cells O 
adhered O 
on O 
the O 
softer O 
honeycomb O 
scaffolds O 
, O 
which O 
has O 
even O 
higher O 
modulus O 
value O 
than O 
conventional O 
gels O 
, O 
comparing O 
with O 
flat O 
films O 
and O 
a O 
hard O 
honeycomb O 
scaffold O 
. O 
These O 
results O 
indicate O 
that O 
the O 
elastomeric O 
honeycomb O 
substrates O 
are O 
useful O 
for O 
evaluating O 
the O 
effect O 
of O 
the O 
mechanical O 
signal O 
- O 
derived O 
geometry O 
on O 
the O 
transduction O 
system O 
of O 
cells O 
. O 

of O 
a O 
DOTA B-ABBREVIATION 
( O 
Gd(3+) B-FORMULA 
)-conjugate O 
of O 
proton O 
- O 
pump O 
inhibitor O 
pantoprazole B-TRIVIAL 
for O 
gastric O 
wall O 
imaging O 
studies O 
. O 

resonance O 
imaging O 
( O 
MRI O 
) O 
is O 
used O 
to O 
evaluate O 
gastrointestinal O 
( O 
GI O 
) O 
structure O 
and O 
functions O 
in O 
humans O 
. O 
Despite O 
filling O 
the O 
viscus O 
lumen O 
with O 
a O 
contrast O 
agent O 
, O 
visualization O 
of O 
the O 
viscus O 
wall O 
is O 
limited O 
. O 
To O 
overcome O 
this O 
limitation O 
, O 
we O 
de O 
novo O 
synthesized O 
a O 
conjugate O 
that O 
covalently O 
combines O 
a O 
Gd B-FORMULA 
-based O 
MRI O 
contrast O 
agent O 
, O 
encaged O 
with O 
a O 
chelating O 
agent O 
( O 
DOTA B-ABBREVIATION 
) O 
, O 
with O 
pantoprazole B-TRIVIAL 
, O 
which O 
is O 
a O 
widely O 
used O 
proton O 
pump O 
inhibitor O 
that O 
binds O 
to O 
proton O 
pumps O 
in O 
the O 
stomach O 
and O 
colon O 
. O 
The O 
DOTA B-ABBREVIATION 
linkage O 
was O 
installed O 
at O 
a O 
mechanism O 
- O 
based O 
strategic O 
location O 
in O 
the O 
pantoprazole B-TRIVIAL 
molecule O 
to O 
minimize O 
a O 
possible O 
negative O 
effect O 
of O 
the O 
structural O 
modification O 
on O 
the O 
drug O 
. O 
It O 
is O 
anticipated O 
that O 
by O 
defining O 
the O 
wall O 
of O 
the O 
stomach O 
and O 
colon O 
, O 
this O 
compound O 
will O 
facilitate O 
functional O 
MRI O 
of O 
the O 
GI O 
tract O 
in O 
humans O 
. O 

of O 
anti-HCV O 
activity O 
and O 
SAR O 
study O 
of O 
(+)-lycoricidine B-TRIVIAL 
through O 
targeting O 
of O 
host O 
heat O 
- O 
stress O 
cognate O 
70 O 
( O 
Hsc70 O 
) O 
. O 

anti O 
hepatitis O 
C O 
virus O 
( O 
HCV O 
) O 
activity O 
of O 
(+)-lycoricidine B-TRIVIAL 
( O 
1 O 
) O 
was O 
evaluated O 
for O 
the O 
first O 
time O 
in O 
this O 
letter O 
, O 
yielding O 
an O 
EC50 O 
value O 
of O 
0.55nmol O 
/ O 
mL O 
and O 
an O 
selection O 
index O 
( O 
SI O 
) O 
value O 
of O 
12.72 O 
. O 
Further O 
studies O 
indicated O 
that O 
1 O 
induced O 
this O 
effect O 
by O 
down O 
- O 
regulating O 
host O 
heat O 
- O 
stress O 
cognate O 
70 O 
( O 
Hsc70 O 
) O 
expression O 
. O 
In O 
addition O 
, O 
20 O 
derivatives O 
were O 
designed O 
and O 
synthesised O 
to O 
investigate O 
the O 
basic O 
structure O 
- O 
activity O 
relationship O 
( O 
SAR O 
) O 
of O 
the O 
title O 
compound O 
. O 
Several O 
of O 
these O 
derivatives O 
exhibit O 
a O 
good O 
inhibition O 
of O 
HCV O 
, O 
such O 
as O 
compound O 
3 O 
( O 
EC50=0.68nmol O 
/ O 
mL O 
, O 
SI=33.86 O 
) O 
, O 
compound O 
2d O 
( O 
EC50=15nmol O 
/ O 
mL O 
, O 
SI=12 O 
) O 
and O 
compound O 
5 O 
( O 
EC50=33nmol O 
/ O 
mL O 
, O 
SI O 
> O 
10.91 O 
) O 
. O 
Meanwhile O 
, O 
the O 
experimental O 
data O 
suggest O 
that O 
the O 
modification O 
of O 
certain O 
groups O 
of O 
(+)-lycoricidine B-TRIVIAL 
can O 
reduce O 
the O 
cytotoxicity O 
of O 
the O 
compounds O 
. O 

protein O 
damage O 
by O 
dimethoxyphosphorus B-SYSTEMATIC 
(V) I-SYSTEMATIC 
tetraphenylporphyrin I-SYSTEMATIC 
. O 

the O 
purpose O 
of O 
the O 
basic O 
study O 
of O 
photodynamic O 
therapy O 
, O 
the O 
activity O 
of O 
the O 
water O 
- O 
soluble O 
P(V)porphyrin B-SYSTEMATIC 
, O 
dimethoxyP(V)tetraphenylporphyrin B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
DMP(V)TPP B-ABBREVIATION 
) O 
, O 
on O 
photosensitized O 
protein O 
damage O 
was O 
examined O 
. O 
The O 
quantum O 
yield O 
of O 
singlet O 
oxygen B-SYSTEMATIC 
generation O 
by O 
DMP(V)TPP B-ABBREVIATION 
( O 
0.64 O 
) O 
was O 
comparable O 
with O 
that O 
of O 
typical O 
porphyrin B-FAMILY 
photosensitizers O 
. O 
Absorption O 
spectrum O 
measurement O 
demonstrated O 
the O 
binding O 
interaction O 
between O 
DMP(V)TPP B-ABBREVIATION 
and O 
human O 
serum O 
albumin O 
, O 
a O 
water O 
- O 
soluble O 
protein O 
. O 
Photo O 
- O 
irradiated O 
DMP(V)TPP B-ABBREVIATION 
damaged O 
the O 
amino B-FAMILY 
acid I-FAMILY 
residue O 
of O 
human O 
serum O 
albumin O 
, O 
resulting O 
in O 
the O 
decrease O 
of O 
the O 
fluorescence O 
intensity O 
from O 
the O 
tryptophan B-TRIVIAL 
residue O 
of O 
human O 
serum O 
albumin O 
. O 
A O 
singlet O 
oxygen B-SYSTEMATIC 
quencher O 
, O 
sodium B-SYSTEMATIC 
azide I-SYSTEMATIC 
, O 
could O 
not O 
completely O 
inhibit O 
the O 
damage O 
of O 
human O 
serum O 
albumin O 
, O 
suggesting O 
that O 
the O 
electron O 
transfer O 
mechanism O 
contributes O 
to O 
protein O 
damage O 
as O 
does O 
singlet O 
oxygen B-SYSTEMATIC 
generation O 
. O 
The O 
decrease O 
of O 
the O 
fluorescence O 
lifetime O 
of O 
DMP(V)TPP B-ABBREVIATION 
by O 
human O 
serum O 
albumin O 
supported O 
the O 
electron O 
transfer O 
mechanism O 
. O 
The O 
estimated O 
contribution O 
of O 
the O 
electron O 
transfer O 
mechanism O 
is O 
0.64 O 
. O 
These O 
results O 
suggest O 
that O 
the O 
activity O 
of O 
DMP(V)TPP B-ABBREVIATION 
can O 
be O 
preserved O 
under O 
lower O 
oxygen B-SYSTEMATIC 
concentration O 
condition O 
such O 
as O 
tumor O 
. O 

disease O 
( O 
human O 
American O 
trypanosomiasis O 
) O 
, O 
which O 
is O 
caused O 
by O 
the O 
protozoan O 
parasite O 
Trypanosoma O 
cruzi O 
, O 
is O 
responsible O 
for O 
numerous O 
deaths O 
each O 
year O 
; O 
however O 
, O 
established O 
treatments O 
for O 
the O 
disease O 
are O 
limited O 
. O 
Differentiation O 
- O 
inducing O 
factor-1 O 
( O 
DIF-1 O 
) O 
and O 
DIF-3 O 
are O 
chlorinated O 
alkylphenones B-FAMILY 
originally O 
found O 
in O 
the O 
cellular O 
slime O 
mold O 
Dictyostelium O 
discoideum O 
that O 
have O 
been O 
shown O 
to O 
possess O 
pharmacological O 
activities O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
DIF-3 O 
derivatives O 
on O 
the O 
infection O 
rate O 
and O 
growth O 
of O 
T O 
. O 
cruzi O 
by O 
using O 
an O 
in O 
vitro O 
assay O 
system O 
utilizing O 
host O 
human O 
fibrosarcoma O 
HT1080 O 
cells O 
. O 
Certain O 
DIF-3 O 
derivatives O 
, O 
such O 
as O 
butoxy B-SYSTEMATIC 
-DIF-3 O 
( O 
Bu-DIF-3 O 
) O 
, O 
at O 
micro O 
- O 
molar O 
levels O 
strongly O 
suppressed O 
both O 
the O 
infection O 
rate O 
and O 
growth O 
of O 
T O 
. O 
cruzi O 
in O 
HT1080 O 
cells O 
and O 
exhibited O 
little O 
toxicity O 
for O 
HT1080 O 
cells O 
. O 
For O 
example O 
, O 
the O 
IC50 O 
of O 
DIF-3 O 
and O 
Bu-DIF-3 O 
versus O 
the O 
growth O 
of O 
T O 
. O 
cruzi O 
in O 
HT1080 O 
cells O 
were O 
3.95 O 
and O 
0.72μM O 
, O 
respectively O 
, O 
and O 
the O 
LD50 O 
of O 
the O 
two O 
compounds O 
versus O 
HT1080 O 
cells O 
were O 
both O 
greater O 
than O 
100μM O 
. O 
We O 
also O 
examined O 
the O 
effects O 
of O 
DIF-3 O 
and O 
Bu-DIF-3 O 
on O 
T O 
. O 
cruzi O 
activity O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 
Intraperitoneally O 
administered O 
Bu-DIF-3 O 
( O 
50mg O 
/ O 
kg O 
) O 
significantly O 
suppressed O 
the O 
number O 
of O 
trypomastigotes O 
in O 
blood O 
with O 
no O 
apparent O 
adverse O 
effects O 
. O 
These O 
results O 
strongly O 
suggest O 
that O 
DIF-3 O 
derivatives O 
could O 
be O 
new O 
lead O 
compounds O 
in O 
the O 
development O 
of O 
anti-trypanosomiasis O 
drugs O 
. O 

inhibition O 
reveals O 
endogenous O 
nicotinic O 
modulation O 
of O 
glutamate B-TRIVIAL 
inputs O 
to O 
CA1 O 
stratum O 
radiatum O 
interneurons O 
in O 
hippocampal O 
slices O 
. O 

involvement O 
of O 
brain O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChRs O 
) O 
in O 
the O 
neurotoxicological O 
effects O 
of O 
soman O 
, O 
a O 
potent O 
acetylcholinesterase O 
( O 
AChE O 
) O 
inhibitor O 
and O 
a O 
chemical O 
warfare O 
agent O 
, O 
is O 
not O 
clear O 
. O 
This O 
is O 
partly O 
due O 
to O 
a O 
poor O 
understanding O 
of O 
the O 
role O 
of O 
AChE O 
in O 
brain O 
nAChR O 
- O 
mediated O 
functions O 
. O 
To O 
test O 
the O 
hypothesis O 
that O 
AChE O 
inhibition O 
builds O 
sufficient O 
acetylcholine B-SYSTEMATIC 
( O 
ACh O 
) O 
in O 
the O 
brain O 
and O 
facilitates O 
nAChR-dependent O 
glutamate B-TRIVIAL 
transmission O 
, O 
we O 
used O 
whole O 
- O 
cell O 
patch O 
- O 
clamp O 
technique O 
to O 
record O 
spontaneous O 
glutamate B-TRIVIAL 
excitatory O 
postsynaptic O 
currents O 
( O 
EPSCs O 
) O 
from O 
CA1 O 
stratum O 
radiatum O 
interneurons O 
( O 
SRI O 
) O 
in O 
hippocampal O 
slices O 
. O 
First O 
, O 
the O 
frequency O 
, O 
amplitude O 
and O 
kinetics O 
of O 
EPSCs O 
recorded O 
from O 
slices O 
of O 
control O 
guinea O 
pigs O 
were O 
compared O 
to O 
those O 
recorded O 
from O 
slices O 
of O 
guinea O 
pigs O 
after O 
a O 
single O 
injection O 
of O 
the O 
irreversible O 
AChE O 
inhibitor O 
soman O 
( O 
25.2μg O 
/ O 
kg O 
, O 
s.c O 
. O 
) O 
. O 
Second O 
, O 
EPSCs O 
were O 
recorded O 
from O 
rat O 
hippocampal O 
slices O 
before O 
and O 
after O 
their O 
superfusion O 
with O 
the O 
reversible O 
AChE O 
inhibitor O 
donepezil B-TRIVIAL 
( O 
100nM O 
) O 
. O 
The O 
frequency O 
of O 
EPSCs O 
was O 
significantly O 
higher O 
in O 
slices O 
taken O 
from O 
guinea O 
pigs O 
24h O 
but O 
not O 
7 O 
days O 
after O 
the O 
soman O 
injection O 
than O 
in O 
slices O 
from O 
control O 
animals O 
. O 
In O 
52% O 
of O 
the O 
rat O 
hippocampal O 
slices O 
tested O 
, O 
bath O 
application O 
of O 
donepezil B-TRIVIAL 
increased O 
the O 
frequency O 
of O 
EPSCs O 
. O 
Further O 
, O 
exposure O 
to O 
donepezil B-TRIVIAL 
increased O 
both O 
burst O 
- O 
like O 
and O 
large O 
- O 
amplitude O 
EPSCs O 
, O 
and O 
increased O 
the O 
proportion O 
of O 
short O 
( O 
20-100ms O 
) O 
inter O 
- O 
event O 
intervals O 
. O 
Donepezil B-TRIVIAL 
' O 
s O 
effects O 
were O 
suppressed O 
significantly O 
in O 
presence O 
of O 
10μM O 
mecamylamine B-TRIVIAL 
or O 
10nM O 
methyllycaconitine B-TRIVIAL 
. O 
These O 
results O 
support O 
the O 
concept O 
that O 
AChE O 
inhibition O 
is O 
able O 
to O 
recruit O 
nAChR-dependent O 
glutamate B-TRIVIAL 
transmission O 
in O 
the O 
hippocampus O 
and O 
such O 
a O 
mechanism O 
can O 
contribute O 
to O 
the O 
acute O 
neurotoxicological O 
actions O 
of O 
soman O 
. O 

: O 
As O 
lowering O 
HbA1c O 
levels O 
is O 
still O 
the O 
main O 
goal O 
of O 
insulin O 
treatment O 
, O 
severe O 
hypoglycaemia O 
( O 
SH O 
) O 
remains O 
a O 
common O 
experience O 
in O 
children O 
with O 
type O 
1 O 
diabetes O 
mellitus O 
( O 
T1DM O 
) O 
and O 
their O 
families O 
. O 
Aim O 
: O 
This O 
study O 
aims O 
to O 
evaluate O 
the O 
incidence O 
and O 
the O 
clinical O 
features O 
of O 
SH O 
episodes O 
in O 
our O 
Centre O 
in O 
the O 
last O 
20 O 
years O 
. O 
Subjects O 
and O 
Methods O 
: O 
We O 
analysed O 
SH O 
incidence O 
in O 
269 O 
patients O 
diagnosed O 
from O 
1990 O 
to O 
2010 O 
( O 
total O 
follow O 
- O 
up O 
2212.9 O 
patient-years O 
) O 
. O 
Inclusion O 
criteria O 
: O 
at O 
least O 
3 O 
visits O 
/ O 
year O 
and O 
1 O 
year O 
of O 
follow O 
- O 
up O 
. O 
SH O 
episode O 
was O 
defined O 
as O 
any O 
condition O 
of O 
low O 
blood O 
glucose B-TRIVIAL 
requiring O 
third O 
- O 
party O 
assistance O 
. O 
Results O 
: O 
50.2% O 
of O 
patients O 
experienced O 
at O 
least O 
1 O 
SH O 
episode O 
for O 
a O 
total O 
of O 
345 O 
episodes O 
. O 
Whole O 
incidence O 
was O 
15.6 O 
/ O 
100 O 
pts O 
/ O 
yr O 
, O 
slightly O 
different O 
between O 
first O 
and O 
second O 
decade O 
( O 
12.6 O 
vs O 
16.5 O 
, O 
p=0.047 O 
) O 
. O 
HbA1c O 
at O 
the O 
time O 
of O 
SH O 
was O 
lower O 
in O 
the O 
non-BB O 
group O 
( O 
7.4±1.3 O 
vs O 
8.2±1.4 O 
; O 
p=0.0001 O 
) O 
and O 
worsened O 
3 O 
months O 
later O 
( O 
p=0.0001 O 
) O 
. O 
Impaired O 
awareness O 
was O 
the O 
main O 
or O 
only O 
symptom O 
in O 
43.5% O 
. O 
SH O 
occurred O 
at O 
night O 
in O 
32% O 
of O 
patients O 
and O 
they O 
were O 
significantly O 
younger O 
than O 
those O 
with O 
SH O 
at O 
other O 
times O 
. O 
5 O 
SH O 
episodes O 
or O 
more O 
occurred O 
in O 
8.1% O 
of O 
patients O 
who O 
presented O 
a O 
lower O 
HbA1c O 
, O 
a O 
younger O 
age O 
and O 
shorter O 
disease O 
duration O 
than O 
the O 
other O 
patients O 
. O 
HbA1c O 
at O 
first O 
SH O 
was O 
negatively O 
correlated O 
with O 
number O 
of O 
SH O 
( O 
r=-0.20 O 
; O 
p=0.05 O 
) O 
. O 
Conclusions O 
: O 
Despite O 
the O 
advent O 
of O 
new O 
insulin O 
regimens O 
, O 
we O 
confirm O 
that O 
SH O 
still O 
represents O 
a O 
relevant O 
risk O 
and O 
a O 
current O 
threat O 
for O 
patients O 
with O 
T1DM O 
and O 
their O 
families O 
. O 

Nanogram O 
Dose O 
of O 
the O 
CYP3A O 
Probe O 
Substrate O 
Midazolam B-TRIVIAL 
to O 
Evaluate O 
Drug O 
Interactions O 
. O 

objective O 
of O 
the O 
study O 
was O 
to O 
establish O 
an O 
in O 
vivo O 
method O 
for O 
assessing O 
cytochrome O 
P450 O 
3A O 
( O 
CYP3A O 
) O 
activity O 
using O 
therapeutically O 
inert O 
nanogram O 
doses O 
of O 
midazolam B-TRIVIAL 
. O 
We O 
administered O 
four O 
escalating O 
single O 
doses O 
of O 
oral O 
midazolam B-TRIVIAL 
( O 
0.0001-3 O 
mg O 
) O 
to O 
12 O 
healthy O 
participants O 
, O 
stratified O 
according O 
to O 
CYP3A5 O 
carrier O 
status O 
, O 
to O 
assess O 
pharmacokinetics O 
linearity O 
. O 
We O 
then O 
evaluated O 
the O 
interactions O 
with O 
the O 
CYP3A O 
inhibitor O 
ketoconazole B-TRIVIAL 
( O 
400 O 
mg O 
q.d O 
. O 
) O 
after O 
nanogram O 
and O 
regular O 
doses O 
of O 
midazolam B-TRIVIAL 
. O 
Area O 
under O 
the O 
plasma O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
and O 
peak O 
plasma O 
concentration O 
( O 
Cmax O 
) O 
were O 
linear O 
over O 
the O 
entire O 
range O 
of O 
doses O 
. O 
Ketoconazole B-TRIVIAL 
reduced O 
midazolam B-TRIVIAL 
oral O 
clearance O 
by O 
92.8% O 
. O 
AUC O 
and O 
Cmax O 
increased O 
by O 
1540 O 
and O 
363% O 
, O 
respectively O 
. O 
CYP3A5 O 
carrier O 
status O 
had O 
no O 
influence O 
on O 
midazolam B-TRIVIAL 
oral O 
clearance O 
or O 
its O 
inhibition O 
by O 
ketoconazole B-TRIVIAL 
. O 
This O 
is O 
the O 
first O 
study O 
showing O 
that O 
midazolam B-TRIVIAL 
pharmacokinetics O 
is O 
linear O 
in O 
a O 
30,000-fold O 
concentration O 
range O 
, O 
and O 
therefore O 
that O 
nano- O 
and O 
microgram O 
doses O 
of O 
midazolam B-TRIVIAL 
can O 
reliably O 
predict O 
the O 
pharmacokinetics O 
of O 
midazolam B-TRIVIAL 
in O 
therapeutic O 
doses O 
and O 
can O 
be O 
used O 
to O 
assess O 
CYP3A O 
activity O 
even O 
in O 
the O 
presence O 
of O 
strong O 
CYP3A O 
inhibitors.Clinical O 
Pharmacology O 
& O 
Therapeutics O 
( O 
2013 O 
) O 
; O 
advance O 
online O 
publication O 
20 O 
March O 
2013 O 
. O 
doi O 
: O 
10.1038 O 
/ O 
clpt.2013.27 O 
. O 

as O 
a O 
spacer O 
arm O 
markedly O 
increases O 
the O 
immunogenicity O 
of O 
meningococcal O 
group O 
Y O 
polysaccharide O 
conjugate O 
vaccine O 
. O 

meningitidis O 
is O 
a O 
life O 
- O 
threatening O 
pathogen O 
that O 
causes O 
meningitis O 
and O 
other O 
clinical O 
manifestations O 
. O 
As O 
a O 
key O 
virulence O 
determinant O 
, O 
meningococcal O 
capsular O 
polysaccharide O 
( O 
PS O 
) O 
can O 
be O 
used O 
to O 
prevent O 
meningococcal O 
diseases O 
. O 
Conjugation O 
of O 
PS O 
to O 
carrier O 
protein O 
can O 
significantly O 
improve O 
the O 
immunogenicity O 
of O 
PS O 
and O 
induce O 
memory O 
response O 
in O 
infants O 
and O 
young O 
children O 
. O 
However O 
, O 
the O 
conjugate O 
vaccine O 
may O 
suffer O 
from O 
steric O 
shielding O 
of O 
antigenic O 
PS O 
epitopes O 
by O 
carrier O 
protein O 
. O 
Here O 
, O 
a O 
heterobifunctional O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
was O 
used O 
as O 
a O 
spacer O 
arm O 
to O 
conjugate O 
meningococcal O 
group O 
Y O 
capsular O 
PS O 
with O 
tetanus O 
toxoid O 
( O 
TT O 
) O 
. O 
PEG B-ABBREVIATION 
can O 
avoid O 
self O 
- O 
crosslink O 
of O 
PS O 
and O 
increase O 
the O 
PS O 
/ O 
TT O 
ratio O 
of O 
the O 
vaccine O 
. O 
Significant O 
structural O 
change O 
in O 
TT O 
and O 
PS O 
was O 
not O 
observed O 
upon O 
conjugation O 
. O 
As O 
compared O 
to O 
the O 
vaccine O 
without O 
PEG B-ABBREVIATION 
, O 
immunization O 
with O 
the O 
vaccine O 
using O 
PEG B-ABBREVIATION 
as O 
the O 
spacer O 
arm O 
led O 
to O 
3.0-fold O 
increase O 
in O 
the O 
PS-specific O 
IgG O 
titers O 
and O 
a O 
prolonged O 
immune O 
persistence O 
. O 
Paradoxically O 
, O 
PEG B-ABBREVIATION 
, O 
a O 
non-immunogenic O 
hydrophilic O 
polymer O 
has O 
been O 
widely O 
used O 
to O 
couple O 
therapeutic O 
protein O 
for O 
increasing O 
its O 
circulatory O 
time O 
and O 
decreasing O 
its O 
immunogenicity O 
. O 
Presumably O 
, O 
PEG B-ABBREVIATION 
can O 
fully O 
decrease O 
the O 
steric O 
shielding O 
effect O 
of O 
TT O 
on O 
antigenic O 
epitopes O 
of O 
PS O 
and O 
suppress O 
the O 
immunogenicity O 
of O 
TT O 
. O 
In O 
addition O 
, O 
PEG B-ABBREVIATION 
can O 
prolong O 
the O 
immune O 
persistence O 
of O 
the O 
conjugate O 
vaccine O 
and O 
improve O 
its O 
ability O 
to O 
elicit O 
cellular O 
immunity O 
. O 
Thus O 
, O 
PEG B-ABBREVIATION 
can O 
be O 
used O 
as O 
a O 
spacer O 
arm O 
to O 
develop O 
more O 
effective O 
PS O 
conjugate O 
vaccine O 
for O 
prevention O 
of O 
bacterial O 
infection O 
. O 

PAA B-ABBREVIATION 
-Based O 
Nanoparticles O 
as O 
Potential O 
Gene O 
and O 
Protein O 
Delivery O 
Systems O 
. O 

series O 
of O 
nanoparticles O 
is O 
prepared O 
via O 
layer O 
- O 
by O 
- O 
layer O 
assembly O 
of O 
oppositely O 
charged O 
, O 
synthetic O 
biocompatible O 
polyamidoamine B-FAMILY 
polymers O 
as O 
potential O 
carriers O 
. O 
Particle O 
size O 
, O 
surface O 
charge O 
and O 
internal O 
chain O 
mobility O 
are O 
quantified O 
as O 
a O 
function O 
of O 
the O 
polymer O 
type O 
and O 
number O 
of O 
layers O 
. O 
The O 
effect O 
of O 
addition O 
of O 
surfactant O 
is O 
examined O 
to O 
simulate O 
the O 
effects O 
of O 
nanoparticle O 
dissolution O 
. O 
The O 
cyctotoxicity O 
of O 
these O 
particles O 
( O 
in O 
epithelia O 
and O 
murine O 
cell O 
lines O 
) O 
are O 
orders O 
of O 
magnitude O 
lower O 
than O 
polyethyleneimine B-SYSTEMATIC 
controls O 
. O 
Stable O 
nanoparticles O 
may O 
be O 
prepared O 
from O 
mixtures O 
of O 
strongly O 
, O 
oppositely O 
charged O 
polymers O 
, O 
but O 
less O 
successfully O 
from O 
weakly O 
charged O 
polymers O 
, O 
and O 
, O 
given O 
their O 
acceptable O 
toxicity O 
characteristics O 
, O 
such O 
modularly O 
designed O 
constructs O 
show O 
promise O 
for O 
drug O 
and O 
gene O 
delivery O 
. O 

of O 
DNA O 
Sequence O 
and O 
Oligonucleotide O 
Length O 
on O 
a O 
Polythiophene B-FAMILY 
-Based O 
Fluorescent O 
DNA O 
Biosensor O 
. O 

hybridization O 
is O 
a O 
universal O 
and O 
specific O 
mechanism O 
for O 
the O 
recognition O 
of O 
biological O 
targets O 
. O 
Some O 
cationic O 
polythiophene B-FAMILY 
transducers O 
sensitive O 
to O 
DNA O 
structure O 
have O 
been O 
previously O 
utilized O 
to O 
detect O 
such O 
biomolecules O 
. O 
Further O 
characterization O 
of O 
these O 
systems O 
indicates O 
that O 
both O 
DNA O 
sequence O 
composition O 
and O 
length O 
modulate O 
the O 
biosensor O 
performance O 
. O 
It O 
appears O 
that O 
different O 
repeated O 
sequence O 
patterns O 
cause O 
different O 
conformational O 
changes O 
of O 
the O 
polythiophene B-FAMILY 
, O 
from O 
a O 
more O 
relaxed O 
form O 
to O 
an O 
extremely O 
rigid O 
one O 
. O 
A O 
length O 
difference O 
between O 
the O 
DNA O 
oligonucleotide O 
probe O 
and O 
target O 
has O 
a O 
detrimental O 
effect O 
on O 
the O 
fluorescent O 
signal O 
, O 
but O 
it O 
can O 
be O 
attenuated O 
by O 
changing O 
the O 
sequence O 
composition O 
of O 
the O 
protruding O 
target O 
sequence O 
. O 
This O 
demonstrates O 
that O 
the O 
nature O 
of O 
DNA O 
can O 
be O 
critical O 
for O 
hybridization O 
- O 
based O 
detection O 
systems O 
. O 

tolerant O 
and O 
phosphorus B-SYSTEMATIC 
solubilizing O 
Pseudomonas O 
sp O 
. O 
strain O 
SGRAJ09 O 
isolated O 
from O 
pesticides O 
treated O 
Achillea O 
clavennae O 
rhizosphere O 
soil O 
. O 

this O 
study O 
, O 
an O 
attempt O 
was O 
made O 
to O 
identify O 
an O 
effective O 
phosphate B-SYSTEMATIC 
solubilizing O 
bacteria O 
from O 
pesticide O 
polluted O 
field O 
soil O 
. O 
Based O 
on O 
the O 
formation O 
of O 
solubilization O 
halo O 
on O 
Pikovskaya's O 
agar O 
, O 
six O 
isolates O 
were O 
selected O 
and O 
screened O 
for O 
pesticide O 
tolerance O 
and O 
phosphate B-SYSTEMATIC 
( O 
P O 
) O 
solubilization O 
ability O 
through O 
liquid O 
assay O 
. O 
The O 
results O 
showed O 
that O 
only O 
one O 
strain O 
( O 
SGRAJ09 O 
) O 
obtained O 
from O 
Achillea O 
clavennae O 
was O 
found O 
to O 
tolerate O 
maximum O 
level O 
of O 
the O 
pesticides O 
tested O 
and O 
it O 
was O 
phylogenetically O 
identified O 
as O 
Pseudomonas O 
sp O 
. O 
It O 
possessed O 
a O 
wide O 
range O 
of O 
pesticide O 
tolerance O 
, O 
ranging O 
from O 
117 O 
μg O 
mL(-1) O 
for O 
alphamethrin B-TRIVIAL 
to O 
2600 O 
μg O 
mL(-1) O 
for O 
endosulfan B-TRIVIAL 
. O 
The O 
available O 
P O 
concentrations O 
increased O 
with O 
the O 
maximum O 
and O 
double O 
the O 
maximum O 
dose O 
of O 
monocrotophos B-TRIVIAL 
and O 
imidacloprid B-TRIVIAL 
, O 
respectively O 
. O 
On O 
subjected O 
to O 
FT-IR O 
and O 
HPLC O 
analysis O 
, O 
the O 
presence O 
of O 
organic O 
acids O 
functional O 
group O 
in O 
the O 
culture O 
broth O 
and O 
the O 
production O 
of O 
gluconic B-TRIVIAL 
acid I-TRIVIAL 
as O 
dominant O 
acid O 
aiding O 
the O 
P O 
solubilization O 
were O 
identified O 
. O 
On O 
comparison O 
with O 
control O 
broth O 
, O 
monocrotophos B-TRIVIAL 
and O 
imidacloprid B-TRIVIAL 
added O 
culture O 
broth O 
showed O 
quantitatively O 
high O 
organic O 
acids O 
production O 
. O 
In O 
addition O 
to O 
gluconic B-TRIVIAL 
acid I-TRIVIAL 
production O 
, O 
citric B-MULTIPLE 
and I-MULTIPLE 
acetic I-MULTIPLE 
acids I-MULTIPLE 
were O 
also O 
observed O 
in O 
the O 
pesticide O 
amended O 
broth O 
. O 
Furthermore O 
, O 
the O 
Pseudomonas O 
sp O 
. O 
strain O 
SGRAJ09 O 
possessed O 
all O 
the O 
plant O 
growth O 
promoting O 
traits O 
tested O 
. O 
In O 
presence O 
of O 
monocrotophos B-TRIVIAL 
and O 
imidacloprid B-TRIVIAL 
, O 
its O 
plant O 
growth O 
promoting O 
activities O 
were O 
lower O 
than O 
that O 
of O 
the O 
pesticides O 
unamended O 
treatment O 
. O 

of O 
the O 
Potent O 
Antiviral O 
1-Cinnamoyl-3,11-Dihydroxymeliacarpin B-SYSTEMATIC 
on O 
Cytokine O 
Production O 
by O 
Murine O 
Macrophages O 
Stimulated O 
with O 
HSV-2 O 
. O 

limonoid O 
1-cinnamoyl-3,11-dihydroxymeliacarpin B-SYSTEMATIC 
( O 
CDM B-ABBREVIATION 
) O 
isolated O 
from O 
leaf O 
extracts O 
of O 
Melia O 
azedarach O 
L O 
, O 
has O 
potent O 
antiherpetic O 
effect O 
in O 
epithelial O 
cells O 
. O 
Since O 
Meliacine O 
, O 
the O 
partially O 
purified O 
extract O 
source O 
of O 
CDM B-ABBREVIATION 
, O 
has O 
therapeutic O 
effect O 
on O 
murine O 
genital O 
herpes O 
, O 
the O 
potential O 
use O 
of O 
CDM B-ABBREVIATION 
as O 
microbicide O 
against O 
herpetic O 
infections O 
was O 
studied O 
here O 
. O 
To O 
determine O 
the O 
cytotoxic O 
effect O 
of O 
CDM B-ABBREVIATION 
, O 
the O 
MTT B-ABBREVIATION 
assay O 
and O 
acridine O 
orange O 
staining O 
of O 
living O 
cells O 
were O 
performed O 
. O 
The O 
antiherpetic O 
action O 
of O 
CDM B-ABBREVIATION 
was O 
measured O 
by O 
plaque O 
reduction O 
assay O 
, O 
and O 
the O 
immunomodulatory O 
effect O 
was O 
determined O 
by O 
measuring O 
the O 
cytokine O 
production O 
using O 
a O 
bioassay O 
and O 
ELISA O 
method O 
. O 
The O 
results O 
presented O 
here O 
showed O 
that O 
CDM B-ABBREVIATION 
inhibited O 
Herpes O 
Simplex O 
Virus O 
type O 
2 O 
( O 
HSV-2 O 
) O 
multiplication O 
in O 
Vero O 
cells O 
but O 
did O 
not O 
affect O 
its O 
replication O 
in O 
macrophages O 
which O 
were O 
not O 
permissive O 
to O 
HSV O 
infection O 
. O 
In O 
macrophages O 
, O 
levels O 
of O 
TNF-α O 
, O 
IFN-γ O 
, O 
NO O 
, O 
IL-6 O 
and O 
IL-10 O 
were O 
increased O 
by O 
CDM B-ABBREVIATION 
used O 
alone O 
or O 
in O 
combination O 
with O 
HSV-2 O 
. O 
Besides O 
, O 
CDM B-ABBREVIATION 
not O 
only O 
synergized O 
TNF-α O 
production O 
combined O 
with O 
IFN-γ O 
, O 
but O 
also O 
prolonged O 
its O 
expression O 
in O 
time O 
. O 
Results O 
indicate O 
that O 
CDM B-ABBREVIATION 
inhibits O 
HSV-2 O 
multiplication O 
in O 
epithelial O 
cells O 
and O 
also O 
increases O 
cytokine O 
production O 
in O 
macrophages O 
, O 
both O 
important O 
actions O 
to O 
the O 
clearance O 
of O 
infecting O 
virus O 
in O 
the O 
mouse O 
vagina O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

to O 
the O 
increased O 
prevalence O 
of O 
bacterial O 
strains O 
that O 
are O 
resistant O 
to O 
existing O 
antibiotics O 
, O 
there O 
is O 
an O 
urgent O 
need O 
for O 
new O 
antibacterial O 
strategies O 
. O 
Bacterial O 
glycans O 
are O 
an O 
attractive O 
target O 
for O 
new O 
treatments O 
, O 
as O 
they O 
are O 
frequently O 
linked O 
to O 
pathogenesis O 
and O 
contain O 
distinctive O 
structures O 
that O 
are O 
absent O 
in O 
humans O 
. O 
We O 
set O 
out O 
to O 
develop O 
a O 
novel O 
targeting O 
strategy O 
based O 
on O 
surface O 
glycans O 
present O 
on O 
the O 
gastric O 
pathogen O 
Helicobacter O 
pylori O 
( O 
Hp O 
) O 
. O 
In O 
this O 
study O 
, O 
metabolic O 
labeling O 
of O 
bacterial O 
glycans O 
with O 
an O 
azide B-SYSTEMATIC 
-containing O 
sugar O 
allowed O 
selective O 
delivery O 
of O 
immune O 
stimulants O 
to O 
azide B-SYSTEMATIC 
-covered O 
Hp O 
. O 
We O 
established O 
that O 
Hp's O 
surface O 
glycans O 
are O 
labeled O 
by O 
treatment O 
with O 
the O 
metabolic O 
substrate O 
peracetylated B-SYSTEMATIC 
N-azidoacetylglucosamine I-SYSTEMATIC 
( O 
Ac4 B-FORMULA 
GlcNAz I-FORMULA 
) O 
. O 
By O 
contrast O 
, O 
mammalian O 
cells O 
treated O 
with O 
Ac4 B-FORMULA 
GlcNAz I-FORMULA 
exhibited O 
no O 
incorporation O 
of O 
the O 
chemical O 
label O 
within O 
extracellular O 
glycans O 
. O 
We O 
further O 
demonstrated O 
that O 
the O 
Staudinger O 
ligation O 
between O 
azides B-FAMILY 
and O 
phosphines B-FAMILY 
proceeds O 
under O 
acidic O 
conditions O 
with O 
only O 
a O 
small O 
loss O 
of O 
efficiency O 
. O 
We O 
then O 
targeted O 
azide B-SYSTEMATIC 
-covered O 
Hp O 
with O 
phosphines B-FAMILY 
conjugated O 
to O 
the O 
immune O 
stimulant O 
2,4-dinitrophenyl B-SYSTEMATIC 
( O 
DNP B-ABBREVIATION 
) O 
, O 
a O 
compound O 
capable O 
of O 
directing O 
a O 
host O 
immune O 
response O 
against O 
these O 
cells O 
. O 
Finally O 
, O 
we O 
report O 
that O 
immune O 
effector O 
cells O 
catalyze O 
selective O 
damage O 
in O 
vitro O 
to O 
DNP B-ABBREVIATION 
-covered O 
Hp O 
in O 
the O 
presence O 
of O 
anti- O 
DNP B-ABBREVIATION 
antibodies O 
. O 
The O 
technology O 
reported O 
herein O 
represents O 
a O 
novel O 
strategy O 
to O 
target O 
Hp O 
based O 
on O 
its O 
glycans O 
. O 

Polymeric O 
Micelles O 
with O 
Aggregation-Induced O 
Emission O 
Properties O 
for O 
Monitoring O 
the O 
Encapsulation O 
of O 
Doxorubicin B-TRIVIAL 
. O 

new O 
type O 
of O 
fluorescent O 
polymeric O 
micelles O 
is O 
developed O 
by O 
self O 
- O 
assembly O 
from O 
a O 
series O 
of O 
amphiphilic O 
block O 
copolymers O 
, O 
poly(ethylene B-SYSTEMATIC 
glycol)-b-poly[styrene-co-(2-(1,2,3,4,5-pentaphenyl-1H-silol-1-yloxy)ethyl I-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
] I-SYSTEMATIC 
[ O 
PEG-b-P(S-co-PPSEMA) B-ABBREVIATION 
] O 
. O 
Their O 
capability O 
of O 
loading O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
is O 
investigated O 
by O 
monitoring O 
the O 
loading O 
content O 
, O 
encapsulation O 
efficiency O 
, O 
and O 
photophysical O 
properties O 
of O 
micelles O 
. O 
Förster O 
resonance O 
energy O 
transfer O 
from O 
PPSEMA B-ABBREVIATION 
to O 
DOX B-ABBREVIATION 
is O 
observed O 
in O 
DOX B-ABBREVIATION 
-loaded O 
micelles O 
, O 
which O 
can O 
serve O 
as O 
an O 
indication O 
of O 
successful O 
encapsulation O 
of O 
DOX B-ABBREVIATION 
in O 
these O 
micelles O 
. O 
The O 
application O 
of O 
this O 
new O 
type O 
of O 
fluorescent O 
polymeric O 
micelles O 
as O 
a O 
fluorescent O 
probe O 
and O 
an O 
anticancer O 
drug O 
carrier O 
simultaneously O 
is O 
explored O 
by O 
studying O 
the O 
intracellular O 
uptake O 
of O 
DOX B-ABBREVIATION 
-loaded O 
micelles O 
. O 

role O 
of O 
platelet O 
/ O 
lymphocyte O 
serotonin B-TRIVIAL 
transporter O 
in O 
depression O 
and O 
beyond O 
. O 

large O 
amount O 
of O 
the O 
data O 
gathered O 
in O 
the O 
last O 
50 O 
years O 
support O 
the O 
hypothesis O 
that O 
alterations O 
of O 
the O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
neurotransmission O 
play O 
a O 
crucial O 
role O 
in O 
the O 
pathophysiology O 
of O 
not O 
only O 
major O 
depression O 
( O 
MD O 
) O 
, O 
but O 
also O 
of O 
different O 
neuropsychiatric O 
disorders O 
. O 
Research O 
in O 
this O 
field O 
has O 
been O 
substantially O 
promoted O 
by O 
the O 
evidence O 
that O 
the O 
reuptake O 
protein O 
( O 
SERT O 
) O 
, O 
present O 
in O 
presynaptic O 
neurons O 
, O 
is O 
a O 
key O 
element O 
in O 
terminating O 
the O 
activity O 
of O 
the O 
neurotransmitter O 
in O 
the O 
synaptic O 
cleft O 
. O 
For O 
this O 
reason O 
, O 
it O 
was O 
specifically O 
targeted O 
for O 
the O 
development O 
of O 
second O 
- O 
generation O 
antidepressants O 
, O 
in O 
particular O 
of O 
selective O 
5-HT B-SYSTEMATIC 
reuptake O 
inhibitors O 
( O 
SSRIs O 
) O 
, O 
with O 
the O 
aim O 
of O 
increasing O 
the O 
intrasynaptic O 
5-HT B-SYSTEMATIC 
concentrations O 
. O 
Moreover O 
, O 
since O 
a O 
lot O 
of O 
studies O 
showed O 
that O 
circulating O 
platelets O 
and O 
, O 
more O 
recently O 
, O 
lymphocytes O 
possess O 
functional O 
SERT O 
proteins O 
, O 
they O 
have O 
been O 
widely O 
used O 
as O 
peripheral O 
mirrors O 
of O 
the O 
same O 
structures O 
located O 
in O 
the O 
central O 
nervous O 
system O 
. O 
The O 
presence O 
of O 
functional O 
SERT O 
in O 
blood O 
cells O 
suggests O 
strict O 
relationships O 
between O 
the O 
nervous O 
and O 
the O 
immune O 
system O 
that O 
need O 
to O 
be O 
better O 
clarified O 
in O 
MD O 
, O 
as O 
well O 
as O 
the O 
possibility O 
of O 
reciprocal O 
modulation O 
of O 
the O 
two O 
systems O 
by O 
different O 
drugs O 
. O 
This O 
paper O 
aims O 
to O 
review O 
briefly O 
the O 
literature O 
on O 
the O 
5-HT B-SYSTEMATIC 
hypothesis O 
of O 
depression O 
with O 
a O 
major O 
focus O 
on O 
the O 
possible O 
role O 
of O 
SERT O 
in O 
this O 
disorder O 
, O 
while O 
highlighting O 
how O 
recent O 
data O 
are O 
more O 
oriented O 
on O 
dimensional O 
rather O 
than O 
nosological O 
involvement O 
of O 
this O 
structure O 
in O 
different O 
conditions O 
spanning O 
from O 
normality O 
to O 
pathology O 
. O 

C8- O 
Linked O 
Pyrrolobenzodiazepine B-FAMILY 
- O 
Biaryl B-FAMILY 
Conjugates O 
with O 
Femtomolar O 
in O 
Vitro O 
Cytotoxicity O 
and O 
in O 
Vivo O 
Antitumor O 
Activity O 
in O 
Mouse O 
Models O 
. O 

binding O 
4-(1-methyl-1H-pyrrol-3-yl)benzenamine B-SYSTEMATIC 
( O 
MPB B-ABBREVIATION 
) O 
building O 
blocks O 
have O 
been O 
developed O 
that O 
span O 
two O 
DNA O 
base O 
pairs O 
with O 
a O 
strong O 
preference O 
for O 
GC-rich O 
DNA O 
. O 
They O 
have O 
been O 
conjugated O 
to O 
a O 
pyrrolo[2,1-c][1,4]benzodiazepine B-SYSTEMATIC 
( O 
PBD B-ABBREVIATION 
) O 
molecule O 
to O 
produce O 
C8- O 
linked O 
PBD-MPB B-ABBREVIATION 
hybrids O 
that O 
can O 
stabilize O 
GC-rich O 
DNA O 
by O 
up O 
to O 
13-fold O 
compared O 
to O 
AT-rich O 
DNA O 
. O 
Some O 
have O 
subpicomolar O 
IC50 O 
values O 
in O 
human O 
tumor O 
cell O 
lines O 
and O 
in O 
primary O 
chronic O 
lymphocytic O 
leukemia O 
cells O 
, O 
while O 
being O 
up O 
to O 
6 O 
orders O 
less O 
cytotoxic O 
in O 
the O 
non-tumor O 
cell O 
line O 
WI38 O 
, O 
suggesting O 
that O 
key O 
DNA O 
sequences O 
may O 
be O 
relevant O 
targets O 
in O 
these O 
ultrasensitive O 
cancer O 
cell O 
lines O 
. O 
One O 
conjugate O 
, O 
7h O 
( O 
KMR-28-39 B-IDENTIFIER 
) O 
, O 
which O 
has O 
femtomolar O 
activity O 
in O 
the O 
breast O 
cancer O 
cell O 
line O 
MDA-MB-231 O 
, O 
has O 
significant O 
dose O 
- O 
dependent O 
antitumor O 
activity O 
in O 
MDA-MB-231 O 
( O 
breast O 
) O 
and O 
MIA O 
PaCa-2 O 
( O 
pancreatic O 
) O 
human O 
tumor O 
xenograft O 
mouse O 
models O 
with O 
insignificant O 
toxicity O 
at O 
therapeutic O 
doses O 
. O 
Preliminary O 
studies O 
suggest O 
that O 
7h O 
may O 
sterically O 
inhibit O 
interaction O 
of O 
the O 
transcription O 
factor O 
NF-κB O 
with O 
its O 
cognate O 
DNA O 
binding O 
sequence O 
. O 

decades O 
high O 
- O 
density O 
lipoproteins O 
( O 
HDL O 
) O 
and O 
HDL- O 
cholesterol B-TRIVIAL 
( O 
HDL-C O 
) O 
levels O 
were O 
viewed O 
as O 
synonymous O 
and O 
modulation O 
of O 
HDL-C O 
levels O 
by O 
drug O 
therapy O 
held O 
great O 
promise O 
for O 
the O 
prevention O 
and O 
treatment O 
of O 
cardiovascular O 
disease O 
. O 
Nevertheless O 
, O 
recent O 
failures O 
of O 
drugs O 
that O 
raise O 
HDL-C O 
to O 
reduce O 
cardiovascular O 
risk O 
and O 
the O 
now O 
greater O 
understanding O 
of O 
the O 
complexity O 
of O 
HDL O 
composition O 
and O 
biology O 
have O 
prompted O 
researchers O 
in O 
the O 
field O 
to O 
redefine O 
HDL O 
. O 
As O 
such O 
, O 
the O 
focus O 
of O 
HDL O 
has O 
now O 
started O 
to O 
shift O 
away O 
from O 
a O 
cholesterol B-TRIVIAL 
centric O 
view O 
towards O 
HDL O 
particle O 
number O 
, O 
subclasses O 
, O 
and O 
other O 
alternative O 
metrics O 
of O 
HDL O 
. O 
Many O 
of O 
the O 
recently O 
discovered O 
functions O 
of O 
HDL O 
are O 
, O 
in O 
fact O 
, O 
not O 
strictly O 
conferred O 
by O 
its O 
ability O 
to O 
promote O 
cholesterol B-TRIVIAL 
flux O 
, O 
but O 
by O 
the O 
other O 
molecules O 
it O 
transports O 
, O 
including O 
a O 
diverse O 
set O 
of O 
proteins O 
, O 
small O 
RNAs O 
, O 
hormones O 
, O 
carotenoids O 
, O 
vitamins O 
, O 
and O 
bioactive O 
lipids O 
. O 
Based O 
on O 
the O 
ability O 
of O 
HDL O 
to O 
interact O 
with O 
almost O 
all O 
cells O 
and O 
transport O 
and O 
deliver O 
fat O 
- O 
soluble O 
cargo O 
, O 
HDL O 
has O 
the O 
remarkable O 
capacity O 
to O 
affect O 
a O 
wide-variety O 
of O 
endocrine O 
- O 
like O 
systems O 
. O 
Here O 
in O 
this O 
review O 
, O 
we O 
characterize O 
the O 
unique O 
cargo O 
on O 
HDL O 
and O 
address O 
the O 
functional O 
relevance O 
and O 
consequences O 
of O 
HDL O 
transport O 
and O 
delivery O 
of O 
non- O 
cholesterol B-TRIVIAL 
molecules O 
to O 
recipient O 
cells O 
and O 
tissues O 
. O 

of O 
estrogenic O 
effects O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
and O 
organochlorinated B-FAMILY 
pesticides O 
using O 
immature O 
rat O 
uterotrophic O 
assay O 
. O 

this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
and O 
organochlorinated B-FAMILY 
pesticides O 
on O 
the O 
serum O 
levels O 
of O 
luteinising O 
hormone O 
( O 
LH O 
) O 
, O 
follicle O 
stimulating O 
hormone O 
( O 
FSH O 
) O 
and O 
weights O 
and O 
histomorphometry O 
of O 
uterine O 
tissue O 
in O 
immature O 
female O 
rats O 
using O 
uterotrophic O 
assay O 
. O 
A O 
total O 
of O 
36 O 
rats O 
were O 
randomly O 
divided O 
into O 
six O 
groups O 
( O 
n O 
= O 
6 O 
per O 
group O 
) O 
as O 
control O 
, O 
oestradiol B-TRIVIAL 
( O 
E2 O 
, O 
100 O 
μg O 
/ O 
kg O 
) O 
, O 
PCB B-IDENTIFIER 
180 I-IDENTIFIER 
, O 
Aroclor B-TRIVIAL 
1221 I-TRIVIAL 
, O 
endosulfan B-TRIVIAL 
and O 
mirex B-TRIVIAL 
at O 
10 O 
mg O 
/ O 
kg O 
dosage O 
. O 
After O 
3 O 
days O 
of O 
injections O 
( O 
subcutaneous O 
) O 
, O 
animals O 
were O 
decapitated O 
and O 
blood O 
samples O 
were O 
collected O 
. O 
Uteri O 
were O 
dissected O 
, O 
weighed O 
out O 
and O 
then O 
fixed O 
in O 
10% O 
formaldehyde B-SYSTEMATIC 
. O 
They O 
were O 
processed O 
for O 
histomorphometry O 
. O 
The O 
serum O 
levels O 
of O 
LH O 
and O 
FSH O 
were O 
determined O 
by O 
enzyme O 
immunoassay.Uterine O 
weight O 
was O 
significantly O 
increased O 
by O 
E2 O 
and O 
reduced O 
by O 
mirex B-TRIVIAL 
( O 
p O 
< O 
0.001 O 
and O 
p O 
< O 
0.05 O 
, O 
respectively O 
) O 
. O 
Total O 
volume O 
of O 
uterus O 
was O 
significantly O 
raised O 
by O 
E2 O 
, O 
Aroclor B-TRIVIAL 
1221 I-TRIVIAL 
and O 
endosulfan B-TRIVIAL 
compared O 
with O 
that O 
of O 
the O 
control O 
group O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
ratio O 
of O 
epithelium O 
was O 
significantly O 
increased O 
by O 
E2 O 
, O 
PCBs B-ABBREVIATION 
and O 
pesticides O 
( O 
p O 
< O 
0.01 O 
) O 
. O 
The O 
uterine O 
cavity O 
ratio O 
was O 
decreased O 
by O 
aroclor O 
( O 
p O 
< O 
0.01 O 
) O 
, O 
PCB B-IDENTIFIER 
180 I-IDENTIFIER 
and O 
mirex B-TRIVIAL 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
serum O 
levels O 
of O 
LH O 
did O 
not O 
significantly O 
differ O 
among O 
the O 
groups O 
but O 
the O 
levels O 
of O 
FSH O 
were O 
decreased O 
by O 
PCB B-IDENTIFIER 
180 I-IDENTIFIER 
and O 
endosulfan B-TRIVIAL 
( O 
p O 
< O 
0.05 O 
and O 
p O 
< O 
0.01 O 
, O 
respectively O 
) O 
. O 
These O 
findings O 
suggest O 
that O 
PCB B-IDENTIFIER 
180 I-IDENTIFIER 
, O 
Aroclor B-TRIVIAL 
1221 I-TRIVIAL 
and O 
endosulfan B-TRIVIAL 
may O 
be O 
estrogenic O 
in O 
immature O 
uterotrophic O 
assay O 
. O 

escitalopram B-TRIVIAL 
treatment O 
inhibits O 
REM O 
sleep O 
rebound O 
and O 
activation O 
of O 
MCH-expressing O 
neurons O 
in O 
the O 
lateral O 
hypothalamus O 
after O 
long O 
term O 
selective O 
REM O 
sleep O 
deprivation O 
. O 

: O 
Selective O 
rapid O 
eye O 
movement O 
sleep O 
( O 
REMS O 
) O 
deprivation O 
using O 
the O 
platform O 
- O 
on O 
- O 
water O 
( O 
" O 
flower O 
pot O 
" O 
) O 
method O 
causes O 
sleep O 
rebound O 
with O 
increased O 
REMS O 
, O 
decreased O 
REMS O 
latency O 
, O 
and O 
activation O 
of O 
the O 
melanin O 
- O 
concentrating O 
hormone O 
( O 
MCH O 
) O 
expressing O 
neurons O 
in O 
the O 
hypothalamus O 
. O 
MCH O 
is O 
implicated O 
in O 
the O 
pathomechanism O 
of O 
depression O 
regarding O 
its O 
influence O 
on O 
mood O 
, O 
feeding O 
behavior O 
, O 
and O 
REMS O 
. O 
OBJECTIVES O 
: O 
We O 
investigated O 
the O 
effects O 
of O 
the O 
most O 
selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitor O 
escitalopram B-TRIVIAL 
on O 
sleep O 
rebound O 
following O 
REMS O 
deprivation O 
and O 
, O 
in O 
parallel O 
, O 
on O 
the O 
activation O 
of O 
MCH O 
- O 
containing O 
neurons O 
. O 
METHODS O 
: O 
Escitalopram B-TRIVIAL 
or O 
vehicle O 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
intraperitoneally O 
) O 
was O 
administered O 
to O 
REMS-deprived O 
( O 
72 O 
h O 
) O 
or O 
home O 
cage O 
male O 
Wistar O 
rats O 
. O 
During O 
the O 
3-h-long O 
" O 
rebound O 
sleep O 
" O 
, O 
electroencephalography O 
was O 
recorded O 
, O 
followed O 
by O 
an O 
MCH O 
/ O 
Fos O 
double O 
immunohistochemistry O 
. O 
RESULTS O 
: O 
During O 
REMS O 
rebound O 
, O 
the O 
time O 
spent O 
in O 
REMS O 
and O 
the O 
number O 
of O 
MCH O 
/ O 
Fos O 
double O 
- O 
labeled O 
neurons O 
in O 
the O 
lateral O 
hypothalamus O 
increased O 
markedly O 
, O 
and O 
REMS O 
latency O 
showed O 
a O 
significant O 
decrease O 
. O 
All O 
these O 
effects O 
of O 
REMS O 
deprivation O 
were O 
significantly O 
attenuated O 
by O 
escitalopram B-TRIVIAL 
treatment O 
. O 
Besides O 
the O 
REMS-suppressing O 
effects O 
, O 
escitalopram B-TRIVIAL 
caused O 
an O 
increase O 
in O 
amount O 
of O 
and O 
decrease O 
in O 
latency O 
of O 
slow O 
wave O 
sleep O 
during O 
the O 
rebound O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
show O 
that O 
despite O 
the O 
high O 
REMS O 
pressure O 
caused O 
by O 
REMS O 
deprivation O 
procedure O 
, O 
escitalopram B-TRIVIAL 
has O 
the O 
ability O 
to O 
suppress O 
REMS O 
rebound O 
, O 
as O 
well O 
as O 
to O 
diminish O 
the O 
activation O 
of O 
MCH O 
- O 
containing O 
neurons O 
, O 
in O 
parallel O 
. O 
Escitalopram B-TRIVIAL 
caused O 
a O 
shift O 
from O 
REMS O 
to O 
slow O 
wave O 
sleep O 
during O 
the O 
rebound O 
. O 
Furthermore O 
, O 
these O 
data O 
point O 
to O 
the O 
potential O 
connection O 
between O 
the O 
serotonergic O 
system O 
and O 
MCH O 
in O 
sleep O 
regulation O 
, O 
which O 
can O 
be O 
relevant O 
in O 
depression O 
and O 
in O 
other O 
mood O 
disorders O 
. O 

involved O 
in O 
the O 
antinociceptive O 
effects O 
of O 
orally O 
administered O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
mouse O 
. O 

antinociceptive O 
effects O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
were O 
examined O 
in O 
ICR O 
mice O 
. O 
Oleanolic B-TRIVIAL 
acid I-TRIVIAL 
administered O 
orally O 
( O 
1 O 
, O 
5 O 
and O 
10 O 
mg O 
/ O 
kg O 
) O 
showed O 
an O 
antinociceptive O 
effect O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
as O 
measured O 
in O 
the O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
-induced O 
writhing O 
test O 
. O 
In O 
the O 
time- O 
course O 
study O 
, O 
duration O 
of O 
antinociceptive O 
action O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
maintained O 
at O 
least O 
for O 
60 O 
min O 
. O 
In O 
addition O 
, O 
the O 
cumulative O 
nociceptive O 
response O 
time O 
for O 
intraplantar O 
formalin O 
injection O 
( O 
2nd O 
phase O 
) O 
, O 
intrathecal O 
injection O 
of O 
substance O 
P O 
( O 
0.7 O 
μg O 
) O 
or O 
glutamate B-TRIVIAL 
( O 
20 O 
μg O 
) O 
was O 
diminished O 
by O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Intraperitoneal O 
( O 
i.p O 
. O 
) O 
pretreatment O 
with O 
naloxone B-TRIVIAL 
( O 
opioid O 
receptor O 
antagonist O 
) O 
or O 
methysergide B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
serotonergic O 
receptor O 
antagonist O 
) O 
attenuated O 
antinociceptive O 
effect O 
induced O 
by O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
writhing O 
test O 
. O 
However O 
, O 
yohimbine B-TRIVIAL 
( O 
adrenergic O 
receptor O 
antagonist O 
) O 
did O 
not O 
affect O 
antinociception O 
induced O 
by O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
results O 
indicate O 
that O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
shows O 
an O 
antinociceptive O 
property O 
in O 
various O 
pain O 
models O 
such O 
as O 
writhing O 
, O 
formalin B-TRIVIAL 
, O 
substance O 
P O 
and O 
glutamate B-TRIVIAL 
pain O 
tests O 
. O 
Furthermore O 
, O 
this O 
antinociceptive O 
effect O 
of O 
oleanolic B-TRIVIAL 
acid I-TRIVIAL 
may O 
be O 
mediated O 
by O 
opioidergic O 
and O 
serotonergic O 
receptors O 
, O 
but O 
not O 
adrenergic O 
receptors O 
. O 

topography O 
effects O 
in O 
protein O 
adsorption O 
on O 
nanostructured O 
carbon B-SYSTEMATIC 
allotropes O 
. O 

report O 
a O 
molecular O 
dynamics O 
( O 
MD O 
) O 
simulation O 
study O 
of O 
protein O 
adsorption O 
on O 
the O 
surface O 
of O 
nanosized O 
carbon B-SYSTEMATIC 
allotropes O 
, O 
namely O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWNT O 
) O 
considering O 
both O 
the O 
convex O 
outer O 
surface O 
and O 
the O 
concave O 
inner O 
surface O 
, O 
together O 
with O 
a O 
graphene B-TRIVIAL 
sheet O 
for O 
comparison O 
. O 
These O 
systems O 
are O 
chosen O 
to O 
investigate O 
the O 
effect O 
of O 
the O 
surface O 
curvature O 
on O 
protein O 
adsorption O 
at O 
the O 
same O 
surface O 
chemistry O 
, O 
given O 
by O 
sp(2) O 
carbon B-SYSTEMATIC 
atoms O 
in O 
all O 
cases O 
. O 
The O 
simulations O 
show O 
that O 
proteins O 
do O 
favorably O 
interact O 
with O 
these O 
hydrophobic O 
surfaces O 
, O 
as O 
previously O 
found O 
on O 
graphite B-TRIVIAL 
which O 
has O 
the O 
same O 
chemical O 
nature O 
. O 
However O 
, O 
the O 
main O 
finding O 
of O 
the O 
present O 
study O 
is O 
that O 
the O 
adsorption O 
strength O 
does O 
depend O 
on O 
the O 
surface O 
topography O 
: O 
in O 
particular O 
, O 
it O 
is O 
slightly O 
weaker O 
on O 
the O 
outer O 
convex O 
surfaces O 
of O 
SWNT O 
and O 
is O 
conversely O 
enhanced O 
on O 
the O 
inner O 
concave O 
SWNT O 
surface O 
, O 
being O 
therefore O 
intermediate O 
for O 
flat O 
graphene B-TRIVIAL 
. O 
We O 
additionally O 
find O 
that O 
oligopeptides O 
may O 
enter O 
the O 
cavity O 
of O 
common O 
SWNT O 
, O 
provided O 
their O 
size O 
is O 
small O 
enough O 
and O 
the O 
tube O 
diameter O 
is O 
large O 
enough O 
for O 
both O 
entropic O 
and O 
energetic O 
reasons O 
. O 
Therefore O 
, O 
we O 
suggest O 
that O 
proteins O 
can O 
effectively O 
be O 
used O 
to O 
solubilize O 
in O 
water O 
single O 
- O 
walled O 
( O 
and O 
by O 
analogy O 
also O 
multiwalled O 
) O 
carbon B-SYSTEMATIC 
nanotubes O 
through O 
adsorption O 
on O 
the O 
outer O 
surface O 
, O 
as O 
indeed O 
experimentally O 
found O 
, O 
and O 
to O 
functionalize O 
them O 
after O 
insertion O 
of O 
oligopeptides O 
within O 
the O 
cavity O 
of O 
nanotubes O 
of O 
appropriate O 
size O 
. O 

experimentally O 
demonstrate O 
that O 
plasmonic O 
nanoparticles O 
embedded O 
in O 
the O 
evanescent O 
field O 
of O 
subwavelength O 
optical O 
waveguides O 
( O 
WGs O 
) O 
are O 
highly O 
sensitive O 
to O 
distances O 
normal O 
to O 
the O 
propagation O 
of O 
light O 
, O 
showing O 
an O 
∼10× O 
increase O 
in O 
spatial O 
resolution O 
compared O 
to O 
the O 
optical O 
field O 
decay O 
of O 
the O 
WG O 
. O 
The O 
scattering O 
cross O 
- O 
section O 
of O 
the O 
Au B-FORMULA 
nanoparticle O 
is O 
increased O 
by O 
the O 
plasmon O 
- O 
dielectric O 
coupling O 
interaction O 
when O 
the O 
nanoparticle O 
is O 
placed O 
near O 
the O 
dielectric O 
surface O 
of O 
the O 
WG O 
, O 
and O 
the O 
decay O 
of O 
the O 
scattering O 
signal O 
is O 
enhanced O 
, O 
showing O 
angstrom O 
level O 
distance O 
sensitivity O 
within O 
10 O 
nm O 
from O 
the O 
WG O 
. O 
Numerical O 
studies O 
with O 
the O 
finite O 
- O 
difference O 
time O 
- O 
domain O 
( O 
FDTD O 
) O 
method O 
correlate O 
well O 
with O 
the O 
experimental O 
results O 
. O 
To O 
demonstrate O 
real O 
- O 
time O 
monitoring O 
of O 
a O 
single O 
molecule O 
stretching O 
in O 
the O 
evanescent O 
field O 
, O 
we O 
linked O 
individual O 
single O 
- O 
stranded O 
DNA O 
molecules O 
between O 
the O 
WG O 
and O 
plasmonic O 
nanoparticles O 
and O 
pushed O 
on O 
the O 
nanoparticles O 
with O 
fluidic O 
forces O 
. O 
The O 
simple O 
design O 
and O 
ease O 
of O 
obtaining O 
optical O 
feedback O 
on O 
molecular O 
displacements O 
makes O 
our O 
approach O 
ideal O 
for O 
new O 
in O 
situ O 
force O 
sensing O 
devices O 
, O 
imaging O 
technologies O 
, O 
and O 
high O 
- O 
throughput O 
molecular O 
analysis O 
. O 

Fragment O 
Screening O 
of O 
the O 
β1-Adrenergic O 
Receptor O 
: O 
Identification O 
of O 
High O 
Affinity O 
Arylpiperazine B-FAMILY 
Leads O 
Using O 
Structure O 
- O 
Based O 
Drug O 
Design O 
. O 

fragment O 
screening O 
of O 
a O 
thermostabilized O 
β1-adrenergic O 
receptor O 
( O 
β1AR O 
) O 
using O 
surface O 
plasmon O 
resonance O 
( O 
SPR O 
) O 
enabled O 
the O 
identification O 
of O 
moderate O 
affinity O 
, O 
high O 
ligand O 
efficiency O 
( O 
LE O 
) O 
arylpiperazine B-FAMILY 
hits O 
7 O 
and O 
8 O 
. O 
Subsequent O 
hit O 
to O 
lead O 
follow O 
- O 
up O 
confirmed O 
the O 
activity O 
of O 
the O 
chemotype O 
, O 
and O 
a O 
structure O 
- O 
based O 
design O 
approach O 
using O 
protein O 
- O 
ligand O 
crystal O 
structures O 
of O 
the O 
β1AR O 
resulted O 
in O 
the O 
identification O 
of O 
several O 
fragments O 
that O 
bound O 
with O 
higher O 
affinity O 
, O 
including O 
indole B-SYSTEMATIC 
19 O 
and O 
quinoline B-SYSTEMATIC 
20 O 
. O 
In O 
the O 
first O 
example O 
of O 
GPCR O 
crystallography O 
with O 
ligands O 
derived O 
from O 
fragment O 
screening O 
, O 
structures O 
of O 
the O 
stabilized O 
β1AR O 
complexed O 
with O 
19 O 
and O 
20 O 
were O 
determined O 
at O 
resolutions O 
of O 
2.8 O 
and O 
2.7 O 
Å O 
, O 
respectively O 
. O 

Discovery O 
of O 
Thailanstatins B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
As O 
Pre-mRNA O 
Splicing O 
Inhibitors O 
and O 
Antiproliferative O 
Agents O 
from O 
Burkholderia O 
thailandensis O 
MSMB43 O 
. O 

the O 
genome O 
sequence O 
of O 
Burkholderia O 
thailandensis O 
MSMB43 O 
revealed O 
a O 
cryptic O 
biosynthetic O 
gene O 
cluster O 
resembling O 
that O 
of O 
FR901464 B-IDENTIFIER 
( O 
4 O 
) O 
, O 
a O 
prototype O 
spliceosome O 
inhibitor O 
produced O 
by O 
Pseudomonas O 
sp O 
. O 
No O 
. O 
2663 O 
. O 
Transcriptional O 
analysis O 
revealed O 
a O 
cultivation O 
condition O 
in O 
which O 
a O 
regulatory O 
gene O 
of O 
the O 
cryptic O 
gene O 
cluster O 
is O 
adequately O 
expressed O 
. O 
Consequently O 
, O 
three O 
new O 
compounds O 
, O 
named O 
thailanstatins B-FAMILY 
A O 
( O 
1 O 
) O 
, O 
B O 
( O 
2 O 
) O 
, O 
and O 
C O 
( O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
fermentation O 
broth O 
of O 
B O 
. O 
thailandensis O 
MSMB43 O 
. O 
Thailanstatins B-FAMILY 
are O 
proposed O 
to O 
be O 
biosynthesized O 
by O 
a O 
hybrid O 
polyketide O 
synthase O 
- O 
nonribosomal O 
peptide O 
synthetase O 
pathway O 
. O 
They O 
differ O 
from O 
4 O 
by O 
lacking O 
an O 
unstable O 
hydroxyl B-SYSTEMATIC 
group O 
and O 
by O 
having O 
an O 
extra O 
carboxyl B-SYSTEMATIC 
moiety O 
; O 
those O 
differences O 
endow O 
thailanstatins B-FAMILY 
with O 
a O 
significantly O 
greater O 
stability O 
than O 
4 O 
as O 
tested O 
in O 
phosphate B-SYSTEMATIC 
buffer O 
at O 
pH O 
7.4 O 
. O 
In O 
vitro O 
assays O 
showed O 
that O 
thailanstatins B-FAMILY 
inhibit O 
pre-mRNA O 
splicing O 
as O 
potently O 
as O 
4 O 
, O 
with O 
half O 
- O 
maximal O 
inhibitory O 
concentrations O 
in O 
the O 
single O 
to O 
sub-μM O 
range O 
. O 
Cell O 
culture O 
assays O 
indicated O 
that O 
thailanstatins B-FAMILY 
also O 
possess O 
potent O 
antiproliferative O 
activities O 
in O 
representative O 
human O 
cancer O 
cell O 
lines O 
, O 
with O 
half O 
- O 
maximal O 
growth O 
inhibitory O 
concentrations O 
in O 
the O 
single O 
nM O 
range O 
. O 
This O 
work O 
provides O 
new O 
chemical O 
entities O 
for O 
research O 
and O 
development O 
and O 
new O 
structure O 
- O 
activity O 
information O 
for O 
chemical O 
optimization O 
of O 
related O 
spliceosome O 
inhibitors O 
. O 

Inhibition O 
of O 
Human O 
Colon O 
Carcinoma O 
Cells O 
by O 
Sesquiterpenoids B-FAMILY 
and O 
Tetralones B-FAMILY 
of O 
Zygogynum O 
calothyrsum O 
. O 

- O 
guided O 
phytochemical O 
investigation O 
of O 
Zygogynum O 
calothyrsum O 
using O 
the O 
human O 
colon O 
carcinoma O 
cell O 
lines O 
COLO205 O 
and O 
KM12 O 
led O 
to O 
the O 
isolation O 
of O 
three O 
new O 
drimane O 
- O 
type O 
sesquiterpenoids B-FAMILY 
, O 
1β-p-hydroxy-E-cinnamoyldrimeninol B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
1β-p-hydroxy-E-cinnamoyl-5α-hydroxydrimeninol B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
methyl B-SYSTEMATIC 
ether I-SYSTEMATIC 
of I-SYSTEMATIC 
1β-p-hydroxy-E-cinnamoyl-12α-methoxydrimeninol I-SYSTEMATIC 
( O 
3 O 
) O 
. O 
Also O 
isolated O 
was O 
the O 
known O 
1β-p-coumaroyloxypolygodial B-SYSTEMATIC 
( O 
4 O 
) O 
together O 
with O 
two O 
new O 
tetralones B-FAMILY 
, O 
3'-deoxyisozygolone B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
5 O 
) O 
and O 
calothyrlone B-TRIVIAL 
A I-TRIVIAL 
( O 
9 O 
) O 
, O 
three O 
known O 
tetralones O 
, O 
isozygolone B-TRIVIAL 
A I-TRIVIAL 
( O 
6 O 
) O 
, O 
zygolone B-TRIVIAL 
A I-TRIVIAL 
( O 
7 O 
) O 
, O 
and O 
4'-O-methylzygolone B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
and O 
a O 
known O 
cinnamolide B-TRIVIAL 
( O 
10 O 
) O 
. O 
Compounds O 
1 O 
, O 
7 O 
, O 
and O 
8 O 
demonstrated O 
higher O 
cytotoxicity O 
against O 
COLO205 O 
( O 
GI50 O 
18 O 
, O 
17 O 
, O 
and O 
11 O 
μM O 
, O 
respectively O 
) O 
and O 
KM12 O 
( O 
GI50 O 
14 O 
, O 
14 O 
, O 
and O 
17 O 
μM O 
, O 
respectively O 
) O 
than O 
the O 
other O 
compounds O 
. O 

Lanostanoids B-FAMILY 
and O 
Lactone B-FAMILY 
Derivatives O 
from O 
Antrodia O 
camphorata O 
. O 

new O 
lanostanoids B-FAMILY 
, O 
ethyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
ethyl B-SYSTEMATIC 
lucidenate I-SYSTEMATIC 
F I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
15-O-acetylganolucidate B-SYSTEMATIC 
A I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
3,11,15,23-tetraoxo-27ξ-lanosta-8,16-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
two O 
new O 
lactone B-FAMILY 
derivatives O 
, O 
5-hydroxy-5-(methoxymethyl)-4-methylfuran-2(5H)-one B-SYSTEMATIC 
( O 
5 O 
) O 
and O 
3-(4-methoxy-2-oxo-2H-pyran-6-yl)propanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
together O 
with O 
four O 
known O 
compounds O 
, O 
11α-hydroxy-3,7-dioxolanost-8,24(E)-dien-26- B-SYSTEMATIC 
oic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
7 O 
) O 
, O 
3,7,11-trioxo-5α-lanosta-8,24(E)-dien-26-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
8 O 
) O 
, O 
methyl B-SYSTEMATIC 
3,7,11,12,15,23-hexaoxo-5α-lanost-8-en-26-oate I-SYSTEMATIC 
( O 
9 O 
) O 
, O 
and O 
ethyl B-SYSTEMATIC 
3,7,11,12,15,23-hexaoxo-5α-lanost-8-en-26-oate I-SYSTEMATIC 
( O 
10 O 
) O 
, O 
were O 
characterized O 
from O 
Antrodia O 
camphorata O 
. O 
The O 
structures O 
of O 
these O 
new O 
compounds O 
were O 
determined O 
by O 
analysis O 
of O 
their O 
spectroscopic O 
data O 
, O 
including O 
1D O 
and O 
2D O 
NMR O 
experiments O 
. O 
Ten O 
components O 
were O 
evaluated O 
for O 
anti-inflammatory O 
activity O 
by O 
examining O 
their O 
effect O 
on O 
LPS-iNOS-dependent O 
NO B-FORMULA 
production O 
in O 
murine O 
macrophage O 
( O 
RAW O 
264.7 O 
) O 
cells O 
. O 
Among O 
them O 
, O 
compounds O 
1 O 
, O 
3 O 
, O 
7 O 
, O 
8 O 
, O 
9 O 
, O 
and O 
10 O 
significantly O 
suppressed O 
the O 
NO B-FORMULA 
concentration O 
in O 
LPS O 
- O 
treated O 
RAW O 
264.7 O 
cells O 
with O 
IC50 O 
values O 
≤ O 
10 O 
μM O 
. O 

- O 
assembly O 
of O 
conjugated O 
2,5-dialkoxy-phenylene- B-SYSTEMATIC 
thienylene I-SYSTEMATIC 
-based O 
oligomers O 
on O 
epitaxial O 
monolayer O 
graphene B-TRIVIAL 
was O 
studied O 
in O 
ultrahigh O 
vacuum O 
by O 
low O 
- O 
temperature O 
scanning O 
tunneling O 
microscopy O 
( O 
STM O 
) O 
. O 
The O 
formation O 
of O 
long O 
one O 
- O 
dimensional O 
( O 
1D O 
) O 
supramolecular O 
chain O 
- O 
like O 
structures O 
has O 
been O 
observed O 
, O 
associated O 
to O 
a O 
physical O 
linking O 
of O 
their O 
ends O 
which O 
involved O 
the O 
rotation O 
of O 
the O 
end O 
thiophene B-SYSTEMATIC 
rings O 
in O 
order O 
to O 
allow O 
π-π O 
stacking O 
of O 
these O 
end O 
- O 
groups O 
. O 
dI O 
/ O 
dV O 
maps O 
taken O 
at O 
an O 
energy O 
corresponding O 
to O 
the O 
excited O 
states O 
showed O 
a O 
continuous O 
electronic O 
density O 
of O 
states O 
, O 
which O 
tentatively O 
suggests O 
that O 
within O 
such O 
molecular O 
chains O 
conjugation O 
of O 
electrons O 
is O 
preserved O 
even O 
across O 
physically O 
linked O 
molecules O 
. O 
Thus O 
, O 
in O 
a O 
self O 
- O 
organization O 
process O 
conjugation O 
may O 
be O 
extended O 
by O 
appropriately O 
adapting O 
conformations O 
of O 
neighboring O 
molecules O 
. O 
Our O 
STM O 
results O 
on O 
such O 
self O 
- O 
organized O 
end O 
- O 
linked O 
molecules O 
potentially O 
represent O 
a O 
direct O 
visualization O 
of O 
J-aggregates O 
. O 

Cross-Linking O 
of O 
Alginates O 
with O 
Caged O 
Ca(2+) B-FORMULA 

strategy O 
to O 
light O 
- O 
trigger O 
ionic O 
cross O 
- O 
linking O 
of O 
alginates O 
by O 
incorporating O 
a O 
photosensitive O 
Ca(2+) B-FORMULA 
cage O 
( O 
nitr-T O 
) O 
is O 
presented O 
. O 
Upon O 
irradiation O 
, O 
free O 
Ca(2+) B-FORMULA 
was O 
released O 
, O 
and O 
this O 
caused O 
gelation O 
of O 
the O 
alginate O 
solution O 
. O 
Addition O 
of O 
Ca(2+) B-FORMULA 
" O 
on O 
- O 
demand O 
" O 
allowed O 
us O 
to O 
obtain O 
homogeneous O 
alginate O 
( O 
ALG O 
) O 
gels O 
using O 
concentrated O 
initial O 
ALG O 
solutions O 
( O 
10% O 
) O 
, O 
not O 
possible O 
with O 
other O 
ionic O 
gelation O 
approaches O 
. O 
The O 
cross O 
- O 
linking O 
degree O 
and O 
derived O 
mechanical O 
properties O 
of O 
the O 
hydrogel O 
were O 
modulated O 
by O 
the O 
exposure O 
dose O 
. O 
The O 
light O 
- O 
mediated O 
cross O 
- O 
linked O 
alginate O 
hydrogel O 
displayed O 
a O 
significant O 
improvement O 
in O 
the O 
mechanical O 
properties O 
and O 
homogeneity O 
when O 
compared O 
to O 
mixtures O 
of O 
alginate O 
and O 
soluble O 
Ca(2+) B-FORMULA 
at O 
comparable O 
concentrations O 
. O 

Bind O 
Only O 
Weakly O 
to O 
Amides B-FAMILY 
in O 
Aqueous O 
Solutions O 
. O 

investigated O 
salt O 
interactions O 
with O 
butyramide B-SYSTEMATIC 
as O 
a O 
simple O 
mimic O 
of O 
cation O 
interactions O 
with O 
protein O 
backbones O 
. O 
The O 
experiments O 
were O 
performed O 
in O 
aqueous O 
metal O 
chloride B-SYSTEMATIC 
solutions O 
using O 
two O 
spectroscopic O 
techniques O 
. O 
In O 
the O 
first O 
, O 
which O 
provided O 
information O 
about O 
contact O 
pair O 
formation O 
, O 
the O 
response O 
of O 
the O 
amide B-FAMILY 
I O 
band O 
to O 
the O 
nature O 
and O 
concentration O 
of O 
salt O 
was O 
monitored O 
in O 
bulk O 
aqueous O 
solutions O 
via O 
attenuated O 
total O 
reflection O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
. O 
It O 
was O 
found O 
that O 
molar O 
concentrations O 
of O 
well O 
- O 
hydrated O 
metal O 
cations O 
( O 
Ca(2+) B-FORMULA 
, O 
Mg(2+) B-FORMULA 
, O 
Li(+) B-FORMULA 
) O 
led O 
to O 
the O 
rise O 
of O 
a O 
peak O 
assigned O 
to O 
metal O 
cation O 
- O 
bound O 
amides B-FAMILY 
( O 
1645 O 
cm(-1) O 
) O 
and O 
a O 
decrease O 
in O 
the O 
peak O 
associated O 
with O 
purely O 
water O 
- O 
bound O 
amides B-FAMILY 
( O 
1620 O 
cm(-1) O 
) O 
. O 
In O 
a O 
complementary O 
set O 
of O 
experiments O 
, O 
the O 
effect O 
of O 
cation O 
identity O 
and O 
concentration O 
was O 
investigated O 
at O 
the O 
air/ O 
butyramide B-SYSTEMATIC 
/ O 
water O 
interface O 
via O 
vibrational O 
sum O 
frequency O 
spectroscopy O 
. O 
In O 
these O 
studies O 
, O 
metal O 
ion- O 
amide B-FAMILY 
binding O 
led O 
to O 
the O 
ordering O 
of O 
the O 
adjacent O 
water O 
layer O 
. O 
Such O 
experiments O 
were O 
sensitive O 
to O 
the O 
interfacial O 
partitioning O 
of O 
cations O 
in O 
either O 
a O 
contact O 
pair O 
with O 
the O 
amide B-FAMILY 
or O 
as O 
a O 
solvent O 
separated O 
pair O 
. O 
In O 
both O 
experiments O 
, O 
the O 
ordering O 
of O 
the O 
interactions O 
of O 
the O 
cations O 
was O 
: O 
Ca(2+) B-FORMULA 
> O 
Mg(2+) B-FORMULA 
> O 
Li(+) B-FORMULA 
> O 
Na(+) B-FORMULA 
≈ O 
K(+) B-FORMULA 
. O 
This O 
is O 
a O 
direct O 
cationic O 
Hofmeister O 
series O 
. O 
Even O 
for O 
Ca(2+) B-FORMULA 
, O 
however O 
, O 
the O 
apparent O 
equilibrium O 
dissociation O 
constant O 
of O 
the O 
cation O 
with O 
the O 
amide B-SYSTEMATIC 
carbonyl I-SYSTEMATIC 
oxygen I-SYSTEMATIC 
was O 
no O 
tighter O 
than O 
∼8.5 O 
M O 
. O 
For O 
Na(+) B-FORMULA 
and O 
K(+) B-FORMULA 
, O 
no O 
evidence O 
was O 
found O 
for O 
any O 
binding O 
. O 
As O 
such O 
, O 
the O 
interactions O 
of O 
metal O 
cations O 
with O 
amides B-FAMILY 
are O 
far O 
weaker O 
than O 
the O 
analogous O 
binding O 
of O 
weakly O 
hydrated O 
anions O 
. O 

pharmacokinetics O 
of O 
N(ω)-hydroxy-nor-L-arginine B-SYSTEMATIC 
, O 
an O 
arginase O 
inhibitor O 
, O 
after O 
single O 
- O 
dose O 
intravenous O 
, O 
intraperitoneal O 
and O 
intratracheal O 
administration O 
to O 
brown O 
Norway O 
rats O 
. O 

1 O 
. O 
Rodent O 
studies O 
have O 
documented O 
that O 
N O 
(ω)-hydroxy-nor-L-arginine B-SYSTEMATIC 
( O 
n O 
or-NOHA B-TRIVIAL 
) I-TRIVIAL 
, O 
an O 
arginase O 
inhibitor O 
, O 
has O 
therapeutic O 
potential O 
in O 
the O 
treatment O 
of O 
cardiovascular O 
and O 
obstructive O 
airway O 
diseases O 
. O 
However O 
, O 
its O 
bioavailability O 
and O 
pharmacokinetics O 
have O 
not O 
been O 
described O 
so O 
far O 
. O 
2 O 
. O 
Anesthetized O 
brown O 
Norway O 
rats O 
were O 
administered O 
single O 
doses O 
of O 
no O 
r-NOHA B-TRIVIAL 
( I-TRIVIAL 
10 O 
, O 
30 O 
or O 
90 O 
mg O 
/ O 
kg O 
) O 
intravenously O 
( O 
i.v O 
. O 
) O 
, O 
intraperitonealy O 
( O 
i.p O 
. O 
) O 
or O 
via O 
intratracheal O 
( O 
i.t O 
. O 
) O 
instillation O 
of O 
aerosol O 
. O 
Plasma O 
n O 
or-NOHA B-TRIVIAL 
was O 
assayed O 
using O 
a O 
validated O 
HPLC O 
method O 
. O 
3 O 
. O 
Upon O 
i.v O 
. O 
administration O 
, O 
the O 
mean O 
concentration O 
showed O 
a O 
biphasic O 
decline O 
and O 
its O 
value O 
dropped O 
below O 
10% O 
of O 
the O 
maximum O 
after O 
20 O 
min O 
. O 
The O 
pharmacokinetics O 
were O 
linear O 
with O 
the O 
total O 
and O 
inter O 
- O 
compartmental O 
clearances O 
of O 
33 O 
and O 
17 O 
mL O 
/ O 
min O 
/ O 
kg O 
, O 
central O 
and O 
peripheral O 
volumes O 
of O 
distribution O 
of O 
0.19 O 
and O 
0.43 O 
L O 
/ O 
kg O 
and O 
terminal O 
half O 
- O 
life O 
of O 
30 O 
min O 
. O 
4 O 
. O 
The O 
average O 
absolute O 
bioavailability O 
of O 
nor O 
-NOHA B-TRIVIAL 
af I-TRIVIAL 
ter O 
i.p O 
. O 
and O 
i.t O 
. O 
delivery O 
was O 
98% O 
and O 
53% O 
, O 
respectively O 
. O 
The O 
absorption O 
from O 
the O 
airways O 
was O 
rate O 
- O 
limiting O 
and O 
its O 
extent O 
decreased O 
with O 
the O 
dose O 
. O 
5 O 
. O 
In O 
conclusion O 
, O 
nor- O 
NOHA B-TRIVIAL 
is I-TRIVIAL 
rapidly O 
cleared O 
from O 
the O 
plasma O 
in O 
concordance O 
with O 
the O 
short O 
time O 
window O 
of O 
its O 
in O 
vivo O 
inhibitory O 
activity O 
reported O 
in O 
the O 
literature O 
. O 
I.t O 
. O 
instillation O 
of O 
aerosol O 
for O 
topical O 
effects O 
of O 
nor- O 
NOHA B-TRIVIAL 
in I-TRIVIAL 
the O 
airways O 
is O 
characterized O 
with O 
significant O 
systemic O 
availability O 
. O 

Zinc-Blende B-SYSTEMATIC 
GaAs B-FORMULA 
/ O 
(Ga,Mn)As B-FORMULA 
Core-Shell O 
Nanowires O 
with O 
Ferromagnetic O 
Ordering O 
. O 

self O 
- O 
catalyzed O 
vapor O 
- O 
liquid O 
- O 
solid O 
growth O 
of O 
GaAs B-FORMULA 
nanowires O 
and O 
low O 
- O 
temperature O 
molecular O 
- O 
beam O 
epitaxy O 
of O 
(Ga,Mn)As B-FORMULA 
, O 
we O 
successfully O 
synthesized O 
all O 
zinc B-SYSTEMATIC 
- I-SYSTEMATIC 
blende I-SYSTEMATIC 
( O 
ZB O 
) O 
GaAs B-FORMULA 
/ O 
(Ga,Mn)As B-FORMULA 
core O 
- O 
shell O 
nanowires O 
on O 
Si B-FORMULA 
( O 
111 O 
) O 
substrates O 
. O 
The O 
ZB O 
GaAs B-FORMULA 
nanowire O 
cores O 
are O 
first O 
fabricated O 
at O 
high O 
temperature O 
by O 
utilizing O 
the O 
Ga B-FORMULA 
droplets O 
as O 
the O 
catalyst O 
and O 
controlling O 
the O 
triple O 
phase O 
line O 
nucleation O 
, O 
then O 
the O 
(Ga,Mn)As B-FORMULA 
shells O 
are O 
epitaxially O 
grown O 
on O 
the O 
side O 
facets O 
of O 
the O 
GaAs B-FORMULA 
core O 
at O 
low O 
temperature O 
. O 
The O 
growth O 
window O 
for O 
the O 
pure O 
phase O 
GaAs B-FORMULA 
/ O 
(Ga,Mn)As B-FORMULA 
core O 
- O 
shell O 
nanowires O 
is O 
found O 
to O 
be O 
very O 
narrow O 
. O 
Both O 
high O 
- O 
resolution O 
transmission O 
electron O 
microscopy O 
and O 
scanning O 
electron O 
microscopy O 
observations O 
confirm O 
that O 
all-ZB O 
GaAs B-FORMULA 
/ O 
(Ga,Mn)As B-FORMULA 
core O 
- O 
shell O 
nanowires O 
with O 
smooth O 
side O 
surface O 
are O 
obtained O 
when O 
the O 
Mn B-FORMULA 
concentration O 
is O 
not O 
more O 
than O 
2% O 
and O 
the O 
growth O 
temperature O 
is O 
245 O 
°C O 
or O 
below O 
. O 
Magnetic O 
measurements O 
with O 
different O 
applied O 
field O 
directions O 
provide O 
strong O 
evidence O 
for O 
ferromagnetic O 
ordering O 
in O 
the O 
all-ZB O 
GaAs B-FORMULA 
/ O 
(Ga,Mn)As B-FORMULA 
nanowires O 
. O 
The O 
hybrid O 
nanowires O 
offer O 
an O 
attractive O 
platform O 
to O 
explore O 
spin O 
transport O 
and O 
device O 
concepts O 
in O 
fully O 
epitaxial O 
all O 
- O 
semiconductor O 
nanospintronic O 
structures O 
. O 

Derivatives O 
of O 
Retro-2 O 
with O 
Enhanced O 
Efficacy O 
against O 
Shiga O 
Toxin O 
. O 

Retro-2 O 
molecule O 
protects O 
cells O 
against O 
Shiga O 
toxins O 
by O 
specifically O 
blocking O 
retrograde O 
transport O 
from O 
early O 
endosomes O 
to O 
the O 
trans-Golgi O 
network O 
. O 
A O 
SAR O 
study O 
has O 
been O 
carried O 
out O 
to O 
identify O 
more O 
potent O 
compounds O 
. O 
Cyclization O 
and O 
modifications O 
of O 
Retro-2 O 
led O 
to O 
a O 
compound O 
with O 
roughly O 
100-fold O 
improvement O 
of O 
the O 
EC50 O 
against O 
Shiga O 
toxin O 
cytotoxicity O 
measured O 
in O 
a O 
cell O 
protein O 
synthesis O 
assay O 
. O 
We O 
also O 
demonstrated O 
that O 
only O 
one O 
enantiomer O 
of O 
the O 
dihydroquinazolinone B-SYSTEMATIC 
reported O 
herein O 
is O 
bioactive O 
. O 

TEMPO B-ABBREVIATION 
: O 
A O 
genotoxic O 
and O 
oxidative O 
stress O 
inducer O 
in O 
cultured O 
cells O 
. O 

( O 
TEMPO B-ABBREVIATION 
) O 
is O 
a O 
low O 
molecular O 
weight O 
nitroxide O 
and O 
stable O 
free O 
radical O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
cytotoxicity O 
and O 
genotoxicity O 
of O 
TEMPO B-ABBREVIATION 
in O 
mammalian O 
cells O 
using O 
the O 
mouse O 
lymphoma O 
assay O 
( O 
MLA O 
) O 
and O 
in O 
vitro O 
micronucleus O 
assay O 
. O 
In O 
the O 
absence O 
of O 
metabolic O 
activation O 
( O 
S9 O 
) O 
, O 
3mM O 
TEMPO B-ABBREVIATION 
produced O 
significant O 
cytotoxicity O 
and O 
marginal O 
mutagenicity O 
in O 
the O 
MLA O 
; O 
in O 
the O 
presence O 
of O 
S9 O 
, O 
treatment O 
of O 
mouse O 
lymphoma O 
cells O 
with O 
1-2mM O 
TEMPO B-ABBREVIATION 
resulted O 
in O 
dose O 
- O 
dependent O 
decreases O 
of O 
the O 
relative O 
total O 
growth O 
and O 
increases O 
in O 
mutant O 
frequency O 
. O 
Treatment O 
of O 
TK6 O 
human O 
lymphoblastoid O 
cells O 
with O 
0.9-2.3mM O 
TEMPO B-ABBREVIATION 
increased O 
the O 
frequency O 
of O 
both O 
micronuclei O 
( O 
a O 
marker O 
for O 
clastogenicity O 
) O 
and O 
hypodiploid O 
nuclei O 
( O 
a O 
marker O 
of O 
aneugenicity O 
) O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
; O 
greater O 
responses O 
were O 
produced O 
in O 
the O 
presence O 
of O 
S9 O 
. O 
Within O 
the O 
dose O 
range O 
tested O 
, O 
TEMPO B-ABBREVIATION 
induced O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
and O 
decreased O 
glutathione B-TRIVIAL 
levels O 
in O 
mouse O 
lymphoma O 
cells O 
. O 
In O 
addition O 
, O 
the O 
majority O 
of O 
TEMPO B-ABBREVIATION 
-induced O 
mutants O 
had O 
loss O 
of O 
heterozygosity O 
at O 
the O 
Tk O 
locus O 
, O 
with O 
allele O 
loss O 
of O 
⩽34Mbp O 
. O 
These O 
results O 
indicate O 
that O 
TEMPO B-ABBREVIATION 
is O 
mutagenic O 
in O 
the O 
MLA O 
and O 
induces O 
micronuclei O 
and O 
hypodiploid O 
nuclei O 
in O 
TK6 O 
cells O 
. O 
Oxidative O 
stress O 
may O 
account O 
for O 
part O 
of O 
the O 
genotoxicity O 
induced O 
by O 
TEMPO B-ABBREVIATION 
in O 
both O 
cell O 
lines O 
. O 

exposure O 
in O 
childhood O 
: O 
discerning O 
pathology O 
from O 
physiology O 
. O 

: O 
Testosterone B-TRIVIAL 
( O 
T O 
) O 
drives O 
normal O 
male O 
sexual O 
development O 
both O 
in O 
utero O 
and O 
at O 
puberty O 
. O 
Aberrant O 
T O 
exposure O 
manifests O 
as O 
virilization O 
of O 
a O 
female O 
fetus O 
, O 
contrasexual O 
precocity O 
in O 
girls O 
, O 
and O 
isosexual O 
precocity O 
in O 
boys O 
. O 
Evidence O 
of O 
pathologic O 
T O 
exposure O 
warrants O 
a O 
prompt O 
evaluation O 
. O 
Areas O 
covered O 
: O 
The O 
authors O 
introduce O 
the O 
topic O 
of O 
T O 
exposure O 
in O 
children O 
by O 
reviewing O 
its O 
physiology O 
in O 
the O 
fetus O 
and O 
during O 
childhood O 
and O 
adolescence O 
. O 
Pathologic O 
conditions O 
leading O 
to O 
virilization O 
of O 
a O 
female O 
fetus O 
as O 
well O 
as O 
androgen B-FAMILY 
-mediated O 
gonadotropin O 
- O 
independent O 
precocious O 
puberty O 
in O 
both O 
genders O 
are O 
then O 
discussed O 
. O 
The O 
authors O 
finish O 
by O 
noting O 
exogenous O 
T O 
exposure O 
in O 
children O 
and O 
adolescents O 
, O 
focusing O 
specifically O 
on O 
secondary O 
exposure O 
to O 
topical O 
T O 
preparations O 
. O 
Expert O 
opinion O 
: O 
Contrasexual O 
precocity O 
in O 
a O 
girl O 
or O 
sexual O 
precocity O 
in O 
a O 
boy O 
should O 
prompt O 
evaluation O 
for O 
causes O 
of O 
gonadotropin O 
- O 
independent O 
pubertal O 
changes O 
. O 
Initial O 
biochemical O 
evaluation O 
includes O 
a O 
bone O 
age O 
, O 
T O 
, O 
17-hydroxyprogesterone B-SYSTEMATIC 
, O 
androstenedione B-TRIVIAL 
, O 
dehydroepiandrosterone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
DHEA-S B-ABBREVIATION 
) O 
and O 
high O 
sensitivity O 
gonadotropin O 
levels O 
. O 
The O 
provider O 
must O 
query O 
exposure O 
to O 
topical O 
androgen B-FAMILY 
-containing O 
preparations O 
as O 
unintentional O 
secondary O 
exposure O 
to O 
topical O 
T O 
must O 
be O 
considered O 
. O 
Hyperandrogenism O 
is O 
temporally O 
related O 
to O 
exposure O 
of O 
topical O 
T O 
and O 
removal O 
of O 
exposure O 
results O 
in O 
a O 
marked O 
decrease O 
in O 
serum O 
T O 
as O 
well O 
as O 
resolution O 
or O 
stabilization O 
of O 
the O 
signs O 
and O 
symptoms O 
. O 

induction O 
of O 
apoptosis O 
in O 
HeLa O 
cells O 
by O 
a O 
novel O 
cationic O 
porphycene B-TRIVIAL 
photosensitizer O 
. O 

the O 
present O 
study O 
we O 
analyze O 
the O 
photobiological O 
properties O 
of O 
2,7,12-tris(α-pyridinio-p-tolyl)-17-(p-(methoxymethyl)phenyl) B-SYSTEMATIC 
porphycene I-SYSTEMATIC 
( O 
Py3MeO-TBPo B-ABBREVIATION 
) O 
in O 
Hela O 
cells O 
, O 
in O 
order O 
to O 
assess O 
its O 
potential O 
as O 
a O 
new O 
photosensitizer O 
for O 
photodynamic O 
therapy O 
of O 
cultured O 
tumor O 
cells O 
. O 
Using O 
0.5 O 
μM O 
Py3MeO-TBPo B-ABBREVIATION 
, O 
flow O 
cytometry O 
studies O 
demonstrated O 
an O 
increase O 
of O 
intracellular O 
drug O 
levels O 
related O 
to O 
the O 
incubation O 
time O 
, O 
reaching O 
a O 
maximum O 
at O 
18 O 
h O 
. O 
LysoTracker(®) O 
Green O 
( O 
LTG O 
) O 
and O 
MitoTracker(®) O 
Green O 
( O 
MTG O 
) O 
probes O 
were O 
used O 
to O 
identify O 
the O 
subcellular O 
localization O 
. O 
Upon O 
exposure O 
to O 
ultraviolet O 
excitation O 
, O 
red O 
porphycene B-TRIVIAL 
fluorescence O 
was O 
detected O 
as O 
red O 
granules O 
in O 
the O 
cytoplasm O 
that O 
colocalized O 
with O 
LTG O 
. O 
No O 
significant O 
toxic O 
effects O 
were O 
detected O 
for O 
Py3MeO-TBPo B-ABBREVIATION 
in O 
the O 
dark O 
at O 
concentrations O 
below O 
1 O 
μM O 
. O 
In O 
contrast O 
, O 
Py3MeO-TBPo B-ABBREVIATION 
combined O 
with O 
red O 
- O 
light O 
irradiation O 
induced O 
concentration- O 
and O 
fluence O 
- O 
dependent O 
HeLa O 
cells O 
inactivation O 
. O 
Besides O 
, O 
all O 
photodynamic O 
protocols O 
assayed O 
induced O 
a O 
clear O 
effect O 
of O 
cell O 
detachment O 
inhibition O 
after O 
trypsin O 
treatment O 
. O 
Both O 
apoptotic O 
and O 
necrotic O 
cell O 
death O 
mechanisms O 
can O 
occur O 
in O 
HeLa O 
cells O 
depending O 
on O 
the O 
experimental O 
protocol O 
. O 
After O 
18 O 
h O 
incubation O 
with O 
0.5 O 
μM O 
Py3MeO-TBPo B-ABBREVIATION 
and O 
subsequent O 
red O 
light O 
irradiation O 
( O 
3.6 O 
J O 
/ O 
cm(2) O 
) O 
, O 
a O 
high O 
number O 
of O 
cells O 
die O 
by O 
apoptosis O 
, O 
as O 
evaluated O 
by O 
morphological O 
alterations O 
, O 
immunofluorescent O 
relocalization O 
of O 
Bax O 
from O 
cytosol O 
to O 
mitochondria O 
, O 
and O 
TUNEL O 
assay O 
. O 
Likewise O 
, O 
immunofluorescence O 
techniques O 
showed O 
that O 
cytochrome O 
c O 
is O 
released O 
from O 
mitochondria O 
into O 
cytosol O 
in O 
cells O 
undergoing O 
apoptosis O 
, O 
which O 
occurs O 
immediately O 
after O 
relocation O 
of O 
Bax O 
in O 
mitochondria O 
. O 
The O 
highest O 
amount O 
of O 
apoptosis O 
appeared O 
24 O 
h O 
after O 
treatment O 
( O 
70% O 
) O 
and O 
this O 
cell O 
death O 
occurred O 
without O 
cell O 
detachment O 
to O 
the O 
substrate O 
. O 
In O 
contrast O 
, O 
with O 
0.75 O 
μM O 
Py3MeO-TBPo B-ABBREVIATION 
and O 
3.6 O 
J O 
/ O 
cm(2) O 
irradiation O 
, O 
morphological O 
changes O 
showed O 
a O 
preferential O 
necrotic O 
cell O 
death O 
. O 
Singlet O 
oxygen B-SYSTEMATIC 
was O 
identified O 
as O 
the O 
cytotoxic O 
agent O 
involved O 
in O 
cell O 
photoinactivation O 
. O 
Moreover O 
, O 
cell O 
cultures O 
pre O 
- O 
exposed O 
to O 
the O 
singlet O 
oxygen B-SYSTEMATIC 
scavenger O 
sodium B-SYSTEMATIC 
azide I-SYSTEMATIC 
showed O 
pronounced O 
protection O 
against O 
the O 
loss O 
of O 
viability O 
induced O 
by O 
Py3MeO-TBPo B-ABBREVIATION 
and O 
light O 
. O 
Different O 
changes O 
in O 
distribution O 
and O 
organization O 
of O 
cytoskeletal O 
elements O 
( O 
microtubules O 
and O 
actin O 
microfilaments O 
) O 
as O 
well O 
as O 
the O 
protein O 
vinculin O 
, O 
after O 
apoptotic O 
and O 
necrotic O 
photodynamic O 
treatments O 
have O 
been O 
analyzed O 
. O 
Neither O 
of O 
these O 
two O 
cell O 
death O 
mechanisms O 
( O 
apoptosis O 
or O 
necrosis O 
) O 
induced O 
cell O 
detachment O 
. O 
In O 
summary O 
, O 
Py3MeO-TBPo B-ABBREVIATION 
appears O 
to O 
meet O 
the O 
requirements O 
for O 
further O 
scrutiny O 
as O 
a O 
very O 
good O 
photosensitizer O 
for O 
photodynamic O 
therapy O 
: O 
it O 
is O 
water O 
soluble O 
, O 
has O 
a O 
high O 
absorption O 
in O 
the O 
red O 
spectral O 
region O 
( O 
where O 
light O 
penetration O 
in O 
tissue O 
is O 
higher O 
) O 
, O 
and O 
is O 
able O 
to O 
induce O 
effective O 
high O 
apoptotic O 
rate O 
( O 
70% O 
) O 
related O 
to O 
the O 
more O 
widely O 
studied O 
photosensitizers O 
. O 

( O 
Oxm O 
) O 
is O 
a O 
37-amino O 
acid O 
peptide O 
linked O 
to O 
alleviation O 
of O 
obesity O 
- O 
diabetes O 
through O 
a O 
dual O 
mode O 
of O 
action O 
mediated O 
at O 
both O 
glucagon O 
and O 
GLP-1 O 
receptors O 
. O 
GIP O 
is O 
the O 
principle O 
physiological O 
regulator O 
of O 
postprandial O 
insulin O 
secretion O 
. O 
Therefore O 
, O 
the O 
primary O 
aim O 
was O 
to O 
design O 
a O 
novel O 
GIP-Oxm O 
peptide O 
incorporating O 
the O 
actions O 
of O 
GIP O 
, O 
GLP-1 O 
and O 
glucagon O 
in O 
a O 
single O 
molecule O 
. O 
The O 
first O 
11 O 
N B-FORMULA 
-terminal O 
residues O 
of O 
Oxm O 
were O 
substituted O 
with O 
the O 
sequence O 
of O 
stable O 
dA(2)GIP O 
molecule O 
to O 
generate O 
a O 
novel O 
GIP-Oxm O 
peptide O 
( O 
dA(2)GIP-Oxm O 
) O 
. O 
dA(2)GIP-Oxm O 
was O 
resistant O 
to O 
DPP-IV O 
and O 
significantly O 
stimulated O 
in O 
vitro O 
insulin O 
release O 
. O 
dA(2)GIP-Oxm O 
stimulated O 
cAMP B-ABBREVIATION 
production O 
in O 
GIP-R O 
, O 
glucagon-R O 
and O 
GLP-1-R O 
transfected O 
cells O 
by O 
up O 
to O 
95% O 
, O 
83% O 
and O 
77% O 
of O 
that O 
elicited O 
by O 
respective O 
native O 
ligands O 
. O 
Acute O 
administration O 
of O 
dA(2)GIP-Oxm O 
to O 
HFF O 
mice O 
resulted O 
in O 
reduced O 
plasma O 
glucose B-TRIVIAL 
( O 
45% O 
reduction O 
) O 
and O 
increased O 
insulin O 
concentrations O 
( O 
1.7-fold O 
increase O 
) O 
. O 
Furthermore O 
, O 
dA(2)GIP-Oxm O 
lowered O 
plasma O 
glucose B-TRIVIAL 
( O 
42% O 
reduction O 
) O 
and O 
increased O 
plasma O 
insulin O 
( O 
1.6-fold O 
increase O 
) O 
when O 
administered O 
to O 
HFF O 
mice O 
four O 
hours O 
prior O 
to O 
a O 
glucose B-TRIVIAL 
load O 
. O 
Once O 
- O 
daily O 
administration O 
of O 
dA(2)GIP-Oxm O 
for O 
15 O 
days O 
in O 
HFF O 
mice O 
lowered O 
body O 
weight O 
( O 
13% O 
reduction O 
) O 
, O 
reduced O 
plasma O 
glucose B-TRIVIAL 
( O 
40% O 
reduction O 
) O 
and O 
increased O 
plasma O 
insulin O 
( O 
1.7-fold O 
increase O 
) O 
. O 
Furthermore O 
, O 
glycemic O 
responses O 
were O 
improved O 
( O 
38% O 
reduction O 
) O 
and O 
glucose B-TRIVIAL 
-mediated O 
plasma O 
insulin O 
concentrations O 
enhanced O 
( O 
2-fold O 
increase O 
) O 
. O 
These O 
improvements O 
in O 
metabolic O 
control O 
were O 
independent O 
of O 
changes O 
in O 
food O 
intake O 
and O 
insulin O 
sensitivity O 
. O 
dA(2)GIP-Oxm O 
exerts O 
positive O 
beneficial O 
actions O 
on O 
glucose B-TRIVIAL 
homeostasis O 
, O 
beta-cell O 
insulin O 
secretion O 
and O 
body O 
weight O 
, O 
mediated O 
through O 
GIP O 
, O 
glucagon O 
and O 
GLP-1 O 
receptors O 
. O 
Such O 
multiple O 
- O 
acting O 
peptides O 
may O 
hold O 
promise O 
as O 
novel O 
therapies O 
for O 
obesity O 
- O 
diabetes O 
. O 

prevents O 
oxidative O 
burst O 
and O 
delays O 
apoptosis O 
in O 
human O 
neutrophils O 
. O 

is O 
a O 
frequently O 
prescribed O 
over O 
- O 
the O 
- O 
counter O 
drug O 
to O 
reduce O 
fever O 
and O 
pain O 
in O 
the O 
event O 
of O 
inflammatory O 
process O 
. O 
As O 
neutrophils O 
are O 
relevant O 
cells O 
in O 
inflammatory O 
processes O 
, O 
the O 
putative O 
interaction O 
of O 
acetaminophen B-TRIVIAL 
with O 
these O 
cells O 
, O 
if O 
present O 
, O 
would O 
be O 
of O 
paramount O 
importance O 
. O 
The O 
present O 
study O 
was O 
undertaken O 
to O 
evaluate O 
the O 
effect O 
of O 
acetaminophen B-TRIVIAL 
in O 
human O 
neutrophils O 
' O 
oxidative O 
burst O 
and O 
lifespan O 
in O 
vitro O 
. O 
The O 
obtained O 
results O 
demonstrate O 
that O 
acetaminophen B-TRIVIAL 
efficiently O 
modulates O 
neutrophils O 
' O 
oxidative O 
burst O 
in O 
phorbol B-SYSTEMATIC 
myristate I-SYSTEMATIC 
acetate I-SYSTEMATIC 
-activated O 
neutrophils O 
, O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
, O 
at O 
in O 
vivo O 
relevant O 
concentrations O 
. O 
It O 
was O 
clearly O 
demonstrated O 
that O 
acetaminophen B-TRIVIAL 
is O 
a O 
strong O 
scavenger O 
of O 
HOCl B-FORMULA 
and O 
H2O2 B-FORMULA 
, O 
which O 
probably O 
contributed O 
to O 
the O 
effect O 
observed O 
in O 
neutrophils O 
. O 
Acetaminophen B-TRIVIAL 
also O 
induced O 
the O 
depletion O 
of O 
glutathione B-TRIVIAL 
in O 
stimulated O 
neutrophils O 
, O 
suggesting O 
its O 
transformation O 
into O 
a O 
reactive O 
intermediate O 
. O 
Obtained O 
results O 
further O 
revealed O 
that O 
acetaminophen B-TRIVIAL 
affects O 
programmed O 
cell O 
death O 
of O 
human O 
neutrophils O 
, O 
resulting O 
in O 
a O 
delay O 
of O 
previously O 
stimulated O 
neutrophils O 
- O 
mediated O 
apoptosis O 
. O 
Overall O 
, O 
our O 
data O 
suggested O 
that O 
acetaminophen B-TRIVIAL 
has O 
considerable O 
potential O 
to O 
be O 
included O 
in O 
anti-inflammatory O 
therapeutic O 
strategies O 
, O 
by O 
preventing O 
biological O 
damage O 
induced O 
by O 
an O 
excessive O 
production O 
of O 
reactive O 
species O 
generated O 
in O 
activated O 
neutrophils O 
and O 
by O 
extending O 
the O 
lifespan O 
of O 
neutrophils O 
, O 
favoring O 
the O 
elimination O 
of O 
pathogens O 
, O 
thus O 
contributing O 
to O 
tissue O 
healing O 
and O 
resolution O 
of O 
inflammation O 
. O 

of O 
rare O 
- O 
earth O 
co O 
- O 
doping O 
on O 
the O 
local O 
structure O 
of O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
using O 
high O 
and O 
low O 
energy O 
X-ray O 
diffraction O 
. O 

- I-FAMILY 
earth I-FAMILY 
co O 
- O 
doping O 
in O 
inorganic O 
materials O 
has O 
a O 
long O 
- O 
held O 
tradition O 
of O 
facilitating O 
highly O 
desirable O 
optoelectronic O 
properties O 
for O 
their O 
application O 
to O 
the O 
laser O 
industry O 
. O 
This O 
study O 
concentrates O 
specifically O 
on O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
, O 
(R2O3)x(R'2O3)y(P2O5)1-(x+y) B-FAMILY 
, O 
where O 
( O 
R O 
, O 
R O 
' O 
) O 
denotes O 
( O 
Ce B-FORMULA 
, O 
Er B-FORMULA 
) O 
or O 
( O 
La B-FORMULA 
, O 
Nd B-FORMULA 
) O 
co O 
- O 
doping O 
and O 
the O 
total O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
composition O 
corresponds O 
to O 
a O 
range O 
between O 
metaphosphate B-FAMILY 
, O 
RP3O9 B-FAMILY 
, O 
and O 
ultraphosphate B-FAMILY 
, O 
RP5O14 B-FAMILY 
. O 
Thereupon O 
, O 
the O 
effects O 
of O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
co O 
- O 
doping O 
on O 
the O 
local O 
structure O 
are O 
assessed O 
at O 
the O 
atomic O 
level O 
. O 
Pair O 
- O 
distribution O 
function O 
analysis O 
of O 
high O 
- O 
energy O 
X-ray O 
diffraction O 
data O 
( O 
Qmax O 
= O 
28 O 
Å(-1) O 
) O 
is O 
employed O 
to O 
make O 
this O 
assessment O 
. O 
Results O 
reveal O 
a O 
stark O 
structural O 
invariance O 
to O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
co O 
- O 
doping O 
which O 
bears O 
testament O 
to O 
the O 
open O 
- O 
framework O 
and O 
rigid O 
nature O 
of O 
these O 
glasses O 
. O 
A O 
range O 
of O 
desirable O 
attributes O 
of O 
these O 
glasses O 
unfold O 
from O 
this O 
finding O 
; O 
in O 
particular O 
, O 
a O 
structural O 
simplicity O 
that O 
will O 
enable O 
facile O 
molecular O 
engineering O 
of O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
with O 
' O 
dial O 
- O 
up O 
' O 
lasing O 
properties O 
. O 
When O 
considered O 
together O 
with O 
other O 
factors O 
, O 
this O 
finding O 
also O 
demonstrates O 
additional O 
prospects O 
for O 
these O 
co O 
- O 
doped O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
in O 
nuclear O 
waste O 
storage O 
applications O 
. O 
This O 
study O 
also O 
reveals O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
ability O 
to O 
distinguish O 
between O 
P-O B-FORMULA 
and O 
P B-FORMULA 
[ O 
double O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
O B-FORMULA 
bonding O 
in O 
these O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
from O 
X-ray O 
diffraction O 
data O 
in O 
a O 
fully O 
quantitative O 
manner O 
. O 
Complementary O 
analysis O 
of O 
high O 
- O 
energy O 
X-ray O 
diffraction O 
data O 
on O 
single O 
rare B-FAMILY 
- I-FAMILY 
earth I-FAMILY 
phosphate I-FAMILY 
glasses O 
of O 
similar O 
rare O 
- O 
earth O 
composition O 
to O 
the O 
co O 
- O 
doped O 
materials O 
is O 
also O 
presented O 
in O 
this O 
context O 
. O 
In O 
a O 
technical O 
sense O 
, O 
all O 
high O 
- O 
energy O 
X-ray O 
diffraction O 
data O 
on O 
these O 
glasses O 
are O 
compared O 
with O 
analogous O 
low O 
- O 
energy O 
diffraction O 
data O 
; O 
their O 
salient O 
differences O 
reveal O 
distinct O 
advantages O 
of O 
high O 
- O 
energy O 
X-ray O 
diffraction O 
data O 
for O 
the O 
study O 
of O 
amorphous O 
materials O 
. O 

- O 
bonding O 
interactions O 
and O 
internal O 
dynamics O 
in O 
CH2F2H2CO B-FORMULA 
: O 
a O 
rotational O 
and O 
model O 
calculations O 
study O 
. O 

rotational O 
spectra O 
of O 
three O 
isotopologues O 
of O 
the O 
1 O 
: O 
1 O 
complex O 
between O 
difluoromethane B-SYSTEMATIC 
and O 
formaldehyde B-SYSTEMATIC 
have O 
been O 
observed O 
and O 
assigned O 
using O 
pulsed O 
jet O 
Fourier O 
transform O 
microwave O 
spectroscopy O 
. O 
The O 
formaldehyde B-SYSTEMATIC 
lies O 
in O 
the O 
FCF B-FORMULA 
plane O 
of O 
difluoromethane B-SYSTEMATIC 
, O 
linked O 
through O 
a O 
C-HF B-FORMULA 
and O 
a O 
bifurcated O 
CH2O B-FORMULA 
weak O 
hydrogen B-SYSTEMATIC 
bonds O 
. O 
The O 
rotational O 
transitions O 
are O 
split O 
into O 
two O 
component O 
lines O 
with O 
a O 
relative O 
intensity O 
ratio O 
of O 
1 O 
: O 
3 O 
, O 
due O 
to O 
the O 
internal O 
rotation O 
of O 
the O 
formaldehyde B-SYSTEMATIC 
moiety O 
along O 
its O 
symmetry O 
axis O 
. O 
The O 
barrier O 
to O 
this O 
motion O 
has O 
been O 
estimated O 
by O 
using O 
a O 
flexible O 
model O 
to O 
be O 
V2 O 
= O 
180(10) O 
cm(-1) O 
. O 

the O 
electronic O 
and O 
photophysical O 
properties O 
of O 
heteroleptic O 
iridium B-SYSTEMATIC 
(iii) I-SYSTEMATIC 
phosphorescent O 
emitters O 
through O 
ancillary O 
ligand O 
substitution O 
: O 
a O 
theoretical O 
perspective O 
. O 

development O 
and O 
application O 
of O 
phosphorescent O 
emitters O 
in O 
organic O 
light O 
- O 
emitting O 
diodes O 
( O 
OLEDs O 
) O 
have O 
played O 
a O 
critical O 
role O 
in O 
the O 
push O 
to O 
commercialization O 
of O 
OLED O 
- O 
based O 
display O 
and O 
lighting O 
technologies O 
. O 
Here O 
, O 
we O 
use O 
density O 
functional O 
theory O 
methods O 
to O 
study O 
how O 
modifying O 
the O 
ancillary O 
ligand O 
influences O 
the O 
electronic O 
and O 
photophysical O 
properties O 
of O 
heteroleptic O 
bis(4,6-difluorophenyl) B-SYSTEMATIC 
pyridinato-N,C I-SYSTEMATIC 
[ I-SYSTEMATIC 
dfppy I-SYSTEMATIC 
] I-SYSTEMATIC 
iridium I-SYSTEMATIC 
(iii) I-SYSTEMATIC 
complexes O 
. O 
We O 
examine O 
three O 
families O 
of O 
bidentate O 
ancillary O 
ligands O 
based O 
on O 
acetylacetonate B-SYSTEMATIC 
, O 
picolinate B-TRIVIAL 
, O 
and O 
pyridylpyrazolate B-SYSTEMATIC 
. O 
It O 
is O 
found O 
that O 
the O 
frontier O 
molecular O 
orbitals O 
of O 
the O 
heteroleptic O 
complexes O 
can O 
be O 
substantially O 
modulated O 
both O 
as O 
a O 
function O 
of O 
the O 
bidentate O 
ligand O 
family O 
and O 
of O 
the O 
substitution O 
patterns O 
within O 
a O 
family O 
. O 
As O 
a O 
consequence O 
, O 
considerable O 
control O 
over O 
the O 
first O 
absorption O 
and O 
phosphorescence O 
emission O 
transitions O 
, O 
both O 
of O 
which O 
are O 
dominated O 
by O 
one O 
- O 
electron O 
transitions O 
between O 
the O 
HOMO O 
and O 
LUMO O 
, O 
is O 
obtained O 
. O 
Tuning O 
the O 
nature O 
of O 
the O 
ancillary O 
ligand O 
, O 
therefore O 
, O 
can O 
be O 
used O 
to O 
readily O 
modulate O 
the O 
photophysical O 
properties O 
of O 
the O 
emitters O 
, O 
providing O 
a O 
powerful O 
tool O 
in O 
the O 
design O 
of O 
the O 
emitter O 
architecture O 
. O 

Long-Evans O 
Cinnamon O 
( O 
LEC O 
) O 
rat O 
shows O 
age O 
- O 
dependent O 
hepatic O 
manifestations O 
that O 
are O 
similar O 
to O 
those O 
of O 
Wilson's O 
disease O 
( O 
WD O 
) O 
. O 
The O 
pathogenic O 
process O 
in O 
the O 
brain O 
has O 
, O 
however O 
, O 
not O 
been O 
evaluated O 
in O 
detail O 
due O 
to O 
the O 
rarity O 
of O 
the O 
neurological O 
symptoms O 
. O 
However O 
, O 
copper B-SYSTEMATIC 
accumulation O 
is O 
noted O 
in O 
LEC O 
rat O 
brain O 
tissue O 
from O 
24 O 
weeks O 
of O 
age O 
, O 
which O 
results O 
in O 
oxidative O 
injuries O 
. O 
The O 
current O 
study O 
investigated O 
the O 
gene O 
expression O 
profiles O 
of O 
LEC O 
rat O 
brains O 
at O 
24 O 
weeks O 
of O 
age O 
in O 
order O 
to O 
identify O 
the O 
important O 
early O 
molecular O 
changes O 
that O 
underlie O 
the O 
development O 
of O 
neurological O 
symptoms O 
in O 
WD O 
. O 
Biological O 
ontology O 
- O 
based O 
analysis O 
revealed O 
diverse O 
altered O 
expressions O 
of O 
the O 
genes O 
related O 
to O 
copper B-SYSTEMATIC 
accumulation O 
. O 
Of O 
particular O 
interest O 
, O 
we O 
found O 
altered O 
expression O 
of O 
genes O 
connected O 
to O 
mitochondrial O 
respiration O 
( O 
Sdhaf2 O 
and O 
Ndufb7 O 
) O 
, O 
calcineurin O 
- O 
mediated O 
cellular O 
processes O 
( O 
Ppp3ca O 
, O 
Ppp3cb O 
, O 
and O 
Camk2a O 
) O 
, O 
amyloid O 
precursor O 
protein O 
( O 
Anks1b O 
and O 
A2m O 
) O 
and O 
alpha-synuclein O 
( O 
Snca O 
) O 
. O 
In O 
addition O 
to O 
copper B-SYSTEMATIC 
-related O 
changes O 
, O 
compensatory O 
upregulations O 
of O 
Cp O 
and O 
Hamp O 
reflect O 
iron B-SYSTEMATIC 
-mediated O 
neurotoxicity O 
. O 
Of O 
note O 
, O 
reciprocal O 
expression O 
of O 
Asmt O 
and O 
Bhmt O 
is O 
an O 
important O 
clue O 
that O 
altered O 
S-adenosylhomocysteine B-TRIVIAL 
metabolism O 
underlies O 
brain O 
injury O 
in O 
WD O 
, O 
which O 
is O 
directly O 
correlated O 
to O 
the O 
decreased O 
expression O 
of O 
S-adenosylhomocysteine B-TRIVIAL 
hydrolase O 
in O 
hepatic O 
tissue O 
in O 
LEC O 
rats O 
. O 
In O 
conclusion O 
, O 
our O 
study O 
indicates O 
that O 
diverse O 
molecular O 
changes O 
, O 
both O 
variable O 
and O 
complex O 
, O 
underlie O 
the O 
development O 
of O 
neurological O 
manifestations O 
in O 
WD O 
. O 
Copper B-SYSTEMATIC 
-related O 
injuries O 
were O 
found O 
to O 
be O 
the O 
principal O 
pathogenic O 
process O 
, O 
but O 
Fe B-FORMULA 
- O 
or O 
adenosylhomocysteine B-TRIVIAL 
-related O 
injuries O 
were O 
also O 
implicated O 
. O 
Investigations O 
using O 
other O 
animal O 
models O 
or O 
accessible O 
human O 
samples O 
will O 
be O 
required O 
to O 
confirm O 
our O 
observations O 
. O 

analysis O 
of O 
isolated O 
protein O 
domains O 
may O 
uncover O 
cryptic O 
activities O 
otherwise O 
missed O 
. O 
The O 
serine B-TRIVIAL 
protease O 
urokinase O 
( O 
uPA O 
) O 
has O 
a O 
clear O 
- O 
cut O 
motogen O 
activity O 
that O 
is O 
catalytically O 
independent O 
and O 
resides O 
in O 
its O 
amino B-FAMILY 
-terminal O 
growth O 
factor O 
domain O 
( O 
GFD O 
, O 
residues O 
1-49 O 
) O 
and O 
connecting O 
peptide O 
region O 
( O 
CP O 
, O 
residues O 
132-158 O 
) O 
. O 
To O 
functionally O 
dissect O 
the O 
CP O 
region O 
, O 
we O 
analysed O 
the O 
biological O 
activity O 
of O 
two O 
synthetic O 
peptides O 
corresponding O 
to O 
the O 
N B-FORMULA 
-terminal O 
[ O 
uPA-(135-143) O 
, O 
residues O 
135-143 O 
] O 
and O 
C B-FORMULA 
-terminal O 
[ O 
uPA-(144-158) O 
, O 
residues O 
144-158 O 
] O 
CP O 
subregions O 
. O 
Most O 
of O 
the O 
chemotactic O 
activity O 
of O 
connecting O 
peptide O 
- O 
derived O 
peptide O 
( O 
CPp O 
, O 
[uPA-(135-158)] O 
) O 
for O 
embryonic O 
kidney O 
HEK293 O 
/ O 
uPAR-25 O 
cells O 
is O 
retained O 
by O 
uPA-(144-158) O 
at O 
nanomolar O 
concentrations O 
. O 
In O 
contrast O 
, O 
uPA-(135-143) O 
inhibits O 
basal O 
, O 
CPp O 
- O 
, O 
vitronectin- O 
and O 
fibronectin O 
- O 
induced O 
cell O 
migration O 
. O 
Radioreceptor O 
binding O 
assays O 
on O 
intact O 
HEK293 O 
cells O 
revealed O 
that O 
uPA-(135-143) O 
and O 
uPA-(144-158) O 
are O 
both O 
able O 
to O 
compete O 
with O 
[ O 
( B-FORMULA 
125 I-FORMULA 
) I-FORMULA 
I I-FORMULA 
]-CPp O 
, O 
albeit O 
with O 
different O 
binding O 
affinities O 
. O 
The O 
consequences O 
of O 
phospho B-SYSTEMATIC 
-mimicking O 
, O 
S138E O 
substitution O 
, O 
were O 
studied O 
using O 
[138E]uPA-(135-158) O 
and O 
[138E]uPA-(135-143) O 
peptides O 
. O 
Unlike O 
CPp O 
, O 
[138E]uPA-(135-158) O 
and O 
[138E]uPA-(135-143) O 
exhibit O 
remarkable O 
inhibitory O 
properties O 
. O 
Finally O 
, O 
analysis O 
of O 
the O 
conformational O 
preferences O 
of O 
the O 
peptides O 
allowed O 
to O 
identify O 
secondary O 
structure O 
elements O 
exclusively O 
characterising O 
the O 
stimulatory O 
CPp O 
and O 
uPA-(144-158) O 
versus O 
the O 
inhibitory O 
uPA-(135-143) O 
, O 
[138E]uPA-(135-158) O 
and O 
[138E]uPA-(135-143) O 
peptides O 
. O 
In O 
conclusion O 
, O 
these O 
data O 
shed O 
light O 
on O 
the O 
cryptic O 
activities O 
of O 
uPA O 
connecting O 
peptide O 
, O 
revealing O 
the O 
occurrence O 
of O 
two O 
adjacent O 
regions O 
, O 
both O 
competing O 
for O 
binding O 
to O 
cell O 
surface O 
but O 
conveying O 
opposite O 
signalling O 
on O 
cell O 
migration O 
. O 

to O 
superfast O 
water O 
transport O 
in O 
carbon B-SYSTEMATIC 
nanotube O 
membranes O 
. O 

nanotube O 
( O 
CNT O 
) O 
membranes O 
hold O 
the O 
promise O 
of O 
extraordinary O 
fast O 
water O 
transport O 
for O 
applications O 
such O 
as O 
energy O 
efficient O 
filtration O 
and O 
molecular O 
level O 
drug O 
delivery O 
. O 
However O 
, O 
experiments O 
and O 
computations O 
have O 
reported O 
flow O 
rate O 
enhancements O 
over O 
continuum O 
hydrodynamics O 
that O 
contradict O 
each O 
other O 
by O 
orders O 
of O 
magnitude O 
. O 
We O 
perform O 
large O 
scale O 
molecular O 
dynamics O 
simulations O 
emulating O 
for O 
the O 
first O 
time O 
the O 
micrometer O 
thick O 
CNTs O 
membranes O 
used O 
in O 
experiments O 
. O 
We O 
find O 
transport O 
enhancement O 
rates O 
that O 
are O 
length O 
dependent O 
due O 
to O 
entrance O 
and O 
exit O 
losses O 
but O 
asymptote O 
to O 
2 O 
orders O 
of O 
magnitude O 
over O 
the O 
continuum O 
predictions O 
. O 
These O 
rates O 
are O 
far O 
below O 
those O 
reported O 
experimentally O 
. O 
The O 
results O 
suggest O 
that O 
the O 
reported O 
superfast O 
water O 
transport O 
rates O 
cannot O 
be O 
attributed O 
to O 
interactions O 
of O 
water O 
with O 
pristine O 
CNTs O 
alone O 
. O 

persistent O 
use O 
of O 
synthetic O 
termiticides O 
is O 
at O 
present O 
of O 
environmental O 
concern O 
and O 
has O 
resulted O 
in O 
the O 
need O 
to O 
search O 
for O 
plant O 
- O 
derived O 
compounds O 
as O 
an O 
alternative O 
for O 
termite O 
control O 
. O 
Antitermitic O 
activity O 
of O 
Chinese O 
cedar O 
( O 
Cryptomeria O 
fortunei O 
Hooibrenk O 
) O 
against O 
Reticulitermes O 
chinensis O 
was O 
demonstrated O 
in O 
laboratory O 
tests O 
. O 
Bioactivity O 
tests O 
against O 
the O 
termite O 
R O 
. O 
chinensis O 
demonstrate O 
that O 
the O 
lethal O 
concentration O 
( O 
LC50 O 
) O 
value O 
of O 
leaf O 
essential O 
oil O 
is O 
2.8 O 
mg O 
/ O 
mL O 
. O 
Furthermore O 
, O 
α-terpineol B-TRIVIAL 
, O 
which O 
was O 
responsible O 
for O 
the O 
antitermitic O 
property O 
and O 
isolated O 
from O 
Chinese O 
cedar O 
that O 
exhibited O 
very O 
strong O 
antitermitic O 
activity O 
, O 
was O 
found O 
to O 
be O 
significantly O 
effective O 
against O 
R O 
. O 
chinensis O 
with O 
median O 
LC50 O 
values O 
of O 
0.86 O 
mg O 
/ O 
mL O 
. O 
The O 
findings O 
suggested O 
that O 
the O 
essential O 
oil O 
from O 
Chinese O 
cedar O 
leaf O 
and O 
α-terpineol B-TRIVIAL 
might O 
be O 
considered O 
as O 
a O 
potent O 
source O 
for O 
the O 
production O 
of O 
effective O 
, O 
environmentally O 
friendly O 
and O 
safe O 
termiticides O 
. O 

methylated B-FAMILY 
flavonol I-FAMILY 
glucosides I-FAMILY 
from O 
Fumana O 
montana O 
Pomel O 
. O 

new O 
methylated B-FAMILY 
flavonol I-FAMILY 
glucosides I-FAMILY 
: O 
3-methoxy-7-O-β-(6″-galloylgluco-pyranoside) B-SYSTEMATIC 
quercetin I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
3,4'-dimethoxy-7-O-β-(6″-galloyl-glucopyranoside) B-SYSTEMATIC 
quercetin I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
3-methoxy-7-O-β-(6″-galloylgluco-pyranoside) B-SYSTEMATIC 
kaempferol I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
in O 
addition O 
to O 
six O 
known O 
flavonols B-FAMILY 
, O 
were O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
of O 
Fumana O 
montana O 
Pomel O 
. O 
Their O 
structures O 
were O 
assigned O 
by O 
spectroscopic O 
methods O 
. O 

Dynamics O 
Simulations O 
of O 
DPPC B-ABBREVIATION 
Bilayers O 
Using O 
" O 
LIME O 
" O 
, O 
a O 
New O 
Coarse-Grained O 
Model O 
. O 

new O 
intermediate O 
resolution O 
model O 
for O 
phospholipids O 
, O 
LIME O 
, O 
designed O 
for O 
use O 
with O 
discontinuous O 
molecular O 
dynamics O 
( O 
DMD O 
) O 
simulations O 
is O 
presented O 
. O 
The O 
implicit O 
- O 
solvent O 
model O 
was O 
developed O 
using O 
a O 
multiscale O 
modeling O 
approach O 
in O 
which O 
the O 
geometric O 
and O 
energetic O 
parameters O 
are O 
obtained O 
by O 
collecting O 
data O 
from O 
atomistic O 
simulations O 
of O 
a O 
system O 
composed O 
of O 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine B-SYSTEMATIC 
( O 
DPPC B-ABBREVIATION 
) O 
molecules O 
and O 
explicit O 
water O 
. O 
In O 
the O 
model O 
, O 
14 O 
coarse O 
- O 
grained O 
sites O 
that O 
are O 
classified O 
as O 
1 O 
of O 
6 O 
types O 
represent O 
DPPC B-ABBREVIATION 
. O 
DMD O 
simulations O 
performed O 
on O 
a O 
random O 
solution O 
of O 
DPPC B-ABBREVIATION 
resulted O 
in O 
the O 
formation O 
of O 
a O 
defect O 
- O 
free O 
bilayer O 
in O 
less O 
than O 
4 O 
h O 
. O 
The O 
bilayer O 
formed O 
quantitatively O 
reproduces O 
the O 
main O 
structural O 
properties O 
( O 
e.g O 
. O 
, O 
area O 
per O 
lipid O 
, O 
bilayer O 
thickness O 
, O 
bond O 
order O 
parameters O 
) O 
that O 
are O 
observed O 
experimentally O 
. O 
In O 
addition O 
, O 
the O 
bilayer O 
transitions O 
from O 
a O 
liquid O 
- O 
crystalline O 
phase O 
to O 
a O 
tilted O 
gel O 
phase O 
when O 
the O 
temperature O 
is O 
reduced O 
. O 
Transbilayer O 
movement O 
of O 
a O 
lipid O 
from O 
the O 
bottom O 
leaflet O 
to O 
the O 
top O 
leaflet O 
is O 
observed O 
when O 
the O 
temperature O 
is O 
increased O 
. O 

- O 
ranging O 
study O 
with O 
the O 
glucokinase O 
activator O 
AZD1656 B-IDENTIFIER 
as O 
monotherapy O 
in O 
Japanese O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
. O 

: O 
To O 
assess O 
the O 
glucose O 
- O 
lowering O 
effects O 
of O 
monotherapy O 
with O 
the O 
glucokinase O 
activator O 
AZD1656 B-IDENTIFIER 
in O 
Japanese O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
. O 
METHODS O 
: O 
This O 
was O 
a O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
study O 
performed O 
in O 
Japan O 
( O 
NCT01152385 O 
) O 
. O 
Patients O 
( O 
n O 
= O 
224 O 
) O 
were O 
randomized O 
to O 
AZD1656 B-IDENTIFIER 
( O 
40-200 O 
, O 
20-140 O 
or O 
10-80 O 
mg O 
titrated O 
doses O 
) O 
or O 
placebo O 
. O 
The O 
primary O 
variable O 
was O 
the O 
placebo O 
- O 
corrected O 
change O 
from O 
baseline O 
to O 
4 O 
months O 
in O 
glycated O 
haemoglobin O 
( O 
HbA1c O 
) O 
. O 
Effects O 
on O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
and O 
safety O 
were O 
also O 
assessed O 
. O 
RESULTS O 
: O 
HbA1c O 
was O 
reduced O 
numerically O 
from O 
baseline O 
by O 
0.3-0.8% O 
with O 
AZD1656 B-IDENTIFIER 
and O 
by O 
0.1% O 
with O 
placebo O 
over O 
the O 
first O 
2 O 
months O 
of O 
treatment O 
, O 
after O 
which O 
effects O 
of O 
AZD1656 B-IDENTIFIER 
started O 
to O 
decline O 
. O 
The O 
changes O 
from O 
baseline O 
to O 
4 O 
months O 
in O 
HbA1c O 
were O 
not O 
significant O 
for O 
the O 
AZD1656 B-IDENTIFIER 
40-200 O 
mg O 
group O 
versus O 
placebo O 
[ O 
mean O 
( O 
95% O 
CI O 
) O 
placebo O 
- O 
corrected O 
change O 
: O 
-0.22 O 
( O 
-0.65 O 
, O 
0.20)% O 
; O 
p O 
= O 
0.3 O 
] O 
. O 
Formal O 
significance O 
testing O 
was O 
not O 
carried O 
out O 
for O 
the O 
other O 
two O 
AZD1656 B-IDENTIFIER 
dose O 
groups O 
. O 
A O 
higher O 
percentage O 
of O 
patients O 
on O 
AZD1656 B-IDENTIFIER 
achieved O 
HbA1c O 
≤ O 
7% O 
after O 
4 O 
months O 
versus O 
placebo O 
, O 
but O 
responder O 
rates O 
were O 
low O 
. O 
Results O 
for O 
FPG O 
reflected O 
those O 
for O 
HbA1c O 
. O 
Cases O 
of O 
hypoglycaemia O 
were O 
rare O 
with O 
AZD1656 B-IDENTIFIER 
( O 
one O 
patient O 
) O 
and O 
no O 
safety O 
concerns O 
were O 
raised O 
. O 
CONCLUSIONS O 
: O 
Although O 
initially O 
favourable O 
plasma O 
glucose B-TRIVIAL 
reductions O 
were O 
observed O 
, O 
there O 
was O 
a O 
loss O 
of O 
effect O 
over O 
time O 
with O 
sustained O 
AZD1656 B-IDENTIFIER 
treatment O 
. O 
The O 
study O 
design O 
did O 
not O 
allow O 
an O 
evaluation O 
of O 
the O 
reasons O 
for O 
this O 
lack O 
of O 
long O 
- O 
term O 
efficacy O 
. O 

entry O 
is O 
mediated O 
by O 
the O 
envelope O 
glycoproteins O 
gp120 O 
and O 
gp41 O 
. O 
The O 
gp41 O 
subunit O 
contains O 
several O 
functional O 
domains O 
: O 
the O 
N B-FORMULA 
-terminal O 
heptad O 
repeat O 
( O 
NHR O 
) O 
domains O 
fold O 
a O 
triple O 
stranded O 
coiled O 
- O 
coil O 
forming O 
a O 
meta-stable O 
prefusion O 
intermediate O 
. O 
C B-FORMULA 
-terminal O 
heptad O 
repeat O 
( O 
CHR O 
) O 
subsequently O 
folds O 
onto O 
the O 
hydrophobic O 
grooves O 
of O 
the O 
NHR O 
coiled O 
- O 
coil O 
to O 
form O 
a O 
stable O 
6-helix O 
bundle O 
, O 
which O 
juxtaposes O 
the O 
viral O 
and O 
cellular O 
membranes O 
for O 
fusion O 
. O 
The O 
C34 O 
which O 
has O 
34 O 
amino B-FAMILY 
acid I-FAMILY 
residues O 
is O 
known O 
as O 
the O 
core O 
structure O 
in O 
CHR O 
. O 
A O 
highly O 
anti-HIV O 
peptide O 
inhibitor O 
derived O 
from O 
C34 O 
was O 
designed O 
. O 
An O 
artificial O 
salt O 
bridge O 
was O 
added O 
in O 
the O 
6-helical O 
bundle O 
by O 
substitution O 
of O 
lysine B-TRIVIAL 
for O 
Ile B-FORMULA 
646 O 
. O 
With O 
a O 
cholesterol B-TRIVIAL 
modification O 
at O 
C B-FORMULA 
-terminal O 
, O 
the O 
inhibitor O 
containing O 
I646K O 
mutation O 
represented O 
higher O 
anti-viral O 
activity O 
than O 
C34- O 
cholesterol B-TRIVIAL 
combination O 
without O 
mutation O 
. O 

catalyzed O 
three O 
component O 
reaction O 
: O 
Efficient O 
synthesis O 
of O 
spiro[indoline-3,4'-pyrano[3,2-b]pyran B-SYSTEMATIC 
derivatives O 
and O 
their O 
anticancer O 
potency O 
towards O 
A549 O 
human O 
lung O 
cancer O 
cell O 
lines O 
. O 

catalyzed O 
efficient O 
synthesis O 
of O 
spiropyrano[3,2-b]pyran-4(8H)-ones B-FAMILY 
is O 
accomplished O 
via O 
one O 
- O 
pot O 
three O 
component O 
reaction O 
between O 
isatin B-TRIVIAL 
, O 
kojic B-TRIVIAL 
acid I-TRIVIAL 
and O 
active O 
methylenes B-FAMILY 
. O 
This O 
synthetic O 
protocol O 
is O 
operationally O 
simple O 
and O 
affords O 
product O 
with O 
good O 
to O 
excellent O 
yields O 
at O 
a O 
short O 
reaction O 
time O 
. O 
The O 
synthesized O 
compounds O 
were O 
evaluated O 
for O 
their O 
tumor O 
cell O 
growth O 
inhibitory O 
activity O 
against O 
the O 
human O 
lung O 
cancer O 
cell O 
line O 
( O 
A549 O 
) O 
and O 
found O 
that O 
13 O 
compounds O 
exhibited O 
moderate O 
to O 
good O 
anticancer O 
potency O 
. O 
Molecular O 
docking O 
studies O 
were O 
performed O 
for O 
all O 
the O 
synthesized O 
compounds O 
and O 
the O 
results O 
showed O 
that O 
compound O 
4e O 
showed O 
greater O 
affinity O 
for O 
anaplastic O 
lymphoma O 
kinase O 
( O 
ALK O 
) O 
receptor O 
. O 

induces O 
apoptosis O 
via O 
activation O 
of O 
caspase O 
and O 
inhibition O 
of O 
survival O 
genes O 
in O 
PC-3 O 
prostate O 
cancer O 
cells O 
. O 

is O 
a O 
natural O 
biflavonoid B-FAMILY 
isolated O 
from O 
leaves O 
of O 
Ginkgo O 
biloba O 
L O 
. O 
Though O 
it O 
was O 
known O 
to O 
have O 
anti-inflammatory O 
, O 
anti-influenza O 
virus O 
, O 
anti-fungal O 
activity O 
, O 
osteoblast O 
differentiation O 
stimulating O 
activity O 
and O 
neuro O 
- O 
protective O 
effects O 
, O 
the O 
underlying O 
antitumor O 
mechanism O 
of O 
ginkgetin B-TRIVIAL 
still O 
remains O 
unclear O 
. O 
Thus O 
, O 
in O 
the O 
present O 
study O 
, O 
anti-cancer O 
mechanism O 
of O 
ginkgetin B-TRIVIAL 
was O 
elucidated O 
in O 
human O 
prostate O 
cancer O 
PC-3 O 
cells O 
. O 
Ginkgetin B-TRIVIAL 
suppressed O 
the O 
viability O 
of O 
PC-3 O 
cells O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
and O 
also O 
significantly O 
increased O 
the O 
sub-G1 O 
DNA O 
contents O 
of O 
cell O 
cycle O 
in O 
PC-3 O 
cells O 
. O 
Ginkgetin B-TRIVIAL 
activated O 
caspase-3 O 
and O 
attenuated O 
the O 
expression O 
of O 
survival O 
genes O 
such O 
as O 
Bcl-2 O 
, O 
Bcl-xL O 
, O 
survivin O 
and O 
Cyclin O 
D1 O 
at O 
protein O 
and O 
mRNA O 
levels O 
. O 
Consistently O 
, O 
pan O 
- O 
caspase O 
inhibitor O 
Z-DEVD-fmk B-ABBREVIATION 
blocked O 
sub O 
G1 O 
accumulation O 
and O 
cleavages O 
of O 
PRAP O 
and O 
caspase O 
3 O 
induced O 
by O 
ginkgetin B-TRIVIAL 
in O 
PC-3 O 
cells O 
. O 
Overall O 
, O 
these O 
findings O 
suggest O 
that O 
ginkgetin B-TRIVIAL 
induces O 
apoptosis O 
in O 
PC-3 O 
cells O 
via O 
activation O 
of O 
caspase O 
3 O 
and O 
inhibition O 
of O 
survival O 
genes O 
as O 
a O 
potent O 
chemotherapeutic O 
agent O 
for O 
prostate O 
cancer O 
treatment O 
. O 

vivo O 
effect O 
of O 
Schisandrin B-TRIVIAL 
B I-TRIVIAL 
on O 
cytochrome O 
P450 O 
enzyme O 
activity O 
. O 

investigate O 
the O 
possible O 
drug O 
interaction O 
, O 
this O 
study O 
is O 
designed O 
to O 
evaluate O 
the O 
ability O 
of O 
Schisandrin B-TRIVIAL 
B I-TRIVIAL 
( O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
) O 
to O 
modulate O 
cytochrome O 
P450 O 
3A O 
activity O 
( O 
CYP3A O 
) O 
in O 
vivo O 
and O 
to O 
alter O 
the O 
pharmacokinetic O 
profiles O 
of O 
CYP3A O 
substrate O 
( O 
midazolam B-TRIVIAL 
) O 
in O 
treated O 
rats O 
. O 
Rats O 
were O 
repeated O 
administered O 
with O 
physiological O 
saline O 
( O 
negative O 
control O 
group O 
) O 
, O 
ketoconazole B-TRIVIAL 
( O 
75mg O 
/ O 
kg O 
, O 
positive O 
control O 
group O 
) O 
or O 
varied O 
doses O 
of O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
( O 
experimental O 
groups O 
) O 
for O 
three O 
consecutive O 
days O 
. O 
Subsequently O 
, O 
changes O 
in O 
hepatic O 
microsomal O 
CYP3A O 
activity O 
and O 
the O 
pharmacokinetic O 
profiles O 
of O 
midazolam B-TRIVIAL 
and O 
1'-hydroxy B-SYSTEMATIC 
midazolam I-SYSTEMATIC 
in O 
plasma O 
were O 
studied O 
to O 
evaluate O 
CYP3A O 
activity O 
. O 
The O 
results O 
indicated O 
that O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
significantly O 
dose O 
- O 
dependently O 
inhibited O 
rat O 
hepatic O 
microsomal O 
CYP3A O 
activity O 
with O 
Ki O 
value O 
of O 
16.64mg O 
/ O 
kg O 
and O 
showed O 
the O 
characteristic O 
of O 
a O 
noncompetitive O 
inhibitor O 
. O 
Oral O 
administration O 
of O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
for O 
3 O 
days O 
in O 
rats O 
produced O 
significant O 
effect O 
on O 
the O 
pharmacokinetics O 
of O 
oral O 
midazolam B-TRIVIAL 
. O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
resulted O 
in O 
a O 
significant O 
, O 
dose O 
- O 
dependent O 
increase O 
in O 
midazolam B-TRIVIAL 
AUC0-∞ O 
except O 
at O 
the O 
dose O 
of O 
2mg O 
/ O 
kg O 
, O 
while O 
AUC0-∞ O 
increased O 
by O 
26.1% O 
( O 
8mg O 
/ O 
kg O 
) O 
and O 
60.6% O 
( O 
16mg O 
/ O 
kg O 
) O 
, O 
respectively O 
. O 
In O 
the O 
pharmacokinetic O 
profiles O 
of O 
1'-hydroxy B-SYSTEMATIC 
midazolam I-SYSTEMATIC 
, O 
the O 
significant O 
, O 
dose O 
- O 
dependent O 
decrease O 
in O 
AUC0-∞ O 
was O 
observed O 
except O 
at O 
the O 
dose O 
of O 
2mg O 
/ O 
kg O 
, O 
while O 
AUC0-∞ O 
reduced O 
by O 
44.5% O 
( O 
8mg O 
/ O 
kg O 
) O 
and O 
49.2% O 
( O 
16mg O 
/ O 
kg O 
) O 
, O 
respectively O 
. O 
These O 
results O 
suggested O 
that O 
3-day O 
treatment O 
of O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
could O 
increase O 
concentration O 
and O 
oral O 
bioavailability O 
of O 
drug O 
metabolized O 
by O 
CYP3A O 
. O 
When O 
the O 
drug O 
, O 
consisting O 
of O 
Sch B-ABBREVIATION 
B I-ABBREVIATION 
, O 
is O 
used O 
in O 
the O 
clinic O 
for O 
more O 
than O 
3 O 
days O 
, O 
the O 
possible O 
drug O 
- O 
drug O 
interactions O 
should O 
be O 
taken O 
into O 
consideration O 
. O 

evaluation O 
in O 
mice O 
of O 
amorphous O 
itraconazole B-TRIVIAL 
-based O 
dry O 
powder O 
formulations O 
for O 
inhalation O 
with O 
high O 
bioavailability O 
and O 
extended O 
lung O 
retention O 
. O 

Itraconazole B-TRIVIAL 
( O 
ITZ B-ABBREVIATION 
) O 
dry O 
powders O 
for O 
inhalation O 
( O 
DPI O 
) O 
were O 
prepared O 
by O 
spray O 
- O 
drying O 
a O 
mannitol B-TRIVIAL 
solution O 
in O 
which O 
the O 
ITZ B-ABBREVIATION 
was O 
in O 
suspension O 
( O 
F1 O 
) O 
or O 
was O 
in O 
solution O 
without O 
( O 
F2 O 
) O 
or O 
with O 
phospholipid O 
( O 
PL O 
) O 
( O 
F3 O 
) O 
. O 
These O 
powders O 
were O 
endotracheally O 
insufflated O 
in O 
vivo O 
at O 
a O 
single O 
dose O 
of O 
0.5mg O 
/ O 
kg O 
for O 
pharmacokinetic O 
profile O 
( O 
lung O 
and O 
plasma O 
concentration O 
) O 
determination O 
in O 
ICR O 
CD-1 O 
mice O 
. O 
ITZ B-ABBREVIATION 
was O 
crystalline O 
in O 
F1 O 
and O 
assumed O 
to O 
be O 
amorphous O 
in O 
the O 
F2 O 
and O 
F3 O 
formulations O 
. O 
The O 
amorphous O 
nature O 
of O 
ITZ B-ABBREVIATION 
in O 
F2 O 
and O 
F3 O 
formulations O 
allowed O 
the O 
in O 
vitro O 
formation O 
of O 
an O 
ITZ B-ABBREVIATION 
supersaturated O 
solution O 
with O 
a O 
maximum O 
solubility O 
of O 
450±124ng O 
/ O 
ml O 
( O 
F2 O 
) O 
and O 
498±44ng O 
/ O 
ml O 
( O 
F3 O 
) O 
, O 
in O 
contrast O 
to O 
formulation O 
F1 O 
( O 
< O 
10ng O 
/ O 
ml O 
) O 
. O 
As O 
a O 
result O 
of O 
these O 
higher O 
solubilities O 
, O 
absorption O 
into O 
the O 
systemic O 
compartment O 
after O 
endotracheal O 
administration O 
was O 
faster O 
for O 
formulations O 
F2 O 
and O 
F3 O 
( O 
shorter O 
tmax O 
) O 
and O 
in O 
larger O 
quantities O 
compared O 
to O 
the O 
F1 O 
formulation O 
( O 
plasmatic O 
AUC0-24h O 
of O 
182ngh O 
/ O 
ml O 
, O 
491.5ngh O 
/ O 
ml O 
and O 
376.8ngh O 
/ O 
ml O 
, O 
and O 
tmax O 
of O 
60min O 
, O 
30min O 
and O 
5min O 
for O 
F1 O 
, O 
F2 O 
and O 
F3 O 
, O 
respectively O 
) O 
. O 
PL O 
increased O 
the O 
systemic O 
bioavailability O 
of O 
ITZ B-ABBREVIATION 
( O 
determined O 
by O 
the O 
AUCplasma O 
to O 
AUClung O 
ratio O 
) O 
as O 
a O 
consequence O 
of O 
their O 
wetting O 
and O 
absorption O 
enhancement O 
effect O 
. O 
ITZ B-ABBREVIATION 
lung O 
concentrations O 
after O 
pulmonary O 
administration O 
remained O 
higher O 
than O 
the O 
targeted O 
dose O 
, O 
based O 
on O 
the O 
minimal O 
inhibitory O 
concentrations O 
for O 
Aspergillus O 
Fumigatus O 
( O 
2μg O 
/ O 
gwetlung O 
) O 
, O 
24h O 
post O 
- O 
administration O 
for O 
both O 
F1 O 
and O 
F2 O 
formulations O 
. O 
However O 
, O 
this O 
was O 
not O 
the O 
case O 
for O 
formulation O 
F3 O 
, O 
which O 
exhibited O 
a O 
faster O 
elimination O 
rate O 
from O 
the O 
lung O 
, O 
with O 
an O 
elimination O 
half O 
- O 
life O 
of O 
4.1h O 
vs O 
. O 
6.5h O 
and O 
14.7h O 
for O 
F1 O 
and O 
F2 O 
, O 
respectively O 
. O 

of O 
the O 
transient O 
receptor O 
potential O 
ankyrin O 
1 O 
( O 
TRPA1 O 
) O 
attenuates O 
hyperalgesia O 
and O 
urinary O 
bladder O 
overactivity O 
in O 
cyclophosphamide B-TRIVIAL 
-induced O 
haemorrhagic O 
cystitis O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
involvement O 
of O 
the O 
transient O 
receptor O 
potential O 
ankyrin O 
1 O 
( O 
TRPA1 O 
) O 
in O 
haemorrhagic O 
cystitis O 
, O 
the O 
main O 
side O 
effect O 
of O 
cyclophosphamide B-TRIVIAL 
-based O 
chemotherapy O 
. O 
Hannover O 
female O 
rats O 
received O 
intraperitoneal O 
( O 
i.p O 
. O 
) O 
injection O 
of O 
cyclophosphamide B-TRIVIAL 
( O 
three O 
doses O 
of O 
100mg O 
/ O 
kg O 
, O 
every O 
other O 
day O 
, O 
in O 
a O 
total O 
of O 
five O 
days O 
) O 
. O 
This O 
treatment O 
was O 
followed O 
by O 
the O 
treatment O 
with O 
TRPA1 O 
antagonist O 
HC B-IDENTIFIER 
30031 I-IDENTIFIER 
( O 
50mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
. O 
The O 
threshold O 
for O 
hindpaw O 
withdrawal O 
or O 
abdominal O 
retraction O 
to O 
von O 
Frey O 
Hair O 
and O 
the O 
locomotor O 
activity O 
were O 
measured O 
. O 
The O 
treatment O 
with O 
the O 
TRPA1 O 
antagonist O 
HC B-IDENTIFIER 
30031 I-IDENTIFIER 
significantly O 
decreased O 
mechanical O 
hyperalgesia O 
induced O 
by O 
cyclophosphamide B-TRIVIAL 
without O 
interfere O 
with O 
locomotor O 
activity O 
. O 
Urodynamic O 
parameters O 
were O 
performed O 
by O 
cystometry O 
24h O 
after O 
a O 
single O 
treatment O 
with O 
cyclophosphamide B-TRIVIAL 
( O 
200mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
in O 
control O 
and O 
HC B-IDENTIFIER 
30031 I-IDENTIFIER 
treated O 
rats O 
. O 
Analyses O 
of O 
the O 
urodynamic O 
parameters O 
showed O 
that O 
a O 
single O 
dose O 
of O 
cyclophosphamide B-TRIVIAL 
was O 
enough O 
to O 
significantly O 
increase O 
the O 
number O 
and O 
amplitude O 
of O 
non-voiding O 
contractions O 
and O 
to O 
decrease O 
the O 
voided O 
volume O 
and O 
voiding O 
efficiency O 
, O 
without O 
significantly O 
altering O 
basal O 
, O 
threshold O 
or O 
maximum O 
pressure O 
. O 
The O 
treatment O 
with O 
HC B-IDENTIFIER 
30031 I-IDENTIFIER 
either O 
before O 
( O 
100mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
or O 
after O 
( O 
30mg O 
/ O 
kg O 
, O 
i.v O 
. O 
) O 
cyclophosphamide B-TRIVIAL 
inhibited O 
the O 
non-voiding O 
contractions O 
but O 
failed O 
to O 
counteract O 
the O 
loss O 
in O 
voiding O 
efficiency O 
. O 
Our O 
data O 
demonstrates O 
that O 
nociceptive O 
symptoms O 
and O 
urinary O 
bladder O 
overactivity O 
caused O 
by O 
cyclophosphamide B-TRIVIAL 
, O 
in O 
part O 
, O 
are O 
dependent O 
upon O 
the O 
activation O 
of O 
TRPA1 O 
. O 
In O 
this O 
context O 
, O 
the O 
antagonism O 
of O 
the O 
receptor O 
may O 
be O 
an O 
alternative O 
to O 
minimise O 
the O 
urotoxic O 
symptoms O 
caused O 
by O 
this O 
chemotherapeutic O 
agent O 
. O 

is O 
a O 
well O 
known O 
P O 
/ O 
Q O 
- O 
type O 
Ca(2+) B-FORMULA 
channel O 
blocker O 
and O 
has O 
been O 
shown O 
to O 
affect O 
presynaptic O 
Ca(2+) B-FORMULA 
currents O 
as O 
well O 
postsynaptic O 
potentials O 
. O 
P O 
/ O 
Q O 
- O 
type O 
voltage O 
gated O 
Ca(2+) B-FORMULA 
channels O 
play O 
a O 
vital O 
role O 
in O 
presynaptic O 
neurotransmitter O 
release O 
and O 
thus O 
play O 
a O 
role O 
in O 
action O 
potential O 
generation O 
. O 
Monitoring O 
spontaneous O 
activity O 
of O 
neuronal O 
networks O 
on O 
microelectrode O 
arrays O 
( O 
MEAs O 
) O 
provides O 
an O 
important O 
tool O 
for O 
examining O 
this O 
neurotoxin O 
. O 
Changes O 
in O 
extracellular O 
action O 
potentials O 
are O 
readily O 
observed O 
and O 
are O 
dependent O 
on O 
synaptic O 
function O 
. O 
Given O 
the O 
efficacy O 
of O 
murine O 
frontal O 
cortex O 
and O 
spinal O 
cord O 
networks O 
to O 
detect O 
neuroactive O 
substances O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
ω-agatoxin O 
on O 
spontaneous O 
action O 
potential O 
firing O 
within O 
these O 
networks O 
. O 
We O 
found O 
that O 
networks O 
derived O 
from O 
spinal O 
cord O 
are O 
more O 
sensitive O 
to O 
the O 
toxin O 
than O 
those O 
from O 
frontal O 
cortex O 
; O 
a O 
concentration O 
of O 
only O 
10nM O 
produced O 
statistically O 
significant O 
effects O 
on O 
activity O 
from O 
spinal O 
cord O 
networks O 
whereas O 
50nM O 
was O 
required O 
to O 
alter O 
activity O 
in O 
frontal O 
cortex O 
networks O 
. O 
Furthermore O 
, O 
the O 
effects O 
of O 
the O 
toxin O 
on O 
frontal O 
cortex O 
are O 
more O 
complex O 
as O 
unit O 
specific O 
responses O 
were O 
observed O 
. O 
These O 
manifested O 
as O 
either O 
a O 
decrease O 
or O 
increase O 
in O 
action O 
potential O 
firing O 
rate O 
which O 
could O 
be O 
statistically O 
separated O 
as O 
unique O 
clusters O 
. O 
Administration O 
of O 
bicuculline B-TRIVIAL 
, O 
a O 
GABAA O 
inhibitor O 
, O 
isolated O 
a O 
single O 
response O 
to O 
ω-agatoxin O 
, O 
which O 
was O 
characterized O 
by O 
a O 
reduction O 
in O 
network O 
activity O 
. O 
These O 
data O 
support O 
the O 
notion O 
that O 
the O 
two O 
clusters O 
detected O 
with O 
ω-agatoxin O 
exposure O 
represent O 
differential O 
responses O 
from O 
excitatory O 
and O 
inhibitory O 
neuronal O 
populations O 
. O 

, O 
neurochemical O 
, O 
stereological O 
and O 
neuropathological O 
studies O 
on O 
the O 
potential O 
effects O 
of O 
paraquat B-TRIVIAL 
in O 
the O 
substantia O 
nigra O 
pars O 
compacta O 
and O 
striatum O 
of O 
male O 
C57BL O 
/ O 
6J O 
mice O 
. O 

pharmacokinetics O 
and O 
neurotoxicity O 
of O 
paraquat B-SYSTEMATIC 
dichloride I-SYSTEMATIC 
( O 
PQ O 
) O 
were O 
assessed O 
following O 
once O 
weekly O 
administration O 
to O 
C57BL O 
/ O 
6J O 
male O 
mice O 
by O 
intraperitoneal O 
injection O 
for O 
1 O 
, O 
2 O 
or O 
3 O 
weeks O 
at O 
doses O 
of O 
10 O 
, O 
15 O 
or O 
25mg O 
/ O 
kg O 
/ O 
week O 
. O 
Approximately O 
0.3% O 
of O 
the O 
administered O 
dose O 
was O 
taken O 
up O 
by O 
the O 
brain O 
and O 
was O 
slowly O 
eliminated O 
, O 
with O 
a O 
half O 
- O 
life O 
of O 
approximately O 
3 O 
weeks O 
. O 
PQ O 
did O 
not O 
alter O 
the O 
concentration O 
of O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
, O 
homovanillic B-TRIVIAL 
acid I-TRIVIAL 
( O 
HVA B-ABBREVIATION 
) O 
or O 
3,4-dihydroxyphenylacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DOPAC B-ABBREVIATION 
) O 
, O 
or O 
increase O 
dopamine B-TRIVIAL 
turnover O 
in O 
the O 
striatum O 
. O 
There O 
was O 
inconsistent O 
stereological O 
evidence O 
of O 
a O 
loss O 
of O 
DA O 
neurons O 
, O 
as O 
identified O 
by O 
chromogenic O 
or O 
fluorescent-tagged O 
antibodies O 
to O 
tyrosine B-TRIVIAL 
hydroxylase O 
in O 
the O 
substantia O 
nigra O 
pars O 
compacta O 
( O 
SNpc O 
) O 
. O 
There O 
was O 
no O 
evidence O 
that O 
PQ O 
induced O 
neuronal O 
degeneration O 
in O 
the O 
SNpc O 
or O 
degenerating O 
neuronal O 
processes O 
in O 
the O 
striatum O 
, O 
as O 
indicated O 
by O 
the O 
absence O 
of O 
uptake O 
of O 
silver B-SYSTEMATIC 
stain O 
or O 
reduced O 
immunolabeling O 
of O 
tyrosine B-TRIVIAL 
-hydroxylase O 
- O 
positive O 
(TH(+)) O 
neurons O 
. O 
There O 
was O 
no O 
evidence O 
of O 
apoptotic O 
cell O 
death O 
, O 
which O 
was O 
evaluated O 
using O 
TUNEL O 
or O 
caspase O 
3 O 
assays O 
. O 
Microglia O 
( O 
IBA-1 O 
immunoreactivity O 
) O 
and O 
astrocytes O 
( O 
GFAP O 
immunoreactivity O 
) O 
were O 
not O 
activated O 
in O 
PQ O 
- O 
treated O 
mice O 
4 O 
, O 
8 O 
, O 
16 O 
, O 
24 O 
, O 
48 O 
, O 
96 O 
or O 
168h O 
after O 
1 O 
, O 
2 O 
or O 
3 O 
doses O 
of O 
PQ O 
. O 
In O 
contrast O 
, O 
mice O 
dosed O 
with O 
the O 
positive O 
control O 
substance O 
, O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
; O 
10mg O 
/ O 
kg O 
/ O 
dose×4 O 
doses O 
, O 
2h O 
apart O 
) O 
, O 
displayed O 
significantly O 
reduced O 
DA O 
and O 
DOPAC B-ABBREVIATION 
concentrations O 
and O 
increased O 
DA O 
turnover O 
in O 
the O 
striatum O 
7 O 
days O 
after O 
dosing O 
. O 
The O 
number O 
of O 
TH(+) O 
neurons O 
in O 
the O 
SNpc O 
was O 
reduced O 
, O 
and O 
there O 
were O 
increased O 
numbers O 
of O 
degenerating O 
neurons O 
and O 
neuronal O 
processes O 
in O 
the O 
SNpc O 
and O 
striatum O 
. O 
MPTP B-ABBREVIATION 
-mediated O 
cell O 
death O 
was O 
not O 
attributed O 
to O 
apoptosis O 
. O 
MPTP B-ABBREVIATION 
activated O 
microglia O 
and O 
astrocytes O 
within O 
4h O 
of O 
the O 
last O 
dose O 
, O 
reaching O 
a O 
peak O 
within O 
48h O 
. O 
The O 
microglial O 
response O 
ended O 
by O 
96h O 
in O 
the O 
SNpc O 
, O 
but O 
the O 
astrocytic O 
response O 
continued O 
through O 
168h O 
in O 
the O 
striatum O 
. O 
These O 
results O 
bring O 
into O 
question O 
previous O 
published O 
stereological O 
studies O 
that O 
report O 
loss O 
of O 
TH(+) O 
neurons O 
in O 
the O 
SNpc O 
of O 
PQ O 
- O 
treated O 
mice O 
. O 
This O 
study O 
also O 
suggests O 
that O 
even O 
if O 
the O 
reduction O 
in O 
TH(+) O 
neurons O 
reported O 
by O 
others O 
occurs O 
in O 
PQ O 
- O 
treated O 
mice O 
, O 
this O 
apparent O 
phenotypic O 
change O 
is O 
unaccompanied O 
by O 
neuronal O 
cell O 
death O 
or O 
by O 
modification O 
of O 
dopamine B-TRIVIAL 
levels O 
in O 
the O 
striatum O 
. O 

attenuates O 
bleomycin B-FAMILY 
induced O 
pulmonary O 
toxicity O 
and O 
fibrosis O 
via O 
suppressing O 
NF-κB O 
dependant O 
TGF-β O 
activation O 
: O 
A O 
biphasic O 
experimental O 
study O 
. O 

pulmonary O 
fibrosis O 
( O 
IPF O 
) O 
is O 
a O 
progressive O 
, O 
debilitating O 
and O 
fatal O 
lung O 
disorder O 
with O 
high O 
mortality O 
rate O 
. O 
Unfortunately O 
, O 
to O 
date O 
the O 
treatment O 
for O 
IPF O 
remains O 
unsatisfying O 
and O 
in O 
severe O 
cases O 
lung O 
transplantations O 
are O 
performed O 
as O 
a O 
therapeutic O 
measure O 
. O 
Thus O 
, O 
it O 
becomes O 
great O 
interest O 
to O 
find O 
novel O 
agents O 
to O 
treat O 
IPF O 
. O 
Berberine B-TRIVIAL 
, O 
a O 
plant O 
alkaloid O 
known O 
for O 
its O 
broad O 
pharmacological O 
activities O 
remains O 
a O 
remedy O 
against O 
multiple O 
diseases O 
. O 
This O 
study O 
was O 
hypothesized O 
to O 
investigate O 
the O 
antifibrotic O 
potential O 
of O 
berberine B-TRIVIAL 
against O 
bleomycin B-FAMILY 
-induced O 
lung O 
injury O 
and O 
fibrosis O 
, O 
a O 
tentative O 
animal O 
model O 
. O 
Male O 
wistar O 
rats O 
were O 
subjected O 
to O 
single O 
intratracheal O 
instillation O 
of O 
2.5U O 
/ O 
kg O 
of O 
bleomycin B-FAMILY 
on O 
day O 
0 O 
. O 
Berberine B-TRIVIAL 
treatments O 
were O 
either O 
provided O 
in O 
preventive O 
or O 
therapeutic O 
mode O 
respectively O 
. O 
Berberine B-TRIVIAL 
administration O 
significantly O 
ameliorated O 
the O 
bleomycin B-FAMILY 
mediated O 
histological O 
alterations O 
and O 
reduced O 
the O 
inflammatory O 
cell O 
infiltrate O 
in O 
BALF O 
. O 
Berberine B-TRIVIAL 
significantly O 
blocked O 
collagen O 
accumulations O 
with O 
parallel O 
reduction O 
in O 
the O 
hydroxyproline B-SYSTEMATIC 
level O 
. O 
The O 
immunological O 
sign O 
of O 
bleomycin B-FAMILY 
stimulated O 
mast O 
cell O 
deposition O 
and O 
histamine B-TRIVIAL 
release O 
were O 
considerably O 
reduced O 
by O 
berberine B-TRIVIAL 
. O 
Berberine B-TRIVIAL 
enhanced O 
the O 
antioxidant O 
status O 
, O 
through O 
upregulating O 
the O 
redox O 
sensing O 
transcription O 
factor O 
nuclear O 
factor O 
E2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
. O 
Berberine B-TRIVIAL 
inhibited O 
the O 
bleomycin B-FAMILY 
mediated O 
activation O 
of O 
inflammatory O 
mediator O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NF-κB O 
) O 
and O 
suppressed O 
its O 
downstream O 
target O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
. O 
Strikingly O 
, O 
berberine B-TRIVIAL 
exhibited O 
target O 
attenuation O 
of O 
tumor O 
necrosis O 
factor O 
alpha O 
( O 
TNF-α O 
) O 
and O 
key O 
pro O 
- O 
fibrotic O 
mediator O 
, O 
transforming O 
growth O 
factor O 
beta O 
1 O 
( O 
TGF-β1 O 
) O 
. O 
Taken O 
together O 
, O 
this O 
study O 
reveals O 
the O 
beneficial O 
effects O 
of O 
berberine B-TRIVIAL 
against O 
bleomycin B-FAMILY 
mediated O 
fibrotic O 
challenge O 
through O 
activating O 
Nrf2 O 
and O 
suppressing O 
NF-κB O 
dependent O 
inflammatory O 
and O 
TGF-β1 O 
mediated O 
fibrotic O 
events O 
. O 

effect O 
of O 
crocin B-TRIVIAL 
on O 
diazinon B-TRIVIAL 
induced O 
cardiotoxicity O 
in O 
rats O 
in O 
subchronic O 
exposure O 
. O 

study O 
was O 
designed O 
to O 
evaluate O 
the O 
effectiveness O 
of O 
crocin B-TRIVIAL 
, O 
main O 
component O 
of O 
Crocus O 
sativus O 
L O 
. O 
( O 
Saffron O 
) O 
against O 
subchronic O 
diazinon B-TRIVIAL 
( O 
DZN B-ABBREVIATION 
) O 
induced O 
cardiotoxicity O 
in O 
rats O 
. O 
METHODS O 
: O 
Rats O 
were O 
divided O 
into O 
7 O 
groups O 
; O 
control O 
( O 
corn O 
oil O 
, O 
gavage O 
) O 
, O 
DZN O 
( O 
15mg O 
/ O 
kg O 
/ O 
day O 
, O 
gavage O 
, O 
) O 
, O 
crocin B-TRIVIAL 
( O 
12.5 O 
, O 
25 O 
or O 
50mg O 
/ O 
kg O 
/ O 
day O 
, O 
i.p O 
) O 
plus O 
DZN B-ABBREVIATION 
, O 
vitamin B-FAMILY 
E I-FAMILY 
( O 
200IU O 
/ O 
kg O 
, O 
i.p O 
, O 
three O 
times O 
per O 
week O 
) O 
plus O 
DZN B-ABBREVIATION 
and O 
crocin B-TRIVIAL 
( O 
50mg O 
/ O 
kg O 
/ O 
day O 
, O 
i.p O 
) O 
groups O 
. O 
Treatments O 
were O 
continued O 
for O 
4weeks O 
. O 
Creatine B-TRIVIAL 
phosphokinase O 
MB O 
( O 
CK-MB O 
) O 
, O 
malondealdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
and O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
levels O 
were O 
evaluated O 
in O 
heart O 
tissue O 
at O 
the O 
end O 
of O 
treatments O 
. O 
Levels O 
of O 
apoptotic O 
proteins O 
( O 
Bax O 
, O 
Bcl2 O 
, O 
caspase O 
3 O 
) O 
and O 
cytosolic O 
cytochrome O 
c O 
were O 
analyzed O 
by O 
Western O 
blotting O 
. O 
Transcript O 
levels O 
of O 
Bax O 
and O 
Bcl2 O 
were O 
also O 
determined O 
using O 
qRT O 
PCR O 
. O 
RESULTS O 
: O 
DZN B-ABBREVIATION 
induced O 
histophatological O 
damages O 
and O 
elevated O 
the O 
level O 
of O 
cardiac O 
marker O 
CK-MB O 
. O 
These O 
effects O 
were O 
associated O 
with O 
increased O 
MDA B-ABBREVIATION 
level O 
, O 
lower O 
level O 
of O 
reduced O 
GSH B-ABBREVIATION 
and O 
induction O 
of O 
apoptosis O 
through O 
elevation O 
of O 
Bax O 
/ O 
Bcl2 O 
ratio O 
( O 
both O 
protein O 
and O 
mRNA O 
levels O 
) O 
, O 
cytochrome O 
c O 
release O 
to O 
the O 
cytosol O 
and O 
activation O 
caspase O 
3 O 
in O 
cardiac O 
tissue O 
. O 
Crocin B-TRIVIAL 
( O 
25 O 
and O 
50mg O 
/ O 
kg O 
) O 
or O 
vitamin B-FAMILY 
E I-FAMILY 
improved O 
histopathological O 
damages O 
, O 
decreased O 
MDA B-ABBREVIATION 
and O 
CK-MB O 
, O 
increased O 
GSH B-ABBREVIATION 
content O 
and O 
attenuated O 
the O 
increase O 
of O 
Bax O 
/ O 
Bcl2 O 
ratio O 
, O 
activation O 
of O 
caspase O 
3 O 
and O 
release O 
of O 
cytochrome O 
c O 
to O 
the O 
cytosol O 
induced O 
by O 
DZN B-ABBREVIATION 
. O 
In O 
summary O 
, O 
DZN B-ABBREVIATION 
induced O 
mitochondrial O 
- O 
mediated O 
apoptosis O 
in O 
heart O 
tissue O 
of O 
rat O 
following O 
subchronic O 
exposure O 
. O 
Crocin B-TRIVIAL 
, O 
as O 
an O 
antioxidant O 
, O 
showed O 
protective O 
effects O 
against O 
DZN B-ABBREVIATION 
cardiotoxicity O 
by O 
reducing O 
lipid O 
peroxidation O 
and O 
alleviating O 
apoptosis O 
. O 

of O 
naloxone B-TRIVIAL 
on O 
ischemic O 
acute O 
kidney O 
injury O 
in O 
the O 
mouse O 
. O 

ischemia O 
produces O 
sympathoexcitation O 
, O 
which O 
is O 
responsible O 
for O 
the O 
development O 
of O 
ischemic O 
acute O 
kidney O 
injury O 
. O 
Stimulation O 
of O 
central O 
opioid O 
receptors O 
activates O 
the O 
renal O 
sympathetic O 
nerve O 
. O 
The O 
present O 
study O 
examined O 
the O 
effect O 
of O 
an O 
opioid O 
receptor O 
antagonist O 
naloxone B-TRIVIAL 
on O 
the O 
ischemia O 
/ O 
reperfusion O 
- O 
induced O 
renal O 
dysfunction O 
in O 
mice O 
. O 
Blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
and O 
plasma O 
creatinine B-TRIVIAL 
increased O 
24 O 
h O 
after O 
the O 
renal O 
ischemia O 
/ O 
reperfusion O 
. O 
Intraperitoneal O 
or O 
intracerebroventricular O 
, O 
but O 
not O 
intrathecal O 
, O 
pretreatment O 
with O 
naloxone B-TRIVIAL 
suppressed O 
the O 
renal O 
ischemia O 
/ O 
reperfusion O 
- O 
induced O 
increases O 
in O 
BUN O 
and O 
plasma O 
creatinine B-TRIVIAL 
. O 
This O 
effect O 
of O 
naloxone B-TRIVIAL 
was O 
reversed O 
by O 
subcutaneous O 
pretreatment O 
with O 
morphine B-TRIVIAL 
. O 
Selective O 
MOP O 
receptor O 
antagonist O 
β-funaltrexamine B-TRIVIAL 
( O 
FNA B-ABBREVIATION 
) O 
also O 
suppressed O 
the O 
renal O 
ischemia O 
/ O 
reperfusion O 
- O 
induced O 
increases O 
in O 
BUN O 
and O 
plasma O 
creatinine B-TRIVIAL 
. O 
Moreover O 
, O 
tyrosine B-TRIVIAL 
hydroxylase O 
expression O 
in O 
the O 
renal O 
tissue O 
increased O 
24 O 
h O 
after O 
renal O 
ischemia O 
/ O 
reperfusion O 
, O 
which O 
was O 
abolished O 
by O 
intraperitoneal O 
or O 
intracerebroventricular O 
pretreatment O 
with O 
naloxone B-TRIVIAL 
and O 
FNA B-ABBREVIATION 
. O 
Immunohistochemical O 
experiments O 
revealed O 
a O 
significant O 
increase O 
in O 
the O 
number O 
of O 
the O 
Fos O 
family O 
proteins O 
( O 
c-Fos O 
, O 
FosB O 
, O 
Fra-1 O 
, O 
and O 
Fra-2 O 
) O 
positive O 
cells O 
in O 
the O 
paraventricular O 
nucleus O 
of O 
hypothalamus O 
and O 
supraoptic O 
nucleus O 
24 O 
h O 
after O 
the O 
renal O 
ischemia O 
/ O 
reperfusion O 
. O 
Intracerebroventricular O 
pretreatment O 
with O 
naloxone B-TRIVIAL 
attenuated O 
the O 
renal O 
ischemia O 
/ O 
reperfusion O 
- O 
induced O 
increase O 
in O 
the O 
number O 
of O 
the O 
Fos O 
family O 
proteins O 
positive O 
cells O 
in O 
these O 
areas O 
. O 
Finally O 
, O 
we O 
observed O 
that O 
i.c.v O 
. O 
pretreatment O 
with O 
antiserum O 
against O 
β-endorphin O 
also O 
suppressed O 
the O 
increased O 
blood O 
urea B-TRIVIAL 
and O 
plasma O 
creatinine B-TRIVIAL 
. O 
These O 
results O 
suggest O 
that O 
the O 
blockade O 
of O 
central O 
opioid O 
receptors O 
can O 
attenuate O 
the O 
ischemic O 
acute O 
kidney O 
injury O 
through O 
the O 
inhibition O 
of O 
renal O 
sympathoexcitation O 
. O 
The O 
central O 
opioid O 
receptors O 
may O 
thus O 
be O 
a O 
new O 
target O 
for O 
the O 
treatment O 
of O 
ischemic O 
organ O 
failures O 
. O 

and O 
biological O 
evaluation O 
of O 
novel O 
pyrrolidine-2,5-dione B-SYSTEMATIC 
derivatives O 
as O 
potential O 
antidepressant O 
agents O 
. O 
Part O 
1 O 
. O 

series O 
of O 
3-(1H-indol-3-yl)pyrrolidine-2,5-dione B-SYSTEMATIC 
derivatives O 
was O 
synthesized O 
and O 
their O 
biological O 
activity O 
was O 
evaluated O 
. O 
The O 
chemical O 
structures O 
of O 
the O 
newly O 
prepared O 
compounds O 
were O 
confirmed O 
by O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
ESI-HRMS O 
spectra O 
data O 
. O 
All O 
tested O 
compounds O 
proved O 
to O 
be O 
potent O 
5-HT1A O 
receptor O 
and O 
serotonin B-TRIVIAL 
transporter O 
protein O 
( O 
SERT O 
) O 
ligands O 
. O 
Among O 
them O 
, O 
compounds O 
15 O 
, O 
18 O 
, O 
19 O 
and O 
30 O 
showed O 
significant O 
affinity O 
for O 
5-HT1A O 
and O 
SERT O 
. O 
Computer O 
docking O 
simulations O 
carried O 
out O 
for O 
compounds O 
15 O 
, O 
31 O 
and O 
32 O 
to O 
models O 
of O 
5-HT1A O 
receptor O 
and O 
SERT O 
confirm O 
the O 
results O 
of O 
biological O 
tests O 
. O 
Due O 
to O 
high O 
affinity O 
for O 
the O 
5-HT1A O 
receptor O 
and O 
moderate O 
affinity O 
for O 
SERT O 
, O 
compounds O 
31 O 
, O 
32 O 
, O 
35 O 
, O 
and O 
37 O 
were O 
evaluated O 
for O 
their O 
affinity O 
for O 
D2L O 
, O 
5-HT6 O 
, O 
5-HT7 O 
and O 
5-HT2A O 
receptors O 
. O 
In O 
vivo O 
tests O 
, O 
in O 
turn O 
, O 
resulted O 
in O 
determining O 
the O 
functional O 
activity O 
of O 
compounds O 
15 O 
, O 
18 O 
, O 
19 O 
and O 
30 O 
to O 
the O 
5-HT1A O 
receptor O 
. O 
The O 
results O 
of O 
these O 
tests O 
indicate O 
that O 
all O 
of O 
the O 
ligands O 
possess O 
properties O 
characteristic O 
of O 
5-HT1A O 
receptor O 
agonists O 
. O 

hyperthermia O 
triggered O 
doxorubicin B-TRIVIAL 
release O 
from O 
optimized O 
stealth O 
thermosensitive O 
liposomes O 
improves O 
intratumoral O 
drug O 
delivery O 
and O 
efficacy O 
. O 

mediated O 
anticancer O 
drug O 
delivery O 
has O 
the O 
advantage O 
of O 
reducing O 
cytotoxicity O 
in O 
healthy O 
tissues O 
. O 
However O 
, O 
undesired O 
slow O 
drug O 
release O 
impedes O 
the O 
therapeutic O 
efficacy O 
of O 
clinically O 
applied O 
PEG B-ABBREVIATION 
-liposomal O 
doxorubicin B-TRIVIAL 
( O 
Dox B-ABBREVIATION 
) O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
combine O 
stealth O 
thermosensitive O 
liposomes O 
( O 
TSL O 
) O 
and O 
local O 
mild O 
hyperthermia O 
( O 
HT O 
) O 
to O 
increase O 
bioavailable O 
Dox B-ABBREVIATION 
levels O 
in O 
tumors O 
. O 
Dox B-ABBREVIATION 
was O 
encapsulated O 
in O 
stealth O 
TSL O 
( O 
~80nm O 
) O 
with O 
optimized O 
PEG B-ABBREVIATION 
concentration O 
in O 
the O 
membrane O 
, O 
and O 
compared O 
with O 
lysolipid O 
- O 
based O 
Dox B-ABBREVIATION 
-LTSL O 
for O 
in O 
vitro O 
stability O 
, O 
release O 
kinetics O 
, O 
and O 
in O 
vivo O 
tumor O 
growth O 
control O 
. O 
In O 
vitro O 
cytotoxicity O 
of O 
Dox B-ABBREVIATION 
-TSL O 
against O 
murine O 
BFS-1 O 
sarcoma O 
and O 
, O 
human O 
BLM O 
melanoma O 
cell O 
lines O 
and O 
Human O 
Umbilical O 
Vein O 
Endothelial O 
Cells O 
( O 
HUVEC O 
) O 
under O 
normothermia O 
( O 
37°C O 
) O 
and O 
HT O 
( O 
42°C O 
) O 
was O 
compared O 
with O 
non-encapsulated O 
Dox B-ABBREVIATION 
. O 
In O 
vitro O 
Dox B-ABBREVIATION 
uptake O 
in O 
nuclei O 
was O 
imaged O 
in O 
BLM O 
and O 
HUVEC O 
. O 
In O 
vivo O 
intravascular O 
Dox B-ABBREVIATION 
release O 
from O 
TSL O 
in O 
BFS-1 O 
tumors O 
under O 
local O 
mild O 
HT O 
in O 
dorsal O 
skin O 
flap O 
window O 
chamber O 
models O 
was O 
captured O 
by O 
intravital O 
confocal O 
microscopy O 
. O 
Intravascular O 
Dox B-ABBREVIATION 
-TSL O 
release O 
kinetics O 
, O 
penetration O 
depth O 
and O 
interstitial O 
Dox B-ABBREVIATION 
density O 
were O 
subjected O 
to O 
quantitative O 
image O 
analysis O 
. O 
Systemic O 
Dox B-ABBREVIATION 
-TSL O 
administration O 
in O 
combination O 
with O 
local O 
mild O 
HT O 
on O 
subcutaneous O 
tumor O 
growth O 
control O 
was O 
compared O 
to O 
Dox B-ABBREVIATION 
-LTSL O 
plus O 
local O 
mild O 
HT O 
. O 
Dox B-ABBREVIATION 
-TSL O 
was O 
stable O 
at O 
37°C O 
, O 
while O 
released O 
over O 
95% O 
Dox B-ABBREVIATION 
within O 
1min O 
in O 
90% O 
serum O 
at O 
42°C O 
. O 
Dox B-ABBREVIATION 
-TSL O 
demonstrated O 
efficient O 
in O 
vivo O 
intratumoral O 
Dox B-ABBREVIATION 
release O 
under O 
local O 
mild O 
HT O 
, O 
followed O 
by O 
significant O 
Dox B-ABBREVIATION 
uptake O 
by O 
tumor O 
and O 
tumor O 
vascular O 
endothelial O 
cells O 
. O 
Dox B-ABBREVIATION 
-TSL O 
plus O 
mild O 
HT O 
showed O 
improved O 
tumor O 
growth O 
control O 
over O 
Dox B-ABBREVIATION 
-LTSL O 
plus O 
mild O 
HT O 
. O 
Survival O 
after O 
a O 
single O 
treatment O 
of O 
Dox B-ABBREVIATION 
-TSL O 
plus O 
mild O 
HT O 
was O 
67% O 
, O 
while O 
survival O 
after O 
Dox B-ABBREVIATION 
-LTSL O 
plus O 
mild O 
HT O 
was O 
22% O 
. O 
This O 
combination O 
of O 
Dox B-ABBREVIATION 
-TSL O 
and O 
local O 
mild O 
HT O 
offers O 
promising O 
clinical O 
opportunities O 
to O 
improve O 
liposomal O 
Dox B-ABBREVIATION 
delivery O 
to O 
solid O 
tumors O 
. O 

stem O 
cells O 
as O 
delivery O 
vehicle O 
of O 
porphyrin B-FAMILY 
loaded O 
nanoparticles O 
: O 
Effective O 
photoinduced O 
in O 
vitro O 
killing O 
of O 
osteosarcoma O 
. O 

stem O 
cells O 
( O 
MSC O 
) O 
have O 
the O 
unique O 
ability O 
to O 
home O 
and O 
engraft O 
in O 
tumor O 
stroma O 
. O 
These O 
features O 
render O 
them O 
potentially O 
a O 
very O 
useful O 
tool O 
as O 
targeted O 
delivery O 
vehicles O 
which O 
can O 
deliver O 
therapeutic O 
drugs O 
to O 
the O 
tumor O 
stroma O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigate O 
whether O 
fluorescent O 
core O 
- O 
shell O 
PMMA O 
nanoparticles O 
( O 
FNPs O 
) O 
post O 
- O 
loaded O 
with O 
a O 
photosensitizer O 
, O 
namely O 
meso-tetrakis B-SYSTEMATIC 
( I-SYSTEMATIC 
4-sulfonatophenyl I-SYSTEMATIC 
) I-SYSTEMATIC 
porphyrin I-SYSTEMATIC 
( O 
TPPS B-ABBREVIATION 
) O 
and O 
uploaded O 
by O 
MSC O 
could O 
trigger O 
osteosarcoma O 
( O 
OS O 
) O 
cell O 
death O 
in O 
vitro O 
upon O 
specific O 
photoactivation O 
. O 
In O 
co O 
- O 
culture O 
studies O 
we O 
demonstrate O 
using O 
laser O 
confocal O 
microscopy O 
and O 
time O 
lapse O 
imaging O 
, O 
that O 
only O 
after O 
laser O 
irradiation O 
MSC O 
loaded O 
with O 
photosensitizer O 
- O 
coated O 
fluorescent O 
NPs O 
( O 
TPPS B-ABBREVIATION 
@FNPs O 
) O 
undergo O 
cell O 
death O 
and O 
release O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
which O 
are O 
sufficient O 
to O 
trigger O 
cell O 
death O 
of O 
all O 
OS O 
cells O 
in O 
the O 
culture O 
. O 
These O 
results O 
encourage O 
further O 
studies O 
aimed O 
at O 
proving O 
the O 
efficacy O 
of O 
this O 
novel O 
tri O 
- O 
component O 
system O 
for O 
PDT O 
applications O 
. O 

activation O 
of O 
vincamine B-TRIVIAL 
mediated O 
by O 
linear O 
polymers O 
: O 
Assessment O 
of O 
some O 
" O 
critical O 
" O 
steps O 
. O 

aim O 
of O 
the O 
research O 
was O 
to O 
investigate O 
three O 
" O 
critical O 
steps O 
" O 
that O 
deserve O 
particular O 
attention O 
during O 
the O 
mechanochemical O 
activation O 
of O 
vincamine B-TRIVIAL 
. O 
The O 
first O 
step O 
consisted O 
in O 
the O 
selection O 
of O 
the O 
best O 
polymeric O 
carrier O 
/ O 
most O 
affine O 
stabiliser O 
between O 
linear O 
PVP B-ABBREVIATION 
and O 
NaCMC O 
by O 
using O 
the O 
GRID O 
and O 
the O 
GRID O 
based O 
AutoDock O 
software O 
packages O 
which O 
permit O 
to O 
calculate O 
their O 
surface O 
features O 
and O 
interactions O 
. O 
Moreover O 
, O 
the O 
calculation O 
of O 
the O 
partial O 
and O 
total O 
solubility O 
parameters O 
supported O 
the O 
results O 
obtained O 
by O 
GRID O 
and O 
AutoDock O 
software O 
. O 
Then O 
, O 
after O 
the O 
selection O 
of O 
linear O 
PVP-K30 B-IDENTIFIER 
as O 
the O 
suitable O 
carrier O 
, O 
the O 
influence O 
of O 
process O 
and O 
formulation O 
variables O 
on O 
the O 
amorphisation O 
degree O 
and O 
solubility O 
enhancement O 
was O 
studied O 
, O 
to O 
select O 
the O 
most O 
suitable O 
process O 
conditions O 
and O 
formulation O 
parameters O 
. O 
Subsequently O 
, O 
the O 
best O 
performing O 
samples O 
were O 
widely O 
characterised O 
using O 
XRPD O 
, O 
TEM O 
and O 
SSNMR O 
( O 
including O 
the O 
proton O 
relaxation O 
( O 
(1)H B-FORMULA 
T1 O 
NMR O 
) O 
time O 
) O 
techniques O 
. O 
These O 
studies O 
highlighted O 
that O 
all O 
the O 
coground O 
samples O 
were O 
nanocrystalline O 
solid O 
dispersions O 
indicating O 
a O 
dramatic O 
difference O 
between O 
the O 
amorphisation O 
capacities O 
of O 
linear O 
PVP-K30 B-IDENTIFIER 
and O 
cross O 
- O 
linked O 
PVP B-ABBREVIATION 
, O 
used O 
in O 
previous O 
analogous O 
experiences O 
. O 
In O 
particular O 
, O 
(13)C B-FORMULA 
, O 
(15)N B-FORMULA 
and O 
(1)H B-FORMULA 
T1 O 
NMR O 
data O 
point O 
to O 
a O 
description O 
of O 
the O 
system O 
as O 
a O 
dispersion O 
of O 
nanocrystals O 
in O 
the O 
polymer O 
. O 
In O 
these O 
dispersions O 
vincamine B-TRIVIAL 
is O 
in O 
a O 
disordered O 
crystalline O 
state O 
due O 
to O 
extensive O 
interactions O 
and O 
contacts O 
with O 
PVP-K30 B-IDENTIFIER 
but O 
the O 
main O 
hydrogen B-SYSTEMATIC 
bonding O 
motif O 
characterising O 
its O 
packing O 
remains O 
. O 
Again O 
, O 
differently O 
from O 
cross O 
- O 
linked O 
PVP B-ABBREVIATION 
, O 
dissolution O 
studies O 
revealed O 
that O 
linear O 
PVP-K30 B-IDENTIFIER 
was O 
able O 
to O 
promote O 
a O 
complete O 
in O 
vitro O 
solubilisation O 
of O 
vincamine B-TRIVIAL 
in O 
some O 
coground O 
samples O 
. O 
What O 
is O 
more O 
important O 
, O 
by O 
using O 
a O 
linear O 
polymer O 
, O 
drug O 
- O 
to O 
- O 
polymer O 
and O 
milling O 
time O 
variables O 
appeared O 
less O 
influent O 
on O 
the O 
solid O 
state O 
and O 
in O 
vitro O 
properties O 
of O 
the O 
composites O 
. O 
Finally O 
, O 
stability O 
studies O 
conducted O 
for O 
a O 
period O 
of O 
1year O 
highlighted O 
the O 
high O 
physical O 
stability O 
of O 
the O 
selected O 
samples O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
binding O 
patterns O 
of O 
Canavalia O 
ensiformis O 
( O 
ConA O 
) O 
, O 
Canavalia O 
boliviana O 
( O 
ConBol O 
) O 
and O 
Canavalia O 
brasiliensis O 
( O 
ConBr O 
) O 
lectins O 
to O 
bovine O 
sperm O 
and O 
their O 
effects O 
on O 
sperm O 
motility O 
, O 
viability O 
, O 
lipid O 
peroxidation O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
production O 
and O 
fertilization O 
ability O 
. O 
ConA O 
bound O 
to O 
whole O 
spermatozoa O 
, O 
with O 
the O 
exception O 
of O 
the O 
equatorial O 
segment O 
, O 
ConBol O 
did O 
not O 
interact O 
with O 
the O 
acrosome O 
region O 
and O 
ConBr O 
exhibited O 
a O 
fragmented O 
binding O 
pattern O 
. O 
The O 
three O 
lectins O 
decreased O 
sperm O 
motility O 
but O 
did O 
not O 
affect O 
cell O 
viability O 
or O 
lipid O 
peroxidation O 
. O 
Nevertheless O 
, O 
ROS O 
production O 
was O 
increased O 
in O 
comparison O 
to O 
controls O 
and O 
a O 
reduction O 
in O 
the O 
cleavage O 
and O 
blastocyst O 
ratio O 
was O 
induced O 
in O 
comparison O 
to O 
controls O 
. O 
In O 
conclusion O 
, O 
this O 
study O 
determined O 
that O 
structurally O 
similar O 
lectins O 
interact O 
differently O 
with O 
bovine O 
sperm O 
and O 
affect O 
sperm O 
motility O 
, O 
viability O 
, O 
lipid O 
peroxidation O 
, O 
ROS O 
production O 
and O 
fertilization O 
ability O 
in O 
various O 
ways O 
. O 

class O 
IIa O 
histone O 
deacetylase O 
inhibition O 
via O 
a O 
nonchelating O 
zinc B-SYSTEMATIC 
-binding O 
group O 
. O 

contrast O 
to O 
studies O 
on O 
class O 
I O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitors O 
, O 
the O 
elucidation O 
of O 
the O 
molecular O 
mechanisms O 
and O 
therapeutic O 
potential O 
of O 
class O 
IIa O 
HDACs O 
( O 
HDAC4 O 
, O 
HDAC5 O 
, O 
HDAC7 O 
and O 
HDAC9 O 
) O 
is O 
impaired O 
by O 
the O 
lack O 
of O 
potent O 
and O 
selective O 
chemical O 
probes O 
. O 
Here O 
we O 
report O 
the O 
discovery O 
of O 
inhibitors O 
that O 
fill O 
this O 
void O 
with O 
an O 
unprecedented O 
metal O 
- O 
binding O 
group O 
, O 
trifluoromethyloxadiazole B-SYSTEMATIC 
( O 
TFMO B-ABBREVIATION 
) O 
, O 
which O 
circumvents O 
the O 
selectivity O 
and O 
pharmacologic O 
liabilities O 
of O 
hydroxamates B-FAMILY 
. O 
We O 
confirm O 
direct O 
metal O 
binding O 
of O 
the O 
TFMO B-ABBREVIATION 
through O 
crystallographic O 
approaches O 
and O 
use O 
chemoproteomics O 
to O 
demonstrate O 
the O 
superior O 
selectivity O 
of O 
the O 
TFMO B-ABBREVIATION 
series O 
relative O 
to O 
a O 
hydroxamate B-SYSTEMATIC 
-substituted O 
analog O 
. O 
We O 
further O 
apply O 
these O 
tool O 
compounds O 
to O 
reveal O 
gene O 
regulation O 
dependent O 
on O 
the O 
catalytic O 
active O 
site O 
of O 
class O 
IIa O 
HDACs O 
. O 
The O 
discovery O 
of O 
these O 
inhibitors O 
challenges O 
the O 
design O 
process O 
for O 
targeting O 
metalloenzymes O 
through O 
a O 
chelating O 
metal O 
- O 
binding O 
group O 
and O 
suggests O 
therapeutic O 
potential O 
for O 
class O 
IIa O 
HDAC O 
enzyme O 
blockers O 
distinct O 
in O 
mechanism O 
and O 
application O 
compared O 
to O 
current O 
HDAC O 
inhibitors O 
. O 

3D-RISM-SCF O 
method O 
with O 
dual O 
solvent O 
boxes O 
for O 
a O 
highly O 
polarized O 
system O 
: O 
application O 
to O 
1,6-anhydrosugar B-FAMILY 
formation O 
reaction O 
of O 
phenyl B-MULTIPLE 
α- I-MULTIPLE 
and I-MULTIPLE 
β-d-glucosides I-MULTIPLE 
under O 
basic O 
conditions O 
. O 

of O 
the O 
difficulties O 
in O 
application O 
of O 
the O 
usual O 
reference O 
interaction O 
site O 
model O 
self O 
- O 
consistent O 
field O 
( O 
RISM-SCF O 
) O 
method O 
to O 
a O 
highly O 
polarized O 
and O 
bulky O 
system O 
arises O 
from O 
the O 
approximate O 
evaluation O 
of O 
electrostatic O 
potential O 
( O 
ESP O 
) O 
with O 
pure O 
point O 
charges O 
. O 
To O 
improve O 
this O 
ESP O 
evaluation O 
, O 
the O 
ESP O 
near O 
a O 
solute O 
is O 
directly O 
calculated O 
with O 
a O 
solute O 
electronic O 
wavefunction O 
, O 
that O 
distant O 
from O 
a O 
solute O 
is O 
approximately O 
calculated O 
with O 
solute O 
point O 
charges O 
, O 
and O 
they O 
are O 
connected O 
with O 
a O 
switching O 
function O 
. O 
To O 
evaluate O 
the O 
fine O 
solvation O 
structure O 
near O 
the O 
solute O 
by O 
incorporating O 
the O 
long O 
- O 
range O 
solute O 
- O 
solvent O 
Coulombic O 
interaction O 
with O 
low O 
computational O 
cost O 
, O 
we O 
introduced O 
the O 
dual O 
solvent O 
box O 
protocol O 
; O 
one O 
small O 
box O 
with O 
the O 
fine O 
spacing O 
is O 
employed O 
for O 
the O 
first O 
and O 
the O 
second O 
solvation O 
shells O 
and O 
the O 
other O 
large O 
box O 
with O 
the O 
normal O 
spacing O 
is O 
employed O 
for O 
long O 
- O 
range O 
solute O 
- O 
solvent O 
interaction O 
. O 
The O 
levoglucosan B-TRIVIAL 
formation O 
from O 
phenyl B-MULTIPLE 
α- I-MULTIPLE 
and I-MULTIPLE 
β-d-glucosides I-MULTIPLE 
under O 
basic O 
conditions O 
is O 
successfully O 
inspected O 
by O 
this O 
3D-RISM-SCF O 
method O 
at O 
the O 
MP2 O 
and O 
SCS-MP2 O 
levels O 
, O 
though O 
the O 
1D-RISM-SCF O 
could O 
not O 
be O 
applied O 
to O 
this O 
reaction O 
due O 
to O 
the O 
presence O 
of O 
highly O 
polarized O 
and O 
bulky O 
species O 
. O 
This O 
3D-RISM-SCF O 
calculation O 
reproduces O 
the O 
experimentally O 
reported O 
higher O 
reactivity O 
of O 
the O 
β-anomer O 
. O 
The O 
3D-RISM-SCF-calculated O 
activation O 
free O 
energy O 
for O 
the O 
β-anomer O 
is O 
closer O 
to O 
the O 
experimental O 
value O 
than O 
the O 
PCM-calculated O 
one O 
. O 
Interestingly O 
, O 
the O 
solvation O 
effect O 
increases O 
the O 
difference O 
in O 
reactivity O 
between O 
these O 
two O 
anomers O 
. O 
The O 
reason O 
is O 
successfully O 
elucidated O 
with O 
3D-RISM-SCF-calculated O 
microscopic O 
solvation O 
structure O 
and O 
decomposition O 
analysis O 
of O 
solute O 
- O 
solvent O 
interaction O 
. O 

Factor O 
κB O 
Mediates O 
Suppression O 
of O 
Canonical O 
Transient O 
Receptor O 
Potential O 
6 O 
Expression O 
by O 
Reactive O 
Oxygen B-SYSTEMATIC 
Species O 
and O 
Protein O 
Kinase O 
C O 
in O 
Kidney O 
Cells O 
. O 

study O 
was O 
carried O 
out O 
to O 
explore O 
the O 
molecular O 
mechanism O 
for O 
down O 
- O 
regulation O 
of O 
TRPC6 O 
expression O 
in O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
/ O 
PKC O 
signaling O 
in O 
kidney O 
cells O 
. O 
In O 
cultured O 
human O 
mesangial O 
cells O 
, O 
H2O2 B-FORMULA 
and O 
TNF-α O 
inhibited O 
TRPC6 O 
mRNA O 
expression O 
in O 
a O 
time O 
- O 
dependent O 
manner O 
. O 
Inhibition O 
of O 
NF-κB O 
reversed O 
both O 
H2O2 B-FORMULA 
- O 
and O 
phorbol B-SYSTEMATIC 
12-myristate I-SYSTEMATIC 
13-acetate I-SYSTEMATIC 
( O 
PMA B-ABBREVIATION 
)-induced O 
decrease O 
in O 
TRPC6 O 
protein O 
expression O 
. O 
Activation O 
of O 
NF-κB O 
by O 
knocking O 
down O 
IκBα O 
using O 
siRNA O 
could O 
mimic O 
the O 
suppressive O 
effect O 
of O 
ROS O 
/ O 
PKC O 
on O 
TRPC6 O 
. O 
a O 
Ca(2+) B-FORMULA 
imaging O 
study O 
showed O 
that O 
activation O 
and O 
inhibition O 
of O 
NF-κB O 
significantly O 
decreased O 
and O 
increased O 
the O 
TRPC6 O 
- O 
mediated O 
Ca(2+) B-FORMULA 
entry O 
, O 
respectively O 
. O 
Further O 
experiments O 
showed O 
that O 
PMA B-ABBREVIATION 
, O 
but O 
not O 
its O 
inactive O 
analog O 
4α-phorbol B-SYSTEMATIC 
12 I-SYSTEMATIC 
, I-SYSTEMATIC 
13-didecanoate I-SYSTEMATIC 
( O 
4α-PDD B-SYSTEMATIC 
) O 
, O 
caused O 
phosphorylation O 
of O 
IκBα O 
and O 
stimulated O 
the O 
nuclear O 
translocation O 
of O 
NF-κB O 
p50 O 
and O 
p65 O 
subunits O 
. O 
The O 
PMA B-ABBREVIATION 
-dependent O 
IκBα O 
phosphorylation O 
was O 
significantly O 
inhibited O 
by O 
Gö6976 B-IDENTIFIER 
. O 
Electrophoretic O 
mobility O 
shift O 
assay O 
revealed O 
that O 
PMA B-ABBREVIATION 
stimulated O 
DNA O 
binding O 
activity O 
of O 
NF-κB O 
. O 
Furthermore O 
, O 
specific O 
knockdown O 
of O 
p65 O 
, O 
but O 
not O 
p50 O 
, O 
prevented O 
an O 
H2O2 B-FORMULA 
inhibitory O 
effect O 
on O 
TRPC6 O 
protein O 
expression O 
, O 
suggesting O 
p65 O 
as O 
a O 
predominant O 
NF-κB O 
subunit O 
repressing O 
TRPC6 O 
. O 
In O 
agreement O 
with O 
a O 
major O 
role O 
of O 
p65 O 
, O 
chromatin O 
immunoprecipitation O 
assays O 
showed O 
that O 
PMA B-ABBREVIATION 
treatment O 
induced O 
p65 O 
binding O 
to O 
the O 
TRPC6 O 
promoter O 
. O 
Moreover O 
, O 
PMA B-ABBREVIATION 
treatment O 
increased O 
the O 
association O 
of O 
p65 O 
with O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
and O 
decreased O 
histone O 
acetylation O 
at O 
the O 
TRPC6 O 
promoter O 
. O 
Consistently O 
, O 
knockdown O 
of O 
HDAC2 O 
by O 
siRNA O 
or O 
inhibition O 
of O 
HDAC O 
with O 
trichostatin B-TRIVIAL 
A I-TRIVIAL 
prevented O 
a O 
H2O2 B-FORMULA 
-induced O 
decrease O 
in O 
TRPC6 O 
mRNA O 
and O 
protein O 
expressions O 
, O 
respectively O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
imply O 
an O 
important O 
role O 
of O 
NF-κB O 
in O 
a O 
negative O 
regulation O 
of O 
TRPC6 O 
expression O 
at O 
the O 
gene O 
transcription O 
level O 
in O 
kidney O 
cells O 
. O 

characterisation O 
of O 
dynamics O 
in O 
solvates O 
and O 
desolvates O 
of O 
formoterol B-TRIVIAL 
fumarate I-TRIVIAL 
. O 

- O 
state O 
NMR O 
is O 
used O 
to O 
characterise O 
dynamics O 
in O 
the O 
ethanol B-SYSTEMATIC 
solvate O 
of O 
the O 
pharmaceutical O 
material O 
formoterol B-TRIVIAL 
fumarate I-TRIVIAL 
and O 
its O 
associated O 
desolvate O 
. O 
Jump O 
rates O 
and O 
activation O 
barriers O 
for O 
dynamic O 
processes O 
such O 
as O 
phenyl B-SYSTEMATIC 
ring O 
rotation O 
and O 
methyl B-SYSTEMATIC 
group O 
rotational O 
diffusion O 
are O 
derived O 
from O 
1D-EXSY O 
and O 
(13)C B-FORMULA 
spin O 
- O 
lattice O 
relaxation O 
times O 
respectively O 
. O 
(2)H B-FORMULA 
and O 
(13)C B-FORMULA 
spin O 
- O 
lattice O 
relaxation O 
times O 
measured O 
under O 
magic O 
- O 
angle O 
spinning O 
conditions O 
are O 
used O 
to O 
show O 
that O 
the O 
fumarate B-TRIVIAL 
ion O 
in O 
the O 
desolvate O 
is O 
undergoing O 
small O 
- O 
amplitude O 
motion O 
on O 
a O 
frequency O 
scale O 
of O 
100s O 
of O 
MHz O 
at O 
ambient O 
temperature O 
with O 
an O 
activation O 
parameter O 
of O 
about O 
32 O 
kJ O 
mol(-1) O 
. O 
Exact O 
calculations O 
of O 
relaxation O 
times O 
under O 
MAS O 
provide O 
a O 
simple O 
and O 
robust O 
means O 
to O 
test O 
motional O 
models O 
in O 
cases O 
where O 
relaxation O 
rate O 
maxima O 
are O 
observed O 
, O 
including O 
for O 
systems O 
where O 
the O 
crystal O 
structure O 
of O 
the O 
material O 
is O 
unknown O 
. O 

the O 
present O 
study O 
, O 
genomic O 
binding O 
sites O 
of O 
glucocorticoid O 
receptors O 
( O 
GR O 
) O 
were O 
identified O 
in O 
vivo O 
in O 
the O 
rat O 
hippocampus O 
applying O 
chromatin O 
immunoprecipitation O 
followed O 
by O 
next O 
- O 
generation O 
sequencing O 
. O 
We O 
identified O 
2470 O 
significant O 
GR O 
- O 
binding O 
sites O 
( O 
GBS O 
) O 
and O 
were O 
able O 
to O 
confirm O 
GR O 
binding O 
to O 
a O 
random O 
selection O 
of O 
these O 
GBS O 
covering O 
a O 
wide O 
range O 
of O 
P O 
values O 
. O 
Analysis O 
of O 
the O 
genomic O 
distribution O 
of O 
the O 
significant O 
GBS O 
revealed O 
a O 
high O 
prevalence O 
of O 
intragenic O 
GBS O 
. O 
Gene O 
ontology O 
clusters O 
involved O 
in O 
neuronal O 
plasticity O 
and O 
other O 
essential O 
neuronal O 
processes O 
were O 
overrepresented O 
among O 
the O 
genes O 
harboring O 
a O 
GBS O 
or O 
located O 
in O 
the O 
vicinity O 
of O 
a O 
GBS O 
. O 
Male O 
adrenalectomized O 
rats O 
were O 
challenged O 
with O 
increasing O 
doses O 
of O 
the O 
GR O 
agonist O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
ranging O 
from O 
3 O 
to O 
3000 O 
μg O 
/ O 
kg O 
, O 
resulting O 
in O 
clear O 
differences O 
in O 
the O 
GR O 
- O 
binding O 
profile O 
to O 
individual O 
GBS O 
. O 
Two O 
groups O 
of O 
GBS O 
could O 
be O 
distinguished O 
: O 
a O 
low- O 
CORT B-ABBREVIATION 
group O 
that O 
displayed O 
GR O 
binding O 
across O 
the O 
full O 
range O 
of O 
CORT B-ABBREVIATION 
concentrations O 
, O 
and O 
a O 
second O 
high- O 
CORT B-ABBREVIATION 
group O 
that O 
displayed O 
significant O 
GR O 
binding O 
only O 
after O 
administering O 
the O 
highest O 
concentration O 
of O 
CORT B-ABBREVIATION 
. O 
All O 
validated O 
GBS O 
, O 
in O 
both O 
the O 
low- O 
CORT B-ABBREVIATION 
and O 
high- O 
CORT B-ABBREVIATION 
groups O 
, O 
displayed O 
mineralocorticoid O 
receptor O 
binding O 
, O 
which O 
remained O 
relatively O 
constant O 
from O 
30 O 
μg O 
/ O 
kg O 
CORT B-ABBREVIATION 
upward O 
. O 
Motif O 
analysis O 
revealed O 
that O 
almost O 
all O 
GBS O 
contained O 
a O 
glucocorticoid O 
response O 
element O 
resembling O 
the O 
consensus O 
motif O 
in O 
literature O 
. O 
In O 
addition O 
, O 
motifs O 
corresponding O 
with O 
new O 
potential O 
GR-interacting O 
proteins O 
were O 
identified O 
, O 
such O 
as O 
zinc B-SYSTEMATIC 
finger O 
and O 
BTB O 
domain O 
containing O 
3 O 
( O 
Zbtb3 O 
) O 
and O 
CUP O 
( O 
CG11181 O 
gene O 
product O 
from O 
transcript O 
CG11181-RB O 
) O 
, O 
which O 
may O 
be O 
involved O 
in O 
GR-dependent O 
transactivation O 
and O 
transrepression O 
, O 
respectively O 
. O 
In O 
conclusion O 
, O 
our O 
results O 
highlight O 
the O 
existence O 
of O 
2 O 
populations O 
of O 
GBS O 
in O 
the O 
rat O 
hippocampal O 
genome O 
. O 

Etomidate O 
Occupancy O 
of O 
its O 
Allosteric O 
Agonist O 
Sites O 
Measured O 
in O 
a O 
Cysteine B-TRIVIAL 
-Substituted O 
GABAA O 
Receptor O 
. O 

central O 
axiom O 
of O 
ligand O 
- O 
receptor O 
theory O 
is O 
that O 
agonists O 
bind O 
more O 
tightly O 
to O 
active O 
than O 
to O 
inactive O 
receptors O 
. O 
However O 
, O 
measuring O 
agonist O 
affinity O 
in O 
inactive O 
receptors O 
is O 
confounded O 
by O 
concomitant O 
activation O 
. O 
We O 
identified O 
a O 
cysteine B-TRIVIAL 
substituted O 
mutant O 
GABAA O 
receptor O 
with O 
unique O 
characteristics O 
allowing O 
determination O 
of O 
allosteric O 
agonist O 
site O 
occupancy O 
in O 
both O 
inactive O 
and O 
active O 
receptors O 
. O 
Etomidate B-TRIVIAL 
, O 
the O 
allosteric O 
agonist O 
, O 
is O 
an O 
anesthetic O 
that O 
activates O 
/ O 
modulates O 
α1β2γ2L O 
GABAA O 
receptors O 
via O 
transmembrane O 
sites O 
near O 
β2M286 O 
residues O 
in O 
M3 O 
domains O 
. O 
Voltage O 
- O 
clamp O 
electrophysiology O 
studies O 
of O 
α1β2M286Cγ2L O 
receptors O 
show O 
that O 
GABA B-ABBREVIATION 
is O 
an O 
efficacious O 
agonist O 
, O 
and O 
etomidate B-TRIVIAL 
modulates O 
GABA B-ABBREVIATION 
-activated O 
activity O 
, O 
but O 
direct O 
etomidate B-TRIVIAL 
agonism O 
is O 
absent O 
. O 
Quantitative O 
analysis O 
of O 
mutant O 
activity O 
using O 
an O 
established O 
Monod-Wyman-Changeux O 
( O 
MWC O 
) O 
allosteric O 
model O 
indicates O 
that O 
the O 
intrinsic O 
efficacy O 
of O 
etomidate B-TRIVIAL 
, O 
defined O 
as O 
its O 
relative O 
affinity O 
for O 
active O 
vs O 
. O 
inactive O 
receptors O 
, O 
is O 
lower O 
than O 
in O 
wild O 
- O 
type O 
receptors O 
. O 
Para-chloromercuribenzene B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
pCMBS B-ABBREVIATION 
) O 
covalently O 
modifies O 
β2M286C O 
sidechain O 
sulfhydryls B-FAMILY 
, O 
irreversibly O 
altering O 
GABA B-ABBREVIATION 
-induced O 
currents O 
. O 
Etomidate B-TRIVIAL 
concentration O 
- O 
dependently O 
reduces O 
the O 
apparent O 
rate O 
of O 
β2M286C-pCMBS O 
bond O 
formation O 
, O 
tracked O 
electrophysiologically O 
. O 
High O 
etomidate B-TRIVIAL 
concentrations O 
completely O 
protect O 
the O 
β2M286C O 
suflhydryl B-SYSTEMATIC 
from O 
covalent O 
modification O 
, O 
suggesting O 
close O 
steric O 
interactions O 
. O 
The O 
50% O 
protective O 
etomidate B-TRIVIAL 
concentration O 
( O 
PC50 O 
) O 
is O 
14 O 
μM O 
in O 
inactive O 
receptors O 
and O 
1.1 O 
to O 
2.2 O 
μM O 
during O 
GABA B-ABBREVIATION 
-activation O 
, O 
experimentally O 
demonstrating O 
that O 
activated O 
receptors O 
bind O 
etomidate B-TRIVIAL 
more O 
avidly O 
than O 
inactive O 
receptors O 
. O 
The O 
experimental O 
PC50 O 
values O 
are O 
remarkably O 
close O 
to O 
, O 
and O 
therefore O 
validate O 
MWC O 
model O 
predictions O 
for O 
etomidate B-TRIVIAL 
dissociation O 
constants O 
in O 
both O 
inactive O 
and O 
active O 
receptors O 
. O 
Our O 
results O 
support O 
MWC O 
models O 
as O 
valid O 
frameworks O 
for O 
understanding O 
agonism O 
, O 
co O 
- O 
agonism O 
, O 
and O 
modulation O 
of O 
ligand O 
- O 
gated O 
ion O 
channels O 
. O 

ovalbumin O 
upstream O 
promoter O 
transcription O 
factors O 
( O 
COUP-TFs O 
) O 
are O 
nuclear O 
receptors O 
belonging O 
to O 
the O 
superfamily O 
of O 
the O 
steroid B-FAMILY 
/ O 
thyroid O 
hormone O 
receptors O 
. O 
Members O 
of O 
this O 
family O 
are O 
internalized O 
to O 
the O 
nucleus O 
both O 
in O 
a O 
ligand O 
- O 
dependent O 
or O 
-independent O 
manner O 
and O 
act O 
as O 
strong O 
transcriptional O 
regulators O 
by O 
binding O 
to O 
the O 
DNA O 
of O 
their O 
target O 
genes O 
. O 
COUP-TFs O 
are O 
defined O 
as O 
orphan O 
receptors O 
, O 
since O 
ligands O 
regulating O 
their O 
activity O 
have O 
not O 
so O 
far O 
been O 
identified O 
. O 
From O 
the O 
very O 
beginning O 
of O 
metazoan O 
evolution O 
, O 
these O 
molecules O 
have O 
been O 
involved O 
in O 
various O 
key O 
events O 
during O 
embryonic O 
development O 
and O 
organogenesis O 
. O 
In O 
this O 
review O 
, O 
we O 
will O 
mainly O 
focus O 
on O 
their O 
function O 
during O 
development O 
and O 
maturation O 
of O 
the O 
central O 
nervous O 
system O 
, O 
which O 
has O 
been O 
well O 
characterized O 
in O 
various O 
animal O 
classes O 
ranging O 
from O 
ctenophores O 
to O 
mammals O 
. O 
We O 
will O 
start O 
by O 
introducing O 
the O 
current O 
knowledge O 
on O 
COUP-TF O 
mechanisms O 
of O 
action O 
and O 
then O 
focus O 
our O 
discussion O 
on O 
the O 
crucial O 
processes O 
underlying O 
forebrain O 
ontogenesis O 
, O 
with O 
special O 
emphasis O 
on O 
mammalian O 
development O 
. O 
Finally O 
, O 
the O 
conserved O 
roles O 
of O 
COUP-TFs O 
along O 
phylogenesis O 
will O 
be O 
highlighted O 
, O 
and O 
some O 
hypotheses O 
, O 
worth O 
exploring O 
in O 
future O 
years O 
to O 
gain O 
more O 
insight O 
into O 
the O 
mechanisms O 
controlled O 
by O 
these O 
factors O 
, O 
will O 
be O 
proposed O 
. O 

during O 
tensile O 
deformation O 
of O 
isothermally O 
crystallized O 
polypropylene B-SYSTEMATIC 
and O 
high O 
- O 
density O 
polyethylene B-SYSTEMATIC 
. O 

cavitation O 
phenomenon O 
was O 
studied O 
in O 
isothermally O 
and O 
non-isothermally O 
crystallized O 
polypropylene B-SYSTEMATIC 
and O 
high O 
- O 
density O 
polyethylene B-SYSTEMATIC 
. O 
It O 
was O 
found O 
that O 
nano O 
- O 
voids O 
were O 
not O 
present O 
in O 
the O 
crystallized O 
samples O 
, O 
but O 
were O 
formed O 
during O 
their O 
tensile O 
deformation O 
. O 
The O 
process O 
of O 
cavitation O 
was O 
initiated O 
before O 
reaching O 
the O 
yield O 
point O 
. O 
The O 
ellipsoidal O 
voids O 
were O 
initially O 
elongated O 
perpendicularly O 
to O 
the O 
deformation O 
direction O 
, O 
but O 
if O 
the O 
polymer O 
( O 
i.e O 
. O 
, O 
high O 
- O 
density O 
polyethylene B-SYSTEMATIC 
) O 
was O 
able O 
to O 
deform O 
beyond O 
the O 
yield O 
, O 
then O 
the O 
reorientation O 
of O 
voids O 
into O 
the O 
deformation O 
direction O 
was O 
observed O 
at O 
local O 
strains O 
of O 
100-200 O 
% O 
. O 
This O 
behavior O 
was O 
similar O 
to O 
that O 
observed O 
previously O 
in O 
the O 
samples O 
crystallized O 
without O 
an O 
exact O 
control O 
of O 
solidification O 
conditions O 
. O 
The O 
calculations O 
of O 
Guinier's O 
radius O 
showed O 
that O 
voids O 
in O 
deformed O 
polypropylene B-SYSTEMATIC 
samples O 
were O 
characterized O 
by O 
the O 
gyration O 
radii O 
of O 
28-50 O 
nm O 
. O 
Smaller O 
voids O 
were O 
observed O 
in O 
polyethylene B-SYSTEMATIC 
. O 
The O 
scale O 
of O 
cavitation O 
during O 
deformation O 
, O 
studied O 
on O 
the O 
example O 
of O 
polyethylene B-SYSTEMATIC 
, O 
depended O 
on O 
the O 
preceding O 
crystallization O 
process O 
and O 
was O 
most O 
intensive O 
for O 
the O 
specimens O 
crystallized O 
at O 
the O 
highest O 
temperature O 
of O 
125 O 
°C O 
. O 

Design O 
of O 
Hydrolytically O 
Degradable O 
, O 
Bone O 
- O 
like O 
Biocomposites O 
Based O 
on O 
PHEMA B-ABBREVIATION 
and O 
Hydroxyapatite B-TRIVIAL 
. O 

advantages O 
such O 
as O 
design O 
flexibility O 
in O 
modifying O 
degradation O 
, O 
surface O 
chemistry O 
, O 
and O 
topography O 
, O 
synthetic O 
bone O 
- O 
graft O 
substitutes O 
are O 
increasingly O 
demanded O 
in O 
orthopedic O 
tissue O 
engineering O 
to O 
meet O 
various O 
requirements O 
in O 
the O 
growing O 
numbers O 
of O 
cases O 
of O 
skeletal O 
impairment O 
worldwide O 
. O 
Using O 
a O 
combinatorial O 
approach O 
, O 
we O 
developed O 
a O 
series O 
of O 
biocompatible O 
, O 
hydrolytically O 
degradable O 
, O 
elastomeric O 
, O 
bone O 
- O 
like O 
biocomposites O 
, O 
comprising O 
60 O 
wt% O 
poly(2-hydroxyethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
- I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
methacrylic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
poly(HEMA-co-MA) B-SYSTEMATIC 
, O 
and O 
40 O 
wt% O 
bioceramic O 
hydroxyapatite B-TRIVIAL 
( O 
HA O 
) O 
. O 
Hydrolytic O 
degradation O 
of O 
the O 
biocomposites O 
is O 
rendered O 
by O 
a O 
degradable O 
macromer O 
/ O 
crosslinker O 
, O 
dimethacrylated B-SYSTEMATIC 
poly(lactide-b-ethylene I-SYSTEMATIC 
glycol-b-lactide I-SYSTEMATIC 
) I-SYSTEMATIC 
, O 
which O 
first O 
degrades O 
to O 
break O 
up O 
3-D O 
hydrogel O 
networks O 
, O 
followed O 
by O 
dissolution O 
of O 
linear O 
pHEMA B-ABBREVIATION 
macromolecules O 
and O 
bioceramic O 
particles O 
. O 
Swelling O 
and O 
degradation O 
were O 
examined O 
at O 
Hank's O 
balanced O 
salt O 
solution O 
at O 
37 O 
°C O 
in O 
a O 
12-week O 
period O 
of O 
time O 
. O 
The O 
degradation O 
is O 
strongly O 
modulated O 
by O 
altering O 
the O 
concentration O 
of O 
the O 
co O 
- O 
monomer O 
of O 
methacrylic B-TRIVIAL 
acid I-TRIVIAL 
and O 
of O 
the O 
macromer O 
, O 
and O 
chain O 
length O 
/ O 
molecular O 
weight O 
of O 
the O 
macromer O 
. O 
95% O 
weight O 
loss O 
in O 
mass O 
is O 
achieved O 
after O 
degradation O 
for O 
12 O 
weeks O 
in O 
a O 
composition O 
consisting O 
of O 
HEMA B-ABBREVIATION 
/ O 
MA O 
/ O 
Macromer O 
= O 
0 O 
/ O 
60 O 
/ O 
40 O 
, O 
while O 
90% O 
weight O 
loss O 
is O 
seen O 
after O 
degradation O 
only O 
for O 
4 O 
weeks O 
in O 
a O 
composition O 
composed O 
of O 
HEMA B-ABBREVIATION 
/ O 
MA O 
/ O 
Macromer O 
= O 
27 O 
/ O 
13 O 
/ O 
60 O 
using O 
a O 
longer O 
chain O 
macromer O 
. O 
For O 
compositions O 
without O 
a O 
co O 
- O 
monomer O 
, O 
only O 
about O 
14% O 
is O 
achieved O 
in O 
weight O 
loss O 
after O 
12-week O 
degradation O 
. O 
These O 
novel O 
biomaterials O 
offer O 
numerous O 
possibilities O 
as O 
drug O 
delivery O 
carriers O 
and O 
bone O 
grafts O 
particularly O 
for O 
low O 
and O 
medium O 
load O 
- O 
bearing O 
applications O 
. O 

- O 
dependent O 
kinase O 
1 O 
( O 
Cdk1 O 
) O 
controls O 
cell O 
proliferation O 
and O 
is O 
inhibited O 
by O 
promising O 
anticancer O 
agents O 
, O 
but O 
its O 
mode O 
of O 
action O 
and O 
the O 
consequences O 
of O 
its O 
inhibition O 
are O 
incompletely O 
understood O 
. O 
Cdk1 O 
promotes O 
S- O 
and O 
M-phases O 
during O 
the O 
cell O 
- O 
cycle O 
but O 
also O 
suppresses O 
endoreduplication O 
, O 
which O 
is O 
associated O 
with O 
polyploidy O 
and O 
genome O 
instability O 
. O 
The O 
complexity O 
of O 
Cdk1 O 
regulation O 
has O 
made O 
it O 
difficult O 
to O 
determine O 
whether O 
these O 
different O 
roles O 
require O 
different O 
thresholds O 
of O 
kinase O 
activity O 
and O 
whether O 
the O 
surge O 
of O 
activity O 
as O 
inhibitory O 
phosphates B-FAMILY 
are O 
removed O 
at O 
mitotic O 
onset O 
is O 
essential O 
for O 
cell O 
proliferation O 
. O 
Here O 
, O 
we O 
have O 
used O 
chemical O 
genetics O 
in O 
a O 
human O 
cell O 
line O 
to O 
address O 
these O 
issues O 
. O 
We O 
rescued O 
cells O 
lethally O 
depleted O 
of O 
endogenous O 
Cdk1 O 
with O 
an O 
exogenous O 
Cdk1 O 
conferring O 
sensitivity O 
to O 
one O 
ATP B-ABBREVIATION 
analogue O 
inhibitor O 
( O 
1NMPP1 B-IDENTIFIER 
) O 
and O 
resistance O 
to O 
another O 
( O 
RO3306 B-IDENTIFIER 
) O 
. O 
At O 
no O 
1NMPP1 B-IDENTIFIER 
concentration O 
was O 
mitosis O 
in O 
rescued O 
clones O 
prevented O 
without O 
also O 
inducing O 
endoreduplication O 
, O 
suggesting O 
that O 
these O 
two O 
key O 
roles O 
for O 
Cdk1 O 
are O 
not O 
simply O 
controlled O 
by O 
different O 
Cdk1 O 
activity O 
thresholds O 
. O 
We O 
also O 
rescued O 
RO3306 B-IDENTIFIER 
-resistant O 
clones O 
using O 
exogenous O 
Cdk1 O 
without O 
inhibitory O 
phosphorylation O 
sites O 
, O 
indicating O 
that O 
the O 
mitotic O 
surge O 
of O 
Cdk1 O 
activity O 
is O 
dispensable O 
for O 
cell O 
proliferation O 
. O 
These O 
results O 
suggest O 
that O 
the O 
basic O 
mammalian O 
cycle O 
requires O 
at O 
least O 
some O 
qualitative O 
changes O 
in O 
Cdk1 O 
activity O 
and O 
that O 
quantitative O 
increases O 
in O 
activity O 
need O 
not O 
be O 
rapid O 
. O 
Furthermore O 
, O 
the O 
viability O 
of O 
cells O 
that O 
are O 
unable O 
to O 
undergo O 
rapid O 
Cdk1 O 
activation O 
, O 
and O 
the O 
strong O 
association O 
between O 
endoreduplication O 
and O 
impaired O 
proliferation O 
, O 
may O 
place O 
restrictions O 
on O 
the O 
therapeutic O 
use O 
of O 
a O 
Cdk1 O 
inhibitors O 
. O 

and O 
eclampsia O 
are O 
fatal O 
medical O 
complications O 
of O 
pregnancy O 
accounting O 
for O 
20-80 O 
% O 
of O 
increased O 
maternal O 
death O 
in O 
developing O 
countries O 
. O 
Their O 
aetiologies O 
are O 
still O 
under O 
investigation O 
. O 
Serum O 
trace O 
elements O 
have O 
been O 
suggested O 
to O 
be O 
involved O 
in O 
the O 
pathogenesis O 
of O 
preeclampsia O 
. O 
Aim O 
of O 
this O 
study O 
was O 
to O 
address O 
the O 
correlation O 
of O 
serum O 
trace O 
elements O 
with O 
preeclampsia O 
and O 
eclampsia O 
. O 
It O 
was O 
a O 
comparative O 
cross O 
- O 
sectional O 
study O 
conducted O 
on O 
conveniently O 
recruited O 
44 O 
preeclampsia O 
, O 
33 O 
eclampsia O 
and O 
27 O 
normotensive O 
pregnant O 
patients O 
. O 
Atomic O 
absorption O 
spectrometry O 
was O 
employed O 
to O 
analyse O 
serum O 
concentrations O 
of O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
, O 
Cu B-FORMULA 
, O 
Zn B-FORMULA 
and O 
Fe B-FORMULA 
. O 
Data O 
were O 
analysed O 
by O 
Student's O 
t O 
test O 
, O 
one O 
- O 
way O 
analysis O 
of O 
variance O 
and O 
multinomial O 
logistic O 
and O 
binary O 
regression O 
analyses O 
. O 
p O 
< O 
0.05 O 
was O 
considered O 
as O 
a O 
level O 
of O 
significance O 
. O 
In O 
preeclampsia O 
, O 
the O 
serum O 
Ca B-FORMULA 
and O 
Mg B-FORMULA 
were O 
significantly O 
lower O 
than O 
those O 
in O 
eclampsia O 
, O 
while O 
Cu B-FORMULA 
and O 
Zn B-FORMULA 
values O 
were O 
higher O 
. O 
Significant O 
changes O 
of O 
Ca B-FORMULA 
, O 
Mg B-FORMULA 
and O 
Cu B-FORMULA 
were O 
noted O 
among O 
preeclampsia O 
, O 
eclampsia O 
and O 
pregnant O 
control O 
. O 
Serum O 
Ca B-FORMULA 
and O 
Mg B-FORMULA 
indicated O 
a O 
positive O 
association O 
, O 
and O 
Cu B-FORMULA 
gave O 
a O 
negative O 
association O 
in O 
preeclampsia O 
. O 
Cu B-FORMULA 
/ O 
Fe B-FORMULA 
ratio O 
was O 
high O 
in O 
eclampsia O 
. O 
Significant O 
correlations O 
of O 
Mg B-FORMULA 
with O 
Zn B-FORMULA 
in O 
eclampsia O 
and O 
Mg B-FORMULA 
with O 
Fe B-FORMULA 
in O 
preeclampsia O 
and O 
eclampsia O 
were O 
predicted O 
. O 
Significant O 
changes O 
in O 
serum O 
trace O 
element O 
levels O 
were O 
present O 
in O 
preeclampsia O 
and O 
eclampsia O 
that O 
may O 
have O 
a O 
link O 
with O 
the O 
pathogenesis O 
of O 
pregnancy O 
disorder O 
. O 

investigation O 
of O 
the O 
ethanol B-SYSTEMATIC 
extract O 
of O 
the O 
bulbs O 
of O 
Lycoris O 
caldwellii O 
afforded O 
four O 
new O 
alkaloids O 
, O 
(+)-N-methoxylcarbonyl-nandigerine B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(+)-N-methoxycarbonyl-lindcarpine B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
(+)-10-O-methylhernovine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
(+)-3-hydroxy-anhydrolycorine B-SYSTEMATIC 
N-oxide I-SYSTEMATIC 
( O 
4 O 
) O 
. O 
Structural O 
elucidation O 
of O 
all O 
the O 
compounds O 
were O 
performed O 
by O 
spectral O 
methods O 
such O 
as O 
1D O 
and O 
2D O 
( O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
HMQC O 
, O 
and O 
HMBC O 
) O 
NMR O 
spectroscopy O 
, O 
in O 
addition O 
to O 
high O 
resolution O 
mass O 
spectrometry O 
. O 
All O 
the O 
alkaloids O 
were O 
in O 
vitro O 
evaluated O 
for O 
their O 
cytotoxic O 
activities O 
against O 
eight O 
tumor O 
cell O 
lines O 
( O 
BEN-MEN-1 O 
, O 
CCF-STTG1 O 
, O 
CHG-5 O 
, O 
SHG-44 O 
, O 
U251 O 
, O 
BGC-823 O 
, O 
HepG2 O 
, O 
and O 
SK-OV-3 O 
) O 
. O 
Alkaloids O 
1 O 
and O 
2 O 
exhibited O 
particular O 
cytotoxic O 
activities O 
against O 
astrocytoma O 
and O 
glioma O 
cell O 
lines O 
with O 
IC50 O 
of O 
9.2-11.3 O 
μM O 
and O 
10.4-12.2 O 
μM O 
respectively O 
. O 

of O 
a O 
Series O 
of O 
Thiazole B-SYSTEMATIC 
Derivatives O 
as O 
Novel O 
Inhibitors O 
of O 
Metastatic O 
Cancer O 
Cell O 
Migration O 
and O 
Invasion O 
. O 

inhibitors O 
of O 
cancer O 
cell O 
migration O 
and O 
invasion O 
can O 
potentially O 
lead O 
to O 
clinical O 
applications O 
as O 
therapy O 
to O 
block O 
tumor O 
metastasis O 
, O 
the O 
primary O 
cause O 
of O 
death O 
in O 
cancer O 
patients O 
. O 
To O 
this O 
end O 
we O 
have O 
designed O 
and O 
synthesized O 
a O 
series O 
of O 
thiazole B-SYSTEMATIC 
derivatives O 
that O 
showed O 
potent O 
efficacy O 
against O 
cell O 
migration O 
and O 
invasion O 
in O 
metastatic O 
cancer O 
cells O 
. O 
The O 
most O 
effective O 
compound O 
, O 
5k O 
, O 
was O 
found O 
to O 
have O 
an O 
IC50 O 
value O 
of O 
176 O 
nM O 
in O 
the O 
dose O 
- O 
dependent O 
transwell O 
migration O 
assays O 
in O 
MDA-MB-231cells O 
. O 
At O 
the O 
dose O 
of O 
10 O 
μM O 
, O 
5k O 
also O 
blocked O 
about O 
80% O 
of O 
migration O 
in O 
HeLa O 
and O 
A549 O 
cells O 
and O 
60% O 
of O 
invasion O 
of O 
MDA-MB-231 O 
cells O 
. O 
Importantly O 
, O 
the O 
majority O 
of O 
the O 
derivatives O 
exhibited O 
no O 
apparent O 
cytotoxicity O 
in O 
the O 
clonogenic O 
assays O 
. O 
The O 
low O 
to O 
negligible O 
inhibition O 
of O 
cell O 
proliferation O 
is O 
a O 
desirable O 
property O 
of O 
these O 
anti-migration O 
derivatives O 
because O 
they O 
hold O 
promise O 
of O 
low O 
toxicity O 
to O 
healthy O 
cells O 
as O 
potential O 
therapeutic O 
agents O 
. O 
Mechanistic O 
studies O 
analyzing O 
the O 
actin O 
cytoskeleton O 
by O 
microscopy O 
demonstrate O 
that O 
compound O 
5k O 
substantially O 
reduced O 
cellular O 
f-actin O 
, O 
and O 
prevented O 
localization O 
of O 
fascin O 
to O 
actin O 
- O 
rich O 
membrane O 
protrusions O 
. O 
These O 
results O 
suggest O 
that O 
the O 
anti-migration O 
activity O 
may O 
result O 
from O 
impaired O 
actin O 
structures O 
in O 
protrusions O 
that O 
are O 
necessary O 
to O 
drive O 
migration O 
. O 

Kidney O 
Injury O 
During O 
Vancomycin B-TRIVIAL 
Therapy O 
in O 
Critically O 
Ill O 
Children O 
. O 

OBJECTIVE O 
: O 
To O 
determine O 
the O 
rate O 
, O 
risk O 
factors O 
, O 
and O 
outcome O 
of O 
vancomycin B-TRIVIAL 
-associated O 
acute O 
kidney O 
injury O 
( O 
AKI O 
) O 
in O 
critically O 
ill O 
children O 
. O 
DESIGN O 
: O 
Retrospective O 
cohort O 
study O 
. O 
SETTING O 
: O 
Tertiary O 
care O 
children's O 
hospital O 
. O 
PATIENTS O 
: O 
We O 
reviewed O 
the O 
charts O 
of O 
children O 
admitted O 
to O 
the O 
pediatric O 
intensive O 
care O 
unit O 
during O 
a O 
2-year O 
period O 
who O 
were O 
treated O 
with O 
vancomycin B-TRIVIAL 
. O 
Courses O 
of O 
vancomycin B-TRIVIAL 
interrupted O 
by O 
3 O 
days O 
or O 
more O 
were O 
counted O 
separately O 
. O 
Patients O 
were O 
excluded O 
if O 
they O 
received O 
vancomycin B-TRIVIAL 
treatment O 
for O 
fewer O 
than O 
3 O 
days O 
, O 
had O 
preexisting O 
renal O 
failure O 
, O 
or O 
had O 
incomplete O 
serum O 
creatinine B-TRIVIAL 
( O 
Scr O 
) O 
data O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
Demographic O 
and O 
laboratory O 
data O 
; O 
vancomycin B-TRIVIAL 
dose O 
, O 
duration O 
, O 
and O 
concentrations O 
; O 
and O 
concurrent O 
use O 
of O 
nephrotoxic O 
drugs O 
were O 
recorded O 
. O 
Acute O 
kidney O 
injury O 
was O 
defined O 
as O 
a O 
decrease O 
in O 
estimated O 
glomerular O 
filtration O 
rate O 
of O 
50% O 
or O 
more O 
from O 
the O 
beginning O 
of O 
vancomycin B-TRIVIAL 
therapy O 
. O 
Descriptive O 
statistics O 
, O 
step O 
- O 
wise O 
logistic O 
regression O 
, O 
and O 
repeated O 
measures O 
ANOVA O 
were O 
used O 
to O 
analyze O 
the O 
data O 
. O 
A O 
total O 
of O 
284 O 
patients O 
were O 
included O 
, O 
for O 
a O 
total O 
of O 
391 O 
courses O 
of O 
vancomycin B-TRIVIAL 
( O 
272 O 
children O 
and O 
119 O 
infants O 
) O 
. O 
The O 
mean O 
duration O 
of O 
vancomycin B-TRIVIAL 
therapy O 
was O 
6.9 O 
± O 
4.5 O 
days O 
. O 
Forty O 
nine O 
( O 
17.2% O 
) O 
patients O 
developed O 
AKI O 
during O 
61 O 
( O 
15.6% O 
) O 
courses O 
. O 
Elevated O 
Scr O 
concentrations O 
returned O 
to O 
baseline O 
after O 
stopping O 
vancomycin B-TRIVIAL 
in O 
53 O 
( O 
87% O 
) O 
courses O 
. O 
Mortality O 
was O 
higher O 
in O 
children O 
who O 
developed O 
AKI O 
( O 
p O 
< O 
0.001 O 
; O 
Fisher's O 
exact O 
test O 
) O 
. O 
Administration O 
of O 
nephrotoxic O 
drugs O 
( O 
odds O 
ratio O 
2.23 O 
, O 
Confidence O 
Interval O 
1.27-3.93 O 
) O 
and O 
presence O 
of O 
high O 
blood O 
urea B-TRIVIAL 
nitrogen B-SYSTEMATIC 
( O 
BUN O 
) O 
: O 
Scr O 
ratio O 
before O 
vancomycin B-TRIVIAL 
therapy O 
( O 
p O 
< O 
0.05 O 
) O 
were O 
associated O 
with O 
AKI O 
. O 
The O 
BUN O 
and O 
Scr O 
concentrations O 
significantly O 
increased O 
during O 
vancomycin B-TRIVIAL 
therapy O 
and O 
decreased O 
after O 
vancomycin B-TRIVIAL 
was O 
discontinued O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
CONCLUSIONS O 
: O 
In O 
critically O 
ill O 
children O 
, O 
the O 
development O 
of O 
reversible O 
AKI O 
during O 
vancomycin B-TRIVIAL 
therapy O 
is O 
associated O 
with O 
administration O 
of O 
nephrotoxic O 
drugs O 
and O 
an O 
elevated O 
BUN O 
: O 
Scr O 
ratio O 
. O 

Mechanisms O 
of O 
Radical O 
SAM/ O 
Cobalamin B-FAMILY 
Methylations O 
: O 
An O 
Evolving O 
Working O 
Hypothesis O 
. O 

about O 
Me O 
: O 
Pierre O 
and O 
co O 
- O 
workers O 
have O 
revealed O 
mechanistic O 
details O 
of O 
a O 
tryptophan B-TRIVIAL 
methyltransferase O 
( O 
TsrM O 
) O 
involved O 
in O 
the O 
biosynthesis O 
of O 
the O 
thiopeptide O 
antibiotic O 
, O 
thiostrepton B-TRIVIAL 
. O 
Utilising O 
cobalamin B-FAMILY 
and O 
a O 
[ O 
4Fe-4S B-FORMULA 
] O 
cluster O 
to O 
generate O 
2-methyltryptophan B-SYSTEMATIC 
from O 
tryptophan B-TRIVIAL 
, O 
a O 
key O 
difference O 
between O 
this O 
enzyme O 
and O 
other O 
radical O 
SAM O 
methyltransferases O 
is O 
that O 
the O 
reaction O 
is O 
not O 
initiated O 
by O 
a O 
single O 
- O 
electron O 
reduction O 
of O 
SAM O 
to O 
generate O 
5'-dA⋅ O 
. O 

-Containing O 
Histone O 
Deacetylase O 
Inhibitors O 
: O 
Apoptosis O 
Induction O 
, O 
Cytodifferentiation O 
, O 
and O 
Antiproliferative O 
Activities O 
in O 
Cancer O 
Cells O 
. O 

we O 
report O 
novel O 
pyrrole B-SYSTEMATIC 
- O 
and O 
benzene B-SYSTEMATIC 
-based O 
hydroxamates B-FAMILY 
( O 
8 O 
, O 
10 O 
) O 
and O 
2'-aminoanilides B-FAMILY 
( O 
9 O 
, O 
11 O 
) O 
bearing O 
the O 
tert-butylcarbamate B-SYSTEMATIC 
group O 
at O 
the O 
CAP O 
moiety O 
as O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitors O 
. O 
Compounds O 
8 O 
b O 
and O 
10 O 
c O 
selectively O 
inhibited O 
HDAC6 O 
at O 
the O 
nanomolar O 
level O 
, O 
whereas O 
the O 
other O 
hydroxamates B-FAMILY 
effected O 
an O 
increase O 
in O 
acetyl-α-tubulin O 
levels O 
in O 
human O 
acute O 
myeloid O 
leukemia O 
U937 O 
cells O 
. O 
In O 
the O 
same O 
cell O 
line O 
, O 
compounds O 
8 O 
b O 
and O 
10 O 
c O 
elicited O 
18.4 O 
and O 
21.4 O 
% O 
apoptosis O 
, O 
respectively O 
( O 
SAHA B-ABBREVIATION 
: O 
16.9 O 
% O 
) O 
, O 
and O 
the O 
pyrrole B-SYSTEMATIC 
anilide I-SYSTEMATIC 
9 O 
c O 
displayed O 
the O 
highest O 
cytodifferentiating O 
effect O 
( O 
90.9 O 
% O 
) O 
. O 
In O 
tests O 
against O 
a O 
wide O 
range O 
of O 
various O 
cancer O 
cell O 
lines O 
to O 
determine O 
its O 
antiproliferative O 
effects O 
, O 
compound O 
10 O 
c O 
exhibited O 
growth O 
inhibition O 
from O 
sub O 
- O 
micromolar O 
( O 
neuroblastoma O 
LAN-5 O 
and O 
SH-SY5Y O 
cells O 
, O 
chronic O 
myeloid O 
leukemia O 
K562 O 
cells O 
) O 
to O 
low O 
- O 
micromolar O 
( O 
lung O 
H1299 O 
and O 
A549 O 
, O 
colon O 
HCT116 O 
and O 
HT29 O 
cancer O 
cells O 
) O 
concentrations O 
. O 
In O 
HT29 O 
cells O 
, O 
10 O 
c O 
increased O 
histone O 
H3 O 
acetylation O 
, O 
and O 
decreased O 
the O 
colony O 
- O 
forming O 
potential O 
of O 
the O 
cancer O 
cells O 
by O 
up O 
to O 
60 O 
% O 
. O 

Carbocyanine B-TRIVIAL 
Dye-Shelled O 
Microbubbles O 
as O 
Ultrasound-Modulated O 
Fluorescent O 
Contrast O 
Agents O 
. O 

the O 
effect O 
of O 
N B-FORMULA 
-substitution O 
in O 
nor-lobelane B-TRIVIAL 
on O 
the O 
interaction O 
with O 
VMAT2 O 
: O 
discovery O 
of O 
a O 
potential O 
clinical O 
candidate O 
for O 
treatment O 
of O 
methamphetamine B-TRIVIAL 
abuse O 
. O 

series O 
of O 
N B-FORMULA 
-substituted O 
lobelane B-TRIVIAL 
analogues O 
was O 
synthesized O 
and O 
evaluated O 
for O 
their O 
[(3)H]dihydrotetrabenazine B-SYSTEMATIC 
binding O 
affinity O 
at O 
the O 
vesicular O 
monoamine B-FAMILY 
transporter O 
and O 
for O 
their O 
inhibition O 
of O 
vesicular O 
[(3)H]dopamine B-SYSTEMATIC 
uptake O 
. O 
Compound O 
19a O 
, O 
which O 
contains O 
an O 
N-1,2(R)-dihydroxypropyl B-SYSTEMATIC 
group O 
, O 
had O 
been O 
identified O 
as O 
a O 
potential O 
clinical O 
candidate O 
for O 
the O 
treatment O 
of O 
methamphetamine B-TRIVIAL 
abuse O 
. O 

Supramolecular O 
Binding O 
Motifs O 
To O 
Provide O 
Precise O 
Control O 
over O 
the O 
Ratio O 
and O 
Distribution O 
of O 
Species O 
in O 
Multiple O 
Component O 
Films O 
Grafted O 
on O 
Surfaces O 
: O 
Demonstration O 
Using O 
Electrochemical O 
Assembly O 
from O 
Aryl B-FAMILY 
Diazonium I-FAMILY 
Salts O 
. O 

interactions O 
between O 
two O 
surface O 
modification O 
species O 
are O 
explored O 
to O 
control O 
the O 
ratio O 
and O 
distribution O 
of O 
these O 
species O 
on O 
the O 
resultant O 
surface O 
. O 
A O 
binary O 
mixture O 
of O 
aryl B-FAMILY 
diazonium I-FAMILY 
salts O 
bearing O 
oppositely O 
charged O 
para- O 
substituents O 
( O 
either O 
- O 
SO3(-) B-FORMULA 
or O 
- O 
N(+)(Me)3 B-FORMULA 
) O 
, O 
which O 
also O 
reduce O 
at O 
different O 
potentials O 
, O 
has O 
been O 
examined O 
on O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
surfaces O 
using O 
cyclic O 
voltammetry O 
and O 
X-ray O 
photoelectron O 
spectroscopy O 
( O 
XPS O 
) O 
. O 
Striking O 
features O 
were O 
observed O 
: O 
( O 
1 O 
) O 
the O 
two O 
aryl B-FAMILY 
diazonium I-FAMILY 
salts O 
in O 
the O 
mixed O 
solution O 
undergo O 
reductive O 
adsorption O 
at O 
the O 
same O 
potential O 
which O 
is O 
distinctively O 
less O 
negative O 
than O 
the O 
potential O 
required O 
for O 
the O 
reduction O 
of O 
either O 
of O 
the O 
two O 
aryl B-FAMILY 
diazonium I-FAMILY 
salts O 
alone O 
; O 
( O 
2 O 
) O 
the O 
surface O 
ratio O 
of O 
the O 
two O 
phenyl O 
derivatives O 
is O 
consistently O 
1 O 
: O 
1 O 
regardless O 
of O 
the O 
ratio O 
of O 
the O 
two O 
aryl B-FAMILY 
diazonium I-FAMILY 
salts O 
in O 
the O 
modification O 
solutions O 
. O 
Homogeneous O 
distribution O 
of O 
the O 
two O 
oppositely O 
charged O 
phenyl B-SYSTEMATIC 
species O 
on O 
the O 
modified O 
surface O 
has O 
also O 
been O 
suggested O 
by O 
XPS O 
survey O 
spectra O 
. O 
Diffusion O 
coefficient O 
measurements O 
by O 
DOSY O 
NMR O 
and O 
DFT O 
based O 
computation O 
have O 
indicated O 
the O 
association O 
of O 
the O 
two O 
aryl B-FAMILY 
diazonium I-FAMILY 
species O 
in O 
the O 
solution O 
, O 
which O 
has O 
led O 
to O 
changes O 
in O 
the O 
molecular O 
orbital O 
energies O 
of O 
the O 
two O 
species O 
. O 
This O 
study O 
highlights O 
the O 
potential O 
of O 
using O 
intermolecular O 
interactions O 
to O 
control O 
the O 
assembly O 
of O 
multicomponent O 
thin O 
layers O 
. O 

Dietary O 
Copper B-SYSTEMATIC 
Supplementation O 
Enhance O 
or O 
Diminish O 
PCB126 O 
Toxicity O 
in O 
the O 
Rodent O 
Liver O 
? O 

is O 
essential O 
for O 
the O 
function O 
of O 
the O 
mitochondrial O 
electron O 
transport O 
chain O 
and O 
several O 
antioxidant O 
proteins O 
. O 
However O 
, O 
in O 
its O 
free O 
form O 
copper B-SYSTEMATIC 
can O 
participate O 
in O 
Fenton O 
- O 
like O 
reactions O 
that O 
produce O 
reactive O 
hydroxyl B-SYSTEMATIC 
radicals O 
. O 
Aryl-hydrocarbon B-FAMILY 
receptor O 
( O 
AhR O 
) O 
agonists O 
, O 
including O 
the O 
most O 
potent O 
polychlorinated B-FAMILY 
biphenyl I-FAMILY 
( O 
PCB B-ABBREVIATION 
) O 
congener O 
, O 
3,3',4,4',5-pentachlorobiphenyl B-SYSTEMATIC 
( O 
PCB126 B-TRIVIAL 
) O 
, O 
increase O 
copper B-SYSTEMATIC 
levels O 
in O 
rodent O 
livers O 
. O 
This O 
is O 
accompanied O 
by O 
biochemical O 
and O 
toxic O 
changes O 
. O 
To O 
assess O 
the O 
involvement O 
of O 
copper O 
in O 
PCB B-ABBREVIATION 
toxicity O 
, O 
male O 
Sprague-Dawley O 
rats O 
were O 
fed O 
an O 
AIN-93G O 
diet O 
with O 
differing O 
dietary O 
copper B-SYSTEMATIC 
levels O 
: O 
low O 
( O 
2 O 
ppm O 
) O 
, O 
adequate O 
( O 
6 O 
ppm O 
) O 
, O 
and O 
high O 
( O 
10 O 
ppm O 
) O 
. O 
After O 
three O 
weeks O 
, O 
rats O 
from O 
each O 
group O 
were O 
given O 
a O 
single O 
ip O 
injection O 
of O 
corn O 
oil O 
( O 
control O 
) O 
, O 
1 O 
, O 
or O 
5 O 
μmol O 
/ O 
kg O 
body O 
weight O 
PCB126 B-TRIVIAL 
. O 
Two O 
weeks O 
following O 
injections O 
, O 
biochemical O 
and O 
morphological O 
markers O 
of O 
hepatic O 
toxicity O 
, O 
trace O 
metal O 
status O 
, O 
and O 
hepatic O 
gene O 
expression O 
of O 
metalloproteins O 
were O 
evaluated O 
. O 
Increasing O 
dietary O 
copper B-SYSTEMATIC 
was O 
associated O 
with O 
elevated O 
tissue O 
levels O 
of O 
copper B-SYSTEMATIC 
and O 
ceruloplasmin O 
. O 
In O 
the O 
livers O 
of O 
PCB126 B-TRIVIAL 
-treated O 
rats O 
, O 
the O 
hallmark O 
signs O 
of O 
AhR O 
activation O 
were O 
present O 
, O 
including O 
increased O 
cytochrome O 
P450 O 
and O 
lipid O 
levels O 
and O 
decreased O 
glutathione B-TRIVIAL 
. O 
In O 
addition O 
, O 
a O 
doubling O 
of O 
hepatic O 
copper B-SYSTEMATIC 
levels O 
was O 
seen O 
, O 
and O 
overall O 
metal O 
homeostasis O 
was O 
disturbed O 
, O 
resulting O 
in O 
decreased O 
hepatic O 
selenium B-SYSTEMATIC 
, O 
manganese B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
, O 
and O 
iron B-SYSTEMATIC 
. O 
Expression O 
of O 
key O 
metalloproteins O 
was O 
either O 
decreased O 
( O 
cytochrome O 
c O 
oxidase O 
) O 
, O 
unchanged O 
( O 
ceruloplasmin O 
and O 
CuZnSOD O 
) O 
, O 
or O 
increased O 
( O 
tyrosinase O 
and O 
metallothioneins O 
1 O 
and O 
2 O 
) O 
with O 
exposure O 
to O 
PCB126 B-TRIVIAL 
. O 
Increases O 
in O 
metallothionein O 
may O 
contribute O 
/ O 
reflect O 
the O 
increased O 
copper B-SYSTEMATIC 
seen O 
. O 
Alterations O 
in O 
dietary O 
copper B-SYSTEMATIC 
did O 
not O 
amplify O 
or O 
abrogate O 
the O 
hepatic O 
toxicity O 
of O 
PCB126 B-TRIVIAL 
. O 
PCB126 B-TRIVIAL 
toxicity O 
, O 
i.e O 
. O 
, O 
oxidative O 
stress O 
and O 
steatosis O 
, O 
is O 
clearly O 
associated O 
with O 
disturbed O 
metal O 
homeostasis O 
. O 
Understanding O 
the O 
mechanisms O 
of O 
this O 
disturbance O 
may O 
provide O 
tools O 
to O 
prevent O 
liver O 
toxicity O 
by O 
other O 
AhR O 
agonists O 
. O 

Cellulose O 
Polyampholyte-Gold O 
Nanoparticle O 
- O 
Based O 
Colorimetric O 
Competition O 
Assay O 
for O 
the O 
Detection O 
of O 
Cysteine B-TRIVIAL 
and O 
Mercury B-SYSTEMATIC 
(II) I-SYSTEMATIC 
. O 

provide O 
a O 
highly O 
sensitive O 
and O 
selective O 
assay O 
to O 
detect O 
cysteine B-TRIVIAL 
( O 
Cys B-FORMULA 
) O 
and O 
Hg(2+) B-FORMULA 
in O 
aqueous O 
solutions O 
using O 
Au B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
stabilized O 
by O 
carboxylethyl B-SYSTEMATIC 
quaternized O 
cellulose O 
( O 
CEQC O 
) O 
. O 
This O 
method O 
is O 
based O 
on O 
the O 
thiophilicity O 
of O 
Hg(2+) B-FORMULA 
and O 
Au B-FORMULA 
NPs O 
as O 
well O 
as O 
the O 
unique O 
optical O 
properties O 
of O 
CEQC-stabilized O 
Au B-FORMULA 
NPs O 
. O 
CEQC O 
chains O 
are O 
good O 
stabilizing O 
agents O 
for O 
Au B-FORMULA 
NPs O 
even O 
in O 
a O 
high O 
- O 
salt O 
solution O 
. O 
The O 
addition O 
of O 
Cys B-FORMULA 
results O 
in O 
the O 
aggregation O 
of O 
CEQC-stabilized O 
Au B-FORMULA 
NPs O 
, O 
which O 
induces O 
the O 
visible O 
color O 
change O 
and O 
obvious O 
redshift O 
in O 
UV-visible O 
absorption O 
spectra O 
. O 
On O 
the O 
other O 
hand O 
, O 
Hg(2+) B-FORMULA 
is O 
more O 
apt O 
to O 
interact O 
with O 
thiols B-FAMILY 
than O 
Au B-FORMULA 
NPs O 
; O 
thus O 
, O 
it O 
can O 
remove O 
the O 
Cys B-FORMULA 
and O 
trigger O 
Au B-FORMULA 
NP O 
aggregate O 
redispersion O 
again O 
. O 
By O 
taking O 
advantage O 
of O 
this O 
mechanism O 
, O 
a O 
novel O 
off O 
- O 
on O 
colorimetric O 
sensor O 
has O 
been O 
established O 
for O 
Cys B-FORMULA 
and O 
Hg(2+) B-FORMULA 
detection O 
. O 
This O 
new O 
assay O 
could O 
selectively O 
detect O 
Cys B-FORMULA 
and O 
Hg(2+) B-FORMULA 
with O 
the O 
detection O 
limits O 
as O 
low O 
as O 
20 O 
and O 
40 O 
nM O 
in O 
aqueous O 
solutions O 
, O 
respectively O 
. O 

- O 
spanning O 
lipid O 
bilayers O 
on O 
silicon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
membranes O 
that O 
seal O 
and O 
selectively O 
transport O 
ions O 
. O 

report O 
the O 
formation O 
of O 
POPC B-ABBREVIATION 
lipid O 
bilayers O 
that O 
span O 
130 O 
nm O 
pores O 
in O 
a O 
freestanding O 
silicon B-SYSTEMATIC 
nitride I-SYSTEMATIC 
film O 
supported O 
on O 
a O 
silicon B-SYSTEMATIC 
substrate O 
. O 
These O 
solvent-free O 
lipid O 
membranes O 
self O 
- O 
assemble O 
on O 
organosilane B-FAMILY 
-treated O 
Si3N4 B-FORMULA 
via O 
the O 
fusion O 
of O 
200 O 
nm O 
unilamellar O 
vesicles O 
. O 
Membrane O 
fluidity O 
is O 
verified O 
by O 
fluorescence O 
recovery O 
after O 
photobleaching O 
( O 
FRAP O 
) O 
, O 
and O 
membrane O 
resistance O 
in O 
excess O 
of O 
1 O 
GΩ O 
is O 
demonstrated O 
using O 
electrical O 
impedance O 
spectroscopy O 
( O 
EIS O 
) O 
. O 
An O 
array O 
of O 
40 O 
0 O 
membranes O 
maintained O 
high O 
impedance O 
over O 
72 O 
h O 
, O 
followed O 
by O 
rupture O 
of O 
most O 
of O 
the O 
membranes O 
by O 
82 O 
h O 
. O 
Membrane O 
incorporation O 
of O 
gramicidin O 
, O 
a O 
model O 
ion O 
channel O 
, O 
resulted O 
in O 
increased O 
membrane O 
conductance O 
. O 
This O 
membrane O 
conductance O 
was O 
diminished O 
when O 
the O 
gramicidin O 
channels O 
were O 
blocked O 
with O 
CaCl2 B-FORMULA 
, O 
indicating O 
that O 
the O 
change O 
in O 
membrane O 
conductance O 
results O 
from O 
gramicidin O 
- O 
mediated O 
ion O 
transport O 
. O 
These O 
very O 
stable O 
, O 
biologically O 
functional O 
pore O 
- O 
spanning O 
membranes O 
open O 
many O 
possibilities O 
for O 
silicon B-SYSTEMATIC 
-based O 
ion O 
- O 
channel O 
devices O 
for O 
applications O 
such O 
as O 
biosensors O 
and O 
high O 
- O 
throughput O 
drug O 
screening O 
. O 

- O 
talk O 
between O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
and O 
hypoxia O 
- O 
inducible O 
factor O 
in O 
the O 
regulation O 
of O 
gene O 
expression O 
. O 

inducible O 
factor O 
( O 
HIF O 
) O 
and O 
5'-AMP B-SYSTEMATIC 
-activated O 
protein O 
kinase O 
are O 
often O 
activated O 
under O 
similar O 
physiological O 
conditions O 
. O 
Constitutive O 
androstane B-TRIVIAL 
receptor O 
( O 
CAR O 
) O 
translocates O 
into O 
the O 
nucleus O 
in O 
accordance O 
with O 
5'-AMP B-SYSTEMATIC 
-activated O 
protein O 
kinase O 
and O 
thus O 
confers O 
transactivation O 
. O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
a O 
possible O 
link O 
between O 
CAR O 
and O 
HIFα O 
. O 
Phenobarbital B-TRIVIAL 
( O 
PB O 
) O 
, O 
a O 
typical O 
CAR O 
activator O 
, O 
increased O 
the O 
gene O 
expression O 
of O 
HIF-target O 
genes O 
in O 
the O 
livers O 
of O 
mice O 
, O 
including O 
erythropoietin O 
, O 
heme O 
oxygenase-1 O 
and O 
vascular O 
endothelial O 
growth O 
factor-a O 
. O 
PB O 
induced O 
an O 
accumulation O 
of O 
nuclear O 
HIF-1α O 
and O 
an O 
increase O 
in O 
the O 
HIF-responsive O 
element O 
- O 
mediated O 
transactivation O 
in O 
HepG2 O 
cells O 
. O 
Cobalt B-SYSTEMATIC 
chloride I-SYSTEMATIC 
, O 
a O 
typical O 
HIF O 
activator O 
, O 
induced O 
the O 
gene O 
expression O 
of O 
CAR-target O 
genes O 
, O 
including O 
cyp2b9 O 
and O 
cyp2b10 O 
, O 
an O 
accumulation O 
of O 
nuclear O 
CAR O 
and O 
an O 
increase O 
in O 
the O 
PB-responsive O 
enhancer O 
module O 
- O 
mediated O 
transactivation O 
in O 
the O 
mouse O 
liver O 
. O 
Immunoprecipitation O 
- O 
immunoblot O 
and O 
chromatin O 
immunoprecipitation O 
analyses O 
suggest O 
that O 
CAR O 
binds O 
to O 
the O 
PB-responsive O 
enhancer O 
module O 
with O 
HIF-1α O 
in O 
the O 
liver O 
of O 
untreated O 
mice O 
and O 
that O 
the O 
complex O 
dissociates O 
upon O 
PB O 
treatment O 
. O 
Taken O 
together O 
these O 
results O 
suggest O 
that O 
CAR O 
and O 
HIF-α O 
interact O 
and O 
reciprocally O 
modulate O 
the O 
functions O 
of O 
each O 
other O 
. O 

androgen B-FAMILY 
receptor O 
expression O 
may O 
contribute O 
to O 
spermatogenesis O 
failure O 
in O 
rats O 
exposed O 
to O 
low O 
concentration O 
of O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
. O 

investigate O 
the O 
effects O 
of O 
a O 
low O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
concentration O 
on O 
male O 
reproduction O 
, O 
adult O 
rats O 
were O 
administered O 
a O 
concentration O 
of O 
BPA B-ABBREVIATION 
that O 
was O 
less O 
than O 
the O 
no O 
observable O 
adverse O 
effect O 
level O 
( O 
0.0005-5mg O 
/ O 
kg O 
/ O 
bw O 
) O 
for O 
8 O 
weeks O 
. O 
General O 
toxicity O 
, O 
reproductive O 
hormones O 
, O 
and O 
spermatogenesis O 
were O 
then O 
determined O 
. O 
The O 
expression O 
of O 
genes O 
related O 
to O 
hormone O 
synthesis O 
and O 
spermatogenesis O 
was O 
also O 
analyzed O 
. O 
These O 
BPA B-ABBREVIATION 
concentrations O 
generated O 
no O 
general O 
toxicity O 
and O 
no O 
significant O 
changes O 
on O 
serum O 
hormones O 
. O 
However O 
, O 
the O 
testicular O 
testosterone B-TRIVIAL 
, O 
hormone O 
synthesis O 
- O 
related O 
genes O 
StAR O 
and O 
Cyp450scc O 
increased O 
, O 
whereas O 
3β-HSD O 
, O 
17β-HSD O 
, O 
and O 
Cyp450arom O 
decreased O 
. O 
Additionally O 
, O 
BPA B-ABBREVIATION 
significantly O 
decreased O 
the O 
epithelial O 
height O 
and O 
round O 
spermatids O 
in O 
seminiferous O 
tubules O 
, O 
sperm O 
count O 
, O 
androgen B-FAMILY 
receptor O 
expression O 
, O 
and O 
the O 
expression O 
of O 
the O 
spermatogenesis O 
- O 
related O 
genes O 
outer O 
dense O 
fiber O 
protein O 
1 O 
( O 
ODF1 O 
) O 
and O 
transition O 
protein O 
1 O 
. O 
Our O 
results O 
indicate O 
that O 
a O 
low O 
BPA B-ABBREVIATION 
concentration O 
can O 
induce O 
spermatogenesis O 
disorders O 
mainly O 
through O 
decreasing O 
androgen B-FAMILY 
receptor O 
expression O 
. O 
The O 
present O 
results O 
may O 
bring O 
attention O 
to O 
the O 
risk O 
of O 
environmental O 
BPA B-ABBREVIATION 
exposure O 
. O 

and O 
synthesis O 
of O 
2- B-FAMILY 
substituted I-FAMILY 
benzoxazoles I-FAMILY 
as O 
novel O 
PTP1B O 
inhibitors O 
. O 

series O 
of O 
benzoxazole B-SYSTEMATIC 
compounds O 
containing O 
oxamic B-TRIVIAL 
acid I-TRIVIAL 
were O 
synthesized O 
and O 
screened O 
for O 
the O 
PTP1B O 
inhibition O 
. O 
Compound O 
31d O 
showed O 
best O 
biochemical O 
potency O 
( O 
Ki O 
) O 
of O 
6.7μM O 
. O 
Structure O 
- O 
activity O 
relationship O 
were O 
explained O 
with O 
the O 
help O 
of O 
molecular O 
modeling O 
approach O 
. O 

action O 
of O 
quinolones B-FAMILY 
: O 
From O 
target O 
to O 
network O 
. O 

are O 
widely O 
used O 
broad O 
- O 
spectrum O 
antibacterials O 
with O 
incomplete O 
elucidated O 
mechanism O 
of O 
action O 
. O 
Here O 
, O 
molecular O 
basis O 
for O 
the O 
antibacterial O 
action O 
of O 
quinolones B-FAMILY 
, O 
from O 
target O 
to O 
network O 
, O 
is O 
fully O 
discussed O 
and O 
updated O 
. O 
Quinolones B-FAMILY 
trap O 
DNA O 
gyrase O 
or O 
topoisomerase O 
IV O 
to O 
form O 
reversible O 
drug O 
- O 
enzyme-DNA O 
cleavage O 
complexes O 
, O 
resulting O 
in O 
bacteriostasis O 
. O 
Cell O 
death O 
arises O 
from O 
chromosome O 
fragmentation O 
in O 
protein O 
synthesis O 
- O 
dependent O 
or O 
-independent O 
pathways O 
according O 
to O 
distinguished O 
quinolone B-FAMILY 
structures O 
. O 
In O 
the O 
former O 
pathway O 
, O 
irreversible O 
oxidative O 
DNA O 
damage O 
caused O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
kills O 
bacteria O 
eventually O 
. O 
Toxin O 
- O 
antitoxin O 
mazEF O 
is O 
triggered O 
as O 
an O 
additional O 
lethal O 
action O 
. O 
Bacteria O 
survive O 
and O 
develop O 
resistance O 
by O 
SOS O 
and O 
other O 
stress O 
responses O 
. O 
Enlarged O 
knowledges O 
of O 
quinolone B-FAMILY 
actions O 
and O 
bacterial O 
response O 
will O 
provide O 
new O 
targets O 
for O 
drug O 
design O 
and O 
approaches O 
to O 
prevent O 
bacterial O 
resistance O 
. O 

growth O 
factor O 
receptor O 
inhibitor O 
PKI-166 B-IDENTIFIER 
governs O 
cardiovascular O 
protection O 
without O 
beneficial O 
effects O 
on O 
the O 
kidney O 
in O 
hypertensive O 
5 O 
/ O 
6 O 
nephrectomised O 
rats O 
. O 

of O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
signaling O 
by O 
G O 
- O 
protein O 
- O 
coupled O 
receptors O 
has O 
been O 
implicated O 
in O 
several O 
cardiovascular O 
( O 
CV O 
) O 
conditions O 
, O 
including O 
hypertension O 
, O 
heart O 
failure O 
, O 
cardiac O 
and O 
vascular O 
hypertrophy O 
. O 
However O 
, O 
the O 
therapeutic O 
potential O 
of O 
EGFR O 
inhibition O 
in O 
these O 
conditions O 
is O 
currently O 
unknown O 
. O 
Main O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
cardiac O 
, O 
vascular O 
and O 
renal O 
effects O 
of O 
EGFR O 
inhibition O 
by O 
PKI-166 B-IDENTIFIER 
in O 
the O 
hypertensive O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
model O 
. O 
Rats O 
underwent O 
5 O 
/ O 
6 O 
nephrectomy O 
( O 
5 O 
/ O 
6Nx O 
) O 
and O 
were O 
treated O 
with O 
PKI-166 B-IDENTIFIER 
or O 
lisinopril B-TRIVIAL 
or O 
vehicle O 
from O 
week O 
6 O 
after O 
disease O 
induction O 
until O 
week O 
12 O 
. O 
Sham O 
animals O 
received O 
either O 
PKI-166 B-IDENTIFIER 
or O 
vehicle O 
. O 
Treatment O 
with O 
PKI-166 B-IDENTIFIER 
did O 
not O 
affect O 
the O 
development O 
of O 
the O 
characteristic O 
renal O 
features O 
in O 
5 O 
/ O 
6Nx O 
including O 
proteinuria O 
, O 
diminished O 
creatinine B-TRIVIAL 
clearance O 
and O 
increased O 
glomerulosclerosis O 
, O 
whereas O 
these O 
were O 
attenuated O 
by O 
lisinopril B-TRIVIAL 
. O 
Despite O 
absence O 
of O 
effects O 
on O 
progressive O 
renal O 
damage O 
, O 
PKI-166 B-IDENTIFIER 
attenuated O 
the O 
progression O 
of O 
hypertension O 
and O 
maintained O 
cardiac O 
function O 
( O 
LVEDP O 
) O 
to O 
a O 
similar O 
extent O 
as O 
lisinopril O 
. O 
Also O 
, O 
PKI-166 B-IDENTIFIER 
attenuated O 
the O 
increase O 
in O 
phosphorylated O 
EGFR O 
in O 
heart O 
as O 
induced O 
by O 
5 O 
/ O 
6Nx O 
. O 
Moreover O 
, O 
PKI-166 B-IDENTIFIER 
and O 
lisinopril B-TRIVIAL 
restored O 
the O 
impaired O 
contraction O 
of O 
isolated O 
thoracic O 
aortic O 
rings O 
to O 
phenylephrine B-TRIVIAL 
and O 
angiotensin O 
II O 
and O 
impaired O 
myogenic O 
constriction O 
of O 
small O 
mesenteric O 
arteries O 
in O 
5 O 
/ O 
6Nx O 
rats O 
. O 
Blockade O 
of O 
the O 
EGFR O 
displays O 
a O 
CV O 
benefit O 
independently O 
of O 
limiting O 
the O 
progression O 
of O 
renal O 
injury O 
. O 
Our O 
findings O 
extend O 
the O 
evidence O 
on O 
EGFR O 
signaling O 
as O 
a O 
target O 
in O 
CV O 
disorders O 
. O 

sensitive O 
, O 
rapid O 
, O 
and O 
cost O 
- O 
effective O 
methods O 
for O 
detection O 
of O 
biomolecules O 
is O 
important O 
for O 
both O 
clinical O 
and O 
numerous O 
non-clinical O 
applications O 
. O 
During O 
the O 
last O 
two O 
decades O 
, O 
functional O 
nanomaterials O 
with O 
unique O 
physical O 
and O 
chemical O 
properties O 
have O 
provided O 
significant O 
advantages O 
for O 
biological O 
detection O 
. O 
In O 
this O 
feature O 
article O 
, O 
we O 
introduce O 
recent O 
progress O 
in O 
nanobiosensor O 
development O 
by O 
exploiting O 
the O 
optical O 
, O 
electrical O 
and O 
catalytic O 
properties O 
of O 
a O 
range O 
of O 
nanomaterials O 
, O 
with O 
a O 
focus O 
on O 
gold O 
nanoparticles O 
, O 
carbon B-SYSTEMATIC 
nanotubes O 
, O 
graphene B-TRIVIAL 
and O 
carbon B-SYSTEMATIC 
dots O 
. O 
In O 
addition O 
, O 
the O 
perspectives O 
on O 
future O 
opportunities O 
and O 
unsolved O 
challenges O 
are O 
also O 
discussed O 
. O 

effects O 
of O 
hyperprolactinemia O 
on O 
metabolic O 
parameters O 
are O 
not O 
clear O 
and O 
a O 
few O 
data O 
evaluating O 
adiponectin O 
levels O 
in O 
prolactinoma O 
and O 
idiopathic O 
hyperprolactinemia O 
exist O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
effects O 
of O 
hyperprolactinemia O 
on O 
body O 
weight O 
, O 
insulin O 
resistance O 
, O 
beta O 
cell O 
function O 
, O 
and O 
leptin O 
and O 
adiponectin O 
levels O 
in O 
premenopausal O 
women O 
with O 
hyperprolactinemia O 
. O 
Forty O 
premenopausal O 
women O 
with O 
prolactinoma O 
or O 
idiopathic O 
hyperprolactinemia O 
were O 
compared O 
to O 
41 O 
age O 
- O 
matched O 
healthy O 
premenopausal O 
women O 
with O 
regard O 
to O 
body O 
weight O 
, O 
body O 
mass O 
index O 
, O 
waist O 
and O 
hip O 
circumferences O 
, O 
waist O 
to O 
hip O 
ratio O 
, O 
fasting O 
plasma O 
glucose B-TRIVIAL 
, O 
insulin O 
levels O 
, O 
insulin O 
resistance O 
measured O 
by O 
homeostasis O 
model O 
assessment O 
(HOMA)-insulin O 
resistance O 
index O 
, O 
beta O 
cell O 
function O 
measured O 
by O 
HOMA-β O 
index O 
, O 
leptin O 
and O 
adiponectin O 
levels O 
. O 
Plasma O 
insulin O 
levels O 
and O 
HOMA O 
indexes O 
( O 
both O 
insulin O 
resistance O 
and O 
beta O 
indexes O 
) O 
were O 
significantly O 
higher O 
in O 
hyperprolactinemic O 
women O 
. O 
The O 
other O 
parameters O 
were O 
similar O 
between O 
both O 
groups O 
. O 
There O 
was O 
a O 
positive O 
correlation O 
between O 
prolactin O 
levels O 
and O 
fasting O 
plasma O 
glucose B-TRIVIAL 
in O 
hyperprolactinemic O 
women O 
. O 
The O 
results O 
of O 
this O 
study O 
showed O 
that O 
high O 
prolactin O 
levels O 
may O 
be O 
associated O 
with O 
hyperinsulinemia O 
and O 
insulin O 
resistance O 
in O 
premenopausal O 
women O 
. O 
This O 
effect O 
seems O 
to O 
be O 
independent O 
of O 
body O 
weight O 
, O 
leptin O 
and O 
adiponectin O 
levels O 
. O 
High O 
prolactin O 
levels O 
may O 
directly O 
stimulate O 
insulin O 
secretion O 
from O 
pancreas O 
and O 
directly O 
cause O 
hepatic O 
and O 
whole O 
- O 
body O 
insulin O 
resistance O 
. O 

strategy O 
allowing O 
both O 
stereocontrol O 
and O 
control O 
over O 
structural O 
isomer O 
formation O 
has O 
been O 
defined O 
for O 
the O 
antimalarial O 
flindersial O 
alkaloids O 
. O 
The O 
recently O 
reported O 
flinderoles B-FAMILY 
were O 
demonstrated O 
to O 
be O 
derived O 
from O 
the O 
natural O 
product O 
borrerine B-TRIVIAL 
. O 
The O 
structural O 
isomers O 
of O 
flinderoles B-FAMILY 
, O 
the O 
borreverines B-FAMILY 
, O 
were O 
also O 
produced O 
in O 
vitro O 
along O 
with O 
the O 
flinderoles B-FAMILY 
through O 
the O 
dimerization O 
of O 
borrerine B-TRIVIAL 
in O 
acidic O 
conditions O 
. O 
This O 
result O 
is O 
thought O 
to O 
replicate O 
the O 
biosynthesis O 
of O 
these O 
compounds O 
. O 
Flinderoles B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
, O 
desmethylflinderole O 
C O 
, O 
isoborreverine B-TRIVIAL 
, O 
and O 
dimethylisoborreverine B-TRIVIAL 
can O 
each O 
be O 
synthesized O 
in O 
three O 
steps O 
from O 
tryptamine B-TRIVIAL 
. O 
Furthermore O 
, O 
progress O 
toward O 
a O 
concise O 
enantioselective O 
synthesis O 
of O 
flinderoles B-MULTIPLE 
A I-MULTIPLE 
, I-MULTIPLE 
B I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
C I-MULTIPLE 
is O 
described O 
. O 
This O 
work O 
includes O 
enantioselective O 
conjugate O 
addition O 
to O 
an O 
unprotected O 
indole B-SYSTEMATIC 
-appended O 
enone B-SYSTEMATIC 
. O 
Chirality O 
0 O 
: O 
000-000 O 
, O 
2013 O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

Hybrid O 
Materials O 
From O 
Poly(3-Hydroxybutyrate) B-SYSTEMATIC 
, O 
TiO2 B-FORMULA 
Nanoparticles O 
, O 
and O 
Chitosan O 
Oligomers O 
by O 
Combining O 
Electrospinning O 
/ O 
Electrospraying O 
and O 
Impregnation O 
. O 

types O 
of O 
fibrous O 
material O 
containing O 
poly(3-hydroxybutyrate) B-SYSTEMATIC 
( O 
PHB B-ABBREVIATION 
) O 
, O 
nanosized O 
TiO2 B-FORMULA 
-anatase O 
( O 
nano O 
TiO2 B-FORMULA 
) O 
, O 
and O 
chitosan O 
oligomers O 
are O 
prepared O 
by O 
combining O 
the O 
electrospinning O 
, O 
electrospraying O 
, O 
and O 
impregnation O 
techniques O 
. O 
Simultaneous O 
electrospinning O 
/ O 
electrospraying O 
provides O 
uniform O 
distribution O 
of O 
electrosprayed O 
nano O 
TiO2 B-FORMULA 
along O 
the O 
PHB B-ABBREVIATION 
fibers O 
and O 
throughout O 
the O 
mat O 
. O 
Hybrid O 
materials O 
of O 
different O 
design O 
manifest O 
excellent O 
photocatalytic O 
activity O 
, O 
even O 
after O 
repeated O 
use O 
. O 
They O 
exhibit O 
high O 
bactericidal O 
activity O 
against O 
Escherichia O 
coli O 
. O 
In O 
addition O 
, O 
the O 
fibrous O 
scaffolds O 
are O 
compatible O 
with O 
human O 
mesenchymal O 
stem O 
cells O 
and O 
provide O 
a O 
favorable O 
environment O 
for O 
their O 
development O 
. O 

hybrid O 
extracellular O 
matrix O 
is O 
one O 
of O 
the O 
main O 
challenges O 
for O 
bone O 
tissue O 
engineering O 
( O 
BTE O 
) O 
. O 
Biocompatible O 
polycaprolactone B-SYSTEMATIC 
/ O 
poly(α,β)-DL-aspartic B-SYSTEMATIC 
acid I-SYSTEMATIC 
/ O 
collagen O 
nanofibrous O 
scaffolds O 
were O 
fabricated O 
by O 
electrospinning O 
and O 
nanohydroxyapatite O 
( O 
n-HA O 
) O 
was O 
deposited O 
by O 
calcium O 
phosphate O 
dipping O 
method O 
for O 
BTE O 
. O 
Human O 
mesenchymal O 
stem O 
cells O 
( O 
hMSCs O 
) O 
were O 
cultured O 
on O 
these O 
hybrid O 
scaffolds O 
to O 
investigate O 
the O 
cell O 
proliferation O 
, O 
osteogenic O 
differentiation O 
by O 
alkaline O 
phosphatase O 
activity O 
, O 
mineralization O 
, O 
double O 
immunofluorescent O 
staining O 
using O 
CD90 O 
and O 
expression O 
of O 
osteocalcin O 
. O 
The O 
present O 
study O 
indicated O 
that O 
the O 
PCL B-ABBREVIATION 
/ O 
PAA B-ABBREVIATION 
/ O 
collagen O 
/ O 
n-HA O 
scaffolds O 
promoted O 
greater O 
osteogenic O 
differentiation O 
of O 
hMSCs O 
, O 
proving O 
to O 
be O 
a O 
potential O 
hybrid O 
scaffolds O 
for O 
BTE O 
. O 

examined O 
if O 
chronic O 
cannabis O 
smoking O 
is O 
associated O 
with O 
hepatic O 
steatosis O 
, O 
insulin O 
resistance O 
, O 
reduced O 
β-cell O 
function O 
, O 
or O 
dyslipidemia O 
in O 
healthy O 
individuals.RESEARCH O 
DESIGN O 
AND O 
METHODSIn O 
a O 
cross O 
- O 
sectional O 
, O 
case O 
- O 
control O 
study O 
, O 
we O 
studied O 
cannabis O 
smokers O 
( O 
n O 
= O 
30 O 
; O 
women O 
, O 
12 O 
; O 
men O 
, O 
18 O 
; O 
27 O 
± O 
8 O 
years O 
) O 
and O 
control O 
subjects O 
( O 
n O 
= O 
30 O 
) O 
matched O 
for O 
age O 
, O 
sex O 
, O 
ethnicity O 
, O 
and O 
BMI O 
( O 
27 O 
± O 
6 O 
) O 
. O 
Abdominal O 
fat O 
depots O 
and O 
intrahepatic O 
fat O 
content O 
were O 
quantified O 
by O 
magnetic O 
resonance O 
imaging O 
and O 
proton O 
magnetic O 
resonance O 
spectroscopy O 
, O 
respectively O 
. O 
Insulin O 
- O 
sensitivity O 
indices O 
and O 
various O 
aspects O 
of O 
β-cell O 
function O 
were O 
derived O 
from O 
oral O 
glucose B-TRIVIAL 
tolerance O 
tests O 
(OGTT).RESULTSSelf O 
- O 
reported O 
cannabis O 
use O 
was O 
: O 
9.5 O 
( O 
2-38 O 
) O 
years O 
; O 
joints O 
/ O 
day O 
: O 
6 O 
( O 
3-30 O 
) O 
[ O 
median O 
( O 
range O 
) O 
] O 
. O 
Carbohydrate B-FAMILY 
intake O 
and O 
percent O 
calories O 
from O 
carbohydrates B-FAMILY 
, O 
but O 
not O 
total O 
energy O 
intake O 
, O 
were O 
significantly O 
higher O 
in O 
cannabis O 
smokers O 
. O 
There O 
were O 
no O 
group O 
differences O 
in O 
percent O 
total O 
body O 
fat O 
, O 
or O 
hepatic O 
fat O 
, O 
but O 
cannabis O 
smokers O 
had O 
a O 
higher O 
percent O 
abdominal O 
visceral O 
fat O 
( O 
18 O 
± O 
9 O 
vs O 
. O 
12 O 
± O 
5% O 
; O 
P O 
= O 
0.004 O 
) O 
. O 
Cannabis O 
smokers O 
had O 
lower O 
plasma O 
HDL O 
cholesterol B-TRIVIAL 
( O 
49 O 
± O 
14 O 
vs O 
. O 
55 O 
± O 
13 O 
mg O 
/ O 
dL O 
; O 
P O 
= O 
0.02 O 
) O 
, O 
but O 
fasting O 
levels O 
of O 
glucose B-TRIVIAL 
, O 
insulin O 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
LDL O 
cholesterol B-TRIVIAL 
, O 
triglycerides B-FAMILY 
, O 
or O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
FFA O 
) O 
were O 
not O 
different O 
. O 
Adipocyte O 
insulin O 
resistance O 
index O 
and O 
percent O 
FFA O 
suppression O 
during O 
an O 
OGTT O 
was O 
lower O 
( O 
P O 
< O 
0.05 O 
) O 
in O 
cannabis O 
smokers O 
. O 
However O 
, O 
oral O 
glucose B-TRIVIAL 
insulin O 
sensitivity O 
index O 
, O 
measures O 
of O 
β-cell O 
function O 
, O 
or O 
incretin O 
concentrations O 
did O 
not O 
differ O 
between O 
the O 
groups.CONCLUSIONSChronic O 
cannabis O 
smoking O 
was O 
associated O 
with O 
visceral O 
adiposity O 
and O 
adipose O 
tissue O 
insulin O 
resistance O 
but O 
not O 
with O 
hepatic O 
steatosis O 
, O 
insulin O 
insensitivity O 
, O 
impaired O 
pancreatic O 
β-cell O 
function O 
, O 
or O 
glucose B-TRIVIAL 
intolerance O 
. O 

Dyes O 
as O 
Differential O 
Modulators O 
of O 
Organic O 
Anion O 
Transport O 
by O 
MRP1 O 
, O 
MRP2 O 
and O 
MRP4 O 
. O 

resistance O 
proteins O 
( O 
MRPs O 
) O 
mediate O 
the O 
ATP B-ABBREVIATION 
-dependent O 
efflux O 
of O 
structurally O 
diverse O 
compounds O 
, O 
including O 
anticancer O 
drugs O 
and O 
physiological O 
organic O 
anions O 
. O 
Five O 
classes O 
of O 
chalcogenopyrylium B-FAMILY 
dyes O 
( O 
CGPs B-ABBREVIATION 
) O 
were O 
examined O 
for O 
their O 
ability O 
to O 
modulate O 
transport O 
of O 
[(3)H]estradiol B-SYSTEMATIC 
glucuronide I-SYSTEMATIC 
( O 
E217βG B-SYSTEMATIC 
) O 
( O 
a O 
prototypical O 
MRP O 
substrate O 
) O 
into O 
MRP O 
- O 
enriched O 
inside-out O 
membrane O 
vesicles O 
. O 
Additionally O 
, O 
some O 
CGPs B-ABBREVIATION 
were O 
tested O 
in O 
intact O 
transfected O 
cells O 
using O 
a O 
calcein B-TRIVIAL 
efflux O 
assay O 
. O 
Sixteen O 
of O 
34 O 
CGPs B-ABBREVIATION 
inhibited O 
MRP1 O 
- O 
mediated O 
E217βG B-SYSTEMATIC 
uptake O 
by O 
> O 
50% O 
( O 
IC50's O 
0.7-7.6 O 
μM O 
) O 
. O 
Of O 
9 O 
CGPs B-ABBREVIATION 
with O 
IC50's O 
≤ O 
2 O 
μM O 
, O 
two O 
belonged O 
to O 
Class O 
I O 
, O 
two O 
to O 
Class O 
III O 
and O 
five O 
to O 
Class O 
V O 
. O 
When O 
tested O 
in O 
the O 
intact O 
cells O 
, O 
only O 
4 O 
of O 
16 O 
CGPs B-ABBREVIATION 
( O 
at O 
10 O 
μM O 
) O 
inhibited O 
MRP1 O 
- O 
mediated O 
calcein B-TRIVIAL 
efflux O 
by O 
> O 
50% O 
( O 
III-1 O 
, O 
V-3 O 
, O 
-4 O 
, O 
-6 O 
) O 
while O 
a O 
fifth O 
( O 
I-5 O 
) O 
inhibited O 
efflux O 
by O 
just O 
23% O 
. O 
These O 
five O 
CGPs B-ABBREVIATION 
also O 
inhibited O 
[(3)H]E217βG B-SYSTEMATIC 
uptake O 
by O 
MRP4 O 
. O 
In O 
contrast O 
, O 
their O 
effects O 
on O 
MRP2 O 
varied O 
with O 
two O 
( O 
V-4 O 
, O 
V-6 O 
) O 
inhibiting O 
E217βG B-SYSTEMATIC 
transport O 
( O 
IC50's O 
2 O 
, O 
9.2 O 
μM O 
) O 
, O 
two O 
( O 
V-3 O 
, O 
III-1 O 
) O 
stimulating O 
transport O 
( O 
> O 
2-fold O 
) O 
, O 
while O 
CGP B-ABBREVIATION 
I-5 O 
had O 
no O 
effect O 
. O 
Strikingly O 
, O 
although O 
V-3 O 
and O 
V-4 O 
had O 
opposite O 
effects O 
on O 
MRP2 O 
activity O 
, O 
they O 
are O 
structurally O 
identical O 
except O 
for O 
their O 
chalcogen B-FAMILY 
atom O 
( O 
Se B-FORMULA 
versus O 
Te B-FORMULA 
) O 
. O 
This O 
study O 
is O 
the O 
first O 
to O 
identify O 
Class O 
V O 
CGPs O 
with O 
their O 
distinctive O 
methine B-SYSTEMATIC 
or O 
trimethine B-SYSTEMATIC 
linkage O 
between O 
two O 
disubstituted O 
pyrylium B-FAMILY 
moieties O 
as O 
a O 
particularly O 
potent O 
class O 
of O 
MRP O 
modulators O 
and O 
also O 
show O 
that O 
within O 
this O 
core O 
structure O 
, O 
differences O 
in O 
the O 
electronegativity O 
associated O 
with O 
a O 
chalcogen B-FAMILY 
atom O 
can O 
be O 
the O 
sole O 
determinant O 
of O 
whether O 
a O 
compound O 
will O 
stimulate O 
or O 
inhibit O 
MRP2 O 
. O 

Kinetics O 
in O 
Zebra O 
Finches O 
in O 
vivo O 
and O 
in O 
vitro O 
. O 

enhances O 
cognitive O 
performance O 
, O 
and O 
in O 
the O 
zebra O 
finch O 
( O 
Taeniopygia O 
guttata O 
) O 
, O 
which O 
is O 
a O 
well O 
- O 
established O 
model O 
of O 
cognition O 
, O 
the O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
song O 
production O 
has O 
been O 
reported O 
. O 
Nicotine B-TRIVIAL 
and O 
cotinine B-TRIVIAL 
plasma O 
levels O 
were O 
assessed O 
in O 
vivo O 
after O 
s.c O 
. O 
injection O 
of O 
0.18 O 
mg O 
/ O 
kg O 
nicotine B-TRIVIAL 
, O 
a O 
dose O 
that O 
elicits O 
changes O 
in O 
song O 
production O 
. O 
The O 
half O 
- O 
life O 
of O 
nicotine B-TRIVIAL 
elimination O 
was O 
33 O 
min O 
, O 
and O 
levels O 
were O 
undetectable O 
by O 
4h O 
. O 
Average O 
plasma O 
nicotine B-TRIVIAL 
over O 
2 O 
hours O 
was O 
32 O 
ng O 
/ O 
ml O 
, O 
similar O 
to O 
levels O 
seen O 
in O 
human O 
smokers O 
and O 
rat O 
models O 
of O 
nicotine B-TRIVIAL 
behavior O 
. O 
Nicotine B-TRIVIAL 
brain O 
levels O 
were O 
30 O 
and O 
14 O 
ng O 
/ O 
g O 
at O 
1 O 
and O 
2 O 
h O 
after O 
treatment O 
. O 
To O 
understand O 
the O 
potential O 
for O 
drug O 
interactions O 
and O 
regulation O 
of O 
nicotine B-TRIVIAL 
metabolism O 
in O 
zebra O 
finches O 
, O 
we O 
characterized O 
in O 
vitro O 
nicotine B-TRIVIAL 
metabolism O 
and O 
the O 
hepatic O 
enzyme O 
involved O 
. O 
In O 
humans O 
, O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
2A6 O 
metabolizes O 
nicotine B-TRIVIAL 
to O 
cotinine B-TRIVIAL 
, O 
and O 
CYP2A O 
- O 
like O 
activity O 
and O 
protein O 
have O 
been O 
reported O 
in O 
some O 
birds O 
. O 
Zebra O 
finch O 
liver O 
microsomes O 
metabolized O 
nicotine B-TRIVIAL 
and O 
bupropion B-TRIVIAL 
( O 
CYP2B O 
substrate O 
) O 
but O 
not O 
coumarin B-TRIVIAL 
( O 
CYP2A O 
substrate O 
) O 
. O 
Nicotine B-TRIVIAL 
was O 
metabolized O 
to O 
cotinine B-TRIVIAL 
with O 
a O 
Km O 
of O 
96 O 
μM O 
and O 
Vmax O 
of O 
56 O 
pmol O 
/ O 
min O 
/ O 
mg O 
. O 
Nicotine B-TRIVIAL 
and O 
bupropion B-TRIVIAL 
metabolism O 
were O 
inhibited O 
by O 
C-8-xanthate B-TRIVIAL 
( O 
specific O 
CYP2B O 
inhibitor O 
) O 
but O 
not O 
CYP2A-specific O 
inhibitors O 
, O 
and O 
hepatic O 
levels O 
of O 
CYP2B O 
- O 
like O 
but O 
not O 
CYP2A O 
- O 
like O 
proteins O 
correlated O 
with O 
nicotine B-TRIVIAL 
( O 
r O 
= O 
0.52 O 
, O 
p O 
= O 
0.04 O 
) O 
and O 
bupropion B-TRIVIAL 
metabolism O 
( O 
r O 
= O 
0.81 O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
suggesting O 
CYP2B-mediation O 
of O 
nicotine B-TRIVIAL 
metabolism O 
as O 
seen O 
in O 
rats O 
. O 
These O 
results O 
will O 
facilitate O 
further O 
investigation O 
of O 
nicotine B-TRIVIAL 
' O 
s O 
effects O 
in O 
zebra O 
finches O 
. O 

- O 
and O 
Lidocaine B-TRIVIAL 
-induced O 
Methemoglobinemia O 
is O 
Caused O 
by O 
Human O 
Carboxylesterase- O 
, O 
CYP2E1- O 
and O 
CYP3A4 O 
- O 
mediated O 
Metabolic O 
Activation O 
. O 

and O 
lidocaine B-TRIVIAL 
are O 
classified O 
as O 
amide B-FAMILY 
-type O 
local O 
anesthetics O 
whose O 
serious O 
adverse O 
effects O 
include O 
methemoglobinemia O 
. O 
Although O 
the O 
hydrolyzed O 
metabolites O 
of O 
prilocaine B-TRIVIAL 
( O 
o-toluidine B-SYSTEMATIC 
) O 
and O 
lidocaine B-TRIVIAL 
( O 
2,6-xylidine B-SYSTEMATIC 
) O 
have O 
been O 
suspected O 
to O 
induce O 
methemoglobinemia O 
, O 
the O 
metabolic O 
enzymes O 
that O 
are O 
involved O 
remain O 
uncharacterized O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
aimed O 
to O 
identify O 
the O 
human O 
enzymes O 
that O 
are O 
responsible O 
for O 
prilocaine B-TRIVIAL 
- O 
and O 
lidocaine B-TRIVIAL 
-induced O 
methemoglobinemia O 
. O 
Our O 
experiments O 
revealed O 
that O 
prilocaine B-TRIVIAL 
was O 
hydrolyzed O 
by O 
recombinant O 
human O 
carboxylesterase O 
( O 
CES O 
) O 
1A O 
and O 
CES2 O 
, O 
whereas O 
lidocaine B-TRIVIAL 
was O 
hydrolyzed O 
only O 
by O 
human O 
CES1A O 
. O 
When O 
the O 
parent O 
compounds O 
( O 
prilocaine B-TRIVIAL 
and O 
lidocaine B-TRIVIAL 
) O 
were O 
incubated O 
with O 
HLM O 
, O 
Met-Hb O 
formation O 
was O 
lower O 
than O 
when O 
the O 
hydrolyzed O 
metabolites O 
were O 
incubated O 
with O 
HLM O 
. O 
In O 
addition O 
, O 
Met-Hb O 
formation O 
when O 
prilocaine B-TRIVIAL 
and O 
o-toluidine B-SYSTEMATIC 
were O 
incubated O 
with O 
HLM O 
was O 
higher O 
than O 
that O 
when O 
lidocaine B-TRIVIAL 
and O 
2,6-xylidine B-SYSTEMATIC 
were O 
incubated O 
with O 
HLM O 
. O 
Incubation O 
with O 
diisopropyl B-SYSTEMATIC 
fluorophosphate I-SYSTEMATIC 
and O 
bis-(4-nitrophenyl) B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
, O 
which O 
are O 
general O 
inhibitors O 
of O 
CES O 
, O 
significantly O 
decreased O 
Met-Hb O 
formation O 
when O 
prilocaine B-TRIVIAL 
and O 
lidocaine B-TRIVIAL 
were O 
incubated O 
with O 
HLM O 
. O 
An O 
anti-CYP3A4 O 
antibody O 
further O 
decreased O 
the O 
residual O 
formation O 
of O 
Met-Hb O 
. O 
Met-Hb O 
formation O 
following O 
the O 
incubation O 
of O 
o-toluidine B-SYSTEMATIC 
and O 
2,6-xylidine B-SYSTEMATIC 
with O 
HLM O 
was O 
only O 
markedly O 
decreased O 
by O 
incubation O 
with O 
an O 
anti-CYP2E1 O 
antibody O 
. O 
o-Toluidine B-SYSTEMATIC 
and O 
2,6-xylidine B-SYSTEMATIC 
were O 
further O 
metabolized O 
by O 
CYP2E1 O 
to O 
4- B-MULTIPLE 
and I-MULTIPLE 
6-hydroxy-o-toluidine I-MULTIPLE 
and O 
4-hydroxy-2,6-xylidine B-SYSTEMATIC 
, O 
respectively O 
, O 
and O 
these O 
metabolites O 
were O 
shown O 
to O 
more O 
efficiently O 
induce O 
Met-Hb O 
formation O 
than O 
the O 
parent O 
compounds O 
. O 
Collectively O 
, O 
we O 
found O 
that O 
the O 
metabolites O 
produced O 
by O 
human O 
CES- O 
, O 
CYP2E1- O 
and O 
CYP3A4 O 
- O 
mediated O 
metabolism O 
were O 
involved O 
in O 
prilocaine B-TRIVIAL 
- O 
and O 
lidocaine B-TRIVIAL 
-induced O 
methemoglobinemia O 
. O 

evidence O 
demonstrates O 
that O 
extracellular O 
matrices O 
( O 
ECMs O 
) O 
regulate O 
many O 
aspects O 
of O 
megakaryocyte O 
( O 
MK O 
) O 
development O 
; O 
however O 
, O 
among O 
the O 
different O 
ECM O 
receptors O 
, O 
integrin O 
alpha2beta1 O 
and O 
GPVI O 
are O 
the O 
only O 
collagen O 
receptors O 
studied O 
in O 
platelets O 
and O 
MKs O 
. O 
In O 
this O 
study O 
, O 
we O 
demonstrate O 
the O 
expression O 
of O 
the O 
novel O 
collagen O 
receptor O 
Discoidin O 
Domain O 
Receptor O 
1 O 
( O 
DDR1 O 
) O 
by O 
human O 
MKs O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
and O 
provide O 
evidence O 
of O 
DDR1 O 
involvement O 
in O 
the O 
regulation O 
of O 
MK O 
motility O 
on O 
type O 
I O 
collagen O 
through O 
a O 
mechanism O 
based O 
on O 
the O 
activity O 
of O 
SHP1 O 
phosphatase O 
and O 
Syk O 
tyrosine B-TRIVIAL 
kinase O 
. O 
Specifically O 
, O 
we O 
demonstrated O 
that O 
inhibition O 
of O 
DDR1 O 
binding O 
to O 
type O 
I O 
collagen O 
, O 
preserving O 
the O 
engagement O 
of O 
the O 
other O 
collagen O 
receptors O 
, O 
GPVI O 
, O 
alpha2beta1 O 
and O 
LAIR-1 O 
determines O 
a O 
decrease O 
in O 
MK O 
migration O 
due O 
to O 
the O 
reduction O 
in O 
SHP1 O 
phosphatase O 
activity O 
and O 
consequent O 
increase O 
in O 
the O 
phosphorylation O 
level O 
of O 
its O 
main O 
substrate O 
Syk O 
. O 
Consistently O 
, O 
inhibition O 
of O 
Syk O 
activity O 
restored O 
MK O 
migration O 
on O 
type O 
I O 
collagen O 
. O 
In O 
conclusion O 
, O 
we O 
report O 
the O 
expression O 
and O 
function O 
of O 
a O 
novel O 
collagen O 
receptor O 
on O 
human O 
MKs O 
and O 
we O 
point O 
out O 
that O 
increasing O 
level O 
of O 
complexity O 
is O 
necessary O 
to O 
better O 
understand O 
MK-collagen O 
interactions O 
in O 
the O 
bone O 
marrow O 
environment O 
. O 

Paramagnetic O 
Resonance O 
Spectroscopic O 
Study O 
of O 
Copper B-SYSTEMATIC 
Hopping O 
in O 
Doped O 
Bis(l-histidinato)cadmium B-SYSTEMATIC 
Dihydrate I-SYSTEMATIC 
. O 

paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spectroscopy O 
was O 
used O 
to O 
study O 
Cu B-FORMULA 
(II) I-FORMULA 
dynamic O 
behavior O 
in O 
a O 
doped O 
biological O 
model O 
crystal O 
, O 
bis(l-histidinato)cadmium B-SYSTEMATIC 
dihydrate I-SYSTEMATIC 
, O 
in O 
order O 
to O 
gain O 
better O 
insight O 
into O 
copper B-SYSTEMATIC 
site O 
stability O 
in O 
metalloproteins O 
. O 
Temperature O 
- O 
dependent O 
changes O 
in O 
the O 
low O 
temperature O 
X-band O 
EPR O 
spectra O 
became O 
visible O 
around O 
100 O 
K O 
and O 
continued O 
up O 
to O 
room O 
temperature O 
. O 
The O 
measured O 
298 O 
K O 
g-tensor O 
( O 
principal O 
values O 
: O 
2.17 O 
, O 
2.16 O 
, O 
2.07 O 
) O 
and O 
copper B-SYSTEMATIC 
hyperfine O 
coupling O 
tensor O 
( O 
principal O 
values O 
: O 
-260 O 
, O 
-190 O 
, O 
-37 O 
MHz O 
) O 
were O 
similar O 
to O 
the O 
average O 
of O 
the O 
77 O 
K O 
tensor O 
values O 
pertaining O 
to O 
two O 
neighboring O 
histidine B-TRIVIAL 
binding O 
sites O 
. O 
The O 
observed O 
temperature O 
dependence O 
was O 
interpreted O 
using O 
Anderson's O 
theory O 
of O 
motional O 
narrowing O 
, O 
where O 
the O 
magnetic O 
parameters O 
for O 
the O 
different O 
states O 
are O 
averaged O 
as O 
the O 
copper B-SYSTEMATIC 
rapidly O 
hops O 
between O 
sites O 
. O 
The O 
EPR O 
pattern O 
was O 
also O 
found O 
to O 
undergo O 
a O 
sharp O 
sigmoidal O 
- O 
shaped O 
, O 
temperature O 
- O 
dependent O 
conversion O 
between O 
two O 
species O 
with O 
a O 
critical O 
temperature O 
Tc O 
≈ O 
160 O 
K O 
. O 
The O 
species O 
below O 
Tc O 
hops O 
between O 
the O 
two O 
low O 
temperature O 
site O 
patterns O 
, O 
and O 
the O 
one O 
above O 
Tc O 
represents O 
an O 
average O 
of O 
the O 
molecular O 
spin O 
Hamiltonian O 
coupling O 
tensors O 
of O 
the O 
two O 
77 O 
K O 
sites O 
. O 
In O 
addition O 
, O 
the O 
low O 
and O 
high O 
temperature O 
species O 
hop O 
between O 
one O 
another O 
, O 
contributing O 
to O 
the O 
dynamic O 
averaging O 
. O 
Spectral O 
simulations O 
using O 
this O 
4-state O 
model O 
determined O 
a O 
hop O 
rate O 
between O 
the O 
two O 
low O 
temperature O 
sites O 
νh4 O 
= O 
4.5 O 
× O 
10(8) O 
s(-1) O 
and O 
between O 
the O 
low O 
and O 
high O 
temperature O 
states O 
νh2 O 
= O 
1.7 O 
× O 
10(8) O 
s(-1) O 
at O 
160 O 
K O 
. O 
An O 
Arrhenius O 
relationship O 
of O 
hop O 
rate O 
and O 
temperature O 
gave O 
energy O 
barriers O 
of O 
ΔE4 O 
= O 
389 O 
cm(-1) O 
and O 
ΔE2 O 
= O 
656 O 
cm(-1) O 
between O 
the O 
two O 
low O 
temperature O 
sites O 
and O 
between O 
the O 
low O 
and O 
high O 
temperature O 
states O 
, O 
respectively O 
. O 

Interfacial O 
Recombination O 
in O 
Colloidal O 
Quantum O 
Dot O 
Solar O 
Cells O 
by O 
Doping O 
the O 
Metal B-FAMILY 
Oxide I-FAMILY 
. O 

research O 
has O 
pushed O 
the O 
efficiency O 
of O 
colloidal O 
quantum O 
dot O 
solar O 
cells O 
toward O 
a O 
level O 
that O 
spurs O 
commercial O 
interest O 
. O 
Quantum O 
dot/ O 
metal B-FAMILY 
oxide I-FAMILY 
bilayers O 
form O 
the O 
most O 
efficient O 
colloidal O 
quantum O 
dot O 
solar O 
cells O 
, O 
and O 
most O 
studies O 
have O 
advanced O 
the O 
understanding O 
of O 
the O 
quantum O 
dot O 
component O 
. O 
We O 
study O 
the O 
interfacial O 
recombination O 
process O 
in O 
depleted O 
heterojunction O 
colloidal O 
quantum O 
dot O 
( O 
QD O 
) O 
solar O 
cells O 
formed O 
with O 
ZnO B-FORMULA 
as O 
the O 
oxide B-SYSTEMATIC 
by O 
varying O 
(i) O 
the O 
carrier O 
concentration O 
of O 
the O 
ZnO B-FORMULA 
layer O 
and O 
(ii) O 
the O 
density O 
of O 
intragap O 
recombination O 
sites O 
in O 
the O 
QD O 
layer O 
. O 
We O 
find O 
that O 
the O 
open O 
- O 
circuit O 
voltage O 
and O 
efficiency O 
of O 
PbS B-FORMULA 
QD/ O 
ZnO B-FORMULA 
devices O 
can O 
be O 
improved O 
by O 
50% O 
upon O 
doping O 
of O 
the O 
ZnO B-FORMULA 
with O 
nitrogen B-SYSTEMATIC 
to O 
reduce O 
its O 
carrier O 
concentration O 
. O 
In O 
contrast O 
, O 
doping O 
the O 
ZnO B-FORMULA 
did O 
not O 
change O 
the O 
performance O 
of O 
PbSe B-FORMULA 
QD/ O 
ZnO B-FORMULA 
solar O 
cells O 
. O 
We O 
use O 
X-ray O 
photoemission O 
spectroscopy O 
, O 
ultraviolet O 
photoemission O 
spectroscopy O 
, O 
transient O 
photovoltage O 
decay O 
measurements O 
, O 
transient O 
absorption O 
spectroscopy O 
, O 
and O 
intensity O 
- O 
dependent O 
photocurrent O 
measurements O 
to O 
investigate O 
the O 
origin O 
of O 
this O 
effect O 
. O 
We O 
find O 
a O 
significant O 
density O 
of O 
intragap O 
states O 
within O 
the O 
band O 
gap O 
of O 
the O 
PbS B-FORMULA 
quantum O 
dots O 
. O 
These O 
states O 
facilitate O 
recombination O 
at O 
the O 
PbS B-FORMULA 
/ O 
ZnO B-FORMULA 
interface O 
, O 
which O 
can O 
be O 
suppressed O 
by O 
reducing O 
the O 
density O 
of O 
occupied O 
states O 
in O 
the O 
ZnO B-FORMULA 
. O 
For O 
the O 
PbSe B-FORMULA 
QD/ O 
ZnO B-FORMULA 
solar O 
cells O 
, O 
where O 
fewer O 
intragap O 
states O 
are O 
observed O 
in O 
the O 
quantum O 
dots O 
, O 
the O 
interfacial O 
recombination O 
channel O 
does O 
not O 
limit O 
device O 
performance O 
. O 
Our O 
study O 
sheds O 
light O 
on O 
the O 
mechanisms O 
of O 
interfacial O 
recombination O 
in O 
colloidal O 
quantum O 
dot O 
solar O 
cells O 
and O 
emphasizes O 
the O 
influence O 
of O 
quantum O 
dot O 
intragap O 
states O 
and O 
metal B-FAMILY 
oxide I-FAMILY 
properties O 
on O 
this O 
loss O 
pathway O 
. O 

- O 
temperature O 
NMR O 
studies O 
on O 
the O 
geometry O 
of O 
base O 
pairs O 
involving O 
5- B-SYSTEMATIC 
substituted I-SYSTEMATIC 
uracil I-SYSTEMATIC 
derivatives O 
. O 

( O 
U O 
) O 
imino O 
proton O 
chemical O 
shifts O 
, O 
measured O 
in O 
the O 
slow O 
hydrogen B-SYSTEMATIC 
-bond O 
exchange O 
regime O 
at O 
low O 
temperatures O 
in O 
a O 
freonic O 
solution O 
, O 
show O 
that O 
electron O 
- O 
withdrawing O 
5-bromo B-SYSTEMATIC 
and O 
5-fluoro B-SYSTEMATIC 
substituents O 
on O 
the O 
uracil B-TRIVIAL 
base O 
strengthen O 
NHN B-FORMULA 
hydrogen B-SYSTEMATIC 
bonds O 
in O 
(X)U·A O 
base O 
pairs O 
formed O 
by O 
the O 
free O 
nucleosides B-FAMILY 
. O 
Whereas O 
the O 
halogens B-FAMILY 
do O 
not O 
alter O 
the O 
preferential O 
formation O 
of O 
Watson-Crick O 
geometries O 
, O 
self O 
- O 
associates O 
of O 
the O 
halouracils B-FAMILY 
point O 
to O 
a O 
more O 
favorable O 
engagement O 
of O 
the O 
2-carbonyl B-SYSTEMATIC 
as O 
proton O 
acceptor O 
in O 
the O 
cyclic O 
hydrogen B-SYSTEMATIC 
bonds O 
, O 
suggesting O 
increased O 
formation O 
of O 
reverse O 
geometries O 
and O 
wobble O 
base O 
pairs O 
with O 
guanine B-TRIVIAL 
when O 
compared O 
to O 
the O 
thymine B-TRIVIAL 
base O 
. O 
Employing O 
(15)N B-FORMULA 
-labeled O 
5-bromouridine B-SYSTEMATIC 
, O 
no O 
noticeable O 
population O 
of O 
minor O 
enol B-SYSTEMATIC 
tautomers O 
is O 
found O 
in O 
the O 
freonic O 
mixture O 
at O 
113 O 
K O 
. O 

, O 
serotonin B-TRIVIAL 
and O 
major O 
depression O 
. O 

understanding O 
of O 
the O 
neurobiological O 
processes O 
leading O 
to O 
major O 
depressive O 
disorder O 
( O 
MDD O 
) O 
is O 
an O 
active O 
field O 
of O 
research O 
in O 
the O 
scientific O 
community O 
. O 
For O 
years O 
, O 
the O 
alteration O 
of O 
monoamine B-FAMILY 
neurotransmission O 
, O 
in O 
particular O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
, O 
has O 
been O 
considered O 
the O 
most O 
significant O 
pathophysiological O 
mechanism O 
of O 
the O 
disorder O 
. O 
However O 
, O 
biological O 
data O 
supporting O 
the O 
postulated O 
MDD O 
- O 
related O 
monoamine O 
alterations O 
have O 
been O 
inconclusive O 
, O 
and O 
the O 
use O 
of O 
monoaminergic O 
antidepressants O 
has O 
not O 
yielded O 
the O 
expected O 
results O 
. O 
In O 
the O 
last O 
few O 
years O 
, O 
it O 
has O 
been O 
demonstrated O 
that O 
inflammatory O 
pathways O 
have O 
a O 
significant O 
role O 
in O 
the O 
pathophysiology O 
of O 
MDD O 
. O 
According O 
to O 
the O 
cytokine O 
hypothesis O 
, O 
the O 
disorder O 
would O 
be O 
due O 
to O 
a O 
stress O 
- O 
related O 
increased O 
production O 
of O 
cytokines O 
, O 
including O 
interleukins O 
, O 
tumor O 
necrosis O 
factor- O 
α O 
and O 
interferon- O 
α O 
and O 
γ O 
. O 
These O 
, O 
in O 
turns O 
, O 
would O 
cause O 
the O 
activation O 
of O 
the O 
indoleamine B-SYSTEMATIC 
2,3 O 
dioxygenase O 
( O 
IDO O 
) O 
, O 
with O 
subsequent O 
production O 
of O 
tryptophan B-TRIVIAL 
( O 
TRP B-ABBREVIATION 
) O 
catabolites O 
along O 
the O 
IDO O 
pathway O 
( O 
TRYCATs O 
) O 
and O 
decreased O 
availability O 
of O 
TRP B-ABBREVIATION 
and O 
5-HT B-SYSTEMATIC 
. O 
Besides O 
monoamines B-FAMILY 
, O 
other O 
molecular O 
mechanisms O 
, O 
as O 
those O 
within O 
the O 
inflammatory O 
pathways O 
, O 
should O 
be O 
taken O 
into O 
account O 
in O 
the O 
attempt O 
to O 
clarify O 
the O 
pathophysiology O 
of O 
MDD O 
and O 
to O 
improve O 
its O 
treatment O 
. O 

is O 
an O 
experimental O 
bis-pyridinium B-SYSTEMATIC 
mono-aldoxime I-SYSTEMATIC 
type O 
cholinesterase O 
reactivator O 
of O 
potential O 
use O 
in O 
organophosphate B-FAMILY 
/ O 
organophosphonate B-FAMILY 
poisoning O 
. O 
Pharmacokinetics O 
of O 
K203 O 
were O 
examined O 
in O 
Wistar O 
rats O 
and O 
beagle O 
dogs O 
using O 
ion O 
- O 
pair O 
HPLC O 
. O 
Serum O 
and O 
cerebrospinal O 
fluid O 
concentrations O 
of O 
K203 O 
were O 
determined O 
using O 
ion O 
- O 
pair O 
reversedphase O 
chromatography O 
on O 
octadecyl B-SYSTEMATIC 
silica I-SYSTEMATIC 
column O 
. O 
HPLC O 
with O 
ultraviolet O 
detection O 
was O 
used O 
for O 
determination O 
of O 
serum O 
concentration O 
of O 
K203 O 
higher O 
than O 
0.1 O 
μg O 
/ O 
mL O 
while O 
its O 
low O 
concentrations O 
in O 
cerebrospinal O 
fluid O 
required O 
electrochemical O 
detection O 
( O 
0.015 O 
through O 
4 O 
μg O 
/ O 
mL O 
range O 
) O 
. O 
In O 
rats O 
the O 
serum O 
levels O 
of O 
K203 O 
followed O 
zero O 
order O 
pharmacokinetics O 
from O 
15 O 
to O 
120 O 
minutes O 
post O 
administration O 
. O 
Zero O 
order O 
pharmacokinetics O 
was O 
also O 
observed O 
in O 
beagle O 
dogs O 
after O 
low O 
dose O 
( O 
15 O 
μmol O 
/ O 
kg O 
) O 
of O 
K203 O 
administration O 
. O 
High O 
dose O 
administration O 
( O 
250 O 
μmol O 
/ O 
kg O 
) O 
led O 
to O 
subsequent O 
hindered O 
elimination O 
from O 
both O 
cerebrospinal O 
fluid O 
and O 
serum O 
. O 

new O 
two O 
- O 
step O 
layer O 
transfer O 
process O 
is O 
introduced O 
that O 
is O 
capable O 
of O 
fabricating O 
mechanically O 
stabilized O 
highly O 
porous O 
nanoparticle O 
layers O 
on O 
various O 
substrates O 
. O 
In O 
a O 
first O 
step O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
nanoparticles O 
were O 
synthesized O 
with O 
Flame-Spray-Pyrolysis O 
and O 
accumulated O 
on O 
a O 
filter O 
paper O 
in O 
the O 
gas O 
phase O 
. O 
In O 
a O 
second O 
step O 
this O 
highly O 
porous O 
filter O 
cake O 
is O 
subsequently O 
transferred O 
to O 
a O 
final O 
substrate O 
via O 
low O 
pressure O 
lamination O 
at O 
room O 
temperature O 
. O 
This O 
leads O 
to O 
mechanical O 
restructuring O 
and O 
stabilization O 
of O 
the O 
porous O 
layer O 
. O 
Pore O 
size O 
analysis O 
indicates O 
homogenization O 
of O 
the O 
layers O 
through O 
rearrangement O 
of O 
the O 
aggregates O 
inside O 
the O 
layers O 
that O 
increases O 
with O 
applied O 
pressure O 
. O 
Additionally O 
, O 
the O 
Young's O 
moduli O 
of O 
the O 
layers O 
were O 
quantified O 
through O 
Colloidal-Probe-Technique O 
indentation O 
measurements O 
with O 
an O 
Atomic-Force-Microscope O 
. O 
The O 
highest O 
lamination O 
pressure O 
of O 
2.5 O 
MPa O 
resulted O 
in O 
triplication O 
of O 
the O 
Young's O 
modulus O 
. O 
The O 
results O 
show O 
that O 
our O 
novel O 
two O 
- O 
step O 
layer O 
transfer O 
process O 
leads O 
to O 
mechanically O 
stabilized O 
layers O 
that O 
preserve O 
their O 
high O 
porosity O 
. O 
Through O 
the O 
decoupling O 
of O 
the O 
high O 
temperature O 
nanoparticle O 
synthesis O 
and O 
the O 
final O 
substrate O 
the O 
process O 
also O 
enables O 
the O 
possibility O 
to O 
apply O 
temperature O 
sensitive O 
substrates O 
such O 
as O 
polypropylene B-SYSTEMATIC 
foil O 
. O 

of O 
the O 
Proline B-TRIVIAL 
Residue O 
on O 
Ligand O 
Binding O 
of O 
Neurotensin O 
Receptor O 
2 O 
(NTS2)-Selective O 
Peptide-Peptoid O 
Hybrids O 
. O 

investigate O 
the O 
binding O 
mode O 
and O 
structure O 
- O 
activity O 
relationships O 
( O 
SARs O 
) O 
of O 
selective O 
neurotensin O 
receptor O 
2 O 
( O 
NTS2 O 
) O 
ligands O 
, O 
novel O 
peptide-peptoid O 
hybrids O 
that O 
simulate O 
the O 
function O 
of O 
the O 
endogenous O 
ligand O 
were O 
developed O 
. O 
Starting O 
from O 
our O 
recently O 
described O 
NTS2 O 
ligands O 
of O 
type O 
1 O 
, O 
structural O 
variants O 
of O 
type O 
2 O 
and O 
the O 
metabolically O 
stable O 
analogues O 
3 O 
a,b O 
were O 
developed O 
. O 
Replacement O 
of O 
the O 
proline B-TRIVIAL 
unit O 
by O 
a O 
collection O 
of O 
structural O 
surrogates O 
and O 
evaluation O 
of O 
the O 
respective O 
molecular O 
probes O 
for O 
NTS2 O 
affinity O 
and O 
selectivity O 
indicated O 
similar O 
SARs O 
as O 
described O 
for O 
NT(8-13) O 
derivatives O 
bound O 
to O 
the O 
subtype O 
NTS1 O 
. O 
Peptide-peptoid O 
hybrids O 
2 O 
d O 
, O 
3 O 
a,b O 
showed O 
substantial O 
NTS2 O 
binding O 
affinity O 
( O 
Ki O 
= O 
8.1-16 O 
nM O 
) O 
and O 
2400-8600-fold O 
selectivity O 
over O 
NTS1 O 
. O 
The O 
thiazolidine B-SYSTEMATIC 
derivative O 
3 O 
b O 
showed O 
metabolic O 
stability O 
over O 
32 O 
h O 
in O 
a O 
serum O 
degradation O 
assay O 
. O 
In O 
an O 
inositol B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
accumulation O 
assay O 
, O 
the O 
neurotensin O 
mimetics O 
3 O 
a O 
and O 
3 O 
b O 
displayed O 
an O 
inhibition O 
of O 
constitutive O 
activity O 
exceeding O 
1.7-2.0 O 
times O 
the O 
activity O 
of O 
NT(8-13) O 
. O 
The O 
fluorinated O 
derivative O 
3 O 
a O 
could O 
afford O 
attractive O 
opportunities O 
to O 
detect O 
NTS2 O 
by O 
( O 
19 O 
) O 
F O 
magnetic O 
resonance O 
imaging O 
. O 

reproductive O 
senescence O 
or O 
gonadectomy O 
, O 
changes O 
occur O 
in O 
neural O 
gene O 
expression O 
, O 
ultimately O 
altering O 
brain O 
function O 
. O 
The O 
endocrine O 
mechanisms O 
underlying O 
these O 
changes O 
in O 
gene O 
expression O 
beyond O 
immediate O 
hormone O 
loss O 
are O 
poorly O 
understood O 
. O 
To O 
investigate O 
this O 
, O 
we O 
measured O 
changes O 
in O 
gene O 
expression O 
the O 
dorsal O 
striatum O 
, O 
where O 
17β-estradiol B-SYSTEMATIC 
modulates O 
catecholamine B-TRIVIAL 
signaling O 
. O 
In O 
human O 
caudate O 
, O 
quantitative O 
PCR O 
determined O 
a O 
significant O 
elevation O 
in O 
β1-adrenergic O 
receptor O 
( O 
β1AR O 
) O 
expression O 
in O 
menopausal O 
females O 
when O 
compared O 
with O 
similarly O 
aged O 
males O 
. O 
No O 
differences O 
were O 
detected O 
in O 
β2-adrenergic O 
and O 
D1- O 
and O 
D2- O 
dopamine B-TRIVIAL 
receptor O 
expression O 
. O 
Consistent O 
with O 
humans O 
, O 
adult O 
ovariectomized O 
female O 
rats O 
exhibited O 
a O 
similar O 
increase O 
in O 
β1AR O 
expression O 
when O 
compared O 
with O 
gonadectomized O 
males O 
. O 
No O 
sex O 
difference O 
in O 
β1AR O 
expression O 
was O 
detected O 
between O 
intact O 
adults O 
, O 
prepubertal O 
juveniles O 
, O 
or O 
adults O 
gonadectomized O 
before O 
puberty O 
, O 
indicating O 
the O 
necessity O 
of O 
pubertal O 
development O 
and O 
adult O 
ovariectomy O 
. O 
Additionally O 
, O 
increased O 
β1AR O 
expression O 
in O 
adult O 
ovariectomized O 
females O 
was O 
not O 
observed O 
if O 
animals O 
were O 
masculinized O 
/ O 
defeminized O 
with O 
testosterone B-TRIVIAL 
injections O 
as O 
neonates O 
. O 
To O 
generate O 
a O 
model O 
system O 
for O 
assessing O 
functional O 
impact O 
, O 
increased O 
β1AR O 
expression O 
was O 
induced O 
in O 
female O 
- O 
derived O 
cultured O 
striatal O 
neurons O 
via O 
exposure O 
to O 
and O 
then O 
removal O 
of O 
hormone O 
- O 
containing O 
serum O 
. O 
Increased O 
β1AR O 
action O 
on O 
cAMP B-ABBREVIATION 
formation O 
, O 
cAMP B-ABBREVIATION 
response O 
element O 
- O 
binding O 
protein O 
phosphorylation O 
and O 
gene O 
expression O 
was O 
observed O 
. O 
This O 
up O 
- O 
regulation O 
of O 
β1AR O 
action O 
was O 
eliminated O 
with O 
17β-estradiol B-SYSTEMATIC 
addition O 
to O 
the O 
media O 
, O 
directly O 
implicating O 
this O 
hormone O 
as O 
a O 
regulator O 
of O 
β1AR O 
expression O 
. O 
Beyond O 
having O 
implications O 
for O 
the O 
known O 
sex O 
differences O 
in O 
striatal O 
function O 
and O 
pathologies O 
, O 
these O 
data O 
collectively O 
demonstrate O 
that O 
critical O 
periods O 
early O 
in O 
life O 
and O 
at O 
puberty O 
program O 
adult O 
gene O 
responsiveness O 
to O 
hormone O 
loss O 
after O 
gonadectomy O 
and O 
potentially O 
reproductive O 
senescence O 
. O 

activity O 
of O 
a O 
newly O 
synthesized O 
coumarin B-TRIVIAL 
derivative O 
3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide B-SYSTEMATIC 
. O 

therapy O 
is O 
a O 
useful O 
strategy O 
to O 
prevent O 
acute O 
thromboembolic O 
artery O 
occlusions O 
. O 
This O 
study O 
was O 
designed O 
to O 
assess O 
the O 
efficacy O 
of O 
seselin B-TRIVIAL 
derivatives O 
against O 
murine O 
pulmonary O 
thromboembolism O 
, O 
bleeding O 
time O 
, O 
platelet O 
activation O 
and O 
thrombosis O 
. O 
Administration O 
of O 
C3 O 
( O 
16 O 
mg O 
/ O 
kg O 
) O 
offered O 
70% O 
protection O 
against O 
collagen- O 
and O 
epinephrine B-TRIVIAL 
-induced O 
pulmonary O 
thromboembolism O 
and O 
30% O 
protection O 
against O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
-induced O 
death O 
in O 
mice O 
, O 
without O 
adversely O 
affecting O 
bleeding O 
time O 
. O 
No O 
significant O 
difference O 
was O 
observed O 
by O 
C3 O 
in O 
ferric B-SYSTEMATIC 
chloride I-SYSTEMATIC 
-induced O 
arterial O 
thrombosis O 
in O 
rats O 
. O 
Significant O 
reduction O 
in O 
thrombus O 
weight O 
was O 
observed O 
in O 
arteriovenous O 
shunt O 
model O 
. O 
In O 
rat O 
PRP O 
, O 
C3 O 
reduced O 
ADP B-ABBREVIATION 
and O 
collagen O 
- O 
induced O 
platelet O 
aggregation O 
. O 
In O 
chronic O 
hamster O 
model O 
of O 
dyslipidemia O 
, O 
administration O 
of O 
C3 O 
( O 
16 O 
mg O 
/ O 
kg O 
p.o O 
. O 
for O 
90 O 
days O 
) O 
had O 
no O 
effect O 
on O 
plasma O 
lipids O 
, O 
vasoreactivity O 
and O 
platelet O 
adhesion O 
. O 
C3 O 
fed O 
hamsters O 
showed O 
reduced O 
whole O 
- O 
blood O 
aggregation O 
response O 
to O 
ADP B-ABBREVIATION 
and O 
collagen O 
compared O 
to O 
HC-fed O 
hamsters O 
. O 
In O 
addition O 
, O 
C3 O 
augmented O 
thrombin O 
time O 
; O 
however O 
, O 
time O 
to O 
occlusion O 
was O 
not O 
increased O 
. O 
These O 
results O 
convincingly O 
demonstrated O 
that O 
C3 O 
is O 
a O 
novel O 
molecule O 
that O 
reduces O 
the O 
risk O 
of O 
thrombosis O 
and O 
alleviates O 
prothrombotic O 
state O 
associated O 
with O 
hyperlipidemia O 
without O 
any O 
adverse O 
effect O 
on O 
bleeding O 
time O 
. O 
The O 
high O 
benefit O 
/ O 
risk O 
ratio O 
of O 
this O 
compound O 
makes O 
it O 
a O 
suitable O 
candidate O 
for O 
future O 
valid O 
studies O 
. O 

and O 
in O 
vitro O 
bioassay O 
screening O 
of O 
phytochemical O 
inhibitors O 
from O 
flavonoids B-FAMILY 
and O 
isoflavones B-FAMILY 
against O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
for O 
gout O 
treatment O 
. O 

drugs O 
such O 
as O 
allopurinol B-TRIVIAL 
and O 
benzbromarone B-TRIVIAL 
are O 
commonly O 
used O 
to O 
treat O 
the O 
complex O 
pathogenesis O 
of O 
gout O 
, O 
a O 
metabolic O 
disease O 
that O 
results O 
from O 
an O 
inflammation O 
of O 
the O 
joints O 
caused O 
by O 
precipitation O 
of O 
uric B-TRIVIAL 
acid I-TRIVIAL 
. O 
We O 
seek O 
to O 
discover O 
novel O 
phytochemicals O 
that O 
could O 
treat O 
gout O 
, O 
by O 
targeting O 
the O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
enzymes O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
the O 
screening O 
of O 
nine O 
compounds O 
of O 
flavonoids B-FAMILY 
from O 
the O 
ZINC O 
and O 
PubChem O 
databases O 
( O 
containing O 
2092 O 
flavonoids B-FAMILY 
) O 
using O 
the O 
IGEMDOCK O 
software O 
tool O 
against O 
the O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
3D O 
protein O 
structures O 
. O 
Each O 
compound O 
was O 
also O 
evaluated O 
by O 
an O 
in O 
vitro O 
bioassay O 
testing O 
the O 
inhibition O 
of O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
. O 
Myricetin B-TRIVIAL 
and O 
luteolin B-TRIVIAL 
were O 
found O 
to O 
be O 
the O 
potential O 
dual O 
inhibitors O 
of O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
as O 
demonstrated O 
by O 
IC(50) O 
: O 
62.7 O 
and O 
3.29 O 
μg O 
/ O 
mL O 
( O 
xanthine B-TRIVIAL 
oxidase O 
) O 
/ O 
70.8 O 
and O 
16.38 O 
μg O 
/ O 
mL O 
( O 
cyclooxygenase-2 O 
) O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
structure O 
- O 
activity O 
relationships O 
and O 
other O 
important O 
factors O 
of O 
the O 
flavonoids B-FAMILY 
binding O 
to O 
the O 
active O 
site O 
of O 
xanthine B-TRIVIAL 
oxidase O 
and O 
cyclooxygenase-2 O 
were O 
discussed O 
, O 
which O 
is O 
expected O 
for O 
further O 
rational O 
drug O 
design O 
. O 

L1 O 
stalk O 
is O 
a O 
prominent O 
mobile O 
element O 
of O 
the O 
large O 
ribosomal O 
subunit O 
. O 
We O 
explore O 
the O 
structure O 
and O 
dynamics O 
of O 
its O 
non-canonical O 
rRNA O 
elements O 
, O 
which O 
include O 
two O 
kink O 
- O 
turns O 
, O 
an O 
internal O 
loop O 
, O 
and O 
a O 
tetraloop O 
. O 
We O 
use O 
bioinformatics O 
to O 
identify O 
the O 
L1 O 
stalk O 
RNA O 
conservation O 
patterns O 
and O 
carry O 
out O 
over O 
11.5 O 
μs O 
of O 
MD O 
simulations O 
for O 
a O 
set O 
of O 
systems O 
ranging O 
from O 
isolated O 
RNA O 
building O 
blocks O 
up O 
to O 
complexes O 
of O 
L1 O 
stalk O 
rRNA O 
with O 
the O 
L1 O 
protein O 
and O 
tRNA O 
fragment O 
. O 
We O 
show O 
that O 
the O 
L1 O 
stalk O 
tetraloop O 
has O 
an O 
unusual O 
GNNA O 
or O 
UNNG O 
conservation O 
pattern O 
deviating O 
from O 
major O 
GNRA O 
and O 
YNMG O 
RNA O 
tetraloop O 
families O 
. O 
We O 
suggest O 
that O 
this O 
deviation O 
is O 
related O 
to O 
a O 
highly O 
conserved O 
tertiary O 
contact O 
within O 
the O 
L1 O 
stalk O 
. O 
The O 
available O 
X-ray O 
structures O 
contain O 
only O 
UCCG O 
tetraloops O 
which O 
in O 
addition O 
differ O 
in O 
orientation O 
( O 
anti O 
vs O 
syn O 
) O 
of O 
the O 
guanine B-TRIVIAL 
. O 
Our O 
analysis O 
suggests O 
that O 
the O 
anti O 
orientation O 
might O 
be O 
a O 
mis O 
- O 
refinement O 
, O 
although O 
even O 
the O 
anti O 
interaction O 
would O 
be O 
compatible O 
with O 
the O 
sequence O 
pattern O 
and O 
observed O 
tertiary O 
interaction O 
. O 
Alternatively O 
, O 
the O 
anti O 
conformation O 
may O 
be O 
a O 
real O 
substate O 
whose O 
population O 
could O 
be O 
pH-dependent O 
, O 
since O 
the O 
guanine B-TRIVIAL 
syn O 
orientation O 
requires O 
protonation O 
of O 
cytosine B-TRIVIAL 
in O 
the O 
tertiary O 
contact O 
. O 
In O 
absence O 
of O 
structural O 
data O 
, O 
we O 
use O 
molecular O 
modeling O 
to O 
explore O 
the O 
GCCA O 
tetraloop O 
that O 
is O 
dominant O 
in O 
bacteria O 
and O 
suggest O 
that O 
the O 
GCCA O 
tetraloop O 
is O 
structurally O 
similar O 
to O 
the O 
YNMG O 
tetraloop O 
. O 
Kink O 
- O 
turn O 
Kt-77 O 
is O 
unusual O 
due O 
to O 
its O 
11- O 
nucleotide B-FAMILY 
bulge O 
. O 
The O 
simulations O 
indicate O 
that O 
the O 
long O 
bulge O 
is O 
a O 
stalk O 
- O 
specific O 
eight- O 
nucleotide B-FAMILY 
insertion O 
into O 
consensual O 
kink O 
- O 
turn O 
only O 
subtly O 
modifying O 
its O 
structural O 
dynamics O 
. O 
We O 
discuss O 
a O 
possible O 
evolutionary O 
role O 
of O 
helix O 
H78 O 
and O 
a O 
mechanism O 
of O 
L1 O 
stalk O 
interaction O 
with O 
tRNA O 
. O 
We O 
also O 
assess O 
the O 
simulation O 
methodology O 
. O 
The O 
simulations O 
provide O 
a O 
good O 
description O 
of O 
the O 
studied O 
systems O 
with O 
the O 
latest O 
bsc0χOL3 O 
force O 
field O 
showing O 
improved O 
performance O 
. O 
Still O 
, O 
even O 
bsc0χOL3 O 
is O 
unable O 
to O 
fully O 
stabilize O 
an O 
essential O 
sugar B-FAMILY 
-edge O 
H B-FORMULA 
-bond O 
between O 
the O 
bulge O 
and O 
non-canonical O 
stem O 
of O 
the O 
kink O 
- O 
turn O 
. O 
Inclusion O 
of O 
Mg(2+) B-FORMULA 
ions O 
may O 
deteriorate O 
the O 
simulations O 
. O 
On O 
the O 
other O 
hand O 
, O 
monovalent O 
ions O 
can O 
in O 
simulations O 
readily O 
occupy O 
experimental O 
Mg(2+) B-FORMULA 
binding O 
sites O 
. O 

analgesic O 
/ O 
anti-inflammatory O 
agents O 
: O 
1,5-diarylpyrrole B-FAMILY 
nitrooxyalkyl I-FAMILY 
ethers I-FAMILY 
and O 
related O 
compounds O 
as O 
cyclooxygenase-2 O 
inhibiting O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
donors O 
. O 

series O 
of O 
3- B-FAMILY 
substituted I-FAMILY 
1,5-diarylpyrroles I-FAMILY 
bearing O 
a O 
nitrooxyalkyl B-FAMILY 
side O 
chain O 
linked O 
to O 
different O 
spacers O 
were O 
designed O 
. O 
New O 
classes O 
of O 
pyrrole B-SYSTEMATIC 
-derived O 
nitrooxyalkyl B-FAMILY 
inverse O 
esters B-FAMILY 
, O 
carbonates B-FAMILY 
, O 
and O 
ethers B-FAMILY 
( O 
7-10 O 
) O 
as O 
COX-2 O 
selective O 
inhibitors O 
and O 
NO B-FORMULA 
donors O 
were O 
synthesized O 
and O 
are O 
herein O 
reported O 
. O 
By O 
taking O 
into O 
account O 
the O 
metabolic O 
conversion O 
of O 
nitrooxyalkyl B-FAMILY 
ethers I-FAMILY 
( O 
9 O 
, O 
10 O 
) O 
into O 
corresponding O 
alcohols B-FAMILY 
, O 
derivatives O 
17 O 
and O 
18 O 
were O 
also O 
studied O 
. O 
Nitrooxy B-SYSTEMATIC 
derivatives O 
showed O 
NO B-FORMULA 
-dependent O 
vasorelaxing O 
properties O 
, O 
while O 
most O 
of O 
the O 
compounds O 
proved O 
to O 
be O 
very O 
potent O 
and O 
selective O 
COX-2 O 
inhibitors O 
in O 
in O 
vitro O 
experimental O 
models O 
. O 
Further O 
in O 
vivo O 
studies O 
on O 
compounds O 
9a,c O 
and O 
17a O 
highlighted O 
good O 
anti-inflammatory O 
and O 
antinociceptive O 
activities O 
. O 
Compound O 
9c O 
was O 
able O 
to O 
inhibit O 
glycosaminoglycan O 
( O 
GAG O 
) O 
release O 
induced O 
by O 
interleukin-1β O 
( O 
IL-1β O 
) O 
, O 
showing O 
cartilage O 
protective O 
properties O 
. O 
Finally O 
, O 
molecular O 
modeling O 
and O 
(1)H B-FORMULA 
- O 
and O 
(13)C B-FORMULA 
-NMR O 
studies O 
performed O 
on O 
compounds O 
6c,d O 
, O 
9c O 
, O 
and O 
10b O 
allowed O 
the O 
right O 
conformation O 
of O 
nitrooxyalkyl B-MULTIPLE 
ester I-MULTIPLE 
and I-MULTIPLE 
ether I-MULTIPLE 
side O 
chain O 
of O 
these O 
molecules O 
within O 
the O 
COX-2 O 
active O 
site O 
to O 
be O 
assessed O 
. O 

structural O 
description O 
of O 
calcium B-SYSTEMATIC 
- I-SYSTEMATIC 
sodium I-SYSTEMATIC 
aluminosilicate I-SYSTEMATIC 
hydrate I-SYSTEMATIC 
gels O 
: O 
the O 
cross O 
- O 
linked O 
substituted O 
tobermorite B-TRIVIAL 
model O 
. O 

models O 
for O 
the O 
primary O 
strength O 
and O 
durability O 
- O 
giving O 
reaction O 
product O 
in O 
modern O 
cements O 
, O 
a O 
calcium B-SYSTEMATIC 
(alumino)silicate I-SYSTEMATIC 
hydrate O 
gel O 
, O 
have O 
previously O 
been O 
based O 
solely O 
on O 
non-cross O 
- O 
linked O 
tobermorite B-TRIVIAL 
structures O 
. O 
However O 
, O 
recent O 
experimental O 
studies O 
of O 
laboratory O 
- O 
synthesized O 
and O 
alkali O 
- O 
activated O 
slag O 
( O 
AAS O 
) O 
binders O 
have O 
indicated O 
that O 
the O 
calcium B-SYSTEMATIC 
- I-SYSTEMATIC 
sodium I-SYSTEMATIC 
aluminosilicate I-SYSTEMATIC 
hydrate I-SYSTEMATIC 
[ O 
C-(N)-A-S-H B-ABBREVIATION 
] O 
gel O 
formed O 
in O 
these O 
systems O 
can O 
be O 
significantly O 
cross O 
- O 
linked O 
. O 
Here O 
, O 
we O 
propose O 
a O 
model O 
that O 
describes O 
the O 
C-(N)-A-S-H B-ABBREVIATION 
gel O 
as O 
a O 
mixture O 
of O 
cross O 
- O 
linked O 
and O 
non-cross O 
- O 
linked O 
tobermorite B-TRIVIAL 
-based O 
structures O 
( O 
the O 
cross O 
- O 
linked O 
substituted O 
tobermorite B-TRIVIAL 
model O 
, O 
CSTM O 
) O 
, O 
which O 
can O 
more O 
appropriately O 
describe O 
the O 
spectroscopic O 
and O 
density O 
information O 
available O 
for O 
this O 
material O 
. O 
Analysis O 
of O 
the O 
phase O 
assemblage O 
and O 
Al O 
coordination O 
environments O 
of O 
AAS O 
binders O 
shows O 
that O 
it O 
is O 
not O 
possible O 
to O 
fully O 
account O 
for O 
the O 
chemistry O 
of O 
AAS O 
by O 
use O 
of O 
the O 
assumption O 
that O 
all O 
of O 
the O 
tetrahedral O 
Al O 
is O 
present O 
in O 
a O 
tobermorite B-TRIVIAL 
-type O 
C-(N)-A-S-H B-ABBREVIATION 
gel O 
, O 
due O 
to O 
the O 
structural O 
constraints O 
of O 
the O 
gel O 
. O 
Application O 
of O 
the O 
CSTM O 
can O 
for O 
the O 
first O 
time O 
reconcile O 
this O 
information O 
, O 
indicating O 
the O 
presence O 
of O 
an O 
additional O 
activation O 
product O 
that O 
contains O 
highly O 
connected O 
four O 
- O 
coordinated O 
silicate B-FAMILY 
and O 
aluminate B-TRIVIAL 
species O 
. O 
The O 
CSTM O 
therefore O 
provides O 
a O 
more O 
advanced O 
description O 
of O 
the O 
chemistry O 
and O 
structure O 
of O 
calcium B-SYSTEMATIC 
- I-SYSTEMATIC 
sodium I-SYSTEMATIC 
aluminosilicate I-SYSTEMATIC 
gel O 
structures O 
than O 
that O 
previously O 
established O 
in O 
the O 
literature O 
. O 

salvage O 
and O 
S-adenosylmethionine B-TRIVIAL 
: O 
essential O 
links O 
between O 
sulfur B-SYSTEMATIC 
, O 
ethylene B-SYSTEMATIC 
and O 
polyamine O 
biosynthesis O 
. O 

Met B-FORMULA 
( O 
methionine B-TRIVIAL 
) O 
and O 
SAM B-ABBREVIATION 
( O 
S-adenosylmethionine B-TRIVIAL 
) O 
, O 
the O 
activated O 
form O 
of O 
Met B-FORMULA 
, O 
participate O 
in O 
a O 
number O 
of O 
essential O 
metabolic O 
pathways O 
in O 
plants O 
. O 
The O 
subcellular O 
compartmentalization O 
of O 
Met B-FORMULA 
fluxes O 
will O 
be O 
discussed O 
in O 
the O 
present O 
review O 
with O 
respect O 
to O 
regulation O 
and O 
communication O 
with O 
the O 
sulfur B-SYSTEMATIC 
assimilation O 
pathway O 
, O 
the O 
network O 
of O 
the O 
aspartate B-TRIVIAL 
-derived O 
amino B-FAMILY 
acids I-FAMILY 
and O 
the O 
demand O 
for O 
production O 
of O 
SAM B-ABBREVIATION 
. O 
SAM B-ABBREVIATION 
enters O 
the O 
ethylene B-SYSTEMATIC 
, O 
nicotianamine B-SYSTEMATIC 
and O 
polyamine O 
biosynthetic O 
pathways O 
and O 
provides O 
the O 
methyl B-SYSTEMATIC 
group O 
for O 
the O 
majority O 
of O 
methylation O 
reactions O 
required O 
for O 
plant O 
growth O 
and O 
development O 
. O 
The O 
multiple O 
essential O 
roles O 
of O 
SAM B-ABBREVIATION 
require O 
regulation O 
of O 
its O 
synthesis O 
, O 
recycling O 
and O 
distribution O 
to O 
sustain O 
these O 
different O 
pathways O 
. O 
A O 
particular O 
focus O 
of O 
the O 
present O 
review O 
will O 
be O 
on O 
the O 
function O 
of O 
recently O 
identified O 
genes O 
of O 
the O 
Met B-FORMULA 
salvage O 
cycle O 
or O 
Yang O 
cycle O 
and O 
the O 
importance O 
of O 
the O 
Met B-FORMULA 
salvage O 
cycle O 
in O 
the O 
metabolism O 
of O 
MTA B-ABBREVIATION 
( O 
5'-methylthioadenosine B-SYSTEMATIC 
) O 
. O 
MTA B-ABBREVIATION 
has O 
the O 
potential O 
for O 
product O 
inhibition O 
of O 
ethylene B-SYSTEMATIC 
, O 
nicotianamine B-SYSTEMATIC 
and O 
polyamine O 
biosynthesis O 
which O 
provides O 
an O 
additional O 
link O 
between O 
these O 
pathways O 
. O 
Interestingly O 
, O 
regulation O 
of O 
Met B-FORMULA 
cycle O 
genes O 
was O 
found O 
to O 
differ O 
between O 
plant O 
species O 
as O 
shown O 
for O 
Arabidopsis O 
thaliana O 
and O 
Oryza O 
sativa O 
. O 

attenuates O 
mast O 
cell O 
- O 
mediated O 
allergic O 
inflammation O 
. O 

great O 
number O 
of O 
people O 
are O 
suffering O 
from O 
allergic O 
inflammatory O 
disease O 
such O 
as O 
asthma O 
, O 
atopic O 
dermatitis O 
, O 
and O 
sinusitis O 
. O 
Therefore O 
discovery O 
of O 
drugs O 
for O 
the O 
treatment O 
of O 
these O 
diseases O 
is O 
an O 
important O 
subject O 
in O 
human O 
health O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
anti-allergic O 
inflammatory O 
effect O 
of O 
galangin B-TRIVIAL 
and O 
underlying O 
mechanisms O 
of O 
action O 
using O 
in O 
vitro O 
and O 
in O 
vivo O 
models O 
. O 
Galangin B-TRIVIAL 
inhibited O 
histamine B-TRIVIAL 
release O 
by O 
the O 
reduction O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
in O 
phorbol B-SYSTEMATIC 
12-mystate I-SYSTEMATIC 
13-acetate I-SYSTEMATIC 
plus O 
calcium B-SYSTEMATIC 
ionophore O 
A23187-stimulated O 
human O 
mast O 
cells O 
( O 
HMC-1 O 
) O 
. O 
Galangin B-TRIVIAL 
decreased O 
expression O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
, O 
such O 
as O 
tumor O 
necrosis O 
factor O 
(TNF)-α O 
, O 
interleukin O 
(IL)-6 O 
, O 
IL-1β O 
, O 
and O 
IL-8 O 
. O 
The O 
inhibitory O 
effect O 
of O 
galangin B-TRIVIAL 
on O 
theses O 
pro O 
- O 
inflammatory O 
cytokines O 
was O 
related O 
with O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinases O 
, O 
and O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
, O 
nuclear O 
factor-κB O 
, O 
and O 
caspase-1 O 
. O 
Furthermore O 
, O 
galangin B-TRIVIAL 
attenuated O 
IgE O 
- O 
mediated O 
passive O 
cutaneous O 
anaphylaxis O 
and O 
the O 
expression O 
of O 
histamine B-TRIVIAL 
receptor O 
1 O 
at O 
the O 
inflamed O 
tissue O 
. O 
The O 
inhibitory O 
effects O 
of O 
galangin B-TRIVIAL 
were O 
more O 
potent O 
than O 
cromolyn B-TRIVIAL 
, O 
a O 
known O 
anti-allergic O 
drug O 
. O 
Our O 
results O 
showed O 
that O 
galangin B-TRIVIAL 
down O 
- O 
regulates O 
mast O 
cell O 
- O 
derived O 
allergic O 
inflammatory O 
reactions O 
by O 
blocking O 
histamine B-TRIVIAL 
release O 
and O 
expression O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
. O 
In O 
light O 
of O 
in O 
vitro O 
and O 
in O 
vivo O 
anti-allergic O 
inflammatory O 
effects O 
, O 
galangin B-TRIVIAL 
could O 
be O 
a O 
beneficial O 
anti-allergic O 
inflammatory O 
agent O 
. O 

attenuates O 
d-galactosamine B-TRIVIAL 
/ O 
lipopolysaccharide-induced O 
fulminant O 
hepatic O 
failure O 
through O 
inhibition O 
of O 
toll O 
- O 
like O 
receptor O 
4 O 
signaling O 
in O 
mice O 
. O 

purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
protective O 
effects O 
and O 
molecular O 
mechanisms O 
of O 
scoparone B-TRIVIAL 
on O 
d-galactosamine B-TRIVIAL 
( O 
d-GalN B-ABBREVIATION 
) O 
/ O 
lipopolysaccharide O 
(LPS)-induced O 
fulminant O 
hepatic O 
failure O 
( O 
FHF O 
) O 
in O 
mice O 
. O 
FHF O 
was O 
induced O 
in O 
mice O 
by O 
intraperitoneal O 
injection O 
of O 
d-GalN B-ABBREVIATION 
( O 
800mg O 
/ O 
kg O 
) O 
/ O 
LPS O 
( O 
40μg O 
/ O 
kg O 
) O 
. O 
Mice O 
were O 
treated O 
intraperitoneally O 
with O 
scoparone B-TRIVIAL 
1h O 
before O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
treatment O 
. O 
Treatment O 
with O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
markedly O 
increased O 
mortality O 
, O 
serum O 
aminotransferase O 
activity O 
, O 
and O 
tolllike O 
receptor O 
4 O 
( O 
TLR4 O 
) O 
protein O 
expression O 
, O 
and O 
these O 
increases O 
were O 
attenuated O 
by O 
scoparone B-TRIVIAL 
. O 
Treatment O 
with O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
markedly O 
increased O 
myeloid O 
differentiation O 
primary O 
response O 
gene O 
88 O 
protein O 
expression O 
, O 
phosphorylation O 
of O 
p38 O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
and O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
, O 
nuclear O 
protein O 
expression O 
of O 
nuclear O 
factor O 
κB O 
and O 
phosphorylated O 
c-Jun O 
, O 
and O 
levels O 
of O 
serum O 
tumor O 
necrosis O 
factor-α O 
and O 
interleukin-6 O 
and O 
these O 
increases O 
were O 
attenuated O 
by O 
scoparone B-TRIVIAL 
. O 
In O 
addition O 
, O 
increased O 
levels O 
of O 
toll O 
- O 
receptor O 
- O 
associated O 
activator O 
of O 
interferon O 
protein O 
expression O 
, O 
phosphorylation O 
of O 
interferon O 
( O 
IFN O 
) O 
regulatory O 
factor O 
3 O 
, O 
and O 
serum O 
IFN-β O 
level O 
in O 
d-GalN B-ABBREVIATION 
/ O 
LPS O 
- O 
treated O 
mice O 
were O 
attenuated O 
by O 
scoparone B-TRIVIAL 
. O 
Our O 
results O 
suggest O 
that O 
scoparone B-TRIVIAL 
attenuates O 
d-GalN B-ABBREVIATION 
/ O 
LPSinduced O 
liver O 
damage O 
by O 
inhibition O 
of O 
the O 
TLR O 
- O 
mediated O 
inflammatory O 
pathway O 
. O 

have O 
previously O 
reported O 
that O 
hepatocarcinogens O 
increase O 
liver O 
cells O 
expressing O 
p21(Cip1) O 
, O 
a O 
G1 O 
checkpoint O 
protein O 
and O 
M O 
phase O 
proteins O 
after O 
28-day O 
treatment O 
in O 
rats O 
. O 
This O 
study O 
aimed O 
to O 
identify O 
early O 
prediction O 
markers O 
of O 
carcinogens O 
available O 
in O 
many O 
target O 
organs O 
after O 
28-day O 
treatment O 
in O 
rats O 
. O 
Immunohistochemical O 
analysis O 
was O 
performed O 
on O 
Ki-67 O 
, O 
p21(Cip1) O 
and O 
M O 
phase O 
proteins O 
[ O 
nuclear O 
Cdc2 O 
, O 
phospho-Histone O 
H3 O 
( O 
p-Histone O 
H3 O 
) O 
, O 
Aurora O 
B O 
and O 
heterochromatin O 
protein O 
1α O 
( O 
HP1α O 
) O 
] O 
with O 
carcinogens O 
targeting O 
different O 
organs O 
. O 
Carcinogens O 
targeting O 
thyroid O 
( O 
sulfadimethoxine B-TRIVIAL 
; O 
SDM B-ABBREVIATION 
) O 
, O 
urinary O 
bladder O 
( O 
phenylethyl B-SYSTEMATIC 
isothiocyanate I-SYSTEMATIC 
) O 
, O 
forestomach O 
( O 
butylated B-SYSTEMATIC 
hydroxyanisole I-SYSTEMATIC 
; O 
BHA B-ABBREVIATION 
) O 
, O 
glandular O 
stomach O 
( O 
catechol B-TRIVIAL 
; O 
CC O 
) O 
, O 
and O 
colon O 
( O 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-SYSTEMATIC 
and O 
chenodeoxycholic B-TRIVIAL 
acid I-TRIVIAL 
) O 
were O 
examined O 
using O 
a O 
non-carcinogenic O 
toxicant O 
( O 
caprolactam B-TRIVIAL 
) O 
and O 
carcinogens O 
targeting O 
other O 
organs O 
as O 
negative O 
controls O 
. O 
All O 
carcinogens O 
increased O 
Ki-67(+) O 
, O 
nuclear O 
Cdc2(+) O 
, O 
p-Histone O 
H3(+) O 
or O 
Aurora O 
B(+) O 
carcinogenic O 
target O 
cells O 
, O 
except O 
for O 
both O 
colon O 
carcinogens O 
, O 
which O 
did O 
not O 
increase O 
cell O 
proliferation O 
. O 
On O 
the O 
other O 
hand O 
, O 
p21(Cip1+) O 
cells O 
increased O 
with O 
SDM O 
and O 
CC O 
. O 
HP1α O 
responded O 
only O 
to O 
BHA B-ABBREVIATION 
. O 
Results O 
revealed O 
carcinogens O 
evoking O 
cell O 
proliferation O 
concurrently O 
induced O 
cell O 
cycle O 
arrest O 
at O 
M O 
phase O 
or O 
showing O 
chromosomal O 
instability O 
reflecting O 
aberration O 
in O 
cell O 
cycle O 
regulation O 
, O 
irrespective O 
of O 
target O 
organs O 
, O 
after O 
28-day O 
treatment O 
. O 
Therefore O 
, O 
M O 
phase O 
proteins O 
may O 
be O 
early O 
prediction O 
markers O 
of O 
carcinogens O 
evoking O 
cell O 
proliferation O 
in O 
many O 
target O 
organs O 
. O 

naphthoquinones B-FAMILY 
against O 
antimony O 
- O 
sensitive O 
and O 
-resistant O 
Leishmania O 
parasites O 
: O 
Synthesis O 
of O 
novel O 
α- B-MULTIPLE 
and I-MULTIPLE 
nor-α-lapachone I-MULTIPLE 
-based O 
1,2,3-triazoles B-FAMILY 
by O 
copper B-SYSTEMATIC 
-catalyzed O 
azide B-SYSTEMATIC 
- O 
alkyne B-FAMILY 
cycloaddition O 
. O 

our O 
screening O 
program O 
for O 
novel O 
anti-parasite O 
compounds O 
, O 
we O 
synthesized O 
seven O 
1,4-naphthoquinones B-FAMILY 
coupled O 
to O 
1,2,3-triazoles B-FAMILY 
, O 
five O 
nor-β-lapachone B-TRIVIAL 
-based O 
1,2,3-triazoles B-FAMILY 
and O 
ten O 
α-lapachone B-TRIVIAL 
-based O 
1,2,3-triazoles B-FAMILY 
. O 
These O 
and O 
other O 
naphthoquinonoid O 
compounds O 
were O 
evaluated O 
for O 
their O 
activity O 
against O 
promastigote O 
forms O 
of O 
antimony O 
- O 
sensitive O 
and O 
-resistant O 
strains O 
of O 
Leishmania O 
infantum O 
( O 
syn O 
. O 
Leishmania O 
chagasi O 
) O 
and O 
Leishmania O 
amazonensis O 
. O 
The O 
toxicity O 
of O 
these O 
compounds O 
to O 
mammalian O 
cells O 
was O 
also O 
examined O 
. O 
The O 
substances O 
were O 
more O 
potent O 
than O 
an O 
antimonial O 
drug O 
, O 
with O 
IC50 O 
values O 
ranging O 
from O 
1 O 
to O 
50.7 O 
μM O 
. O 
Nor-α-lapachone B-TRIVIAL 
derivatives O 
showed O 
the O 
highest O 
antileishmanial O 
activity O 
, O 
with O 
selectivity O 
indices O 
in O 
the O 
range O 
of O 
10- O 
15 O 
. O 
These O 
compounds O 
emerged O 
as O 
important O 
leads O 
for O 
further O 
investigation O 
as O 
antileishmanial O 
agents O 
. O 
Additionally O 
, O 
one O 
of O 
these O 
compounds O 
exhibited O 
cross O 
- O 
resistance O 
in O 
Sb-resistant O 
Leishmania O 
and O 
could O 
provide O 
a O 
molecular O 
tool O 
for O 
investigating O 
the O 
multidrug O 
resistance O 
mechanisms O 
in O 
Leishmania O 
parasites O 
. O 

bismuth I-FAMILY 
carboxylates I-FAMILY 
based O 
on O 
a O 
diphenyl B-SYSTEMATIC 
sulfone I-SYSTEMATIC 
scaffold O 
: O 
Synthesis O 
and O 
antifungal O 
activity O 
against O 
Saccharomycescerevisiae O 
. O 

series O 
of O 
heterocyclic B-FAMILY 
organobismuth I-FAMILY 
(III) I-FAMILY 
carboxylates I-FAMILY 
4 O 
and O 
5 O 
[ O 
RCO2Bi(C6H4-2-SO2C6H4-1'-) B-FAMILY 
] O 
derived O 
from O 
diphenyl B-SYSTEMATIC 
sulfone I-SYSTEMATIC 
was O 
synthesized O 
to O 
determine O 
the O 
influence O 
of O 
the O 
carboxylate B-SYSTEMATIC 
ligand O 
structure O 
on O 
the O 
lipophilicity O 
and O 
antifungal O 
activity O 
against O 
the O 
yeast O 
Saccharomyces O 
cerevisiae O 
. O 
In O 
contrast O 
to O 
the O 
clear O 
structure O 
- O 
activity O 
relationship O 
between O 
the O 
size O 
of O 
the O 
inhibition O 
zone O 
and O 
the O 
value O 
of O 
ClogP O 
for O 
specific O 
substitution O 
on O 
diphenyl B-SYSTEMATIC 
sulfone I-SYSTEMATIC 
scaffold O 
1 O 
[ O 
ClBi(5-RC6H3-2-SO2C6H4-1'-) B-FAMILY 
] O 
, O 
scaffolds O 
4 O 
and O 
5 O 
showed O 
similar O 
inhibition O 
activities O 
irrespective O 
of O 
the O 
ClogP O 
value O 
. O 
This O 
suggests O 
that O 
these O 
molecules O 
function O 
inside O 
the O 
yeast O 
cell O 
by O 
separating O 
into O 
the O 
cationic O 
heterocyclic O 
bismuth B-SYSTEMATIC 
scaffold O 
and O 
the O 
anionic O 
carboxylate B-SYSTEMATIC 
moiety O 
, O 
and O 
that O 
the O 
bismuth B-SYSTEMATIC 
scaffold O 
plays O 
an O 
important O 
role O 
in O 
the O 
inhibition O 
activity O 
. O 

and O 
highly O 
potent O 
histamine B-TRIVIAL 
H3 O 
receptor O 
ligands O 
. O 
Part O 
3 O 
: O 
An O 
alcohol B-FAMILY 
function O 
to O 
improve O 
the O 
pharmacokinetic O 
profile O 
. O 

and O 
biological O 
evaluation O 
of O 
potent O 
histamine B-TRIVIAL 
H3 O 
receptor O 
antagonists O 
incorporating O 
a O 
hydroxyl B-SYSTEMATIC 
function O 
are O 
described O 
. O 
Compounds O 
in O 
this O 
series O 
exhibited O 
nanomolar O 
binding O 
affinities O 
for O 
human O 
receptor O 
, O 
illustrating O 
a O 
new O 
possible O 
component O 
for O 
the O 
H3 O 
pharmacophore O 
. O 
As O 
demonstrated O 
with O 
compound O 
BP1.4160 B-IDENTIFIER 
( O 
cyclohexanol B-SYSTEMATIC 
19 O 
) O 
, O 
the O 
introduction O 
of O 
an O 
alcohol B-FAMILY 
function O 
counter O 
- O 
intuitively O 
allowed O 
to O 
reach O 
high O 
in O 
vivo O 
efficiency O 
and O 
favorable O 
pharmacokinetic O 
profile O 
with O 
reduced O 
half O 
- O 
life O 
. O 

cereals O 
, O 
the O 
primary O 
cell O 
wall O 
is O 
built O 
of O 
a O 
skeleton O 
of O 
cellulosic O 
microfibrils O 
embedded O 
in O 
a O 
matrix O 
of O 
hemicelluloses O 
and O 
smaller O 
amounts O 
of O 
pectins O 
, O 
glycoproteins O 
and O 
hydroxycinnamates B-FAMILY 
. O 
Later O 
, O 
during O 
secondary O 
wall O 
development O 
, O 
p-coumaryl B-MULTIPLE 
, I-MULTIPLE 
coniferyl I-MULTIPLE 
and I-MULTIPLE 
sinapyl I-MULTIPLE 
alcohols I-MULTIPLE 
are O 
copolymerized O 
to O 
form O 
mixed O 
lignins O 
. O 
Several O 
of O 
these O 
cell O 
wall O 
components O 
show O 
a O 
determinative O 
role O 
in O 
maize O 
resistance O 
to O 
pest O 
and O 
diseases O 
. O 
However O 
, O 
defense O 
mechanisms O 
are O 
very O 
complex O 
and O 
vary O 
among O 
the O 
same O 
plant O 
species O 
, O 
different O 
tissues O 
or O 
even O 
the O 
same O 
tissue O 
at O 
different O 
developmental O 
stages O 
. O 
Thus O 
, O 
it O 
is O 
important O 
to O 
highlight O 
that O 
the O 
role O 
of O 
the O 
cell O 
wall O 
components O 
needs O 
to O 
be O 
tested O 
in O 
diverse O 
genotypes O 
and O 
specific O 
tissues O 
where O 
the O 
feeding O 
or O 
attacking O 
by O 
the O 
pathogen O 
takes O 
place O 
. O 
Understanding O 
the O 
role O 
of O 
cell O 
wall O 
constituents O 
as O 
defense O 
mechanisms O 
may O 
allow O 
modifications O 
of O 
crops O 
to O 
withstand O 
pests O 
and O 
diseases O 
. O 

of O 
schizophrenia O 
: O 
clinical O 
experience O 
with O 
asenapine B-TRIVIAL 
. O 

is O 
a O 
chronic O 
brain O 
disorder O 
comprising O 
a O 
range O 
of O 
clinical O 
features O 
, O 
including O 
positive O 
and O 
negative O 
symptoms O 
, O 
cognitive O 
dysfunction O 
and O 
mood O 
symptoms O 
( O 
particularly O 
depression O 
and O 
anxiety O 
) O 
. O 
The O 
management O 
of O 
schizophrenia O 
requires O 
effective O 
short- O 
and O 
long O 
- O 
term O 
treatment O 
with O 
antipsychotic O 
medication O 
that O 
is O 
effective O 
across O 
these O 
symptom O 
domains O 
, O 
while O 
being O 
well O 
tolerated O 
over O 
the O 
long O 
term O 
. O 
Asenapine B-TRIVIAL 
is O 
the O 
first O 
tetracyclic O 
atypical O 
antipsychotic O 
to O 
be O 
licensed O 
in O 
the O 
USA O 
and O 
several O 
other O 
countries O 
outside O 
Europe O 
for O 
the O 
acute O 
and O 
maintenance O 
treatment O 
of O 
schizophrenia O 
in O 
adults O 
. O 
It O 
has O 
a O 
unique O 
receptor O 
- O 
binding O 
profile O 
and O 
a O 
broad O 
range O 
of O 
therapeutic O 
effects O 
. O 
Since O 
clinical O 
trials O 
are O 
conducted O 
under O 
strict O 
conditions O 
in O 
tightly O 
defined O 
patient O 
populations O 
, O 
evidence O 
of O 
an O 
agent's O 
efficacy O 
and O 
tolerability O 
under O 
' O 
real O 
- O 
world O 
' O 
clinical O 
practice O 
conditions O 
is O 
also O 
required O 
. O 
As O 
in O 
clinical O 
trials O 
, O 
real O 
- O 
life O 
case O 
reports O 
demonstrate O 
that O 
asenapine B-TRIVIAL 
is O 
effective O 
in O 
treating O 
the O 
positive O 
symptoms O 
of O 
schizophrenia O 
, O 
both O 
in O 
the O 
acute O 
setting O 
and O 
for O 
relapse O 
prevention O 
. O 
It O 
is O 
also O 
effective O 
in O 
treating O 
negative O 
symptoms O 
and O 
shows O 
promise O 
in O 
the O 
treatment O 
of O 
depressive O 
symptoms O 
associated O 
with O 
schizophrenia O 
. O 
Asenapine B-TRIVIAL 
has O 
a O 
favourable O 
tolerability O 
profile O 
, O 
having O 
a O 
minimal O 
impact O 
on O 
weight O 
and O 
metabolic O 
parameters O 
. O 
As O 
such O 
, O 
asenapine B-TRIVIAL 
is O 
valuable O 
option O 
for O 
the O 
treatment O 
of O 
schizophrenia O 
in O 
adults O 
. O 

of O 
Chemical O 
Sensitizers O 
Toward O 
Amino B-FAMILY 
Acids I-FAMILY 
In O 
Cellulo O 
Plays O 
a O 
Role O 
in O 
the O 
Activation O 
of O 
the O 
Nrf2-ARE O 
Pathway O 
in O 
Human O 
Monocyte O 
Dendritic O 
Cells O 
and O 
the O 
THP-1 O 
Cell O 
Line O 
. O 

contact O 
dermatitis O 
resulting O 
from O 
skin O 
sensitization O 
is O 
an O 
inflammatory O 
skin O 
disease O 
linked O 
to O 
the O 
use O 
of O 
chemicals O 
termed O 
haptens O 
. O 
Chemical O 
reactivity O 
is O 
necessary O 
for O 
a O 
chemical O 
to O 
be O 
a O 
sensitizer O 
, O 
allowing O 
both O 
covalent O 
binding O 
to O 
proteins O 
and O 
maturation O 
of O 
dendritic O 
cells O 
( O 
DCs O 
) O 
by O 
mimicking O 
" O 
danger O 
signals O 
. O 
" O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
how O 
the O 
reactivity O 
of O 
chemical O 
sensitizers O 
toward O 
amino B-FAMILY 
acids I-FAMILY 
translates O 
into O 
a O 
biological O 
response O 
using O 
the O 
activation O 
of O 
the O 
nuclear O 
factor O 
- O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
pathway O 
, O 
which O 
was O 
assessed O 
by O 
the O 
induction O 
of O 
three O 
Nrf2 O 
target O 
genes O 
( O 
ho-1 O 
, O 
nqo1 O 
, O 
and O 
il-8 O 
) O 
and O 
Nrf2 O 
protein O 
accumulation O 
. O 
Nrf2 O 
activation O 
is O 
known O 
to O 
play O 
a O 
role O 
in O 
numerous O 
detoxification O 
mechanisms O 
that O 
could O 
regulate O 
danger O 
signal O 
outcomes O 
in O 
myeloid O 
cells O 
. O 
Monocyte O 
- O 
derived O 
DCs O 
and O 
THP-1 O 
cells O 
were O 
exposed O 
to O 
( O 
a O 
) O 
haptens O 
with O 
cysteine B-TRIVIAL 
, O 
lysine B-TRIVIAL 
, O 
or O 
cysteine B-TRIVIAL 
/ O 
lysine B-TRIVIAL 
reactivity O 
, O 
( O 
b O 
) O 
pro- O 
/ O 
prehaptens O 
, O 
and O 
( O 
c O 
) O 
nonsensitizing O 
molecules O 
with O 
reducing O 
or O 
oxidative O 
properties O 
( O 
17 O 
molecules O 
in O 
total O 
) O 
. O 
Chemicals O 
were O 
classified O 
as O 
" O 
Nrf2 O 
pathway O 
activators O 
" O 
when O 
at O 
least O 
two O 
Nrf2 O 
target O 
genes O 
associated O 
with O 
Nrf2 O 
protein O 
expression O 
were O 
induced O 
. O 
Results O 
showed O 
that O 
most O 
chemical O 
sensitizers O 
having O 
cysteine B-TRIVIAL 
and O 
cysteine B-TRIVIAL 
/ O 
lysine B-TRIVIAL 
affinities O 
were O 
inducers O 
of O 
the O 
Nrf2 O 
pathway O 
in O 
both O 
cell O 
models O 
, O 
whereas O 
lysine B-TRIVIAL 
-reactive O 
chemicals O 
were O 
less O 
efficient O 
. O 
In O 
THP-1 O 
cells O 
, O 
the O 
Nrf2 O 
pathway O 
was O 
also O 
activated O 
by O 
pro- O 
/ O 
prehaptens O 
. O 
Regression O 
analysis O 
revealed O 
that O 
ho-1 O 
and O 
nqo1 O 
expressions O 
were O 
found O 
to O 
be O 
associated O 
with O 
chemical O 
sensitizer O 
reactivity O 
to O 
cysteine B-TRIVIAL 
, O 
providing O 
evidence O 
of O 
the O 
importance O 
of O 
chemical O 
reactivity O 
, O 
as O 
a O 
part O 
of O 
danger O 
signals O 
, O 
in O 
DC O 
biology O 
. O 

overview O 
on O 
the O 
marine O 
neurotoxin O 
, O 
saxitoxin B-TRIVIAL 
: O 
genetics O 
, O 
molecular O 
targets O 
, O 
methods O 
of O 
detection O 
and O 
ecological O 
functions O 
. O 

neurotoxins O 
are O 
natural O 
products O 
produced O 
by O 
phytoplankton O 
and O 
select O 
species O 
of O 
invertebrates O 
and O 
fish O 
. O 
These O 
compounds O 
interact O 
with O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
and O 
calcium B-SYSTEMATIC 
channels O 
and O 
modulate O 
the O 
flux O 
of O 
these O 
ions O 
into O 
various O 
cell O 
types O 
. O 
This O 
review O 
provides O 
a O 
summary O 
of O 
marine O 
neurotoxins O 
, O 
including O 
their O 
structures O 
, O 
molecular O 
targets O 
and O 
pharmacologies O 
. O 
Saxitoxin B-TRIVIAL 
and O 
its O 
derivatives O 
, O 
collectively O 
referred O 
to O 
as O 
paralytic O 
shellfish O 
toxins O 
( O 
PSTs O 
) O 
, O 
are O 
unique O 
among O 
neurotoxins O 
in O 
that O 
they O 
are O 
found O 
in O 
both O 
marine O 
and O 
freshwater O 
environments O 
by O 
organisms O 
inhabiting O 
two O 
kingdoms O 
of O 
life O 
. O 
Prokaryotic O 
cyanobacteria O 
are O 
responsible O 
for O 
PST O 
production O 
in O 
freshwater O 
systems O 
, O 
while O 
eukaryotic O 
dinoflagellates O 
are O 
the O 
main O 
producers O 
in O 
marine O 
waters O 
. O 
Bioaccumulation O 
by O 
filter O 
- O 
feeding O 
bivalves O 
and O 
fish O 
and O 
subsequent O 
transfer O 
through O 
the O 
food O 
web O 
results O 
in O 
the O 
potentially O 
fatal O 
human O 
illnesses O 
, O 
paralytic O 
shellfish O 
poisoning O 
and O 
saxitoxin B-TRIVIAL 
pufferfish O 
poisoning O 
. O 
These O 
illnesses O 
are O 
a O 
result O 
of O 
saxitoxin B-TRIVIAL 
' O 
s O 
ability O 
to O 
bind O 
to O 
the O 
voltage O 
- O 
gated O 
sodium B-SYSTEMATIC 
channel O 
, O 
blocking O 
the O 
passage O 
of O 
nerve O 
impulses O 
and O 
leading O 
to O 
death O 
via O 
respiratory O 
paralysis O 
. O 
Recent O 
advances O 
in O 
saxitoxin B-TRIVIAL 
research O 
are O 
discussed O 
, O 
including O 
the O 
molecular O 
biology O 
of O 
toxin O 
synthesis O 
, O 
new O 
protein O 
targets O 
, O 
association O 
with O 
metal O 
- O 
binding O 
motifs O 
and O 
methods O 
of O 
detection O 
. O 
The O 
eco O 
- O 
evolutionary O 
role(s) O 
PSTs O 
may O 
serve O 
for O 
phytoplankton O 
species O 
that O 
produce O 
them O 
are O 
also O 
discussed O 
. O 

janus O 
kinases O 
( O 
JAK O 
) O 
, O 
extracellular O 
signal O 
- O 
regulated O 
kinases O 
( O 
ERK O 
) O 
and O 
signal O 
transducers O 
and O 
activators O 
of O 
transcription O 
( O 
STAT O 
) O 
pathways O 
have O 
been O 
shown O 
to O 
play O 
a O 
cardioprotective O 
role O 
. O 
We O 
previously O 
gave O 
evidence O 
that O 
melanocortins O 
afford O 
cardioprotection O 
in O 
conditions O 
of O 
myocardial O 
ischemia O 
/ O 
reperfusion O 
. O 
Here O 
we O 
aimed O 
to O 
investigate O 
the O 
influence O 
of O 
melanocortins O 
on O 
the O 
JAK O 
/ O 
ERK O 
/ O 
STAT O 
signaling O 
in O 
cardiac O 
and O 
systemic O 
responses O 
to O 
prolonged O 
myocardial O 
ischemia O 
/ O 
reperfusion O 
. O 
Ischemia O 
was O 
produced O 
in O 
rats O 
by O 
ligature O 
of O 
the O 
left O 
anterior O 
descending O 
coronary O 
artery O 
for O 
30min O 
. O 
At O 
the O 
end O 
of O 
the O 
2-h O 
reperfusion O 
, O 
western O 
blot O 
analysis O 
of O 
the O 
cardioprotective O 
transcription O 
factors O 
pJAK2 O 
, O 
pERK1 O 
/ O 
2 O 
, O 
pTyr-STAT3 O 
and O 
pSer-STAT3 O 
, O 
the O 
inflammatory O 
mediator O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
the O 
pro O 
- O 
apoptotic O 
factors O 
BAX O 
and O 
c-jun O 
N B-FORMULA 
-terminal O 
kinases O 
( O 
pJNK O 
) O 
, O 
the O 
anti-apoptotic O 
protein O 
Bcl-XL O 
, O 
as O 
well O 
as O 
of O 
the O 
cardioprotective O 
enzyme O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
, O 
was O 
performed O 
in O 
the O 
left O 
ventricle O 
and O 
spleen O 
. O 
Intravenous O 
treatment O 
, O 
during O 
coronary O 
artery O 
occlusion O 
, O 
with O 
the O 
melanocortin O 
analogs O 
[ O 
Nle B-FORMULA 
( O 
4 O 
) O 
, O 
D-Phe B-FORMULA 
(7)]α-melanocyte O 
- O 
stimulating O 
hormone O 
( O 
NDP-α-MSH O 
) O 
and O 
adrenocorticotropic O 
hormone O 
1-24 O 
[ACTH-(1-24)] O 
, O 
induced O 
a O 
left O 
ventricle O 
up O 
- O 
regulation O 
of O 
pJAK2 O 
, O 
pERK1 O 
/ O 
2 O 
and O 
pTyr-STAT3 O 
( O 
JAK-dependent O 
) O 
, O 
and O 
a O 
reduction O 
in O 
pJNK O 
and O 
TNF-α O 
levels O 
; O 
these O 
effects O 
of O 
NDP-α-MSH O 
and O 
ACTH-(1-24) O 
were O 
associated O 
with O 
over O 
- O 
expression O 
of O 
the O 
pro O 
- O 
survival O 
proteins O 
HO-1 O 
and O 
Bcl-XL O 
, O 
and O 
marked O 
decrease O 
of O 
the O 
myocardial O 
infarct O 
size O 
. O 
Melanocortin O 
treatment O 
did O 
not O 
affect O 
left O 
ventricle O 
pSer-STAT3 O 
( O 
ERK1 O 
/ O 
2-dependent O 
) O 
and O 
BAX O 
levels O 
. O 
In O 
the O 
spleen O 
, O 
NDP-α-MSH O 
and O 
ACTH-(1-24) O 
induced O 
similar O 
effects O 
on O 
the O 
expression O 
of O 
the O 
above O 
transcription O 
factors O 
/ O 
proteins O 
, O 
except O 
for O 
pERK1 O 
/ O 
2 O 
( O 
down O 
- O 
regulated O 
) O 
and O 
HO-1 O 
( O 
unaffected O 
) O 
. O 
Blockade O 
of O 
JAK O 
and O 
ERK O 
pathways O 
with O 
AG490 B-TRIVIAL 
and O 
U0126 B-IDENTIFIER 
, O 
respectively O 
, O 
abrogated O 
the O 
myocardial O 
infarct O 
size O 
reduction O 
by O 
NDP-α-MSH O 
. O 
These O 
results O 
indicate O 
that O 
melanocortins O 
inhibit O 
local O 
and O 
systemic O 
inflammatory O 
and O 
apoptotic O 
cascades O 
triggered O 
by O 
prolonged O 
myocardial O 
ischemia O 
/ O 
reperfusion O 
, O 
with O 
consequent O 
reduction O 
in O 
myocardium O 
infarct O 
size O 
, O 
seemingly O 
via O 
activation O 
of O 
the O 
JAK O 
/ O 
STAT O 
signaling O 
and O 
with O 
modulation O 
of O 
an O 
ERK O 
( O 
STAT O 
unrelated O 
) O 
signaling O 
pathway O 
. O 

potassium B-SYSTEMATIC 
selectivity O 
and O 
proton O 
blocking O 
in O 
a O 
hybrid O 
biological O 
/ O 
solid O 
- O 
state O 
polymer O 
nanoporous O 
membrane O 
. O 

the O 
sensitivity O 
of O 
geographically O 
distinct O 
Lemna O 
minor O 
populations O 
to O 
atrazine B-TRIVIAL 
. O 

objectives O 
of O 
this O 
study O 
were O 
to O 
compare O 
the O 
sensitivities O 
of O 
field O 
populations O 
and O 
a O 
laboratory O 
culture O 
of O 
a O 
duckweed O 
species O 
( O 
Lemna O 
minor O 
) O 
to O 
the O 
herbicide O 
atrazine B-TRIVIAL 
using O 
three O 
different O 
endpoints O 
and O 
to O 
determine O 
whether O 
sensitivity O 
to O 
atrazine B-TRIVIAL 
was O 
affected O 
by O 
past O 
exposure O 
to O 
the O 
herbicide O 
. O 
L O 
. O 
minor O 
cultures O 
were O 
purchased O 
commercially O 
or O 
collected O 
from O 
field O 
sites O 
within O 
an O 
agricultural O 
watershed O 
and O 
exposed O 
to O 
atrazine B-TRIVIAL 
for O 
7 O 
days O 
under O 
greenhouse O 
conditions O 
. O 
Populations O 
differed O 
significantly O 
in O 
their O 
sensitivity O 
to O 
atrazine B-TRIVIAL 
. O 
Biomass O 
was O 
more O 
sensitive O 
than O 
frond O 
number O 
, O 
while O 
chlorophyll O 
fluorescence O 
was O 
not O 
a O 
sensitive O 
endpoint O 
. O 
Overall O 
, O 
the O 
sensitivity O 
of O 
the O 
various O 
populations O 
to O 
atrazine B-TRIVIAL 
was O 
not O 
strongly O 
related O 
to O 
measures O 
of O 
past O 
exposure O 
to O 
agriculture O 
stressors O 
. O 
Positive O 
correlations O 
between O 
biomass O 
twenty O 
- O 
five O 
percent O 
inhibition O 
concentrations O 
( O 
IC25s O 
) O 
, O 
biomass O 
estimated O 
marginal O 
means O 
and O 
in O 
- O 
stream O 
atrazine B-TRIVIAL 
concentrations O 
were O 
observed O 
, O 
providing O 
evidence O 
that O 
atrazine B-TRIVIAL 
exposure O 
is O 
linked O 
to O 
a O 
decrease O 
in O 
sensitivity O 
to O 
atrazine B-TRIVIAL 
. O 
However O 
, O 
IC25s O 
generated O 
for O 
each O 
population O 
were O 
similar O 
, O 
ranging O 
from O 
19 O 
to O 
40 O 
and O 
57 O 
to O 
92 O 
μg O 
/ O 
L O 
atrazine B-TRIVIAL 
for O 
biomass O 
and O 
frond O 
data O 
respectively O 
, O 
and O 
likely O 
do O 
not O 
represent O 
biologically O 
significant O 
differences O 
in O 
atrazine B-TRIVIAL 
sensitivity O 
. O 
Given O 
the O 
small O 
range O 
in O 
sensitivity O 
observed O 
between O 
populations O 
, O 
commercial O 
laboratory O 
cultures O 
appear O 
to O 
provide O 
a O 
good O 
estimate O 
of O 
the O 
sensitivity O 
of O 
field O 
populations O 
of O 
L O 
. O 
minor O 
to O 
atrazine B-TRIVIAL 
and O 
should O 
continue O 
to O 
be O 
used O 
in O 
regulatory O 
phytotoxicity O 
testing O 
. O 

arrests O 
cell O 
cycle O 
of O 
gastric O 
carcinoma O 
cancer O 
cells O 
by O 
a O 
MAPK O 
pathway O 
. O 

is O 
an O 
end O 
ring O 
analog O 
of O 
β-carotenoid O 
which O 
has O 
been O 
shown O 
to O 
possess O 
potent O 
anti-proliferative O 
activity O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
To O 
investigate O 
the O 
possible O 
inhibitory O 
effects O 
of O 
β-ionone B-TRIVIAL 
, O 
we O 
studied O 
cell O 
growth O 
characteristics O 
, O 
DNA O 
synthesis O 
, O 
cell O 
cycle O 
progression O 
, O 
as O 
well O 
as O 
mitogen O 
- O 
activated O 
protein O 
kinases O 
( O 
MAPKs O 
) O 
pathways O 
in O 
the O 
human O 
gastric O 
adenocarcinoma O 
cancer O 
cell O 
line O 
( O 
SGC-7901 O 
) O 
. O 
Our O 
results O 
show O 
that O 
cell O 
growth O 
and O 
DNA O 
synthesis O 
were O 
inhibited O 
, O 
and O 
the O 
cell O 
cycle O 
was O 
arrested O 
at O 
the O 
G0 O 
/ O 
G1 O 
phase O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
in O 
cells O 
treated O 
with O 
β-ionone B-TRIVIAL 
( O 
25 O 
, O 
50 O 
, O 
100 O 
and O 
200 O 
μmol O 
/ O 
L O 
) O 
for O 
24 O 
h O 
. O 
We O 
found O 
that O 
the O 
β-ionone B-TRIVIAL 
significantly O 
decreased O 
the O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
protein O 
expression O 
and O 
significantly O 
increased O 
the O 
levels O 
of O 
p38 O 
and O 
Jun- O 
amino B-FAMILY 
-terminal O 
kinase O 
protein O 
expression O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
β-Ionone B-TRIVIAL 
also O 
inhibited O 
cell O 
cycle O 
- O 
related O 
proteins O 
of O 
Cdk4 O 
, O 
Cyclin O 
B1 O 
, O 
D1 O 
and O 
increased O 
p27 O 
protein O 
expression O 
in O 
SGC-7901 O 
cells O 
. O 
These O 
results O 
suggested O 
that O 
the O 
cell O 
cycle O 
arrest O 
observed O 
may O 
be O 
regulated O 
through O 
a O 
MAPK O 
pathway O 
by O 
transcriptional O 
down O 
- O 
regulation O 
of O 
cell O 
cycle O 
proteins O 
. O 
These O 
results O 
demonstrate O 
potent O 
ability O 
of O 
β-ionone B-TRIVIAL 
to O 
arrest O 
cell O 
cycle O 
of O 
SGC-7901 O 
cells O 
and O 
decrease O 
proliferation O 
. O 

formation O 
of O 
neutrophil O 
extracellular O 
traps O 
( O 
NETs O 
) O 
is O 
a O 
newly O 
described O 
phenomenon O 
that O 
increases O 
the O 
bacteria O 
killing O 
ability O 
and O 
the O 
inflammatory O 
response O 
of O 
neutrophils O 
. O 
Because O 
NET O 
generation O 
occurs O 
in O 
an O 
inflammatory O 
microenvironment O 
, O 
we O 
examined O 
its O 
regulation O 
by O 
anti-inflammatory O 
drugs O 
. O 
Treatment O 
of O 
neutrophils O 
with O 
dexamethasone B-TRIVIAL 
had O 
no O 
effect O 
while O 
acetylsalicylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
ASA B-ABBREVIATION 
) O 
treatment O 
prevented O 
NET O 
formation O 
. O 
NETosis O 
was O 
also O 
abrogated O 
by O 
the O 
presence O 
of O 
BAY B-IDENTIFIER 
11-7082 I-IDENTIFIER 
and O 
Ro B-IDENTIFIER 
106-9920 I-IDENTIFIER 
, O 
two O 
structurally O 
unrelated O 
NF-κB O 
inhibitors O 
. O 
The O 
decrease O 
in O 
NET O 
formation O 
mediated O 
by O 
ASA B-ABBREVIATION 
, O 
BAY-11-7082 B-IDENTIFIER 
and O 
Ro B-IDENTIFIER 
106-9920 I-IDENTIFIER 
was O 
correlated O 
with O 
a O 
significant O 
reduction O 
in O 
the O 
phosphorylation O 
of O 
NF-κB O 
p65 O 
subunit O 
, O 
indicating O 
that O 
the O 
activation O 
of O 
this O 
transcription O 
factor O 
is O 
a O 
relevant O 
signaling O 
pathway O 
involved O 
in O 
the O 
generation O 
of O 
DNA O 
traps O 
. O 
The O 
inhibitory O 
effect O 
of O 
these O 
drugs O 
was O 
also O 
observed O 
when O 
NET O 
generation O 
was O 
induced O 
under O 
acidic O 
or O 
hyperthermic O 
conditions O 
, O 
two O 
stress O 
signals O 
of O 
the O 
inflammatory O 
microenvironment O 
. O 
In O 
a O 
mouse O 
peritonitis O 
model O 
, O 
while O 
pretreatment O 
of O 
animals O 
with O 
ASA B-ABBREVIATION 
or O 
BAY B-IDENTIFIER 
11-7082 I-IDENTIFIER 
resulted O 
in O 
a O 
marked O 
suppression O 
of O 
NET O 
formation O 
along O 
with O 
increased O 
bacteremia O 
, O 
dexamethasone B-TRIVIAL 
had O 
no O 
effect O 
. O 
Our O 
results O 
show O 
that O 
NETs O 
have O 
an O 
important O 
role O 
in O 
the O 
local O 
control O 
of O 
infection O 
and O 
that O 
ASA B-ABBREVIATION 
and O 
NF-κB O 
blockade O 
could O 
be O 
useful O 
therapies O 
to O 
avoid O 
undesired O 
effect O 
of O 
persistent O 
neutrophil O 
activation O 
. O 

Plasma O 
Glucose B-TRIVIAL 
at O 
24-28 O 
Weeks O 
to O 
Screen O 
for O 
Gestational O 
Diabetes O 
Mellitus O 
: O 
New O 
evidence O 
from O 
China O 
. O 

evaluate O 
the O 
usefulness O 
of O 
a O 
fasting O 
plasma O 
glucose B-TRIVIAL 
( O 
FPG O 
) O 
at O 
24-28 O 
weeks O 
' O 
gestation O 
to O 
screen O 
for O 
gestational O 
diabetes O 
mellitus O 
(GDM).RESEARCH O 
DESIGN O 
AND O 
METHODSThe O 
medical O 
records O 
and O 
results O 
of O 
a O 
75-g O 
2-h O 
oral O 
glucose B-TRIVIAL 
tolerance O 
test O 
( O 
OGTT O 
) O 
of O 
24854 O 
pregnant O 
women O 
without O 
known O 
pre-GDM O 
attending O 
prenatal O 
clinics O 
in O 
15 O 
hospitals O 
in O 
China O 
were O 
examined.RESULTSFPG O 
cutoff O 
value O 
of O 
5.1 O 
mmol O 
/ O 
L O 
identified O 
3149 O 
( O 
12.1% O 
) O 
pregnant O 
women O 
with O 
GDM O 
. O 
FPG O 
cutoff O 
value O 
of O 
4.4 O 
mmol O 
/ O 
L O 
ruled O 
out O 
GDM O 
in O 
15369 O 
( O 
38.2% O 
) O 
women O 
. O 
With O 
use O 
of O 
this O 
cutoff O 
point O 
, O 
12.2% O 
of O 
patients O 
with O 
mild O 
GDM O 
will O 
be O 
missed O 
. O 
The O 
positive O 
predictive O 
value O 
is O 
0.322 O 
, O 
and O 
the O 
negative O 
predictive O 
value O 
is O 
0.928.CONCLUSIONSFPG O 
at O 
24-28 O 
weeks O 
' O 
gestation O 
could O 
be O 
used O 
as O 
a O 
screening O 
test O 
to O 
identify O 
GDM O 
patients O 
in O 
low O 
- O 
resource O 
regions O 
. O 
Women O 
with O 
an O 
FPG O 
between O 
≥ O 
4.4 O 
and O 
≤ O 
5 O 
mmol O 
/ O 
L O 
would O 
require O 
a O 
75-g O 
OGTT O 
to O 
diagnose O 
GDM O 
. O 
This O 
would O 
help O 
to O 
avoid O 
approximately O 
one O 
- O 
half O 
( O 
50.3% O 
) O 
of O 
the O 
formal O 
75-g O 
OGTTs O 
in O 
China O 
. O 

and O 
Safety O 
of O 
Lixisenatide O 
Once-Daily O 
Morning O 
or O 
Evening O 
Injections O 
in O 
Type O 
2 O 
Diabetes O 
Inadequately O 
Controlled O 
on O 
Metformin B-TRIVIAL 
( O 
GetGoal-M O 
) O 
. O 

the O 
efficacy O 
and O 
safety O 
of O 
lixisenatide O 
( O 
20 O 
μg O 
once O 
daily O 
, O 
administered O 
before O 
the O 
morning O 
or O 
evening O 
meal O 
) O 
as O 
add O 
- O 
on O 
therapy O 
in O 
type O 
2 O 
diabetes O 
patients O 
insufficiently O 
controlled O 
with O 
metformin B-TRIVIAL 
alone.RESEARCH O 
DESIGN O 
AND O 
METHODSA O 
24-week O 
, O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
study O 
in O 
680 O 
patients O 
with O 
inadequately O 
controlled O 
type O 
2 O 
diabetes O 
( O 
HbA1c O 
7-10% O 
[ O 
53-86 O 
mmol O 
/ O 
mol O 
] O 
) O 
. O 
Patients O 
were O 
randomized O 
to O 
lixisenatide O 
morning O 
( O 
n O 
= O 
255 O 
) O 
, O 
lixisenatide O 
evening O 
( O 
n O 
= O 
255 O 
) O 
, O 
placebo O 
morning O 
( O 
n O 
= O 
85 O 
) O 
, O 
or O 
placebo O 
evening O 
( O 
n O 
= O 
85 O 
) O 
injections.RESULTSLixisenatide O 
morning O 
injection O 
significantly O 
reduced O 
mean O 
HbA1c O 
versus O 
combined O 
placebo O 
( O 
mean O 
change O 
-0.9% O 
[ O 
9.8 O 
mmol O 
/ O 
mol O 
] O 
vs O 
. O 
-0.4% O 
[ O 
4.4 O 
mmol O 
/ O 
mol O 
] O 
; O 
least O 
squares O 
[ O 
LS O 
] O 
mean O 
difference O 
vs O 
. O 
placebo O 
-0.5% O 
[ O 
5.5 O 
mmol O 
/ O 
mol O 
] O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
HbA1c O 
was O 
significantly O 
reduced O 
by O 
lixisenatide O 
evening O 
injection O 
( O 
mean O 
change O 
-0.8% O 
[ O 
8.7 O 
mmol O 
/ O 
mol O 
] O 
vs O 
. O 
-0.4% O 
[ O 
4.4 O 
mmol O 
/ O 
mol O 
] O 
; O 
LS O 
mean O 
difference O 
-0.4% O 
[ O 
4.4 O 
mmol O 
/ O 
mol O 
] O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
Lixisenatide O 
morning O 
injection O 
significantly O 
reduced O 
2-h O 
postprandial O 
glucose B-TRIVIAL 
versus O 
morning O 
placebo O 
( O 
mean O 
change O 
-5.9 O 
vs O 
. O 
-1.4 O 
mmol O 
/ O 
L O 
; O 
LS O 
mean O 
difference O 
-4.5 O 
mmol O 
/ O 
L O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
LS O 
mean O 
difference O 
in O 
fasting O 
plasma O 
glucose B-TRIVIAL 
was O 
significant O 
in O 
both O 
morning O 
( O 
-0.9 O 
mmol O 
/ O 
L O 
, O 
P O 
< O 
0.0001 O 
) O 
and O 
evening O 
( O 
-0.6 O 
mmol O 
/ O 
L O 
, O 
P O 
= O 
0.0046 O 
) O 
groups O 
versus O 
placebo O 
. O 
Mean O 
body O 
weight O 
decreased O 
to O 
a O 
similar O 
extent O 
in O 
all O 
groups O 
. O 
Rates O 
of O 
adverse O 
events O 
were O 
69.4% O 
in O 
both O 
lixisenatide O 
groups O 
and O 
60.0% O 
in O 
the O 
placebo O 
group O 
. O 
Rates O 
for O 
nausea O 
and O 
vomiting O 
were O 
22.7 O 
and O 
9.4% O 
for O 
lixisenatide O 
morning O 
and O 
21.2 O 
and O 
13.3% O 
for O 
lixisenatide O 
evening O 
versus O 
7.6 O 
and O 
2.9% O 
for O 
placebo O 
, O 
respectively O 
. O 
Symptomatic O 
hypoglycemia O 
occurred O 
in O 
6 O 
, O 
13 O 
, O 
and O 
1 O 
patient O 
for O 
lixisenatide O 
morning O 
, O 
evening O 
, O 
and O 
placebo O 
, O 
respectively O 
, O 
with O 
no O 
severe O 
episodes.CONCLUSIONSIn O 
patients O 
with O 
type O 
2 O 
diabetes O 
inadequately O 
controlled O 
on O 
metformin B-TRIVIAL 
, O 
lixisenatide O 
20 O 
μg O 
once O 
daily O 
administered O 
in O 
the O 
morning O 
or O 
evening O 
significantly O 
improved O 
glycemic O 
control O 
, O 
with O 
a O 
pronounced O 
postprandial O 
effect O 
, O 
and O 
was O 
well O 
tolerated O 
. O 

Suppressor O 
Protein O 
p53 O 
Negatively O 
Regulates O 
Human O 
Pregnane B-TRIVIAL 
X O 
Receptor O 
Activity O 
. O 

anodic O 
allylation O 
and O 
benzylation O 
of O 
carbons B-FAMILY 
using O 
allyl B-SYSTEMATIC 
and O 
benzyl B-SYSTEMATIC 
trimethylsilanes B-FAMILY 
. O 

easy O 
process O 
for O 
allylation O 
and O 
benzylation O 
of O 
different O 
carbon B-SYSTEMATIC 
materials O 
, O 
primarily O 
of O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
, O 
in O 
acetonitrile B-SYSTEMATIC 
solutions O 
containing O 
tetraalkyammonium B-FAMILY 
salts O 
is O 
described O 
. O 
The O 
method O 
relies O 
on O 
the O 
capability O 
of O 
C B-FORMULA 
(sp(2)) O 
zones O 
of O 
glassy B-TRIVIAL 
carbon I-TRIVIAL 
( O 
graphite B-TRIVIAL 
and O 
fullerene B-TRIVIAL 
-like O 
inclusions O 
) O 
to O 
be O 
anodically O 
charged O 
at O 
potentials O 
> O 
1.5 O 
V O 
versus O 
Ag B-FORMULA 
/ O 
AgCl B-FORMULA 
to O 
form O 
electrophilic O 
centers O 
reacting O 
with O 
substituted O 
trimethylsilanes B-FAMILY 
RSiMe3 B-FAMILY 
. O 
Great O 
propensity O 
of O 
the O 
trimethylsilyl B-SYSTEMATIC 
group O 
( O 
TMS(+) B-ABBREVIATION 
) O 
to O 
act O 
as O 
a O 
cationic O 
leaving O 
group O 
facilitates O 
electrophilic O 
reactions O 
of O 
the O 
charged O 
anodic O 
surface O 
with O 
R-carrying O 
silylated O 
precursors O 
, O 
permitting O 
efficient O 
grafting O 
of O 
a O 
large O 
variety O 
of O 
R O 
groups O 
. O 
The O 
present O 
preliminary O 
work O 
focuses O 
only O 
on O 
the O 
efficient O 
grafting O 
of O 
benzyl B-SYSTEMATIC 
and O 
allyl B-SYSTEMATIC 
moieties O 
. O 

-soluble O 
nanocatalysts O 
with O 
no O 
bulk O 
phase O 
: O 
coplanar O 
, O 
two O 
- O 
coordinate O 
arrays O 
of O 
the O 
base O 
metals O 
. O 

structurally O 
unique O 
class O 
of O 
hydrocarbon B-FAMILY 
-soluble O 
, O 
ancillary O 
- O 
ligand O 
- O 
free O 
, O 
tetrametallic O 
Co B-FORMULA 
(I) I-FORMULA 
and O 
Ni B-FORMULA 
(I) I-FORMULA 
clusters O 
is O 
reported O 
. O 
The O 
highly O 
unsaturated O 
complexes O 
are O 
supported O 
by O 
simple O 
, O 
sterically O 
bulky O 
phosphoranimide B-SYSTEMATIC 
ligands O 
, O 
one O 
per O 
metal O 
. O 
The O 
electron O 
- O 
rich O 
nitrogen B-SYSTEMATIC 
centers O 
are O 
strongly O 
bridging O 
but O 
sterically O 
limited O 
to O 
bimetallic O 
interactions O 
. O 
The O 
hydrocarbon B-FAMILY 
-soluble O 
clusters O 
consist O 
of O 
four O 
coplanar O 
metal O 
centers O 
, O 
mutually O 
bridged O 
by O 
single O 
nitrogen B-SYSTEMATIC 
atoms O 
. O 
Each O 
metal O 
center O 
is O 
monovalent O 
, O 
rigorously O 
linear O 
, O 
and O 
two O 
- O 
coordinate O 
. O 
The O 
clusters O 
are O 
in O 
essence O 
two O 
- O 
dimensional O 
atomic O 
- O 
scale O 
" O 
molecular O 
squares O 
, O 
" O 
a O 
structural O 
motif O 
adapted O 
from O 
supramolecular O 
chemistry O 
. O 
Both O 
clusters O 
exhibit O 
high O 
solution O 
- O 
phase O 
magnetic O 
susceptibility O 
at O 
room O 
temperature O 
, O 
suggesting O 
the O 
potential O 
for O 
applications O 
in O 
molecular O 
electronics O 
. O 
Designed O 
to O 
be O 
catalyst O 
precursors O 
, O 
both O 
clusters O 
exhibit O 
high O 
activity O 
for O 
catalytic O 
hydrogenation O 
of O 
unsaturated B-FAMILY 
hydrocarbons I-FAMILY 
at O 
low O 
pressure O 
and O 
temperature O 
. O 

drying O 
method O 
for O 
large O 
- O 
scale O 
and O 
high O 
- O 
performance O 
silicon B-SYSTEMATIC 
negative O 
electrodes O 
in O 
li B-FORMULA 
-ion O 
batteries O 
. O 

silicon B-SYSTEMATIC 
electrodes O 
have O 
shown O 
great O 
potential O 
as O 
lithium B-SYSTEMATIC 
ion O 
battery O 
anodes O 
because O 
they O 
can O 
address O 
capacity O 
fading O 
mechanisms O 
originating O 
from O 
large O 
volume O 
changes O 
of O 
silicon B-SYSTEMATIC 
alloys O 
while O 
delivering O 
extraordinarily O 
large O 
gravimetric O 
capacities O 
. O 
Nonetheless O 
, O 
synthesis O 
of O 
well O 
- O 
defined O 
silicon B-SYSTEMATIC 
nanostructures O 
in O 
an O 
industrially O 
adaptable O 
scale O 
still O 
remains O 
as O 
a O 
challenge O 
. O 
Herein O 
, O 
we O 
adopt O 
an O 
industrially O 
established O 
spray O 
drying O 
process O 
to O 
enable O 
scalable O 
synthesis O 
of O 
silicon B-SYSTEMATIC 
- O 
carbon B-SYSTEMATIC 
composite O 
particles O 
in O 
which O 
silicon B-SYSTEMATIC 
nanoparticles O 
are O 
embedded O 
in O 
porous O 
carbon B-SYSTEMATIC 
particles O 
. O 
The O 
void O 
space O 
existing O 
in O 
the O 
porous O 
carbon B-SYSTEMATIC 
accommodates O 
the O 
volume O 
expansion O 
of O 
silicon B-SYSTEMATIC 
and O 
thus O 
addresses O 
the O 
chronic O 
fading O 
mechanisms O 
of O 
silicon B-SYSTEMATIC 
anodes O 
. O 
The O 
composite O 
electrodes O 
exhibit O 
excellent O 
electrochemical O 
performance O 
, O 
such O 
as O 
1956 O 
mAh O 
/ O 
g O 
at O 
0.05C O 
rate O 
and O 
91% O 
capacity O 
retention O 
after O 
150 O 
cycles O 
. O 
Moreover O 
, O 
the O 
spray O 
drying O 
method O 
requires O 
only O 
2 O 
s O 
for O 
the O 
formation O 
of O 
each O 
particle O 
and O 
allows O 
a O 
production O 
capability O 
of O 
∼10 O 
g O 
/ O 
h O 
even O 
with O 
an O 
ultrasonic O 
- O 
based O 
lab O 
- O 
scale O 
equipment O 
. O 
This O 
investigation O 
suggests O 
that O 
established O 
industrial O 
processes O 
could O 
be O 
adaptable O 
to O 
the O 
production O 
of O 
battery O 
active O 
materials O 
that O 
require O 
sophisticated O 
nanostructures O 
as O 
well O 
as O 
large O 
quantity O 
syntheses O 
. O 

Iron B-SYSTEMATIC 
-Catalyzed O 
Azidation O 
of O 
β-Keto B-FAMILY 
Esters I-FAMILY 
and O 
Oxindoles B-FAMILY 
. O 

first O 
example O 
of O 
Fe B-FORMULA 
-catalyzed O 
enantioselective O 
azidations O 
of O 
β-keto B-FAMILY 
esters I-FAMILY 
and O 
oxindoles B-FAMILY 
using O 
a O 
readily O 
available O 
N3-transfer O 
reagent O 
is O 
reported O 
. O 
A O 
number O 
of O 
α-azido-β-keto B-FAMILY 
esters I-FAMILY 
were O 
obtained O 
with O 
up O 
to O 
93% O 
ee O 
, O 
and O 
this O 
methodology O 
also O 
generates O 
3-substitued B-FAMILY 
3-azidooxindoles I-FAMILY 
with O 
high O 
enantioselectivities O 
( O 
up O 
to O 
94% O 
) O 
. O 

poisoning O 
is O 
a O 
global O 
environmental O 
disease O 
that O 
induces O 
lifelong O 
adverse O 
health O 
effects O 
. O 
The O 
effect O 
of O 
a O 
milk O 
formula O 
consisting O 
of O 
antioxidant O 
of O 
bamboo O 
leaves O 
( O 
AOB O 
) O 
, O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
( O 
Vc O 
) O 
, O 
calcium B-SYSTEMATIC 
lactate I-SYSTEMATIC 
( O 
CaLac B-ABBREVIATION 
) O 
, O 
ferrous B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
FeSO4 B-FORMULA 
) O 
and O 
zinc B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
ZnSO4 B-FORMULA 
) O 
on O 
the O 
reduction O 
of O 
lead O 
and O 
lead O 
- O 
induced O 
oxidative O 
damage O 
in O 
lead O 
- O 
exposed O 
mice O 
was O 
studied O 
. O 
The O 
lead O 
- O 
reducing O 
effect O 
of O 
milk O 
formula O 
was O 
investigated O 
via O 
a O 
7-week O 
toxicokinetics O 
study O 
and O 
a O 
tissue O 
distribution O 
level O 
examination O 
. O 
The O 
ameliorating O 
effect O 
of O 
milk O 
formula O 
on O 
lead O 
- O 
induced O 
oxidative O 
damage O 
was O 
investigated O 
. O 
Results O 
demonstrated O 
current O 
milk O 
formula O 
could O 
effectively O 
reduce O 
blood O 
lead O 
levels O 
( O 
BLLs O 
) O 
and O 
lead O 
distribution O 
levels O 
of O 
liver O 
, O 
kidneys O 
, O 
thighbones O 
and O 
brain O 
in O 
mice O 
based O 
on O 
metal O 
ion O 
- O 
mediated O 
antagonism O 
and O 
chelation O 
mechanisms O 
. O 
This O 
milk O 
formula O 
could O 
not O 
only O 
protect O 
lead O 
- O 
susceptible O 
tissues O 
against O 
lead O 
poisoning O 
, O 
but O 
also O 
maintain O 
normal O 
absorption O 
and O 
distribution O 
of O 
essential O 
elements O 
in O 
vivo O 
. O 
Meanwhile O 
, O 
current O 
milk O 
formula O 
could O 
prevent O 
the O 
reduction O 
of O 
δ-aminolevulinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
dehydratase O 
( O 
δ-ALAD O 
) O 
activity O 
and O 
enhancement O 
of O 
free O 
erythrocyte O 
protoporphyrins B-FAMILY 
( O 
FEP O 
) O 
levels O 
in O 
blood O 
erythrocytes O 
of O 
mice O 
. O 
Also O 
, O 
this O 
formula O 
could O 
indirectly O 
protect O 
blood O 
cell O 
membranes O 
against O 
lead O 
- O 
induced O 
lipid O 
peroxidation O 
. O 
We O 
conclude O 
that O 
current O 
optimized O 
milk O 
formula O 
effectively O 
reduces O 
lead O 
poisoning O 
and O 
lead O 
- O 
induced O 
in O 
vivo O 
oxidative O 
damage O 
in O 
lead O 
- O 
exposed O 
mice O 
. O 

present O 
study O 
focuses O 
on O 
the O 
short O 
term O 
effects O 
of O 
repeated O 
low O 
level O 
administration O 
of O 
turinabol B-TRIVIAL 
and O 
methanabol B-TRIVIAL 
on O 
cardiac O 
function O 
in O 
young O 
rabbits O 
( O 
4months O 
- O 
old O 
) O 
. O 
The O 
experimental O 
scheme O 
consisted O 
of O 
two O 
oral O 
administration O 
periods O 
, O 
lasting O 
1month O 
each O 
, O 
interrupted O 
by O 
1-month O 
wash O 
- O 
out O 
period O 
. O 
Serial O 
echocardiographic O 
evaluation O 
at O 
the O 
end O 
of O 
all O 
three O 
experimental O 
periods O 
was O 
performed O 
in O 
all O 
animals O 
. O 
Oxidative O 
stress O 
markers O 
have O 
also O 
been O 
monitored O 
at O 
the O 
end O 
of O 
each O 
administration O 
period O 
. O 
Treated O 
animals O 
originally O 
showed O 
significantly O 
increased O 
myocardial O 
mass O 
and O 
systolic O 
cardiac O 
output O 
, O 
which O 
normalized O 
at O 
the O 
end O 
of O 
the O 
wash O 
out O 
period O 
. O 
Re-administration O 
led O 
to O 
increased O 
cardiac O 
output O 
, O 
at O 
the O 
cost O 
though O 
of O 
a O 
progressive O 
myocardial O 
mass O 
reduction O 
. O 
A O 
dose O 
- O 
dependent O 
trend O 
towards O 
impaired O 
longitudinal O 
systolic O 
, O 
diastolic O 
and O 
global O 
myocardial O 
function O 
was O 
also O 
observed O 
. O 
The O 
adverse O 
effects O 
were O 
more O 
pronounced O 
in O 
the O 
methanabol B-TRIVIAL 
group O 
. O 
For O 
both O 
anabolic O 
steroids O 
studied O 
, O 
the O 
low O 
dose O 
had O 
no O 
significant O 
effects O 
on O 
oxidative O 
stress O 
markers O 
monitored O 
, O 
while O 
the O 
high O 
dose O 
created O 
a O 
hostile O 
oxidative O 
environment O 
. O 
In O 
conclusion O 
, O 
anabolic O 
administration O 
has O 
been O 
found O 
to O 
create O 
a O 
possible O 
deleterious O 
long O 
term O 
effect O 
on O 
the O 
growth O 
of O 
the O 
immature O 
heart O 
and O 
should O 
be O 
strongly O 
discouraged O 
especially O 
in O 
young O 
human O 
subjects O 
. O 

events O 
can O 
reprogram O 
the O 
hypothalamo O 
- O 
pituitary O 
- O 
adrenal O 
axis O 
for O 
the O 
entire O 
lifespan O 
leading O 
to O 
abnormal O 
glucocorticoid O 
stress O 
- O 
response O 
( O 
GSR O 
) O 
in O 
adulthood O 
: O 
a O 
phenomenon O 
reported O 
to O 
be O 
mediated O 
by O 
changes O 
in O 
DNA O 
methylation O 
of O 
the O 
glucocorticoid O 
receptor O 
( O 
GR O 
) O 
gene O 
promoter O 
. O 
We O 
examined O 
whether O 
in O 
utero O 
and O 
/ O 
or O 
lactational O 
exposure O 
to O 
mixtures O 
of O 
environmental O 
contaminants O 
can O 
also O 
induce O 
abnormal O 
GSR O 
during O 
adulthood O 
. O 
The O 
experiment O 
included O 
nine O 
treatment O 
groups O 
. O 
From O 
gestation O 
day O 
( O 
GD O 
) O 
0 O 
until O 
postnatal O 
day O 
( O 
PND O 
) O 
20 O 
, O 
dams O 
were O 
fed O 
daily O 
with O 
a O 
cookie O 
laced O 
with O 
corn O 
oil O 
( O 
control O 
) O 
or O 
a O 
chemical O 
mixture O 
( O 
M O 
) O 
[ O 
polychlorinated B-FAMILY 
biphenyls I-FAMILY 
( O 
PCBs B-ABBREVIATION 
) O 
, O 
organochlorine B-FAMILY 
pesticides O 
, O 
and O 
methylmercury B-SYSTEMATIC 
] O 
at O 
0.5 O 
or O 
1.0mg O 
/ O 
kg O 
/ O 
day O 
( O 
0.5M O 
, O 
and O 
M O 
) O 
. O 
At O 
birth O 
, O 
some O 
control O 
( O 
C O 
) O 
and O 
M O 
litters O 
were O 
cross O 
- O 
fostered O 
to O 
create O 
four O 
groups O 
with O 
the O 
following O 
in O 
utero O 
/ O 
postnatal O 
exposure O 
: O 
C O 
/ O 
C O 
, O 
M O 
/ O 
C O 
, O 
C O 
/ O 
M O 
, O 
M O 
/ O 
M O 
. O 
Other O 
dams O 
received O 
1.8ng O 
/ O 
kg O 
/ O 
day O 
of O 
a O 
mixture O 
of O 
aryl O 
hydrocarbon B-FAMILY 
receptor O 
( O 
AhR O 
) O 
agonists O 
( O 
non-ortho B-FAMILY 
PCB I-FAMILY 
s O 
, O 
PC-dibenzodioxins B-FAMILY 
and O 
PC-dibenzofurans B-FAMILY 
) O 
without O 
or O 
with O 
0.5M O 
( O 
0.5MAhR O 
) O 
. O 
In O 
adult O 
male O 
offspring O 
the O 
abundance O 
of O 
GR O 
in O 
treated O 
groups O 
was O 
not O 
different O 
from O 
the O 
control O 
, O 
but O 
the O 
AhR O 
and O 
M O 
groups O 
were O 
significantly O 
different O 
from O 
each O 
other O 
with O 
opposite O 
effects O 
in O 
the O 
hippocampus O 
and O 
liver O 
. O 
There O 
was O 
no O 
change O 
in O 
DNA O 
methylation O 
of O 
the O 
GR O 
promoter O 
( O 
exon-17 O 
and O 
-110 O 
) O 
. O 
Abnormal O 
GSRs O 
were O 
detected O 
in O 
the O 
AhR O 
, O 
0.5MAhR O 
, O 
CM O 
, O 
and O 
MM O 
groups O 
. O 
The O 
literature O 
associates O 
abnormal O 
GSR O 
with O 
metabolic O 
and O 
mental O 
health O 
impairments O 
, O 
thus O 
these O 
results O 
support O 
further O 
investigation O 
of O 
the O 
influence O 
of O 
developmental O 
exposure O 
to O 
environmental O 
contaminants O 
and O 
predisposition O 
to O 
stress O 
- O 
induced O 
diseases O 
. O 

pyruvate B-TRIVIAL 
kinase O 
modifications O 
in O 
glioblastoma O 
cells O 
by O 
7β-hydroxycholesterol B-SYSTEMATIC 
and O 
glutamine B-TRIVIAL 
withdrawal O 
. O 

possess O 
anti-proliferative O 
properties O 
that O 
may O 
be O 
used O 
with O 
much O 
effect O 
in O 
the O 
treatment O 
of O 
cancer O 
. O 
We O 
have O 
demonstrated O 
previously O 
that O 
7 B-SYSTEMATIC 
beta-hydroxycholesterol I-SYSTEMATIC 
( O 
7b-HC B-SYSTEMATIC 
) O 
provokes O 
both O 
metabolic O 
stress O 
, O 
as O 
witnessed O 
by O 
AMPK O 
activation O 
, O 
and O 
changes O 
in O 
lipid O 
raft O 
composition O 
in O 
C6 O 
glioblastoma O 
cells O 
. O 
These O 
observations O 
suggested O 
that O 
glycolysis O 
might O 
have O 
been O 
changed O 
. O 
Here O 
we O 
will O 
show O 
that O 
7b-HC B-SYSTEMATIC 
increases O 
cell O 
cycle O 
time O 
and O 
that O 
it O 
changes O 
the O 
affinity O 
of O 
pyruvate B-TRIVIAL 
kinase O 
to O 
its O 
substrate O 
, O 
phosphoenol B-TRIVIAL 
pyruvate I-TRIVIAL 
. O 
The O 
latter O 
effect O 
is O 
mimicked O 
by O 
glutamine B-TRIVIAL 
withdrawal O 
. O 

attenuates O 
metastasis O 
via O 
both O 
ERK O 
and O 
PI3K O 
/ O 
Akt O 
pathways O 
in O 
HGF O 
- O 
treated O 
liver O 
cancer O 
HepG2 O 
cells O 
. O 

growth O 
factor O 
( O 
HGF O 
) O 
, O 
and O 
its O 
receptor O 
, O 
c-Met O 
activation O 
has O 
recently O 
been O 
shown O 
to O 
play O 
important O 
roles O 
in O 
cancer O 
invasion O 
and O 
metastasis O 
in O 
a O 
wide O 
variety O 
of O 
tumor O 
cells O 
. O 
We O 
use O 
HGF O 
as O 
an O 
invasive O 
inducer O 
of O 
human O 
HepG2 O 
cells O 
to O 
investigate O 
the O 
effect O 
of O 
four O 
flavones O 
including O 
apigenin B-TRIVIAL 
, O 
tricetin B-TRIVIAL 
, O 
tangeretin B-TRIVIAL 
, O 
and O 
nobiletin B-TRIVIAL 
on O 
HGF O 
/ O 
c-Met O 
- O 
mediated O 
tumor O 
invasion O 
and O 
metastasis O 
. O 
Among O 
them O 
, O 
nobiletin B-TRIVIAL 
markedly O 
inhibited O 
HGF-induced O 
the O 
abilities O 
of O 
the O 
adhesion O 
, O 
invasion O 
, O 
and O 
migration O 
by O 
cell O 
- O 
matrix O 
adhesion O 
assay O 
and O 
transwell O 
- O 
chamber O 
invasion O 
/ O 
migration O 
assay O 
under O 
non-cytotoxic O 
concentrations O 
. O 
Data O 
also O 
showed O 
nobiletin B-TRIVIAL 
inhibited O 
HGF-induced O 
cell O 
scattering O 
and O 
cytoskeleton O 
changed O 
such O 
as O 
filopodia O 
and O 
lamellipodia O 
. O 
Furthermore O 
, O 
nobiletin B-TRIVIAL 
could O 
inhibit O 
HGF-induced O 
the O 
membrane O 
localization O 
of O 
phosphorylated O 
c-Met O 
, O 
ERK2 O 
, O 
and O 
Akt O 
, O 
but O 
not O 
phosphorylated O 
JNK1 O 
/ O 
2 O 
and O 
p38 O 
. O 
Next O 
, O 
nobiletin B-TRIVIAL 
significantly O 
decreased O 
the O 
levels O 
of O 
phospho B-SYSTEMATIC 
-ERK2 O 
and O 
phospho B-SYSTEMATIC 
-Akt O 
in O 
ERK2 O 
or O 
Akt O 
siRNA-transfected O 
cells O 
concomitantly O 
with O 
a O 
marked O 
reduction O 
on O 
cell O 
invasion O 
and O 
migration O 
. O 
In O 
conclusion O 
, O 
nobiletin B-TRIVIAL 
attenuates O 
HGF-induced O 
HepG2 O 
cells O 
metastasis O 
involving O 
both O 
ERK O 
and O 
PI3K O 
/ O 
Akt O 
pathways O 
and O 
are O 
potentially O 
useful O 
as O 
anti-metastatic O 
agents O 
for O 
the O 
treatment O 
of O 
hepatoma O 
. O 

antibacterial O 
effect O 
of O 
curcumin B-TRIVIAL 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
. O 

-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
are O 
spread O 
among O 
infected O 
patients O 
, O 
with O 
infection O 
rates O 
increasing O 
at O 
an O 
alarming O 
rate O 
. O 
Furthermore O 
, O 
increased O 
resistance O 
to O 
antibiotics O 
has O 
resulted O 
in O 
serious O 
challenges O 
in O 
the O 
treatment O 
of O 
infectious O 
diseases O 
worldwide O 
. O 
Under O 
the O 
selection O 
pressure O 
of O 
exposure O 
to O 
antibiotics O 
, O 
microorganisms O 
evolve O 
to O 
survive O 
against O 
the O 
new O 
conditions O 
imposed O 
by O 
therapy O 
. O 
Therefore O 
, O 
there O 
exists O 
a O 
need O 
to O 
develop O 
alternative O 
natural O 
or O 
combination O 
drug O 
therapies O 
. O 
Curcumin B-TRIVIAL 
( O 
CCM B-ABBREVIATION 
) O 
, O 
a O 
natural O 
polyphenolic B-FAMILY 
flavonoid I-FAMILY 
isolated O 
from O 
the O 
rhizome O 
of O 
a O 
plant O 
, O 
Curcuma O 
longa O 
Linné O 
. O 
, O 
has O 
been O 
found O 
to O 
possess O 
many O 
beneficial O 
biological O 
activities O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
synergistic O 
effect O 
of O 
curcumin B-TRIVIAL 
and O 
antibiotics O 
as O 
well O 
as O 
to O 
determine O 
the O 
antibacterial O 
activity O 
of O 
CCM B-ABBREVIATION 
against O 
specific O 
MRSA O 
strains O 
. O 
The O 
antibacterial O 
activity O 
of O 
CCM B-ABBREVIATION 
was O 
assessed O 
by O 
the O 
broth O 
microdilution O 
method O 
( O 
by O 
calculating O 
the O 
minimal O 
inhibitory O 
concentration O 
[ O 
MIC O 
] O 
) O 
, O 
checkerboard O 
dilution O 
test O 
, O 
and O 
time O 
- O 
kill O 
assay O 
. O 
Antimicrobial O 
activity O 
of O 
CCM B-ABBREVIATION 
was O 
observed O 
against O 
all O 
tested O 
strains O 
. O 
The O 
MICs O 
of O 
CCM B-ABBREVIATION 
against O 
10 O 
strains O 
of O 
S O 
. O 
aureus O 
ranged O 
from O 
125 O 
to O 
250μg O 
/ O 
ml O 
. O 
In O 
the O 
checkerboard O 
test O 
, O 
CCM B-ABBREVIATION 
markedly O 
reduced O 
the O 
MICs O 
of O 
the O 
antibiotics O 
oxacillin B-TRIVIAL 
( O 
OXI B-ABBREVIATION 
) O 
, O 
ampicillin B-TRIVIAL 
( O 
AMP B-ABBREVIATION 
) O 
, O 
ciprofloxacin B-TRIVIAL 
( O 
CIP B-ABBREVIATION 
) O 
, O 
and O 
norfloxacin B-TRIVIAL 
( O 
NOR B-ABBREVIATION 
) O 
used O 
against O 
MRSA O 
. O 
The O 
time O 
- O 
kill O 
curves O 
showed O 
that O 
a O 
combined O 
CCM B-ABBREVIATION 
and O 
OXI B-ABBREVIATION 
treatment O 
reduced O 
the O 
bacterial O 
counts O 
below O 
the O 
lowest O 
detectable O 
limit O 
after O 
24h O 
. O 
This O 
study O 
suggested O 
that O 
CCM B-ABBREVIATION 
reduced O 
the O 
MICs O 
of O 
several O 
antibiotics O 
tested O 
, O 
notably O 
of O 
OXI B-ABBREVIATION 
, O 
AMP B-ABBREVIATION 
, O 
CIP B-ABBREVIATION 
, O 
and O 
NOR B-ABBREVIATION 
, O 
and O 
that O 
CCM B-ABBREVIATION 
in O 
combination O 
with O 
antibiotics O 
could O 
lead O 
to O 
the O 
development O 
of O 
new O 
combination O 
of O 
antibiotics O 
against O 
MRSA O 
infection O 
. O 

activity O 
of O 
novel O 
hybrid O 
molecules O 
containing O 
5-benzylidene B-SYSTEMATIC 
thiazolidine-2,4-dione I-SYSTEMATIC 
. O 

of O 
two O 
different O 
bioactive O 
molecules O 
with O 
different O 
mechanism O 
of O 
action O 
is O 
one O 
of O 
the O 
methods O 
that O 
are O 
being O 
adopted O 
to O 
treat O 
cancer O 
. O 
Molecules O 
bearing O 
a O 
thiazolidine-2,4-dione B-SYSTEMATIC 
scaffold O 
have O 
been O 
recognized O 
as O 
antineoplastic O 
agents O 
with O 
a O 
broad O 
spectrum O 
of O 
activity O 
against O 
many O 
cancer O 
cell O 
lines O 
. O 
In O 
this O 
manuscript O 
we O 
have O 
described O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
two O 
series O 
of O 
N-3- B-FAMILY 
substituted-5-arylidene I-FAMILY 
thiazolidine-2,4-diones I-FAMILY 
, O 
bearing O 
the O 
α-bromoacryloylamido B-SYSTEMATIC 
moiety O 
at O 
the O 
para- O 
or O 
meta- O 
position O 
on O 
the O 
phenyl B-SYSTEMATIC 
of O 
the O 
arylidene B-FAMILY 
portion O 
. O 
We O 
have O 
observed O 
that O 
selected O 
compounds O 
5a O 
, O 
5c O 
and O 
5g O 
suppress O 
proliferation O 
of O 
human O 
myeloid O 
leukaemia O 
HL-60 O 
and O 
U937 O 
cells O 
by O 
triggering O 
morphological O 
changes O 
and O 
internucleosomal O 
DNA O 
fragmentation O 
, O 
which O 
are O 
well O 
- O 
known O 
features O 
of O 
apoptosis O 
. O 
Finally O 
, O 
our O 
results O 
indicated O 
that O 
the O 
investigated O 
compounds O 
induced O 
apoptotic O 
cell O 
death O 
through O 
a O 
mechanism O 
that O 
involved O 
activation O 
of O 
multiple O 
caspases O 
and O 
was O 
also O 
associated O 
with O 
the O 
release O 
of O 
cytochrome O 
c O 
from O 
the O 
mitochondria O 
. O 

Brazil O 
, O 
common O 
bean O 
( O 
Phaseolus O 
vulgaris O 
L O 
. O 
) O 
productivity O 
is O 
severely O 
affected O 
by O 
drought O 
stress O 
due O 
to O 
low O 
technology O 
cultivation O 
systems O 
. O 
Our O 
purpose O 
was O 
to O 
identify O 
differentially O 
expressed O 
genes O 
in O 
roots O 
of O 
a O 
genotype O 
tolerant O 
to O 
water O 
deficit O 
( O 
BAT O 
477 O 
) O 
when O 
submitted O 
to O 
an O 
interruption O 
of O 
irrigation O 
during O 
its O 
development O 
. O 
A O 
SSH O 
library O 
was O 
constructed O 
taking O 
as O 
" O 
driver O 
" O 
the O 
genotype O 
Carioca O 
80SH O 
( O 
susceptible O 
to O 
drought O 
) O 
. O 
After O 
clustering O 
and O 
data O 
mining O 
, O 
1572 O 
valid O 
reads O 
were O 
obtained O 
, O 
resulting O 
in O 
1120 O 
ESTs O 
( O 
expressed O 
sequence O 
tags O 
) O 
. O 
We O 
found O 
sequences O 
for O 
transcription O 
factors O 
, O 
carbohydrates B-FAMILY 
metabolism O 
, O 
proline B-TRIVIAL 
-rich O 
proteins O 
, O 
aquaporins O 
, O 
chaperones O 
and O 
ubiquitins O 
, O 
all O 
of O 
them O 
organized O 
according O 
to O 
their O 
biological O 
processes O 
. O 
Our O 
suppressive O 
subtractive O 
hybridization O 
( O 
SSH O 
) O 
library O 
was O 
validated O 
through O 
RT-qPCR O 
experiment O 
by O 
assessing O 
the O 
expression O 
patterns O 
of O 
10 O 
selected O 
genes O 
in O 
both O 
genotypes O 
under O 
stressed O 
and O 
control O 
conditions O 
. O 
Finally O 
, O 
the O 
expression O 
patterns O 
of O 
31 O 
ESTs O 
, O 
putatively O 
related O 
to O 
drought O 
responses O 
, O 
were O 
analyzed O 
in O 
a O 
time O 
- O 
course O 
experiment O 
. O 
Our O 
results O 
confirmed O 
that O 
such O 
genes O 
are O 
more O 
expressed O 
in O 
the O 
tolerant O 
genotype O 
during O 
stress O 
; O 
however O 
, O 
they O 
are O 
not O 
exclusive O 
, O 
since O 
different O 
levels O 
of O 
these O 
transcripts O 
were O 
also O 
detected O 
in O 
the O 
susceptible O 
genotype O 
. O 
In O 
addition O 
, O 
we O 
observed O 
a O 
fluctuation O 
in O 
gene O 
regulation O 
over O 
time O 
for O 
both O 
the O 
genotypes O 
, O 
which O 
seem O 
to O 
adopt O 
and O 
adapt O 
different O 
strategies O 
in O 
order O 
to O 
develop O 
tolerance O 
against O 
this O 
stress O 
. O 

Derivatives O 
from O 
the O 
Marine O 
- O 
Derived O 
Actinomycete O 
Streptomyces O 
sp O 
. O 
FXJ7.328 O 
. O 

new O 
diketopiperazine B-FAMILY 
derivatives O 
, O 
(3Z,6E)-1-N-methyl-3-benzy B-SYSTEMATIC 
lidene-6-(2S-methyl-3-hydroxypropylidene)piperazine-2,5-dione I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
(3Z,6E)-1-N-methyl-3-benzylidene-6-(2R-methyl-3-hydroxypropylidene)piperazine-2,5-dione B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
(3Z,6Z)-3- B-SYSTEMATIC 
(4-hydroxybenzylidene)-6-isobutylidenepiperazine-2,5-dione I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
(3Z,6Z)-3-((1H-imidazol-5-yl)-methylene)-6-isobutylidenepiperazine-2,5-dione B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
(3Z,6S)-3-benzylidene-6-(2S-but-2-yl)piperazine-2,5-dione B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
marine O 
- O 
derived O 
actinomycete O 
Streptomyces O 
sp O 
. O 
FXJ7.328 O 
. O 
The O 
structures O 
of O 
1-5 O 
were O 
determined O 
by O 
spectroscopic O 
analysis O 
, O 
CD O 
exciton O 
chirality O 
, O 
the O 
modified O 
Mosher's O 
, O 
Marfey's O 
and O 
the O 
C3 O 
Marfey's O 
methods O 
. O 
Compound O 
3 O 
showed O 
modest O 
antivirus O 
activity O 
against O 
influenza O 
A O 
( O 
H1N1 O 
) O 
virus O 
with O 
an O 
IC50 O 
value O 
of O 
41.5 O 
± O 
4.5 O 
μM O 
. O 
In O 
addition O 
, O 
compound O 
6 O 
and O 
7 O 
displayed O 
potent O 
anti-H1N1 O 
activity O 
with O 
IC50 O 
value O 
of O 
28.9 O 
± O 
2.2 O 
and O 
6.8 O 
± O 
1.5 O 
μM O 
, O 
respectively O 
. O 
Due O 
to O 
the O 
lack O 
of O 
corresponding O 
data O 
in O 
the O 
literature O 
, O 
the O 
13C B-FORMULA 
NMR O 
data O 
of O 
(3Z,6S)-3-benzylidene-6-isobutylpiperazine-2,5-dione B-SYSTEMATIC 
( O 
6 O 
) O 
were O 
also O 
reported O 
here O 
for O 
the O 
first O 
time O 
. O 

- O 
Derived O 
Kocuria O 
and O 
Micrococcus O 
spp O 
. O 
as O 
Sources O 
of O 
the O 
New O 
Thiazolyl B-SYSTEMATIC 
Peptide O 
Antibiotic O 
Kocurin B-TRIVIAL 
. O 

four O 
marine O 
actinomycetes O 
of O 
the O 
family O 
Microccocaceae O 
isolated O 
from O 
sponges O 
collected O 
primarily O 
in O 
Florida O 
Keys O 
( O 
USA O 
) O 
were O 
selected O 
from O 
our O 
strain O 
collection O 
to O 
be O 
studied O 
as O 
new O 
sources O 
for O 
the O 
production O 
of O 
bioactive O 
natural O 
products O 
. O 
A O 
16S O 
rRNA O 
gene O 
based O 
phylogenetic O 
analysis O 
showed O 
that O 
the O 
strains O 
are O 
members O 
of O 
the O 
genera O 
Kocuria O 
and O 
Micrococcus O 
. O 
To O 
assess O 
their O 
biosynthetic O 
potential O 
, O 
the O 
strains O 
were O 
PCR O 
screened O 
for O 
the O 
presence O 
of O 
secondary O 
metabolite O 
genes O 
encoding O 
nonribosomal O 
synthetase O 
( O 
NRPS O 
) O 
and O 
polyketide O 
synthases O 
( O 
PKS O 
) O 
. O 
A O 
small O 
extract O 
collection O 
of O 
528 O 
crude O 
extracts O 
generated O 
from O 
nutritional O 
microfermentation O 
arrays O 
was O 
tested O 
for O 
the O 
production O 
of O 
bioactive O 
secondary O 
metabolites O 
against O 
clinically O 
relevant O 
strains O 
( O 
Bacillus O 
subtilis O 
, O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
, O 
Acinetobacter O 
baumannii O 
and O 
Candida O 
albicans O 
) O 
. O 
Three O 
independent O 
isolates O 
were O 
shown O 
to O 
produce O 
a O 
new O 
anti-MRSA O 
bioactive O 
compound O 
that O 
was O 
identified O 
as O 
kocurin B-TRIVIAL 
, O 
a O 
new O 
member O 
of O 
the O 
thiazolyl B-SYSTEMATIC 
peptide O 
family O 
of O 
antibiotics O 
emphasizing O 
the O 
role O 
of O 
this O 
family O 
as O 
a O 
prolific O 
resource O 
for O 
novel O 
drugs O 
. O 

measurement O 
of O 
cardiac O 
natriuretic O 
peptides O 
constitutes O 
promising O 
markers O 
of O 
congenital O 
heart O 
disease O 
. O 
However O 
, O 
concentrations O 
change O 
rapidly O 
and O 
dramatically O 
during O 
the O 
first O 
days O 
after O 
delivery O 
even O 
in O 
healthy O 
neonates O 
, O 
which O 
complicates O 
clinical O 
interpretation O 
. O 
It O 
is O 
unknown O 
whether O 
these O 
changes O 
in O 
plasma O 
concentrations O 
are O 
explained O 
by O 
corresponding O 
changes O 
in O 
the O 
cardiac O 
gene O 
expression O 
. O 
We O 
quantified O 
the O 
chamber O 
- O 
specific O 
mRNA O 
levels O 
of O 
ANP O 
( O 
A O 
- O 
type O 
natriuretic O 
peptide O 
) O 
and O 
BNP O 
( O 
B O 
- O 
type O 
natriuretic O 
peptide O 
) O 
and O 
plasma O 
pro-ANP O 
and O 
BNP-32 O 
concentrations O 
in O 
healthy O 
piglets O 
during O 
the O 
first O 
72 O 
hours O 
of O 
life O 
( O 
from O 
2 O 
litters O 
, O 
n O 
= O 
44 O 
) O 
. O 
Chamber O 
- O 
specific O 
ANP O 
and O 
BNP O 
mRNA O 
levels O 
reflected O 
hemodynamic O 
neonate O 
changes O 
at O 
birth O 
but O 
did O 
not O 
correlate O 
with O 
circulating O 
natriuretic O 
peptide O 
concentrations O 
. O 
However O 
, O 
plasma O 
pro-ANP O 
and O 
creatinine B-TRIVIAL 
concentrations O 
were O 
closely O 
correlated O 
( O 
P O 
< O 
0.0001 O 
; O 
r O 
= O 
0.73 O 
) O 
. O 
Plasma O 
pro-ANP O 
levels O 
were O 
highest O 
on O 
the O 
day O 
of O 
delivery O 
( O 
5580 O 
pmol O 
/ O 
L O 
[ O 
4320-6786 O 
] O 
decreasing O 
to O 
2484 O 
pmol O 
/ O 
L O 
[ O 
1602-2898 O 
] O 
after O 
72 O 
hours O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
During O 
the O 
72 O 
hours O 
, O 
gel O 
chromatography O 
suggested O 
that O 
the O 
translational O 
products O 
in O 
circulation O 
and O 
in O 
atrial O 
tissue O 
were O 
immature O 
, O 
ie O 
, O 
unprocessed O 
pro-ANP O 
. O 
In O 
contrast O 
to O 
pro-ANP O 
, O 
BNP-32 O 
plasma O 
concentrations O 
were O 
low O 
at O 
delivery O 
and O 
peaked O 
after O 
48 O 
hours O 
( O 
12 O 
[ O 
10.5-20.6 O 
] O 
vs O 
. O 
88.8 O 
[ O 
71.7-101.4 O 
] O 
pmol O 
/ O 
L O 
, O 
P O 
< O 
0.0001 O 
) O 
. O 
To O 
conclude O 
, O 
ANP O 
and O 
BNP O 
gene O 
expression O 
differs O 
considerably O 
between O 
cardiac O 
chambers O 
in O 
the O 
first O 
72 O 
hours O 
of O 
life O 
in O 
healthy O 
piglets O 
, O 
resembling O 
the O 
transition O 
from O 
fetal O 
to O 
neonate O 
circulation O 
. O 
However O 
, O 
the O 
cardiac O 
gene O 
expression O 
does O 
not O 
explain O 
plasma O 
concentrations O 
. O 

human O 
skin O 
models O 
employing O 
primary O 
cells O 
and O 
immortalised O 
cell O 
lines O 
, O 
used O 
as O 
monocultures O 
or O 
combined O 
to O 
produce O 
reconstituted O 
3D O 
skin O 
constructs O 
, O 
have O 
been O 
developed O 
. O 
Furthermore O 
, O 
these O 
models O 
have O 
been O 
included O 
in O 
European O 
genotoxicity O 
and O 
sensitization O 
/ O 
irritation O 
assay O 
validation O 
projects O 
. O 
In O 
order O 
to O 
help O 
interpret O 
data O 
, O 
Cosmetics O 
Europe O 
( O 
formerly O 
COLIPA O 
) O 
facilitated O 
research O 
projects O 
that O 
measured O 
a O 
variety O 
of O 
defined O 
phase O 
1 O 
and O 
2 O 
enzyme O 
activities O 
and O 
created O 
a O 
complete O 
proteomic O 
profile O 
of O 
xenobiotic O 
metabolising O 
enzymes O 
( O 
XMEs O 
) O 
in O 
native O 
human O 
skin O 
and O 
compared O 
them O 
with O 
data O 
obtained O 
from O 
a O 
number O 
of O 
in O 
vitro O 
models O 
of O 
human O 
skin O 
. O 
Here O 
, O 
we O 
have O 
summarised O 
our O 
findings O 
on O 
the O 
current O 
knowledge O 
of O 
the O 
metabolic O 
capacity O 
of O 
native O 
human O 
skin O 
and O 
in O 
vitro O 
models O 
, O 
and O 
make O 
an O 
overall O 
assessment O 
of O 
the O 
metabolic O 
capacity O 
from O 
gene O 
expression O 
, O 
proteomic O 
expression O 
and O 
substrate O 
metabolism O 
data O 
. O 
The O 
known O 
low O 
expression O 
and O 
function O 
of O 
phase O 
1 O 
enzymes O 
in O 
native O 
whole O 
skin O 
was O 
reflected O 
in O 
the O 
in O 
vitro O 
models O 
. O 
Some O 
XMEs O 
in O 
whole O 
skin O 
were O 
not O 
detected O 
in O 
in O 
vitro O 
models O 
and O 
vice O 
versa O 
, O 
and O 
some O 
major O 
hepatic O 
XMEs O 
such O 
as O 
cytochrome O 
P450-monooxygenases O 
were O 
absent O 
or O 
measured O 
only O 
at O 
very O 
low O 
levels O 
in O 
the O 
skin O 
. O 
Conversely O 
, O 
despite O 
varying O 
mRNA O 
and O 
protein O 
levels O 
of O 
phase O 
2 O 
enzymes O 
, O 
functional O 
activity O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
, O 
N B-FORMULA 
-acetyltransferase O 
1 O 
, O 
and O 
UDP B-ABBREVIATION 
-glucuronosyltransferases O 
were O 
all O 
readily O 
measurable O 
in O 
whole O 
skin O 
and O 
in O 
vitro O 
skin O 
models O 
at O 
activity O 
levels O 
similar O 
to O 
those O 
measured O 
in O 
the O 
liver O 
. O 
These O 
projects O 
have O 
enabled O 
a O 
better O 
understanding O 
of O 
the O 
contribution O 
of O 
XMEs O 
to O 
toxicity O 
endpoints O 
. O 

central O 
neurokinin-1 O 
receptor O 
blockade O 
is O 
required O 
for O 
efficacy O 
in O 
depression O 
: O 
evidence O 
from O 
orvepitant B-TRIVIAL 
clinical O 
studies O 
. O 

, O 
persistent O 
blockade O 
of O 
central O 
neurokinin-1 O 
( O 
NK1 O 
) O 
receptors O 
may O 
be O 
a O 
potential O 
antidepressant O 
mechanism O 
. O 
The O 
selective O 
NK1 O 
antagonist O 
orvepitant B-TRIVIAL 
( O 
GW823296 B-IDENTIFIER 
) O 
was O 
used O 
to O 
test O 
this O 
hypothesis O 
. O 
A O 
preliminary O 
positron O 
emission O 
tomography O 
study O 
in O 
eight O 
male O 
volunteers O 
drove O 
dose O 
selection O 
for O 
two O 
randomized O 
six O 
week O 
studies O 
in O 
patients O 
with O 
major O 
depressive O 
disorder O 
( O 
MDD O 
) O 
. O 
Displacement O 
of O 
central O 
[(11)C]GR205171 B-SYSTEMATIC 
binding O 
indicated O 
that O 
oral O 
orvepitant B-TRIVIAL 
doses O 
of O 
30-60 O 
mg O 
/ O 
day O 
provided O 
> O 
99% O 
receptor O 
occupancy O 
for O 
≥ O 
24 O 
h O 
. O 
Studies O 
733 O 
and O 
833 O 
randomized O 
patients O 
with O 
MDD O 
and O 
17-item O 
Hamilton O 
Depression O 
Rating O 
Scale O 
(HAM-D)≥22 O 
to O 
double O 
- O 
blind O 
treatment O 
with O 
orvepitant B-TRIVIAL 
30 O 
mg O 
/ O 
day O 
, O 
orvepitant B-TRIVIAL 
60 O 
mg O 
/ O 
day O 
or O 
placebo O 
( O 
1 O 
: O 
1 O 
: O 
1 O 
) O 
. O 
Primary O 
outcome O 
measure O 
was O 
change O 
from O 
baseline O 
in O 
17-item O 
HAM-D O 
total O 
score O 
at O 
Week O 
6 O 
analyzed O 
using O 
mixed O 
models O 
repeated O 
measures O 
. O 
Study O 
733 O 
( O 
n=328 O 
) O 
demonstrated O 
efficacy O 
on O 
the O 
primary O 
endpoint O 
( O 
estimated O 
drug O 
- O 
placebo O 
differences O 
of O 
30 O 
mg O 
: O 
-2.41 O 
, O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
( O 
-4.5 O 
to O 
-0.31 O 
) O 
p=0.0245 O 
; O 
60 O 
mg O 
: O 
-2.86 O 
, O 
95% O 
CI O 
( O 
-4.97 O 
to O 
-0.75 O 
) O 
p=0.0082 O 
) O 
. O 
Study O 
833 O 
( O 
n=345 O 
) O 
did O 
not O 
show O 
significance O 
( O 
estimated O 
drug O 
- O 
placebo O 
differences O 
of O 
30 O 
mg O 
: O 
-1.67 O 
, O 
95% O 
CI O 
( O 
-3.73 O 
to O 
0.39 O 
) O 
p=0.1122 O 
; O 
60 O 
mg O 
: O 
-0.76 O 
, O 
95% O 
CI O 
( O 
-2.85 O 
to O 
1.32 O 
) O 
p=0.4713 O 
) O 
. O 
The O 
results O 
support O 
the O 
hypothesis O 
that O 
full O 
, O 
long O 
lasting O 
blockade O 
of O 
central O 
NK1 O 
receptors O 
may O 
be O 
an O 
efficacious O 
mechanism O 
for O 
the O 
treatment O 
of O 
MDD O 
. O 

Polylactide B-SYSTEMATIC 
-block-Polypeptide-block- O 
Polylactide B-SYSTEMATIC 
Nanocarrier O 
. O 

are O 
successfully O 
incorporated O 
into O 
poly(l-lactide) B-SYSTEMATIC 
( O 
PLLA B-ABBREVIATION 
) O 
chains O 
in O 
a O 
ring O 
- O 
opening O 
polymerization O 
( O 
ROP O 
) O 
of O 
l-lactide B-SYSTEMATIC 
by O 
using O 
them O 
as O 
initiators O 
. O 
The O 
resulting O 
ABA O 
triblock O 
copolymers O 
possess O 
molecular O 
weights O 
up O 
to O 
11000 O 
g·mol(-1) O 
and O 
polydispersities O 
as O 
low O 
as O 
1.13 O 
, O 
indicating O 
the O 
living O 
character O 
of O 
the O 
polymerization O 
process O 
. O 
In O 
a O 
nonaqueous O 
emulsion O 
, O 
peptide O 
- O 
initiated O 
polymerization O 
of O 
l-lactide B-SYSTEMATIC 
leads O 
to O 
well O 
- O 
defined O 
nanoparticles O 
, O 
consisting O 
of O 
PLLA B-ABBREVIATION 
-block O 
- O 
peptide-block- O 
PLLA B-ABBREVIATION 
copolymer O 
. O 
These O 
nanoparticles O 
are O 
easily O 
loaded O 
by O 
dye O 
- O 
encapsulation O 
and O 
transferred O 
into O 
aqueous O 
media O 
without O 
aggregation O 
( O 
average O 
diameter O 
of O 
100 O 
nm O 
) O 
or O 
significant O 
dye O 
leakage O 
. O 
Finally O 
, O 
internalization O 
of O 
PLLA B-ABBREVIATION 
-block O 
- O 
peptide-block- O 
PLLA B-ABBREVIATION 
nanoparticles O 
by O 
HeLa O 
cells O 
is O 
demonstrated O 
by O 
a O 
combination O 
of O 
coherent O 
anti-Stokes O 
Raman O 
spectroscopy O 
( O 
CARS O 
) O 
and O 
fluorescence O 
microscopy O 
. O 
This O 
demonstrates O 
the O 
promise O 
of O 
their O 
utilization O 
as O 
cargo O 
delivery O 
vehicles O 
. O 

deprivation O 
from O 
pre O 
- O 
puberty O 
to O 
peripuberty O 
interferes O 
in O 
proteins O 
expression O 
in O 
pubertal O 
and O 
adult O 
rat O 
epididymis O 
. O 

studies O 
have O 
focused O 
on O 
experimental O 
testosterone B-TRIVIAL 
deprivation O 
in O 
immature O 
animals O 
. O 
Therefore O 
, O 
this O 
study O 
used O 
sexually O 
immature O 
rats O 
aiming O 
to O 
evaluate O 
the O 
testes O 
and O 
epididymis O 
histology O 
and O 
proteins O 
expression O 
in O 
these O 
organs O 
on O 
PND50 O 
and O 
75 O 
, O 
after O 
premature O 
antiandrogen O 
exposure O 
, O 
from O 
PND21 O 
to O 
44 O 
. O 
Although O 
the O 
androgen B-FAMILY 
deprivation O 
from O 
pre O 
- O 
puberty O 
up O 
to O 
peripuberty O 
did O 
not O 
alter O 
the O 
histological O 
organization O 
of O 
the O 
testes O 
and O 
epididymis O 
either O 
at O 
puberty O 
or O 
at O 
adulthood O 
, O 
the O 
treatment O 
impaired O 
the O 
expression O 
of O 
specific O 
proteins O 
in O 
epididymal O 
tissue O 
at O 
puberty O 
and O 
adulthood O 
( O 
androgen B-FAMILY 
receptor O 
, O 
calmodulin O 
, O 
Rab11A O 
) O 
. O 
These O 
changes O 
may O 
be O 
related O 
to O 
impaired O 
epididymal O 
function O 
, O 
sperm O 
quality O 
and O 
fertility O 
capacity O 
as O 
observed O 
in O 
a O 
previous O 
study O 
. O 
Further O 
studies O 
are O 
necessary O 
to O 
better O 
investigate O 
the O 
molecular O 
mechanisms O 
involved O 
in O 
the O 
impairment O 
on O 
reproductive O 
competence O 
of O 
male O 
rats O 
after O 
precocious O 
hormonal O 
injury O 
. O 

investigated O 
the O 
composition O 
of O 
essential O 
oil O 
from O 
fingered O 
citron O 
( O 
Citrus O 
medica O 
L O 
. O 
var O 
. O 
sarcodactylis O 
) O 
( O 
FCEO O 
) O 
peels O 
by O 
GC-MS O 
and O 
its O 
anti-inflammatory O 
effects O 
on O 
lipopolysaccharide O 
( O 
LPS O 
) O 
- O 
stimulated O 
mouse O 
macrophage O 
( O 
RAW O 
264.7 O 
) O 
cells O 
. O 
Fifteen O 
compounds O 
, O 
representing O 
98.97% O 
of O 
the O 
essential O 
oil O 
, O 
were O 
tentatively O 
identified O 
; O 
the O 
main O 
constituents O 
were O 
limonene B-TRIVIAL 
( O 
52.44% O 
) O 
and O 
γ-terpinene B-TRIVIAL 
( O 
28.41% O 
) O 
. O 
FCEO O 
significantly O 
inhibited O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
by O 
suppressing O 
the O 
protein O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
and O 
cyclooxygenase O 
(COX)-2 O 
, O 
respectively O 
. O 
Additionally O 
, O 
FCEO O 
suppressed O 
the O 
production O 
of O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
interleukin O 
(IL)-1β O 
, O 
and O 
IL-6 O 
. O 
FCEO O 
attenuated O 
LPS-induced O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
activation O 
via O 
inhibition O 
of O 
inhibitor O 
κB-α O 
phosphorylation O 
. O 
Furthermore O 
, O 
FCEO O 
blocked O 
activation O 
of O 
c-Jun O 
N- O 
terminal O 
kinase O 
( O 
JNK O 
) O 
and O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
but O 
not O 
that O 
of O 
p38 O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
. O 
These O 
results O 
indicate O 
that O 
FCEO O 
inhibits O 
LPS-stimulated O 
inflammation O 
by O 
blocking O 
the O 
NF-κB O 
, O 
JNK O 
, O 
and O 
ERK O 
pathways O 
in O 
macrophages O 
, O 
and O 
demonstrate O 
that O 
FCEO O 
possesses O 
anti-inflammatory O 
properties O 
. O 

-induced O 
ENaC O 
and O 
basal O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
trafficking O 
via O 
protein O 
kinase O 
D1- O 
phosphatidylinositol B-TRIVIAL 
4-kinaseIIIβ O 
trans O 
Golgi O 
signalling O 
in O 
M1 O 
cortical O 
collecting O 
duct O 
cells O 
. O 

regulates O 
Na(+) B-FORMULA 
transport O 
in O 
the O 
distal O 
nephron O 
through O 
multiple O 
mechanisms O 
that O 
include O 
the O 
transcriptional O 
control O 
of O 
epithelial O 
sodium O 
channel O 
( O 
ENaC O 
) O 
and O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
subunits O 
. O 
Aldosterone B-TRIVIAL 
also O 
induces O 
the O 
rapid O 
phosphorylation O 
of O 
Protein O 
Kinase O 
D1 O 
( O 
PKD1 O 
) O 
. O 
PKD O 
isoforms O 
regulate O 
protein O 
trafficking O 
, O 
by O 
the O 
control O 
of O 
vesicle O 
fission O 
from O 
the O 
trans O 
Golgi O 
network O 
( O 
TGN O 
) O 
through O 
activation O 
of O 
phosphatidylinositol B-TRIVIAL 
4-kinaseIIIβ O 
( O 
PI4KIIIβ O 
) O 
. O 
We O 
report O 
rapid O 
ENaCγ O 
translocation O 
to O 
the O 
plasma O 
membrane O 
after O 
30min O 
aldosterone O 
treatment O 
in O 
polarized O 
M1 O 
cortical O 
collecting O 
duct O 
cells O 
, O 
which O 
was O 
significantly O 
impaired O 
in O 
PKD1 O 
shRNA O 
- O 
mediated O 
knockdown O 
cells O 
. O 
In O 
PKD1-deficient O 
cells O 
, O 
the O 
ouabain B-TRIVIAL 
-sensitive O 
current O 
was O 
significantly O 
reduced O 
and O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
α O 
and O 
β O 
subunits O 
showed O 
aberrant O 
localization O 
. O 
PKD1 O 
and O 
PI4KIIIβ O 
localize O 
to O 
the O 
TGN O 
, O 
and O 
aldosterone B-TRIVIAL 
induced O 
an O 
interaction O 
between O 
PKD1 O 
and O 
PI4KIIIβ O 
following O 
aldosterone B-TRIVIAL 
treatment O 
. O 
This O 
study O 
reveals O 
a O 
novel O 
mechanism O 
for O 
rapid O 
regulation O 
of O 
ENaC O 
and O 
the O 
Na(+) B-FORMULA 
/ O 
K(+) B-FORMULA 
-ATPase O 
, O 
via O 
directed O 
trafficking O 
through O 
PKD1-PI4KIIIβ O 
signalling O 
at O 
the O 
level O 
of O 
the O 
TGN O 
. O 

acid I-TRIVIAL 
and O 
its O 
analogs O 
: O 
A O 
new O 
class O 
of O 
antifilarial O 
agents O 
. O 

a O 
number O 
of O 
chemicals O 
have O 
been O 
isolated O 
from O 
Glycyrrhiza O 
glabra O 
, O 
only O 
a O 
few O 
have O 
been O 
evaluated O 
for O 
their O 
biological O 
significance O 
. O 
As O 
part O 
of O 
our O 
drug O 
discovery O 
program O 
for O 
antifilarial O 
agents O 
from O 
Indian O 
medicinal O 
plants O 
, O 
the O 
roots O 
of O 
G O 
. O 
glabra O 
were O 
chemically O 
investigated O 
, O 
which O 
resulted O 
in O 
the O 
isolation O 
and O 
characterization O 
of O 
an O 
antifilarial O 
agent O 
, O 
glycyrrhetinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
GA O 
, O 
1a O 
) O 
effective O 
against O 
microfilariae O 
( O 
mf O 
) O 
in O 
vitro O 
( O 
LC100 O 
: O 
12.5μM O 
; O 
IC50 O 
: O 
1.20μM O 
) O 
, O 
but O 
was O 
inactive O 
against O 
adult O 
worms O 
. O 
Further O 
, O 
GA O 
( O 
1a O 
) O 
was O 
converted O 
into O 
six O 
analogs O 
( O 
2a-7a O 
) O 
and O 
their O 
antifilarial O 
potential O 
was O 
evaluated O 
by O 
studying O 
in O 
vitro O 
motility O 
and O 
MTT B-ABBREVIATION 
reduction O 
assays O 
employing O 
mf O 
and O 
adult O 
worms O 
of O 
Brugia O 
malayi O 
. O 
The O 
results O 
showed O 
that O 
out O 
of O 
six O 
GA O 
analogs O 
, O 
the O 
benzyl B-SYSTEMATIC 
amide I-SYSTEMATIC 
analog O 
( O 
6a O 
) O 
killed O 
adults O 
and O 
mf O 
at O 
25 O 
and O 
50μM O 
concentration O 
, O 
respectively O 
, O 
and O 
inhibited O 
49% O 
MTT B-ABBREVIATION 
reduction O 
potential O 
of O 
the O 
adult O 
parasites O 
. O 
The O 
IC50 O 
values O 
were O 
found O 
to O 
be O 
8.8 O 
and O 
2.2μM O 
for O 
adults O 
and O 
mf O 
, O 
respectively O 
. O 
The O 
SI O 
of O 
the O 
compound O 
was O 
> O 
60 O 
. O 
On O 
the O 
other O 
hand O 
the O 
octylamide B-SYSTEMATIC 
analog O 
( O 
7a O 
) O 
required O 
much O 
higher O 
concentration O 
to O 
adversely O 
affect O 
the O 
parasites O 
. O 
Finally O 
, O 
both O 
active O 
amide B-FAMILY 
analogs O 
( O 
6a O 
and O 
7a O 
) O 
were O 
in O 
vivo O 
evaluated O 
using O 
B O 
. O 
malayi O 
- O 
jird O 
model O 
, O 
which O 
showed O 
that O 
analog O 
6a O 
possesses O 
promising O 
macrofilaricidal O 
activity O 
at O 
100mg O 
/ O 
kg O 
, O 
s.c O 
. O 
×5days O 
and O 
around O 
40% O 
of O 
the O 
treated O 
animals O 
showed O 
calcified O 
masses O 
of O 
worm O 
fragments O 
in O 
peritoneal O 
cavity O 
of O 
the O 
animals O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
this O 
is O 
the O 
first O 
ever O 
report O 
on O 
the O 
antifilarial O 
potential O 
of O 
GA O 
analogs O 
. O 
Further O 
work O 
on O 
optimization O 
of O 
the O 
antifilarial O 
lead O 
is O 
under O 
progress O 
. O 

of O 
a O 
series O 
of O 
novel O 
5H-pyrrolo[2,3-b]pyrazine-2-phenyl B-FAMILY 
ethers I-FAMILY 
, O 
as O 
potent O 
JAK3 O 
kinase O 
inhibitors O 
. O 

report O 
the O 
discovery O 
of O 
a O 
novel O 
series O 
of O 
ATP B-ABBREVIATION 
-competitive O 
Janus O 
kinase O 
3 O 
( O 
JAK3 O 
) O 
inhibitors O 
based O 
on O 
the O 
5H-pyrrolo[2,3-b]pyrazine B-SYSTEMATIC 
scaffold O 
. O 
The O 
initial O 
leads O 
in O 
this O 
series O 
, O 
compounds O 
1a O 
and O 
1h O 
, O 
showed O 
promising O 
potencies O 
, O 
but O 
a O 
lack O 
of O 
selectivity O 
against O 
other O 
isoforms O 
in O 
the O 
JAK O 
family O 
. O 
Computational O 
and O 
crystallographic O 
analysis O 
suggested O 
that O 
the O 
phenyl O 
ether O 
moiety O 
possessed O 
a O 
favorable O 
vector O 
to O 
achieve O 
selectivity O 
. O 
Exploration O 
of O 
this O 
vector O 
resulted O 
in O 
the O 
identification O 
of O 
12b O 
and O 
12d O 
, O 
as O 
potent O 
JAK3 O 
inhibitors O 
, O 
demonstrating O 
improved O 
JAK O 
family O 
and O 
kinase O 
selectivity O 
. O 

antagonistic O 
clock O 
- O 
regulated O 
histidine B-TRIVIAL 
kinases O 
time O 
the O 
activation O 
of O 
circadian O 
gene O 
expression O 
. O 

effects O 
of O 
RFRP-3 B-ABBREVIATION 
, O 
the O 
mammalian O 
ortholog O 
of O 
GnIH O 
, O 
on O 
the O 
female O 
pig O 
reproductive O 
axis O 
in O 
vitro O 
. O 

- I-SYSTEMATIC 
related I-SYSTEMATIC 
peptide-3 I-SYSTEMATIC 
( O 
RFRP-3 B-ABBREVIATION 
) O 
has O 
been O 
proposed O 
as O 
a O 
key O 
inhibitory O 
regulator O 
of O 
mammalian O 
reproduction O 
. O 
To O 
further O 
determine O 
the O 
potential O 
mechanisms O 
and O 
sites O 
of O 
action O 
of O 
RFRP-3 B-ABBREVIATION 
, O 
we O 
systematically O 
investigated O 
the O 
direct O 
effect O 
of O 
RFRP-3 B-ABBREVIATION 
on O 
the O 
female O 
pig O 
reproductive O 
axis O 
in O 
vitro O 
. O 
Initially O 
, O 
we O 
confirmed O 
that O 
G O 
protein O 
- O 
coupled O 
receptor O 
147 O 
( O 
GPR147 O 
) O 
was O 
distributed O 
in O 
isolated O 
hypothalamic O 
, O 
anterior O 
pituitary O 
and O 
ovarian O 
granulosa O 
cells O 
, O 
suggesting O 
that O 
RFRP-3 B-ABBREVIATION 
could O 
act O 
on O 
these O 
cells O 
in O 
vitro O 
. O 
Subsequently O 
, O 
the O 
direct O 
effects O 
of O 
RFRP-3 B-ABBREVIATION 
on O 
hormone O 
and O 
steroid B-FAMILY 
secretion O 
, O 
the O 
synthesis O 
of O 
subunit O 
genes O 
and O 
the O 
expression O 
of O 
proteins O 
related O 
to O 
proliferation O 
in O 
the O 
hypothalamus O 
, O 
pituitary O 
and O 
ovary O 
were O 
evaluated O 
. O 
Our O 
results O 
demonstrate O 
that O 
different O 
doses O 
of O 
RFRP-3 B-ABBREVIATION 
inhibited O 
the O 
release O 
and O 
synthesis O 
of O 
gonadotrophin O 
releasing O 
hormone O 
, O 
gonadotrophin O 
and O 
steroid B-FAMILY 
hormones O 
and O 
impacted O 
the O 
relative O 
gene O 
expression O 
of O 
KISS1 O 
and O 
GnRHR O 
and O 
the O 
protein O 
expression O 
of O 
cyclin O 
B1 O 
, O 
PCNA O 
and O 
ERK O 
1 O 
/ O 
2 O 
. O 

- O 
wide O 
association O 
studies O 
on O 
serum O 
sex O 
steroid B-FAMILY 
levels O 
. O 

though O 
the O 
levels O 
of O 
circulating O 
sex O 
steroid B-FAMILY 
hormones O 
are O 
to O 
a O 
large O 
extent O 
heritable O 
, O 
their O 
genetic O 
determinants O 
are O 
largely O 
unknown O 
. O 
With O 
the O 
advent O 
of O 
genome O 
- O 
wide O 
association O 
studies O 
( O 
GWAS O 
) O 
, O 
much O 
progress O 
has O 
been O 
made O 
and O 
several O 
genetic O 
loci O 
have O 
been O 
identified O 
to O 
be O 
associated O 
with O 
serum O 
levels O 
of O 
dehydroepiandrosterone B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
, O 
testosterone B-TRIVIAL 
and O 
sex O 
hormone O 
- O 
binding O 
globulin O 
. O 
The O 
variants O 
identified O 
so O 
far O 
only O 
explain O 
a O 
small O 
amount O 
of O 
the O 
overall O 
heritability O 
, O 
but O 
may O 
help O 
to O 
elucidate O 
the O 
role O 
of O 
sex O 
steroid B-FAMILY 
hormones O 
in O 
common O 
disorders O 
such O 
as O 
hypogonadism O 
, O 
type O 
2 O 
diabetes O 
and O 
hormone O 
- O 
sensitive O 
cancers O 
. O 
This O 
review O 
provides O 
an O 
overview O 
of O 
the O 
current O 
state O 
of O 
knowledge O 
of O 
the O 
genetic O 
determinants O 
of O 
sex O 
steroid B-FAMILY 
hormones O 
, O 
with O 
a O 
focus O 
on O 
recent O 
GWAS O 
and O 
brief O 
directions O 
for O 
elucidating O 
the O 
remaining O 
heritability O 
. O 

tRNA O 
selection O 
by O 
the O 
ribosome O 
is O 
essential O 
for O 
the O 
synthesis O 
of O 
functional O 
proteins O 
. O 
Previous O 
structural O 
studies O 
indicated O 
that O 
the O 
ribosome O 
distinguishes O 
between O 
cognate O 
and O 
near O 
- O 
cognate O 
tRNAs O 
by O 
monitoring O 
the O 
geometry O 
of O 
the O 
codon O 
- O 
anticodon O 
helix O 
in O 
the O 
decoding O 
center O 
using O 
the O 
universally O 
conserved O 
16S O 
ribosomal O 
RNA O 
bases O 
G530 O 
, O 
A1492 O 
and O 
A1493 O 
. O 
These O 
bases O 
form O 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
the O 
2'-hydroxyl B-SYSTEMATIC 
groups O 
of O 
the O 
codon O 
- O 
anticodon O 
helix O 
, O 
which O 
are O 
expected O 
to O 
be O 
disrupted O 
with O 
a O 
near O 
- O 
cognate O 
codon O 
- O 
anticodon O 
helix O 
. O 
However O 
, O 
a O 
recent O 
structural O 
study O 
showed O 
that O 
G530 O 
, O 
A1492 O 
and O 
A1493 O 
form O 
hydrogen B-SYSTEMATIC 
bonds O 
in O 
a O 
manner O 
identical O 
with O 
that O 
of O 
both O 
cognate O 
and O 
near O 
- O 
cognate O 
codon O 
- O 
anticodon O 
helices O 
. O 
To O 
understand O 
how O 
the O 
ribosome O 
discriminates O 
between O 
cognate O 
and O 
near O 
- O 
cognate O 
tRNAs O 
, O 
we O 
made O 
2'-deoxynucleotide O 
and O 
2'-fluoro B-SYSTEMATIC 
substituted O 
mRNAs O 
, O 
which O 
disrupt O 
the O 
hydrogen B-SYSTEMATIC 
bonds O 
between O 
the O 
A O 
site O 
codon O 
and O 
G530 O 
, O 
A1492 O 
and O 
A1493 O 
. O 
Our O 
results O 
show O 
that O 
multiple O 
2'-deoxynucleotide O 
substitutions O 
in O 
the O 
mRNA O 
substantially O 
inhibit O 
tRNA O 
selection O 
, O 
whereas O 
multiple O 
2'-fluoro B-SYSTEMATIC 
substitutions O 
in O 
the O 
mRNA O 
have O 
only O 
modest O 
effects O 
on O 
tRNA O 
selection O 
. O 
Furthermore O 
, O 
the O 
miscoding O 
antibiotics O 
paromomycin O 
and O 
streptomycin O 
rescue O 
the O 
defects O 
in O 
tRNA O 
selection O 
with O 
the O 
multiple O 
2'-deoxynucleotide O 
substituted O 
mRNA O 
. O 
These O 
results O 
suggest O 
that O 
steric O 
complementarity O 
in O 
the O 
decoding O 
center O 
is O 
more O 
important O 
than O 
the O 
hydrogen B-SYSTEMATIC 
bonds O 
between O 
the O 
A O 
site O 
codon O 
and O 
G530 O 
, O 
A1492 O 
and O 
A1493 O 
for O 
tRNA O 
selection O 
. O 

smoke O 
contains O 
more O 
than O 
5600 O 
constituents O 
, O 
of O 
which O 
approximately O 
150 O 
are O 
toxicants O 
. O 
This O 
paper O 
describes O 
the O 
activities O 
in O 
the O 
Neutral B-TRIVIAL 
Red I-TRIVIAL 
uptake O 
( O 
NRU O 
) O 
assay O 
, O 
the O 
Salmonella O 
mutagenicity O 
test O 
( O 
SAL O 
) O 
, O 
the O 
mouse O 
lymphoma O 
mammalian O 
cell O 
mutation O 
assay O 
( O 
MLA O 
) O 
and O 
the O 
in O 
vitro O 
micronucleus O 
test O 
( O 
IVMNT O 
) O 
of O 
Particulate O 
Matter O 
( O 
PM O 
) O 
obtained O 
from O 
experimental O 
cigarettes O 
( O 
ECs O 
) O 
, O 
designed O 
to O 
produce O 
reduced O 
levels O 
of O 
toxicants O 
. O 
The O 
designs O 
included O 
tobacco O 
substitute O 
sheet O 
( O 
TSS O 
) O 
containing O 
glycerol B-TRIVIAL 
, O 
which O 
dilutes O 
toxicants O 
in O 
smoke O 
, O 
or O 
the O 
incorporation O 
of O 
blend O 
- O 
treated O 
( O 
BT O 
) O 
tobacco O 
to O 
reduce O 
the O 
levels O 
of O 
nitrogenous O 
toxicant O 
precursors O 
and O 
some O 
polyphenols B-FAMILY 
. O 
All O 
samples O 
were O 
cytotoxic O 
in O 
the O 
NRU O 
, O 
however O 
TSS O 
reduced O 
PM O 
cytotoxicity O 
in O 
this O 
assay O 
. O 
All O 
PMs O 
were O 
mutagenic O 
in O 
the O 
SAL O 
, O 
MLA O 
and O 
IVMNT O 
. O 
Reductions O 
in O 
bacterial O 
mutagenicity O 
were O 
observed O 
in O 
the O 
SAL O 
, O 
for O 
cigarettes O 
with O 
BT O 
tobacco O 
, O 
compared O 
with O 
their O 
respective O 
controls O 
. O 
The O 
quantitative O 
changes O 
in O 
bacterial O 
mutagenicity O 
could O 
be O 
explained O 
by O 
analytical O 
chemistry O 
data O 
on O 
smoke O 
generated O 
from O 
the O 
ECs O 
used O 
in O 
the O 
study O 
. O 
These O 
observations O 
, O 
and O 
the O 
absence O 
of O 
consistent O 
qualitative O 
differences O 
in O 
the O 
activities O 
of O 
the O 
experimental O 
, O 
control O 
and O 
reference O 
cigarettes O 
, O 
suggest O 
that O 
reduced O 
toxicity O 
cigarettes O 
, O 
as O 
measured O 
by O 
the O 
tests O 
described O 
in O 
this O 
paper O 
, O 
may O 
be O 
developed O 
without O 
introducing O 
any O 
additional O 
cytotoxic O 
or O 
genotoxic O 
hazards O 
, O 
but O 
the O 
impact O 
of O 
this O 
on O 
human O 
health O 
risks O 
remains O 
unknown O 
. O 

RELEVANCE O 
: O 
Lentinus O 
polychrous O 
is O 
a O 
Thai O 
local O 
edible O 
mushroom O 
, O 
traditionally O 
used O 
for O 
the O 
treatments O 
of O 
fever O 
and O 
inflammation O 
due O 
to O 
snake O 
or O 
scorpion O 
envenomation O 
. O 
AIM O 
OF O 
STUDY O 
: O 
The O 
present O 
study O 
aimed O 
to O 
investigate O 
an O 
anti-inflammatory O 
effect O 
of O 
Lentinus O 
polychrous O 
mycelial O 
extract O 
( O 
LPME O 
) O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
cytotoxicity O 
and O 
suppressive O 
effects O 
of O 
LPME O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
, O 
intracellular O 
O2(-) B-FORMULA 
production O 
, O 
pro O 
- O 
inflammatory O 
mediator O 
expression O 
, O 
TNF-α O 
production O 
were O 
determined O 
by O 
using O 
LPS-activated O 
RAW O 
264.7 O 
cells O 
. O 
In O 
addition O 
, O 
Anti-inflammatory O 
effect O 
of O 
LPME O 
was O 
evaluated O 
by O 
using O 
carageenan O 
- O 
induced O 
paw O 
edema O 
in O 
rats O 
. O 
RESULTS O 
: O 
The O 
LPME O 
exhibited O 
cytotoxicity O 
with O 
50% O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
of O 
280.25±10.10μg O 
/ O 
ml O 
and O 
significantly O 
suppressed O 
the O 
productions O 
of O 
NO B-FORMULA 
and O 
intracellular O 
O2(-) B-FORMULA 
with O 
dose O 
- O 
dependent O 
manner O 
. O 
LPME O 
decreased O 
the O 
expressions O 
of O 
iNOS O 
, O 
IL-1β O 
, O 
IL-6 O 
, O 
TNF-α O 
and O 
COX-2 O 
and O 
significantly O 
decreased O 
the O 
TNF-α O 
production O 
in O 
LPS-activated O 
macrophage O 
with O 
dose O 
- O 
dependent O 
manners O 
. O 
Moreover O 
, O 
LPME O 
showed O 
significant O 
suppressive O 
effect O 
on O 
paw O 
edema O 
in O 
rats O 
. O 
CONCLUSION O 
: O 
The O 
results O 
clearly O 
revealed O 
that O 
the O 
LPME O 
inhibited O 
NO B-FORMULA 
and O 
pro O 
- O 
inflammatory O 
productions O 
by O 
down O 
- O 
regulating O 
the O 
gene O 
expressions O 
of O 
pro O 
- O 
inflammatory O 
mediators O 
leading O 
to O 
the O 
decrease O 
paw O 
edema O 
in O 
rat O 
which O 
support O 
the O 
traditional O 
use O 
. O 

aim O 
of O 
this O 
pilot O 
study O 
was O 
to O 
investigate O 
variability O 
of O 
oxidative O 
stress O 
during O 
sepsis O 
evolution O 
. O 
ICU O 
patients O 
with O 
the O 
diagnosis O 
of O 
septic O 
shock O 
were O 
included O 
. O 
Thiobarbituric B-TRIVIAL 
- I-TRIVIAL 
acid I-TRIVIAL 
reactive O 
substances O 
, O 
total O 
antioxidant O 
capacity O 
, O 
protein O 
carbonyls B-FAMILY 
in O 
plasma O 
, O 
reduced O 
, O 
oxidized O 
glutathione B-TRIVIAL 
and O 
catalase O 
activity O 
in O 
erythrocyte O 
lysate O 
were O 
assessed O 
in O 
the O 
1st O 
, O 
3rd O 
, O 
5th O 
and O 
8thday O 
after O 
sepsis O 
appearance O 
. O 
A O 
total O 
of O 
17 O 
patients O 
were O 
divided O 
in O 
two O 
groups O 
: O 
survivors O 
( O 
n=7 O 
) O 
and O 
non-survivors O 
( O 
n=10 O 
) O 
. O 
APACHE O 
II O 
was O 
11.5±5.4 O 
and O 
19.9±4.97 O 
in O 
survivors O 
and O 
non-survivors O 
respectively O 
( O 
p=0.005 O 
) O 
, O 
while O 
mean O 
age O 
and O 
SOFA O 
score O 
at O 
sepsis O 
diagnosis O 
, O 
were O 
similar O 
between O 
the O 
two O 
groups O 
. O 
GSH B-ABBREVIATION 
levels O 
, O 
catalase O 
activity O 
and O 
protein O 
carbonyls B-FAMILY 
presented O 
significant O 
different O 
course O 
in O 
time O 
between O 
survivors O 
and O 
non-survivors O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Catalase O 
activity O 
was O 
significantly O 
higher O 
in O 
survivors O 
( O 
238.8±51.5 O 
) O 
than O 
non-survivors O 
( O 
166.4±40.2 O 
; O 
p=0.005 O 
) O 
, O 
while O 
protein O 
carbonyls B-FAMILY 
levels O 
were O 
significantly O 
lower O 
in O 
survivors O 
( O 
0.32±0.09 O 
) O 
than O 
non-survivors O 
( O 
0.48±0.16 O 
; O 
p=0.036 O 
) O 
on O 
the O 
1stday O 
. O 
Yet O 
, O 
non-survivors O 
exhibited O 
a O 
declining O 
course O 
in O 
GSH B-ABBREVIATION 
levels O 
during O 
time O 
, O 
while O 
GSH B-ABBREVIATION 
levels O 
were O 
maintained O 
in O 
survivors O 
. O 
Conclusively O 
, O 
a O 
longstanding O 
antioxidant O 
deficiency O 
in O 
non-surviving O 
patients O 
was O 
noted O 
. O 
This O 
phenomenon O 
was O 
clearly O 
prominent O 
in O 
patients O 
' O 
erythrocytes O 
. O 

controllable O 
polyion O 
complex O 
vesicles O 
( O 
PICsomes O 
) O 
, O 
composed O 
of O 
biocompatible O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
poly(amino B-FAMILY 
acid)s I-FAMILY 
, O 
have O 
an O 
extremely O 
prolonged O 
lifetime O 
in O 
the O 
bloodstream O 
that O 
enables O 
them O 
to O 
accumulate O 
effectively O 
in O 
tumors O 
via O 
the O 
enhanced O 
permeability O 
and O 
retention O 
( O 
EPR O 
) O 
effect O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
use O 
PICsomes O 
to O 
synthesize O 
a O 
highly O 
sensitive O 
MRI O 
contrast O 
agent O 
for O 
more O 
precise O 
tumor O 
detection O 
. O 
We O 
synthesized O 
SPIO-Cy5-PICsomes O 
( O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticle O 
- O 
loaded O 
Cy5-cross O 
- O 
linked O 
Nano-PICsomes O 
) O 
and O 
characterized O 
them O 
using O 
dynamic O 
light O 
scattering O 
and O 
transmission O 
electron O 
microscopy O 
in O 
vitro O 
and O 
evaluated O 
their O 
ability O 
to O 
detect O 
subcutaneously O 
grafted O 
tumors O 
in O 
vivo O 
with O 
MRI O 
. O 
The O 
transverse O 
relaxivity O 
( O 
r2 O 
) O 
of O 
the O 
SPIO-Cy5-PICsomes O 
(r2=663±28mM(-1)s(-1)) O 
was O 
2.54 O 
times O 
higher O 
than O 
that O 
of O 
bare O 
clinically O 
- O 
used O 
SPIO O 
. O 
In O 
in O 
vivo O 
MRI O 
experiments O 
on O 
mice O 
subcutaneously O 
grafted O 
with O 
colon-26 O 
tumor O 
cells O 
, O 
the O 
tumor O 
signal O 
was O 
significantly O 
altered O 
at O 
3h O 
after O 
SPIO-Cy5-PICsome O 
administration O 
and O 
persisted O 
for O 
at O 
least O 
24h O 
. O 
Small O 
and O 
early O 
- O 
stage O 
in O 
vivo O 
tumors O 
( O 
3days O 
after O 
grafting O 
, O 
approximately O 
4mm(3) O 
) O 
were O 
also O 
clearly O 
detected O 
with O 
MRI O 
. O 
SPIO-loaded O 
PICsomes O 
are O 
sensitive O 
MRI O 
contrast O 
agents O 
that O 
can O 
act O 
as O 
a O 
powerful O 
nanocarrier O 
to O 
detect O 
small O 
tumors O 
for O 
early O 
diagnosis O 
. O 

of O 
restraint O 
- O 
induced O 
corticosterone B-TRIVIAL 
secretion O 
after O 
chronic O 
restraint O 
in O 
rats O 
: O 
Involvement O 
of O 
5-HT7 O 
receptors O 
. O 

( O 
5-HT B-SYSTEMATIC 
) O 
modulates O 
the O 
hypothalamic O 
- O 
pituitary O 
- O 
adrenal O 
( O 
HPA O 
) O 
axis O 
response O 
to O 
stress O 
. O 
We O 
examined O 
the O 
effect O 
of O 
chronic O 
restraint O 
stress O 
( O 
CRS O 
; O 
20 O 
min O 
/ O 
day O 
) O 
as O 
compared O 
to O 
control O 
( O 
CTRL O 
) O 
conditions O 
for O 
14 O 
days O 
, O 
on O 
: O 
1 O 
) O 
restraint O 
- O 
induced O 
ACTH O 
and O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
secretion O 
in O 
rats O 
pretreated O 
with O 
vehicle O 
or O 
SB-656104 B-IDENTIFIER 
( O 
a O 
5-HT7 O 
receptor O 
antagonist O 
) O 
; O 
2 O 
) O 
5-HT7 O 
receptor O 
- O 
like O 
immunoreactivity O 
( O 
5-HT7-LI O 
) O 
and O 
protein O 
in O 
the O 
hypothalamic O 
paraventricular O 
nucleus O 
( O 
PVN O 
) O 
and O 
adrenal O 
glands O 
( O 
AG O 
) O 
; O 
3 O 
) O 
baseline O 
levels O 
of O 
5-HT B-SYSTEMATIC 
and O 
5-hydroxyindolacetic B-ABBREVIATION 
acid I-ABBREVIATION 
( O 
5-HIAA B-SYSTEMATIC 
) O 
, O 
and O 
5-HIAA B-SYSTEMATIC 
/ O 
5-HT B-SYSTEMATIC 
ratio O 
in O 
PVN O 
and O 
AG O 
; O 
and O 
4 O 
) O 
5-HT B-SYSTEMATIC 
-like O 
immunoreactivity O 
( O 
5-HT B-SYSTEMATIC 
-LI O 
) O 
in O 
AG O 
and O 
tryptophan B-TRIVIAL 
hydroxylase O 
( O 
TPH O 
) O 
protein O 
in O 
PVN O 
and O 
AG O 
. O 
On O 
day O 
15 O 
, O 
animals O 
were O 
subdivided O 
into O 
Treatment O 
and O 
No O 
treatment O 
groups O 
. O 
Treatment O 
animals O 
received O 
an O 
i.p O 
. O 
injection O 
of O 
vehicle O 
or O 
SB-656104 B-IDENTIFIER 
; O 
No O 
Treatment O 
animals O 
received O 
no O 
injection O 
. O 
Sixty O 
min O 
later O 
, O 
Treatment O 
animals O 
were O 
either O 
decapitated O 
with O 
no O 
further O 
stress O 
( O 
0 O 
min O 
) O 
or O 
submitted O 
to O 
acute O 
restraint O 
( O 
10 O 
, O 
30 O 
, O 
60 O 
or O 
120 O 
min O 
) O 
; O 
hormone O 
serum O 
levels O 
were O 
measured O 
. O 
No O 
Treatment O 
animals O 
were O 
employed O 
for O 
the O 
rest O 
of O 
measurements O 
. O 
CRS O 
decreased O 
body O 
weight O 
gain O 
and O 
increased O 
adrenal O 
weight O 
. O 
In O 
CTRL O 
animals O 
, O 
acute O 
restraint O 
increased O 
ACTH O 
and O 
CORT B-ABBREVIATION 
secretion O 
in O 
a O 
time O 
of O 
restraint O 
- O 
dependent O 
manner O 
; O 
both O 
responses O 
were O 
inhibited O 
by O 
SB-656104 B-IDENTIFIER 
. O 
Exposure O 
to O 
CRS O 
abolished O 
ACTH O 
but O 
magnified O 
CORT B-ABBREVIATION 
responses O 
to O 
restraint O 
as O 
compared O 
to O 
CTRL O 
conditions O 
; O 
SB-656104 B-IDENTIFIER 
had O 
no O 
effect O 
on O 
ACTH O 
levels O 
but O 
significantly O 
inhibited O 
sensitized O 
CORT B-ABBREVIATION 
responses O 
. O 
In O 
CTRL O 
animals O 
, O 
5-HT7-LI O 
was O 
detected O 
in O 
magnocellular O 
and O 
parvocellular O 
subdivisions O 
of O 
PVN O 
and O 
sparsely O 
in O 
adrenal O 
cortex O 
. O 
Exposure O 
to O 
CRS O 
decreased O 
5-HT7-LI O 
and O 
protein O 
in O 
the O 
PVN O 
, O 
but O 
increased O 
5-HT7-LI O 
in O 
the O 
adrenal O 
cortex O 
and O 
protein O 
in O 
whole O 
AG O 
. O 
Higher O 
5-HT B-SYSTEMATIC 
and O 
5-HIAA B-SYSTEMATIC 
levels O 
were O 
detected O 
in O 
PVN O 
and O 
AG O 
from O 
CRS O 
animals O 
but O 
5-HIAA B-SYSTEMATIC 
/ O 
5-HT B-SYSTEMATIC 
ratio O 
increased O 
in O 
AG O 
only O 
. O 
Finally O 
, O 
whereas O 
5-HT B-SYSTEMATIC 
-LI O 
was O 
sparsely O 
observed O 
in O 
the O 
adrenal O 
cortex O 
of O 
CTRL O 
animals O 
, O 
it O 
strongly O 
increased O 
in O 
the O 
adrenal O 
cortex O 
of O 
CRS O 
animals O 
. O 
No O 
TPH O 
protein O 
was O 
detected O 
in O 
AG O 
from O 
both O 
animal O 
groups O 
. O 
Results O 
suggest O 
that O 
CRS O 
promotes O 
endocrine O 
disruption O 
involving O 
decreased O 
ACTH O 
and O 
sensitized O 
CORT B-ABBREVIATION 
responses O 
to O 
acute O 
restraint O 
. O 
This O 
phenomenon O 
may O 
be O 
associated O 
with O 
increased O 
function O 
and O 
expression O 
of O 
5-HT7 O 
receptors O 
as O 
well O 
as O 
5-HT B-SYSTEMATIC 
turnover O 
in O 
AG O 
. O 

inhibits O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
lipopolysaccharide-stimulated O 
BV2 O 
microglia O 
via O 
NF-κB O 
suppression O 
and O 
Nrf-2-dependent O 
heme O 
oxygenase-1 O 
induction O 
. O 

this O 
study O 
, O 
we O 
found O 
that O 
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone B-SYSTEMATIC 
( O 
5HHMF B-SYSTEMATIC 
) O 
from O 
Hizikia O 
fusiforme O 
considerably O 
inhibits O 
lipopolysaccharide O 
(LPS)-stimulated O 
NO B-FORMULA 
production O 
by O 
suppressing O 
the O 
expression O 
of O 
inducible O 
NO B-FORMULA 
synthase O 
( O 
iNOS O 
) O 
in O 
BV2 O 
microglia O 
. O 
In O 
addition O 
, O 
5HHMF B-SYSTEMATIC 
blocked O 
LPS-induced O 
phosphorylation O 
of O 
IκB O 
, O 
resulting O 
in O 
suppression O 
of O 
the O 
nuclear O 
translocation O 
of O 
nuclear O 
factor-κB O 
( O 
NF-κB O 
) O 
subunits O 
, O 
namely O 
p65 O 
and O 
p50 O 
, O 
which O 
are O 
important O 
molecules O 
involved O 
in O 
the O 
regulation O 
of O 
iNOS O 
expression O 
. O 
Pyrrolidine B-SYSTEMATIC 
dithiocarbamate I-SYSTEMATIC 
( O 
PDTC B-ABBREVIATION 
) O 
, O 
a O 
specific O 
NF-κB O 
inhibitor O 
, O 
along O 
with O 
20S O 
proteasome O 
inhibitor O 
( O 
PSI O 
) O 
significantly O 
inhibited O 
LPS-induced O 
iNOS O 
expression O 
, O 
which O 
indirectly O 
suggested O 
that O 
5HHMF B-SYSTEMATIC 
downregulated O 
iNOS O 
expression O 
by O 
suppressing O 
NF-κB O 
activity O 
. O 
Thus O 
, O 
we O 
found O 
that O 
5HHMF B-SYSTEMATIC 
enhances O 
heme O 
oxygenase-1 O 
( O 
HO-1 O 
) O 
expression O 
via O 
nuclear O 
factor O 
- O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
activation O 
. O 
In O 
addition O 
, O 
cobalt B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
( O 
CoPP B-FORMULA 
) O 
, O 
a O 
specific O 
HO-1 O 
inducer O 
, O 
predominantly O 
suppressed O 
LPS-induced O 
NO B-FORMULA 
production O 
. O 
In O 
contrast O 
, O 
zinc B-SYSTEMATIC 
protoporphyrin I-SYSTEMATIC 
( O 
ZnPP B-FORMULA 
) O 
, O 
a O 
specific O 
HO-1 O 
inhibitor O 
, O 
showed O 
a O 
partial O 
suppressive O 
effect O 
of O 
5HHMF B-SYSTEMATIC 
on O 
LPS-induced O 
NO B-FORMULA 
production O 
. O 
Further O 
, O 
5HHMF B-SYSTEMATIC 
increased O 
specific O 
DNA O 
- O 
binding O 
activity O 
of O 
Nrf2 O 
, O 
and O 
transient O 
knockdown O 
with O 
Nrf2 O 
siRNA O 
subsequently O 
reversed O 
5HHMF B-SYSTEMATIC 
-induced O 
NO B-FORMULA 
inhibition O 
, O 
which O 
was O 
followed O 
by O 
suppression O 
of O 
HO-1 O 
activity O 
. O 
Taken O 
together O 
, O 
our O 
findings O 
indicate O 
that O 
5HHMF B-SYSTEMATIC 
suppresses O 
NO B-FORMULA 
production O 
through O 
modulation O 
of O 
iNOS O 
, O 
consequently O 
suppressing O 
NF-κB O 
activity O 
and O 
induction O 
of O 
Nrf2-dependent O 
HO-1 O 
activity O 
. O 

nanotubes O 
( O 
CNTs O 
) O 
represent O 
promising O 
vectors O 
to O 
facilitate O 
cellular O 
drug O 
delivery O 
and O 
to O 
overcome O 
biological O 
barriers O 
, O 
but O 
some O 
types O 
may O 
also O 
elicit O 
persistent O 
pulmonary O 
inflammation O 
based O 
on O 
their O 
fibre O 
characteristics O 
. O 
Here O 
, O 
we O 
show O 
the O 
pulmonary O 
response O 
to O 
aqueous O 
suspensions O 
of O 
block O 
copolymer O 
dispersed O 
, O 
double O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
DWCNT O 
, O 
length O 
1-10μm O 
) O 
in O 
mice O 
by O 
bronchoalveolar O 
lavage O 
( O 
BAL O 
) O 
analysis O 
, O 
and O 
BAL O 
and O 
blood O 
cytokine O 
and O 
lung O 
antioxidant O 
profiling O 
. O 
The O 
intratracheally O 
instilled O 
dose O 
of O 
50μg O 
DWCNT O 
caused O 
significant O 
pulmonary O 
inflammation O 
that O 
was O 
not O 
resolved O 
during O 
a O 
7-day O 
observation O 
period O 
. O 
Light O 
microscopy O 
investigation O 
of O 
the O 
uptake O 
of O 
DWCNT O 
agglomerates O 
revealed O 
no O 
particle O 
ingestion O 
for O 
granulocytes O 
, O 
but O 
only O 
for O 
macrophages O 
. O 
Accumulating O 
macrophage O 
, O 
multinucleated O 
macrophage O 
and O 
lymphocyte O 
numbers O 
in O 
the O 
alveolar O 
region O 
further O 
indicated O 
ineffective O 
resolution O 
with O 
chronification O 
of O 
the O 
inflammation O 
. O 
The O 
local O 
inflammatory O 
impairment O 
of O 
the O 
lung O 
was O 
accompanied O 
by O 
pulmonary O 
antioxidant O 
depletion O 
and O 
haematological O 
signs O 
of O 
systemic O 
inflammation O 
. O 
While O 
the O 
observed O 
inflammation O 
during O 
its O 
acute O 
phase O 
was O 
dominated O 
by O 
neutrophils O 
and O 
neutrophil O 
recruiting O 
cytokines O 
, O 
the O 
contribution O 
of O 
macrophages O 
and O 
lymphocytes O 
with O 
related O 
cytokines O 
became O 
more O 
significant O 
after O 
day O 
3 O 
of O 
exposure O 
. O 
This O 
study O 
confirms O 
that O 
acute O 
pulmonary O 
toxicity O 
can O 
occur O 
on O 
exposure O 
of O 
high O 
doses O 
of O 
DWCNT O 
agglomerates O 
and O 
offers O 
further O 
insight O 
for O 
improved O 
nanotube O 
design O 
parameters O 
to O 
avoid O 
potential O 
long O 
- O 
term O 
toxicity O 
. O 

effects O 
of O 
17-α-ethinylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
on O 
molecular O 
signaling O 
cascades O 
in O 
mummichog O 
( O 
Fundulus O 
heteroclitus O 
) O 
. O 

to O 
≤ O 
10ng O 
/ O 
L O 
of O 
17-α-ethinylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
will O 
reduce O 
or O 
shut O 
down O 
egg O 
production O 
in O 
freshwater O 
fish O 
models O 
, O 
while O 
mummichog O 
( O 
Fundulus O 
heteroclitus O 
) O 
, O 
an O 
estuarine O 
species O 
, O 
are O 
able O 
to O 
produce O 
eggs O 
at O 
EE2 B-ABBREVIATION 
concentrations O 
> O 
3000ng O 
/ O 
L O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
gain O 
mechanistic O 
insight O 
into O 
how O 
mummichog O 
are O 
able O 
to O 
produce O 
eggs O 
during O 
exposures O 
to O 
high O 
EE2 B-ABBREVIATION 
. O 
Mummichog O 
were O 
exposed O 
to O 
0 O 
, O 
50 O 
or O 
250ng O 
/ O 
L O 
of O 
EE2 B-ABBREVIATION 
for O 
14d O 
. O 
There O 
were O 
no O 
changes O 
in O 
gonadosomatic O 
index O 
, O 
liversomatic O 
index O 
, O 
gonad O 
development O 
, O 
or O 
plasma O 
estradiol B-TRIVIAL 
levels O 
after O 
exposure O 
to O 
EE2 B-ABBREVIATION 
. O 
However O 
, O 
testosterone O 
significantly O 
decreased O 
with O 
EE2 B-ABBREVIATION 
exposures O 
( O 
50 O 
, O 
250ng O 
/ O 
L O 
) O 
. O 
Microarray O 
analysis O 
in O 
the O 
liver O 
revealed O 
that O 
cell O 
processes O 
associated O 
with O 
lipids O 
were O 
affected O 
by O 
EE2 B-ABBREVIATION 
at O 
the O 
transcriptome O 
level O 
. O 
Based O 
on O 
the O 
transcriptomics O 
data O 
, O 
we O 
hypothesize O 
that O 
mummichog O 
are O 
able O 
to O 
maintain O 
lipid O 
transport O 
and O 
uptake O 
into O 
the O 
ovary O 
and O 
this O 
may O 
be O 
associated O 
with O 
apolipoproteins O 
, O 
facilitating O 
normal O 
oocyte O 
development O 
. O 
Novel O 
gene O 
regulatory O 
networks O 
for O 
protein O 
modification O 
targets O 
were O 
also O 
constructed O 
to O 
learn O 
more O 
about O 
the O 
potential O 
roles O 
of O 
estrogens B-FAMILY 
in O 
the O 
teleost O 
liver O 
. O 
Although O 
post O 
- O 
translational O 
modifications O 
( O 
PTMs O 
) O 
are O 
important O 
regulatory O 
mechanisms O 
, O 
the O 
roles O 
of O 
PTMs O 
in O 
protein O 
regulation O 
in O 
fish O 
and O 
the O 
susceptibility O 
of O 
PTMs O 
to O 
aquatic O 
pollutants O 
are O 
largely O 
unexplored O 
and O 
may O 
offer O 
novel O 
insight O 
into O 
mechanisms O 
of O 
endocrine O 
disruption O 
. O 

silencing O 
of O 
three O 
homologues O 
of O 
S-adenosylmethionine B-TRIVIAL 
decarboxylase O 
gene O 
in O 
tapetal O 
tissue O 
of O 
tomato O 
results O 
in O 
male O 
sterility O 
. O 

play O 
very O 
important O 
role O 
in O 
various O 
cellular O 
metabolic O 
functions O 
, O 
including O 
floral O 
induction O 
, O 
floral O 
differentiation O 
and O 
fertility O 
regulation O 
. O 
In O 
the O 
present O 
study O 
, O 
S-adenosylmethionine B-TRIVIAL 
decarboxylase O 
( O 
SAMDC O 
) O 
, O 
a O 
key O 
gene O 
involved O 
in O 
polyamine B-FAMILY 
biosynthesis O 
, O 
has O 
been O 
targeted O 
in O 
tapetal O 
tissue O 
of O 
tomato O 
using O 
RNAi O 
to O 
examine O 
its O 
effect O 
on O 
tapetum O 
development O 
and O 
pollen O 
viability O 
. O 
The O 
target O 
SAMDC O 
gene O 
fragments O 
of O 
three O 
homologues O 
were O 
cloned O 
in O 
a O 
hairpin O 
RNA O 
construct O 
under O 
the O 
control O 
of O 
tapetal O 
- O 
specific O 
A9 O 
promoter O 
, O 
which O 
was O 
used O 
to O 
generate O 
several O 
RNAi O 
tomato O 
plants O 
. O 
These O 
RNAi O 
lines O 
expressed O 
the O 
intended O 
small O 
interfering O 
RNAs O 
in O 
the O 
anther O 
and O 
showed O 
the O 
aborted O 
and O 
sterile O 
pollen O 
exhibiting O 
shrunken O 
and O 
distorted O 
morphology O 
. O 
These O 
RNAi O 
tomato O 
plants O 
having O 
sterile O 
pollen O 
, O 
failed O 
to O 
set O 
fruits O 
but O 
female O 
fertility O 
of O 
the O 
plants O 
remained O 
unaffected O 
as O 
cross O 
pollination O 
resulted O 
in O 
fruit O 
setting O 
. O 
Expression O 
profiling O 
of O 
SAMDC O 
genes O 
showed O 
considerable O 
decrease O 
in O 
transcripts O 
of O 
SAMDC1 O 
( O 
5-8 O 
fold O 
) O 
and O 
SAMDC2 O 
and O 
SAMDC3 O 
( O 
2-3 O 
fold O 
) O 
in O 
the O 
anthers O 
of O 
RNAi O 
plants O 
. O 
The O 
other O 
polyamine B-FAMILY 
biosynthesis O 
genes O 
, O 
ADC O 
and O 
SPDSYN O 
exhibited O 
~1.5 O 
fold O 
decrease O 
in O 
their O 
transcript O 
levels O 
. O 
Presence O 
of O 
siRNA O 
molecules O 
specific O 
to O 
SAMDC O 
homologues O 
in O 
anther O 
and O 
tapetal O 
- O 
specific O 
activity O 
of O 
A9 O 
promoter O 
as O 
shown O 
with O 
GUS O 
reporter O 
system O 
of O 
RNAi O 
plants O 
suggested O 
down O 
- O 
regulation O 
of O 
the O 
target O 
genes O 
in O 
tapetum O 
by O 
RNAi O 
. O 
These O 
observations O 
indicate O 
the O 
importance O 
of O 
SAMDC O 
, O 
in O 
turn O 
polyamines B-FAMILY 
in O 
pollen O 
development O 
, O 
and O 
thus O 
tapetum O 
- O 
specific O 
down O 
- O 
regulation O 
of O 
SAMDC O 
genes O 
using O 
RNAi O 
can O 
be O 
used O 
for O 
developing O 
male O 
sterile O 
plants O 
. O 

Re-evaluation O 
of O 
the O 
Role O 
of O 
hCTR1 O 
, O 
the O 
Human O 
High O 
Affinity O 
Cu B-FORMULA 
Transporter O 
in O 
Pt B-FORMULA 
-Drug O 
Entry O 
into O 
Human O 
Cells O 
. O 

( O 
cDDP B-ABBREVIATION 
) O 
is O 
an O 
anti-cancer O 
drug O 
used O 
in O 
a O 
number O 
of O 
malignancies O 
including O 
testicular O 
, O 
ovarian O 
, O 
cervical O 
, O 
bladder O 
, O 
lung O 
, O 
head O 
, O 
and O 
neck O 
cancers O 
. O 
Its O 
use O 
is O 
limited O 
by O 
the O 
development O 
of O 
resistance O 
, O 
often O 
rationalized O 
via O 
effects O 
on O 
cellular O 
uptake O 
. O 
It O 
has O 
been O 
claimed O 
that O 
hCTR1 O 
, O 
the O 
human O 
high O 
affinity O 
copper B-SYSTEMATIC 
transporter O 
, O 
is O 
the O 
major O 
entry O 
pathway O 
for O 
cDDP B-ABBREVIATION 
and O 
related O 
drugs O 
via O 
a O 
mechanism O 
that O 
mimics O 
copper O 
. O 
This O 
is O 
an O 
unexpected O 
property O 
of O 
hCTR1 O 
, O 
a O 
highly O 
selective O 
copper O 
(I) O 
transporter O 
. O 
We O 
compared O 
the O 
uptake O 
rates O 
of O 
copper O 
with O 
cDDP O 
( O 
and O 
several O 
analogs O 
) O 
into O 
HEK293 O 
cells O 
over O 
- O 
expressing O 
wild O 
- O 
type O 
or O 
mutant O 
hCTR1 O 
, O 
mouse O 
embryonic O 
fibroblasts O 
( O 
mefs O 
) O 
that O 
do O 
or O 
do O 
not O 
express O 
CTR1 O 
, O 
and O 
human O 
ovarian O 
tumor O 
cells O 
, O 
sensitive O 
or O 
resistant O 
to O 
cDDP B-ABBREVIATION 
. O 
We O 
have O 
also O 
compared O 
the O 
effects O 
of O 
extracellular O 
copper B-SYSTEMATIC 
, O 
which O 
causes O 
regulatory O 
endocytosis O 
of O 
hCTR1 O 
, O 
to O 
those O 
of O 
cDDP B-ABBREVIATION 
. O 
We O 
confirm O 
the O 
correlation O 
between O 
higher O 
hCTR1 O 
levels O 
and O 
higher O 
Pt B-FORMULA 
-drug O 
uptake O 
in O 
tumor O 
cells O 
sensitive O 
to O 
the O 
drug O 
. O 
However O 
, O 
we O 
show O 
that O 
hCTR1 O 
is O 
not O 
the O 
major O 
entry O 
route O 
of O 
platinum B-SYSTEMATIC 
-drugs O 
and O 
that O 
the O 
copper B-SYSTEMATIC 
transporter O 
is O 
not O 
internalized O 
in O 
response O 
to O 
extracellular O 
drug O 
. O 
Our O 
data O 
suggest O 
the O 
major O 
entry O 
pathway O 
for O 
platinum B-SYSTEMATIC 
-drugs O 
is O 
not O 
saturable O 
at O 
relevant O 
concentrations O 
and O 
not O 
protein O 
- O 
mediated O 
. O 
Clinical O 
trials O 
have O 
been O 
initiated O 
that O 
depend O 
upon O 
regulating O 
membrane O 
levels O 
of O 
hCTR1 O 
. O 
If O 
reduced O 
drug O 
uptake O 
is O 
a O 
major O 
factor O 
in O 
resistance O 
, O 
hCTR1 O 
is O 
unlikely O 
to O 
be O 
a O 
productive O 
target O 
in O 
attempts O 
to O 
enhance O 
efficacy O 
, O 
although O 
the O 
proteins O 
involved O 
in O 
copper B-SYSTEMATIC 
homeostasis O 
may O 
play O 
a O 
role O 
. O 

induces O 
apoptosis O 
in O 
human O 
thyroid O 
tissue O 
in O 
culture O 
. O 

( O 
(131)I B-FORMULA 
) O 
is O 
routinely O 
used O 
for O 
the O 
treatment O 
of O 
toxic O 
adenoma O 
, O 
Graves' O 
disease O 
, O 
and O 
for O 
ablation O 
of O 
thyroid O 
remnant O 
after O 
thyroidectomy O 
in O 
patients O 
with O 
thyroid O 
cancer O 
. O 
The O 
toxic O 
effects O 
of O 
ionizing O 
radiations O 
on O 
living O 
cells O 
can O 
be O 
mediated O 
by O 
a O 
necrotic O 
and O 
/ O 
or O 
apoptotic O 
process O 
. O 
The O 
involvement O 
of O 
apoptosis O 
in O 
radiation O 
- O 
induced O 
cell O 
death O 
in O 
the O 
thyrocytes O 
has O 
been O 
questioned O 
. O 
The O 
knowledge O 
of O 
the O 
mechanisms O 
that O 
underlie O 
the O 
thyrocyte O 
death O 
in O 
response O 
to O 
radiations O 
can O 
help O 
to O 
achieve O 
a O 
successful O 
treatment O 
with O 
the O 
lowest O 
(131)I B-FORMULA 
dose O 
. O 
We O 
developed O 
a O 
method O 
to O 
study O 
the O 
effects O 
of O 
(131)I B-FORMULA 
in O 
human O 
thyroid O 
tissue O 
in O 
culture O 
, O 
by O 
which O 
we O 
demonstrated O 
that O 
(131)I B-FORMULA 
induces O 
thyroid O 
cell O 
apoptosis O 
. O 
Human O 
thyroid O 
tissues O 
of O 
about O 
1 O 
mm(3) O 
were O 
cultured O 
in O 
vitro O 
and O 
cell O 
viability O 
was O 
determined O 
up O 
to O 
3 O 
weeks O 
by O 
the O 
MTT B-ABBREVIATION 
assay O 
. O 
Radioiodide B-SYSTEMATIC 
added O 
to O 
the O 
culture O 
medium O 
was O 
actively O 
taken O 
up O 
by O 
the O 
tissues O 
. O 
The O 
occurrence O 
of O 
apoptosis O 
in O 
the O 
thyrocytes O 
was O 
assessed O 
by O 
measuring O 
the O 
production O 
of O 
a O 
caspase O 
- O 
cleavage O 
fragment O 
of O 
cytokeratin O 
18 O 
( O 
M30 O 
) O 
by O 
an O 
enzyme O 
- O 
linked O 
immunoassay O 
. O 
Neither O 
variation O 
of O 
cell O 
number O 
nor O 
spontaneous O 
apoptosis O 
was O 
revealed O 
after O 
1 O 
week O 
of O 
culture O 
. O 
(131)I B-FORMULA 
added O 
to O 
the O 
culture O 
medium O 
induced O 
a O 
dose O 
- O 
dependent O 
and O 
a O 
time O 
- O 
dependent O 
generation O 
of O 
M30 O 
fragment O 
. O 
The O 
apoptotic O 
process O 
was O 
confirmed O 
by O 
the O 
generation O 
of O 
caspase-3 O 
and O 
PARP O 
cleavage O 
products O 
. O 
These O 
results O 
demonstrate O 
that O 
(131)I B-FORMULA 
induces O 
apoptosis O 
in O 
human O 
thyrocytes O 
. O 
Human O 
thyroid O 
tissue O 
cultures O 
may O 
be O 
useful O 
to O 
investigate O 
the O 
cell O 
death O 
pathways O 
induced O 
by O 
(131)I B-FORMULA 
. O 

nanocrystals O 
and O 
cellulose O 
nanofibers O 
with O 
I O 
and O 
II O 
crystalline O 
allomorphs O 
( O 
designated O 
as O 
CNC O 
I O 
, O 
CNC O 
II O 
, O 
CNF O 
I O 
, O 
and O 
CNF O 
II O 
) O 
were O 
isolated O 
from O 
bleached O 
wood O 
fibers O 
by O 
alkaline O 
pretreatment O 
and O 
acid O 
hydrolysis O 
. O 
The O 
effects O 
of O 
concentration O 
, O 
particle O 
size O 
, O 
surface O 
charge O 
, O 
and O 
crystal O 
structure O 
on O 
the O 
lyophilization O 
- O 
induced O 
self O 
- O 
assembly O 
of O 
cellulose O 
particles O 
in O 
aqueous O 
suspensions O 
were O 
studied O 
. O 
Within O 
the O 
concentration O 
range O 
of O 
0.5 O 
to O 
1 O 
wt O 
% O 
, O 
cellulose O 
particles O 
self O 
- O 
organized O 
into O 
lamellar O 
structured O 
foam O 
composed O 
of O 
aligned O 
membrane O 
layers O 
with O 
widths O 
between O 
0.5 O 
and O 
3 O 
μm O 
. O 
At O 
0.05 O 
wt O 
% O 
, O 
CNC O 
I O 
, O 
CNF O 
I O 
, O 
CNC O 
II O 
, O 
and O 
CNF O 
II O 
self O 
- O 
assembled O 
into O 
oriented O 
ultrafine O 
fibers O 
with O 
mean O 
diameters O 
of O 
0.57 O 
, O 
1.02 O 
, O 
1.5 O 
, O 
and O 
1 O 
μm O 
, O 
respectively O 
. O 
The O 
size O 
of O 
self O 
- O 
assembled O 
fibers O 
became O 
larger O 
when O 
more O 
hydroxyl B-SYSTEMATIC 
groups O 
and O 
fewer O 
sulfates B-FAMILY 
( O 
weaker O 
electrostatic O 
repulsion O 
) O 
were O 
on O 
cellulose O 
surfaces O 
. O 
Possible O 
formation O 
mechanism O 
was O 
inferred O 
from O 
ice O 
growth O 
and O 
interaction O 
between O 
cellulose O 
nanoparticles O 
in O 
liquid O 
- O 
crystalline O 
suspensions O 
. O 

Strategy O 
to O 
Build O 
Structural O 
Models O 
of O 
Microhydrated O 
Inorganic O 
Systems O 
for O 
the O 
Knowledge O 
of O 
Their O 
Vibrational O 
Properties O 
: O 
The O 
Case O 
of O 
the O 
Hydrated B-SYSTEMATIC 
Nitrate I-SYSTEMATIC 
Aerosols O 
. O 

study O 
provides O 
theoretical O 
anharmonic O 
calculations O 
for O 
microhydrated O 
NaNO3 B-SYSTEMATIC 
-labeled O 
( B-FORMULA 
NaNO3 I-FORMULA 
, I-FORMULA 
nH2O)x I-FORMULA 
with O 
a O 
water O 
- O 
to O 
- O 
solute O 
ratio O 
( O 
n O 
) O 
ranging O 
from O 
1 O 
to O 
3 O 
. O 
A O 
representative O 
geometrical O 
model O 
of O 
these O 
forms O 
was O 
first O 
investigated O 
by O 
simulating O 
the O 
molecular O 
clusters O 
as O 
(NaNO3,1H2O)x B-FORMULA 
with O 
x O 
= O 
1 O 
to O 
4 O 
. O 
The O 
comparison O 
between O 
the O 
calculated O 
time O 
independent O 
anharmonic O 
frequencies O 
using O 
the O 
B3LYP-D O 
/ O 
6-311 O 
+ O 
G(d,p) O 
method O 
and O 
their O 
experimental O 
counterparts O 
led O 
to O 
the O 
choice O 
of O 
a O 
supercluster O 
model O 
. O 
The O 
most O 
probable O 
structures O 
of O 
(NaNO3,nH2O)3 B-FORMULA 
molecular O 
system O 
were O 
investigated O 
by O 
using O 
our O 
global O 
search O 
algorithm O 
we O 
developed O 
recently O 
( O 
GSAM O 
code O 
) O 
both O 
at O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G(d,p) O 
and O 
the O 
B3LYP-D O 
/ O 
6-311 O 
+ O 
G(d,p) O 
levels O 
of O 
theory O 
. O 
The O 
quality O 
of O 
the O 
structural O 
model O 
is O 
illustrated O 
by O 
comparing O 
the O 
B3LYP O 
/ O 
6-311 O 
+ O 
G(d,p) O 
and O 
B3LYP-D O 
/ O 
6-311 O 
+ O 
G(d,p) O 
anharmonic O 
vibrational O 
signatures O 
with O 
those O 
obtained O 
from O 
IR O 
experiments O 
. O 
While O 
an O 
average O 
deviation O 
of O 
16 O 
cm(-1) O 
is O 
observed O 
in O 
the O 
case O 
of O 
the O 
B3LYP O 
computations O 
, O 
the O 
deviation O 
is O 
reduced O 
to O 
7 O 
cm(-1) O 
for O 
the O 
B3LYP-D O 
computations O 
. O 

friction O 
induced O 
by O 
tribochemical O 
reactions O 
: O 
a O 
novel O 
mechanism O 
of O 
lubrication O 
on O 
steel B-TRIVIAL 
surfaces O 
. O 

tribological O 
properties O 
of O 
two O 
steel B-TRIVIAL 
surfaces O 
rubbing O 
against O 
each O 
other O 
are O 
measured O 
while O 
they O 
are O 
in O 
contact O 
with O 
1,3-diketones B-FAMILY 
of O 
varying O 
structure O 
. O 
Such O 
systems O 
show O 
after O 
a O 
short O 
running O 
- O 
in O 
period O 
ultralow O 
friction O 
properties O 
with O 
a O 
coefficient O 
of O 
friction O 
of O 
as O 
low O 
as O 
μ O 
= O 
0.005 O 
. O 
It O 
is O 
suggested O 
that O 
the O 
extremely O 
favorable O 
friction O 
properties O 
are O 
caused O 
by O 
a O 
tribochemical O 
reaction O 
between O 
the O 
1,3-diketones B-FAMILY 
and O 
the O 
steel O 
surfaces O 
, O 
leading O 
to O 
formation O 
of O 
a O 
chelated O 
iron B-SYSTEMATIC 
- O 
diketo B-SYSTEMATIC 
complex O 
. O 
The O 
influence O 
of O 
temperature O 
and O 
the O 
molecular O 
structure O 
of O 
the O 
1,3 B-SYSTEMATIC 
diketo I-SYSTEMATIC 
-lubricants O 
onto O 
the O 
friction O 
properties O 
of O 
the O 
system O 
is O 
elucidated O 
under O 
both O 
static O 
and O 
dynamic O 
conditions O 
. O 
With O 
progression O 
of O 
the O 
tribochemical O 
reaction O 
, O 
the O 
sliding O 
surfaces O 
become O 
very O 
conformal O 
and O 
smooth O 
, O 
so O 
that O 
the O 
pressure O 
is O 
greatly O 
reduced O 
and O 
further O 
wear O 
is O 
strongly O 
reduced O 
. O 
All O 
iron B-SYSTEMATIC 
particles O 
potentially O 
generated O 
by O 
wear O 
during O 
the O 
initial O 
running O 
- O 
in O 
period O 
are O 
completely O 
dissolved O 
through O 
complex O 
formation O 
. O 
It O 
is O 
proposed O 
that O 
the O 
tribochemical O 
polishing O 
reaction O 
causes O 
a O 
transition O 
from O 
boundary O 
lubrication O 
to O 
fluid O 
lubrication O 
. O 

of O 
a O 
novel O 
series O 
of O 
non- O 
nucleoside B-FAMILY 
thumb O 
pocket O 
2 O 
HCV O 
NS5B O 
polymerase O 
inhibitors O 
. O 

novel O 
series O 
of O 
non- O 
nucleoside B-FAMILY 
thumb O 
pocket O 
2 O 
HCV O 
NS5B O 
polymerase O 
inhibitors O 
were O 
derived O 
from O 
a O 
fragment O 
- O 
based O 
approach O 
using O 
information O 
from O 
X-ray O 
crystallographic O 
analysis O 
of O 
NS5B-inhibitor O 
complexes O 
and O 
iterative O 
rounds O 
of O 
parallel O 
synthesis O 
. O 
Structure O 
- O 
based O 
drug O 
design O 
strategies O 
led O 
to O 
the O 
discovery O 
of O 
potent O 
sub O 
- O 
micromolar O 
inhibitors O 
11a-c O 
and O 
12a-c O 
from O 
a O 
weak O 
- O 
binding O 
fragment O 
- O 
like O 
structure O 
1 O 
as O 
a O 
starting O 
point O 
. O 

reduces O 
lipopolysaccharide-induced O 
fever O 
by O 
inhibiting O 
cyclooxygenase-2 O 
. O 

is O 
one O 
of O 
the O 
world's O 
most O 
commonly O 
used O 
drugs O 
to O 
treat O 
fever O 
and O 
pain O 
, O 
yet O 
its O 
mechanism O 
of O 
action O 
has O 
remained O 
unclear O 
. O 
Here O 
we O 
tested O 
the O 
hypothesis O 
that O 
acetaminophen B-TRIVIAL 
blocks O 
fever O 
through O 
inhibition O 
of O 
cyclooxygenase-2 O 
( O 
Cox-2 O 
) O 
, O 
by O 
monitoring O 
lipopolysaccharide O 
induced O 
fever O 
in O 
mice O 
with O 
genetic O 
manipulations O 
of O 
enzymes O 
in O 
the O 
prostaglandin B-FAMILY 
cascade O 
. O 
We O 
exploited O 
the O 
fact O 
that O 
lowered O 
levels O 
of O 
a O 
specific O 
enzyme O 
make O 
the O 
system O 
more O 
sensitive O 
to O 
any O 
further O 
inhibition O 
of O 
the O 
same O 
enzyme O 
. O 
Mice O 
were O 
immune O 
challenged O 
by O 
an O 
intraperitoneal O 
injection O 
of O 
bacterial O 
wall O 
lipopolysaccharide O 
and O 
their O 
body O 
temperature O 
recorded O 
by O 
telemetry O 
. O 
We O 
found O 
that O 
mice O 
heterozygous O 
for O 
Cox-2 O 
, O 
but O 
not O 
for O 
microsomal O 
prostaglandin B-FAMILY 
E I-FAMILY 
synthase-1 O 
( O 
mPGES-1 O 
) O 
, O 
displayed O 
attenuated O 
fever O 
, O 
indicating O 
a O 
rate O 
limiting O 
role O 
of O 
Cox-2 O 
. O 
We O 
then O 
titrated O 
a O 
dose O 
of O 
acetaminophen B-TRIVIAL 
that O 
did O 
not O 
inhibit O 
the O 
lipopolysaccharide-induced O 
fever O 
in O 
wild O 
- O 
type O 
mice O 
. O 
However O 
, O 
when O 
the O 
same O 
dose O 
of O 
acetaminophen B-TRIVIAL 
was O 
given O 
to O 
Cox-2 O 
heterozygous O 
mice O 
, O 
the O 
febrile O 
response O 
to O 
lipopolysaccharide O 
was O 
strongly O 
attenuated O 
, O 
resulting O 
in O 
an O 
almost O 
normalized O 
temperature O 
curve O 
, O 
whereas O 
no O 
difference O 
was O 
seen O 
between O 
wild O 
- O 
type O 
and O 
heterozygous O 
mPGES-1 O 
mice O 
. O 
Furthermore O 
, O 
the O 
fever O 
to O 
intracerebrally O 
injected O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
was O 
unaffected O 
by O 
acetaminophen B-TRIVIAL 
treatment O 
. O 
These O 
findings O 
reveal O 
that O 
acetaminophen B-TRIVIAL 
, O 
similar O 
to O 
aspirin B-TRIVIAL 
and O 
other O 
non-steroidal O 
anti-inflammatory O 
drugs O 
, O 
is O 
antipyretic O 
by O 
inhibiting O 
cyclooxygenase-2 O 
, O 
and O 
not O 
by O 
inhibiting O 
mPGES-1 O 
or O 
signaling O 
cascades O 
downstream O 
of O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
. O 

by O 
Australian O 
black O 
snakes O 
( O 
Pseudechis O 
spp O 
. O 
) O 
do O 
not O 
cause O 
neurotoxicity O 
in O 
human O 
envenoming O 
. O 
This O 
is O 
unusual O 
as O 
in O 
vitro O 
neurotoxicity O 
has O 
been O 
reported O 
for O 
all O 
Pseudechis O 
spp O 
. O 
venoms O 
. O 
The O 
present O 
study O 
aimed O 
to O 
identify O 
, O 
isolate O 
and O 
characterise O 
neurotoxins O 
from O 
the O 
venoms O 
of O 
Pseudechis O 
porphyriacus O 
and O 
Pseudechis O 
colletti O 
to O 
elucidate O 
the O 
reason O 
for O 
the O 
lack O 
of O 
neurotoxicity O 
in O 
humans O 
. O 
α-Elapitoxin-Ppr1 O 
and O 
α-elapitoxin-Pc1 O 
were O 
isolated O 
from O 
P O 
. O 
porphyriacus O 
and O 
P O 
. O 
colletti O 
, O 
respectively O 
, O 
using O 
reverse O 
- O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
. O 
Each O 
toxin O 
consisted O 
of O 
62 O 
amino O 
acids O 
with O 
molecular O 
weights O 
of O 
6746.5Da O 
and O 
6759.6Da O 
, O 
respectively O 
. O 
α-Elapitoxin-Ppr1 O 
and O 
α-elapitoxin-Pc1 O 
caused O 
concentration O 
- O 
dependent O 
( O 
0.1-0.3μM O 
) O 
inhibition O 
of O 
indirect O 
twitches O 
in O 
the O 
chick O 
biventer O 
cervicis O 
nerve O 
- O 
muscle O 
preparation O 
. O 
Both O 
toxins O 
inhibited O 
contractile O 
responses O 
to O 
exogenous O 
ACh B-ABBREVIATION 
and O 
CCh O 
, O 
but O 
not O 
KCl B-FORMULA 
, O 
suggesting O 
a O 
post O 
- O 
synaptic O 
mode O 
of O 
action O 
at O 
the O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
nAChR O 
) O 
. O 
CCh O 
concentration O 
- O 
response O 
curves O 
obtained O 
in O 
the O 
presence O 
or O 
absence O 
of O 
α-elapitoxin-Ppr1 O 
or O 
α-elapitoxin-Pc1 O 
indicated O 
pA2 O 
values O 
of O 
6.97±0.03 O 
and O 
7.04±0.07 O 
, O 
respectively O 
. O 
Neither O 
α-elapitoxin-Ppr1 O 
( O 
0.1μM O 
) O 
nor O 
α-elapitoxin-Pc1 O 
( O 
0.1μM O 
) O 
had O 
a O 
significant O 
effect O 
on O 
the O 
electrically O 
- O 
induced O 
twitches O 
of O 
the O 
rat O 
isolated O 
phrenic O 
nerve O 
- O 
diaphragm O 
preparation O 
. O 
When O 
the O 
venom O 
with O 
the O 
toxin O 
removed O 
( O 
10μg O 
/ O 
ml O 
) O 
was O 
added O 
to O 
both O 
the O 
rat O 
and O 
chick O 
preparations O 
, O 
the O 
inhibition O 
was O 
significantly O 
less O 
than O 
that O 
caused O 
by O 
the O 
intact O 
whole O 
venoms O 
( O 
10μg O 
/ O 
ml O 
) O 
. O 
The O 
current O 
study O 
shows O 
that O 
α-elapitoxin-Ppr1 O 
and O 
α-elapitoxin-Pc1 O 
act O 
as O 
pseudo O 
- O 
irreversible O 
antagonists O 
at O 
the O 
nAChR O 
of O 
the O 
skeletal O 
neuromuscular O 
junction O 
and O 
that O 
the O 
avian O 
preparation O 
is O 
more O 
sensitive O 
to O 
the O 
neurotoxic O 
effects O 
of O 
these O 
toxins O 
than O 
the O 
mammalian O 
preparation O 
. O 

saponins B-FAMILY 
of O 
Panax O 
notoginseng O 
enhance O 
VEGF O 
and O 
relative O 
receptors O 
signals O 
and O 
promote O 
angiogenesis O 
derived O 
from O 
rat O 
bone O 
marrow O 
mesenchymal O 
stem O 
cells O 
. O 

Vitro O 
Metabolism O 
and O 
Kinetics O 
Studies O 
on O 
Methylone B-TRIVIAL 
. O 

of O 
the O 
stimulant O 
designer O 
drug O 
methylone B-TRIVIAL 
( O 
methylenedioxymethcathinone B-SYSTEMATIC 
) O 
has O 
been O 
documented O 
in O 
most O 
parts O 
of O 
the O 
world O 
. O 
As O 
with O 
many O 
of O 
the O 
new O 
designer O 
drugs O 
that O 
continuously O 
appear O 
in O 
the O 
illicit O 
drug O 
market O 
, O 
little O 
is O 
known O 
about O 
the O 
pharmacokinetics O 
of O 
methylone B-TRIVIAL 
. O 
Using O 
in O 
vitro O 
studies O 
, O 
CYP2D6 O 
was O 
determined O 
to O 
be O 
the O 
primary O 
enzyme O 
that O 
metabolizes O 
methylone B-TRIVIAL 
, O 
with O 
minor O 
contributions O 
from O 
CYP1A2 O 
, O 
CYP2B6 O 
, O 
and O 
CYP2C19 O 
. O 
The O 
major O 
metabolite O 
was O 
identified O 
as O 
dihydroxymethcathinone B-SYSTEMATIC 
, O 
and O 
the O 
minor O 
metabolites O 
were O 
N-hydroxy-methylone B-SYSTEMATIC 
, O 
nor-methylone O 
, O 
and O 
dihydro-methylone B-SYSTEMATIC 
. O 
Measuring O 
the O 
formation O 
of O 
the O 
major O 
metabolite O 
, O 
biphasic O 
Michaelis-Menten O 
kinetic O 
parameters O 
were O 
determined O 
: O 
Vmax,1 O 
= O 
0.046 O 
± O 
0.005 O 
( O 
S.E O 
. O 
) O 
nmol O 
/ O 
min O 
/ O 
mg O 
protein O 
, O 
Km,1 O 
= O 
19 O 
± O 
4.2 O 
μM O 
, O 
Vmax,2 O 
= O 
0.22 O 
± O 
0.04 O 
nmol O 
/ O 
min O 
/ O 
mg O 
protein O 
, O 
and O 
Km,2 O 
= O 
1953 O 
± O 
761 O 
μM O 
; O 
the O 
low O 
- O 
capacity O 
and O 
high O 
- O 
affinity O 
contribution O 
was O 
assigned O 
to O 
the O 
activity O 
of O 
CYP2D6 O 
. O 
Additionally O 
, O 
a O 
time O 
- O 
dependent O 
loss O 
of O 
CYP2D6 O 
activity O 
was O 
observed O 
when O 
the O 
enzyme O 
was O 
preincubated O 
with O 
methylone O 
, O 
reaching O 
a O 
maximum O 
rate O 
of O 
inactivation O 
at O 
high O 
methylone B-TRIVIAL 
concentrations O 
, O 
indicating O 
that O 
methylone B-TRIVIAL 
is O 
a O 
mechanism O 
- O 
based O 
inhibitor O 
of O 
CYP2D6 O 
. O 
The O 
inactivation O 
parameters O 
were O 
determined O 
to O 
be O 
KI O 
= O 
15.1 O 
± O 
3.4 O 
( O 
S.E O 
) O 
μM O 
and O 
kinact O 
= O 
0.075 O 
± O 
0.005 O 
min(-1) O 
. O 

of O 
Five O 
New O 
Flavonoids B-FAMILY 
from O 
Melicope O 
triphylla O 
. O 

new O 
flavonoids B-FAMILY 
, O 
5,8-dihydroxy-3,7-dimethoxy-3',4'-methylenedioxyflavone B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
7-hydroxy-3,5-dimethoxy-3',4'-methylenedioxyflavone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
7-(2,3-dihydroxy-3-methylbutoxy)-3,5-dimethoxy-3',4'-methylenedioxyflavone B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
7-(2,3-dihydroxy-3-methylbutoxy)-3,3',4',5-tetramethoxyflavone B-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
7-(2,3-dihydroxy-3-methylbutoxy)-3,3',4',5,8-pentamethoxyflavone B-SYSTEMATIC 
( O 
5 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
leaves O 
of O 
Melicope O 
triphylla O 
. O 
In O 
addition O 
, O 
six O 
known O 
flavonoids B-FAMILY 
were O 
detected O 
: O 
3,4',5-trihydroxy-3',7,8-trimethoxyflavone B-SYSTEMATIC 
( O 
6 O 
) O 
, O 
5,7-dihydroxy-3-methoxy-3',4'-methylenedioxyflavone B-SYSTEMATIC 
( O 
7 O 
) O 
, O 
4',5,7-trihydroxy-3,3'-dimethoxyflavone B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
4',7-dihydroxy-3,3',5,8-tetramethoxyflavone B-SYSTEMATIC 
( O 
9 O 
) O 
, O 
4',7-dihydroxy-3,3',5-trimethoxyflavone B-SYSTEMATIC 
( O 
10 O 
) O 
, O 
and O 
4',5,7-trihydroxy-3,3',8-trimethoxyflavone B-SYSTEMATIC 
( O 
11 O 
) O 
. O 
The O 
new O 
compound O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
methods O 
. O 
Compounds O 
1-5 O 
did O 
not O 
exhibit O 
any O 
ichthyotoxic O 
activity O 
against O 
Japanese O 
killifish O 
( O 
medaka O 
in O 
Japanese O 
) O 
( O 
Oryzias O 
latipes O 
var O 
. O 
) O 
at O 
10 O 
ppm O 
. O 

of O 
2,3-Bis(halomethyl)quinoxaline B-FAMILY 
Derivatives O 
and O 
Evaluation O 
of O 
Their O 
Antibacterial O 
and O 
Antifungal O 
Activities O 
. O 

derivatives O 
having O 
bis(fluoromethyl) B-SYSTEMATIC 
, O 
bis(chloromethyl) B-SYSTEMATIC 
, O 
or O 
bis(iodomethyl) B-SYSTEMATIC 
groups O 
at O 
the O 
2- O 
and O 
3- O 
positions O 
, O 
and O 
various O 
electron O 
- O 
donating O 
/ O 
withdrawing O 
substituents O 
at O 
the O 
6- O 
and O 
/ O 
or O 
7- O 
positions O 
, O 
were O 
synthesized O 
. O 
Their O 
antibacterial O 
and O 
antifungal O 
activities O 
were O 
evaluated O 
by O 
means O 
of O 
minimum O 
inhibitory O 
concentration O 
assays O 
. O 
The O 
relationships O 
between O 
the O 
substituents O 
and O 
the O 
antimicrobial O 
activities O 
of O 
the O 
quinoxaline B-SYSTEMATIC 
derivatives O 
indicate O 
that O 
the O 
electrophilicity O 
of O 
the O 
halomethyl B-FAMILY 
units O 
plays O 
an O 
important O 
role O 
in O 
generating O 
the O 
antimicrobial O 
activity O 
. O 

Flowers O 
. O 
XXXVIII O 
. O 
Structures O 
of O 
Acylated B-FAMILY 
Sucroses I-FAMILY 
and O 
Inhibitory O 
Effects O 
of O 
Constituents O 
on O 
Aldose O 
Reducatase O 
from O 
the O 
Flower O 
Buds O 
of O 
Prunus O 
mume O 
. O 

methanolic O 
extract O 
from O 
the O 
flower O 
buds O 
of O 
Prunus O 
mume O 
, O 
cultivated O 
in O 
Zhejiang O 
province O 
, O 
China O 
, O 
showed O 
an O 
inhibitory O 
effect O 
on O 
aldose B-FAMILY 
reductase O 
. O 
From O 
the O 
methanolic O 
extract O 
, O 
five O 
new O 
acylated B-FAMILY 
sucroses I-FAMILY 
, O 
mumeoses B-MULTIPLE 
F-J I-MULTIPLE 
, O 
were O 
isolated O 
together O 
with O 
29 O 
known O 
compounds O 
. O 
The O 
chemical O 
structures O 
of O 
the O 
new O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
chemical O 
and O 
physicochemical O 
evidence O 
. O 
The O 
inhibitory O 
effects O 
of O 
the O 
isolated O 
compounds O 
on O 
aldose B-FAMILY 
reductase O 
were O 
also O 
investigated O 
. O 
Acylated B-FAMILY 
quinic I-FAMILY 
acid I-FAMILY 
analogs O 
, O 
which O 
are O 
one O 
of O 
the O 
major O 
compounds O 
of O 
the O 
flower O 
buds O 
of O 
P O 
. O 
mume O 
, O 
were O 
shown O 
to O 
substantially O 
inhibit O 
aldose B-FAMILY 
reductase O 
. O 
In O 
particular O 
, O 
mumeic B-TRIVIAL 
acid-A I-TRIVIAL 
was O 
found O 
to O 
exhibit O 
a O 
potent O 
inhibitory O 
effect O 
[ O 
IC50=0.4 O 
µm O 
] O 
. O 

abstract O 
> O 
Aim O 
of O 
the O 
study O 
: O 
Traditionally O 
herbal O 
formulations O 
have O 
been O 
used O 
effectively O 
for O 
the O 
management O 
of O 
disorders O 
that O 
are O 
now O 
being O 
accepted O 
worldwide O 
. O 
Saraca O 
asoca O 
bark O 
extract O 
( O 
SAE O 
) O 
finds O 
use O 
in O 
traditional O 
herbal O 
medicine O 
. O 
In O 
the O 
present O 
study O 
, O 
SAE O 
were O 
studied O 
for O 
their O 
antioxidant O 
, O 
antimutagenic O 
, O 
and O 
antigenotoxic O 
properties O 
. O 
METHODS O 
: O 
SAE O 
were O 
evaluated O 
for O 
antimutagenic O 
property O 
in O 
Salmonella O 
strains O 
( O 
TA97a O 
, O 
TA98 O 
, O 
TA100 O 
, O 
and O 
TA102 O 
) O 
, O 
in O 
the O 
presence O 
and O 
absence O 
of O 
metabolic O 
activation O 
( O 
S9 O 
) O 
. O 
The O 
SAE O 
was O 
also O 
studied O 
for O 
antigenotoxic O 
property O 
against O 
cyclophosphamide B-TRIVIAL 
( O 
CP O 
) O 
in O 
Swiss O 
albino O 
male O 
mice O 
in O 
vivo O 
. O 
The O 
extract O 
was O 
analyzed O 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
. O 
RESULTS O 
: O 
The O 
study O 
reveals O 
antimutagenic O 
property O 
of O 
the O 
bark O 
extract O 
in O 
Salmonella O 
strains O 
in O 
the O 
presence O 
and O 
absence O 
of O 
metabolic O 
activation O 
( O 
S9 O 
) O 
. O 
The O 
study O 
reports O 
antigenotoxic O 
property O 
of O 
the O 
bark O 
extract O 
against O 
CP O 
in O 
vivo O 
. O 
Thiobarbituric B-TRIVIAL 
acid I-TRIVIAL 
reactive O 
species O 
assay O 
on O 
the O 
bark O 
extract O 
revealed O 
antioxidant O 
property O 
. O 
HPLC O 
revealed O 
the O 
presence O 
of O 
two O 
peaks O 
corresponding O 
to O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
and O 
(-)-epicatechin B-SYSTEMATIC 
, O 
respectively O 
. O 
CONCLUSION O 
: O 
The O 
study O 
clearly O 
reveals O 
the O 
antimutagenic O 
and O 
antigenotoxic O 
properties O 
of O 
SAE O 
. O 
< O 
/ O 
abstract> O 

- O 
interpretation O 
of O 
gas O 
phase O 
infrared O 
spectra O 
based O 
on O 
high O 
- O 
level O 
vibrational O 
configuration O 
interaction O 
calculations O 
. O 

is O 
a O 
highly O 
explosive O 
substance O 
, O 
which O 
has O 
been O 
synthesized O 
and O 
characterized O 
for O 
the O 
first O 
time O 
quite O 
recently O 
[ O 
Banert O 
et O 
al O 
. O 
, O 
Angew O 
. O 
Chem O 
. O 
, O 
Int O 
. O 
Ed O 
. O 
, O 
2012 O 
, O 
51 O 
, O 
7515 O 
] O 
. O 
As O 
outlined O 
in O 
this O 
work O 
, O 
the O 
vibrational O 
spectrum O 
of O 
azidoacetylene B-SYSTEMATIC 
is O 
dominated O 
by O 
strong O 
couplings O 
. O 
For O 
that O 
reason O 
, O 
we O 
have O 
studied O 
the O 
vibrational O 
spectrum O 
of O 
the O 
title O 
compound O 
by O 
gas O 
phase O 
measurements O 
and O 
high O 
- O 
level O 
vibrational O 
structure O 
calculations O 
beyond O 
the O 
harmonic O 
approximation O 
. O 
Based O 
on O 
the O 
interplay O 
of O 
theory O 
and O 
experiment O 
, O 
we O 
were O 
able O 
to O 
identify O 
all O 
fundamentals O 
, O 
strong O 
Fermi O 
resonances O 
and O 
intense O 
overtones O 
, O 
which O 
contribute O 
to O 
the O 
spectrum O 
. O 

5 O 
' O 
flanking O 
region O 
of O 
Gonadotropin O 
Regulated O 
Testicular O 
RNA O 
Helicase O 
( O 
GRTH O 
/ O 
DDX25 O 
) O 
gene O 
directs O 
its O 
cell O 
specific O 
androgen B-FAMILY 
regulated O 
gene O 
expression O 
in O 
testicular O 
germ O 
cells O 
. O 

Regulated O 
Testicular O 
RNA O 
Helicase O 
( O 
GRTH O 
/ O 
Ddx25 O 
) O 
is O 
a O 
post O 
- O 
transcriptional O 
regulator O 
of O 
genes O 
that O 
are O 
essential O 
for O 
spermatid O 
elongation O 
and O 
completion O 
of O 
spermatogenesis O 
. O 
It O 
also O 
prevents O 
Leydig O 
cells O 
( O 
LC O 
) O 
from O 
gonadotropin O 
overstimulation O 
of O 
androgen B-FAMILY 
production O 
. O 
In O 
transgenic O 
( O 
Tg O 
) O 
mice O 
carrying O 
deletions O 
of O 
the O 
GRTH O 
5 O 
' O 
flanking O 
regions O 
we O 
previously O 
demonstrated O 
that O 
the O 
-1085 O 
bp O 
to O 
ATG O 
contains O 
the O 
elements O 
for O 
basal O 
and O 
androgen B-FAMILY 
-induced O 
LC O 
specific O 
expression O 
. O 
No O 
expression O 
in O 
germ O 
cells O 
( O 
GC O 
) O 
was O 
found O 
with O 
sequences O 
extended O 
up O 
to O 
-3.6 O 
Kb O 
. O 
To O 
define O 
regulatory O 
regions O 
of O 
GRTH O 
required O 
for O 
expression O 
in O 
GC O 
, O 
Tg O 
mice O 
were O 
generated O 
with O 
5 O 
' O 
flanking O 
sequence O 
6.4 O 
Kb O 
( O 
6.4 O 
Kb-Tg O 
) O 
and O 
/ O 
or O 
deletion O 
using O 
GFP O 
as O 
reporter O 
gene O 
in O 
the O 
present O 
study O 
. O 
GFP O 
was O 
expressed O 
in O 
all O 
lines O 
. O 
Immuno O 
- O 
histochemistry O 
analysis O 
showed O 
that O 
6.4Kb-Tg O 
directed O 
GFP O 
expression O 
in O 
both O 
GC O 
and O 
LC O 
. O 
Deletion O 
of O 
the O 
sequence O 
-205 O 
bp O 
to O 
-3.6 O 
Kb O 
( O 
6.4Kb O 
/ O 
del-Tg O 
) O 
directs O 
GFP O 
expression O 
only O 
in O 
meiotic O 
and O 
haploid O 
GCs O 
. O 
This O 
indicated O 
that O 
the O 
distal O 
region O 
-6.4 O 
Kb O 
/ O 
-3.6 O 
Kb O 
is O 
required O 
for O 
GRTH O 
cell O 
specific O 
expression O 
in O 
GC O 
. O 
Also O 
, O 
it O 
inhibits O 
the O 
expression O 
of O 
GRTH O 
in O 
LC O 
directed O 
by O 
the O 
205 O 
bp O 
promoter O 
, O 
an O 
effect O 
that O 
is O 
neutralized O 
by O 
the O 
-3.6Kb O 
/ O 
-205bp O 
sequence O 
. O 
Flutamide O 
treatment O 
prevents O 
GFP O 
/ O 
GRTH O 
expression O 
in O 
Tg O 
lines O 
demonstrating O 
in O 
vivo O 
direct O 
and O 
indirect O 
effects O 
of O 
endogenous O 
androgen B-FAMILY 
on O 
GC O 
and O 
LC O 
, O 
respectively O 
. O 
Our O 
studies O 
have O 
generated O 
and O 
characterized O 
transgenic O 
lines O 
that O 
can O 
be O 
utilized O 
to O 
define O 
requirements O 
for O 
cell O 
specific O 
expression O 
of O 
the O 
GRTH O 
gene O 
and O 
to O 
further O 
advance O 
our O 
knowledge O 
on O 
the O 
regulation O 
of O 
GRTH O 
by O 
androgen B-FAMILY 
in O 
germ O 
cells O 
. O 

Receptor-α O 
Variant O 
, O 
ER-α36 O 
, O 
is O 
Involved O 
in O 
Tamoxifen B-TRIVIAL 
Resistance O 
and O 
Estrogen B-FAMILY 
Hypersensitivity O 
. O 

such O 
as O 
tamoxifen B-TRIVIAL 
provided O 
a O 
successful O 
treatment O 
for O 
ER-positive O 
breast O 
cancer O 
for O 
the O 
past O 
two O 
decades O 
. O 
However O 
, O 
most O 
breast O 
tumors O 
are O 
eventually O 
resistant O 
to O 
tamoxifen B-TRIVIAL 
therapy O 
. O 
The O 
molecular O 
mechanisms O 
underlying O 
tamoxifen B-TRIVIAL 
resistance O 
have O 
not O 
been O 
well O 
established O 
. O 
Recently O 
, O 
we O 
reported O 
that O 
breast O 
cancer O 
patients O 
with O 
tumors O 
expressing O 
high O 
concentrations O 
of O 
ER-α36 O 
, O 
a O 
variant O 
of O 
ER-α O 
, O 
benefited O 
less O 
from O 
tamoxifen B-TRIVIAL 
therapy O 
than O 
those O 
with O 
low O 
concentrations O 
of O 
ER-α36 O 
, O 
suggesting O 
that O 
increased O 
ER-α36 O 
concentration O 
is O 
one O 
of O 
the O 
underlying O 
mechanisms O 
of O 
tamoxifen B-TRIVIAL 
resistance O 
. O 
Here O 
, O 
we O 
investigated O 
the O 
function O 
and O 
underlying O 
mechanism O 
of O 
ER-α36 O 
in O 
tamoxifen B-TRIVIAL 
resistance O 
. O 
We O 
found O 
that O 
tamoxifen B-TRIVIAL 
increased O 
ER-α36 O 
concentrations O 
and O 
tamoxifen B-TRIVIAL 
-resistant O 
MCF7 O 
cells O 
expressed O 
high O 
concentrations O 
of O 
ER-α36 O 
. O 
In O 
addition O 
, O 
MCF7 O 
cells O 
with O 
forced O 
expression O 
of O 
recombinant O 
ER-α36 O 
and O 
H3396 O 
cells O 
expressing O 
high O 
concentrations O 
of O 
endogenous O 
ER-α36 O 
were O 
resistant O 
to O 
tamoxifen B-TRIVIAL 
. O 
ER-α36 O 
downregulation O 
in O 
tamoxifen B-TRIVIAL 
-resistant O 
cells O 
with O 
the O 
shRNA O 
method O 
restored O 
tamoxifen B-TRIVIAL 
sensitivity O 
. O 
We O 
also O 
found O 
tamoxifen B-TRIVIAL 
acted O 
as O 
a O 
potent O 
agonist O 
by O 
activating O 
phosphorylation O 
of O 
the O 
AKT O 
kinase O 
in O 
ER-α36 O 
expressing O 
cells O 
. O 
Finally O 
, O 
we O 
found O 
that O 
cells O 
with O 
high O 
concentration O 
of O 
ER-α36 O 
protein O 
were O 
hypersensitive O 
to O 
estrogen B-FAMILY 
; O 
activating O 
ERK O 
phosphorylation O 
at O 
pM O 
range O 
. O 
Our O 
results O 
thus O 
demonstrated O 
that O 
elevated O 
ER-α36 O 
concentration O 
is O 
one O 
of O 
the O 
mechanisms O 
by O 
which O 
ER-positive O 
breast O 
cancer O 
cells O 
escape O 
tamoxifen B-TRIVIAL 
therapy O 
and O 
provided O 
a O 
rational O 
to O 
develop O 
novel O 
therapeutic O 
approaches O 
for O 
tamoxifen B-TRIVIAL 
resistant O 
patients O 
by O 
targeting O 
ER-α36 O 
. O 

- O 
like O 
peptide O 
3 O 
( O 
INSL3 O 
) O 
, O 
a O 
major O 
product O 
of O 
testicular O 
Leydig O 
cells O 
, O 
is O 
also O 
expressed O 
by O 
the O 
ovary O 
, O 
but O 
its O 
functional O 
role O 
remains O 
poorly O 
understood O 
. O 
Here O 
, O 
we O 
quantified O 
expression O 
of O 
INSL3 O 
and O 
its O 
receptor O 
RXFP2 O 
in O 
theca O 
interna O 
cell O 
( O 
TIC O 
) O 
and O 
granulosa O 
cell O 
compartments O 
of O 
developing O 
bovine O 
antral O 
follicles O 
and O 
in O 
corpora O 
lutea O 
( O 
CL O 
) O 
. O 
INSL3 O 
and O 
RXFP2 O 
mRNA O 
levels O 
were O 
much O 
higher O 
in O 
TIC O 
than O 
granulosa O 
cell O 
and O 
increased O 
progressively O 
during O 
follicle O 
maturation O 
with O 
INSL3 O 
peaking O 
in O 
large O 
( O 
11-18 O 
mm O 
) O 
estrogen B-FAMILY 
-active O 
follicles O 
and O 
RXFP2 O 
peaking O 
in O 
9- O 
to O 
10-mm O 
follicles O 
before O 
declining O 
in O 
larger O 
( O 
11-18 O 
mm O 
) O 
follicles O 
. O 
Expression O 
of O 
both O 
INSL3 O 
and O 
RXFP2 O 
in O 
CL O 
was O 
much O 
lower O 
than O 
in O 
TIC O 
. O 
In O 
situ O 
hybridization O 
and O 
immunohistochemistry O 
confirmed O 
abundant O 
expression O 
of O 
INSL3 O 
mRNA O 
and O 
protein O 
in O 
TIC O 
. O 
These O 
observations O 
indicate O 
follicular O 
TIC O 
rather O 
than O 
CL O 
as O 
the O 
primary O 
site O 
of O 
both O 
INSL3 O 
production O 
and O 
action O 
, O 
implying O 
a O 
predominantly O 
autocrine O 
/ O 
paracrine O 
role O 
in O 
TIC O 
. O 
To O 
corroborate O 
the O 
above O 
findings O 
, O 
we O 
showed O 
that O 
in O 
vitro O 
exposure O 
of O 
TIC O 
to O 
a O 
luteinizing O 
concentration O 
of O 
LH O 
greatly O 
attenuated O 
expression O 
of O 
both O 
INSL3 O 
and O 
its O 
receptor O 
while O 
increasing O 
progesterone B-TRIVIAL 
secretion O 
and O 
expression O 
of O 
STAR O 
and O 
CYP11A1 O 
. O 
Moreover O 
, O 
in O 
vivo O 
, O 
a O 
significant O 
cyclic O 
variation O 
in O 
plasma O 
INSL3 O 
was O 
observed O 
during O 
synchronized O 
estrous O 
cycles O 
. O 
INSL3 O 
and O 
estradiol-17β B-SYSTEMATIC 
followed O 
a O 
similar O 
pattern O 
, O 
both O 
increasing O 
after O 
luteolysis O 
, O 
before O 
falling O 
sharply O 
after O 
the O 
LH O 
surge O 
. O 
Thus O 
, O 
theca O 
- O 
derived O 
INSL3 O 
, O 
likely O 
from O 
the O 
dominant O 
preovulatory O 
follicle O 
, O 
is O 
detectable O 
in O 
peripheral O 
blood O 
of O 
cattle O 
, O 
and O 
expression O 
is O 
down O 
- O 
regulated O 
during O 
luteinization O 
induced O 
by O 
the O 
preovulatory O 
LH O 
surge O 
. O 
Collectively O 
, O 
these O 
findings O 
underscore O 
the O 
likely O 
role O 
of O 
INSL3 O 
as O 
an O 
important O 
intrafollicular O 
modulator O 
of O 
TIC O 
function O 
/ O 
steroidogenesis O 
, O 
while O 
raising O 
doubts O 
about O 
its O 
potential O 
contribution O 
to O 
CL O 
function O 
. O 

functions O 
of O 
microRNAs O 
( O 
miRNAs O 
) O 
as O 
either O 
oncogenes O 
or O 
tumor O 
suppressors O 
in O 
regulating O 
cancer O 
- O 
related O 
events O 
have O 
been O 
established O 
. O 
We O 
analyzed O 
the O 
alterations O 
in O 
the O 
miRNA O 
expression O 
profile O 
of O 
the O 
glioma O 
cell O 
line O 
U-251 O 
caused O 
by O 
ionizing O 
radiation O 
( O 
IR O 
) O 
by O 
using O 
an O 
miRNA O 
array O 
and O 
identified O 
several O 
miRNAs O 
whose O 
expression O 
was O 
significantly O 
affected O 
by O 
IR O 
. O 
Among O 
the O 
IR-responsive O 
miRNAs O 
, O 
we O 
further O 
examined O 
the O 
function O 
of O 
miR-193a-3p O 
, O 
which O 
exhibited O 
the O 
most O 
significant O 
growth O 
- O 
inhibiting O 
effect O 
. O 
miR-193a-3p O 
was O 
observed O 
to O 
induce O 
apoptosis O 
in O 
both O 
U-251 O 
and O 
HeLa O 
cells O 
. O 
We O 
also O 
demonstrated O 
that O 
miR-193a-3p O 
induces O 
the O 
accumulation O 
of O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
and O 
DNA O 
damage O 
as O 
determined O 
by O 
the O 
level O 
of O 
γH2AX O 
and O 
by O 
performing O 
the O 
comet O 
assay O 
. O 
The O 
induction O 
of O 
both O 
apoptosis O 
and O 
DNA O 
damage O 
by O 
miR-193a-3p O 
was O 
blocked O 
by O 
antioxidant O 
treatment O 
, O 
indicating O 
the O 
crucial O 
role O 
of O 
ROS O 
in O 
the O 
action O 
of O 
miR-193a-3p O 
. O 
Among O 
the O 
putative O 
target O 
proteins O 
, O 
the O 
expression O 
of O 
Mcl-1 O 
, O 
an O 
anti-apoptotic O 
Bcl-2 O 
family O 
member O 
, O 
decreased O 
because O 
of O 
miR-193a-3p O 
transfection O 
. O 
A O 
reporter O 
assay O 
using O 
a O 
luciferase O 
construct O 
containing O 
the O 
3'-untranslated O 
region O 
of O 
Mcl-1 O 
confirmed O 
that O 
Mcl-1 O 
is O 
a O 
direct O 
target O 
of O 
miR-193a-3p O 
. O 
Down O 
- O 
regulation O 
of O 
Mcl-1 O 
by O 
siRNA O 
transfection O 
closely O 
mimicked O 
the O 
outcome O 
of O 
miR-193a-3p O 
transfection O 
showing O 
increased O 
ROS O 
, O 
DNA O 
damage O 
, O 
cytochrome O 
c O 
release O 
, O 
and O 
apoptosis O 
. O 
Ectopic O 
expression O 
of O 
Mcl-1 O 
suppressed O 
the O 
pro O 
- O 
apoptotic O 
action O 
of O 
miR-193a-3p O 
, O 
suggesting O 
that O 
Mcl-1 O 
depletion O 
is O 
critical O 
for O 
miR-193a-3p O 
induced O 
apoptosis O 
. O 
Collectively O 
, O 
our O 
results O 
suggest O 
a O 
novel O 
function O 
for O 
miR-193a-3p O 
and O 
its O 
potential O 
application O 
in O 
cancer O 
therapy O 
. O 

- O 
specific O 
O B-FORMULA 
-glycosylation O 
on O 
the O 
MUC2 O 
mucin O 
inhibits O 
cleavage O 
by O 
the O 
Porphyromonas O 
gingivalis O 
secreted O 
cysteine B-TRIVIAL 
protease O 
( O 
RgpB O 
) O 
. O 

colonic O 
epithelial O 
surface O 
is O 
protected O 
by O 
an O 
inner O 
mucus O 
layer O 
which O 
the O 
commensal O 
microflora O 
cannot O 
penetrate O 
. O 
We O 
previously O 
demonstrated O 
that O 
Entamoeba O 
histolytica O 
( O 
E.h O 
. O 
) O 
secretes O 
a O 
protease O 
capable O 
of O 
dissolving O 
this O 
layer O 
that O 
is O 
required O 
for O 
parasite O 
penetration O 
. O 
Here O 
, O 
we O 
asked O 
if O 
there O 
are O 
bacteria O 
that O 
can O 
secrete O 
similar O 
proteases O 
. O 
We O 
screened O 
bacterial O 
culture O 
supernatants O 
for O 
such O 
activity O 
using O 
recombinant O 
fragments O 
of O 
the O 
MUC2 O 
mucin O 
, O 
the O 
major O 
structural O 
component O 
and O 
the O 
only O 
gel O 
- O 
forming O 
mucin O 
in O 
the O 
colonic O 
mucus O 
. O 
MUC2 O 
has O 
two O 
central O 
heavily O 
O B-FORMULA 
-glycosylated O 
mucin O 
domains O 
that O 
are O 
protease O 
- O 
resistant O 
and O 
has O 
cysteine B-TRIVIAL 
rich O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
-termini O 
responsible O 
for O 
polymerization O 
. O 
Culture O 
supernatants O 
of O 
Porphyromonas O 
gingivalis O 
( O 
P.g O 
. O 
) O 
, O 
a O 
bacterium O 
that O 
secretes O 
proteases O 
responsible O 
for O 
periodontitis O 
, O 
cleaved O 
the O 
MUC2-C O 
terminal O 
region O 
, O 
whereas O 
the O 
N- O 
terminal O 
region O 
was O 
unaffected O 
. O 
The O 
active O 
enzyme O 
was O 
isolated O 
and O 
identified O 
as O 
Arg O 
- O 
gingipain O 
B O 
( O 
RgpB O 
) O 
. O 
Two O 
cleavage O 
sites O 
were O 
localized O 
to O 
IR↓TT O 
and O 
NR↓QA O 
. O 
IR↓TT O 
cleavage O 
will O 
disrupt O 
the O 
MUC2 O 
polymers O 
. O 
As O 
this O 
site O 
has O 
two O 
potential O 
O-glycosylation O 
sites O 
we O 
tested O 
whether O 
recombinant O 
GalNA B-FORMULA 
c-transferases O 
( B-FORMULA 
GalNA I-FORMULA 
c-Ts O 
) O 
could O 
glycosylate O 
a O 
synthetic O 
peptide O 
covering O 
the O 
IRTT O 
sequence O 
. O 
Only O 
GalNA B-FORMULA 
c-T3 O 
was O 
able O 
to O 
glycosylate O 
the O 
second O 
Thr O 
in O 
IRTT O 
, O 
rendering O 
the O 
sequence O 
resistant O 
to O 
cleavage O 
by O 
RgpB O 
. O 
Furthermore O 
, O 
when O 
GalNA B-FORMULA 
c-T3 O 
was O 
expressed O 
in O 
CHO-cells O 
expressing O 
the O 
MUC2 O 
C- O 
terminal O 
, O 
the O 
second O 
threonin B-TRIVIAL 
e O 
was O 
glycosylated O 
and O 
the O 
protein O 
became O 
resistant O 
to O 
RgpB O 
cleavage O 
. O 
These O 
findings O 
suggest O 
that O 
bacteria O 
can O 
produce O 
proteases O 
capable O 
of O 
dissolving O 
the O 
inner O 
protective O 
mucus O 
layer O 
by O 
specific O 
cleavages O 
in O 
the O 
MUC2 O 
mucin O 
and O 
that O 
this O 
cleavage O 
can O 
be O 
modulated O 
by O 
site O 
- O 
specific O 
O-glycosylation O 
. O 

Active O 
Analogues O 
of O 
the O 
Opioid O 
Peptide O 
Biphalin B-TRIVIAL 
: O 
Mixed O 
α O 
/ O 
β(3) O 
- O 
Peptides O 
. O 

residues O 
of O 
the O 
dimeric O 
opioid O 
peptide O 
Biphalin B-TRIVIAL 
were O 
replaced O 
by O 
the O 
corresponding O 
homo-β(3) B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
. O 
The O 
derivative O 
1 O 
containing O 
hβ(3) B-SYSTEMATIC 
Phe I-SYSTEMATIC 
in O 
place O 
of O 
Phe B-FORMULA 
showed O 
good O 
μ- O 
and O 
δ-receptor O 
affinities O 
( O 
Ki(δ) O 
= O 
0.72 O 
nM O 
; O 
Ki(μ) O 
= O 
1.1 O 
nM O 
) O 
and O 
antinociceptive O 
activity O 
in O 
vivo O 
together O 
with O 
an O 
increased O 
enzymatic O 
stability O 
in O 
human O 
plasma O 
. O 

as O 
Novel O 
Zinc B-SYSTEMATIC 
Binding O 
Group O 
for O 
Selective O 
Histone O 
Deacetylase O 
Inhibition O 
. O 

molecules O 
bearing O 
hydroxamic O 
acid O 
as O 
the O 
zinc B-SYSTEMATIC 
binding O 
group O 
( O 
ZBG O 
) O 
have O 
been O 
the O 
most O 
effective O 
histone O 
deacetylase O 
inhibitors O 
( O 
HDACi O 
) O 
to O 
date O 
. O 
However O 
, O 
concerns O 
about O 
the O 
pharmacokinetic O 
liabilities O 
of O 
the O 
hydroxamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
moiety O 
have O 
stimulated O 
research O 
efforts O 
aimed O 
at O 
finding O 
alternative O 
nonhydroxamate O 
ZBGs O 
. O 
We O 
have O 
identified O 
3-hydroxypyridin-2-thione B-SYSTEMATIC 
( O 
3-HPT B-SYSTEMATIC 
) O 
as O 
a O 
novel O 
ZBG O 
that O 
is O 
compatible O 
with O 
HDAC O 
inhibition O 
. O 
3-HPT B-SYSTEMATIC 
inhibits O 
HDAC O 
6 O 
and O 
HDAC O 
8 O 
with O 
an O 
IC50 O 
of O 
681 O 
and O 
3675 O 
nM O 
, O 
respectively O 
. O 
Remarkably O 
, O 
3-HPT B-SYSTEMATIC 
gives O 
no O 
inhibition O 
of O 
HDAC O 
1 O 
. O 
Subsequent O 
optimization O 
led O 
to O 
several O 
novel O 
3HPT B-SYSTEMATIC 
-based O 
HDACi O 
that O 
are O 
selective O 
for O 
HDAC O 
6 O 
and O 
HDAC O 
8 O 
. O 
Furthermore O 
, O 
a O 
subset O 
of O 
these O 
inhibitors O 
induces O 
apoptosis O 
in O 
various O 
cancer O 
cell O 
lines O 
. O 

- I-FAMILY 
isopropylamides I-FAMILY 
as O 
potent O 
and O 
non-covalent O 
proteasome O 
inhibitors O 
. O 

Screening O 
of O 
the O 
50000 O 
ChemBridge O 
compound O 
library O 
led O 
to O 
the O 
identification O 
of O 
the O 
oxadiazole B-FAMILY 
- I-FAMILY 
isopropylamide I-FAMILY 
1 O 
( O 
PI-1833 B-IDENTIFIER 
) O 
which O 
inhibited O 
CT-L O 
activity O 
( O 
IC50 O 
0.6 O 
μM O 
) O 
with O 
little O 
effects O 
on O 
the O 
other O 
2 O 
major O 
proteasome O 
proteolytic O 
activities O 
, O 
T-L O 
and O 
PGPH-L O 
. O 
LC O 
/ O 
MS-MS O 
and O 
dialysis O 
show O 
that O 
1 O 
is O 
a O 
non-covalent O 
and O 
rapidly O 
reversible O 
CT-L O 
inhibitor O 
. O 
Focused O 
library O 
synthesis O 
provided O 
11ad O 
( O 
PI-1840 B-IDENTIFIER 
) O 
with O 
CT-L O 
activity O 
( O 
IC50 O 
27 O 
nM O 
) O 
. O 
Detailed O 
SAR O 
studies O 
indicate O 
that O 
the O 
amide B-FAMILY 
moiety O 
and O 
the O 
2 O 
phenyl B-SYSTEMATIC 
rings O 
are O 
sensitive O 
toward O 
modifications O 
. O 
Hydrophobic O 
residues O 
, O 
such O 
as O 
propyl B-SYSTEMATIC 
or O 
butyl B-SYSTEMATIC 
, O 
in O 
the O 
para- O 
position O 
( O 
not O 
ortho O 
or O 
meta O 
) O 
of O 
the O 
A-ring O 
and O 
a O 
meta-pyridyl B-SYSTEMATIC 
group O 
as O 
B-ring O 
significantly O 
improve O 
activity O 
. O 
Compound O 
11ad O 
( O 
IC50 O 
0.37 O 
µM O 
) O 
is O 
more O 
potent O 
than O 
1 O 
( O 
IC50 O 
3.5 O 
µM O 
) O 
at O 
inhibiting O 
CT-L O 
activity O 
in O 
intact O 
MDA-MB-468 O 
human O 
breast O 
cancer O 
cells O 
and O 
inhibiting O 
their O 
survival O 
. O 
The O 
activity O 
of O 
11ad O 
warrants O 
further O 
pre O 
- O 
clinical O 
investigation O 
of O 
this O 
class O 
as O 
non-covalent O 
proteasome O 
inhibitors O 
. O 

Proteasome O 
Inhibitors O 
Derived O 
from O 
the O 
Unnatural O 
Cis-Cyclopropane B-SYSTEMATIC 
Isomer O 
of O 
Belactosin B-TRIVIAL 
A I-TRIVIAL 
: O 
Synthesis O 
, O 
Biological O 
Activity O 
, O 
and O 
Mode O 
of O 
Action O 
. O 

natural O 
product O 
belactosin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
with O 
a O 
trans-cyclopropane B-SYSTEMATIC 
structure O 
is O 
a O 
useful O 
prototype O 
compound O 
for O 
developing O 
potent O 
proteasome O 
( O 
core O 
particle O 
, O 
CP O 
) O 
inhibitors O 
. O 
To O 
date O 
, O 
1 O 
and O 
its O 
analogs O 
are O 
the O 
only O 
CP O 
ligands O 
bind O 
to O 
both O 
the O 
non-primed O 
S1 O 
pocket O 
as O 
well O 
as O 
the O 
primed O 
substrate O 
binding O 
channel O 
, O 
however O 
, O 
these O 
molecules O 
harbor O 
a O 
high O 
IC50 O 
value O 
of O 
more O 
than O 
1 O 
µM O 
. O 
We O 
have O 
performed O 
structure O 
activity O 
relationship O 
studies O 
, O 
hereby O 
elucidating O 
unnatural O 
cis-cyclopropane B-SYSTEMATIC 
derivatives O 
of O 
1 O 
that O 
exhibit O 
high O 
potency O 
to O 
primarily O 
block O 
the O 
chymotrypsin O 
- O 
like O 
active O 
site O 
of O 
the O 
human O 
constitutive O 
( O 
cCP O 
) O 
and O 
immunoproteasome O 
( O 
iCP O 
) O 
. O 
The O 
most O 
active O 
compound O 
3e O 
reversibly O 
inhibits O 
cCP O 
and O 
iCP O 
similarly O 
with O 
an O 
IC50 O 
of O 
5.7 O 
nM O 
. O 
X-ray O 
crystallographic O 
analysis O 
of O 
the O 
yeast O 
proteasome O 
in O 
complex O 
with O 
3e O 
revealed O 
that O 
the O 
ligand O 
accommodates O 
predominantly O 
to O 
the O 
primed O 
substrate O 
binding O 
channel O 
and O 
covalently O 
binds O 
to O 
the O 
active O 
site O 
threonine B-TRIVIAL 
residue O 
via O 
its O 
β-lactone B-SYSTEMATIC 
ring O 
- O 
opening O 
. O 

bone O 
morphogenetic O 
protein O 
( O 
BMP O 
) O 
signaling O 
pathway O 
has O 
essential O 
functions O 
in O 
development O 
, O 
homeostasis O 
, O 
and O 
the O 
normal O 
and O 
pathophysiologic O 
remodeling O 
of O 
tissues O 
. O 
Small O 
molecule O 
inhibitors O 
of O 
the O 
BMP O 
receptor O 
kinase O 
family O 
have O 
been O 
useful O 
for O 
probing O 
physiologic O 
functions O 
of O 
BMP O 
signaling O 
in O 
vitro O 
and O 
in O 
vivo O 
and O 
may O 
have O 
roles O 
in O 
the O 
treatment O 
of O 
BMP O 
- O 
mediated O 
diseases O 
. O 
Here O 
we O 
describe O 
the O 
development O 
of O 
a O 
selective O 
and O 
potent O 
inhibitor O 
of O 
the O 
BMP O 
type O 
I O 
receptor O 
kinases O 
, O 
LDN-212854 B-IDENTIFIER 
, O 
which O 
in O 
contrast O 
to O 
previously O 
described O 
BMP O 
receptor O 
kinase O 
inhibitors O 
exhibits O 
nearly O 
4 O 
orders O 
of O 
selectivity O 
for O 
BMP O 
versus O 
the O 
closely O 
related O 
TGF-β O 
and O 
Activin O 
type O 
I O 
receptors O 
. O 
In O 
vitro O 
, O 
LDN-212854 B-IDENTIFIER 
exhibits O 
some O 
selectivity O 
for O 
ALK2 O 
in O 
preference O 
to O 
other O 
BMP O 
type O 
I O 
receptors O 
, O 
ALK1 O 
and O 
ALK3 O 
, O 
which O 
may O 
permit O 
the O 
interrogation O 
of O 
ALK2 O 
- O 
mediated O 
signaling O 
, O 
transcriptional O 
activity O 
, O 
and O 
function O 
. O 
LDN-212854 B-IDENTIFIER 
potently O 
inhibits O 
heterotopic O 
ossification O 
in O 
an O 
inducible O 
transgenic O 
mutant O 
ALK2 O 
mouse O 
model O 
of O 
fibrodysplasia O 
ossificans O 
progressiva O 
. O 
These O 
findings O 
represent O 
a O 
significant O 
step O 
toward O 
developing O 
selective O 
inhibitors O 
targeting O 
individual O 
members O 
of O 
the O 
highly O 
homologous O 
BMP O 
type O 
I O 
receptor O 
family O 
. O 
Such O 
inhibitors O 
would O 
provide O 
greater O 
resolution O 
as O 
probes O 
of O 
physiologic O 
function O 
and O 
improved O 
selectivity O 
against O 
therapeutic O 
targets O 
. O 

- O 
adsorbed O 
palygorskite B-TRIVIAL 
stabilizes O 
the O 
quaternary B-FAMILY 
phosphonium I-FAMILY 
salt I-FAMILY 
with O 
specific O 
- O 
targeting O 
capability O 
, O 
long O 
- O 
term O 
antibacterial O 
activity O 
, O 
and O 
lower O 
cytotoxicity O 
. O 

order O 
to O 
extend O 
the O 
antibacterial O 
time O 
of O 
quaternary B-FAMILY 
phosphonium I-FAMILY 
salt I-FAMILY 
in O 
bacteria O 
, O 
palygorskite B-TRIVIAL 
( O 
PGS B-ABBREVIATION 
) O 
is O 
used O 
as O 
the O 
carrier O 
of O 
dodecyl B-SYSTEMATIC 
triphenyl I-SYSTEMATIC 
phosphonium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
( O 
DTP B-ABBREVIATION 
) O 
, O 
and O 
a O 
DTP B-ABBREVIATION 
- O 
PGS B-ABBREVIATION 
hybrid O 
is O 
prepared O 
. O 
Antibacterial O 
performance O 
of O 
this O 
novel O 
hybrid O 
is O 
investigated O 
for O 
both O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
bacteria O 
. O 
The O 
results O 
show O 
that O 
the O 
DTP B-ABBREVIATION 
could O 
be O 
absorbed O 
on O 
the O 
surface O 
of O 
PGS B-ABBREVIATION 
which O 
had O 
bacteria O 
- O 
adsorbed O 
capability O 
. O 
The O 
DTP B-ABBREVIATION 
- O 
PGS B-ABBREVIATION 
hybrid O 
, O 
combining O 
the O 
advantages O 
of O 
PGS B-ABBREVIATION 
and O 
DTP B-ABBREVIATION 
, O 
display O 
specific O 
- O 
targeting O 
capability O 
, O 
long O 
- O 
term O 
antibacterial O 
activity O 
, O 
and O 
lower O 
cytotoxicity O 
, O 
suggesting O 
the O 
great O 
potential O 
application O 
as O 
PGS B-ABBREVIATION 
-based O 
antibacterial O 
powder O 
. O 

/ O 
FBPase-2 O 
( O 
6-phosphofructo-2-kinase O 
/ O 
fructose-2,6-bisphosphatase O 
) O 
catalyses O 
the O 
synthesis O 
and O 
degradation O 
of O 
Fru-2,6-P2 B-SYSTEMATIC 
( O 
fructose-2,6-bisphosphate B-SYSTEMATIC 
) O 
, O 
a O 
key O 
modulator O 
of O 
glycolysis O 
and O 
gluconeogenesis O 
. O 
The O 
PFKFB3 O 
gene O 
is O 
involved O 
in O 
cell O 
proliferation O 
owing O 
to O 
its O 
role O 
in O 
carbohydrate B-FAMILY 
metabolism O 
. O 
Here O 
we O 
analyze O 
its O 
mechanism O 
of O 
regulation O 
as O 
an O 
immediately O 
early O 
gene O 
controlled O 
by O 
stress O 
stimuli O 
that O 
activate O 
p38 O 
/ O 
MK2 O 
pathway O 
. O 
We O 
report O 
that O 
exposure O 
of O 
HeLa O 
and O 
T98G O 
cells O 
to O 
different O 
stress O 
stimuli O 
( O 
NaCl B-FORMULA 
, O 
H2O2 B-FORMULA 
, O 
UV O 
radiation O 
and O 
anisomycin B-TRIVIAL 
) O 
leads O 
to O 
a O 
rapid O 
increase O 
( O 
15-30 O 
minutes O 
) O 
in O 
PFKFB3 O 
mRNA O 
levels O 
. O 
The O 
use O 
of O 
specific O 
inhibitors O 
in O 
combination O 
with O 
MK2-deficient O 
cells O 
implicate O 
control O 
by O 
MK2 O 
protein O 
kinase O 
. O 
Transient O 
transfection O 
of O 
HeLa O 
cells O 
with O 
deleted O 
gene O 
promoter O 
constructs O 
allowed O 
us O 
to O 
identify O 
a O 
Serum O 
Response O 
Element O 
( O 
SRE O 
) O 
to O 
which O 
Serum O 
Response O 
Factor O 
( O 
SRF O 
) O 
binds O 
and O 
thus O 
transactivates O 
PFKFB3 O 
gene O 
transcription O 
. O 
Direct O 
Binding O 
of O 
phospho-SRF O 
to O 
the O 
SRE O 
sequence O 
( O 
-918 O 
nt O 
) O 
was O 
confirmed O 
by O 
ChIP O 
( O 
chromatin O 
immunoprecipiation O 
) O 
assays O 
. O 
Moreover O 
, O 
PFKFB3 O 
isoenzyme O 
phosphorylation O 
at O 
Ser B-FORMULA 
461 O 
by O 
MK2 O 
increases O 
PFK-2 O 
activity O 
. O 
Together O 
, O 
the O 
results O 
suggest O 
a O 
multimodal O 
mechanism O 
of O 
stress O 
stimuli O 
affecting O 
PFKFB3 O 
transcriptional O 
regulation O 
and O 
kinase O 
activation O 
by O 
protein O 
phosphorylation O 
, O 
resulting O 
in O 
an O 
increase O 
in O 
Fru-2,6-P2 B-SYSTEMATIC 
concentration O 
and O 
stimulation O 
of O 
glycolysis O 
in O 
cancer O 
cells O 
. O 

of O 
a O 
new O 
interaction O 
mode O 
between O 
the O 
Src O 
homology O 
2 O 
( O 
SH2 O 
) O 
domain O 
of O 
C B-FORMULA 
-terminal O 
Src O 
kinase O 
( O 
Csk O 
) O 
and O 
Csk O 
- O 
binding O 
protein O 
( O 
Cbp O 
) O 
/ O 
phosphoprotein O 
associated O 
with O 
glycosphingolipid O 
microdomains O 
( O 
PAG O 
) O 
. O 

with O 
Src O 
homology O 
2 O 
( O 
SH2 O 
) O 
domains O 
play O 
major O 
roles O 
in O 
tyrosine B-TRIVIAL 
kinase O 
signaling O 
. O 
Structures O 
of O 
many O 
SH2 O 
domains O 
have O 
been O 
studied O 
, O 
and O 
the O 
regions O 
involved O 
in O 
their O 
interactions O 
with O 
ligands O 
have O 
been O 
elucidated O 
. O 
However O 
, O 
these O 
analyses O 
have O 
been O 
performed O 
using O 
short O 
peptides O 
comprising O 
phosphotyrosine B-SYSTEMATIC 
followed O 
by O 
a O 
few O 
amino B-FAMILY 
acids I-FAMILY 
, O 
which O 
are O 
described O 
as O 
the O 
canonical O 
recognition O 
sites O 
. O 
Here O 
we O 
report O 
the O 
solution O 
structure O 
of O 
the O 
SH2 O 
domain O 
of O 
C B-FORMULA 
-terminal O 
Src O 
kinase O 
( O 
Csk O 
) O 
in O 
complex O 
with O 
a O 
longer O 
phosphopeptide O 
from O 
Csk O 
- O 
binding O 
protein O 
( O 
Cbp O 
) O 
. O 
This O 
structure O 
, O 
together O 
with O 
biochemical O 
experiments O 
, O 
revealed O 
the O 
existence O 
of O 
a O 
novel O 
binding O 
region O 
in O 
addition O 
to O 
the O 
canonical O 
phosphotyrosine B-SYSTEMATIC 
-314 O 
binding O 
site O 
of O 
Cbp O 
. O 
Mutational O 
analysis O 
of O 
this O 
second O 
region O 
in O 
cells O 
showed O 
that O 
both O 
canonical O 
and O 
novel O 
binding O 
sites O 
are O 
required O 
for O 
tumor O 
suppression O 
through O 
the O 
Cbp-Csk O 
interaction O 
. O 
Furthermore O 
, O 
the O 
data O 
indicate O 
an O 
allosteric O 
connection O 
between O 
Cbp O 
binding O 
and O 
Csk O 
activation O 
that O 
arises O 
from O 
residues O 
in O 
the O 
βB O 
/ O 
βC O 
loop O 
of O 
the O 
SH2 O 
domain O 
. O 

evoked O 
potentials O 
in O 
children O 
prenatally O 
exposed O 
to O 
methylmercury B-SYSTEMATIC 
. O 

exposure O 
to O 
methylmercury B-SYSTEMATIC 
can O 
cause O 
both O 
neurobehavioral O 
deficits O 
and O 
neurophysiological O 
changes O 
. O 
However O 
, O 
evidence O 
of O 
neurotoxic O 
effects O 
within O 
the O 
visual O 
nervous O 
system O 
is O 
inconsistent O 
, O 
possibly O 
due O 
to O 
incomplete O 
statistical O 
adjustment O 
for O 
beneficial O 
nutritional O 
factors O 
. O 
We O 
evaluated O 
the O 
effect O 
of O 
prenatal O 
methylmercury B-SYSTEMATIC 
exposure O 
on O 
visual O 
evoked O 
potential O 
( O 
VEP O 
) O 
latencies O 
in O 
Faroese O 
children O 
with O 
elevated O 
prenatal O 
methylmercury B-SYSTEMATIC 
exposure O 
. O 
A O 
cohort O 
of O 
182 O 
singleton O 
term O 
births O 
was O 
assembled O 
in O 
the O 
Faroe O 
Islands O 
during O 
1994-1995 O 
. O 
At O 
age O 
7 O 
years O 
, O 
VEP O 
tracings O 
were O 
obtained O 
from O 
139 O 
cohort O 
subjects O 
after O 
exclusion O 
of O 
subjects O 
with O 
abnormal O 
vision O 
conditions O 
. O 
We O 
used O 
multiple O 
regression O 
analysis O 
to O 
evaluate O 
the O 
association O 
of O 
mercury B-SYSTEMATIC 
concentrations O 
in O 
cord O 
blood O 
and O 
maternal O 
hair O 
at O 
parturition O 
with O 
VEP O 
latencies O 
after O 
adjustment O 
for O 
potential O 
confounders O 
that O 
included O 
the O 
cord O 
- O 
serum O 
phospholipid O 
concentration O 
of O 
n-3 O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
( O 
PUFAs B-ABBREVIATION 
) O 
and O 
the O 
duration O 
of O 
breastfeeding O 
. O 
Unadjusted O 
correlations O 
between O 
mercury B-SYSTEMATIC 
exposure O 
and O 
VEP O 
latencies O 
were O 
equivocal O 
. O 
Multiple O 
regression O 
models O 
showed O 
that O 
increased O 
mercury B-SYSTEMATIC 
concentrations O 
, O 
especially O 
in O 
maternal O 
hair O 
, O 
were O 
associated O 
with O 
delayed O 
latencies O 
for O 
VEP O 
peak O 
N145 O 
. O 
After O 
covariate O 
adjustment O 
, O 
a O 
delay O 
of O 
2.22ms O 
( O 
p=0.02 O 
) O 
was O 
seen O 
for O 
each O 
doubling O 
of O 
the O 
mercury B-SYSTEMATIC 
concentration O 
in O 
maternal O 
hair O 
. O 
In O 
agreement O 
with O 
neuropsychological O 
findings O 
, O 
the O 
present O 
study O 
suggests O 
that O 
prenatal O 
methylmercury B-SYSTEMATIC 
exposure O 
may O 
have O 
an O 
adverse O 
effect O 
on O 
VEP O 
findings O 
despite O 
the O 
absence O 
of O 
clinical O 
toxicity O 
to O 
the O 
visual O 
system O 
. O 
However O 
, O 
this O 
association O 
was O 
apparent O 
only O 
after O 
adjustment O 
for O 
n-3 O 
PUFA B-ABBREVIATION 
status O 
. O 

inhibits O 
nuclear O 
factor O 
kappa O 
B O 
activation O 
and O 
induces O 
apoptosis O 
in O 
pancreatic O 
cancer O 
cells O 
. O 

cancer O 
, O 
the O 
fourth O 
leading O 
cause O 
of O 
cancer O 
death O 
in O 
the O 
US O 
, O 
is O 
highly O 
resistant O 
to O 
all O 
current O 
chemotherapies O 
, O 
and O 
its O 
growth O 
is O 
facilitated O 
by O 
chronic O 
inflammation O 
. O 
The O 
majority O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
initiate O 
signaling O 
cascades O 
that O 
converge O 
at O 
the O 
activation O 
of O 
the O 
Nuclear O 
Factor O 
Kappa O 
B O 
( O 
NFκB O 
) O 
, O 
a O 
signal O 
transduction O 
molecule O 
that O 
promotes O 
cell O 
survival O 
, O 
proliferation O 
and O 
angiogenesis O 
. O 
In O 
an O 
effort O 
to O 
identify O 
novel O 
inhibitors O 
of O 
NFκB O 
, O 
the O 
HBOI O 
library O 
of O 
pure O 
compounds O 
was O 
screened O 
using O 
a O 
reporter O 
cell O 
line O 
that O 
produces O 
luciferin O 
under O 
the O 
transcriptional O 
control O 
of O 
NFκB O 
. O 
Seven O 
compounds O 
were O 
identified O 
through O 
this O 
screen O 
, O 
but O 
in O 
the O 
case O 
of O 
five O 
of O 
them O 
, O 
their O 
reported O 
mechanism O 
of O 
action O 
made O 
them O 
unlikely O 
to O 
be O 
specific O 
NFκB O 
inhibitors O 
. O 
Spongiatriol B-TRIVIAL 
, O 
a O 
marine O 
furanoditerpenoid B-FAMILY 
that O 
was O 
first O 
isolated O 
in O 
the O 
1970s O 
, O 
is O 
shown O 
here O 
to O 
inhibit O 
NFκB O 
transcriptional O 
activity O 
in O 
a O 
reporter O 
cell O 
line O 
, O 
to O 
reduce O 
levels O 
of O 
phosphorylated O 
( O 
active O 
) O 
NFκB O 
in O 
the O 
AsPC-1 O 
cell O 
line O 
, O 
to O 
have O 
an O 
IC50 O 
for O 
cytotoxicity O 
in O 
the O 
low O 
micromolar O 
range O 
against O 
the O 
AsPC-1 O 
, O 
BxPC-3 O 
, O 
MiaPaCa-2 O 
and O 
Panc-1 O 
pancreatic O 
cancer O 
cell O 
lines O 
, O 
and O 
to O 
induce O 
moderate O 
but O 
significant O 
apoptosis O 
in O 
both O 
the O 
AsPC-1 O 
and O 
the O 
Panc-1 O 
cell O 
lines O 
. O 

fact O 
that O 
obesity O 
is O 
a O 
prominent O 
feature O 
of O 
Cushing's O 
syndrome O 
( O 
systemic O 
hypercortisolism O 
of O 
adrenocortical O 
origin O 
) O 
stimulated O 
a O 
40-year O 
search O 
for O 
evidence O 
of O 
systemic O 
hypercortisolism O 
in O 
human O 
obesity O 
. O 
That O 
search O 
has O 
failed O 
to O 
find O 
such O 
evidence O 
. O 
For O 
the O 
past O 
15 O 
years O 
, O 
however O 
, O 
studies O 
have O 
been O 
done O 
to O 
evaluate O 
a O 
possible O 
alternative O 
type O 
of O 
hypercortisolism O 
in O 
obesity O 
, O 
namely O 
visceral O 
adipose O 
tissue O 
( O 
VAT O 
) O 
intracellular O 
hypercortisolism O 
. O 
The O 
current O 
review O 
summarizes O 
the O 
evidence O 
published O 
so O 
far O 
about O 
this O 
possibility O 
. O 
There O 
have O 
been O 
three O 
types O 
of O 
evidence O 
studied O 
: O 
direct O 
measurement O 
of O 
the O 
VAT O 
levels O 
of O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
I O 
( O 
11-HSD-1 O 
) O 
, O 
which O 
converts O 
biologically O 
inactive O 
cortisone B-TRIVIAL 
to O 
biologically O 
active O 
cortisol B-TRIVIAL 
; O 
direct O 
measurement O 
of O 
splanchnic O 
cortisol B-TRIVIAL 
production O 
; O 
and O 
evaluation O 
of O 
the O 
effect O 
of O 
a O 
specific O 
inhibitor O 
of O 
11-HSD-1 O 
on O 
metabolic O 
abnormalities O 
associated O 
with O 
obesity O 
, O 
particularly O 
diabetes O 
mellitus O 
. O 
The O 
results O 
are O 
complex O 
and O 
difficult O 
to O 
interpret O 
. O 
Our O 
conclusion O 
is O 
that O 
the O 
presence O 
of O 
VAT O 
intracellular O 
hypercortisolism O 
in O 
human O 
obesity O 
is O 
possible O 
but O 
unlikely O 
. O 

is O 
known O 
that O 
during O 
sex O 
differentiation O 
, O 
fetal O 
androgens B-FAMILY 
are O 
critical O 
determinants O 
of O 
the O 
male O 
phenotype O 
. O 
Although O 
testosterone B-TRIVIAL 
is O 
necessary O 
for O 
normal O 
development O 
of O 
male O 
sexual O 
behavior O 
, O 
perinatal O 
androgen B-FAMILY 
treatment O 
can O 
result O 
in O 
disruption O 
of O 
normal O 
male O 
sexual O 
reproduction O 
. O 
Pregnant O 
Wistar O 
rats O 
were O 
administered O 
either O 
corn O 
oil O 
( O 
vehicle O 
) O 
or O 
testosterone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
at O 
0.2 O 
mg O 
/ O 
kg O 
from O 
gestational O 
day O 
12 O 
until O 
the O 
end O 
of O 
lactation O 
and O 
the O 
reproductive O 
function O 
of O 
male O 
offspring O 
was O 
evaluated O 
at O 
90 O 
( O 
adulthood O 
) O 
and O 
270 O 
( O 
middle O 
age O 
) O 
days O 
of O 
age O 
. O 
Perinatal O 
androgenization O 
in O 
the O 
rat O 
provoked O 
a O 
reduction O 
in O 
sperm O 
production O 
and O 
reserves O 
in O 
adulthood O 
that O 
did O 
not O 
affect O 
fertility O 
and O 
did O 
not O 
persist O 
at O 
more O 
advanced O 
ages O 
, O 
as O 
shown O 
by O 
the O 
results O 
at O 
post O 
- O 
natal O 
day O 
270 O 
. O 
If O 
perinatal O 
androgenization O 
promotes O 
similar O 
effects O 
in O 
humans O 
of O 
reproductive O 
age O 
, O 
the O 
results O 
of O 
the O 
present O 
work O 
can O 
impact O 
male O 
reproduction O 
health O 
, O 
given O 
the O 
less O 
efficient O 
spermatogenesis O 
and O 
lower O 
sperm O 
reserves O 
in O 
the O 
human O 
epididymis O 
, O 
compared O 
to O 
rodents O 
. O 

CYP2B6*6 O 
Allele O 
Significantly O 
Alters O 
the O 
N-demethylation O 
of O 
Ketamine B-TRIVIAL 
Enantiomers O 
In O 
Vitro O 
. O 

is O 
primarily O 
metabolized O 
to O 
norketamine B-TRIVIAL 
by O 
hepatic O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
2B6 O 
and O 
CYP3A4 O 
- O 
mediated O 
N-demethylation O 
. O 
However O 
, O 
the O 
relative O 
contribution O 
from O 
each O 
enzyme O 
remains O 
controversial O 
. O 
The O 
CYP2B6*6 O 
allele O 
is O 
associated O 
with O 
reduced O 
enzyme O 
expression O 
and O 
activity O 
that O 
may O 
lead O 
to O 
interindividual O 
variability O 
in O 
ketamine B-TRIVIAL 
metabolism O 
. O 
We O 
examined O 
the O 
N-demethylation O 
of O 
individual O 
ketamine B-TRIVIAL 
enantiomers O 
using O 
human O 
liver O 
microsomes O 
( O 
HLMs O 
) O 
genotyped O 
for O 
the O 
CYP2B6*6 O 
allele O 
, O 
insect O 
cell O 
expressed O 
recombinant O 
CYP2B6 O 
and O 
CYP3A4 O 
enzymes O 
and O 
COS-1 O 
cell O 
expressed O 
recombinant O 
CYP2B6.1 O 
and O 
CYP2B6.6 O 
protein O 
variant O 
. O 
Effects O 
of O 
CYP-selective O 
inhibitors O 
on O 
norketamine B-TRIVIAL 
formation O 
were O 
also O 
determined O 
in O 
HLMs O 
. O 
The O 
two O 
- O 
enzyme O 
Michaelis-Menten O 
model O 
best O 
fitted O 
the O 
HLM O 
kinetic O 
data O 
. O 
The O 
Km O 
value O 
for O 
the O 
high O 
affinity O 
enzyme O 
and O 
the O 
low O 
affinity O 
enzyme O 
were O 
similar O 
to O 
those O 
for O 
the O 
expressed O 
CYP2B6 O 
and O 
CYP3A4 O 
, O 
respectively O 
. O 
The O 
intrinsic O 
clearance O 
for O 
both O 
ketamine B-TRIVIAL 
enantiomers O 
by O 
the O 
high O 
affinity O 
enzyme O 
in O 
HLMs O 
with O 
CYP2B6*1 O 
/ O 
*1 O 
genotype O 
were O 
at O 
least O 
2-fold O 
and O 
6-fold O 
higher O 
, O 
respectively O 
, O 
than O 
those O 
for O 
CYP2B6*1 O 
/ O 
*6 O 
genotype O 
and O 
CYP2B6*6 O 
/ O 
*6 O 
genotype O 
. O 
The O 
Vmax O 
and O 
Km O 
values O 
for O 
CYP2B6.1 O 
were O 
approximately O 
160% O 
and O 
70% O 
of O 
those O 
for O 
CYP2B6.6 O 
, O 
respectively O 
. O 
ThioTEPA B-SYSTEMATIC 
( O 
CYP2B6 O 
inhibitor O 
, O 
25 O 
μM O 
) O 
and O 
the O 
monoclonal O 
antibody O 
against O 
CYP2B6 O 
but O 
not O 
troleandomycin B-TRIVIAL 
( O 
CYP3A4 O 
inhibitor O 
, O 
25 O 
μM O 
) O 
or O 
the O 
monoclonal O 
antibody O 
against O 
CYP3A4 O 
inhibited O 
ketamine B-TRIVIAL 
N-demethylation O 
at O 
clinically O 
relevant O 
concentrations O 
. O 
The O 
degree O 
of O 
inhibition O 
was O 
significantly O 
reduced O 
in O 
HLMs O 
with O 
the O 
CYP2B6*6 O 
allele O 
( O 
gene O 
- O 
dose O 
P O 
< O 
0.05 O 
) O 
. O 
These O 
results O 
indicate O 
a O 
major O 
role O 
of O 
CYP2B6 O 
in O 
ketamine B-TRIVIAL 
N-demethylation O 
in O 
vitro O 
and O 
a O 
significant O 
impact O 
of O 
the O 
CYP2B6*6 O 
allele O 
on O 
enzyme- O 
ketamine B-TRIVIAL 
binding O 
and O 
catalytic O 
activity O 
. O 

Dynamics O 
Simulations O 
of O 
CO2 B-FORMULA 
Formation O 
in O 
Interstellar O 
Ices O 
. O 

ice O 
is O 
one O 
of O 
the O 
most O 
abundant O 
components O 
in O 
ice O 
- O 
coated O 
interstellar O 
ices O 
besides O 
H2O B-FORMULA 
and O 
CO B-FORMULA 
, O 
but O 
the O 
most O 
favorable O 
path O 
to O 
CO2 B-FORMULA 
ice O 
is O 
still O 
unclear O 
. O 
Molecular O 
dynamics O 
calculations O 
on O 
the O 
ultraviolet O 
photodissociation O 
of O 
different O 
kinds O 
of O 
CO B-FORMULA 
- O 
H2O B-FORMULA 
ice O 
systems O 
have O 
been O 
performed O 
at O 
10 O 
K O 
in O 
order O 
to O 
demonstrate O 
that O 
the O 
reaction O 
between O 
CO B-FORMULA 
and O 
an O 
OH B-FORMULA 
molecule O 
resulting O 
from O 
H2O B-FORMULA 
photodissociation O 
through O 
the O 
first O 
excited O 
state O 
is O 
a O 
possible O 
route O 
to O 
form O 
CO2 B-FORMULA 
ice O 
. O 
However O 
, O 
our O 
calculations O 
, O 
which O 
take O 
into O 
account O 
different O 
ice O 
surface O 
models O 
, O 
suggest O 
that O 
there O 
is O 
another O 
product O 
with O 
a O 
higher O 
formation O 
probability O 
( O 
( O 
3 O 
± O 
0.07 O 
) O 
× O 
10(-2) O 
) O 
, O 
which O 
is O 
the O 
HOCO B-FORMULA 
complex O 
, O 
whereas O 
the O 
formation O 
of O 
CO2 B-FORMULA 
has O 
a O 
probability O 
of O 
only O 
( O 
3.6 O 
± O 
0.7 O 
) O 
× O 
10(-4) O 
. O 
The O 
initial O 
location O 
of O 
the O 
CO B-FORMULA 
is O 
key O 
to O 
obtain O 
reaction O 
and O 
form O 
CO2 B-FORMULA 
: O 
the O 
CO B-FORMULA 
needs O 
to O 
be O 
located O 
deep O 
into O 
the O 
ice O 
. O 
The O 
HOCO B-FORMULA 
complex O 
becomes O 
trapped O 
in O 
the O 
cold O 
ice O 
surface O 
in O 
the O 
trans-HOCO B-SYSTEMATIC 
minimum O 
because O 
it O 
quickly O 
loses O 
its O 
internal O 
energy O 
to O 
the O 
surrounding O 
ice O 
, O 
preventing O 
further O 
reaction O 
to O 
H B-FORMULA 
+ O 
CO2 B-FORMULA 
. O 
Several O 
laboratory O 
experiments O 
have O 
been O 
carried O 
out O 
recently O 
, O 
and O 
they O 
confirm O 
that O 
CO2 B-FORMULA 
can O 
also O 
be O 
formed O 
through O 
other O 
, O 
different O 
routes O 
. O 
Here O 
we O 
compare O 
our O 
theoretical O 
results O 
with O 
the O 
data O 
available O 
from O 
experiments O 
studying O 
the O 
formation O 
of O 
CO2 B-FORMULA 
through O 
a O 
similar O 
pathway O 
as O 
ours O 
, O 
even O 
though O 
the O 
initial O 
conditions O 
were O 
not O 
exactly O 
the O 
same O 
. O 
Our O 
results O 
also O 
show O 
that O 
the O 
HCO B-FORMULA 
van O 
der O 
Waals O 
complex O 
can O 
be O 
formed O 
through O 
the O 
interaction O 
of O 
CO B-FORMULA 
with O 
the O 
H B-FORMULA 
atom O 
that O 
is O 
formed O 
as O 
a O 
product O 
of O 
H2O B-FORMULA 
photodissociation O 
. O 
Thus O 
, O 
the O 
reaction O 
of O 
the O 
H B-FORMULA 
atom O 
photofragment O 
following O 
H2O B-FORMULA 
photodissociation O 
with O 
CO B-FORMULA 
can O 
be O 
a O 
possible O 
route O 
to O 
form O 
HCO B-FORMULA 
ice O 
. O 

Stability O 
of O 
Peroxy B-FAMILY 
Acyl I-FAMILY 
Nitrates I-FAMILY 
Formed O 
in O 
the O 
Oxidation O 
of O 
CxF2x B-FAMILY 
+ I-FAMILY 
1CH2C(O)H I-FAMILY 
( O 
x O 
= O 
1,6 O 
) O 
in O 
the O 
Presence O 
of O 
NO2 B-FORMULA 
. O 

formation O 
of O 
CxF2x B-FAMILY 
+ I-FAMILY 
1CH2C(O)OONO2 I-FAMILY 
( O 
x O 
= O 
1,6 O 
) O 
from O 
the O 
photooxidation O 
of O 
CxF2x B-FAMILY 
+ I-FAMILY 
1CH2C(O)H I-FAMILY 
( O 
x O 
= O 
1,6 O 
) O 
in O 
the O 
presence O 
of O 
NO2 B-FORMULA 
was O 
investigated O 
. O 
The O 
infrared O 
spectrum O 
of O 
C6F13CH2C(O)OONO2 B-FORMULA 
is O 
reported O 
for O 
the O 
first O 
time O 
, O 
and O 
thermal O 
stability O 
for O 
both O 
peroxynitrates O 
at O 
295 O 
K O 
and O 
9 O 
mbar O 
is O 
informed O 
. O 
Kinetic O 
parameters O 
( O 
activation O 
energy O 
and O 
pre O 
- O 
exponential O 
factor O 
) O 
for O 
CF3CH2C(O)OONO2 B-FORMULA 
at O 
9 O 
and O 
1000 O 
mbar O 
are O 
: O 
108 O 
± O 
2 O 
kJ O 
/ O 
mol O 
, O 
1.5 O 
× O 
10(15) O 
and O 
114 O 
± O 
2 O 
kJ O 
/ O 
mol O 
, O 
2.4 O 
× O 
10(16) O 
, O 
respectively O 
. O 
A O 
comparison O 
is O 
made O 
between O 
fluoro O 
and O 
hydrogenated O 
peroxy B-FAMILY 
acyl I-FAMILY 
nitrates I-FAMILY 
. O 

of O 
pioglitazone B-TRIVIAL 
on O 
body O 
composition O 
and O 
bone O 
density O 
in O 
subjects O 
with O 
prediabetes O 
in O 
the O 
ACT O 
NOW O 
trial O 
. O 

: O 
This O 
study O 
examined O 
the O 
effects O 
of O 
pioglitazone B-TRIVIAL 
on O 
body O 
weight O 
and O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
prospectively O 
in O 
patients O 
with O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
as O 
pioglitazone B-TRIVIAL 
( O 
TZD B-ABBREVIATION 
) O 
increases O 
body O 
weight O 
and O 
body O 
fat O 
in O 
diabetic O 
patients O 
and O 
increases O 
the O 
risk O 
of O 
bone O 
fractures O 
. O 
METHODS O 
: O 
A O 
total O 
of O 
71 O 
men O 
and O 
163 O 
women O 
aged O 
49.3 O 
( O 
10.7 O 
) O 
years O 
[ O 
mean O 
( O 
s.d O 
. O 
) O 
] O 
; O 
body O 
mass O 
index O 
( O 
BMI O 
) O 
, O 
34.5 O 
( O 
5.9 O 
) O 
kg O 
/ O 
m(2) O 
were O 
recruited O 
at O 
five O 
sites O 
for O 
measurements O 
of O 
body O 
composition O 
by O 
dual O 
energy O 
X-ray O 
absorptiometry O 
at O 
baseline O 
and O 
at O 
conversion O 
to O 
diabetes O 
or O 
study O 
end O 
, O 
if O 
they O 
had O 
not O 
converted O 
. O 
RESULTS O 
: O 
Mean O 
follow O 
- O 
up O 
was O 
33.6 O 
months O 
in O 
the O 
pioglitazon B-TRIVIAL 
e O 
group O 
and O 
32.1 O 
months O 
in O 
the O 
placebo O 
group O 
. O 
Body O 
weight O 
increased O 
4.63 O 
± O 
0.6 O 
( O 
m O 
± O 
s.e O 
. O 
) O 
kg O 
in O 
the O 
pioglitazon B-TRIVIAL 
e O 
group O 
compared O 
to O 
0.98 O 
± O 
0.62 O 
kg O 
in O 
the O 
PIO O 
group O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
Body O 
fat O 
rose O 
4.89 O 
± O 
0.42 O 
kg O 
in O 
the O 
pioglitazon B-TRIVIAL 
e O 
group O 
compared O 
to O 
1.41 O 
± O 
0.44 O 
kg O 
, O 
( O 
p O 
< O 
0.0001 O 
) O 
in O 
placebo O 
- O 
treated O 
subjects O 
. O 
The O 
increase O 
in O 
fat O 
was O 
greater O 
in O 
legs O 
and O 
trunk O 
than O 
in O 
the O 
arms O 
. O 
BMD O 
was O 
higher O 
in O 
all O 
regions O 
in O 
men O 
and O 
significantly O 
so O 
in O 
most O 
. O 
PIO O 
decreased O 
BMD O 
significantly O 
in O 
the O 
pelvis O 
in O 
men O 
and O 
women O 
, O 
decreased O 
BMD O 
in O 
the O 
thoracic O 
spine O 
and O 
ribs O 
of O 
women O 
and O 
the O 
lumbar O 
spine O 
and O 
legs O 
of O 
men O 
. O 
Bone O 
mineral O 
content O 
also O 
decreased O 
significantly O 
in O 
arms O 
, O 
legs O 
, O 
trunk O 
and O 
in O 
the O 
total O 
body O 
. O 
CONCLUSIONS O 
: O 
Pioglitazon B-TRIVIAL 
e O 
increased O 
peripheral O 
fat O 
more O 
than O 
truncal O 
fat O 
and O 
decreased O 
BMD O 
in O 
several O 
regions O 
of O 
the O 
body O 
. O 

ataxia O 
( O 
FRDA O 
) O 
is O 
a O 
progressive O 
neurodegenerative O 
disease O 
characterized O 
by O 
ataxia O 
, O 
variously O 
associating O 
heart O 
disease O 
, O 
diabetes O 
mellitus O 
and O 
/ O 
or O 
glucose B-TRIVIAL 
intolerance O 
. O 
It O 
results O 
from O 
intronic O 
expansion O 
of O 
GAA O 
triplet O 
repeats O 
at O 
the O 
FXN O 
locus O 
. O 
Homozygous O 
expansions O 
cause O 
silencing O 
of O 
the O 
FXN O 
gene O 
and O 
subsequent O 
decreased O 
expression O 
of O 
the O 
encoded O 
mitochondrial O 
frataxin O 
. O 
Detailed O 
analyses O 
in O 
fibroblasts O 
and O 
neuronal O 
tissues O 
from O 
FRDA O 
patients O 
have O 
revealed O 
profound O 
cytoskeleton O 
anomalies O 
. O 
So O 
far O 
, O 
however O 
, O 
the O 
molecular O 
mechanism O 
underlying O 
these O 
cytoskeleton O 
defects O 
remains O 
unknown O 
. O 
We O 
show O 
here O 
that O 
gene O 
silencing O 
spreads O 
in O 
cis O 
over O 
the O 
PIP5K1B O 
gene O 
in O 
cells O 
from O 
FRDA O 
patients O 
( O 
circulating O 
lymphocytes O 
and O 
primary O 
fibroblasts O 
) O 
, O 
correlating O 
with O 
expanded O 
GAA O 
repeat O 
size O 
. O 
PIP5K1B O 
encodes O 
phosphatidylinositol B-SYSTEMATIC 
4-phosphate I-SYSTEMATIC 
5-kinase O 
β O 
type O 
I O 
( O 
pip5k1β O 
) O 
, O 
an O 
enzyme O 
functionally O 
linked O 
to O 
actin O 
cytoskeleton O 
dynamics O 
that O 
phosphorylates O 
phosphatidylinositol B-SYSTEMATIC 
4-phosphate I-SYSTEMATIC 
[ O 
PI(4)P B-FORMULA 
] O 
to O 
generate O 
phosphatidylinositol-4,5-bisphosphate B-SYSTEMATIC 
[ O 
PI(4,5)P2 B-FORMULA 
] O 
. O 
Accordingly O 
, O 
loss O 
of O 
pip5k1β O 
function O 
in O 
FRDA O 
cells O 
was O 
accompanied O 
by O 
decreased O 
PI(4,5)P2 B-FORMULA 
levels O 
and O 
was O 
shown O 
instrumental O 
for O 
destabilization O 
of O 
the O 
actin O 
network O 
and O 
delayed O 
cell O 
spreading O 
. O 
Knockdown O 
of O 
PIP5K1B O 
in O 
control O 
fibroblasts O 
using O 
shRNA O 
reproduced O 
abnormal O 
actin O 
cytoskeleton O 
remodeling O 
, O 
whereas O 
over O 
- O 
expression O 
of O 
PIP5K1B O 
, O 
but O 
not O 
FXN O 
, O 
suppressed O 
this O 
phenotype O 
in O 
FRDA O 
cells O 
. O 
In O 
addition O 
to O 
provide O 
new O 
insights O 
into O 
the O 
consequences O 
of O 
the O 
FXN O 
gene O 
expansion O 
, O 
these O 
findings O 
raise O 
the O 
question O 
whether O 
PIP5K1B O 
silencing O 
may O 
contribute O 
to O 
the O 
variable O 
manifestation O 
of O 
this O 
complex O 
disease O 
. O 

of O 
in O 
vitro O 
and O 
in O 
vivo O 
genotoxicity O 
of O 
single O 
- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
. O 

- O 
walled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
SWCNTs O 
) O 
have O 
extensive O 
potential O 
industrial O 
applications O 
due O 
to O 
their O 
unique O 
physical O 
and O 
chemical O 
properties O 
; O 
yet O 
this O 
also O 
increases O 
the O 
chance O 
of O 
human O 
and O 
environment O 
exposure O 
to O 
SWCNTs O 
. O 
Due O 
to O 
the O 
current O 
lack O 
of O 
hazardous O 
effect O 
information O 
on O 
SWNCTs O 
, O 
a O 
standardized O 
genotoxicity O 
battery O 
test O 
was O 
conducted O 
to O 
clarify O 
the O 
genetic O 
toxicity O 
potential O 
of O 
SWCNTs O 
( O 
diameter O 
: O 
1-1.2 O 
nm O 
, O 
length O 
: O 
∼20 O 
μm O 
) O 
according O 
to O 
Organization O 
for O 
Economic O 
Cooperation O 
and O 
Development O 
test O 
guidelines O 
471 O 
( O 
bacterial O 
reverse O 
mutation O 
test O 
) O 
, O 
473 O 
( O 
in O 
vitro O 
chromosome O 
aberration O 
test O 
) O 
, O 
and O 
474 O 
( O 
in O 
vivo O 
micronuclei O 
test O 
) O 
with O 
a O 
good O 
laboratory O 
practice O 
system O 
. O 
The O 
test O 
results O 
showed O 
that O 
the O 
SWCNTs O 
did O 
not O 
induce O 
significant O 
bacterial O 
reverse O 
mutations O 
at O 
31.3-500 O 
μg O 
/ O 
plate O 
in O 
Salmonella O 
typhimurium O 
strains O 
TA98 O 
, O 
TA100 O 
, O 
TA1535 O 
, O 
and O 
TA1537 O 
or O 
in O 
Escherichia O 
coli O 
strain O 
WP2uvrA O 
, O 
with O 
and O 
without O 
a O 
metabolic O 
activation O 
system O 
. O 
Furthermore O 
, O 
the O 
in O 
vitro O 
chromosome O 
aberration O 
test O 
showed O 
no O 
significant O 
increase O 
in O 
structural O 
or O 
numerical O 
chromosome O 
aberration O 
frequencies O 
at O 
SWCNT O 
dose O 
levels O 
of O 
12.5-50 O 
μg O 
/ O 
ml O 
in O 
the O 
presence O 
and O 
absence O 
of O 
metabolic O 
activation O 
. O 
However O 
, O 
dose O 
- O 
dependent O 
cell O 
growth O 
inhibition O 
was O 
found O 
at O 
all O 
the O 
SWCNT O 
dose O 
levels O 
and O 
statistically O 
significant O 
cytotoxic O 
effects O 
observed O 
at O 
certain O 
concentrations O 
in O 
the O 
presence O 
and O 
absence O 
of O 
metabolic O 
activation O 
. O 
Finally O 
, O 
the O 
SWCNTs O 
did O 
not O 
evoke O 
significant O 
in O 
vivo O 
micronuclei O 
frequencies O 
in O 
the O 
polychromatic O 
erythrocytes O 
of O 
an O 
imprinting O 
control O 
region O 
mice O 
at O 
25-100 O 
mg O 
/ O 
kg O 
. O 
Thus O 
, O 
according O 
to O 
the O 
results O 
of O 
the O 
present O 
study O 
, O 
the O 
SWCNTs O 
were O 
not O 
found O 
to O 
have O 
a O 
genotoxic O 
effect O 
on O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
test O 
systems O 
. O 

anticancer O 
activity O 
of O 
carvone B-TRIVIAL 
in O 
N2a O 
neuroblastoma O 
cell O 
line O 
. O 

( O 
CVN B-ABBREVIATION 
) O 
is O 
a O 
monocyclic B-FAMILY 
monoterpene I-FAMILY 
found O 
in O 
the O 
essential O 
oils O 
of O 
Mentha O 
spicata O 
var O 
. O 
crispa O 
( O 
Lamiaceae O 
) O 
and O 
Carum O 
carvi O 
L O 
. O 
( O 
Apiaceae O 
) O 
plants O 
and O 
has O 
been O 
reported O 
to O 
have O 
antioxidant O 
, O 
antimicrobial O 
, O 
anticonvulsant O 
, O 
and O 
antitumor O 
activities O 
. O 
The O 
beneficial O 
health O 
properties O 
of O 
CVN B-ABBREVIATION 
have O 
encouraged O 
us O 
to O 
look O 
into O 
its O 
anticancer O 
activity O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
reports O 
are O 
not O 
available O 
on O 
the O 
anticancer O 
activity O 
of O 
CVN B-ABBREVIATION 
in O 
cultured O 
primary O 
rat O 
neuron O 
and O 
N2a O 
neuroblastoma O 
( O 
NB O 
) O 
cells O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
is O 
an O 
attempt O 
toward O 
exploring O 
the O 
potential O 
anticancer O 
activity O 
of O 
CVN B-ABBREVIATION 
, O 
if O 
any O 
, O 
in O 
cultured O 
primary O 
rat O 
neuron O 
and O 
N2a O 
NB O 
cells O 
. O 
Our O 
results O 
indicated O 
that O 
CVN B-ABBREVIATION 
( O 
only O 
at O 
25 O 
mg O 
/ O 
L O 
) O 
treatment O 
led O 
to O 
an O 
increase O 
in O 
the O 
total O 
antioxidant O 
capacity O 
levels O 
in O 
cultured O 
primary O 
rat O 
neuron O 
cells O 
compared O 
with O 
control O 
cells O 
. O 
Also O 
, O 
CVN B-ABBREVIATION 
( O 
at O 
concentrations O 
higher O 
than O 
100 O 
mg O 
/ O 
L O 
) O 
treatment O 
led O 
to O 
an O 
increase O 
in O 
the O 
total O 
oxidative O 
stress O 
levels O 
in O 
both O 
cell O 
types O 
. O 
The O 
mean O 
values O 
of O 
the O 
total O 
scores O 
of O 
cells O 
showing O 
DNA O 
damage O 
( O 
for O 
comet O 
assay O 
) O 
were O 
not O 
found O 
to O 
be O 
significantly O 
different O 
from O 
the O 
control O 
values O 
in O 
both O 
cells O 
( O 
p O 
> O 
0.05 O 
) O 
. O 
On O 
the O 
other O 
hand O 
, O 
after O 
24 O 
h O 
treatment O 
with O 
CVN B-ABBREVIATION 
, O 
3-(4,5-dimethylthiazol-2-yl)-2,5 B-SYSTEMATIC 
diphenyltetrazolium I-SYSTEMATIC 
bromide I-SYSTEMATIC 
assay O 
showed O 
that O 
CVN B-ABBREVIATION 
application O 
significantly O 
reduced O 
the O 
cell O 
viability O 
rates O 
in O 
both O 
cell O 
types O 
at O 
concentrations O 
higher O 
than O 
100 O 
mg O 
/ O 
L O 
. O 
Summarizing O 
, O 
our O 
data O 
suggest O 
that O 
CVN B-ABBREVIATION 
represents O 
little O 
potential O 
for O 
promising O 
anticancer O 
agent O 
to O 
improve O 
brain O 
tumors O 
therapy O 
. O 

CO2 B-FORMULA 
reduction O 
on O 
Pt(111) B-FORMULA 
. O 

functional O 
theory O 
was O 
used O 
to O 
model O 
the O 
electrochemical O 
reduction O 
of O 
CO2 B-FORMULA 
on O 
Pt(111) B-FORMULA 
with O 
an O 
explicit O 
solvation O 
layer O 
and O 
the O 
presence O 
of O 
extra O 
hydrogen B-SYSTEMATIC 
atoms O 
to O 
represent O 
a O 
negatively O 
charged O 
electrode O 
. O 
We O 
focused O 
on O 
the O 
electronic O 
energy O 
barriers O 
for O 
the O 
first O 
four O 
lowest O 
energy O 
proton O 
- O 
electron O 
transfer O 
steps O 
for O 
reducing O 
CO2 B-FORMULA 
on O 
Pt(111) B-FORMULA 
beginning O 
with O 
adsorbed O 
* O 
CO2 B-FORMULA 
and O 
continuing O 
with O 
* O 
COOH B-FORMULA 
, O 
* O 
CO B-FORMULA 
+ O 
H2O B-FORMULA 
, O 
* O 
COH B-FORMULA 
, O 
and O 
ending O 
with O 
* O 
C B-FORMULA 
+ O 
H2O B-FORMULA 
. O 
We O 
find O 
that O 
simple O 
elementary O 
steps O 
in O 
which O 
a O 
proton O 
is O 
transferred O 
to O 
an O 
adsorbate O 
( O 
such O 
as O 
the O 
protonation O 
of O 
* O 
CO B-FORMULA 
to O 
* O 
COH B-FORMULA 
) O 
have O 
small O 
barriers O 
on O 
the O 
order O 
of O 
0.1 O 
eV O 
. O 
Elementary O 
steps O 
in O 
which O 
a O 
proton O 
is O 
transferred O 
and O 
a O 
C-O B-FORMULA 
bond O 
is O 
simultaneously O 
cleaved O 
show O 
barriers O 
on O 
the O 
order O 
of O 
0.5 O 
eV O 
. O 
All O 
barriers O 
calculated O 
for O 
these O 
steps O 
show O 
no O 
sign O 
of O 
being O 
insurmountable O 
at O 
room O 
temperature O 
. O 
To O 
explain O 
why O 
these O 
barriers O 
are O 
so O 
small O 
, O 
we O 
analyze O 
the O 
charge O 
density O 
and O 
the O 
density O 
of O 
states O 
plots O 
to O 
see O 
that O 
first O 
, O 
the O 
electron O 
transfer O 
is O 
decoupled O 
from O 
the O 
proton O 
transfer O 
so O 
that O 
in O 
the O 
initial O 
state O 
, O 
the O 
surface O 
and O 
adsorbate O 
are O 
already O 
charged O 
up O 
and O 
can O 
easily O 
accept O 
the O 
proton O 
from O 
solution O 
. O 
Also O 
, O 
we O 
see O 
that O 
in O 
the O 
cases O 
where O 
barriers O 
are O 
on O 
the O 
order O 
of O 
0.1 O 
eV O 
, O 
electron O 
density O 
in O 
the O 
initial O 
state O 
localizes O 
on O 
the O 
oxygen B-SYSTEMATIC 
end O 
of O 
the O 
adsorbate O 
, O 
while O 
electron O 
density O 
is O 
more O 
spread O 
out O 
on O 
the O 
surface O 
for O 
initial O 
states O 
of O 
the O 
C-O B-FORMULA 
bond O 
cleaving O 
elementary O 
steps O 
. O 

article O 
explores O 
the O 
extent O 
to O 
which O 
insights O 
gleaned O 
from O 
detailed O 
studies O 
of O 
molecular O 
photodissociations O 
in O 
the O 
gas O 
phase O 
( O 
i.e O 
. O 
under O 
isolated O 
molecule O 
conditions O 
) O 
can O 
inform O 
our O 
understanding O 
of O 
the O 
corresponding O 
photofragmentation O 
processes O 
in O 
solution O 
. O 
Systems O 
selected O 
for O 
comparison O 
include O 
a O 
thiophenol B-SYSTEMATIC 
( O 
p-methylthiophenol B-SYSTEMATIC 
) O 
, O 
a O 
thioanisole B-SYSTEMATIC 
( O 
p-methylthioanisole B-SYSTEMATIC 
) O 
and O 
phenol B-SYSTEMATIC 
, O 
in O 
vacuum O 
and O 
in O 
cyclohexane B-SYSTEMATIC 
solution O 
. O 
UV O 
excitation O 
in O 
the O 
gas O 
phase O 
results O 
in O 
RX-Y B-FAMILY 
( O 
X O 
= O 
O B-FORMULA 
, O 
S B-FORMULA 
; O 
Y O 
= O 
H B-FORMULA 
, O 
CH3 B-FORMULA 
) O 
bond O 
fission O 
in O 
all O 
cases O 
, O 
but O 
over O 
timescales O 
that O 
vary O 
by O 
∼4 O 
orders O 
of O 
magnitude O 
- O 
all O 
of O 
which O 
behaviours O 
can O 
be O 
rationalised O 
on O 
the O 
basis O 
of O 
the O 
relevant O 
bound O 
and O 
dissociative O 
excited O 
state O 
potential O 
energy O 
surfaces O 
( O 
PESs O 
) O 
accessed O 
by O 
UV O 
photoexcitation O 
, O 
and O 
of O 
the O 
conical O 
intersections O 
that O 
facilitate O 
radiationless O 
transfer O 
between O 
these O 
PESs O 
. O 
Time O 
- O 
resolved O 
UV O 
pump O 
- O 
broadband O 
UV O 
/ O 
visible O 
probe O 
and O 
/ O 
or O 
UV O 
pump O 
- O 
broadband O 
IR O 
probe O 
studies O 
of O 
the O 
corresponding O 
systems O 
in O 
cyclohexane B-SYSTEMATIC 
solution O 
reveal O 
additional O 
processes O 
that O 
are O 
unique O 
to O 
the O 
condensed O 
phase O 
. O 
Thus O 
, O 
for O 
example O 
, O 
the O 
data O 
clearly O 
reveal O 
evidence O 
of O 
(i) O 
vibrational O 
relaxation O 
of O 
the O 
photoexcited O 
molecules O 
prior O 
to O 
their O 
dissociation O 
and O 
of O 
the O 
radical O 
fragments O 
formed O 
upon O 
X-Y O 
bond O 
fission O 
, O 
and O 
(ii) O 
geminate O 
recombination O 
of O 
the O 
RX B-FAMILY 
and O 
Y O 
products O 
( O 
leading O 
to O 
reformation O 
of O 
the O 
ground O 
state O 
parent O 
and O 
/ O 
or O 
isomeric O 
adducts O 
) O 
. O 
Nonetheless O 
, O 
the O 
data O 
also O 
show O 
that O 
, O 
in O 
each O 
case O 
, O 
the O 
characteristics O 
( O 
and O 
the O 
timescale O 
) O 
of O 
the O 
initial O 
bond O 
fission O 
process O 
that O 
occurs O 
under O 
isolated O 
molecule O 
conditions O 
are O 
barely O 
changed O 
by O 
the O 
presence O 
of O 
a O 
weakly O 
interacting O 
solvent O 
like O 
cyclohexane B-SYSTEMATIC 
. O 
These O 
condensed O 
phase O 
studies O 
are O 
then O 
extended O 
to O 
an O 
ether B-SYSTEMATIC 
analogue O 
of O 
phenol B-SYSTEMATIC 
( O 
allyl B-SYSTEMATIC 
phenyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
) O 
, O 
wherein O 
UV O 
photo O 
- O 
induced O 
RO B-FAMILY 
- O 
allyl B-SYSTEMATIC 
bond O 
fission O 
constitutes O 
the O 
first O 
step O 
of O 
a O 
photo-Claisen O 
rearrangement O 
. O 

the O 
protozoan O 
ciliate O 
Euplotes O 
, O 
a O 
transduction O 
pathway O 
resulting O 
in O 
a O 
mitogenic O 
cell O 
growth O 
response O 
is O 
activated O 
by O 
autocrine O 
receptor O 
binding O 
of O 
cell O 
type O 
- O 
specific O 
, O 
water O 
- O 
borne O 
signaling O 
protein O 
pheromones O 
. O 
In O 
Euplotes O 
raikovi O 
, O 
a O 
marine O 
species O 
of O 
temperate O 
waters O 
, O 
this O 
transduction O 
pathway O 
was O 
previously O 
shown O 
to O 
involve O 
the O 
phosphorylation O 
of O 
a O 
nuclear O 
protein O 
kinase O 
structurally O 
similar O 
to O 
the O 
intestinal O 
- O 
cell O 
and O 
male O 
germ O 
cell O 
- O 
associated O 
kinases O 
described O 
in O 
mammals O 
. O 
In O 
E O 
. O 
nobilii O 
, O 
which O 
is O 
phylogenetically O 
closely O 
related O 
to O 
E O 
. O 
raikovi O 
but O 
inhabits O 
Antarctic O 
and O 
Arctic O 
waters O 
, O 
we O 
have O 
now O 
characterized O 
a O 
gene O 
encoding O 
a O 
structurally O 
homologous O 
kinase O 
. O 
The O 
expression O 
of O 
this O 
gene O 
requires O 
1 O 
translational O 
frameshifting O 
and O 
a O 
process O 
of O 
intron O 
splicing O 
for O 
the O 
production O 
of O 
the O 
active O 
protein O 
, O 
designated O 
En-MAPK1 O 
, O 
which O 
contains O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
of O 
potential O 
significance O 
for O 
cold O 
- O 
adaptation O 
. O 

cleavable O 
poly(2-dimethylaminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
functionalized O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
for O 
efficient O 
siRNA O 
delivery O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

low O 
cytotoxicity O 
and O 
high O 
efficiency O 
delivery O 
system O 
with O 
the O 
advantages O 
of O 
low O 
cost O 
and O 
facile O 
fabrication O 
is O 
needed O 
for O 
the O 
application O 
of O 
small O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
delivery O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
For O 
these O 
prerequisites O 
, O 
cationic O 
polymer O 
- O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
( O 
ssCP-MSNs O 
) O 
were O 
prepared O 
by O 
surface O 
functionalized O 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
with O 
disulfide B-SYSTEMATIC 
bond O 
cross O 
- O 
linked O 
poly(2-dimethylaminoethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PDMAEMA B-ABBREVIATION 
) O 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
evaluations O 
were O 
performed O 
. O 
The O 
synthesized O 
ssCP-MSNs O 
are O 
100-150 O 
nm O 
in O 
diameter O 
with O 
a O 
pore O 
size O 
of O 
10 O 
nm O 
and O 
a O 
positively O 
charged O 
surface O 
with O 
a O 
high O 
zeta O 
potential O 
of O 
27 O 
mV O 
. O 
Consequently O 
, O 
the O 
ssCP-MSNs O 
showed O 
an O 
excellent O 
binding O 
capacity O 
for O 
siRNA O 
, O 
and O 
an O 
enhancement O 
in O 
the O 
cell O 
uptake O 
and O 
cytosolic O 
availability O 
of O 
siRNA O 
. O 
Furthermore O 
, O 
the O 
intracellular O 
reducing O 
cleavage O 
of O 
the O 
disulfide B-SYSTEMATIC 
bonds O 
cross O 
- O 
linking O 
the O 
PDMAEMA B-ABBREVIATION 
segments O 
led O 
to O 
intracellular O 
cleavage O 
of O 
PDMAEMA B-ABBREVIATION 
from O 
ssCP-MSNs O 
, O 
which O 
facilitated O 
the O 
intracellular O 
triggered O 
release O 
of O 
siRNA O 
. O 
Therefore O 
, O 
promoted O 
RNA O 
interference O 
was O 
observed O 
in O 
HeLa-Luc O 
cells O 
, O 
which O 
was O 
equal O 
to O 
that O 
of O 
Lipofectamine O 
2000 O 
. O 
Significantly O 
, O 
compared O 
to O 
Lipofectamine O 
2000 O 
, O 
the O 
ssCP-MSNs O 
were O 
more O 
biocompatible O 
, O 
with O 
low O 
cytotoxicity O 
( O 
even O 
non-cytotoxicity O 
) O 
and O 
promotion O 
of O 
cell O 
proliferation O 
to O 
HeLa-Luc O 
cells O 
. O 
The O 
in O 
vivo O 
systemic O 
distribution O 
studies O 
certified O 
that O 
ssCP-MSNs O 
/ O 
siRNA O 
could O 
prolong O 
the O 
duration O 
of O 
siRNA O 
in O 
vivo O 
, O 
and O 
that O 
they O 
accumulated O 
in O 
the O 
adrenal O 
gland O 
, O 
liver O 
, O 
lung O 
, O 
spleen O 
, O 
kidney O 
, O 
heart O 
and O 
thymus O 
after O 
intravenous O 
injection O 
. O 
Encouragingly O 
, O 
with O 
the O 
ability O 
to O 
deliver O 
siRNA O 
to O 
a O 
tumor O 
, O 
ssCP-MSNs O 
/ O 
siRNA O 
showed O 
a O 
tumor O 
suppression O 
effect O 
in O 
the O 
HeLa-Luc O 
xenograft O 
murine O 
model O 
after O 
intravenous O 
injection O 
. O 
Therefore O 
, O 
the O 
ssCP-MSNs O 
cationic O 
polymer O 
- O 
mesoporous O 
silica O 
nanoparticles O 
with O 
low O 
cytotoxicity O 
are O 
promising O 
for O 
siRNA O 
delivery O 
. O 

of O 
mixtures O 
of O 
azole B-FAMILY 
fungicides O 
in O 
postimplantation O 
rat O 
whole O 
- O 
embryo O 
cultures O 
. O 

effect O 
of O 
mixtures O 
of O 
azole B-FAMILY 
fungicides O 
on O 
development O 
of O 
postimplantation O 
rat O 
whole O 
- O 
embryos O 
cultured O 
in O 
vitro O 
has O 
been O 
tested O 
. O 
On O 
the O 
basis O 
of O 
bench O 
mark O 
dose O 
( O 
BMD O 
) O 
modeling O 
of O 
the O 
in O 
vitro O 
effect O 
in O 
rat O 
embryo O 
, O 
the O 
potency O 
of O 
7 O 
azoles B-FAMILY 
was O 
determined O 
and O 
compared O 
. O 
Then O 
, O 
relative O 
potency O 
factors O 
have O 
been O 
derived O 
based O 
on O 
either O 
the O 
NOAEL O 
or O 
on O 
the O 
BMD O 
curve O 
. O 
Alternatively O 
, O 
each O 
compound O 
was O 
used O 
as O 
index O 
compound O 
( O 
IC O 
) O 
, O 
and O 
IC-equivalent O 
concentrations O 
have O 
been O 
calculated O 
for O 
each O 
mixture O 
. O 
Expected O 
effects O 
of O 
such O 
IC-equivalent O 
concentrations O 
of O 
the O 
mixture O 
were O 
derived O 
from O 
the O 
appropriate O 
BMD O 
curve O 
. O 
Test O 
mixture O 
includes O 
the O 
agrochemicals O 
triadimefon B-TRIVIAL 
and O 
imazalil B-TRIVIAL 
( O 
MIX2 O 
) O 
or O 
triadimefon B-TRIVIAL 
, O 
imazalil B-TRIVIAL 
, O 
and O 
the O 
clinically O 
used O 
fluconazole B-TRIVIAL 
( O 
MIX3 O 
) O 
at O 
their O 
previously O 
determined O 
no O 
- O 
effect O 
concentration O 
, O 
corresponding O 
to O 
approximately O 
a O 
benchmark O 
response O 
of O 
5-10 O 
% O 
. O 
Subsequently O 
, O 
we O 
tested O 
the O 
effect O 
of O 
a O 
mixture O 
of O 
the O 
agrochemicals O 
triadimefon B-TRIVIAL 
, O 
imazalil B-TRIVIAL 
, O 
triadimenol B-TRIVIAL 
, O 
cyproconazole B-TRIVIAL 
, O 
tebuconazole B-TRIVIAL 
, O 
and O 
flusilazole B-TRIVIAL 
( O 
MIX6 O 
) O 
at O 
concentration O 
levels O 
derived O 
from O 
their O 
established O 
human O 
acceptable O 
daily O 
intake O 
. O 
MIX6 O 
was O 
also O 
added O 
with O 
fluconazole B-TRIVIAL 
at O 
concentration O 
levels O 
indicated O 
as O 
the O 
minimum O 
therapeutically O 
effective O 
plasmatic O 
concentration O 
( O 
MIX7A O 
) O 
or O 
ten O 
times O 
this O 
level O 
( O 
MIX7B O 
) O 
. O 
Generally O 
, O 
the O 
experimental O 
response O 
was O 
higher O 
than O 
the O 
estimated O 
one O 
, O 
by O 
a O 
factor O 
of O 
2-6 O 
. O 
Our O 
data O 
suggest O 
that O 
it O 
is O 
in O 
principle O 
correct O 
to O 
assume O 
that O 
azoles O 
act O 
as O 
teratogens O 
via O 
a O 
common O 
mode O 
of O 
action O 
and O 
therefore O 
should O 
be O 
grouped O 
together O 
for O 
risk O 
assessment O 
. O 
The O 
synergistic O 
effect O 
needs O 
to O 
be O 
confirmed O 
with O 
more O 
combinations O 
of O 
concentrations O 
/ O 
compounds O 
in O 
vitro O 
and O 
with O 
specific O 
in O 
vivo O 
experiments O 
. O 

responsivity O 
, O 
fast O 
ultraviolet O 
photodetector O 
fabricated O 
from O 
ZnO B-FORMULA 
nanoparticle- O 
graphene B-TRIVIAL 
core O 
- O 
shell O 
structures O 
. O 

report O 
a O 
simple O 
, O 
efficient O 
and O 
versatile O 
method O 
for O 
assembling O 
metal B-FAMILY 
oxide I-FAMILY 
nanomaterial- O 
graphene B-TRIVIAL 
core O 
- O 
shell O 
structures O 
. O 
An O 
ultraviolet O 
photodetector O 
fabricated O 
from O 
the O 
ZnO B-FORMULA 
nanoparticle- O 
graphene B-TRIVIAL 
core O 
- O 
shell O 
structures O 
showed O 
high O 
responsivity O 
and O 
fast O 
transient O 
response O 
, O 
which O 
are O 
attributed O 
to O 
the O 
improved O 
carrier O 
transport O 
efficiency O 
arising O 
from O 
graphene B-TRIVIAL 
encapsulation O 
. O 

of O 
diferrocenylacetylene B-SYSTEMATIC 
on O 
Au(111) B-FORMULA 
studied O 
by O 
scanning O 
tunneling O 
microscopy O 
. O 

tunneling O 
microscopy O 
images O 
of O 
diferrocenylacetylene B-SYSTEMATIC 
( O 
DFA B-ABBREVIATION 
) O 
coadsorbed O 
with O 
benzene B-SYSTEMATIC 
on O 
Au(111) B-FORMULA 
show O 
individual O 
and O 
close O 
- O 
packed O 
DFA B-ABBREVIATION 
molecules O 
, O 
either O 
adsorbed O 
alongside O 
benzene B-SYSTEMATIC 
or O 
on O 
top O 
of O 
a O 
benzene B-SYSTEMATIC 
monolayer O 
. O 
Images O 
acquired O 
over O 
a O 
range O 
of O 
positive O 
and O 
negative O 
tip O 
- O 
sample O 
bias O 
voltages O 
show O 
a O 
shift O 
in O 
contrast O 
, O 
with O 
the O 
acetylene B-SYSTEMATIC 
linker O 
appearing O 
brighter O 
than O 
the O 
ferrocenes B-FAMILY 
at O 
positive O 
sample O 
bias O 
( O 
where O 
unoccupied O 
states O 
primarily O 
contribute O 
) O 
and O 
the O 
reverse O 
contrast O 
at O 
negative O 
bias O 
. O 
Density O 
functional O 
theory O 
was O 
used O 
to O 
calculate O 
the O 
electronic O 
structure O 
of O 
the O 
gas-phase O 
DFA B-ABBREVIATION 
molecule O 
, O 
and O 
simulated O 
images O 
produced O 
through O 
two O 
- O 
dimensional O 
projections O 
of O 
these O 
calculations O 
approximate O 
the O 
experimental O 
images O 
. O 
The O 
symmetry O 
of O 
both O 
experimental O 
and O 
calculated O 
molecular O 
features O 
for O 
DFA B-ABBREVIATION 
rules O 
out O 
a O 
cis O 
adsorption O 
geometry O 
, O 
and O 
comparison O 
of O 
experiment O 
to O 
simulation O 
indicates O 
torsion O 
around O 
the O 
inter- O 
ferrocene B-TRIVIAL 
axis O 
between O 
90° O 
and O 
180° O 
( O 
trans O 
) O 
; O 
the O 
cyclopentadienyl B-SYSTEMATIC 
rings O 
are O 
thus O 
angled O 
with O 
respect O 
to O 
the O 
surface O 
. O 

in O 
metastatic O 
renal O 
cell O 
carcinoma O 
: O 
results O 
of O 
a O 
pharmacokinetic O 
and O 
pharmacodynamic O 
analysis O 
. O 

is O 
a O 
potent O 
and O 
selective O 
inhibitor O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
receptors O 
1 O 
, O 
2 O 
, O 
and O 
3 O 
, O 
approved O 
for O 
second O 
- O 
line O 
therapy O 
for O 
advanced O 
renal O 
cell O 
carcinoma O 
( O 
RCC O 
) O 
. O 
Axitinib B-TRIVIAL 
population O 
pharmacokinetic O 
and O 
pharmacokinetic O 
/ O 
pharmacodynamic O 
relationships O 
were O 
evaluated O 
. O 
Using O 
nonlinear O 
mixed O 
effects O 
modeling O 
with O 
pooled O 
data O 
from O 
383 O 
healthy O 
volunteers O 
, O 
181 O 
patients O 
with O 
metastatic O 
RCC O 
, O 
and O 
26 O 
patients O 
with O 
other O 
solid O 
tumors O 
in O 
17 O 
trials O 
, O 
the O 
disposition O 
of O 
axitinib B-TRIVIAL 
was O 
best O 
described O 
by O 
a O 
2-compartment O 
model O 
with O 
first O 
- O 
order O 
absorption O 
and O 
a O 
lag O 
time O 
, O 
with O 
estimated O 
mean O 
systemic O 
clearance O 
( O 
CL O 
) O 
of O 
14.6 O 
L O 
/ O 
h O 
and O 
central O 
volume O 
of O 
distribution O 
( O 
Vc O 
) O 
of O 
47.3 O 
L O 
. O 
Of O 
12 O 
covariates O 
tested O 
, O 
age O 
over O 
60 O 
years O 
and O 
Japanese O 
ethnicity O 
were O 
associated O 
with O 
decreased O 
CL O 
, O 
whereas O 
Vc O 
increased O 
with O 
body O 
weight O 
. O 
However O 
, O 
the O 
magnitude O 
of O 
predicted O 
changes O 
in O 
exposure O 
based O 
on O 
these O 
covariates O 
does O 
not O 
warrant O 
dose O 
adjustments O 
. O 
Multivariate O 
Cox O 
proportional O 
hazard O 
regression O 
and O 
logistic O 
regression O 
analyses O 
showed O 
that O 
higher O 
exposure O 
and O 
diastolic O 
blood O 
pressure O 
were O 
independently O 
associated O 
with O 
longer O 
progression O 
- O 
free O 
and O 
overall O 
survivals O 
and O 
higher O 
probability O 
of O 
partial O 
response O 
in O 
metastatic O 
RCC O 
patients O 
. O 
These O 
findings O 
support O 
axitinib B-TRIVIAL 
dose O 
titration O 
to O 
increase O 
plasma O 
exposure O 
in O 
patients O 
who O 
tolerate O 
axitinib B-TRIVIAL 
, O 
and O 
also O 
demonstrate O 
diastolic O 
blood O 
pressure O 
as O 
a O 
potential O 
marker O 
of O 
efficacy O 
. O 

vitro O 
measures O 
of O 
aerosol O 
particles O 
size O 
, O 
such O 
as O 
the O 
fine O 
particle O 
mass O 
, O 
play O 
a O 
pivotal O 
role O 
for O 
approval O 
of O 
inhaled O 
anti-asthmatic O 
drugs O 
. O 
However O 
, O 
the O 
validity O 
as O 
a O 
measure O 
of O 
dose O 
to O 
the O 
lungs O 
in O 
children O 
lacks O 
evidence O 
. O 
In O 
this O 
study O 
we O 
investigated O 
for O 
the O 
first O 
time O 
the O 
association O 
between O 
an O 
in O 
vivo O 
estimate O 
of O 
lung O 
dose O 
of O 
inhaled O 
drug O 
in O 
children O 
and O 
the O 
corresponding O 
particle O 
size O 
segments O 
assessed O 
ex O 
vivo O 
. O 
Lung O 
dose O 
of O 
fluticasone B-SYSTEMATIC 
propionate I-SYSTEMATIC 
after O 
inhalation O 
from O 
a O 
dry O 
powder O 
inhaler O 
( O 
Diskus B-TRIVIAL 
® O 
) O 
was O 
studied O 
in O 
23 O 
children O 
aged O 
4-7 O 
and O 
12- O 
15 O 
years O 
with O 
mild O 
asthma O 
. O 
Six O 
- O 
hour O 
pharmacokinetics O 
was O 
assessed O 
after O 
single O 
inhalation O 
. O 
The O 
corresponding O 
emitted O 
mass O 
of O 
drug O 
in O 
segments O 
of O 
aerosol O 
particle O 
size O 
was O 
assessed O 
ex O 
vivo O 
by O 
replicating O 
the O 
inhalation O 
flows O 
recorded O 
by O 
transducers O 
built O 
into O 
the O 
Diskus B-TRIVIAL 
® O 
inhaler O 
and O 
re O 
- O 
playing O 
them O 
in O 
a O 
breathing O 
simulator O 
. O 
There O 
was O 
no O 
correlation O 
between O 
any O 
inhaled O 
particle O 
size O 
segment O 
and O 
lung O 
dose O 
assessed O 
by O 
pharmacokinetics O 
and O 
adjusted O 
for O 
age O 
and O 
body O 
size O 
. O 
Measures O 
of O 
particles O 
size O 
segments O 
were O 
not O 
related O 
to O 
lung O 
dose O 
in O 
children O 
. O 
Until O 
further O 
evidence O 
is O 
provided O 
it O 
may O 
be O 
warranted O 
to O 
emphasize O 
pharmacokinetic O 
or O 
pharmacodynamic O 
assessments O 
of O 
drug O 
delivery O 
to O 
the O 
lung O 
. O 

proteins O 
and O 
functional O 
protein O 
networks O 
of O 
the O 
tight O 
junction O 
remain O 
incompletely O 
defined O 
. O 
Among O 
the O 
currently O 
known O 
proteins O 
are O 
barrier O 
forming O 
proteins O 
like O 
occludin O 
and O 
the O 
claudin O 
family O 
, O 
scaffolding O 
proteins O 
like O 
ZO-1 O 
, O 
and O 
some O 
cytoskeletal O 
, O 
signaling O 
and O 
cell O 
polarity O 
proteins O 
. O 
To O 
define O 
a O 
more O 
complete O 
list O 
of O 
proteins O 
and O 
infer O 
their O 
functional O 
implications O 
, O 
we O 
identified O 
the O 
proteins O 
which O 
are O 
within O 
molecular O 
dimensions O 
of O 
ZO-1 O 
by O 
fusing O 
biotin B-TRIVIAL 
ligase O 
to O 
either O 
its O 
N- O 
or O 
C-terminus O 
, O 
expressing O 
these O 
fusion O 
proteins O 
in O 
MDCK O 
epithelial O 
cells O 
and O 
purifying O 
and O 
identifying O 
the O 
resulting O 
biotinylated O 
proteins O 
by O 
mass O 
spectrometry O 
. O 
Out O 
of O 
a O 
predicted O 
proteome O 
of O 
≈ O 
9000 O 
we O 
identified O 
more O 
than O 
400 O 
proteins O 
tagged O 
by O 
biotin B-TRIVIAL 
ligase O 
fused O 
to O 
ZO-1 O 
, O 
with O 
both O 
identical O 
and O 
distinct O 
proteins O 
near O 
the O 
N B-FORMULA 
- O 
and O 
C B-FORMULA 
- O 
terminal O 
ends O 
. O 
Those O 
proximal O 
to O 
the O 
N-terminus O 
were O 
enriched O 
in O 
transmembrane O 
tight O 
junction O 
proteins O 
and O 
those O 
proximal O 
to O 
the O 
C-terminus O 
were O 
enriched O 
in O 
cytoskeletal O 
proteins O 
. O 
We O 
also O 
identified O 
many O 
unexpected O 
, O 
but O 
easily O 
rationalized O 
proteins O 
. O 
In O 
addition O 
, O 
functional O 
networks O 
of O 
interacting O 
proteins O 
were O 
tagged O 
, O 
such O 
as O 
the O 
basolateral O 
but O 
not O 
apical O 
polarity O 
network O 
. O 
These O 
results O 
provide O 
a O 
rich O 
inventory O 
of O 
proteins O 
and O 
potential O 
novel O 
insights O 
into O 
functions O 
and O 
protein O 
networks O 
that O 
should O 
catalyze O 
further O 
understanding O 
of O 
tight O 
junction O 
biology O 
. O 
Unexpectedly O 
, O 
the O 
technique O 
demonstrates O 
high O 
spatial O 
resolution O 
which O 
could O 
be O 
generally O 
applied O 
to O 
defining O 
subcellular O 
protein O 
compartmentalization O 
. O 

, O 
Patient- O 
, O 
and O 
Disease O 
- O 
Related O 
Factors O 
and O 
the O 
Emergence O 
of O 
Adverse O 
Events O 
with O 
Tyrosine B-TRIVIAL 
Kinase O 
Inhibitors O 
for O 
the O 
Treatment O 
of O 
Chronic O 
Myeloid O 
Leukemia O 
. O 

breakpoint O 
cluster O 
region O 
(BCR)-ABL1 O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
( O 
TKIs O 
) O 
are O 
currently O 
available O 
for O 
the O 
treatment O 
of O 
chronic O 
myeloid O 
leukemia O 
( O 
CML O 
) O 
: O 
imatinib B-TRIVIAL 
, O 
nilotinib B-TRIVIAL 
, O 
dasatinib B-TRIVIAL 
, O 
and O 
bosutinib B-TRIVIAL 
. O 
Choosing O 
the O 
most O 
appropriate O 
TKI O 
requires O 
clinicians O 
to O 
consider O 
a O 
host O 
of O 
patient- O 
, O 
disease- O 
, O 
and O 
treatment O 
- O 
related O 
factors O 
, O 
not O 
the O 
least O 
of O 
which O 
include O 
the O 
safety O 
profiles O 
of O 
the O 
agents O 
. O 
This O 
review O 
discusses O 
the O 
potential O 
impact O 
of O 
treatment- O 
, O 
patient- O 
, O 
and O 
disease O 
- O 
related O 
characteristics O 
on O 
the O 
emergence O 
of O 
adverse O 
events O 
during O 
TKI O 
therapy O 
, O 
with O 
a O 
focus O 
on O 
the O 
underlying O 
mechanisms O 
believed O 
to O 
be O 
responsible O 
for O 
a O 
number O 
of O 
important O 
adverse O 
events O 
associated O 
with O 
these O 
agents O 
and O 
what O 
implications O 
they O 
may O 
have O 
for O 
treatment O 
choice O 
, O 
particularly O 
in O 
the O 
setting O 
of O 
first O 
- O 
line O 
treatment O 
. O 
A O 
literature O 
search O 
of O 
the O 
PubMed O 
database O 
was O 
conducted O 
to O 
identify O 
articles O 
that O 
described O 
the O 
molecular O 
mechanisms O 
of O 
BCR-ABL1 O 
- O 
mediated O 
leukemic O 
transformation O 
, O 
the O 
efficacy O 
and O 
safety O 
of O 
imatinib B-TRIVIAL 
, O 
nilotinib B-TRIVIAL 
, O 
dasatinib B-TRIVIAL 
, O 
and O 
bosutinib B-TRIVIAL 
in O 
patients O 
with O 
CML O 
, O 
the O 
kinase O 
- O 
binding O 
spectrum O 
of O 
each O 
TKI O 
, O 
and O 
evidence O 
suggesting O 
a O 
link O 
between O 
the O 
TKI O 
- O 
binding O 
profile O 
and O 
adverse O 
events O 
. O 
The O 
pattern O 
of O 
adverse O 
events O 
associated O 
with O 
each O 
agent O 
is O 
important O 
when O 
selecting O 
treatment O 
with O 
a O 
TKI O 
. O 
Clinical O 
studies O 
suggest O 
that O 
imatinib B-TRIVIAL 
, O 
nilotinib B-TRIVIAL 
, O 
dasatinib B-TRIVIAL 
, O 
and O 
bosutinib B-TRIVIAL 
have O 
differing O 
safety O 
profiles O 
, O 
which O 
are O 
in O 
part O 
attributable O 
to O 
the O 
specificity O 
and O 
selectivity O 
of O 
each O 
agent O 
. O 
Although O 
much O 
basic O 
research O 
must O 
be O 
conducted O 
to O 
further O 
illuminate O 
the O 
mechanisms O 
responsible O 
for O 
TKI O 
- O 
related O 
adverse O 
events O 
, O 
on- O 
and O 
off O 
- O 
target O 
effects O 
are O 
believed O 
to O 
be O 
at O 
least O 
partly O 
responsible O 
for O 
cardiovascular O 
toxicity O 
, O 
myelosuppression O 
, O 
fluid O 
retention O 
, O 
gastrointestinal O 
toxicity O 
, O 
and O 
dermatologic O 
toxicity O 
. O 
Increased O 
understanding O 
of O 
the O 
factors O 
that O 
affect O 
TKI-associated O 
adverse O 
events O 
and O 
long O 
- O 
term O 
safety O 
data O 
will O 
enable O 
a O 
more O 
informed O 
approach O 
to O 
the O 
selection O 
of O 
therapy O 
best O 
suited O 
to O 
the O 
individual O 
needs O 
of O 
patients O 
with O 
CML O 
. O 

Localized O 
Surface O 
Plasmon O 
Resonance O 
- O 
Based O 
Multicolor O 
Electrochromic O 
Device O 
with O 
Electrochemically O 
Size-Controlled O 
Silver B-SYSTEMATIC 
Nanoparticles O 
. O 

first O 
localized O 
surface O 
plasmon O 
resonance O 
( O 
LSPR O 
) O 
- O 
based O 
multicolor O 
electrochromic O 
device O 
with O 
reversible O 
five O 
optical O 
states O 
is O 
demonstrated O 
. O 
In O 
this O 
device O 
, O 
the O 
size O 
of O 
deposited O 
silver B-SYSTEMATIC 
nanoparticles O 
is O 
electrochemically O 
controlled O 
using O 
a O 
voltage O 
- O 
step O 
method O 
in O 
which O 
two O 
different O 
voltages O 
are O 
applied O 
successively O 
. O 
The O 
electrochemically O 
size O 
- O 
controlled O 
silver B-SYSTEMATIC 
nanoparticles O 
enable O 
a O 
reversible O 
multiple O 
- O 
color O 
change O 
by O 
a O 
shift O 
of O 
the O 
LSPR O 
band O 
. O 

of O 
a O 
Novel O 
Approach O 
for O 
Dose O 
Individualization O 
in O 
Pharmacotherapy O 
Using O 
Gabapentin B-TRIVIAL 
in O 
a O 
Proof O 
of O 
Principles O 
Study O 
. O 

OBJECTIVE O 
: O 
To O 
demonstrate O 
the O 
premise O 
of O 
individualized O 
dosing O 
charts O 
( O 
IDCs O 
) O 
as O 
a O 
clinical O 
- O 
bedside O 
decision O 
- O 
support O 
tool O 
to O 
individualize O 
dosage O 
regimens O 
for O 
drugs O 
in O 
which O 
the O 
interpatient O 
variability O 
is O 
controlled O 
by O 
the O 
pharmacokinetic O 
( O 
PK O 
) O 
behavior O 
of O 
the O 
patient O 
, O 
to O 
calculate O 
the O 
optimal O 
sampling O 
schedule O 
( O 
OSS O 
) O 
, O 
which O 
minimizes O 
the O 
number O 
of O 
blood O 
samples O 
per O 
patient O 
. O 
The O 
approach O 
is O 
illustrated O 
with O 
available O 
PK O 
data O 
for O 
gabapentin B-TRIVIAL 
. O 
DESIGN O 
: O 
Retrospective O 
proof O 
of O 
principles O 
study O 
using O 
gabapentin B-TRIVIAL 
PK O 
data O 
from O 
a O 
published O 
clinical O 
trial O 
. O 
PATIENTS O 
: O 
Nineteen O 
subjects O 
in O 
a O 
trial O 
designed O 
to O 
uncover O 
the O 
importance O 
of O 
the O 
genetic O 
contributions O 
to O 
variability O 
in O 
gabapentin B-TRIVIAL 
absorption O 
, O 
renal O 
elimination O 
, O 
and O 
transport O 
; O 
subjects O 
were O 
monitored O 
for O 
36 O 
hours O 
after O 
administration O 
of O 
a O 
single O 
dose O 
of O 
gabapentin B-TRIVIAL 
400 O 
mg O 
, O 
and O 
plasma O 
concentrations O 
were O 
determined O 
at O 
14 O 
time O 
points O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
When O 
the O 
PK O 
profiles O 
were O 
different O 
between O 
subjects O 
, O 
the O 
IDCs O 
are O 
dramatically O 
different O 
from O 
each O 
other O 
and O 
from O 
the O 
IDC O 
for O 
an O 
" O 
average O 
" O 
patient O 
representing O 
the O 
patient O 
population O 
. O 
The O 
dose O 
amount O 
and O 
dosing O 
interval O 
must O 
be O 
adjusted O 
to O 
maximize O 
the O 
probability O 
of O 
staying O 
within O 
the O 
target O 
concentration O 
range O 
. O 
An O 
optimal O 
sampling O 
methodology O 
based O 
on O 
the O 
assumption O 
- O 
free O 
Bayesian O 
approach O 
is O 
used O 
to O 
distinguish O 
the O 
PK O 
profile O 
of O 
an O 
individual O 
patient O 
from O 
the O 
patient O 
population O 
. O 
In O 
the O 
case O 
of O 
gabapentin B-TRIVIAL 
, O 
only O 
two O 
optimally O 
selected O 
test O 
blood O 
samples O 
, O 
at O 
1.5 O 
and O 
6 O 
hours O 
after O 
administration O 
of O 
a O 
single O 
doses O 
, O 
were O 
necessary O 
. O 
The O 
average O 
sensitivity O 
and O 
the O 
average O 
specificity O 
of O 
the O 
OSS O 
was O 
99% O 
and O 
96% O 
, O 
respectively O 
. O 
CONCLUSION O 
: O 
IDCs O 
display O 
the O 
risk O 
of O 
a O 
patient O 
violating O 
the O 
target O 
concentration O 
range O 
for O 
any O 
dosage O 
regimen O 
. O 
They O 
can O 
be O 
used O 
as O 
a O 
clinical O 
- O 
bedside O 
decision O 
- O 
support O 
tool O 
in O 
a O 
patient-physician O 
partnership O 
to O 
decide O 
on O 
a O 
dose O 
amount O 
and O 
dosing O 
interval O 
that O 
are O 
medically O 
acceptable O 
while O 
practical O 
and O 
convenient O 
to O 
ensure O 
compliance O 
. O 
By O 
using O 
the O 
assumption O 
- O 
free O 
Bayesian O 
approach O 
and O 
the O 
OSS O 
, O 
the O 
number O 
of O 
samples O 
required O 
from O 
a O 
new O 
patient O 
to O 
individualize O 
the O 
dosage O 
regimen O 
can O 
be O 
reduced O 
significantly O 
while O 
preserving O 
high O 
levels O 
of O 
sensitivity O 
and O 
specificity O 
. O 
Prospective O 
studies O 
are O 
being O 
planned O 
to O 
validate O 
the O 
encouraging O 
results O 
. O 
This O 
approach O 
can O 
be O 
extended O 
to O 
any O 
drug O 
if O 
PK O 
data O 
and O 
a O 
target O 
concentration O 
range O 
are O 
available O 
for O 
either O 
therapeutic O 
drug O 
monitoring O 
or O 
target O 
concentration O 
intervention O 
. O 

of O 
Sildenafil B-TRIVIAL 
on O 
Survival O 
of O 
Patients O 
With O 
Eisenmenger O 
Syndrome O 
. O 

favorable O 
effects O 
of O 
short O 
- O 
term O 
use O 
of O 
sildenafil B-TRIVIAL 
on O 
patients O 
with O 
Eisenmenger O 
syndrome O 
have O 
been O 
reported O 
. O 
We O 
further O 
studied O 
the O 
impact O 
of O 
long O 
- O 
term O 
use O 
of O 
sildenafil B-TRIVIAL 
on O 
survival O 
of O 
these O 
patients O 
. O 
In O 
this O 
study O 
, O 
the O 
baseline O 
data O 
of O 
patients O 
newly O 
diagnosed O 
as O 
Eisenmenger O 
syndrome O 
in O 
our O 
hospital O 
between O 
January O 
2005 O 
and O 
December O 
2009 O 
were O 
retrospectively O 
collected O 
. O 
Patients O 
were O 
followed O 
- O 
up O 
either O 
by O 
telephone O 
contacts O 
or O 
during O 
visits O 
in O 
our O 
out O 
- O 
patient O 
clinic O 
. O 
A O 
total O 
of O 
121 O 
patients O 
( O 
68 O 
patients O 
in O 
conventional O 
group O 
and O 
53 O 
patients O 
in O 
sildenafil B-TRIVIAL 
group O 
) O 
were O 
finally O 
included O 
and O 
29 O 
patients O 
were O 
re O 
- O 
evaluated O 
after O 
sildenafil B-TRIVIAL 
therapy O 
for O 
3-4 O 
months O 
. O 
Compared O 
with O 
the O 
baseline O 
, O 
a O 
6-minute O 
walk O 
distance O 
, O 
functional O 
classes O 
, O 
plasma O 
hemoglobin O 
level O 
, O 
and O 
hemodynamics O 
were O 
significantly O 
improved O 
after O 
sildenafil B-TRIVIAL 
treatment O 
. O 
During O 
a O 
median O 
follow O 
- O 
up O 
period O 
of O 
35.8 O 
months O 
, O 
15 O 
patients O 
died O 
( O 
11 O 
patients O 
in O 
conventional O 
group O 
) O 
. O 
The O 
1- O 
and O 
3-year O 
survival O 
rates O 
in O 
sildenafil B-TRIVIAL 
group O 
were O 
97.0% O 
and O 
95.2% O 
, O 
significantly O 
higher O 
than O 
90.6% O 
and O 
82.9% O 
in O 
conventional O 
group O 
P O 
= O 
0.025 O 
) O 
. O 
Multivariate O 
analysis O 
showed O 
that O 
sildenafil B-TRIVIAL 
therapy O 
, O 
functional O 
class O 
and O 
mean O 
pulmonary O 
arterial O 
pressure O 
were O 
independently O 
associated O 
with O 
survival O 
. O 
Therefore O 
, O 
long O 
- O 
term O 
sildenafil B-TRIVIAL 
therapy O 
improved O 
survival O 
in O 
patients O 
with O 
Eisenmenger O 
syndrome O 
. O 

fibrillation O 
( O 
AF O 
) O 
is O 
a O 
cardiac O 
arrhythmia O 
associated O 
with O 
significant O 
morbidity O 
and O 
mortality O 
, O 
affecting O 
more O 
than O 
3 O 
million O 
people O 
in O 
the O 
United O 
States O 
and O 
1-2% O 
of O 
the O 
population O 
worldwide O 
. O 
Its O 
estimated O 
prevalence O 
is O 
expected O 
to O 
double O 
within O 
the O 
next O 
50 O 
years O 
. O 
During O 
the O 
past O 
decade O 
, O 
there O 
have O 
been O 
significant O 
advances O 
in O 
the O 
treatment O 
of O 
AF O 
. O 
Studies O 
have O 
demonstrated O 
that O 
a O 
rate O 
control O 
strategy O 
, O 
with O 
a O 
target O 
resting O 
heart O 
rate O 
between O 
80 O 
and O 
100 O 
beats O 
/ O 
minute O 
, O 
is O 
recommended O 
over O 
rhythm O 
control O 
in O 
the O 
vast O 
majority O 
of O 
patients O 
. O 
The O 
CHA2 O 
DS2 O 
≥ O 
( O 
congestive O 
heart O 
failure O 
, O 
hypertension O 
, O 
age O 
≥ O 
65 O 
yrs O 
, O 
diabetes O 
mellitus O 
, O 
stroke O 
or O 
transient O 
ischemic O 
attack O 
, O 
vascular O 
disease O 
, O 
female O 
gender O 
) O 
scoring O 
system O 
is O 
a O 
potentially O 
useful O 
stroke O 
risk O 
stratification O 
tool O 
that O 
incorporates O 
additional O 
risk O 
factors O 
to O 
the O 
commonly O 
used O 
CHADS2 O 
( O 
congestive O 
heart O 
failure O 
, O 
hypertension O 
, O 
age O 
≥ O 
75 O 
years O 
, O 
diabetes O 
mellitus O 
, O 
stroke O 
transient O 
ischemic O 
attack O 
) O 
scoring O 
tool O 
. O 
Similarly O 
, O 
a O 
convenient O 
scheme O 
, O 
termed O 
HAS-BLED O 
( O 
hypertension O 
, O 
abnormal O 
renal O 
/ O 
liver O 
function O 
, O 
stroke O 
, O 
bleeding O 
history O 
or O 
predisposition O 
, O 
labile O 
international O 
normalized O 
ratio O 
, O 
elderly O 
, O 
drugs/ O 
alcohol B-FAMILY 
concomitantly O 
) O 
, O 
to O 
assess O 
bleeding O 
risk O 
has O 
emerged O 
that O 
may O 
be O 
useful O 
in O 
select O 
patients O 
. O 
Furthermore O 
, O 
new O 
antithrombotic O 
strategies O 
have O 
been O 
developed O 
as O 
potential O 
alternatives O 
to O 
warfarin B-TRIVIAL 
, O 
including O 
dual O 
- O 
antiplatelet O 
therapy O 
with O 
clopidogrel B-TRIVIAL 
plus O 
aspirin B-TRIVIAL 
and O 
the O 
development O 
of O 
new O 
oral O 
anticoagulants O 
such O 
as O 
dabigatran B-TRIVIAL 
, O 
rivaroxaban B-TRIVIAL 
, O 
and O 
apixaban B-TRIVIAL 
. O 
Vernakalant B-TRIVIAL 
has O 
emerged O 
as O 
another O 
potential O 
option O 
for O 
pharmacologic O 
conversion O 
of O 
AF O 
, O 
whereas O 
recent O 
trials O 
have O 
better O 
defined O 
the O 
role O 
of O 
dronedarone B-TRIVIAL 
in O 
the O 
maintenance O 
of O 
sinus O 
rhythm O 
. O 
Finally O 
, O 
catheter O 
ablation O 
represents O 
another O 
alternative O 
to O 
manage O 
AF O 
, O 
whereas O 
upstream O 
therapy O 
with O 
inhibitors O 
of O 
the O 
renin-angiotensin- O 
aldosterone B-TRIVIAL 
system O 
, O 
statins B-FAMILY 
, O 
and O 
polyunsaturated B-FAMILY 
fatty I-FAMILY 
acids I-FAMILY 
could O 
potentially O 
prevent O 
the O 
occurrence O 
of O 
AF O 
. O 
Despite O 
substantial O 
progress O 
in O 
the O 
management O 
of O 
AF O 
, O 
significant O 
uncertainty O 
surrounds O 
the O 
optimal O 
treatment O 
of O 
this O 
condition O 
. O 

gene O 
deletion O 
studies O 
in O 
mice O 
and O 
humans O 
have O 
established O 
the O 
pivotal O 
role O 
of O 
runt O 
related O 
transcription O 
factor-2 O 
( O 
Runx2 O 
) O 
in O 
both O 
intramembranous O 
and O 
endochondral O 
ossification O 
processes O 
during O 
skeletogenesis O 
. O 
In O 
this O 
study O 
, O 
we O 
for O 
the O 
first O 
time O 
generated O 
mice O 
carrying O 
a O 
conditional O 
Runx2 O 
allele O 
with O 
exon O 
4 O 
, O 
which O 
encodes O 
the O 
Runt O 
domain O 
, O 
flanked O 
by O 
loxP O 
sites O 
. O 
These O 
mice O 
were O 
crossed O 
with O 
α1(I)-collagen-Cre O 
or O 
α1(II)-collagen-Cre O 
transgenic O 
mice O 
to O 
obtain O 
osteoblast- O 
or O 
chondrocyte O 
- O 
specific O 
Runx2 O 
deficient O 
mice O 
, O 
respectively O 
. O 
As O 
seen O 
in O 
Runx2(- O 
/ O 
- O 
) O 
mice O 
, O 
perinatal O 
lethality O 
was O 
observed O 
in O 
α1(II)-Cre;Runx2(flox O 
/ O 
flox O 
) O 
mice O 
, O 
but O 
this O 
was O 
not O 
the O 
case O 
in O 
animals O 
in O 
which O 
α1(I)-collagen-Cre O 
was O 
used O 
to O 
delete O 
Runx2 O 
. O 
When O 
using O 
double O 
staining O 
with O 
Alizarin B-TRIVIAL 
red I-TRIVIAL 
for O 
mineralized O 
matrix O 
and O 
Alcian B-TRIVIAL 
blue I-TRIVIAL 
for O 
cartilaginous O 
matrix O 
, O 
we O 
observed O 
previously O 
that O 
mineralization O 
was O 
totally O 
absent O 
at O 
embryonic O 
day O 
15.5 O 
throughout O 
the O 
body O 
in O 
Runx2(- O 
/ O 
- O 
) O 
mice O 
, O 
but O 
was O 
found O 
in O 
areas O 
undergoing O 
intramembranous O 
ossification O 
such O 
as O 
skull O 
and O 
clavicles O 
in O 
α1(II)-Cre;Runx2(flox O 
/ O 
flox O 
) O 
mice O 
. O 
In O 
newborn O 
α1(II)-Cre;Runx2(flox O 
/ O 
flox O 
) O 
mice O 
, O 
mineralization O 
impairment O 
was O 
restricted O 
to O 
skeletal O 
areas O 
undergoing O 
endochondral O 
ossification O 
including O 
long O 
bones O 
and O 
vertebrae O 
. O 
In O 
contrast O 
, O 
no O 
apparent O 
skeletal O 
abnormalities O 
were O 
seen O 
in O 
mutant O 
embryo O 
, O 
newborn O 
, O 
and O 
3- O 
to O 
6-week O 
old O 
- O 
mice O 
in O 
which O 
Runx2 O 
had O 
been O 
deleted O 
with O 
the O 
α1(I)-collagen-Cre O 
driver O 
. O 
These O 
results O 
suggest O 
that O 
Runx2 O 
is O 
absolutely O 
required O 
for O 
endochondral O 
ossification O 
during O 
embryonic O 
and O 
postnatal O 
skeletogenesis O 
, O 
but O 
that O 
disrupting O 
its O 
expression O 
in O 
already O 
committed O 
osteoblasts O 
as O 
achieved O 
here O 
with O 
the O 
α1(I)-collagen-Cre O 
driver O 
does O 
not O 
affect O 
overtly O 
intramembranous O 
and O 
endochondral O 
ossification O 
. O 
The O 
Runx2 O 
floxed O 
allele O 
established O 
here O 
is O 
undoubtedly O 
useful O 
for O 
investigating O 
the O 
role O 
of O 
Runx2 O 
in O 
particular O 
cells O 
. O 
© O 
2013 O 
American O 
Society O 
for O 
Bone O 
and O 
Mineral O 
Research O 
. O 

Situ O 
Study O 
of O 
CO B-FORMULA 
Oxidation O 
on O 
HOPG-Supported O 
Pt B-FORMULA 
Nanoparticles O 
. O 

CO B-FORMULA 
oxidation O 
: O 
A O 
newly O 
designed O 
high O 
- O 
pressure O 
flow O 
cell O 
is O 
utilized O 
to O 
study O 
CO B-FORMULA 
oxidation O 
on O 
Pt B-FORMULA 
nanoparticles O 
in O 
situ O 
by O 
simultaneous O 
quadrupole O 
mass O 
spectrometry O 
and O 
high O 
- O 
pressure O 
X-ray O 
photoelectron O 
spectroscopy O 
. O 
The O 
spectroscopy O 
data O 
show O 
that O 
the O 
active O 
catalyst O 
consists O 
of O 
metallic O 
Pt B-FORMULA 
with O 
both O 
chemisorbed O 
O B-FORMULA 
and O 
patches O 
/ O 
shell O 
of O 
surface O 
oxides B-FAMILY 
. O 

present O 
study O 
investigated O 
the O 
efficacy O 
and O 
safety O 
effects O 
of O 
Sinetrol-XPur O 
( O 
polyphenolic O 
citrus O 
dry O 
extract O 
) O 
in O 
weight O 
management O 
; O 
metabolic O 
parameters O 
; O 
and O 
inflammatory O 
, O 
glycemic O 
and O 
oxidative O 
status O 
. O 
In O 
a O 
12-week O 
, O 
randomized O 
, O 
double O 
- O 
blind O 
, O 
placebo O 
- O 
controlled O 
trial O 
, O 
Sinetrol-XPur O 
was O 
given O 
to O 
overweight O 
subjects O 
twice O 
daily O 
with O 
meals O 
in O 
the O 
tested O 
group O 
( O 
N O 
= O 
47 O 
) O 
versus O 
a O 
placebo O 
group O 
( O 
N O 
= O 
48 O 
) O 
. O 
Waist O 
and O 
hip O 
circumference O 
and O 
abdominal O 
fat O 
were O 
decreased O 
in O 
the O 
Sinetrol-XPur O 
group O 
as O 
compared O 
with O 
the O 
placebo O 
group O 
( O 
p O 
< O 
0.0001 O 
) O 
( O 
-5.71% O 
vs O 
-1.56% O 
for O 
waist O 
, O 
-4.71% O 
vs O 
-1.35% O 
for O 
hip O 
and O 
-9.73% O 
vs O 
-3.18% O 
for O 
fat O 
) O 
. O 
Inflammatory O 
markers O 
were O 
reduced O 
( O 
C-reactive O 
protein O 
: O 
-22.87% O 
vs O 
+ O 
61% O 
; O 
fibrinogen O 
: O 
-19.93% O 
vs O 
-1.61% O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
Oxidative O 
stress O 
was O 
lowered O 
as O 
seen O 
by O 
the O 
reduction O 
of O 
malondialdehyde B-TRIVIAL 
( O 
-14.03% O 
vs O 
2.76% O 
) O 
and O 
the O 
increase O 
in O 
superoxide B-TRIVIAL 
dismutase O 
and O 
glutathione B-TRIVIAL 
( O 
17.38% O 
vs O 
2.19% O 
and O 
4.63% O 
vs O 
-2.36% O 
, O 
respectively O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
No O 
adverse O 
effects O 
were O 
observed O 
. O 
Kidney O 
, O 
liver O 
, O 
and O 
lipid O 
panels O 
remained O 
unchanged O 
. O 
These O 
results O 
indicated O 
that O 
Sinetrol-XPur O 
supplementation O 
is O 
a O 
viable O 
option O 
for O 
reducing O 
abdominal O 
fat O 
, O 
waist O 
and O 
hip O 
circumference O 
, O 
and O 
body O 
weight O 
and O 
for O 
improving O 
inflammatory O 
, O 
glycemic O 
, O 
and O 
oxidative O 
status O 
in O 
healthy O 
overweight O 
individuals O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

electronic O 
origin O 
of O 
unusually O 
large O 
( O 
n O 
) O 
JFN O 
coupling O 
constants O 
in O 
some O 
fluoroximes B-FAMILY 
. O 

calculations O 
show O 
that O 
the O 
FC O 
term O 
is O 
the O 
most O 
important O 
contribution O 
to O 
the O 
through O 
- O 
space O 
transmission O 
of O 
JFN O 
coupling O 
constants O 
for O 
the O 
fluoroximes B-FAMILY 
studied O 
in O 
this O 
work O 
. O 
Because O 
of O 
the O 
well O 
- O 
known O 
behavior O 
of O 
FC O 
term O 
, O 
a O 
new O 
rationalization O 
for O 
the O 
experimental O 
( O 
TS O 
) O 
JFN O 
SSCC O 
is O 
presented O 
. O 
It O 
is O 
mainly O 
based O 
on O 
the O 
overlap O 
matrix O 
( O 
Sij O 
) O 
between O 
fluorine B-SYSTEMATIC 
and O 
nitrogen B-SYSTEMATIC 
lone O 
pairs O 
obtained O 
from O 
NBO O 
analyses O 
. O 
An O 
expression O 
is O 
proposed O 
to O 
take O 
into O 
account O 
the O 
influence O 
of O 
the O 
electronic O 
density O 
( O 
Dij O 
) O 
between O 
coupled O 
nuclei O 
as O 
well O 
as O 
the O 
s% O 
character O 
at O 
the O 
site O 
of O 
the O 
coupling O 
nuclei O 
of O 
bonds O 
and O 
non O 
- O 
bonding O 
electron O 
pairs O 
involved O 
in O 
Dij O 
. O 
In O 
using O 
this O 
approach O 
, O 
a O 
linear O 
correlation O 
between O 
( O 
TS O 
) O 
JFN O 
versus O 
Dij O 
is O 
obtained O 
. O 
The O 
most O 
important O 
aspect O 
of O 
this O 
rationalization O 
is O 
related O 
to O 
the O 
facility O 
for O 
understanding O 
the O 
behavior O 
of O 
some O 
unusual O 
experimental O 
coupling O 
constants O 
. O 
It O 
is O 
shown O 
that O 
, O 
at O 
least O 
in O 
this O 
case O 
, O 
the O 
electronic O 
origin O 
of O 
the O 
so O 
- O 
called O 
through O 
- O 
space O 
coupling O 
is O 
transmitted O 
through O 
to O 
the O 
overlap O 
of O 
orbitals O 
on O 
the O 
coupled O 
atoms O 
, O 
suggesting O 
that O 
, O 
at O 
least O 
for O 
these O 
compounds O 
, O 
instead O 
of O 
through O 
- O 
space O 
coupling O 
, O 
it O 
should O 
better O 
be O 
dubbed O 
as O 
' O 
through O 
overlapping O 
orbital O 
coupling O 
' O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

sum O 
- O 
frequency O 
generation O 
activity O 
of O 
a O 
2,4-dinitrophenyl B-SYSTEMATIC 
phospholipid O 
hybrid O 
bilayer O 
: O 
retrieving O 
orientational O 
parameters O 
from O 
a O 
DFT O 
analysis O 
of O 
experimental O 
data O 
. O 

vibrational O 
nonlinear O 
activity O 
of O 
films O 
of O 
2,4-dinitrophenyl B-SYSTEMATIC 
phospholipid O 
( O 
DNP O 
) O 
at O 
the O 
solid O 
interface O 
is O 
measured O 
by O 
sum O 
- O 
frequency O 
generation O 
spectroscopy O 
( O 
SFG O 
) O 
. O 
Hybrid O 
bilayers O 
are O 
formed O 
by O 
a O 
Langmuir-Schaefer O 
approach O 
in O 
which O 
the O 
lipid O 
layer O 
is O 
physisorbed O 
on O 
top O 
of O 
a O 
self O 
- O 
assembled O 
monolayer O 
of O 
dodecanethiol B-SYSTEMATIC 
on O 
Pt B-FORMULA 
with O 
the O 
polar O 
heads O 
pointing O 
out O 
from O 
the O 
surface O 
. O 
The O 
SFG O 
response O 
is O 
investigated O 
in O 
two O 
vibrational O 
frequency O 
domains O 
, O 
namely O 
, O 
3050-2750 O 
and O 
1375-1240 O 
cm(-1) O 
. O 
The O 
first O 
region O 
probes O 
the O 
CH B-FORMULA 
stretching O 
modes O 
of O 
DNP O 
films O 
, O 
and O 
the O 
latter O 
explores O 
the O 
vibrational O 
nonlinear O 
activity O 
of O 
the O 
2,4-dinitroaniline B-SYSTEMATIC 
moiety O 
of O 
the O 
polar O 
head O 
of O 
the O 
lipid O 
. O 
Analysis O 
of O 
the O 
CH B-FORMULA 
stretching O 
vibrations O 
suggests O 
substantial O 
conformational O 
order O 
of O 
the O 
aliphatic O 
chains O 
with O 
only O 
a O 
few O 
gauche O 
defects O 
. O 
To O 
reliably O 
assign O 
the O 
detected O 
SFG O 
signals O 
to O 
specific O 
molecular O 
vibrations O 
, O 
DFT O 
calculations O 
of O 
the O 
IR O 
and O 
Raman O 
activities O 
of O 
molecular O 
models O 
are O 
performed O 
and O 
compared O 
to O 
experimental O 
solid O 
- O 
state O 
spectra O 
. O 
This O 
allows O 
unambiguous O 
assignment O 
of O 
the O 
observed O 
SFG O 
vibrations O 
to O 
molecular O 
modes O 
localized O 
on O 
the O 
2,4-dinitroaniline B-SYSTEMATIC 
moiety O 
of O 
the O 
polar O 
head O 
of O 
DNP O 
. O 
Then O 
, O 
SFG O 
spectra O 
of O 
DNP O 
in O 
the O 
1375-1240 O 
cm(-1) O 
frequency O 
range O 
are O 
simulated O 
and O 
compared O 
with O 
experimental O 
ones O 
, O 
and O 
thus O 
the O 
1,4-axis O 
of O 
the O 
2,4-dinitrophenyl B-SYSTEMATIC 
head O 
is O 
estimated O 
to O 
have O 
tilt O 
and O 
rotation O 
angles O 
of O 
45±5° O 
and O 
0±30° O 
, O 
respectively O 
. O 

variation O 
in O 
the O 
MAP3K5 O 
gene O 
is O 
associated O 
with O 
β-thalassemia O 
disease O 
severity O 
and O 
hydroxyurea B-SYSTEMATIC 
treatment O 
efficacy O 
. O 

: O 
In O 
this O 
study O 
we O 
explored O 
the O 
association O 
between O 
genetic O 
variations O 
in O 
MAP3K5 O 
and O 
PDE7B O 
genes O 
, O 
residing O 
on O 
chromosome O 
6q23 O 
, O 
and O 
disease O 
severity O 
in O 
β-hemoglobinopathy O 
patients O 
, O 
as O 
well O 
as O 
the O 
association O 
between O 
these O 
variants O 
with O 
response O 
to O 
hydroxyurea B-SYSTEMATIC 
( O 
HU O 
) O 
treatment O 
. O 
Furthermore O 
, O 
we O 
examined O 
MAP3K5 O 
expression O 
in O 
the O 
context O 
of O 
high O 
fetal O 
hemoglobin O 
( O 
HbF O 
) O 
and O 
upon O 
HU O 
treatment O 
in O 
erythroid O 
progenitor O 
cells O 
from O 
healthy O 
and O 
KLF1 O 
haploinsufficient O 
individuals O 
. O 
Materials O 
& O 
methods O 
: O 
For O 
this O 
purpose O 
, O 
we O 
genotyped O 
β-thalassemia O 
intermedia O 
and O 
major O 
patients O 
and O 
healthy O 
controls O 
, O 
as O 
well O 
as O 
a O 
cohort O 
of O 
compound O 
heterozygous O 
sickle O 
cell O 
disease O 
/ O 
β-thalassemia O 
patients O 
receiving O 
HU O 
as O 
HbF O 
augmentation O 
treatment O 
. O 
Furthermore O 
, O 
we O 
examined O 
MAP3K5 O 
expression O 
in O 
the O 
context O 
of O 
high O 
HbF O 
and O 
upon O 
HU O 
treatment O 
in O 
erythroid O 
progenitor O 
cells O 
from O 
healthy O 
and O 
KLF1 O 
haploinsufficient O 
individuals O 
. O 
Results O 
: O 
A O 
short O 
tandem O 
repeat O 
in O 
the O 
MAP3K5 O 
promoter O 
and O 
two O 
intronic O 
MAP3K5 O 
gene O 
variants O 
, O 
as O 
well O 
as O 
a O 
PDE7B O 
variant O 
, O 
are O 
associated O 
with O 
low O 
HbF O 
levels O 
and O 
a O 
severe O 
disease O 
phenotype O 
. O 
Moreover O 
, O 
MAP3K5 O 
mRNA O 
expression O 
levels O 
are O 
altered O 
in O 
the O 
context O 
of O 
high O 
HbF O 
and O 
are O 
affected O 
by O 
the O 
presence O 
of O 
HU O 
. O 
Lastly O 
, O 
the O 
abovementioned O 
MAP3K5 O 
variants O 
are O 
associated O 
with O 
HU O 
treatment O 
efficacy O 
. O 
Conclusion O 
: O 
Our O 
data O 
suggest O 
that O 
these O 
MAP3K5 O 
variants O 
are O 
indicative O 
of O 
β-thalassemia O 
disease O 
severity O 
and O 
response O 
to O 
HU O 
treatment O 
. O 
Original O 
submitted O 
24 O 
September O 
2012 O 
; O 
Revision O 
submitted O 
4 O 
February O 
2013 O 
. O 

of O 
ATP B-ABBREVIATION 
-binding O 
cassette O 
transporter O 
variants O 
with O 
the O 
risk O 
of O 
Alzheimer's O 
disease O 
. O 

of O 
a O 
functional O 
FAAH O 
polymorphism O 
with O 
methamphetamine B-TRIVIAL 
-induced O 
symptoms O 
and O 
dependence O 
in O 
a O 
Malaysian O 
population O 
. O 

: O 
FAAH O 
is O 
a O 
membrane O 
enzyme O 
that O 
terminates O 
the O 
activity O 
of O 
a O 
large O 
class O 
of O 
endogenous O 
signaling O 
lipids O 
. O 
Recent O 
studies O 
suggest O 
that O 
the O 
FAAH O 
Pro129Thr O 
polymorphism O 
is O 
a O 
common O 
mutation O 
in O 
the O 
FAAH O 
gene O 
that O 
is O 
significantly O 
associated O 
with O 
drug O 
- O 
addictive O 
traits O 
. O 
This O 
study O 
investigated O 
the O 
association O 
of O 
the O 
Pro129Thr O 
polymorphism O 
of O 
the O 
FAAH O 
gene O 
with O 
methamphetamine B-TRIVIAL 
dependence O 
, O 
methamphetamine B-TRIVIAL 
-induced O 
psychosis O 
, O 
manic O 
episodes O 
and O 
panic O 
disorder O 
in O 
a O 
Malaysian O 
population O 
. O 
Materials O 
& O 
methods O 
: O 
This O 
polymorphism O 
was O 
genotyped O 
in O 
232 O 
male O 
methamphetamine B-TRIVIAL 
-dependent O 
subjects O 
and O 
in O 
241 O 
male O 
controls O 
of O 
four O 
different O 
ethnicities O 
: O 
Malay O 
, O 
Chinese O 
, O 
Kadazan-Dusun O 
and O 
Bajau O 
. O 
Intergroup O 
statistical O 
analyses O 
were O 
performed O 
by O 
using O 
the O 
χ(2)-square O 
test O 
and O 
Fisher's O 
exact O 
test O 
, O 
where O 
necessary O 
. O 
In O 
cases O 
of O 
multiple O 
comparisons O 
, O 
the O 
Bonferroni O 
correction O 
was O 
performed O 
. O 
Results O 
: O 
Our O 
results O 
indicated O 
that O 
the O 
FAAH O 
Pro129Thr O 
polymorphism O 
showed O 
a O 
significant O 
association O 
with O 
risk O 
of O 
methamphetamine B-TRIVIAL 
dependence O 
in O 
the O 
pooled O 
subjects O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
: O 
2.017 O 
; O 
p O 
< O 
0.001 O 
) O 
and O 
in O 
the O 
Malay O 
( O 
OR O 
: O 
2.829 O 
; O 
p O 
< O 
0.001 O 
) O 
and O 
Chinese O 
( O 
OR O 
: O 
3.685 O 
; O 
p O 
< O 
0.001 O 
) O 
groups O 
. O 
We O 
also O 
found O 
an O 
association O 
of O 
this O 
polymorphism O 
with O 
episodes O 
of O 
methamphetamine B-TRIVIAL 
-induced O 
mania O 
in O 
the O 
Malay O 
group O 
( O 
OR O 
: O 
2.836 O 
; O 
p O 
= O 
0.035 O 
) O 
. O 
However O 
, O 
there O 
was O 
no O 
association O 
between O 
this O 
polymorphism O 
and O 
age O 
of O 
onset O 
of O 
drug O 
use O 
or O 
the O 
occurrence O 
of O 
methamphetamine B-TRIVIAL 
-induced O 
psychosis O 
or O 
of O 
panic O 
disorder O 
. O 
Conclusion O 
: O 
Our O 
findings O 
suggest O 
that O 
the O 
FAAH O 
Pro129Thr O 
polymorphism O 
may O 
contribute O 
to O 
methamphetamine B-TRIVIAL 
dependence O 
in O 
the O 
Malay O 
and O 
Chinese O 
ethnic O 
groups O 
. O 
Original O 
submitted O 
4 O 
October O 
2012 O 
; O 
Revision O 
submitted O 
1 O 
February O 
2013 O 
. O 

Analysis O 
of O 
the O 
ν3 O 
and O 
ν4 O 
Bands O 
of O 
HNO3 B-FORMULA 
in O 
the O 
7.6 O 
μm O 
Region O 
. O 

new O 
line O 
position O 
analysis O 
of O 
the O 
nu3 O 
and O 
nu4 O 
bands O 
of O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HNO3 B-FORMULA 
) O 
at O 
1326.186 O 
and O 
1303.072 O 
cm-1 O 
together O 
with O 
its O 
associated O 
interacting O 
bands O 
is O 
presented O 
. O 
The O 
3^1 O 
and O 
4^1 O 
energy O 
levels O 
were O 
obtained O 
from O 
an O 
extended O 
analysis O 
of O 
high O 
resolution O 
Fourier O 
transform O 
spectra O 
recorded O 
at O 
Giessen O 
in O 
the O 
7.6 O 
µm O 
region O 
. O 
The O 
energy O 
levels O 
of O 
3^1 O 
and O 
4^1 O 
upper O 
states O 
of O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
are O 
strongly O 
interacting O 
with O 
those O 
of O 
the O 
9^3 O 
, O 
6^2 O 
, O 
5^19^1 O 
and O 
7^18^1 O 
dark O 
states O 
centered O 
at O 
1288.899 O 
, O 
1289.46 O 
, O 
1341.05 O 
and O 
1343.78 O 
cm-1 O 
, O 
respectively O 
. O 
Informations O 
on O 
these O 
perturbing O 
dark O 
states O 
were O 
achieved O 
through O 
previous O 
partial O 
investigations O 
of O 
hot O 
bands O 
in O 
high O 
resolution O 
Fourier O 
transform O 
spectra O 
recorded O 
at O 
22 O 
µm O 
in O 
Giessen O 
( O 
for O 
3nu9-2nu9 O 
and O 
3nu9-nu5 O 
) O 
, O 
at O 
12 O 
µm O 
in O 
Denver O 
( O 
for O 
3nu9-nu9 O 
) O 
, O 
and O 
at O 
11 O 
µm O 
in O 
Orsay O 
( O 
for O 
nu5 O 
+ O 
nu9-nu9 O 
) O 
. O 
The O 
energy O 
levels O 
calculation O 
accounts O 
for O 
the O 
various O 
Fermi O 
, O 
anharmonic O 
, O 
A O 
- O 
type O 
, O 
B O 
- O 
type O 
and O 
C- O 
type O 
Coriolis O 
resonances O 
which O 
couple O 
together O 
the O 
{ O 
6^2,9^3,4^1,3^1,5^19^1,7^18^1 O 
} O 
interacting O 
energy O 
levels O 
. O 
For O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
the O 
nu9 O 
mode O 
( O 
OH B-FORMULA 
torsion O 
relative O 
to O 
the O 
- O 
NO2 B-FORMULA 
moiety O 
) O 
is O 
a O 
large O 
amplitude O 
motion O 
. O 
The O 
theoretical O 
model O 
used O 
in O 
this O 
work O 
accounts O 
also O 
for O 
large O 
amplitude O 
effects O 
in O 
the O 
93 O 
dark O 
state O 
which O 
lead O 
to O 
a O 
splitting O 
of O 
the O 
93 O 
energy O 
levels O 
of O 
about O 
0.06 O 
cm-1 O 
. O 
In O 
this O 
way O 
the O 
existence O 
of O 
" O 
torsional O 
" O 
splittings O 
for O 
several O 
nu4 O 
perturbed O 
lines O 
was O 
explained O 
by O 
the O 
occurrence O 
of O 
local O 
A O 
- O 
type O 
and O 
B O 
- O 
type O 
Coriolis O 
resonances O 
coupling O 
the O 
4^1 O 
energy O 
levels O 
with O 
those O 
of O 
93 O 
. O 
Because O 
four O 
dark O 
bands O 
had O 
to O 
be O 
accounted O 
for O 
in O 
the O 
model O 
, O 
the O 
results O 
of O 
the O 
energy O 
levels O 
calculations O 
are O 
reasonable O 
, O 
although O 
not O 
perfect O 
. O 
However O 
a O 
very O 
significant O 
improvement O 
was O 
achieved O 
in O 
term O 
of O 
understanding O 
the O 
7.6 O 
µm O 
absorbing O 
bands O 
of O 
nitric B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
compared O 
to O 
the O 
analysis O 
of O 
the O 
nu3 O 
and O 
nu4 O 
bands O 
performed O 
several O 
years O 
ago O 
[ O 
Perrin O 
, O 
A O 
. O 
; O 
Lado-Bordowski O 
, O 
O O 
. O 
; O 
Valentin O 
, O 
A O 
. O 
Mol O 
. O 
Phys O 
. O 
1989 O 
, O 
67 O 
, O 
249-267 O 
] O 
. O 
Finally O 
the O 
present O 
analysis O 
also O 
features O 
, O 
for O 
the O 
first O 
time O 
, O 
the O 
nu3 O 
+ O 
nu9-nu9 O 
hot O 
band O 
located O 
at O 
1331.09 O 
cm-1 O 
. O 

of O 
longitudinal O 
exposure O 
to O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
on O 
acute O 
rejection O 
in O 
renal O 
- O 
transplant O 
recipients O 
using O 
a O 
joint O 
modeling O 
approach O 
. O 

study O 
aimed O 
to O 
investigate O 
the O 
association O 
between O 
longitudinal O 
exposure O 
to O 
mycophenolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
MPA B-ABBREVIATION 
) O 
and O 
acute O 
rejection O 
( O 
AR O 
) O 
risk O 
in O 
the O 
first O 
year O 
after O 
renal O 
transplantation O 
, O 
and O 
to O 
propose O 
MPA B-ABBREVIATION 
exposure O 
targets O 
conditionally O 
to O 
this O 
association O 
. O 
A O 
joint O 
model O 
, O 
adjusted O 
for O 
monitoring O 
strategy O 
( O 
fixed O 
- O 
dose O 
versus O 
concentration O 
- O 
controlled O 
) O 
and O 
recipient O 
age O 
, O 
was O 
developed O 
; O 
it O 
combined O 
a O 
mixed O 
- O 
effects O 
model O 
to O 
describe O 
the O 
whole O 
pattern O 
of O 
MPA B-ABBREVIATION 
exposure O 
( O 
i.e O 
. O 
area O 
under O 
the O 
concentration O 
- O 
time O 
curve O 
( O 
AUC O 
) O 
) O 
and O 
a O 
survival O 
model O 
. O 
MPA B-ABBREVIATION 
AUC O 
thresholds O 
were O 
determined O 
using O 
time O 
- O 
dependent O 
receiver O 
- O 
operating O 
characteristics O 
( O 
ROC O 
) O 
curves O 
. O 
Data O 
from O 
490 O 
adult O 
renal O 
- O 
transplant O 
recipients O 
, O 
representative O 
of O 
the O 
general O 
population O 
of O 
adult O 
renal O 
- O 
transplant O 
patients O 
( O 
i.e O 
. O 
including O 
patients O 
considered O 
at O 
low O 
immunological O 
risk O 
- O 
enrolled O 
in O 
the O 
OPERA O 
trial O 
as O 
well O 
as O 
second O 
renal O 
transplant O 
and O 
patients O 
co O 
- O 
treated O 
by O 
either O 
cyclosporine B-TRIVIAL 
or O 
tacrolimus B-TRIVIAL 
) O 
, O 
were O 
analyzed O 
. O 
A O 
significant O 
association O 
was O 
found O 
between O 
the O 
longitudinal O 
exposure O 
to O 
MPA B-ABBREVIATION 
( O 
MPA B-ABBREVIATION 
AUCs=f(t) O 
) O 
and O 
AR O 
( O 
p=0.0081 O 
) O 
, O 
and O 
validated O 
by O 
bootstrapping O 
. O 
A O 
significant O 
positive O 
correlation O 
was O 
observed O 
between O 
time O 
post O 
- O 
transplantation O 
and O 
ROC O 
thresholds O 
which O 
increased O 
in O 
average O 
from O 
35mgh O 
/ O 
L O 
in O 
the O 
first O 
days O 
to O 
41mgh O 
/ O 
L O 
beyond O 
six O 
months O 
post O 
- O 
transplantation O 
( O 
p O 
< O 
0.001 O 
) O 
. O 
Using O 
a O 
new O 
modeling O 
approach O 
which O 
recognizes O 
the O 
repeated O 
measures O 
in O 
a O 
same O 
patient O 
, O 
this O 
study O 
supports O 
the O 
association O 
between O 
MPA B-ABBREVIATION 
exposure O 
and O 
AR O 
. O 

- O 
year O 
supplementation O 
with O 
a O 
grape O 
extract O 
containing O 
resveratrol B-TRIVIAL 
modulates O 
inflammatory O 
- O 
related O 
microRNAs O 
and O 
cytokines O 
expression O 
in O 
peripheral O 
blood O 
mononuclear O 
cells O 
of O 
type O 
2 O 
diabetes O 
and O 
hypertensive O 
patients O 
with O 
coronary O 
artery O 
disease O 
. O 

studies O 
have O 
shown O 
that O 
resveratrol B-TRIVIAL 
( O 
RES B-ABBREVIATION 
) O 
exerts O 
anti-inflammatory O 
effects O 
but O 
human O 
trials O 
evidencing O 
these O 
effects O 
in O 
vivo O 
are O 
limited O 
. O 
Furthermore O 
, O 
the O 
molecular O 
mechanisms O 
triggered O 
in O 
humans O 
following O 
the O 
oral O 
intake O 
of O 
RES B-ABBREVIATION 
are O 
not O 
yet O 
understood O 
. O 
Therefore O 
, O 
the O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
molecular O 
changes O 
in O 
peripheral O 
blood O 
mononuclear O 
cells O 
( O 
PBMCs O 
) O 
associated O 
to O 
the O 
one O 
- O 
year O 
daily O 
intake O 
of O 
a O 
RES B-ABBREVIATION 
enriched O 
( O 
8mg O 
) O 
grape O 
extract O 
( O 
GE- O 
RES B-ABBREVIATION 
) O 
in O 
hypertensive O 
male O 
patients O 
with O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
. O 
We O 
used O 
microarrays O 
and O 
RT-PCR O 
to O 
analyze O 
expression O 
changes O 
in O 
genes O 
and O 
microRNAs O 
( O 
miRs O 
) O 
involved O 
in O 
the O 
inflammatory O 
response O 
modulated O 
by O 
the O 
consumption O 
of O 
GE- O 
RES B-ABBREVIATION 
in O 
comparison O 
to O 
a O 
placebo O 
and O 
GE O 
lacking O 
RES B-ABBREVIATION 
. O 
We O 
also O 
examined O 
the O 
changes O 
in O 
several O 
serobiochemical O 
variables O 
, O 
inflammatory O 
and O 
fibrinolytic O 
markers O 
. O 
Our O 
results O 
showed O 
that O 
supplementation O 
with O 
GE O 
or O 
GE- O 
RES B-ABBREVIATION 
did O 
not O 
affect O 
body O 
weight O 
, O 
blood O 
pressure O 
, O 
glucose B-TRIVIAL 
, O 
HbA1c O 
or O 
lipids O 
, O 
beyond O 
the O 
values O 
regulated O 
by O 
gold O 
standard O 
medication O 
in O 
these O 
patients O 
. O 
We O 
did O 
not O 
find O 
either O 
any O 
significant O 
change O 
on O 
serum O 
inflammatory O 
markers O 
except O 
for O 
a O 
significant O 
reduction O 
of O 
ALP O 
and O 
IL-6 O 
levels O 
. O 
The O 
expression O 
of O 
the O 
pro O 
- O 
inflammatory O 
cytokines O 
CCL3 O 
, O 
IL-1β O 
and O 
TNF-α O 
was O 
significantly O 
reduced O 
and O 
that O 
of O 
the O 
transcriptional O 
repressor O 
LRRFIP-1 O 
increased O 
in O 
PBMCs O 
from O 
patients O 
taking O 
the O 
GE- O 
RES B-ABBREVIATION 
extract O 
. O 
Also O 
, O 
a O 
group O 
of O 
miRs O 
involved O 
in O 
the O 
regulation O 
of O 
the O 
inflammatory O 
response O 
: O 
miR-21 O 
, O 
miR-181b O 
, O 
miR-663 O 
, O 
miR-30c2 O 
, O 
miR-155 O 
and O 
miR-34a O 
were O 
found O 
to O 
be O 
highly O 
correlated O 
and O 
altered O 
in O 
the O 
group O 
consuming O 
the O 
GE- O 
RES B-ABBREVIATION 
for O 
12 O 
months O 
. O 
Our O 
results O 
provide O 
preliminary O 
evidence O 
that O 
long O 
- O 
term O 
supplementation O 
with O 
a O 
grape O 
extract O 
containing O 
RES B-ABBREVIATION 
downregulates O 
the O 
expression O 
of O 
key O 
pro O 
- O 
inflammatory O 
cytokines O 
with O 
the O 
involvement O 
of O 
inflammation O 
- O 
related O 
miRs O 
in O 
circulating O 
immune O 
cells O 
of O 
T2DM O 
hypertensive O 
medicated O 
patients O 
and O 
support O 
a O 
beneficial O 
immunomodulatory O 
effect O 
in O 
these O 
patients O 
. O 

analysis O 
of O 
genetic O 
variation O 
in O 
MPTP B-ABBREVIATION 
neurotoxicity O 
in O 
mice O 
. O 

analyzed O 
genetic O 
variation O 
in O 
severity O 
of O 
neuronal O 
damage O 
using O 
the O 
known O 
dopaminergic O 
neurotoxicant O 
, O 
MPTP B-ABBREVIATION 
, O 
as O 
a O 
prototypical O 
chemical O 
denervation O 
agent O 
. O 
Male O 
mice O 
from O 
ten O 
members O 
of O 
the O 
BXD O 
family O 
of O 
recombinant O 
inbred O 
strains O 
received O 
12.5mg O 
/ O 
kg O 
MPTP B-ABBREVIATION 
s.c O 
. O 
( O 
vs O 
. O 
saline O 
) O 
and O 
48h O 
later O 
brains O 
were O 
taken O 
for O 
multiple O 
related O 
biochemical O 
analyses O 
. O 
Striatal O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
and O 
its O 
metabolites O 
, O 
DOPAC B-ABBREVIATION 
and O 
HVA B-ABBREVIATION 
, O 
and O 
serotonin B-TRIVIAL 
and O 
its O 
metabolite O 
, O 
5-HIAAA B-ABBREVIATION 
, O 
were O 
analyzed O 
by O 
HPLC O 
. O 
DA O 
turnover O 
was O 
assessed O 
using O 
DOPAC B-ABBREVIATION 
/ O 
DA O 
and O 
HVA B-ABBREVIATION 
/ O 
DA O 
ratios O 
. O 
Striatal O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
, O 
glial O 
fibrilary O 
acidic O 
protein O 
( O 
GFAP O 
) O 
, O 
and O 
iron B-SYSTEMATIC 
content O 
in O 
ventral O 
midbrain O 
were O 
quantified O 
. O 
All O 
dopamine B-TRIVIAL 
measures O 
, O 
as O 
well O 
as O 
TH O 
and O 
GFAP O 
, O 
demonstrated O 
wide O 
, O 
genotype O 
- O 
dependent O 
differences O 
in O 
response O 
to O 
MPTP B-ABBREVIATION 
. O 
Serotonin B-TRIVIAL 
was O 
largely O 
unaffected O 
. O 
Principal O 
components O 
analysis O 
( O 
PC O 
) O 
on O 
difference O 
values O 
, O 
saline O 
minus O 
MPTP B-ABBREVIATION 
, O 
for O 
DA O 
, O 
DOPAC B-ABBREVIATION 
, O 
HVA B-ABBREVIATION 
, O 
and O 
TH O 
, O 
yielded O 
a O 
dominant O 
principal O 
component O 
. O 
The O 
PC O 
trait O 
residuals O 
for O 
each O 
genotype O 
were O 
compared O 
against O 
complementary O 
expression O 
data O 
for O 
striatum O 
of O 
the O 
same O 
strains O 
. O 
Three O 
transcripts O 
representing O 
Mtap2 O 
, O 
Lancl O 
1 O 
, O 
and O 
Kansl1l O 
were O 
highly O 
correlated O 
with O 
the O 
PC O 
, O 
as O 
was O 
the O 
difference O 
score O 
, O 
MPTP B-ABBREVIATION 
minus O 
saline O 
for O 
GFAP O 
. O 
This O 
systems O 
approach O 
to O 
the O 
study O 
of O 
environmental O 
neurotoxicants O 
holds O 
promise O 
to O 
define O 
individual O 
genetic O 
differences O 
that O 
contribute O 
to O 
variability O 
in O 
susceptibility O 
to O 
risk O 
factors O 
for O 
diseases O 
such O 
as O 
Parkinson's O 
disease O 
. O 

, O 
synthesis O 
and O 
cytotoxicity O 
of O 
cell O 
death O 
mechanism O 
of O 
rotundic B-TRIVIAL 
acid I-TRIVIAL 
derivatives O 
. O 

the O 
present O 
investigation O 
, O 
16 O 
new O 
rotundic B-TRIVIAL 
acid I-TRIVIAL 
( O 
RA O 
) O 
derivatives O 
modified O 
at O 
the O 
C-3 O 
, O 
C-23 O 
and O 
C-28 O 
positions O 
were O 
synthesized O 
. O 
The O 
cytotoxicities O 
of O 
the O 
derivatives O 
were O 
evaluated O 
against O 
HeLa O 
, O 
A375 O 
, O 
HepG2 O 
, O 
SPC-A1 O 
and O 
NCI-H446 O 
human O 
tumor O 
cell O 
lines O 
by O 
MTT B-ABBREVIATION 
assay O 
. O 
Among O 
these O 
derivatives O 
, O 
compounds O 
4-7 O 
exhibited O 
stronger O 
cell O 
growth O 
inhibitory O 
than O 
RA O 
and O 
compound O 
4 O 
was O 
found O 
to O 
be O 
the O 
best O 
inhibition O 
activity O 
on O 
five O 
human O 
tumor O 
cell O 
lines O 
with O 
IC50 O 
< O 
10μM O 
. O 
The O 
apoptosis O 
mechanism O 
of O 
compound O 
4 O 
in O 
HeLa O 
cells O 
was O 
investigated O 
by O 
western O 
blot O 
analysis O 
. O 
The O 
results O 
indicated O 
that O 
compound O 
4 O 
could O 
induce O 
apoptosis O 
through O 
increasing O 
protein O 
expression O 
of O 
cleaved O 
caspase-3 O 
and O 
Bax O 
, O 
and O 
decreasing O 
protein O 
expression O 
of O 
Bcl-2 O 
. O 
In O 
summary O 
, O 
the O 
present O 
work O 
suggests O 
that O 
compound O 
4 O 
might O 
serve O 
as O 
an O 
effective O 
chemotherapeutic O 
candidate O 
. O 

- O 
derived O 
growth O 
factor O 
receptor O 
alpha O 
( O 
PDGFRα O 
) O 
is O 
a O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
that O 
promotes O 
cell O 
survival O 
and O 
is O 
expressed O 
in O 
both O 
the O 
tumor O 
and O 
the O 
stromal O 
components O 
of O 
human O 
cancers O 
. O 
We O 
have O 
developed O 
a O 
fully O 
human O 
monoclonal O 
antibody O 
, O 
MEDI-575 O 
, O 
that O 
selectively O 
binds O 
to O 
human O 
PDGFRα O 
with O 
high O 
affinity O 
, O 
with O 
no O 
observable O 
affinity O 
for O 
murine O 
PDGFRα O 
. O 
To O 
more O 
fully O 
characterize O 
the O 
role O 
of O 
PDGFRα O 
in O 
the O 
regulation O 
of O 
tumor O 
stroma O 
, O 
we O 
evaluated O 
the O 
in O 
vivo O 
antitumor O 
effects O 
of O 
MEDI-575 O 
in O 
tumor O 
- O 
bearing O 
SCID O 
mice O 
and O 
in O 
genetically O 
altered O 
SCID O 
mice O 
expressing O 
human O 
PDGFRα O 
in O 
place O 
of O 
murine O 
PDGFRα O 
. O 
We O 
utilized O 
the O 
Calu-6 O 
non-small O 
cell O 
lung O 
cancer O 
model O 
, O 
because O 
it O 
lacks O 
an O 
in O 
vitro O 
proliferative O 
response O 
to O 
PDGFRα O 
activation O 
. O 
Antitumor O 
activity O 
was O 
observed O 
when O 
the O 
study O 
was O 
performed O 
in O 
mice O 
expressing O 
the O 
human O 
receptor O 
, O 
but O 
no O 
activity O 
was O 
observed O 
in O 
the O 
mice O 
expressing O 
the O 
murine O 
receptor O 
. O 
Immunohistological O 
analysis O 
of O 
tumors O 
from O 
mice O 
expressing O 
human O 
PDGFRα O 
showed O 
a O 
highly O 
significant O 
reduction O 
in O 
stromal O 
fibroblast O 
content O 
and O 
only O 
minor O 
changes O 
in O 
tumor O 
proliferative O 
index O 
in O 
tumors O 
exposed O 
to O 
MEDI-575 O 
compared O 
to O 
the O 
results O 
seen O 
in O 
vehicle O 
- O 
treated O 
tumors O 
or O 
tumors O 
from O 
mice O 
expressing O 
murine O 
PDGFRα O 
. O 
Additional O 
in O 
vitro O 
studies O 
indicated O 
that O 
exposure O 
of O 
primary O 
cancer O 
- O 
associated O 
fibroblasts O 
to O 
MEDI-575 O 
can O 
directly O 
affect O 
proliferation O 
and O 
key O 
signaling O 
pathways O 
in O 
these O 
cells O 
. O 
These O 
results O 
highlight O 
the O 
potential O 
for O 
observing O 
antitumor O 
activity O 
with O 
MEDI-575 O 
through O 
modulation O 
of O 
the O 
stromal O 
component O 
of O 
tumors O 
and O 
confirm O 
that O 
the O 
PDGFRα O 
pathway O 
can O 
play O 
a O 
role O 
in O 
maintaining O 
a O 
tumor O 
microenvironment O 
conducive O 
to O 
tumor O 
growth O 
. O 

H B-FORMULA 
-bonded O 
porous O 
networks O 
at O 
surfaces O 
: O 
exploiting O 
primary O 
and O 
secondary O 
interactions O 
in O 
a O 
bi O 
- O 
component O 
melamine B-TRIVIAL 
- O 
xanthine B-TRIVIAL 
system O 
. O 

control O 
over O 
the O 
formation O 
of O 
a O 
bi O 
- O 
component O 
porous O 
network O 
was O 
attained O 
by O 
the O 
self O 
- O 
assembly O 
at O 
a O 
solid O 
- O 
liquid O 
interface O 
by O 
exploiting O 
both O 
primary O 
and O 
secondary O 
non-covalent O 
interactions O 
between O 
melamine B-TRIVIAL 
and O 
N(3)-alkylated B-FAMILY 
xanthine I-FAMILY 
modules O 
. O 

gingivalis O 
virulence O 
factor O 
gingipain O 
RgpB O 
shows O 
a O 
unique O 
zymogenic O 
mechanism O 
for O 
cysteine B-TRIVIAL 
peptidases O 
. O 

is O 
a O 
regulatory O 
mechanism O 
which O 
prevents O 
inadequate O 
catalytic O 
activity O 
in O 
the O 
wrong O 
context O 
. O 
It O 
plays O 
a O 
central O 
role O 
in O 
maintaining O 
microbial O 
virulence O 
factors O 
in O 
an O 
inactive O 
form O 
inside O 
the O 
pathogen O 
until O 
secretion O 
. O 
Among O 
these O 
virulence O 
factors O 
is O 
the O 
cysteine B-TRIVIAL 
peptidase O 
gingipain O 
B O 
( O 
RgpB O 
) O 
, O 
which O 
is O 
the O 
major O 
virulence O 
factor O 
secreted O 
by O 
the O 
periodontopathogen O 
Porphyromonas O 
gingivalis O 
that O 
attacks O 
host O 
vasculature O 
and O 
defense O 
proteins O 
. O 
The O 
structure O 
of O 
the O 
complex O 
between O 
soluble O 
mature O 
RgpB O 
, O 
consisting O 
of O 
a O 
catalytic O 
domain O 
and O 
an O 
immunoglobulin O 
- O 
superfamily O 
domain O 
, O 
and O 
its O 
205-residue O 
N B-FORMULA 
-terminal O 
pro O 
- O 
domain O 
, O 
the O 
largest O 
structurally O 
characterized O 
to O 
date O 
for O 
a O 
cysteine B-TRIVIAL 
peptidase O 
, O 
reveals O 
a O 
novel O 
fold O 
for O 
the O 
pro O 
- O 
domain O 
that O 
is O 
distantly O 
related O 
to O 
sugar B-FAMILY 
-binding O 
lectins O 
. O 
It O 
attaches O 
laterally O 
to O 
the O 
catalytic O 
domain O 
through O 
a O 
large O 
concave O 
surface O 
. O 
The O 
main O 
determinant O 
for O 
latency O 
is O 
a O 
surface O 
inhibitory O 
loop O 
, O 
which O 
approaches O 
the O 
active O 
- O 
site O 
cleft O 
of O 
the O 
enzyme O 
on O 
its O 
non-primed O 
side O 
in O 
a O 
substrate O 
- O 
like O 
manner O 
. O 
It O 
inserts O 
an O 
arginine B-TRIVIAL 
( O 
R126 O 
) O 
into O 
the O 
S1 O 
pocket O 
, O 
thus O 
matching O 
the O 
substrate O 
specificity O 
of O 
the O 
enzyme O 
. O 
Downstream O 
of O 
R126 O 
, O 
the O 
polypeptide O 
leaves O 
the O 
cleft O 
, O 
thereby O 
preventing O 
cleavage O 
. O 
Moreover O 
, O 
the O 
carbonyl B-FAMILY 
group O 
of O 
R126 O 
establishes O 
a O 
very O 
strong O 
hydrogen B-SYSTEMATIC 
bond O 
with O 
the O 
co O 
- O 
catalytic O 
histidine B-TRIVIAL 
, O 
H440 O 
, O 
pulling O 
it O 
away O 
from O 
the O 
catalytic O 
cysteine B-TRIVIAL 
, O 
C473 O 
, O 
and O 
towards O 
E381 O 
, O 
which O 
probably O 
plays O 
a O 
role O 
orienting O 
the O 
side O 
chain O 
of O 
H440 O 
during O 
catalysis O 
. O 
The O 
present O 
results O 
provide O 
the O 
structural O 
determinants O 
of O 
zymogenic O 
inhibition O 
of O 
RgpB O 
by O 
way O 
of O 
a O 
novel O 
inhibitory O 
mechanism O 
for O 
peptidases O 
in O 
general O 
and O 
open O 
the O 
field O 
for O 
the O 
design O 
of O 
novel O 
inhibitory O 
strategies O 
in O 
the O 
treatment O 
of O 
human O 
periodontal O 
disease O 
. O 

tyrosine O 
ligase O 
- O 
like O 
family O 
member O 
5 O 
( O 
TTLL5 O 
/ O 
STAMP O 
) O 
has O 
multiple O 
activities O 
in O 
cells O 
. O 
TTLL5 O 
is O 
one O 
of O 
13 O 
TTLLs O 
, O 
has O 
polyglutamylation O 
activity O 
, O 
augments O 
the O 
activity O 
of O 
p160 O 
coactivators O 
( O 
SRC-1 O 
and O 
TIF2 O 
) O 
in O 
glucocorticoid O 
receptor O 
- O 
regulated O 
gene O 
induction O 
and O 
repression O 
, O 
and O 
displays O 
steroid O 
- O 
independent O 
growth O 
activity O 
with O 
several O 
cell O 
types O 
. O 
To O 
examine O 
TTLL5 O 
/ O 
STAMP O 
functions O 
in O 
whole O 
animals O 
, O 
mice O 
were O 
prepared O 
with O 
an O 
internal O 
deletion O 
that O 
eliminated O 
several O 
activities O 
of O 
the O 
Stamp O 
gene O 
. O 
This O 
mutation O 
causes O 
both O 
reduced O 
levels O 
of O 
STAMP O 
mRNA O 
and O 
C B-FORMULA 
-terminal O 
truncation O 
of O 
STAMP O 
protein O 
. O 
Homozygous O 
targeted O 
mutant O 
( O 
Stamptm O 
/ O 
tm O 
) O 
mice O 
appear O 
normal O 
except O 
for O 
marked O 
decreases O 
in O 
male O 
fertility O 
associated O 
with O 
defects O 
in O 
progressive O 
sperm O 
motility O 
. O 
Abnormal O 
axonemal O 
structures O 
with O 
loss O 
of O 
tubulin O 
doublets O 
occur O 
in O 
most O 
Stamptm O 
/ O 
tm O 
sperm O 
tails O 
in O 
conjunction O 
with O 
substantial O 
reduction O 
in O 
α-tubulin O 
polyglutamylation O 
, O 
which O 
closely O 
correlates O 
with O 
the O 
reduction O 
in O 
mutant O 
STAMP O 
mRNA O 
. O 
The O 
axonemes O 
in O 
other O 
structures O 
appear O 
unaffected O 
. O 
There O 
is O 
no O 
obvious O 
change O 
in O 
the O 
organs O 
for O 
sperm O 
development O 
of O 
wt O 
vs O 
. O 
Stamptm O 
/ O 
tm O 
males O 
despite O 
the O 
levels O 
of O 
wt O 
STAMP O 
mRNA O 
in O 
testes O 
being O 
20-fold O 
higher O 
than O 
in O 
any O 
other O 
organ O 
examined O 
. O 
This O 
defect O 
in O 
male O 
fertility O 
is O 
unrelated O 
to O 
other O 
Ttll O 
genes O 
or O 
24 O 
genes O 
previously O 
identified O 
as O 
important O 
for O 
sperm O 
function O 
. O 
Thus O 
, O 
STAMP O 
appears O 
to O 
participate O 
in O 
a O 
unique O 
, O 
tissue O 
- O 
selective O 
TTLL O 
- O 
mediated O 
pathway O 
for O 
α-tubulin O 
polyglutamylation O 
that O 
is O 
required O 
for O 
sperm O 
maturation O 
and O 
motility O 
and O 
may O 
be O 
relevant O 
for O 
male O 
fertility O 
. O 

in O 
vivo O 
binding O 
of O 
MeCP2 O 
to O 
chromatin O 
in O 
the O 
absence O 
of O 
its O 
DNA O 
methyl B-SYSTEMATIC 
-binding O 
domain O 
. O 

is O 
a O 
methyl B-SYSTEMATIC 
-CpG O 
- O 
binding O 
protein O 
that O 
is O 
a O 
main O 
component O 
of O 
brain O 
chromatin O 
in O 
vertebrates O 
. O 
In O 
vitro O 
studies O 
have O 
determined O 
that O 
in O 
addition O 
to O 
its O 
specific O 
methyl B-SYSTEMATIC 
-CpG O 
- O 
binding O 
domain O 
( O 
MBD O 
) O 
MeCP2 O 
also O 
has O 
several O 
chromatin O 
association O 
domains O 
. O 
However O 
, O 
the O 
specific O 
interactions O 
of O 
MeCP2 O 
with O 
methylated O 
or O 
non-methylated O 
chromatin O 
regions O 
and O 
the O 
structural O 
characteristics O 
of O 
the O 
resulting O 
DNA O 
associations O 
in O 
vivo O 
remain O 
poorly O 
understood O 
. O 
We O 
analysed O 
the O 
role O 
of O 
the O 
MBD O 
in O 
MeCP2-chromatin O 
associations O 
in O 
vivo O 
using O 
an O 
MeCP2 O 
mutant O 
Rett O 
syndrome O 
mouse O 
model O 
( O 
Mecp2(tm)(1)( O 
. O 
)(1)(Jae O 
) O 
) O 
in O 
which O 
exon O 
3 O 
deletion O 
results O 
in O 
an O 
N- O 
terminal O 
truncation O 
of O 
the O 
protein O 
, O 
including O 
most O 
of O 
the O 
MBD O 
. O 
Our O 
results O 
show O 
that O 
in O 
mutant O 
mice O 
, O 
the O 
truncated O 
form O 
of O 
MeCP2 O 
( O 
ΔMeCP2 O 
) O 
is O 
expressed O 
in O 
different O 
regions O 
of O 
the O 
brain O 
and O 
liver O 
, O 
albeit O 
at O 
50% O 
of O 
its O 
wild O 
- O 
type O 
( O 
wt O 
) O 
counterpart O 
. O 
In O 
contrast O 
to O 
the O 
punctate O 
nuclear O 
distribution O 
characteristic O 
of O 
wt O 
MeCP2 O 
, O 
ΔMeCP2 O 
exhibits O 
both O 
diffuse O 
nuclear O 
localization O 
and O 
a O 
substantial O 
retention O 
in O 
the O 
cytoplasm O 
, O 
suggesting O 
a O 
dysfunction O 
of O 
nuclear O 
transport O 
. O 
In O 
mutant O 
brain O 
tissue O 
, O 
neuronal O 
nuclei O 
are O 
smaller O 
, O 
and O 
ΔMeCP2 O 
chromatin O 
is O 
digested O 
faster O 
by O 
nucleases O 
, O 
producing O 
a O 
characteristic O 
nuclease O 
- O 
resistant O 
dinucleosome O 
. O 
Although O 
a O 
fraction O 
of O 
ΔMeCP2 O 
is O 
found O 
associated O 
with O 
nucleosomes O 
, O 
its O 
interaction O 
with O 
chromatin O 
is O 
transient O 
and O 
weak O 
. O 
Thus O 
, O 
our O 
results O 
unequivocally O 
demonstrate O 
that O 
in O 
vivo O 
the O 
MBD O 
of O 
MeCP2 O 
together O 
with O 
its O 
adjacent O 
region O 
in O 
the O 
N- O 
terminal O 
domain O 
are O 
critical O 
for O 
the O 
proper O 
interaction O 
of O 
the O 
protein O 
with O 
chromatin O 
, O 
which O 
cannot O 
be O 
replaced O 
by O 
any O 
other O 
of O 
its O 
protein O 
domains O 
. O 

and O 
memory O 
: O 
The O 
influence O 
of O 
drink O 
, O 
expectancy O 
, O 
and O 
beliefs O 
. O 

: O 
An O 
increasing O 
number O 
of O 
studies O 
suggest O 
that O 
glucose B-TRIVIAL 
can O 
enhance O 
aspects O 
of O 
memory O 
and O 
the O 
central O 
methodology O 
is O 
the O 
use O 
of O 
the O 
glucose B-TRIVIAL 
-placebo O 
design O 
. O 
One O 
critical O 
issue O 
therefore O 
is O 
separating O 
the O 
pharmacological O 
effects O 
of O 
glucose B-TRIVIAL 
from O 
the O 
expectancies O 
created O 
by O 
consuming O 
a O 
drink O 
that O 
might O 
contain O 
glucose O 
. O 
OBJECTIVE O 
: O 
A O 
modified O 
balanced O 
placebo O 
design O 
examined O 
the O 
role O 
that O 
expectancy O 
and O 
belief O 
about O 
the O 
drink O 
consumed O 
has O 
on O 
the O 
pharmacological O 
changes O 
observed O 
following O 
glucose B-TRIVIAL 
consumption O 
. O 
METHOD O 
: O 
Ninety O 
- O 
three O 
participants O 
, O 
allocated O 
according O 
to O 
a O 
drink O 
( O 
glucose B-TRIVIAL 
, O 
placebo O 
) O 
× O 
message O 
( O 
told O 
glucose B-TRIVIAL 
, O 
told O 
nothing O 
, O 
told O 
placebo O 
) O 
unrelated O 
design O 
, O 
were O 
administered O 
tasks O 
assessing O 
immediate O 
and O 
delayed O 
verbal O 
free O 
recall O 
, O 
spatial O 
recognition O 
and O 
semantic O 
verification O 
. O 
Each O 
task O 
has O 
some O 
evidence O 
for O 
hippocampus O 
involvement O 
, O 
and O 
variations O 
in O 
task O 
difficulty O 
were O 
used O 
to O 
assess O 
the O 
idea O 
that O 
glucose B-TRIVIAL 
effects O 
are O 
sensitive O 
to O 
task O 
difficulty O 
. O 
RESULTS O 
: O 
While O 
the O 
messages O 
biased O 
drink O 
judgements O 
in O 
the O 
expected O 
direction O 
, O 
judgements O 
of O 
drink O 
content O 
were O 
at O 
chance O 
and O 
glucose B-TRIVIAL 
only O 
enhanced O 
delayed O 
free O 
recall O 
. O 
The O 
subtle O 
effects O 
of O 
the O 
messages O 
did O 
not O 
modify O 
the O 
glucose B-TRIVIAL 
enhancement O 
. O 
However O 
, O 
believing O 
glucose B-TRIVIAL 
had O 
been O 
consumed O 
showed O 
an O 
independent O 
improvement O 
in O 
delayed O 
free O 
recall O 
. O 
There O 
was O 
no O 
evidence O 
that O 
task O 
complexity O 
enhanced O 
the O 
glucose B-TRIVIAL 
effect O 
. O 
CONCLUSIONS O 
: O 
The O 
findings O 
indicate O 
that O 
expectancy O 
effects O 
are O 
unlikely O 
to O 
be O 
confused O 
with O 
glucose B-TRIVIAL 
enhancements O 
, O 
but O 
beliefs O 
about O 
consuming O 
glucose B-TRIVIAL 
can O 
augment O 
performance O 
on O 
delayed O 
free O 
recall O 
. O 
The O 
discussion O 
considers O 
the O 
hippocampus O 
and O 
complexity O 
hypotheses O 
of O 
glucose B-TRIVIAL 
' O 
s O 
mode O 
of O 
action O 
and O 
proposes O 
the O 
routine O 
collection O 
of O 
drink O 
beliefs O 
in O 
future O 
studies O 
. O 

Peroxide B-SYSTEMATIC 
Homolysis O 
. O 

homolytic O 
cleavage O 
of O 
peroxide B-SYSTEMATIC 
bonds O 
, O 
leading O 
to O 
the O 
formation O 
of O 
free O 
radicals O 
, O 
plays O 
an O 
important O 
role O 
in O 
the O 
( O 
spontaneous O 
) O 
oxidation O 
of O 
a O 
wide O 
variety O 
of O 
hydrocarbons B-FAMILY 
in O 
the O 
presence O 
of O 
oxygen B-SYSTEMATIC 
. O 
Such O 
aerobic O 
oxidations O 
can O 
be O 
desired O 
( O 
e.g O 
. O 
for O 
industrially O 
applied O 
autoxidations O 
) O 
or O 
undesired O 
( O 
e.g O 
. O 
food O 
deterioration O 
) O 
. O 
In O 
this O 
contribution O 
we O 
provide O 
experimental O 
and O 
computational O 
evidence O 
for O 
a O 
molecule O 
- O 
induced O 
homolytic O 
dissociation O 
mechanism O 
between O 
alkyl B-FAMILY 
peroxide I-FAMILY 
and O 
compounds O 
featuring O 
weakly O 
bonded O 
H B-FORMULA 
atoms O 
such O 
as O 
(di)unsaturated B-FAMILY 
hydrocarbons I-FAMILY 
. O 

: O 
Takotsubo O 
or O 
stress O 
- O 
induced O 
cardiomyopathy O 
is O 
a O 
form O 
of O 
reversible O 
cardiomyopathy O 
, O 
commonly O 
associated O 
with O 
emotional O 
or O 
physical O 
stress O 
. O 
Thyrotoxicosis O 
has O 
been O 
identified O 
as O 
a O 
rare O 
cause O 
of O 
Takotsubo O 
cardiomyopathy O 
with O 
only O 
eleven O 
cases O 
reported O 
in O 
the O 
literature O 
. O 
Here O 
, O 
we O 
report O 
a O 
case O 
of O 
thyroid O 
storm O 
presenting O 
with O 
Takotsubo O 
cardiomyopathy O 
in O 
the O 
setting O 
of O 
Graves' O 
disease O 
. O 
Patient O 
Findings O 
: O 
A O 
71-year- O 
old O 
woman O 
presented O 
with O 
abdominal O 
pain O 
, O 
vomiting O 
, O 
confusion O 
and O 
history O 
of O 
weight O 
loss O 
. O 
She O 
was O 
initially O 
diagnosed O 
and O 
treated O 
for O 
diabetic O 
ketoacidosis O 
at O 
another O 
hospital O 
and O 
was O 
transferred O 
to O 
our O 
hospital O 
one O 
day O 
after O 
initial O 
presentation O 
due O 
to O 
concern O 
for O 
acute O 
coronary O 
syndrome O 
. O 
A O 
diagnosis O 
of O 
Takotsubo O 
cardiomyopathy O 
was O 
made O 
on O 
the O 
basis O 
of O 
cardiac O 
catheterization O 
. O 
At O 
that O 
time O 
, O 
she O 
was O 
diagnosed O 
and O 
treated O 
for O 
thyroid O 
storm O 
. O 
Follow O 
- O 
up O 
7-weeks O 
later O 
, O 
revealed O 
improvement O 
of O 
her O 
cardiac O 
function O 
and O 
near O 
- O 
normalization O 
of O 
thyroid O 
hormone O 
levels O 
. O 
Summary O 
: O 
In O 
this O 
patient O 
who O 
presented O 
with O 
symptoms O 
of O 
congestive O 
heart O 
failure O 
, O 
acute O 
coronary O 
syndrome O 
was O 
initially O 
considered O 
, O 
but O 
the O 
diagnosis O 
of O 
Takotsubo O 
cardiomyopathy O 
associated O 
with O 
thyroid O 
storm O 
was O 
ultimately O 
made O 
based O 
on O 
cardiac O 
catheterization O 
and O 
laboratory O 
investigation O 
. O 
Conclusions O 
: O 
Thyrotoxicosis O 
is O 
associated O 
with O 
adverse O 
disturbances O 
in O 
the O 
cardiovascular O 
system O 
. O 
Takotsubo O 
cardiomyopathy O 
could O 
be O 
a O 
presenting O 
manifestation O 
of O 
thyroid O 
storm O 
, O 
perhaps O 
related O 
to O 
excess O 
catecholamine B-TRIVIAL 
levels O 
or O 
sensitivity O 
. O 

phosphorylation O 
is O 
an O 
important O 
post O 
- O 
translational O 
modification O 
that O 
regulates O 
almost O 
every O 
aspect O 
of O 
signal O 
transduction O 
in O 
cells O 
. O 
Activation O 
of O 
the O 
mitogen O 
- O 
activated O 
protein O 
kinase O 
( O 
MAPK O 
) O 
family O 
kinase O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
( O 
ERK O 
) O 
is O 
a O 
point O 
of O 
convergence O 
for O 
many O 
cellular O 
activities O 
in O 
response O 
to O 
external O 
stimulation O 
. O 
With O 
stimuli O 
, O 
ERK O 
activity O 
is O 
significantly O 
increased O 
by O 
the O 
phosphorylation O 
of O 
Thr B-FORMULA 
202 O 
and O 
Tyr B-FORMULA 
204 O 
at O 
its O 
activation O 
loop O 
. O 
Downregulation O 
of O 
ERK O 
phosphorylation O 
at O 
these O 
two O 
sites O 
by O 
several O 
phosphatases O 
, O 
such O 
as O 
protein O 
phosphatase O 
2A O 
, O 
HePTP O 
and O 
MAPK O 
phosphatase O 
3 O 
, O 
is O 
essential O 
for O 
maintaining O 
appropriate O 
ERK O 
function O 
in O 
different O 
cellular O 
processes O 
. O 
However O 
, O 
it O 
is O 
unknown O 
whether O 
metal O 
- O 
dependent O 
protein O 
phosphatase O 
( O 
PPM O 
) O 
family O 
phosphatases O 
directly O 
dephosphorylate O 
ERK O 
. O 
In O 
this O 
study O 
, O 
we O 
found O 
that O 
PPM1A O 
negatively O 
regulated O 
ERK O 
by O 
directly O 
dephosphorylating O 
its O 
pThr202 O 
position O 
early O 
in O 
EGF O 
stimulation O 
. O 
Additional O 
kinetic O 
studies O 
revealed O 
that O 
key O 
residues O 
participated O 
in O 
phospho B-SYSTEMATIC 
-ERK O 
recognition O 
by O 
PPM1A O 
. O 
Importantly O 
, O 
PPM1A O 
preferred O 
the O 
phospho B-SYSTEMATIC 
-ERK O 
peptide O 
sequence O 
over O 
a O 
panel O 
of O 
other O 
phosphopeptides O 
through O 
the O 
interactions O 
of O 
basic O 
residues O 
in O 
the O 
active O 
site O 
of O 
PPM1A O 
with O 
the O 
pThr-Glu-pTyr B-FORMULA 
motif O 
of O 
ERK O 
. O 
Whereas O 
Lys B-FORMULA 
165 O 
and O 
Arg B-FORMULA 
33 O 
were O 
required O 
for O 
efficient O 
catalysis O 
or O 
phosphosubstrate O 
binding O 
of O 
PPM1A O 
, O 
Gln B-FORMULA 
185 O 
and O 
Arg B-FORMULA 
186 O 
were O 
determinants O 
of O 
PPM1A O 
substrate O 
specificity O 
. O 
The O 
interaction O 
between O 
Arg B-FORMULA 
186 O 
of O 
PPM1A O 
and O 
Glu B-FORMULA 
203 O 
and O 
pTyr204 O 
of O 
phospho B-SYSTEMATIC 
-ERK O 
was O 
identified O 
as O 
a O 
hot O 
- O 
spot O 
for O 
phospho B-SYSTEMATIC 
-ERK-PPM1A O 
interaction O 
. O 
STRUCTURED O 
DIGITAL O 
ABSTRACT O 
: O 
PPM1A O 
physically O 
interacts O 
with O 
ERK2 O 
by O 
pull O 
down O 
( O 
View O 
interaction O 
) O 
PPM1A O 
dephosphorylates O 
p38 O 
by O 
phosphatase O 
assay O 
( O 
View O 
Interaction O 
: O 
1 O 
, O 
2 O 
) O 
PPM1A O 
binds O 
to O 
ERK2 O 
by O 
pull O 
down O 
( O 
View O 
interaction O 
) O 
PPM1A O 
dephosphorylates O 
ERK2 O 
by O 
phosphatase O 
assay O 
( O 
View O 
Interaction O 
: O 
1 O 
, O 
2 O 
, O 
3 O 
, O 
4 O 
, O 
5 O 
, O 
6 O 
, O 
7 O 
, O 
8 O 
, O 
9 O 
, O 
10 O 
, O 
11 O 
, O 
12 O 
, O 
13 O 
, O 
14 O 
, O 
15 O 
, O 
16 O 
, O 
17 O 
, O 
18 O 
, O 
19 O 
, O 
20 O 
) O 
. O 

glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
- O 
based O 
star O 
polymers O 
with O 
a O 
cationic O 
core O 
were O 
prepared O 
by O 
atom O 
transfer O 
radical O 
polymerization O 
( O 
ATRP O 
) O 
for O 
in O 
vitro O 
nucleic O 
acid O 
( O 
nan O 
) O 
delivery O 
. O 
The O 
star O 
polymers O 
were O 
synthesized O 
by O 
ATRP O 
of O 
2-(dimethylamino)ethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
DMAEMA B-ABBREVIATION 
) O 
and O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
dimethacrylate I-SYSTEMATIC 
( O 
EGDMA B-ABBREVIATION 
) O 
. O 
Star O 
polymers O 
were O 
characterized O 
by O 
gel O 
permeation O 
chromatography O 
, O 
zeta O 
potential O 
, O 
and O 
dynamic O 
light O 
scattering O 
. O 
These O 
star O 
polymers O 
were O 
combined O 
with O 
either O 
plasmid O 
DNA O 
( O 
pDNA O 
) O 
or O 
short O 
interfering O 
RNA O 
( O 
siRNA O 
) O 
duplexes O 
to O 
form O 
polyplexes O 
for O 
intracellular O 
delivery O 
. O 
These O 
polyplexes O 
with O 
either O 
siRNA O 
or O 
pDNA O 
were O 
highly O 
effective O 
in O 
nan O 
delivery O 
, O 
particularly O 
at O 
relatively O 
low O 
star O 
polymer O 
weight O 
or O 
molar O 
ratios O 
, O 
highlighting O 
the O 
importance O 
of O 
nan O 
release O 
in O 
efficient O 
delivery O 
systems O 
. O 

this O 
study O 
, O 
the O 
anti-obesity O 
effect O 
of O 
1-deoxynojirimycin B-SYSTEMATIC 
( O 
DNJ B-ABBREVIATION 
) O 
was O 
examined O 
in O 
the O 
diet O 
- O 
induced O 
obese O 
mouse O 
model O 
. O 
Mulberry O 
DNJ B-ABBREVIATION 
was O 
administered O 
to O 
the O 
obese O 
mice O 
for O 
12weeks O 
. O 
As O 
a O 
result O 
, O 
DNJ B-ABBREVIATION 
decreased O 
both O 
the O 
visceral O 
fat O 
weight O 
and O 
adipocyte O 
size O 
. O 
To O 
determine O 
the O 
influence O 
of O 
DNJ B-ABBREVIATION 
on O 
lipid O 
metabolism O 
, O 
lipid O 
parameters O 
of O 
the O 
plasma O 
and O 
the O 
liver O 
and O 
the O 
activities O 
of O 
several O 
molecules O 
related O 
to O 
lipid O 
metabolism O 
in O 
the O 
liver O 
were O 
measured O 
. O 
DNJ B-ABBREVIATION 
activated O 
the O 
β-oxidation O 
system O 
, O 
suppressed O 
lipid O 
accumulation O 
in O 
the O 
liver O 
and O 
reduced O 
plasma O 
triacylglycerol B-FAMILY 
. O 
Since O 
it O 
was O 
thought O 
that O 
the O 
factor O 
activated O 
in O 
the O 
β-oxidation O 
system O 
was O 
adiponectin O 
, O 
plasma O 
adiponectin O 
levels O 
were O 
measured O 
and O 
it O 
was O 
shown O 
that O 
plasma O 
adiponectin O 
was O 
increased O 
with O 
DNJ B-ABBREVIATION 
. O 
Therefore O 
, O 
it O 
was O 
suggested O 
that O 
DNJ B-ABBREVIATION 
promoted O 
an O 
increase O 
in O 
plasma O 
adiponectin O 
and O 
activated O 
the O 
β-oxidation O 
system O 
. O 
Overall O 
, O 
it O 
was O 
shown O 
that O 
DNJ B-ABBREVIATION 
prevents O 
diet O 
- O 
induced O 
obesity O 
through O 
an O 
increase O 
in O 
adiponectin O 
. O 

profile O 
of O 
cowpea O 
( O 
Vigna O 
unguiculata O 
) O 
reveals O 
catechin-O-glucoside B-SYSTEMATIC 
as O 
the O 
dominant O 
compound O 
. O 

( O 
PA O 
) O 
profile O 
and O 
content O 
can O 
have O 
important O 
nutritional O 
and O 
health O 
implications O 
on O 
plant O 
foods O 
. O 
Six O 
diverse O 
cowpea O 
phenotypes O 
( O 
black O 
, O 
red O 
, O 
green O 
, O 
white O 
, O 
light O 
- O 
brown O 
and O 
golden O 
- O 
brown O 
) O 
were O 
investigated O 
for O 
PA O 
composition O 
using O 
normal O 
- O 
phase O 
HPLC O 
and O 
reversed O 
- O 
phase O 
UPLC-TQD-MS O 
. O 
Catechin B-TRIVIAL 
and O 
(epi)afzelechin B-TRIVIAL 
were O 
the O 
major O 
flavan-3-ol B-FAMILY 
units O 
. O 
Unusual O 
composition O 
was O 
observed O 
in O 
all O 
cowpea O 
phenotypes O 
with O 
significant O 
degrees O 
of O 
glycosylation O 
in O 
the O 
monomers O 
and O 
dimers O 
. O 
The O 
PA O 
content O 
of O 
cowpea O 
( O 
dry O 
basis O 
) O 
ranged O 
between O 
2.2 O 
and O 
6.3mg O 
/ O 
g O 
. O 
Monomeric O 
flavan-3-ols B-FAMILY 
were O 
the O 
largest O 
group O 
of O 
PA O 
( O 
36-69% O 
) O 
in O 
cowpea O 
, O 
with O 
catechin-7-O-glucoside B-SYSTEMATIC 
accounting O 
for O 
most O 
( O 
about O 
88% O 
) O 
of O 
the O 
monomers O 
. O 
The O 
oligomers O 
with O 
degree O 
of O 
polymerization O 
( O 
DP O 
) O 
2-4 O 
ranged O 
from O 
0.41 O 
to O 
1.3mg O 
/ O 
g O 
( O 
15-20% O 
) O 
, O 
whereas O 
DP O 
> O 
10 O 
polymers O 
accounted O 
for O 
only O 
13.5% O 
of O 
PA O 
. O 
Future O 
studies O 
that O 
highlight O 
the O 
impact O 
of O 
the O 
unusual O 
cowpea O 
PA O 
profile O 
on O 
nutritional O 
and O 
bioactive O 
properties O 
of O 
this O 
important O 
legume O 
are O 
warranted O 
. O 

estimated O 
harvest O 
from O 
seven O 
new O 
cultivars O 
: O 
Fruit O 
and O 
anthocyanins B-FAMILY 
. O 

study O 
compares O 
the O 
yields O 
, O 
weights O 
and O 
anthocyanin B-FAMILY 
contents O 
of O 
fruit O 
from O 
a O 
group O 
of O 
seven O 
new O 
cultivars O 
released O 
from O 
the O 
New O 
Zealand O 
blueberry O 
breeding O 
programme O 
and O 
selected O 
for O 
the O 
longest O 
possible O 
combined O 
harvest O 
season O 
. O 
The O 
measured O 
factors O 
were O 
primarily O 
influenced O 
by O 
cultivar O 
, O 
and O 
seasonal O 
variations O 
had O 
relatively O 
minor O 
effects O 
. O 
The O 
late O 
- O 
ripening O 
cultivars O 
' O 
Velluto O 
Blue O 
' O 
and O 
' O 
Centra O 
Blue O 
' O 
had O 
the O 
highest O 
fruit O 
yields O 
, O 
anthocyanin B-FAMILY 
contents O 
and O 
estimated O 
total O 
anthocyanin B-FAMILY 
harvestable O 
from O 
a O 
given O 
area O 
. O 
' O 
Blue O 
Moon O 
' O 
and O 
' O 
Sky O 
Blue O 
' O 
had O 
the O 
largest O 
fruit O 
sizes O 
. O 
The O 
early O 
- O 
ripening O 
cultivars O 
' O 
Blue O 
Bayou O 
' O 
, O 
' O 
Blue O 
Moon O 
' O 
and O 
' O 
Sunset O 
Blue O 
' O 
had O 
the O 
lowest O 
anthocyanin B-FAMILY 
contents O 
. O 
The O 
yield O 
, O 
fruit O 
size O 
and O 
total O 
anthocyanin B-FAMILY 
content O 
results O 
obtained O 
from O 
any O 
single O 
year O 
were O 
highly O 
correlated O 
with O 
the O 
average O 
of O 
the O 
three O 
years O 
, O 
which O 
makes O 
pursuing O 
the O 
evaluation O 
for O 
these O 
traits O 
from O 
a O 
single O 
year O 
and O 
at O 
an O 
early O 
stage O 
of O 
plant O 
development O 
a O 
practical O 
proposition O 
. O 

effect O 
of O 
inoculation O 
with O 
a O 
probiotic O 
strain O 
, O 
Lactobacillus O 
casei O 
ŁOCK O 
900 O 
, O 
on O 
selected O 
parameters O 
related O 
to O 
proteolysis O 
of O 
dry O 
- O 
cured O 
pork O 
loins O 
during O 
ageing O 
was O 
studied O 
. O 
Moisture O 
content O 
decreased O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
throughout O 
ageing O 
, O 
accompanied O 
by O 
a O 
progressive O 
reduction O 
in O 
water O 
activity O 
. O 
The O 
total O 
nitrogen B-SYSTEMATIC 
( O 
TN O 
) O 
content O 
increased O 
during O 
ageing O 
with O 
no O 
effect O 
( O 
p O 
< O 
0.05 O 
) O 
of O 
inoculation O 
with O 
L O 
. O 
casei O 
on O 
its O 
level O 
. O 
The O 
greatest O 
increase O 
in O 
non O 
- O 
protein O 
nitrogen B-SYSTEMATIC 
( O 
NPN O 
) O 
content O 
during O 
ageing O 
occurred O 
in O 
an O 
inoculated O 
sample O 
, O 
corresponding O 
with O 
the O 
more O 
pronounced O 
decrease O 
in O 
pH O 
. O 
The O 
intensity O 
of O 
proteolysis O 
, O 
as O 
assessed O 
by O 
proteolysis O 
index O 
( O 
PI O 
) O 
, O 
remained O 
statistically O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
unchanged O 
during O 
examined O 
ageing O 
periods O 
. O 
Inoculation O 
with O 
a O 
probiotic O 
strain O 
does O 
not O 
significantly O 
affect O 
the O 
degree O 
of O 
proteolysis O 
in O 
examined O 
meat O 
products O 
after O 
21 O 
and O 
28days O 
of O 
ageing O 
. O 

evaluate O 
the O 
total O 
phenolic B-FAMILY 
compounds O 
( O 
TPC O 
) O 
content O 
and O 
the O 
antioxidant O 
activity O 
( O 
AA O 
) O 
of O 
extracts O 
obtained O 
from O 
ground O 
fresh O 
thyme O 
( O 
FT O 
) O 
and O 
depleted O 
thyme O 
( O 
DT O 
) O 
, O 
a O 
by O 
- O 
product O 
of O 
the O 
process O 
of O 
essential O 
oil O 
extraction O 
. O 
In O 
addition O 
, O 
enzymatic O 
treatments O 
were O 
evaluated O 
to O 
improve O 
the O 
extraction O 
yields O 
of O 
polyphenolic B-FAMILY 
compounds O 
from O 
thyme O 
. O 
Extractions O 
were O 
performed O 
using O 
several O 
solvents O 
as O 
methanol B-SYSTEMATIC 
, O 
ethanol B-SYSTEMATIC 
, O 
and O 
water O 
. O 
Enzymes O 
were O 
applied O 
prior O 
to O 
extraction O 
or O 
during O 
the O 
extraction O 
process O 
. O 
The O 
best O 
results O 
were O 
obtained O 
using O 
a O 
mixture O 
of O 
methanol B-SYSTEMATIC 
and O 
water O 
, O 
resulting O 
in O 
2790 O 
and O 
220mg O 
Gallic B-TRIVIAL 
acid I-TRIVIAL 
equivalent O 
( O 
GAE O 
) O 
/ O 
L O 
of O 
TPC O 
for O 
FT O 
and O 
DT O 
, O 
respectively O 
. O 
A O 
similar O 
result O 
was O 
observed O 
for O 
AA O 
. O 
With O 
regard O 
to O 
enzymatic O 
treatment O 
, O 
application O 
of O 
Grindamyl O 
CA O 
150 O 
enzyme O 
as O 
a O 
pre O 
- O 
treatment O 
resulted O 
in O 
the O 
production O 
of O 
an O 
extract O 
from O 
DT O 
with O 
614mg O 
TE O 
( O 
trolox B-TRIVIAL 
equivalent O 
) O 
/ O 
L O 
of O 
AA O 
, O 
70% O 
more O 
than O 
the O 
control O 
, O 
and O 
an O 
AA O 
of O 
621mg O 
TE O 
/ O 
L O 
( O 
74% O 
more O 
than O 
the O 
control O 
sample O 
) O 
was O 
obtained O 
using O 
Grindamyl O 
CA O 
150 O 
during O 
the O 
extraction O 
process O 
. O 
These O 
results O 
suggest O 
that O 
enzymatic O 
treatment O 
is O 
an O 
interesting O 
alternative O 
for O 
producing O 
antioxidant O 
extracts O 
from O 
DT O 
. O 

from O 
the O 
capitula O 
of O 
Eriocaulon O 
australe O 
. O 

flavan B-FAMILY 
, O 
eriocaulin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
and O 
three O 
flavone B-FAMILY 
acyl I-FAMILY 
glucosides I-FAMILY 
, O 
eriocaulosides B-MULTIPLE 
A-C I-MULTIPLE 
( O 
2-4 O 
) O 
were O 
isolated O 
from O 
the O 
capitula O 
of O 
Eriocaulon O 
australe O 
R O 
. O 
Br O 
. O 
( O 
Eriocaulaceae O 
) O 
, O 
a O 
Chinese O 
medicine O 
and O 
an O 
herb O 
for O 
health O 
care O 
beverages O 
, O 
together O 
with O 
seven O 
known O 
flavones B-FAMILY 
and O 
three O 
isoflavones B-FAMILY 
( O 
5-14 O 
) O 
. O 
The O 
new O 
flavonoids B-FAMILY 
were O 
elucidated O 
as O 
(2S)-3',4'-methylenedioxy-5-methoxy-7-hydroxyflavan B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
hispidulin B-SYSTEMATIC 
7-O-β-d-(6-O-cinnamoyl)glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
jaceosidin B-SYSTEMATIC 
7-O-β-d-(6-O-p-coumaroyl)glucopyranoside I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
jaceosidin B-SYSTEMATIC 
7-O-β-d-(6-O-p-hydroxybenzoyl)glucopyranoside I-SYSTEMATIC 
( O 
4 O 
) O 
based O 
on O 
their O 
spectroscopic O 
data O 
. O 
All O 
the O 
14 O 
flavonoids B-FAMILY 
were O 
obtained O 
from O 
this O 
species O 
for O 
the O 
first O 
time O 
. O 
The O 
in O 
vitro O 
cytotoxicity O 
of O 
compounds O 
1-14 O 
against O 
human O 
lung O 
adenocarcinoma O 
A549 O 
, O 
human O 
breast O 
adenocarcinoma O 
MCF-7 O 
, O 
and O 
human O 
cervical O 
carcinoma O 
HeLa O 
cell O 
lines O 
was O 
evaluated O 
using O 
the O 
MTT B-ABBREVIATION 
colourimetric O 
assay O 
. O 
Compounds O 
1 O 
, O 
7 O 
, O 
and O 
9 O 
were O 
cytotoxic O 
to O 
A549 O 
, O 
compounds O 
1 O 
, O 
2 O 
, O 
7 O 
, O 
9 O 
, O 
12 O 
, O 
and O 
14 O 
to O 
MCF-7 O 
, O 
and O 
compounds O 
7 O 
, O 
9 O 
, O 
and O 
14 O 
to O 
HeLa O 
cells O 
, O 
with O 
IC50 O 
values O 
ranging O 
from O 
7.17 O 
to O 
29.57μg O 
/ O 
ml O 
, O 
while O 
the O 
others O 
were O 
inactive O 
( O 
IC50 O 
> O 
50μg O 
/ O 
ml O 
) O 
. O 

this O 
work O 
the O 
drying O 
kinetics O 
of O 
Atlantic O 
salmon O 
( O 
Salmo O 
salar O 
L O 
. O 
) O 
fillets O 
and O 
the O 
influence O 
of O 
air O 
drying O 
temperature O 
on O 
colour O 
, O 
firmness O 
and O 
biochemical O 
characteristics O 
were O 
studied O 
. O 
Experiments O 
were O 
conducted O 
at O 
40 O 
, O 
50 O 
and O 
60°C O 
. O 
Effective O 
moisture O 
diffusivity O 
increased O 
with O 
temperature O 
from O 
1.08×10(-10) O 
to O 
1.90×10(-10)m(2)s(-1) O 
. O 
The O 
colour O 
difference O 
, O 
determined O 
as O 
ΔE O 
values O 
( O 
from O 
9.3 O 
to O 
19.3 O 
) O 
, O 
as O 
well O 
as O 
firmness O 
( O 
from O 
25 O 
to O 
75Nmm(-1) O 
) O 
of O 
dried O 
samples O 
increased O 
with O 
dehydration O 
temperature O 
. O 
The O 
lightness O 
value O 
L(∗) O 
and O 
yellowness O 
value O 
b(∗) O 
indicated O 
formation O 
of O 
browning O 
products O 
at O 
higher O 
drying O 
temperatures O 
, O 
while O 
redness O 
value O 
a(∗) O 
showed O 
dependence O 
on O 
astaxanthin B-TRIVIAL 
value O 
. O 
Compared O 
with O 
fresh O 
fish O 
samples O 
, O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
and O 
tocopherol B-FAMILY 
content O 
decreased O 
in O 
a O 
20% O 
and O 
40% O 
, O 
respectively O 
, O 
with O 
temperature O 
. O 
While O 
eicosapentaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
) O 
content O 
remained O 
unchanged O 
and O 
docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
content O 
changed O 
slightly O 
. O 
Anisidine B-TRIVIAL 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
values O 
indicated O 
the O 
formation O 
of O 
secondary O 
lipid O 
oxidation O 
products O 
, O 
which O 
is O 
more O 
relevant O 
for O 
longer O 
drying O 
time O 
than O 
for O 
higher O 
drying O 
temperatures O 
. O 

of O 
β-carotene B-TRIVIAL 
in O 
beta-lactoglobulin O 
aggregates O 
produced O 
under O 
high O 
pressure O 
. O 

A I-FAMILY 
deficiency O 
is O 
one O 
of O 
the O 
major O 
causes O 
of O 
mortality O 
and O 
morbidity O 
in O 
the O 
developing O 
World O 
. O 
This O 
deficiency O 
can O 
be O 
prevented O 
by O 
alimentary O 
or O 
pharmaceutical O 
supplementation O 
. O 
However O 
, O 
both O 
vitamin B-FAMILY 
A I-FAMILY 
oxidation O 
and O 
isomerization O 
should O 
be O 
prevented O 
, O 
as O 
these O 
phenomenons O 
result O 
in O 
loss O 
of O 
nutritional O 
efficacy O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
effect O 
of O 
a O 
food O 
protein O 
matrix O 
, O 
β-lactoglobulin O 
( O 
β-Lg O 
) O 
aggregates O 
produced O 
by O 
high O 
pressure O 
( O 
HP O 
) O 
, O 
on O 
the O 
stabilization O 
of O 
β-carotene B-TRIVIAL 
during O 
storage O 
and O 
gastro O 
- O 
duodenal O 
digestion O 
and O 
therefore O 
on O 
its O 
bioavailability O 
. O 
In O 
vitro O 
gastro O 
- O 
duodenal O 
digestion O 
of O 
β-Lg O 
aggregates O 
entrapping O 
β-carotene B-TRIVIAL 
showed O 
that O 
up O 
to O 
12% O 
and O 
33% O 
of O 
total O 
β-carotene B-TRIVIAL 
was O 
released O 
after O 
peptic O 
and O 
pancreatic O 
digestion O 
, O 
respectively O 
. O 
Overall O 
, O 
our O 
study O 
showed O 
that O 
β-Lg O 
aggregates O 
are O 
efficient O 
for O 
caging O 
and O 
stabilization O 
of O 
β-carotene B-TRIVIAL 
during O 
storage O 
and O 
digestion O 
. O 
Hence O 
, O 
it O 
may O 
be O 
an O 
interesting O 
approach O 
for O 
the O 
protection O 
and O 
the O 
delivery O 
of O 
vitamin B-FAMILY 
A I-FAMILY 
. O 

white O 
protein O 
powder O 
, O 
one O 
of O 
the O 
main O 
egg O 
products O 
, O 
was O 
hydrolysed O 
by O 
Alcalase O 
, O 
Trypsin O 
, O 
and O 
Pepsin O 
respectively O 
to O 
prepare O 
antioxidant O 
peptides O 
. O 
All O 
hydrolysates O 
were O 
assayed O 
by O 
determination O 
of O 
reducing O 
power O 
( O 
RP O 
) O 
ability O 
. O 
Three O 
kinds O 
of O 
hydrolysates O 
were O 
prepared O 
under O 
optimal O 
enzymatic O 
parameters O 
that O 
were O 
obtained O 
from O 
the O 
preliminary O 
one-factor-at-a-time O 
( O 
OFAT O 
) O 
and O 
response O 
surface O 
methodology O 
( O 
RSM O 
) O 
experiments O 
. O 
The O 
results O 
showed O 
that O 
the O 
Alcalase O 
hydrolysates O 
exerted O 
the O 
best O 
RP O 
ability O 
. O 
Thereafter O 
, O 
the O 
Alcalase O 
hydrolysates O 
were O 
sequentially O 
fractionated O 
by O 
ultra O 
filtration O 
membranes O 
in O 
cut O 
- O 
off O 
molecular O 
weight O 
( O 
MW O 
) O 
of O 
30 O 
, O 
10 O 
, O 
and O 
1kDa O 
, O 
and O 
tested O 
their O 
antioxidant O 
activities O 
in O 
terms O 
of O 
RP O 
ability O 
, O 
DPPH B-ABBREVIATION 
radical O 
scavenging O 
ability O 
, O 
ABTS B-ABBREVIATION 
radical O 
scavenging O 
ability O 
, O 
and O 
FRAP O 
assay O 
. O 
Effects O 
of O 
high O 
intensity O 
pulsed O 
electric O 
field O 
treatment O 
were O 
further O 
investigated O 
on O 
antioxidant O 
peptides O 
to O 
improve O 
their O 
activities O 
. O 
The O 
results O 
showed O 
that O 
Alcalase O 
hydrolysates O 
possessed O 
the O 
strongest O 
antioxidant O 
ability O 
compared O 
with O 
the O 
other O 
two O 
hydrolysates O 
, O 
particularly O 
for O 
the O 
Fraction-3 O 
with O 
MW O 
< O 
1kDa O 
. O 
After O 
PEF O 
treatment O 
, O 
this O 
fraction O 
showed O 
a O 
significant O 
improvement O 
of O 
RP O 
ability O 
within O 
5h O 
( O 
P O 
< O 
0.05 O 
) O 
. O 

cucumbers O 
have O 
been O 
a O 
dietary O 
delicacy O 
and O 
important O 
ingredient O 
in O 
Asian O 
traditional O 
medicinal O 
over O 
many O 
centuries O 
. O 
In O 
this O 
study O 
, O 
edible O 
sea O 
cucumber O 
Holothuria O 
edulis O 
was O 
evaluated O 
for O 
its O 
in O 
vitro O 
anticancer O 
potential O 
. O 
An O 
aqueous O 
fraction O 
of O 
the O 
edible O 
sea O 
cucumber O 
( O 
ESC-AQ O 
) O 
has O 
been O 
shown O 
to O 
deliver O 
a O 
strong O 
cytotoxic O 
effect O 
against O 
the O 
human O 
HL-60 O 
leukaemia O 
cell O 
line O 
. O 
An O 
induction O 
effect O 
of O 
apoptotic O 
body O 
formation O 
in O 
response O 
to O 
ESC-AQ O 
treatment O 
was O 
confirmed O 
in O 
HL-60 O 
cells O 
stained O 
with O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
and O 
confirmed O 
via O 
flow O 
cytometry O 
analysis O 
. O 
The O 
up O 
regulation O 
of O 
Bax O 
and O 
caspase-3 O 
protein O 
expression O 
was O 
observed O 
while O 
the O 
expression O 
of O 
Bcl-xL O 
protein O 
was O 
down O 
regulated O 
in O 
ESC-AQ O 
treated O 
HL-60 O 
cells O 
. O 
Due O 
to O 
the O 
profound O 
anticancer O 
activity O 
, O 
ESC-AQ O 
appears O 
to O 
be O 
an O 
economically O 
important O 
biomass O 
fraction O 
that O 
can O 
be O 
exploited O 
in O 
numerous O 
industrial O 
applications O 
as O 
a O 
source O 
of O 
functional O 
ingredients O 
. O 

new O 
process O 
for O 
obtaining O 
hydroxytyrosol B-SYSTEMATIC 
using O 
transformed O 
Escherichia O 
coli O 
whole O 
cells O 
with O 
phenol B-SYSTEMATIC 
hydroxylase O 
gene O 
from O 
Geobacillus O 
thermoglucosidasius O 
. O 

hydroxylase O 
gene O 
cloning O 
from O 
the O 
thermophilic O 
bacteria O 
Geobacillus O 
thermoglucosidasius O 
was O 
used O 
to O 
develop O 
an O 
effective O 
method O 
to O 
convert O 
tyrosol B-TRIVIAL 
into O 
the O 
high O 
- O 
added O 
- O 
value O 
compound O 
hydroxytyrosol B-SYSTEMATIC 
by O 
hydroxylation O 
. O 
Phenol B-SYSTEMATIC 
hydroxylase O 
is O 
a O 
two O 
- O 
component O 
enzyme O 
encoded O 
by O 
pheA1 O 
and O 
pheA2 O 
genes O 
and O 
strictly O 
dependent O 
on O 
NADH B-ABBREVIATION 
and O 
FAD B-ABBREVIATION 
. O 
These O 
two O 
genes O 
were O 
subcloned O 
together O 
as O 
a O 
2kb O 
fragment O 
into O 
Escherichia O 
coli O 
Rosetta O 
cells O 
, O 
and O 
the O 
transformants O 
were O 
able O 
to O 
grow O 
and O 
effectively O 
transform O 
up O 
to O 
5mM O 
of O 
phenol B-SYSTEMATIC 
and O 
tyrosol B-TRIVIAL 
using O 
IPTG B-ABBREVIATION 
( O 
isopropyl-β-d-thiogalactopyranoside B-SYSTEMATIC 
) O 
as O 
inducer O 
. O 
In O 
addition O 
, O 
when O 
a O 
new O 
fragment O 
with O 
a O 
340pb O 
upstream O 
pheA1 O 
gene O 
was O 
subcloned O 
, O 
a O 
similar O 
biotransformation O 
rate O 
was O 
attained O 
without O 
IPTG B-ABBREVIATION 
, O 
confirming O 
that O 
this O 
fragment O 
encodes O 
for O 
a O 
phenol B-SYSTEMATIC 
hydroxylase O 
promoter O 
that O 
can O 
be O 
recognised O 
by O 
E O 
. O 
coli O 
. O 
Both O 
transformants O 
brought O 
about O 
the O 
total O 
bioconversion O 
of O 
monophenols B-FAMILY 
at O 
a O 
high O 
concentration O 
( O 
5mM O 
) O 
, O 
which O 
represents O 
an O 
increase O 
, O 
both O 
in O 
concentration O 
and O 
in O 
yield O 
, O 
compared O 
with O 
that O 
previously O 
described O 
in O 
the O 
bibliography O 
. O 
The O 
use O 
of O 
the O 
transformant O 
with O 
its O 
constitutive O 
promoter O 
was O 
more O 
interesting O 
from O 
a O 
biotechnological O 
point O 
of O 
view O 
, O 
since O 
it O 
is O 
not O 
necessary O 
to O 
use O 
IPTG B-ABBREVIATION 
. O 
It O 
also O 
gave O 
rise O 
to O 
greater O 
operational O 
stability O 
. O 

of O 
biogenic O 
amine B-SYSTEMATIC 
and O 
polyphenol B-FAMILY 
profiles O 
of O 
grape O 
berries O 
and O 
wines O 
obtained O 
following O 
conventional O 
, O 
organic O 
and O 
biodynamic O 
agricultural O 
and O 
oenological O 
practices O 
. O 

bio O 
- O 
active O 
compounds O 
present O 
in O 
food O 
and O 
beverages O 
have O 
a O 
high O 
potential O 
influence O 
on O 
the O 
future O 
health O 
of O 
humans O 
. O 
The O 
levels O 
of O 
biogenic O 
amines B-FAMILY 
, O 
anthocyanins B-FAMILY 
, O 
polyphenols B-FAMILY 
and O 
antioxidant O 
activity O 
were O 
measured O 
in O 
white O 
( O 
Pignoletto O 
) O 
and O 
red O 
( O 
Sangiovese O 
) O 
grape O 
berries O 
and O 
wines O 
from O 
the O 
Emilia-Romagna O 
region O 
( O 
Italy O 
) O 
obtained O 
following O 
conventional O 
, O 
organic O 
and O 
biodynamic O 
agricultural O 
and O 
oenological O 
practices O 
. O 
No O 
significant O 
difference O 
was O 
shown O 
among O 
the O 
samples O 
coming O 
from O 
different O 
agricultural O 
and O 
winemaking O 
practices O 
. O 
Principal O 
Component O 
Analysis O 
was O 
also O 
performed O 
. O 
Biogenic O 
amine B-SYSTEMATIC 
amounts O 
were O 
higher O 
in O 
red O 
than O 
in O 
white O 
berries O 
, O 
while O 
in O 
the O 
wines O 
an O 
opposite O 
trend O 
was O 
observed O 
, O 
with O 
histamine B-TRIVIAL 
, O 
tyramine B-TRIVIAL 
and O 
putrescine B-TRIVIAL 
being O 
the O 
most O 
abundant O 
in O 
Pignoletto O 
wines O 
. O 
Red O 
grapes O 
and O 
wines O 
were O 
richer O 
in O 
anthocyanins B-FAMILY 
and O 
showed O 
higher O 
antioxidant O 
activity O 
than O 
white O 
ones O 
. O 
The O 
total O 
level O 
of O 
polyphenols B-FAMILY 
was O 
similar O 
in O 
red O 
and O 
white O 
berries O 
, O 
but O 
with O 
different O 
metabolite O 
profiles O 
depending O 
on O 
the O 
grape O 
variety O 
. O 

of O 
nitrite B-SYSTEMATIC 
on O 
the O 
odourant O 
volatile O 
fraction O 
of O 
cooked O 
ham O 
. O 

aim O 
of O 
this O 
work O 
was O 
to O 
reliably O 
identify O 
the O 
key O 
odour O 
compounds O 
in O 
cooked O 
ham O 
and O 
acquire O 
new O 
knowledge O 
on O 
the O 
role O 
of O 
sodium B-SYSTEMATIC 
nitrite I-SYSTEMATIC 
on O 
the O 
formation O 
of O 
its O 
aroma O 
. O 
Gas O 
chromatography O 
coupled O 
with O 
mass O 
spectrometry O 
and O 
( O 
or O 
) O 
olfactometry O 
was O 
used O 
. O 
In O 
all O 
, O 
24 O 
odourants O 
were O 
identified O 
in O 
the O 
volatile O 
fraction O 
of O 
cooked O 
ham O 
. O 
Their O 
main O 
origins O 
are O 
discussed O 
. O 
Orthonasal O 
sniffing O 
of O 
the O 
hams O 
was O 
used O 
to O 
study O 
how O 
these O 
substances O 
contributed O 
to O 
the O 
overall O 
aroma O 
of O 
the O 
product O 
. O 
The O 
aroma O 
of O 
cooked O 
ham O 
is O 
a O 
balance O 
between O 
that O 
of O 
certain O 
sulfur B-SYSTEMATIC 
compounds O 
produced O 
during O 
cooking O 
and O 
that O 
of O 
oxidation O 
compounds O 
commonly O 
found O 
in O 
cooked O 
meats O 
. O 
In O 
the O 
absence O 
of O 
nitrite B-SYSTEMATIC 
, O 
this O 
balance O 
is O 
disturbed O 
by O 
extensive O 
formation O 
of O 
oxidation O 
compounds O 
that O 
mask O 
the O 
meaty O 
notes O 
induced O 
by O 
the O 
sulfur B-SYSTEMATIC 
compounds O 
. O 

of O 
new O 
monoterpene B-FAMILY 
coumarins I-FAMILY 
from O 
Micromelum O 
minutum O 
leaves O 
and O 
their O 
cytotoxic O 
activity O 
against O 
Leishmania O 
major O 
and O 
cancer O 
cells O 
. O 

the O 
basis O 
of O 
a O 
leishmanicidal O 
assay O 
- O 
guided O 
isolation O 
, O 
two O 
new O 
monoterpene B-FAMILY 
coumarins I-FAMILY 
, O 
minutin B-TRIVIAL 
A I-TRIVIAL 
and O 
minutin B-TRIVIAL 
B I-TRIVIAL 
, O 
were O 
purified O 
from O 
Micromelum O 
minutum O 
leaves O 
together O 
with O 
four O 
known O 
coumarins B-FAMILY 
, O 
8,4″-dihydroxy-3″,4″-dihydrocapnolactone-2',3'-diol B-SYSTEMATIC 
, O 
8-hydroxyisocapnolactone-2',3'-diol B-SYSTEMATIC 
, O 
8-hydroxy-3″,4″-dihydrocapnolactone-2',3'-diol B-SYSTEMATIC 
, O 
and O 
clauslactone B-TRIVIAL 
E I-TRIVIAL 
. O 
Among O 
these O 
compounds O 
, O 
minutin B-TRIVIAL 
A I-TRIVIAL 
, O 
minutin B-TRIVIAL 
B I-TRIVIAL 
, O 
8-hydroxyisocapnolactone-2',3'-diol B-SYSTEMATIC 
and O 
clauslactone B-TRIVIAL 
E I-TRIVIAL 
showed O 
a O 
significant O 
cytotoxic O 
activity O 
against O 
Leishmania O 
major O 
with O 
IC50 O 
values O 
of O 
26.2 O 
, O 
20.2 O 
, O 
12.1 O 
, O 
and O 
9.8μM O 
, O 
respectively O 
, O 
while O 
8,4″-dihydroxy-3″4″-dihydrocapnolactone-2',3'-diol B-SYSTEMATIC 
and O 
8-hydroxy-3″,4″-dihydrocapnolactone-2',3'-diol B-SYSTEMATIC 
were O 
not O 
active O 
. O 
However O 
, O 
all O 
these O 
compounds O 
exhibited O 
some O 
inhibitory O 
activity O 
against O 
one O 
or O 
more O 
lung O 
adenocarcinoma O 
( O 
SBC3 O 
and O 
A549 O 
) O 
and O 
leukaemia O 
( O 
K562 O 
, O 
and O 
K562 O 
/ O 
ADM O 
) O 
cell O 
lines O 
. O 
Amongst O 
these O 
, O 
clauslactone B-TRIVIAL 
E I-TRIVIAL 
, O 
minutin B-TRIVIAL 
B I-TRIVIAL 
and O 
8-hydroxyisocapnolactone-2',3'-diol B-SYSTEMATIC 
possessed O 
the O 
strongest O 
cytotoxic O 
activity O 
against O 
SBC3 O 
, O 
A549 O 
, O 
K562 O 
, O 
and O 
K562 O 
/ O 
ADM O 
cell O 
lines O 
, O 
with O 
IC50 O 
values O 
of O 
3.7 O 
, O 
10.4 O 
, O 
12.1 O 
, O 
and O 
10.8μM O 
for O 
clauslactone B-TRIVIAL 
E I-TRIVIAL 
; O 
9.6 O 
, O 
17.5 O 
, O 
8.7 O 
and O 
6.7μM O 
for O 
minutin B-TRIVIAL 
B I-TRIVIAL 
; O 
8.8 O 
, O 
10.1 O 
, O 
16.9 O 
, O 
and O 
10.1μM O 
for O 
8-hydroxyisocapnolactone-2',3'-diol B-SYSTEMATIC 
, O 
respectively O 
. O 

antifungal O 
and O 
antioxidant O 
activity O 
enhancement O 
by O 
substitution O 
with O 
thiosemicarbazide B-SYSTEMATIC 
and O 
thiazolidinone B-SYSTEMATIC 
moieties O 
. O 

to O 
literature O 
data O 
, O 
thiosemicarbazide B-SYSTEMATIC 
and O 
thiazolidinone B-SYSTEMATIC 
moieties O 
should O 
enhance O 
biological O 
properties O 
of O 
coumarin B-TRIVIAL 
. O 
Antioxidant O 
, O 
metal O 
- O 
chelating O 
and O 
antifungal O 
activities O 
of O 
all O 
compounds O 
were O 
investigated O 
and O 
compared O 
to O 
the O 
activity O 
of O 
the O 
starting O 
material O 
, O 
7-hydroxy-4-methylcoumarin B-SYSTEMATIC 
, O 
and O 
were O 
proven O 
to O 
possess O 
potent O 
antioxidant O 
and O 
antifungal O 
activity O 
. O 
In O 
general O 
, O 
thiosemicarbazides B-FAMILY 
showed O 
higher O 
scavenging O 
activity O 
towards O 
DPPH B-ABBREVIATION 
and O 
galvinoxyl B-TRIVIAL 
radicals O 
than O 
did O 
4-thiazolidinones B-FAMILY 
and O 
some O 
of O 
them O 
had O 
the O 
same O 
or O 
even O 
better O 
activity O 
than O 
had O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
itself O 
, O 
depending O 
on O 
the O 
free O 
radical O 
used O 
. O 
In O 
antifungal O 
activity O 
tests O 
towards O 
four O 
foodborne O 
mycotoxigenic O 
fungi O 
, O 
Aspergillus O 
flavus O 
, O 
Aspergillus O 
ochraceus O 
. O 
Fusarium O 
graminearum O 
and O 
Fusarium O 
verticillioides O 
, O 
coumarin B-TRIVIAL 
derivatives O 
were O 
proven O 
to O 
possess O 
a O 
very O 
high O 
activity O 
in O 
terms O 
of O 
growth O 
inhibition O 
, O 
depending O 
on O 
the O 
fungi O 
investigated O 
. O 
In O 
general O 
, O 
4-thiazolidinones B-FAMILY 
showed O 
better O 
antifungal O 
activity O 
than O 
did O 
thiosemicarbazides B-FAMILY 
. O 
F O 
. O 
graminearum O 
was O 
the O 
most O 
susceptible O 
to O 
the O 
compounds O 
investigated O 
and O 
F O 
. O 
verticillioides O 
was O 
proven O 
to O 
be O 
the O 
most O 
resistant O 
. O 
Two O 
compounds O 
, O 
both O 
coumarinyl B-FAMILY 
thiosemicarbazides I-FAMILY 
, O 
were O 
found O 
to O 
possess O 
both O 
antifungal O 
and O 
antioxidant O 
activity O 
which O 
could O 
be O 
useful O 
for O 
applications O 
in O 
medicine O 
, O 
food O 
industry O 
and O 
agriculture O 
. O 

Inonotus O 
obliquus O 
( O 
I O 
. O 
obliquus O 
) O 
has O 
been O 
used O 
as O 
functional O 
food O 
and O 
traditional O 
Chinese O 
herbs O 
for O 
long O 
time O 
. O 
An O 
efficient O 
method O 
for O 
bioassay O 
- O 
guided O 
preparative O 
isolation O 
was O 
used O 
for O 
identifying O 
the O 
anti-inflammatory O 
and O 
anticancer O 
constituents O 
in O 
I O 
. O 
obliquus O 
. O 
The O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
and O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fractions O 
were O 
found O 
to O 
have O 
significant O 
inhibition O 
effects O 
on O 
NO B-FORMULA 
production O 
and O 
NF-κB O 
luciferase O 
activity O 
in O 
macrophage O 
RAW O 
264.7 O 
cells O 
and O 
cytotoxicity O 
against O 
human O 
prostatic O 
carcinoma O 
cell O 
PC3 O 
and O 
breast O 
carcinoma O 
cell O 
MDA-MB-231 O 
. O 
Six O 
main O 
constituents O 
were O 
isolated O 
from O 
these O 
two O 
fractions O 
and O 
they O 
were O 
identified O 
as O 
lanosterol B-TRIVIAL 
( O 
1 O 
) O 
, O 
3β-hydroxy-8,24-dien-21-al B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
ergosterol B-TRIVIAL 
( O 
3 O 
) O 
, O 
inotodiol B-TRIVIAL 
( O 
4 O 
) O 
, O 
ergosterol B-TRIVIAL 
peroxide I-TRIVIAL 
( O 
5 O 
) O 
and O 
trametenolic B-TRIVIAL 
acid I-TRIVIAL 
( O 
6 O 
) O 
. O 
Compound O 
ergosterol B-TRIVIAL 
, O 
ergosterol B-TRIVIAL 
peroxide I-TRIVIAL 
and O 
trametenolic B-TRIVIAL 
acid I-TRIVIAL 
showed O 
anti-inflammatory O 
activities O 
and O 
ergosterol B-TRIVIAL 
peroxide I-TRIVIAL 
and O 
trametenolic B-TRIVIAL 
acid I-TRIVIAL 
showed O 
obviously O 
cytotoxicity O 
on O 
human O 
prostatic O 
carcinoma O 
cell O 
PC3 O 
and O 
breast O 
carcinoma O 
MDA-MB-231 O 
cell O 
. O 
The O 
results O 
obtained O 
in O 
this O 
work O 
might O 
contribute O 
to O 
understanding O 
the O 
biological O 
activity O 
of O 
mushroom O 
I O 
. O 
obliquus O 
for O 
food O 
and O 
drug O 
application O 
. O 

( O 
Zingiber O 
officinale O 
R O 
. O 
) O 
is O 
a O 
popular O 
spice O 
used O 
in O 
various O 
foods O 
and O 
beverages O 
. O 
6-Gingerol B-SYSTEMATIC 
is O 
the O 
major O 
bioactive O 
constituent O 
responsible O 
for O 
the O 
antiinflammatory O 
, O 
antitumour O 
and O 
antioxidant O 
activities O 
of O 
ginger O 
. O 
The O 
effect O 
of O 
application O 
of O 
α-amylase O 
, O 
viscozyme O 
, O 
cellulase O 
, O 
protease O 
and O 
pectinase O 
enzymes O 
to O 
ginger O 
on O 
the O 
oleoresin O 
yield O 
and O 
6-gingerol B-SYSTEMATIC 
content O 
has O 
been O 
investigated O 
. O 
Pre O 
- O 
treatment O 
of O 
ginger O 
with O 
α-amylase O 
or O 
viscozyme O 
followed O 
by O 
extraction O 
with O 
acetone B-SYSTEMATIC 
afforded O 
higher O 
yield O 
of O 
oleoresin O 
( O 
20%±0.5 O 
) O 
and O 
gingerol B-TRIVIAL 
( O 
12.2%±0.4 O 
) O 
compared O 
to O 
control O 
( O 
15%±0.6 O 
oleoresin O 
, O 
6.4%±0.4 O 
gingerol B-TRIVIAL 
) O 
. O 
Extraction O 
of O 
ginger O 
pre O 
- O 
treated O 
with O 
enzymes O 
followed O 
by O 
extraction O 
with O 
ethanol B-SYSTEMATIC 
provided O 
higher O 
yield O 
of O 
gingerol B-TRIVIAL 
( O 
6.2-6.3% O 
) O 
than O 
the O 
control O 
( O 
5.5% O 
) O 
with O 
comparable O 
yields O 
of O 
the O 
oleoresin O 
( O 
31-32% O 
) O 
. O 
Also O 
, O 
ethanol B-SYSTEMATIC 
extract O 
of O 
cellulase O 
pre O 
- O 
treated O 
ginger O 
had O 
the O 
maximum O 
polyphenol B-FAMILY 
content O 
( O 
37.5mg O 
/ O 
g O 
) O 
. O 
Apart O 
from O 
6-gingerol B-SYSTEMATIC 
, O 
6-paradol B-SYSTEMATIC 
along O 
with O 
6- B-MULTIPLE 
and I-MULTIPLE 
8-methyl I-MULTIPLE 
shogaols I-MULTIPLE 
were O 
the O 
other O 
important O 
bio O 
- O 
active O 
constituents O 
in O 
the O 
oleoresin O 
from O 
cellulase O 
- O 
treated O 
ginger O 
. O 

frequency O 
( O 
RF O 
) O 
heating O 
has O 
been O 
used O 
for O 
numerous O 
applications O 
in O 
the O 
food O 
industry O 
such O 
as O 
baking O 
, O 
thawing O 
or O 
pasteurisation O 
. O 
It O 
reduces O 
cooking O 
time O 
, O 
and O 
it O 
helps O 
to O 
retain O 
acceptable O 
food O 
colour O 
and O 
texture O 
. O 
In O 
this O 
paper O 
, O 
chemical O 
and O 
sensory O 
data O 
obtained O 
from O 
broccoli O 
, O 
potatoes O 
, O 
salmon O 
and O 
cocoa O 
cakes O 
cooked O 
using O 
an O 
innovative O 
RF O 
oven O 
were O 
reported O 
. O 
The O 
oven O 
has O 
an O 
algorithm O 
able O 
to O 
monitor O 
the O 
energy O 
feedback O 
from O 
the O 
cavity O 
and O 
to O 
adjust O 
the O 
energy O 
output O 
accordingly O 
. O 
The O 
different O 
foods O 
were O 
cooked O 
to O 
the O 
same O 
end O 
point O 
and O 
the O 
concentration O 
of O 
phytochemicals O 
, O 
vitamins B-FAMILY 
and O 
acrylamide B-TRIVIAL 
were O 
assessed O 
. O 
Results O 
demonstrated O 
that O 
RF O 
oven O 
preserved O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
and O 
increased O 
glucosinolates B-FAMILY 
concentration O 
in O 
broccoli O 
and O 
it O 
decreased O 
the O 
formation O 
of O 
acrylamide B-TRIVIAL 
in O 
roasted O 
potatoes O 
more O 
than O 
50% O 
. O 
The O 
total O 
amount O 
of O 
vitamins B-FAMILY 
B I-FAMILY 
was O 
30% O 
and O 
50% O 
higher O 
in O 
RF O 
cooked O 
salmon O 
than O 
conventionally O 
cooked O 
salmon O 
prepared O 
at O 
55 O 
and O 
75°C O 
, O 
respectively O 
. O 

in O 
polyphenol B-FAMILY 
content O 
during O 
production O 
of O 
grape O 
juice O 
concentrate O 
. O 

production O 
of O 
grape O 
juice O 
concentrate O 
on O 
an O 
industrial O 
scale O 
was O 
evaluated O 
and O 
samples O 
from O 
the O 
main O 
steps O 
of O 
processing O 
have O 
been O 
collected O 
and O 
analyzed O 
. O 
The O 
sampling O 
steps O 
included O 
the O 
selection O 
and O 
washing O 
of O 
grapes O 
( O 
Nevsehir O 
Patlak O 
variety O 
) O 
, O 
pressing O 
in O 
order O 
to O 
obtain O 
the O 
juice O 
separate O 
from O 
the O 
seed O 
and O 
the O 
skin O 
fraction O 
, O 
pasteurization O 
, O 
clarification O 
, O 
filtration O 
, O 
evaporation O 
, O 
and O 
filling O 
- O 
packing O 
at O 
27°C O 
with O 
a O 
Brix O 
of O 
45° O 
. O 
Samples O 
from O 
each O 
of O 
the O 
processing O 
steps O 
were O 
analyzed O 
by O 
a O 
number O 
of O 
spectrophotometric O 
analyses O 
. O 
A O 
series O 
of O 
anthocyanin B-FAMILY 
compounds O 
was O 
identified O 
using O 
HPLC-MS O 
, O 
and O 
the O 
fate O 
of O 
anthocyanins B-FAMILY 
, O 
quercetin B-TRIVIAL 
rutinoside I-TRIVIAL 
and O 
procyanidins B-FAMILY 
was O 
followed O 
using O 
HPLC O 
. O 
The O 
results O 
indicate O 
that O 
the O 
removal O 
of O 
seed O 
and O 
fruit O 
skin O 
removes O 
most O 
of O 
the O 
procyanidins B-FAMILY 
and O 
anthocyanins B-FAMILY 
, O 
while O 
subsequent O 
clarification O 
and O 
filtration O 
treatments O 
further O 
reduce O 
the O 
anthocyanin B-FAMILY 
content O 
. O 

stability O 
of O 
astaxanthin B-TRIVIAL 
nanodispersions O 
in O 
orange O 
juice O 
and O 
skimmed O 
milk O 
as O 
model O 
food O 
systems O 
. O 

astaxanthin B-TRIVIAL 
in O 
nanodispersion O 
systems O 
is O 
a O 
promising O 
approach O 
to O 
incorporate O 
astaxanthin B-TRIVIAL 
into O 
water O 
- O 
based O 
food O 
formulations O 
. O 
In O 
this O 
research O 
, O 
the O 
chemical O 
stabilities O 
of O 
astaxanthin B-TRIVIAL 
nanodispersions O 
diluted O 
in O 
orange O 
juice O 
and O 
skimmed O 
milk O 
as O 
model O 
food O 
systems O 
and O 
in O 
deionised O 
water O 
as O 
a O 
control O 
were O 
evaluated O 
. O 
The O 
nanodispersions O 
displayed O 
significantly O 
( O 
p O 
< O 
0.05 O 
) O 
better O 
stability O 
in O 
food O 
systems O 
compared O 
to O 
the O 
control O 
. O 
The O 
effects O 
of O 
stabilisers O 
and O 
dilution O 
factor O 
were O 
also O 
studied O 
. O 
In O 
skimmed O 
milk O 
and O 
deionised O 
water O 
, O 
the O 
type O 
of O 
stabiliser O 
had O 
a O 
significant O 
effect O 
( O 
p O 
< O 
0.05 O 
) O 
on O 
astaxanthin B-TRIVIAL 
degradation O 
during O 
storage O 
. O 
In O 
vitro O 
cellular O 
uptake O 
of O 
astaxanthin B-TRIVIAL 
from O 
diluted O 
astaxanthin B-TRIVIAL 
nanodispersions O 
in O 
selected O 
food O 
systems O 
was O 
also O 
evaluated O 
. O 
The O 
cellular O 
uptake O 
of O 
astaxanthin B-TRIVIAL 
nanodispersions O 
in O 
skimmed O 
milk O 
was O 
significantly O 
higher O 
( O 
p O 
< O 
0.05 O 
) O 
than O 
that O 
of O 
astaxanthin B-TRIVIAL 
nanodispersions O 
in O 
orange O 
juice O 
and O 
deionised O 
water O 
. O 
High O 
in O 
vitro O 
cellular O 
uptake O 
of O 
astaxanthin B-TRIVIAL 
from O 
the O 
prepared O 
astaxanthin B-TRIVIAL 
nanodispersions O 
can O 
be O 
achieved O 
via O 
incorporation O 
into O 
protein O 
- O 
based O 
foods O 
such O 
as O 
milk O 
. O 

effect O 
of O 
interesterification O 
on O 
the O 
bioavailability O 
of O 
fatty B-FAMILY 
acids I-FAMILY 
in O 
structured O 
lipids O 
. O 

acid I-FAMILY 
( O 
FA O 
) O 
profile O 
is O 
a O 
critical O 
factor O 
in O 
the O 
nutritional O 
properties O 
of O 
fats O 
, O 
but O 
, O 
stereochemistry O 
may O 
also O 
play O 
a O 
fundamental O 
role O 
in O 
the O 
rate O 
and O 
extent O 
to O 
which O 
FAs B-ABBREVIATION 
are O 
absorbed O 
and O 
become O 
available O 
. O 
To O 
better O 
understand O 
this O 
phenomenon O 
, O 
we O 
evaluated O 
the O 
bioavailability O 
of O 
FAs B-ABBREVIATION 
in O 
linseed O 
- O 
oil O 
and O 
palm O 
- O 
stearin O 
blends O 
compared O 
to O 
their O 
interesterified O 
mix O 
, O 
using O 
a O 
sn-1,3 O 
stereospecific O 
lipase O 
, O 
to O 
determine O 
if O 
there O 
was O 
any O 
difference O 
in O 
terms O 
of O 
FA O 
availability O 
when O 
using O 
this O 
technology O 
. O 
Test O 
meals O 
were O 
fed O 
through O 
an O 
intragastric O 
feeding O 
tube O 
on O 
Sprague-Dawley O 
male O 
rats O 
after O 
18h O 
fasting O 
. O 
Postprandial O 
blood O 
samples O 
were O 
collected O 
after O 
meal O 
or O 
physiological O 
serum O 
( O 
control O 
) O 
administration O 
and O 
the O 
FA O 
profile O 
of O 
plasma O 
lipids O 
was O 
determined O 
. O 
Results O 
showed O 
that O 
modification O 
of O 
the O 
melting O 
profile O 
through O 
interesterification O 
, O 
without O 
altering O 
the O 
bioavailability O 
determined O 
by O 
sn-2 O 
stereochemistry O 
, O 
could O 
delay O 
lipid O 
absorption O 
at O 
the O 
beginning O 
, O 
but O 
had O 
no O 
effect O 
on O 
total O 
lipid O 
absorption O 
. O 

the O 
binding O 
between O 
norbixin B-TRIVIAL 
and O 
dairy O 
proteins O 
by O 
spectroscopy O 
methods O 
. O 

( O 
norbixin B-TRIVIAL 
) O 
has O 
been O 
used O 
to O 
color O 
cheeses O 
for O 
centuries O 
, O 
but O 
there O 
is O 
very O 
little O 
knowledge O 
about O 
interactions O 
between O 
the O 
pigment O 
and O 
dairy O 
proteins O 
. O 
In O 
this O 
study O 
, O 
binding O 
of O 
norbixin B-TRIVIAL 
with O 
whey O 
protein O 
isolate O 
( O 
WPI O 
) O 
, O 
sodium B-SYSTEMATIC 
caseinate O 
( O 
NaCN O 
) O 
, O 
and O 
6 O 
individual O 
dairy O 
proteins O 
was O 
investigated O 
by O 
using O 
fluorescence O 
spectroscopy O 
, O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FTIR O 
) O 
, O 
circular O 
dichroism O 
( O 
CD O 
) O 
and O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
. O 
Norbixin B-TRIVIAL 
was O 
observed O 
to O 
effectively O 
quench O 
the O 
fluorescence O 
of O 
WPI O 
and O 
NaCN O 
by O 
forming O 
complexes O 
. O 
The O 
binding O 
affinity O 
between O 
NaCN O 
and O 
norbixin B-TRIVIAL 
was O 
higher O 
than O 
that O 
of O 
WPI- O 
norbixin B-TRIVIAL 
. O 
For O 
individual O 
proteins O 
, O 
bovine O 
serum O 
albumin O 
had O 
higher O 
binding O 
affinity O 
with O 
norbixin B-TRIVIAL 
than O 
β-lactoglobulin O 
and O 
α-lactalbumin O 
, O 
while O 
κ-casein O 
bound O 
with O 
norbixin B-TRIVIAL 
better O 
than O 
α- O 
and O 
β-caseins O 
. O 
Binding O 
changed O 
the O 
conformation O 
of O 
WPI O 
and O 
NaCN O 
, O 
but O 
the O 
extent O 
and O 
trend O 
varied O 
for O 
individual O 
proteins O 
. O 

this O 
work O 
, O 
the O 
characteristics O 
of O 
fat O 
from O 
the O 
hump O 
of O 
young O 
camels O 
( O 
Hachi O 
) O 
were O 
evaluated O 
. O 
The O 
physicochemical O 
properties O 
of O 
the O 
fat O 
were O 
as O 
follows O 
: O 
melting O 
point O 
, O 
45°C O 
; O 
saponification O 
value O 
, O 
202.3mg O 
KOH B-FORMULA 
/g O 
oil O 
; O 
refractive O 
index O 
( O 
60°C O 
) O 
, O 
1.468 O 
; O 
unsaponifiable O 
matter O 
, O 
1.37% O 
; O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
( O 
as O 
the O 
percentage O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
) O 
, O 
0.96% O 
; O 
and O 
peroxide B-SYSTEMATIC 
value O 
, O 
3.37mequiv O 
. O 
O2 B-FORMULA 
/ O 
kg O 
oil O 
. O 
High O 
- O 
resolution O 
(1)H B-FORMULA 
nuclear O 
magnetic O 
resonance O 
( O 
(1)H B-FORMULA 
NMR O 
) O 
was O 
used O 
for O 
the O 
direct O 
determination O 
of O 
the O 
iodine B-SYSTEMATIC 
value O 
of O 
Hachi O 
fat O 
( O 
62.74g O 
/ O 
100g O 
oil O 
) O 
. O 
The O 
Hachi O 
fat O 
was O 
composed O 
primarily O 
of O 
oleic B-TRIVIAL 
acid I-TRIVIAL 
( O 
33.35% O 
) O 
, O 
followed O 
by O 
palmitic B-TRIVIAL 
acid I-TRIVIAL 
( O 
26.16% O 
) O 
, O 
stearic B-TRIVIAL 
acid I-TRIVIAL 
( O 
10.07% O 
) O 
, O 
palmitelaidic B-TRIVIAL 
acid I-TRIVIAL 
( O 
9.56% O 
) O 
and O 
myristic B-TRIVIAL 
acid I-TRIVIAL 
( O 
8.83% O 
) O 
. O 
The O 
thermal O 
properties O 
were O 
assessed O 
by O 
thermogravimetry O 
( O 
TG O 
) O 
and O 
derivative O 
thermogravimetry O 
( O 
DTG O 
) O 
. O 
The O 
results O 
of O 
the O 
present O 
analytical O 
study O 
showed O 
that O 
Hachi O 
fat O 
could O 
be O 
used O 
in O 
food O 
products O 
and O 
as O 
an O 
important O 
source O 
of O 
biological O 
materials O 
. O 

method O 
for O 
determining O 
regioisomer O 
abundances O 
of O 
polyunsaturated B-FAMILY 
triacylglycerols I-FAMILY 
in O 
omega-3 O 
enriched O 
fish O 
oils O 
using O 
reversed O 
- O 
phase O 
liquid O 
chromatography O 
and O 
triple O 
- O 
stage O 
mass O 
spectrometry O 
. O 

- O 
phase O 
high O 
performance O 
liquid O 
chromatography O 
( O 
RP-HPLC O 
) O 
, O 
followed O 
by O 
post O 
- O 
column O 
addition O 
of O 
lithium O 
salts O 
and O 
electrospray O 
ionisation O 
triple O 
- O 
stage O 
mass O 
spectrometry O 
(ESI-MS(3)) O 
of O 
lithiated B-ABBREVIATION 
TAG I-ABBREVIATION 
adducts O 
, O 
is O 
shown O 
to O 
provide O 
a O 
useful O 
method O 
for O 
the O 
positional O 
analysis O 
of O 
triacylglycerols B-FAMILY 
( O 
TAGs B-ABBREVIATION 
) O 
in O 
fish O 
oils O 
containing O 
eicosapentaenoic B-SYSTEMATIC 
( O 
EPA B-ABBREVIATION 
, O 
20 O 
: O 
5 O 
) O 
and O 
docosahexaenoic B-FAMILY 
acids I-FAMILY 
( O 
DHA B-ABBREVIATION 
, O 
22 O 
: O 
6 O 
) O 
. O 
One O 
prominent O 
fragmentation O 
pathway O 
in O 
the O 
ESI-MS(3) O 
of O 
these O 
adduct O 
ions O 
involves O 
the O 
loss O 
of O 
a O 
fatty B-FAMILY 
acid I-FAMILY 
from O 
the O 
sn-1 O 
/ O 
3 O 
position O 
in O 
the O 
first O 
step O 
followed O 
by O 
the O 
loss O 
of O 
an O 
α,β- B-FAMILY 
unsaturated I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
from O 
the O 
sn-2 O 
position O 
in O 
the O 
second O 
. O 
Regioisomeric O 
TAGs B-ABBREVIATION 
of O 
the O 
type O 
ABA O 
and O 
AAB O 
produced O 
abundant O 
product O 
ions O 
- O 
[ O 
ABA+ O 
Li-RACOOH B-FAMILY 
- O 
R'BCHCHCOOH B-FAMILY 
](+ O 
) O 
and O 
[ O 
AAB+ O 
Li-RACOOH B-FAMILY 
- O 
R'ACHCHCOOH B-FAMILY 
](+ O 
) O 
- O 
the O 
relative O 
intensities O 
of O 
which O 
were O 
dependent O 
on O 
the O 
position O 
of O 
acyl B-FAMILY 
substituents O 
. O 
Standard O 
solutions O 
of O 
TAGs B-ABBREVIATION 
containing O 
different O 
ratios O 
of O 
the O 
regioisomeric O 
pairs O 
MME O 
/ O 
MEM O 
, O 
PPE O 
/ O 
PEP O 
, O 
PPD O 
/ O 
PDP O 
, O 
EEP O 
/ O 
EPE O 
and O 
DDP O 
/ O 
DPD O 
( O 
M=14 O 
: O 
0 O 
, O 
P=16 O 
: O 
0 O 
, O 
E=20 O 
: O 
5 O 
, O 
D=22 O 
: O 
6 O 
) O 
were O 
analysed O 
by O 
ESI-MS(3) O 
with O 
a O 
quadrupole O 
linear O 
ion O 
trap O 
instrument O 
. O 
Methodology O 
developed O 
on O 
the O 
standards O 
was O 
applied O 
to O 
quantifying O 
the O 
relative O 
isomeric O 
abundances O 
of O 
EPA B-ABBREVIATION 
and O 
DHA B-ABBREVIATION 
in O 
several O 
fish O 
oil O 
samples O 
. O 
DHA B-ABBREVIATION 
was O 
preferentially O 
located O 
at O 
the O 
sn-2 O 
position O 
in O 
both O 
DHA B-ABBREVIATION 
-containing O 
TAGs B-ABBREVIATION 
studied O 
, O 
while O 
EPA B-ABBREVIATION 
was O 
either O 
observed O 
at O 
near O 
equal O 
levels O 
in O 
all O 
positions O 
, O 
or O 
predominantly O 
at O 
the O 
sn-1 O 
and O 
-3 O 
positions O 
in O 
some O 
cases O 
. O 
The O 
analysis O 
protocol O 
allows O 
for O 
quantification O 
of O 
the O 
designated O 
regioisomers O 
in O 
one O 
simple O 
, O 
rapid O 
chromatographic O 
procedure O 
using O 
a O 
single O 
column O 
and O 
has O 
the O 
advantage O 
of O 
specificity O 
over O 
other O 
methods O 
for O 
the O 
positional O 
analysis O 
of O 
TAGs B-ABBREVIATION 
, O 
since O 
it O 
eliminates O 
interferences O 
associated O 
with O 
co O 
- O 
eluting O 
TAGs B-ABBREVIATION 
of O 
the O 
same O 
molecular O 
weight O 
that O 
yield O 
isobaric O 
diacylglycerol B-FAMILY 
-like O 
product O 
ions O 
. O 

of O 
calcium B-SYSTEMATIC 
on O 
the O 
kinetics O 
of O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
release O 
during O 
in O 
vitro O 
lipid O 
digestion O 
in O 
model O 
emulsions O 
. O 

effects O 
of O 
different O 
calcium B-SYSTEMATIC 
salts O 
on O 
in O 
vitro O 
lipid O 
digestion O 
were O 
examined O 
by O 
determining O 
the O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
released O 
from O 
various O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
. O 
The O 
kinetics O 
of O 
the O 
total O 
and O 
individual O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
released O 
by O 
lipolysis O 
were O 
monitored O 
by O 
the O 
pH-stat O 
method O 
and O 
gas O 
chromatography O 
, O 
respectively O 
. O 
The O 
rate O 
and O 
the O 
extent O 
of O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
release O 
increased O 
with O 
an O 
increase O 
in O 
the O 
added O 
calcium B-SYSTEMATIC 
concentration O 
, O 
but O 
the O 
increase O 
was O 
dependent O 
on O 
the O 
emulsifying O 
agent O 
. O 
The O 
effect O 
of O 
calcium B-SYSTEMATIC 
was O 
diminished O 
when O 
the O 
emulsion O 
contained O 
phosphate B-SYSTEMATIC 
. O 
Soluble O 
calcium B-SYSTEMATIC 
salts O 
, O 
such O 
as O 
calcium B-SYSTEMATIC 
gluconate I-SYSTEMATIC 
, O 
calcium B-SYSTEMATIC 
acetate I-SYSTEMATIC 
and O 
CaCl2 B-FORMULA 
, O 
had O 
greater O 
effects O 
on O 
the O 
rate O 
and O 
extent O 
of O 
free O 
fatty B-FAMILY 
acid I-FAMILY 
release O 
than O 
did O 
insoluble O 
salts O 
, O 
such O 
as O 
CaO B-FORMULA 
and O 
CaSO4 B-FORMULA 
, O 
suggesting O 
that O 
the O 
ionic O 
state O 
of O 
calcium B-SYSTEMATIC 
plays O 
a O 
critical O 
role O 
in O 
lipid O 
digestion O 
in O 
emulsions O 
. O 
The O 
addition O 
of O 
calcium B-SYSTEMATIC 
did O 
not O 
alter O 
the O 
profiles O 
of O 
the O 
individual O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
released O 
. O 
This O 
study O 
provides O 
useful O 
information O 
for O 
food O 
formulation O 
with O 
respect O 
to O 
lipid O 
digestion O 
. O 

chemical O 
and O 
rheological O 
properties O 
of O 
spent O 
hen O 
proteins O 
recovered O 
by O 
acid O 
and O 
alkaline O 
extraction O 
have O 
been O 
studied O 
with O 
/ O 
without O 
cryoprotectants O 
( O 
CP O 
) O 
after O 
3weeks O 
of O 
frozen O 
storage O 
. O 
Four O 
pH O 
values O 
( O 
2 O 
, O 
2.5 O 
, O 
11.5 O 
, O 
and O 
12 O 
) O 
were O 
used O 
for O 
extraction O 
. O 
CP O 
addition O 
prevented O 
freeze O 
- O 
induced O 
denaturation O 
and O 
oxidation O 
in O 
all O 
extracted O 
proteins O 
, O 
as O 
revealed O 
by O 
significant O 
increases O 
in O 
reactive O 
sulphydryl B-FAMILY 
groups O 
( O 
p O 
< O 
0.0001 O 
) O 
, O 
and O 
a O 
decrease O 
in O 
the O 
formation O 
of O 
carbonyl B-FAMILY 
groups O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
The O 
alkaline O 
extracted O 
proteins O 
with O 
CP O 
formed O 
more O 
viscoelastic O 
gels O 
compared O 
to O 
the O 
others O 
, O 
while O 
samples O 
without O 
CP O 
failed O 
to O 
form O 
a O 
gel O 
network O 
. O 
FTIR O 
of O 
the O 
protein O 
isolates O 
with O 
CP O 
showed O 
a O 
protective O 
effect O 
on O 
the O 
secondary O 
structure O 
of O 
the O 
isolated O 
proteins O 
. O 
Scanning O 
electron O 
micrographs O 
showed O 
a O 
protective O 
shield O 
of O 
CP O 
around O 
the O 
isolated O 
proteins O 
. O 

and O 
tocopherols B-FAMILY 
in O 
yellow O 
and O 
red O 
raspberries O 
. O 

composition O 
of O 
carotenoids O 
, O 
chlorophyll B-FAMILY 
derivatives O 
and O 
tocopherols B-FAMILY 
in O 
raspberries O 
of O 
different O 
varieties O 
, O 
including O 
yellow O 
and O 
red O 
varieties O 
, O 
over O 
different O 
ripening O 
stages O 
has O 
been O 
studied O 
. O 
The O 
profile O 
of O 
pigments O 
in O 
ripening O 
raspberries O 
changes O 
drastically O 
, O 
with O 
a O 
dramatic O 
decrease O 
of O 
β-carotene B-TRIVIAL 
and O 
chlorophyll B-FAMILY 
derivatives O 
, O 
the O 
xanthophyll B-FAMILY 
lutein B-TRIVIAL 
has O 
also O 
decreased O 
but O 
not O 
to O 
the O 
same O 
extent O 
. O 
In O 
contrast O 
esterified O 
lutein B-TRIVIAL 
increased O 
and O 
is O 
present O 
in O 
ripe O 
raspberries O 
esterified O 
with O 
saturated O 
fatty B-FAMILY 
acids I-FAMILY 
with O 
C8-C16 B-MULTIPLE 
chains O 
. O 
Ripe O 
raspberries O 
contain O 
considerable O 
amounts O 
of O 
free O 
lutein B-TRIVIAL 
, O 
esterified O 
lutein B-TRIVIAL 
, O 
and O 
tocopherols B-FAMILY 
( O 
up O 
to O 
20 O 
, O 
49 O 
and O 
366mg O 
/ O 
kg O 
dry O 
weight O 
, O 
respectively O 
) O 
. O 
The O 
different O 
samples O 
analysed O 
show O 
different O 
contents O 
of O 
carotenoids O 
and O 
tocopherols B-FAMILY 
. O 
Whether O 
the O 
differences O 
arise O 
from O 
the O 
variety O 
or O 
other O 
factors O 
such O 
as O 
the O 
environmental O 
conditions O 
needs O 
to O 
be O 
ascertained O 
but O 
isoprenoids B-FAMILY 
should O 
not O 
be O 
neglected O 
when O 
considering O 
raspberry O 
antioxidant O 
and O 
nutraceutical O 
composition O 
. O 

chemical O 
profiling O 
of O 
saponins B-FAMILY 
in O 
the O 
flower O 
buds O 
of O 
Panax O 
notoginseng O 
by O 
integrating O 
MCI O 
gel O 
column O 
chromatography O 
and O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
analysis O 
. O 

flower O 
buds O 
of O 
Panax O 
notoginseng O 
( O 
Notoginseng O 
flower O 
, O 
FBP O 
) O 
are O 
used O 
as O 
the O 
traditional O 
Chinese O 
medicine O 
San-Qi-Hua O 
. O 
In O 
this O 
study O 
, O 
we O 
conducted O 
column O 
chromatography O 
fractionation O 
and O 
liquid O 
chromatography O 
/ O 
mass O 
spectrometry O 
( O 
LC O 
/ O 
MS O 
) O 
analysis O 
to O 
comprehensively O 
profile O 
bioactive O 
notoginseng O 
saponins B-FAMILY 
( O 
ginsenosides B-FAMILY 
) O 
in O 
FBP O 
. O 
MCI O 
gel O 
column O 
chromatography O 
allowed O 
separation O 
and O 
enrichment O 
of O 
minor O 
saponins B-FAMILY 
. O 
Electrospray O 
ionization O 
tandem O 
mass O 
spectrometry O 
of O 
[ O 
M- O 
H B-FORMULA 
](- O 
) O 
and O 
[ O 
M+ O 
Na B-FORMULA 
](+ O 
) O 
precursor O 
ions O 
of O 
the O 
saponins O 
provided O 
reliable O 
structural O 
information O 
for O 
the O 
sapogenin O 
, O 
and O 
sequence O 
of O 
sugar B-FAMILY 
chains O 
. O 
Confirmed O 
by O 
high O 
- O 
accuracy O 
Q-TOF O 
analysis O 
, O 
170 O 
notoginseng O 
saponins B-FAMILY 
were O 
characterized O 
from O 
FBP O 
, O 
and O 
91 O 
of O 
them O 
were O 
reported O 
from O 
Panax O 
species O 
for O 
the O 
first O 
time O 
. O 
The O 
new O 
ginsenosides B-FAMILY 
contain O 
acyl B-FAMILY 
groups O 
on O 
α-chain O 
, O 
malonyl B-SYSTEMATIC 
group O 
at O 
20- O 
OH B-FORMULA 
, O 
or O 
di B-SYSTEMATIC 
- I-SYSTEMATIC 
malonyl I-SYSTEMATIC 
groups O 
. O 
This O 
study O 
also O 
indicated O 
that O 
the O 
flower O 
buds O 
of O 
P O 
. O 
notoginseng O 
contained O 
more O 
protopanaxadiol B-TRIVIAL 
-type O 
but O 
less O 
protopanaxatriol B-TRIVIAL 
-type O 
ginsenosides B-FAMILY 
than O 
the O 
roots O 
. O 

of O 
flavonoid B-FAMILY 
structure O 
on O 
the O 
fluidity O 
of O 
model O 
lipid O 
membranes O 
. O 

investigated O 
how O 
the O 
structural O 
properties O 
of O 
(+)-catechin B-TRIVIAL 
, O 
(-)-epicatechin B-SYSTEMATIC 
, O 
(-)-epigallocatechin B-TRIVIAL 
( O 
EGC B-ABBREVIATION 
) O 
and O 
(-)-epigallocatechin-3-gallate B-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
and O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
( O 
BHT B-ABBREVIATION 
) O 
correlate O 
with O 
structural O 
changes O 
of O 
phosphatidylcholine B-FAMILY 
plus O 
sphingomyelin B-FAMILY 
( O 
2.4 O 
: O 
1 O 
) O 
model O 
lipid O 
membranes O 
. O 
Changes O 
were O 
measured O 
by O 
fluorescence O 
anisotropy O 
, O 
electron O 
paramagnetic O 
resonance O 
, O 
and O 
differential O 
scanning O 
calorimetry O 
. O 
Two O 
fluorophores O 
and O 
two O 
spin O 
probes O 
were O 
used O 
to O 
monitor O 
membrane O 
characteristics O 
close O 
to O 
water O 
- O 
lipid O 
interface O 
and O 
in O 
the O 
middle O 
of O 
the O 
bilayer O 
. O 
The O 
data O 
obtained O 
were O 
correlated O 
to O 
the O 
amount O 
of O 
bounded O 
compounds O 
, O 
the O 
number O 
of O 
H B-FORMULA 
-bonds O 
, O 
and O 
the O 
topological O 
polar O 
surface O 
area O 
( O 
TPSA O 
) O 
of O 
the O 
compounds O 
. O 
These O 
correlations O 
reflect O 
the O 
behaviours O 
of O 
(+)-catechin B-TRIVIAL 
, O 
(-)-epicatechin B-SYSTEMATIC 
, O 
EGC B-ABBREVIATION 
, O 
EGCG B-ABBREVIATION 
and O 
BHT B-ABBREVIATION 
. O 
Our O 
results O 
confirm O 
that O 
phenolics O 
studied O 
here O 
are O 
bounded O 
to O 
a O 
membrane O 
surface O 
predominantly O 
via O 
hydrogen B-SYSTEMATIC 
bonds O 
, O 
while O 
BTH B-ABBREVIATION 
is O 
inserted O 
into O 
the O 
lipid O 
bilayer O 
. O 

of O 
industrial O 
processing O 
on O 
folate B-TRIVIAL 
content O 
in O 
green O 
vegetables O 
. O 

are O 
described O 
to O 
be O 
sensitive O 
to O 
different O 
physical O 
parameters O 
such O 
as O 
heat O 
, O 
light O 
, O 
pH O 
and O 
leaching O 
. O 
Most O 
studies O 
on O 
folates B-FAMILY 
degradation O 
during O 
processing O 
or O 
cooking O 
treatments O 
were O 
carried O 
out O 
on O 
model O 
solutions O 
or O 
vegetables O 
only O 
with O 
thermal O 
treatments O 
. O 
Our O 
aim O 
was O 
to O 
identify O 
which O 
steps O 
were O 
involved O 
in O 
folates B-FAMILY 
loss O 
in O 
industrial O 
processing O 
chains O 
, O 
and O 
which O 
mechanisms O 
were O 
underlying O 
these O 
losses O 
. O 
For O 
this O 
, O 
the O 
folates B-FAMILY 
contents O 
were O 
monitored O 
along O 
an O 
industrial O 
canning O 
chain O 
of O 
green O 
beans O 
and O 
along O 
an O 
industrial O 
freezing O 
chain O 
of O 
spinach O 
. O 
Folates B-FAMILY 
contents O 
decreased O 
significantly O 
by O 
25% O 
during O 
the O 
washing O 
step O 
for O 
spinach O 
in O 
the O 
freezing O 
process O 
, O 
and O 
by O 
30% O 
in O 
the O 
green O 
beans O 
canning O 
process O 
after O 
sterilisation O 
, O 
with O 
20% O 
of O 
the O 
initial O 
amount O 
being O 
transferred O 
into O 
the O 
covering O 
liquid O 
. O 
The O 
main O 
mechanism O 
involved O 
in O 
folate B-TRIVIAL 
loss O 
during O 
both O 
canning O 
green O 
beans O 
and O 
freezing O 
spinach O 
was O 
leaching O 
. O 
Limiting O 
the O 
contact O 
between O 
vegetables O 
and O 
water O 
or O 
using O 
steaming O 
seems O 
to O 
be O 
an O 
adequate O 
measure O 
to O 
limit O 
folates B-FAMILY 
losses O 
during O 
processing O 
. O 

of O 
dissatisfaction O 
with O 
tomato O 
aroma O 
prompted O 
us O 
to O 
lead O 
this O 
study O 
on O 
the O 
impact O 
of O 
domestic O 
storage O 
conditions O 
on O 
volatile O 
compounds O 
. O 
Two O 
storage O 
modalities O 
( O 
20 O 
and O 
4°C O 
) O 
and O 
two O 
cultivars O 
( O 
Levovil O 
and O 
LCx O 
) O 
were O 
used O 
. O 
Volatile O 
compounds O 
were O 
analysed O 
by O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
detection O 
after O 
accelerated O 
solvent O 
extraction O 
. O 
Physical O 
characteristics O 
, O 
lipoxygenase O 
activity O 
, O 
hydroperoxide B-FAMILY 
lyase O 
activity O 
; O 
linoleic B-TRIVIAL 
acid I-TRIVIAL 
and O 
linolenic B-TRIVIAL 
acid I-TRIVIAL 
were O 
monitored O 
. O 
Storing O 
tomatoes O 
at O 
4°C O 
induced O 
a O 
drastic O 
loss O 
in O 
volatiles O 
, O 
whatever O 
their O 
biosynthetic O 
origin O 
. O 
After O 
30days O 
at O 
4°C O 
, O 
the O 
concentration O 
of O 
volatiles O 
had O 
decreased O 
by O 
66% O 
. O 
Reconditioning O 
for O 
24h O 
at O 
20°C O 
was O 
able O 
to O 
recover O 
some O 
aroma O 
production O 
after O 
up O 
to O 
6days O 
storage O 
at O 
4°C O 
. O 
Volatile O 
degradation O 
products O 
arising O 
from O 
carotenoids O 
and O 
amino B-FAMILY 
acids I-FAMILY 
increased O 
when O 
tomatoes O 
were O 
kept O 
at O 
20°C O 
, O 
while O 
lipid O 
degradation O 
products O 
did O 
not O 
vary O 
. O 
Storing O 
tomatoes O 
at O 
fridge O 
temperature O 
, O 
even O 
for O 
short O 
durations O 
, O 
was O 
detrimental O 
for O 
their O 
aroma O 
. O 
This O 
should O 
be O 
taken O 
into O 
account O 
to O 
formulate O 
practical O 
advice O 
for O 
consumers O 
. O 

method O 
for O 
selective O 
quantitation O 
of O 
catechin B-TRIVIAL 
, O 
proanthocyanidin B-FAMILY 
( O 
PAC B-ABBREVIATION 
) O 
A2 O 
and O 
PAC-B1 B-ABBREVIATION 
in O 
American O 
cranberry O 
( O 
Vaccinium O 
macrocarpon O 
) O 
extracts O 
using O 
high O 
performance O 
thin O 
layer O 
chromatography O 
(HPTLC)-densitometry O 
is O 
presented O 
. O 
Methylene B-SYSTEMATIC 
chloride I-SYSTEMATIC 
/ O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
/ O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
6 O 
: O 
10 O 
: O 
1 O 
, O 
v O 
/ O 
v O 
) O 
as O 
the O 
mobile O 
phase O 
and O 
1% O 
vanillin B-SYSTEMATIC 
hydrochloric I-SYSTEMATIC 
solution O 
as O 
staining O 
reagent O 
were O 
used O 
. O 
In O 
these O 
conditions O 
, O 
three O 
standards O 
considered O 
as O 
quality O 
markers O 
, O 
catechin B-TRIVIAL 
, O 
PAC-A2 B-ABBREVIATION 
and O 
PAC-B1 B-ABBREVIATION 
, O 
were O 
well O 
resolved O 
allowing O 
simultaneous O 
quantitation O 
on O 
one O 
plate O 
. O 
All O 
standards O 
were O 
quantified O 
in O 
the O 
range O 
of O 
0.7-5μg O 
with O 
RSD O 
of O 
repeatability O 
and O 
intermediate O 
precision O 
not O 
exceeding O 
5% O 
. O 
Catechin B-TRIVIAL 
, O 
PAC-A2 B-ABBREVIATION 
and O 
PAC-B1 B-ABBREVIATION 
profiles O 
of O 
cranberry O 
extracts O 
were O 
analysed O 
regarding O 
global O 
PAC B-ABBREVIATION 
amounts O 
obtained O 
by O 
BL-DMAC O 
assay O 
. O 
It O 
appears O 
clearly O 
that O 
HPTLC-densitometry O 
process O 
provides O 
additional O 
information O 
which O 
, O 
combined O 
with O 
BL-DMAC O 
results O 
, O 
allows O 
qualitative O 
and O 
quantitative O 
control O 
of O 
cranberry O 
extracts O 
. O 
Particularly O 
, O 
densitometric O 
assay O 
highlighted O 
degradation O 
of O 
PAC B-ABBREVIATION 
s O 
in O 
a O 
7day O 
- O 
extract O 
, O 
leading O 
to O 
high O 
overestimation O 
with O 
BL-DMAC O 
protocol O 
. O 

β-carotene B-TRIVIAL 
bioaccessibility O 
by O 
controlling O 
oil O 
composition O 
and O 
concentration O 
in O 
edible O 
nanoemulsions O 
. O 

rich O 
in O 
carotenoids O 
have O 
been O 
correlated O 
with O 
a O 
reduced O 
risk O 
of O 
developing O 
certain O 
types O 
of O 
chronic O 
diseases O 
, O 
but O 
these O 
bioactive O 
components O 
have O 
low O 
intestinal O 
absorption O 
due O 
to O 
their O 
hydrophobic O 
nature O 
. O 
The O 
aim O 
of O 
this O 
work O 
was O 
to O 
study O 
the O 
effect O 
of O 
carrier O 
oil O 
composition O 
( O 
medium O 
- O 
chain O 
triglyceride B-FAMILY 
( O 
MCT O 
) O 
to O 
long O 
- O 
chain O 
triglyceride B-FAMILY 
( O 
LCT O 
) O 
ratio O 
) O 
and O 
total O 
carrier O 
oil O 
concentration O 
( O 
1% O 
or O 
4% O 
w O 
/ O 
w O 
) O 
on O 
the O 
physical O 
stability O 
, O 
lipid O 
digestibility O 
and O 
bioaccessibility O 
of O 
β-carotene B-TRIVIAL 
-loaded O 
nanoemulsions O 
, O 
using O 
a O 
simulated O 
digestion O 
process O 
. O 
Lipolysis O 
led O 
to O 
an O 
appreciable O 
increase O 
in O 
the O 
size O 
and O 
negative O 
charge O 
on O 
the O 
particles O 
in O 
the O 
system O 
. O 
The O 
total O 
fraction O 
of O 
triacylglycerols B-FAMILY 
converted O 
to O 
free O 
fatty B-FAMILY 
acids I-FAMILY 
decreased O 
as O 
the O 
percentage O 
of O 
LCT O 
within O 
the O 
lipid O 
phase O 
increased O 
, O 
particularly O 
for O 
the O 
nanoemulsions O 
with O 
higher O 
fat O 
contents O 
. O 
There O 
was O 
an O 
increase O 
in O 
β-carotene B-TRIVIAL 
bioaccessibility O 
as O 
the O 
LCT O 
within O 
the O 
lipid O 
phase O 
increased O 
for O 
low O 
fat O 
nanoemulsions O 
, O 
which O 
was O 
attributed O 
to O 
the O 
increased O 
solubilisation O 
capacity O 
of O 
mixed O 
micelles O 
formed O 
by O 
LCT O 
. O 
β-carotene B-TRIVIAL 
bioaccessibility O 
showed O 
a O 
complex O 
relationship O 
on O 
LCT O 
content O 
for O 
high O 
fat O 
nanoemulsions O 
, O 
due O 
to O 
the O 
opposing O 
effects O 
of O 
lipid O 
digestion O 
and O 
micelle O 
solubilisation O 
. O 
These O 
results O 
may O 
facilitate O 
the O 
optimisation O 
of O 
delivery O 
systems O 
for O 
lipophilic O 
bioactive O 
compounds O 
for O 
food O 
or O 
pharmaceutical O 
applications O 
. O 

activity O 
- O 
guided O 
purification O 
and O 
identification O 
of O 
a O 
novel O 
C-20 B-FAMILY 
oxygenated I-FAMILY 
ent-kaurane I-FAMILY 
from O 
Rabdosia O 
serra O 
( O 
MAXIM O 
. O 
) O 
HARA O 
. O 

objective O 
of O 
this O 
work O 
was O 
to O 
conduct O 
an O 
activity O 
- O 
guided O 
isolation O 
of O 
antibacterial O 
compounds O 
from O 
Rabdosia O 
serra O 
. O 
The O 
ethanol B-SYSTEMATIC 
extracts O 
of O 
R O 
. O 
serra O 
leaf O 
and O 
stem O 
were O 
partitioned O 
sequentially O 
into O 
petroleum B-TRIVIAL 
ether I-TRIVIAL 
, O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
butanol B-SYSTEMATIC 
and O 
water O 
fractions O 
, O 
respectively O 
. O 
The O 
ethanol B-SYSTEMATIC 
extract O 
of O 
leaf O 
evidenced O 
broad O 
- O 
spectrum O 
antibacterial O 
activity O 
against O 
Gram O 
- O 
positive O 
bacterial O 
, O 
including O 
Bacillus O 
subtilis O 
, O 
Bacillus O 
cereus O 
, O 
Staphylococcus O 
aureus O 
, O 
and O 
Listeria O 
monocytogenes O 
. O 
The O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
fractions O 
of O 
leaf O 
and O 
stem O 
exhibited O 
strong O 
inhibition O 
against O 
Gram O 
- O 
positive O 
bacteria O 
, O 
and O 
were O 
then O 
purified O 
further O 
. O 
On O 
the O 
basis O 
of O 
antibacterial O 
assay O 
- O 
guided O 
purification O 
, O 
three O 
phenolic O 
compounds O 
( O 
rosmarinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
methyl B-SYSTEMATIC 
rosmarinate I-SYSTEMATIC 
and O 
pedalitin B-TRIVIAL 
) O 
and O 
four O 
C-20 B-FAMILY 
oxygenated I-FAMILY 
ent-kauranes I-FAMILY 
( O 
effusanin B-TRIVIAL 
E I-TRIVIAL 
, O 
lasiodin B-TRIVIAL 
, O 
rabdosichuanin B-TRIVIAL 
D I-TRIVIAL 
and O 
a O 
new O 
compound O 
namely O 
effusanin B-TRIVIAL 
F I-TRIVIAL 
) O 
were O 
obtained O 
, O 
whose O 
contents O 
were O 
determined O 
by O 
HPLC O 
analysis O 
. O 
The O 
broth O 
microdilution O 
method O 
confirmed O 
the O 
important O 
inhibition O 
potential O 
of O 
C-20 B-FAMILY 
oxygenated I-FAMILY 
ent-kauranes I-FAMILY 
with O 
low O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
values O 
. O 
Effusanin B-TRIVIAL 
E I-TRIVIAL 
, O 
lasiodin B-TRIVIAL 
and O 
effusanin B-TRIVIAL 
F I-TRIVIAL 
could O 
be O 
useful O 
for O 
the O 
development O 
of O 
new O 
antibacterial O 
agents O 
. O 

separation O 
of O 
triterpene B-FAMILY 
alcohol I-FAMILY 
ferulates O 
from O 
rice O 
bran O 
oil O 
using O 
a O 
high O 
performance O 
counter O 
- O 
current O 
chromatography O 
. O 

novel O 
method O 
for O 
the O 
separation O 
of O 
two O 
major O 
triterpene B-FAMILY 
alcohol I-FAMILY 
ferulates O 
from O 
rice O 
bran O 
oil O 
( O 
RBO O 
) O 
was O 
developed O 
using O 
a O 
high O 
performance O 
counter O 
- O 
current O 
chromatography O 
( O 
HPCCC O 
) O 
. O 
A O 
two O 
- O 
phase O 
solvent O 
system O 
of O 
n-hexane B-SYSTEMATIC 
- O 
acetonitrile B-SYSTEMATIC 
( O 
1 O 
: O 
1 O 
, O 
v O 
/ O 
v O 
) O 
was O 
applied O 
to O 
purify O 
cycloartenyl B-TRIVIAL 
ferulate I-TRIVIAL 
( O 
CAF B-ABBREVIATION 
) O 
and O 
24-methylene B-SYSTEMATIC 
cycloartanyl I-SYSTEMATIC 
ferulate I-SYSTEMATIC 
( O 
24-mCAF B-SYSTEMATIC 
) O 
from O 
RBO O 
. O 
The O 
yields O 
were O 
20.50±2.60mg O 
CAF B-ABBREVIATION 
and O 
12.62±1.15mg O 
24-mCAF B-SYSTEMATIC 
from O 
390mg O 
RBO O 
through O 
a O 
two O 
- O 
step O 
separation O 
procedure O 
. O 
The O 
purities O 
of O 
the O 
two O 
compounds O 
were O 
97.97±0.90% O 
and O 
95.50±0.75% O 
, O 
respectively O 
, O 
as O 
determined O 
by O 
high O 
performance O 
liquid O 
chromatography O 
( O 
HPLC O 
) O 
. O 
Their O 
chemical O 
structures O 
were O 
confirmed O 
by O 
ultra O 
performance O 
liquid O 
chromatography O 
- O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
UPLC-Q-TOF-MS O 
) O 
, O 
and O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
and O 
2D O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
. O 
This O 
represents O 
the O 
first O 
report O 
on O 
direct O 
separation O 
of O 
CAF B-ABBREVIATION 
and O 
24-mCAF B-SYSTEMATIC 
from O 
RBO O 
by O 
HPCCC O 
. O 

biotransformation O 
of O 
alkylresorcinols B-FAMILY 
is O 
mediated O 
via O 
cytochrome O 
P450 O 
and O 
β-oxidation O 
: O 
A O 
proof O 
of O 
concept O 
study O 
. O 

( O 
AR O 
) O 
are O 
phenolic B-FAMILY 
lipids O 
present O 
in O 
the O 
bran O 
of O 
some O 
cereals O 
. O 
AR O 
may O 
serve O 
as O 
a O 
biomarker O 
for O 
whole O 
grain O 
wheat O 
and O 
rye O 
intake O 
. O 
While O 
AR O 
pharmacokinetics O 
and O 
two O 
major O 
metabolites O 
have O 
been O 
reported O 
, O 
the O 
metabolic O 
pathways O 
contributing O 
to O 
their O 
relatively O 
rapid O 
elimination O 
from O 
the O 
circulation O 
remain O 
to O 
be O 
speculative O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
if O 
ω- O 
and O 
β-oxidation O 
mediate O 
catabolism O 
of O 
the O 
AR O 
homologue O 
C19 O 
: O 
0 O 
to O 
form O 
3,5-dihydroxybenzoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
and O 
3-(3,5-dihydroxyphenyl)-1-propanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHPPA B-ABBREVIATION 
) O 
, O 
using O 
3 O 
in O 
vitro O 
platforms O 
, O 
human O 
cytochrome O 
P450 O 
4F2 O 
( O 
CYP4F2 O 
) O 
, O 
human O 
liver O 
S9 O 
, O 
and O 
HepG2 O 
cells O 
. O 
One O 
hydroxylated O 
C19 O 
: O 
0 O 
metabolite O 
was O 
formed O 
by O 
CYP4F2 O 
and O 
one O 
hydroxylated O 
and O 
one O 
carboxylated O 
C19 O 
: O 
0 O 
were O 
tentatively O 
identified O 
after O 
incubation O 
of O 
AR O 
with O 
S9 O 
. O 
The O 
formation O 
of O 
DHPPA B-ABBREVIATION 
was O 
quantifiable O 
when O 
HepG2 O 
cells O 
were O 
treated O 
with O 
C19 O 
: O 
0 O 
for O 
48h O 
. O 
Our O 
results O 
are O 
consistent O 
with O 
a O 
metabolic O 
pathway O 
by O 
which O 
AR O 
are O 
degraded O 
to O 
phenolic O 
acids O 
via O 
CYP4F2 O 
- O 
mediated O 
ω-oxidation O 
and O 
subsequent O 
β-oxidation O 
. O 

of O 
Kyoho O 
grape O 
berry O 
quality O 
under O 
long O 
- O 
term O 
NaCl B-FORMULA 
treatment O 
. O 

concentrations O 
of O 
a O 
sodium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
spray O 
were O 
applied O 
to O 
the O 
grapevine O 
cultivar O 
Kyoho O 
to O 
determine O 
the O 
effects O 
of O 
salinity O 
on O 
berry O 
quality O 
. O 
The O 
fruit's O 
fresh O 
weight O 
, O 
relative O 
water O 
content O 
, O 
hardness O 
and O 
titratable O 
acid O 
were O 
gradually O 
enhanced O 
with O 
increased O 
salt O 
concentrations O 
. O 
Anthocyanin B-FAMILY 
and O 
soluble O 
solids O 
increased O 
after O 
treatment O 
with O 
moderate O 
salinity O 
( O 
20 O 
and O 
60mM O 
) O 
; O 
however O 
, O 
the O 
results O 
were O 
reversed O 
under O 
high O 
salinity O 
( O 
100 O 
and O 
150mM O 
) O 
. O 
The O 
soluble O 
sugars B-FAMILY 
glucose B-TRIVIAL 
, O 
fructose B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
increased O 
after O 
treatment O 
with O 
moderate O 
salinity O 
, O 
whereas O 
glucose B-TRIVIAL 
and O 
fructose B-TRIVIAL 
declined O 
under O 
high O 
salinity O 
. O 
For O 
the O 
six O 
organic O 
acids O 
tested O 
, O 
their O 
total O 
levels O 
were O 
elevated O 
by O 
salinity O 
, O 
which O 
increased O 
the O 
production O 
of O 
tartaric B-MULTIPLE 
and I-MULTIPLE 
malic I-MULTIPLE 
acids I-MULTIPLE 
. O 
The O 
aroma O 
of O 
the O 
berry O 
was O 
extremely O 
sensitive O 
to O 
salinity O 
and O 
showed O 
a O 
considerable O 
decline O 
in O 
abundance O 
and O 
variety O 
at O 
20mM O 
NaCl B-FORMULA 
. O 
In O 
summary O 
, O 
moderate O 
salinity O 
enhanced O 
the O 
overall O 
berry O 
quality O 
, O 
but O 
decreased O 
the O 
aroma O 
quality O 
, O 
whereas O 
high O 
salinity O 
decreased O 
the O 
berry O 
quality O 
. O 

impact O 
of O 
Ca(2+) B-FORMULA 
combination O 
with O 
organic O 
acids O 
on O 
green O 
tea O 
infusions O 
. O 

effect O 
of O 
Ca(2+) B-FORMULA 
in O 
brewing O 
water O 
on O 
the O 
organic O 
acid O 
content O 
, O 
turbidity O 
, O 
and O 
formation O 
of O 
tea O 
cream O 
and O 
sediment O 
in O 
green O 
tea O 
infusions O 
was O 
studied O 
. O 
When O 
the O 
Ca(2+) B-FORMULA 
concentration O 
of O 
the O 
brewing O 
water O 
was O 
> O 
40mgL(-1) O 
, O 
the O 
green O 
tea O 
infusion O 
became O 
more O 
turbid O 
. O 
The O 
turbidity O 
of O 
the O 
tea O 
infusion O 
was O 
highly O 
negatively O 
correlated O 
with O 
the O 
contents O 
of O 
oxalic B-TRIVIAL 
acid I-TRIVIAL 
( O 
R=-0.89 O 
, O 
p O 
< O 
0.01 O 
) O 
, O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
( O 
R=-0.90 O 
, O 
p O 
< O 
0.01 O 
) O 
and O 
tartaric B-TRIVIAL 
acid I-TRIVIAL 
( O 
R=-0.82 O 
, O 
p O 
< O 
0.01 O 
) O 
. O 
Oxalic B-TRIVIAL 
acid I-TRIVIAL 
on O 
its O 
own O 
interacted O 
with O 
Ca(2+) B-FORMULA 
at O 
low O 
concentrations O 
, O 
whereas O 
polyphenols B-FAMILY 
and O 
protein O 
did O 
not O 
. O 
In O 
conclusion O 
, O 
Ca(2+) B-FORMULA 
in O 
brewing O 
water O 
influences O 
the O 
quality O 
of O 
a O 
tea O 
infusion O 
by O 
inducing O 
tea O 
cream O 
and O 
sediment O 
formation O 
from O 
combination O 
of O 
Ca(2+) B-FORMULA 
and O 
organic O 
acids O 
, O 
such O 
as O 
oxalic B-TRIVIAL 
acid I-TRIVIAL 
, O 
quinic B-TRIVIAL 
acid I-TRIVIAL 
and O 
tartaric B-TRIVIAL 
acid I-TRIVIAL 
. O 
Ca(2+) B-FORMULA 
and O 
oxalate B-SYSTEMATIC 
are O 
the O 
main O 
metal O 
ion O 
and O 
anion O 
, O 
respectively O 
, O 
involved O 
in O 
tea O 
cream O 
and O 
sediment O 
formation O 
on O 
tea O 
infusion O 
cooling O 
or O 
concentrating O 
. O 

of O 
electrochemical O 
biosensor O 
with O 
nano O 
- O 
interface O 
for O 
xanthine B-TRIVIAL 
sensing O 
- O 
A O 
novel O 
approach O 
for O 
fish O 
freshness O 
estimation O 
. O 

sensitive O 
, O 
selective O 
and O 
mediator O 
- O 
free O 
electrochemical O 
biosensor O 
with O 
nano O 
- O 
interface O 
for O 
sensing O 
xanthine B-TRIVIAL 
using O 
xanthine B-TRIVIAL 
oxidase O 
( O 
XOx O 
) O 
has O 
been O 
developed O 
. O 
Towards O 
the O 
preparation O 
of O 
nano O 
- O 
interface O 
, O 
Fe3O4 B-FORMULA 
nanoparticles O 
were O 
synthesized O 
by O 
thermal O 
co O 
- O 
precipitation O 
method O 
and O 
structural O 
, O 
morphological O 
characterizations O 
were O 
carried O 
out O 
using O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
field O 
emission O 
scanning O 
electron O 
microscope O 
( O 
FE-SEM O 
) O 
and O 
field O 
emission O 
transmission O 
electron O 
microscope O 
( O 
FE-TEM O 
) O 
respectively O 
. O 
The O 
modified O 
electrode O 
with O 
the O 
covalently O 
linked O 
XOx O 
was O 
confirmed O 
by O 
FT-IR O 
. O 
With O 
the O 
modified O 
electrode O 
as O 
working O 
electrode O 
, O 
electrochemical O 
studies O 
were O 
carried O 
out O 
. O 
The O 
linear O 
range O 
was O 
found O 
to O 
be O 
from O 
0.4 O 
to O 
2.4nM O 
. O 
The O 
biosensor O 
exhibited O 
an O 
optimum O 
response O 
in O 
less O 
than O 
2s O 
and O 
was O 
not O 
prone O 
to O 
interferences O 
from O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
urea B-TRIVIAL 
and O 
sucrose B-TRIVIAL 
. O 
The O 
Michaelis-Menten O 
constant O 
( O 
Km O 
) O 
was O 
found O 
to O 
be O 
1.3nM O 
. O 
The O 
limit O 
of O 
detection O 
is O 
found O 
to O 
be O 
2.5pM O 
and O 
limit O 
of O 
quantification O 
as O 
8.3pM O 
. O 
The O 
developed O 
biosensor O 
was O 
used O 
for O 
the O 
real O 
time O 
measurement O 
of O 
fish O 
freshness O 
. O 

conditions O 
effects O 
on O 
kefiran O 
production O 
by O 
the O 
mixed O 
culture O 
of O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
bacteria O 
imbedded O 
within O 
kefir O 
grains O 
. O 

influence O 
of O 
fermentation O 
temperature O 
, O 
agitation O 
rate O 
, O 
and O 
additions O 
of O 
carbon B-SYSTEMATIC 
sources O 
, O 
nitrogen B-SYSTEMATIC 
sources O 
, O 
vitamins O 
and O 
minerals O 
on O 
production O 
of O 
kefiran O 
by O 
kefir O 
grains O 
lactic B-TRIVIAL 
acid I-TRIVIAL 
bacteria O 
was O 
studied O 
in O 
a O 
series O 
of O 
experiments O 
. O 
The O 
main O 
aim O 
of O 
the O 
work O 
was O 
to O 
increase O 
the O 
exopolysaccharide O 
( O 
EPS O 
) O 
production O 
where O 
customised O 
milk O 
was O 
used O 
as O 
fermentation O 
medium O 
. O 
It O 
was O 
proved O 
that O 
the O 
controlling O 
of O 
culturing O 
conditions O 
and O 
the O 
modifying O 
of O 
fermentation O 
medium O 
conditions O 
( O 
i.e O 
. O 
, O 
carbon B-SYSTEMATIC 
, O 
nitrogen B-SYSTEMATIC 
, O 
mineral O 
sources O 
and O 
vitamins O 
) O 
can O 
dramatically O 
enhance O 
the O 
production O 
of O 
the O 
EPS O 
. O 
The O 
temperature O 
and O 
agitation O 
rate O 
were O 
critical O 
for O 
kefiran O 
production O 
during O 
the O 
24h O 
cultivation O 
of O 
grains O 
; O 
our O 
optimised O 
conditions O 
being O 
25°C O 
and O 
80rpm O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
when O 
optimising O 
the O 
effects O 
of O 
additional O 
nutrition O 
, O 
it O 
was O 
found O 
that O 
5% O 
( O 
w O 
/ O 
v O 
) O 
lactose B-TRIVIAL 
, O 
0.1% O 
( O 
w O 
/ O 
v O 
) O 
thiamine B-TRIVIAL 
, O 
and O 
0.1% O 
( O 
w O 
/ O 
v O 
) O 
FeCl3 B-FORMULA 
led O 
to O 
the O 
maximal O 
production O 
of O 
EPS O 
. O 
The O 
results O 
indicate O 
that O 
nutrients O 
can O 
be O 
utilised O 
to O 
improve O 
the O 
production O 
of O 
EPS O 
and O 
that O 
good O 
kefir O 
grains O 
growth O 
does O 
not O 
appear O 
to O 
be O 
a O 
determining O 
factor O 
for O 
a O 
high O 
production O 
yield O 
of O 
EPS O 
. O 

micellar O 
improved O 
method O 
for O 
trace O 
levels O 
selenium B-SYSTEMATIC 
quantification O 
in O 
food O 
samples O 
, O 
alcoholic O 
and O 
nonalcoholic O 
beverages O 
through O 
CPE O 
/ O 
FAAS O 
. O 

useful O 
preconcentration O 
and O 
determination O 
method O 
was O 
proposed O 
for O 
trace O 
selenium B-SYSTEMATIC 
in O 
food O 
samples O 
. O 
The O 
procedure O 
is O 
based O 
on O 
complex O 
formation O 
of O 
Pyronine B-TRIVIAL 
B I-TRIVIAL 
with O 
Se B-FORMULA 
(IV) I-FORMULA 
ions O 
in O 
the O 
presence O 
of O 
sodium B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
sulphate I-SYSTEMATIC 
( O 
SDS B-ABBREVIATION 
) O 
and O 
Ponpe O 
7.5 O 
. O 
The O 
variables O 
affecting O 
complex O 
formation O 
, O 
extraction O 
and O 
phase O 
separation O 
were O 
studied O 
and O 
optimised O 
. O 
Under O 
the O 
experimental O 
conditions O 
used O 
, O 
the O 
calibration O 
graph O 
was O 
linear O 
in O 
the O 
range O 
of O 
20-1700μgL(-1) O 
for O 
Se B-FORMULA 
(IV) I-FORMULA 
ions O 
. O 
The O 
limit O 
of O 
detection O 
was O 
3.81μgL(-1) O 
of O 
Se B-FORMULA 
(IV) I-FORMULA 
and O 
the O 
relative O 
standard O 
deviation O 
for O 
5 O 
replicate O 
determinations O 
at O 
250μgL(-1)concentration O 
level O 
was O 
2.45% O 
. O 
Recovery O 
values O 
were O 
obtained O 
between O 
97.8% O 
and O 
102.8% O 
for O 
spiked O 
samples O 
. O 
The O 
method O 
was O 
successfully O 
applied O 
to O 
the O 
determination O 
of O 
total O 
selenium B-SYSTEMATIC 
in O 
some O 
food O 
samples O 
and O 
alcoholic O 
and O 
nonalcoholic O 
beverages O 
. O 
Its O 
validity O 
was O 
checked O 
by O 
the O 
analysis O 
of O 
four O 
certified O 
reference O 
materials O 
. O 
The O 
results O 
obtained O 
by O 
the O 
proposed O 
method O 
were O 
quantitatively O 
in O 
good O 
agreement O 
with O 
the O 
certified O 
values O 
. O 

on O 
lees O 
involves O 
ageing O 
the O 
wine O 
in O 
contact O 
with O 
yeast O 
cells O 
after O 
fermentation O 
. O 
If O 
combined O 
with O 
the O 
addition O 
of O 
oak O 
chips O 
, O 
it O 
can O 
soften O 
the O 
wood O 
flavour O 
and O 
increase O 
the O 
aromatic O 
complexity O 
of O 
wine O 
. O 
The O 
aim O 
of O 
the O 
present O 
work O 
is O 
to O 
optimise O 
both O 
ageing O 
techniques O 
through O 
selection O 
of O 
an O 
adequate O 
Saccharomyces O 
cerevisiae O 
strain O 
. O 
The O 
study O 
lasted O 
6months O 
and O 
content O 
of O 
polysaccharides O 
, O 
anthocyanins B-FAMILY 
, O 
proanthocyanidins B-FAMILY 
, O 
volatile O 
compounds O 
, O 
colour O 
parameters O 
and O 
sensory O 
analysis O 
, O 
were O 
periodically O 
evaluated O 
. O 
Among O 
the O 
strains O 
tested O 
, O 
G37 O 
showed O 
the O 
highest O 
release O 
of O 
polysaccharides O 
(24.4±5.5mgl(-1)) O 
. O 
Vanillin B-TRIVIAL 
, O 
syringaldehyde B-TRIVIAL 
and O 
furfuryl B-TRIVIAL 
alcohol I-TRIVIAL 
increased O 
with O 
ageing O 
time O 
in O 
7VA2 O 
treatment O 
. O 
The O 
wine O 
aged O 
with O 
CTPL14 O 
strain O 
presented O 
fewer O 
monomeric O 
and O 
oligomeric O 
proanthocyanidins B-FAMILY 
( O 
12.4±0.6 O 
and O 
83.4±8.3mgl(-1) O 
, O 
respectively O 
) O 
, O 
and O 
showed O 
the O 
lowest O 
astringency O 
and O 
bitterness O 
sensations O 
. O 
Results O 
show O 
an O 
improvement O 
in O 
the O 
sensory O 
profile O 
of O 
the O 
red O 
wine O 
aged O 
with O 
a O 
combination O 
of O 
these O 
two O 
techniques O 
. O 

of O 
( B-SYSTEMATIC 
dihydro I-SYSTEMATIC 
) I-SYSTEMATIC 
hydroxycinnamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
conjugates O 
in O 
Colombian O 
potato O 
tubers O 
. O 

potato O 
tuber O 
, O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
the O 
predominant O 
hydroxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
HCA B-ABBREVIATION 
) O 
) O 
, O 
its O 
conjugates O 
( O 
HCAcs O 
; O 
i.e O 
. O 
chlorogenic B-TRIVIAL 
acid I-TRIVIAL 
( O 
ChA B-ABBREVIATION 
) O 
, O 
crypto-ChA B-TRIVIAL 
, O 
and O 
neo-ChA B-TRIVIAL 
) O 
, O 
and O 
anthocyanin B-FAMILY 
-linked O 
HCAs B-ABBREVIATION 
have O 
been O 
extensively O 
described O 
in O 
the O 
literature O 
. O 
In O 
contrast O 
, O 
only O 
little O 
information O 
is O 
available O 
on O 
the O 
occurrence O 
of O 
other O 
HCAcs O 
and O 
didydrohydroxycinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
conjugates O 
( O 
DHCAcs O 
) O 
. O 
Fifteen O 
Colombian O 
potato O 
cultivars O 
were O 
screened O 
for O 
these O 
less O 
commonly O 
described O 
conjugates O 
by O 
reversed O 
- O 
phase O 
ultrahigh O 
performance O 
liquid O 
chromatography O 
coupled O 
to O 
a O 
diode O 
array O 
detector O 
and O 
a O 
heated O 
electrospray O 
ionisation O 
mass O 
spectrometer O 
. O 
A O 
total O 
of O 
62 O 
HCAs B-ABBREVIATION 
/ O 
HCAcs O 
/ O 
DHCAcs O 
were O 
found O 
in O 
extracts O 
from O 
peel O 
and O 
flesh O 
. O 
Among O 
them O 
, O 
only O 
twelve O 
compounds O 
were O 
common O 
to O 
all O 
cultivars O 
in O 
both O 
peel O 
and O 
flesh O 
. O 
The O 
less O 
commonly O 
described O 
compounds O 
accounted O 
for O 
7.1-20.1% O 
w O 
/ O 
w O 
of O 
the O 
total O 
amount O 
of O 
HCAs B-ABBREVIATION 
/ O 
HCAcs O 
/ O 
DHCAcs O 
in O 
whole O 
tubers O 
, O 
highlighting O 
their O 
contribution O 
to O 
the O 
total O 
phenolic O 
profile O 
of O 
potato O 
tubers O 
. O 
Among O 
all O 
cultivars O 
, O 
the O 
abundance O 
( O 
mg O 
/ O 
100g O 
DW O 
whole O 
tuber O 
) O 
of O 
neo-ChA B-TRIVIAL 
( O 
0.8-7.4 O 
) O 
ranged O 
in O 
similar O 
quantities O 
as O 
the O 
less O 
commonly O 
reported O 
feruloyl B-TRIVIAL 
octopamine I-TRIVIAL 
( O 
1.2-5.2 O 
) O 
, O 
5-O-feruloyl B-SYSTEMATIC 
quinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
0.1-7.5 O 
) O 
, O 
cis-ChA B-TRIVIAL 
( O 
1.1-2.2 O 
) O 
, O 
caffeoyl B-TRIVIAL 
putrescine I-TRIVIAL 
( O 
0.6-2.5 O 
) O 
, O 
sinapoyl B-FAMILY 
hexose I-FAMILY 
( O 
0.1-1.8 O 
) O 
, O 
N(1),N(14)-bis-(dihydrocaffeoyl) B-SYSTEMATIC 
spermine I-SYSTEMATIC 
( O 
0.2-1.7 O 
) O 
, O 
N(1),N(10)-bis-(dihydrocaffeoyl) B-SYSTEMATIC 
spermidine I-SYSTEMATIC 
( O 
1.1-2.6 O 
) O 
, O 
and O 
N(1),N(5),N(14)-tris-(dihydrocaffeoyl) B-SYSTEMATIC 
spermine I-SYSTEMATIC 
( O 
trace O 
- O 
11.1 O 
) O 
. O 

and O 
purification O 
of O 
the O 
antioxidant O 
compounds O 
, O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
and O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
from O 
mushrooms O 
by O 
molecularly O 
imprinted O 
polymer O 
. O 

acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
CAPE B-ABBREVIATION 
) O 
and O 
caffeic B-TRIVIAL 
acid I-TRIVIAL 
( O 
CA O 
) O 
, O 
two O 
naturally O 
occurring O 
phenolic O 
antioxidants O 
, O 
have O 
been O 
reported O 
to O 
have O 
a O 
diversity O 
of O 
biological O 
activities O 
. O 
In O 
this O 
investigation O 
, O 
a O 
novel O 
approach O 
to O 
separate O 
and O 
enrich O 
CAPE B-ABBREVIATION 
and O 
CA O 
from O 
25 O 
species O 
of O 
mushrooms O 
using O 
molecularly O 
imprinted O 
polymers O 
( O 
MIPs O 
) O 
as O 
the O 
sorbent O 
material O 
is O 
reported O 
. O 
The O 
MIPs O 
were O 
synthesized O 
using O 
CAPE B-ABBREVIATION 
as O 
the O 
template O 
, O 
and O 
its O 
adsorption O 
behavior O 
was O 
investigated O 
in O 
detail O 
. O 
In O 
comparison O 
with O 
C18-solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
, O 
MIP-SPE O 
displayed O 
high O 
selectivity O 
and O 
good O 
affinity O 
for O 
CAPE B-ABBREVIATION 
and O 
CA O 
. O 
The O 
antioxidant O 
potential O 
of O 
the O 
mushroom O 
extracts O 
, O 
before O 
and O 
after O 
preconcentration O 
using O 
MIPs O 
, O 
was O 
assayed O 
by O 
inhibition O 
of O 
erythrocyte O 
hemolysis O 
and O 
lipid O 
peroxidation O 
. O 
Application O 
of O 
MIPs O 
with O 
a O 
high O 
affinity O 
toward O 
CAPE B-ABBREVIATION 
and O 
CA O 
provides O 
a O 
novel O 
method O 
for O 
obtaining O 
active O 
compounds O 
from O 
natural O 
products O 
. O 

- O 
grade O 
inflammation O 
in O 
fat O 
is O 
associated O 
with O 
insulin O 
resistance O 
, O 
although O 
the O 
mechanisms O 
are O 
unclear O 
. O 
We O 
report O 
that O 
mice O 
deficient O 
in O 
the O 
immune O 
cell O 
transcription O 
factor O 
T-bet O 
have O 
lower O 
energy O 
expenditure O 
and O 
increased O 
visceral O 
fat O 
compared O 
with O 
wild O 
- O 
type O 
mice O 
, O 
yet O 
paradoxically O 
are O 
more O 
insulin O 
sensitive O 
. O 
This O 
striking O 
phenotype O 
, O 
present O 
in O 
young O 
T-bet(- O 
/ O 
- O 
) O 
mice O 
, O 
persisted O 
with O 
high O 
- O 
fat O 
diet O 
and O 
increasing O 
host O 
age O 
and O 
was O 
associated O 
with O 
altered O 
immune O 
cell O 
numbers O 
and O 
cytokine O 
secretion O 
specifically O 
in O 
visceral O 
adipose O 
tissue O 
. O 
However O 
, O 
the O 
favorable O 
metabolic O 
phenotype O 
observed O 
in O 
T-bet O 
- O 
deficient O 
hosts O 
was O 
lost O 
in O 
T-bet(- O 
/ O 
- O 
) O 
mice O 
also O 
lacking O 
adaptive O 
immunity O 
( O 
T-bet(- O 
/ O 
-)xRag2(- O 
/ O 
- O 
) O 
) O 
, O 
demonstrating O 
that O 
T-bet O 
expression O 
in O 
the O 
adaptive O 
rather O 
than O 
the O 
innate O 
immune O 
system O 
impacts O 
host O 
glucose B-TRIVIAL 
homeostasis O 
. O 
Indeed O 
, O 
adoptive O 
transfer O 
of O 
T-bet O 
- O 
deficient O 
, O 
but O 
not O 
wild O 
- O 
type O 
, O 
CD4(+) O 
T O 
cells O 
to O 
Rag2(- O 
/ O 
- O 
) O 
mice O 
improved O 
insulin O 
sensitivity O 
. O 
Our O 
results O 
reveal O 
a O 
role O 
for O 
T-bet O 
in O 
metabolic O 
physiology O 
and O 
obesity O 
- O 
associated O 
insulin O 
resistance O 
. O 

protein O 
analysis O 
using O 
(13)C7 B-FORMULA 
-labeled O 
iodoacetanilide B-SYSTEMATIC 
and O 
d5 B-FORMULA 
-labeled O 
N-ethylmaleimide B-SYSTEMATIC 
by O 
nano O 
liquid O 
chromatography O 
/ O 
nanoelectrospray O 
ionization O 
ion O 
trap O 
mass O 
spectrometry O 
. O 

have O 
developed O 
a O 
methodology O 
for O 
quantitative O 
analysis O 
and O 
concurrent O 
identification O 
of O 
proteins O 
by O 
the O 
modification O 
of O 
cysteine B-TRIVIAL 
residues O 
with O 
a O 
combination O 
of O 
iodoacetanilide B-SYSTEMATIC 
( O 
IAA B-ABBREVIATION 
, O 
1 O 
) O 
and O 
(13)C7 B-FORMULA 
-labeled O 
iodoacetanilide B-SYSTEMATIC 
( O 
(13)C7 B-FORMULA 
- O 
IAA B-ABBREVIATION 
, O 
2 O 
) O 
, O 
or O 
N-ethylmaleimide B-SYSTEMATIC 
( O 
NEM B-ABBREVIATION 
, O 
3 O 
) O 
and O 
d5 B-FORMULA 
-labeled O 
N-ethylmaleimide B-SYSTEMATIC 
( O 
d5 B-FORMULA 
- O 
NEM B-ABBREVIATION 
, O 
4 O 
) O 
, O 
followed O 
by O 
mass O 
spectrometric O 
analysis O 
using O 
nano O 
liquid O 
chromatography O 
/ O 
nanoelectrospray O 
ionization O 
ion O 
trap O 
mass O 
spectrometry O 
( O 
nano O 
LC O 
/ O 
nano-ESI-IT-MS O 
) O 
. O 
The O 
combinations O 
of O 
these O 
stable O 
isotope O 
- O 
labeled O 
and O 
unlabeled O 
modifiers O 
coupled O 
with O 
LC O 
separation O 
and O 
ESI O 
mass O 
spectrometric O 
analysis O 
allow O 
accurate O 
quantitative O 
analysis O 
and O 
identification O 
of O 
proteins O 
, O 
and O 
therefore O 
are O 
expected O 
to O 
be O 
a O 
useful O 
tool O 
for O 
proteomics O 
research O 
. O 

have O 
previously O 
identified O 
Heminecrolysin O 
, O 
a O 
sphingomyelinase O 
D O 
( O 
SMaseD O 
) O 
, O 
as O 
the O 
major O 
protein O 
responsible O 
for O 
the O 
main O 
pathological O 
effects O 
observed O 
following O 
Hemiscorpius O 
( O 
H O 
. O 
) O 
lepturus O 
scorpion O 
envenomation O 
. O 
We O 
aimed O 
herein O 
to O 
further O 
investigate O 
the O 
kinetics O 
and O 
molecular O 
mechanisms O 
triggered O 
by O 
Heminecrolysin O 
to O 
initiate O 
hematological O 
disorders O 
and O 
inflammatory O 
reaction O 
. O 
We O 
show O 
that O 
Heminecrolysin O 
highly O 
hydrolyzes O 
lysophosphatidylcholine B-FAMILY 
( O 
LPC B-ABBREVIATION 
) O 
into O 
lysophosphatidic B-TRIVIAL 
acid I-TRIVIAL 
( O 
LPA B-ABBREVIATION 
) O 
and O 
choline B-FAMILY 
, O 
with O 
a O 
Vmax O 
= O 
1481 O 
± O 
51 O 
μmol O 
/ O 
min O 
/ O 
mg O 
and O 
a O 
Km O 
= O 
97 O 
± O 
16.78 O 
μM O 
, O 
at O 
a O 
much O 
lesser O 
extend O 
sphingomyelin B-FAMILY 
but O 
not O 
phosphatidylcholine B-FAMILY 
substrates O 
. O 
Its O 
lysophospholipase O 
D O 
( O 
lysoPLD O 
) O 
catalytic O 
efficiency O 
, O 
up O 
to O 
three O 
orders O 
of O 
magnitude O 
higher O 
, O 
comparatively O 
to O 
spider's O 
SMaseDs O 
( O 
newly O 
referred O 
as O 
phospholipases O 
D O 
; O 
PLDs O 
) O 
, O 
could O 
explain O 
its O 
strong O 
hemolytic O 
capacity O 
. O 
Chelating O 
agents O 
such O 
as O 
EDTA B-ABBREVIATION 
, O 
EGTA B-ABBREVIATION 
, O 
and O 
1 B-SYSTEMATIC 
, I-SYSTEMATIC 
10-phenantroline I-SYSTEMATIC 
blocked O 
Heminecrolysin O 
- O 
induced O 
LPC O 
hydrolysis O 
at O 
98 O 
, O 
48 O 
, O 
and O 
70% O 
respectively O 
. O 
Hemolysis O 
blockade O 
occurs O 
only O 
when O 
the O 
toxin O 
is O 
added O 
to O 
erythrocytes O 
in O 
the O 
presence O 
of O 
serum O 
, O 
source O 
of O 
LPC B-ABBREVIATION 
and O 
complement O 
, O 
indicating O 
that O 
the O 
production O 
of O 
LPA B-ABBREVIATION 
and O 
the O 
presence O 
of O 
complement O 
are O 
mandatory O 
for O 
hemolysis O 
. O 
Moreover O 
, O 
we O 
show O 
that O 
Heminecrolysin O 
efficiently O 
binds O 
to O 
erythrocyte's O 
membrane O 
and O 
provokes O 
phosphatidylserine B-FAMILY 
( O 
PS O 
) O 
translocation O 
without O 
cleavage O 
of O 
glycophorin O 
A O 
, O 
suggesting O 
that O 
, O 
unlike O 
spider's O 
PLDs O 
, O 
complement O 
was O 
activated O 
only O 
via O 
the O 
classical O 
pathway O 
. O 
Interestingly O 
, O 
Heminecrolysin O 
was O 
found O 
to O 
induce O 
PS O 
exposure O 
on O 
human O 
nucleated O 
Jurkat O 
T O 
cells O 
, O 
to O 
stimulate O 
secretion O 
of O 
the O 
pro O 
- O 
inflammatory O 
( O 
TNF-α O 
, O 
IL-6 O 
) O 
, O 
and O 
anti-inflammatory O 
( O 
IL-10 O 
) O 
cytokines O 
by O 
human O 
monocytes O 
, O 
and O 
to O 
provoke O 
a O 
disseminated O 
intravascular O 
coagulation O 
on O 
chick O 
embryo O 
chorioallantoic O 
membrane O 
model O 
system O 
. O 
Taken O 
together O 
, O 
our O 
results O 
indicate O 
that O 
Heminecrolysin O 
evokes O 
the O 
major O 
characteristic O 
clinical O 
features O 
of O 
H O 
. O 
lepturus O 
envenomation O 
by O 
using O 
mainly O 
its O 
lysoPLD O 
, O 
rather O 
than O 
its O 
SMaseD's O 
, O 
activity O 
. O 

- O 
activity O 
relationship O 
of O 
cytochrome O 
bc1 O 
reductase O 
inhibitor O 
broad O 
spectrum O 
antifungal O 
ilicicolin B-TRIVIAL 
H I-TRIVIAL 
. O 

H I-TRIVIAL 
is O 
a O 
broad O 
spectrum O 
antifungal O 
agent O 
showing O 
sub O 
micro O 
g O 
/ O 
mL O 
MICs O 
against O 
Candida O 
spp O 
. O 
, O 
Aspergillus O 
fumigatus O 
and O 
Cryptococcus O 
spp O 
. O 
It O 
is O 
a O 
potent O 
inhibitor O 
( O 
C50 O 
2-3ng O 
/ O 
mL O 
) O 
of O 
the O 
mitochondrial O 
cytochrome O 
bc1 O 
reductase O 
with O 
over O 
1000-fold O 
selectivity O 
against O 
rat O 
liver O 
cytochrome O 
bc1 O 
reductase O 
. O 
Structure O 
- O 
activity O 
relationship O 
of O 
semisynthetic O 
derivatives O 
by O 
chemical O 
modification O 
of O 
ilicicolin B-TRIVIAL 
H I-TRIVIAL 
and O 
its O 
19-hydroxy B-SYSTEMATIC 
derivative O 
produced O 
by O 
biotransformation O 
have O 
been O 
described O 
. O 
Basic O 
4'-esters B-SYSTEMATIC 
and O 
moderately O 
polar O 
N B-FORMULA 
- O 
and O 
O B-FORMULA 
-alkyl O 
derivatives O 
retained O 
antifungal O 
and O 
the O 
cytochrome O 
bc1 O 
reductase O 
activities O 
. O 
4',19-Diacetate B-SYSTEMATIC 
and O 
19-cyclopropyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
retained O 
antifungal O 
and O 
enzyme O 
activity O 
and O 
selectivity O 
with O 
over O 
20-fold O 
improvement O 
of O 
plasma O 
protein O 
binding O 
. O 

targeting O 
of O 
chitosan- O 
PEG B-ABBREVIATION 
- O 
folate B-TRIVIAL 
-complexed O 
oncolytic O 
adenovirus O 
for O 
active O 
and O 
systemic O 
cancer O 
gene O 
therapy O 
. O 

( O 
Ad O 
) O 
- O 
based O 
cancer O 
therapies O 
have O 
shown O 
much O 
promise O 
. O 
However O 
, O 
until O 
now O 
, O 
Ad O 
has O 
only O 
been O 
delivered O 
directly O 
to O 
primary O 
tumors O 
because O 
the O 
therapeutic O 
efficacy O 
of O 
systemic O 
delivery O 
is O 
limited O 
by O 
the O 
immune O 
response O 
of O 
the O 
host O 
, O 
short O 
blood O 
circulation O 
times O 
, O 
and O 
non-specific O 
liver O 
uptake O 
of O 
Ad O 
. O 
In O 
order O 
to O 
circumvent O 
the O 
issues O 
regarding O 
systemic O 
delivery O 
and O 
to O 
increase O 
the O 
safety O 
and O 
efficacy O 
of O 
Ad O 
therapies O 
, O 
the O 
surface O 
of O 
oncolytic O 
Ad O 
was O 
coated O 
with O 
cationic O 
polymer O 
chitosan O 
via O 
ionic O 
crosslinking O 
( O 
Ad O 
/ O 
chitosan O 
) O 
, O 
after O 
which O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
and O 
/ O 
or O 
folic B-TRIVIAL 
acid I-TRIVIAL 
( O 
FA O 
) O 
was O 
chemically O 
conjugated O 
onto O 
the O 
surface O 
of O 
Ad O 
/ O 
chitosan O 
, O 
generating O 
Ad O 
/ O 
chitosan-FA O 
, O 
Ad O 
/ O 
chitosan- O 
PEG B-ABBREVIATION 
, O 
and O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
nanocomplex O 
. O 
The O 
FA O 
- O 
coordinated O 
Ad O 
nanocomplexes O 
( O 
Ad O 
/ O 
chitosan-FA O 
& O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
) O 
elicited O 
folate B-TRIVIAL 
receptor O 
(FR)-selective O 
cancer O 
cell O 
killing O 
efficacy O 
. O 
In O 
vivo O 
administration O 
of O 
Ad O 
/ O 
chitosan- O 
PEG B-ABBREVIATION 
or O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
into O 
mice O 
demonstrated O 
that O 
PEGylation O 
greatly O 
increased O 
blood O 
circulation O 
time O 
, O 
resulting O 
in O 
9.0-fold O 
and O 
48.9-fold O 
increases O 
at O 
24h O 
after O 
injection O 
compared O 
with O 
naked O 
Ad O 
, O 
respectively O 
. O 
In O 
addition O 
, O 
generation O 
of O 
Ad-specific O 
neutralizing O 
antibodies O 
in O 
mice O 
treated O 
with O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
was O 
markedly O 
decreased O 
by O 
75.3% O 
compared O 
with O 
naked O 
Ad O 
. O 
The O 
quantitative O 
polymerase O 
chain O 
reaction O 
assay O 
results O 
showed O 
a O 
285.0-fold O 
increase O 
in O 
tumor O 
tissues O 
and O 
a O 
378-fold O 
reduction O 
of O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
in O 
liver O 
tissues O 
compared O 
with O 
naked O 
Ad O 
. O 
Bioluminescence O 
imaging O 
study O 
further O 
supported O 
the O 
enhanced O 
tumor O 
- O 
to O 
- O 
liver O 
ratio O 
of O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
. O 
Consequently O 
, O 
systemic O 
delivery O 
of O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
significantly O 
inhibited O 
the O 
growth O 
of O 
FR-positive O 
tumor O 
, O 
decreasing O 
52.8% O 
compared O 
to O 
the O 
naked O 
Ad O 
- O 
treated O 
group O 
. O 
Importantly O 
, O 
PEGylated O 
oncolytic O 
Ad O 
nanocomplexes O 
showed O 
no O 
elevation O 
of O 
both O 
alanine B-TRIVIAL 
transaminase O 
and O 
aspartate B-TRIVIAL 
transaminase O 
levels O 
, O 
demonstrating O 
that O 
systemically O 
delivered O 
Ad O 
- O 
related O 
hepatic O 
damage O 
can O 
be O 
completely O 
eliminated O 
with O 
PEG B-ABBREVIATION 
conjugation O 
. O 
In O 
sum O 
, O 
these O 
results O 
demonstrate O 
that O 
conjugation O 
of O 
chitosan- O 
PEG-FA B-ABBREVIATION 
to O 
oncolytic O 
Ad O 
significantly O 
improves O 
antitumor O 
efficacy O 
and O 
safety O 
profiles O 
, O 
suggesting O 
that O 
Ad O 
/ O 
chitosan- O 
PEG-FA B-ABBREVIATION 
has O 
potential O 
as O 
a O 
therapeutic O 
agent O 
to O 
target O 
FR-positive O 
cancer O 
via O 
systemic O 
administration O 
. O 

drug O 
therapy O 
is O 
a O 
novel O 
therapeutic O 
approach O 
for O 
primary O 
breast O 
cancers O 
, O 
particularly O 
those O 
involving O 
ductal O 
carcinoma O 
in O 
situ O 
lesions O 
. O 
Total O 
or O 
partial O 
mastectomy O 
with O 
or O 
without O 
radiotherapy O 
is O 
the O 
standard O 
local O 
therapy O 
for O 
primary O 
breast O 
cancer O 
. O 
Here O 
, O 
we O 
propose O 
a O 
novel O 
drug O 
administration O 
method O 
for O 
ductal O 
drug O 
therapy O 
based O 
on O 
a O 
drug O 
delivery O 
system O 
( O 
DDS O 
) O 
for O 
primary O 
breast O 
cancer O 
. O 
This O 
DDS O 
was O 
designed O 
to O 
deliver O 
miproxifen B-TRIVIAL 
phosphate I-TRIVIAL 
( O 
TAT-59 B-IDENTIFIER 
) O 
, O 
an O 
antiestrogen O 
drug O 
, O 
to O 
ductal O 
lesions O 
via O 
the O 
milk O 
duct O 
, O 
where O 
carcinomas O 
originate O 
, O 
more O 
efficiently O 
than O 
systemic O 
administration O 
, O 
using O 
an O 
iontophoretic O 
technique O 
applied O 
to O 
the O 
nipple O 
( O 
IP O 
administration O 
) O 
. O 
Autoradiography O 
imaging O 
confirmed O 
that O 
TAT-59 B-IDENTIFIER 
was O 
directly O 
delivered O 
to O 
the O 
milk O 
duct O 
using O 
IP O 
administration O 
. O 
The O 
plasma O 
concentrations O 
of O 
TAT-59 B-IDENTIFIER 
and O 
its O 
active O 
metabolite O 
DP-TAT-59 B-IDENTIFIER 
were O 
quite O 
low O 
with O 
IP O 
administration O 
. O 
The O 
area O 
under O 
the O 
curve O 
value O 
of O 
DP-TAT-59 B-IDENTIFIER 
in O 
the O 
mammary O 
tissue O 
was O 
approximately O 
3 O 
times O 
higher O 
with O 
IP O 
administration O 
than O 
with O 
oral O 
administration O 
, O 
at O 
a O 
6-fold O 
lower O 
dose O 
, O 
indicating O 
higher O 
availability O 
of O 
the O 
drug O 
delivered O 
via O 
DDS O 
than O 
via O 
systemic O 
administration O 
. O 
The O 
low O 
plasma O 
concentrations O 
would O 
limit O 
adverse O 
effects O 
to O 
minor O 
ones O 
. O 
These O 
characteristics O 
show O 
that O 
this O 
DDS O 
is O 
suitable O 
for O 
the O 
delivery O 
of O 
active O 
DP-TAT-59 B-IDENTIFIER 
to O 
ductal O 
lesions O 
. O 

and O 
combined O 
cytotoxic O 
effects O 
of O 
Fusarium O 
toxins O 
( O 
deoxynivalenol B-TRIVIAL 
, O 
nivalenol B-TRIVIAL 
, O 
zearalenone B-TRIVIAL 
and O 
fumonisins B-TRIVIAL 
B1 I-TRIVIAL 
) O 
on O 
swine O 
jejunal O 
epithelial O 
cells O 
. O 

mycotoxins O 
occur O 
worldwide O 
in O 
foods O 
such O 
as O 
cereals O 
and O 
animal O 
forages O 
, O 
leading O 
to O 
acute O 
and O 
chronic O 
exposures O 
in O 
human O 
and O 
animals O 
. O 
Intestinal O 
epithelial O 
cells O 
( O 
IECs O 
) O 
are O 
an O 
important O 
first O 
target O 
site O 
for O 
these O 
dietary O 
toxins O 
. O 
This O 
study O 
investigated O 
the O 
cytotoxicity O 
of O 
four O 
common O 
Fusarium O 
mycotoxins O 
, O 
deoxynivalenol B-TRIVIAL 
( O 
DON B-ABBREVIATION 
) O 
, O 
nivalenol B-TRIVIAL 
( O 
NIV B-ABBREVIATION 
) O 
, O 
zearalenone B-TRIVIAL 
( O 
ZEA B-ABBREVIATION 
) O 
and O 
fumonisin B-TRIVIAL 
B1 I-TRIVIAL 
( O 
FB1 B-ABBREVIATION 
) O 
on O 
a O 
normal O 
porcine O 
jejunal O 
epithelial O 
cell O 
line O 
, O 
IPEC-J2 O 
. O 
A O 
dose O 
response O 
relationship O 
between O 
individual O 
mycotoxins O 
and O 
cell O 
viability O 
( O 
MTT B-ABBREVIATION 
assay O 
) O 
was O 
initially O 
investigated O 
, O 
and O 
subsequently O 
cytotoxic O 
and O 
non-cytotoxic O 
concentrations O 
were O 
selected O 
to O 
investigate O 
combinations O 
of O 
two O 
, O 
three O 
and O 
all O 
four O 
of O 
the O 
mycotoxins O 
. O 
For O 
individual O 
mycotoxins O 
, O 
a O 
dose O 
response O 
was O 
observed O 
with O 
cell O 
viability O 
, O 
such O 
that O 
the O 
potency O 
ranking O 
was O 
NIV B-ABBREVIATION 
> O 
DON B-ABBREVIATION 
> O 
ZEA B-ABBREVIATION 
> O 
FB1 B-ABBREVIATION 
. O 
At O 
cytotoxic O 
doses O 
of O 
individual O 
mycotoxins O 
, O 
all O 
mixtures O 
gave O 
reduced O 
cell O 
viability O 
compared O 
to O 
control O 
. O 
At O 
noncytotoxic O 
concentrations O 
of O 
individual O 
mycotoxins O 
, O 
all O 
mixtures O 
were O 
cytotoxic O 
with O 
DON B-ABBREVIATION 
- O 
NIV B-ABBREVIATION 
, O 
DON B-ABBREVIATION 
- O 
ZEA B-ABBREVIATION 
, O 
DON B-ABBREVIATION 
- O 
NIV B-ABBREVIATION 
- O 
FB1 B-ABBREVIATION 
, O 
DON B-ABBREVIATION 
- O 
ZEA B-ABBREVIATION 
- O 
FB1 B-ABBREVIATION 
, O 
NIV B-ABBREVIATION 
- O 
ZEA B-ABBREVIATION 
- O 
FB1 B-ABBREVIATION 
and O 
all O 
four O 
mixed O 
causing O 
the O 
greatest O 
loss O 
of O 
cell O 
viability O 
. O 
The O 
latter O 
observation O 
in O 
particular O 
raises O 
concerns O 
over O 
safety O 
margins O 
based O 
on O 
single O 
toxin O 
species O 
, O 
and O 
suggests O 
that O 
the O 
effects O 
of O 
multiple O 
complex O 
mixtures O 
need O 
to O 
be O 
better O 
understood O 
to O 
assess O 
health O 
risks O 
. O 

isoenzymes O 
catalyze O 
the O 
generation O 
of O 
hazardous O 
aromatic B-FAMILY 
amines I-FAMILY 
after O 
reaction O 
with O 
the O 
azo B-SYSTEMATIC 
dye O 
Sudan B-TRIVIAL 
III I-TRIVIAL 
. O 

work O 
describes O 
the O 
mutagenic O 
response O 
of O 
Sudan B-TRIVIAL 
III I-TRIVIAL 
, O 
an O 
adulterant O 
food O 
dye O 
, O 
using O 
Salmonella O 
typhimurium O 
assay O 
and O 
the O 
generation O 
of O 
hazardous O 
aromatic B-FAMILY 
amines I-FAMILY 
after O 
different O 
oxidation O 
methods O 
of O 
this O 
azo B-SYSTEMATIC 
dye O 
. O 
For O 
that O 
, O 
we O 
used O 
metabolic O 
activation O 
by O 
S9 O 
, O 
catalytic O 
oxidation O 
by O 
ironporphyrin B-SYSTEMATIC 
and O 
electrochemistry O 
oxidation O 
in O 
order O 
to O 
simulate O 
endogenous O 
oxidation O 
conditions O 
. O 
The O 
oxidation O 
reactions O 
promoted O 
discoloration O 
from O 
65% O 
to O 
95% O 
of O 
Sudan B-TRIVIAL 
III I-TRIVIAL 
at O 
1×10(-4)molL(-1) O 
and O 
generation O 
of O 
7.6×10(-7)molL(-1) O 
to O 
0.31×10(-4)molL(-1) O 
of O 
aniline B-SYSTEMATIC 
, O 
o-anisidine B-TRIVIAL 
, O 
2-methoxi-5-methylaniline B-SYSTEMATIC 
, O 
4-aminobiphenyl B-SYSTEMATIC 
, O 
4,4'-oxydianiline B-SYSTEMATIC 
; O 
4,4'-diaminodiphenylmethane B-SYSTEMATIC 
and O 
2,6-dimethylaniline B-SYSTEMATIC 
. O 
The O 
results O 
were O 
confirmed O 
by O 
LC-MS-MS O 
experiments O 
. O 
We O 
also O 
correlate O 
the O 
mutagenic O 
effects O 
of O 
Sudan B-TRIVIAL 
III I-TRIVIAL 
using O 
S O 
. O 
typhimurium O 
with O 
the O 
strain O 
TA1535 O 
in O 
the O 
presence O 
of O 
exogenous O 
metabolic O 
activation O 
( O 
S9 O 
) O 
with O 
the O 
metabolization O 
products O 
of O 
this O 
compound O 
. O 
Our O 
findings O 
clearly O 
indicate O 
that O 
aromatic B-FAMILY 
amines I-FAMILY 
are O 
formed O 
due O 
to O 
oxidative O 
reactions O 
that O 
can O 
be O 
promoted O 
by O 
hepatic O 
cells O 
, O 
after O 
the O 
ingestion O 
of O 
Sudan B-TRIVIAL 
III I-TRIVIAL 
. O 
Considering O 
that O 
, O 
the O 
use O 
of O 
azo B-SYSTEMATIC 
compounds O 
as O 
food O 
dyestuffs O 
should O 
be O 
carefully O 
controlled O 
. O 

A I-TRIVIAL 
affects O 
androgen B-FAMILY 
receptor O 
function O 
via O 
multiple O 
mechanisms O 
. O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
, O 
is O 
a O 
well O 
- O 
known O 
endocrine O 
disruptor O 
compound O 
( O 
EDC O 
) O 
that O 
affects O 
the O 
normal O 
development O 
and O 
function O 
of O 
the O 
female O 
and O 
male O 
reproductive O 
system O 
, O 
however O 
the O 
mechanisms O 
of O 
action O 
remain O 
unclear O 
. O 
To O 
investigate O 
the O 
molecular O 
mechanisms O 
of O 
how O 
BPA B-ABBREVIATION 
may O 
affect O 
ten O 
different O 
nuclear O 
receptors O 
, O 
stable O 
cell O 
lines O 
containing O 
individual O 
nuclear O 
receptor O 
ligand O 
binding O 
domain O 
( O 
LBD O 
) O 
- O 
linked O 
to O 
the O 
β-Gal O 
reporter O 
were O 
examined O 
by O 
a O 
quantitative O 
high O 
throughput O 
screening O 
( O 
qHTS O 
) O 
format O 
in O 
the O 
Tox21 O 
Screening O 
Program O 
of O 
the O 
NIH O 
. O 
The O 
results O 
showed O 
that O 
two O 
receptors O 
, O 
estrogen B-FAMILY 
receptor O 
alpha O 
( O 
ERα O 
) O 
and O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
, O 
are O 
affected O 
by O 
BPA B-ABBREVIATION 
in O 
opposite O 
direction O 
. O 
To O 
confirm O 
the O 
observed O 
effects O 
of O 
BPA B-ABBREVIATION 
on O 
ERα O 
and O 
AR O 
, O 
we O 
performed O 
transient O 
transfection O 
experiments O 
with O 
full O 
- O 
length O 
receptors O 
and O 
their O 
corresponding O 
response O 
elements O 
linked O 
to O 
luciferase O 
reporters O 
. O 
We O 
also O 
included O 
in O 
this O 
study O 
two O 
BPA B-ABBREVIATION 
analogs O 
, O 
bisphenol B-TRIVIAL 
AF I-TRIVIAL 
( O 
BPAF B-ABBREVIATION 
) O 
and O 
bisphenol B-TRIVIAL 
S I-TRIVIAL 
( O 
BPS B-ABBREVIATION 
) O 
. O 
As O 
seen O 
in O 
African O 
green O 
monkey O 
kidney O 
CV1 O 
cells O 
, O 
the O 
present O 
study O 
confirmed O 
that O 
BPA B-ABBREVIATION 
and O 
BPAF B-ABBREVIATION 
act O 
as O 
ERα O 
agonists O 
( O 
half O 
maximal O 
effective O 
concentration O 
EC50 O 
of O 
10-100nM O 
) O 
and O 
as O 
AR O 
antagonists O 
( O 
half O 
maximal O 
inhibitory O 
concentration O 
IC50 O 
of O 
1-2μM O 
) O 
. O 
Both O 
BPA B-ABBREVIATION 
and O 
BPAF B-ABBREVIATION 
antagonized O 
AR O 
function O 
via O 
competitive O 
inhibition O 
of O 
the O 
action O 
of O 
synthetic O 
androgen B-FAMILY 
R1881 B-IDENTIFIER 
. O 
BPS B-ABBREVIATION 
with O 
lower O 
estrogenic O 
activity O 
( O 
EC50 O 
of O 
2.2μM O 
) O 
, O 
did O 
not O 
compete O 
with O 
R1881 B-IDENTIFIER 
for O 
AR O 
binding O 
, O 
when O 
tested O 
at O 
30μM O 
. O 
Finally O 
, O 
the O 
effects O 
of O 
BPA B-ABBREVIATION 
were O 
also O 
evaluated O 
in O 
a O 
nuclear O 
translocation O 
assays O 
using O 
EGPF-tagged O 
receptors O 
. O 
Similar O 
to O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
which O 
was O 
used O 
as O 
control O 
, O 
BPA B-ABBREVIATION 
was O 
able O 
to O 
enhance O 
ERα O 
nuclear O 
foci O 
formation O 
but O 
at O 
a O 
100-fold O 
higher O 
concentration O 
. O 
Although O 
BPA B-ABBREVIATION 
was O 
able O 
to O 
bind O 
AR O 
, O 
the O 
nuclear O 
translocation O 
was O 
reduced O 
. O 
Furthermore O 
, O 
BPA B-ABBREVIATION 
was O 
unable O 
to O 
induce O 
functional O 
foci O 
in O 
the O 
nuclei O 
and O 
is O 
consistent O 
with O 
the O 
transient O 
transfection O 
study O 
that O 
BPA B-ABBREVIATION 
is O 
unable O 
to O 
activate O 
AR O 
. O 

modulation O 
of O 
ZnO B-FORMULA 
microwire O 
optical O 
resonators O 
with O 
a O 
parallelogram O 
cross O 
- O 
section O 
. O 

novel O 
ZnO B-FORMULA 
microwire O 
optical O 
resonator O 
with O 
a O 
parallelogram O 
cross O 
- O 
section O 
is O 
fabricated O 
, O 
which O 
can O 
effectively O 
control O 
the O 
light O 
field O 
in O 
two O 
dimensions O 
. O 
Wave O 
- O 
guided O 
Fabry-Pérot O 
modes O 
with O 
different O 
polarizations O 
are O 
directly O 
observed O 
and O 
further O 
investigated O 
systematically O 
. O 
Such O 
a O 
ZnO B-FORMULA 
optical O 
resonator O 
offers O 
another O 
building O 
block O 
for O 
the O 
development O 
of O 
optoelectronic O 
devices O 
. O 

dynamics O 
in O 
liquid O 
and O 
glassy O 
states O 
of O 
non-steroidal O 
anti-inflammatory O 
drug O 
: O 
Ketoprofen B-TRIVIAL 
. O 

is O 
a O 
well O 
known O 
nonsteroidal O 
anti-inflammatory O 
drug O 
( O 
NSAID O 
) O 
with O 
analgesic O 
and O 
antipyretic O 
effects O 
. O 
It O 
acts O 
by O 
inhibiting O 
the O 
body's O 
production O 
of O 
prostaglandin B-FAMILY 
. O 
The O 
molecular O 
mobility O 
of O 
amorphous O 
ketoprofen B-TRIVIAL 
has O 
been O 
investigated O 
by O 
broadband O 
dielectric O 
spectroscopy O 
( O 
BDS O 
) O 
covering O 
wide O 
temperature O 
and O 
frequency O 
range O 
. O 
Multiple O 
relaxation O 
processes O 
were O 
observed O 
. O 
Besides O 
the O 
primary O 
α-relaxation O 
, O 
one O 
secondary O 
relaxation O 
, O 
γ-have O 
been O 
identified O 
. O 
The O 
γ-process O 
visible O 
in O 
the O 
dielectric O 
spectra O 
at O 
very O 
low O 
temperature O 
is O 
non-JG O 
relaxation O 
, O 
and O 
has O 
an O 
activation O 
energy O 
E=37.91kJ O 
/ O 
mol O 
typical O 
for O 
local O 
mobility O 
. O 
Based O 
on O 
Ngai's O 
coupling O 
model O 
smaller O 
n O 
or O 
a O 
larger O 
Kohlrausch O 
exponent O 
( O 
1-n O 
) O 
of O 
the O 
α-relaxation O 
associated O 
with O 
larger O 
τβ O 
( O 
Tg O 
) O 
. O 
In O 
the O 
case O 
of O 
ketoprofen B-TRIVIAL 
we O 
conclude O 
that O 
the O 
secondary O 
relaxation O 
( O 
β O 
) O 
emerging O 
from O 
intermolecular O 
motions O 
, O 
is O 
hidden O 
under O 
the O 
dominant O 
α-peak O 
. O 
The O 
temperature O 
dependence O 
of O 
the O 
relaxation O 
time O 
of O 
the O 
α-process O 
can O 
be O 
described O 
over O 
the O 
entire O 
measured O 
range O 
by O 
a O 
single O 
Vogel-Fulcher-Tammann O 
( O 
VFT O 
) O 
equation O 
. O 
From O 
VFT O 
fits O 
, O 
the O 
glass O 
transition O 
temperature O 
( O 
Tg O 
) O 
was O 
estimated O 
as O 
267.07K O 
, O 
and O 
a O 
fragility O 
or O 
steepness O 
index O 
m=86.57 O 
was O 
calculated O 
, O 
showing O 
that O 
ketoprofen B-TRIVIAL 
is O 
a O 
fragile O 
glass O 
former O 
. O 
Our O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
study O 
shows O 
that O 
ketoprofen B-TRIVIAL 
is O 
a O 
non-crystallizing O 
compound O 
. O 
To O 
confirm O 
the O 
hydrogen O 
bond O 
patterns O 
of O 
ketoprofen B-TRIVIAL 
FTIR O 
spectroscopy O 
was O 
applied O 
in O 
both O 
crystalline O 
and O 
amorphous O 
phases O 
. O 
Solubility O 
test O 
performed O 
at O 
37°C O 
proved O 
that O 
amorphous O 
phase O 
is O 
more O 
soluble O 
than O 
the O 
crystalline O 
phase O 
. O 

SIGNIFICANCE O 
: O 
Eremophila O 
longifolia O 
is O 
one O 
of O 
the O 
most O 
respected O 
of O 
the O 
traditional O 
medicines O 
used O 
by O 
Australian O 
Aboriginal O 
people O 
. O 
Customary O 
use O 
involves O 
smoldering O 
the O 
leaves O 
over O 
hot O 
embers O 
of O 
a O 
fire O 
to O 
produce O 
an O 
acrid O 
smoke O 
, O 
believed O 
to O 
have O 
therapeutic O 
effects O 
broadly O 
consistent O 
with O 
antimicrobial O 
, O 
antifungal O 
and O 
anti-inflammatory O 
capacity O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
current O 
study O 
aims O 
to O 
examine O 
the O 
contribution O 
of O 
partially O 
pyrolysed O 
and O 
non-pyrolysed O 
essential O 
oils O 
in O 
traditional O 
usage O 
of O 
Eremophila O 
longifolia O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Non-pyrolysed O 
and O 
partially O 
pyrolysed O 
essential O 
oils O 
were O 
produced O 
by O 
hydrodistillation O 
and O 
part O 
- O 
wet O 
/ O 
part O 
- O 
dry O 
distillation O 
, O 
respectively O 
. O 
All O 
samples O 
were O 
tested O 
for O 
antimicrobial O 
activity O 
by O 
broth O 
dilution O 
. O 
Some O 
of O 
these O 
samples O 
were O 
further O 
treated O 
to O 
an O 
incrementally O 
stepped O 
temperature O 
profile O 
in O 
a O 
novel O 
procedure O 
employing O 
a O 
commercial O 
thermocycler O 
in O 
an O 
attempt O 
to O 
mimic O 
the O 
effect O 
of O 
temperature O 
gradients O 
produced O 
during O 
smoking O 
ceremonies O 
. O 
Components O 
from O 
the O 
pyrodistilled O 
oils O 
were O 
compared O 
with O 
the O 
non-pyrodistilled O 
oils O 
, O 
using O 
GC-MS O 
, O 
GC-FID O 
and O 
HPLC-PAD O 
. O 
The O 
2,2-diphenyl-1-picrylhydrazyl B-SYSTEMATIC 
method O 
, O 
was O 
used O 
to O 
compare O 
free O 
radical O 
scavenging O 
ability O 
. O 
RESULTS O 
: O 
Partially O 
pyrolysed O 
oils O 
had O 
approximately O 
three O 
or O 
more O 
times O 
greater O 
antimicrobial O 
activity O 
, O 
enhanced O 
in O 
cultures O 
warmed O 
incrementally O 
to O 
60°C O 
and O 
held O 
for O 
30s O 
and O 
further O 
enhanced O 
if O 
held O 
for O 
2min O 
. O 
Partially O 
pyrolysed O 
oils O 
showed O 
a O 
radical O 
scavenging O 
capacity O 
30-700 O 
times O 
greater O 
than O 
the O 
corresponding O 
non-pyrolysed O 
oils O 
. O 
HPLC-PAD O 
revealed O 
the O 
presence O 
of O 
additional O 
constituents O 
not O 
present O 
in O 
the O 
fresh O 
essential O 
oil O 
. O 
CONCLUSION O 
: O 
These O 
results O 
, O 
by O 
showing O 
enhanced O 
antimicrobial O 
and O 
antioxidant O 
activities O 
, O 
provide O 
the O 
first O 
known O 
Western O 
scientific O 
justification O 
for O 
the O 
smoking O 
ceremonies O 
involving O 
leaves O 
of O 
Eremophila O 
longifolia O 
. O 
During O 
customary O 
use O 
, O 
both O 
partially O 
pyrolysed O 
as O 
well O 
as O 
non-pyrolysed O 
essential O 
oils O 
may O 
contribute O 
significantly O 
to O 
the O 
overall O 
intended O 
medicinal O 
effect O 
. O 

between O 
activation O 
of O 
PPARγ O 
and O 
resistin O 
downregulation O 
in O 
a O 
mouse O 
adipocyte O 
cell O 
line O 
by O 
a O 
series O 
of O 
thiazolidinediones B-FAMILY 
. O 

mutations O 
in O 
the O 
serotonin B-TRIVIAL 
related O 
TPH1 O 
and O 
HTR1B O 
genes O 
in O 
patients O 
with O 
monogenic O 
sclerosing O 
bone O 
disorders O 
. O 

the O 
identification O 
of O 
LRP5 O 
as O 
the O 
causative O 
gene O 
for O 
the O 
osteoporosis O 
pseudoglioma O 
syndrome O 
( O 
OPPG O 
) O 
as O 
well O 
as O 
the O 
high O 
bone O 
mass O 
( O 
HBM O 
) O 
phenotype O 
, O 
LRP5 O 
and O 
the O 
Wnt O 
/ O 
β-catenin O 
signaling O 
have O 
been O 
extensively O 
studied O 
for O 
their O 
role O 
in O 
the O 
differentiation O 
and O 
proliferation O 
of O 
osteoblasts O 
, O 
in O 
the O 
apoptosis O 
of O 
osteoblasts O 
and O 
osteocytes O 
and O 
in O 
the O 
response O 
of O 
bone O 
to O 
mechanical O 
loading O 
. O 
However O 
, O 
more O 
recently O 
the O 
direct O 
effect O 
of O 
LRP5 O 
on O 
osteoblasts O 
and O 
bone O 
formation O 
has O 
been O 
questioned O 
. O 
Gene O 
expression O 
studies O 
showed O 
that O 
mice O 
lacking O 
lrp5 O 
have O 
increased O 
expression O 
of O 
tph1 O 
, O 
the O 
rate O 
limiting O 
enzyme O 
for O 
the O 
production O 
of O 
serotonin B-TRIVIAL 
in O 
the O 
gut O 
. O 
Furthermore O 
mice O 
lacking O 
either O 
tph1 O 
or O 
htr1B O 
, O 
the O 
receptor O 
for O 
serotonin B-TRIVIAL 
on O 
the O 
osteoblasts O 
, O 
were O 
reported O 
to O 
have O 
an O 
increased O 
bone O 
mass O 
due O 
to O 
increased O 
bone O 
formation O 
. O 
This O 
led O 
to O 
the O 
still O 
controversial O 
hypothesis O 
that O 
LRP5 O 
influences O 
bone O 
formation O 
indirectly O 
by O 
regulating O 
the O 
expression O 
of O 
thp1 O 
and O 
as O 
a O 
consequence O 
influencing O 
the O 
production O 
of O 
serotonin B-TRIVIAL 
in O 
the O 
gut O 
. O 
Based O 
on O 
these O 
data O 
we O 
decided O 
to O 
evaluate O 
the O 
role O 
of O 
TPH1 O 
and O 
HTR1B O 
in O 
the O 
development O 
of O 
craniotubular O 
hyperostoses O 
, O 
a O 
group O 
of O 
monogenic O 
sclerosing O 
bone O 
dysplasias O 
. O 
We O 
screened O 
the O 
coding O 
regions O 
of O 
both O 
genes O 
in O 
53 O 
patients O 
lacking O 
a O 
mutation O 
in O 
the O 
known O 
causative O 
genes O 
LRP5 O 
, O 
LRP4 O 
and O 
SOST O 
. O 
We O 
could O 
not O 
find O 
disease O 
- O 
causing O 
coding O 
variants O 
in O 
neither O 
of O 
the O 
tested O 
genes O 
and O 
therefore O 
, O 
we O 
cannot O 
provide O 
support O 
for O 
an O 
important O 
function O 
of O 
TPH1 O 
and O 
HTR1B O 
in O 
the O 
pathogenesis O 
of O 
sclerosing O 
bone O 
dysplasias O 
in O 
our O 
tested O 
patient O 
cohort O 
. O 

: O 
P-glycoprotein O 
( O 
P-gp O 
) O 
is O 
a O 
drug O 
efflux O 
pump O 
expressed O 
, O 
amongst O 
others O 
, O 
on O 
the O 
luminal O 
surface O 
of O 
the O 
cerebral O 
endothelial O 
cells O 
forming O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
Studies O 
in O 
rodents O 
have O 
demonstrated O 
that O 
antihistamines O 
that O 
are O 
substrates O 
of O 
the O 
P-gp O 
transporter O 
display O 
no O 
or O 
minor O 
central O 
nervous O 
system O 
( O 
CNS O 
) O 
effects O 
as O 
compared O 
to O 
antihistamines O 
that O 
are O 
not O 
P-gp O 
transporter O 
substrates O 
. O 
OBJECTIVES O 
: O 
The O 
present O 
study O 
explored O 
whether O 
P-gp O 
contributes O 
in O 
similar O 
ways O 
to O 
the O 
occurrence O 
of O 
sedative O 
effects O 
of O 
antihistamines O 
in O 
humans O 
. O 
METHODS O 
: O 
An O 
fMRI O 
study O 
was O 
conducted O 
according O 
to O 
a O 
double O 
- O 
blind O 
, O 
randomized O 
, O 
placebo O 
- O 
controlled O 
, O 
cross O 
- O 
over O 
design O 
in O 
13 O 
healthy O 
volunteers O 
. O 
Participants O 
received O 
cetirizine B-TRIVIAL 
15 O 
mg O 
( O 
an O 
antihistamine O 
) O 
, O 
verapamil B-TRIVIAL 
120 O 
mg O 
( O 
a O 
P-gp O 
blocker O 
) O 
, O 
a O 
combination O 
of O 
cetirizine B-TRIVIAL 
+ O 
verapamil B-TRIVIAL 
, O 
and O 
a O 
placebo O 
. O 
Brain O 
activity O 
was O 
assessed O 
while O 
conducting O 
the O 
attention O 
network O 
test O 
( O 
ANT O 
) O 
in O 
a O 
3T O 
magnetic O 
resonance O 
scanner O 
. O 
The O 
ANT O 
measures O 
three O 
independent O 
attention O 
domains O 
: O 
i.e O 
. O 
, O 
alerting O 
, O 
orienting O 
, O 
and O 
executive O 
attention O 
. O 
It O 
was O 
expected O 
that O 
the O 
combined O 
treatment O 
of O 
cetirizine B-TRIVIAL 
with O 
verapamil B-TRIVIAL 
would O 
prevent O 
efflux O 
of O 
cetirizine B-TRIVIAL 
from O 
the O 
CNS O 
, O 
thus O 
increasing O 
attentional O 
impairment O 
, O 
as O 
compared O 
to O 
cetirizine B-TRIVIAL 
administered O 
alone O 
. O 
RESULTS O 
: O 
The O 
present O 
study O 
provides O 
evidence O 
that O 
the O 
P-gp O 
transporter O 
is O 
involved O 
in O 
central O 
antihistamine O 
effects O 
in O 
humans O 
. O 
Participants O 
were O 
less O 
alert O 
during O 
the O 
combined O 
treatment O 
of O 
cetirizine B-TRIVIAL 
and O 
verapamil B-TRIVIAL 
as O 
indicated O 
by O 
longer O 
reaction O 
times O 
and O 
decreased O 
blood O 
oxygen B-SYSTEMATIC 
level O 
- O 
dependent O 
response O 
in O 
the O 
right O 
superior O 
temporal O 
gyrus O 
. O 
CONCLUSION O 
: O 
It O 
is O 
concluded O 
that O 
the O 
affinity O 
for O 
the O 
P-gp O 
transporter O 
may O 
contribute O 
to O 
the O 
lower O 
incidence O 
of O 
CNS O 
side O 
effects O 
of O 
certain O 
antihistamines O 
. O 

large O 
gap O 
opening O 
of O 
graphene B-TRIVIAL 
induced O 
by O 
the O 
adsorption O 
of O 
CO B-FORMULA 
on O 
the O 
Al B-FORMULA 
-doped O 
site O 
. O 

investigated O 
CO B-FORMULA 
adsorption O 
on O 
the O 
pristine O 
, O 
Stone-Wales O 
( O 
SW O 
) O 
defected O 
, O 
Al B-FORMULA 
- O 
and O 
Si B-FORMULA 
- O 
doped O 
graphenes B-FAMILY 
by O 
using O 
density O 
functional O 
calculations O 
in O 
terms O 
of O 
geometric O 
, O 
energetic O 
and O 
electronic O 
properties O 
. O 
It O 
was O 
found O 
that O 
CO B-FORMULA 
molecule O 
is O 
weakly O 
adsorbed O 
on O 
the O 
pristine O 
and O 
SW O 
defected O 
graphenes B-FAMILY 
and O 
their O 
electronic O 
properties O 
were O 
slightly O 
changed O 
. O 
The O 
Al B-FORMULA 
- O 
and O 
Si B-FORMULA 
- O 
doped O 
graphenes O 
show O 
high O 
reactivity O 
toward O 
CO B-FORMULA 
, O 
so O 
calculated O 
adoption O 
energies O 
are O 
about O 
-11.4 O 
and O 
-13.75 O 
kcal O 
mol(-1) O 
in O 
the O 
most O 
favorable O 
states O 
. O 
It O 
was O 
found O 
that O 
, O 
among O 
all O 
the O 
structures O 
, O 
the O 
electronic O 
properties O 
of O 
Al B-FORMULA 
-doped O 
graphene B-TRIVIAL 
are O 
strongly O 
sensitive O 
to O 
the O 
presence O 
of O 
CO B-FORMULA 
molecule O 
. O 
We O 
demonstrate O 
the O 
existence O 
of O 
a O 
large O 
Eg O 
opening O 
of O 
0.87 O 
eV O 
in O 
graphene B-TRIVIAL 
which O 
is O 
induced O 
by O 
Al B-FORMULA 
-doping O 
and O 
CO B-FORMULA 
adsorption O 
. O 

Hydroxylated O 
Metabolite O 
of O 
Flame-Retardant O 
PBDE-47 B-ABBREVIATION 
Decreases O 
the O 
Survival O 
, O 
Proliferation O 
, O 
and O 
Neuronal O 
Differentiation O 
of O 
Primary O 
Cultured O 
Adult O 
Neural O 
Stem O 
Cells O 
and O 
Interferes O 
with O 
Signaling O 
of O 
ERK5 O 
MAP O 
Kinase O 
and O 
Neurotrophin O 
3 O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
are O 
a O 
group O 
of O 
organobromine B-FAMILY 
compounds O 
widely O 
used O 
as O 
flame O 
retardants O 
. O 
PBDE-47 B-ABBREVIATION 
is O 
one O 
of O 
the O 
most O 
prominent O 
PBDE B-ABBREVIATION 
congeners O 
found O 
in O 
human O 
tissues O 
, O 
and O 
it O 
can O 
be O 
transformed O 
into O 
several O 
metabolites O 
, O 
including O 
6-OH-PBDE-47 B-SYSTEMATIC 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
PBDE-47 B-ABBREVIATION 
is O 
neurotoxic O 
to O 
animals O 
and O 
possibly O 
humans O 
. O 
However O 
, O 
the O 
basis O 
for O 
the O 
neurotoxicity O 
of O 
PBDEs B-ABBREVIATION 
and O 
their O 
metabolites O 
is O 
unclear O 
. O 
For O 
example O 
, O 
it O 
is O 
not O 
known O 
whether O 
PBDEs B-ABBREVIATION 
affect O 
adult O 
neurogenesis O 
, O 
a O 
process O 
implicated O 
in O 
learning O 
and O 
memory O 
and O 
in O 
olfactory O 
behavior O 
. O 
In O 
this O 
study O 
, O 
we O 
examined O 
the O 
toxicity O 
of O 
PBDEs B-ABBREVIATION 
for O 
primary O 
adult O 
neural O 
stem O 
/ O 
progenitor O 
cells O 
( O 
aNSCs O 
) O 
isolated O 
from O 
the O 
subventricular O 
zone O 
( O 
SVZ O 
) O 
of O 
adult O 
mice O 
. O 
We O 
discovered O 
that O 
6-OH-PBDE-47 B-SYSTEMATIC 
, O 
but O 
not O 
its O 
parent O 
compound O 
PBDE-47 B-ABBREVIATION 
, O 
is O 
cytotoxic O 
for O 
aNCSs O 
using O 
MTS O 
metabolism O 
and O 
cell O 
number O 
as O 
a O 
measure O 
of O 
cytotoxicity O 
. O 
Interestingly O 
, O 
6-OH-PBDE-47 B-SYSTEMATIC 
induced O 
apoptosis O 
at O 
concentrations O 
above O 
7.5μM O 
inhibited O 
proliferation O 
at O 
2.5-5μM O 
while O 
suppressing O 
neuronal O 
and O 
oligodendrocyte O 
differentiation O 
at O 
submicromolar O 
concentrations O 
( O 
≤ O 
1μM O 
) O 
. O 
The O 
effect O 
on O 
proliferation O 
was O 
reversed O 
upon O 
removal O 
of O 
6-OH-PBDE-47 B-SYSTEMATIC 
and O 
correlated O 
with O 
selective O 
but O 
reversible O 
inhibition O 
of O 
ERK5 O 
activation O 
by O 
mitogenic O 
growth O 
factors O 
EGF O 
and O 
bFGF O 
. O 
6-OH-PBDE-47 B-SYSTEMATIC 
also O 
inhibited O 
the O 
proneuronal O 
differentiation O 
effect O 
of O 
neurotrophin O 
3 O 
( O 
NT3 O 
) O 
and O 
NT3 O 
activation O 
of O 
ERK5 O 
. O 
Together O 
, O 
these O 
data O 
show O 
that O 
6-OH-PBDE-47 B-SYSTEMATIC 
is O 
more O 
toxic O 
than O 
its O 
parent O 
compound O 
for O 
SVZ O 
- O 
derived O 
aNSCs O 
and O 
that O 
it O 
inhibits O 
multiple O 
aspects O 
of O 
adult O 
neurogenesis O 
. O 
Furthermore O 
, O 
inhibition O 
of O 
ERK5 O 
signaling O 
may O 
underlie O 
the O 
adverse O 
effect O 
of O 
6-OH-PBDE-47 B-SYSTEMATIC 
on O 
proliferation O 
and O 
neuronal O 
differentiation O 
. O 
Our O 
data O 
suggest O 
that O 
exposure O 
to O 
PBDE B-ABBREVIATION 
-based O 
flame O 
retardants O 
could O 
cause O 
neurotoxicity O 
in O 
the O 
adult O 
brain O 
by O 
interfering O 
with O 
adult O 
neurogenesis O 
. O 

contact O 
dermatitis O 
( O 
ACD O 
) O 
is O 
induced O 
by O 
low O 
molecular O 
weight O 
electrophilic O 
chemicals O 
and O 
metal O 
ions O 
. O 
Chemical O 
contact O 
sensitizers O 
trigger O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
production O 
and O 
provoke O 
electrophilic O 
stress O 
leading O 
to O 
the O 
accumulation O 
of O 
the O 
transcription O 
factor O 
nuclear O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
in O 
innate O 
immune O 
cell O 
types O 
. O 
The O 
objective O 
of O 
this O 
work O 
was O 
to O 
identify O 
the O 
role O 
of O 
Nrf2 O 
in O 
the O 
regulation O 
of O 
ACD O 
. O 
We O 
used O 
the O 
Local O 
Lymph O 
Node O 
Assay O 
( O 
LLNA O 
) O 
and O 
the O 
Mouse O 
Ear O 
Swelling O 
Test O 
( O 
MEST O 
) O 
to O 
study O 
the O 
role O 
of O 
Nrf2 O 
in O 
both O 
the O 
sensitization O 
and O 
elicitation O 
phase O 
in O 
nrf2 O 
knock O 
out O 
( O 
nrf2(- O 
/ O 
- O 
) O 
) O 
and O 
wild O 
type O 
( O 
nrf2(+ O 
/ O 
+ O 
) O 
) O 
mice O 
. O 
Five O 
chemicals O 
were O 
used O 
: O 
two O 
compounds O 
known O 
to O 
react O 
with O 
cysteine B-TRIVIAL 
residues O 
, O 
2,4-dinitrochlorobenzene B-SYSTEMATIC 
( O 
DNCB B-ABBREVIATION 
) O 
and O 
cinnamaldehyde B-TRIVIAL 
( O 
CinA B-ABBREVIATION 
) O 
; O 
one O 
sensitizer O 
known O 
to O 
exhibit O 
mixed O 
reactivity O 
to O 
cysteine B-TRIVIAL 
and O 
lysine B-TRIVIAL 
residues O 
, O 
isophorone B-SYSTEMATIC 
diisocyanate I-SYSTEMATIC 
( O 
IPDI B-ABBREVIATION 
) O 
; O 
and O 
one O 
reacting O 
specifically O 
with O 
lysine B-TRIVIAL 
residues O 
, O 
trimellitic B-SYSTEMATIC 
anhydride I-SYSTEMATIC 
( O 
TMA B-ABBREVIATION 
) O 
and O 
croton O 
oil O 
a O 
well O 
- O 
known O 
irritant O 
. O 
In O 
the O 
MEST O 
assay O 
, O 
DNCB B-ABBREVIATION 
( O 
1% O 
and O 
2% O 
) O 
induced O 
a O 
significant O 
increase O 
in O 
ear O 
thickness O 
in O 
nrf2(- O 
/ O 
- O 
) O 
as O 
compared O 
to O 
nrf2(+ O 
/ O 
+ O 
) O 
mice O 
suggesting O 
a O 
role O 
for O 
Nrf2 O 
in O 
the O 
control O 
of O 
the O 
inflammatory O 
process O 
. O 
When O 
DNCB B-ABBREVIATION 
was O 
used O 
at O 
0.25% O 
and O 
0.5% O 
or O 
when O 
mice O 
were O 
treated O 
with O 
CinA B-ABBREVIATION 
, O 
inflammation O 
was O 
found O 
only O 
in O 
nrf2(- O 
/ O 
- O 
) O 
mice O 
. O 
In O 
the O 
LLNA O 
all O 
chemical O 
sensitizers O 
induced O 
an O 
increase O 
of O 
lymphocyte O 
proliferation O 
in O 
nrf2(- O 
/ O 
- O 
) O 
compared O 
to O 
nrf2(+ O 
/ O 
+ O 
) O 
mice O 
for O 
the O 
same O 
chemical O 
concentration.These O 
results O 
reveal O 
an O 
important O 
role O 
for O 
Nrf2 O 
in O 
controlling O 
ACD O 
and O 
lymphocyte O 
proliferation O 
in O 
response O 
to O 
sensitizers O 
. O 

-Terminal O 
Probrain O 
Natriuretic O 
Peptide O 
Is O 
a O 
Stronger O 
Predictor O 
of O 
Cardiovascular O 
Mortality O 
Than O 
C-Reactive O 
Protein O 
and O 
Albumin O 
Excretion O 
Rate O 
in O 
Elderly O 
Patients O 
With O 
Type O 
2 O 
Diabetes O 
: O 
The O 
Casale O 
Monferrato O 
population O 
- O 
based O 
study O 
. O 

study O 
whether O 
NH2 B-FORMULA 
-terminal O 
probrain O 
natriuretic O 
peptide O 
( O 
NT-proBNP O 
) O 
is O 
a O 
short O 
- O 
term O 
independent O 
predictor O 
of O 
both O 
all O 
- O 
cause O 
and O 
cardiovascular O 
( O 
CV O 
) O 
mortality O 
in O 
type O 
2 O 
diabetic O 
patients O 
and O 
to O 
establish O 
whether O 
albuminuria O 
and O 
C-reactive O 
protein O 
( O 
CRP O 
) O 
affect O 
this O 
relationship.RESEARCH O 
DESIGN O 
AND O 
METHODSThe O 
prospective O 
study O 
included O 
1825 O 
type O 
2 O 
diabetic O 
patients O 
from O 
the O 
population O 
- O 
based O 
cohort O 
of O 
the O 
Casale O 
Monferrato O 
study O 
. O 
CV O 
risk O 
factors O 
, O 
preexisting O 
CVD O 
, O 
and O 
NT-proBNP O 
levels O 
were O 
evaluated O 
at O 
baseline O 
. O 
All O 
- O 
cause O 
and O 
CV O 
mortality O 
were O 
assessed O 
5.5 O 
years O 
after O 
baseline O 
examination O 
. O 
Multivariate O 
Cox O 
proportional O 
hazards O 
modeling O 
was O 
used O 
to O 
estimate O 
mortality O 
hazard O 
ratios O 
(HRs).RESULTSDuring O 
the O 
follow O 
- O 
up O 
period O 
, O 
390 O 
people O 
died O 
( O 
175 O 
for O 
CVD O 
) O 
out O 
of O 
9101 O 
person O 
- O 
years O 
of O 
observations O 
. O 
A O 
significantly O 
increased O 
mortality O 
risk O 
by O 
quartiles O 
of O 
NT-proBNP O 
was O 
observed O 
( O 
test O 
for O 
trend O 
, O 
P O 
< O 
0.001 O 
) O 
. O 
NT-proBN O 
P O 
values O 
> O 
91 O 
pg O 
/ O 
mL O 
conferred O 
HRs O 
of O 
2.05 O 
( O 
95% O 
CI O 
1.47-2.86 O 
) O 
for O 
all O 
- O 
cause O 
and O 
4.47 O 
( O 
2.38-8.39 O 
) O 
for O 
CV O 
mortality O 
, O 
independently O 
of O 
CV O 
risk O 
factors O 
, O 
including O 
CRP O 
and O 
albumin O 
excretion O 
rate O 
( O 
AER O 
) O 
. O 
The O 
association O 
was O 
also O 
significant O 
for O 
modest O 
rises O 
in O 
NT-proBNP O 
levels O 
and O 
in O 
patients O 
without O 
microalbuminuria O 
and O 
CVD O 
at O 
baseline O 
( O 
upper O 
quartiles O 
HRs O 
3.82 O 
[ O 
95% O 
CI O 
1.24-13.75 O 
] O 
) O 
and O 
3.14 O 
[ O 
1.00-9.94 O 
] O 
) O 
. O 
Albuminuria O 
and O 
NT-proBNP O 
had O 
an O 
additive O 
effect O 
on O 
mortality O 
, O 
though O 
the O 
association O 
was O 
stronger O 
for O 
NT-proBNP.CONCLUSIONSNT-proBNP O 
is O 
a O 
strong O 
independent O 
predictor O 
of O 
short O 
- O 
term O 
CV O 
mortality O 
risk O 
in O 
elderly O 
people O 
with O 
type O 
2 O 
diabetes O 
, O 
including O 
those O 
without O 
preexisting O 
CVD O 
. O 
This O 
association O 
is O 
evident O 
even O 
in O 
people O 
with O 
slightly O 
increased O 
values O 
, O 
is O 
not O 
modified O 
by O 
CRP O 
, O 
and O 
is O 
additive O 
to O 
that O 
provided O 
by O 
AER O 
. O 

Objective O 
: O 
To O 
evaluate O 
the O 
effects O 
of O 
various O 
additives O 
or O 
polymers O 
on O 
the O 
in O 
vitro O 
characteristics O 
of O 
nerve O 
growth O 
factor O 
( O 
NGF O 
) O 
microspheres O 
. O 
Materials O 
and O 
methods O 
: O 
NGF O 
microspheres O 
were O 
fabricated O 
using O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
) O 
, O 
ovalbumin O 
( O 
OVA O 
) O 
, O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
or O 
glucose B-TRIVIAL 
as O 
protein O 
protectors O 
, O 
and O 
poly(lactide-co-glycolide) B-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
or O 
poly(lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PLA B-ABBREVIATION 
)/ O 
PLGA B-ABBREVIATION 
blends O 
as O 
encapsulation O 
materials O 
. O 
Results O 
: O 
Encapsulation O 
efficiencies O 
of O 
the O 
NGF O 
microspheres O 
with O 
various O 
additives O 
or O 
polymers O 
were O 
not O 
more O 
than O 
30% O 
. O 
A O 
comparative O 
study O 
revealed O 
that O 
OVA O 
was O 
somewhat O 
superior O 
over O 
others O 
, O 
and O 
was O 
thus O 
chosen O 
as O 
the O 
protective O 
additive O 
in O 
subsequent O 
experiments O 
. O 
Polymer O 
analysis O 
showed O 
that O 
NGF O 
release O 
from O 
1 O 
: O 
1 O 
PLA B-ABBREVIATION 
( O 
η O 
= O 
0.8 O 
) O 
: O 
PLGA B-ABBREVIATION 
( O 
75 O 
/ O 
25 O 
, O 
η O 
= O 
0.45 O 
) O 
microspheres O 
lasted O 
for O 
90 O 
d O 
with O 
a O 
burst O 
release O 
rate O 
of O 
12.7% O 
. O 
About O 
40% O 
of O 
the O 
original O 
bioactivity O 
was O 
retained O 
on O 
the O 
28th O 
day O 
, O 
while O 
10% O 
was O 
left O 
on O 
the O 
90th O 
day O 
. O 
Discussion O 
and O 
conclusion O 
: O 
The O 
combination O 
of O 
OVA O 
as O 
an O 
additive O 
and O 
the O 
PLA B-ABBREVIATION 
/ O 
PLGA B-ABBREVIATION 
blend O 
as O 
the O 
coating O 
matrix O 
is O 
suitable O 
for O 
encapsulation O 
of O 
NGF O 
in O 
microspheres O 
for O 
extended O 
release O 
. O 

Chloride I-SYSTEMATIC 
as O 
a O 
Heterogeneous O 
Nucleant O 
for O 
the O 
Growth O 
of O 
Silver B-SYSTEMATIC 
Nanowires O 
. O 

additives O 
are O 
employed O 
in O 
the O 
polyol B-FAMILY 
synthesis O 
of O 
silver B-SYSTEMATIC 
nanowires O 
( O 
Ag B-FORMULA 
NWs O 
) O 
, O 
which O 
are O 
typically O 
halide B-FAMILY 
salts O 
such O 
as O 
NaCl B-FORMULA 
. O 
A O 
variety O 
of O 
mechanistic O 
roles O 
have O 
been O 
suggested O 
for O 
these O 
additives O 
. O 
We O 
now O 
show O 
that O 
the O 
early O 
addition O 
of O 
NaCl B-FORMULA 
in O 
the O 
polyol B-FAMILY 
synthesis O 
of O 
Ag B-FORMULA 
NWs O 
from O 
AgNO3 B-FORMULA 
in O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
results O 
in O 
the O 
rapid O 
formation O 
of O 
AgCl B-FORMULA 
nanocubes O 
, O 
which O 
induce O 
the O 
heterogeneous O 
nucleation O 
of O 
metallic O 
Ag B-FORMULA 
upon O 
their O 
surfaces O 
. O 
Ag B-FORMULA 
NWs O 
subsequently O 
grow O 
from O 
these O 
nucleation O 
sites O 
. O 
The O 
conclusions O 
are O 
supported O 
by O 
studies O 
using O 
ex O 
situ O 
generated O 
AgCl B-FORMULA 
nanocubes O 
. O 

receptor O 
: O 
past O 
, O 
present O 
and O 
future O 
. O 

and O 
the O 
androgen B-FAMILY 
receptor O 
have O 
been O 
the O 
focus O 
of O 
prostate O 
cancer O 
research O 
since O 
the O 
early O 
1940s O 
, O 
when O 
Huggins O 
and O 
Hodges O 
demonstrated O 
that O 
removal O 
of O 
androgens B-FAMILY 
caused O 
advanced O 
prostate O 
cancer O 
to O 
regress O 
. O 
Since O 
that O 
time O 
, O 
a O 
large O 
number O 
of O 
androgen B-FAMILY 
deprivation O 
therapies O 
have O 
been O 
developed O 
in O 
an O 
effort O 
to O 
cure O 
this O 
disease O 
, O 
but O 
prostate O 
cancer O 
remains O 
one O 
of O 
the O 
leading O 
causes O 
of O 
cancer O 
death O 
in O 
males O 
worldwide O 
. O 
This O 
is O 
due O 
in O 
part O 
to O 
the O 
emergence O 
of O 
castration- O 
recurrent O 
prostate O 
cancer O 
in O 
patients O 
with O 
advanced O 
disease O 
who O 
have O 
failed O 
androgen B-FAMILY 
deprivation O 
therapy O 
. O 
The O 
androgen B-FAMILY 
receptor O 
is O 
still O 
a O 
major O 
player O 
in O 
castration O 
- O 
recurrent O 
disease O 
, O 
and O 
though O 
much O 
has O 
been O 
discovered O 
since O 
the O 
early O 
work O 
of O 
Huggins O 
and O 
Hodges O 
regarding O 
how O 
prostate O 
cancer O 
cells O 
manage O 
to O 
avoid O 
the O 
effects O 
of O 
androgen B-FAMILY 
deprivation O 
, O 
survival O 
times O 
for O 
men O 
with O 
advanced O 
prostate O 
cancer O 
have O 
changed O 
only O 
modestly O 
. O 
Research O 
is O 
now O 
directed O 
toward O 
delineating O 
the O 
mechanisms O 
of O 
action O 
of O 
the O 
androgen B-FAMILY 
receptor O 
under O 
castrate O 
conditions O 
, O 
whether O 
through O 
amplification O 
of O 
the O 
AR O 
, O 
mutation O 
, O 
expression O 
of O 
splice O 
variants O 
, O 
use O 
of O 
alternate O 
signaling O 
pathways O 
, O 
aberrant O 
expression O 
and O 
activation O 
of O 
coregulators O 
, O 
or O 
intratumoral O 
androgen O 
biosynthesis O 
. O 
Genome O 
- O 
wide O 
association O 
studies O 
are O 
also O 
adding O 
to O 
the O 
wealth O 
of O 
knowledge O 
surrounding O 
the O 
androgen B-FAMILY 
receptor O 
, O 
and O 
with O 
this O 
knowledge O 
comes O 
the O 
ability O 
to O 
design O 
new O 
drug O 
therapies O 
directed O 
toward O 
eradication O 
of O 
this O 
disease O 
. O 

therapeutic O 
targeting O 
of O 
the O 
androgen B-FAMILY 
receptor O 
: O 
rational O 
drug O 
design O 
improves O 
survival O 
in O 
castration O 
- O 
resistant O 
prostate O 
cancer O 
. O 

growth O 
and O 
dependence O 
of O 
Prostate O 
Cancer O 
( O 
PCa O 
) O 
on O 
androgen B-FAMILY 
stimulation O 
led O 
to O 
the O 
use O 
of O 
castration O 
to O 
reduce O 
circulating O 
levels O 
of O 
androgens B-FAMILY 
and O 
anti- O 
androgens B-FAMILY 
to O 
directly O 
target O 
the O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
ligand O 
- O 
binding O 
domain O 
( O 
LBD O 
) O 
. O 
However O 
, O 
castration O 
- O 
resistant O 
prostate O 
cancer O 
( O 
CRPC O 
) O 
resistant O 
to O 
anti- O 
androgens B-FAMILY 
invariably O 
develops O 
and O 
can O 
be O 
associated O 
with O 
AR O 
genomic O 
aberrations O 
( O 
mutations O 
, O 
amplification O 
) O 
and O 
/ O 
or O 
an O 
increase O 
in O 
AR O 
mRNA O 
expression O 
. O 
Efforts O 
to O 
more O 
effectively O 
target O 
the O 
AR O 
in O 
CRPC O 
led O 
to O 
the O 
rational O 
design O 
of O 
CYP17A1 O 
inhibitors O 
and O 
more O 
potent O 
anti O 
androgens B-FAMILY 
. O 
The O 
front O 
- O 
runner O 
2nd O 
generation O 
rationally O 
- O 
designed O 
therapeutics O 
targeting O 
the O 
AR O 
, O 
abiraterone O 
and O 
enzalutamide O 
have O 
been O 
shown O 
to O 
improve O 
survival O 
and O 
clinical O 
outcome O 
for O 
CRPC O 
patients O 
. O 
Several O 
other O 
CYP17A1 O 
inhibitors O 
and O 
anti- O 
androgens B-FAMILY 
are O 
in O 
clinical O 
and O 
preclinical O 
development O 
. O 
However O 
, O 
patients O 
ultimately O 
progress O 
and O 
current O 
evidence O 
suggests O 
that O 
this O 
can O 
occur O 
through O 
reactivation O 
of O 
AR O 
signaling O 
. O 
Several O 
ongoing O 
programs O 
aim O 
to O 
develop O 
LBD O 
independent O 
therapeutic O 
strategies O 
that O 
for O 
example O 
target O 
the O 
N B-FORMULA 
terminus O 
domain O 
( O 
NTD O 
) O 
of O 
the O 
AR O 
or O 
chaperone O 
proteins O 
. O 
Rationally O 
- O 
designed O 
approaches O 
combining O 
different O 
strategies O 
for O 
targeting O 
the O 
AR O 
or O 
associated O 
pathways O 
also O 
warrant O 
clinical O 
evaluation O 
. O 

Acid I-FAMILY 
- O 
nucleotide B-FAMILY 
-lipids O 
: O 
effect O 
of O 
amino B-FAMILY 
Acid I-FAMILY 
on O 
the O 
self O 
- O 
assembly O 
properties O 
. O 

amphiphiles O 
composed O 
of O 
a O 
lipid O 
covalently O 
linked O 
to O 
biomolecules O 
are O 
attracting O 
considerable O 
attention O 
, O 
owing O 
to O 
their O 
unique O 
physicochemical O 
and O 
biological O 
properties O 
. O 
Herein O 
, O 
we O 
have O 
synthesized O 
novel O 
amino B-FAMILY 
acid I-FAMILY 
- O 
nucleotide B-FAMILY 
-lipids O 
( O 
ANLs O 
) O 
, O 
presenting O 
phenylalanine B-TRIVIAL 
and O 
thymidine B-TRIVIAL 
residues O 
and O 
saturated B-MULTIPLE 
or I-MULTIPLE 
unsaturated I-MULTIPLE 
diacyl I-MULTIPLE 
glycerol I-MULTIPLE 
lipid O 
moieties O 
to O 
investigate O 
the O 
effect O 
of O 
the O 
specific O 
aminoacid B-FAMILY 
moieties O 
on O 
both O 
aggregation O 
properties O 
and O 
interactions O 
of O 
ANLs O 
with O 
single O 
strand O 
polyA O 
RNA O 
. O 
Physicochemical O 
studies O 
( O 
DLS O 
, O 
cryo-TEM O 
, O 
and O 
small O 
angle O 
X-ray O 
scattering O 
) O 
indicate O 
that O 
phenylanaline B-TRIVIAL 
amino B-FAMILY 
acids I-FAMILY 
inserted O 
at O 
the O 
5 O 
' O 
position O 
of O 
the O 
nucleotide B-FAMILY 
-lipids O 
stabilize O 
multilamellar O 
systems O 
, O 
whereas O 
unilamellar O 
vesicles O 
are O 
formed O 
preferentially O 
in O 
the O 
case O 
of O 
nucleotide B-FAMILY 
-lipids O 
( O 
NLs O 
) O 
. O 
Both O 
NLs O 
and O 
ANLs O 
exhibit O 
weak O 
interactions O 
with O 
complementary O 
polyA O 
RNA O 
as O 
revealed O 
by O 
isothermal O 
titration O 
calorimetry O 
investigations O 
. O 
The O 
multilamellar O 
vesicles O 
obtained O 
with O 
ANLs O 
could O 
be O 
used O 
as O 
a O 
versatile O 
carrier O 
, O 
suitable O 
for O 
both O 
hydrophobic O 
and O 
hydrophilic O 
therapeutic O 
molecules O 
. O 

Resolved O 
Mapping O 
of O 
Oxygen B-SYSTEMATIC 
Reduction O 
/ O 
Evolution O 
Reaction O 
on O 
Solid-Oxide O 
Fuel O 
Cell O 
Cathodes O 
with O 
Sub-10 O 
nm O 
Resolution O 
. O 

localization O 
of O 
the O 
oxygen B-SYSTEMATIC 
reduction O 
/ O 
evolution O 
reactions O 
on O 
lanthanum B-SYSTEMATIC 
strontium I-SYSTEMATIC 
cobaltite I-SYSTEMATIC 
( O 
LSCO B-ABBREVIATION 
) O 
surfaces O 
with O 
perovskite B-TRIVIAL 
and O 
layered O 
perovskite B-TRIVIAL 
structures O 
is O 
studied O 
at O 
the O 
sub-10 O 
nm O 
level O 
. O 
Comparison O 
between O 
electrochemical O 
strain O 
microscopy O 
( O 
ESM O 
) O 
and O 
structural O 
imaging O 
by O 
scanning O 
transmission O 
electron O 
microscopy O 
( O 
STEM O 
) O 
suggests O 
that O 
small O 
- O 
angle O 
grain O 
boundaries O 
act O 
as O 
regions O 
with O 
enhanced O 
electrochemical O 
activity O 
. O 
The O 
ESM O 
activity O 
is O 
compared O 
across O 
a O 
family O 
of O 
LSCO B-ABBREVIATION 
samples O 
, O 
demonstrating O 
excellent O 
agreement O 
with O 
macroscopic O 
behaviors O 
. O 
This O 
study O 
potentially O 
paves O 
the O 
way O 
for O 
deciphering O 
the O 
mechanisms O 
of O 
electrochemical O 
activity O 
of O 
solids O 
on O 
the O 
level O 
of O 
single O 
extended O 
structural O 
defects O 
such O 
as O 
grain O 
boundaries O 
and O 
dislocations O 
. O 

Plasticity O 
of O 
Hydrogen B-SYSTEMATIC 
Bonded O 
Bis-urea B-SYSTEMATIC 
Supramolecular O 
Polymers O 
. O 

report O 
a O 
detailed O 
structural O 
investigation O 
of O 
supramolecular O 
polymers O 
formed O 
by O 
hydrogen B-SYSTEMATIC 
bonded O 
self O 
- O 
assembly O 
of O 
bis-urea B-SYSTEMATIC 
monomers O 
. O 
The O 
careful O 
exploration O 
of O 
the O 
energy O 
landscape O 
by O 
molecular O 
mechanics O 
/ O 
molecular O 
dynamics O 
( O 
MM O 
/ O 
MD O 
) O 
simulations O 
has O 
allowed O 
us O 
to O 
identify O 
three O 
distinct O 
self O 
- O 
assembled O 
structures O 
of O 
similar O 
stabilities O 
. O 
These O 
structures O 
have O 
been O 
compared O 
to O 
X-ray O 
crystal O 
data O 
. O 
We O 
observe O 
that O 
a O 
slight O 
change O 
in O 
the O 
molecular O 
structure O 
can O 
favor O 
a O 
particular O 
structure O 
over O 
the O 
others O 
. O 
Detailed O 
analysis O 
shows O 
that O 
hydrogen B-SYSTEMATIC 
bonds O 
stabilize O 
all O 
three O 
structures O 
to O 
a O 
similar O 
extent O 
. O 
Therefore O 
, O 
it O 
is O 
the O 
interactions O 
among O 
the O 
lateral O 
substituents O 
, O 
and O 
with O 
the O 
filament O 
environment O 
, O 
that O 
are O 
the O 
decisive O 
factors O 
in O 
the O 
competition O 
between O 
the O 
possible O 
self O 
- O 
assembled O 
structures O 
. O 
This O 
study O 
constitutes O 
a O 
clear O 
reminder O 
that O 
the O 
conformation O 
of O 
a O 
supramolecular O 
polymer O 
is O 
a O 
sensitive O 
function O 
of O 
the O 
molecular O 
structure O 
and O 
may O 
significantly O 
differ O 
from O 
the O 
solid O 
- O 
state O 
conformation O 
of O 
a O 
model O 
compound O 
. O 

Derivatives O 
as O 
Novel O 
d-Amino B-FAMILY 
Acid I-FAMILY 
Oxidase O 
Inhibitors O 
. O 

acid I-FAMILY 
oxidase O 
( O 
DAAO O 
) O 
catalyzes O 
the O 
oxidation O 
of O 
d-amino B-FAMILY 
acids I-FAMILY 
including O 
d-serine B-TRIVIAL 
, O 
a O 
coagonist O 
of O 
the O 
N-methyl-d-aspartate B-SYSTEMATIC 
receptor O 
. O 
We O 
identified O 
a O 
series O 
of O 
4-hydroxypyridazin-3(2H)-one B-SYSTEMATIC 
derivatives O 
as O 
novel O 
DAAO O 
inhibitors O 
with O 
high O 
potency O 
and O 
substantial O 
cell O 
permeability O 
using O 
fragment O 
- O 
based O 
drug O 
design O 
. O 
Comparisons O 
of O 
complex O 
structures O 
deposited O 
in O 
the O 
Protein O 
Data O 
Bank O 
as O 
well O 
as O 
those O 
determined O 
with O 
in O 
- O 
house O 
fragment O 
hits O 
revealed O 
that O 
a O 
hydrophobic O 
subpocket O 
was O 
formed O 
perpendicular O 
to O 
the O 
flavin O 
ring O 
by O 
flipping O 
Tyr B-FORMULA 
224 O 
in O 
a O 
ligand O 
- O 
dependent O 
manner O 
. O 
We O 
investigated O 
the O 
ability O 
of O 
the O 
initial O 
fragment O 
hit O 
, O 
3-hydroxy-pyridine-2(1H)-one B-SYSTEMATIC 
, O 
to O 
fill O 
this O 
subpocket O 
with O 
the O 
aid O 
of O 
complex O 
structure O 
information O 
. O 
3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one B-SYSTEMATIC 
exhibited O 
the O 
predicted O 
binding O 
mode O 
and O 
demonstrated O 
high O 
inhibitory O 
activity O 
for O 
human O 
DAAO O 
in O 
enzyme- O 
and O 
cell O 
- O 
based O 
assays O 
. O 
We O 
further O 
designed O 
and O 
synthesized O 
4-hydroxypyridazin-3(2H)-one B-SYSTEMATIC 
derivatives O 
, O 
which O 
are O 
equivalent O 
to O 
the O 
3-hydroxy-pyridine-2(1H)-one B-SYSTEMATIC 
series O 
but O 
lack O 
cell O 
toxicity O 
. O 
6-[2-(3,5-Difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one B-SYSTEMATIC 
was O 
found O 
to O 
be O 
effective O 
against O 
MK-801 B-IDENTIFIER 
-induced O 
cognitive O 
deficit O 
in O 
the O 
Y-maze O 
. O 

of O 
the O 
α-Conotoxin O 
Vc1.1 O 
Binding O 
Site O 
on O 
the O 
α9α10 O 
Nicotinic O 
Acetylcholine B-SYSTEMATIC 
Receptor O 
. O 

Vc1.1 O 
specifically O 
and O 
potently O 
inhibits O 
the O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
subtype O 
α9α10 O 
( O 
α9α10 O 
nAChR O 
) O 
and O 
is O 
a O 
potential O 
novel O 
treatment O 
for O 
neuropathic O 
pain O 
. O 
Here O 
, O 
we O 
used O 
a O 
combination O 
of O 
computational O 
modeling O 
and O 
electrophysiology O 
experiments O 
to O 
determine O 
the O 
Vc1.1 O 
binding O 
site O 
on O 
the O 
α9α10 O 
nAChR O 
. O 
Interactions O 
of O 
Vc1.1 O 
with O 
two O 
probable O 
binding O 
sites O 
, O 
α9α10 O 
and O 
α10α9 O 
, O 
were O 
modeled O 
. O 
Mutational O 
energies O 
calculated O 
by O 
assuming O 
specific O 
interactions O 
in O 
the O 
α10α9 O 
binding O 
site O 
correlated O 
better O 
with O 
electrophysiological O 
recordings O 
than O 
those O 
assuming O 
interactions O 
with O 
the O 
α9α10 O 
binding O 
site O 
. O 
Two O 
novel O 
Vc1.1 O 
analogues O 
, O 
[N9F]Vc1.1 O 
and O 
[N9W]Vc1.1 O 
, O 
were O 
predicted O 
to O 
have O 
large O 
differences O 
in O 
affinity O 
between O 
the O 
two O 
binding O 
sites O 
. O 
Data O 
from O 
functional O 
studies O 
were O 
consistent O 
with O 
computational O 
predictions O 
that O 
assumed O 
preferred O 
binding O 
of O 
Vc1.1 O 
to O 
the O 
α10α9 O 
pocket O 
. O 
Moreover O 
, O 
our O 
modeling O 
study O 
suggested O 
that O 
a O 
single O 
hydrogen B-SYSTEMATIC 
bond O 
formed O 
between O 
Vc1.1 O 
and O 
position O 
59 O 
of O 
the O 
α10α9 O 
pocket O 
confers O 
specificity O 
to O 
rat O 
versus O 
human O 
α9α10 O 
nAChRs O 
. O 

and O 
synthesis O 
of O 
novel O 
4-aminopyrrolopyrimidine B-SYSTEMATIC 
Tie-2 O 
kinase O 
inhibitors O 
for O 
the O 
treatment O 
of O 
solid O 
tumors O 
. O 

synthesis O 
and O 
biological O 
evaluation O 
of O 
novel O 
Tie-2 O 
kinase O 
inhibitors O 
are O 
presented O 
. O 
Based O 
on O 
the O 
pyrrolopyrimidine B-SYSTEMATIC 
chemotype O 
, O 
several O 
new O 
series O 
are O 
described O 
, O 
including O 
the O 
benzimidazole B-SYSTEMATIC 
series O 
by O 
linking O 
a O 
benzimidazole B-SYSTEMATIC 
to O 
the O 
C5- O 
position O 
of O 
the O 
4-amino-pyrrolopyrimidine B-SYSTEMATIC 
core O 
and O 
the O 
ketophenyl B-SYSTEMATIC 
series O 
synthesized O 
by O 
incorporating O 
a O 
ketophenyl B-SYSTEMATIC 
group O 
to O 
the O 
C5- O 
position O 
. O 
Medicinal O 
chemistry O 
efforts O 
led O 
to O 
potent O 
Tie-2 O 
inhibitors O 
. O 
Compound O 
15 O 
, O 
a O 
ketophenyl B-SYSTEMATIC 
pyrrolopyrimidine I-SYSTEMATIC 
urea I-SYSTEMATIC 
analog O 
with O 
improved O 
physicochemical O 
properties O 
, O 
demonstrated O 
favorable O 
in O 
vitro O 
attributes O 
as O 
well O 
as O 
dose O 
responsive O 
and O 
robust O 
oral O 
tumor O 
growth O 
inhibition O 
in O 
animal O 
models O 
. O 

of O 
dose O 
- O 
hepatotoxic O 
response O 
in O 
humans O 
based O 
on O 
toxicokinetic O 
/ O 
toxicodynamic O 
modeling O 
with O 
or O 
without O 
in O 
vivo O 
data O 
: O 
A O 
case O 
study O 
with O 
acetaminophen B-TRIVIAL 
. O 

the O 
present O 
legislations O 
, O 
the O 
use O 
of O 
methods O 
alternative O 
to O 
animal O 
testing O 
is O 
explicitly O 
encouraged O 
, O 
to O 
use O 
animal O 
testing O 
only O 
' O 
as O 
a O 
last O 
resort O 
' O 
or O 
to O 
ban O 
it O 
. O 
The O 
use O 
of O 
alternative O 
methods O 
to O 
replace O 
kinetics O 
or O 
repeated O 
dose O 
in O 
vivo O 
tests O 
is O 
a O 
challenging O 
issue O 
. O 
We O 
propose O 
here O 
a O 
strategy O 
based O 
on O 
in O 
vitro O 
tests O 
and O 
QSAR O 
( O 
Quantitative O 
Structure O 
Activity O 
Relationship O 
) O 
models O 
to O 
calibrate O 
a O 
dose O 
- O 
response O 
model O 
predicting O 
hepatotoxicity O 
. O 
The O 
dose O 
response O 
consists O 
in O 
calibrating O 
and O 
coupling O 
a O 
PBPK O 
( O 
physiologically O 
- O 
based O 
pharmacokinetic O 
) O 
model O 
with O 
a O 
toxicodynamic O 
model O 
for O 
cell O 
viability O 
. O 
We O 
applied O 
our O 
strategy O 
to O 
acetaminophen B-TRIVIAL 
and O 
compared O 
three O 
different O 
ways O 
to O 
calibrate O 
the O 
PBPK O 
model O 
: O 
only O 
with O 
in O 
vitro O 
and O 
in O 
silico O 
methods O 
, O 
using O 
rat O 
data O 
or O 
using O 
all O 
available O 
data O 
including O 
data O 
on O 
humans O 
. O 
Some O 
estimates O 
of O 
kinetic O 
parameters O 
differed O 
substantially O 
among O 
the O 
three O 
calibration O 
processes O 
, O 
but O 
, O 
at O 
the O 
end O 
, O 
the O 
three O 
models O 
were O 
quite O 
comparable O 
in O 
terms O 
of O 
liver O 
toxicity O 
predictions O 
and O 
close O 
to O 
the O 
usual O 
range O 
of O 
human O 
overdose O 
. O 
For O 
the O 
model O 
based O 
on O 
alternative O 
methods O 
, O 
the O 
good O 
adequation O 
with O 
the O 
two O 
other O 
models O 
resulted O 
from O 
an O 
overestimated O 
renal O 
elimination O 
rate O 
which O 
compensated O 
for O 
the O 
underestimation O 
of O 
the O 
metabolism O 
rate O 
. O 
Our O 
study O 
points O 
out O 
that O 
toxicokinetics O 
/ O 
toxicodynamics O 
approaches O 
, O 
based O 
on O 
alternative O 
methods O 
and O 
modelling O 
only O 
, O 
can O 
predict O 
in O 
vivo O 
liver O 
toxicity O 
with O 
accuracy O 
comparable O 
to O 
in O 
vivo O 
methods O 
. O 

RELEVANCE O 
: O 
Zanthoxylum O 
leprieurii O 
( O 
Syn O 
. O 
Fagara O 
leprieurii O 
) O 
is O 
a O 
plant O 
extensively O 
used O 
by O 
traditional O 
healers O 
in O 
Cameroon O 
for O 
the O 
treatment O 
of O 
stomach O 
disorders O 
, O 
gonorrhea O 
, O 
intestinal O 
parasites O 
and O 
sterility O 
. O 
The O 
infusion O 
from O 
the O 
fruit O 
is O 
taken O 
in O 
Cameroon O 
for O 
the O 
treatment O 
of O 
sickle O 
cell O 
anemia O 
, O 
as O 
well O 
. O 
Similarly O 
, O 
the O 
roots O 
of O 
Zanthoxylum O 
zanthoxyloides O 
( O 
Syn O 
. O 
Fagara O 
zanthoxyloides O 
) O 
are O 
also O 
used O 
for O 
wound O 
dressing O 
, O 
sickle O 
cell O 
anemia O 
and O 
as O 
pain O 
reliever O 
, O 
in O 
addition O 
to O 
the O 
uses O 
mentioned O 
for O 
Zanthoxylum O 
leprieurii O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
scientifically O 
validate O 
their O 
traditional O 
use O 
, O 
the O 
in O 
vitro O 
antimicrobial O 
and O 
anticancer O 
assays O 
were O 
performed O 
. O 
In O 
addition O 
, O 
chemical O 
compositions O 
of O 
their O 
fruit O 
extracts O 
and O 
essential O 
oils O 
were O 
also O 
studied O 
. O 
MATERIAL O 
AND O 
METHODS O 
: O 
The O 
chemical O 
compositions O 
of O 
their O 
essential O 
oils O 
and O 
methanol O 
extracts O 
were O 
studied O 
. O 
GC O 
and O 
GC-MS O 
were O 
used O 
for O 
analyzing O 
the O 
essential O 
oils O 
while O 
various O 
chromatographic O 
methods O 
were O 
used O 
to O 
isolate O 
the O 
pure O 
compounds O 
from O 
methanol B-SYSTEMATIC 
extracts O 
. O 
MTT B-ABBREVIATION 
assay O 
was O 
used O 
for O 
the O 
cytotoxic O 
studies O 
of O 
methanol B-SYSTEMATIC 
extracts O 
, O 
their O 
fractions O 
and O 
some O 
pure O 
compounds O 
. O 
Antimicrobial O 
activity O 
of O 
methanol B-SYSTEMATIC 
extracts O 
, O 
some O 
isolated O 
compounds O 
as O 
well O 
as O 
essential O 
oils O 
was O 
tested O 
against O 
a O 
panel O 
of O 
human O 
pathogenic O 
bacteria O 
by O 
diffusion O 
and O 
dilution O 
methods O 
. O 
RESULTS O 
: O 
The O 
principal O 
constituents O 
of O 
the O 
essential O 
oil O 
of O 
Zanthoxylum O 
zanthoxyloides O 
were O 
identified O 
as O 
citronellol B-TRIVIAL 
and O 
geraniol B-TRIVIAL 
whereas O 
Zanthoxylum O 
leprieurii O 
was O 
rich O 
in O 
E-β-ocimene B-TRIVIAL 
. O 
Furthermore O 
, O 
we O 
report O 
for O 
the O 
first O 
time O 
, O 
the O 
presence O 
of O 
7,8-dimethoxycoumarin B-SYSTEMATIC 
and O 
sinapic B-TRIVIAL 
acid I-TRIVIAL 
in O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Zanthoxylum O 
leprieurii O 
. O 
In O 
vitro O 
bioassays O 
reveal O 
that O 
the O 
methanol B-SYSTEMATIC 
extracts O 
, O 
essential O 
oil O 
and O 
some O 
of O 
the O 
isolated O 
compounds O 
from O 
fruits O 
of O 
both O 
the O 
plants O 
exhibit O 
moderate O 
anticancer O 
and O 
antimicrobial O 
activities O 
. O 
CONCLUSION O 
: O 
Altogether O 
, O 
the O 
present O 
findings O 
justify O 
the O 
traditional O 
use O 
of O 
Zanthoxylum O 
zanthoxyloides O 
and O 
Zanthoxylum O 
leprieurii O 
in O 
the O 
treatment O 
of O 
stomach O 
disorders O 
and O 
cancer O 
disease O 
. O 
The O 
antimicrobial O 
properties O 
in O 
the O 
essential O 
oil O 
of O 
Zanthoxylum O 
zanthoxyloides O 
are O 
of O 
additional O 
significance O 
. O 

( O 
HlyA O 
) O 
produced O 
by O 
some O 
stains O 
of O 
Escherichia O 
coli O 
is O 
considered O 
to O 
be O 
an O 
important O 
virulence O 
factor O 
of O 
those O 
bacteria O 
. O 
On O 
the O 
other O 
hand O 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
have O 
been O 
reported O 
to O 
be O 
involved O 
in O 
the O 
pathogenesis O 
of O 
different O 
diseases O 
via O 
oxidative O 
stress O 
generation O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
analyze O 
the O 
capacity O 
of O 
HlyA O 
to O 
induce O 
oxidative O 
stress O 
in O 
whole O 
blood O 
cultures O 
( O 
WBCs O 
) O 
. O 
To O 
this O 
end O 
, O 
ROS O 
production O 
, O 
the O 
damage O 
induced O 
in O 
lipids O 
and O 
proteins O 
, O 
and O 
the O 
antioxidant O 
defense O 
system O 
was O 
evaluated O 
in O 
blood O 
cultures O 
exposed O 
to O 
low O 
concentrations O 
of O 
HlyA O 
. O 
We O 
found O 
that O 
HlyA O 
increased O 
the O 
level O 
of O 
free O 
radicals O 
detected O 
by O 
chemiluminescence O 
assay O 
. O 
Moreover O 
, O 
lipid O 
peroxidation O 
and O 
protein O 
damage O 
was O 
significantly O 
increased O 
in O 
cultures O 
treated O 
with O 
HlyA O 
in O 
comparation O 
with O 
those O 
found O 
in O 
control O 
cultures O 
. O 
On O 
the O 
other O 
hand O 
, O 
a O 
decrease O 
in O 
total O 
antioxidant O 
capacity O 
of O 
plasma O 
and O 
in O 
the O 
activity O 
of O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
was O 
observed O 
in O 
plasma O 
from O 
blood O 
treated O 
with O 
HlyA O 
. O 
Collectively O 
, O 
our O 
data O 
demonstrate O 
that O 
low O 
concentrations O 
of O 
E O 
. O 
coli O 
hemolysin O 
induced O 
oxidative O 
stress O 
in O 
WBCs O 
with O 
the O 
induction O 
of O 
different O 
oxidative O 
damage O 
biomarkers O 
. O 

promising O 
approach O 
for O 
local O 
drug O 
delivery O 
is O 
high O 
- O 
intensity O 
focused O 
ultrasound O 
(HIFU)-triggered O 
release O 
of O 
drugs O 
from O 
stimuli O 
- O 
responsive O 
nanoparticles O 
such O 
as O 
liposomes O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
another O 
release O 
mechanism O 
is O 
involved O 
with O 
HIFU-triggered O 
release O 
from O 
liposomes O 
beside O 
cavitation O 
and O 
temperature O 
. O 
Furthermore O 
, O 
it O 
was O 
studied O 
whether O 
this O 
new O 
release O 
mechanism O 
allows O 
the O 
release O 
of O 
lipophilic O 
compounds O 
. O 
Therefore O 
, O 
both O 
a O 
lipophilic O 
( O 
Nile B-TRIVIAL 
red I-TRIVIAL 
) O 
and O 
a O 
hydrophilic O 
( O 
fluorescein B-TRIVIAL 
) O 
compound O 
were O 
loaded O 
into O 
thermosensitive O 
( O 
TSL O 
) O 
or O 
non O 
- O 
thermosensitive O 
liposomes O 
( O 
NTSL O 
) O 
and O 
the O 
liposomes O 
were O 
subjected O 
both O 
to O 
continuous O 
wave- O 
( O 
CW O 
) O 
and O 
pulsed O 
wave O 
(PW)-HIFU O 
. O 
The O 
mean O 
liposome O 
size O 
varied O 
from O 
97 O 
to O 
139nm O 
with O 
a O 
polydispersity O 
index O 
(PDI)≤0.06 O 
for O 
the O 
different O 
formulations O 
. O 
The O 
Tm O 
of O 
the O 
phospholipid O 
bilayer O 
of O 
the O 
TSL O 
was O 
around O 
42°C O 
. O 
Approximately O 
80% O 
of O 
fluorescein B-TRIVIAL 
was O 
released O 
within O 
15min O 
from O 
TSL O 
at O 
temperatures≥42°C O 
. O 
In O 
contrast O 
, O 
no O 
fluorescein B-TRIVIAL 
release O 
from O 
NTSL O 
and O 
NR O 
release O 
from O 
both O 
TSL O 
and O 
NTSL O 
was O 
observed O 
at O 
temperatures O 
up O 
to O 
60°C O 
. O 
CW-HIFU O 
exposure O 
of O 
TSL O 
resulted O 
in O 
rapid O 
temperature O 
elevation O 
up O 
to O 
52°C O 
and O 
subsequently O 
almost O 
quantitative O 
fluorescein B-TRIVIAL 
release O 
. O 
Fluorescein B-TRIVIAL 
release O 
from O 
NTSL O 
was O 
also O 
substantial O 
( O 
~64% O 
after O 
16min O 
at O 
20W O 
) O 
. O 
Surprisingly O 
, O 
CW-HIFU O 
exposure O 
( O 
20W O 
for O 
16min O 
) O 
resulted O 
in O 
the O 
release O 
of O 
NR O 
from O 
TSL O 
( O 
~66% O 
of O 
the O 
loaded O 
amount O 
) O 
, O 
and O 
this O 
was O 
even O 
higher O 
from O 
NTSL O 
( O 
~78% O 
) O 
. O 
PW-HIFU O 
exposure O 
did O 
not O 
result O 
in O 
temperatures O 
above O 
the O 
Tm O 
of O 
TSL O 
. O 
However O 
, O 
nearly O 
85% O 
of O 
fluorescein B-TRIVIAL 
was O 
released O 
from O 
TSL O 
after O 
32min O 
at O 
20W O 
of O 
PW-HIFU O 
exposure O 
, O 
whereas O 
the O 
release O 
from O 
NTSL O 
was O 
around O 
27% O 
. O 
Interestingly O 
, O 
NR O 
release O 
from O 
NTSL O 
was~30% O 
after O 
2min O 
PW-HIFU O 
exposure O 
and O 
increased O 
to~70% O 
after O 
32min O 
. O 
Furthermore O 
, O 
addition O 
of O 
microbubbles O 
to O 
the O 
liposomes O 
prior O 
to O 
PW-HIFU O 
exposure O 
did O 
not O 
result O 
in O 
more O 
release O 
, O 
which O 
suggests O 
that O 
cavitation O 
can O 
be O 
excluded O 
as O 
the O 
main O 
mechanism O 
responsible O 
for O 
the O 
triggered O 
release O 
of O 
both O 
a O 
hydrophilic O 
and O 
a O 
lipophilic O 
model O 
compound O 
from O 
liposomes O 
. O 
Dynamic O 
light O 
scattering O 
analysis O 
showed O 
that O 
the O 
mean O 
size O 
and O 
PDI O 
of O 
the O 
liposomes O 
did O 
not O 
significantly O 
change O 
after O 
CW- O 
and O 
PW-HIFU O 
exposure O 
. O 
Taken O 
together O 
, O 
it O 
is O 
therefore O 
concluded O 
that O 
neither O 
temperature O 
elevation O 
nor O 
inertial O 
cavitation O 
is O 
essential O 
for O 
the O 
release O 
of O 
both O 
hydrophilic O 
and O 
lipophilic O 
compounds O 
from O 
liposomes O 
. O 
It O 
is O 
assumed O 
that O 
the O 
release O 
originates O 
from O 
radiation O 
force O 
- O 
induced O 
acoustic O 
streaming O 
, O 
causing O 
the O 
liposomes O 
to O 
collide O 
at O 
the O 
walls O 
of O 
the O 
exposure O 
chamber O 
leading O 
to O 
shear O 
forces O 
which O 
in O 
turn O 
results O 
in O 
reversible O 
liposome O 
destabilization O 
and O 
release O 
of O 
both O 
hydrophilic O 
and O 
lipophilic O 
compounds O 
. O 

gramicidin O 
- O 
containing O 
lipid O 
nanoparticles O 
( O 
Lac-GLN O 
) O 
were O 
developed O 
for O 
delivery O 
of O 
anti-microRNA-155 O 
( O 
anti-miR-155 O 
) O 
to O 
hepatocellular O 
carcinoma O 
( O 
HCC O 
) O 
cells O 
. O 
MiR-155 O 
is O 
an O 
oncomiR O 
frequently O 
elevated O 
in O 
HCC O 
. O 
The O 
Lac-GLN O 
formulation O 
contained O 
N-lactobionyl-dioleoyl B-SYSTEMATIC 
phosphatidylethanolamine I-SYSTEMATIC 
( O 
Lac-DOPE B-ABBREVIATION 
) O 
, O 
a O 
ligand O 
for O 
the O 
asialoglycoprotein O 
receptor O 
( O 
ASGR O 
) O 
, O 
and O 
an O 
antibiotic O 
peptide O 
gramicidin O 
A O 
. O 
The O 
nanoparticles O 
exhibited O 
a O 
mean O 
particle O 
diameter O 
of O 
73nm O 
, O 
zeta O 
potential O 
of O 
+ O 
3.5mV O 
, O 
anti-miR O 
encapsulation O 
efficiency O 
of O 
88% O 
, O 
and O 
excellent O 
colloidal O 
stability O 
at O 
4°C O 
. O 
Lac-GLN O 
effectively O 
delivered O 
anti-miR-155 O 
to O 
HCC O 
cells O 
with O 
a O 
16.1- O 
and O 
4.1-fold O 
up O 
- O 
regulation O 
of O 
miR-155 O 
targets O 
C O 
/ O 
EBPβ O 
and O 
FOXP3 O 
genes O 
, O 
respectively O 
, O 
and O 
exhibited O 
significant O 
greater O 
efficiency O 
over O 
Lipofectamine O 
2000 O 
. O 
In O 
mice O 
, O 
intravenous O 
injection O 
of O 
Lac-GLN O 
containing O 
Cy3-anti-miR-155 O 
led O 
to O 
preferential O 
accumulation O 
of O 
the O 
anti-miR-155 O 
in O 
hepatocytes O 
. O 
Intravenous O 
administration O 
of O 
1.5mg O 
/ O 
kg O 
anti-miR-155 O 
loaded O 
Lac-GLN O 
resulted O 
in O 
up O 
- O 
regulation O 
of O 
C O 
/ O 
EBPβ O 
and O 
FOXP3 O 
by O 
6.9- O 
and O 
2.2-fold O 
, O 
respectively O 
. O 
These O 
results O 
suggest O 
potential O 
application O 
of O 
Lac-GLN O 
as O 
a O 
liver O 
- O 
specific O 
delivery O 
vehicle O 
for O 
anti-miR O 
therapy O 
. O 

advances O 
in O 
theranostic O 
nanocarriers O 
of O 
doxorubicin B-TRIVIAL 
based O 
on O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
gold O 
nanoparticles O 
. O 

( O 
organic O 
/ O 
inorganic O 
) O 
nanoparticles O 
emerged O 
as O 
a O 
simple O 
solution O 
to O 
build O 
" O 
theranostic O 
" O 
systems O 
. O 
Due O 
to O 
their O 
physical O 
properties O 
, O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
SPIONs O 
) O 
and O 
plasmonic O 
gold O 
nanoparticles O 
( O 
Au B-FORMULA 
-NPs O 
) O 
are O 
extensively O 
studied O 
as O 
a O 
part O 
of O 
diagnostic O 
and O 
therapeutic O 
strategies O 
in O 
cancer O 
treatments O 
. O 
They O 
can O 
be O 
used O 
as O 
agents O 
for O 
in O 
vitro O 
or O 
in O 
vivo O 
imaging O 
, O 
for O 
magnetic O 
drug O 
targeting O 
and O 
/ O 
or O 
thermal O 
therapy O 
. O 
Their O 
functionalization O 
with O 
organic O 
shells O 
enhances O 
their O 
potential O 
performance O 
in O 
tumor O 
targeting O 
and O 
drug O 
delivery O 
. O 
The O 
advances O 
in O 
such O 
hybrid O 
nanocarriers O 
are O 
well O 
illustrated O 
with O 
the O 
example O 
of O 
the O 
anticancer O 
drug O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
give O 
a O 
multidisciplinary O 
overview O 
of O 
such O 
smart O 
nanosystems O 
loaded O 
with O 
DOX B-ABBREVIATION 
, O 
based O 
on O 
examples O 
taken O 
from O 
recent O 
publications O 
. O 
From O 
a O 
physico O 
- O 
chemical O 
point O 
of O 
view O 
, O 
we O 
discuss O 
the O 
choices O 
for O 
the O 
strategies O 
for O 
loading O 
DOX B-ABBREVIATION 
and O 
the O 
consequences O 
on O 
drug O 
release O 
. O 
From O 
a O 
biological O 
point O 
of O 
view O 
, O 
we O 
analyze O 
the O 
in O 
vitro O 
and O 
in O 
vivo O 
assays O 
concerning O 
tumor O 
imaging O 
, O 
targeted O 
drug O 
delivery O 
and O 
anticancer O 
efficiency O 
. O 
Future O 
opportunities O 
and O 
challenges O 
are O 
also O 
addressed O 
. O 

A I-TRIVIAL 
: O 
Update O 
on O 
newly O 
developed O 
data O 
and O 
how O 
they O 
address O 
NTP's O 
2008 O 
finding O 
of O 
" O 
Some O 
Concern O 
" O 

A I-TRIVIAL 
( O 
BPA B-ABBREVIATION 
) O 
is O 
a O 
component O 
of O 
polycarbonate B-FAMILY 
plastics O 
and O 
epoxy B-SYSTEMATIC 
resins O 
used O 
in O 
many O 
commercial O 
products O 
including O 
coatings O 
and O 
liners O 
of O 
food O 
containers O 
. O 
Low O 
levels O 
of O 
BPA B-ABBREVIATION 
can O 
be O 
detected O 
in O 
over O 
90% O 
of O 
human O 
urine O 
samples O 
in O 
the O 
US O 
, O 
indicating O 
that O 
exposure O 
to O 
BPA B-ABBREVIATION 
is O 
widespread O 
. O 
In O 
2008 O 
, O 
the O 
US O 
National O 
Toxicology O 
Program's O 
Center O 
for O 
the O 
Evaluation O 
of O 
Risks O 
to O 
Human O 
Reproduction O 
( O 
NTP-CERHR O 
) O 
expressed O 
concerns O 
regarding O 
BPA B-ABBREVIATION 
' O 
s O 
potential O 
health O 
effects O 
, O 
and O 
suggested O 
improved O 
study O 
designs O 
and O 
methodologies O 
that O 
they O 
believed O 
would O 
address O 
those O 
concerns O 
. O 
This O 
paper O 
discusses O 
some O 
of O 
the O 
controversial O 
issues O 
surrounding O 
BPA B-ABBREVIATION 
, O 
summarizes O 
the O 
current O 
regulatory O 
status O 
of O 
BPA B-ABBREVIATION 
, O 
reviews O 
recent O 
pharmacokinetic O 
studies O 
, O 
and O 
describes O 
ongoing O 
and O 
planned O 
research O 
on O 
the O 
effects O 
of O 
BPA B-ABBREVIATION 
. O 
In O 
addition O 
, O 
we O 
evaluate O 
two O 
papers O 
studying O 
BPA B-ABBREVIATION 
neurobehavioral O 
effects O 
, O 
identified O 
by O 
the O 
European O 
Food O 
Safety O 
Authority O 
and O 
the O 
German O 
Federal O 
Institute O 
for O 
Risk O 
Assessment O 
as O 
being O 
valid O 
for O 
use O 
in O 
risk O 
assessment O 
, O 
to O 
determine O 
whether O 
they O 
address O 
the O 
NTP-CERHR O 
methodological O 
concerns O 
. O 
The O 
data O 
from O 
these O 
studies O 
would O 
likely O 
be O 
sufficient O 
for O 
NTP O 
to O 
lower O 
its O 
concern O 
level O 
for O 
neurobehavioral O 
effects O 
of O 
BPA B-ABBREVIATION 
. O 
At O 
this O 
time O 
, O 
many O 
regulatory O 
agencies O 
from O 
around O 
the O 
world O 
support O 
the O 
use O 
of O 
BPA B-ABBREVIATION 
in O 
food O 
contact O 
materials O 
. O 

and O 
ecological O 
constraints O 
that O 
cause O 
the O 
slow O 
growth O 
and O 
depleted O 
production O 
of O 
crops O 
have O 
raised O 
a O 
major O 
concern O 
in O 
the O 
agriculture O 
industry O 
as O 
they O 
represent O 
a O 
possible O 
threat O 
of O 
short O 
food O 
supply O 
in O 
the O 
future O 
. O 
The O 
key O 
feature O 
that O 
regulates O 
the O 
stress O 
signaling O 
pathway O 
is O 
always O 
related O 
to O 
the O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
. O 
The O 
accumulation O 
of O 
ROS O 
in O 
plant O 
cells O 
would O 
leave O 
traces O 
of O 
biomarkers O 
at O 
the O 
genome O 
, O 
proteome O 
, O 
and O 
metabolome O 
levels O 
, O 
which O 
could O 
be O 
identified O 
with O 
the O 
recent O 
technological O 
breakthrough O 
coupled O 
with O 
improved O 
performance O 
of O 
bioinformatics O 
. O 
This O 
review O 
highlights O 
the O 
recent O 
breakthrough O 
in O 
molecular O 
strategies O 
( O 
comprising O 
transcriptomics O 
, O 
proteomics O 
, O 
and O 
metabolomics O 
) O 
in O 
identifying O 
oxidative O 
stress O 
biomarkers O 
and O 
the O 
arising O 
opportunities O 
and O 
obstacles O 
observed O 
in O 
research O 
on O 
biomarkers O 
in O 
rice O 
. O 
The O 
major O 
issue O 
in O 
incorporating O 
bioinformatics O 
to O 
validate O 
the O 
biomarkers O 
from O 
different O 
omic O 
platforms O 
for O 
the O 
use O 
of O 
rice O 
- O 
breeding O 
programs O 
is O 
also O 
discussed O 
. O 
The O 
development O 
of O 
powerful O 
techniques O 
for O 
identification O 
of O 
oxidative O 
stress O 
- O 
related O 
biomarkers O 
and O 
the O 
integration O 
of O 
data O 
from O 
different O 
disciplines O 
shed O 
light O 
on O 
the O 
oxidative O 
response O 
pathways O 
in O 
plants O 
. O 

of O 
perfluoroalkyl B-FAMILY 
acid I-FAMILY 
activity O 
using O 
primary O 
mouse O 
and O 
human O 
hepatocytes O 
. O 

perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
and O 
perfluorooctane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
have O 
been O 
studied O 
at O 
length O 
, O 
less O 
is O 
known O 
about O 
the O 
biological O 
activity O 
of O 
other O 
perfluoroalkyl B-FAMILY 
acids I-FAMILY 
( O 
PFAAs B-ABBREVIATION 
) O 
detected O 
in O 
the O 
environment O 
. O 
Using O 
a O 
transient O 
transfection O 
assay O 
developed O 
in O 
COS-1 O 
cells O 
, O 
our O 
group O 
has O 
previously O 
evaluated O 
a O 
variety O 
of O 
PFAAs B-ABBREVIATION 
for O 
activity O 
associated O 
with O 
activation O 
of O 
peroxisome O 
proliferator O 
- O 
activated O 
receptor O 
alpha O 
( O 
PPARα O 
) O 
. O 
Here O 
we O 
use O 
primary O 
heptatocytes O 
to O 
further O 
assess O 
the O 
biological O 
activity O 
of O 
a O 
similar O 
group O 
of O 
PFAAs B-ABBREVIATION 
using O 
custom O 
designed O 
Taqman O 
Low O 
Density O 
Arrays O 
. O 
Primary O 
mouse O 
and O 
human O 
hepatoyctes O 
were O 
cultured O 
for O 
48h O 
in O 
the O 
presence O 
of O 
varying O 
concentrations O 
of O 
12 O 
different O 
PFAAs B-ABBREVIATION 
or O 
Wy14,643 B-IDENTIFIER 
, O 
a O 
known O 
activator O 
of O 
PPARα O 
. O 
Total O 
RNA O 
was O 
collected O 
and O 
the O 
expression O 
of O 
48 O 
mouse O 
or O 
human O 
genes O 
evaluated O 
. O 
Gene O 
selection O 
was O 
based O 
on O 
either O 
in O 
- O 
house O 
liver O 
microarray O 
data O 
( O 
mouse O 
) O 
or O 
published O 
data O 
using O 
primary O 
hepatocytes O 
( O 
human O 
) O 
. O 
Gene O 
expression O 
in O 
primary O 
mouse O 
hepatocytes O 
was O 
more O 
restricted O 
than O 
expected O 
. O 
Genes O 
typically O 
regulated O 
in O 
whole O 
tissue O 
by O 
PPARα O 
agonists O 
were O 
not O 
altered O 
in O 
mouse O 
cells O 
including O 
Acox1 O 
, O 
Me1 O 
, O 
Acaa1a O 
, O 
Hmgcs1 O 
, O 
and O 
Slc27a1 O 
. O 
Cyp2b10 O 
, O 
a O 
gene O 
regulated O 
by O 
the O 
constitutive O 
androstane B-TRIVIAL 
receptor O 
and O 
a O 
transcript O 
normally O 
up O 
- O 
regulated O 
by O 
in O 
vivo O 
exposure O 
to O 
PFAAs B-ABBREVIATION 
, O 
was O 
also O 
unchanged O 
in O 
cultured O 
mouse O 
hepatocytes O 
. O 
Cyp4a14 O 
, O 
Ehhadh O 
, O 
Pdk4 O 
, O 
Cpt1b O 
, O 
and O 
Fabp1 O 
were O 
regulated O 
as O 
expected O 
in O 
mouse O 
cells O 
. O 
A O 
larger O 
group O 
of O 
genes O 
were O 
differentially O 
expressed O 
in O 
human O 
primary O 
hepatocytes O 
, O 
however O 
, O 
little O 
consistency O 
was O 
observed O 
across O 
compounds O 
with O 
respect O 
to O 
which O 
genes O 
produced O 
a O 
significant O 
dose O 
response O 
making O 
the O 
determination O 
of O 
relative O 
biological O 
activity O 
difficult O 
. O 
This O 
likely O 
reflects O 
weaker O 
activation O 
of O 
PPARα O 
in O 
human O 
versus O 
rodent O 
cells O 
as O 
well O 
as O 
variation O 
among O 
individual O 
cell O 
donors O 
. O 
Unlike O 
mouse O 
cells O 
, O 
CYP2B6 O 
was O 
up O 
- O 
regulated O 
in O 
human O 
hepatocytes O 
by O 
a O 
number O 
of O 
PFAAs B-ABBREVIATION 
as O 
was O 
PPARδ O 
. O 
Rankings O 
were O 
conducted O 
on O 
the O 
limited O 
dataset O 
. O 
In O 
mouse O 
hepatocytes O 
, O 
the O 
pattern O 
was O 
similar O 
to O 
that O 
previously O 
observed O 
in O 
the O 
COS-1 O 
reporter O 
cell O 
assay O 
. O 
With O 
the O 
exception O 
of O 
PFHxA O 
, O 
longer O 
chain O 
PFAA B-ABBREVIATION 
carboxylates B-FAMILY 
were O 
the O 
most O 
active O 
. O 
The O 
pattern O 
was O 
similar O 
in O 
human O 
hepatocytes O 
, O 
although O 
PFDA B-ABBREVIATION 
and O 
PFOS B-ABBREVIATION 
showed O 
higher O 
activity O 
than O 
previously O 
observed O 
while O 
PFOA B-ABBREVIATION 
showed O 
somewhat O 
less O 
activity O 
. O 
These O 
data O 
reflect O 
inherent O 
challenges O 
in O 
using O 
primary O 
hepatocytes O 
to O 
predict O 
toxicological O 
response O 
. O 

xylanases O 
are O 
rather O 
less O 
studied O 
compared O 
to O 
terrestrial O 
xylanases O 
. O 
In O 
this O 
study O 
, O 
a O 
new O 
xylanase O 
gene O 
, O 
xynB O 
, O 
was O 
cloned O 
from O 
the O 
marine O 
bacterium O 
, O 
Glaciecola O 
mesophila O 
KMM241 O 
, O 
and O 
expressed O 
in O 
Escherichia O 
coli O 
. O 
xynB O 
encodes O 
a O 
multi O 
- O 
domain O 
xylanase O 
XynB O 
of O 
glycoside O 
hydrolase O 
( O 
GH O 
) O 
family O 
8 O 
. O 
The O 
recombinant O 
XynB O 
comprises O 
an O 
N B-FORMULA 
-terminal O 
domain O 
( O 
NTD O 
) O 
with O 
unknown O 
function O 
and O 
a O 
catalytic O 
domain O 
, O 
which O 
is O 
structurally O 
novel O 
among O 
the O 
characterized O 
xylanases O 
of O 
GH O 
family O 
8 O 
. O 
XynB O 
has O 
the O 
highest O 
identity O 
( O 
38% O 
) O 
to O 
rXyn8 O 
among O 
the O 
characterized O 
xylanases O 
. O 
The O 
recombinant O 
XynB O 
showed O 
maximal O 
activity O 
at O 
pH O 
6-7 O 
and O 
35 O 
°C O 
. O 
It O 
is O 
thermolabile O 
and O 
salt O 
- O 
tolerant O 
. O 
XynB O 
is O 
an O 
endo-xylanase O 
that O 
demands O 
at O 
least O 
five O 
sugar O 
moieties O 
for O 
effective O 
cleavage O 
and O 
to O 
hydrolyze O 
xylohexaose B-FAMILY 
and O 
xylopentaose B-FAMILY 
into O 
xylotetraose B-FAMILY 
, O 
xylotriose B-FAMILY 
and O 
xylobiose B-FAMILY 
. O 
NTD O 
was O 
expressed O 
in O 
Escherichia O 
coli O 
to O 
analyze O 
its O 
function O 
. O 
The O 
recombinant O 
NTD O 
exhibited O 
a O 
high O 
binding O 
ability O 
to O 
insoluble O 
xylan O 
and O 
avicel O 
and O 
little O 
binding O 
ability O 
to O 
chitosan O 
and O 
chitin O 
. O 
Since O 
the O 
NTD O 
shows O 
no O 
obvious O 
homology O 
to O 
any O 
known O 
carbohydrate B-FAMILY 
-binding O 
module O 
( O 
CBM O 
) O 
sequence O 
in O 
public O 
databases O 
, O 
XynB O 
may O 
contain O 
a O 
new O 
type O 
of O 
CBM O 
. O 

in O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
brands O 
and O 
their O 
influence O 
on O 
the O 
preparation O 
process O 
of O 
hydrogel O 
microspheres O 
. O 

microspheres O 
, O 
e.g O 
. O 
for O 
the O 
use O 
as O 
protein O 
carriers O 
, O 
can O 
be O 
prepared O 
without O 
the O 
use O 
of O 
organic O 
solvents O 
via O 
an O 
emulsified O 
aqueous O 
two O 
- O 
phase O 
system O 
( O 
ATPS O 
) O 
that O 
is O 
based O 
on O 
two O 
immiscible O 
polymer O 
solutions O 
. O 
The O 
type O 
and O 
concentration O 
of O 
the O 
polymers O 
can O 
affect O 
the O 
ATPS O 
and O 
finally O 
the O 
distribution O 
of O 
incorporated O 
drugs O 
between O 
the O 
aqueous O 
phases O 
. O 
For O 
the O 
preparation O 
of O 
hydrogel O 
microspheres O 
based O 
on O 
hydroxyethyl B-SYSTEMATIC 
starch- O 
hydroxyethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
HES-HEMA B-ABBREVIATION 
) O 
, O 
hydroxyethyl B-SYSTEMATIC 
starch- O 
methacrylate B-TRIVIAL 
( O 
HES-MA B-ABBREVIATION 
) O 
, O 
and O 
hydroxyethyl B-SYSTEMATIC 
starch- O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
HES-P(EG)6MA B-FORMULA 
) O 
, O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
12000 O 
( O 
PEG B-ABBREVIATION 
12000 O 
) O 
was O 
used O 
as O 
second O 
polymer O 
. O 
The O 
particle O 
size O 
distribution O 
and O 
encapsulation O 
efficiency O 
of O 
the O 
microspheres O 
depended O 
dramatically O 
on O 
the O 
type O 
of O 
PEG B-ABBREVIATION 
12000 O 
that O 
was O 
used O 
in O 
the O 
second O 
phase O 
of O 
the O 
ATPS O 
. O 
Analysis O 
of O 
different O 
PEG B-ABBREVIATION 
12000 O 
brands O 
by O 
various O 
methods O 
revealed O 
differences O 
in O 
the O 
salt O 
composition O 
and O 
molecular O 
weight O 
distribution O 
of O 
the O 
polymers O 
which O 
can O 
explain O 
the O 
results O 
from O 
the O 
production O 
process O 
. O 
The O 
results O 
illustrate O 
that O 
the O 
range O 
of O 
product O 
specifications O 
may O 
not O 
always O 
be O 
tight O 
enough O 
to O 
avoid O 
variability O 
in O 
pharmaceutical O 
processes O 
like O 
the O 
preparation O 
of O 
hydrogel O 
microspheres O 
by O 
an O 
aqueous O 
two O 
- O 
phase O 
preparation O 
process O 
. O 

of O 
7-O-galloyl-d-sedoheptulose B-SYSTEMATIC 
, O 
isolated O 
from O 
Corni O 
Fructus O 
, O 
in O 
the O 
adipose O 
tissue O 
of O 
type O 
2 O 
diabetic O 
db O 
/ O 
db O 
mice O 
. O 

aim O 
of O 
the O 
present O 
study O 
was O 
to O 
evaluate O 
the O 
beneficial O 
effects O 
of O 
7-O-galloyl-d-sedoheptulose B-SYSTEMATIC 
( O 
GS O 
) O 
, O 
isolated O 
from O 
Corni O 
Fructus O 
, O 
using O 
type O 
2 O 
diabetic O 
mice O 
. O 
GS O 
was O 
orally O 
administered O 
to O 
db O 
/ O 
db O 
mice O 
at O 
doses O 
of O 
20 O 
and O 
100mg O 
/ O 
kg O 
body O 
weight O 
per O 
day O 
for O 
6weeks O 
, O 
and O 
the O 
effects O 
of O 
GS O 
on O 
biochemical O 
factors O 
in O 
serum O 
and O 
adipose O 
tissue O 
were O 
investigated O 
. O 
To O 
define O 
the O 
underlying O 
mechanism O 
of O 
these O 
effects O 
, O 
protein O 
expressions O 
related O 
to O 
lipid O 
metabolism O 
, O 
inflammation O 
, O 
fibrosis O 
, O 
and O 
apoptosis O 
, O 
were O 
measured O 
. O 
The O 
results O 
showed O 
that O 
levels O 
of O 
glucose B-TRIVIAL 
, O 
leptin O 
, O 
insulin O 
, O 
C- O 
peptide O 
, O 
resistin O 
, O 
tumor O 
necrosis O 
factor-α O 
, O 
interleukin-6 O 
, O 
triglycerides B-FAMILY 
, O 
total O 
cholesterol B-TRIVIAL 
, O 
non-esterified O 
fatty B-FAMILY 
acids I-FAMILY 
, O 
high O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
very O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
/ O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
, O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substance O 
( O 
TBARS O 
) O 
in O 
serum O 
were O 
down O 
- O 
regulated O 
, O 
while O 
adiponectin O 
was O 
augmented O 
by O 
GS O 
treatment O 
. O 
In O 
addition O 
, O 
the O 
elevated O 
lipid O 
, O 
ROS O 
, O 
and O 
TBARS O 
contents O 
in O 
adipose O 
tissue O 
as O 
well O 
as O 
serum O 
levels O 
in O 
db O 
/ O 
db O 
mice O 
were O 
significantly O 
decreased O 
by O 
the O 
oral O 
administration O 
of O 
GS O 
. O 
From O 
protein O 
analysis O 
, O 
the O 
decreased O 
expressions O 
of O 
peroxisome O 
proliferator O 
activated O 
receptor O 
(PPAR)α O 
, O 
PPARγ O 
, O 
and O 
B-cell O 
lymphoma O 
2 O 
were O 
up O 
- O 
regulated O 
in O 
the O 
adipose O 
tissue O 
of O 
db O 
/ O 
db O 
mice O 
. O 
The O 
administration O 
of O 
GS O 
significantly O 
decreased O 
sterol B-FAMILY 
regulatory O 
element O 
binding O 
protein-1 O 
, O 
nuclear O 
factor O 
- O 
kappa O 
? O 
> O 
Bp65 O 
, O 
cyclooxygenase-2 O 
, O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
, O 
monocyte O 
chemotactic O 
protein-1 O 
, O 
intracellular O 
adhesion O 
molecule-1 O 
, O 
phosphor O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinase O 
, O 
activator O 
protein-1 O 
, O 
transforming O 
growth O 
factor-β1 O 
, O 
Bax O 
, O 
cytochrome O 
c O 
, O 
and O 
caspase-3 O 
expressions O 
. O 
These O 
results O 
suggest O 
that O 
GS O 
acts O 
as O 
a O 
regulator O 
of O 
oxidative O 
stress O 
, O 
inflammation O 
, O 
fibrosis O 
, O 
and O 
apoptosis O 
in O 
the O 
adipose O 
tissue O 
of O 
db O 
/ O 
db O 
mice O 
. O 

of O 
new O 
structural O 
types O 
as O 
perspective O 
antioxidant O 
agents O 
. O 

series O 
of O 
polysulfones B-FAMILY 
of O 
new O 
structural O 
types O 
on O 
the O 
basis O 
of O 
azanorbornenes B-FAMILY 
, O 
2,2-diallyl-1,1,3,3-tetraethylguanidiniumchloride B-MULTIPLE 
and I-MULTIPLE 
tris(diethylamino)diallylaminophosphonium I-MULTIPLE 
salts I-MULTIPLE 
were O 
obtained O 
by O 
free O 
radical O 
polymerization O 
reaction O 
. O 
Their O 
antioxidant O 
properties O 
in O 
lipid O 
peroxidation O 
induced O 
by O 
iron B-SYSTEMATIC 
/ O 
ascorbate B-TRIVIAL 
and O 
in O 
erythrocyte O 
hemolysis O 
by O 
H2O2 B-FORMULA 
were O 
evaluated O 
. O 
The O 
polysulfone B-FAMILY 
of O 
2,2-diallyl-1,1,3,3-tetraethylguanidinium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
showed O 
protection O 
of O 
erythrocytes O 
against O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
and O 
thermal O 
shock O 
, O 
protected O 
epithelial O 
cells O 
against O 
UV O 
irradiation O 
, O 
was O 
not O 
toxic O 
for O 
erythrocytes O 
, O 
epithelial O 
cells O 
SPEV O 
and O 
3T3 O 
fibroblasts O 
. O 
The O 
polysulfone B-FAMILY 
of O 
N-benzyl-2-azanorbornene-5 B-SYSTEMATIC 
inhibited O 
lipid O 
peroxidation O 
in O 
liver O 
homogenate O 
, O 
did O 
not O 
exhibit O 
cytotoxicity O 
in O 
SPEV O 
and O 
3T3 O 
cells O 
, O 
protected O 
these O 
against O 
UV O 
irradiation O 
. O 
Both O 
compounds O 
had O 
low O 
bioavailability O 
and O 
may O 
be O 
recommended O 
for O 
further O 
investigations O 
as O 
excipients O 
to O 
be O 
externally O 
applied O 
. O 

, O 
synthesis O 
and O 
antiproliferative O 
properties O 
of O 
some O 
new O 
5- B-FAMILY 
substituted-2-iminobenzimidazole I-FAMILY 
derivatives O 
. O 

new O 
1,3,5- B-FAMILY 
substituted-2,3-dihydro-2-imino- I-FAMILY 
benzimidazoles I-FAMILY 
were O 
synthesized O 
under O 
solid O 
- O 
liquid O 
phase O 
transfer O 
catalysis O 
conditions O 
using O 
5- B-FAMILY 
substituted-2-aminobenzimidazoles I-FAMILY 
as O 
precursors O 
in O 
order O 
to O 
assess O 
their O 
cytotoxicity O 
respectively O 
proliferative O 
activity O 
. O 
The O 
structures O 
of O 
the O 
compounds O 
were O 
confirmed O 
by O 
IR O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
and O 
elemental O 
analysis O 
. O 
Compounds O 
9-10 O 
, O 
12 O 
and O 
16-17 O 
were O 
evaluated O 
for O 
their O 
cytotoxical O 
effect O 
on O 
four O 
cancer O 
cell O 
lines O 
: O 
HT-29 O 
, O 
breast O 
cancer O 
cells O 
MDA-MB-231 O 
, O 
HeLa O 
, O 
HepG2 O 
and O 
as O 
well O 
as O 
human O 
diploid O 
cell O 
line O 
Lep-3 O 
. O 
Significant O 
cytotoxicity O 
of O 
hydrazone B-FAMILY 
16 O 
against O 
MDA-MB-231 O 
was O 
established O 
by O 
biologically O 
study O 
, O 
the O 
IC50 O 
was O 
6.2 O 
nM O 
while O 
the O 
EC50 O 
value O 
to O 
Lep O 
3 O 
is O 
0.21 O 
nM O 
. O 
Relative O 
high O 
antiproliferative O 
effects O 
of O 
the O 
acetate B-SYSTEMATIC 
12 O 
and O 
compound O 
16 O 
against O 
HT-29 O 
were O 
ascertained O 
and O 
the O 
calculated O 
IC50 O 
values O 
were O 
IC50 O 
- O 
0.85 O 
nM O 
and O 
IC50 O 
- O 
2.83 O 
nM O 
respectively O 
. O 
Cytotoxic O 
activity O 
against O 
HeLa O 
and O 
HepG2 O 
cells O 
was O 
demonstrated O 
by O 
hydrazone B-FAMILY 
17 O 
, O 
IC50 O 
was O 
7.2 O 
nM O 
and O 
117 O 
nM O 
respectively O 
. O 
All O 
tested O 
compounds O 
revealed O 
proliferative O 
activities O 
to O 
human O 
diploid O 
cell O 
line O 
Lep-3 O 
. O 
The O 
EC50 O 
values O 
were O 
in O 
the O 
range O 
from O 
0.05 O 
to O 
16.91 O 
nM O 
. O 
The O 
obtained O 
results O 
prove O 
the O 
selective O 
cytotoxicity O 
of O 
the O 
tested O 
compounds O 
and O 
are O 
promising O 
for O 
further O 
evaluation O 
of O 
the O 
investigated O 
compounds O 
in O 
vivo O 
experiments O 
using O 
experimentally O 
induced O 
tumors O 
in O 
laboratory O 
animals O 
. O 

, O 
structural O 
and O 
pharmacological O 
characterization O 
of O 
τ-CnVA B-TRIVIAL 
, O 
a O 
conopeptide O 
that O 
selectively O 
interacts O 
with O 
somatostatin O 
sst3 O 
receptor O 
. O 

are O 
a O 
diverse O 
array O 
of O 
small O 
linear O 
and O 
reticulated O 
peptides O 
that O 
interact O 
with O 
high O 
potency O 
and O 
selectivity O 
with O 
a O 
large O 
diversity O 
of O 
receptors O 
and O 
ion O 
channels O 
. O 
They O 
are O 
used O 
by O 
cone O 
snails O 
for O 
prey O 
capture O 
or O 
defense O 
. O 
Recent O 
advances O 
in O 
venom O 
gland O 
transcriptomic O 
and O 
venom O 
peptidomic O 
/ O 
proteomic O 
technologies O 
combined O 
with O 
bioactivity O 
screening O 
approaches O 
lead O 
to O 
the O 
identification O 
of O 
new O 
toxins O 
with O 
original O 
pharmacological O 
profiles O 
. O 
Here O 
, O 
from O 
transcriptomic O 
/ O 
proteomic O 
analyses O 
of O 
the O 
Conus O 
consors O 
cone O 
snail O 
, O 
we O 
identified O 
a O 
new O 
conopeptide O 
called O 
τ-CnVA B-TRIVIAL 
, O 
which O 
displays O 
the O 
typical O 
cysteine B-TRIVIAL 
framework O 
V O 
of O 
the O 
T1-conotoxin O 
superfamily O 
. O 
This O 
peptide O 
was O 
chemically O 
synthesized O 
and O 
its O 
three O 
- O 
dimensional O 
structure O 
was O 
solved O 
by O 
NMR O 
analysis O 
and O 
compared O 
to O 
that O 
of O 
TxVA O 
belonging O 
to O 
the O 
same O 
family O 
, O 
revealing O 
very O 
few O 
common O 
structural O 
features O 
apart O 
a O 
common O 
orientation O 
of O 
the O 
intercysteine O 
loop O 
. O 
Because O 
of O 
the O 
lack O 
of O 
a O 
clear O 
biological O 
function O 
associated O 
with O 
the O 
T-conotoxin O 
family O 
, O 
τ-CnVA B-TRIVIAL 
was O 
screened O 
against O 
more O 
than O 
fifty O 
different O 
ion O 
channels O 
and O 
receptors O 
, O 
highlighting O 
its O 
capacity O 
to O 
interact O 
selectively O 
with O 
the O 
somatostatine O 
sst3 O 
receptor O 
. O 
Pharmacological O 
and O 
functional O 
studies O 
show O 
that O 
τ-CnVA B-TRIVIAL 
displays O 
a O 
micromolar O 
( O 
Ki O 
of O 
1.5μM O 
) O 
antagonist O 
property O 
for O 
the O 
sst3 O 
receptor O 
, O 
being O 
currently O 
the O 
only O 
known O 
toxin O 
to O 
interact O 
with O 
this O 
GPCR O 
subfamily O 
. O 

the O 
past O 
50 O 
years O 
, O 
numerous O 
advances O 
in O 
treatment O 
have O 
produced O 
dramatic O 
increases O 
in O 
the O 
cure O 
rates O 
of O 
pediatric O 
leukemias O 
. O 
Despite O 
this O 
progress O 
, O 
the O 
majority O 
of O 
children O 
with O 
relapsed O 
leukemia O 
are O 
not O 
expected O 
to O 
survive O 
. O 
With O 
current O 
chemotherapy O 
regimens O 
, O 
approximately O 
15 O 
% O 
of O 
children O 
with O 
acute O 
lymphoblastic O 
leukemia O 
and O 
45 O 
% O 
of O 
children O 
with O 
acute O 
myeloid O 
leukemia O 
will O 
have O 
refractory O 
disease O 
or O 
experience O 
a O 
relapse O 
. O 
Advances O 
in O 
the O 
treatment O 
of O 
pediatric O 
relapsed O 
leukemia O 
have O 
not O 
mirrored O 
the O 
successes O 
of O 
upfront O 
therapy O 
, O 
and O 
newer O 
treatments O 
are O 
desperately O 
needed O 
in O 
order O 
to O 
improve O 
survival O 
in O 
these O 
challenging O 
patients O 
. O 
Recent O 
improvements O 
in O 
our O 
knowledge O 
of O 
cancer O 
biology O 
have O 
revealed O 
an O 
extensive O 
number O 
of O 
targets O 
that O 
have O 
the O 
potential O 
to O 
be O 
exploited O 
for O 
anticancer O 
therapy O 
. O 
These O 
advances O 
have O 
led O 
to O 
the O 
development O 
of O 
a O 
number O 
of O 
new O 
treatments O 
that O 
are O 
now O 
being O 
explored O 
in O 
children O 
with O 
relapsed O 
or O 
refractory O 
leukemia O 
. O 
Novel O 
agents O 
seek O 
to O 
exploit O 
the O 
same O 
molecular O 
aberrations O 
that O 
contribute O 
to O 
leukemia O 
development O 
and O 
resistance O 
to O 
therapy O 
. O 
Newer O 
classes O 
of O 
drugs O 
, O 
including O 
monoclonal O 
antibodies O 
, O 
tyrosine B-TRIVIAL 
kinase O 
inhibitors O 
and O 
epigenetic O 
modifiers O 
are O 
transforming O 
the O 
treatment O 
of O 
patients O 
who O 
are O 
not O 
cured O 
with O 
conventional O 
therapies O 
. O 
As O 
the O 
side O 
effects O 
of O 
many O 
new O 
agents O 
are O 
distinct O 
from O 
those O 
seen O 
with O 
conventional O 
chemotherapy O 
, O 
these O 
treatments O 
are O 
often O 
explored O 
in O 
combination O 
with O 
each O 
other O 
or O 
combined O 
with O 
conventional O 
treatment O 
regimens O 
. O 
This O 
review O 
discusses O 
the O 
biological O 
rationale O 
for O 
the O 
most O 
promising O 
new O 
agents O 
and O 
the O 
results O 
of O 
recent O 
studies O 
conducted O 
in O 
pediatric O 
patients O 
with O 
relapsed O 
leukemia O 
. O 

glycosyltransferase O 
activities O 
by O 
tritium B-SYSTEMATIC 
imaging O 
of O 
glycan O 
microarrays O 
. O 

- O 
throughput O 
microarray O 
technology O 
has O 
been O 
combined O 
with O 
ultrasensitive O 
and O 
high O 
- O 
resolution O 
tritium B-SYSTEMATIC 
autoradiography O 
to O 
create O 
a O 
new O 
platform O 
for O 
the O 
quantitative O 
detection O 
of O 
glycosyltransferase O 
activity O 
on O 
glycan O 
arrays O 
. O 
In O 
addition O 
, O 
we O 
show O 
full O 
compatibility O 
with O 
the O 
use O 
of O 
fluorescently O 
labeled O 
lectins O 
to O 
help O 
with O 
the O 
stereochemical O 
assignment O 
of O 
newly O 
formed O 
glycoside O 
linkages O 
. O 

Inhibitors O 
of O 
Phosphatidylinositol B-TRIVIAL 
3 O 
( O 
PI3 O 
) O 
Kinase O 
that O 
have O 
Antiproliferative O 
Activity O 
Only O 
When O 
Delivered O 
as O 
Prodrug O 
Forms O 
. O 

for O 
PI3K O 
: O 
A O 
series O 
of O 
substituted O 
analogues O 
of O 
the O 
phosphatidylinositol B-TRIVIAL 
3 O 
kinase O 
( O 
PI3K O 
) O 
inhibitor O 
LY294002 B-IDENTIFIER 
were O 
prepared O 
and O 
found O 
to O 
potently O 
inhibit O 
the O 
isolated O 
enzyme O 
but O 
not O 
MCF7 O 
cell O 
proliferation O 
. O 
Two O 
tetrazolyl B-SYSTEMATIC 
-substituted O 
analogues O 
were O 
further O 
derivatized O 
as O 
prodrugs O 
resulting O 
in O 
restoration O 
of O 
cell O 
- O 
based O 
activity O 
. O 
These O 
data O 
provide O 
a O 
conceptual O 
model O 
for O 
development O 
of O 
tumor O 
- O 
targeting O 
prodrug O 
forms O 
of O 
cell O 
- O 
impermeable O 
PI3K O 
inhibitors O 
. O 

Complexes O 
with O 
Visible-Light-Induced O 
Anticancer O 
Activity O 
. O 

light O 
on O 
the O 
matter O 
: O 
Rhenium B-FAMILY 
(I) I-FAMILY 
indolato I-FAMILY 
complexes I-FAMILY 
with O 
highly O 
potent O 
visible O 
- O 
light O 
- O 
triggered O 
antiproliferative O 
activity O 
( O 
complex O 
1 O 
: O 
EC50 O 
light=0.1 O 
μM O 
vs O 
EC50 O 
dark=100 O 
μM O 
) O 
in O 
2D- O 
and O 
3D-organized O 
cancer O 
cells O 
are O 
reported O 
and O 
can O 
be O 
traced O 
back O 
to O 
an O 
efficient O 
generation O 
of O 
singlet O 
oxygen B-SYSTEMATIC 
, O 
causing O 
rapid O 
morphological O 
changes O 
and O 
an O 
induction O 
of O 
apoptosis O 
. O 

of O 
acrylamide B-TRIVIAL 
in O 
primary O 
rat O 
hepatocytes O 
: O 
coupling O 
to O 
glutathione B-TRIVIAL 
is O 
faster O 
than O 
conversion O 
to O 
glycidamide B-TRIVIAL 
. O 

( O 
AA O 
) O 
, O 
classified O 
as O 
class O 
2A O 
carcinogen O 
( O 
probably O 
carcinogenic O 
to O 
humans O 
) O 
by O 
the O 
International O 
Agency O 
for O 
Research O 
on O 
Cancer O 
( O 
IARC O 
) O 
, O 
is O 
formed O 
during O 
heating O 
of O 
food O 
from O 
reducing O 
carbohydrates B-FAMILY 
and O 
asparagine B-TRIVIAL 
by O 
Maillard O 
reaction O 
chemistry O 
. O 
After O 
dietary O 
uptake O 
, O 
AA O 
is O 
in O 
part O 
metabolically O 
converted O 
into O 
the O 
proximate O 
genotoxic O 
phase O 
I O 
metabolite O 
glycidamide B-TRIVIAL 
( O 
GA O 
) O 
. O 
GA O 
reacts O 
with O 
nucleophilic O 
base O 
positions O 
in O 
DNA O 
, O 
primarily O 
forming O 
N7-(2-carbamoyl-2-hydroxyethyl)guanine B-SYSTEMATIC 
( O 
N7-GA-Gua B-FORMULA 
) O 
adducts O 
. O 
In O 
a O 
competing O 
phase O 
II O 
biotransformation O 
pathway O 
AA O 
, O 
as O 
well O 
as O 
its O 
phase O 
I O 
metabolite O 
GA O 
, O 
is O 
coupled O 
to O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
. O 
The O 
GSH B-ABBREVIATION 
coupling O 
products O 
are O 
further O 
biotransformed O 
and O 
excreted O 
via O 
urine O 
as O 
mercapturic B-FAMILY 
acids I-FAMILY 
( O 
MA O 
) O 
, O 
N-acetyl-S-(2-carbamoylethyl)cysteine B-SYSTEMATIC 
( O 
AAMA B-ABBREVIATION 
) O 
, O 
and O 
N-acetyl-S-(2-hydroxy-2-carbamoylethyl)cysteine B-SYSTEMATIC 
( O 
GAMA B-ABBREVIATION 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
hepatic O 
biotransformation O 
pathways O 
and O 
DNA O 
adduct O 
formation O 
were O 
studied O 
in O 
primary O 
rat O 
hepatocytes O 
, O 
incubated O 
with O 
AA O 
( O 
0.2-2,000 O 
μM O 
) O 
for O 
up O 
to O 
24 O 
h O 
. O 
Contents O 
of O 
AA-GSH B-ABBREVIATION 
, O 
GA O 
, O 
AAMA B-ABBREVIATION 
, O 
and O 
GAMA B-ABBREVIATION 
were O 
measured O 
in O 
the O 
cell O 
culture O 
medium O 
after O 
solid O 
phase O 
extraction O 
( O 
SPE O 
) O 
. O 
N7-GA-Gua B-FORMULA 
adducts O 
in O 
DNA O 
of O 
hepatocytes O 
were O 
determined O 
by O 
HPLC-ESI-MS O 
/ O 
MS O 
after O 
lysis O 
of O 
the O 
cells O 
and O 
neutral O 
thermal O 
hydrolysis O 
. O 
Formation O 
of O 
AA-GSH B-ABBREVIATION 
was O 
linear O 
with O 
AA O 
concentration O 
and O 
incubation O 
time O 
and O 
became O 
detectable O 
already O 
at O 
0.2 O 
μM O 
( O 
4 O 
h O 
) O 
. O 
In O 
contrast O 
to O 
AA O 
, O 
GA O 
was O 
not O 
detected O 
before O 
16 O 
h O 
incubation O 
at O 
10-fold O 
higher O 
AA O 
concentration O 
( O 
2 O 
μM O 
) O 
. O 
In O 
summary O 
, O 
the O 
rate O 
of O 
AA-GSH B-ABBREVIATION 
formation O 
was O 
found O 
to O 
be O 
about O 
1.5-3 O 
times O 
higher O 
than O 
that O 
of O 
GA O 
formation O 
. O 
N7-GA-Gua B-FORMULA 
adducts O 
were O 
found O 
only O 
at O 
the O 
highest O 
AA O 
concentration O 
tested O 
( O 
2000 O 
μM O 
) O 
. O 

levels O 
of O 
brain O 
amino B-FAMILY 
acids I-FAMILY 
in O 
rat O 
models O 
presenting O 
learned O 
helplessness O 
or O 
non-learned O 
helplessness O 
. O 

: O 
Glutamatergic O 
and O 
γ-aminobutyric B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
GABA B-ABBREVIATION 
)ergic O 
abnormalities O 
have O 
recently O 
been O 
proposed O 
to O 
contribute O 
to O 
depression O 
. O 
The O 
learned O 
helplessness O 
( O 
LH O 
) O 
paradigm O 
produces O 
a O 
reliable O 
animal O 
model O 
of O 
depression O 
that O 
expresses O 
a O 
deficit O 
in O 
escape O 
behavior O 
( O 
LH O 
model O 
) O 
; O 
an O 
alternative O 
phenotype O 
that O 
does O 
not O 
exhibit O 
LH O 
is O 
a O 
model O 
of O 
resilience O 
to O 
depression O 
( O 
non-LH O 
model O 
) O 
. O 
OBJECTIVES O 
: O 
We O 
measured O 
the O 
contents O 
of O 
amino B-FAMILY 
acids I-FAMILY 
in O 
the O 
brain O 
to O 
investigate O 
the O 
mechanisms O 
involved O 
in O 
the O 
pathology O 
of O 
depression O 
. O 
METHODS O 
: O 
LH O 
and O 
non-LH O 
models O 
were O 
subjected O 
to O 
inescapable O 
electric O 
footshocks O 
at O 
random O 
intervals O 
following O 
a O 
conditioned O 
avoidance O 
test O 
to O 
determine O 
acquirement O 
of O 
predicted O 
escape O 
deficits O 
. O 
Tissue O 
amino B-FAMILY 
acid I-FAMILY 
contents O 
in O 
eight O 
brain O 
regions O 
were O 
measured O 
via O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
RESULTS O 
: O 
The O 
non-LH O 
model O 
showed O 
increased O 
GABA B-ABBREVIATION 
levels O 
in O 
the O 
dentate O 
gyrus O 
and O 
nucleus O 
accumbens O 
and O 
increased O 
glutamine B-TRIVIAL 
levels O 
in O 
the O 
dentate O 
gyrus O 
and O 
the O 
orbitofrontal O 
cortex O 
. O 
The O 
LH O 
model O 
had O 
reduced O 
glutamine B-TRIVIAL 
levels O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
. O 
Changes O 
in O 
the O 
ratios O 
of O 
GABA B-ABBREVIATION 
, O 
glutamine B-TRIVIAL 
, O 
and O 
glutamate B-TRIVIAL 
were O 
detected O 
in O 
the O 
non-LH O 
model O 
, O 
but O 
not O 
in O 
the O 
LH O 
model O 
. O 
Reductions O 
in O 
threonine B-TRIVIAL 
levels O 
occurred O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
in O 
both O 
models O 
, O 
whereas O 
elevated O 
alanine B-TRIVIAL 
levels O 
were O 
detected O 
in O 
the O 
medial O 
prefrontal O 
cortex O 
in O 
non-LH O 
animals O 
. O 
CONCLUSIONS O 
: O 
The O 
present O 
study O 
demonstrates O 
region O 
- O 
specific O 
compensatory O 
elevations O 
in O 
GABA B-ABBREVIATION 
levels O 
in O 
the O 
dentate O 
gyrus O 
and O 
nucleus O 
accumbens O 
of O 
non-LH O 
animals O 
, O 
supporting O 
the O 
implication O 
of O 
the O 
GABAergic O 
system O 
in O 
the O 
recovery O 
of O 
depression O 
. O 

the O 
persistence O 
of O 
cocaine B-TRIVIAL 
-induced O 
place O 
preferences O 
and O 
aversions O 
in O 
rats O 
. O 

: O 
Rats O 
develop O 
preferences O 
for O 
places O 
associated O 
with O 
the O 
immediate O 
rewarding O 
effects O 
of O 
cocaine B-TRIVIAL 
and O 
aversions O 
for O 
places O 
paired O 
with O 
the O 
drug's O 
delayed O 
negative O 
effects O 
. O 
The O 
motivation O 
to O 
seek O 
cocaine B-TRIVIAL 
should O 
therefore O 
depend O 
upon O 
the O 
relative O 
magnitude O 
of O 
these O 
two O 
opposing O 
effects O 
of O 
the O 
drug O 
. O 
OBJECTIVE O 
: O 
The O 
current O 
study O 
tested O 
this O 
notion O 
by O 
assessing O 
the O 
relative O 
persistence O 
of O 
the O 
positive O 
and O 
negative O 
associations O 
formed O 
between O 
environmental O 
cues O 
and O 
the O 
immediate O 
or O 
delayed O 
effects O 
of O 
cocaine B-TRIVIAL 
. O 
METHODS O 
: O 
Rats O 
were O 
administered O 
1 O 
mg O 
/ O 
kg O 
intravenous O 
cocaine B-TRIVIAL 
and O 
placed O 
into O 
a O 
distinctive O 
environment O 
either O 
immediately O 
or O 
15-min O 
after O 
injection O 
, O 
alternating O 
daily O 
with O 
pairings O 
of O 
a O 
second O 
environment O 
with O 
saline O 
. O 
After O 
four O 
drug O 
- O 
place O 
and O 
four O 
saline O 
- O 
place O 
pairings O 
, O 
rats O 
were O 
returned O 
to O 
their O 
home O 
cages O 
for O 
1 O 
, O 
7 O 
, O 
or O 
21 O 
days O 
after O 
which O 
a O 
15-min O 
place O 
preference O 
test O 
was O 
conducted O 
. O 
In O 
a O 
second O 
experiment O 
, O 
the O 
effectiveness O 
of O 
a O 
single O 
reconditioning O 
session O 
( O 
one O 
drug O 
- O 
place O 
and O 
one O 
saline O 
- O 
place O 
pairing O 
) O 
to O 
reactivate O 
learned O 
cocaine B-TRIVIAL 
-place O 
associations O 
was O 
assessed O 
after O 
1 O 
or O 
3 O 
weeks O 
of O 
drug O 
abstinence O 
. O 
RESULTS O 
: O 
Places O 
associated O 
with O 
the O 
immediate O 
effects O 
of O 
cocaine B-TRIVIAL 
were O 
preferred O 
( O 
CPP O 
) O 
, O 
while O 
places O 
associated O 
with O 
the O 
delayed O 
effects O 
of O 
cocaine B-TRIVIAL 
were O 
avoided O 
( O 
CPA O 
) O 
. O 
The O 
persistence O 
of O 
these O 
effects O 
differed O 
with O 
CPP O 
remaining O 
viable O 
at O 
3 O 
weeks O 
of O 
withdrawal O 
, O 
while O 
CPA O 
was O 
no O 
longer O 
present O 
after O 
1 O 
week O 
. O 
Reconditioning O 
with O 
an O 
additional O 
cocaine B-TRIVIAL 
-place O 
pairing O 
failed O 
to O 
reinstate O 
the O 
CPA O 
. O 
CONCLUSIONS O 
: O 
Cue O 
- O 
induced O 
" O 
relapse O 
" O 
of O 
cocaine B-TRIVIAL 
-seeking O 
behavior O 
may O 
be O 
fueled O 
in O 
part O 
by O 
an O 
increased O 
persistence O 
of O 
positive O 
relative O 
to O 
negative O 
associations O 
with O 
drug O 
- O 
paired O 
stimuli O 
. O 

measurement O 
of O 
contact O 
angles O 
of O 
silica B-TRIVIAL 
particles O 
in O 
relation O 
to O 
double O 
inversion O 
of O 
pickering O 
emulsions O 
. O 

an O 
alkane O 
- O 
water O 
system O 
containing O 
submicrometer O 
silica B-TRIVIAL 
particles O 
at O 
high O 
pH O 
, O 
double O 
emulsion O 
inversion O 
from O 
oil O 
- O 
in O 
- O 
water O 
( O 
o O 
/ O 
w O 
) O 
to O 
water O 
- O 
in O 
- O 
oil O 
( O 
w O 
/ O 
o O 
) O 
to O 
oil O 
- O 
in O 
- O 
water O 
can O 
be O 
effected O 
by O 
increasing O 
the O 
concentration O 
of O 
a O 
dichain O 
cationic O 
surfactant O 
in O 
water O 
. O 
The O 
contact O 
angle O 
θ O 
of O 
the O 
particles O 
at O 
the O 
planar O 
oil O 
- O 
water O 
interface O 
has O 
been O 
measured O 
directly O 
using O 
freeze O 
- O 
fracture O 
shadow O 
- O 
casting O 
cryo O 
- O 
scanning O 
electron O 
microscopy O 
, O 
enabling O 
single O 
- O 
particle O 
measurements O 
of O 
high O 
accuracy O 
. O 
θ O 
passes O 
through O 
a O 
maximum O 
with O 
respect O 
to O 
surfactant O 
concentration O 
. O 
It O 
is O 
shown O 
that O 
particles O 
undergo O 
a O 
hydrophilic O 
- O 
hydrophobic O 
- O 
hydrophilic O 
transition O 
corresponding O 
closely O 
to O 
the O 
o O 
/ O 
w-w O 
/ O 
o-o O 
/ O 
w O 
transformation O 
observed O 
in O 
emulsions O 
. O 
These O 
results O 
unequivocally O 
link O 
the O 
single O 
- O 
particle O 
contact O 
angles O 
to O 
the O 
type O 
of O 
particle O 
- O 
stabilized O 
emulsion O 
, O 
confirming O 
macroscopic O 
emulsion O 
inversion O 
on O 
the O 
microscopic O 
level O 
. O 

efficient O 
organocatalytic O 
method O 
for O 
chemoselective O 
aerobic O 
oxidation O 
of O 
secondary O 
benzylic B-FAMILY 
alcohols I-FAMILY 
within O 
lignin O 
model O 
compounds O 
has O 
been O 
identified O 
. O 
Extension O 
to O 
selective O 
oxidation O 
in O 
natural O 
lignins O 
has O 
also O 
been O 
demonstrated O 
. O 
The O 
optimal O 
catalyst O 
system O 
consists O 
of O 
4-acetamido-TEMPO B-SYSTEMATIC 
( O 
5 O 
mol O 
% O 
; O 
TEMPO B-ABBREVIATION 
= O 
2,2,6,6-tetramethylpiperidine-N-oxyl B-SYSTEMATIC 
) O 
in O 
combination O 
with O 
HNO3 B-FORMULA 
and O 
HCl B-FORMULA 
( O 
10 O 
mol O 
% O 
each O 
) O 
. O 
Preliminary O 
studies O 
highlight O 
the O 
prospect O 
of O 
combining O 
this O 
method O 
with O 
a O 
subsequent O 
oxidation O 
step O 
to O 
achieve O 
C-C B-FORMULA 
bond O 
cleavage O 
. O 

Charge O 
Transfer O 
at O 
Monolayer O 
Graphene B-TRIVIAL 
Surfaces O 
with O 
Varied O 
Substrate O 
Coupling O 
. O 

charge O 
transfer O 
rates O 
of O 
a O 
localized O 
excited O 
electron O 
to O 
graphene B-TRIVIAL 
monolayers O 
with O 
variable O 
substrate O 
coupling O 
have O 
been O 
investigated O 
by O 
the O 
core O 
hole O 
clock O 
method O 
with O 
adsorbed O 
argon O 
. O 
Expressed O 
as O 
charge O 
transfer O 
times O 
, O 
we O 
find O 
strong O 
variations O 
between O 
∼3 O 
fs O 
( O 
on O 
graphene B-TRIVIAL 
" O 
valleys O 
" O 
on O 
Ru B-FORMULA 
( O 
1 O 
) O 
) O 
to O 
∼16 O 
fs O 
( O 
quasi O 
- O 
free O 
graphene B-TRIVIAL 
on O 
SiC B-FORMULA 
, O 
O B-FORMULA 
/ O 
Ru B-FORMULA 
( O 
1 O 
) O 
, O 
or O 
SiO2 B-FORMULA 
/ O 
Ru B-FORMULA 
) O 
. O 
The O 
values O 
for O 
the O 
" O 
hills O 
" O 
on O 
Gr/ O 
Ru B-FORMULA 
and O 
on O 
Gr/ O 
Pt(111) B-FORMULA 
are O 
in O 
between O 
, O 
with O 
the O 
ratio O 
1.7 O 
between O 
the O 
charge O 
transfer O 
times O 
measured O 
on O 
" O 
hills O 
" O 
and O 
" O 
valleys O 
" O 
of O 
Gr/ O 
Ru B-FORMULA 
. O 
We O 
discuss O 
the O 
results O 
for O 
Gr O 
on O 
metals O 
in O 
terms O 
of O 
hybridized O 
Ru B-FORMULA 
- O 
C B-FORMULA 
orbitals O 
, O 
which O 
change O 
with O 
the O 
relative O 
Gr- O 
Ru B-FORMULA 
alignment O 
and O 
distance O 
. O 
The O 
charge O 
transfer O 
on O 
the O 
decoupled O 
graphene B-TRIVIAL 
layers O 
must O 
represent O 
the O 
intrinsic O 
coupling O 
to O 
the O 
graphene B-TRIVIAL 
empty O 
π* O 
states O 
. O 
Its O 
low O 
rate O 
may O 
be O 
influenced O 
by O 
processes O 
retarding O 
the O 
spreading O 
of O 
charge O 
after O 
transfer O 
. O 

of O 
droplets O 
or O 
particles O 
dispersed O 
in O 
a O 
liquid O 
may O 
evolve O 
through O 
Brownian O 
collisions O 
, O 
aggregation O 
, O 
and O 
coalescence O 
. O 
We O 
have O 
found O 
a O 
set O 
of O 
conditions O 
under O 
which O 
these O 
populations O 
evolve O 
spontaneously O 
toward O 
a O 
narrow O 
size O 
distribution O 
. O 
The O 
experimental O 
system O 
consists O 
of O 
poly(methyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PMMA B-ABBREVIATION 
) O 
nanodroplets O 
dispersed O 
in O 
a O 
solvent O 
( O 
acetone B-SYSTEMATIC 
) O 
+ O 
nonsolvent O 
( O 
water O 
) O 
mixture O 
. O 
These O 
droplets O 
carry O 
electrical O 
charges O 
, O 
located O 
on O 
the O 
ionic O 
end O 
groups O 
of O 
the O 
macromolecules O 
. O 
We O 
used O 
time O 
- O 
resolved O 
small O 
angle O 
X-ray O 
scattering O 
to O 
determine O 
their O 
size O 
distribution O 
. O 
We O 
find O 
that O 
the O 
droplets O 
grow O 
through O 
coalescence O 
events O 
: O 
the O 
average O 
radius O 
⟨R⟩ O 
increases O 
logarithmically O 
with O 
elapsed O 
time O 
while O 
the O 
relative O 
width O 
σR O 
/ O 
⟨R⟩ O 
of O 
the O 
distribution O 
decreases O 
as O 
the O 
inverse O 
square O 
root O 
of O 
⟨R⟩ O 
. O 
We O 
interpret O 
this O 
evolution O 
as O 
resulting O 
from O 
coalescence O 
events O 
that O 
are O 
hindered O 
by O 
ionic O 
repulsions O 
between O 
droplets O 
. O 
We O 
generalize O 
this O 
evolution O 
through O 
a O 
simulation O 
of O 
the O 
Smoluchowski O 
kinetic O 
equation O 
, O 
with O 
a O 
kernel O 
that O 
takes O 
into O 
account O 
the O 
interactions O 
between O 
droplets O 
. O 
In O 
the O 
case O 
of O 
vanishing O 
or O 
attractive O 
interactions O 
, O 
all O 
droplet O 
encounters O 
lead O 
to O 
coalescence O 
. O 
The O 
corresponding O 
kernel O 
leads O 
to O 
the O 
well O 
- O 
known O 
" O 
self O 
- O 
preserving O 
" O 
particle O 
distribution O 
of O 
the O 
coalescence O 
process O 
, O 
where O 
σR O 
/ O 
⟨R⟩ O 
increases O 
to O 
a O 
plateau O 
value O 
. O 
However O 
, O 
for O 
droplets O 
that O 
interact O 
through O 
long O 
- O 
range O 
ionic O 
repulsions O 
, O 
" O 
large O 
+ O 
small O 
" O 
droplet O 
encounters O 
are O 
more O 
successful O 
at O 
coalescence O 
than O 
" O 
large O 
+ O 
large O 
" O 
encounters O 
. O 
We O 
show O 
that O 
the O 
corresponding O 
kernel O 
leads O 
to O 
a O 
particular O 
scaling O 
of O 
the O 
droplet O 
- O 
size O 
distribution O 
- O 
known O 
as O 
the O 
" O 
second O 
- O 
scaling O 
law O 
" O 
in O 
the O 
theory O 
of O 
critical O 
phenomena O 
, O 
where O 
σR O 
/ O 
⟨R⟩ O 
decreases O 
as O 
1 O 
/ O 
√⟨R⟩ O 
and O 
becomes O 
independent O 
of O 
the O 
initial O 
distribution O 
. O 
We O 
argue O 
that O 
this O 
scaling O 
explains O 
the O 
narrow O 
size O 
distributions O 
of O 
colloidal O 
dispersions O 
that O 
have O 
been O 
synthesized O 
through O 
aggregation O 
processes O 
. O 

series O 
of O 
well O 
- O 
defined O 
thermoresponsive O 
diblock O 
copolymers O 
( O 
PEO45 B-ABBREVIATION 
-b-PtNEAn O 
, O 
n O 
= O 
22 O 
, O 
44 O 
, O 
63 O 
, O 
91 O 
, O 
172 O 
) O 
were O 
prepared O 
by O 
the O 
atom O 
transfer O 
radical O 
polymerization O 
of O 
trans-N-(2-ethoxy-1,3-dioxan-5-yl) B-SYSTEMATIC 
acrylamide I-SYSTEMATIC 
( O 
tNEA B-ABBREVIATION 
) O 
using O 
a O 
poly(ethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEO45 B-ABBREVIATION 
) O 
macroinitiator O 
. O 
All O 
copolymers O 
are O 
water O 
- O 
soluble O 
at O 
low O 
temperature O 
, O 
but O 
upon O 
quickly O 
heating O 
to O 
37 O 
°C O 
, O 
laser O 
light O 
scattering O 
( O 
LLS O 
) O 
and O 
transmission O 
electron O 
microscopy O 
( O 
TEM O 
) O 
characterizations O 
indicate O 
that O 
these O 
copolymers O 
self O 
- O 
assemble O 
into O 
aggregates O 
with O 
different O 
morphologies O 
depending O 
on O 
the O 
chain O 
length O 
of O 
PtNEA B-ABBREVIATION 
and O 
the O 
polymer O 
concentration O 
; O 
the O 
morphologies O 
gradually O 
evolved O 
from O 
spherical O 
solid O 
nanoparticles O 
to O 
a O 
polymersome O 
as O 
the O 
degree O 
of O 
polymerization O 
( O 
" O 
n O 
" O 
) O 
of O 
PtNEA B-ABBREVIATION 
block O 
increased O 
from O 
22 O 
to O 
172 O 
, O 
with O 
the O 
formation O 
of O 
clusters O 
with O 
rod O 
- O 
like O 
structure O 
at O 
the O 
intermediate O 
PtNEA B-ABBREVIATION 
length O 
. O 
Both O 
the O 
spherical O 
nanoparticle O 
and O 
the O 
polymersome O 
are O 
stable O 
at O 
physiological O 
pH O 
but O 
susceptible O 
to O 
the O 
mildly O 
acidic O 
medium O 
. O 
Acid O 
- O 
triggered O 
hydrolysis O 
behaviors O 
of O 
the O 
aggregates O 
were O 
investigated O 
by O 
LLS O 
, O 
Nile O 
red O 
fluorescence O 
, O 
TEM O 
, O 
and O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
. O 
The O 
results O 
revealed O 
that O 
the O 
spherical O 
nanoparticles O 
formed O 
from O 
PEO45 B-ABBREVIATION 
-b-PtNEA44 O 
dissociated O 
faster O 
than O 
the O 
polymersomes O 
of O 
PEO45 B-ABBREVIATION 
-b-PtNEA172 O 
, O 
and O 
both O 
aggregates O 
showed O 
an O 
enhanced O 
hydrolysis O 
under O 
acidic O 
conditions O 
. O 
Both O 
the O 
spherical O 
nanoparticle O 
and O 
polymersome O 
are O 
able O 
to O 
efficiently O 
load O 
the O 
hydrophobic O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
, O 
and O 
water O 
- O 
soluble O 
fluorescein B-TRIVIAL 
isothiocyanate I-TRIVIAL 
-lysozyme O 
( O 
FITC B-ABBREVIATION 
-Lys O 
) O 
can O 
be O 
conveniently O 
encapsulated O 
into O 
the O 
polymersome O 
without O 
using O 
any O 
organic O 
solvent O 
. O 
Moreover O 
, O 
FITC B-ABBREVIATION 
-Lys O 
and O 
DOX B-ABBREVIATION 
could O 
be O 
coloaded O 
in O 
the O 
polymersome O 
. O 
The O 
drugs O 
loaded O 
either O 
in O 
the O 
polymersome O 
or O 
in O 
the O 
spherical O 
nanoparticle O 
could O 
be O 
released O 
by O 
acid O 
triggering O 
. O 
Finally O 
, O 
the O 
DOX B-ABBREVIATION 
-loaded O 
assemblies O 
display O 
concentration O 
- O 
dependent O 
cytotoxicity O 
to O 
HepG2 O 
cells O 
, O 
while O 
the O 
copolymers O 
themselves O 
are O 
nontoxic O 
. O 

of O 
Thieno[3,2-d]pyrimidine-6-carboxamides B-FAMILY 
as O 
Potent O 
Inhibitors O 
of O 
SIRT1 O 
, O 
SIRT2 O 
, O 
and O 
SIRT3 O 
. O 

sirtuins O 
SIRT1 O 
, O 
SIRT2 O 
, O 
and O 
SIRT3 O 
are O 
NAD(+) B-ABBREVIATION 
dependent O 
deacetylases O 
that O 
are O 
considered O 
potential O 
targets O 
for O 
metabolic O 
, O 
inflammatory O 
, O 
oncologic O 
, O 
and O 
neurodegenerative O 
disorders O 
. O 
Encoded O 
library O 
technology O 
( O 
ELT O 
) O 
was O 
used O 
to O 
affinity O 
screen O 
a O 
1.2 O 
million O 
heterocycle O 
enriched O 
library O 
of O 
DNA O 
encoded O 
small O 
molecules O 
, O 
which O 
identified O 
pan O 
- O 
inhibitors O 
of O 
SIRT1 O 
/ O 
2 O 
/ O 
3 O 
with O 
nanomolar O 
potency O 
( O 
e.g O 
. O 
, O 
11c O 
: O 
IC50 O 
= O 
3.6 O 
, O 
2.7 O 
, O 
and O 
4 O 
nM O 
for O 
SIRT1 O 
, O 
SIRT2 O 
, O 
and O 
SIRT3 O 
, O 
respectively O 
) O 
. O 
Subsequent O 
SAR O 
studies O 
to O 
improve O 
physiochemical O 
properties O 
identified O 
the O 
potent O 
drug O 
like O 
analogues O 
28 O 
and O 
31 O 
. O 
Crystallographic O 
studies O 
of O 
11c O 
, O 
28 O 
, O 
and O 
31 O 
bound O 
in O 
the O 
SIRT3 O 
active O 
site O 
revealed O 
that O 
the O 
common O 
carboxamide B-SYSTEMATIC 
binds O 
in O 
the O 
nicotinamide B-TRIVIAL 
C-pocket O 
and O 
the O 
aliphatic O 
portions O 
of O 
the O 
inhibitors O 
extend O 
through O 
the O 
substrate O 
channel O 
, O 
explaining O 
the O 
observable O 
SAR O 
. O 
These O 
pan O 
SIRT1 O 
/ O 
2 O 
/ O 
3 O 
inhibitors O 
, O 
representing O 
a O 
novel O 
chemotype O 
, O 
are O 
significantly O 
more O 
potent O 
than O 
currently O 
available O 
inhibitors O 
, O 
which O 
makes O 
them O 
valuable O 
tools O 
for O 
sirtuin O 
research O 
. O 

investigate O 
the O 
use O 
of O 
laccase O 
enzymes O 
for O 
coupling O 
short O 
nonpolar O 
chains O 
containing O 
aromatic O 
rings O 
onto O 
flax O 
fibers O 
and O 
nanofibrillated O 
cellulose O 
( O 
NFC O 
) O 
with O 
different O 
lignin B-FAMILY 
contents O 
. O 
Trametes O 
villosa O 
, O 
Pycnoporus O 
cinnabarinus O 
and O 
Myceliophthora O 
thermophila O 
were O 
used O 
to O 
facilitate O 
surface O 
coupling O 
and O 
to O 
produce O 
materials O 
with O 
different O 
levels O 
of O 
hydrophobicity O 
. O 
Heat O 
treatment O 
of O 
fiber O 
webs O 
after O 
lacccase O 
- O 
mediated O 
coupling O 
markedly O 
increased O 
the O 
resistance O 
to O 
water O 
absorption O 
. O 
The O 
highest O 
hydrophobization O 
levels O 
of O 
flax O 
fibers O 
was O 
achieved O 
by O 
coupling O 
dodecyl B-SYSTEMATIC 
3,4,5-trihydroxybenzoate I-SYSTEMATIC 
( O 
HB-C12 B-ABBREVIATION 
) O 
, O 
which O 
yielded O 
water O 
contact O 
angles O 
( O 
WCA O 
) O 
of O 
80-96 O 
degrees O 
and O 
water O 
absorption O 
times O 
( O 
drop O 
tests O 
) O 
of O 
ca O 
. O 
73 O 
min O 
. O 
The O 
results O 
from O 
apparent O 
aromatic O 
content O 
and O 
FTIR O 
analyses O 
confirmed O 
the O 
laccase O 
- O 
mediated O 
coupling O 
of O 
HB-C12 B-ABBREVIATION 
onto O 
the O 
cellulose O 
fibers O 
. O 
Substrates O 
consisting O 
of O 
ultrathin O 
films O 
of O 
NFC O 
were O 
also O 
used O 
as O 
substrates O 
for O 
enzyme O 
- O 
mediated O 
hydrophobization O 
with O 
HB-C12 B-ABBREVIATION 
. O 
In O 
these O 
cases O 
water O 
contact O 
angles O 
in O 
the O 
range O 
of O 
87-104 O 
degrees O 
were O 
achieved O 
, O 
depending O 
on O 
the O 
conditions O 
. O 
Quartz B-TRIVIAL 
crystal O 
microgravimetry O 
( O 
QCM O 
) O 
was O 
used O 
to O 
study O 
the O 
dynamics O 
and O 
the O 
extent O 
of O 
the O 
coupling O 
process O 
onto O 
cellulose O 
. O 
The O 
results O 
help O 
to O 
better O 
understand O 
the O 
mechanisms O 
involved O 
in O 
laccase O 
- O 
mediated O 
hydrophobization O 
and O 
provide O 
a O 
proof O 
of O 
a O 
biotechnological O 
platform O 
for O 
the O 
development O 
of O 
added O 
- O 
value O 
fiber O 
products O 
. O 

and O 
Release O 
of O 
Cinnamaldehyde B-TRIVIAL 
from O 
Wheat O 
Protein O 
Matrices O 
. O 

treatment O 
of O 
gliadin O 
films O 
provided O 
a O 
means O 
of O 
decreasing O 
their O 
solubility O 
, O 
increasing O 
their O 
molecular O 
weight O 
profile O 
, O 
and O 
reducing O 
their O 
overall O 
migration O 
into O 
food O 
simulants O 
as O 
a O 
consequence O 
of O 
the O 
high O 
degree O 
of O 
polymerization O 
achieved O 
. O 
Despite O 
losses O 
incurred O 
in O 
the O 
film O 
manufacturing O 
process O 
, O 
and O 
the O 
amount O 
that O 
remained O 
covalently O 
bonded O 
with O 
protein O 
because O 
of O 
cross O 
- O 
linking O 
, O 
the O 
addition O 
of O 
1.5 O 
, O 
3 O 
, O 
and O 
5% O 
of O 
cinnamaldehyde B-TRIVIAL 
( O 
g O 
/ O 
100 O 
g O 
protein O 
) O 
to O 
gliadins O 
at O 
pH O 
2 O 
rendered O 
1.8 O 
, O 
4.8 O 
, O 
and O 
11 O 
mg O 
cinnamaldehyde B-TRIVIAL 
/g O 
film O 
, O 
respectively O 
, O 
available O 
to O 
be O 
released O 
, O 
and O 
therefore O 
to O 
exert O 
antimicrobial O 
activity O 
. O 
Cinnamaldehyde B-TRIVIAL 
diffusivity O 
was O 
largely O 
dependent O 
on O 
environmental O 
conditions O 
, O 
increasing O 
from O 
0.49 O 
× O 
10(-15) O 
m(2) O 
/ O 
s O 
at O 
30% O 
relative O 
humidity O 
( O 
RH O 
) O 
to O 
13.1 O 
× O 
10(-15) O 
m(2) O 
/ O 
s O 
at O 
90% O 
RH O 
and O 
23 O 
°C O 
. O 
This O 
water O 
sensitivity O 
of O 
films O 
provides O 
a O 
mechanism O 
with O 
a O 
noteworthy O 
potential O 
to O 
retain O 
the O 
compound O 
before O 
its O 
use O 
, O 
to O 
trigger O 
its O 
release O 
when O 
needed O 
, O 
and O 
to O 
modulate O 
the O 
release O 
rate O 
according O 
to O 
the O 
product O 
humidity O 
. O 

and O 
Biological O 
Evaluation O 
of O 
Urea B-TRIVIAL 
Derivatives O 
as O 
Highly O 
Potent O 
and O 
Selective O 
Rho O 
Kinase O 
Inhibitors O 
. O 

and O 
its O 
downstream O 
effector O 
ROCK O 
mediate O 
stress O 
fiber O 
formation O 
and O 
cell O 
contraction O 
through O 
their O 
effects O 
on O 
the O 
phosphorylation O 
of O 
myosin O 
light O 
chain O 
( O 
MLC O 
) O 
. O 
Inhibition O 
of O 
the O 
RhoA O 
/ O 
ROCK O 
pathway O 
has O 
proven O 
to O 
be O 
a O 
promising O 
strategy O 
for O 
several O 
indications O 
such O 
as O 
cardiovascular O 
disease O 
, O 
glaucoma O 
, O 
and O 
inflammatory O 
disease O 
. O 
In O 
2010 O 
, O 
our O 
group O 
reported O 
urea B-TRIVIAL 
-based O 
ROCK O 
inhibitors O 
as O 
potential O 
antiglaucoma O 
agents O 
. O 
These O 
compounds O 
showed O 
potent O 
IC50 O 
values O 
in O 
enzymatic O 
and O 
cell O 
- O 
based O 
assays O 
and O 
significant O 
intraocular O 
pressure O 
(IOP)-lowering O 
effects O 
in O 
rats O 
( O 
∼7 O 
mmHg O 
) O 
. O 
( O 
22 O 
) O 
To O 
develop O 
more O 
advanced O 
ROCK O 
inhibitors O 
targeting O 
various O 
potential O 
applications O 
( O 
such O 
as O 
myocardial O 
infarction O 
, O 
erectile O 
dysfunction O 
, O 
multiple O 
sclerosis O 
, O 
etc O 
. O 
) O 
in O 
addition O 
to O 
glaucoma O 
, O 
a O 
thorough O 
SAR O 
for O 
this O 
urea B-TRIVIAL 
-based O 
scaffold O 
was O 
studied O 
. O 
The O 
detailed O 
optimization O 
process O 
, O 
counter O 
- O 
screening O 
, O 
and O 
in O 
vitro O 
and O 
in O 
vivo O 
DMPK O 
studies O 
are O 
discussed O 
. O 
Potent O 
and O 
selective O 
ROCK O 
inhibitors O 
with O 
various O 
in O 
vivo O 
pharmacokinetic O 
properties O 
were O 
discovered O 
. O 

and O 
evaluation O 
of O 
polyamidoamine B-FAMILY 
dendrimer O 
conjugate O 
with O 
PEG B-ABBREVIATION 
, O 
α-cyclodextrin B-TRIVIAL 
and O 
lactose B-TRIVIAL 
as O 
a O 
novel O 
hepatocyte O 
- O 
selective O 
gene O 
carrier O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

To O 
develop O 
a O 
novel O 
hepatocyte O 
- O 
selective O 
gene O 
carrier O 
, O 
we O 
prepared O 
polyamidoamine B-FAMILY 
starburst O 
dendrimer O 
( O 
generation O 
3 O 
, O 
G3 O 
) O 
conjugates O 
with O 
three O 
functional O 
molecules O 
, O 
i.e O 
. O 
α-cyclodextrin B-TRIVIAL 
, O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
( O 
PEG B-ABBREVIATION 
, O 
molecular O 
weight O 
= O 
2170 O 
) O 
and O 
lactose B-TRIVIAL 
( O 
PEG-LαCs B-ABBREVIATION 
) O 
, O 
and O 
evaluated O 
gene O 
delivery O 
efficiency O 
of O 
these O 
conjugates O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
PEG-LαC B-ABBREVIATION 
( O 
G3 O 
, O 
degrees O 
of O 
substitution O 
of O 
the O 
PEG B-ABBREVIATION 
moiety O 
( O 
DSP O 
) O 
2.1 O 
) O 
showed O 
higher O 
gene O 
transfer O 
activity O 
than O 
other O 
PEG-LαCs B-ABBREVIATION 
( O 
G3 O 
, O 
DSP4.0 O 
, O 
6.2 O 
) O 
in O 
HepG2 O 
cells O 
, O 
expressing O 
asialoglycoprotein O 
receptor O 
, O 
and O 
the O 
activity O 
decreased O 
in O 
HeLa O 
cells O 
, O 
non-expressing O 
the O 
receptor O 
and O 
in O 
the O 
presence O 
of O 
asialofetuin O 
. O 
High O 
gene O 
transfer O 
activity O 
of O 
PEG-LαC B-ABBREVIATION 
( O 
G3 O 
, O 
DSP2.1 O 
) O 
was O 
retained O 
even O 
in O 
the O 
presence O 
of O 
50% O 
serum O 
, O 
although O 
the O 
activity O 
of O 
α-cyclodextrin B-TRIVIAL 
/ O 
lactosylated O 
dendrimer O 
( O 
G3 O 
) O 
conjugate O 
( O 
Lac-α-CDE B-ABBREVIATION 
( O 
G3 O 
) O 
) O 
, O 
which O 
is O 
lacking O 
a O 
PEG B-ABBREVIATION 
moiety O 
, O 
was O 
severely O 
decreased O 
in O 
the O 
presence O 
of O 
20% O 
serum O 
. O 
PEG-LαC B-ABBREVIATION 
( O 
G3 O 
, O 
DSP2.1 O 
) O 
provided O 
negligible O 
cytotoxicity O 
up O 
to O 
a O 
charge O 
ratio O 
of O 
50 O 
( O 
carrier O 
/ O 
pDNA O 
) O 
in O 
HepG2 O 
cells O 
and O 
less O 
acute O 
organ O 
toxicity O 
. O 
PEG-LαC B-ABBREVIATION 
( O 
G3 O 
, O 
DSP2.1 O 
) O 
showed O 
selective O 
gene O 
transfer O 
activity O 
to O 
hepatic O 
parenchymal O 
cells O 
rather O 
than O 
hepatic O 
non-parenchymal O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
PEG-LαC B-ABBREVIATION 
( O 
G3 O 
, O 
DSP2.1 O 
) O 
is O 
useful O 
as O 
a O 
hepatocyte O 
- O 
selective O 
gene O 
carrier O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

dimeric O 
and O 
trimeric O 
coumarin B-TRIVIAL 
glucosides O 
from O 
Daphne O 
retusa O 
Hemsl O 
. O 

dimeric O 
and O 
a O 
trimeric O 
coumarin B-TRIVIAL 
glucosides O 
namely O 
Daphneretusin B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
Daphneretusin B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
along O 
with O 
three O 
known O 
oligomers O 
( O 
3-5 O 
) O 
were O 
obtained O 
as O 
a O 
result O 
of O 
bioassay O 
guided O 
fractionation O 
of O 
Daphne O 
retusa O 
Hemsl O 
. O 
Fractions O 
( O 
n-hexane B-SYSTEMATIC 
, O 
CHCl3 B-FORMULA 
, O 
AcOEt B-FORMULA 
, O 
CH3OH B-FORMULA 
and O 
water O 
) O 
exhibited O 
potent O 
radical O 
scavenging O 
activity O 
in O 
relevant O 
non-physiological O 
bioassays O 
. O 
The O 
structures O 
of O 
isolated O 
compounds O 
were O 
elucidated O 
by O 
UV O 
, O 
IR O 
, O 
EIMS O 
, O 
FAB-MS O 
, O 
1D O 
, O 
and O 
2D O 
NMR O 
spectroscopic O 
analysis O 
. O 

A I-MULTIPLE 
and I-MULTIPLE 
B I-MULTIPLE 
from O 
Goniothalamus O 
macrophyllus O 
. O 

macrophyllus O 
( O 
Blume O 
) O 
Hook O 
. O 
f O 
. O 
& O 
Thoms O 
. O 
is O 
a O 
plant O 
widely O 
distributed O 
in O 
Malaysia O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
to O 
identify O 
compounds O 
from O 
the O 
roots O 
of O 
G O 
. O 
macrophyllus O 
. O 
The O 
ground O 
roots O 
were O 
extracted O 
with O 
aqueous O 
methanol B-SYSTEMATIC 
and O 
partitioned O 
sequentially O 
with O 
n-hexane B-SYSTEMATIC 
, O 
chloroform B-TRIVIAL 
and O 
butanol B-SYSTEMATIC 
. O 
Purification O 
from O 
this O 
extracts O 
afforded O 
six O 
compounds O 
with O 
two O 
new O 
compounds O 
, O 
namely O 
goniolandrene-A B-MULTIPLE 
( I-MULTIPLE 
1 I-MULTIPLE 
) I-MULTIPLE 
, I-MULTIPLE 
-B I-MULTIPLE 
( I-MULTIPLE 
2 I-MULTIPLE 
) I-MULTIPLE 
. O 
The O 
absolute O 
configuration O 
of O 
goniolandrene B-TRIVIAL 
B I-TRIVIAL 
( O 
2 O 
) O 
was O 
established O 
by O 
circular O 
dichrosim O 
. O 
The O 
compounds O 
were O 
cytotoxic O 
against O 
the O 
P388 O 
cells O 
with O 
IC50 O 
values O 
ranging O 
from O 
0.42 O 
to O 
160μM O 
. O 
Goniothalamin B-TRIVIAL 
( O 
3 O 
) O 
exhibited O 
the O 
highest O 
inhibition O 
of O 
0.42μM O 
. O 

of O 
nuclear O 
factor O 
erythroid O 
2- O 
related O 
factor O 
2 O 
via O 
extracellular O 
signal O 
- O 
regulated O 
kinase O 
contributes O 
to O 
bleomycin B-FAMILY 
-induced O 
oxidative O 
stress O 
and O 
fibrogenesis O 
. O 

fibrosis O 
is O 
a O 
serious O 
and O 
irreversible O 
lung O 
injury O 
with O 
obscure O 
etiologic O 
mechanisms O 
and O 
no O 
effective O 
treatment O 
to O 
date O 
. O 
This O 
study O 
explored O 
a O 
crucial O 
link O 
between O 
oxidative O 
stress O 
and O 
pulmonary O 
fibrogenesis O 
, O 
focusing O 
on O 
nuclear O 
factor O 
erythroid O 
2- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
, O 
a O 
core O 
transcription O 
factor O 
in O 
antioxidative O 
regulation O 
systems O 
. O 
Treatment O 
of O 
C57 O 
BL O 
/ O 
6 O 
mice O 
with O 
bleomycin B-FAMILY 
increased O 
fibroblast O 
viability O 
and O 
collagen O 
production O 
and O 
significantly O 
downregulated O 
Nrf2 O 
. O 
In O 
addition O 
, O 
prominent O 
oxidative O 
stress O 
was O 
indicated O 
by O 
changes O 
in O 
superoxide B-TRIVIAL 
dismutase O 
, O 
catalase O 
activity O 
, O 
and O 
glutathione B-TRIVIAL 
and O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
-reactive O 
substance O 
levels O 
. O 
In O 
a O 
cell O 
- O 
based O 
model O 
, O 
bleomycin B-FAMILY 
suppressed O 
Nrf2 O 
activation O 
via O 
extracellular O 
signal O 
- O 
related O 
kinase O 
phosphorylation O 
, O 
enhancing O 
intracellular O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
lung O 
fibroblasts O 
and O 
stimulating O 
abnormal O 
cell O 
proliferation O 
and O 
collagen O 
secretion O 
. O 
To O 
confirm O 
this O 
novel O 
mechanism O 
of O 
bleomycin B-FAMILY 
-induced O 
fibrogenesis O 
, O 
we O 
attempted O 
to O 
upregulate O 
Nrf2 O 
and O 
related O 
antioxidant O 
proteins O 
in O 
bleomycin O 
- O 
treated O 
fibroblasts O 
using O 
a O 
putative O 
Nrf2 O 
activator O 
, O 
caffeic B-SYSTEMATIC 
acid I-SYSTEMATIC 
phenethyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
, O 
and O 
the O 
results O 
showed O 
that O 
bleomycin B-FAMILY 
-induced O 
fibroblast O 
proliferation O 
and O 
collagen O 
content O 
were O 
attenuated O 
through O 
improved O 
redox O 
balance O 
. O 
Collectively O 
, O 
these O 
results O 
disclose O 
a O 
potential O 
regulatory O 
mechanism O 
in O 
pulmonary O 
fibrosis O 
that O 
will O 
aid O 
the O 
development O 
of O 
new O 
therapies O 
. O 

Analysis O 
of O 
Arsenic B-SYSTEMATIC 
-Exposed O 
Zebrafish O 
( O 
Danio O 
rerio O 
) O 
Identifies O 
Altered O 
Expression O 
in O 
Proteins O 
Involved O 
in O 
Fibrosis O 
and O 
Lipid O 
Uptake O 
in O 
a O 
Gender-Specific O 
Manner O 
. O 

zebrafish O 
( O 
Danio O 
rerio O 
) O 
was O 
used O 
to O 
investigate O 
protein O 
expression O 
in O 
the O 
liver O 
following O 
arsenic B-SYSTEMATIC 
exposure O 
. O 
Several O 
disorders O 
have O 
been O 
linked O 
to O 
arsenic B-SYSTEMATIC 
exposure O 
, O 
including O 
cancer O 
, O 
diabetes O 
, O 
and O 
cardiovascular O 
disease O 
. O 
The O 
mechanisms O 
of O 
arsenic B-SYSTEMATIC 
toxicity O 
are O 
poorly O 
understood O 
. O 
Prior O 
studies O 
have O 
described O 
altered O 
gene O 
expression O 
, O 
inflammation O 
, O 
and O 
mitogenic O 
signaling O 
in O 
acute O 
or O 
chronic O 
exposure O 
models O 
. O 
A O 
proteomic O 
approach O 
was O 
employed O 
to O 
investigate O 
arsenic B-SYSTEMATIC 
-induced O 
alteration O 
in O 
the O 
zebrafish O 
liver O 
proteome O 
following O 
a O 
7-day O 
exposure O 
to O 
50 O 
ppb O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
. O 
Over O 
740 O 
unique O 
proteins O 
were O 
identified O 
, O 
with O 
fewer O 
than O 
2% O 
showing O 
differential O 
expression O 
. O 
Molecular O 
pathway O 
analysis O 
software O 
identified O 
lipid O 
metabolism O 
and O 
transport O 
as O 
potential O 
molecular O 
targets O 
. O 
Immunoblots O 
were O 
used O 
to O 
confirm O 
protein O 
expression O 
changes O 
, O 
whereas O 
qPCR O 
was O 
employed O 
to O 
investigate O 
gene O 
expression O 
changes O 
. O 
Overall O 
, O 
25 O 
proteins O 
were O 
differentially O 
expressed O 
in O 
a O 
gender O 
- O 
specific O 
manner O 
, O 
11 O 
in O 
males O 
and O 
14 O 
in O 
females O 
. O 
Of O 
these O 
25 O 
, O 
a O 
single O 
protein O 
, O 
hydroxysteroid B-FAMILY 
dehydrogenase O 
like O 
2 O 
, O 
showed O 
decreased O 
expression O 
in O 
both O 
males O 
and O 
females O 
following O 
arsenic B-SYSTEMATIC 
exposure O 
. O 
These O 
findings O 
indicate O 
that O 
protein O 
expression O 
is O 
altered O 
following O 
arsenic B-SYSTEMATIC 
exposure O 
. O 
The O 
changes O 
presented O 
here O 
seem O 
to O 
be O 
most O 
prevalent O 
in O 
lipid O 
transport O 
and O 
metabolic O 
pathways O 
, O 
suggesting O 
a O 
potential O 
increase O 
in O 
fibrosis O 
in O 
males O 
and O 
decreased O 
lipid O 
accumulation O 
and O 
uptake O 
in O 
females O 
. O 

Histopathologic O 
Examination O 
of O 
the O 
Lungs O 
from O 
a O 
3-Month O 
Inhalation O 
Toxicity O 
Study O 
with O 
Multiwall O 
Carbon B-SYSTEMATIC 
Nanotubes O 
in O 
Rats O 
. O 

hazard O 
assessment O 
of O 
multiwalled O 
carbon B-SYSTEMATIC 
nanotubes O 
( O 
MWCNTs O 
) O 
, O 
a O 
90-day O 
inhalation O 
toxicity O 
study O 
has O 
been O 
performed O 
with O 
Nanocyl O 
NC O 
7000 O 
in O 
accordance O 
with O 
OECD O 
413 O 
test O 
guideline O 
. O 
MWCNTs O 
produced O 
no O 
systemic O 
toxicity O 
. O 
However O 
, O 
increased O 
lung O 
weights O 
, O 
multifocal O 
granulomatous O 
inflammation O 
, O 
diffuse O 
histiocytic O 
and O 
neutrophilic O 
infiltrates O 
, O 
and O 
intra O 
- O 
alveolar O 
lipoproteinosis O 
were O 
observed O 
in O 
lung O 
and O 
lung O 
- O 
associated O 
lymph O 
nodes O 
at O 
0.5 O 
and O 
2.5mg O 
/ O 
m(3) O 
. O 
Additional O 
investigations O 
of O 
the O 
lungs O 
were O 
performed O 
, O 
including O 
special O 
stains O 
for O 
examination O 
of O 
connective O 
tissue O 
, O 
and O 
electron O 
microscopy O 
was O 
performed O 
to O 
determine O 
the O 
location O 
of O 
the O 
MWCNTs O 
. O 
The O 
alveolar O 
walls O 
revealed O 
no O 
increase O 
of O 
collagen O 
fibers O 
, O 
whereas O 
within O 
the O 
microgranulomas O 
a O 
slight O 
increase O 
of O 
collagen O 
fibers O 
was O 
observed O 
. O 
The O 
pleura O 
did O 
not O 
reveal O 
any O 
increase O 
in O 
collagen O 
fibers O 
. O 
Only O 
a O 
slight O 
increase O 
in O 
reticulin O 
fibers O 
in O 
the O 
alveolar O 
walls O 
in O 
animals O 
of O 
the O 
0.5 O 
and O 
2.5mg O 
/ O 
m(3) O 
concentration O 
group O 
was O 
noted O 
. O 
In O 
the O 
0.1mg O 
/ O 
m(3) O 
group O 
, O 
the O 
only O 
animal O 
revealing O 
minimal O 
granulomas O 
exhibited O 
a O 
minimal O 
increase O 
in O 
collagen O 
within O 
the O 
granuloma O 
. O 
No O 
increase O 
in O 
reticulin O 
was O 
observed O 
. O 
Electron O 
microscopy O 
demonstrated O 
entangled O 
MWCNTs O 
within O 
alveolar O 
macrophages O 
. O 
Occasionally O 
electron O 
dense O 
particles O 
/ O 
detritus O 
were O 
observed O 
within O 
membrane O 
- O 
bound O 
vesicles O 
( O 
interpreted O 
as O 
phagosomes O 
) O 
, O 
which O 
could O 
represent O 
degraded O 
MWCNTs O 
. O 
If O 
so O 
, O 
MWCNTs O 
were O 
degradable O 
by O 
alveolar O 
macrophages O 
and O 
not O 
persistent O 
within O 
the O 
lung O 
. O 
Inhalation O 
of O 
MWCNTs O 
caused O 
granulomatous O 
inflammation O 
within O 
the O 
lung O 
parenchyma O 
but O 
not O 
the O 
pleura O 
in O 
any O 
of O 
the O 
concentration O 
groups O 
. O 
Thus O 
, O 
there O 
are O 
some O 
similarities O 
to O 
effects O 
caused O 
by O 
inhaled O 
asbestos O 
, O 
but O 
the O 
hallmark O 
effects O 
, O 
namely O 
pleural O 
inflammation O 
and O 
/ O 
or O 
fibrosis O 
leading O 
to O 
mesotheliomas O 
, O 
are O 
absent O 
. O 

of O 
the O 
role O 
of O 
flavonoids B-FAMILY 
for O 
inducing O 
osteoblast O 
differentiation O 
in O 
isolated O 
mouse O 
bone O 
marrow O 
derived O 
mesenchymal O 
stem O 
cells O 
. O 

and O 
rutin B-TRIVIAL 
are O 
common O 
flavonoids B-FAMILY 
in O 
fruit O 
and O 
vegetables O 
, O 
and O 
have O 
been O 
reported O 
to O 
affect O 
bone O 
development O 
. O 
However O 
, O 
the O 
effect O 
of O 
flavonoids B-FAMILY 
on O 
osteoblast O 
differentiation O 
remains O 
a O 
matter O 
of O 
controversy O 
. O 
In O 
the O 
present O 
study O 
, O 
mouse O 
bone O 
marrow O 
mesenchymal O 
stem O 
cells O 
( O 
BMMSCs O 
) O 
were O 
isolated O 
and O 
characterized O 
for O 
their O 
use O 
in O 
osteoblast O 
differentiation O 
using O 
two O 
flavonoids B-FAMILY 
, O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
. O 
BMMSCs O 
were O 
cultured O 
in O 
various O 
concentrations O 
of O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
during O 
the O 
osteoblast O 
differentiation O 
period O 
of O 
10 O 
days O 
. O 
Both O 
quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
were O 
found O 
to O 
up O 
regulate O 
the O 
osteoblast O 
differentiation O 
in O 
dose O 
dependent O 
manner O 
, O 
albeit O 
to O 
lesser O 
extent O 
in O 
case O 
of O 
former O 
than O 
that O 
of O 
latter O 
. O 
Quercetin B-TRIVIAL 
and O 
rutin B-TRIVIAL 
also O 
increased O 
alkaline O 
phosphatase O 
activity O 
by O 
about O 
150 O 
and O 
240% O 
and O 
demonstrated O 
mineralization O 
up O 
to O 
110 O 
and O 
200% O 
respectively O 
as O 
compared O 
to O 
control O 
( O 
which O 
was O 
considered O 
as O 
100% O 
) O 
. O 
Further O 
, O 
both O 
the O 
flavonoids B-FAMILY 
were O 
also O 
found O 
to O 
increase O 
the O 
expression O 
of O 
some O 
of O 
the O 
prominent O 
markers O 
for O 
differentiation O 
of O 
osteoblast O 
like O 
osteopontin O 
, O 
osterix O 
, O 
RunX2 O 
, O 
osteoprotegerin O 
and O 
osteocalcin O 
. O 
The O 
current O 
data O 
suggests O 
that O 
certain O 
classes O 
of O 
flavonoids B-FAMILY 
like O 
rutin B-TRIVIAL 
and O 
quercetin B-TRIVIAL 
can O 
be O 
used O 
in O 
the O 
cure O 
and O 
management O 
of O 
osteodegenerative O 
disorders O 
due O 
to O 
their O 
osteoblast O 
specific O 
differentiation O 
activities O 
. O 

recent O 
studies O 
show O 
that O 
inhibition O 
of O 
the O 
hepatic O 
transport O 
proteins O 
organic O 
- O 
anion O 
transporting O 
polypeptide O 
1B1 O 
( O 
OATP1B1 O 
) O 
and O 
1B3 O 
( O 
OATP1B3 O 
) O 
can O 
result O 
in O 
clinically O 
relevant O 
drug O 
- O 
drug O 
interactions O 
( O 
DDI O 
) O 
. O 
To O 
avoid O 
late O 
- O 
stage O 
development O 
drug O 
failures O 
due O 
to O 
OATP1B O 
- O 
mediated O 
DDI O 
, O 
predictive O 
in O 
vitro O 
and O 
in O 
silico O 
methods O 
should O 
be O 
implemented O 
at O 
an O 
early O 
stage O 
of O 
the O 
drug O 
candidate O 
evaluation O 
process O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
first O 
developed O 
a O 
high O 
- O 
throughput O 
in O 
vitro O 
transporter O 
inhibition O 
assay O 
for O 
the O 
OATP1B O 
subfamily O 
. O 
A O 
total O 
of O 
2000 O 
compounds O 
were O 
tested O 
as O 
potential O 
modulators O 
of O 
the O 
uptake O 
of O 
the O 
OATP1B O 
substrate O 
sodium B-SYSTEMATIC 
fluorescein I-SYSTEMATIC 
, O 
in O 
OATP1B1 O 
or O 
1B3-transfected O 
CHO O 
cells O 
. O 
At O 
an O 
equimolar O 
substrate O 
- O 
inhibitor O 
concentration O 
of O 
10 O 
μM O 
, O 
212 O 
and O 
139 O 
molecules O 
were O 
identified O 
as O 
OATP1B1 O 
and O 
OATP1B3 O 
inhibitors O 
, O 
respectively O 
( O 
min O 
50 O 
% O 
inhibition O 
) O 
. O 
For O 
69 O 
compounds O 
, O 
previously O 
not O 
identified O 
as O 
OATP1B O 
inhibitors O 
, O 
concentration O 
dependent O 
inhibition O 
was O 
also O 
determined O 
, O 
yielding O 
Ki O 
values O 
ranging O 
from O 
0.06 O 
to O 
6.5 O 
μM O 
. O 
Based O 
on O 
these O 
in O 
vitro O 
data O 
, O 
we O 
subsequently O 
developed O 
a O 
proteochemometrics O 
- O 
based O 
in O 
silico O 
model O 
, O 
which O 
predicted O 
OATP1B O 
inhibitors O 
in O 
the O 
test O 
group O 
( O 
20 O 
% O 
of O 
the O 
dataset O 
) O 
with O 
high O 
specificity O 
( O 
86 O 
% O 
) O 
and O 
sensitivity O 
( O 
78 O 
% O 
) O 
. O 
Moreover O 
, O 
several O 
physicochemical O 
compound O 
properties O 
and O 
substructures O 
related O 
to O 
OATP1B1 O 
/ O 
1B3 O 
inhibition O 
or O 
inactivity O 
were O 
identified O 
. O 
Finally O 
, O 
model O 
performance O 
was O 
prospectively O 
verified O 
with O 
a O 
set O 
of O 
54 O 
compounds O 
not O 
included O 
in O 
the O 
original O 
dataset O 
. O 
This O 
validation O 
indicated O 
that O 
80 O 
% O 
and O 
74 O 
% O 
of O 
the O 
compounds O 
were O 
correctly O 
classified O 
for O 
OATP1B1 O 
and O 
OATP1B3 O 
inhibition O 
, O 
respectively O 
. O 

: O 
first O 
global O 
approval O 
. O 

( O 
Pomalyst B-TRIVIAL 
( O 
® O 
) O 
) O 
is O 
a O 
small O 
molecule O 
analogue O 
of O 
thalidomide B-TRIVIAL 
under O 
development O 
with O 
Celgene O 
Corporation O 
for O 
the O 
oral O 
treatment O 
of O 
haematological O 
and O 
connective O 
tissue O 
diseases O 
. O 
Pomalidomide B-TRIVIAL 
has O 
been O 
approved O 
in O 
the O 
USA O 
and O 
is O 
awaiting O 
approval O 
in O 
the O 
EU O 
for O 
use O 
with O 
low O 
- O 
dose O 
dexamethasone B-TRIVIAL 
for O 
the O 
treatment O 
of O 
relapsed O 
and O 
refractory O 
multiple O 
myeloma O 
that O 
has O 
progressed O 
following O 
at O 
least O 
two O 
prior O 
therapies O 
, O 
including O 
lenalidomide B-TRIVIAL 
and O 
bortezomib B-TRIVIAL 
. O 
The O 
efficacy O 
and O 
safety O 
of O 
pomalidomide B-TRIVIAL 
as O 
monotherapy O 
in O 
patients O 
with O 
relapsed O 
and O 
refractory O 
multiple O 
myeloma O 
has O 
also O 
been O 
evaluated O 
in O 
a O 
phase O 
III O 
trial O 
. O 
The O 
agent O 
is O 
in O 
phase O 
III O 
clinical O 
development O 
for O 
the O 
treatment O 
of O 
myelofibrosis O 
and O 
in O 
phase O 
II O 
development O 
for O 
systemic O 
sclerosis O 
. O 
Pomalidomide B-TRIVIAL 
is O 
also O 
being O 
investigated O 
in O 
patients O 
with O 
amyloidosis O 
, O 
prostate O 
cancer O 
, O 
small O 
cell O 
lung O 
cancer O 
, O 
pancreatic O 
cancer O 
, O 
graft O 
- O 
versus O 
- O 
host O 
disease O 
, O 
and O 
Waldenstrom's O 
macroglobulinaemia O 
. O 
This O 
article O 
summarizes O 
the O 
milestones O 
in O 
the O 
development O 
of O 
pomalidomide B-TRIVIAL 
leading O 
to O 
this O 
first O 
global O 
approval O 
for O 
relapsed O 
and O 
refractory O 
multiple O 
myeloma O 
. O 

-nitrosation O 
of O 
glutathione B-TRIVIAL 
transferase O 
P1-1 O 
is O 
controlled O 
by O 
the O 
conformation O 
of O 
a O 
dynamic O 
active O 
- O 
site O 
helix O 
. O 

-nitrosation O 
is O 
a O 
post O 
- O 
translational O 
modification O 
of O 
protein O 
cysteine B-TRIVIAL 
residues O 
which O 
occurs O 
in O 
response O 
to O 
cellular O 
oxidative O 
stress O 
. O 
Although O 
it O 
is O 
increasingly O 
being O 
linked O 
to O 
physiologically O 
important O 
processes O 
, O 
the O 
molecular O 
basis O 
for O 
protein O 
regulation O 
by O 
this O 
modification O 
remains O 
poorly O 
understood O 
. O 
We O 
used O 
transient O 
kinetic O 
methods O 
to O 
determine O 
a O 
minimal O 
mechanism O 
for O 
spontaneous O 
GSNO O 
- O 
mediated O 
transnitrosation O 
of O 
human O 
glutathione B-TRIVIAL 
transferase O 
( O 
GST O 
) O 
P1-1 O 
, O 
a O 
major O 
detoxification O 
enzyme O 
and O 
key O 
regulator O 
of O 
cell O 
proliferation O 
. O 
C47 O 
of O 
GSTP1-1 O 
is O 
S B-FORMULA 
-nitrosated O 
in O 
two O 
steps O 
, O 
with O 
the O 
chemical O 
step O 
limited O 
by O 
a O 
pre O 
- O 
equilibrium O 
between O 
the O 
open O 
and O 
closed O 
conformations O 
of O 
helix O 
α2 O 
at O 
the O 
active O 
site O 
. O 
C101 O 
, O 
in O 
contrast O 
, O 
is O 
S B-FORMULA 
-nitrosated O 
in O 
a O 
single O 
step O 
but O 
is O 
subject O 
to O 
negative O 
cooperativity O 
due O 
to O 
steric O 
hindrance O 
at O 
the O 
dimer O 
interface O 
. O 
Despite O 
the O 
presence O 
of O 
a O 
GSNO O 
binding O 
site O 
at O 
the O 
active O 
site O 
of O 
GSTP1-1 O 
, O 
isothermal O 
titration O 
calorimetry O 
as O 
well O 
as O 
nitrosation O 
experiments O 
using O 
CysNO B-FORMULA 
demonstrate O 
that O 
GSNO O 
binding O 
does O 
not O 
precede O 
S B-FORMULA 
-nitrosation O 
of O 
GSTP1-1 O 
. O 
Kinetics O 
experiments O 
using O 
the O 
cellular O 
reductant O 
GSH B-ABBREVIATION 
show O 
that O 
C101- O 
NO B-FORMULA 
is O 
substantially O 
more O 
resistant O 
to O 
denitrosation O 
than O 
C47- O 
NO B-FORMULA 
, O 
suggesting O 
a O 
potential O 
role O 
for O 
C101- O 
NO B-FORMULA 
in O 
long O 
term O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
storage O 
or O 
transfer O 
. O 
These O 
results O 
constitute O 
the O 
first O 
report O 
of O 
the O 
molecular O 
mechanism O 
of O 
spontaneous O 
protein O 
transnitrosation O 
, O 
providing O 
insight O 
into O 
the O 
post O 
- O 
translational O 
control O 
of O 
GSTP1-1 O 
as O 
well O 
as O 
the O 
process O 
of O 
protein O 
transnitrosation O 
in O 
general O 
. O 

series O 
of O 
symmetrical O 
E-stilbene B-TRIVIAL 
prolinamides B-FAMILY 
that O 
originated O 
from O 
the O 
library O 
- O 
synthesized O 
lead O 
3 O 
was O 
studied O 
with O 
respect O 
to O 
HCV O 
genotype O 
1a O 
( O 
G-1a O 
) O 
and O 
genotype O 
1b O 
( O 
G-1b O 
) O 
replicon O 
inhibition O 
and O 
selectivity O 
against O 
BVDV O 
and O 
cytotoxicity O 
. O 
SAR O 
emerging O 
from O 
an O 
examination O 
of O 
the O 
prolinamide B-TRIVIAL 
cap O 
region O 
revealed O 
11 O 
to O 
be O 
a O 
selective O 
HCV O 
NS5A O 
inhibitor O 
exhibiting O 
submicromolar O 
potency O 
against O 
both O 
G-1a O 
and O 
G-1b O 
replicons O 
. O 
Additional O 
structural O 
refinements O 
resulted O 
in O 
the O 
identification O 
of O 
30 O 
as O 
a O 
potent O 
, O 
dual O 
G-1a O 
/ O 
1b O 
HCV O 
NS5A O 
inhibitor O 
. O 

of O 
morphology O 
and O 
surface O 
properties O 
of O 
syndiotactic B-FAMILY 
polystyrene I-FAMILY 
aerogels O 
. O 

study O 
evaluates O 
a O 
method O 
for O 
rendering O 
syndiotactic B-FAMILY 
polystyrene I-FAMILY 
( O 
sPS B-ABBREVIATION 
) O 
aerogels O 
hydrophilic O 
using O 
polyethylene B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
PEO B-ABBREVIATION 
) O 
of O 
different O 
molecular O 
weights O 
. O 
The O 
highly O 
porous O 
sPS B-ABBREVIATION 
aerogels O 
are O 
inherently O 
hydrophobic O 
although O 
applications O 
involving O 
absorption O 
of O 
moisture O 
and O 
removal O 
of O 
particulate O 
solids O 
may O 
benefit O 
from O 
the O 
high O 
surface O 
area O 
of O 
sPS B-ABBREVIATION 
aerogels O 
provided O 
some O 
degree O 
of O 
hydrophilicity O 
is O 
induced O 
in O 
these O 
materials O 
. O 
In O 
this O 
work O 
, O 
sPS B-ABBREVIATION 
gels O 
are O 
prepared O 
by O 
thermo O 
- O 
reversible O 
gelation O 
in O 
tetrahydrofuran B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
PEO B-ABBREVIATION 
. O 
The O 
gels O 
are O 
dried O 
under O 
supercritical O 
conditions O 
to O 
obtain O 
aerogels O 
. O 
The O 
aerogels O 
are O 
characterized O 
by O 
scanning O 
electron O 
microscopy O 
, O 
nitrogen B-SYSTEMATIC 
-adsorption O 
porosimetry O 
, O 
helium B-SYSTEMATIC 
pycnometry O 
, O 
and O 
contact O 
angle O 
measurements O 
. O 
The O 
data O 
reveal O 
that O 
the O 
pore O 
structures O 
and O 
surface O 
energy O 
can O 
be O 
controlled O 
by O 
varying O 
the O 
concentration O 
and O 
molecular O 
weight O 
of O 
PEO B-ABBREVIATION 
and O 
using O 
different O 
cooling O 
rates O 
during O 
thermo O 
- O 
reversible O 
gelation O 
. O 
In O 
the O 
first O 
case O 
, O 
sPS B-ABBREVIATION 
aerogels O 
, O 
aerogels O 
containing O 
PEO B-ABBREVIATION 
of O 
a O 
low O 
molecular O 
weight O 
or O 
low O 
concentration O 
show O 
superhydrophobic O 
surface O 
presenting O 
the O 
" O 
lotus O 
effect O 
" O 
. O 
In O 
the O 
second O 
case O 
, O 
PEO B-ABBREVIATION 
at O 
a O 
higher O 
concentration O 
or O 
with O 
higher O 
molecular O 
weight O 
forms O 
phase O 
- O 
separated O 
domains O 
yielding O 
new O 
hydrophilic O 
macropores O 
( O 
> O 
10 O 
μm O 
) O 
in O 
the O 
aerogel O 
structures O 
. O 
These O 
macropores O 
contribute O 
to O 
the O 
superhydrophobic O 
surface O 
with O 
the O 
" O 
petal O 
effect O 
" O 
. O 
The O 
cooling O 
rate O 
during O 
gelation O 
shows O 
a O 
strong O 
influence O 
on O 
these O 
two O 
cases O 
. O 

, O 
we O 
have O 
reported O 
a O 
new O 
cinnamic B-TRIVIAL 
acid I-TRIVIAL 
-type O 
photocleavable O 
surfactant O 
, O 
C4-C-N-PEG9 B-NO_CLASS 
that O 
experiences O 
a O 
photocleavage O 
through O 
UV-induced O 
cyclization O 
in O 
aqueous O 
solution O 
, O 
yielding O 
a O 
coumarin B-TRIVIAL 
derivative O 
( O 
7-butoxy-2H-chromen-2-one B-SYSTEMATIC 
) O 
and O 
an O 
aminated O 
polyoxyethylene B-SYSTEMATIC 
compound O 
. O 
Here O 
, O 
we O 
have O 
studied O 
the O 
effects O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
on O 
the O 
photorheological O 
behavior O 
of O 
viscoelastic O 
wormlike O 
micelles O 
formed O 
by O 
aqueous O 
mixture O 
of O 
nonionic O 
surfactants O 
, O 
polyoxyethylene B-SYSTEMATIC 
phytosterol I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
PhyEO20 B-FORMULA 
) O 
and O 
tetraoxyethylene B-SYSTEMATIC 
dodecyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
( O 
C12EO4 B-FORMULA 
) O 
. O 
The O 
4.9 O 
wt O 
% O 
PhyEO20 B-FORMULA 
/ O 
H2O B-FORMULA 
+ O 
2.4 O 
wt O 
% O 
C12EO4 B-FORMULA 
solution O 
forms O 
wormlike O 
micelles O 
, O 
and O 
its O 
viscosity O 
is O 
∼10 O 
Pa·s O 
. O 
We O 
have O 
found O 
that O 
the O 
addition O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
into O 
this O 
viscous O 
, O 
non-Newtonian O 
fluid O 
system O 
decreases O 
the O 
viscosity O 
. O 
Viscosity O 
decreased O 
in O 
parallel O 
to O 
the O 
C4-C-N-PEG9 B-NO_CLASS 
concentration O 
reaching O 
∼0.003 O 
Pa·s O 
at O 
2.5 O 
wt O 
% O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
. O 
However O 
, O 
viscosity O 
of O 
the O 
C4-C-N-PEG9 B-NO_CLASS 
incorporated O 
system O 
increased O 
significantly O 
( O 
∼200 O 
times O 
at O 
1.5 O 
wt O 
% O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
system O 
) O 
upon O 
UV O 
irradiation O 
. O 
Small-Angle O 
X-ray O 
scattering O 
studies O 
have O 
shown O 
that O 
addition O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
favors O 
wormlike O 
- O 
to O 
- O 
sphere O 
type O 
transition O 
in O 
the O 
micellar O 
structure O 
. O 
However O 
, O 
UV O 
irradiation O 
in O 
the O 
C4-C-N-PEG9 B-NO_CLASS 
incorporated O 
system O 
causes O 
one O 
- O 
dimensional O 
micellar O 
growth O 
. O 
Since O 
C4-C-N-PEG9 B-NO_CLASS 
has O 
relatively O 
bigger O 
headgroup O 
size O 
compared O 
to O 
the O 
C12EO4 B-FORMULA 
, O 
addition O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
into O 
wormlike O 
micelles O 
reduces O 
the O 
critical O 
packing O 
parameter O 
resulting O 
in O 
the O 
formation O 
of O 
spherical O 
aggregates O 
. O 
UV O 
irradiation O 
induced O 
one O 
- O 
dimensional O 
micellar O 
growth O 
is O 
caused O 
due O 
to O 
photocleavage O 
of O 
the O 
C4-C-N-PEG9 B-NO_CLASS 
into O 
a O 
less O 
surface O 
- O 
active O 
coumarin B-TRIVIAL 
derivative O 
and O 
an O 
aminated O 
polyoxyethylene B-SYSTEMATIC 
compound O 
, O 
as O 
confirmed O 
by O 
UV-vis O 
spectrometry O 
and O 
HPLC O 
measurements O 
. O 
The O 
hydrophobic O 
coumarin B-TRIVIAL 
derivative O 
formed O 
after O 
cleavage O 
of O 
C4-C-N-PEG9 B-NO_CLASS 
goes O 
to O 
the O 
micellar O 
core O 
and O 
is O 
responsible O 
for O 
decreasing O 
the O 
viscosity O 
. O 
However O 
, O 
the O 
hydrophilic O 
aminated O 
polyoxyethylene B-SYSTEMATIC 
prefers O 
to O 
reside O 
at O 
the O 
vicinity O 
of O 
headgroup O 
of O 
PhyEO20 B-FORMULA 
reducing O 
the O 
interhead O 
repulsion O 
, O 
increasing O 
the O 
critical O 
packing O 
parameter O 
and O 
the O 
viscosity O 
as O 
well O 
. O 

describe O 
the O 
synthesis O 
and O 
characterization O 
of O 
a O 
family O 
of O 
poly(N-alkylacrylamide) B-SYSTEMATIC 
polymers O 
carrying O 
2-6 O 
fluorescent O 
dye O 
molecules O 
, O 
∼70 O 
pendant O 
DTPA B-ABBREVIATION 
( O 
diethylenetriaminepentaacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
groups O 
, O 
and O 
an O 
orthogonal O 
maleimide B-SYSTEMATIC 
end O 
- O 
group O 
for O 
covalent O 
attachment O 
to O 
an O 
antibody O 
( O 
Ab O 
) O 
. O 
These O 
dual O 
- O 
purpose O 
labels O 
were O 
designed O 
for O 
use O 
in O 
multiplexed O 
immunoassays O 
based O 
on O 
both O 
mass O 
cytometry O 
and O 
fluorescent O 
flow O 
cytometry O 
. O 
A O 
challenge O 
in O 
the O 
polymer O 
synthesis O 
was O 
finding O 
conditions O 
for O 
attaching O 
a O 
sufficient O 
number O 
of O 
dye O 
molecules O 
to O 
each O 
polymer O 
chain O 
. O 
Although O 
attachment O 
of O 
a O 
terminal O 
maleimide B-SYSTEMATIC 
to O 
the O 
polymers O 
was O 
not O 
as O 
efficient O 
as O 
anticipated O 
, O 
the O 
end O 
- O 
functional O 
polymers O 
were O 
still O 
effective O 
in O 
labeling O 
Abs O 
. O 
Secondary O 
goat O 
antimouse O 
IgG O 
was O 
labeled O 
with O 
the O 
four O 
dual O 
- O 
label O 
polymers O 
as O 
well O 
as O 
a O 
control O 
polymer O 
, O 
and O 
while O 
the O 
resultant O 
antibody O 
- O 
polymer O 
conjugates O 
showed O 
positive O 
performance O 
in O 
mass O 
cytometric O 
and O 
fluorescent O 
assays O 
, O 
some O 
trials O 
showed O 
problems O 
such O 
as O 
low O 
signal O 
and O 
nonspecific O 
adsorption O 
. O 
Four O 
primary O 
antibody O 
conjugates O 
were O 
prepared O 
and O 
used O 
to O 
stain O 
cells O 
in O 
4-plex O 
assays O 
. O 
The O 
results O 
of O 
both O 
primary O 
assays O 
are O 
bittersweet O 
in O 
that O 
the O 
CD3-FITC O 
and O 
CD45-DyLight O 
649 O 
conjugates O 
performed O 
well O 
, O 
while O 
the O 
CD13-DyLight O 
405 O 
and O 
the O 
CD38-DyLight O 
549 O 
conjugates O 
did O 
not O 
. O 

Facile O 
Integration O 
of O 
Zero- O 
( O 
I-III-VI O 
Quantum O 
Dots O 
) O 
and O 
One- O 
( O 
Single O 
SnO2 B-FORMULA 
Nanowire O 
) O 
Dimensional O 
Nanomaterials O 
: O 
Fabrication O 
of O 
a O 
Nanocomposite O 
Photodetector O 
with O 
Ultrahigh O 
Gain O 
and O 
Wide O 
Spectral O 
Response O 
. O 

the O 
integration O 
of O 
nanocomposites O 
comprising O 
I-III-VI O 
semiconductor O 
quantum O 
dots O 
( O 
QDs O 
) O 
decorated O 
onto O 
a O 
single O 
SnO2 B-FORMULA 
nanowire O 
( O 
NW O 
) O 
, O 
we O 
successfully O 
fabricate O 
an O 
ultrahigh O 
- O 
sensitivity O 
and O 
wide O 
spectral O 
- O 
response O 
photodetector O 
. O 
Under O 
the O 
illumination O 
of O 
He B-FORMULA 
- O 
Cd B-FORMULA 
laser O 
( O 
325 O 
nm O 
) O 
with O 
the O 
photon O 
energy O 
larger O 
than O 
the O 
band O 
gap O 
of O 
SnO2 B-FORMULA 
nanowire O 
, O 
remarkably O 
, O 
an O 
ultrahigh O 
photocurrent O 
gain O 
up O 
to O 
2.5 O 
× O 
10(5) O 
has O 
been O 
achieved O 
, O 
and O 
an O 
enhancement O 
factor O 
can O 
reach O 
up O 
to O 
700% O 
( O 
cf O 
. O 
bare O 
SnO2 B-FORMULA 
NW O 
) O 
as O 
light O 
illumination O 
onto O 
the O 
wire O 
with O 
an O 
excitation O 
intensity O 
of O 
15 O 
W O 
/ O 
m(2) O 
. O 
Also O 
, O 
a O 
high O 
gain O 
value O 
up O 
to O 
1.3 O 
× O 
10(5) O 
is O 
attained O 
with O 
the O 
excited O 
photon O 
energy O 
( O 
488 O 
nm O 
) O 
smaller O 
than O 
the O 
band O 
gap O 
of O 
SnO2 B-FORMULA 
nanowire O 
. O 
Several O 
key O 
factors O 
contribute O 
to O 
ultrahigh O 
photocurrent O 
gain O 
and O 
wide O 
spectral O 
response O 
. O 
First O 
, O 
the O 
decorated O 
quantum O 
dot O 
processes O 
an O 
inherent O 
nature O 
of O 
a O 
large O 
absorption O 
coefficient O 
above O 
its O 
band O 
gap O 
. O 
Furthermore O 
, O 
the O 
single O 
SnO2 B-FORMULA 
nanowire O 
provides O 
an O 
excellent O 
conduction O 
path O 
for O 
the O 
photogenerated O 
carriers O 
as O 
well O 
as O 
bears O 
a O 
large O 
surface O 
- O 
to O 
- O 
volume O 
ratio O 
so O 
that O 
the O 
coupling O 
strength O 
with O 
quantum O 
dots O 
can O 
be O 
greatly O 
enhanced O 
. O 
Most O 
importantly O 
, O 
the O 
spatial O 
separation O 
of O 
photogenerated O 
electrons O 
and O 
holes O 
can O 
be O 
easily O 
achieved O 
due O 
to O 
the O 
charge O 
transfer O 
arising O 
from O 
a O 
type O 
II O 
band O 
alignment O 
between O 
QDs O 
and O 
SnO2 B-FORMULA 
NW O 
. O 
This O 
work O 
thus O 
demonstrates O 
a O 
new O 
approach O 
in O 
which O 
by O 
selectively O 
decorating O 
suitable O 
QDs O 
the O 
photocurrent O 
gain O 
of O 
SnO2 B-FORMULA 
NWs O 
can O 
be O 
greatly O 
enhanced O 
and O 
extended O 
to O 
a O 
wide O 
spectral O 
range O 
of O 
photoresponse O 
previously O 
inaccessible O 
, O 
providing O 
a O 
very O 
useful O 
guideline O 
to O 
create O 
cheap O 
, O 
nontoxic O 
, O 
and O 
highly O 
efficient O 
photodetectors O 
. O 

hispidus O 
is O 
one O 
of O 
the O 
most O 
common O 
filefish O 
species O 
in O 
Brazil O 
. O 
Its O 
skin O 
is O 
traditionally O 
used O 
as O 
a O 
complementary O 
treatment O 
for O 
inflammatory O 
disorders O 
. O 
However O 
, O 
there O 
are O 
very O 
few O 
studies O 
on O 
chemical O 
and O 
pharmacological O 
properties O 
using O 
the O 
skin O 
of O 
this O 
fish O 
. O 
This O 
study O 
was O 
undertaken O 
in O 
order O 
to O 
investigate O 
the O 
effect O 
of O 
aqueous O 
crude O 
extract O 
of O 
S O 
. O 
hispidus O 
skin O 
( O 
SAE O 
) O 
in O 
different O 
nociception O 
models O 
. O 
Here O 
, O 
we O 
report O 
that O 
intraperitoneal O 
administration O 
of O 
SAE O 
inhibited O 
the O 
abdominal O 
constrictions O 
induced O 
by O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
in O 
mice O 
. O 
In O 
addition O 
to O 
the O 
effect O 
seen O 
in O 
the O 
abdominal O 
constriction O 
model O 
, O 
SAE O 
was O 
also O 
able O 
to O 
inhibit O 
the O 
hyperalgesia O 
induced O 
by O 
carrageenan O 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
( O 
PGE2 B-ABBREVIATION 
) O 
in O 
mice O 
. O 
This O 
potent O 
antinociceptive O 
effect O 
was O 
observed O 
in O 
the O 
hot O 
plate O 
model O 
too O 
, O 
but O 
not O 
in O 
tail O 
- O 
flick O 
test O 
. O 
Naloxone B-TRIVIAL 
, O 
an O 
opioid O 
receptor O 
antagonist O 
, O 
was O 
able O 
to O 
block O 
the O 
antinociceptive O 
effect O 
of O 
SAE O 
in O 
the O 
abdominal O 
constriction O 
and O 
hot O 
plate O 
models O 
. O 
In O 
addition O 
, O 
SAE O 
did O 
not O 
present O 
cytotoxic O 
or O 
genotoxic O 
effect O 
in O 
human O 
peripheral O 
blood O 
cells O 
. O 
Our O 
results O 
suggest O 
that O 
aqueous O 
crude O 
extract O 
from O 
S O 
. O 
hispidus O 
skin O 
has O 
antinociceptive O 
activity O 
in O 
close O 
relationship O 
with O 
the O 
partial O 
activation O 
of O 
opioid O 
receptors O 
in O 
the O 
nervous O 
system O 
. O 
Moreover O 
, O 
aqueous O 
crude O 
extract O 
from O 
S O 
. O 
hispidus O 
skin O 
does O 
not O 
present O 
toxicity O 
and O 
is O 
therefore O 
endowed O 
with O 
the O 
potential O 
for O 
pharmacological O 
control O 
of O 
pain O 
. O 

processed O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanopyramid/ O 
silver B-SYSTEMATIC 
nanowire O 
transparent O 
network O 
films O 
with O 
highly O 
tunable O 
light O 
scattering O 
properties O 
. O 

nanowire O 
transparent O 
networks O 
are O 
promising O 
replacements O 
to O 
indium B-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ITO B-ABBREVIATION 
) O 
transparent O 
electrodes O 
for O 
optoelectronic O 
devices O 
. O 
While O 
the O 
transparency O 
and O 
sheet O 
resistance O 
are O 
key O 
metrics O 
for O 
transparent O 
electrode O 
performance O 
, O 
independent O 
control O 
of O 
the O 
film O 
light O 
scattering O 
properties O 
is O 
important O 
to O 
developing O 
multifunctional O 
electrodes O 
for O 
improved O 
photovoltaic O 
absorption O 
. O 
Here O 
we O 
show O 
that O 
controlled O 
incorporation O 
of O 
ZnO B-FORMULA 
nanopyramids O 
into O 
a O 
metal O 
nanowire O 
network O 
film O 
affords O 
independent O 
, O 
highly O 
tunable O 
control O 
of O 
the O 
scattering O 
properties O 
( O 
haze O 
) O 
with O 
minimal O 
effects O 
on O 
the O 
transparency O 
and O 
sheet O 
resistance O 
. O 
Varying O 
the O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
/ O 
silver B-SYSTEMATIC 
nanostructure O 
ratios O 
prior O 
to O 
spray O 
deposition O 
results O 
in O 
sheet O 
resistances O 
, O 
transmission O 
( O 
600 O 
nm O 
) O 
, O 
and O 
haze O 
( O 
600 O 
nm O 
) O 
of O 
6-30 O 
Ω O 
□(-1) O 
, O 
68-86% O 
, O 
and O 
34-66% O 
, O 
respectively O 
. O 
Incorporation O 
of O 
zinc B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanopyramid O 
scattering O 
agents O 
into O 
the O 
conducting O 
nanowire O 
mesh O 
has O 
a O 
negligible O 
effect O 
on O 
mesh O 
connectivity O 
, O 
providing O 
a O 
straightforward O 
method O 
of O 
controlling O 
electrode O 
scattering O 
properties O 
. O 
The O 
decoupling O 
of O 
the O 
film O 
scattering O 
power O 
and O 
electrical O 
characteristics O 
makes O 
these O 
films O 
promising O 
candidates O 
for O 
highly O 
scattering O 
transparent O 
electrodes O 
in O 
optoelectronic O 
devices O 
and O 
can O 
be O 
generalized O 
to O 
other O 
metal O 
nanowire O 
films O 
as O 
well O 
as O 
carbon B-SYSTEMATIC 
nanotube O 
transparent O 
electrodes O 
. O 

A I-MULTIPLE 
to I-MULTIPLE 
F I-MULTIPLE 
, O 
New O 
Mono- B-MULTIPLE 
and I-MULTIPLE 
Dimeric I-MULTIPLE 
Alkenylphenols I-MULTIPLE 
from O 
Piper O 
sarmentosum O 
. O 

new O 
mono- O 
and O 
four O 
new O 
dimeric B-FAMILY 
alkenylphenols I-FAMILY 
, O 
namely O 
sarmentosumols B-MULTIPLE 
A I-MULTIPLE 
to I-MULTIPLE 
F I-MULTIPLE 
( O 
1-6 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
aerial O 
parts O 
of O 
Piper O 
sarmentosum O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
determined O 
through O 
a O 
detailed O 
analysis O 
of O 
NMR O 
and O 
MS O 
data O 
. O 
Their O 
antimicrobial O 
activity O 
against O 
Escherichia O 
coli O 
, O 
Staphyloccocus O 
aureus O 
, O 
and O 
Candida O 
albicans O 
, O 
and O 
their O 
cytotoxic O 
activity O 
against O 
human O 
myeloid O 
leukemia O 
( O 
K562 O 
) O 
and O 
human O 
lung O 
adenocarcinoma O 
( O 
A549 O 
) O 
cell O 
lines O 
were O 
also O 
evaluated O 
. O 
Except O 
for O 
sarmentosumol B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
, O 
whose O 
MIC O 
on O 
S O 
. O 
aureus O 
was O 
reported O 
to O 
be O 
7 O 
µg O 
/ O 
mL O 
, O 
none O 
of O 
the O 
other O 
newly O 
discovered O 
compounds O 
exhibited O 
antimicrobial O 
property O 
. O 
The O 
studied O 
compounds O 
did O 
not O 
possess O 
any O 
cytotoxic O 
property O 
. O 

Vitro O 
and O 
In O 
Vivo O 
Enzyme O 
- O 
Mediated O 
Biomineralization O 
of O 
Oligo(poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
Fumarate I-SYSTEMATIC 
Hydrogels O 
. O 

enzyme O 
alkaline O 
phosphatase O 
( O 
ALP O 
) O 
is O 
added O 
at O 
different O 
concentrations O 
( O 
i.e O 
. O 
, O 
0 O 
, O 
2.5 O 
, O 
and O 
10 O 
mg O 
· O 
ml(-1) O 
) O 
to O 
oligo(poly(ethylene B-SYSTEMATIC 
glycol)fumarate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
OPF B-ABBREVIATION 
) O 
hydrogels O 
. O 
The O 
scaffolds O 
are O 
either O 
incubated O 
in O 
10 O 
mM O 
calcium B-SYSTEMATIC 
glycerophosphate I-SYSTEMATIC 
( O 
Ca-GP B-FORMULA 
) O 
solution O 
for O 
2 O 
weeks O 
or O 
implanted O 
in O 
a O 
rat O 
subcutaneous O 
model O 
for O 
4 O 
weeks O 
. O 
Fourier O 
transform O 
infrared O 
( O 
FTIR O 
) O 
spectroscopy O 
, O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
, O 
scanning O 
electron O 
microscopy O 
( O 
SEM O 
) O 
, O 
energy O 
dispersive O 
spectroscopy O 
( O 
EDS O 
) O 
, O 
and O 
alizarin B-TRIVIAL 
red I-TRIVIAL 
staining O 
show O 
a O 
strong O 
ability O 
to O 
form O 
minerals O 
exclusively O 
in O 
ALP O 
- O 
containing O 
hydrogels O 
in O 
vitro O 
. O 
Additionally O 
, O 
the O 
calcium B-SYSTEMATIC 
content O 
increases O 
with O 
increasing O 
ALP O 
concentration O 
. O 
Similarly O 
, O 
only O 
ALP O 
- O 
containing O 
hydrogels O 
induce O 
mineralization O 
in O 
vivo O 
. O 
Specifically O 
, O 
small O 
( O 
≈5-20 O 
µm O 
) O 
mineral O 
deposits O 
are O 
observed O 
at O 
the O 
periphery O 
of O 
the O 
hydrogels O 
near O 
the O 
dermis O 
/ O 
scaffold O 
interface O 
using O 
Von O 
Kossa O 
and O 
alizarin B-TRIVIAL 
red I-TRIVIAL 
staining O 
. O 

Raisin O 
Bun O 
" O 
- O 
Like O 
Nanocomposites O 
of O 
Palladium B-SYSTEMATIC 
Clusters O 
and O 
Porphyrin B-FAMILY 
for O 
Superior O 
Formic B-SYSTEMATIC 
Acid I-SYSTEMATIC 
Oxidation O 
. O 

novel O 
" O 
raisin O 
bun O 
" O 
- O 
like O 
nanocomposite O 
, O 
where O 
Pd B-FORMULA 
clusters O 
are O 
embedded O 
in O 
porphyrin B-FAMILY 
matrix O 
, O 
is O 
developed O 
as O 
a O 
promising O 
electrocatalyst O 
. O 
Thanks O 
to O 
the O 
synergy O 
between O 
the O 
Pd B-FORMULA 
clusters O 
and O 
the O 
porphyrin B-FAMILY 
matrix O 
, O 
this O 
composite O 
exhibits O 
a O 
low O 
oxidation O 
potential O 
, O 
high O 
mass O 
activity O 
and O 
excellent O 
stability O 
toward O 
electrochemical O 
oxidation O 
of O 
formic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
which O 
opens O 
new O 
routes O 
for O 
the O 
design O 
of O 
high O 
- O 
performance O 
catalysts O 
in O 
fuel O 
cells O 
. O 

-Assisted O 
Formation O 
of O 
Alkylcarbonate B-FAMILY 
Species O 
from O 
CO2 B-FORMULA 
and O 
Tetramethylammonium B-SYSTEMATIC 
Salts O 
with O 
a O 
β-Amino B-FAMILY 
Acid I-FAMILY 
Anion O 
. O 

-based O 
molten O 
salts O 
bearing O 
a O 
β-amino B-FAMILY 
acid I-FAMILY 
anion O 
( O 
TMAAs O 
) O 
are O 
synthesized O 
through O 
Michael O 
addition O 
reactions O 
of O 
amines B-FAMILY 
with O 
methyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
followed O 
by O 
hydrolysis O 
and O 
subsequent O 
neutralization O 
by O 
using O 
aqueous O 
tetramethylammonium B-SYSTEMATIC 
hydroxide I-SYSTEMATIC 
. O 
The O 
CO2 B-FORMULA 
capture O 
performances O 
of O 
the O 
TMAAs O 
are O 
evaluated O 
and O 
are O 
shown O 
to O 
interact O 
with O 
CO2 B-FORMULA 
in O 
a O 
1 O 
: O 
1 O 
mode O 
in O 
both O 
water O 
and O 
alcohol B-FAMILY 
. O 
FTIR O 
and O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
NMR O 
spectroscopic O 
studies O 
on O 
the O 
interactions O 
of O 
TMAAs O 
with O 
CO2 B-FORMULA 
indicate O 
that O 
the O 
type O 
of O 
CO2 B-FORMULA 
adduct O 
varies O 
with O 
the O 
solvent O 
used O 
. O 
When O 
water O 
is O 
used O 
as O 
the O 
solvent O 
, O 
a O 
bicarbonate B-SYSTEMATIC 
species O 
is O 
produced O 
, O 
whereas O 
hydroxyethylcarbonate B-SYSTEMATIC 
and O 
methylcarbonate B-SYSTEMATIC 
species O 
are O 
generated O 
in O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
and O 
methanol B-SYSTEMATIC 
, O 
respectively O 
. O 
Computational O 
calculations O 
show O 
that O 
the O 
carboxylate B-SYSTEMATIC 
groups O 
of O 
TMAAs O 
contribute O 
towards O 
the O 
formation O 
and O 
stabilization O 
of O 
1 O 
: O 
1 O 
CO2 B-FORMULA 
adducts O 
through O 
hydrogen B-SYSTEMATIC 
bonding O 
interactions O 
with O 
the O 
hydrogen B-SYSTEMATIC 
atoms O 
of O 
the O 
amino B-FAMILY 
groups O 
. O 

and O 
evaluation O 
of O 
biphenyl B-SYSTEMATIC 
compounds O 
as O 
Kinesin O 
spindle O 
protein O 
inhibitors O 
. O 

spindle O 
protein O 
( O 
KSP O 
) O 
, O 
an O 
ATP B-ABBREVIATION 
-dependent O 
motor O 
protein O 
, O 
plays O 
an O 
essential O 
role O 
in O 
bipolar O 
spindle O 
formation O 
during O 
the O 
mitotic O 
phase O 
( O 
M O 
phase O 
) O 
of O 
the O 
normal O 
cell O 
cycle O 
. O 
KSP O 
has O 
emerged O 
as O 
a O 
novel O 
target O 
for O 
antimitotic O 
anticancer O 
drug O 
development O 
. O 
In O 
this O 
work O 
, O 
we O 
synthesized O 
a O 
range O 
of O 
new O 
biphenyl B-SYSTEMATIC 
compounds O 
and O 
investigated O 
their O 
properties O 
in O 
vitro O 
as O 
potential O 
antimitotic O 
agents O 
targeting O 
KSP O 
expression O 
. O 
Antiproliferation O 
( O 
MTT B-ABBREVIATION 
( O 
= O 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium B-SYSTEMATIC 
bromide I-SYSTEMATIC 
) O 
) O 
assays O 
, O 
combined O 
with O 
fluorescence O 
- O 
assisted O 
cell O 
sorting O 
( O 
FACS O 
) O 
and O 
Western O 
blot O 
studies O 
analyzing O 
cell O 
- O 
cycle O 
arrest O 
confirmed O 
the O 
mechanism O 
and O 
potency O 
of O 
these O 
biphenyl B-SYSTEMATIC 
compounds O 
in O 
a O 
range O 
of O 
human O 
cancer O 
cell O 
lines O 
. O 
Structural O 
variants O 
revealed O 
that O 
functionalization O 
of O 
biphenyl B-SYSTEMATIC 
compounds O 
with O 
bulky O 
aliphatic O 
or O 
aromatic O 
groups O 
led O 
to O 
a O 
loss O 
of O 
activity O 
. O 
However O 
, O 
replacement O 
of O 
the O 
urea B-TRIVIAL 
group O 
with O 
a O 
thiourea O 
led O 
to O 
an O 
increase O 
in O 
antiproliferative O 
activity O 
in O 
selected O 
cell O 
lines O 
. O 
Further O 
studies O 
using O 
confocal O 
fluorescence O 
microscopy O 
confirmed O 
that O 
the O 
most O 
potent O 
biphenyl B-SYSTEMATIC 
derivative O 
identified O 
thus O 
far O 
, O 
compound O 
7 O 
, O 
exerts O 
its O 
pharmacologic O 
effect O 
specifically O 
in O 
the O 
M O 
phase O 
and O 
induces O 
monoaster O 
formation O 
. O 
These O 
studies O 
confirm O 
that O 
chemical O 
scope O 
remains O 
for O 
improving O 
the O 
potency O 
and O 
treatment O 
efficacy O 
of O 
antimitotic O 
KSP O 
inhibition O 
in O 
this O 
class O 
of O 
biphenyl B-SYSTEMATIC 
compounds O 
. O 

Triterpenoids B-FAMILY 
from O 
the O 
Stems O 
of O 
Brucea O 
mollis O 
. O 

new O 
tirucallane B-TRIVIAL 
triterpenoids B-FAMILY 
, O 
brumollisols B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
, O 
resp O 
. O 
) O 
, O 
together O 
with O 
five O 
known O 
analogues O 
, O 
(23R,24S)-23,24,25-trihydroxytirucall-7-ene-3,6-dion B-SYSTEMATIC 
e O 
( O 
4 O 
) O 
, O 
piscidinol B-TRIVIAL 
A O 
( O 
5 O 
) O 
, O 
24-epipiscidinol B-SYSTEMATIC 
A O 
( O 
6 O 
) O 
, O 
21α-methylmelianodio B-SYSTEMATIC 
l O 
( O 
7 O 
) O 
, O 
and O 
21β-methylmelianodio B-SYSTEMATIC 
l O 
( O 
8 O 
) O 
, O 
were O 
isolated O 
from O 
an O 
EtO B-FORMULA 
H O 
extract O 
of O 
the O 
stems O 
of O 
Brucea O 
mollis O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
means O 
of O 
spectroscopic O 
methods O 
including O 
1D- O 
and O 
2D-NMR O 
techniques O 
and O 
mass O 
spectrometry O 
. O 
In O 
the O 
in O 
vitro O 
assays O 
, O 
compound O 
6 O 
exhibited O 
significant O 
cytotoxic O 
activity O 
against O 
A549 O 
and O 
BGC-823 O 
cancer O 
cells O 
with O 
IC50 O 
values O 
of O 
1.16 O 
and O 
3.01 O 
μM O 
, O 
respectively O 
. O 
At O 
a O 
concentration O 
of O 
10 O 
μM O 
, O 
compounds O 
1-5 O 
, O 
7 O 
, O 
and O 
8 O 
were O 
found O 
to O 
inhibit O 
N B-FORMULA 
O O 
production O 
in O 
mouse O 
peritoneal O 
macrophages O 
with O 
inhibitory O 
ratios O 
ranging O 
from O 
39.8±7.7 O 
to O 
68.2±4.5% O 
. O 

, O 
Synthesis O 
, O 
and O 
Antibacterial O 
Activity O 
of O 
Demethylvancomycin B-SYSTEMATIC 
Analogues O 
against O 
Drug-Resistant O 
Bacteria O 
. O 

novel O 
N- O 
substituted O 
demethylvancomycin B-SYSTEMATIC 
derivatives O 
were O 
rationally O 
designed O 
and O 
synthesized O 
by O 
using O 
a O 
structure O 
- O 
based O 
approach O 
. O 
The O 
in O 
vitro O 
antibacterial O 
activities O 
against O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
( O 
MRSA O 
) O 
, O 
gentamicin B-FAMILY 
-resistant O 
Enterococcus O 
faecalis O 
( O 
GRE O 
) O 
, O 
methicillin B-TRIVIAL 
-resistant O 
Streptococcus O 
pneumoniae O 
( O 
MRS O 
) O 
, O 
and O 
vancomycin B-TRIVIAL 
-resistant O 
Enterococcus O 
faecalis O 
( O 
VRE O 
) O 
were O 
evaluated O 
. O 
One O 
of O 
the O 
compounds O 
, O 
N-(6-phenylheptyl)demethylvancomycin B-SYSTEMATIC 
( O 
12 O 
a O 
) O 
, O 
was O 
found O 
to O 
exhibit O 
more O 
potent O 
antibacterial O 
activity O 
than O 
vancomycin B-TRIVIAL 
and O 
demethylvancomycin B-SYSTEMATIC 
. O 
Compound O 
12 O 
a O 
was O 
also O 
found O 
to O 
be O 
~18-fold O 
more O 
efficacious O 
than O 
vancomycin B-TRIVIAL 
against O 
MRSA O 
; O 
however O 
, O 
the O 
two O 
compounds O 
were O 
found O 
to O 
have O 
similar O 
efficacy O 
against O 
MRS O 
. O 
Furthermore O 
, O 
compound O 
12 O 
a O 
exhibited O 
a O 
favorable O 
pharmacokinetic O 
profile O 
with O 
a O 
half O 
- O 
life O 
of O 
5.11±0.52 O 
h O 
, O 
which O 
is O 
longer O 
than O 
that O 
of O 
vancomycin B-TRIVIAL 
( O 
4.3±1.9 O 
h O 
) O 
. O 
These O 
results O 
suggest O 
that O 
12 O 
a O 
is O 
a O 
promising O 
antibacterial O 
drug O 
candidate O 
for O 
further O 
preclinical O 
evaluation O 
. O 

determine O 
the O 
time- O 
and O 
force O 
- O 
dependent O 
viscoelastic O 
responses O 
of O 
reconstituted O 
networks O 
of O 
microtubules O 
that O 
have O 
been O 
strongly O 
crosslinked O 
by O 
biotin B-TRIVIAL 
-streptavidin O 
bonds O 
. O 
To O 
measure O 
the O 
microscale O 
viscoelasticity O 
of O 
such O 
networks O 
, O 
we O 
use O 
a O 
magnetic O 
tweezers O 
device O 
to O 
apply O 
localized O 
forces O 
. O 
At O 
short O 
time O 
scales O 
, O 
the O 
networks O 
respond O 
nonlinearly O 
to O 
applied O 
force O 
, O 
with O 
stiffening O 
at O 
small O 
forces O 
, O 
followed O 
by O 
a O 
reduction O 
in O 
the O 
stiffening O 
response O 
at O 
high O 
forces O 
, O 
which O 
we O 
attribute O 
to O 
the O 
force O 
- O 
induced O 
unbinding O 
of O 
crosslinks O 
. O 
At O 
long O 
time O 
scales O 
, O 
force O 
- O 
induced O 
bond O 
unbinding O 
leads O 
to O 
local O 
network O 
rearrangement O 
and O 
significant O 
bead O 
creep O 
. O 
Interestingly O 
, O 
the O 
network O 
retains O 
its O 
elastic O 
modulus O 
even O 
under O 
conditions O 
of O 
significant O 
plastic O 
flow O 
, O 
suggesting O 
that O 
crosslinker O 
breakage O 
is O 
balanced O 
by O 
the O 
formation O 
of O 
new O 
bonds O 
. O 
To O 
better O 
understand O 
this O 
effect O 
, O 
we O 
developed O 
a O 
finite O 
element O 
model O 
of O 
such O 
a O 
stiff O 
filament O 
network O 
with O 
labile O 
crosslinkers O 
obeying O 
force O 
- O 
dependent O 
Bell O 
model O 
unbinding O 
dynamics O 
. O 
The O 
coexistence O 
of O 
dissipation O 
, O 
due O 
to O 
bond O 
breakage O 
, O 
and O 
the O 
elastic O 
recovery O 
of O 
the O 
network O 
is O 
possible O 
because O 
each O 
filament O 
has O 
many O 
crosslinkers O 
. O 
Recovery O 
can O 
occur O 
as O 
long O 
as O 
a O 
sufficient O 
number O 
of O 
the O 
original O 
crosslinkers O 
are O 
preserved O 
under O 
the O 
loading O 
period O 
. O 
When O 
these O 
remaining O 
original O 
crosslinkers O 
are O 
broken O 
, O 
plastic O 
flow O 
results O 
. O 

treatment O 
in O 
type O 
1 O 
and O 
type O 
2 O 
diabetes O 
( O 
T1D O 
and O 
T2D O 
) O 
is O 
highly O 
efficacious O 
, O 
but O 
in O 
practice O 
, O 
non-adherence O 
and O 
ineffective O 
dose O 
titration O 
limit O 
its O 
effectiveness O 
. O 
Barriers O 
to O 
more O 
effective O 
insulin O 
treatment O 
are O 
numerous O 
, O 
including O 
hypoglycaemia O 
, O 
fear O 
of O 
hypoglycaemia O 
and O 
concern O 
about O 
weight O 
gain O 
. O 
The O 
regular O 
treatment O 
timing O 
needed O 
with O 
conventional O 
basal O 
insulins O 
[ O 
neutral O 
protamine O 
Hagedorn O 
( O 
NPH O 
) O 
insulin O 
and O 
the O 
first O 
- O 
generation O 
analogues O 
glargine O 
and O 
detemir O 
] O 
may O 
also O 
make O 
adherence O 
to O 
these O 
treatments O 
problematic O 
for O 
many O 
patients O 
. O 
Indeed O 
, O 
surveys O 
indicate O 
that O 
the O 
rigidity O 
of O 
this O 
schedule O 
induces O 
some O 
patients O 
with O 
T1D O 
and O 
T2D O 
to O 
omit O 
insulin O 
doses O 
. O 
Degludec O 
is O 
a O 
novel O 
, O 
ultra O 
- O 
long O 
- O 
acting O 
basal O 
insulin O 
analogue O 
that O 
is O 
as O 
effective O 
as O 
insulin O 
glargine O 
, O 
but O 
significantly O 
reduces O 
patients O 
' O 
risk O 
of O 
nocturnal O 
hypoglycaemia O 
. O 
Because O 
of O 
its O 
peakless O 
, O 
extended O 
and O 
highly O 
predictable O 
glucose B-TRIVIAL 
-lowering O 
effect O 
, O 
once O 
- O 
daily O 
dosing O 
on O 
a O 
flexible O 
schedule O 
may O 
be O 
feasible O 
with O 
degludec O 
. O 
Studies O 
testing O 
this O 
possibility O 
suggest O 
that O 
degludec O 
tolerates O 
day O 
- O 
to O 
- O 
day O 
variation O 
in O 
dose O 
timing O 
while O 
maintaining O 
full O 
efficacy O 
and O 
low O 
risk O 
of O 
nocturnal O 
hypoglycaemia O 
. O 
Degludec O 
would O 
appear O 
to O 
be O 
an O 
appropriate O 
choice O 
for O 
patients O 
being O 
considered O 
for O 
a O 
basal O 
analogue O 
, O 
and O 
it O 
may O 
be O 
particularly O 
well O 
suited O 
to O 
patients O 
with O 
unpredictable O 
social O 
or O 
work O 
schedules O 
, O 
those O 
who O 
travel O 
frequently O 
and O 
those O 
who O 
find O 
rigid O 
scheduling O 
of O 
their O 
insulin O 
injections O 
a O 
burden O 
or O 
barrier O 
to O 
regular O 
treatment O 
. O 

dipyranocoumarin B-FAMILY 
from O 
the O 
leaves O 
of O 
Calophyllum O 
apetalum O 
Willd O 
. O 

new O 
dipyranocoumarin B-FAMILY 
, O 
α-hydroxytomentolide B-TRIVIAL 
A I-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
from O 
the O 
leaves O 
of O 
Calophyllum O 
apetalum O 
together O 
with O 
the O 
known O 
compounds O 
friedelin B-TRIVIAL 
( O 
2 O 
) O 
, O 
apetalactone B-TRIVIAL 
( O 
3 O 
) O 
, O 
inophyllum B-TRIVIAL 
C I-TRIVIAL 
( O 
4 O 
) O 
and O 
canophyllol B-TRIVIAL 
( O 
5 O 
) O 
. O 
The O 
structure O 
of O 
the O 
new O 
compound O 
was O 
established O 
by O 
spectroscopic O 
studies O 
which O 
include O 
(1)H B-FORMULA 
NMR O 
, O 
(13)C B-FORMULA 
NMR O 
, O 
NOESY O 
, O 
HetCOSY O 
, O 
COLOC O 
experiments O 
and O 
single O 
crystal O 
X-ray O 
diffraction O 
analysis O 
. O 

and O 
aqueous O 
extracts O 
of O 
some O 
climber O 
species O 
from O 
the O 
Bignoniaceae O 
family O 
that O 
grow O 
in O 
the O 
north O 
of O 
Argentina O 
were O 
evaluated O 
for O 
in O 
vitro O 
antibacterial O 
activity O 
against O 
Gram O 
- O 
positive O 
and O 
Gram O 
- O 
negative O 
strains O 
. O 
By O 
means O 
of O 
bioautography O 
and O 
disc O 
diffusion O 
methods O 
, O 
it O 
could O 
be O 
determined O 
that O 
all O 
infusions O 
were O 
not O 
active O 
, O 
whereas O 
the O 
hydroalcoholic O 
extracts O 
of O 
seven O 
species O 
were O 
able O 
to O 
inhibit O 
bacterial O 
growth O 
. O 
The O 
minimum O 
inhibitory O 
concentration O 
and O 
minimum O 
bactericidal O 
concentration O 
observed O 
were O 
between O 
62.5 O 
and O 
1000 O 
μg O 
gallic B-TRIVIAL 
acid I-TRIVIAL 
equivalent O 
( O 
GAE O 
) O 
/ O 
mL O 
and O 
between O 
125 O 
and O 
1000 O 
μg O 
GAE O 
/ O 
mL O 
, O 
respectively O 
. O 
The O 
tested O 
extracts O 
were O 
more O 
active O 
against O 
Gram O 
- O 
positive O 
microorganisms O 
. O 
Time O 
- O 
kill O 
experiments O 
indicated O 
that O 
all O 
extracts O 
have O 
bacteriostatic O 
activity O 
. O 
Phytochemical O 
screening O 
showed O 
the O 
presence O 
of O 
terpenoids B-FAMILY 
, O 
phenols B-FAMILY 
and O 
flavonoids B-FAMILY 
. O 
The O 
amount O 
of O 
phenolic B-FAMILY 
compounds O 
and O 
flavonoids B-FAMILY 
was O 
higher O 
in O 
tinctures O 
when O 
compared O 
with O 
infusions O 
. O 
These O 
results O 
suggest O 
the O 
presence O 
of O 
antibacterial O 
substances O 
in O 
the O 
hydroalcoholic O 
extracts O 
, O 
which O 
could O 
be O 
used O 
for O 
the O 
treatment O 
of O 
infections O 
. O 

transient O 
receptor O 
potential O 
( O 
TRP O 
) O 
channels O 
are O 
involved O 
in O 
many O 
physiologically O 
important O 
processes O 
. O 
Here O 
, O 
we O 
have O 
studied O 
the O 
significance O 
of O 
the O 
TRPC2 O 
channel O 
in O 
the O 
regulation O 
of O 
rat O 
thyroid O 
FRTL-5 O 
cell O 
proliferation O 
, O 
migration O 
, O 
adhesion O 
and O 
invasion O 
, O 
using O 
stable O 
TRPC2 O 
( O 
shTRPC2 O 
) O 
knock O 
- O 
down O 
cells O 
. O 
In O 
the O 
shTRPC2 O 
cells O 
, O 
proliferation O 
was O 
decreased O 
due O 
to O 
a O 
prolonged O 
G1 O 
/ O 
S O 
cell O 
cycle O 
phase O 
. O 
The O 
tumor O 
suppressor O 
p53 O 
and O 
the O 
cyclin O 
- O 
dependant O 
kinase O 
inhibitors O 
p27 O 
and O 
p21 O 
were O 
upregulated O 
. O 
Cell O 
invasion O 
, O 
adhesion O 
and O 
migration O 
were O 
also O 
attenuated O 
in O 
shTRPC2 O 
cells O 
, O 
probably O 
due O 
to O 
decreased O 
activity O 
of O 
both O 
Rac O 
and O 
calpain O 
, O 
and O 
a O 
decreased O 
secretion O 
and O 
activity O 
of O 
matrix O 
metalloproteinase O 
2 O 
. O 
The O 
attenuated O 
proliferation O 
, O 
migration O 
, O 
invasion O 
and O 
ATP B-ABBREVIATION 
-evoked O 
calcium B-SYSTEMATIC 
entry O 
was O 
mimicked O 
by O 
overexpressing O 
a O 
non-conducting O 
, O 
truncated O 
TRPC2 O 
( O 
TRPC2-DN O 
) O 
in O 
wild O 
type O 
cells O 
, O 
and O 
was O 
reversed O 
by O 
overexpression O 
of O 
TRPC2-GFP O 
in O 
shTRPC2 O 
cells O 
. O 
In O 
conclusion O 
, O 
TRPC2 O 
is O 
an O 
important O 
regulator O 
of O 
rat O 
thyroid O 
cell O 
function O 
. O 

baicalensis O 
Georgi O 
( O 
skullcap O 
) O 
has O 
been O 
widely O 
used O 
as O 
a O 
dietary O 
ingredient O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
reveal O 
novel O 
function O 
of O 
skullcap O 
and O 
its O 
mechanism O 
on O 
allergen O 
permeation O 
in O 
intestinal O 
epithelial O 
cells O 
. O 
Intestinal O 
epithelial O 
Caco-2 O 
cell O 
monolayers O 
were O 
used O 
to O 
evaluate O 
the O 
inhibitory O 
effect O 
of O 
skullcap O 
on O 
ovalbumin O 
( O 
OVA O 
) O 
permeation O 
by O 
measuring O 
transepithelial O 
electrical O 
resistance O 
( O 
TEER O 
) O 
and O 
the O 
quantity O 
of O 
permeated O 
OVA O 
. O 
TEER O 
increased O 
and O 
the O 
OVA O 
flux O 
decreased O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
through O 
up O 
- O 
regulating O 
tight O 
junction O 
- O 
related O 
proteins O 
in O 
cells O 
incubated O 
with O 
increasing O 
concentrations O 
of O 
skullcap O 
extract O 
. O 
In O 
the O 
in O 
vivo O 
study O 
, O 
the O 
amounts O 
of O 
OVA O 
from O 
orally O 
ingested O 
albumen O 
reduced O 
on O 
administration O 
of O 
the O 
skullcap O 
extract O 
. O 
We O 
also O 
revealed O 
for O 
the O 
first O 
time O 
that O 
the O 
active O 
component O 
of O 
skullcap O 
extract O 
for O 
inhibition O 
of O 
OVA O 
permeation O 
was O 
baicalein B-TRIVIAL 
. O 
These O 
findings O 
demonstrated O 
that O 
skullcap O 
extract O 
might O 
attenuate O 
a O 
food O 
allergic O 
response O 
by O 
inhibiting O 
allergen O 
permeation O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 

relationship O 
between O 
emulsion O 
structure O 
and O 
the O 
release O 
of O 
volatile O 
organic O 
compounds O 
( O 
VOCs O 
) O 
was O 
investigated O 
using O 
a O 
model O 
mouth O 
system O 
under O 
oral O 
conditions O 
( O 
tongue O 
mastication O 
, O 
artificial O 
saliva O 
, O 
pH O 
and O 
salt O 
) O 
. O 
The O 
VOCs O 
were O 
monitored O 
on O 
- O 
line O 
by O 
proton O 
transfer O 
reaction O 
mass O 
spectrometry O 
( O 
PTR-MS O 
) O 
. O 
Two O 
types O 
of O 
emulsion O 
system O 
were O 
compared O 
: O 
primary O 
and O 
multilayer O 
oil O 
- O 
in O 
- O 
water O 
( O 
P-O O 
/ O 
W O 
, O 
M-O O 
/ O 
W O 
) O 
emulsions O 
consisting O 
of O 
soy O 
oil O 
coated O 
by O 
β-lactoglobulin O 
and O 
pectin O 
layers O 
. O 
The O 
P-O O 
/ O 
W O 
emulsions O 
showed O 
intensive O 
flocculation O 
at O 
pH O 
5 O 
and O 
above O 
200mM O 
NaCl B-FORMULA 
where O 
the O 
electrostatic O 
repulsive O 
charge O 
was O 
at O 
a O 
minimum O 
. O 
Bridging O 
and O 
depletion O 
flocculation O 
were O 
mostly O 
observed O 
for O 
P-O O 
/ O 
W O 
emulsions O 
containing O 
artificial O 
saliva O 
with O 
1wt% O 
mucin O 
. O 
The O 
VOC O 
release O 
was O 
found O 
to O 
increase O 
when O 
the O 
emulsion O 
droplets O 
flocculated O 
, O 
thus O 
changing O 
the O 
oil O 
volume O 
phase O 
distribution O 
. O 
The O 
adsorbed O 
pectin O 
layer O 
stabilised O 
the O 
emulsion O 
structure O 
under O 
conditions O 
of O 
short O 
- O 
time O 
oral O 
processing O 
, O 
and O 
hindered O 
the O 
release O 
of O 
hydrophobic O 
VOCs O 
. O 

study O 
of O 
the O 
precursors O 
of O 
the O 
natural O 
antioxidant O 
phenol B-SYSTEMATIC 
3,4-dihydroxyphenylglycol I-SYSTEMATIC 
in O 
olive O 
oil O 
waste O 
. O 

( O 
DHPG B-ABBREVIATION 
) O 
is O 
a O 
potent O 
antioxidant O 
recently O 
found O 
in O 
the O 
free O 
form O 
in O 
olive O 
oil O 
and O 
table O 
olives O 
. O 
DHPG B-ABBREVIATION 
can O 
be O 
recovered O 
from O 
olive O 
oil O 
solid O 
waste O 
by O 
a O 
hydrothermal O 
treatment O 
. O 
It O 
was O 
observed O 
that O 
an O 
increase O 
in O 
the O 
concentration O 
of O 
DHPG B-ABBREVIATION 
occurred O 
when O 
alperujo O 
aqueous O 
extracts O 
were O 
subjected O 
to O 
mild O 
thermal O 
conditions O 
( O 
post O 
- O 
treatment O 
) O 
. O 
This O 
fact O 
indicates O 
that O 
certain O 
solubilized O 
compounds O 
or O 
precursors O 
containing O 
DHPG B-ABBREVIATION 
which O 
is O 
released O 
with O 
the O 
post O 
- O 
treatment O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
precursors O 
of O 
DHPG B-ABBREVIATION 
were O 
identified O 
and O 
characterized O 
after O 
extraction O 
from O 
alperujo O 
using O 
thermal O 
treatment O 
and O 
purification O 
by O 
fractionation O 
on O 
Amberlite O 
® O 
XAD16 O 
polyamide O 
and O 
semi-preparative O 
reverse O 
- O 
phase O 
HPLC O 
columns O 
. O 
Their O 
structures O 
were O 
elucidated O 
using O 
HPLC O 
coupled O 
to O 
diode O 
array O 
detector O 
( O 
DAD O 
) O 
and O 
electrospray O 
ionization O 
mass O 
spectrometry O 
( O 
ESI-MS O 
) O 
. O 
The O 
results O 
identified O 
three O 
compounds O 
as O 
precursors O 
, O 
and O 
their O 
structures O 
can O 
be O 
attributed O 
to O 
the O 
diastereoisomeric O 
forms O 
of O 
the O 
two O 
β-hydroxy B-SYSTEMATIC 
derivatives O 
of O 
verbascoside B-TRIVIAL 
and O 
isoverbascoside B-TRIVIAL 
( O 
β-hydroxyacteoside B-SYSTEMATIC 
and O 
β-hydroxyisoacteoside B-SYSTEMATIC 
) O 
, O 
and O 
2″-hydroxyoleuropein B-SYSTEMATIC 
, O 
all O 
of O 
which O 
contain O 
a O 
DHPG B-ABBREVIATION 
moiety O 
, O 
potentially O 
explaining O 
the O 
increases O 
in O 
the O 
concentration O 
of O 
this O 
phenolic B-FAMILY 
compound O 
in O 
olive O 
oil O 
waste O 
. O 

isolated O 
from O 
frozen O 
and O 
dried O 
apple O 
peels O 
were O 
studied O 
as O 
potential O 
natural O 
antioxidants O 
to O 
stabilize O 
omega-3 B-FAMILY 
polyunsaturated I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
( O 
ω3 B-ABBREVIATION 
PUFA I-ABBREVIATION 
) O 
enriched O 
fish O 
oil O 
. O 
The O 
ethanolic O 
extracts O 
of O 
apple O 
peels O 
were O 
fractionated O 
by O 
reversed O 
phase O 
chromatography O 
using O 
gradient O 
elution O 
of O 
20-100% O 
aqueous O 
ethanol B-SYSTEMATIC 
. O 
The O 
collected O 
fractions O 
were O 
analyzed O 
by O 
ultra O 
pressure O 
liquid O 
chromatography O 
coupled O 
with O 
tandem O 
mass O 
spectrometry O 
( O 
UPLC-MS O 
/ O 
MS O 
) O 
. O 
The O 
total O 
phenolic O 
content O 
and O 
antioxidant O 
capacity O 
of O 
each O 
fraction O 
were O 
evaluated O 
by O 
Folin-Ciocalteu O 
( O 
FC O 
) O 
, O 
ferric B-SYSTEMATIC 
reducing O 
antioxidant O 
power O 
( O 
FRAP O 
) O 
and O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
radical O 
( O 
DPPH B-ABBREVIATION 
) O 
scavenging O 
assays O 
. O 
Inhibition O 
of O 
fish O 
oil O 
oxidation O 
was O 
studied O 
using O 
the O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
( O 
TBARS O 
) O 
assay O 
. O 
Polyphenols B-FAMILY 
fractionated O 
using O 
frozen O 
apple O 
peel O 
extract O 
had O 
significantly O 
higher O 
FC O 
, O 
FRAP O 
and O 
DPPH(·) B-ABBREVIATION 
scavenging O 
values O 
than O 
those O 
of O 
dried O 
apple O 
peel O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
The O 
flavonol O 
- O 
rich O 
fractions O 
inhibited O 
fish O 
oil O 
oxidation O 
by O 
40-62% O 
at O 
a O 
total O 
phenolic O 
concentration O 
of O 
200μg O 
/ O 
ml O 
. O 
The O 
fractionated O 
polyphenols B-FAMILY 
from O 
both O 
dried O 
and O 
frozen O 
apple O 
peel O 
showed O 
higher O 
inhibition O 
of O 
lipid O 
oxidation O 
compared O 
to O 
α-tocopherol B-TRIVIAL 
, O 
butylated B-SYSTEMATIC 
hydroxytoluene I-SYSTEMATIC 
and O 
crude O 
apple O 
peel O 
extracts O 
. O 

study O 
on O 
levels O 
of O 
perfluorooctane B-SYSTEMATIC 
sulfonic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
and O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
in O 
selected O 
foodstuffs O 
and O 
human O 
milk O 
from O 
Italy O 
. O 

the O 
health O 
risks O 
associated O 
with O 
perfluorinated O 
compounds O 
( O 
PFC O 
) O 
exposure O 
and O 
the O 
detection O 
of O 
these O 
compounds O 
in O 
many O 
countries O 
around O 
the O 
world O 
, O 
little O 
is O 
known O 
on O 
their O 
occurrence O 
in O 
Italy O 
. O 
The O 
results O 
of O 
a O 
study O 
on O 
levels O 
of O 
perfluorooctane B-SYSTEMATIC 
sulfonate I-SYSTEMATIC 
( O 
PFOS B-ABBREVIATION 
) O 
and O 
perfluorooctanoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PFOA B-ABBREVIATION 
) O 
, O 
analysed O 
by O 
HPLC-ESI-MS O 
, O 
in O 
human O 
milk O 
and O 
food O 
samples O 
from O 
the O 
city O 
of O 
Siena O 
and O 
its O 
province O 
( O 
central O 
Italy O 
) O 
are O 
here O 
reported O 
. O 
PFOS B-ABBREVIATION 
was O 
found O 
in O 
13 O 
out O 
of O 
49 O 
breast O 
milk O 
samples O 
( O 
0.76±1.27ng O 
/ O 
g O 
) O 
, O 
while O 
PFOA B-ABBREVIATION 
was O 
detected O 
in O 
one O 
sample O 
( O 
8.04ng O 
/ O 
g O 
) O 
. O 
Only O 
PFOS B-ABBREVIATION 
was O 
found O 
in O 
food O 
samples O 
. O 
Fish O 
were O 
the O 
most O 
contaminated O 
samples O 
( O 
7.65±34.2ng O 
/ O 
g O 
) O 
; O 
mean O 
concentrations O 
in O 
meat O 
and O 
milk O 
and O 
dairy O 
products O 
were O 
similar O 
( O 
1.43±7.21ng O 
/ O 
g O 
and O 
1.35±3.45ng O 
/ O 
g O 
, O 
respectively O 
) O 
. O 
In O 
all O 
cereal O 
- O 
based O 
food O 
, O 
eggs O 
, O 
vegetables O 
, O 
honey O 
and O 
beverages O 
PFOS B-ABBREVIATION 
concentration O 
was O 
< O 
LOD O 
. O 
These O 
data O 
show O 
that O 
consumption O 
of O 
most O 
breast O 
milk O 
analysed O 
would O 
not O 
result O 
in O 
children O 
exceeding O 
their O 
total O 
daily O 
intakes O 
for O 
perfluorinated O 
compounds O 
. O 

activity O 
in O 
whole O 
wheat O 
flour O 
( O 
WWF O 
) O 
is O 
largely O 
responsible O 
for O 
the O 
loss O 
in O 
baking O 
quality O 
during O 
storage O 
. O 
Metal O 
ions O 
affect O 
the O 
activity O 
of O 
seed O 
lipases O 
; O 
however O 
, O 
no O 
previous O 
studies O 
have O 
applied O 
this O 
information O 
to O 
WWF O 
in O 
a O 
way O 
that O 
reduces O 
lipase O 
activity O 
, O 
is O 
practical O 
for O 
commercial O 
manufacture O 
, O 
and O 
uses O 
common O 
food O 
ingredients O 
. O 
NaCl B-FORMULA 
, O 
KCl B-FORMULA 
, O 
Ca-propionate B-SYSTEMATIC 
, O 
or O 
FeNa-ethylenediaminetetraacetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
FeNa-EDTA B-FORMULA 
) O 
were O 
applied O 
to O 
hard O 
red O 
winter O 
( O 
HRW O 
) O 
and O 
hard O 
white O 
spring O 
( O 
HWS O 
) O 
wheats O 
during O 
conditioning O 
as O 
aqueous O 
solutions O 
at O 
concentrations O 
that O 
would O 
be O 
acceptable O 
in O 
baked O 
goods O 
. O 
Salts O 
affected O 
lipase O 
activity O 
to O 
different O 
degrees O 
depending O 
on O 
the O 
type O 
of O 
wheat O 
used O 
. O 
Inhibition O 
was O 
greater O 
in O 
HRW O 
compared O 
with O 
HWS O 
WWF O 
, O 
probably O 
due O 
to O 
higher O 
lipase O 
activity O 
in O 
HRW O 
wheat O 
. O 
In O 
HRW O 
WWF O 
, O 
1% O 
NaCl B-FORMULA 
( O 
flour O 
weight O 
) O 
reduced O 
hydrolytic O 
and O 
oxidative O 
rancidity O 
and O 
resulted O 
in O 
higher O 
loaf O 
volume O 
and O 
lower O 
firmness O 
than O 
untreated O 
WWF O 
after O 
24weeks O 
of O 
storage O 
. O 

( O 
the O 
N.W O 
. O 
corner O 
of O 
Spain O 
) O 
wants O 
to O 
promote O 
the O 
production O 
and O 
marketing O 
of O 
new O 
sweet O 
wines O 
. O 
The O 
present O 
work O 
represents O 
the O 
first O 
study O 
on O 
sweet O 
wines O 
manufactured O 
with O 
red O 
grapes O 
Vitis O 
vinifera O 
L O 
. O 
Garnacha O 
Tintorera O 
, O 
a O 
teinturier O 
cultivar O 
. O 
Two O 
different O 
red O 
sweet O 
wines O 
were O 
elaborated O 
: O 
the O 
first O 
one O 
was O 
made O 
with O 
dried O 
grapes O 
; O 
Vitis O 
vinifera O 
L O 
. O 
Garnacha O 
Tintorera O 
has O 
excellent O 
potential O 
to O 
produce O 
wines O 
from O 
raisined O 
grapes O 
; O 
the O 
second O 
one O 
, O 
a O 
fortified O 
sweet O 
wine O 
aged O 
in O 
oak O 
barrels O 
. O 
Different O 
red O 
Garnacha O 
Tintorera O 
- O 
based O 
wines O 
( O 
a O 
dry O 
base O 
wine O 
, O 
GBW O 
; O 
a O 
naturally O 
sweet O 
wine O 
, O 
GNSW O 
; O 
and O 
a O 
fortified O 
sweet O 
wine O 
, O 
GFSW O 
) O 
were O 
characterized O 
. O 
Chromatic O 
characteristics O 
and O 
phenolic B-FAMILY 
compounds O 
were O 
established O 
by O 
spectrophotometric O 
methods O 
in O 
order O 
to O 
assess O 
the O 
technology O 
of O 
Garnacha O 
Tintorera O 
- O 
based O 
sweet O 
wines O 
. O 
High O 
molecular O 
weight O 
brown O 
polymers O 
, O 
produced O 
during O 
the O 
grape O 
drying O 
process O 
and O 
isolated O 
from O 
sweet O 
wines O 
by O 
the O 
dialysis O 
process O 
, O 
were O 
responsible O 
for O 
the O 
brown O 
colour O 
of O 
sweet O 
wines O 
. O 
As O 
a O 
consequence O 
, O 
yellowness O 
of O 
sweet O 
wines O 
was O 
also O 
higher O 
which O 
was O 
confirmed O 
by O 
colorimetric O 
indexes O 
. O 
With O 
respect O 
to O 
phenolic O 
content O 
, O 
GFSW O 
presented O 
the O 
lowest O 
content O 
because O 
the O 
maceration- O 
alcoholic B-FAMILY 
fermentation O 
was O 
stopped O 
through O 
the O 
addition O 
of O 
alcohol B-FAMILY 
before O 
the O 
diffusion O 
of O 
red O 
pigments O 
from O 
skins O 
to O 
must O 
was O 
complete O 
. O 
GNSW O 
presented O 
the O 
highest O 
phenolic O 
content O 
due O 
to O 
the O 
concentration O 
effect O 
resulting O 
from O 
evaporation O 
of O 
water O 
from O 
the O 
grapes O 
. O 
Anthocyanins B-FAMILY 
of O 
sweet O 
wines O 
were O 
polymerised O 
in O 
great O 
extent O 
. O 
The O 
percentage O 
of O 
polymerised O 
tannins B-FAMILY 
was O 
sufficient O 
to O 
guarantee O 
the O 
aging O 
process O 
of O 
sweet O 
wines O 
. O 

study O 
was O 
undertaken O 
to O 
develop O 
an O 
efficient O 
single O 
step O 
chromatographic O 
method O 
for O 
purification O 
of O 
C-phycocyanin O 
( O 
CPC O 
) O 
from O 
species O 
of O 
Oscillatoria O 
tenuis O 
. O 
Purification O 
of O 
CPC O 
involves O 
a O 
multistep O 
treatment O 
of O 
the O 
crude O 
extract O 
by O 
precipitation O 
with O 
ammonium B-SYSTEMATIC 
sulphate I-SYSTEMATIC 
, O 
followed O 
by O 
gel O 
filtration O 
chromatography O 
. O 
Pure O 
CPC O 
was O 
finally O 
obtained O 
from O 
O O 
. O 
tenuis O 
with O 
purity O 
ratio O 
( O 
A620 O 
/ O 
A280 O 
) O 
4.88 O 
. O 
SDS-PAGE O 
of O 
pure O 
CPC O 
yielded O 
two O 
bands O 
corresponding O 
to O 
α O 
and O 
β O 
subunits O 
; O 
the O 
molecular O 
weight O 
of O 
α O 
subunit O 
is O 
17.0kDa O 
, O 
whereas O 
the O 
molecular O 
weight O 
of O 
β O 
subunit O 
is O 
19.5kDa O 
. O 
Fluorescence O 
and O 
phase O 
contrast O 
microscopy O 
revealed O 
characteristic O 
apoptotic O 
features O 
like O 
cell O 
shrinkage O 
, O 
membrane O 
blebbing O 
, O 
nuclear O 
condensation O 
and O 
DNA O 
fragmentation O 
. O 
CPC O 
exhibited O 
antioxidant O 
and O 
antiproliferative O 
activity O 
against O 
human O 
cancer O 
cells O 
through O 
apoptosis O 
; O 
nuclear O 
apoptosis O 
induction O 
was O 
accompanied O 
by O 
G0 O 
/ O 
G1 O 
phase O 
arrest O 
and O 
DNA O 
fragmentation O 
. O 
CPC O 
is O 
a O 
natural O 
pigment O 
with O 
potential O 
as O 
an O 
anticancer O 
agent O 
. O 

of O 
5-hydroxymethylfurfural B-SYSTEMATIC 
derived O 
from O 
processed O 
Cornus O 
officinalis O 
on O 
the O 
prevention O 
of O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
and O 
its O 
mechanism O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
protective O 
effect O 
of O 
5-HMF B-SYSTEMATIC 
on O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
injured O 
by O 
high O 
glucose B-TRIVIAL 
in O 
vitro O 
, O 
and O 
the O 
mechanism O 
underlying O 
this O 
process O 
. O 
Our O 
results O 
demonstrated O 
that O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
in O 
HUVECs O 
was O 
mainly O 
mediated O 
through O 
activation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
, O 
Jun O 
N-kinase O 
2 O 
/ O 
3 O 
( O 
JNK2 O 
/ O 
3 O 
) O 
and O 
plasma O 
interleukin-8 O 
( O 
IL-8 O 
) O 
, O 
and O 
inactivation O 
of O 
phosphorylated O 
protein O 
kinase O 
B O 
( O 
P-Akt O 
) O 
. O 
Treatment O 
of O 
HUVECs O 
with O 
media O 
containing O 
high O 
glucose B-TRIVIAL 
( O 
4.5% O 
) O 
in O 
the O 
presence O 
of O 
5-HMF B-SYSTEMATIC 
( O 
100 O 
, O 
200 O 
and O 
400μM O 
) O 
resulted O 
in O 
significant O 
inhibition O 
of O 
high O 
glucose B-TRIVIAL 
-induced O 
oxidative O 
stress O 
and O 
expression O 
of O 
JNK1 O 
and O 
JNK2 O 
/ O 
3 O 
. O 
Furthermore O 
, O 
5-HMF B-SYSTEMATIC 
rapidly O 
inhibited O 
high O 
glucose B-TRIVIAL 
-induced O 
activation O 
of O 
IL-8 O 
, O 
a O 
downstream O 
activator O 
of O 
P-Akt O 
. O 
Diabetes O 
mellitus O 
can O 
cause O 
a O 
wide O 
variety O 
of O 
vascular O 
complications O 
and O 
high O 
glucose B-TRIVIAL 
can O 
induce O 
vascular O 
endothelial O 
cell O 
apoptosis O 
. O 
Free O 
radicals O 
are O 
formed O 
disproportionately O 
in O 
diabetes O 
by O 
glucose B-TRIVIAL 
oxidation O 
. O 
The O 
finding O 
of O 
this O 
study O 
highlights O 
the O 
pharmacological O 
application O 
of O 
5-HMF B-SYSTEMATIC 
for O 
preventing O 
cardiovascular O 
and O 
diabetes O 
mellitus O 
diseases O 
, O 
and O 
provides O 
the O 
theoretical O 
basis O 
for O 
further O 
development O 
of O 
a O 
Cornus O 
officinalis O 
agent O 
for O 
diabetes O 
- O 
associated O 
vascular O 
diseases O 
. O 

and O 
validation O 
of O 
ethylenethiourea B-SYSTEMATIC 
determination O 
in O 
foods O 
using O 
methanol B-SYSTEMATIC 
-based O 
extraction O 
, O 
solid O 
- O 
phase O 
extraction O 
cleanup O 
and O 
LC-MS O 
/ O 
MS O 
. O 

response O 
to O 
the O 
need O 
for O 
a O 
rapid O 
, O 
cost O 
- O 
effective O 
, O 
eco O 
- O 
friendly O 
and O 
efficient O 
extraction O 
process O 
, O 
a O 
sensitive O 
method O 
for O 
the O 
determination O 
of O 
ethylenethiourea B-SYSTEMATIC 
( O 
ETU B-ABBREVIATION 
) O 
in O 
food O 
matrices O 
by O 
high O 
- O 
performance O 
liquid O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
HPLC-LC O 
/ O 
MS O 
) O 
was O 
developed O 
and O 
validated O 
. O 
ETU B-ABBREVIATION 
was O 
extracted O 
from O 
food O 
commodities O 
with O 
methanol B-SYSTEMATIC 
, O 
cleaned O 
up O 
by O 
alumina B-TRIVIAL 
-SPE O 
column O 
, O 
and O 
then O 
determined O 
by O 
HPLC-MS O 
/ O 
MS O 
. O 
The O 
MS O 
detection O 
was O 
operated O 
in O 
positive O 
ionization O 
mode O 
. O 
For O 
confirmation O 
of O 
target O 
compound O 
, O 
two O 
precursor O 
ion O 
> O 
product O 
ion O 
transitions O 
were O 
selected O 
by O 
multi O 
- O 
reaction O 
monitoring O 
mode O 
( O 
MRM O 
) O 
. O 
The O 
method O 
showed O 
good O 
linearity O 
with O 
correlation O 
coefficient O 
higher O 
than O 
0.995 O 
. O 
Recoveries O 
at O 
three O 
spiked O 
levels O 
( O 
10 O 
, O 
50 O 
, O 
100ng O 
/ O 
g O 
) O 
in O 
random O 
selected O 
food O 
matrices O 
were O 
in O 
range O 
of O 
71-121% O 
with O 
RSDs O 
not O 
larger O 
than O 
25% O 
. O 
The O 
limit O 
of O 
quantitation O 
for O 
the O 
analyte O 
was O 
estimated O 
at O 
5ng O 
/ O 
g O 
. O 

of O 
antioxidant O 
activity O 
of O 
hydroethanolic B-FAMILY 
fresh O 
and O 
aged O 
garlic O 
extracts O 
and O 
their O 
effects O 
on O 
cerebral O 
ischemia O 
. O 

properties O 
and O 
protective O 
effect O 
of O 
aged O 
garlic O 
extract O 
( O 
AGE O 
) O 
and O 
of O 
20% O 
hydroethanolic B-FAMILY 
fresh O 
extracts O 
from O 
garlic O 
clove O 
( O 
GCE O 
) O 
and O 
skin O 
( O 
GSE O 
) O 
on O 
cerebral O 
ischemia O 
were O 
evaluated O 
by O 
administering O 
extracts O 
at O 
the O 
beginning O 
of O 
reperfusion O 
in O 
a O 
rat O 
model O 
of O 
stroke O 
. O 
All O 
three O 
extracts O 
scavenged O 
superoxide B-TRIVIAL 
anion O 
, O 
peroxynitrite B-SYSTEMATIC 
anion O 
, O 
and O 
peroxyl B-SYSTEMATIC 
radicals O 
, O 
but O 
with O 
different O 
efficiencies O 
; O 
furthermore O 
, O 
GCE O 
and O 
GSE O 
scavenged O 
hydroxyl B-SYSTEMATIC 
radicals O 
and O 
GSE O 
scavenged O 
singlet O 
oxygen B-SYSTEMATIC 
. O 
These O 
extracts O 
significantly O 
prevented O 
reduction O 
of O 
neuronal O 
nuclear O 
antigen O 
in O 
the O 
infarcted O 
area O 
, O 
although O 
no O 
improvement O 
in O 
neurological O 
function O 
was O 
observed O 
. O 
Importantly O 
, O 
GCE O 
and O 
GSE O 
contained O 
S-allylcystein B-SYSTEMATIC 
, O 
a O 
compound O 
associated O 
with O 
AGE's O 
neuroprotective O 
effect O 
against O 
damage O 
induced O 
by O 
cerebral O 
ischemia O 
. O 
Extracts O 
decreased O 
mRNA O 
expression O 
of O 
NR1- O 
and O 
NR2B- O 
NMDA B-ABBREVIATION 
-receptor O 
subunits O 
and O 
prevented O 
ischemia O 
- O 
induced O 
reduction O 
in O 
mitochondrial O 
potential O 
and O 
in O 
ATP B-ABBREVIATION 
synthesis O 
. O 
These O 
results O 
indicate O 
that O 
antioxidants O 
present O 
in O 
garlic O 
extracts O 
may O 
regulate O 
ROS O 
concentrations O 
during O 
ischemia O 
, O 
favour O 
pro O 
- O 
survival O 
pathways O 
, O 
and O 
attenuate O 
mitochondrial O 
dysfunction O 
. O 

ROS-activated O 
agents O 
utilize O 
a O 
tethered B-FAMILY 
amine I-FAMILY 
to O 
selectively O 
target O 
acute O 
myeloid O 
leukemia O 
. O 

study O 
explores O 
the O 
possible O 
use O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
-activated O 
DNA O 
modifying O 
agents O 
against O 
acute O 
myeloid O 
leukemia O 
( O 
AML O 
) O 
. O 
A O 
key O 
amine B-SYSTEMATIC 
on O 
the O 
lead O 
agent O 
was O 
investigated O 
via O 
cytotoxicity O 
assays O 
and O 
was O 
found O 
necessary O 
for O 
potency O 
. O 
The O 
two O 
best O 
compounds O 
were O 
screened O 
via O 
the O 
NCI-60 O 
cell O 
panel O 
. O 
These O 
two O 
compounds O 
had O 
potency O 
between O 
200 O 
and O 
800nM O 
against O 
many O 
of O 
the O 
leukemia O 
cancer O 
cell O 
types O 
. O 
Subsequent O 
experiments O 
explored O 
activity O 
against O 
a O 
transformed O 
AML O 
model O 
that O 
mimics O 
the O 
molecular O 
signatures O 
identified O 
in O 
primary O 
AML O 
patient O 
samples O 
. O 
A O 
lead O 
compound O 
had O 
an O 
IC50 O 
of O 
760nM O 
against O 
this O 
AML O 
cell O 
line O 
as O 
well O 
as O 
a O 
therapeutic O 
index O 
of O 
7.7±3 O 
between O 
the O 
transformed O 
AML O 
model O 
cell O 
line O 
and O 
non-cancerous O 
human O 
CD34+ O 
blood O 
stem O 
/ O 
progenitor O 
cells O 
( O 
UCB O 
) O 
. O 
The O 
selectivity O 
was O 
much O 
greater O 
than O 
the O 
mainstays O 
of O 
AML O 
treatment O 
: O 
doxorubicin B-TRIVIAL 
and O 
cytarabine B-TRIVIAL 
. O 
This O 
manuscript O 
demonstrates O 
that O 
this O 
novel O 
type O 
of O 
agent O 
may O 
be O 
useful O 
against O 
AML O 
. O 

medicine O 
where O 
each O 
patient O 
receives O 
the O 
right O 
drug O 
and O 
the O 
right O 
intensity O 
of O 
drug O 
treatment O 
for O 
as O 
long O 
as O 
needed O 
or O 
safe O 
is O 
the O 
goal O 
of O 
medicine O 
. O 
The O 
identification O 
of O 
predictors O 
of O 
response O 
is O 
the O 
first O 
step O 
toward O 
this O 
. O 
In O 
rheumatoid O 
arthritis O 
( O 
RA O 
) O 
, O 
several O 
prediction O 
matrices O 
were O 
designed O 
to O 
predict O 
the O 
risk O 
of O 
rapid O 
radiological O 
progression O 
( O 
RRP O 
) O 
in O 
the O 
first O 
year O 
of O 
treatment O 
, O 
on O 
either O 
disease O 
modifying O 
anti-rheumatic O 
drug O 
( O 
DMARD O 
) O 
monotherapy O 
or O 
combination O 
therapy O 
with O 
prednisone B-TRIVIAL 
or O 
a O 
biological O 
agent O 
. O 
Both O 
clinical O 
markers O 
and O 
biomarkers O 
of O 
response O 
to O 
either O 
anti-TNF O 
or O 
different O 
mode O 
of O 
action O 
biological O 
agents O 
, O 
and O 
of O 
successful O 
discontinuation O 
of O 
these O 
agents O 
once O 
the O 
treatment O 
goal O 
has O 
been O 
achieved O 
, O 
have O 
been O 
identified O 
in O 
different O 
studies O 
. O 
Most O 
of O 
these O 
markers O 
need O 
validation O 
in O 
other O 
cohorts O 
. O 
Research O 
into O 
combining O 
clinical O 
markers O 
and O 
biomarkers O 
of O 
response O 
could O 
lead O 
to O 
identification O 
of O 
risk O 
profiles O 
resulting O 
in O 
a O 
new O 
step O 
toward O 
personalized O 
medicine O 
in O 
RA O 
. O 

of O 
a O 
predictive O 
in O 
vitro O 
Leydig O 
cell O 
assay O 
for O 
anti-androgenicity O 
of O 
phthalate B-FAMILY 
esters I-FAMILY 
in O 
the O 
rat O 
. O 

in O 
vitro O 
assay O 
using O 
the O 
rat O 
Leydig O 
cell O 
line O 
R2C O 
was O 
evaluated O 
for O 
its O 
ability O 
to O 
quantitatively O 
predict O 
inhibition O 
of O 
testosterone B-TRIVIAL 
synthesis O 
. O 
Results O 
obtained O 
for O 
endocrine O 
active O 
phthalates B-FAMILY 
( O 
MEHP B-ABBREVIATION 
, O 
MBP B-ABBREVIATION 
) O 
, O 
and O 
inactive O 
phthalates B-FAMILY 
( O 
MMP B-ABBREVIATION 
and O 
MEP B-ABBREVIATION 
) O 
were O 
highly O 
consistent O 
with O 
in O 
vivo O 
results O 
based O 
on O 
tissue O 
and O 
media O 
concentrations O 
. O 
Statistically O 
significant O 
inhibition O 
of O 
testosterone B-TRIVIAL 
synthesis O 
( O 
p O 
< O 
0.05 O 
, O 
1-way O 
ANOVA O 
) O 
was O 
observed O 
at O 
1μM O 
MBP B-ABBREVIATION 
and O 
3μM O 
MEHP B-ABBREVIATION 
, O 
while O 
MEP B-ABBREVIATION 
and O 
MMP B-ABBREVIATION 
did O 
not O 
affect O 
inhibition O 
of O 
testosterone B-TRIVIAL 
synthesis O 
until O 
much O 
higher O 
concentrations O 
( O 
≫ O 
100μM O 
) O 
. O 
Concentrations O 
causing O 
50% O 
inhibition O 
of O 
testosterone B-TRIVIAL 
synthesis O 
for O 
MBP B-ABBREVIATION 
and O 
MEHP B-ABBREVIATION 
( O 
3 O 
and O 
6μM O 
respectively O 
) O 
, O 
were O 
similar O 
to O 
in O 
vivo O 
values O 
( O 
3 O 
and O 
7μM O 
) O 
. O 
The O 
R2C O 
assay O 
was O 
used O 
to O 
determine O 
the O 
relative O 
potency O 
of O 
14 O 
structurally O 
diverse O 
monoesters B-FAMILY 
and O 
oxidative O 
metabolites O 
of O 
MEHP B-ABBREVIATION 
. O 
Monoesters B-FAMILY 
with O 
alkyl O 
chains O 
4-5 O 
carbons B-FAMILY 
in O 
length O 
had O 
the O 
highest O 
potency O 
for O 
testosterone B-TRIVIAL 
inhibition O 
, O 
while O 
0-2 O 
carbon B-SYSTEMATIC 
alkyl O 
chains O 
were O 
least O 
potent O 
. O 
Phase O 
I O 
metabolism O 
did O 
not O 
completely O 
inactivate O 
MEHP B-ABBREVIATION 
, O 
underscoring O 
the O 
need O 
for O 
metabolism O 
data O 
when O 
interpreting O 
in O 
vitro O 
pharmacodynamic O 
data O 
. O 
This O 
steroid B-FAMILY 
inhibition O 
assay O 
provides O 
a O 
predictive O 
in O 
vitro O 
alternative O 
to O 
expensive O 
and O 
timeconsuming O 
developmental O 
rat O 
studies O 
for O 
phthalate B-FAMILY 
-induced O 
antiandrogenicity O 
. O 

of O 
chronic O 
methylphenidate B-SYSTEMATIC 
on O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
under O 
a O 
progressive O 
- O 
ratio O 
schedule O 
of O 
reinforcement O 
in O 
rhesus O 
monkeys O 
. O 

has O 
been O 
hypothesized O 
that O 
drugs O 
that O 
serve O 
as O 
substrates O 
for O 
dopamine B-TRIVIAL 
( O 
DA O 
) O 
and O 
norepinephrine B-TRIVIAL 
( O 
NE O 
) O 
transporters O 
may O 
be O 
more O 
suitable O 
medications O 
for O 
cocaine B-TRIVIAL 
dependence O 
than O 
drugs O 
that O 
inhibit O 
DA O 
and O 
NE O 
uptake O 
by O 
binding O 
to O 
transporters O 
. O 
Previous O 
studies O 
have O 
shown O 
that O 
the O 
DA O 
/ O 
NE O 
releaser O 
d-amphetamine B-TRIVIAL 
can O 
decrease O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
in O 
preclinical O 
and O 
clinical O 
studies O 
. O 
The O 
present O 
study O 
examined O 
the O 
effects O 
of O 
methylphenidate B-SYSTEMATIC 
( O 
MPD B-ABBREVIATION 
) O 
, O 
a O 
DA O 
uptake O 
inhibitor O 
, O 
for O 
its O 
ability O 
to O 
decrease O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
under O 
conditions O 
designed O 
to O 
reflect O 
clinically O 
relevant O 
regimens O 
of O 
cocaine B-TRIVIAL 
exposure O 
and O 
pharmacotherapy O 
. O 
Each O 
morning O 
, O 
rhesus O 
monkeys O 
pressed O 
a O 
lever O 
to O 
receive O 
food O 
pellets O 
under O 
a O 
fixed O 
- O 
ratio O 
50 O 
schedule O 
of O 
reinforcement O 
; O 
cocaine B-TRIVIAL 
was O 
self O 
- O 
administered O 
under O 
a O 
progressiveratio O 
schedule O 
of O 
reinforcement O 
in O 
the O 
evening O 
. O 
After O 
cocaine B-TRIVIAL 
( O 
0.003-0.56 O 
mg O 
/ O 
kg O 
per O 
injection O 
, O 
i.v O 
. O 
) O 
dose O 
- O 
response O 
curves O 
were O 
determined O 
, O 
self O 
- O 
administration O 
sessions O 
were O 
suspended O 
and O 
MPD B-ABBREVIATION 
( O 
0.003-0.0056 O 
mg O 
/ O 
kg O 
per O 
hr O 
, O 
i.v O 
. O 
or O 
1.0-9.0 O 
mg O 
/ O 
kg O 
p.o O 
. O 
, O 
b.i.d O 
. O 
) O 
was O 
administered O 
for O 
several O 
weeks O 
. O 
A O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
session O 
was O 
conducted O 
every O 
7 O 
days O 
. O 
When O 
a O 
MPD B-ABBREVIATION 
dose O 
was O 
reached O 
that O 
either O 
persistently O 
decreased O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
or O 
produced O 
disruptive O 
effects O 
, O 
the O 
cocaine B-TRIVIAL 
dose O 
- O 
effect O 
curve O 
was O 
re O 
- O 
determined O 
. O 
In O 
most O 
cases O 
, O 
MPD B-ABBREVIATION 
treatment O 
either O 
produced O 
behaviorally O 
disruptive O 
effects O 
or O 
increased O 
cocaine B-TRIVIAL 
selfadministration O 
; O 
it O 
took O 
several O 
weeks O 
for O 
these O 
effects O 
to O 
dissipate O 
. O 
These O 
data O 
are O 
consistent O 
with O 
the O 
largely O 
negative O 
results O 
of O 
clinical O 
trials O 
with O 
MPD B-ABBREVIATION 
. O 
In O 
contrast O 
to O 
the O 
positive O 
effects O 
with O 
the O 
monoamine B-FAMILY 
releaser O 
d-amphetamine B-TRIVIAL 
under O 
identical O 
conditions O 
, O 
these O 
results O 
do O 
not O 
support O 
use O 
of O 
monoamine B-FAMILY 
uptake O 
inhibitors O 
like O 
MPD B-ABBREVIATION 
as O 
a O 
medication O 
for O 
cocaine B-TRIVIAL 
dependence O 
. O 

disease O 
may O 
contribute O 
to O 
increased O 
risk O 
of O 
accelerated O 
cognitive O 
decline O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 
We O 
aimed O 
to O 
determine O 
associations O 
of O 
measures O 
of O 
macrovascular O 
disease O 
with O 
cognitive O 
change O 
in O 
a O 
cognitively O 
healthy O 
older O 
population O 
with O 
type O 
2 O 
diabetes.RESEARCH O 
DESIGN O 
AND O 
METHODSEight O 
- O 
hundred O 
thirty O 
- O 
one O 
men O 
and O 
women O 
( O 
aged O 
60-75 O 
years O 
) O 
attended O 
two O 
waves O 
of O 
the O 
prospective O 
Edinburgh O 
Type O 
2 O 
Diabetes O 
Study O 
( O 
ET2DS O 
) O 
. O 
At O 
baseline O 
, O 
clinical O 
and O 
subclinical O 
macrovascular O 
disease O 
was O 
measured O 
, O 
including O 
cardiovascular O 
event O 
history O 
, O 
carotid O 
intima O 
- O 
media O 
thickness O 
( O 
cIMT O 
) O 
, O 
ankle O 
brachial O 
index O 
( O 
ABI O 
) O 
, O 
and O 
serum O 
N B-FORMULA 
-terminal O 
probrain O 
natriuretic O 
peptide O 
( O 
NT-proBNP O 
) O 
. O 
Seven O 
neuropsychological O 
tests O 
were O 
administered O 
at O 
baseline O 
and O 
after O 
4 O 
years O 
; O 
scores O 
were O 
combined O 
to O 
a O 
standardized O 
general O 
ability O 
factor O 
( O 
g O 
) O 
. O 
Adjustment O 
of O 
follow O 
- O 
up O 
g O 
for O 
baseline O 
g O 
assessed O 
4-year O 
cognitive O 
change O 
. O 
Adjustment O 
for O 
vocabulary O 
( O 
estimated O 
premorbid O 
ability O 
) O 
was O 
used O 
to O 
estimate O 
lifetime O 
cognitive O 
change.RESULTSMeasures O 
of O 
cognitive O 
decline O 
were O 
significantly O 
associated O 
with O 
stroke O 
, O 
NT-proBNP O 
, O 
ABI O 
, O 
and O 
cIMT O 
, O 
but O 
not O 
with O 
nonstroke O 
vascular O 
events O 
. O 
The O 
association O 
of O 
stroke O 
with O 
increased O 
estimated O 
lifetime O 
cognitive O 
decline O 
( O 
standardized O 
β O 
, O 
-0.12 O 
) O 
and O 
of O 
subclinical O 
markers O 
with O 
actual O 
4-year O 
decline O 
( O 
standardized O 
β O 
, O 
-0.12 O 
, O 
0.12 O 
, O 
and O 
-0.15 O 
for O 
NT-proBNP O 
, O 
ABI O 
, O 
and O 
cIMT O 
, O 
respectively O 
) O 
reached O 
the O 
Bonferroni O 
- O 
adjusted O 
level O 
of O 
statistical O 
significance O 
( O 
P O 
< O 
0.006 O 
) O 
. O 
Results O 
altered O 
only O 
slightly O 
on O 
adjustment O 
for O 
vascular O 
risk O 
factors.CONCLUSIONSStroke O 
and O 
subclinical O 
markers O 
of O 
cardiac O 
stress O 
and O 
generalized O 
atherosclerosis O 
are O 
associated O 
with O 
cognitive O 
decline O 
in O 
older O 
patients O 
with O 
type O 
2 O 
diabetes O 
. O 
Further O 
investigation O 
into O 
the O 
potential O 
use O 
of O 
subclinical O 
vascular O 
disease O 
markers O 
in O 
predicting O 
cognitive O 
decline O 
is O 
warranted O 
. O 

- O 
Ni B-FORMULA 
layered O 
double O 
hydroxides B-FAMILY 
for O 
water O 
oxidation O 
in O 
neutral O 
electrolyte O 
. O 

electrochemical O 
properties O 
of O 
Co B-FORMULA 
- O 
Ni B-FORMULA 
layered O 
double O 
hydroxides B-FAMILY 
( O 
LDHs O 
) O 
as O 
efficient O 
electrocatalysts O 
for O 
water O 
oxidation O 
were O 
investigated O 
in O 
potassium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
electrolyte O 
under O 
neutral O 
pH O 
condition O 
. O 
The O 
Co B-FORMULA 
- O 
Ni B-FORMULA 
LDHs O 
with O 
a O 
core O 
- O 
shell O 
structure O 
were O 
fabricated O 
using O 
a O 
facile O 
route O 
from O 
a O 
Co B-FORMULA 
- O 
Ni B-FORMULA 
hydroxide B-SYSTEMATIC 
precursor O 
with O 
iodine B-SYSTEMATIC 
as O 
a O 
topotactic O 
oxidizer O 
. O 
The O 
unique O 
core O 
- O 
shell O 
morphology O 
is O 
likely O 
due O 
to O 
the O 
enrichment O 
of O 
Co B-FORMULA 
(iii) I-FORMULA 
hydroxide B-SYSTEMATIC 
in O 
the O 
inner O 
core O 
indicated O 
by O 
selected O 
area O 
electron O 
diffraction O 
and O 
energy O 
- O 
dispersive O 
spectroscopy O 
. O 
Through O 
a O 
self O 
- O 
assembling O 
process O 
at O 
the O 
organic O 
/ O 
inorganic O 
interface O 
and O 
dip O 
- O 
coating O 
, O 
the O 
Co B-FORMULA 
- O 
Ni B-FORMULA 
LDHs O 
were O 
deposited O 
onto O 
FTO O 
glass O 
substrates O 
to O 
prepare O 
composite O 
electrodes O 
. O 
Low O 
over O 
- O 
potential O 
and O 
high O 
current O 
density O 
was O 
achieved O 
in O 
the O 
oxygen B-SYSTEMATIC 
evolution O 
reaction O 
. O 
The O 
excellent O 
electrocatalytic O 
activity O 
of O 
Co B-FORMULA 
- O 
Ni B-FORMULA 
LDHs O 
may O 
be O 
attributed O 
to O 
more O 
accessible O 
Co B-FORMULA 
active O 
sites O 
and O 
rapid O 
movement O 
of O 
interlayer O 
ions O 
within O 
their O 
layered O 
structure O 
. O 

alcohol B-FAMILY 
effects O 
on O 
subtypes O 
of O 
impulsivity O 
and O 
the O 
role O 
of O 
alcohol B-FAMILY 
-outcome O 
expectancies O 
. O 

: O 
It O 
is O 
well O 
established O 
that O 
alcohol B-FAMILY 
acutely O 
impairs O 
the O 
ability O 
to O 
inhibit O 
a O 
pre O 
- O 
potent O 
response O 
( O 
motor O 
impulsivity O 
) O 
, O 
but O 
its O 
effects O 
on O 
cognitive O 
impulsivity O 
, O 
including O 
temporal O 
( O 
delayed O 
gratification O 
) O 
and O 
reflection O 
( O 
decision O 
making O 
) O 
impulsivity O 
, O 
are O 
not O 
clear O 
. O 
An O 
important O 
factor O 
contributing O 
to O 
the O 
effects O 
of O 
alcohol B-FAMILY 
is O 
cognitive O 
expectancies O 
of O 
alcohol B-FAMILY 
-related O 
outcomes O 
. O 
OBJECTIVES O 
: O 
The O 
current O 
study O 
investigated O 
the O 
effect O 
of O 
alcohol B-FAMILY 
, O 
and O 
alcohol B-FAMILY 
outcome O 
expectancies O 
, O 
on O 
subtypes O 
of O 
impulsivity O 
. O 
METHODS O 
: O 
Impulsivity O 
was O 
tested O 
using O 
the O 
Stop O 
Signal O 
, O 
the O 
Single O 
Key O 
Impulsivity O 
and O 
the O 
Information O 
Sampling O 
Task O 
for O 
motor O 
, O 
temporal O 
and O 
reflection O 
impulsivity O 
, O 
respectively O 
. O 
Participants O 
( O 
n O 
= O 
48 O 
) O 
received O 
placebo O 
, O 
a O 
low O 
( O 
0.4 O 
g O 
/ O 
kg O 
) O 
or O 
high O 
dose O 
( O 
0.8 O 
g O 
/ O 
kg O 
) O 
of O 
alcohol B-FAMILY 
, O 
before O 
completing O 
the O 
impulsivity O 
measures O 
. O 
RESULTS O 
: O 
Motor O 
impulsivity O 
was O 
affected O 
by O 
alcohol B-FAMILY 
dose O 
; O 
participants O 
receiving O 
a O 
high O 
dose O 
displayed O 
reduced O 
inhibitory O 
control O 
. O 
Reflection O 
impulsivity O 
was O 
affected O 
by O 
cognitive O 
alcohol B-FAMILY 
expectancies O 
, O 
but O 
not O 
by O 
alcohol B-FAMILY 
condition O 
; O 
participants O 
expecting O 
greater O 
cognitive O 
and O 
behavioural O 
impairment O 
by O 
alcohol B-FAMILY 
exhibited O 
low O 
impulsivity O 
. O 
Temporal O 
impulsivity O 
was O 
not O 
affected O 
by O 
either O 
alcohol B-FAMILY 
dose O 
or O 
outcome O 
expectancies O 
. O 
CONCLUSIONS O 
: O 
These O 
data O 
suggest O 
that O 
the O 
effects O 
of O 
alcohol B-FAMILY 
on O 
the O 
subtypes O 
of O 
impulsivity O 
are O 
dissociable O 
. O 
Motor O 
impulsivity O 
is O 
sensitive O 
to O 
the O 
pharmacological O 
effects O 
of O 
alcohol B-FAMILY 
, O 
whereas O 
the O 
reflection O 
subtype O 
is O 
affected O 
by O 
cognitive O 
alcohol B-FAMILY 
expectancies O 
. O 
The O 
findings O 
have O 
implications O 
for O 
the O 
understanding O 
of O 
impulsive O 
behaviour O 
under O 
the O 
influence O 
of O 
alcohol B-FAMILY 
. O 

New O 
Strategy O 
for O 
Selective O 
Targeting O 
of O 
Progesterone B-TRIVIAL 
Receptor O 
with O 
Passive O 
Antagonists O 
. O 

available O 
progesterone B-TRIVIAL 
receptor O 
( O 
PR O 
) O 
antagonists O 
, O 
such O 
as O 
mifepristone B-TRIVIAL 
( O 
RU486 B-IDENTIFIER 
) O 
, O 
lack O 
specificity O 
and O 
display O 
partial O 
agonist O 
properties O 
, O 
leading O 
to O 
potential O 
drawbacks O 
in O 
their O 
clinical O 
use O 
. O 
Recent O 
X-ray O 
crystallographic O 
studies O 
have O 
identified O 
key O 
contacts O 
involved O 
in O 
the O 
binding O 
of O 
agonists O 
and O 
antagonists O 
with O 
PR O 
opening O 
the O 
way O 
for O 
a O 
new O 
rational O 
strategy O 
for O 
inactivating O 
PR O 
. O 
We O 
report O 
here O 
the O 
synthesis O 
and O 
characterization O 
of O 
a O 
novel O 
class O 
of O 
PR O 
antagonists O 
designed O 
from O 
such O 
studies O 
. O 
The O 
lead O 
molecule O 
, O 
the O 
homosteroid B-FAMILY 
APR19 B-IDENTIFIER 
, O 
displays O 
in O 
vivo O 
endometrial O 
antiprogesterone O 
activity O 
. O 
APR19 B-IDENTIFIER 
inhibits O 
progesterone B-TRIVIAL 
-induced O 
PR O 
recruitment O 
and O 
transactivation O 
from O 
synthetic O 
and O 
endogenous O 
gene O 
promoters O 
. O 
Importantly O 
, O 
it O 
exhibits O 
high O 
PR O 
selectivity O 
with O 
respect O 
to O 
other O 
steroid B-FAMILY 
hormone O 
receptors O 
, O 
and O 
is O 
devoid O 
of O 
any O 
partial O 
agonist O 
activity O 
on O 
PR O 
target O 
gene O 
transcription O 
. O 
Two O 
- O 
hybrid O 
and O 
immunostaining O 
experiments O 
reveal O 
that O 
APR19 B-IDENTIFIER 
-bound O 
PR O 
is O 
unable O 
to O 
interact O 
with O 
either O 
transcriptional O 
coactivators O 
( O 
SRC1 O 
, O 
SCR2 O 
) O 
or O 
corepressors O 
( O 
NCoR O 
, O 
SMRT O 
) O 
, O 
in O 
contrast O 
to O 
RU486 B-IDENTIFIER 
-PR O 
complexes O 
. O 
APR19 B-IDENTIFIER 
also O 
inhibits O 
agonist O 
- O 
induced O 
phosphorylation O 
of O 
serine B-TRIVIAL 
294 O 
regulating O 
PR O 
transcriptional O 
activity O 
and O 
turnover O 
kinetics O 
. O 
In-silico O 
docking O 
studies O 
based O 
on O 
the O 
crystal O 
structure O 
of O 
the O 
PR O 
ligand O 
- O 
binding O 
domain O 
show O 
that O 
, O 
in O 
contrast O 
to O 
progesterone B-TRIVIAL 
, O 
APR19 B-IDENTIFIER 
does O 
not O 
establish O 
stabilizing O 
hydrogen B-SYSTEMATIC 
bonds O 
with O 
the O 
ligand O 
binding O 
cavity O 
, O 
resulting O 
in O 
an O 
unstable O 
ligand O 
- O 
receptor O 
complex O 
. O 
Altogether O 
, O 
these O 
properties O 
highly O 
distinguish O 
APR19 B-IDENTIFIER 
from O 
RU486 B-IDENTIFIER 
and O 
likely O 
its O 
derivatives O 
, O 
suggesting O 
that O 
it O 
belongs O 
to O 
a O 
new O 
class O 
of O 
pure O 
antiprogestins O 
which O 
inactivate O 
PR O 
by O 
a O 
passive O 
mechanism O 
. O 
These O 
specific O 
PR O 
antagonists O 
open O 
new O 
perspectives O 
for O 
long O 
term O 
hormonal O 
therapy O 
. O 

resistance O 
to O 
the O 
actions O 
of O 
insulin O 
and O 
leptin O 
is O 
associated O 
with O 
the O 
onset O 
of O 
obesity O 
and O 
type O 
2 O 
diabetes O 
mellitus O 
( O 
T2DM O 
) O 
, O 
whereas O 
leptin O 
and O 
insulin O 
signaling O 
is O 
essential O 
for O 
both O 
glucose B-TRIVIAL 
and O 
energy O 
homeostasis O 
. O 
Although O 
it O 
is O 
known O 
that O 
leptin O 
resistance O 
can O 
lead O 
to O 
attenuated O 
insulin O 
signaling O 
, O 
whether O 
insulin O 
resistance O 
can O 
lead O 
to O 
or O 
exacerbate O 
leptin O 
resistance O 
is O 
unknown O 
. O 
To O 
investigate O 
the O 
molecular O 
events O 
underlying O 
crosstalk O 
between O 
these O 
signaling O 
pathways O 
, O 
immortalized O 
hypothalamic O 
neuronal O 
models O 
, O 
rHypoE-19 O 
and O 
mHypoA-2 O 
/ O 
10 O 
, O 
were O 
utilized O 
. O 
Prolonged O 
insulin O 
exposure O 
was O 
used O 
to O 
induce O 
cellular O 
insulin O 
resistance O 
, O 
and O 
thereafter O 
leptin O 
- O 
mediated O 
regulation O 
of O 
signal O 
transduction O 
and O 
gene O 
expression O 
was O 
assessed O 
. O 
Leptin O 
directly O 
repressed O 
agouti O 
- O 
related O 
peptide O 
( O 
AgRP O 
) O 
mRNA O 
levels O 
, O 
but O 
induced O 
urocortin-2 O 
( O 
UCN2 O 
) O 
, O 
insulin O 
receptor O 
substrate-1 O 
( O 
IRS1 O 
) O 
, O 
IRS2 O 
, O 
and O 
IR O 
transcription O 
, O 
through O 
leptin O 
- O 
mediated O 
phosphatidylinositol B-TRIVIAL 
-3-kinase O 
( O 
PI3K O 
) O 
/ O 
Akt O 
activation O 
. O 
Neuronal O 
insulin O 
resistance O 
, O 
as O 
assessed O 
by O 
attenuated O 
Akt O 
phosphorylation O 
, O 
blocked O 
leptin O 
- O 
mediated O 
signal O 
transduction O 
, O 
and O 
AgRP O 
, O 
UCN2 O 
, O 
IRS1 O 
, O 
IRS2 O 
and O 
IR O 
synthesis O 
. O 
Insulin O 
resistance O 
caused O 
a O 
substantial O 
decrease O 
in O 
IR O 
protein O 
levels O 
, O 
forkhead O 
box O 
protein O 
1 O 
( O 
FoxO1 O 
) O 
phosphorylation O 
, O 
and O 
an O 
increase O 
in O 
suppressor O 
of O 
cytokine O 
signaling O 
3 O 
( O 
SOCS3 O 
) O 
protein O 
levels O 
. O 
Cellular O 
insulin O 
resistance O 
may O 
cause O 
or O 
exacerbate O 
neuronal O 
leptin O 
resistance O 
, O 
and O 
by O 
extension O 
, O 
obesity O 
. O 
It O 
is O 
essential O 
to O 
unravel O 
the O 
effects O 
of O 
neuronal O 
insulin O 
resistance O 
given O 
that O 
both O 
peripheral O 
, O 
as O 
well O 
as O 
the O 
less O 
widely O 
studied O 
central O 
insulin O 
resistance O 
, O 
may O 
contribute O 
to O 
the O 
development O 
of O 
metabolic O 
, O 
reproductive O 
and O 
cardiovascular O 
disorders O 
. O 
This O 
study O 
provides O 
an O 
improved O 
understanding O 
of O 
the O 
complex O 
cellular O 
crosstalk O 
between O 
insulin O 
- O 
leptin O 
signal O 
transduction O 
that O 
is O 
disrupted O 
during O 
neuronal O 
insulin O 
resistance O 
. O 

XAS O 
study O 
of O 
the O 
luminescent O 
Eu B-FORMULA 
centers O 
in O 
thiosilicate B-SYSTEMATIC 
phosphors O 
. O 

to O 
its O 
bright O 
yellow O 
- O 
to O 
- O 
red O 
emission O 
, O 
europium B-SYSTEMATIC 
doped O 
Ca2SiS4 B-FORMULA 
is O 
a O 
very O 
interesting O 
material O 
for O 
phosphor O 
converted O 
light O 
emitting O 
diodes O 
. O 
The O 
emission O 
spectrum O 
is O 
highly O 
dependent O 
on O 
the O 
Eu B-FORMULA 
concentration O 
and O 
can O 
consist O 
of O 
more O 
than O 
one O 
emission O 
band O 
. O 
We O 
combined O 
X-ray O 
absorption O 
fine O 
structure O 
and O 
photoluminescence O 
measurements O 
to O 
analyze O 
the O 
structure O 
of O 
europium B-SYSTEMATIC 
centers O 
in O 
(Ca,Eu)2SiS4 B-FORMULA 
luminescent O 
powders O 
. O 
This O 
paper O 
provides O 
an O 
explanation O 
for O 
the O 
concentration O 
dependency O 
of O 
the O 
emission O 
spectra O 
. O 
We O 
find O 
that O 
at O 
low O 
dopant O 
concentrations O 
a O 
large O 
fraction O 
of O 
trivalent O 
europium B-SYSTEMATIC 
ions O 
is O 
unexpectedly O 
present O 
in O 
the O 
powders O 
. O 
These O 
trivalent O 
europium B-SYSTEMATIC 
ions O 
tend O 
to O 
form O 
defect O 
clusters O 
in O 
the O 
luminescent O 
powders O 
. O 
Furthermore O 
we O 
observe O 
a O 
preferential O 
substitution O 
of O 
the O 
europium B-SYSTEMATIC 
ions O 
over O 
the O 
two O 
different O 
substitutional O 
Ca B-FORMULA 
sites O 
, O 
which O 
changes O 
upon O 
increasing O 
the O 
dopant O 
concentration O 
. O 
At O 
high O 
dopant O 
concentration O 
, O 
the O 
powder O 
crystallizes O 
in O 
the O 
monoclinic B-FORMULA 
Eu2SiS4 I-FORMULA 
structure O 
. O 
Once O 
more O 
a O 
preferential O 
substitution O 
of O 
the O 
europium B-SYSTEMATIC 
ions O 
is O 
observed O 
. O 
Summarizing O 
, O 
the O 
influence O 
of O 
the O 
concentration O 
on O 
the O 
emission O 
spectrum O 
is O 
explained O 
by O 
a O 
difference O 
in O 
preferential O 
occupation O 
of O 
the O 
Eu B-FORMULA 
ions O 
in O 
the O 
lattice O 
. O 

Effects O 
of O 
Baicalin B-TRIVIAL 
in O 
a O 
Mouse O 
Model O 
of O 
Allergic O 
Asthma O 
. O 

aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
anti-asthmatic O 
effects O 
of O 
baicalin B-TRIVIAL 
( O 
BA O 
) O 
and O 
the O 
possible O 
mechanisms O 
. O 
Asthma O 
model O 
was O 
established O 
by O 
ovalbumin O 
( O 
OVA O 
) O 
intraperitoneal O 
injection O 
. O 
A O 
total O 
of O 
60 O 
mice O 
were O 
randomly O 
assigned O 
to O 
six O 
experimental O 
groups O 
: O 
control O 
, O 
model O 
, O 
dexamethasone B-TRIVIAL 
( O 
2 O 
mg O 
/ O 
kg O 
) O 
, O 
and O 
BA O 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
20 O 
mg O 
/ O 
kg O 
, O 
40 O 
mg O 
/ O 
kg O 
) O 
. O 
Airway O 
resistance O 
( O 
RI O 
) O 
and O 
lung O 
compliance O 
( O 
Cdyn O 
) O 
were O 
measured O 
, O 
histological O 
studies O 
were O 
evaluated O 
by O 
the O 
hematoxylin B-TRIVIAL 
and O 
eosin B-FAMILY 
staining O 
, O 
Th1 O 
/ O 
Th2 O 
, O 
OVA-specific O 
serum O 
, O 
and O 
BALF O 
IgE O 
levels O 
and O 
Th17 O 
cytokines O 
were O 
evaluated O 
by O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
, O 
and O 
Th17 O 
cells O 
was O 
evaluated O 
by O 
flow O 
cytometry O 
( O 
FCM O 
) O 
. O 
Our O 
study O 
demonstrated O 
that O 
BA O 
inhibited O 
OVA-induced O 
increases O 
in O 
RI O 
and O 
eosinophil O 
count O 
; O 
interleukin O 
(IL)-4 O 
, O 
IL-17A O 
levels O 
, O 
and O 
Cdyn O 
were O 
recovered O 
and O 
increased O 
IFN-γ O 
level O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
. O 
Histological O 
studies O 
demonstrated O 
that O 
BA O 
substantially O 
inhibited O 
OVA-induced O 
eosinophilia O 
in O 
lung O 
tissue O 
and O 
airway O 
tissue O 
. O 
FCM O 
studies O 
demonstrated O 
that O 
BA O 
substantially O 
inhibited O 
Th17 O 
cells O 
. O 
These O 
findings O 
suggest O 
that O 
BA O 
may O 
effectively O 
ameliorate O 
the O 
progression O 
of O 
asthma O 
and O 
could O 
be O 
used O 
as O 
a O 
therapy O 
for O 
patients O 
with O 
allergic O 
asthma O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

- O 
related O 
macular O 
degeneration O 
( O 
AMD O 
) O 
is O 
the O 
leading O 
cause O 
of O 
blindness O 
in O 
the O 
elderly O 
, O 
and O 
the O 
prevalence O 
of O 
the O 
disease O 
increases O 
exponentially O 
with O 
every O 
decade O 
after O 
age O 
50 O 
years O 
. O 
It O 
is O 
a O 
multifactorial O 
disease O 
involving O 
a O 
complex O 
interplay O 
of O 
genetic O 
, O 
environmental O 
, O 
metabolic O 
, O 
and O 
functional O 
factors O 
. O 
Besides O 
smoking O 
, O 
hypertension O 
, O 
obesity O 
, O 
and O 
certain O 
dietary O 
habits O 
, O 
a O 
growing O 
body O 
of O 
evidence O 
indicates O 
that O 
inflammation O 
and O 
the O 
immune O 
system O 
may O 
play O 
a O 
key O 
role O 
in O 
the O 
development O 
of O 
the O 
disease O 
. O 
AMD O 
may O 
progress O 
from O 
the O 
early O 
form O 
to O 
the O 
intermediate O 
form O 
and O 
then O 
to O 
the O 
advanced O 
form O 
, O 
where O 
two O 
subtypes O 
exist O 
: O 
the O 
nonneovascular O 
( O 
dry O 
) O 
type O 
and O 
the O 
neovascular O 
( O 
wet O 
) O 
type O 
. O 
The O 
results O 
from O 
the O 
Age O 
- O 
Related O 
Eye O 
Disease O 
Study O 
have O 
shown O 
that O 
for O 
the O 
nonneovascular O 
type O 
of O 
AMD O 
, O 
supplementation O 
with O 
high O 
- O 
dose O 
antioxidants O 
( O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
, O 
vitamin B-FAMILY 
E I-FAMILY 
, O 
and O 
β-carotene B-TRIVIAL 
) O 
and O 
zinc B-SYSTEMATIC 
is O 
recommended O 
for O 
those O 
with O 
the O 
intermediate O 
form O 
of O 
AMD O 
in O 
one O 
or O 
both O 
eyes O 
or O 
with O 
advanced O 
AMD O 
or O 
vision O 
loss O 
due O 
to O 
AMD O 
in O 
one O 
eye O 
. O 
As O 
for O 
the O 
neovascular O 
type O 
of O 
the O 
advanced O 
AMD O 
, O 
the O 
current O 
standard O 
of O 
therapy O 
is O 
intravitreal O 
injections O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
inhibitors O 
. O 
In O 
addition O 
, O 
lifestyle O 
and O 
dietary O 
modifications O 
including O 
improved O 
physical O 
activity O 
, O 
reduced O 
daily O 
sodium B-SYSTEMATIC 
intake O 
, O 
and O 
reduced O 
intake O 
of O 
solid O 
fats O 
, O 
added O 
sugars B-FAMILY 
, O 
cholesterol B-TRIVIAL 
, O 
and O 
refined O 
grain O 
foods O 
are O 
recommended O 
. O 
To O 
date O 
, O 
no O 
study O 
has O 
demonstrated O 
that O 
AMD O 
can O 
be O 
cured O 
or O 
effectively O 
prevented O 
. O 
Clearly O 
, O 
more O 
research O 
is O 
needed O 
to O 
fully O 
understand O 
the O 
pathophysiology O 
as O 
well O 
as O 
to O 
develop O 
prevention O 
and O 
treatment O 
strategies O 
for O 
this O 
devastating O 
disease O 
. O 

Driving O 
Voltage O 
and O 
High O 
Mobility O 
Ambipolar O 
Field-Effect O 
Transistors O 
with O 
PbS B-FORMULA 
Colloidal O 
Nanocrystals O 
. O 

colloidal O 
nanocrystals O 
( O 
NCs O 
) O 
are O 
promising O 
materials O 
for O 
optoelectronic O 
devices O 
, O 
due O 
to O 
their O 
size O 
- O 
tunable O 
properties O 
. O 
However O 
, O 
there O 
is O 
still O 
minimal O 
understanding O 
of O 
their O 
charge O 
transport O 
mechanism O 
. O 
Through O 
a O 
combination O 
of O 
ligand O 
selections O 
, O 
ambipolar O 
transistor O 
structure O 
optimization O 
, O 
and O 
electrochemical O 
gating O 
usage O 
, O 
high O 
carrier O 
mobility O 
is O 
achieved O 
. O 
The O 
outstanding O 
device O 
characteristics O 
open O 
possibility O 
to O 
investigate O 
the O 
intrinsic O 
transport O 
properties O 
of O 
PbS B-FORMULA 
NCs O 
. O 

Areal O 
Mass O 
, O 
Flexible O 
and O 
Free-Standing O 
Reduced O 
Graphene B-SYSTEMATIC 
Oxide I-SYSTEMATIC 
/ O 
Manganese B-SYSTEMATIC 
Dioxide I-SYSTEMATIC 
Paper O 
for O 
Asymmetric O 
Supercapacitor O 
Device O 
. O 

- O 
separated O 
RGO O 
sheets O 
decorated O 
with O 
MnO2 B-FORMULA 
nanoparticles O 
facilitate O 
easy O 
access O 
of O 
the O 
electrolyte O 
ions O 
to O 
the O 
high O 
surface O 
area O 
of O 
the O 
paper O 
electrode O 
, O 
enabling O 
fabrication O 
of O 
thicker O 
electrode O 
with O 
heavier O 
areal O 
mass O 
and O 
higher O 
areal O 
capacitance O 
( O 
up O 
to O 
897 O 
mF O 
cm(-2) O 
) O 
. O 
Electrochemical O 
performance O 
of O 
the O 
bent O 
asymmetric O 
device O 
with O 
total O 
active O 
mass O 
of O 
15 O 
mg O 
remains O 
similar O 
to O 
the O 
one O 
in O 
the O 
flat O 
configuration O 
, O 
demonstrating O 
good O 
mechanical O 
robustness O 
of O 
the O 
device O 
. O 

low O 
- O 
density O 
lipoprotein O 
receptor O 
- O 
related O 
protein-1 O 
( O 
sLRP1 O 
) O 
binds O 
~ O 
70% O 
of O 
amyloid O 
β- O 
peptide O 
( O 
Aβ O 
) O 
in O 
human O 
plasma O 
. O 
In O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
and O 
individuals O 
with O 
mild O 
cognitive O 
impairment O 
converting O 
to O 
AD O 
, O 
plasma O 
sLRP1 O 
levels O 
are O 
reduced O 
and O 
sLRP1 O 
is O 
oxidized O 
which O 
results O 
in O 
diminished O 
Aβ O 
peripheral O 
binding O 
and O 
higher O 
levels O 
of O 
free O 
Aβ O 
in O 
plasma O 
. O 
Experimental O 
studies O 
have O 
shown O 
that O 
free O 
circulating O 
Aβ O 
re O 
- O 
enters O 
the O 
brain O 
and O 
that O 
sLRP1 O 
and O 
/ O 
or O 
its O 
recombinant O 
wild O 
- O 
type O 
cluster O 
IV O 
( O 
WT-LRPIV O 
) O 
prevent O 
Aβ O 
from O 
entering O 
the O 
brain O 
. O 
Treatment O 
of O 
Alzheimer's O 
APPsw+ O 
/ O 
0 O 
mice O 
with O 
WT-LRPIV O 
has O 
been O 
shown O 
to O 
reduce O 
brain O 
Aβ O 
pathology O 
. O 
In O 
addition O 
to O 
Aβ O 
, O 
LRPIV O 
binds O 
multiple O 
ligands O 
. O 
To O 
enhance O 
LRPIV O 
binding O 
for O 
Aβ O 
relative O 
to O 
other O 
LRP1 O 
ligands O 
, O 
we O 
generated O 
a O 
library O 
of O 
LRPIV O 
- O 
derived O 
fragments O 
and O 
full O 
- O 
length O 
LRPIV O 
variants O 
with O 
glycine B-TRIVIAL 
( O 
G O 
) O 
replacing O 
aspartic B-TRIVIAL 
acid I-TRIVIAL 
( O 
D O 
) O 
residues O 
3394 O 
, O 
3556 O 
and O 
3674 O 
in O 
the O 
calcium B-SYSTEMATIC 
binding O 
sites O 
. O 
Compared O 
to O 
WT-LRPIV O 
, O 
a O 
lead O 
LRPIV-D3674G O 
mutant O 
had O 
1.6-fold O 
and O 
2.7-fold O 
higher O 
binding O 
affinity O 
for O 
Aβ40 O 
and O 
Aβ42 O 
in O 
vitro O 
, O 
respectively O 
, O 
and O 
a O 
lower O 
binding O 
affinity O 
for O 
other O 
LRP1 O 
ligands O 
, O 
e.g O 
. O 
, O 
apoliporotein O 
E2 O 
, O 
E3 O 
and O 
E4 O 
( O 
1.3-1.8-fold O 
) O 
, O 
tissue O 
plasminogen O 
activator O 
( O 
2.7-fold O 
) O 
, O 
matrix O 
metalloproteinase-9 O 
( O 
4.1-fold O 
) O 
and O 
Factor O 
Xa O 
( O 
3.8-fold O 
) O 
. O 
LRPIV-D3674G O 
cleared O 
mouse O 
endogenous O 
brain O 
Aβ40 O 
and O 
Aβ42 O 
25-27% O 
better O 
than O 
WT-LRPIV O 
. O 
A O 
3-month O 
subcutaneous O 
treatment O 
of O 
APPsw+ O 
/ O 
0 O 
mice O 
with O 
LRPIV-D3674G O 
( O 
40 O 
μg O 
/ O 
kg O 
/ O 
day O 
) O 
reduced O 
Aβ40 O 
and O 
Aβ42 O 
levels O 
in O 
the O 
hippocampus O 
, O 
cortex O 
and O 
cerebrospinal O 
fluid O 
by O 
60-80% O 
, O 
and O 
improved O 
cerebral O 
blood O 
flow O 
responses O 
and O 
hippocampal O 
function O 
at O 
9 O 
months O 
of O 
age O 
. O 
Thus O 
, O 
LRPIV-D3674G O 
is O 
an O 
efficient O 
new O 
Aβ O 
clearance O 
therapy O 
. O 

of O 
diazenido B-SYSTEMATIC 
-ligated O 
vanadium B-SYSTEMATIC 
nanoparticles O 
. O 

vanadium B-SYSTEMATIC 
nanoparticles O 
stabilized O 
with O 
4-octylphenyldiazenido B-SYSTEMATIC 
groups O 
( O 
particle O 
size O 
: O 
1.7 O 
± O 
0.2 O 
nm O 
) O 
were O 
synthesized O 
via O 
the O 
reduction O 
of O 
VCl4 B-FORMULA 
with O 
superhydride B-TRIVIAL 
( O 
LiBHEt3 B-FORMULA 
) O 
in O 
the O 
presence O 
of O 
4-octylphenyldiazonium B-SYSTEMATIC 
salt O 
in O 
an O 
Ar O 
- O 
filled O 
glovebox O 
. O 
The O 
resulting O 
particles O 
were O 
characterized O 
using O 
TEM O 
, O 
elemental O 
analysis O 
, O 
and O 
XPS O 
measurements O 
. O 
The O 
unusual O 
reaction O 
on O 
the O 
surface O 
resulted O 
in O 
the O 
passivation O 
of O 
V-N═N-Ar B-FORMULA 
covalent O 
bonds O 
. O 

stabilization O 
effect O 
of O 
dielectric O 
constant O 
and O 
acidic B-FAMILY 
amino I-FAMILY 
acids I-FAMILY 
on O 
arginine B-TRIVIAL 
- O 
arginine B-TRIVIAL 
( O 
arg O 
- O 
arg O 
) O 
pairings O 
: O 
database O 
survey O 
and O 
computational O 
studies O 
. O 

survey O 
in O 
this O 
study O 
revealed O 
that O 
about O 
one O 
- O 
third O 
of O 
the O 
protein O 
structures O 
deposited O 
in O 
the O 
Protein O 
Data O 
Bank O 
( O 
PDB O 
) O 
contain O 
arginine B-TRIVIAL 
- O 
arginine B-TRIVIAL 
( O 
Arg-Arg B-FORMULA 
) O 
pairing O 
with O 
a O 
carbon B-SYSTEMATIC 
··· O 
carbon B-SYSTEMATIC 
( O 
CZ···CZ O 
) O 
interaction O 
distance O 
less O 
than O 
5 O 
Å O 
. O 
All O 
the O 
Arg-Arg B-FORMULA 
pairings O 
were O 
found O 
to O 
bury O 
in O 
a O 
polar O 
environment O 
composed O 
of O 
acidic O 
residues O 
, O 
water O 
molecules O 
, O 
and O 
strong O 
polarizable O 
or O 
negatively O 
charged O 
moieties O 
from O 
binding O 
site O 
or O 
bound O 
ligand O 
. O 
Most O 
of O 
the O 
Arg-Arg B-FORMULA 
pairings O 
are O 
solvent O 
exposed O 
and O 
68.3% O 
Arg-Arg B-FORMULA 
pairings O 
are O 
stabilized O 
by O 
acidic O 
residues O 
, O 
forming O 
Arg-Arg-Asp B-FORMULA 
/ O 
Glu B-FORMULA 
clusters O 
. O 
Density O 
functional O 
theory O 
( O 
DFT O 
) O 
was O 
then O 
employed O 
to O 
study O 
the O 
effect O 
of O 
environment O 
on O 
the O 
pairing O 
structures O 
. O 
It O 
was O 
revealed O 
that O 
Arg-Arg B-FORMULA 
pairings O 
become O 
thermodynamically O 
stable O 
( O 
about O 
-1 O 
kcal O 
/ O 
mol O 
) O 
as O 
the O 
dielectric O 
constant O 
increases O 
to O 
46.8 O 
( O 
DMSO O 
) O 
, O 
in O 
good O 
agreement O 
with O 
the O 
results O 
of O 
the O 
PDB O 
survey O 
. O 
DFT O 
calculations O 
also O 
demonstrated O 
that O 
perpendicular O 
Arg-Arg B-FORMULA 
pairing O 
structures O 
are O 
favorable O 
in O 
low O 
dielectric O 
constant O 
environment O 
, O 
while O 
in O 
high O 
dielectric O 
constant O 
environment O 
parallel O 
structures O 
are O 
favorable O 
. O 
Additionally O 
, O 
the O 
acidic O 
residues O 
can O 
stabilize O 
the O 
Arg-Arg B-FORMULA 
pairing O 
structures O 
to O 
a O 
large O 
degree O 
. O 
Energy O 
decomposition O 
analysis O 
of O 
Arg-Arg B-FORMULA 
pairings O 
and O 
Arg-Arg-Asp B-FORMULA 
/ O 
Glu B-FORMULA 
clusters O 
showed O 
that O 
both O 
solvation O 
and O 
electrostatic O 
energies O 
contribute O 
significantly O 
to O 
their O 
stability O 
. O 
The O 
results O 
reported O 
herein O 
should O 
be O 
very O 
helpful O 
for O 
understanding O 
Arg-Arg B-FORMULA 
pairing O 
and O 
its O 
application O 
in O 
drug O 
design O 
. O 

Hematite B-TRIVIAL 
Water O 
Electrolysis O 
Using O 
a O 
3D O 
Antimony-Doped B-SYSTEMATIC 
Tin I-SYSTEMATIC 
Oxide I-SYSTEMATIC 
Electrode O 
. O 

present O 
herein O 
an O 
example O 
of O 
nanocrystalline O 
antimony B-SYSTEMATIC 
- I-SYSTEMATIC 
doped I-SYSTEMATIC 
tin I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
nc- O 
ATO B-ABBREVIATION 
) O 
disordered O 
macroporous O 
" O 
inverse O 
opal O 
" O 
3D O 
electrodes O 
as O 
efficient O 
charge O 
- O 
collecting O 
support O 
structures O 
for O 
the O 
electrolysis O 
of O 
water O 
using O 
a O 
hematite B-TRIVIAL 
surface O 
catalyst O 
. O 
The O 
3D O 
macroporous O 
structures O 
were O 
created O 
via O 
templating O 
of O 
polystyrene B-SYSTEMATIC 
spheres O 
, O 
followed O 
by O 
infiltration O 
of O 
the O 
desired O 
precursor O 
solution O 
and O 
annealing O 
at O 
high O 
temperature O 
. O 
Using O 
cyclic O 
voltammetry O 
and O 
electrochemical O 
impedance O 
spectroscopy O 
, O 
it O 
was O 
determined O 
that O 
the O 
use O 
of O 
this O 
3D O 
transparent O 
conducting O 
oxide B-SYSTEMATIC 
with O 
a O 
hematite B-TRIVIAL 
surface O 
catalyst O 
allowed O 
for O 
a O 
seven O 
- O 
fold O 
increase O 
in O 
active O 
surface O 
area O 
for O 
water O 
splitting O 
with O 
respect O 
to O 
its O 
2D O 
planar O 
counterpart O 
. O 
This O 
ratio O 
of O 
surface O 
areas O 
was O 
evaluated O 
based O 
on O 
the O 
presence O 
of O 
oxidized O 
trap O 
states O 
on O 
the O 
hematite B-TRIVIAL 
surface O 
, O 
as O 
determined O 
from O 
the O 
equivalent O 
circuit O 
analysis O 
of O 
the O 
Nyquist O 
plots O 
. O 
Furthermore O 
, O 
the O 
presence O 
of O 
nc- O 
ATO B-ABBREVIATION 
2D O 
and O 
3D O 
" O 
underlayer O 
" O 
structures O 
with O 
hematite B-TRIVIAL 
deposited O 
on O 
top O 
resulted O 
in O 
decreased O 
charge O 
transfer O 
resistances O 
and O 
an O 
increase O 
in O 
the O 
number O 
of O 
available O 
active O 
surface O 
sites O 
at O 
the O 
semiconductor O 
- O 
liquid O 
junction O 
when O 
compared O 
to O 
hematite B-TRIVIAL 
films O 
lacking O 
any O 
nc- O 
ATO B-ABBREVIATION 
substructures O 
. O 
Finally O 
, O 
absorption O 
, O 
transmission O 
and O 
reflectance O 
spectra O 
of O 
all O 
of O 
the O 
tested O 
films O 
were O 
measured O 
, O 
suggesting O 
the O 
feasibility O 
of O 
using O 
3D O 
disordered O 
structures O 
in O 
photoelectrochemical O 
reactions O 
, O 
due O 
to O 
the O 
high O 
absorption O 
of O 
photons O 
by O 
the O 
surface O 
catalyst O 
material O 
and O 
trapping O 
of O 
light O 
within O 
the O 
structure O 
. O 

are O 
difficult O 
to O 
selectively O 
remove O 
from O 
surface O 
waters O 
by O 
present O 
treatment O 
methods O 
. O 
Bacterial O 
efflux O 
pumps O 
have O 
evolved O 
the O 
ability O 
to O 
discriminately O 
expel O 
antibiotics O 
and O 
other O 
noxious O 
agents O 
via O 
proton O 
and O 
ATP B-ABBREVIATION 
driven O 
pathways O 
. O 
Here O 
, O 
we O 
describe O 
light O 
- O 
dependent O 
removal O 
of O 
antibiotics O 
by O 
engineering O 
the O 
bacterial O 
efflux O 
pump O 
AcrB O 
into O 
a O 
proteovesicle O 
system O 
. O 
We O 
have O 
created O 
a O 
chimeric O 
protein O 
with O 
the O 
requisite O 
proton O 
motive O 
force O 
by O 
coupling O 
AcrB O 
to O 
the O 
light O 
- O 
driven O 
proton O 
pump O 
Delta-rhodopsin O 
( O 
dR O 
) O 
via O 
a O 
glycophorin O 
A O 
transmembrane O 
domain O 
. O 
This O 
creates O 
a O 
solar O 
powered O 
protein O 
material O 
capable O 
of O 
selectively O 
capturing O 
antibiotics O 
from O 
bulk O 
solutions O 
. O 
Using O 
environmental O 
water O 
and O 
direct O 
sunlight O 
, O 
our O 
AcrB-dR O 
vesicles O 
removed O 
almost O 
twice O 
as O 
much O 
antibiotic O 
as O 
the O 
treatment O 
standard O 
, O 
activated O 
carbon B-SYSTEMATIC 
. O 
Altogether O 
, O 
the O 
AcrB-dR O 
system O 
provides O 
an O 
effective O 
means O 
of O 
extracting O 
antibiotics O 
from O 
surface O 
waters O 
as O 
well O 
as O 
potential O 
antibiotic O 
recovery O 
through O 
vesicle O 
solubilization O 
. O 

Promotes O 
the O 
Death O 
of O 
Hypoxic O 
Astrocytes O 
by O 
Upregulating O 
Hypoxia-Induced O 
Hypoxia-Inducible O 
Factor-1alpha O 
Expression O 
via O 
Poly(ADP-ribose) B-SYSTEMATIC 
Polymerase-1 O 
. O 

: O 
Pathological O 
release O 
of O 
excess O 
zinc B-SYSTEMATIC 
ions O 
has O 
been O 
implicated O 
in O 
ischemic O 
brain O 
cell O 
death O 
. O 
However O 
, O 
the O 
underlying O 
mechanisms O 
remain O 
to O 
be O 
elucidated O 
. O 
In O 
stroke O 
, O 
ischemia O 
- O 
induced O 
zinc B-SYSTEMATIC 
release O 
and O 
hypoxia O 
- O 
inducible O 
factor-1 O 
( O 
HIF-1 O 
) O 
accumulation O 
concurrently O 
occur O 
in O 
the O 
ischemic O 
tissue O 
. O 
The O 
present O 
study O 
tests O 
the O 
hypothesis O 
that O 
the O 
presence O 
of O 
high O 
intracellular O 
zinc B-SYSTEMATIC 
concentration O 
is O 
a O 
major O 
cause O 
of O 
modifications O 
to O 
PARP-1 O 
and O 
HIF-1α O 
during O 
hypoxia O 
, O 
which O 
significantly O 
contributes O 
to O 
cell O 
death O 
during O 
ischemia O 
. O 
METHODS O 
: O 
Primary O 
cortical O 
astrocytes O 
and O 
C8-D1A O 
cells O 
were O 
exposed O 
to O 
different O 
concentrations O 
of O 
zinc B-SYSTEMATIC 
chloride I-SYSTEMATIC 
. O 
Cell O 
death O 
rate O 
and O 
protein O 
expression O 
of O 
HIF-1 O 
and O 
Poly(ADP-ribose) B-SYSTEMATIC 
polymerase O 
(PARP)-1 O 
were O 
examined O 
after O 
3-h O 
hypoxic O 
treatment O 
. O 
RESULTS O 
: O 
Although O 
3-h O 
hypoxia O 
or O 
100 O 
μM O 
of O 
zinc B-SYSTEMATIC 
alone O 
did O 
not O 
induce O 
noticeable O 
cytotoxicity O 
, O 
their O 
combination O 
led O 
to O 
a O 
dramatic O 
increase O 
in O 
astrocytic O 
cell O 
death O 
in O 
a O 
zinc B-SYSTEMATIC 
-concentration O 
- O 
dependent O 
manner O 
. O 
Exposure O 
of O 
astrocytes O 
to O 
hypoxia O 
for O 
3 O 
h O 
remarkably O 
increased O 
the O 
levels O 
of O 
intracellular O 
zinc B-SYSTEMATIC 
and O 
HIF-1α O 
protein O 
, O 
which O 
was O 
further O 
augmented O 
by O 
added O 
exogenous O 
zinc B-SYSTEMATIC 
. O 
Notably O 
, O 
HIF-1α O 
knockdown O 
blocked O 
zinc B-SYSTEMATIC 
-induced O 
astrocyte O 
death O 
. O 
Moreover O 
, O 
knockdown O 
of O 
PARP-1 O 
, O 
another O 
important O 
protein O 
in O 
the O 
response O 
of O 
hypoxia O 
, O 
attenuated O 
the O 
overexpression O 
of O 
HIF-1α O 
and O 
reduced O 
the O 
cell O 
death O 
rate O 
. O 
CONCLUSIONS O 
: O 
Our O 
studies O 
show O 
that O 
zinc B-SYSTEMATIC 
promotes O 
hypoxic O 
cell O 
death O 
through O 
overexpression O 
of O 
the O 
hypoxia O 
response O 
factor O 
HIF-1α O 
via O 
the O 
cell O 
fate O 
determine O 
factor O 
PARP-1 O 
modification O 
, O 
which O 
provides O 
a O 
novel O 
mechanism O 
for O 
zinc B-SYSTEMATIC 
-mediated O 
ischemic O 
brain O 
injury O 
. O 

RNA O 
- O 
Mediated O 
Activation O 
of O 
Sugar B-FAMILY 
Phosphatase O 
mRNA O 
Regulates O 
Glucose B-TRIVIAL 
Homeostasis O 
. O 

homeostasis O 
is O 
strictly O 
controlled O 
in O 
all O 
domains O 
of O 
life O 
. O 
Bacteria O 
that O 
are O 
unable O 
to O 
balance O 
intracellular O 
sugar B-FAMILY 
levels O 
and O 
deal O 
with O 
potentially O 
toxic O 
phosphosugars B-FAMILY 
cease O 
growth O 
and O 
risk O 
being O 
outcompeted O 
. O 
Here O 
, O 
we O 
identify O 
the O 
conserved O 
haloacid B-FAMILY 
dehalogenase O 
( O 
HAD O 
) O 
- O 
like O 
enzyme O 
YigL O 
as O 
the O 
previously O 
hypothesized O 
phosphatase O 
for O 
detoxification O 
of O 
phosphosugars B-FAMILY 
and O 
reveal O 
that O 
its O 
synthesis O 
is O 
activated O 
by O 
an O 
Hfq O 
- O 
dependent O 
small O 
RNA O 
in O 
Salmonella O 
typhimurium O 
. O 
We O 
show O 
that O 
the O 
glucose B-TRIVIAL 
-6-P-responsive O 
small O 
RNA O 
SgrS O 
activates O 
YigL O 
synthesis O 
in O 
a O 
translation O 
- O 
independent O 
fashion O 
by O 
the O 
selective O 
stabilization O 
of O 
a O 
decay O 
intermediate O 
of O 
the O 
dicistronic O 
pldB-yigL O 
messenger O 
RNA O 
( O 
mRNA O 
) O 
. O 
Intriguingly O 
, O 
the O 
major O 
endoribonuclease O 
RNase O 
E O 
, O 
previously O 
known O 
to O 
function O 
together O 
with O 
small O 
RNAs O 
to O 
degrade O 
mRNA O 
targets O 
, O 
is O 
also O 
essential O 
for O 
this O 
process O 
of O 
mRNA O 
activation O 
. O 
The O 
exploitation O 
of O 
and O 
targeted O 
interference O 
with O 
regular O 
RNA O 
turnover O 
described O 
here O 
may O 
constitute O 
a O 
general O 
route O 
for O 
small O 
RNAs O 
to O 
rapidly O 
activate O 
both O 
coding O 
and O 
noncoding O 
genes O 
. O 

GPR40 O 
( O 
FFA1 O 
) O 
has O 
emerged O 
as O 
an O 
attractive O 
target O 
for O 
a O 
novel O 
insulin O 
secretagogue O 
with O 
glucose B-TRIVIAL 
dependency O 
. O 
A O 
series O 
of O 
novel O 
orally O 
bioavailable O 
GPR40 O 
agonists O 
was O 
discovered O 
. O 
SAR O 
study O 
and O 
structural O 
optimization O 
led O 
to O 
identification O 
of O 
compounds O 
28a O 
and O 
30a O 
as O 
potent O 
GPR40 O 
agonists O 
with O 
superior O 
physiochemical O 
properties O 
and O 
robust O 
in O 
vivo O 
efficacy O 
in O 
rhesus O 
monkeys O 
. O 

distribution O 
is O 
closely O 
linked O 
to O 
metabolic O 
disease O 
risk O 
. O 
Distribution O 
varies O 
with O 
sex O 
, O 
genetic O 
background O 
, O 
disease O 
state O 
, O 
certain O 
drugs O 
and O 
hormones O 
, O 
development O 
, O 
and O 
aging O 
. O 
Preadipocyte O 
replication O 
and O 
differentiation O 
, O 
developmental O 
gene O 
expression O 
, O 
susceptibility O 
to O 
apoptosis O 
and O 
cellular O 
senescence O 
, O 
vascularity O 
, O 
inflammatory O 
cell O 
infiltration O 
, O 
and O 
adipokine O 
secretion O 
vary O 
among O 
depots O 
, O 
as O 
do O 
fatty B-FAMILY 
- I-FAMILY 
acid I-FAMILY 
handling O 
and O 
mechanisms O 
of O 
enlargement O 
with O 
positive O 
- O 
energy O 
and O 
loss O 
with O 
negative O 
- O 
energy O 
balance O 
. O 
How O 
interdepot O 
differences O 
in O 
these O 
molecular O 
, O 
cellular O 
, O 
and O 
pathophysiological O 
properties O 
are O 
related O 
is O 
incompletely O 
understood O 
. O 
Whether O 
fat O 
redistribution O 
causes O 
metabolic O 
disease O 
or O 
whether O 
it O 
is O 
a O 
marker O 
of O 
underlying O 
processes O 
that O 
are O 
primarily O 
responsible O 
is O 
an O 
open O 
question O 
. O 

of O 
heat O 
shock O 
protein O 
70 O 
( O 
Hsp70 O 
) O 
commonly O 
promote O 
cancer O 
cell O 
viability O 
whereas O 
inhibitors O 
of O 
Hsp90 O 
reduce O 
it O 
. O 
The O 
anticancer O 
agent O 
celastrol B-TRIVIAL 
, O 
interferes O 
with O 
signal O 
transduction O 
pathways O 
involving O 
these O 
heat O 
shock O 
proteins O 
. O 
The O 
objective O 
of O 
this O 
in O 
vitro O 
study O 
was O 
to O 
silence O 
inducible O 
Hsp70 O 
and O 
to O 
promote O 
celastrol B-TRIVIAL 
-induced O 
tumor O 
cell O 
death O 
. O 
Hsp70 O 
siRNA O 
loaded O 
chitosan- O 
TPP B-ABBREVIATION 
carriers O 
were O 
prepared O 
by O 
ionic O 
gelation O 
and O 
characterized O 
by O 
photon O 
correlation O 
spectroscopy O 
and O 
asymmetric O 
flow O 
field O 
- O 
flow O 
fractionation O 
combined O 
with O 
dynamic O 
light O 
scattering O 
. O 
Viability O 
of O 
human O 
leukemia O 
and O 
glioblastoma O 
cells O 
and O 
Hsp70 O 
silencing O 
was O 
determined O 
following O 
treatment O 
with O 
chitosan- O 
TPP B-ABBREVIATION 
-Hsp70 O 
siRNA O 
particles O 
. O 
The O 
results O 
showed O 
that O 
silencing O 
of O 
Hsp70 O 
by O 
chitosan- O 
TPP B-ABBREVIATION 
-Hsp70 O 
siRNA O 
treatment O 
significantly O 
reduced O 
cell O 
viability O 
, O 
and O 
enhanced O 
antiproliferative O 
effects O 
of O 
celastrol B-TRIVIAL 
in O 
leukemia O 
and O 
glioblastoma O 
cells O 
. O 
In O 
glioblastoma O 
spheroids O 
, O 
higher O 
concentrations O 
of O 
celastrol B-TRIVIAL 
and O 
Hsp70 O 
siRNA O 
in O 
chitosan- O 
TPP B-ABBREVIATION 
nanocarriers O 
were O 
necessary O 
to O 
induce O 
cell O 
death O 
. O 

new O 
steroidal B-FAMILY 
saponins I-FAMILY 
from O 
Selaginella O 
uncinata O 
( O 
Desv O 
. O 
) O 
Spring O 
and O 
their O 
protective O 
effect O 
against O 
anoxia O 
. O 

steroidal B-FAMILY 
saponins I-FAMILY 
were O 
isolated O 
from O 
the O 
anti-anoxic O 
fraction O 
of O 
the O 
60% O 
EtOH B-FORMULA 
extract O 
of O 
Selaginella O 
uncinata O 
, O 
including O 
two O 
new O 
compounds O 
, O 
( B-SYSTEMATIC 
3β I-SYSTEMATIC 
, I-SYSTEMATIC 
7β I-SYSTEMATIC 
, I-SYSTEMATIC 
12β I-SYSTEMATIC 
, I-SYSTEMATIC 
25R)-spirost-5-ene-3 I-SYSTEMATIC 
, I-SYSTEMATIC 
7 I-SYSTEMATIC 
, I-SYSTEMATIC 
12-triol-3-O-α-L-rhamnopyranosyl-(1→2)-O-[α-L-rhamnopyranosyl-(1→4)]-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
( B-SYSTEMATIC 
2α I-SYSTEMATIC 
, I-SYSTEMATIC 
3β I-SYSTEMATIC 
, I-SYSTEMATIC 
12β I-SYSTEMATIC 
, I-SYSTEMATIC 
25R)-spirost-5-ene-2 I-SYSTEMATIC 
, I-SYSTEMATIC 
3 I-SYSTEMATIC 
, I-SYSTEMATIC 
12-triol-3-O-α-L-rhamnopyranosyl-(1→2)-O-[α-L-rhamnopyranosyl-(1→4)]-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
two O 
known O 
compounds O 
, O 
( B-SYSTEMATIC 
3β I-SYSTEMATIC 
, I-SYSTEMATIC 
12β I-SYSTEMATIC 
, I-SYSTEMATIC 
25R)-spirost-5-ene-3,12-diol-3-O-α-L-rhamnopyranosyl-(1→2)-O-[α-L-rhamnopyranosyl-(1→4)]-O-β-d-glucopyranoside I-SYSTEMATIC 
, O 
( O 
3 O 
) O 
, O 
( B-SYSTEMATIC 
1α I-SYSTEMATIC 
, I-SYSTEMATIC 
3β I-SYSTEMATIC 
, I-SYSTEMATIC 
25R)-spirost-5-ene-2-diol-3-O-α-L-rhamnopyranosyl-(1→2)-O-[α-L-rhamnopyranosyl(1→4)]-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
4 O 
) O 
. O 
The O 
four O 
compounds O 
showed O 
potent O 
protective O 
effect O 
against O 
anoxia O 
in O 
the O 
anoxic O 
PC12 O 
cells O 
assay O 
, O 
among O 
which O 
compounds O 
1 O 
and O 
2 O 
were O 
the O 
most O 
active O 
. O 
To O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
study O 
to O 
report O 
the O 
steroidal B-FAMILY 
saponins I-FAMILY 
in O 
the O 
plant O 
S O 
. O 
uncinata O 
and O 
demonstrate O 
their O 
protective O 
effect O 
against O 
anoxia O 
in O 
PC12 O 
cell O 
assay O 
. O 

methcathinones B-FAMILY 
differ O 
in O 
transporter O 
and O 
receptor O 
interactions O 
. O 

use O 
of O 
synthetic O 
methcathinones B-FAMILY 
, O 
components O 
of O 
" O 
bath O 
salts O 
, O 
" O 
is O 
a O 
world O 
- O 
wide O 
health O 
concern O 
. O 
These O 
compounds O 
, O 
structurally O 
similar O 
to O 
methamphetamine B-TRIVIAL 
( O 
METH B-ABBREVIATION 
) O 
and O 
3,4-methylendioxymethamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
) O 
, O 
cause O 
tachycardia O 
, O 
hallucinations O 
and O 
psychosis O 
. O 
We O 
hypothesized O 
that O 
these O 
potentially O 
neurotoxic O 
and O 
abused O 
compounds O 
display O 
differences O 
in O 
their O 
transporter O 
and O 
receptor O 
interactions O 
as O 
compared O 
to O 
amphetamine B-TRIVIAL 
counterparts O 
. O 
3,4-Methylenedioxypyrovalerone B-SYSTEMATIC 
and O 
naphyrone B-TRIVIAL 
had O 
high O 
affinity O 
for O 
radioligand O 
binding O 
sites O 
on O 
recombinant O 
human O 
dopamine B-TRIVIAL 
( O 
hDAT O 
) O 
, O 
serotonin B-TRIVIAL 
( O 
hSERT O 
) O 
and O 
norepinephrine B-TRIVIAL 
( O 
hNET O 
) O 
transporters O 
, O 
potently O 
inhibited O 
[ B-FORMULA 
(3)H I-FORMULA 
] I-FORMULA 
neurotransmitter O 
uptake O 
, O 
and O 
, O 
like O 
cocaine B-TRIVIAL 
, O 
did O 
not O 
induce O 
transporter O 
- O 
mediated O 
release O 
. O 
Butylone B-TRIVIAL 
was O 
a O 
lower O 
affinity O 
uptake O 
inhibitor O 
. O 
In O 
contrast O 
, O 
4-fluoromethcathinone B-SYSTEMATIC 
, O 
mephedrone B-TRIVIAL 
and O 
methylone B-TRIVIAL 
had O 
higher O 
inhibitory O 
potency O 
at O 
uptake O 
compared O 
to O 
binding O 
and O 
generally O 
induced O 
release O 
of O 
preloaded O 
[ B-FORMULA 
(3)H I-FORMULA 
] I-FORMULA 
neurotransmitter O 
from O 
hDAT O 
, O 
hSERT O 
and O 
hNET O 
( O 
highest O 
potency O 
at O 
hNET O 
) O 
, O 
and O 
thus O 
are O 
transporter O 
substrates O 
, O 
similar O 
to O 
METH B-ABBREVIATION 
and O 
MDMA B-ABBREVIATION 
. O 
At O 
hNET O 
, O 
4-fluoromethcathinone B-SYSTEMATIC 
was O 
a O 
more O 
efficacious O 
releaser O 
than O 
METH B-ABBREVIATION 
. O 
These O 
substituted O 
methcathinones B-FAMILY 
had O 
low O 
uptake O 
inhibitory O 
potency O 
and O 
low O 
efficacy O 
at O 
inducing O 
release O 
via O 
human O 
vesicular O 
monoamine B-FAMILY 
transporters O 
( O 
hVMAT2 O 
) O 
. O 
These O 
compounds O 
were O 
low O 
potency O 
( O 
1 O 
) O 
h5-HT1A O 
receptor O 
partial O 
agonists O 
, O 
( O 
2 O 
) O 
h5-HT2A O 
receptor O 
antagonists O 
, O 
( O 
3 O 
) O 
weak O 
h5-HT2C O 
receptor O 
antagonists O 
. O 
This O 
is O 
the O 
first O 
report O 
on O 
aspects O 
of O 
substituted O 
methcathinone B-TRIVIAL 
efficacies O 
at O 
serotonin B-TRIVIAL 
( O 
5-HT B-SYSTEMATIC 
) O 
receptors O 
and O 
in O 
superfusion O 
release O 
assays O 
. O 
Additionally O 
, O 
the O 
drugs O 
had O 
no O 
affinity O 
for O 
dopamine B-TRIVIAL 
receptors O 
, O 
and O 
high O 
- O 
nanomolar O 
to O 
mid O 
- O 
micromolar O 
affinity O 
for O 
hSigma1 O 
receptors O 
. O 
Thus O 
, O 
direct O 
interactions O 
with O 
hVMAT2 O 
and O 
serotonin B-TRIVIAL 
, O 
dopamine B-TRIVIAL 
, O 
and O 
hSigma1 O 
receptors O 
may O 
not O 
explain O 
psychoactive O 
effects O 
. O 
The O 
primary O 
mechanisms O 
of O 
action O 
may O 
be O 
as O 
inhibitors O 
or O 
substrates O 
of O 
DAT O 
, O 
SERT O 
and O 
NET O 
. O 

of O 
a O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
series O 
of O 
HIV O 
capsid O 
assembly O 
inhibitors O 
1 O 
: O 
Addressing O 
configurational O 
instability O 
through O 
scaffold O 
modification O 
. O 

optimization O 
of O 
a O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
series O 
of O 
inhibitors O 
of O 
HIV-1 O 
capsid O 
assembly O 
that O 
possess O 
a O 
labile O 
stereocenter O 
at O 
C3 O 
is O 
described O 
. O 
Quaternization O 
of O 
the O 
C3 O 
position O 
of O 
compound O 
1 O 
in O 
order O 
to O 
prevent O 
racemization O 
gave O 
compound O 
2 O 
, O 
which O 
was O 
inactive O 
in O 
our O 
capsid O 
disassembly O 
assay O 
. O 
A O 
likely O 
explanation O 
for O 
this O 
finding O 
was O 
revealed O 
by O 
in O 
silico O 
analysis O 
predicting O 
a O 
dramatic O 
increase O 
in O 
energy O 
of O 
the O 
bioactive O 
conformation O 
upon O 
quaternization O 
of O 
the O 
C3 O 
position O 
. O 
Replacement O 
of O 
the O 
C3 O 
of O 
the O 
diazepine B-TRIVIAL 
ring O 
with O 
a O 
nitrogen O 
atom O 
to O 
give O 
the O 
1,5-dihydro-benzo[f][1,3,5]triazepine-2,4-dione B-SYSTEMATIC 
analog O 
4 O 
was O 
well O 
tolerated O 
. O 
Introduction O 
of O 
a O 
rigid O 
spirocyclic O 
system O 
at O 
the O 
C3 O 
position O 
gave O 
configurationally O 
stable O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
analog O 
5 O 
, O 
which O 
was O 
able O 
to O 
access O 
the O 
bioactive O 
conformation O 
without O 
a O 
severe O 
energetic O 
penalty O 
and O 
inhibit O 
capsid O 
assembly O 
. O 
Preliminary O 
structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
and O 
X-ray O 
crystallographic O 
data O 
show O 
that O 
knowledge O 
from O 
the O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
series O 
of O 
inhibitors O 
of O 
HIV-1 O 
capsid O 
assembly O 
can O 
be O 
transferred O 
to O 
these O 
new O 
scaffolds O 
. O 

air O 
particulate O 
matter O 
( O 
PM O 
) O 
as O 
well O 
as O 
microbial O 
contaminants O 
in O 
the O 
indoor O 
air O 
are O 
known O 
to O 
cause O 
severe O 
adverse O 
health O 
effects O 
. O 
It O 
has O 
been O 
shown O 
that O 
there O 
is O 
a O 
clear O 
seasonal O 
variation O 
in O 
the O 
potency O 
of O 
outdoor O 
air O 
particles O 
to O 
evoke O 
inflammation O 
and O 
cytotoxicity O 
. O 
However O 
, O 
the O 
role O 
of O 
outdoor O 
sources O 
in O 
the O 
indoor O 
air O 
quality O 
, O 
especially O 
on O 
its O 
toxicological O 
properties O 
, O 
remains O 
largely O 
unknown O 
. O 
In O 
this O 
study O 
, O 
we O 
collected O 
size O 
segregated O 
( O 
PM10-2.5 O 
, O 
PM2.5-0.2 O 
and O 
PM0.2 O 
) O 
particulate O 
samples O 
with O 
a O 
high O 
volume O 
cascade O 
impactor O 
( O 
HVCI O 
) O 
on O 
polyurethane B-SYSTEMATIC 
foam O 
and O 
fluoropore O 
membrane O 
filters O 
. O 
The O 
samples O 
were O 
collected O 
during O 
four O 
different O 
seasons O 
simultaneously O 
from O 
indoor O 
and O 
outdoor O 
air O 
. O 
Thereafter O 
, O 
the O 
samples O 
were O 
weighed O 
and O 
extracted O 
with O 
methanol B-SYSTEMATIC 
from O 
the O 
filters O 
before O 
undergoing O 
toxicological O 
analyses O 
. O 
Mouse O 
macrophages O 
( O 
RAW264.7 O 
) O 
were O 
exposed O 
to O 
particulate O 
sample O 
doses O 
of O 
50 O 
, O 
150 O 
and O 
300μg O 
/ O 
ml O 
for O 
24h O 
. O 
Thereafter O 
, O 
the O 
levels O 
of O 
the O 
proinflammatory O 
cytokine O 
( O 
TNF-α O 
) O 
, O 
NO B-FORMULA 
-production O 
, O 
cytotoxicity O 
( O 
MTT B-ABBREVIATION 
-test O 
) O 
and O 
changes O 
in O 
the O 
cell O 
cycle O 
( O 
SubG1 O 
, O 
G1 O 
, O 
S O 
and O 
G2 O 
/ O 
M O 
phases O 
) O 
were O 
investigated O 
. O 
PM10-2.5 O 
particles O 
evoked O 
the O 
highest O 
inflammatory O 
and O 
cytotoxic O 
responses O 
. O 
Instead O 
, O 
PM2.5-0.2 O 
samples O 
exerted O 
the O 
greatest O 
effect O 
on O 
apoptotic O 
activity O 
in O 
the O 
macrophages O 
. O 
With O 
respect O 
to O 
the O 
outdoor O 
air O 
samples O 
, O 
particles O 
collected O 
during O 
warm O 
seasons O 
had O 
a O 
stronger O 
potency O 
to O 
induce O 
inflammatory O 
and O 
cytotoxic O 
responses O 
, O 
whereas O 
no O 
such O 
clear O 
effect O 
was O 
seen O 
with O 
the O 
corresponding O 
indoor O 
air O 
samples O 
. O 
Outdoor O 
air O 
samples O 
were O 
associated O 
with O 
higher O 
inflammatory O 
potential O 
, O 
whereas O 
indoor O 
air O 
samples O 
had O 
overall O 
higher O 
cytotoxic O 
properties O 
. O 
This O 
indicates O 
that O 
the O 
outdoor O 
air O 
has O 
a O 
limited O 
influence O 
on O 
the O 
indoor O 
air O 
quality O 
in O 
a O 
modern O 
house O 
. O 
Thus O 
, O 
the O 
indoor O 
sources O 
dominate O 
the O 
toxicological O 
responses O 
obtained O 
from O 
samples O 
collected O 
inside O 
house O 
. O 

NMR O 
- O 
based O 
metabonomics O 
study O 
on O 
the O 
toxicity O 
alleviation O 
effect O 
of O 
other O 
traditional O 
Chinese O 
medicines O 
in O 
Niuhuang O 
Jiedu O 
tablet O 
to O 
realgar O 
( O 
As2S2 O 
) O 
. O 

RELEVANCE O 
: O 
Niuhuang O 
Jiedu O 
Tablet O 
( O 
NJT O 
) O 
is O 
an O 
effective O 
prescription O 
of O 
traditional O 
Chinese O 
medicine O 
( O 
TCM O 
) O 
used O 
in O 
treating O 
acute O 
tonsillitis O 
, O 
pharyngitis O 
, O 
periodontitis O 
and O 
mouth O 
ulcer O 
. O 
NJT O 
is O 
prepared O 
from O 
Xionghuang O 
( O 
Realgar O 
, O 
As2S2 O 
) O 
, O 
Rengong O 
Niuhuang O 
( O 
Bovis O 
Calculus O 
Artificialis O 
) O 
, O 
Bingpian O 
( O 
Borneolum O 
Synthcticum O 
) O 
, O 
Shigao O 
( O 
Gypsum O 
Fibrosum O 
) O 
, O 
Dahuang O 
( O 
Rhei O 
Radix O 
et O 
Rhizoma O 
) O 
, O 
Huangqin O 
( O 
Scutellariae O 
Radix O 
) O 
, O 
Jiegeng O 
( O 
Platycodonis O 
Radix O 
) O 
and O 
Gancao O 
( O 
Glycyrrhizae O 
Radix O 
et O 
Rhizoma O 
) O 
. O 
In O 
the O 
prescription O 
, O 
significant O 
level O 
of O 
realgar B-TRIVIAL 
( O 
As2S2 B-FORMULA 
) O 
as O 
a O 
potentially O 
toxic O 
element O 
is O 
contained O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
In O 
this O 
study O 
, O 
(1)H B-FORMULA 
NMR O 
- O 
based O 
metabonomics O 
approach O 
has O 
been O 
used O 
to O 
investigate O 
the O 
toxicity O 
of O 
realgar B-TRIVIAL 
( O 
As2S2 B-FORMULA 
) O 
after O 
being O 
counterbalanced O 
by O 
other O 
TCMs O 
in O 
NJT O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Male O 
Wistar O 
rats O 
were O 
divided O 
into O 
five O 
groups O 
: O 
control O 
, O 
group O 
I O 
( O 
treated O 
with O 
Realgar B-TRIVIAL 
) O 
, O 
group O 
II O 
( O 
treated O 
with O 
Realgar B-TRIVIAL 
, O 
Bovis O 
Calculus O 
Artificialis O 
, O 
Borneolum O 
Synthcticum O 
, O 
Gypsum O 
Fibrosum O 
, O 
Rhei O 
Radix O 
et O 
Rhizoma O 
, O 
Scutellariae O 
Radix O 
, O 
Platycodonis O 
Radix O 
and O 
Glycyrrhizae O 
Radix O 
et O 
Rhizoma O 
) O 
, O 
group O 
III O 
( O 
treated O 
with O 
Realgar B-TRIVIAL 
, O 
Bovis O 
Calculus O 
Artificialis O 
, O 
Borneolum O 
Synthcticum O 
and O 
Gypsum O 
Fibrosum O 
) O 
and O 
group O 
IV O 
( O 
treated O 
with O 
Realgar B-TRIVIAL 
, O 
Rhei O 
Radix O 
et O 
Rhizoma O 
, O 
Scutellariae O 
Radix O 
, O 
Platycodonis O 
Radix O 
and O 
Glycyrrhizae O 
Radix O 
et O 
Rhizoma O 
) O 
. O 
Based O 
on O 
(1)H B-FORMULA 
-NMR O 
spectra O 
of O 
urine O 
and O 
serum O 
from O 
rats O 
, O 
PCA O 
and O 
PLS-DA O 
were O 
performed O 
to O 
identify O 
different O 
metabolic O 
profiles O 
. O 
Liver O 
and O 
kidney O 
histopathology O 
examinations O 
and O 
serum O 
clinical O 
chemistry O 
analysis O 
were O 
also O 
performed O 
. O 
RESULTS O 
: O 
PLS-DA O 
scores O 
plots O 
demonstrated O 
that O 
the O 
cluster O 
of O 
group O 
I O 
was O 
separated O 
from O 
that O 
of O 
control O 
rats O 
, O 
while O 
group O 
II O 
was O 
located O 
close O 
to O 
control O 
rats O 
, O 
indicating O 
that O 
metabolic O 
profiles O 
of O 
group O 
II O 
were O 
restored O 
toward O 
those O 
of O 
control O 
rats O 
. O 
The O 
metabolic O 
profiles O 
of O 
group O 
III O 
were O 
similar O 
to O 
those O 
of O 
group O 
I O 
, O 
while O 
the O 
metabolic O 
profiles O 
of O 
group O 
II O 
were O 
almost O 
in O 
line O 
with O 
those O 
of O 
group O 
II O 
. O 
Statistics O 
results O 
were O 
confirmed O 
by O 
the O 
histopathological O 
examination O 
and O 
biochemical O 
assay O 
. O 
CONCLUSION O 
: O 
Our O 
results O 
indicated O 
that O 
it O 
was O 
more O 
secure O 
and O 
much O 
less O 
toxic O 
for O 
counterbalanced O 
realgar B-TRIVIAL 
( O 
As2S2 B-FORMULA 
) O 
in O 
NJT O 
. O 
The O 
effective O 
material O 
bases O 
of O 
toxicity O 
alleviation O 
to O 
realgar B-TRIVIAL 
( O 
As2S2 B-FORMULA 
) O 
were O 
Dahuang O 
( O 
Rhei O 
Radix O 
et O 
Rhizoma O 
) O 
, O 
Huangqin O 
( O 
Scutellariae O 
Radix O 
) O 
, O 
Jiegeng O 
( O 
Platycodonis O 
Radix O 
) O 
and O 
Gancao O 
( O 
Glycyrrhizae O 
Radix O 
et O 
Rhizoma O 
) O 
, O 
which O 
regulated O 
energy O 
metabolism O 
, O 
choline B-FAMILY 
metabolism O 
, O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
and O 
gut O 
flora O 
disorder O 
affected O 
by O 
realgar B-TRIVIAL 
( O 
As2S2 B-FORMULA 
) O 
exposure O 
. O 

oral O 
exposure O 
to O 
environmental O 
immunosuppressive O 
chemicals O 
methoxychlor B-TRIVIAL 
, O 
parathion B-TRIVIAL 
, O 
or O 
piperonyl B-SYSTEMATIC 
butoxide I-SYSTEMATIC 
aggravates O 
allergic O 
airway O 
inflammation O 
in O 
NC O 
/ O 
Nga O 
mice O 
. O 

: O 
Immunosuppressive O 
environmental O 
chemicals O 
may O 
increase O 
the O 
potency O 
of O 
allergens O 
and O 
thereby O 
play O 
a O 
role O 
in O 
the O 
development O 
of O 
respiratory O 
tract O 
allergies O 
, O 
such O 
as O 
allergic O 
rhinitis O 
and O 
asthma O 
. O 
OBJECTIVES O 
: O 
We O 
investigated O 
the O 
association O 
between O 
environmental O 
immunosuppressive O 
chemicals O 
and O 
the O 
allergic O 
airway O 
inflammation O 
development O 
. O 
METHODS O 
: O 
We O 
used O 
a O 
mouse O 
model O 
of O 
ovalbumin O 
(OVA)-induced O 
allergic O 
airway O 
inflammation O 
. O 
NC O 
/ O 
Nga O 
mice O 
were O 
exposed O 
orally O 
to O 
pesticides O 
parathion B-TRIVIAL 
( O 
an O 
organophosphate B-FAMILY 
compound O 
) O 
or O 
methoxychlor B-TRIVIAL 
( O 
an O 
organochlorine B-FAMILY 
compound O 
) O 
, O 
or O 
to O 
an O 
insecticide O 
synergist O 
piperonyl B-SYSTEMATIC 
butoxide I-SYSTEMATIC 
, O 
prior O 
to O 
OVA O 
intraperitoneal O 
sensitization O 
and O 
inhalation O 
challenge O 
. O 
We O 
assessed O 
serum O 
IgE O 
levels O 
, O 
B-cell O 
counts O 
, O 
cytokine O 
production O 
, O 
IgE O 
production O 
in O 
hilar O 
lymph O 
nodes O 
, O 
eosinophil O 
counts O 
, O 
chemokine O 
levels O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
, O 
and O 
cytokine O 
gene O 
expression O 
in O 
the O 
lung O 
. O 
RESULTS O 
: O 
Exposure O 
to O 
environmental O 
immunosuppressive O 
chemicals O 
markedly O 
increased O 
serum O 
IgE O 
- O 
IgE-positive O 
B-cells O 
, O 
IgE O 
and O 
cytokines O 
in O 
lymph O 
nodes O 
- O 
eosinophils O 
and O 
chemokines O 
in O 
BALF O 
- O 
IL-10a O 
and O 
IL-17 O 
in O 
the O 
lung O 
. O 
CONCLUSIONS O 
: O 
Allergic O 
airway O 
inflammation O 
can O 
be O 
aggravated O 
by O 
prior O 
exposure O 
to O 
immunosuppressive O 
environmental O 
chemicals O 
. O 

derived O 
from O 
Grundmann's B-TRIVIAL 
ketone I-TRIVIAL 
as O 
a O 
novel O 
chemotype O 
of O 
oxidosqualene O 
cyclase O 
inhibitors O 
. O 

series O 
of O 
aminopropylindenes B-FAMILY 
, O 
designed O 
as O 
mimics O 
of O 
a O 
cationic O 
high O 
energy O 
intermediate O 
in O 
the O 
oxidosqualene B-FAMILY 
cyclase(1) O 
( O 
OSC O 
) O 
- O 
mediated O 
cyclization O 
of O 
2,3-oxidosqualen B-TRIVIAL 
to O 
lanosterol B-TRIVIAL 
was O 
prepared O 
from O 
Grundmann's B-TRIVIAL 
ketone I-TRIVIAL 
. O 
Screening O 
on O 
OSCs O 
from O 
five O 
different O 
organisms O 
revealed O 
interesting O 
activities O 
and O 
selectivities O 
of O 
some O 
of O 
the O 
compounds O 
. O 
A O 
N,N-dimethylaminopropyl B-SYSTEMATIC 
derivative O 
showed O 
promising O 
inhibition O 
of O 
Trypanosoma O 
cruzi O 
OSC O 
in O 
combination O 
with O 
low O 
cytotoxicity O 
, O 
and O 
showed O 
significant O 
reduction O 
of O 
cholesterol B-TRIVIAL 
biosynthesis O 
in O 
a O 
human O 
cell O 
line O 
. O 

effect O 
of O 
histamine B-TRIVIAL 
H4 O 
receptor O 
modulation O 
in O 
the O 
central O 
nervous O 
system O 
. O 

histamine B-TRIVIAL 
H4 O 
receptor O 
( O 
H4R O 
) O 
is O 
expressed O 
primarily O 
on O 
cells O 
involved O 
in O 
inflammation O 
and O 
immune O 
responses O 
. O 
Recently O 
, O 
it O 
has O 
been O 
reported O 
the O 
functional O 
expression O 
of O 
H4R O 
within O 
neurons O 
of O 
the O 
central O 
nervous O 
system O 
, O 
but O 
their O 
role O 
has O 
been O 
poorly O 
understood O 
. O 
The O 
present O 
study O 
aimed O 
to O 
elucidate O 
the O 
physiopathological O 
role O 
of O 
cerebral O 
H4R O 
in O 
animal O 
models O 
by O 
the O 
intracerebroventricular O 
administration O 
of O 
the O 
H4R O 
agonist O 
VUF B-IDENTIFIER 
8430 I-IDENTIFIER 
( O 
20-40 O 
μg O 
per O 
mouse O 
) O 
. O 
Selectivity O 
of O 
results O 
was O 
confirmed O 
by O 
the O 
prevention O 
of O 
the O 
effects O 
produced O 
by O 
the O 
H4R O 
antagonist O 
JNJ B-IDENTIFIER 
10191584 I-IDENTIFIER 
( O 
3-9 O 
mg O 
/ O 
kg O 
p.o O 
. O 
) O 
. O 
Neuronal O 
H4R O 
activation O 
induced O 
acute O 
thermal O 
antinociception O 
, O 
indicating O 
that O 
neuronal O 
histamine B-TRIVIAL 
H4R O 
might O 
be O 
involved O 
in O 
the O 
production O 
of O 
antinociception O 
in O 
the O 
absence O 
of O 
an O 
inflammatory O 
process O 
. O 
An O 
anxiolytic O 
- O 
like O 
effect O 
of O 
intensity O 
comparable O 
to O 
that O 
exerted O 
by O 
diazepam B-TRIVIAL 
, O 
used O 
as O 
reference O 
drug O 
, O 
was O 
produced O 
in O 
the O 
light O 
- O 
dark O 
box O 
test O 
. O 
VUF B-IDENTIFIER 
8430 I-IDENTIFIER 
reversed O 
the O 
scopolamine B-TRIVIAL 
-induced O 
amnesia O 
in O 
the O 
passive O 
avoidance O 
test O 
and O 
showed O 
anorexant O 
activity O 
in O 
food O 
deprived O 
mice O 
. O 
Conversely O 
, O 
the O 
H4R O 
activation O 
did O 
not O 
modify O 
the O 
immobility O 
time O 
in O 
the O 
tail O 
suspension O 
test O 
. O 
Rotarod O 
performance O 
test O 
was O 
employed O 
to O 
demonstrate O 
that O 
the O 
effects O 
observed O 
following O 
the O 
administration O 
of O 
VUF B-IDENTIFIER 
8430 I-IDENTIFIER 
and O 
JNJ B-IDENTIFIER 
10191584 I-IDENTIFIER 
were O 
not O 
due O 
to O 
impaired O 
motor O 
function O 
of O 
animals O 
. O 
Furthermore O 
, O 
both O 
compounds O 
did O 
not O 
alter O 
spontaneous O 
mobility O 
and O 
exploratory O 
activity O 
in O 
the O 
hole O 
board O 
test O 
. O 
These O 
results O 
show O 
the O 
antinociceptive O 
, O 
antiamnesic O 
, O 
anxiolytic O 
and O 
anorexant O 
effects O 
induced O 
by O 
neuronal O 
H4R O 
agonism O 
, O 
suggesting O 
that O 
H4 O 
modulators O 
may O 
have O 
broader O 
utility O 
further O 
the O 
control O 
of O 
inflammatory O 
and O 
immune O 
processes O 
. O 

flexibility O 
refers O 
to O 
the O 
ability O 
to O 
rapidly O 
adapt O 
to O 
novel O 
situations O 
and O 
it O 
has O 
been O 
suggested O 
that O 
the O 
frontal O 
lobe O 
and O 
basal O 
ganglia O 
are O 
implicated O 
in O 
various O 
components O 
of O 
adjusting O 
to O 
changes O 
in O 
environmental O 
contingencies O 
. O 
Behavioural O 
flexibility O 
can O 
be O 
assessed O 
using O 
attentional O 
set O 
- O 
shifting O 
tasks O 
, O 
in O 
which O 
performance O 
is O 
impaired O 
after O 
damage O 
to O 
the O 
prefrontal O 
cortex O 
. O 
The O 
present O 
study O 
explores O 
the O 
downstream O 
contribution O 
of O 
the O 
prefrontal O 
projection O 
zone O 
in O 
the O 
dorsomedial O 
striatum O 
( O 
DMS O 
) O 
to O 
attentional O 
set O 
shifting O 
. O 
Rats O 
were O 
tested O 
in O 
two O 
set O 
- O 
shifting O 
tasks O 
following O 
quinolinic B-TRIVIAL 
acid I-TRIVIAL 
injections O 
bilaterally O 
into O 
the O 
DMS O 
. O 
When O 
tested O 
in O 
a O 
rodent O 
version O 
of O 
the O 
set O 
- O 
shifting O 
task O 
, O 
rats O 
with O 
a O 
DMS O 
lesion O 
displayed O 
a O 
greater O 
number O 
of O 
errors O 
during O 
the O 
reversal O 
stages O 
of O 
the O 
task O 
than O 
sham O 
lesion O 
controls O 
but O 
the O 
nature O 
of O 
the O 
errors O 
did O 
not O 
differ O 
between O 
the O 
two O 
groups O 
. O 
Interestingly O 
, O 
when O 
the O 
rats O 
were O 
tested O 
in O 
a O 
modified O 
version O 
of O 
the O 
set O 
- O 
shifting O 
task O 
, O 
directly O 
designed O 
for O 
measuring O 
the O 
formation O 
of O 
an O 
attentional O 
set O 
, O 
sham O 
lesion O 
controls O 
displayed O 
a O 
pronounced O 
shift O 
- O 
cost O 
, O 
evident O 
of O 
successful O 
set O 
- O 
formation O 
. O 
In O 
contrast O 
, O 
rats O 
with O 
DMS O 
lesions O 
failed O 
to O 
form O 
an O 
attentional O 
set O 
, O 
showing O 
no O 
performance O 
cost O 
when O 
a O 
shift O 
of O 
attention O 
was O 
required O 
. O 
These O 
results O 
support O 
previous O 
reports O 
of O 
the O 
importance O 
of O 
the O 
DMS O 
in O 
behavioural O 
flexibility O 
but O 
also O 
suggest O 
that O 
this O 
region O 
is O 
vital O 
for O 
the O 
formation O 
of O 
set O 
, O 
possibly O 
by O 
extrapolating O 
different O 
perceptions O 
into O 
a O 
unified O 
representation O 
of O 
a O 
dimension O 
. O 

cancer O 
is O 
a O 
clinically O 
diverse O 
disease O 
. O 
This O 
heterogeneity O 
makes O 
it O 
difficult O 
to O 
determine O 
which O 
patients O 
will O 
benefit O 
most O 
from O 
adjuvant O 
therapy O 
and O 
impedes O 
the O 
development O 
of O 
new O 
targeted O 
agents O 
. O 
More O 
insight O 
into O 
the O 
biological O 
diversity O 
of O 
colon O 
cancers O 
, O 
especially O 
in O 
relation O 
to O 
clinical O 
features O 
, O 
is O 
therefore O 
needed O 
. O 
We O 
demonstrate O 
, O 
using O 
an O 
unsupervised O 
classification O 
strategy O 
involving O 
over O 
1100 O 
individuals O 
with O 
colon O 
cancer O 
, O 
that O 
three O 
main O 
molecularly O 
distinct O 
subtypes O 
can O 
be O 
recognized O 
. O 
Two O 
subtypes O 
have O 
been O 
previously O 
identified O 
and O 
are O 
well O 
characterized O 
( O 
chromosomal O 
- O 
instable O 
and O 
microsatellite O 
- O 
instable O 
cancers O 
) O 
. O 
The O 
third O 
subtype O 
is O 
largely O 
microsatellite O 
stable O 
and O 
contains O 
relatively O 
more O 
CpG B-ABBREVIATION 
island O 
methylator O 
phenotype O 
- O 
positive O 
carcinomas O 
but O 
cannot O 
be O 
identified O 
on O 
the O 
basis O 
of O 
characteristic O 
mutations O 
. O 
We O 
provide O 
evidence O 
that O 
this O 
subtype O 
relates O 
to O 
sessile O 
- O 
serrated O 
adenomas O 
, O 
which O 
show O 
highly O 
similar O 
gene O 
expression O 
profiles O 
, O 
including O 
upregulation O 
of O 
genes O 
involved O 
in O 
matrix O 
remodeling O 
and O 
epithelial O 
- O 
mesenchymal O 
transition O 
. O 
The O 
identification O 
of O 
this O 
subtype O 
is O 
crucial O 
, O 
as O 
it O 
has O 
a O 
very O 
unfavorable O 
prognosis O 
and O 
, O 
moreover O 
, O 
is O 
refractory O 
to O 
epidermal O 
growth O 
factor O 
receptor O 
- O 
targeted O 
therapy O 
. O 

and O 
mechanism O 
of O 
oxygen B-SYSTEMATIC 
reduction O 
in O 
a O 
protic O 
ionic O 
liquid O 
. O 

oxygen B-SYSTEMATIC 
reduction O 
reaction O 
( O 
ORR O 
) O 
has O 
been O 
studied O 
at O 
Pt O 
surfaces O 
in O 
the O 
protic O 
ionic O 
liquid O 
diethylmethylammonium B-SYSTEMATIC 
trifluoromethanesulfonate I-SYSTEMATIC 
. O 
Water O 
content O 
measurements O 
suggested O 
that O 
the O 
ORR O 
proceeded O 
in O 
the O 
ionic O 
liquid O 
predominantly O 
via O 
a O 
4-electron O 
reduction O 
to O 
water O 
. O 
A O 
mechanistic O 
analysis O 
using O 
rotating O 
ring O 
- O 
disk O 
electrode O 
( O 
RRDE O 
) O 
voltammetry O 
confirmed O 
that O 
negligible O 
amounts O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
were O 
formed O 
during O 
the O 
ORR O 
. O 
A O 
kinetic O 
analysis O 
of O 
the O 
ORR O 
was O 
performed O 
using O 
rotating O 
disk O 
electrode O 
( O 
RDE O 
) O 
voltammetry O 
and O 
the O 
importance O 
of O 
correcting O 
for O 
ohmic O 
( O 
iR O 
) O 
drop O 
prior O 
to O 
performing O 
kinetic O 
measurements O 
in O 
the O 
ionic O 
liquid O 
is O 
demonstrated O 
. O 
A O 
Tafel O 
analysis O 
of O 
the O 
RDE O 
voltammetry O 
data O 
revealed O 
a O 
change O 
in O 
the O 
ORR O 
Tafel O 
slope O 
from O 
70 O 
mV O 
per O 
decade O 
at O 
low O 
ORR O 
overpotentials O 
to O 
117 O 
mV O 
per O 
decade O 
at O 
high O 
overpotentials O 
, O 
and O 
the O 
reason O 
for O 
this O 
change O 
is O 
discussed O 
. O 
The O 
change O 
in O 
the O 
Tafel O 
slope O 
for O 
the O 
ORR O 
with O 
increasing O 
overpotential O 
meant O 
that O 
the O 
exchange O 
current O 
density O 
for O 
the O 
ORR O 
varied O 
from O 
0.007 O 
nA O 
cm(-2) O 
to O 
10 O 
nA O 
cm(-2) O 
, O 
depending O 
on O 
the O 
applied O 
potential O 
. O 
Finally O 
, O 
the O 
implications O 
of O 
these O 
results O 
for O 
the O 
development O 
of O 
protic O 
ionic O 
liquid O 
fuel O 
cells O 
are O 
discussed O 
. O 

: O 
An O 
antidepressant O 
with O 
new O 
potent O 
hepatoprotective O 
effects O 
on O 
paracetamol B-TRIVIAL 
-induced O 
liver O 
damage O 
in O 
rats O 
. O 

was O 
shown O 
to O 
induce O 
hepatotoxicity O 
or O 
more O 
severe O 
fatal O 
acute O 
hepatic O 
damage O 
. O 
Agomelatine B-TRIVIAL 
, O 
commonly O 
known O 
as O 
melatonin B-TRIVIAL 
receptor O 
agonist O 
, O 
is O 
a O 
new O 
antidepressant O 
, O 
which O 
resynchronizes O 
circadian O 
rhythms O 
with O 
subjective O 
and O 
objective O 
improvements O 
in O 
sleep O 
quality O 
and O 
architecture O 
, O 
as O 
melatonin B-TRIVIAL 
does O 
. O 
In O 
the O 
present O 
study O 
, O 
it O 
was O 
aimed O 
to O 
evaluate O 
the O 
hepatoprotective O 
activity O 
of O 
agomelatine B-TRIVIAL 
on O 
paracetamol B-TRIVIAL 
-induced O 
hepatotoxicity O 
and O 
to O 
understand O 
the O 
relationship O 
between O 
the O 
hepatoprotective O 
mechanism O 
of O 
agomelatine B-TRIVIAL 
and O 
antioxidant O 
system O 
and O 
proinflammatory O 
cytokines O 
. O 
A O 
total O 
of O 
42 O 
rats O 
were O 
divided O 
into O 
7 O 
groups O 
as O 
each O 
composed O 
of O 
6 O 
rats O 
: O 
( O 
1 O 
) O 
intact O 
, O 
( O 
2 O 
) O 
40 O 
mg O 
/ O 
kg O 
agomelatine B-TRIVIAL 
, O 
( O 
3 O 
) O 
140 O 
mg O 
/ O 
kg O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
( O 
4 O 
) O 
2 O 
g O 
/ O 
kg O 
paracetamol B-TRIVIAL 
, O 
( O 
5 O 
) O 
2 O 
g O 
/ O 
kg O 
paracetamol B-TRIVIAL 
+ O 
140 O 
mg O 
/ O 
kg O 
NAC B-ABBREVIATION 
, O 
( O 
6 O 
) O 
2 O 
g O 
/ O 
kg O 
paracetamol B-TRIVIAL 
+ O 
20 O 
mg O 
/ O 
kg O 
agomelatine B-TRIVIAL 
, O 
and O 
( O 
7 O 
) O 
2 O 
g O 
/ O 
kg O 
paracetamol B-TRIVIAL 
+ O 
40 O 
mg O 
/ O 
kg O 
agomelatine B-TRIVIAL 
groups O 
. O 
Paracetamol B-TRIVIAL 
-induced O 
hepatotoxicity O 
was O 
applied O 
and O 
liver O 
and O 
blood O 
samples O 
were O 
analyzed O 
histopathologically O 
and O 
biochemically O 
. O 
There O 
were O 
statistically O 
significant O 
increases O 
in O 
the O 
activities O 
of O 
aspartate B-TRIVIAL 
aminotransferase O 
, O 
alanine B-TRIVIAL 
aminotransferase O 
, O 
levels O 
of O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
( O 
TNF-α O 
) O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
and O 
8-iso-prostane B-TRIVIAL 
, O 
and O 
decreases O 
in O 
the O 
activity O 
of O 
superoxide B-TRIVIAL 
dismutase O 
and O 
level O 
of O 
glutathione B-TRIVIAL 
in O 
the O 
group O 
treated O 
with O 
paracetamol B-TRIVIAL 
. O 
Administration O 
of O 
agomelatine B-TRIVIAL 
and O 
NAC B-ABBREVIATION 
separately O 
reversed O 
these O 
changes O 
significantly O 
. O 
In O 
conclusion O 
, O 
agomelatine B-TRIVIAL 
administration O 
protects O 
liver O 
cells O 
from O 
paracetamol B-TRIVIAL 
-induced O 
hepatotoxicity O 
via O 
antioxidant O 
activity O 
and O 
reduced O 
proinflammatory O 
cytokines O 
, O 
such O 
as O 
TNF-α O 
and O 
IL-6 O 
. O 

influence O 
of O 
thermal O 
degradation O 
on O 
the O 
electrodeposition O 
of O 
aluminium B-SYSTEMATIC 
from O 
an O 
air- O 
and O 
water O 
- O 
stable O 
ionic O 
liquid O 
. O 

electrodeposition O 
is O 
demonstrated O 
from O 
a O 
thermally O 
degraded O 
ionic O 
liquid O 
solution O 
. O 
NMR O 
and O 
voltammetric O 
analyses O 
established O 
that O 
Al(3+) B-FORMULA 
reduction O 
was O 
remarkably O 
similar O 
to O 
that O 
in O 
non-degraded O 
IL O 
solutions O 
suggesting O 
that O 
the O 
electroactive O 
metal O 
- O 
containing O 
species O 
was O 
unaffected O 
by O 
heat O 
treatment O 
. O 
Electron O 
microscopy O 
revealed O 
a O 
significant O 
grain O 
refinement O 
of O 
the O 
deposited O 
metal O 
. O 

toxicity O 
of O 
ferroferric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
and O 
arsenic B-SYSTEMATIC 
to O 
the O 
ciliated O 
protozoa O 
Tetrahymena O 
Pyriformis O 
. O 

nanoparticles O 
( O 
NPs O 
) O 
have O 
a O 
high O 
affinity O 
for O 
arsenic B-SYSTEMATIC 
. O 
As O 
a O 
result O 
of O 
this O 
association O 
, O 
Fe3O4 B-FORMULA 
NPs O 
loaded O 
with O 
high O 
concentration O 
of O 
arsenic B-SYSTEMATIC 
can O 
enter O 
into O 
organisms O 
and O 
produce O 
locally O 
high O 
concentrations O 
of O 
arsenic B-SYSTEMATIC 
, O 
which O 
may O 
lead O 
to O 
some O 
unexpected O 
toxicity O 
to O 
aquatic O 
organisms O 
. O 
The O 
objectives O 
of O 
this O 
research O 
were O 
to O 
investigate O 
the O 
toxic O 
effect O 
of O 
Fe3O4 B-FORMULA 
NPs O 
in O 
combination O 
with O 
As B-FORMULA 
(V) I-FORMULA 
. O 
Cultured O 
Tetrahymena O 
pyriformis O 
was O 
chosen O 
as O 
a O 
research O 
model O 
organism O 
to O 
evaluate O 
the O 
toxic O 
effects O 
of O 
the O 
combined O 
agents O 
. O 
The O 
results O 
showed O 
that O 
after O 
24h O 
of O 
As B-FORMULA 
(V) I-FORMULA 
exposure O 
, O 
the O 
median O 
effective O 
concentration O 
of O 
As B-FORMULA 
(V) I-FORMULA 
to O 
T O 
. O 
pyriformis O 
was O 
1.29mg O 
/ O 
L O 
. O 
Fe3O4 B-FORMULA 
NPs O 
alone O 
were O 
not O 
only O 
non-toxic O 
, O 
but O 
actually O 
promoted O 
the O 
growth O 
of O 
T O 
. O 
pyriformis O 
at O 
the O 
experimental O 
doses O 
. O 
After O 
24h O 
exposure O 
, O 
the O 
cell O 
number O 
increased O 
by O 
32.2% O 
at O 
an O 
exposure O 
level O 
of O 
3mg O 
/ O 
L O 
Fe3O4 B-FORMULA 
NPs O 
. O 
After O 
24h O 
exposure O 
to O 
1.0mg O 
/ O 
L O 
As B-FORMULA 
(V) I-FORMULA 
, O 
the O 
survival O 
rate O 
increased O 
from O 
60.5% O 
in O 
the O 
absence O 
of O 
Fe3O4 B-FORMULA 
NPs O 
to O 
73.8% O 
and O 
83.8% O 
in O 
the O 
presence O 
of O 
13mg O 
/ O 
L O 
and O 
19mg O 
/ O 
L O 
Fe3O4 B-FORMULA 
NPs O 
, O 
respectively O 
. O 
However O 
, O 
after O 
30h O 
, O 
the O 
combined O 
toxic O 
effect O 
of O 
As B-FORMULA 
(V) I-FORMULA 
and O 
Fe3O4 B-FORMULA 
NPs O 
on O 
T O 
. O 
pyriformis O 
was O 
significantly O 
enhanced O 
and O 
the O 
survival O 
rates O 
for O 
co O 
- O 
exposure O 
to O 
1.5mg O 
/ O 
L O 
As B-FORMULA 
(V) I-FORMULA 
and O 
13mg O 
/ O 
L O 
Fe3O4 B-FORMULA 
NPs O 
decreased O 
from O 
92.3% O 
after O 
18h O 
to O 
45.3% O 
after O 
30h O 
. O 
After O 
18h O 
of O 
exposure O 
to O 
Fe3O4 B-FORMULA 
NPs O 
alone O 
, O 
the O 
intracellular O 
ROS O 
levels O 
were O 
markedly O 
increased O 
and O 
achieved O 
steady O 
state O 
. O 
Compared O 
with O 
the O 
control O 
group O 
, O 
the O 
intracellular O 
ROS O 
levels O 
were O 
significantly O 
increased O 
( O 
2.56-fold O 
) O 
by O 
the O 
combination O 
of O 
19mg O 
/ O 
L O 
Fe3O4 B-FORMULA 
NPs O 
and O 
1.0mg O 
/ O 
L O 
As B-FORMULA 
(V) I-FORMULA 
. O 
Accumulation O 
of O 
As B-FORMULA 
(V) I-FORMULA 
in O 
T O 
. O 
pyriformis O 
led O 
to O 
an O 
increase O 
in O 
trivalent O 
arsenics B-FAMILY 
as O 
a O 
result O 
of O 
the O 
saturation O 
of O 
the O 
cellular O 
arsenic B-SYSTEMATIC 
methylation O 
capability O 
or O 
/ O 
and O 
redox O 
reactions O 
. O 
These O 
exposures O 
also O 
resulted O 
in O 
an O 
imbalance O 
between O 
oxidants O 
and O 
antioxidants O 
, O 
resulting O 
in O 
oxidative O 
damage O 
and O 
cell O 
death O 
. O 

analysis O 
of O 
cultured O 
whale O 
skin O 
cells O 
exposed O 
to O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
[ O 
Cr B-FORMULA 
(VI) I-FORMULA 
] O 
. O 

chromium I-SYSTEMATIC 
Cr B-FORMULA 
(VI) I-FORMULA 
is O 
known O 
to O 
produce O 
cytotoxic O 
effects O 
in O 
humans O 
and O 
is O 
a O 
highly O 
toxic O 
environmental O 
contaminant O 
. O 
Interestingly O 
, O 
it O 
has O 
been O 
shown O 
that O 
free O 
ranging O 
sperm O 
whales O 
( O 
Phyester O 
macrocephalus O 
) O 
may O 
have O 
exceedingly O 
high O 
levels O 
of O 
Cr B-FORMULA 
in O 
their O 
skin O 
. O 
Also O 
, O 
it O 
has O 
been O 
demonstrated O 
that O 
skin O 
cells O 
from O 
whales O 
appear O 
more O 
resistant O 
to O 
both O 
cytotoxicity O 
and O 
clastogenicity O 
upon O 
Cr B-FORMULA 
exposure O 
compared O 
to O 
human O 
cells O 
. O 
However O 
, O 
the O 
molecular O 
genetic O 
mechanisms O 
employed O 
in O 
whale O 
skin O 
cells O 
that O 
might O 
lead O 
to O 
Cr B-FORMULA 
tolerance O 
are O 
unknown O 
. O 
In O 
an O 
effort O 
to O 
understand O 
the O 
underlying O 
mechanisms O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
tolerance O 
and O 
to O 
illuminate O 
global O 
gene O 
expression O 
patterns O 
modulated O 
by O 
Cr B-FORMULA 
, O 
we O 
exposed O 
whale O 
skin O 
cells O 
in O 
culture O 
to O 
varying O 
levels O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
( O 
i.e O 
. O 
, O 
0 O 
, O 
0.5 O 
, O 
1 O 
and O 
5.0μg O 
/ O 
cm(2) O 
) O 
followed O 
by O 
short O 
read O 
( O 
100bp O 
) O 
next O 
generation O 
RNA O 
sequencing O 
( O 
RNA-seq O 
) O 
. O 
RNA-seq O 
reads O 
from O 
all O 
exposures O 
( O 
≈280 O 
million O 
reads O 
) O 
were O 
pooled O 
to O 
generate O 
a O 
de O 
novo O 
reference O 
transcriptome O 
assembly O 
. O 
The O 
resulting O 
whale O 
reference O 
assembly O 
had O 
11K O 
contigs O 
and O 
an O 
N50 O 
of O 
2954bp O 
. O 
Using O 
the O 
reads O 
from O 
each O 
dose O 
( O 
0 O 
, O 
0.5 O 
, O 
1 O 
and O 
5.0μg O 
/ O 
cm(2) O 
) O 
we O 
performed O 
RNA-seq O 
based O 
gene O 
expression O 
analysis O 
that O 
identified O 
35 O 
up O 
- O 
regulated O 
genes O 
and O 
19 O 
down O 
- O 
regulated O 
genes O 
. O 
The O 
experimental O 
results O 
suggest O 
that O 
low O 
dose O 
exposure O 
to O 
Cr B-FORMULA 
( O 
1.0μg O 
/ O 
cm(2) O 
) O 
serves O 
to O 
induce O 
up O 
- O 
regulation O 
of O 
oxidative O 
stress O 
response O 
genes O 
, O 
DNA O 
repair O 
genes O 
and O 
cell O 
cycle O 
regulator O 
genes O 
. O 
However O 
, O 
at O 
higher O 
doses O 
( O 
5.0μg O 
/ O 
cm(2) O 
) O 
the O 
DNA O 
repair O 
genes O 
appeared O 
down O 
- O 
regulated O 
while O 
other O 
genes O 
that O 
were O 
induced O 
suggest O 
the O 
initiation O 
of O 
cytotoxicity O 
. O 
The O 
set O 
of O 
genes O 
identified O 
that O 
show O 
regulatory O 
modulation O 
at O 
different O 
Cr B-FORMULA 
doses O 
provide O 
specific O 
candidates O 
for O 
further O 
studies O 
aimed O 
at O 
determination O 
of O 
how O 
whales O 
exhibit O 
resistance O 
to O 
Cr B-FORMULA 
toxicity O 
and O 
what O 
role(s) O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
may O 
play O 
in O 
this O 
process O 
. O 

of O 
3-O-propargylated B-MULTIPLE 
betulinic I-MULTIPLE 
acid I-MULTIPLE 
and I-MULTIPLE 
its I-MULTIPLE 
1,2,3-triazoles I-MULTIPLE 
as O 
potential O 
apoptotic O 
agents O 
. O 

agents O 
from O 
nature O 
are O 
presently O 
the O 
mainstay O 
of O 
anticancer O 
chemotherapy O 
, O 
and O 
the O 
need O 
to O 
reinforce O 
the O 
arsenal O 
of O 
anticancer O 
agents O 
is O 
highly O 
desired O 
. O 
Chemical O 
transformation O 
studies O 
carried O 
out O 
on O 
betulinic B-TRIVIAL 
acid I-TRIVIAL 
, O 
through O 
concise O 
1,2,3-triazole B-SYSTEMATIC 
synthesis O 
via O 
click O 
chemistry O 
approach O 
at O 
C B-FORMULA 
-3position O 
in O 
ring O 
A O 
have O 
been O 
evaluated O 
for O 
their O 
cytotoxic O 
potentiation O 
against O 
nine O 
human O 
cancer O 
cell O 
lines O 
. O 
Most O 
of O 
the O 
derivatives O 
have O 
shown O 
higher O 
cytotoxic O 
profiles O 
than O 
the O 
parent O 
molecule O 
. O 
Two O 
compounds O 
i.e O 
. O 
3{1N(2-cyanophenyl)-1H-1,2,3-triazol-4yl}methyloxy B-SYSTEMATIC 
betulinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
7 O 
) O 
and O 
3{1N(5-hydroxy-naphth-1yl)-1H-1,2,3-triazol-4yl}methyloxy B-SYSTEMATIC 
betulinic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
13 O 
) O 
displayed O 
impressive O 
IC50 O 
values O 
( O 
2.5 O 
and O 
3.5 O 
μM O 
respectively O 
) O 
against O 
leukemia O 
cell O 
line O 
HL-60 O 
( O 
5-7-fold O 
higher O 
potency O 
than O 
betulinic O 
acid O 
) O 
. O 
As O 
evident O 
from O 
various O 
biological O 
end O 
points O 
, O 
inhibition O 
of O 
cell O 
migration O 
and O 
colony O 
formation O 
, O 
mitochondrial O 
membrane O 
disruption O 
followed O 
by O 
DNA O 
fragmentation O 
and O 
apoptosis O 
, O 
is O 
demonstrated O 
. O 

and O 
in O 
vitro O 
antiproliferative O 
effect O 
of O 
novel O 
quinoline B-SYSTEMATIC 
-based O 
potential O 
anticancer O 
agents O 
. O 

derivatives O 
with O 
a O 
quinoline B-SYSTEMATIC 
scaffold O 
and O 
a O 
flexible O 
, O 
semi-flexible O 
or O 
rigid O 
side O 
chains O 
at O 
position O 
8 O 
of O 
the O 
quinoline B-SYSTEMATIC 
ring O 
were O 
synthesized O 
and O 
assessed O 
for O 
their O 
in O 
vitro O 
activity O 
versus O 
the O 
human O 
colon O 
cancer O 
cell O 
line O 
HT29 O 
and O 
the O 
human O 
breast O 
cancer O 
cell O 
line O 
MDA-MB231 O 
. O 
The O 
HT29 O 
cell O 
line O 
was O 
more O 
refractory O 
to O 
the O 
cytotoxic O 
activity O 
of O 
some O 
compounds O 
, O 
meanwhile O 
all O 
the O 
quinoline B-SYSTEMATIC 
derivatives O 
except O 
one O 
displayed O 
high O 
to O 
moderate O 
activity O 
against O 
MDA-MB231 O 
with O 
IC50 O 
values O 
ranging O 
between O 
4.6 O 
and O 
48.2 O 
μM O 
. O 
The O 
most O 
active O 
derivative O 
in O 
this O 
study O 
against O 
both O 
tested O 
cell O 
lines O 
was O 
the O 
Schiff's B-FAMILY 
base I-FAMILY 
4e O 
with O 
IC50 O 
of O 
4.7 O 
and O 
4.6 O 
μM O 
against O 
HT29 O 
and O 
MDA-MB231 O 
, O 
respectively O 
. O 

rangeli O 
is O 
a O 
hemoflagellate O 
parasite O 
which O 
is O 
able O 
to O 
infect O 
humans O 
. O 
Distinct O 
from O 
Trypanosoma O 
cruzi O 
, O 
the O 
causative O 
agent O 
of O 
Chagas O 
disease O 
, O 
T O 
. O 
rangeli O 
is O 
non-pathogenic O 
to O 
the O 
vertebrate O 
host O 
. O 
The O 
manner O 
by O 
which O 
the O 
T O 
. O 
rangeli O 
interacts O 
with O 
the O 
host O 
is O 
still O 
unknown O 
, O 
but O 
it O 
certainly O 
depends O 
on O 
the O 
surface O 
molecules O 
. O 
Major O 
surface O 
proteins O 
( O 
MSP O 
) O 
are O 
GPI-anchored O 
, O 
zinc O 
- O 
dependent O 
metalloproteases O 
present O 
in O 
the O 
surface O 
of O 
all O 
trypanosomatids O 
studied O 
so O 
far O 
, O 
which O 
are O 
implicated O 
as O 
virulence O 
factors O 
in O 
pathogenic O 
trypanosomatids O 
, O 
such O 
as O 
Leishmania O 
spp O 
and O 
T O 
. O 
cruzi O 
. O 
The O 
aims O 
of O 
this O 
work O 
were O 
to O 
generate O 
the O 
complete O 
sequence O 
of O 
a O 
T O 
. O 
rangeli O 
MSP O 
( O 
TrMSP O 
) O 
gene O 
and O 
to O 
determine O 
the O 
3D-structure O 
of O 
the O 
predicted O 
protein O 
by O 
homology O 
modeling O 
. O 
The O 
plasmid O 
bearing O 
a O 
complete O 
copy O 
of O 
a O 
TrMSP O 
gene O 
was O 
completely O 
sequenced O 
and O 
the O 
predicted O 
protein O 
was O 
modeled O 
using O 
Modeller O 
software O 
. O 
Results O 
indicate O 
that O 
TrMSP O 
open O 
reading O 
frame O 
( O 
ORF O 
) O 
codes O 
for O 
a O 
predicted O 
588 O 
amino B-FAMILY 
acid I-FAMILY 
protein O 
and O 
shows O 
all O 
elements O 
required O 
for O 
its O 
posttranslational O 
processing O 
. O 
Multiple O 
sequence O 
alignment O 
of O 
TrMSP O 
with O 
other O 
trypanosomatids O 
' O 
MSPs O 
showed O 
an O 
extensive O 
conservation O 
of O 
the O 
N B-FORMULA 
-terminal O 
and O 
central O 
regions O 
and O 
a O 
more O 
divergent O 
C B-FORMULA 
-terminal O 
region O 
. O 
Leishmania O 
major O 
MSP O 
( O 
LmMSP O 
) O 
, O 
which O 
had O 
its O 
crystal O 
structure O 
previously O 
determined O 
, O 
has O 
an O 
overall O 
35 O 
% O 
identity O 
with O 
TrMSP O 
. O 
This O 
identity O 
allowed O 
the O 
comparative O 
molecular O 
modeling O 
of O 
TrMSP O 
, O 
which O 
demonstrated O 
a O 
high O 
degree O 
of O 
structural O 
conservation O 
between O 
MSPs O 
from O 
other O 
trypanosomatids O 
( O 
TrypMSPs O 
) O 
. O 
All O 
modeled O 
MSPs O 
have O 
a O 
conserved O 
folding O 
pattern O 
, O 
apart O 
from O 
structural O 
divergences O 
in O 
the O 
C-domain O 
and O 
discrete O 
differences O 
of O 
charge O 
and O 
topology O 
in O 
the O 
catalytic O 
cleft O 
, O 
and O 
present O 
the O 
same O 
geometry O 
of O 
the O 
canonical O 
HEXXH O 
zinc B-SYSTEMATIC 
-binding O 
motif O 
. O 
The O 
determination O 
of O 
surface O 
charges O 
of O 
the O 
molecules O 
revealed O 
that O 
TrMSP O 
is O 
a O 
predominantly O 
positive O 
protein O 
, O 
whereas O 
LmMSP O 
and O 
Trypanosoma O 
cruzi O 
MSP O 
( O 
TcMSP O 
) O 
are O 
negative O 
proteins O 
, O 
suggesting O 
that O 
substrates O 
recognized O 
by O 
TcMSP O 
and O 
LmMSP O 
could O 
not O 
interact O 
with O 
TrMSP O 
. O 
Moreover O 
, O 
the O 
comparison O 
between O 
TrMSP O 
and O 
TcMSP O 
protein O 
sequences O 
has O 
revealed O 
45 O 
non-neutral O 
amino B-FAMILY 
acid I-FAMILY 
substitutions O 
, O 
which O 
can O 
be O 
further O 
assessed O 
through O 
protein O 
engineering O 
. O 
The O 
characteristics O 
of O 
TrMSP O 
could O 
explain O 
, O 
at O 
least O 
in O 
part O 
, O 
the O 
lack O 
of O 
pathogenicity O 
of O 
T O 
. O 
rangeli O 
to O 
humans O 
and O 
point O 
to O 
the O 
necessity O 
of O 
identifying O 
the O 
biological O 
targets O 
of O 
this O 
enzyme O 
. O 

single O 
ZnO B-FORMULA 
nanowire O 
for O 
logic O 
and O 
memory O 
circuits O 
: O 
NOT O 
, O 
NAND O 
, O 
NOR O 
gate O 
, O 
and O 
SRAM O 
. O 

demonstrate O 
logic O 
and O 
static O 
random O 
access O 
memory O 
( O 
SRAM O 
) O 
circuits O 
using O 
a O 
100 O 
μm O 
long O 
and O 
100 O 
nm O 
thin O 
single O 
ZnO B-FORMULA 
nanowire O 
( O 
NW O 
) O 
, O 
which O 
acts O 
as O 
a O 
channel O 
of O 
field O 
- O 
effect O 
transistors O 
( O 
FETs O 
) O 
with O 
Al2O3 B-FORMULA 
dielectrics O 
. O 
NW O 
FETs O 
are O 
thus O 
arrayed O 
in O 
one O 
dimension O 
to O 
consist O 
of O 
NOT O 
, O 
NAND O 
, O 
and O 
NOR O 
gate O 
logic O 
, O 
and O 
SRAM O 
circuits O 
. O 
Two O 
respective O 
top O 
- O 
gate O 
NW O 
FETs O 
with O 
Au B-FORMULA 
and O 
indium B-SYSTEMATIC 
- I-SYSTEMATIC 
tin I-SYSTEMATIC 
- I-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
ITO B-ABBREVIATION 
) O 
were O 
connected O 
to O 
form O 
an O 
inverter O 
, O 
the O 
basic O 
NOT O 
gate O 
component O 
, O 
since O 
the O 
former O 
gate O 
leads O 
to O 
an O 
enhanced O 
mode O 
FET O 
while O 
the O 
latter O 
to O 
depletion O 
mode O 
due O 
to O 
their O 
work O 
function O 
difference O 
. O 
Our O 
inverters O 
showed O 
a O 
high O 
voltage O 
gain O 
of O 
22 O 
under O 
a O 
5 O 
V O 
operational O 
voltage O 
, O 
resulting O 
in O 
successful O 
operation O 
of O 
all O 
other O 
devices O 
. O 
We O 
thus O 
conclude O 
that O 
our O 
long O 
single O 
NW O 
approach O 
is O 
quite O 
promising O 
to O 
extend O 
the O 
field O 
of O 
nano O 
- O 
electronics O 
. O 

is O 
a O 
physiological O 
state O 
characterised O 
by O 
controlled O 
lowering O 
of O 
metabolic O 
rate O 
and O 
core O 
body O 
temperature O 
, O 
allowing O 
substantial O 
energy O 
savings O 
during O 
periods O 
of O 
reduced O 
food O 
availability O 
or O 
harsh O 
environmental O 
conditions O 
. O 
The O 
hypothalamus O 
coordinates O 
energy O 
homeostasis O 
and O 
thermoregulation O 
, O 
and O 
plays O 
a O 
key O 
role O 
in O 
directing O 
torpor O 
. O 
We O 
recently O 
showed O 
that O 
mice O 
lacking O 
the O 
orphan O 
G O 
protein O 
coupled O 
receptor O 
Gpr50 O 
readily O 
enter O 
torpor O 
in O 
response O 
to O 
fasting O 
, O 
and O 
have O 
now O 
used O 
these O 
mice O 
to O 
conduct O 
a O 
microarray O 
analysis O 
of O 
hypothalamic O 
gene O 
expression O 
changes O 
related O 
to O 
the O 
torpor O 
state O 
. O 
This O 
revealed O 
a O 
strong O 
induction O 
of O 
thioredoxin O 
interacting O 
protein O 
( O 
Txnip O 
) O 
in O 
the O 
hypothalamus O 
of O 
torpid O 
mice O 
, O 
which O 
was O 
confirmed O 
by O 
quantitative O 
RT-PCR O 
and O 
Western O 
blot O 
analyses O 
. O 
In O 
situ O 
hybridisation O 
identified O 
the O 
ependyma O 
lining O 
the O 
third O 
ventricle O 
as O 
the O 
principal O 
site O 
of O 
torpor O 
- O 
related O 
expression O 
of O 
Txnip O 
. O 
To O 
characterise O 
further O 
the O 
relationship O 
between O 
Txnip O 
and O 
torpor O 
, O 
we O 
profiled O 
Txnip O 
expression O 
in O 
mice O 
during O 
prolonged O 
fasting O 
, O 
cold O 
exposure O 
, O 
and O 
2-deoxyglucose B-SYSTEMATIC 
-induced O 
hypometabolism O 
, O 
as O 
well O 
as O 
in O 
naturally O 
occurring O 
torpor O 
bouts O 
in O 
the O 
Siberian O 
hamster O 
. O 
Strikingly O 
, O 
pronounced O 
upregulation O 
of O 
Txnip O 
expression O 
was O 
only O 
observed O 
in O 
WT O 
mice O 
when O 
driven O 
into O 
torpor O 
, O 
and O 
during O 
torpor O 
in O 
the O 
Siberian O 
hamster O 
. O 
Increase O 
of O 
Txnip O 
was O 
not O 
limited O 
to O 
the O 
hypothalamus O 
, O 
with O 
exaggerated O 
expression O 
in O 
white O 
adipose O 
tissue O 
, O 
brown O 
adipose O 
tissue O 
, O 
and O 
liver O 
also O 
demonstrated O 
in O 
torpid O 
mice O 
. O 
Given O 
the O 
recent O 
identification O 
of O 
Txnip O 
as O 
a O 
molecular O 
nutrient O 
sensor O 
important O 
in O 
the O 
regulation O 
of O 
energy O 
metabolism O 
, O 
our O 
data O 
suggest O 
that O 
elevated O 
Txnip O 
expression O 
is O 
critical O 
to O 
regulating O 
energy O 
expenditure O 
and O 
fuel O 
utilisation O 
during O 
the O 
extreme O 
hypometabolic O 
state O 
of O 
torpor O 
. O 

is O 
a O 
potent O 
CYP3A O 
inhibitor O 
used O 
to O 
assess O 
the O 
contribution O 
of O 
CYP3A O 
to O 
drug O 
clearance O 
and O 
quantify O 
the O 
increase O 
in O 
drug O 
exposure O 
due O 
to O 
a O 
strong O 
inhibitor O 
. O 
Physiologically O 
based O 
pharmacokinetic O 
( O 
PBPK O 
) O 
models O 
have O 
been O 
employed O 
to O 
evaluate O 
dosing O 
regimens O 
resulting O 
in O 
maximal O 
CYP3A O 
inhibition O 
by O 
ketoconazole B-TRIVIAL 
but O 
have O 
reached O 
different O 
conclusions O 
. O 
We O 
compare O 
two O 
PBPK O 
models O 
of O 
the O 
ketoconazole B-TRIVIAL 
- O 
midazolam B-TRIVIAL 
interaction O 
, O 
Model O 
1 O 
( O 
Chien O 
et O 
al O 
. O 
, O 
2006 O 
) O 
and O 
Model O 
2 O 
implemented O 
in O 
Simcyp O 
( O 
version O 
11 O 
) O 
to O 
predict O 
16 O 
published O 
dosing O 
regimens O 
. O 
Using O 
Model O 
2 O 
, O 
41% O 
of O 
the O 
study O 
point O 
estimates O 
of O 
AUC O 
ratio O 
and O 
71% O 
of O 
the O 
90% O 
confidence O 
intervals O 
were O 
predicted O 
within O 
1.5-fold O 
of O 
the O 
observed O 
but O 
these O 
increased O 
to O 
82% O 
and O 
100% O 
respectively O 
with O 
Model O 
1 O 
. O 
For O 
midazolam B-TRIVIAL 
, O 
Model O 
2 O 
predicted O 
a O 
maximal O 
midazolam B-TRIVIAL 
AUC O 
ratio O 
of O 
8 O 
and O 
a O 
hepatic O 
fraction O 
metabolized O 
by O 
CYP3A O 
of O 
0.97 O 
whereas O 
Model O 
1 O 
predicted O 
17 O 
and O 
0.9 O 
respectively O 
, O 
which O 
are O 
more O 
consistent O 
with O 
observed O 
data O 
. O 
Based O 
on O 
Model O 
1 O 
, O 
ketoconazole B-TRIVIAL 
400mg O 
QD O 
for O 
at O 
least O 
3 O 
days O 
and O 
substrate O 
administration O 
within O 
2 O 
hours O 
is O 
required O 
for O 
maximal O 
CYP3A O 
inhibition O 
. O 
Ketoconazole B-TRIVIAL 
dosing O 
regimens O 
that O 
employ O 
200 O 
mg O 
BID O 
underestimate O 
the O 
systemic O 
fraction O 
metabolized O 
by O 
CYP3A O 
( O 
0.86 O 
vs O 
. O 
0.9 O 
) O 
for O 
midazolam B-TRIVIAL 
. O 
The O 
systematic O 
underprediction O 
also O 
applies O 
to O 
CYP3A O 
substrates O 
with O 
high O 
bioavailability O 
and O 
long O 
half O 
- O 
lives O 
. O 
The O 
superior O 
predictive O 
performance O 
of O 
Model O 
1 O 
reflects O 
the O 
need O 
for O 
accumulation O 
of O 
ketoconazole B-TRIVIAL 
at O 
enzyme O 
site O 
and O 
protracted O 
inhibition O 
. O 
Model O 
2 O 
is O 
not O 
recommended O 
for O 
inferring O 
optimal O 
study O 
design O 
and O 
estimation O 
of O 
fraction O 
metabolized O 
by O 
CYP3A O 
. O 

: O 
opening O 
a O 
new O 
treatment O 
practice O 
in O 
advanced O 
medullary O 
thyroid O 
carcinoma O 
. O 

thyroid O 
cancer O 
( O 
MTC O 
) O 
is O 
frequently O 
diagnosed O 
in O 
a O 
locally O 
advanced O 
or O 
metastatic O 
stage O 
, O 
and O 
10-year O 
survival O 
rates O 
in O 
these O 
cases O 
are O 
below O 
20 O 
% O 
. O 
Cytotoxic O 
chemotherapy O 
has O 
no O 
significant O 
impact O 
on O 
overall O 
or O 
progression O 
- O 
free O 
survival O 
. O 
Vandetanib B-TRIVIAL 
( O 
Caprelsa B-TRIVIAL 
( O 
® O 
) O 
, O 
AstraZeneca O 
) O 
is O 
a O 
once O 
- O 
daily O 
oral O 
tyrosine B-TRIVIAL 
kinase O 
inhibitor O 
that O 
selectively O 
inhibits O 
signalling O 
mediated O 
by O 
growth O 
- O 
factor O 
receptor O 
tyrosine B-TRIVIAL 
kinase O 
RET O 
( O 
constitutively O 
activated O 
in O 
roughly O 
60 O 
% O 
of O 
all O 
MTCs O 
) O 
, O 
vascular O 
endothelial O 
growth O 
- O 
factor O 
receptors O 
2 O 
and O 
3 O 
, O 
and O 
epidermal O 
growth O 
- O 
factor O 
receptors O 
. O 
It O 
is O 
the O 
first O 
systemic O 
drug O 
with O 
demonstrated O 
anti-tumor O 
benefits O 
in O 
advanced O 
MTC O 
, O 
and O 
it O 
has O 
recently O 
been O 
approved O 
for O 
locally O 
advanced O 
or O 
metastatic O 
MTC O 
by O 
the O 
United O 
States O 
Food O 
and O 
Drug O 
Administration O 
( O 
April O 
2011 O 
) O 
and O 
the O 
European O 
Medicines O 
Agency O 
( O 
February O 
2012 O 
) O 
. O 
This O 
review O 
, O 
starting O 
from O 
the O 
phases O 
II O 
and O 
III O 
efficacy O 
and O 
safety O 
data O 
that O 
led O 
to O 
these O 
approvals O 
, O 
explores O 
important O 
issues O 
related O 
to O 
dosing O 
, O 
patient O 
selection O 
, O 
and O 
strategies O 
for O 
managing O 
the O 
substantial O 
risk O 
of O 
toxicity O 
associated O 
with O 
the O 
drug O 
( O 
including O 
life O 
- O 
threatening O 
cardiac O 
events O 
that O 
are O 
the O 
subject O 
of O 
a O 
black O 
- O 
box O 
warning O 
in O 
the O 
United O 
States O 
) O 
. O 
All O 
these O 
issues O 
still O 
remain O 
to O 
be O 
defined O 
. O 
Vandetanib B-TRIVIAL 
is O 
becoming O 
a O 
standard O 
of O 
care O 
for O 
symptomatic O 
, O 
progressive O 
, O 
metastatic O 
MTCs O 
, O 
to O 
be O 
used O 
selectively O 
in O 
those O 
patients O 
who O 
are O 
likely O 
to O 
benefit O 
from O 
it O 
. O 

Receptor O 
Activation O 
Down-Regulates O 
Expression O 
of O 
δ O 
Subunit O 
- O 
Containing O 
GABA B-ABBREVIATION 
-A O 
Receptors O 
in O 
Cultured O 
Hippocampal O 
Neurons O 
. O 

are O 
endogenous O 
allosteric O 
modulators O 
of O 
γ B-SYSTEMATIC 
amino-butyric I-SYSTEMATIC 
acid I-SYSTEMATIC 
type O 
A O 
receptors O 
( O 
GABARs O 
) O 
, O 
and O 
enhance O 
GABAR O 
- O 
mediated O 
inhibition O 
. O 
However O 
, O 
GABARs O 
expressed O 
on O 
hippocampal O 
dentate O 
granule O 
neurons O 
of O 
epileptic O 
animals O 
are O 
modified O 
such O 
that O 
their O 
neurosteroid O 
sensitivity O 
is O 
reduced O 
and O 
δ O 
subunit O 
expression O 
is O 
diminished O 
. O 
The O 
molecular O 
mechanisms O 
triggering O 
this O 
GABAR O 
plasticity O 
were O 
explored O 
. O 
In O 
the O 
cultured O 
hippocampal O 
neurons O 
treatment O 
with O 
NMDA B-ABBREVIATION 
( O 
10 O 
μM O 
) O 
for O 
48 O 
hrs O 
reduced O 
surface O 
expression O 
of O 
δ O 
and O 
α4 O 
subunits O 
, O 
but O 
did O 
not O 
increase O 
expression O 
of O 
γ2 O 
subunits O 
. O 
The O 
tonic O 
current O 
recorded O 
from O 
neurons O 
in O 
NMDA B-ABBREVIATION 
-treated O 
cultures O 
was O 
reduced O 
, O 
and O 
its O 
neurosteroid O 
modulation O 
was O 
also O 
diminished O 
. O 
In O 
contrast O 
, O 
synaptic O 
inhibition O 
and O 
its O 
modulation O 
by O 
neurosteroids O 
were O 
preserved O 
in O 
these O 
neurons O 
. O 
The O 
time O 
course O 
of O 
NMDA B-ABBREVIATION 
effects O 
on O 
surface O 
and O 
total O 
δ O 
subunit O 
expression O 
were O 
distinct O 
; O 
shorter O 
( O 
6 O 
hrs O 
) O 
treatment O 
decreased O 
surface O 
expression O 
, O 
whereas O 
longer O 
treatment O 
reduced O 
both O 
surface O 
and O 
total O 
expression O 
. O 
APV B-ABBREVIATION 
blocked O 
NMDA B-ABBREVIATION 
effects O 
on O 
δ O 
subunit O 
expression O 
. O 
Chelation O 
of O 
calcium B-SYSTEMATIC 
ions O 
by O 
BAPTA-AM B-ABBREVIATION 
or O 
blockade O 
of O 
ERK1 O 
/ O 
2 O 
activation O 
by O 
UO126 B-IDENTIFIER 
also O 
prevented O 
the O 
NMDA B-ABBREVIATION 
effects O 
. O 
Thus O 
prolonged O 
activation O 
of O 
NMDA B-ABBREVIATION 
receptors O 
in O 
hippocampal O 
neurons O 
reduced O 
GABAR O 
δ O 
subunit O 
expression O 
through O 
Ca2+ B-FORMULA 
entry O 
and O 
at O 
least O 
in O 
part O 
by O 
ERK1 O 
/ O 
2 O 
activation O 
. O 

Evidence O 
for O 
a O 
Non-Langmuir-Hinshelwood O 
Surface O 
Reaction O 
: O 
H B-FORMULA 
/ O 
D B-FORMULA 
Exchange O 
over O 
Pd B-FORMULA 
Nanoparticles O 
and O 
Pd(111) B-FORMULA 
. O 

mechanism O 
of O 
hydrogen B-SYSTEMATIC 
recombination O 
on O 
a O 
Pd(111) B-FORMULA 
single O 
crystal O 
and O 
well O 
- O 
defined O 
Pd B-FORMULA 
nanoparticles O 
is O 
studied O 
using O 
pulsed O 
multi O 
- O 
molecular O 
beam O 
techniques O 
and O 
the O 
H2 B-FORMULA 
/ O 
D2 B-FORMULA 
isotope O 
exchange O 
reaction O 
. O 
The O 
focus O 
of O 
this O 
study O 
is O 
to O 
obtain O 
a O 
microscopic O 
understanding O 
of O 
the O 
role O 
of O 
subsurface O 
hydrogen B-SYSTEMATIC 
in O 
enhancing O 
the O 
associative O 
desorption O 
of O 
molecular O 
hydrogen B-SYSTEMATIC 
. O 
HD B-FORMULA 
production O 
from O 
H2 B-FORMULA 
and O 
D2 B-FORMULA 
over O 
Pd B-FORMULA 
is O 
investigated O 
using O 
pulsed O 
molecular O 
beams O 
, O 
and O 
the O 
temperature O 
dependence O 
and O 
reaction O 
orders O 
are O 
obtained O 
for O 
the O 
rate O 
of O 
HD B-FORMULA 
production O 
under O 
various O 
reaction O 
conditions O 
designed O 
to O 
modulate O 
the O 
amount O 
of O 
subsurface O 
hydrogen B-SYSTEMATIC 
present O 
. O 
The O 
experimental O 
data O 
are O 
compared O 
to O 
the O 
results O 
of O 
kinetic O 
modeling O 
based O 
on O 
different O 
mechanisms O 
for O 
hydrogen B-SYSTEMATIC 
recombination O 
. O 
We O 
found O 
that O 
under O 
conditions O 
where O 
virtually O 
no O 
subsurface O 
hydrogen B-SYSTEMATIC 
species O 
are O 
present O 
, O 
the O 
HD B-FORMULA 
formation O 
rate O 
can O 
be O 
described O 
exceptionally O 
well O 
by O 
a O 
classic O 
Langmuir-Hinshelwood O 
model O 
. O 
However O 
, O 
this O 
model O 
completely O 
fails O 
to O 
reproduce O 
the O 
experimentally O 
observed O 
high O 
HD B-FORMULA 
formation O 
rates O 
and O 
the O 
reaction O 
orders O 
under O 
reaction O 
conditions O 
where O 
subsurface O 
hydrogen B-SYSTEMATIC 
is O 
present O 
. O 
To O 
analyze O 
this O 
phenomenon O 
, O 
we O 
develop O 
two O 
kinetic O 
models O 
that O 
account O 
for O 
the O 
role O 
of O 
subsurface O 
hydrogen B-SYSTEMATIC 
. O 
First O 
, O 
we O 
investigate O 
the O 
possibility O 
of O 
a O 
change O 
in O 
the O 
reaction O 
mechanism O 
, O 
where O 
recombination O 
of O 
one O 
subsurface O 
and O 
one O 
surface O 
hydrogen B-SYSTEMATIC 
species O 
( O 
known O 
as O 
a O 
breakthrough O 
mechanism O 
) O 
becomes O 
dominant O 
when O 
subsurface O 
hydrogen B-SYSTEMATIC 
is O 
present O 
. O 
Second O 
, O 
we O 
investigate O 
the O 
possibility O 
of O 
the O 
modified O 
Langmuir-Hinshelwood O 
mechanism O 
with O 
subsurface O 
hydrogen B-SYSTEMATIC 
lowering O 
the O 
activation O 
energy O 
for O 
recombination O 
of O 
two O 
hydrogen B-SYSTEMATIC 
species O 
adsorbed O 
on O 
the O 
surface O 
. O 
We O 
show O 
that O 
the O 
experimental O 
reaction O 
kinetics O 
can O 
be O 
well O 
described O 
by O 
both O 
kinetic O 
models O 
based O 
on O 
non-Langmuir-Hinshelwood O 
- O 
type O 
mechanisms O 
. O 

covalent O 
organic O 
nanoframeworks O 
up O 
to O 
generation O 
2.5 O 
( O 
G2.5 O 
) O 
are O 
synthesized O 
with O 
self O 
- O 
similar O 
H O 
- O 
shaped O 
conformations O 
by O 
using O 
a O 
bottom O 
- O 
up O 
approach O 
including O 
iterative O 
C-H B-FORMULA 
bond O 
functionalization O 
. O 
The O 
electrical O 
characteristics O 
of O 
nanoscale O 
thin O 
- O 
film O 
semiconductors O 
of O 
the O 
conjugation O 
- O 
interrupted O 
frameworks O 
can O 
be O 
tuned O 
by O 
post O 
- O 
modification O 
with O 
diazonium B-SYSTEMATIC 
salt O 
. O 

optimized O 
electrodropping O 
system O 
produces O 
homogeneous O 
core O 
- O 
shell O 
microcapsules O 
( O 
C-S O 
MCs O 
) O 
by O 
using O 
poly(L-lactic B-SYSTEMATIC 
- I-SYSTEMATIC 
co I-SYSTEMATIC 
- I-SYSTEMATIC 
glycolic I-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PLGA B-ABBREVIATION 
) O 
and O 
alginate O 
. O 
Fluorescence O 
imaging O 
clearly O 
shows O 
the O 
C-S O 
domain O 
in O 
the O 
MC O 
. O 
For O 
release O 
control O 
, O 
the O 
use O 
of O 
high O 
- O 
molecular O 
- O 
weight O 
PLGA B-ABBREVIATION 
( O 
HMW O 
270 O 
0 O 
) O 
restrains O 
the O 
initial O 
burst O 
release O 
of O 
protein O 
compared O 
to O 
that O 
of O 
low-MW O 
PLGA B-ABBREVIATION 
( O 
LMW O 
40 O 
0 O 
) O 
. O 
Layer O 
- O 
by O 
- O 
layer O 
( O 
LBL O 
) O 
assembly O 
of O 
chitosan O 
and O 
alginate O 
on O 
MCs O 
is O 
also O 
useful O 
in O 
controlling O 
the O 
release O 
profile O 
of O 
biomolecules O 
. O 
LBL O 
( O 
7- O 
layer O 
) O 
treatment O 
is O 
effective O 
in O 
suppressing O 
the O 
initial O 
burst O 
release O 
of O 
protein O 
compared O 
to O 
no O 
LBL O 
( O 
0- O 
layer O 
) O 
. O 
The O 
difference O 
of O 
cumulative O 
albumin O 
release O 
between O 
HMW O 
( O 
7- O 
layer O 
LBL O 
) O 
and O 
LMW O 
( O 
0- O 
layer O 
LBL O 
) O 
PLGA B-ABBREVIATION 
is O 
determined O 
to O 
be O 
more O 
than O 
40% O 
on O 
day O 
5 O 
. O 
When O 
dual O 
angiogenic O 
growth O 
factors O 
( O 
GFs O 
) O 
, O 
such O 
as O 
platelet O 
- O 
derived O 
GF O 
( O 
PDGF O 
) O 
and O 
vascular O 
endothelial O 
GF O 
( O 
VEGF O 
) O 
, O 
are O 
encapsulated O 
separately O 
in O 
the O 
core O 
and O 
shell O 
domains O 
, O 
respectively O 
, O 
the O 
VEGF O 
release O 
rate O 
is O 
much O 
greater O 
than O 
that O 
of O 
PDGF O 
, O 
and O 
the O 
difference O 
of O 
the O 
cumulative O 
release O 
percentage O 
between O 
the O 
two O 
GFs O 
is O 
about O 
30% O 
on O 
day O 
7 O 
with O 
LMW O 
core O 
PLGA B-ABBREVIATION 
and O 
more O 
than O 
45% O 
with O 
HMW O 
core O 
PLGA B-ABBREVIATION 
. O 
As O 
for O 
the O 
angiogenic O 
potential O 
of O 
MC O 
GFs O 
with O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
( O 
HUVECs O 
) O 
, O 
the O 
fluorescence O 
signal O 
of O 
CD31+ O 
suggests O 
that O 
the O 
angiogenic O 
sprout O 
of O 
ECs O 
is O 
more O 
active O 
in O 
MC O 
- O 
mediated O 
GF O 
delivery O 
than O 
conventional O 
GF O 
delivery O 
, O 
and O 
this O 
difference O 
is O 
significant O 
, O 
based O 
on O 
the O 
number O 
of O 
capillary O 
branches O 
in O 
the O 
unit O 
area O 
. O 
This O 
study O 
demonstrates O 
that O 
the O 
fabrication O 
of O 
biocompatible O 
C-S O 
MCs O 
is O 
possible O 
, O 
and O 
that O 
the O 
release O 
control O 
of O 
biomolecules O 
is O 
adjustable O 
. O 
Furthermore O 
, O 
MC O 
- O 
mediated O 
GFs O 
remain O 
in O 
an O 
active O 
form O 
and O 
can O 
upregulate O 
the O 
angiogenic O 
activity O 
of O 
ECs O 
. O 

Matters O 
: O 
Enhanced O 
Bactericidal O 
Property O 
of O 
Core-Shell O 
Ag B-FORMULA 
- O 
Fe2 B-FORMULA 
O3 I-FORMULA 
Nanostructures O 
to O 
Their O 
Heteromer O 
Counterparts O 
from O 
One-Pot O 
Synthesis O 
. O 

facile O 
one O 
- O 
pot O 
synthesis O 
of O 
Ag B-FORMULA 
@ O 
Fe2 B-FORMULA 
O3 I-FORMULA 
core O 
- O 
shell O 
and O 
Ag B-FORMULA 
- O 
Fe2 B-FORMULA 
O3 I-FORMULA 
heteromer O 
nanoparticles O 
is O 
developed O 
, O 
and O 
the O 
core O 
- O 
shell O 
nanoparticles O 
have O 
shown O 
superior O 
antibacterial O 
properties O 
compared O 
to O 
their O 
heteromer O 
counterparts O 
and O 
plain O 
Ag B-FORMULA 
nanoparticles O 
. O 
The O 
mechanism O 
for O 
the O 
increased O 
efficiency O 
is O 
proposed O 
to O 
be O 
due O 
to O 
the O 
enhanced O 
Ag B-FORMULA 
ion O 
release O 
from O 
the O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
shell O 
- O 
protected O 
pristine O 
Ag B-FORMULA 
surface O 
. O 

Interfacial O 
Dynamics O 
of O 
Ni B-FORMULA 
Nanoparticles O 
: O 
Part O 
II O 
Discrete O 
Breathers O 
as O 
an O 
Explanation O 
of O 
Two-Level O 
Energy O 
Fluctuations O 
. O 

studies O 
of O 
the O 
dynamics O 
of O 
diverse O 
condensed O 
amorphous O 
materials O 
have O 
indicated O 
significant O 
heterogeneity O 
in O 
the O 
local O 
mobility O 
and O 
a O 
progressive O 
increase O 
in O 
collective O 
particle O 
motion O 
upon O 
cooling O 
that O 
takes O 
the O 
form O 
of O 
string O 
- O 
like O 
particle O 
rearrangements O 
. O 
In O 
a O 
previous O 
paper O 
( O 
Part O 
I O 
) O 
, O 
we O 
examined O 
the O 
possibility O 
that O 
fluctuations O 
in O 
potential O 
energy O 
E O 
and O 
particle O 
mobility O 
μ O 
associated O 
with O 
this O 
' O 
dynamic O 
heterogeneity O 
' O 
might O 
offer O 
information O 
about O 
the O 
scale O 
of O 
collective O 
motion O 
in O 
glassy O 
materials O 
based O 
on O 
molecular O 
dynamics O 
simulations O 
of O 
the O 
glassy O 
interfacial O 
region O 
of O 
Ni B-FORMULA 
nanoparticles O 
( O 
NPs O 
) O 
at O 
elevated O 
temperatures O 
. O 
We O 
found O 
that O 
the O 
noise O 
exponent O 
associated O 
with O 
fluctuations O 
in O 
the O 
Debye-Waller O 
factor O 
, O 
a O 
mobility O 
related O 
quantity O 
, O 
was O 
directly O 
proportional O 
to O 
the O 
scale O 
of O 
collective O 
motion O 
L O 
under O 
a O 
broad O 
range O 
of O 
conditions O 
, O 
but O 
the O 
noise O 
exponent O 
associated O 
with O 
E(t) O 
fluctuations O 
was O 
seemingly O 
unrelated O 
to O 
L O 
. O 
In O 
the O 
present O 
work O 
, O 
we O 
focus O 
on O 
this O 
unanticipated O 
difference O 
between O 
potential O 
energy O 
and O 
mobility O 
fluctuations O 
by O 
examining O 
these O 
quantities O 
at O 
an O 
atomic O 
scale O 
. O 
We O 
find O 
that O 
the O 
string O 
atoms O 
exhibit O 
a O 
jump O 
- O 
like O 
motion O 
between O 
two O 
well O 
- O 
separated O 
bands O 
of O 
energy O 
states O 
and O 
the O 
rate O 
at O 
which O 
these O 
jumps O 
occur O 
seems O 
to O 
be O 
consistent O 
with O 
the O 
phenomenology O 
of O 
the O 
' O 
slow O 
- O 
beta O 
' O 
relaxation O 
process O 
of O 
glass O 
- O 
forming O 
liquids O 
. O 
Concurrently O 
with O 
these O 
local O 
E(t) O 
jumps O 
, O 
we O 
also O 
find O 
' O 
quake O 
- O 
like O 
' O 
particle O 
displacements O 
having O 
a O 
power O 
- O 
law O 
distribution O 
in O 
magnitude O 
so O 
that O 
particle O 
displacement O 
fluctuations O 
within O 
the O 
strings O 
are O 
strikingly O 
different O 
from O 
local O 
E(t) O 
fluctuations O 
. O 
An O 
analysis O 
of O 
these O 
E(t) O 
fluctuations O 
suggests O 
that O 
we O 
are O 
dealing O 
with O 
' O 
discrete O 
breather O 
' O 
excitations O 
in O 
which O 
large O 
energy O 
fluctuations O 
develop O 
in O 
arrays O 
of O 
non-linear O 
oscillators O 
by O 
virtue O 
of O 
large O 
anharmonicity O 
in O 
the O 
interparticle O 
interactions O 
and O 
discreteness O 
effects O 
associated O 
with O 
particle O 
packing O 
. O 
We O 
quantify O 
string O 
collective O 
motions O 
on O 
a O 
fast O 
caging O 
times O 
scale O 
( O 
picoseconds O 
) O 
and O 
explore O 
the O 
significance O 
of O 
these O 
collective O 
motions O 
for O 
understanding O 
the O 
Boson O 
peak O 
of O 
glass O 
- O 
forming O 
materials O 
. O 

the O 
Emission O 
Properties O 
of O 
Fluorescent O 
Ligands O 
by O 
Changing O 
pH O 
: O 
The O 
Unusual O 
Case O 
of O 
an O 
Acridine B-TRIVIAL 
-Containing O 
Polyamine O 
Macrocycle O 
. O 

and O 
characterization O 
of O 
a O 
new O 
macrocyclic O 
compound O 
, O 
composed O 
by O 
a O 
triethylentetraamine B-SYSTEMATIC 
chain O 
linking O 
the O 
4 O 
and O 
5 O 
positions O 
of O 
an O 
acridine B-TRIVIAL 
moiety O 
, O 
are O 
reported O 
. O 
The O 
molecule O 
, O 
devised O 
as O 
a O 
fluorescent O 
chemosensor O 
for O 
anions O 
, O 
has O 
revealed O 
an O 
intriguing O 
pH-dependent O 
spectroscopic O 
behavior O 
, O 
whose O 
features O 
are O 
the O 
specific O 
object O 
of O 
this O 
article O 
. O 
Ligand O 
protonation O 
in O 
aqueous O 
solution O 
has O 
been O 
analyzed O 
by O 
means O 
of O 
potentiometric O 
, O 
(1)H B-FORMULA 
NMR O 
, O 
UV-vis O 
, O 
and O 
fluorescence O 
emission O 
measurements O 
. O 
The O 
molecule O 
binds O 
up O 
to O 
four O 
protons O 
in O 
the O 
pH O 
range O 
2-11 O 
. O 
Protonation O 
takes O 
place O 
on O 
the O 
aliphatic O 
tetraamine B-SYSTEMATIC 
chain O 
, O 
while O 
the O 
acridine B-TRIVIAL 
nitrogen B-SYSTEMATIC 
does O 
not O 
participate O 
to O 
proton O 
binding O 
even O 
at O 
very O 
low O 
pH O 
. O 
Differently O 
from O 
acridine B-TRIVIAL 
, O 
the O 
UV-vis O 
spectra O 
are O 
almost O 
unaffected O 
by O 
the O 
pH O 
. O 
On O 
the O 
opposite O 
, O 
the O 
emission O 
spectra O 
are O 
strongly O 
pH-dependent O 
. O 
In O 
fact O 
, O 
at O 
low O 
pH O 
values O 
, O 
the O 
spectra O 
show O 
a O 
blue O 
- O 
shifted O 
emission O 
, O 
resembling O 
that O 
of O 
unprotonated O 
acridine O 
, O 
while O 
at O 
slightly O 
acidic O 
and O 
alkaline O 
pH O 
the O 
fluorescence O 
features O 
a O 
red O 
- O 
shifted O 
band O 
similar O 
to O 
that O 
of O 
acridinium B-SYSTEMATIC 
cation O 
. O 
This O 
unusual O 
behavior O 
occurs O 
in O 
the O 
mono- O 
, O 
bi- O 
, O 
and O 
triprotonated O 
forms O 
of O 
the O 
compound O 
and O 
is O 
interpreted O 
as O 
due O 
to O 
an O 
excited O 
state O 
proton O 
transfer O 
from O 
an O 
aliphatic B-FAMILY 
ammonium I-FAMILY 
group O 
adjacent O 
to O 
the O 
acridine B-TRIVIAL 
moiety O 
to O 
the O 
acridine B-TRIVIAL 
nitrogen B-SYSTEMATIC 
. O 
In O 
the O 
fully O 
protonated O 
state O 
, O 
this O 
process O 
is O 
prevented O 
owing O 
to O 
unfavorable O 
molecular O 
arrangements O 
mainly O 
determined O 
by O 
electrostatic O 
repulsions O 
. O 
This O 
interpretation O 
is O 
supported O 
by O 
quantum O 
mechanical O 
calculations O 
as O 
well O 
as O 
molecular O 
dynamics O 
simulations O 
. O 

- O 
dimensional O 
micelles O 
formed O 
by O 
the O 
self O 
- O 
assembly O 
of O 
crystalline O 
- O 
coil O 
poly(ferrocenyldimethylsilane) B-SYSTEMATIC 
( O 
PFS B-ABBREVIATION 
) O 
block O 
copolymers O 
exhibit O 
self O 
- O 
seeding O 
behavior O 
when O 
solutions O 
of O 
short O 
micelle O 
fragments O 
are O 
heated O 
above O 
a O 
certain O 
temperature O 
and O 
then O 
cooled O 
back O 
to O 
room O 
temperature O 
. O 
In O 
this O 
process O 
, O 
a O 
fraction O 
of O 
the O 
fragments O 
( O 
the O 
least O 
crystalline O 
fragments O 
) O 
dissolves O 
at O 
elevated O 
temperature O 
, O 
but O 
the O 
dissolved O 
polymer O 
crystallizes O 
onto O 
the O 
ends O 
of O 
the O 
remaining O 
seed O 
fragments O 
upon O 
cooling O 
. O 
This O 
process O 
yields O 
longer O 
nanostructures O 
( O 
up O 
to O 
1 O 
μm O 
) O 
with O 
uniform O 
width O 
( O 
ca O 
. O 
15 O 
nm O 
) O 
and O 
a O 
narrow O 
length O 
distribution O 
. O 
In O 
this O 
paper O 
, O 
we O 
describe O 
a O 
systematic O 
investigation O 
of O 
factors O 
that O 
affect O 
the O 
self O 
- O 
seeding O 
behavior O 
of O 
PFS B-ABBREVIATION 
block O 
copolymer O 
micelle O 
fragments O 
. O 
For O 
PI1000-PFS50 O 
( O 
the O 
subscripts O 
refer O 
to O 
the O 
number O 
average O 
degree O 
of O 
polymerization O 
) O 
in O 
decane B-SYSTEMATIC 
, O 
these O 
factors O 
include O 
the O 
presence O 
of O 
a O 
good O 
solvent O 
( O 
THF B-ABBREVIATION 
) O 
for O 
PFS B-ABBREVIATION 
and O 
the O 
effect O 
of O 
annealing O 
the O 
fragments O 
prior O 
to O 
the O 
self O 
- O 
seeding O 
experiments O 
. O 
THF B-ABBREVIATION 
promoted O 
the O 
dissolution O 
of O 
the O 
micelle O 
fragments O 
, O 
while O 
preannealing O 
improved O 
their O 
stability O 
. O 
We O 
also O 
extended O 
our O 
experiments O 
to O 
other O 
PFS B-ABBREVIATION 
block O 
copolymers O 
with O 
different O 
corona O 
- O 
forming O 
blocks O 
. O 
These O 
included O 
PI637-PFS53 O 
in O 
decane O 
, O 
PFS60-PDMS660 O 
in O 
decane O 
( O 
PDMS B-ABBREVIATION 
= O 
polydimethylsiloxane B-SYSTEMATIC 
) O 
, O 
and O 
PFS30-P2VP300 O 
in O 
2-propanol B-SYSTEMATIC 
( O 
P2VP B-ABBREVIATION 
= O 
poly(2-vinylpyridine B-SYSTEMATIC 
) O 
) O 
. O 
The O 
most O 
remarkable O 
result O 
of O 
these O 
experiments O 
is O 
our O 
finding O 
that O 
the O 
corona O 
- O 
forming O 
chain O 
plays O 
an O 
important O 
role O 
in O 
affecting O 
how O 
the O 
PFS B-ABBREVIATION 
chains O 
crystallize O 
in O 
the O 
core O 
of O 
the O 
micelles O 
and O 
, O 
subsequently O 
, O 
the O 
range O 
of O 
temperatures O 
over O 
which O 
the O 
micelle O 
fragments O 
dissolve O 
. O 
Our O 
results O 
also O 
show O 
that O 
self O 
- O 
seeding O 
is O 
a O 
versatile O 
approach O 
to O 
generate O 
uniform O 
PFS B-ABBREVIATION 
fiber O 
- O 
like O 
nanostructures O 
, O 
and O 
in O 
principle O 
, O 
the O 
method O 
should O 
be O 
extendable O 
to O 
a O 
wide O 
variety O 
of O 
crystalline O 
- O 
coil O 
block O 
copolymers O 
. O 

and O 
Mechanism O 
of O 
the O 
Tropospheric O 
Oxidation O 
of O 
Vinyl B-SYSTEMATIC 
Acetate I-SYSTEMATIC 
Initiated O 
by O 
OH B-FORMULA 
Radical O 
: O 
A O 
Theoretical O 
Study O 
. O 

acetate I-SYSTEMATIC 
[ O 
VA O 
( O 
CH3COOC2H3 B-FORMULA 
) O 
] O 
is O 
an O 
important O 
unsaturated O 
and O 
oxygenated O 
volatile O 
organic O 
compound O 
responsible O 
for O 
atmospheric O 
pollution O 
. O 
In O 
this O 
work O 
, O 
possible O 
reaction O 
mechanisms O 
for O 
the O 
degradation O 
of O 
OH B-FORMULA 
-initiated O 
atmospheric O 
oxidation O 
of O 
VA O 
are O 
investigated O 
. O 
The O 
potential O 
energy O 
surfaces O 
( O 
PESs O 
) O 
for O 
the O 
reaction O 
of O 
OH B-FORMULA 
radical O 
with O 
VA O 
in O 
the O 
presence O 
of O 
O2 B-FORMULA 
and O 
NO B-FORMULA 
have O 
been O 
studied O 
using O 
the O 
M06-2X O 
/ O 
6-311 O 
+ O 
+ O 
G(d,p) O 
method O 
. O 
The O 
initial O 
addition O 
reactions O 
of O 
more O 
and O 
less O 
substituted O 
ethylenic B-SYSTEMATIC 
C B-FORMULA 
-atoms O 
of O 
VA O 
are O 
treated O 
separately O 
, O 
followed O 
by O 
a O 
conventional O 
transition O 
state O 
theory O 
( O 
TST O 
) O 
calculation O 
for O 
reaction O 
rates O 
. O 
The O 
direct O 
H B-FORMULA 
-abstraction O 
mechanism O 
and O 
kinetics O 
have O 
also O 
been O 
studied O 
. O 
The O 
initial O 
OH B-FORMULA 
addition O 
occurs O 
through O 
a O 
prereactive O 
complex O 
, O 
and O 
the O 
calculated O 
rate O 
constants O 
in O 
the O 
temperature O 
range O 
250-350 O 
K O 
for O 
both O 
the O 
addition O 
reactions O 
are O 
found O 
to O 
have O 
negative O 
temperature O 
dependence O 
. O 
The O 
calculation O 
indicates O 
that O 
the O 
reaction O 
proceeds O 
predominantly O 
via O 
the O 
addition O 
of O 
OH B-FORMULA 
radical O 
to O 
the O 
double O 
bond O 
rather O 
than O 
the O 
direct O 
abstraction O 
of O 
H B-FORMULA 
-atoms O 
in O 
VA O 
. O 
IM1 O 
[ O 
CH3C(O)O(•)CHCH2OH B-FORMULA 
] O 
and O 
IM2 O 
[ O 
CH3C(O)OCH(OH)(•)CH2 B-FORMULA 
] O 
, O 
the O 
OH B-FORMULA 
adduct O 
complexes O 
formed O 
initially O 
, O 
react O 
with O 
ubiquitous O 
O2 B-FORMULA 
followed O 
by O 
NO B-FORMULA 
before O 
their O 
rearrangement O 
. O 
The O 
formation O 
of O 
the O 
prereactive O 
complex O 
plays O 
an O 
important O 
role O 
in O 
reaction O 
mechanism O 
and O 
kinetics O 
. O 
The O 
calculated O 
rate O 
constant O 
, O 
k298K O 
= O 
1.61 O 
× O 
10(-11) O 
cm(3) O 
molecule(-1) O 
s(-1) O 
, O 
is O 
well O 
harmonized O 
with O 
the O 
previous O 
experimental O 
data O 
, O 
k298K O 
= O 
( O 
2.48 O 
± O 
0.61 O 
) O 
× O 
10(-11) O 
cm(3) O 
molecule(-1) O 
s(-1) O 
( O 
Blanco O 
et O 
al O 
. O 
) O 
and O 
k298K O 
= O 
( O 
2.3 O 
± O 
0.3 O 
) O 
× O 
10(-11) O 
cm(3) O 
molecule(-1) O 
s(-1) O 
( O 
Picquet-Varrult O 
et O 
al O 
. O 
) O 
. O 
Additionally O 
, O 
consistent O 
and O 
reliable O 
enthalpies O 
of O 
formation O 
at O 
298.15 O 
K O 
( O 
ΔfH°298.15 O 
) O 
have O 
been O 
computed O 
for O 
all O 
the O 
species O 
involved O 
in O 
the O 
title O 
reaction O 
using O 
the O 
composite O 
CBS-QB3 O 
method O 
. O 
The O 
theoretical O 
results O 
confirm O 
that O 
the O 
major O 
products O 
are O 
formic B-SYSTEMATIC 
acetic I-SYSTEMATIC 
anhydride I-SYSTEMATIC 
, O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
formaldehyde B-SYSTEMATIC 
in O 
the O 
OH B-FORMULA 
-initiated O 
oxidation O 
of O 
VA O 
in O 
the O 
presence O 
of O 
O2 B-FORMULA 
and O 
NO B-FORMULA 
, O 
which O 
are O 
in O 
excellent O 
agreement O 
with O 
the O 
experimental O 
findings O 
. O 

of O 
the O 
Dehydrogenation O 
Products O 
of O 
Methane B-SYSTEMATIC 
Activation O 
by O 
5d O 
Transition B-FAMILY 
Metal I-FAMILY 
Cations O 
. O 

activation O 
of O 
methane B-SYSTEMATIC 
by O 
gas-phase O 
transition B-FAMILY 
metal I-FAMILY 
cations O 
( O 
M+ O 
) O 
has O 
been O 
studied O 
extensively O 
, O 
both O 
experimentally O 
and O 
using O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
. O 
Methane B-SYSTEMATIC 
is O 
exothermically O 
dehydrogenated O 
by O 
several O 
5d O 
metal O 
ions O 
to O 
form O 
[ O 
M O 
, O 
C B-FORMULA 
, O 
2H B-FORMULA 
]+ O 
and O 
H2 B-FORMULA 
. O 
However O 
, O 
the O 
structure O 
of O 
the O 
dehydrogenation O 
product O 
has O 
not O 
been O 
established O 
unambiguously O 
. O 
Two O 
types O 
of O 
structures O 
have O 
been O 
considered O 
: O 
a O 
carbene B-FAMILY 
structure O 
where O 
an O 
intact O 
CH2 B-FORMULA 
fragment O 
is O 
bound O 
to O 
the O 
metal O 
( O 
M+- O 
CH2 B-FORMULA 
) O 
and O 
a O 
carbyne B-FAMILY 
( O 
hydrido B-SYSTEMATIC 
- I-SYSTEMATIC 
methylidyne I-SYSTEMATIC 
) O 
structure O 
with O 
both O 
a O 
CH B-FORMULA 
and O 
a O 
hydrogen B-SYSTEMATIC 
bound O 
to O 
the O 
metal O 
separately O 
( O 
H B-FORMULA 
-M+- O 
CH B-FORMULA 
) O 
. O 
For O 
metal O 
ions O 
with O 
empty O 
d-orbitals O 
, O 
an O 
agostic O 
interaction O 
can O 
occur O 
that O 
could O 
influence O 
the O 
competition O 
between O 
carbene B-FAMILY 
and O 
carbyne B-FAMILY 
structures O 
. O 
In O 
this O 
work O 
, O 
the O 
gas O 
phase O 
[ O 
M O 
, O 
C B-FORMULA 
, O 
2H B-FORMULA 
]+ O 
( O 
M O 
= O 
Ta B-FORMULA 
, O 
W B-FORMULA 
, O 
Ir B-FORMULA 
, O 
Pt B-FORMULA 
) O 
products O 
are O 
investigated O 
by O 
infrared O 
multiple O 
- O 
photon O 
dissociation O 
( O 
IR-MPD O 
) O 
spectroscopy O 
using O 
the O 
Free O 
Electron O 
Laser O 
for O 
IntraCavity O 
Experiments O 
( O 
FELICE O 
) O 
. O 
Metal O 
cations O 
are O 
formed O 
in O 
a O 
laser O 
ablation O 
source O 
and O 
react O 
with O 
methane O 
pulsed O 
into O 
a O 
reaction O 
channel O 
downstream O 
. O 
IRMPD O 
spectra O 
of O 
the O 
[ O 
M O 
, O 
C B-FORMULA 
, O 
2H B-FORMULA 
]+ O 
species O 
are O 
measured O 
in O 
the O 
300 O 
- O 
3500 O 
cm-1 O 
spectral O 
range O 
by O 
monitoring O 
the O 
loss O 
of O 
H B-FORMULA 
( O 
2H B-FORMULA 
in O 
the O 
case O 
of O 
[ O 
Ir B-FORMULA 
, O 
C B-FORMULA 
, O 
2H B-FORMULA 
]+ O 
) O 
. O 
For O 
each O 
system O 
, O 
the O 
experimental O 
spectrum O 
closely O 
resembles O 
the O 
calculated O 
spectrum O 
of O 
the O 
lowest O 
energy O 
structure O 
calculated O 
using O 
DFT O 
: O 
for O 
Pt B-FORMULA 
, O 
a O 
classic O 
C2v O 
carbene B-FAMILY 
structure O 
; O 
for O 
Ta B-FORMULA 
and O 
W B-FORMULA 
, O 
carbene B-FAMILY 
structures O 
that O 
are O 
distorted O 
by O 
agostic O 
interactions O 
; O 
and O 
a O 
carbyne B-FAMILY 
structure O 
for O 
the O 
Ir B-FORMULA 
complex O 
. O 
The O 
Ir B-FORMULA 
carbyne B-FAMILY 
structure O 
was O 
not O 
considered O 
previously O 
. O 
To O 
obtain O 
this O 
agreement O 
, O 
the O 
calculated O 
harmonic O 
frequencies O 
are O 
scaled O 
with O 
a O 
scaling O 
factor O 
of O 
0.939 O 
, O 
which O 
is O 
fairly O 
low O 
and O 
can O 
be O 
attributed O 
to O 
the O 
strong O 
redshift O 
induced O 
by O 
the O 
IR O 
multiple O 
- O 
photon O 
excitation O 
process O 
of O 
these O 
small O 
molecules O 
. O 
These O 
four O 
- O 
atomic O 
species O 
are O 
among O 
the O 
smallest O 
systems O 
studied O 
by O 
IR-FEL O 
based O 
IR-MPD O 
spectroscopy O 
and O 
their O 
spectra O 
demonstrate O 
the O 
power O 
of O 
IR O 
spectroscopy O 
in O 
resolving O 
long O 
- O 
standing O 
chemical O 
questions O 
. O 

of O 
a O 
Cross-Link O 
Formed O 
by O 
a O 
Major O 
Purine B-TRIVIAL 
Adduct O 
of O 
a O 
Metabolite O 
of O 
the O 
Carcinogen O 
N-Nitrosomorpholine B-SYSTEMATIC 
by O 
Inorganic O 
and O 
Biological O 
Reductants O 
. O 

in O 
buffered O 
aqueous O 
media O 
in O 
the O 
presence O 
of O 
calf O 
thymus O 
DNA O 
was O 
treated O 
with O 
a O 
phosphine O 
reductant O 
to O 
generate O 
the O 
transient O 
α-hydroxynitrosamine B-SYSTEMATIC 
and O 
subsequent O 
diazonium B-SYSTEMATIC 
ion O 
that O 
alkylated O 
the O 
DNA O 
, O 
as O 
previously O 
reported O 
. O 
Subsequent O 
addition O 
of O 
hydride B-SYSTEMATIC 
donors O 
, O 
for O 
30 O 
min O 
, O 
followed O 
by O 
acid O 
hydrolysis O 
of O 
the O 
mixture O 
allowed O 
detection O 
and O 
quantification O 
of O 
6-(2-{2-[(9H-purin-6-yl)amino]ethoxy}ethoxy)-9H-purin-2-amine B-SYSTEMATIC 
, O 
the O 
reduced O 
cross O 
- O 
link O 
formed O 
from O 
deposition O 
, O 
via O 
the O 
diazonium B-SYSTEMATIC 
ion O 
, O 
of O 
a O 
3-oxapentanal B-SYSTEMATIC 
fragment O 
on O 
O B-FORMULA 
(6)- O 
Gua B-ABBREVIATION 
, O 
and O 
condensation O 
with O 
N B-FORMULA 
(6)- O 
Ade B-ABBREVIATION 
, O 
presumably O 
in O 
the O 
vicinity O 
. O 
Decreasing O 
the O 
temperature O 
of O 
the O 
reaction O 
mixtures O 
and O 
decreasing O 
the O 
pH O 
modestly O 
increased O 
the O 
yields O 
of O 
the O 
trapped O 
cross O 
- O 
link O 
. O 
Among O 
three O 
borohydride B-SYSTEMATIC 
reductants O 
, O 
NaNCBH3 B-FORMULA 
is O 
superior O 
, O 
being O 
∼4 O 
times O 
more O 
effective O 
on O 
a O 
molar O 
basis O 
, O 
as O 
opposed O 
to O 
a O 
hydride B-SYSTEMATIC 
equivalent O 
basis O 
, O 
than O 
NaBH4 B-FORMULA 
or O 
Na(AcO)3BH B-FORMULA 
. O 
For O 
trapping O 
with O 
NaNCBH3 B-FORMULA 
, O 
it O 
is O 
deduced O 
that O 
the O 
reaction O 
likely O 
occurs O 
with O 
the O 
iminium B-SYSTEMATIC 
ion O 
that O 
is O 
in O 
protonic O 
equilibrium O 
with O 
its O 
conjugate O 
base O 
imine B-SYSTEMATIC 
. O 
In O 
an O 
experiment O 
in O 
which O 
the O 
hydroperoxide B-FAMILY 
was O 
decomposed O 
and O 
NaNCBH3 B-FORMULA 
was O 
introduced O 
after O 
various O 
periods O 
of O 
time O 
, O 
the O 
amount O 
of O 
cross O 
- O 
link O 
was O 
observed O 
to O 
increase O 
, O 
nearly O 
linearly O 
, O 
by O 
∼4-fold O 
over O 
1 O 
week O 
. O 
These O 
data O 
indicate O 
that O 
there O 
are O 
a O 
minimum O 
of O 
two O 
populations O 
of O 
cross O 
- O 
links O 
, O 
one O 
that O 
forms O 
rapidly O 
, O 
in O 
minutes O 
, O 
and O 
another O 
that O 
grows O 
in O 
with O 
time O 
, O 
over O 
days O 
. O 
Reduced O 
nicotinamide B-TRIVIAL 
cofactors O 
and O 
ascorbate B-TRIVIAL 
are O 
observed O 
to O 
effect O 
reduction O 
( O 
over O 
3 O 
days O 
) O 
of O 
the O 
cross O 
- O 
links O 
, O 
confirming O 
the O 
possibility O 
that O 
otherwise O 
reversible O 
cross O 
- O 
links O 
might O 
be O 
immortalized O 
under O 
biological O 
conditions O 
. O 

histone O 
acetyltransferase O 
Rtt109 O 
is O 
the O 
sole O 
enzyme O 
responsible O 
for O 
acetylation O 
of O 
histone O 
H3 O 
lysine B-TRIVIAL 
56 O 
( O 
H3K56 O 
) O 
in O 
fungal O 
organisms O 
. O 
Loss O 
of O 
Rtt109 O 
renders O 
fungal O 
cells O 
extremely O 
sensitive O 
to O 
genotoxic O 
agents O 
, O 
and O 
prevents O 
pathogenesis O 
in O 
several O 
clinically O 
important O 
species O 
. O 
Here O 
, O 
via O 
a O 
high O 
throughput O 
chemical O 
screen O 
of O 
> O 
300000 O 
compounds O 
, O 
we O 
discovered O 
a O 
chemical O 
inhibitor O 
of O 
Rtt109 O 
that O 
does O 
not O 
inhibit O 
other O 
acetyltransferase O 
enzymes O 
. O 
This O 
compound O 
inhibits O 
Rtt109 O 
regardless O 
of O 
which O 
histone O 
chaperone O 
cofactor O 
protein O 
( O 
Asf1 O 
or O 
Vps75 O 
) O 
is O 
present O 
, O 
and O 
appears O 
to O 
inhibit O 
Rtt109 O 
via O 
a O 
tight O 
- O 
binding O 
, O 
uncompetitive O 
mechanism O 
. O 

and O 
antimicrobial O 
activity O 
of O 
novel O 
amphiphilic O 
aromatic B-FAMILY 
amino I-FAMILY 
alcohols I-FAMILY 
. O 

report O 
in O 
this O 
work O 
the O 
preparation O 
and O 
in O 
vitro O 
antimicrobial O 
evaluation O 
of O 
novel O 
amphiphilic O 
aromatic B-FAMILY 
amino I-FAMILY 
alcohols I-FAMILY 
synthesized O 
by O 
reductive O 
amination O 
of O 
4-alkyloxybenzaldehyde B-FAMILY 
with O 
2-amino-2-hydroxymethyl-propane-1,3-diol B-SYSTEMATIC 
. O 
The O 
antibacterial O 
activity O 
was O 
determined O 
against O 
four O 
standard O 
strains O 
( O 
Staphylococcus O 
aureus O 
, O 
Staphylococcus O 
epidermidis O 
, O 
Escherichia O 
coli O 
, O 
Pseudomonas O 
aeruginosa O 
) O 
and O 
21 O 
clinical O 
isolates O 
of O 
methicillin B-TRIVIAL 
-resistant O 
Staphylococcus O 
aureus O 
. O 
The O 
antifungal O 
activity O 
was O 
evaluated O 
against O 
four O 
yeast O 
( O 
Candida O 
albicans O 
, O 
Candida O 
tropicalis O 
, O 
Candida O 
glabrata O 
and O 
Candida O 
parapsilosis O 
) O 
. O 
The O 
results O 
obtained O 
showed O 
a O 
strong O 
positive O 
correlation O 
between O 
the O 
lipophilicity O 
and O 
the O 
antibiotic O 
activity O 
of O 
the O 
tested O 
compounds O 
. O 
The O 
best O 
activities O 
were O 
obtained O 
against O 
the O 
Gram O 
- O 
positive O 
bacteria O 
(MIC=2-16μgml(-1)) O 
for O 
the O 
five O 
compounds O 
bearing O 
longer O 
alkyl O 
chains O 
( O 
4c-g O 
; O 
8-14 O 
carbons O 
) O 
, O 
which O 
were O 
also O 
the O 
most O 
active O 
against O 
Candida O 
(MIC=2-64μgml(-1)) O 
. O 
Compound O 
4e O 
exhibited O 
the O 
highest O 
levels O 
of O 
inhibitory O 
activity O 
(MIC=2-16μgml(-1)) O 
against O 
clinical O 
isolates O 
of O 
MRSA O 
. O 
A O 
concentration O 
of O 
twice O 
the O 
MIC O 
resulted O 
in O 
bactericidal O 
activity O 
of O 
4d O 
against O 
19 O 
of O 
the O 
21 O 
clinical O 
isolates O 
. O 

of O 
Korean O 
pear O 
( O 
Pyruspyrifolia O 
cv O 
. O 
Shingo O 
) O 
juice O 
on O 
hangover O 
severity O 
following O 
alcohol B-FAMILY 
consumption O 
. O 

pear O 
has O 
been O 
used O 
as O 
a O 
traditional O 
prophylactic O 
agent O 
for O 
alcohol B-FAMILY 
hangover O 
. O 
However O 
, O 
its O 
mechanism O 
was O 
not O 
investigated O 
in O 
human O 
yet O 
. O 
Therefore O 
, O 
we O 
performed O 
a O 
randomized O 
single O 
blind O 
crossover O 
trial O 
with O 
14 O 
healthy O 
young O 
men O 
to O 
examine O 
effects O 
of O 
Korean O 
pear O 
juice O 
on O 
alcohol B-FAMILY 
hangover O 
. O 
All O 
subjects O 
consumed O 
540ml O 
of O 
spirits O 
( O 
alcohol B-FAMILY 
conc O 
. O 
20.1v O 
/ O 
v% O 
) O 
after O 
30min O 
from O 
the O 
intervention O 
, O 
i.e O 
. O 
placebo O 
or O 
Korean O 
pear O 
juice O 
treatment O 
. O 
Blood O 
and O 
urine O 
specimens O 
were O 
collected O 
in O 
time O 
- O 
courses O 
( O 
9 O 
time O 
- O 
points O 
for O 
15h O 
after O 
alcohol B-FAMILY 
consumption O 
) O 
. O 
The O 
total O 
and O 
average O 
of O 
hangover O 
severity O 
were O 
alleviated O 
to O 
16% O 
and O 
21% O 
by O 
Korean O 
pear O 
juice O 
at O 
15h O 
after O 
the O 
alcohol O 
consumption O 
( O 
ps O 
< O 
0.05 O 
) O 
. O 
Particularly O 
, O 
' O 
trouble O 
concentrating O 
' O 
was O 
significantly O 
improved O 
by O 
the O 
pear O 
juice O 
treatment O 
( O 
p O 
< O 
0.05 O 
) O 
. O 
Impaired O 
memory O 
, O 
sensitivity O 
to O 
light O 
and O 
sound O 
, O 
and O 
mean O 
of O 
hangover O 
severity O 
were O 
significantly O 
improved O 
by O 
Korean O 
pear O 
juice O 
among O 
the O 
subjects O 
with O 
ALDH2*1 O 
/ O 
*1 O 
or O 
ALDH2*1 O 
/ O 
*2 O 
genotypes O 
( O 
ps O 
< O 
0.05 O 
) O 
but O 
not O 
in O 
the O 
subjects O 
with O 
ALDH2*2 O 
/ O 
*2 O 
genotype O 
. O 
In O 
addition O 
, O 
the O 
pear O 
juice O 
treatment O 
lowered O 
levels O 
of O 
blood O 
alcohol B-FAMILY 
( O 
p O 
< O 
0.01 O 
) O 
. O 
Therefore O 
, O 
Korean O 
pear O 
juice O 
may O 
alleviate O 
alcohol O 
- O 
hangover O 
and O 
its O 
detoxification O 
of O 
alcohol B-FAMILY 
seems O 
to O 
be O 
modified O 
by O 
the O 
genetic O 
variation O 
of O 
ALDH2 O 
. O 

RELEVANCE O 
: O 
Artemisia O 
copa O 
Phil O 
. O 
( O 
Asteraceae O 
) O 
is O 
a O 
medicinal O 
plant O 
commonly O 
used O 
in O 
traditional O 
medicine O 
in O 
Argentina O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
vasorelaxant O 
and O 
hypotensive O 
activities O 
of O 
the O 
aqueous O 
extract O 
of O 
Artemisia O 
copa O 
have O 
been O 
investigated O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
in O 
vitro O 
effect O 
of O 
the O 
extract O 
and O 
isolated O 
compounds O 
from O 
Artemisia O 
copa O 
was O 
investigated O 
using O 
isolated O 
rat O 
aortic O 
rings O 
. O 
The O 
acute O 
effect O 
caused O 
by O 
the O 
intravenous O 
( O 
i.v O 
. O 
) O 
infusion O 
( O 
0.1-300mg O 
/ O 
kg O 
) O 
on O 
blood O 
pressure O 
and O 
heart O 
rate O 
was O 
evaluated O 
in O 
spontaneous O 
hypertensive O 
rats O 
. O 
In O 
addition O 
, O 
a O 
phytochemical O 
analysis O 
of O 
the O 
extract O 
was O 
performed O 
by O 
HPLC O 
. O 
RESULTS O 
: O 
Artemisia O 
copa O 
had O 
a O 
relaxant O 
effect O 
in O 
endothelium O 
- O 
intact O 
aortic O 
rings O 
that O 
had O 
been O 
pre O 
- O 
contracted O 
with O 
10(-7)M O 
phenylephrine B-TRIVIAL 
( O 
Emax=96.7±1.3% O 
, O 
EC50=1.1mg O 
/ O 
ml O 
) O 
, O 
10(-5)M O 
5-hydroxytriptamine B-SYSTEMATIC 
( O 
Emax=96.7±3.5% O 
, O 
EC50=1.5mg O 
/ O 
ml O 
) O 
and O 
80mM O 
KCl B-FORMULA 
( O 
Emax=97.9± O 
4.4% O 
, O 
EC50=1.6mg O 
/ O 
ml O 
) O 
. O 
In O 
denuded O 
aortic O 
rings O 
contracted O 
by O 
phenylephrine B-TRIVIAL 
, O 
a O 
similar O 
pattern O 
was O 
observed O 
( O 
Emax=92.7±6.5% O 
, O 
EC50=1.8mg O 
/ O 
ml O 
) O 
. O 
l-NAME B-ABBREVIATION 
, O 
indomethacin B-TRIVIAL 
, O 
tetraethylammonium B-SYSTEMATIC 
and O 
glibenclamide B-TRIVIAL 
were O 
not O 
able O 
to O 
block O 
the O 
relaxation O 
induced O 
by O 
the O 
extract O 
. O 
Nevertheless O 
, O 
the O 
pre O 
- O 
treatment O 
with O 
Artemisia O 
copa O 
attenuated O 
the O 
CaCl2 B-FORMULA 
-induced O 
contraction O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
Emax O 
: O 
86% O 
of O 
inhibition O 
for O 
3mg O 
/ O 
ml O 
and O 
52% O 
de-inhibition O 
for O 
1mg O 
/ O 
ml O 
) O 
. O 
This O 
pre O 
- O 
treatment O 
also O 
induced O 
a O 
significant O 
attenuation O 
of O 
the O 
norepinephrine B-TRIVIAL 
-induced O 
contraction O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
( O 
Emax O 
: O 
72.7% O 
of O 
inhibition O 
for O 
3mg O 
/ O 
ml O 
and O 
27% O 
de O 
inhibition O 
for O 
1mg O 
/ O 
ml O 
) O 
in O 
a O 
Ca(2+) B-FORMULA 
free O 
medium O 
. O 
Upon O 
analyzing O 
the O 
composition O 
of O 
the O 
extract O 
, O 
the O 
presence O 
of O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
, O 
isovitexin B-TRIVIAL 
, O 
luteolin B-TRIVIAL 
and O 
chrysoeriol B-TRIVIAL 
were O 
found O 
. O 
Luteolin B-TRIVIAL 
( O 
CE50 O 
: O 
1.5μg O 
/ O 
ml O 
) O 
, O 
chrysoeriol B-TRIVIAL 
( O 
CE50 O 
: O 
13.2μg O 
/ O 
ml O 
) O 
and O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
( O 
CE50 O 
: O 
95.2μg O 
/ O 
ml O 
) O 
, O 
isolated O 
from O 
the O 
aqueous O 
extract O 
, O 
caused O 
dilatation O 
of O 
thoracic O 
aortic O 
rings O 
pre O 
- O 
contracted O 
with O 
phenylephrine B-TRIVIAL 
. O 
Artemisia O 
copa O 
administered O 
i.v O 
. O 
also O 
induced O 
a O 
decrease O 
in O 
the O 
mean O 
arterial O 
pressure O 
but O 
did O 
not O 
affect O 
the O 
heart O 
rate O 
in O 
hypertensive O 
rats O 
. O 
CONCLUSIONS O 
: O 
The O 
aqueous O 
extract O 
of O 
Artemisia O 
copa O 
proved O 
to O 
have O 
vasorelaxing O 
and O 
hypotensive O 
effects O 
through O 
the O 
inhibition O 
of O 
Ca(2+) B-FORMULA 
influx O 
via O 
membranous O 
calcium B-SYSTEMATIC 
channels O 
and O 
intracellular O 
stores O 
. O 
The O 
presence O 
of O 
luteolin B-TRIVIAL 
, O 
chrysoeriol B-TRIVIAL 
and O 
p-coumaric B-TRIVIAL 
acid I-TRIVIAL 
found O 
in O 
this O 
plant O 
could O 
be O 
involved O 
in O 
this O 
effect O 
. O 

RELEVANCE O 
: O 
Sweetgum O 
, O 
Styrax O 
liquidus O 
( O 
Turkish O 
sweetgum O 
) O 
is O 
a O 
resinous O 
exudate O 
obtained O 
from O 
the O 
wounded O 
barks O 
of O 
Liquidambar O 
orientalis O 
Miller O 
tree O 
which O 
belongs O 
to O 
Altingiaceae O 
( O 
Hamamelidaceae O 
) O 
. O 
The O 
plant O 
material O 
has O 
been O 
used O 
for O 
the O 
treatment O 
of O 
peptic O 
ulcer O 
symptoms O 
in O 
Turkish O 
folk O 
medicine O 
since O 
centuries O 
. O 
In O 
order O 
to O 
evaluate O 
the O 
claimed O 
activity O 
, O 
we O 
studied O 
the O 
anti-ulcerogenic O 
effect O 
of O 
Styrax O 
liquidus O 
by O 
using O 
an O 
in O 
vivo O 
anti-ulcerogenic O 
activity O 
model O 
and O 
to O 
determine O 
the O 
chemical O 
composition O 
of O 
the O 
balsam O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Anti-ulcerogenic O 
effects O 
of O 
the O 
balsam O 
" O 
Styrax O 
liquidus O 
" O 
itself O 
and O 
its O 
fractions O 
obtained O 
by O 
successive O 
solvent O 
extractions O 
with O 
chloroform B-TRIVIAL 
and O 
n-butanol B-SYSTEMATIC 
, O 
were O 
investigated O 
against O 
the O 
ethanol B-SYSTEMATIC 
-induced O 
peptic O 
ulcer O 
model O 
in O 
rats O 
. O 
The O 
chloroform O 
extract O 
demonstrated O 
a O 
statistically O 
significant O 
gastroprotective O 
effect O 
. O 
In O 
addition O 
, O 
the O 
chemical O 
characterization O 
of O 
the O 
volatiles O 
obtained O 
by O 
microdistillation O 
technique O 
from O 
the O 
balsam O 
and O 
the O 
sub O 
- O 
extracts O 
were O 
analyzed O 
by O 
gas O 
chromatography O 
( O 
GC O 
) O 
and O 
gas O 
chromatography O 
- O 
mass O 
spectrometry O 
( O 
GC-MS O 
) O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Pharmacological O 
experiments O 
have O 
clearly O 
demonstrated O 
that O 
150 O 
and O 
300mg O 
/ O 
kg O 
doses O 
of O 
Styrax O 
liquidus O 
given O 
orally O 
to O 
rats O 
showed O 
significant O 
gastric O 
protection O 
. O 
On O 
GC-MS O 
analysis O 
of O 
the O 
resin O 
, O 
overall O 
, O 
31 O 
compounds O 
representing O 
99.8% O 
of O 
the O 
total O 
oil O 
were O 
identified O 
where O 
styrene B-TRIVIAL 
( O 
81.9% O 
) O 
, O 
cinnamyl B-TRIVIAL 
alcohol I-TRIVIAL 
( O 
6.9% O 
) O 
and O 
α-pinene B-TRIVIAL 
( O 
3.5% O 
) O 
were O 
identified O 
as O 
the O 
major O 
components O 
. O 
CONCLUSION O 
: O 
Present O 
study O 
confirmed O 
the O 
anti-ulcerogenic O 
activity O 
of O 
the O 
local O 
ethnobotanical O 
usage O 
of O 
Styrax O 
liquidus O 
in O 
Turkey O 
. O 

( O 
5-FU B-SYSTEMATIC 
) O 
is O 
used O 
to O 
treat O 
many O 
aggressive O 
cancers O 
, O 
such O 
as O 
those O 
of O 
the O 
colon O 
, O 
breast O 
, O 
and O 
head O 
and O 
neck O 
. O 
The O 
responses O 
to O 
5-FU B-SYSTEMATIC 
, O 
with O 
respect O 
to O 
both O 
toxicity O 
and O 
efficacy O 
, O 
vary O 
among O 
racial O 
groups O 
, O 
potentially O 
because O 
of O 
variability O 
in O 
the O 
activity O 
levels O 
of O 
the O 
enzyme O 
dihydropyrimidine B-SYSTEMATIC 
dehydrogenase O 
( O 
DPD O 
, O 
encoded O 
by O 
the O 
DPYD O 
gene O 
) O 
. O 
In O 
this O 
study O 
, O 
the O 
genetic O 
associations O 
between O 
DPYD O 
variations O 
and O 
circulating O 
mononuclear O 
- O 
cell O 
DPD O 
enzyme O 
activity O 
were O 
evaluated O 
in O 
94 O 
African-American O 
and O 
81 O 
European-American O 
volunteers O 
. O 
The O 
DPYD-Y186C O 
variant O 
was O 
unique O 
to O 
individuals O 
of O 
African O 
ancestry O 
, O 
and O 
DPD O 
activity O 
was O 
46% O 
lower O 
in O 
carriers O 
as O 
compared O 
with O 
noncarriers O 
( O 
279 O 
± O 
35 O 
vs O 
. O 
514 O 
± O 
168 O 
pmol O 
5-FU B-SYSTEMATIC 
min(-1) O 
mg(-1) O 
; O 
P O 
= O 
0.00029 O 
) O 
. O 
In O 
this O 
study O 
, O 
26% O 
of O 
the O 
African O 
Americans O 
with O 
reduced O 
DPD O 
activity O 
were O 
carriers O 
of O 
Y186C O 
. O 
In O 
the O 
African-American O 
cohort O 
, O 
after O 
excluding O 
Y186C O 
carriers O 
, O 
homozygous O 
carriers O 
of O 
C29R O 
showed O 
27% O 
higher O 
DPD O 
activity O 
as O 
compared O 
with O 
noncarriers O 
( O 
609 O 
± O 
152 O 
and O 
480 O 
± O 
152 O 
pmol O 
5-FU B-SYSTEMATIC 
min(-1) O 
mg(-1) O 
, O 
respectively O 
; O 
P O 
= O 
0.013).Clinical O 
Pharmacology O 
& O 
Therapeutics O 
( O 
2013 O 
) O 
; O 
advance O 
online O 
publication O 
1 O 
May O 
2013 O 
. O 
doi O 
: O 
10.1038 O 
/ O 
clpt.2013.69 O 
. O 

targeting O 
/ O 
prodrug O 
strategies O 
for O 
intravesical O 
drug O 
delivery O 
- O 
Lectin O 
- O 
modified O 
PLGA B-ABBREVIATION 
microparticles O 
enhance O 
cytotoxicity O 
of O 
stearoyl B-TRIVIAL 
gemcitabine I-TRIVIAL 
by O 
contact O 
- O 
dependent O 
transfer O 
. O 

direct O 
access O 
to O 
the O 
urothelial O 
tissue O 
via O 
intravesical O 
therapy O 
has O 
emerged O 
as O 
a O 
promising O 
means O 
for O 
reducing O 
the O 
high O 
recurrence O 
rate O 
of O 
bladder O 
cancer O 
. O 
However O 
, O 
few O 
advanced O 
delivery O 
concepts O 
have O 
so O 
far O 
been O 
evaluated O 
to O 
overcome O 
critical O 
inherent O 
efficacy O 
limitations O 
imposed O 
by O 
short O 
exposure O 
times O 
, O 
low O 
tissue O 
permeability O 
, O 
and O 
extensive O 
washout O 
. O 
This O 
study O 
reports O 
on O 
a O 
novel O 
strategy O 
to O 
enhance O 
gemcitabine B-TRIVIAL 
treatment O 
impact O 
on O 
urothelial O 
cells O 
by O 
combining O 
a O 
pharmacologically O 
advantageous O 
prodrug O 
approach O 
with O 
the O 
pharmacokinetic O 
benefits O 
of O 
a O 
glycan O 
- O 
targeted O 
carrier O 
system O 
. O 
The O 
conversion O 
of O 
gemcitabine B-TRIVIAL 
to O 
its O 
4-(N)-stearoyl B-SYSTEMATIC 
derivative O 
( O 
GEM-C18 B-FORMULA 
) O 
allowed O 
for O 
stable O 
, O 
homogeneous O 
incorporation O 
into O 
PLGA B-ABBREVIATION 
microparticles O 
( O 
MP O 
) O 
without O 
compromising O 
intracellular O 
drug O 
activation O 
. O 
Fluorescence O 
- O 
labeled O 
GEM-C18-PLGA B-FORMULA 
-MP O 
were O 
surface O 
- O 
functionalized O 
with O 
wheat O 
germ O 
agglutinin O 
( O 
WGA O 
) O 
or O 
human O 
serum O 
albumin O 
( O 
HSA O 
) O 
to O 
assess O 
in O 
direct O 
comparison O 
the O 
impact O 
of O 
biorecognitive O 
interaction O 
on O 
binding O 
rate O 
and O 
anchoring O 
stability O 
. O 
MP O 
adhesion O 
on O 
urothelial O 
cells O 
of O 
non-malignant O 
origin O 
( O 
SV-HUC-1 O 
) O 
, O 
and O 
low- O 
( O 
5637 O 
) O 
or O 
high O 
- O 
grade O 
( O 
HT-1376 O 
) O 
carcinoma O 
was O 
correlated O 
to O 
the O 
resultant O 
antiproliferative O 
and O 
antimetabolic O 
effect O 
in O 
BrdU B-ABBREVIATION 
and O 
XTT O 
assays O 
. O 
More O 
extensive O 
and O 
durable O 
binding O 
of O 
the O 
WGA- O 
GEM-C18-PLGA B-FORMULA 
-MP O 
induced O 
a O 
change O 
in O 
the O 
pharmacological O 
profile O 
and O 
substantially O 
higher O 
cytotoxicity O 
, O 
allowing O 
for O 
maximum O 
response O 
within O 
the O 
temporal O 
restrictions O 
of O 
instillative O 
administration O 
( O 
120min O 
) O 
. O 
Mechanistically O 
, O 
a O 
direct O 
, O 
contact O 
- O 
dependent O 
transfer O 
of O 
stearoyl B-TRIVIAL 
derivatives O 
from O 
the O 
particle O 
matrix O 
to O 
the O 
urothelial O 
membrane O 
was O 
found O 
to O 
account O 
for O 
this O 
effect O 
. O 
With O 
versatile O 
options O 
for O 
future O 
application O 
, O 
our O 
results O 
highlight O 
the O 
potential O 
offered O 
by O 
the O 
synergistic O 
implementation O 
of O 
targeting O 
/ O 
prodrug O 
strategies O 
in O 
delivery O 
systems O 
tailored O 
to O 
the O 
intravesical O 
route O 
. O 

to O 
preventive O 
statin B-FAMILY 
therapy O 
according O 
to O 
socioeconomic O 
position O 
. O 

pharmacokinetic O 
analysis O 
of O 
tacrolimus B-TRIVIAL 
in O 
the O 
first O 
year O 
after O 
pediatric O 
liver O 
transplantation O 
. O 

: O 
Tacrolimus B-TRIVIAL 
( O 
TAC B-ABBREVIATION 
) O 
is O 
the O 
most O 
widely O 
used O 
immunosuppressant O 
for O 
the O 
prevention O 
of O 
acute O 
rejection O 
after O 
solid O 
organ O 
transplantation O 
. O 
Its O 
pharmacokinetics O 
( O 
PK O 
) O 
show O 
considerable O 
variability O 
, O 
making O 
TAC B-ABBREVIATION 
a O 
good O 
candidate O 
for O 
therapeutic O 
drug O 
monitoring O 
( O 
TDM O 
) O 
. O 
The O 
principal O 
aim O 
of O 
the O 
study O 
was O 
to O 
describe O 
the O 
PK O 
of O 
TAC B-ABBREVIATION 
in O 
pediatric O 
patients O 
during O 
the O 
first O 
year O 
after O 
transplantation O 
. O 
METHODS O 
: O 
Routine O 
TDM O 
trough O 
levels O 
of O 
TAC B-ABBREVIATION 
were O 
obtained O 
from O 
42 O 
pediatric O 
liver O 
allograft O 
recipients O 
during O 
the O 
first O 
year O 
after O 
transplantation O 
. O 
A O 
population O 
PK O 
model O 
was O 
developed O 
using O 
nonlinear O 
mixed O 
- O 
effects O 
modeling O 
to O 
describe O 
TAC B-ABBREVIATION 
PK O 
during O 
this O 
period O 
and O 
to O 
explain O 
the O 
observed O 
variability O 
by O 
means O 
of O 
patients O 
' O 
demographics O 
, O 
biochemical O 
test O 
results O 
and O 
physiological O 
characteristics O 
. O 
RESULTS O 
: O 
The O 
PK O 
of O 
TAC B-ABBREVIATION 
were O 
best O 
described O 
by O 
a O 
two O 
- O 
compartment O 
model O 
with O 
first O 
- O 
order O 
elimination O 
. O 
Apparent O 
volumes O 
of O 
the O 
central O 
compartment O 
, O 
intercomparmental O 
clearance O 
and O 
maximum O 
blood O 
clearance O 
estimates O 
were O 
253 O 
L O 
, O 
115 O 
L O 
/ O 
day O 
and O 
314 O 
L O 
/ O 
day O 
, O 
respectively O 
. O 
The O 
absorption O 
first O 
- O 
order O 
rate O 
and O 
volume O 
of O 
peripheral O 
compartment O 
were O 
fixed O 
to O 
4.5 O 
h(-1) O 
and O 
100 O 
L O 
, O 
respectively O 
. O 
While O 
hematocrit O 
levels O 
, O 
time O 
after O 
transplantation O 
and O 
bodyweight O 
influenced O 
TAC B-ABBREVIATION 
clearance O 
, O 
bodyweight O 
was O 
the O 
only O 
covariate O 
retained O 
on O 
volume O 
of O 
distribution O 
. O 
CONCLUSIONS O 
: O 
We O 
developed O 
a O 
TAC B-ABBREVIATION 
population O 
PK O 
model O 
in O 
pediatrics O 
covering O 
the O 
first O 
year O 
after O 
liver O 
transplantation O 
that O 
may O 
serve O 
as O 
a O 
tool O 
for O 
TAC B-ABBREVIATION 
dose O 
individualization O 
as O 
part O 
of O 
TDM O 
. O 

: O 
A O 
growing O 
number O 
of O 
countries O 
are O 
providing O 
pharmaceutical O 
grade O 
cannabis O 
to O 
chronically O 
ill O 
patients O 
. O 
However O 
, O 
little O 
published O 
data O 
is O 
known O 
about O 
the O 
extent O 
of O 
medicinal O 
cannabis O 
use O 
and O 
the O 
characteristics O 
of O 
patients O 
using O 
cannabis O 
on O 
doctor's O 
prescription O 
. O 
This O 
study O 
describes O 
a O 
retrospective O 
database O 
study O 
of O 
The O 
Netherlands O 
. O 
METHODS O 
: O 
Complete O 
dispensing O 
histories O 
were O 
obtained O 
of O 
all O 
patients O 
with O 
at O 
least O 
one O 
medicinal O 
cannabis O 
prescription O 
gathered O 
at O 
pharmacies O 
in O 
The O 
Netherlands O 
in O 
the O 
period O 
2003-2010 O 
. O 
Data O 
revealed O 
prevalence O 
and O 
incidence O 
of O 
use O 
of O 
prescription O 
cannabis O 
as O 
well O 
as O 
characteristics O 
of O 
patients O 
using O 
different O 
cannabis O 
varieties O 
. O 
RESULTS O 
: O 
Five O 
thousand O 
five O 
hundred O 
forty O 
patients O 
were O 
identified O 
. O 
After O 
an O 
initial O 
incidence O 
of O 
about O 
6 O 
/ O 
100000 O 
inhabitants O 
/ O 
year O 
in O 
2003 O 
and O 
2004 O 
, O 
the O 
incidence O 
remained O 
stable O 
at O 
3 O 
/ O 
100000 O 
/ O 
year O 
in O 
2005-2010 O 
. O 
The O 
prevalence O 
rate O 
ranged O 
from O 
5 O 
to O 
8 O 
per O 
100000 O 
inhabitants O 
. O 
Virtually O 
all O 
patients O 
used O 
some O 
form O 
of O 
prescription O 
medication O 
in O 
the O 
6 O 
months O 
preceding O 
start O 
of O 
cannabis O 
use O 
, O 
most O 
particularly O 
psycholeptics O 
( O 
45.5 O 
% O 
) O 
, O 
analgesics O 
( O 
44.3 O 
% O 
) O 
, O 
anti-ulcer O 
agents O 
( O 
35.9 O 
% O 
) O 
and O 
NSAIDs O 
( O 
30.7 O 
% O 
) O 
. O 
We O 
found O 
no O 
significant O 
association O 
between O 
use O 
of O 
medication O 
of O 
common O 
indications O 
for O 
cannabis O 
( O 
pain O 
, O 
HIV O 
/ O 
AIDS O 
, O 
cancer O 
, O 
nausea O 
, O 
glaucoma O 
) O 
and O 
variety O 
of O 
cannabis O 
used O 
. O 
CONCLUSIONS O 
: O 
This O 
is O 
the O 
first O 
nationwide O 
study O 
into O 
the O 
extent O 
of O 
prescription O 
of O 
medicinal O 
cannabis O 
. O 
Although O 
the O 
cannabis O 
varieties O 
studied O 
are O 
believed O 
to O 
possess O 
different O 
therapeutic O 
effects O 
based O 
on O 
their O 
different O 
content O 
of O 
tetrahydrocannabinol B-SYSTEMATIC 
( O 
THC B-ABBREVIATION 
) O 
and O 
cannabidiol B-TRIVIAL 
( O 
CBD B-ABBREVIATION 
) O 
, O 
no O 
differences O 
in O 
choice O 
of O 
variety O 
was O 
found O 
associated O 
with O 
indication O 
. O 

down O 
- O 
regulates O 
endothelial O 
protein O 
C O 
receptor O 
shedding O 
. O 

protein O 
C O 
receptor O 
( O 
EPCR O 
) O 
plays O 
an O 
important O 
role O 
in O 
the O 
protein O 
C O 
anticoagulation O 
pathway O 
and O 
in O 
the O 
cytoprotective O 
pathway O 
. O 
Previously O 
, O 
EPCR O 
can O 
be O 
shed O 
from O 
the O 
cell O 
surface O 
, O 
which O 
is O 
mediated O 
by O 
tumor O 
necrosis O 
factor-α O 
converting O 
enzyme O 
( O 
TACE O 
) O 
. O 
Soluble O 
EPCR O 
levels O 
are O 
increased O 
in O 
patients O 
with O 
systemic O 
inflammatory O 
diseases O 
. O 
Recently O 
, O 
we O 
reported O 
that O 
a O 
new O 
active O 
compound O 
, O 
emodin-6-O-β-D-glucoside B-SYSTEMATIC 
( O 
EG O 
) O 
from O 
Reynoutria O 
japonica O 
, O 
has O 
anti-inflammatory O 
activities O 
. O 
However O 
, O 
little O 
is O 
known O 
of O 
the O 
effects O 
of O 
EG O 
on O 
EPCR O 
shedding O 
. O 
Here O 
, O 
we O 
investigated O 
this O 
issue O 
by O 
monitoring O 
the O 
effects O 
of O 
EG O 
on O 
the O 
phorbol-12-myristate B-SYSTEMATIC 
13-acetate I-SYSTEMATIC 
( O 
PMA B-ABBREVIATION 
) O 
or O 
the O 
cecal O 
ligation O 
and O 
puncture O 
( O 
CLP O 
) O 
- O 
mediated O 
EPCR O 
shedding O 
and O 
its O 
underlying O 
mechanisms O 
. O 
Data O 
showed O 
that O 
EG O 
potently O 
inhibited O 
the O 
PMA B-ABBREVIATION 
and O 
CLP-induced O 
EPCR O 
shedding O 
by O 
suppressing O 
TACE O 
expression O 
. O 
Given O 
these O 
results O 
, O 
EG O 
could O 
be O 
used O 
as O 
a O 
candidate O 
therapeutic O 
for O 
the O 
treatment O 
of O 
vascular O 
inflammatory O 
diseases O 
. O 

delivery O 
of O 
venlafaxine B-TRIVIAL 
by O 
linseed O 
mucilage O 
based O 
gel O 
: O 
in O 
vitro O 
and O 
in O 
vivo O 
evaluation O 
in O 
rabbits O 
. O 

is O 
the O 
crop O 
that O 
is O 
used O 
as O 
a O 
foodstuff O 
in O 
European O 
and O 
Asian O 
countries O 
. O 
The O 
objective O 
of O 
the O 
present O 
work O 
was O 
to O 
extract O 
mucilage O 
from O 
linseed O 
, O 
utilize O 
it O 
as O 
mucoadhesive O 
gelling O 
agent O 
along O 
with O 
synthetic O 
polymers O 
and O 
administration O 
of O 
venlafaxine B-TRIVIAL 
by O 
buccal O 
route O 
in O 
the O 
gel O 
form O 
. O 
Buccal O 
administration O 
of O 
venlafaxine B-TRIVIAL 
will O 
avoid O 
first O 
pass O 
metabolism O 
, O 
which O 
will O 
increase O 
the O 
bioavailability O 
of O 
the O 
drug O 
. O 
Linseed O 
mucilage O 
based O 
buccal O 
mucoadhesive O 
gel O 
preparations O 
in O 
combination O 
with O 
chitosan O 
, O 
carbopol O 
934P O 
, O 
carboxy B-SYSTEMATIC 
methylcellulose O 
and O 
polyvinyl B-SYSTEMATIC 
pyrrolidone I-SYSTEMATIC 
were O 
formulated O 
and O 
the O 
viscosity O 
, O 
gel O 
strength O 
, O 
percentage O 
mucoadhesion O 
and O 
in O 
vitro O 
diffusion O 
of O 
the O 
formulation O 
was O 
evaluated O 
. O 
Formulation O 
( O 
F2 O 
) O 
was O 
subjected O 
to O 
in O 
vivo O 
analysis O 
in O 
rabbits O 
. O 
Formulation O 
F2 O 
, O 
which O 
contained O 
linseed O 
mucilage O 
( O 
2 O 
% O 
) O 
and O 
chitosan O 
( O 
0.5 O 
% O 
) O 
, O 
showed O 
the O 
highest O 
percentage O 
of O 
mucoadhesion O 
, O 
gel O 
strength O 
and O 
sustained O 
drug O 
diffusion O 
. O 
The O 
bioavailability O 
by O 
the O 
oral O 
route O 
and O 
buccal O 
route O 
were O 
compared O 
with O 
that O 
of O 
the O 
intravenous O 
route O 
. O 
The O 
bioavailability O 
of O 
venlafaxine B-TRIVIAL 
in O 
the O 
formulation O 
F2 O 
was O 
63.08 O 
± O 
1.28 O 
% O 
by O 
buccal O 
route O 
, O 
which O 
was O 
higher O 
than O 
by O 
the O 
oral O 
route O 
( O 
39.21 O 
± O 
6.18 O 
% O 
) O 
. O 
Based O 
on O 
these O 
results O 
, O 
the O 
combination O 
of O 
linseed O 
mucilage O 
and O 
chitosan O 
can O 
be O 
used O 
to O 
form O 
a O 
buccal O 
mucoadhesive O 
gel O 
and O 
increase O 
the O 
bioavailability O 
of O 
venlafaxine B-TRIVIAL 
. O 

space O 
- O 
charge O 
region O 
of O 
an O 
organic O 
semiconductor O 
(OS)-insulator O 
interface O 
is O 
probed O 
by O 
analyzing O 
the O 
spontaneous O 
, O 
thermally O 
driven O 
drain O 
current O 
fluctuations O 
of O 
a O 
field O 
- O 
effect O 
transistor O 
in O 
which O 
the O 
OS O 
forms O 
the O 
gate O 
electrode O 
. O 
This O 
so O 
called O 
" O 
excess O 
drain O 
current O 
noise O 
" O 
is O 
the O 
outcome O 
of O 
local O 
fluctuations O 
of O 
the O 
Fermi O 
level O 
, O 
resulting O 
from O 
stochastic O 
exchange O 
of O 
electrons O 
between O 
traps O 
near O 
the O 
Fermi O 
level O 
. O 
The O 
power O 
spectral O 
density O 
of O 
this O 
noise O 
is O 
characteristic O 
of O 
a O 
Lorentzian O 
process O 
with O 
a O 
distribution O 
of O 
time O 
constants O 
, O 
which O 
is O 
attributed O 
to O 
the O 
disorder O 
in O 
the O 
OS O 
film O 
. O 
Furthermore O 
, O 
this O 
disorder O 
leads O 
to O 
local O 
inhomogeneity O 
of O 
the O 
work O 
function O 
in O 
the O 
film O 
and O 
a O 
finite O 
correlation O 
length O 
of O 
the O 
work O 
function O 
fluctuations O 
. O 
The O 
measurement O 
of O 
work O 
function O 
noise O 
is O 
only O 
possible O 
within O 
a O 
correlation O 
length O 
of O 
the O 
OS-insulator O 
interface O 
. O 
Through O 
systematic O 
variation O 
of O 
gate O 
voltage O 
, O 
primary O 
doping O 
and O 
secondary O 
doping O 
levels O 
, O 
the O 
correlation O 
length O 
, O 
disorder O 
, O 
and O 
the O 
trapping O 
/ O 
de-trapping O 
time O 
constant O 
are O 
examined O 
on O 
polyaniline B-SYSTEMATIC 
as O 
a O 
representative O 
OS O 
. O 
A O 
model O 
is O 
proposed O 
for O 
local O 
work O 
function O 
variations O 
and O 
spontaneous O 
charge O 
- O 
carrier O 
fluctuations O 
within O 
polyaniline B-SYSTEMATIC 
films O 
with O 
consequences O 
for O 
organic O 
electronics O 
using O 
organic O 
semiconductors O 
. O 

zirconium B-FAMILY 
hydrides I-FAMILY 
using O 
the O 
special O 
quasirandom O 
structure O 
approach O 
. O 

study O 
of O 
the O 
structure O 
and O 
properties O 
of O 
zirconium B-FAMILY 
hydrides I-FAMILY 
is O 
important O 
for O 
understanding O 
the O 
embrittlement O 
of O 
zirconium B-FAMILY 
alloys O 
used O 
as O 
cladding O 
in O 
light O 
water O 
nuclear O 
reactors O 
. O 
Simulation O 
of O 
the O 
defect O 
processes O 
is O 
complicated O 
due O 
to O 
the O 
random O 
distribution O 
of O 
the O 
hydrogen B-SYSTEMATIC 
atoms O 
. O 
We O 
propose O 
the O 
use O 
of O 
the O 
special O 
quasirandom O 
structure O 
approach O 
as O 
a O 
computationally O 
efficient O 
way O 
to O 
describe O 
this O 
random O 
distribution O 
. O 
We O 
have O 
generated O 
six O 
special O 
quasirandom O 
structure O 
cells O 
based O 
on O 
face O 
centered O 
cubic O 
and O 
face O 
centered O 
tetragonal O 
unit O 
cells O 
to O 
describe O 
ZrH2 B-FORMULA 
-x O 
( O 
x O 
= O 
0.25-0.5 O 
) O 
. O 
Using O 
density O 
functional O 
theory O 
calculations O 
we O 
investigate O 
the O 
mechanical O 
properties O 
, O 
stability O 
, O 
and O 
electronic O 
structure O 
of O 
the O 
alloys O 
. O 

Nanoarchitectonics O 
: O 
From O 
Zero O 
to O 
Higher O 
Dimensions O 
. O 

strategic O 
design O 
of O 
nanostructured O 
materials O 
, O 
the O 
properties O 
of O 
which O 
could O 
be O 
controlled O 
across O 
different O 
length O 
scales O 
and O 
which O 
, O 
at O 
the O 
same O 
time O 
, O 
could O 
be O 
used O 
as O 
building O 
blocks O 
for O 
the O 
construction O 
of O 
devices O 
and O 
functional O 
systems O 
into O 
new O 
technological O 
platforms O 
that O 
are O 
based O 
on O 
sustainable O 
processes O 
, O 
is O 
an O 
important O 
issue O 
in O 
bottom O 
- O 
up O 
nanotechnology.Such O 
strategic O 
design O 
has O 
enabled O 
the O 
fabrication O 
of O 
materials O 
by O 
using O 
convergent O 
bottom O 
- O 
up O 
and O 
top O 
- O 
down O 
strategies O 
. O 
Recent O 
developments O 
in O 
the O 
assembly O 
of O 
functional O 
fullerene B-TRIVIAL 
( O 
C60 B-TRIVIAL 
) O 
molecules O 
, O 
either O 
in O 
bulk O 
or O 
at O 
interfaces O 
, O 
have O 
allowed O 
the O 
production O 
of O 
shape O 
- O 
controlled O 
nano O 
- O 
to O 
- O 
microsized O 
objects O 
that O 
possess O 
excellent O 
optoelectronic O 
properties O 
, O 
thus O 
enabling O 
the O 
fabrication O 
of O 
optoelectronic O 
devices O 
. O 
Because O 
fullerene B-TRIVIAL 
molecules O 
can O 
be O 
regarded O 
as O 
an O 
ideal O 
zero O 
- O 
dimensional O 
( O 
0D O 
) O 
building O 
units O 
with O 
attractive O 
functions O 
, O 
the O 
construction O 
of O 
higher O 
- O 
dimensional O 
objects O 
, O 
that O 
is O 
, O 
1D O 
, O 
2D O 
, O 
and O 
3D O 
nanomaterials O 
may O 
realize O 
important O 
aspects O 
of O 
nanoarchitectonics O 
. O 
This O 
Focus O 
Review O 
summarizes O 
the O 
recent O 
developments O 
in O 
the O 
production O 
of O 
nanostructured O 
fullerenes O 
and O 
techniques O 
for O 
the O 
elaboration O 
of O 
fullerene B-TRIVIAL 
nanomaterials O 
into O 
hierarchic O 
structures O 
. O 

inhibits O 
autophagic O 
flux O 
activating O 
the O 
Nrf2-Keap1 O 
pathway O 
in O 
a O 
p62-dependent O 
manner O 
. O 

Nrf2-Keap1 O 
signaling O 
pathway O 
is O 
a O 
protective O 
mechanism O 
promoting O 
cell O 
survival O 
. O 
Activation O 
of O 
the O 
Nrf2 O 
pathway O 
by O 
natural O 
compounds O 
has O 
been O 
proven O 
to O 
be O 
an O 
effective O 
strategy O 
for O 
chemoprevention O 
. O 
Interestingly O 
, O 
a O 
cancer O 
- O 
promoting O 
function O 
of O 
Nrf2 O 
has O 
been O 
recently O 
observed O 
in O 
many O 
types O 
of O 
tumors O 
due O 
to O 
deregulation O 
of O 
the O 
Nrf2-Keap1 O 
axis O 
, O 
which O 
leads O 
to O 
constitutive O 
activation O 
of O 
Nrf2 O 
. O 
Here O 
, O 
we O 
report O 
a O 
novel O 
mechanism O 
of O 
Nrf2 O 
activation O 
by O 
arsenic O 
that O 
is O 
distinct O 
from O 
that O 
of O 
chemopreventive O 
compounds O 
. O 
Arsenic B-SYSTEMATIC 
deregulates O 
the O 
autophagic O 
pathway O 
through O 
blockage O 
of O 
autophagic O 
flux O 
, O 
resulting O 
in O 
accumulation O 
of O 
autophagosomes O 
and O 
sequestration O 
of O 
p62 O 
, O 
Keap1 O 
, O 
and O 
LC3 O 
. O 
Thus O 
, O 
arsenic B-SYSTEMATIC 
activates O 
Nrf2 O 
through O 
a O 
non-canonical O 
mechanism O 
( O 
p62-dependent O 
) O 
, O 
leading O 
to O 
a O 
chronic O 
, O 
sustained O 
activation O 
of O 
Nrf2 O 
. O 
In O 
contrast O 
, O 
activation O 
of O 
Nrf2 O 
by O 
sulforaphane B-TRIVIAL 
and O 
tert-butylhydroquinone B-SYSTEMATIC 
depend O 
upon O 
Keap1-C151 O 
and O 
not O 
p62 O 
( O 
the O 
canonical O 
mechanism O 
) O 
. O 
More O 
importantly O 
, O 
SF O 
and O 
tBHQ B-ABBREVIATION 
do O 
not O 
have O 
any O 
effect O 
on O 
autophagy O 
. O 
In O 
fact O 
, O 
SF O 
and O 
tBHQ B-ABBREVIATION 
alleviate O 
arsenic B-SYSTEMATIC 
-mediated O 
deregulation O 
of O 
autophagy O 
. O 
Collectively O 
, O 
these O 
findings O 
provide O 
evidence O 
that O 
arsenic B-SYSTEMATIC 
causes O 
prolonged O 
activation O 
of O 
Nrf2 O 
through O 
autophagy O 
dysfunction O 
, O 
possibly O 
providing O 
a O 
similar O 
scenario O 
to O 
constitutive O 
activation O 
of O 
Nrf2 O 
found O 
in O 
certain O 
human O 
cancers O 
. O 
This O 
may O 
represent O 
a O 
previously O 
unrecognized O 
mechanism O 
underlying O 
arsenic B-SYSTEMATIC 
toxicity O 
and O 
carcinogenicity O 
in O 
humans O 
. O 

13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
-Detected O 
Through O 
- O 
Bond O 
Correlation O 
Experiments O 
for O 
Protein O 
Resonance O 
Assignment O 
by O 
Ultra-Fast O 
MAS O 
Solid-State O 
NMR O 
. O 

present O 
two O 
sequences O 
which O 
combine O 
( O 
( B-FORMULA 
1 I-FORMULA 
) I-FORMULA 
H I-FORMULA 
, O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
) O 
and O 
( O 
( B-FORMULA 
15 I-FORMULA 
) I-FORMULA 
N I-FORMULA 
, O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
) O 
selective O 
cross O 
- O 
polarization O 
steps O 
with O 
an O 
efficient O 
variant O 
of O 
the O 
J O 
- O 
based O 
homonuclear O 
transfer O 
scheme O 
, O 
in O 
which O 
a O 
spin O 
- O 
state O 
- O 
selective O 
( O 
S(3) O 
E O 
) O 
block O 
is O 
incorporated O 
to O 
improve O 
both O 
resolution O 
and O 
sensitivity O 
in O 
the O 
direct O 
( B-FORMULA 
13 I-FORMULA 
) I-FORMULA 
C I-FORMULA 
dimension O 
. O 
We O 
propose O 
these O 
two O 
sequences O 
as O 
a O 
part O 
of O 
a O 
suite O 
of O 
four O 
N-C B-FORMULA 
correlation O 
experiments O 
allowing O 
for O 
the O 
assignment O 
of O 
protein O 
backbone O 
resonances O 
in O 
the O 
solid O 
state O 
. O 
We O 
illustrate O 
these O 
experiments O 
under O 
ultra O 
- O 
fast O 
magic O 
angle O 
spinning O 
conditions O 
on O 
two O 
samples O 
of O 
microcrystalline O 
dimeric O 
human O 
superoxide O 
dismutase O 
( O 
SOD O 
, O 
153×2 O 
amino B-FAMILY 
acids I-FAMILY 
) O 
, O 
in O 
its O 
diamagnetic O 
( O 
" O 
empty O 
" O 
, O 
Zn B-FORMULA 
(II) I-FORMULA 
) O 
and O 
paramagnetic O 
( O 
Cu B-FORMULA 
(II) I-FORMULA 
, O 
Zn B-FORMULA 
(II) I-FORMULA 
) O 
states O 
. O 

present O 
paper O 
features O 
an O 
exciting O 
time O 
in O 
the O 
late O 
1980s O 
when O 
I O 
, O 
as O 
a O 
visiting O 
scientist O 
, O 
had O 
the O 
privilege O 
to O 
participate O 
in O 
the O 
early O 
and O 
very O 
exciting O 
development O 
of O 
the O 
in O 
vivo O 
redox O 
- O 
polymer O 
- O 
wired O 
glucose B-TRIVIAL 
sensor O 
in O 
Professor O 
Adam O 
Heller's O 
laboratory O 
at O 
the O 
Department O 
of O 
Chemical O 
Engineering O 
at O 
University O 
of O 
Texas O 
at O 
Austin O 
. O 
This O 
story O 
is O 
followed O 
by O 
an O 
overview O 
of O 
the O 
research O 
my O 
visit O 
initiated O 
at O 
Uppsala O 
University O 
. O 
In O 
collaboration O 
with O 
Swedish O 
colleagues O 
, O 
we O 
explored O 
a O 
few O 
of O 
the O 
many O 
possibilities O 
to O 
form O 
new O 
biosensors O 
by O 
utilizing O 
Prof O 
. O 
Heller's O 
concept O 
of O 
cross O 
- O 
linked O 
redox O 
- O 
polymer O 
/ O 
redox O 
- O 
enzyme O 
electrodes O 
. O 

Bio O 
- O 
electrocatalysis O 
of O 
O2 B-FORMULA 
Reduction O 
by O 
Streptomyces O 
coelicolor O 
Laccase O 
Orientated O 
at O 
Promoter O 
- O 
Modified O 
Graphite O 
Electrodes O 
. O 

laccase O 
from O 
Streptomyces O 
coelicolor O 
( O 
SLAC O 
) O 
has O 
been O 
immobilised O 
and O 
orientated O 
at O 
promoter O 
( O 
pyrene B-SYSTEMATIC 
and O 
neocuproine B-TRIVIAL 
) O 
- O 
modified O 
electrodes O 
productively O 
both O 
for O 
direct O 
electron O 
transfer O 
( O 
ET O 
) O 
between O 
the O 
electrode O 
and O 
the O 
T1 O 
Cu B-FORMULA 
site O 
of O 
SLAC O 
and O 
direct O 
( O 
unmediated O 
) O 
bio O 
- O 
electrocatalysis O 
of O 
dioxygen B-SYSTEMATIC 
reduction O 
. O 
Its O 
T1 O 
Cu B-FORMULA 
potential O 
ranges O 
between O 
471 O 
and O 
318 O 
mV O 
versus O 
the O 
normal O 
hydrogen B-SYSTEMATIC 
electrode O 
, O 
at O 
pH O 
5.5 O 
and O 
8 O 
, O 
respectively O 
; O 
this O 
value O 
is O 
dependent O 
both O 
on O 
the O 
solution O 
pH O 
and O 
electrode O 
modification O 
. O 
In O 
the O 
presence O 
of O 
O2 B-FORMULA 
, O 
Cu B-FORMULA 
of O 
the O 
T2 O 
/ O 
T3 O 
trinuclear O 
centre O 
is O 
distinguished O 
electrochemically O 
at O 
748-623 O 
mV O 
. O 
Depending O 
on O 
the O 
promoter O 
nature O 
, O 
different O 
orientations O 
of O 
SLAC O 
at O 
pyrene B-SYSTEMATIC 
- O 
and O 
neocuproine B-TRIVIAL 
-modified O 
electrodes O 
can O 
be O 
followed O 
from O 
the O 
kinetic O 
analysis O 
of O 
the O 
ET O 
rates O 
. O 
Bio O 
- O 
electrocatalytic O 
reduction O 
of O 
oxygen B-SYSTEMATIC 
starts O 
from O 
the O 
T1 O 
Cu B-FORMULA 
potentials O 
of O 
SLAC O 
, O 
and O 
is O 
most O 
efficient O 
at O 
the O 
promoter O 
- O 
modified O 
electrodes O 
, O 
thereby O 
demonstrating O 
good O 
performance O 
both O 
in O 
neutral O 
and O 
basic O 
media O 
and O 
in O 
solutions O 
with O 
a O 
high O 
NaCl B-FORMULA 
content O 
, O 
such O 
as O 
sea O 
water O 
. O 
The O 
obtained O 
results O 
allow O 
consideration O 
of O 
a O 
broader O 
bioenergetic O 
application O 
of O 
laccases O 
as O 
biocathodes O 
operating O 
directly O 
in O 
such O 
environmental O 
media O 
as O 
sea O 
water O 
and O 
physiological O 
fluids O 
. O 

- O 
free O 
co O 
- O 
production O 
of O 
an O 
orthogonal O 
transfer O 
RNA O 
activates O 
efficient O 
site O 
- O 
specific O 
non-natural O 
amino B-FAMILY 
acid I-FAMILY 
incorporation O 
. O 

describe O 
a O 
new O 
cell O 
- O 
free O 
protein O 
synthesis O 
( O 
CFPS O 
) O 
method O 
for O 
site O 
- O 
specific O 
incorporation O 
of O 
non-natural O 
amino B-FAMILY 
acids I-FAMILY 
( O 
nnAAs O 
) O 
into O 
proteins O 
in O 
which O 
the O 
orthogonal O 
tRNA O 
( O 
o-tRNA O 
) O 
and O 
the O 
modified O 
protein O 
( O 
i.e O 
. O 
the O 
protein O 
containing O 
the O 
nnAA O 
) O 
are O 
produced O 
simultaneously O 
. O 
Using O 
this O 
method O 
, O 
0.9-1.7 O 
mg O 
/ O 
ml O 
of O 
modified O 
soluble O 
super O 
- O 
folder O 
green O 
fluorescent O 
protein O 
( O 
sfGFP O 
) O 
containing O 
either O 
p-azido-l-phenylalanine B-SYSTEMATIC 
( O 
pAzF B-ABBREVIATION 
) O 
or O 
p-propargyloxy-l-phenylalanine B-SYSTEMATIC 
( O 
pPaF B-ABBREVIATION 
) O 
accumulated O 
in O 
the O 
CFPS O 
solutions O 
; O 
these O 
yields O 
correspond O 
to O 
50-88% O 
suppression O 
efficiency O 
. O 
The O 
o-tRNA O 
can O 
be O 
transcribed O 
either O 
from O 
a O 
linearized O 
plasmid O 
or O 
from O 
a O 
crude O 
PCR O 
product O 
. O 
Comparison O 
of O 
two O 
different O 
o-tRNAs O 
suggests O 
that O 
the O 
new O 
platform O 
is O 
not O 
limited O 
by O 
Ef-Tu O 
recognition O 
of O 
the O 
acylated O 
o-tRNA O 
at O 
sufficiently O 
high O 
o-tRNA O 
template O 
concentrations O 
. O 
Analysis O 
of O 
nnAA O 
incorporation O 
across O 
12 O 
different O 
sites O 
in O 
sfGFP O 
suggests O 
that O 
modified O 
protein O 
yields O 
and O 
suppression O 
efficiencies O 
( O 
i.e O 
. O 
the O 
position O 
effect O 
) O 
do O 
not O 
correlate O 
with O 
any O 
of O 
the O 
reported O 
trends O 
. O 
Sites O 
that O 
were O 
ineffectively O 
suppressed O 
with O 
the O 
original O 
o-tRNA O 
were O 
better O 
suppressed O 
with O 
an O 
optimized O 
o-tRNA O 
(o-tRNA(opt)) O 
that O 
was O 
evolved O 
to O 
be O 
better O 
recognized O 
by O 
Ef-Tu O 
. O 
This O 
new O 
platform O 
can O 
also O 
be O 
used O 
to O 
screen O 
scissile O 
ribozymes O 
for O 
improved O 
catalysis O 
. O 

Antioxidant O 
Nanoparticles O 
Based O 
on O 
a O 
Polymeric O 
Prodrug O 
of O 
Vanillin B-TRIVIAL 
. O 

stress O 
is O 
induced O 
by O 
accumulation O 
of O 
hydrogen B-SYSTEMATIC 
peroxide I-SYSTEMATIC 
( O 
H2O2 B-FORMULA 
) O 
, O 
and O 
therefore O 
, O 
H2O2 B-FORMULA 
could O 
serve O 
as O 
a O 
potential O 
biomarker O 
of O 
various O 
oxidative O 
stress O 
- O 
associated O 
inflammatory O 
diseases O 
. O 
Vanillin B-TRIVIAL 
is O 
one O 
of O 
the O 
major O 
components O 
of O 
natural O 
vanilla O 
and O 
has O 
potent O 
antioxidant O 
and O 
anti-inflammatory O 
activities O 
. O 
In O 
this O 
work O 
, O 
we O 
developed O 
a O 
novel O 
inflammation O 
- O 
responsive O 
antioxidant O 
polymeric O 
prodrug O 
of O 
vanillin B-TRIVIAL 
, O 
termed O 
poly(vanillin B-SYSTEMATIC 
oxalate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PVO B-ABBREVIATION 
) O 
. O 
In O 
design O 
, O 
PVO B-ABBREVIATION 
incorporates O 
H2O2 B-FORMULA 
-reacting O 
peroxalate B-SYSTEMATIC 
ester I-SYSTEMATIC 
bonds O 
and O 
bioactive O 
vanillin B-TRIVIAL 
via O 
acid O 
- O 
responsive O 
acetal B-SYSTEMATIC 
linkages O 
in O 
its O 
backbone O 
. O 
Therefore O 
, O 
in O 
cells O 
undergoing O 
damages O 
by O 
oxidative O 
stress O 
, O 
PVO B-ABBREVIATION 
readily O 
degrades O 
into O 
three O 
nontoxic O 
components O 
, O 
one O 
of O 
which O 
is O 
antioxidant O 
and O 
anti-inflammatory O 
vanillin B-TRIVIAL 
. O 
PVO B-ABBREVIATION 
nanoparticles O 
exhibit O 
potent O 
antioxidant O 
activities O 
by O 
scavenging O 
H2O2 B-FORMULA 
and O 
inhibiting O 
the O 
generation O 
of O 
ROS O 
( O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
) O 
and O 
also O 
reduce O 
the O 
expression O 
of O 
pro O 
- O 
inflammatory O 
cytokines O 
in O 
activated O 
macrophages O 
in O 
vitro O 
and O 
in O 
vivo O 
. O 
We O 
, O 
therefore O 
, O 
anticipate O 
that O 
PVO B-ABBREVIATION 
nanoparticles O 
have O 
great O 
potential O 
as O 
novel O 
antioxidant O 
therapeutics O 
and O 
drug O 
delivery O 
systems O 
for O 
ROS-associated O 
inflammatory O 
diseases O 
. O 

Morphology O 
of O 
Derivatives O 
of O 
Poly(3-alkylthiophene)s B-FAMILY 
by O 
Solvent O 
Vapor O 
Annealing O 
: O 
Effects O 
of O 
Conformational O 
Transition O 
and O 
Conjugate O 
Length O 
. O 

fibrillar O 
morphology O 
was O 
obtained O 
, O 
compared O 
to O 
the O 
featherless O 
pristine O 
films O 
, O 
via O 
solvent O 
annealing O 
the O 
films O 
of O 
a O 
series O 
of O 
derivatives O 
of O 
poly(3-alkylthiophene)s B-FAMILY 
( O 
P3ATs B-SYSTEMATIC 
) O 
: O 
poly(3-dodecylthiophene) B-SYSTEMATIC 
( O 
P3DDT B-SYSTEMATIC 
) O 
, O 
poly(3,3‴-didodecyl-quaterthiophene) B-SYSTEMATIC 
( O 
PQT12 B-ABBREVIATION 
) O 
, O 
and O 
poly(2,5-bis(3-dodecylthiophen-2-yl)thieno[3,2-b]thiophene) B-SYSTEMATIC 
( O 
pBTTT12 B-ABBREVIATION 
) O 
. O 
Among O 
the O 
solvents O 
used O 
, O 
including O 
dichloromethane B-SYSTEMATIC 
, O 
chloroform B-TRIVIAL 
, O 
tetrahydrofuran B-SYSTEMATIC 
, O 
and O 
carbon B-SYSTEMATIC 
disulfide I-SYSTEMATIC 
( O 
CS2 B-FORMULA 
) O 
, O 
CS2 B-FORMULA 
was O 
the O 
best O 
to O 
induce O 
fibril O 
formation O 
because O 
its O 
solubility O 
parameter O 
is O 
closest O 
to O 
those O 
of O 
the O 
P3AT B-SYSTEMATIC 
derivatives O 
. O 
It O 
was O 
found O 
that O 
higher O 
critical O 
CS2 B-FORMULA 
vapor O 
pressures O 
were O 
needed O 
to O 
form O 
crystal O 
nuclei O 
with O 
increasing O 
conjugation O 
length O 
and O 
molecular O 
weight O 
of O 
the O 
P3AT B-SYSTEMATIC 
derivatives O 
; O 
i.e O 
. O 
, O 
the O 
critical O 
vapor O 
pressures O 
for O 
P3DDT B-SYSTEMATIC 
13.9k O 
and O 
PQT12 B-ABBREVIATION 
15.5k O 
were O 
59.0% O 
and O 
80.7% O 
, O 
respectively O 
, O 
and O 
there O 
were O 
no O 
nuclei O 
of O 
fibrils O 
for O 
pBTTT12 B-ABBREVIATION 
15.6k O 
with O 
the O 
highest O 
conjugation O 
length O 
, O 
even O 
at O 
a O 
CS2 B-FORMULA 
vapor O 
pressure O 
of O 
98.3% O 
. O 
Meanwhile O 
, O 
at O 
the O 
highest O 
vapor O 
pressure O 
, O 
the O 
fibril O 
density O 
decreased O 
with O 
increasing O 
conjugation O 
length O 
and O 
molecular O 
weight O 
of O 
the O 
P3AT B-SYSTEMATIC 
derivatives O 
. O 
This O 
is O 
attributed O 
to O 
the O 
rod O 
- O 
like O 
conformation O 
prevailing O 
for O 
polymers O 
with O 
larger O 
conjugation O 
length O 
and O 
higher O 
molecular O 
weight O 
during O 
solvent O 
annealing O 
, O 
making O 
the O 
conformational O 
transition O 
toward O 
coils O 
more O 
difficult O 
and O 
hindering O 
diffusion O 
of O 
molecules O 
. O 
The O 
results O 
presented O 
here O 
are O 
expected O 
to O 
be O 
helpful O 
for O 
the O 
design O 
and O 
processing O 
of O 
conjugated O 
semiconductor O 
polymers O 
. O 

matrices O 
are O 
steadily O 
gaining O 
recognition O 
as O 
biological O 
samples O 
for O 
toxicological O 
analyses O 
. O 
Hair O 
presents O 
many O 
advantages O 
over O 
traditional O 
matrices O 
, O 
such O 
as O 
urine O 
and O 
blood O 
, O 
since O 
it O 
provides O 
retrospective O 
information O 
regarding O 
drug O 
exposure O 
, O 
can O 
distinguish O 
between O 
chronic O 
and O 
acute O 
or O 
recent O 
drug O 
use O 
by O 
segmental O 
analysis O 
, O 
is O 
easy O 
to O 
obtain O 
, O 
and O 
has O 
considerable O 
stability O 
for O 
long O 
periods O 
of O 
time O 
. O 
For O 
this O 
reason O 
, O 
it O 
has O 
been O 
employed O 
in O 
a O 
wide O 
variety O 
of O 
contexts O 
, O 
namely O 
to O 
evaluate O 
workplace O 
drug O 
exposure O 
, O 
drug O 
- O 
facilitated O 
sexual O 
assault O 
, O 
pre O 
- O 
natal O 
drug O 
exposure O 
, O 
anti-doping O 
control O 
, O 
pharmacological O 
monitoring O 
and O 
alcohol B-FAMILY 
abuse O 
. O 
In O 
this O 
article O 
, O 
issues O 
concerning O 
hair O 
structure O 
, O 
collection O 
, O 
storage O 
and O 
analysis O 
are O 
reviewed O 
. O 
The O 
mechanisms O 
of O 
drug O 
incorporation O 
into O 
hair O 
are O 
briefly O 
discussed O 
. O 
Analytical O 
techniques O 
for O 
simultaneous O 
drug O 
quantification O 
in O 
hair O 
are O 
addressed O 
. O 
Finally O 
, O 
representative O 
examples O 
of O 
drug O 
quantification O 
using O 
hair O 
are O 
summarized O 
, O 
emphasizing O 
its O 
potentialities O 
and O 
limitations O 
as O 
an O 
alternative O 
biological O 
matrix O 
for O 
toxicological O 
analyses O 
. O 

- O 
Layer O 
MoS2 B-FORMULA 
with O 
High O 
Broadband O 
Photogain O 
and O 
Fast O 
Optical O 
Switching O 
for O 
Use O 
in O 
Harsh O 
Environments O 
. O 

- O 
layered O 
MoS2 B-FORMULA 
as O 
Schottky O 
metal O 
- O 
semiconductor O 
- O 
metal O 
photodetectors O 
( O 
MSM O 
PDs O 
) O 
for O 
use O 
in O 
harsh O 
environments O 
makes O 
its O 
debut O 
as O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
optoelectronics O 
with O 
high O 
broadband O 
gain O 
( O 
up O 
to O 
13.3 O 
) O 
, O 
high O 
detectivity O 
( O 
up O 
to O 
∼10(10) O 
cm O 
Hz(1 O 
/ O 
2 O 
) O 
/ O 
W O 
) O 
, O 
fast O 
photoresponse O 
( O 
rise O 
time O 
of O 
∼70 O 
μs O 
and O 
fall O 
time O 
of O 
∼110 O 
μs O 
) O 
, O 
and O 
high O 
thermal O 
stability O 
( O 
at O 
a O 
working O 
temperature O 
of O 
up O 
to O 
200 O 
°C O 
) O 
. O 
Ultrahigh O 
responsivity O 
( O 
0.57 O 
A O 
/ O 
W O 
) O 
of O 
few O 
- O 
layer O 
MoS2 B-FORMULA 
at O 
532 O 
nm O 
is O 
due O 
to O 
the O 
high O 
optical O 
absorption O 
( O 
∼10% O 
despite O 
being O 
less O 
than O 
2 O 
nm O 
in O 
thickness O 
) O 
and O 
a O 
high O 
photogain O 
, O 
which O 
sets O 
up O 
a O 
new O 
record O 
that O 
was O 
not O 
achievable O 
in O 
2D O 
nanomaterials O 
previously O 
. O 
This O 
study O 
opens O 
avenues O 
to O 
develop O 
2D O 
nanomaterial O 
- O 
based O 
optoelectronics O 
for O 
harsh O 
environments O 
in O 
imaging O 
techniques O 
and O 
light O 
- O 
wave O 
communications O 
as O 
well O 
as O 
in O 
future O 
memory O 
storage O 
and O 
optoelectronic O 
circuits O 
. O 

Level O 
ab O 
initio O 
Calculations O 
for O 
ClFn(+) B-FAMILY 
( O 
n=1-6 O 
) O 
Ions O 
: O 
Refining O 
the O 
Recoupled O 
Pair O 
Bonding O 
Model O 
. O 

on O 
detailed O 
, O 
high O 
level O 
ab O 
initio O 
calculations O 
on O 
a O 
number O 
of O 
halogenated O 
compounds O 
of O 
second O 
row O 
, O 
late O 
p-block O 
elements O 
, O 
the O 
SFn B-FAMILY 
, O 
ClFn B-FAMILY 
, O 
PFn B-FAMILY 
, O 
SCln B-FAMILY 
, O 
and O 
SFnCl B-FAMILY 
families O 
, O 
we O 
found O 
that O 
a O 
new O 
type O 
of O 
bond O 
- O 
the O 
recoupled O 
pair O 
bond O 
- O 
accounts O 
for O 
the O 
ability O 
of O 
these O 
elements O 
to O 
form O 
hypervalent O 
, O 
or O 
hypercoordinated O 
, O 
compounds O 
. O 
Hypervalent O 
molecules O 
are O 
formed O 
when O 
it O 
is O 
energetically O 
favorable O 
for O 
the O 
electrons O 
in O 
a O 
lone O 
pair O 
orbital O 
to O 
be O 
recoupled O 
, O 
allowing O 
each O 
of O 
the O 
electrons O 
to O 
form O 
chemical O 
bonds O 
with O 
ligands O 
. O 
In O 
this O 
paper O 
, O 
we O 
characterize O 
the O 
structures O 
and O 
energetics O 
of O 
the O 
ground O 
and O 
low O 
- O 
lying O 
excited O 
states O 
of O 
the O 
ClFn(+) B-FAMILY 
( O 
n=1-6 O 
) O 
ions O 
, O 
using O 
high O 
level O 
ab O 
initio O 
methods O 
[ O 
MRCI O 
, O 
CCSD(T) O 
/ O 
RCCSD(T) O 
] O 
with O 
large O 
correlation O 
consistent O 
basis O 
sets O 
. O 
We O 
computed O 
a O 
number O 
of O 
quantities O 
, O 
including O 
ClFn(+) B-FAMILY 
structures O 
, O 
bond O 
dissociation O 
energies O 
and O 
ClFn B-FAMILY 
ionization O 
energies O 
, O 
and O 
compare O 
our O 
results O 
with O 
the O 
available O 
experimental O 
data O 
. O 
Both O 
the O 
bond O 
dissociation O 
energies O 
and O 
ionization O 
energies O 
oscillate O 
, O 
variations O 
that O 
are O 
readily O 
explained O 
using O 
the O 
recoupled O 
pair O 
bonding O 
model O 
. O 
Comparisons O 
are O 
drawn O 
between O 
the O 
ClFn(+) B-FAMILY 
cations O 
and O 
their O 
counterparts O 
in O 
the O 
isoelectronic O 
SFn B-FAMILY 
series O 
, O 
which O 
possess O 
many O 
similarities O 
. O 
We O 
found O 
two O 
significant O 
differences O 
between O 
the O 
ClFn(+) B-FAMILY 
and O 
SFn B-FAMILY 
series O 
: O 
(i) O 
the O 
bond O 
dissociation O 
energies O 
of O 
ClFn(+) B-FAMILY 
are O 
much O 
weaker O 
than O 
those O 
of O 
the O 
corresponding O 
SFn B-FAMILY 
species O 
, O 
and O 
(ii) O 
there O 
is O 
no O 
stable O 
(3)A2 O 
state O 
in O 
ClF2(+) B-FORMULA 
corresponding O 
to O 
the O 
stable O 
state O 
found O 
in O 
SF2 B-FORMULA 
. O 
Examination O 
of O 
the O 
Mulliken O 
populations O 
at O 
the O 
HF B-FORMULA 
/ O 
AVTZ O 
level O 
for O 
ClFn(+) B-FAMILY 
and O 
SFn B-FAMILY 
species O 
predicts O 
that O 
the O 
F B-FORMULA 
atom O 
in O 
the O 
axial O 
( O 
recoupled O 
pair O 
bonding O 
) O 
position O 
is O 
more O 
highly O 
charged O 
than O 
the O 
F B-FORMULA 
atom O 
in O 
the O 
equatorial O 
( O 
covalent O 
bonding O 
) O 
position O 
; O 
there O 
is O 
also O 
less O 
change O 
transfer O 
to O 
the O 
F B-FORMULA 
atoms O 
in O 
ClFn(+) B-FAMILY 
than O 
in O 
SFn B-FAMILY 
. O 
The O 
positive O 
charge O 
on O 
Cl(+) B-FORMULA 
makes O 
it O 
more O 
difficult O 
for O 
an O 
F B-FORMULA 
atom O 
to O 
attract O 
electrons O 
from O 
Cl(+) B-FORMULA 
than O 
from O 
S B-FORMULA 
and O 
correspondingly O 
less O 
favorable O 
to O 
recouple O 
the O 
electrons O 
in O 
the O 
lone O 
pair O 
orbitals O 
in O 
the O 
ClFn(+) B-FAMILY 
species O 
. O 

Glutamate B-TRIVIAL 
Receptor O 
- O 
Like O 
Proteins O 
in O 
Phloem O 
Regulate O 
Lateral O 
Root O 
Initiation O 
in O 
Arabidopsis O 
. O 

, O 
genetic O 
, O 
and O 
electrophysiological O 
evidence O 
indicates O 
that O 
at O 
least O 
one O 
of O 
the O 
plant O 
Glu O 
receptor O 
- O 
like O 
molecules O 
, O 
GLR3.4 O 
, O 
functions O 
as O 
an O 
amino B-FAMILY 
acid I-FAMILY 
-gated O 
Ca(2+) B-FORMULA 
channel O 
at O 
the O 
plasma O 
membrane O 
. O 
The O 
aspect O 
of O 
plant O 
physiology O 
, O 
growth O 
, O 
or O 
development O 
to O 
which O 
GLR3.4 O 
contributes O 
is O 
an O 
open O 
question O 
. O 
Protein O 
localization O 
studies O 
performed O 
here O 
provide O 
important O 
information O 
. O 
In O 
roots O 
, O 
GLR3.4 O 
and O 
the O 
related O 
GLR3.2 O 
protein O 
were O 
present O 
primarily O 
in O 
the O 
phloem O 
, O 
especially O 
in O 
the O 
vicinity O 
of O 
the O 
sieve O 
plates O 
. O 
GLR3.3 O 
was O 
expressed O 
in O 
most O 
cells O 
of O 
the O 
growing O 
primary O 
root O 
but O 
was O 
not O 
enriched O 
in O 
the O 
phloem O 
, O 
including O 
the O 
sieve O 
plate O 
area O 
. O 
GLR3.2 O 
and O 
GLR3.4 O 
physically O 
interacted O 
with O 
each O 
other O 
better O 
than O 
with O 
themselves O 
as O 
evidenced O 
by O 
a O 
biophotonic O 
assay O 
performed O 
in O 
human O 
embryonic O 
kidney O 
cells O 
and O 
Nicotiana O 
benthamiana O 
leaf O 
cells O 
. O 
GLR3.3 O 
interacted O 
poorly O 
with O 
itself O 
or O 
the O 
other O 
two O 
GLRs O 
. O 
Mutations O 
in O 
GLR3.2 O 
, O 
GLR3.4 O 
, O 
or O 
GLR3.2 O 
and O 
GLR3.4 O 
caused O 
the O 
same O 
and O 
equally O 
severe O 
phenotype O 
, O 
namely O 
, O 
a O 
large O 
overproduction O 
and O 
aberrant O 
placement O 
of O 
lateral O 
root O 
primordia O 
. O 
Loss O 
of O 
GLR3.3 O 
did O 
not O 
affect O 
lateral O 
root O 
primordia O 
. O 
These O 
results O 
support O 
the O 
hypothesis O 
that O 
apoplastic O 
amino B-FAMILY 
acids I-FAMILY 
acting O 
through O 
heteromeric O 
GLR3.2 O 
/ O 
GLR3.4 O 
channels O 
affect O 
lateral O 
root O 
development O 
via O 
Ca(2+) B-FORMULA 
signaling O 
in O 
the O 
phloem O 
. O 

acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
ameliorates O 
paraquat B-TRIVIAL 
-induced O 
pulmonary O 
fibrosis O 
in O 
rats O 
possibly O 
through O 
up O 
- O 
regulation O 
of O 
Smad O 
7 O 
and O 
SnoN O 
. O 

( O 
PQ O 
) O 
poisoning O 
has O 
caused O 
a O 
large O 
number O 
of O 
human O 
fatalities O 
due O 
to O 
the O 
progressive O 
and O 
irreversible O 
pulmonary O 
fibrosis O 
. O 
Docosahexaenoic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
DHA B-ABBREVIATION 
) O 
is O 
well O 
- O 
recognized O 
as O 
important O 
modulators O 
of O 
multiple O 
biological O 
pathways O 
that O 
affect O 
health O 
and O 
disease O 
. O 
A O 
line O 
of O 
studies O 
have O 
shown O 
that O 
DHA B-ABBREVIATION 
supplementation O 
is O 
associated O 
with O 
the O 
alleviation O 
of O 
some O 
tissue O 
fibrosis O 
. O 
In O 
the O 
current O 
study O 
, O 
pulmonary O 
fibrosis O 
of O 
rats O 
was O 
produced O 
by O 
a O 
single O 
oral O 
dose O 
of O 
50mg O 
/ O 
kgbw O 
PQ O 
treatment O 
. O 
Daily O 
500mg O 
/ O 
kgbw O 
DHA B-ABBREVIATION 
supplementation O 
was O 
provided O 
7days O 
before O 
PQ O 
treatment O 
and O 
lasted O 
for O 
consecutive O 
35days O 
. O 
DHA B-ABBREVIATION 
was O 
found O 
to O 
ameliorate O 
the O 
pulmonary O 
fibrotic O 
alterations O 
induced O 
by O 
PQ O 
, O 
which O 
was O 
evidenced O 
by O 
significant O 
reduction O 
of O 
histological O 
changes O 
, O 
hydroxyproline B-SYSTEMATIC 
content O 
and O 
level O 
of O 
the O 
transforming O 
growth O 
factor-β1 O 
( O 
TGF-β1 O 
) O 
mRNA O 
. O 
Furthermore O 
, O 
the O 
protein O 
levels O 
of O 
Smad O 
7 O 
and O 
SnoN O 
in O 
the O 
DHA B-ABBREVIATION 
supplemented O 
rats O 
were O 
significantly O 
increased O 
compared O 
with O 
those O 
in O 
the O 
rats O 
of O 
the O 
PQ O 
group O 
. O 
These O 
results O 
suggested O 
that O 
DHA B-ABBREVIATION 
ameliorated O 
pulmonary O 
fibrosis O 
induced O 
by O 
PQ O 
might O 
be O 
attributed O 
to O 
its O 
enhancement O 
of O 
Smad O 
7 O 
and O 
SnoN O 
expression O 
. O 

and O 
ethanol B-SYSTEMATIC 
intake O 
exert O 
opposite O 
effects O 
on O 
circulating O 
estradiol B-TRIVIAL 
and O 
progesterone B-TRIVIAL 
and O 
differentially O 
regulate O 
sex O 
steroid B-FAMILY 
receptors O 
in O 
the O 
ovaries O 
, O 
oviducts O 
, O 
and O 
uteri O 
of O 
adult O 
rats O 
. O 

ethanol B-SYSTEMATIC 
intake O 
is O 
associated O 
with O 
sex O 
hormone O 
disturbances O 
, O 
and O 
it O 
is O 
well O 
known O 
that O 
melatonin B-TRIVIAL 
plays O 
a O 
key O 
role O 
in O 
regulating O 
several O 
reproductive O 
processes O 
. O 
We O 
report O 
the O 
effects O 
of O 
ethanol B-SYSTEMATIC 
intake O 
and O 
melatonin B-TRIVIAL 
treatment O 
( O 
at O 
doses O 
of O 
100μg O 
/ O 
100gBW O 
/ O 
day O 
) O 
on O 
sex O 
hormones O 
and O 
steroid B-FAMILY 
receptors O 
in O 
the O 
ovaries O 
, O 
oviducts O 
and O 
uteri O 
of O 
ethanol B-SYSTEMATIC 
-preferring O 
rats O 
. O 
After O 
150 O 
days O 
of O 
treatment O 
, O 
animals O 
were O 
euthanized O 
, O 
and O 
tissue O 
samples O 
were O 
harvested O 
to O 
evaluate O 
androgen B-FAMILY 
, O 
estrogen B-FAMILY 
, O 
progesterone B-TRIVIAL 
and O 
melatonin B-TRIVIAL 
receptor O 
subunits O 
( O 
AR O 
, O 
ER-α O 
and O 
ER-β O 
, O 
PRA O 
, O 
PRB O 
and O 
MT1R O 
, O 
respectively O 
) O 
. O 
Melatonin B-TRIVIAL 
decreased O 
estradiol B-TRIVIAL 
( O 
E2 O 
) O 
and O 
increased O 
progesterone B-TRIVIAL 
( O 
P4 O 
) O 
and O 
6-sulfatoxymelatonin B-SYSTEMATIC 
( O 
6-STM B-SYSTEMATIC 
) O 
, O 
while O 
an O 
ethanol B-SYSTEMATIC 
- O 
melatonin B-TRIVIAL 
combination O 
reduced O 
both O 
P4 O 
and O 
E2 O 
. O 
Ovarian O 
AR O 
was O 
not O 
influenced O 
by O 
either O 
treatment O 
, O 
and O 
oviduct O 
AR O 
was O 
reduced O 
after O 
ethanol B-SYSTEMATIC 
- O 
melatonin B-TRIVIAL 
combination O 
. O 
Oviduct O 
ER-α O 
, O 
ER-β O 
and O 
uterine O 
ER-β O 
were O 
down O 
- O 
regulated O 
by O 
either O 
ethanol B-SYSTEMATIC 
or O 
melatonin B-TRIVIAL 
. O 
Conversely O 
, O 
ovarian O 
PRA O 
and O 
PRB O 
were O 
positively O 
regulated O 
by O 
ethanol B-SYSTEMATIC 
and O 
ethanol B-SYSTEMATIC 
- O 
melatonin B-TRIVIAL 
combination O 
, O 
whereas O 
PRA O 
was O 
down O 
- O 
regulated O 
in O 
the O 
uterus O 
and O 
oviduct O 
after O 
ethanol B-SYSTEMATIC 
consumption O 
. O 
MT1R O 
was O 
increased O 
in O 
ovaries O 
and O 
uteri O 
of O 
melatonin B-TRIVIAL 
-treated O 
rats O 
. O 
Ethanol B-SYSTEMATIC 
and O 
melatonin B-TRIVIAL 
exert O 
opposite O 
effects O 
on O 
E2 O 
and O 
P4 O 
, O 
and O 
they O 
differentially O 
regulate O 
the O 
expression O 
of O 
sex O 
steroid B-FAMILY 
receptors O 
in O 
female O 
reproductive O 
tissues O 
. O 

have O 
synthesized O 
a O 
β-cyclodextrin B-TRIVIAL 
( O 
βCD B-ABBREVIATION 
)-capped O 
histone O 
deacetylase O 
( O 
HDAC O 
) O 
inhibitor O 
3 O 
containing O 
an O 
alkyl O 
linker O 
and O 
a O 
zinc B-SYSTEMATIC 
-binding O 
hydroxamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
motif O 
. O 
Biological O 
evaluation O 
( O 
HDAC O 
inhibition O 
studies O 
) O 
of O 
3 O 
enabled O 
us O 
to O 
establish O 
the O 
effect O 
of O 
replacing O 
an O 
aryl O 
cap O 
( O 
in O 
SAHA B-ABBREVIATION 
( O 
vorinostat B-TRIVIAL 
, O 
) O 
) O 
1 O 
by O 
a O 
large O 
saccharidic O 
scaffold O 
" O 
cap O 
" O 
. O 
HDAC O 
inhibition O 
was O 
observed O 
for O 
3 O 
, O 
to O 
a O 
lesser O 
extent O 
than O 
SAHA B-ABBREVIATION 
, O 
and O 
rationalized O 
by O 
molecular O 
docking O 
into O 
the O 
active O 
site O 
of O 
HDAC8 O 
. O 
However O 
, O 
compound O 
3 O 
displayed O 
no O 
cellular O 
activity O 
. O 

secondary O 
ion O 
mass O 
spectrometry O 
is O 
now O 
widely O 
used O 
for O 
the O 
characterization O 
of O 
nanostructures O 
. O 
In O 
order O 
to O 
gain O 
a O 
better O 
understanding O 
of O 
the O 
physics O 
of O 
keV O 
cluster O 
bombardment O 
of O 
surfaces O 
and O 
nanoparticles O 
( O 
NPs O 
) O 
, O 
the O 
effects O 
of O 
the O 
atomic O 
masses O 
of O 
the O 
projectile O 
and O 
of O 
the O 
target O 
on O 
the O 
energy O 
deposition O 
and O 
induced O 
sputtering O 
have O 
been O 
studied O 
by O 
means O 
of O 
molecular O 
dynamics O 
simulations O 
. O 
10 O 
keV O 
C60 B-TRIVIAL 
was O 
used O 
as O 
a O 
model O 
projectile O 
and O 
impacts O 
on O 
both O 
a O 
flat O 
polymer O 
surface O 
and O 
a O 
metal O 
NP O 
were O 
analyzed O 
. O 
In O 
the O 
first O 
case O 
, O 
the O 
mass O 
of O 
the O 
impinging O 
carbon B-SYSTEMATIC 
atoms O 
was O 
artificially O 
varied O 
and O 
, O 
in O 
the O 
second O 
case O 
, O 
the O 
mass O 
of O 
the O 
NP O 
atoms O 
was O 
varied O 
. O 
The O 
results O 
can O 
be O 
rationalized O 
on O 
the O 
basis O 
of O 
the O 
different O 
atomic O 
mass O 
ratios O 
of O 
the O 
projectile O 
and O 
target O 
. O 
In O 
general O 
, O 
the O 
emission O 
is O 
at O 
its O 
maximum O 
, O 
when O 
the O 
projectile O 
and O 
target O 
have O 
the O 
same O 
atomic O 
masses O 
. O 
In O 
the O 
case O 
of O 
the O 
supported O 
NP O 
, O 
the O 
emission O 
of O 
the O 
underlying O 
organic O 
material O 
increases O 
as O 
the O 
atomic O 
mass O 
of O 
the O 
NP O 
decreases O 
. O 
However O 
, O 
it O 
is O 
always O 
less O 
than O 
that O 
calculated O 
for O 
the O 
bare O 
organic O 
surface O 
, O 
irrespective O 
of O 
the O 
mass O 
ratio O 
. O 
The O 
results O 
obtained O 
with O 
C60 B-TRIVIAL 
impacts O 
on O 
the O 
flat O 
polymer O 
are O 
also O 
compared O 
to O 
simulations O 
of O 
C60 B-TRIVIAL 
and O 
monoatomic O 
Ga B-FORMULA 
impacts O 
on O 
the O 
NP O 
. O 

effect O 
of O 
methylsulfonylmethane B-SYSTEMATIC 
against O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-induced O 
acute O 
liver O 
injury O 
in O 
rats O 
. O 

study O 
evaluated O 
the O 
effect O 
of O 
methylsulfonylmethane B-SYSTEMATIC 
( O 
MSM B-ABBREVIATION 
) O 
on O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
( O 
CCl4 B-FORMULA 
)-induced O 
acute O 
liver O 
injury O 
in O 
rats O 
. O 
A O 
single O 
injection O 
of O 
CCl4 B-FORMULA 
( O 
2 O 
ml O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
increased O 
serum O 
aminotransferases O 
( O 
ALT O 
and O 
AST O 
) O 
activities O 
. O 
In O 
addition O 
, O 
CCl4 B-FORMULA 
treatment O 
led O 
to O 
elevation O 
of O 
hepatic O 
malondialdehyde B-TRIVIAL 
( O 
MDA B-ABBREVIATION 
) O 
content O 
as O 
well O 
as O 
decrease O 
in O 
superoxide B-TRIVIAL 
dismutase O 
( O 
SOD O 
) O 
and O 
catalase O 
( O 
CAT O 
) O 
activities O 
. O 
Furthermore O 
, O 
cytochrome O 
P450 O 
20 O 
( O 
CYP2E1 O 
) O 
content O 
was O 
suppressed O 
while O 
proinflammatory O 
cytokines O 
tumour O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
and O 
interleukin-6 O 
( O 
IL-6 O 
) O 
levels O 
increased O 
in O 
liver O 
tissue O 
after O 
CCl4 B-FORMULA 
administration O 
. O 
We O 
showed O 
that O 
acute O 
CCl4 B-FORMULA 
-induced O 
damage O 
was O 
accompanied O 
by O 
a O 
rise O 
in O 
Bax O 
/ O 
Bcl2 O 
ratio O 
indicating O 
apoptosis O 
. O 
Pre O 
- O 
treatment O 
with O 
MSM B-ABBREVIATION 
( O 
400 O 
mg O 
/ O 
kg O 
) O 
inhibited O 
the O 
increases O 
of O 
serum O 
ALT O 
and O 
AST O 
activities O 
, O 
decreased O 
hepatic O 
MDA B-ABBREVIATION 
, O 
TNF-α O 
, O 
IL-6 O 
and O 
Bax O 
/ O 
Bcl2 O 
ratio O 
compared O 
to O 
CCl4 B-FORMULA 
treated O 
group O 
. O 
On O 
the O 
other O 
hand O 
, O 
MSM B-ABBREVIATION 
raised O 
SOD O 
and O 
CAT O 
activities O 
as O 
well O 
as O 
CYP2E1 O 
level O 
in O 
liver O 
tissues O 
. O 
The O 
present O 
study O 
shows O 
that O 
MSM B-ABBREVIATION 
possesses O 
a O 
hepatoprotective O 
effect O 
against O 
CCl4 B-FORMULA 
-induced O 
liver O 
injury O 
in O 
rats O 
. O 
This O 
protective O 
effect O 
might O 
be O 
through O 
its O 
antioxidant O 
, O 
anti-inflammatory O 
and O 
antiapoptotic O 
properties O 
. O 

ischemia O 
is O 
a O 
leading O 
cause O 
of O 
death O 
, O 
especially O 
in O 
diabetic O 
patients O 
. O 
The O 
diabetic O 
ischemic O 
heart O 
is O 
resistant O 
experimentally O 
to O 
established O 
cardioprotective O 
treatments O 
. O 
New O 
pharmacological O 
approaches O 
to O 
cardiac O 
protection O 
are O 
warranted O 
. O 
The O 
kallikrein O 
- O 
kinin O 
system O 
is O 
involved O 
in O 
myocardial O 
protection O 
in O 
ischemia O 
. O 
Respective O 
role O 
of O 
B1 O 
( O 
B1R O 
) O 
and O 
B2 O 
( O 
B2R O 
) O 
receptors O 
remains O 
controversial O 
. O 
We O 
tested O 
whether O 
pharmacological O 
activation O 
of O 
kinin O 
receptors O 
may O 
have O 
therapeutic O 
effect O 
in O 
cardiac O 
ischemia O 
- O 
reperfusion O 
in O 
non O 
diabetic O 
( O 
NDiab O 
) O 
and O 
diabetic O 
( O 
Diab O 
) O 
mice O 
. O 
We O 
assessed O 
effect O 
on O 
infarct O 
size O 
( O 
IS O 
) O 
and O 
signaling O 
pathways O 
involved O 
in O 
myocardial O 
protection O 
of O 
potent O 
selective O 
pharmacological O 
agonists O 
of O 
B1R O 
or O 
B2R O 
given O 
at O 
reperfusion O 
. O 
In O 
NDiab O 
mice O 
, O 
a O 
B2R O 
agonist O 
reduced O 
significantly O 
IS O 
by O 
47% O 
, O 
similarly O 
to O 
ramiprilat O 
or O 
ischemic O 
postconditioning O 
, O 
via O 
activation O 
of O 
PI3K O 
/ O 
Akt O 
pathway O 
leading O 
to O 
inhibition O 
of O 
GSK3β O 
. O 
B1R O 
agonist O 
has O 
no O 
effect O 
on O 
IS O 
. O 
In O 
contrast O 
, O 
in O 
Diab O 
mice O 
, O 
the O 
B2R O 
agonist O 
, O 
ramiprilat B-TRIVIAL 
or O 
ischemic O 
postconditioning O 
failed O 
to O 
reduce O 
IS O 
but O 
a O 
B1R O 
agonist O 
significantly O 
reduced O 
IS O 
by O 
44% O 
via O 
activation O 
of O 
PI3K O 
/ O 
Akt O 
and O 
ERK1 O 
/ O 
2 O 
, O 
both O 
leading O 
to O 
GSK3β O 
inhibition O 
. O 
Differential O 
effect O 
of O 
B2R O 
or O 
B1R O 
agonists O 
in O 
NDiab O 
and O 
Diab O 
mice O 
can O 
be O 
linked O 
to O 
inactivation O 
of O 
B2R O 
signaling O 
and O 
induction O 
of O 
B1R O 
in O 
heart O 
of O 
Diab O 
mice O 
. O 
Thus O 
, O 
a O 
pharmacological O 
B2R O 
agonist O 
is O 
cardioprotective O 
in O 
acute O 
ischemia O 
in O 
non O 
diabetic O 
animals O 
. O 
B1R O 
agonist O 
overcomes O 
resistance O 
of O 
diabetic O 
heart O 
to O 
cardioprotective O 
treatments O 
. O 
Pharmacological O 
activation O 
of O 
B1R O 
and O 
B2R O 
may O 
become O 
treatment O 
for O 
diabetic O 
and O 
non O 
diabetic O 
patients O 
respectively O 
in O 
acute O 
coronary O 
syndromes O 
. O 

: O 
androgen B-FAMILY 
metabolism O 
in O 
castration O 
- O 
resistant O 
prostate O 
cancer O 
. O 

decades O 
- O 
old O 
terminology O 
of O 
androgen B-FAMILY 
independence O 
has O 
been O 
replaced O 
in O 
recent O 
years O 
with O 
castration O 
- O 
resistant O 
prostate O 
cancer O 
. O 
Biological O 
and O 
clinical O 
evidence O 
have O 
together O 
conspired O 
to O 
support O 
the O 
use O 
of O 
this O 
revised O 
terminology O 
by O 
demonstrating O 
that O 
in O 
the O 
vast O 
majority O 
of O 
cases O 
tumors O 
are O 
neither O 
truly O 
depleted O 
of O 
androgens B-FAMILY 
, O 
nor O 
are O 
they O 
free O 
of O 
the O 
requirement O 
for O 
androgens B-FAMILY 
to O 
sustain O 
growth O 
and O 
progression O 
. O 
Abiraterone B-SYSTEMATIC 
acetate I-SYSTEMATIC 
, O 
an O 
androgen B-FAMILY 
synthesis O 
inhibitor O 
, O 
and O 
enzalutamide B-TRIVIAL 
, O 
a O 
potent O 
androgen B-FAMILY 
receptor O 
antagonist O 
, O 
both O 
exploit O 
the O 
continued O 
requirement O 
for O 
androgens B-FAMILY 
. O 
A O 
central O 
question O 
, O 
given O 
the O 
therapeutic O 
gains O 
enabled O 
by O 
further O 
suppression O 
of O 
the O 
androgen B-FAMILY 
axis O 
with O 
these O 
newer O 
agents O 
, O 
is O 
whether O 
there O 
may O 
be O 
additional O 
clinical O 
benefit O 
gained O 
by O 
moving O 
the O 
goal O 
posts O 
of O 
androgen B-FAMILY 
suppression O 
even O 
further O 
. O 
The O 
answer O 
lies O 
in O 
part O 
with O 
the O 
mechanisms O 
utilized O 
by O 
tumors O 
that O 
enable O 
resistance O 
to O 
these O 
therapies O 
. O 
The O 
aims O 
of O 
this O 
review O 
were O 
to O 
give O 
a O 
broad O 
outline O 
of O 
steroidogenesis O 
in O 
prostate O 
cancer O 
and O 
to O 
highlight O 
recent O 
developments O 
in O 
understanding O 
resistance O 
to O 
hormonal O 
therapies O 
. O 

stress O 
is O 
considered O 
to O 
be O 
a O 
key O 
mechanism O 
of O 
hepatocellular O 
injury O 
and O 
disease O 
progression O 
in O 
patients O 
with O 
nonalcoholic O 
steatohepatitis O 
( O 
NASH O 
) O 
. O 
The O 
transcription O 
factor O 
Nrf2 O 
plays O 
a O 
central O 
role O 
in O 
stimulating O 
expression O 
of O 
various O 
antioxidant O 
- O 
associated O 
genes O 
in O 
the O 
cellular O 
defense O 
against O 
oxidative O 
stress O 
. O 
As O 
the O 
cytosolic O 
repressor O 
Keap1 O 
negatively O 
regulates O 
Nrf2 O 
, O 
activation O 
of O 
Nrf2 O 
facilitated O 
by O 
its O 
release O 
from O 
Keap1 O 
may O 
represent O 
a O 
promising O 
strategy O 
in O 
the O 
treatment O 
of O 
NASH O 
. O 
To O 
test O 
this O 
hypothesis O 
, O 
we O 
utilized O 
two O 
chemically O 
distinct O 
types O 
of O 
Nrf2-activator O 
. O 
One O 
is O 
the O 
thiol B-FAMILY 
-reactive O 
agent O 
oltipraz B-TRIVIAL 
( O 
OPZ B-ABBREVIATION 
) O 
, O 
a O 
typical O 
Nrf2-activator O 
, O 
and O 
the O 
other O 
is O 
a O 
novel O 
biaryl O 
urea B-TRIVIAL 
compound O 
, O 
termed O 
NK-252 B-IDENTIFIER 
. O 
NK-252 B-IDENTIFIER 
exhibits O 
a O 
greater O 
Nrf2-activating O 
potential O 
than O 
OPZ B-ABBREVIATION 
. O 
Furthermore O 
, O 
in O 
vitro O 
binding O 
studies O 
revealed O 
that O 
NK-252 B-IDENTIFIER 
interacts O 
with O 
the O 
domain O 
containing O 
the O 
Nrf2 O 
- O 
binding O 
site O 
of O 
Keap1 O 
, O 
whereas O 
OPZ B-ABBREVIATION 
does O 
not O 
. O 
This O 
finding O 
indicates O 
that O 
NK-252 B-IDENTIFIER 
is O 
more O 
potent O 
than O 
OPZ B-ABBREVIATION 
due O 
to O 
its O 
unique O 
mechanism O 
of O 
action O 
. O 
For O 
in O 
vivo O 
animal O 
model O 
studies O 
, O 
we O 
employed O 
rats O 
on O 
a O 
choline B-FAMILY 
-deficient O 
L-amino B-FAMILY 
acid I-FAMILY 
-defined O 
(CDAA)-diet O 
, O 
which O 
demonstrate O 
pathological O 
findings O 
similar O 
to O 
those O 
seen O 
in O 
human O 
NASH O 
. O 
The O 
administration O 
of O 
OPZ B-ABBREVIATION 
or O 
NK-252 B-IDENTIFIER 
significantly O 
attenuated O 
the O 
progression O 
of O 
histological O 
abnormalities O 
in O 
rats O 
on O 
a O 
CDAA O 
diet O 
, O 
especially O 
hepatic O 
fibrosis O 
. O 
In O 
conclusion O 
, O 
by O 
using O 
Nrf2-activators O 
with O 
independent O 
mechanisms O 
of O 
action O 
, O 
we O 
show O 
in O 
a O 
rat O 
model O 
of O 
NASH O 
that O 
the O 
activation O 
of O 
Nrf2 O 
is O 
responsible O 
for O 
the O 
anti-fibrotic O 
effects O 
of O 
these O 
drugs O 
. O 
This O 
strategy O 
of O 
Nrf2 O 
activation O 
presents O 
new O 
opportunities O 
for O 
treatment O 
of O 
NASH O 
patients O 
with O 
hepatic O 
fibrosis O 
. O 

, O 
Synthesis O 
and O 
Biological O 
Evaluation O 
of O 
Trimethine B-SYSTEMATIC 
Cyanine I-SYSTEMATIC 
Dyes O 
as O 
Fluorescent O 
Probes O 
for O 
the O 
Detection O 
of O 
Tau O 
Fibrils O 
in O 
Alzheimer's O 
Disease O 
Brain O 
and O 
Olfactory O 
Epithelium O 
. O 

light O 
on O 
grey O 
matter O 
: O 
Fluorescent O 
trimethine B-FAMILY 
cyanines I-FAMILY 
were O 
evaluated O 
as O 
imaging O 
probes O 
for O 
neurofibrillary O 
tangles O 
in O 
post O 
- O 
mortem O 
brain O 
sections O 
of O 
Alzheimer's O 
disease O 
patients O 
. O 
These O 
probes O 
bind O 
to O 
neurofibrillary O 
tangles O 
with O 
high O 
contrast O 
and O 
selectivity O 
over O 
amyloid O 
β O 
plaques O 
. O 

( O 
Cubn O 
) O 
is O 
a O 
multiligand O 
endocytic O 
receptor O 
critical O 
for O 
the O 
intestinal O 
absorption O 
of O 
vitamin B-TRIVIAL 
B12 I-TRIVIAL 
and O 
renal O 
protein O 
reabsorption O 
. O 
During O 
mouse O 
development O 
Cubn O 
is O 
expressed O 
in O 
both O 
embryonic O 
and O 
extra O 
- O 
embryonic O 
tissues O 
and O 
Cubn O 
gene O 
inactivation O 
results O 
in O 
early O 
embryo O 
- O 
lethality O 
most O 
likely O 
due O 
to O 
the O 
impairment O 
of O 
the O 
function O 
of O 
extra O 
- O 
embryonic O 
Cubn O 
. O 
We O 
here O 
focus O 
on O 
the O 
developmental O 
role O 
of O 
Cubn O 
expressed O 
in O 
the O 
embryonic O 
head O 
. O 
We O 
report O 
that O 
Cubn O 
is O 
a O 
novel O 
, O 
interspecies O 
conserved O 
Fgf O 
receptor O 
. O 
Epiblast O 
- O 
specific O 
inactivation O 
of O 
Cubn O 
in O 
the O 
mouse O 
embryo O 
as O 
well O 
as O 
Cubn O 
silencing O 
in O 
the O 
anterior O 
head O 
of O 
frog O 
or O 
the O 
cephalic O 
neural O 
crest O 
of O 
chick O 
embryos O 
show O 
that O 
Cubn O 
is O 
required O 
during O 
early O 
somite O 
stages O 
to O 
convey O 
survival O 
signals O 
in O 
the O 
developing O 
vertebrate O 
head O 
. O 
Surface O 
Plasmon O 
resonance O 
analysis O 
reveals O 
that O 
fibroblast O 
growth O 
factor O 
8 O 
( O 
Fgf8 O 
) O 
, O 
a O 
key O 
mediator O 
of O 
cell O 
survival O 
, O 
migration O 
, O 
proliferation O 
and O 
patterning O 
in O 
the O 
developing O 
head O 
is O 
a O 
high O 
affinity O 
ligand O 
for O 
Cubn O 
. O 
Cell O 
uptake O 
studies O 
show O 
that O 
binding O 
to O 
Cubn O 
is O 
necessary O 
for O 
the O 
phosphorylation O 
of O 
the O 
Fgf O 
signaling O 
mediators O 
MAPK O 
and O 
Smad1 O 
. O 
Although O 
Cubn O 
may O 
not O 
form O 
stable O 
ternary O 
complexes O 
with O 
Fgf O 
receptors O 
( O 
FgfRs O 
) O 
it O 
acts O 
together O 
with O 
and O 
/ O 
or O 
is O 
necessary O 
for O 
optimal O 
FgfR O 
activity O 
. O 
We O 
propose O 
that O 
plasma O 
membrane O 
binding O 
of O 
Fgf8 O 
, O 
and O 
most O 
likely O 
of O 
the O 
Fgf8 O 
family O 
members O 
Fgf17 O 
and O 
Fgf18 O 
, O 
to O 
Cubn O 
improves O 
Fgf O 
ligand O 
endocytosis O 
and O 
availability O 
to O 
FgfRs O 
, O 
thus O 
modulating O 
Fgf O 
signaling O 
activity O 
. O 

are O 
hydrophilic O 
structural O 
proteins O 
produced O 
by O 
caterpillars O 
in O 
the O 
middle O 
section O 
of O 
silk O 
glands O 
and O 
are O 
layered O 
over O 
fibroin O 
proteins O 
secreted O 
in O 
the O 
posterior O 
section O 
. O 
In O 
the O 
process O 
of O 
spinning O 
, O 
fibroins O 
form O 
strong O 
solid O 
filaments O 
, O 
while O 
sericins O 
seal O 
the O 
pair O 
of O 
filaments O 
into O 
a O 
single O 
fiber O 
and O 
glue O 
the O 
fiber O 
into O 
a O 
cocoon O 
. O 
Galleria O 
mellonella O 
and O 
the O 
previously O 
examined O 
Bombyx O 
mori O 
harbor O 
three O 
sericin O 
genes O 
that O 
encode O 
proteins O 
containing O 
long O 
repetitive O 
regions O 
. O 
Galleria O 
sericin O 
genes O 
are O 
similar O 
to O 
each O 
other O 
and O 
the O 
protein O 
repeats O 
are O 
built O 
from O 
short O 
and O 
extremely O 
serine B-TRIVIAL 
-rich O 
motifs O 
, O 
while O 
Bombyx O 
sericin O 
genes O 
are O 
diversified O 
and O 
encode O 
proteins O 
with O 
long O 
and O 
complex O 
repeats O 
. O 
Developmental O 
changes O 
in O 
sericin O 
properties O 
are O 
controlled O 
at O 
the O 
level O 
of O 
gene O 
expression O 
and O 
splicing O 
. O 
In O 
Galleria O 
, O 
MG-1 O 
sericin O 
is O 
produced O 
throughout O 
larval O 
life O 
until O 
the O 
wandering O 
stage O 
, O 
while O 
the O 
production O 
of O 
MG-2 O 
and O 
MG-3 O 
reaches O 
a O 
peak O 
during O 
cocoon O 
spinning O 
. O 

Diacetyl B-SYSTEMATIC 
a O 
Respiratory O 
Sensitizer O 
? O 
A O 
Reconsideration O 
Using O 
QSAR O 
, O 
QMM O 
, O 
and O 
Competition O 
Experiments O 
. O 

have O 
been O 
raised O 
that O 
diacetyl B-SYSTEMATIC 
( O 
DA O 
) O 
might O 
be O 
a O 
respiratory O 
sensitizer O 
based O 
on O 
its O 
LUMO O 
energy O 
similar O 
to O 
that O 
of O 
the O 
respiratory O 
allergen O 
toluene-2,4-diisocyanate B-SYSTEMATIC 
( O 
TDI B-ABBREVIATION 
) O 
and O 
results O 
of O 
a O 
local O 
lymph O 
node O 
assay O 
( O 
LLNA O 
) O 
that O 
reported O 
an O 
EC3 O 
of O 
1.9% O 
. O 
To O 
better O 
understand O 
the O 
concerns O 
, O 
we O 
performed O 
a O 
systematic O 
literature O 
review O 
and O 
experimental O 
competition O 
reactions O 
between O 
DA O 
and O 
TDI B-ABBREVIATION 
. O 
The O 
experimental O 
evidence O 
demonstrates O 
that O 
DA O 
is O 
at O 
least O 
400-fold O 
less O 
reactive O 
than O 
TDI B-ABBREVIATION 
. O 
The O 
literature O 
review O 
finds O 
evidence O 
that O 
the O 
EC3 O 
for O 
DA O 
is O 
actually O 
> O 
11% O 
. O 
We O 
conclude O 
that O 
DA O 
is O 
unlikely O 
to O 
have O 
significant O 
respiratory O 
sensitization O 
potential O 
. O 

of O 
aqueous O 
stability O 
of O 
taxol B-TRIVIAL 
in O 
different O 
release O 
media O 
. O 

In O 
the O 
present O 
study O 
, O 
the O 
aqueous O 
stability O 
of O 
taxol B-TRIVIAL 
in O 
different O 
aqueous O 
media O 
and O 
immiscible O 
aqueous O 
/ O 
organic O 
systems O 
at O 
37 O 
°C O 
was O 
investigated O 
. O 
The O 
aqueous O 
media O 
included O 
phosphate B-SYSTEMATIC 
buffered O 
saline O 
( O 
PBS O 
) O 
and O 
PBS O 
containing O 
10% O 
methanol B-SYSTEMATIC 
, O 
10% O 
ethanol B-SYSTEMATIC 
, O 
10% O 
hydroxypropyl B-SYSTEMATIC 
β-cyclodextrin I-SYSTEMATIC 
( O 
HP-βCD B-ABBREVIATION 
) O 
, O 
1% O 
sodium B-SYSTEMATIC 
citrate I-SYSTEMATIC 
and O 
1% O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
. O 
The O 
immiscible O 
systems O 
consisted O 
of O 
PBS/ O 
octanol B-SYSTEMATIC 
, O 
PBS/ O 
dichloromethane B-SYSTEMATIC 
, O 
PBS/ O 
chloroform B-TRIVIAL 
and O 
PBS/ O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
. O 
The O 
concentrations O 
of O 
taxol B-TRIVIAL 
and O 
related O 
derivatives O 
in O 
each O 
of O 
the O 
media O 
were O 
determined O 
through O 
the O 
high O 
- O 
performance O 
liquid O 
chromatography O 
assay O 
. O 
Results O 
showed O 
that O 
hydrolysis O 
and O 
epimerization O 
were O 
two O 
major O 
types O 
of O 
degradation O 
for O 
taxol B-TRIVIAL 
in O 
the O 
aqueous O 
media O 
starting O 
from O 
the O 
initial O 
hours O 
of O 
contact O 
( O 
6 O 
hours O 
) O 
. O 
Addition O 
of O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
to O 
PBS O 
moderately O 
increased O 
the O 
aqueous O 
stability O 
of O 
taxol B-TRIVIAL 
. O 
As O 
well O 
, O 
using O 
PBS O 
containing O 
10% O 
HP-βCD B-ABBREVIATION 
inhibited O 
the O 
taxol B-TRIVIAL 
hydrolysis O 
, O 
while O 
epimerization O 
still O 
in O 
process O 
. O 
In O 
the O 
case O 
of O 
immiscible O 
systems O 
, O 
except O 
for O 
PBS/ O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
system O 
, O 
no O 
evidences O 
of O 
taxol B-TRIVIAL 
hydrolysis O 
were O 
observed O 
. O 
Meanwhile O 
, O 
epimerization O 
of O 
taxol B-TRIVIAL 
in O 
PBS/ O 
dichloromethane B-SYSTEMATIC 
and O 
PBS/ O 
chloroform B-TRIVIAL 
systems O 
underwent O 
due O 
to O 
the O 
ability O 
of O 
C B-FORMULA 
- O 
Cl B-FORMULA 
bonds O 
to O 
form O 
hydrogen B-SYSTEMATIC 
bonding O 
with O 
the O 
hydroxyl B-SYSTEMATIC 
group O 
of O 
C7 O 
of O 
taxol B-TRIVIAL 
. O 

of O 
cardiac O 
tissue O 
thyroid B-FAMILY 
hormone I-FAMILY 
status O 
in O 
experimental O 
hypothyroidism O 
: O 
a O 
dose O 
- O 
response O 
study O 
in O 
female O 
rats O 
. O 

hormones I-FAMILY 
( O 
THs O 
) O 
play O 
a O 
pivotal O 
role O 
in O 
regulating O 
cardiovascular O 
homeostasis O 
. O 
To O 
provide O 
a O 
better O 
understanding O 
of O 
the O 
coordinated O 
processes O 
that O 
govern O 
cardiac O 
TH O 
bioavailability O 
, O 
this O 
study O 
investigated O 
the O 
influence O 
of O 
serum O 
and O 
cardiac O 
TH O 
status O 
on O 
the O 
expression O 
of O 
TH O 
transporters O 
and O 
cytosolic O 
binding O 
proteins O 
in O 
the O 
myocardium O 
. O 
In O 
addition O 
, O 
we O 
sought O 
to O 
determine O 
if O 
administration O 
of O 
T3 O 
( O 
instead O 
of O 
T4 O 
) O 
improves O 
the O 
relationship O 
between O 
THs O 
in O 
serum O 
and O 
cardiac O 
tissue O 
, O 
and O 
cardiac O 
function O 
over O 
a O 
short O 
- O 
term O 
treatment O 
period O 
. O 
Adult O 
female O 
SD O 
rats O 
were O 
made O 
hypothyroid O 
by O 
seven O 
weeks O 
treatment O 
with O 
the O 
anti-thyroid O 
drug O 
PTU B-ABBREVIATION 
( O 
6-n-propyl-2-thiouracil B-SYSTEMATIC 
) O 
. O 
After O 
establishing O 
hypothyroidism O 
, O 
rats O 
were O 
assigned O 
to O 
one O 
of O 
five O 
graded O 
T3 O 
( O 
triiodothyronine B-TRIVIAL 
) O 
dosages O 
plus O 
PTU B-ABBREVIATION 
for O 
a O 
two O 
week O 
dose O 
- O 
response O 
experiment O 
. O 
Untreated O 
, O 
age O 
matched O 
rats O 
served O 
as O 
euthyroid O 
controls O 
. O 
PTU B-ABBREVIATION 
was O 
associated O 
with O 
depressed O 
serum O 
and O 
cardiac O 
tissue O 
T3 O 
and O 
T4 O 
levels O 
, O 
arteriolar O 
atrophy O 
, O 
altered O 
TH O 
transporter O 
and O 
cytosolic O 
TH O 
binding O 
protein O 
expression O 
, O 
fetal O 
gene O 
re O 
- O 
expression O 
, O 
and O 
cardiac O 
dysfunction O 
. O 
Short O 
- O 
term O 
administration O 
of O 
T3 O 
led O 
to O 
a O 
mismatch O 
between O 
serum O 
and O 
cardiac O 
tissue O 
TH O 
levels O 
. O 
Normalization O 
of O 
serum O 
T3 O 
levels O 
was O 
not O 
associated O 
with O 
restoration O 
of O 
cardiac O 
tissue O 
T3 O 
levels O 
or O 
cardiac O 
function O 
. O 
In O 
fact O 
, O 
a O 
3 O 
fold O 
higher O 
T3 O 
dosage O 
was O 
necessary O 
to O 
normalize O 
cardiac O 
tissue O 
T3 O 
levels O 
and O 
cardiac O 
function O 
. O 
Importantly O 
, O 
this O 
study O 
provides O 
the O 
first O 
comprehensive O 
data O 
on O 
the O 
relationship O 
between O 
altered O 
TH O 
status O 
( O 
serum O 
and O 
cardiac O 
tissue O 
) O 
, O 
cardiac O 
function O 
, O 
and O 
the O 
coordinated O 
in O 
vivo O 
changes O 
in O 
cardiac O 
TH O 
membrane O 
transporters O 
and O 
cytosolic O 
TH O 
binding O 
proteins O 
in O 
altered O 
TH O 
states O 
. O 

possess O 
a O 
skeleton O 
made O 
of O 
a O 
composite O 
material O 
with O 
various O 
organic O 
constituents O 
and O 
/ O 
or O 
siliceous O 
spicules O 
. O 
Chitin O 
is O 
an O 
integral O 
part O 
of O 
the O 
skeleton O 
of O 
different O 
sponges O 
of O 
the O 
order O 
Verongida O 
. O 
Moreover O 
, O 
sponges O 
of O 
the O 
order O 
Verongida O 
, O 
such O 
as O 
Aplysina O 
cavernicola O 
or O 
Ianthella O 
basta O 
, O 
are O 
well O 
- O 
known O 
for O 
the O 
biosynthesis O 
of O 
brominated B-TRIVIAL 
tyrosine I-TRIVIAL 
derivates O 
, O 
characteristic O 
bioactive O 
natural O 
products O 
. O 
It O 
has O 
been O 
unknown O 
so O 
far O 
whether O 
these O 
compounds O 
are O 
exclusively O 
present O 
in O 
the O 
cellular O 
matrix O 
or O 
whether O 
they O 
may O 
also O 
be O 
incorporated O 
into O 
the O 
chitin O 
- O 
based O 
skeletons O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
therefore O 
examined O 
the O 
skeletons O 
of O 
A O 
. O 
cavernicola O 
and O 
I O 
. O 
basta O 
with O 
respect O 
to O 
the O 
presence O 
of O 
bromotyrosine B-SYSTEMATIC 
metabolites O 
. O 
The O 
chitin O 
- O 
based O 
- O 
skeletons O 
isolated O 
from O 
these O 
sponges O 
indeed O 
contain O 
significant O 
amounts O 
of O 
brominated O 
compounds O 
, O 
which O 
are O 
not O 
easily O 
extractable O 
from O 
the O 
skeletons O 
by O 
common O 
solvents O 
, O 
such O 
as O 
MeOH B-FORMULA 
, O 
as O 
shown O 
by O 
HPLC O 
analyses O 
in O 
combination O 
with O 
NMR O 
and O 
IR O 
spectroscopic O 
measurements O 
. O 
Quantitative O 
potentiometric O 
analyses O 
confirm O 
that O 
the O 
skeleton O 
- O 
associated O 
bromine B-SYSTEMATIC 
mainly O 
withstands O 
the O 
MeOH B-FORMULA 
-based O 
extraction O 
. O 
This O 
observation O 
suggests O 
that O 
the O 
respective O 
, O 
but O 
yet O 
unidentified O 
, O 
brominated O 
compounds O 
are O 
strongly O 
bound O 
to O 
the O 
sponge O 
skeletons O 
, O 
possibly O 
by O 
covalent O 
bonding O 
. O 
Moreover O 
, O 
gene O 
fragments O 
of O 
halogenases O 
suggested O 
to O 
be O 
responsible O 
for O 
the O 
incorporation O 
of O 
bromine B-SYSTEMATIC 
into O 
organic O 
molecules O 
could O 
be O 
amplified O 
from O 
DNA O 
isolated O 
from O 
sponge O 
samples O 
enriched O 
for O 
sponge O 
- O 
associated O 
bacteria O 
. O 

selective O 
lithium B-SYSTEMATIC 
recovery O 
from O 
brine O 
using O 
a O 
λ- O 
MnO2 B-FORMULA 
- O 
Ag B-FORMULA 
battery O 
. O 

demand O 
for O 
lithium B-SYSTEMATIC 
has O 
greatly O 
increased O 
with O 
the O 
rapid O 
development O 
of O 
rechargeable O 
batteries O 
. O 
Currently O 
, O 
the O 
main O 
lithium B-SYSTEMATIC 
resource O 
is O 
brine O 
lakes O 
, O 
but O 
the O 
conventional O 
lithium B-SYSTEMATIC 
recovery O 
process O 
is O 
time O 
consuming O 
, O 
inefficient O 
, O 
and O 
environmentally O 
harmful O 
. O 
Rechargeable O 
batteries O 
have O 
been O 
recently O 
used O 
for O 
lithium B-SYSTEMATIC 
recovery O 
, O 
and O 
consist O 
of O 
lithium B-SYSTEMATIC 
iron I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
as O 
a O 
cathode O 
. O 
These O 
batteries O 
feature O 
promising O 
selectivity O 
between O 
lithium B-SYSTEMATIC 
and O 
sodium B-SYSTEMATIC 
, O 
but O 
they O 
suffer O 
from O 
severe O 
interference O 
from O 
coexisting O 
magnesium B-SYSTEMATIC 
ions O 
, O 
an O 
essential O 
component O 
of O 
brine O 
, O 
which O 
has O 
prompted O 
further O 
study O 
. O 
This O 
study O 
reports O 
on O 
a O 
highly O 
selective O 
and O 
energy O 
- O 
efficient O 
lithium B-SYSTEMATIC 
recovery O 
system O 
using O 
a O 
rechargeable O 
battery O 
that O 
consists O 
of O 
a O 
λ- O 
MnO2 B-FORMULA 
positive O 
electrode O 
and O 
a O 
chloride B-SYSTEMATIC 
-capturing O 
negative O 
electrode O 
. O 
This O 
system O 
can O 
be O 
used O 
to O 
recover O 
lithium B-SYSTEMATIC 
from O 
brine O 
even O 
in O 
the O 
presence O 
of O 
magnesium B-SYSTEMATIC 
ions O 
as O 
well O 
as O 
other O 
dissolved O 
cations O 
. O 
In O 
addition O 
, O 
lithium B-SYSTEMATIC 
recovery O 
from O 
simulated O 
brine O 
is O 
successfully O 
demonstrated O 
, O 
consuming O 
1 O 
W O 
h O 
per O 
1 O 
mole O 
of O 
lithium B-SYSTEMATIC 
recovered O 
, O 
using O 
water O 
similar O 
to O 
that O 
from O 
the O 
artificial O 
brine O 
, O 
which O 
contains O 
various O 
cations O 
( O 
mole O 
ratio O 
: O 
Na B-FORMULA 
/ O 
Li B-FORMULA 
≈ O 
15.7 O 
, O 
K B-FORMULA 
/ O 
Li B-FORMULA 
≈ O 
2.2 O 
, O 
Mg B-FORMULA 
/ O 
Li B-FORMULA 
≈ O 
1.9 O 
) O 
. O 

magnetic O 
resonance O 
study O 
of O 
ion O 
adsorption O 
on O 
microporous O 
carbide B-FAMILY 
-derived O 
carbon B-SYSTEMATIC 
. O 

detailed O 
understanding O 
of O 
ion O 
adsorption O 
within O 
porous O 
carbon B-SYSTEMATIC 
is O 
key O 
to O 
the O 
design O 
and O 
improvement O 
of O 
electric O 
double O 
- O 
layer O 
capacitors O 
, O 
more O 
commonly O 
known O 
as O 
supercapacitors O 
. O 
In O 
this O 
work O 
nuclear O 
magnetic O 
resonance O 
( O 
NMR O 
) O 
spectroscopy O 
is O 
used O 
to O 
study O 
ion O 
adsorption O 
in O 
porous O 
carbide B-FAMILY 
-derived O 
carbons B-FAMILY 
. O 
These O 
predominantly O 
microporous O 
materials O 
have O 
a O 
tuneable O 
pore O 
size O 
which O 
enables O 
a O 
systematic O 
study O 
of O 
the O 
effect O 
of O 
pore O 
size O 
on O 
ion O 
adsorption O 
. O 
Multinuclear O 
NMR O 
experiments O 
performed O 
on O 
the O 
electrolyte O 
anions O 
and O 
cations O 
reveal O 
two O 
main O 
environments O 
inside O 
the O 
carbon B-SYSTEMATIC 
. O 
In-pore O 
ions O 
( O 
observed O 
at O 
low O 
frequencies O 
) O 
are O 
adsorbed O 
inside O 
the O 
pores O 
, O 
whilst O 
ex O 
- O 
pore O 
ions O 
( O 
observed O 
at O 
higher O 
frequencies O 
) O 
are O 
not O 
adsorbed O 
and O 
are O 
in O 
large O 
reservoirs O 
of O 
electrolyte O 
between O 
carbon B-SYSTEMATIC 
particles O 
. O 
All O 
our O 
experiments O 
were O 
carried O 
out O 
in O 
the O 
absence O 
of O 
an O 
applied O 
electrical O 
potential O 
in O 
order O 
to O 
assess O 
the O 
mechanisms O 
related O 
to O 
ion O 
adsorption O 
without O 
the O 
contribution O 
of O 
electrosorption O 
. O 
Our O 
results O 
indicate O 
similar O 
adsorption O 
behaviour O 
for O 
anions O 
and O 
cations O 
. O 
Furthermore O 
, O 
we O 
probe O 
the O 
effect O 
of O 
sample O 
orientation O 
, O 
which O 
is O 
shown O 
to O 
have O 
a O 
marked O 
effect O 
on O 
the O 
NMR O 
spectra O 
. O 
Finally O 
, O 
we O 
show O 
that O 
a O 
(13)C B-FORMULA 
→ O 
(1)H B-FORMULA 
cross O 
polarisation O 
experiment O 
enables O 
magnetisation O 
transfer O 
from O 
the O 
carbon B-SYSTEMATIC 
architecture O 
to O 
the O 
adsorbed O 
species O 
, O 
allowing O 
selective O 
observation O 
of O 
the O 
adsorbed O 
ions O 
and O 
confirming O 
our O 
spectral O 
assignments O 
. O 

the O 
documented O 
risk O 
of O 
secondary O 
poisoning O 
to O 
non-target O 
species O 
by O 
anticoagulant O 
rodenticides O 
there O 
is O 
no O 
statutory O 
post O 
- O 
approval O 
monitoring O 
of O 
their O 
use O 
in O 
the O 
UK O 
. O 
This O 
paper O 
presents O 
results O 
from O 
two O 
Scottish O 
monitoring O 
schemes O 
for O 
the O 
period O 
2000-2010 O 
; O 
recording O 
rodenticide O 
use O 
on O 
arable O 
farms O 
and O 
the O 
presence O 
of O 
residues O 
in O 
raptor O 
carcasses O 
. O 
More O 
than O 
three O 
quarters O 
of O 
arable O 
farms O 
used O 
anticoagulant O 
rodenticides O 
; O 
predominately O 
the O 
second O 
generation O 
compounds O 
difenacoum B-TRIVIAL 
and O 
bromadiolone B-TRIVIAL 
. O 
There O 
was O 
widespread O 
exposure O 
to O 
anticoagulant O 
rodenticides O 
in O 
liver O 
tissues O 
of O 
the O 
raptor O 
species O 
tested O 
and O 
the O 
residues O 
encountered O 
generally O 
reflected O 
agricultural O 
use O 
patterns O 
. O 
As O 
found O 
in O 
other O 
studies O 
, O 
Red O 
Kites O 
( O 
Milvus O 
milvus O 
) O 
appeared O 
to O 
be O 
particularly O 
vulnerable O 
to O 
rodenticide O 
exposure O 
, O 
70 O 
% O 
of O 
those O 
sampled O 
( O 
n O 
= O 
114 O 
) O 
contained O 
residues O 
and O 
10 O 
% O 
died O 
as O 
a O 
result O 
of O 
rodenticide O 
ingestion O 
. O 
More O 
unexpectedly O 
, O 
sparrowhawks O 
( O 
Accipiter O 
nisus O 
) O 
, O 
which O 
prey O 
almost O 
exclusively O 
on O 
birds O 
, O 
had O 
similar O 
exposure O 
rates O 
to O 
species O 
which O 
prey O 
on O 
rodents O 
. O 
Although O 
, O 
with O 
the O 
exception O 
of O 
kites O 
, O 
confirmed O 
mortality O 
from O 
rodenticides O 
was O 
low O 
, O 
the O 
widespread O 
exposure O 
recorded O 
is O 
concerning O 
. O 
Particularly O 
when O 
coupled O 
with O 
a O 
lack O 
of O 
data O 
about O 
the O 
sub O 
- O 
lethal O 
effects O 
of O 
these O 
compounds O 
. O 
This O 
raises O 
questions O 
regarding O 
whether O 
statutory O 
monitoring O 
of O 
use O 
is O 
needed O 
; O 
both O 
to O 
address O 
whether O 
there O 
are O 
deficiencies O 
in O 
compliance O 
with O 
approval O 
conditions O 
or O 
whether O 
the O 
recommended O 
risk O 
management O 
procedures O 
are O 
themselves O 
adequate O 
to O 
protect O 
non-target O 
wildlife O 
. O 

Oil I-TRIVIAL 
Effects O 
on O 
Chemical O 
and O 
Thermal O 
Injury O 
in O 
Mice O 
and O 
Cultured O 
Mouse O 
Dorsal O 
Root O 
Ganglion O 
Neurons O 
. O 

commercial O 
resin O 
- O 
based O 
pine B-TRIVIAL 
oil I-TRIVIAL 
( O 
PO O 
) O 
derived O 
from O 
Pinus O 
palustris O 
and O 
Pinus O 
elliottii O 
was O 
the O 
major O 
focus O 
of O 
this O 
investigation O 
. O 
Extracts O 
of O 
pine O 
resins O 
, O 
needles O 
, O 
and O 
bark O 
are O 
folk O 
medicines O 
commonly O 
used O 
to O 
treat O 
skin O 
ailments O 
, O 
including O 
burns O 
. O 
The O 
American O 
Burn O 
Association O 
estimates O 
that O 
500000 O 
people O 
with O 
burn O 
injuries O 
receive O 
medical O 
treatment O 
each O 
year O 
; O 
one O 
- O 
half O 
of O 
US O 
burn O 
victims O 
are O 
children O 
, O 
most O 
with O 
scald O 
burns O 
. O 
This O 
systematic O 
study O 
was O 
initiated O 
as O 
follow O 
- O 
up O 
to O 
personal O 
anecdotal O 
evidence O 
acquired O 
over O 
more O 
than O 
10 O 
years O 
by O 
MH O 
Bhattacharyya O 
regarding O 
PO's O 
efficacy O 
for O 
treating O 
burns O 
. O 
The O 
results O 
demonstrate O 
that O 
PO O 
counteracted O 
dermal O 
inflammation O 
in O 
both O 
a O 
mouse O 
ear O 
model O 
of O 
contact O 
irritant O 
- O 
induced O 
dermal O 
inflammation O 
and O 
a O 
second O 
degree O 
scald O 
burn O 
to O 
the O 
mouse O 
paw O 
. O 
Furthermore O 
, O 
PO O 
significantly O 
counteracted O 
the O 
tactile O 
allodynia O 
and O 
soft O 
tissue O 
injury O 
caused O 
by O 
the O 
scald O 
burn O 
. O 
In O 
mouse O 
dorsal O 
root O 
ganglion O 
neuronal O 
cultures O 
, O 
PO O 
added O 
to O 
the O 
medium O 
blocked O 
adenosine B-SYSTEMATIC 
triphosphate I-SYSTEMATIC 
-activated O 
, O 
but O 
not O 
capsaicin B-TRIVIAL 
-activated O 
, O 
pain O 
pathways O 
, O 
demonstrating O 
specificity O 
. O 
These O 
results O 
together O 
support O 
the O 
hypothesis O 
that O 
a O 
pine B-TRIVIAL 
- I-TRIVIAL 
oil I-TRIVIAL 
-based O 
treatment O 
can O 
be O 
developed O 
to O 
provide O 
effective O 
in O 
- O 
home O 
care O 
for O 
second O 
degree O 
burns O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

of O 
the O 
Molecular O 
Structure O 
of O 
Surface-Attached O 
Poly(N-alkyl B-FAMILY 
Acrylamide I-FAMILY 
) I-FAMILY 
Coatings O 
on O 
the O 
Interaction O 
of O 
Surfaces O 
with O 
Proteins O 
, O 
Cells O 
and O 
Blood O 
Platelets O 
. O 

protein O 
adsorption O 
and O 
blood O 
platelet O 
adhesion O 
onto O 
surface O 
- O 
attached O 
poly(alkylacrylamide) B-FAMILY 
networks O 
that O 
exhibit O 
small O 
and O 
systematic O 
variations O 
in O 
chemical O 
composition O 
are O 
investigated O 
. O 
The O 
polymer O 
coatings O 
are O 
generated O 
by O 
depositing O 
a O 
thin O 
layer O 
of O 
benzophenone B-SYSTEMATIC 
-group O 
- O 
containing O 
copolymer O 
onto O 
a O 
solid O 
substrate O 
, O 
followed O 
by O 
photo O 
crosslinking O 
and O 
simultaneous O 
surface O 
- O 
attachment O 
. O 
The O 
correlation O 
of O 
the O 
swelling O 
of O 
the O 
obtained O 
surface O 
- O 
attached O 
networks O 
with O 
the O 
adsorption O 
of O 
blood O 
proteins O 
and O 
cellular O 
adhesion O 
is O 
studied O 
. O 
The O 
swollen O 
surface O 
- O 
attached O 
layers O 
are O 
inert O 
to O 
blood O 
proteins O 
and O 
platelet O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
the O 
hydrogel O 
- O 
coated O 
materials O 
are O 
promising O 
candidates O 
for O 
the O 
generation O 
of O 
hemocompatible O 
surfaces O 
. O 

isothiocyanate I-SYSTEMATIC 
( O 
FITC B-ABBREVIATION 
) O 
, O 
a O 
fluorescent O 
probe O 
, O 
is O 
coupled O 
to O 
amphiphilic O 
monomethoxy B-SYSTEMATIC 
poly(ethylene I-SYSTEMATIC 
glycol)-block-poly(ε-caprolactone I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
mPEG-PCL B-ABBREVIATION 
) O 
copolymers O 
. O 
FITC-labeled B-ABBREVIATION 
mPEG-PCL I-ABBREVIATION 
copolymers O 
self O 
- O 
assemble O 
into O 
micelles O 
through O 
the O 
solvent O 
evaporation O 
method O 
. O 
The O 
cellular O 
internalization O 
is O 
examined O 
using O 
fluorescence O 
microscopy O 
on O 
incubation O 
of O 
NIH-3T3 O 
fibroblasts O 
with O 
micelles O 
or O 
free O 
FITC B-ABBREVIATION 
solution O 
. O 
The O 
effect O 
of O 
the O 
hydrophilic O 
/ O 
hydrophobic O 
ratio O 
on O 
the O 
endocytosis O 
mechanisms O 
is O 
evaluated O 
by O 
fluorescence O 
microscopy O 
on O 
culturing O 
of O 
human O 
hepatoblastoma O 
cells O 
and O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
, O 
individually O 
, O 
mixed O 
with O 
the O 
micelles O 
holding O 
the O 
same O 
parameters O 
including O 
micelle O 
size O 
, O 
shape O 
, O 
and O 
surface O 
charges O 
. O 

assessment O 
of O 
liver O 
lipid O 
content O 
and O 
composition O 
is O 
needed O 
in O 
preclinical O 
research O 
to O 
investigate O 
steatosis O 
and O 
steatosis O 
- O 
related O 
disorders O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
quantify O 
in O 
vivo O 
hepatic O 
fatty B-FAMILY 
acid I-FAMILY 
content O 
and O 
composition O 
using O 
a O 
method O 
based O 
on O 
short O 
echo O 
- O 
time O 
proton O 
magnetic O 
resonance O 
spectroscopy O 
at O 
7T O 
. O 
Mouse O 
model O 
of O 
glycogen O 
storage O 
disease O 
type O 
1a O 
with O 
inducible O 
liver O 
- O 
specific O 
deletion O 
of O 
the O 
glucose B-TRIVIAL 
-6-phosphatase O 
gene O 
( O 
L-G6pc- O 
/ O 
- O 
) O 
and O 
control O 
mice O 
were O 
fed O 
a O 
standard O 
diet O 
or O 
a O 
high O 
fat O 
/ O 
high O 
sucrose B-TRIVIAL 
diet O 
( O 
HF O 
/ O 
HS O 
) O 
during O 
9 O 
months O 
. O 
In O 
control O 
mice O 
, O 
hepatic O 
lipid O 
content O 
was O 
found O 
significantly O 
higher O 
with O 
HF O 
/ O 
HS O 
diet O 
than O 
with O 
standard O 
diet O 
. O 
As O 
expected O 
, O 
hepatic O 
lipid O 
content O 
was O 
already O 
elevated O 
in O 
L-G6pc- O 
/ O 
- O 
mice O 
fed O 
a O 
standard O 
diet O 
compared O 
to O 
control O 
mice O 
. O 
L-G6pc- O 
/ O 
- O 
mice O 
rapidly O 
developed O 
steatosis O 
which O 
was O 
not O 
modified O 
by O 
HF O 
/ O 
HS O 
diet O 
. O 
On O 
standard O 
diet O 
, O 
estimated O 
amplitudes O 
from O 
olefinic O 
protons O 
were O 
found O 
significantly O 
higher O 
in O 
L-G6pc O 
/ O 
- O 
mice O 
compared O 
to O 
that O 
in O 
control O 
mice O 
. O 
L-G6pc- O 
/ O 
- O 
mice O 
showed O 
no O 
noticeable O 
polyunsaturation O 
from O 
diallylic O 
protons O 
. O 
Total O 
unsaturated B-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
indexes O 
measured O 
by O 
gas O 
chromatography O 
were O 
in O 
agreement O 
with O 
MRS O 
measurements O 
. O 
These O 
results O 
showed O 
the O 
great O 
potential O 
of O 
high O 
magnetic O 
field O 
MRS O 
to O 
follow O 
the O 
diet O 
impact O 
and O 
lipid O 
alterations O 
in O 
mouse O 
liver O 
. O 

the O 
Energy O 
Landscapes O 
of O 
Cyclic B-FAMILY 
Tetrapeptides I-FAMILY 
with O 
Discrete O 
Path O 
Sampling O 
. O 

tetrapeptides I-FAMILY 
are O 
an O 
important O 
class O 
of O 
biologically O 
active O 
molecules O 
that O 
exhibit O 
interesting O 
conformational O 
dynamics O 
, O 
with O 
slow O 
interconversion O 
of O 
several O 
different O 
structures O 
. O 
We O 
present O 
calculations O 
on O 
their O 
energy O 
landscapes O 
using O 
discrete O 
path O 
sampling O 
. O 
In O 
acyclic O 
peptides O 
and O 
large O 
cyclic O 
peptides O 
, O 
isomers O 
containing O 
cis- O 
peptide O 
groups O 
are O 
much O 
less O 
stable O 
than O 
the O 
all O 
- O 
trans O 
isomers O 
and O 
separated O 
from O 
them O 
by O 
large O 
barriers O 
. O 
Strain O 
in O 
small O 
cyclic O 
peptides O 
causes O 
the O 
cis O 
and O 
trans O 
isomers O 
to O 
be O 
closer O 
in O 
energy O 
and O 
separated O 
by O 
much O 
lower O 
barriers O 
. O 
If O 
d-amino B-FAMILY 
acids I-FAMILY 
or O 
proline B-TRIVIAL 
residues O 
are O 
introduced O 
, O 
isomers O 
containing O 
cis- O 
peptides O 
become O 
more O 
stable O 
than O 
the O 
all O 
- O 
trans O 
structures O 
. O 
We O 
also O 
show O 
that O 
changing O 
the O 
polarity O 
of O 
the O 
solvent O 
has O 
a O 
significant O 
effect O 
on O 
the O 
energy O 
landscapes O 
of O 
cyclic B-FAMILY 
tetrapeptides I-FAMILY 
, O 
causing O 
changes O 
in O 
the O 
orientations O 
of O 
the O 
peptide O 
groups O 
and O 
in O 
the O 
degree O 
of O 
intramolecular O 
hydrogen B-SYSTEMATIC 
bonding O 
. O 

Context O 
: O 
Chitosan O 
does O 
not O 
rank O 
highly O 
regarding O 
its O 
employment O 
as O 
tablet O 
filler O 
due O 
to O 
certain O 
limitations O 
. O 
Undesirable O 
properties O 
that O 
limit O 
its O 
utilization O 
as O 
excipient O 
in O 
solid O 
dosage O 
forms O 
include O 
its O 
hydration O 
propensity O 
that O 
negatively O 
affects O 
tablet O 
stability O 
, O 
strength O 
and O 
disintegration O 
. O 
Objective O 
: O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
investigate O 
the O 
physical O 
stability O 
of O 
chitosan O 
powder O 
, O 
mixtures O 
, O 
granules O 
and O 
tablets O 
under O 
accelerated O 
conditions O 
such O 
as O 
elevated O 
temperatures O 
and O 
humidity O 
over O 
different O 
periods O 
of O 
time O 
. O 
Methods O 
: O 
Selected O 
physico O 
- O 
chemical O 
properties O 
of O 
pure O 
chitosan O 
powder O 
, O 
physical O 
mixtures O 
of O 
chitosan O 
with O 
Kollidon O 
® O 
VA64 B-IDENTIFIER 
( O 
BASF O 
, O 
Ludwigshafen O 
, O 
Germany O 
) O 
, O 
chitosan O 
granules O 
, O 
as O 
well O 
as O 
tablets O 
were O 
evaluated O 
under O 
conditions O 
of O 
elevated O 
humidity O 
and O 
temperature O 
. O 
Results O 
and O 
discussion O 
: O 
The O 
physical O 
stability O 
of O 
chitosan O 
tablets O 
exhibited O 
sensitivity O 
towards O 
varying O 
exposure O 
conditions O 
. O 
It O 
was O 
furthermore O 
evident O 
that O 
the O 
presence O 
of O 
moisture O 
( O 
sorbed O 
water O 
) O 
had O 
a O 
marked O 
influence O 
on O 
the O 
physical O 
stability O 
of O 
chitosan O 
powder O 
and O 
tablets O 
. O 
It O 
was O 
evident O 
that O 
the O 
presence O 
of O 
Kollidon O 
® O 
VA64 B-IDENTIFIER 
as O 
well O 
as O 
the O 
method O 
of O 
inclusion O 
of O 
this O 
binder O 
influenced O 
the O 
properties O 
of O 
chitosan O 
tablets O 
. O 
The O 
physical O 
stability O 
of O 
chitosan O 
powder O 
deteriorated O 
to O 
a O 
greater O 
extent O 
compared O 
to O 
that O 
of O 
the O 
chitosan O 
tablets O 
, O 
which O 
were O 
subjected O 
to O 
the O 
same O 
conditions O 
. O 
Conclusion O 
: O 
It O 
is O 
recommended O 
that O 
tablets O 
containing O 
chitosan O 
should O 
be O 
stored O 
at O 
a O 
temperature O 
not O 
exceeding O 
25 O 
°C O 
as O 
well O 
as O 
at O 
a O 
relatively O 
low O 
humidity O 
( O 
< O 
60% O 
) O 
to O 
prevent O 
deterioration O 
of O 
physical O 
properties O 
. O 
Direct O 
compression O 
of O 
chitosan O 
granules O 
which O 
contained O 
5%w O 
/ O 
w O 
Kollidon O 
® O 
VA64 B-IDENTIFIER 
produced O 
the O 
best O 
formulation O 
in O 
terms O 
of O 
physical O 
stability O 
at O 
the O 
different O 
conditions O 
. O 

Philip O 
S O 
. O 
Portoghese O 
Medicinal O 
Chemistry O 
Lectureship O 
: O 
Structure O 
- O 
Based O 
Approaches O 
to O 
Ligands O 
for O 
G O 
Protein-Coupled O 
Adenosine B-TRIVIAL 
and O 
P2Y O 
Receptors O 
, O 
From O 
Small O 
Molecules O 
to O 
Nanoconjugates O 
. O 

receptor O 
( O 
ARs O 
) O 
and O 
P2Y O 
receptors O 
( O 
P2YRs O 
) O 
that O 
respond O 
to O 
extracellular O 
nucleosides B-MULTIPLE 
/ I-MULTIPLE 
tides I-MULTIPLE 
are O 
associated O 
with O 
new O 
directions O 
for O 
therapeutics O 
. O 
The O 
X-ray O 
structures O 
of O 
the O 
A2AAR O 
complexes O 
with O 
agonists O 
and O 
antagonists O 
are O 
examined O 
in O 
relationship O 
to O 
the O 
G O 
protein O 
- O 
coupled O 
receptor O 
( O 
GPCR O 
) O 
superfamily O 
and O 
applied O 
to O 
drug O 
discovery O 
. O 
Much O 
of O 
the O 
data O 
on O 
AR O 
ligand O 
structure O 
from O 
early O 
SAR O 
studies O 
, O 
now O 
is O 
explainable O 
from O 
the O 
A2AAR O 
X-ray O 
crystallography O 
. O 
The O 
ligand O 
- O 
receptor O 
interactions O 
in O 
related O 
GPCR O 
complexes O 
can O 
be O 
identified O 
by O 
means O 
of O 
modeling O 
approaches O 
, O 
e.g O 
. O 
molecular O 
docking O 
. O 
Thus O 
, O 
molecular O 
recognition O 
in O 
binding O 
and O 
activation O 
processes O 
has O 
been O 
studied O 
effectively O 
using O 
homology O 
modeling O 
and O 
applied O 
to O 
ligand O 
design O 
. O 
Virtual O 
screening O 
has O 
yielded O 
new O 
nonnucleoside O 
AR O 
antagonists O 
, O 
and O 
existing O 
ligands O 
have O 
been O 
improved O 
with O 
knowledge O 
of O 
the O 
receptor O 
interactions O 
. O 
New O 
agonists O 
are O 
being O 
explored O 
for O 
CNS O 
and O 
peripheral O 
therapeutics O 
based O 
on O 
in O 
vivo O 
activity O 
, O 
such O 
as O 
chronic O 
neuropathic O 
pain O 
. O 
Ligands O 
for O 
receptors O 
more O 
distantly O 
related O 
to O 
the O 
X-ray O 
template O 
, O 
i.e O 
. O 
P2YRs O 
, O 
have O 
been O 
introduced O 
and O 
are O 
mainly O 
used O 
as O 
pharmacological O 
tools O 
for O 
elucidating O 
the O 
physiological O 
role O 
of O 
extracellular O 
nucleotides B-FAMILY 
. O 
Other O 
ligand O 
tools O 
for O 
drug O 
discovery O 
include O 
fluorescent O 
probes O 
, O 
radioactive O 
probes O 
, O 
multivalent O 
probes O 
, O 
and O 
functionalized O 
nanoparticles O 
. O 

dot O 
( O 
QD O 
) O 
based O 
micro- O 
/ O 
nanopatterned O 
arrays O 
are O 
of O 
broad O 
interest O 
in O 
applications O 
ranging O 
from O 
electronics O 
, O 
photonics O 
, O 
to O 
sensor O 
devices O 
for O 
biomedical O 
purposes O 
. O 
Here O 
, O 
we O 
report O 
on O 
a O 
rapid O 
, O 
physico O 
- O 
chemically O 
mild O 
approach O 
to O 
generate O 
high O 
fidelity O 
micropattern O 
arrays O 
of O 
prefunctionalized O 
water O 
- O 
soluble O 
quantum O 
dots O 
using O 
electron O 
beam O 
lithography O 
. O 
We O 
show O 
that O 
such O 
patterns O 
retain O 
their O 
fluorescence O 
and O 
bioaffinity O 
upon O 
electron O 
beam O 
lithography O 
and O 
, O 
based O 
on O 
the O 
streptavidin- O 
biotin B-TRIVIAL 
interaction O 
, O 
allow O 
for O 
detection O 
of O 
proteins O 
, O 
colloidal O 
gold O 
nanoparticles O 
and O 
magnetic O 
microparticles O 
. O 
Furthermore O 
, O 
we O 
demonstrate O 
the O 
applicability O 
of O 
QD O 
based O 
microarray O 
patterns O 
differing O 
in O 
their O 
shape O 
( O 
circles O 
, O 
squares O 
, O 
grid O 
- O 
like O 
) O 
, O 
size O 
( O 
from O 
1 O 
to O 
10 O 
μm O 
) O 
and O 
pitch O 
distance O 
to O 
study O 
the O 
adhesion O 
, O 
spreading O 
and O 
migration O 
of O 
human O 
blood O 
derived O 
neutrophils O 
. O 
Using O 
live O 
cell O 
confocal O 
fluorescence O 
microscopy O 
, O 
we O 
show O 
that O 
pattern O 
geometry O 
and O 
pitch O 
distance O 
influence O 
the O 
adhesion O 
, O 
spreading O 
and O 
migratory O 
behavior O 
of O 
neutrophils O 
. O 
Research O 
reported O 
in O 
this O 
work O 
paves O 
the O 
way O 
for O 
producing O 
QD O 
microarrays O 
with O 
multiplexed O 
functionalities O 
relevant O 
for O 
applications O 
in O 
analyte O 
sensing O 
and O 
cellular O 
dynamics O 
. O 

Induces O 
Apoptosis O 
in O 
HepG2 O 
Human O 
Hepatocellular O 
Carcinoma O 
Cells O 
and O 
Exhibits O 
in O 
Vivo O 
Antitumor O 
Activity O 
in O 
a O 
H22 O 
Mouse O 
Hepatocellular O 
Carcinoma O 
Model O 
. O 

order O 
to O 
discover O 
anticancer O 
agents O 
from O 
natural O 
sources O 
, O 
an O 
ethanol B-SYSTEMATIC 
-soluble O 
extract O 
of O 
the O 
root O 
bark O 
of O 
Juglans O 
cathayensis O 
was O 
investigated O 
and O 
showed O 
cytotoxic O 
effects O 
against O 
various O 
human O 
cancer O 
cell O 
lines O 
. O 
A O 
subsequent O 
phytochemical O 
study O 
on O 
the O 
EtOAc B-FORMULA 
-soluble O 
fraction O 
determined O 
2-methoxyjuglone B-SYSTEMATIC 
( O 
1 O 
) O 
as O 
one O 
of O 
the O 
main O 
active O 
constituents O 
. O 
Compound O 
1 O 
was O 
shown O 
to O 
be O 
cytotoxic O 
against O 
HepG2 O 
cells O 
. O 
Morphological O 
features O 
of O 
apoptosis O 
were O 
observed O 
in O 
1- O 
treated O 
HepG2 O 
cells O 
, O 
including O 
cell O 
shrinkage O 
, O 
membrane O 
blebbing O 
, O 
nuclear O 
condensation O 
, O 
and O 
apoptotic O 
body O 
formation O 
. O 
Cell O 
cycle O 
analysis O 
with O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
staining O 
showed O 
that O 
1 O 
induced O 
cell O 
cycle O 
arrest O 
at O 
the O 
S O 
phase O 
in O 
HepG2 O 
cells O 
. O 
Flow O 
cytometric O 
analysis O 
with O 
annexin O 
V O 
and O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
staining O 
demonstrated O 
that O 
1 O 
induced O 
HepG2 O 
cell O 
apoptotic O 
events O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
( O 
0-8 O 
μg O 
/ O 
mL O 
) O 
. O 
Western O 
blot O 
analysis O 
of O 
apoptosis O 
- O 
related O 
proteins O 
revealed O 
that O 
1 O 
induces O 
HepG2 O 
cell O 
apoptosis O 
through O 
mitochondrial O 
cytochrome O 
c-dependent O 
activation O 
of O 
the O 
caspase-9 O 
and O 
caspase-3 O 
cascade O 
pathway O 
( O 
intrinsic O 
pathway O 
) O 
. O 
An O 
in O 
vivo O 
experiment O 
using O 
tumor O 
- O 
bearing O 
mice O 
showed O 
that O 
treatment O 
with O 
1 O 
at O 
0.5 O 
and O 
1 O 
mg O 
/ O 
kg O 
per O 
day O 
decreased O 
the O 
tumor O 
mass O 
by O 
56% O 
and O 
67% O 
, O 
respectively O 
. O 

Ab O 
Initio O 
Potential O 
Energy O 
Surface O 
for O 
H-CO(X̃(2)A') B-FAMILY 
. O 

present O 
an O 
ab O 
initio O 
potential O 
for O 
the O 
H-CO(X̃(2)A') B-FAMILY 
complex O 
in O 
which O 
the O 
CO B-FORMULA 
bond O 
length O 
is O 
varied O 
and O 
the O 
long O 
- O 
range O 
interactions O 
between O 
H B-FORMULA 
and O 
CO B-FORMULA 
are O 
accurately O 
represented O 
. O 
It O 
was O 
computed O 
using O 
the O 
spin O 
- O 
unrestricted O 
open O 
- O 
shell O 
single O 
and O 
double O 
excitation O 
coupled O 
cluster O 
method O 
with O 
perturbative O 
triples O 
[RHF-UCCSD(T)] O 
. O 
Three O 
doubly O 
augmented O 
correlation O 
- O 
consistent O 
basis O 
sets O 
were O 
utilized O 
to O 
extrapolate O 
the O 
correlation O 
energy O 
to O 
the O 
complete O 
basis O 
set O 
limit O 
. O 
More O 
than O 
4400 O 
data O 
points O 
were O 
calculated O 
and O 
used O 
for O 
an O 
analytic O 
fit O 
of O 
the O 
potential O 
: O 
long O 
- O 
range O 
terms O 
with O 
inverse O 
power O 
dependence O 
on O 
the O 
H B-FORMULA 
- O 
CO B-FORMULA 
distance O 
R O 
were O 
fit O 
to O 
the O 
data O 
points O 
for O 
large O 
R O 
, O 
the O 
reproducing O 
kernel O 
Hilbert O 
space O 
( O 
RKHS O 
) O 
method O 
was O 
applied O 
to O 
the O 
data O 
at O 
smaller O 
distances O 
. O 
Our O 
potential O 
was O 
compared O 
with O 
previous O 
calculations O 
and O 
with O 
some O 
data O 
extracted O 
from O 
spectroscopy O 
. O 
Furthermore O 
, O 
it O 
was O 
used O 
in O 
three O 
- O 
dimensional O 
discrete O 
variable O 
representation O 
( O 
DVR O 
) O 
calculations O 
of O 
the O 
vibrational O 
frequencies O 
and O 
rotational O 
constants O 
of O 
HCO B-FORMULA 
, O 
which O 
agree O 
very O 
well O 
with O 
the O 
most O 
recently O 
measured O 
data O 
. O 
Also O 
the O 
dissociation O 
energy O 
D0 O 
= O 
0.623 O 
eV O 
of O 
HCO B-FORMULA 
into O 
H B-FORMULA 
+ O 
CO B-FORMULA 
obtained O 
from O 
these O 
calculations O 
agrees O 
well O 
with O 
experimental O 
values O 
. O 
Finally O 
, O 
we O 
made O 
preliminary O 
two O 
- O 
dimensional O 
( O 
2D O 
) O 
calculations O 
of O 
the O 
cross O 
sections O 
for O 
rotationally O 
inelastic O 
H B-FORMULA 
- O 
CO B-FORMULA 
collisions O 
with O 
the O 
CO B-FORMULA 
bond O 
length O 
fixed O 
and O 
obtained O 
good O 
agreement O 
with O 
recently O 
published O 
2D O 
results O 
. O 

effect O 
of O 
prunetin B-TRIVIAL 
via O 
the O 
suppression O 
of O 
NF-κB O 
pathway O 
. O 

is O 
an O 
O-methylated B-FAMILY 
isoflavone I-FAMILY 
, O 
which O 
is O 
found O 
in O 
Prunus O 
yedoensis O 
. O 
To O 
date O 
no O 
report O 
has O 
been O 
published O 
on O 
anti-inflammatory O 
activities O 
of O 
prunetin B-TRIVIAL 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
anti-inflammatory O 
effect O 
of O 
prunetin B-TRIVIAL 
on O 
LPS-stimulated O 
RAW O 
264.7 O 
macrophage O 
and O 
LPS-induced O 
septic O 
shock O 
model O 
were O 
investigated O 
. O 
Inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
( O 
iNOS O 
) O 
, O 
cyclooxygenase-2 O 
( O 
COX-2 O 
) O 
, O 
tumor O 
necrosis O 
factor-α O 
( O 
TNF-α O 
) O 
, O 
interleukin-6 O 
( O 
IL-6 O 
) O 
, O 
and O 
interleukin-1β O 
( O 
IL-1β O 
) O 
expressions O 
were O 
determined O 
by O 
western O 
blot O 
and O 
or O 
realtime-PCR O 
( O 
RT-PCR O 
) O 
. O 
To O 
elucidate O 
its O 
underlying O 
mechanism O 
, O 
nuclear O 
factor O 
- O 
kappa O 
B O 
( O 
NF-κb O 
) O 
activation O 
and O 
its O 
downstream O 
pathways O 
were O 
investigated O 
by O 
NF-κB O 
transcription O 
factor O 
assay O 
, O 
reporter O 
gene O 
expression O 
, O 
and O 
western O 
blot O 
. O 
In O 
vivo O 
anti-inflammatory O 
effects O 
of O 
prunetin B-TRIVIAL 
were O 
evaluated O 
in O 
LPS-induced O 
endotoxemia O 
. O 
Promoter O 
assay O 
revealed O 
that O 
prunetin B-TRIVIAL 
inhibits O 
LPS-induced O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
and O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
production O 
through O 
the O 
suppression O 
of O 
iNOS O 
and O 
COX-2 O 
at O 
the O 
transcriptional O 
level O 
. O 
In O 
addition O 
, O 
prunetin B-TRIVIAL 
inhibits O 
NF-κB-dependent O 
inflammatory O 
responses O 
by O 
modulating O 
IκB O 
kinase O 
(IKK)-inhibitor O 
κBα O 
(IκBα)-NF-κB O 
signaling O 
. O 
Consistent O 
with O 
these O 
results O 
, O 
prunetin B-TRIVIAL 
significantly O 
reduced O 
serum O 
levels O 
of O 
inflammatory O 
cytokines O 
and O 
mortality O 
in O 
mice O 
challenged O 
with O 
lipopolysaccharide O 
. O 
These O 
findings O 
offer O 
a O 
potential O 
mechanism O 
for O 
the O 
anti-inflammatory O 
activity O 
of O 
prunetin B-TRIVIAL 
. O 

activity O 
of O 
embelin B-TRIVIAL 
: O 
Involvement O 
of O 
cellular O 
inflammatory O 
mediators O 
, O 
oxidative O 
stress O 
and O 
other O 
biomarkers O 
. O 

( O 
benzoquinone B-SYSTEMATIC 
) O 
, O 
an O 
active O 
constituent O 
of O 
methanolic O 
extracts O 
of O 
the O 
fruit O 
of O 
Embelia O 
basal O 
( O 
Myrsinaceae O 
) O 
, O 
was O 
studied O 
in O 
high O 
fat O 
diet O 
(HFD)+ O 
streptozotocin B-TRIVIAL 
( O 
STZ B-ABBREVIATION 
) O 
diabetic O 
rats O 
. O 
Treatment O 
of O 
embelin B-TRIVIAL 
( O 
25 O 
and O 
50mg O 
/ O 
kg O 
/ O 
day O 
, O 
p.o O 
. O 
) O 
for O 
3 O 
weeks O 
to O 
HFD+ O 
STZ B-ABBREVIATION 
diabetic O 
rats O 
elicited O 
insignificant O 
increase O 
in O 
body O 
weight O 
, O 
reduced O 
the O 
elevated O 
plasma O 
glucose B-TRIVIAL 
, O 
glycosylated O 
haemoglobin O 
and O 
pro O 
- O 
inflammatory O 
mediators O 
( O 
interleukin O 
6 O 
and O 
tumour O 
necrosis O 
factor O 
α O 
) O 
significantly O 
. O 
Furthermore O 
, O 
embelin O 
treatment O 
at O 
both O 
the O 
doses O 
significantly O 
decreased O 
the O 
elevated O 
malondialdehyde B-TRIVIAL 
, O 
restored O 
depleted O 
glutathione B-TRIVIAL 
, O 
antioxidant O 
enzymes O 
, O 
superoxide B-TRIVIAL 
dismutase O 
and O 
catalase O 
in O 
liver O 
. O 
The O 
increased O 
lipid O 
profiles O 
in O 
HFD+ O 
STZ B-ABBREVIATION 
diabetic O 
rats O 
were O 
also O 
reduced O 
by O 
embelin B-TRIVIAL 
treatment O 
significantly O 
. O 
Embelin B-TRIVIAL 
treatment O 
to O 
HFD+ O 
STZ B-ABBREVIATION 
diabetic O 
rats O 
also O 
improved O 
the O 
altered O 
histoarchitecture O 
of O 
β-islets O 
of O 
pancreas O 
and O 
hepatocytes O 
. O 
The O 
embelin B-TRIVIAL 
effect O 
on O 
progression O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
in O 
rats O 
appears O 
to O 
be O 
through O 
the O 
inhibition O 
of O 
intracellular O 
pro O 
- O 
inflammatory O 
mediators O 
, O 
lowering O 
of O 
lipid O 
profile O 
and O 
amelioration O 
of O 
oxidative O 
stress O 
. O 
Considering O 
the O 
pharmacological O 
activity O 
profile O 
of O 
embelin B-TRIVIAL 
, O 
it O 
is O 
suggested O 
that O 
embelin B-TRIVIAL 
be O 
a O 
useful O 
diabetic O 
modulator O 
or O 
adjuvant O 
along O 
with O 
clinically O 
effective O 
anti-diabetic O 
drugs O 
in O 
the O 
treatment O 
of O 
type O 
2 O 
diabetes O 
mellitus O 
and O 
needs O 
to O 
be O 
clinically O 
evaluated O 
on O 
human O 
subjects O 
. O 

toxin O 
prevents O 
capsaicin B-TRIVIAL 
-induced O 
nociceptive O 
behavior O 
and O 
mechanical O 
hypersensitivity O 
without O 
acting O 
on O 
TRPV1 O 
channels O 
. O 

toxin O 
is O 
a O 
peptide O 
purified O 
from O 
the O 
venom O 
of O 
the O 
armed O 
spider O 
Phoneutria O 
nigriventer O 
, O 
with O 
markedly O 
antinociceptive O 
action O 
in O 
models O 
of O 
acute O 
and O 
persistent O 
pain O 
in O 
rats O 
. O 
Similarly O 
to O 
ziconotide O 
, O 
its O 
analgesic O 
action O 
is O 
related O 
to O 
inhibition O 
of O 
high O 
voltage O 
activated O 
calcium B-SYSTEMATIC 
channels O 
with O 
more O 
selectivity O 
for O 
N- O 
type O 
. O 
In O 
this O 
study O 
we O 
evaluated O 
the O 
effect O 
of O 
Phα1β O 
when O 
injected O 
peripherally O 
or O 
intrathecally O 
in O 
a O 
rat O 
model O 
of O 
spontaneous O 
pain O 
induced O 
by O 
capsaicin B-TRIVIAL 
. O 
We O 
also O 
investigated O 
the O 
effect O 
of O 
Phα1β O 
on O 
Ca(2+) B-FORMULA 
transients O 
in O 
cultured O 
dorsal O 
root O 
ganglia O 
( O 
DRG O 
) O 
neurons O 
and O 
HEK293 O 
cells O 
expressing O 
the O 
TRPV1 O 
receptor O 
. O 
Intraplantar O 
or O 
intrathecal O 
administered O 
Phα1β O 
reduced O 
both O 
nocifensive O 
behavior O 
and O 
mechanical O 
hypersensitivity O 
induced O 
by O 
capsaicin B-TRIVIAL 
similarly O 
to O 
that O 
observed O 
with O 
SB366791 B-IDENTIFIER 
, O 
a O 
specific O 
TRPV1 O 
antagonist O 
. O 
Peripheral O 
nifedipine B-TRIVIAL 
and O 
mibefradil B-TRIVIAL 
did O 
also O 
decrease O 
nociceptive O 
behavior O 
induced O 
by O 
intraplantar O 
capsaicin B-TRIVIAL 
. O 
In O 
contrast O 
, O 
ω-conotoxin O 
MVIIA O 
( O 
a O 
selective O 
N- O 
type O 
Ca(2+) B-FORMULA 
channel O 
blocker O 
) O 
was O 
effective O 
only O 
when O 
administered O 
intrathecally O 
. O 
Phα1β O 
, O 
MVIIA O 
and O 
SB366791 B-IDENTIFIER 
inhibited O 
, O 
with O 
similar O 
potency O 
, O 
the O 
capsaicin B-TRIVIAL 
-induced O 
Ca(2+) B-FORMULA 
transients O 
in O 
DRG O 
neurons O 
. O 
The O 
simultaneous O 
administration O 
of O 
Phα1β O 
and O 
SB366791 B-IDENTIFIER 
inhibited O 
the O 
capsaicin B-TRIVIAL 
-induced O 
Ca(2+) B-FORMULA 
transients O 
that O 
were O 
additive O 
suggesting O 
that O 
they O 
act O 
through O 
different O 
targets O 
. O 
Moreover O 
, O 
Phα1β O 
did O 
not O 
inhibit O 
capsaicin B-TRIVIAL 
-activated O 
currents O 
in O 
patch O 
- O 
clamp O 
recordings O 
of O 
HEK293 O 
cells O 
that O 
expressed O 
TRPV1 O 
receptors O 
. O 
Our O 
results O 
show O 
that O 
Phα1β O 
may O 
be O 
effective O 
as O 
a O 
therapeutic O 
strategy O 
for O 
pain O 
and O 
this O 
effect O 
is O 
not O 
related O 
to O 
the O 
inhibition O 
of O 
TRPV1 O 
receptors O 
. O 

primes O 
the O 
effect O 
of O 
cocaine B-TRIVIAL 
on O 
the O 
induction O 
of O 
LTP O 
in O 
the O 
amygdala O 
. O 

human O 
populations O 
, O 
there O 
is O 
a O 
well O 
- O 
defined O 
sequence O 
of O 
involvement O 
in O 
drugs O 
of O 
abuse O 
, O 
in O 
which O 
the O 
use O 
of O 
nicotine B-TRIVIAL 
or O 
alcohol B-FAMILY 
precedes O 
the O 
use O 
of O 
marijuana O 
, O 
which O 
in O 
turn O 
, O 
precedes O 
the O 
use O 
of O 
cocaine B-TRIVIAL 
. O 
The O 
term O 
" O 
Gateway O 
Hypothesis O 
" O 
describes O 
this O 
developmental O 
sequence O 
of O 
drug O 
involvement O 
. O 
In O 
prior O 
work O 
, O 
we O 
have O 
developed O 
a O 
mouse O 
model O 
to O 
study O 
the O 
underlying O 
metaplastic O 
behavioral O 
, O 
cellular O 
and O 
molecular O 
mechanisms O 
by O 
which O 
exposure O 
to O 
one O 
drug O 
, O 
namely O 
nicotine B-TRIVIAL 
, O 
affects O 
the O 
response O 
to O 
another O 
drug O 
, O 
namely O 
cocaine B-TRIVIAL 
. O 
We O 
found O 
that O 
nicotine B-TRIVIAL 
enhances O 
significantly O 
the O 
changes O 
in O 
synaptic O 
plasticity O 
in O 
the O 
striatum O 
induced O 
by O 
cocaine B-TRIVIAL 
( O 
Levine O 
et O 
al O 
. O 
, O 
2011 O 
) O 
. O 
Here O 
we O 
ask O 
: O 
does O 
the O 
metaplastic O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
cocaine B-TRIVIAL 
also O 
apply O 
in O 
the O 
amygdala O 
, O 
a O 
brain O 
region O 
that O 
is O 
involved O 
in O 
the O 
orchestration O 
of O 
emotions O 
and O 
in O 
drug O 
addiction O 
? O 
We O 
find O 
that O 
pretreatment O 
with O 
nicotine B-TRIVIAL 
enhances O 
long O 
- O 
term O 
synaptic O 
potentiation O 
( O 
LTP O 
) O 
in O 
response O 
to O 
cocaine B-TRIVIAL 
in O 
the O 
amygdala O 
. O 
Both O 
short O 
- O 
term O 
( O 
1 O 
day O 
) O 
and O 
long O 
- O 
term O 
( O 
7 O 
days O 
) O 
pre O 
- O 
exposure O 
to O 
nicotine B-TRIVIAL 
facilitate O 
the O 
induction O 
of O 
LTP O 
by O 
cocaine B-TRIVIAL 
. O 
The O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
LTP O 
is O 
unidirectional O 
; O 
exposure O 
to O 
nicotine B-TRIVIAL 
following O 
treatment O 
with O 
cocaine B-TRIVIAL 
is O 
ineffective O 
. O 
This O 
metaplastic O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
cocaine B-TRIVIAL 
is O 
long O 
lasting O 
but O 
reversible O 
. O 
The O 
facilitation O 
of O 
LTP O 
can O 
be O 
obtained O 
for O 
24 O 
but O 
not O 
40 O 
days O 
after O 
cessation O 
of O 
nicotine B-TRIVIAL 
. O 
As O 
is O 
the O 
case O 
in O 
the O 
striatum O 
, O 
pretreatment O 
with O 
Suberoylanilide B-SYSTEMATIC 
hydroxamic I-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
SAHA B-ABBREVIATION 
) O 
, O 
a O 
histone O 
deacetylase O 
inhibitor O 
, O 
simulates O 
the O 
priming O 
effect O 
of O 
nicotine B-TRIVIAL 
. O 
These O 
results O 
provide O 
further O 
evidence O 
that O 
the O 
priming O 
effect O 
of O 
nicotine B-TRIVIAL 
may O 
be O 
achieved O 
, O 
at O 
least O 
partially O 
, O 
by O 
the O 
inhibition O 
of O 
histone O 
acetylation O 
and O 
indicate O 
that O 
the O 
amygdala O 
appears O 
to O 
be O 
an O 
important O 
brain O 
structure O 
for O 
the O 
processing O 
of O 
the O 
metaplastic O 
effect O 
of O 
nicotine B-TRIVIAL 
on O 
cocaine B-TRIVIAL 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
GluR-dep O 
synaptic O 
plasticity O 
' O 
. O 

, O 
synthesis O 
and O 
in O 
combo O 
studies O 
of O 
a O 
tetrazole B-FAMILY 
analogue O 
of O 
clofibric B-TRIVIAL 
acid I-TRIVIAL 
as O 
a O 
potent O 
hypoglycemic O 
agent O 
. O 

tetrazole B-FAMILY 
isosteric O 
analogue O 
of O 
clofibric B-TRIVIAL 
acid I-TRIVIAL 
( O 
1 O 
) O 
was O 
prepared O 
using O 
a O 
short O 
synthetic O 
route O 
and O 
was O 
characterized O 
by O 
elemental O 
analysis O 
, O 
NMR O 
( O 
(1)H B-FORMULA 
, O 
(13)C B-FORMULA 
) O 
spectroscopy O 
, O 
and O 
single O 
- O 
crystal O 
X-ray O 
diffraction O 
. O 
The O 
in O 
vitro O 
inhibitory O 
activity O 
of O 
1 O 
against O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
( O 
11β-HSD1 O 
) O 
was O 
evaluated O 
, O 
showing O 
a O 
moderate O 
inhibitory O 
enzyme O 
activity O 
( O 
51.17% O 
of O 
inhibition O 
at O 
10μM O 
) O 
, O 
being O 
more O 
active O 
than O 
clofibrate B-TRIVIAL 
and O 
clofibric B-TRIVIAL 
acid I-TRIVIAL 
. O 
The O 
antidiabetic O 
activity O 
of O 
compound O 
1 O 
was O 
determined O 
at O 
50mg O 
/ O 
Kg O 
single O 
dose O 
using O 
a O 
non O 
insulin O 
dependent O 
diabetes O 
mellitus O 
rat O 
model O 
. O 
The O 
results O 
indicated O 
a O 
significant O 
decrease O 
of O 
plasma O 
glucose B-TRIVIAL 
levels O 
, O 
during O 
the O 
7h O 
post O 
- O 
administration O 
. O 
Additionally O 
, O 
we O 
performed O 
a O 
molecular O 
docking O 
of O 
1 O 
into O 
the O 
ligand O 
binding O 
pocket O 
of O 
one O 
subunit O 
of O 
human O 
11β-HSD1 O 
. O 
In O 
this O 
model O 
, O 
compound O 
1 O 
binds O 
into O 
the O 
catalytic O 
site O 
of O 
11β-HSD1 O 
in O 
two O 
different O 
orientations O 
. O 
Both O 
of O 
them O 
, O 
show O 
important O 
short O 
contacts O 
with O 
the O 
catalytic O 
residues O 
Ser B-FORMULA 
170 O 
, O 
Tyr B-FORMULA 
183 O 
, O 
Asp B-FORMULA 
259 O 
and O 
also O 
with O 
the O 
nicotinamide B-TRIVIAL 
ring O 
of O 
NADP(+) B-ABBREVIATION 
. O 

- O 
picometer O 
structural O 
information O 
of O 
graphene B-TRIVIAL 
hidden O 
in O 
a O 
50 O 
pm O 
resolved O 
image O 
. O 

a O 
2D O 
self O 
- O 
organized O 
crystalline O 
structure O 
more O 
than O 
1000 O 
unit O 
- O 
cells O 
can O 
be O 
observed O 
in O 
a O 
single O 
image O 
. O 
Here O 
we O 
exploit O 
the O 
benefits O 
from O 
having O 
a O 
large O 
number O 
of O 
observations O 
of O 
the O 
same O 
unit O 
cell O 
utilizing O 
an O 
image O 
processing O 
methodology O 
. O 
We O 
obtain O 
sub O 
- O 
picometer O 
resolution O 
data O 
from O 
a O 
50 O 
pm O 
image O 
of O 
graphene B-TRIVIAL 
, O 
revealing O 
a O 
1% O 
axial O 
elongation O 
and O 
a O 
3 O 
fold O 
symmetry O 
, O 
indicating O 
a O 
chair O 
conformation O 
. O 

of O 
ZIP8 O 
expression O 
is O 
a O 
common O 
feature O 
of O 
cadmium B-SYSTEMATIC 
-resistant O 
and O 
manganese B-SYSTEMATIC 
-resistant O 
RBL-2H3 O 
cells O 
. O 

basophilic O 
leukemia O 
RBL-2H3 O 
cells O 
show O 
markedly O 
high O 
sensitivity O 
to O 
both O 
CdCl2 B-FORMULA 
and O 
MnCl2 B-FORMULA 
compared O 
with O 
other O 
rat O 
cell O 
lines O 
, O 
due O 
to O 
efficient O 
accumulation O 
of O 
cadmium B-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
. O 
To O 
clarify O 
the O 
roles O 
of O 
metal O 
transporters O 
in O 
hyperaccumulation O 
of O 
cadmium B-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
in O 
RBL-2H3 O 
cells O 
, O 
Cd B-FORMULA 
-resistant O 
and O 
Mn B-FORMULA 
-resistant O 
cells O 
were O 
developed O 
from O 
RBL-2H3 O 
cells O 
by O 
continuous O 
exposure O 
to O 
CdCl2 B-FORMULA 
and O 
MnCl2 B-FORMULA 
, O 
respectively O 
. O 
The O 
established O 
Cd B-FORMULA 
-resistant O 
( O 
RBL-Cdr O 
) O 
and O 
Mn B-FORMULA 
-resistant O 
( O 
RBL-Mnr O 
) O 
cells O 
exhibited O 
about O 
20 O 
times O 
higher O 
LC50 O 
values O 
of O 
CdCl2 B-FORMULA 
and O 
MnCl2 B-FORMULA 
, O 
respectively O 
, O 
than O 
parental O 
RBL-2H3 O 
cells O 
, O 
and O 
showed O 
cross O 
- O 
resistance O 
to O 
each O 
metal O 
. O 
The O 
resistance O 
to O 
cadmium B-SYSTEMATIC 
and O 
manganese B-SYSTEMATIC 
was O 
primarily O 
conferred O 
by O 
a O 
marked O 
decrease O 
in O 
the O 
uptake O 
of O 
both O 
metals O 
. O 
RBL-Cdr O 
cells O 
also O 
showed O 
cross O 
- O 
resistance O 
to O 
HgCl2 B-FORMULA 
and O 
AgNO3 B-FORMULA 
probably O 
due O 
to O 
enhanced O 
expression O 
of O 
metallothionein O 
. O 
Among O 
the O 
possible O 
transporters O 
involved O 
in O 
the O 
uptake O 
of O 
Cd(2+) B-FORMULA 
and O 
Mn(2+) B-FORMULA 
, O 
the O 
expression O 
of O 
ZIP8 O 
( O 
Zrt- O 
, O 
Irt O 
- O 
related O 
protein O 
8 O 
) O 
, O 
encoded O 
by O 
Slc39a8 O 
, O 
showed O 
a O 
marked O 
suppression O 
in O 
both O 
RBL-Cdr O 
and O 
RBL-Mnr O 
cells O 
. O 
These O 
results O 
suggest O 
that O 
ZIP8 O 
plays O 
a O 
pivotal O 
role O 
in O 
the O 
transport O 
and O 
toxicity O 
of O 
Cd(2+) B-FORMULA 
and O 
Mn(2+) B-FORMULA 
in O 
RBL-2H3 O 
cells O 
. O 

aerial O 
parts O 
of O 
Ageratina O 
pichinchensis O 
are O 
used O 
in O 
Mexican O 
traditional O 
medicine O 
for O 
the O 
treatment O 
of O 
skin O 
wounds O 
. O 
Recently O 
, O 
it O 
was O 
demonstrated O 
that O 
the O 
aqueous O 
extract O 
of O 
this O 
plant O 
reduced O 
the O 
time O 
required O 
to O 
cicatrize O 
a O 
wound O 
induced O 
in O 
the O 
rat O 
. O 
The O 
same O 
extract O 
showed O 
a O 
capability O 
to O 
induce O 
overgrowth O 
in O 
normal O 
fetal O 
lung O 
cells O 
( O 
MRC-5 O 
) O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
isolating O 
and O 
identifying O 
the O 
active O 
compounds O 
in O 
A. O 
pichinchensis O 
that O 
are O 
capable O 
of O 
inducing O 
cellular O 
overgrowth O 
, O 
as O 
well O 
as O 
performing O 
a O 
preliminary O 
evaluation O 
of O 
their O 
anti-inflammatory O 
and O 
toxic O 
effects O 
. O 
By O 
means O 
of O 
bioguided O 
chemical O 
separation O 
of O 
an O 
aqueous O 
extract O 
of O 
A. O 
pichinchensis O 
, O 
the O 
most O 
active O 
compound O 
capable O 
of O 
inducing O 
cellular O 
overgrowth O 
was O 
identified O 
as O 
7-O-(β-D-glucopyranosyl)-galactin B-SYSTEMATIC 
. O 
In O 
vivo O 
inflammation O 
induced O 
with O 
carrageenan O 
in O 
mice O 
was O 
significantly O 
reduced O 
by O 
the O 
aqueous O 
extract O 
of O 
A. O 
pichinchensis O 
, O 
reaching O 
a O 
decrease O 
of O 
up O 
to O 
60.6 O 
% O 
. O 
Acute O 
( O 
2 O 
g O 
/ O 
kg O 
) O 
and O 
subchronic O 
( O 
1 O 
g O 
/ O 
kg O 
for O 
28 O 
days O 
) O 
oral O 
administration O 
of O 
the O 
aqueous O 
extract O 
of O 
this O 
plant O 
did O 
not O 
affect O 
hepatic O 
function O 
( O 
through O 
alanine B-TRIVIAL 
aminotransferase O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
activity O 
evaluation O 
) O 
, O 
while O 
no O 
alterations O 
of O 
the O 
histologic O 
samples O 
of O 
liver O 
and O 
kidney O 
were O 
evidenced O 
. O 

discovery O 
of O 
CXCR7 O 
as O 
a O 
new O 
receptor O 
for O 
SDF-1 O 
places O 
many O 
previously O 
described O 
SDF-1 O 
functions O 
attributed O 
to O 
CXCR4 O 
in O 
question O 
, O 
though O 
whether O 
CXCR7 O 
acts O 
as O 
a O 
signaling O 
or O 
decoy O 
receptor O 
has O 
been O 
in O 
debate O 
. O 
It O 
is O 
known O 
that O 
CXCR7 O 
is O 
not O 
expressed O 
in O 
normal O 
blood O 
leukocytes O 
; O 
however O 
, O 
the O 
potential O 
role O 
of O 
leukocyte O 
CXCR7 O 
in O 
disease O 
states O 
has O 
not O 
been O 
addressed O 
. O 
The O 
aim O 
of O 
this O 
study O 
was O 
to O 
determine O 
the O 
expression O 
and O 
function O 
of O 
macrophage O 
CXCR7 O 
linked O 
to O 
atherosclerosis O 
. O 
Here O 
, O 
we O 
show O 
that O 
CXCR7 O 
was O 
detected O 
in O 
macrophage O 
- O 
positive O 
area O 
of O 
aortic O 
atheroma O 
of O 
ApoE-null O 
mice O 
, O 
but O 
not O 
in O 
healthy O 
aorta O 
. O 
During O 
monocytes O 
differentiation O 
to O 
macrophages O 
, O 
CXCR7 O 
was O 
up O 
- O 
regulated O 
at O 
mRNA O 
and O 
protein O 
levels O 
, O 
with O 
more O 
expression O 
in O 
M1 O 
than O 
in O 
M2 O 
phenotype O 
. O 
In O 
addition O 
, O 
CXCR7 O 
induction O 
was O 
associated O 
with O 
a O 
SDF-1 O 
signaling O 
switch O 
from O 
the O 
pro O 
- O 
survival O 
ERK O 
and O 
AKT O 
pathways O 
in O 
monocytes O 
to O 
the O 
pro O 
- O 
inflammatory O 
JNK O 
and O 
p38 O 
pathways O 
in O 
macrophages O 
. O 
The O 
latter O 
effect O 
was O 
mimicked O 
by O 
a O 
CXCR7-selective O 
agonist O 
TC14012 B-IDENTIFIER 
and O 
abolished O 
by O 
siRNA O 
knockdown O 
of O 
CXCR7 O 
. O 
Furthermore O 
, O 
CXCR7 O 
activation O 
increased O 
macrophage O 
phagocytic O 
activity O 
, O 
which O 
was O 
suppressed O 
by O 
CXCR7 O 
siRNA O 
silencing O 
or O 
by O 
inhibiting O 
either O 
the O 
JNK O 
or O 
p38 O 
pathways O 
, O 
but O 
was O 
not O 
affected O 
by O 
blocking O 
CXCR4 O 
. O 
Finally O 
, O 
activation O 
of O 
CXCR7 O 
by O 
I-TAC O 
showed O 
a O 
similar O 
signaling O 
and O 
phagocytic O 
activity O 
in O 
macrophages O 
with O 
no O 
detectable O 
CXCR3 O 
. O 
We O 
conclude O 
that O 
CXCR7 O 
is O 
induced O 
during O 
monocyte O 
- O 
to O 
- O 
macrophage O 
differentiation O 
, O 
which O 
is O 
required O 
for O 
SDF-1 O 
and O 
I-TAC O 
signaling O 
to O 
JNK O 
and O 
p38 O 
pathways O 
, O 
leading O 
to O 
enhanced O 
macrophage O 
phagocytosis O 
, O 
thus O 
possibly O 
contributing O 
to O 
atherogenesis O 
. O 

functions O 
to O 
stabilize O 
and O 
activate O 
the O 
testis O 
- O 
specific O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinases O 
, O 
a O 
family O 
of O 
kinases O 
essential O 
for O 
male O 
fertility O 
. O 

is O 
characterized O 
by O 
a O 
profound O 
morphological O 
differentiation O 
of O 
the O 
haploid O 
spermatid O 
into O 
spermatozoa O 
. O 
The O 
testis O 
- O 
specific O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinases O 
( O 
TSSKs O 
) O 
comprise O 
a O 
family O 
of O 
post O 
- O 
meiotic O 
kinases O 
expressed O 
in O 
spermatids O 
, O 
are O 
critical O 
to O 
spermiogenesis O 
and O 
are O 
required O 
for O 
male O 
fertility O 
in O 
mammals O 
. O 
To O 
explore O 
the O 
role O 
of O 
HSP90 O 
in O 
regulation O 
of O 
TSSKs O 
, O 
the O 
stability O 
and O 
catalytic O 
activity O 
of O 
epitope O 
- O 
tagged O 
murine O 
TSSKs O 
were O 
assessed O 
in O 
293T O 
and O 
COS-7 O 
cells O 
. O 
TSSK1 O 
, O 
2 O 
, O 
4 O 
, O 
and O 
6 O 
( O 
SSTK O 
) O 
were O 
all O 
found O 
to O 
associate O 
with O 
HSP90 O 
and O 
pharmacological O 
inhibition O 
of O 
HSP90 O 
function O 
using O 
the O 
highly O 
specific O 
drugs O 
17-AAG O 
, O 
SNX-5422 O 
, O 
or O 
NVP-AUY922 O 
reduced O 
TSSK O 
protein O 
levels O 
in O 
cells O 
. O 
The O 
attenuation O 
of O 
HSP90 O 
function O 
abolished O 
the O 
catalytic O 
activities O 
of O 
TSSK4 O 
and O 
6 O 
, O 
but O 
did O 
not O 
significantly O 
alter O 
the O 
specific O 
activities O 
of O 
TSSK1 O 
and O 
2 O 
. O 
Inhibition O 
of O 
HSP90 O 
resulted O 
in O 
increased O 
TSSK O 
ubiquitination O 
and O 
proteasomal O 
degradation O 
indicating O 
that O 
HSP90 O 
acts O 
to O 
control O 
ubiquitin O 
- O 
mediated O 
catabolism O 
of O 
the O 
TSSKs O 
. O 
To O 
study O 
HSP90 O 
and O 
TSSKs O 
in O 
germ O 
cells O 
a O 
mouse O 
primary O 
spermatid O 
culture O 
model O 
was O 
developed O 
and O 
characterized O 
. O 
Using O 
specific O 
antibodies O 
against O 
murine O 
TSSK2 O 
and O 
6 O 
, O 
it O 
was O 
demonstrated O 
that O 
HSP90 O 
inhibition O 
resulted O 
in O 
a O 
marked O 
decrease O 
of O 
the O 
endogenous O 
kinases O 
in O 
spermatids O 
. O 
Together O 
, O 
our O 
findings O 
demonstrate O 
that O 
HSP90 O 
plays O 
a O 
broad O 
and O 
critical O 
role O 
in O 
stabilization O 
and O 
activation O 
of O 
the O 
TSSK O 
family O 
of O 
protein O 
kinases O 
. O 

: O 
5-Lipoxygenase O 
( O 
5-LO O 
) O 
is O 
a O 
crucial O 
enzyme O 
of O 
the O 
arachidonic B-TRIVIAL 
acid I-TRIVIAL 
( O 
AA O 
) O 
cascade O 
and O 
catalyzes O 
the O 
formation O 
of O 
bioactive O 
leukotrienes O 
( O 
LTs O 
) O 
with O 
the O 
help O 
of O 
FLAP O 
, O 
the O 
5-LO-activating O 
protein O 
. O 
LTs O 
are O 
inflammatory O 
mediators O 
playing O 
a O 
pathophysiological O 
role O 
in O 
different O 
diseases O 
like O 
asthma O 
, O 
allergic O 
rhinitis O 
as O 
well O 
as O 
cardiovascular O 
diseases O 
and O 
certain O 
types O 
of O 
cancer O 
. O 
With O 
the O 
rising O 
number O 
of O 
indications O 
for O 
anti-LT O 
therapy O 
, O 
5-LO O 
inhibitor O 
drug O 
development O 
becomes O 
increasingly O 
important O 
. O 
Areas O 
covered O 
: O 
Here O 
, O 
both O 
recent O 
findings O 
regarding O 
the O 
pathophysiological O 
role O 
of O 
5-LO O 
and O 
the O 
patents O 
claimed O 
for O 
5-LO O 
inhibitors O 
are O 
discussed O 
. O 
Focusing O 
on O 
direct O 
inhibitors O 
, O 
several O 
patents O 
disclosing O 
FLAP O 
antagonists O 
are O 
also O 
subject O 
of O 
this O 
review O 
. O 
Novel O 
compounds O 
include O 
1,5-diarylpyrazoles B-FAMILY 
, O 
indolizines B-FAMILY 
and O 
indoles B-FAMILY 
and O 
several O 
natural O 
product O 
extracts O 
. O 
Expert O 
opinion O 
: O 
Evaluation O 
of O 
the O 
patent O 
activities O 
revealed O 
only O 
quite O 
moderate O 
action O 
. O 
Nevertheless O 
, O 
several O 
auspicious O 
drug O 
- O 
like O 
molecules O 
were O 
disclosed O 
. O 
It O 
seems O 
that O 
in O 
the O 
near O 
future O 
, O 
FLAP O 
inhibitors O 
can O 
be O 
expected O 
to O 
enter O 
the O 
market O 
for O 
the O 
treatment O 
of O 
asthma O 
. O 
With O 
the O 
resolved O 
structure O 
of O 
5-LO O 
, O 
structure O 
- O 
based O 
drug O 
design O 
is O 
now O 
applicable O 
. O 
Together O 
with O 
the O 
identification O 
of O 
downstream O 
enzyme O 
inhibitors O 
and O 
dual O 
- O 
targeting O 
drugs O 
within O 
the O 
AA O 
cascade O 
, O 
several O 
tools O 
are O 
at O 
hand O 
to O 
cope O 
with O 
5-LOs O 
increasing O 
pathophysiological O 
roles O 
. O 

Singlet O 
Biradicaloid O 
Zinc B-SYSTEMATIC 
Compound O 
and O 
Its O 
Nonradical O 
Counterpart O 
. O 

ions O 
with O 
radical O 
centers O 
in O 
their O 
coordination O 
sphere O 
are O 
key O 
participants O 
in O 
biological O 
and O 
catalytic O 
processes O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
describe O 
the O 
synthesis O 
of O 
the O 
cAAC O 
: O 
ZnCl2 B-FORMULA 
adduct O 
( O 
1 O 
) O 
using O 
a O 
cyclic B-FAMILY 
alkylaminocarbene I-FAMILY 
( O 
cAAC B-ABBREVIATION 
) O 
as O 
donor O 
ligand O 
. O 
Compound O 
1 O 
was O 
treated O 
with O 
2 O 
equiv O 
of O 
KC8 B-ABBREVIATION 
and O 
LiB(sec-Bu)3H B-FORMULA 
to O 
yield O 
a O 
deep O 
blue O 
- O 
colored O 
dicarbene B-SYSTEMATIC 
zinc I-SYSTEMATIC 
compound O 
(cAAC)2Zn B-FORMULA 
( O 
2 O 
) O 
and O 
the O 
colorless O 
hydrogenated O 
zinc B-SYSTEMATIC 
compound O 
(cAACH)2Zn B-FORMULA 
( O 
3 O 
) O 
, O 
respectively O 
. O 
Compounds O 
2 O 
and O 
3 O 
were O 
well O 
characterized O 
by O 
spectroscopic O 
methods O 
and O 
single O 
- O 
crystal O 
X-ray O 
structural O 
analysis O 
. O 
Density O 
functional O 
theory O 
calculations O 
were O 
performed O 
for O 
2 O 
which O 
indicate O 
that O 
this O 
molecule O 
possesses O 
a O 
singlet O 
biradicaloid O 
character O 
. O 
Moreover O 
, O 
we O 
show O 
the O 
application O 
of O 
2 O 
in O 
CO2 B-FORMULA 
activation O 
, O 
which O 
yields O 
a O 
zwitterionic O 
cAAC B-ABBREVIATION 
· O 
CO2 B-FORMULA 
adduct O 
. O 

new O 
compounds O 
, O 
8-dehydroxymethylvisanol B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
9-O-[3-O-acetyl-β-d-glucopyranosyl]-4-hydroxy-cinnamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
together O 
with O 
two O 
known O 
lignans B-FAMILY 
, O 
visanol B-TRIVIAL 
( O 
2 O 
) O 
and O 
9-aldehydevibsanol B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
80% O 
EtOH B-FORMULA 
extract O 
of O 
Solidago O 
canadensis O 
. O 
The O 
structures O 
of O 
the O 
two O 
new O 
compounds O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
1D O 
, O 
2D O 
NMR O 
, O 
and O 
mass O 
spectral O 
analysis O 
. O 
All O 
the O 
lignans B-FAMILY 
exhibited O 
moderate O 
hypolipidemic O 
activity O 
in O 
high O 
- O 
fat O 
diet O 
- O 
fed O 
hamsters O 
. O 

coacervates O 
prepared O 
from O 
poly(aspartic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
polyAsp B-ABBREVIATION 
) O 
and O 
poly-l-histidine B-SYSTEMATIC 
( O 
polyHis B-ABBREVIATION 
) O 
were O 
investigated O 
as O 
models O 
of O 
the O 
metastable O 
protein O 
phases O 
used O 
in O 
the O 
formation O 
of O 
biological O 
structures O 
such O 
as O 
squid O 
beak O 
. O 
When O 
mixed O 
, O 
polyHis B-ABBREVIATION 
and O 
polyAsp B-ABBREVIATION 
form O 
coacervates O 
whereas O 
poly-l-glutamic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
polyGlu B-ABBREVIATION 
) O 
forms O 
precipitates O 
with O 
polyHis B-ABBREVIATION 
. O 
Layer O 
- O 
by O 
- O 
layer O 
( O 
LbL O 
) O 
structures O 
of O 
polyHis B-ABBREVIATION 
- O 
polyAsp B-ABBREVIATION 
on O 
gold O 
substrates O 
were O 
compared O 
with O 
those O 
of O 
precipitate O 
- O 
forming O 
polyHis B-ABBREVIATION 
- O 
polyGlu B-ABBREVIATION 
by O 
monitoring O 
with O 
iSPR O 
and O 
QCM-D O 
. O 
PolyHis B-ABBREVIATION 
- O 
polyAsp B-ABBREVIATION 
LbL O 
was O 
found O 
to O 
be O 
stiffer O 
than O 
polyHis B-ABBREVIATION 
- O 
polyGlu B-ABBREVIATION 
LbL O 
with O 
most O 
water O 
evicted O 
from O 
the O 
structure O 
but O 
with O 
sufficient O 
interfacial O 
water O 
remaining O 
for O 
molecular O 
rearrangement O 
to O 
occur O 
. O 
This O 
thin O 
layer O 
is O 
believed O 
to O 
be O 
fluid O 
and O 
like O 
preformed O 
coacervate O 
films O 
, O 
capable O 
of O 
spreading O 
over O 
both O 
hydrophilic O 
ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
as O 
well O 
as O 
hydrophobic O 
monolayers O 
. O 
These O 
results O 
suggest O 
that O 
coacervate O 
- O 
forming O 
polyelectrolytes O 
deserve O 
consideration O 
for O 
potential O 
LbL O 
applications O 
and O 
point O 
to O 
LbL O 
as O 
an O 
important O 
process O 
by O 
which O 
biological O 
materials O 
form O 
. O 

Fe3O4 B-FORMULA 
@ O 
TiO2 B-FORMULA 
: O 
Reusable O 
, O 
Magnetic O 
Nanoparticles O 
for O 
Photocatalytic O 
Degradation O 
of O 
Endocrine-Disrupting O 
Chemicals O 
in O 
Water O 
Supplies O 
. O 

- O 
dispersible O 
, O 
photocatalytic O 
Fe3O4 B-FORMULA 
@ O 
TiO2 B-FORMULA 
core O 
- O 
shell O 
magnetic O 
nanoparticles O 
have O 
been O 
prepared O 
by O 
anchoring O 
cyclodextrin O 
cavities O 
to O 
the O 
TiO2 B-FORMULA 
shell O 
, O 
and O 
their O 
ability O 
to O 
capture O 
and O 
photocatalytically O 
destroy O 
endocrine O 
- O 
disrupting O 
chemicals O 
, O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
, O 
present O 
in O 
water O 
, O 
has O 
been O 
demonstrated O 
. O 
The O 
functionalized O 
nanoparticles O 
can O 
be O 
magnetically O 
separated O 
from O 
the O 
dispersion O 
after O 
photocatalysis O 
and O 
hence O 
reused O 
. O 
Each O 
component O 
of O 
the O 
cyclodextrin O 
- O 
functionalized O 
Fe3O4 B-FORMULA 
@ O 
TiO2 B-FORMULA 
core O 
- O 
shell O 
nanoparticle O 
has O 
a O 
crucial O 
role O 
in O 
its O 
functioning O 
. O 
The O 
tethered O 
cyclodextrins O 
are O 
responsible O 
for O 
the O 
aqueous O 
dispersibility O 
of O 
the O 
nanoparticles O 
and O 
their O 
hydrophobic O 
cavities O 
for O 
the O 
capture O 
of O 
the O 
organic O 
pollutants O 
that O 
may O 
be O 
present O 
in O 
water O 
samples O 
. O 
The O 
amorphous O 
TiO2 B-FORMULA 
shell O 
is O 
the O 
photocatalyst O 
for O 
the O 
degradation O 
and O 
mineralization O 
of O 
the O 
organics O 
, O 
bisphenol B-TRIVIAL 
A I-TRIVIAL 
and O 
dibutyl B-SYSTEMATIC 
phthalate I-SYSTEMATIC 
, O 
under O 
UV O 
illumination O 
, O 
and O 
the O 
magnetism O 
associated O 
with O 
the O 
9 O 
nm O 
crystalline O 
Fe3O4 B-FORMULA 
core O 
allows O 
for O 
the O 
magnetic O 
separation O 
from O 
the O 
dispersion O 
once O 
photocatalytic O 
degradation O 
is O 
complete O 
. O 
An O 
attractive O 
feature O 
of O 
these O 
" O 
capture O 
and O 
destroy O 
" O 
nanomaterials O 
is O 
that O 
they O 
may O 
be O 
completely O 
removed O 
from O 
the O 
dispersion O 
and O 
reused O 
with O 
little O 
or O 
no O 
loss O 
of O 
catalytic O 
activity O 
. O 

new O 
glycoside O 
compounds O 
, O 
named O 
saffloquinoside B-TRIVIAL 
C I-TRIVIAL 
( O 
1 O 
) O 
and O 
(-)-4-hydroxybenzoic B-SYSTEMATIC 
acid-4-O-[6'-O-(2″-methylbutyryl)-β-D-glucopyranoside] I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
florets O 
of O 
Carthamus O 
tinctorius O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
detailed O 
spectroscopic O 
means O 
including O 
UV O 
, O 
IR O 
, O 
HR-ESI-MS O 
, O 
1D O 
and O 
2D O 
NMR O 
, O 
and O 
CD O 
data O 
. O 
Compound O 
1 O 
was O 
a O 
rare O 
quinochalcone B-FAMILY 
glycoside I-FAMILY 
with O 
six O 
five O 
- O 
membered O 
dioxaspirocycle B-FAMILY 
. O 

-loaded O 
liposomes O 
composed O 
of O 
HSPC O 
and O 
DPPC O 
at O 
different O 
ratios O 
: O 
in O 
vitro O 
and O 
in O 
vivo O 
evaluation O 
. O 

Objective O 
: O 
The O 
objective O 
of O 
this O 
study O 
is O 
to O 
test O 
the O 
hypothesis O 
that O 
the O 
phase O 
transition O 
temperature O 
( O 
Tm O 
) O 
, O 
the O 
main O 
property O 
of O 
liposomes O 
, O 
can O 
be O 
easily O 
controlled O 
by O 
changing O 
the O 
molar O 
ratio O 
of O 
hydrogenated O 
soy O 
phosphatidylcholine B-FAMILY 
( O 
HSPC O 
) O 
and O 
1,2-dipalmitoyl-sn-glycero-3-phosphacholine B-SYSTEMATIC 
( O 
DPPC B-ABBREVIATION 
) O 
after O 
drug O 
encapsulation O 
. O 
Materials O 
and O 
methods O 
: O 
Brucine B-TRIVIAL 
, O 
an O 
antitumor O 
alkaloid O 
, O 
was O 
encapsulated O 
into O 
the O 
liposomes O 
with O 
different O 
HSPC/ O 
DPPC B-ABBREVIATION 
compositions O 
. O 
The O 
Tms O 
of O 
the O 
brucine B-TRIVIAL 
-loaded O 
liposomes O 
( O 
BLs O 
) O 
were O 
determined O 
by O 
differential O 
scanning O 
calorimetry O 
( O 
DSC O 
) O 
. O 
Then O 
the O 
physicochemical O 
properties O 
and O 
pharmacokinetics O 
of O 
the O 
BLs O 
with O 
different O 
HSPC/ O 
DPPC B-ABBREVIATION 
compositions O 
were O 
investigated O 
and O 
compared O 
. O 
Results O 
: O 
The O 
results O 
of O 
DSC O 
revealed O 
that O 
HSPC O 
and O 
DPPC B-ABBREVIATION 
can O 
combine O 
into O 
one O 
phase O 
. O 
The O 
findings O 
of O 
molecular O 
modeling O 
study O 
suggested O 
that O 
HSPC O 
interacts O 
with O 
DPPC B-ABBREVIATION 
via O 
electrostatic O 
interaction O 
. O 
The O 
molar O 
ratio O 
of O 
HSPC/ O 
DPPC B-ABBREVIATION 
influenced O 
the O 
sizes O 
of O 
BLs O 
but O 
had O 
little O 
effect O 
on O 
the O 
entrapment O 
efficiency O 
( O 
EE O 
) O 
. O 
The O 
stability O 
of O 
BLs O 
was O 
improved O 
with O 
the O 
increase O 
of O 
the O 
HSPC O 
ratios O 
, O 
especially O 
with O 
the O 
presence O 
of O 
plasma O 
. O 
Following O 
i.v O 
. O 
administration O 
, O 
it O 
was O 
found O 
that O 
AUC O 
values O 
of O 
BLs O 
in O 
vivo O 
were O 
directly O 
related O 
to O 
the O 
HSPC/ O 
DPPC B-ABBREVIATION 
ratios O 
of O 
BLs O 
, O 
namely O 
the O 
Tms O 
of O 
BLs O 
. O 
Discussion O 
: O 
The O 
behavior O 
of O 
liposomes O 
, O 
especially O 
in O 
vivo O 
pharmacokinetic O 
behavior O 
, O 
can O 
be O 
controlled O 
by O 
the O 
modification O 
of O 
Tm O 
. O 
Conclusion O 
: O 
The O 
characterization O 
of O 
BLs O 
in O 
vitro O 
and O 
in O 
vivo O 
had O 
demonstrated O 
that O 
the O 
Tm O 
could O 
be O 
flexibly O 
modified O 
for O 
liposomes O 
composed O 
of O 
both O 
HSPC O 
and O 
DPPC B-ABBREVIATION 
. O 
Using O 
HSPC/ O 
DPPC B-ABBREVIATION 
composition O 
may O 
be O 
an O 
efficient O 
strategy O 
to O 
control O 
the O 
Tm O 
, O 
thus O 
control O 
the O 
in O 
vivo O 
pharmacokinetic O 
behavio O 
, O 
of O 
BLs O 
. O 

investigation O 
on O 
the O 
crude O 
alkaloid O 
portion O 
of O 
Lycopodium O 
obscurum O 
led O 
to O 
isolation O 
of O 
three O 
new O 
fawcettimine B-TRIVIAL 
-type O 
Lycopodium O 
alkaloids O 
, O 
lycobscurines B-MULTIPLE 
A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
together O 
with O 
three O 
known O 
compounds O 
. O 
Their O 
structures O 
were O 
determined O 
by O 
spectroscopic O 
methods O 
including O 
HR-ESI-MS O 
and O 
NMR O 
techniques O 
. O 
All O 
compounds O 
were O 
tested O 
in O 
an O 
assay O 
for O 
acetylcholinesterase O 
inhibitory O 
activity O 
. O 

paper O 
presents O 
the O 
chemical O 
and O 
preclinical O 
anticancer O 
research O 
on O 
Hedyotis O 
diffusa O 
Willd O 
. O 
in O 
detail O 
, O 
one O 
of O 
the O 
most O 
renowned O 
herbs O 
often O 
prescribed O 
in O 
the O 
polyherbal O 
formulas O 
for O 
cancer O 
treatment O 
in O 
traditional O 
Chinese O 
medicine O 
. O 
Anthraquinones B-FAMILY 
, O 
flavonoids B-FAMILY 
, O 
and O 
terpenoids B-FAMILY 
constitute O 
the O 
majority O 
of O 
the O 
69 O 
compounds O 
that O 
have O 
been O 
isolated O 
and O 
identified O 
from O 
H O 
. O 
diffusa O 
. O 
The O 
anticancer O 
effects O 
of O 
the O 
methanolic O 
, O 
ethanolic O 
, O 
and O 
aqueous O 
extracts O 
in O 
various O 
preclinical O 
cancer O 
models O 
have O 
been O 
described O 
. O 
This O 
review O 
also O 
summarized O 
the O 
anticancer O 
activity O 
of O 
constituents O 
of O 
the O 
herb O 
and O 
the O 
mechanisms O 
of O 
action O 
. O 
All O 
the O 
studies O 
suggest O 
that O 
H O 
. O 
diffusa O 
has O 
enormous O 
potential O 
in O 
the O 
therapy O 
of O 
cancer O 
and O 
warrants O 
further O 
chemical O 
and O 
pharmacological O 
investigation O 
. O 

transformation O 
of O 
the O 
triterpene O 
nigranoic B-TRIVIAL 
acid I-TRIVIAL 
by O 
the O 
freshwater O 
fungus O 
Dictyosporium O 
heptasporum O 
. O 

microbiological O 
transformation O 
of O 
the O 
triterpene O 
nigranoic B-TRIVIAL 
acid I-TRIVIAL 
( O 
3,4-secocycloarta-4(28),24(Z)-diene-3,26-dioic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) O 
( O 
1 O 
) O 
to O 
3,4-secocycloarta-4(28),17(20),24(Z)-triene-7β-hydroxy-16β,26-lactone-3-oic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
2 O 
) O 
and O 
3,4-secocycloarta-4(28),17(20)(Z),24(Z)-triene-7β-hydroxy-16β-methoxy-3,26-dioic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3 O 
) O 
by O 
the O 
freshwater O 
fungus O 
Dictyosporium O 
heptasporum O 
YMF1.01213 O 
has O 
been O 
demonstrated O 
. O 
The O 
structures O 
of O 
the O 
biotransformation O 
products O 
were O 
determined O 
by O 
spectroscopic O 
and O 
MS O 
analyses O 
. O 
Compound O 
2 O 
, O 
characterized O 
by O 
the O 
presence O 
of O 
a O 
formed O 
C-16 O 
/ O 
C-26 O 
ester B-FAMILY 
bridge O 
, O 
provided O 
a O 
novel O 
nine O 
- O 
membered O 
lactone B-FAMILY 
ring O 
structural O 
skeleton O 
for O 
3,4-secocycloartane B-SYSTEMATIC 
triterpenoid O 
derivatives O 
. O 
In O 
addition O 
, O 
Compounds O 
1-3 O 
exhibited O 
weak O 
anti-HIV O 
activity O 
in O 
vitro O 
. O 
Compounds O 
2 O 
and O 
3 O 
were O 
reported O 
for O 
the O 
first O 
time O 
as O 
natural O 
product O 
derivatives O 
. O 

-gated O 
P2X3 O 
receptors O 
of O 
sensory O 
ganglion O 
neurons O 
are O 
important O 
transducers O 
of O 
painful O 
stimuli O 
and O 
are O 
modulated O 
by O 
extracellular O 
algogenic O 
substances O 
, O 
via O 
changes O 
in O 
the O 
receptor O 
phosphorylation O 
state O 
. O 
The O 
present O 
study O 
investigated O 
the O 
role O 
of O 
calcium B-SYSTEMATIC 
/ O 
calmodulin O 
- O 
dependent O 
serine B-TRIVIAL 
protein O 
kinase O 
CASK O 
in O 
interacting O 
and O 
controlling O 
P2X3 O 
receptor O 
expression O 
and O 
function O 
in O 
mouse O 
trigeminal O 
ganglia O 
. O 
Most O 
ganglion O 
neurons O 
in O 
situ O 
or O 
in O 
culture O 
co O 
- O 
expressed O 
P2X3 O 
and O 
CASK O 
. O 
CASK O 
was O 
immunoprecipitated O 
with O 
P2X3 O 
receptors O 
from O 
trigeminal O 
ganglia O 
and O 
from O 
P2X3 O 
/ O 
CASK-cotransfected O 
HEK O 
cells O 
. O 
Recombinant O 
P2X3 O 
/ O 
CASK O 
expression O 
in O 
HEK O 
cells O 
increased O 
serine B-TRIVIAL 
phosphorylation O 
of O 
P2X3 O 
receptors O 
, O 
typically O 
associated O 
with O 
receptor O 
upregulation O 
. O 
CASK O 
deletion O 
mutants O 
also O 
enhanced O 
P2X3 O 
subunit O 
expression O 
. O 
After O 
silencing O 
CASK O 
, O 
cell O 
surface O 
P2X3 O 
receptor O 
expression O 
was O 
decreased O 
, O 
which O 
is O 
consistent O 
with O 
depressed O 
P2X3 O 
currents O 
. O 
The O 
reduction O 
of O 
P2X3 O 
expression O 
levels O 
was O 
reversed O 
by O 
the O 
proteasomal O 
inhibitor O 
MG-132 B-IDENTIFIER 
. O 
Moreover O 
, O 
neuronal O 
CASK O 
/ O 
P2X3 O 
interaction O 
was O 
upregulated O 
by O 
NGF O 
signaling O 
and O 
downregulated O 
by O 
P2X3 O 
agonist O 
- O 
induced O 
desensitization O 
. O 
These O 
data O 
suggest O 
a O 
novel O 
interaction O 
between O 
CASK O 
and O 
P2X3 O 
receptors O 
with O 
positive O 
outcome O 
for O 
receptor O 
stability O 
and O 
function O 
. O 
As O 
CASK O 
- O 
mediated O 
control O 
of O 
P2X3 O 
receptors O 
was O 
dependent O 
on O 
the O 
receptor O 
activation O 
state O 
, O 
CASK O 
represents O 
an O 
intracellular O 
gateway O 
to O 
regulate O 
purinergic O 
nociceptive O 
signaling O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

new O 
compounds O 
, O 
rhodostegone B-FAMILY 
( O 
1 O 
) O 
from O 
endophytic O 
fungus O 
Penicillium O 
polonicum O 
and O 
cyclo-(l-Val-l-Leu) B-SYSTEMATIC 
( O 
2 O 
) O 
from O 
Aspergillus O 
fumigatus O 
, O 
together O 
with O 
six O 
known O 
diketopiperazines B-FAMILY 
( O 
3-8 O 
) O 
, O 
were O 
isolated O 
. O 
The O 
structures O 
of O 
these O 
compounds O 
were O 
characterized O 
through O 
a O 
combination O 
of O 
extensive O 
IR O 
, O 
MS O 
, O 
NMR O 
, O 
and O 
CD O 
analysis O 
. O 

novel O 
furostanol B-TRIVIAL 
saponins B-FAMILY 
from O 
the O 
tubers O 
of O 
Ophiopogon O 
japonicus O 
. O 

investigation O 
of O 
the O 
fresh O 
tubers O 
of O 
Ophiopogon O 
japonicus O 
led O 
to O 
the O 
isolation O 
of O 
two O 
new O 
furostanol B-TRIVIAL 
saponins B-FAMILY 
( O 
1 O 
and O 
2 O 
) O 
together O 
with O 
two O 
known O 
steroidal B-FAMILY 
saponins I-FAMILY 
( O 
3 O 
and O 
4 O 
) O 
. O 
Comprehensive O 
spectroscopic O 
analysis O 
allowed O 
the O 
chemical O 
structures O 
of O 
two O 
new O 
compounds O 
to O 
be O 
elucidated O 
as O 
(25R)-26-O-[β-d-glucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-β-d-glucopyranosyl]-5-ene-furost-1β,3β,22α,26-tetraol-3-O-α-l-rhamnopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-[β-d-xylopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
4)]-β-d-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
, O 
ophiopogonin B-TRIVIAL 
P I-TRIVIAL 
) O 
and O 
(25R)-26-O-[β-d-glucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
6)-β-d-glucopyranosyl]-5-ene-furost-1β,3β,22α,26-tetraol-3-O-α-l-rhamnopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-[β-d-xylopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
4)]-β-d-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
, O 
ophiopogonin B-TRIVIAL 
Q I-TRIVIAL 
) O 
. O 
Furostanol B-TRIVIAL 
saponins B-FAMILY 
with O 
the O 
disaccharide B-FAMILY 
chain O 
linked O 
at O 
C-26 B-SYSTEMATIC 
hydroxy I-SYSTEMATIC 
group O 
of O 
the O 
aglycone O 
have O 
been O 
rarely O 
reported O 
from O 
natural O 
sources O 
. O 

is O 
actively O 
eliminated O 
from O 
neuronal O 
cells O 
by O 
ABCA1 O 
. O 

cholesterol B-TRIVIAL 
turnover O 
catalyzed O 
by O 
cholesterol B-TRIVIAL 
24-hydroxylase O 
is O 
essential O 
for O 
neural O 
functions O 
, O 
especially O 
learning O 
. O 
Because O 
24(S)-hydroxycholesterol B-SYSTEMATIC 
( O 
24-OHC B-SYSTEMATIC 
) O 
, O 
produced O 
by O 
24-hydroxylase O 
, O 
induces O 
apoptosis O 
of O 
neuronal O 
cells O 
, O 
it O 
is O 
vital O 
to O 
eliminate O 
it O 
rapidly O 
from O 
cells O 
. O 
Here O 
, O 
using O 
differentiated O 
SH-SY5Y O 
neuron O 
- O 
like O 
cells O 
as O 
a O 
model O 
, O 
we O 
examined O 
whether O 
24-OHC B-SYSTEMATIC 
is O 
actively O 
eliminated O 
via O 
transporters O 
induced O 
by O 
its O 
accumulation O 
. O 
The O 
expression O 
of O 
ABCA1 O 
and O 
ABCG1 O 
was O 
induced O 
by O 
24-OHC B-SYSTEMATIC 
, O 
as O 
well O 
as O 
TO901317 B-IDENTIFIER 
and O 
retinoic B-TRIVIAL 
acid I-TRIVIAL 
, O 
which O 
are O 
ligands O 
of O 
the O 
nuclear O 
receptors O 
LXR O 
/ O 
RXR O 
. O 
When O 
the O 
expression O 
of O 
ABCA1 O 
and O 
ABCG1 O 
was O 
induced O 
, O 
24-OHC B-SYSTEMATIC 
efflux O 
was O 
stimulated O 
in O 
the O 
presence O 
of O 
high O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
, O 
whereas O 
apolipoprotein O 
A-I O 
was O 
not O 
an O 
efficient O 
acceptor O 
. O 
The O 
efflux O 
was O 
suppressed O 
by O 
the O 
addition O 
of O 
siRNA O 
against O 
ABCA1 O 
, O 
but O 
not O 
by O 
ABCG1 O 
siRNA O 
. O 
To O 
confirm O 
the O 
role O 
of O 
each O 
transporter O 
, O 
we O 
analyzed O 
HEK293 O 
cells O 
stably O 
expressing O 
human O 
ABCA1 O 
or O 
ABCG1 O 
; O 
we O 
clearly O 
observed O 
24-OHC B-SYSTEMATIC 
efflux O 
in O 
the O 
presence O 
of O 
HDL O 
, O 
whereas O 
efflux O 
in O 
the O 
presence O 
of O 
apolipoprotein O 
A-I O 
was O 
marginal O 
. O 
Furthermore O 
, O 
the O 
treatment O 
of O 
primary O 
cerebral O 
neurons O 
with O 
LXR O 
/ O 
RXR O 
ligands O 
suppressed O 
the O 
toxicity O 
of O 
24-OHC B-SYSTEMATIC 
. O 
These O 
results O 
suggest O 
that O 
ABCA1 O 
actively O 
eliminates O 
24-OHC B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
HDL O 
as O 
a O 
lipid O 
acceptor O 
and O 
protects O 
neuronal O 
cells O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

of O 
Highly O 
Potent O 
and O 
Selective O 
Diaminothiazole B-FAMILY 
Inhibitors O 
of O 
Cyclin-Dependent O 
Kinases O 
. O 

- O 
dependent O 
kinases O 
( O 
CDKs O 
) O 
are O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
protein O 
kinases O 
that O 
act O 
as O 
key O 
regulatory O 
elements O 
in O 
cell O 
cycle O 
progression O 
. O 
We O 
describe O 
the O 
development O 
of O 
highly O 
potent O 
diaminothiazole B-FAMILY 
inhibitors O 
of O 
CDK2 O 
( O 
IC50 O 
= O 
0.0009-0.0015 O 
μM O 
) O 
from O 
a O 
single O 
hit O 
compound O 
with O 
weak O 
inhibitory O 
activity O 
( O 
IC50 O 
= O 
15 O 
μM O 
) O 
, O 
discovered O 
by O 
high O 
- O 
throughput O 
screening O 
. O 
Structure O 
- O 
based O 
design O 
was O 
performed O 
using O 
35 O 
cocrystal O 
structures O 
of O 
CDK2 O 
liganded O 
with O 
distinct O 
analogues O 
of O 
the O 
parent O 
compound O 
. O 
The O 
profiling O 
of O 
compound O 
51 O 
against O 
a O 
panel O 
of O 
339 O 
kinases O 
revealed O 
high O 
selectivity O 
for O 
CDKs O 
, O 
with O 
preference O 
for O 
CDK2 O 
and O 
CDK5 O 
over O 
CDK9 O 
, O 
CDK1 O 
, O 
CDK4 O 
, O 
and O 
CDK6 O 
. O 
Compound O 
51 O 
inhibited O 
the O 
proliferation O 
of O 
13 O 
out O 
of O 
15 O 
cancer O 
cell O 
lines O 
with O 
IC50 O 
values O 
between O 
0.27 O 
and O 
6.9 O 
μM O 
, O 
which O 
correlated O 
with O 
the O 
complete O 
suppression O 
of O 
retinoblastoma O 
phosphorylation O 
and O 
the O 
onset O 
of O 
apoptosis O 
. O 
Combined O 
, O 
the O 
results O 
demonstrate O 
the O 
potential O 
of O 
this O 
new O 
inhibitors O 
series O 
for O 
further O 
development O 
into O 
CDK-specific O 
chemical O 
probes O 
or O 
therapeutics O 
. O 

influence O 
of O 
latitude O 
on O 
the O 
concentration O 
of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
25-hydroxy-vitamin B-SYSTEMATIC 
D3 I-SYSTEMATIC 
in O 
Australian O 
red O 
meat O 
. O 

is O 
little O 
information O 
on O 
the O 
vitamin B-FAMILY 
D I-FAMILY 
content O 
of O 
Australian O 
red O 
meat O 
or O 
on O 
the O 
possible O 
influence O 
of O 
latitude O 
on O 
this O 
content O 
. O 
To O 
determine O 
the O 
content O 
of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
25-hydroxy-vitamin B-SYSTEMATIC 
D3 I-SYSTEMATIC 
( O 
25OHD3 B-SYSTEMATIC 
) O 
, O 
lamb O 
and O 
beef O 
were O 
analysed O 
from O 
34° O 
S O 
with O 
LC-IT-MS O 
. O 
To O 
investigate O 
the O 
possible O 
influence O 
of O 
latitude O 
on O 
vitamin B-FAMILY 
D I-FAMILY 
in O 
meat O 
, O 
the O 
lean O 
meat O 
and O 
fat O 
from O 
five O 
cuts O 
of O 
beef O 
were O 
analysed O 
from O 
17° O 
S O 
and O 
41° O 
S O 
. O 
Lamb O 
contained O 
0.10μg O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
/ O 
100g O 
and O 
0.20μg O 
25OHD3 B-SYSTEMATIC 
/ O 
100g O 
lean O 
meat O 
, O 
while O 
beef O 
contained O 
0.12μg O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
and O 
0.27μg O 
25OHD3 B-SYSTEMATIC 
/ O 
100g O 
( O 
lean O 
meat O 
) O 
. O 
Latitude O 
had O 
no O 
effect O 
on O 
the O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
( O 
P=0.21 O 
) O 
or O 
25OHD3 B-SYSTEMATIC 
( O 
P=0.29 O 
) O 
content O 
of O 
lean O 
beef O 
, O 
but O 
fat O 
from O 
cattle O 
in O 
the O 
17° O 
S O 
latitude O 
group O 
contained O 
significantly O 
higher O 
( O 
P O 
< O 
0.01 O 
) O 
concentrations O 
of O 
vitamin B-TRIVIAL 
D3 I-TRIVIAL 
than O 
fat O 
from O 
the O 
41° O 
S O 
group O 
of O 
cattle O 
. O 

energy O 
, O 
saturated O 
fat O 
, O 
sugar B-FAMILY 
and O 
salt O 
from O 
processed O 
and O 
fast O 
foods O 
are O 
a O 
major O 
cause O 
of O 
chronic O 
disease O 
worldwide O 
. O 
In O 
2010 O 
The O 
Food O 
Monitoring O 
Group O 
established O 
a O 
global O 
branded O 
food O 
composition O 
database O 
to O 
track O 
the O 
nutritional O 
content O 
of O 
foods O 
and O 
make O 
comparisons O 
between O 
countries O 
, O 
food O 
companies O 
and O 
over O 
time O 
. O 
A O 
protocol O 
for O 
the O 
project O 
was O 
agreed O 
and O 
published O 
in O 
2011 O 
with O 
24 O 
collaborating O 
countries O 
. O 
Standardised O 
tools O 
and O 
a O 
website O 
have O 
been O 
developed O 
to O 
facilitate O 
data O 
collection O 
and O 
entry O 
. O 
In O 
2010 O 
data O 
were O 
obtained O 
from O 
nine O 
countries O 
, O 
in O 
2011 O 
from O 
12 O 
and O 
in O 
2012 O 
data O 
are O 
anticipated O 
from O 
10 O 
additional O 
countries O 
. O 
This O 
collaborative O 
approach O 
to O 
the O 
collation O 
of O 
food O 
composition O 
data O 
offers O 
potential O 
for O 
cross O 
- O 
border O 
collaboration O 
and O 
support O 
in O 
developed O 
and O 
developing O 
countries O 
. O 
The O 
project O 
should O 
contribute O 
significantly O 
to O 
tracking O 
progress O 
of O 
the O 
food O 
industry O 
and O 
governments O 
towards O 
commitments O 
made O 
at O 
the O 
recent O 
UN O 
high O 
level O 
meeting O 
on O 
chronic O 
disease O 
. O 

line O 
of O 
the O 
development O 
of O 
a O 
food O 
composition O 
database O 
for O 
Bangladesh O 
, O 
10 O 
minor O 
indigenous O 
fruits O 
were O 
analysed O 
for O 
their O 
nutrient O 
composition O 
comprising O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
, O 
carotenoids O 
and O 
mineral O 
values O 
. O 
Nutrient O 
data O 
obtained O 
have O 
been O 
compared O 
with O 
published O 
data O 
reported O 
in O 
different O 
literatures O 
, O 
book O 
and O 
United O 
States O 
Department O 
of O 
Agriculture-National O 
Nutrient O 
Database O 
for O 
Standard O 
Reference O 
. O 
Ascorbic B-TRIVIAL 
acid I-TRIVIAL 
was O 
highest O 
in O 
Wood O 
apple O 
and O 
lowest O 
in O 
Roselle O 
. O 
Monkey O 
jack O 
contained O 
the O 
highest O 
amount O 
of O 
carotenoids O 
, O 
zinc B-SYSTEMATIC 
and O 
copper B-SYSTEMATIC 
. O 
Content O 
of O 
calcium B-SYSTEMATIC 
, O 
magnesium B-SYSTEMATIC 
and O 
phosphorous B-SYSTEMATIC 
were O 
found O 
highest O 
in O 
Antidesma O 
velutinum O 
. O 
Potassium B-SYSTEMATIC 
was O 
the O 
highest O 
in O 
Wood O 
apple O 
followed O 
by O 
in O 
Moneky O 
jack O 
. O 
It O 
was O 
noted O 
that O 
most O 
of O 
the O 
minor O 
fruits O 
have O 
much O 
higher O 
amount O 
of O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
than O 
the O 
national O 
fruit O 
- O 
Jack O 
fruit O 
ripe O 
, O 
the O 
king O 
fruit O 
- O 
Mango O 
ripe O 
of O 
Bangladesh O 
and O 
exotic O 
fruits O 
- O 
Apple O 
and O 
Grapes O 
. O 
The O 
nutrient O 
values O 
of O 
these O 
minor O 
fruits O 
would O 
make O 
awareness O 
among O 
the O 
people O 
for O 
their O 
mass O 
consumption O 
for O 
healthy O 
life O 
and O 
to O 
grow O 
more O 
minor O 
fruit O 
trees O 
from O 
extinction O 
in O 
order O 
to O 
maintain O 
biodiversity O 
. O 

paper O 
reviews O 
published O 
data O 
that O 
contributes O 
to O 
the O 
knowledge O 
of O 
the O 
ingredients O 
and O 
nutrients O 
of O 
Cameroon O 
traditional O 
dishes O 
. O 
Macronutrient O 
( O 
energy O 
, O 
carbohydrates B-FAMILY 
, O 
protein O 
, O 
total O 
fat O 
, O 
fibre O 
and O 
ash O 
) O 
and O 
mineral O 
( O 
iron B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
, O 
magnesium B-SYSTEMATIC 
, O 
calcium B-SYSTEMATIC 
, O 
phosphorus B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
manganese B-SYSTEMATIC 
, O 
potassium B-SYSTEMATIC 
, O 
sodium B-SYSTEMATIC 
and O 
selenium B-SYSTEMATIC 
) O 
data O 
are O 
presented O 
for O 
117 O 
commonly O 
consumed O 
dishes O 
from O 
three O 
eco O 
- O 
regions O 
. O 
Tables O 
providing O 
an O 
overview O 
of O 
the O 
main O 
ingredients O 
and O 
nutrient O 
values O 
( O 
range O 
of O 
means O 
per O 
100g O 
edible O 
portion O 
) O 
are O 
presented O 
. O 
Considerable O 
variability O 
in O 
nutrient O 
values O 
has O 
been O 
reported O 
among O 
dishes O 
. O 
Water O 
contents O 
range O 
from O 
29.8 O 
to O 
95.9g O 
/ O 
100g O 
edible O 
portion O 
while O 
energy O 
values O 
range O 
from O 
12 O 
to O 
403kcal O 
/ O 
100g O 
. O 
Energy O 
yielding O 
- O 
constituents O 
are O 
the O 
major O 
nutrients O 
recorded O 
in O 
published O 
data O 
, O 
followed O 
by O 
iron B-SYSTEMATIC 
, O 
zinc B-SYSTEMATIC 
and O 
magnesium B-SYSTEMATIC 
. O 

dietary O 
fibre O 
( O 
DF O 
) O 
content O 
in O 
wheat O 
grain O 
based O 
food O 
products O 
have O 
been O 
established O 
with O 
both O 
the O 
classical O 
AOAC O 
985.29 O 
dietary O 
fibre O 
and O 
the O 
new O 
AOAC O 
2009.01 O 
total O 
dietary O 
fibre O 
protocol O 
. O 
There O 
is O 
a O 
good O 
agreement O 
between O 
the O 
high O 
molecular O 
weight O 
dietary O 
fibre O 
( O 
HMWDF O 
) O 
contents O 
measured O 
with O 
the O 
AOAC O 
2009.01 O 
method O 
and O 
( O 
DF O 
) O 
content O 
measured O 
with O 
the O 
classical O 
AOAC O 
985.29 O 
method O 
in O 
wheat O 
grain O 
based O 
food O 
products O 
. O 
With O 
the O 
AOAC O 
2009.01 O 
method O 
also O 
a O 
significant O 
amount O 
of O 
low O 
molar O 
weight O 
dietary O 
fibre O 
( O 
LMWDF O 
) O 
, O 
ranging O 
from O 
1% O 
to O 
3% O 
w O 
/ O 
w O 
, O 
was O 
measured O 
which O 
is O 
not O 
quantified O 
with O 
the O 
AOAC O 
985.29 O 
method O 
. O 
With O 
semi-preparative O 
GPC O 
the O 
LMWDF O 
( O 
DP⩾3 O 
) O 
fractions O 
in O 
the O 
wheat O 
grain O 
based O 
food O 
products O 
were O 
isolated O 
. O 
The O 
monosaccharide B-FAMILY 
composition O 
of O 
the O 
dissolved O 
LMWDF O 
constituents O 
was O 
determined O 
. O 
Glucose B-TRIVIAL 
was O 
by O 
far O 
the O 
most O 
abundant O 
monosaccharide B-FAMILY 
present O 
with O 
arabinose B-TRIVIAL 
, O 
galactose B-TRIVIAL 
, O 
xylose B-TRIVIAL 
and O 
mannose B-TRIVIAL 
as O 
minor O 
constituents O 
. O 
It O 
appeared O 
that O 
the O 
LMWDF O 
contains O 
still O 
not O 
fully O 
converted O 
digestible O 
starch O 
/ O 
malto O 
- O 
oligosaccharide O 
fragments O 
with O 
DP⩾3 O 
, O 
which O 
are O 
erroneously O 
quantified O 
as O 
LMWDF O 
. O 
By O 
introducing O 
an O 
extra O 
AMG O 
hydrolysis O 
step O 
in O 
the O 
AOAC O 
2009.01 O 
protocol O 
after O 
evaporation O 
of O 
the O 
ethanol B-SYSTEMATIC 
and O 
dissolving O 
the O 
residue O 
in O 
deionised O 
water O 
, O 
these O 
malto O 
- O 
oligosaccharides O 
are O 
fully O 
hydrolysed O 
resulting O 
in O 
that O 
way O 
in O 
a O 
correct O 
and O 
lower O 
LMWDF O 
content O 
. O 

and O 
evaluation O 
of O 
[(11)C]EMPA B-SYSTEMATIC 
as O 
a O 
potential O 
PET O 
tracer O 
for O 
orexin O 
2 O 
receptors O 
. O 

is O 
a O 
selective O 
antagonist O 
of O 
orexin O 
2 O 
( O 
OX2 O 
) O 
receptors O 
. O 
Previous O 
literature O 
with O 
[(3)H]-EMPA B-SYSTEMATIC 
suggest O 
that O 
it O 
may O 
be O 
used O 
as O 
an O 
imaging O 
agent O 
for O 
OX2 O 
receptors O 
; O 
however O 
, O 
brain O 
penetration O 
is O 
known O 
to O 
be O 
modest O 
. O 
To O 
evaluate O 
the O 
potential O 
of O 
EMPA O 
as O 
a O 
PET O 
radiotracer O 
in O 
non-human O 
primate O 
( O 
as O 
a O 
step O 
to O 
imaging O 
in O 
man O 
) O 
, O 
we O 
radiolabeled O 
EMPA B-ABBREVIATION 
with O 
carbon B-SYSTEMATIC 
-11 O 
. O 
Radiosynthesis O 
of O 
[(11)C]N-ethyl-2-(N-(6-methoxypyridin-3-yl)-2-methylphenylsulfonamido)-N-(pyridin-3-ylmethyl)acetamide B-SYSTEMATIC 
( O 
[(11)C]EMPA B-SYSTEMATIC 
) O 
, O 
and O 
evaluation O 
as O 
a O 
potential O 
PET O 
tracer O 
for O 
OX2 O 
receptors O 
is O 
described O 
. O 
Synthesis O 
of O 
an O 
appropriate O 
non-radioactive O 
O B-FORMULA 
-desmethyl O 
precursor O 
was O 
achieved O 
from O 
EMPA B-ABBREVIATION 
with O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
and O 
chlorotrimethylsilane B-SYSTEMATIC 
. O 
Selective O 
O B-FORMULA 
-methylation O 
using O 
[(11)C]CH3I B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
cesium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
in O 
DMSO B-ABBREVIATION 
at O 
room O 
temp O 
afforded O 
[(11)C]EMPA B-SYSTEMATIC 
in O 
1.5-2.5% O 
yield O 
( O 
non-decay O 
corrected O 
relative O 
to O 
trapped O 
[(11)C]CH3I B-SYSTEMATIC 
at O 
EOS O 
) O 
with O 
⩾95% O 
chemical O 
and O 
radiochemical O 
purities O 
. O 
The O 
total O 
synthesis O 
time O 
was O 
34-36min O 
from O 
EOB O 
. O 
Studies O 
in O 
rodent O 
suggested O 
that O 
uptake O 
in O 
tissue O 
was O 
dominated O 
by O 
nonspecific O 
binding O 
. O 
However O 
, O 
[(11)C]EMPA B-SYSTEMATIC 
also O 
showed O 
poor O 
uptake O 
in O 
both O 
rats O 
and O 
baboon O 
as O 
measured O 
with O 
PET O 
imaging O 
. O 

of O 
a O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
series O 
of O 
HIV O 
capsid O 
assembly O 
inhibitors O 
2 O 
: O 
Structure O 
- O 
activity O 
relationships O 
( O 
SAR O 
) O 
of O 
the O 
C3- O 
phenyl B-SYSTEMATIC 
moiety O 
. O 

structure O 
- O 
activity O 
relationships O 
of O 
the O 
C3- O 
phenyl B-SYSTEMATIC 
moiety O 
that O 
allow O 
for O 
the O 
optimization O 
of O 
antiviral O 
potency O 
of O 
a O 
series O 
of O 
1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione B-SYSTEMATIC 
inhibitors O 
of O 
HIV O 
capsid O 
( O 
CA O 
) O 
assembly O 
are O 
described O 
. O 
Combination O 
of O 
favorable O 
substitutions O 
gave O 
additive O 
SAR O 
and O 
allowed O 
for O 
the O 
identification O 
of O 
the O 
most O 
potent O 
compound O 
in O 
the O 
series O 
, O 
analog O 
27 O 
. O 
Productive O 
SAR O 
also O 
transferred O 
to O 
the O 
benzotriazepine B-FAMILY 
and O 
spirobenzodiazepine B-FAMILY 
scaffolds O 
, O 
providing O 
a O 
solution O 
to O 
the O 
labile O 
stereocenter O 
at O 
the O 
C3 O 
position O 
. O 
The O 
molecular O 
basis O 
of O 
how O 
compound O 
27 O 
inhibits O 
mature O 
CA O 
assembly O 
is O 
rationalized O 
using O 
high O 
- O 
resolution O 
structural O 
information O 
. O 
Our O 
understanding O 
of O 
how O 
compound O 
27 O 
may O 
inhibit O 
immature O 
Gag O 
assembly O 
is O 
also O 
discussed O 
. O 

of O 
S14161 B-IDENTIFIER 
and O 
its O 
analogues O 
and O 
the O 
discovery O 
of O 
6-bromo-8-ethoxy-3-nitro-2H-chromene B-SYSTEMATIC 
as O 
a O 
more O 
potent O 
antitumor O 
agent O 
in O 
vitro O 
. O 

small O 
chemical O 
compound O 
8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene B-SYSTEMATIC 
( O 
S14161 B-IDENTIFIER 
) O 
was O 
recently O 
identified O 
as O 
an O 
inhibitor O 
of O 
the O 
phosphoinositide O 
3-kinase O 
( O 
PI3K O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
designed O 
a O 
novel O 
synthesis O 
of O 
S14161 B-IDENTIFIER 
and O 
prepared O 
a O 
series O 
of O 
its O 
analogues O 
via O 
the O 
oxa-Michael-Henry O 
reaction O 
in O 
the O 
presence O 
of O 
catalytic O 
amounts O 
of O 
l-proline B-SYSTEMATIC 
and O 
triethylamine B-SYSTEMATIC 
. O 
Further O 
structural O 
simplification O 
led O 
to O 
the O 
identification O 
of O 
6-bromo-8-ethoxy-3-nitro-2H-chromene B-SYSTEMATIC 
( O 
BENC-511 B-IDENTIFIER 
) O 
that O 
exhibited O 
potent O 
antiproliferative O 
activities O 
against O 
a O 
panel O 
of O 
12 O 
tumor O 
cell O 
lines O 
. O 
Compared O 
with O 
S14161 B-IDENTIFIER 
, O 
BENC-511 B-IDENTIFIER 
was O 
more O 
potent O 
in O 
blocking O 
the O 
AKT O 
phosphorylation O 
and O 
inducing O 
cancer O 
cell O 
apoptosis O 
. O 
BENC-511 B-IDENTIFIER 
also O 
displayed O 
more O 
potent O 
effects O 
on O 
human O 
umbilical O 
vein O 
epithelial O 
cells O 
( O 
HUVEC O 
) O 
migration O 
, O 
suggesting O 
its O 
anti-angiogenesis O 
activity O 
. O 

of O 
the O 
fused O 
bicyclic O 
4-amino-2-phenylpyrimidine B-SYSTEMATIC 
derivatives O 
as O 
novel O 
and O 
potent O 
PDE4 O 
inhibitors O 
. O 

derivative O 
( O 
2 O 
) O 
was O 
found O 
to O 
be O 
a O 
new O 
PDE4 O 
inhibitor O 
with O 
moderate O 
PDE4B O 
activity O 
( O 
IC50=150nM O 
) O 
. O 
A O 
number O 
of O 
derivatives O 
with O 
a O 
variety O 
of O 
4-amino B-SYSTEMATIC 
substituents O 
and O 
fused O 
bicyclic O 
pyrimidines B-FAMILY 
were O 
synthesized O 
. O 
Among O 
these O 
, O 
5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine B-SYSTEMATIC 
derivative O 
( O 
18 O 
) O 
showed O 
potent O 
PDE4B O 
inhibitory O 
activity O 
( O 
IC50=25 O 
nM O 
) O 
. O 
Finally O 
, O 
N-propylacetamide B-SYSTEMATIC 
derivative O 
( O 
31b O 
) O 
was O 
determined O 
as O 
a O 
potent O 
inhibitor O 
for O 
both O 
PDE4B O 
( O 
IC50=7.5nM O 
) O 
and O 
TNF-α O 
production O 
in O 
mouse O 
splenocytes O 
( O 
IC50=9.8nM O 
) O 
and O 
showed O 
good O 
in O 
vivo O 
anti-inflammatory O 
activity O 
in O 
the O 
LPS-induced O 
lung O 
inflammation O 
model O 
in O 
mice O 
( O 
ID50=18mg O 
/ O 
kg O 
) O 
. O 
The O 
binding O 
mode O 
of O 
the O 
new O 
inhibitor O 
( O 
31e O 
) O 
in O 
the O 
catalytic O 
site O 
of O 
PDE4B O 
is O 
presented O 
based O 
on O 
an O 
X-ray O 
crystal O 
structure O 
of O 
the O 
ligand O 
- O 
enzyme O 
complex O 
. O 

of O 
diarylurea B-FAMILY 
P2Y1 O 
antagonists O 
with O 
improved O 
aqueous O 
solubility O 
. O 

data O 
suggests O 
that O 
P2Y1 O 
antagonists O 
, O 
such O 
as O 
diarylurea B-FAMILY 
compound O 
1 O 
, O 
may O 
provide O 
antithrombotic O 
efficacy O 
similar O 
to O 
P2Y12 O 
antagonists O 
and O 
may O 
have O 
the O 
potential O 
of O 
providing O 
reduced O 
bleeding O 
liabilities O 
. O 
This O 
manuscript O 
describes O 
a O 
series O 
of O 
diarylureas B-FAMILY 
bearing O 
solublizing O 
amine B-SYSTEMATIC 
side O 
chains O 
as O 
potent O 
P2Y1 O 
antagonists O 
. O 
Among O 
them O 
, O 
compounds O 
2l O 
and O 
3h O 
had O 
improved O 
aqueous O 
solubility O 
and O 
maintained O 
antiplatelet O 
activity O 
compared O 
with O 
compound O 
1 O 
. O 
Compound O 
2l O 
was O 
moderately O 
efficacious O 
in O 
both O 
rat O 
and O 
rabbit O 
thrombosis O 
models O 
and O 
had O 
a O 
moderate O 
prolongation O 
of O 
bleeding O 
time O 
in O 
rats O 
similar O 
to O 
that O 
of O 
compound O 
1 O 
. O 

-induced O 
cell O 
death O 
in O 
Saccharomyces O 
cerevisiae O 
is O 
programmed O 
and O 
rescued O 
by O 
proteasome O 
inhibition O 
. O 

is O 
a O 
highly O 
effective O 
chemotherapeutic O 
drug O 
used O 
in O 
the O 
treatment O 
of O 
several O 
tumors O 
. O 
It O 
is O 
a O 
DNA-damaging O 
agent O 
that O 
induces O 
apoptosis O 
of O 
rapidly O 
proliferating O 
cells O 
, O 
an O 
important O 
factor O 
underlying O 
its O 
therapeutic O 
efficacy O 
. O 
Unfortunately O 
, O 
cellular O 
resistance O 
occurs O 
often O 
. O 
A O 
large O 
fraction O 
of O 
tumor O 
cells O 
harbor O 
mutations O 
in O 
p53 O 
, O 
contributing O 
to O 
defects O 
in O 
apoptotic O 
pathways O 
and O 
drug O 
resistance O 
. O 
However O 
, O 
cisplatin B-TRIVIAL 
-induced O 
apoptosis O 
can O 
also O 
occur O 
in O 
p53 O 
deficient O 
cells O 
; O 
thus O 
, O 
elucidation O 
of O 
the O 
molecular O 
mechanism O 
involved O 
will O 
potentially O 
yield O 
new O 
strategies O 
to O 
eliminate O 
tumors O 
that O 
have O 
defects O 
in O 
the O 
p53 O 
pathway O 
. O 
Most O 
of O 
the O 
studies O 
in O 
this O 
field O 
have O 
been O 
conducted O 
in O 
cultured O 
mammalian O 
cells O 
, O 
not O 
amenable O 
to O 
systematic O 
genetic O 
manipulation O 
. O 
Therefore O 
, O 
we O 
aimed O 
to O 
establish O 
a O 
simplified O 
model O 
devoid O 
of O 
a O 
p53 O 
ortholog O 
to O 
study O 
cisplatin B-TRIVIAL 
-induced O 
programmed O 
cell O 
death O 
( O 
PCD O 
) O 
, O 
using O 
the O 
yeast O 
Saccharomyces O 
cerevisiae O 
. O 
Our O 
results O 
indicate O 
cisplatin B-TRIVIAL 
induces O 
an O 
active O 
form O 
of O 
cell O 
death O 
in O 
yeast O 
, O 
as O 
this O 
process O 
was O 
partially O 
dependent O 
on O 
de O 
novo O 
protein O 
synthesis O 
and O 
did O 
not O 
lead O 
to O 
loss O 
of O 
membrane O 
integrity O 
. O 
Cisplatin B-TRIVIAL 
also O 
increased O 
DNA O 
condensation O 
and O 
fragmentation O 
/ O 
degradation O 
, O 
but O 
no O 
significant O 
mitochondrial O 
dysfunction O 
other O 
than O 
partial O 
fragmentation O 
. O 
Co-incubation O 
with O 
the O 
proteasome O 
inhibitor O 
MG132 O 
increased O 
resistance O 
to O 
cisplatin B-TRIVIAL 
and O 
, O 
accordingly O 
, O 
yeast O 
strains O 
deficient O 
in O 
proteasome O 
activity O 
were O 
more O 
resistant O 
to O 
cisplatin B-TRIVIAL 
than O 
wild O 
- O 
type O 
strains O 
. O 
Proteasome O 
inhibitors O 
can O 
sensitize O 
tumor O 
cells O 
to O 
cisplatin B-TRIVIAL 
, O 
but O 
protect O 
others O 
from O 
cisplatin B-TRIVIAL 
-induced O 
cell O 
death O 
. O 
Our O 
results O 
indicate O 
inhibition O 
of O 
the O 
proteasome O 
protects O 
budding O 
yeast O 
from O 
cisplatin B-TRIVIAL 
-induced O 
cell O 
death O 
and O 
validate O 
yeast O 
as O 
a O 
model O 
to O 
study O 
the O 
role O 
of O 
the O 
proteasome O 
in O 
cisplatin B-TRIVIAL 
-induced O 
PCD O 
. O 
Elucidation O 
of O 
this O 
mechanism O 
will O 
aid O 
in O 
the O 
development O 
of O 
new O 
strategies O 
to O 
increase O 
the O 
efficacy O 
of O 
chemotherapy O 
. O 

RELEVANCE O 
: O 
Acer O 
tegmentosum O 
, O 
which O 
contains O 
salidroside B-TRIVIAL 
and O 
tyrosol B-TRIVIAL 
, O 
has O 
been O 
used O 
for O 
the O 
treatment O 
of O 
hepatic O 
disorders O 
in O 
eastern O 
Asia O 
. O 
However O 
, O 
little O 
is O 
known O 
about O 
its O 
safety O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
To O 
determine O 
the O 
safety O 
of O 
Acer O 
tegmentosum O 
, O 
we O 
evaluated O 
its O 
acute O 
oral O 
toxicity O 
and O 
genotoxicity O 
profiles O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Salidroside B-TRIVIAL 
and O 
tyrosol B-TRIVIAL 
present O 
in O 
Acer O 
tegmentosum O 
were O 
quantified O 
using O 
high O 
- O 
performance O 
liquid O 
chromatography O 
. O 
Acute O 
oral O 
toxicity O 
testing O 
of O 
Acer O 
tegmentosum O 
was O 
performed O 
in O 
rats O 
. O 
Genotoxicity O 
of O 
Acer O 
tegmentosum O 
was O 
assessed O 
by O 
bacterial O 
reverse O 
mutation O 
, O 
chromosomal O 
aberration O 
, O 
and O 
bone O 
marrow O 
micronucleus O 
tests O 
. O 
All O 
the O 
tests O 
were O 
conducted O 
in O 
accordance O 
with O 
the O 
good O 
laboratory O 
practices O 
. O 
RESULTS O 
: O 
The O 
amounts O 
of O 
salidroside B-TRIVIAL 
and O 
tyrosol B-TRIVIAL 
in O 
Acer O 
tegmentosum O 
were O 
found O 
to O 
be O 
85.01±1.21mg O 
/ O 
g O 
and O 
3.12±0.04mg O 
/ O 
g O 
, O 
respectively O 
. O 
In O 
the O 
bacterial O 
reverse O 
mutation O 
test O 
, O 
Acer O 
tegmentosum O 
increased O 
the O 
number O 
of O 
revertant O 
Salmonella O 
typhimurium O 
TA98 O 
colonies O 
, O 
regardless O 
of O 
metabolic O 
activation O 
by O 
S9 O 
mixture O 
. O 
In O 
contrast O 
, O 
Acer O 
tegmentosum O 
application O 
did O 
not O 
significantly O 
increase O 
the O 
number O 
of O 
chromosomal O 
aberrations O 
in O 
Chinese O 
hamster O 
ovary O 
(CHO)-K1 O 
cells O 
and O 
micronucleated O 
polychromatic O 
erythrocytes O 
in O 
mice O 
. O 
In O 
the O 
acute O 
oral O 
toxicity O 
test O 
, O 
the O 
median O 
lethal O 
dose O 
( O 
LD50 O 
) O 
of O 
Acer O 
tegmentosum O 
was O 
found O 
to O 
be O 
> O 
2000mg O 
/ O 
kg O 
in O 
rats O 
. O 
CONCLUSION O 
: O 
Take O 
together O 
, O 
Acer O 
tegmentosum O 
exhibits O 
mutagenicity O 
, O 
which O 
was O 
evident O 
from O 
the O 
bacterial O 
reverse O 
mutation O 
test O 
. O 
Further O 
studies O 
are O 
needed O 
to O 
identify O 
the O 
components O 
responsible O 
for O 
such O 
an O 
effect O 
and O 
the O 
underlying O 
mechanisms O 
. O 

Outcome O 
following O 
in O 
utero O 
Exposure O 
to O 
Hydroxychloroquine B-SYSTEMATIC 
: O 
A O 
prospective O 
comparative O 
observational O 
study O 
. O 

: O 
To O 
evaluate O 
pregnancy O 
safety O 
of O 
hydroxychloroquine B-SYSTEMATIC 
( O 
HCQ B-ABBREVIATION 
) O 
for O 
rheumatologic O 
diseases O 
. O 
DESIGN O 
: O 
Prospective O 
comparative O 
observational O 
study O 
done O 
at O 
the O 
Israeli O 
teratology O 
information O 
service O 
between O 
1998 O 
and O 
2006 O 
. O 
RESULTS O 
: O 
114 O 
HCQ B-ABBREVIATION 
-exposed O 
pregnancies O 
( O 
98.2% O 
in O 
the O 
first O 
trimester O 
, O 
T1 O 
) O 
were O 
followed O 
- O 
up O 
and O 
compared O 
with O 
455 O 
pregnancies O 
of O 
women O 
counseled O 
for O 
non-teratogenic O 
exposure O 
. O 
The O 
difference O 
in O 
the O 
rate O 
of O 
congenital O 
anomalies O 
was O 
not O 
statistically O 
significant O 
[ O 
7 O 
/ O 
97 O 
( O 
7.2% O 
) O 
vs O 
. O 
15 O 
/ O 
440 O 
( O 
3.4% O 
) O 
, O 
p=0.094 O 
] O 
. O 
The O 
analysis O 
was O 
repeated O 
among O 
those O 
exposed O 
in O 
T1 O 
excluding O 
genetic O 
or O 
cytogenetic O 
anomalies O 
or O 
congenital O 
infections O 
[ O 
5 O 
/ O 
95 O 
( O 
5.3% O 
) O 
vs O 
. O 
14 O 
/ O 
440 O 
( O 
3.2% O 
) O 
, O 
p=0.355 O 
] O 
. O 
There O 
were O 
no O 
cases O 
of O 
neonatal O 
lupus O 
erythematosus O 
. O 
The O 
gestational O 
age O 
at O 
delivery O 
was O 
earlier O 
, O 
rate O 
of O 
preterm O 
delivery O 
higher O 
, O 
and O 
birth O 
weight O 
lower O 
, O 
in O 
the O 
HCQ B-ABBREVIATION 
group O 
. O 
CONCLUSION O 
: O 
The O 
present O 
study O 
suggests O 
that O 
HCQ B-ABBREVIATION 
treatment O 
in O 
pregnancy O 
is O 
not O 
a O 
major O 
human O 
teratogen O 
. O 
The O 
earlier O 
gestational O 
age O 
and O 
lower O 
birth O 
weight O 
might O 
be O 
associated O 
with O 
maternal O 
disease O 
. O 

pyridine I-FAMILY 
alkaloids I-FAMILY 
and O 
phenolics B-FAMILY 
from O 
Scrophularia O 
ningpoensis O 
and O 
their O 
cardioprotective O 
effect O 
. O 

A-C I-MULTIPLE 
( O 
1-3 O 
) O 
, O 
three O 
new O 
unusual O 
monoterpene B-FAMILY 
pyridine I-FAMILY 
alkaloids I-FAMILY 
with O 
cyclopenta B-SYSTEMATIC 
[ I-SYSTEMATIC 
c I-SYSTEMATIC 
] I-SYSTEMATIC 
pyridine I-SYSTEMATIC 
skeleton O 
reported O 
from O 
the O 
genus O 
Scrophularia O 
for O 
the O 
first O 
time O 
, O 
together O 
with O 
15 O 
known O 
compounds O 
( O 
4-18 O 
) O 
, O 
were O 
isolated O 
from O 
the O 
extract O 
of O 
Scrophularia O 
ningpoensis O 
. O 
Their O 
structures O 
were O 
elucidated O 
on O 
the O 
basis O 
of O 
extensive O 
analyses O 
of O 
spectroscopic O 
evidences O 
. O 
The O 
biogenetic O 
relationship O 
between O 
monoterpene B-FAMILY 
pyridine I-FAMILY 
alkaloids O 
and O 
iridoids B-FAMILY 
was O 
proposed O 
preliminarily O 
. O 
The O 
myocardial O 
protective O 
bioassay O 
indicated O 
that O 
compounds O 
13 O 
and O 
14 O 
with O 
a O 
concentration O 
of O 
10(-4)M O 
exhibited O 
significantly O 
protective O 
effect O 
against O 
H2O2 B-FORMULA 
-induced O 
apoptosis O 
in O 
cardiomyocytes O 
. O 

effects O 
of O 
cotinine B-TRIVIAL 
on O 
the O 
hippocampus O 
: O 
Behavioral O 
and O 
biochemical O 
parameters O 
. O 

present O 
work O 
evaluated O 
the O 
effects O 
of O 
nicotine B-TRIVIAL 
( O 
NIC B-ABBREVIATION 
) O 
, O 
cotinine B-TRIVIAL 
( O 
COT B-ABBREVIATION 
) O 
, O 
mecamylamine B-TRIVIAL 
( O 
MEC B-ABBREVIATION 
) O 
, O 
methyllycaconitine B-TRIVIAL 
( O 
MLA B-ABBREVIATION 
) O 
and O 
dihydro-beta-eritroidine B-SYSTEMATIC 
( O 
DHβE B-ABBREVIATION 
) O 
on O 
memory O 
extinction O 
and O 
the O 
following O 
biochemical O 
parameters O 
of O 
the O 
hippocampus O 
: O 
lipid O 
peroxidation O 
( O 
LPO O 
) O 
, O 
antioxidant O 
capacity O 
( O 
AC O 
) O 
and O 
the O 
phosphorylation O 
of O 
Extracellular-Signal-Regulated O 
Kinase O 
( O 
ERK O 
1 O 
/ O 
2 O 
) O 
. O 
Young O 
male O 
rats O 
that O 
were O 
implanted O 
bilaterally O 
with O 
cannulae O 
were O 
submitted O 
to O 
memory O 
extinction O 
tests O 
sessions O 
, O 
and O 
their O 
hippocampi O 
were O 
dissected O 
for O 
biochemical O 
assays O 
. O 
The O 
extinction O 
of O 
fear O 
memory O 
was O 
significantly O 
improved O 
by O 
both O 
nicotine B-TRIVIAL 
and O 
its O 
metabolite O 
. O 
Cotinine B-TRIVIAL 
significantly O 
increased O 
LPO O 
, O 
while O 
nicotine B-TRIVIAL 
significantly O 
decreased O 
it O 
. O 
Antioxidant O 
capacity O 
was O 
increased O 
by O 
all O 
treatments O 
. O 
Our O 
results O 
showed O 
that O 
cotinine B-TRIVIAL 
, O 
unlike O 
nicotine B-TRIVIAL 
, O 
may O 
increase O 
oxidative O 
stress O 
in O 
the O 
hippocampus O 
, O 
but O 
this O 
increase O 
depends O 
upon O 
the O 
dose O 
used O 
and O 
happens O 
without O 
causing O 
corresponding O 
impairments O 
in O 
cognitive O 
function O 
. O 
Cotinine B-TRIVIAL 
also O 
increased O 
the O 
phosphorylation O 
of O 
ERK O 
1 O 
/ O 
2 O 
in O 
a O 
similar O 
fashion O 
as O 
nicotine B-TRIVIAL 
. O 
Considering O 
these O 
results O 
, O 
it O 
is O 
plausible O 
to O 
wonder O 
to O 
what O 
extent O 
nicotine B-TRIVIAL 
-attributed O 
effects O 
are O 
really O 
due O 
to O 
the O 
actions O 
of O 
this O 
alkaloid O 
and O 
whether O 
they O 
could O 
be O 
due O 
instead O 
to O 
cotinine B-TRIVIAL 
or O 
to O 
cotinine B-TRIVIAL 
- O 
nicotine B-TRIVIAL 
interactions O 
within O 
the O 
brain O 
. O 

CaMKIIα O 
modulates O 
dopamine B-TRIVIAL 
D3 O 
receptor O 
activation O 
in O 
striatonigral O 
terminals O 
of O 
the O 
rat O 
brain O 
in O 
a O 
Ca(2+) B-FORMULA 
dependent O 
manner O 
. O 

is O 
expressed O 
at O 
high O 
density O 
in O 
the O 
nucleus O 
accumbens O 
where O 
it O 
binds O 
to O 
postsynaptic O 
D3 O 
receptors O 
inhibiting O 
their O 
effects O 
. O 
In O 
striatonigral O 
projections O 
, O 
activation O 
of O 
presynaptic O 
D3 O 
receptors O 
potentiates O 
D1 O 
receptor O 
- O 
induced O 
stimulation O 
of O 
cAMP O 
production O 
and O 
GABA O 
release O 
. O 
In O 
this O 
study O 
we O 
examined O 
whether O 
the O 
presynaptic O 
effects O 
of O 
D3 O 
receptor O 
stimulation O 
in O 
the O 
substantia O 
nigra O 
reticulata O 
( O 
SNr O 
) O 
are O 
modulated O 
by O 
Ca(2+) B-FORMULA 
activation O 
of O 
CaMKIIα O 
. O 
In O 
SNr O 
synaptosomes O 
two O 
procedures O 
that O 
increase O 
cytoplasmic O 
Ca(2+) B-FORMULA 
, O 
ionomycin B-TRIVIAL 
and O 
K(+) B-FORMULA 
-depolarization O 
, O 
blocked O 
the O 
additional O 
stimulation O 
of O 
cAMP B-ABBREVIATION 
accumulation O 
produced O 
by O 
coactivating O 
D3 O 
and O 
D1 O 
dopamine B-TRIVIAL 
receptors O 
. O 
The O 
selective O 
CaMKIIα O 
inhibitor O 
KN-62 B-IDENTIFIER 
reversed O 
the O 
blockade O 
produced O 
by O 
ionomycin B-TRIVIAL 
and O 
K(+) B-FORMULA 
-depolarization O 
. O 
Incubation O 
in O 
either O 
Ca(2) B-FORMULA 
-free O 
solutions O 
or O 
with O 
the O 
selective O 
Ca(2+) B-FORMULA 
blocker O 
nifedipine B-TRIVIAL 
, O 
also O 
reversed O 
the O 
blocking O 
effects O 
of O 
K(+) B-FORMULA 
-depolarization O 
. O 
Immunoblot O 
studies O 
showed O 
that O 
K(+) B-FORMULA 
-depolarization O 
increased O 
CaMKIIα O 
phosphorylation O 
in O 
a O 
KN-62 B-IDENTIFIER 
sensitive O 
manner O 
and O 
promoted O 
CaMKIIα O 
binding O 
to O 
D3 O 
receptors O 
. O 
In O 
K(+) B-FORMULA 
-depolarized O 
tissues O 
, O 
D3 O 
receptors O 
potentiated O 
D1 O 
receptor O 
- O 
induced O 
stimulation O 
of O 
[(3)H]GABA B-FORMULA 
release O 
only O 
when O 
CaMKIIα O 
was O 
blocked O 
with O 
KN-62 B-IDENTIFIER 
. O 
In O 
the O 
presence O 
of O 
this O 
inhibitor O 
, O 
the O 
selective O 
D3 O 
agonist O 
PD B-IDENTIFIER 
128907 I-IDENTIFIER 
reduced O 
the O 
ED50 O 
for O 
the O 
D1 O 
agonist O 
SKF B-IDENTIFIER 
38393 I-IDENTIFIER 
from O 
56 O 
to O 
4 O 
nM O 
. O 
KN-62 B-IDENTIFIER 
also O 
enhanced O 
the O 
effects O 
of O 
dopamine B-TRIVIAL 
on O 
depolarization O 
induced O 
[(3)H]GABA B-FORMULA 
release O 
. O 
KN-62 B-IDENTIFIER 
changed O 
ED50 O 
for O 
dopamine B-TRIVIAL 
from O 
584 O 
to O 
56 O 
nM O 
. O 
KN-62 B-IDENTIFIER 
did O 
not O 
affect O 
D1 O 
and O 
D4 O 
receptor O 
responses O 
. O 
These O 
experiments O 
show O 
that O 
in O 
striatonigral O 
projections O 
, O 
CaMKIIα O 
inhibits O 
the O 
action O 
of O 
D3 O 
receptors O 
in O 
a O 
Ca(2+) B-FORMULA 
dependent O 
manner O 
blocking O 
their O 
modulatory O 
effects O 
on O 
GABA B-ABBREVIATION 
release O 
. O 
These O 
findings O 
suggest O 
a O 
mechanism O 
through O 
which O 
the O 
frequency O 
of O 
action O 
potential O 
discharge O 
in O 
presynaptic O 
terminals O 
regulates O 
dopamine B-TRIVIAL 
effects O 
. O 

- O 
dependent O 
activities O 
of O 
hydroxylated B-FAMILY 
polybrominated I-FAMILY 
diphenyl I-FAMILY 
ethers I-FAMILY 
on O 
human O 
estrogen B-FAMILY 
receptor O 
. O 

diphenyl I-FAMILY 
ethers I-FAMILY 
( O 
PBDEs B-ABBREVIATION 
) O 
have O 
been O 
shown O 
to O 
affect O 
the O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
signaling O 
pathway O 
, O 
and O 
one O 
of O 
the O 
proposed O 
disruption O 
mechanisms O 
is O 
direct O 
binding O 
of O 
hydroxylated O 
PBDE B-ABBREVIATION 
( O 
OH-PBDE B-FORMULA 
) O 
to O 
ER O 
. O 
In O 
this O 
paper O 
, O 
the O 
binding O 
affinity O 
of O 
22 O 
OH-PBDEs B-FAMILY 
with O 
different O 
degrees O 
of O 
bromination O 
to O 
ER O 
was O 
assessed O 
quantitatively O 
using O 
a O 
surface O 
plasmon O 
resonance O 
biosensor O 
technique O 
. O 
Seven O 
OH-PBDEs B-FAMILY 
were O 
found O 
to O 
bind O 
directly O 
with O 
ER O 
with O 
KD O 
ranging O 
from O 
1.46×10(-7)M O 
to O 
7.90×10(-6)M O 
, O 
and O 
the O 
affinity O 
is O 
in O 
the O 
order O 
of O 
6-OH-BDE-047 B-SYSTEMATIC 
≧ O 
4'-OH-BDE-049 B-SYSTEMATIC 
> O 
4'-OH-BDE-017 B-SYSTEMATIC 
> O 
6'-OH-BDE-099 B-SYSTEMATIC 
≧ O 
5'-OH-BDE-099 B-SYSTEMATIC 
> O 
2'-OH-BDE-007 B-SYSTEMATIC 
> O 
3'-OH-BDE-028 B-SYSTEMATIC 
. O 
In O 
MVLN O 
luciferase O 
gene O 
reporter O 
assays O 
, O 
10 O 
low O 
- O 
brominated O 
OH-PBDEs B-FAMILY 
induced O 
luciferase O 
activity O 
alone O 
, O 
but O 
are O 
10(5) O 
to O 
10(7) O 
fold O 
less O 
potent O 
than O 
E2 O 
. O 
Their O 
estrogenic O 
activity O 
is O 
in O 
the O 
order O 
of O 
4'-OH-BDE-049 B-SYSTEMATIC 
> O 
4'-OH-BDE-017 B-SYSTEMATIC 
> O 
2'-OH-BDE-007 B-SYSTEMATIC 
> O 
3'-OH-BDE-028 B-SYSTEMATIC 
> O 
3-OH-BDE-047 B-SYSTEMATIC 
≧ O 
3'-OH-BDE-007 B-SYSTEMATIC 
. O 
The O 
good O 
correlation O 
between O 
estrogenic O 
activity O 
and O 
ER O 
binding O 
affinity O 
of O 
the O 
low O 
- O 
brominated O 
OH-PBDEs B-FAMILY 
strongly O 
suggest O 
that O 
these O 
compounds O 
induce O 
ER O 
transcriptional O 
activity O 
by O 
binding O 
directly O 
with O 
ER O 
. O 
The O 
other O 
12 O 
high O 
- O 
brominated O 
OH-PBDEs B-FAMILY 
inhibited O 
luciferase O 
activity O 
of O 
E2 O 
to O 
various O 
degrees O 
, O 
demonstrating O 
their O 
antagonistic O 
activity O 
. O 
Molecular O 
docking O 
analysis O 
of O 
the O 
ER/ O 
OH-PBDE B-FORMULA 
complexes O 
revealed O 
two O 
distinctive O 
binding O 
modes O 
between O 
low- O 
and O 
high O 
- O 
brominated O 
OH-PBDEs B-FAMILY 
which O 
provided O 
rationale O 
for O 
the O 
difference O 
in O 
their O 
ER O 
activity O 
. O 

upregulates O 
the O 
expression O 
of O 
angiotensin O 
II O 
Type O 
I O 
receptor O 
in O 
mouse O 
aortic O 
endothelial O 
cells O 
. O 

chronic O 
arsenic B-SYSTEMATIC 
exposure O 
is O 
a O 
well O 
- O 
known O 
risk O 
for O 
cardiovascular O 
disease O 
and O 
has O 
a O 
strong O 
correlation O 
with O 
hypertension O 
, O 
the O 
molecular O 
pathogenesis O 
underlying O 
arsenic B-SYSTEMATIC 
exposure O 
- O 
induced O 
hypertension O 
remains O 
poorly O 
understood O 
. O 
To O 
delineate O 
the O 
pathogenesis O 
, O 
we O 
examined O 
changes O 
in O 
the O 
mRNA O 
levels O 
of O 
2 O 
angiotensin O 
II O 
Type O 
I O 
receptor O 
( O 
AT1R O 
) O 
subtypes O 
, O 
AT1AR O 
and O 
AT1BR O 
, O 
in O 
a O 
mouse O 
aortic O 
endothelial O 
cell O 
line O 
, O 
END-D O 
. O 
Quantitative O 
real O 
- O 
time O 
PCR O 
analysis O 
revealed O 
significant O 
increases O 
in O 
the O 
mRNA O 
levels O 
of O 
2 O 
AT1R O 
subtypes O 
, O 
AT1AR O 
and O 
AT1BR O 
following O 
sodium B-SYSTEMATIC 
arsenite I-SYSTEMATIC 
( O 
SA O 
) O 
treatment O 
. O 
Flow O 
cytometry O 
analysis O 
revealed O 
that O 
SA O 
increases O 
the O 
generation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
( O 
ROS O 
) O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
addition O 
, O 
western O 
blot O 
analysis O 
revealed O 
that O 
SA O 
enhances O 
the O 
phosphorylations O 
of O 
c-Jun O 
N B-FORMULA 
-terminal O 
kinases O 
( O 
JNK O 
) O 
and O 
activated O 
protein O 
1 O 
( O 
AP-1 O 
) O 
. O 
These O 
phosphorylations O 
were O 
inhibited O 
by O 
N-acetylcysteine B-SYSTEMATIC 
( O 
NAC B-ABBREVIATION 
) O 
, O 
an O 
anti-oxidant O 
. O 
Finally O 
, O 
SA-induced O 
AT1R O 
expression O 
was O 
found O 
to O 
be O 
prevented O 
both O 
by O 
NAC O 
and O 
specific O 
JNK O 
inhibitor O 
, O 
SP6001325 B-IDENTIFIER 
, O 
strongly O 
indicating O 
that O 
AT1R O 
upregulation O 
is O 
a O 
result O 
of O 
the O 
ROS O 
- O 
mediated O 
activation O 
of O 
the O 
JNK O 
signaling O 
pathway O 
. O 
Taken O 
together O 
, O 
our O 
results O 
indicate O 
that O 
arsenic B-SYSTEMATIC 
indeed O 
upregulates O 
the O 
AT1R O 
expression O 
, O 
thus O 
highlighting O 
a O 
role O 
of O 
arsenic B-SYSTEMATIC 
-induced O 
aberrant O 
AT1R O 
signaling O 
in O 
the O 
pathogenesis O 
of O 
hypertension O 
. O 

of O 
new O 
cationic O 
porphyrin B-FAMILY 
- O 
tetrapeptide B-FAMILY 
conjugates O 
to O 
nucleoprotein O 
complexes O 
. O 

research O 
on O 
DNA O 
binding O 
of O 
cationic O 
porphyrin B-FAMILY 
derivatives O 
and O 
their O 
conjugates O 
is O 
a O 
subject O 
of O 
growing O 
interest O 
because O 
of O 
their O 
possible O 
DNA O 
binding O 
and O 
demonstrated O 
biological O 
properties O 
. O 
In O 
this O 
study O 
nucleoprotein O 
binding O 
of O 
tri B-SYSTEMATIC 
- I-SYSTEMATIC 
cationic I-SYSTEMATIC 
meso-tri(4-N-methylpyridyl)-mono-(4-carboxyphenyl)porphyrin I-SYSTEMATIC 
( O 
TMPCP B-ABBREVIATION 
) O 
and O 
tetrapeptides B-FAMILY 
conjugated O 
TMPCP B-ABBREVIATION 
( O 
TMPCP-4P B-ABBREVIATION 
) O 
and O 
bi B-SYSTEMATIC 
- I-SYSTEMATIC 
cationic I-SYSTEMATIC 
meso-5,10-bis(4-N-methylpyridyl)-15,20-di-(4-carboxyphenyl)porphyrin I-SYSTEMATIC 
( O 
BMPCP-4P2 B-ABBREVIATION 
) O 
was O 
investigated O 
with O 
comprehensive O 
spectroscopic O 
methods O 
. O 
The O 
key O 
observation O 
is O 
that O 
tetrapeptide B-FAMILY 
-conjugates O 
of O 
cationic O 
porphyrins B-FAMILY 
with O 
two O 
or O 
three O 
positive O 
charges O 
bind O 
to O 
encapsidated O 
DNA O 
in O 
T7 O 
phage O 
nucleoprotein O 
complex O 
. O 
The O 
binding O 
modes O 
were O 
analyzed O 
by O 
fluorescent O 
energy O 
transfer O 
, O 
fluorescent O 
life O 
time O 
and O 
CD O 
measurements O 
. O 
Intercalative O 
binding O 
is O 
most O 
feasible O 
when O 
tricationic O 
ligands O 
complex O 
with O 
DNA O 
, O 
especially O 
when O 
it O 
is O 
in O 
close O 
connection O 
with O 
protein O 
capsid O 
. O 
It O 
was O 
found O 
that O 
larger O 
ligand O 
BMPCP-4P2 B-ABBREVIATION 
binds O 
externally O 
to O 
encapsidated O 
T7 O 
DNA O 
, O 
and O 
complex O 
externally O 
as O 
well O 
as O 
by O 
intercalation O 
when O 
the O 
DNA O 
accommodate O 
to O 
relaxed O 
B-conformation O 
. O 
In O 
the O 
case O 
of O 
TMPCP B-ABBREVIATION 
and O 
TMPCP-4P B-ABBREVIATION 
the O 
intercalation O 
is O 
the O 
predominant O 
binding O 
form O 
both O 
in O 
nucleoprotein O 
( O 
NP O 
) O 
and O 
preheated O 
complexes O 
. O 
Further O 
, O 
melting O 
experiments O 
revealed O 
that O 
bound O 
porphyrins B-FAMILY 
do O 
not O 
influence O 
the O 
capsid O 
stability O 
or O 
protein-DNA O 
interactions O 
, O 
but O 
efficiently O 
stabilize O 
the O 
double O 
helical O 
structure O 
of O 
DNA O 
without O 
respect O 
to O 
binding O 
form O 
. O 
A O 
good O 
correlation O 
was O 
found O 
between O 
porphyrin B-FAMILY 
/ O 
base O 
pair O 
ration O 
and O 
DNA O 
strand O 
separation O 
temperature O 
. O 

and O 
antioxidant O 
effect O 
of O 
Lavandula O 
officinalis O 
aerial O 
part O 
extract O 
against O 
pentylenetetrazol B-TRIVIAL 
-induced O 
kindling O 
in O 
male O 
mice O 
. O 

RELEVANCE O 
: O 
Repeated O 
application O 
of O 
Lavandula O 
officinalis O 
( O 
L O 
. O 
officinalis O 
) O 
has O 
been O 
recommended O 
for O 
a O 
long O 
time O 
in O 
Iranian O 
traditional O 
medicine O 
for O 
some O 
of O 
nervous O 
disorders O 
like O 
epilepsy O 
and O 
dementia O 
. O 
However O 
, O 
there O 
is O 
no O 
available O 
report O 
for O 
the O 
effect O 
of O 
chronic O 
administration O 
of O 
Lavandula O 
extract O 
in O 
development O 
( O 
acquisition O 
) O 
of O 
epilepsy O 
. O 
Therefore O 
, O 
this O 
study O 
was O 
designed O 
to O 
investigate O 
the O 
anti-epileptogenic O 
and O 
antioxidant O 
activity O 
of O 
repeated O 
administration O 
of O 
Lavandula O 
officinalis O 
extract O 
on O 
pentylenetetrazol B-TRIVIAL 
( O 
PTZ B-ABBREVIATION 
) O 
kindling O 
seizures O 
in O 
mice O 
model O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Lavandula O 
officinalis O 
was O 
tested O 
for O 
its O 
ability O 
(i) O 
to O 
suppress O 
the O 
seizure O 
intensity O 
and O 
lethal O 
effects O 
of O 
PTZ B-ABBREVIATION 
in O 
kindled O 
mice O 
( O 
anti-epileptogenic O 
effect O 
) O 
, O 
(ii) O 
to O 
attenuate O 
the O 
PTZ B-ABBREVIATION 
-induced O 
oxidative O 
injury O 
in O 
the O 
brain O 
tissue O 
( O 
antioxidant O 
effect O 
) O 
when O 
given O 
as O 
a O 
pretreatment O 
prior O 
to O 
each O 
PTZ B-ABBREVIATION 
injection O 
during O 
kindling O 
development O 
. O 
Valproate B-TRIVIAL 
( O 
Val B-ABBREVIATION 
) O 
, O 
a O 
major O 
antiepileptic O 
drug O 
, O 
was O 
also O 
tested O 
for O 
comparison O 
. O 
RESULTS O 
: O 
Val B-ABBREVIATION 
and O 
Lavandula O 
officinalis O 
extract O 
showed O 
anti-epileptogenic O 
properties O 
as O 
they O 
reduced O 
seizure O 
score O 
of O 
kindled O 
mice O 
and O 
PTZ B-ABBREVIATION 
-induced O 
mortality O 
. O 
In O 
this O 
regard O 
, O 
Lavandula O 
officinalis O 
was O 
more O 
effective O 
than O 
Val B-ABBREVIATION 
. O 
Both O 
Lavandula O 
officinalis O 
and O 
Val B-ABBREVIATION 
suppressed O 
brain O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
NO B-FORMULA 
) O 
level O 
of O 
kindled O 
mice O 
in O 
comparison O 
with O 
the O 
control O 
and O 
PTZ B-ABBREVIATION 
group O 
. O 
Meanwhile O 
, O 
Lavandula O 
officinalis O 
suppressed O 
NO B-FORMULA 
level O 
more O 
than O 
Val B-ABBREVIATION 
and O 
Lavandula O 
officinalis O 
also O 
decreased O 
brain O 
MDA B-ABBREVIATION 
level O 
relative O 
to O 
PTZ B-ABBREVIATION 
group O 
. O 
CONCLUSION O 
: O 
This O 
is O 
the O 
first O 
report O 
to O 
demonstrate O 
NO B-FORMULA 
suppressing O 
and O 
anti-epileptogenic O 
effect O 
of O 
chronic O 
administration O 
of O 
Lavandula O 
officinalis O 
extract O 
on O 
acquisition O 
of O 
epilepsy O 
in O 
PTZ B-ABBREVIATION 
kindling O 
mice O 
model O 
. O 
In O 
this O 
regard O 
, O 
Lavandula O 
officinalis O 
extract O 
was O 
more O 
effective O 
than O 
Val B-ABBREVIATION 
, O 
possibly O 
and O 
in O 
part O 
via O 
brain O 
NO B-FORMULA 
suppression O 
. O 

, O 
a O 
marine O 
fungus O 
metabolite O 
, O 
is O 
a O 
new O 
angiosuppresor O 
that O 
interferes O 
the O 
Akt O 
pathway O 
. O 

, O 
a O 
methylhydroquinone B-SYSTEMATIC 
produced O 
by O 
a O 
marine O 
fungus O 
, O 
was O 
selected O 
in O 
the O 
course O 
of O 
a O 
blind O 
screening O 
for O 
new O 
potential O 
inhibitors O 
of O 
angiogenesis O 
. O 
In O 
the O 
present O 
study O 
we O 
provide O 
the O 
first O 
evidence O 
that O 
toluquinol B-TRIVIAL 
is O 
a O 
new O 
anti-angiogenic- O 
compound O 
. O 
In O 
a O 
variety O 
of O 
experimental O 
systems O 
, O 
representing O 
the O 
sequential O 
events O 
of O 
the O 
angiogenic O 
process O 
, O 
toluquinol B-TRIVIAL 
treatment O 
of O 
activated O 
endothelial O 
cells O 
resulted O 
in O 
strong O 
inhibitory O 
effect O 
. O 
Toluquinol B-TRIVIAL 
inhibited O 
the O 
growth O 
of O 
endothelial O 
and O 
tumor O 
cells O 
in O 
culture O 
in O 
the O 
micromolar O 
range O 
. O 
Our O 
results O 
indicate O 
that O 
the O 
observed O 
growth O 
inhibitory O 
effect O 
could O 
be O 
due O 
, O 
at O 
least O 
in O 
part O 
, O 
to O 
an O 
induction O 
of O 
apoptosis O 
. O 
Toluquinol B-TRIVIAL 
induced O 
endothelial O 
cell O 
death O 
is O 
mediated O 
via O 
apoptosis O 
after O 
a O 
cell O 
cycle O 
block O 
and O 
caspase O 
activation O 
. O 
Capillary O 
tube O 
formation O 
on O 
Matrigel O 
and O 
migratory O 
, O 
invasive O 
and O 
proteolytic O 
capabilities O 
of O 
endothelial O 
cells O 
were O 
inhibited O 
by O 
addition O 
of O 
toluquinol B-TRIVIAL 
at O 
subtoxic O 
concentrations O 
. O 
Inhibition O 
of O 
the O 
mentioned O 
essential O 
steps O 
of O 
in O 
vitro O 
angiogenesis O 
agrees O 
with O 
the O 
observed O 
inhibition O 
of O 
the O 
in O 
vivo O 
angiogenesis O 
, O 
substantiated O 
by O 
using O 
the O 
chick O 
chorioallatoic O 
membrane O 
assay O 
and O 
confirmed O 
by O 
the O 
murine O 
Matrigel O 
plug O 
, O 
the O 
zebrafish O 
embryo O 
neovascularization O 
and O 
the O 
zebrafish O 
caudal O 
fin O 
regeneration O 
assays O 
. O 
Data O 
here O 
shown O 
altogether O 
indicate O 
that O 
toluquinol B-TRIVIAL 
has O 
antiangiogenic O 
effects O 
both O 
in O 
vitro O 
and O 
in O 
vivo O 
that O 
are O 
exerted O 
partly O 
by O 
suppression O 
of O 
the O 
VEGF O 
and O 
FGF-induced O 
Akt O 
activation O 
of O 
endothelial O 
cells O 
. O 
These O 
effects O 
are O 
carried O 
out O 
at O 
lower O 
concentrations O 
to O 
those O 
required O 
for O 
other O 
inhibitors O 
of O 
angiogenesis O 
, O 
what O 
makes O 
toluquinol B-TRIVIAL 
a O 
promising O 
drug O 
candidate O 
for O 
further O 
evaluation O 
in O 
the O 
treatment O 
of O 
cancer O 
and O 
other O 
angiogenesis O 
- O 
related O 
pathologies O 
. O 

post O 
- O 
transcriptionally O 
modifies O 
CYP1A2 O 
induction O 
involving O 
androgen B-FAMILY 
receptor O 
. O 

pharmacological O 
dosage O 
of O 
dehydroepiandrosterone B-TRIVIAL 
( O 
DHEA B-ABBREVIATION 
) O 
protects O 
against O 
chemically O 
induced O 
carcinogenesis O 
. O 
The O 
chemoprotective O 
activity O 
of O 
DHEA B-ABBREVIATION 
is O 
attributed O 
to O 
its O 
inhibitory O 
potential O 
for O 
the O 
expression O 
of O 
CYP1A O 
enzymes O 
, O 
which O 
are O 
highly O 
responsible O 
for O 
metabolic O 
activation O 
of O 
several O 
mutagenic O 
and O 
carcinogenic O 
chemicals O 
. O 
The O 
present O 
work O 
investigated O 
whether O 
the O 
chemoprevention O 
by O 
DHEA B-ABBREVIATION 
was O 
due O 
to O 
diminished O 
transcriptional O 
activation O 
of O 
CYP1A O 
genes O 
or O 
to O 
the O 
post O 
- O 
transcriptional O 
modulation O 
of O 
CYP1A O 
expression O 
. O 
In O 
primary O 
human O 
hepatocytes O 
, O 
DHEA B-ABBREVIATION 
diminished O 
the O 
increase O 
in O 
CYP1A O 
activities O 
( O 
7-ethoxyresorufin B-SYSTEMATIC 
O B-FORMULA 
-dealkylation O 
and O 
phenacetin B-TRIVIAL 
O B-FORMULA 
-dealkylation O 
) O 
and O 
in O 
CYP1A2 O 
mRNA O 
level O 
induced O 
by O 
3-methylcholanthrene B-SYSTEMATIC 
, O 
but O 
did O 
not O 
alter O 
the O 
amount O 
of O 
CYP1A1 O 
and O 
CYP1B1 O 
mRNA O 
. O 
The O 
androgen B-FAMILY 
receptor O 
seemed O 
to O 
be O 
involved O 
in O 
DHEA B-ABBREVIATION 
-mediated O 
diminishment O 
of O 
CYP1A2 O 
induction O 
, O 
which O 
was O 
attenuated O 
in O 
the O 
presence O 
of O 
bicalutamide B-TRIVIAL 
, O 
the O 
androgen B-FAMILY 
receptor O 
antagonist O 
. O 
The O 
potential O 
role O 
of O 
the O 
glucocorticoid O 
receptor O 
and O 
estrogen B-FAMILY 
receptor O 
in O 
DHEA B-ABBREVIATION 
-mediated O 
decrease O 
in O 
CYP1A2 O 
induction O 
was O 
excluded O 
. O 
The O 
developed O 
computational O 
model O 
of O 
CYP1A2 O 
induction O 
kinetics O 
and O 
CYP1A2 O 
mRNA O 
degradation O 
proposed O 
that O 
a O 
post O 
- O 
transcriptional O 
mechanism O 
was O 
likely O 
to O 
be O 
the O 
primary O 
mechanism O 
of O 
the O 
DHEA B-ABBREVIATION 
-mediated O 
diminishment O 
of O 
CYP1A2 O 
induction O 
. O 
The O 
hypothesis O 
was O 
confirmed O 
by O 
the O 
results O 
of O 
actinomycin B-TRIVIAL 
D I-TRIVIAL 
-chase O 
experiments O 
in O 
MCF-7 O 
and O 
LNCaP O 
cells O 
, O 
displaying O 
that O 
the O 
degradation O 
rates O 
of O 
CYP1A2 O 
mRNA O 
were O 
significantly O 
higher O 
in O 
the O 
cells O 
exposed O 
to O 
DHEA B-ABBREVIATION 
. O 
The O 
novel O 
findings O 
on O 
DHEA B-ABBREVIATION 
-mediated O 
modulation O 
of O 
CYP1A2 O 
mRNA O 
stability O 
may O 
account O 
for O 
the O 
beneficial O 
effects O 
of O 
DHEA B-ABBREVIATION 
by O 
decreasing O 
the O 
metabolic O 
activation O 
of O 
pro O 
- O 
carcinogenic O 
compounds O 
. O 

, O 
pyridine B-FAMILY 
alkaloid I-FAMILY 
inhibition O 
of O 
fetal O 
movement O 
in O 
a O 
day O 
40 O 
pregnant O 
goat O 
model O 
. O 

of O 
fetal O 
movement O 
is O 
one O 
mechanism O 
behind O 
the O 
development O 
of O 
multiple O 
congenital O 
contracture O 
- O 
type O 
defects O 
in O 
developing O 
fetuses O 
of O 
humans O 
and O 
animals O 
. O 
We O 
tested O 
the O 
alkaloids O 
anabasine B-TRIVIAL 
, O 
lobeline B-TRIVIAL 
, O 
and O 
myosmine B-TRIVIAL 
for O 
agonist O 
actions O 
, O 
and O 
sensitivity O 
to O 
alpha O 
conotoxins O 
EI O 
and O 
GI O 
blockade O 
at O 
fetal O 
muscle O 
- O 
type O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptors O 
( O 
nAChR O 
) O 
expressed O 
by O 
TE-671 O 
cells O 
. O 
We O 
also O 
determined O 
if O 
the O 
alkaloids O 
decreased O 
fetal O 
movement O 
in O 
an O 
IV O 
dosed O 
, O 
day O 
40 O 
pregnant O 
goat O 
model O 
. O 
In O 
TE-671 O 
cells O 
, O 
all O 
three O 
alkaloids O 
elicited O 
concentration O 
- O 
dependent O 
changes O 
in O 
membrane O 
potential O 
sensing O 
dye O 
fluorescence O 
. O 
1.0μM O 
alpha B-TRIVIAL 
conotoxin I-TRIVIAL 
GI I-TRIVIAL 
shifted O 
the O 
concentration O 
- O 
effect O 
curves O 
of O 
anabasine B-TRIVIAL 
and O 
myosmine B-TRIVIAL 
to O 
the O 
right O 
, O 
and O 
decreased O 
maximal O 
responses O 
. O 
Neither O 
of O 
the O 
conotoxins O 
blocked O 
the O 
actions O 
of O 
lobeline B-TRIVIAL 
in O 
TE-671 O 
cells O 
. O 
In O 
the O 
day O 
40 O 
pregnant O 
goats O 
, O 
0.8mg O 
/ O 
kg O 
anabasine B-TRIVIAL 
abolished O 
fetal O 
movement O 
at O 
30 O 
and O 
60min O 
after O 
dosing O 
and O 
fetal O 
movement O 
was O 
reduced O 
by O 
lobeline B-TRIVIAL 
and O 
myosmine B-TRIVIAL 
. O 
The O 
blockade O 
of O 
anabasine B-TRIVIAL 
and O 
myosmine B-TRIVIAL 
actions O 
in O 
TE-671 O 
cells O 
by O 
alpha B-TRIVIAL 
conotoxin I-TRIVIAL 
GI I-TRIVIAL 
indicates O 
that O 
they O 
are O 
agonists O 
at O 
fetal O 
muscle O 
- O 
type O 
nAChR O 
. O 
All O 
three O 
alkaloids O 
did O 
significantly O 
decrease O 
fetal O 
movement O 
in O 
the O 
day O 
40 O 
pregnant O 
goat O 
model O 
suggesting O 
a O 
potential O 
for O 
these O 
alkaloids O 
to O 
cause O 
multiple O 
congenital O 
contracture O 
- O 
type O 
defects O 
in O 
developing O 
fetuses O 
. O 

acid I-TRIVIAL 
attenuates O 
bleomycin B-FAMILY 
and O 
cyclophosphamide B-TRIVIAL 
-induced O 
pulmonary O 
toxicity O 
in O 
Wistar O 
rats O 
. O 

of O 
bleomycin B-FAMILY 
( O 
BLM B-ABBREVIATION 
) O 
and O 
cyclophosphamide B-TRIVIAL 
( O 
CP O 
) O 
as O 
chemotherapeutic O 
drugs O 
is O 
associated O 
with O 
side O 
effects O 
including O 
toxicity O 
to O 
respiratory O 
system O 
. O 
Their O 
co O 
- O 
administration O 
may O 
enhance O 
lung O 
toxicity O 
which O 
may O 
subsequently O 
progress O 
to O 
the O 
lung O 
fibrosis O 
. O 
Natural O 
compounds O 
have O 
shown O 
mitigating O 
effects O 
against O 
toxicity O 
of O 
anticancer O 
drugs O 
. O 
Ellagic B-TRIVIAL 
acid I-TRIVIAL 
( O 
EA O 
) O 
, O 
a O 
polyphenolic O 
compound O 
present O 
in O 
many O 
fruits O 
and O 
nuts O 
in O 
addition O 
to O 
walnut O 
has O 
shown O 
promising O 
protective O 
effect O 
against O 
toxicity O 
of O 
drugs O 
and O 
chemicals O 
. O 
We O 
studied O 
the O 
ameliorative O 
effect O 
of O 
EA O 
on O 
lung O 
toxicity O 
in O 
rats O 
exposed O 
to O 
CP O 
( O 
150mg O 
/ O 
kgb.w O 
. O 
, O 
i.p O 
. O 
) O 
and O 
BLM B-ABBREVIATION 
( O 
10U O 
/ O 
kgb.w O 
. O 
, O 
i.t O 
. O 
) O 
. O 
EA O 
( O 
15mg O 
/ O 
kgb.w O 
. O 
, O 
p.o.×14days O 
) O 
treatment O 
modulated O 
enhanced O 
hydroxyproline B-SYSTEMATIC 
level O 
, O 
lipid O 
peroxidation O 
, O 
myeloperoxidase O 
activity O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
and O 
protein O 
carbonyl B-FAMILY 
formation O 
in O 
lungs O 
of O 
rats O 
exposed O 
to O 
toxic O 
anticancer O 
drugs O 
. O 
There O 
was O 
a O 
marked O 
decrease O 
in O 
GSH B-ABBREVIATION 
content O 
and O 
activities O 
of O 
antioxidant O 
enzymes O 
as O 
a O 
result O 
of O 
BLM B-ABBREVIATION 
and O 
CP O 
treatment O 
. O 
Bronchoalveolar O 
lavage O 
fluid O 
showed O 
increased O 
level O 
of O 
cytotoxicity O 
markers O 
in O 
drug O 
treated O 
animals O 
. O 
Treatment O 
with O 
EA O 
attenuated O 
these O 
changes O 
. O 
Histopathological O 
findings O 
also O 
showed O 
protective O 
effects O 
of O 
EA O 
. O 
In O 
conclusion O 
, O 
EA O 
emerged O 
as O 
a O 
natural O 
protectant O 
with O 
an O 
ability O 
to O 
protect O 
lungs O 
from O 
onslaught O 
of O 
pulmonary O 
toxicity O 
of O 
anticancer O 
drugs O 
. O 

to O 
measure O 
hazards O 
/ O 
risks O 
following O 
exposures O 
to O 
nanoscale O 
or O 
pigment-grade O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
particles O 
. O 

to O 
its O 
multifunctional O 
applications O 
, O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
particles O 
have O 
widespread O 
use O 
in O 
commerce O 
. O 
The O 
particle O 
- O 
types O 
function O 
as O 
sources O 
of O 
pigment O 
color O 
, O 
in O 
food O 
products O 
, O 
anti-bacterial O 
components O 
, O 
ultraviolet O 
radiation O 
scavengers O 
, O 
catalysts O 
, O 
as O 
well O 
as O 
in O 
cosmetics O 
. O 
Because O 
of O 
its O 
inherent O 
properties O 
in O 
a O 
diverse O 
number O 
of O 
products O 
, O 
exposures O 
may O 
occur O 
via O 
any O 
of O 
the O 
major O 
point O 
- O 
of O 
- O 
entry O 
routes O 
, O 
i.e O 
. O 
, O 
inhalation O 
, O 
oral O 
or O 
dermal O 
. O 
Although O 
the O 
majority O 
of O 
TiO2 B-FORMULA 
applications O 
are O 
known O 
to O 
exist O 
in O 
the O 
pigment-grade O 
form O 
, O 
nanoscale O 
forms O 
of O 
TiO2 B-FORMULA 
are O 
also O 
common O 
components O 
in O 
several O 
products O 
. O 
This O 
brief O 
review O 
is O 
designed O 
to O 
identify O 
relevant O 
toxicology O 
and O 
risk O 
- O 
related O 
issues O 
which O 
inform O 
health O 
effects O 
assessments O 
on O 
the O 
various O 
forms O 
of O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
particles O 
. O 
While O 
there O 
has O 
been O 
an O 
abundance O 
of O 
hazard O 
data O 
generated O 
on O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
particulates O 
, O 
many O 
of O 
the O 
published O 
reports O 
have O 
limited O 
informational O 
value O 
for O 
assessing O 
health O 
effects O 
due O 
, O 
in O 
large O 
part O 
, O 
to O 
shortcomings O 
in O 
experimental O 
design O 
issues O 
, O 
such O 
as O 
: O 
( O 
1 O 
) O 
inadequate O 
material O 
characterization O 
of O 
test O 
samples O 
; O 
( O 
2 O 
) O 
questionable O 
relevance O 
of O 
experimental O 
systems O 
employed O 
to O 
simulate O 
human O 
exposures O 
; O 
( O 
3 O 
) O 
applications O 
of O 
generally O 
high O 
doses O 
, O 
exclusive O 
focus O 
on O 
acute O 
toxicity O 
endpoints O 
, O 
and O 
a O 
lack O 
of O 
reference O 
benchmark O 
control O 
materials O 
, O 
to O 
afford O 
interpretation O 
of O 
measured O 
results O 
; O 
and O 
/ O 
or O 
( O 
4 O 
) O 
failure O 
to O 
recognize O 
fundamental O 
differences O 
between O 
hazard O 
and O 
risk O 
concepts O 
. O 
Accordingly O 
, O 
a O 
number O 
of O 
important O 
toxicology O 
issues O 
are O 
identified O 
and O 
integrated O 
herein O 
to O 
provide O 
a O 
more O 
comprehensive O 
assessment O 
of O 
the O 
health O 
risks O 
of O 
different O 
forms O 
of O 
pigment-grade O 
and O 
nanoscale O 
titanium B-SYSTEMATIC 
dioxide I-SYSTEMATIC 
particles O 
. O 
It O 
is O 
important O 
to O 
note O 
that O 
particle O 
- O 
types O 
of O 
different O 
TiO2 B-FORMULA 
compositions O 
may O 
have O 
variable O 
toxicity O 
potencies O 
, O 
depending O 
upon O 
crystal O 
structure O 
, O 
particle O 
size O 
, O 
particle O 
surface O 
characteristics O 
and O 
surface O 
coatings O 
. O 
In O 
order O 
to O 
develop O 
a O 
more O 
robust O 
health O 
risk O 
evaluation O 
of O 
TiO2 B-FORMULA 
particle O 
exposures O 
, O 
this O 
review O 
focuses O 
on O 
the O 
following O 
issues O 
: O 
A O 
comprehensive O 
evaluation O 
of O 
the O 
existing O 
animal O 
and O 
human O 
health O 
data O 
is O 
a O 
necessary O 
prerequisite O 
for O 
facilitating O 
accurate O 
assessments O 
of O 
human O 
health O 
risks O 
to O 
TiO2 B-FORMULA 
exposures O 
. O 

has O 
an O 
important O 
role O 
in O 
the O 
maintenance O 
of O 
blood O 
sugar O 
. O 
It O 
is O 
the O 
only O 
available O 
therapeutic O 
agent O 
for O 
the O 
treatment O 
of O 
type O 
1 O 
diabetes O 
mellitus O 
and O 
there O 
is O 
a O 
dire O 
need O 
for O 
an O 
oral O 
substitute O 
. O 
Different O 
categories O 
of O 
compounds O 
including O 
mono O 
and O 
di O 
substituted O 
benzoquinones B-FAMILY 
, O 
vanadium B-SYSTEMATIC 
based O 
compounds O 
and O 
natural O 
products O 
have O 
been O 
reported O 
to O 
cause O 
insulin O 
- O 
like O 
effects O 
either O 
by O 
increasing O 
phosphorylation O 
of O 
insulin O 
receptor O 
( O 
IR O 
) O 
or O 
inhibiting O 
the O 
protein O 
tyrosine B-TRIVIAL 
phosphatases O 
. O 
This O 
review O 
summarizes O 
the O 
development O 
of O 
various O 
insulin O 
mimetics O 
with O 
special O 
emphasis O 
on O 
their O 
structure O 
- O 
activity O 
relationships O 
and O 
various O 
biological O 
actions O 
they O 
produce O 
. O 

binding O 
properties O 
apply O 
to O 
a O 
variety O 
of O 
muscarinic O 
compounds O 
that O 
span O 
and O 
simultaneously O 
bind O 
to O 
both O 
the O 
orthosteric O 
and O 
allosteric O 
receptor O 
sites O 
. O 
We O 
provide O 
evidence O 
that O 
fluorescent O 
pirenzepine B-TRIVIAL 
derivatives O 
, O 
with O 
the O 
M1 O 
antagonist O 
fused O 
to O 
the O 
Bodipy B-IDENTIFIER 
[ I-IDENTIFIER 
558 I-IDENTIFIER 
/ I-IDENTIFIER 
568 I-IDENTIFIER 
] I-IDENTIFIER 
fluorophore O 
via O 
spacers O 
of O 
varying O 
lengths O 
, O 
exhibit O 
orthosteric O 
/ O 
allosteric O 
binding O 
properties O 
at O 
muscarinic O 
M1 O 
receptors O 
. O 
This O 
behaviour O 
was O 
inferred O 
from O 
a O 
combination O 
of O 
functional O 
, O 
radioligand O 
and O 
FRET O 
binding O 
experiments O 
, O 
performed O 
under O 
equilibrium O 
and O 
kinetic O 
conditions O 
on O 
EGFP-fused O 
M1 O 
receptors O 
. O 
Though O 
displaying O 
a O 
common O 
orthosteric O 
component O 
, O 
the O 
fluorescent O 
compounds O 
inherit O 
bitopic O 
properties O 
from O 
a O 
linker O 
- O 
guided O 
positioning O 
of O 
their O 
Bodipy B-TRIVIAL 
moiety O 
within O 
the O 
M1 O 
allosteric O 
vestibule O 
. O 
Depending O 
on O 
linker O 
length O 
, O 
the O 
fluorophore O 
is O 
allowed O 
to O 
reach O 
neighbouring O 
allosteric O 
domains O 
, O 
overlapping O 
or O 
not O 
with O 
the O 
classical O 
gallamine B-TRIVIAL 
site O 
, O 
but O 
distinct O 
from O 
the O 
allosteric O 
indocarbazolole B-SYSTEMATIC 
' O 
WIN O 
' O 
site O 
. O 
Site O 
- O 
directed O 
mutagenesis O 
, O 
as O 
well O 
as O 
molecular O 
modeling O 
and O 
ligand O 
docking O 
studies O 
based O 
on O 
recently O 
solved O 
muscarinic O 
receptor O 
structures O 
, O 
further O 
support O 
the O 
definition O 
of O 
two O 
groups O 
of O 
Bodipy B-TRIVIAL 
- O 
pirenzepine B-TRIVIAL 
derivatives O 
exhibiting O 
distinct O 
allosteric O 
binding O 
poses O 
. O 
Thus O 
, O 
the O 
linker O 
may O 
dictate O 
pharmacological O 
outcomes O 
for O 
bitopic O 
molecules O 
that O 
are O 
hardly O 
predictable O 
from O 
the O 
properties O 
of O 
individual O 
orthosteric O 
and O 
allosteric O 
building O 
blocks O 
. O 
Our O 
findings O 
also O 
demonstrate O 
that O 
the O 
fusion O 
of O 
a O 
fluorophore O 
to O 
an O 
orthosteric O 
ligand O 
is O 
not O 
neutral O 
as O 
it O 
may O 
confer O 
, O 
unless O 
carefully O 
controlled O 
, O 
unexpected O 
properties O 
to O 
the O 
resultant O 
fluorescent O 
tracer O 
. O 
Altogether O 
, O 
this O 
study O 
illustrates O 
the O 
importance O 
of O 
a O 
' O 
multifacette O 
' O 
experimental O 
approach O 
to O 
unravel O 
and O 
validate O 
bitopic O 
ligand O 
binding O 
mechanisms O 
. O 

exposure O 
to O 
As B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
-mixture O 
diminishes O 
skeletal O 
growth O 
and O 
causes O 
osteopenia O 
at O 
maturity O 
via O 
osteoblast O 
and O 
chondrocyte O 
malfunctioning O 
in O 
female O 
rats O 
. O 

studied O 
the O 
effect O 
of O 
metal O 
mixture O 
( O 
MM O 
) O 
, O 
comprising O 
of O 
As B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
, O 
in O 
developing O 
female O 
rat O 
skeleton O 
from O 
gestation O 
day-5 O 
until O 
postnatal O 
day-60 O 
( O 
P-60 O 
) O 
. O 
MM O 
resulted O 
in O 
synergistic O 
inhibition O 
in O 
viability O 
and O 
differentiation O 
of O 
osteoblasts O 
in O 
vitro O 
, O 
likely O 
induced O 
by O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
. O 
MM O 
, O 
administered O 
at O 
their O 
most O 
frequently O 
occurring O 
concentrations O 
present O 
in O 
the O 
ground O 
- O 
water O 
of O 
India O 
, O 
i.e O 
. O 
As B-FORMULA 
: O 
0.38ppm O 
, O 
Pb B-FORMULA 
: O 
0.22 O 
ppm O 
and O 
Cd B-FORMULA 
: O 
0.098 O 
ppm O 
or O 
10× O 
of O 
the O 
ratio O 
to O 
developing O 
rats O 
exhibited O 
a O 
synergistic O 
decrease O 
in O 
ex O 
vivo O 
mineralization O 
of O 
bone O 
marrow O 
stromal O 
( O 
osteoprogenitor O 
) O 
cells O 
. O 
MM O 
group O 
showed O 
a O 
dose O 
- O 
dependent O 
attenuation O 
in O 
weight O 
and O 
axial O 
lengths O 
, O 
and O 
shortening O 
of O 
tibias O 
at O 
P-60 O 
. O 
Furthermore O 
, O 
the O 
growth O 
plate O 
was O 
shortened O 
, O 
which O 
was O 
associated O 
with O 
shorter O 
proliferative- O 
and O 
hypertrophic O 
zones O 
, O 
decreased O 
parathyroid O 
hormone O 
- O 
related O 
protein O 
and O 
Indian O 
hedgehog O 
expression O 
in O 
the O 
chondrocytes O 
, O 
reduced O 
primary- O 
and O 
secondary O 
spongiosa O 
, O 
and O 
hypomineralized O 
osteoids O 
- O 
a O 
major O 
characteristic O 
of O 
osteomalacia O 
. O 
In O 
addition O 
, O 
compared O 
to O 
the O 
control O 
, O 
MM O 
treated O 
rats O 
were O 
clearly O 
osteopenic O 
based O 
on O 
BMD O 
, O 
micro O 
- O 
architecture O 
, O 
biomechanical O 
strength O 
, O 
and O 
particularly O 
the O 
biochemical O 
profile O 
, O 
that O 
suggested O 
high O 
turnover O 
bone O 
loss O 
. O 
Finally O 
, O 
in O 
comparison O 
to O 
the O 
control O 
, O 
the O 
fracture O 
healing O 
ability O 
of O 
MM O 
group O 
was O 
delayed O 
and O 
accompanied O 
by O 
inferior O 
quality O 
of O 
the O 
healed O 
bone O 
. O 
Together O 
, O 
these O 
data O 
demonstrated O 
that O 
the O 
mixture O 
of O 
As B-FORMULA 
, O 
Cd B-FORMULA 
and O 
Pb B-FORMULA 
induced O 
synergistic O 
toxicity O 
to O 
developing O 
skeleton O 
thereby O 
diminishing O 
modeling O 
- O 
directed O 
bone O 
accrual O 
, O 
inducing O 
osteopenia O 
and O 
dampening O 
fracture O 
healing O 
. O 

determination O 
of O 
five O 
flavonoids B-FAMILY 
during O 
the O 
growth O 
of O 
Fructus O 
Sophorae O 
by O 
capillary O 
electrophoresis O 
. O 

method O 
of O 
simultaneous O 
determination O 
of O 
five O 
flavonoids B-FAMILY 
during O 
the O 
growth O 
of O 
Fructus O 
Sophorae O 
by O 
β-cyclodextrin B-TRIVIAL 
( O 
β-CD B-ABBREVIATION 
- O 
) O 
modified O 
capillary O 
zone O 
electrophoresis O 
was O 
developed O 
. O 
The O 
effects O 
of O 
various O 
parameters O 
such O 
as O 
buffer O 
concentration O 
, O 
pH O 
, O 
applied O 
voltage O 
, O 
and O 
β-CD B-ABBREVIATION 
concentrations O 
were O 
investigated O 
. O 
After O 
a O 
series O 
of O 
optimization O 
processes O 
, O 
the O 
determination O 
of O 
five O 
flavonoids B-FAMILY 
in O 
Fructus O 
Sophorae O 
was O 
successfully O 
achieved O 
in O 
20 O 
mmol O 
/ O 
L O 
borax O 
buffer O 
( O 
pH O 
9.5 O 
) O 
, O 
25 O 
kV O 
applied O 
voltage O 
, O 
and O 
8 O 
mmol O 
/ O 
L O 
β-CD B-ABBREVIATION 
. O 
The O 
linearity O 
, O 
detection O 
limits O 
, O 
repeatability O 
, O 
and O 
recovery O 
were O 
satisfactory O 
. O 
Thus O 
, O 
the O 
proposed O 
β-CD B-ABBREVIATION 
-modified O 
capillary O 
zone O 
electrophoresis O 
method O 
was O 
satisfactorily O 
used O 
to O 
analyze O 
Fructus O 
Sophorae O 
samples O 
. O 
The O 
results O 
can O 
be O 
useful O 
for O 
the O 
quality O 
control O 
and O 
medicinal O 
resource O 
development O 
of O 
Fructus O 
Sophorae O 
. O 

II O 
inhibitory O 
activity O 
of O 
flavonoid B-FAMILY 
compounds O 
from O 
Scutellaria O 
indica O 
. O 

II O 
has O 
recently O 
reported O 
as O 
a O 
novel O 
therapeutic O 
target O 
for O 
the O 
treatment O 
of O 
cardiovascular O 
diseases O 
such O 
as O 
atherosclerosis O 
. O 
In O 
the O 
course O 
of O 
screening O 
plants O 
used O 
in O 
natural O 
medicines O 
as O 
arginase O 
II O 
inhibitory O 
activity O 
, O 
a O 
methanol B-SYSTEMATIC 
extract O 
of O 
Scutellaria O 
indica O 
showed O 
significant O 
inhibitory O 
effect O 
. O 
Further O 
fractionation O 
and O 
repeated O 
column O 
chromatography O 
led O 
to O 
the O 
isolation O 
of O 
a O 
new O 
flavan B-FAMILY 
-type O 
( O 
1 O 
) O 
, O 
and O 
seven O 
known O 
compounds O 
( O 
2-8 O 
) O 
. O 
The O 
chemical O 
structures O 
of O 
isolated O 
compounds O 
were O 
elucidated O 
based O 
on O 
extensive O 
1D O 
and O 
2D O 
NMR O 
spectroscopic O 
data O 
. O 
The O 
isolates O 
1-8 O 
were O 
investigated O 
in O 
vitro O 
for O 
their O 
arginase O 
II O 
inhibitory O 
activity O 
using O 
enzyme O 
solution O 
prepared O 
from O 
kidney O 
of O 
anesthetized O 
C57BL O 
/ O 
6 O 
mice O 
. O 
Compounds O 
3 O 
and O 
5 O 
significantly O 
inhibited O 
arginase O 
II O 
activity O 
with O 
IC50 O 
values O 
of O 
25.1 O 
and O 
11.6 O 
μM O 
, O 
respectively O 
, O 
whereas O 
the O 
other O 
compounds O 
were O 
apparently O 
inactive O 
. O 

, O 
cytotoxicity O 
and O 
QSAR O 
study O 
of O 
N-tosyl-1,2,3,4-tetrahydroisoquinoline B-SYSTEMATIC 
derivatives O 
. O 

Substituted-N-tosyl-1,2,3,4-tetrahydroisoquinoline I-FAMILY 
analogs O 
( O 
4a-4l O 
) O 
were O 
synthesized O 
using O 
the O 
modified O 
Pictet-Spengler O 
reaction O 
and O 
evaluated O 
for O 
cytotoxicity O 
. O 
All O 
tetrahydroisoquinolines B-FAMILY 
displayed O 
cytotoxicity O 
against O 
MOLT-3 O 
cell O 
lines O 
, O 
except O 
for O 
p-methoxy B-SYSTEMATIC 
analog O 
4d O 
. O 
Interestingly O 
, O 
the O 
o-hydroxy B-SYSTEMATIC 
derivative O 
4k O 
was O 
shown O 
to O 
be O 
the O 
most O 
potent O 
cytotoxic O 
against O 
HuCCA-1 O 
, O 
A-549 O 
and O 
MOLT-3 O 
cell O 
lines O 
. O 
The O 
lowest O 
IC50 O 
value O 
of O 
1.23 O 
μM O 
was O 
observed O 
for O 
MOLT-3 O 
cells O 
. O 
Trimethoxy B-SYSTEMATIC 
analog O 
4f O 
exerted O 
the O 
most O 
potent O 
activity O 
against O 
HepG2 O 
with O 
an O 
IC50 O 
of O 
22.7 O 
μM O 
, O 
which O 
is O 
lower O 
than O 
the O 
reference O 
drug O 
, O 
etoposide O 
. O 
QSAR O 
studies O 
showed O 
that O 
total O 
symmetry O 
index O 
( O 
Gu O 
) O 
, O 
3D-MoRSE O 
( O 
Mor31v O 
and O 
Mor32u O 
) O 
and O 
3D O 
Petitjean O 
index O 
( O 
PJI3 O 
) O 
were O 
the O 
most O 
important O 
descriptors O 
accounting O 
for O 
the O 
observed O 
cytotoxicities O 
. O 
The O 
most O 
potent O 
cytotoxic O 
compound O 
( O 
4k O 
) O 
against O 
MOLT-3 O 
had O 
the O 
highest O 
Gu O 
value O 
, O 
correspondingly O 
the O 
inactive O 
p-methoxy B-SYSTEMATIC 
analog O 
( O 
4d O 
) O 
had O 
the O 
lowest O 
Gu O 
value O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
highest O 
molecular O 
mass O 
compound O 
( O 
4f O 
) O 
was O 
shown O 
to O 
be O 
the O 
most O 
potent O 
cytotoxic O 
against O 
HepG2 O 
cells O 
. O 
The O 
studies O 
disclose O 
that O 
tetrahydroisoquinolines B-FAMILY 
4f O 
and O 
4k O 
are O 
potentially O 
interesting O 
lead O 
pharmacophores O 
that O 
should O 
be O 
further O 
explored O 
. O 
The O 
QSAR O 
models O 
provided O 
insights O 
into O 
the O 
physicochemical O 
properties O 
of O 
the O 
investigated O 
compounds O 
. O 

stroke O 
functional O 
outcomes O 
are O 
independently O 
associated O 
with O 
C-reactive O 
protein O 
concentrations O 
and O 
cognitive O 
outcomes O 
with O 
triiodothyronine B-TRIVIAL 
concentrations O 
: O 
a O 
pilot O 
study O 
. O 

concentrations O 
of O 
C-reactive O 
protein O 
( O 
CRP O 
) O 
and O 
decreased O 
concentrations O 
of O 
triiodothyronine B-TRIVIAL 
( O 
T3 O 
) O 
were O 
shown O 
to O 
predict O 
poor O 
outcomes O 
in O 
patients O 
with O 
stroke O 
. O 
However O 
, O 
the O 
prognostic O 
value O 
of O 
CRP O 
and O 
T3 O 
has O 
not O 
been O 
studied O 
simultaneously O 
in O 
relation O 
to O 
stroke O 
functional O 
and O 
cognitive O 
outcomes O 
despite O 
of O 
close O 
interaction O 
between O 
inflammatory O 
markers O 
and O 
thyroid O 
function O 
. O 
We O 
evaluated O 
the O 
association O 
of O 
thyroid O 
hormone O 
and O 
CRP O 
concentrations O 
with O 
immediate O 
outcomes O 
after O 
ischemic O 
stroke O 
. O 
Eighty O 
- O 
eight O 
ischemic O 
stroke O 
patients O 
on O 
admission O 
to O 
the O 
stroke O 
unit O 
were O 
evaluated O 
for O 
clinical O 
stroke O 
severity O 
( O 
Scandinavian O 
stroke O 
scale O 
or O 
SSS O 
) O 
and O 
concentrations O 
of O 
thyroid O 
- O 
stimulating O 
hormone O 
, O 
free O 
thyroxin B-TRIVIAL 
, O 
free O 
T3 O 
, O 
and O 
CRP O 
. O 
Functional O 
outcome O 
( O 
modified O 
Rankin O 
scale O 
) O 
and O 
cognitive O 
outcome O 
( O 
Mini O 
mental O 
state O 
examination O 
) O 
were O 
evaluated O 
at O 
discharge O 
. O 
Greater O 
ln O 
CRP O 
concentrations O 
( O 
r O 
= O 
-0.35 O 
, O 
p O 
= O 
0.001 O 
) O 
, O 
but O 
not O 
thyroid O 
hormone O 
concentrations O 
, O 
correlated O 
with O 
score O 
on O 
the O 
SSS O 
. O 
In O 
univariate O 
analyses O 
lower O 
free O 
T3 O 
concentrations O 
and O 
higher O 
CRP O 
concentrations O 
were O 
associated O 
with O 
poor O 
functional O 
and O 
poor O 
cognitive O 
outcomes O 
. O 
After O 
adjustment O 
for O 
clinical O 
stroke O 
severity O 
, O 
higher O 
CRP O 
concentrations O 
( O 
β O 
= O 
0.18 O 
, O 
p O 
= O 
0.04 O 
) O 
remained O 
associated O 
with O 
worse O 
functional O 
outcome O 
and O 
lower O 
free O 
T3 O 
concentrations O 
with O 
worse O 
cognitive O 
outcome O 
( O 
β O 
= O 
0.23 O 
, O 
p O 
= O 
0.03 O 
) O 
. O 
In O 
sum O 
, O 
clinical O 
stroke O 
severity O 
is O 
associated O 
with O 
elevated O 
CRP O 
concentration O 
. O 
Higher O 
CRP O 
concentration O 
is O 
independently O 
associated O 
with O 
worse O 
functional O 
outcomes O 
and O 
lower O 
free O 
T3 O 
concentration O 
with O 
worse O 
cognitive O 
outcomes O 
at O 
discharge O 
. O 
T3 O 
and O 
CRP O 
can O 
be O 
important O 
biomarkers O 
in O 
patients O 
with O 
acute O 
ischemic O 
stroke O 
. O 

Growth O 
of O 
TiO2 B-FORMULA 
Nanorod O 
Arrays O 
and O 
In O 
Situ O 
Conversion O 
to O 
Nanotube O 
Arrays O 
for O 
Highly O 
Efficient O 
Quantum O 
Dot-Sensitized O 
Solar O 
Cells O 
. O 

nanorod O 
( O 
NR O 
) O 
and O 
nanotube O 
( O 
NT O 
) O 
arrays O 
grown O 
on O 
transparent O 
conductive O 
substrates O 
are O 
attractive O 
electrode O 
for O 
solar O 
cells O 
. O 
In O 
this O 
paper O 
, O 
TiO2 B-FORMULA 
NR O 
arrays O 
are O 
hydrothermally O 
grown O 
on O 
FTO B-ABBREVIATION 
substrate O 
, O 
and O 
are O 
in O 
situ O 
converted O 
into O 
NT O 
arrays O 
by O 
hydrothermally O 
etching O 
. O 
The O 
TiO2 B-FORMULA 
NR O 
arrays O 
are O 
reported O 
as O 
single O 
crystalline O 
, O 
but O 
the O 
TiO2 B-FORMULA 
NR O 
arrays O 
are O 
demonstrated O 
to O 
be O 
polycrystalline O 
with O 
a O 
bundle O 
of O 
2-5 O 
nm O 
single O 
crystalline O 
nanocolumns O 
grown O 
along O 
[ O 
1 O 
] O 
throughout O 
the O 
whole O 
NR O 
from O 
bottom O 
to O 
top O 
. O 
TiO2 B-FORMULA 
NRs O 
can O 
be O 
converted O 
to O 
NTs O 
by O 
hydrothermal O 
selective O 
etching O 
of O 
the O 
( O 
1 O 
) O 
core O 
and O 
remaining O 
the O 
inert O 
sidewall O 
of O 
( O 
110 O 
) O 
face O 
. O 
A O 
growth O 
mechanism O 
of O 
the O 
NR O 
and O 
NT O 
arrays O 
is O 
proposed O 
. O 
Quantum O 
dot O 
- O 
sensitized O 
solar O 
cells O 
( O 
QDSCs O 
) O 
are O 
fabricated O 
by O 
coating O 
CdSe B-FORMULA 
QDs O 
on O 
to O 
the O 
TiO2 B-FORMULA 
arrays O 
. O 
After O 
conversion O 
from O 
NRs O 
to O 
NTs O 
, O 
more O 
QDs O 
can O 
be O 
filled O 
in O 
the O 
NTs O 
and O 
the O 
energy O 
conversion O 
efficiency O 
of O 
the O 
QDSCs O 
almost O 
double O 
. O 

Statins B-FAMILY 
: O 
Lipid O 
Management O 
to O 
Reduce O 
Cardiovascular O 
Risk O 
. O 

discovery O 
that O 
elevated O 
total O 
cholesterol B-TRIVIAL 
levels O 
and O 
the O 
subsequent O 
understanding O 
that O 
low O 
- O 
density O 
lipoprotein O 
cholesterol B-TRIVIAL 
levels O 
are O 
associated O 
with O 
higher O 
risk O 
for O 
cardiovascular O 
disease O 
( O 
CVD O 
) O 
has O 
led O 
to O 
the O 
development O 
of O 
lipid O 
management O 
strategies O 
that O 
seek O 
to O 
reduce O 
the O 
burden O 
of O 
CVD O 
. O 
Although O 
substantive O 
progress O 
has O 
been O 
made O 
in O 
reducing O 
death O 
and O 
cardiovascular O 
events O 
, O 
questions O 
remain O 
regarding O 
the O 
optimal O 
approach O 
to O 
further O 
reduce O 
CVD-associated O 
death O 
and O 
disability O 
. O 
Based O 
on O 
current O 
evidence O 
, O 
statins B-FAMILY 
are O 
the O 
clear O 
first O 
- O 
line O 
agents O 
for O 
the O 
management O 
of O 
hyperlipidemia O 
in O 
patients O 
at O 
high O 
risk O 
for O 
cardiovascular O 
events O 
. O 
However O 
, O 
due O 
to O 
the O 
failure O 
of O 
recent O 
clinical O 
trials O 
evaluating O 
antihyperlipidemic O 
drugs O 
, O 
the O 
most O 
appropriate O 
lipid O 
management O 
strategy O 
in O 
patients O 
who O 
cannot O 
tolerate O 
statin O 
therapy O 
or O 
who O 
warrant O 
antihyperlipidemic O 
therapies O 
in O 
addition O 
to O 
statins O 
is O 
a O 
major O 
therapeutic O 
controversy O 
. O 
In O 
this O 
review O 
, O 
we O 
summarize O 
the O 
clinical O 
trial O 
evidence O 
evaluating O 
the O 
efficacy O 
of O 
second O 
- O 
line O 
antihyperlipidemic O 
drug O 
classes O 
for O 
reducing O 
cardiovascular O 
risk O 
, O 
provide O 
recommendations O 
for O 
appropriate O 
use O 
of O 
nonstatin O 
lipid O 
- O 
altering O 
drugs O 
, O 
and O 
identify O 
key O 
areas O 
of O 
future O 
research O 
to O 
support O 
evidence O 
- O 
based O 
lipid O 
management O 
. O 
Given O 
the O 
complexity O 
, O 
magnitude O 
, O 
and O 
burden O 
of O 
CVD O 
, O 
opportunities O 
to O 
improve O 
processes O 
of O 
care O 
and O 
identify O 
new O 
therapeutic O 
options O 
clearly O 
exist O 
. O 

Surface-Enhanced O 
Raman O 
Scattering O 
Sensors O 
Based O 
on O 
Nanopillar O 
Forests O 
Realized O 
by O 
an O 
Oxygen B-SYSTEMATIC 
-Plasma-Stripping-of-Photoresist O 
Technique O 
. O 

novel O 
surface O 
- O 
enhanced O 
Raman O 
scattering O 
( O 
SERS O 
) O 
sensor O 
is O 
developed O 
for O 
real O 
- O 
time O 
and O 
highly O 
repeatable O 
detection O 
of O 
trace O 
chemical O 
and O 
biological O 
indicators O 
. O 
The O 
sensor O 
consists O 
of O 
a O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
microchannel O 
cap O 
and O 
a O 
nanopillar O 
forest O 
- O 
based O 
open O 
SERS-active O 
substrate O 
. O 
The O 
nanopillar O 
forests O 
are O 
fabricated O 
based O 
on O 
a O 
new O 
oxygen B-SYSTEMATIC 
-plasma O 
- O 
stripping O 
- O 
of O 
- O 
photoresist O 
technique O 
. O 
The O 
enhancement O 
factor O 
( O 
EF O 
) O 
of O 
the O 
SERS-active O 
substrate O 
reaches O 
6.06 O 
× O 
10(6) O 
, O 
and O 
the O 
EF O 
of O 
the O 
SERS O 
sensor O 
is O 
about O 
4 O 
times O 
lower O 
due O 
to O 
the O 
influence O 
of O 
the O 
PDMS O 
cap O 
. O 
However O 
, O 
the O 
sensor O 
shows O 
much O 
higher O 
measurement O 
repeatability O 
than O 
the O 
open O 
substrate O 
, O 
and O 
it O 
reduces O 
the O 
sample O 
preparation O 
time O 
from O 
several O 
hours O 
to O 
a O 
few O 
minutes O 
, O 
which O 
makes O 
the O 
device O 
more O 
reliable O 
and O 
facile O 
for O 
trace O 
chemical O 
and O 
biological O 
analysis O 
. O 

the O 
use O 
of O 
dabigatran B-TRIVIAL 
and O 
rivaroxaban B-TRIVIAL 
are O 
increasing O 
, O 
data O 
on O 
the O 
reversal O 
of O 
their O 
effects O 
are O 
limited O 
. O 
The O 
lack O 
of O 
reliable O 
monitoring O 
methods O 
and O 
specific O 
reversal O 
agents O 
renders O 
treatment O 
strategies O 
empirical O 
, O 
and O 
as O 
a O 
result O 
, O 
treatment O 
consists O 
mainly O 
of O 
supportive O 
measures O 
. O 
Therefore O 
, O 
we O 
performed O 
a O 
systematic O 
search O 
of O 
the O 
PubMed O 
database O 
to O 
find O 
studies O 
and O 
reviews O 
pertaining O 
to O 
oral O 
anticoagulation O 
reversal O 
strategies O 
. O 
This O 
review O 
discusses O 
current O 
anticoagulation O 
reversal O 
recommendations O 
for O 
the O 
oral O 
anticoagulants O 
warfarin B-TRIVIAL 
, O 
dabigatran B-TRIVIAL 
, O 
and O 
rivaroxaban B-TRIVIAL 
for O 
patients O 
at O 
a O 
heightened O 
risk O 
of O 
bleeding O 
, O 
actively O 
bleeding O 
, O 
or O 
those O 
in O 
need O 
of O 
preprocedural O 
anticoagulation O 
reversal O 
. O 
We O 
highlight O 
the O 
literature O 
that O 
shaped O 
these O 
recommendations O 
and O 
provide O 
directions O 
for O 
future O 
research O 
to O 
address O 
knowledge O 
gaps O 
. O 
Although O 
reliable O 
recommendations O 
are O 
available O 
for O 
anticoagulation O 
reversal O 
in O 
patients O 
treated O 
with O 
warfarin B-TRIVIAL 
, O 
guidance O 
on O 
the O 
reversal O 
of O 
dabigatran B-TRIVIAL 
and O 
rivaroxaban B-TRIVIAL 
is O 
varied O 
and O 
equivocal O 
. O 
Given O 
the O 
increasing O 
use O 
of O 
the O 
newer O 
agents O 
, O 
focused O 
research O 
is O 
needed O 
to O 
identify O 
effective O 
reversal O 
strategies O 
and O 
develop O 
and O 
implement O 
an O 
accurate O 
method O 
( O 
assay O 
) O 
to O 
guide O 
reversal O 
of O 
the O 
newer O 
agents O 
. O 
Determining O 
patient-specific O 
factors O 
that O 
influence O 
the O 
effectiveness O 
of O 
reversal O 
treatments O 
and O 
comparing O 
the O 
effectiveness O 
of O 
various O 
treatment O 
strategies O 
are O 
pertinent O 
areas O 
for O 
future O 
anticoagulation O 
reversal O 
research O 
. O 

triblock O 
copolymers O 
with O 
carbonyl B-FAMILY 
groups O 
located O 
either O 
in O 
the O 
middle O 
segment O 
or O 
in O 
the O 
third O 
side O 
block O 
are O 
synthesized O 
by O 
adjusting O 
feeding O 
sequence O 
of O 
the O 
comonomers O 
. O 
The O 
conjugation O 
of O 
hemoglobin O 
( O 
Hb O 
) O 
on O 
the O 
copolymer O 
micelles O 
is O 
realized O 
by O 
condensation O 
reactions O 
of O 
carbonyl B-FAMILY 
with O 
the O 
amino B-FAMILY 
groups O 
of O 
Hb O 
, O 
and O 
the O 
gas O 
- O 
binding O 
capacity O 
of O 
Hb O 
is O 
well O 
preserved O 
. O 
Interestingly O 
, O 
the O 
reassembly O 
behavior O 
of O 
Hb-conjugated O 
micelles O 
( O 
HbM O 
) O 
is O 
explored O 
by O 
adjusting O 
the O 
pH O 
. O 
As O 
for O 
triblock O 
copolymers O 
with O 
a O 
carbonyl B-FAMILY 
-functionalized O 
segment O 
as O 
the O 
third O 
block O 
, O 
Hb O 
is O 
rearranged O 
into O 
the O 
inner O 
core O 
of O 
micelles O 
when O 
the O 
pH O 
is O 
adjusted O 
close O 
to O 
the O 
isoelectric O 
point O 
of O 
Hb O 
. O 
Therefore O 
, O 
it O 
may O 
provide O 
a O 
new O 
needed O 
route O 
for O 
fabrication O 
of O 
protein O 
carriers O 
, O 
which O 
is O 
different O 
from O 
the O 
traditional O 
encapsulation O 
technique O 
. O 

and O 
Anti-herpetic O 
Activity O 
of O 
Phosphoramidate B-SYSTEMATIC 
ProTides O 
. O 

the O 
many O 
prodrug O 
approaches O 
aimed O 
at O 
delivering O 
nucleoside B-FAMILY 
monophosphates I-FAMILY 
into O 
cells O 
, O 
the O 
phosphoramidate B-SYSTEMATIC 
ProTide O 
approach O 
is O 
one O 
that O 
has O 
shown O 
success O 
, O 
which O 
has O 
made O 
it O 
possible O 
for O 
some O 
of O 
the O 
phosphoramidates B-FAMILY 
to O 
enter O 
into O 
clinical O 
trials O 
. O 
Herein O 
, O 
we O 
report O 
the O 
synthesis O 
and O 
antiviral O 
activity O 
of O 
a O 
series O 
of O 
phosphoramidate B-SYSTEMATIC 
ProTides O 
designed O 
to O 
bypass O 
the O 
thymidine B-TRIVIAL 
kinase O 
( O 
TK O 
) O 
dependence O 
of O 
the O 
parent O 
nucleoside B-FAMILY 
analogues O 
. O 
Phosphoramidate B-SYSTEMATIC 
derivatives O 
of O 
(E)-5-(2-bromovinyl)-2'-deoxyuridine B-SYSTEMATIC 
( O 
BVDU B-ABBREVIATION 
) O 
that O 
contain O 
L-alanine B-TRIVIAL 
or O 
pivaloyloxymethyl B-SYSTEMATIC 
iminodiacetate I-SYSTEMATIC 
( O 
IDA-POM B-ABBREVIATION 
) O 
exhibit O 
anti-HSV-1 O 
and O 
anti-VZV O 
activity O 
in O 
cell O 
cultures O 
, O 
but O 
they O 
largely O 
lost O 
antiviral O 
potency O 
against O 
TK-deficient O 
virus O 
strains O 
. O 
Among O 
deazapurine O 
nucleosides B-FAMILY 
and O 
their O 
phosphoramidate B-SYSTEMATIC 
derivatives O 
, O 
the O 
7-deazaadenine O 
containing O 
nucleosides B-FAMILY 
and O 
their O 
phosphoramidate B-FAMILY 
triester I-FAMILY 
derivatives O 
showed O 
weak O 
antiviral O 
activity O 
against O 
VZV O 
. O 
Apparently O 
, O 
intracellular O 
nucleotide B-FAMILY 
delivery O 
with O 
these O 
phosphoramidates B-FAMILY 
is O 
partly O 
successful O 
. O 
However O 
, O 
none O 
of O 
the O 
compound O 
prodrugs O 
showed O 
superior O 
activity O 
to O 
their O 
parent O 
drugs O 
. O 

Insights O 
into O 
Pyralomicin B-TRIVIAL 
Biosynthesis O 
in O 
Nonomuraea O 
spiralis O 
IMC O 
A-0156 O 
. O 

biosynthetic O 
gene O 
cluster O 
for O 
the O 
pyralomicin B-TRIVIAL 
antibiotics O 
has O 
been O 
cloned O 
and O 
sequenced O 
from O 
Nonomuraea O 
spiralis O 
IMC O 
A-0156 O 
. O 
The O 
41 O 
kb O 
gene O 
cluster O 
contains O 
27 O 
ORFs O 
predicted O 
to O 
encode O 
all O 
of O 
the O 
functions O 
for O 
pyralomicin B-TRIVIAL 
biosynthesis O 
. O 
This O 
includes O 
nonribosomal O 
peptide O 
synthetases O 
( O 
NRPS O 
) O 
and O 
polyketide O 
synthases O 
( O 
PKS O 
) O 
required O 
for O 
the O 
formation O 
of O 
the O 
benzopyranopyrrole B-FAMILY 
core O 
unit O 
, O 
as O 
well O 
as O 
a O 
suite O 
of O 
tailoring O 
enzymes O 
( O 
e.g O 
. O 
, O 
four O 
halogenases O 
, O 
an O 
O B-FORMULA 
-methyltransferase O 
, O 
and O 
an O 
N B-FORMULA 
-glycosyltransferase O 
) O 
necessary O 
for O 
further O 
modifications O 
of O 
the O 
core O 
structure O 
. O 
The O 
N B-FORMULA 
-glycosyltransferase O 
is O 
predicted O 
to O 
transfer O 
either O 
glucose B-TRIVIAL 
or O 
a O 
pseudosugar O 
( O 
cyclitol B-FAMILY 
) O 
to O 
the O 
aglycone O 
. O 
A O 
gene O 
cassette O 
encoding O 
C7 B-FORMULA 
- O 
cyclitol B-FAMILY 
biosynthetic O 
enzymes O 
was O 
identified O 
upstream O 
of O 
the O 
benzopyranopyrrole B-FAMILY 
-specific O 
ORFs O 
. O 
Targeted O 
disruption O 
of O 
the O 
gene O 
encoding O 
the O 
N B-FORMULA 
-glycosyltransferase O 
, O 
prlH O 
, O 
abolished O 
pyralomicin B-TRIVIAL 
production O 
, O 
and O 
recombinant O 
expression O 
of O 
PrlA O 
confirms O 
the O 
activity O 
of O 
this O 
enzyme O 
as O 
a O 
sugar B-FAMILY 
phosphate B-SYSTEMATIC 
cyclase O 
involved O 
in O 
the O 
formation O 
of O 
the O 
C7 B-FORMULA 
- O 
cyclitol B-FAMILY 
moiety O 
. O 

Vortex O 
- O 
Assisted O 
Self-Assembly O 
of O 
Carbon B-SYSTEMATIC 
Nanoparticles O 
on O 
Air-Water O 
Interface O 
. O 

this O 
work O 
a O 
new O 
self O 
- O 
assembly O 
technique O 
is O 
presented O 
, O 
allowing O 
the O 
fast O 
formation O 
of O 
carbon B-TRIVIAL 
black I-TRIVIAL 
thin O 
films O 
. O 
It O 
consists O 
in O 
the O 
controlled O 
addition O 
of O 
a O 
stable O 
carbon B-SYSTEMATIC 
material's O 
dispersion O 
over O 
the O 
water O 
surface O 
, O 
disturbed O 
by O 
a O 
vortex O 
. O 
The O 
vortex O 
, O 
although O 
not O 
essential O 
for O 
the O 
film O 
formation O 
, O 
was O 
found O 
to O 
drastically O 
improve O 
film O 
homogeneity O 
. O 
A O 
physical O 
chemical O 
study O 
concerning O 
how O 
several O 
parameters O 
could O 
be O 
used O 
to O 
tune O 
film O 
properties O 
was O 
also O 
conducted O 
. O 
The O 
self O 
- O 
assembled O 
films O 
, O 
which O 
can O 
be O 
picked O 
up O 
in O 
any O 
hydrophilic O 
substrate O 
, O 
showed O 
a O 
good O 
electrical O 
conductivity O 
and O 
a O 
high O 
optical O 
transparency O 
. O 
As O 
an O 
application O 
example O 
, O 
films O 
about O 
200 O 
nm O 
thick O 
were O 
employed O 
as O 
supercapacitor O 
electrodes O 
. O 

dienes B-FAMILY 
as O 
" O 
ligands O 
" O 
for O 
borane B-SYSTEMATIC 
-catalyzed O 
metal O 
- O 
free O 
asymmetric O 
hydrogenation O 
of O 
imines B-FAMILY 
. O 

paper O 
describes O 
a O 
highly O 
enantioselective O 
metal O 
- O 
free O 
hydrogenation O 
of O 
imines B-FAMILY 
using O 
chiral O 
dienes B-FAMILY 
as O 
" O 
ligands O 
" O 
for O 
the O 
generation O 
of O 
catalysts O 
with O 
HB(C6F5)2 B-FORMULA 
by O 
hydroboration O 
in O 
situ O 
to O 
furnish O 
a O 
variety O 
of O 
chiral O 
amines B-FAMILY 
with O 
up O 
to O 
89% O 
ee O 
, O 
which O 
provides O 
a O 
practical O 
strategy O 
for O 
the O 
development O 
of O 
novel O 
chiral O 
frustrated O 
Lewis O 
pairs O 
for O 
asymmetric O 
hydrogenation O 
. O 

amphiphilic O 
block O 
copolymers O 
self O 
- O 
assemble O 
into O 
micelles O 
above O 
their O 
lower O 
critical O 
solution O 
temperature O 
in O 
water O 
, O 
however O 
the O 
micelles O 
generally O 
display O 
mediocre O 
physical O 
stability O 
. O 
To O 
stabilize O 
such O 
micelles O 
and O 
increase O 
their O 
loading O 
capacity O 
for O 
chemotherapeutic O 
drugs O 
, O 
block O 
copolymers O 
with O 
novel O 
aromatic O 
monomers O 
were O 
synthesized O 
by O 
free O 
radical O 
polymerization O 
of O 
N-(2-benzoyloxypropyl B-SYSTEMATIC 
methacrylamide I-SYSTEMATIC 
( O 
HPMAm-Bz O 
) O 
or O 
the O 
corresponding O 
naphthoyl B-SYSTEMATIC 
analogue O 
( O 
HPMAm-Nt O 
) O 
, O 
with O 
N-(2-hydroxypropyl) B-SYSTEMATIC 
methacrylamide I-SYSTEMATIC 
monolactate I-SYSTEMATIC 
, O 
using O 
a O 
polyethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
based O 
macroinitiator O 
. O 
The O 
critical O 
micelle O 
temperatures O 
and O 
critical O 
micelle O 
concentrations O 
decreased O 
with O 
increasing O 
the O 
HPMAm-Bz O 
/ O 
Nt O 
content O 
. O 
The O 
micelles O 
of O 
30 O 
to O 
50 O 
nm O 
were O 
prepared O 
by O 
heating O 
the O 
polymer O 
aqueous O 
solutions O 
from O 
0 O 
to O 
50 O 
oC O 
and O 
were O 
colloidally O 
stable O 
for O 
at O 
least O 
48 O 
h O 
at O 
pH O 
7.4 O 
and O 
37 O 
oC O 
. O 
Paclitaxel B-TRIVIAL 
and O 
docetaxel B-TRIVIAL 
encapsulation O 
was O 
performed O 
by O 
mixing O 
drug O 
solutions O 
in O 
ethanol B-SYSTEMATIC 
with O 
polymer O 
aqueous O 
solutions O 
and O 
heating O 
from O 
0 O 
to O 
50 O 
oC O 
. O 
The O 
micelles O 
had O 
a O 
drug O 
loading O 
capacity O 
up O 
to O 
34 O 
weight O 
% O 
for O 
docetaxel B-TRIVIAL 
, O 
which O 
is O 
amongst O 
the O 
highest O 
loadings O 
reported O 
for O 
polymeric O 
micelles O 
, O 
with O 
loaded O 
micelle O 
sizes O 
ranging O 
from O 
60 O 
to O 
80 O 
nm O 
. O 
The O 
micelles O 
without O 
aromatic O 
groups O 
almost O 
completely O 
released O 
loaded O 
paclitaxel B-TRIVIAL 
in O 
10 O 
days O 
, O 
whereas O 
the O 
HPMAm-Bz O 
/ O 
Nt O 
containing O 
micelles O 
released O 
50% O 
of O 
the O 
paclitaxel B-TRIVIAL 
at O 
the O 
same O 
time O 
, O 
which O 
showed O 
a O 
better O 
retention O 
for O 
the O 
drug O 
of O 
the O 
latter O 
micelles O 
. O 
1H B-FORMULA 
solid O 
- O 
state O 
NMR O 
spectroscopy O 
data O 
are O 
compatible O 
with O 
π-π O 
stacking O 
between O 
aromatic O 
groups O 
. O 
The O 
empty O 
micelles O 
demonstrated O 
good O 
cytocompatibility O 
, O 
and O 
paclitaxel B-TRIVIAL 
loaded O 
micelles O 
showed O 
high O 
cytotoxicity O 
to O 
tumor O 
cells O 
. O 
In O 
conclusion O 
, O 
the O 
π-π O 
stacking O 
effect O 
introduced O 
by O 
aromatic O 
groups O 
increases O 
the O 
stability O 
and O 
loading O 
capacity O 
of O 
polymeric O 
micelles O 
. O 

of O 
relative O 
bond O 
dissociation O 
enthalpies O 
and O 
their O 
use O 
to O 
efficiently O 
compute O 
accurate O 
absolute O 
bond O 
dissociation O 
enthalpies O 
for O 
C-h B-FORMULA 
, O 
C-C B-FORMULA 
, O 
and O 
C-f B-FORMULA 
bonds O 
. O 

driver O 
mutations O 
frequently O 
occur O 
in O 
lung O 
cancer O 
and O 
play O 
role O 
in O 
carcinogenesis O 
. O 
These O 
mutations O 
are O 
usually O 
associated O 
with O 
distinct O 
clinical O 
and O 
histological O 
features O 
and O 
are O 
attractive O 
targets O 
for O 
anticancer O 
therapy O 
. O 
Recently O 
, O 
several O 
molecularly O 
distinct O 
phenotypes O 
of O 
NSCLC O 
based O 
on O 
specific O 
and O 
mutually O 
exclusive O 
genetic O 
derangements O 
have O 
been O 
described O 
. O 
Few O 
targets O 
like O 
epidermal O 
growth O 
factor O 
receptor O 
( O 
EGFR O 
) O 
mutations O 
and O 
anaplastic O 
lymphoma O 
kinase O 
( O 
ALK O 
) O 
gene O 
rearrangements O 
have O 
successfully O 
been O 
targeted O 
with O 
EGFR O 
tyrosine O 
kinase O 
inhibitors O 
( O 
TKIs O 
) O 
and O 
crizotinib B-TRIVIAL 
, O 
respectively O 
. O 
Many O 
more O 
inhibitors O 
of O 
specific O 
driver O 
mutations O 
involving O 
genes O 
like O 
ROS O 
, O 
c-MET O 
, O 
FGFR O 
, O 
mTOR O 
, O 
IGFR O 
and O 
RET O 
are O 
currently O 
under O 
development O 
. O 
However O 
, O 
efforts O 
to O 
target O 
some O 
mutated O 
genes O 
like O 
K-RAS O 
have O 
been O 
unsuccessful O 
. O 
Moreover O 
, O 
the O 
emerging O 
challenge O 
of O 
acquired O 
resistance O 
to O 
initially O 
effective O 
therapy O 
is O 
becoming O 
another O 
major O 
concern O 
. O 
In O 
this O 
review O 
recent O 
data O 
on O 
novel O 
molecular O 
targets O 
and O 
their O 
future O 
prospects O 
are O 
discussed O 
. O 

effect O 
of O 
mitragynine B-TRIVIAL 
on O 
cAMP B-ABBREVIATION 
formation O 
and O 
mRNA O 
expression O 
of O 
mu-opioid O 
receptors O 
mediated O 
by O 
chronic O 
morphine O 
treatment O 
in O 
SK-N-SH O 
neuroblastoma O 
cell O 
. O 

RELEVANCE O 
: O 
Mitragynine B-TRIVIAL 
is O 
an O 
indole B-FAMILY 
alkaloid I-FAMILY 
compound O 
of O 
Mitragyna O 
speciosa O 
( O 
M O 
. O 
speciosa O 
) O 
Korth O 
. O 
( O 
Rubiaceae O 
) O 
. O 
This O 
plant O 
is O 
native O 
to O 
the O 
southern O 
regions O 
of O 
Thailand O 
and O 
northern O 
regions O 
of O 
Malaysia O 
and O 
is O 
frequently O 
used O 
to O 
manage O 
the O 
withdrawal O 
symptoms O 
in O 
both O 
countries O 
. O 
AIM O 
OF O 
STUDY O 
: O 
To O 
investigate O 
the O 
effect O 
of O 
mitragynine B-TRIVIAL 
after O 
chronic O 
morphine B-TRIVIAL 
treatment O 
on O 
cyclic B-TRIVIAL 
AMP I-TRIVIAL 
( O 
cAMP B-ABBREVIATION 
) O 
level O 
and O 
mRNA O 
expression O 
of O 
mu-opioid O 
receptor O 
( O 
MOR O 
) O 
in O 
human O 
neuroblastoma O 
SK-N-SH O 
cell O 
. O 
METHOD O 
AND O 
MATERIALS O 
: O 
Mitragynine B-TRIVIAL 
was O 
isolated O 
from O 
the O 
Mitragyna O 
speciosa O 
plant O 
using O 
the O 
acid O 
- O 
base O 
extraction O 
method O 
. O 
The O 
cAMP B-ABBREVIATION 
level O 
upon O 
forskolin B-TRIVIAL 
stimulation O 
in O 
the O 
cells O 
was O 
determined O 
using O 
the O 
Calbiochem(®) O 
Direct O 
Immunoassay O 
Kit O 
. O 
The O 
mRNA O 
expression O 
of O 
the O 
MOR O 
was O 
carried O 
out O 
using O 
quantitative O 
RT-PCR O 
. O 
RESULT O 
: O 
Cotreatment O 
and O 
pretreatment O 
of O 
morphine B-TRIVIAL 
and O 
mitragynine B-TRIVIAL 
significantly O 
reduced O 
the O 
production O 
of O 
cAMP B-ABBREVIATION 
level O 
at O 
a O 
lower O 
concentration O 
of O 
nitrogen B-SYSTEMATIC 
while O 
the O 
higher O 
concentration O 
of O 
this O 
compound O 
could O 
lead O 
to O 
the O 
development O 
of O 
tolerance O 
and O 
dependence O 
as O 
shown O 
by O 
the O 
increase O 
of O 
the O 
cAMP B-ABBREVIATION 
level O 
production O 
in O 
foskolin B-TRIVIAL 
stimulation O 
. O 
In O 
MOR O 
mRNA O 
expression O 
study O 
, O 
cotreatment O 
of O 
morphine B-TRIVIAL 
with O 
mitragynine B-TRIVIAL 
significantly O 
reduced O 
the O 
down O 
- O 
regulation O 
of O 
MOR O 
mRNA O 
expression O 
as O 
compared O 
to O 
morphine B-TRIVIAL 
treatment O 
only O 
. O 
CONCLUSION O 
: O 
These O 
finding O 
suggest O 
that O 
mitragynine B-TRIVIAL 
could O 
possibly O 
avoid O 
the O 
tolerance O 
and O 
dependence O 
on O 
chronic O 
morphine B-TRIVIAL 
treatment O 
by O 
reducing O 
the O 
up O 
- O 
regulation O 
of O 
cAMP B-ABBREVIATION 
level O 
as O 
well O 
as O 
reducing O 
the O 
down O 
- O 
regulation O 
of O 
MOR O 
at O 
a O 
lower O 
concentration O 
of O 
mitragynine B-TRIVIAL 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
and O 
modify O 
commercial O 
dry O 
powder O 
inhalers O 
( O 
DPIs O 
) O 
for O 
the O 
aerosolization O 
of O 
a O 
submicrometer O 
excipient O 
enhanced O 
growth O 
( O 
EEG O 
) O 
formulation O 
. O 
The O 
optimized O 
device O 
and O 
formulation O 
was O 
then O 
tested O 
in O 
a O 
realistic O 
in O 
vitro O 
mouth O 
- O 
throat O 
- O 
tracheobronchial O 
( O 
MT-TB O 
) O 
model O 
. O 
An O 
optimized O 
EEG O 
submicrometer O 
powder O 
formulation O 
, O 
consisting O 
of O 
albuterol B-SYSTEMATIC 
sulfate I-SYSTEMATIC 
( O 
drug O 
) O 
, O 
mannitol B-TRIVIAL 
( O 
hygroscopic O 
excipient O 
) O 
, O 
l-leucine B-TRIVIAL 
( O 
dispersion O 
enhancer O 
) O 
and O 
poloxamer B-TRIVIAL 
188 I-TRIVIAL 
( O 
surfactant O 
) O 
in O 
a O 
ratio O 
of O 
30 O 
: O 
48 O 
: O 
20 O 
: O 
2 O 
was O 
prepared O 
using O 
a O 
Büchi O 
Nano O 
spray O 
dryer O 
. O 
The O 
aerosolization O 
performance O 
of O 
the O 
EEG O 
formulation O 
was O 
evaluated O 
with O 
five O 
conventional O 
DPIs O 
: O 
Aerolizer O 
, O 
Novolizer O 
, O 
HandiHaler O 
, O 
Exubera O 
and O 
Spiros O 
. O 
To O 
improve O 
powder O 
dispersion O 
, O 
the O 
HandiHaler O 
was O 
modified O 
with O 
novel O 
mouth O 
piece O 
( O 
MP O 
) O 
designs O 
. O 
The O 
aerosol O 
performance O 
of O 
each O 
device O 
was O 
assessed O 
using O 
a O 
next O 
generation O 
impactor O 
( O 
NGI O 
) O 
at O 
airflow O 
rates O 
generating O 
a O 
pressure O 
drop O 
of O 
4kPa O 
across O 
the O 
DPI O 
. O 
In O 
silico O 
and O 
in O 
vitro O 
deposition O 
and O 
hygroscopic O 
growth O 
of O 
formulations O 
was O 
studied O 
using O 
a O 
MT-TB O 
airway O 
geometry O 
model O 
. O 
Both O 
HandiHaler O 
and O 
Aerolizer O 
produced O 
high O 
emitted O 
doses O 
( O 
EDs O 
) O 
together O 
with O 
a O 
significant O 
submicrometer O 
aerosol O 
fraction O 
. O 
A O 
modified O 
HandiHaler O 
with O 
a O 
MP O 
including O 
a O 
three O 
- O 
dimensional O 
( O 
3D O 
) O 
array O 
of O 
rods O 
( O 
HH-3D O 
) O 
produced O 
a O 
submicrometer O 
particle O 
fraction O 
of O 
38.8% O 
with O 
a O 
conventional O 
fine O 
particle O 
fraction O 
( O 
% O 
< O 
5μm O 
) O 
of O 
97.3% O 
. O 
The O 
mass O 
median O 
diameter O 
( O 
MMD O 
) O 
of O 
the O 
aerosol O 
was O 
reduced O 
below O 
1μm O 
using O 
this O 
HH-3D O 
DPI O 
. O 
The O 
aerosol O 
generated O 
from O 
the O 
modified O 
HandiHaler O 
increased O 
to O 
micrometer O 
size O 
( O 
2.8μm O 
) O 
suitable O 
for O 
pulmonary O 
deposition O 
, O 
when O 
exposed O 
to O 
simulated O 
respiratory O 
conditions O 
, O 
with O 
negligible O 
mouth O 
- O 
throat O 
( O 
MT O 
) O 
deposition O 
( O 
2.6% O 
) O 
. O 

of O 
17α-ethinylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
on O 
reproductive O 
endocrine O 
status O 
in O 
mummichog O 
( O 
Fundulus O 
heteroclitus O 
) O 
under O 
differing O 
salinity O 
and O 
temperature O 
conditions O 
. O 

to O 
17α-ethinylestradiol B-SYSTEMATIC 
( O 
EE2 B-ABBREVIATION 
) O 
, O 
a O 
synthetic O 
estrogen B-FAMILY 
, O 
has O 
previously O 
been O 
shown O 
to O 
decrease O 
reproductive O 
endocrine O 
status O 
and O 
egg O 
production O 
in O 
northern O 
mummichog O 
( O 
Fundulus O 
heteroclitus O 
macrolepidotus O 
) O 
. O 
The O 
objective O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
if O 
variations O 
in O 
salinity O 
or O 
temperature O 
conditions O 
of O 
EE2 B-ABBREVIATION 
-exposed O 
mummichog O 
modify O 
the O 
effect O 
on O 
whole O 
organism O 
reproductive O 
endocrine O 
status O 
and O 
gonadal O 
steroidogenesis O 
. O 
Mummichog O 
were O 
exposed O 
in O 
vivo O 
for O 
14 O 
days O 
to O 
0 O 
, O 
50 O 
and O 
250ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
in O 
0 O 
, O 
16 O 
and O 
32ppt O 
salinity O 
at O 
18°C O 
and O 
to O 
0 O 
and O 
250ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
at O 
10 O 
, O 
18 O 
and O 
26°C O 
at O 
16ppt O 
. O 
There O 
was O 
a O 
little O 
overall O 
effect O 
of O 
salinity O 
on O 
measured O 
endpoints O 
. O 
In O 
the O 
salinity O 
exposure O 
, O 
250ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
-exposed O 
females O 
had O 
significantly O 
reduced O 
17β-estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
levels O 
. O 
Increased O 
temperature O 
triggered O 
gonadal O 
growth O 
in O 
both O 
sexes O 
and O 
increased O 
plasma O 
E2 O 
and O 
E2 O 
production O 
and O 
decreased O 
11-KT B-ABBREVIATION 
( O 
11-ketotestosterone B-SYSTEMATIC 
) O 
production O 
. O 
EE2 B-ABBREVIATION 
counteracted O 
the O 
effect O 
of O 
temperature O 
by O 
depressing O 
gonadal O 
growth O 
in O 
males O 
. O 
In O 
both O 
exposures O 
, O 
EE2 B-ABBREVIATION 
effects O 
on O 
testosterone B-TRIVIAL 
( O 
T O 
) O 
production O 
were O 
variable O 
. O 
The O 
use O 
of O 
steroidogenic O 
precursors O 
( O 
25-OH-cholesterol B-SYSTEMATIC 
, O 
and O 
/ O 
or O 
pregnenolone B-TRIVIAL 
and O 
/ O 
or O 
testosterone B-TRIVIAL 
) O 
in O 
the O 
in O 
vitro O 
gonadal O 
incubations O 
indicated O 
decreased O 
E2 O 
production O 
in O 
females O 
and O 
11-KT B-ABBREVIATION 
production O 
in O 
males O 
were O 
predominately O 
due O 
to O 
suppression O 
of O 
the O 
terminal O 
conversion O 
step O 
between O 
T O 
and O 
E2 O 
or O 
11-KT B-ABBREVIATION 
. O 
Ovarian O 
aromatase O 
A O 
( O 
cyp19a O 
) O 
gene O 
expression O 
at O 
16ppt O 
and O 
18°C O 
was O 
not O 
affected O 
by O 
250ng O 
/ O 
L O 
EE2 B-ABBREVIATION 
( O 
the O 
only O 
treatment O 
combinations O 
tested O 
) O 
. O 
Overall O 
, O 
temperature O 
is O 
a O 
factor O 
regulating O 
northern O 
mummichog O 
reproduction O 
; O 
EE2 B-ABBREVIATION 
overrides O 
its O 
effects O 
and O 
disrupts O 
the O 
terminal O 
step O 
of O 
steroidogenesis O 
. O 
Our O 
results O 
should O 
be O 
considered O 
in O 
designing O 
future O 
estuarine O 
fish O 
bioassays O 
and O 
in O 
understanding O 
effects O 
of O 
estrogenic O 
endocrine O 
disruptors O 
in O 
estuaries O 
. O 

- O 
dimensionally O 
ordered O 
macroporous O 
Cu2O B-FORMULA 
/ O 
Ni B-FORMULA 
inverse O 
opal O 
electrodes O 
for O 
electrochemical O 
supercapacitors O 
. O 

an O 
ordered O 
polystyrene B-SYSTEMATIC 
( O 
PS O 
) O 
template O 
- O 
assisted O 
electrochemical O 
approach O 
we O 
synthesized O 
three O 
- O 
dimensional O 
ordered O 
macroporous O 
( O 
3DOM O 
) O 
Cu2O B-FORMULA 
/ O 
Ni B-FORMULA 
inverse O 
opals O 
as O 
electrodes O 
for O 
supercapacitors O 
. O 
The O 
3DOM O 
Cu2O B-FORMULA 
/ O 
Ni B-FORMULA 
electrodes O 
display O 
superior O 
kinetic O 
performance O 
, O 
and O 
satisfactory O 
rate O 
capability O 
and O 
cycling O 
performance O 
. O 

utmost O 
importance O 
in O 
understanding O 
water O 
ionization O 
process O 
, O 
reliable O 
theoretical O 
results O 
of O 
structural O 
changes O 
and O 
molecular O 
dynamics O 
( O 
MD O 
) O 
of O 
water O 
clusters O 
on O 
ionization O 
have O 
hardly O 
been O 
reported O 
yet O 
. O 
Here O 
, O 
we O 
investigate O 
the O 
water O 
cations O 
[ O 
( B-FAMILY 
H2 I-FAMILY 
O)n I-FAMILY 
= O 
2-6 O 
( O 
+ O 
) O 
] O 
with O 
density O 
functional O 
theory O 
( O 
DFT O 
) O 
, O 
Möller-Plesset O 
second O 
- O 
order O 
perturbation O 
theory O 
( O 
MP2 O 
) O 
, O 
and O 
coupled O 
cluster O 
theory O 
with O 
single O 
, O 
double O 
, O 
and O 
perturbative O 
triple O 
excitations O 
[CCSD(T)] O 
. O 
The O 
complete O 
basis O 
set O 
limits O 
of O 
interaction O 
energies O 
at O 
the O 
CCSD(T) O 
level O 
are O 
reported O 
, O 
and O 
the O 
geometrical O 
structures O 
, O 
electronic O 
properties O 
, O 
and O 
infrared O 
spectra O 
are O 
investigated O 
. O 
The O 
characteristics O 
of O 
structures O 
and O 
spectra O 
of O 
the O 
water O 
cluster O 
cations O 
reflect O 
the O 
formation O 
of O 
the O 
hydronium B-SYSTEMATIC 
cation O 
moiety O 
( O 
H3 B-FORMULA 
O(+) I-FORMULA 
) O 
and O 
the O 
hydroxyl B-SYSTEMATIC 
radical O 
. O 
Although O 
most O 
density O 
functionals O 
fail O 
to O 
predict O 
reasonable O 
energetics O 
of O 
the O 
water O 
cations O 
, O 
some O 
functionals O 
are O 
found O 
to O 
be O 
reliable O 
, O 
in O 
reasonable O 
agreement O 
with O 
high O 
- O 
level O 
ab O 
initio O 
results O 
. O 
To O 
understand O 
the O 
ionization O 
process O 
of O 
water O 
clusters O 
, O 
DFT- O 
and O 
MP2 O 
- O 
based O 
Born-Oppenheimer O 
MD O 
( O 
BOMD O 
) O 
simulations O 
are O 
performed O 
on O 
ionization O 
. O 
On O 
ionization O 
, O 
the O 
water O 
clusters O 
tend O 
to O 
have O 
an O 
Eigen O 
- O 
like O 
form O 
with O 
the O 
hydronium B-SYSTEMATIC 
cation O 
instead O 
of O 
a O 
Zundel O 
- O 
like O 
form O 
, O 
based O 
on O 
reliable O 
BOMD O 
simulations O 
. O 
For O 
the O 
vertically O 
ionized O 
water O 
hexamer O 
, O 
the O 
relatively O 
stable O 
( B-FORMULA 
H2 I-FORMULA 
O)5 I-FORMULA 
( I-FORMULA 
+ I-FORMULA 
) I-FORMULA 
( O 
5sL4A O 
) O 
cluster O 
tends O 
to O 
form O 
with O 
a O 
detached O 
water O 
molecule O 
( O 
H2 B-FORMULA 
O I-FORMULA 
) O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

of O 
the O 
Proton-Coupled O 
Folate B-TRIVIAL 
Transporter O 
( O 
PCFT-SLC46A1 O 
) O 
by O 
Bicarbonate B-SYSTEMATIC 
and O 
Other O 
Anions O 
. O 

proton O 
- O 
coupled O 
folate B-TRIVIAL 
transporter O 
( O 
PCFT O 
) O 
plays O 
a O 
key O 
role O 
in O 
intestinal O 
folate B-TRIVIAL 
absorption O 
and O 
loss O 
- O 
of O 
- O 
function O 
mutations O 
in O 
the O 
gene O 
encoding O 
this O 
transporter O 
are O 
the O 
molecular O 
basis O 
for O 
hereditary O 
folate B-TRIVIAL 
malabsorption O 
. O 
Using O 
a O 
stable O 
transfectant O 
with O 
high O 
expression O 
of O 
PCFT O 
, O 
physiological O 
levels O 
of O 
bicarbonate B-SYSTEMATIC 
produced O 
potent O 
and O 
rapidly O 
reversible O 
inhibition O 
of O 
PCFT O 
- O 
mediated O 
transport O 
at O 
neutral O 
pH O 
. O 
Bisulfite B-SYSTEMATIC 
and O 
nitrite B-SYSTEMATIC 
also O 
inhibited O 
PCFT O 
function O 
at O 
neutral O 
pH O 
, O 
whereas O 
sulfate B-SYSTEMATIC 
, O 
nitrate B-SYSTEMATIC 
and O 
phosphate B-SYSTEMATIC 
had O 
no O 
impact O 
at O 
all O 
. O 
At O 
weakly O 
acidic O 
pH O 
( O 
6.5 O 
) O 
, O 
bisulfite B-SYSTEMATIC 
and O 
nitrite B-SYSTEMATIC 
exhibited O 
much O 
stronger O 
inhibition O 
of O 
PCFT O 
- O 
mediated O 
transport O 
while O 
sulfate B-SYSTEMATIC 
and O 
nitrate B-SYSTEMATIC 
remained O 
non-inhibitory O 
. O 
Inhibition O 
by O 
bisulfite B-SYSTEMATIC 
and O 
nitrite B-SYSTEMATIC 
at O 
pH O 
6.5 O 
was O 
associated O 
with O 
a O 
marked O 
decrease O 
in O 
the O 
influx O 
Vmax O 
and O 
collapse O 
of O 
the O 
transmembrane O 
proton O 
gradient O 
attributed O 
to O 
the O 
diffusion O 
of O 
the O 
protonated O 
forms O 
into O 
these O 
cells O 
. O 
Monocarboxylates B-FAMILY 
such O 
as O 
pyruvate B-TRIVIAL 
and O 
acetate B-SYSTEMATIC 
also O 
collapsed O 
the O 
pH O 
gradient O 
and O 
were O 
also O 
inhibitory O 
, O 
while O 
citrate B-FAMILY 
and O 
glycine B-TRIVIAL 
neither O 
altered O 
the O 
proton O 
gradient O 
nor O 
inhibited O 
PCFT O 
- O 
mediated O 
transport O 
. O 
These O 
observations O 
add O 
another O 
dimension O 
to O 
the O 
unfavorable O 
pH O 
environment O 
for O 
PCFT O 
function O 
in O 
systemic O 
tissues O 
, O 
the O 
presence O 
of O 
high O 
concentrations O 
of O 
bicarbonate B-SYSTEMATIC 
. O 

Intermediate O 
- O 
conductance O 
Calcium B-SYSTEMATIC 
-activated O 
Potassium B-SYSTEMATIC 
Channel O 
KCa3.1 O 
Regulates O 
Vascular O 
Smooth O 
Muscle O 
Cell O 
Proliferation O 
via O 
Controlling O 
Calcium B-SYSTEMATIC 
-dependent O 
Signaling O 
. O 

intermediate O 
- O 
conductance O 
calcium B-SYSTEMATIC 
-activated O 
potassium B-SYSTEMATIC 
channel O 
KCa3.1 O 
contributes O 
to O 
a O 
variety O 
of O 
cell O 
activation O 
processes O 
in O 
pathologies O 
such O 
as O 
inflammation O 
, O 
carcinogenesis O 
and O 
vascular O 
remodeling O 
. O 
We O 
examined O 
the O 
electrophysiological O 
and O 
transcriptional O 
mechanisms O 
by O 
which O 
KCa3.1 O 
regulates O 
vascular O 
smooth O 
muscle O 
cell O 
( O 
VSMC O 
) O 
proliferation O 
. O 
Platelet O 
- O 
derived O 
growth O 
factor-BB O 
(PDGF)-induced O 
proliferation O 
of O 
human O 
coronary O 
artery O 
VSMCs O 
was O 
attenuated O 
by O 
lowering O 
intracellular O 
Ca(2+) B-FORMULA 
concentration O 
( O 
[ O 
Ca(2+) B-FORMULA 
]i O 
) O 
and O 
was O 
enhanced O 
by O 
elevating O 
[ O 
Ca(2+) B-FORMULA 
]i O 
. O 
KCa3.1 O 
blockade O 
or O 
knockdown O 
inhibited O 
proliferation O 
by O 
suppressing O 
the O 
rise O 
in O 
[ O 
Ca(2+) B-FORMULA 
]i O 
and O 
attenuating O 
the O 
expression O 
of O 
phosphorylated O 
cAMP B-ABBREVIATION 
response O 
element O 
binding O 
protein O 
( O 
CREB O 
) O 
, O 
c-fos O 
and O 
neuron O 
- O 
derived O 
orphan O 
receptor-1 O 
( O 
NOR-1 O 
) O 
. O 
This O 
anti-proliferative O 
effect O 
was O 
abolished O 
by O 
elevating O 
[ O 
Ca(2+) B-FORMULA 
]i O 
. O 
KCa3.1 O 
overexpression O 
induced O 
VSMC O 
proliferation O 
, O 
and O 
potentiated O 
PDGF-induced O 
proliferation O 
, O 
by O 
inducing O 
CREB O 
phosphorylation O 
, O 
c-fos O 
and O 
NOR-1 O 
. O 
Pharmacological O 
stimulation O 
of O 
KCa3.1 O 
unexpectedly O 
suppressed O 
proliferation O 
by O 
inhibiting O 
the O 
rise O 
in O 
[ O 
Ca(2+) B-FORMULA 
]i O 
and O 
abolishing O 
the O 
expression O 
and O 
activity O 
of O 
KCa3.1 O 
and O 
PDGF O 
β-receptors O 
. O 
The O 
stimulation O 
also O 
attenuated O 
the O 
levels O 
of O 
phosphorylated O 
CREB O 
, O 
c-fos O 
and O 
cyclins O 
expression O 
. O 
After O 
KCa3.1 O 
blockade O 
, O 
the O 
characteristic O 
round O 
shape O 
of O 
VSMCs O 
expressing O 
high O 
l-caldesmon O 
and O 
low O 
calponin-1 O 
( O 
dedifferentiation O 
state O 
) O 
was O 
maintained O 
, O 
whereas O 
KCa3.1 O 
stimulation O 
induced O 
a O 
spindle O 
- O 
shape O 
cellular O 
appearance O 
, O 
with O 
low O 
l-caldesmon O 
and O 
high O 
calponin-1 O 
. O 
In O 
conclusion O 
, O 
KCa3.1 O 
plays O 
an O 
important O 
role O 
in O 
VSMC O 
proliferation O 
via O 
controlling O 
Ca(2+) B-FORMULA 
-dependent O 
signaling O 
pathways O 
and O 
its O 
modulation O 
may O 
therefore O 
constitute O 
a O 
new O 
therapeutic O 
target O 
for O 
cell O 
proliferative O 
diseases O 
such O 
as O 
atherosclerosis O 
. O 

vitro O 
exploration O 
of O 
potential O 
mechanisms O 
of O 
toxicity O 
of O 
the O 
human O 
hepatotoxic O 
drug O 
fenclozic B-TRIVIAL 
acid I-TRIVIAL 
. O 

carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
NSAID O 
fenclozic B-TRIVIAL 
acid I-TRIVIAL 
exhibited O 
an O 
excellent O 
preclinical O 
safety O 
profile O 
and O 
promising O 
clinical O 
efficacy O 
, O 
yet O 
was O 
withdrawn O 
from O 
clinical O 
development O 
in O 
1971 O 
due O 
to O 
hepatotoxicity O 
observed O 
in O 
clinical O 
trials O 
. O 
A O 
variety O 
of O 
modern O 
in O 
vitro O 
approaches O 
have O 
been O 
used O 
to O 
explore O 
potential O 
underlying O 
mechanisms O 
. O 
Covalent O 
binding O 
studies O 
were O 
undertaken O 
with O 
[(14)C]-fenclozic B-SYSTEMATIC 
acid I-SYSTEMATIC 
to O 
investigate O 
the O 
possible O 
role O 
of O 
reactive O 
metabolites O 
. O 
Time O 
- O 
dependent O 
covalent O 
binding O 
to O 
protein O 
was O 
observed O 
in O 
NADPH B-ABBREVIATION 
-supplemented O 
liver O 
microsomes O 
, O 
although O 
no O 
metabolites O 
were O 
detected O 
in O 
these O 
incubations O 
or O 
in O 
reactive O 
metabolite O 
trapping O 
experiments O 
. O 
In O 
human O 
hepatocytes O 
, O 
covalent O 
binding O 
was O 
observed O 
at O 
lower O 
levels O 
than O 
in O 
microsomes O 
and O 
a O 
minor O 
uncharacterizable O 
metabolite O 
was O 
also O 
observed O 
. O 
In O 
addition O 
, O 
covalent O 
binding O 
was O 
observed O 
in O 
incubations O 
undertaken O 
with O 
dog O 
and O 
rat O 
hepatocytes O 
, O 
where O 
a O 
taurine B-TRIVIAL 
conjugate O 
of O 
the O 
drug O 
was O 
detected O 
. O 
Although O 
an O 
acyl B-SYSTEMATIC 
glucuronide I-SYSTEMATIC 
metabolite O 
was O 
detected O 
when O 
liver O 
microsomes O 
from O 
human O 
, O 
rat O 
and O 
dog O 
were O 
supplemented O 
with O 
UDPGA B-ABBREVIATION 
, O 
there O 
was O 
no O 
detectable O 
UDPGA B-ABBREVIATION 
-dependent O 
covalent O 
binding O 
. O 
No O 
effects O 
were O 
observed O 
when O 
fenclozic B-TRIVIAL 
acid I-TRIVIAL 
was O 
assessed O 
for O 
P450-dependent O 
and O 
P450 O 
- O 
independent O 
cytotoxicity O 
to O 
THLE O 
cell O 
lines O 
, O 
time O 
- O 
dependent O 
inhibition O 
of O 
five O 
major O 
human O 
cytochrome O 
P450 O 
enzymes O 
, O 
inhibition O 
of O 
the O 
biliary O 
efflux O 
transporters O 
BSEP O 
and O 
MRP2 O 
or O 
mitochondrial O 
toxicity O 
to O 
THLE O 
or O 
HepG2 O 
cells O 
. O 
These O 
data O 
suggest O 
that O 
Phase O 
1 O 
bioactivation O 
plays O 
a O 
role O 
in O 
the O 
hepatotoxicity O 
of O 
fenclozic B-TRIVIAL 
acid I-TRIVIAL 
and O 
highlight O 
the O 
unique O 
insight O 
into O 
mechanisms O 
of O 
human O 
drug O 
toxicity O 
that O 
can O 
be O 
provided O 
by O 
investigations O 
of O 
biotransformation O 
and O 
covalent O 
binding O 
to O 
proteins O 
. O 

visual O 
perception O 
in O 
long O 
- O 
term O 
ecstasy B-TRIVIAL 
( O 
MDMA B-ABBREVIATION 
) O 
users O 
. O 

: O 
The O 
present O 
study O 
investigated O 
the O 
long O 
- O 
term O 
consequences O 
of O 
ecstasy B-TRIVIAL 
use O 
on O 
visual O 
processes O 
thought O 
to O 
reflect O 
serotonergic O 
functions O 
in O 
the O 
occipital O 
lobe O 
. O 
Evidence O 
indicates O 
that O 
the O 
main O 
psychoactive O 
ingredient O 
in O 
ecstasy B-TRIVIAL 
( O 
methylendioxymethamphetamine B-SYSTEMATIC 
) O 
causes O 
long O 
- O 
term O 
changes O 
to O 
the O 
serotonin B-TRIVIAL 
system O 
in O 
human O 
users O 
. O 
Previous O 
research O 
has O 
found O 
that O 
amphetamine B-TRIVIAL 
-abstinent O 
ecstasy O 
users O 
have O 
disrupted O 
visual O 
processing O 
in O 
the O 
occipital O 
lobe O 
which O 
relies O 
on O 
serotonin B-TRIVIAL 
, O 
with O 
researchers O 
concluding O 
that O 
ecstasy B-TRIVIAL 
broadens O 
orientation O 
tuning O 
bandwidths O 
. O 
However O 
, O 
other O 
processes O 
may O 
have O 
accounted O 
for O 
these O 
results O 
. O 
OBJECTIVES O 
: O 
The O 
aim O 
of O 
the O 
present O 
research O 
was O 
to O 
determine O 
if O 
amphetamine B-TRIVIAL 
-abstinent O 
ecstasy B-TRIVIAL 
users O 
have O 
changes O 
in O 
occipital O 
lobe O 
functioning O 
, O 
as O 
revealed O 
by O 
two O 
studies O 
: O 
a O 
masking O 
study O 
that O 
directly O 
measured O 
the O 
width O 
of O 
orientation O 
tuning O 
bandwidths O 
and O 
a O 
contour O 
integration O 
task O 
that O 
measured O 
the O 
strength O 
of O 
long O 
- O 
range O 
connections O 
in O 
the O 
visual O 
cortex O 
of O 
drug O 
users O 
compared O 
to O 
controls O 
. O 
METHOD O 
: O 
Participants O 
were O 
compared O 
on O 
the O 
width O 
of O 
orientation O 
tuning O 
bandwidths O 
( O 
26 O 
controls O 
, O 
12 O 
ecstasy B-TRIVIAL 
users O 
, O 
10 O 
ecstasy B-TRIVIAL 
+ O 
amphetamine B-TRIVIAL 
users O 
) O 
and O 
the O 
strength O 
of O 
long O 
- O 
range O 
connections O 
( O 
38 O 
controls O 
, O 
15 O 
ecstasy B-TRIVIAL 
user O 
, O 
12 O 
ecstasy B-TRIVIAL 
+ O 
amphetamine B-TRIVIAL 
users O 
) O 
in O 
the O 
occipital O 
lobe O 
. O 
RESULTS O 
: O 
Amphetamine B-TRIVIAL 
-abstinent O 
ecstasy B-TRIVIAL 
users O 
had O 
significantly O 
broader O 
orientation O 
tuning O 
bandwidths O 
than O 
controls O 
and O 
significantly O 
lower O 
contour O 
detection O 
thresholds O 
( O 
CDTs O 
) O 
, O 
indicating O 
worse O 
performance O 
on O 
the O 
task O 
, O 
than O 
both O 
controls O 
and O 
ecstasy B-TRIVIAL 
+ O 
amphetamine B-TRIVIAL 
users O 
. O 
CONCLUSION O 
: O 
These O 
results O 
extend O 
on O 
previous O 
research O 
, O 
which O 
is O 
consistent O 
with O 
the O 
proposal O 
that O 
ecstasy B-TRIVIAL 
may O 
damage O 
the O 
serotonin B-TRIVIAL 
system O 
, O 
resulting O 
in O 
behavioral O 
changes O 
on O 
tests O 
of O 
visual O 
perception O 
processes O 
which O 
are O 
thought O 
to O 
reflect O 
serotonergic O 
functions O 
in O 
the O 
occipital O 
lobe O 
. O 

of O 
responding O 
with O 
a O 
remifentanil B-TRIVIAL 
-associated O 
conditioned O 
reinforcer O 
in O 
the O 
rat O 
. O 

: O 
Drug O 
- O 
associated O 
environmental O 
stimuli O 
may O 
serve O 
as O 
conditioned O 
reinforcers O 
to O 
enhance O 
drug O 
self O 
- O 
administration O 
behaviors O 
in O 
humans O 
and O 
laboratory O 
animals O 
. O 
However O 
, O 
it O 
can O 
be O 
difficult O 
to O 
distinguish O 
experimentally O 
the O 
conditioned O 
reinforcing O 
effects O 
of O 
a O 
stimulus O 
from O 
other O 
behavioral O 
processes O 
that O 
can O 
change O 
rates O 
of O 
responding O 
. O 
OBJECTIVES O 
: O 
To O 
characterize O 
the O 
conditioned O 
reinforcing O 
effects O 
of O 
a O 
stimulus O 
paired O 
with O 
the O 
μ-opioid O 
agonist O 
, O 
remifentanil B-TRIVIAL 
, O 
using O 
a O 
new O 
- O 
response O 
acquisition O 
procedure O 
in O 
the O 
rat O 
. O 
METHODS O 
: O 
First O 
, O 
in O 
Pavlovian O 
conditioning O 
( O 
PAV O 
) O 
sessions O 
, O 
rats O 
received O 
response O 
- O 
independent O 
IV O 
injections O 
of O 
remifentanil B-TRIVIAL 
and O 
presentations O 
of O 
a O 
light O 
- O 
noise O 
compound O 
stimulus O 
. O 
In O 
paired O 
PAV O 
groups O 
, O 
injections O 
and O 
stimulus O 
presentations O 
always O 
co O 
- O 
occurred O 
. O 
In O 
random O 
PAV O 
control O 
groups O 
, O 
injections O 
and O 
stimulus O 
presentations O 
occurred O 
with O 
no O 
consistent O 
relationship O 
. O 
Second O 
, O 
in O 
instrumental O 
acquisition O 
( O 
ACQ O 
) O 
sessions O 
, O 
all O 
animals O 
could O 
respond O 
in O 
an O 
active O 
nose O 
- O 
poke O 
that O 
produced O 
the O 
stimulus O 
alone O 
or O 
in O 
an O 
inactive O 
nose O 
- O 
poke O 
that O 
had O 
no O 
scheduled O 
consequences O 
. O 
RESULTS O 
: O 
During O 
ACQ O 
, O 
rats O 
made O 
significantly O 
more O 
active O 
nose O 
- O 
pokes O 
than O 
inactive O 
nose O 
- O 
pokes O 
after O 
paired O 
PAV O 
, O 
but O 
not O 
after O 
random O 
PAV O 
. O 
Between O 
groups O 
, O 
rats O 
also O 
made O 
more O 
active O 
nose O 
- O 
pokes O 
after O 
paired O 
PAV O 
than O 
after O 
random O 
PAV O 
. O 
After O 
paired O 
PAV O 
, O 
increased O 
active O 
responding O 
was O 
obtained O 
under O 
different O 
schedules O 
of O 
reinforcement O 
, O 
persisted O 
across O 
multiple O 
ACQ O 
sessions O 
, O 
and O 
depended O 
on O 
the O 
number O 
of O 
PAV O 
sessions O 
conducted O 
. O 
CONCLUSIONS O 
: O 
The O 
remifentanil B-TRIVIAL 
-paired O 
stimulus O 
served O 
as O 
a O 
conditioned O 
reinforcer O 
for O 
nose O 
- O 
poking O 
: O 
responding O 
depended O 
on O 
both O 
the O 
contingency O 
between O 
the O 
stimulus O 
and O 
remifentanil B-TRIVIAL 
and O 
the O 
contingency O 
between O 
the O 
nose O 
- O 
poke O 
and O 
the O 
stimulus O 
. O 
Generally O 
, O 
new O 
- O 
response O 
acquisition O 
procedures O 
may O 
provide O 
valid O 
, O 
flexible O 
models O 
for O 
studying O 
opioid O 
- O 
based O 
conditioned O 
reinforcement O 
. O 

development O 
for O 
multiple O 
sclerosis O 
( O 
MS O 
) O 
, O 
as O 
with O 
any O 
other O 
neurological O 
disease O 
, O 
faces O 
numerous O 
challenges O 
, O 
with O 
many O 
drugs O 
failing O 
at O 
various O 
stages O 
of O 
development O 
. O 
The O 
disease O 
- O 
modifying O 
therapies O 
( O 
DMTs O 
) O 
first O 
introduced O 
for O 
MS O 
are O 
only O 
moderately O 
effective O 
, O 
but O 
given O 
the O 
lack O 
of O 
competition O 
, O 
they O 
have O 
been O 
widely O 
accepted O 
in O 
clinical O 
practice O 
. O 
Although O 
safety O 
and O 
efficacy O 
continue O 
to O 
be O 
the O 
two O 
main O 
metrics O 
by O 
which O 
drugs O 
will O 
be O 
judged O 
, O 
the O 
newer O 
agents O 
in O 
the O 
market O 
also O 
face O 
challenges O 
of O 
a O 
more O 
comparative O 
nature O 
- O 
are O 
they O 
more O 
efficacious O 
than O 
the O 
currently O 
available O 
drugs O 
on O 
the O 
market O 
? O 
Are O 
they O 
safer O 
or O 
better O 
tolerated O 
? O 
Do O 
they O 
offer O 
any O 
practical O 
advantages O 
over O 
current O 
treatments O 
? O 
Fingolimod B-TRIVIAL 
represented O 
a O 
milestone O 
following O 
its O 
approval O 
as O 
an O 
oral O 
drug O 
for O 
MS O 
in O 
2010 O 
, O 
offering O 
patients O 
a O 
far O 
more O 
convenient O 
administration O 
route O 
. O 
However O 
, O 
association O 
with O 
cardiovascular O 
complications O 
has O 
led O 
to O 
a O 
more O 
cautious O 
approach O 
in O 
its O 
initial O 
prescribing O 
, O 
now O 
requiring O 
cardiac O 
monitoring O 
for O 
the O 
first O 
6 O 
h O 
as O 
well O 
as O 
subsequent O 
monitoring O 
of O 
blood O 
pressure O 
and O 
for O 
macular O 
oedema O 
. O 
Natalizumab O 
, O 
amongst O 
licensed O 
drugs O 
, O 
represents O 
the O 
current O 
benchmark O 
for O 
efficacy O 
. O 
The O 
risk O 
of O 
progressive O 
multifocal O 
leukoencephalopathy O 
during O 
natalizumab O 
treatment O 
is O 
now O 
more O 
quantifiable O 
. O 
Other O 
monoclonal O 
antibodies O 
are O 
in O 
various O 
phases O 
of O 
development O 
. O 
Marketing O 
authorisation O 
for O 
alemtuzumab O 
has O 
been O 
filed O 
, O 
and O 
whilst O 
trial O 
data O 
suggest O 
that O 
its O 
efficacy O 
outperforms O 
both O 
licensed O 
drugs O 
and O 
others O 
in O 
development O 
, O 
there O 
is O 
a O 
significant O 
risk O 
of O 
secondary O 
autoimmunity O 
. O 
Its O 
once O 
- O 
yearly O 
administration O 
, O 
however O 
, O 
seems O 
particularly O 
advantageous O 
. O 
Rituximab O 
is O 
unlikely O 
to O 
be O 
developed O 
further O 
as O 
its O 
license O 
will O 
expire O 
, O 
but O 
ocrelizumab O 
, O 
another O 
monoclonal O 
antibody O 
directly O 
targeting O 
B O 
cells O 
, O 
is O 
currently O 
in O 
phase O 
2 O 
development O 
and O 
looks O 
promising O 
. O 
Daclizumab O 
is O 
also O 
moderately O 
efficacious O 
but O 
may O 
struggle O 
to O 
establish O 
itself O 
given O 
its O 
monthly O 
subcutaneous O 
dosing O 
. O 
There O 
are O 
new O 
oral O 
drugs O 
in O 
development O 
, O 
and O 
it O 
is O 
likely O 
that O 
BG-12 B-IDENTIFIER 
will O 
be O 
licensed O 
this O 
year O 
. O 
This O 
has O 
been O 
licensed O 
for O 
psoriasis O 
so O 
there O 
are O 
good O 
safety O 
data O 
in O 
humans O 
that O 
may O 
also O 
hold O 
true O 
in O 
MS O 
; O 
however O 
, O 
its O 
three O 
times O 
daily O 
dosage O 
will O 
probably O 
impact O 
on O 
patient O 
compliance O 
. O 
Laquinimod B-TRIVIAL 
has O 
lower O 
efficacy O 
than O 
BG-12 B-IDENTIFIER 
but O 
appears O 
safe O 
and O 
could O 
find O 
a O 
place O 
as O 
a O 
first O 
- O 
line O 
agent O 
. O 
Teriflunomide B-TRIVIAL 
has O 
just O 
been O 
licensed O 
by O 
the O 
US O 
FDA O 
and O 
may O 
challenge O 
the O 
current O 
injectable O 
first O 
- O 
line O 
therapies O 
as O 
it O 
has O 
a O 
similar O 
efficacy O 
but O 
the O 
advantage O 
of O 
being O 
taken O 
orally O 
. O 
However O 
, O 
risk O 
of O 
teratogenicity O 
may O 
caution O 
against O 
its O 
use O 
in O 
some O 
women O 
of O 
child O 
- O 
bearing O 
potential O 
. O 
This O 
review O 
will O 
examine O 
drugs O 
that O 
have O 
been O 
recently O 
approved O 
as O 
well O 
as O 
those O 
that O 
are O 
in O 
late O 
phase O 
2 O 
or O 
3 O 
development O 
as O 
treatment O 
for O 
relapsing O 
MS O 
, O 
highlighting O 
their O 
mechanism O 
of O 
action O 
as O 
well O 
as O 
the O 
clinical O 
trial O 
and O 
safety O 
data O 
before O 
discussing O 
their O 
potential O 
for O 
success O 
in O 
an O 
increasingly O 
florid O 
and O 
complex O 
DMT O 
armamentarium O 
. O 

amino B-FAMILY 
acids I-FAMILY 
: O 
modular O 
building O 
blocks O 
for O 
the O 
assembly O 
of O 
new O 
tools O 
for O 
chemical O 
biology O 
. O 

spectroscopy O 
is O 
a O 
powerful O 
tool O 
for O 
probing O 
complex O 
biological O 
processes O 
. O 
The O 
ubiquity O 
of O 
peptide O 
- O 
protein O 
and O 
protein O 
- O 
protein O 
interactions O 
in O 
these O 
processes O 
has O 
made O 
them O 
important O 
targets O 
for O 
fluorescence O 
labeling O 
, O 
and O 
to O 
allow O 
sensitive O 
readout O 
of O 
information O 
concerning O 
location O 
, O 
interactions O 
with O 
other O 
biomolecules O 
, O 
and O 
macromolecular O 
dynamics O 
. O 
This O 
review O 
describes O 
recent O 
advances O 
in O 
design O 
, O 
properties O 
and O 
applications O 
in O 
the O 
area O 
of O 
fluorescent O 
amino B-FAMILY 
acids I-FAMILY 
( O 
FlAAs O 
) O 
. O 
The O 
ability O 
to O 
site O 
- O 
selectively O 
incorporate O 
fluorescent O 
amino B-FAMILY 
acid I-FAMILY 
building O 
blocks O 
into O 
a O 
protein O 
or O 
peptide O 
of O 
interest O 
provides O 
the O 
advantage O 
of O 
closely O 
retaining O 
native O 
function O 
and O 
appearance O 
. O 
The O 
development O 
of O 
an O 
array O 
of O 
fluorescent O 
amino B-FAMILY 
acids I-FAMILY 
with O 
a O 
variety O 
of O 
properties O 
, O 
such O 
as O 
environment O 
sensitivity O 
, O 
chelation O 
- O 
enhanced O 
fluorescence O 
, O 
and O 
profluorescence O 
, O 
has O 
allowed O 
researchers O 
to O 
gain O 
insights O 
into O 
biological O 
processes O 
, O 
including O 
protein O 
conformational O 
changes O 
, O 
binding O 
events O 
, O 
enzyme O 
activities O 
, O 
and O 
protein O 
trafficking O 
and O 
localization O 
. O 

in O 
the O 
nervous O 
system O 
are O 
represented O 
by O 
cholesterol B-TRIVIAL 
and O 
phospholipids O 
as O 
constituents O 
of O 
cell O 
membranes O 
and O 
, O 
in O 
particular O 
, O 
of O 
myelin O 
. O 
Therefore O 
, O 
lipids O 
are O 
finely O 
regulated O 
to O 
guarantee O 
physiological O 
functions O 
. O 
In O 
the O 
central O 
nervous O 
system O 
, O 
cholesterol B-TRIVIAL 
is O 
locally O 
synthesized O 
due O 
to O 
the O 
presence O 
of O 
the O 
blood O 
brain O 
barrier O 
. O 
In O 
the O 
peripheral O 
nervous O 
system O 
cholesterol B-TRIVIAL 
is O 
either O 
uptaken O 
by O 
lipoproteins O 
and O 
/ O 
or O 
produced O 
by O 
de O 
novo O 
biosynthesis O 
. O 
Defects O 
in O 
lipid O 
homeostasis O 
in O 
these O 
tissues O 
lead O 
to O 
structural O 
and O 
functional O 
changes O 
that O 
often O 
result O 
in O 
different O 
pathological O 
conditions O 
depending O 
on O 
the O 
affected O 
pathways O 
( O 
i.e O 
. O 
cholesterol B-TRIVIAL 
biosynthesis O 
, O 
cholesterol B-TRIVIAL 
efflux O 
, O 
fatty B-FAMILY 
acid I-FAMILY 
biosynthesis O 
etc O 
. O 
) O 
. O 
Alterations O 
in O 
cholesterol B-TRIVIAL 
metabolism O 
in O 
the O 
central O 
nervous O 
system O 
are O 
linked O 
to O 
several O 
disorders O 
such O 
as O 
Alzheimer's O 
disease O 
, O 
Huntington O 
disease O 
, O 
Parkinson O 
disease O 
, O 
Multiple O 
Sclerosis O 
, O 
Smith-Lemli-Opitz O 
syndrome O 
, O 
Niemann-Pick O 
type O 
C O 
disease O 
, O 
and O 
glioblastoma O 
. O 
In O 
the O 
peripheral O 
nervous O 
system O 
changes O 
in O 
lipid O 
metabolism O 
are O 
associated O 
with O 
the O 
development O 
of O 
peripheral O 
neuropathy O 
that O 
may O 
be O 
caused O 
by O 
metabolic O 
disorders O 
, O 
injuries O 
, O 
therapeutics O 
and O 
autoimmune O 
diseases O 
. O 
Transcription O 
factors O 
, O 
such O 
as O 
the O 
Liver O 
X O 
receptors O 
( O 
LXRs O 
) O 
, O 
regulate O 
both O 
cholesterol B-TRIVIAL 
and O 
fatty B-FAMILY 
acid I-FAMILY 
metabolism O 
in O 
several O 
tissues O 
including O 
the O 
nervous O 
system O 
. O 
In O 
the O 
last O 
few O 
years O 
several O 
studies O 
elucidated O 
the O 
biology O 
of O 
LXRs O 
in O 
nervous O 
system O 
due O 
to O 
the O 
availability O 
of O 
knock O 
- O 
out O 
mice O 
and O 
the O 
development O 
of O 
synthetic O 
ligands O 
. O 
Here O 
, O 
we O 
review O 
a O 
survey O 
of O 
the O 
literature O 
focused O 
on O 
central O 
and O 
peripheral O 
nervous O 
system O 
and O 
in O 
physiological O 
and O 
pathological O 
settings O 
with O 
particular O 
attention O 
on O 
the O 
roles O 
played O 
by O 
LXRs O 
in O 
both O 
districts O 
. O 

SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
-Supported O 
Gold O 
Nanoparticles O 
: O 
Highly O 
Improved O 
Catalytic O 
Activity O 
and O 
Selectivity O 
toward O 
Hydrophobic O 
Substrates O 
. O 

groups O 
on O 
a O 
silica B-TRIVIAL 
surface O 
affect O 
the O 
activity O 
of O 
immobilized O 
catalysts O 
because O 
they O 
can O 
influence O 
the O 
hydrophilicity O 
/ O 
hydrophobicity O 
, O 
matter O 
transfer O 
, O 
or O 
even O 
transition O 
state O 
in O 
a O 
catalytic O 
reaction O 
. O 
Previously O 
, O 
these O 
silanol B-SYSTEMATIC 
groups O 
have O 
usually O 
been O 
passivated O 
by O 
using O 
surface O 
- O 
passivation O 
reagents O 
, O 
such O 
as O 
alkoxysilanes B-FAMILY 
, O 
bis-silylamine B-SYSTEMATIC 
reagents O 
, O 
chlorosilanes B-FAMILY 
, O 
etc O 
. O 
, O 
and O 
surface O 
passivation O 
has O 
typically O 
been O 
found O 
in O 
mesoporous-silicas-supported O 
molecular O 
catalysts O 
and O 
heteroatomic O 
catalysts O 
. O 
However O 
, O 
this O 
property O 
has O 
rarely O 
been O 
reported O 
in O 
mesoporous-silicas-supported O 
metal O 
- O 
nanoparticle O 
catalysts O 
. O 
Herein O 
, O 
we O 
prepared O 
an O 
almost O 
- O 
superhydrophobic O 
SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
-supported O 
gold O 
- O 
nanoparticle O 
catalyst O 
by O 
using O 
surface O 
passivation O 
, O 
in O 
which O 
the O 
catalytic O 
activity O 
increased O 
more O 
than O 
14 O 
times O 
for O 
the O 
reduction O 
of O 
nitrobenzene B-SYSTEMATIC 
compared O 
with O 
non-passivated O 
SBA B-IDENTIFIER 
- I-IDENTIFIER 
15 I-IDENTIFIER 
. O 
In O 
addition O 
, O 
this O 
catalyst O 
can O 
selectively O 
catalyze O 
hydrophobic O 
molecules O 
under O 
our O 
experimental O 
conditions O 
, O 
owing O 
to O 
its O 
high O 
( O 
almost O 
superhydrophobic O 
) O 
hydrophobic O 
properties O 
. O 

Metabolite O 
Trapping O 
Studies O 
on O 
Imidazo- B-MULTIPLE 
and I-MULTIPLE 
2-Methylimidazo[2,1-b]thiazole I-MULTIPLE 
-based O 
Inverse O 
Agonists O 
of O 
the O 
Ghrelin O 
Receptor O 
. O 

current O 
study O 
examined O 
the O 
bioactivation O 
potential O 
of O 
ghrelin O 
receptor O 
inverse O 
agonists O 
, O 
1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
containing O 
a O 
fused O 
imidazo[2,1-b]thiazole B-SYSTEMATIC 
motif O 
in O 
the O 
core O 
structure O 
. O 
Both O 
compounds O 
underwent O 
oxidative O 
metabolism O 
in O 
NADPH B-ABBREVIATION 
- O 
and O 
glutathione B-TRIVIAL 
-supplemented O 
human O 
liver O 
microsomes O 
to O 
yield O 
glutathione B-TRIVIAL 
conjugates O 
, O 
which O 
was O 
consistent O 
with O 
their O 
bioactivation O 
to O 
reactive O 
species O 
. O 
Mass O 
spectral O 
fragmentation O 
and O 
NMR O 
analysis O 
indicated O 
that O 
the O 
site O 
of O 
attachment O 
of O 
the O 
glutathionyl B-TRIVIAL 
moiety O 
in O 
the O 
thiol B-FAMILY 
conjugates O 
was O 
on O 
the O 
thiazole B-SYSTEMATIC 
ring O 
within O 
the O 
bicycle O 
. O 
Two O 
glutathione B-TRIVIAL 
conjugates O 
were O 
discerned O 
with O 
the O 
imidazo[2,1-b]thiazole B-SYSTEMATIC 
derivative O 
1 O 
. O 
One O 
adduct O 
was O 
derived O 
from O 
the O 
Michael O 
addition O 
of O 
glutathione B-TRIVIAL 
to O 
a O 
putative O 
S-oxide B-SYSTEMATIC 
metabolite O 
of O 
1 O 
, O 
whereas O 
, O 
the O 
second O 
adduct O 
was O 
formed O 
via O 
the O 
reaction O 
of O 
a O 
second O 
glutathione B-TRIVIAL 
molecule O 
with O 
the O 
initial O 
glutathione-S-oxide B-SYSTEMATIC 
adduct O 
. O 
In O 
the O 
case O 
of O 
the O 
2-methylimidazo[2,1-b]thiazole B-SYSTEMATIC 
analog O 
2 O 
, O 
glutathione B-TRIVIAL 
conjugation O 
occurred O 
via O 
an O 
oxidative O 
desulfation O 
mechanism O 
, O 
possibly O 
involving O 
thiazole B-SYSTEMATIC 
ring O 
epoxidation O 
as O 
the O 
rate O 
- O 
limiting O 
step O 
. O 
Additional O 
insights O 
into O 
the O 
mechanism O 
were O 
obtained O 
via O 
18O B-FORMULA 
exchange O 
and O 
trapping O 
studies O 
with O 
potassium B-SYSTEMATIC 
cyanide I-SYSTEMATIC 
. O 
The O 
mechanistic O 
insights O 
into O 
the O 
bioactivation O 
pathways O 
of O 
1 O 
and O 
2 O 
allowed O 
the O 
deployment O 
of O 
a O 
rational O 
chemical O 
intervention O 
strategy O 
that O 
involved O 
replacement O 
of O 
the O 
thiazole B-SYSTEMATIC 
ring O 
with O 
a O 
1,2,4-thiadiazole B-SYSTEMATIC 
group O 
to O 
yield O 
-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b][1,3,4]thiadiazol-6-yl)ethanone B-SYSTEMATIC 
( O 
3 O 
) O 
. O 
These O 
structural O 
changes O 
not O 
only O 
abrogated O 
the O 
bioactivation O 
liability O 
but O 
also O 
retained O 
the O 
attractive O 
pharmacological O 
attributes O 
of O 
the O 
prototype O 
agents O 
. O 

- I-TRIVIAL 
Glucose I-TRIVIAL 
hydrogenation O 
over O 
Ru B-FORMULA 
Nanoparticles O 
Embedded O 
in O 
Mesoporous O 
Hypercrosslinked O 
Polystyrene B-SYSTEMATIC 
. O 

kinetics O 
of O 
D-glucose B-SYSTEMATIC 
hydrogenation O 
on O 
the O 
catalyst O 
containing O 
Ru B-FORMULA 
nanoparticles O 
in O 
the O 
matrix O 
of O 
hypercrosslinked O 
polystyrene B-SYSTEMATIC 
was O 
studied O 
. O 
Two O 
routes O 
of O 
the O 
hydrogenation O 
reaction O 
were O 
revealed O 
, O 
their O 
rates O 
differ O 
by O 
several O 
digits O 
. O 
The O 
first O 
route O 
includes O 
the O 
interaction O 
of O 
D-glucose B-SYSTEMATIC 
with O 
the O 
spilled O 
- O 
over O 
hydrogen B-SYSTEMATIC 
supplied O 
by O 
the O 
catalyst O 
; O 
the O 
second O 
one O 
includes O 
classical O 
interaction O 
of O 
the O 
sorbed O 
substrate O 
with O 
incident O 
hydrogen B-SYSTEMATIC 
from O 
the O 
reaction O 
medium O 
. O 
Mathematical O 
description O 
of O 
D-glucose B-SYSTEMATIC 
conversion O 
and O 
the O 
change O 
of O 
the O 
catalyst O 
activity O 
by O 
the O 
fist O 
way O 
of O 
D-glucose B-SYSTEMATIC 
hydrogenation O 
were O 
obtained O 
. O 
The O 
most O 
probable O 
scheme O 
of O 
the O 
process O 
flow O 
was O 
suggested O 
. O 
The O 
main O 
kinetic O 
parameters O 
were O 
calculated O 
. O 
The O 
role O 
of O 
hydrogen B-SYSTEMATIC 
spillover O 
phenomenon O 
in O 
the O 
kinetics O 
of O 
the O 
processes O 
is O 
discussed O 
. O 

Structure-Activity O 
Relationships O 
and O 
Biological O 
Evaluation O 
of O 
Novel O 
Antitubercular O 
Indolecarboxamide B-FAMILY 
Derivatives O 
Against O 
Drug-Susceptible O 
and O 
Drug-Resistant O 
Mycobacterium O 
tuberculosis O 
Strains O 
. O 

( O 
TB O 
) O 
remains O 
one O 
of O 
the O 
leading O 
causes O 
of O 
mortality O 
and O 
morbidity O 
worldwide O 
, O 
with O 
approximately O 
one O 
- O 
third O 
of O 
the O 
world's O 
population O 
infected O 
with O 
latent O 
TB O 
. O 
This O 
is O 
further O 
aggravated O 
by O 
HIV O 
coinfection O 
and O 
the O 
emergence O 
of O 
multidrug- O 
and O 
extensively O 
drug O 
- O 
resistant O 
( O 
MDR O 
and O 
XDR O 
, O 
respectively O 
) O 
TB O 
; O 
hence O 
the O 
quest O 
for O 
highly O 
effective O 
antitubercular O 
drugs O 
with O 
novel O 
modes O 
of O 
action O 
is O 
imperative O 
. O 
We O 
report O 
herein O 
the O 
discovery O 
of O 
an O 
indole-2-carboxamide B-SYSTEMATIC 
analogue O 
, O 
3 O 
, O 
as O 
a O 
highly O 
potent O 
antitubercular O 
agent O 
, O 
and O 
the O 
subsequent O 
chemical O 
modifications O 
aimed O 
at O 
establishing O 
a O 
preliminary O 
body O 
of O 
structure O 
- O 
activity O 
relationships O 
( O 
SARs O 
) O 
. O 
These O 
efforts O 
led O 
to O 
the O 
identification O 
of O 
three O 
molecules O 
( O 
12-14 O 
) O 
possessing O 
an O 
exceptional O 
activity O 
in O 
the O 
low O 
nanomolar O 
range O 
against O 
actively O 
replicating O 
Mycobacterium O 
tuberculosis O 
, O 
with O 
minimum O 
inhibitory O 
concentration O 
( O 
MIC O 
) O 
values O 
lower O 
than O 
those O 
of O 
the O 
most O 
prominent O 
antitubercular O 
agents O 
currently O 
in O 
use O 
. O 
These O 
compounds O 
were O 
also O 
devoid O 
of O 
apparent O 
toxicity O 
to O 
Vero O 
cells O 
. O 
Importantly O 
, O 
compound O 
12 O 
was O 
found O 
to O 
be O 
active O 
against O 
the O 
tested O 
XDR-TB O 
strains O 
and O 
orally O 
active O 
in O 
the O 
serum O 
inhibition O 
titration O 
assay O 
. O 

between O 
peroxynitrite B-SYSTEMATIC 
and O 
triphenylphosphonium B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
arylboronic I-FAMILY 
acid I-FAMILY 
isomers O 
- O 
Identification O 
of O 
diagnostic O 
marker O 
products O 
and O 
biological O 
implications O 
. O 

/ O 
i> O 
Aromatic B-FAMILY 
boronic I-FAMILY 
acids I-FAMILY 
react O 
rapidly O 
with O 
peroxynitrite B-SYSTEMATIC 
( O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
) O 
to O 
yield O 
phenols B-FAMILY 
as O 
major O 
products O 
. O 
This O 
reaction O 
was O 
used O 
to O 
monitor O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
formation O 
in O 
cellular O 
systems O 
. O 
Previously O 
, O 
we O 
proposed O 
that O 
the O 
reaction O 
between O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
and O 
arylboronates B-FAMILY 
( O 
PhB(OH) B-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
) O 
yields O 
a O 
phenolic B-FAMILY 
product O 
( O 
major O 
pathway O 
) O 
and O 
a O 
radical O 
pair O 
PhB(OH) B-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
O I-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
•- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
… O 
< B-FORMULA 
sup I-FORMULA 
> I-FORMULA 
• I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
NO I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
( O 
minor O 
pathway O 
) O 
. O 
[ O 
Sikora O 
A O 
. O 
< O 
i O 
> O 
et O 
al O 
. O 
, O 
Chem O 
Res O 
Toxicol O 
< O 
/ O 
i> O 
24 O 
, O 
687-97 O 
] O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
influence O 
of O 
a O 
bulky O 
triphenylphosphonium B-SYSTEMATIC 
( O 
TPP B-ABBREVIATION 
) O 
group O 
on O 
the O 
reaction O 
between O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
and O 
mitochondria O 
- O 
targeted O 
arylboronate B-FAMILY 
isomers O 
( O 
< B-MULTIPLE 
i I-MULTIPLE 
> I-MULTIPLE 
o I-MULTIPLE 
< I-MULTIPLE 
/i I-MULTIPLE 
> I-MULTIPLE 
- I-MULTIPLE 
, I-MULTIPLE 
< I-MULTIPLE 
i I-MULTIPLE 
> I-MULTIPLE 
m I-MULTIPLE 
< I-MULTIPLE 
/i I-MULTIPLE 
> I-MULTIPLE 
- I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
< I-MULTIPLE 
i I-MULTIPLE 
> I-MULTIPLE 
p I-MULTIPLE 
< I-MULTIPLE 
/i I-MULTIPLE 
> I-MULTIPLE 
-MitoPhB(OH) I-MULTIPLE 
< I-MULTIPLE 
sub I-MULTIPLE 
> I-MULTIPLE 
2 I-MULTIPLE 
< I-MULTIPLE 
/ I-MULTIPLE 
sub> I-MULTIPLE 
) O 
. O 
Results O 
from O 
the O 
electron O 
paramagnetic O 
resonance O 
( O 
EPR O 
) O 
spin O 
- O 
trapping O 
experiments O 
unequivocally O 
showed O 
the O 
presence O 
of O 
a O 
phenyl B-SYSTEMATIC 
radical O 
intermediate O 
from O 
< O 
i O 
> O 
meta O 
< O 
/ O 
i> O 
and O 
< O 
i O 
> O 
para O 
< O 
/ O 
i> O 
isomers O 
, O 
and O 
not O 
from O 
the O 
< O 
i O 
> O 
ortho O 
< O 
/ O 
i> O 
isomer O 
. O 
The O 
yield O 
of O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhNO I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
formed O 
from O 
the O 
reaction O 
between O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
and O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
was O 
not O 
diminished O 
by O 
phenyl B-SYSTEMATIC 
radical O 
scavengers O 
, O 
suggesting O 
a O 
rapid O 
fragmentation O 
of O 
the O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
O I-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
•- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
radical O 
anion O 
with O 
subsequent O 
reaction O 
of O 
the O 
resulting O 
phenyl B-SYSTEMATIC 
radical O 
with O 
< B-FORMULA 
sup I-FORMULA 
> I-FORMULA 
• I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
NO I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
in O 
the O 
solvent O 
cage O 
. O 
The O 
DFT O 
quantum O 
mechanical O 
calculations O 
showed O 
that O 
the O 
energy O 
barrier O 
for O 
the O 
dissociation O 
of O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
O I-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
•- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
radical O 
anion O 
is O 
significantly O 
lower O 
than O 
that O 
of O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
m I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
O I-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
•- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
and O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
p I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
O I-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
•- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
radical O 
anions O 
. O 
We O 
conclude O 
that O 
the O 
reaction O 
of O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
with O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
ortho I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhB(OH) I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
forming O 
the O 
minor O 
nitrated O 
product O 
, O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhNO I-FORMULA 
< I-FORMULA 
sub I-FORMULA 
> I-FORMULA 
2 I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sub> I-FORMULA 
, O 
and O 
the O 
corresponding O 
major O 
phenolic B-FAMILY 
product O 
( O 
< B-FORMULA 
i I-FORMULA 
> I-FORMULA 
o I-FORMULA 
< I-FORMULA 
/i I-FORMULA 
> I-FORMULA 
-MitoPhOH I-FORMULA 
) O 
can O 
be O 
employed O 
as O 
a O 
diagnostic O 
tool O 
to O 
specifically O 
detect O 
ONOO B-FORMULA 
< I-FORMULA 
sup I-FORMULA 
> I-FORMULA 
- I-FORMULA 
< I-FORMULA 
/ I-FORMULA 
sup> I-FORMULA 
in O 
biological O 
systems O 
. O 

lack O 
of O 
an O 
effective O 
technique O 
for O 
three O 
- O 
dimensional O 
flow O 
visualization O 
has O 
limited O 
the O 
experimental O 
exploration O 
of O 
the O 
" O 
coffee O 
ring O 
effect O 
" O 
to O 
the O 
two O 
dimensional O 
, O 
top O 
- O 
down O 
viewpoint O 
. O 
In O 
this O 
report O 
, O 
high O 
- O 
speed O 
, O 
cross O 
- O 
sectional O 
imaging O 
of O 
the O 
flow O 
fields O 
was O 
obtained O 
by O 
using O 
optical O 
coherence O 
tomography O 
to O 
track O 
particle O 
motion O 
in O 
an O 
evaporating O 
colloidal O 
water O 
drop O 
. O 
This O 
approach O 
enables O 
z-dimensional O 
mapping O 
of O 
primary O 
and O 
secondary O 
flow O 
fields O 
and O 
changes O 
in O 
these O 
fields O 
over O 
time O 
. O 
These O 
sectional O 
images O 
show O 
that O 
1μm O 
diameter O 
polystyrene B-SYSTEMATIC 
particles O 
have O 
a O 
highly O 
non-uniform O 
vertical O 
distribution O 
with O 
particles O 
accumulating O 
at O 
both O 
the O 
air O 
- O 
water O 
interface O 
and O 
water O 
- O 
glass O 
interface O 
during O 
drop O 
evaporation O 
. O 
Particle O 
density O 
and O 
relative O 
humidity O 
are O 
shown O 
to O 
influence O 
interfacial O 
entrapment O 
, O 
which O 
suggests O 
that O 
both O 
sedimentation O 
rate O 
and O 
evaporation O 
rate O 
affect O 
the O 
dynamic O 
changes O 
in O 
the O 
cross O 
- O 
sectional O 
distribution O 
of O 
particles O 
. O 
Furthermore O 
, O 
entrapment O 
at O 
the O 
air O 
- O 
water O 
interface O 
delays O 
the O 
time O 
at O 
which O 
particles O 
reach O 
the O 
ring O 
structure O 
. O 
These O 
results O 
suggest O 
that O 
the O 
organization O 
of O 
the O 
ring O 
structure O 
can O 
be O 
controlled O 
based O 
on O 
the O 
ratio O 
of O 
different O 
density O 
particles O 
in O 
a O 
colloidal O 
solution O 
. O 

the O 
Molecular O 
Mechanism(s) O 
by O 
Which O 
EGCG B-ABBREVIATION 
Treatment O 
Remodels O 
Mature O 
Amyloid O 
Fibrils O 
. O 

misfolding O 
and O 
/ O 
or O 
aggregation O 
has O 
been O 
implicated O 
as O 
the O 
cause O 
of O 
several O 
human O 
diseases O 
, O 
such O 
as O 
Alzheimer's O 
and O 
Parkinson's O 
diseases O 
and O 
familial O 
amyloid O 
polyneuropathy O 
. O 
These O 
maladies O 
are O 
referred O 
to O 
as O 
amyloid O 
diseases O 
, O 
named O 
after O 
the O 
cross-β-sheet O 
amyloid O 
fibril O 
aggregates O 
or O 
deposits O 
common O 
to O 
these O 
disorders O 
. O 
Epigallocatechin-3-gallate B-TRIVIAL 
( O 
EGCG B-ABBREVIATION 
) O 
, O 
the O 
principal O 
polyphenol B-FAMILY 
present O 
in O 
green O 
tea O 
, O 
has O 
been O 
shown O 
to O 
be O 
effective O 
at O 
preventing O 
aggregation O 
and O 
is O 
able O 
to O 
remodel O 
amyloid O 
fibrils O 
comprising O 
different O 
amyloidogenic O 
proteins O 
, O 
although O 
the O 
mechanistic O 
underpinnings O 
are O 
unclear O 
. O 
Herein O 
, O 
we O 
work O 
toward O 
an O 
understanding O 
of O 
the O 
molecular O 
mechanism(s) O 
by O 
which O 
EGCG B-ABBREVIATION 
remodels O 
mature O 
amyloid O 
fibrils O 
made O 
up O 
of O 
Aβ1-40 O 
, O 
IAPP8-24 O 
, O 
or O 
Sup35NM7-16 O 
. O 
We O 
show O 
that O 
EGCG B-ABBREVIATION 
amyloid O 
remodeling O 
activity O 
in O 
vitro O 
is O 
dependent O 
on O 
auto O 
- O 
oxidation O 
of O 
the O 
EGCG B-ABBREVIATION 
. O 
Oxidized O 
and O 
unoxidized O 
EGCG B-ABBREVIATION 
binds O 
to O 
amyloid O 
fibrils O 
, O 
preventing O 
the O 
binding O 
of O 
thioflavin B-TRIVIAL 
T I-TRIVIAL 
. O 
This O 
engagement O 
of O 
the O 
hydrophobic O 
binding O 
sites O 
in O 
Aβ1-40 O 
, O 
IAPP8-24 O 
, O 
or O 
Sup35NMAc7-16 O 
Y→F O 
amyloid O 
fibrils O 
seems O 
to O 
be O 
sufficient O 
to O 
explain O 
the O 
majority O 
of O 
the O 
amyloid O 
remodeling O 
observed O 
by O 
EGCG B-ABBREVIATION 
treatment O 
, O 
although O 
how O 
EGCG B-ABBREVIATION 
oxidation O 
drives O 
remodeling O 
remains O 
unclear O 
. O 
Oxidized O 
EGCG B-ABBREVIATION 
molecules O 
react O 
with O 
free O 
amines B-FAMILY 
within O 
the O 
amyloid O 
fibril O 
through O 
the O 
formation O 
of O 
Schiff B-FAMILY 
bases I-FAMILY 
, O 
cross O 
- O 
linking O 
the O 
fibrils O 
, O 
which O 
may O 
prevent O 
dissociation O 
and O 
toxicity O 
, O 
but O 
these O 
aberrant O 
post O 
- O 
translational O 
modifications O 
do O 
not O 
appear O 
to O 
be O 
the O 
major O 
driving O 
force O 
for O 
amyloid O 
remodeling O 
by O 
EGCG B-ABBREVIATION 
treatment O 
. O 
These O 
insights O 
into O 
the O 
molecular O 
mechanism O 
of O 
action O 
of O 
EGCG B-ABBREVIATION 
provide O 
boundary O 
conditions O 
for O 
exploring O 
amyloid O 
remodeling O 
in O 
more O 
detail O 
. O 

observations O 
revealed O 
that O 
human O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
( O 
UGT O 
) O 
2B10 O 
catalyzes O 
N-glucuronidation O 
of O 
amine B-SYSTEMATIC 
-containing O 
compounds O 
. O 
Knowledge O 
of O 
the O 
substrate O 
specificity O 
and O 
clinical O 
significance O 
of O 
UGT2B10 O 
is O 
still O 
limited O 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
expand O 
the O 
knowledge O 
of O 
UGT2B10 O 
substrates O 
and O 
to O 
evaluate O 
its O 
significance O 
in O 
drug O 
clearance O 
. O 
Using O 
recombinant O 
UGT2B10 O 
, O 
we O 
found O 
that O 
it O 
catalyzes O 
the O 
N-glucuronidation O 
of O 
amitriptyline B-TRIVIAL 
, O 
imipramine B-TRIVIAL 
, O 
ketotifen B-TRIVIAL 
, O 
pizotifen B-TRIVIAL 
, O 
olanzapine B-TRIVIAL 
, O 
diphenhydramine B-TRIVIAL 
, O 
tamoxifen B-TRIVIAL 
, O 
ketoconazole B-TRIVIAL 
and O 
midazolam B-TRIVIAL 
. O 
These O 
are O 
drugs O 
that O 
were O 
previously O 
reported O 
to O 
be O 
substrates O 
for O 
UGT1A4 O 
or O 
UGT1A3 O 
and O 
that O 
contain O 
in O 
their O 
structure O 
either O 
tertiary B-FAMILY 
aliphatic I-FAMILY 
amines I-FAMILY 
, O 
cyclic B-FAMILY 
amines I-FAMILY 
, O 
or O 
an O 
imidazole B-SYSTEMATIC 
group O 
. O 
UGT2B10 O 
was O 
inactive O 
in O 
the O 
glucuronidation O 
of O 
desipramine B-TRIVIAL 
, O 
nortriptyline B-TRIVIAL 
, O 
carbamazepine B-TRIVIAL 
and O 
afloqualone B-TRIVIAL 
. O 
This O 
group O 
of O 
drugs O 
contains O 
secondary B-MULTIPLE 
or I-MULTIPLE 
primary I-MULTIPLE 
amines I-MULTIPLE 
, O 
and O 
these O 
results O 
suggest O 
that O 
UGT2B10 O 
preferably O 
conjugates O 
tertiary B-FAMILY 
amines I-FAMILY 
. O 
This O 
preference O 
is O 
partial O 
because O 
UGT2B10 O 
did O 
not O 
conjugate O 
the O 
tertiary B-MULTIPLE 
cyclic I-MULTIPLE 
amine I-MULTIPLE 
in O 
trifluoperazine B-TRIVIAL 
. O 
Kinetic O 
analyses O 
revealed O 
that O 
the O 
affinity O 
and O 
clearance O 
of O 
UGT2B10 O 
for O 
amitriptyline B-TRIVIAL 
, O 
imipramine B-TRIVIAL 
, O 
and O 
diphenhydramine B-TRIVIAL 
are O 
significantly O 
higher O 
than O 
the O 
corresponding O 
values O 
of O 
UGT1A4 O 
and O 
UGT1A3 O 
, O 
although O 
the O 
Vmax O 
values O 
of O 
UGT1A4 O 
toward O 
these O 
drugs O 
are O 
considerably O 
higher O 
. O 
These O 
findings O 
suggest O 
that O 
UGT2B10 O 
plays O 
a O 
major O 
role O 
in O 
the O 
N-glucuronidation O 
of O 
these O 
drugs O 
at O 
therapeutic O 
concentrations O 
. O 
These O 
results O 
are O 
also O 
supported O 
by O 
inhibition O 
studies O 
with O 
nicotine B-TRIVIAL 
and O 
hecogenin B-TRIVIAL 
. O 
In O 
conclusion O 
, O 
this O 
study O 
expands O 
the O 
understanding O 
of O 
the O 
substrate O 
specificity O 
of O 
UGT2B10 O 
, O 
highlighting O 
its O 
preference O 
for O 
tertiary B-FAMILY 
amines I-FAMILY 
with O 
higher O 
affinities O 
and O 
clearance O 
values O 
than O 
those O 
of O 
UGT1A4 O 
and O 
UGT1A3 O 
. O 

and O 
biotransformation O 
pathways O 
are O 
widely O 
studied O 
in O 
marine O 
organisms O 
exposed O 
to O 
environmental O 
stressors O 
. O 
However O 
, O 
mechanisms O 
of O 
responses O 
and O 
links O 
between O 
different O 
intracellular O 
levels O 
are O 
not O 
always O 
easy O 
to O 
elucidate O 
and O 
conflicting O 
results O 
are O 
frequently O 
observed O 
between O 
molecular O 
and O 
enzymatic O 
data O 
. O 
In O 
this O 
study O 
, O 
transcriptional O 
and O 
catalytic O 
responses O 
of O 
antioxidant O 
and O 
biotransformation O 
parameters O 
were O 
analyzed O 
after O 
a O 
4-week O 
exposure O 
of O 
a O 
marine O 
invertebrate O 
, O 
Mytilus O 
galloprovincialis O 
, O 
to O 
chemical O 
mixtures O 
from O 
low O 
polluted O 
and O 
highly O 
polluted O 
sediments O 
. O 
A O 
significant O 
, O 
dose O 
- O 
dependent O 
bioaccumulation O 
was O 
observed O 
for O 
polycyclic B-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
, O 
especially O 
low O 
molecular O 
weight O 
compounds O 
. O 
Among O 
antioxidant O 
defences O 
, O 
catalase O 
and O 
glutathione B-TRIVIAL 
peroxidases O 
did O 
not O 
exhibit O 
variations O 
in O 
enzymatic O 
activity O 
, O 
while O 
the O 
corresponding O 
gene O 
transcriptions O 
were O 
up- O 
and O 
down O 
- O 
regulated O 
, O 
respectively O 
; O 
unchanged O 
mRNA O 
levels O 
of O 
superoxide B-TRIVIAL 
dismutase O 
confirmed O 
the O 
non-synchronous O 
pathways O 
of O 
variations O 
for O 
such O 
antioxidants O 
. O 
Biotransformation O 
responses O 
also O 
revealed O 
inconsistent O 
trends O 
between O 
transcriptional O 
and O 
catalytic O 
variations O 
of O 
glutathione B-TRIVIAL 
S B-FORMULA 
-transferases O 
, O 
and O 
a O 
significant O 
increase O 
in O 
mRNA O 
levels O 
for O 
cytochrome O 
P450 O 
3A1 O 
. O 
The O 
overall O 
results O 
indicated O 
that O 
transcriptional O 
responses O 
might O 
be O 
sensitive O 
but O 
do O 
not O 
necessarily O 
correspond O 
to O 
functional O 
changes O 
, O 
being O 
more O 
useful O 
as O 
" O 
exposure O 
" O 
rather O 
than O 
" O 
effect O 
" O 
biomarkers O 
. O 
Data O 
on O 
gene O 
transcription O 
and O 
catalytic O 
activities O 
should O 
be O 
carefully O 
interpreted O 
when O 
assessing O 
the O 
impact O 
of O 
chemical O 
pollutants O 
and O 
additional O 
studies O 
are O 
needed O 
on O 
modulation O 
of O 
post O 
- O 
transcriptional O 
mechanisms O 
by O 
environmental O 
stressors O 
. O 

RELEVANCE O 
: O 
Poria O 
cocos O 
Wolf O 
( O 
Polyporaceae O 
) O 
is O 
a O 
well O 
- O 
known O 
medicinal O 
fungus O 
. O 
the O 
epidermis O 
of O 
the O 
sclerotia O 
( O 
" O 
Fu-Ling-Pi O 
" O 
in O 
Chinese O 
) O 
is O 
used O 
as O 
a O 
diuretic O 
and O 
traditionally O 
used O 
for O 
promoting O 
urination O 
and O 
reduce O 
edema O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
Traditional O 
Chinese O 
medicines O 
( O 
TCM O 
) O 
treat O 
many O 
diseases O 
through O 
multi O 
- O 
components O 
, O 
multi O 
- O 
ways O 
and O 
multi O 
- O 
targets O 
. O 
However O 
, O 
the O 
molecular O 
mechanisms O 
of O 
TCM O 
are O 
not O 
yet O 
well O 
understood O 
. O 
In O 
the O 
present O 
work O 
, O 
ultra O 
performance O 
liquid O 
chromatography O 
- O 
based O 
metabonomics O 
analysis O 
was O 
applied O 
to O 
investigate O 
the O 
urinary O 
metabolite O 
profiling O 
of O 
the O 
renoprotective O 
effect O 
of O 
FLP O 
on O 
adenine B-TRIVIAL 
-induced O 
chronic O 
kidney O 
disease O 
( O 
CKD O 
) O 
rat O 
model O 
and O 
involved O 
possible O 
mechanism O 
. O 
MATERIAL O 
AND O 
METHODS O 
: O 
A O 
metabonomic O 
approach O 
based O 
on O 
ultra O 
performance O 
liquid O 
chromatography O 
coupled O 
with O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
high O 
- O 
sensitivity O 
mass O 
spectrometry O 
and O 
a O 
novel O 
mass O 
spectrometry(Elevated O 
Energy O 
) O 
data O 
collection O 
technique O 
was O 
developed O 
. O 
The O 
resulting O 
dataset O 
was O 
analyzed O 
by O 
principal O 
component O 
analysis O 
and O 
partial O 
least O 
squares O 
discriminant O 
analysis O 
. O 
The O 
identification O 
of O 
all O 
potential O 
biomarkers O 
was O 
performed O 
using O 
reference O 
standard O 
by O 
comparing O 
their O 
mass O 
spectra O 
, O 
MS(E) O 
fragments O 
information O 
, O 
isotopic O 
pattern O 
and O 
MassLynx O 
i-FIT O 
algorithm O 
. O 
RESULTS O 
: O 
By O 
partial O 
least O 
squares O 
- O 
discriminate O 
analysis O 
analyses O 
, O 
15 O 
biomarkers O 
in O 
rat O 
urine O 
were O 
identified O 
and O 
11 O 
of O 
them O 
were O 
related O 
to O 
the O 
pathway O 
of O 
adenine B-TRIVIAL 
metabolism O 
and O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
. O 
Among O 
these O 
biomarkers O 
, O 
eight O 
biomarkers O 
like O 
adenine B-TRIVIAL 
, O 
L-acetylcarnitine B-SYSTEMATIC 
, O 
8-hydroxyadenine B-SYSTEMATIC 
, O 
hypoxanthine B-TRIVIAL 
, O 
creatine B-TRIVIAL 
, O 
methionine B-TRIVIAL 
, O 
phytosphingosine B-TRIVIAL 
and O 
phenylalanine B-TRIVIAL 
were O 
reversed O 
to O 
the O 
control O 
level O 
in O 
FLP O 
- O 
treated O 
groups O 
and O 
six O 
biomarkers O 
like O 
2,8-dihydroxyadenine B-SYSTEMATIC 
, O 
indole-3-carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
3-methyldioxyindole B-SYSTEMATIC 
, I-SYSTEMATIC 
ethyl-N2-acetyl-L-argininate B-SYSTEMATIC 
, I-SYSTEMATIC 
3-O-methyldopa B-SYSTEMATIC 
and O 
xanthurenic B-TRIVIAL 
acid I-TRIVIAL 
were O 
reversed O 
to O 
high O 
normal O 
group O 
by O 
FLP O 
, O 
which O 
indicates O 
that O 
the O 
urinary O 
metabolic O 
pattern O 
significantly O 
changed O 
after O 
FLP O 
treatment O 
. O 
CONCLUSIONS O 
: O 
Our O 
study O 
indicates O 
that O 
FLP O 
treatment O 
can O 
ameliorate O 
CKD O 
by O 
intervening O 
in O 
some O 
dominating O 
metabolic O 
pathways O 
, O 
such O 
as O 
adenine B-TRIVIAL 
metabolism O 
and O 
amino B-FAMILY 
acid I-FAMILY 
metabolism O 
. O 
The O 
metabonomic O 
results O 
not O 
only O 
supplied O 
a O 
systematic O 
view O 
of O 
the O 
development O 
and O 
progression O 
of O 
CKD O 
and O 
mechanism O 
studies O 
of O 
FLP O 
but O 
also O 
provided O 
the O 
theoretical O 
basis O 
for O 
the O 
prevention O 
or O 
treatment O 
of O 
CKD O 
. O 

RELEVANCE O 
: O 
Bauhinia O 
thonningii O 
Schum O 
. O 
( O 
Cesalpiniaceae O 
) O 
is O 
locally O 
known O 
as O 
Tambarib O 
and O 
used O 
to O 
treat O 
various O 
diseases O 
including O 
gastric O 
ulcer O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
The O 
current O 
study O 
aims O 
to O 
evaluate O 
the O 
gastroprotecive O 
mechanism(s) O 
of O 
methanolic O 
( O 
MEBT O 
) O 
and O 
chloroform B-TRIVIAL 
( O 
CEBT O 
) O 
extracts O 
of O 
Bauhinia O 
thonningii O 
leaves O 
on O 
ethanol B-SYSTEMATIC 
-induced O 
gastric O 
ulceration O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Gastric O 
acidity O 
, O 
quantification O 
and O 
histochemistry O 
of O 
mucus O 
, O 
gross O 
and O 
microscopic O 
examination O 
, O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
, O 
lipid O 
peroxidation O 
, O 
2D O 
gel O 
electrophoresis O 
, O 
mass O 
spectroscopy O 
and O 
biochemical O 
tests O 
were O 
utilized O 
to O 
assess O 
the O 
mechanism(s) O 
underlying O 
the O 
gastroprotective O 
effects O 
of O 
MEBT O 
and O 
CEBT O 
. O 
Effect O 
of O 
these O 
extracts O 
into O 
lipopolysaccharide O 
/ O 
interferon-γ O 
stimulated O 
rodent O 
cells O 
were O 
done O 
in O 
vitro O 
. O 
In O 
vitro O 
and O 
in O 
vivo O 
toxicity O 
studies O 
were O 
also O 
conducted O 
. O 
Antioxidant O 
activities O 
of O 
MEBT O 
and O 
CEBT O 
were O 
examined O 
using O 
DPPH B-ABBREVIATION 
, O 
FRAP O 
and O 
ORAC O 
assays O 
. O 
Phytochemical O 
analyses O 
of O 
MEBT O 
and O 
CEBT O 
were O 
conducted O 
using O 
chemical O 
and O 
spectroscopic O 
methods O 
. O 
RESULTS O 
: O 
Gross O 
and O 
histological O 
features O 
confirmed O 
the O 
anti-ulcerogenic O 
properties O 
of O 
Bauhinia O 
thonningii O 
. O 
Gastroprotective O 
mechanism O 
of O 
MEBT O 
was O 
observed O 
to O 
be O 
mediated O 
through O 
the O 
modulation O 
of O 
PAS-reactive O 
substances O 
, O 
MDA B-ABBREVIATION 
and O 
proteomics O 
biomarkers O 
( O 
creatine B-TRIVIAL 
kinase O 
, O 
malate B-TRIVIAL 
dehydrogenase O 
, O 
ATP B-ABBREVIATION 
synthase O 
, O 
actin O 
and O 
thioredoxin O 
) O 
. O 
MEBT O 
and O 
CEBT O 
showed O 
no O 
significant O 
in O 
vitro O 
and O 
in O 
vivo O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
. O 
Methanolic O 
extract O 
( O 
MEBT O 
) O 
showed O 
superior O 
gastroprotective O 
effects O 
, O 
polyphenolic O 
content O 
and O 
antioxidant O 
activities O 
compared O 
to O 
CEBT O 
. O 
The O 
plant O 
extracts O 
showed O 
no O 
in O 
vitro O 
or O 
in O 
vivo O 
toxicity O 
. O 
CONCLUSION O 
: O 
It O 
could O 
be O 
concluded O 
that O 
MEBT O 
possesses O 
anti-ulcer O 
activity O 
, O 
which O 
could O 
be O 
attributed O 
to O 
the O 
inhibition O 
of O 
ethanol B-SYSTEMATIC 
-induced O 
oxidative O 
damage O 
and O 
the O 
intervention O 
in O 
proteomic O 
pathways O 
but O 
not O 
the O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
pathway O 
. O 

promotes O 
the O 
nuclear O 
translocation O 
of O 
β-catenin O 
and O 
thereby O 
induces O 
osteoprotegerin O 
gene O 
expression O 
in O 
osteoblast O 
- O 
like O 
cell O 
lines O 
. O 

( O 
S1P B-ABBREVIATION 
) O 
is O 
a O 
well O 
- O 
known O 
signaling O 
sphingolipid B-FAMILY 
and O 
bioactive O 
lipid O 
mediator O 
. O 
Recently O 
, O 
it O 
was O 
reported O 
that O 
S1P B-ABBREVIATION 
inhibits O 
osteoclast O 
differentiation O 
and O 
bone O 
resorption O 
. O 
On O 
the O 
other O 
hand O 
, O 
S1P B-ABBREVIATION 
effects O 
on O 
osteoblasts O 
and O 
bone O 
formation O 
are O 
little O 
known O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
S1P B-ABBREVIATION 
on O 
osteoblasts O 
, O 
using O 
two O 
osteoblast O 
- O 
like O 
cell O 
lines O 
, O 
SaOS-2 O 
and O 
MC3T3-E1 O 
. O 
S1P B-ABBREVIATION 
activated O 
phosphatidylinositol B-TRIVIAL 
3-kinase O 
( O 
PI3K O 
) O 
/ O 
Akt O 
signaling O 
, O 
leading O 
to O 
the O 
inhibition O 
of O 
glycogen O 
synthase O 
kinase-3β O 
and O 
the O 
nuclear O 
translocation O 
of O 
β-catenin O 
, O 
followed O 
by O 
the O 
increase O 
of O 
the O 
transcriptional O 
activity O 
by O 
β-catenin O 
/ O 
T-cell O 
factor O 
complex O 
formation O 
in O 
both O 
SaOS-2 O 
cells O 
and O 
MC3T3-E1 O 
cells O 
. O 
The O 
inhibitors O 
of O 
PI3K O 
and O 
Akt O 
suppressed O 
S1P B-ABBREVIATION 
-induced O 
nuclear O 
localization O 
of O 
β-catenin O 
. O 
We O 
further O 
investigated O 
the O 
effects O 
of O 
PI3K O 
/ O 
Akt O 
signaling O 
on O 
the O 
Wnt O 
/ O 
β-catenin O 
signaling O 
pathway O 
, O 
since O 
β-catenin O 
takes O 
a O 
central O 
role O 
in O 
this O 
signaling O 
pathway O 
. O 
Both O 
inhibitors O 
for O 
PI3K O 
and O 
Akt O 
suppressed O 
the O 
nuclear O 
localization O 
of O 
β-catenin O 
and O 
T-cell O 
factor O 
transcriptional O 
activity O 
induced O 
by O 
Wnt-3a O 
. O 
S1P B-ABBREVIATION 
increased O 
the O 
amount O 
of O 
osteoprotegerin O 
at O 
both O 
mRNA O 
and O 
protein O 
levels O 
, O 
and O 
increased O 
the O 
activity O 
of O 
alkaline O 
phosphatase O 
, O 
leading O 
to O 
the O 
mineralization O 
. O 
These O 
findings O 
suggest O 
that O 
S1P B-ABBREVIATION 
activates O 
the O 
PI3K O 
/ O 
Akt O 
signaling O 
pathway O 
leading O 
to O 
the O 
promotion O 
of O 
nuclear O 
translocation O 
of O 
β-catenin O 
in O 
osteoblast O 
- O 
like O 
cells O 
, O 
resulting O 
in O 
the O 
upregulation O 
of O 
osteoptotegerin O 
and O 
osteoblast O 
differentiation O 
markers O 
including O 
alkaline O 
phosphatase O 
, O 
probably O 
relating O 
to O 
the O 
inhibition O 
of O 
osteoclast O 
formation O 
and O 
the O 
mineralization O 
, O 
respectively O 
. O 

fusion O 
is O 
a O 
critical O 
process O 
that O 
contributes O 
to O 
the O 
growth O 
of O 
muscle O 
during O 
development O 
and O 
to O 
the O 
regeneration O 
of O 
myofibers O 
upon O 
injury O 
. O 
Myoblasts O 
fuse O 
with O 
each O 
other O 
as O 
well O 
as O 
with O 
multinucleated O 
myotubes O 
to O 
enlarge O 
the O 
myofiber O 
. O 
Initial O 
studies O 
demonstrated O 
that O 
myoblast O 
fusion O 
requires O 
extracellular O 
calcium B-SYSTEMATIC 
and O 
changes O 
in O 
cell O 
membrane O 
topography O 
and O 
cytoskeletal O 
organization O 
. O 
More O 
recent O 
studies O 
have O 
identified O 
several O 
cell O 
- O 
surface O 
and O 
intracellular O 
proteins O 
that O 
mediate O 
myoblast O 
fusion O 
. O 
Furthermore O 
, O 
emerging O 
evidence O 
suggests O 
that O 
myoblast O 
fusion O 
is O 
also O 
regulated O 
by O 
the O 
activation O 
of O 
specific O 
cell O 
- O 
signaling O 
pathways O 
that O 
lead O 
to O 
the O 
expression O 
of O 
genes O 
whose O 
products O 
are O 
essential O 
for O 
the O 
fusion O 
process O 
and O 
for O 
modulating O 
the O 
activity O 
of O 
molecules O 
that O 
are O 
involved O 
in O 
cytoskeletal O 
rearrangement O 
. O 
Here O 
, O 
we O 
review O 
the O 
roles O 
of O 
the O 
major O 
signaling O 
pathways O 
in O 
mammalian O 
myoblast O 
fusion O 
. O 

of O 
one O 
- O 
dimensional O 
magnetism O 
in O 
graphene B-TRIVIAL 
via O 
spontaneous O 
hydrogenation O 
of O 
the O 
grain O 
boundary O 
. O 

propose O 
that O 
control O 
of O 
one O 
- O 
dimensional O 
( O 
1D O 
) O 
magnetism O 
in O 
graphene B-TRIVIAL 
could O 
be O 
made O 
easier O 
by O 
spontaneous O 
hydrogenation O 
of O 
chemically O 
reactive O 
grain O 
boundaries O 
( O 
GBs O 
) O 
in O 
polycrystalline O 
graphenes B-FAMILY 
. O 
Unlike O 
pristine O 
graphene B-TRIVIAL 
, O 
where O 
hydrogen B-SYSTEMATIC 
adsorption O 
favors O 
the O 
formation O 
of O 
zero O 
- O 
dimensional O 
( O 
0D O 
) O 
clusters O 
, O 
the O 
defect O 
cores O 
( O 
pentagon O 
, O 
heptagon O 
and O 
octagon O 
) O 
at O 
the O 
GBs O 
in O 
polycrystalline O 
graphene B-TRIVIAL 
promote O 
hydrogenation O 
along O 
the O 
GBs O 
. O 
The O 
hydrogenation O 
in O 
polycrystalline O 
graphene B-TRIVIAL 
starts O 
at O 
the O 
GBs O 
, O 
proceeds O 
gradually O 
towards O 
the O 
grain O 
interior O 
( O 
GI O 
) O 
and O 
results O 
in O 
smooth O 
1D O 
graphane B-TRIVIAL 
- O 
graphene B-TRIVIAL 
interfaces O 
. O 
Our O 
calculations O 
show O 
that O 
the O 
type O 
( O 
ferro B-TRIVIAL 
- O 
or O 
antiferro O 
- O 
magnetism O 
) O 
and O 
strength O 
of O 
the O 
magnetism O 
can O 
be O 
controlled O 
by O 
controlling O 
the O 
orientation O 
of O 
GBs O 
. O 
Since O 
GBs O 
in O 
single O 
- O 
layer O 
graphenes B-FAMILY 
can O 
be O 
fabricated O 
in O 
a O 
controllable O 
way O 
in O 
experiments O 
, O 
the O 
hydrogenation O 
of O 
GBs O 
could O 
be O 
a O 
unique O 
method O 
to O 
realize O 
large O 
- O 
area O 
magnetic O 
graphenes B-FAMILY 
for O 
future O 
spintronic O 
applications O 
. O 

Cholesterol B-TRIVIAL 
Subfractions O 
and O 
the O 
Effect O 
of O 
Testosterone B-TRIVIAL 
Replacement O 
in O 
Hypogonadism O 
. O 

disorders O 
and O 
cardiovascular O 
events O 
are O 
increased O 
in O 
hypogonadism O 
. O 
Serum O 
HDL O 
composition O 
is O 
a O 
better O 
cardiovascular O 
predictor O 
than O 
the O 
HDL O 
counts O 
. O 
However O 
, O 
there O 
is O 
no O 
information O 
about O 
the O 
HDL O 
subfractions O 
in O 
patients O 
with O 
hypogonadism O 
. O 
We O 
designed O 
a O 
prospective O 
study O 
to O 
investigate O 
the O 
HDL O 
subfractions O 
in O 
treatment O 
naïve O 
subjects O 
with O 
hypogonadism O 
and O 
the O 
effects O 
of O 
2 O 
different O 
testosterone B-TRIVIAL 
replacement O 
regimens O 
on O 
the O 
HDL O 
subfractions O 
. O 
Seventy O 
young O 
male O 
patients O 
with O 
congenital O 
hypogonadotropic O 
hypogonadism O 
( O 
CHH O 
) O 
and O 
70 O 
age O 
and O 
BMI-matched O 
healthy O 
males O 
were O 
enrolled O 
in O 
the O 
present O 
study O 
. O 
The O 
patients O 
were O 
assigned O 
to O 
receive O 
intramuscular O 
injections O 
of O 
testosterone B-FAMILY 
esters I-FAMILY 
250 O 
mg O 
every O 
3 O 
weeks O 
and O 
transdermal O 
testosterone O 
applications O 
50 O 
mg O 
daily O 
. O 
Biochemical O 
investigations O 
including O 
HDL O 
subfractions O 
and O 
insulin O 
resistance O 
were O 
done O 
. O 
Patients O 
with O 
CHH O 
had O 
higher O 
levels O 
of O 
insulin O 
, O 
HOMA-IR O 
, O 
WC O 
, O 
triglyceride B-FAMILY 
, O 
and O 
diastolic O 
blood O 
pressure O 
. O 
Although O 
, O 
the O 
HDL O 
cholesterol B-TRIVIAL 
concentrations O 
were O 
similar O 
in O 
both O 
groups O 
, O 
hypogonadal O 
patients O 
had O 
lower O 
HDL2 O 
and O 
higher O 
HDL3 O 
levels O 
. O 
The O 
total O 
testosterone B-TRIVIAL 
levels O 
were O 
independent O 
determinants O 
of O 
the O 
HDL2 O 
subfractions O 
. O 
During O 
the O 
follow O 
- O 
up O 
, O 
a O 
significant O 
increase O 
in O 
the O 
BMI O 
and O 
WC O 
values O 
and O 
a O 
significant O 
decrease O 
in O 
the O 
levels O 
of O 
total O 
cholesterol B-TRIVIAL 
, O 
HDL O 
cholesterol B-TRIVIAL 
, O 
and O 
HDL3 O 
were O 
observed O 
. O 
No O 
difference O 
was O 
present O 
between O 
the O 
2 O 
treatment O 
arms O 
. O 
These O 
results O 
show O 
that O 
patients O 
with O 
hypogonadism O 
have O 
unfavorable O 
HDL O 
compositions O 
in O 
addition O 
to O 
the O 
other O 
dysmetabolic O 
features O 
. O 
However O 
, O 
testosterone B-TRIVIAL 
replacement O 
for O 
about O 
six O 
months O 
neither O 
improves O 
the O 
metabolic O 
problems O 
nor O 
the O 
HDL O 
composition O 
. O 
Mechanistic O 
studies O 
are O 
warranted O 
to O 
better O 
understand O 
the O 
cardiovascular O 
effects O 
of O 
unfavorable O 
HDL O 
compositions O 
in O 
hypogonadism O 
. O 

NiO B-FORMULA 
microflake O 
films O 
with O 
high O 
coloration O 
efficiency O 
, O 
cyclic O 
stability O 
and O 
low O 
power O 
consumption O 
for O 
applications O 
in O 
a O 
complementary O 
electrochromic O 
device O 
. O 

have O 
demonstrated O 
that O 
thin O 
films O 
of O 
hierarchical O 
NiO B-FORMULA 
microflakes O 
assembled O 
from O 
nanoleaves O 
can O 
be O 
grown O 
directly O 
on O 
FTO B-ABBREVIATION 
-coated O 
glass O 
substrates O 
using O 
a O 
facile O 
and O 
template O 
- O 
free O 
hydrothermal O 
technique O 
. O 
This O 
hierarchical O 
structure O 
holds O 
the O 
advantages O 
of O 
both O 
nanometre O 
- O 
sized O 
building O 
blocks O 
and O 
microsized O 
assemblies O 
. O 
Thus O 
, O 
the O 
films O 
exhibit O 
highly O 
enhanced O 
electrochromic O 
performances O 
and O 
cyclic O 
stability O 
due O 
to O 
their O 
high O 
surface O 
area O 
and O 
good O 
electrochemical O 
stability O 
. O 
Moreover O 
, O 
a O 
complementary O 
electrochromic O 
device O 
combining O 
the O 
hierarchical O 
NiO B-FORMULA 
microflake O 
film O 
with O 
a O 
self O 
- O 
weaving O 
WO3 B-FORMULA 
nanoflake O 
film O 
is O 
fabricated O 
to O 
further O 
improve O 
the O 
electrochromic O 
performance O 
. O 
As O 
a O 
result O 
, O 
the O 
complementary O 
electrochromic O 
device O 
shows O 
a O 
high O 
optical O 
modulation O 
( O 
73.2% O 
at O 
550 O 
nm O 
) O 
, O 
large O 
coloration O 
efficiency O 
( O 
146.9 O 
cm(2) O 
C(-1) O 
at O 
550 O 
nm O 
by O 
applying O 
a O 
low O 
coloration O 
voltage O 
of O 
-1 O 
V O 
) O 
and O 
fast O 
switching O 
responses O 
with O 
a O 
coloring O 
time O 
of O 
1.8 O 
s O 
and O 
a O 
bleaching O 
time O 
of O 
3.2 O 
s O 
. O 
It O 
is O 
also O 
observed O 
that O 
there O 
is O 
no O 
significant O 
degradation O 
of O 
the O 
electrochromic O 
properties O 
after O 
2000 O 
continuous O 
coloration O 
/ O 
bleaching O 
cycles O 
, O 
making O 
it O 
attractive O 
for O 
practical O 
applications O 
. O 

, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
cyclopropyl B-SYSTEMATIC 
analogues O 
of O 
stilbene B-TRIVIAL 
with O 
raloxifene B-TRIVIAL 
side O 
chain O 
as O 
subtype O 
- O 
selective O 
ligands O 
for O 
estrogen B-FAMILY 
receptor O 
. O 

have O 
designed O 
the O 
cyclopropane B-SYSTEMATIC 
analog O 
of O 
stilbene B-TRIVIAL 
as O 
subtype O 
- O 
selective O 
ligands O 
for O 
estrogen B-FAMILY 
receptor O 
based O 
on O 
the O 
bioisosterism O 
that O 
cyclopropane B-SYSTEMATIC 
could O 
act O 
as O 
alkene B-FAMILY 
bioisoster O 
. O 
Three O 
cyclopropane B-SYSTEMATIC 
analogs O 
were O 
prepared O 
efficiently O 
starting O 
from O 
4-benzyloxybenzaldehyde B-SYSTEMATIC 
, O 
and O 
evaluated O 
for O 
their O 
binding O 
to O 
estrogen B-FAMILY 
receptors O 
ERα O 
and O 
ERβ O 
. O 
These O 
cyclopropane B-SYSTEMATIC 
analogs O 
were O 
also O 
found O 
to O 
be O 
full O 
agonists O 
in O 
estrogen B-FAMILY 
receptor O 
- O 
mediated O 
gene O 
transcription O 
assay O 
. O 
Compared O 
to O 
the O 
stilbene B-TRIVIAL 
analogs O 
such O 
as O 
tamoxifen B-TRIVIAL 
and O 
raloxifene B-TRIVIAL 
, O 
the O 
three O 
cyclopropane B-SYSTEMATIC 
analogs O 
showed O 
lower O 
binding O 
affinity O 
for O 
estrogen B-FAMILY 
receptor O 
, O 
but O 
higher O 
subtype O 
selectivity O 
for O 
ERα O 
. O 
The O 
structure O 
- O 
activity O 
relationship O 
revealed O 
from O 
this O 
study O 
might O 
provide O 
clues O 
for O 
improving O 
subtype O 
selectivity O 
for O 
ERα O 
. O 

Biodegradable O 
Polymersome O 
Containing O 
Bcl-xL O 
siRNA O 
and O 
Doxorubicin B-TRIVIAL 
as O 
a O 
Dual O 
Delivery O 
Vehicle O 
for O 
a O 
Synergistic O 
Anticancer O 
Effect O 
. O 

cancer O 
treatment O 
via O 
co O 
- O 
delivery O 
of O 
siRNAs O 
and O 
an O 
anticancer O 
drug O 
can O 
be O 
a O 
promising O 
strategy O 
due O 
to O 
the O 
synergistic O 
effect O 
of O 
simultaneously O 
minimizing O 
gene O 
/ O 
drug O 
administration O 
. O 
In O 
this O 
study O 
, O 
Bcl-xL O 
siRNA O 
and O 
doxorubicin B-TRIVIAL 
( O 
DOX B-ABBREVIATION 
) O 
are O 
encapsulated O 
into O 
designed O 
methoxy B-SYSTEMATIC 
- O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
-block- O 
poly(D,L-lactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
mPEG B-ABBREVIATION 
-b- O 
PLA B-ABBREVIATION 
) O 
block O 
copolymer O 
polymersomes O 
( O 
PSomes O 
) O 
. O 
A O 
study O 
of O 
the O 
cytotoxicity O 
of O 
Bcl-xL O 
siRNA O 
and O 
DOX B-ABBREVIATION 
co O 
- O 
encapsulated O 
PSomes O 
( O 
CPSomes O 
) O 
shows O 
more O 
inhibited O 
proliferation O 
of O 
MKN-45 O 
and O 
MKN-28 O 
human O 
gastric O 
cancer O 
cell O 
lines O 
than O 
only O 
gene- O 
and O 
drug O 
- O 
loaded O 
ones O 
. O 
Consequently O 
, O 
these O 
results O 
demonstrate O 
that O 
co O 
- O 
delivery O 
of O 
genes O 
and O 
drugs O 
using O 
PSomes O 
results O 
in O 
a O 
synergistic O 
efficacy O 
and O 
indicates O 
the O 
potential O 
of O 
PSomes O 
as O 
efficient O 
nanocarriers O 
for O 
combined O 
cancer O 
therapy O 
. O 

new O 
glycosidic O 
constituents O 
( O 
1-6 O 
) O 
, O 
together O 
with O 
10 O 
known O 
analogs O 
, O 
have O 
been O 
isolated O 
from O 
the O 
bark O 
of O 
Machilus O 
robusta O 
. O 
Structures O 
of O 
the O 
new O 
compounds O 
, O 
including O 
the O 
absolute O 
configurations O 
, O 
were O 
determined O 
by O 
spectroscopic O 
and O 
chemical O 
methods O 
as O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-nectandrin I-SYSTEMATIC 
B-β-d-glucopyranoside I-SYSTEMATIC 
( O 
1 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(7R,7'R,8S,8'R)-4,4'-dihydroxy-3,3'-dimethoxy-7,7'-epoxylignan-4-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
2 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(7R,7'R,8S,8'R)-4,4'-dihydroxy-3,3'-dimethoxy-7,7'-epoxylignan-4'-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
3 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(8S,8'R)-4,4'-dihydroxy-3,3',5'-trimethoxylignan-4'-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-(7R,8R)-syringylglycerol-8-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
5 O 
) O 
, O 
and O 
( B-SYSTEMATIC 
- I-SYSTEMATIC 
)-3-hydroxy-2-methyl-4-pyrone-3-O-β-d-xylopyranosyl-(1 I-SYSTEMATIC 
→ I-SYSTEMATIC 
6)-O-β-d-glucopyranoside I-SYSTEMATIC 
( O 
6 O 
) O 
, O 
respectively O 
. O 

from O 
the O 
Chinese O 
liverwort O 
Plagiochila O 
pulcherrima O 
and O 
their O 
cytotoxic O 
effects O 
. O 

new O 
pimarane B-TRIVIAL 
-type O 
diterpenoids B-FAMILY 
, O 
7β,11α-dihydroxypimara-8(14),15-diene B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
1β,11α-dihydroxypimara-8(14),15-diene B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
and O 
11α-hydroxypimara-8(14),15-diene B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
five O 
2,3-secoaromadendrane B-SYSTEMATIC 
-type O 
sesquiterpenoids B-FAMILY 
, O 
including O 
a O 
new O 
one O 
, O 
ethyoxyplagiochiline B-SYSTEMATIC 
A2 I-SYSTEMATIC 
( O 
4 O 
) O 
, O 
and O 
three O 
known O 
fusicoccane B-FAMILY 
-type O 
diterpenoids B-FAMILY 
were O 
isolated O 
from O 
the O 
Chinese O 
liverwort O 
Plagiochila O 
pulcherrima O 
. O 
Their O 
structures O 
were O 
established O 
on O 
the O 
basis O 
of O 
extensive O 
spectroscopic O 
analysis O 
. O 
Compounds O 
6 O 
and O 
7 O 
exhibited O 
moderate O 
inhibitory O 
activity O 
on O 
the O 
proliferation O 
of O 
human O 
cancer O 
cell O 
lines O 
Hela O 
, O 
A172 O 
, O 
and O 
H460 O 
. O 
Moreover O 
, O 
the O 
cytotoxicity O 
of O 
compound O 
6 O 
to O 
Hela O 
cells O 
was O 
related O 
to O 
apoptotis O 
as O 
confirmed O 
by O 
DAPI O 
nuclear O 
staining O 
and O 
flow O 
cytometry O 
. O 

of O 
2'- B-FAMILY 
substituted I-FAMILY 
(2S,1'R,2'S)-2-(carboxycyclopropyl)glycine I-FAMILY 
analogues O 
as O 
potent O 
N-methyl-D-aspartic B-SYSTEMATIC 
acid I-SYSTEMATIC 
receptor O 
ligands O 
. O 

series O 
of O 
2'- O 
substituted O 
analogues O 
of O 
the O 
selective O 
NMDA B-ABBREVIATION 
receptor O 
ligand O 
(2S,1'R,2'S)-2-(carboxycyclopropyl)glycine B-SYSTEMATIC 
( O 
(S)-CCG-IV B-ABBREVIATION 
) O 
have O 
been O 
designed O 
, O 
synthesized O 
and O 
pharmacologically O 
characterized O 
. O 
The O 
design O 
was O 
based O 
on O 
a O 
docking O 
study O 
hypothesizing O 
that O 
substituents O 
in O 
the O 
2'- O 
position O 
would O 
protrude O 
into O 
a O 
region O 
where O 
differences O 
among O 
the O 
NMDA B-ABBREVIATION 
receptors O 
GluN2 O 
subunits O 
exist O 
. O 
Various O 
synthetic O 
routes O 
were O 
explored O 
, O 
and O 
two O 
different O 
routes O 
provided O 
a O 
series O 
of O 
alkyl O 
- O 
substituted O 
analogues O 
. O 
Pharmacological O 
characterization O 
disclosed O 
that O 
these O 
compounds O 
are O 
NMDA B-ABBREVIATION 
receptor O 
agonists O 
and O 
that O 
potency O 
decreases O 
with O 
increasing O 
size O 
of O 
the O 
alkyl O 
groups O 
. O 
Variations O 
in O 
agonist O 
activity O 
are O 
observed O 
at O 
recombinant O 
NMDA B-ABBREVIATION 
receptor O 
subtypes O 
with O 
increasing O 
size O 
of O 
the O 
alkyl O 
- O 
substituents O 
and O 
are O 
developing O 
differently O 
depending O 
on O 
the O 
GluN2 O 
subunit O 
. O 
This O 
study O 
demonstrates O 
that O 
it O 
is O 
possible O 
to O 
introduce O 
substituents O 
in O 
the O 
2'- O 
position O 
of O 
(S)-CCG-IV B-ABBREVIATION 
while O 
maintaining O 
agonist O 
activity O 
and O 
that O 
variation O 
among O 
NMDA B-ABBREVIATION 
receptor O 
subtypes O 
may O 
be O 
achieved O 
by O 
probing O 
this O 
region O 
of O 
the O 
receptor O 
. O 

: O 
Postmenopausal O 
osteoporosis O 
is O 
a O 
chronic O 
disease O 
that O 
exerts O 
a O 
significant O 
burden O 
on O 
both O 
individuals O 
and O 
the O 
community O 
. O 
Hence O 
, O 
there O 
is O 
a O 
requirement O 
for O 
long O 
- O 
term O 
treatment O 
to O 
be O 
associated O 
with O 
a O 
positive O 
benefit O 
- O 
risk O 
balance O 
. O 
Areas O 
covered O 
: O 
In O 
this O 
descriptive O 
review O 
, O 
the O 
long O 
- O 
term O 
safety O 
of O 
calcitonin O 
, O 
selective O 
estrogen B-FAMILY 
receptor O 
modulators O 
( O 
SERMs O 
) O 
, O 
bisphosphonates B-FAMILY 
, O 
denosumab O 
and O 
strontium B-SYSTEMATIC 
ranelate I-SYSTEMATIC 
was O 
reviewed O 
based O 
on O 
randomized O 
controlled O 
trials O 
of O 
3 O 
years O 
or O 
longer O 
supplemented O 
by O 
extension O 
study O 
data O 
and O 
data O 
from O 
large O 
, O 
observational O 
studies O 
. O 
Expert O 
opinion O 
: O 
Rare O 
adverse O 
events O 
become O 
apparent O 
with O 
all O 
currently O 
available O 
treatments O 
for O 
osteoporosis O 
with O 
long O 
- O 
term O 
therapy O 
. O 
Due O 
to O 
the O 
rarity O 
of O 
these O 
adverse O 
events O 
and O 
to O 
the O 
worldwide O 
burden O 
of O 
osteoporosis O 
, O 
the O 
benefit O 
- O 
risk O 
balance O 
remains O 
in O 
favor O 
of O 
the O 
beneficial O 
effects O 
of O 
treatment O 
on O 
an O 
outcome O 
rather O 
than O 
the O 
probability O 
of O 
an O 
adverse O 
effect O 
. O 
No O 
single O 
antiosteoporosis O 
agent O 
is O 
appropriate O 
for O 
all O 
patients O 
. O 
Treatment O 
decisions O 
should O 
be O 
made O 
on O 
an O 
individual O 
basis O 
, O 
taking O 
into O 
account O 
the O 
relative O 
benefits O 
and O 
risks O 
in O 
different O 
patient O 
populations O 
. O 

( O 
PGs O 
) O 
modulate O 
numerous O 
signaling O 
pathways O 
during O 
development O 
through O 
binding O 
of O 
their O 
glycosaminoglycan O 
( O 
GAG O 
) O 
side O 
chains O 
to O 
various O 
signaling O 
molecules O 
, O 
including O 
fibroblast O 
growth O 
factors O 
( O 
FGFs O 
) O 
. O 
A O 
majority O 
of O 
PGs O 
possess O 
two O 
or O 
more O 
GAG O 
side O 
chains O 
, O 
suggesting O 
that O 
GAG O 
multivalency O 
is O 
imperative O 
for O 
biological O 
functions O 
in O 
vivo O 
. O 
However O 
, O 
only O 
a O 
few O 
studies O 
have O 
examined O 
the O 
biological O 
significance O 
of O 
GAG O 
multivalency O 
. O 
In O 
this O 
report O 
, O 
we O 
utilized O 
a O 
library O 
of O 
bis- B-MULTIPLE 
and I-MULTIPLE 
tris I-MULTIPLE 
- I-MULTIPLE 
xylosides I-MULTIPLE 
that O 
produce O 
two O 
and O 
three O 
GAG O 
chains O 
on O 
the O 
same O 
scaffold O 
, O 
respectively O 
, O 
thus O 
mimicking O 
PGs O 
, O 
to O 
examine O 
the O 
importance O 
of O 
GAG O 
valency O 
and O 
chain O 
type O 
in O 
regulating O 
FGF O 
/ O 
FGFR O 
interactions O 
in O 
vivo O 
in O 
zebrafish O 
. O 
A O 
number O 
of O 
bis- B-MULTIPLE 
and I-MULTIPLE 
tris I-MULTIPLE 
- I-MULTIPLE 
xylosides I-MULTIPLE 
, O 
but O 
not O 
mono-xylosides B-FAMILY 
, O 
caused O 
an O 
elongation O 
phenotype O 
upon O 
their O 
injection O 
into O 
embryos O 
. O 
In O 
situ O 
hybridization O 
showed O 
that O 
elongated O 
embryos O 
have O 
elevated O 
expression O 
of O 
the O 
FGF O 
target O 
gene O 
mkp3 O 
but O 
unchanged O 
expression O 
of O 
reporters O 
for O 
other O 
pathways O 
, O 
indicating O 
that O 
FGF O 
/ O 
FGFR O 
signaling O 
was O 
specifically O 
hyperactivated O 
. O 
In O 
support O 
of O 
this O 
observation O 
, O 
elongation O 
can O 
be O 
reversed O 
by O 
the O 
tyrosine O 
kinase O 
inhibitor O 
SU5402 B-IDENTIFIER 
, O 
mRNA O 
for O 
the O 
FGFR O 
antagonist O 
sprouty4 O 
, O 
or O 
FGF8 O 
morpholino O 
. O 
Endogenous O 
GAGs O 
seem O 
to O 
be O 
unaffected O 
after O 
xyloside B-FAMILY 
treatment O 
, O 
suggesting O 
that O 
this O 
is O 
a O 
gain O 
- O 
of O 
- O 
function O 
phenotype O 
. O 
Furthermore O 
, O 
expression O 
of O 
a O 
multivalent O 
but O 
not O 
a O 
monovalent O 
GAG O 
containing O 
syndecan-1 O 
proteoglycan O 
recapitulates O 
the O 
elongation O 
phenotype O 
observed O 
with O 
the O 
bivalent O 
xylosides B-FAMILY 
. O 
On O 
the O 
basis O 
of O 
these O 
in O 
vivo O 
findings O 
, O 
we O 
propose O 
a O 
new O 
model O 
for O 
GAG O 
/ O 
FGF O 
/ O 
FGFR O 
interactions O 
in O 
which O 
dimerized O 
GAG O 
chains O 
can O 
activate O 
FGF O 
- O 
mediated O 
signal O 
transduction O 
pathways O 
. O 

of O 
Aristolochic B-TRIVIAL 
Acid I-TRIVIAL 
I I-TRIVIAL 
into O 
Aristolic B-TRIVIAL 
Acid I-TRIVIAL 
by O 
Reaction O 
with O 
Cysteine B-TRIVIAL 
and O 
Glutathione B-TRIVIAL 
: O 
Biological O 
Implications O 
. O 

acid I-TRIVIAL 
I I-TRIVIAL 
( O 
AA-I B-ABBREVIATION 
) O 
, O 
naturally O 
occurring O 
in O 
Aristolochia O 
plants O 
, O 
is O 
a O 
potent O 
nephrotoxin O 
and O 
carcinogen O 
. O 
Here O 
we O 
report O 
that O 
AA-I B-ABBREVIATION 
suffers O 
hydrogenolysis O 
with O 
loss O 
of O 
the O 
nitro B-SYSTEMATIC 
group O 
by O 
reaction O 
with O 
cysteine B-TRIVIAL 
or O 
glutathione B-TRIVIAL 
to O 
give O 
aristolic B-TRIVIAL 
acid I-TRIVIAL 
. O 
Since O 
the O 
reaction O 
can O 
proceed O 
in O 
aqueous O 
solutions O 
at O 
pH O 
7 O 
and O 
37 O 
°C O 
, O 
it O 
is O 
inferred O 
that O 
it O 
may O 
also O 
occur O 
in O 
biological O 
systems O 
and O 
contribute O 
to O 
the O 
nephrotoxic O 
effects O 
induced O 
by O 
AA-I B-ABBREVIATION 
. O 

- O 
delivered O 
angiopoietin-1 O 
treatment O 
for O 
phosgene B-TRIVIAL 
-induced O 
acute O 
lung O 
injury O 
. O 

Context O 
: O 
Exposure O 
to O 
phosgene B-TRIVIAL 
can O 
result O 
in O 
an O 
acute O 
lung O 
injury O 
, O 
leading O 
to O 
pulmonary O 
edema O 
and O 
even O 
death O 
. O 
Angiopoietin-1 O 
( O 
Ang1 O 
) O 
is O 
a O 
critical O 
factor O 
for O 
vascular O 
stabilization O 
due O 
to O 
its O 
ability O 
to O 
reduce O 
endothelial O 
permeability O 
and O 
inflammation O 
. O 
Objective O 
: O 
In O 
this O 
study O 
, O 
the O 
histopathological O 
changes O 
of O 
the O 
lungs O 
after O 
exposure O 
to O 
phosgene B-TRIVIAL 
and O 
the O 
effect O 
of O 
Ang1 O 
treatment O 
were O 
examined O 
. O 
Materials O 
and O 
methods O 
: O 
Rats O 
were O 
exposed O 
to O 
phosgene B-TRIVIAL 
gas O 
at O 
8.33 O 
g O 
/ O 
m(3) O 
for O 
5 O 
min O 
. O 
Ang1 O 
overexpressing O 
rats O 
were O 
established O 
by O 
an O 
intravenous O 
injection O 
of O 
adenovirus-Ang1 O 
( O 
Ad O 
/ O 
Ang1 O 
) O 
. O 
The O 
histological O 
changes O 
of O 
the O 
lung O 
were O 
examined O 
by O 
Haematoxylin B-TRIVIAL 
- O 
Eosin B-FAMILY 
( O 
H&E O 
) O 
staining O 
and O 
fluorescence O 
microscopy O 
. O 
The O 
inferior O 
lobe O 
was O 
used O 
for O 
the O 
determination O 
of O 
the O 
ratio O 
of O 
wet O 
weight O 
to O 
dry O 
weight O 
of O 
the O 
lung O 
. O 
The O 
concentration O 
of O 
cytokines O 
in O 
the O 
serum O 
and O 
bronchoalveolar O 
lavage O 
fluid O 
was O 
determined O 
by O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
. O 
Results O 
: O 
The O 
pathological O 
analysis O 
showed O 
signs O 
of O 
inflammation O 
and O 
edema O 
, O 
evident O 
from O 
a O 
significant O 
increase O 
in O 
the O 
number O 
of O 
leukocytes O 
in O 
bronchoalveolar O 
lavage O 
fluid O 
and O 
the O 
ratio O 
of O 
wet O 
to O 
dry O 
weight O 
of O 
the O 
lungs O 
. O 
The O 
lung O 
injury O 
induced O 
by O 
phosgene B-TRIVIAL 
was O 
markedly O 
reduced O 
after O 
the O 
injection O 
of O 
Ad O 
/ O 
Ang1 O 
. O 
The O 
increase O 
of O 
IL-1β O 
and O 
IL-17 O 
and O 
decrease O 
of O 
vascular O 
endothelial O 
growth O 
factor O 
in O 
the O 
serum O 
and O 
bronchoalveolar O 
lavage O 
fluid O 
of O 
phosgene B-TRIVIAL 
-exposed O 
animals O 
were O 
abolished O 
by O 
the O 
administration O 
of O 
Ad O 
/ O 
Ang1 O 
. O 
Discussion O 
and O 
conclusions O 
: O 
Ang1 O 
has O 
the O 
beneficial O 
effects O 
on O 
phosgene B-TRIVIAL 
-induced O 
lung O 
injury O 
. O 
The O 
adenovirus O 
- O 
delivered O 
Ang1 O 
may O 
have O 
the O 
potential O 
as O 
a O 
novel O 
approach O 
for O 
the O 
treatment O 
of O 
the O 
acute O 
lung O 
injury O 
caused O 
by O 
phosgene B-TRIVIAL 
gas O 
inhalation O 
in O 
humans O 
. O 

reduced O 
genomes O 
of O 
the O 
apicoplast O 
and O 
mitochondrion O 
of O 
the O 
malaria O 
parasite O 
Plasmodium O 
falciparum O 
are O 
actively O 
translated O 
and O 
antibiotic O 
- O 
mediated O 
translation O 
inhibition O 
is O 
detrimental O 
to O 
parasite O 
survival O 
. O 
In O 
order O 
to O 
understand O 
recycling O 
of O 
organellar O 
ribosomes O 
, O 
a O 
critical O 
step O 
in O 
protein O 
translation O 
, O 
we O 
identified O 
ribosome O 
recycling O 
factors O 
( O 
RRF O 
) O 
encoded O 
by O 
the O 
parasite O 
nuclear O 
genome O 
. O 
Targeting O 
of O 
PfRRF1 O 
and O 
PfRRF2 O 
to O 
the O 
apicoplast O 
and O 
mitochondrion O 
respectively O 
was O 
established O 
by O 
localization O 
of O 
leader O 
sequence-GFP O 
fusions O 
. O 
Unlike O 
any O 
RRF O 
characterized O 
thus O 
far O 
, O 
PfRRF2 O 
formed O 
dimers O 
with O 
disulphide B-SYSTEMATIC 
interaction(s) O 
and O 
additionally O 
localized O 
in O 
the O 
cytoplasm O 
, O 
thus O 
suggesting O 
adjunct O 
functions O 
for O 
the O 
factor O 
. O 
PfRRF1 O 
carries O 
a O 
large O 
108- O 
amino-acid B-FAMILY 
insertion O 
in O 
the O 
functionally O 
critical O 
hinge O 
region O 
between O 
the O 
head O 
and O 
tail O 
domains O 
of O 
the O 
protein O 
, O 
yet O 
complemented O 
Escherichia O 
coli O 
RRF O 
in O 
the O 
LJ14frr(ts) O 
mutant O 
and O 
disassembled O 
surrogate O 
E. O 
coli O 
70S O 
ribosomes O 
in O 
the O 
presence O 
of O 
apicoplast O 
- O 
targeted O 
EF-G O 
. O 
Recombinant O 
PfRRF2 O 
bound O 
E. O 
coli O 
ribosomes O 
and O 
could O 
split O 
monosomes O 
in O 
the O 
presence O 
of O 
the O 
relevant O 
mitochondrial O 
EF-G O 
but O 
failed O 
to O 
complement O 
the O 
LJ14frr(ts) O 
mutant O 
. O 
Although O 
proteins O 
comprising O 
subunits O 
of O 
P. O 
falciparum O 
organellar O 
ribosomes O 
are O 
predicted O 
to O 
differ O 
from O 
bacterial O 
and O 
mitoribosomal O 
counterparts O 
, O 
our O 
results O 
indicate O 
that O 
the O 
essential O 
interactions O 
required O 
for O 
recycling O 
are O 
conserved O 
in O 
parasite O 
organelles O 
. O 

new O 
lignan O 
(7S,8R,7'R,8'R)-7-(3,4-methylenedioxyphenyl)-8,8'-dimethyl-8'-hydroxyl-7'-methoxyl-7'-(3',4'-methylenedioxyphenyl)-tetrahydrofuran B-SYSTEMATIC 
( O 
1 O 
) O 
, O 
one O 
new O 
sesquiterpene O 
2-hydroxy-11,12-dehydrocalamenene B-SYSTEMATIC 
( O 
2 O 
) O 
, O 
one O 
new O 
natural O 
product O 
erythro-1-(3,4-dimethoxyphenyl)-4-(3,4-methylenedioxyphenyl)-2,3-dimethyl-butane B-SYSTEMATIC 
( O 
3 O 
) O 
, O 
and O 
two O 
known O 
lignans B-FAMILY 
(+)-anwulignan(erythro-1-(4-hydroxy-3-methoxyphenyl)-4-(3,4-methylenedioxyphenyl)-2,3-dimethyl-butane) B-SYSTEMATIC 
( O 
4 O 
) O 
and O 
( B-TRIVIAL 
- I-TRIVIAL 
)-zuonin-A I-TRIVIAL 
( O 
5 O 
) O 
were O 
isolated O 
from O 
the O 
stems O 
of O 
Schisandra O 
glaucescens O 
Diels O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
spectroscopic O 
methods O 
. O 
The O 
cytotoxicity O 
of O 
compounds O 
1 O 
and O 
2 O 
was O 
assayed O 
. O 

of O 
different O 
polymers O 
on O 
crystallization O 
tendency O 
and O 
dissolution O 
behavior O 
of O 
cilnidipine B-TRIVIAL 
in O 
solid O 
dispersions O 
. O 

Context O 
: O 
Cilnidipine B-TRIVIAL 
( O 
CN O 
) O 
is O 
a O 
novel O 
dihydropyridine B-SYSTEMATIC 
calcium B-SYSTEMATIC 
antagonist O 
that O 
is O 
practically O 
insoluble O 
in O 
aqueous O 
media O 
and O 
exhibits O 
a O 
low O 
oral O 
bioavailability O 
or O 
limited O 
clinical O 
efficacy O 
. O 
Objective O 
: O 
This O 
study O 
investigated O 
the O 
effects O 
of O 
three O 
commercial O 
and O 
chemically O 
diverse O 
polymers O 
- O 
PVP B-ABBREVIATION 
, O 
PVP B-ABBREVIATION 
/ O 
VA O 
and O 
Soluplus B-TRIVIAL 
- O 
on O 
crystallization O 
tendency O 
and O 
in O 
vitro O 
dissolution O 
profiles O 
of O 
CN O 
in O 
order O 
to O 
determine O 
an O 
optimum O 
carrier O 
for O 
composing O 
the O 
preferred O 
solid O 
dispersion O 
( O 
SD O 
) O 
of O 
CN O 
. O 
Methods O 
: O 
All O 
these O 
co O 
- O 
evaporated O 
systems O 
were O 
characterized O 
up O 
to O 
3 O 
months O 
by O 
thermoanalytical O 
( O 
DSC O 
) O 
, O 
crystallographic O 
( O 
POM O 
, O 
PXRD O 
) O 
, O 
microscopic O 
( O 
SEM O 
) O 
and O 
spectroscopic O 
( O 
FTIR O 
) O 
techniques O 
. O 
Results O 
: O 
The O 
results O 
showed O 
that O 
the O 
polymers O 
could O 
be O 
sorted O 
by O 
their O 
effects O 
of O 
inhibiting O 
CN O 
crystallization O 
in O 
the O 
ascending O 
order O 
: O 
Soluplus B-TRIVIAL 
, O 
PVP B-ABBREVIATION 
/ O 
VA O 
, O 
PVP B-ABBREVIATION 
. O 
The O 
sequence O 
was O 
in O 
accordance O 
with O 
that O 
of O 
the O 
strength O 
of O 
drug O 
- O 
polymer O 
hydrogen O 
bonds O 
revealed O 
by O 
FTIR O 
spectra O 
. O 
It O 
could O 
be O 
ascribed O 
to O 
relative O 
hydrogen B-SYSTEMATIC 
-bonding O 
acceptor O 
strengths O 
of O 
N-vinylpyrrolidone B-SYSTEMATIC 
moiety O 
in O 
the O 
polymer O 
molecules O 
. O 
On O 
the O 
other O 
hand O 
, O 
all O 
the O 
SDs O 
showed O 
enhanced O 
dissolution O 
profiles O 
compared O 
to O 
pure O 
CN O 
alone O 
. O 
On O 
their O 
effects O 
of O 
enhancing O 
CN O 
dissolution O 
, O 
the O 
polymers O 
could O 
be O 
sorted O 
in O 
the O 
descending O 
order O 
: O 
Soluplus B-TRIVIAL 
, O 
PVP B-ABBREVIATION 
, O 
PVP B-ABBREVIATION 
/ O 
VA O 
. O 
Conclusions O 
: O 
It O 
implied O 
that O 
the O 
dissolution O 
behavior O 
of O 
CN O 
could O 
bear O 
a O 
close O 
relationship O 
to O 
both O 
hydration O 
capacity O 
and O 
hydrogen B-SYSTEMATIC 
-bonding O 
interaction O 
tendency O 
of O 
moieties O 
of O 
the O 
polymers O 
. O 
It O 
might O 
suggest O 
an O 
optimal O 
formulation O 
for O 
CN O 
comprising O 
both O 
PVP B-ABBREVIATION 
and O 
Soluplus B-TRIVIAL 
. O 

Acid I-FAMILY 
and O 
Sterol B-FAMILY 
Metabolism O 
with O 
Combined O 
HMGCoA O 
Reductase O 
and O 
PCSK9 O 
Suppression O 
. O 

inhibition O 
markedly O 
augments O 
the O 
LDL O 
lowering O 
action O 
of O 
statins O 
. O 
The O 
combination O 
is O 
being O 
evaluated O 
for O 
long O 
- O 
term O 
effects O 
on O 
atherosclerotic O 
disease O 
outcomes O 
. O 
However O 
, O 
effects O 
of O 
combined O 
treatment O 
on O 
hepatic O 
cholesterol B-TRIVIAL 
and O 
bile B-FAMILY 
acid I-FAMILY 
metabolism O 
have O 
not O 
yet O 
been O 
reported O 
. O 
To O 
study O 
this O 
, O 
PCSK9-Y119X O 
mutant O 
( O 
knockout O 
) O 
and O 
wild O 
type O 
mice O 
were O 
treated O 
± O 
atorvastatin B-TRIVIAL 
for O 
12 O 
wks O 
. O 
Atorvastatin B-TRIVIAL 
progressively O 
lowered O 
plasma O 
LDL O 
in O 
each O 
group O 
, O 
but O 
no O 
differences O 
in O 
liver O 
cholesterol B-TRIVIAL 
, O 
cholesterol B-FAMILY 
ester I-FAMILY 
, O 
or O 
total O 
bile B-FAMILY 
acid I-FAMILY 
concentrations O 
, O 
or O 
in O 
plasma O 
total O 
bile B-FAMILY 
acid I-FAMILY 
levels O 
were O 
seen O 
. O 
In O 
contrast O 
, O 
atorvastatin B-TRIVIAL 
increased O 
fecal O 
total O 
bile B-FAMILY 
acids I-FAMILY 
( O 
~2-fold O 
, O 
P O 
< O 
0.01 O 
) O 
and O 
cholesterol B-TRIVIAL 
concentrations O 
( O 
~3-fold O 
, O 
P O 
< O 
0.01 O 
) O 
vs O 
. O 
controls O 
for O 
both O 
PCSK9-Y119X O 
and O 
wild O 
type O 
mice O 
. O 
All O 
14 O 
individual O 
bile B-FAMILY 
acids I-FAMILY 
resolved O 
by O 
LC-MS O 
, O 
including O 
primary O 
, O 
secondary O 
, O 
and O 
conjugated O 
species O 
, O 
reflected O 
similar O 
increases O 
. O 
Expression O 
of O 
key O 
liver O 
bile B-FAMILY 
acid I-FAMILY 
synthesis O 
genes O 
CYP7A1 O 
and O 
CYP8B1 O 
were O 
~2.5-fold O 
higher O 
with O 
atorvastatin B-TRIVIAL 
in O 
both O 
strains O 
, O 
but O 
mRNA O 
for O 
liver O 
bile B-FAMILY 
acid I-FAMILY 
export O 
and O 
reuptake O 
transporters O 
and O 
conjugating O 
enzymes O 
were O 
not O 
unaffected O 
. O 
The O 
data O 
suggest O 
that O 
hepatocyte O 
cholesterol B-TRIVIAL 
and O 
bile B-FAMILY 
acid I-FAMILY 
homeostasis O 
is O 
maintained O 
with O 
combined O 
PCSK9 O 
and O 
HMGCoA O 
reductase O 
inhibition O 
through O 
efficient O 
liver O 
enzymatic O 
conversion O 
of O 
LDL O 
- O 
derived O 
cholesterol B-TRIVIAL 
into O 
bile B-FAMILY 
acids I-FAMILY 
and O 
excretion O 
of O 
both O 
, O 
with O 
undisturbed O 
enterohepatic O 
recycling O 
. O 

is O 
one O 
of O 
the O 
most O 
popularly O 
consumed O 
beverage O 
. O 
Depending O 
on O 
the O 
manufacturing O 
process O 
, O 
different O 
varieties O 
of O 
tea O 
can O 
be O 
produced O 
. O 
The O 
antioxidative O 
and O 
antimutagenic O 
potential O 
of O 
tea O 
in O 
cardiovascular O 
diseases O 
, O 
cancer O 
and O 
obesity O 
have O 
long O 
been O 
studied O 
. O 
These O 
therapeutic O 
and O 
nutritional O 
benefits O 
of O 
tea O 
can O 
be O 
attributed O 
to O 
the O 
presence O 
of O 
flavanoids B-FAMILY 
. O 
However O 
, O 
these O 
flavanoids B-FAMILY 
also O 
have O 
certain O 
detrimental O 
effects O 
on O 
human O 
health O 
when O 
their O 
consumption O 
exceeds O 
certain O 
limits O 
. O 
The O 
toxicity O 
of O 
these O 
flavanoids B-FAMILY 
can O 
be O 
attributed O 
to O 
the O 
formation O 
of O 
reactive O 
oxygen B-SYSTEMATIC 
species O 
in O 
the O 
body O 
which O 
causes O 
damage O 
to O 
the O 
DNA O 
, O 
lipid O 
membranes O 
etc O 
. O 
The O 
aim O 
of O 
this O 
review O 
is O 
to O 
summarize O 
briefly O 
, O 
the O 
less O 
studied O 
evidences O 
of O 
various O 
forms O 
of O 
toxicity O 
associated O 
with O 
tea O 
and O 
its O 
harmful O 
effects O 
on O 
human O 
health O 
. O 

/ O 
HYPOTHESIS O 
: O 
PPARGC1A O 
and O 
PPARGC1B O 
encode O 
transcriptional O 
coactivators O 
that O 
regulate O 
numerous O 
type O 
2 O 
diabetes O 
- O 
related O 
metabolic O 
processes O 
. O 
Common O 
genetic O 
variation O 
across O 
PPARGC1A O 
/ O 
B O 
was O 
characterised O 
by O 
genotyping O 
tagging O 
variants O 
. O 
We O 
then O 
tested O 
associations O 
of O 
these O 
variants O 
with O 
diabetes O 
incidence O 
or O 
change O 
in O 
quantifiable O 
metabolic O 
traits O 
directly O 
or O 
via O 
interactions O 
( O 
with O 
metformin B-TRIVIAL 
treatment O 
or O 
intensive O 
lifestyle O 
modification O 
) O 
in O 
the O 
Diabetes O 
Prevention O 
Program O 
( O 
DPP O 
) O 
, O 
a O 
randomised O 
controlled O 
trial O 
in O 
persons O 
at O 
high O 
risk O 
of O 
type O 
2 O 
diabetes O 
. O 
METHODS O 
: O 
We O 
used O 
Tagger O 
software O 
to O 
select O 
75 O 
PPARGC1A O 
and O 
94 O 
PPARGC1B O 
tag O 
single O 
nucleotide O 
polymorphisms O 
( O 
SNPs O 
) O 
for O 
analysis O 
. O 
These O 
SNPs O 
were O 
tested O 
for O 
association O 
with O 
diabetes O 
incidence O 
using O 
Cox O 
proportional O 
hazards O 
regression O 
models O 
, O 
and O 
a O 
range O 
of O 
relevant O 
metabolic O 
quantifiable O 
traits O 
, O 
using O 
generalised O 
linear O 
models O 
. O 
RESULTS O 
: O 
Eight O 
PPARGC1A O 
variants O 
were O 
nominally O 
( O 
p O 
< O 
0.05 O 
) O 
associated O 
with O 
diabetes O 
incidence O 
, O 
of O 
which O 
one O 
( O 
rs3736265 O 
/ O 
Thr612Met O 
) O 
was O 
associated O 
with O 
diabetes O 
in O 
the O 
DPP O 
( O 
HR O 
1.31 O 
, O 
95% O 
CI O 
1.05 O 
, O 
1.63 O 
per O 
copy O 
of O 
the O 
612 O 
Met B-FORMULA 
allele O 
) O 
and O 
in O 
the O 
DIAGRAM O 
database O 
( O 
OR O 
1.11 O 
, O 
95% O 
CI O 
1.01 O 
, O 
1.21 O 
) O 
. O 
Consistent O 
with O 
earlier O 
reports O 
, O 
the O 
Gly482Ser O 
( O 
rs8192678 O 
) O 
variant O 
showed O 
nominally O 
significant O 
effects O 
on O 
1 O 
year O 
accumulation O 
of O 
adiposity O 
and O 
worsening O 
insulin O 
resistance O 
( O 
both O 
p O 
< O 
0.05 O 
) O 
. O 
A O 
third O 
PPARGC1A O 
variant O 
( O 
rs2970852 O 
) O 
modified O 
the O 
effects O 
of O 
metformin B-TRIVIAL 
on O 
triacylglycerol B-FAMILY 
levels O 
( O 
p O 
interaction O 
= O 
0.04 O 
; O 
p O 
= O 
0.0001 O 
for O 
association O 
of O 
SNP O 
with O 
triacylglycerol B-FAMILY 
concentrations O 
in O 
metformin B-TRIVIAL 
-treated O 
participants O 
) O 
. O 
A O 
number O 
of O 
other O 
PPARGC1A O 
/ O 
B O 
variants O 
were O 
nominally O 
directly O 
associated O 
with O 
diabetes O 
incidence O 
or O 
modified O 
treatment O 
effects O 
on O 
diabetes O 
incidence O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
These O 
findings O 
provide O 
some O 
novel O 
and O 
confirmatory O 
insights O 
into O 
the O 
roles O 
of O 
PPARGC1A O 
/ O 
B O 
variation O 
in O 
type O 
2 O 
diabetes O 
and O 
related O 
metabolic O 
traits O 
. O 
TRIAL O 
REGISTRATION O 
: O 
ClinicalTrials.gov O 
NCT00004992 O 
. O 

- O 
operating O 
- O 
voltage O 
flexible O 
organic O 
thin O 
- O 
film O 
transistors O 
with O 
high O 
thermal O 
stability O 
using O 
DPh-DNTT B-ABBREVIATION 
and O 
SAM O 
gate O 
dielectrics O 
are O 
reported O 
. O 
The O 
mobility O 
of O 
the O 
transistors O 
are O 
decreased O 
by O 
23% O 
after O 
heating O 
to O 
250 O 
°C O 
for O 
30 O 
min O 
. O 
Furthermore O 
, O 
flexible O 
organic O 
pseudo-CMOS O 
inverter O 
circuits O 
, O 
which O 
are O 
functional O 
after O 
heating O 
to O 
200 O 
°C O 
. O 

copper B-SYSTEMATIC 
-catalyzed O 
azide-alkyne B-FAMILY 
" O 
click O 
" O 
cycloaddition O 
reaction O 
is O 
an O 
efficient O 
coupling O 
reaction O 
that O 
results O 
in O 
the O 
formation O 
of O 
a O 
triazole B-FAMILY 
ring O 
. O 
The O 
wide O 
range O 
of O 
applicable O 
substrates O 
for O 
this O 
reaction O 
allows O 
the O 
construction O 
of O 
a O 
variety O 
of O 
conjugated O 
systems O 
. O 
The O 
additional O 
function O 
of O 
triazoles B-FAMILY 
as O 
metal O 
- O 
ion O 
ligands O 
has O 
led O 
to O 
the O 
click O 
reaction O 
being O 
used O 
for O 
the O 
construction O 
of O 
optical O 
sensors O 
for O 
metal O 
ions O 
. O 
The O 
triazoles B-FAMILY 
are O 
integral O 
binding O 
elements O 
, O 
which O 
are O 
formed O 
in O 
an O 
efficient O 
modular O 
synthesis O 
. O 
Herein O 
, O 
we O 
review O 
recent O 
examples O 
of O 
triazoles B-FAMILY 
as O 
a O 
metal O 
- O 
binding O 
element O 
in O 
conjugated O 
metal O 
- O 
ion O 
sensors O 
. O 

Induced O 
Luminescence O 
Quenching O 
: O 
Static O 
and O 
Time-Resolved O 
X-Ray O 
Absorption O 
Spectroscopy O 
of O 
a O 
Copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
Phenanthroline I-SYSTEMATIC 
Complex O 
. O 

present O 
a O 
static O 
and O 
picosecond O 
X-ray O 
absorption O 
study O 
at O 
the O 
Cu B-FORMULA 
K-edge O 
of O 
Bis(2,9-dimethyl-1,10-phenanthroline)copper B-SYSTEMATIC 
(I) I-SYSTEMATIC 
( O 
[Cu(dmp)2]+ B-FORMULA 
; O 
dmp B-ABBREVIATION 
= O 
2,9-dimethyl-1,10-phenanthroline B-SYSTEMATIC 
) O 
dissolved O 
in O 
acetonitrile B-SYSTEMATIC 
and O 
dichloromethane B-SYSTEMATIC 
. O 
The O 
steady O 
state O 
photoluminescence O 
spectra O 
in O 
dichloromethane B-SYSTEMATIC 
and O 
acetonitrile B-SYSTEMATIC 
are O 
also O 
presented O 
and O 
show O 
a O 
shift O 
to O 
longer O 
wavelengths O 
for O 
the O 
latter O 
, O 
which O 
points O 
to O 
a O 
stronger O 
stabilisation O 
of O 
the O 
excited O 
complex O 
. O 
The O 
fine O 
structure O 
features O 
of O 
the O 
static O 
and O 
transient O 
X-ray O 
spectra O 
allow O 
an O 
unambiguous O 
assignment O 
of O 
the O 
electronic O 
and O 
geometric O 
structure O 
of O 
the O 
molecule O 
in O 
both O 
its O 
ground O 
and O 
excited O 
3MLCT O 
states O 
. O 
Importantly O 
, O 
the O 
transient O 
spectra O 
are O 
remarkably O 
similar O 
for O 
both O 
solvents O 
and O 
the O 
spectral O 
changes O 
can O 
be O 
rationalised O 
using O 
the O 
optimised O 
ground O 
and O 
excited O 
state O 
structures O 
of O 
the O 
complex O 
. O 
The O 
proposed O 
assignment O 
of O 
the O 
lifetime O 
shortening O 
of O 
the O 
excited O 
state O 
in O 
donor O 
solvents O 
( O 
acetonitrile B-SYSTEMATIC 
) O 
to O 
a O 
metal O 
centred O 
exciplex O 
is O 
not O 
corroborated O 
here O 
. O 
Molecular O 
dynamics O 
simulations O 
confirm O 
the O 
lack O 
of O 
complexation O 
, O 
however O 
in O 
both O 
solvents O 
the O 
molecules O 
come O 
close O 
to O 
the O 
metal O 
but O 
undergo O 
rapid O 
exchange O 
with O 
the O 
bulk O 
. O 
The O 
shortening O 
of O 
the O 
lifetime O 
of O 
the O 
title O 
complex O 
and O 
nine O 
additional O 
related O 
complexes O 
can O 
be O 
rationalised O 
by O 
the O 
decrease O 
of O 
the O 
3MLCT O 
energy O 
. O 
Deviations O 
from O 
this O 
trend O 
may O 
be O 
explained O 
by O 
means O 
of O 
the O 
effects O 
of O 
the O 
dihedral O 
angle O 
between O 
the O 
ligand O 
planes O 
, O 
the O 
solvent O 
and O 
the O 
3MLCT-1MLCT O 
energy O 
gap O 
. O 

Xerogel O 
Microspheres O 
and O 
Monoliths O 
from O 
Resorcinol B-TRIVIAL 
- O 
Formaldehyde B-SYSTEMATIC 
Mixtures O 
with O 
Varying O 
Dilution O 
Ratios O 
: O 
Preparation O 
, O 
Surface O 
Characteristics O 
, O 
and O 
Electrochemical O 
Double O 
- O 
Layer O 
Capacitances O 
. O 

xerogels O 
in O 
the O 
form O 
of O 
microspheres O 
and O 
monoliths O 
were O 
obtained O 
from O 
the O 
sol O 
- O 
gel O 
polymerization O 
of O 
resorcinol B-TRIVIAL 
and O 
formaldehyde B-SYSTEMATIC 
in O 
the O 
presence O 
of O 
potassium B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
as O 
catalyst O 
, O 
using O 
water O 
as O 
solvent O 
and O 
two O 
different O 
molar O 
dilution O 
ratios O 
. O 
The O 
objectives O 
of O 
this O 
study O 
were O 
as O 
follows O 
: O 
to O 
investigate O 
the O 
effect O 
of O 
the O 
dilution O 
ratio O 
, O 
polymerization O 
reaction O 
time O 
, O 
and O 
temperature O 
on O 
the O 
rheological O 
properties O 
of O 
the O 
sols O 
used O 
to O 
prepare O 
the O 
carbon B-SYSTEMATIC 
xerogel O 
microspheres O 
and O 
monoliths O 
; O 
and O 
to O 
determine O 
the O 
influence O 
of O 
their O 
preparation O 
methods O 
and O 
shapes O 
on O 
their O 
surface O 
characteristics O 
and O 
electrochemical O 
double O 
- O 
layer O 
( O 
EDL O 
) O 
capacitance O 
. O 
An O 
increase O 
in O 
the O 
molar O 
dilution O 
ratio O 
produced O 
a O 
decrease O 
in O 
the O 
apparent O 
activation O 
energy O 
of O 
the O 
sol O 
- O 
gel O 
transition O 
. O 
Carbon B-SYSTEMATIC 
xerogel O 
microspheres O 
were O 
steam O 
- O 
activated O 
at O 
different O 
burnoff O 
percentages O 
. O 
The O 
morphology O 
, O 
surface O 
area O 
, O 
porosity O 
, O 
and O 
surface O 
chemistry O 
of O 
samples O 
were O 
determined O 
. O 
The O 
main O 
difference O 
between O 
the O 
carbon B-SYSTEMATIC 
xerogel O 
microspheres O 
and O 
monoliths O 
was O 
that O 
the O 
latter O 
are O 
largely O 
mesoporous O 
. O 
Better O 
electrochemical O 
behavior O 
was O 
shown O 
by O 
carbon B-SYSTEMATIC 
xerogels O 
in O 
monolith O 
than O 
in O 
microsphere O 
form O 
, O 
but O 
higher O 
gravimetric O 
and O 
volumetric O 
capacitances O 
were O 
found O 
in O 
activated O 
carbon B-SYSTEMATIC 
xerogel O 
microspheres O 
than O 
in O 
carbon B-SYSTEMATIC 
xerogel O 
monoliths O 
. O 

substituted I-FAMILY 
thymidine I-FAMILY 
bioconjugates O 
for O 
cancer O 
therapy O 
and O 
imaging O 
. O 

compound O 
class O 
of O 
3-carboranyl B-SYSTEMATIC 
thymidine I-SYSTEMATIC 
analogues O 
( O 
3CTAs O 
) O 
are O 
boron B-SYSTEMATIC 
delivery O 
agents O 
for O 
boron B-SYSTEMATIC 
neutron O 
capture O 
therapy O 
( O 
BNCT O 
) O 
, O 
a O 
binary O 
treatment O 
modality O 
for O 
cancer O 
. O 
Presumably O 
, O 
these O 
compounds O 
accumulate O 
selectively O 
in O 
tumor O 
cells O 
via O 
intracellular O 
trapping O 
, O 
which O 
is O 
mediated O 
by O 
hTK1 O 
. O 
Favorable O 
in O 
vivo O 
biodistribution O 
profiles O 
of O 
3CTAs O 
led O 
to O 
promising O 
results O 
in O 
preclinical O 
BNCT O 
of O 
rats O 
with O 
intracerebral O 
brain O 
tumors O 
. O 
This O 
review O 
presents O 
an O 
overview O 
on O 
the O 
design O 
, O 
synthesis O 
, O 
and O 
biological O 
evaluation O 
of O 
first- O 
and O 
second O 
- O 
generation O 
3CTAs O 
. O 
Boronated O 
nucleosides O 
developed O 
prior O 
to O 
3CTAs O 
for O 
BNCT O 
and O 
non-boronated O 
N3- B-FAMILY 
substituted I-FAMILY 
thymidine I-FAMILY 
conjugates O 
for O 
other O 
areas O 
of O 
cancer O 
therapy O 
and O 
imaging O 
are O 
also O 
described O 
. O 
In O 
addition O 
, O 
basic O 
features O 
of O 
carborane B-SYSTEMATIC 
clusters O 
, O 
which O 
are O 
used O 
as O 
boron B-SYSTEMATIC 
moieties O 
in O 
the O 
design O 
and O 
synthesis O 
of O 
3CTAs O 
, O 
and O 
the O 
biological O 
and O 
structural O 
features O 
of O 
TK1 O 
- O 
like O 
enzymes O 
, O 
which O 
are O 
the O 
molecular O 
targets O 
of O 
3CTAs O 
, O 
are O 
discussed O 
. O 

Derivatives O 
with O 
Anti-Schistosomal O 
Activity O 
: O 
Aromatic O 
ring O 
Modification O 
. O 

series O 
of O 
aromatic O 
ring O 
modified O 
praziquantel B-TRIVIAL 
( O 
PZQ B-ABBREVIATION 
) O 
derivatives O 
were O 
prepared O 
and O 
evaluated O 
against O 
juvenile O 
and O 
adult O 
stage O 
of O 
Schistosoma O 
japonicumin O 
. O 
Several O 
analogues O 
comparable O 
in O 
activity O 
to O 
the O 
drug O 
PZQ B-ABBREVIATION 
have O 
been O 
identified O 
based O 
on O 
in O 
vitro O 
and O 
in O 
vivo O 
japonuicum O 
schistosomes O 
worm O 
viability O 
assay O 
. O 
Structure O 
and O 
activity O 
relationship O 
of O 
these O 
PZQ B-ABBREVIATION 
aromatic O 
ring O 
modified O 
compounds O 
was O 
revealed O 
. O 
Specifically O 
, O 
a O 
compound O 
in O 
which O 
a O 
bromine B-SYSTEMATIC 
has O 
been O 
introduced O 
in O 
the O 
aromatic O 
ring O 
of O 
praziquantel B-TRIVIAL 
demonstrated O 
close O 
antischistosomal O 
activity O 
to O 
praziquentel B-TRIVIAL 
in O 
vivo O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

Adsorption O 
of O 
Di-hydroxy B-MULTIPLE 
and I-MULTIPLE 
Tri I-MULTIPLE 
- I-MULTIPLE 
hydroxy I-MULTIPLE 
Bile I-MULTIPLE 
Salts I-MULTIPLE 
with O 
Whey O 
Protein O 
and O 
Casein O 
in O 
Oil-in-Water O 
Emulsions O 
. O 

competitive O 
adsorption O 
between O 
whey O 
protein O 
concentrate O 
( O 
WPC O 
) O 
or O 
sodium B-SYSTEMATIC 
caseinate O 
( O 
SCN O 
) O 
and O 
four O 
bile B-FAMILY 
salts I-FAMILY 
, O 
sodium B-SYSTEMATIC 
cholate I-SYSTEMATIC 
( O 
NaC B-ABBREVIATION 
) O 
, O 
dexocycholate B-TRIVIAL 
( O 
NaDC B-FORMULA 
) O 
, O 
taurocholate B-TRIVIAL 
( O 
NaTC B-FORMULA 
) O 
and O 
glycodeoxycholate B-TRIVIAL 
( O 
NaGDC B-FORMULA 
) O 
has O 
been O 
studied O 
in O 
protein O 
stabilized O 
oil O 
- O 
in O 
- O 
water O 
emulsions O 
. O 
The O 
bile O 
salts O 
that O 
contain O 
a O 
conjugated O 
amino B-FAMILY 
acid I-FAMILY 
( O 
NaTC B-FORMULA 
and O 
NaGDC B-FORMULA 
) O 
were O 
considerably O 
more O 
efficient O 
at O 
displacing O 
both O 
WPC O 
and O 
SCN O 
proteins O 
from O 
the O 
emulsion O 
droplet O 
interface O 
, O 
even O 
though O 
they O 
are O 
known O 
to O 
have O 
a O 
lower O 
hydrophobicity O 
than O 
NaC B-ABBREVIATION 
and O 
NaDC B-FORMULA 
. O 
This O 
is O 
explained O 
in O 
terms O 
of O 
a O 
steric O 
resistance O 
to O 
adsorption O 
from O 
the O 
conjugated O 
amino B-FAMILY 
acids I-FAMILY 
in O 
NaTC B-FORMULA 
and O 
NaGDC B-FORMULA 
. O 
This O 
leads O 
to O 
them O 
adopting O 
an O 
adsorbed O 
conformation O 
at O 
the O 
oil O 
- O 
water O 
interface O 
that O 
penetrates O 
less O 
into O 
the O 
oil O 
phase O 
causing O 
greater O 
disruption O 
of O 
the O 
adsorbed O 
layer O 
and O 
hence O 
leads O 
to O 
greater O 
displacement O 
of O 
protein O 
from O 
the O 
interface O 
. O 
Complementary O 
computer O 
simulations O 
of O 
the O 
adsorption O 
of O 
the O 
four O 
bile B-FAMILY 
salts I-FAMILY 
at O 
the O 
decane B-SYSTEMATIC 
-water O 
interface O 
support O 
the O 
hypothesis O 
that O 
the O 
NaTC B-FORMULA 
and O 
NaGDC B-FORMULA 
adopt O 
flatter O 
conformations O 
that O 
stick O 
out O 
further O 
in O 
to O 
the O 
aqueous O 
phase O 
, O 
which O 
arises O 
from O 
a O 
lower O 
free O 
energy O 
of O 
adsorption O 
. O 
The O 
adsorption O 
isotherms O 
for O 
the O 
four O 
bile B-FAMILY 
salts I-FAMILY 
have O 
also O 
been O 
measured O 
. O 
These O 
have O 
been O 
found O 
to O 
have O 
a O 
form O 
that O 
fits O 
closely O 
the O 
Langmuir-Freundlich O 
isotherm O 
. O 
The O 
results O 
for O 
NaC B-ABBREVIATION 
suggest O 
that O 
it O 
adsorbs O 
as O 
individual O 
molecules O 
and O 
forms O 
a O 
saturated O 
monolayer O 
over O 
much O 
of O 
the O 
concentration O 
range O 
used O 
in O 
the O 
displacement O 
experiments O 
, O 
since O 
it O 
is O 
below O 
its O 
critical O 
micelle O 
concentration O 
in O 
this O 
range O 
. O 
For O 
the O 
other O 
three O 
bile B-FAMILY 
salts I-FAMILY 
on O 
the O 
other O 
hand O 
, O 
the O 
primary O 
adsorbing O 
species O 
appears O 
to O 
be O 
the O 
micelle O 
form O 
, O 
since O 
the O 
surface O 
coverage O 
is O 
above O 
that O 
of O 
a O 
saturated O 
monolayer O 
for O 
much O 
of O 
the O 
concentration O 
range O 
studied O 
. O 

previously O 
reported O 
the O 
discovery O 
of O 
BRD0476 B-IDENTIFIER 
( O 
1 O 
) O 
, O 
a O 
small O 
molecule O 
generated O 
by O 
diversity O 
- O 
oriented O 
synthesis O 
that O 
suppresses O 
cytokine O 
- O 
induced O 
β-cell O 
apoptosis O 
. O 
Herein O 
, O 
we O 
report O 
the O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
1 O 
and O 
analogs O 
with O 
improved O 
aqueous O 
solubility O 
. O 
By O 
replacing O 
naphthyl B-SYSTEMATIC 
with O 
quinoline B-SYSTEMATIC 
moieties O 
, O 
we O 
prepared O 
active O 
analogs O 
with O 
up O 
to O 
a O 
1400-fold O 
increase O 
in O 
solubility O 
from O 
1 O 
. O 
In O 
addition O 
, O 
we O 
demonstrated O 
that O 
compound O 
1 O 
and O 
analogs O 
inhibit O 
STAT1 O 
signal O 
transduction O 
induced O 
by O 
IFN-γ O 
. O 

Differences O 
in O 
the O 
Sublimation O 
Energy O 
of O 
Benzene B-SYSTEMATIC 
and O 
Hexahalogenbenzenes B-FAMILY 
Are O 
Caused O 
by O 
Dispersion O 
Energy O 
. O 

crystals O 
of O 
benzene B-SYSTEMATIC 
and O 
hexahalogenbenzenes B-FAMILY 
have O 
been O 
studied O 
by O 
means O 
of O 
the O 
density O 
- O 
functional O 
theory O 
augmented O 
by O 
an O 
empirical O 
dispersion O 
correction O 
term O 
as O 
well O 
as O 
by O 
the O 
symmetry O 
- O 
adapted O 
perturbation O 
theory O 
. O 
In O 
order O 
to O 
elucidate O 
the O 
nature O 
of O 
noncovalent O 
binding O 
, O 
pairwise O 
interactions O 
have O 
been O 
investigated O 
. O 
It O 
has O 
been O 
demonstrated O 
that O 
the O 
structures O 
of O 
dimers O 
with O 
the O 
highest O 
stabilization O 
energy O 
differ O 
notably O 
along O 
the O 
crystals O 
. O 
It O 
has O 
been O 
shown O 
that O 
the O 
differences O 
in O 
the O 
experimental O 
sublimation O 
energies O 
might O 
be O 
attributed O 
to O 
the O 
dispersion O 
interaction O 
. O 
To O 
our O 
surprise O 
, O 
the O 
dihalogen B-FAMILY 
bonding O 
observed O 
in O 
the O 
hexachloro- B-MULTIPLE 
and I-MULTIPLE 
hexabromobenzenes I-MULTIPLE 
plays O 
a O 
rather O 
minor O 
role O 
in O 
energy O 
stabilization O 
, O 
because O 
they O 
are O 
energetically O 
comparable O 
with O 
the O 
other O 
binding O 
motifs O 
. O 
However O 
, O 
the O 
dihalogen B-FAMILY 
bond O 
is O 
by O 
far O 
the O 
most O 
frequent O 
binding O 
motif O 
in O 
hexachloro- B-MULTIPLE 
and I-MULTIPLE 
hexabromobenzenes I-MULTIPLE 
. O 

therapeutic O 
effects O 
of O 
probiotic O 
treatment O 
in O 
alcoholic O 
liver O 
disease O 
( O 
ALD O 
) O 
have O 
been O 
studied O 
in O 
both O 
patients O 
and O 
experimental O 
animal O 
models O 
. O 
Although O 
the O 
precise O 
mechanisms O 
of O 
the O 
pathogenesis O 
of O 
ALD O 
are O 
not O 
fully O 
understood O 
, O 
gut O 
- O 
derived O 
endotoxin O 
has O 
been O 
postulated O 
to O 
play O 
a O 
crucial O 
role O 
in O 
hepatic O 
inflammation O 
. O 
Previous O 
studies O 
have O 
demonstrated O 
that O 
probiotic O 
therapy O 
reduces O 
circulating O 
endotoxin O 
derived O 
from O 
intestinal O 
gram O 
- O 
negative O 
bacteria O 
in O 
ALD O 
. O 
In O 
this O 
study O 
, O 
we O 
investigated O 
the O 
effects O 
of O 
probiotics O 
on O 
hepatic O 
tumor O 
necrosis O 
factor-α O 
( O 
TNFα O 
) O 
production O 
and O 
inflammation O 
in O 
response O 
to O 
chronic O 
alcohol O 
ingestion O 
. O 
Mice O 
were O 
fed O 
Lieber O 
DeCarli O 
liquid O 
diet O 
containing O 
5% O 
alcohol O 
for O 
8weeks O 
, O 
and O 
Lactobacillus O 
rhamnosus O 
GG O 
( O 
LGG O 
) O 
was O 
supplemented O 
in O 
the O 
last O 
2 O 
weeks O 
. O 
Eight O 
- O 
week O 
alcohol O 
feeding O 
caused O 
a O 
significant O 
increase O 
in O 
hepatic O 
inflammation O 
as O 
shown O 
by O 
histological O 
assessment O 
and O 
hepatic O 
tissue O 
myeloperoxidase O 
activity O 
assay O 
. O 
Two O 
weeks O 
of O 
LGG O 
supplementation O 
reduced O 
hepatic O 
inflammation O 
and O 
liver O 
injury O 
and O 
markedly O 
reduced O 
TNFα O 
expression O 
. O 
Alcohol O 
feeding O 
increased O 
hepatic O 
mRNA O 
expression O 
of O 
Toll O 
- O 
like O 
receptors O 
( O 
TLRs O 
) O 
and O 
CYP2E1 O 
and O 
decreased O 
nuclear O 
factor O 
erythroid O 
2- O 
related O 
factor O 
2 O 
expression O 
. O 
LGG O 
supplementation O 
attenuated O 
these O 
changes O 
. O 
Using O 
human O 
peripheral O 
blood O 
monocytes O 
- O 
derived O 
macrophages O 
, O 
we O 
also O 
demonstrated O 
that O 
incubation O 
with O 
ethanol B-SYSTEMATIC 
primes O 
both O 
lipopolysaccharide- O 
and O 
flagellin O 
- O 
induced O 
TNFα O 
production O 
, O 
and O 
LGG O 
culture O 
supernatant O 
reduced O 
this O 
induction O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
In O 
addition O 
, O 
LGG O 
treatment O 
also O 
significantly O 
decreased O 
alcohol O 
- O 
induced O 
phosphorylation O 
of O 
p38 O 
MAP O 
kinase O 
. O 
In O 
conclusion O 
, O 
probiotic O 
LGG O 
treatment O 
reduced O 
alcohol O 
- O 
induced O 
hepatic O 
inflammation O 
by O 
attenuation O 
of O 
TNFα O 
production O 
via O 
inhibition O 
of O 
TLR4- O 
and O 
TLR5 O 
- O 
mediated O 
endotoxin O 
activation O 
. O 

- O 
activity O 
relationships O 
in O 
aminosterol B-FAMILY 
antibiotics O 
: O 
The O 
effect O 
of O 
stereochemistry O 
at O 
the O 
7-OH O 
group O 
. O 

and O 
three O 
aminosterol B-FAMILY 
analogs O 
have O 
been O 
shown O 
to O 
inhibit O 
bacterial O 
cell O 
growth O 
and O 
induce O 
lysis O 
of O 
large O 
unilamellar O 
phospholipid O 
vesicles O 
. O 
The O 
analogs O 
differ O 
in O 
the O 
identity O 
of O 
the O 
polyamine B-FAMILY 
attached O 
at O 
C3 O 
of O 
the O 
sterol B-FAMILY 
, O 
and O 
the O 
stereochemistry O 
of O 
a O 
hydroxyl B-SYSTEMATIC 
substituent O 
at O 
C7 O 
. O 
Analogs O 
with O 
a O 
tetraammonium B-SYSTEMATIC 
spermine I-SYSTEMATIC 
polyamine I-SYSTEMATIC 
are O 
somewhat O 
more O 
active O 
than O 
analogs O 
with O 
a O 
shorter O 
trisammonium B-SYSTEMATIC 
spermidine I-SYSTEMATIC 
polyamine I-SYSTEMATIC 
, O 
and O 
analogs O 
with O 
an O 
axial O 
( O 
α O 
) O 
hydroxyl B-SYSTEMATIC 
substituent O 
at O 
C7 O 
are O 
more O 
active O 
than O 
analogs O 
with O 
the O 
corresponding O 
equatorial O 
( O 
β O 
) O 
hydroxyl O 
group O 
. O 
There O 
is O 
some O 
variability O 
noted O 
; O 
the O 
7β-OH B-SYSTEMATIC 
spermine I-SYSTEMATIC 
analog O 
is O 
the O 
most O 
active O 
compound O 
against O 
Escherichia O 
coli O 
, O 
but O 
the O 
least O 
effective O 
against O 
Pseudomonas O 
aeruginosa O 
. O 
Lytic O 
activity O 
correlates O 
well O 
with O 
antimicrobial O 
activity O 
of O 
the O 
compounds O 
, O 
but O 
the O 
lytic O 
activity O 
varies O 
with O 
the O 
phospholipid O 
composition O 
of O 
the O 
vesicles O 
. O 

Regulation O 
of O 
the O 
Transcription O 
Factors O 
Nrf2 O 
and O 
ATF4 O 
Mediates O 
the O 
Enhancement O 
of O 
Glutathione B-TRIVIAL 
Levels O 
by O 
the O 
Flavonoid B-FAMILY 
Fisetin B-TRIVIAL 
. O 

( O 
GSH B-ABBREVIATION 
) O 
and O 
GSH B-ABBREVIATION 
-associated O 
metabolism O 
provide O 
the O 
major O 
line O 
of O 
defense O 
for O 
the O 
protection O 
of O 
cells O 
from O 
various O 
forms O 
of O 
toxic O 
stress O 
. O 
GSH B-ABBREVIATION 
also O 
plays O 
a O 
key O 
role O 
in O 
regulating O 
the O 
intracellular O 
redox O 
environment O 
. O 
Thus O 
, O 
maintenance O 
of O 
GSH B-ABBREVIATION 
levels O 
is O 
developing O 
into O 
an O 
important O 
therapeutic O 
objective O 
for O 
the O 
treatment O 
of O 
a O 
variety O 
of O 
diseases O 
. O 
Among O 
the O 
transcription O 
factors O 
that O 
play O 
critical O 
roles O 
in O 
GSH B-ABBREVIATION 
metabolism O 
are O 
NF-E2 O 
- O 
related O 
factor O 
2 O 
( O 
Nrf2 O 
) O 
and O 
activating O 
transcription O 
factor O 
4 O 
( O 
ATF4 O 
) O 
. O 
Thus O 
, O 
compounds O 
that O 
can O 
upregulate O 
these O 
transcription O 
factors O 
may O 
be O 
particularly O 
useful O 
as O 
treatment O 
options O 
through O 
their O 
effects O 
on O 
GSH B-ABBREVIATION 
metabolism O 
. O 
We O 
previously O 
showed O 
that O 
the O 
flavonoid B-FAMILY 
fisetin B-TRIVIAL 
not O 
only O 
increases O 
basal O 
levels O 
of O 
GSH B-ABBREVIATION 
but O 
also O 
maintains O 
GSH B-ABBREVIATION 
levels O 
under O 
oxidative O 
stress O 
conditions O 
. O 
However O 
, O 
the O 
mechanisms O 
underlying O 
these O 
effects O 
have O 
remained O 
unknown O 
until O 
now O 
. O 
Here O 
we O 
show O 
that O 
fisetin B-TRIVIAL 
rapidly O 
increases O 
the O 
levels O 
of O 
both O 
Nrf2 O 
and O 
ATF4 O 
as O 
well O 
as O 
Nrf2- O 
and O 
ATF4-dependent O 
gene O 
transcription O 
via O 
distinct O 
mechanisms O 
. O 
Although O 
fisetin B-TRIVIAL 
greatly O 
increases O 
the O 
stability O 
of O 
both O 
Nrf2 O 
and O 
ATF4 O 
, O 
only O 
the O 
effect O 
on O 
ATF4 O 
is O 
dependent O 
on O 
protein O 
kinase O 
activity O 
. O 
Using O 
siRNA O 
we O 
found O 
that O 
ATF4 O 
, O 
but O 
not O 
Nrf2 O 
, O 
is O 
important O 
for O 
fisetin B-TRIVIAL 
' O 
s O 
ability O 
to O 
increase O 
GSH B-ABBREVIATION 
levels O 
under O 
basal O 
conditions O 
whereas O 
both O 
ATF4 O 
and O 
Nrf2 O 
appear O 
to O 
cooperate O 
to O 
increase O 
GSH B-ABBREVIATION 
levels O 
under O 
oxidative O 
stress O 
conditions O 
. O 
Based O 
upon O 
these O 
results O 
, O 
we O 
hypothesize O 
that O 
compounds O 
able O 
to O 
increase O 
GSH B-ABBREVIATION 
levels O 
via O 
multiple O 
mechanisms O 
, O 
such O 
as O 
fisetin B-TRIVIAL 
, O 
will O 
be O 
particularly O 
effective O 
for O 
maintaining O 
GSH B-ABBREVIATION 
levels O 
under O 
a O 
variety O 
of O 
different O 
stresses O 
. O 

RELEVANCE O 
: O 
The O 
YiQiFuMai O 
injection O 
( O 
YQFM O 
) O 
is O 
a O 
traditional O 
Chinese O 
medicine O 
for O 
the O 
treatment O 
of O 
chronic O 
heart O 
failure O 
( O 
CHF O 
) O 
. O 
The O 
present O 
study O 
not O 
only O 
evaluated O 
the O 
cardioprotective O 
effect O 
and O 
anti-inflammatory O 
mechanism O 
of O 
the O 
YQFM O 
injection O 
in O 
an O 
experimental O 
model O 
of O 
CHF O 
but O 
also O 
investigated O 
its O 
bioactive O 
constituents O 
in O 
vitro O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
left O 
anterior O 
descending O 
coronary O 
artery O 
( O 
LAD O 
) O 
in O 
rats O 
was O 
ligated O 
to O 
make O 
an O 
animal O 
model O 
of O 
CHF O 
. O 
From O 
this O 
, O 
electrocardiographic O 
parameters O 
and O 
exterior O 
signs O 
of O 
rat O 
hearts O 
were O 
recorded O 
. O 
Additionally O 
, O 
the O 
histopathology O 
of O 
heart O 
tissues O 
was O 
examined O 
, O 
and O 
parameters O 
of O 
inflammatory O 
stress O 
were O 
measured O 
. O 
Experiments O 
were O 
performed O 
over O 
two O 
months O 
in O 
LAD-ligation O 
rats O 
treated O 
with O 
YQFM O 
or O 
vehicle O 
. O 
Treatment O 
with O 
Captopril B-TRIVIAL 
was O 
used O 
as O 
a O 
positive O 
control O 
, O 
which O 
has O 
previously O 
been O 
shown O 
to O 
prevent O 
CHF O 
, O 
and O 
rats O 
without O 
LAD-ligation O 
were O 
used O 
as O 
a O 
negative O 
control O 
. O 
Furthermore O 
, O 
we O 
screened O 
and O 
identified O 
potential O 
anti-inflammatory O 
constituents O 
by O 
ultra O 
- O 
performance O 
liquid O 
chromatography O 
/ O 
quadrupole O 
time O 
- O 
of O 
- O 
flight O 
mass O 
spectrometry O 
( O 
UPLC O 
/ O 
Q-TOF-MS O 
) O 
combined O 
with O 
NF-κB O 
activity O 
luciferase O 
reporter O 
assay O 
systems O 
. O 
Further O 
cytokine O 
detection O 
confirmed O 
the O 
anti-inflammatory O 
effects O 
of O 
the O 
potential O 
NF-κB O 
inhibitors O 
from O 
YQFM O 
. O 
RESULTS O 
: O 
The O 
administration O 
of O 
YQFM O 
significantly O 
improved O 
cardiac O 
function O 
and O 
ameliorated O 
the O 
activity O 
level O 
of O 
inflammatory O 
mediators O 
( O 
such O 
as O 
tumor O 
necrosis O 
factor O 
- O 
alpha O 
, O 
interleukin-6 O 
, O 
and O 
interleukin-1β O 
) O 
in O 
CHF O 
rats O 
. O 
Eight O 
potential O 
anti-inflammatory O 
ingredients O 
, O 
ginsenosides B-MULTIPLE 
Rb1 I-MULTIPLE 
, I-MULTIPLE 
Rg1 I-MULTIPLE 
, I-MULTIPLE 
Rf I-MULTIPLE 
, I-MULTIPLE 
Rh1 I-MULTIPLE 
, I-MULTIPLE 
Rc I-MULTIPLE 
, I-MULTIPLE 
Rb2 I-MULTIPLE 
, I-MULTIPLE 
Ro I-MULTIPLE 
, I-MULTIPLE 
and I-MULTIPLE 
Rg3 I-MULTIPLE 
, O 
were O 
characterized O 
and O 
confirmed O 
. O 
Among O 
these O 
compounds O 
, O 
ginsenoside B-TRIVIAL 
Ro I-TRIVIAL 
was O 
revealed O 
as O 
a O 
new O 
NF-κB O 
inhibitor O 
. O 
CONCLUSION O 
: O 
The O 
results O 
suggested O 
that O 
NF-κB O 
inactivation O 
and O 
cytokine O 
suppression O 
might O 
be O 
one O 
of O 
the O 
main O 
mechanisms O 
of O 
YQFM O 
that O 
caused O 
ameliorative O 
effects O 
in O 
CHF O 
rats O 
, O 
and O 
the O 
major O 
constituents O 
of O 
ginsenosides B-FAMILY 
were O 
identified O 
playing O 
a O 
key O 
role O 
in O 
the O 
treatment O 
of O 
CHF O 
. O 

: O 
Novel O 
oral O 
anticoagulants O 
are O 
approved O 
in O 
several O 
indications O 
: O 
rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
, O 
and O 
dabigatran B-TRIVIAL 
for O 
the O 
prevention O 
of O 
venous O 
thromboembolism O 
after O 
elective O 
hip O 
or O 
knee O 
replacement O 
surgery O 
, O 
and O 
edoxaban B-TRIVIAL 
for O 
hip O 
or O 
knee O 
replacement O 
surgery O 
and O 
hip O 
fracture O 
surgery O 
( O 
in O 
Japan O 
only O 
) O 
; O 
rivaroxaban B-TRIVIAL 
for O 
the O 
treatment O 
of O 
deep O 
vein O 
thrombosis O 
( O 
DVT O 
) O 
and O 
pulmonary O 
embolism O 
( O 
PE O 
) O 
, O 
and O 
prevention O 
of O 
recurrent O 
DVT O 
and O 
PE O 
; O 
and O 
rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
, O 
and O 
dabigatran B-TRIVIAL 
for O 
the O 
prevention O 
of O 
stroke O 
and O 
systemic O 
embolism O 
in O 
patients O 
with O 
non-valvular O 
atrial O 
fibrillation O 
. O 
These O 
agents O 
overcome O 
some O 
limitations O 
of O 
traditional O 
anticoagulants O 
, O 
are O 
suggested O 
to O 
have O 
no O 
requirement O 
for O 
routine O 
coagulation O 
monitoring O 
, O 
and O 
are O 
administered O 
orally O 
. O 
Rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
, O 
and O 
dabigatran B-TRIVIAL 
have O 
different O 
pharmacological O 
characteristics O 
, O 
and O 
guidance O 
is O 
needed O 
on O 
optimum O 
doses O 
and O 
dosing O 
intervals O 
and O 
the O 
effects O 
of O 
renal O 
or O 
hepatic O 
impairment O 
, O 
age O 
, O 
food O 
, O 
and O 
other O 
drugs O 
. O 
Dabigatran B-TRIVIAL 
has O 
stricter O 
prescribing O 
advice O 
than O 
rivaroxaban B-TRIVIAL 
or O 
apixaban B-TRIVIAL 
for O 
patients O 
with O 
moderate O 
- O 
to O 
- O 
severe O 
renal O 
impairment O 
. O 
All O 
three O 
drugs O 
have O 
restrictions O 
on O 
use O 
in O 
patients O 
with O 
hepatic O 
impairment O 
. O 
Apixaban B-TRIVIAL 
requires O 
twice O 
- O 
daily O 
dosing O 
in O 
all O 
indications O 
, O 
whereas O 
rivaroxaban B-TRIVIAL 
and O 
dabigatran B-TRIVIAL 
are O 
dosed O 
once- O 
or O 
twice O 
- O 
daily O 
depending O 
on O 
indication O 
. O 
Although O 
head O 
- O 
to O 
- O 
head O 
comparisons O 
are O 
lacking O 
, O 
the O 
novel O 
oral O 
anticoagulants O 
may O 
show O 
favorable O 
cost O 
- O 
benefit O 
relations O 
compared O 
with O 
traditional O 
vitamin B-FAMILY 
K I-FAMILY 
antagonists O 
or O 
no O 
therapy O 
. O 
AIM O 
: O 
This O 
review O 
summarizes O 
the O 
pharmacology O 
of O 
rivaroxaban B-TRIVIAL 
, O 
apixaban B-TRIVIAL 
, O 
edoxaban B-TRIVIAL 
, O 
and O 
dabigatran B-TRIVIAL 
, O 
and O 
the O 
indications O 
for O 
which O 
they O 
are O 
approved O 
. O 
Issues O 
regarding O 
the O 
optimization O 
of O 
the O 
use O 
of O 
these O 
anticoagulants O 
for O 
the O 
management O 
of O 
thromboembolic O 
disorders O 
will O 
also O 
be O 
discussed O 
. O 

modification O 
of O 
the O 
neural O 
cell O 
adhesion O 
molecule O 
( O 
NCAM O 
) O 
by O 
polysialic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
polySia B-ABBREVIATION 
) O 
is O 
well O 
studied O 
in O 
the O 
nervous O 
system O 
and O 
described O 
as O 
a O 
dynamic O 
modulator O 
of O 
plastic O 
processes O 
like O 
precursor O 
cell O 
migration O 
, O 
axon O 
fasciculation O 
, O 
and O 
synaptic O 
plasticity O 
. O 
Here O 
, O 
we O 
describe O 
a O 
novel O 
function O 
of O 
polysialylated O 
NCAM O 
( O 
polySia B-ABBREVIATION 
-NCAM O 
) O 
in O 
innate O 
immunity O 
of O 
the O 
lung O 
. O 
In O 
mature O 
lung O 
tissue O 
of O 
healthy O 
donors O 
, O 
polySia B-ABBREVIATION 
was O 
exclusively O 
attached O 
to O 
the O 
transmembrane O 
isoform O 
NCAM-140 O 
and O 
located O 
to O 
intracellular O 
compartments O 
of O 
epithelial O 
cells O 
. O 
In O 
patients O 
with O 
chronic O 
obstructive O 
pulmonary O 
disease O 
, O 
however O 
, O 
increased O 
polySia B-ABBREVIATION 
levels O 
and O 
processing O 
of O 
the O 
NCAM O 
carrier O 
were O 
observed O 
. O 
Processing O 
of O 
polysialylated O 
NCAM O 
was O 
reproduced O 
in O 
a O 
mouse O 
model O 
by O 
bleomycin B-FAMILY 
administration O 
leading O 
to O 
an O 
activation O 
of O 
the O 
inflammasome O 
and O 
secretion O 
of O 
interleukin O 
(IL)-1β O 
. O 
As O 
shown O 
in O 
a O 
cell O 
culture O 
model O 
, O 
polySia B-ABBREVIATION 
-NCAM-140 O 
was O 
kept O 
in O 
the O 
late O 
trans-Golgi O 
apparatus O 
of O 
lung O 
epithelial O 
cells O 
and O 
stimulation O 
by O 
IL-1β O 
or O 
lipopolysaccharide O 
induced O 
metalloprotease O 
- O 
mediated O 
ectodomain O 
shedding O 
, O 
resulting O 
in O 
the O 
secretion O 
of O 
soluble O 
polySia B-ABBREVIATION 
-NCAM O 
. O 
Interestingly O 
, O 
polySia B-ABBREVIATION 
chains O 
of O 
secreted O 
NCAM O 
neutralized O 
the O 
cytotoxic O 
activity O 
of O 
extracellular O 
histones O 
as O 
well O 
as O 
DNA O 
/ O 
histone O 
- O 
network O 
- O 
containing O 
" O 
neutrophil O 
extracellular O 
traps O 
" O 
, O 
which O 
are O 
formed O 
during O 
invasion O 
of O 
microorganisms O 
. O 
Thus O 
, O 
shedding O 
of O 
polySia B-ABBREVIATION 
-NCAM O 
by O 
lung O 
epithelial O 
cells O 
may O 
provide O 
a O 
host O 
- O 
protective O 
mechanism O 
to O 
reduce O 
tissue O 
damage O 
during O 
inflammatory O 
processes O 
. O 

/ O 
HYPOTHESIS O 
: O 
While O 
it O 
is O 
well O 
known O 
that O 
diet O 
- O 
induced O 
obesity O 
causes O 
insulin O 
resistance O 
, O 
the O 
precise O 
mechanisms O 
underpinning O 
the O 
initiation O 
of O 
insulin O 
resistance O 
are O 
unclear O 
. O 
To O 
determine O 
factors O 
that O 
may O 
cause O 
insulin O 
resistance O 
, O 
we O 
have O 
performed O 
a O 
detailed O 
time O 
- O 
course O 
study O 
in O 
mice O 
fed O 
a O 
high O 
- O 
fat O 
diet O 
( O 
HFD O 
) O 
. O 
METHODS O 
: O 
C57Bl O 
/ O 
6 O 
mice O 
were O 
fed O 
chow O 
or O 
an O 
HFD O 
from O 
3 O 
days O 
to O 
16 O 
weeks O 
and O 
glucose B-TRIVIAL 
tolerance O 
and O 
tissue O 
- O 
specific O 
insulin O 
action O 
were O 
determined O 
. O 
Tissue O 
lipid O 
profiles O 
were O 
analysed O 
by O 
mass O 
spectrometry O 
and O 
inflammatory O 
markers O 
were O 
measured O 
in O 
adipose O 
tissue O 
, O 
liver O 
and O 
skeletal O 
muscle O 
. O 
RESULTS O 
: O 
Glucose B-TRIVIAL 
intolerance O 
developed O 
within O 
3 O 
days O 
of O 
the O 
HFD O 
and O 
did O 
not O 
deteriorate O 
further O 
in O 
the O 
period O 
to O 
12 O 
weeks O 
. O 
Whole O 
- O 
body O 
insulin O 
resistance O 
, O 
measured O 
by O 
hyperinsulinaemic O 
- O 
euglycaemic O 
clamp O 
, O 
was O 
detected O 
after O 
1 O 
week O 
of O 
HFD O 
and O 
was O 
due O 
to O 
hepatic O 
insulin O 
resistance O 
. O 
Adipose O 
tissue O 
was O 
insulin O 
resistant O 
after O 
1 O 
week O 
, O 
while O 
skeletal O 
muscle O 
displayed O 
insulin O 
resistance O 
at O 
3 O 
weeks O 
, O 
coinciding O 
with O 
a O 
defect O 
in O 
glucose B-TRIVIAL 
disposal O 
. O 
Interestingly O 
, O 
no O 
further O 
deterioration O 
in O 
insulin O 
sensitivity O 
was O 
observed O 
in O 
any O 
tissue O 
after O 
this O 
initial O 
defect O 
. O 
Diacylglycerol B-FAMILY 
content O 
was O 
increased O 
in O 
liver O 
and O 
muscle O 
when O 
insulin O 
resistance O 
first O 
developed O 
, O 
while O 
the O 
onset O 
of O 
insulin O 
resistance O 
in O 
adipose O 
tissue O 
was O 
associated O 
with O 
increases O 
in O 
ceramide O 
and O 
sphingomyelin B-FAMILY 
. O 
Adipose O 
tissue O 
inflammation O 
was O 
only O 
detected O 
at O 
16 O 
weeks O 
of O 
HFD O 
and O 
did O 
not O 
correlate O 
with O 
the O 
induction O 
of O 
insulin O 
resistance O 
. O 
CONCLUSIONS O 
/ O 
INTERPRETATION O 
: O 
HFD-induced O 
whole O 
- O 
body O 
insulin O 
resistance O 
is O 
initiated O 
by O 
impaired O 
hepatic O 
insulin O 
action O 
and O 
exacerbated O 
by O 
skeletal O 
muscle O 
insulin O 
resistance O 
and O 
is O 
associated O 
with O 
the O 
accumulation O 
of O 
specific O 
bioactive O 
lipid O 
species O 
. O 

changes O 
in O 
supercooled O 
Al2O3 B-FORMULA 
- O 
Y2O3 B-FORMULA 
liquids O 
. O 

changes O 
in O 
liquids O 
between O 
Al2O3 B-FORMULA 
and O 
Y2O3 B-FORMULA 
are O 
investigated O 
as O 
a O 
function O 
of O 
the O 
composition O 
and O 
during O 
supercooling O 
using O 
high O 
energy O 
X-ray O 
diffraction O 
( O 
HEXRD O 
) O 
techniques O 
combined O 
with O 
containerless O 
aerodynamic O 
levitation O 
. O 
Many O 
- O 
body O 
molecular O 
dynamics O 
simulation O 
techniques O 
utilizing O 
potential O 
models O 
that O 
incorporate O 
anion O 
polarization O 
effects O 
are O 
applied O 
to O 
study O 
the O 
same O 
liquid O 
systems O 
. O 
The O 
X-ray O 
scattering O 
experiments O 
indicate O 
a O 
change O 
in O 
liquid O 
structure O 
during O 
supercooling O 
around O 
a O 
composition O 
20% O 
Y2O3 B-FORMULA 
( O 
AlY20 B-FORMULA 
) O 
that O 
occurs O 
over O 
a O 
narrow O 
temperature O 
interval O 
. O 
We O 
have O 
associated O 
this O 
change O 
in O 
structure O 
with O 
the O 
onset O 
of O 
a O 
liquid O 
- O 
liquid O 
phase O 
transformation O 
. O 
Analysis O 
of O 
the O 
MD O 
simulated O 
structures O 
has O 
allowed O 
the O 
structure O 
changes O 
to O 
be O 
interpreted O 
in O 
terms O 
of O 
Al(3+) B-FORMULA 
and O 
Y(3+) B-FORMULA 
coordination O 
environments O 
and O 
particularly O 
the O 
Y(3+) B-FORMULA 
- O 
Y(3+) B-FORMULA 
structural O 
correlations O 
. O 
We O 
show O 
that O 
the O 
incipient O 
liquid O 
- O 
liquid O 
phase O 
transition O 
behaviour O 
is O 
correlated O 
with O 
local O 
density O 
fluctuations O 
that O 
represent O 
different O 
coordination O 
polyhedra O 
surrounding O 
oxygen B-SYSTEMATIC 
ions O 
. O 
The O 
difference O 
in O 
energy O 
and O 
volume O 
associated O 
with O 
this O 
sampling O 
of O 
high O 
and O 
low O 
density O 
basins O 
in O 
the O 
underlying O 
energy O 
landscape O 
is O 
consistent O 
with O 
independent O 
verifications O 
of O 
the O 
volume O 
and O 
enthalpy O 
differences O 
between O 
different O 
amorphous O 
forms O 
. O 
The O 
differences O 
in O 
the O 
high- O 
and O 
low O 
- O 
density O 
configurations O 
match O 
the O 
difference O 
in O 
diffraction O 
patterns O 
observed O 
experimentally O 
. O 

and O 
ImmunoGen O 
are O 
collaborating O 
on O 
the O 
development O 
of O 
trastuzumab O 
emtansine O 
, O 
a O 
HER2 O 
antibody O 
- O 
drug O 
conjugate O 
that O 
comprises O 
Genentech's O 
trastuzumab O 
antibody O 
linked O 
to O 
ImmunoGen's O 
anti-mitotic O 
agent O 
, O 
mertansine B-TRIVIAL 
( O 
a O 
maytansine B-TRIVIAL 
derivative O 
; O 
also O 
known O 
as O 
DM1 B-ABBREVIATION 
) O 
. O 
The O 
conjugate O 
combines O 
two O 
strategies O 
: O 
the O 
anti-HER2 O 
activity O 
of O 
trastuzumab O 
, O 
and O 
the O 
targeted O 
intracellular O 
delivery O 
of O 
mertansine B-TRIVIAL 
, O 
a O 
tubulin O 
polymerisation O 
inhibitor O 
which O 
interferes O 
with O 
mitosis O 
and O 
promotes O 
apoptosis O 
. O 
The O 
linker O 
in O 
trastuzumab O 
emtansine O 
is O 
a O 
non-reducible O 
thioether B-SYSTEMATIC 
linker O 
, O 
N-succinimidyl-4-(N-maleimidomethyl) B-SYSTEMATIC 
cyclohexane-1-carboxylate I-SYSTEMATIC 
( O 
SMCC B-ABBREVIATION 
, O 
designated O 
MCC B-ABBREVIATION 
after O 
conjugation O 
) O 
. O 
Trastuzumab O 
emtansine O 
( O 
Kadcyla O 
™ O 
) O 
has O 
been O 
launched O 
in O 
the O 
USA O 
as O 
second O 
- O 
line O 
monotherapy O 
for O 
HER2-positive O 
metastatic O 
breast O 
cancer O 
, O 
and O 
has O 
been O 
filed O 
for O 
approval O 
in O 
the O 
EU O 
and O 
Japan O 
in O 
this O 
indication O 
. O 
Trastuzumab O 
emtansine O 
is O 
in O 
phase O 
III O 
development O 
as O 
first O 
- O 
line O 
combination O 
therapy O 
or O 
monotherapy O 
for O 
metastatic O 
HER2-positive O 
breast O 
cancer O 
, O 
and O 
as O 
third O 
- O 
line O 
monotherapy O 
for O 
metastatic O 
HER2-positive O 
breast O 
cancer O 
. O 
Phase O 
II O 
development O 
is O 
underway O 
for O 
early O 
- O 
stage O 
breast O 
cancer O 
and O 
phase O 
II O 
/ O 
III O 
development O 
is O 
underway O 
in O 
patients O 
with O 
HER2-positive O 
gastric O 
cancer O 
. O 
This O 
article O 
summarizes O 
the O 
milestones O 
in O 
the O 
development O 
of O 
trastuzumab O 
emtansine O 
leading O 
to O 
this O 
first O 
approval O 
for O 
the O 
treatment O 
of O 
patients O 
with O 
HER2-positive O 
, O 
metastatic O 
breast O 
cancer O 
who O 
previously O 
received O 
trastuzumab O 
and O 
a O 
taxane B-FAMILY 
, O 
separately O 
or O 
in O 
combination O 
. O 

degludec O 
(Tresiba(®)) O 
is O 
an O 
ultra O 
- O 
long O 
- O 
acting O 
insulin O 
analogue O 
that O 
is O 
also O 
available O 
as O 
a O 
coformulation O 
with O 
rapid O 
- O 
acting O 
insulin O 
aspart O 
( O 
insulin O 
degludec O 
/ O 
insulin O 
aspart O 
) O 
[Ryzodeg(®)] O 
. O 
Insulin O 
degludec O 
has O 
a O 
flat O 
, O 
stable O 
glucose B-TRIVIAL 
-lowering O 
profile O 
with O 
a O 
duration O 
of O 
action O 
of O 
> O 
42 O 
h O 
, O 
and O 
less O 
within O 
- O 
patient O 
day O 
- O 
to O 
- O 
day O 
variability O 
in O 
glucose B-TRIVIAL 
-lowering O 
effect O 
than O 
the O 
long O 
- O 
acting O 
insulin O 
analogue O 
insulin O 
glargine O 
. O 
In O 
clinical O 
trials O 
, O 
insulin O 
degludec O 
achieved O 
similar O 
glycaemic O 
control O 
to O 
that O 
seen O 
with O 
insulin O 
glargine O 
in O 
patients O 
with O 
type O 
1 O 
or O 
2 O 
diabetes O 
, O 
but O 
with O 
a O 
lower O 
risk O 
of O 
nocturnal O 
hypoglycaemia O 
. O 
In O 
addition O 
, O 
trials O 
examining O 
a O 
flexible O 
dosing O 
regimen O 
of O 
insulin O 
degludec O 
in O 
patients O 
with O 
type O 
1 O 
or O 
2 O 
diabetes O 
show O 
the O 
potential O 
for O 
adjusting O 
the O 
injection O 
time O 
, O 
without O 
compromising O 
glycaemic O 
control O 
or O 
safety O 
. O 
A O 
200 O 
U O 
/ O 
mL O 
formulation O 
of O 
insulin O 
degludec O 
is O 
also O 
available O 
for O 
use O 
in O 
patients O 
who O 
require O 
large O 
volumes O 
of O 
basal O 
insulin O 
. O 
Insulin O 
degludec O 
/ O 
insulin O 
aspart O 
was O 
noninferior O 
to O 
the O 
long O 
- O 
acting O 
insulin O 
analogue O 
insulin O 
detemir O 
in O 
patients O 
with O 
type O 
1 O 
diabetes O 
and O 
has O 
the O 
potential O 
to O 
reduce O 
the O 
number O 
of O 
daily O 
injections O 
. O 
Trial O 
results O 
also O 
indicate O 
that O 
insulin O 
degludec O 
/ O 
insulin O 
aspart O 
may O 
be O 
an O 
appropriate O 
option O 
for O 
initiating O 
insulin O 
therapy O 
in O 
patients O 
with O 
type O 
2 O 
diabetes O 
inadequately O 
controlled O 
with O 
oral O 
antidiabetic O 
drugs O 
. O 
Subcutaneous O 
insulin O 
degludec O 
was O 
generally O 
well O 
tolerated O 
in O 
patients O 
with O 
type O 
1 O 
or O 
2 O 
diabetes O 
. O 
In O 
conclusion O 
, O 
insulin O 
degludec O 
and O 
insulin O 
degludec O 
/ O 
insulin O 
aspart O 
represent O 
a O 
useful O 
advance O 
in O 
the O 
treatment O 
of O 
type O 
1 O 
or O 
2 O 
diabetes O 
. O 

better O 
understand O 
how O 
hyperglycemia O 
induces O 
endothelial O 
cell O 
dysfunction O 
under O 
the O 
diabetic O 
conditions O 
, O 
a O 
hemodynamic O 
microfluidic O 
chip O 
system O 
was O 
developed O 
. O 
The O 
system O 
combines O 
a O 
caspase-3 O 
- O 
based O 
fluorescence O 
resonance O 
energy O 
transfer O 
( O 
FRET O 
) O 
biosensor O 
cell O 
line O 
which O 
can O 
detect O 
endothelial O 
cell O 
apoptosis O 
in O 
real O 
- O 
time O 
, O 
post O 
- O 
treatment O 
effect O 
and O 
with O 
a O 
limited O 
cell O 
sample O 
, O 
by O 
using O 
a O 
microfluidic O 
chip O 
which O 
can O 
mimic O 
the O 
physiological O 
pulsatile O 
flow O 
profile O 
in O 
the O 
blood O 
vessel O 
. O 
The O 
caspase-3 O 
- O 
based O 
FRET O 
biosensor O 
endothelial O 
cell O 
line O 
( O 
HUVEC-C3 O 
) O 
can O 
produce O 
a O 
FRET O 
- O 
based O 
sensor O 
protein O 
capable O 
of O 
probing O 
caspase-3 O 
activation O 
. O 
When O 
the O 
endothelial O 
cells O 
undergo O 
apoptosis O 
, O 
the O 
color O 
of O 
the O 
sensor O 
cells O 
changes O 
from O 
green O 
to O 
blue O 
, O 
thus O 
sensing O 
apoptosis O 
. O 
A O 
double O 
- O 
labeling O 
fluorescent O 
technique O 
( O 
yo B-TRIVIAL 
pro-1 I-TRIVIAL 
and O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
) O 
was O 
used O 
to O 
validate O 
the O 
findings O 
revealed O 
by O 
the O 
FRET O 
- O 
based O 
caspase O 
sensor O 
. O 
The O 
results O 
show O 
high O 
rates O 
of O 
apoptosis O 
and O 
necrosis O 
of O 
endothelial O 
cells O 
when O 
high O 
glucose B-TRIVIAL 
concentration O 
was O 
applied O 
in O 
our O 
hemodynamic O 
microfluidic O 
chip O 
combined O 
with O 
an O 
exhaustive O 
pulsatile O 
flow O 
profile O 
. O 
The O 
two O 
apoptosis O 
detection O 
techniques O 
( O 
fluorescent O 
method O 
and O 
FRET O 
biosensor O 
) O 
are O 
comparable O 
; O 
but O 
FRET O 
biosensor O 
offers O 
more O 
advantages O 
such O 
as O 
real O 
- O 
time O 
observation O 
and O 
a O 
convenient O 
operating O 
process O 
to O 
generate O 
more O 
accurate O 
and O 
reliable O 
data O 
. O 
Furthermore O 
, O 
the O 
activation O 
of O 
the O 
FRET O 
biosensor O 
also O 
confirms O 
the O 
endothelial O 
cell O 
apoptosis O 
induced O 
by O 
the O 
abnormal O 
pulsatile O 
shear O 
stress O 
and O 
high O 
glucose B-TRIVIAL 
concentration O 
is O 
through O 
caspase-3 O 
pathway O 
. O 
A O 
12% O 
apoptotic O 
rate O 
( O 
nearly O 
a O 
4-fold O 
increase O 
compared O 
to O 
the O 
static O 
condition O 
) O 
was O 
observed O 
when O 
the O 
endothelial O 
cells O 
were O 
exposed O 
to O 
a O 
high O 
glucose B-TRIVIAL 
concentration O 
of O 
20 O 
mM O 
under O 
2 O 
h O 
exhaustive O 
pulsatile O 
shear O 
stress O 
of O 
30 O 
dyne O 
cm(-2) O 
and O 
followed O 
with O 
another O 
10 O 
h O 
normal O 
pulsatile O 
shear O 
stress O 
of O 
15 O 
dyne O 
cm(-2) O 
. O 
Therefore O 
, O 
the O 
most O 
important O 
finding O 
of O 
this O 
study O 
is O 
to O 
develop O 
a O 
novel O 
endothelial O 
cell O 
apoptosis O 
detection O 
method O 
, O 
which O 
combines O 
the O 
microfluidic O 
chip O 
system O 
and O 
FRET O 
biosensor O 
. O 
This O 
finding O 
may O 
provide O 
new O 
insight O 
into O 
how O 
glucose B-TRIVIAL 
causes O 
endothelial O 
cell O 
dysfunction O 
, O 
which O 
is O 
the O 
major O 
cause O 
of O 
diabetes O 
- O 
derived O 
complications O 
. O 

fraction O 
determination O 
of O 
2-arylpropionic B-FAMILY 
acids I-FAMILY 
in O 
a O 
package O 
plant O 
membrane O 
bioreactor O 
. O 

compositions O 
of O 
three O 
2-arylpropionic B-FAMILY 
acid I-FAMILY 
( O 
2-APA B-ABBREVIATION 
) O 
drugs O 
, O 
ibuprofen B-TRIVIAL 
, O 
naproxen B-TRIVIAL 
, O 
and O 
ketoprofen B-TRIVIAL 
, O 
were O 
monitored O 
in O 
a O 
membrane O 
bioreactor O 
( O 
MBR O 
) O 
treating O 
municipal O 
effluent O 
in O 
a O 
small O 
rural O 
town O 
in O 
Australia O 
. O 
Specific O 
enantiomers O 
were O 
determined O 
as O 
amide B-FAMILY 
diastereomers O 
using O 
the O 
chiral O 
derivatizing O 
reagent O 
, O 
(R)-1-phenylethylamine B-SYSTEMATIC 
( O 
PEA B-ABBREVIATION 
) O 
, O 
followed O 
by O 
gas O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
GC-MS O 
/ O 
MS O 
) O 
. O 
The O 
six O 
individual O 
enantiomers O 
were O 
quantified O 
by O 
isotope O 
dilution O 
and O 
the O 
enantiomeric O 
fractions O 
( O 
EFs O 
) O 
were O 
determined O 
. O 
Over O 
four O 
separate O 
sampling O 
events O 
, O 
ibuprofen B-TRIVIAL 
EF O 
ranged O 
from O 
0.88 O 
to O 
0.94 O 
( O 
median O 
0.93 O 
) O 
in O 
the O 
influent O 
and O 
0.38 O 
to O 
0.4 O 
( O 
median O 
0.39 O 
) O 
in O 
the O 
effluent O 
. O 
However O 
, O 
no O 
significant O 
change O 
in O 
ketoprofen B-TRIVIAL 
EF O 
was O 
observed O 
, O 
with O 
influent O 
EFs O 
of O 
0.56-0.60 O 
( O 
median O 
0.58 O 
) O 
and O 
effluent O 
EFs O 
0.54-0.68 O 
( O 
median O 
0.56 O 
) O 
. O 
This O 
is O 
the O 
first O 
report O 
of O 
enantiospecific O 
analysis O 
of O 
ketoprofen B-TRIVIAL 
in O 
municipal O 
wastewater O 
and O 
it O 
is O 
not O 
yet O 
clear O 
why O 
such O 
different O 
behavior O 
was O 
observed O 
compared O 
to O 
ibuprofen B-TRIVIAL 
. O 
Naproxen B-TRIVIAL 
EF O 
was O 
consistently O 
measured O 
at O 
0.99 O 
in O 
the O 
influent O 
and O 
ranged O 
from O 
0.86 O 
to O 
0.94 O 
( O 
median O 
0.91 O 
) O 
in O 
the O 
effluent O 
. O 
This O 
study O 
demonstrates O 
that O 
EF O 
is O 
a O 
relatively O 
stable O 
parameter O 
and O 
does O 
not O 
fluctuate O 
according O 
to O 
concentration O 
or O 
other O 
short O 
- O 
term O 
variables O 
introduced O 
by O 
sampling O 
limitations O 
. O 
The O 
enantiospecific O 
analysis O 
of O 
chiral O 
chemicals O 
presents O 
a O 
promising O 
approach O 
to O 
elucidate O 
a O 
more O 
thorough O 
understanding O 
of O 
biological O 
treatment O 
processes O 
and O 
a O 
potential O 
tool O 
for O 
monitoring O 
the O 
performance O 
of O 
key O 
biological O 
pathways O 
. O 
Chirality O 
25 O 
: O 
301-307 O 
, O 
2013 O 
. O 
© O 
2013 O 
Wiley O 
Periodicals O 
, O 
Inc O 
. O 

of O 
skeletal O 
muscle O 
cells O 
is O 
accompanied O 
by O 
drastic O 
changes O 
in O 
gene O 
expression O 
programs O 
that O 
depend O 
on O 
activation O 
and O 
repression O 
of O 
genes O 
at O 
defined O 
time O 
points O 
. O 
Here O 
we O 
identify O 
the O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
homeodomain O 
- O 
interacting O 
protein O 
kinase O 
2 O 
( O 
HIPK2 O 
) O 
as O 
a O 
corepressor O 
that O 
inhibits O 
myocyte O 
enhancer O 
factor O 
2 O 
(MEF2)-dependent O 
gene O 
expression O 
in O 
undifferentiated O 
myoblasts O 
. O 
Downregulation O 
of O 
HIPK2 O 
expression O 
by O 
shRNAs O 
results O 
in O 
elevated O 
expression O 
of O 
muscle O 
- O 
specific O 
genes O 
, O 
whereas O 
overexpression O 
of O 
the O 
kinase O 
dampens O 
transcription O 
of O 
these O 
genes O 
. O 
HIPK2 O 
is O 
constitutively O 
associated O 
with O 
a O 
multi O 
- O 
protein O 
complex O 
containing O 
histone O 
deacetylase O 
(HDAC)3 O 
and O 
HDAC4 O 
that O 
serves O 
to O 
silence O 
MEF2C-dependent O 
transcription O 
in O 
undifferentiated O 
myoblasts O 
. O 
HIPK2 O 
interferes O 
with O 
gene O 
expression O 
on O 
phosphorylation O 
and O 
HDAC3-dependent O 
deacetylation O 
of O 
MEF2C O 
. O 
Ongoing O 
muscle O 
differentiation O 
is O 
accompanied O 
by O 
elevated O 
caspase O 
activity O 
, O 
which O 
results O 
in O 
caspase O 
- O 
mediated O 
cleavage O 
of O 
HIPK2 O 
following O 
aspartic O 
acids O 
916 O 
and O 
977 O 
and O 
the O 
generation O 
of O 
a O 
C B-FORMULA 
-terminally O 
truncated O 
HIPK2 O 
protein O 
. O 
The O 
short O 
form O 
of O 
the O 
kinase O 
loses O 
its O 
affinity O 
to O 
the O 
repressive O 
multi O 
- O 
protein O 
complex O 
and O 
its O 
ability O 
to O 
bind O 
HDAC3 O 
and O 
HDAC4 O 
, O 
thus O 
alleviating O 
its O 
repressive O 
function O 
for O 
expression O 
of O 
muscle O 
genes O 
. O 
This O 
study O 
identifies O 
HIPK2 O 
as O 
a O 
further O 
protein O 
that O 
determines O 
the O 
threshold O 
and O 
kinetics O 
of O 
gene O 
expression O 
in O 
proliferating O 
myoblasts O 
and O 
during O 
the O 
initial O 
steps O 
of O 
myogenesis O 
. O 

of O 
CYP2C19 O 
and O 
CYP3A4 O 
by O 
Omeprazole B-TRIVIAL 
Metabolites O 
and O 
their O 
Contribution O 
to O 
Drug-Drug O 
Interactions O 
. O 

aim O 
of O 
this O 
study O 
was O 
to O 
evaluate O 
the O 
contribution O 
of O 
metabolites O 
to O 
drug O 
- O 
drug O 
interactions O 
( O 
DDI O 
) O 
using O 
the O 
inhibition O 
of O 
CYP2C19 O 
and O 
CYP3A4 O 
by O 
omeprazole B-TRIVIAL 
and O 
its O 
metabolites O 
as O 
a O 
model O 
. O 
Of O 
the O 
metabolites O 
identified O 
in O 
vivo O 
, O 
5-hydroxyomeprazole B-SYSTEMATIC 
, O 
5'-O-desmethylomeprazole B-SYSTEMATIC 
, O 
omeprazole B-TRIVIAL 
sulfone I-TRIVIAL 
and O 
carboxyomeprazole B-SYSTEMATIC 
had O 
an O 
AUCm O 
/ O 
AUCp O 
≥ O 
0.25 O 
when O 
either O 
total O 
or O 
unbound O 
concentrations O 
were O 
measured O 
following O 
a O 
single O 
20 O 
mg O 
dose O 
of O 
omeprazole B-TRIVIAL 
in O 
a O 
cocktail O 
. O 
All O 
of O 
the O 
metabolites O 
inhibited O 
CYP2C19 O 
and O 
CYP3A4 O 
reversibly O 
. O 
In O 
addition O 
omeprazole B-TRIVIAL 
, O 
omeprazole B-TRIVIAL 
sulfone I-TRIVIAL 
and O 
5'-O-desmethylomeprazole B-SYSTEMATIC 
were O 
mechanism O 
- O 
based O 
inhibitors O 
( O 
MBI O 
) O 
of O 
CYP2C19 O 
while O 
omeprazole B-TRIVIAL 
and O 
5'-O-desmethylomeprazole B-SYSTEMATIC 
were O 
found O 
to O 
be O 
MBIs O 
of O 
CYP3A4 O 
. O 
Reversible O 
[ O 
I O 
] O 
/ O 
Ki O 
ratios O 
and O 
irreversible O 
λ O 
/ O 
kdeg O 
ratios O 
were O 
used O 
to O 
evaluate O 
whether O 
characterization O 
of O 
the O 
metabolites O 
affected O 
DDI O 
risk O 
assessment O 
. O 
Identifying O 
omeprazole B-TRIVIAL 
as O 
an O 
MBI O 
of O 
both O 
CYP2C19 O 
and O 
CYP3A4 O 
was O 
the O 
most O 
important O 
factor O 
in O 
DDI O 
risk O 
assessment O 
. O 
Consideration O 
of O 
reversible O 
inhibition O 
by O 
omeprazole B-TRIVIAL 
and O 
its O 
metabolites O 
would O 
not O 
identify O 
DDI O 
risk O 
with O 
CYP3A4 O 
, O 
and O 
with O 
CYP2C19 O 
reversible O 
inhibition O 
values O 
would O 
only O 
identify O 
DDI O 
risk O 
if O 
the O 
metabolites O 
are O 
included O 
in O 
the O 
assessment O 
. O 
Based O 
on O 
inactivation O 
data O 
, O 
CYP2C19 O 
and O 
CYP3A4 O 
inactivation O 
by O 
omeprazole B-TRIVIAL 
would O 
be O 
sufficient O 
to O 
identify O 
risk O 
, O 
but O 
metabolites O 
were O 
predicted O 
to O 
contribute O 
30-63% O 
to O 
the O 
in O 
vivo O 
hepatic O 
interactions O 
. O 
Hence O 
, O 
consideration O 
of O 
metabolites O 
may O 
be O 
important O 
in O 
quantitative O 
predictions O 
of O 
in O 
vivo O 
DDIs O 
. O 
The O 
results O 
of O 
this O 
study O 
show O 
that O 
while O 
metabolites O 
contribute O 
to O 
in O 
vivo O 
DDIs O 
their O 
relative O 
abundance O 
in O 
circulation O 
or O 
logP O 
values O 
do O 
not O 
predict O 
their O 
contribution O 
to O 
in O 
vivo O 
DDI O 
risk O 
. O 

MICELLES O 
FOR O 
A O 
RIBAVIRIN B-TRIVIAL 
PRODRUG O 
TARGETING O 
TO O 
HEPATOCYTES O 
. O 

micelles O 
potentially O 
able O 
to O 
carry O 
to O 
hepatocytes O 
a O 
ribavirin B-TRIVIAL 
( O 
RBV B-ABBREVIATION 
) O 
prodrug O 
, O 
exploiting O 
the O 
presence O 
of O 
carbohydrate B-FAMILY 
receptors O 
, O 
i.e O 
. O 
, O 
ASGPR O 
, O 
were O 
prepared O 
starting O 
from O 
a O 
galactosylated B-SYSTEMATIC 
polylactide-polyaminoacid I-SYSTEMATIC 
conjugate O 
. O 
This O 
latter O 
was O 
obtained O 
by O 
chemical O 
reaction O 
of O 
alpha,beta-poly(N-2-hydroxyethyl) B-SYSTEMATIC 
(2-aminoethylcarbamate)-DL-aspartamide I-SYSTEMATIC 
( O 
PHEA-EDA B-ABBREVIATION 
) O 
with O 
polylactic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
PLA B-ABBREVIATION 
) O 
, O 
and O 
subsequent O 
reaction O 
with O 
lactose B-TRIVIAL 
, O 
obtaining O 
PHEA-EDA-PLA-GAL B-ABBREVIATION 
copolymer O 
. O 
To O 
enhance O 
the O 
entrapment O 
into O 
obtained O 
nanostructures O 
, O 
a O 
hydrophobic O 
RBV B-ABBREVIATION 
prodrug O 
, O 
i.e O 
. O 
RBV B-TRIVIAL 
tripalmitate I-TRIVIAL 
, O 
was O 
synthesized O 
and O 
its O 
capability O 
to O 
release O 
RBV B-ABBREVIATION 
in O 
the O 
presence O 
of O 
an O 
adequate O 
enzymatic O 
activity O 
was O 
demonstrated O 
. O 
Liver O 
- O 
targeted O 
RBV B-TRIVIAL 
tripalmitate I-TRIVIAL 
-loaded O 
micelles O 
were O 
obtained O 
in O 
aqueous O 
media O 
at O 
low O 
PHEA-EDA-PLA-GAL B-ABBREVIATION 
copolymer O 
concentration O 
value O 
with O 
nanometric O 
size O 
. O 
By O 
in O 
vitro O 
experiments O 
, O 
the O 
specificity O 
of O 
RBV B-TRIVIAL 
tripalmitate I-TRIVIAL 
-loaded O 
PHEA-EDA-PLA-GAL B-ABBREVIATION 
micelles O 
toward O 
HepG2 O 
was O 
demonstrated O 
by O 
using O 
a O 
competitive O 
inhibition O 
assay O 
in O 
the O 
presence O 
of O 
free O 
GAL B-ABBREVIATION 
. O 
This O 
finding O 
raises O 
hope O 
in O 
terms O 
of O 
future O 
micelles O 
- O 
based O 
liver O 
- O 
targeted O 
drug O 
delivery O 
strategy O 
for O 
the O 
hepatitis O 
C O 
treatment O 
. O 

the O 
Enzymes O 
that O 
Catalyze O 
the O 
Final O 
Steps O 
in O 
Oxytetracycline B-SYSTEMATIC 
Biosynthesis O 
. O 

are O 
a O 
group O 
of O 
natural O 
products O 
sharing O 
a O 
linearly O 
fused O 
four O 
- O 
ring O 
scaffold O 
, O 
which O 
is O 
essential O 
for O 
their O 
broad O 
- O 
spectrum O 
antibiotic O 
activities O 
. O 
Formation O 
of O 
the O 
key O 
precursor O 
anhydrotetracycline B-SYSTEMATIC 
3 O 
during O 
oxytetracycline B-SYSTEMATIC 
1 O 
biosynthesis O 
has O 
been O 
previously O 
characterized O 
. O 
However O 
, O 
the O 
enzymatic O 
steps O 
that O 
transform O 
3 O 
into O 
1 O 
, O 
including O 
the O 
additional O 
hydroxylation O 
at O 
C5 O 
and O 
the O 
final O 
C5a-C11a O 
reduction O 
, O 
have O 
remained O 
elusive O 
. O 
Here O 
we O 
report O 
two O 
redox O 
enzymes O 
, O 
OxyS O 
and O 
OxyR O 
, O 
are O 
sufficient O 
to O 
convert O 
3 O 
to O 
1 O 
. O 
OxyS O 
catalyzes O 
two O 
sequential O 
hydroxylations O 
at O 
C6 O 
and O 
C5 O 
positions O 
of O 
3 O 
with O 
opposite O 
stereochemistry O 
, O 
while O 
OxyR O 
catalyzes O 
the O 
C5a-C11a O 
reduction O 
using O 
F420 O 
as O 
a O 
cofactor O 
to O 
produce O 
1 O 
. O 
The O 
crystal O 
structure O 
of O 
OxyS O 
was O 
obtained O 
to O 
provide O 
insights O 
into O 
the O 
tandem O 
C6- O 
and O 
C5-hydroxylation O 
steps O 
. O 
The O 
substrate O 
specificities O 
of O 
OxyS O 
and O 
OxyR O 
were O 
shown O 
to O 
influence O 
the O 
relative O 
ratio O 
of O 
1 O 
and O 
tetracycline B-FAMILY 
2 O 
. O 

Confined O 
Tunable O 
Mid-Infrared O 
Plasmonics O 
in O 
Graphene B-TRIVIAL 
Nanoresonators O 
. O 

- O 
layer O 
graphene B-TRIVIAL 
has O 
been O 
shown O 
to O 
have O 
intriguing O 
prospects O 
as O 
a O 
plasmonic O 
material O 
, O 
as O 
modes O 
having O 
plasmon O 
wavelengths O 
∼20 O 
times O 
smaller O 
than O 
free O 
space O 
( O 
λp O 
∼ O 
λ0 O 
/ O 
20 O 
) O 
have O 
been O 
observed O 
in O 
the O 
2-6 O 
THz O 
range O 
, O 
and O 
active O 
graphene B-TRIVIAL 
plasmonic O 
devices O 
operating O 
in O 
that O 
regime O 
have O 
been O 
explored O 
. O 
However O 
there O 
is O 
great O 
interest O 
in O 
understanding O 
the O 
properties O 
of O 
graphene B-TRIVIAL 
plasmons O 
across O 
the O 
infrared O 
spectrum O 
, O 
especially O 
at O 
energies O 
exceeding O 
the O 
graphene B-TRIVIAL 
optical O 
phonon O 
energy O 
. O 
We O 
use O 
infrared O 
microscopy O 
to O 
observe O 
the O 
modes O 
of O 
tunable O 
plasmonic O 
graphene B-TRIVIAL 
nanoresonator O 
arrays O 
as O 
small O 
as O 
15 O 
nm O 
. O 
We O 
map O 
the O 
wavevector O 
- O 
dependent O 
dispersion O 
relations O 
for O 
graphene B-TRIVIAL 
plasmons O 
at O 
mid O 
- O 
infrared O 
energies O 
from O 
measurements O 
of O 
resonant O 
frequency O 
changes O 
with O 
nanoresonator O 
width O 
. O 
By O 
tuning O 
resonator O 
width O 
and O 
charge O 
density O 
, O 
we O 
probe O 
graphene B-TRIVIAL 
plasmons O 
with O 
λp O 
≤ O 
λ0 O 
/ O 
100 O 
and O 
plasmon O 
resonances O 
as O 
high O 
as O 
310 O 
meV O 
( O 
2500 O 
cm(-1) O 
) O 
for O 
15 O 
nm O 
nanoresonators O 
. O 
Electromagnetic O 
calculations O 
suggest O 
that O 
the O 
confined O 
plasmonic O 
modes O 
have O 
a O 
local O 
density O 
of O 
optical O 
states O 
more O 
than O 
10(6) O 
larger O 
than O 
free O 
space O 
and O 
thus O 
could O 
strongly O 
increase O 
light O 
- O 
matter O 
interactions O 
at O 
infrared O 
energies O 
. O 

and O 
Cytotoxic O 
Evaluation O 
of O 
Acylated B-TRIVIAL 
Brefeldin I-TRIVIAL 
A I-TRIVIAL 
Derivatives O 
as O 
Potential O 
Anticancer O 
Agents O 
. O 

A I-TRIVIAL 
( O 
BFA B-ABBREVIATION 
) O 
has O 
attracted O 
considerable O 
attention O 
because O 
of O 
its O 
potential O 
function O 
in O 
cancer O 
prevention O 
. O 
However O 
, O 
its O 
therapeutic O 
use O 
is O 
limited O 
by O 
its O 
poor O 
bioavailability O 
. O 
The O 
modifications O 
on O 
BFA B-ABBREVIATION 
were O 
difficult O 
because O 
of O 
its O 
low O 
stability O 
and O 
selectivity O 
toward O 
two O 
hydroxyl B-SYSTEMATIC 
groups O 
within O 
the O 
same O 
molecule O 
. O 
In O 
this O 
study O 
, O 
we O 
report O 
the O 
selective O 
acylation O 
of O 
BFA B-ABBREVIATION 
under O 
mild O 
conditions O 
and O 
the O 
preparation O 
of O 
a O 
series O 
of O 
monoacylated B-MULTIPLE 
and I-MULTIPLE 
diacylated I-MULTIPLE 
BFA I-MULTIPLE 
derivatives O 
. O 
Their O 
cytotoxicity O 
, O 
antitumor O 
activity O 
against O 
TE-1 O 
cell O 
, O 
and O 
molecular O 
properties O 
of O 
adsorption O 
, O 
distribution O 
, O 
metabolism O 
, O 
and O 
elimination O 
were O 
evaluated O 
. O 
BFA B-SYSTEMATIC 
7-O-benzoate I-SYSTEMATIC 
, O 
BFA B-SYSTEMATIC 
4,7-O-dibenzoate I-SYSTEMATIC 
, O 
and O 
BFA B-SYSTEMATIC 
7-O-biotin I-SYSTEMATIC 
carboxylate I-SYSTEMATIC 
showed O 
the O 
most O 
potent O 
cytotoxic O 
activity O 
, O 
with O 
GI50 O 
values O 
of O 
0.39 O 
, O 
0.46 O 
, O 
and O 
0.50μM O 
respectively O 
. O 
Molecular O 
docking O 
of O 
these O 
analogs O 
revealed O 
that O 
the O 
derivatives O 
were O 
well O 
tolerated O 
at O 
the O 
interface O 
between O 
ARF1 O 
and O 
its O 
guanine B-TRIVIAL 
nucleotide I-TRIVIAL 
exchange O 
factor O 
ARNO O 
. O 
Our O 
results O 
may O 
serve O 
as O 
a O 
basis O 
for O 
the O 
development O 
of O 
novel O 
potential O 
anti-cancer O 
agents O 
from O 
BFA B-ABBREVIATION 
derivatives O 
. O 
This O 
article O 
is O 
protected O 
by O 
copyright O 
. O 
All O 
rights O 
reserved O 
. O 

and O 
antifungal O 
evaluation O 
of O 
pentyloxyl B-SYSTEMATIC 
- O 
diphenylisoxazoloyl B-SYSTEMATIC 
pneumocandins B-FAMILY 
and O 
echinocandins B-FAMILY 
. O 

and O 
pneumocandins B-FAMILY 
are O 
classes O 
of O 
lipocyclohexapeptides B-FAMILY 
that O 
are O 
broad O 
spectrum O 
antifungal O 
agents O 
. O 
They O 
inhibit O 
fungal O 
specific O 
1,3-β-glucan O 
synthase O 
activity O 
which O 
is O 
an O 
essential O 
component O 
of O 
the O 
fungal O 
cell O 
wall O 
. O 
Chemical O 
modifications O 
of O 
these O 
two O 
leads O 
have O 
produced O 
three O 
clinical O 
agents O 
namely O 
caspofungin B-TRIVIAL 
, O 
micafungin B-TRIVIAL 
and O 
anidulafungin B-TRIVIAL 
. O 
The O 
presence O 
of O 
hydroxy-glutamine B-SYSTEMATIC 
versus O 
threonine B-TRIVIAL 
and O 
unsaturated B-FAMILY 
linear I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
versus O 
branched B-FAMILY 
chain I-FAMILY 
saturated I-FAMILY 
fatty I-FAMILY 
acid I-FAMILY 
differentiate O 
the O 
two O 
classes O 
of O 
compounds O 
with O 
profound O 
differences O 
in O 
their O 
hemolytic O 
properties O 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
have O 
replaced O 
the O 
side O 
chain O 
of O 
the O 
cyclohexapeptides B-FAMILY 
with O 
a O 
common O 
aromatic O 
heterocyclic O 
acyl B-FAMILY 
side O 
chain O 
and O 
compared O 
the O 
biological O 
activities O 
of O 
the O 
cores O 
head O 
- O 
to O 
- O 
head O 
and O 
for O 
the O 
first O 
time O 
demonstrated O 
the O 
role O 
played O 
by O 
the O 
acyl B-FAMILY 
chain O 
and O 
the O 
hydroxy-glutamine B-SYSTEMATIC 
for O 
the O 
antifungal O 
potency O 
. O 

synthesis O 
of O 
new O 
imidazo[1,2-a]pyridines B-FAMILY 
carrying O 
1,2,3-triazoles B-FAMILY 
via O 
click O 
chemistry O 
and O 
their O 
antiepileptic O 
studies O 
. O 

present O 
article O 
reports O 
the O 
synthesis O 
and O 
anticonvulsant O 
studies O 
of O 
new O 
2-arylimidazo[1,2-a]pyridines B-FAMILY 
carrying O 
suitably O 
substituted O 
1,2,3-triazoles B-FAMILY 
as O 
well O 
as O 
their O 
intermediates O 
. O 
The O 
structures O 
of O 
newly O 
synthesized O 
compounds O 
were O 
confirmed O 
by O 
various O 
spectroscopic O 
techniques O 
. O 
The O 
anticonvulsant O 
study O 
was O 
carried O 
out O 
by O 
MES O 
and O 
scPTZ O 
screening O 
methods O 
, O 
while O 
their O 
toxicity O 
study O 
was O 
performed O 
following O 
Rotarod O 
method O 
. O 
The O 
active O 
compounds O 
showed O 
enhanced O 
seizure O 
control O 
in O 
scPTZ O 
method O 
when O 
compared O 
with O 
that O 
of O 
MES O 
method O 
. O 
Compounds O 
3f O 
, O 
4c O 
, O 
4f O 
, O 
5k O 
, O 
5p O 
and O 
5w O 
carrying O 
active O 
pharmacophores O 
exhibited O 
complete O 
protection O 
against O 
seizure O 
and O 
their O 
results O 
were O 
comparable O 
with O 
standard O 
drug O 
diazepam B-TRIVIAL 
. O 
Majority O 
of O 
new O 
compounds O 
were O 
found O 
to O 
be O 
non-toxic O 
, O 
while O 
few O 
of O 
them O 
showed O 
toxicity O 
at O 
100mg O 
/ O 
kg O 
. O 
The O 
clogP O 
values O 
of O 
target O 
compounds O 
are O 
in O 
the O 
range O 
of O 
3.5-5.3 O 
, O 
which O 
confirm O 
their O 
lipophilic O 
nature O 
. O 

, O 
characterization O 
and O 
cytotoxic O 
activity O 
on O 
breast O 
cancer O 
cells O 
of O 
new O 
half B-TRIVIAL 
- I-TRIVIAL 
titanocene I-TRIVIAL 
derivatives O 
. O 

series O 
of O 
novel O 
titanocene B-TRIVIAL 
-complexes O 
has O 
been O 
prepared O 
and O 
evaluated O 
for O 
their O 
growth O 
regulatory O 
effects O 
in O 
MCF7 O 
and O 
SkBr3 O 
breast O 
cancer O 
cells O 
. O 
The O 
capability O 
of O 
some O 
of O 
these O 
compound O 
to O 
elicit O 
relevant O 
repressive O 
effects O 
on O 
cancer O 
cell O 
growth O 
could O 
be O 
taken O 
into O 
account O 
towards O 
novel O 
pharmacological O 
approaches O 
in O 
cancer O 
therapy O 
. O 

comparative O 
study O 
of O 
protein O 
carbonylation O 
and O 
mitochondrial O 
dysfunction O 
using O 
the O 
neurotoxicants O 
1,3-dinitrobenzene B-SYSTEMATIC 
, O 
3-nitropropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
, O 
and O 
3-chloropropanediol B-SYSTEMATIC 
. O 

comparative O 
evaluation O 
of O 
neurotoxicants O 
previously O 
identified O 
as O 
models O 
of O 
chemical O 
- O 
induced O 
mitochondrial O 
dysfunction O 
and O 
energy O 
deprivation O 
demonstrated O 
that O 
subtoxic O 
concentrations O 
of O 
1,3-dinitrobenzene B-SYSTEMATIC 
( O 
1,3-DNB B-SYSTEMATIC 
) O 
, O 
3-nitropropionic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
3-NPA B-SYSTEMATIC 
) O 
, O 
and O 
3-chloropropanediol B-SYSTEMATIC 
( O 
3-CPD B-SYSTEMATIC 
) O 
each O 
led O 
to O 
concentration O 
- O 
dependent O 
loss O 
of O 
the O 
mitochondrial O 
membrane O 
potential O 
( O 
ΔΨm O 
) O 
associated O 
with O 
similar O 
patterns O 
of O 
protein O 
carbonylation O 
. O 
Subtoxic O 
concentrations O 
of O 
each O 
neurotoxicant O 
were O 
determined O 
by O 
measuring O 
DI O 
TNC1 O 
cell O 
viability O 
using O 
the O 
MTS O 
cell O 
proliferation O 
assay O 
. O 
Although O 
exposure O 
1μM O 
, O 
10μM O 
, O 
and O 
100μM O 
concentrations O 
of O 
each O 
toxicant O 
did O 
not O 
result O 
in O 
loss O 
of O 
cell O 
viability O 
after O 
48h O 
, O 
exposure O 
to O 
each O 
toxicant O 
at O 
these O 
concentrations O 
led O 
to O 
concentration O 
- O 
dependent O 
loss O 
of O 
tetramethyl B-SYSTEMATIC 
rhodamine I-SYSTEMATIC 
methyl I-SYSTEMATIC 
ester I-SYSTEMATIC 
( O 
TMRM B-ABBREVIATION 
) O 
fluorescence O 
over O 
the O 
same O 
exposure O 
period O 
. O 
Preincubation O 
with O 
the O 
antioxidant O 
, O 
deferoxamine B-TRIVIAL 
, O 
was O 
effective O 
in O 
preventing O 
loss O 
of O 
TMRM B-ABBREVIATION 
flurorescence O 
. O 
Through O 
the O 
combined O 
use O 
of O 
two O 
- O 
dimensional O 
polyacrylamide B-SYSTEMATIC 
gel O 
electrophoresis O 
( O 
2D O 
PAGE O 
) O 
and O 
Oxyblot O 
analysis O 
, O 
this O 
study O 
demonstrated O 
that O 
exposure O 
to O 
each O 
toxicant O 
resulted O 
in O 
the O 
formation O 
of O 
distinctly O 
similar O 
patterns O 
of O 
protein O 
carbonylation O 
comprised O 
of O 
specific O 
proteins O 
identified O 
with O 
tandem O 
MS O 
/ O 
MS O 
. O 
Our O 
results O 
provide O 
insight O 
as O 
to O 
how O 
exposure O 
to O 
different O 
neurotoxicants O 
that O 
enhance O 
oxidative O 
stress O 
may O 
, O 
in O 
fact O 
, O 
lead O 
to O 
mitochondrial O 
injury O 
and O 
subsequent O 
toxicity O 
through O 
selective O 
, O 
yet O 
shared O 
, O 
pathways O 
of O 
protein O 
modification O 
by O 
oxidative O 
carbonylation O 
. O 

methylphenidate B-SYSTEMATIC 
treatment O 
in O 
a O 
rodent O 
model O 
of O 
attention O 
deficit O 
/ O 
hyperactivity O 
disorder O 
: O 
Dopamine B-TRIVIAL 
transporter O 
function O 
and O 
cellular O 
distribution O 
in O 
adulthood O 
. O 

deficit O 
/ O 
hyperactivity O 
disorder O 
( O 
ADHD O 
) O 
is O 
attributed O 
to O 
dysfunction O 
of O 
the O 
prefrontal O 
cortex O 
. O 
Methylphenidate B-SYSTEMATIC 
, O 
an O 
inhibitor O 
of O 
dopamine B-TRIVIAL 
and O 
norepinephrine B-TRIVIAL 
transporters O 
( O 
DAT O 
and O 
NET O 
, O 
respectively O 
) O 
, O 
is O 
a O 
standard O 
treatment O 
for O 
ADHD O 
. O 
The O 
Spontaneously O 
Hypertensive O 
Rat O 
( O 
SHR O 
) O 
is O 
a O 
well O 
- O 
established O 
animal O 
model O 
of O 
ADHD O 
. O 
Our O 
previous O 
results O 
showed O 
that O 
methylphenidate B-SYSTEMATIC 
treatment O 
in O 
adolescent O 
SHR O 
enhanced O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
during O 
adulthood O 
, O 
and O 
alterations O 
in O 
DAT O 
function O 
in O 
prefrontal O 
cortex O 
play O 
a O 
role O 
in O 
this O 
response O 
. O 
Importantly O 
, O 
prefrontal O 
cortex O 
subregions O 
, O 
orbitofrontal O 
cortex O 
( O 
OFC O 
) O 
and O 
medial O 
prefrontal O 
cortex O 
( O 
mPFC O 
) O 
, O 
have O 
been O 
shown O 
to O 
have O 
distinct O 
roles O 
in O 
ADHD O 
and O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
. O 
In O 
the O 
current O 
study O 
, O 
SHR O 
, O 
Wistar-Kyoto O 
( O 
WKY O 
) O 
and O 
Wistar O 
( O 
WIS O 
) O 
rats O 
received O 
a O 
therapeutically O 
relevant O 
dose O 
of O 
methylphenidate B-SYSTEMATIC 
( O 
1.5mg O 
/ O 
kg O 
, O 
p.o O 
. O 
) O 
or O 
vehicle O 
during O 
adolescence O 
and O 
then O 
OFC O 
and O 
mPFC O 
DAT O 
function O 
and O 
cellular O 
expression O 
were O 
assessed O 
during O 
adulthood O 
. O 
In O 
both O 
OFC O 
and O 
mPFC O 
, O 
no O 
strain O 
differences O 
in O 
Vmax O 
or O 
Km O 
for O 
dopamine B-TRIVIAL 
uptake O 
into O 
synaptosomes O 
were O 
found O 
between O 
vehicle O 
- O 
treated O 
SHR O 
, O 
WKY O 
and O 
WIS O 
. O 
Methylphenidate B-SYSTEMATIC 
increased O 
DAT O 
Vmax O 
in O 
SHR O 
mPFC O 
and O 
decreased O 
DAT O 
Vmax O 
in O 
WKY O 
OFC O 
. O 
Also O 
, O 
methylphenidate B-SYSTEMATIC 
decreased O 
DAT O 
Km O 
in O 
WIS O 
OFC O 
. O 
Further O 
, O 
methylphenidate B-SYSTEMATIC 
did O 
not O 
alter O 
DAT O 
cellular O 
localization O 
, O 
indicating O 
that O 
methylphenidate B-SYSTEMATIC 
treatment O 
during O 
adolescence O 
regulated O 
DAT O 
function O 
in O 
SHR O 
mPFC O 
in O 
a O 
trafficking O 
- O 
independent O 
manner O 
. O 
Thus O 
, O 
the O 
increase O 
in O 
mPFC O 
DAT O 
function O 
was O 
an O 
SHR-specific O 
long O 
term O 
consequence O 
of O 
methylphenidate B-SYSTEMATIC 
treatment O 
during O 
adolescence O 
, O 
which O 
may O 
be O 
responsible O 
for O 
the O 
treatment-induced O 
alterations O 
in O 
behavior O 
including O 
the O 
observed O 
increases O 
in O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
. O 

objective O 
of O 
this O 
study O 
was O 
to O 
explore O 
the O 
effects O 
of O 
freeze O 
- O 
drying O 
parameters O 
and O 
formulation O 
composition O 
on O 
polyclonal O 
IgG O 
stability O 
during O 
processing O 
. O 
Samples O 
were O 
freeze O 
- O 
dried O 
with O 
different O 
primary O 
drying O 
pressures O 
and O 
secondary O 
drying O 
heating O 
rates O 
. O 
After O 
drying O 
, O 
changes O 
in O 
IgG O 
in O 
vitro O 
binding O 
activity O 
, O 
monomer O 
recovery O 
, O 
average O 
particle O 
size O 
, O 
and O 
polydispersity O 
were O 
studied O 
from O 
the O 
rehydrated O 
lyophilizates O 
. O 
Significant O 
trends O 
were O 
not O 
observed O 
in O 
binding O 
activities O 
or O 
monomer O 
recoveries O 
, O 
but O 
increases O 
in O 
particle O 
size O 
and O 
polydispersity O 
were O 
observed O 
when O 
using O 
lower O 
primary O 
drying O 
pressure O 
. O 
This O 
effect O 
could O 
no O 
longer O 
be O 
observed O 
when O 
sodium B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
buffer O 
was O 
removed O 
from O 
the O 
formulation O 
. O 
Altering O 
the O 
secondary O 
drying O 
heating O 
rates O 
did O 
not O 
result O 
in O 
any O 
measurable O 
changes O 
in O 
protein O 
stability O 
. O 

effects O 
of O 
Keemun O 
black O 
tea O 
polysaccharides O 
on O 
acute O 
carbon B-SYSTEMATIC 
tetrachloride I-SYSTEMATIC 
-caused O 
oxidative O 
hepatotoxicity O 
in O 
mice O 
. O 

study O 
was O 
designed O 
to O 
investigate O 
chemical O 
characterization O 
of O 
the O 
water O 
- O 
soluble O 
polysaccharides O 
extracted O 
from O 
Keemun O 
black O 
tea O 
( O 
KBTP O 
) O 
, O 
and O 
their O 
antioxidant O 
and O 
hepatoprotective O 
effects O 
against O 
CCl4 B-FORMULA 
-induced O 
oxidative O 
damage O 
in O 
mice O 
. O 
HPLC O 
analysis O 
revealed O 
that O 
KBTP O 
is O 
the O 
typical O 
acidic O 
heteropolysaccharides O 
and O 
consisted O 
of O 
nine O 
monosaccharides B-FAMILY 
. O 
Furthermore O 
, O 
KBTP O 
showed O 
highly O 
ferric B-SYSTEMATIC 
-reducing O 
antioxidant O 
power O 
and O 
scavenging O 
effects O 
against O 
DPPH B-ABBREVIATION 
, O 
OH B-FORMULA 
and O 
O2(-) B-FORMULA 
in O 
vitro O 
. O 
Administration O 
of O 
KBTP O 
( O 
200 O 
, O 
400 O 
and O 
800mg O 
/ O 
kgbw O 
) O 
in O 
mice O 
ahead O 
of O 
CCl4 B-FORMULA 
injection O 
could O 
observably O 
antagonize O 
the O 
CCl4 B-FORMULA 
-induced O 
increases O 
in O 
serum O 
ALT O 
, O 
AST O 
, O 
TG O 
and O 
TC O 
, O 
and O 
the O 
hepatic O 
MDA B-ABBREVIATION 
and O 
8-iso-PGF2a B-SYSTEMATIC 
levels O 
, O 
respectively O 
. O 
Mice O 
with O 
KBTP O 
pretreatment O 
displayed O 
a O 
better O 
profile O 
of O 
hepatosomatic O 
index O 
and O 
the O 
improved O 
GSH B-ABBREVIATION 
and O 
SOD O 
activities O 
in O 
comparison O 
with O 
CCl4 B-FORMULA 
-intoxicated O 
mice O 
. O 
These O 
biochemical O 
results O 
were O 
further O 
supported O 
with O 
liver O 
histopathological O 
assessment O 
, O 
revealing O 
that O 
KBTP O 
has O 
an O 
observable O 
prevention O 
of O 
liver O 
damage O 
induced O 
by O 
CCl4 B-FORMULA 
in O 
mice O 
. O 

adrenal O 
hyperplasia O 
( O 
CAH O 
) O 
is O 
among O 
the O 
most O 
common O 
genetic O 
disorders O 
. O 
Deficiency O 
of O 
adrenal O 
steroid B-FAMILY 
21-hydroxylase O 
deficiency O 
due O 
to O 
mutations O 
in O 
the O 
CYP21A2 O 
gene O 
accounts O 
for O 
about O 
95% O 
cases O 
of O 
CAH O 
. O 
This O 
disorder O 
manifests O 
with O 
androgen B-FAMILY 
excess O 
with O 
or O 
without O 
salt O 
wasting O 
. O 
It O 
also O 
is O 
a O 
potentially O 
life O 
threatening O 
disorder O 
; O 
neonatal O 
screening O 
with O 
17-hydroxyprogesterone B-SYSTEMATIC 
measurement O 
can O 
diagnose O 
the O 
condition O 
in O 
asymptomatic O 
children O 
. O 
Carefully O 
monitored O 
therapy O 
with O 
glucocorticoid O 
and O 
mineralocorticoid O 
supplementation O 
will O 
ensure O 
optimal O 
growth O 
and O 
development O 
for O 
children O 
with O 
CAH O 
. O 
Genital O 
surgery O 
may O 
be O 
required O 
for O 
girls O 
with O 
CAH O 
. O 
Continued O 
care O 
is O 
required O 
for O 
individuals O 
with O 
CAH O 
as O 
adults O 
to O 
prevent O 
long O 
- O 
term O 
adverse O 
consequences O 
of O 
the O 
disease O 
, O 
including O 
infertility O 
, O 
metabolic O 
syndrome O 
and O 
osteoporosis O 
. O 

vitro O 
assessment O 
of O 
cobalt B-SYSTEMATIC 
oxide I-SYSTEMATIC 
particle O 
toxicity O 
: O 
Identifying O 
and O 
circumventing O 
interference O 
. O 

continuing O 
development O 
of O 
nanotechnology O 
necessitates O 
the O 
reliable O 
assessment O 
of O 
potential O 
adverse O 
health O 
consequences O 
associated O 
with O 
human O 
exposures O 
. O 
The O 
physicochemical O 
properties O 
of O 
nanomaterials O 
can O 
be O 
responsible O 
for O 
unexpected O 
interactions O 
with O 
components O 
of O 
classical O 
toxicity O 
assays O 
, O 
which O 
may O 
generate O 
erroneous O 
interpretations O 
. O 
In O 
this O 
paper O 
, O 
we O 
describe O 
how O 
particle O 
interference O 
can O 
be O 
observed O 
in O 
in O 
vitro O 
toxicity O 
tests O 
( O 
CellTiter O 
Blue O 
, O 
CyQUANT O 
, O 
WST-1 O 
and O 
CellTiter-Glo O 
assay O 
) O 
and O 
in O 
cell O 
biology O 
tests O 
using O 
flow O 
cytometry O 
( O 
cell O 
cycle O 
analysis O 
) O 
. O 
We O 
used O 
cobalt B-SYSTEMATIC 
oxide I-SYSTEMATIC 
( O 
Co3O4 B-FORMULA 
) O 
particles O 
as O 
an O 
example O 
, O 
but O 
these O 
assays O 
can O 
be O 
performed O 
, O 
in O 
principle O 
, O 
regardless O 
of O 
the O 
nanoparticle O 
considered O 
. O 
We O 
have O 
shown O 
that O 
cobalt B-SYSTEMATIC 
particles O 
interfere O 
with O 
most O 
of O 
these O 
tests O 
. O 
We O 
adapted O 
the O 
protocol O 
of O 
the O 
CellTiter-Glo O 
assay O 
to O 
circumvent O 
this O 
interference O 
and O 
demonstrated O 
that O 
, O 
using O 
this O 
protocol O 
, O 
the O 
toxicity O 
level O 
is O 
consistent O 
with O 
results O 
obtained O 
using O 
the O 
clonogenic O 
assay O 
, O 
which O 
is O 
considered O 
to O 
be O 
the O 
reference O 
test O 
. O 
Before O 
assessing O 
particle O 
toxicity O 
using O 
in O 
vitro O 
toxicity O 
tests O 
, O 
interference O 
testing O 
should O 
be O 
performed O 
to O 
avoid O 
false O 
interpretations O 
. O 
Furthermore O 
, O 
in O 
some O 
cases O 
of O 
interference O 
, O 
protocol O 
adaptation O 
can O 
be O 
considered O 
to O 
allow O 
the O 
reliable O 
use O 
of O 
these O 
quick O 
and O 
convenient O 
in O 
vitro O 
tests O 
. O 

coatings O 
of O 
glass O 
vials O 
for O 
protein O 
resistance O 
. O 

are O 
surface O 
active O 
molecules O 
which O 
undergo O 
non-specific O 
adsorption O 
when O 
getting O 
in O 
contact O 
with O 
surfaces O 
such O 
as O 
the O 
primary O 
packaging O 
material O 
. O 
This O 
process O 
is O 
critical O 
as O 
it O 
may O 
cause O 
a O 
loss O 
of O 
protein O 
content O 
or O 
protein O 
aggregation O 
. O 
To O 
prevent O 
unspecific O 
adsorption O 
, O 
protein O 
repellent O 
coatings O 
are O 
of O 
high O 
interest O 
. O 
We O 
describe O 
the O 
coating O 
of O 
industrial O 
relevant O 
borosilicate B-SYSTEMATIC 
glass O 
vials O 
with O 
linear B-SYSTEMATIC 
methoxylated I-SYSTEMATIC 
polyglycerol I-SYSTEMATIC 
, O 
hyperbranched B-SYSTEMATIC 
polyglycerol I-SYSTEMATIC 
, O 
and O 
hyperbranched B-SYSTEMATIC 
methoxylated I-SYSTEMATIC 
polyglycerol I-SYSTEMATIC 
. O 
All O 
coatings O 
provide O 
excellent O 
protein O 
repellent O 
effects O 
. O 
The O 
hyperbranched O 
, O 
non-methoxylated O 
coating O 
performed O 
best O 
. O 
The O 
protein O 
repellent O 
properties O 
were O 
maintained O 
also O 
after O 
applying O 
industrial O 
relevant O 
sterilization O 
methods O 
( O 
⩾200°C O 
) O 
. O 
Marginal O 
differences O 
in O 
antibody O 
stability O 
between O 
formulations O 
stored O 
in O 
bare O 
glass O 
vials O 
and O 
coated O 
vials O 
were O 
detected O 
after O 
3months O 
storage O 
; O 
the O 
protein O 
repellent O 
effect O 
remained O 
largely O 
stable O 
. O 
Here O 
, O 
we O 
describe O 
a O 
new O 
material O 
suitable O 
for O 
the O 
coating O 
of O 
primary O 
packaging O 
material O 
of O 
proteins O 
which O 
significantly O 
reduces O 
the O 
protein O 
adsorption O 
and O 
thus O 
could O 
present O 
an O 
interesting O 
new O 
possibility O 
for O 
biomedical O 
applications O 
. O 

of O 
the O 
positive O 
effects O 
on O 
insulin O 
- O 
resistance O 
and O 
β-cell O 
measurements O 
of O 
vildagliptin B-TRIVIAL 
in O 
addition O 
to O 
metformin B-TRIVIAL 
in O 
type O 
2 O 
diabetic O 
patients O 
. O 

evaluated O 
the O 
positive O 
effects O 
of O 
vildagliptin B-TRIVIAL 
in O 
addition O 
to O 
metformin B-TRIVIAL 
on O 
glycemic O 
control O 
and O 
β-cell O 
function O 
in O 
type O 
2 O 
diabetic O 
patients O 
. O 
One O 
hundred O 
and O 
seventy O 
- O 
one O 
type O 
2 O 
diabetic O 
patients O 
were O 
instructed O 
to O 
add O 
vildaglipin B-TRIVIAL 
50mg O 
twice O 
a O 
day O 
or O 
placebo O 
to O 
metformin B-TRIVIAL 
for O 
12 O 
months O 
. O 
Body O 
mass O 
index O 
( O 
BMI O 
) O 
, O 
glycemic O 
control O 
, O 
fasting O 
plasma O 
insulin O 
( O 
FPI O 
) O 
, O 
HOMA-IR O 
, O 
HOMA-β O 
, O 
fasting O 
plasma O 
proinsulin O 
( O 
FPPr O 
) O 
, O 
proinsulin O 
/ O 
fasting O 
plasma O 
insulin O 
ratio O 
( O 
Pr O 
/ O 
FPI O 
ratio O 
) O 
, O 
C- O 
peptide O 
, O 
glucagon O 
, O 
vaspin O 
, O 
visfatin O 
, O 
and O 
omentin-1 O 
were O 
evaluated O 
. O 
Before O 
, O 
and O 
after O 
12 O 
months O 
since O 
the O 
addition O 
of O 
vildagliptin B-TRIVIAL 
, O 
patients O 
underwent O 
a O 
combined O 
euglycemic O 
hyperinsulinemic O 
and O 
hyperglycemic O 
clamp O 
, O 
with O 
subsequent O 
arginine B-TRIVIAL 
stimulation O 
. O 
Vildagliptin B-TRIVIAL 
+ O 
metformin B-TRIVIAL 
were O 
more O 
effective O 
than O 
placebo+ O 
metformin B-TRIVIAL 
in O 
reducing O 
body O 
weight O 
and O 
BMI O 
, O 
glycemic O 
control O 
, O 
HOMA-IR O 
, O 
glucagon O 
and O 
insulin O 
resistance O 
measurements O 
. O 
Vildagliptin B-TRIVIAL 
+ O 
metformin B-TRIVIAL 
gave O 
also O 
a O 
better O 
increase O 
of O 
HOMA-β O 
, O 
and O 
of O 
all O 
β-cell O 
parameters O 
after O 
the O 
clamp O 
. O 
We O 
also O 
recorded O 
a O 
significant O 
correlation O 
between O 
M O 
value O 
increase O 
and O 
the O 
decrease O 
of O 
vaspin O 
, O 
visfatin O 
, O 
and O 
omentin-1 O 
obtained O 
with O 
vildagliptin B-TRIVIAL 
+ O 
metformin B-TRIVIAL 
. O 
Vildagliptin B-TRIVIAL 
, O 
in O 
addition O 
to O 
metformin B-TRIVIAL 
, O 
proved O 
to O 
be O 
effective O 
in O 
improving O 
β-cell O 
function O 
and O 
in O 
reducing O 
insulin O 
resistance O 
measurements O 
. O 

-stimulated O 
processing O 
of O 
cyclin O 
E O 
is O 
mediated O 
via O 
G O 
protein O 
- O 
coupled O 
receptor O 
30 O 
( O 
GPR30 O 
) O 
and O 
accompanied O 
by O 
enhanced O 
migration O 
in O 
MCF-7 O 
breast O 
cancer O 
cells O 
. O 

- O 
expression O 
of O 
cleaved O 
cyclin O 
E O 
in O 
breast O 
tumors O 
is O 
closely O 
associated O 
with O 
tumor O 
progression O 
and O 
resistance O 
to O 
antiestrogens O 
. O 
17β-Estradiol B-SYSTEMATIC 
( O 
E2 O 
) O 
has O 
been O 
recently O 
shown O 
to O 
induce O 
cyclin O 
E O 
processing O 
in O 
breast O 
cancer O 
cells O 
. O 
Tamoxifen B-TRIVIAL 
has O 
been O 
used O 
in O 
patients O 
with O 
estrogen B-FAMILY 
-sensitive O 
breast O 
cancer O 
, O 
yet O 
resistance O 
to O 
antiestrogens O 
and O 
recurrence O 
will O 
appear O 
in O 
some O 
of O 
the O 
patients O 
after O 
its O 
continued O 
use O 
. O 
We O 
therefore O 
addressed O 
possible O 
effects O 
of O 
tamoxifen B-TRIVIAL 
on O 
the O 
generation O 
of O 
cleaved O 
cyclin O 
E O 
and O 
its O 
signal O 
mechanism(s) O 
in O 
estrogen B-FAMILY 
-responsive O 
MCF-7 O 
breast O 
cancer O 
cells O 
that O 
express O 
both O 
G O 
protein O 
- O 
coupled O 
protein O 
( O 
GPR O 
) O 
30 O 
and O 
estrogen B-FAMILY 
receptor O 
α O 
( O 
ERα O 
) O 
. O 
4-Hydroxytamoxifen B-SYSTEMATIC 
( O 
OHT B-FORMULA 
, O 
tamoxifen B-TRIVIAL 
' O 
s O 
active O 
form O 
) O 
failed O 
to O 
prevent O 
E2-induced O 
proteolysis O 
of O 
cyclin O 
E O 
and O 
migration O 
, O 
but O 
rather O 
triggered O 
cyclin O 
E O 
cleavage O 
coincident O 
with O 
augmented O 
migration O 
. O 
OHT B-FORMULA 
-induced O 
cyclin O 
E O 
truncation O 
also O 
occurred O 
in O 
SK-BR-3 O 
cells O 
that O 
express O 
GPR30 O 
and O 
lack O 
ERα O 
, O 
but O 
not O 
in O 
MDA-MB-231 O 
cells O 
that O 
express O 
neither O 
GPR30 O 
nor O 
ERα O 
. O 
G1 O 
, O 
a O 
specific O 
GPR O 
30 O 
agonist O 
, O 
caused O 
dramatic O 
proteolysis O 
of O 
cyclin O 
E O 
and O 
enhanced O 
migration O 
. O 
Furthermore O 
, O 
OHT B-FORMULA 
-stimulated O 
cleavage O 
of O 
cyclin O 
E O 
and O 
migration O 
were O 
tremendously O 
attenuated O 
by O 
G15 O 
, O 
a O 
GPR30 O 
antagonist O 
, O 
or O 
siRNA O 
against O 
GPR30 O 
. O 
In O 
addition O 
, O 
inhibitors O 
for O 
EGFR O 
or O 
ERK1 O 
/ O 
2 O 
remarkably O 
suppressed O 
OHT B-FORMULA 
-induced O 
truncation O 
of O 
cyclin O 
E O 
, O 
suggesting O 
involvement O 
of O 
EGFR O 
signaling O 
. O 
Collectively O 
, O 
our O 
data O 
indicate O 
that O 
OHT B-FORMULA 
contributes O 
to O 
the O 
production O 
of O 
proteolyzed O 
cyclin O 
E O 
via O 
GPR30 O 
with O 
augmented O 
migration O 
in O 
MCF-7 O 
cells O 
. O 

lithium B-SYSTEMATIC 
storage O 
in O 
Fe2O3 B-FORMULA 
- O 
SnO2 B-FORMULA 
- O 
C B-FORMULA 
nanocomposite O 
anode O 
with O 
a O 
breathable O 
structure O 
. O 

novel O 
nanocomposite O 
architecture O 
of O 
a O 
Fe2O3 B-FORMULA 
- O 
SnO2 B-FORMULA 
- O 
C B-FORMULA 
anode O 
, O 
based O 
on O 
clusters O 
of O 
Fe2O3 B-FORMULA 
and O 
SnO2 B-FORMULA 
nanoparticles O 
dispersed O 
along O 
the O 
conductive O 
chains O 
of O 
Super O 
P O 
Li B-FORMULA 
™ O 
carbon B-TRIVIAL 
black I-TRIVIAL 
( O 
Timcal O 
Ltd O 
. O 
) O 
, O 
is O 
presented O 
as O 
a O 
breathable O 
structure O 
in O 
this O 
paper O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 
The O 
synthesis O 
of O 
the O 
nanocomposite O 
is O 
achieved O 
by O 
combining O 
a O 
molten B-FAMILY 
salt I-FAMILY 
precipitation O 
process O 
and O 
a O 
ball O 
milling O 
method O 
for O 
the O 
first O 
time O 
. O 
The O 
crystalline O 
structure O 
, O 
morphology O 
, O 
and O 
electrochemical O 
characterization O 
of O 
the O 
synthesised O 
product O 
are O 
investigated O 
systematically O 
. O 
Electrochemical O 
results O 
demonstrate O 
that O 
the O 
reversible O 
capacity O 
of O 
the O 
composite O 
anode O 
is O 
1110 O 
mA O 
h O 
g(-1) O 
at O 
a O 
current O 
rate O 
of O 
158 O 
mA O 
g(-1) O 
with O 
only O 
31% O 
of O 
initial O 
irreversible O 
capacity O 
in O 
the O 
first O 
cycle O 
. O 
A O 
high O 
reversible O 
capacity O 
of O 
502 O 
mA O 
h O 
g(-1) O 
( O 
higher O 
than O 
the O 
theoretical O 
capacity O 
of O 
graphite O 
, O 
∼372 O 
mA O 
h O 
g(-1) O 
) O 
can O 
be O 
obtained O 
at O 
a O 
high O 
current O 
rate O 
of O 
3950 O 
mA O 
g(-1) O 
. O 
The O 
electrochemical O 
performance O 
is O 
compared O 
favourably O 
with O 
those O 
of O 
Fe2O3 B-FORMULA 
- O 
SnO2 B-FORMULA 
and O 
Fe2O3 B-FORMULA 
- O 
SnO2 B-FORMULA 
- O 
C B-FORMULA 
composite O 
anodes O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
reported O 
in O 
the O 
literature O 
. O 
This O 
work O 
reports O 
a O 
promising O 
method O 
for O 
the O 
design O 
and O 
preparation O 
of O 
nanocomposite O 
electrodes O 
for O 
lithium B-SYSTEMATIC 
-ion O 
batteries O 
. O 

activity O 
of O 
central O 
oxytocin B-TRIVIAL 
in O 
male O 
rats O 
. O 

: O 
A O 
substantial O 
body O 
of O 
research O 
suggests O 
that O 
the O 
neuropeptide O 
oxytocin B-TRIVIAL 
promotes O 
social O 
affiliative O 
behaviors O 
in O 
a O 
wide O 
range O 
of O 
animals O 
including O 
humans O 
. O 
However O 
, O 
its O 
antiaggressive O 
action O 
has O 
not O 
been O 
unequivocally O 
demonstrated O 
in O 
male O 
laboratory O 
rodents O 
. O 
OBJECTIVE O 
: O 
Our O 
primary O 
goal O 
was O 
to O 
examine O 
the O 
putative O 
serenic O 
effect O 
of O 
oxytocin B-TRIVIAL 
in O 
a O 
feral O 
strain O 
( O 
wild O 
type O 
Groningen O 
, O 
WTG O 
) O 
of O 
rats O 
that O 
generally O 
show O 
a O 
much O 
broader O 
variation O 
and O 
higher O 
levels O 
of O 
intermale O 
aggression O 
than O 
commonly O 
used O 
laboratory O 
strains O 
of O 
rats O 
. O 
METHODS O 
: O 
Resident O 
animals O 
were O 
intracerebroventricularly O 
( O 
icv O 
) O 
administered O 
with O 
different O 
doses O 
of O 
synthetic O 
oxytocin B-TRIVIAL 
and O 
oxytocin B-TRIVIAL 
receptor O 
antagonist O 
, O 
alone O 
and O 
in O 
combination O 
, O 
in O 
order O 
to O 
manipulate O 
brain O 
oxytocin B-TRIVIAL 
functioning O 
and O 
to O 
assess O 
their O 
behavioral O 
response O 
to O 
an O 
intruder O 
. O 
RESULTS O 
: O 
Our O 
data O 
clearly O 
demonstrate O 
that O 
acute O 
icv O 
administered O 
oxytocin B-TRIVIAL 
produces O 
dose O 
- O 
dependent O 
and O 
receptor O 
- O 
selective O 
changes O 
in O 
social O 
behavior O 
, O 
reducing O 
aggression O 
and O 
potentiating O 
social O 
exploration O 
. O 
These O 
antiaggressive O 
effects O 
are O 
stronger O 
in O 
the O 
more O 
offensive O 
rats O 
. O 
On O 
the O 
other O 
hand O 
, O 
administration O 
of O 
an O 
oxytocin B-TRIVIAL 
receptor O 
antagonist O 
tends O 
to O 
increase O 
( O 
nonsignificantly O 
) O 
aggression O 
only O 
in O 
low O 
- O 
medium O 
aggressive O 
animals O 
. O 
CONCLUSIONS O 
: O 
These O 
results O 
suggest O 
that O 
transiently O 
enhancing O 
brain O 
oxytocin B-TRIVIAL 
function O 
has O 
potent O 
antiaggressive O 
effects O 
, O 
whereas O 
its O 
attenuation O 
tends O 
to O 
enhance O 
aggressiveness O 
. O 
In O 
addition O 
, O 
a O 
possible O 
inverse O 
relationship O 
between O 
trait O 
aggression O 
and O 
endogenous O 
oxytocinergic O 
signaling O 
is O 
revealed O 
. O 
Overall O 
, O 
this O 
study O 
emphasizes O 
the O 
importance O 
of O 
brain O 
oxytocinergic O 
signaling O 
for O 
regulating O 
intermale O 
offensive O 
aggression O 
. O 
This O 
study O 
supports O 
the O 
suggestion O 
that O 
oxytocin B-TRIVIAL 
receptor O 
agonists O 
could O 
clinically O 
be O 
useful O 
for O 
curbing O 
heightened O 
aggression O 
seen O 
in O 
a O 
range O 
of O 
neuropsychiatric O 
disorders O 
like O 
antisocial O 
personality O 
disorder O 
, O 
autism O 
, O 
and O 
addiction O 
. O 

translation O 
elongation O 
, O 
the O 
ribosome O 
compositional O 
factors O 
elongation O 
factor O 
G O 
( O 
EF-G O 
; O 
encoded O 
by O 
fusA O 
) O 
and O 
tRNA O 
alternately O 
bind O 
to O 
the O 
ribosome O 
to O 
direct O 
protein O 
synthesis O 
and O 
regulate O 
the O 
conformation O 
of O 
the O 
ribosome O 
. O 
Here O 
, O 
we O 
use O 
single O 
- O 
molecule O 
fluorescence O 
with O 
zero O 
- O 
mode O 
waveguides O 
to O 
directly O 
correlate O 
ribosome O 
conformation O 
and O 
composition O 
during O 
multiple O 
rounds O 
of O 
elongation O 
at O 
high O 
factor O 
concentrations O 
in O 
Escherichia O 
coli O 
. O 
Our O 
results O 
show O 
that O 
EF-G O 
bound O 
to O 
GTP B-ABBREVIATION 
( O 
EF-G- O 
GTP B-ABBREVIATION 
) O 
continuously O 
samples O 
both O 
rotational O 
states O 
of O 
the O 
ribosome O 
, O 
binding O 
with O 
higher O 
affinity O 
to O 
the O 
rotated O 
state O 
. O 
Upon O 
successful O 
accommodation O 
into O 
the O 
rotated O 
ribosome O 
, O 
the O 
EF-G-ribosome O 
complex O 
evolves O 
through O 
several O 
rate O 
- O 
limiting O 
conformational O 
changes O 
and O 
the O 
hydrolysis O 
of O 
GTP B-ABBREVIATION 
, O 
which O 
results O 
in O 
a O 
transition O 
back O 
to O 
the O 
nonrotated O 
state O 
and O 
in O 
turn O 
drives O 
translocation O 
and O 
facilitates O 
release O 
of O 
both O 
EF-G- O 
GDP B-ABBREVIATION 
and O 
E-site O 
tRNA O 
. O 
These O 
experiments O 
highlight O 
the O 
power O 
of O 
tracking O 
single O 
- O 
molecule O 
conformation O 
and O 
composition O 
simultaneously O 
in O 
real O 
time O 
. O 

Acute O 
and O 
Chronic O 
Effects O 
of O 
Monosodium B-SYSTEMATIC 
L-Glutamate I-SYSTEMATIC 
on O 
Serum O 
Iron O 
and O 
Total O 
Iron O 
- O 
Binding O 
Capacity O 
in O 
the O 
Jugular O 
Artery O 
and O 
Vein O 
of O 
Pigs O 
. O 

analyzed O 
the O 
effects O 
of O 
acute O 
and O 
chronic O 
oral O 
administration O 
of O 
monosodium B-SYSTEMATIC 
L-glutamate I-SYSTEMATIC 
( O 
MSG B-ABBREVIATION 
) O 
on O 
serum O 
iron B-SYSTEMATIC 
( O 
Fe O 
) O 
levels O 
and O 
total O 
iron B-SYSTEMATIC 
-binding O 
capacity O 
( O 
TIBC O 
) O 
in O 
piglets O 
. O 
In O 
the O 
first O 
experiment O 
, O 
12 O 
piglets O 
were O 
randomly O 
assigned O 
to O 
two O 
groups O 
: O 
one O 
fed O 
a O 
standard O 
diet O 
( O 
SD O 
) O 
and O 
the O 
other O 
fed O 
an O 
SD O 
containing O 
MSG B-ABBREVIATION 
( O 
10 O 
g O 
/ O 
kg O 
) O 
. O 
On O 
day O 
30 O 
, O 
serum O 
, O 
liver O 
, O 
kidney O 
, O 
and O 
spleen O 
samples O 
were O 
collected O 
to O 
determine O 
the O 
Fe B-FORMULA 
levels O 
. O 
In O 
the O 
second O 
experiment O 
, O 
six O 
pigs O 
were O 
surgically O 
fitted O 
with O 
a O 
catheter O 
in O 
the O 
jugular O 
artery O 
and O 
vein O 
to O 
investigate O 
the O 
dynamic O 
changes O 
of O 
serum O 
Fe B-FORMULA 
and O 
TIBC O 
. O 
Blood O 
samples O 
were O 
taken O 
from O 
each O 
pig O 
via O 
the O 
catheter O 
every O 
30 O 
min O 
, O 
for O 
a O 
period O 
of O 
4 O 
h O 
. O 
The O 
results O 
show O 
that O 
MSG B-ABBREVIATION 
increases O 
Fe B-FORMULA 
levels O 
in O 
the O 
spleen O 
( O 
P O 
< O 
0.05 O 
) O 
and O 
in O 
serum O 
obtained O 
from O 
the O 
jugular O 
artery O 
( O 
P O 
< O 
0.01 O 
) O 
. O 
In O 
addition O 
, O 
TIBC O 
in O 
serum O 
obtained O 
from O 
the O 
jugular O 
artery O 
demonstrated O 
an O 
increasing O 
trend O 
in O 
pigs O 
fed O 
the O 
MSG B-ABBREVIATION 
diet O 
; O 
however O 
, O 
this O 
trend O 
was O 
not O 
observed O 
in O 
the O 
jugular O 
vein O 
. O 
In O 
conclusion O 
, O 
MSG B-ABBREVIATION 
increases O 
Fe B-FORMULA 
retention O 
by O 
enhancing O 
TIBC O 
in O 
serum O 
. O 

is O 
frequently O 
present O 
in O 
patients O 
with O 
polycystic O 
ovary O 
syndrome O 
( O 
PCOS O 
) O 
and O 
plays O 
an O 
important O 
role O 
in O 
the O 
pathogenesis O 
of O 
the O 
metabolic O 
, O 
endocrine O 
, O 
and O 
reproductive O 
abnormalities O 
associated O 
with O 
this O 
syndrome O 
. O 
We O 
aimed O 
to O 
summarize O 
the O 
effects O 
of O 
lifestyle O 
changes O 
and O 
anti-obesity O 
pharmacotherapy O 
in O 
patients O 
with O 
PCOS O 
. O 
We O 
reviewed O 
the O 
literature O 
regarding O 
the O 
effects O 
of O 
lifestyle O 
changes O 
and O 
anti-obesity O 
agents O 
on O 
the O 
metabolic O 
and O 
endocrine O 
abnormalities O 
of O 
PCOS O 
. O 
Lifestyle O 
changes O 
, O 
including O 
diet O 
, O 
exercise O 
, O 
and O 
behavioral O 
modification O 
, O 
appear O 
to O 
improve O 
the O 
metabolic O 
and O 
reproductive O 
abnormalities O 
of O 
overweight O 
and O 
obese O 
patients O 
with O 
PCOS O 
. O 
Therefore O 
, O 
lifestyle O 
changes O 
appear O 
to O 
represent O 
the O 
first O 
- O 
line O 
management O 
for O 
all O 
overweight O 
and O 
obese O 
patients O 
with O 
PCOS O 
. O 
However O 
, O 
the O 
optimal O 
composition O 
of O 
diet O 
and O 
the O 
optimal O 
type O 
of O 
exercise O 
in O 
these O 
patients O 
are O 
unknown O 
. O 
Anti-obesity O 
agents O 
that O 
have O 
been O 
studied O 
in O 
PCOS O 
include O 
orlistat B-TRIVIAL 
, O 
sibutramine B-TRIVIAL 
, O 
and O 
rimonabant B-TRIVIAL 
. O 
However O 
, O 
the O 
latter O 
two O 
agents O 
have O 
been O 
withdrawn O 
from O 
the O 
market O 
because O 
of O 
side O 
effects O 
. O 
Long O 
- O 
term O 
studies O 
with O 
orlistat B-TRIVIAL 
in O 
overweight O 
and O 
obese O 
diabetic O 
patients O 
showed O 
greater O 
weight O 
loss O 
and O 
metabolic O 
and O 
cardiovascular O 
benefits O 
than O 
those O 
achieved O 
with O 
lifestyle O 
changes O 
alone O 
. O 
However O 
, O 
there O 
are O 
limited O 
data O 
on O 
the O 
efficacy O 
of O 
orlistat B-TRIVIAL 
in O 
women O 
with O 
PCOS O 
. O 
In O 
conclusion O 
, O 
lifestyle O 
changes O 
( O 
diet O 
, O 
exercise O 
and O 
behavioral O 
modification O 
) O 
, O 
particularly O 
when O 
combined O 
with O 
anti-obesity O 
agents O 
, O 
exert O 
beneficial O 
effects O 
on O 
the O 
endocrine O 
abnormalities O 
of O 
obese O 
patients O 
with O 
PCOS O 
and O 
improve O 
metabolic O 
parameters O 
. O 

: O 
To O 
evaluate O 
the O 
effectiveness O 
of O 
a O 
care O 
management O 
program O 
provided O 
by O 
clinical O 
pharmacists O 
for O 
veterans O 
with O 
dyslipidemia O 
. O 
DESIGN O 
: O 
Retrospective O 
cohort O 
design O 
. O 
SETTING O 
: O 
Two O 
primary O 
care O 
clinics O 
at O 
a O 
Veterans O 
Affairs O 
Medical O 
Center O 
. O 
PATIENTS O 
: O 
An O 
intervention O 
( O 
IT O 
) O 
cohort O 
of O 
213 O 
patients O 
referred O 
for O 
management O 
of O 
dyslipidemia O 
by O 
clinical O 
pharmacists O 
and O 
a O 
control O 
cohort O 
of O 
219 O 
patients O 
with O 
dyslipidemia O 
receiving O 
usual O 
care O 
( O 
UC O 
) O 
. O 
METHODS O 
: O 
Data O 
were O 
obtained O 
from O 
electronic O 
medical O 
records O 
regarding O 
drug O 
therapy O 
, O 
lipid O 
levels O 
, O 
and O 
patient O 
characteristics O 
. O 
Using O 
multivariable O 
regression O 
models O 
to O 
adjust O 
for O 
baseline O 
characteristics O 
, O 
the O 
primary O 
analyses O 
compared O 
mean O 
final O 
measured O 
values O 
of O 
low O 
- O 
density O 
lipoprotein O 
( O 
LDL O 
) O 
cholesterol B-TRIVIAL 
, O 
total O 
cholesterol B-TRIVIAL 
( O 
TC O 
) O 
, O 
high O 
- O 
density O 
lipoprotein O 
( O 
HDL O 
) O 
cholesterol B-TRIVIAL 
, O 
and O 
triglycerides B-FAMILY 
( O 
TGs O 
) O 
among O 
the O 
IT O 
and O 
UC O 
cohorts O 
at O 
the O 
final O 
follow O 
- O 
up O 
visits O 
. O 
Secondary O 
analyses O 
compared O 
the O 
proportion O 
of O 
patients O 
achieving O 
National O 
Cholesterol B-TRIVIAL 
Education O 
Program O 
/ O 
Third O 
Report O 
of O 
the O 
Expert O 
Panel O 
on O 
Detection O 
, O 
Evaluation O 
, O 
and O 
Treatment O 
of O 
High O 
Blood O 
Cholesterol O 
in O 
Adults O 
( O 
NCEP O 
/ O 
ATPIII O 
) O 
concordant O 
LDL O 
goals O 
and O 
the O 
time O 
to O 
achieve O 
LDL O 
goals O 
between O 
the O 
two O 
groups O 
. O 
RESULTS O 
: O 
Compared O 
with O 
the O 
UC O 
cohort O 
, O 
the O 
adjusted O 
difference O 
in O 
the O 
mean O 
final O 
measured O 
LDL O 
for O 
the O 
IT O 
cohort O 
was O 
-10.4 O 
mg O 
/ O 
dl O 
( O 
95% O 
confidence O 
interval O 
[ O 
CI O 
] O 
-16.1 O 
to O 
-4.6 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
TC O 
was O 
-12.7 O 
( O 
95% O 
CI O 
-21.3 O 
to O 
-4.1 O 
, O 
p=0.004 O 
) O 
. O 
There O 
were O 
no O 
significant O 
differences O 
in O 
the O 
adjusted O 
mean O 
final O 
measured O 
HDL O 
or O 
TGs O 
between O 
the O 
two O 
groups O 
. O 
The O 
NCEP O 
/ O 
ATPIII O 
goal O 
LDL O 
was O 
met O 
in O 
80.3% O 
of O 
patients O 
in O 
the O 
IT O 
cohort O 
and O 
65.3% O 
of O 
patients O 
in O 
the O 
UC O 
cohort O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
, O 
2.6 O 
; O 
95% O 
CI O 
1.6-4.3 O 
, O 
p O 
< O 
0.001 O 
) O 
. O 
Time O 
to O 
achieve O 
goal O 
LDL O 
was O 
significantly O 
shorter O 
for O 
the O 
IT O 
cohort O 
compared O 
with O 
the O 
UC O 
cohort O 
( O 
risk O 
ratio O 
, O 
1.8 O 
; O 
95% O 
CI O 
1.2-2.8 O 
, O 
log O 
- O 
rank O 
p=0.002 O 
) O 
. O 
CONCLUSION O 
: O 
Veterans O 
referred O 
to O 
a O 
clinical O 
pharmacist O 
for O 
treatment O 
of O 
dyslipidemia O 
achieved O 
significant O 
reductions O 
in O 
TC O 
and O 
LDL O 
. O 
A O 
greater O 
proportion O 
of O 
patients O 
achieved O 
NCEP O 
/ O 
ATPIII O 
goal O 
LDL O 
, O 
and O 
the O 
time O 
to O 
attainment O 
of O 
LDL O 
goals O 
was O 
shorter O 
in O 
the O 
pharmacist O 
- O 
managed O 
cohort O 
, O 
supporting O 
a O 
continued O 
role O 
for O 
pharmacy O 
care O 
management O 
in O 
the O 
treatment O 
of O 
patients O 
with O 
dyslipidemia O 
. O 

effects O 
of O 
the O 
adenosine B-TRIVIAL 
A3 O 
receptor O 
agonist O 
IB-MECA B-IDENTIFIER 
on O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
-induced O 
experimental O 
acute O 
pancreatitis O 
. O 

role O 
of O 
adenosine B-TRIVIAL 
A3 O 
receptors O 
and O 
their O 
distribution O 
in O 
the O 
gastrointestinal O 
tract O 
have O 
been O 
widely O 
investigated O 
. O 
Most O 
of O 
the O 
reports O 
discuss O 
their O 
role O 
in O 
intestinal O 
inflammations O 
. O 
However O 
, O 
the O 
role O 
of O 
adenosine B-TRIVIAL 
A3 O 
receptor O 
agonist O 
in O 
pancreatitis O 
has O 
not O 
been O 
well O 
established O 
. O 
The O 
aim O 
of O 
this O 
study O 
is O 
( O 
Ed O 
note O 
: O 
Purpose O 
statements O 
should O 
be O 
in O 
present O 
tense O 
) O 
to O 
evaluate O 
the O 
effects O 
of O 
the O 
adenosine B-TRIVIAL 
A3 O 
receptor O 
agonist O 
on O 
the O 
course O 
of O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
-induced O 
experimental O 
acute O 
pancreatitis O 
( O 
EAP O 
) O 
. O 
The O 
experiments O 
were O 
performed O 
on O 
80 O 
male O 
Wistar O 
rats O 
, O 
58 O 
of O 
which O 
survived O 
, O 
subdivided O 
into O 
3 O 
groups O 
: O 
C-control O 
rats O 
, O 
I-EAP O 
group O 
, O 
and O 
II-EAP O 
group O 
treated O 
with O 
the O 
adenosine B-TRIVIAL 
A3 O 
receptor O 
agonist O 
IB-MECA B-IDENTIFIER 
( B-SYSTEMATIC 
1-deoxy-1-6[[(3-iodophenyl) I-SYSTEMATIC 
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide I-SYSTEMATIC 
at O 
a O 
dose O 
of O 
0.75 O 
mg O 
/ O 
kg O 
b.w O 
. O 
i.p O 
. O 
at O 
48 O 
, O 
24 O 
, O 
12 O 
and O 
1 O 
h O 
before O 
and O 
1 O 
h O 
after O 
the O 
injection O 
of O 
5 O 
% O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
solution O 
into O 
the O 
biliary O 
- O 
pancreatic O 
duct O 
. O 
Serum O 
for O 
α-amylase O 
and O 
lipase O 
determinations O 
and O 
tissue O 
samples O 
for O 
morphological O 
examinations O 
were O 
collected O 
at O 
2 O 
, O 
6 O 
, O 
and O 
24 O 
h O 
of O 
the O 
experiment O 
. O 
In O 
the O 
IB-MECA B-IDENTIFIER 
group O 
, O 
α-amylase O 
activity O 
was O 
decreased O 
with O 
statistically O 
high O 
significance O 
compared O 
to O 
group O 
I O 
. O 
The O 
activity O 
of O 
lipase O 
was O 
not O 
significantly O 
different O 
among O 
the O 
experimental O 
groups O 
but O 
higher O 
than O 
in O 
the O 
control O 
group O 
. O 
The O 
administration O 
of O 
IB-MECA B-IDENTIFIER 
attenuated O 
the O 
histological O 
parameters O 
of O 
inflammation O 
as O 
compared O 
to O 
untreated O 
animals O 
. O 
The O 
use O 
of O 
A3 O 
receptor O 
agonist O 
IB-MECA B-IDENTIFIER 
attenuates O 
EAP O 
. O 
Our O 
findings O 
suggest O 
that O 
stimulation O 
of O 
adenosine B-TRIVIAL 
A3 O 
receptors O 
plays O 
a O 
positive O 
role O 
in O 
the O 
sodium B-SYSTEMATIC 
taurocholate I-SYSTEMATIC 
-induced O 
EAP O 
in O 
rats O 
. O 

7-Year O 
Case O 
of O 
Furosemide B-TRIVIAL 
-Induced O 
Immune O 
Thrombocytopenia O 
. O 

thrombocytopenia O 
has O 
been O 
attributed O 
to O 
many O 
causes O 
. O 
Several O 
drugs O 
have O 
been O 
implicated O 
as O 
culprits O 
in O 
causing O 
drug O 
- O 
induced O 
thrombocytopenia O 
. O 
Although O 
the O 
mechanism O 
for O 
this O 
type O 
of O 
thrombocytopenia O 
is O 
not O 
well O 
understood O 
, O 
at O 
least O 
three O 
types O 
of O 
antibodies O 
appear O 
to O 
be O 
involved O 
: O 
drug O 
- O 
dependent O 
antibodies O 
, O 
hapten O 
- O 
dependent O 
antibodies O 
, O 
and O 
drug O 
- O 
induced O 
platelet O 
- O 
reactive O 
autoantibodies O 
. O 
In O 
this O 
report O 
, O 
we O 
describe O 
a O 
case O 
in O 
which O 
furosemide B-TRIVIAL 
was O 
identified O 
as O 
the O 
probable O 
cause O 
of O 
drug O 
- O 
induced O 
thrombocytopenia O 
in O 
an O 
84-year- O 
old O 
man O 
with O 
chronic O 
symptomatic O 
idiopathic O 
thrombocytopenia O 
for O 
seven O 
years O 
before O 
discovery O 
. O 
The O 
patient's O 
platelet O 
count O 
and O 
daily O 
furosemide B-TRIVIAL 
dose O 
, O 
both O 
intravenous O 
and O 
oral O 
, O 
were O 
documented O 
throughout O 
his O 
medical O 
history O 
. O 
A O 
dose O 
- O 
dependent O 
change O 
in O 
platelet O 
count O 
was O 
observed O 
in O 
association O 
with O 
the O 
furosemide B-TRIVIAL 
dose O 
. O 
His O 
platelet O 
count O 
increased O 
on O 
discontinuation O 
of O 
furosemide B-TRIVIAL 
and O 
beginning O 
of O 
torsemide B-TRIVIAL 
. O 
Several O 
months O 
after O 
discontinuation O 
of O 
furosemide B-TRIVIAL 
, O 
his O 
platelet O 
count O 
increased O 
to O 
a O 
9-year O 
high O 
of O 
206 O 
× O 
10(3) O 
/ O 
mm(3) O 
from O 
a O 
low O 
of O 
36 O 
× O 
10(3) O 
/ O 
mm(3) O 
while O 
receiving O 
furosemide B-TRIVIAL 
therapy O 
. O 
Based O 
on O 
the O 
observations O 
of O 
this O 
case O 
report O 
, O 
clinicians O 
should O 
more O 
readily O 
consider O 
furosemide B-TRIVIAL 
as O 
a O 
potential O 
cause O 
of O 
thrombocytopenia O 
. O 

Silica B-TRIVIAL 
Nanoparticles O 
Act O 
as O 
a O 
Self-Adjuvant O 
for O 
Ovalbumin O 
Model O 
Antigen O 
in O 
Mice O 
. O 

to O 
the O 
model O 
protein O 
antigen O 
ovalbumin O 
( O 
OVA O 
) O 
is O 
investigated O 
using O 
MCM-41 B-IDENTIFIER 
mesoporous O 
silica B-TRIVIAL 
nanoparticles O 
as O 
a O 
novel O 
vaccine O 
delivery O 
vehicle O 
and O 
adjuvant O 
system O 
in O 
mice O 
. O 
The O 
effects O 
of O 
amino B-FAMILY 
surface O 
functionalization O 
and O 
adsorption O 
time O 
on O 
OVA O 
adsorption O 
to O 
nanoparticles O 
are O 
assessed O 
. O 
Amino B-SYSTEMATIC 
-functionalized O 
MCM-41 B-IDENTIFIER 
( O 
AM-41 O 
) O 
shows O 
an O 
effect O 
on O 
the O 
amount O 
of O 
OVA O 
binding O 
, O 
with O 
2.5-fold O 
increase O 
in O 
binding O 
capacity O 
( O 
72 O 
mg O 
OVA O 
/ O 
g O 
AM-41 O 
) O 
compared O 
to O 
nonfunctionalized O 
MCM-41 B-IDENTIFIER 
( O 
29 O 
mg O 
OVA O 
/ O 
g O 
MCM-41 B-IDENTIFIER 
) O 
. O 
Immunization O 
studies O 
in O 
mice O 
with O 
a O 
10 O 
μg O 
dose O 
of O 
OVA O 
adsorbed O 
to O 
AM-41 O 
elicits O 
both O 
antibody O 
and O 
cell O 
- O 
mediated O 
immune O 
responses O 
following O 
three O 
subcutaneous O 
injections O 
. O 
Immunizations O 
at O 
a O 
lower O 
2 O 
μg O 
dose O 
of O 
OVA O 
adsorbed O 
to O 
AM-41 O 
particles O 
results O 
in O 
an O 
antibody O 
response O 
but O 
not O 
cell O 
- O 
mediated O 
immunity O 
. O 
The O 
level O 
of O 
antibody O 
responses O 
following O 
immunization O 
with O 
nanoformulations O 
containing O 
either O 
2 O 
μg O 
or O 
10 O 
μg O 
of O 
OVA O 
are O 
only O 
slightly O 
lower O 
than O 
that O 
in O 
mice O 
which O 
receive O 
50 O 
μg O 
OVA O 
adjuvanted O 
with O 
QuilA O 
, O 
a O 
crude O 
mixture O 
of O 
saponins B-FAMILY 
extracted O 
from O 
the O 
bark O 
of O 
the O 
Quillaja O 
saponaria O 
Molina O 
tree O 
. O 
This O 
is O 
a O 
significant O 
result O 
, O 
since O 
it O 
demonstrates O 
that O 
AM-41 O 
nanoparticles O 
are O 
self O 
- O 
adjuvanting O 
and O 
elicit O 
immune O 
responses O 
at O 
reduced O 
antigen O 
doses O 
in O 
vivo O 
compared O 
to O 
a O 
conventional O 
delivery O 
system O 
. O 
Importantly O 
, O 
there O 
are O 
no O 
local O 
or O 
systemic O 
negative O 
effects O 
in O 
animals O 
injected O 
with O 
AM-41 O 
. O 
Histopathological O 
studies O 
of O 
a O 
range O 
of O 
tissue O 
organs O 
show O 
no O 
changes O 
in O 
histopathology O 
of O 
the O 
animals O 
receiving O 
nanoparticles O 
over O 
a O 
six O 
week O 
period O 
. O 
These O 
results O 
establish O 
the O 
biocompatible O 
MCM-41 B-IDENTIFIER 
silica B-TRIVIAL 
nanoparticles O 
as O 
a O 
new O 
method O 
for O 
vaccine O 
delivery O 
which O 
incorporates O 
a O 
self O 
- O 
adjuvant O 
effect O 
. O 

Factors O 
for O 
Excessive O 
Anticoagulation O 
Among O 
Hospitalized O 
Adults O 
Receiving O 
Warfarin B-TRIVIAL 
Therapy O 
Using O 
a O 
Pharmacist-Managed O 
Dosing O 
Protocol O 
. O 

OBJECTIVE O 
: O 
To O 
identify O 
specific O 
risk O 
factors O 
for O 
excessive O 
anticoagulation O 
, O 
defined O 
as O 
an O 
international O 
normalized O 
ratio O 
( O 
INR O 
) O 
higher O 
than O 
5 O 
, O 
in O 
hospitalized O 
adults O 
receiving O 
warfarin B-TRIVIAL 
therapy O 
using O 
a O 
pharmacist O 
- O 
managed O 
dosing O 
protocol O 
. O 
DESIGN O 
: O 
Retrospective O 
nested O 
case O 
- O 
control O 
study O 
. O 
SETTING O 
: O 
Large O 
academic O 
tertiary O 
care O 
medical O 
center O 
. O 
PATIENTS O 
: O 
Hospitalized O 
nonsurgical O 
patients O 
18 O 
years O 
or O 
older O 
who O 
received O 
at O 
least O 
one O 
dose O 
of O 
warfarin B-TRIVIAL 
according O 
to O 
the O 
pharmacist O 
- O 
managed O 
protocol O 
from O 
January O 
1 O 
, O 
2009 O 
, O 
to O 
January O 
31 O 
, O 
2012 O 
, O 
were O 
included O 
. O 
Patients O 
who O 
experienced O 
an O 
INR O 
higher O 
than O 
5 O 
were O 
designated O 
as O 
case O 
patients O 
; O 
those O 
who O 
received O 
warfarin B-TRIVIAL 
for O 
at O 
least O 
as O 
many O 
days O 
as O 
the O 
case O 
patients O 
but O 
who O 
did O 
not O 
experience O 
an O 
INR O 
more O 
than O 
5 O 
were O 
deemed O 
control O 
patients O 
. O 
Controls O 
were O 
matched O 
to O 
cases O 
in O 
a O 
2 O 
: O 
1 O 
ratio O 
by O 
age O 
, O 
sex O 
, O 
INR O 
goal O 
, O 
and O 
type O 
of O 
warfarin B-TRIVIAL 
therapy O 
( O 
new O 
start O 
or O 
continuation O 
) O 
. O 
MEASUREMENTS O 
AND O 
MAIN O 
RESULTS O 
: O 
A O 
total O 
of O 
87 O 
case O 
patients O 
were O 
matched O 
to O 
174 O 
controls O 
. O 
Ten O 
different O 
hypothesized O 
risk O 
factors O 
were O 
examined O 
. O 
Two O 
variables O 
, O 
severity O 
of O 
illness O 
score O 
( O 
odds O 
ratio O 
[ O 
OR O 
] O 
4.89 O 
, O 
p O 
< O 
0.001 O 
) O 
and O 
poor O 
nutritional O 
status O 
( O 
OR O 
4.27 O 
, O 
p O 
< O 
0.001 O 
) O 
, O 
demonstrated O 
strong O 
independent O 
associations O 
with O 
risk O 
of O 
excessive O 
anticoagulation O 
. O 
Administration O 
of O 
interacting O 
drugs O 
that O 
highly O 
potentiate O 
warfarin B-TRIVIAL 
' O 
s O 
effect O 
( O 
OR O 
2.26 O 
, O 
p=0.011 O 
) O 
and O 
concurrent O 
diarrheal O 
illness O 
( O 
OR O 
4.75 O 
, O 
p O 
< O 
0.001 O 
) O 
also O 
displayed O 
a O 
statistically O 
significant O 
risk O 
for O 
excessive O 
anticoagulation O 
. O 
CONCLUSION O 
: O 
Even O 
in O 
a O 
highly O 
standardized O 
system O 
for O 
warfarin B-TRIVIAL 
dosing O 
by O 
a O 
pharmacist O 
- O 
managed O 
protocol O 
, O 
higher O 
disease O 
severity O 
and O 
poor O 
nutritional O 
status O 
placed O 
hospitalized O 
patients O 
at O 
greater O 
risk O 
of O 
experiencing O 
excessive O 
anticoagulation O 
. O 
In O 
addition O 
, O 
administration O 
of O 
interacting O 
drugs O 
that O 
highly O 
potentiate O 
warfarin B-TRIVIAL 
' O 
s O 
effect O 
or O 
the O 
occurrence O 
of O 
diarrheal O 
illness O 
may O 
predict O 
increased O 
risk O 
. O 

-Substituted O 
Thymidine B-TRIVIAL 
Derivatives O 
as O 
a O 
Novel O 
Class O 
of O 
Antileishmanial O 
Agents O 
: O 
Leishmania O 
infantum O 
EndoG O 
as O 
a O 
Potential O 
Target O 
. O 

series O 
of O 
5'-triphenylmethyl B-SYSTEMATIC 
( I-SYSTEMATIC 
trityl I-SYSTEMATIC 
) I-SYSTEMATIC 
-substituted O 
thymidine B-TRIVIAL 
derivatives O 
were O 
synthesized O 
and O 
tested O 
against O 
Leishmania O 
infantum O 
axenic O 
promastigotes O 
and O 
amastigotes O 
. O 
Several O 
of O 
these O 
compounds O 
show O 
significant O 
antileishmanial O 
activity O 
, O 
with O 
IC50 O 
values O 
in O 
the O 
low O 
micromolar O 
range O 
. O 
Among O 
these O 
, O 
3'-O-(isoleucylisoleucyl)-5'-O-(3,3,3-triphenylpropanoyl)thymidine B-SYSTEMATIC 
displays O 
particularly O 
good O 
activity O 
against O 
intracellular O 
amastigotes O 
. O 
Assays O 
performed O 
to O 
characterize O 
the O 
nature O 
of O 
parasite O 
cell O 
death O 
in O 
the O 
presence O 
of O 
the O 
tritylthymidines B-FAMILY 
indicated O 
significant O 
alterations O 
in O 
mitochondrial O 
transmembrane O 
potential O 
, O 
an O 
increase O 
in O 
superoxide B-TRIVIAL 
concentrations O 
, O 
and O 
also O 
significant O 
decreases O 
in O 
DNA O 
degradation O 
during O 
the O 
cell O 
death O 
process O 
. O 
Results O 
point O 
to O 
the O 
mitochondrial O 
nuclease O 
LiEndoG O 
as O 
a O 
target O 
for O 
the O 
action O 
of O 
this O 
family O 
of O 
compounds O 
. O 

of O 
chromium B-SYSTEMATIC 
(VI) I-SYSTEMATIC 
exposure O 
on O 
antioxidant O 
defense O 
status O 
and O 
trace O 
element O 
homeostasis O 
in O 
acute O 
experiment O 
in O 
rat O 
. O 

exposure O 
to O 
hexavalent B-SYSTEMATIC 
chromium I-SYSTEMATIC 
( O 
Cr B-FORMULA 
(VI) I-FORMULA 
) O 
compounds O 
is O 
of O 
concern O 
in O 
many O 
Cr B-FORMULA 
-related O 
industries O 
and O 
their O 
surrounding O 
environment O 
. O 
Cr B-FORMULA 
(VI) I-FORMULA 
is O 
a O 
proven O 
toxin O 
and O 
carcinogen O 
. O 
The O 
Cr B-FORMULA 
(VI) I-FORMULA 
compounds O 
are O 
easily O 
absorbed O 
, O 
can O 
diffuse O 
across O 
cell O 
membranes O 
, O 
and O 
have O 
strong O 
oxidative O 
potential O 
. O 
Despite O 
intensive O 
studies O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
pro O 
- O 
oxidative O 
effects O 
, O 
limited O 
data O 
exist O 
on O 
the O 
influence O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
on O 
selenoenzymes O 
thioredoxin O 
reductase O 
( O 
TrxR O 
) O 
and O 
glutathione B-TRIVIAL 
peroxidase O 
(GPx)-important O 
components O 
of O 
antioxidant O 
defense O 
system O 
. O 
This O 
study O 
investigates O 
the O 
effect O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
exposure O 
on O 
antioxidant O 
defense O 
status O 
, O 
with O 
focus O 
on O 
these O 
selenoenzymes O 
, O 
and O 
on O 
trace O 
element O 
homeostasis O 
in O 
an O 
acute O 
experiment O 
in O 
rat O 
. O 
Male O 
Wistar O 
rats O 
( O 
130-140g O 
) O 
were O 
assigned O 
to O 
two O 
groups O 
of O 
8 O 
animals O 
: O 
I O 
. O 
control O 
; O 
and O 
II O 
. O 
Cr B-FORMULA 
(VI) I-FORMULA 
treated O 
. O 
The O 
animals O 
in O 
Cr B-FORMULA 
(VI) I-FORMULA 
group O 
were O 
administered O 
a O 
single O 
dose O 
of O 
K2Cr2O7 B-FORMULA 
( O 
20 O 
mg O 
/ O 
kg O 
, O 
intraperitoneally O 
( O 
ip O 
) O 
) O 
. O 
The O 
control O 
group O 
received O 
saline O 
solution O 
. O 
After O 
24 O 
h O 
, O 
the O 
animals O 
were O 
sacrificed O 
and O 
the O 
liver O 
and O 
kidneys O 
were O 
examined O 
for O 
lipid O 
peroxidation O 
( O 
LP O 
; O 
thiobarbituric B-SYSTEMATIC 
acid I-SYSTEMATIC 
reactive O 
substances O 
( O 
TBARS O 
) O 
concentration O 
) O 
, O 
the O 
level O 
of O 
reduced O 
glutathione B-TRIVIAL 
( O 
GSH B-ABBREVIATION 
) O 
and O 
the O 
activities O 
of O 
GPx-1 O 
, O 
TrxR-1 O 
, O 
and O 
glutathione B-TRIVIAL 
reductase O 
( O 
GR O 
) O 
. O 
Samples O 
of O 
tissues O 
were O 
also O 
used O 
to O 
estimate O 
Cr B-FORMULA 
accumulation O 
and O 
alterations O 
in O 
zinc B-SYSTEMATIC 
, O 
copper B-SYSTEMATIC 
, O 
and O 
iron B-SYSTEMATIC 
levels O 
. O 
The O 
acute O 
Cr B-FORMULA 
(VI) I-FORMULA 
exposure O 
caused O 
an O 
increase O 
in O 
both O 
hepatic O 
and O 
renal O 
LP O 
( O 
by O 
70% O 
, O 
p O 
< O 
0.01 O 
and O 
by O 
15% O 
, O 
p O 
< O 
0.05 O 
, O 
respectively O 
) O 
, O 
increased O 
hepatic O 
GSH B-ABBREVIATION 
level O 
and O 
GPx-1 O 
activity O 
, O 
and O 
decreased O 
renal O 
GPx-1 O 
activity O 
. O 
The O 
activity O 
of O 
GR O 
was O 
not O 
changed O 
. O 
A O 
significant O 
inhibitory O 
effect O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
was O 
found O 
on O 
TrxR-1 O 
activity O 
in O 
both O 
the O 
liver O 
and O 
the O 
kidneys O 
. O 
The O 
ability O 
of O 
Cr B-FORMULA 
(VI) I-FORMULA 
to O 
cause O 
TrxR O 
inhibition O 
could O 
contribute O 
to O 
its O 
cytotoxic O 
effects O 
. O 
Further O 
investigation O 
of O 
oxidative O 
responses O 
in O 
different O 
in O 
vivo O 
models O 
may O 
enable O 
the O 
development O 
of O 
strategies O 
to O 
protect O 
against O 
Cr B-FORMULA 
(VI) I-FORMULA 
oxidative O 
damage O 
. O 

this O 
research O 
, O 
the O 
mathematical O 
models O 
, O 
indicating O 
the O 
capability O 
of O 
various O 
units O 
, O 
such O 
as O 
rapid O 
mixing O 
, O 
coagulation O 
and O 
flocculation O 
, O 
sedimentation O 
, O 
and O 
the O 
rapid O 
sand O 
filtration O 
are O 
used O 
. O 
Moreover O 
, O 
cost O 
functions O 
were O 
used O 
for O 
the O 
formulation O 
of O 
conventional O 
water O 
and O 
wastewater O 
treatment O 
plant O 
by O 
applying O 
Clark's O 
formula O 
( O 
Clark O 
, O 
1982 O 
) O 
. O 
Also O 
, O 
by O 
applying O 
dynamic O 
programming O 
algorithm O 
, O 
it O 
is O 
easy O 
to O 
design O 
a O 
conventional O 
treatment O 
system O 
with O 
minimal O 
cost O 
. O 
The O 
application O 
of O 
the O 
model O 
for O 
a O 
case O 
reduced O 
the O 
annual O 
cost O 
. O 
This O 
reduction O 
was O 
approximately O 
in O 
the O 
range O 
of O 
4.5-9.5% O 
considering O 
variable O 
limitations O 
. O 
Sensitivity O 
analysis O 
and O 
prediction O 
of O 
system's O 
feedbacks O 
were O 
performed O 
for O 
different O 
alterations O 
in O 
proportion O 
from O 
parameters O 
optimized O 
amounts O 
. O 
The O 
results O 
indicated O 
( O 
1 O 
) O 
that O 
the O 
objective O 
function O 
is O 
more O 
sensitive O 
to O 
design O 
flow O 
rate O 
( O 
Q O 
) O 
, O 
( O 
2 O 
) O 
the O 
variations O 
in O 
the O 
alum B-FAMILY 
dosage O 
( O 
A O 
) O 
, O 
and O 
( O 
3 O 
) O 
the O 
sand O 
filter O 
head O 
loss O 
( O 
H O 
) O 
. O 
Increasing O 
the O 
inflow O 
by O 
20% O 
, O 
the O 
total O 
annual O 
cost O 
would O 
increase O 
to O 
about O 
12.6% O 
, O 
while O 
20% O 
reduction O 
in O 
inflow O 
leads O 
to O 
15.2% O 
decrease O 
in O 
the O 
total O 
annual O 
cost O 
. O 
Similarly O 
, O 
20% O 
increase O 
in O 
alum B-FAMILY 
dosage O 
causes O 
7.1% O 
increase O 
in O 
the O 
total O 
annual O 
cost O 
, O 
while O 
20% O 
decrease O 
results O 
in O 
7.9% O 
decrease O 
in O 
the O 
total O 
annual O 
cost O 
. O 
Furthermore O 
, O 
the O 
pressure O 
decrease O 
causes O 
2.95 O 
and O 
3.39% O 
increase O 
and O 
decrease O 
in O 
total O 
annual O 
cost O 
of O 
treatment O 
plants O 
. O 

of O 
aluminum B-SYSTEMATIC 
chloride I-SYSTEMATIC 
on O 
some O 
trace O 
elements O 
and O 
erythrocyte O 
osmotic O 
fragility O 
in O 
rats O 
. O 

( O 
Al B-FORMULA 
) O 
is O 
a O 
nonessential O 
, O 
toxic O 
element O 
to O 
which O 
humans O 
are O 
constantly O 
exposed O 
as O 
a O 
result O 
of O 
an O 
increase O 
in O 
industrialization O 
and O 
improving O 
technology O 
practices O 
. O 
The O 
aim O 
of O 
the O 
study O 
was O 
to O 
investigate O 
the O 
effects O 
of O 
different O 
durations O 
and O 
doses O 
of O 
Al B-FORMULA 
exposure O 
on O 
serum O 
and O 
tissue O 
element O 
levels O 
and O 
erythrocyte O 
osmotic O 
fragility O 
in O 
rats O 
. O 
A O 
total O 
of O 
40 O 
male O 
Wistar O 
Albino O 
rats O 
were O 
divided O 
into O 
five O 
groups O 
: O 
control O 
, O 
group O 
I O 
( O 
3 O 
weeks O 
, O 
8 O 
mg O 
/ O 
kg O 
) O 
, O 
group O 
II O 
( O 
6 O 
weeks O 
, O 
8 O 
mg O 
/ O 
kg O 
) O 
, O 
group O 
III O 
( O 
3 O 
weeks O 
, O 
16 O 
mg O 
/ O 
kg O 
) O 
, O 
and O 
group O 
IV O 
( O 
6 O 
weeks O 
, O 
16 O 
mg O 
/ O 
kg O 
) O 
. O 
Al B-SYSTEMATIC 
chloride I-SYSTEMATIC 
( O 
AlCl3 B-FORMULA 
) O 
was O 
injected O 
intraperitoneally O 
( O 
i.p O 
. O 
) O 
five O 
times O 
a O 
week O 
. O 
At O 
the O 
end O 
of O 
the O 
experimental O 
period O 
, O 
levels O 
of O 
Al B-FORMULA 
, O 
iron B-SYSTEMATIC 
( O 
Fe B-FORMULA 
) O 
, O 
copper B-SYSTEMATIC 
( O 
Cu B-FORMULA 
) O 
, O 
and O 
zinc B-SYSTEMATIC 
( O 
Zn B-FORMULA 
) O 
in O 
serum O 
, O 
liver O 
, O 
and O 
kidney O 
tissues O 
were O 
measured O 
using O 
inductively O 
coupled O 
plasma O 
optical O 
emission O 
spectrometry O 
. O 
Osmotic O 
fragility O 
was O 
determined O 
using O 
a O 
spectrophotometer O 
. O 
The O 
results O 
of O 
the O 
experiment O 
indicate O 
that O 
Al B-FORMULA 
induced O 
a O 
statistically O 
significant O 
increase O 
in O 
Al B-FORMULA 
and O 
Fe B-FORMULA 
concentrations O 
in O 
liver O 
and O 
serum O 
as O 
well O 
as O 
in O 
Cu B-FORMULA 
in O 
the O 
kidney O 
. O 
The O 
Fe B-FORMULA 
concentration O 
in O 
serum O 
and O 
kidney O 
tissues O 
was O 
significantly O 
lower O 
in O 
all O 
the O 
groups O 
. O 
As O 
a O 
result O 
of O 
our O 
study O 
, O 
it O 
may O 
be O 
concluded O 
that O 
tissue O 
Al B-FORMULA 
accumulation O 
may O 
lead O 
to O 
an O 
increase O 
in O 
osmotic O 
fragility O 
of O 
erythrocytes O 
and O 
abnormal O 
trace O 
element O 
levels O 
. O 

- O 
responsive O 
capsules O 
sensitive O 
to O 
pH O 
and O 
temperature O 
changes O 
were O 
successfully O 
prepared O 
by O 
grafting O 
random O 
copolymer O 
brushes O 
of O 
2-(2-methoxyethoxy)ethyl B-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
MEO2MA B-ABBREVIATION 
) O 
and O 
oligo(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
methacrylate I-SYSTEMATIC 
( O 
OEGMA B-ABBREVIATION 
) O 
from O 
polydopamine B-TRIVIAL 
( O 
Pdop B-ABBREVIATION 
) O 
- O 
coated O 
SiO2 B-FORMULA 
via O 
a O 
surface O 
- O 
initiated O 
atom O 
- O 
transfer O 
radical O 
polymerization O 
( O 
SI-ATRP O 
) O 
method O 
with O 
subsequent O 
removal O 
of O 
the O 
SiO2 B-FORMULA 
core O 
. O 
The O 
uptake O 
and O 
release O 
properties O 
of O 
the O 
resulting O 
capsules O 
are O 
highly O 
affected O 
by O 
changes O 
in O 
the O 
pH O 
values O 
and O 
temperature O 
of O 
the O 
solution O 
. O 
The O 
capsules O 
can O 
take O 
up O 
cationic O 
dye O 
rhodamine B-TRIVIAL 
6G I-TRIVIAL 
( O 
Rh6G B-ABBREVIATION 
) O 
at O 
high O 
pH O 
and O 
T O 
< O 
LCST O 
but O 
not O 
at O 
low O 
pH O 
and O 
T O 
> O 
LCST O 
. O 
In O 
contrast O 
, O 
the O 
capsules O 
can O 
release O 
Rh6G B-ABBREVIATION 
at O 
pH O 
< O 
7 O 
and O 
temperature O 
below O 
the O 
LCST O 
, O 
but O 
release O 
is O 
less O 
efficient O 
under O 
the O 
opposite O 
conditions O 
. O 
This O 
dual O 
- O 
responsive O 
property O 
was O 
also O 
observed O 
for O 
the O 
anionic O 
dye O 
methyl B-TRIVIAL 
orange I-TRIVIAL 
. O 

mutualisms O 
between O 
social O 
insects O 
and O 
microorganisms O 
have O 
been O 
described O 
in O 
the O 
literature O 
. O 
The O 
present O 
article O 
describes O 
the O 
discovery O 
of O 
a O 
Pseudallescheria O 
boydii O 
strain O 
isolated O 
from O 
Nasutitermes O 
sp O 
. O 
The O 
microbial O 
symbiont O 
produces O 
two O 
antifungal O 
metabolites O 
: O 
tyroscherin B-TRIVIAL 
and O 
N-methyltyroscherin B-SYSTEMATIC 
, O 
a O 
compound O 
not O 
previously O 
described O 
in O 
the O 
literature O 
. O 
Methylation O 
of O 
tyroscherin B-TRIVIAL 
has O 
confirmed O 
the O 
structure O 
of O 
N-methyltyroscherin B-SYSTEMATIC 
. O 
Both O 
compounds O 
are O 
effective O 
antifungal O 
agents O 
with O 
favorable O 
selectivity O 
indices O 
for O 
Candida O 
albicans O 
and O 
Trichophyton O 
rubrum O 
. O 

: O 
active O 
component O 
from O 
Taxus O 
chinensis O 
for O 
anti-Alzheimer's O 
disease O 
. O 

taxane B-FAMILY 
diterpenoids I-FAMILY 
derived O 
from O 
the O 
95% O 
ethanol B-SYSTEMATIC 
extract O 
of O 
Taxus O 
chinensis O 
were O 
tested O 
for O 
the O 
inhibitory O 
activities O 
on O 
amyloid O 
- O 
beta O 
( O 
Aβ O 
) O 
peptide O 
aggregation O 
. O 
Using O 
thioflavin-T B-TRIVIAL 
fluorescence O 
assay O 
, O 
sciadopitysin B-TRIVIAL 
was O 
found O 
to O 
exhibit O 
the O 
most O 
potency O 
against O 
Aβ O 
aggregation O 
and O 
the O 
formation O 
of O 
fibrils O 
. O 
Further O 
cellular O 
assay O 
indicated O 
that O 
sciadopitysin B-TRIVIAL 
increased O 
the O 
cell O 
viability O 
of O 
SH-SY5Y O 
cell O 
and O 
demonstrated O 
neuroprotection O 
against O 
Aβ O 
protein O 
- O 
induced O 
insult O 
in O 
primary O 
cortical O 
neurons O 
. O 
According O 
to O 
the O 
authors O 
' O 
best O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
that O 
sciadopitysin B-TRIVIAL 
can O 
inhibit O 
the O 
Aβ O 
aggregation O 
and O 
reduce O 
Aβ-induced O 
toxicity O 
in O 
the O 
primary O 
cortical O 
neurons O 
. O 

Objective O 
: O 
The O 
conventional O 
liposomal O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
causes O 
many O 
unwanted O 
side O 
effects O 
like O 
blood O 
disorder O 
, O 
nephrotoxicity O 
, O 
dose O 
- O 
dependent O 
side O 
effects O 
, O 
highly O 
variable O 
oral O 
absorption O 
and O 
formulation O 
- O 
related O 
instability O 
. O 
The O 
objective O 
of O 
the O 
present O 
investigation O 
was O 
to O 
develop O 
cost O 
- O 
effective O 
nanoemulsion O 
as O 
nanocarreir O 
for O 
enhanced O 
and O 
sustained O 
delivery O 
of O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
into O 
the O 
skin O 
. O 
Methods O 
and O 
characterizations O 
: O 
Different O 
oil O 
- O 
in O 
- O 
water O 
nanoemulsions O 
were O 
developed O 
by O 
varying O 
the O 
composition O 
of O 
hydrophilic O 
( O 
Tween B-FAMILY 
® O 
80 O 
) O 
surfactants O 
and O 
co O 
- O 
surfactant O 
by O 
the O 
spontaneous O 
titration O 
method O 
. O 
The O 
developed O 
formulation O 
were O 
characterized O 
, O 
optimized O 
, O 
evaluated O 
and O 
compared O 
for O 
the O 
skin O 
permeation O 
with O 
commercial O 
formulation O 
( O 
fungisome O 
0.01% O 
w O 
/ O 
w O 
) O 
. O 
Optimized O 
formulations O 
loaded O 
with O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
were O 
screened O 
using O 
varied O 
concentrations O 
of O 
surfactants O 
and O 
co O 
- O 
surfactants O 
as O 
decided O 
by O 
the O 
ternary O 
phase O 
diagram O 
. O 
Results O 
and O 
discussion O 
: O 
The O 
maximum O 
% O 
transmittance O 
obtained O 
were O 
96.9 O 
± O 
1.0% O 
, O 
95.9 O 
± O 
3.0% O 
and O 
93.7 O 
± O 
1.2% O 
for O 
the O 
optimized O 
formulations O 
F-I O 
, O 
F-III O 
and O 
F-VI O 
, O 
respectively O 
. O 
These O 
optimized O 
nanoemulsions O 
were O 
subjected O 
to O 
thermodynamic O 
stability O 
study O 
to O 
get O 
the O 
most O 
stable O 
nanoemulsions O 
( O 
F-I O 
) O 
. O 
The O 
results O 
of O 
the O 
particle O 
size O 
and O 
zeta O 
potential O 
value O 
were O 
found O 
to O 
be O 
67.32 O 
± O 
0.8 O 
nm O 
and O 
-3.7 O 
± O 
1.2 O 
mV O 
for O 
the O 
final O 
optimized O 
nanoemulsion O 
F-I O 
supporting O 
transparency O 
and O 
stable O 
nanoemulsion O 
for O 
better O 
skin O 
permeation O 
. O 
The O 
steady O 
state O 
transdermal O 
flux O 
for O 
the O 
formulations O 
was O 
observed O 
between O 
5.89 O 
± O 
2.06 O 
and O 
18.02 O 
± O 
4.3 O 
µg O 
/ O 
cm(2) O 
/ O 
h O 
whereas O 
the O 
maximum O 
enhancement O 
ratio O 
were O 
found O 
1.85- O 
and O 
3.0-fold O 
higher O 
than O 
fungisome O 
and O 
drug O 
solution O 
, O 
respectively O 
, O 
for O 
F-I O 
. O 
The O 
results O 
of O 
the O 
skin O 
deposition O 
study O 
suggests O 
that O 
231.37 O 
± O 
3.6 O 
µg O 
/ O 
cm(2) O 
drug O 
deposited O 
from O 
optimized O 
nanoemulsion O 
F-I O 
and O 
2.11-fold O 
higher O 
enhancement O 
ratio O 
as O 
compared O 
to O 
fungisome O 
. O 
Optimized O 
surfactants O 
and O 
co O 
- O 
surfactant O 
combination O 
- O 
mediated O 
transport O 
of O 
the O 
drug O 
through O 
the O 
skin O 
was O 
also O 
tried O 
and O 
the O 
results O 
were O 
shown O 
to O 
have O 
facilitated O 
drug O 
permeation O 
and O 
skin O 
perturbation O 
( O 
SEM O 
) O 
. O 
Conclusion O 
: O 
The O 
combined O 
results O 
suggested O 
that O 
amphotericin B-TRIVIAL 
B I-TRIVIAL 
nanoemulsion O 
could O 
be O 
a O 
better O 
option O 
for O 
localized O 
topical O 
drug O 
delivery O 
and O 
have O 
greater O 
potential O 
as O 
an O 
effective O 
, O 
efficient O 
and O 
safe O 
approach O 
. O 

- O 
Catalyzed O 
Cycloisomerization O 
of O 
1,6-Diyne B-MULTIPLE 
Carbonates I-MULTIPLE 
and I-MULTIPLE 
Esters I-MULTIPLE 
to O 
2,4a-Dihydro-1H-fluorenes B-FAMILY 
. O 

synthetic O 
method O 
to O 
prepare O 
2,4a-dihydro-1H-fluorenes B-FAMILY 
efficiently O 
from O 
gold B-SYSTEMATIC 
(I) I-SYSTEMATIC 
-catalyzed O 
1,2-acyloxy B-SYSTEMATIC 
migration O 
/ O 
cyclopropenation O 
/ O 
Nazarov O 
cyclization O 
of O 
1,6-diyne B-MULTIPLE 
carbonates I-MULTIPLE 
and I-MULTIPLE 
esters I-MULTIPLE 
is O 
described O 
. O 
The O 
suggested O 
reaction O 
pathway O 
provides O 
rare O 
examples O 
of O 
[2,3]-sigmatropic O 
rearrangement O 
in O 
this O 
class O 
of O 
compounds O 
as O 
well O 
as O 
the O 
involvement O 
of O 
an O 
in O 
situ O 
formed O 
cyclopropene B-SYSTEMATIC 
intermediate O 
in O 
gold O 
catalysis O 
. O 
Experimental O 
and O 
ONIOM(QM:QM') O 
( O 
our O 
own O 
n O 
- O 
layered O 
integrated O 
molecular O 
orbital O 
and O 
molecular O 
mechanics(quantum O 
mechanics O 
: O 
quantum O 
mechanics O 
' O 
) O 
) O 
computational O 
studies O 
based O 
on O 
the O 
proposed O 
Au B-FORMULA 
carbenoid O 
species O 
provide O 
insight O 
into O 
this O 
unique O 
selectivity O 
. O 

Graphene B-TRIVIAL 
Slides O 
: O 
Measurement O 
and O 
Theory O 
of O 
Strain-Dependent O 
Frictional O 
Forces O 
between O 
Graphene B-TRIVIAL 
and O 
SiO2 B-FORMULA 
. O 

, O 
bending O 
rigidity O 
, O 
and O 
adhesion O 
are O 
interwoven O 
in O 
determining O 
how O 
graphene B-TRIVIAL 
responds O 
when O 
pulled O 
across O 
a O 
substrate O 
. O 
Using O 
Raman O 
spectroscopy O 
of O 
circular O 
, O 
graphene B-TRIVIAL 
-sealed O 
microchambers O 
under O 
variable O 
external O 
pressure O 
, O 
we O 
demonstrate O 
that O 
graphene B-TRIVIAL 
is O 
not O 
firmly O 
anchored O 
to O 
the O 
substrate O 
when O 
pulled O 
. O 
Instead O 
, O 
as O 
the O 
suspended O 
graphene B-TRIVIAL 
is O 
pushed O 
into O 
the O 
chamber O 
under O 
pressure O 
, O 
the O 
supported O 
graphene B-TRIVIAL 
outside O 
the O 
microchamber O 
is O 
stretched O 
and O 
slides O 
, O 
pulling O 
in O 
an O 
annulus O 
. O 
Analyzing O 
Raman O 
G O 
band O 
line O 
scans O 
with O 
a O 
continuum O 
model O 
extended O 
to O 
include O 
sliding O 
, O 
we O 
extract O 
the O 
pressure O 
dependent O 
sliding O 
friction O 
between O 
the O 
SiO2 B-FORMULA 
substrate O 
and O 
mono- O 
, O 
bi- O 
, O 
and O 
trilayer O 
graphene B-TRIVIAL 
. O 
The O 
sliding O 
friction O 
for O 
trilayer O 
graphene B-TRIVIAL 
is O 
directly O 
proportional O 
to O 
the O 
applied O 
load O 
, O 
but O 
the O 
friction O 
for O 
monolayer O 
and O 
bilayer O 
graphene B-TRIVIAL 
is O 
inversely O 
proportional O 
to O 
the O 
strain O 
in O 
the O 
graphene B-TRIVIAL 
, O 
which O 
is O 
in O 
violation O 
of O 
Amontons' O 
law O 
. O 
We O 
attribute O 
this O 
behavior O 
to O 
the O 
high O 
surface O 
conformation O 
enabled O 
by O 
the O 
low O 
bending O 
rigidity O 
and O 
strong O 
adhesion O 
of O 
few O 
layer O 
graphene B-TRIVIAL 
. O 

Morphology-Controlled O 
Synthesis O 
of O 
Zinc B-SYSTEMATIC 
Nanoparticles O 
and O 
Their O 
Characteristics O 
of O 
Hydrolysis O 
Reaction O 
. O 

- O 
step O 
thermochemical O 
water O 
- O 
splitting O 
cycle O 
based O 
on O 
a O 
Zn B-FORMULA 
/ O 
ZnO B-FORMULA 
redox O 
pair O 
is O 
considered O 
as O 
a O 
potential O 
route O 
for O 
carbon B-SYSTEMATIC 
-free O 
production O 
of O 
hydrogen B-SYSTEMATIC 
because O 
the O 
first O 
hydrolysis O 
step O 
of O 
the O 
cycle O 
highly O 
depends O 
on O 
the O 
method O 
of O 
preparation O 
and O 
the O 
resultant O 
particle O 
characteristics O 
, O 
such O 
as O 
size O 
, O 
morphology O 
, O 
surface O 
state O 
, O 
and O 
initial O 
oxide B-SYSTEMATIC 
content O 
. O 
Here O 
, O 
employing O 
a O 
conventional O 
evaporation O 
and O 
condensation O 
method O 
, O 
we O 
successfully O 
produce O 
three O 
types O 
of O 
Zn B-FORMULA 
nanoparticles O 
ranging O 
from O 
nanorods O 
, O 
mesoporous O 
nanorods O 
with O 
nanospheres O 
on O 
their O 
surfaces O 
, O 
and O 
fully O 
sintered O 
nanocrystals O 
. O 
The O 
achievement O 
in O 
morphology O 
control O 
is O 
realized O 
simply O 
by O 
changing O 
the O 
injection O 
position O 
of O 
the O 
quenching O 
gas O 
. O 
We O 
found O 
that O 
the O 
resultant O 
hydrolysis O 
kinetics O 
is O 
highly O 
dependent O 
on O 
the O 
morphology O 
and O 
porosity O 
of O 
the O 
Zn B-FORMULA 
nanoparticles O 
. O 
Finally O 
, O 
a O 
series O 
of O 
simple O 
mathematical O 
modeling O 
is O 
made O 
in O 
an O 
effort O 
to O 
understand O 
the O 
formation O 
mechanism O 
of O 
Zn B-FORMULA 
nanoparticles O 
. O 

of O 
multiple O 
equilibria O 
in O 
the O 
self O 
- O 
aggregation O 
of O 
di-n-decyldimethylammonium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
/ O 
octaethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
monododecyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
/ O 
cyclodextrin O 
ternary O 
systems O 
. O 

surface O 
tension O 
equations O 
of O 
binary O 
surfactant O 
mixtures O 
( O 
di-n-decyldimethylammonium B-SYSTEMATIC 
chloride I-SYSTEMATIC 
and O 
octaethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
monododecyl I-SYSTEMATIC 
ether I-SYSTEMATIC 
) O 
are O 
established O 
by O 
combining O 
the O 
Szyszkowski O 
equation O 
of O 
surfactant O 
solutions O 
, O 
the O 
ideal O 
or O 
nonideal O 
mixing O 
theory O 
and O 
the O 
phase O 
separation O 
model O 
. O 
For O 
surfactant O 
mixtures O 
, O 
the O 
surface O 
tension O 
at O 
the O 
air O 
- O 
water O 
interface O 
is O 
calculated O 
using O 
nonideal O 
theory O 
due O 
to O 
synergism O 
between O 
the O 
two O 
adsorbed O 
surfactant O 
types O 
. O 
The O 
incorporation O 
of O 
cyclodextrin O 
complexation O 
model O 
to O 
the O 
surface O 
tension O 
equations O 
gives O 
a O 
robust O 
model O 
for O 
the O 
description O 
of O 
the O 
surface O 
tension O 
isotherms O 
of O 
binary O 
, O 
ternary O 
and O 
more O 
complex O 
systems O 
involving O 
numerous O 
inclusion O 
complexes O 
. O 
The O 
surface O 
tension O 
data O 
obtained O 
experimentally O 
shows O 
excellent O 
agreement O 
with O 
the O 
theoretical O 
model O 
below O 
and O 
above O 
the O 
formation O 
of O 
micelles O 
. O 
The O 
strong O 
synergistic O 
effect O 
observed O 
between O 
the O 
two O 
surfactants O 
is O 
disrupted O 
by O 
the O 
presence O 
of O 
CDs O 
, O 
leading O 
to O 
ideal O 
behavior O 
of O 
ternary O 
systems O 
. O 
Indeed O 
, O 
depending O 
on O 
the O 
nature O 
of O 
the O 
cyclodextrin O 
( O 
i.e O 
. O 
 O 
, O 
 O 
or O 
 O 
) O 
which O 
allows O 
a O 
tuning O 
of O 
the O 
cavity O 
size O 
, O 
the O 
binding O 
constants O 
with O 
the O 
surfactants O 
are O 
modified O 
as O 
well O 
as O 
the O 
surface O 
properties O 
due O 
to O 
strong O 
modification O 
of O 
equilibria O 
involved O 
in O 
the O 
ternary O 
mixture O 
. O 

hybrid O 
nanogels O 
were O 
prepared O 
first O 
by O 
co O 
- O 
assembly O 
of O 
the O 
citric B-TRIVIAL 
acid I-TRIVIAL 
-coated O 
superparamagnetic O 
iron B-SYSTEMATIC 
oxide I-SYSTEMATIC 
nanoparticles O 
( O 
SPIONs O 
) O 
( O 
44 O 
wt% O 
) O 
with O 
the O 
graft O 
copolymer O 
( O 
56 O 
wt% O 
) O 
comprising O 
acrylic B-TRIVIAL 
acid I-TRIVIAL 
and O 
2-methacryloylethyl B-SYSTEMATIC 
acrylate I-SYSTEMATIC 
units O 
as O 
the O 
backbone O 
and O 
poly(ethylene B-SYSTEMATIC 
glycol I-SYSTEMATIC 
) I-SYSTEMATIC 
and O 
poly(N-isopropylacrylamide) B-SYSTEMATIC 
as O 
the O 
grafts O 
in O 
aqueous O 
phase O 
of O 
pH O 
3 O 
into O 
the O 
hybrid O 
vesicle O 
structure O 
, O 
followed O 
by O 
in O 
situ O 
covalent O 
stabilization O 
via O 
the O 
photo O 
- O 
initiated O 
polymerization O 
of O 
MEA B-ABBREVIATION 
residues O 
within O 
vesicles O 
. O 
The O 
resultant O 
hollow O 
nanogels O 
, O 
though O 
slightly O 
swollen O 
, O 
satisfactorily O 
retain O 
the O 
structural O 
integrity O 
while O 
the O 
medium O 
pH O 
being O 
adjusted O 
to O 
7.4 O 
. O 
Confining O 
SPION O 
clusters O 
to O 
such O 
a O 
high O 
level O 
( O 
44 O 
wt% O 
) O 
within O 
the O 
pH-responsive O 
thin O 
gel O 
layer O 
remarkably O 
enhances O 
the O 
transverse O 
relaxivity O 
( O 
r2 O 
) O 
and O 
renders O 
the O 
MR O 
imaging O 
highly O 
pH-tunable O 
. O 
For O 
example O 
, O 
with O 
the O 
pH O 
being O 
adjusted O 
from O 
4 O 
to O 
7.4 O 
, O 
the O 
r2 O 
value O 
can O 
be O 
dramatically O 
increased O 
from O 
138.5 O 
to O 
265.5 O 
mM-1 O 
s-1 O 
. O 
The O 
DOX-loaded O 
hybrid O 
nanogels O 
also O 
exhibit O 
accelerated O 
drug O 
release O 
in O 
response O 
to O 
both O 
pH O 
reduction O 
and O 
temperature O 
increase O 
due O 
to O 
the O 
substantial O 
disruption O 
of O 
the O 
interactions O 
between O 
drug O 
molecules O 
and O 
copolymer O 
components O 
. O 
With O 
magnetic O 
transport O 
guidance O 
toward O 
the O 
target O 
and O 
subsequent O 
exposure O 
to O 
alternating O 
magnetic O 
field O 
, O 
this O 
DOX-loaded O 
nanogel O 
system O 
possessing O 
combined O 
capabilities O 
of O 
hyperthermia O 
and O 
stimuli O 
- O 
triggered O 
drug O 
release O 
showed O 
superior O 
in O 
vitro O 
cytotoxicity O 
against O 
HeLa O 
cells O 
as O 
compared O 
to O 
the O 
case O 
with O 
only O 
free O 
drug O 
or O 
hyperthermia O 
alone O 
. O 
This O 
work O 
demonstrates O 
that O 
the O 
hollow O 
inorganic O 
/ O 
organic O 
hybrid O 
nanogels O 
show O 
great O 
potential O 
to O 
serve O 
as O 
a O 
multimodal O 
theranostic O 
vehicle O 
functionalized O 
with O 
such O 
desirable O 
features O 
as O 
guidable O 
delivery O 
of O 
stimuli O 
- O 
mediated O 
diagnostic O 
imaging O 
and O 
hyperthermia O 
/ O 
chemotherapies O 
. O 

Stimuli-Responsive O 
Poly(N-isopropylacrylamide)-b-poly(l-histidine) B-SYSTEMATIC 
Chimeric O 
Materials O 
for O 
the O 
Controlled O 
Delivery O 
of O 
Doxorubicin B-TRIVIAL 
into O 
Liver O 
Carcinoma O 
. O 

series O 
of O 
dual O 
stimuli O 
responsive O 
synthetic O 
polymer O 
bioconjugate O 
chimeric O 
materials O 
, O 
poly(N-isopropylacrylamide)55-block-poly(l-histidine)n B-FAMILY 
[ O 
p(NIPAM)55-b-p(His)n B-FAMILY 
] O 
( O 
n O 
= O 
50 O 
, O 
75 O 
, O 
100 O 
, O 
125 O 
) O 
, O 
have O 
been O 
synthesized O 
by O 
employing O 
reversible O 
addition O 
- O 
fragmentation O 
chain O 
transfer O 
polymerization O 
of O 
NIPAM B-ABBREVIATION 
, O 
followed O 
by O 
ring O 
- O 
opening O 
polymerization O 
of O 
α-amino B-FAMILY 
acid I-FAMILY 
N-carboxyanhydrides I-FAMILY 
. O 
The O 
dual O 
stimuli O 
responsive O 
properties O 
of O 
the O 
resulting O 
biocompatiable O 
and O 
membrenolytic O 
p(NIPAM)55-b-p(His)n B-FAMILY 
polymers O 
are O 
investigated O 
for O 
their O 
use O 
as O 
a O 
stimuli O 
responsive O 
drug O 
carrier O 
for O 
tumor O 
targeting O 
. O 
Highly O 
uniform O 
self O 
- O 
assembled O 
micelles O 
( O 
∼55 O 
nm O 
) O 
fabricated O 
by O 
p(NIPAM)55-b-p(His)n B-FAMILY 
polymers O 
display O 
sharp O 
thermal O 
and O 
pH O 
responses O 
in O 
aqueous O 
media O 
. O 
An O 
anticancer O 
drug O 
, O 
doxorubicin B-TRIVIAL 
( O 
Dox B-ABBREVIATION 
) O 
, O 
is O 
effectively O 
encapsulated O 
in O 
the O 
micelles O 
and O 
the O 
controlled O 
Dox B-ABBREVIATION 
release O 
is O 
investigated O 
in O 
different O 
temperature O 
and O 
pH O 
conditions O 
. O 
Antitumor O 
effect O 
of O 
the O 
released O 
Dox B-ABBREVIATION 
is O 
also O 
assessed O 
using O 
the O 
HepG2 O 
human O 
hepatocellular O 
carcinoma O 
cell O 
lines O 
. O 
Dox B-ABBREVIATION 
molecules O 
released O 
from O 
the O 
[ O 
p(NIPAM)55-b-p(His)n B-FAMILY 
] O 
micelles O 
remain O 
biologically O 
active O 
and O 
have O 
stimuli O 
responsive O 
capability O 
to O 
kill O 
cancer O 
cells O 
. O 
The O 
self O 
- O 
assembling O 
ability O 
of O 
these O 
hybrid O 
materials O 
into O 
uniform O 
micelles O 
and O 
their O 
efficiency O 
to O 
encapsulate O 
Dox B-ABBREVIATION 
makes O 
them O 
a O 
promising O 
drug O 
carrier O 
to O 
cancer O 
cells O 
. O 
The O 
new O 
chimeric O 
materials O 
thus O 
display O 
tunable O 
properties O 
that O 
can O 
make O 
them O 
useful O 
for O 
a O 
molecular O 
switching O 
device O 
and O 
controlled O 
drug O 
delivery O 
applications O 
needing O 
responses O 
to O 
temperature O 
and O 
pH O 
for O 
the O 
improvement O 
of O 
cancer O 
chemotherapy O 
. O 

Characterization O 
and O 
Molecular O 
Order O 
of O 
Rodlike O 
Mesogens O 
with O 
Three- O 
and O 
Four-Ring O 
Core O 
by O 
XRD O 
and O 
(13)C B-FORMULA 
NMR O 
Spectroscopy O 
. O 

characterizations O 
using O 
XRD O 
and O 
(13)C B-FORMULA 
NMR O 
spectroscopy O 
of O 
two O 
rodlike O 
mesogens O 
consisting O 
of O 
(i) O 
three O 
phenyl B-SYSTEMATIC 
ring O 
core O 
with O 
a O 
polar O 
cyano B-FAMILY 
terminal O 
and O 
(ii) O 
four O 
phenyl B-SYSTEMATIC 
ring O 
core O 
with O 
flexible O 
dodecyl B-SYSTEMATIC 
terminal O 
chain O 
are O 
presented O 
. O 
The O 
three O 
- O 
ring O 
- O 
core O 
mesogen O 
with O 
cyano B-FAMILY 
terminal O 
exhibits O 
enantiotropic O 
smectic O 
A O 
phase O 
while O 
the O 
four O 
- O 
ring O 
mesogen O 
reveals O 
polymesomorphism O 
and O 
shows O 
enantiotropic O 
nematic O 
, O 
smectic O 
C O 
, O 
and O 
tilted O 
hexatic O 
phases O 
. O 
The O 
molecular O 
organization O 
in O 
the O 
three O 
- O 
ring O 
mesogen O 
is O 
found O 
to O 
be O 
partial O 
bilayer O 
smectic O 
Ad O 
type O 
, O 
and O 
the O 
interdigitation O 
of O 
the O 
molecules O 
in O 
the O 
neighboring O 
layers O 
is O 
attributed O 
to O 
the O 
presence O 
of O 
the O 
polar O 
terminal O 
group O 
. O 
For O 
the O 
four O 
- O 
ring O 
mesogen O 
, O 
the O 
XRD O 
results O 
confirm O 
the O 
existence O 
of O 
the O 
smectic O 
C O 
and O 
the O 
tilted O 
hexatic O 
mesophases O 
. O 
A O 
thermal O 
variation O 
of O 
the O 
layer O 
spacing O 
across O 
the O 
smectic O 
C O 
phase O 
followed O 
by O 
a O 
discrete O 
jump O 
at O 
the O 
transition O 
to O 
the O 
tilted O 
hexatic O 
phase O 
is O 
also O 
observed O 
. O 
The O 
tilt O 
angles O 
have O 
been O 
estimated O 
to O 
be O 
about O 
45° O 
in O 
the O 
smectic O 
C O 
phase O 
and O 
about O 
40° O 
in O 
tilted O 
hexatic O 
phase O 
. O 
(13)C B-FORMULA 
NMR O 
results O 
indicate O 
that O 
in O 
the O 
mesophase O 
the O 
molecules O 
are O 
aligned O 
parallel O 
to O 
the O 
magnetic O 
field O 
. O 
From O 
the O 
(13)C B-FORMULA 
- O 
(1)H B-FORMULA 
dipolar O 
couplings O 
determined O 
from O 
the O 
2D O 
experiments O 
, O 
the O 
overall O 
order O 
parameter O 
for O 
the O 
three O 
- O 
ring O 
mesogen O 
in O 
its O 
smectic O 
A O 
phase O 
has O 
been O 
estimated O 
to O 
be O 
0.72 O 
while O 
values O 
ranging O 
from O 
0.88 O 
to O 
0.44 O 
have O 
been O 
obtained O 
for O 
the O 
four O 
- O 
ring O 
mesogen O 
as O 
it O 
passes O 
from O 
the O 
tilted O 
hexatic O 
to O 
the O 
nematic O 
phase O 
. O 
The O 
orientations O 
of O 
the O 
different O 
rings O 
of O 
the O 
core O 
unit O 
with O 
respect O 
to O 
each O 
other O 
and O 
also O 
with O 
respect O 
to O 
the O 
long O 
axis O 
of O 
the O 
molecule O 
have O 
also O 
been O 
obtained O 
. O 

previous O 
studies O 
showed O 
that O 
after O 
oral O 
administration O 
of O 
an O 
Huang-Lian-Jie-Du-Tang O 
( O 
HLJDT O 
) O 
decoction O 
, O 
there O 
is O 
a O 
higher O 
concentration O 
of O 
the O 
pure O 
components O 
, O 
berberine B-TRIVIAL 
, O 
baicalin B-TRIVIAL 
and O 
gardenoside B-TRIVIAL 
in O 
the O 
plasma O 
of O 
Middle O 
cerebral O 
artery O 
occlusion O 
( O 
MCAO O 
) O 
rats O 
than O 
in O 
sham O 
- O 
operated O 
rats O 
, O 
The O 
aim O 
of O 
the O 
present O 
study O 
was O 
to O 
determine O 
whether O 
these O 
components O 
could O 
be O 
reliably O 
measured O 
in O 
MCAO O 
rat O 
tissues O 
. O 
First O 
, O 
the O 
plasma O 
concentration O 
- O 
time O 
profiles O 
of O 
berberine B-TRIVIAL 
, O 
palmatine B-TRIVIAL 
, O 
baicalin B-TRIVIAL 
, O 
baicalein B-TRIVIAL 
and O 
gardenoside B-TRIVIAL 
were O 
characterised O 
in O 
MCAO O 
rats O 
after O 
oral O 
administration O 
of O 
the O 
aqueous O 
extract O 
of O 
HLJDT O 
. O 
Subsequently O 
, O 
liver O 
, O 
lung O 
and O 
kidney O 
tissues O 
were O 
obtained O 
from O 
sudden O 
death O 
MCAO O 
rats O 
in O 
the O 
absorption O 
phase O 
( O 
0.25h O 
) O 
, O 
the O 
distribution O 
phase O 
( O 
1.0h O 
) O 
and O 
the O 
elimination O 
phase O 
( O 
8.0h O 
) O 
after O 
administration O 
of O 
the O 
HLJDT O 
aqueous O 
extract O 
. O 
An O 
HPLC O 
method O 
was O 
developed O 
and O 
validated O 
for O 
the O 
determination O 
of O 
the O 
distribution O 
characteristics O 
of O 
berberine B-TRIVIAL 
, O 
palmatine B-TRIVIAL 
, O 
baicalin B-TRIVIAL 
, O 
baicalein B-TRIVIAL 
and O 
gardenoside B-TRIVIAL 
simultaneously O 
from O 
the O 
above O 
- O 
mentioned O 
rat O 
tissues O 
. O 
The O 
results O 
indicated O 
that O 
berberine B-TRIVIAL 
, O 
palmatine B-TRIVIAL 
, O 
baicalin B-TRIVIAL 
and O 
baicalein B-TRIVIAL 
distributed O 
rapidly O 
and O 
accumulated O 
at O 
high O 
levels O 
in O 
the O 
lung O 
, O 
while O 
gardenoside B-TRIVIAL 
distributed O 
widely O 
in O 
the O 
lung O 
and O 
the O 
kidney O 
. O 
To O 
the O 
best O 
of O 
our O 
knowledge O 
, O 
this O 
is O 
the O 
first O 
report O 
to O 
describe O 
the O 
distribution O 
of O 
the O 
active O 
ingredients O 
derived O 
from O 
HLJDT O 
in O 
MCAO O 
rat O 
tissues O 
. O 
The O 
tissue O 
distribution O 
results O 
provide O 
a O 
biopharmaceutical O 
basis O 
for O 
the O 
design O 
of O 
the O 
clinic O 
application O 
of O 
HLJDT O 
in O 
cerebrovascular O 
disease O 
. O 

, O 
obesity O 
is O 
a O 
complex O 
multifactorial O 
chronic O 
disease O 
increasing O 
the O 
risk O 
for O 
type O 
2 O 
diabetes O 
, O 
coronary O 
heart O 
disease O 
and O 
hypertension O 
, O 
and O 
has O 
become O 
a O 
major O 
worldwide O 
health O 
problem O 
. O 
In O 
the O 
course O 
of O 
screening O 
natural O 
products O 
employing O 
3T3-L1 O 
cells O 
as O 
an O 
in O 
vitro O 
system O 
, O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
Idesia O 
polycarpa O 
Maxim O 
. O 
Fruits O 
( O 
Flacourtiaceae O 
) O 
significantly O 
inhibited O 
adipocyte O 
differentiation O 
by O 
measuring O 
lipid O 
contents O 
using O 
oil O 
red O 
O O 
staining O 
. O 
One O 
new O 
compound O 
, O 
6-(oxymethyl)-2-hydroxyphenyl-O-β-d-glucopyranosyl-(1→6)-β-d-glucopyranoside B-SYSTEMATIC 
( O 
8 O 
) O 
, O 
was O 
isolated O 
along O 
with O 
nine O 
known O 
compounds O 
( O 
1-7 O 
and O 
9-10 O 
) O 
from O 
CHCl3 B-FORMULA 
and O 
n-BuOH B-FORMULA 
fractions O 
of O 
the O 
methanol B-SYSTEMATIC 
extract O 
of O 
I O 
. O 
polycarpa O 
fruits O 
. O 
Among O 
them O 
, O 
idescarpin B-TRIVIAL 
( O 
1 O 
) O 
with O 
1-hydroxy-6-oxo-2-cyclohexenecarboxylate B-SYSTEMATIC 
moiety O 
showed O 
the O 
most O 
potent O 
inhibitory O 
activity O 
on O 
adipocyte O 
differentiation O 
with O 
IC50 O 
values O 
of O 
23.2μM O 
. O 
Idescarpin B-TRIVIAL 
( O 
1 O 
) O 
dramatically O 
suppressed O 
the O 
induction O 
of O 
C O 
/ O 
EBPα O 
expression O 
, O 
whereas O 
it O 
significantly O 
increased O 
the O 
induction O 
of O 
PPARγ O 
expression O 
, O 
supported O 
by O 
quantitative O 
real O 
time O 
PCR O 
and O 
Western O 
blot O 
analysis O 
. O 
The O 
down O 
- O 
regulation O 
in O 
mRNA O 
levels O 
of O 
SREBP1c O 
, O 
SCD-1 O 
, O 
and O 
FAS O 
by O 
idescarpin B-TRIVIAL 
( O 
1 O 
) O 
during O 
adipocyte O 
differentiation O 
revealed O 
that O 
the O 
inhibition O 
of O 
adipocyte O 
differentiation O 
was O 
mediated O 
by O 
the O 
regulation O 
of O 
lipogenesis O 
. O 
Taken O 
together O 
, O 
we O 
suggest O 
that O 
idescarpin B-TRIVIAL 
( O 
1 O 
) O 
shows O 
a O 
great O 
potential O 
against O 
obesity O 
and O 
diabetes O 
though O 
the O 
anti-adipogenic O 
activity O 
and O 
the O 
up O 
- O 
regulation O 
of O 
PPARγ O 
. O 

of O 
substituted O 
2-thio-6-oxo-1,6-dihydropyrimidines B-FAMILY 
as O 
inhibitors O 
of O 
human O 
lactate B-FAMILY 
dehydrogenase O 
. O 

novel O 
2-thio-6-oxo-1,6-dihydropyrimidine B-SYSTEMATIC 
-containing O 
inhibitor O 
of O 
human O 
lactate B-FAMILY 
dehydrogenase O 
( O 
LDH O 
) O 
was O 
identified O 
by O 
high O 
- O 
throughput O 
screening O 
( O 
IC50=8.1μM O 
) O 
. O 
Biochemical O 
, O 
surface O 
plasmon O 
resonance O 
, O 
and O 
saturation O 
transfer O 
difference O 
NMR O 
experiments O 
indicated O 
that O 
the O 
compound O 
specifically O 
associated O 
with O 
human O 
LDHA O 
in O 
a O 
manner O 
that O 
required O 
simultaneous O 
binding O 
of O 
the O 
NADH B-ABBREVIATION 
co O 
- O 
factor O 
. O 
Structural O 
variation O 
of O 
the O 
screening O 
hit O 
resulted O 
in O 
significant O 
improvements O 
in O 
LDHA O 
biochemical O 
inhibition O 
activity O 
( O 
best O 
IC50=0.48μM O 
) O 
. O 
A O 
crystal O 
structure O 
of O 
an O 
optimized O 
compound O 
bound O 
to O 
human O 
LDHA O 
was O 
obtained O 
and O 
explained O 
many O 
of O 
the O 
observed O 
structure O 
- O 
activity O 
relationships O 
. O 

effect O 
of O 
a O 
salt O 
- O 
based O 
diet O 
on O 
the O 
coronary O 
responsiveness O 
in O 
aged O 
hypertensive O 
rats O 
( O 
SHR O 
) O 
still O 
unclear O 
. O 
We O 
investigated O 
the O 
effects O 
of O 
high O 
salt O 
intake O 
on O 
the O 
relaxation O 
properties O 
of O 
coronary O 
arteries O 
of O 
aged O 
SHRs O 
. O 
Male O 
SHR O 
( O 
32week O 
- O 
old O 
) O 
received O 
drink O 
water O 
( O 
SHR O 
) O 
or O 
1% O 
NaCl B-FORMULA 
solution O 
( O 
SHR-Salt O 
) O 
for O 
8weeks O 
. O 
Isolated O 
coronary O 
segments O 
were O 
subjected O 
to O 
concentration O 
- O 
response O 
curves O 
to O 
acetylcholine B-SYSTEMATIC 
( O 
ACh B-ABBREVIATION 
) O 
in O 
the O 
presence O 
or O 
absence O 
of O 
L-NAME B-ABBREVIATION 
( O 
100μmol O 
) O 
, O 
enalaprilate B-TRIVIAL 
( O 
10μM O 
) O 
, O 
losartan B-TRIVIAL 
( O 
10μM O 
) O 
, O 
and O 
spironolactone B-TRIVIAL 
( O 
100μM O 
) O 
. O 
Salt O 
intake O 
did O 
not O 
increase O 
blood O 
pressure O 
in O 
old O 
SHRs O 
, O 
but O 
caused O 
ventricular O 
hypertrophy O 
. O 
The O 
endothelium O 
- O 
dependent O 
relaxation O 
in O 
SHRs O 
was O 
lower O 
than O 
in O 
Wistar O 
rats O 
. O 
However O 
, O 
salt O 
intake O 
did O 
not O 
add O 
further O 
impairment O 
. O 
Both O 
enalaprilate B-TRIVIAL 
and O 
losartan B-TRIVIAL 
reduced O 
the O 
vasodilator O 
response O 
in O 
coronary O 
arteries O 
from O 
Wistar O 
, O 
but O 
did O 
not O 
affect O 
SHR-salt O 
rats O 
. O 
Conversely O 
, O 
losartan B-TRIVIAL 
attenuated O 
the O 
impaired O 
ACh B-ABBREVIATION 
relaxation O 
observed O 
in O 
SHR O 
. O 
Spironolactone B-TRIVIAL 
reduced O 
the O 
relaxation O 
induced O 
by O 
ACh O 
in O 
coronary O 
arteries O 
from O 
Wistar O 
rats O 
but O 
not O 
in O 
SHR O 
. O 
The O 
renin-angiotensin- O 
aldosterone B-TRIVIAL 
system O 
participates O 
in O 
the O 
impaired O 
coronary O 
relaxation O 
in O 
aged O 
SHR O 
, O 
but O 
does O 
not O 
participate O 
in O 
deleterious O 
effects O 
under O 
increased O 
salt O 
intake O 
, O 
indicating O 
that O 
age O 
could O 
differentiate O 
the O 
effects O 
of O 
high O 
sodium B-SYSTEMATIC 
intake O 
in O 
coronary O 
arteries O 
of O 
SHR O 
. O 

BB I-TRIVIAL 
, O 
a O 
phloroglucinol B-TRIVIAL 
derivative O 
, O 
induces O 
cell O 
cycle O 
arrest O 
and O 
apoptosis O 
in O 
human O 
ovarian O 
HO-8910 O 
cells O 
. O 

BB I-TRIVIAL 
, O 
an O 
effective O 
phloroglucinol B-TRIVIAL 
derivative O 
from O 
Dryopteris O 
fragrans O 
( O 
L O 
. O 
) O 
Schott O 
, O 
has O 
been O 
previously O 
reported O 
to O 
exert O 
high O 
biological O 
activities O 
. O 
In O 
this O 
study O 
, O 
we O 
analyzed O 
the O 
underlying O 
mechanisms O 
of O 
aspidin B-TRIVIAL 
BB I-TRIVIAL 
on O 
human O 
ovarian O 
cancer O 
cell O 
line O 
, O 
HO-8910 O 
. O 
Aspidin B-TRIVIAL 
BB I-TRIVIAL 
significantly O 
inhibited O 
HO-8910 O 
cell O 
proliferation O 
in O 
a O 
dose- O 
and O 
time O 
- O 
dependent O 
manner O 
. O 
The O 
IC50 O 
values O 
were O 
15.02 O 
, O 
25.79 O 
and O 
68.81μM O 
after O 
72 O 
, O 
48 O 
and O 
24h O 
treatment O 
, O 
respectively O 
. O 
Meanwhile O 
, O 
aspidin B-TRIVIAL 
BB I-TRIVIAL 
markedly O 
induced O 
apoptosis O 
evidenced O 
by O 
characteristic O 
apoptotic O 
morphological O 
changes O 
, O 
nuclear O 
DNA O 
fragmentation O 
, O 
annexin O 
V-FITC/ O 
propidium B-TRIVIAL 
iodide I-TRIVIAL 
( O 
PI O 
) O 
double O 
staining O 
and O 
S O 
peak O 
. O 
Western O 
blot O 
analysis O 
showed O 
that O 
aspidin B-TRIVIAL 
BB I-TRIVIAL 
suppressed O 
Bcl-2 O 
expression O 
and O 
enhanced O 
Bax O 
expression O 
to O 
desintegrate O 
the O 
outer O 
mitochondrial O 
membrane O 
, O 
then O 
caused O 
cytochrome O 
c O 
release O 
which O 
led O 
to O 
the O 
activation O 
of O 
effector O 
caspase-3 O 
, O 
and O 
further O 
cleaved O 
the O 
poly B-SYSTEMATIC 
ADP-ribose I-SYSTEMATIC 
polymerase O 
( O 
PARP O 
) O 
in O 
the O 
nucleus O 
, O 
finally O 
induced O 
cell O 
apoptosis O 
. O 
Furthermore O 
, O 
aspidin B-TRIVIAL 
BB I-TRIVIAL 
provoked O 
S O 
phase O 
arrest O 
in O 
HO-8910 O 
cells O 
with O 
up O 
- O 
regulation O 
of O 
pRb O 
, O 
E2F1 O 
, O 
CDK2 O 
, O 
cyclin O 
E O 
and O 
cyclin O 
A O 
proteins O 
. O 
Taken O 
together O 
, O 
these O 
findings O 
support O 
the O 
conclusion O 
that O 
aspidin B-TRIVIAL 
BB I-TRIVIAL 
exhibits O 
cytotoxicity O 
towards O 
human O 
ovarian O 
cancer O 
HO-8910 O 
cells O 
through O 
induction O 
of O 
apoptosis O 
via O 
mitochondrial O 
pathway O 
and O 
arresting O 
cell O 
cycle O 
progression O 
in O 
S O 
phase O 
. O 

- O 
Chemistry O 
and O 
biological O 
activity O 
. O 

cyclopenta B-FAMILY 
- I-FAMILY 
fused I-FAMILY 
polycyclic I-FAMILY 
aromatic I-FAMILY 
hydrocarbons I-FAMILY 
( O 
CP-PAHs B-ABBREVIATION 
) O 
having O 
been O 
detected O 
in O 
the O 
environment O 
, O 
the O 
ability O 
of O 
these O 
compounds O 
to O 
induce O 
cellular O 
and O 
tissue O 
responses O 
remains O 
poorly O 
characterized O 
. O 
In O 
this O 
review O 
, O 
we O 
look O 
at O 
the O 
chemistry O 
and O 
biological O 
activity O 
of O 
the O 
cyclopenta[c]phenanthrenes B-FAMILY 
( O 
CP[c]Ph B-ABBREVIATION 
) O 
as O 
potential O 
chemicals O 
of O 
concern O 
in O 
the O 
process O 
of O 
risk O 
assessment O 
. O 
The O 
first O 
part O 
of O 
the O 
review O 
deals O 
with O 
the O 
environmental O 
occurrence O 
and O 
chemistry O 
of O 
CP-PAHs B-ABBREVIATION 
, O 
focusing O 
on O 
available O 
methods O 
of O 
CP[c]Ph B-ABBREVIATION 
chemical O 
synthesis O 
. O 
The O 
most O 
interesting O 
structural O 
feature O 
of O 
the O 
CP[c]Ph B-ABBREVIATION 
is O 
the O 
presence O 
of O 
a O 
pseudo O 
fjord O 
- O 
region O 
constructed O 
by O 
the O 
cyclopentane B-SYSTEMATIC 
ring O 
. O 
This O 
compound O 
can O 
be O 
treated O 
either O 
as O 
a O 
structurally O 
similar O 
one O 
to O 
B[c]Ph B-ABBREVIATION 
, O 
or O 
as O 
a O 
phenanthrene B-SYSTEMATIC 
skeleton O 
with O 
an O 
electrodonating O 
alkyl B-FAMILY 
substituent O 
in O 
the O 
bay O 
- O 
region O 
of O 
the O 
molecule O 
. O 
The O 
second O 
thread O 
, O 
providing O 
available O 
data O 
on O 
the O 
adverse O 
effects O 
of O 
CP[c]Ph B-ABBREVIATION 
compounds O 
on O 
cells O 
and O 
tissues O 
of O 
living O 
organisms O 
, O 
mainly O 
fish O 
, O 
improves O 
our O 
understanding O 
of O 
these O 
possible O 
environmental O 
hazards O 
. O 
The O 
data O 
show O 
that O 
CP[c]Ph B-ABBREVIATION 
is O 
less O 
potent O 
at O 
inducing O 
CYP1A O 
gene O 
expression O 
in O 
rainbow O 
trout O 
than O 
benzo[a]pyrene B-SYSTEMATIC 
( O 
B[a]P B-ABBREVIATION 
) O 
, O 
a O 
well O 
- O 
known O 
Ah-receptor O 
agonist O 
. O 
Interestingly O 
, O 
the O 
CP[c]Ph B-ABBREVIATION 
dependent O 
up O 
- O 
regulation O 
of O 
CYP1A O 
mRNA O 
is O 
positively O 
correlated O 
with O 
the O 
incidences O 
of O 
clastogenic O 
changes O 
in O 
rainbow O 
trout O 
erythrocytes O 
. O 
CP[c]Ph B-ABBREVIATION 
has O 
, O 
comparably O 
to O 
B[a]P B-ABBREVIATION 
, O 
a O 
potential O 
to O 
repress O 
expression O 
of O 
tumor O 
suppressor O 
p53 O 
, O 
in O 
the O 
head O 
kidney O 
of O 
rainbow O 
trout O 
. O 
Furthermore O 
, O 
estrogen B-FAMILY 
responsive O 
genes O 
in O 
fish O 
liver O 
, O 
ERα O 
and O 
VTG O 
, O 
are O 
not O 
induced O 
by O 
CP[c]Ph B-ABBREVIATION 
, O 
suggesting O 
that O 
the O 
compound O 
has O 
no O 
endocrine O 
disrupting O 
potential O 
. O 
However O 
, O 
some O 
CP[c]Phs B-ABBREVIATION 
show O 
mutagenic O 
activity O 
when O 
investigated O 
in O 
the O 
Ames O 
test O 
, O 
and O 
exhibit O 
genotoxic O 
properties O 
in O 
in O 
vitro O 
micronucleus O 
assay O 
. O 
The O 
above O 
characteristics O 
suggest O 
that O 
CP-PAHs B-ABBREVIATION 
are O 
chemicals O 
of O 
concern O 
for O 
which O 
potential O 
pathways O 
of O 
exposure O 
should O 
be O 
further O 
identified O 
. O 

hormone O 
synthesis O 
in O 
mitochondria O 
. O 

are O 
essential O 
sites O 
for O 
steroid B-FAMILY 
hormone O 
biosynthesis O 
. O 
Mitochondria O 
in O 
the O 
steroidogenic O 
cells O 
of O 
the O 
adrenal O 
, O 
gonad O 
, O 
placenta O 
and O 
brain O 
contain O 
the O 
cholesterol B-TRIVIAL 
side-chain O 
cleavage O 
enzyme O 
, O 
P450scc O 
, O 
and O 
its O 
two O 
electron O 
- O 
transfer O 
partners O 
, O 
ferredoxin O 
reductase O 
and O 
ferredoxin O 
. O 
This O 
enzyme O 
system O 
converts O 
cholesterol B-TRIVIAL 
to O 
pregnenolone B-TRIVIAL 
and O 
determines O 
net O 
steroidogenic O 
capacity O 
, O 
so O 
that O 
it O 
serves O 
as O 
the O 
chronic O 
regulator O 
of O 
steroidogenesis O 
. O 
Several O 
other O 
steroidogenic O 
enzymes O 
, O 
including O 
3β-hydroxysteroid B-FAMILY 
dehydrogenase O 
, O 
11β-hydroxylase O 
and O 
aldosterone B-TRIVIAL 
synthase O 
also O 
reside O 
in O 
mitochondria O 
. O 
Similarly O 
, O 
the O 
mitochondria O 
of O 
renal O 
tubular O 
cells O 
contain O 
two O 
key O 
enzymes O 
participating O 
in O 
the O 
activation O 
and O 
degradation O 
of O 
vitamin B-FAMILY 
D I-FAMILY 
. O 
The O 
access O 
of O 
cholesterol B-TRIVIAL 
to O 
the O 
mitochondria O 
is O 
regulated O 
by O 
the O 
steroidogenic O 
acute O 
regulatory O 
protein O 
, O 
StAR O 
, O 
serving O 
as O 
the O 
acute O 
regulator O 
of O 
steroidogenesis O 
. O 
StAR O 
action O 
requires O 
a O 
complex O 
multi O 
- O 
component O 
molecular O 
machine O 
on O 
the O 
outer O 
mitochondrial O 
membrane O 
( O 
OMM O 
) O 
. O 
Components O 
of O 
this O 
machine O 
include O 
the O 
18kDa O 
translocator O 
protein O 
( O 
TSPO O 
) O 
, O 
the O 
voltage O 
- O 
dependent O 
anion O 
chanel O 
( O 
VDAC-1 O 
) O 
, O 
TSPO-associated O 
protein O 
7 O 
( O 
PAP7 O 
, O 
ACBD3 O 
) O 
, O 
and O 
protein O 
kinase O 
A O 
regulatory O 
subunit O 
1α O 
( O 
PKAR1A O 
) O 
. O 
The O 
precise O 
fashion O 
in O 
which O 
these O 
proteins O 
interact O 
and O 
move O 
cholesterol B-TRIVIAL 
from O 
the O 
OMM O 
to O 
P450scc O 
, O 
and O 
the O 
means O 
by O 
which O 
cholesterol B-TRIVIAL 
is O 
loaded O 
into O 
the O 
OMM O 
, O 
remain O 
unclear O 
. O 
Human O 
deficiency O 
diseases O 
have O 
been O 
described O 
for O 
StAR O 
and O 
for O 
all O 
the O 
mitochondrial O 
steroidogenic O 
enzymes O 
, O 
but O 
not O 
for O 
the O 
electron O 
transfer O 
proteins O 
or O 
for O 
the O 
components O 
of O 
the O 
cholesterol B-TRIVIAL 
import O 
machine O 
. O 

sought O 
to O 
determine O 
levels O 
of O 
adherence O 
in O 
eight O 
European O 
countries O 
to O 
recommendations O 
for O 
the O 
management O 
of O 
type O 
2 O 
diabetes O 
and O 
to O 
investigate O 
factors O 
associated O 
with O 
key O 
intermediate O 
outcomes.RESEARCH O 
DESIGN O 
AND O 
METHODSGUIDANCE O 
was O 
a O 
cross O 
- O 
sectional O 
study O 
including O 
retrospective O 
data O 
extraction O 
from O 
the O 
medical O 
records O 
of O 
people O 
with O 
type O 
2 O 
diabetes O 
recruited O 
, O 
using O 
a O 
shared O 
protocol O 
, O 
from O 
primary O 
and O 
specialist O 
care O 
sites O 
in O 
the O 
following O 
eight O 
European O 
countries O 
: O 
Belgium O 
, O 
France O 
, O 
Germany O 
, O 
Italy O 
, O 
Ireland O 
, O 
Sweden O 
, O 
the O 
Netherlands O 
, O 
and O 
the O 
United O 
Kingdom O 
. O 
The O 
dataset O 
for O 
analysis O 
comprised O 
7597 O 
cases O 
. O 
Proportions O 
meeting O 
process O 
and O 
outcome O 
criteria O 
were O 
determined O 
, O 
including O 
between O 
- O 
country O 
variations O 
. O 
Logistic O 
regression O 
was O 
used O 
to O 
investigate O 
potential O 
predictors O 
of O 
meeting O 
targets O 
for O 
HbA1c O 
, O 
blood O 
pressure O 
, O 
and O 
LDL O 
cholesterol B-TRIVIAL 
.RESULTSIn O 
the O 
total O 
sample O 
, O 
adherence O 
to O 
process O 
recommendations O 
was O 
high O 
for O 
some O 
measures O 
, O 
for O 
example O 
, O 
HbA1c O 
recorded O 
in O 
past O 
12 O 
months O 
in O 
97.6% O 
of O 
cases O 
. O 
Target O 
achievement O 
for O 
intermediate O 
outcome O 
measures O 
was O 
lower O 
, O 
with O 
only O 
53.6% O 
having O 
HbA1c O 
< O 
7% O 
. O 
Considerable O 
between O 
- O 
country O 
variation O 
was O 
identified O 
for O 
both O 
processes O 
and O 
outcomes O 
. O 
The O 
following O 
characteristics O 
were O 
associated O 
with O 
an O 
increased O 
likelihood O 
of O 
meeting O 
targets O 
for O 
all O 
three O 
measures O 
considered O 
( O 
HbA1c O 
, O 
blood O 
pressure O 
, O 
LDL O 
cholesterol B-TRIVIAL 
) O 
: O 
shorter O 
diagnosis O 
of O 
diabetes O 
; O 
having O 
one O 
or O 
more O 
macrovascular O 
complications O 
; O 
lower O 
BMI O 
; O 
being O 
prescribed O 
lipid O 
- O 
lowering O 
medication O 
; O 
and O 
no O 
current O 
antihypertensive O 
prescribing.CONCLUSIONSCompared O 
with O 
earlier O 
reports O 
, O 
we O 
have O 
suggested O 
some O 
encouraging O 
positive O 
trends O 
in O 
Europe O 
in O 
relation O 
to O 
meeting O 
targets O 
for O 
the O 
management O 
of O 
people O 
with O 
type O 
2 O 
diabetes O 
, O 
but O 
there O 
is O 
still O 
scope O 
for O 
further O 
improvement O 
and O 
greater O 
between O 
- O 
country O 
consistency O 
. O 

of O 
Traditional O 
Chinese O 
Medicine O 
Wuzhi O 
Capsule O 
on O 
Pharmacokinetics O 
of O 
Tacrolimus B-TRIVIAL 
in O 
Rats O 
. O 

capsule O 
( O 
WZC O 
) O 
is O 
a O 
preparation O 
of O 
an O 
ethanol B-SYSTEMATIC 
herbal O 
extract O 
of O 
Schisandra O 
sphenanthera(Nan-Wuweizi) O 
, O 
with O 
its O 
main O 
active O 
ingredients O 
including O 
schisandrin B-TRIVIAL 
, O 
schisandrol B-TRIVIAL 
B I-TRIVIAL 
, O 
schisantherin B-TRIVIAL 
A I-TRIVIAL 
, O 
schisanhenol B-TRIVIAL 
and O 
deoxyshisandrin B-TRIVIAL 
. O 
WZC O 
and O 
tacrolimus B-TRIVIAL 
are O 
often O 
co O 
- O 
administered O 
for O 
the O 
treatment O 
of O 
drug O 
- O 
induced O 
hepatitis O 
in O 
organ O 
transplant O 
recipients O 
in O 
China O 
. O 
Recently O 
, O 
it O 
was O 
reported O 
that O 
WZC O 
could O 
significantly O 
increase O 
the O 
blood O 
concentration O 
of O 
tacrolimus B-TRIVIAL 
. O 
The O 
purpose O 
of O 
this O 
study O 
was O 
to O 
investigate O 
whether O 
and O 
how O 
WZC O 
affects O 
the O 
pharmacokinetics O 
of O 
tacrolimus B-TRIVIAL 
in O 
rats O 
. O 
Liquid O 
chromatography O 
- O 
tandem O 
mass O 
spectrometry O 
( O 
LC-MS O 
/ O 
MS O 
) O 
method O 
was O 
used O 
to O 
determine O 
the O 
plasma O 
concentration O 
of O 
tacrolimus B-TRIVIAL 
. O 
The O 
results O 
showed O 
that O 
WZC O 
increased O 
the O 
mean O 
plasma O 
concentration O 
of O 
tacrolimus B-TRIVIAL 
. O 
Compared O 
with O 
administration O 
of O 
tacrolimus B-TRIVIAL 
alone O 
( O 
Cmax O 
, O 
18.87±10.29 O 
ng O 
/ O 
mL O 
; O 
AUC0&→t O 
, O 
40.98±37.07 O 
) O 
, O 
a O 
single O 
intragastric O 
administered O 
dose O 
of O 
WZC O 
increased O 
, O 
the O 
pharmacokinetic O 
parameters O 
of O 
tacrolimus B-TRIVIAL 
( O 
Cmax O 
, O 
59.42±30.32 O 
ng O 
/ O 
mL O 
; O 
AUC0→t O 
, O 
239.71±28.86 O 
) O 
by O 
five O 
folds O 
in O 
rat O 
plasma O 
. O 
After O 
pretreatment O 
with O 
WZC O 
for O 
12 O 
days O 
, O 
there O 
were O 
still O 
significant O 
increases O 
in O 
AUC0→t O 
( O 
from O 
40.98±37.07 O 
to O 
89.21±26.39 O 
h O 
ng O 
/ O 
mL O 
; O 
p O 
< O 
0.05 O 
) O 
and O 
Cmax O 
( O 
from O 
18.87±10.29 O 
to O 
43.16±10.61 O 
ng O 
/ O 
mL O 
; O 
p O 
< O 
0.05 O 
) O 
of O 
tacrolimus B-TRIVIAL 
compared O 
with O 
oral O 
of O 
tacrolimus B-TRIVIAL 
alone O 
, O 
suggesting O 
that O 
WZC O 
increased O 
the O 
exposure O 
of O 
tacrolimus B-TRIVIAL 
by O 
one O 
or O 
more O 
mechanisms O 
. O 
The O 
increase O 
in O 
tacolimus B-TRIVIAL 
Cmax O 
by O 
WZC O 
was O 
dose O 
dependent O 
. O 
The O 
effect O 
of O 
WZC O 
on O 
Tacrolimus B-TRIVIAL 
AUC0→t O 
also O 
increased O 
with O 
dose O 
with O 
a O 
maximal O 
effect O 
observed O 
at O 
450 O 
mg O 
/ O 
kg O 
( O 
825.34 O 
ng O 
h O 
/ O 
mL O 
) O 
. O 
No O 
further O 
increases O 
in O 
tacolimus B-TRIVIAL 
AUC0→t O 
were O 
observed O 
at O 
WZC O 
dose O 
above O 
450 O 
mg O 
/ O 
kg O 
. O 
It O 
is O 
suggested O 
that O 
due O 
to O 
the O 
effect O 
of O 
WZC O 
on O 
the O 
pharmacokinetics O 
of O 
tacrolimus B-TRIVIAL 
, O 
the O 
herb O 
- O 
drug O 
interaction O 
between O 
WZC O 
and O 
tacrolimus B-TRIVIAL 
should O 
be O 
taken O 
into O 
considered O 
in O 
clinical O 
practice O 
. O 

sensitizers O 
with O 
π-extended O 
pull O 
units O 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
. O 

π-extended O 
porphyrin B-FAMILY 
dyes O 
with O 
long O 
alkoxyl O 
chains O 
at O 
the O 
ortho O 
positions O 
of O 
the O 
meso-phenyls B-FAMILY 
, O 
and O 
meta B-FAMILY 
di-tert-butylphenyl I-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
porphyrins I-FAMILY 
, O 
and O 
were O 
synthesized O 
for O 
dye O 
- O 
sensitized O 
solar O 
cells O 
, O 
and O 
their O 
optical O 
, O 
electrochemical O 
and O 
photovoltaic O 
properties O 
were O 
investigated O 
and O 
compared O 
with O 
those O 
of O 
and O 
. O 
The O 
absorption O 
spectra O 
of O 
showed O 
a O 
slight O 
red O 
shift O 
of O 
Soret O 
bands O 
and O 
blue O 
shift O 
of O 
Q O 
bands O 
as O 
compared O 
to O 
the O 
meta- B-FAMILY 
substituted I-FAMILY 
porphyrins I-FAMILY 
due O 
to O 
the O 
electron O 
- O 
donating O 
effects O 
of O 
dioctyloxy B-SYSTEMATIC 
substituents O 
at O 
the O 
ortho- O 
positions O 
of O 
the O 
meso-phenyl B-SYSTEMATIC 
rings O 
. O 
Replacement O 
of O 
the O 
carboxyl B-SYSTEMATIC 
with O 
a O 
cyanoacrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
as O 
the O 
anchoring O 
group O 
results O 
in O 
significant O 
broadening O 
and O 
red O 
shifts O 
of O 
the O 
absorptions O 
, O 
which O 
is O 
due O 
to O 
the O 
strong O 
electronic O 
coupling O 
between O 
the O 
pull O 
unit O 
and O 
the O 
porphyrin B-FAMILY 
ring O 
facilitated O 
by O 
the O 
C B-FORMULA 
[ O 
triple O 
bond O 
, O 
length O 
as O 
m-dash O 
] O 
C B-FORMULA 
triple O 
bond O 
. O 
The O 
electrochemical O 
studies O 
and O 
quantum O 
- O 
chemical O 
calculations O 
( O 
DFT O 
) O 
indicated O 
that O 
the O 
ortho O 
alkoxy O 
- O 
substituted O 
sensitizers O 
exhibit O 
lower O 
oxidation O 
potential O 
, O 
i.e O 
. O 
a O 
higher O 
HOMO O 
energy O 
level O 
, O 
and O 
their O 
HOMO-LUMO O 
gaps O 
are O 
comparable O 
to O 
the O 
meta- O 
substituted O 
analogues O 
. O 
The O 
photovoltaic O 
measurements O 
confirmed O 
that O 
the O 
ortho-octyloxy B-SYSTEMATIC 
groups O 
in O 
the O 
two O 
meso-phenyls B-FAMILY 
of O 
and O 
play O 
a O 
significant O 
role O 
in O 
preventing O 
dye O 
aggregation O 
thereby O 
enhancing O 
the O 
corresponding O 
short O 
- O 
circuit O 
current O 
density O 
and O 
open O 
- O 
circuit O 
voltage O 
. O 
The O 
power O 
conversion O 
efficiency O 
( O 
η O 
) O 
of O 
is O 
8.04% O 
, O 
which O 
is O 
11% O 
higher O 
than O 
that O 
of O 
, O 
whereas O 
the O 
efficiency O 
of O 
is O 
6.03% O 
, O 
which O 
is O 
135% O 
higher O 
than O 
that O 
of O 
. O 
On O 
the O 
other O 
hand O 
, O 
the O 
poor O 
performance O 
of O 
and O 
is O 
due O 
to O 
the O 
floppy O 
structural O 
nature O 
and O 
limited O 
molecular O 
rigidity O 
of O 
the O 
cyanoacrylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
anchor O 
. O 

ovo O 
effects O 
of O 
two O 
organophosphate B-FAMILY 
flame O 
retardants O 
, O 
TCPP B-ABBREVIATION 
and O 
TDCPP B-ABBREVIATION 
, O 
on O 
pipping O 
success O 
, O 
development O 
, O 
mRNA O 
expression O 
and O 
thyroid O 
hormone O 
levels O 
in O 
chicken O 
embryos O 
. O 

phosphate I-SYSTEMATIC 
( O 
TCPP B-ABBREVIATION 
) O 
and O 
tris(1,3-dichloro-2-propyl) B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
( O 
TDCPP B-ABBREVIATION 
) O 
are O 
organic O 
flame O 
retardants O 
detected O 
in O 
the O 
environment O 
and O 
biota O 
for O 
which O 
toxicological O 
data O 
for O 
avian O 
species O 
are O 
limited O 
. O 
In O 
this O 
study O 
, O 
domestic O 
chicken O 
eggs O 
were O 
injected O 
with O 
TCPP B-ABBREVIATION 
or O 
TDCPP B-ABBREVIATION 
( O 
maximum O 
dose O 
= O 
51600 O 
and O 
45000 O 
ng O 
/ O 
g O 
egg O 
, O 
respectively O 
) O 
to O 
determine O 
dose O 
- O 
dependent O 
effects O 
on O 
pipping O 
success O 
, O 
development O 
, O 
hepatic O 
messenger O 
RNA O 
( O 
mRNA O 
) O 
expression O 
levels O 
of O 
genes O 
associated O 
with O 
xenobiotic O 
metabolism O 
and O 
the O 
thyroid O 
hormone O 
( O 
TH O 
) O 
pathway O 
, O 
and O 
TH O 
levels O 
following O 
20-22 O 
days O 
of O 
incubation O 
. O 
Neither O 
compound O 
reduced O 
pipping O 
success O 
; O 
however O 
, O 
TCPP B-ABBREVIATION 
significantly O 
delayed O 
pipping O 
at O 
9240 O 
and O 
51600 O 
ng O 
/ O 
g O 
and O 
reduced O 
tarsus O 
length O 
at O 
51600 O 
ng O 
/ O 
g O 
. O 
TDCPP B-ABBREVIATION 
exposure O 
resulted O 
in O 
significant O 
decreases O 
in O 
head O 
plus O 
bill O 
length O 
, O 
embryo O 
mass O 
and O 
gallbladder O 
size O 
at O 
45000 O 
ng O 
/ O 
g O 
and O 
reduced O 
plasma O 
free O 
T4 O 
levels O 
at O 
7640 O 
ng O 
/ O 
g O 
. O 
Type O 
I O 
deiodinase O 
, O 
liver O 
fatty O 
- O 
acid O 
binding O 
protein O 
and O 
cytochrome O 
P450 O 
( O 
CYP O 
) O 
3A37 O 
mRNA O 
levels O 
were O 
significantly O 
induced O 
by O 
TCPP B-ABBREVIATION 
, O 
while O 
TDCPP B-ABBREVIATION 
induced O 
CYP3A37 O 
and O 
CYP2H1 O 
. O 
Chemical O 
analysis O 
of O 
egg O 
contents O 
at O 
incubation O 
days O 
0 O 
, O 
5 O 
, O 
11 O 
, O 
18 O 
, O 
and O 
19 O 
revealed O 
that O 
> O 
92% O 
of O 
the O 
injected O 
TCPP B-ABBREVIATION 
or O 
TDCPP B-ABBREVIATION 
concentration O 
was O 
detectable O 
up O 
to O 
day O 
5 O 
; O 
however O 
, O 
< O 
1% O 
was O 
detected O 
by O 
day O 
19 O 
. O 
The O 
observed O 
phenotypic O 
responses O 
to O 
TCPP B-ABBREVIATION 
and O 
TDCPP B-ABBREVIATION 
exposure O 
may O 
be O 
associated O 
with O 
disruption O 
of O 
the O 
TH-axis O 
, O 
which O 
is O 
critical O 
for O 
normal O 
growth O 
and O 
development O 
in O 
birds O 
. O 
The O 
effects O 
of O 
TDCPP B-ABBREVIATION 
on O 
the O 
gallbladder O 
indicate O 
that O 
the O 
disturbance O 
of O 
lipid O 
metabolism O 
is O 
a O 
likely O 
target O 
in O 
its O 
mechanism O 
of O 
toxicity O 
. O 

Nutritive O 
Quality O 
and O 
Salt O 
Resistance O 
in O 
Transgenic O 
Maize O 
by O 
Simultaneously O 
Overexpression O 
of O 
a O 
Natural O 
Lysine B-TRIVIAL 
-Rich O 
Protein O 
Gene O 
, O 
SBgLR O 
, O 
and O 
an O 
ERF O 
Transcription O 
Factor O 
Gene O 
, O 
TSRF1 O 
. O 

( O 
Zea O 
mays O 
L O 
. O 
) O 
, O 
as O 
one O 
of O 
the O 
most O 
important O 
crops O 
in O 
the O 
world O 
, O 
is O 
deficient O 
in O 
lysine B-TRIVIAL 
and O 
tryptophan B-TRIVIAL 
. O 
Environmental O 
conditions O 
greatly O 
impact O 
plant O 
growth O 
, O 
development O 
and O 
productivity O 
. O 
In O 
this O 
study O 
, O 
we O 
used O 
particle O 
bombardment O 
mediated O 
co O 
- O 
transformation O 
to O 
obtain O 
marker O 
- O 
free O 
transgenic O 
maize O 
inbred O 
X178 O 
lines O 
harboring O 
a O 
lysine B-TRIVIAL 
-rich O 
protein O 
gene O 
SBgLR O 
from O 
potato O 
and O 
an O 
ethylene B-SYSTEMATIC 
responsive O 
factor O 
( O 
ERF O 
) O 
transcription O 
factor O 
gene O 
, O 
TSRF1 O 
, O 
from O 
tomato O 
. O 
Both O 
of O 
the O 
target O 
genes O 
were O 
successfully O 
expressed O 
and O 
showed O 
various O 
expression O 
levels O 
in O 
different O 
transgenic O 
lines O 
. O 
Analysis O 
showed O 
that O 
the O 
protein O 
and O 
lysine B-TRIVIAL 
content O 
in O 
T1 O 
transgenic O 
maize O 
seeds O 
increased O 
significantly O 
. O 
Compared O 
to O 
non-transformed O 
maize O 
, O 
the O 
protein O 
and O 
lysine B-TRIVIAL 
content O 
increased O 
by O 
7.7% O 
to O 
24.38% O 
and O 
8.70% O 
to O 
30.43% O 
, O 
respectively O 
. O 
Moreover O 
, O 
transgenic O 
maize O 
exhibited O 
more O 
tolerance O 
to O 
salt O 
stress O 
. O 
When O 
treated O 
with O 
200 O 
mM O 
NaCl B-FORMULA 
for O 
48 O 
h O 
, O 
both O 
non-transformed O 
and O 
transgenic O 
plant O 
leaves O 
displayed O 
wilting O 
and O 
losing O 
green O 
symptoms O 
and O 
dramatic O 
increase O 
of O 
the O 
free O 
proline B-TRIVIAL 
contents O 
. O 
However O 
, O 
the O 
degree O 
of O 
control O 
seedlings O 
was O 
much O 
more O 
serious O 
than O 
that O 
of O 
transgenic O 
lines O 
and O 
much O 
more O 
increases O 
of O 
the O 
free O 
proline B-TRIVIAL 
contents O 
in O 
the O 
transgenic O 
lines O 
than O 
that O 
in O 
the O 
control O 
seedlings O 
were O 
observed O 
. O 
Meanwhile O 
, O 
lower O 
extent O 
decreases O 
of O 
the O 
chlorophyll O 
contents O 
were O 
detected O 
in O 
the O 
transgenic O 
seedlings O 
. O 
Quantitative O 
RT-PCR O 
was O 
performed O 
to O 
analyze O 
the O 
expression O 
of O 
ten O 
stress O 
- O 
related O 
genes O 
, O 
including O 
stress O 
responsive O 
transcription O 
factor O 
genes O 
, O 
ZmMYB59 O 
and O 
ZmMYC1 O 
, O 
proline B-TRIVIAL 
synthesis O 
related O 
genes O 
, O 
ZmP5CS1 O 
and O 
ZmP5CS2 O 
, O 
photosynthesis O 
- O 
related O 
genes O 
, O 
ZmELIP O 
, O 
ZmPSI-N O 
, O 
ZmOEE O 
, O 
Zmrbcs O 
and O 
ZmPLAS O 
, O 
and O 
one O 
ABA O 
biosynthesis O 
related O 
gene O 
, O 
ZmSDR O 
. O 
The O 
results O 
showed O 
that O 
with O 
the O 
exception O 
of O 
ZmP5CS1 O 
and O 
ZmP5CS2 O 
in O 
line O 
9-10 O 
and O 
19-11 O 
, O 
ZmMYC1 O 
in O 
line O 
19-11 O 
and O 
ZmSDR O 
in O 
line O 
19-11 O 
, O 
the O 
expression O 
of O 
other O 
stress O 
- O 
related O 
genes O 
were O 
inhibited O 
in O 
transgenic O 
lines O 
under O 
normal O 
conditions O 
. O 
After O 
salt O 
treatment O 
, O 
the O 
expressions O 
of O 
the O 
ten O 
stress O 
- O 
related O 
genes O 
were O 
significantly O 
induced O 
in O 
both O 
wild O 
- O 
type O 
( O 
WT O 
) O 
and O 
transgenic O 
lines O 
. O 
However O 
, O 
compared O 
to O 
WT O 
, O 
the O 
increases O 
of O 
ZmP5CS1 O 
in O 
all O 
these O 
three O 
transgenic O 
lines O 
and O 
ZmP5CS2 O 
in O 
line O 
9-10 O 
were O 
less O 
than O 
WT O 
plants O 
. O 
This O 
study O 
provides O 
an O 
effective O 
approach O 
of O 
maize O 
genetic O 
engineering O 
for O 
improved O 
nutritive O 
quality O 
and O 
salt O 
tolerance O 
. O 

and O 
Characterization O 
of O 
5-(1,2,4-Triazol-3-yl)tetrazoles B-FAMILY 
with O 
various O 
energetic O 
functionalities O 
. O 

this O 
contribution O 
the O 
synthesis O 
and O 
full O 
structural O 
as O 
well O 
as O 
spectroscopic O 
characterization O 
of O 
three O 
5-(1,2,4-triazol-3-yl)tetrazoles B-FAMILY 
along O 
with O 
selected O 
energetic O 
moieties O 
like O 
nitro B-SYSTEMATIC 
, O 
nitrimino B-SYSTEMATIC 
, O 
and O 
azido B-SYSTEMATIC 
groups O 
are O 
presented O 
. O 
The O 
main O 
goal O 
is O 
a O 
comparative O 
study O 
on O 
the O 
influence O 
of O 
those O 
variable O 
energetic O 
moieties O 
on O 
structural O 
and O 
energetic O 
properties O 
. O 
A O 
complete O 
characterization O 
including O 
IR O 
and O 
Raman O 
as O 
well O 
as O 
multinuclear O 
NMR O 
spectroscopy O 
of O 
all O 
compounds O 
is O 
presented O 
. O 
Additionally O 
, O 
X-ray O 
crystallographic O 
measurements O 
were O 
performed O 
and O 
reveal O 
insights O 
into O 
structural O 
characteristics O 
as O 
well O 
as O 
inter- O 
and O 
intramolecular O 
interactions O 
. O 
The O 
standard O 
enthalpies O 
of O 
formation O 
were O 
calculated O 
for O 
all O 
compounds O 
at O 
the O 
CBS-4M O 
level O 
of O 
theory O 
and O 
reveal O 
high O 
positive O 
heats O 
of O 
formation O 
for O 
all O 
compounds O 
. O 
The O 
calculated O 
detonation O 
parameters O 
( O 
using O 
the O 
EXPLO5.05 O 
program O 
) O 
are O 
in O 
the O 
range O 
of O 
8000 O 
m O 
s(-1) O 
( O 
8097 O 
m O 
s(-1) O 
( O 
5 O 
) O 
, O 
8020 O 
m O 
s(-1) O 
( O 
6 O 
) O 
, O 
7874 O 
m O 
s(-1) O 
( O 
7 O 
) O 
) O 
. O 
As O 
expected O 
, O 
the O 
measured O 
impact O 
and O 
friction O 
sensitivities O 
as O 
well O 
as O 
decomposition O 
temperatures O 
strongly O 
depend O 
on O 
the O 
energetic O 
moiety O 
at O 
the O 
triazole B-FAMILY 
ring O 
. O 
The O 
CC B-FORMULA 
connection O 
of O 
a O 
triazole B-FAMILY 
ring O 
with O 
its O 
opportunity O 
to O 
introduce O 
a O 
large O 
variety O 
of O 
energetic O 
moieties O 
and O 
a O 
tetrazole B-FAMILY 
ring O 
, O 
implying O 
a O 
large O 
energy O 
content O 
, O 
leads O 
to O 
the O 
selective O 
synthesis O 
of O 
primary O 
and O 
secondary O 
explosives O 
. O 

acetylated B-FAMILY 
chalcone I-FAMILY 
and O 
biflavonoid B-FAMILY 
glycosides I-FAMILY 
from O 
Trigonosciadium O 
brachytaenium O 
( O 
Boiss O 
. O 
) O 
Alava O 
. O 

new O 
acetylated B-FAMILY 
chalcone I-FAMILY 
glycoside I-FAMILY 
, O 
trans-2',6'-dihydroxy-4'-O-(4″-acetyl-rhamnoside)-4-methoxychalcone B-SYSTEMATIC 
( O 
1 O 
) O 
and O 
a O 
new O 
biflavonoid B-FAMILY 
glycosides I-FAMILY 
, O 
5,3',5″,4″'-tetrahydroxy-3″',5″'dimethoxy-biflavone B-SYSTEMATIC 
( I-SYSTEMATIC 
4' I-SYSTEMATIC 
→ I-SYSTEMATIC 
8″)-7-O-((2-rhamnoside I-SYSTEMATIC 
) I-SYSTEMATIC 
rhamnoside I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
2 O 
) O 
were O 
isolated O 
from O 
the O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
soluble O 
fraction O 
of O 
the O 
methanol B-SYSTEMATIC 
extract O 
obtained O 
from O 
Trigonosciadium O 
brachytaenium O 
and O 
have O 
been O 
purified O 
by O 
column O 
chromatography O 
and O 
preparative O 
TLC O 
. O 
Those O 
structures O 
were O 
elucidated O 
by O 
UV O 
, O 
(1)H B-FORMULA 
NMR O 
and O 
(13)C B-FORMULA 
NMR O 
, O 
HMBC O 
, O 
EI-MS O 
and O 
IR O 
spectra O 
. O 
The O 
antioxidant O 
activity O 
of O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
was O 
evaluated O 
by O 
1,1-diphenyl-2-picrylhydrazyl B-SYSTEMATIC 
method O 
. O 
The O 
results O 
indicate O 
that O 
ethyl B-SYSTEMATIC 
acetate I-SYSTEMATIC 
extract O 
from O 
aerial O 
part O 
of O 
T O 
. O 
brachytaenium O 
possesses O 
considerable O 
antioxidant O 
activity O 
. O 

Targeting O 
of O 
the O 
Adenosine B-TRIVIAL 
A2A O 
Receptors O 
and O 
Monoamine B-SYSTEMATIC 
Oxidase O 
B O 
by O 
4H-3,1-Benzothiazin-4-ones O 
. O 

of O 
A2A O 
adenosine B-TRIVIAL 
receptors O 
( O 
A2AARs O 
) O 
and O 
inhibition O 
of O 
monoamine B-FAMILY 
oxidase O 
B O 
( O 
MAO-B O 
) O 
in O 
brain O 
are O 
considered O 
attractive O 
strategies O 
for O 
the O 
treatment O 
of O 
neurodegenerative O 
diseases O 
such O 
as O 
Parkinson's O 
disease O 
( O 
PD O 
) O 
. O 
In O 
the O 
present O 
study O 
benzothiazinones B-FAMILY 
, O 
e.g O 
. O 
2-(3-chlorophenoxy)-N-(4-oxo-4H-3,1-benzothiazin-2-yl)acetamide B-SYSTEMATIC 
( O 
13 O 
) O 
, O 
were O 
identified O 
as O 
a O 
novel O 
class O 
of O 
potent O 
MAO-B O 
inhibitors O 
( O 
IC50 O 
human O 
MAO-B O 
: O 
1.63 O 
nM O 
) O 
. O 
Benzothiazinones B-TRIVIAL 
with O 
large O 
substituents O 
in O 
the O 
2- O 
position O 
, O 
e.g O 
. O 
methoxy B-SYSTEMATIC 
- O 
cinnamoylamino B-SYSTEMATIC 
, O 
phenylbutyrylamino B-SYSTEMATIC 
, O 
or O 
chlorobenzylpiperazinylbenzamido B-SYSTEMATIC 
residues O 
( O 
14 O 
, O 
17 O 
, O 
27 O 
, O 
28 O 
) O 
showed O 
high O 
affinity O 
and O 
selectivity O 
for O 
A2AARs O 
( O 
Ki O 
human O 
A2AAR O 
: O 
39.5-69.5 O 
nM O 
) O 
. O 
By O 
optimizing O 
benzothiazinones B-FAMILY 
for O 
both O 
targets O 
the O 
first O 
potent O 
, O 
dual O 
- O 
acting O 
A2AAR O 
/ O 
MAO-B O 
inhibitors O 
with O 
a O 
non- O 
xanthine B-TRIVIAL 
structure O 
were O 
developed O 
. O 
The O 
best O 
derivative O 
was O 
N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide B-SYSTEMATIC 
( O 
17 O 
, O 
Ki O 
human O 
A2A O 
39.5 O 
nM O 
, O 
IC50 O 
human O 
MAO-B O 
34.9 O 
nM O 
; O 
selective O 
versus O 
other O 
AR O 
subtypes O 
and O 
MAO-A O 
) O 
, O 
which O 
inhibited O 
A2AAR-induced O 
cAMP O 
accumulation O 
and O 
showed O 
competitive O 
, O 
reversible O 
MAO O 
B O 
inhibition O 
. O 
The O 
new O 
compounds O 
may O 
be O 
useful O 
tools O 
for O 
validating O 
the O 
A2AAR O 
/ O 
MAO-B O 
dual O 
target O 
approach O 
in O 
PD O 
. O 

Tea O 
Polyphenols B-FAMILY 
Improve O 
Bone O 
Microarchitecture O 
in O 
High-Fat-Diet-Induced O 
Obese O 
Female O 
Rats O 
Through O 
Suppressing O 
Bone O 
Formation O 
and O 
Erosion O 
. O 

This O 
study O 
evaluates O 
the O 
effects O 
of O 
green O 
tea O 
polyphenols B-FAMILY 
( O 
GTPs O 
) O 
on O 
bone O 
microarchitecture O 
in O 
high O 
- O 
fat O 
- O 
diet O 
(HFD)-induced O 
obese O 
female O 
rats O 
. O 
Thirty O 
- O 
six O 
3-month- O 
old O 
female O 
rats O 
were O 
fed O 
either O 
a O 
control O 
diet O 
or O 
a O 
HFD O 
for O 
4 O 
months O 
. O 
Animals O 
in O 
the O 
control O 
group O 
continued O 
on O 
the O 
control O 
diet O 
for O 
another O 
4 O 
months O 
. O 
Animals O 
in O 
the O 
HFD O 
group O 
were O 
divided O 
into O 
two O 
groups O 
, O 
with O 
0.5 O 
g O 
/ O 
100 O 
mL O 
GTP O 
( O 
the O 
HFD O 
+ O 
GTP O 
group O 
) O 
or O 
without O 
GTP O 
( O 
the O 
HFD O 
group O 
) O 
in O 
drinking O 
water O 
, O 
in O 
addition O 
to O 
the O 
HFD O 
for O 
another O 
4 O 
months O 
. O 
Compared O 
to O 
the O 
control O 
group O 
, O 
the O 
HFD O 
group O 
increased O 
bone O 
formation O 
and O 
erosion O 
rates O 
at O 
the O 
tibia O 
, O 
decreased O 
trabecular O 
volume O 
and O 
thickness O 
, O 
but O 
had O 
no O 
impact O 
on O 
bone O 
mineral O 
density O 
( O 
BMD O 
) O 
, O 
trabecular O 
number O 
( O 
Tb.N O 
) O 
, O 
and O 
separation O 
. O 
Compared O 
to O 
the O 
control O 
group O 
, O 
the O 
HFD O 
+ O 
GTP O 
group O 
demonstrates O 
a O 
greater O 
Tb.N O 
at O 
the O 
proximal O 
tibia O 
, O 
and O 
a O 
greater O 
trabecular O 
thickness O 
at O 
the O 
femur O 
and O 
the O 
lumbar O 
vertebrae O 
, O 
but O 
a O 
smaller O 
trabecular O 
separation O 
( O 
Tb.Sp O 
) O 
and O 
mineralizing O 
surface O 
at O 
the O 
proximal O 
tibia O 
, O 
and O 
a O 
reduced O 
endocortical O 
mineral O 
apposition O 
rate O 
( O 
MAR O 
) O 
at O 
the O 
tibia O 
shaft O 
. O 
Relative O 
to O 
the O 
HFD O 
group O 
, O 
the O 
HFD O 
+ O 
GTP O 
group O 
demonstrates O 
( O 
1 O 
) O 
a O 
higher O 
BMD O 
at O 
the O 
femur O 
, O 
a O 
greater O 
trabecular O 
volume O 
, O 
thickness O 
, O 
and O 
number O 
at O 
the O 
proximal O 
tibia O 
, O 
a O 
larger O 
cortical O 
area O 
and O 
thickness O 
at O 
the O 
tibial O 
shaft O 
, O 
and O 
a O 
greater O 
trabecular O 
volume O 
and O 
thickness O 
at O 
the O 
femur O 
and O 
the O 
lumbar O 
vertebrae O 
, O 
( O 
2 O 
) O 
a O 
smaller O 
Tb.Sp O 
, O 
MAR O 
, O 
bone O 
formation O 
rate O 
, O 
and O 
eroded O 
surface O 
at O 
the O 
tibia O 
. O 
We O 
concluded O 
that O 
GTP O 
supplementation O 
in O 
drinking O 
water O 
improves O 
bone O 
microarchitecture O 
in O 
the O 
HFD-induced O 
obese O 
female O 
rats O 
, O 
possibly O 
through O 
suppressing O 
bone O 
turnover O 
, O 
resulting O 
in O 
a O 
larger O 
net O 
bone O 
volume O 
. O 

of O 
Lycopene B-TRIVIAL 
Supplementation O 
on O 
Oxidative O 
Stress O 
: O 
An O 
Exploratory O 
Systematic O 
Review O 
and O 
Meta-Analysis O 
of O 
Randomized O 
Controlled O 
Trials O 
. O 

Lycopene B-TRIVIAL 
is O 
a O 
potentially O 
useful O 
compound O 
for O 
preventing O 
and O 
treating O 
cardiovascular O 
diseases O 
and O 
cancers O 
. O 
Studies O 
on O 
the O 
effects O 
of O 
lycopene B-TRIVIAL 
on O 
oxidative O 
stress O 
offer O 
insights O 
into O 
its O 
mechanism O 
of O 
action O 
and O 
provide O 
evidence O 
- O 
based O 
rationale O 
for O 
its O 
supplementation O 
. O 
In O 
this O 
analysis O 
, O 
randomized O 
controlled O 
trials O 
of O 
the O 
effects O 
of O 
oral O 
lycopene B-TRIVIAL 
supplementation O 
on O 
any O 
valid O 
outcomes O 
of O 
oxidative O 
stress O 
were O 
identified O 
and O 
pooled O 
through O 
a O 
search O 
of O 
international O 
journal O 
databases O 
and O 
reference O 
lists O 
of O 
relevant O 
publications O 
. O 
Two O 
reviewers O 
extracted O 
data O 
from O 
each O 
of O 
the O 
identified O 
studies O 
. O 
Only O 
studies O 
of O 
sufficient O 
quality O 
were O 
included O 
. O 
Twelve O 
parallel O 
trials O 
and O 
one O 
crossover O 
trial O 
were O 
included O 
in O 
the O 
systematic O 
review O 
, O 
and O 
six O 
trials O 
provided O 
data O 
for O 
quantitative O 
meta-analysis O 
. O 
Our O 
results O 
indicate O 
that O 
lycopene B-TRIVIAL 
supplementation O 
significantly O 
decreases O 
the O 
DNA O 
tail O 
length O 
, O 
as O 
determined O 
using O 
comet O 
assays O 
, O 
with O 
a O 
mean O 
difference O 
( O 
MD O 
) O 
of O 
-6.27 O 
[ O 
95% O 
confidence O 
interval O 
( O 
CI O 
) O 
-10.74 O 
, O 
-1.9 O 
] O 
( O 
P=.006 O 
) O 
between O 
the O 
lycopene B-TRIVIAL 
intervention O 
groups O 
and O 
the O 
control O 
groups O 
. O 
Lycopene B-TRIVIAL 
supplementation O 
does O 
not O 
significantly O 
prolong O 
the O 
lag O 
time O 
of O 
low O 
- O 
density O 
lipoprotein O 
( O 
MD O 
3.76 O 
[ O 
95% O 
CI O 
-2.48 O 
, O 
10.01 O 
] O 
; O 
P=.24 O 
) O 
. O 
Lycopene B-TRIVIAL 
possibly O 
alleviates O 
oxidative O 
stress O 
; O 
however O 
, O 
biomarker O 
research O 
for O 
oxidative O 
stress O 
needs O 
be O 
more O 
consistent O 
with O 
the O 
outcomes O 
in O 
lycopene B-TRIVIAL 
intervention O 
trials O 
for O 
disease O 
prevention O 
. O 

This O 
study O 
aimed O 
to O 
investigate O 
the O 
role O 
of O 
Salvia O 
triloba O 
L O 
. O 
and O 
Piper O 
nigrum O 
extracts O 
in O 
ameliorating O 
neuroinflammatory O 
insults O 
characteristic O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
in O 
an O 
experimentally O 
induced O 
rat O 
model O 
. O 
Adult O 
male O 
Sprague-Dawley O 
rats O 
were O 
classified O 
into O 
Group O 
1 O 
( O 
n=10 O 
) O 
: O 
normal O 
healthy O 
animals O 
serving O 
as O 
the O 
negative O 
control O 
group O 
; O 
Group O 
2 O 
( O 
n=60 O 
) O 
: O 
the O 
AD-induced O 
group O 
. O 
After O 
AD O 
induction O 
, O 
animals O 
in O 
the O 
AD-induced O 
group O 
were O 
divided O 
randomly O 
and O 
equally O 
into O 
6 O 
subgroups O 
. O 
The O 
first O 
subgroup O 
served O 
as O 
AD O 
control O 
; O 
the O 
second O 
one O 
, O 
which O 
served O 
as O 
positive O 
control O 
, O 
was O 
treated O 
orally O 
with O 
the O 
conventional O 
therapy O 
for O 
AD O 
( O 
rivastigmine B-TRIVIAL 
) O 
at O 
a O 
dose O 
of O 
0.3 O 
mg O 
/ O 
kg O 
body O 
weight O 
( O 
b.w O 
. O 
) O 
daily O 
for O 
3 O 
months O 
. O 
The O 
third O 
and O 
fourth O 
subgroups O 
were O 
, O 
respectively O 
, O 
treated O 
orally O 
with O 
the O 
S O 
. O 
triloba O 
extract O 
at O 
a O 
dose O 
of O 
750 O 
and O 
375 O 
mg O 
/ O 
kg O 
b.w O 
. O 
daily O 
for O 
3 O 
months O 
. O 
The O 
fifth O 
and O 
sixth O 
subgroups O 
were O 
, O 
respectively O 
, O 
treated O 
orally O 
with O 
the O 
P O 
. O 
nigrum O 
extract O 
at O 
a O 
dose O 
of O 
187.5 O 
and O 
93.75 O 
mg O 
/ O 
kg O 
b.w O 
. O 
daily O 
for O 
3 O 
months O 
. O 
Levels O 
of O 
brain O 
acetylcholine B-SYSTEMATIC 
( O 
Ach O 
) O 
, O 
serum O 
and O 
brain O 
acetylcholinesterase O 
( O 
AchE O 
) O 
activity O 
, O 
C-reactive O 
protein O 
( O 
CRP O 
) O 
, O 
total O 
nuclear O 
factor O 
kappa-B O 
( O 
NF-κB O 
) O 
, O 
and O 
monocyte O 
chemoattractant O 
protein-1 O 
( O 
MCP-1 O 
) O 
were O 
estimated O 
. O 
The O 
results O 
showed O 
that O 
administration O 
of O 
AlCl3 B-FORMULA 
resulted O 
in O 
a O 
significant O 
elevation O 
in O 
the O 
levels O 
of O 
AchE O 
activity O 
, O 
CRP O 
, O 
NF-κB O 
, O 
and O 
MCP-1 O 
accompanied O 
with O 
a O 
significant O 
depletion O 
in O 
the O 
Ach O 
level O 
. O 
Treatment O 
of O 
AD O 
rats O 
with O 
each O 
of O 
the O 
selected O 
medicinal O 
plant O 
extracts O 
caused O 
marked O 
improvement O 
in O 
the O 
measured O 
biochemical O 
parameters O 
. O 
In O 
conclusion O 
, O 
S O 
. O 
triloba O 
and O 
P O 
. O 
nigrum O 
methanolic O 
extracts O 
have O 
potent O 
anti-inflammatory O 
effects O 
against O 
neuroinflammation O 
characterizing O 
AD O 
. O 

- O 
based O 
Chitosan/ O 
Polybenzoxazine B-FAMILY 
Crosslinked O 
Films O 
: O 
Preparation O 
in O 
Aqueous O 
Media O 
and O 
Synergistic O 
Improvements O 
in O 
Thermal O 
and O 
Mechanical O 
Properties O 
. O 

novel O 
class O 
of O 
polymer O 
blends O 
has O 
been O 
prepared O 
from O 
main O 
- O 
chain O 
type O 
benzoxazine B-FAMILY 
polymer O 
( O 
MCBP O 
) O 
and O 
chitosan O 
( O 
CTS O 
) O 
, O 
a O 
modified O 
biomacromolecule O 
. O 
A O 
water O 
- O 
soluble O 
, O 
main O 
- O 
chain O 
type O 
benzoxazine B-FAMILY 
polymer O 
, O 
MCBP(BA-tepa) O 
, O 
was O 
synthesized O 
from O 
the O 
reaction O 
of O 
bisphenol-A B-TRIVIAL 
( O 
BA O 
) O 
, O 
tetraethylenepentamine B-SYSTEMATIC 
( O 
TEPA B-ABBREVIATION 
) O 
and O 
formalin B-TRIVIAL 
. O 
The O 
structure O 
of O 
the O 
MCBP(BA-tepa) O 
was O 
confirmed O 
by O 
proton O 
nuclear O 
magnetic O 
resonance O 
spectroscopy O 
( O 
1H B-FORMULA 
-NMR O 
) O 
and O 
Fourier O 
transform O 
infrared O 
spectroscopy O 
( O 
FT-IR O 
) O 
. O 
The O 
polymer O 
blends O 
were O 
prepared O 
by O 
mixing O 
MCBP(BA-tepa) O 
and O 
chitosan O 
( O 
CTS O 
) O 
in O 
aqueous O 
acetic B-SYSTEMATIC 
acid I-SYSTEMATIC 
solution O 
( O 
1% O 
) O 
. O 
The O 
CTS O 
/ O 
MCBP(BA-tepa) O 
films O 
are O 
crosslinked O 
by O 
thermal O 
treatment O 
via O 
the O 
ring O 
- O 
opening O 
polymerization O 
of O 
benzoxazine B-FAMILY 
structures O 
in O 
the O 
main O 
chain O 
to O 
produce O 
AB-crosslinked O 
network O 
. O 
Differential O 
scanning O 
calorimetry O 
and O 
FT-IR O 
were O 
used O 
to O 
study O 
the O 
effects O 
of O 
chitosan O 
on O 
the O 
polymerization O 
behavior O 
of O 
benzoxazine B-FAMILY 
. O 
Hydrogen B-SYSTEMATIC 
bonding O 
between O 
polybenzoxazine B-FAMILY 
and O 
chitosan O 
structures O 
was O 
also O 
observed O 
. O 
The O 
mechanical O 
and O 
thermal O 
properties O 
of O 
crosslinked O 
CTS O 
/ O 
MCBP(BA-tepa) O 
films O 
were O 
evaluated O 
and O 
the O 
results O 
show O 
unusual O 
levels O 
of O 
synergism O 
. O 
In O 
particular O 
, O 
the O 
tensile O 
strength O 
and O 
thermal O 
stability O 
were O 
significantly O 
enhanced O 
in O 
a O 
non-linear O 
fashion O 
. O 
Keywords O 
: O 
Polybenzoxazine B-FAMILY 
; O 
chitosan O 
; O 
crosslinked O 
films O 
; O 
mechanical O 
and O 
thermal O 
properties O 
. O 

method O 
of O 
extracting O 
membranes O 
from O 
red O 
blood O 
cells O 
( O 
RBCs O 
) O 
is O 
described O 
, O 
which O 
were O 
in O 
turn O 
used O 
to O 
assay O 
acetylcholinesterase O 
( O 
AChE O 
) O 
activity O 
. O 
The O 
evidence O 
for O 
the O 
enzyme O 
activity O 
was O 
established O 
by O 
selective O 
inhibition O 
using O 
1,5-bis(4-allyldimethylammoniumphenyl) B-SYSTEMATIC 
pentan-3-one I-SYSTEMATIC 
dibromide I-SYSTEMATIC 
, O 
tetraisopropyl B-SYSTEMATIC 
pyrophosphoramide I-SYSTEMATIC 
and O 
neostigmine B-TRIVIAL 
. O 
Blood O 
samples O 
were O 
exposed O 
to O 
three O 
organophosphorus B-FAMILY 
( O 
dichlorvos B-TRIVIAL 
, O 
chlorpyrifos B-TRIVIAL 
and O 
diazinon B-TRIVIAL 
) O 
and O 
two O 
carbamate B-FAMILY 
( O 
carbaryl B-TRIVIAL 
and O 
carbofuran B-TRIVIAL 
) O 
pesticides O 
. O 
Afterwards O 
AChE O 
activities O 
in O 
RBC O 
membranes O 
were O 
determined O 
. O 
The O 
concentrations O 
capable O 
to O 
inhibit O 
the O 
enzyme O 
activity O 
by O 
50% O 
( O 
IC50 O 
) O 
for O 
the O 
pesticides O 
were O 
10.66 O 
µM O 
( O 
dichlorvos B-TRIVIAL 
) O 
, O 
21.42 O 
µM O 
( O 
chlorpyrifos B-TRIVIAL 
) O 
, O 
109.98 O 
µM O 
( O 
carbaryl B-TRIVIAL 
) O 
and O 
5.44 O 
µM O 
( O 
carbofuran B-TRIVIAL 
) O 
. O 
The O 
results O 
related O 
to O 
20% O 
enzyme O 
inhibition O 
( O 
level O 
used O 
in O 
the O 
estimation O 
of O 
threshold O 
limits O 
for O 
anticholinesterase O 
compounds O 
) O 
were O 
below O 
those O 
acceptable O 
daily O 
intake O 
values O 
enacted O 
by O 
relevant O 
national O 
and O 
international O 
regulations O 
. O 
These O 
results O 
suggest O 
that O 
the O 
proposed O 
AChE O 
extraction O 
from O 
RBC O 
and O 
assay O 
could O 
be O 
a O 
suitable O 
method O 
for O 
monitoring O 
occupational O 
exposure O 
to O 
pesticides O 
. O 

of O 
an O 
Allosteric O 
Modulator O 
of O 
Serotonin B-TRIVIAL 
Transporter O 
with O 
Novel O 
Mechanism O 
of O 
Action O 
. O 

transporters O 
( O 
SERT O 
) O 
play O 
an O 
essential O 
role O 
in O 
the O 
termination O 
and O 
regulation O 
of O 
serotonin B-TRIVIAL 
signaling O 
in O 
the O 
brain O 
. O 
SERT O 
is O 
also O 
the O 
target O 
of O 
antidepressants O 
and O 
psychostimulants O 
. O 
Molecules O 
with O 
novel O 
activities O 
and O 
modes O 
of O 
interaction O 
with O 
regard O 
to O 
SERT O 
function O 
are O 
of O 
great O 
scientific O 
and O 
clinical O 
interest O 
. O 
We O 
explored O 
structural O 
regions O 
outside O 
the O 
putative O 
serotonin B-TRIVIAL 
translocation O 
pathway O 
to O 
identify O 
potential O 
binding O 
sites O 
for O 
allosteric O 
transporter O 
modulators O 
( O 
ATMs O 
) O 
. O 
Mutational O 
studies O 
revealed O 
a O 
pocket O 
of O 
amino B-FAMILY 
acids I-FAMILY 
outside O 
the O 
orthosteric O 
substrate O 
binding O 
sites O 
located O 
in O 
the O 
interface O 
between O 
extracellular O 
loops O 
1 O 
and O 
3 O 
that O 
when O 
mutated O 
affect O 
transporter O 
function O 
. O 
Using O 
the O 
structure O 
of O 
the O 
bacterial O 
transporter O 
homologue O 
leucine B-TRIVIAL 
transporter O 
as O 
a O 
template O 
, O 
we O 
developed O 
a O 
structural O 
model O 
of O 
SERT O 
. O 
We O 
performed O 
molecular O 
dynamics O 
simulations O 
to O 
further O 
characterize O 
the O 
allosteric O 
pocket O 
that O 
was O 
identified O 
by O 
site O 
- O 
directed O 
mutagenesis O 
studies O 
and O 
employed O 
this O 
pocket O 
in O 
a O 
virtual O 
screen O 
for O 
small O 
- O 
molecule O 
modulators O 
of O 
SERT O 
function O 
. O 
In O 
functional O 
transport O 
assays O 
, O 
we O 
found O 
that O 
one O 
of O 
the O 
identified O 
molecules O 
, O 
ATM7 O 
, O 
increased O 
the O 
reuptake O 
of O 
serotonin B-TRIVIAL 
, O 
possibly O 
by O 
facilitating O 
the O 
interaction O 
of O 
serotonin B-TRIVIAL 
with O 
transport O 
- O 
ready O 
conformations O 
of O 
SERT O 
when O 
concentrations O 
of O 
serotonin B-TRIVIAL 
were O 
low O 
and O 
rate O 
limiting O 
. O 
In O 
addition O 
, O 
ATM7 O 
potentiates O 
3,4-methylenedioxy-N-methylamphetamine B-SYSTEMATIC 
( O 
MDMA B-ABBREVIATION 
, O 
" O 
Ecstasy")-induced O 
reversed O 
transport O 
by O 
SERT O 
. O 
Taking O 
advantage O 
of O 
a O 
conformationally O 
sensitive O 
residue O 
in O 
transmembrane O 
domain O 
6 O 
, O 
we O 
demonstrate O 
that O 
ATM7 O 
mechanistically O 
stabilizes O 
an O 
outward O 
- O 
facing O 
conformation O 
of O 
SERT O 
. O 
Taken O 
together O 
these O 
observations O 
demonstrate O 
that O 
ATM7 O 
acts O 
through O 
a O 
novel O 
mechanism O 
that O 
involves O 
allosteric O 
modulation O 
of O 
SERT O 
function O 
. O 

- O 
like O 
and O 
TRPC O 
- O 
like O 
conductances O 
mediate O 
thyrotropin B-TRIVIAL 
-releasing O 
hormone O 
- O 
induced O 
increases O 
in O 
excitability O 
in O 
thalamic O 
paraventricular O 
nucleus O 
neurons O 
. O 

thalamic O 
paraventricular O 
nucleus O 
( O 
PVT O 
) O 
, O 
reported O 
to O 
participate O 
in O 
arousal O 
and O 
motivated O 
behaviors O 
, O 
contains O 
abundant O 
receptors O 
for O 
thyrotropin B-TRIVIAL 
-releasing O 
hormone O 
( O 
TRH B-ABBREVIATION 
) O 
, O 
a O 
neuropeptide O 
also O 
known O 
to O 
modulate O 
arousal O 
and O 
mood O 
. O 
To O 
test O 
the O 
hypothesis O 
that O 
TRH B-ABBREVIATION 
could O 
influence O 
the O 
excitability O 
of O 
PVT O 
neurons O 
, O 
whole O 
call O 
patch O 
clamp O 
recordings O 
obtained O 
in O 
rat O 
brain O 
slice O 
preparations O 
were O 
evaluated O 
during O 
bath O 
applied O 
TRH B-ABBREVIATION 
. O 
In O 
the O 
majority O 
of O 
neurons O 
tested O 
, O 
TRH B-ABBREVIATION 
induced O 
reversible O 
TTX B-ABBREVIATION 
-resistant O 
membrane O 
depolarization O 
. O 
Under O 
voltage O 
- O 
clamp O 
, O 
TRH B-ABBREVIATION 
induced O 
a O 
concentration O 
- O 
dependent O 
G O 
protein- O 
mediated O 
inward O 
current O 
. O 
The O 
mean O 
net O 
TRH B-ABBREVIATION 
-induced O 
current O 
exhibited O 
a O 
decrease O 
in O 
membrane O 
conductance O 
. O 
Further O 
analyses O 
identified O 
two O 
concurrent O 
conductances O 
contributing O 
to O 
the O 
TRH B-ABBREVIATION 
-induced O 
response O 
. O 
One O 
conductance O 
featured O 
a O 
Na(+) B-FORMULA 
-independent O 
and O 
K(+) B-FORMULA 
-dependent O 
net O 
current O 
that O 
displayed O 
rectification O 
and O 
was O 
suppressed O 
by O 
micromolar O 
concentrations O 
of O 
Ba(2+) B-FORMULA 
and O 
two O 
GIRK O 
antagonists O 
, O 
tertiapin O 
Q O 
and O 
SCH B-IDENTIFIER 
23390 I-IDENTIFIER 
. O 
The O 
second O 
conductance O 
featured O 
a O 
Na(+) B-FORMULA 
-dependent O 
net O 
inward O 
current O 
with O 
an O 
I-V O 
relationship O 
that O 
exhibited O 
double O 
rectification O 
with O 
a O 
negative O 
slope O 
conductance O 
below O 
-40 O 
mV O 
. O 
This O 
conductance O 
was O 
suppressed O 
by O 
nonselective O 
TRPC O 
channel O 
blockers O 
2-APB B-SYSTEMATIC 
, O 
flufenamic B-TRIVIAL 
acid I-TRIVIAL 
and O 
ML204 B-IDENTIFIER 
, O 
enhanced O 
by O 
La(3+) B-FORMULA 
in O 
a O 
subpopulation O 
of O 
cells O 
, O 
and O 
unchanged O 
by O 
the O 
TRPV1 O 
antagonist O 
capsazepine B-TRIVIAL 
or O 
a O 
Na(+) B-FORMULA 
/ O 
Ca(2+) B-FORMULA 
exchanger O 
blocker O 
KB-R7943 B-IDENTIFIER 
. O 
TRH B-ABBREVIATION 
also O 
enhanced O 
hyperpolarization O 
- O 
activated O 
low O 
threshold O 
spikes O 
, O 
a O 
feature O 
that O 
was O 
sensitive O 
to O 
pretreatment O 
with O 
either O 
2-APB B-SYSTEMATIC 
or O 
ML204 B-IDENTIFIER 
. O 
Collectively O 
, O 
the O 
data O 
imply O 
that O 
TRH B-ABBREVIATION 
enhances O 
excitability O 
in O 
PVT O 
neurons O 
via O 
concurrently O 
decreasing O 
a O 
G O 
- O 
protein O 
- O 
gated O 
inwardly O 
rectifying O 
K(+) B-FORMULA 
conductance O 
and O 
activating O 
a O 
cationic O 
conductance O 
with O 
characteristics O 
reminiscent O 
of O 
TRPC O 
- O 
like O 
channels O 
, O 
possibly O 
involving O 
TRPC4 O 
/ O 
C5 O 
subunits O 
. O 

toxin O 
( O 
ET O 
) O 
, O 
produced O 
by O 
Clostridium O 
perfringens O 
types O 
B O 
and O 
D O 
, O 
ranks O 
among O 
the O 
four O 
most O 
potent O 
poisonous O 
substances O 
known O 
so O 
far O 
. O 
ET-intoxication O 
is O 
responsible O 
for O 
enterotoxaemia O 
in O 
animals O 
, O 
mainly O 
sheep O 
and O 
goats O 
. O 
This O 
disease O 
comprises O 
several O 
manifestations O 
indicating O 
the O 
attack O 
of O 
the O 
nervous O 
system O 
. O 
This O 
review O 
aims O 
to O 
summarize O 
the O 
effects O 
of O 
ET O 
on O 
central O 
nervous O 
system O 
. O 
ET O 
binds O 
to O 
endothelial O 
cells O 
of O 
brain O 
capillary O 
vessels O 
before O 
passing O 
through O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
Therefore O 
, O 
it O 
induces O 
perivascular O 
oedema O 
and O 
accumulates O 
into O 
brain O 
. O 
ET O 
binding O 
to O 
different O 
brain O 
structures O 
and O 
to O 
different O 
component O 
in O 
the O 
brain O 
indicates O 
regional O 
susceptibility O 
to O 
the O 
toxin O 
. O 
Histological O 
examination O 
has O 
revealed O 
nerve O 
tissue O 
and O 
cellular O 
lesions O 
, O 
which O 
may O 
be O 
directly O 
or O 
indirectly O 
caused O 
by O 
ET O 
. O 
The O 
naturally O 
occurring O 
disease O 
caused O 
by O 
ET-intoxication O 
can O 
be O 
reproduced O 
experimentally O 
in O 
rodents O 
. O 
In O 
mice O 
and O 
rats O 
, O 
ET O 
recognizes O 
receptor O 
at O 
the O 
surface O 
of O 
different O 
neural O 
cell O 
types O 
, O 
including O 
certain O 
neurons O 
( O 
e.g O 
. O 
the O 
granule O 
cells O 
in O 
cerebellum O 
) O 
as O 
well O 
as O 
oligodendrocytes O 
, O 
which O 
are O 
the O 
glial O 
cells O 
responsible O 
for O 
the O 
axons O 
myelination O 
. O 
Moreover O 
, O 
ET O 
induces O 
release O 
of O 
glutamate B-TRIVIAL 
and O 
other O 
transmitters O 
, O 
leading O 
to O 
firing O 
of O 
neural O 
network O 
. O 
The O 
precise O 
mode O 
of O 
action O 
of O 
ET O 
on O 
neural O 
cells O 
remains O 
to O 
be O 
determined O 
. O 

RELEVANCE O 
: O 
: O 
Abelmoschus O 
manihot O 
( O 
L O 
. O 
) O 
Medik O 
. O 
var O 
. O 
manihot O 
is O 
one O 
of O 
the O 
most O 
commonly O 
used O 
Chinese O 
medicines O 
and O 
has O 
played O 
an O 
important O 
role O 
in O 
treating O 
chronic O 
glomerulonephritis O 
and O 
diabetic O 
nephropathy O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
: O 
Metabolites O 
identification O 
of O 
traditional O 
Chinese O 
medicine O 
( O 
TCM O 
) O 
is O 
a O 
complex O 
and O 
time O 
- O 
consuming O 
process O 
due O 
to O 
the O 
complicity O 
of O 
TCM O 
and O 
subsequent O 
large O 
number O 
of O 
detected O 
ions O 
. O 
In O 
this O 
paper O 
, O 
UPLC-MS O 
combined O 
with O 
pattern O 
recognition O 
analysis O 
approach O 
were O 
used O 
to O 
simplify O 
and O 
quicken O 
the O 
identification O 
of O 
the O 
metabolites O 
of O 
Abelmoschus O 
Manihot O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
: O 
Rat O 
urine O 
samples O 
were O 
collected O 
before O 
( O 
as O 
control O 
sample O 
) O 
and O 
after O 
Abelmoschus O 
Manihot O 
administration O 
. O 
Pattern O 
recognition O 
analysis O 
method O 
was O 
used O 
to O 
differentiate O 
components O 
between O 
Abelmoschus O 
Manihot O 
- O 
treated O 
group O 
and O 
its O 
controlled O 
comparison O 
. O 
These O 
components O 
could O 
be O 
considered O 
as O 
Abelmoschus O 
Manihot O 
- O 
related O 
metabolites O 
in O 
vivo O 
. O 
RESULTS O 
: O 
: O 
LC-MS O 
based O 
metabolomics O 
could O 
be O 
an O 
advanced O 
tool O 
to O 
help O 
us O 
find O 
metabolites O 
with O 
regards O 
to O 
its O 
capacity O 
of O 
processing O 
large O 
datasets O 
, O 
differentiating O 
and O 
classifying O 
of O 
sample O 
groups O 
, O 
as O 
well O 
as O 
its O 
indiscriminative O 
nature O 
of O 
biomarker O 
and O 
metabolite O 
identification O 
. O 
Using O 
this O 
method O 
, O 
seven O 
metabolites O 
were O 
identified O 
, O 
which O 
are O 
flavonoid B-FAMILY 
aglycone O 
glucuronidation O 
, O 
sulfatation O 
, O 
and O 
methylation O 
metabolites O 
. O 
CONCLUSION O 
: O 
: O 
Our O 
results O 
showed O 
that O 
UPLC-MS O 
based- O 
pattern O 
recognition O 
analysis O 
approach O 
can O 
be O 
used O 
to O 
quickly O 
identify O 
Abelmoschus O 
Manihot O 
related O 
metabolites O 
in O 
biological O 
fluids O 
. O 
Furthermore O 
, O 
this O 
work O 
demonstrates O 
the O 
potential O 
application O 
of O 
combining O 
the O 
UPLC-MS O 
approach O 
with O 
the O 
metabolomics O 
approach O 
in O 
identifying O 
the O 
metabolites O 
of O 
TCM O 
. O 

- O 
like O 
Factor O 
3 O 
( O 
KLF3 O 
) O 
is O 
a O 
transcriptional O 
regulator O 
that O 
we O 
have O 
shown O 
to O 
be O 
involved O 
in O 
the O 
regulation O 
of O 
adipogenesis O 
in O 
vitro O 
. O 
Here O 
we O 
report O 
that O 
KLF3 O 
nan O 
mice O 
are O 
lean O 
and O 
protected O 
from O 
diet O 
- O 
induced O 
obesity O 
and O 
glucose B-TRIVIAL 
intolerance O 
. O 
On O 
a O 
chow O 
diet O 
, O 
plasma O 
levels O 
of O 
leptin O 
are O 
decreased O 
, O 
and O 
adiponectin O 
is O 
increased O 
. O 
Despite O 
significant O 
reductions O 
in O 
body O 
weight O 
and O 
adiposity O 
, O 
wildtype O 
and O 
knockout O 
animals O 
show O 
equivalent O 
energy O 
intake O 
, O 
expenditure O 
and O 
excretion O 
. O 
To O 
investigate O 
the O 
molecular O 
events O 
underlying O 
these O 
observations O 
, O 
we O 
used O 
microarray O 
analysis O 
to O 
compare O 
gene O 
expression O 
in O 
Klf3(+ O 
/ O 
+ O 
) O 
and O 
Klf3(- O 
/ O 
- O 
) O 
tissues O 
. O 
We O 
found O 
that O 
mRNA O 
expression O 
of O 
Fam132a O 
, O 
which O 
encodes O 
a O 
newly O 
identified O 
insulin O 
- O 
sensitizing O 
adipokine O 
, O 
adipolin O 
, O 
is O 
significantly O 
upregulated O 
in O 
the O 
absence O 
of O 
KLF3 O 
. O 
We O 
confirmed O 
that O 
KLF3 O 
binds O 
the O 
Fam132a O 
promoter O 
in O 
vitro O 
and O 
in O 
vivo O 
and O 
that O 
this O 
leads O 
to O 
repression O 
of O 
promoter O 
activity O 
. O 
Further O 
, O 
plasma O 
adipolin O 
levels O 
were O 
significantly O 
increased O 
in O 
Klf3(- O 
/ O 
- O 
) O 
mice O 
compared O 
to O 
wild O 
- O 
type O 
littermates O 
. O 
Boosting O 
levels O 
of O 
adipolin O 
via O 
targeting O 
of O 
KLF3 O 
offers O 
a O 
novel O 
potential O 
therapeutic O 
strategy O 
for O 
the O 
treatment O 
of O 
insulin O 
resistance O 
. O 

alkaline O 
phosphatases O 
( O 
IALPs O 
) O 
are O 
widely O 
expressed O 
in O 
the O 
brush O 
border O 
of O 
epithelial O 
cells O 
of O 
the O 
intestinal O 
mucosa O 
. O 
Although O 
their O 
physiological O 
role O 
is O 
unclear O 
, O 
they O 
are O 
very O 
significant O 
when O 
it O 
comes O 
to O 
the O 
release O 
of O 
bioactive O 
parent O 
from O 
orally O 
dosed O 
phosphate B-SYSTEMATIC 
prodrugs O 
. O 
Such O 
prodrugs O 
can O 
be O 
resistant O 
to O 
cleavage O 
by O 
IALP O 
, O 
or O 
alternatively O 
undergo O 
rapid O 
cleavage O 
leading O 
to O 
the O 
release O 
and O 
precipitation O 
of O 
the O 
less O 
soluble O 
parent O 
. O 
Because O 
purified O 
IALPs O 
from O 
pre O 
- O 
clinical O 
species O 
are O 
not O 
commercially O 
available O 
, O 
and O 
species O 
differences O 
have O 
not O 
been O 
investigated O 
to O 
date O 
, O 
an O 
effort O 
was O 
made O 
to O 
recombinantly O 
express O 
, O 
purify O 
and O 
characterize O 
rat O 
and O 
cynomolgus O 
monkey O 
IALP O 
( O 
rIALP O 
) O 
. O 
Specifically O 
, O 
rIALP O 
- O 
catalyzed O 
cleavage O 
of O 
five O 
prodrugs O 
( O 
fosphenytoin B-TRIVIAL 
, O 
clindamycin B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
, O 
dexamethasone B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
, O 
ritonavir B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
and O 
ritonavir B-SYSTEMATIC 
oxymethyl I-SYSTEMATIC 
phosphate I-SYSTEMATIC 
) O 
was O 
tested O 
in O 
vitro O 
and O 
parent O 
exposure O 
was O 
assessed O 
in O 
vivo O 
( O 
rat O 
only O 
) O 
following O 
an O 
oral O 
dose O 
of O 
each O 
prodrug O 
. O 
It O 
was O 
determined O 
that O 
the O 
rate O 
of O 
phosphate B-SYSTEMATIC 
cleavage O 
in O 
vitro O 
varied O 
widely O 
; O 
direct O 
phosphates B-FAMILY 
were O 
more O 
resistant O 
to O 
bioconversion O 
, O 
whereas O 
faster O 
conversion O 
was O 
observed O 
with O 
oxymethyl B-SYSTEMATIC 
linked O 
prodrugs O 
. O 
Overall O 
, O 
the O 
rat O 
rIALP O 
- O 
derived O 
data O 
were O 
qualitatively O 
consistent O 
with O 
in O 
- O 
vivo O 
data O 
; O 
prodrugs O 
that O 
were O 
readily O 
cleaved O 
in O 
vitro O 
rendered O 
higher O 
parent O 
drug O 
exposure O 
in O 
vivo O 
. O 
Of O 
the O 
five O 
prodrugs O 
tested O 
, O 
one O 
( O 
ritonavir B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
) O 
showed O 
no O 
conversion O 
in O 
vitro O 
and O 
minimal O 
parent O 
exposure O 
in O 
vivo O 
. O 
Finally O 
, O 
the O 
apparent O 
Km O 
values O 
obtained O 
for O 
fosphenytoin B-TRIVIAL 
and O 
clindamycin B-SYSTEMATIC 
phosphate I-SYSTEMATIC 
in O 
vitro O 
suggest O 
that O 
IALP O 
is O 
not O 
likely O 
to O 
be O 
saturated O 
at O 
therapeutic O 
doses O 
. O 

prevalence O 
of O 
insulin O 
resistance O 
and O 
type O 
2 O 
diabetes O 
mellitus O 
are O 
rising O 
dramatically O 
and O 
as O 
a O 
consequence O 
there O 
is O 
an O 
urgent O 
need O 
to O 
understand O 
the O 
pathogenesis O 
underpinning O 
these O 
conditions O 
to O 
develop O 
new O 
and O 
more O 
efficacious O 
treatments.We O 
have O 
tested O 
the O 
hypothesis O 
that O 
glucocorticoid O 
- O 
mediated O 
changes O 
in O 
insulin O 
sensitivity O 
may O 
be O 
associated O 
with O 
changes O 
in O 
lipid O 
flux O 
. O 
Furthermore O 
, O 
pre O 
- O 
receptor O 
modulation O 
of O 
glucocorticoid O 
availability O 
by O 
11β-hydroxysteroid B-FAMILY 
dehydrogenase O 
type O 
1 O 
( O 
11β-HSD1 O 
) O 
may O 
represent O 
a O 
critical O 
regulatory O 
step O 
. O 
Dexamethasone B-TRIVIAL 
decreased O 
lipogenesis O 
in O 
both O 
murine O 
C2C12 O 
and O 
human O 
LHC-NM2 O 
myotubes O 
. O 
Inactivating O 
p- O 
Ser B-FORMULA 
-79 O 
/ O 
218 O 
of O 
acetyl-CoA B-SYSTEMATIC 
carboxylase O 
1 O 
/ O 
2 O 
( O 
ACC1 O 
/ O 
2 O 
) O 
and O 
activating O 
p- O 
Thr B-FORMULA 
-172 O 
of O 
AMP B-ABBREVIATION 
-activated O 
protein O 
kinase O 
( O 
AMPK O 
) O 
were O 
both O 
increased O 
following O 
dexamethasone B-TRIVIAL 
treatment O 
in O 
C2C12 O 
myotubes O 
. O 
By O 
contrast O 
, O 
dexamethasone B-TRIVIAL 
increased O 
β-oxidation O 
. O 
Selective O 
11β-HSD1 O 
inhibition O 
blocked O 
the O 
11-dehydrocorticosterone B-SYSTEMATIC 
( O 
11DHC B-SYSTEMATIC 
) O 
- O 
mediated O 
decrease O 
in O 
lipogenic O 
, O 
and O 
increase O 
in O 
lipolytic O 
gene O 
expression O 
. O 
Lipogenic O 
gene O 
expression O 
was O 
decreased O 
, O 
whilst O 
lipolytic O 
and O 
β-oxidative O 
genes O 
expression O 
increased O 
in O 
corticosterone B-TRIVIAL 
( O 
CORT B-ABBREVIATION 
) O 
and O 
11DHC B-SYSTEMATIC 
treated O 
wild O 
- O 
type O 
mice O 
, O 
and O 
CORT B-ABBREVIATION 
( O 
but O 
not O 
11DHC B-SYSTEMATIC 
) O 
treated O 
11β-HSD1(- O 
/ O 
- O 
) O 
mice O 
. O 
Furthermore O 
, O 
CORT B-ABBREVIATION 
and O 
11DHC B-SYSTEMATIC 
treated O 
wild O 
- O 
type O 
mice O 
, O 
and O 
CORT B-ABBREVIATION 
( O 
but O 
not O 
11DHC B-SYSTEMATIC 
) O 
treated O 
11β-HSD1(- O 
/ O 
- O 
) O 
mice O 
had O 
increased O 
p- O 
Ser B-FORMULA 
-79 O 
/ O 
218 O 
ACC1 O 
/ O 
2 O 
, O 
p- O 
Thr B-FORMULA 
-172 O 
AMPK O 
and O 
intramyocellular O 
diacylglyderide B-FAMILY 
content.In O 
summary O 
, O 
we O 
have O 
shown O 
that O 
glucocorticoids O 
have O 
potent O 
actions O 
upon O 
intramyocellular O 
lipid O 
homeostasis O 
by O 
decreasing O 
lipid O 
storage O 
, O 
increasing O 
lipid O 
mobilisation O 
and O 
utilisation O 
and O 
increasing O 
diacylglyderide B-FAMILY 
content O 
. O 
It O 
is O 
plausible O 
that O 
dysregulated O 
intramyocellular O 
lipid O 
metabolism O 
may O 
underpin O 
GC-induced O 
insulin O 
resistance O 
of O 
skeletal O 
muscle O 
. O 

studies O 
demonstrate O 
that O 
the O 
link O 
between O 
impaired O 
fetal O 
development O 
and O 
glucose B-TRIVIAL 
intolerance O 
in O 
later O 
life O 
is O 
exacerbated O 
by O 
postnatal O 
catch O 
- O 
up O 
growth O 
. O 
Maternal O 
protein O 
restriction O 
( O 
MPR O 
) O 
during O 
pregnancy O 
and O 
lactation O 
in O 
the O 
rat O 
has O 
been O 
previously O 
demonstrated O 
to O 
lead O 
to O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
in O 
adulthood O 
, O 
however O 
the O 
effects O 
of O 
protein O 
restoration O 
during O 
weaning O 
on O 
glucose B-TRIVIAL 
homeostasis O 
are O 
largely O 
unknown O 
. O 
Recent O 
in O 
vitro O 
studies O 
have O 
identified O 
that O 
the O 
Liver O 
X O 
Receptor-α O 
( O 
LXRα O 
) O 
maintains O 
glucose B-TRIVIAL 
homeostasis O 
by O 
inhibiting O 
critical O 
genes O 
involved O 
in O 
gluconeogenesis O 
including O 
G6Pase O 
, O 
11β-HSD1 O 
and O 
PEPCK O 
. O 
Therefore O 
, O 
we O 
hypothesized O 
MPR O 
with O 
postnatal O 
catch O 
- O 
up O 
growth O 
would O 
impair O 
LXRα O 
in O 
vivo O 
, O 
which O 
in O 
turn O 
would O 
lead O 
to O 
augmented O 
gluconeogenic O 
LXRα-target O 
gene O 
expression O 
and O 
glucose B-TRIVIAL 
intolerance O 
. O 
To O 
examine O 
this O 
hypothesis O 
, O 
pregnant O 
Wistar O 
rats O 
were O 
fed O 
a O 
control O 
( O 
20% O 
) O 
protein O 
diet O 
( O 
C O 
) O 
or O 
a O 
low O 
( O 
8% O 
) O 
protein O 
diet O 
during O 
pregnancy O 
and O 
switched O 
to O 
a O 
control O 
diet O 
at O 
birth O 
( O 
LP O 
) O 
. O 
At O 
four O 
months O 
, O 
the O 
LP O 
offspring O 
had O 
impaired O 
glucose B-TRIVIAL 
tolerance O 
. O 
In O 
additional O 
, O 
LP O 
offspring O 
had O 
decreased O 
LXRα O 
expression O 
, O 
while O 
hepatic O 
expression O 
of O 
11β-HSD1 O 
and O 
G6Pase O 
were O 
significantly O 
higher O 
. O 
This O 
was O 
concomitant O 
with O 
decreased O 
binding O 
of O 
LXRα O 
to O 
the O 
putative O 
LXRE O 
on O 
11β-HSD1 O 
and O 
G6Pase O 
. O 
Finally O 
, O 
we O 
demonstrated O 
that O 
the O 
acetylation O 
of O 
Histone O 
H3 O 
[ O 
K9,14 O 
] O 
surrounding O 
the O 
transcriptional O 
start O 
site O 
of O 
hepatic O 
LXRα O 
was O 
decreased O 
in O 
LP O 
offspring O 
, O 
suggesting O 
MPR-induced O 
epigenetic O 
silencing O 
of O 
the O 
LXRα O 
promoter O 
. O 
In O 
summary O 
, O 
our O 
study O 
demonstrates O 
for O 
the O 
first O 
time O 
the O 
important O 
role O 
of O 
LXRα O 
in O 
mediating O 
enhanced O 
hepatic O 
gluconeogenic O 
gene O 
expression O 
and O 
consequent O 
glucose B-TRIVIAL 
intolerance O 
in O 
adult O 
MPR O 
offspring O 
. O 

Triterpenoids I-FAMILY 
from O 
the O 
Mushroom O 
Naematoloma O 
fasciculare O 
. O 

our O 
continuing O 
search O 
for O 
structurally O 
interesting O 
and O 
bioactive O 
metabolites O 
from O 
Korean O 
wild O 
mushrooms O 
, O 
bioassay O 
- O 
guided O 
fractionation O 
and O 
a O 
chemical O 
investigation O 
of O 
the O 
MeOH B-FORMULA 
extracts O 
of O 
the O 
fruiting O 
bodies O 
of O 
the O 
mushroom O 
Naematoloma O 
fasciculare O 
resulted O 
in O 
the O 
isolation O 
of O 
four O 
new O 
lanostane B-FAMILY 
triterpenoids I-FAMILY 
( O 
1-4 O 
) O 
, O 
together O 
with O 
11 O 
known O 
compounds O 
( O 
5- O 
15 O 
) O 
. O 
The O 
structures O 
of O 
1-5 O 
were O 
determined O 
by O 
a O 
combination O 
of O 
1D O 
and O 
2D O 
NMR O 
and O 
HRMS O 
. O 
The O 
absolute O 
configuration O 
of O 
the O 
3-hydroxy-3-methylglutaryl B-SYSTEMATIC 
group O 
as O 
a O 
side O 
chain O 
in O 
1 O 
and O 
2 O 
was O 
determined O 
by O 
the O 
alkaline O 
methanolysis O 
method O 
. O 
The O 
full O 
NMR O 
data O 
assignment O 
of O 
the O 
known O 
compound O 
fasciculol B-TRIVIAL 
G I-TRIVIAL 
( O 
5 O 
) O 
is O 
reported O 
for O 
the O 
first O 
time O 
. O 
Compounds O 
1- O 
15 O 
were O 
tested O 
for O 
their O 
antiproliferative O 
activities O 
against O 
four O 
human O 
cancer O 
cell O 
lines O 
( O 
A549 O 
, O 
SK-OV-3 O 
, O 
SK-MEL-2 O 
, O 
and O 
HCT O 
- O 
15 O 
) O 
and O 
evaluated O 
for O 
their O 
inhibitory O 
effects O 
on O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
in O 
a O 
lipopolysaccharide-activated O 
murine O 
microglial O 
cell O 
line O 
. O 

Spectra O 
of O 
the O 
Hydroxyl B-SYSTEMATIC 
Radical O 
. O 

spectra O 
of O 
OH B-FORMULA 
and O 
its O 
isotopologues O 
have O 
been O 
precisely O 
measured O 
using O 
high O 
efficiency O 
Terahertz O 
( O 
THz O 
) O 
sources O 
. O 
The O 
measurements O 
are O 
compared O 
with O 
existing O 
data O 
and O 
are O 
useful O 
for O 
global O 
modeling O 
. O 
For O 
the O 
first O 
time O 
microwave O 
measurements O 
of O 
the O 
$\Lambda$-doubling O 
transitions O 
of O 
$^{17}$OH B-FORMULA 
isotopologue O 
are O 
combined O 
with O 
THz O 
data O 
successfully O 
. O 
Precise O 
rotational O 
, O 
fine O 
- O 
structure O 
and O 
hyperfine O 
structure O 
parameters O 
for O 
the O 
$^{17}$OH B-FORMULA 
isotopologue O 
are O 
reported O 
. O 
An O 
isotopically O 
independent O 
Dunham O 
model O 
for O 
all O 
isotopologues O 
of O 
$^2\Pi$ O 
OH B-FORMULA 
v O 
$ O 
< O 
$ O 
3 O 
is O 
presented O 
. O 

Antioxidative O 
Carbohydrate B-FAMILY 
Polymer O 
from O 
Enhydra O 
fluctuans O 
and O 
Its O 
Interaction O 
with O 
Bovine O 
Serum O 
Albumin O 
. O 

fluctuans O 
leaves O 
are O 
traditionally O 
sold O 
on O 
Indian O 
markets O 
for O 
various O 
health O 
benefits O 
. O 
However O 
no O 
phytochemical O 
study O 
on O 
its O 
high O 
molecular O 
weight O 
compound O 
has O 
so O 
far O 
been O 
performed O 
. O 
Chemical O 
, O 
chromatographic O 
, O 
ESI-TOF-MS O 
and O 
NMR O 
analyses O 
of O 
the O 
water O 
extracted O 
carbohydrate B-FAMILY 
polymer O 
( O 
CP O 
) O 
of O 
E O 
. O 
fluctuans O 
leaves O 
showed O 
the O 
presence O 
of O 
a O 
24 O 
kDa O 
arabinogalactan O 
having O 
a O 
( O 
1,3 O 
) O 
- O 
linked O 
β-D-Galp B-ABBREVIATION 
main O 
chain O 
, O 
substituted O 
at O 
O-6 O 
by O 
( O 
1,6 O 
) O 
- O 
linked O 
β-D-Galp B-ABBREVIATION 
side O 
chains O 
. O 
The O 
latter O 
residues O 
were O 
substituted O 
at O 
O-3 O 
by O 
(1,3)- O 
, O 
(1,5)- O 
and O 
( O 
1,3,5 O 
) O 
- O 
linked O 
α-L-Araf B-ABBREVIATION 
chains O 
, O 
and O 
nonreducing O 
end O 
- O 
units O 
of O 
α-L-Araf B-ABBREVIATION 
and O 
β-D-Galp B-ABBREVIATION 
. O 
This O 
polymer O 
contained O 
esterified B-FAMILY 
phenolic I-FAMILY 
acids I-FAMILY 
. O 
Biochemical O 
analysis O 
revealed O 
similarity O 
in O 
antioxidative O 
potential O 
between O 
the O 
identified O 
carbohydrate B-FAMILY 
polymer O 
and O 
known O 
standard O 
antioxidants O 
. O 
The O 
highly O 
branched O 
side O 
chains O 
and O 
the O 
phenolic B-FAMILY 
acid I-FAMILY 
residues O 
of O 
the O 
arabinogalactan O 
might O 
be O 
the O 
functional O 
sites O 
. O 
Fluorimetric O 
and O 
ultraviolet O 
spectrometric O 
analyses O 
showed O 
that O 
the O 
studied O 
carbohydrate B-FAMILY 
polymer O 
can O 
form O 
complex O 
with O 
bovine O 
serum O 
albumin O 
having O 
binding O 
constant O 
K=2.42×10(6) O 
/ O 
M O 
and O 
changes O 
its O 
microenvironment O 
. O 
Thus O 
, O 
traditional O 
aqueous O 
extraction O 
method O 
provides O 
a O 
carbohydrate B-FAMILY 
polymer O 
, O 
which O 
stimulates O 
a O 
fair O 
biological O 
response O 
: O 
this O 
could O 
represent O 
an O 
interesting O 
approach O 
in O 
phytotherapeutic O 
treatments O 
. O 

Barrier-All-Around O 
High O 
Electron O 
Mobility O 
Transistor O 
with O 
Planar O 
GaAs B-FORMULA 
Nanowire O 
Channel O 
. O 

quality O 
growth O 
of O 
planar O 
GaAs B-FORMULA 
nanowires O 
( O 
NWs O 
) O 
with O 
widths O 
as O 
small O 
as O 
35 O 
nm O 
is O 
realized O 
by O 
comprehensively O 
mapping O 
the O 
parameter O 
space O 
of O 
group O 
III O 
flow O 
, O 
V O 
/ O 
III O 
ratio O 
, O 
and O 
temperature O 
as O 
the O 
size O 
of O 
the O 
NWs O 
scale O 
down O 
. O 
Using O 
a O 
growth O 
mode O 
modulation O 
scheme O 
for O 
the O 
NW O 
and O 
thin O 
film O 
barrier O 
layers O 
, O 
monolithically O 
integrated O 
AlGaAs B-FORMULA 
barrier O 
- O 
all O 
- O 
around O 
planar O 
GaAs B-FORMULA 
NW O 
high O 
electron O 
mobility O 
transistors O 
( O 
NW-HEMTs O 
) O 
are O 
achieved O 
. O 
The O 
peak O 
extrinsic O 
transconductance O 
, O 
drive O 
current O 
, O 
and O 
effective O 
electron O 
velocity O 
are O 
550 O 
µS O 
/ O 
µm O 
, O 
435 O 
µA O 
/ O 
µm O 
, O 
and O 
~2.9 O 
×〖10〗^7 O 
cm O 
/ O 
s O 
, O 
respectively O 
, O 
at O 
2V O 
supply O 
voltage O 
with O 
a O 
gate O 
length O 
of O 
120 O 
nm O 
. O 
The O 
excellent O 
DC O 
performance O 
demonstrated O 
here O 
shows O 
the O 
potential O 
of O 
this O 
bottom O 
- O 
up O 
planar O 
NW O 
technology O 
for O 
low O 
- O 
power O 
high O 
- O 
speed O 
very O 
- O 
large O 
- O 
scale O 
- O 
integration O 
( O 
VLSI O 
) O 
circuits O 
. O 

of O 
serotonin B-TRIVIAL 
5-HT3 O 
receptors O 
in O 
the O 
modulation O 
of O 
noradrenergic O 
transmission O 
by O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
: O 
a O 
microdialysis O 
study O 
in O 
rat O 
brain O 
. O 

: O 
Selective O 
serotonin B-TRIVIAL 
reuptake O 
inhibitors O 
( O 
SSRIs O 
) O 
, O 
in O 
addition O 
to O 
being O 
able O 
to O 
enhance O 
serotonergic O 
neurotransmission O 
, O 
are O 
able O 
to O 
modulate O 
other O 
brain O 
systems O 
involved O 
in O 
depression O 
. O 
OBJECTIVES O 
: O 
This O 
study O 
evaluates O 
the O 
neurochemical O 
effect O 
of O 
the O 
SSRI O 
citalopram O 
on O 
brain O 
noradrenergic O 
activity O 
and O 
the O 
serotonin B-TRIVIAL 
receptor O 
involved O 
in O 
this O 
effect O 
. O 
METHODS O 
: O 
Dual O 
- O 
probe O 
microdialysis O 
in O 
the O 
locus O 
coeruleus O 
( O 
LC O 
) O 
and O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
was O 
performed O 
in O 
freely O 
awake O 
rats O 
. O 
RESULTS O 
: O 
Systemic O 
citalopram B-TRIVIAL 
( O 
10 O 
mg O 
/ O 
kg O 
, O 
i.p O 
. O 
) O 
increased O 
noradrenaline B-TRIVIAL 
( O 
nan O 
) O 
in O 
the O 
LC O 
( O 
E O 
max O 
= O 
141 O 
± O 
13 O 
% O 
) O 
and O 
simultaneously O 
decreased O 
nan O 
in O 
the O 
PFC O 
( O 
Emax O 
= O 
-46 O 
± O 
7 O 
% O 
) O 
. O 
In O 
the O 
local O 
presence O 
into O 
the O 
LC O 
of O 
the O 
α2-adrenoceptor O 
antagonist O 
RS79948 B-IDENTIFIER 
( O 
1 O 
μM O 
) O 
, O 
systemic O 
citalopram B-TRIVIAL 
increased O 
nan O 
in O 
the O 
LC O 
( O 
Emax O 
= O 
157 O 
± O 
25 O 
% O 
) O 
and O 
PFC O 
( O 
Emax O 
= O 
175 O 
± O 
24 O 
% O 
) O 
. O 
Local O 
citalopram B-TRIVIAL 
( O 
0.1-100 O 
μM O 
) O 
into O 
the O 
LC O 
induced O 
nan O 
increase O 
in O 
the O 
LC O 
( O 
Emax O 
= O 
210 O 
± O 
25 O 
% O 
) O 
and O 
decrease O 
in O 
the O 
PFC O 
( O 
Emax O 
= O 
-38 O 
± O 
9 O 
% O 
) O 
. O 
Local O 
LC O 
citalopram B-TRIVIAL 
effect O 
was O 
abolished O 
by O 
LC O 
presence O 
of O 
the O 
5-HT3 O 
receptor O 
antagonist O 
MDL72222 B-IDENTIFIER 
( O 
1 O 
μM O 
) O 
but O 
not O 
the O 
5-HT1 O 
/ O 
2 O 
receptor O 
antagonist O 
methiothepin B-TRIVIAL 
( O 
1 O 
μM O 
) O 
. O 
Systemic O 
citalopram B-TRIVIAL 
in O 
the O 
LC O 
presence O 
of O 
MDL72222 B-IDENTIFIER 
did O 
not O 
modify O 
nan O 
in O 
the O 
LC O 
but O 
increased O 
nan O 
in O 
the O 
PFC O 
( O 
Emax O 
= O 
158 O 
± O 
26 O 
% O 
) O 
. O 
Local O 
citalopram B-TRIVIAL 
into O 
the O 
PFC O 
enhanced O 
nan O 
( O 
Emax O 
= O 
376 O 
± O 
18 O 
% O 
) O 
in O 
the O 
area O 
, O 
which O 
was O 
prevented O 
by O 
MDL72222 B-IDENTIFIER 
. O 
CONCLUSIONS O 
: O 
The O 
SSRI O 
citalopram B-TRIVIAL 
modulates O 
central O 
noradrenergic O 
neurotransmission O 
by O 
activation O 
, O 
through O 
endogenous O 
serotonin B-TRIVIAL 
, O 
of O 
5-HT3 O 
receptors O 
expressed O 
in O 
the O 
somatodendritic O 
( O 
LC O 
) O 
and O 
terminal O 
( O 
PFC O 
) O 
areas O 
, O 
which O 
subsequently O 
promote O 
an O 
enhancement O 
of O 
local O 
nan O 
. O 
Therefore O 
, O 
5-HT3 O 
receptors O 
and O 
somatodendritic O 
α2-adrenoceptors O 
in O 
the O 
LC O 
play O 
an O 
important O 
role O 
in O 
the O 
global O 
effect O 
of O 
SSRIs O 
. O 

: O 
To O 
assess O 
self O 
- O 
management O 
in O 
patients O 
receiving O 
glucocorticoid O 
replacement O 
therapy O 
for O 
primary O 
or O 
secondary O 
adrenal O 
failure O 
before O 
and O 
6 O 
months O 
after O 
a O 
glucocorticoid O 
education O 
group O 
meeting O 
. O 
METHODS O 
: O 
All O 
patients O 
with O 
primary O 
or O 
secondary O 
adrenal O 
insufficiency O 
, O 
treated O 
at O 
the O 
department O 
of O 
Medicine O 
, O 
Division O 
of O 
Endocrinology O 
were O 
invited O 
by O 
their O 
endocrinologist O 
to O 
participate O 
in O 
a O 
three O 
- O 
hour O 
glucocorticoid O 
education O 
group O 
meeting O 
, O 
consisting O 
of O 
a O 
lecture O 
about O 
the O 
disease O 
and O 
glucocorticoid O 
doses O 
adjustments O 
in O 
case O 
of O 
stress O 
, O 
followed O 
by O 
an O 
instruction O 
how O 
to O 
inject O 
hydrocortisone B-TRIVIAL 
intramusculary O 
. O 
Finally O 
, O 
all O 
participants O 
could O 
practice O 
the O 
intramuscular O 
injection O 
and O 
discuss O 
their O 
experience O 
with O 
( O 
imminent O 
) O 
adrenal O 
crises O 
with O 
other O 
patients O 
and O 
the O 
health O 
care O 
providers O 
. O 
Two O 
weeks O 
before O 
the O 
meeting O 
and O 
6 O 
months O 
after O 
the O 
meeting O 
, O 
patients O 
were O 
asked O 
to O 
fill O 
out O 
a O 
questionnaire O 
about O 
how O 
they O 
would O 
act O 
in O 
6 O 
different O 
conditions O 
( O 
e.g O 
. O 
febrile O 
illness O 
or O 
vomiting O 
) O 
. O 
RESULTS O 
: O 
Of O 
the O 
405 O 
patients O 
who O 
were O 
invited O 
, O 
246 O 
patients O 
( O 
61% O 
) O 
participated O 
. O 
At O 
baseline O 
the O 
response O 
by O 
the O 
participants O 
on O 
the O 
questionnaire O 
was O 
100% O 
( O 
N=246 O 
) O 
and O 
at O 
follow O 
- O 
up O 
74% O 
( O 
N=183 O 
) O 
. O 
At O 
follow O 
- O 
up O 
, O 
significantly O 
more O 
participants O 
( O 
p= O 
< O 
0.005 O 
) O 
gave O 
the O 
correct O 
answers O 
how O 
to O 
act O 
in O 
the O 
different O 
situations O 
( O 
e.g O 
. O 
self O 
administration O 
of O 
a O 
glucocorticoid O 
injection O 
and O 
phone O 
contact O 
in O 
case O 
of O 
vomiting O 
/ O 
diarrhoea O 
without O 
fever O 
) O 
. O 
Moreover O 
, O 
the O 
use O 
of O 
self O 
- O 
management O 
tools O 
, O 
such O 
as O 
having O 
a O 
' O 
medicine O 
passport O 
( O 
travel O 
document O 
with O 
information O 
about O 
disease O 
and O 
medication O 
) O 
( O 
p=0.007 O 
) O 
or O 
SOS O 
medallion O 
( O 
p=0.0007 O 
) O 
' O 
increased O 
. O 
CONCLUSION O 
: O 
A O 
glucocorticoid O 
education O 
group O 
meeting O 
for O 
patients O 
with O 
adrenal O 
failure O 
seems O 
helpful O 
to O 
improve O 
self O 
- O 
management O 
and O 
proper O 
use O 
of O 
stress O 
- O 
related O 
glucocorticoid O 
dose O 
adjustment O 
. O 

report O 
an O 
on O 
- O 
chip O 
gradient O 
generator O 
that O 
has O 
been O 
designed O 
, O 
modelled O 
, O 
fabricated O 
, O 
and O 
characterized O 
to O 
facilitate O 
temporal O 
tuning O 
of O 
several O 
unique O 
gradients O 
in O 
parallel O 
for O 
multiple O 
applications O 
. O 
This O 
design O 
allows O 
for O 
steady O 
state O 
programming O 
of O 
the O 
intensities O 
across O 
multiple O 
orders O 
of O 
magnitude O 
while O 
producing O 
exponential O 
, O 
linear O 
, O 
and O 
logarithmic O 
gradient O 
profiles O 
. O 
The O 
magnitude O 
of O 
the O 
gradients O 
is O 
controlled O 
through O 
regulating O 
the O 
ratio O 
of O 
the O 
two O 
on O 
- O 
chip O 
flow O 
inlets O 
without O 
the O 
need O 
for O 
valves O 
or O 
other O 
active O 
mixers O 
. O 
On-chip O 
binding O 
of O 
biotin B-TRIVIAL 
by O 
a O 
fluorescent O 
streptavidin O 
complex O 
creates O 
a O 
diffusive O 
barrier O 
that O 
regulates O 
access O 
to O 
the O 
gradient O 
inlets O 
, O 
providing O 
a O 
second O 
orthogonal O 
mechanism O 
for O 
regulating O 
the O 
microgradient O 
intensities O 
. O 
The O 
device O 
is O 
also O 
characterized O 
using O 
an O 
on O 
- O 
chip O 
enzymatic O 
reaction O 
to O 
produce O 
an O 
array O 
of O 
tuneable O 
product O 
concentrations O 
within O 
the O 
various O 
microchannels O 
. O 

activity O 
against O 
various O 
gram O 
positive O 
bacteria O 
including O 
Staphylococcus O 
aureus O 
and O 
Enterococcus O 
was O 
ascertained O 
from O 
a O 
soil O 
- O 
isolated O 
microbial O 
strain O 
Streptomyces O 
sp O 
. O 
CS392 O 
. O 
The O 
antibiotic O 
activity O 
of O 
the O 
strain O 
was O 
maximized O 
by O 
using O 
a O 
dual O 
- O 
stage O 
, O 
multivariate O 
statistical O 
optimization O 
framework O 
based O 
on O 
the O 
response O 
surface O 
methodology O 
considering O 
a O 
lab O 
- O 
scale O 
fermentation O 
process O 
. O 
Multiple O 
nutrient O 
constituents O 
of O 
the O 
fermentation O 
broth O 
were O 
jointly O 
optimized O 
in O 
the O 
first O 
stage O 
, O 
while O 
the O 
fermentation O 
culture O 
conditions O 
were O 
optimized O 
in O 
the O 
subsequent O 
stage O 
. O 
Based O 
on O 
the O 
empirical O 
models O 
derived O 
from O 
the O 
dual O 
- O 
stage O 
statistical O 
optimization O 
framework O 
, O 
39.79 O 
% O 
of O 
cumulative O 
enhancement O 
in O 
the O 
antibiotic O 
activity O 
was O 
obtained O 
( O 
analytically O 
) O 
at O 
the O 
concurrent O 
optimal O 
settings O 
( O 
Optimal O 
nutrient O 
composition O 
for O 
the O 
first O 
stage O 
of O 
optimization O 
: O 
29.82 O 
glucose B-TRIVIAL 
, O 
7.6 O 
peptone O 
, O 
4.678 O 
MgCl2 B-FORMULA 
and O 
0.5005 O 
g O 
/ O 
l O 
casamino O 
acid O 
; O 
and O 
optimal O 
fermentation O 
condition O 
for O 
the O 
second O 
stage O 
of O 
optimization O 
: O 
incubation O 
period O 
47.55 O 
h O 
; O 
incubation O 
temperature O 
29.15 O 
°C O 
; O 
and O 
pH O 
8.36 O 
) O 
. O 
The O 
analytically O 
depicted O 
enhancement O 
in O 
the O 
antibiotic O 
activity O 
was O 
validated O 
experimentally O 
. O 

study O 
was O 
aimed O 
at O 
investigating O 
alterations O 
in O 
renal O 
and O 
hepatic O 
toxicity O 
induced O 
by O 
exposing O 
to O 
a O 
combination O 
of O 
three O 
solvents O 
, O 
namely O 
, O 
benzene B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
and O 
xylene B-FAMILY 
in O 
adult O 
mice O 
. O 
The O 
mice O 
were O 
divided O 
into O 
three O 
groups O 
( O 
control O 
, O 
low O 
- O 
dose O 
- O 
treated O 
( O 
450 O 
ppm O 
) O 
and O 
high O 
- O 
dose O 
( O 
675 O 
ppm O 
) O 
groups O 
) O 
using O 
randomization O 
methods O 
. O 
The O 
treated O 
groups O 
were O 
exposed O 
to O 
vapours O 
of O 
a O 
mixture O 
of O 
benzene B-SYSTEMATIC 
, O 
toluene B-TRIVIAL 
and O 
xylene B-FAMILY 
at O 
doses O 
of O 
450 O 
and O 
675 O 
ppm O 
, O 
for O 
6 O 
h O 
day(-1) O 
for O 
a O 
short O 
- O 
term O 
of O 
7-day O 
exposure O 
period O 
. O 
The O 
study O 
revealed O 
that O 
the O 
solvent O 
exposure O 
resulted O 
in O 
an O 
increase O 
in O 
the O 
weight O 
of O 
liver O 
and O 
kidney O 
as O 
compared O 
to O 
the O 
control O 
. O 
Biochemical O 
analyses O 
indicated O 
a O 
significant O 
decline O 
in O 
the O 
activities O 
of O 
superoxide B-TRIVIAL 
dismutase O 
and O 
catalase O 
in O 
both O 
the O 
treated O 
groups O 
, O 
with O 
concomitant O 
increase O 
in O 
lipid O 
peroxidation O 
. O 
Liver O 
aminotransferases O 
( O 
alanine B-TRIVIAL 
aminotransferase O 
and O 
aspartate B-TRIVIAL 
aminotransferase O 
) O 
were O 
elevated O 
with O 
significant O 
alterations O 
in O 
the O 
levels O 
of O 
protein O 
, O 
creatinine B-TRIVIAL 
and O 
cholesterol B-TRIVIAL 
in O 
these O 
tissues O 
upon O 
solvent O 
exposure O 
. O 
Correlated O 
with O 
these O 
changes O 
, O 
serum O 
thyroid O 
hormones O 
T3 O 
and O 
T4 O 
were O 
also O 
significantly O 
altered O 
. O 
This O 
study O 
, O 
therefore O 
, O 
demonstrates O 
that O 
inhalation O 
of O 
vapours O 
from O 
the O 
solvent O 
mixture O 
resulted O 
in O 
significant O 
dose O 
- O 
dependent O 
biochemical O 
and O 
functional O 
changes O 
in O 
the O 
vital O 
tissues O 
( O 
liver O 
and O 
kidney O 
) O 
studied O 
. O 
The O 
study O 
has O 
specific O 
relevance O 
since O 
humans O 
are O 
increasingly O 
being O 
exposed O 
to O 
such O 
solvents O 
due O 
to O 
increased O 
industrial O 
use O 
in O 
such O 
combinations O 
. O 

-conjugated O 
metabolite O 
of O 
ginger O 
component O 
[6]-shogaol B-TRIVIAL 
serves O 
as O 
a O 
carrier O 
of O 
[6]-shogaol B-TRIVIAL 
in O 
cancer O 
cells O 
and O 
in O 
mice O 
. O 

, O 
a O 
series O 
of O 
major O 
constituents O 
in O 
dried O 
ginger O 
( O 
Zingiber O 
officinale O 
) O 
, O 
show O 
high O 
anti-cancer O 
potencies O 
. O 
Previously O 
, O 
we O 
reported O 
that O 
a O 
major O 
metabolite O 
resulting O 
from O 
the O 
mercapturic B-TRIVIAL 
acid I-TRIVIAL 
pathway O 
, O 
5-cysteinyl-[6]-shogaol B-SYSTEMATIC 
( O 
M2 O 
) O 
, O 
showed O 
comparable O 
growth O 
inhibitory O 
effects O 
towards O 
cancer O 
cells O 
to O 
[6]-shogaol B-TRIVIAL 
( O 
6S O 
) O 
. O 
Here O 
we O 
probe O 
the O 
mechanism O 
by O 
which O 
M2 O 
exerts O 
its O 
bioactivity O 
. O 
We O 
utilized O 
a O 
series O 
of O 
chemical O 
stability O 
tests O 
in O 
conjunction O 
with O 
bioassays O 
to O 
show O 
that O 
thiol B-FAMILY 
-conjugates O 
display O 
chemopreventative O 
potency O 
by O 
acting O 
as O 
carriers O 
of O 
active O 
ginger O 
component O 
6S O 
. O 
M2 O 
chemical O 
degradation O 
to O 
6S O 
was O 
observed O 
in O 
an O 
environment O 
most O 
resembling O 
physiological O 
conditions O 
, O 
with O 
a O 
pH O 
of O 
7.4 O 
at O 
37°C O 
. O 
The O 
metabolic O 
profiles O 
of O 
M2 O 
in O 
cancer O 
cells O 
HCT-116 O 
and O 
H-1299 O 
resembled O 
those O 
of O 
6S O 
, O 
indicating O 
that O 
its O 
biotransformation O 
route O 
was O 
initiated O 
by O 
deconjugation O 
. O 
Further O 
, O 
the O 
presence O 
of O 
excess O 
glutathione B-TRIVIAL 
significantly O 
delayed O 
6S O 
and O 
M2 O 
metabolism O 
and O 
counteracted O 
cell O 
death O 
induced O 
by O 
6S O 
and O 
M2 O 
, O 
suggesting O 
that O 
increasing O 
available O 
free O 
thiols B-FAMILY 
exogenously O 
both O 
promoted O 
formation O 
of O 
5-glutathionyl-[6]-shogaol B-SYSTEMATIC 
( O 
M13 O 
) O 
and O 
inhibited O 
the O 
production O 
of O 
free O 
6S O 
from O 
M2 O 
deconjugation O 
, O 
resulting O 
in O 
delayed O 
6S O 
cell O 
entry O 
and O 
bioactivity O 
. O 
Given O 
the O 
chemopreventative O 
properties O 
of O 
M2 O 
and O 
our O 
observations O 
in O 
vitro O 
, O 
we O 
investigated O 
its O 
metabolism O 
in O 
mice O 
. O 
M2 O 
and O 
6S O 
showed O 
similar O 
metabolic O 
profiles O 
in O 
mouse O 
urine O 
and O 
fecal O 
samples O 
. O 
Six O 
new O 
thiol B-FAMILY 
-conjugated O 
metabolites O 
( O 
M16-M21 O 
) O 
, O 
together O 
with O 
previously O 
reported O 
ones O 
, O 
were O 
identified O 
by O 
LC O 
/ O 
MS O 
. O 
In O 
particular O 
, O 
the O 
increase O 
of O 
5-N-acetylcystenyl-[6]-shogaol B-SYSTEMATIC 
( O 
M5 O 
) O 
and O 
its O 
3-demethylated O 
product O 
( O 
M16 O 
) O 
abundance O 
in O 
mouse O 
feces O 
after O 
treatment O 
with O 
M2 O 
indicate O 
that O 
in O 
addition O 
to O 
acting O 
as O 
a O 
carrier O 
of O 
6S O 
, O 
M2 O 
is O 
also O 
directly O 
acetylated O 
to O 
M5 O 
, O 
which O 
is O 
further O 
demethylated O 
to O 
M16 O 
in O 
vivo O 
. O 
In O 
conclusion O 
, O 
cysteine B-TRIVIAL 
-conjugated O 
metabolite O 
of O 
[6]-shogaol B-TRIVIAL 
M2 O 
exerts O 
its O 
bioactivity O 
by O 
acting O 
as O 
a O 
carrier O 
of O 
6S O 
in O 
both O 
cancer O 
cells O 
and O 
in O 
mice O 
. O 

Self-Assembly O 
of O 
Chalcopyrite B-TRIVIAL 
Copper B-SYSTEMATIC 
Indium I-SYSTEMATIC 
Diselenide I-SYSTEMATIC 
Nanocrystals O 
into O 
Oriented O 
Films O 
. O 

, O 
which O 
is O 
one O 
of O 
the O 
highest O 
efficiency O 
thin O 
- O 
film O 
solar O 
cell O 
active O 
layer O 
materials O 
, O 
has O 
been O 
an O 
attractive O 
target O 
for O 
nanocrystal O 
synthesis O 
and O 
manipulation O 
. O 
Here O 
, O 
we O 
report O 
unprecedented O 
, O 
simultaneous O 
control O 
of O 
the O 
synthesis O 
and O 
self O 
- O 
assembly O 
behavior O 
of O 
CuInSe2 B-FORMULA 
nanocrystals O 
. O 
These O 
nanocrystals O 
are O 
solution O 
- O 
processable O 
, O 
monodisperse O 
tetragonal O 
bipyramids O 
that O 
exhibit O 
photoconductivity O 
and O 
self O 
- O 
assemble O 
into O 
crystallographically O 
oriented O 
thin O 
films O 
. O 
Structural O 
characterization O 
indicates O 
that O 
these O 
nanocrystals O 
are O 
tetragonal O 
phase O 
, O 
as O 
is O 
used O 
in O 
high O 
- O 
efficiency O 
, O 
second O 
- O 
generation O 
, O 
thin O 
- O 
film O 
solar O 
cells O 
. O 
Elemental O 
analysis O 
indicates O 
that O 
approximately O 
1 O 
: O 
1 O 
: O 
2 O 
Cu B-FORMULA 
/ O 
In B-FORMULA 
/ O 
Se B-FORMULA 
stoichiometry O 
can O 
be O 
achieved O 
, O 
and O 
that O 
the O 
elemental O 
composition O 
can O 
be O 
adjusted O 
from O 
copper B-SYSTEMATIC 
-rich O 
to O 
indium B-SYSTEMATIC 
-rich O 
with O 
reaction O 
time O 
. O 

, O 
a O 
new O 
protopanaxatriol B-TRIVIAL 
-type O 
saponin B-FAMILY 
with O 
inhibitory O 
activity O 
on O 
LPS-activated O 
NO B-FORMULA 
production O 
in O 
macrophage O 
RAW O 
264.7 O 
cells O 
from O 
the O 
roots O 
and O 
rhizomes O 
of O 
Panax O 
ginseng O 
. O 

new O 
dammarane B-TRIVIAL 
triterpene B-FAMILY 
saponin B-FAMILY 
named O 
ginsenjilinol B-TRIVIAL 
( O 
1 O 
) O 
was O 
isolated O 
from O 
the O 
roots O 
and O 
rhizomes O 
of O 
Panax O 
ginseng O 
C.A O 
. O 
Mey O 
. O 
, O 
together O 
with O 
two O 
known O 
saponins B-FAMILY 
ginsenoside B-TRIVIAL 
Rf I-TRIVIAL 
( O 
2 O 
) O 
and O 
ginsenoside B-TRIVIAL 
Re5 I-TRIVIAL 
( O 
= O 
panajaponol B-TRIVIAL 
A I-TRIVIAL 
, O 
3 O 
) O 
. O 
Based O 
on O 
IR O 
, O 
HR-ESI-MS O 
, O 
and O 
1D O 
as O 
well O 
as O 
2D O 
NMR O 
( O 
(1)H B-FORMULA 
- O 
(1)H B-FORMULA 
COSY O 
, O 
NOESY O 
, O 
HSQC O 
, O 
and O 
HMBC O 
) O 
spectral O 
data O 
, O 
the O 
chemical O 
structure O 
of O 
the O 
new O 
saponin B-FAMILY 
was O 
elucidated O 
as O 
3β,12β,20S,26-tetrahydroxydammar-24E-en-6α-O-β-d-glucopyranosyl-(1 B-SYSTEMATIC 
→ I-SYSTEMATIC 
2)-O-β-d-glucopyranoside I-SYSTEMATIC 
. O 
The O 
ability O 
of O 
the O 
isolated O 
saponins B-FAMILY 
to O 
inhibit O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
production O 
by O 
lipopolysaccharide-activated O 
RAW O 
264.7 O 
cells O 
was O 
also O 
assayed O 
. O 
All O 
of O 
the O 
isolated O 
saponins B-FAMILY 
exhibited O 
the O 
significant O 
activity O 
in O 
a O 
concentration O 
- O 
dependent O 
manner O 
at O 
concentrations O 
of O 
60-200 O 
μM O 
with O 
the O 
half O 
maximal O 
inhibitory O 
concentration O 
( O 
IC50 O 
) O 
values O 
of O 
70.96 O 
± O 
2.05 O 
μM O 
for O 
1 O 
, O 
74.14 O 
± O 
2.65 O 
μM O 
for O 
2 O 
, O 
and O 
79.83 O 
± O 
1.78 O 
μM O 
for O 
3 O 
, O 
respectively O 
, O 
whereas O 
indomethacin B-TRIVIAL 
had O 
an O 
IC50 O 
of O 
63.75 O 
± O 
3.33 O 
μM O 
as O 
a O 
positive O 
control O 
drug O 
. O 

new O 
cytotoxic O 
iridoid B-FAMILY 
esters I-FAMILY 
from O 
the O 
rhizomes O 
and O 
roots O 
of O 
Patrinia O 
heterophylla O 
Bunge O 
. O 

new O 
iridoid B-FAMILY 
esters I-FAMILY 
, O 
named O 
patriheterdoid B-NO_CLASS 
B I-NO_CLASS 
, I-NO_CLASS 
C I-NO_CLASS 
, O 
have O 
been O 
isolated O 
from O 
the O 
rhizomes O 
and O 
roots O 
of O 
Patrinia O 
heterophylla O 
Bunge O 
. O 
Their O 
structures O 
were O 
elucidated O 
by O 
extensive O 
spectroscopic O 
technologies O 
. O 
Together O 
with O 
patriheterdoid B-NO_CLASS 
B I-NO_CLASS 
, I-NO_CLASS 
C I-NO_CLASS 
, O 
two O 
known O 
analogues O 
have O 
been O 
isolated O 
and O 
identified O 
by O 
means O 
of O 
mass O 
spectrometry O 
and O 
(1)H B-FORMULA 
and O 
(13)C B-FORMULA 
NMR O 
spectrometry O 
. O 
These O 
compounds O 
showed O 
cytotoxic O 
activity O 
against O 
SGC-7901 O 
, O 
PC3 O 
cell O 
lines O 
. O 

- O 
inspired O 
, O 
Calcium B-SYSTEMATIC 
-free O 
Alginate O 
Hydrogels O 
with O 
Tunable O 
Physical O 
and O 
Mechanical O 
Properties O 
and O 
Improved O 
Biocompatibility O 
. O 

hydrogels O 
are O 
for O 
various O 
biomedical O 
applications O 
including O 
tissue O 
engineering O 
, O 
cell O 
therapy O 
, O 
and O 
drug O 
delivery O 
. O 
However O 
, O 
it O 
is O 
not O 
easy O 
to O 
control O 
swelling O 
, O 
or O 
viscoelastic O 
and O 
biophysical O 
properties O 
of O 
alginate O 
hydrogels O 
prepared O 
by O 
conventional O 
crosslinking O 
methods O 
( O 
ionic O 
interaction O 
using O 
divalent O 
cations O 
) O 
. O 
In O 
this O 
study O 
, O 
we O 
describe O 
a O 
bio O 
- O 
inspired O 
approach O 
for O 
preparing O 
divalent O 
ion O 
- O 
free O 
alginate O 
hydrogels O 
that O 
exhibit O 
tunable O 
physical O 
and O 
mechanical O 
properties O 
and O 
improved O 
biocompatibility O 
due O 
to O 
the O 
absence O 
of O 
cations O 
in O 
the O 
gel O 
matrices O 
. O 
We O 
conjugated O 
dopamine B-TRIVIAL 
, O 
a O 
minimalized O 
adhesive O 
motif O 
found O 
in O 
the O 
holdfast O 
pads O 
of O 
mussels O 
, O 
to O 
alginate O 
backbones O 
( O 
alginate- O 
catechol B-TRIVIAL 
) O 
and O 
the O 
tethered O 
catechols B-FAMILY 
underwent O 
oxidative O 
crosslinking O 
. O 
This O 
resulted O 
in O 
divalent O 
cation O 
- O 
free O 
alginate O 
hydrogels O 
. O 
The O 
swelling O 
ratios O 
and O 
moduli O 
of O 
the O 
alginate- O 
catechol B-TRIVIAL 
hydrogels O 
are O 
readily O 
tunable O 
, O 
which O 
is O 
difficult O 
to O 
achieve O 
in O 
ionic O 
bond O 
- O 
based O 
alginate O 
hydrogels O 
. O 
Furthermore O 
, O 
alginate- O 
catechol B-TRIVIAL 
hydrogels O 
enhanced O 
the O 
survival O 
of O 
various O 
human O 
primary O 
cells O 
including O 
stem O 
cells O 
in O 
the O 
three O 
- O 
dimensional O 
gel O 
matrix O 
, O 
indicating O 
that O 
intrinsic O 
cytotoxicity O 
caused O 
by O 
divalent O 
cations O 
becomes O 
negligible O 
when O 
employing O 
catechol B-TRIVIAL 
oxidation O 
for O 
alginate O 
crosslinking O 
. O 
The O 
inflammatory O 
response O 
in O 
vivo O 
was O 
also O 
significantly O 
attenuated O 
compared O 
to O 
conventional O 
alginate O 
hydrogels O 
with O 
calcium B-SYSTEMATIC 
crosslinking O 
. O 
This O 
biomimetic O 
approach O 
for O 
the O 
preparation O 
of O 
alginate O 
hydrogels O 
may O 
provide O 
a O 
novel O 
platform O 
technology O 
to O 
develop O 
tunable O 
, O 
functional O 
, O 
biocompatible O 
three O 
- O 
dimensional O 
scaffolds O 
for O 
tissue O 
engineering O 
and O 
cell O 
therapy O 
. O 

effects O 
of O 
anthranoids B-FAMILY 
from O 
Alternaria O 
sp O 
. O 
, O 
an O 
endophytic O 
fungus O 
in O 
a O 
Thai O 
medicinal O 
plant O 
Erythrina O 
variegata O 
. O 

fungi O 
are O 
known O 
as O 
a O 
prolific O 
source O 
for O 
the O 
discovery O 
of O 
structurally O 
interesting O 
and O 
biologically O 
active O 
secondary O 
metabolites O 
, O 
some O 
of O 
which O 
are O 
promising O 
candidates O 
for O 
drug O 
development O 
. O 
In O 
the O 
present O 
study O 
, O 
three O 
anthranoids B-FAMILY 
were O 
isolated O 
from O 
an O 
Alternaria O 
sp O 
. O 
endophytic O 
fungus O 
and O 
evaluated O 
for O 
their O 
antiangiogenic O 
activity O 
in O 
a O 
rat O 
aortic O 
sprouting O 
assay O 
, O 
an O 
ex O 
vivo O 
model O 
of O 
angiogenesis O 
. O 
Of O 
these O 
three O 
compounds O 
, O 
altersolanol B-FAMILY 
( O 
2 O 
) O 
was O 
further O 
characterized O 
and O 
found O 
to O 
show O 
a O 
promising O 
activity O 
in O 
ex O 
vivo O 
, O 
in O 
vitro O 
and O 
in O 
vivo O 
angiogenesis O 
asssays O 
. O 
Using O 
human O 
umbilical O 
vein O 
endothelial O 
cells O 
as O 
an O 
in O 
vitro O 
model O 
, O 
the O 
angiogenic O 
effect O 
of O 
2 O 
was O 
found O 
to O 
occur O 
via O 
suppression O 
of O 
all O 
three O 
main O 
functions O 
of O 
endothelial O 
cells O 
, O 
namely O 
proliferation O 
, O 
tube O 
formation O 
and O 
migration O 
. O 

stimulates O 
proliferation O 
and O 
differentiation O 
and O 
protects O 
against O 
cell O 
death O 
in O 
human O 
osteoblastic O 
MG-63 O 
cells O 
via O 
ER-dependent O 
MEK O 
/ O 
ERK O 
and O 
PI3K O 
/ O 
Akt O 
activation O 
. O 

, O 
the O 
main O 
isoflavone B-FAMILY 
glycoside I-FAMILY 
found O 
in O 
the O 
Chinese O 
herb O 
radix O 
of O 
Pueraria O 
lobata O 
( O 
Willd O 
. O 
) O 
Ohwi O 
, O 
has O 
received O 
increasing O 
attention O 
because O 
of O 
its O 
possible O 
role O 
in O 
the O 
prevention O 
of O 
osteoporosis O 
. O 
Previously O 
, O 
we O 
showed O 
that O 
puerarin B-TRIVIAL 
could O 
inhibit O 
the O 
bone O 
absorption O 
of O 
osteoclasts O 
and O 
promote O 
long O 
bone O 
growth O 
in O 
fetal O 
mouse O 
in O 
vitro O 
. O 
Further O 
study O 
confirmed O 
that O 
puerarin B-TRIVIAL 
stimulated O 
proliferation O 
and O 
differentiation O 
of O 
osteoblasts O 
in O 
rat O 
. O 
However O 
, O 
the O 
mechanisms O 
underlying O 
its O 
actions O 
on O 
human O 
bone O 
cells O 
have O 
not O 
been O 
well O 
defined O 
. O 
Here O 
we O 
show O 
that O 
puerarin B-TRIVIAL 
increases O 
proliferation O 
and O 
differentiation O 
and O 
opposes O 
cisplatin B-TRIVIAL 
-induced O 
apoptosis O 
in O 
human O 
osteoblastic O 
MG-63 O 
cells O 
containing O 
two O 
estrogen B-FAMILY 
receptor O 
( O 
ER O 
) O 
isoforms O 
. O 
Puerarin B-TRIVIAL 
promotes O 
proliferation O 
by O 
altering O 
cell O 
cycle O 
distribution O 
whereas O 
puerarin B-TRIVIAL 
-mediated O 
survival O 
may O 
be O 
associated O 
with O 
up O 
- O 
regulation O 
of O 
Bcl-xL O 
expression O 
. O 
Treatment O 
with O 
the O 
ER O 
antagonist O 
ICI B-IDENTIFIER 
182780 I-IDENTIFIER 
abolishes O 
the O 
above O 
actions O 
of O 
puerarin B-TRIVIAL 
on O 
osteoblast O 
- O 
derived O 
cells O 
. O 
Using O 
small O 
interfering O 
double O 
- O 
stranded O 
RNA O 
technology O 
, O 
we O 
further O 
demonstrate O 
that O 
the O 
effects O 
of O 
puerarin B-TRIVIAL 
on O 
proliferation O 
, O 
differentiation O 
and O 
survival O 
are O 
mediated O 
by O 
both O 
ERα O 
and O 
ERβ O 
. O 
Moreover O 
, O 
we O 
also O 
demonstrate O 
that O 
puerarin B-TRIVIAL 
functions O 
at O 
least O 
partially O 
through O 
activation O 
of O 
MEK O 
/ O 
ERK O 
and O 
PI3K O 
/ O 
Akt O 
signaling O 
. O 
This O 
agent O 
also O 
shows O 
much O 
weaker O 
effect O 
on O 
breast O 
epithelial O 
cell O 
growth O 
than O 
that O 
of O 
estrogen B-FAMILY 
. O 
Therefore O 
, O 
puerarin B-TRIVIAL 
will O 
be O 
a O 
promising O 
agent O 
that O 
prevents O 
or O 
retards O 
osteoporosis O 
. O 

Morphogenetic O 
Protein-7 O 
inhibits O 
silica B-TRIVIAL 
-induced O 
pulmonary O 
fibrosis O 
in O 
rats O 
. O 

morphogenetic O 
protein-7 O 
( O 
BMP-7 O 
) O 
has O 
been O 
shown O 
to O 
inhibit O 
liver O 
and O 
renal O 
fibrosis O 
in O 
in O 
vivo O 
and O 
in O 
vitro O 
studies O 
. O 
There O 
is O 
no O 
study O 
to O 
investigate O 
BMP-7's O 
role O 
in O 
the O 
development O 
of O 
pulmonary O 
fibrosis O 
induced O 
by O 
silica B-TRIVIAL 
. O 
In O 
the O 
current O 
study O 
, O 
we O 
used O 
the O 
rat O 
model O 
to O 
explore O 
the O 
potential O 
antifibrotic O 
role O 
of O 
BMP-7 O 
and O 
its O 
underlying O 
mechanism O 
in O 
silica B-TRIVIAL 
-induced O 
pulmonary O 
fibrosis O 
. O 
Sixty O 
Wistar O 
rats O 
were O 
randomly O 
assigned O 
into O 
three O 
groups O 
. O 
Control O 
group O 
received O 
saline O 
, O 
silica B-TRIVIAL 
group O 
received O 
silica B-TRIVIAL 
and O 
BMP-7 O 
treated O 
group O 
received O 
silica B-TRIVIAL 
and O 
BMP-7 O 
. O 
BMP-7 O 
was O 
administered O 
to O 
silica B-TRIVIAL 
-treated O 
rats O 
intraperitoneally O 
at O 
a O 
dose O 
of O 
300μg O 
/ O 
kg O 
/ O 
injection O 
from O 
day O 
8 O 
to O 
day O 
30 O 
every O 
other O 
day O 
. O 
After O 
the O 
animals O 
were O 
sacrificed O 
on O 
day O 
15 O 
and O 
30 O 
, O 
hydroxyproline B-SYSTEMATIC 
levels O 
, O 
the O 
protein O 
expressions O 
of O 
BMP O 
/ O 
Smad O 
and O 
TGF-β O 
/ O 
Smad O 
signaling O 
, O 
and O 
histopathology O 
in O 
lung O 
tissues O 
were O 
analyzed O 
. O 
The O 
hydroxyproline B-SYSTEMATIC 
contents O 
in O 
BMP-7 O 
treated O 
groups O 
were O 
significantly O 
lower O 
than O 
the O 
silica B-TRIVIAL 
groups O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
Histopathological O 
results O 
showed O 
BMP-7 O 
could O 
reduce O 
the O 
progression O 
of O 
silica B-TRIVIAL 
induced O 
fibrosis O 
. O 
Furthermore O 
, O 
the O 
expression O 
of O 
p-Smad1 O 
/ O 
5 O 
/ O 
8 O 
, O 
a O 
marker O 
of O 
BMP O 
/ O 
Smad O 
signaling O 
, O 
was O 
significantly O 
up O 
- O 
regulated O 
in O 
BMP-7 O 
treated O 
groups O 
( O 
P O 
< O 
0.05 O 
) O 
compared O 
with O 
the O 
silica B-TRIVIAL 
groups O 
. O 
On O 
the O 
contrary O 
, O 
the O 
expression O 
of O 
p-Smad2 O 
/ O 
3 O 
, O 
a O 
marker O 
for O 
TGF-β O 
/ O 
Smad O 
signaling O 
, O 
reduced O 
significantly O 
in O 
BMP-7 O 
- O 
treated O 
groups O 
compared O 
with O 
silica B-TRIVIAL 
groups O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
In O 
conclusion O 
, O 
the O 
pulmonary O 
fibrosis O 
induced O 
by O 
silica B-TRIVIAL 
in O 
rats O 
was O 
significantly O 
reduced O 
with O 
the O 
therapeutic O 
treatment O 
of O 
BMP-7 O 
. O 
The O 
antifibrotic O 
effect O 
of O 
BMP-7 O 
could O 
be O 
related O 
to O 
the O 
activation O 
of O 
BMP O 
/ O 
Smad O 
signaling O 
and O 
inhibition O 
of O 
TGF-β O 
/ O 
Smad O 
pathways O 
. O 

receptor O 
is O 
activated O 
by O 
naringin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
, O 
constituents O 
of O 
a O 
prokinetic O 
agent O 
Poncirus O 
fructus O 
. O 

RELEVANCE O 
: O 
Poncirus O 
fructus O 
( O 
PF O 
) O 
, O 
also O 
known O 
as O 
a O 
dried O 
immature O 
fruit O 
of O 
Poncirus O 
trifoliata O 
( O 
L O 
. O 
) O 
Raf O 
, O 
has O 
long O 
been O 
traditionally O 
used O 
for O 
the O 
various O 
gastrointestinal O 
disorders O 
in O 
Eastern O 
Asia O 
. O 
AIM O 
OF O 
STUDY O 
: O 
The O 
aqueous O 
extract O 
of O 
PF O 
( O 
PF-W O 
) O 
has O 
the O 
strong O 
prokinetic O 
effect O 
, O 
yet O 
the O 
underlying O 
mechanism O 
is O 
still O 
elusive O 
. O 
The O 
present O 
study O 
investigated O 
whether O 
PF-W O 
has O 
any O 
effect O 
on O 
motilin O 
receptor O 
or O 
ghrelin O 
receptor O 
, O 
since O 
these O 
receptors O 
enhance O 
intestinal O 
motility O 
when O 
activated O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
The O 
effect O 
of O 
PF-W O 
and O 
its O 
components O 
on O 
motilin O 
or O 
ghrelin O 
receptor O 
was O 
determined O 
by O 
calcium B-SYSTEMATIC 
imaging O 
and O 
whole O 
- O 
cell O 
patch O 
clamp O 
methods O 
. O 
RESULTS O 
: O 
PF-W O 
activates O 
the O 
ghrelin O 
receptor O 
, O 
but O 
not O 
the O 
motilin O 
receptor O 
, O 
resulting O 
in O 
a O 
transient O 
increase O 
of O 
intracellular O 
calcium B-SYSTEMATIC 
levels O 
. O 
Furthermore O 
, O 
among O 
various O 
constituents O 
of O 
PF O 
, O 
only O 
naringin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
evoked O 
the O 
intracellular O 
calcium B-SYSTEMATIC 
augmentation O 
via O 
the O 
ghrelin O 
receptor O 
. O 
Moreover O 
, O 
cortistatin-8 B-TRIVIAL 
- O 
a O 
ghrelin O 
receptor O 
inhibitor O 
- O 
specifically O 
blocked O 
naringin B-TRIVIAL 
- O 
and O 
naringenin B-TRIVIAL 
-induced O 
calcium B-SYSTEMATIC 
increases O 
. O 
In O 
addition O 
, O 
naringin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
induced O 
inward O 
currents O 
in O 
ghrelin O 
receptor O 
- O 
expressing O 
cells O 
under O 
whole O 
- O 
cell O 
patch O 
clamp O 
configuration O 
. O 
CONCLUSION O 
: O 
PF-W O 
activates O 
the O 
ghrelin O 
receptor O 
, O 
and O 
naringin B-TRIVIAL 
and O 
naringenin B-TRIVIAL 
are O 
key O 
constituents O 
responsible O 
for O 
the O 
activation O 
of O 
ghrelin O 
receptor O 
. O 
Therefore O 
, O 
the O 
present O 
study O 
suggests O 
that O 
the O 
ghrelin O 
receptor O 
is O 
a O 
molecular O 
entity O 
responsible O 
for O 
the O 
strong O 
prokinetic O 
activity O 
of O 
PF-W O 
. O 

a O 
good O 
taste O 
turns O 
bad O 
: O 
Neural O 
mechanisms O 
underlying O 
the O 
emergence O 
of O 
negative O 
affect O 
and O 
associated O 
natural O 
reward O 
devaluation O 
by O 
cocaine B-TRIVIAL 
. O 

important O 
feature O 
of O 
cocaine B-TRIVIAL 
addiction O 
in O 
humans O 
is O 
the O 
emergence O 
of O 
negative O 
affect O 
( O 
e.g O 
. O 
, O 
dysphoria O 
, O 
irritability O 
, O 
anhedonia O 
) O 
, O 
postulated O 
to O 
play O 
a O 
key O 
role O 
in O 
craving O 
and O 
relapse O 
. O 
Indeed O 
, O 
the O 
DSM-IV O 
recognizes O 
that O 
social O 
, O 
occupational O 
and O 
/ O 
or O 
recreational O 
activities O 
become O 
reduced O 
as O 
a O 
consequence O 
of O 
repeated O 
drug O 
use O 
where O 
previously O 
rewarding O 
experiences O 
( O 
e.g O 
. O 
, O 
food O 
, O 
job O 
, O 
family O 
) O 
become O 
devalued O 
as O 
the O 
addict O 
continues O 
to O 
seek O 
and O 
use O 
drug O 
despite O 
serious O 
negative O 
consequences O 
. O 
Here O 
, O 
research O 
in O 
the O 
Carelli O 
laboratory O 
is O 
reviewed O 
that O 
examined O 
neurobiological O 
mechanisms O 
that O 
may O 
underlie O 
these O 
processes O 
using O 
a O 
novel O 
animal O 
model O 
. O 
Oromotor O 
responses O 
( O 
taste O 
reactivity O 
) O 
were O 
examined O 
as O 
rats O 
learned O 
that O 
intraoral O 
infusion O 
of O 
a O 
sweet O 
( O 
e.g O 
. O 
, O 
saccharin B-TRIVIAL 
) O 
predicts O 
impending O 
but O 
delayed O 
access O 
to O 
cocaine B-TRIVIAL 
self O 
- O 
administration O 
. O 
We O 
showed O 
that O 
rats O 
exhibit O 
aversive O 
taste O 
reactivity O 
( O 
i.e O 
. O 
, O 
gapes O 
/ O 
rejection O 
responses O 
) O 
during O 
infusion O 
of O 
the O 
sweet O 
paired O 
with O 
impending O 
cocaine B-TRIVIAL 
, O 
similar O 
to O 
aversive O 
responses O 
observed O 
during O 
infusion O 
of O 
quinine B-TRIVIAL 
, O 
a O 
bitter O 
tastant O 
. O 
Critically O 
, O 
the O 
expression O 
of O 
this O 
pronounced O 
aversion O 
to O 
the O 
sweet O 
predicted O 
the O 
subsequent O 
motivation O 
to O 
self O 
- O 
administer O 
cocaine B-TRIVIAL 
. O 
Electrophysiology O 
studies O 
show O 
that O 
this O 
shift O 
in O 
palatability O 
corresponds O 
to O 
an O 
alteration O 
in O 
nucleus O 
accumbens O 
( O 
NAc O 
) O 
cell O 
firing O 
; O 
neurons O 
that O 
previously O 
responded O 
with O 
inhibition O 
during O 
infusion O 
of O 
the O 
palatable O 
sweet O 
shifted O 
to O 
excitatory O 
activity O 
during O 
infusion O 
of O 
the O 
cocaine B-TRIVIAL 
-devalued O 
tastant O 
. O 
This O 
excitatory O 
response O 
profile O 
is O 
typically O 
observed O 
during O 
infusion O 
of O 
quinine B-TRIVIAL 
, O 
indicating O 
that O 
the O 
once O 
palatable O 
sweet O 
becomes O 
aversive O 
following O 
its O 
association O 
with O 
impending O 
but O 
delayed O 
cocaine B-TRIVIAL 
, O 
and O 
NAc O 
neurons O 
encode O 
this O 
aversive O 
state O 
. O 
We O 
also O 
review O 
electrochemical O 
studies O 
showing O 
a O 
shift O 
( O 
from O 
increase O 
to O 
decrease O 
) O 
in O 
rapid O 
NAc O 
dopamine B-TRIVIAL 
release O 
during O 
infusion O 
of O 
the O 
cocaine B-TRIVIAL 
-paired O 
tastant O 
as O 
the O 
aversive O 
state O 
developed O 
, O 
again O 
, O 
resulting O 
in O 
responses O 
similar O 
to O 
quinine B-TRIVIAL 
infusion O 
. O 
Collectively O 
, O 
our O 
findings O 
suggest O 
that O 
cocaine B-TRIVIAL 
-conditioned O 
cues O 
elicit O 
a O 
cocaine B-TRIVIAL 
-need O 
state O 
that O 
is O 
aversive O 
, O 
is O 
encoded O 
by O 
a O 
distinct O 
subset O 
of O 
NAc O 
neurons O 
and O 
rapid O 
dopamine B-TRIVIAL 
signaling O 
, O 
and O 
promotes O 
cocaine B-TRIVIAL 
-seeking O 
behavior O 
. O 
Finally O 
, O 
we O 
present O 
data O 
showing O 
that O 
experimentally O 
induced O 
abstinence O 
( O 
30 O 
days O 
) O 
exacerbates O 
this O 
natural O 
reward O 
devaluation O 
by O 
cocaine B-TRIVIAL 
, O 
and O 
this O 
effect O 
is O 
correlated O 
with O 
a O 
greater O 
motivation O 
to O 
lever O 
press O 
during O 
extinction O 
. O 
Dissecting O 
the O 
neural O 
mechanisms O 
underlying O 
these O 
detrimental O 
consequences O 
of O 
addiction O 
is O 
critical O 
since O 
it O 
may O 
lead O 
to O 
novel O 
treatments O 
that O 
ameliorate O 
negative O 
affective O 
states O 
associated O 
with O 
drug O 
use O 
and O 
decrease O 
the O 
drive O 
( O 
craving O 
) O 
for O 
the O 
drug O 
. O 
This O 
article O 
is O 
part O 
of O 
a O 
Special O 
Issue O 
entitled O 
' O 
NIDA O 
40th O 
Anniversary O 
Issue O 
' O 
. O 

Function O 
During O 
Nicotine B-TRIVIAL 
Withdrawal O 
: O 
Implications O 
for O 
Nicotine B-TRIVIAL 
Dependence O 
Treatment O 
. O 

withdrawal O 
is O 
associated O 
with O 
deficits O 
in O 
neurocognitive O 
function O 
including O 
sustained O 
attention O 
, O 
working O 
memory O 
, O 
and O 
response O 
inhibition O 
. O 
Several O 
convergent O 
lines O 
of O 
evidence O 
suggest O 
that O 
these O 
deficits O 
may O 
represent O 
a O 
core O 
dependence O 
phenotype O 
and O 
a O 
target O 
for O 
treatment O 
development O 
efforts O 
. O 
A O 
better O 
understanding O 
of O 
the O 
mechanisms O 
underlying O 
withdrawal O 
- O 
related O 
cognitive O 
deficits O 
may O 
lead O 
to O 
improve O 
nicotine B-TRIVIAL 
dependence O 
treatment O 
. O 
We O 
begin O 
with O 
an O 
overview O 
of O 
the O 
neurocognitive O 
effects O 
of O 
withdrawal O 
in O 
rodent O 
and O 
human O 
models O 
, O 
followed O 
by O 
discussion O 
of O 
the O 
neurobehavioral O 
mechanisms O 
that O 
are O 
thought O 
to O 
underlie O 
these O 
effects O 
. O 
We O 
then O 
review O 
individual O 
differences O 
in O 
withdrawal O 
- O 
related O 
neurocognitive O 
effects O 
including O 
genetics O 
, O 
gender O 
, O 
and O 
psychiatric O 
comorbidity O 
. O 
We O 
conclude O 
with O 
a O 
discussion O 
of O 
the O 
implications O 
of O 
this O 
research O 
for O 
developing O 
improved O 
therapies O 
, O 
both O 
pharmacotherapy O 
and O 
behavioral O 
treatments O 
, O 
that O 
target O 
cognitive O 
symptoms O 
of O 
nicotine B-TRIVIAL 
withdrawal O 
. O 

, O 
synthesis O 
and O 
biological O 
evaluation O 
of O 
indeno[1,2-d]thiazole B-SYSTEMATIC 
derivatives O 
as O 
potent O 
histone O 
deacetylase O 
inhibitors O 
. O 

indeno[1,2-d]thiazole B-FAMILY 
hydroxamic I-FAMILY 
acids I-FAMILY 
were O 
designed O 
, O 
synthesized O 
, O 
and O 
evaluated O 
for O 
histone O 
deacetylases O 
( O 
HDACs O 
) O 
inhibition O 
and O 
antiproliferative O 
activities O 
on O 
tumor O 
cell O 
lines O 
. O 
Most O 
of O 
the O 
tested O 
compounds O 
exhibited O 
HDAC O 
inhibition O 
and O 
antiproliferative O 
activity O 
against O 
both O 
MCF7 O 
and O 
HCT116 O 
cells O 
with O 
GI50 O 
values O 
in O 
the O 
sub O 
- O 
micromolar O 
range O 
. O 
Among O 
them O 
, O 
compound O 
6o O 
showed O 
good O 
inhibitory O 
activity O 
against O 
pan-HDAC O 
with O 
IC50 O 
value O 
of O 
0.14μM O 
and O 
significant O 
growth O 
inhibition O 
on O 
MCF7 O 
and O 
HCT116 O 
cells O 
with O 
GI50 O 
values O 
of O 
0.869 O 
and O 
0.535μM O 
, O 
respectively O 
. O 

of O 
2'-α-fluorine B-SYSTEMATIC 
modified O 
nucleoside B-FAMILY 
phosphonates I-FAMILY 
as O 
potential O 
inhibitors O 
of O 
HCV O 
polymerase O 
. O 

phosphonate I-FAMILY 
analogues O 
containing O 
2'-α-fluoro B-SYSTEMATIC 
modifications O 
were O 
synthesized O 
and O 
their O 
potency O 
evaluated O 
against O 
HCV O 
RNA O 
polymerase O 
. O 
The O 
diphosphophosphonate B-SYSTEMATIC 
( O 
triphosphate B-SYSTEMATIC 
equivalent O 
) O 
adenine B-TRIVIAL 
and O 
cytidine B-TRIVIAL 
analogues O 
displayed O 
potent O 
inhibition O 
of O 
the O 
HCV O 
polymerase O 
in O 
the O 
range O 
of O 
1.9-2.1μM O 
, O 
but O 
only O 
modest O 
cell O 
- O 
based O 
activity O 
in O 
the O 
HCV O 
replicon O 
. O 
Pro O 
- O 
drugs O 
of O 
the O 
parent O 
nucleoside B-FAMILY 
phosphonates I-FAMILY 
improved O 
the O 
cell O 
- O 
based O 
activity O 
. O 

and O 
ionophoric O 
activities O 
of O 
functionalized O 
bis(choloyl) B-FAMILY 
conjugates O 
with O 
a O 
rigid O 
core O 
. O 

bis(choloyl) B-FAMILY 
conjugates O 
bearing O 
a O 
rigid O 
p-phenylenediamine B-SYSTEMATIC 
/ O 
p-bis(aminomethyl)benzene B-SYSTEMATIC 
linker O 
and O 
amino B-FAMILY 
/ O 
acetamido B-FAMILY 
groups O 
were O 
synthesized O 
, O 
and O 
fully O 
characterized O 
on O 
the O 
basis O 
of O 
(1)H B-FORMULA 
NMR O 
, O 
ESI-MS O 
and O 
HRMS O 
. O 
Their O 
ionophoric O 
activities O 
were O 
investigated O 
by O 
means O 
of O 
pH O 
discharge O 
assay O 
. O 
The O 
results O 
indicate O 
that O 
these O 
conjugates O 
exhibit O 
potent O 
ionophoric O 
activities O 
across O 
egg O 
- O 
yolk O 
l-α-phosphatidylcholine B-FAMILY 
( O 
EYPC O 
) O 
- O 
based O 
liposomal O 
membranes O 
, O 
via O 
a O 
cation O 
/ O 
proton O 
antiport O 
mechanism O 
. O 
They O 
show O 
moderate O 
ion O 
selectivity O 
among O 
alkali O 
metal O 
ions O 
. O 
Of O 
the O 
three O 
conjugates O 
, O 
the O 
ones O 
having O 
amino B-FAMILY 
groups O 
transport O 
alkali O 
metal O 
ions O 
in O 
the O 
order O 
of O 
Na(+) B-FORMULA 
> O 
Li(+) B-FORMULA 
> O 
K(+) B-FORMULA 
≈ O 
Rb(+) B-FORMULA 
≈ O 
Cs(+) B-FORMULA 
, O 
whereas O 
the O 
one O 
having O 
acetamido B-FAMILY 
groups O 
functions O 
in O 
the O 
order O 
of O 
Li(+) B-FORMULA 
> O 
Na(+) B-FORMULA 
> O 
K(+) B-FORMULA 
≈ O 
Rb(+) B-FORMULA 
≈ O 
Cs(+) B-FORMULA 
. O 

induces O 
protein O 
ubiquitination O 
and O 
inhibits O 
proteasome O 
activity O 
during O 
cardiotoxicity O 
. O 

-induced O 
cardiotoxicity O 
is O 
a O 
clinically O 
complex O 
syndrome O 
that O 
leads O 
to O 
substantial O 
morbidity O 
and O 
mortality O 
for O 
cancer O 
survivors O 
. O 
Despite O 
several O 
years O 
of O 
research O 
, O 
the O 
underlying O 
molecular O 
mechanisms O 
remain O 
largely O 
undefined O 
and O 
thus O 
effective O 
therapies O 
to O 
manage O 
this O 
condition O 
are O 
currently O 
non-existent O 
. O 
This O 
study O 
therefore O 
aimed O 
to O 
determine O 
the O 
contribution O 
of O 
the O 
ubiquitin O 
- O 
proteasome O 
pathway O 
( O 
UPP O 
) O 
and O 
endoplasmic O 
reticulum O 
(ER)-stress O 
within O 
this O 
context O 
. O 
Cardiotoxicity O 
was O 
induced O 
with O 
the O 
use O 
of O 
doxorubicin B-TRIVIAL 
( O 
DXR B-ABBREVIATION 
) O 
in O 
H9C2 O 
rat O 
cardiomyoblasts O 
( O 
3μM O 
) O 
for O 
24hrs O 
, O 
whereas O 
the O 
tumour O 
- O 
bearing O 
GFP-LC3 O 
mouse O 
model O 
was O 
treated O 
with O 
a O 
cumulative O 
dose O 
of O 
20mg O 
/ O 
kg O 
. O 
Markers O 
for O 
proteasome O 
- O 
specific O 
protein O 
degradation O 
were O 
significantly O 
upregulated O 
in O 
both O 
models O 
following O 
DXR B-ABBREVIATION 
treatment O 
, O 
however O 
proteasome O 
activity O 
was O 
lost O 
. O 
Moreover O 
, O 
ER-stress O 
as O 
assessed O 
by O 
increased O 
ER O 
load O 
was O 
considerably O 
augmented O 
( O 
in O 
vitro O 
) O 
with O 
modest O 
binding O 
of O 
DXR B-ABBREVIATION 
with O 
ER O 
. O 
These O 
results O 
suggest O 
that O 
DXR B-ABBREVIATION 
induces O 
intrinsic O 
activation O 
of O 
the O 
UPP O 
and O 
ER O 
stress O 
which O 
ultimately O 
contributes O 
to O 
dysfunction O 
of O 
the O 
myocardium O 
during O 
this O 
phenomenon O 
. O 

chalcones B-FAMILY 
and O 
sulfonamides B-FAMILY 
as O 
new O 
classes O 
of O 
Yersinia O 
enterocolitica O 
YopH O 
tyrosine B-TRIVIAL 
phosphatase O 
inhibitors O 
. O 

plays O 
a O 
relevant O 
role O 
in O 
three O 
pathogenic O 
species O 
of O 
Yersinia O 
. O 
Due O 
to O 
its O 
importance O 
in O 
the O 
prevention O 
of O 
the O 
inflammatory O 
response O 
of O 
the O 
host O 
, O 
this O 
enzyme O 
has O 
become O 
a O 
valid O 
target O 
for O 
the O 
identification O 
and O 
development O 
of O 
new O 
inhibitors O 
. O 
In O 
this O 
work O 
, O 
an O 
in O 
- O 
house O 
library O 
of O 
283 O 
synthetic O 
compounds O 
was O 
assayed O 
against O 
recombinant O 
YopH O 
from O 
Yersinia O 
enterocolitica O 
. O 
From O 
these O 
, O 
four O 
chalcone B-FAMILY 
derivatives O 
and O 
one O 
sulfonamide B-SYSTEMATIC 
were O 
identified O 
for O 
the O 
first O 
time O 
as O 
competitive O 
inhibitors O 
of O 
YopH O 
with O 
binding O 
affinity O 
in O 
the O 
low O 
micromolar O 
range O 
. O 
Molecular O 
modeling O 
investigations O 
indicated O 
that O 
the O 
new O 
inhibitors O 
showed O 
similar O 
binding O 
modes O 
, O 
establishing O 
polar O 
and O 
hydrophobic O 
contacts O 
with O 
key O 
residues O 
of O 
the O 
YopH O 
binding O 
site O 
. O 

- O 
responsive O 
surface O 
erosion O 
of O 
poly(ethylene B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
) I-SYSTEMATIC 
for O 
controlled O 
drug O 
release O 
. O 

esterase O 
( O 
CE O 
) O 
induced O 
surface O 
erosion O 
of O 
poly(ethylene B-SYSTEMATIC 
carbonate I-SYSTEMATIC 
) I-SYSTEMATIC 
( O 
PEC B-ABBREVIATION 
) O 
and O 
drug O 
release O 
from O 
PEC B-ABBREVIATION 
under O 
mild O 
physiological O 
environment O 
was O 
investigated O 
. O 
The O 
degradation O 
process O 
was O 
monitored O 
by O 
changes O 
of O 
mass O 
and O 
molecular O 
weight O 
( O 
MW O 
) O 
and O 
surface O 
morphology O 
of O 
polymer O 
films O 
. O 
During O 
the O 
whole O 
period O 
of O 
degradation O 
, O 
MW O 
of O 
PEC B-ABBREVIATION 
was O 
unchanged O 
. O 
Water O 
uptake O 
of O 
the O 
polymer O 
was O 
only O 
2.8 O 
and O 
0.2% O 
for O 
PEC B-ABBREVIATION 
with O 
the O 
MW O 
of O 
200 O 
kDa O 
( O 
PEC B-ABBREVIATION 
200 O 
) O 
and O 
PEC B-ABBREVIATION 
with O 
the O 
MW O 
of O 
41 O 
kDa O 
( O 
PEC B-ABBREVIATION 
41 O 
) O 
, O 
respectively O 
. O 
Degradation O 
of O 
less O 
hydrophilic O 
PEC B-ABBREVIATION 
41 O 
with O 
higher O 
density O 
was O 
slower O 
than O 
that O 
of O 
PEC B-ABBREVIATION 
200 O 
. O 
By O 
this O 
mechanism O 
, O 
CE-responsive O 
drug O 
in O 
vitro O 
release O 
from O 
PEC B-ABBREVIATION 
in O 
situ O 
forming O 
depots O 
( O 
ISFD O 
) O 
was O 
conducted O 
successfully O 
. O 
As O 
expected O 
, O 
less O 
bovine O 
serum O 
albumin O 
( O 
BSA O 
) O 
was O 
released O 
from O 
PEC B-ABBREVIATION 
41 O 
compared O 
with O 
that O 
of O 
PEC B-ABBREVIATION 
200 O 
in O 
the O 
same O 
time O 
period O 
. O 
In O 
conclusion O 
, O 
this O 
work O 
enabled O 
the O 
in O 
vitro O 
drug O 
release O 
evaluation O 
of O 
existing O 
PEC B-ABBREVIATION 
devices O 
and O 
implied O 
a O 
new O 
candidate O 
for O 
the O 
development O 
of O 
enzyme O 
- O 
responsive O 
systems O 
. O 

this O 
work O 
, O 
the O 
neuroregenerative O 
potentials O 
of O 
microencapsulated O 
VEGF O 
, O 
GDNF O 
and O 
their O 
combination O 
on O 
a O 
severely O 
lesioned O 
rat O 
model O 
were O 
compared O 
with O 
the O 
aim O 
of O 
developing O 
a O 
new O 
strategy O 
to O 
treat O 
advanced O 
stages O 
of O 
Parkinson's O 
disease O 
. O 
Both O 
neurotrophic O 
factors O 
were O 
separately O 
encapsulated O 
into O 
polymeric O 
microspheres O 
( O 
MS O 
) O 
to O 
obtain O 
a O 
continuous O 
drug O 
release O 
over O 
time O 
. O 
The O 
regenerative O 
effects O 
of O 
these O 
growth O 
factors O 
were O 
evaluated O 
using O 
a O 
rotation O 
behaviour O 
test O 
and O 
quantified O 
by O 
the O 
number O 
of O 
surviving O 
TH+ O 
cells O 
. O 
The O 
biological O 
activities O 
of O 
encapsulated O 
vascular O 
endothelial O 
growth O 
factor O 
( O 
VEGF O 
) O 
and O 
glial O 
cell O 
line O 
derived O 
neurotrophic O 
factor O 
( O 
GDNF O 
) O 
were O 
investigated O 
in O 
HUVEC O 
and O 
PC12 O 
cells O 
, O 
respectively O 
. O 
The O 
treatment O 
of O 
6-OHDA B-SYSTEMATIC 
-lesioned O 
rats O 
with O 
GDNF O 
microspheres O 
and O 
with O 
both O 
VEGF O 
and O 
GDNF O 
microspheres O 
resulted O 
in O 
improved O 
results O 
in O 
the O 
rotation O 
behaviour O 
test O 
. O 
Both O 
groups O 
also O 
showed O 
higher O 
levels O 
of O 
neuroregeneration O 
/ O 
neuroreparation O 
in O 
the O 
substantia O 
nigra O 
than O 
the O 
control O 
group O 
did O 
. O 
These O 
results O 
were O 
confirmed O 
by O 
the O 
pronounced O 
TH O 
+ O 
neuron O 
recovery O 
in O 
the O 
group O 
receiving O 
VEGF O 
+ O 
GDNF-MS O 
, O 
demonstrating O 
regenerative O 
effects O 
. O 

- O 
assisted O 
extraction O 
of O 
Na B-FORMULA 
and O 
K B-FORMULA 
from O 
swine O 
feed O 
and O 
its O 
application O 
in O 
a O 
digestibility O 
assay O 
: O 
A O 
green O 
analytical O 
procedure O 
. O 

study O 
is O 
aimed O 
to O 
evaluate O 
the O 
efficiency O 
of O 
ultrasound O 
- O 
assisted O 
extraction O 
( O 
UAE O 
) O 
as O 
a O 
simple O 
strategy O 
focused O 
on O 
sample O 
preparation O 
for O 
metal O 
determination O 
in O 
biological O 
samples O 
. O 
The O 
extraction O 
of O 
sodium B-SYSTEMATIC 
and O 
potassium B-SYSTEMATIC 
extraction O 
was O 
carried O 
out O 
from O 
swine O 
feed O 
followed O 
by O 
determination O 
of O 
the O 
concentration O 
of O 
these O 
metals O 
by O 
flame O 
atomic O 
emission O 
spectrometry O 
( O 
FAES O 
) O 
. O 
The O 
experiment O 
was O 
performed O 
to O 
cover O 
the O 
study O 
of O 
the O 
variables O 
influencing O 
the O 
extraction O 
process O 
and O 
its O 
optimal O 
conditions O 
( O 
sample O 
mass O 
, O 
particle O 
size O 
, O 
acid O 
concentration O 
, O 
sonication O 
time O 
and O 
ultrasound O 
power O 
) O 
; O 
the O 
determination O 
of O 
these O 
analytical O 
characteristics O 
and O 
method O 
validation O 
using O 
certified O 
reference O 
material O 
; O 
and O 
the O 
analysis O 
of O 
pre O 
- O 
starter O 
diets O 
. O 
The O 
optimal O 
conditions O 
established O 
conditions O 
were O 
as O 
follows O 
: O 
mass O 
: O 
100mg O 
, O 
particle O 
size O 
: O 
< O 
60μm O 
, O 
acid O 
concentration O 
: O 
0.10molL(-1) O 
HCl B-FORMULA 
, O 
sonication O 
time O 
: O 
50s O 
and O 
ultrasound O 
power O 
: O 
102W O 
. O 
The O 
proposed O 
method O 
( O 
UAE O 
) O 
was O 
applied O 
in O 
digestibility O 
assays O 
of O 
those O 
nutrients O 
present O 
in O 
different O 
piglet O 
pre O 
- O 
starter O 
feeds O 
and O 
their O 
results O 
proved O 
to O 
be O 
compatible O 
with O 
those O 
obtained O 
from O 
mineralized O 
samples O 
( O 
P O 
< O 
0.05 O 
) O 
. O 
The O 
ultrasound O 
extraction O 
method O 
was O 
demonstrated O 
to O 
be O 
an O 
excellent O 
alternative O 
for O 
handless O 
sampling O 
and O 
operational O 
costs O 
and O 
the O 
method O 
also O 
has O 
the O 
advantage O 
of O 
does O 
not O 
generating O 
toxic O 
residues O 
that O 
may O 
negatively O 
affect O 
human O 
health O 
and O 
contaminate O 
the O 
environment O 
. O 

describe O 
a O 
generic O 
microfluidic O 
interface O 
design O 
that O 
allows O 
the O 
connection O 
of O 
microfluidic O 
chips O 
to O 
established O 
industrial O 
liquid O 
handling O 
stations O 
( O 
LHS O 
) O 
. O 
A O 
molding O 
tool O 
has O 
been O 
designed O 
that O 
allows O 
fabrication O 
of O 
low O 
- O 
cost O 
disposable O 
polydimethylsiloxane B-SYSTEMATIC 
( O 
PDMS B-ABBREVIATION 
) O 
chips O 
with O 
interfaces O 
that O 
provide O 
convenient O 
and O 
reversible O 
connection O 
of O 
the O 
microfluidic O 
chip O 
to O 
industrial O 
LHS O 
. O 
The O 
concept O 
allows O 
complete O 
freedom O 
of O 
design O 
for O 
the O 
microfluidic O 
chip O 
itself O 
. O 
In O 
this O 
setup O 
all O 
peripheral O 
fluidic O 
components O 
( O 
such O 
as O 
valves O 
and O 
pumps O 
) O 
usually O 
required O 
for O 
microfluidic O 
experiments O 
are O 
provided O 
by O 
the O 
LHS O 
. O 
Experiments O 
( O 
including O 
readout O 
) O 
can O 
be O 
carried O 
out O 
fully O 
automated O 
using O 
the O 
hardware O 
and O 
software O 
provided O 
by O 
LHS O 
manufacturer O 
. O 
Our O 
approach O 
uses O 
a O 
chip O 
interface O 
that O 
is O 
compatible O 
with O 
widely O 
used O 
and O 
industrially O 
established O 
LHS O 
which O 
is O 
a O 
significant O 
advancement O 
towards O 
near O 
- O 
industrial O 
experimental O 
design O 
in O 
microfluidics O 
and O 
will O 
greatly O 
facilitate O 
the O 
acceptance O 
and O 
translation O 
of O 
microfluidics O 
technology O 
in O 
industry O 
. O 

magnetic O 
nanoparticles O 
( O 
MNPs O 
) O 
have O 
been O 
characterized O 
by O 
laser O 
desorption O 
/ O 
ionization O 
mass O 
spectrometry O 
( O 
LDI-MS O 
) O 
. O 
Quantitative O 
information O 
about O 
surface O 
ligand O 
composition O 
and O 
structure O 
for O 
monolayer O 
and O 
mixed O 
monolayer O 
protected O 
Fe3O4 B-FORMULA 
and O 
FePt B-FORMULA 
NPs O 
can O 
be O 
obtained O 
rapidly O 
with O 
very O 
little O 
sample O 
consumption O 
. O 

the O 
current O 
work O 
, O 
free O 
volume O 
concepts O 
, O 
primarily O 
applied O 
to O 
glass O 
formers O 
in O 
the O 
literature O 
, O 
were O 
transferred O 
to O 
ionic O 
liquids O 
( O 
ILs O 
) O 
. O 
A O 
series O 
of O 
1-butyl-3-methylimidazolium B-SYSTEMATIC 
( O 
[C4MIM](+) B-FORMULA 
) O 
based O 
ILs O 
was O 
investigated O 
by O 
Positron O 
Annihilation O 
Lifetime O 
Spectroscopy O 
( O 
PALS O 
) O 
. O 
The O 
phase O 
transition O 
and O 
dynamic O 
properties O 
of O 
the O 
ILs O 
[ O 
C4MIM B-ABBREVIATION 
][X O 
] O 
with O 
[X](-) O 
= O 
[Cl](-) B-FORMULA 
, O 
[BF4](-) B-FORMULA 
, O 
[PF6](-) B-FORMULA 
, O 
[OTf](-) B-FORMULA 
, O 
[NTf2](-) B-FORMULA 
and O 
[B(hfip)4](-) B-FORMULA 
were O 
reported O 
recently O 
( O 
Yu O 
et O 
al O 
. O 
, O 
Phys O 
. O 
Chem O 
. O 
Chem O 
. O 
Phys O 
. O 
, O 
2012 O 
, O 
14 O 
, O 
6856-6868 O 
) O 
. O 
In O 
this O 
subsequent O 
work O 
, O 
attention O 
was O 
paid O 
to O 
the O 
connection O 
of O 
the O 
free O 
volume O 
from O 
PALS O 
( O 
here O 
the O 
mean O 
hole O 
volume O 
, O 
〈vh〉 O 
) O 
with O 
the O 
molecular O 
structure O 
, O 
represented O 
by O 
volumes O 
derived O 
from O 
X-ray O 
diffraction O 
( O 
XRD O 
) O 
data O 
. O 
These O 
were O 
the O 
scaled O 
molecular O 
volume O 
Vm,scaled O 
and O 
the O 
van O 
der O 
Waals O 
volume O 
Vvdw O 
. O 
Linear O 
correlations O 
of O 
〈vh〉 O 
at O 
the O 
" O 
knee O 
" O 
temperature O 
(〈vh〉(Tk)) O 
with O 
Vm,scaled O 
and O 
Vvdw O 
gave O 
good O 
results O 
for O 
the O 
[C4MIM](+) B-FORMULA 
series O 
. O 
Further O 
relationships O 
between O 
volumes O 
from O 
XRD O 
data O 
with O 
the O 
occupied O 
volume O 
Vocc O 
determined O 
from O 
PALS O 
/ O 
PVT O 
( O 
Pressure O 
Volume O 
Temperature O 
) O 
measurements O 
and O 
from O 
Sanchez-Lacombe O 
Equation O 
of O 
State O 
( O 
SL-EOS O 
) O 
fits O 
were O 
elaborated O 
( O 
Vocc(SL-EOS) O 
≈ O 
1.63 O 
Vvdw O 
, O 
R(2) O 
= O 
0.981 O 
and O 
Vocc(SL-EOS) O 
≈ O 
1.12 O 
Vm,scaled O 
, O 
R(2) O 
= O 
0.98 O 
) O 
. O 
Finally O 
, O 
the O 
usability O 
of O 
Vm,scaled O 
was O 
justified O 
in O 
terms O 
of O 
the O 
Cohen-Turnbull O 
( O 
CT O 
) O 
free O 
volume O 
theory O 
. O 
Empirical O 
CT O 
type O 
plots O 
of O 
viscosity O 
and O 
electrical O 
conductivity O 
showed O 
a O 
systematic O 
increase O 
in O 
the O 
critical O 
free O 
volume O 
with O 
molecular O 
size O 
. O 
Such O 
correlations O 
allow O 
descriptions O 
of O 
IL O 
properties O 
with O 
the O 
easily O 
accessible O 
quantity O 
Vm,scaled O 
within O 
the O 
context O 
of O 
the O 
free O 
volume O 
. O 

Relationships O 
of O 
Quinoxaline B-SYSTEMATIC 
-Based O 
5-HT3 O 
A O 
and O 
5-HT3 O 
AB O 
Receptor-Selective O 
Ligands O 
. O 

recently O 
, O 
discriminating O 
between O 
homomeric O 
5-HT3 O 
A O 
and O 
heteromeric O 
5-HT3 O 
AB O 
receptors O 
was O 
only O 
possible O 
with O 
ligands O 
that O 
bind O 
in O 
the O 
receptor O 
pore O 
. O 
This O 
study O 
describes O 
the O 
first O 
series O 
of O 
ligands O 
that O 
can O 
discriminate O 
between O 
these O 
receptor O 
types O 
at O 
the O 
level O 
of O 
the O 
orthosteric O 
binding O 
site O 
. O 
During O 
a O 
recent O 
fragment O 
screen O 
, O 
2-chloro-3-(4-methylpiperazin-1-yl)quinoxaline B-SYSTEMATIC 
( O 
VUF10166 B-IDENTIFIER 
) O 
was O 
identified O 
as O 
a O 
ligand O 
that O 
displays O 
an O 
83-fold O 
difference O 
in O 
[ B-SYSTEMATIC 
( I-SYSTEMATIC 
3 I-SYSTEMATIC 
) I-SYSTEMATIC 
H]granisetron I-SYSTEMATIC 
binding O 
affinity O 
between O 
5-HT3 O 
A O 
and O 
5-HT3 O 
AB O 
receptors O 
. O 
Fragment O 
hit O 
exploration O 
, O 
initiated O 
from O 
VUF10166 B-IDENTIFIER 
and O 
3-(4-methylpiperazin-1-yl)quinoxalin-2-ol B-SYSTEMATIC 
, O 
resulted O 
in O 
a O 
series O 
of O 
compounds O 
with O 
higher O 
affinity O 
at O 
either O 
5-HT3 O 
A O 
or O 
5-HT3 O 
AB O 
receptors O 
. O 
These O 
ligands O 
reveal O 
that O 
a O 
single O 
atom O 
is O 
sufficient O 
to O 
change O 
the O 
selectivity O 
profile O 
of O 
a O 
compound O 
. O 
At O 
the O 
extremes O 
of O 
the O 
new O 
compounds O 
were O 
2-amino-3-(4-methylpiperazin-1-yl)quinoxaline B-SYSTEMATIC 
, O 
which O 
showed O 
11-fold O 
selectivity O 
for O 
the O 
5-HT3 O 
A O 
receptor O 
, O 
and O 
2-(4-methylpiperazin-1-yl)quinoxaline B-SYSTEMATIC 
, O 
which O 
showed O 
an O 
8.3-fold O 
selectivity O 
for O 
the O 
5-HT3 O 
AB O 
receptor O 
. O 
These O 
compounds O 
represent O 
novel O 
molecular O 
tools O 
for O 
studying O 
5-HT3 O 
receptor O 
subtypes O 
and O 
could O 
help O 
elucidate O 
their O 
physiological O 
roles O 
. O 

post O 
- O 
translational O 
modifications O 
of O 
histone O 
proteins O 
are O 
highly O 
diverse O 
and O 
dynamic O 
processes O 
. O 
It O 
is O 
becoming O 
increasingly O 
evident O 
that O 
modifying O 
histone O 
proteins O 
can O 
have O 
a O 
direct O 
influence O 
on O 
both O 
cellular O 
homeostasis O 
and O 
disease O 
states O 
. O 
Protein O 
arginine B-TRIVIAL 
deiminase O 
4 O 
( O 
PAD4 O 
) O 
is O 
an O 
enzyme O 
that O 
converts O 
peptidyl- O 
arginine B-TRIVIAL 
to O 
citrulline O 
. O 
The O 
overexpression O 
of O 
PAD4 O 
has O 
been O 
found O 
in O 
numerous O 
types O 
of O 
human O 
cancer O 
and O 
autoimmune O 
diseases O 
. O 
We O 
report O 
a O 
new O 
, O 
facile O 
, O 
fluorescence O 
- O 
based O 
assay O 
for O 
the O 
detection O 
of O 
PAD4 O 
activity O 
that O 
exploits O 
the O 
substrate O 
specificity O 
of O 
trypsin B-TRIVIAL 
to O 
monitor O 
the O 
citrullination O 
reaction O 
carried O 
out O 
by O 
PAD4 O 
based O 
on O 
the O 
fact O 
that O 
, O 
upon O 
citrullination O 
, O 
the O 
positively O 
charged O 
arginine O 
side O 
chain O 
is O 
converted O 
to O 
the O 
neutral O 
citrulline B-TRIVIAL 
. O 
We O 
show O 
that O 
the O 
assay O 
can O 
be O 
performed O 
rapidly O 
with O 
readily O 
available O 
reagents O 
and O 
that O 
it O 
responds O 
accordingly O 
to O 
a O 
known O 
PAD4 O 
inhibitor O 
. O 

Distorted O 
Tropane B-TRIVIAL 
of O 
Scopoline B-TRIVIAL 
. O 

structural O 
isomerization O 
of O 
scopine B-TRIVIAL 
into O 
scopoline B-TRIVIAL 
( O 
oscine B-TRIVIAL 
) O 
has O 
been O 
observed O 
in O 
a O 
supersonic O 
jet O 
expansion O 
using O 
microwave O 
spectroscopy O 
. O 
The O 
rotational O 
spectrum O 
evidences O 
a O 
single O 
structure O 
in O 
the O 
gas O 
phase O 
, O 
providing O 
a O 
first O 
description O 
of O 
the O 
( O 
three O 
- O 
ring O 
) O 
structurally O 
distorted O 
tropane B-TRIVIAL 
in O 
scopoline B-TRIVIAL 
. O 
The O 
absence O 
of O 
rotational O 
signatures O 
of O 
any O 
scopine B-TRIVIAL 
conformation O 
suggests O 
a O 
practically O 
quantitative O 
isomerization O 
at O 
the O 
vaporization O 
temperatures O 
of O 
the O 
experiment O 
( O 
ca O 
. O 
90 O 
°C O 
) O 
. O 
The O 
determined O 
rotational O 
parameters O 
of O 
scopoline B-TRIVIAL 
reveal O 
the O 
structural O 
consequences O 
of O 
the O 
intramolecular O 
cyclation O 
of O 
scopine B-TRIVIAL 
, O 
which O 
breaks O 
the O 
original O 
epoxy B-SYSTEMATIC 
group O 
and O 
creates O 
a O 
new O 
ether O 
bridge O 
and O 
a O 
7β-hydroxytropane B-SYSTEMATIC 
configuration O 
. O 
The O 
hydroxy B-SYSTEMATIC 
group O 
further O 
stabilizes O 
the O 
molecule O 
by O 
an O 
OH B-FORMULA 
⋅⋅⋅ O 
N B-FORMULA 
intramolecular O 
hydrogen B-SYSTEMATIC 
bond O 
, O 
which O 
, O 
in O 
turn O 
, O 
forces O 
the O 
N-methyl B-SYSTEMATIC 
group O 
to O 
the O 
less O 
stable O 
axial O 
form O 
. O 
Supporting O 
ab O 
initio O 
( O 
MP2 O 
) O 
and O 
DFT O 
( O 
B3LYP O 
, O 
M06-2X O 
) O 
calculations O 
are O 
included O 
. O 

root O 
of O 
Astragalus O 
membranaceus O 
( O 
AR O 
) O 
, O 
which O 
has O 
been O 
widely O 
used O 
in O 
Traditional O 
Chinese O 
herbal O 
formulae O 
for O 
treating O 
foot O 
ulcer O 
, O 
was O 
found O 
to O 
exhibit O 
anti-inflammatory O 
property O 
, O 
but O 
its O 
molecular O 
mechanism O 
still O 
remains O 
unknown O 
. O 
We O 
previously O 
identified O 
the O 
anti-inflammatory O 
sub O 
- O 
fraction O 
using O 
bioassay O 
- O 
guided O 
fractionation O 
. O 
The O 
objective O 
of O 
the O 
present O 
study O 
was O 
to O 
investigate O 
the O 
anti-inflammatory O 
mechanism O 
of O 
the O 
major O 
active O 
fraction O 
( O 
MAF O 
) O 
( O 
0.039 O 
to O 
0.156 O 
mg O 
/ O 
mL O 
) O 
using O 
lipopolysaccharide O 
(LPS)-stimulated O 
mouse O 
macrophage O 
RAW O 
264.7 O 
cells O 
. O 
MAF O 
was O 
shown O 
to O 
inhibit O 
LPS-induced O 
mRNA O 
and O 
protein O 
expression O 
of O 
inducible O 
nitric B-SYSTEMATIC 
oxide I-SYSTEMATIC 
synthase O 
by O 
54.7% O 
and O 
65.1% O 
, O 
respectively O 
. O 
Additionally O 
, O 
MAF O 
down O 
- O 
regulated O 
the O 
protein O 
expression O 
of O 
cyclooxygenase-2 O 
and O 
MAPK O 
regulator O 
by O 
45.0% O 
to O 
74.6% O 
, O 
as O 
well O 
as O 
the O 
reduction O 
of O 
DNA O 
binding O 
activity O 
of O 
nuclear O 
factor O 
kappa O 
B O 
( O 
NFκB O 
) O 
by O 
66.5% O 
. O 
It O 
also O 
attenuated O 
the O 
production O 
of O 
prostaglandin B-TRIVIAL 
E2 I-TRIVIAL 
, O 
interleukin-1 O 
beta O 
( O 
IL-1β O 
) O 
, O 
IL-6 O 
and O 
tumor O 
necrosis O 
factor O 
alpha O 
by O 
21.2% O 
to O 
86.2% O 
. O 
Furthermore O 
, O 
the O 
chemical O 
constituents O 
of O 
MAF O 
were O 
identified O 
. O 
A O 
total O 
of O 
13 O 
known O 
chemical O 
compounds O 
were O 
found O 
in O 
MAF O 
, O 
including O 
five O 
isoflavonoids B-FAMILY 
and O 
eight O 
saponins B-FAMILY 
. O 
In O 
conclusion O 
, O 
a O 
bioactive O 
fraction O 
of O 
AR O 
was O 
identified O 
which O 
possessed O 
anti-inflammatory O 
property O 
by O 
reducing O 
the O 
release O 
of O 
inflammatory O 
mediators O 
and O 
inactivation O 
of O 
NFκB O 
through O 
MAPK O 
signalling O 
pathway O 
. O 
Copyright O 
© O 
2013 O 
John O 
Wiley O 
& O 
Sons O 
, O 
Ltd O 
. O 

In O 
cross O 
- O 
sectional O 
studies O 
, O 
TSH O 
levels O 
within O 
the O 
reference O 
range O 
have O 
been O 
positively O 
associated O 
with O 
blood O 
pressure O 
and O 
adverse O 
serum O 
lipid O 
levels O 
. O 
In O 
a O 
prospective O 
study O 
, O 
we O 
aimed O 
to O 
find O 
out O 
if O 
differences O 
in O 
TSH O 
within O 
the O 
reference O 
range O 
are O 
associated O 
with O 
future O 
levels O 
of O 
blood O 
pressure O 
and O 
lipids.Design O 
Prospective O 
population O 
- O 
based O 
study.Methods O 
Among O 
9709 O 
women O 
and O 
4644 O 
men O 
without O 
previous O 
thyroid O 
disease O 
who O 
had O 
a O 
baseline O 
TSH O 
of O 
0.45-4.5 O 
mU O 
/ O 
l O 
, O 
we O 
studied O 
the O 
associations O 
of O 
baseline O 
TSH O 
with O 
blood O 
pressure O 
and O 
lipid O 
levels O 
at O 
follow O 
- O 
up O 
11 O 
years O 
later.Results O 
Higher O 
TSH O 
at O 
baseline O 
was O 
associated O 
with O 
higher O 
systolic O 
( O 
P=0.002 O 
in O 
women O 
) O 
and O 
diastolic O 
( O 
P=0.03 O 
in O 
women O 
) O 
blood O 
pressure O 
, O 
non-HDL O 
cholesterol B-TRIVIAL 
( O 
P=0.01 O 
in O 
men O 
) O 
, O 
and O 
triglycerides B-FAMILY 
( O 
P=0.008 O 
in O 
men O 
) O 
, O 
and O 
lower O 
HDL O 
cholesterol B-TRIVIAL 
( O 
P O 
< O 
0.001 O 
in O 
women O 
and O 
men O 
) O 
at O 
follow O 
- O 
up O 
, O 
but O 
the O 
associations O 
were O 
very O 
modest O 
and O 
not O 
consistent O 
between O 
sexes O 
. O 
Among O 
people O 
who O 
remained O 
free O 
of O 
thyroid O 
disease O 
, O 
changes O 
in O 
TSH O 
during O 
follow O 
- O 
up O 
were O 
associated O 
with O 
concomitant O 
changes O 
in O 
systolic O 
and O 
diastolic O 
blood O 
pressure O 
, O 
non-HDL O 
cholesterol B-TRIVIAL 
, O 
and O 
triglyceride B-FAMILY 
levels O 
( O 
all O 
P O 
< O 
0.001 O 
) O 
, O 
with O 
similar O 
results O 
for O 
women O 
and O 
men O 
. O 
Thus O 
, O 
blood O 
pressure O 
and O 
lipid O 
levels O 
increased O 
among O 
people O 
with O 
increase O 
in O 
TSH O 
, O 
and O 
decreased O 
among O 
people O 
with O 
a O 
decrease O 
in O 
TSH O 
, O 
compared O 
to O 
people O 
with O 
no O 
change O 
in O 
TSH.Conclusions O 
High O 
TSH O 
levels O 
within O 
the O 
reference O 
range O 
may O 
be O 
associated O 
with O 
modestly O 
higher O 
future O 
levels O 
of O 
blood O 
pressure O 
and O 
adverse O 
serum O 
lipids O 
. O 
TSH O 
may O 
co O 
- O 
vary O 
with O 
blood O 
pressure O 
and O 
lipid O 
levels O 
among O 
people O 
with O 
apparently O 
normal O 
thyroid O 
function O 
. O 

Ringdown O 
Spectroscopy O 
of O 
the O 
Hydroxy-Methyl-Peroxy B-SYSTEMATIC 
Radical O 
. O 

report O 
vibrational O 
and O 
electronic O 
spectra O 
of O 
the O 
hydroxyl-methyl-peroxy B-SYSTEMATIC 
radical O 
( O 
HOCH2OO B-FORMULA 
, O 
or O 
HMP B-ABBREVIATION 
) O 
, O 
the O 
primary O 
product O 
of O 
the O 
reaction O 
of O 
the O 
hydroperoxy B-SYSTEMATIC 
radical O 
, O 
HO2 B-FORMULA 
, O 
and O 
formaldehyde B-SYSTEMATIC 
, O 
HCHO B-FORMULA 
. O 
The O 
ν1 O 
vibrational O 
( O 
OH B-FORMULA 
stretch O 
) O 
spectrum O 
and O 
the O 
Ã-X O 
electronic O 
spectrum O 
of O 
HMP B-ABBREVIATION 
were O 
detected O 
by O 
Infrared O 
Cavity O 
Ringdown O 
Spectroscopy O 
( O 
IR-CRDS O 
) O 
, O 
and O 
assignments O 
were O 
verified O 
with O 
density O 
functional O 
calculations O 
. O 
The O 
HMP B-ABBREVIATION 
radical O 
was O 
generated O 
in O 
reactions O 
of O 
HCHO B-FORMULA 
with O 
HO2 B-FORMULA 
. O 
Free O 
radical O 
reactions O 
were O 
initiated O 
by O 
pulsed O 
laser O 
photolysis O 
( O 
PLP O 
) O 
of O 
Cl2 B-FORMULA 
in O 
the O 
presence O 
of O 
HCHO B-FORMULA 
and O 
O2 B-FORMULA 
in O 
a O 
flow O 
reactor O 
at O 
300-330 O 
Torr O 
and O 
295K O 
. O 
IR-CRDS O 
spectra O 
were O 
measured O 
in O 
mid-IR O 
and O 
near-IR O 
regions O 
over O 
the O 
ranges O 
3525-3700 O 
cm(-1) O 
( O 
ν1 O 
) O 
and O 
7250-7800 O 
cm(-1) O 
( O 
Ã-X O 
) O 
( O 
respectively O 
, O 
at O 
a O 
delay O 
time O 
100 O 
µs O 
after O 
photolysis O 
. O 
The O 
ν1 O 
spectrum O 
had O 
an O 
origin O 
at O 
3622 O 
cm(-1) O 
and O 
exhibited O 
partially O 
resolved O 
P- O 
and O 
R-branch O 
contours O 
and O 
a O 
small O 
Q O 
branch O 
. O 
At O 
these O 
short O 
delay O 
times O 
, O 
spectral O 
interference O 
from O 
HOOH B-FORMULA 
and O 
HCOOH B-FORMULA 
was O 
minimal O 
, O 
and O 
could O 
be O 
subtracted O 
. O 
From O 
B3LYP O 
/ O 
6-31G O 
+ O 
( O 
d,p O 
) O 
calculations O 
, O 
we O 
found O 
that O 
the O 
anharmonic O 
vibrational O 
frequency O 
and O 
band O 
contour O 
predicted O 
for O 
the O 
lowest O 
energy O 
conformer O 
, O 
HMP B-ABBREVIATION 
-A O 
, O 
The O 
calculated O 
anharmonic O 
vibrational O 
frequency O 
and O 
band O 
contour O 
computed O 
using O 
B3LYP O 
/ O 
63-1G(d,p) O 
level O 
were O 
in O 
good O 
agreement O 
with O 
the O 
observed O 
spectrum O 
. O 
In O 
the O 
near-IR O 
, O 
we O 
observed O 
four O 
well O 
spaced O 
vibronic O 
bands O 
, O 
each O 
with O 
partially O 
resolved O 
rotational O 
contours O 
. O 
We O 
assigned O 
the O 
apparent O 
origin O 
of O 
the O 
electronic O 
spectrum O 
of O 
HMP B-ABBREVIATION 
at O 
7392 O 
cm(-1) O 
and O 
two O 
bands O 
to O 
the O 
blue O 
to O 
a O 
progression O 
in O 
ν15 O 
' O 
, O 
the O 
lowest O 
torsional O 
mode O 
of O 
the O 
state O 
( O 
ν15'= O 
171 O 
cm(-1) O 
) O 
. O 
The O 
band O 
furthest O 
to O 
the O 
red O 
was O 
assigned O 
as O 
a O 
hot O 
band O 
in O 
ν15 O 
" O 
, O 
leading O 
to O 
a O 
ground O 
state O 
torsional O 
frequency O 
of O 
( O 
ν15"= O 
122 O 
cm(-1) O 
) O 
. O 
We O 
simulated O 
the O 
spectrum O 
using O 
second O 
order O 
vibrational O 
perturbation O 
theory O 
( O 
VPT2 O 
) O 
with O 
B3LYP O 
/ O 
6-31 O 
+ O 
G(d,p) O 
calculations O 
at O 
the O 
minimum O 
energy O 
geometries O 
of O 
the O 
HMP B-ABBREVIATION 
-A O 
conformer O 
on O 
the O 
X O 
̃ O 
and O 
A O 
̃ O 
states O 
. O 
The O 
predictions O 
of O 
the O 
electronic O 
origin O 
frequency O 
, O 
torsional O 
frequencies O 
, O 
anharmonicities O 
and O 
rotational O 
band O 
contours O 
matched O 
the O 
observed O 
spectrum O 
. O 
We O 
investigated O 
the O 
torsional O 
modes O 
more O 
explicitly O 
by O 
computing O 
potential O 
energy O 
surfaces O 
of O 
HMP B-ABBREVIATION 
as O 
a O 
function O 
of O 
the O 
two O 
dihedral O 
angles O 
τ O 
OCOH B-FORMULA 
and O 
τ O 
OOCO B-FORMULA 
. O 
Wave O 
functions O 
and O 
energy O 
levels O 
were O 
calculated O 
based O 
on O 
this O 
potential O 
surface O 
; O 
these O 
results O 
were O 
used O 
to O 
calculate O 
the O 
Franck-Condon O 
factors O 
, O 
which O 
reproduced O 
the O 
vibronic O 
band O 
intensities O 
in O 
the O 
observed O 
electronic O 
spectrum O 
. O 
The O 
transitions O 
that O 
we O 
observed O 
all O 
involved O 
states O 
with O 
wave O 
functions O 
localized O 
on O 
the O 
minimum O 
energy O 
conformer O 
, O 
HMP B-ABBREVIATION 
-A O 
. O 
Our O 
calculations O 
indicated O 
that O 
the O 
observed O 
near-IR O 
spectrum O 
was O 
that O 
of O 
the O 
minimum O 
energy O 
conformer O 
HMP B-ABBREVIATION 
-A O 
, O 
but O 
that O 
this O 
conformer O 
is O 
not O 
the O 
lowest O 
energy O 
conformer O 
in O 
the O 
state O 
, O 
which O 
remains O 
unobserved O 
. O 
We O 
estimated O 
that O 
the O 
energy O 
of O 
this O 
lowest O 
conformer O 
( O 
HMP B-ABBREVIATION 
-B O 
) O 
of O 
the O 
Ã O 
state O 
to O 
be O 
T0 O 
( O 
Ã O 
) O 
≈ O 
7200 O 
cm(-1) O 
, O 
based O 
on O 
the O 
energy O 
difference O 
E0( O 
HMP B-ABBREVIATION 
-B O 
) O 
- O 
E0( O 
HMP B-ABBREVIATION 
-A O 
) O 
on O 
the O 
Ã O 
state O 
computed O 
at O 
the O 
B3LYP O 
/ O 
6-31 O 
+ O 
G(d,p) O 
level O 
. O 

human O 
recombinant O 
UDP B-ABBREVIATION 
-glucuronosyltransferase O 
isoforms O 
and O 
a O 
relative O 
activity O 
factor O 
approach O 
to O 
model O 
total O 
body O 
clearance O 
of O 
laropiprant B-TRIVIAL 
( O 
MK-0524 B-IDENTIFIER 
) O 
in O 
humans O 
. O 

1 O 
. O 
A O 
major O 
pathway O 
of O 
elimination O 
of O 
the O 
p O 
rostaglandin B-TRIVIAL 
D2 I-TRIVIAL 
receptor O 
1 O 
antagonist O 
l O 
aropiprant B-TRIVIAL 
in O 
humans O 
is O 
by O 
u O 
ridine B-SYSTEMATIC 
diphosphate- I-SYSTEMATIC 
glucuronosyltransferase O 
( O 
UGT O 
) O 
- O 
mediated O 
biotransformation O 
. O 
In O 
this O 
study O 
, O 
liver O 
and O 
kidney O 
relative O 
activity O 
factors O 
were O 
developed O 
for O 
UGT1A1 O 
, O 
1A9 O 
and O 
2B7 O 
to O 
allow O 
for O 
in O 
vitro O 
- O 
in O 
vivo O 
extrapolation O 
of O 
intrinsic O 
clearance O 
data O 
to O 
whole O 
organ O 
clearance O 
using O 
recombinant O 
human O 
UGT O 
isoforms O 
applying O 
this O 
to O 
l O 
aropiprant B-TRIVIAL 
as O 
a O 
model O 
substrate O 
. O 
2 O 
. O 
The O 
total O 
body O 
metabolic O 
clearance O 
of O 
la O 
ropiprant B-TRIVIAL 
d I-TRIVIAL 
etermined O 
using O 
this O 
approach O 
( O 
5 O 
L O 
/ O 
hr O 
) O 
agreed O 
well O 
with O 
the O 
value O 
determined O 
in O 
vivo O 
following O 
intravenous O 
administration O 
to O 
healthy O 
human O 
volunteers O 
( O 
5.1 O 
L O 
/ O 
hr O 
) O 
. O 
3 O 
. O 
The O 
results O 
suggest O 
that O 
approximately O 
36% O 
, O 
36% O 
and O 
28% O 
of O 
the O 
hepatic O 
metabolic O 
clearance O 
of O 
lar O 
opiprant B-TRIVIAL 
wa I-TRIVIAL 
s O 
mediated O 
by O 
UGT1A1 O 
, O 
1A9 O 
and O 
2B7 O 
, O 
respectively O 
. O 
Likewise O 
, O 
80% O 
and O 
20% O 
of O 
the O 
renal O 
metabolic O 
clearance O 
was O 
mediated O 
by O 
UGT1A9 O 
and O 
2B7 O 
, O 
respectively O 
. O 
Furthermore O 
, O 
the O 
data O 
suggested O 
that O 
the O 
contribution O 
of O 
the O 
kidney O 
to O 
the O 
overall O 
total O 
metabolic O 
clearance O 
was O 
minor O 
relative O 
to O 
the O 
liver O 
( O 
∼ O 
12% O 
) O 
. O 

of O 
radiolabeled O 
amino B-FAMILY 
acid I-FAMILY 
and O 
lipid O 
brevetoxin B-FAMILY 
metabolites O 
and O 
their O 
blood O 
elimination O 
kinetics O 
in O 
C57BL O 
/ O 
6 O 
mice O 
. O 

B I-FAMILY 
( O 
BTX-B B-ABBREVIATION 
) O 
, O 
produced O 
by O 
dinoflagellates O 
of O 
the O 
species O 
Karenia O 
, O 
is O 
a O 
highly O 
reactive O 
molecule O 
, O 
due O 
in O 
part O 
to O 
an O 
α,β- B-SYSTEMATIC 
unsaturated I-SYSTEMATIC 
aldehyde I-SYSTEMATIC 
group O 
at O 
the O 
terminal O 
side O 
chain O 
, O 
leading O 
to O 
the O 
production O 
of O 
metabolites O 
by O 
reduction O 
, O 
oxidation O 
, O 
and O 
conjugation O 
. O 
We O 
have O 
investigated O 
in O 
mice O 
the O 
blood O 
elimination O 
of O 
three O 
common O 
bioactive O 
brevetoxin B-FAMILY 
metabolites O 
found O 
in O 
shellfish O 
, O 
which O 
have O 
been O 
semi-synthesized O 
from O 
BTX-B B-ABBREVIATION 
in O 
radioactive O 
forms O 
. O 
BTX-B B-ABBREVIATION 
was O 
reduced O 
at O 
C42 O 
to O 
yield O 
[ B-SYSTEMATIC 
3H I-SYSTEMATIC 
] I-SYSTEMATIC 
dihydro-BTX-B I-SYSTEMATIC 
. O 
[ B-SYSTEMATIC 
3H I-SYSTEMATIC 
] I-SYSTEMATIC 
S-desoxy-BTX-B2 I-SYSTEMATIC 
( O 
cysteine B-TRIVIAL 
brevetoxin I-TRIVIAL 
B I-TRIVIAL 
) O 
was O 
semi-synthesized O 
from O 
BTX-B B-ABBREVIATION 
by O 
conjugation O 
of O 
cysteine B-TRIVIAL 
at O 
the O 
C50 O 
olefinic B-FAMILY 
group O 
, O 
then O 
[ B-FORMULA 
3H I-FORMULA 
] I-FORMULA 
radiolabeled O 
by O 
C42 O 
aldehyde B-SYSTEMATIC 
reduction O 
. O 
[ B-SYSTEMATIC 
14C I-SYSTEMATIC 
] I-SYSTEMATIC 
N-palmitoyl-S-desoxy-BTX-B2 I-SYSTEMATIC 
was O 
prepared O 
using O 
S-desoxy-BTX-B2 B-SYSTEMATIC 
as O 
the O 
starting O 
material O 
with O 
addition O 
of O 
the O 
[ B-FORMULA 
14C I-FORMULA 
] I-FORMULA 
radiolabeled O 
fatty B-FAMILY 
acid I-FAMILY 
via O 
the O 
cysteine B-TRIVIAL 
- O 
amide B-FAMILY 
linkage O 
. O 
The O 
elimination O 
of O 
intravenously O 
administered O 
[ B-SYSTEMATIC 
3H I-SYSTEMATIC 
] I-SYSTEMATIC 
S-desoxy-BTX-B2 I-SYSTEMATIC 
, O 
[ B-SYSTEMATIC 
14C I-SYSTEMATIC 
] I-SYSTEMATIC 
N-palmitoyl-S-desoxy-BTX-B2 I-SYSTEMATIC 
, O 
or O 
[ B-SYSTEMATIC 
3H I-SYSTEMATIC 
] I-SYSTEMATIC 
dihydro-BTX-B I-SYSTEMATIC 
was O 
measured O 
in O 
blood O 
collected O 
from O 
C57BL O 
/ O 
6 O 
mice O 
over O 
a O 
48 O 
hour O 
period O 
. O 
Each O 
brevetoxin B-FAMILY 
metabolite O 
tested O 
exhibited O 
biexponential O 
elimination O 
kinetics O 
and O 
fit O 
a O 
two O 
- O 
compartment O 
model O 
of O 
elimination O 
that O 
was O 
applied O 
to O 
generate O 
toxicokinetic O 
parameters O 
. O 
The O 
rate O 
of O 
transfer O 
between O 
the O 
central O 
compartment O 
( O 
i.e O 
. O 
, O 
blood O 
) O 
and O 
the O 
peripheral O 
compartment O 
( O 
e.g O 
. O 
, O 
tissue O 
) O 
for O 
each O 
brevetoxin B-FAMILY 
differed O 
substantially O 
, O 
with O 
dihydro-BTX-B B-SYSTEMATIC 
exchanging O 
rapidly O 
with O 
the O 
peripheral O 
compartment O 
, O 
and O 
S-desoxy-BTX-B2 B-SYSTEMATIC 
eliminating O 
rapidly O 
from O 
the O 
central O 
compartment O 
and O 
N-palmitoyl-S-desoxy-BTX-B2 B-SYSTEMATIC 
eliminating O 
slowly O 
from O 
the O 
central O 
compartment O 
. O 
Toxicokinetic O 
parameters O 
were O 
analyzed O 
in O 
the O 
context O 
of O 
the O 
unique O 
structure O 
of O 
each O 
brevetoxin B-FAMILY 
metabolite O 
resulting O 
from O 
a O 
reduction O 
, O 
amino B-FAMILY 
acid I-FAMILY 
conjugation O 
, O 
or O 
fatty B-FAMILY 
acid I-FAMILY 
addition O 
to O 
BTX-B B-ABBREVIATION 
. O 

of O 
7-oxabicyclo[2.2.1]hept-5-en-2-yl B-SYSTEMATIC 
derivatives O 
and O 
their O 
screening O 
for O 
antimicrobial O 
and O 
antioxidant O 
properties O 
. O 

7-oxabicyclo[2.2.1]hept-5-en-2-yl B-SYSTEMATIC 
derivatives O 
have O 
been O 
synthesized O 
using O 
boron B-SYSTEMATIC 
trifluoride I-SYSTEMATIC 
diethyl I-SYSTEMATIC 
etherate I-SYSTEMATIC 
catalyzed O 
Diels-Alder O 
reaction O 
. O 
This O 
method O 
presents O 
considerable O 
synthetic O 
advantages O 
in O 
terms O 
of O 
high O 
atom O 
economy O 
, O 
mild O 
reaction O 
condition O 
and O 
good O 
yields O 
. O 
The O 
synthesized O 
compounds O 
have O 
been O 
screened O 
for O 
their O 
antibacterial O 
and O 
antioxidant O 
activities O 
. O 

RELEVANCE O 
: O 
Licorice O 
( O 
Glycyrrhiza O 
uralensis O 
Fisch O 
. O 
, O 
Leguminosae O 
) O 
has O 
been O 
used O 
in O 
herbal O 
medicine O 
and O 
food O 
supplement O 
worldwide O 
for O 
centuries O 
. O 
Licorice O 
is O 
a O 
common O 
ingredient O 
of O 
several O 
prescriptions O 
of O 
traditional O 
Chinese O 
medicine O 
which O 
have O 
been O 
proved O 
to O 
inhibit O 
infection O 
of O 
human O 
respiratory O 
syncytial O 
virus O 
( O 
HRSV O 
) O 
. O 
There O 
are O 
two O 
preparations O 
of O 
licorice O 
, O 
Radix O 
Glycyrrhizae O 
and O 
Radix O 
Glycyrrhizae O 
Preparata O 
. O 
However O 
, O 
it O 
is O 
unknown O 
whether O 
licorice O 
or O 
which O 
preparation O 
of O 
licorice O 
is O 
effective O 
against O 
HRSV O 
, O 
nor O 
is O 
its O 
active O 
constituent O 
. O 
AIM O 
OF O 
THE O 
STUDY O 
: O 
We O 
tested O 
the O 
hypothesis O 
that O 
Radix O 
Glycyrrhizae O 
can O 
effectively O 
decrease O 
HRSV-induced O 
plaque O 
formation O 
in O 
respiratory O 
mucosal O 
cell O 
lines O 
. O 
We O 
also O 
tried O 
to O 
find O 
out O 
the O 
active O 
constituent O 
. O 
MATERIALS O 
AND O 
METHODS O 
: O 
Anti-HRSV O 
activities O 
of O 
hot O 
water O 
extracts O 
of O 
preparations O 
of O 
licorice O 
, O 
glycyrrhizin B-TRIVIAL 
and O 
18β-glycyrrhetinic B-SYSTEMATIC 
acid I-SYSTEMATIC 
( O 
18β-GA B-FORMULA 
) O 
, O 
the O 
active O 
constituents O 
of O 
licorice O 
, O 
were O 
examined O 
by O 
plaque O 
reduction O 
assay O 
in O 
both O 
human O 
upper O 
( O 
HEp-2 O 
) O 
and O 
low O 
( O 
A549 O 
) O 
respiratory O 
tract O 
cell O 
lines O 
. O 
Abilities O 
of O 
crude O 
licorice O 
to O 
inhibit O 
viral O 
replication O 
and O 
to O 
stimulate O 
IFN-β O 
were O 
evaluated O 
by O 
reverse O 
transcription O 
polymerase O 
chain O 
reaction O 
( O 
RT-PCR O 
) O 
and O 
enzyme O 
- O 
linked O 
immunosorbent O 
assay O 
( O 
ELISA O 
) O 
, O 
respectively O 
. O 
RESULTS O 
: O 
Radix O 
Glycyrrhizae O 
and O 
Radix O 
Glycyrrhizae O 
Preparata O 
dose O 
- O 
dependently O 
inhibited O 
HRSV-induced O 
plaque O 
formation O 
in O 
both O 
HEp-2 O 
and O 
A549 O 
cell O 
lines O 
( O 
p O 
< O 
0.0001 O 
) O 
. O 
The O 
effect O 
of O 
Radix O 
Glycyrrhizae O 
was O 
better O 
than O 
that O 
of O 
Radix O 
Glycyrrhizae O 
Preparata O 
on O 
HEp-2 O 
cells O 
. O 
However O 
, O 
there O 
was O 
no O 
difference O 
of O 
their O 
anti-HRSV O 
effects O 
on O 
A549 O 
cells O 
. O 
Besides O 
, O 
glycyrrhizin B-TRIVIAL 
was O 
ineffective O 
at O 
all O 
. O 
Nevertheless O 
, O 
18β-GA B-FORMULA 
showed O 
a O 
potent O 
anti-HRSV O 
activity O 
. O 
Radix O 
Glycyrrhizae O 
was O 
more O 
effective O 
when O 
given O 
before O 
viral O 
inoculation O 
( O 
p O 
< O 
0.0001 O 
) O 
which O 
may O 
be O 
due O 
to O 
its O 
inhibition O 
of O 
viral O 
attachment O 
on O 
( O 
p O 
< O 
0.0001 O 
) O 
and O 
penetration O 
( O 
p O 
< O 
0.0001 O 
) O 
into O 
the O 
host O 
cells O 
. O 
The O 
anti-HRSV O 
activity O 
of O 
Radix O 
Glycyrrhizae O 
was O 
further O 
confirmed O 
by O 
RT-PCR O 
and O 
qRT-PCR O 
. O 
300μg O 
/ O 
ml O 
Radix O 
Glycyrrhizae O 
markedly O 
decreased O 
the O 
viral O 
amounts O 
within O 
the O 
cells O 
and O 
in O 
the O 
suspension O 
. O 
Radix O 
Glycyrrhizae O 
might O 
further O 
stimulate O 
mucosal O 
cells O 
to O 
secrete O 
IFN-β O 
to O 
counteract O 
viral O 
infection O 
. O 
CONCLUSIONS O 
: O 
Both O 
Radix O 
Glycyrrhizae O 
and O 
Radix O 
Glycyrrhizae O 
Preparata O 
are O 
effective O 
against O 
HRSV O 
infection O 
on O 
airway O 
epithelial O 
cells O 
. O 
Radix O 
Glycyrrhizae O 
inhibited O 
HRSV O 
mainly O 
by O 
preventing O 
viral O 
attachment O 
, O 
internalization O 
, O 
and O 
by O 
stimulating O 
IFN O 
secretion O 
. O 
18β-GA B-FORMULA 
may O 
be O 
one O 
of O 
its O 
active O 
constituents O 
. O 

resistance O 
to O 
acute O 
MPTP B-ABBREVIATION 
toxicity O 
by O 
hypothalamic O 
dopamine B-TRIVIAL 
neurons O 
following O 
chronic O 
neurotoxicant O 
exposure O 
is O 
associated O 
with O 
sustained O 
up O 
- O 
regulation O 
of O 
parkin O 
protein O 
. O 

tuberoinfundibular O 
dopamine B-TRIVIAL 
( O 
TIDA O 
) O 
neurons O 
remain O 
unaffected O 
in O 
Parkinson O 
disease O 
( O 
PD O 
) O 
while O 
there O 
is O 
significant O 
degeneration O 
of O 
midbrain O 
nigrostriatal O 
dopamine B-TRIVIAL 
( O 
NSDA O 
) O 
neurons O 
. O 
A O 
similar O 
pattern O 
of O 
susceptibility O 
is O 
observed O 
following O 
acute O 
exposure O 
to O 
the O 
neurotoxicant O 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-SYSTEMATIC 
( O 
MPTP B-ABBREVIATION 
) O 
, O 
and O 
the O 
resistance O 
of O 
TIDA O 
neurons O 
to O 
MPTP B-ABBREVIATION 
is O 
associated O 
with O 
increased O 
expression O 
of O 
parkin O 
and O 
ubiquitin O 
carboxy B-SYSTEMATIC 
-terminal O 
hydrolase O 
L-1 O 
( O 
UCHL- O 
1 O 
) O 
. O 
In O 
the O 
present O 
study O 
, O 
the O 
response O 
of O 
TIDA O 
and O 
NSDA O 
neurons O 
to O 
acute O 
MPTP B-ABBREVIATION 
administration O 
following O 
chronic O 
MPTP B-ABBREVIATION 
exposure O 
was O 
examined O 
. O 
Mice O 
were O 
treated O 
with O 
ten O 
injections O 
of O 
either O 
MPTP B-ABBREVIATION 
( O 
20 O 
mg O 
/ O 
kg O 
; O 
s.c O 
. O 
; O 
every O 
3.5 O 
days O 
) O 
or O 
saline O 
vehicle O 
( O 
10 O 
ml O 
/ O 
kg O 
; O 
s.c O 
. O 
; O 
every O 
3.5 O 
days O 
) O 
. O 
Following O 
a O 
21 O 
day O 
recovery O 
period O 
, O 
chronic O 
saline- O 
and O 
MPTP B-ABBREVIATION 
-treated O 
mice O 
received O 
an O 
additional O 
injection O 
of O 
either O 
saline O 
( O 
10 O 
ml O 
/ O 
kg O 
; O 
s.c O 
. O 
) O 
or O 
MPTP B-ABBREVIATION 
( O 
20 O 
mg O 
/ O 
kg O 
; O 
s.c O 
. O 
) O 
and O 
were O 
sacrificed O 
24 O 
h O 
later O 
. O 
NSDA O 
neurons O 
displayed O 
significant O 
axon O 
terminal O 
degeneration O 
( O 
as O 
indexed O 
by O 
decreases O 
in O 
DA O 
, O 
tyrosine B-TRIVIAL 
hydroxylase O 
( O 
TH O 
) O 
and O 
DA O 
transporter O 
concentrations O 
in O 
the O 
striatum O 
) O 
as O 
well O 
as O 
loss O 
of O 
TH-immunoreactive O 
( O 
IR O 
) O 
neurons O 
in O 
the O 
substantia O 
nigra O 
( O 
SN O 
) O 
following O 
MPTP B-ABBREVIATION 
, O 
whereas O 
TIDA O 
neurons O 
revealed O 
no O 
overt O 
axon O 
terminal O 
pathology O 
or O 
loss O 
of O 
TH-IR O 
cell O 
bodies O 
. O 
NSDA O 
neuronal O 
pathology O 
was O 
associated O 
with O 
transient O 
decreases O 
in O 
concentrations O 
of O 
parkin O 
and O 
UCHL-1 O 
protein O 
in O 
the O 
SN O 
, O 
which O 
returned O 
to O 
normal O 
levels O 
by O 
21 O 
days O 
following O 
cessation O 
of O 
chronic O 
neurotoxicant O 
exposure O 
. O 
Resistance O 
of O 
TIDA O 
neurons O 
to O 
MPTP B-ABBREVIATION 
toxicity O 
was O 
correlated O 
with O 
a O 
transient O 
increase O 
in O 
UCHL-1 O 
and O 
a O 
sustained O 
elevation O 
in O 
parkin O 
in O 
the O 
arcuate O 
nucleus O 
. O 
TIDA O 
neurons O 
represent O 
a O 
DA O 
neuron O 
population O 
with O 
a O 
unique O 
and O 
inherent O 
ability O 
to O 
adapt O 
to O 
acute O 
and O 
chronic O 
toxicant O 
administration O 
with O 
a O 
sustained O 
elevation O 
of O 
the O 
neuroprotective O 
protein O 
parkin O 
. O 
The O 
correlation O 
between O 
the O 
ability O 
to O 
increase O 
parkin O 
and O 
UCHL-1 O 
expression O 
and O 
the O 
resistance O 
of O 
DA O 
neurons O 
to O 
neurotoxicant O 
exposure O 
is O 
consistent O 
with O 
a O 
functional O 
link O 
between O 
these O 
features O 
and O 
an O 
underlying O 
differential O 
susceptibility O 
to O 
toxicant O 
- O 
associated O 
neurodegeneration O 
. O 

C I-TRIVIAL 
and O 
Lifespan O 
in O 
Model O 
Organisms O 
. O 

process O 
of O 
ageing O 
has O 
been O 
repeatedly O 
associated O 
with O 
increasing O 
oxidative O 
damage O 
which O 
has O 
led O 
to O 
the O 
hypothesis O 
that O 
reducing O 
oxidative O 
stress O 
through O 
antioxidant O 
dietary O 
factors O 
may O 
prolong O 
lifespan O 
. O 
Ascorbic B-TRIVIAL 
acid I-TRIVIAL 
is O 
an O 
essential O 
antioxidant O 
in O 
human O 
diets O 
and O 
is O 
widely O 
used O 
for O 
supplementation O 
. O 
However O 
, O 
it O 
is O 
rather O 
unclear O 
if O 
and O 
to O 
what O 
extent O 
ascorbic B-TRIVIAL 
acid I-TRIVIAL 
may O 
affect O 
lifespan O 
in O 
humans O 
and O 
model O 
organisms O 
. O 
In O 
our O 
review O 
of O 
literature O 
on O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
supplementation O 
and O 
its O 
effect O 
on O 
lifespan O 
in O 
different O 
model O 
organisms O 
we O 
found O 
that O 
some O 
studies O 
suggest O 
an O 
increase O 
in O 
lifespan O 
, O 
other O 
studies O 
failed O 
to O 
observe O 
any O 
beneficial O 
effect O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
on O 
longevity O 
and O 
some O 
studies O 
even O 
reported O 
a O 
decrease O 
in O 
lifespan O 
following O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
supplementation O 
. O 
Of O 
the O 
14 O 
studies O 
included O 
in O 
our O 
analysis O 
, O 
3 O 
were O 
carried O 
out O 
in O 
worms O 
, O 
4 O 
in O 
flies O 
and O 
7 O 
in O 
rodents O 
. O 
The O 
discrepancies O 
between O 
the O 
studies O 
may O 
be O 
related O 
to O 
species O 
- O 
specific O 
differences O 
, O 
the O 
concentration O 
of O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
administered O 
, O 
the O 
duration O 
of O 
supplementation O 
and O 
whether O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
was O 
used O 
alone O 
or O 
as O 
part O 
of O 
a O 
combined O 
antioxidant O 
diet O 
. O 
Potential O 
underlying O 
mechanisms O 
through O 
which O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
may O 
influence O 
lifespan O 
and O 
differences O 
amongst O 
species O 
regarding O 
the O 
capacity O 
to O 
produce O 
vitamin B-TRIVIAL 
C I-TRIVIAL 
endogenously O 
are O 
discussed O 
. O 

study O 
aims O 
to O 
investigate O 
the O 
potential O 
of O 
antioxidant O 
enzyme O 
activities O 
( O 
AEA O 
) O 
as O 
biomarkers O 
of O 
oxidative O 
stress O 
in O 
freshwater O 
biofilms O 
. O 
Therefore O 
, O 
biofilms O 
were O 
grown O 
in O 
channels O 
for O 
38 O 
days O 
and O 
then O 
exposed O 
to O 
different O 
concentrations O 
(0-150μgL(-1)) O 
of O 
the O 
herbicide O 
oxyfluorfen B-TRIVIAL 
for O 
5 O 
more O 
weeks O 
. O 
Under O 
control O 
conditions O 
, O 
the O 
AEA O 
of O 
biofilms O 
were O 
found O 
to O 
change O 
throughout O 
time O 
with O 
a O 
significant O 
increase O 
in O 
ascorbate B-TRIVIAL 
peroxidase O 
( O 
APX O 
) O 
activity O 
during O 
the O 
exponential O 
growth O 
and O 
a O 
more O 
important O 
role O 
of O 
catalase O 
( O 
CAT O 
) O 
and O 
glutathione B-TRIVIAL 
reductase O 
( O 
GR O 
) O 
activities O 
during O 
the O 
slow O 
growth O 
phase O 
. O 
Chronic O 
exposure O 
to O 
oxyfluorfen B-TRIVIAL 
led O 
to O 
slight O 
variations O 
in O 
AEA O 
, O 
however O 
, O 
the O 
ranges O 
of O 
variability O 
of O 
AEA O 
in O 
controls O 
and O 
exposed O 
communities O 
were O 
similar O 
, O 
highlighting O 
the O 
difficulty O 
of O 
a O 
direct O 
interpretation O 
of O 
AEA O 
values O 
. O 
After O 
5 O 
weeks O 
of O 
exposure O 
to O 
oxyfluorfen B-TRIVIAL 
, O 
no O 
clear O 
effects O 
were O 
observed O 
on O 
chl-a B-ABBREVIATION 
concentration O 
or O 
on O 
the O 
composition O 
of O 
other O 
pigments O 
suggesting O 
that O 
algal O 
group O 
composition O 
was O 
not O 
affected O 
. O 
Eukaryotic O 
communities O 
were O 
structured O 
clearly O 
by O 
toxicant O 
concentration O 
and O 
both O 
eukaryotic O 
and O 
bacterial O 
richness O 
were O 
reduced O 
in O 
communities O 
exposed O 
to O 
the O 
highest O 
concentration O 
. O 
In O 
addition O 
, O 
during O 
acute O 
exposure O 
tests O 
performed O 
at O 
the O 
end O 
of O 
the O 
chronic O 
exposure O 
, O 
biofilms O 
chronically O 
exposed O 
to O 
75 O 
and O 
150μgL(-1) O 
oxyfluorfen B-TRIVIAL 
showed O 
a O 
higher O 
CAT O 
activity O 
than O 
controls O 
. O 
Chronic O 
exposure O 
to O 
oxyfluorfen B-TRIVIAL 
provoked O 
then O 
structural O 
changes O 
but O 
also O 
functional O 
changes O 
in O 
the O 
capacity O 
of O 
biofilm O 
CAT O 
activity O 
to O 
respond O 
to O 
a O 
sudden O 
increase O 
in O 
concentration O 
, O 
suggesting O 
a O 
selection O 
of O 
species O 
with O 
higher O 
antioxidant O 
capacity O 
. O 
This O 
study O 
highlighted O 
the O 
difficulty O 
of O 
interpretation O 
of O 
AEA O 
values O 
due O 
to O 
their O 
temporal O 
variation O 
and O 
to O 
the O 
absence O 
of O 
absolute O 
threshold O 
value O 
indicative O 
of O 
oxidative O 
stress O 
induced O 
by O 
contaminants O 
. O 
Nevertheless O 
, O 
the O 
determination O 
of O 
AEA O 
pattern O 
throughout O 
acute O 
exposure O 
test O 
is O 
of O 
high O 
interest O 
to O 
compare O 
oxidative O 
stress O 
levels O 
undergone O 
by O 
different O 
biofilm O 
communities O 
and O 
thus O 
determine O 
their O 
antioxidant O 
capacity O 
. O 

, O 
isolated O 
from O 
Juglans O 
mandshurica O 
Maxim O 
, O 
induces O 
apoptosis O 
via O 
down O 
- O 
regulation O 
of O 
AR O 
expression O 
in O 
human O 
prostate O 
cancer O 
LNCaP O 
cells O 
. O 

is O 
a O 
natural O 
compound O 
which O 
has O 
been O 
isolated O 
from O 
Juglans O 
mandshurica O 
Maxim O 
. O 
Recent O 
studies O 
have O 
shown O 
that O 
juglone B-TRIVIAL 
had O 
various O 
pharmacological O 
effects O 
such O 
as O 
anti-viral O 
, O 
anti-bacterial O 
and O 
anti-cancer O 
. O 
However O 
, O 
its O 
anti-cancer O 
activity O 
on O 
human O 
prostate O 
cancer O 
LNCaP O 
cell O 
has O 
not O 
been O 
examined O 
. O 
Thus O 
, O 
the O 
current O 
study O 
was O 
designed O 
to O 
elucidate O 
the O 
molecular O 
mechanism O 
of O 
apoptosis O 
induced O 
by O 
juglone B-TRIVIAL 
in O 
androgen B-FAMILY 
-sensitive O 
prostate O 
cancer O 
LNCaP O 
cells O 
. O 
MTT B-ABBREVIATION 
assay O 
was O 
performed O 
to O 
examine O 
the O 
anti-proliferative O 
effect O 
of O 
juglone B-TRIVIAL 
. O 
Occurrence O 
of O 
apoptosis O 
was O 
detected O 
by O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
staining O 
and O 
flow O 
cytometry O 
in O 
LNCaP O 
cells O 
treated O 
with O 
juglone B-TRIVIAL 
for O 
24h O 
. O 
The O 
result O 
shown O 
that O 
juglone B-TRIVIAL 
inhibited O 
the O 
growth O 
of O 
LNCaP O 
cells O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
. O 
Morphological O 
changes O 
of O 
apoptotic O 
body O 
formation O 
after O 
juglone B-TRIVIAL 
treatment O 
were O 
observed O 
by O 
Hoechst B-TRIVIAL 
33342 I-TRIVIAL 
staining O 
. O 
This O 
apoptotic O 
induction O 
was O 
associated O 
with O 
loss O 
of O 
mitochondrial O 
membrane O 
potential O 
, O 
and O 
caspase-3 O 
, O 
-9 O 
activation O 
. O 
Moreover O 
, O 
we O 
found O 
that O 
juglone B-TRIVIAL 
significantly O 
inhibited O 
the O 
expression O 
levels O 
of O 
androgen B-FAMILY 
receptor O 
( O 
AR O 
) O 
and O 
prostate O 
- O 
specific O 
antigen O 
( O 
PSA O 
) O 
in O 
a O 
dose O 
- O 
dependent O 
manner O 
, O 
as O 
well O 
as O 
abrogated O 
up O 
- O 
regulation O 
of O 
AR O 
and O 
PSA O 
genes O 
with O 
and O 
/ O 
or O 
without O 
dihydrotestosterone B-SYSTEMATIC 
( O 
DHT B-ABBREVIATION 
) O 
. O 
Take O 
together O 
, O 
our O 
results O 
demonstrated O 
that O 
juglone B-TRIVIAL 
might O 
induce O 
the O 
apoptosis O 
in O 
LNCaP O 
cell O 
via O 
down O 
- O 
regulation O 
of O 
AR O 
expression O 
. O 
Therefore O 
, O 
our O 
results O 
indicated O 
that O 
juglone B-TRIVIAL 
may O 
be O 
a O 
potential O 
candidate O 
of O 
drug O 
for O 
androgen B-FAMILY 
-sensitive O 
prostate O 
cancer O 
. O 

Substituted I-FAMILY 
4-(1H)-pyridylene- I-FAMILY 
hydrazone I-FAMILY 
-type O 
inhibitors O 
of O 
AChE O 
, O 
BuChE O 
, O 
and O 
amyloid-β O 
aggregation O 
crossing O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 

the O 
fundamentally O 
multifactorial O 
character O 
of O 
Alzheimer's O 
disease O 
( O 
AD O 
) O 
, O 
addressing O 
more O 
than O 
one O 
target O 
for O 
disease O 
modification O 
or O 
therapy O 
is O 
expected O 
to O 
be O 
highly O 
advantageous O 
. O 
Here O 
, O 
following O 
the O 
cholinergic O 
hypothesis O 
, O 
we O 
aimed O 
to O 
inhibit O 
both O 
acetyl B-SYSTEMATIC 
- O 
and O 
butyrylcholinesterase O 
( O 
AChE O 
and O 
BuChE O 
) O 
in O 
order O 
to O 
increase O 
the O 
concentration O 
of O 
acetylcholine B-SYSTEMATIC 
in O 
the O 
synaptic O 
cleft O 
. O 
In O 
addition O 
, O 
the O 
formation O 
of O 
the O 
amyloid O 
fibrils O 
should O 
be O 
inhibited O 
and O 
already O 
preformed O 
fibrils O 
should O 
be O 
destroyed O 
. O 
Based O 
on O 
a O 
recently O 
identified O 
AChE O 
inhibitor O 
with O 
a O 
1,4- B-FAMILY 
substituted I-FAMILY 
4-(1H)-pyridylene- I-FAMILY 
hydrazone I-FAMILY 
skeleton O 
, O 
a O 
substance O 
library O 
has O 
been O 
generated O 
and O 
tested O 
for O 
inhibition O 
of O 
AChE O 
, O 
BuChE O 
, O 
and O 
fibril O 
formation O 
. O 
Blood O 
- O 
brain O 
barrier O 
mobility O 
was O 
ensured O 
by O 
a O 
transwell O 
assay O 
. O 
Whereas O 
the O 
p-nitrosubstituted O 
compound O 
18C O 
shows O 
an O 
anti-AChE O 
activity O 
in O 
the O 
nanomolar O 
range O 
of O 
concentration O 
( O 
IC50 O 
= O 
90 O 
nM O 
) O 
, O 
the O 
bisnaphthyl O 
substituted O 
compound O 
20L O 
was O 
found O 
to O 
be O 
the O 
best O 
overall O 
inhibitor O 
of O 
AChE O 
/ O 
BuChE O 
and O 
enhances O 
the O 
fibril O 
destruction O 
. O 

and O 
urea B-TRIVIAL 
can O 
be O 
used O 
to O 
increase O 
skin O 
permeability O 
in O 
reduced O 
hydration O 
conditions O 
. O 

natural O 
moisturizing O 
factor O 
( O 
NMF O 
) O 
is O 
a O 
group O 
of O 
hygroscopic O 
molecules O 
that O 
is O 
naturally O 
present O 
in O 
skin O 
and O 
protects O 
from O 
severe O 
drying O 
. O 
Glycerol B-TRIVIAL 
and O 
urea B-TRIVIAL 
are O 
two O 
examples O 
of O 
NMF O 
components O 
that O 
are O 
also O 
used O 
in O 
skin O 
care O 
applications O 
. O 
In O 
the O 
present O 
study O 
, O 
we O 
investigate O 
the O 
influence O 
of O 
glycerol B-TRIVIAL 
and O 
urea B-TRIVIAL 
on O 
the O 
permeability O 
of O 
a O 
model O 
drug O 
( O 
metronidazole B-TRIVIAL 
, O 
Mz O 
) O 
across O 
excised O 
pig O 
skin O 
membranes O 
at O 
different O 
hydrating O 
conditions O 
. O 
The O 
degree O 
of O 
skin O 
hydration O 
is O 
regulated O 
by O 
the O 
gradient O 
in O 
water O 
activity O 
across O 
the O 
membrane O 
, O 
which O 
in O 
turn O 
depends O 
on O 
the O 
water O 
activity O 
of O 
the O 
formulation O 
in O 
contact O 
with O 
the O 
skin O 
membrane O 
. O 
Here O 
, O 
we O 
determine O 
the O 
water O 
activity O 
of O 
all O 
formulations O 
employed O 
using O 
an O 
isothermal O 
calorimetric O 
method O 
. O 
Thus O 
, O 
the O 
gradient O 
in O 
water O 
activity O 
is O 
controlled O 
by O 
a O 
novel O 
experimental O 
set O 
- O 
up O 
with O 
well O 
- O 
defined O 
boundary O 
conditions O 
on O 
both O 
sides O 
of O 
the O 
skin O 
membrane O 
. O 
The O 
results O 
demonstrate O 
that O 
glycerol B-TRIVIAL 
and O 
urea B-TRIVIAL 
can O 
retain O 
high O 
steady O 
state O 
flux O 
of O 
Mz O 
across O 
skin O 
membranes O 
at O 
dehydrating O 
conditions O 
, O 
which O 
otherwise O 
would O 
decrease O 
the O 
permeability O 
due O 
to O 
dehydration O 
. O 
X-ray O 
diffraction O 
measurements O 
are O 
performed O 
to O 
give O 
insight O 
into O 
the O 
effects O 
of O 
glycerol B-TRIVIAL 
and O 
urea B-TRIVIAL 
on O 
SC O 
molecular O 
organization O 
. O 
The O 
novel O 
steady O 
state O 
flux O 
results O 
can O 
be O 
related O 
to O 
the O 
observation O 
that O 
water O 
, O 
glycerol B-TRIVIAL 
, O 
and O 
urea B-TRIVIAL 
all O 
affect O 
the O 
structural O 
features O 
of O 
the O 
SC O 
molecular O 
components O 
in O 
a O 
similar O 
manner O 
. O 

potentiation O 
of O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
5 O 
and O 
the O 
alpha O 
7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
modulates O 
behavioural O 
and O 
GABAergic O 
deficits O 
induced O 
by O 
early O 
postnatal O 
phencyclidine B-TRIVIAL 
( O 
PCP B-ABBREVIATION 
) O 
treatment O 
. O 

underlying O 
mechanism O 
of O 
the O 
GABAergic O 
deficits O 
observed O 
in O 
schizophrenia O 
has O 
been O 
proposed O 
to O 
involve O 
NMDA B-ABBREVIATION 
receptor O 
hypofunction O 
. O 
An O 
emerging O 
treatment O 
strategy O 
therefore O 
aims O 
at O 
enhancing O 
GABAergic O 
signalling O 
by O 
increasing O 
the O 
excitatory O 
transmission O 
onto O 
interneurons O 
. O 
We O 
wanted O 
to O 
determine O 
whether O 
behavioural O 
and O 
GABAergic O 
functional O 
deficits O 
induced O 
by O 
the O 
NMDA B-ABBREVIATION 
receptor O 
channel O 
blocker O 
, O 
phencyclidine B-TRIVIAL 
( O 
PCP B-ABBREVIATION 
) O 
, O 
could O 
be O 
reversed O 
by O 
repeated O 
administration O 
of O 
two O 
drugs O 
known O 
to O 
enhance O 
GABAergic O 
transmission O 
: O 
the O 
positive O 
allosteric O 
modulator O 
( O 
PAM O 
) O 
of O 
the O 
metabotropic O 
glutamate B-TRIVIAL 
receptor O 
5 O 
( O 
mGluR5 O 
) O 
, O 
ADX47273 O 
, O 
and O 
the O 
partial O 
agonist O 
of O 
the O 
α7 O 
nicotinic O 
acetylcholine B-SYSTEMATIC 
receptor O 
( O 
α7 O 
nAChR O 
) O 
, O 
SSR180711 B-IDENTIFIER 
. O 
Adolescent O 
rats O 
( O 
4-5 O 
weeks O 
) O 
subjected O 
to O 
PCP B-ABBREVIATION 
treatment O 
during O 
the O 
second O 
postnatal O 
week O 
displayed O 
a O 
consistent O 
deficit O 
in O 
prepulse O 
inhibition O 
( O 
PPI O 
) O 
, O 
which O 
was O 
reversed O 
by O 
a O 
one O 
week O 
treatment O 
with O 
ADX47273 B-IDENTIFIER 
or O 
SSR180711 B-IDENTIFIER 
. O 
We O 
examined O 
GABAergic O 
transmission O 
by O 
whole O 
cell O 
patch O 
- O 
clamp O 
recordings O 
of O 
miniature O 
inhibitory O 
postsynaptic O 
currents O 
( O 
mIPSC O 
) O 
in O 
pyramidal O 
neurons O 
in O 
layer O 
II O 
/ O 
III O 
of O 
prefrontal O 
cortex O 
( O 
PFC O 
) O 
and O 
by O 
activation O 
of O 
extrasynaptic O 
δ- O 
containing O 
GABAA O 
receptors O 
by O 
THIP B-ABBREVIATION 
. O 
Following O 
PCP B-ABBREVIATION 
treatment O 
, O 
pyramidal O 
neurons O 
displayed O 
a O 
reduced O 
mIPSC O 
frequency O 
and O 
up O 
- O 
regulation O 
of O 
extrasynaptic O 
THIP B-ABBREVIATION 
-induced O 
current O 
. O 
ADX47273 B-IDENTIFIER 
treatment O 
restored O 
this O 
up O 
- O 
regulation O 
of O 
THIP B-ABBREVIATION 
-induced O 
current O 
. O 
Finally O 
, O 
we O 
showed O 
that O 
repeated O 
treatment O 
with O 
ADX47273 B-IDENTIFIER 
and O 
SSR180711 B-IDENTIFIER 
decreased O 
the O 
induction O 
of O 
spontaneous O 
inhibitory O 
current O 
caused O 
by O 
acute O 
and O 
direct O 
agonism O 
of O 
mGluR5s O 
and O 
α7 O 
nAChRs O 
in O 
slices O 
. O 
These O 
results O 
show O 
that O 
repeated O 
administration O 
of O 
ADX47273 B-IDENTIFIER 
or O 
SSR180711 B-IDENTIFIER 
reverses O 
certain O 
behavioural O 
and O 
functional O 
deficits O 
induced O 
by O 
PCP B-ABBREVIATION 
, O 
likely O 
through O 
down O 
- O 
regulation O 
or O 
desensitisation O 
of O 
mGluR5s O 
and O 
α7 O 
nAChRs O 
, O 
respectively O 
. O 

combined O 
pharmacological O 
and O 
genetic O 
approach O 
was O 
undertaken O 
to O 
investigate O 
the O 
contribution O 
of O 
endogenous O 
dopamine B-TRIVIAL 
to O 
the O 
motor O 
actions O 
of O 
nociceptin O 
/ O 
orphanin O 
FQ O 
( O 
N O 
/ O 
OFQ O 
) O 
receptor O 
( O 
NOP O 
receptor O 
) O 
ligands O 
. O 
Motor O 
activity O 
was O 
evaluated O 
by O 
a O 
battery O 
of O 
behavioural O 
tests O 
in O 
mice O 
. O 
The O 
involvement O 
of O 
the O 
various O 
DA O 
receptor O 
subtypes O 
in O 
the O 
motor O 
effects O 
of O 
N O 
/ O 
OFQ O 
and O 
NOP O 
receptor O 
antagonists O 
was O 
evaluated O 
pharmacologically O 
, O 
using O 
D1 O 
/ O 
D5 O 
( O 
SCH23390 B-IDENTIFIER 
) O 
, O 
D2 O 
/ O 
D3 O 
( O 
raclopride B-TRIVIAL 
, O 
amisulpride B-TRIVIAL 
) O 
and O 
D3 O 
( O 
S33084 B-IDENTIFIER 
) O 
receptor O 
antagonists O 
, O 
and O 
by O 
using O 
D2 O 
receptor O 
knockout O 
mice O 
. O 
Low O 
doses O 
of O 
N O 
/ O 
OFQ O 
and O 
NOP O 
receptor O 
antagonists O 
promoted O 
movement O 
whereas O 
higher O 
doses O 
inhibited O 
it O 
. O 
Motor O 
facilitation O 
was O 
selectively O 
prevented O 
by O 
raclopride B-TRIVIAL 
while O 
motor O 
inhibition O 
was O 
prevented O 
by O 
amisulpride B-TRIVIAL 
. O 
Amisulpride B-TRIVIAL 
also O 
attenuated O 
the O 
hypolocomotion O 
induced O 
by O 
the O 
D2 O 
/ O 
D3 O 
receptor O 
agonist O 
pramipexole B-TRIVIAL 
and O 
dopamine B-TRIVIAL 
precursor O 
L-3,4-dihydroxyphenylalanine B-SYSTEMATIC 
, O 
whereas O 
raclopride B-TRIVIAL 
( O 
and O 
S33084 B-IDENTIFIER 
) O 
worsened O 
it O 
. O 
To O 
dissect O 
out O 
the O 
contribution O 
of O 
pre- O 
and O 
postsynaptic O 
D2 O 
receptors O 
, O 
mice O 
lacking O 
the O 
D2 O 
receptor O 
( O 
D2R(- O 
/ O 
- O 
) O 
) O 
or O 
its O 
long O 
isoform O 
( O 
D2L(- O 
/ O 
- O 
) O 
) O 
were O 
used O 
. O 
Motor O 
facilitation O 
induced O 
by O 
N O 
/ O 
OFQ O 
and O 
NOP O 
receptor O 
antagonists O 
was O 
lost O 
in O 
D2R(- O 
/ O 
- O 
) O 
and O 
D2L(- O 
/ O 
- O 
) O 
mice O 
whereas O 
motor O 
inhibition O 
induced O 
by O 
NOP O 
receptor O 
antagonists O 
( O 
and O 
pramipexole B-TRIVIAL 
) O 
was O 
lost O 
in O 
D2R(- O 
/ O 
- O 
) O 
but O 
preserved O 
in O 
D2L(- O 
/ O 
- O 
) O 
mice O 
. O 
N O 
/ O 
OFQ-induced O 
hypolocomotion O 
was O 
observed O 
in O 
both O 
genotypes O 
. O 
We O 
demonstrate O 
that O 
motor O 
actions O 
of O 
NOP O 
receptor O 
ligands O 
rely O 
on O 
the O 
modulation O 
of O 
endogenous O 
dopamine B-TRIVIAL 
. O 
Motor O 
facilitation O 
induced O 
by O 
NOP O 
receptor O 
antagonists O 
as O 
well O 
as O 
low O 
dose O 
N O 
/ O 
OFQ O 
is O 
mediated O 
through O 
D2L O 
postsynaptic O 
receptors O 
whereas O 
motor O 
inhibition O 
observed O 
with O 
higher O 
doses O 
of O 
N O 
/ O 
OFQ O 
occurs O 
by O 
direct O 
inhibition O 
of O 
mesencephalic O 
DA O 
neurons O 
. O 
Motor O 
inhibition O 
seen O 
with O 
high O 
doses O 
of O 
NOP O 
receptor O 
antagonists O 
appears O 
to O 
be O 
mediated O 
through O 
the O 
D2 O 
presynaptic O 
autoreceptors O 
. O 
These O 
data O 
confirm O 
that O 
endogenous O 
N O 
/ O 
OFQ O 
is O 
a O 
powerful O 
modulator O 
of O 
dopamine O 
transmission O 
in O 
vivo O 
and O 
that O 
the O 
effects O 
of O 
NOP O 
receptor O 
antagonists O 
on O 
motor O 
function O 
reflect O 
the O 
blockade O 
of O 
this O 
endogenous O 
N O 
/ O 
OFQ O 
tone O 
. O 

effects O 
of O 
oxytocin B-TRIVIAL 
in O 
two O 
mouse O 
models O 
of O 
autism O 
spectrum O 
disorders O 
. O 

evidence O 
suggests O 
that O 
oxytocin B-TRIVIAL 
treatment O 
improves O 
social O 
deficits O 
and O 
repetitive O 
behavior O 
in O 
autism O 
spectrum O 
disorders O 
( O 
ASDs O 
) O 
. O 
However O 
, O 
the O 
neuropeptide O 
has O 
a O 
short O 
plasma O 
half O 
- O 
life O 
and O 
poor O 
ability O 
to O 
penetrate O 
the O 
blood O 
- O 
brain O 
barrier O 
. O 
In O 
order O 
to O 
facilitate O 
the O 
development O 
of O 
more O 
bioavailable O 
oxytocinergic O 
compounds O 
as O 
therapeutics O 
to O 
treat O 
core O 
ASD O 
symptoms O 
, O 
small O 
animal O 
models O 
must O 
be O 
validated O 
for O 
preclinical O 
screens O 
. O 
This O 
study O 
examined O 
the O 
preclinical O 
utility O 
of O 
two O 
inbred O 
mouse O 
strains O 
, O 
BALB O 
/ O 
cByJ O 
and O 
C58 O 
/ O 
J O 
, O 
that O 
exhibit O 
phenotypes O 
relevant O 
to O 
core O 
ASD O 
symptoms O 
. O 
Mice O 
from O 
both O 
strains O 
were O 
intraperitoneally O 
administered O 
oxytocin B-TRIVIAL 
, O 
using O 
either O 
acute O 
or O 
sub O 
- O 
chronic O 
regimens O 
. O 
Acute O 
oxytocin B-TRIVIAL 
did O 
not O 
increase O 
sociability O 
in O 
BALB O 
/ O 
cByJ O 
; O 
however O 
, O 
sub O 
- O 
chronic O 
oxytocin B-TRIVIAL 
had O 
significant O 
prosocial O 
effects O 
in O 
both O 
BALB O 
/ O 
cByJ O 
and O 
C58 O 
/ O 
J O 
. O 
Increased O 
sociability O 
was O 
observed O 
24 O 
hours O 
following O 
the O 
final O 
oxytocin B-TRIVIAL 
dose O 
in O 
BALB O 
/ O 
cByJ O 
, O 
while O 
prosocial O 
effects O 
of O 
oxytocin B-TRIVIAL 
emerged O 
1-2 O 
weeks O 
post O 
- O 
treatment O 
in O 
C58 O 
/ O 
J O 
. O 
Furthermore O 
, O 
acute O 
oxytocin B-TRIVIAL 
decreased O 
motor O 
stereotypy O 
in O 
C58 O 
/ O 
J O 
and O 
did O 
not O 
induce O 
hypoactivity O 
or O 
anxiolytic O 
- O 
like O 
effects O 
in O 
an O 
open O 
field O 
test O 
. O 
This O 
study O 
demonstrates O 
that O 
oxytocin B-TRIVIAL 
administration O 
can O 
attenuate O 
social O 
deficits O 
and O 
repetitive O 
behavior O 
in O 
mouse O 
models O 
of O 
ASD O 
, O 
dependent O 
on O 
dose O 
regimen O 
and O 
genotype O 
. O 
These O 
findings O 
provide O 
validation O 
of O 
the O 
BALB O 
/ O 
cByJ O 
and O 
C58 O 
/ O 
J O 
models O 
as O 
useful O 
platforms O 
for O 
screening O 
novel O 
drugs O 
for O 
intervention O 
in O 
ASDs O 
and O 
for O 
elucidating O 
the O 
mechanisms O 
contributing O 
to O 
the O 
prosocial O 
effects O 
of O 
oxytocin B-TRIVIAL 
. O 

nanocarriers O 
have O 
shown O 
great O 
promise O 
as O 
delivery O 
systems O 
. O 
An O 
alternative O 
strategy O 
has O 
been O 
to O 
explore O 
new O 
delivery O 
routes O 
, O 
such O 
as O 
intradermal O 
( O 
i.d O 
. O 
) O 
that O 
can O 
be O 
used O 
for O 
vaccines O 
and O 
patch O 
- O 
based O 
drug O 
delivery O 
. O 
Despite O 
their O 
many O 
advantages O 
, O 
there O 
are O 
few O 
toxicity O 
studies O 
, O 
especially O 
in O 
vivo O 
. O 
We O 
report O 
a O 
safety O 
assessment O 
of O 
biodegradable O 
poly(-caprolactone) B-SYSTEMATIC 
lipid O 
- O 
core O 
nanocapsules O 
( O 
LNC O 
) O 
with O 
a O 
mean O 
size O 
of O 
245 O 
± O 
10 O 
nm O 
following O 
single O 
and O 
repeated O 
intradermal O 
injections O 
to O 
Wistar O 
rats O 
. O 
Suspensions O 
were O 
prepared O 
by O 
interfacial O 
deposition O 
of O 
polymer O 
. O 
The O 
animals O 
( O 
n O 
= O 
6 O 
/ O 
group O 
) O 
received O 
a O 
single O 
dose O 
of O 
saline O 
solution O 
( O 
1.2 O 
ml O 
/ O 
kg O 
) O 
or O 
LNC O 
( O 
7.2 O 
× O 
10(12) O 
LNC O 
/ O 
kg O 
) O 
, O 
or O 
repeated O 
doses O 
of O 
two O 
controls O 
, O 
saline O 
solution O 
or O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
( O 
0.9 O 
ml O 
/ O 
kg O 
) O 
, O 
or O 
three O 
different O 
concentrations O 
of O 
LNC O 
( O 
1.8 O 
, O 
3.6 O 
, O 
and O 
5.4 O 
× O 
10(12) O 
LNC O 
/ O 
kg O 
) O 
for O 
28 O 
consecutive O 
days O 
. O 
Clinical O 
and O 
physiological O 
signs O 
and O 
mortality O 
were O 
observed O 
. O 
Samples O 
of O 
urine O 
, O 
blood O 
, O 
and O 
tissue O 
were O 
used O 
to O 
perform O 
toxicological O 
evaluation O 
. O 
There O 
were O 
no O 
clinical O 
signs O 
of O 
toxicity O 
or O 
mortality O 
, O 
but O 
there O 
was O 
a O 
slight O 
decrease O 
in O 
the O 
relative O 
body O 
weights O 
in O 
the O 
Tween B-TRIVIAL 
80 I-TRIVIAL 
-treated O 
group O 
( O 
p O 
< O 
0.01 O 
) O 
after O 
repeated O 
administration O 
. O 
No O 
histopathological O 
alterations O 
were O 
observed O 
in O 
tissues O 
or O 
significant O 
changes O 
in O 
blood O 
and O 
urinary O 
biomarkers O 
for O 
tissue O 
damage O 
. O 
Mild O 
alterations O 
in O 
white O 
blood O 
cells O 
count O 
with O 
increases O 
in O 
granulocytes O 
in O 
the O 
Tween-80 B-TRIVIAL 
group O 
( O 
p O 
< O 
0.05 O 
) O 
were O 
found O 
. O 
Genotoxicity O 
was O 
evaluated O 
through O 
the O 
comet O 
assay O 
and O 
no O 
statistical O 
difference O 
was O 
observed O 
among O 
the O 
groups O 
. O 
Therefore O 
, O 
we O 
conclude O 
that O 
, O 
under O 
the O 
conditions O 
of O 
these O 
experiments O 
, O 
biodegradable O 
LNC O 
did O 
not O 
present O 
appreciable O 
toxicity O 
after O 
28 O 
consecutive O 
days O 
of O 
intradermal O 
administration O 
and O 
is O 
promising O 
for O 
its O 
future O 
application O 
in O 
vaccines O 
and O 
patch O 
- O 
based O 
devices O 
for O 
enhancing O 
the O 
delivery O 
of O 
drugs O 
. O 

synthase O 
kinase-3 O 
( O 
GSK-3 O 
) O 
is O 
a O 
cytoplasmic O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
protein O 
kinase O 
that O 
phosphorylates O 
and O 
inhibits O 
glycogen O 
synthase O 
, O 
thereby O 
inhibiting O 
glycogen O 
synthesis O 
from O 
glucose B-TRIVIAL 
. O 
However O 
, O 
this O 
serine B-TRIVIAL 
/ O 
threonine B-TRIVIAL 
kinase O 
is O 
now O 
known O 
to O 
regulate O 
numerous O 
cellular O 
processes O 
through O 
a O 
number O 
of O 
signaling O 
pathways O 
important O 
for O 
cell O 
proliferation O 
, O 
stem O 
cell O 
renewal O 
, O 
apoptosis O 
and O 
development O 
. O 
Because O 
of O 
these O 
diverse O 
roles O 
, O 
malfunction O 
of O 
this O 
kinase O 
is O 
also O 
known O 
to O 
be O 
involved O 
in O 
the O 
pathogenesis O 
of O 
human O 
diseases O 
, O 
such O 
as O 
nervous O 
system O 
disorders O 
, O 
diabetes O 
, O 
bone O 
formation O 
, O 
inflammation O 
, O 
cancer O 
and O 
heart O 
failure O 
. O 
Therefore O 
, O 
GSK-3 O 
is O 
recognized O 
as O 
an O 
attractive O 
target O 
for O 
the O 
development O 
of O 
new O 
drugs O 
. O 
The O 
present O 
review O 
summarizes O 
the O 
roles O 
of O 
GSK-3 O 
in O 
the O 
insulin O 
, O 
Wnt O 
/ O 
β-catenin O 
and O 
hedgehog O 
signaling O 
pathways O 
including O 
the O 
regulation O 
of O 
their O 
activities O 
. O 
The O 
roles O 
of O 
GSK-3 O 
in O 
the O 
development O 
of O 
human O 
diseases O 
within O 
the O 
context O 
of O 
its O 
participation O 
in O 
various O 
signaling O 
pathways O 
are O 
also O 
summarized O 
. O 
Finally O 
, O 
the O 
possibility O 
of O 
new O 
drug O 
development O 
targeting O 
this O 
kinase O 
is O 
discussed O 
with O 
recent O 
information O 
about O 
inhibitors O 
and O 
activators O 
of O 
GSK-3 O 
. O 

of O 
the O 
liver O 
cancer O 
- O 
down O 
- O 
regulated O 
long O 
noncoding O 
RNA O 
uc002mbe.2 O 
mediates O 
trichostatin B-TRIVIAL 
-induced O 
apoptosis O 
of O 
liver O 
cancer O 
cells O 
. O 

expression O 
of O 
long O 
non-coding O 
RNAs O 
( O 
lncRNAs O 
) O 
plays O 
critical O 
roles O 
in O 
hepatocarcinogenesis O 
. O 
Considerable O 
attention O 
has O 
focused O 
on O 
the O 
antitumor O 
effect O 
of O 
histone O 
deacetylase O 
inhibitor O 
( O 
Trichostatin B-TRIVIAL 
A I-TRIVIAL 
, O 
TSA B-ABBREVIATION 
) O 
as O 
well O 
as O 
the O 
coding O 
gene O 
expression O 
- O 
induced O 
apoptosis O 
of O 
cancer O 
cells O 
. O 
However O 
, O 
it O 
is O 
not O 
known O 
whether O 
lncRNA O 
has O 
a O 
role O 
in O 
TSA B-ABBREVIATION 
-induced O 
apoptosis O 
of O 
human O 
hepatocellular O 
carcinoma O 
( O 
HCC O 
) O 
cells O 
. O 
The O 
global O 
expression O 
of O 
lncRNAs O 
and O 
coding O 
genes O 
was O 
analyzed O 
with O 
the O 
Human O 
LncRNA O 
Array O 
V2.0 O 
after O 
24h O 
treatment O 
. O 
Expression O 
was O 
verified O 
in O 
cell O 
lines O 
and O 
tissues O 
by O 
quantitative O 
real O 
- O 
time O 
PCR O 
. O 
The O 
data O 
showed O 
that O 
4.8% O 
( O 
959 O 
) O 
of O 
lncRNA O 
and O 
6.1% O 
( O 
1849 O 
) O 
of O 
protein O 
coding O 
gene O 
were O 
significantly O 
differentially O 
expressed O 
. O 
The O 
differential O 
expressions O 
of O 
lncRNA O 
and O 
protein O 
coding O 
genes O 
had O 
distinguishable O 
hierarchical O 
clustering O 
expression O 
profiling O 
pattern O 
. O 
Among O 
these O 
differentially O 
expressed O 
lncRNAs O 
, O 
the O 
greatest O 
change O 
was O 
noted O 
for O 
uc002mbe.2 O 
, O 
which O 
had O 
more O 
than O 
300 O 
folds O 
induction O 
upon O 
TSA B-ABBREVIATION 
treatment O 
. O 
TSA B-ABBREVIATION 
selectively O 
induced O 
uc002mbe.2 O 
in O 
four O 
studied O 
HCC O 
cell O 
lines O 
. O 
Compared O 
with O 
normal O 
human O 
hepatocytes O 
and O 
adjacent O 
noncancerous O 
tissues O 
, O 
uc002mbe.2 O 
expression O 
level O 
was O 
significantly O 
lower O 
in O 
the O 
HCC O 
cell O 
lines O 
and O 
liver O 
cancer O 
tissues O 
. O 
The O 
TSA B-ABBREVIATION 
-induced O 
uc002mbe.2 O 
expression O 
was O 
positively O 
correlated O 
with O 
the O 
apoptotic O 
effect O 
of O 
TSA B-ABBREVIATION 
in O 
HCC O 
cells O 
. O 
In O 
addition O 
, O 
knockdown O 
the O 
expression O 
of O 
uc002mbe.2 O 
significantly O 
reduced O 
TSA B-ABBREVIATION 
-induced O 
apoptosis O 
of O 
Huh7cells O 
. O 
Therefore O 
, O 
TSA B-ABBREVIATION 
-induced O 
apoptosis O 
of O 
HCC O 
cells O 
is O 
uc002mbe.2 O 
dependent O 
and O 
reduced O 
expression O 
of O 
uc002mbe.2 O 
may O 
be O 
associated O 
with O 
liver O 
carcinogenesis O 
. O 

dibenzylideneacetone I-SYSTEMATIC 
derivatives O 
as O 
potential O 
SPECT O 
probes O 
for O 
in O 
vivo O 
imaging O 
of O 
β-amyloid O 
plaque O 
. O 

(99m)Tc-labeled B-SYSTEMATIC 
dibenzylideneacetone I-SYSTEMATIC 
derivatives O 
and O 
corresponding O 
rhenium B-SYSTEMATIC 
complexes O 
were O 
successfully O 
synthesized O 
and O 
biologically O 
evaluated O 
as O 
potential O 
imaging O 
probes O 
for O 
Aβ O 
plaques O 
using O 
SPECT O 
. O 
All O 
rhenium B-SYSTEMATIC 
complexes O 
( O 
5a-d O 
) O 
showed O 
affinity O 
for O 
Aβ(1-42) O 
aggregates O 
( O 
Ki O 
= O 
13.6-120.9 O 
nM O 
) O 
, O 
and O 
selectively O 
stained O 
the O 
Aβ O 
plaques O 
on O 
brain O 
sections O 
of O 
transgenic O 
mice O 
. O 
Biodistribution O 
in O 
normal O 
mice O 
revealed O 
that O 
[ O 
(99m)Tc B-FORMULA 
]5a-d O 
exhibited O 
moderate O 
initial O 
uptake O 
( O 
0.31%-0.49% O 
ID O 
/ O 
g O 
at O 
2 O 
min O 
) O 
and O 
reasonable O 
brain O 
washout O 
at O 
60 O 
min O 
post O 
- O 
injection O 
. O 
Although O 
additional O 
optimizations O 
are O 
still O 
needed O 
to O 
facilitate O 
it's O 
penetration O 
through O 
BBB O 
, O 
the O 
present O 
results O 
indicate O 
that O 
[ O 
(99m)Tc B-FORMULA 
]5a O 
may O 
be O 
a O 
potential O 
SPECT O 
probe O 
for O 
imaging O 
Aβ O 
plaques O 
in O 
Alzheimer's O 
brains O 
. O 

vitro O 
biosynthesis O 
, O 
isolation O 
, O 
and O 
identification O 
of O 
predominant O 
metabolites O 
of O 
2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one B-SYSTEMATIC 
( O 
RVX-208 B-IDENTIFIER 
) O 
. O 

structures O 
of O 
the O 
two O 
predominant O 
metabolites O 
( O 
M4 O 
and O 
M5 O 
) O 
of O 
RVX-208 B-IDENTIFIER 
, O 
observed O 
both O 
in O 
in O 
vitro O 
human O 
and O 
animal O 
liver O 
microsomal O 
incubations O 
, O 
as O 
well O 
as O 
in O 
plasma O 
from O 
animal O 
in O 
vivo O 
studies O 
, O 
were O 
determined O 
. O 
A O 
panel O 
of O 
biocatalytic O 
systems O 
was O 
tested O 
to O 
identify O 
biocatalysts O 
suitable O 
for O 
milligram O 
scale O 
production O 
of O 
metabolite O 
M4 O 
from O 
RVX-208 B-IDENTIFIER 
. O 
Rabbit O 
liver O 
S9 O 
fraction O 
was O 
selected O 
as O 
the O 
most O 
suitable O 
system O 
, O 
primarily O 
based O 
on O 
pragmatic O 
metrics O 
such O 
as O 
catalyst O 
cost O 
and O 
estimated O 
yield O 
of O 
M4 O 
( O 
∼55% O 
) O 
. O 
Glucuronidation O 
of O 
RVX-208 B-IDENTIFIER 
catalyzed O 
by O 
rabbit O 
liver O 
S9 O 
fraction O 
was O 
optimized O 
to O 
produce O 
M4 O 
in O 
amounts O 
sufficient O 
for O 
structural O 
characterization O 
. O 
Structural O 
studies O 
using O 
LC O 
/ O 
MS O 
/ O 
MS O 
analysis O 
and O 
(1)H B-FORMULA 
NMR O 
spectroscopy O 
showed O 
the O 
formation O 
of O 
a O 
glycosidic O 
bond O 
between O 
the O 
primary B-FAMILY 
hydroxyl I-FAMILY 
group O 
of O 
RVX-208 B-IDENTIFIER 
and O 
glucuronic B-TRIVIAL 
acid I-TRIVIAL 
. O 
NMR O 
results O 
suggested O 
that O 
the O 
glycosidic O 
bond O 
has O 
the O 
β-anomeric O 
configuration O 
. O 
A O 
synthetic O 
sample O 
of O 
M4 O 
confirmed O 
the O 
proposed O 
structure O 
. O 
Metabolite O 
M5 O 
, O 
hypothesized O 
to O 
be O 
the O 
carboxylate B-SYSTEMATIC 
of O 
RVX-208 B-IDENTIFIER 
, O 
was O 
prepared O 
using O 
human O 
liver O 
microsomes O 
, O 
purified O 
by O 
HPLC O 
, O 
and O 
characterized O 
by O 
LC O 
/ O 
MS O 
/ O 
MS O 
and O 
(1)H B-FORMULA 
NMR O 
. O 
The O 
structure O 
was O 
confirmed O 
by O 
comparison O 
to O 
a O 
synthetic O 
sample O 
. O 
Both O 
samples O 
confirmed O 
M5 O 
as O 
a O 
product O 
of O 
oxidation O 
of O 
primary B-FAMILY 
hydroxyl I-FAMILY 
group O 
of O 
RVX-208 B-IDENTIFIER 
to O 
carboxylic B-SYSTEMATIC 
acid I-SYSTEMATIC 
. O 

enhances O 
the O 
anti-migratory O 
activities O 
of O 
isomalyngamide B-TRIVIAL 
A I-TRIVIAL 
analogs O 
. O 

, O 
new O 
, O 
fully O 
synthetic O 
glycosylated B-FAMILY 
isomalyngamide I-FAMILY 
A I-FAMILY 
analogs O 
4-6 O 
were O 
prepared O 
and O 
evaluated O 
for O 
their O 
anti-migratory O 
activities O 
in O 
human O 
breast O 
cancer O 
cells O 
. O 
The O 
results O 
of O 
the O 
study O 
show O 
that O 
two O 
glycosylated O 
derivatives O 
4 O 
and O 
5 O 
, O 
containing O 
mannose B-TRIVIAL 
and O 
galactose B-TRIVIAL 
appendages O 
, O 
suppress O 
metastatic O 
events O 
( O 
e.g O 
. O 
, O 
migration O 
, O 
invasion O 
and O 
adhesion O 
) O 
in O 
human O 
breast O 
adenocarcinoma O 
MDA-MB-231 O 
cells O 
at O 
" O 
nontoxic O 
" O 
concentration O 
levels O 
. O 
In O 
contrast O 
, O 
derivative O 
6 O 
that O 
contains O 
a O 
lactose B-TRIVIAL 
moiety O 
, O 
displays O 
a O 
less O 
potent O 
activity O 
. O 
The O 
findings O 
show O 
that O 
monosaccharide B-FAMILY 
rather O 
than O 
disaccharide B-FAMILY 
appendages O 
to O 
the O 
isomalyngamide B-TRIVIAL 
A I-TRIVIAL 
backbone O 
more O 
greatly O 
influence O 
cell O 
migration O 
and O 
invasive O 
ability O 
. O 
Evidence O 
has O 
been O 
gained O 
for O 
a O 
mechanism O 
for O 
inhibition O 
of O 
metastatic O 
activities O 
in O 
MDA-MB-231 O 
cells O 
by O 
4 O 
and O 
5 O 
, O 
involving O 
inactivation O 
of O 
the O 
expression O 
of O 
p-FAK O 
and O 
paxillin O 
through O 
the O 
integrin O 
- O 
mediated O 
antimetastatic O 
pathway O 
. O 

, O 
characterization O 
and O 
in O 
vitro O 
pharmacological O 
evaluation O 
of O 
new O 
water O 
soluble O 
Ni B-FORMULA 
(II) I-FORMULA 
complexes O 
of O 
4N B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
thiosemicarbazones I-FAMILY 
of O 
2-oxo-1,2-dihydroquinoline-3-carbaldehyde B-SYSTEMATIC 
. O 

new O 
Ni B-FORMULA 
(II) I-FORMULA 
complexes O 
of O 
general O 
formula O 
[Ni(H2-Qtsc-R)2](NO3)2 B-FAMILY 
( O 
H2-Qtsc-R B-FAMILY 
= O 
4N B-FAMILY 
- I-FAMILY 
substituted I-FAMILY 
thiosemicarbazones I-FAMILY 
of O 
2-oxo-1,2-dihydroquinoline-3-carbaldehyde B-SYSTEMATIC 
, O 
where O 
R O 
= O 
H B-FORMULA 
( O 
1 O 
) O 
, O 
Me B-FORMULA 
( O 
2 O 
) O 
, O 
Et B-FORMULA 
( O 
3 O 
) O 
, O 
or O 
Ph B-FORMULA 
( O 
4 O 
) O 
) O 
have O 
been O 
synthesized O 
and O 
characterized O 
. O 
The O 
geometry O 
of O 
the O 
complexes O 
was O 
confirmed O 
by O 
single O 
crystal O 
X-ray O 
crystallography O 
for O 
one O 
of O 
the O 
complexes O 
( O 
3 O 
) O 
. O 
The O 
binding O 
affinity O 
of O 
the O 
complexes O 
with O 
DNA O 
and O 
protein O 
have O 
been O 
studied O 
which O 
indicate O 
that O 
they O 
could O 
interact O 
with O 
calf O 
thymus O 
DNA O 
and O 
bovine O 
serum O 
albumin O 
protein O 
. O 
Investigations O 
of O 
antioxidative O 
properties O 
showed O 
that O 
all O 
the O 
complexes O 
have O 
strong O 
radical O 
scavenging O 
properties O 
. O 
Cytotoxic O 
studies O 
showed O 
that O 
the O 
complexes O 
exhibited O 
effective O 
cytotoxic O 
activity O 
against O 
a O 
panel O 
of O 
human O 
cancer O 
cells O 
without O 
affecting O 
the O 
normal O 
cells O 
much O 
. O 

tactics O 
of O 
new O 
class O 
of O 
4-aminothieno[2,3-d]pyrimidine-6-carbonitrile B-SYSTEMATIC 
derivatives O 
acting O 
as O 
antimicrobial O 
agents O 
. O 

selective O 
reactions O 
were O 
studied O 
on O 
oxothieno[2,3-d]pyrimidine-6-carboxamide B-SYSTEMATIC 
3 O 
with O 
POCl3 B-FORMULA 
and O 
PCl5 B-FORMULA 
. O 
At O 
25-50 O 
°C O 
, O 
the O 
C B-FORMULA 
7-amide O 
rearranges O 
to O 
nitrile B-SYSTEMATIC 
furnished O 
compound O 
4 O 
in O 
85-90% O 
yield O 
, O 
while O 
at O 
80-110 O 
°C O 
furnished O 
mixture O 
of O 
products O 
4 O 
and O 
5 O 
in O 
28-68% O 
yields O 
. O 
The O 
chloro B-SYSTEMATIC 
displacement O 
with O 
amines B-FAMILY 
in O 
compound O 
5 O 
yielded O 
4-aminothieno[2,3-d]pyrimidine-6-carbonitrile B-SYSTEMATIC 
derivatives O 
8(a-h) O 
and O 
9(a-e) O 
. O 
Antimicrobial O 
activity O 
of O 
new O 
compounds O 
was O 
studied O 
against O 
several O 
bacteria O 
such O 
as O 
Staphylococcus O 
aureus O 
MTCC-96 O 
, O 
Escherichia O 
coli O 
MTCC-443 O 
, O 
Pseudomonas O 
aeruginosa O 
MTCC-4 O 
41 O 
, O 
Streptococcus O 
pyogenes O 
MTCC-442 O 
and O 
fungi O 
Aspergillus O 
niger O 
MTCC-282 O 
, O 
Aspergillus O 
clavatus O 
MTCC-1323 O 
, O 
Candida O 
albicans O 
MTCC-227 O 
using O 
broth O 
microdilution O 
method O 
. O 
Compounds O 
4 O 
, O 
8b O 
, O 
8d O 
, O 
8e O 
, O 
8h O 
and O 
9a O 
showed O 
promising O 
antibacterial O 
activity O 
compared O 
to O 
ampicillin B-TRIVIAL 
and O 
compounds O 
8b O 
, O 
8h O 
showed O 
better O 
antifungal O 
activity O 
compared O 
to O 
greseofulvin B-TRIVIAL 
. O 

plus O 
Isosorbide B-SYSTEMATIC 
Dinitrate I-SYSTEMATIC 
treatment O 
in O 
the O 
mdx O 
mice O 
ameliorates O 
dystrophic O 
heart O 
structure O 
. O 

: O 
Co-administration O 
of O 
ibuprofen B-TRIVIAL 
( O 
IBU B-ABBREVIATION 
) O 
and O 
isosorbide B-SYSTEMATIC 
dinitrate I-SYSTEMATIC 
( O 
ISDN B-ABBREVIATION 
) O 
provides O 
synergistic O 
beneficial O 
effects O 
on O 
dystrophic O 
skeletal O 
muscle O 
. O 
Whether O 
this O 
treatment O 
has O 
also O 
cardioprotective O 
effects O 
in O 
this O 
disease O 
was O 
still O 
unknown O 
. O 
Aims O 
: O 
to O 
evaluate O 
the O 
effects O 
of O 
co O 
- O 
administration O 
of O 
IBU B-ABBREVIATION 
and O 
ISDN B-ABBREVIATION 
( O 
a O 
) O 
on O 
left O 
ventricular O 
( O 
LV O 
) O 
structure O 
and O 
function O 
, O 
and O 
( O 
b O 
) O 
on O 
cardiac O 
inflammatory O 
response O 
and O 
fibrosis O 
in O 
mdx O 
mice O 
. O 
METHODS O 
: O 
three O 
groups O 
of O 
mice O 
were O 
studied O 
: O 
mdx O 
mice O 
treated O 
with O 
IBU B-ABBREVIATION 
(50mgkg(-1))+ O 
ISDN B-ABBREVIATION 
(30mgkg(-1)) O 
administered O 
daily O 
in O 
the O 
diet O 
, O 
mdx O 
mice O 
that O 
received O 
standard O 
diet O 
without O 
drugs O 
and O 
wild O 
type O 
aged O 
- O 
matched O 
mice O 
. O 
Animals O 
were O 
analysed O 
after O 
10-11 O 
months O 
of O 
treatment O 
. O 
Structural O 
and O 
functional O 
parameters O 
were O 
evaluated O 
by O 
echocardiography O 
while O 
histological O 
analyses O 
were O 
performed O 
to O 
evaluate O 
inflammatory O 
response O 
, O 
collagen O 
deposition O 
, O 
cardiomyocyte O 
number O 
and O 
area O 
. O 
RESULTS O 
: O 
treatment O 
for O 
10-11 O 
months O 
with O 
IBU B-ABBREVIATION 
+ O 
ISDN B-ABBREVIATION 
preserved O 
LV O 
wall O 
thickness O 
and O 
LV O 
mass O 
. O 
Drug O 
treatment O 
also O 
preserved O 
the O 
total O 
number O 
of O 
cardiomyocytes O 
in O 
the O 
LV O 
and O 
attenuated O 
the O 
increase O 
in O 
cardiomyocyte O 
size O 
, O 
when O 
compared O 
to O 
untreated O 
mdx O 
mice O 
. O 
Moreover O 
, O 
a O 
trend O 
towards O 
a O 
decreased O 
number O 
of O 
inflammatory O 
cells O 
, O 
a O 
reduced O 
LV O 
myocardial O 
interstitial O 
fibrosis O 
and O 
an O 
enhanced O 
global O 
LV O 
function O 
response O 
to O 
stress O 
was O 
observed O 
in O 
treated O 
mdx O 
mice O 
. O 
CONCLUSIONS O 
: O 
treatment O 
for O 
10-11 O 
months O 
with O 
IBU B-ABBREVIATION 
+ O 
ISDN B-ABBREVIATION 
is O 
effective O 
in O 
preventing O 
the O 
alterations O 
in O 
LV O 
morphology O 
of O 
mdx O 
mice O 
while O 
not O 
reaching O 
statistical O 
significance O 
on O 
LV O 
function O 
and O 
cardiac O 
inflammation O 
. O 

polymers O 
and O 
small O 
organic O 
molecules O 
are O 
enabling O 
new O 
, O 
flexible O 
, O 
large O 
- O 
area O 
, O 
low O 
- O 
cost O 
optoelectronic O 
devices O 
, O 
such O 
as O 
organic O 
light O 
- O 
emitting O 
diodes O 
, O 
transistors O 
and O 
solar O 
cells O 
. O 
Owing O 
to O 
their O 
exceptionally O 
long O 
spin O 
lifetimes O 
, O 
these O 
carbon B-SYSTEMATIC 
-based O 
materials O 
could O 
also O 
have O 
an O 
important O 
impact O 
on O 
spintronics O 
, O 
where O 
carrier O 
spins O 
play O 
a O 
key O 
role O 
in O 
transmitting O 
, O 
processing O 
and O 
storing O 
information O 
. O 
However O 
, O 
to O 
exploit O 
this O 
potential O 
, O 
a O 
method O 
for O 
direct O 
conversion O 
of O 
spin O 
information O 
into O 
an O 
electric O 
signal O 
is O 
indispensable O 
. O 
Here O 
we O 
show O 
that O 
a O 
pure O 
spin O 
current O 
can O 
be O 
produced O 
in O 
a O 
solution O 
- O 
processed O 
conducting O 
polymer O 
by O 
pumping O 
spins O 
through O 
a O 
ferromagnetic O 
resonance O 
in O 
an O 
adjacent O 
magnetic O 
insulator O 
, O 
and O 
that O 
this O 
generates O 
an O 
electric O 
voltage O 
across O 
the O 
polymer O 
film O 
. O 
We O 
demonstrate O 
that O 
the O 
experimental O 
characteristics O 
of O 
the O 
generated O 
voltage O 
are O 
consistent O 
with O 
it O 
being O 
generated O 
through O 
an O 
inverse O 
spin O 
Hall O 
effect O 
in O 
the O 
conducting O 
polymer O 
. O 
In O 
contrast O 
with O 
inorganic O 
materials O 
, O 
the O 
conducting O 
polymer O 
exhibits O 
coexistence O 
of O 
high O 
spin O 
- O 
current O 
to O 
charge O 
- O 
current O 
conversion O 
efficiency O 
and O 
long O 
spin O 
lifetimes O 
. O 
Our O 
discovery O 
opens O 
a O 
route O 
for O 
a O 
new O 
generation O 
of O 
molecular O 
- O 
structure O 
- O 
engineered O 
spintronic O 
devices O 
, O 
which O 
could O 
lead O 
to O 
important O 
advances O 
in O 
plastic O 
spintronics O 
. O 

action O 
on O 
thyroid O 
progenitor O 
cells O 
: O 
relevant O 
for O 
the O 
pathogenesis O 
of O 
thyroid O 
nodules O 
? O 

and O 
malignant O 
thyroid O 
nodules O 
are O 
more O 
prevalent O 
in O 
females O 
than O 
in O 
men O 
. O 
Experimental O 
data O 
suggest O 
that O 
the O 
proliferative O 
effect O 
of O 
oestrogen B-FAMILY 
rather O 
than O 
polymorphisms O 
is O 
responsible O 
for O 
this O 
gender O 
difference O 
. O 
This O 
study O 
analysed O 
whether O 
both O 
differentiated O 
thyroid O 
cells O 
and O 
thyroid O 
stem O 
and O 
progenitor O 
cells O 
are O 
a O 
target O 
of O 
oestrogen B-FAMILY 
action O 
. O 
In O 
thyroid O 
stem O 
/ O 
progenitor O 
cells O 
derived O 
from O 
nodular O 
goitres O 
the O 
ability O 
of O 
17beta-oestradiol B-SYSTEMATIC 
to O 
induce O 
thyrosphere O 
formation O 
, O 
the O 
expression O 
of O 
oestrogen B-FAMILY 
receptors O 
and O 
the O 
effect O 
of O 
17beta-oestradiol B-SYSTEMATIC 
on O 
growth O 
, O 
expression O 
of O 
marker O 
of O 
stem O 
cells O 
and O 
thyroid O 
differentiation O 
( O 
TSH O 
receptor O 
, O 
thyroperoxidase O 
, O 
thyroglobulin O 
, O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
expression O 
) O 
were O 
analysed O 
. O 
17beta-oestradiol B-SYSTEMATIC 
induced O 
thyrosphere O 
formation O 
, O 
albeit O 
to O 
lower O 
extent O 
than O 
other O 
growth O 
factors O 
. O 
Thyroid O 
stem O 
and O 
progenitor O 
cells O 
expressed O 
oestrogen B-FAMILY 
receptor O 
alpha O 
and O 
beta O 
with O 
an O 
8 O 
time O 
higher O 
expression O 
level O 
of O 
oestrogen B-FAMILY 
receptor O 
alpha O 
mRNA O 
compared O 
to O 
differentiated O 
thyrocytes O 
. O 
17beta-oestradiol B-SYSTEMATIC 
was O 
a O 
potent O 
stimulator O 
of O 
thyroid O 
stem/ O 
progenitor O 
cell O 
growth O 
. O 
In O 
contrast O 
, O 
TSH-induced O 
differentiation O 
of O 
progenitor O 
cells O 
, O 
in O 
particular O 
the O 
expression O 
of O 
the O 
sodium B-SYSTEMATIC 
iodide I-SYSTEMATIC 
symporter O 
, O 
was O 
significantly O 
inhibited O 
by O 
17beta-oestradiol B-SYSTEMATIC 
.In O 
conclusion O 
, O 
oestrogen B-FAMILY 
stimulated O 
growth O 
and O 
simultaneously O 
inhibited O 
differentiation O 
of O 
thyroid O 
nodules O 
derived O 
stem O 
/ O 
progenitor O 
cells O 
. O 
From O 
these O 
data O 
and O 
based O 
on O 
the O 
concept O 
of O 
cellular O 
heterogeneity O 
, O 
we O 
hypothesize O 
a O 
supportive O 
role O 
of O 
oestrogen B-FAMILY 
in O 
the O 
propagation O 
of O 
thyroid O 
stem O 
/ O 
progenitor O 
cells O 
leading O 
to O 
a O 
selection O 
of O 
a O 
progeny O 
of O 
growth O 
- O 
prone O 
cells O 
with O 
a O 
decreased O 
differentiation O 
. O 
These O 
cells O 
may O 
be O 
the O 
origin O 
of O 
hypo- O 
or O 
non-functioning O 
thyroid O 
nodules O 
in O 
females O 
. O 

of O 
mammary O 
adipogenesis O 
by O 
genistein B-TRIVIAL 
limits O 
mammosphere O 
formationof O 
human O 
MCF-7 O 
cells O 
. O 

adipose O 
tissue O 
may O 
contribute O 
to O 
breast O 
cancer O 
development O 
and O 
progression O 
by O 
altering O 
neighboring O 
epithelial O 
cell O 
behavior O 
and O 
phenotype O 
through O 
paracrine O 
signaling O 
. O 
Dietary O 
exposure O 
to O 
soy O 
foods O 
is O 
associated O 
with O 
lower O 
mammary O 
tumor O 
risk O 
and O 
reduced O 
body O 
weight O 
and O 
adiposity O 
in O 
humans O 
and O 
in O 
rodent O 
breast O 
cancer O 
models O 
. O 
Despite O 
the O 
suggested O 
linkage O 
between O 
obesity O 
and O 
breast O 
cancer O 
, O 
the O 
local O 
influence O 
of O 
bioactive O 
dietary O 
components O 
on O 
mammary O 
adiposity O 
for O 
anti-tumor O 
effects O 
remains O 
unknown O 
. O 
Herein O 
, O 
we O 
report O 
that O 
post O 
- O 
weaning O 
dietary O 
exposure O 
to O 
soy O 
protein O 
isolate O 
and O 
its O 
bioactive O 
isoflavone B-FAMILY 
genistein B-TRIVIAL 
lowered O 
mammary O 
adiposity O 
and O 
increased O 
mammary O 
tumor O 
suppressor O 
PTEN O 
and O 
E-cadherin O 
expression O 
in O 
female O 
mice O 
, O 
relative O 
to O 
control O 
casein O 
diet O 
. O 
To O 
ascertain O 
genistein B-TRIVIAL 
' O 
s O 
role O 
in O 
mammary O 
adipose O 
deposition O 
that O 
may O 
affect O 
underlying O 
epithelial O 
cell O 
phenotype O 
, O 
we O 
evaluated O 
genistein B-TRIVIAL 
' O 
s O 
effects O 
on O 
SV40-immortalized O 
mouse O 
mammary O 
stromal O 
fibroblast O 
- O 
like O 
( O 
MSF O 
) O 
cells O 
during O 
differentiation O 
to O 
adipocytes O 
